cancer_type	qtl_type	tag_SNP	LD	SNP_id	gene_id	gene_symbol	t-stat	p-value	FDR	beta	r	Traits	SNP_position	Gene_position
LUAD	cis	rs2739330	0.892	rs5751776	ENSG00000273295.1	AP000350.5	30.44	3.14e-114	4.25e-107	0.92	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23901432~23907068:-
LUAD	cis	rs2739330	0.929	rs5751777	ENSG00000273295.1	AP000350.5	30.43	3.65e-114	4.25e-107	0.92	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23901432~23907068:-
LUAD	cis	rs9326248	0.906	rs171052	ENSG00000254851.1	RP11-109L13.1	30.08	1.34e-112	9.42e-106	1.07	0.81	Blood protein levels;	chr11:117211047	chr11:117135528~117138582:+
LUAD	cis	rs916888	0.687	rs199456	ENSG00000262539.1	RP11-259G18.3	29.55	3.36e-110	1.73e-103	1.31	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46259551~46260606:-
LUAD	cis	rs916888	0.773	rs199457	ENSG00000262539.1	RP11-259G18.3	29.46	9.13e-110	3.65e-103	1.31	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46259551~46260606:-
LUAD	cis	rs9326248	1	rs585849	ENSG00000254851.1	RP11-109L13.1	-29.21	1.23e-108	4.06e-102	-1.08	-0.8	Blood protein levels;	chr11:117198345	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.954	rs8521	ENSG00000254851.1	RP11-109L13.1	-29.17	1.98e-108	5.92e-102	-1.08	-0.8	Blood protein levels;	chr11:117196983	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.817	rs1242127	ENSG00000254851.1	RP11-109L13.1	29.13	2.97e-108	8.23e-102	1.05	0.8	Blood protein levels;	chr11:117205848	chr11:117135528~117138582:+
LUAD	cis	rs916888	0.773	rs169201	ENSG00000262539.1	RP11-259G18.3	28.99	1.25e-107	3.22e-101	1.31	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46259551~46260606:-
LUAD	cis	rs916888	0.773	rs199448	ENSG00000262539.1	RP11-259G18.3	28.79	1.08e-106	2.59e-100	1.25	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46259551~46260606:-
LUAD	cis	rs9326248	0.954	rs521171	ENSG00000254851.1	RP11-109L13.1	-28.74	1.71e-106	3.85e-100	-1.08	-0.8	Blood protein levels;	chr11:117193977	chr11:117135528~117138582:+
LUAD	cis	rs916888	0.773	rs1378358	ENSG00000262539.1	RP11-259G18.3	28.52	1.92e-105	4.06e-99	1.29	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46259551~46260606:-
LUAD	cis	rs916888	0.773	rs199439	ENSG00000262539.1	RP11-259G18.3	28.49	2.52e-105	5.04e-99	1.28	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46259551~46260606:-
LUAD	cis	rs1577917	0.655	rs1059307	ENSG00000203875.9	SNHG5	28.47	3.29e-105	6.22e-99	0.95	0.79	Response to antipsychotic treatment;	chr6:85678170	chr6:85660950~85678736:-
LUAD	cis	rs9326248	0.953	rs634960	ENSG00000254851.1	RP11-109L13.1	28.42	5.25e-105	9.44e-99	1.05	0.79	Blood protein levels;	chr11:117202247	chr11:117135528~117138582:+
LUAD	cis	rs916888	0.773	rs199534	ENSG00000262539.1	RP11-259G18.3	28.38	8.12e-105	1.39e-98	1.3	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46259551~46260606:-
LUAD	cis	rs9326248	1	rs3736120	ENSG00000254851.1	RP11-109L13.1	-28.29	2.23e-104	3.48e-98	-1.06	-0.79	Blood protein levels;	chr11:117161409	chr11:117135528~117138582:+
LUAD	cis	rs2739330	0.929	rs5751775	ENSG00000273295.1	AP000350.5	28.26	2.87e-104	4.3e-98	0.9	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23901432~23907068:-
LUAD	cis	rs9326248	0.954	rs10790177	ENSG00000254851.1	RP11-109L13.1	-28.22	4.26e-104	5.53e-98	-1.06	-0.79	Blood protein levels;	chr11:117177701	chr11:117135528~117138582:+
LUAD	cis	rs9326248	1	rs664922	ENSG00000254851.1	RP11-109L13.1	-28.22	4.32e-104	5.53e-98	-1.05	-0.79	Blood protein levels;	chr11:117200179	chr11:117135528~117138582:+
LUAD	cis	rs9326248	1	rs664082	ENSG00000254851.1	RP11-109L13.1	-28.22	4.32e-104	5.53e-98	-1.05	-0.79	Blood protein levels;	chr11:117200354	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.953	rs488962	ENSG00000254851.1	RP11-109L13.1	28.19	6.04e-104	7.01e-98	1.05	0.79	Blood protein levels;	chr11:117201809	chr11:117135528~117138582:+
LUAD	cis	rs916888	0.773	rs199451	ENSG00000262539.1	RP11-259G18.3	28.1	1.61e-103	1.56e-97	1.29	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46259551~46260606:-
LUAD	cis	rs9326248	0.954	rs4938349	ENSG00000254851.1	RP11-109L13.1	-28.04	3.11e-103	2.94e-97	-1.06	-0.79	Blood protein levels;	chr11:117151207	chr11:117135528~117138582:+
LUAD	cis	rs9326248	1	rs4938354	ENSG00000254851.1	RP11-109L13.1	-27.93	1e-102	8.4e-97	-1.06	-0.79	Blood protein levels;	chr11:117180449	chr11:117135528~117138582:+
LUAD	cis	rs9326248	1	rs7946257	ENSG00000254851.1	RP11-109L13.1	-27.93	1e-102	8.4e-97	-1.06	-0.79	Blood protein levels;	chr11:117182449	chr11:117135528~117138582:+
LUAD	cis	rs916888	0.773	rs199533	ENSG00000262539.1	RP11-259G18.3	27.86	2.04e-102	1.47e-96	1.29	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46259551~46260606:-
LUAD	cis	rs916888	0.773	rs538628	ENSG00000262539.1	RP11-259G18.3	27.81	3.62e-102	2.5e-96	1.26	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46259551~46260606:-
LUAD	cis	rs2739330	0.892	rs4822455	ENSG00000273295.1	AP000350.5	27.75	6.99e-102	4.74e-96	0.9	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23901432~23907068:-
LUAD	cis	rs9326248	0.911	rs11216284	ENSG00000254851.1	RP11-109L13.1	-27.57	4.39e-101	2.68e-95	-1.07	-0.78	Blood protein levels;	chr11:117132344	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.911	rs474339	ENSG00000254851.1	RP11-109L13.1	-27.46	1.42e-100	7.75e-95	-1.05	-0.78	Blood protein levels;	chr11:117188836	chr11:117135528~117138582:+
LUAD	cis	rs916888	0.773	rs199535	ENSG00000262539.1	RP11-259G18.3	27.45	1.6e-100	8.57e-95	1.27	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46259551~46260606:-
LUAD	cis	rs916888	0.773	rs199445	ENSG00000262539.1	RP11-259G18.3	27.24	1.56e-99	7.71e-94	1.27	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46259551~46260606:-
LUAD	cis	rs916888	0.773	rs199443	ENSG00000262539.1	RP11-259G18.3	27.24	1.56e-99	7.71e-94	1.27	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46259551~46260606:-
LUAD	cis	rs916888	0.773	rs199447	ENSG00000262539.1	RP11-259G18.3	27.17	3.44e-99	1.59e-93	1.3	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46259551~46260606:-
LUAD	cis	rs916888	0.779	rs199528	ENSG00000262539.1	RP11-259G18.3	26.93	4.29e-98	1.86e-92	1.28	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46259551~46260606:-
LUAD	cis	rs916888	0.821	rs199525	ENSG00000262539.1	RP11-259G18.3	26.93	4.29e-98	1.86e-92	1.28	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46259551~46260606:-
LUAD	cis	rs9326248	1	rs10790175	ENSG00000254851.1	RP11-109L13.1	-26.79	1.91e-97	7.71e-92	-1.01	-0.77	Blood protein levels;	chr11:117164013	chr11:117135528~117138582:+
LUAD	cis	rs1577917	0.655	rs9444354	ENSG00000203875.9	SNHG5	26.63	1.15e-96	4.29e-91	0.93	0.77	Response to antipsychotic treatment;	chr6:85582217	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.561	rs3087978	ENSG00000203875.9	SNHG5	26.44	8.18e-96	2.83e-90	0.93	0.77	Response to antipsychotic treatment;	chr6:85678505	chr6:85660950~85678736:-
LUAD	cis	rs9326248	1	rs7107152	ENSG00000254851.1	RP11-109L13.1	26.32	3.04e-95	1.02e-89	1	0.77	Blood protein levels;	chr11:117185364	chr11:117135528~117138582:+
LUAD	cis	rs2739330	0.828	rs5751770	ENSG00000273295.1	AP000350.5	26.22	9.21e-95	3.03e-89	0.87	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23901432~23907068:-
LUAD	cis	rs2739330	0.892	rs5751776	ENSG00000218537.1	MIF-AS1	26.15	2.07e-94	6.52e-89	0.97	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23894426~23898930:-
LUAD	cis	rs2739330	0.753	rs4822452	ENSG00000273295.1	AP000350.5	26.13	2.53e-94	7.84e-89	0.88	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23901432~23907068:-
LUAD	cis	rs62445005	1	rs62445005	ENSG00000211697.3	TRGV5	26.12	2.76e-94	8.47e-89	1.03	0.77	Shingles;	chr7:38346957	chr7:38343894~38350022:-
LUAD	cis	rs1577917	0.655	rs7766485	ENSG00000203875.9	SNHG5	26.11	2.9e-94	8.75e-89	0.93	0.77	Response to antipsychotic treatment;	chr6:85553837	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.655	rs9444352	ENSG00000203875.9	SNHG5	26.08	4.45e-94	1.3e-88	0.91	0.77	Response to antipsychotic treatment;	chr6:85547817	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.566	rs2842611	ENSG00000203875.9	SNHG5	-26.07	4.52e-94	1.31e-88	-0.92	-0.77	Response to antipsychotic treatment;	chr6:85592316	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.61	rs11752795	ENSG00000203875.9	SNHG5	26.07	4.82e-94	1.39e-88	0.92	0.77	Response to antipsychotic treatment;	chr6:85577411	chr6:85660950~85678736:-
LUAD	cis	rs2739330	0.929	rs5751777	ENSG00000218537.1	MIF-AS1	26.03	7.35e-94	2.08e-88	0.97	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23894426~23898930:-
LUAD	cis	rs1577917	0.655	rs9450311	ENSG00000203875.9	SNHG5	26	1.01e-93	2.81e-88	0.92	0.76	Response to antipsychotic treatment;	chr6:85666868	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.56	rs12193777	ENSG00000203875.9	SNHG5	25.95	1.64e-93	4.47e-88	0.92	0.76	Response to antipsychotic treatment;	chr6:85536991	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.655	rs9444351	ENSG00000203875.9	SNHG5	25.95	1.7e-93	4.49e-88	0.92	0.76	Response to antipsychotic treatment;	chr6:85538081	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.655	rs2842600	ENSG00000203875.9	SNHG5	-25.94	2e-93	5.24e-88	-0.92	-0.76	Response to antipsychotic treatment;	chr6:85615914	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.655	rs12203963	ENSG00000203875.9	SNHG5	25.88	3.66e-93	9.4e-88	0.92	0.76	Response to antipsychotic treatment;	chr6:85513598	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.629	rs6927475	ENSG00000203875.9	SNHG5	25.87	4.08e-93	1.03e-87	0.92	0.76	Response to antipsychotic treatment;	chr6:85497055	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.655	rs2842605	ENSG00000203875.9	SNHG5	-25.86	4.33e-93	1.07e-87	-0.92	-0.76	Response to antipsychotic treatment;	chr6:85625432	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.655	rs2758848	ENSG00000203875.9	SNHG5	-25.86	4.33e-93	1.07e-87	-0.92	-0.76	Response to antipsychotic treatment;	chr6:85637887	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.559	rs1173418	ENSG00000203875.9	SNHG5	25.85	5.14e-93	1.26e-87	0.92	0.76	Response to antipsychotic treatment;	chr6:85693198	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.655	rs9342045	ENSG00000203875.9	SNHG5	25.82	7.29e-93	1.75e-87	0.92	0.76	Response to antipsychotic treatment;	chr6:85715430	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.727	rs9344539	ENSG00000203875.9	SNHG5	-25.8	9.11e-93	2.16e-87	-0.92	-0.76	Response to antipsychotic treatment;	chr6:85643903	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.771	rs9362232	ENSG00000203875.9	SNHG5	-25.8	9.11e-93	2.16e-87	-0.92	-0.76	Response to antipsychotic treatment;	chr6:85643904	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.681	rs4707211	ENSG00000203875.9	SNHG5	25.77	1.26e-92	2.9e-87	0.92	0.76	Response to antipsychotic treatment;	chr6:85522992	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.629	rs9450285	ENSG00000203875.9	SNHG5	25.75	1.47e-92	3.28e-87	0.92	0.76	Response to antipsychotic treatment;	chr6:85498378	chr6:85660950~85678736:-
LUAD	cis	rs2739330	0.828	rs2154593	ENSG00000273295.1	AP000350.5	25.72	1.99e-92	4.42e-87	0.87	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23901432~23907068:-
LUAD	cis	rs2739330	0.828	rs2877178	ENSG00000273295.1	AP000350.5	25.71	2.27e-92	4.97e-87	0.87	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23901432~23907068:-
LUAD	cis	rs2739330	0.828	rs5760108	ENSG00000273295.1	AP000350.5	25.71	2.4e-92	5.23e-87	0.87	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23901432~23907068:-
LUAD	cis	rs9326248	0.798	rs10892079	ENSG00000254851.1	RP11-109L13.1	-25.63	5.39e-92	1.13e-86	-1.03	-0.76	Blood protein levels;	chr11:117146108	chr11:117135528~117138582:+
LUAD	cis	rs1577917	0.655	rs2758849	ENSG00000203875.9	SNHG5	-25.62	6.24e-92	1.3e-86	-0.92	-0.76	Response to antipsychotic treatment;	chr6:85634578	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.681	rs4348284	ENSG00000203875.9	SNHG5	-25.6	7.79e-92	1.6e-86	-0.91	-0.76	Response to antipsychotic treatment;	chr6:85640676	chr6:85660950~85678736:-
LUAD	cis	rs916888	0.821	rs70600	ENSG00000262539.1	RP11-259G18.3	25.36	1.07e-90	2.08e-85	1.24	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46259551~46260606:-
LUAD	cis	rs9326248	1	rs4938344	ENSG00000254851.1	RP11-109L13.1	-25.23	4.23e-90	8.15e-85	-1.03	-0.75	Blood protein levels;	chr11:117133033	chr11:117135528~117138582:+
LUAD	cis	rs1577917	0.655	rs6454472	ENSG00000203875.9	SNHG5	25.12	1.38e-89	2.58e-84	0.91	0.75	Response to antipsychotic treatment;	chr6:85514335	chr6:85660950~85678736:-
LUAD	cis	rs9326248	1	rs664971	ENSG00000254851.1	RP11-109L13.1	24.98	6.77e-89	1.26e-83	0.97	0.75	Blood protein levels;	chr11:117200141	chr11:117135528~117138582:+
LUAD	cis	rs2882667	0.69	rs288016	ENSG00000253404.1	AC034243.1	-24.94	9.77e-89	1.79e-83	-0.95	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859299	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.929	rs5751775	ENSG00000218537.1	MIF-AS1	24.85	2.59e-88	4.66e-83	0.95	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23894426~23898930:-
LUAD	cis	rs2739330	0.828	rs5760099	ENSG00000273295.1	AP000350.5	24.77	6.17e-88	1.1e-82	0.87	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23901432~23907068:-
LUAD	cis	rs2739330	0.828	rs5760102	ENSG00000273295.1	AP000350.5	24.77	6.36e-88	1.13e-82	0.87	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23901432~23907068:-
LUAD	cis	rs2739330	0.796	rs5760097	ENSG00000273295.1	AP000350.5	24.76	6.78e-88	1.2e-82	0.87	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23901432~23907068:-
LUAD	cis	rs2739330	0.828	rs4822451	ENSG00000273295.1	AP000350.5	24.75	7.82e-88	1.37e-82	0.87	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23901432~23907068:-
LUAD	cis	rs2739330	0.828	rs5760098	ENSG00000273295.1	AP000350.5	24.75	7.82e-88	1.37e-82	0.87	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23901432~23907068:-
LUAD	cis	rs2739330	0.828	rs2186366	ENSG00000273295.1	AP000350.5	-24.64	2.52e-87	4.29e-82	-0.85	-0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23901432~23907068:-
LUAD	cis	rs2882667	0.587	rs288015	ENSG00000253404.1	AC034243.1	-24.52	9.8e-87	1.63e-81	-0.96	-0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859528	chr5:138744434~138753309:-
LUAD	cis	rs8013143	1	rs11846575	ENSG00000279656.1	RP11-298I3.6	-24.48	1.44e-86	2.38e-81	-0.94	-0.74	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23022075	chr14:23023083~23024217:-
LUAD	cis	rs9326248	1	rs9326248	ENSG00000254851.1	RP11-109L13.1	-24.45	2.2e-86	3.59e-81	-1.02	-0.74	Blood protein levels;	chr11:117128509	chr11:117135528~117138582:+
LUAD	cis	rs2739330	0.828	rs4822454	ENSG00000273295.1	AP000350.5	24.44	2.37e-86	3.83e-81	0.86	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23901432~23907068:-
LUAD	cis	rs2882667	0.69	rs495638	ENSG00000253404.1	AC034243.1	-24.33	8.03e-86	1.28e-80	-0.96	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138865253	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288042	ENSG00000253404.1	AC034243.1	24.33	8.03e-86	1.28e-80	0.96	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138867345	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs6880786	ENSG00000253404.1	AC034243.1	-24.29	1.14e-85	1.81e-80	-0.95	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138845874	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs160405	ENSG00000253404.1	AC034243.1	24.24	2.07e-85	3.25e-80	0.96	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748387	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.828	rs2330635	ENSG00000273295.1	AP000350.5	24.2	3.18e-85	4.98e-80	0.85	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23901432~23907068:-
LUAD	cis	rs2882667	0.69	rs288030	ENSG00000253404.1	AC034243.1	24.19	3.46e-85	5.38e-80	0.96	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880594	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.828	rs5760107	ENSG00000273295.1	AP000350.5	24.12	7.6e-85	1.15e-79	0.85	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23901432~23907068:-
LUAD	cis	rs2739330	0.789	rs5760109	ENSG00000273295.1	AP000350.5	24.12	7.6e-85	1.15e-79	0.85	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23901432~23907068:-
LUAD	cis	rs2882667	0.654	rs1972072	ENSG00000253404.1	AC034243.1	-24.1	9.93e-85	1.49e-79	-0.95	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849604	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs9327826	ENSG00000253404.1	AC034243.1	-24.08	1.16e-84	1.73e-79	-0.94	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846318	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.654	rs160406	ENSG00000253404.1	AC034243.1	-24.05	1.71e-84	2.54e-79	-0.95	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748032	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs1039788	ENSG00000253404.1	AC034243.1	-24.02	2.41e-84	3.52e-79	-0.95	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835812	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs1828188	ENSG00000253404.1	AC034243.1	-24.02	2.41e-84	3.52e-79	-0.95	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836307	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.654	rs288019	ENSG00000253404.1	AC034243.1	-24	3.02e-84	4.36e-79	-0.94	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138855704	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288013	ENSG00000253404.1	AC034243.1	-23.97	4.12e-84	5.9e-79	-0.94	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860128	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs176381	ENSG00000253404.1	AC034243.1	-23.97	4.12e-84	5.9e-79	-0.94	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138861042	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs4835706	ENSG00000253404.1	AC034243.1	-23.95	4.89e-84	6.98e-79	-0.95	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138829037	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.654	rs6863054	ENSG00000253404.1	AC034243.1	-23.91	7.38e-84	1.05e-78	-0.94	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853166	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs1725335	ENSG00000253404.1	AC034243.1	-23.86	1.4e-83	1.73e-78	-0.95	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745541	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.722	rs4835649	ENSG00000253404.1	AC034243.1	-23.81	2.25e-83	2.57e-78	-0.95	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810534	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs1828187	ENSG00000253404.1	AC034243.1	23.78	3.25e-83	3.69e-78	0.92	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836531	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288011	ENSG00000253404.1	AC034243.1	-23.78	3.33e-83	3.72e-78	-0.94	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864250	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288010	ENSG00000253404.1	AC034243.1	-23.78	3.33e-83	3.72e-78	-0.94	-0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864340	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288041	ENSG00000253404.1	AC034243.1	23.78	3.33e-83	3.72e-78	0.94	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138868322	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288039	ENSG00000253404.1	AC034243.1	23.78	3.33e-83	3.72e-78	0.94	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138870511	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288038	ENSG00000253404.1	AC034243.1	23.78	3.33e-83	3.72e-78	0.94	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138871844	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs825754	ENSG00000253404.1	AC034243.1	-23.75	4.63e-83	5.06e-78	-0.95	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138796200	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.722	rs825751	ENSG00000253404.1	AC034243.1	-23.75	4.63e-83	5.06e-78	-0.95	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138798180	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288031	ENSG00000253404.1	AC034243.1	23.71	7.22e-83	7.78e-78	0.94	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880377	chr5:138744434~138753309:-
LUAD	cis	rs916888	0.773	rs9896243	ENSG00000262539.1	RP11-259G18.3	23.69	8.58e-83	9.18e-78	1.16	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46259551~46260606:-
LUAD	cis	rs2882667	0.69	rs4835707	ENSG00000253404.1	AC034243.1	-23.68	9.49e-83	9.99e-78	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138838831	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs12656942	ENSG00000253404.1	AC034243.1	-23.68	9.49e-83	9.99e-78	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840769	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.686	rs62381196	ENSG00000253404.1	AC034243.1	-23.68	9.49e-83	9.99e-78	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841000	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.621	rs55901834	ENSG00000253404.1	AC034243.1	-23.67	1.11e-82	1.16e-77	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844094	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs1651358	ENSG00000253404.1	AC034243.1	-23.65	1.35e-82	1.4e-77	-0.96	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745318	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs1976568	ENSG00000253404.1	AC034243.1	-23.61	1.95e-82	2.02e-77	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844627	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs6873425	ENSG00000253404.1	AC034243.1	-23.59	2.54e-82	2.61e-77	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819556	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs6860780	ENSG00000253404.1	AC034243.1	-23.59	2.54e-82	2.61e-77	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138824367	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs6884198	ENSG00000253404.1	AC034243.1	-23.59	2.54e-82	2.61e-77	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138828618	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.654	rs12517514	ENSG00000253404.1	AC034243.1	-23.58	2.94e-82	3.02e-77	-0.95	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138814430	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs891996	ENSG00000253404.1	AC034243.1	23.58	2.97e-82	3.02e-77	0.94	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138932127	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.892	rs4822455	ENSG00000218537.1	MIF-AS1	23.58	3.01e-82	3.05e-77	0.94	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23894426~23898930:-
LUAD	cis	rs2882667	0.69	rs7714455	ENSG00000253404.1	AC034243.1	-23.57	3.21e-82	3.26e-77	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818281	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288025	ENSG00000253404.1	AC034243.1	23.56	3.72e-82	3.75e-77	0.95	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887944	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs160399	ENSG00000253404.1	AC034243.1	23.52	5.38e-82	5.39e-77	0.93	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727552	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.6	rs7785842	ENSG00000230658.1	KLHL7-AS1	23.51	6.32e-82	6.29e-77	0.89	0.73	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs2662543	ENSG00000253404.1	AC034243.1	23.51	6.35e-82	6.3e-77	0.94	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898441	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs17207772	ENSG00000253404.1	AC034243.1	23.51	6.35e-82	6.3e-77	0.94	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138906131	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288033	ENSG00000253404.1	AC034243.1	23.5	6.59e-82	6.48e-77	0.93	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138878405	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.6	rs10235786	ENSG00000230658.1	KLHL7-AS1	23.5	7.18e-82	7.04e-77	0.89	0.73	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs10043478	ENSG00000253404.1	AC034243.1	23.48	8.33e-82	8.14e-77	0.93	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853022	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs6421921	ENSG00000253404.1	AC034243.1	-23.48	8.55e-82	8.33e-77	-0.93	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831581	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs1627698	ENSG00000253404.1	AC034243.1	-23.48	8.63e-82	8.39e-77	-0.95	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138741777	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.654	rs1703211	ENSG00000253404.1	AC034243.1	-23.47	9.4e-82	9.09e-77	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138740587	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.6	rs7456915	ENSG00000230658.1	KLHL7-AS1	23.46	1.08e-81	1.04e-76	0.89	0.73	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs10233039	ENSG00000230658.1	KLHL7-AS1	23.44	1.3e-81	1.25e-76	0.89	0.73	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs825748	ENSG00000253404.1	AC034243.1	-23.44	1.31e-81	1.25e-76	-0.96	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800378	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs825746	ENSG00000253404.1	AC034243.1	-23.44	1.31e-81	1.25e-76	-0.96	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800930	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs825762	ENSG00000253404.1	AC034243.1	-23.43	1.47e-81	1.39e-76	-0.96	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138801981	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs825761	ENSG00000253404.1	AC034243.1	-23.43	1.47e-81	1.39e-76	-0.96	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138802318	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.6	rs1468592	ENSG00000230658.1	KLHL7-AS1	-23.43	1.51e-81	1.43e-76	-0.89	-0.73	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.587	rs6596450	ENSG00000253404.1	AC034243.1	-23.41	1.74e-81	1.64e-76	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810831	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.796	rs5760106	ENSG00000273295.1	AP000350.5	-23.39	2.28e-81	2.13e-76	-0.84	-0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23901432~23907068:-
LUAD	cis	rs3814244	0.569	rs2051993	ENSG00000255733.4	IFNG-AS1	23.38	2.64e-81	2.45e-76	0.68	0.73	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019898	chr12:67989445~68234686:+
LUAD	cis	rs858239	0.6	rs10256524	ENSG00000230658.1	KLHL7-AS1	23.37	2.93e-81	2.71e-76	0.88	0.73	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs160401	ENSG00000253404.1	AC034243.1	-23.35	3.48e-81	3.2e-76	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138725652	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs2351463	ENSG00000253404.1	AC034243.1	23.35	3.49e-81	3.2e-76	0.93	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923113	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs700625	ENSG00000253404.1	AC034243.1	-23.35	3.56e-81	3.2e-76	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763908	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.654	rs2940595	ENSG00000253404.1	AC034243.1	-23.35	3.56e-81	3.2e-76	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138765348	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs851278	ENSG00000253404.1	AC034243.1	-23.35	3.56e-81	3.2e-76	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767577	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.589	rs825770	ENSG00000253404.1	AC034243.1	-23.35	3.56e-81	3.2e-76	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779530	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs825769	ENSG00000253404.1	AC034243.1	-23.35	3.56e-81	3.2e-76	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779666	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs700627	ENSG00000253404.1	AC034243.1	-23.35	3.56e-81	3.2e-76	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138783711	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs825758	ENSG00000253404.1	AC034243.1	-23.35	3.56e-81	3.2e-76	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138791288	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs3749664	ENSG00000253404.1	AC034243.1	23.34	4.15e-81	3.72e-76	0.94	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935732	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs6872423	ENSG00000253404.1	AC034243.1	23.32	5.13e-81	4.59e-76	0.94	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138911089	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs176382	ENSG00000253404.1	AC034243.1	23.32	5.18e-81	4.62e-76	0.93	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891078	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs1039789	ENSG00000253404.1	AC034243.1	-23.31	5.42e-81	4.82e-76	-0.93	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835734	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288012	ENSG00000253404.1	AC034243.1	-23.3	6.26e-81	5.53e-76	-0.92	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860584	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288014	ENSG00000253404.1	AC034243.1	-23.28	7.91e-81	6.96e-76	-0.92	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860104	chr5:138744434~138753309:-
LUAD	cis	rs916888	0.821	rs199506	ENSG00000262539.1	RP11-259G18.3	-23.28	7.97e-81	6.99e-76	-1.17	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46259551~46260606:-
LUAD	cis	rs2882667	0.69	rs700616	ENSG00000253404.1	AC034243.1	-23.26	9.03e-81	7.87e-76	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752184	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.654	rs700617	ENSG00000253404.1	AC034243.1	-23.26	9.03e-81	7.87e-76	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752290	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs700618	ENSG00000253404.1	AC034243.1	-23.26	9.03e-81	7.87e-76	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752429	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.654	rs884470	ENSG00000253404.1	AC034243.1	-23.26	9.6e-81	8.31e-76	-0.93	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820236	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs4835705	ENSG00000253404.1	AC034243.1	-23.26	9.6e-81	8.31e-76	-0.93	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827887	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.753	rs4822452	ENSG00000218537.1	MIF-AS1	23.23	1.27e-80	1.09e-75	0.93	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23894426~23898930:-
LUAD	cis	rs2882667	0.628	rs3749663	ENSG00000253404.1	AC034243.1	23.23	1.28e-80	1.09e-75	0.94	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935498	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.6	rs13438179	ENSG00000230658.1	KLHL7-AS1	23.23	1.31e-80	1.12e-75	0.88	0.73	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.587	rs1848506	ENSG00000253404.1	AC034243.1	-23.23	1.34e-80	1.13e-75	-0.92	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846768	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs1848505	ENSG00000253404.1	AC034243.1	-23.23	1.34e-80	1.13e-75	-0.92	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846841	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.654	rs884469	ENSG00000253404.1	AC034243.1	-23.22	1.42e-80	1.2e-75	-0.92	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820270	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.591	rs56322405	ENSG00000253404.1	AC034243.1	-23.22	1.43e-80	1.21e-75	-0.93	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138837693	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.722	rs2011462	ENSG00000253404.1	AC034243.1	-23.21	1.68e-80	1.4e-75	-0.92	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827083	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.62	rs3789151	ENSG00000253404.1	AC034243.1	-23.21	1.69e-80	1.42e-75	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138809771	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.828	rs5751770	ENSG00000218537.1	MIF-AS1	23.2	1.88e-80	1.57e-75	0.93	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23894426~23898930:-
LUAD	cis	rs2882667	0.69	rs10068280	ENSG00000253404.1	AC034243.1	23.19	1.95e-80	1.62e-75	0.95	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931394	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs13178601	ENSG00000253404.1	AC034243.1	23.19	2.13e-80	1.77e-75	0.95	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931688	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.6	rs10256361	ENSG00000230658.1	KLHL7-AS1	23.16	2.7e-80	2.22e-75	0.9	0.73	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs6960001	ENSG00000230658.1	KLHL7-AS1	23.16	2.92e-80	2.38e-75	0.89	0.73	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs10237755	ENSG00000230658.1	KLHL7-AS1	23.16	2.92e-80	2.38e-75	0.89	0.73	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs6961131	ENSG00000230658.1	KLHL7-AS1	23.16	2.92e-80	2.38e-75	0.89	0.73	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs2014768	ENSG00000230658.1	KLHL7-AS1	23.16	2.99e-80	2.42e-75	0.9	0.73	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs6978827	ENSG00000230658.1	KLHL7-AS1	23.16	2.99e-80	2.42e-75	0.9	0.73	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs7790157	ENSG00000230658.1	KLHL7-AS1	23.16	2.99e-80	2.42e-75	0.9	0.73	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs825669	ENSG00000253404.1	AC034243.1	-23.15	3.08e-80	2.49e-75	-0.94	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138731258	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs6887841	ENSG00000253404.1	AC034243.1	-23.14	3.5e-80	2.81e-75	-0.93	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840221	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.72	rs56044552	ENSG00000253404.1	AC034243.1	-23.14	3.5e-80	2.81e-75	-0.93	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841265	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs9327829	ENSG00000253404.1	AC034243.1	-23.13	4.14e-80	3.31e-75	-0.95	-0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925982	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs311602	ENSG00000253404.1	AC034243.1	23.12	4.36e-80	3.45e-75	0.94	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717370	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs930063	ENSG00000253404.1	AC034243.1	23.12	4.36e-80	3.45e-75	0.94	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717929	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs930062	ENSG00000253404.1	AC034243.1	23.12	4.36e-80	3.45e-75	0.94	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717934	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.658	rs172664	ENSG00000253404.1	AC034243.1	23.12	4.36e-80	3.45e-75	0.94	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720617	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288023	ENSG00000253404.1	AC034243.1	23.1	5.73e-80	4.48e-75	0.93	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888359	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.828	rs4820572	ENSG00000273295.1	AP000350.5	23.09	6.4e-80	4.97e-75	0.84	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23901432~23907068:-
LUAD	cis	rs2882667	0.69	rs7710288	ENSG00000253404.1	AC034243.1	-23.08	7.01e-80	5.44e-75	-0.93	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844049	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs274119	ENSG00000253404.1	AC034243.1	23.07	7.31e-80	5.66e-75	0.94	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138728530	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.599	rs288008	ENSG00000253404.1	AC034243.1	23.05	9.66e-80	7.38e-75	0.93	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138893632	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288004	ENSG00000253404.1	AC034243.1	23.05	9.66e-80	7.38e-75	0.93	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138895956	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs13172507	ENSG00000253404.1	AC034243.1	23.05	9.66e-80	7.38e-75	0.93	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138907409	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs1651032	ENSG00000253404.1	AC034243.1	-23.04	1.06e-79	8.03e-75	-0.94	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138743151	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.658	rs311592	ENSG00000253404.1	AC034243.1	23.04	1.06e-79	8.05e-75	0.96	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138734506	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs160402	ENSG00000253404.1	AC034243.1	23.02	1.27e-79	9.61e-75	0.95	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138723599	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.601	rs73272048	ENSG00000230658.1	KLHL7-AS1	23.02	1.37e-79	1.03e-74	0.88	0.72	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs700623	ENSG00000253404.1	AC034243.1	-22.98	2.09e-79	1.56e-74	-0.92	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762993	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.601	rs15775	ENSG00000230658.1	KLHL7-AS1	22.98	2.14e-79	1.59e-74	0.88	0.72	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23101228~23105703:-
LUAD	cis	rs916888	0.773	rs199533	ENSG00000214401.4	KANSL1-AS1	22.97	2.19e-79	1.63e-74	1.19	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46193576~46196723:+
LUAD	cis	rs2882667	0.659	rs311595	ENSG00000253404.1	AC034243.1	22.97	2.23e-79	1.66e-74	0.92	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736183	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs6596456	ENSG00000253404.1	AC034243.1	-22.97	2.33e-79	1.72e-74	-0.91	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831808	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs274118	ENSG00000253404.1	AC034243.1	22.96	2.7e-79	1.98e-74	0.93	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729198	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs274117	ENSG00000253404.1	AC034243.1	22.96	2.7e-79	1.98e-74	0.93	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729359	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs1059110	ENSG00000253404.1	AC034243.1	22.95	2.7e-79	1.98e-74	0.95	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138930857	chr5:138744434~138753309:-
LUAD	cis	rs916888	0.773	rs199534	ENSG00000214401.4	KANSL1-AS1	22.94	3.09e-79	2.26e-74	1.18	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46193576~46196723:+
LUAD	cis	rs916888	0.821	rs199505	ENSG00000262539.1	RP11-259G18.3	-22.93	3.41e-79	2.47e-74	-1.14	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46259551~46260606:-
LUAD	cis	rs916888	0.821	rs70602	ENSG00000262539.1	RP11-259G18.3	-22.93	3.41e-79	2.47e-74	-1.14	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46259551~46260606:-
LUAD	cis	rs858239	0.6	rs7341483	ENSG00000230658.1	KLHL7-AS1	-22.93	3.51e-79	2.53e-74	-0.89	-0.72	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23101228~23105703:-
LUAD	cis	rs916888	0.821	rs199504	ENSG00000262539.1	RP11-259G18.3	-22.93	3.53e-79	2.55e-74	-1.13	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46259551~46260606:-
LUAD	cis	rs2882667	0.69	rs311599	ENSG00000253404.1	AC034243.1	22.92	3.78e-79	2.71e-74	0.95	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138718994	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs311597	ENSG00000253404.1	AC034243.1	22.92	3.78e-79	2.71e-74	0.95	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720212	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.6	rs2072369	ENSG00000230658.1	KLHL7-AS1	22.91	4.27e-79	3.05e-74	0.88	0.72	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs13438188	ENSG00000230658.1	KLHL7-AS1	-22.91	4.32e-79	3.09e-74	-0.85	-0.72	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs160398	ENSG00000253404.1	AC034243.1	22.91	4.54e-79	3.23e-74	0.95	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727750	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs13181762	ENSG00000253404.1	AC034243.1	22.9	4.73e-79	3.35e-74	0.93	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914417	chr5:138744434~138753309:-
LUAD	cis	rs3814244	0.528	rs17104682	ENSG00000255733.4	IFNG-AS1	-22.9	4.9e-79	3.46e-74	-0.66	-0.72	Itch intensity from mosquito bite adjusted by bite size;	chr12:68033256	chr12:67989445~68234686:+
LUAD	cis	rs2882667	0.69	rs2693963	ENSG00000253404.1	AC034243.1	-22.9	5.09e-79	3.57e-74	-0.93	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138770637	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs1567313	ENSG00000253404.1	AC034243.1	-22.9	5.09e-79	3.57e-74	-0.93	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138775013	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs700624	ENSG00000253404.1	AC034243.1	-22.89	5.31e-79	3.7e-74	-0.93	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763332	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.587	rs2174972	ENSG00000253404.1	AC034243.1	-22.89	5.31e-79	3.7e-74	-0.93	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138766229	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.601	rs7805206	ENSG00000230658.1	KLHL7-AS1	22.89	5.51e-79	3.83e-74	0.82	0.72	Cerebrospinal fluid biomarker levels;	chr7:23120591	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs1703212	ENSG00000253404.1	AC034243.1	-22.87	6.99e-79	4.82e-74	-0.92	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138742863	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.6	rs2072368	ENSG00000230658.1	KLHL7-AS1	22.87	7.24e-79	4.98e-74	0.88	0.72	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23101228~23105703:-
LUAD	cis	rs916888	0.738	rs199515	ENSG00000262539.1	RP11-259G18.3	-22.84	9.21e-79	6.31e-74	-1.09	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46259551~46260606:-
LUAD	cis	rs858239	0.632	rs13438452	ENSG00000230658.1	KLHL7-AS1	22.82	1.14e-78	7.81e-74	0.88	0.72	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.601	rs10255228	ENSG00000230658.1	KLHL7-AS1	22.82	1.18e-78	8.04e-74	0.88	0.72	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.601	rs1034963	ENSG00000230658.1	KLHL7-AS1	22.82	1.24e-78	8.46e-74	0.87	0.72	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs700629	ENSG00000253404.1	AC034243.1	-22.8	1.49e-78	1.01e-73	-0.92	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138788305	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.6	rs28646184	ENSG00000230658.1	KLHL7-AS1	22.8	1.52e-78	1.03e-73	0.89	0.72	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs311596	ENSG00000253404.1	AC034243.1	-22.8	1.55e-78	1.04e-73	-0.93	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736393	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.601	rs4599714	ENSG00000230658.1	KLHL7-AS1	22.78	1.86e-78	1.25e-73	0.88	0.72	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.601	rs10278776	ENSG00000230658.1	KLHL7-AS1	22.78	1.86e-78	1.25e-73	0.88	0.72	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23101228~23105703:-
LUAD	cis	rs916888	0.821	rs415430	ENSG00000262539.1	RP11-259G18.3	-22.77	1.95e-78	1.3e-73	-1.13	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46259551~46260606:-
LUAD	cis	rs916888	0.779	rs430685	ENSG00000262539.1	RP11-259G18.3	-22.77	1.95e-78	1.3e-73	-1.13	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46259551~46260606:-
LUAD	cis	rs858239	0.601	rs3735228	ENSG00000230658.1	KLHL7-AS1	22.77	1.95e-78	1.3e-73	0.88	0.72	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs9942422	ENSG00000253404.1	AC034243.1	22.74	2.71e-78	1.8e-73	0.95	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936847	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.57	rs10271613	ENSG00000230658.1	KLHL7-AS1	22.74	2.76e-78	1.83e-73	0.87	0.72	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.57	rs10242166	ENSG00000230658.1	KLHL7-AS1	22.74	2.76e-78	1.83e-73	0.87	0.72	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs423469	ENSG00000253404.1	AC034243.1	22.74	2.84e-78	1.88e-73	0.92	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898427	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs160403	ENSG00000253404.1	AC034243.1	22.73	3.04e-78	2.01e-73	0.93	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138722793	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs13158360	ENSG00000253404.1	AC034243.1	22.72	3.59e-78	2.35e-73	0.92	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922488	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.6	rs7787110	ENSG00000230658.1	KLHL7-AS1	22.71	3.82e-78	2.5e-73	0.88	0.72	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23101228~23105703:-
LUAD	cis	rs2739330	0.828	rs5760108	ENSG00000218537.1	MIF-AS1	22.71	4.06e-78	2.65e-73	0.92	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23894426~23898930:-
LUAD	cis	rs2882667	0.69	rs13174008	ENSG00000253404.1	AC034243.1	22.7	4.23e-78	2.75e-73	0.92	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922220	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.828	rs2154593	ENSG00000218537.1	MIF-AS1	22.69	4.71e-78	3.06e-73	0.92	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23894426~23898930:-
LUAD	cis	rs2882667	0.69	rs3804199	ENSG00000253404.1	AC034243.1	-22.66	6.83e-78	4.39e-73	-0.91	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138826440	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs7709789	ENSG00000253404.1	AC034243.1	22.65	8.11e-78	5.2e-73	0.94	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138938762	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.598	rs10078179	ENSG00000253404.1	AC034243.1	22.63	9.95e-78	6.36e-73	0.91	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920410	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.728	rs7722413	ENSG00000253404.1	AC034243.1	22.6	1.31e-77	8.32e-73	0.94	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942562	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.654	rs6862845	ENSG00000253404.1	AC034243.1	22.59	1.46e-77	9.22e-73	0.94	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937456	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs4835708	ENSG00000253404.1	AC034243.1	-22.58	1.58e-77	9.95e-73	-0.91	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844204	chr5:138744434~138753309:-
LUAD	cis	rs916888	0.697	rs199516	ENSG00000262539.1	RP11-259G18.3	-22.57	1.9e-77	1.19e-72	-1.13	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46259551~46260606:-
LUAD	cis	rs858239	0.601	rs1981665	ENSG00000230658.1	KLHL7-AS1	22.55	2.19e-77	1.37e-72	0.88	0.72	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.659	rs12719515	ENSG00000253404.1	AC034243.1	22.55	2.2e-77	1.38e-72	0.91	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905629	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs6877187	ENSG00000253404.1	AC034243.1	-22.54	2.71e-77	1.69e-72	-0.92	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138823655	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.57	rs6968242	ENSG00000230658.1	KLHL7-AS1	22.53	2.91e-77	1.81e-72	0.88	0.72	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.659	rs10056014	ENSG00000253404.1	AC034243.1	22.52	3.04e-77	1.89e-72	0.91	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920329	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs2016720	ENSG00000253404.1	AC034243.1	22.52	3.1e-77	1.92e-72	0.91	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138928369	chr5:138744434~138753309:-
LUAD	cis	rs916888	0.821	rs199512	ENSG00000262539.1	RP11-259G18.3	-22.52	3.18e-77	1.95e-72	-1.12	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46259551~46260606:-
LUAD	cis	rs916888	0.821	rs199509	ENSG00000262539.1	RP11-259G18.3	-22.52	3.18e-77	1.95e-72	-1.12	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46259551~46260606:-
LUAD	cis	rs916888	0.821	rs199507	ENSG00000262539.1	RP11-259G18.3	-22.52	3.18e-77	1.95e-72	-1.12	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46259551~46260606:-
LUAD	cis	rs2739330	0.796	rs2154594	ENSG00000273295.1	AP000350.5	-22.52	3.2e-77	1.97e-72	-0.83	-0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23901432~23907068:-
LUAD	cis	rs2882667	0.69	rs10038162	ENSG00000253404.1	AC034243.1	-22.51	3.72e-77	2.27e-72	-0.91	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901066	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.828	rs2186366	ENSG00000218537.1	MIF-AS1	-22.5	3.96e-77	2.41e-72	-0.92	-0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23894426~23898930:-
LUAD	cis	rs858239	0.601	rs1558313	ENSG00000230658.1	KLHL7-AS1	22.5	3.98e-77	2.41e-72	0.87	0.72	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.601	rs6962526	ENSG00000230658.1	KLHL7-AS1	22.5	3.98e-77	2.41e-72	0.87	0.72	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.539	rs6971673	ENSG00000230658.1	KLHL7-AS1	22.5	3.98e-77	2.41e-72	0.87	0.72	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs7446631	ENSG00000253404.1	AC034243.1	22.49	4.47e-77	2.71e-72	0.91	0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891376	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs700620	ENSG00000253404.1	AC034243.1	-22.47	5.39e-77	3.22e-72	-0.91	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762247	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.659	rs700621	ENSG00000253404.1	AC034243.1	-22.47	5.39e-77	3.22e-72	-0.91	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762741	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.601	rs10278700	ENSG00000230658.1	KLHL7-AS1	22.47	5.4e-77	3.22e-72	0.87	0.72	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.601	rs10263110	ENSG00000230658.1	KLHL7-AS1	22.47	5.4e-77	3.22e-72	0.87	0.72	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.654	rs1095374	ENSG00000253404.1	AC034243.1	-22.45	6.98e-77	4.15e-72	-0.91	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759517	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs10515504	ENSG00000253404.1	AC034243.1	-22.43	8.61e-77	5.1e-72	-0.93	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887305	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.828	rs2877178	ENSG00000218537.1	MIF-AS1	22.42	9.1e-77	5.38e-72	0.92	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23894426~23898930:-
LUAD	cis	rs858239	0.601	rs11982002	ENSG00000230658.1	KLHL7-AS1	22.42	1e-76	5.93e-72	0.87	0.71	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.601	rs929507	ENSG00000230658.1	KLHL7-AS1	22.4	1.24e-76	7.33e-72	0.87	0.71	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.601	rs929508	ENSG00000230658.1	KLHL7-AS1	22.4	1.24e-76	7.33e-72	0.87	0.71	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.728	rs10037071	ENSG00000253404.1	AC034243.1	22.39	1.35e-76	7.92e-72	0.93	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942158	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs3763016	ENSG00000253404.1	AC034243.1	22.36	1.82e-76	1.07e-71	0.92	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935043	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.6	rs1115941	ENSG00000230658.1	KLHL7-AS1	22.35	1.98e-76	1.16e-71	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs6890932	ENSG00000253404.1	AC034243.1	22.35	2.04e-76	1.19e-71	0.9	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138910639	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.6	rs7776649	ENSG00000230658.1	KLHL7-AS1	22.34	2.25e-76	1.31e-71	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs825749	ENSG00000253404.1	AC034243.1	-22.34	2.26e-76	1.31e-71	-0.93	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800232	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.6	rs4628176	ENSG00000230658.1	KLHL7-AS1	22.34	2.27e-76	1.32e-71	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23101228~23105703:-
LUAD	cis	rs916888	0.773	rs199448	ENSG00000214401.4	KANSL1-AS1	22.34	2.42e-76	1.4e-71	1.12	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46193576~46196723:+
LUAD	cis	rs2882667	0.69	rs9327830	ENSG00000253404.1	AC034243.1	22.33	2.71e-76	1.57e-71	0.93	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936560	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs160400	ENSG00000253404.1	AC034243.1	-22.32	2.91e-76	1.68e-71	-0.93	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727330	chr5:138744434~138753309:-
LUAD	cis	rs916888	0.821	rs199514	ENSG00000262539.1	RP11-259G18.3	-22.31	3.19e-76	1.84e-71	-1.13	-0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46259551~46260606:-
LUAD	cis	rs858239	0.57	rs10235467	ENSG00000230658.1	KLHL7-AS1	22.31	3.22e-76	1.85e-71	0.86	0.71	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs28483572	ENSG00000230658.1	KLHL7-AS1	22.29	4.05e-76	2.32e-71	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs906695	ENSG00000253404.1	AC034243.1	22.28	4.27e-76	2.44e-71	0.91	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138803588	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.601	rs6948469	ENSG00000230658.1	KLHL7-AS1	22.28	4.5e-76	2.57e-71	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs13177415	ENSG00000253404.1	AC034243.1	22.28	4.69e-76	2.67e-71	0.9	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914251	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.654	rs700626	ENSG00000253404.1	AC034243.1	-22.25	6.12e-76	3.49e-71	-0.93	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138782249	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.658	rs10076442	ENSG00000253404.1	AC034243.1	22.25	6.32e-76	3.58e-71	0.93	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941090	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.541	rs4624924	ENSG00000230658.1	KLHL7-AS1	22.23	7.46e-76	4.22e-71	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs9691762	ENSG00000230658.1	KLHL7-AS1	22.22	8.37e-76	4.72e-71	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.601	rs987257	ENSG00000230658.1	KLHL7-AS1	22.22	9e-76	5.07e-71	0.86	0.71	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23101228~23105703:-
LUAD	cis	rs916888	0.773	rs199457	ENSG00000214401.4	KANSL1-AS1	22.2	1.12e-75	6.32e-71	1.16	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46193576~46196723:+
LUAD	cis	rs2739330	0.828	rs4822454	ENSG00000218537.1	MIF-AS1	22.19	1.18e-75	6.62e-71	0.92	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23894426~23898930:-
LUAD	cis	rs858239	0.6	rs10256359	ENSG00000230658.1	KLHL7-AS1	22.18	1.42e-75	7.91e-71	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs2003555	ENSG00000230658.1	KLHL7-AS1	22.17	1.55e-75	8.62e-71	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs7784929	ENSG00000230658.1	KLHL7-AS1	22.17	1.55e-75	8.62e-71	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs6961406	ENSG00000230658.1	KLHL7-AS1	22.17	1.58e-75	8.76e-71	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs6461690	ENSG00000230658.1	KLHL7-AS1	22.17	1.58e-75	8.76e-71	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs6967419	ENSG00000230658.1	KLHL7-AS1	22.17	1.58e-75	8.76e-71	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23101228~23105703:-
LUAD	cis	rs2739330	0.791	rs4822458	ENSG00000273295.1	AP000350.5	22.15	1.94e-75	1.07e-70	0.8	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23901432~23907068:-
LUAD	cis	rs858239	0.6	rs7799422	ENSG00000230658.1	KLHL7-AS1	22.14	2.13e-75	1.17e-70	0.89	0.71	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs10241208	ENSG00000230658.1	KLHL7-AS1	22.12	2.6e-75	1.43e-70	0.86	0.71	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs10488077	ENSG00000230658.1	KLHL7-AS1	22.1	3.3e-75	1.81e-70	0.87	0.71	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs7776644	ENSG00000230658.1	KLHL7-AS1	22.08	4.01e-75	2.2e-70	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23101228~23105703:-
LUAD	cis	rs916888	0.687	rs199456	ENSG00000214401.4	KANSL1-AS1	22.06	4.76e-75	2.6e-70	1.16	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46193576~46196723:+
LUAD	cis	rs916888	0.773	rs199451	ENSG00000214401.4	KANSL1-AS1	22.04	5.94e-75	3.24e-70	1.16	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46193576~46196723:+
LUAD	cis	rs2882667	0.69	rs288022	ENSG00000253404.1	AC034243.1	22.04	6.14e-75	3.34e-70	0.91	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888586	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.598	rs288020	ENSG00000253404.1	AC034243.1	22.04	6.14e-75	3.34e-70	0.91	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888609	chr5:138744434~138753309:-
LUAD	cis	rs916888	0.779	rs199528	ENSG00000214401.4	KANSL1-AS1	22.03	6.75e-75	3.66e-70	1.17	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46193576~46196723:+
LUAD	cis	rs916888	0.821	rs199525	ENSG00000214401.4	KANSL1-AS1	22.03	6.75e-75	3.66e-70	1.17	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46193576~46196723:+
LUAD	cis	rs858239	0.601	rs6971002	ENSG00000230658.1	KLHL7-AS1	22.02	8.12e-75	4.39e-70	0.87	0.71	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs9327831	ENSG00000253404.1	AC034243.1	22	9.61e-75	5.19e-70	0.92	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936597	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs6596455	ENSG00000253404.1	AC034243.1	-21.96	1.46e-74	7.85e-70	-0.93	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831416	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs995177	ENSG00000253404.1	AC034243.1	-21.96	1.46e-74	7.85e-70	-0.93	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138833874	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.654	rs7710300	ENSG00000253404.1	AC034243.1	-21.96	1.46e-74	7.85e-70	-0.93	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138834793	chr5:138744434~138753309:-
LUAD	cis	rs1577917	0.56	rs9450288	ENSG00000203875.9	SNHG5	21.96	1.52e-74	8.12e-70	0.83	0.71	Response to antipsychotic treatment;	chr6:85511868	chr6:85660950~85678736:-
LUAD	cis	rs2882667	0.69	rs288018	ENSG00000253404.1	AC034243.1	-21.96	1.58e-74	8.47e-70	-0.93	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138856727	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288035	ENSG00000253404.1	AC034243.1	21.95	1.65e-74	8.79e-70	0.93	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138876728	chr5:138744434~138753309:-
LUAD	cis	rs3814244	0.528	rs2870960	ENSG00000255733.4	IFNG-AS1	21.94	1.81e-74	9.61e-70	0.65	0.71	Itch intensity from mosquito bite adjusted by bite size;	chr12:68032848	chr12:67989445~68234686:+
LUAD	cis	rs916888	0.61	rs199529	ENSG00000262539.1	RP11-259G18.3	21.93	2.19e-74	1.16e-69	1.08	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46259551~46260606:-
LUAD	cis	rs9322193	0.736	rs10457851	ENSG00000231760.4	RP11-350J20.5	21.91	2.47e-74	1.28e-69	0.88	0.71	Lung cancer;	chr6:149775216	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.886	rs10872652	ENSG00000231760.4	RP11-350J20.5	21.91	2.47e-74	1.28e-69	0.88	0.71	Lung cancer;	chr6:149775303	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.886	rs17672976	ENSG00000231760.4	RP11-350J20.5	21.91	2.47e-74	1.28e-69	0.88	0.71	Lung cancer;	chr6:149776207	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs2184369	ENSG00000231760.4	RP11-350J20.5	21.91	2.47e-74	1.28e-69	0.88	0.71	Lung cancer;	chr6:149776681	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs2342861	ENSG00000231760.4	RP11-350J20.5	21.91	2.47e-74	1.28e-69	0.88	0.71	Lung cancer;	chr6:149777561	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.926	rs2342860	ENSG00000231760.4	RP11-350J20.5	21.91	2.47e-74	1.28e-69	0.88	0.71	Lung cancer;	chr6:149777641	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs10872653	ENSG00000231760.4	RP11-350J20.5	21.91	2.47e-74	1.28e-69	0.88	0.71	Lung cancer;	chr6:149778907	chr6:149796151~149826294:-
LUAD	cis	rs858239	0.632	rs7811903	ENSG00000230658.1	KLHL7-AS1	21.91	2.59e-74	1.34e-69	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23101228~23105703:-
LUAD	cis	rs3814244	0.528	rs7306466	ENSG00000255733.4	IFNG-AS1	21.89	3.25e-74	1.68e-69	0.64	0.71	Itch intensity from mosquito bite adjusted by bite size;	chr12:68014942	chr12:67989445~68234686:+
LUAD	cis	rs3814244	0.528	rs56393928	ENSG00000255733.4	IFNG-AS1	21.89	3.39e-74	1.75e-69	0.65	0.71	Itch intensity from mosquito bite adjusted by bite size;	chr12:68029927	chr12:67989445~68234686:+
LUAD	cis	rs3814244	0.528	rs12228471	ENSG00000255733.4	IFNG-AS1	21.88	3.62e-74	1.87e-69	0.65	0.71	Itch intensity from mosquito bite adjusted by bite size;	chr12:68027842	chr12:67989445~68234686:+
LUAD	cis	rs2882667	0.69	rs288040	ENSG00000253404.1	AC034243.1	21.88	3.82e-74	1.97e-69	0.93	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138869205	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288036	ENSG00000253404.1	AC034243.1	21.86	4.36e-74	2.23e-69	0.93	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138875206	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288017	ENSG00000253404.1	AC034243.1	-21.86	4.36e-74	2.23e-69	-0.93	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138857826	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs167009	ENSG00000253404.1	AC034243.1	-21.86	4.36e-74	2.23e-69	-0.93	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864768	chr5:138744434~138753309:-
LUAD	cis	rs9322193	0.962	rs12175575	ENSG00000231760.4	RP11-350J20.5	21.84	5.85e-74	2.96e-69	0.88	0.71	Lung cancer;	chr6:149763351	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs4869966	ENSG00000231760.4	RP11-350J20.5	21.84	5.85e-74	2.96e-69	0.88	0.71	Lung cancer;	chr6:149763714	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs1112730	ENSG00000231760.4	RP11-350J20.5	21.84	5.85e-74	2.96e-69	0.88	0.71	Lung cancer;	chr6:149766383	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs1112729	ENSG00000231760.4	RP11-350J20.5	21.84	5.85e-74	2.96e-69	0.88	0.71	Lung cancer;	chr6:149766491	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs10452626	ENSG00000231760.4	RP11-350J20.5	21.84	5.85e-74	2.96e-69	0.88	0.71	Lung cancer;	chr6:149767481	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs62441303	ENSG00000231760.4	RP11-350J20.5	21.84	5.85e-74	2.96e-69	0.88	0.71	Lung cancer;	chr6:149767547	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs2342857	ENSG00000231760.4	RP11-350J20.5	21.83	6.36e-74	3.22e-69	0.89	0.71	Lung cancer;	chr6:149809537	chr6:149796151~149826294:-
LUAD	cis	rs2882667	0.622	rs34645817	ENSG00000253404.1	AC034243.1	-21.82	6.75e-74	3.4e-69	-0.94	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816944	chr5:138744434~138753309:-
LUAD	cis	rs9322193	0.884	rs11155689	ENSG00000231760.4	RP11-350J20.5	21.82	6.8e-74	3.41e-69	0.88	0.71	Lung cancer;	chr6:149808470	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.884	rs933055	ENSG00000231760.4	RP11-350J20.5	21.82	6.8e-74	3.41e-69	0.88	0.71	Lung cancer;	chr6:149809701	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs4869731	ENSG00000231760.4	RP11-350J20.5	21.82	6.8e-74	3.41e-69	0.88	0.71	Lung cancer;	chr6:149810072	chr6:149796151~149826294:-
LUAD	cis	rs2882667	0.619	rs6861556	ENSG00000253404.1	AC034243.1	-21.81	7.59e-74	3.8e-69	-0.93	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138852351	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.796	rs1006771	ENSG00000273295.1	AP000350.5	21.8	8.65e-74	4.32e-69	0.82	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23901432~23907068:-
LUAD	cis	rs2882667	0.69	rs288032	ENSG00000253404.1	AC034243.1	21.8	8.9e-74	4.43e-69	0.93	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138879639	chr5:138744434~138753309:-
LUAD	cis	rs916888	0.773	rs1378358	ENSG00000214401.4	KANSL1-AS1	21.8	9.09e-74	4.51e-69	1.15	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46193576~46196723:+
LUAD	cis	rs2739330	0.828	rs5760107	ENSG00000218537.1	MIF-AS1	21.79	1.02e-73	5.05e-69	0.91	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23894426~23898930:-
LUAD	cis	rs2739330	0.789	rs5760109	ENSG00000218537.1	MIF-AS1	21.79	1.02e-73	5.05e-69	0.91	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23894426~23898930:-
LUAD	cis	rs2882667	0.654	rs2351247	ENSG00000253404.1	AC034243.1	-21.78	1.1e-73	5.44e-69	-0.93	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849456	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.601	rs10224327	ENSG00000230658.1	KLHL7-AS1	21.78	1.13e-73	5.56e-69	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23122201	chr7:23101228~23105703:-
LUAD	cis	rs916888	0.773	rs169201	ENSG00000214401.4	KANSL1-AS1	21.78	1.14e-73	5.59e-69	1.15	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46193576~46196723:+
LUAD	cis	rs2882667	0.69	rs7736925	ENSG00000253404.1	AC034243.1	-21.75	1.51e-73	7.36e-69	-0.93	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818841	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.654	rs883333	ENSG00000253404.1	AC034243.1	-21.75	1.51e-73	7.36e-69	-0.93	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819781	chr5:138744434~138753309:-
LUAD	cis	rs9322193	0.962	rs3805748	ENSG00000231760.4	RP11-350J20.5	21.74	1.64e-73	7.98e-69	0.88	0.7	Lung cancer;	chr6:149772542	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.886	rs12525871	ENSG00000231760.4	RP11-350J20.5	21.74	1.64e-73	7.98e-69	0.88	0.7	Lung cancer;	chr6:149775882	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs13215691	ENSG00000231760.4	RP11-350J20.5	21.74	1.74e-73	8.42e-69	0.88	0.7	Lung cancer;	chr6:149792666	chr6:149796151~149826294:-
LUAD	cis	rs3814244	0.528	rs12582272	ENSG00000255733.4	IFNG-AS1	21.73	1.84e-73	8.93e-69	0.65	0.7	Itch intensity from mosquito bite adjusted by bite size;	chr12:68006298	chr12:67989445~68234686:+
LUAD	cis	rs9322193	0.962	rs9765929	ENSG00000231760.4	RP11-350J20.5	21.73	1.96e-73	9.45e-69	0.88	0.7	Lung cancer;	chr6:149769680	chr6:149796151~149826294:-
LUAD	cis	rs858239	0.509	rs57611130	ENSG00000230658.1	KLHL7-AS1	21.73	1.98e-73	9.55e-69	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23144933	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs10266123	ENSG00000230658.1	KLHL7-AS1	21.7	2.51e-73	1.2e-68	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23101228~23105703:-
LUAD	cis	rs916888	0.773	rs199445	ENSG00000214401.4	KANSL1-AS1	21.7	2.64e-73	1.26e-68	1.14	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46193576~46196723:+
LUAD	cis	rs916888	0.773	rs199443	ENSG00000214401.4	KANSL1-AS1	21.7	2.64e-73	1.26e-68	1.14	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46193576~46196723:+
LUAD	cis	rs2739330	0.627	rs9608219	ENSG00000273295.1	AP000350.5	21.68	3.2e-73	1.52e-68	0.8	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23901432~23907068:-
LUAD	cis	rs9322193	0.923	rs9479810	ENSG00000231760.4	RP11-350J20.5	21.68	3.31e-73	1.57e-68	0.88	0.7	Lung cancer;	chr6:149751359	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.828	rs2330635	ENSG00000218537.1	MIF-AS1	21.68	3.35e-73	1.58e-68	0.91	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23894426~23898930:-
LUAD	cis	rs9322193	0.926	rs3805751	ENSG00000231760.4	RP11-350J20.5	21.66	3.89e-73	1.84e-68	0.88	0.7	Lung cancer;	chr6:149791193	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs10872656	ENSG00000231760.4	RP11-350J20.5	21.66	3.89e-73	1.84e-68	0.88	0.7	Lung cancer;	chr6:149799444	chr6:149796151~149826294:-
LUAD	cis	rs858239	0.601	rs4140959	ENSG00000230658.1	KLHL7-AS1	21.66	3.94e-73	1.86e-68	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.628	rs311606	ENSG00000253404.1	AC034243.1	21.66	4.09e-73	1.93e-68	0.94	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138709551	chr5:138744434~138753309:-
LUAD	cis	rs9322193	0.962	rs4869730	ENSG00000231760.4	RP11-350J20.5	21.65	4.35e-73	2.04e-68	0.88	0.7	Lung cancer;	chr6:149808187	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs2151913	ENSG00000231760.4	RP11-350J20.5	21.65	4.35e-73	2.04e-68	0.88	0.7	Lung cancer;	chr6:149809506	chr6:149796151~149826294:-
LUAD	cis	rs2882667	0.728	rs10068766	ENSG00000253404.1	AC034243.1	21.65	4.43e-73	2.07e-68	0.92	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941095	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.659	rs288037	ENSG00000253404.1	AC034243.1	21.65	4.72e-73	2.2e-68	0.93	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138872752	chr5:138744434~138753309:-
LUAD	cis	rs9322193	0.962	rs3805753	ENSG00000231760.4	RP11-350J20.5	21.65	4.72e-73	2.2e-68	0.87	0.7	Lung cancer;	chr6:149795662	chr6:149796151~149826294:-
LUAD	cis	rs2882667	0.554	rs1368425	ENSG00000253404.1	AC034243.1	21.64	4.98e-73	2.32e-68	0.92	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944528	chr5:138744434~138753309:-
LUAD	cis	rs9322193	0.923	rs11155683	ENSG00000231760.4	RP11-350J20.5	21.63	5.38e-73	2.47e-68	0.87	0.7	Lung cancer;	chr6:149779341	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9372044	ENSG00000231760.4	RP11-350J20.5	21.63	5.38e-73	2.47e-68	0.87	0.7	Lung cancer;	chr6:149780867	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs11155685	ENSG00000231760.4	RP11-350J20.5	21.63	5.38e-73	2.47e-68	0.87	0.7	Lung cancer;	chr6:149781649	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs9689269	ENSG00000231760.4	RP11-350J20.5	21.63	5.38e-73	2.47e-68	0.87	0.7	Lung cancer;	chr6:149791861	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs62441335	ENSG00000231760.4	RP11-350J20.5	21.63	5.38e-73	2.47e-68	0.87	0.7	Lung cancer;	chr6:149792658	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs4816	ENSG00000231760.4	RP11-350J20.5	21.63	5.38e-73	2.47e-68	0.87	0.7	Lung cancer;	chr6:149793609	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.926	rs952166	ENSG00000231760.4	RP11-350J20.5	21.63	5.38e-73	2.47e-68	0.87	0.7	Lung cancer;	chr6:149798774	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs952165	ENSG00000231760.4	RP11-350J20.5	21.63	5.38e-73	2.47e-68	0.87	0.7	Lung cancer;	chr6:149798900	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.926	rs9285525	ENSG00000231760.4	RP11-350J20.5	21.63	5.38e-73	2.47e-68	0.87	0.7	Lung cancer;	chr6:149801253	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.884	rs2342858	ENSG00000231760.4	RP11-350J20.5	21.63	5.38e-73	2.47e-68	0.87	0.7	Lung cancer;	chr6:149805967	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.884	rs2095375	ENSG00000231760.4	RP11-350J20.5	21.63	5.38e-73	2.47e-68	0.87	0.7	Lung cancer;	chr6:149807037	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs4552	ENSG00000231760.4	RP11-350J20.5	21.63	5.74e-73	2.62e-68	0.88	0.7	Lung cancer;	chr6:149811183	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs9505974	ENSG00000231760.4	RP11-350J20.5	21.63	5.88e-73	2.68e-68	0.88	0.7	Lung cancer;	chr6:149779294	chr6:149796151~149826294:-
LUAD	cis	rs2882667	0.69	rs160404	ENSG00000253404.1	AC034243.1	21.62	6.23e-73	2.84e-68	0.88	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748580	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.539	rs10280815	ENSG00000230658.1	KLHL7-AS1	21.61	7.13e-73	3.24e-68	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23148751	chr7:23101228~23105703:-
LUAD	cis	rs3814244	0.528	rs61923060	ENSG00000255733.4	IFNG-AS1	21.61	7.43e-73	3.37e-68	0.65	0.7	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997341	chr12:67989445~68234686:+
LUAD	cis	rs1577917	0.654	rs9450284	ENSG00000203875.9	SNHG5	21.59	8.35e-73	3.78e-68	0.86	0.7	Response to antipsychotic treatment;	chr6:85489611	chr6:85660950~85678736:-
LUAD	cis	rs916888	0.773	rs199447	ENSG00000214401.4	KANSL1-AS1	21.59	8.47e-73	3.83e-68	1.17	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46193576~46196723:+
LUAD	cis	rs2882667	0.654	rs7709770	ENSG00000253404.1	AC034243.1	-21.58	1.03e-72	4.65e-68	-0.94	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138813650	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.828	rs5760102	ENSG00000218537.1	MIF-AS1	21.57	1.09e-72	4.91e-68	0.91	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23894426~23898930:-
LUAD	cis	rs858239	0.539	rs10225608	ENSG00000230658.1	KLHL7-AS1	21.56	1.27e-72	5.7e-68	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23149289	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs6461691	ENSG00000230658.1	KLHL7-AS1	21.55	1.31e-72	5.86e-68	0.86	0.7	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23101228~23105703:-
LUAD	cis	rs9322193	0.962	rs6914319	ENSG00000231760.4	RP11-350J20.5	21.55	1.38e-72	6.16e-68	0.88	0.7	Lung cancer;	chr6:149806304	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.828	rs4822451	ENSG00000218537.1	MIF-AS1	21.55	1.39e-72	6.22e-68	0.91	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23894426~23898930:-
LUAD	cis	rs2739330	0.828	rs5760098	ENSG00000218537.1	MIF-AS1	21.55	1.39e-72	6.22e-68	0.91	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23894426~23898930:-
LUAD	cis	rs916888	0.773	rs199439	ENSG00000214401.4	KANSL1-AS1	21.55	1.42e-72	6.33e-68	1.13	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46193576~46196723:+
LUAD	cis	rs2739330	0.796	rs5760097	ENSG00000218537.1	MIF-AS1	21.55	1.43e-72	6.37e-68	0.91	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23894426~23898930:-
LUAD	cis	rs2739330	0.828	rs5760099	ENSG00000218537.1	MIF-AS1	21.55	1.44e-72	6.39e-68	0.91	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23894426~23898930:-
LUAD	cis	rs9326248	0.861	rs1871757	ENSG00000254851.1	RP11-109L13.1	-21.54	1.55e-72	6.89e-68	-1.04	-0.7	Blood protein levels;	chr11:117159865	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.861	rs4938352	ENSG00000254851.1	RP11-109L13.1	-21.52	1.81e-72	8.04e-68	-1.05	-0.7	Blood protein levels;	chr11:117156765	chr11:117135528~117138582:+
LUAD	cis	rs858239	0.571	rs2390755	ENSG00000230658.1	KLHL7-AS1	21.51	2.06e-72	9.12e-68	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23151097	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.539	rs4365988	ENSG00000230658.1	KLHL7-AS1	21.51	2.06e-72	9.12e-68	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23151252	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.539	rs28624974	ENSG00000230658.1	KLHL7-AS1	21.51	2.07e-72	9.12e-68	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23149317	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.539	rs6955726	ENSG00000230658.1	KLHL7-AS1	21.51	2.15e-72	9.45e-68	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23147072	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.539	rs6976957	ENSG00000230658.1	KLHL7-AS1	21.51	2.15e-72	9.45e-68	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23147714	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.539	rs6956828	ENSG00000230658.1	KLHL7-AS1	21.51	2.15e-72	9.45e-68	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23147728	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.539	rs4294098	ENSG00000230658.1	KLHL7-AS1	21.5	2.45e-72	1.07e-67	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23146376	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.539	rs6955969	ENSG00000230658.1	KLHL7-AS1	21.5	2.46e-72	1.08e-67	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23147080	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.601	rs10239760	ENSG00000230658.1	KLHL7-AS1	21.49	2.51e-72	1.1e-67	0.86	0.7	Cerebrospinal fluid biomarker levels;	chr7:23110331	chr7:23101228~23105703:-
LUAD	cis	rs9322193	0.923	rs10872645	ENSG00000231760.4	RP11-350J20.5	21.49	2.74e-72	1.2e-67	0.88	0.7	Lung cancer;	chr6:149742840	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs12211511	ENSG00000231760.4	RP11-350J20.5	21.49	2.74e-72	1.2e-67	0.88	0.7	Lung cancer;	chr6:149745206	chr6:149796151~149826294:-
LUAD	cis	rs858239	0.601	rs6461693	ENSG00000230658.1	KLHL7-AS1	-21.49	2.76e-72	1.2e-67	-0.85	-0.7	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23101228~23105703:-
LUAD	cis	rs9326248	0.768	rs4936366	ENSG00000254851.1	RP11-109L13.1	-21.48	2.78e-72	1.21e-67	-1.05	-0.7	Blood protein levels;	chr11:117156169	chr11:117135528~117138582:+
LUAD	cis	rs9322193	0.926	rs9689036	ENSG00000231760.4	RP11-350J20.5	21.48	2.8e-72	1.21e-67	0.87	0.7	Lung cancer;	chr6:149780563	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs9322218	ENSG00000231760.4	RP11-350J20.5	21.48	2.8e-72	1.21e-67	0.87	0.7	Lung cancer;	chr6:149782183	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs9322219	ENSG00000231760.4	RP11-350J20.5	21.48	2.8e-72	1.21e-67	0.87	0.7	Lung cancer;	chr6:149782263	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs9322223	ENSG00000231760.4	RP11-350J20.5	21.48	2.8e-72	1.21e-67	0.87	0.7	Lung cancer;	chr6:149801509	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs9689447	ENSG00000231760.4	RP11-350J20.5	21.48	2.92e-72	1.26e-67	0.88	0.7	Lung cancer;	chr6:149789350	chr6:149796151~149826294:-
LUAD	cis	rs9326248	0.727	rs4938347	ENSG00000254851.1	RP11-109L13.1	-21.48	2.97e-72	1.28e-67	-1.05	-0.7	Blood protein levels;	chr11:117151043	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.813	rs4938350	ENSG00000254851.1	RP11-109L13.1	-21.48	2.97e-72	1.28e-67	-1.05	-0.7	Blood protein levels;	chr11:117151560	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.652	rs7128382	ENSG00000254851.1	RP11-109L13.1	-21.47	3.11e-72	1.34e-67	-1.05	-0.7	Blood protein levels;	chr11:117152771	chr11:117135528~117138582:+
LUAD	cis	rs9322193	0.962	rs2065664	ENSG00000231760.4	RP11-350J20.5	21.47	3.12e-72	1.34e-67	0.89	0.7	Lung cancer;	chr6:149762485	chr6:149796151~149826294:-
LUAD	cis	rs5850	0.557	rs10270788	ENSG00000230658.1	KLHL7-AS1	21.47	3.16e-72	1.35e-67	0.87	0.7	Blood protein levels;	chr7:23149381	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.539	rs28716381	ENSG00000230658.1	KLHL7-AS1	21.47	3.16e-72	1.35e-67	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23149396	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.601	rs764534	ENSG00000230658.1	KLHL7-AS1	21.47	3.17e-72	1.35e-67	0.86	0.7	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.601	rs2068459	ENSG00000230658.1	KLHL7-AS1	21.47	3.17e-72	1.35e-67	0.86	0.7	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.601	rs73272053	ENSG00000230658.1	KLHL7-AS1	21.47	3.17e-72	1.35e-67	0.86	0.7	Cerebrospinal fluid biomarker levels;	chr7:23115906	chr7:23101228~23105703:-
LUAD	cis	rs9326248	0.813	rs7115562	ENSG00000254851.1	RP11-109L13.1	-21.47	3.22e-72	1.37e-67	-1.05	-0.7	Blood protein levels;	chr11:117149754	chr11:117135528~117138582:+
LUAD	cis	rs9322193	0.962	rs7818	ENSG00000231760.4	RP11-350J20.5	21.44	4.65e-72	1.97e-67	0.85	0.7	Lung cancer;	chr6:149810956	chr6:149796151~149826294:-
LUAD	cis	rs858239	0.539	rs57864591	ENSG00000230658.1	KLHL7-AS1	21.44	4.72e-72	1.99e-67	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23144805	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.602	rs6953996	ENSG00000230658.1	KLHL7-AS1	21.43	5.26e-72	2.22e-67	0.88	0.7	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.539	rs7791200	ENSG00000230658.1	KLHL7-AS1	21.42	5.76e-72	2.43e-67	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23142502	chr7:23101228~23105703:-
LUAD	cis	rs3814244	0.528	rs11177002	ENSG00000255733.4	IFNG-AS1	21.42	5.8e-72	2.44e-67	0.64	0.7	Itch intensity from mosquito bite adjusted by bite size;	chr12:68003377	chr12:67989445~68234686:+
LUAD	cis	rs858239	0.539	rs4504540	ENSG00000230658.1	KLHL7-AS1	21.41	6.1e-72	2.56e-67	0.86	0.7	Cerebrospinal fluid biomarker levels;	chr7:23146579	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.509	rs6975524	ENSG00000230658.1	KLHL7-AS1	21.41	6.1e-72	2.56e-67	0.86	0.7	Cerebrospinal fluid biomarker levels;	chr7:23146833	chr7:23101228~23105703:-
LUAD	cis	rs9326248	0.861	rs7120309	ENSG00000254851.1	RP11-109L13.1	-21.41	6.48e-72	2.71e-67	-1.04	-0.7	Blood protein levels;	chr11:117172100	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.861	rs7120449	ENSG00000254851.1	RP11-109L13.1	-21.41	6.48e-72	2.71e-67	-1.04	-0.7	Blood protein levels;	chr11:117172183	chr11:117135528~117138582:+
LUAD	cis	rs9322193	0.736	rs3828701	ENSG00000231760.4	RP11-350J20.5	21.41	6.5e-72	2.71e-67	0.88	0.7	Lung cancer;	chr6:149791063	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.736	rs3805750	ENSG00000231760.4	RP11-350J20.5	21.41	6.5e-72	2.71e-67	0.88	0.7	Lung cancer;	chr6:149791065	chr6:149796151~149826294:-
LUAD	cis	rs3814244	0.528	rs10878723	ENSG00000255733.4	IFNG-AS1	21.4	7.25e-72	3.02e-67	0.64	0.7	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005493	chr12:67989445~68234686:+
LUAD	cis	rs858239	0.6	rs61292332	ENSG00000230658.1	KLHL7-AS1	21.4	7.36e-72	3.05e-67	0.86	0.7	Cerebrospinal fluid biomarker levels;	chr7:23092243	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs59073109	ENSG00000230658.1	KLHL7-AS1	21.4	7.36e-72	3.05e-67	0.86	0.7	Cerebrospinal fluid biomarker levels;	chr7:23093607	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs7788821	ENSG00000230658.1	KLHL7-AS1	21.4	7.36e-72	3.05e-67	0.86	0.7	Cerebrospinal fluid biomarker levels;	chr7:23094026	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs6956595	ENSG00000230658.1	KLHL7-AS1	21.4	7.36e-72	3.05e-67	0.86	0.7	Cerebrospinal fluid biomarker levels;	chr7:23094637	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.539	rs1358442	ENSG00000230658.1	KLHL7-AS1	21.4	7.42e-72	3.07e-67	0.86	0.7	Cerebrospinal fluid biomarker levels;	chr7:23150120	chr7:23101228~23105703:-
LUAD	cis	rs9326248	0.861	rs7931335	ENSG00000254851.1	RP11-109L13.1	-21.38	8.9e-72	3.68e-67	-1.04	-0.7	Blood protein levels;	chr11:117166089	chr11:117135528~117138582:+
LUAD	cis	rs2882667	0.69	rs10155636	ENSG00000253404.1	AC034243.1	21.38	9.28e-72	3.83e-67	0.93	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926301	chr5:138744434~138753309:-
LUAD	cis	rs9322193	0.632	rs3828700	ENSG00000231760.4	RP11-350J20.5	21.35	1.2e-71	4.92e-67	0.87	0.7	Lung cancer;	chr6:149791033	chr6:149796151~149826294:-
LUAD	cis	rs9326248	0.813	rs588534	ENSG00000254851.1	RP11-109L13.1	-21.35	1.21e-71	4.99e-67	-1.06	-0.7	Blood protein levels;	chr11:117197788	chr11:117135528~117138582:+
LUAD	cis	rs2882667	0.654	rs825760	ENSG00000253404.1	AC034243.1	-21.34	1.35e-71	5.54e-67	-0.95	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804285	chr5:138744434~138753309:-
LUAD	cis	rs916888	0.773	rs538628	ENSG00000214401.4	KANSL1-AS1	21.34	1.38e-71	5.65e-67	1.12	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46193576~46196723:+
LUAD	cis	rs3814244	0.569	rs11177008	ENSG00000255733.4	IFNG-AS1	21.31	1.84e-71	7.54e-67	0.65	0.7	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021024	chr12:67989445~68234686:+
LUAD	cis	rs9322193	0.962	rs17673294	ENSG00000231760.4	RP11-350J20.5	21.3	2.22e-71	9.04e-67	0.88	0.7	Lung cancer;	chr6:149813857	chr6:149796151~149826294:-
LUAD	cis	rs858239	0.632	rs1985769	ENSG00000230658.1	KLHL7-AS1	21.28	2.7e-71	1.09e-66	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs28499396	ENSG00000230658.1	KLHL7-AS1	21.28	2.7e-71	1.09e-66	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs7789237	ENSG00000230658.1	KLHL7-AS1	21.28	2.7e-71	1.09e-66	0.87	0.7	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs4321896	ENSG00000230658.1	KLHL7-AS1	21.26	3.28e-71	1.32e-66	0.86	0.7	Cerebrospinal fluid biomarker levels;	chr7:23088437	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs311608	ENSG00000253404.1	AC034243.1	21.26	3.41e-71	1.38e-66	0.92	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138708000	chr5:138744434~138753309:-
LUAD	cis	rs9326248	0.861	rs4938348	ENSG00000254851.1	RP11-109L13.1	-21.25	3.55e-71	1.43e-66	-1.05	-0.7	Blood protein levels;	chr11:117151161	chr11:117135528~117138582:+
LUAD	cis	rs858239	0.601	rs12539331	ENSG00000230658.1	KLHL7-AS1	21.24	3.89e-71	1.56e-66	0.86	0.7	Cerebrospinal fluid biomarker levels;	chr7:23111711	chr7:23101228~23105703:-
LUAD	cis	rs9326248	0.817	rs6589598	ENSG00000254851.1	RP11-109L13.1	-21.24	4.12e-71	1.65e-66	-0.98	-0.7	Blood protein levels;	chr11:117131687	chr11:117135528~117138582:+
LUAD	cis	rs2882667	0.69	rs4835703	ENSG00000253404.1	AC034243.1	-21.23	4.55e-71	1.82e-66	-0.93	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815048	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.654	rs4835704	ENSG00000253404.1	AC034243.1	-21.23	4.55e-71	1.82e-66	-0.93	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815636	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs6596453	ENSG00000253404.1	AC034243.1	-21.23	4.55e-71	1.82e-66	-0.93	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816202	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs825747	ENSG00000253404.1	AC034243.1	-21.22	4.87e-71	1.94e-66	-0.92	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800896	chr5:138744434~138753309:-
LUAD	cis	rs9322193	0.962	rs3763162	ENSG00000231760.4	RP11-350J20.5	-21.21	5.71e-71	2.27e-66	-0.87	-0.7	Lung cancer;	chr6:149819674	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs1413655	ENSG00000231760.4	RP11-350J20.5	21.2	6.07e-71	2.41e-66	0.88	0.7	Lung cancer;	chr6:149821815	chr6:149796151~149826294:-
LUAD	cis	rs2882667	0.69	rs10054682	ENSG00000253404.1	AC034243.1	21.19	7.1e-71	2.81e-66	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923754	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs11953339	ENSG00000253404.1	AC034243.1	21.19	7.1e-71	2.81e-66	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923853	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs9327828	ENSG00000253404.1	AC034243.1	21.19	7.1e-71	2.81e-66	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925859	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.628	rs311605	ENSG00000253404.1	AC034243.1	21.19	7.23e-71	2.86e-66	0.94	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138710150	chr5:138744434~138753309:-
LUAD	cis	rs1577917	0.629	rs7761762	ENSG00000203875.9	SNHG5	21.19	7.27e-71	2.87e-66	0.85	0.69	Response to antipsychotic treatment;	chr6:85496250	chr6:85660950~85678736:-
LUAD	cis	rs9322193	0.923	rs14314	ENSG00000231760.4	RP11-350J20.5	21.18	7.58e-71	2.99e-66	0.88	0.69	Lung cancer;	chr6:149820395	chr6:149796151~149826294:-
LUAD	cis	rs9326248	0.813	rs474488	ENSG00000254851.1	RP11-109L13.1	-21.17	8.63e-71	3.4e-66	-1.05	-0.69	Blood protein levels;	chr11:117198261	chr11:117135528~117138582:+
LUAD	cis	rs2882667	0.628	rs311607	ENSG00000253404.1	AC034243.1	21.16	9.77e-71	3.84e-66	0.94	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138709231	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs825672	ENSG00000253404.1	AC034243.1	-21.16	1.01e-70	3.97e-66	-0.92	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759954	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs10071381	ENSG00000253404.1	AC034243.1	21.16	1.03e-70	4.05e-66	0.91	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937159	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs10463975	ENSG00000253404.1	AC034243.1	21.16	1.04e-70	4.08e-66	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138927560	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.601	rs764533	ENSG00000230658.1	KLHL7-AS1	21.15	1.11e-70	4.36e-66	0.84	0.69	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23101228~23105703:-
LUAD	cis	rs9322193	0.923	rs12174035	ENSG00000231760.4	RP11-350J20.5	21.14	1.18e-70	4.62e-66	0.87	0.69	Lung cancer;	chr6:149763311	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs6899661	ENSG00000231760.4	RP11-350J20.5	21.14	1.23e-70	4.78e-66	0.87	0.69	Lung cancer;	chr6:149818093	chr6:149796151~149826294:-
LUAD	cis	rs916888	0.773	rs199535	ENSG00000214401.4	KANSL1-AS1	21.14	1.25e-70	4.85e-66	1.12	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46193576~46196723:+
LUAD	cis	rs2882667	0.652	rs700622	ENSG00000253404.1	AC034243.1	-21.1	1.93e-70	7.42e-66	-0.93	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762862	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs7722965	ENSG00000253404.1	AC034243.1	-21.1	1.93e-70	7.42e-66	-0.93	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138764766	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs825677	ENSG00000253404.1	AC034243.1	-21.1	1.93e-70	7.42e-66	-0.93	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138769081	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs1976562	ENSG00000253404.1	AC034243.1	-21.1	1.94e-70	7.43e-66	-0.93	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138774905	chr5:138744434~138753309:-
LUAD	cis	rs916888	0.821	rs70600	ENSG00000214401.4	KANSL1-AS1	21.09	2.14e-70	8.17e-66	1.13	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46193576~46196723:+
LUAD	cis	rs858239	0.539	rs2141305	ENSG00000230658.1	KLHL7-AS1	21.06	3.11e-70	1.18e-65	0.86	0.69	Cerebrospinal fluid biomarker levels;	chr7:23152280	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs6461692	ENSG00000230658.1	KLHL7-AS1	21.05	3.21e-70	1.22e-65	0.86	0.69	Cerebrospinal fluid biomarker levels;	chr7:23100076	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs4409314	ENSG00000230658.1	KLHL7-AS1	21.04	3.54e-70	1.34e-65	0.87	0.69	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.539	rs2178140	ENSG00000230658.1	KLHL7-AS1	21.04	3.64e-70	1.38e-65	0.86	0.69	Cerebrospinal fluid biomarker levels;	chr7:23152006	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.539	rs2178139	ENSG00000230658.1	KLHL7-AS1	21.03	4e-70	1.5e-65	0.86	0.69	Cerebrospinal fluid biomarker levels;	chr7:23152017	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.539	rs2141306	ENSG00000230658.1	KLHL7-AS1	21.03	4e-70	1.5e-65	0.86	0.69	Cerebrospinal fluid biomarker levels;	chr7:23152045	chr7:23101228~23105703:-
LUAD	cis	rs9322193	0.962	rs9688412	ENSG00000231760.4	RP11-350J20.5	-21.02	4.56e-70	1.72e-65	-0.87	-0.69	Lung cancer;	chr6:149803147	chr6:149796151~149826294:-
LUAD	cis	rs858239	0.539	rs10279194	ENSG00000230658.1	KLHL7-AS1	21.01	4.92e-70	1.85e-65	0.86	0.69	Cerebrospinal fluid biomarker levels;	chr7:23151464	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.539	rs3950345	ENSG00000230658.1	KLHL7-AS1	21.01	4.92e-70	1.85e-65	0.86	0.69	Cerebrospinal fluid biomarker levels;	chr7:23151495	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs700619	ENSG00000253404.1	AC034243.1	-21	5.65e-70	2.11e-65	-0.92	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138753060	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs11750163	ENSG00000253404.1	AC034243.1	21	5.7e-70	2.13e-65	0.91	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138705920	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.628	rs10076629	ENSG00000253404.1	AC034243.1	21	5.94e-70	2.22e-65	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920272	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.659	rs11750067	ENSG00000253404.1	AC034243.1	21	5.94e-70	2.22e-65	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920589	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288029	ENSG00000253404.1	AC034243.1	20.99	6.19e-70	2.31e-65	0.89	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138881616	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.654	rs10044432	ENSG00000253404.1	AC034243.1	20.98	6.79e-70	2.52e-65	0.94	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138939207	chr5:138744434~138753309:-
LUAD	cis	rs9322193	0.926	rs9383546	ENSG00000231760.4	RP11-350J20.5	20.98	6.97e-70	2.59e-65	0.88	0.69	Lung cancer;	chr6:149822743	chr6:149796151~149826294:-
LUAD	cis	rs3814244	0.528	rs7962511	ENSG00000255733.4	IFNG-AS1	20.98	7.27e-70	2.7e-65	0.64	0.69	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002854	chr12:67989445~68234686:+
LUAD	cis	rs858239	0.539	rs6945510	ENSG00000230658.1	KLHL7-AS1	20.96	8.7e-70	3.21e-65	0.86	0.69	Cerebrospinal fluid biomarker levels;	chr7:23152621	chr7:23101228~23105703:-
LUAD	cis	rs9322193	0.962	rs3763163	ENSG00000231760.4	RP11-350J20.5	20.96	8.76e-70	3.23e-65	0.87	0.69	Lung cancer;	chr6:149819770	chr6:149796151~149826294:-
LUAD	cis	rs2882667	0.69	rs288026	ENSG00000253404.1	AC034243.1	20.96	9.14e-70	3.34e-65	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886905	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288024	ENSG00000253404.1	AC034243.1	20.96	9.14e-70	3.34e-65	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888103	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288009	ENSG00000253404.1	AC034243.1	20.96	9.14e-70	3.34e-65	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138892973	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs185956	ENSG00000253404.1	AC034243.1	20.96	9.14e-70	3.34e-65	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894574	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.658	rs288003	ENSG00000253404.1	AC034243.1	20.96	9.14e-70	3.34e-65	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896266	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs288002	ENSG00000253404.1	AC034243.1	20.96	9.14e-70	3.34e-65	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896398	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs10044401	ENSG00000253404.1	AC034243.1	20.96	9.14e-70	3.34e-65	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901868	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs10067361	ENSG00000253404.1	AC034243.1	20.96	9.14e-70	3.34e-65	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905185	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs12186373	ENSG00000253404.1	AC034243.1	20.96	9.14e-70	3.34e-65	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138912885	chr5:138744434~138753309:-
LUAD	cis	rs9322193	0.962	rs9322220	ENSG00000231760.4	RP11-350J20.5	20.94	1.08e-69	3.88e-65	0.87	0.69	Lung cancer;	chr6:149782897	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs10214845	ENSG00000231760.4	RP11-350J20.5	20.94	1.08e-69	3.88e-65	0.87	0.69	Lung cancer;	chr6:149783124	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs9767122	ENSG00000231760.4	RP11-350J20.5	20.94	1.08e-69	3.88e-65	0.87	0.69	Lung cancer;	chr6:149783553	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs1413654	ENSG00000231760.4	RP11-350J20.5	20.94	1.08e-69	3.88e-65	0.87	0.69	Lung cancer;	chr6:149783956	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs9688809	ENSG00000231760.4	RP11-350J20.5	20.94	1.08e-69	3.88e-65	0.87	0.69	Lung cancer;	chr6:149787920	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs9689242	ENSG00000231760.4	RP11-350J20.5	20.94	1.08e-69	3.88e-65	0.87	0.69	Lung cancer;	chr6:149787970	chr6:149796151~149826294:-
LUAD	cis	rs9322193	1	rs9767077	ENSG00000231760.4	RP11-350J20.5	20.94	1.08e-69	3.88e-65	0.87	0.69	Lung cancer;	chr6:149788479	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9688938	ENSG00000231760.4	RP11-350J20.5	20.94	1.08e-69	3.88e-65	0.87	0.69	Lung cancer;	chr6:149788941	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs9688940	ENSG00000231760.4	RP11-350J20.5	20.94	1.08e-69	3.88e-65	0.87	0.69	Lung cancer;	chr6:149788977	chr6:149796151~149826294:-
LUAD	cis	rs2882667	0.69	rs825759	ENSG00000253404.1	AC034243.1	-20.93	1.23e-69	4.44e-65	-0.93	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138790250	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.601	rs2141307	ENSG00000230658.1	KLHL7-AS1	20.93	1.24e-69	4.47e-65	0.88	0.69	Cerebrospinal fluid biomarker levels;	chr7:23151805	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.601	rs4440529	ENSG00000230658.1	KLHL7-AS1	20.91	1.58e-69	5.67e-65	0.85	0.69	Cerebrospinal fluid biomarker levels;	chr7:23129132	chr7:23101228~23105703:-
LUAD	cis	rs9322193	0.962	rs9397022	ENSG00000231760.4	RP11-350J20.5	20.9	1.81e-69	6.48e-65	0.87	0.69	Lung cancer;	chr6:149812052	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs9397357	ENSG00000231760.4	RP11-350J20.5	20.9	1.81e-69	6.48e-65	0.87	0.69	Lung cancer;	chr6:149812465	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs7753812	ENSG00000231760.4	RP11-350J20.5	20.88	2.22e-69	7.94e-65	0.87	0.69	Lung cancer;	chr6:149690150	chr6:149796151~149826294:-
LUAD	cis	rs858239	0.571	rs6953020	ENSG00000230658.1	KLHL7-AS1	20.86	2.54e-69	9.04e-65	0.85	0.69	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.728	rs10068786	ENSG00000253404.1	AC034243.1	20.85	2.89e-69	1.03e-64	0.94	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941255	chr5:138744434~138753309:-
LUAD	cis	rs9322193	0.923	rs12175504	ENSG00000231760.4	RP11-350J20.5	20.85	3.13e-69	1.11e-64	0.86	0.69	Lung cancer;	chr6:149664079	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs62439843	ENSG00000231760.4	RP11-350J20.5	20.85	3.13e-69	1.11e-64	0.86	0.69	Lung cancer;	chr6:149676521	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs12195866	ENSG00000231760.4	RP11-350J20.5	20.83	3.6e-69	1.27e-64	0.87	0.69	Lung cancer;	chr6:149693334	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs2151912	ENSG00000231760.4	RP11-350J20.5	20.83	3.65e-69	1.29e-64	0.87	0.69	Lung cancer;	chr6:149831772	chr6:149796151~149826294:-
LUAD	cis	rs858239	0.601	rs6969733	ENSG00000230658.1	KLHL7-AS1	20.82	3.99e-69	1.41e-64	0.85	0.69	Cerebrospinal fluid biomarker levels;	chr7:23128758	chr7:23101228~23105703:-
LUAD	cis	rs9322193	0.926	rs9766562	ENSG00000231760.4	RP11-350J20.5	20.82	4e-69	1.41e-64	0.86	0.69	Lung cancer;	chr6:149788709	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.685	rs4822453	ENSG00000273295.1	AP000350.5	20.82	4.33e-69	1.52e-64	0.77	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23901432~23907068:-
LUAD	cis	rs9322193	0.683	rs113281309	ENSG00000231760.4	RP11-350J20.5	20.79	5.67e-69	1.98e-64	0.87	0.69	Lung cancer;	chr6:149787289	chr6:149796151~149826294:-
LUAD	cis	rs2882667	0.69	rs10078079	ENSG00000253404.1	AC034243.1	20.78	6.19e-69	2.16e-64	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920450	chr5:138744434~138753309:-
LUAD	cis	rs916888	0.821	rs199513	ENSG00000262539.1	RP11-259G18.3	-20.77	6.83e-69	2.38e-64	-1.05	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46259551~46260606:-
LUAD	cis	rs9322193	0.923	rs1984111	ENSG00000231760.4	RP11-350J20.5	20.76	7.99e-69	2.78e-64	0.87	0.69	Lung cancer;	chr6:149831720	chr6:149796151~149826294:-
LUAD	cis	rs2882667	0.69	rs17031	ENSG00000253404.1	AC034243.1	20.76	8.39e-69	2.92e-64	0.9	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138934853	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.601	rs6980224	ENSG00000230658.1	KLHL7-AS1	20.75	8.49e-69	2.95e-64	0.84	0.69	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.587	rs825674	ENSG00000253404.1	AC034243.1	-20.73	1.08e-68	3.74e-64	-0.92	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767031	chr5:138744434~138753309:-
LUAD	cis	rs9326248	0.773	rs1060211	ENSG00000254851.1	RP11-109L13.1	-20.73	1.13e-68	3.9e-64	-1.04	-0.69	Blood protein levels;	chr11:117169081	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.861	rs4938353	ENSG00000254851.1	RP11-109L13.1	-20.73	1.14e-68	3.93e-64	-1.03	-0.69	Blood protein levels;	chr11:117175481	chr11:117135528~117138582:+
LUAD	cis	rs2739330	0.828	rs4820572	ENSG00000218537.1	MIF-AS1	20.72	1.28e-68	4.43e-64	0.89	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23894426~23898930:-
LUAD	cis	rs9322193	0.962	rs35443312	ENSG00000231760.4	RP11-350J20.5	20.72	1.29e-68	4.43e-64	0.86	0.69	Lung cancer;	chr6:149670625	chr6:149796151~149826294:-
LUAD	cis	rs2882667	0.69	rs288007	ENSG00000253404.1	AC034243.1	20.72	1.29e-68	4.44e-64	0.92	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894939	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.728	rs13181830	ENSG00000253404.1	AC034243.1	-20.71	1.41e-68	4.84e-64	-0.88	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944727	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.69	rs311601	ENSG00000253404.1	AC034243.1	20.7	1.58e-68	5.43e-64	0.93	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717697	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.539	rs6965833	ENSG00000230658.1	KLHL7-AS1	20.69	1.68e-68	5.74e-64	0.86	0.69	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.539	rs6949363	ENSG00000230658.1	KLHL7-AS1	20.69	1.68e-68	5.74e-64	0.86	0.69	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.539	rs4559148	ENSG00000230658.1	KLHL7-AS1	20.68	1.98e-68	6.73e-64	0.87	0.69	Cerebrospinal fluid biomarker levels;	chr7:23146348	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.539	rs4377861	ENSG00000230658.1	KLHL7-AS1	20.68	1.98e-68	6.73e-64	0.87	0.69	Cerebrospinal fluid biomarker levels;	chr7:23146350	chr7:23101228~23105703:-
LUAD	cis	rs9322193	0.923	rs9285524	ENSG00000231760.4	RP11-350J20.5	20.67	2.16e-68	7.33e-64	0.86	0.69	Lung cancer;	chr6:149694122	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.734	rs2000467	ENSG00000273295.1	AP000350.5	-20.67	2.18e-68	7.4e-64	-0.81	-0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23901432~23907068:-
LUAD	cis	rs858239	0.539	rs10247268	ENSG00000230658.1	KLHL7-AS1	20.65	2.79e-68	9.46e-64	0.87	0.69	Cerebrospinal fluid biomarker levels;	chr7:23147560	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.539	rs6461694	ENSG00000230658.1	KLHL7-AS1	20.65	2.79e-68	9.46e-64	0.87	0.69	Cerebrospinal fluid biomarker levels;	chr7:23148160	chr7:23101228~23105703:-
LUAD	cis	rs2739330	0.703	rs5760112	ENSG00000273295.1	AP000350.5	20.64	2.86e-68	9.69e-64	0.78	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23901432~23907068:-
LUAD	cis	rs858239	0.508	rs7805071	ENSG00000230658.1	KLHL7-AS1	20.63	3.35e-68	1.13e-63	0.87	0.69	Cerebrospinal fluid biomarker levels;	chr7:23150593	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.508	rs7805085	ENSG00000230658.1	KLHL7-AS1	20.63	3.35e-68	1.13e-63	0.87	0.69	Cerebrospinal fluid biomarker levels;	chr7:23150624	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.539	rs4295546	ENSG00000230658.1	KLHL7-AS1	20.62	3.61e-68	1.21e-63	0.85	0.69	Cerebrospinal fluid biomarker levels;	chr7:23151402	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.601	rs11984129	ENSG00000230658.1	KLHL7-AS1	20.61	4.23e-68	1.42e-63	0.84	0.68	Cerebrospinal fluid biomarker levels;	chr7:23113058	chr7:23101228~23105703:-
LUAD	cis	rs9322193	0.962	rs1889473	ENSG00000231760.4	RP11-350J20.5	20.57	6.67e-68	2.23e-63	0.86	0.68	Lung cancer;	chr6:149825485	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.76	rs1002286	ENSG00000273295.1	AP000350.5	-20.57	6.7e-68	2.24e-63	-0.77	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23901432~23907068:-
LUAD	cis	rs9322193	0.962	rs35031906	ENSG00000231760.4	RP11-350J20.5	20.56	7.53e-68	2.51e-63	0.85	0.68	Lung cancer;	chr6:149677438	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs7745915	ENSG00000231760.4	RP11-350J20.5	20.55	8.19e-68	2.73e-63	0.87	0.68	Lung cancer;	chr6:149834111	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs6903998	ENSG00000231760.4	RP11-350J20.5	20.55	8.22e-68	2.74e-63	0.86	0.68	Lung cancer;	chr6:149831357	chr6:149796151~149826294:-
LUAD	cis	rs2882667	0.69	rs288021	ENSG00000253404.1	AC034243.1	20.54	8.94e-68	2.97e-63	0.92	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888594	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.539	rs6975852	ENSG00000230658.1	KLHL7-AS1	20.54	9.05e-68	3.01e-63	0.87	0.68	Cerebrospinal fluid biomarker levels;	chr7:23147035	chr7:23101228~23105703:-
LUAD	cis	rs9322193	1	rs9377229	ENSG00000231760.4	RP11-350J20.5	20.49	1.57e-67	5.2e-63	0.85	0.68	Lung cancer;	chr6:149607655	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.796	rs5760106	ENSG00000218537.1	MIF-AS1	-20.48	1.73e-67	5.72e-63	-0.88	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23894426~23898930:-
LUAD	cis	rs9322193	0.962	rs2275046	ENSG00000231760.4	RP11-350J20.5	20.47	2e-67	6.59e-63	0.87	0.68	Lung cancer;	chr6:149835865	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs9322206	ENSG00000231760.4	RP11-350J20.5	20.41	3.6e-67	1.18e-62	0.85	0.68	Lung cancer;	chr6:149641481	chr6:149796151~149826294:-
LUAD	cis	rs9322193	1	rs9322193	ENSG00000231760.4	RP11-350J20.5	20.36	6.65e-67	2.18e-62	0.84	0.68	Lung cancer;	chr6:149598007	chr6:149796151~149826294:-
LUAD	cis	rs9326248	0.861	rs4938343	ENSG00000254851.1	RP11-109L13.1	-20.35	7.42e-67	2.43e-62	-1.05	-0.68	Blood protein levels;	chr11:117132812	chr11:117135528~117138582:+
LUAD	cis	rs2739330	0.796	rs2154594	ENSG00000218537.1	MIF-AS1	-20.34	8.4e-67	2.74e-62	-0.88	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23894426~23898930:-
LUAD	cis	rs9322193	0.962	rs9688750	ENSG00000231760.4	RP11-350J20.5	20.33	8.8e-67	2.87e-62	0.85	0.68	Lung cancer;	chr6:149657633	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs9478848	ENSG00000231760.4	RP11-350J20.5	20.32	9.83e-67	3.2e-62	0.85	0.68	Lung cancer;	chr6:149825080	chr6:149796151~149826294:-
LUAD	cis	rs2882667	0.69	rs288028	ENSG00000253404.1	AC034243.1	20.3	1.24e-66	4.04e-62	0.91	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886300	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.508	rs2390754	ENSG00000230658.1	KLHL7-AS1	20.28	1.51e-66	4.92e-62	0.86	0.68	Cerebrospinal fluid biomarker levels;	chr7:23150875	chr7:23101228~23105703:-
LUAD	cis	rs9322193	0.961	rs9027	ENSG00000231760.4	RP11-350J20.5	20.28	1.53e-66	4.95e-62	0.84	0.68	Lung cancer;	chr6:149594921	chr6:149796151~149826294:-
LUAD	cis	rs2882667	0.69	rs10045605	ENSG00000253404.1	AC034243.1	20.27	1.65e-66	5.35e-62	0.91	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936458	chr5:138744434~138753309:-
LUAD	cis	rs9322193	0.923	rs9322197	ENSG00000231760.4	RP11-350J20.5	20.26	1.94e-66	6.27e-62	0.85	0.68	Lung cancer;	chr6:149622577	chr6:149796151~149826294:-
LUAD	cis	rs916888	0.773	rs9896243	ENSG00000214401.4	KANSL1-AS1	20.21	3.21e-66	1.03e-61	1.07	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46193576~46196723:+
LUAD	cis	rs9322193	0.884	rs9688858	ENSG00000231760.4	RP11-350J20.5	20.21	3.48e-66	1.12e-61	0.85	0.68	Lung cancer;	chr6:149637911	chr6:149796151~149826294:-
LUAD	cis	rs858239	0.539	rs2390757	ENSG00000230658.1	KLHL7-AS1	20.13	7.88e-66	2.52e-61	0.86	0.68	Cerebrospinal fluid biomarker levels;	chr7:23151873	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.6	rs6967475	ENSG00000230658.1	KLHL7-AS1	20.12	9.32e-66	2.98e-61	0.83	0.68	Cerebrospinal fluid biomarker levels;	chr7:23089363	chr7:23101228~23105703:-
LUAD	cis	rs2739330	0.791	rs4822458	ENSG00000218537.1	MIF-AS1	20.07	1.52e-65	4.86e-61	0.85	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23894426~23898930:-
LUAD	cis	rs858239	0.509	rs6962213	ENSG00000230658.1	KLHL7-AS1	20.03	2.26e-65	7.19e-61	0.84	0.67	Cerebrospinal fluid biomarker levels;	chr7:23148490	chr7:23101228~23105703:-
LUAD	cis	rs2739330	0.731	rs4822450	ENSG00000273295.1	AP000350.5	19.89	1.09e-64	3.42e-60	0.75	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23901432~23907068:-
LUAD	cis	rs2882667	0.69	rs11749163	ENSG00000253404.1	AC034243.1	19.86	1.58e-64	4.95e-60	0.85	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926981	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.627	rs9608219	ENSG00000218537.1	MIF-AS1	19.73	6.09e-64	1.89e-59	0.85	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23894426~23898930:-
LUAD	cis	rs2882667	0.69	rs11954103	ENSG00000253404.1	AC034243.1	19.73	6.45e-64	2e-59	0.91	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138933459	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.669	rs12539467	ENSG00000230658.1	KLHL7-AS1	19.7	8.95e-64	2.77e-59	0.84	0.67	Cerebrospinal fluid biomarker levels;	chr7:23076240	chr7:23101228~23105703:-
LUAD	cis	rs3814244	0.528	rs7952790	ENSG00000255733.4	IFNG-AS1	19.68	1.12e-63	3.46e-59	0.6	0.67	Itch intensity from mosquito bite adjusted by bite size;	chr12:68012672	chr12:67989445~68234686:+
LUAD	cis	rs3814244	0.528	rs2906854	ENSG00000255733.4	IFNG-AS1	-19.67	1.29e-63	3.97e-59	-0.6	-0.67	Itch intensity from mosquito bite adjusted by bite size;	chr12:67993566	chr12:67989445~68234686:+
LUAD	cis	rs2882667	0.628	rs13171173	ENSG00000253404.1	AC034243.1	-19.66	1.3e-63	4.01e-59	-0.89	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138706775	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.539	rs870476	ENSG00000230658.1	KLHL7-AS1	19.63	1.81e-63	5.55e-59	0.8	0.67	Cerebrospinal fluid biomarker levels;	chr7:23153652	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.69	rs9327827	ENSG00000253404.1	AC034243.1	19.62	2.1e-63	6.42e-59	0.86	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846639	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.76	rs5751760	ENSG00000273295.1	AP000350.5	19.6	2.75e-63	8.4e-59	0.74	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23901432~23907068:-
LUAD	cis	rs9322193	0.962	rs4870048	ENSG00000231760.4	RP11-350J20.5	19.5	8.11e-63	2.47e-58	0.85	0.66	Lung cancer;	chr6:149834324	chr6:149796151~149826294:-
LUAD	cis	rs2882667	0.628	rs13173618	ENSG00000253404.1	AC034243.1	19.47	1.1e-62	3.34e-58	0.94	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804091	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.796	rs1006771	ENSG00000218537.1	MIF-AS1	19.43	1.62e-62	4.9e-58	0.87	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23894426~23898930:-
LUAD	cis	rs2739330	0.76	rs1007888	ENSG00000273295.1	AP000350.5	19.39	2.65e-62	7.98e-58	0.74	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23901432~23907068:-
LUAD	cis	rs9322193	0.923	rs10747276	ENSG00000231760.4	RP11-350J20.5	19.38	3.04e-62	9.13e-58	0.82	0.66	Lung cancer;	chr6:149758739	chr6:149796151~149826294:-
LUAD	cis	rs2882667	0.628	rs13154573	ENSG00000253404.1	AC034243.1	19.35	3.97e-62	1.19e-57	0.92	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138812375	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.632	rs6952947	ENSG00000230658.1	KLHL7-AS1	-19.32	5.69e-62	1.7e-57	-0.82	-0.66	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23101228~23105703:-
LUAD	cis	rs1577917	0.74	rs2475792	ENSG00000203875.9	SNHG5	19.26	1.11e-61	3.27e-57	0.8	0.66	Response to antipsychotic treatment;	chr6:85682384	chr6:85660950~85678736:-
LUAD	cis	rs9322193	0.923	rs11155677	ENSG00000231760.4	RP11-350J20.5	19.25	1.23e-61	3.63e-57	0.8	0.66	Lung cancer;	chr6:149756953	chr6:149796151~149826294:-
LUAD	cis	rs916888	0.697	rs199516	ENSG00000214401.4	KANSL1-AS1	-19.23	1.43e-61	4.22e-57	-1.03	-0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46193576~46196723:+
LUAD	cis	rs9322193	0.923	rs10782317	ENSG00000231760.4	RP11-350J20.5	-19.23	1.54e-61	4.53e-57	-0.8	-0.66	Lung cancer;	chr6:149753911	chr6:149796151~149826294:-
LUAD	cis	rs858239	0.539	rs2103281	ENSG00000230658.1	KLHL7-AS1	19.2	1.97e-61	5.8e-57	0.83	0.66	Cerebrospinal fluid biomarker levels;	chr7:23154612	chr7:23101228~23105703:-
LUAD	cis	rs9322193	0.923	rs9480031	ENSG00000231760.4	RP11-350J20.5	19.19	2.32e-61	6.78e-57	0.81	0.66	Lung cancer;	chr6:149758875	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs10872649	ENSG00000231760.4	RP11-350J20.5	19.19	2.32e-61	6.78e-57	0.81	0.66	Lung cancer;	chr6:149759454	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs10872650	ENSG00000231760.4	RP11-350J20.5	19.19	2.32e-61	6.78e-57	0.81	0.66	Lung cancer;	chr6:149760959	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9766037	ENSG00000231760.4	RP11-350J20.5	19.14	4.14e-61	1.21e-56	0.81	0.66	Lung cancer;	chr6:149616921	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.734	rs2000467	ENSG00000218537.1	MIF-AS1	-19.13	4.5e-61	1.31e-56	-0.87	-0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23894426~23898930:-
LUAD	cis	rs9322193	0.884	rs9480009	ENSG00000231760.4	RP11-350J20.5	19.12	5.02e-61	1.46e-56	0.81	0.66	Lung cancer;	chr6:149758502	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9322209	ENSG00000231760.4	RP11-350J20.5	19.11	5.8e-61	1.68e-56	0.81	0.66	Lung cancer;	chr6:149691226	chr6:149796151~149826294:-
LUAD	cis	rs916888	0.821	rs199514	ENSG00000214401.4	KANSL1-AS1	-19.02	1.47e-60	4.25e-56	-1.03	-0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46193576~46196723:+
LUAD	cis	rs2739330	0.732	rs5760175	ENSG00000273295.1	AP000350.5	19.02	1.52e-60	4.4e-56	0.76	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23901432~23907068:-
LUAD	cis	rs3814244	0.528	rs1468487	ENSG00000255733.4	IFNG-AS1	-19.01	1.61e-60	4.64e-56	-0.6	-0.66	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996602	chr12:67989445~68234686:+
LUAD	cis	rs3814244	0.528	rs2860609	ENSG00000255733.4	IFNG-AS1	-19.01	1.61e-60	4.64e-56	-0.6	-0.66	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997215	chr12:67989445~68234686:+
LUAD	cis	rs9322193	0.923	rs10782315	ENSG00000231760.4	RP11-350J20.5	19.01	1.66e-60	4.77e-56	0.82	0.65	Lung cancer;	chr6:149743093	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.685	rs4822453	ENSG00000218537.1	MIF-AS1	19	1.87e-60	5.37e-56	0.82	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23894426~23898930:-
LUAD	cis	rs9322193	0.923	rs55993747	ENSG00000231760.4	RP11-350J20.5	18.99	1.93e-60	5.56e-56	0.82	0.65	Lung cancer;	chr6:149622016	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs17745062	ENSG00000231760.4	RP11-350J20.5	18.99	1.99e-60	5.73e-56	0.81	0.65	Lung cancer;	chr6:149721079	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs62441279	ENSG00000231760.4	RP11-350J20.5	18.99	1.99e-60	5.73e-56	0.81	0.65	Lung cancer;	chr6:149721194	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs62441284	ENSG00000231760.4	RP11-350J20.5	18.98	2.18e-60	6.25e-56	0.81	0.65	Lung cancer;	chr6:149751542	chr6:149796151~149826294:-
LUAD	cis	rs916888	0.821	rs199505	ENSG00000214401.4	KANSL1-AS1	-18.98	2.27e-60	6.49e-56	-1.03	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46193576~46196723:+
LUAD	cis	rs916888	0.821	rs70602	ENSG00000214401.4	KANSL1-AS1	-18.98	2.27e-60	6.49e-56	-1.03	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46193576~46196723:+
LUAD	cis	rs9322193	0.923	rs2297928	ENSG00000231760.4	RP11-350J20.5	18.95	3.31e-60	9.42e-56	0.81	0.65	Lung cancer;	chr6:149718584	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs11155674	ENSG00000231760.4	RP11-350J20.5	18.94	3.37e-60	9.54e-56	0.81	0.65	Lung cancer;	chr6:149711111	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs2185352	ENSG00000231760.4	RP11-350J20.5	18.94	3.37e-60	9.54e-56	0.81	0.65	Lung cancer;	chr6:149714640	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs2297932	ENSG00000231760.4	RP11-350J20.5	18.94	3.37e-60	9.54e-56	0.81	0.65	Lung cancer;	chr6:149718225	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs2297930	ENSG00000231760.4	RP11-350J20.5	18.94	3.37e-60	9.54e-56	0.81	0.65	Lung cancer;	chr6:149718360	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.76	rs5760095	ENSG00000273295.1	AP000350.5	18.94	3.5e-60	9.88e-56	0.75	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23901432~23907068:-
LUAD	cis	rs9322193	0.923	rs4870529	ENSG00000231760.4	RP11-350J20.5	18.94	3.66e-60	1.03e-55	0.81	0.65	Lung cancer;	chr6:149716436	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs10782316	ENSG00000231760.4	RP11-350J20.5	18.93	3.75e-60	1.06e-55	0.8	0.65	Lung cancer;	chr6:149752755	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9767309	ENSG00000231760.4	RP11-350J20.5	18.92	4.43e-60	1.24e-55	0.81	0.65	Lung cancer;	chr6:149716807	chr6:149796151~149826294:-
LUAD	cis	rs916888	0.821	rs199506	ENSG00000214401.4	KANSL1-AS1	-18.91	4.63e-60	1.3e-55	-1.05	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46193576~46196723:+
LUAD	cis	rs916888	0.821	rs199512	ENSG00000214401.4	KANSL1-AS1	-18.9	5.16e-60	1.44e-55	-1.02	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46193576~46196723:+
LUAD	cis	rs916888	0.821	rs199509	ENSG00000214401.4	KANSL1-AS1	-18.9	5.16e-60	1.44e-55	-1.02	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46193576~46196723:+
LUAD	cis	rs916888	0.821	rs199507	ENSG00000214401.4	KANSL1-AS1	-18.9	5.16e-60	1.44e-55	-1.02	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46193576~46196723:+
LUAD	cis	rs9322193	0.884	rs10872646	ENSG00000231760.4	RP11-350J20.5	18.9	5.37e-60	1.5e-55	0.81	0.65	Lung cancer;	chr6:149746539	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.884	rs12528279	ENSG00000231760.4	RP11-350J20.5	18.9	5.37e-60	1.5e-55	0.81	0.65	Lung cancer;	chr6:149750892	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.847	rs12191643	ENSG00000231760.4	RP11-350J20.5	18.88	6.5e-60	1.81e-55	0.82	0.65	Lung cancer;	chr6:149628912	chr6:149796151~149826294:-
LUAD	cis	rs916888	0.61	rs199436	ENSG00000262539.1	RP11-259G18.3	-18.86	8.05e-60	2.22e-55	-0.9	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46259551~46260606:-
LUAD	cis	rs2906856	0.848	rs3015001	ENSG00000255733.4	IFNG-AS1	-18.86	8.26e-60	2.27e-55	-0.59	-0.65	Mosquito bite size;	chr12:68003593	chr12:67989445~68234686:+
LUAD	cis	rs9322193	0.923	rs66516768	ENSG00000231760.4	RP11-350J20.5	18.85	9.1e-60	2.5e-55	0.81	0.65	Lung cancer;	chr6:149671999	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs35830138	ENSG00000231760.4	RP11-350J20.5	18.85	9.64e-60	2.64e-55	0.81	0.65	Lung cancer;	chr6:149668635	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.809	rs9479808	ENSG00000231760.4	RP11-350J20.5	18.84	1e-59	2.74e-55	0.8	0.65	Lung cancer;	chr6:149751328	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs10872651	ENSG00000231760.4	RP11-350J20.5	18.83	1.11e-59	3.03e-55	0.83	0.65	Lung cancer;	chr6:149768273	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs1572229	ENSG00000231760.4	RP11-350J20.5	18.83	1.2e-59	3.27e-55	0.8	0.65	Lung cancer;	chr6:149743841	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9479094	ENSG00000231760.4	RP11-350J20.5	18.81	1.38e-59	3.73e-55	0.81	0.65	Lung cancer;	chr6:149725083	chr6:149796151~149826294:-
LUAD	cis	rs916888	0.821	rs415430	ENSG00000214401.4	KANSL1-AS1	-18.81	1.41e-59	3.82e-55	-1.02	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46193576~46196723:+
LUAD	cis	rs916888	0.779	rs430685	ENSG00000214401.4	KANSL1-AS1	-18.81	1.41e-59	3.82e-55	-1.02	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46193576~46196723:+
LUAD	cis	rs9322193	0.923	rs1934534	ENSG00000231760.4	RP11-350J20.5	18.78	1.9e-59	5.09e-55	0.8	0.65	Lung cancer;	chr6:149711896	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs7767622	ENSG00000231760.4	RP11-350J20.5	18.78	1.98e-59	5.28e-55	0.81	0.65	Lung cancer;	chr6:149681766	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs4421206	ENSG00000231760.4	RP11-350J20.5	18.78	1.98e-59	5.28e-55	0.81	0.65	Lung cancer;	chr6:149682891	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs3798761	ENSG00000231760.4	RP11-350J20.5	18.78	1.98e-59	5.28e-55	0.81	0.65	Lung cancer;	chr6:149683643	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs12176034	ENSG00000231760.4	RP11-350J20.5	18.78	2.11e-59	5.61e-55	0.84	0.65	Lung cancer;	chr6:149800557	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs3805749	ENSG00000231760.4	RP11-350J20.5	18.77	2.33e-59	6.18e-55	0.83	0.65	Lung cancer;	chr6:149772546	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.847	rs9505972	ENSG00000231760.4	RP11-350J20.5	18.77	2.33e-59	6.18e-55	0.83	0.65	Lung cancer;	chr6:149775255	chr6:149796151~149826294:-
LUAD	cis	rs916888	0.61	rs199529	ENSG00000214401.4	KANSL1-AS1	18.76	2.39e-59	6.32e-55	0.99	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46193576~46196723:+
LUAD	cis	rs2739330	0.731	rs2000468	ENSG00000273295.1	AP000350.5	18.76	2.48e-59	6.56e-55	0.71	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23901432~23907068:-
LUAD	cis	rs1577917	0.74	rs9344542	ENSG00000203875.9	SNHG5	18.75	2.85e-59	7.5e-55	0.79	0.65	Response to antipsychotic treatment;	chr6:85684187	chr6:85660950~85678736:-
LUAD	cis	rs9322193	0.923	rs12174349	ENSG00000231760.4	RP11-350J20.5	18.75	2.88e-59	7.59e-55	0.8	0.65	Lung cancer;	chr6:149718012	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs4354168	ENSG00000231760.4	RP11-350J20.5	18.73	3.47e-59	9.08e-55	0.8	0.65	Lung cancer;	chr6:149696642	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs4455682	ENSG00000231760.4	RP11-350J20.5	18.73	3.47e-59	9.08e-55	0.8	0.65	Lung cancer;	chr6:149700161	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.76	rs1002286	ENSG00000218537.1	MIF-AS1	-18.72	3.74e-59	9.77e-55	-0.82	-0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23894426~23898930:-
LUAD	cis	rs9322193	0.962	rs3805752	ENSG00000231760.4	RP11-350J20.5	18.71	4.29e-59	1.12e-54	0.83	0.65	Lung cancer;	chr6:149795490	chr6:149796151~149826294:-
LUAD	cis	rs916888	0.821	rs199504	ENSG00000214401.4	KANSL1-AS1	-18.7	4.56e-59	1.19e-54	-1.01	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46193576~46196723:+
LUAD	cis	rs9322193	0.923	rs9404048	ENSG00000231760.4	RP11-350J20.5	18.7	4.78e-59	1.24e-54	0.81	0.65	Lung cancer;	chr6:149616188	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.886	rs2065663	ENSG00000231760.4	RP11-350J20.5	18.69	5.46e-59	1.42e-54	0.83	0.65	Lung cancer;	chr6:149760331	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs12205092	ENSG00000231760.4	RP11-350J20.5	18.69	5.46e-59	1.42e-54	0.83	0.65	Lung cancer;	chr6:149761375	chr6:149796151~149826294:-
LUAD	cis	rs2882667	0.628	rs13162420	ENSG00000253404.1	AC034243.1	18.67	6.41e-59	1.65e-54	0.91	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138839070	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.628	rs13167462	ENSG00000253404.1	AC034243.1	18.67	6.41e-59	1.65e-54	0.91	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841572	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.539	rs6461695	ENSG00000230658.1	KLHL7-AS1	18.67	6.57e-59	1.69e-54	0.83	0.65	Cerebrospinal fluid biomarker levels;	chr7:23158165	chr7:23101228~23105703:-
LUAD	cis	rs9322193	0.884	rs62439836	ENSG00000231760.4	RP11-350J20.5	18.66	7.69e-59	1.97e-54	0.8	0.65	Lung cancer;	chr6:149669173	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs4869812	ENSG00000231760.4	RP11-350J20.5	18.66	7.69e-59	1.97e-54	0.8	0.65	Lung cancer;	chr6:149669447	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs56397000	ENSG00000231760.4	RP11-350J20.5	18.65	7.97e-59	2.04e-54	0.81	0.65	Lung cancer;	chr6:149739347	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9478291	ENSG00000231760.4	RP11-350J20.5	18.65	8.07e-59	2.06e-54	0.8	0.65	Lung cancer;	chr6:149729434	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs35961297	ENSG00000231760.4	RP11-350J20.5	18.65	8.12e-59	2.07e-54	0.8	0.65	Lung cancer;	chr6:149667929	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs35967444	ENSG00000231760.4	RP11-350J20.5	18.65	8.12e-59	2.07e-54	0.8	0.65	Lung cancer;	chr6:149675588	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs62439842	ENSG00000231760.4	RP11-350J20.5	18.65	8.12e-59	2.07e-54	0.8	0.65	Lung cancer;	chr6:149675847	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.703	rs5760112	ENSG00000218537.1	MIF-AS1	18.65	8.29e-59	2.11e-54	0.83	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23894426~23898930:-
LUAD	cis	rs9322193	0.923	rs12660304	ENSG00000231760.4	RP11-350J20.5	18.65	8.65e-59	2.2e-54	0.81	0.65	Lung cancer;	chr6:149739647	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.884	rs9689702	ENSG00000231760.4	RP11-350J20.5	18.63	9.8e-59	2.49e-54	0.8	0.65	Lung cancer;	chr6:149740720	chr6:149796151~149826294:-
LUAD	cis	rs1577917	0.839	rs9450333	ENSG00000203875.9	SNHG5	-18.63	9.84e-59	2.5e-54	-0.82	-0.65	Response to antipsychotic treatment;	chr6:85810037	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.839	rs6929514	ENSG00000203875.9	SNHG5	-18.63	1.04e-58	2.64e-54	-0.82	-0.65	Response to antipsychotic treatment;	chr6:85816050	chr6:85660950~85678736:-
LUAD	cis	rs3814244	0.528	rs2906859	ENSG00000255733.4	IFNG-AS1	18.61	1.31e-58	3.31e-54	0.58	0.65	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002355	chr12:67989445~68234686:+
LUAD	cis	rs9322193	0.923	rs11155670	ENSG00000231760.4	RP11-350J20.5	18.61	1.31e-58	3.31e-54	0.81	0.65	Lung cancer;	chr6:149644992	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs3924871	ENSG00000231760.4	RP11-350J20.5	18.61	1.33e-58	3.36e-54	0.8	0.65	Lung cancer;	chr6:149662080	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9383812	ENSG00000231760.4	RP11-350J20.5	18.59	1.58e-58	3.98e-54	0.8	0.65	Lung cancer;	chr6:149712355	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.847	rs9383844	ENSG00000231760.4	RP11-350J20.5	18.59	1.58e-58	3.98e-54	0.8	0.65	Lung cancer;	chr6:149716268	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9479494	ENSG00000231760.4	RP11-350J20.5	18.58	1.84e-58	4.61e-54	0.79	0.65	Lung cancer;	chr6:149739108	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9800806	ENSG00000231760.4	RP11-350J20.5	18.58	1.84e-58	4.61e-54	0.79	0.65	Lung cancer;	chr6:149740350	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9800736	ENSG00000231760.4	RP11-350J20.5	18.57	1.88e-58	4.68e-54	0.79	0.65	Lung cancer;	chr6:149661281	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.884	rs9322210	ENSG00000231760.4	RP11-350J20.5	18.57	1.88e-58	4.68e-54	0.8	0.65	Lung cancer;	chr6:149695440	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9688517	ENSG00000231760.4	RP11-350J20.5	18.56	2.18e-58	5.42e-54	0.79	0.65	Lung cancer;	chr6:149740655	chr6:149796151~149826294:-
LUAD	cis	rs7301826	0.651	rs4759525	ENSG00000256250.1	RP11-989F5.1	-18.56	2.28e-58	5.66e-54	-0.73	-0.65	Plasma plasminogen activator levels;	chr12:130831736	chr12:130810606~130812438:+
LUAD	cis	rs9322193	0.923	rs9766004	ENSG00000231760.4	RP11-350J20.5	18.55	2.41e-58	5.99e-54	0.78	0.65	Lung cancer;	chr6:149754363	chr6:149796151~149826294:-
LUAD	cis	rs916888	0.61	rs199438	ENSG00000262539.1	RP11-259G18.3	18.55	2.46e-58	6.11e-54	0.9	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46259551~46260606:-
LUAD	cis	rs9322193	0.962	rs2342764	ENSG00000231760.4	RP11-350J20.5	18.55	2.53e-58	6.28e-54	0.82	0.65	Lung cancer;	chr6:149835068	chr6:149796151~149826294:-
LUAD	cis	rs916888	0.738	rs199515	ENSG00000214401.4	KANSL1-AS1	-18.54	2.82e-58	6.99e-54	-0.98	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46193576~46196723:+
LUAD	cis	rs9322193	0.923	rs12529698	ENSG00000231760.4	RP11-350J20.5	18.54	2.84e-58	7.02e-54	0.8	0.65	Lung cancer;	chr6:149650951	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs12174716	ENSG00000231760.4	RP11-350J20.5	18.53	2.92e-58	7.23e-54	0.8	0.65	Lung cancer;	chr6:149644487	chr6:149796151~149826294:-
LUAD	cis	rs7301826	0.627	rs1077317	ENSG00000256250.1	RP11-989F5.1	-18.53	2.95e-58	7.28e-54	-0.73	-0.65	Plasma plasminogen activator levels;	chr12:130830432	chr12:130810606~130812438:+
LUAD	cis	rs9322193	0.923	rs10782314	ENSG00000231760.4	RP11-350J20.5	18.53	3.02e-58	7.46e-54	0.81	0.65	Lung cancer;	chr6:149735527	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9800871	ENSG00000231760.4	RP11-350J20.5	18.53	3.05e-58	7.53e-54	0.8	0.65	Lung cancer;	chr6:149644540	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9800614	ENSG00000231760.4	RP11-350J20.5	18.53	3.05e-58	7.53e-54	0.8	0.65	Lung cancer;	chr6:149644604	chr6:149796151~149826294:-
LUAD	cis	rs7301826	0.651	rs10848209	ENSG00000256250.1	RP11-989F5.1	-18.5	4.2e-58	1.03e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130826727	chr12:130810606~130812438:+
LUAD	cis	rs916888	0.61	rs199453	ENSG00000262539.1	RP11-259G18.3	18.49	4.63e-58	1.14e-53	0.89	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46259551~46260606:-
LUAD	cis	rs9322193	0.923	rs10872644	ENSG00000231760.4	RP11-350J20.5	18.49	4.66e-58	1.14e-53	0.79	0.64	Lung cancer;	chr6:149741819	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.761	rs5760176	ENSG00000250470.1	AP000351.3	-18.48	5.09e-58	1.25e-53	-0.79	-0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23976904~23977585:-
LUAD	cis	rs9322193	0.962	rs4380763	ENSG00000231760.4	RP11-350J20.5	18.48	5.38e-58	1.32e-53	0.79	0.64	Lung cancer;	chr6:149678086	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.884	rs9688699	ENSG00000231760.4	RP11-350J20.5	18.47	5.58e-58	1.36e-53	0.81	0.64	Lung cancer;	chr6:149733680	chr6:149796151~149826294:-
LUAD	cis	rs2486288	0.656	rs6493144	ENSG00000259520.4	CTD-2651B20.3	-18.47	5.88e-58	1.44e-53	-0.77	-0.64	Glomerular filtration rate;	chr15:45281291	chr15:45251580~45279251:-
LUAD	cis	rs9322193	0.923	rs9377230	ENSG00000231760.4	RP11-350J20.5	18.45	6.91e-58	1.69e-53	0.8	0.64	Lung cancer;	chr6:149613607	chr6:149796151~149826294:-
LUAD	cis	rs9322193	1	rs9399693	ENSG00000231760.4	RP11-350J20.5	18.44	7.77e-58	1.89e-53	0.8	0.64	Lung cancer;	chr6:149612718	chr6:149796151~149826294:-
LUAD	cis	rs9326248	0.581	rs10892076	ENSG00000254851.1	RP11-109L13.1	-18.44	7.83e-58	1.9e-53	-0.82	-0.64	Blood protein levels;	chr11:117118220	chr11:117135528~117138582:+
LUAD	cis	rs9322193	0.884	rs7450246	ENSG00000231760.4	RP11-350J20.5	18.43	8.49e-58	2.06e-53	0.8	0.64	Lung cancer;	chr6:149702517	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs4870267	ENSG00000231760.4	RP11-350J20.5	18.43	8.53e-58	2.06e-53	0.79	0.64	Lung cancer;	chr6:149671572	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9505982	ENSG00000231760.4	RP11-350J20.5	18.43	8.76e-58	2.11e-53	0.8	0.64	Lung cancer;	chr6:149618465	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs10782310	ENSG00000231760.4	RP11-350J20.5	18.43	8.76e-58	2.11e-53	0.8	0.64	Lung cancer;	chr6:149622458	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs10782311	ENSG00000231760.4	RP11-350J20.5	18.43	8.76e-58	2.11e-53	0.8	0.64	Lung cancer;	chr6:149622592	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs10747275	ENSG00000231760.4	RP11-350J20.5	18.43	8.76e-58	2.11e-53	0.8	0.64	Lung cancer;	chr6:149622782	chr6:149796151~149826294:-
LUAD	cis	rs7301826	0.651	rs10848210	ENSG00000256250.1	RP11-989F5.1	-18.43	8.95e-58	2.16e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130827475	chr12:130810606~130812438:+
LUAD	cis	rs9322193	0.923	rs12526675	ENSG00000231760.4	RP11-350J20.5	-18.43	9.18e-58	2.21e-53	-0.82	-0.64	Lung cancer;	chr6:149729540	chr6:149796151~149826294:-
LUAD	cis	rs9322193	1	rs58189451	ENSG00000231760.4	RP11-350J20.5	18.43	9.26e-58	2.23e-53	0.82	0.64	Lung cancer;	chr6:149600252	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9767123	ENSG00000231760.4	RP11-350J20.5	18.42	9.98e-58	2.39e-53	0.79	0.64	Lung cancer;	chr6:149660323	chr6:149796151~149826294:-
LUAD	cis	rs7301826	0.627	rs10773823	ENSG00000256250.1	RP11-989F5.1	-18.42	1.02e-57	2.43e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130809956	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.627	rs73162873	ENSG00000256250.1	RP11-989F5.1	-18.42	1.02e-57	2.43e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130811468	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.651	rs12228957	ENSG00000256250.1	RP11-989F5.1	-18.42	1.02e-57	2.43e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130811521	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.651	rs12228959	ENSG00000256250.1	RP11-989F5.1	-18.42	1.02e-57	2.43e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130811523	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.61	rs4759791	ENSG00000256250.1	RP11-989F5.1	-18.42	1.02e-57	2.43e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130811950	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.61	rs9668291	ENSG00000256250.1	RP11-989F5.1	-18.42	1.02e-57	2.43e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130812363	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.651	rs4759521	ENSG00000256250.1	RP11-989F5.1	-18.42	1.02e-57	2.43e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130812768	chr12:130810606~130812438:+
LUAD	cis	rs9322193	0.923	rs9767554	ENSG00000231760.4	RP11-350J20.5	18.42	1.05e-57	2.49e-53	0.8	0.64	Lung cancer;	chr6:149616860	chr6:149796151~149826294:-
LUAD	cis	rs7301826	0.651	rs7971046	ENSG00000256250.1	RP11-989F5.1	-18.41	1.11e-57	2.63e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130802262	chr12:130810606~130812438:+
LUAD	cis	rs2486288	0.656	rs6493145	ENSG00000259520.4	CTD-2651B20.3	18.41	1.12e-57	2.66e-53	0.78	0.64	Glomerular filtration rate;	chr15:45281664	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs8024620	ENSG00000259520.4	CTD-2651B20.3	18.41	1.12e-57	2.66e-53	0.78	0.64	Glomerular filtration rate;	chr15:45282131	chr15:45251580~45279251:-
LUAD	cis	rs7301826	0.627	rs4325342	ENSG00000256250.1	RP11-989F5.1	-18.41	1.16e-57	2.75e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130827937	chr12:130810606~130812438:+
LUAD	cis	rs9322193	0.923	rs11155671	ENSG00000231760.4	RP11-350J20.5	18.4	1.26e-57	2.99e-53	0.8	0.64	Lung cancer;	chr6:149650996	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9688350	ENSG00000231760.4	RP11-350J20.5	18.39	1.35e-57	3.19e-53	0.8	0.64	Lung cancer;	chr6:149730977	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9767652	ENSG00000231760.4	RP11-350J20.5	18.39	1.35e-57	3.19e-53	0.8	0.64	Lung cancer;	chr6:149734502	chr6:149796151~149826294:-
LUAD	cis	rs7301826	0.651	rs4759794	ENSG00000256250.1	RP11-989F5.1	-18.38	1.46e-57	3.42e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130812803	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.651	rs10734981	ENSG00000256250.1	RP11-989F5.1	-18.38	1.46e-57	3.42e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130813350	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.651	rs10744483	ENSG00000256250.1	RP11-989F5.1	-18.38	1.46e-57	3.42e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130813661	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.651	rs10744484	ENSG00000256250.1	RP11-989F5.1	-18.38	1.46e-57	3.42e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130813961	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.651	rs10744485	ENSG00000256250.1	RP11-989F5.1	-18.38	1.46e-57	3.42e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130814005	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.651	rs7132657	ENSG00000256250.1	RP11-989F5.1	-18.38	1.59e-57	3.73e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130800642	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.651	rs7968675	ENSG00000256250.1	RP11-989F5.1	-18.37	1.63e-57	3.82e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130818832	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.651	rs1554807	ENSG00000256250.1	RP11-989F5.1	18.37	1.69e-57	3.95e-53	0.73	0.64	Plasma plasminogen activator levels;	chr12:130795872	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.61	rs7957899	ENSG00000256250.1	RP11-989F5.1	-18.36	1.86e-57	4.33e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130794531	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.651	rs10773825	ENSG00000256250.1	RP11-989F5.1	-18.36	1.87e-57	4.34e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130814368	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.651	rs7295705	ENSG00000256250.1	RP11-989F5.1	-18.36	1.87e-57	4.34e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130817340	chr12:130810606~130812438:+
LUAD	cis	rs9322193	0.923	rs9689084	ENSG00000231760.4	RP11-350J20.5	18.36	1.93e-57	4.47e-53	0.8	0.64	Lung cancer;	chr6:149639648	chr6:149796151~149826294:-
LUAD	cis	rs1577917	0.74	rs7752502	ENSG00000203875.9	SNHG5	18.36	1.98e-57	4.58e-53	0.79	0.64	Response to antipsychotic treatment;	chr6:85700933	chr6:85660950~85678736:-
LUAD	cis	rs7301826	0.651	rs10734979	ENSG00000256250.1	RP11-989F5.1	-18.35	2.12e-57	4.88e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130804409	chr12:130810606~130812438:+
LUAD	cis	rs9322193	0.884	rs9688794	ENSG00000231760.4	RP11-350J20.5	18.35	2.22e-57	5.09e-53	0.8	0.64	Lung cancer;	chr6:149632121	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9322204	ENSG00000231760.4	RP11-350J20.5	18.35	2.22e-57	5.09e-53	0.8	0.64	Lung cancer;	chr6:149636047	chr6:149796151~149826294:-
LUAD	cis	rs1577917	0.74	rs9353327	ENSG00000203875.9	SNHG5	-18.34	2.31e-57	5.29e-53	-0.78	-0.64	Response to antipsychotic treatment;	chr6:85684348	chr6:85660950~85678736:-
LUAD	cis	rs916888	0.779	rs199526	ENSG00000262539.1	RP11-259G18.3	-18.34	2.34e-57	5.35e-53	-0.92	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:46259551~46260606:-
LUAD	cis	rs7301826	0.651	rs1973834	ENSG00000256250.1	RP11-989F5.1	-18.33	2.76e-57	6.28e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130795612	chr12:130810606~130812438:+
LUAD	cis	rs2486288	0.656	rs2413771	ENSG00000259520.4	CTD-2651B20.3	18.32	2.85e-57	6.48e-53	0.77	0.64	Glomerular filtration rate;	chr15:45260942	chr15:45251580~45279251:-
LUAD	cis	rs7301826	0.651	rs4759519	ENSG00000256250.1	RP11-989F5.1	-18.32	3.04e-57	6.91e-53	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130804963	chr12:130810606~130812438:+
LUAD	cis	rs9322193	0.923	rs9689716	ENSG00000231760.4	RP11-350J20.5	18.31	3.38e-57	7.68e-53	0.8	0.64	Lung cancer;	chr6:149655662	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9689723	ENSG00000231760.4	RP11-350J20.5	18.28	4.38e-57	9.93e-53	0.8	0.64	Lung cancer;	chr6:149655935	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.886	rs9485408	ENSG00000231760.4	RP11-350J20.5	18.27	4.81e-57	1.09e-52	0.79	0.64	Lung cancer;	chr6:149618888	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs1080670	ENSG00000231760.4	RP11-350J20.5	18.27	4.81e-57	1.09e-52	0.79	0.64	Lung cancer;	chr6:149620161	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.884	rs10782312	ENSG00000231760.4	RP11-350J20.5	18.27	4.81e-57	1.09e-52	0.79	0.64	Lung cancer;	chr6:149622669	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.886	rs9322198	ENSG00000231760.4	RP11-350J20.5	18.27	4.81e-57	1.09e-52	0.79	0.64	Lung cancer;	chr6:149623772	chr6:149796151~149826294:-
LUAD	cis	rs3814244	0.868	rs11177007	ENSG00000255733.4	IFNG-AS1	18.27	4.85e-57	1.09e-52	0.56	0.64	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020964	chr12:67989445~68234686:+
LUAD	cis	rs2739330	0.731	rs5751792	ENSG00000250470.1	AP000351.3	18.27	5.31e-57	1.19e-52	0.79	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23976904~23977585:-
LUAD	cis	rs9322193	0.923	rs9322207	ENSG00000231760.4	RP11-350J20.5	18.26	5.55e-57	1.24e-52	0.8	0.64	Lung cancer;	chr6:149657185	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9322208	ENSG00000231760.4	RP11-350J20.5	18.26	5.55e-57	1.24e-52	0.8	0.64	Lung cancer;	chr6:149658547	chr6:149796151~149826294:-
LUAD	cis	rs7301826	0.651	rs10773824	ENSG00000256250.1	RP11-989F5.1	-18.25	6.34e-57	1.42e-52	-0.72	-0.64	Plasma plasminogen activator levels;	chr12:130814306	chr12:130810606~130812438:+
LUAD	cis	rs9322193	0.923	rs9968911	ENSG00000231760.4	RP11-350J20.5	18.24	7.09e-57	1.58e-52	0.8	0.64	Lung cancer;	chr6:149657419	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9322196	ENSG00000231760.4	RP11-350J20.5	18.23	7.45e-57	1.66e-52	0.79	0.64	Lung cancer;	chr6:149619645	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9688861	ENSG00000231760.4	RP11-350J20.5	18.23	8.06e-57	1.8e-52	0.79	0.64	Lung cancer;	chr6:149637924	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs7740278	ENSG00000231760.4	RP11-350J20.5	18.23	8.06e-57	1.8e-52	0.79	0.64	Lung cancer;	chr6:149640116	chr6:149796151~149826294:-
LUAD	cis	rs9322193	1	rs9377228	ENSG00000231760.4	RP11-350J20.5	18.22	8.31e-57	1.85e-52	0.79	0.64	Lung cancer;	chr6:149600862	chr6:149796151~149826294:-
LUAD	cis	rs2486288	0.656	rs12908818	ENSG00000259520.4	CTD-2651B20.3	18.22	9.04e-57	2.01e-52	0.78	0.64	Glomerular filtration rate;	chr15:45279470	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.586	rs12909625	ENSG00000259520.4	CTD-2651B20.3	18.22	9.04e-57	2.01e-52	0.78	0.64	Glomerular filtration rate;	chr15:45279855	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.586	rs12909883	ENSG00000259520.4	CTD-2651B20.3	18.22	9.04e-57	2.01e-52	0.78	0.64	Glomerular filtration rate;	chr15:45279856	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs12910009	ENSG00000259520.4	CTD-2651B20.3	18.22	9.04e-57	2.01e-52	0.78	0.64	Glomerular filtration rate;	chr15:45280210	chr15:45251580~45279251:-
LUAD	cis	rs7301826	0.651	rs4514465	ENSG00000256250.1	RP11-989F5.1	-18.21	9.14e-57	2.03e-52	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130829124	chr12:130810606~130812438:+
LUAD	cis	rs9322193	0.923	rs9800580	ENSG00000231760.4	RP11-350J20.5	18.21	9.31e-57	2.06e-52	0.79	0.64	Lung cancer;	chr6:149632845	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.884	rs11155669	ENSG00000231760.4	RP11-350J20.5	18.21	9.31e-57	2.06e-52	0.79	0.64	Lung cancer;	chr6:149633501	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.887	rs9505824	ENSG00000231760.4	RP11-350J20.5	18.21	9.31e-57	2.06e-52	0.79	0.64	Lung cancer;	chr6:149633663	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9505826	ENSG00000231760.4	RP11-350J20.5	18.21	9.31e-57	2.06e-52	0.79	0.64	Lung cancer;	chr6:149633912	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9766886	ENSG00000231760.4	RP11-350J20.5	18.21	9.31e-57	2.06e-52	0.79	0.64	Lung cancer;	chr6:149637048	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.732	rs5760175	ENSG00000250470.1	AP000351.3	18.21	9.8e-57	2.16e-52	0.81	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23976904~23977585:-
LUAD	cis	rs916888	0.61	rs199452	ENSG00000262539.1	RP11-259G18.3	18.2	1.03e-56	2.28e-52	0.87	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46259551~46260606:-
LUAD	cis	rs9322193	0.923	rs4870052	ENSG00000231760.4	RP11-350J20.5	18.18	1.27e-56	2.79e-52	0.82	0.64	Lung cancer;	chr6:149839978	chr6:149796151~149826294:-
LUAD	cis	rs9326248	0.861	rs11216172	ENSG00000254851.1	RP11-109L13.1	-18.18	1.29e-56	2.84e-52	-0.89	-0.64	Blood protein levels;	chr11:116879162	chr11:117135528~117138582:+
LUAD	cis	rs2739330	0.731	rs5751792	ENSG00000273295.1	AP000350.5	18.18	1.3e-56	2.86e-52	0.72	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23901432~23907068:-
LUAD	cis	rs7301826	0.571	rs4759788	ENSG00000256250.1	RP11-989F5.1	-18.17	1.43e-56	3.13e-52	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130811769	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.61	rs4759789	ENSG00000256250.1	RP11-989F5.1	-18.17	1.43e-56	3.13e-52	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130811835	chr12:130810606~130812438:+
LUAD	cis	rs9322193	0.847	rs62439808	ENSG00000231760.4	RP11-350J20.5	18.17	1.46e-56	3.2e-52	0.79	0.64	Lung cancer;	chr6:149629690	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.924	rs9322189	ENSG00000231760.4	RP11-350J20.5	18.17	1.56e-56	3.4e-52	0.79	0.64	Lung cancer;	chr6:149588797	chr6:149796151~149826294:-
LUAD	cis	rs916888	0.531	rs183211	ENSG00000262539.1	RP11-259G18.3	18.15	1.78e-56	3.88e-52	0.88	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46259551~46260606:-
LUAD	cis	rs9322193	0.923	rs9322200	ENSG00000231760.4	RP11-350J20.5	18.15	1.85e-56	4.03e-52	0.79	0.64	Lung cancer;	chr6:149630078	chr6:149796151~149826294:-
LUAD	cis	rs916888	0.61	rs142167	ENSG00000262539.1	RP11-259G18.3	-18.13	2.39e-56	5.2e-52	-0.87	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46259551~46260606:-
LUAD	cis	rs1577917	0.839	rs6454492	ENSG00000203875.9	SNHG5	-18.13	2.41e-56	5.24e-52	-0.82	-0.64	Response to antipsychotic treatment;	chr6:85773496	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.796	rs12661231	ENSG00000203875.9	SNHG5	-18.12	2.45e-56	5.33e-52	-0.82	-0.64	Response to antipsychotic treatment;	chr6:85834753	chr6:85660950~85678736:-
LUAD	cis	rs9322193	0.924	rs9498382	ENSG00000231760.4	RP11-350J20.5	18.11	2.77e-56	6.01e-52	0.79	0.64	Lung cancer;	chr6:149610982	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9322214	ENSG00000231760.4	RP11-350J20.5	18.11	2.8e-56	6.07e-52	0.81	0.64	Lung cancer;	chr6:149703986	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs7740784	ENSG00000231760.4	RP11-350J20.5	18.1	3.17e-56	6.86e-52	0.82	0.64	Lung cancer;	chr6:149833364	chr6:149796151~149826294:-
LUAD	cis	rs7301826	0.651	rs10848206	ENSG00000256250.1	RP11-989F5.1	-18.09	3.54e-56	7.65e-52	-0.73	-0.64	Plasma plasminogen activator levels;	chr12:130796926	chr12:130810606~130812438:+
LUAD	cis	rs9322193	0.887	rs9767113	ENSG00000231760.4	RP11-350J20.5	18.09	3.67e-56	7.92e-52	0.81	0.64	Lung cancer;	chr6:149718157	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs10782318	ENSG00000231760.4	RP11-350J20.5	18.07	4.51e-56	9.69e-52	0.82	0.64	Lung cancer;	chr6:149754137	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs4870050	ENSG00000231760.4	RP11-350J20.5	18.05	5.22e-56	1.12e-51	0.8	0.64	Lung cancer;	chr6:149838917	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs7752089	ENSG00000231760.4	RP11-350J20.5	18.03	6.8e-56	1.45e-51	0.8	0.64	Lung cancer;	chr6:149839298	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9505823	ENSG00000231760.4	RP11-350J20.5	18.02	7.86e-56	1.68e-51	0.78	0.63	Lung cancer;	chr6:149628899	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9689599	ENSG00000231760.4	RP11-350J20.5	18.02	7.86e-56	1.68e-51	0.78	0.63	Lung cancer;	chr6:149631973	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.884	rs2064521	ENSG00000231760.4	RP11-350J20.5	-18.01	8.39e-56	1.79e-51	-0.79	-0.63	Lung cancer;	chr6:149625336	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.761	rs5760176	ENSG00000273295.1	AP000350.5	-18	9.42e-56	2e-51	-0.71	-0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23901432~23907068:-
LUAD	cis	rs1577917	0.839	rs12055653	ENSG00000203875.9	SNHG5	-17.98	1.19e-55	2.52e-51	-0.82	-0.63	Response to antipsychotic treatment;	chr6:85836945	chr6:85660950~85678736:-
LUAD	cis	rs9322193	0.923	rs4870509	ENSG00000231760.4	RP11-350J20.5	17.97	1.31e-55	2.78e-51	0.81	0.63	Lung cancer;	chr6:149702212	chr6:149796151~149826294:-
LUAD	cis	rs2486288	0.656	rs12911861	ENSG00000259520.4	CTD-2651B20.3	17.96	1.36e-55	2.88e-51	0.77	0.63	Glomerular filtration rate;	chr15:45274520	chr15:45251580~45279251:-
LUAD	cis	rs916888	0.821	rs199513	ENSG00000214401.4	KANSL1-AS1	-17.96	1.49e-55	3.16e-51	-0.96	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46193576~46196723:+
LUAD	cis	rs9322193	0.847	rs12234128	ENSG00000231760.4	RP11-350J20.5	17.95	1.62e-55	3.41e-51	0.78	0.63	Lung cancer;	chr6:149627553	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs57012784	ENSG00000231760.4	RP11-350J20.5	17.95	1.62e-55	3.41e-51	0.78	0.63	Lung cancer;	chr6:149627691	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.886	rs4870049	ENSG00000231760.4	RP11-350J20.5	17.94	1.76e-55	3.7e-51	0.8	0.63	Lung cancer;	chr6:149837058	chr6:149796151~149826294:-
LUAD	cis	rs1577917	0.771	rs7762321	ENSG00000203875.9	SNHG5	17.94	1.82e-55	3.83e-51	0.78	0.63	Response to antipsychotic treatment;	chr6:85702428	chr6:85660950~85678736:-
LUAD	cis	rs9322193	0.923	rs4242279	ENSG00000231760.4	RP11-350J20.5	17.93	1.92e-55	4.03e-51	0.8	0.63	Lung cancer;	chr6:149839815	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs62439840	ENSG00000231760.4	RP11-350J20.5	17.93	2.08e-55	4.35e-51	0.81	0.63	Lung cancer;	chr6:149674639	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.962	rs9393175	ENSG00000231760.4	RP11-350J20.5	17.93	2.08e-55	4.35e-51	0.81	0.63	Lung cancer;	chr6:149677587	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.886	rs9718079	ENSG00000231760.4	RP11-350J20.5	17.92	2.11e-55	4.41e-51	0.79	0.63	Lung cancer;	chr6:149645947	chr6:149796151~149826294:-
LUAD	cis	rs2486288	0.656	rs11637364	ENSG00000259520.4	CTD-2651B20.3	17.92	2.12e-55	4.43e-51	0.77	0.63	Glomerular filtration rate;	chr15:45287040	chr15:45251580~45279251:-
LUAD	cis	rs1577917	0.839	rs1596990	ENSG00000203875.9	SNHG5	-17.92	2.15e-55	4.49e-51	-0.81	-0.63	Response to antipsychotic treatment;	chr6:85840974	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.637	rs1838957	ENSG00000203875.9	SNHG5	-17.92	2.15e-55	4.49e-51	-0.81	-0.63	Response to antipsychotic treatment;	chr6:85855338	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.839	rs1838956	ENSG00000203875.9	SNHG5	-17.92	2.15e-55	4.49e-51	-0.81	-0.63	Response to antipsychotic treatment;	chr6:85855545	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.839	rs12216103	ENSG00000203875.9	SNHG5	-17.92	2.15e-55	4.49e-51	-0.81	-0.63	Response to antipsychotic treatment;	chr6:85861410	chr6:85660950~85678736:-
LUAD	cis	rs9322193	0.851	rs9322194	ENSG00000231760.4	RP11-350J20.5	17.88	3.39e-55	7.02e-51	0.79	0.63	Lung cancer;	chr6:149599113	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs6913486	ENSG00000231760.4	RP11-350J20.5	-17.88	3.41e-55	7.04e-51	-0.79	-0.63	Lung cancer;	chr6:149705060	chr6:149796151~149826294:-
LUAD	cis	rs916888	0.647	rs199449	ENSG00000262539.1	RP11-259G18.3	17.87	3.68e-55	7.59e-51	0.87	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46259551~46260606:-
LUAD	cis	rs9322193	0.847	rs56103941	ENSG00000231760.4	RP11-350J20.5	17.87	3.73e-55	7.7e-51	0.81	0.63	Lung cancer;	chr6:149816095	chr6:149796151~149826294:-
LUAD	cis	rs7301826	0.557	rs7953184	ENSG00000256250.1	RP11-989F5.1	17.87	3.82e-55	7.87e-51	0.72	0.63	Plasma plasminogen activator levels;	chr12:130800307	chr12:130810606~130812438:+
LUAD	cis	rs2486288	0.656	rs62026703	ENSG00000259520.4	CTD-2651B20.3	17.86	4.09e-55	8.4e-51	0.77	0.63	Glomerular filtration rate;	chr15:45277731	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs7171312	ENSG00000259520.4	CTD-2651B20.3	17.86	4.09e-55	8.4e-51	0.77	0.63	Glomerular filtration rate;	chr15:45278027	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs7165039	ENSG00000259520.4	CTD-2651B20.3	17.86	4.09e-55	8.4e-51	0.77	0.63	Glomerular filtration rate;	chr15:45278215	chr15:45251580~45279251:-
LUAD	cis	rs916888	0.61	rs199444	ENSG00000262539.1	RP11-259G18.3	17.86	4.22e-55	8.66e-51	0.87	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46259551~46260606:-
LUAD	cis	rs916888	0.61	rs199442	ENSG00000262539.1	RP11-259G18.3	17.86	4.22e-55	8.66e-51	0.87	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46259551~46260606:-
LUAD	cis	rs2486288	0.656	rs6493143	ENSG00000259520.4	CTD-2651B20.3	17.84	5.07e-55	1.04e-50	0.77	0.63	Glomerular filtration rate;	chr15:45278583	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs7166580	ENSG00000259520.4	CTD-2651B20.3	17.83	5.52e-55	1.13e-50	0.77	0.63	Glomerular filtration rate;	chr15:45279011	chr15:45251580~45279251:-
LUAD	cis	rs9322193	0.847	rs12210605	ENSG00000231760.4	RP11-350J20.5	17.83	6.12e-55	1.25e-50	0.81	0.63	Lung cancer;	chr6:149817267	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9371199	ENSG00000231760.4	RP11-350J20.5	17.83	6.12e-55	1.25e-50	0.81	0.63	Lung cancer;	chr6:149817526	chr6:149796151~149826294:-
LUAD	cis	rs7301826	0.651	rs4759517	ENSG00000256250.1	RP11-989F5.1	-17.82	6.41e-55	1.31e-50	-0.72	-0.63	Plasma plasminogen activator levels;	chr12:130799153	chr12:130810606~130812438:+
LUAD	cis	rs9322193	0.961	rs2064520	ENSG00000231760.4	RP11-350J20.5	17.81	7.2e-55	1.46e-50	0.77	0.63	Lung cancer;	chr6:149603650	chr6:149796151~149826294:-
LUAD	cis	rs2486288	0.656	rs8039153	ENSG00000259520.4	CTD-2651B20.3	17.8	8.06e-55	1.64e-50	0.77	0.63	Glomerular filtration rate;	chr15:45287615	chr15:45251580~45279251:-
LUAD	cis	rs9322193	0.887	rs3777949	ENSG00000231760.4	RP11-350J20.5	17.8	8.37e-55	1.7e-50	0.79	0.63	Lung cancer;	chr6:149596021	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.731	rs4822450	ENSG00000218537.1	MIF-AS1	17.79	8.53e-55	1.73e-50	0.79	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23894426~23898930:-
LUAD	cis	rs1577917	0.793	rs9362245	ENSG00000203875.9	SNHG5	-17.79	8.95e-55	1.81e-50	-0.81	-0.63	Response to antipsychotic treatment;	chr6:85786602	chr6:85660950~85678736:-
LUAD	cis	rs916888	0.61	rs199454	ENSG00000262539.1	RP11-259G18.3	-17.78	1.03e-54	2.07e-50	-0.87	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46259551~46260606:-
LUAD	cis	rs9322193	0.884	rs62439837	ENSG00000231760.4	RP11-350J20.5	17.76	1.3e-54	2.61e-50	0.81	0.63	Lung cancer;	chr6:149670380	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.76	rs1007888	ENSG00000218537.1	MIF-AS1	17.75	1.42e-54	2.85e-50	0.78	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23894426~23898930:-
LUAD	cis	rs1577917	0.883	rs12214536	ENSG00000203875.9	SNHG5	-17.75	1.42e-54	2.85e-50	-0.8	-0.63	Response to antipsychotic treatment;	chr6:86080592	chr6:85660950~85678736:-
LUAD	cis	rs9326248	0.581	rs7106437	ENSG00000254851.1	RP11-109L13.1	-17.73	1.69e-54	3.37e-50	-0.8	-0.63	Blood protein levels;	chr11:117121360	chr11:117135528~117138582:+
LUAD	cis	rs1577917	0.682	rs1173417	ENSG00000203875.9	SNHG5	17.73	1.73e-54	3.45e-50	0.77	0.63	Response to antipsychotic treatment;	chr6:85694223	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.696	rs2842617	ENSG00000203875.9	SNHG5	-17.73	1.74e-54	3.47e-50	-0.77	-0.63	Response to antipsychotic treatment;	chr6:85599980	chr6:85660950~85678736:-
LUAD	cis	rs7301826	0.651	rs2037789	ENSG00000256250.1	RP11-989F5.1	17.72	1.96e-54	3.9e-50	0.71	0.63	Plasma plasminogen activator levels;	chr12:130803747	chr12:130810606~130812438:+
LUAD	cis	rs9322193	0.923	rs9688452	ENSG00000231760.4	RP11-350J20.5	17.72	1.97e-54	3.92e-50	0.79	0.63	Lung cancer;	chr6:149658764	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.884	rs10872647	ENSG00000231760.4	RP11-350J20.5	17.72	2e-54	3.98e-50	0.83	0.63	Lung cancer;	chr6:149758687	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.884	rs10872648	ENSG00000231760.4	RP11-350J20.5	17.72	2e-54	3.98e-50	0.83	0.63	Lung cancer;	chr6:149758699	chr6:149796151~149826294:-
LUAD	cis	rs9326248	0.581	rs7120515	ENSG00000254851.1	RP11-109L13.1	-17.7	2.32e-54	4.62e-50	-0.8	-0.63	Blood protein levels;	chr11:117121210	chr11:117135528~117138582:+
LUAD	cis	rs3814244	0.868	rs10878726	ENSG00000255733.4	IFNG-AS1	17.7	2.36e-54	4.68e-50	0.55	0.63	Itch intensity from mosquito bite adjusted by bite size;	chr12:68022865	chr12:67989445~68234686:+
LUAD	cis	rs9322193	0.923	rs2342765	ENSG00000231760.4	RP11-350J20.5	17.7	2.39e-54	4.74e-50	0.8	0.63	Lung cancer;	chr6:149858873	chr6:149796151~149826294:-
LUAD	cis	rs2882667	0.893	rs10054796	ENSG00000253404.1	AC034243.1	17.68	3.06e-54	6.06e-50	0.8	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958655	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.893	rs10069961	ENSG00000253404.1	AC034243.1	17.68	3.06e-54	6.06e-50	0.8	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958879	chr5:138744434~138753309:-
LUAD	cis	rs1577917	0.916	rs12661611	ENSG00000203875.9	SNHG5	-17.67	3.14e-54	6.2e-50	-0.8	-0.63	Response to antipsychotic treatment;	chr6:85844117	chr6:85660950~85678736:-
LUAD	cis	rs9322193	0.923	rs57938011	ENSG00000231760.4	RP11-350J20.5	17.67	3.27e-54	6.45e-50	0.81	0.63	Lung cancer;	chr6:149642969	chr6:149796151~149826294:-
LUAD	cis	rs1577917	0.682	rs1173419	ENSG00000203875.9	SNHG5	-17.66	3.45e-54	6.78e-50	-0.77	-0.63	Response to antipsychotic treatment;	chr6:85692445	chr6:85660950~85678736:-
LUAD	cis	rs9326248	0.689	rs236916	ENSG00000254851.1	RP11-109L13.1	17.65	4.19e-54	8.24e-50	1.07	0.63	Blood protein levels;	chr11:117218912	chr11:117135528~117138582:+
LUAD	cis	rs9322193	0.923	rs4869750	ENSG00000231760.4	RP11-350J20.5	17.64	4.36e-54	8.57e-50	0.78	0.63	Lung cancer;	chr6:149855996	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.892	rs5751776	ENSG00000225282.1	AP000350.6	17.63	5.25e-54	1.03e-49	0.73	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23926900~23929574:+
LUAD	cis	rs9322193	0.884	rs11155679	ENSG00000231760.4	RP11-350J20.5	17.62	5.37e-54	1.05e-49	0.83	0.63	Lung cancer;	chr6:149758881	chr6:149796151~149826294:-
LUAD	cis	rs1577917	0.883	rs9450375	ENSG00000203875.9	SNHG5	17.59	7.58e-54	1.48e-49	0.79	0.63	Response to antipsychotic treatment;	chr6:86046911	chr6:85660950~85678736:-
LUAD	cis	rs2486288	0.656	rs11631021	ENSG00000259520.4	CTD-2651B20.3	17.59	7.63e-54	1.49e-49	0.76	0.63	Glomerular filtration rate;	chr15:45264631	chr15:45251580~45279251:-
LUAD	cis	rs9322193	0.884	rs11155675	ENSG00000231760.4	RP11-350J20.5	17.59	8e-54	1.56e-49	0.83	0.63	Lung cancer;	chr6:149742883	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.929	rs5751777	ENSG00000225282.1	AP000350.6	17.58	8.28e-54	1.61e-49	0.73	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23926900~23929574:+
LUAD	cis	rs9322193	0.923	rs55849538	ENSG00000231760.4	RP11-350J20.5	17.56	1.1e-53	2.14e-49	0.8	0.62	Lung cancer;	chr6:149635330	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9800686	ENSG00000231760.4	RP11-350J20.5	17.54	1.27e-53	2.46e-49	0.8	0.62	Lung cancer;	chr6:149634464	chr6:149796151~149826294:-
LUAD	cis	rs9326248	0.861	rs494356	ENSG00000254851.1	RP11-109L13.1	-17.54	1.3e-53	2.52e-49	-1.03	-0.62	Blood protein levels;	chr11:117201254	chr11:117135528~117138582:+
LUAD	cis	rs2739330	0.791	rs4822458	ENSG00000250470.1	AP000351.3	17.54	1.33e-53	2.57e-49	0.76	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23976904~23977585:-
LUAD	cis	rs2882667	0.893	rs7717375	ENSG00000253404.1	AC034243.1	17.52	1.59e-53	3.08e-49	0.8	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138955716	chr5:138744434~138753309:-
LUAD	cis	rs9322193	0.81	rs62439811	ENSG00000231760.4	RP11-350J20.5	17.52	1.69e-53	3.25e-49	0.8	0.62	Lung cancer;	chr6:149640416	chr6:149796151~149826294:-
LUAD	cis	rs2486288	0.656	rs8039352	ENSG00000259520.4	CTD-2651B20.3	17.52	1.72e-53	3.31e-49	0.76	0.62	Glomerular filtration rate;	chr15:45259592	chr15:45251580~45279251:-
LUAD	cis	rs858239	0.601	rs6461702	ENSG00000230658.1	KLHL7-AS1	17.5	1.95e-53	3.75e-49	0.81	0.62	Cerebrospinal fluid biomarker levels;	chr7:23209654	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.511	rs10256996	ENSG00000230658.1	KLHL7-AS1	-17.5	1.98e-53	3.81e-49	-0.74	-0.62	Cerebrospinal fluid biomarker levels;	chr7:23105676	chr7:23101228~23105703:-
LUAD	cis	rs1577917	0.74	rs2758842	ENSG00000203875.9	SNHG5	-17.5	2.09e-53	4e-49	-0.77	-0.62	Response to antipsychotic treatment;	chr6:85599013	chr6:85660950~85678736:-
LUAD	cis	rs2739330	0.76	rs5751760	ENSG00000218537.1	MIF-AS1	17.49	2.21e-53	4.23e-49	0.78	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23894426~23898930:-
LUAD	cis	rs9326248	0.689	rs4516002	ENSG00000254851.1	RP11-109L13.1	-17.49	2.22e-53	4.26e-49	-1.01	-0.62	Blood protein levels;	chr11:117128343	chr11:117135528~117138582:+
LUAD	cis	rs1577917	0.572	rs911927	ENSG00000203875.9	SNHG5	-17.49	2.32e-53	4.44e-49	-0.77	-0.62	Response to antipsychotic treatment;	chr6:85618142	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.883	rs13212415	ENSG00000203875.9	SNHG5	-17.47	2.79e-53	5.34e-49	-0.79	-0.62	Response to antipsychotic treatment;	chr6:85898365	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.839	rs1447159	ENSG00000203875.9	SNHG5	-17.47	2.79e-53	5.34e-49	-0.79	-0.62	Response to antipsychotic treatment;	chr6:85899531	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.74	rs2842614	ENSG00000203875.9	SNHG5	-17.46	3.02e-53	5.78e-49	-0.77	-0.62	Response to antipsychotic treatment;	chr6:85596351	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.74	rs2758843	ENSG00000203875.9	SNHG5	-17.46	3.22e-53	6.15e-49	-0.77	-0.62	Response to antipsychotic treatment;	chr6:85618713	chr6:85660950~85678736:-
LUAD	cis	rs2882667	0.893	rs10044672	ENSG00000253404.1	AC034243.1	17.45	3.4e-53	6.48e-49	0.79	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138954790	chr5:138744434~138753309:-
LUAD	cis	rs2486288	0.656	rs1706770	ENSG00000259520.4	CTD-2651B20.3	17.44	3.68e-53	7e-49	0.75	0.62	Glomerular filtration rate;	chr15:45282864	chr15:45251580~45279251:-
LUAD	cis	rs916888	0.779	rs199498	ENSG00000262539.1	RP11-259G18.3	17.44	3.96e-53	7.53e-49	0.94	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46259551~46260606:-
LUAD	cis	rs1577917	0.839	rs12664634	ENSG00000203875.9	SNHG5	-17.43	4.51e-53	8.57e-49	-0.79	-0.62	Response to antipsychotic treatment;	chr6:85869696	chr6:85660950~85678736:-
LUAD	cis	rs2739330	0.76	rs5751761	ENSG00000273295.1	AP000350.5	-17.42	4.64e-53	8.81e-49	-0.67	-0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23901432~23907068:-
LUAD	cis	rs2882667	0.893	rs13180851	ENSG00000253404.1	AC034243.1	17.4	6.17e-53	1.17e-48	0.79	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138954918	chr5:138744434~138753309:-
LUAD	cis	rs1577917	0.839	rs6454504	ENSG00000203875.9	SNHG5	-17.38	7.23e-53	1.36e-48	-0.79	-0.62	Response to antipsychotic treatment;	chr6:85870612	chr6:85660950~85678736:-
LUAD	cis	rs7301826	0.627	rs4334059	ENSG00000256250.1	RP11-989F5.1	-17.37	7.93e-53	1.49e-48	-0.72	-0.62	Plasma plasminogen activator levels;	chr12:130829669	chr12:130810606~130812438:+
LUAD	cis	rs1577917	0.883	rs6454505	ENSG00000203875.9	SNHG5	-17.37	8.35e-53	1.57e-48	-0.78	-0.62	Response to antipsychotic treatment;	chr6:85882644	chr6:85660950~85678736:-
LUAD	cis	rs2739330	0.732	rs5760175	ENSG00000218537.1	MIF-AS1	17.36	9.16e-53	1.72e-48	0.81	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23894426~23898930:-
LUAD	cis	rs1577917	0.655	rs7742691	ENSG00000203875.9	SNHG5	17.35	9.89e-53	1.85e-48	0.76	0.62	Response to antipsychotic treatment;	chr6:85568973	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.71	rs9342041	ENSG00000203875.9	SNHG5	17.35	9.89e-53	1.85e-48	0.76	0.62	Response to antipsychotic treatment;	chr6:85571157	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.682	rs6935918	ENSG00000203875.9	SNHG5	17.35	1.03e-52	1.92e-48	0.76	0.62	Response to antipsychotic treatment;	chr6:85573857	chr6:85660950~85678736:-
LUAD	cis	rs9322193	0.961	rs9767713	ENSG00000231760.4	RP11-350J20.5	17.34	1.08e-52	2.02e-48	0.79	0.62	Lung cancer;	chr6:149588241	chr6:149796151~149826294:-
LUAD	cis	rs858239	0.738	rs7807879	ENSG00000230658.1	KLHL7-AS1	17.34	1.08e-52	2.02e-48	0.77	0.62	Cerebrospinal fluid biomarker levels;	chr7:23220969	chr7:23101228~23105703:-
LUAD	cis	rs2486288	0.554	rs1719235	ENSG00000259520.4	CTD-2651B20.3	17.34	1.14e-52	2.12e-48	0.75	0.62	Glomerular filtration rate;	chr15:45283910	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs1719232	ENSG00000259520.4	CTD-2651B20.3	17.33	1.24e-52	2.32e-48	0.76	0.62	Glomerular filtration rate;	chr15:45279874	chr15:45251580~45279251:-
LUAD	cis	rs1577917	0.883	rs1415749	ENSG00000203875.9	SNHG5	17.31	1.6e-52	2.97e-48	0.79	0.62	Response to antipsychotic treatment;	chr6:86069366	chr6:85660950~85678736:-
LUAD	cis	rs7301826	0.585	rs6486600	ENSG00000256250.1	RP11-989F5.1	-17.3	1.74e-52	3.22e-48	-0.72	-0.62	Plasma plasminogen activator levels;	chr12:130808432	chr12:130810606~130812438:+
LUAD	cis	rs9322193	0.923	rs9371486	ENSG00000231760.4	RP11-350J20.5	17.29	1.97e-52	3.65e-48	0.82	0.62	Lung cancer;	chr6:149832090	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs7769101	ENSG00000231760.4	RP11-350J20.5	17.28	2.23e-52	4.13e-48	0.79	0.62	Lung cancer;	chr6:149848768	chr6:149796151~149826294:-
LUAD	cis	rs2486288	0.656	rs11639349	ENSG00000259520.4	CTD-2651B20.3	17.24	3.12e-52	5.74e-48	0.75	0.62	Glomerular filtration rate;	chr15:45276062	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs12440356	ENSG00000259520.4	CTD-2651B20.3	-17.24	3.12e-52	5.74e-48	-0.75	-0.62	Glomerular filtration rate;	chr15:45275331	chr15:45251580~45279251:-
LUAD	cis	rs1577917	0.883	rs2782263	ENSG00000203875.9	SNHG5	-17.23	3.49e-52	6.39e-48	-0.77	-0.62	Response to antipsychotic treatment;	chr6:86081589	chr6:85660950~85678736:-
LUAD	cis	rs916888	0.61	rs199446	ENSG00000262539.1	RP11-259G18.3	-17.23	3.49e-52	6.39e-48	-0.85	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46259551~46260606:-
LUAD	cis	rs916888	0.61	rs199536	ENSG00000262539.1	RP11-259G18.3	-17.23	3.49e-52	6.39e-48	-0.85	-0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46259551~46260606:-
LUAD	cis	rs858239	0.738	rs13225593	ENSG00000230658.1	KLHL7-AS1	17.23	3.73e-52	6.83e-48	0.77	0.62	Cerebrospinal fluid biomarker levels;	chr7:23220688	chr7:23101228~23105703:-
LUAD	cis	rs9322193	0.886	rs4870055	ENSG00000231760.4	RP11-350J20.5	17.22	3.96e-52	7.24e-48	0.77	0.62	Lung cancer;	chr6:149848433	chr6:149796151~149826294:-
LUAD	cis	rs1577917	0.959	rs2816822	ENSG00000203875.9	SNHG5	-17.21	4.49e-52	8.2e-48	-0.78	-0.62	Response to antipsychotic treatment;	chr6:85948574	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.883	rs2166664	ENSG00000203875.9	SNHG5	-17.19	5.86e-52	1.06e-47	-0.79	-0.62	Response to antipsychotic treatment;	chr6:85886904	chr6:85660950~85678736:-
LUAD	cis	rs9322193	0.884	rs9397036	ENSG00000231760.4	RP11-350J20.5	17.18	6.03e-52	1.09e-47	0.79	0.62	Lung cancer;	chr6:149851787	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.884	rs9383864	ENSG00000231760.4	RP11-350J20.5	17.18	6.03e-52	1.09e-47	0.79	0.62	Lung cancer;	chr6:149851969	chr6:149796151~149826294:-
LUAD	cis	rs1577917	0.804	rs2786854	ENSG00000203875.9	SNHG5	-17.17	6.81e-52	1.23e-47	-0.77	-0.62	Response to antipsychotic treatment;	chr6:85959022	chr6:85660950~85678736:-
LUAD	cis	rs2486288	0.656	rs1706768	ENSG00000259520.4	CTD-2651B20.3	17.16	7.66e-52	1.38e-47	0.75	0.62	Glomerular filtration rate;	chr15:45277245	chr15:45251580~45279251:-
LUAD	cis	rs2739330	0.627	rs9608219	ENSG00000250470.1	AP000351.3	17.16	7.69e-52	1.39e-47	0.76	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23976904~23977585:-
LUAD	cis	rs1577917	0.883	rs9450348	ENSG00000203875.9	SNHG5	-17.13	1.09e-51	1.95e-47	-0.78	-0.62	Response to antipsychotic treatment;	chr6:85888318	chr6:85660950~85678736:-
LUAD	cis	rs2486288	0.656	rs8041702	ENSG00000259520.4	CTD-2651B20.3	17.13	1.12e-51	2e-47	0.75	0.62	Glomerular filtration rate;	chr15:45254895	chr15:45251580~45279251:-
LUAD	cis	rs9322193	0.886	rs9767555	ENSG00000231760.4	RP11-350J20.5	17.11	1.28e-51	2.29e-47	0.79	0.62	Lung cancer;	chr6:149647022	chr6:149796151~149826294:-
LUAD	cis	rs858239	0.536	rs6961109	ENSG00000230658.1	KLHL7-AS1	17.1	1.52e-51	2.71e-47	0.77	0.61	Cerebrospinal fluid biomarker levels;	chr7:23212794	chr7:23101228~23105703:-
LUAD	cis	rs2486288	0.656	rs2461705	ENSG00000259520.4	CTD-2651B20.3	17.09	1.54e-51	2.75e-47	0.75	0.61	Glomerular filtration rate;	chr15:45278043	chr15:45251580~45279251:-
LUAD	cis	rs1577917	0.74	rs7771612	ENSG00000203875.9	SNHG5	17.09	1.56e-51	2.77e-47	0.76	0.61	Response to antipsychotic treatment;	chr6:85554656	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.92	rs1337842	ENSG00000203875.9	SNHG5	-17.09	1.63e-51	2.91e-47	-0.77	-0.61	Response to antipsychotic treatment;	chr6:85965379	chr6:85660950~85678736:-
LUAD	cis	rs2739330	0.731	rs2000468	ENSG00000218537.1	MIF-AS1	17.07	2.02e-51	3.58e-47	0.75	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23894426~23898930:-
LUAD	cis	rs1577917	0.816	rs1838952	ENSG00000203875.9	SNHG5	-17.05	2.41e-51	4.26e-47	-0.79	-0.61	Response to antipsychotic treatment;	chr6:85891426	chr6:85660950~85678736:-
LUAD	cis	rs2882667	0.964	rs67296915	ENSG00000253404.1	AC034243.1	17.04	2.66e-51	4.7e-47	0.78	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138965910	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.536	rs6956974	ENSG00000230658.1	KLHL7-AS1	-17.04	2.87e-51	5.06e-47	-0.75	-0.61	Cerebrospinal fluid biomarker levels;	chr7:23212699	chr7:23101228~23105703:-
LUAD	cis	rs1577917	0.74	rs2758845	ENSG00000203875.9	SNHG5	-17.03	2.95e-51	5.2e-47	-0.76	-0.61	Response to antipsychotic treatment;	chr6:85625130	chr6:85660950~85678736:-
LUAD	cis	rs2739330	0.929	rs5751775	ENSG00000225282.1	AP000350.6	17.03	3.21e-51	5.64e-47	0.72	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23926900~23929574:+
LUAD	cis	rs9322193	0.884	rs9383865	ENSG00000231760.4	RP11-350J20.5	17.03	3.22e-51	5.66e-47	0.79	0.61	Lung cancer;	chr6:149852043	chr6:149796151~149826294:-
LUAD	cis	rs1577917	0.74	rs9450302	ENSG00000203875.9	SNHG5	17.03	3.24e-51	5.69e-47	0.77	0.61	Response to antipsychotic treatment;	chr6:85579955	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.696	rs2842603	ENSG00000203875.9	SNHG5	-17.02	3.26e-51	5.73e-47	-0.76	-0.61	Response to antipsychotic treatment;	chr6:85626619	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.883	rs2660575	ENSG00000203875.9	SNHG5	-17	4.37e-51	7.65e-47	-0.77	-0.61	Response to antipsychotic treatment;	chr6:85975277	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.74	rs12212560	ENSG00000203875.9	SNHG5	-16.99	4.91e-51	8.57e-47	-0.76	-0.61	Response to antipsychotic treatment;	chr6:85632961	chr6:85660950~85678736:-
LUAD	cis	rs2739330	0.731	rs5751792	ENSG00000218537.1	MIF-AS1	16.96	6.5e-51	1.13e-46	0.78	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23894426~23898930:-
LUAD	cis	rs9322193	0.923	rs9371207	ENSG00000231760.4	RP11-350J20.5	16.96	6.58e-51	1.14e-46	0.8	0.61	Lung cancer;	chr6:149858087	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.884	rs9371201	ENSG00000231760.4	RP11-350J20.5	16.96	6.73e-51	1.17e-46	0.82	0.61	Lung cancer;	chr6:149823865	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.76	rs5760095	ENSG00000218537.1	MIF-AS1	16.94	7.77e-51	1.34e-46	0.78	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23894426~23898930:-
LUAD	cis	rs9322193	0.923	rs2880436	ENSG00000231760.4	RP11-350J20.5	16.94	8.28e-51	1.43e-46	0.8	0.61	Lung cancer;	chr6:149859123	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.892	rs4822455	ENSG00000225282.1	AP000350.6	16.91	1.16e-50	1.99e-46	0.72	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23926900~23929574:+
LUAD	cis	rs9326248	0.581	rs10892072	ENSG00000254851.1	RP11-109L13.1	-16.9	1.18e-50	2.03e-46	-0.79	-0.61	Blood protein levels;	chr11:117089597	chr11:117135528~117138582:+
LUAD	cis	rs1577917	0.633	rs7770835	ENSG00000203875.9	SNHG5	-16.88	1.45e-50	2.48e-46	-0.78	-0.61	Response to antipsychotic treatment;	chr6:85899189	chr6:85660950~85678736:-
LUAD	cis	rs7301826	0.651	rs7956851	ENSG00000256250.1	RP11-989F5.1	-16.88	1.51e-50	2.58e-46	-0.68	-0.61	Plasma plasminogen activator levels;	chr12:130834554	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.61	rs36051740	ENSG00000256250.1	RP11-989F5.1	16.88	1.55e-50	2.64e-46	0.71	0.61	Plasma plasminogen activator levels;	chr12:130808177	chr12:130810606~130812438:+
LUAD	cis	rs858239	0.669	rs10950940	ENSG00000230658.1	KLHL7-AS1	-16.87	1.65e-50	2.82e-46	-0.75	-0.61	Cerebrospinal fluid biomarker levels;	chr7:23157197	chr7:23101228~23105703:-
LUAD	cis	rs7301826	0.651	rs2277336	ENSG00000256250.1	RP11-989F5.1	16.87	1.71e-50	2.92e-46	0.71	0.61	Plasma plasminogen activator levels;	chr12:130801574	chr12:130810606~130812438:+
LUAD	cis	rs1577917	0.883	rs1337854	ENSG00000203875.9	SNHG5	16.85	2.01e-50	3.42e-46	0.77	0.61	Response to antipsychotic treatment;	chr6:86014297	chr6:85660950~85678736:-
LUAD	cis	rs858239	0.539	rs10270695	ENSG00000230658.1	KLHL7-AS1	-16.81	3.18e-50	5.36e-46	-0.74	-0.61	Cerebrospinal fluid biomarker levels;	chr7:23149369	chr7:23101228~23105703:-
LUAD	cis	rs1577917	0.74	rs9353320	ENSG00000203875.9	SNHG5	16.8	3.52e-50	5.92e-46	0.75	0.61	Response to antipsychotic treatment;	chr6:85535130	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.74	rs9344533	ENSG00000203875.9	SNHG5	16.79	4.1e-50	6.9e-46	0.75	0.61	Response to antipsychotic treatment;	chr6:85526470	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.74	rs7775864	ENSG00000203875.9	SNHG5	16.79	4.1e-50	6.9e-46	0.75	0.61	Response to antipsychotic treatment;	chr6:85538041	chr6:85660950~85678736:-
LUAD	cis	rs9322193	0.884	rs7743823	ENSG00000231760.4	RP11-350J20.5	16.75	6.13e-50	1.02e-45	0.78	0.61	Lung cancer;	chr6:149849744	chr6:149796151~149826294:-
LUAD	cis	rs3814244	0.515	rs2906856	ENSG00000255733.4	IFNG-AS1	-16.75	6.27e-50	1.05e-45	-0.54	-0.61	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996421	chr12:67989445~68234686:+
LUAD	cis	rs1577917	0.655	rs9359658	ENSG00000203875.9	SNHG5	16.74	6.92e-50	1.15e-45	0.75	0.61	Response to antipsychotic treatment;	chr6:85596051	chr6:85660950~85678736:-
LUAD	cis	rs9322193	0.884	rs7744105	ENSG00000231760.4	RP11-350J20.5	16.73	7.83e-50	1.3e-45	0.78	0.61	Lung cancer;	chr6:149849308	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.884	rs1125	ENSG00000231760.4	RP11-350J20.5	16.71	9.07e-50	1.51e-45	0.81	0.61	Lung cancer;	chr6:149658280	chr6:149796151~149826294:-
LUAD	cis	rs9326248	0.648	rs11216257	ENSG00000254851.1	RP11-109L13.1	-16.69	1.2e-49	1.98e-45	-0.88	-0.61	Blood protein levels;	chr11:117061845	chr11:117135528~117138582:+
LUAD	cis	rs7847628	0.587	rs10760117	ENSG00000226752.6	PSMD5-AS1	-16.68	1.23e-49	2.04e-45	-0.66	-0.61	Birth weight;	chr9:120824459	chr9:120824828~120854385:+
LUAD	cis	rs9322193	0.772	rs7738696	ENSG00000231760.4	RP11-350J20.5	16.66	1.56e-49	2.58e-45	0.77	0.6	Lung cancer;	chr6:149848985	chr6:149796151~149826294:-
LUAD	cis	rs7847628	0.587	rs12684934	ENSG00000226752.6	PSMD5-AS1	-16.62	2.31e-49	3.8e-45	-0.66	-0.6	Birth weight;	chr9:120830881	chr9:120824828~120854385:+
LUAD	cis	rs2906856	0.921	rs1019076	ENSG00000255733.4	IFNG-AS1	-16.61	2.55e-49	4.19e-45	-0.54	-0.6	Mosquito bite size;	chr12:68004338	chr12:67989445~68234686:+
LUAD	cis	rs3814244	0.515	rs2906862	ENSG00000255733.4	IFNG-AS1	-16.61	2.55e-49	4.19e-45	-0.54	-0.6	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005371	chr12:67989445~68234686:+
LUAD	cis	rs858239	0.669	rs1006709	ENSG00000230658.1	KLHL7-AS1	16.61	2.73e-49	4.48e-45	0.72	0.6	Cerebrospinal fluid biomarker levels;	chr7:23100480	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.964	rs12055237	ENSG00000253404.1	AC034243.1	16.58	3.65e-49	5.97e-45	0.77	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138971617	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.761	rs5760176	ENSG00000218537.1	MIF-AS1	-16.57	3.92e-49	6.42e-45	-0.76	-0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23894426~23898930:-
LUAD	cis	rs858239	0.699	rs955187	ENSG00000230658.1	KLHL7-AS1	-16.57	4.13e-49	6.76e-45	-0.75	-0.6	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23101228~23105703:-
LUAD	cis	rs1577917	0.696	rs10806334	ENSG00000203875.9	SNHG5	-16.46	1.24e-48	2.02e-44	-0.74	-0.6	Response to antipsychotic treatment;	chr6:85729611	chr6:85660950~85678736:-
LUAD	cis	rs858239	0.806	rs10268610	ENSG00000230658.1	KLHL7-AS1	16.46	1.27e-48	2.06e-44	0.75	0.6	Cerebrospinal fluid biomarker levels;	chr7:23235145	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.67	rs6967526	ENSG00000230658.1	KLHL7-AS1	16.46	1.37e-48	2.22e-44	0.72	0.6	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.964	rs12108892	ENSG00000253404.1	AC034243.1	16.44	1.59e-48	2.58e-44	0.76	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138963941	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.964	rs2288824	ENSG00000253404.1	AC034243.1	16.43	1.77e-48	2.88e-44	0.77	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138962707	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.964	rs11958050	ENSG00000253404.1	AC034243.1	16.42	2e-48	3.25e-44	0.75	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138966139	chr5:138744434~138753309:-
LUAD	cis	rs9326248	0.581	rs4938331	ENSG00000254851.1	RP11-109L13.1	-16.41	2.33e-48	3.77e-44	-0.77	-0.6	Blood protein levels;	chr11:117059966	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.51	rs4938332	ENSG00000254851.1	RP11-109L13.1	-16.41	2.33e-48	3.77e-44	-0.77	-0.6	Blood protein levels;	chr11:117060082	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.559	rs4938334	ENSG00000254851.1	RP11-109L13.1	-16.41	2.33e-48	3.77e-44	-0.77	-0.6	Blood protein levels;	chr11:117060326	chr11:117135528~117138582:+
LUAD	cis	rs1577917	0.682	rs6909767	ENSG00000203875.9	SNHG5	16.39	2.76e-48	4.45e-44	0.74	0.6	Response to antipsychotic treatment;	chr6:85518391	chr6:85660950~85678736:-
LUAD	cis	rs9326248	0.559	rs12808524	ENSG00000254851.1	RP11-109L13.1	-16.38	3.06e-48	4.93e-44	-0.78	-0.6	Blood protein levels;	chr11:117020277	chr11:117135528~117138582:+
LUAD	cis	rs7301826	0.627	rs7978987	ENSG00000256250.1	RP11-989F5.1	16.37	3.39e-48	5.46e-44	0.69	0.6	Plasma plasminogen activator levels;	chr12:130796949	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.651	rs12820597	ENSG00000256250.1	RP11-989F5.1	16.36	3.58e-48	5.75e-44	0.7	0.6	Plasma plasminogen activator levels;	chr12:130795640	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.651	rs34749116	ENSG00000256250.1	RP11-989F5.1	16.36	3.74e-48	6e-44	0.69	0.6	Plasma plasminogen activator levels;	chr12:130796207	chr12:130810606~130812438:+
LUAD	cis	rs7847628	0.587	rs1060817	ENSG00000226752.6	PSMD5-AS1	-16.36	3.9e-48	6.25e-44	-0.65	-0.6	Birth weight;	chr9:120820914	chr9:120824828~120854385:+
LUAD	cis	rs7301826	0.627	rs34103763	ENSG00000256250.1	RP11-989F5.1	16.36	3.94e-48	6.31e-44	0.69	0.6	Plasma plasminogen activator levels;	chr12:130805604	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.61	rs7961690	ENSG00000256250.1	RP11-989F5.1	16.36	3.94e-48	6.31e-44	0.69	0.6	Plasma plasminogen activator levels;	chr12:130812335	chr12:130810606~130812438:+
LUAD	cis	rs9326248	0.581	rs10892061	ENSG00000254851.1	RP11-109L13.1	-16.33	5.32e-48	8.51e-44	-0.77	-0.6	Blood protein levels;	chr11:117015398	chr11:117135528~117138582:+
LUAD	cis	rs858239	0.72	rs10227559	ENSG00000230658.1	KLHL7-AS1	16.33	5.4e-48	8.64e-44	0.75	0.6	Cerebrospinal fluid biomarker levels;	chr7:23232525	chr7:23101228~23105703:-
LUAD	cis	rs9326248	0.581	rs11216267	ENSG00000254851.1	RP11-109L13.1	-16.32	5.45e-48	8.71e-44	-0.77	-0.6	Blood protein levels;	chr11:117081676	chr11:117135528~117138582:+
LUAD	cis	rs7301826	0.58	rs61938969	ENSG00000256250.1	RP11-989F5.1	16.32	5.47e-48	8.74e-44	0.69	0.6	Plasma plasminogen activator levels;	chr12:130831525	chr12:130810606~130812438:+
LUAD	cis	rs9326248	0.581	rs10892048	ENSG00000254851.1	RP11-109L13.1	-16.32	5.96e-48	9.51e-44	-0.77	-0.6	Blood protein levels;	chr11:116943880	chr11:117135528~117138582:+
LUAD	cis	rs7301826	0.651	rs6486601	ENSG00000256250.1	RP11-989F5.1	16.31	6.38e-48	1.02e-43	0.69	0.6	Plasma plasminogen activator levels;	chr12:130816692	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.627	rs61937256	ENSG00000256250.1	RP11-989F5.1	16.31	6.38e-48	1.02e-43	0.69	0.6	Plasma plasminogen activator levels;	chr12:130818100	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.651	rs10848210	ENSG00000256299.1	RP11-989F5.3	-16.3	6.78e-48	1.08e-43	-0.67	-0.6	Plasma plasminogen activator levels;	chr12:130827475	chr12:130810821~130812622:-
LUAD	cis	rs9326248	0.581	rs11216242	ENSG00000254851.1	RP11-109L13.1	-16.29	7.5e-48	1.19e-43	-0.77	-0.6	Blood protein levels;	chr11:117030833	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.581	rs12804122	ENSG00000254851.1	RP11-109L13.1	-16.29	7.5e-48	1.19e-43	-0.77	-0.6	Blood protein levels;	chr11:117031900	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.581	rs6589590	ENSG00000254851.1	RP11-109L13.1	-16.29	7.52e-48	1.2e-43	-0.77	-0.6	Blood protein levels;	chr11:117065365	chr11:117135528~117138582:+
LUAD	cis	rs9322193	0.847	rs880246	ENSG00000231760.4	RP11-350J20.5	16.29	7.96e-48	1.26e-43	0.77	0.6	Lung cancer;	chr6:149845972	chr6:149796151~149826294:-
LUAD	cis	rs9326248	0.581	rs10892063	ENSG00000254851.1	RP11-109L13.1	-16.28	8.45e-48	1.34e-43	-0.77	-0.6	Blood protein levels;	chr11:117025439	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.559	rs10892064	ENSG00000254851.1	RP11-109L13.1	-16.28	8.65e-48	1.37e-43	-0.77	-0.6	Blood protein levels;	chr11:117025837	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.539	rs10892065	ENSG00000254851.1	RP11-109L13.1	-16.28	8.65e-48	1.37e-43	-0.77	-0.6	Blood protein levels;	chr11:117026308	chr11:117135528~117138582:+
LUAD	cis	rs2739330	0.828	rs5751770	ENSG00000225282.1	AP000350.6	16.28	8.68e-48	1.37e-43	0.7	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23926900~23929574:+
LUAD	cis	rs9322193	0.884	rs7769115	ENSG00000231760.4	RP11-350J20.5	16.25	1.16e-47	1.83e-43	0.77	0.6	Lung cancer;	chr6:149848796	chr6:149796151~149826294:-
LUAD	cis	rs2882667	0.964	rs11739351	ENSG00000253404.1	AC034243.1	16.24	1.3e-47	2.05e-43	0.76	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138976053	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.899	rs28458177	ENSG00000230658.1	KLHL7-AS1	16.24	1.35e-47	2.13e-43	0.74	0.6	Cerebrospinal fluid biomarker levels;	chr7:23255253	chr7:23101228~23105703:-
LUAD	cis	rs2739330	0.703	rs5760112	ENSG00000250470.1	AP000351.3	16.23	1.41e-47	2.22e-43	0.73	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23976904~23977585:-
LUAD	cis	rs9322193	0.923	rs9767105	ENSG00000231760.4	RP11-350J20.5	16.23	1.42e-47	2.23e-43	0.75	0.59	Lung cancer;	chr6:149659591	chr6:149796151~149826294:-
LUAD	cis	rs7301826	0.56	rs12829294	ENSG00000256250.1	RP11-989F5.1	16.23	1.53e-47	2.41e-43	0.69	0.59	Plasma plasminogen activator levels;	chr12:130825427	chr12:130810606~130812438:+
LUAD	cis	rs3814244	0.515	rs3015002	ENSG00000255733.4	IFNG-AS1	-16.22	1.63e-47	2.56e-43	-0.52	-0.59	Itch intensity from mosquito bite adjusted by bite size;	chr12:68010853	chr12:67989445~68234686:+
LUAD	cis	rs858239	0.899	rs1881203	ENSG00000230658.1	KLHL7-AS1	16.19	2.22e-47	3.48e-43	0.74	0.59	Cerebrospinal fluid biomarker levels;	chr7:23253189	chr7:23101228~23105703:-
LUAD	cis	rs9326248	0.581	rs6589582	ENSG00000254851.1	RP11-109L13.1	-16.19	2.23e-47	3.5e-43	-0.76	-0.59	Blood protein levels;	chr11:116958484	chr11:117135528~117138582:+
LUAD	cis	rs7847628	0.587	rs4837796	ENSG00000226752.6	PSMD5-AS1	16.17	2.66e-47	4.15e-43	0.63	0.59	Birth weight;	chr9:120848010	chr9:120824828~120854385:+
LUAD	cis	rs858239	0.899	rs10262243	ENSG00000230658.1	KLHL7-AS1	16.17	2.72e-47	4.25e-43	0.74	0.59	Cerebrospinal fluid biomarker levels;	chr7:23251368	chr7:23101228~23105703:-
LUAD	cis	rs9326248	0.581	rs7120706	ENSG00000254851.1	RP11-109L13.1	16.17	2.83e-47	4.42e-43	0.76	0.59	Blood protein levels;	chr11:116959371	chr11:117135528~117138582:+
LUAD	cis	rs7301826	0.651	rs7299281	ENSG00000256250.1	RP11-989F5.1	16.16	3.08e-47	4.81e-43	0.69	0.59	Plasma plasminogen activator levels;	chr12:130818587	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.627	rs4325342	ENSG00000256299.1	RP11-989F5.3	-16.14	3.76e-47	5.84e-43	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130827937	chr12:130810821~130812622:-
LUAD	cis	rs858239	0.867	rs10250602	ENSG00000230658.1	KLHL7-AS1	16.12	4.68e-47	7.26e-43	0.75	0.59	Cerebrospinal fluid biomarker levels;	chr7:23264082	chr7:23101228~23105703:-
LUAD	cis	rs7301826	0.651	rs7968675	ENSG00000256299.1	RP11-989F5.3	-16.1	5.92e-47	9.17e-43	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130818832	chr12:130810821~130812622:-
LUAD	cis	rs9326248	0.581	rs10502222	ENSG00000254851.1	RP11-109L13.1	-16.09	6.57e-47	1.02e-42	-0.76	-0.59	Blood protein levels;	chr11:116963014	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.559	rs10892052	ENSG00000254851.1	RP11-109L13.1	-16.09	6.57e-47	1.02e-42	-0.76	-0.59	Blood protein levels;	chr11:116963597	chr11:117135528~117138582:+
LUAD	cis	rs7301826	0.651	rs4759525	ENSG00000256299.1	RP11-989F5.3	-16.08	7.12e-47	1.1e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130831736	chr12:130810821~130812622:-
LUAD	cis	rs7617773	0.817	rs6796490	ENSG00000229759.1	MRPS18AP1	16.08	7.36e-47	1.14e-42	0.59	0.59	Coronary artery disease;	chr3:48195614	chr3:48256350~48256938:-
LUAD	cis	rs1577917	0.771	rs9450319	ENSG00000203875.9	SNHG5	16.07	7.67e-47	1.18e-42	0.75	0.59	Response to antipsychotic treatment;	chr6:85717607	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.538	rs6454483	ENSG00000203875.9	SNHG5	16.07	8.32e-47	1.28e-42	0.72	0.59	Response to antipsychotic treatment;	chr6:85708565	chr6:85660950~85678736:-
LUAD	cis	rs9322193	0.884	rs1108889	ENSG00000231760.4	RP11-350J20.5	16.05	9.41e-47	1.45e-42	0.77	0.59	Lung cancer;	chr6:149845433	chr6:149796151~149826294:-
LUAD	cis	rs7301826	0.651	rs10734979	ENSG00000256299.1	RP11-989F5.3	-16.05	9.93e-47	1.53e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130804409	chr12:130810821~130812622:-
LUAD	cis	rs7301826	0.627	rs10773823	ENSG00000256299.1	RP11-989F5.3	-16.05	1.01e-46	1.55e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130809956	chr12:130810821~130812622:-
LUAD	cis	rs7301826	0.627	rs73162873	ENSG00000256299.1	RP11-989F5.3	-16.05	1.01e-46	1.55e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130811468	chr12:130810821~130812622:-
LUAD	cis	rs7301826	0.651	rs12228957	ENSG00000256299.1	RP11-989F5.3	-16.05	1.01e-46	1.55e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130811521	chr12:130810821~130812622:-
LUAD	cis	rs7301826	0.651	rs12228959	ENSG00000256299.1	RP11-989F5.3	-16.05	1.01e-46	1.55e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130811523	chr12:130810821~130812622:-
LUAD	cis	rs7301826	0.61	rs4759791	ENSG00000256299.1	RP11-989F5.3	-16.05	1.01e-46	1.55e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130811950	chr12:130810821~130812622:-
LUAD	cis	rs7301826	0.61	rs9668291	ENSG00000256299.1	RP11-989F5.3	-16.05	1.01e-46	1.55e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130812363	chr12:130810821~130812622:-
LUAD	cis	rs7301826	0.651	rs4759521	ENSG00000256299.1	RP11-989F5.3	-16.05	1.01e-46	1.55e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130812768	chr12:130810821~130812622:-
LUAD	cis	rs2739330	0.732	rs5760175	ENSG00000231271.1	AP000350.8	16.04	1.06e-46	1.62e-42	0.72	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23949918~23954042:+
LUAD	cis	rs3814244	1	rs3814244	ENSG00000255733.4	IFNG-AS1	-16.04	1.07e-46	1.63e-42	-0.5	-0.59	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019691	chr12:67989445~68234686:+
LUAD	cis	rs9326248	0.581	rs10790167	ENSG00000254851.1	RP11-109L13.1	-16.04	1.08e-46	1.65e-42	-0.77	-0.59	Blood protein levels;	chr11:116930227	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.731	rs90192	ENSG00000254851.1	RP11-109L13.1	-16.04	1.14e-46	1.74e-42	-0.95	-0.59	Blood protein levels;	chr11:117188631	chr11:117135528~117138582:+
LUAD	cis	rs7301826	0.627	rs1077317	ENSG00000256299.1	RP11-989F5.3	-16.03	1.26e-46	1.92e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130830432	chr12:130810821~130812622:-
LUAD	cis	rs2882667	0.931	rs11955952	ENSG00000253404.1	AC034243.1	16.02	1.31e-46	2e-42	0.73	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138993430	chr5:138744434~138753309:-
LUAD	cis	rs7301826	0.651	rs4759519	ENSG00000256299.1	RP11-989F5.3	-16.01	1.43e-46	2.18e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130804963	chr12:130810821~130812622:-
LUAD	cis	rs7301826	0.651	rs4759794	ENSG00000256299.1	RP11-989F5.3	-16.01	1.45e-46	2.21e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130812803	chr12:130810821~130812622:-
LUAD	cis	rs7301826	0.651	rs10734981	ENSG00000256299.1	RP11-989F5.3	-16.01	1.45e-46	2.21e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130813350	chr12:130810821~130812622:-
LUAD	cis	rs7301826	0.651	rs10744483	ENSG00000256299.1	RP11-989F5.3	-16.01	1.45e-46	2.21e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130813661	chr12:130810821~130812622:-
LUAD	cis	rs7301826	0.651	rs10744484	ENSG00000256299.1	RP11-989F5.3	-16.01	1.45e-46	2.21e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130813961	chr12:130810821~130812622:-
LUAD	cis	rs7301826	0.651	rs10744485	ENSG00000256299.1	RP11-989F5.3	-16.01	1.45e-46	2.21e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130814005	chr12:130810821~130812622:-
LUAD	cis	rs7301826	0.651	rs10848209	ENSG00000256299.1	RP11-989F5.3	-16	1.66e-46	2.52e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130826727	chr12:130810821~130812622:-
LUAD	cis	rs2739330	0.761	rs5760176	ENSG00000231271.1	AP000350.8	-16	1.69e-46	2.56e-42	-0.7	-0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23949918~23954042:+
LUAD	cis	rs7617773	0.817	rs11720622	ENSG00000229759.1	MRPS18AP1	15.99	1.77e-46	2.69e-42	0.58	0.59	Coronary artery disease;	chr3:48205189	chr3:48256350~48256938:-
LUAD	cis	rs858239	0.636	rs28706766	ENSG00000230658.1	KLHL7-AS1	15.99	1.81e-46	2.74e-42	0.71	0.59	Cerebrospinal fluid biomarker levels;	chr7:23130215	chr7:23101228~23105703:-
LUAD	cis	rs9326248	0.581	rs10892053	ENSG00000254851.1	RP11-109L13.1	-15.98	1.96e-46	2.97e-42	-0.76	-0.59	Blood protein levels;	chr11:116986287	chr11:117135528~117138582:+
LUAD	cis	rs1577917	0.771	rs9362239	ENSG00000203875.9	SNHG5	15.98	2.1e-46	3.18e-42	0.74	0.59	Response to antipsychotic treatment;	chr6:85719545	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.771	rs4383777	ENSG00000203875.9	SNHG5	15.97	2.22e-46	3.35e-42	0.75	0.59	Response to antipsychotic treatment;	chr6:85726242	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.739	rs9450318	ENSG00000203875.9	SNHG5	15.97	2.29e-46	3.45e-42	0.74	0.59	Response to antipsychotic treatment;	chr6:85717459	chr6:85660950~85678736:-
LUAD	cis	rs2739330	0.731	rs5751792	ENSG00000231271.1	AP000350.8	15.97	2.31e-46	3.49e-42	0.7	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23949918~23954042:+
LUAD	cis	rs7301826	0.651	rs10773825	ENSG00000256299.1	RP11-989F5.3	-15.96	2.54e-46	3.82e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130814368	chr12:130810821~130812622:-
LUAD	cis	rs7301826	0.651	rs7295705	ENSG00000256299.1	RP11-989F5.3	-15.96	2.54e-46	3.82e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130817340	chr12:130810821~130812622:-
LUAD	cis	rs7301826	0.651	rs4514465	ENSG00000256299.1	RP11-989F5.3	-15.95	2.94e-46	4.4e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130829124	chr12:130810821~130812622:-
LUAD	cis	rs9322193	0.847	rs868375	ENSG00000231760.4	RP11-350J20.5	15.91	4.43e-46	6.56e-42	0.75	0.59	Lung cancer;	chr6:149844905	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.76	rs1002286	ENSG00000250470.1	AP000351.3	-15.89	5.1e-46	7.52e-42	-0.72	-0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23976904~23977585:-
LUAD	cis	rs2739330	0.753	rs4822452	ENSG00000225282.1	AP000350.6	15.89	5.28e-46	7.78e-42	0.69	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23926900~23929574:+
LUAD	cis	rs7301826	0.571	rs4759788	ENSG00000256299.1	RP11-989F5.3	-15.88	5.6e-46	8.25e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130811769	chr12:130810821~130812622:-
LUAD	cis	rs7301826	0.61	rs4759789	ENSG00000256299.1	RP11-989F5.3	-15.88	5.6e-46	8.25e-42	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130811835	chr12:130810821~130812622:-
LUAD	cis	rs7617773	0.817	rs6806112	ENSG00000229759.1	MRPS18AP1	15.88	5.82e-46	8.56e-42	0.58	0.59	Coronary artery disease;	chr3:48234587	chr3:48256350~48256938:-
LUAD	cis	rs9326248	0.581	rs7121898	ENSG00000254851.1	RP11-109L13.1	-15.87	6.26e-46	9.19e-42	-0.77	-0.59	Blood protein levels;	chr11:116926130	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.52	rs1446105	ENSG00000254851.1	RP11-109L13.1	-15.87	6.26e-46	9.19e-42	-0.77	-0.59	Blood protein levels;	chr11:116927828	chr11:117135528~117138582:+
LUAD	cis	rs7301826	0.651	rs10773824	ENSG00000256299.1	RP11-989F5.3	-15.87	6.37e-46	9.35e-42	-0.65	-0.59	Plasma plasminogen activator levels;	chr12:130814306	chr12:130810821~130812622:-
LUAD	cis	rs2739330	0.828	rs2154593	ENSG00000225282.1	AP000350.6	15.87	6.45e-46	9.47e-42	0.69	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23926900~23929574:+
LUAD	cis	rs7104764	1	rs6598060	ENSG00000277290.1	RP11-326C3.16	-15.86	7.02e-46	1.03e-41	-0.58	-0.59	Menarche (age at onset);	chr11:243987	chr11:243099~243483:-
LUAD	cis	rs916888	0.647	rs199523	ENSG00000262539.1	RP11-259G18.3	-15.86	7.22e-46	1.06e-41	-0.79	-0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46259551~46260606:-
LUAD	cis	rs2739330	0.828	rs5760108	ENSG00000225282.1	AP000350.6	15.86	7.27e-46	1.06e-41	0.69	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23926900~23929574:+
LUAD	cis	rs7301826	0.651	rs7971046	ENSG00000256299.1	RP11-989F5.3	-15.85	7.89e-46	1.15e-41	-0.66	-0.59	Plasma plasminogen activator levels;	chr12:130802262	chr12:130810821~130812622:-
LUAD	cis	rs916888	0.61	rs199530	ENSG00000262539.1	RP11-259G18.3	-15.85	8.11e-46	1.18e-41	-0.79	-0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46259551~46260606:-
LUAD	cis	rs9326248	0.581	rs7120963	ENSG00000254851.1	RP11-109L13.1	15.83	9.81e-46	1.43e-41	0.75	0.59	Blood protein levels;	chr11:116959545	chr11:117135528~117138582:+
LUAD	cis	rs1577917	0.785	rs1885607	ENSG00000203875.9	SNHG5	15.83	9.97e-46	1.45e-41	0.76	0.59	Response to antipsychotic treatment;	chr6:85685187	chr6:85660950~85678736:-
LUAD	cis	rs2739330	0.587	rs4820571	ENSG00000273295.1	AP000350.5	15.83	1.02e-45	1.49e-41	0.67	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23901432~23907068:-
LUAD	cis	rs7301826	0.651	rs1554807	ENSG00000256299.1	RP11-989F5.3	15.82	1.06e-45	1.53e-41	0.66	0.59	Plasma plasminogen activator levels;	chr12:130795872	chr12:130810821~130812622:-
LUAD	cis	rs2882667	0.867	rs11749045	ENSG00000253404.1	AC034243.1	15.82	1.1e-45	1.6e-41	0.74	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085271	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.67	rs3807452	ENSG00000230658.1	KLHL7-AS1	-15.81	1.26e-45	1.82e-41	-0.67	-0.58	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.896	rs1637193	ENSG00000230658.1	KLHL7-AS1	15.8	1.36e-45	1.97e-41	0.7	0.58	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23101228~23105703:-
LUAD	cis	rs7301826	0.651	rs7132657	ENSG00000256299.1	RP11-989F5.3	-15.79	1.43e-45	2.06e-41	-0.66	-0.58	Plasma plasminogen activator levels;	chr12:130800642	chr12:130810821~130812622:-
LUAD	cis	rs9326248	0.581	rs12225187	ENSG00000254851.1	RP11-109L13.1	-15.79	1.44e-45	2.08e-41	-0.76	-0.58	Blood protein levels;	chr11:116922515	chr11:117135528~117138582:+
LUAD	cis	rs2882667	0.931	rs10075893	ENSG00000253404.1	AC034243.1	-15.79	1.48e-45	2.14e-41	-0.74	-0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020182	chr5:138744434~138753309:-
LUAD	cis	rs7617773	0.694	rs13099560	ENSG00000229759.1	MRPS18AP1	-15.79	1.55e-45	2.24e-41	-0.58	-0.58	Coronary artery disease;	chr3:48163278	chr3:48256350~48256938:-
LUAD	cis	rs858239	0.899	rs2268745	ENSG00000230658.1	KLHL7-AS1	15.79	1.57e-45	2.26e-41	0.75	0.58	Cerebrospinal fluid biomarker levels;	chr7:23277981	chr7:23101228~23105703:-
LUAD	cis	rs1153858	0.621	rs1719237	ENSG00000259520.4	CTD-2651B20.3	-15.78	1.6e-45	2.31e-41	-0.81	-0.58	Homoarginine levels;	chr15:45287624	chr15:45251580~45279251:-
LUAD	cis	rs1153858	0.621	rs1706824	ENSG00000259520.4	CTD-2651B20.3	-15.78	1.65e-45	2.38e-41	-0.81	-0.58	Homoarginine levels;	chr15:45287750	chr15:45251580~45279251:-
LUAD	cis	rs6452524	0.618	rs1478487	ENSG00000249664.1	CTD-2227C6.2	15.76	1.99e-45	2.87e-41	0.65	0.58	Hypertension (SNP x SNP interaction);	chr5:83080900	chr5:83012285~83013109:-
LUAD	cis	rs858239	0.699	rs1881201	ENSG00000230658.1	KLHL7-AS1	-15.76	2.03e-45	2.92e-41	-0.7	-0.58	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.899	rs28635122	ENSG00000230658.1	KLHL7-AS1	15.75	2.21e-45	3.18e-41	0.74	0.58	Cerebrospinal fluid biomarker levels;	chr7:23270562	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.899	rs7794684	ENSG00000230658.1	KLHL7-AS1	15.75	2.21e-45	3.18e-41	0.74	0.58	Cerebrospinal fluid biomarker levels;	chr7:23271186	chr7:23101228~23105703:-
LUAD	cis	rs9322193	0.884	rs880245	ENSG00000231760.4	RP11-350J20.5	-15.73	2.65e-45	3.81e-41	-0.76	-0.58	Lung cancer;	chr6:149846262	chr6:149796151~149826294:-
LUAD	cis	rs916888	0.647	rs199524	ENSG00000262539.1	RP11-259G18.3	-15.71	3.4e-45	4.86e-41	-0.79	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46259551~46260606:-
LUAD	cis	rs4423214	1	rs12785878	ENSG00000254682.1	RP11-660L16.2	15.71	3.43e-45	4.9e-41	0.75	0.58	Vitamin D levels;	chr11:71456403	chr11:71448674~71452157:+
LUAD	cis	rs1577917	0.518	rs2475787	ENSG00000203875.9	SNHG5	15.71	3.59e-45	5.12e-41	0.71	0.58	Response to antipsychotic treatment;	chr6:85705518	chr6:85660950~85678736:-
LUAD	cis	rs7301826	0.651	rs2037789	ENSG00000256299.1	RP11-989F5.3	15.7	3.74e-45	5.33e-41	0.65	0.58	Plasma plasminogen activator levels;	chr12:130803747	chr12:130810821~130812622:-
LUAD	cis	rs1577917	0.771	rs2484355	ENSG00000203875.9	SNHG5	-15.7	3.98e-45	5.67e-41	-0.75	-0.58	Response to antipsychotic treatment;	chr6:85684685	chr6:85660950~85678736:-
LUAD	cis	rs2882667	0.931	rs10070021	ENSG00000253404.1	AC034243.1	15.68	4.52e-45	6.42e-41	0.73	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138989017	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.898	rs11952020	ENSG00000253404.1	AC034243.1	15.68	4.66e-45	6.62e-41	0.74	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059467	chr5:138744434~138753309:-
LUAD	cis	rs7617773	0.817	rs6787500	ENSG00000229759.1	MRPS18AP1	15.68	4.75e-45	6.74e-41	0.59	0.58	Coronary artery disease;	chr3:48257949	chr3:48256350~48256938:-
LUAD	cis	rs7301826	0.58	rs12821464	ENSG00000256250.1	RP11-989F5.1	15.68	4.8e-45	6.81e-41	0.68	0.58	Plasma plasminogen activator levels;	chr12:130838174	chr12:130810606~130812438:+
LUAD	cis	rs2882667	0.898	rs3828600	ENSG00000253404.1	AC034243.1	15.68	4.93e-45	7e-41	0.75	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051170	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.828	rs2877178	ENSG00000225282.1	AP000350.6	15.67	5.44e-45	7.71e-41	0.69	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23926900~23929574:+
LUAD	cis	rs1577917	0.771	rs2842613	ENSG00000203875.9	SNHG5	15.65	6.27e-45	8.87e-41	0.75	0.58	Response to antipsychotic treatment;	chr6:85595984	chr6:85660950~85678736:-
LUAD	cis	rs858239	0.899	rs10085838	ENSG00000230658.1	KLHL7-AS1	15.64	7.29e-45	1.03e-40	0.73	0.58	Cerebrospinal fluid biomarker levels;	chr7:23258796	chr7:23101228~23105703:-
LUAD	cis	rs6452524	0.618	rs4266384	ENSG00000249664.1	CTD-2227C6.2	15.63	7.92e-45	1.12e-40	0.65	0.58	Hypertension (SNP x SNP interaction);	chr5:83080872	chr5:83012285~83013109:-
LUAD	cis	rs1577917	0.518	rs6454482	ENSG00000203875.9	SNHG5	15.62	8.44e-45	1.19e-40	0.71	0.58	Response to antipsychotic treatment;	chr6:85708470	chr6:85660950~85678736:-
LUAD	cis	rs2882667	1	rs10515505	ENSG00000253404.1	AC034243.1	15.61	9.42e-45	1.32e-40	0.73	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138977457	chr5:138744434~138753309:-
LUAD	cis	rs1577917	0.816	rs12664099	ENSG00000203875.9	SNHG5	-15.59	1.15e-44	1.61e-40	-0.75	-0.58	Response to antipsychotic treatment;	chr6:85938854	chr6:85660950~85678736:-
LUAD	cis	rs1153858	0.621	rs12913645	ENSG00000259520.4	CTD-2651B20.3	15.59	1.24e-44	1.73e-40	0.8	0.58	Homoarginine levels;	chr15:45262868	chr15:45251580~45279251:-
LUAD	cis	rs7617773	0.817	rs11130162	ENSG00000229759.1	MRPS18AP1	15.59	1.25e-44	1.75e-40	0.58	0.58	Coronary artery disease;	chr3:48256121	chr3:48256350~48256938:-
LUAD	cis	rs2882667	0.898	rs11950819	ENSG00000253404.1	AC034243.1	15.58	1.39e-44	1.95e-40	0.75	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061411	chr5:138744434~138753309:-
LUAD	cis	rs997154	0.579	rs12889177	ENSG00000279656.1	RP11-298I3.6	-15.58	1.4e-44	1.95e-40	-0.82	-0.58	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:23022120	chr14:23023083~23024217:-
LUAD	cis	rs2882667	0.931	rs10077796	ENSG00000253404.1	AC034243.1	-15.56	1.66e-44	2.31e-40	-0.74	-0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021086	chr5:138744434~138753309:-
LUAD	cis	rs1799949	0.965	rs8176322	ENSG00000198496.9	NBR2	-15.53	2.27e-44	3.17e-40	-0.61	-0.58	Menopause (age at onset);	chr17:43043756	chr17:43125610~43153671:+
LUAD	cis	rs858239	0.899	rs2268747	ENSG00000230658.1	KLHL7-AS1	15.52	2.41e-44	3.36e-40	0.74	0.58	Cerebrospinal fluid biomarker levels;	chr7:23273843	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.896	rs1637192	ENSG00000230658.1	KLHL7-AS1	15.52	2.52e-44	3.5e-40	0.69	0.58	Cerebrospinal fluid biomarker levels;	chr7:23220895	chr7:23101228~23105703:-
LUAD	cis	rs2739330	0.76	rs5751761	ENSG00000218537.1	MIF-AS1	-15.52	2.59e-44	3.6e-40	-0.7	-0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23894426~23898930:-
LUAD	cis	rs7301826	0.557	rs7953184	ENSG00000256299.1	RP11-989F5.3	15.51	2.72e-44	3.78e-40	0.65	0.58	Plasma plasminogen activator levels;	chr12:130800307	chr12:130810821~130812622:-
LUAD	cis	rs801193	1	rs2659909	ENSG00000226824.5	RP4-756H11.3	-15.51	2.84e-44	3.94e-40	-0.73	-0.58	Aortic root size;	chr7:66695292	chr7:66654538~66669855:+
LUAD	cis	rs2882667	0.838	rs11958529	ENSG00000253404.1	AC034243.1	15.51	2.84e-44	3.94e-40	0.75	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059379	chr5:138744434~138753309:-
LUAD	cis	rs1577917	0.771	rs2842608	ENSG00000203875.9	SNHG5	-15.5	3.15e-44	4.35e-40	-0.75	-0.58	Response to antipsychotic treatment;	chr6:85586140	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.771	rs2842601	ENSG00000203875.9	SNHG5	-15.49	3.37e-44	4.65e-40	-0.75	-0.58	Response to antipsychotic treatment;	chr6:85620415	chr6:85660950~85678736:-
LUAD	cis	rs2882667	0.931	rs10075951	ENSG00000253404.1	AC034243.1	15.49	3.39e-44	4.67e-40	0.74	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020274	chr5:138744434~138753309:-
LUAD	cis	rs1577917	0.771	rs2842612	ENSG00000203875.9	SNHG5	-15.49	3.4e-44	4.68e-40	-0.75	-0.58	Response to antipsychotic treatment;	chr6:85593373	chr6:85660950~85678736:-
LUAD	cis	rs2882667	0.861	rs11959727	ENSG00000253404.1	AC034243.1	15.49	3.44e-44	4.72e-40	0.75	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061276	chr5:138744434~138753309:-
LUAD	cis	rs4423214	0.879	rs4945008	ENSG00000254682.1	RP11-660L16.2	15.49	3.46e-44	4.75e-40	0.74	0.58	Vitamin D levels;	chr11:71510202	chr11:71448674~71452157:+
LUAD	cis	rs1577917	0.727	rs2758840	ENSG00000203875.9	SNHG5	-15.49	3.48e-44	4.78e-40	-0.75	-0.58	Response to antipsychotic treatment;	chr6:85594907	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.771	rs9362230	ENSG00000203875.9	SNHG5	-15.49	3.48e-44	4.78e-40	-0.75	-0.58	Response to antipsychotic treatment;	chr6:85595295	chr6:85660950~85678736:-
LUAD	cis	rs7301826	0.603	rs7975825	ENSG00000256250.1	RP11-989F5.1	-15.48	3.81e-44	5.22e-40	-0.66	-0.58	Plasma plasminogen activator levels;	chr12:130803899	chr12:130810606~130812438:+
LUAD	cis	rs7301826	0.61	rs7957899	ENSG00000256299.1	RP11-989F5.3	-15.47	3.95e-44	5.41e-40	-0.65	-0.58	Plasma plasminogen activator levels;	chr12:130794531	chr12:130810821~130812622:-
LUAD	cis	rs4423214	0.959	rs12793224	ENSG00000254682.1	RP11-660L16.2	15.47	4.04e-44	5.53e-40	0.75	0.58	Vitamin D levels;	chr11:71457664	chr11:71448674~71452157:+
LUAD	cis	rs4423214	0.959	rs12794668	ENSG00000254682.1	RP11-660L16.2	15.47	4.04e-44	5.53e-40	0.75	0.58	Vitamin D levels;	chr11:71457669	chr11:71448674~71452157:+
LUAD	cis	rs2882667	0.894	rs10054478	ENSG00000253404.1	AC034243.1	15.46	4.78e-44	6.54e-40	0.74	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018386	chr5:138744434~138753309:-
LUAD	cis	rs3814244	0.54	rs2159064	ENSG00000255733.4	IFNG-AS1	-15.45	5.07e-44	6.94e-40	-0.5	-0.58	Itch intensity from mosquito bite adjusted by bite size;	chr12:68017126	chr12:67989445~68234686:+
LUAD	cis	rs9326248	0.52	rs10892060	ENSG00000254851.1	RP11-109L13.1	-15.45	5.26e-44	7.18e-40	-0.75	-0.58	Blood protein levels;	chr11:117010946	chr11:117135528~117138582:+
LUAD	cis	rs2882667	0.931	rs10069528	ENSG00000253404.1	AC034243.1	15.44	5.61e-44	7.64e-40	0.74	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018338	chr5:138744434~138753309:-
LUAD	cis	rs7301826	0.651	rs1973834	ENSG00000256299.1	RP11-989F5.3	-15.44	5.73e-44	7.8e-40	-0.65	-0.58	Plasma plasminogen activator levels;	chr12:130795612	chr12:130810821~130812622:-
LUAD	cis	rs2739330	0.828	rs2186366	ENSG00000225282.1	AP000350.6	-15.41	8.12e-44	1.1e-39	-0.68	-0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23926900~23929574:+
LUAD	cis	rs1577917	0.771	rs12199873	ENSG00000203875.9	SNHG5	-15.4	8.25e-44	1.12e-39	-0.75	-0.57	Response to antipsychotic treatment;	chr6:85585229	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.771	rs2842609	ENSG00000203875.9	SNHG5	-15.4	8.25e-44	1.12e-39	-0.75	-0.57	Response to antipsychotic treatment;	chr6:85587070	chr6:85660950~85678736:-
LUAD	cis	rs4423214	1	rs4944958	ENSG00000254682.1	RP11-660L16.2	15.39	9.69e-44	1.31e-39	0.75	0.57	Vitamin D levels;	chr11:71457027	chr11:71448674~71452157:+
LUAD	cis	rs2882667	0.898	rs11749944	ENSG00000253404.1	AC034243.1	15.38	1.02e-43	1.37e-39	0.73	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077090	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.931	rs10075039	ENSG00000253404.1	AC034243.1	15.38	1.03e-43	1.39e-39	0.73	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002165	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.931	rs13153618	ENSG00000253404.1	AC034243.1	15.37	1.2e-43	1.61e-39	0.73	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139017087	chr5:138744434~138753309:-
LUAD	cis	rs801193	1	rs10234018	ENSG00000226824.5	RP4-756H11.3	15.37	1.22e-43	1.65e-39	0.73	0.57	Aortic root size;	chr7:66681297	chr7:66654538~66669855:+
LUAD	cis	rs2739330	0.828	rs5760107	ENSG00000225282.1	AP000350.6	15.36	1.31e-43	1.76e-39	0.68	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23926900~23929574:+
LUAD	cis	rs2739330	0.789	rs5760109	ENSG00000225282.1	AP000350.6	15.36	1.31e-43	1.76e-39	0.68	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23926900~23929574:+
LUAD	cis	rs1799949	0.965	rs8176323	ENSG00000198496.9	NBR2	-15.36	1.33e-43	1.79e-39	-0.61	-0.57	Menopause (age at onset);	chr17:43043694	chr17:43125610~43153671:+
LUAD	cis	rs801193	1	rs2420824	ENSG00000226824.5	RP4-756H11.3	15.36	1.35e-43	1.81e-39	0.73	0.57	Aortic root size;	chr7:66666129	chr7:66654538~66669855:+
LUAD	cis	rs1799949	1	rs4793190	ENSG00000198496.9	NBR2	-15.35	1.42e-43	1.9e-39	-0.61	-0.57	Menopause (age at onset);	chr17:43048092	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs8176297	ENSG00000198496.9	NBR2	-15.35	1.42e-43	1.9e-39	-0.61	-0.57	Menopause (age at onset);	chr17:43051308	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs8176296	ENSG00000198496.9	NBR2	-15.35	1.42e-43	1.9e-39	-0.61	-0.57	Menopause (age at onset);	chr17:43051574	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs4793191	ENSG00000198496.9	NBR2	-15.35	1.42e-43	1.9e-39	-0.61	-0.57	Menopause (age at onset);	chr17:43052360	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs4793192	ENSG00000198496.9	NBR2	-15.35	1.42e-43	1.9e-39	-0.61	-0.57	Menopause (age at onset);	chr17:43052373	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs8176289	ENSG00000198496.9	NBR2	-15.35	1.42e-43	1.9e-39	-0.61	-0.57	Menopause (age at onset);	chr17:43054039	chr17:43125610~43153671:+
LUAD	cis	rs1153858	0.621	rs2413769	ENSG00000259520.4	CTD-2651B20.3	-15.35	1.51e-43	2.01e-39	-0.8	-0.57	Homoarginine levels;	chr15:45269670	chr15:45251580~45279251:-
LUAD	cis	rs2882667	0.898	rs10079634	ENSG00000253404.1	AC034243.1	15.34	1.57e-43	2.09e-39	0.73	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077364	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.898	rs10058347	ENSG00000253404.1	AC034243.1	15.34	1.58e-43	2.1e-39	0.73	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025669	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.931	rs10068237	ENSG00000253404.1	AC034243.1	15.34	1.59e-43	2.12e-39	0.73	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002271	chr5:138744434~138753309:-
LUAD	cis	rs992157	0.965	rs62182826	ENSG00000261338.2	RP11-378A13.1	15.34	1.61e-43	2.15e-39	0.56	0.57	Colorectal cancer;	chr2:218284000	chr2:218255319~218257366:+
LUAD	cis	rs992157	1	rs13429408	ENSG00000261338.2	RP11-378A13.1	15.34	1.62e-43	2.16e-39	0.56	0.57	Colorectal cancer;	chr2:218278137	chr2:218255319~218257366:+
LUAD	cis	rs9326248	0.574	rs1263173	ENSG00000254851.1	RP11-109L13.1	-15.34	1.66e-43	2.21e-39	-0.74	-0.57	Blood protein levels;	chr11:116810292	chr11:117135528~117138582:+
LUAD	cis	rs7301826	0.651	rs4759517	ENSG00000256299.1	RP11-989F5.3	-15.34	1.67e-43	2.23e-39	-0.64	-0.57	Plasma plasminogen activator levels;	chr12:130799153	chr12:130810821~130812622:-
LUAD	cis	rs4423214	1	rs7935125	ENSG00000254682.1	RP11-660L16.2	15.33	1.73e-43	2.3e-39	0.75	0.57	Vitamin D levels;	chr11:71473144	chr11:71448674~71452157:+
LUAD	cis	rs2882667	0.931	rs3749665	ENSG00000253404.1	AC034243.1	15.33	1.74e-43	2.32e-39	0.74	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021522	chr5:138744434~138753309:-
LUAD	cis	rs6538678	0.857	rs4762626	ENSG00000258343.1	RP11-536G4.2	-15.32	1.89e-43	2.52e-39	-0.9	-0.57	Lupus nephritis in systemic lupus erythematosus;	chr12:95811383	chr12:95795345~95858839:-
LUAD	cis	rs801193	1	rs2707850	ENSG00000226824.5	RP4-756H11.3	-15.32	1.94e-43	2.57e-39	-0.72	-0.57	Aortic root size;	chr7:66738883	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.967	rs1110414	ENSG00000226824.5	RP4-756H11.3	-15.32	1.94e-43	2.57e-39	-0.72	-0.57	Aortic root size;	chr7:66740595	chr7:66654538~66669855:+
LUAD	cis	rs801193	1	rs7783924	ENSG00000226824.5	RP4-756H11.3	-15.32	1.94e-43	2.57e-39	-0.72	-0.57	Aortic root size;	chr7:66744070	chr7:66654538~66669855:+
LUAD	cis	rs801193	1	rs7789184	ENSG00000226824.5	RP4-756H11.3	-15.32	1.94e-43	2.57e-39	-0.72	-0.57	Aortic root size;	chr7:66745208	chr7:66654538~66669855:+
LUAD	cis	rs2882667	1	rs10064130	ENSG00000253404.1	AC034243.1	15.32	1.94e-43	2.57e-39	0.74	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973618	chr5:138744434~138753309:-
LUAD	cis	rs801193	1	rs2707854	ENSG00000226824.5	RP4-756H11.3	-15.32	2.04e-43	2.7e-39	-0.72	-0.57	Aortic root size;	chr7:66747610	chr7:66654538~66669855:+
LUAD	cis	rs2739330	0.828	rs4822454	ENSG00000225282.1	AP000350.6	15.32	2.05e-43	2.72e-39	0.68	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23926900~23929574:+
LUAD	cis	rs1799949	1	rs12516	ENSG00000198496.9	NBR2	-15.31	2.11e-43	2.78e-39	-0.61	-0.57	Menopause (age at onset);	chr17:43044391	chr17:43125610~43153671:+
LUAD	cis	rs2882667	0.931	rs10077896	ENSG00000253404.1	AC034243.1	15.3	2.33e-43	3.07e-39	0.73	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021067	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.898	rs2116789	ENSG00000253404.1	AC034243.1	15.3	2.35e-43	3.1e-39	0.74	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058573	chr5:138744434~138753309:-
LUAD	cis	rs4423214	1	rs2002063	ENSG00000254682.1	RP11-660L16.2	15.3	2.37e-43	3.11e-39	0.74	0.57	Vitamin D levels;	chr11:71452430	chr11:71448674~71452157:+
LUAD	cis	rs4423214	1	rs11600860	ENSG00000254682.1	RP11-660L16.2	15.3	2.37e-43	3.11e-39	0.74	0.57	Vitamin D levels;	chr11:71452973	chr11:71448674~71452157:+
LUAD	cis	rs4423214	0.959	rs11606611	ENSG00000254682.1	RP11-660L16.2	15.3	2.37e-43	3.11e-39	0.74	0.57	Vitamin D levels;	chr11:71453000	chr11:71448674~71452157:+
LUAD	cis	rs4423214	1	rs11606612	ENSG00000254682.1	RP11-660L16.2	15.3	2.37e-43	3.11e-39	0.74	0.57	Vitamin D levels;	chr11:71453001	chr11:71448674~71452157:+
LUAD	cis	rs4423214	1	rs11606631	ENSG00000254682.1	RP11-660L16.2	15.3	2.37e-43	3.11e-39	0.74	0.57	Vitamin D levels;	chr11:71453075	chr11:71448674~71452157:+
LUAD	cis	rs4423214	1	rs12789751	ENSG00000254682.1	RP11-660L16.2	15.3	2.37e-43	3.11e-39	0.74	0.57	Vitamin D levels;	chr11:71453425	chr11:71448674~71452157:+
LUAD	cis	rs4423214	1	rs12791871	ENSG00000254682.1	RP11-660L16.2	15.3	2.37e-43	3.11e-39	0.74	0.57	Vitamin D levels;	chr11:71453498	chr11:71448674~71452157:+
LUAD	cis	rs4423214	1	rs7944926	ENSG00000254682.1	RP11-660L16.2	15.3	2.37e-43	3.11e-39	0.74	0.57	Vitamin D levels;	chr11:71454579	chr11:71448674~71452157:+
LUAD	cis	rs858239	0.669	rs1990365	ENSG00000230658.1	KLHL7-AS1	15.3	2.38e-43	3.12e-39	0.69	0.57	Cerebrospinal fluid biomarker levels;	chr7:23076347	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.861	rs13176902	ENSG00000253404.1	AC034243.1	15.29	2.55e-43	3.34e-39	0.74	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139057640	chr5:138744434~138753309:-
LUAD	cis	rs7104764	1	rs6598069	ENSG00000277290.1	RP11-326C3.16	-15.29	2.57e-43	3.37e-39	-0.57	-0.57	Menarche (age at onset);	chr11:240664	chr11:243099~243483:-
LUAD	cis	rs2882667	0.861	rs10075541	ENSG00000253404.1	AC034243.1	15.29	2.66e-43	3.49e-39	0.74	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054629	chr5:138744434~138753309:-
LUAD	cis	rs1577917	0.771	rs2758844	ENSG00000203875.9	SNHG5	-15.28	2.85e-43	3.73e-39	-0.75	-0.57	Response to antipsychotic treatment;	chr6:85620397	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.538	rs7755996	ENSG00000203875.9	SNHG5	15.28	2.94e-43	3.84e-39	0.69	0.57	Response to antipsychotic treatment;	chr6:85714002	chr6:85660950~85678736:-
LUAD	cis	rs4423214	1	rs3794060	ENSG00000254682.1	RP11-660L16.2	15.28	2.97e-43	3.88e-39	0.74	0.57	Vitamin D levels;	chr11:71476633	chr11:71448674~71452157:+
LUAD	cis	rs2882667	0.931	rs10038799	ENSG00000253404.1	AC034243.1	15.28	2.99e-43	3.91e-39	0.74	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139026594	chr5:138744434~138753309:-
LUAD	cis	rs6597981	0.592	rs10902218	ENSG00000279672.1	CMB9-55F22.1	-15.28	3.06e-43	4e-39	-0.59	-0.57	Breast cancer;	chr11:743813	chr11:779617~780755:+
LUAD	cis	rs2882667	0.898	rs2043272	ENSG00000253404.1	AC034243.1	15.28	3.08e-43	4.01e-39	0.74	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054942	chr5:138744434~138753309:-
LUAD	cis	rs4423214	1	rs12790010	ENSG00000254682.1	RP11-660L16.2	15.28	3.09e-43	4.03e-39	0.74	0.57	Vitamin D levels;	chr11:71459607	chr11:71448674~71452157:+
LUAD	cis	rs4423214	1	rs12806844	ENSG00000254682.1	RP11-660L16.2	15.28	3.09e-43	4.03e-39	0.74	0.57	Vitamin D levels;	chr11:71459724	chr11:71448674~71452157:+
LUAD	cis	rs4423214	1	rs12790558	ENSG00000254682.1	RP11-660L16.2	15.28	3.09e-43	4.03e-39	0.74	0.57	Vitamin D levels;	chr11:71459859	chr11:71448674~71452157:+
LUAD	cis	rs4423214	0.959	rs11233747	ENSG00000254682.1	RP11-660L16.2	15.28	3.09e-43	4.03e-39	0.74	0.57	Vitamin D levels;	chr11:71460596	chr11:71448674~71452157:+
LUAD	cis	rs4423214	1	rs11600569	ENSG00000254682.1	RP11-660L16.2	15.28	3.09e-43	4.03e-39	0.74	0.57	Vitamin D levels;	chr11:71462701	chr11:71448674~71452157:+
LUAD	cis	rs858239	0.899	rs5850	ENSG00000230658.1	KLHL7-AS1	15.27	3.42e-43	4.45e-39	0.72	0.57	Cerebrospinal fluid biomarker levels;	chr7:23274928	chr7:23101228~23105703:-
LUAD	cis	rs9322193	0.651	rs9322188	ENSG00000231760.4	RP11-350J20.5	-15.26	3.5e-43	4.54e-39	-0.7	-0.57	Lung cancer;	chr6:149588355	chr6:149796151~149826294:-
LUAD	cis	rs1153858	0.621	rs2687512	ENSG00000259520.4	CTD-2651B20.3	15.26	3.62e-43	4.69e-39	0.81	0.57	Homoarginine levels;	chr15:45289297	chr15:45251580~45279251:-
LUAD	cis	rs858239	0.932	rs1624451	ENSG00000230658.1	KLHL7-AS1	-15.26	3.79e-43	4.9e-39	-0.68	-0.57	Cerebrospinal fluid biomarker levels;	chr7:23222816	chr7:23101228~23105703:-
LUAD	cis	rs1799949	1	rs35330014	ENSG00000198496.9	NBR2	-15.26	3.79e-43	4.9e-39	-0.61	-0.57	Menopause (age at onset);	chr17:43060530	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs3092994	ENSG00000198496.9	NBR2	-15.26	3.79e-43	4.9e-39	-0.61	-0.57	Menopause (age at onset);	chr17:43063808	chr17:43125610~43153671:+
LUAD	cis	rs2882667	0.898	rs6882330	ENSG00000253404.1	AC034243.1	15.26	3.81e-43	4.93e-39	0.73	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046493	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.898	rs6882526	ENSG00000253404.1	AC034243.1	15.26	3.81e-43	4.93e-39	0.73	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046679	chr5:138744434~138753309:-
LUAD	cis	rs1799949	1	rs8176220	ENSG00000198496.9	NBR2	-15.26	3.84e-43	4.96e-39	-0.61	-0.57	Menopause (age at onset);	chr17:43070445	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs1799966	ENSG00000198496.9	NBR2	-15.26	3.84e-43	4.96e-39	-0.61	-0.57	Menopause (age at onset);	chr17:43071077	chr17:43125610~43153671:+
LUAD	cis	rs2882667	0.861	rs10043676	ENSG00000253404.1	AC034243.1	15.25	3.87e-43	5e-39	0.74	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053872	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.898	rs10038121	ENSG00000253404.1	AC034243.1	15.25	3.87e-43	5e-39	0.74	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053913	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.898	rs10045761	ENSG00000253404.1	AC034243.1	15.25	4.02e-43	5.18e-39	0.74	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061600	chr5:138744434~138753309:-
LUAD	cis	rs7104764	1	rs7395328	ENSG00000277290.1	RP11-326C3.16	-15.25	4.22e-43	5.4e-39	-0.57	-0.57	Menarche (age at onset);	chr11:242624	chr11:243099~243483:-
LUAD	cis	rs7104764	0.917	rs6598068	ENSG00000277290.1	RP11-326C3.16	-15.25	4.22e-43	5.4e-39	-0.57	-0.57	Menarche (age at onset);	chr11:243092	chr11:243099~243483:-
LUAD	cis	rs7104764	0.917	rs6598067	ENSG00000277290.1	RP11-326C3.16	-15.25	4.22e-43	5.4e-39	-0.57	-0.57	Menarche (age at onset);	chr11:243093	chr11:243099~243483:-
LUAD	cis	rs7104764	1	rs6598065	ENSG00000277290.1	RP11-326C3.16	-15.25	4.22e-43	5.4e-39	-0.57	-0.57	Menarche (age at onset);	chr11:243211	chr11:243099~243483:-
LUAD	cis	rs7104764	0.957	rs6598064	ENSG00000277290.1	RP11-326C3.16	-15.25	4.22e-43	5.4e-39	-0.57	-0.57	Menarche (age at onset);	chr11:243557	chr11:243099~243483:-
LUAD	cis	rs7104764	1	rs6598063	ENSG00000277290.1	RP11-326C3.16	-15.25	4.22e-43	5.4e-39	-0.57	-0.57	Menarche (age at onset);	chr11:243672	chr11:243099~243483:-
LUAD	cis	rs7104764	1	rs6598062	ENSG00000277290.1	RP11-326C3.16	-15.25	4.22e-43	5.4e-39	-0.57	-0.57	Menarche (age at onset);	chr11:243712	chr11:243099~243483:-
LUAD	cis	rs7104764	1	rs6598061	ENSG00000277290.1	RP11-326C3.16	-15.25	4.22e-43	5.4e-39	-0.57	-0.57	Menarche (age at onset);	chr11:243853	chr11:243099~243483:-
LUAD	cis	rs7104764	1	rs10902112	ENSG00000277290.1	RP11-326C3.16	-15.25	4.22e-43	5.4e-39	-0.57	-0.57	Menarche (age at onset);	chr11:244106	chr11:243099~243483:-
LUAD	cis	rs7104764	0.917	rs7107362	ENSG00000277290.1	RP11-326C3.16	-15.25	4.22e-43	5.4e-39	-0.57	-0.57	Menarche (age at onset);	chr11:244108	chr11:243099~243483:-
LUAD	cis	rs7104764	1	rs7128044	ENSG00000277290.1	RP11-326C3.16	-15.25	4.22e-43	5.4e-39	-0.57	-0.57	Menarche (age at onset);	chr11:244115	chr11:243099~243483:-
LUAD	cis	rs7104764	0.957	rs7116130	ENSG00000277290.1	RP11-326C3.16	-15.25	4.22e-43	5.4e-39	-0.57	-0.57	Menarche (age at onset);	chr11:244129	chr11:243099~243483:-
LUAD	cis	rs7104764	1	rs7128029	ENSG00000277290.1	RP11-326C3.16	-15.25	4.22e-43	5.4e-39	-0.57	-0.57	Menarche (age at onset);	chr11:244141	chr11:243099~243483:-
LUAD	cis	rs7104764	1	rs1128320	ENSG00000277290.1	RP11-326C3.16	-15.25	4.22e-43	5.4e-39	-0.57	-0.57	Menarche (age at onset);	chr11:244167	chr11:243099~243483:-
LUAD	cis	rs7104764	0.957	rs1128321	ENSG00000277290.1	RP11-326C3.16	-15.25	4.22e-43	5.4e-39	-0.57	-0.57	Menarche (age at onset);	chr11:244171	chr11:243099~243483:-
LUAD	cis	rs7104764	1	rs2272565	ENSG00000277290.1	RP11-326C3.16	-15.25	4.22e-43	5.4e-39	-0.57	-0.57	Menarche (age at onset);	chr11:244414	chr11:243099~243483:-
LUAD	cis	rs7104764	1	rs10902113	ENSG00000277290.1	RP11-326C3.16	-15.25	4.22e-43	5.4e-39	-0.57	-0.57	Menarche (age at onset);	chr11:245523	chr11:243099~243483:-
LUAD	cis	rs7104764	1	rs7482591	ENSG00000277290.1	RP11-326C3.16	-15.25	4.22e-43	5.4e-39	-0.57	-0.57	Menarche (age at onset);	chr11:245861	chr11:243099~243483:-
LUAD	cis	rs2882667	1	rs10064201	ENSG00000253404.1	AC034243.1	15.25	4.26e-43	5.45e-39	0.74	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973716	chr5:138744434~138753309:-
LUAD	cis	rs801193	1	rs3800812	ENSG00000226824.5	RP4-756H11.3	-15.24	4.32e-43	5.51e-39	-0.72	-0.57	Aortic root size;	chr7:66758474	chr7:66654538~66669855:+
LUAD	cis	rs801193	1	rs4279493	ENSG00000226824.5	RP4-756H11.3	-15.24	4.32e-43	5.51e-39	-0.72	-0.57	Aortic root size;	chr7:66761633	chr7:66654538~66669855:+
LUAD	cis	rs9326248	0.559	rs609177	ENSG00000254851.1	RP11-109L13.1	-15.24	4.39e-43	5.6e-39	-0.75	-0.57	Blood protein levels;	chr11:116899801	chr11:117135528~117138582:+
LUAD	cis	rs2739330	0.791	rs4822458	ENSG00000231271.1	AP000350.8	15.24	4.57e-43	5.83e-39	0.68	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23949918~23954042:+
LUAD	cis	rs9326248	0.539	rs660443	ENSG00000254851.1	RP11-109L13.1	-15.24	4.63e-43	5.89e-39	-0.75	-0.57	Blood protein levels;	chr11:116889977	chr11:117135528~117138582:+
LUAD	cis	rs2739330	0.791	rs4822458	ENSG00000225282.1	AP000350.6	15.23	4.74e-43	6.03e-39	0.66	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23926900~23929574:+
LUAD	cis	rs7617773	0.746	rs4130995	ENSG00000229759.1	MRPS18AP1	15.23	5.04e-43	6.4e-39	0.57	0.57	Coronary artery disease;	chr3:48316765	chr3:48256350~48256938:-
LUAD	cis	rs801193	1	rs2707845	ENSG00000226824.5	RP4-756H11.3	-15.23	5.15e-43	6.54e-39	-0.72	-0.57	Aortic root size;	chr7:66733811	chr7:66654538~66669855:+
LUAD	cis	rs7104764	1	rs10902114	ENSG00000277290.1	RP11-326C3.16	-15.22	5.28e-43	6.7e-39	-0.57	-0.57	Menarche (age at onset);	chr11:246234	chr11:243099~243483:-
LUAD	cis	rs1577917	0.771	rs7742201	ENSG00000203875.9	SNHG5	-15.22	5.51e-43	6.99e-39	-0.74	-0.57	Response to antipsychotic treatment;	chr6:85723212	chr6:85660950~85678736:-
LUAD	cis	rs3091242	1	rs3091242	ENSG00000261349.1	RP3-465N24.5	-15.21	6.07e-43	7.68e-39	-0.62	-0.57	Erythrocyte sedimentation rate;	chr1:25348294	chr1:25266102~25267136:-
LUAD	cis	rs3091242	0.967	rs3091240	ENSG00000261349.1	RP3-465N24.5	-15.21	6.08e-43	7.7e-39	-0.62	-0.57	Erythrocyte sedimentation rate;	chr1:25350444	chr1:25266102~25267136:-
LUAD	cis	rs3091242	0.935	rs3093632	ENSG00000261349.1	RP3-465N24.5	-15.21	6.09e-43	7.71e-39	-0.62	-0.57	Erythrocyte sedimentation rate;	chr1:25357521	chr1:25266102~25267136:-
LUAD	cis	rs12439619	0.846	rs28697264	ENSG00000278603.1	RP13-608F4.5	15.21	6.12e-43	7.74e-39	0.78	0.57	Intelligence (multi-trait analysis);	chr15:82265559	chr15:82472203~82472426:+
LUAD	cis	rs2486288	0.656	rs11637838	ENSG00000259520.4	CTD-2651B20.3	15.21	6.22e-43	7.86e-39	0.68	0.57	Glomerular filtration rate;	chr15:45258459	chr15:45251580~45279251:-
LUAD	cis	rs2882667	0.898	rs6867343	ENSG00000253404.1	AC034243.1	15.21	6.24e-43	7.88e-39	0.74	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038739	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.828	rs5760099	ENSG00000225282.1	AP000350.6	15.2	6.64e-43	8.37e-39	0.68	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23926900~23929574:+
LUAD	cis	rs7104764	1	rs10902110	ENSG00000277290.1	RP11-326C3.16	-15.19	7.39e-43	9.3e-39	-0.57	-0.57	Menarche (age at onset);	chr11:237648	chr11:243099~243483:-
LUAD	cis	rs7104764	1	rs7481993	ENSG00000277290.1	RP11-326C3.16	-15.19	7.39e-43	9.3e-39	-0.57	-0.57	Menarche (age at onset);	chr11:237875	chr11:243099~243483:-
LUAD	cis	rs992157	1	rs992157	ENSG00000261338.2	RP11-378A13.1	-15.19	7.49e-43	9.41e-39	-0.56	-0.57	Colorectal cancer;	chr2:218290058	chr2:218255319~218257366:+
LUAD	cis	rs7301826	0.651	rs10848206	ENSG00000256299.1	RP11-989F5.3	-15.18	7.95e-43	9.97e-39	-0.64	-0.57	Plasma plasminogen activator levels;	chr12:130796926	chr12:130810821~130812622:-
LUAD	cis	rs1799949	1	rs4793194	ENSG00000198496.9	NBR2	-15.18	8.33e-43	1.04e-38	-0.6	-0.57	Menopause (age at onset);	chr17:43066316	chr17:43125610~43153671:+
LUAD	cis	rs12439619	0.774	rs2867649	ENSG00000278603.1	RP13-608F4.5	15.18	8.38e-43	1.05e-38	0.79	0.57	Intelligence (multi-trait analysis);	chr15:82262331	chr15:82472203~82472426:+
LUAD	cis	rs2739330	0.828	rs2330635	ENSG00000225282.1	AP000350.6	15.18	8.49e-43	1.06e-38	0.68	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23926900~23929574:+
LUAD	cis	rs1577917	0.771	rs4441928	ENSG00000203875.9	SNHG5	15.18	8.5e-43	1.06e-38	0.73	0.57	Response to antipsychotic treatment;	chr6:85532176	chr6:85660950~85678736:-
LUAD	cis	rs2739330	0.828	rs4822451	ENSG00000225282.1	AP000350.6	15.17	8.92e-43	1.11e-38	0.68	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23926900~23929574:+
LUAD	cis	rs2739330	0.828	rs5760098	ENSG00000225282.1	AP000350.6	15.17	8.92e-43	1.11e-38	0.68	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23926900~23929574:+
LUAD	cis	rs2882667	0.898	rs6862393	ENSG00000253404.1	AC034243.1	15.17	8.98e-43	1.12e-38	0.74	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029009	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.894	rs1433008	ENSG00000253404.1	AC034243.1	15.17	9.11e-43	1.14e-38	0.72	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:138997975	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.931	rs12719518	ENSG00000253404.1	AC034243.1	15.17	9.19e-43	1.15e-38	0.73	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139005287	chr5:138744434~138753309:-
LUAD	cis	rs801193	0.935	rs11772264	ENSG00000226824.5	RP4-756H11.3	-15.17	9.57e-43	1.19e-38	-0.72	-0.57	Aortic root size;	chr7:66711400	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.967	rs2707853	ENSG00000226824.5	RP4-756H11.3	-15.16	9.75e-43	1.22e-38	-0.72	-0.57	Aortic root size;	chr7:66749023	chr7:66654538~66669855:+
LUAD	cis	rs801193	1	rs2659889	ENSG00000226824.5	RP4-756H11.3	-15.16	9.75e-43	1.22e-38	-0.72	-0.57	Aortic root size;	chr7:66752125	chr7:66654538~66669855:+
LUAD	cis	rs2882667	0.898	rs2882792	ENSG00000253404.1	AC034243.1	15.16	9.78e-43	1.22e-38	0.73	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044791	chr5:138744434~138753309:-
LUAD	cis	rs9326248	0.559	rs482371	ENSG00000254851.1	RP11-109L13.1	-15.16	9.79e-43	1.22e-38	-0.75	-0.57	Blood protein levels;	chr11:116881447	chr11:117135528~117138582:+
LUAD	cis	rs801193	1	rs62466793	ENSG00000226824.5	RP4-756H11.3	-15.16	9.98e-43	1.24e-38	-0.72	-0.57	Aortic root size;	chr7:66726530	chr7:66654538~66669855:+
LUAD	cis	rs801193	1	rs2707856	ENSG00000226824.5	RP4-756H11.3	-15.16	1.03e-42	1.28e-38	-0.72	-0.57	Aortic root size;	chr7:66746023	chr7:66654538~66669855:+
LUAD	cis	rs801193	1	rs2659906	ENSG00000226824.5	RP4-756H11.3	-15.16	1.05e-42	1.3e-38	-0.72	-0.57	Aortic root size;	chr7:66700323	chr7:66654538~66669855:+
LUAD	cis	rs7617773	0.817	rs11130163	ENSG00000229759.1	MRPS18AP1	15.16	1.05e-42	1.3e-38	0.57	0.57	Coronary artery disease;	chr3:48271168	chr3:48256350~48256938:-
LUAD	cis	rs7301826	0.585	rs6486600	ENSG00000256299.1	RP11-989F5.3	-15.16	1.05e-42	1.31e-38	-0.65	-0.57	Plasma plasminogen activator levels;	chr12:130808432	chr12:130810821~130812622:-
LUAD	cis	rs801193	1	rs1553610	ENSG00000226824.5	RP4-756H11.3	-15.15	1.1e-42	1.36e-38	-0.72	-0.57	Aortic root size;	chr7:66732246	chr7:66654538~66669855:+
LUAD	cis	rs2739330	0.796	rs5760097	ENSG00000225282.1	AP000350.6	15.15	1.1e-42	1.36e-38	0.68	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23926900~23929574:+
LUAD	cis	rs801193	1	rs7782320	ENSG00000226824.5	RP4-756H11.3	-15.15	1.12e-42	1.39e-38	-0.72	-0.57	Aortic root size;	chr7:66712111	chr7:66654538~66669855:+
LUAD	cis	rs1577917	0.71	rs1059306	ENSG00000203875.9	SNHG5	15.15	1.13e-42	1.39e-38	0.75	0.57	Response to antipsychotic treatment;	chr6:85678391	chr6:85660950~85678736:-
LUAD	cis	rs801193	0.935	rs2659899	ENSG00000226824.5	RP4-756H11.3	-15.15	1.16e-42	1.43e-38	-0.72	-0.57	Aortic root size;	chr7:66721734	chr7:66654538~66669855:+
LUAD	cis	rs801193	1	rs62466794	ENSG00000226824.5	RP4-756H11.3	-15.15	1.16e-42	1.43e-38	-0.72	-0.57	Aortic root size;	chr7:66726592	chr7:66654538~66669855:+
LUAD	cis	rs801193	1	rs1553609	ENSG00000226824.5	RP4-756H11.3	-15.15	1.17e-42	1.44e-38	-0.72	-0.57	Aortic root size;	chr7:66732152	chr7:66654538~66669855:+
LUAD	cis	rs2882667	0.898	rs11956089	ENSG00000253404.1	AC034243.1	-15.15	1.19e-42	1.46e-38	-0.72	-0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058915	chr5:138744434~138753309:-
LUAD	cis	rs1577917	0.727	rs9444361	ENSG00000203875.9	SNHG5	15.14	1.2e-42	1.48e-38	0.74	0.57	Response to antipsychotic treatment;	chr6:85691182	chr6:85660950~85678736:-
LUAD	cis	rs2882667	0.898	rs6882583	ENSG00000253404.1	AC034243.1	15.14	1.23e-42	1.51e-38	0.73	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139050107	chr5:138744434~138753309:-
LUAD	cis	rs7104764	1	rs1128322	ENSG00000277290.1	RP11-326C3.16	15.14	1.25e-42	1.54e-38	0.57	0.57	Menarche (age at onset);	chr11:244197	chr11:243099~243483:-
LUAD	cis	rs2882667	0.861	rs11242445	ENSG00000253404.1	AC034243.1	15.14	1.25e-42	1.54e-38	0.72	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139081365	chr5:138744434~138753309:-
LUAD	cis	rs6538678	0.824	rs7299632	ENSG00000258343.1	RP11-536G4.2	-15.13	1.39e-42	1.71e-38	-0.9	-0.57	Lupus nephritis in systemic lupus erythematosus;	chr12:95838376	chr12:95795345~95858839:-
LUAD	cis	rs2882667	0.861	rs10037106	ENSG00000253404.1	AC034243.1	15.13	1.42e-42	1.74e-38	0.73	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029801	chr5:138744434~138753309:-
LUAD	cis	rs4423214	1	rs732934	ENSG00000254682.1	RP11-660L16.2	15.11	1.75e-42	2.14e-38	0.74	0.57	Vitamin D levels;	chr11:71475430	chr11:71448674~71452157:+
LUAD	cis	rs12439619	0.846	rs62013464	ENSG00000278603.1	RP13-608F4.5	15.11	1.76e-42	2.15e-38	0.78	0.57	Intelligence (multi-trait analysis);	chr15:82288250	chr15:82472203~82472426:+
LUAD	cis	rs1577917	0.771	rs2842602	ENSG00000203875.9	SNHG5	-15.11	1.77e-42	2.16e-38	-0.75	-0.57	Response to antipsychotic treatment;	chr6:85622169	chr6:85660950~85678736:-
LUAD	cis	rs2882667	0.964	rs12719517	ENSG00000253404.1	AC034243.1	15.1	1.86e-42	2.28e-38	0.74	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:138969813	chr5:138744434~138753309:-
LUAD	cis	rs992157	1	rs2168704	ENSG00000261338.2	RP11-378A13.1	15.1	1.87e-42	2.28e-38	0.56	0.57	Colorectal cancer;	chr2:218277769	chr2:218255319~218257366:+
LUAD	cis	rs858239	0.614	rs2014816	ENSG00000230658.1	KLHL7-AS1	15.1	1.9e-42	2.32e-38	0.7	0.57	Cerebrospinal fluid biomarker levels;	chr7:23083417	chr7:23101228~23105703:-
LUAD	cis	rs1577917	0.727	rs9351065	ENSG00000203875.9	SNHG5	-15.1	1.98e-42	2.41e-38	-0.75	-0.57	Response to antipsychotic treatment;	chr6:85650710	chr6:85660950~85678736:-
LUAD	cis	rs12439619	0.81	rs28876157	ENSG00000278603.1	RP13-608F4.5	15.09	2.01e-42	2.45e-38	0.78	0.57	Intelligence (multi-trait analysis);	chr15:82216708	chr15:82472203~82472426:+
LUAD	cis	rs7104764	1	rs76552490	ENSG00000277290.1	RP11-326C3.16	15.09	2.06e-42	2.5e-38	0.57	0.57	Menarche (age at onset);	chr11:212015	chr11:243099~243483:-
LUAD	cis	rs7104764	1	rs1533825	ENSG00000277290.1	RP11-326C3.16	15.09	2.06e-42	2.5e-38	0.57	0.57	Menarche (age at onset);	chr11:214163	chr11:243099~243483:-
LUAD	cis	rs1799949	1	rs8176202	ENSG00000198496.9	NBR2	-15.09	2.17e-42	2.64e-38	-0.61	-0.57	Menopause (age at onset);	chr17:43078211	chr17:43125610~43153671:+
LUAD	cis	rs801193	1	rs2707836	ENSG00000226824.5	RP4-756H11.3	-15.09	2.18e-42	2.65e-38	-0.71	-0.57	Aortic root size;	chr7:66695448	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.844	rs7779971	ENSG00000226824.5	RP4-756H11.3	-15.09	2.18e-42	2.65e-38	-0.71	-0.57	Aortic root size;	chr7:66696803	chr7:66654538~66669855:+
LUAD	cis	rs1577917	0.74	rs6926049	ENSG00000203875.9	SNHG5	15.09	2.2e-42	2.67e-38	0.74	0.57	Response to antipsychotic treatment;	chr6:85556415	chr6:85660950~85678736:-
LUAD	cis	rs2739330	0.828	rs5760102	ENSG00000225282.1	AP000350.6	15.08	2.27e-42	2.76e-38	0.67	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23926900~23929574:+
LUAD	cis	rs801193	0.904	rs4718405	ENSG00000226824.5	RP4-756H11.3	-15.08	2.28e-42	2.76e-38	-0.72	-0.57	Aortic root size;	chr7:66789659	chr7:66654538~66669855:+
LUAD	cis	rs3091242	0.9	rs669063	ENSG00000261349.1	RP3-465N24.5	-15.08	2.38e-42	2.88e-38	-0.62	-0.57	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25266102~25267136:-
LUAD	cis	rs6538678	0.746	rs4762630	ENSG00000258343.1	RP11-536G4.2	-15.08	2.39e-42	2.9e-38	-0.89	-0.57	Lupus nephritis in systemic lupus erythematosus;	chr12:95850631	chr12:95795345~95858839:-
LUAD	cis	rs801193	1	rs4717310	ENSG00000226824.5	RP4-756H11.3	-15.07	2.55e-42	3.08e-38	-0.71	-0.57	Aortic root size;	chr7:66696020	chr7:66654538~66669855:+
LUAD	cis	rs9326248	0.539	rs518181	ENSG00000254851.1	RP11-109L13.1	-15.07	2.62e-42	3.17e-38	-0.74	-0.57	Blood protein levels;	chr11:116902071	chr11:117135528~117138582:+
LUAD	cis	rs10716631	1	rs10716631	ENSG00000261338.2	RP11-378A13.1	15.06	2.73e-42	3.3e-38	0.56	0.57	Plateletcrit;High light scatter reticulocyte percentage of red cells;	chr2:218273447	chr2:218255319~218257366:+
LUAD	cis	rs7104764	0.957	rs1045454	ENSG00000277290.1	RP11-326C3.16	15.06	2.76e-42	3.33e-38	0.57	0.57	Menarche (age at onset);	chr11:204228	chr11:243099~243483:-
LUAD	cis	rs7104764	0.957	rs56357554	ENSG00000277290.1	RP11-326C3.16	15.06	2.76e-42	3.33e-38	0.57	0.57	Menarche (age at onset);	chr11:204715	chr11:243099~243483:-
LUAD	cis	rs9326248	0.603	rs7396061	ENSG00000254851.1	RP11-109L13.1	-15.06	2.85e-42	3.43e-38	-0.74	-0.57	Blood protein levels;	chr11:116880158	chr11:117135528~117138582:+
LUAD	cis	rs1799949	1	rs8176234	ENSG00000198496.9	NBR2	-15.06	2.87e-42	3.45e-38	-0.6	-0.57	Menopause (age at onset);	chr17:43067763	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs8176233	ENSG00000198496.9	NBR2	-15.06	2.87e-42	3.45e-38	-0.6	-0.57	Menopause (age at onset);	chr17:43067787	chr17:43125610~43153671:+
LUAD	cis	rs2882667	1	rs2060222	ENSG00000253404.1	AC034243.1	15.05	3.03e-42	3.64e-38	0.73	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:138972777	chr5:138744434~138753309:-
LUAD	cis	rs9326248	0.515	rs2727793	ENSG00000254851.1	RP11-109L13.1	-15.05	3.12e-42	3.75e-38	-0.74	-0.57	Blood protein levels;	chr11:116812658	chr11:117135528~117138582:+
LUAD	cis	rs1577917	0.771	rs12205013	ENSG00000203875.9	SNHG5	-15.05	3.15e-42	3.77e-38	-0.75	-0.57	Response to antipsychotic treatment;	chr6:85623311	chr6:85660950~85678736:-
LUAD	cis	rs6538678	0.824	rs2367583	ENSG00000258343.1	RP11-536G4.2	-15.05	3.18e-42	3.82e-38	-0.9	-0.57	Lupus nephritis in systemic lupus erythematosus;	chr12:95856582	chr12:95795345~95858839:-
LUAD	cis	rs7104764	1	rs6598066	ENSG00000277290.1	RP11-326C3.16	-15.05	3.33e-42	3.99e-38	-0.58	-0.57	Menarche (age at onset);	chr11:243185	chr11:243099~243483:-
LUAD	cis	rs7104764	0.957	rs3782120	ENSG00000277290.1	RP11-326C3.16	15.05	3.34e-42	3.99e-38	0.57	0.57	Menarche (age at onset);	chr11:206089	chr11:243099~243483:-
LUAD	cis	rs1799949	1	rs16942	ENSG00000198496.9	NBR2	-15.05	3.34e-42	4e-38	-0.6	-0.57	Menopause (age at onset);	chr17:43091983	chr17:43125610~43153671:+
LUAD	cis	rs1153858	0.723	rs1719238	ENSG00000259520.4	CTD-2651B20.3	15.04	3.35e-42	4.01e-38	0.82	0.57	Homoarginine levels;	chr15:45302568	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs7167146	ENSG00000259520.4	CTD-2651B20.3	-15.04	3.39e-42	4.05e-38	-0.73	-0.57	Glomerular filtration rate;	chr15:45279188	chr15:45251580~45279251:-
LUAD	cis	rs1577917	0.771	rs4351223	ENSG00000203875.9	SNHG5	15.04	3.42e-42	4.08e-38	0.74	0.57	Response to antipsychotic treatment;	chr6:85528079	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.771	rs9294337	ENSG00000203875.9	SNHG5	15.04	3.42e-42	4.08e-38	0.74	0.57	Response to antipsychotic treatment;	chr6:85538742	chr6:85660950~85678736:-
LUAD	cis	rs1799949	0.965	rs8176161	ENSG00000198496.9	NBR2	-15.04	3.44e-42	4.1e-38	-0.6	-0.57	Menopause (age at onset);	chr17:43089373	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.894	rs8176160	ENSG00000198496.9	NBR2	-15.04	3.44e-42	4.1e-38	-0.6	-0.57	Menopause (age at onset);	chr17:43089486	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs2070834	ENSG00000198496.9	NBR2	-15.04	3.44e-42	4.1e-38	-0.6	-0.57	Menopause (age at onset);	chr17:43090268	chr17:43125610~43153671:+
LUAD	cis	rs2882667	0.931	rs6596457	ENSG00000253404.1	AC034243.1	15.04	3.55e-42	4.22e-38	0.72	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:138987690	chr5:138744434~138753309:-
LUAD	cis	rs1799949	1	rs3092988	ENSG00000198496.9	NBR2	-15.03	3.83e-42	4.55e-38	-0.6	-0.57	Menopause (age at onset);	chr17:43049685	chr17:43125610~43153671:+
LUAD	cis	rs1577917	0.771	rs4145082	ENSG00000203875.9	SNHG5	-15.03	4e-42	4.75e-38	-0.75	-0.57	Response to antipsychotic treatment;	chr6:85642298	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.771	rs7452605	ENSG00000203875.9	SNHG5	15.02	4.17e-42	4.94e-38	0.74	0.57	Response to antipsychotic treatment;	chr6:85531233	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.771	rs9362233	ENSG00000203875.9	SNHG5	-15.02	4.42e-42	5.23e-38	-0.74	-0.56	Response to antipsychotic treatment;	chr6:85648529	chr6:85660950~85678736:-
LUAD	cis	rs2882667	0.898	rs13163536	ENSG00000253404.1	AC034243.1	15.01	4.59e-42	5.42e-38	0.73	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041530	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.931	rs10074461	ENSG00000253404.1	AC034243.1	15.01	4.64e-42	5.47e-38	0.7	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:138984126	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.698	rs858295	ENSG00000230658.1	KLHL7-AS1	15.01	4.69e-42	5.54e-38	0.69	0.56	Cerebrospinal fluid biomarker levels;	chr7:23205950	chr7:23101228~23105703:-
LUAD	cis	rs7104764	1	rs2293167	ENSG00000277290.1	RP11-326C3.16	15.01	4.98e-42	5.87e-38	0.57	0.56	Menarche (age at onset);	chr11:211644	chr11:243099~243483:-
LUAD	cis	rs2486288	0.656	rs9921025	ENSG00000259520.4	CTD-2651B20.3	15	5.06e-42	5.97e-38	0.67	0.56	Glomerular filtration rate;	chr15:45254404	chr15:45251580~45279251:-
LUAD	cis	rs6538678	0.784	rs7297403	ENSG00000258343.1	RP11-536G4.2	-15	5.26e-42	6.19e-38	-0.89	-0.56	Lupus nephritis in systemic lupus erythematosus;	chr12:95846683	chr12:95795345~95858839:-
LUAD	cis	rs2882667	0.898	rs6890272	ENSG00000253404.1	AC034243.1	15	5.42e-42	6.36e-38	0.73	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035427	chr5:138744434~138753309:-
LUAD	cis	rs12439619	0.846	rs7496227	ENSG00000278603.1	RP13-608F4.5	14.99	5.84e-42	6.84e-38	0.79	0.56	Intelligence (multi-trait analysis);	chr15:82275241	chr15:82472203~82472426:+
LUAD	cis	rs858239	0.73	rs858290	ENSG00000230658.1	KLHL7-AS1	14.99	6.05e-42	7.09e-38	0.69	0.56	Cerebrospinal fluid biomarker levels;	chr7:23208417	chr7:23101228~23105703:-
LUAD	cis	rs858239	0.73	rs858289	ENSG00000230658.1	KLHL7-AS1	14.99	6.05e-42	7.09e-38	0.69	0.56	Cerebrospinal fluid biomarker levels;	chr7:23208539	chr7:23101228~23105703:-
LUAD	cis	rs1799949	1	rs8176126	ENSG00000198496.9	NBR2	14.99	6.09e-42	7.13e-38	0.6	0.56	Menopause (age at onset);	chr17:43107032	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs3950989	ENSG00000198496.9	NBR2	-14.99	6.1e-42	7.13e-38	-0.6	-0.56	Menopause (age at onset);	chr17:43085936	chr17:43125610~43153671:+
LUAD	cis	rs2739330	0.76	rs5760095	ENSG00000250470.1	AP000351.3	14.98	6.46e-42	7.55e-38	0.7	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23976904~23977585:-
LUAD	cis	rs801193	1	rs7788576	ENSG00000226824.5	RP4-756H11.3	14.98	6.49e-42	7.58e-38	0.71	0.56	Aortic root size;	chr7:66683315	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.935	rs2659916	ENSG00000226824.5	RP4-756H11.3	-14.98	6.49e-42	7.58e-38	-0.71	-0.56	Aortic root size;	chr7:66686365	chr7:66654538~66669855:+
LUAD	cis	rs801193	1	rs6958520	ENSG00000226824.5	RP4-756H11.3	-14.98	6.49e-42	7.58e-38	-0.71	-0.56	Aortic root size;	chr7:66686466	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.967	rs2707849	ENSG00000226824.5	RP4-756H11.3	-14.98	6.49e-42	7.58e-38	-0.71	-0.56	Aortic root size;	chr7:66687725	chr7:66654538~66669855:+
LUAD	cis	rs801193	1	rs2659912	ENSG00000226824.5	RP4-756H11.3	-14.98	6.54e-42	7.63e-38	-0.71	-0.56	Aortic root size;	chr7:66693012	chr7:66654538~66669855:+
LUAD	cis	rs9326248	0.559	rs1269329	ENSG00000254851.1	RP11-109L13.1	-14.98	6.8e-42	7.93e-38	-0.74	-0.56	Blood protein levels;	chr11:116884325	chr11:117135528~117138582:+
LUAD	cis	rs1577917	0.771	rs2842607	ENSG00000203875.9	SNHG5	-14.97	7.34e-42	8.53e-38	-0.74	-0.56	Response to antipsychotic treatment;	chr6:85635321	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.771	rs2758847	ENSG00000203875.9	SNHG5	-14.97	7.34e-42	8.53e-38	-0.74	-0.56	Response to antipsychotic treatment;	chr6:85639385	chr6:85660950~85678736:-
LUAD	cis	rs801193	0.967	rs2707841	ENSG00000226824.5	RP4-756H11.3	-14.97	7.6e-42	8.82e-38	-0.71	-0.56	Aortic root size;	chr7:66692033	chr7:66654538~66669855:+
LUAD	cis	rs7301826	0.627	rs4334059	ENSG00000256299.1	RP11-989F5.3	-14.96	7.79e-42	9.01e-38	-0.64	-0.56	Plasma plasminogen activator levels;	chr12:130829669	chr12:130810821~130812622:-
LUAD	cis	rs6452524	0.618	rs6452501	ENSG00000249664.1	CTD-2227C6.2	14.96	7.84e-42	9.05e-38	0.63	0.56	Hypertension (SNP x SNP interaction);	chr5:83068681	chr5:83012285~83013109:-
LUAD	cis	rs950027	0.549	rs1719250	ENSG00000259520.4	CTD-2651B20.3	-14.96	7.99e-42	9.22e-38	-0.7	-0.56	Response to fenofibrate (adiponectin levels);	chr15:45317575	chr15:45251580~45279251:-
LUAD	cis	rs1153858	0.723	rs4580098	ENSG00000259520.4	CTD-2651B20.3	-14.95	8.54e-42	9.83e-38	-0.82	-0.56	Homoarginine levels;	chr15:45304711	chr15:45251580~45279251:-
LUAD	cis	rs2882667	0.898	rs13182437	ENSG00000253404.1	AC034243.1	14.95	8.96e-42	1.03e-37	0.72	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051460	chr5:138744434~138753309:-
LUAD	cis	rs1799949	1	rs8176269	ENSG00000198496.9	NBR2	-14.95	9.18e-42	1.05e-37	-0.6	-0.56	Menopause (age at onset);	chr17:43061609	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs8176265	ENSG00000198496.9	NBR2	-14.95	9.18e-42	1.05e-37	-0.6	-0.56	Menopause (age at onset);	chr17:43061979	chr17:43125610~43153671:+
LUAD	cis	rs6452524	0.618	rs6452506	ENSG00000249664.1	CTD-2227C6.2	14.95	9.26e-42	1.06e-37	0.64	0.56	Hypertension (SNP x SNP interaction);	chr5:83075844	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.618	rs1993948	ENSG00000249664.1	CTD-2227C6.2	14.94	9.35e-42	1.07e-37	0.64	0.56	Hypertension (SNP x SNP interaction);	chr5:83076461	chr5:83012285~83013109:-
LUAD	cis	rs2882667	0.898	rs2351465	ENSG00000253404.1	AC034243.1	14.94	9.47e-42	1.08e-37	0.72	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028162	chr5:138744434~138753309:-
LUAD	cis	rs6452524	0.618	rs2306336	ENSG00000249664.1	CTD-2227C6.2	14.94	9.64e-42	1.1e-37	0.64	0.56	Hypertension (SNP x SNP interaction);	chr5:83064964	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.589	rs6882386	ENSG00000249664.1	CTD-2227C6.2	14.94	9.64e-42	1.1e-37	0.64	0.56	Hypertension (SNP x SNP interaction);	chr5:83065555	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.618	rs6860752	ENSG00000249664.1	CTD-2227C6.2	14.94	9.64e-42	1.1e-37	0.64	0.56	Hypertension (SNP x SNP interaction);	chr5:83065587	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.618	rs3899556	ENSG00000249664.1	CTD-2227C6.2	14.94	9.64e-42	1.1e-37	0.64	0.56	Hypertension (SNP x SNP interaction);	chr5:83067862	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.618	rs7723639	ENSG00000249664.1	CTD-2227C6.2	14.94	9.65e-42	1.1e-37	0.64	0.56	Hypertension (SNP x SNP interaction);	chr5:83062610	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.618	rs1871203	ENSG00000249664.1	CTD-2227C6.2	14.94	9.69e-42	1.11e-37	0.64	0.56	Hypertension (SNP x SNP interaction);	chr5:83059567	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.618	rs6867727	ENSG00000249664.1	CTD-2227C6.2	14.94	9.69e-42	1.11e-37	0.64	0.56	Hypertension (SNP x SNP interaction);	chr5:83061333	chr5:83012285~83013109:-
LUAD	cis	rs1799949	1	rs8176273	ENSG00000198496.9	NBR2	-14.94	9.69e-42	1.11e-37	-0.6	-0.56	Menopause (age at onset);	chr17:43059636	chr17:43125610~43153671:+
LUAD	cis	rs1577917	0.666	rs6454471	ENSG00000203875.9	SNHG5	14.94	9.81e-42	1.12e-37	0.73	0.56	Response to antipsychotic treatment;	chr6:85504738	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.665	rs4304137	ENSG00000203875.9	SNHG5	14.94	9.81e-42	1.12e-37	0.73	0.56	Response to antipsychotic treatment;	chr6:85507730	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.771	rs2783171	ENSG00000203875.9	SNHG5	14.94	9.85e-42	1.12e-37	0.74	0.56	Response to antipsychotic treatment;	chr6:85673047	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.771	rs2475791	ENSG00000203875.9	SNHG5	-14.94	9.85e-42	1.12e-37	-0.74	-0.56	Response to antipsychotic treatment;	chr6:85658446	chr6:85660950~85678736:-
LUAD	cis	rs801193	0.761	rs2659888	ENSG00000226824.5	RP4-756H11.3	-14.94	9.86e-42	1.12e-37	-0.71	-0.56	Aortic root size;	chr7:66765184	chr7:66654538~66669855:+
LUAD	cis	rs1799949	1	rs8176318	ENSG00000198496.9	NBR2	-14.94	9.89e-42	1.13e-37	-0.59	-0.56	Menopause (age at onset);	chr17:43045257	chr17:43125610~43153671:+
LUAD	cis	rs7301826	0.61	rs36051740	ENSG00000256299.1	RP11-989F5.3	14.94	1.03e-41	1.17e-37	0.64	0.56	Plasma plasminogen activator levels;	chr12:130808177	chr12:130810821~130812622:-
LUAD	cis	rs7104764	1	rs2272563	ENSG00000277290.1	RP11-326C3.16	-14.93	1.04e-41	1.18e-37	-0.57	-0.56	Menarche (age at onset);	chr11:236871	chr11:243099~243483:-
LUAD	cis	rs7104764	0.917	rs1045288	ENSG00000277290.1	RP11-326C3.16	-14.93	1.04e-41	1.18e-37	-0.57	-0.56	Menarche (age at onset);	chr11:237087	chr11:243099~243483:-
LUAD	cis	rs7104764	0.957	rs3817629	ENSG00000277290.1	RP11-326C3.16	-14.93	1.04e-41	1.18e-37	-0.57	-0.56	Menarche (age at onset);	chr11:237312	chr11:243099~243483:-
LUAD	cis	rs1577917	0.739	rs9344532	ENSG00000203875.9	SNHG5	14.93	1.04e-41	1.18e-37	0.74	0.56	Response to antipsychotic treatment;	chr6:85524352	chr6:85660950~85678736:-
LUAD	cis	rs1799949	0.93	rs3092987	ENSG00000198496.9	NBR2	-14.93	1.05e-41	1.19e-37	-0.6	-0.56	Menopause (age at onset);	chr17:43070706	chr17:43125610~43153671:+
LUAD	cis	rs801193	1	rs6975195	ENSG00000226824.5	RP4-756H11.3	14.93	1.09e-41	1.23e-37	0.71	0.56	Aortic root size;	chr7:66659787	chr7:66654538~66669855:+
LUAD	cis	rs801193	1	rs3857688	ENSG00000226824.5	RP4-756H11.3	14.93	1.09e-41	1.23e-37	0.71	0.56	Aortic root size;	chr7:66662819	chr7:66654538~66669855:+
LUAD	cis	rs801193	1	rs2286684	ENSG00000226824.5	RP4-756H11.3	14.93	1.09e-41	1.23e-37	0.71	0.56	Aortic root size;	chr7:66664843	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.935	rs2286683	ENSG00000226824.5	RP4-756H11.3	14.93	1.09e-41	1.23e-37	0.71	0.56	Aortic root size;	chr7:66664856	chr7:66654538~66669855:+
LUAD	cis	rs801193	1	rs10274773	ENSG00000226824.5	RP4-756H11.3	14.93	1.09e-41	1.23e-37	0.71	0.56	Aortic root size;	chr7:66668591	chr7:66654538~66669855:+
LUAD	cis	rs1799949	0.965	rs8176193	ENSG00000198496.9	NBR2	-14.93	1.1e-41	1.24e-37	-0.6	-0.56	Menopause (age at onset);	chr17:43079499	chr17:43125610~43153671:+
LUAD	cis	rs801193	1	rs2003301	ENSG00000226824.5	RP4-756H11.3	14.92	1.22e-41	1.38e-37	0.71	0.56	Aortic root size;	chr7:66682669	chr7:66654538~66669855:+
LUAD	cis	rs6452524	0.56	rs6895174	ENSG00000249664.1	CTD-2227C6.2	14.92	1.24e-41	1.39e-37	0.63	0.56	Hypertension (SNP x SNP interaction);	chr5:83071606	chr5:83012285~83013109:-
LUAD	cis	rs2486288	0.656	rs11632724	ENSG00000259520.4	CTD-2651B20.3	14.92	1.25e-41	1.4e-37	0.67	0.56	Glomerular filtration rate;	chr15:45258593	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs11632651	ENSG00000259520.4	CTD-2651B20.3	14.92	1.25e-41	1.4e-37	0.67	0.56	Glomerular filtration rate;	chr15:45258640	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs11637920	ENSG00000259520.4	CTD-2651B20.3	14.92	1.25e-41	1.4e-37	0.67	0.56	Glomerular filtration rate;	chr15:45258707	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs11632777	ENSG00000259520.4	CTD-2651B20.3	14.92	1.25e-41	1.4e-37	0.67	0.56	Glomerular filtration rate;	chr15:45258847	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs11632778	ENSG00000259520.4	CTD-2651B20.3	14.92	1.25e-41	1.4e-37	0.67	0.56	Glomerular filtration rate;	chr15:45258858	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs11632752	ENSG00000259520.4	CTD-2651B20.3	14.92	1.25e-41	1.4e-37	0.67	0.56	Glomerular filtration rate;	chr15:45258942	chr15:45251580~45279251:-
LUAD	cis	rs9326248	0.53	rs7112513	ENSG00000254851.1	RP11-109L13.1	-14.92	1.25e-41	1.4e-37	-0.99	-0.56	Blood protein levels;	chr11:117166645	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.559	rs476399	ENSG00000254851.1	RP11-109L13.1	-14.92	1.25e-41	1.41e-37	-0.72	-0.56	Blood protein levels;	chr11:116863012	chr11:117135528~117138582:+
LUAD	cis	rs801193	1	rs7785213	ENSG00000226824.5	RP4-756H11.3	14.91	1.27e-41	1.42e-37	0.71	0.56	Aortic root size;	chr7:66673991	chr7:66654538~66669855:+
LUAD	cis	rs801193	1	rs11773829	ENSG00000226824.5	RP4-756H11.3	14.91	1.29e-41	1.45e-37	0.71	0.56	Aortic root size;	chr7:66676087	chr7:66654538~66669855:+
LUAD	cis	rs2882667	0.858	rs4643949	ENSG00000253404.1	AC034243.1	14.91	1.38e-41	1.54e-37	0.73	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139036656	chr5:138744434~138753309:-
LUAD	cis	rs1577917	0.74	rs2842604	ENSG00000203875.9	SNHG5	-14.91	1.39e-41	1.55e-37	-0.74	-0.56	Response to antipsychotic treatment;	chr6:85626582	chr6:85660950~85678736:-
LUAD	cis	rs801193	0.935	rs3800820	ENSG00000226824.5	RP4-756H11.3	14.91	1.4e-41	1.57e-37	0.71	0.56	Aortic root size;	chr7:66682191	chr7:66654538~66669855:+
LUAD	cis	rs1577917	0.739	rs2758846	ENSG00000203875.9	SNHG5	-14.9	1.42e-41	1.58e-37	-0.74	-0.56	Response to antipsychotic treatment;	chr6:85639852	chr6:85660950~85678736:-
LUAD	cis	rs9326248	0.59	rs2542063	ENSG00000254851.1	RP11-109L13.1	-14.9	1.46e-41	1.63e-37	-0.72	-0.56	Blood protein levels;	chr11:116814051	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.559	rs484646	ENSG00000254851.1	RP11-109L13.1	-14.9	1.47e-41	1.64e-37	-0.72	-0.56	Blood protein levels;	chr11:116862140	chr11:117135528~117138582:+
LUAD	cis	rs1577917	0.771	rs9362237	ENSG00000203875.9	SNHG5	14.9	1.52e-41	1.69e-37	0.75	0.56	Response to antipsychotic treatment;	chr6:85699346	chr6:85660950~85678736:-
LUAD	cis	rs55794721	0.509	rs12027110	ENSG00000261349.1	RP3-465N24.5	-14.9	1.55e-41	1.73e-37	-0.61	-0.56	Mean corpuscular volume;Plateletcrit;	chr1:25449191	chr1:25266102~25267136:-
LUAD	cis	rs2882667	1	rs2882667	ENSG00000253404.1	AC034243.1	14.89	1.58e-41	1.75e-37	0.73	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:138978417	chr5:138744434~138753309:-
LUAD	cis	rs3091242	0.904	rs6661533	ENSG00000261349.1	RP3-465N24.5	-14.89	1.6e-41	1.78e-37	-0.61	-0.56	Erythrocyte sedimentation rate;	chr1:25445224	chr1:25266102~25267136:-
LUAD	cis	rs55794721	0.509	rs6699113	ENSG00000261349.1	RP3-465N24.5	-14.89	1.6e-41	1.78e-37	-0.61	-0.56	Mean corpuscular volume;Plateletcrit;	chr1:25451252	chr1:25266102~25267136:-
LUAD	cis	rs55794721	0.509	rs7554255	ENSG00000261349.1	RP3-465N24.5	-14.89	1.6e-41	1.78e-37	-0.61	-0.56	Mean corpuscular volume;Plateletcrit;	chr1:25451615	chr1:25266102~25267136:-
LUAD	cis	rs55794721	0.509	rs4649085	ENSG00000261349.1	RP3-465N24.5	-14.89	1.6e-41	1.78e-37	-0.61	-0.56	Mean corpuscular volume;Plateletcrit;	chr1:25452341	chr1:25266102~25267136:-
LUAD	cis	rs6538678	0.746	rs1865736	ENSG00000258343.1	RP11-536G4.2	-14.89	1.65e-41	1.83e-37	-0.91	-0.56	Lupus nephritis in systemic lupus erythematosus;	chr12:95854051	chr12:95795345~95858839:-
LUAD	cis	rs1577917	0.771	rs10944133	ENSG00000203875.9	SNHG5	-14.89	1.67e-41	1.84e-37	-0.74	-0.56	Response to antipsychotic treatment;	chr6:85649266	chr6:85660950~85678736:-
LUAD	cis	rs2486288	0.656	rs8039540	ENSG00000259520.4	CTD-2651B20.3	14.88	1.74e-41	1.93e-37	0.67	0.56	Glomerular filtration rate;	chr15:45259644	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs8040185	ENSG00000259520.4	CTD-2651B20.3	14.88	1.74e-41	1.93e-37	0.67	0.56	Glomerular filtration rate;	chr15:45259883	chr15:45251580~45279251:-
LUAD	cis	rs858239	0.932	rs858272	ENSG00000230658.1	KLHL7-AS1	14.88	1.76e-41	1.95e-37	0.68	0.56	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.861	rs7703288	ENSG00000253404.1	AC034243.1	14.87	1.97e-41	2.17e-37	0.72	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139030850	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.898	rs12719519	ENSG00000253404.1	AC034243.1	14.87	2e-41	2.2e-37	0.72	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139039998	chr5:138744434~138753309:-
LUAD	cis	rs1577917	0.771	rs9450290	ENSG00000203875.9	SNHG5	14.87	2.05e-41	2.26e-37	0.74	0.56	Response to antipsychotic treatment;	chr6:85523679	chr6:85660950~85678736:-
LUAD	cis	rs1799949	1	rs8176145	ENSG00000198496.9	NBR2	-14.87	2.08e-41	2.28e-37	-0.6	-0.56	Menopause (age at onset);	chr17:43097077	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.965	rs8176140	ENSG00000198496.9	NBR2	-14.87	2.08e-41	2.28e-37	-0.6	-0.56	Menopause (age at onset);	chr17:43099629	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.965	rs8176130	ENSG00000198496.9	NBR2	-14.86	2.12e-41	2.33e-37	-0.6	-0.56	Menopause (age at onset);	chr17:43106026	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs8176120	ENSG00000198496.9	NBR2	-14.86	2.12e-41	2.33e-37	-0.6	-0.56	Menopause (age at onset);	chr17:43109216	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs8176242	ENSG00000198496.9	NBR2	-14.86	2.15e-41	2.35e-37	-0.6	-0.56	Menopause (age at onset);	chr17:43065857	chr17:43125610~43153671:+
LUAD	cis	rs2486288	0.656	rs12911186	ENSG00000259520.4	CTD-2651B20.3	14.86	2.17e-41	2.37e-37	0.67	0.56	Glomerular filtration rate;	chr15:45259225	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs12915314	ENSG00000259520.4	CTD-2651B20.3	14.86	2.17e-41	2.37e-37	0.67	0.56	Glomerular filtration rate;	chr15:45259293	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs8039138	ENSG00000259520.4	CTD-2651B20.3	14.86	2.17e-41	2.37e-37	0.67	0.56	Glomerular filtration rate;	chr15:45259394	chr15:45251580~45279251:-
LUAD	cis	rs12439619	0.846	rs62012003	ENSG00000278603.1	RP13-608F4.5	14.86	2.21e-41	2.42e-37	0.78	0.56	Intelligence (multi-trait analysis);	chr15:82183236	chr15:82472203~82472426:+
LUAD	cis	rs2486288	0.656	rs11629807	ENSG00000259520.4	CTD-2651B20.3	14.86	2.3e-41	2.51e-37	0.67	0.56	Glomerular filtration rate;	chr15:45254839	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.587	rs12899942	ENSG00000259520.4	CTD-2651B20.3	14.86	2.3e-41	2.51e-37	0.67	0.56	Glomerular filtration rate;	chr15:45255082	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs12899058	ENSG00000259520.4	CTD-2651B20.3	14.86	2.3e-41	2.51e-37	0.67	0.56	Glomerular filtration rate;	chr15:45255126	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs12904150	ENSG00000259520.4	CTD-2651B20.3	14.86	2.3e-41	2.51e-37	0.67	0.56	Glomerular filtration rate;	chr15:45255407	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs9920290	ENSG00000259520.4	CTD-2651B20.3	14.86	2.3e-41	2.51e-37	0.67	0.56	Glomerular filtration rate;	chr15:45255837	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs1719236	ENSG00000259520.4	CTD-2651B20.3	14.86	2.31e-41	2.51e-37	0.7	0.56	Glomerular filtration rate;	chr15:45285585	chr15:45251580~45279251:-
LUAD	cis	rs1799949	0.896	rs35908185	ENSG00000198496.9	NBR2	-14.86	2.32e-41	2.53e-37	-0.6	-0.56	Menopause (age at onset);	chr17:43103094	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs8176109	ENSG00000198496.9	NBR2	-14.85	2.52e-41	2.73e-37	-0.6	-0.56	Menopause (age at onset);	chr17:43113759	chr17:43125610~43153671:+
LUAD	cis	rs4423214	1	rs4944959	ENSG00000254682.1	RP11-660L16.2	-14.85	2.53e-41	2.74e-37	-0.73	-0.56	Vitamin D levels;	chr11:71457188	chr11:71448674~71452157:+
LUAD	cis	rs6452524	0.618	rs2075685	ENSG00000249664.1	CTD-2227C6.2	14.84	2.7e-41	2.91e-37	0.64	0.56	Hypertension (SNP x SNP interaction);	chr5:83076846	chr5:83012285~83013109:-
LUAD	cis	rs2882667	0.898	rs3925110	ENSG00000253404.1	AC034243.1	14.84	2.81e-41	3.03e-37	0.72	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035676	chr5:138744434~138753309:-
LUAD	cis	rs9326248	0.539	rs10892058	ENSG00000254851.1	RP11-109L13.1	-14.83	2.92e-41	3.14e-37	-0.72	-0.56	Blood protein levels;	chr11:117005905	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.52	rs7127881	ENSG00000254851.1	RP11-109L13.1	-14.83	2.92e-41	3.14e-37	-0.72	-0.56	Blood protein levels;	chr11:117010082	chr11:117135528~117138582:+
LUAD	cis	rs6452524	0.618	rs255561	ENSG00000249664.1	CTD-2227C6.2	14.82	3.2e-41	3.44e-37	0.63	0.56	Hypertension (SNP x SNP interaction);	chr5:83054991	chr5:83012285~83013109:-
LUAD	cis	rs2486288	0.656	rs2413773	ENSG00000259520.4	CTD-2651B20.3	14.82	3.23e-41	3.46e-37	0.67	0.56	Glomerular filtration rate;	chr15:45257244	chr15:45251580~45279251:-
LUAD	cis	rs1799949	0.896	rs8176098	ENSG00000198496.9	NBR2	-14.82	3.23e-41	3.47e-37	-0.6	-0.56	Menopause (age at onset);	chr17:43116189	chr17:43125610~43153671:+
LUAD	cis	rs3091242	0.933	rs35148262	ENSG00000261349.1	RP3-465N24.5	-14.82	3.32e-41	3.56e-37	-0.61	-0.56	Erythrocyte sedimentation rate;	chr1:25440132	chr1:25266102~25267136:-
LUAD	cis	rs7104764	1	rs10400248	ENSG00000277290.1	RP11-326C3.16	-14.81	3.64e-41	3.88e-37	-0.56	-0.56	Menarche (age at onset);	chr11:247029	chr11:243099~243483:-
LUAD	cis	rs992157	0.932	rs56109829	ENSG00000261338.2	RP11-378A13.1	14.81	3.89e-41	4.14e-37	0.55	0.56	Colorectal cancer;	chr2:218285017	chr2:218255319~218257366:+
LUAD	cis	rs9322193	0.847	rs4870054	ENSG00000231760.4	RP11-350J20.5	14.8	3.93e-41	4.18e-37	0.74	0.56	Lung cancer;	chr6:149848402	chr6:149796151~149826294:-
LUAD	cis	rs1799949	1	rs8176103	ENSG00000198496.9	NBR2	-14.8	4.23e-41	4.49e-37	-0.6	-0.56	Menopause (age at onset);	chr17:43115033	chr17:43125610~43153671:+
LUAD	cis	rs1577917	0.771	rs9353318	ENSG00000203875.9	SNHG5	14.79	4.41e-41	4.67e-37	0.73	0.56	Response to antipsychotic treatment;	chr6:85522003	chr6:85660950~85678736:-
LUAD	cis	rs2486288	0.656	rs1060896	ENSG00000259520.4	CTD-2651B20.3	14.79	4.42e-41	4.69e-37	0.67	0.56	Glomerular filtration rate;	chr15:45262069	chr15:45251580~45279251:-
LUAD	cis	rs1577917	0.739	rs6922	ENSG00000203875.9	SNHG5	14.79	4.53e-41	4.8e-37	0.73	0.56	Response to antipsychotic treatment;	chr6:85495605	chr6:85660950~85678736:-
LUAD	cis	rs4423214	1	rs12808368	ENSG00000254682.1	RP11-660L16.2	14.79	4.66e-41	4.92e-37	0.73	0.56	Vitamin D levels;	chr11:71459771	chr11:71448674~71452157:+
LUAD	cis	rs2882667	0.867	rs6868085	ENSG00000253404.1	AC034243.1	14.78	4.89e-41	5.16e-37	0.73	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139096757	chr5:138744434~138753309:-
LUAD	cis	rs2486288	0.656	rs11632419	ENSG00000259520.4	CTD-2651B20.3	14.78	5.06e-41	5.34e-37	0.67	0.56	Glomerular filtration rate;	chr15:45265258	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs2271438	ENSG00000259520.4	CTD-2651B20.3	14.78	5.06e-41	5.34e-37	0.67	0.56	Glomerular filtration rate;	chr15:45265270	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs11854365	ENSG00000259520.4	CTD-2651B20.3	14.78	5.06e-41	5.34e-37	0.67	0.56	Glomerular filtration rate;	chr15:45265885	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs2413774	ENSG00000259520.4	CTD-2651B20.3	14.78	5.3e-41	5.59e-37	0.67	0.56	Glomerular filtration rate;	chr15:45257225	chr15:45251580~45279251:-
LUAD	cis	rs1577917	0.771	rs4419647	ENSG00000203875.9	SNHG5	14.77	5.33e-41	5.61e-37	0.73	0.56	Response to antipsychotic treatment;	chr6:85516021	chr6:85660950~85678736:-
LUAD	cis	rs6452524	0.618	rs10051445	ENSG00000249664.1	CTD-2227C6.2	14.77	5.36e-41	5.64e-37	0.64	0.56	Hypertension (SNP x SNP interaction);	chr5:83060280	chr5:83012285~83013109:-
LUAD	cis	rs7104764	0.879	rs6598072	ENSG00000277290.1	RP11-326C3.16	-14.77	5.37e-41	5.64e-37	-0.57	-0.56	Menarche (age at onset);	chr11:219793	chr11:243099~243483:-
LUAD	cis	rs7104764	0.957	rs6598071	ENSG00000277290.1	RP11-326C3.16	-14.77	5.37e-41	5.64e-37	-0.57	-0.56	Menarche (age at onset);	chr11:219800	chr11:243099~243483:-
LUAD	cis	rs7104764	0.957	rs10794301	ENSG00000277290.1	RP11-326C3.16	-14.77	5.37e-41	5.64e-37	-0.57	-0.56	Menarche (age at onset);	chr11:220401	chr11:243099~243483:-
LUAD	cis	rs858239	0.665	rs858306	ENSG00000230658.1	KLHL7-AS1	14.77	5.38e-41	5.65e-37	0.68	0.56	Cerebrospinal fluid biomarker levels;	chr7:23203135	chr7:23101228~23105703:-
LUAD	cis	rs2739330	0.796	rs5760106	ENSG00000225282.1	AP000350.6	-14.77	5.51e-41	5.79e-37	-0.66	-0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23926900~23929574:+
LUAD	cis	rs1577917	0.771	rs2475790	ENSG00000203875.9	SNHG5	-14.77	5.58e-41	5.85e-37	-0.74	-0.56	Response to antipsychotic treatment;	chr6:85658350	chr6:85660950~85678736:-
LUAD	cis	rs992157	1	rs2292553	ENSG00000261338.2	RP11-378A13.1	14.77	5.58e-41	5.85e-37	0.56	0.56	Colorectal cancer;	chr2:218282080	chr2:218255319~218257366:+
LUAD	cis	rs4423214	0.918	rs11233789	ENSG00000254682.1	RP11-660L16.2	14.77	5.71e-41	5.99e-37	0.72	0.56	Vitamin D levels;	chr11:71470039	chr11:71448674~71452157:+
LUAD	cis	rs992157	0.965	rs13427681	ENSG00000261338.2	RP11-378A13.1	14.77	5.84e-41	6.12e-37	0.56	0.56	Colorectal cancer;	chr2:218302840	chr2:218255319~218257366:+
LUAD	cis	rs858239	0.932	rs1637190	ENSG00000230658.1	KLHL7-AS1	14.77	5.87e-41	6.15e-37	0.67	0.56	Cerebrospinal fluid biomarker levels;	chr7:23229446	chr7:23101228~23105703:-
LUAD	cis	rs9326248	0.53	rs7940310	ENSG00000254851.1	RP11-109L13.1	-14.76	6.41e-41	6.7e-37	-0.99	-0.56	Blood protein levels;	chr11:117153765	chr11:117135528~117138582:+
LUAD	cis	rs2882667	0.931	rs1433009	ENSG00000253404.1	AC034243.1	14.76	6.44e-41	6.72e-37	0.71	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998095	chr5:138744434~138753309:-
LUAD	cis	rs6452524	0.618	rs7722924	ENSG00000249664.1	CTD-2227C6.2	14.76	6.45e-41	6.73e-37	0.64	0.56	Hypertension (SNP x SNP interaction);	chr5:83060223	chr5:83012285~83013109:-
LUAD	cis	rs55794721	0.543	rs1293260	ENSG00000261349.1	RP3-465N24.5	-14.75	6.74e-41	7.01e-37	-0.61	-0.56	Mean corpuscular volume;Plateletcrit;	chr1:25382613	chr1:25266102~25267136:-
LUAD	cis	rs4423214	1	rs12278461	ENSG00000254682.1	RP11-660L16.2	14.75	6.88e-41	7.15e-37	0.72	0.56	Vitamin D levels;	chr11:71471139	chr11:71448674~71452157:+
LUAD	cis	rs12439619	0.768	rs28694364	ENSG00000278603.1	RP13-608F4.5	14.75	7.05e-41	7.32e-37	0.78	0.56	Intelligence (multi-trait analysis);	chr15:82208119	chr15:82472203~82472426:+
LUAD	cis	rs3091242	0.806	rs35189848	ENSG00000261349.1	RP3-465N24.5	14.75	7.21e-41	7.48e-37	0.62	0.56	Erythrocyte sedimentation rate;	chr1:25461931	chr1:25266102~25267136:-
LUAD	cis	rs3091242	0.836	rs35346083	ENSG00000261349.1	RP3-465N24.5	14.75	7.21e-41	7.48e-37	0.62	0.56	Erythrocyte sedimentation rate;	chr1:25461934	chr1:25266102~25267136:-
LUAD	cis	rs2486288	0.656	rs11854325	ENSG00000259520.4	CTD-2651B20.3	14.74	7.49e-41	7.76e-37	0.66	0.56	Glomerular filtration rate;	chr15:45256761	chr15:45251580~45279251:-
LUAD	cis	rs12439619	0.846	rs62010071	ENSG00000278603.1	RP13-608F4.5	14.74	7.6e-41	7.87e-37	0.78	0.56	Intelligence (multi-trait analysis);	chr15:82289442	chr15:82472203~82472426:+
LUAD	cis	rs2486288	0.656	rs2413768	ENSG00000259520.4	CTD-2651B20.3	14.73	8.17e-41	8.45e-37	0.67	0.56	Glomerular filtration rate;	chr15:45269786	chr15:45251580~45279251:-
LUAD	cis	rs12439619	0.739	rs62012046	ENSG00000278603.1	RP13-608F4.5	14.73	8.28e-41	8.56e-37	0.78	0.56	Intelligence (multi-trait analysis);	chr15:82236824	chr15:82472203~82472426:+
LUAD	cis	rs12439619	0.774	rs62012047	ENSG00000278603.1	RP13-608F4.5	14.73	8.28e-41	8.56e-37	0.78	0.56	Intelligence (multi-trait analysis);	chr15:82236852	chr15:82472203~82472426:+
LUAD	cis	rs12439619	0.81	rs62012049	ENSG00000278603.1	RP13-608F4.5	14.73	8.28e-41	8.56e-37	0.78	0.56	Intelligence (multi-trait analysis);	chr15:82237722	chr15:82472203~82472426:+
LUAD	cis	rs992157	1	rs4674280	ENSG00000261338.2	RP11-378A13.1	-14.73	8.43e-41	8.71e-37	-0.55	-0.56	Colorectal cancer;	chr2:218276735	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.965	rs13419763	ENSG00000261338.2	RP11-378A13.1	14.73	8.48e-41	8.76e-37	0.56	0.56	Colorectal cancer;	chr2:218270227	chr2:218255319~218257366:+
LUAD	cis	rs2486288	0.656	rs10519018	ENSG00000259520.4	CTD-2651B20.3	14.73	8.5e-41	8.77e-37	0.66	0.56	Glomerular filtration rate;	chr15:45257067	chr15:45251580~45279251:-
LUAD	cis	rs55794721	0.509	rs6699896	ENSG00000261349.1	RP3-465N24.5	-14.73	8.71e-41	8.99e-37	-0.61	-0.56	Mean corpuscular volume;Plateletcrit;	chr1:25436411	chr1:25266102~25267136:-
LUAD	cis	rs858239	1	rs858240	ENSG00000230658.1	KLHL7-AS1	14.72	8.94e-41	9.22e-37	0.67	0.56	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23101228~23105703:-
LUAD	cis	rs10793273	1	rs10793273	ENSG00000246174.6	KCTD21-AS1	-14.72	9.08e-41	9.33e-37	-0.66	-0.56	Pelvic organ prolapse;	chr11:78031549	chr11:78139771~78175323:+
LUAD	cis	rs1799949	1	rs1060915	ENSG00000198496.9	NBR2	-14.72	9.5e-41	9.76e-37	-0.6	-0.56	Menopause (age at onset);	chr17:43082453	chr17:43125610~43153671:+
LUAD	cis	rs2486288	0.656	rs2413772	ENSG00000259520.4	CTD-2651B20.3	14.72	9.78e-41	1e-36	0.67	0.56	Glomerular filtration rate;	chr15:45257664	chr15:45251580~45279251:-
LUAD	cis	rs7104764	1	rs7483951	ENSG00000277290.1	RP11-326C3.16	-14.71	1e-40	1.02e-36	-0.56	-0.56	Menarche (age at onset);	chr11:231758	chr11:243099~243483:-
LUAD	cis	rs7301826	0.651	rs2277336	ENSG00000256299.1	RP11-989F5.3	14.71	1.03e-40	1.06e-36	0.64	0.56	Plasma plasminogen activator levels;	chr12:130801574	chr12:130810821~130812622:-
LUAD	cis	rs7104764	1	rs9795476	ENSG00000277290.1	RP11-326C3.16	-14.71	1.04e-40	1.07e-36	-0.56	-0.56	Menarche (age at onset);	chr11:235894	chr11:243099~243483:-
LUAD	cis	rs6452524	0.648	rs27364	ENSG00000249664.1	CTD-2227C6.2	14.7	1.1e-40	1.13e-36	0.64	0.56	Hypertension (SNP x SNP interaction);	chr5:83052137	chr5:83012285~83013109:-
LUAD	cis	rs12439619	0.846	rs62012056	ENSG00000278603.1	RP13-608F4.5	14.7	1.12e-40	1.14e-36	0.78	0.56	Intelligence (multi-trait analysis);	chr15:82247278	chr15:82472203~82472426:+
LUAD	cis	rs801193	1	rs3778909	ENSG00000226824.5	RP4-756H11.3	-14.7	1.12e-40	1.14e-36	-0.7	-0.56	Aortic root size;	chr7:66790659	chr7:66654538~66669855:+
LUAD	cis	rs1799949	1	rs8070085	ENSG00000198496.9	NBR2	14.69	1.24e-40	1.26e-36	0.61	0.56	Menopause (age at onset);	chr17:43189967	chr17:43125610~43153671:+
LUAD	cis	rs2019137	0.56	rs6707386	ENSG00000189223.12	PAX8-AS1	-14.69	1.29e-40	1.31e-36	-0.76	-0.56	Lymphocyte counts;	chr2:113223445	chr2:113211522~113276581:+
LUAD	cis	rs858239	0.633	rs858300	ENSG00000230658.1	KLHL7-AS1	14.68	1.46e-40	1.48e-36	0.68	0.56	Cerebrospinal fluid biomarker levels;	chr7:23205012	chr7:23101228~23105703:-
LUAD	cis	rs2658782	1	rs2658779	ENSG00000279684.1	RP11-755E23.2	14.68	1.46e-40	1.48e-36	0.86	0.56	Pulmonary function decline;	chr11:93429971	chr11:93286629~93288903:-
LUAD	cis	rs1799949	1	rs11655505	ENSG00000198496.9	NBR2	-14.67	1.51e-40	1.53e-36	-0.6	-0.56	Menopause (age at onset);	chr17:43126360	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.965	rs4793204	ENSG00000198496.9	NBR2	-14.67	1.51e-40	1.53e-36	-0.6	-0.56	Menopause (age at onset);	chr17:43127281	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs11651341	ENSG00000198496.9	NBR2	-14.67	1.53e-40	1.54e-36	-0.59	-0.56	Menopause (age at onset);	chr17:43350693	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs34572725	ENSG00000198496.9	NBR2	-14.67	1.53e-40	1.54e-36	-0.59	-0.56	Menopause (age at onset);	chr17:43351298	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs4534897	ENSG00000198496.9	NBR2	-14.67	1.53e-40	1.54e-36	-0.59	-0.56	Menopause (age at onset);	chr17:43354440	chr17:43125610~43153671:+
LUAD	cis	rs875971	0.638	rs7793569	ENSG00000226824.5	RP4-756H11.3	14.67	1.54e-40	1.55e-36	0.7	0.56	Aortic root size;	chr7:66651646	chr7:66654538~66669855:+
LUAD	cis	rs2739330	0.76	rs1007888	ENSG00000250470.1	AP000351.3	14.67	1.58e-40	1.59e-36	0.67	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23976904~23977585:-
LUAD	cis	rs6452524	0.618	rs6452503	ENSG00000249664.1	CTD-2227C6.2	14.67	1.62e-40	1.63e-36	0.64	0.56	Hypertension (SNP x SNP interaction);	chr5:83074596	chr5:83012285~83013109:-
LUAD	cis	rs12439619	0.846	rs62012059	ENSG00000278603.1	RP13-608F4.5	14.67	1.63e-40	1.63e-36	0.78	0.56	Intelligence (multi-trait analysis);	chr15:82251669	chr15:82472203~82472426:+
LUAD	cis	rs858239	1	rs199351	ENSG00000230658.1	KLHL7-AS1	14.66	1.68e-40	1.69e-36	0.67	0.56	Cerebrospinal fluid biomarker levels;	chr7:23260430	chr7:23101228~23105703:-
LUAD	cis	rs1799949	1	rs11659028	ENSG00000198496.9	NBR2	-14.66	1.71e-40	1.71e-36	-0.6	-0.56	Menopause (age at onset);	chr17:43043008	chr17:43125610~43153671:+
LUAD	cis	rs55794721	0.509	rs2375313	ENSG00000261349.1	RP3-465N24.5	-14.66	1.72e-40	1.72e-36	-0.61	-0.56	Mean corpuscular volume;Plateletcrit;	chr1:25421744	chr1:25266102~25267136:-
LUAD	cis	rs1799949	1	rs16941	ENSG00000198496.9	NBR2	-14.65	1.82e-40	1.82e-36	-0.6	-0.56	Menopause (age at onset);	chr17:43092418	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs16940	ENSG00000198496.9	NBR2	-14.65	1.82e-40	1.82e-36	-0.6	-0.56	Menopause (age at onset);	chr17:43093220	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.896	rs8176086	ENSG00000198496.9	NBR2	-14.65	1.87e-40	1.87e-36	-0.6	-0.56	Menopause (age at onset);	chr17:43122761	chr17:43125610~43153671:+
LUAD	cis	rs7617773	0.746	rs7619865	ENSG00000229759.1	MRPS18AP1	14.65	1.92e-40	1.91e-36	0.55	0.56	Coronary artery disease;	chr3:48329090	chr3:48256350~48256938:-
LUAD	cis	rs67383717	0.777	rs591486	ENSG00000175611.10	LINC00476	-14.65	1.97e-40	1.96e-36	-0.57	-0.56	Parkinson's disease (pesticide exposure interaction);	chr9:95887764	chr9:95759231~95875977:-
LUAD	cis	rs9326248	0.569	rs10892082	ENSG00000254851.1	RP11-109L13.1	-14.64	2.02e-40	2e-36	-0.94	-0.56	Blood protein levels;	chr11:117168609	chr11:117135528~117138582:+
LUAD	cis	rs4423214	1	rs2282621	ENSG00000254682.1	RP11-660L16.2	14.64	2.04e-40	2.03e-36	0.72	0.56	Vitamin D levels;	chr11:71472428	chr11:71448674~71452157:+
LUAD	cis	rs4423214	1	rs2282620	ENSG00000254682.1	RP11-660L16.2	14.64	2.04e-40	2.03e-36	0.72	0.56	Vitamin D levels;	chr11:71472431	chr11:71448674~71452157:+
LUAD	cis	rs2486288	0.656	rs11639420	ENSG00000259520.4	CTD-2651B20.3	14.64	2.16e-40	2.14e-36	0.66	0.56	Glomerular filtration rate;	chr15:45267070	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs11632920	ENSG00000259520.4	CTD-2651B20.3	14.63	2.39e-40	2.35e-36	0.66	0.55	Glomerular filtration rate;	chr15:45259066	chr15:45251580~45279251:-
LUAD	cis	rs2882667	0.858	rs7724108	ENSG00000253404.1	AC034243.1	-14.62	2.49e-40	2.45e-36	-0.72	-0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139075233	chr5:138744434~138753309:-
LUAD	cis	rs2019137	0.539	rs11123170	ENSG00000189223.12	PAX8-AS1	-14.62	2.51e-40	2.47e-36	-0.75	-0.55	Lymphocyte counts;	chr2:113221363	chr2:113211522~113276581:+
LUAD	cis	rs801193	1	rs4717319	ENSG00000226824.5	RP4-756H11.3	-14.62	2.54e-40	2.49e-36	-0.7	-0.55	Aortic root size;	chr7:66777606	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.904	rs4718403	ENSG00000226824.5	RP4-756H11.3	-14.62	2.54e-40	2.49e-36	-0.7	-0.55	Aortic root size;	chr7:66777742	chr7:66654538~66669855:+
LUAD	cis	rs2882667	0.931	rs10044736	ENSG00000253404.1	AC034243.1	-14.62	2.56e-40	2.51e-36	-0.7	-0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138985120	chr5:138744434~138753309:-
LUAD	cis	rs858239	0.932	rs1728313	ENSG00000230658.1	KLHL7-AS1	14.62	2.66e-40	2.61e-36	0.66	0.55	Cerebrospinal fluid biomarker levels;	chr7:23231412	chr7:23101228~23105703:-
LUAD	cis	rs2019137	0.56	rs7578633	ENSG00000189223.12	PAX8-AS1	-14.62	2.69e-40	2.64e-36	-0.75	-0.55	Lymphocyte counts;	chr2:113221073	chr2:113211522~113276581:+
LUAD	cis	rs1799949	0.93	rs8176194	ENSG00000198496.9	NBR2	-14.61	2.75e-40	2.69e-36	-0.59	-0.55	Menopause (age at onset);	chr17:43079204	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.93	rs66499067	ENSG00000198496.9	NBR2	-14.61	2.77e-40	2.71e-36	-0.6	-0.55	Menopause (age at onset);	chr17:43096467	chr17:43125610~43153671:+
LUAD	cis	rs2739330	0.731	rs4822450	ENSG00000250470.1	AP000351.3	14.61	2.83e-40	2.77e-36	0.67	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23976904~23977585:-
LUAD	cis	rs2019137	0.539	rs4849177	ENSG00000189223.12	PAX8-AS1	-14.61	2.89e-40	2.82e-36	-0.75	-0.55	Lymphocyte counts;	chr2:113225007	chr2:113211522~113276581:+
LUAD	cis	rs2019137	0.539	rs6755040	ENSG00000189223.12	PAX8-AS1	-14.61	2.92e-40	2.85e-36	-0.75	-0.55	Lymphocyte counts;	chr2:113223560	chr2:113211522~113276581:+
LUAD	cis	rs1799949	1	rs67060599	ENSG00000198496.9	NBR2	-14.61	2.94e-40	2.87e-36	-0.6	-0.55	Menopause (age at onset);	chr17:43103085	chr17:43125610~43153671:+
LUAD	cis	rs7104764	1	rs7104764	ENSG00000277290.1	RP11-326C3.16	-14.6	3.11e-40	3.03e-36	-0.55	-0.55	Menarche (age at onset);	chr11:229977	chr11:243099~243483:-
LUAD	cis	rs2019137	0.56	rs4849179	ENSG00000189223.12	PAX8-AS1	-14.6	3.14e-40	3.06e-36	-0.75	-0.55	Lymphocyte counts;	chr2:113227593	chr2:113211522~113276581:+
LUAD	cis	rs1799949	0.93	rs3765640	ENSG00000198496.9	NBR2	-14.6	3.23e-40	3.14e-36	-0.6	-0.55	Menopause (age at onset);	chr17:43124230	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs8176077	ENSG00000198496.9	NBR2	-14.6	3.23e-40	3.14e-36	-0.6	-0.55	Menopause (age at onset);	chr17:43124331	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.965	rs12947782	ENSG00000198496.9	NBR2	-14.6	3.23e-40	3.14e-36	-0.6	-0.55	Menopause (age at onset);	chr17:43127865	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs33945274	ENSG00000198496.9	NBR2	-14.6	3.23e-40	3.14e-36	-0.6	-0.55	Menopause (age at onset);	chr17:43128056	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.965	rs33925201	ENSG00000198496.9	NBR2	-14.6	3.23e-40	3.14e-36	-0.6	-0.55	Menopause (age at onset);	chr17:43128665	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs11653069	ENSG00000198496.9	NBR2	-14.6	3.23e-40	3.14e-36	-0.6	-0.55	Menopause (age at onset);	chr17:43131360	chr17:43125610~43153671:+
LUAD	cis	rs2739330	0.828	rs4820572	ENSG00000225282.1	AP000350.6	14.6	3.27e-40	3.18e-36	0.66	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23926900~23929574:+
LUAD	cis	rs1799949	1	rs8074136	ENSG00000198496.9	NBR2	-14.59	3.48e-40	3.38e-36	-0.59	-0.55	Menopause (age at onset);	chr17:43190296	chr17:43125610~43153671:+
LUAD	cis	rs7104764	0.879	rs6421986	ENSG00000277290.1	RP11-326C3.16	-14.59	3.55e-40	3.45e-36	-0.56	-0.55	Menarche (age at onset);	chr11:221659	chr11:243099~243483:-
LUAD	cis	rs2019137	0.56	rs10175462	ENSG00000189223.12	PAX8-AS1	-14.58	3.98e-40	3.86e-36	-0.75	-0.55	Lymphocyte counts;	chr2:113230915	chr2:113211522~113276581:+
LUAD	cis	rs2486288	0.656	rs7162022	ENSG00000259520.4	CTD-2651B20.3	14.58	4e-40	3.87e-36	0.67	0.55	Glomerular filtration rate;	chr15:45273055	chr15:45251580~45279251:-
LUAD	cis	rs858239	0.669	rs6461687	ENSG00000230658.1	KLHL7-AS1	14.57	4.25e-40	4.11e-36	0.67	0.55	Cerebrospinal fluid biomarker levels;	chr7:23076961	chr7:23101228~23105703:-
LUAD	cis	rs9326248	0.559	rs573549	ENSG00000254851.1	RP11-109L13.1	-14.57	4.27e-40	4.13e-36	-0.71	-0.55	Blood protein levels;	chr11:116865963	chr11:117135528~117138582:+
LUAD	cis	rs7104764	0.879	rs6598070	ENSG00000277290.1	RP11-326C3.16	-14.57	4.28e-40	4.13e-36	-0.57	-0.55	Menarche (age at onset);	chr11:225466	chr11:243099~243483:-
LUAD	cis	rs7104764	1	rs10794302	ENSG00000277290.1	RP11-326C3.16	-14.57	4.41e-40	4.25e-36	-0.56	-0.55	Menarche (age at onset);	chr11:234102	chr11:243099~243483:-
LUAD	cis	rs801193	0.967	rs34356500	ENSG00000226824.5	RP4-756H11.3	-14.57	4.5e-40	4.34e-36	-0.7	-0.55	Aortic root size;	chr7:66771620	chr7:66654538~66669855:+
LUAD	cis	rs1799949	1	rs35668327	ENSG00000198496.9	NBR2	-14.56	4.53e-40	4.37e-36	-0.59	-0.55	Menopause (age at onset);	chr17:43121078	chr17:43125610~43153671:+
LUAD	cis	rs9326248	0.53	rs2471884	ENSG00000254851.1	RP11-109L13.1	-14.56	4.7e-40	4.53e-36	-0.98	-0.55	Blood protein levels;	chr11:117139604	chr11:117135528~117138582:+
LUAD	cis	rs12439619	0.846	rs62012004	ENSG00000278603.1	RP13-608F4.5	14.55	5.15e-40	4.95e-36	0.77	0.55	Intelligence (multi-trait analysis);	chr15:82183924	chr15:82472203~82472426:+
LUAD	cis	rs1799949	0.931	rs34410138	ENSG00000198496.9	NBR2	-14.55	5.27e-40	5.07e-36	-0.6	-0.55	Menopause (age at onset);	chr17:43127753	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs2175957	ENSG00000198496.9	NBR2	-14.55	5.45e-40	5.23e-36	-0.6	-0.55	Menopause (age at onset);	chr17:43134805	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.965	rs33988650	ENSG00000198496.9	NBR2	-14.55	5.45e-40	5.23e-36	-0.6	-0.55	Menopause (age at onset);	chr17:43135863	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs11656097	ENSG00000198496.9	NBR2	-14.55	5.45e-40	5.23e-36	-0.6	-0.55	Menopause (age at onset);	chr17:43138596	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs11658754	ENSG00000198496.9	NBR2	-14.55	5.45e-40	5.23e-36	-0.6	-0.55	Menopause (age at onset);	chr17:43140722	chr17:43125610~43153671:+
LUAD	cis	rs858239	0.669	rs6461688	ENSG00000230658.1	KLHL7-AS1	14.55	5.51e-40	5.28e-36	0.67	0.55	Cerebrospinal fluid biomarker levels;	chr7:23076996	chr7:23101228~23105703:-
LUAD	cis	rs1799949	1	rs2292595	ENSG00000198496.9	NBR2	-14.54	5.83e-40	5.59e-36	-0.6	-0.55	Menopause (age at onset);	chr17:43138657	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs4793231	ENSG00000198496.9	NBR2	-14.54	6.07e-40	5.81e-36	-0.59	-0.55	Menopause (age at onset);	chr17:43350101	chr17:43125610~43153671:+
LUAD	cis	rs12439619	0.846	rs28470877	ENSG00000278603.1	RP13-608F4.5	14.53	6.13e-40	5.86e-36	0.77	0.55	Intelligence (multi-trait analysis);	chr15:82245797	chr15:82472203~82472426:+
LUAD	cis	rs1799949	0.965	rs35954893	ENSG00000198496.9	NBR2	-14.53	6.57e-40	6.27e-36	-0.59	-0.55	Menopause (age at onset);	chr17:43181769	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs11653231	ENSG00000198496.9	NBR2	-14.53	6.57e-40	6.27e-36	-0.59	-0.55	Menopause (age at onset);	chr17:43179443	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs1399323	ENSG00000198496.9	NBR2	-14.53	6.57e-40	6.27e-36	-0.59	-0.55	Menopause (age at onset);	chr17:43180313	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.93	rs4445938	ENSG00000198496.9	NBR2	-14.53	6.57e-40	6.27e-36	-0.59	-0.55	Menopause (age at onset);	chr17:43185883	chr17:43125610~43153671:+
LUAD	cis	rs7104764	1	rs6598074	ENSG00000277290.1	RP11-326C3.16	-14.53	6.7e-40	6.39e-36	-0.57	-0.55	Menarche (age at onset);	chr11:219398	chr11:243099~243483:-
LUAD	cis	rs2486288	0.656	rs11629858	ENSG00000259520.4	CTD-2651B20.3	14.52	7.13e-40	6.78e-36	0.66	0.55	Glomerular filtration rate;	chr15:45254916	chr15:45251580~45279251:-
LUAD	cis	rs2486288	0.656	rs11629859	ENSG00000259520.4	CTD-2651B20.3	14.52	7.13e-40	6.78e-36	0.66	0.55	Glomerular filtration rate;	chr15:45254923	chr15:45251580~45279251:-
LUAD	cis	rs1799949	1	rs12952790	ENSG00000198496.9	NBR2	-14.52	7.21e-40	6.85e-36	-0.59	-0.55	Menopause (age at onset);	chr17:43147590	chr17:43125610~43153671:+
LUAD	cis	rs6452524	0.618	rs6452504	ENSG00000249664.1	CTD-2227C6.2	14.51	7.96e-40	7.55e-36	0.63	0.55	Hypertension (SNP x SNP interaction);	chr5:83074625	chr5:83012285~83013109:-
LUAD	cis	rs7301826	0.651	rs7956851	ENSG00000256299.1	RP11-989F5.3	-14.5	8.71e-40	8.25e-36	-0.61	-0.55	Plasma plasminogen activator levels;	chr12:130834554	chr12:130810821~130812622:-
LUAD	cis	rs9326248	0.53	rs7122944	ENSG00000254851.1	RP11-109L13.1	-14.49	9.21e-40	8.72e-36	-0.98	-0.55	Blood protein levels;	chr11:117163903	chr11:117135528~117138582:+
LUAD	cis	rs7115242	0.514	rs4936367	ENSG00000254851.1	RP11-109L13.1	-14.49	9.21e-40	8.72e-36	-0.98	-0.55	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117171661	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.53	rs4604928	ENSG00000254851.1	RP11-109L13.1	-14.49	9.21e-40	8.72e-36	-0.98	-0.55	Blood protein levels;	chr11:117173487	chr11:117135528~117138582:+
LUAD	cis	rs1799949	1	rs8176133	ENSG00000198496.9	NBR2	-14.49	9.79e-40	9.26e-36	-0.6	-0.55	Menopause (age at onset);	chr17:43105441	chr17:43125610~43153671:+
LUAD	cis	rs992157	1	rs13003334	ENSG00000261338.2	RP11-378A13.1	14.48	1.02e-39	9.66e-36	0.56	0.55	Colorectal cancer;	chr2:218260198	chr2:218255319~218257366:+
LUAD	cis	rs6452524	0.618	rs6452502	ENSG00000249664.1	CTD-2227C6.2	14.48	1.06e-39	1e-35	0.63	0.55	Hypertension (SNP x SNP interaction);	chr5:83074578	chr5:83012285~83013109:-
LUAD	cis	rs7301826	0.651	rs7299281	ENSG00000256299.1	RP11-989F5.3	14.48	1.06e-39	1e-35	0.63	0.55	Plasma plasminogen activator levels;	chr12:130818587	chr12:130810821~130812622:-
LUAD	cis	rs1799949	1	rs12950607	ENSG00000198496.9	NBR2	-14.48	1.06e-39	1e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43147911	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs11079056	ENSG00000198496.9	NBR2	-14.48	1.06e-39	1e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43148782	chr17:43125610~43153671:+
LUAD	cis	rs875971	0.66	rs3764903	ENSG00000226824.5	RP4-756H11.3	14.48	1.09e-39	1.03e-35	0.7	0.55	Aortic root size;	chr7:66633495	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.66	rs1860470	ENSG00000226824.5	RP4-756H11.3	14.47	1.14e-39	1.07e-35	0.7	0.55	Aortic root size;	chr7:66638707	chr7:66654538~66669855:+
LUAD	cis	rs2882667	0.822	rs11738376	ENSG00000253404.1	AC034243.1	14.47	1.2e-39	1.12e-35	0.73	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139062483	chr5:138744434~138753309:-
LUAD	cis	rs55794721	0.509	rs873308	ENSG00000261349.1	RP3-465N24.5	14.46	1.31e-39	1.23e-35	0.59	0.55	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25266102~25267136:-
LUAD	cis	rs2739330	0.627	rs9608219	ENSG00000231271.1	AP000350.8	14.44	1.54e-39	1.43e-35	0.66	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23949918~23954042:+
LUAD	cis	rs2882667	0.931	rs7706391	ENSG00000253404.1	AC034243.1	14.44	1.54e-39	1.44e-35	0.7	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139013475	chr5:138744434~138753309:-
LUAD	cis	rs7301826	0.627	rs34103763	ENSG00000256299.1	RP11-989F5.3	14.44	1.55e-39	1.45e-35	0.63	0.55	Plasma plasminogen activator levels;	chr12:130805604	chr12:130810821~130812622:-
LUAD	cis	rs7301826	0.61	rs7961690	ENSG00000256299.1	RP11-989F5.3	14.44	1.55e-39	1.45e-35	0.63	0.55	Plasma plasminogen activator levels;	chr12:130812335	chr12:130810821~130812622:-
LUAD	cis	rs858239	1	rs858239	ENSG00000230658.1	KLHL7-AS1	14.44	1.56e-39	1.45e-35	0.66	0.55	Cerebrospinal fluid biomarker levels;	chr7:23246696	chr7:23101228~23105703:-
LUAD	cis	rs4423214	1	rs4944946	ENSG00000254682.1	RP11-660L16.2	14.44	1.6e-39	1.49e-35	0.72	0.55	Vitamin D levels;	chr11:71448383	chr11:71448674~71452157:+
LUAD	cis	rs1799949	1	rs33926631	ENSG00000198496.9	NBR2	-14.44	1.68e-39	1.56e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43152446	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs1960605	ENSG00000198496.9	NBR2	-14.44	1.68e-39	1.56e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43153380	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs2037076	ENSG00000198496.9	NBR2	-14.44	1.68e-39	1.56e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43153866	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs12936816	ENSG00000198496.9	NBR2	-14.43	1.72e-39	1.6e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43149692	chr17:43125610~43153671:+
LUAD	cis	rs2882667	0.858	rs11957527	ENSG00000253404.1	AC034243.1	14.43	1.73e-39	1.61e-35	0.73	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139069206	chr5:138744434~138753309:-
LUAD	cis	rs1799949	0.965	rs12950779	ENSG00000198496.9	NBR2	-14.43	1.74e-39	1.62e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43154506	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.93	rs33968979	ENSG00000198496.9	NBR2	-14.43	1.75e-39	1.62e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43145975	chr17:43125610~43153671:+
LUAD	cis	rs2739330	0.627	rs9608219	ENSG00000225282.1	AP000350.6	14.43	1.76e-39	1.64e-35	0.64	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23926900~23929574:+
LUAD	cis	rs2486288	0.656	rs9921035	ENSG00000259520.4	CTD-2651B20.3	14.43	1.77e-39	1.65e-35	0.66	0.55	Glomerular filtration rate;	chr15:45254462	chr15:45251580~45279251:-
LUAD	cis	rs858239	0.899	rs858271	ENSG00000230658.1	KLHL7-AS1	14.43	1.82e-39	1.69e-35	0.66	0.55	Cerebrospinal fluid biomarker levels;	chr7:23238664	chr7:23101228~23105703:-
LUAD	cis	rs4423214	1	rs28364617	ENSG00000254682.1	RP11-660L16.2	14.43	1.82e-39	1.69e-35	0.72	0.55	Vitamin D levels;	chr11:71448718	chr11:71448674~71452157:+
LUAD	cis	rs1799949	0.929	rs12937015	ENSG00000198496.9	NBR2	-14.42	1.91e-39	1.77e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43155456	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs4340367	ENSG00000198496.9	NBR2	-14.42	1.91e-39	1.77e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43155755	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs4792981	ENSG00000198496.9	NBR2	-14.42	1.91e-39	1.77e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43156257	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.965	rs35521261	ENSG00000198496.9	NBR2	-14.42	1.91e-39	1.77e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43161595	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.896	rs33933393	ENSG00000198496.9	NBR2	-14.42	1.91e-39	1.77e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43165415	chr17:43125610~43153671:+
LUAD	cis	rs2739330	0.685	rs4822453	ENSG00000250470.1	AP000351.3	14.42	1.97e-39	1.82e-35	0.67	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23976904~23977585:-
LUAD	cis	rs2739330	0.587	rs4820571	ENSG00000218537.1	MIF-AS1	14.41	2.13e-39	1.97e-35	0.7	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23894426~23898930:-
LUAD	cis	rs7301826	0.651	rs6486601	ENSG00000256299.1	RP11-989F5.3	14.41	2.27e-39	2.09e-35	0.63	0.55	Plasma plasminogen activator levels;	chr12:130816692	chr12:130810821~130812622:-
LUAD	cis	rs7301826	0.627	rs61937256	ENSG00000256299.1	RP11-989F5.3	14.41	2.27e-39	2.09e-35	0.63	0.55	Plasma plasminogen activator levels;	chr12:130818100	chr12:130810821~130812622:-
LUAD	cis	rs992157	1	rs3731859	ENSG00000261338.2	RP11-378A13.1	14.4	2.34e-39	2.16e-35	0.56	0.55	Colorectal cancer;	chr2:218259499	chr2:218255319~218257366:+
LUAD	cis	rs992157	1	rs11554825	ENSG00000261338.2	RP11-378A13.1	14.4	2.34e-39	2.16e-35	0.56	0.55	Colorectal cancer;	chr2:218261086	chr2:218255319~218257366:+
LUAD	cis	rs8040855	0.644	rs4635318	ENSG00000259295.5	CSPG4P12	-14.4	2.35e-39	2.16e-35	-0.66	-0.55	Bulimia nervosa;	chr15:85183506	chr15:85191438~85213905:+
LUAD	cis	rs858239	1	rs199347	ENSG00000230658.1	KLHL7-AS1	14.39	2.55e-39	2.34e-35	0.66	0.55	Cerebrospinal fluid biomarker levels;	chr7:23254127	chr7:23101228~23105703:-
LUAD	cis	rs1799949	0.501	rs2343819	ENSG00000198496.9	NBR2	-14.39	2.55e-39	2.34e-35	-0.58	-0.55	Menopause (age at onset);	chr17:43332285	chr17:43125610~43153671:+
LUAD	cis	rs12439619	0.846	rs62011975	ENSG00000278603.1	RP13-608F4.5	14.39	2.58e-39	2.36e-35	0.77	0.55	Intelligence (multi-trait analysis);	chr15:82159213	chr15:82472203~82472426:+
LUAD	cis	rs9326248	0.53	rs7123517	ENSG00000254851.1	RP11-109L13.1	-14.38	2.82e-39	2.58e-35	-0.98	-0.55	Blood protein levels;	chr11:117157039	chr11:117135528~117138582:+
LUAD	cis	rs2486288	0.656	rs8039354	ENSG00000259520.4	CTD-2651B20.3	-14.38	2.83e-39	2.59e-35	-0.65	-0.55	Glomerular filtration rate;	chr15:45259558	chr15:45251580~45279251:-
LUAD	cis	rs992157	1	rs4791	ENSG00000261338.2	RP11-378A13.1	14.38	2.89e-39	2.64e-35	0.55	0.55	Colorectal cancer;	chr2:218274217	chr2:218255319~218257366:+
LUAD	cis	rs1799949	1	rs33994002	ENSG00000198496.9	NBR2	-14.38	2.94e-39	2.69e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43176801	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs33920795	ENSG00000198496.9	NBR2	-14.38	2.94e-39	2.69e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43176993	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs33918839	ENSG00000198496.9	NBR2	-14.38	2.94e-39	2.69e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43177155	chr17:43125610~43153671:+
LUAD	cis	rs858239	1	rs156407	ENSG00000230658.1	KLHL7-AS1	14.37	3.09e-39	2.82e-35	0.67	0.55	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23101228~23105703:-
LUAD	cis	rs1799949	1	rs4793197	ENSG00000198496.9	NBR2	-14.37	3.1e-39	2.82e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43079885	chr17:43125610~43153671:+
LUAD	cis	rs7301826	0.603	rs7975825	ENSG00000256299.1	RP11-989F5.3	-14.36	3.52e-39	3.18e-35	-0.61	-0.55	Plasma plasminogen activator levels;	chr12:130803899	chr12:130810821~130812622:-
LUAD	cis	rs1799949	1	rs12944430	ENSG00000198496.9	NBR2	-14.35	3.95e-39	3.55e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43178803	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.965	rs11658499	ENSG00000198496.9	NBR2	-14.35	3.95e-39	3.55e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43182732	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.93	rs35292991	ENSG00000198496.9	NBR2	-14.35	3.96e-39	3.56e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43181999	chr17:43125610~43153671:+
LUAD	cis	rs7301826	0.56	rs12829294	ENSG00000256299.1	RP11-989F5.3	14.34	4.22e-39	3.79e-35	0.62	0.55	Plasma plasminogen activator levels;	chr12:130825427	chr12:130810821~130812622:-
LUAD	cis	rs7104764	0.957	rs3829998	ENSG00000277290.1	RP11-326C3.16	-14.34	4.26e-39	3.83e-35	-0.55	-0.55	Menarche (age at onset);	chr11:230751	chr11:243099~243483:-
LUAD	cis	rs1577917	0.771	rs6454486	ENSG00000203875.9	SNHG5	14.34	4.41e-39	3.95e-35	0.68	0.55	Response to antipsychotic treatment;	chr6:85723869	chr6:85660950~85678736:-
LUAD	cis	rs73086581	0.787	rs67724338	ENSG00000229539.1	RP11-119B16.2	14.34	4.42e-39	3.96e-35	0.8	0.55	Response to antidepressants in depression;	chr20:3888410	chr20:3888239~3888868:-
LUAD	cis	rs2019137	0.56	rs11123172	ENSG00000189223.12	PAX8-AS1	14.34	4.47e-39	4e-35	0.74	0.55	Lymphocyte counts;	chr2:113226726	chr2:113211522~113276581:+
LUAD	cis	rs875971	0.66	rs1860468	ENSG00000226824.5	RP4-756H11.3	14.33	4.7e-39	4.21e-35	0.7	0.55	Aortic root size;	chr7:66642265	chr7:66654538~66669855:+
LUAD	cis	rs3814244	0.933	rs12423194	ENSG00000255733.4	IFNG-AS1	14.33	4.77e-39	4.27e-35	0.45	0.55	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020387	chr12:67989445~68234686:+
LUAD	cis	rs3814244	0.966	rs10784666	ENSG00000255733.4	IFNG-AS1	-14.33	4.78e-39	4.27e-35	-0.46	-0.55	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021923	chr12:67989445~68234686:+
LUAD	cis	rs6538678	0.824	rs4762631	ENSG00000258343.1	RP11-536G4.2	-14.33	5.01e-39	4.47e-35	-0.87	-0.55	Lupus nephritis in systemic lupus erythematosus;	chr12:95855698	chr12:95795345~95858839:-
LUAD	cis	rs1799949	1	rs8077486	ENSG00000198496.9	NBR2	-14.33	5.12e-39	4.57e-35	-0.56	-0.55	Menopause (age at onset);	chr17:43060788	chr17:43125610~43153671:+
LUAD	cis	rs6538678	0.824	rs1436120	ENSG00000258343.1	RP11-536G4.2	14.32	5.22e-39	4.65e-35	0.83	0.55	Lupus nephritis in systemic lupus erythematosus;	chr12:95826872	chr12:95795345~95858839:-
LUAD	cis	rs6538678	0.824	rs2887026	ENSG00000258343.1	RP11-536G4.2	-14.32	5.41e-39	4.82e-35	-0.86	-0.55	Lupus nephritis in systemic lupus erythematosus;	chr12:95854713	chr12:95795345~95858839:-
LUAD	cis	rs1799949	1	rs11653460	ENSG00000198496.9	NBR2	-14.32	5.48e-39	4.88e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43179289	chr17:43125610~43153671:+
LUAD	cis	rs73086581	0.787	rs68127408	ENSG00000229539.1	RP11-119B16.2	14.32	5.56e-39	4.94e-35	0.8	0.55	Response to antidepressants in depression;	chr20:3887800	chr20:3888239~3888868:-
LUAD	cis	rs73086581	0.787	rs67202952	ENSG00000229539.1	RP11-119B16.2	14.32	5.56e-39	4.94e-35	0.8	0.55	Response to antidepressants in depression;	chr20:3888452	chr20:3888239~3888868:-
LUAD	cis	rs9326248	0.52	rs74830	ENSG00000254851.1	RP11-109L13.1	14.32	5.59e-39	4.97e-35	0.7	0.55	Blood protein levels;	chr11:117219842	chr11:117135528~117138582:+
LUAD	cis	rs1799949	0.965	rs7212284	ENSG00000198496.9	NBR2	-14.31	5.7e-39	5.06e-35	-0.56	-0.55	Menopause (age at onset);	chr17:43053924	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.965	rs11650913	ENSG00000198496.9	NBR2	-14.31	5.74e-39	5.09e-35	-0.58	-0.55	Menopause (age at onset);	chr17:43179580	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs12936831	ENSG00000198496.9	NBR2	-14.31	5.74e-39	5.09e-35	-0.58	-0.55	Menopause (age at onset);	chr17:43179799	chr17:43125610~43153671:+
LUAD	cis	rs2882667	0.858	rs6596460	ENSG00000253404.1	AC034243.1	14.31	6.26e-39	5.55e-35	0.71	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078491	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.898	rs4380651	ENSG00000253404.1	AC034243.1	14.3	6.33e-39	5.6e-35	0.71	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139055383	chr5:138744434~138753309:-
LUAD	cis	rs875971	0.66	rs2013222	ENSG00000226824.5	RP4-756H11.3	14.3	6.53e-39	5.77e-35	0.68	0.55	Aortic root size;	chr7:66570949	chr7:66654538~66669855:+
LUAD	cis	rs992157	1	rs736731	ENSG00000261338.2	RP11-378A13.1	14.3	6.55e-39	5.79e-35	0.55	0.55	Colorectal cancer;	chr2:218255865	chr2:218255319~218257366:+
LUAD	cis	rs2882667	0.858	rs6882112	ENSG00000253404.1	AC034243.1	-14.29	7.02e-39	6.19e-35	-0.7	-0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078046	chr5:138744434~138753309:-
LUAD	cis	rs1799949	0.965	rs33961729	ENSG00000198496.9	NBR2	-14.29	7.29e-39	6.41e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43135907	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs11657835	ENSG00000198496.9	NBR2	-14.29	7.29e-39	6.41e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43139936	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs1135214	ENSG00000198496.9	NBR2	-14.29	7.29e-39	6.41e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43140306	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs11652332	ENSG00000198496.9	NBR2	-14.29	7.29e-39	6.41e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43143472	chr17:43125610~43153671:+
LUAD	cis	rs5850	0.602	rs1005786	ENSG00000230658.1	KLHL7-AS1	14.29	7.5e-39	6.59e-35	0.65	0.55	Blood protein levels;	chr7:23106218	chr7:23101228~23105703:-
LUAD	cis	rs1799949	1	rs33946455	ENSG00000198496.9	NBR2	-14.29	7.57e-39	6.65e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43169829	chr17:43125610~43153671:+
LUAD	cis	rs3091242	0.866	rs11249249	ENSG00000261349.1	RP3-465N24.5	-14.28	8.01e-39	7.03e-35	-0.6	-0.55	Erythrocyte sedimentation rate;	chr1:25431643	chr1:25266102~25267136:-
LUAD	cis	rs1799949	0.501	rs35399157	ENSG00000198496.9	NBR2	-14.28	8.31e-39	7.28e-35	-0.58	-0.55	Menopause (age at onset);	chr17:43334234	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.602	rs4600503	ENSG00000198496.9	NBR2	-14.28	8.31e-39	7.28e-35	-0.58	-0.55	Menopause (age at onset);	chr17:43336956	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.965	rs2236762	ENSG00000198496.9	NBR2	-14.28	8.38e-39	7.34e-35	-0.57	-0.55	Menopause (age at onset);	chr17:43074658	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs4793189	ENSG00000198496.9	NBR2	-14.28	8.42e-39	7.37e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43038698	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs11657053	ENSG00000198496.9	NBR2	-14.28	8.42e-39	7.37e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43039112	chr17:43125610~43153671:+
LUAD	cis	rs992157	1	rs736730	ENSG00000261338.2	RP11-378A13.1	14.27	8.65e-39	7.57e-35	0.55	0.55	Colorectal cancer;	chr2:218255532	chr2:218255319~218257366:+
LUAD	cis	rs7115242	0.8	rs7131536	ENSG00000254851.1	RP11-109L13.1	-14.27	8.93e-39	7.8e-35	-0.96	-0.55	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117128730	chr11:117135528~117138582:+
LUAD	cis	rs1799949	0.55	rs2343818	ENSG00000198496.9	NBR2	-14.26	9.53e-39	8.3e-35	-0.58	-0.55	Menopause (age at onset);	chr17:43332406	chr17:43125610~43153671:+
LUAD	cis	rs2739330	0.929	rs5751775	ENSG00000250470.1	AP000351.3	14.26	1.01e-38	8.7e-35	0.67	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23976904~23977585:-
LUAD	cis	rs1799949	0.965	rs11657883	ENSG00000198496.9	NBR2	-14.26	1.03e-38	8.87e-35	-0.59	-0.55	Menopause (age at onset);	chr17:43178007	chr17:43125610~43153671:+
LUAD	cis	rs8040855	0.559	rs6496801	ENSG00000259295.5	CSPG4P12	-14.25	1.08e-38	9.31e-35	-0.68	-0.54	Bulimia nervosa;	chr15:85185168	chr15:85191438~85213905:+
LUAD	cis	rs7301826	0.58	rs61938969	ENSG00000256299.1	RP11-989F5.3	14.25	1.11e-38	9.59e-35	0.62	0.54	Plasma plasminogen activator levels;	chr12:130831525	chr12:130810821~130812622:-
LUAD	cis	rs2882667	0.858	rs11744972	ENSG00000253404.1	AC034243.1	14.25	1.12e-38	9.67e-35	0.72	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139093100	chr5:138744434~138753309:-
LUAD	cis	rs6452524	0.618	rs10462394	ENSG00000249664.1	CTD-2227C6.2	14.24	1.17e-38	1.01e-34	0.61	0.54	Hypertension (SNP x SNP interaction);	chr5:83058735	chr5:83012285~83013109:-
LUAD	cis	rs2882667	0.929	rs17207828	ENSG00000253404.1	AC034243.1	14.24	1.17e-38	1.01e-34	0.71	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:138964146	chr5:138744434~138753309:-
LUAD	cis	rs992157	0.835	rs6707559	ENSG00000261338.2	RP11-378A13.1	14.24	1.17e-38	1.01e-34	0.54	0.54	Colorectal cancer;	chr2:218278050	chr2:218255319~218257366:+
LUAD	cis	rs1799949	1	rs1973646	ENSG00000198496.9	NBR2	-14.24	1.18e-38	1.02e-34	-0.59	-0.54	Menopause (age at onset);	chr17:43158478	chr17:43125610~43153671:+
LUAD	cis	rs992157	0.798	rs2382817	ENSG00000261338.2	RP11-378A13.1	14.24	1.19e-38	1.03e-34	0.54	0.54	Colorectal cancer;	chr2:218286495	chr2:218255319~218257366:+
LUAD	cis	rs1799949	0.965	rs4793234	ENSG00000198496.9	NBR2	-14.24	1.26e-38	1.09e-34	-0.59	-0.54	Menopause (age at onset);	chr17:43358815	chr17:43125610~43153671:+
LUAD	cis	rs7617773	0.817	rs3729577	ENSG00000229759.1	MRPS18AP1	14.23	1.39e-38	1.2e-34	0.57	0.54	Coronary artery disease;	chr3:48187504	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.817	rs3731497	ENSG00000229759.1	MRPS18AP1	14.22	1.5e-38	1.29e-34	0.57	0.54	Coronary artery disease;	chr3:48185063	chr3:48256350~48256938:-
LUAD	cis	rs916888	0.61	rs199453	ENSG00000214401.4	KANSL1-AS1	14.22	1.54e-38	1.32e-34	0.75	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46193576~46196723:+
LUAD	cis	rs1799949	1	rs4793215	ENSG00000198496.9	NBR2	-14.21	1.61e-38	1.37e-34	-0.59	-0.54	Menopause (age at onset);	chr17:43166915	chr17:43125610~43153671:+
LUAD	cis	rs801193	1	rs13239306	ENSG00000226824.5	RP4-756H11.3	14.21	1.67e-38	1.43e-34	0.69	0.54	Aortic root size;	chr7:66671030	chr7:66654538~66669855:+
LUAD	cis	rs73086581	0.787	rs67633417	ENSG00000229539.1	RP11-119B16.2	14.21	1.68e-38	1.44e-34	0.8	0.54	Response to antidepressants in depression;	chr20:3887610	chr20:3888239~3888868:-
LUAD	cis	rs1799949	0.965	rs11651623	ENSG00000198496.9	NBR2	-14.2	1.73e-38	1.47e-34	-0.59	-0.54	Menopause (age at onset);	chr17:43177830	chr17:43125610~43153671:+
LUAD	cis	rs875971	0.638	rs35986979	ENSG00000226824.5	RP4-756H11.3	14.2	1.73e-38	1.47e-34	0.69	0.54	Aortic root size;	chr7:66624003	chr7:66654538~66669855:+
LUAD	cis	rs2882667	0.822	rs13187096	ENSG00000253404.1	AC034243.1	14.2	1.73e-38	1.48e-34	0.73	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139068399	chr5:138744434~138753309:-
LUAD	cis	rs916888	0.61	rs199452	ENSG00000214401.4	KANSL1-AS1	14.2	1.75e-38	1.49e-34	0.74	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46193576~46196723:+
LUAD	cis	rs875971	0.642	rs35526611	ENSG00000226824.5	RP4-756H11.3	14.2	1.79e-38	1.53e-34	0.69	0.54	Aortic root size;	chr7:66629021	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.967	rs3800823	ENSG00000226824.5	RP4-756H11.3	14.2	1.8e-38	1.53e-34	0.7	0.54	Aortic root size;	chr7:66682123	chr7:66654538~66669855:+
LUAD	cis	rs1799949	0.864	rs60309406	ENSG00000198496.9	NBR2	-14.2	1.85e-38	1.58e-34	-0.59	-0.54	Menopause (age at onset);	chr17:43358297	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs2271574	ENSG00000198496.9	NBR2	-14.2	1.87e-38	1.59e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43175631	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs11649954	ENSG00000198496.9	NBR2	-14.19	1.9e-38	1.62e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43342667	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs1824889	ENSG00000198496.9	NBR2	-14.19	1.9e-38	1.62e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43344508	chr17:43125610~43153671:+
LUAD	cis	rs7617773	0.784	rs11715799	ENSG00000229759.1	MRPS18AP1	14.19	1.98e-38	1.69e-34	0.57	0.54	Coronary artery disease;	chr3:48213730	chr3:48256350~48256938:-
LUAD	cis	rs6538678	0.857	rs4762626	ENSG00000199506.1	RNU6-247P	-14.18	2.1e-38	1.78e-34	-0.8	-0.54	Lupus nephritis in systemic lupus erythematosus;	chr12:95811383	chr12:95792529~95792635:-
LUAD	cis	rs2019137	0.56	rs10206269	ENSG00000189223.12	PAX8-AS1	-14.18	2.12e-38	1.8e-34	-0.74	-0.54	Lymphocyte counts;	chr2:113232816	chr2:113211522~113276581:+
LUAD	cis	rs1799949	1	rs9646412	ENSG00000198496.9	NBR2	-14.18	2.2e-38	1.86e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43348525	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.93	rs4584865	ENSG00000198496.9	NBR2	-14.18	2.23e-38	1.88e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43347551	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs4793212	ENSG00000198496.9	NBR2	-14.18	2.25e-38	1.9e-34	-0.59	-0.54	Menopause (age at onset);	chr17:43150733	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs34534709	ENSG00000198496.9	NBR2	-14.18	2.25e-38	1.9e-34	-0.59	-0.54	Menopause (age at onset);	chr17:43150923	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs34059614	ENSG00000198496.9	NBR2	-14.18	2.25e-38	1.9e-34	-0.59	-0.54	Menopause (age at onset);	chr17:43151054	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.965	rs11656945	ENSG00000198496.9	NBR2	-14.18	2.26e-38	1.91e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43178248	chr17:43125610~43153671:+
LUAD	cis	rs3814244	0.966	rs10784667	ENSG00000255733.4	IFNG-AS1	-14.18	2.29e-38	1.93e-34	-0.46	-0.54	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021996	chr12:67989445~68234686:+
LUAD	cis	rs1799949	0.965	rs4793233	ENSG00000198496.9	NBR2	-14.17	2.49e-38	2.1e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43358069	chr17:43125610~43153671:+
LUAD	cis	rs2882667	0.931	rs7720150	ENSG00000253404.1	AC034243.1	14.17	2.52e-38	2.12e-34	0.69	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998380	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.858	rs11242444	ENSG00000253404.1	AC034243.1	14.17	2.56e-38	2.15e-34	0.72	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070690	chr5:138744434~138753309:-
LUAD	cis	rs1799949	1	rs2037075	ENSG00000198496.9	NBR2	-14.16	2.59e-38	2.18e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43153809	chr17:43125610~43153671:+
LUAD	cis	rs7617773	0.71	rs36064160	ENSG00000229759.1	MRPS18AP1	14.16	2.66e-38	2.24e-34	0.57	0.54	Coronary artery disease;	chr3:48201611	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.817	rs34728236	ENSG00000229759.1	MRPS18AP1	14.16	2.66e-38	2.24e-34	0.57	0.54	Coronary artery disease;	chr3:48217618	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.817	rs79310258	ENSG00000229759.1	MRPS18AP1	14.16	2.66e-38	2.24e-34	0.57	0.54	Coronary artery disease;	chr3:48218177	chr3:48256350~48256938:-
LUAD	cis	rs1799949	1	rs12944458	ENSG00000198496.9	NBR2	-14.15	2.83e-38	2.38e-34	-0.59	-0.54	Menopause (age at onset);	chr17:43028755	chr17:43125610~43153671:+
LUAD	cis	rs992157	1	rs10932766	ENSG00000261338.2	RP11-378A13.1	14.15	2.86e-38	2.4e-34	0.55	0.54	Colorectal cancer;	chr2:218257367	chr2:218255319~218257366:+
LUAD	cis	rs875971	0.619	rs12533585	ENSG00000226824.5	RP4-756H11.3	-14.15	2.9e-38	2.43e-34	-0.68	-0.54	Aortic root size;	chr7:66519618	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.66	rs12698534	ENSG00000226824.5	RP4-756H11.3	-14.15	2.9e-38	2.43e-34	-0.68	-0.54	Aortic root size;	chr7:66521858	chr7:66654538~66669855:+
LUAD	cis	rs7617773	0.78	rs3731489	ENSG00000229759.1	MRPS18AP1	14.15	2.93e-38	2.45e-34	0.57	0.54	Coronary artery disease;	chr3:48187416	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.779	rs3731487	ENSG00000229759.1	MRPS18AP1	14.15	2.93e-38	2.45e-34	0.57	0.54	Coronary artery disease;	chr3:48188134	chr3:48256350~48256938:-
LUAD	cis	rs1799949	0.501	rs9675035	ENSG00000198496.9	NBR2	-14.15	2.93e-38	2.45e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43337648	chr17:43125610~43153671:+
LUAD	cis	rs7617773	0.746	rs6796343	ENSG00000229759.1	MRPS18AP1	14.15	2.94e-38	2.46e-34	0.57	0.54	Coronary artery disease;	chr3:48240531	chr3:48256350~48256938:-
LUAD	cis	rs2019137	0.56	rs7421852	ENSG00000189223.12	PAX8-AS1	-14.15	2.97e-38	2.49e-34	-0.74	-0.54	Lymphocyte counts;	chr2:113232684	chr2:113211522~113276581:+
LUAD	cis	rs1799949	0.526	rs4352088	ENSG00000198496.9	NBR2	-14.14	3.16e-38	2.64e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43337311	chr17:43125610~43153671:+
LUAD	cis	rs875971	0.638	rs801205	ENSG00000226824.5	RP4-756H11.3	14.14	3.41e-38	2.84e-34	0.68	0.54	Aortic root size;	chr7:66557157	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.617	rs810400	ENSG00000226824.5	RP4-756H11.3	14.14	3.41e-38	2.84e-34	0.68	0.54	Aortic root size;	chr7:66557902	chr7:66654538~66669855:+
LUAD	cis	rs1799949	1	rs35956818	ENSG00000198496.9	NBR2	-14.13	3.61e-38	3e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43345617	chr17:43125610~43153671:+
LUAD	cis	rs801193	1	rs17566701	ENSG00000226824.5	RP4-756H11.3	-14.12	3.91e-38	3.25e-34	-0.7	-0.54	Aortic root size;	chr7:66728196	chr7:66654538~66669855:+
LUAD	cis	rs916888	0.61	rs199436	ENSG00000214401.4	KANSL1-AS1	-14.12	3.93e-38	3.26e-34	-0.74	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46193576~46196723:+
LUAD	cis	rs2882667	0.858	rs11949916	ENSG00000253404.1	AC034243.1	14.12	4.17e-38	3.46e-34	0.72	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139060588	chr5:138744434~138753309:-
LUAD	cis	rs9326248	0.53	rs2127905	ENSG00000254851.1	RP11-109L13.1	-14.11	4.24e-38	3.52e-34	-0.96	-0.54	Blood protein levels;	chr11:117155658	chr11:117135528~117138582:+
LUAD	cis	rs1799949	1	rs36036395	ENSG00000198496.9	NBR2	-14.11	4.34e-38	3.6e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43029280	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs72829113	ENSG00000198496.9	NBR2	-14.11	4.34e-38	3.6e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43029818	chr17:43125610~43153671:+
LUAD	cis	rs9326248	0.52	rs236919	ENSG00000254851.1	RP11-109L13.1	-14.11	4.59e-38	3.8e-34	-0.69	-0.54	Blood protein levels;	chr11:117224645	chr11:117135528~117138582:+
LUAD	cis	rs2882667	0.858	rs11956159	ENSG00000253404.1	AC034243.1	14.1	4.74e-38	3.92e-34	0.72	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139072879	chr5:138744434~138753309:-
LUAD	cis	rs875971	0.66	rs801193	ENSG00000226824.5	RP4-756H11.3	14.1	4.75e-38	3.93e-34	0.67	0.54	Aortic root size;	chr7:66565625	chr7:66654538~66669855:+
LUAD	cis	rs1799949	0.965	rs8176087	ENSG00000198496.9	NBR2	-14.1	4.77e-38	3.94e-34	-0.59	-0.54	Menopause (age at onset);	chr17:43118649	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs34942571	ENSG00000198496.9	NBR2	-14.1	4.77e-38	3.94e-34	-0.59	-0.54	Menopause (age at onset);	chr17:43121362	chr17:43125610~43153671:+
LUAD	cis	rs2882667	0.858	rs11959851	ENSG00000253404.1	AC034243.1	14.1	4.81e-38	3.97e-34	0.71	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085716	chr5:138744434~138753309:-
LUAD	cis	rs7617773	0.746	rs11713476	ENSG00000229759.1	MRPS18AP1	14.1	4.92e-38	4.06e-34	0.56	0.54	Coronary artery disease;	chr3:48333944	chr3:48256350~48256938:-
LUAD	cis	rs1799949	1	rs11653253	ENSG00000198496.9	NBR2	-14.1	4.93e-38	4.06e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43030645	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs12951869	ENSG00000198496.9	NBR2	-14.1	4.93e-38	4.06e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43035550	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs11654452	ENSG00000198496.9	NBR2	-14.1	4.93e-38	4.06e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43037366	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.965	rs9897425	ENSG00000198496.9	NBR2	-14.09	5.19e-38	4.27e-34	-0.56	-0.54	Menopause (age at onset);	chr17:43352811	chr17:43125610~43153671:+
LUAD	cis	rs10129255	0.5	rs2105989	ENSG00000223648.3	IGHV3-64	14.09	5.28e-38	4.34e-34	0.49	0.54	Kawasaki disease;	chr14:106682199	chr14:106643132~106658258:-
LUAD	cis	rs1799949	1	rs4793229	ENSG00000198496.9	NBR2	14.09	5.3e-38	4.35e-34	0.57	0.54	Menopause (age at onset);	chr17:43340966	chr17:43125610~43153671:+
LUAD	cis	rs7617773	0.817	rs17786132	ENSG00000229759.1	MRPS18AP1	14.09	5.61e-38	4.58e-34	0.56	0.54	Coronary artery disease;	chr3:48207930	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.817	rs35456569	ENSG00000229759.1	MRPS18AP1	14.09	5.61e-38	4.58e-34	0.56	0.54	Coronary artery disease;	chr3:48209409	chr3:48256350~48256938:-
LUAD	cis	rs7104764	0.957	rs519592	ENSG00000277290.1	RP11-326C3.16	-14.08	5.99e-38	4.88e-34	-0.55	-0.54	Menarche (age at onset);	chr11:236811	chr11:243099~243483:-
LUAD	cis	rs2658782	1	rs2658778	ENSG00000279684.1	RP11-755E23.2	-14.08	6.24e-38	5.09e-34	-0.87	-0.54	Pulmonary function decline;	chr11:93415782	chr11:93286629~93288903:-
LUAD	cis	rs858239	0.932	rs858275	ENSG00000230658.1	KLHL7-AS1	14.07	6.51e-38	5.3e-34	0.65	0.54	Cerebrospinal fluid biomarker levels;	chr7:23254525	chr7:23101228~23105703:-
LUAD	cis	rs7104764	0.957	rs6598075	ENSG00000277290.1	RP11-326C3.16	14.07	6.82e-38	5.54e-34	0.53	0.54	Menarche (age at onset);	chr11:207275	chr11:243099~243483:-
LUAD	cis	rs7104764	0.957	rs58692051	ENSG00000277290.1	RP11-326C3.16	14.07	6.82e-38	5.54e-34	0.53	0.54	Menarche (age at onset);	chr11:207410	chr11:243099~243483:-
LUAD	cis	rs875971	0.638	rs6960778	ENSG00000226824.5	RP4-756H11.3	14.07	6.82e-38	5.54e-34	0.68	0.54	Aortic root size;	chr7:66606610	chr7:66654538~66669855:+
LUAD	cis	rs1799949	1	rs8176083	ENSG00000198496.9	NBR2	-14.06	7.4e-38	5.99e-34	-0.59	-0.54	Menopause (age at onset);	chr17:43123134	chr17:43125610~43153671:+
LUAD	cis	rs858239	0.965	rs156429	ENSG00000230658.1	KLHL7-AS1	14.06	7.43e-38	6.01e-34	0.65	0.54	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23101228~23105703:-
LUAD	cis	rs875971	0.505	rs1167386	ENSG00000226824.5	RP4-756H11.3	14.06	7.43e-38	6.01e-34	0.68	0.54	Aortic root size;	chr7:66048109	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.505	rs1167385	ENSG00000226824.5	RP4-756H11.3	14.06	7.43e-38	6.01e-34	0.68	0.54	Aortic root size;	chr7:66048321	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.66	rs10272357	ENSG00000226824.5	RP4-756H11.3	14.06	7.47e-38	6.04e-34	0.68	0.54	Aortic root size;	chr7:66598087	chr7:66654538~66669855:+
LUAD	cis	rs1799949	0.965	rs34633610	ENSG00000198496.9	NBR2	-14.06	7.47e-38	6.04e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43342017	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.965	rs11654051	ENSG00000198496.9	NBR2	-14.06	7.47e-38	6.04e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43342288	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.93	rs56729776	ENSG00000198496.9	NBR2	-14.06	7.47e-38	6.04e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43344763	chr17:43125610~43153671:+
LUAD	cis	rs3814244	0.933	rs11610126	ENSG00000255733.4	IFNG-AS1	-14.06	7.53e-38	6.09e-34	-0.45	-0.54	Itch intensity from mosquito bite adjusted by bite size;	chr12:68026493	chr12:67989445~68234686:+
LUAD	cis	rs7617773	0.817	rs3731513	ENSG00000229759.1	MRPS18AP1	14.05	8.09e-38	6.53e-34	0.57	0.54	Coronary artery disease;	chr3:48178047	chr3:48256350~48256938:-
LUAD	cis	rs1799949	0.86	rs8176279	ENSG00000198496.9	NBR2	-14.04	8.64e-38	6.96e-34	-0.56	-0.54	Menopause (age at onset);	chr17:43058379	chr17:43125610~43153671:+
LUAD	cis	rs875971	0.505	rs2462573	ENSG00000226824.5	RP4-756H11.3	14.04	8.65e-38	6.97e-34	0.68	0.54	Aortic root size;	chr7:66042405	chr7:66654538~66669855:+
LUAD	cis	rs3814244	0.902	rs2870961	ENSG00000255733.4	IFNG-AS1	-14.04	8.82e-38	7.1e-34	-0.45	-0.54	Itch intensity from mosquito bite adjusted by bite size;	chr12:68024262	chr12:67989445~68234686:+
LUAD	cis	rs2739330	0.76	rs5751760	ENSG00000250470.1	AP000351.3	14.03	9.8e-38	7.86e-34	0.65	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23976904~23977585:-
LUAD	cis	rs4853012	0.941	rs60291089	ENSG00000217702.2	RP11-287D1.4	14.03	1.02e-37	8.16e-34	0.82	0.54	Gestational age at birth (maternal effect);	chr2:74117763	chr2:74130583~74135395:+
LUAD	cis	rs4853012	0.838	rs58759652	ENSG00000217702.2	RP11-287D1.4	14.03	1.02e-37	8.16e-34	0.82	0.54	Gestational age at birth (maternal effect);	chr2:74117775	chr2:74130583~74135395:+
LUAD	cis	rs875971	0.66	rs801217	ENSG00000226824.5	RP4-756H11.3	14.02	1.06e-37	8.44e-34	0.68	0.54	Aortic root size;	chr7:66545590	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.638	rs801216	ENSG00000226824.5	RP4-756H11.3	14.02	1.06e-37	8.44e-34	0.68	0.54	Aortic root size;	chr7:66546680	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.66	rs801211	ENSG00000226824.5	RP4-756H11.3	14.02	1.06e-37	8.44e-34	0.68	0.54	Aortic root size;	chr7:66550702	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.66	rs79009421	ENSG00000226824.5	RP4-756H11.3	14.02	1.07e-37	8.53e-34	0.68	0.54	Aortic root size;	chr7:66603522	chr7:66654538~66669855:+
LUAD	cis	rs1799949	0.965	rs11650132	ENSG00000198496.9	NBR2	-14.02	1.08e-37	8.64e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43174070	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs11654731	ENSG00000198496.9	NBR2	-14.02	1.08e-37	8.64e-34	-0.58	-0.54	Menopause (age at onset);	chr17:43174923	chr17:43125610~43153671:+
LUAD	cis	rs7617773	0.851	rs7647817	ENSG00000229759.1	MRPS18AP1	14.01	1.24e-37	9.82e-34	0.56	0.54	Coronary artery disease;	chr3:48195017	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.817	rs11707606	ENSG00000229759.1	MRPS18AP1	14.01	1.24e-37	9.82e-34	0.56	0.54	Coronary artery disease;	chr3:48195597	chr3:48256350~48256938:-
LUAD	cis	rs2658782	1	rs2605583	ENSG00000279684.1	RP11-755E23.2	-14	1.29e-37	1.02e-33	-0.87	-0.54	Pulmonary function decline;	chr11:93431791	chr11:93286629~93288903:-
LUAD	cis	rs9326248	0.52	rs6589602	ENSG00000254851.1	RP11-109L13.1	-14	1.3e-37	1.03e-33	-0.69	-0.54	Blood protein levels;	chr11:117166349	chr11:117135528~117138582:+
LUAD	cis	rs1799949	1	rs2298862	ENSG00000198496.9	NBR2	-14	1.38e-37	1.09e-33	-0.58	-0.54	Menopause (age at onset);	chr17:43024671	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.93	rs2298861	ENSG00000198496.9	NBR2	-14	1.38e-37	1.09e-33	-0.58	-0.54	Menopause (age at onset);	chr17:43024814	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.965	rs1842147	ENSG00000198496.9	NBR2	-14	1.41e-37	1.1e-33	-0.58	-0.54	Menopause (age at onset);	chr17:43357824	chr17:43125610~43153671:+
LUAD	cis	rs9326248	0.539	rs7120565	ENSG00000254851.1	RP11-109L13.1	-13.99	1.46e-37	1.14e-33	-0.69	-0.54	Blood protein levels;	chr11:117172233	chr11:117135528~117138582:+
LUAD	cis	rs2739330	0.929	rs5751777	ENSG00000250470.1	AP000351.3	13.99	1.46e-37	1.14e-33	0.66	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23976904~23977585:-
LUAD	cis	rs2739330	0.796	rs1006771	ENSG00000225282.1	AP000350.6	13.99	1.47e-37	1.15e-33	0.65	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23926900~23929574:+
LUAD	cis	rs1799949	1	rs9646417	ENSG00000198496.9	NBR2	-13.99	1.48e-37	1.15e-33	-0.58	-0.54	Menopause (age at onset);	chr17:43346885	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs1545764	ENSG00000198496.9	NBR2	-13.99	1.48e-37	1.15e-33	-0.58	-0.54	Menopause (age at onset);	chr17:43347197	chr17:43125610~43153671:+
LUAD	cis	rs12439619	0.705	rs4778665	ENSG00000278603.1	RP13-608F4.5	13.99	1.51e-37	1.18e-33	0.78	0.54	Intelligence (multi-trait analysis);	chr15:82144163	chr15:82472203~82472426:+
LUAD	cis	rs8040855	0.644	rs7495437	ENSG00000259295.5	CSPG4P12	-13.98	1.58e-37	1.23e-33	-0.65	-0.54	Bulimia nervosa;	chr15:85183059	chr15:85191438~85213905:+
LUAD	cis	rs875971	0.66	rs7807930	ENSG00000226824.5	RP4-756H11.3	13.98	1.6e-37	1.25e-33	0.68	0.54	Aortic root size;	chr7:66622178	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.66	rs7807944	ENSG00000226824.5	RP4-756H11.3	13.98	1.6e-37	1.25e-33	0.68	0.54	Aortic root size;	chr7:66622208	chr7:66654538~66669855:+
LUAD	cis	rs7617773	0.78	rs3731550	ENSG00000229759.1	MRPS18AP1	13.98	1.67e-37	1.3e-33	0.57	0.54	Coronary artery disease;	chr3:48165093	chr3:48256350~48256938:-
LUAD	cis	rs992157	0.835	rs10932769	ENSG00000261338.2	RP11-378A13.1	-13.98	1.69e-37	1.32e-33	-0.54	-0.54	Colorectal cancer;	chr2:218282522	chr2:218255319~218257366:+
LUAD	cis	rs2658782	1	rs2658782	ENSG00000279684.1	RP11-755E23.2	-13.98	1.71e-37	1.33e-33	-0.86	-0.54	Pulmonary function decline;	chr11:93433565	chr11:93286629~93288903:-
LUAD	cis	rs992157	0.775	rs7559428	ENSG00000261338.2	RP11-378A13.1	-13.97	1.78e-37	1.39e-33	-0.54	-0.54	Colorectal cancer;	chr2:218285515	chr2:218255319~218257366:+
LUAD	cis	rs1799949	0.683	rs55737636	ENSG00000198496.9	NBR2	-13.97	1.82e-37	1.41e-33	-0.56	-0.54	Menopause (age at onset);	chr17:43112722	chr17:43125610~43153671:+
LUAD	cis	rs8040855	0.542	rs2342122	ENSG00000259295.5	CSPG4P12	-13.97	1.83e-37	1.42e-33	-0.64	-0.54	Bulimia nervosa;	chr15:85185304	chr15:85191438~85213905:+
LUAD	cis	rs8040855	0.644	rs2342120	ENSG00000259295.5	CSPG4P12	-13.97	1.83e-37	1.42e-33	-0.64	-0.54	Bulimia nervosa;	chr15:85185589	chr15:85191438~85213905:+
LUAD	cis	rs992157	0.835	rs2045434	ENSG00000261338.2	RP11-378A13.1	-13.97	1.87e-37	1.46e-33	-0.54	-0.54	Colorectal cancer;	chr2:218279775	chr2:218255319~218257366:+
LUAD	cis	rs2658782	1	rs2019814	ENSG00000279684.1	RP11-755E23.2	-13.96	1.99e-37	1.54e-33	-0.87	-0.54	Pulmonary function decline;	chr11:93435719	chr11:93286629~93288903:-
LUAD	cis	rs992157	0.835	rs6729058	ENSG00000261338.2	RP11-378A13.1	-13.96	2.03e-37	1.57e-33	-0.54	-0.54	Colorectal cancer;	chr2:218283646	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.717	rs11692780	ENSG00000261338.2	RP11-378A13.1	-13.96	2.03e-37	1.57e-33	-0.54	-0.54	Colorectal cancer;	chr2:218284440	chr2:218255319~218257366:+
LUAD	cis	rs3814244	0.933	rs10748093	ENSG00000255733.4	IFNG-AS1	-13.96	2.05e-37	1.58e-33	-0.45	-0.54	Itch intensity from mosquito bite adjusted by bite size;	chr12:68024469	chr12:67989445~68234686:+
LUAD	cis	rs6538678	0.824	rs7299632	ENSG00000199506.1	RNU6-247P	-13.96	2.07e-37	1.6e-33	-0.8	-0.54	Lupus nephritis in systemic lupus erythematosus;	chr12:95838376	chr12:95792529~95792635:-
LUAD	cis	rs10935480	0.935	rs4857414	ENSG00000239445.4	ST3GAL6-AS1	-13.95	2.24e-37	1.73e-33	-0.66	-0.54	Blood protein levels;	chr3:98713715	chr3:98714330~98732651:-
LUAD	cis	rs2658782	1	rs2608216	ENSG00000279684.1	RP11-755E23.2	-13.94	2.33e-37	1.8e-33	-0.86	-0.54	Pulmonary function decline;	chr11:93416006	chr11:93286629~93288903:-
LUAD	cis	rs2658782	0.95	rs2446061	ENSG00000279684.1	RP11-755E23.2	-13.94	2.33e-37	1.8e-33	-0.86	-0.54	Pulmonary function decline;	chr11:93416111	chr11:93286629~93288903:-
LUAD	cis	rs875971	0.505	rs1723275	ENSG00000226824.5	RP4-756H11.3	13.94	2.39e-37	1.84e-33	0.68	0.54	Aortic root size;	chr7:66039646	chr7:66654538~66669855:+
LUAD	cis	rs801193	1	rs10252765	ENSG00000226824.5	RP4-756H11.3	-13.94	2.46e-37	1.89e-33	-0.68	-0.54	Aortic root size;	chr7:66763745	chr7:66654538~66669855:+
LUAD	cis	rs2882667	0.858	rs11948429	ENSG00000253404.1	AC034243.1	13.94	2.46e-37	1.89e-33	0.72	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139122895	chr5:138744434~138753309:-
LUAD	cis	rs1799949	0.931	rs34474989	ENSG00000198496.9	NBR2	-13.93	2.59e-37	1.99e-33	-0.56	-0.54	Menopause (age at onset);	chr17:43368042	chr17:43125610~43153671:+
LUAD	cis	rs73086581	0.787	rs73084505	ENSG00000229539.1	RP11-119B16.2	13.93	2.61e-37	2e-33	0.79	0.54	Response to antidepressants in depression;	chr20:3876227	chr20:3888239~3888868:-
LUAD	cis	rs4423214	1	rs12797951	ENSG00000254682.1	RP11-660L16.2	-13.93	2.69e-37	2.06e-33	-0.68	-0.54	Vitamin D levels;	chr11:71432220	chr11:71448674~71452157:+
LUAD	cis	rs875971	0.66	rs6460308	ENSG00000226824.5	RP4-756H11.3	13.93	2.79e-37	2.13e-33	0.68	0.54	Aortic root size;	chr7:66619753	chr7:66654538~66669855:+
LUAD	cis	rs2739330	0.892	rs5751776	ENSG00000250470.1	AP000351.3	13.93	2.79e-37	2.13e-33	0.66	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23976904~23977585:-
LUAD	cis	rs7301826	0.651	rs12820597	ENSG00000256299.1	RP11-989F5.3	13.93	2.79e-37	2.13e-33	0.62	0.54	Plasma plasminogen activator levels;	chr12:130795640	chr12:130810821~130812622:-
LUAD	cis	rs73086581	0.687	rs16989002	ENSG00000229539.1	RP11-119B16.2	13.93	2.82e-37	2.16e-33	0.78	0.54	Response to antidepressants in depression;	chr20:3870056	chr20:3888239~3888868:-
LUAD	cis	rs916888	0.779	rs199526	ENSG00000214401.4	KANSL1-AS1	-13.92	2.86e-37	2.18e-33	-0.76	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:46193576~46196723:+
LUAD	cis	rs1799949	0.773	rs2137990	ENSG00000198496.9	NBR2	13.92	2.97e-37	2.26e-33	0.56	0.54	Menopause (age at onset);	chr17:43165879	chr17:43125610~43153671:+
LUAD	cis	rs10129255	0.5	rs4774008	ENSG00000223648.3	IGHV3-64	13.92	2.99e-37	2.28e-33	0.49	0.54	Kawasaki disease;	chr14:106681273	chr14:106643132~106658258:-
LUAD	cis	rs2739330	0.76	rs5751760	ENSG00000225282.1	AP000350.6	13.92	3.07e-37	2.33e-33	0.61	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23926900~23929574:+
LUAD	cis	rs7617773	0.817	rs3731534	ENSG00000229759.1	MRPS18AP1	13.92	3.1e-37	2.36e-33	0.56	0.54	Coronary artery disease;	chr3:48170287	chr3:48256350~48256938:-
LUAD	cis	rs73086581	0.741	rs17212649	ENSG00000229539.1	RP11-119B16.2	13.91	3.14e-37	2.38e-33	0.79	0.54	Response to antidepressants in depression;	chr20:3872446	chr20:3888239~3888868:-
LUAD	cis	rs916888	0.61	rs199444	ENSG00000214401.4	KANSL1-AS1	13.91	3.14e-37	2.38e-33	0.74	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46193576~46196723:+
LUAD	cis	rs916888	0.61	rs199442	ENSG00000214401.4	KANSL1-AS1	13.91	3.14e-37	2.38e-33	0.74	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46193576~46196723:+
LUAD	cis	rs2882667	0.929	rs34846849	ENSG00000253404.1	AC034243.1	13.91	3.23e-37	2.45e-33	0.71	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139024889	chr5:138744434~138753309:-
LUAD	cis	rs875971	0.66	rs801192	ENSG00000226824.5	RP4-756H11.3	13.91	3.27e-37	2.47e-33	0.67	0.54	Aortic root size;	chr7:66566965	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.66	rs801190	ENSG00000226824.5	RP4-756H11.3	13.91	3.27e-37	2.47e-33	0.67	0.54	Aortic root size;	chr7:66568046	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.66	rs3857686	ENSG00000226824.5	RP4-756H11.3	13.91	3.27e-37	2.47e-33	0.67	0.54	Aortic root size;	chr7:66571204	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.638	rs3898855	ENSG00000226824.5	RP4-756H11.3	13.91	3.27e-37	2.47e-33	0.67	0.54	Aortic root size;	chr7:66571411	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.638	rs10278816	ENSG00000226824.5	RP4-756H11.3	13.91	3.27e-37	2.47e-33	0.67	0.54	Aortic root size;	chr7:66572000	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.66	rs10281080	ENSG00000226824.5	RP4-756H11.3	13.91	3.27e-37	2.47e-33	0.67	0.54	Aortic root size;	chr7:66577454	chr7:66654538~66669855:+
LUAD	cis	rs10935480	1	rs10935480	ENSG00000239445.4	ST3GAL6-AS1	-13.91	3.33e-37	2.52e-33	-0.66	-0.54	Blood protein levels;	chr3:98713142	chr3:98714330~98732651:-
LUAD	cis	rs7617773	0.817	rs3731555	ENSG00000229759.1	MRPS18AP1	13.91	3.43e-37	2.59e-33	0.56	0.54	Coronary artery disease;	chr3:48164612	chr3:48256350~48256938:-
LUAD	cis	rs992157	0.866	rs2292554	ENSG00000261338.2	RP11-378A13.1	-13.91	3.44e-37	2.6e-33	-0.54	-0.54	Colorectal cancer;	chr2:218282145	chr2:218255319~218257366:+
LUAD	cis	rs2882667	0.858	rs2043271	ENSG00000253404.1	AC034243.1	13.9	3.5e-37	2.65e-33	0.72	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139123419	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.796	rs2154594	ENSG00000225282.1	AP000350.6	-13.9	3.54e-37	2.67e-33	-0.64	-0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23926900~23929574:+
LUAD	cis	rs916888	0.647	rs199449	ENSG00000214401.4	KANSL1-AS1	13.9	3.69e-37	2.78e-33	0.74	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46193576~46196723:+
LUAD	cis	rs7301826	0.651	rs34749116	ENSG00000256299.1	RP11-989F5.3	13.9	3.72e-37	2.8e-33	0.61	0.54	Plasma plasminogen activator levels;	chr12:130796207	chr12:130810821~130812622:-
LUAD	cis	rs2882667	0.858	rs13177503	ENSG00000253404.1	AC034243.1	13.89	3.83e-37	2.88e-33	0.72	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139097070	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.858	rs13170388	ENSG00000253404.1	AC034243.1	13.89	3.83e-37	2.88e-33	0.72	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139101176	chr5:138744434~138753309:-
LUAD	cis	rs9326248	0.53	rs11216316	ENSG00000254851.1	RP11-109L13.1	13.89	3.86e-37	2.9e-33	0.99	0.54	Blood protein levels;	chr11:117210784	chr11:117135528~117138582:+
LUAD	cis	rs3091242	0.9	rs1811832	ENSG00000261349.1	RP3-465N24.5	-13.89	3.86e-37	2.9e-33	-0.59	-0.54	Erythrocyte sedimentation rate;	chr1:25427074	chr1:25266102~25267136:-
LUAD	cis	rs1799949	0.931	rs9912203	ENSG00000198496.9	NBR2	13.89	4.02e-37	3.02e-33	0.56	0.54	Menopause (age at onset);	chr17:43367777	chr17:43125610~43153671:+
LUAD	cis	rs2739330	0.76	rs1002286	ENSG00000225282.1	AP000350.6	-13.89	4.09e-37	3.07e-33	-0.62	-0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23926900~23929574:+
LUAD	cis	rs7617773	0.817	rs936427	ENSG00000229759.1	MRPS18AP1	-13.89	4.15e-37	3.11e-33	-0.56	-0.53	Coronary artery disease;	chr3:48259584	chr3:48256350~48256938:-
LUAD	cis	rs1799949	0.929	rs799906	ENSG00000198496.9	NBR2	-13.89	4.19e-37	3.14e-33	-0.56	-0.53	Menopause (age at onset);	chr17:43126099	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.965	rs799908	ENSG00000198496.9	NBR2	-13.89	4.19e-37	3.14e-33	-0.56	-0.53	Menopause (age at onset);	chr17:43126899	chr17:43125610~43153671:+
LUAD	cis	rs4853012	0.838	rs59570457	ENSG00000217702.2	RP11-287D1.4	13.89	4.21e-37	3.16e-33	0.8	0.53	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74130583~74135395:+
LUAD	cis	rs2658782	1	rs2658781	ENSG00000279684.1	RP11-755E23.2	13.89	4.22e-37	3.16e-33	0.83	0.53	Pulmonary function decline;	chr11:93433202	chr11:93286629~93288903:-
LUAD	cis	rs6952407	1	rs6952407	ENSG00000226824.5	RP4-756H11.3	13.88	4.23e-37	3.17e-33	0.67	0.53	Cotinine glucuronidation;	chr7:66580525	chr7:66654538~66669855:+
LUAD	cis	rs4853012	0.793	rs6707619	ENSG00000217702.2	RP11-287D1.4	13.88	4.29e-37	3.21e-33	0.8	0.53	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74130583~74135395:+
LUAD	cis	rs507080	0.733	rs4393358	ENSG00000255422.1	AP002954.4	-13.88	4.33e-37	3.24e-33	-0.66	-0.53	Serum metabolite levels;	chr11:118698388	chr11:118704607~118750263:+
LUAD	cis	rs875971	0.619	rs10278371	ENSG00000226824.5	RP4-756H11.3	13.88	4.4e-37	3.28e-33	0.67	0.53	Aortic root size;	chr7:66586553	chr7:66654538~66669855:+
LUAD	cis	rs1799949	1	rs915945	ENSG00000198496.9	NBR2	-13.88	4.49e-37	3.35e-33	-0.58	-0.53	Menopause (age at onset);	chr17:43027847	chr17:43125610~43153671:+
LUAD	cis	rs1799949	1	rs12942277	ENSG00000198496.9	NBR2	-13.88	4.49e-37	3.35e-33	-0.58	-0.53	Menopause (age at onset);	chr17:43035957	chr17:43125610~43153671:+
LUAD	cis	rs1799949	0.965	rs34616041	ENSG00000198496.9	NBR2	-13.88	4.49e-37	3.35e-33	-0.58	-0.53	Menopause (age at onset);	chr17:43036769	chr17:43125610~43153671:+
LUAD	cis	rs2882667	0.898	rs6863347	ENSG00000253404.1	AC034243.1	13.88	4.55e-37	3.39e-33	0.67	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025446	chr5:138744434~138753309:-
LUAD	cis	rs10129255	0.5	rs9324092	ENSG00000223648.3	IGHV3-64	-13.88	4.56e-37	3.4e-33	-0.48	-0.53	Kawasaki disease;	chr14:106683806	chr14:106643132~106658258:-
LUAD	cis	rs875971	0.66	rs10215132	ENSG00000226824.5	RP4-756H11.3	13.88	4.57e-37	3.41e-33	0.67	0.53	Aortic root size;	chr7:66589419	chr7:66654538~66669855:+
LUAD	cis	rs1799949	1	rs12944597	ENSG00000198496.9	NBR2	-13.88	4.65e-37	3.47e-33	-0.58	-0.53	Menopause (age at onset);	chr17:43035667	chr17:43125610~43153671:+
LUAD	cis	rs10129255	0.5	rs1974468	ENSG00000223648.3	IGHV3-64	13.87	4.68e-37	3.48e-33	0.48	0.53	Kawasaki disease;	chr14:106686149	chr14:106643132~106658258:-
LUAD	cis	rs875971	0.66	rs10950044	ENSG00000226824.5	RP4-756H11.3	13.87	4.77e-37	3.55e-33	0.67	0.53	Aortic root size;	chr7:66577989	chr7:66654538~66669855:+
LUAD	cis	rs4423214	1	rs909217	ENSG00000254682.1	RP11-660L16.2	13.87	4.79e-37	3.56e-33	0.68	0.53	Vitamin D levels;	chr11:71435531	chr11:71448674~71452157:+
LUAD	cis	rs2882667	0.858	rs66839813	ENSG00000253404.1	AC034243.1	13.87	4.88e-37	3.62e-33	0.71	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106633	chr5:138744434~138753309:-
LUAD	cis	rs7301826	0.627	rs7978987	ENSG00000256299.1	RP11-989F5.3	13.87	4.95e-37	3.68e-33	0.61	0.53	Plasma plasminogen activator levels;	chr12:130796949	chr12:130810821~130812622:-
LUAD	cis	rs858239	1	rs166663	ENSG00000230658.1	KLHL7-AS1	13.87	5.11e-37	3.79e-33	0.66	0.53	Cerebrospinal fluid biomarker levels;	chr7:23277123	chr7:23101228~23105703:-
LUAD	cis	rs992157	0.835	rs12987219	ENSG00000261338.2	RP11-378A13.1	-13.86	5.17e-37	3.83e-33	-0.54	-0.53	Colorectal cancer;	chr2:218279426	chr2:218255319~218257366:+
LUAD	cis	rs875971	0.66	rs28698552	ENSG00000226824.5	RP4-756H11.3	-13.86	5.4e-37	4e-33	-0.67	-0.53	Aortic root size;	chr7:66540031	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.66	rs62465434	ENSG00000226824.5	RP4-756H11.3	-13.86	5.4e-37	4e-33	-0.67	-0.53	Aortic root size;	chr7:66540165	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.66	rs13224319	ENSG00000226824.5	RP4-756H11.3	-13.86	5.4e-37	4e-33	-0.67	-0.53	Aortic root size;	chr7:66542376	chr7:66654538~66669855:+
LUAD	cis	rs2739330	0.703	rs5760112	ENSG00000225282.1	AP000350.6	13.86	5.48e-37	4.06e-33	0.62	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23926900~23929574:+
LUAD	cis	rs9326248	0.53	rs236918	ENSG00000254851.1	RP11-109L13.1	13.86	5.5e-37	4.07e-33	0.99	0.53	Blood protein levels;	chr11:117220893	chr11:117135528~117138582:+
LUAD	cis	rs4853012	0.838	rs6707729	ENSG00000217702.2	RP11-287D1.4	13.86	5.6e-37	4.14e-33	0.8	0.53	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74130583~74135395:+
LUAD	cis	rs2882667	0.858	rs13174479	ENSG00000253404.1	AC034243.1	13.85	5.92e-37	4.36e-33	0.72	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139108481	chr5:138744434~138753309:-
LUAD	cis	rs2882667	0.858	rs11741150	ENSG00000253404.1	AC034243.1	13.83	7.06e-37	5.18e-33	0.72	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095768	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.731	rs2000468	ENSG00000225282.1	AP000350.6	13.82	7.71e-37	5.64e-33	0.6	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23926900~23929574:+
LUAD	cis	rs875971	0.638	rs6460305	ENSG00000226824.5	RP4-756H11.3	13.82	7.71e-37	5.64e-33	0.67	0.53	Aortic root size;	chr7:66595421	chr7:66654538~66669855:+
LUAD	cis	rs3814244	0.933	rs10878725	ENSG00000255733.4	IFNG-AS1	-13.82	8e-37	5.84e-33	-0.45	-0.53	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020930	chr12:67989445~68234686:+
LUAD	cis	rs875971	0.522	rs1968127	ENSG00000226824.5	RP4-756H11.3	13.82	8.07e-37	5.89e-33	0.67	0.53	Aortic root size;	chr7:66591816	chr7:66654538~66669855:+
LUAD	cis	rs2739330	0.703	rs5760112	ENSG00000231271.1	AP000350.8	13.82	8.07e-37	5.89e-33	0.64	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23949918~23954042:+
LUAD	cis	rs992157	0.835	rs4674282	ENSG00000261338.2	RP11-378A13.1	-13.82	8.11e-37	5.92e-33	-0.53	-0.53	Colorectal cancer;	chr2:218279507	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.835	rs7559416	ENSG00000261338.2	RP11-378A13.1	-13.82	8.29e-37	6.04e-33	-0.53	-0.53	Colorectal cancer;	chr2:218285488	chr2:218255319~218257366:+
LUAD	cis	rs801193	0.967	rs2420827	ENSG00000226824.5	RP4-756H11.3	13.82	8.33e-37	6.07e-33	0.68	0.53	Aortic root size;	chr7:66682114	chr7:66654538~66669855:+
LUAD	cis	rs9326248	0.501	rs4938351	ENSG00000254851.1	RP11-109L13.1	-13.82	8.47e-37	6.17e-33	-0.69	-0.53	Blood protein levels;	chr11:117151636	chr11:117135528~117138582:+
LUAD	cis	rs4853012	0.838	rs60705299	ENSG00000217702.2	RP11-287D1.4	13.81	8.55e-37	6.22e-33	0.8	0.53	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74130583~74135395:+
LUAD	cis	rs7115242	0.8	rs6589597	ENSG00000254851.1	RP11-109L13.1	13.81	8.55e-37	6.23e-33	0.9	0.53	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117127082	chr11:117135528~117138582:+
LUAD	cis	rs1799949	1	rs35070007	ENSG00000198496.9	NBR2	13.81	8.6e-37	6.26e-33	0.55	0.53	Menopause (age at onset);	chr17:43164730	chr17:43125610~43153671:+
LUAD	cis	rs2739330	0.76	rs1002286	ENSG00000231271.1	AP000350.8	-13.81	8.9e-37	6.47e-33	-0.63	-0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23949918~23954042:+
LUAD	cis	rs4853012	0.838	rs4452177	ENSG00000217702.2	RP11-287D1.4	13.81	8.95e-37	6.51e-33	0.8	0.53	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74130583~74135395:+
LUAD	cis	rs801193	1	rs2055682	ENSG00000226824.5	RP4-756H11.3	-13.81	8.96e-37	6.51e-33	-0.68	-0.53	Aortic root size;	chr7:66795302	chr7:66654538~66669855:+
LUAD	cis	rs6538678	0.746	rs4762630	ENSG00000199506.1	RNU6-247P	-13.81	8.96e-37	6.51e-33	-0.78	-0.53	Lupus nephritis in systemic lupus erythematosus;	chr12:95850631	chr12:95792529~95792635:-
LUAD	cis	rs1799949	0.894	rs36062488	ENSG00000198496.9	NBR2	13.81	9.26e-37	6.72e-33	0.55	0.53	Menopause (age at onset);	chr17:43185455	chr17:43125610~43153671:+
LUAD	cis	rs8040855	0.621	rs6496796	ENSG00000259295.5	CSPG4P12	-13.8	9.37e-37	6.8e-33	-0.64	-0.53	Bulimia nervosa;	chr15:85183617	chr15:85191438~85213905:+
LUAD	cis	rs1799949	0.93	rs1554063	ENSG00000198496.9	NBR2	-13.8	9.78e-37	7.08e-33	-0.56	-0.53	Menopause (age at onset);	chr17:43135128	chr17:43125610~43153671:+
LUAD	cis	rs6538678	0.824	rs4762633	ENSG00000258343.1	RP11-536G4.2	-13.8	9.98e-37	7.22e-33	-0.82	-0.53	Lupus nephritis in systemic lupus erythematosus;	chr12:95860295	chr12:95795345~95858839:-
LUAD	cis	rs2658782	1	rs2605585	ENSG00000279684.1	RP11-755E23.2	-13.8	1.02e-36	7.36e-33	-0.87	-0.53	Pulmonary function decline;	chr11:93438696	chr11:93286629~93288903:-
LUAD	cis	rs2658782	0.951	rs2608215	ENSG00000279684.1	RP11-755E23.2	-13.8	1.02e-36	7.4e-33	-0.85	-0.53	Pulmonary function decline;	chr11:93415651	chr11:93286629~93288903:-
LUAD	cis	rs200367988	1	rs200367988	ENSG00000271670.1	RP11-95I16.4	-13.78	1.16e-36	8.37e-33	-0.6	-0.53	Prostate-specific antigen levels (conditioned on lead SNPs);Prostate-specific antigen levels;	chr10:120915337	chr10:120879256~120880667:-
LUAD	cis	rs2739330	0.685	rs4822453	ENSG00000225282.1	AP000350.6	13.78	1.16e-36	8.38e-33	0.61	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23926900~23929574:+
LUAD	cis	rs2882667	0.858	rs11242447	ENSG00000253404.1	AC034243.1	13.78	1.19e-36	8.57e-33	0.71	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139090484	chr5:138744434~138753309:-
LUAD	cis	rs507080	0.733	rs4486664	ENSG00000255422.1	AP002954.4	-13.77	1.29e-36	9.22e-33	-0.67	-0.53	Serum metabolite levels;	chr11:118698358	chr11:118704607~118750263:+
LUAD	cis	rs875971	0.638	rs10249404	ENSG00000226824.5	RP4-756H11.3	13.76	1.43e-36	1.02e-32	0.67	0.53	Aortic root size;	chr7:66581737	chr7:66654538~66669855:+
LUAD	cis	rs992157	0.835	rs13005100	ENSG00000261338.2	RP11-378A13.1	-13.76	1.44e-36	1.03e-32	-0.54	-0.53	Colorectal cancer;	chr2:218287044	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.835	rs13031757	ENSG00000261338.2	RP11-378A13.1	-13.76	1.44e-36	1.03e-32	-0.54	-0.53	Colorectal cancer;	chr2:218287203	chr2:218255319~218257366:+
LUAD	cis	rs2882667	0.858	rs10900856	ENSG00000253404.1	AC034243.1	-13.76	1.46e-36	1.04e-32	-0.69	-0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139082057	chr5:138744434~138753309:-
LUAD	cis	rs1799949	0.794	rs116409325	ENSG00000198496.9	NBR2	-13.76	1.51e-36	1.08e-32	-0.57	-0.53	Menopause (age at onset);	chr17:43368092	chr17:43125610~43153671:+
LUAD	cis	rs992157	0.835	rs34353396	ENSG00000261338.2	RP11-378A13.1	-13.75	1.65e-36	1.18e-32	-0.53	-0.53	Colorectal cancer;	chr2:218289259	chr2:218255319~218257366:+
LUAD	cis	rs5760092	0.755	rs4585126	ENSG00000273295.1	AP000350.5	-13.75	1.66e-36	1.18e-32	-0.69	-0.53	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23901432~23907068:-
LUAD	cis	rs6538678	0.895	rs7137751	ENSG00000258343.1	RP11-536G4.2	-13.75	1.68e-36	1.2e-32	-0.77	-0.53	Lupus nephritis in systemic lupus erythematosus;	chr12:95861806	chr12:95795345~95858839:-
LUAD	cis	rs858239	0.932	rs199355	ENSG00000230658.1	KLHL7-AS1	13.74	1.76e-36	1.25e-32	0.63	0.53	Cerebrospinal fluid biomarker levels;	chr7:23256914	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.858	rs11957633	ENSG00000253404.1	AC034243.1	13.74	1.76e-36	1.25e-32	0.7	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028705	chr5:138744434~138753309:-
LUAD	cis	rs992157	0.835	rs10932768	ENSG00000261338.2	RP11-378A13.1	-13.74	1.85e-36	1.32e-32	-0.53	-0.53	Colorectal cancer;	chr2:218281476	chr2:218255319~218257366:+
LUAD	cis	rs7617773	0.817	rs13100815	ENSG00000229759.1	MRPS18AP1	13.73	1.91e-36	1.36e-32	0.56	0.53	Coronary artery disease;	chr3:48245959	chr3:48256350~48256938:-
LUAD	cis	rs992157	1	rs6736362	ENSG00000261338.2	RP11-378A13.1	13.73	1.91e-36	1.36e-32	0.54	0.53	Colorectal cancer;	chr2:218250385	chr2:218255319~218257366:+
LUAD	cis	rs2882667	0.858	rs11750382	ENSG00000253404.1	AC034243.1	-13.73	2.07e-36	1.46e-32	-0.69	-0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121305	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.76	rs1007888	ENSG00000225282.1	AP000350.6	13.72	2.21e-36	1.56e-32	0.61	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23926900~23929574:+
LUAD	cis	rs507080	0.733	rs7108144	ENSG00000255422.1	AP002954.4	-13.72	2.23e-36	1.58e-32	-0.67	-0.53	Serum metabolite levels;	chr11:118698985	chr11:118704607~118750263:+
LUAD	cis	rs1799949	0.894	rs71367985	ENSG00000198496.9	NBR2	-13.72	2.28e-36	1.61e-32	-0.55	-0.53	Menopause (age at onset);	chr17:43222443	chr17:43125610~43153671:+
LUAD	cis	rs992157	0.835	rs2292555	ENSG00000261338.2	RP11-378A13.1	-13.71	2.3e-36	1.62e-32	-0.53	-0.53	Colorectal cancer;	chr2:218282159	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.835	rs2292550	ENSG00000261338.2	RP11-378A13.1	-13.71	2.31e-36	1.63e-32	-0.53	-0.53	Colorectal cancer;	chr2:218275565	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.804	rs6758540	ENSG00000261338.2	RP11-378A13.1	-13.71	2.36e-36	1.66e-32	-0.53	-0.53	Colorectal cancer;	chr2:218273902	chr2:218255319~218257366:+
LUAD	cis	rs875971	0.522	rs709604	ENSG00000226824.5	RP4-756H11.3	13.71	2.39e-36	1.69e-32	0.67	0.53	Aortic root size;	chr7:66032447	chr7:66654538~66669855:+
LUAD	cis	rs6538678	0.824	rs2367583	ENSG00000199506.1	RNU6-247P	-13.7	2.54e-36	1.79e-32	-0.79	-0.53	Lupus nephritis in systemic lupus erythematosus;	chr12:95856582	chr12:95792529~95792635:-
LUAD	cis	rs992157	0.804	rs7559525	ENSG00000261338.2	RP11-378A13.1	-13.7	2.56e-36	1.8e-32	-0.53	-0.53	Colorectal cancer;	chr2:218285584	chr2:218255319~218257366:+
LUAD	cis	rs2882667	0.858	rs13176497	ENSG00000253404.1	AC034243.1	13.7	2.59e-36	1.82e-32	0.72	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139110385	chr5:138744434~138753309:-
LUAD	cis	rs6597981	0.604	rs7945912	ENSG00000279672.1	CMB9-55F22.1	13.7	2.61e-36	1.83e-32	0.57	0.53	Breast cancer;	chr11:750849	chr11:779617~780755:+
LUAD	cis	rs7617773	0.779	rs77957078	ENSG00000229759.1	MRPS18AP1	13.7	2.65e-36	1.86e-32	0.56	0.53	Coronary artery disease;	chr3:48289796	chr3:48256350~48256938:-
LUAD	cis	rs992157	0.835	rs7585702	ENSG00000261338.2	RP11-378A13.1	-13.7	2.66e-36	1.87e-32	-0.53	-0.53	Colorectal cancer;	chr2:218281884	chr2:218255319~218257366:+
LUAD	cis	rs507080	0.663	rs523793	ENSG00000255422.1	AP002954.4	-13.69	2.81e-36	1.96e-32	-0.67	-0.53	Serum metabolite levels;	chr11:118699988	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.736	rs659564	ENSG00000255422.1	AP002954.4	-13.69	2.81e-36	1.96e-32	-0.67	-0.53	Serum metabolite levels;	chr11:118700205	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.736	rs642224	ENSG00000255422.1	AP002954.4	-13.69	2.81e-36	1.96e-32	-0.67	-0.53	Serum metabolite levels;	chr11:118700210	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.733	rs541631	ENSG00000255422.1	AP002954.4	-13.69	2.81e-36	1.96e-32	-0.67	-0.53	Serum metabolite levels;	chr11:118700314	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.736	rs658676	ENSG00000255422.1	AP002954.4	-13.69	2.81e-36	1.96e-32	-0.67	-0.53	Serum metabolite levels;	chr11:118700414	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.733	rs488141	ENSG00000255422.1	AP002954.4	-13.69	2.81e-36	1.96e-32	-0.67	-0.53	Serum metabolite levels;	chr11:118700459	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.733	rs657769	ENSG00000255422.1	AP002954.4	-13.69	2.81e-36	1.96e-32	-0.67	-0.53	Serum metabolite levels;	chr11:118700607	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.733	rs544452	ENSG00000255422.1	AP002954.4	-13.69	2.81e-36	1.96e-32	-0.67	-0.53	Serum metabolite levels;	chr11:118700648	chr11:118704607~118750263:+
LUAD	cis	rs7301826	0.932	rs1007246	ENSG00000256250.1	RP11-989F5.1	-13.69	2.81e-36	1.97e-32	-0.59	-0.53	Plasma plasminogen activator levels;	chr12:130795585	chr12:130810606~130812438:+
LUAD	cis	rs6538678	0.818	rs7976294	ENSG00000258343.1	RP11-536G4.2	-13.69	3.05e-36	2.12e-32	-0.79	-0.53	Lupus nephritis in systemic lupus erythematosus;	chr12:95876868	chr12:95795345~95858839:-
LUAD	cis	rs6538678	0.818	rs1036429	ENSG00000258343.1	RP11-536G4.2	-13.69	3.05e-36	2.12e-32	-0.79	-0.53	Lupus nephritis in systemic lupus erythematosus;	chr12:95877650	chr12:95795345~95858839:-
LUAD	cis	rs2658782	0.789	rs2605574	ENSG00000279684.1	RP11-755E23.2	-13.68	3.34e-36	2.32e-32	-0.79	-0.53	Pulmonary function decline;	chr11:93403278	chr11:93286629~93288903:-
LUAD	cis	rs9326248	0.53	rs10750101	ENSG00000254851.1	RP11-109L13.1	-13.68	3.36e-36	2.34e-32	-0.91	-0.53	Blood protein levels;	chr11:117108973	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.53	rs1242229	ENSG00000254851.1	RP11-109L13.1	-13.67	3.68e-36	2.55e-32	-0.96	-0.53	Blood protein levels;	chr11:117191654	chr11:117135528~117138582:+
LUAD	cis	rs916888	0.779	rs199498	ENSG00000214401.4	KANSL1-AS1	13.66	3.87e-36	2.68e-32	0.8	0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46193576~46196723:+
LUAD	cis	rs875971	0.522	rs1880556	ENSG00000226824.5	RP4-756H11.3	-13.66	4.01e-36	2.77e-32	-0.67	-0.53	Aortic root size;	chr7:65967557	chr7:66654538~66669855:+
LUAD	cis	rs2882667	0.858	rs17207870	ENSG00000253404.1	AC034243.1	13.65	4.14e-36	2.86e-32	0.7	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139052048	chr5:138744434~138753309:-
LUAD	cis	rs7617773	0.817	rs13059037	ENSG00000229759.1	MRPS18AP1	13.65	4.18e-36	2.88e-32	0.56	0.53	Coronary artery disease;	chr3:48246389	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.817	rs35414021	ENSG00000229759.1	MRPS18AP1	13.65	4.18e-36	2.88e-32	0.56	0.53	Coronary artery disease;	chr3:48252034	chr3:48256350~48256938:-
LUAD	cis	rs2658782	0.951	rs72972364	ENSG00000279684.1	RP11-755E23.2	13.64	4.8e-36	3.3e-32	0.88	0.53	Pulmonary function decline;	chr11:93388962	chr11:93286629~93288903:-
LUAD	cis	rs1799949	0.965	rs7223952	ENSG00000198496.9	NBR2	-13.64	5.03e-36	3.45e-32	-0.55	-0.53	Menopause (age at onset);	chr17:43042868	chr17:43125610~43153671:+
LUAD	cis	rs3814244	0.897	rs4141135	ENSG00000255733.4	IFNG-AS1	13.63	5.35e-36	3.67e-32	0.44	0.53	Itch intensity from mosquito bite adjusted by bite size;	chr12:68025050	chr12:67989445~68234686:+
LUAD	cis	rs1799949	0.859	rs11657004	ENSG00000198496.9	NBR2	-13.63	5.43e-36	3.72e-32	-0.55	-0.53	Menopause (age at onset);	chr17:43365383	chr17:43125610~43153671:+
LUAD	cis	rs992157	0.835	rs2292551	ENSG00000261338.2	RP11-378A13.1	-13.62	5.7e-36	3.9e-32	-0.53	-0.53	Colorectal cancer;	chr2:218278506	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.835	rs12987180	ENSG00000261338.2	RP11-378A13.1	-13.62	5.7e-36	3.9e-32	-0.53	-0.53	Colorectal cancer;	chr2:218279366	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.835	rs4674283	ENSG00000261338.2	RP11-378A13.1	-13.62	5.7e-36	3.9e-32	-0.53	-0.53	Colorectal cancer;	chr2:218279531	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.698	rs6746089	ENSG00000261338.2	RP11-378A13.1	13.61	6.22e-36	4.26e-32	0.53	0.53	Colorectal cancer;	chr2:218305654	chr2:218255319~218257366:+
LUAD	cis	rs875971	0.522	rs781144	ENSG00000226824.5	RP4-756H11.3	-13.61	6.23e-36	4.26e-32	-0.67	-0.53	Aortic root size;	chr7:65975357	chr7:66654538~66669855:+
LUAD	cis	rs916888	0.61	rs199438	ENSG00000214401.4	KANSL1-AS1	13.61	6.33e-36	4.32e-32	0.73	0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46193576~46196723:+
LUAD	cis	rs992157	0.717	rs3817266	ENSG00000261338.2	RP11-378A13.1	-13.61	6.38e-36	4.36e-32	-0.53	-0.53	Colorectal cancer;	chr2:218277871	chr2:218255319~218257366:+
LUAD	cis	rs2739330	0.731	rs4822450	ENSG00000225282.1	AP000350.6	13.61	6.53e-36	4.46e-32	0.6	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23926900~23929574:+
LUAD	cis	rs992157	0.767	rs2014615	ENSG00000261338.2	RP11-378A13.1	13.61	6.71e-36	4.58e-32	0.53	0.53	Colorectal cancer;	chr2:218306468	chr2:218255319~218257366:+
LUAD	cis	rs875971	0.558	rs4433015	ENSG00000226824.5	RP4-756H11.3	13.59	7.59e-36	5.18e-32	0.66	0.53	Aortic root size;	chr7:66174736	chr7:66654538~66669855:+
LUAD	cis	rs507080	0.733	rs611733	ENSG00000255422.1	AP002954.4	-13.59	7.62e-36	5.2e-32	-0.66	-0.53	Serum metabolite levels;	chr11:118702051	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.733	rs552079	ENSG00000255422.1	AP002954.4	-13.59	7.62e-36	5.2e-32	-0.66	-0.53	Serum metabolite levels;	chr11:118702313	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.733	rs673547	ENSG00000255422.1	AP002954.4	-13.59	7.62e-36	5.2e-32	-0.66	-0.53	Serum metabolite levels;	chr11:118702630	chr11:118704607~118750263:+
LUAD	cis	rs7104764	0.917	rs3825075	ENSG00000277290.1	RP11-326C3.16	13.59	7.71e-36	5.26e-32	0.5	0.53	Menarche (age at onset);	chr11:217140	chr11:243099~243483:-
LUAD	cis	rs950027	0.549	rs11070452	ENSG00000259520.4	CTD-2651B20.3	13.59	7.93e-36	5.4e-32	0.65	0.53	Response to fenofibrate (adiponectin levels);	chr15:45302638	chr15:45251580~45279251:-
LUAD	cis	rs507080	0.733	rs489126	ENSG00000255422.1	AP002954.4	-13.59	8.01e-36	5.46e-32	-0.66	-0.53	Serum metabolite levels;	chr11:118702038	chr11:118704607~118750263:+
LUAD	cis	rs2486288	0.656	rs8037583	ENSG00000259520.4	CTD-2651B20.3	13.59	8.19e-36	5.57e-32	0.62	0.53	Glomerular filtration rate;	chr15:45254180	chr15:45251580~45279251:-
LUAD	cis	rs801193	1	rs2659915	ENSG00000226824.5	RP4-756H11.3	-13.57	9.23e-36	6.26e-32	-0.67	-0.53	Aortic root size;	chr7:66688114	chr7:66654538~66669855:+
LUAD	cis	rs7617773	0.743	rs13081633	ENSG00000229759.1	MRPS18AP1	13.57	9.46e-36	6.41e-32	0.56	0.53	Coronary artery disease;	chr3:48315791	chr3:48256350~48256938:-
LUAD	cis	rs2882667	0.858	rs11242442	ENSG00000253404.1	AC034243.1	13.57	9.49e-36	6.43e-32	0.7	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044800	chr5:138744434~138753309:-
LUAD	cis	rs7617773	0.78	rs3197223	ENSG00000229759.1	MRPS18AP1	13.57	9.75e-36	6.6e-32	0.56	0.53	Coronary artery disease;	chr3:48294367	chr3:48256350~48256938:-
LUAD	cis	rs9326248	0.53	rs2000614	ENSG00000254851.1	RP11-109L13.1	-13.57	9.88e-36	6.69e-32	-0.89	-0.53	Blood protein levels;	chr11:117045026	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.53	rs2000616	ENSG00000254851.1	RP11-109L13.1	-13.57	9.88e-36	6.69e-32	-0.89	-0.53	Blood protein levels;	chr11:117045813	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.53	rs10750100	ENSG00000254851.1	RP11-109L13.1	-13.57	9.88e-36	6.69e-32	-0.89	-0.53	Blood protein levels;	chr11:117046528	chr11:117135528~117138582:+
LUAD	cis	rs1815787	1	rs1815787	ENSG00000254851.1	RP11-109L13.1	-13.57	9.88e-36	6.69e-32	-0.89	-0.53	Subjective well-being;	chr11:117050681	chr11:117135528~117138582:+
LUAD	cis	rs7617773	0.817	rs13068265	ENSG00000229759.1	MRPS18AP1	13.56	1.01e-35	6.82e-32	0.55	0.53	Coronary artery disease;	chr3:48260124	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.746	rs4371540	ENSG00000229759.1	MRPS18AP1	13.56	1.01e-35	6.83e-32	0.56	0.53	Coronary artery disease;	chr3:48312053	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.817	rs34225441	ENSG00000229759.1	MRPS18AP1	13.56	1.05e-35	7.08e-32	0.56	0.53	Coronary artery disease;	chr3:48267401	chr3:48256350~48256938:-
LUAD	cis	rs10256972	0.552	rs2960830	ENSG00000229043.2	AC091729.9	-13.56	1.08e-35	7.32e-32	-0.57	-0.53	Endometriosis;Longevity;	chr7:1161005	chr7:1160374~1165267:+
LUAD	cis	rs801193	0.844	rs2244022	ENSG00000226824.5	RP4-756H11.3	-13.55	1.16e-35	7.84e-32	-0.66	-0.53	Aortic root size;	chr7:66737443	chr7:66654538~66669855:+
LUAD	cis	rs507080	0.697	rs656287	ENSG00000255422.1	AP002954.4	-13.55	1.17e-35	7.88e-32	-0.66	-0.53	Serum metabolite levels;	chr11:118701081	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.733	rs570949	ENSG00000255422.1	AP002954.4	-13.55	1.17e-35	7.88e-32	-0.66	-0.53	Serum metabolite levels;	chr11:118701202	chr11:118704607~118750263:+
LUAD	cis	rs7301826	1	rs7301826	ENSG00000256250.1	RP11-989F5.1	-13.55	1.17e-35	7.89e-32	-0.58	-0.53	Plasma plasminogen activator levels;	chr12:130806556	chr12:130810606~130812438:+
LUAD	cis	rs2739330	0.734	rs2000467	ENSG00000225282.1	AP000350.6	-13.55	1.18e-35	7.94e-32	-0.64	-0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23926900~23929574:+
LUAD	cis	rs2882667	0.754	rs11746434	ENSG00000253404.1	AC034243.1	13.55	1.18e-35	7.96e-32	0.71	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:139099614	chr5:138744434~138753309:-
LUAD	cis	rs7617773	0.78	rs77044321	ENSG00000229759.1	MRPS18AP1	13.54	1.25e-35	8.38e-32	0.56	0.53	Coronary artery disease;	chr3:48307824	chr3:48256350~48256938:-
LUAD	cis	rs10256972	0.552	rs2960831	ENSG00000229043.2	AC091729.9	-13.54	1.25e-35	8.38e-32	-0.57	-0.53	Endometriosis;Longevity;	chr7:1161556	chr7:1160374~1165267:+
LUAD	cis	rs2658782	0.951	rs72972357	ENSG00000279684.1	RP11-755E23.2	13.54	1.33e-35	8.91e-32	0.85	0.53	Pulmonary function decline;	chr11:93385674	chr11:93286629~93288903:-
LUAD	cis	rs2658782	1	rs2605582	ENSG00000279684.1	RP11-755E23.2	-13.54	1.33e-35	8.96e-32	-0.84	-0.53	Pulmonary function decline;	chr11:93430633	chr11:93286629~93288903:-
LUAD	cis	rs507080	0.733	rs517445	ENSG00000255422.1	AP002954.4	-13.53	1.37e-35	9.18e-32	-0.66	-0.53	Serum metabolite levels;	chr11:118702826	chr11:118704607~118750263:+
LUAD	cis	rs9326248	0.52	rs2735183	ENSG00000254851.1	RP11-109L13.1	-13.53	1.46e-35	9.78e-32	-0.68	-0.52	Blood protein levels;	chr11:117144479	chr11:117135528~117138582:+
LUAD	cis	rs4423214	1	rs2852853	ENSG00000254682.1	RP11-660L16.2	13.53	1.46e-35	9.78e-32	0.66	0.52	Vitamin D levels;	chr11:71439171	chr11:71448674~71452157:+
LUAD	cis	rs7301826	0.58	rs12821464	ENSG00000256299.1	RP11-989F5.3	13.52	1.51e-35	1.01e-31	0.61	0.52	Plasma plasminogen activator levels;	chr12:130838174	chr12:130810821~130812622:-
LUAD	cis	rs2739330	0.731	rs2000468	ENSG00000250470.1	AP000351.3	13.52	1.62e-35	1.09e-31	0.62	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23976904~23977585:-
LUAD	cis	rs6452524	0.534	rs7727691	ENSG00000249664.1	CTD-2227C6.2	13.52	1.64e-35	1.09e-31	0.61	0.52	Hypertension (SNP x SNP interaction);	chr5:83075876	chr5:83012285~83013109:-
LUAD	cis	rs2658782	0.756	rs2658777	ENSG00000279684.1	RP11-755E23.2	-13.51	1.69e-35	1.13e-31	-0.82	-0.52	Pulmonary function decline;	chr11:93415257	chr11:93286629~93288903:-
LUAD	cis	rs4853012	0.838	rs72911122	ENSG00000217702.2	RP11-287D1.4	13.51	1.75e-35	1.17e-31	0.78	0.52	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74130583~74135395:+
LUAD	cis	rs10129255	0.536	rs3944157	ENSG00000223648.3	IGHV3-64	13.51	1.79e-35	1.2e-31	0.47	0.52	Kawasaki disease;	chr14:106682286	chr14:106643132~106658258:-
LUAD	cis	rs916888	0.531	rs183211	ENSG00000214401.4	KANSL1-AS1	13.5	1.89e-35	1.26e-31	0.72	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46193576~46196723:+
LUAD	cis	rs2739330	0.76	rs5751761	ENSG00000250470.1	AP000351.3	-13.5	1.93e-35	1.29e-31	-0.61	-0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23976904~23977585:-
LUAD	cis	rs2658782	0.951	rs117384439	ENSG00000279684.1	RP11-755E23.2	13.5	1.94e-35	1.3e-31	0.84	0.52	Pulmonary function decline;	chr11:93378312	chr11:93286629~93288903:-
LUAD	cis	rs7301826	1	rs10773822	ENSG00000256250.1	RP11-989F5.1	-13.5	1.95e-35	1.3e-31	-0.58	-0.52	Plasma plasminogen activator levels;	chr12:130804562	chr12:130810606~130812438:+
LUAD	cis	rs7617773	0.78	rs11718350	ENSG00000229759.1	MRPS18AP1	13.5	1.98e-35	1.32e-31	0.56	0.52	Coronary artery disease;	chr3:48319502	chr3:48256350~48256938:-
LUAD	cis	rs6538678	0.746	rs1865736	ENSG00000199506.1	RNU6-247P	-13.49	2.02e-35	1.34e-31	-0.79	-0.52	Lupus nephritis in systemic lupus erythematosus;	chr12:95854051	chr12:95792529~95792635:-
LUAD	cis	rs7617773	0.643	rs78159520	ENSG00000229759.1	MRPS18AP1	13.49	2.12e-35	1.41e-31	0.56	0.52	Coronary artery disease;	chr3:48307533	chr3:48256350~48256938:-
LUAD	cis	rs875971	0.522	rs1617484	ENSG00000226824.5	RP4-756H11.3	-13.49	2.18e-35	1.45e-31	-0.66	-0.52	Aortic root size;	chr7:65998108	chr7:66654538~66669855:+
LUAD	cis	rs1799949	0.536	rs4793227	ENSG00000198496.9	NBR2	-13.49	2.19e-35	1.45e-31	-0.54	-0.52	Menopause (age at onset);	chr17:43334882	chr17:43125610~43153671:+
LUAD	cis	rs992157	0.835	rs2271543	ENSG00000261338.2	RP11-378A13.1	-13.49	2.2e-35	1.46e-31	-0.53	-0.52	Colorectal cancer;	chr2:218277768	chr2:218255319~218257366:+
LUAD	cis	rs2658782	0.789	rs2658776	ENSG00000279684.1	RP11-755E23.2	-13.49	2.21e-35	1.47e-31	-0.82	-0.52	Pulmonary function decline;	chr11:93414761	chr11:93286629~93288903:-
LUAD	cis	rs7617773	0.817	rs11709691	ENSG00000229759.1	MRPS18AP1	13.48	2.28e-35	1.51e-31	0.55	0.52	Coronary artery disease;	chr3:48262179	chr3:48256350~48256938:-
LUAD	cis	rs6452524	0.534	rs11746747	ENSG00000249664.1	CTD-2227C6.2	13.48	2.29e-35	1.52e-31	0.61	0.52	Hypertension (SNP x SNP interaction);	chr5:83067666	chr5:83012285~83013109:-
LUAD	cis	rs4423214	1	rs12422045	ENSG00000254682.1	RP11-660L16.2	13.48	2.34e-35	1.55e-31	0.67	0.52	Vitamin D levels;	chr11:71443774	chr11:71448674~71452157:+
LUAD	cis	rs858239	0.932	rs1728320	ENSG00000230658.1	KLHL7-AS1	13.48	2.43e-35	1.61e-31	0.65	0.52	Cerebrospinal fluid biomarker levels;	chr7:23280170	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.858	rs35812969	ENSG00000253404.1	AC034243.1	13.47	2.45e-35	1.62e-31	0.7	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041861	chr5:138744434~138753309:-
LUAD	cis	rs7617773	0.817	rs17647717	ENSG00000229759.1	MRPS18AP1	13.47	2.55e-35	1.68e-31	0.56	0.52	Coronary artery disease;	chr3:48263966	chr3:48256350~48256938:-
LUAD	cis	rs2882667	0.858	rs11242448	ENSG00000253404.1	AC034243.1	13.47	2.61e-35	1.72e-31	0.71	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139107465	chr5:138744434~138753309:-
LUAD	cis	rs507080	0.771	rs687664	ENSG00000255422.1	AP002954.4	-13.47	2.64e-35	1.74e-31	-0.66	-0.52	Serum metabolite levels;	chr11:118703476	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.771	rs523715	ENSG00000255422.1	AP002954.4	-13.47	2.64e-35	1.74e-31	-0.66	-0.52	Serum metabolite levels;	chr11:118703479	chr11:118704607~118750263:+
LUAD	cis	rs10256972	0.577	rs6962809	ENSG00000229043.2	AC091729.9	-13.47	2.65e-35	1.75e-31	-0.57	-0.52	Endometriosis;Longevity;	chr7:1169253	chr7:1160374~1165267:+
LUAD	cis	rs2739330	0.76	rs1007888	ENSG00000231271.1	AP000350.8	13.47	2.67e-35	1.76e-31	0.61	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23949918~23954042:+
LUAD	cis	rs10129255	0.556	rs9324093	ENSG00000223648.3	IGHV3-64	13.46	2.81e-35	1.85e-31	0.47	0.52	Kawasaki disease;	chr14:106683893	chr14:106643132~106658258:-
LUAD	cis	rs1799949	0.965	rs9646413	ENSG00000198496.9	NBR2	-13.46	2.81e-35	1.85e-31	-0.55	-0.52	Menopause (age at onset);	chr17:43348789	chr17:43125610~43153671:+
LUAD	cis	rs6452524	0.507	rs28592576	ENSG00000249664.1	CTD-2227C6.2	13.46	2.89e-35	1.9e-31	0.61	0.52	Hypertension (SNP x SNP interaction);	chr5:83074772	chr5:83012285~83013109:-
LUAD	cis	rs858239	1	rs199348	ENSG00000230658.1	KLHL7-AS1	13.46	2.93e-35	1.93e-31	0.63	0.52	Cerebrospinal fluid biomarker levels;	chr7:23253479	chr7:23101228~23105703:-
LUAD	cis	rs2882667	0.858	rs11959803	ENSG00000253404.1	AC034243.1	13.45	2.99e-35	1.97e-31	0.71	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139115626	chr5:138744434~138753309:-
LUAD	cis	rs7301826	1	rs4759787	ENSG00000256250.1	RP11-989F5.1	-13.45	3e-35	1.97e-31	-0.58	-0.52	Plasma plasminogen activator levels;	chr12:130805635	chr12:130810606~130812438:+
LUAD	cis	rs7617773	0.779	rs9833309	ENSG00000229759.1	MRPS18AP1	13.45	3.01e-35	1.98e-31	0.55	0.52	Coronary artery disease;	chr3:48285960	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.817	rs9853804	ENSG00000229759.1	MRPS18AP1	13.45	3.01e-35	1.98e-31	0.55	0.52	Coronary artery disease;	chr3:48286239	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.817	rs9834095	ENSG00000229759.1	MRPS18AP1	13.45	3.01e-35	1.98e-31	0.55	0.52	Coronary artery disease;	chr3:48286261	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.817	rs4131361	ENSG00000229759.1	MRPS18AP1	13.45	3.01e-35	1.98e-31	0.55	0.52	Coronary artery disease;	chr3:48287322	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.817	rs6791930	ENSG00000229759.1	MRPS18AP1	13.45	3.01e-35	1.98e-31	0.55	0.52	Coronary artery disease;	chr3:48288410	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.817	rs6794644	ENSG00000229759.1	MRPS18AP1	13.45	3.01e-35	1.98e-31	0.55	0.52	Coronary artery disease;	chr3:48288547	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.674	rs13069029	ENSG00000229759.1	MRPS18AP1	13.45	3.03e-35	1.99e-31	0.55	0.52	Coronary artery disease;	chr3:48313534	chr3:48256350~48256938:-
LUAD	cis	rs992157	0.798	rs1017698	ENSG00000261338.2	RP11-378A13.1	-13.45	3.04e-35	1.99e-31	-0.52	-0.52	Colorectal cancer;	chr2:218305802	chr2:218255319~218257366:+
LUAD	cis	rs6538678	0.784	rs7297403	ENSG00000199506.1	RNU6-247P	-13.45	3.14e-35	2.06e-31	-0.77	-0.52	Lupus nephritis in systemic lupus erythematosus;	chr12:95846683	chr12:95792529~95792635:-
LUAD	cis	rs7301826	0.967	rs4759792	ENSG00000256250.1	RP11-989F5.1	-13.45	3.25e-35	2.13e-31	-0.58	-0.52	Plasma plasminogen activator levels;	chr12:130812086	chr12:130810606~130812438:+
LUAD	cis	rs3091242	0.9	rs1883427	ENSG00000261349.1	RP3-465N24.5	-13.44	3.31e-35	2.16e-31	-0.57	-0.52	Erythrocyte sedimentation rate;	chr1:25417977	chr1:25266102~25267136:-
LUAD	cis	rs7301826	0.966	rs10734980	ENSG00000256250.1	RP11-989F5.1	-13.44	3.31e-35	2.17e-31	-0.58	-0.52	Plasma plasminogen activator levels;	chr12:130810081	chr12:130810606~130812438:+
LUAD	cis	rs7301826	1	rs4759793	ENSG00000256250.1	RP11-989F5.1	-13.44	3.31e-35	2.17e-31	-0.58	-0.52	Plasma plasminogen activator levels;	chr12:130812693	chr12:130810606~130812438:+
LUAD	cis	rs7617773	0.815	rs6793150	ENSG00000229759.1	MRPS18AP1	13.44	3.32e-35	2.17e-31	0.55	0.52	Coronary artery disease;	chr3:48310070	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs6793239	ENSG00000229759.1	MRPS18AP1	13.44	3.32e-35	2.17e-31	0.55	0.52	Coronary artery disease;	chr3:48310128	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs6782166	ENSG00000229759.1	MRPS18AP1	13.44	3.32e-35	2.17e-31	0.55	0.52	Coronary artery disease;	chr3:48310193	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs4130522	ENSG00000229759.1	MRPS18AP1	13.44	3.32e-35	2.17e-31	0.55	0.52	Coronary artery disease;	chr3:48310823	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs13081169	ENSG00000229759.1	MRPS18AP1	13.44	3.32e-35	2.17e-31	0.55	0.52	Coronary artery disease;	chr3:48315307	chr3:48256350~48256938:-
LUAD	cis	rs992157	0.798	rs10193383	ENSG00000261338.2	RP11-378A13.1	13.44	3.38e-35	2.21e-31	0.53	0.52	Colorectal cancer;	chr2:218292969	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.798	rs10206064	ENSG00000261338.2	RP11-378A13.1	13.44	3.38e-35	2.21e-31	0.53	0.52	Colorectal cancer;	chr2:218293236	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.7	rs10165153	ENSG00000261338.2	RP11-378A13.1	13.44	3.38e-35	2.21e-31	0.53	0.52	Colorectal cancer;	chr2:218294906	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.835	rs11677953	ENSG00000261338.2	RP11-378A13.1	-13.44	3.4e-35	2.22e-31	-0.54	-0.52	Colorectal cancer;	chr2:218256940	chr2:218255319~218257366:+
LUAD	cis	rs875971	0.505	rs6955582	ENSG00000226824.5	RP4-756H11.3	-13.44	3.49e-35	2.27e-31	-0.66	-0.52	Aortic root size;	chr7:65966699	chr7:66654538~66669855:+
LUAD	cis	rs992157	0.798	rs2382818	ENSG00000261338.2	RP11-378A13.1	-13.43	3.81e-35	2.48e-31	-0.53	-0.52	Colorectal cancer;	chr2:218291184	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.798	rs2382819	ENSG00000261338.2	RP11-378A13.1	-13.43	3.81e-35	2.48e-31	-0.53	-0.52	Colorectal cancer;	chr2:218291186	chr2:218255319~218257366:+
LUAD	cis	rs10129255	0.536	rs8004835	ENSG00000223648.3	IGHV3-64	13.43	3.81e-35	2.48e-31	0.47	0.52	Kawasaki disease;	chr14:106686361	chr14:106643132~106658258:-
LUAD	cis	rs6452524	0.534	rs7724935	ENSG00000249664.1	CTD-2227C6.2	13.43	3.87e-35	2.52e-31	0.6	0.52	Hypertension (SNP x SNP interaction);	chr5:83057264	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.506	rs7707143	ENSG00000249664.1	CTD-2227C6.2	13.43	3.87e-35	2.52e-31	0.6	0.52	Hypertension (SNP x SNP interaction);	chr5:83057268	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.534	rs9293328	ENSG00000249664.1	CTD-2227C6.2	13.43	3.93e-35	2.56e-31	0.61	0.52	Hypertension (SNP x SNP interaction);	chr5:83066855	chr5:83012285~83013109:-
LUAD	cis	rs2739330	0.732	rs5760175	ENSG00000225282.1	AP000350.6	13.43	3.96e-35	2.58e-31	0.62	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23926900~23929574:+
LUAD	cis	rs6452524	0.561	rs4331874	ENSG00000249664.1	CTD-2227C6.2	13.42	4.07e-35	2.65e-31	0.61	0.52	Hypertension (SNP x SNP interaction);	chr5:83068253	chr5:83012285~83013109:-
LUAD	cis	rs2882667	0.66	rs3088052	ENSG00000253404.1	AC034243.1	13.42	4.17e-35	2.71e-31	0.66	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121126	chr5:138744434~138753309:-
LUAD	cis	rs7617773	0.78	rs35297395	ENSG00000229759.1	MRPS18AP1	13.42	4.36e-35	2.82e-31	0.55	0.52	Coronary artery disease;	chr3:48301392	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs36075665	ENSG00000229759.1	MRPS18AP1	13.42	4.36e-35	2.82e-31	0.55	0.52	Coronary artery disease;	chr3:48301597	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs34630841	ENSG00000229759.1	MRPS18AP1	13.42	4.36e-35	2.82e-31	0.55	0.52	Coronary artery disease;	chr3:48301771	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs35190747	ENSG00000229759.1	MRPS18AP1	13.42	4.36e-35	2.82e-31	0.55	0.52	Coronary artery disease;	chr3:48301800	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.743	rs7621785	ENSG00000229759.1	MRPS18AP1	13.42	4.36e-35	2.82e-31	0.55	0.52	Coronary artery disease;	chr3:48302218	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs4511915	ENSG00000229759.1	MRPS18AP1	13.42	4.36e-35	2.82e-31	0.55	0.52	Coronary artery disease;	chr3:48302368	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs13066758	ENSG00000229759.1	MRPS18AP1	13.42	4.36e-35	2.82e-31	0.55	0.52	Coronary artery disease;	chr3:48302387	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs4392440	ENSG00000229759.1	MRPS18AP1	13.42	4.36e-35	2.82e-31	0.55	0.52	Coronary artery disease;	chr3:48302430	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs13082859	ENSG00000229759.1	MRPS18AP1	13.42	4.36e-35	2.82e-31	0.55	0.52	Coronary artery disease;	chr3:48303185	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs36121690	ENSG00000229759.1	MRPS18AP1	13.42	4.36e-35	2.82e-31	0.55	0.52	Coronary artery disease;	chr3:48304021	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs35778847	ENSG00000229759.1	MRPS18AP1	13.42	4.36e-35	2.82e-31	0.55	0.52	Coronary artery disease;	chr3:48305495	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs34749846	ENSG00000229759.1	MRPS18AP1	13.42	4.36e-35	2.82e-31	0.55	0.52	Coronary artery disease;	chr3:48305678	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs7632297	ENSG00000229759.1	MRPS18AP1	13.42	4.36e-35	2.82e-31	0.55	0.52	Coronary artery disease;	chr3:48306673	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs79089926	ENSG00000229759.1	MRPS18AP1	13.42	4.36e-35	2.82e-31	0.55	0.52	Coronary artery disease;	chr3:48307074	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs4511916	ENSG00000229759.1	MRPS18AP1	13.42	4.36e-35	2.82e-31	0.55	0.52	Coronary artery disease;	chr3:48308876	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.815	rs7624450	ENSG00000229759.1	MRPS18AP1	13.42	4.36e-35	2.82e-31	0.55	0.52	Coronary artery disease;	chr3:48308885	chr3:48256350~48256938:-
LUAD	cis	rs6452524	0.506	rs7891	ENSG00000249664.1	CTD-2227C6.2	13.42	4.4e-35	2.85e-31	0.61	0.52	Hypertension (SNP x SNP interaction);	chr5:83053558	chr5:83012285~83013109:-
LUAD	cis	rs1153858	1	rs59889118	ENSG00000259520.4	CTD-2651B20.3	-13.41	4.51e-35	2.92e-31	-0.71	-0.52	Homoarginine levels;	chr15:45326532	chr15:45251580~45279251:-
LUAD	cis	rs10129255	0.5	rs8021941	ENSG00000223648.3	IGHV3-64	13.41	4.72e-35	3.05e-31	0.47	0.52	Kawasaki disease;	chr14:106781490	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.5	rs10142931	ENSG00000223648.3	IGHV3-64	13.41	4.82e-35	3.11e-31	0.47	0.52	Kawasaki disease;	chr14:106782288	chr14:106643132~106658258:-
LUAD	cis	rs1153858	1	rs4775895	ENSG00000259520.4	CTD-2651B20.3	-13.4	5.06e-35	3.27e-31	-0.71	-0.52	Homoarginine levels;	chr15:45325759	chr15:45251580~45279251:-
LUAD	cis	rs3091242	0.933	rs1534954	ENSG00000261349.1	RP3-465N24.5	-13.4	5.08e-35	3.28e-31	-0.57	-0.52	Erythrocyte sedimentation rate;	chr1:25435433	chr1:25266102~25267136:-
LUAD	cis	rs12439619	0.693	rs7165536	ENSG00000278603.1	RP13-608F4.5	13.4	5.19e-35	3.35e-31	0.72	0.52	Intelligence (multi-trait analysis);	chr15:82273743	chr15:82472203~82472426:+
LUAD	cis	rs1799949	0.965	rs799916	ENSG00000198496.9	NBR2	13.39	5.37e-35	3.46e-31	0.53	0.52	Menopause (age at onset);	chr17:43091173	chr17:43125610~43153671:+
LUAD	cis	rs7617773	0.817	rs13072018	ENSG00000229759.1	MRPS18AP1	13.39	5.5e-35	3.54e-31	0.55	0.52	Coronary artery disease;	chr3:48278842	chr3:48256350~48256938:-
LUAD	cis	rs7301826	1	rs4759524	ENSG00000256250.1	RP11-989F5.1	-13.39	5.64e-35	3.63e-31	-0.58	-0.52	Plasma plasminogen activator levels;	chr12:130831065	chr12:130810606~130812438:+
LUAD	cis	rs875971	0.66	rs10229345	ENSG00000226824.5	RP4-756H11.3	-13.39	5.7e-35	3.66e-31	-0.67	-0.52	Aortic root size;	chr7:66517181	chr7:66654538~66669855:+
LUAD	cis	rs10129255	0.53	rs11624912	ENSG00000223648.3	IGHV3-64	13.39	5.8e-35	3.72e-31	0.47	0.52	Kawasaki disease;	chr14:106673891	chr14:106643132~106658258:-
LUAD	cis	rs6452524	0.562	rs10474080	ENSG00000249664.1	CTD-2227C6.2	13.38	5.96e-35	3.82e-31	0.61	0.52	Hypertension (SNP x SNP interaction);	chr5:83078300	chr5:83012285~83013109:-
LUAD	cis	rs3091242	0.836	rs34997029	ENSG00000261349.1	RP3-465N24.5	13.38	5.97e-35	3.83e-31	0.57	0.52	Erythrocyte sedimentation rate;	chr1:25457332	chr1:25266102~25267136:-
LUAD	cis	rs7115242	0.8	rs4245168	ENSG00000254851.1	RP11-109L13.1	-13.38	6e-35	3.85e-31	-0.89	-0.52	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117011922	chr11:117135528~117138582:+
LUAD	cis	rs10129255	0.536	rs10139058	ENSG00000223648.3	IGHV3-64	13.38	6.11e-35	3.92e-31	0.47	0.52	Kawasaki disease;	chr14:106685899	chr14:106643132~106658258:-
LUAD	cis	rs55794721	0.509	rs12027135	ENSG00000261349.1	RP3-465N24.5	-13.38	6.15e-35	3.94e-31	-0.57	-0.52	Mean corpuscular volume;Plateletcrit;	chr1:25449242	chr1:25266102~25267136:-
LUAD	cis	rs875971	0.706	rs1643374	ENSG00000226824.5	RP4-756H11.3	-13.38	6.29e-35	4.03e-31	-0.67	-0.52	Aortic root size;	chr7:66407695	chr7:66654538~66669855:+
LUAD	cis	rs9399135	1	rs1014021	ENSG00000232876.1	CTA-212D2.2	13.38	6.31e-35	4.04e-31	0.57	0.52	Red blood cell count;	chr6:135013462	chr6:135055033~135060550:+
LUAD	cis	rs6452524	0.534	rs10037377	ENSG00000249664.1	CTD-2227C6.2	13.38	6.33e-35	4.05e-31	0.6	0.52	Hypertension (SNP x SNP interaction);	chr5:83071150	chr5:83012285~83013109:-
LUAD	cis	rs3814244	0.788	rs3741649	ENSG00000255733.4	IFNG-AS1	-13.38	6.34e-35	4.06e-31	-0.44	-0.52	Itch intensity from mosquito bite adjusted by bite size;	chr12:68028351	chr12:67989445~68234686:+
LUAD	cis	rs6452524	0.563	rs10473863	ENSG00000249664.1	CTD-2227C6.2	13.38	6.38e-35	4.08e-31	0.6	0.52	Hypertension (SNP x SNP interaction);	chr5:83057500	chr5:83012285~83013109:-
LUAD	cis	rs7617773	0.78	rs35411187	ENSG00000229759.1	MRPS18AP1	13.37	6.79e-35	4.34e-31	0.55	0.52	Coronary artery disease;	chr3:48318527	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs11714176	ENSG00000229759.1	MRPS18AP1	13.37	6.79e-35	4.34e-31	0.55	0.52	Coronary artery disease;	chr3:48319372	chr3:48256350~48256938:-
LUAD	cis	rs7301826	1	rs1106369	ENSG00000256250.1	RP11-989F5.1	-13.37	6.82e-35	4.36e-31	-0.57	-0.52	Plasma plasminogen activator levels;	chr12:130815550	chr12:130810606~130812438:+
LUAD	cis	rs17711722	0.701	rs781143	ENSG00000226824.5	RP4-756H11.3	-13.37	7.05e-35	4.5e-31	-0.66	-0.52	Calcium levels;	chr7:65974892	chr7:66654538~66669855:+
LUAD	cis	rs7115242	0.8	rs7931770	ENSG00000254851.1	RP11-109L13.1	-13.37	7.15e-35	4.56e-31	-0.89	-0.52	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116995574	chr11:117135528~117138582:+
LUAD	cis	rs1153858	1	rs1980288	ENSG00000259520.4	CTD-2651B20.3	-13.36	7.24e-35	4.62e-31	-0.7	-0.52	Homoarginine levels;	chr15:45328414	chr15:45251580~45279251:-
LUAD	cis	rs10129255	0.509	rs756583	ENSG00000223648.3	IGHV3-64	13.36	7.49e-35	4.77e-31	0.47	0.52	Kawasaki disease;	chr14:106680002	chr14:106643132~106658258:-
LUAD	cis	rs6452524	0.534	rs72765386	ENSG00000249664.1	CTD-2227C6.2	13.36	7.49e-35	4.78e-31	0.6	0.52	Hypertension (SNP x SNP interaction);	chr5:83061502	chr5:83012285~83013109:-
LUAD	cis	rs3091242	0.9	rs35345536	ENSG00000261349.1	RP3-465N24.5	-13.36	7.51e-35	4.78e-31	-0.57	-0.52	Erythrocyte sedimentation rate;	chr1:25439997	chr1:25266102~25267136:-
LUAD	cis	rs1799949	1	rs2271573	ENSG00000198496.9	NBR2	-13.36	7.77e-35	4.95e-31	-0.57	-0.52	Menopause (age at onset);	chr17:43175604	chr17:43125610~43153671:+
LUAD	cis	rs9326248	0.53	rs2000615	ENSG00000254851.1	RP11-109L13.1	-13.35	8.25e-35	5.25e-31	-0.89	-0.52	Blood protein levels;	chr11:117045103	chr11:117135528~117138582:+
LUAD	cis	rs1799949	0.965	rs9911630	ENSG00000198496.9	NBR2	-13.35	8.5e-35	5.4e-31	-0.54	-0.52	Menopause (age at onset);	chr17:43036325	chr17:43125610~43153671:+
LUAD	cis	rs7115242	0.8	rs519794	ENSG00000254851.1	RP11-109L13.1	-13.34	8.77e-35	5.57e-31	-0.88	-0.52	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116988737	chr11:117135528~117138582:+
LUAD	cis	rs12439619	0.693	rs4778989	ENSG00000278603.1	RP13-608F4.5	13.34	8.8e-35	5.59e-31	0.72	0.52	Intelligence (multi-trait analysis);	chr15:82276963	chr15:82472203~82472426:+
LUAD	cis	rs3091242	0.934	rs666686	ENSG00000261349.1	RP3-465N24.5	-13.34	8.9e-35	5.65e-31	-0.57	-0.52	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25266102~25267136:-
LUAD	cis	rs10129255	0.5	rs2027903	ENSG00000223648.3	IGHV3-64	13.34	9.3e-35	5.9e-31	0.47	0.52	Kawasaki disease;	chr14:106807047	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.518	rs28378320	ENSG00000223648.3	IGHV3-64	13.34	9.3e-35	5.9e-31	0.47	0.52	Kawasaki disease;	chr14:106808609	chr14:106643132~106658258:-
LUAD	cis	rs507080	0.845	rs481903	ENSG00000255422.1	AP002954.4	-13.34	9.41e-35	5.97e-31	-0.65	-0.52	Serum metabolite levels;	chr11:118697024	chr11:118704607~118750263:+
LUAD	cis	rs875971	0.508	rs10258739	ENSG00000226824.5	RP4-756H11.3	13.34	9.55e-35	6.06e-31	0.65	0.52	Aortic root size;	chr7:66597948	chr7:66654538~66669855:+
LUAD	cis	rs7617773	0.817	rs9818937	ENSG00000229759.1	MRPS18AP1	13.33	1.06e-34	6.71e-31	0.54	0.52	Coronary artery disease;	chr3:48283791	chr3:48256350~48256938:-
LUAD	cis	rs5760092	0.755	rs4585126	ENSG00000218537.1	MIF-AS1	-13.32	1.1e-34	6.99e-31	-0.75	-0.52	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23894426~23898930:-
LUAD	cis	rs875971	0.66	rs10263935	ENSG00000226824.5	RP4-756H11.3	-13.32	1.14e-34	7.21e-31	-0.65	-0.52	Aortic root size;	chr7:66631041	chr7:66654538~66669855:+
LUAD	cis	rs10129255	0.5	rs34326748	ENSG00000223648.3	IGHV3-64	13.32	1.16e-34	7.3e-31	0.47	0.52	Kawasaki disease;	chr14:106782523	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.5	rs10143385	ENSG00000223648.3	IGHV3-64	13.32	1.16e-34	7.3e-31	0.47	0.52	Kawasaki disease;	chr14:106782559	chr14:106643132~106658258:-
LUAD	cis	rs1577917	0.958	rs6454487	ENSG00000203875.9	SNHG5	13.31	1.22e-34	7.71e-31	0.69	0.52	Response to antipsychotic treatment;	chr6:85737150	chr6:85660950~85678736:-
LUAD	cis	rs6452524	0.534	rs10061690	ENSG00000249664.1	CTD-2227C6.2	13.31	1.24e-34	7.81e-31	0.6	0.52	Hypertension (SNP x SNP interaction);	chr5:83063226	chr5:83012285~83013109:-
LUAD	cis	rs7301826	0.967	rs4759790	ENSG00000256250.1	RP11-989F5.1	-13.31	1.25e-34	7.84e-31	-0.57	-0.52	Plasma plasminogen activator levels;	chr12:130811845	chr12:130810606~130812438:+
LUAD	cis	rs3814244	0.788	rs11177014	ENSG00000255733.4	IFNG-AS1	-13.31	1.25e-34	7.88e-31	-0.44	-0.52	Itch intensity from mosquito bite adjusted by bite size;	chr12:68031871	chr12:67989445~68234686:+
LUAD	cis	rs7301826	1	rs4759523	ENSG00000256250.1	RP11-989F5.1	-13.3	1.32e-34	8.28e-31	-0.57	-0.52	Plasma plasminogen activator levels;	chr12:130830867	chr12:130810606~130812438:+
LUAD	cis	rs9326248	0.53	rs10790172	ENSG00000254851.1	RP11-109L13.1	-13.3	1.37e-34	8.58e-31	-0.89	-0.52	Blood protein levels;	chr11:117057024	chr11:117135528~117138582:+
LUAD	cis	rs858239	0.73	rs10255155	ENSG00000230658.1	KLHL7-AS1	-13.3	1.37e-34	8.59e-31	-0.65	-0.52	Cerebrospinal fluid biomarker levels;	chr7:23362528	chr7:23101228~23105703:-
LUAD	cis	rs7617773	0.817	rs13094727	ENSG00000229759.1	MRPS18AP1	13.3	1.38e-34	8.67e-31	0.55	0.52	Coronary artery disease;	chr3:48281999	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs11706277	ENSG00000229759.1	MRPS18AP1	13.29	1.46e-34	9.15e-31	0.56	0.52	Coronary artery disease;	chr3:48318943	chr3:48256350~48256938:-
LUAD	cis	rs2882667	0.66	rs11951084	ENSG00000253404.1	AC034243.1	13.29	1.5e-34	9.42e-31	0.66	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139125858	chr5:138744434~138753309:-
LUAD	cis	rs17711722	0.727	rs1880555	ENSG00000226824.5	RP4-756H11.3	-13.29	1.57e-34	9.83e-31	-0.66	-0.52	Calcium levels;	chr7:65967580	chr7:66654538~66669855:+
LUAD	cis	rs7617773	0.78	rs7653152	ENSG00000229759.1	MRPS18AP1	13.28	1.69e-34	1.06e-30	0.55	0.52	Coronary artery disease;	chr3:48320607	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.709	rs4404473	ENSG00000229759.1	MRPS18AP1	13.27	1.83e-34	1.14e-30	0.55	0.52	Coronary artery disease;	chr3:48312136	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.817	rs11928691	ENSG00000229759.1	MRPS18AP1	13.27	1.83e-34	1.14e-30	0.52	0.52	Coronary artery disease;	chr3:48245275	chr3:48256350~48256938:-
LUAD	cis	rs992157	0.767	rs2382822	ENSG00000261338.2	RP11-378A13.1	-13.27	1.91e-34	1.19e-30	-0.52	-0.52	Colorectal cancer;	chr2:218308604	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.71	rs6752254	ENSG00000261338.2	RP11-378A13.1	13.26	1.95e-34	1.21e-30	0.52	0.52	Colorectal cancer;	chr2:218194020	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.798	rs7557709	ENSG00000261338.2	RP11-378A13.1	13.26	2.01e-34	1.25e-30	0.52	0.52	Colorectal cancer;	chr2:218302806	chr2:218255319~218257366:+
LUAD	cis	rs73086581	0.947	rs73084531	ENSG00000229539.1	RP11-119B16.2	13.26	2.06e-34	1.29e-30	0.74	0.52	Response to antidepressants in depression;	chr20:3897782	chr20:3888239~3888868:-
LUAD	cis	rs7617773	0.817	rs4131362	ENSG00000229759.1	MRPS18AP1	13.26	2.08e-34	1.3e-30	0.54	0.52	Coronary artery disease;	chr3:48287546	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.817	rs6800492	ENSG00000229759.1	MRPS18AP1	13.26	2.09e-34	1.3e-30	0.54	0.52	Coronary artery disease;	chr3:48282400	chr3:48256350~48256938:-
LUAD	cis	rs10935480	0.904	rs13065271	ENSG00000239445.4	ST3GAL6-AS1	-13.25	2.16e-34	1.34e-30	-0.62	-0.52	Blood protein levels;	chr3:98715649	chr3:98714330~98732651:-
LUAD	cis	rs7617773	0.78	rs13079728	ENSG00000229759.1	MRPS18AP1	13.25	2.22e-34	1.37e-30	0.55	0.52	Coronary artery disease;	chr3:48297870	chr3:48256350~48256938:-
LUAD	cis	rs2019137	0.56	rs4849179	ENSG00000274877.1	RP11-65I12.1	-13.25	2.25e-34	1.4e-30	-0.66	-0.52	Lymphocyte counts;	chr2:113227593	chr2:113237595~113240825:+
LUAD	cis	rs10129255	0.5	rs8022547	ENSG00000223648.3	IGHV3-64	13.25	2.27e-34	1.41e-30	0.47	0.52	Kawasaki disease;	chr14:106781985	chr14:106643132~106658258:-
LUAD	cis	rs2739330	0.587	rs4820571	ENSG00000250470.1	AP000351.3	13.25	2.28e-34	1.41e-30	0.64	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23976904~23977585:-
LUAD	cis	rs10129255	0.5	rs8006888	ENSG00000223648.3	IGHV3-64	13.25	2.32e-34	1.44e-30	0.47	0.52	Kawasaki disease;	chr14:106782219	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.536	rs10142951	ENSG00000223648.3	IGHV3-64	13.25	2.32e-34	1.44e-30	0.47	0.52	Kawasaki disease;	chr14:106782337	chr14:106643132~106658258:-
LUAD	cis	rs3091242	0.867	rs602052	ENSG00000261349.1	RP3-465N24.5	-13.24	2.37e-34	1.46e-30	-0.57	-0.52	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25266102~25267136:-
LUAD	cis	rs7396835	0.537	rs10892035	ENSG00000254851.1	RP11-109L13.1	-13.24	2.38e-34	1.47e-30	-0.76	-0.52	Quantitative traits;	chr11:116824222	chr11:117135528~117138582:+
LUAD	cis	rs73086581	0.947	rs73084523	ENSG00000229539.1	RP11-119B16.2	13.24	2.42e-34	1.49e-30	0.74	0.52	Response to antidepressants in depression;	chr20:3894979	chr20:3888239~3888868:-
LUAD	cis	rs2739330	0.731	rs4822450	ENSG00000231271.1	AP000350.8	13.24	2.46e-34	1.52e-30	0.6	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23949918~23954042:+
LUAD	cis	rs2658782	0.906	rs2658791	ENSG00000279684.1	RP11-755E23.2	-13.24	2.48e-34	1.53e-30	-0.86	-0.52	Pulmonary function decline;	chr11:93465817	chr11:93286629~93288903:-
LUAD	cis	rs10129255	0.5	rs6576230	ENSG00000223648.3	IGHV3-64	13.24	2.5e-34	1.54e-30	0.47	0.52	Kawasaki disease;	chr14:106778539	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.518	rs11847766	ENSG00000223648.3	IGHV3-64	13.24	2.5e-34	1.54e-30	0.47	0.52	Kawasaki disease;	chr14:106779186	chr14:106643132~106658258:-
LUAD	cis	rs7301826	1	rs2001483	ENSG00000256250.1	RP11-989F5.1	-13.24	2.56e-34	1.58e-30	-0.58	-0.52	Plasma plasminogen activator levels;	chr12:130834100	chr12:130810606~130812438:+
LUAD	cis	rs7104764	0.833	rs12574034	ENSG00000277290.1	RP11-326C3.16	13.23	2.57e-34	1.59e-30	0.5	0.52	Menarche (age at onset);	chr11:212262	chr11:243099~243483:-
LUAD	cis	rs10256972	0.577	rs4999286	ENSG00000229043.2	AC091729.9	-13.23	2.6e-34	1.6e-30	-0.56	-0.52	Endometriosis;Longevity;	chr7:1159870	chr7:1160374~1165267:+
LUAD	cis	rs17711722	0.701	rs781145	ENSG00000226824.5	RP4-756H11.3	-13.23	2.6e-34	1.6e-30	-0.65	-0.52	Calcium levels;	chr7:65975383	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.54	rs1723268	ENSG00000226824.5	RP4-756H11.3	-13.23	2.6e-34	1.6e-30	-0.65	-0.52	Aortic root size;	chr7:66008093	chr7:66654538~66669855:+
LUAD	cis	rs7301826	1	rs10773819	ENSG00000256250.1	RP11-989F5.1	-13.23	2.63e-34	1.62e-30	-0.58	-0.52	Plasma plasminogen activator levels;	chr12:130794477	chr12:130810606~130812438:+
LUAD	cis	rs2019137	0.539	rs4849177	ENSG00000274877.1	RP11-65I12.1	-13.23	2.65e-34	1.63e-30	-0.66	-0.52	Lymphocyte counts;	chr2:113225007	chr2:113237595~113240825:+
LUAD	cis	rs2658782	0.789	rs2658775	ENSG00000279684.1	RP11-755E23.2	-13.23	2.74e-34	1.69e-30	-0.8	-0.52	Pulmonary function decline;	chr11:93393633	chr11:93286629~93288903:-
LUAD	cis	rs2658782	0.789	rs2658773	ENSG00000279684.1	RP11-755E23.2	-13.23	2.74e-34	1.69e-30	-0.8	-0.52	Pulmonary function decline;	chr11:93393748	chr11:93286629~93288903:-
LUAD	cis	rs10129255	0.5	rs59939897	ENSG00000223648.3	IGHV3-64	13.23	2.75e-34	1.69e-30	0.47	0.52	Kawasaki disease;	chr14:106783414	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.5	rs8014529	ENSG00000223648.3	IGHV3-64	13.23	2.75e-34	1.69e-30	0.47	0.52	Kawasaki disease;	chr14:106784065	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.5	rs12101190	ENSG00000223648.3	IGHV3-64	13.23	2.75e-34	1.69e-30	0.47	0.52	Kawasaki disease;	chr14:106784149	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.518	rs8004895	ENSG00000223648.3	IGHV3-64	13.23	2.75e-34	1.69e-30	0.47	0.52	Kawasaki disease;	chr14:106785139	chr14:106643132~106658258:-
LUAD	cis	rs992157	0.798	rs12053514	ENSG00000261338.2	RP11-378A13.1	-13.23	2.78e-34	1.71e-30	-0.52	-0.52	Colorectal cancer;	chr2:218303242	chr2:218255319~218257366:+
LUAD	cis	rs4423214	0.921	rs11603330	ENSG00000254682.1	RP11-660L16.2	13.22	2.9e-34	1.78e-30	0.67	0.52	Vitamin D levels;	chr11:71442413	chr11:71448674~71452157:+
LUAD	cis	rs2019137	0.539	rs6755040	ENSG00000274877.1	RP11-65I12.1	-13.22	2.99e-34	1.84e-30	-0.66	-0.52	Lymphocyte counts;	chr2:113223560	chr2:113237595~113240825:+
LUAD	cis	rs1577917	0.958	rs12197463	ENSG00000203875.9	SNHG5	-13.22	3.04e-34	1.86e-30	-0.7	-0.52	Response to antipsychotic treatment;	chr6:85735524	chr6:85660950~85678736:-
LUAD	cis	rs992157	0.775	rs1877714	ENSG00000261338.2	RP11-378A13.1	-13.22	3.05e-34	1.87e-30	-0.51	-0.52	Colorectal cancer;	chr2:218270205	chr2:218255319~218257366:+
LUAD	cis	rs17711722	0.727	rs2658585	ENSG00000226824.5	RP4-756H11.3	-13.21	3.12e-34	1.91e-30	-0.65	-0.52	Calcium levels;	chr7:65996954	chr7:66654538~66669855:+
LUAD	cis	rs6452524	0.537	rs1583	ENSG00000249664.1	CTD-2227C6.2	13.21	3.13e-34	1.92e-30	0.6	0.52	Hypertension (SNP x SNP interaction);	chr5:83052403	chr5:83012285~83013109:-
LUAD	cis	rs17507216	0.958	rs72751643	ENSG00000278603.1	RP13-608F4.5	13.21	3.15e-34	1.93e-30	0.72	0.52	Excessive daytime sleepiness;	chr15:82559444	chr15:82472203~82472426:+
LUAD	cis	rs875971	0.666	rs13242072	ENSG00000226824.5	RP4-756H11.3	13.21	3.4e-34	2.08e-30	0.66	0.52	Aortic root size;	chr7:66301001	chr7:66654538~66669855:+
LUAD	cis	rs9326248	0.53	rs2155583	ENSG00000254851.1	RP11-109L13.1	-13.21	3.4e-34	2.08e-30	-0.88	-0.52	Blood protein levels;	chr11:117044501	chr11:117135528~117138582:+
LUAD	cis	rs950027	0.549	rs9920634	ENSG00000259520.4	CTD-2651B20.3	13.2	3.57e-34	2.18e-30	0.63	0.52	Response to fenofibrate (adiponectin levels);	chr15:45304348	chr15:45251580~45279251:-
LUAD	cis	rs3091242	0.933	rs12402120	ENSG00000261349.1	RP3-465N24.5	-13.2	3.7e-34	2.26e-30	-0.56	-0.52	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25266102~25267136:-
LUAD	cis	rs858239	1	rs156425	ENSG00000230658.1	KLHL7-AS1	-13.2	3.72e-34	2.27e-30	-0.62	-0.52	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23101228~23105703:-
LUAD	cis	rs875971	0.522	rs2949690	ENSG00000226824.5	RP4-756H11.3	13.2	3.72e-34	2.27e-30	0.65	0.52	Aortic root size;	chr7:66018255	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.901	rs4273746	ENSG00000226824.5	RP4-756H11.3	13.2	3.77e-34	2.3e-30	0.67	0.52	Aortic root size;	chr7:66836124	chr7:66654538~66669855:+
LUAD	cis	rs2019137	0.56	rs10175462	ENSG00000274877.1	RP11-65I12.1	-13.19	3.83e-34	2.34e-30	-0.66	-0.52	Lymphocyte counts;	chr2:113230915	chr2:113237595~113240825:+
LUAD	cis	rs10129255	0.518	rs7143784	ENSG00000223648.3	IGHV3-64	13.19	3.89e-34	2.38e-30	0.47	0.52	Kawasaki disease;	chr14:106687277	chr14:106643132~106658258:-
LUAD	cis	rs1577917	0.958	rs66807489	ENSG00000203875.9	SNHG5	-13.19	3.94e-34	2.4e-30	-0.69	-0.52	Response to antipsychotic treatment;	chr6:85730984	chr6:85660950~85678736:-
LUAD	cis	rs6452524	0.532	rs27363	ENSG00000249664.1	CTD-2227C6.2	13.19	4.04e-34	2.46e-30	0.6	0.52	Hypertension (SNP x SNP interaction);	chr5:83040943	chr5:83012285~83013109:-
LUAD	cis	rs10129255	0.5	rs1024350	ENSG00000223648.3	IGHV3-64	13.18	4.2e-34	2.56e-30	0.46	0.52	Kawasaki disease;	chr14:106685105	chr14:106643132~106658258:-
LUAD	cis	rs1577917	0.958	rs12213343	ENSG00000203875.9	SNHG5	-13.18	4.25e-34	2.59e-30	-0.7	-0.52	Response to antipsychotic treatment;	chr6:85733301	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs12215265	ENSG00000203875.9	SNHG5	-13.18	4.25e-34	2.59e-30	-0.7	-0.52	Response to antipsychotic treatment;	chr6:85734251	chr6:85660950~85678736:-
LUAD	cis	rs858239	0.862	rs1728292	ENSG00000230658.1	KLHL7-AS1	13.18	4.39e-34	2.67e-30	0.61	0.52	Cerebrospinal fluid biomarker levels;	chr7:23223855	chr7:23101228~23105703:-
LUAD	cis	rs916888	0.61	rs199446	ENSG00000214401.4	KANSL1-AS1	-13.18	4.49e-34	2.73e-30	-0.71	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46193576~46196723:+
LUAD	cis	rs916888	0.61	rs199536	ENSG00000214401.4	KANSL1-AS1	-13.18	4.49e-34	2.73e-30	-0.71	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46193576~46196723:+
LUAD	cis	rs875971	0.577	rs35072105	ENSG00000226824.5	RP4-756H11.3	13.18	4.52e-34	2.74e-30	0.66	0.52	Aortic root size;	chr7:66144830	chr7:66654538~66669855:+
LUAD	cis	rs3814244	0.788	rs3741647	ENSG00000255733.4	IFNG-AS1	-13.18	4.54e-34	2.75e-30	-0.43	-0.51	Itch intensity from mosquito bite adjusted by bite size;	chr12:68028249	chr12:67989445~68234686:+
LUAD	cis	rs17711722	0.701	rs4467826	ENSG00000226824.5	RP4-756H11.3	-13.17	4.63e-34	2.81e-30	-0.64	-0.51	Calcium levels;	chr7:65903721	chr7:66654538~66669855:+
LUAD	cis	rs6538678	0.963	rs11108310	ENSG00000258343.1	RP11-536G4.2	-13.17	4.64e-34	2.81e-30	-0.72	-0.51	Lupus nephritis in systemic lupus erythematosus;	chr12:95864164	chr12:95795345~95858839:-
LUAD	cis	rs992157	0.687	rs10206984	ENSG00000261338.2	RP11-378A13.1	13.17	4.64e-34	2.81e-30	0.52	0.51	Colorectal cancer;	chr2:218202257	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.697	rs13384682	ENSG00000261338.2	RP11-378A13.1	13.17	4.64e-34	2.81e-30	0.52	0.51	Colorectal cancer;	chr2:218204414	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.71	rs7569907	ENSG00000261338.2	RP11-378A13.1	13.17	4.64e-34	2.81e-30	0.52	0.51	Colorectal cancer;	chr2:218205828	chr2:218255319~218257366:+
LUAD	cis	rs875971	0.54	rs736270	ENSG00000226824.5	RP4-756H11.3	-13.17	4.85e-34	2.93e-30	-0.65	-0.51	Aortic root size;	chr7:65963835	chr7:66654538~66669855:+
LUAD	cis	rs9326248	0.53	rs7121347	ENSG00000254851.1	RP11-109L13.1	-13.17	4.98e-34	3.02e-30	-0.89	-0.51	Blood protein levels;	chr11:116996493	chr11:117135528~117138582:+
LUAD	cis	rs2906856	0.524	rs56236103	ENSG00000255733.4	IFNG-AS1	13.16	5.31e-34	3.21e-30	0.53	0.51	Mosquito bite size;	chr12:67937437	chr12:67989445~68234686:+
LUAD	cis	rs11763147	1	rs11763147	ENSG00000226824.5	RP4-756H11.3	13.16	5.32e-34	3.21e-30	0.64	0.51	Corneal structure;	chr7:65861834	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.628	rs6974355	ENSG00000226824.5	RP4-756H11.3	-13.16	5.53e-34	3.33e-30	-0.66	-0.51	Aortic root size;	chr7:66376994	chr7:66654538~66669855:+
LUAD	cis	rs1153858	0.895	rs12593402	ENSG00000259520.4	CTD-2651B20.3	-13.15	5.75e-34	3.46e-30	-0.7	-0.51	Homoarginine levels;	chr15:45325194	chr15:45251580~45279251:-
LUAD	cis	rs9326248	0.53	rs7114963	ENSG00000254851.1	RP11-109L13.1	-13.15	5.8e-34	3.48e-30	-0.89	-0.51	Blood protein levels;	chr11:117005267	chr11:117135528~117138582:+
LUAD	cis	rs7115242	0.72	rs10790169	ENSG00000254851.1	RP11-109L13.1	-13.15	5.8e-34	3.48e-30	-0.89	-0.51	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117006443	chr11:117135528~117138582:+
LUAD	cis	rs1153858	1	rs12593370	ENSG00000259520.4	CTD-2651B20.3	-13.15	6.16e-34	3.7e-30	-0.7	-0.51	Homoarginine levels;	chr15:45325219	chr15:45251580~45279251:-
LUAD	cis	rs73086581	0.947	rs56123574	ENSG00000229539.1	RP11-119B16.2	13.14	6.17e-34	3.7e-30	0.74	0.51	Response to antidepressants in depression;	chr20:3897434	chr20:3888239~3888868:-
LUAD	cis	rs875971	0.619	rs2302918	ENSG00000226824.5	RP4-756H11.3	-13.14	6.19e-34	3.72e-30	-0.65	-0.51	Aortic root size;	chr7:66535945	chr7:66654538~66669855:+
LUAD	cis	rs4423214	0.879	rs12803256	ENSG00000254682.1	RP11-660L16.2	13.14	6.32e-34	3.79e-30	0.67	0.51	Vitamin D levels;	chr11:71421822	chr11:71448674~71452157:+
LUAD	cis	rs2658782	0.756	rs3019205	ENSG00000279684.1	RP11-755E23.2	-13.13	6.86e-34	4.11e-30	-0.79	-0.51	Pulmonary function decline;	chr11:93376387	chr11:93286629~93288903:-
LUAD	cis	rs2882667	0.755	rs55650316	ENSG00000253404.1	AC034243.1	13.13	6.91e-34	4.14e-30	0.68	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139131603	chr5:138744434~138753309:-
LUAD	cis	rs3091242	0.933	rs932372	ENSG00000261349.1	RP3-465N24.5	-13.13	7.08e-34	4.24e-30	-0.56	-0.51	Erythrocyte sedimentation rate;	chr1:25428523	chr1:25266102~25267136:-
LUAD	cis	rs2739330	0.731	rs5751792	ENSG00000225282.1	AP000350.6	13.13	7.19e-34	4.3e-30	0.6	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23926900~23929574:+
LUAD	cis	rs7617773	0.78	rs13067450	ENSG00000229759.1	MRPS18AP1	13.13	7.22e-34	4.32e-30	0.54	0.51	Coronary artery disease;	chr3:48295716	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs4479622	ENSG00000229759.1	MRPS18AP1	13.13	7.22e-34	4.32e-30	0.54	0.51	Coronary artery disease;	chr3:48296683	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs34946886	ENSG00000229759.1	MRPS18AP1	13.13	7.22e-34	4.32e-30	0.54	0.51	Coronary artery disease;	chr3:48296997	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs34589064	ENSG00000229759.1	MRPS18AP1	13.13	7.22e-34	4.32e-30	0.54	0.51	Coronary artery disease;	chr3:48298059	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs2541	ENSG00000229759.1	MRPS18AP1	13.13	7.22e-34	4.32e-30	0.54	0.51	Coronary artery disease;	chr3:48298128	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs13085251	ENSG00000229759.1	MRPS18AP1	13.13	7.22e-34	4.32e-30	0.54	0.51	Coronary artery disease;	chr3:48298555	chr3:48256350~48256938:-
LUAD	cis	rs10129255	0.5	rs6576231	ENSG00000223648.3	IGHV3-64	13.13	7.33e-34	4.38e-30	0.47	0.51	Kawasaki disease;	chr14:106783693	chr14:106643132~106658258:-
LUAD	cis	rs916888	0.61	rs142167	ENSG00000214401.4	KANSL1-AS1	-13.12	7.71e-34	4.61e-30	-0.7	-0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46193576~46196723:+
LUAD	cis	rs858239	1	rs156421	ENSG00000230658.1	KLHL7-AS1	13.12	7.75e-34	4.63e-30	0.63	0.51	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23101228~23105703:-
LUAD	cis	rs9399135	0.967	rs2150681	ENSG00000232876.1	CTA-212D2.2	13.12	7.82e-34	4.67e-30	0.57	0.51	Red blood cell count;	chr6:135054094	chr6:135055033~135060550:+
LUAD	cis	rs4853012	0.941	rs2421752	ENSG00000217702.2	RP11-287D1.4	13.12	8.16e-34	4.86e-30	0.83	0.51	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74130583~74135395:+
LUAD	cis	rs3091242	0.967	rs3093614	ENSG00000224183.1	SDHDP6	13.12	8.25e-34	4.91e-30	0.65	0.51	Erythrocyte sedimentation rate;	chr1:25351353	chr1:25294164~25294643:-
LUAD	cis	rs10129255	0.5	rs2105991	ENSG00000223648.3	IGHV3-64	13.11	8.39e-34	4.99e-30	0.46	0.51	Kawasaki disease;	chr14:106682022	chr14:106643132~106658258:-
LUAD	cis	rs6452524	0.532	rs26263	ENSG00000249664.1	CTD-2227C6.2	13.11	8.61e-34	5.12e-30	0.6	0.51	Hypertension (SNP x SNP interaction);	chr5:83044465	chr5:83012285~83013109:-
LUAD	cis	rs7301826	1	rs4619189	ENSG00000256250.1	RP11-989F5.1	-13.11	8.85e-34	5.26e-30	-0.57	-0.51	Plasma plasminogen activator levels;	chr12:130829252	chr12:130810606~130812438:+
LUAD	cis	rs10256972	0.552	rs6978842	ENSG00000229043.2	AC091729.9	-13.11	9.08e-34	5.4e-30	-0.53	-0.51	Endometriosis;Longevity;	chr7:1164963	chr7:1160374~1165267:+
LUAD	cis	rs9326248	0.53	rs6589589	ENSG00000254851.1	RP11-109L13.1	-13.1	9.27e-34	5.51e-30	-0.87	-0.51	Blood protein levels;	chr11:117061712	chr11:117135528~117138582:+
LUAD	cis	rs875971	0.522	rs1701760	ENSG00000226824.5	RP4-756H11.3	-13.1	9.38e-34	5.57e-30	-0.65	-0.51	Aortic root size;	chr7:66008701	chr7:66654538~66669855:+
LUAD	cis	rs55794721	0.509	rs2982358	ENSG00000261349.1	RP3-465N24.5	-13.1	9.59e-34	5.69e-30	-0.57	-0.51	Mean corpuscular volume;Plateletcrit;	chr1:25418713	chr1:25266102~25267136:-
LUAD	cis	rs9399135	1	rs4896130	ENSG00000232876.1	CTA-212D2.2	-13.09	1e-33	5.95e-30	-0.57	-0.51	Red blood cell count;	chr6:135033980	chr6:135055033~135060550:+
LUAD	cis	rs875971	0.522	rs1917563	ENSG00000226824.5	RP4-756H11.3	13.09	1.07e-33	6.32e-30	0.65	0.51	Aortic root size;	chr7:65950660	chr7:66654538~66669855:+
LUAD	cis	rs9399135	0.967	rs1854865	ENSG00000232876.1	CTA-212D2.2	-13.08	1.11e-33	6.56e-30	-0.56	-0.51	Red blood cell count;	chr6:135039162	chr6:135055033~135060550:+
LUAD	cis	rs4423214	1	rs1981412	ENSG00000254682.1	RP11-660L16.2	13.08	1.12e-33	6.64e-30	0.66	0.51	Vitamin D levels;	chr11:71427664	chr11:71448674~71452157:+
LUAD	cis	rs4423214	1	rs12419279	ENSG00000254682.1	RP11-660L16.2	13.08	1.12e-33	6.64e-30	0.66	0.51	Vitamin D levels;	chr11:71428015	chr11:71448674~71452157:+
LUAD	cis	rs2739330	0.76	rs5760095	ENSG00000231271.1	AP000350.8	13.08	1.13e-33	6.71e-30	0.61	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23949918~23954042:+
LUAD	cis	rs7301826	1	rs10848205	ENSG00000256250.1	RP11-989F5.1	-13.08	1.14e-33	6.72e-30	-0.58	-0.51	Plasma plasminogen activator levels;	chr12:130796169	chr12:130810606~130812438:+
LUAD	cis	rs17711722	0.585	rs6942660	ENSG00000226824.5	RP4-756H11.3	-13.08	1.15e-33	6.8e-30	-0.64	-0.51	Calcium levels;	chr7:65837419	chr7:66654538~66669855:+
LUAD	cis	rs17711722	0.64	rs13237956	ENSG00000226824.5	RP4-756H11.3	-13.08	1.15e-33	6.8e-30	-0.64	-0.51	Calcium levels;	chr7:65853042	chr7:66654538~66669855:+
LUAD	cis	rs3091242	0.967	rs1053438	ENSG00000224183.1	SDHDP6	13.08	1.15e-33	6.8e-30	0.65	0.51	Erythrocyte sedimentation rate;	chr1:25361410	chr1:25294164~25294643:-
LUAD	cis	rs950027	0.572	rs12910764	ENSG00000259520.4	CTD-2651B20.3	13.08	1.2e-33	7.08e-30	0.62	0.51	Response to fenofibrate (adiponectin levels);	chr15:45317162	chr15:45251580~45279251:-
LUAD	cis	rs7617773	0.744	rs2125482	ENSG00000229759.1	MRPS18AP1	13.07	1.24e-33	7.26e-30	0.54	0.51	Coronary artery disease;	chr3:48281643	chr3:48256350~48256938:-
LUAD	cis	rs3091242	0.933	rs28530483	ENSG00000261349.1	RP3-465N24.5	-13.07	1.25e-33	7.33e-30	-0.57	-0.51	Erythrocyte sedimentation rate;	chr1:25414356	chr1:25266102~25267136:-
LUAD	cis	rs875971	0.54	rs4717275	ENSG00000226824.5	RP4-756H11.3	13.07	1.27e-33	7.47e-30	0.65	0.51	Aortic root size;	chr7:65800193	chr7:66654538~66669855:+
LUAD	cis	rs2882667	0.858	rs11951899	ENSG00000253404.1	AC034243.1	13.07	1.31e-33	7.69e-30	0.69	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038621	chr5:138744434~138753309:-
LUAD	cis	rs875971	0.522	rs4502988	ENSG00000226824.5	RP4-756H11.3	-13.06	1.35e-33	7.89e-30	-0.64	-0.51	Aortic root size;	chr7:65832759	chr7:66654538~66669855:+
LUAD	cis	rs10129255	0.518	rs12590732	ENSG00000223648.3	IGHV3-64	-13.06	1.36e-33	7.97e-30	-0.46	-0.51	Kawasaki disease;	chr14:106779612	chr14:106643132~106658258:-
LUAD	cis	rs6538678	0.864	rs7308921	ENSG00000258343.1	RP11-536G4.2	13.06	1.36e-33	7.98e-30	0.69	0.51	Lupus nephritis in systemic lupus erythematosus;	chr12:95870757	chr12:95795345~95858839:-
LUAD	cis	rs2019137	0.56	rs6707386	ENSG00000274877.1	RP11-65I12.1	-13.06	1.42e-33	8.28e-30	-0.66	-0.51	Lymphocyte counts;	chr2:113223445	chr2:113237595~113240825:+
LUAD	cis	rs2739330	0.761	rs5760176	ENSG00000225282.1	AP000350.6	-13.06	1.43e-33	8.36e-30	-0.59	-0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23926900~23929574:+
LUAD	cis	rs4423214	1	rs2276360	ENSG00000254682.1	RP11-660L16.2	13.06	1.46e-33	8.5e-30	0.67	0.51	Vitamin D levels;	chr11:71458501	chr11:71448674~71452157:+
LUAD	cis	rs916888	0.61	rs199454	ENSG00000214401.4	KANSL1-AS1	-13.06	1.46e-33	8.52e-30	-0.7	-0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46193576~46196723:+
LUAD	cis	rs55794721	0.509	rs909834	ENSG00000261349.1	RP3-465N24.5	-13.06	1.47e-33	8.57e-30	-0.56	-0.51	Mean corpuscular volume;Plateletcrit;	chr1:25431505	chr1:25266102~25267136:-
LUAD	cis	rs7617773	0.817	rs9311421	ENSG00000229759.1	MRPS18AP1	13.05	1.57e-33	9.17e-30	0.52	0.51	Coronary artery disease;	chr3:48251588	chr3:48256350~48256938:-
LUAD	cis	rs992157	0.798	rs7587220	ENSG00000261338.2	RP11-378A13.1	-13.05	1.6e-33	9.32e-30	-0.52	-0.51	Colorectal cancer;	chr2:218296141	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.798	rs4674284	ENSG00000261338.2	RP11-378A13.1	-13.05	1.6e-33	9.32e-30	-0.52	-0.51	Colorectal cancer;	chr2:218296518	chr2:218255319~218257366:+
LUAD	cis	rs12439619	0.705	rs17354185	ENSG00000278603.1	RP13-608F4.5	-13.05	1.61e-33	9.36e-30	-0.73	-0.51	Intelligence (multi-trait analysis);	chr15:82133829	chr15:82472203~82472426:+
LUAD	cis	rs4853012	0.887	rs77148265	ENSG00000217702.2	RP11-287D1.4	13.05	1.61e-33	9.37e-30	0.83	0.51	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74130583~74135395:+
LUAD	cis	rs1153858	1	rs2056493	ENSG00000259520.4	CTD-2651B20.3	-13.04	1.63e-33	9.49e-30	-0.67	-0.51	Homoarginine levels;	chr15:45356074	chr15:45251580~45279251:-
LUAD	cis	rs9399135	0.967	rs1590975	ENSG00000232876.1	CTA-212D2.2	-13.04	1.64e-33	9.54e-30	-0.56	-0.51	Red blood cell count;	chr6:135030950	chr6:135055033~135060550:+
LUAD	cis	rs1153858	1	rs12909158	ENSG00000259520.4	CTD-2651B20.3	-13.04	1.64e-33	9.56e-30	-0.69	-0.51	Homoarginine levels;	chr15:45328976	chr15:45251580~45279251:-
LUAD	cis	rs17507216	1	rs17507216	ENSG00000278603.1	RP13-608F4.5	-13.04	1.66e-33	9.63e-30	-0.7	-0.51	Excessive daytime sleepiness;	chr15:82558175	chr15:82472203~82472426:+
LUAD	cis	rs7396835	0.5	rs5092	ENSG00000254851.1	RP11-109L13.1	-13.04	1.66e-33	9.68e-30	-0.8	-0.51	Quantitative traits;	chr11:116822748	chr11:117135528~117138582:+
LUAD	cis	rs9399135	0.933	rs41294852	ENSG00000232876.1	CTA-212D2.2	-13.04	1.67e-33	9.69e-30	-0.56	-0.51	Red blood cell count;	chr6:135055241	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs6569990	ENSG00000232876.1	CTA-212D2.2	-13.04	1.7e-33	9.87e-30	-0.56	-0.51	Red blood cell count;	chr6:135044680	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs13191501	ENSG00000232876.1	CTA-212D2.2	-13.04	1.7e-33	9.87e-30	-0.56	-0.51	Red blood cell count;	chr6:135045742	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs6908512	ENSG00000232876.1	CTA-212D2.2	-13.04	1.7e-33	9.87e-30	-0.56	-0.51	Red blood cell count;	chr6:135046619	chr6:135055033~135060550:+
LUAD	cis	rs12439619	0.693	rs9944185	ENSG00000278603.1	RP13-608F4.5	13.04	1.78e-33	1.03e-29	0.68	0.51	Intelligence (multi-trait analysis);	chr15:82157927	chr15:82472203~82472426:+
LUAD	cis	rs9399135	0.967	rs11755229	ENSG00000232876.1	CTA-212D2.2	-13.03	1.81e-33	1.05e-29	-0.56	-0.51	Red blood cell count;	chr6:135048775	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs9389261	ENSG00000232876.1	CTA-212D2.2	-13.03	1.81e-33	1.05e-29	-0.56	-0.51	Red blood cell count;	chr6:135050010	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs9376085	ENSG00000232876.1	CTA-212D2.2	-13.03	1.81e-33	1.05e-29	-0.56	-0.51	Red blood cell count;	chr6:135050086	chr6:135055033~135060550:+
LUAD	cis	rs7115242	0.8	rs10736487	ENSG00000254851.1	RP11-109L13.1	-13.03	1.83e-33	1.06e-29	-0.87	-0.51	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117079516	chr11:117135528~117138582:+
LUAD	cis	rs2739330	0.685	rs4822453	ENSG00000231271.1	AP000350.8	13.03	1.84e-33	1.06e-29	0.6	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23949918~23954042:+
LUAD	cis	rs6538678	0.824	rs2887026	ENSG00000199506.1	RNU6-247P	-13.03	1.88e-33	1.09e-29	-0.76	-0.51	Lupus nephritis in systemic lupus erythematosus;	chr12:95854713	chr12:95792529~95792635:-
LUAD	cis	rs875971	0.522	rs7784623	ENSG00000226824.5	RP4-756H11.3	-13.03	1.89e-33	1.09e-29	-0.64	-0.51	Aortic root size;	chr7:65930047	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.522	rs34973832	ENSG00000226824.5	RP4-756H11.3	-13.03	1.89e-33	1.09e-29	-0.64	-0.51	Aortic root size;	chr7:65931217	chr7:66654538~66669855:+
LUAD	cis	rs9399135	0.967	rs34546690	ENSG00000232876.1	CTA-212D2.2	-13.03	1.9e-33	1.1e-29	-0.56	-0.51	Red blood cell count;	chr6:135048571	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs9373122	ENSG00000232876.1	CTA-212D2.2	-13.03	1.9e-33	1.1e-29	-0.56	-0.51	Red blood cell count;	chr6:135052396	chr6:135055033~135060550:+
LUAD	cis	rs3091242	0.933	rs3093584	ENSG00000224183.1	SDHDP6	13.03	1.97e-33	1.14e-29	0.65	0.51	Erythrocyte sedimentation rate;	chr1:25342223	chr1:25294164~25294643:-
LUAD	cis	rs9326248	0.53	rs473188	ENSG00000254851.1	RP11-109L13.1	-13.02	1.98e-33	1.14e-29	-0.88	-0.51	Blood protein levels;	chr11:116941313	chr11:117135528~117138582:+
LUAD	cis	rs2882667	0.638	rs6895690	ENSG00000253404.1	AC034243.1	13.02	1.99e-33	1.15e-29	0.64	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139130162	chr5:138744434~138753309:-
LUAD	cis	rs9399135	1	rs6569988	ENSG00000232876.1	CTA-212D2.2	-13.02	2.01e-33	1.16e-29	-0.57	-0.51	Red blood cell count;	chr6:135031165	chr6:135055033~135060550:+
LUAD	cis	rs6538678	0.824	rs4762631	ENSG00000199506.1	RNU6-247P	-13.02	2.1e-33	1.21e-29	-0.76	-0.51	Lupus nephritis in systemic lupus erythematosus;	chr12:95855698	chr12:95792529~95792635:-
LUAD	cis	rs950027	0.549	rs12909409	ENSG00000259520.4	CTD-2651B20.3	13.02	2.18e-33	1.25e-29	0.62	0.51	Response to fenofibrate (adiponectin levels);	chr15:45316384	chr15:45251580~45279251:-
LUAD	cis	rs875971	0.522	rs4718285	ENSG00000226824.5	RP4-756H11.3	-13.01	2.24e-33	1.29e-29	-0.64	-0.51	Aortic root size;	chr7:65827018	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.522	rs4718286	ENSG00000226824.5	RP4-756H11.3	-13.01	2.24e-33	1.29e-29	-0.64	-0.51	Aortic root size;	chr7:65827777	chr7:66654538~66669855:+
LUAD	cis	rs17711722	1	rs17711722	ENSG00000226824.5	RP4-756H11.3	13.01	2.33e-33	1.34e-29	0.64	0.51	Calcium levels;	chr7:65806210	chr7:66654538~66669855:+
LUAD	cis	rs17711722	0.675	rs6947132	ENSG00000226824.5	RP4-756H11.3	13.01	2.33e-33	1.34e-29	0.64	0.51	Calcium levels;	chr7:65808508	chr7:66654538~66669855:+
LUAD	cis	rs10129255	0.536	rs17113249	ENSG00000223648.3	IGHV3-64	13.01	2.35e-33	1.35e-29	0.46	0.51	Kawasaki disease;	chr14:106678273	chr14:106643132~106658258:-
LUAD	cis	rs977987	0.735	rs11149831	ENSG00000261783.1	RP11-252K23.2	-13	2.4e-33	1.38e-29	-0.69	-0.51	Dupuytren's disease;	chr16:75417563	chr16:75379818~75381260:-
LUAD	cis	rs7617773	0.78	rs13082158	ENSG00000229759.1	MRPS18AP1	13	2.41e-33	1.38e-29	0.55	0.51	Coronary artery disease;	chr3:48330980	chr3:48256350~48256938:-
LUAD	cis	rs9399135	0.967	rs7763836	ENSG00000232876.1	CTA-212D2.2	-13	2.43e-33	1.4e-29	-0.56	-0.51	Red blood cell count;	chr6:135041240	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.933	rs28384512	ENSG00000232876.1	CTA-212D2.2	-12.99	2.68e-33	1.54e-29	-0.56	-0.51	Red blood cell count;	chr6:135055094	chr6:135055033~135060550:+
LUAD	cis	rs7104764	0.673	rs3782118	ENSG00000277290.1	RP11-326C3.16	-12.99	2.75e-33	1.57e-29	-0.49	-0.51	Menarche (age at onset);	chr11:222620	chr11:243099~243483:-
LUAD	cis	rs7617773	0.78	rs7645425	ENSG00000229759.1	MRPS18AP1	12.98	2.99e-33	1.7e-29	0.54	0.51	Coronary artery disease;	chr3:48320879	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs6793223	ENSG00000229759.1	MRPS18AP1	12.98	2.99e-33	1.7e-29	0.54	0.51	Coronary artery disease;	chr3:48322611	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs4541431	ENSG00000229759.1	MRPS18AP1	12.98	2.99e-33	1.7e-29	0.54	0.51	Coronary artery disease;	chr3:48323728	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs11714944	ENSG00000229759.1	MRPS18AP1	12.98	2.99e-33	1.7e-29	0.54	0.51	Coronary artery disease;	chr3:48325481	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.743	rs13071960	ENSG00000229759.1	MRPS18AP1	12.98	2.99e-33	1.7e-29	0.54	0.51	Coronary artery disease;	chr3:48326047	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.743	rs4632568	ENSG00000229759.1	MRPS18AP1	12.98	2.99e-33	1.7e-29	0.54	0.51	Coronary artery disease;	chr3:48326329	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs11130164	ENSG00000229759.1	MRPS18AP1	12.98	2.99e-33	1.7e-29	0.54	0.51	Coronary artery disease;	chr3:48327544	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs7653336	ENSG00000229759.1	MRPS18AP1	12.98	2.99e-33	1.7e-29	0.54	0.51	Coronary artery disease;	chr3:48327974	chr3:48256350~48256938:-
LUAD	cis	rs992157	0.735	rs13393821	ENSG00000261338.2	RP11-378A13.1	12.98	3.02e-33	1.72e-29	0.51	0.51	Colorectal cancer;	chr2:218212019	chr2:218255319~218257366:+
LUAD	cis	rs875971	0.516	rs6945322	ENSG00000226824.5	RP4-756H11.3	-12.98	3.02e-33	1.72e-29	-0.64	-0.51	Aortic root size;	chr7:65871069	chr7:66654538~66669855:+
LUAD	cis	rs17711722	0.701	rs55773927	ENSG00000226824.5	RP4-756H11.3	-12.98	3.02e-33	1.72e-29	-0.64	-0.51	Calcium levels;	chr7:65872915	chr7:66654538~66669855:+
LUAD	cis	rs17711722	0.727	rs35850374	ENSG00000226824.5	RP4-756H11.3	-12.98	3.02e-33	1.72e-29	-0.64	-0.51	Calcium levels;	chr7:65892789	chr7:66654538~66669855:+
LUAD	cis	rs1153858	1	rs12593230	ENSG00000259520.4	CTD-2651B20.3	-12.98	3.09e-33	1.76e-29	-0.69	-0.51	Homoarginine levels;	chr15:45354770	chr15:45251580~45279251:-
LUAD	cis	rs992157	0.71	rs56364928	ENSG00000261338.2	RP11-378A13.1	12.98	3.11e-33	1.77e-29	0.51	0.51	Colorectal cancer;	chr2:218194335	chr2:218255319~218257366:+
LUAD	cis	rs7301826	1	rs10744482	ENSG00000256250.1	RP11-989F5.1	-12.98	3.14e-33	1.79e-29	-0.57	-0.51	Plasma plasminogen activator levels;	chr12:130813650	chr12:130810606~130812438:+
LUAD	cis	rs950027	0.549	rs2899375	ENSG00000259520.4	CTD-2651B20.3	12.98	3.17e-33	1.8e-29	0.62	0.51	Response to fenofibrate (adiponectin levels);	chr15:45306137	chr15:45251580~45279251:-
LUAD	cis	rs3091242	0.933	rs61775167	ENSG00000261349.1	RP3-465N24.5	12.98	3.19e-33	1.81e-29	0.56	0.51	Erythrocyte sedimentation rate;	chr1:25454402	chr1:25266102~25267136:-
LUAD	cis	rs992157	0.731	rs1399132	ENSG00000261338.2	RP11-378A13.1	12.98	3.2e-33	1.82e-29	0.51	0.51	Colorectal cancer;	chr2:218295047	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.796	rs55680399	ENSG00000261338.2	RP11-378A13.1	12.98	3.2e-33	1.82e-29	0.51	0.51	Colorectal cancer;	chr2:218295898	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.735	rs13388024	ENSG00000261338.2	RP11-378A13.1	12.97	3.37e-33	1.91e-29	0.51	0.51	Colorectal cancer;	chr2:218233050	chr2:218255319~218257366:+
LUAD	cis	rs10129255	0.518	rs10136903	ENSG00000223648.3	IGHV3-64	12.97	3.45e-33	1.95e-29	0.46	0.51	Kawasaki disease;	chr14:106778866	chr14:106643132~106658258:-
LUAD	cis	rs7301826	0.966	rs4759795	ENSG00000256250.1	RP11-989F5.1	-12.96	3.77e-33	2.13e-29	-0.56	-0.51	Plasma plasminogen activator levels;	chr12:130816355	chr12:130810606~130812438:+
LUAD	cis	rs7617773	0.747	rs34076262	ENSG00000229759.1	MRPS18AP1	12.96	3.79e-33	2.14e-29	0.54	0.51	Coronary artery disease;	chr3:48328926	chr3:48256350~48256938:-
LUAD	cis	rs3091242	0.933	rs9438905	ENSG00000261349.1	RP3-465N24.5	-12.96	3.84e-33	2.17e-29	-0.56	-0.51	Erythrocyte sedimentation rate;	chr1:25437686	chr1:25266102~25267136:-
LUAD	cis	rs3091242	1	rs9689	ENSG00000261349.1	RP3-465N24.5	-12.95	3.91e-33	2.21e-29	-0.55	-0.51	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25266102~25267136:-
LUAD	cis	rs6452524	0.534	rs10514246	ENSG00000249664.1	CTD-2227C6.2	12.95	3.98e-33	2.24e-29	0.58	0.51	Hypertension (SNP x SNP interaction);	chr5:83069979	chr5:83012285~83013109:-
LUAD	cis	rs9399135	0.967	rs13199205	ENSG00000232876.1	CTA-212D2.2	-12.95	4.13e-33	2.33e-29	-0.56	-0.51	Red blood cell count;	chr6:134965367	chr6:135055033~135060550:+
LUAD	cis	rs10129255	0.5	rs988134	ENSG00000223648.3	IGHV3-64	12.95	4.25e-33	2.39e-29	0.46	0.51	Kawasaki disease;	chr14:106776698	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.5	rs988133	ENSG00000223648.3	IGHV3-64	12.95	4.25e-33	2.39e-29	0.46	0.51	Kawasaki disease;	chr14:106776724	chr14:106643132~106658258:-
LUAD	cis	rs9399135	1	rs11754265	ENSG00000232876.1	CTA-212D2.2	-12.94	4.33e-33	2.43e-29	-0.57	-0.51	Red blood cell count;	chr6:135035078	chr6:135055033~135060550:+
LUAD	cis	rs2658782	0.724	rs1869914	ENSG00000279684.1	RP11-755E23.2	-12.94	4.43e-33	2.49e-29	-0.78	-0.51	Pulmonary function decline;	chr11:93379326	chr11:93286629~93288903:-
LUAD	cis	rs992157	0.71	rs10167446	ENSG00000261338.2	RP11-378A13.1	12.94	4.44e-33	2.5e-29	0.51	0.51	Colorectal cancer;	chr2:218192143	chr2:218255319~218257366:+
LUAD	cis	rs17507216	1	rs17356118	ENSG00000278603.1	RP13-608F4.5	12.94	4.46e-33	2.5e-29	0.68	0.51	Excessive daytime sleepiness;	chr15:82569149	chr15:82472203~82472426:+
LUAD	cis	rs10256972	0.577	rs2949179	ENSG00000229043.2	AC091729.9	-12.94	4.52e-33	2.54e-29	-0.53	-0.51	Endometriosis;Longevity;	chr7:1170249	chr7:1160374~1165267:+
LUAD	cis	rs10256972	0.504	rs2949178	ENSG00000229043.2	AC091729.9	-12.94	4.52e-33	2.54e-29	-0.53	-0.51	Endometriosis;Longevity;	chr7:1170289	chr7:1160374~1165267:+
LUAD	cis	rs875971	0.522	rs10807697	ENSG00000226824.5	RP4-756H11.3	-12.94	4.54e-33	2.55e-29	-0.63	-0.51	Aortic root size;	chr7:65951183	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.522	rs2008188	ENSG00000226824.5	RP4-756H11.3	-12.94	4.57e-33	2.56e-29	-0.63	-0.51	Aortic root size;	chr7:65964026	chr7:66654538~66669855:+
LUAD	cis	rs6452524	0.534	rs17284134	ENSG00000249664.1	CTD-2227C6.2	-12.94	4.65e-33	2.61e-29	-0.59	-0.51	Hypertension (SNP x SNP interaction);	chr5:83068325	chr5:83012285~83013109:-
LUAD	cis	rs875971	0.54	rs35510581	ENSG00000226824.5	RP4-756H11.3	12.94	4.67e-33	2.62e-29	0.65	0.51	Aortic root size;	chr7:66113790	chr7:66654538~66669855:+
LUAD	cis	rs7617773	0.676	rs13060020	ENSG00000229759.1	MRPS18AP1	12.94	4.68e-33	2.63e-29	0.54	0.51	Coronary artery disease;	chr3:48331156	chr3:48256350~48256938:-
LUAD	cis	rs9399135	0.816	rs4134030	ENSG00000232876.1	CTA-212D2.2	-12.93	4.77e-33	2.67e-29	-0.56	-0.51	Red blood cell count;	chr6:135032956	chr6:135055033~135060550:+
LUAD	cis	rs10129255	0.518	rs8010020	ENSG00000223648.3	IGHV3-64	12.93	4.79e-33	2.68e-29	0.46	0.51	Kawasaki disease;	chr14:106778016	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.5	rs6576225	ENSG00000223648.3	IGHV3-64	12.93	4.79e-33	2.68e-29	0.46	0.51	Kawasaki disease;	chr14:106778120	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.5	rs6576226	ENSG00000223648.3	IGHV3-64	12.93	4.79e-33	2.68e-29	0.46	0.51	Kawasaki disease;	chr14:106778135	chr14:106643132~106658258:-
LUAD	cis	rs2739330	0.892	rs4822455	ENSG00000250470.1	AP000351.3	12.93	5.03e-33	2.82e-29	0.63	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23976904~23977585:-
LUAD	cis	rs3814244	0.751	rs12832728	ENSG00000255733.4	IFNG-AS1	-12.92	5.26e-33	2.94e-29	-0.43	-0.51	Itch intensity from mosquito bite adjusted by bite size;	chr12:68026623	chr12:67989445~68234686:+
LUAD	cis	rs17711722	0.74	rs7809991	ENSG00000226824.5	RP4-756H11.3	-12.92	5.29e-33	2.96e-29	-0.63	-0.51	Calcium levels;	chr7:65941231	chr7:66654538~66669855:+
LUAD	cis	rs7617773	0.743	rs11716371	ENSG00000229759.1	MRPS18AP1	12.92	5.34e-33	2.99e-29	0.54	0.51	Coronary artery disease;	chr3:48321260	chr3:48256350~48256938:-
LUAD	cis	rs2739330	0.76	rs5751761	ENSG00000225282.1	AP000350.6	-12.92	5.38e-33	3.01e-29	-0.56	-0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23926900~23929574:+
LUAD	cis	rs992157	0.661	rs17653757	ENSG00000261338.2	RP11-378A13.1	12.91	5.83e-33	3.25e-29	0.51	0.51	Colorectal cancer;	chr2:218244641	chr2:218255319~218257366:+
LUAD	cis	rs3091242	0.933	rs34006994	ENSG00000261349.1	RP3-465N24.5	12.91	5.88e-33	3.27e-29	0.56	0.51	Erythrocyte sedimentation rate;	chr1:25454177	chr1:25266102~25267136:-
LUAD	cis	rs3091242	0.902	rs36003018	ENSG00000261349.1	RP3-465N24.5	12.91	5.88e-33	3.27e-29	0.56	0.51	Erythrocyte sedimentation rate;	chr1:25457827	chr1:25266102~25267136:-
LUAD	cis	rs10129255	0.5	rs7161740	ENSG00000223648.3	IGHV3-64	12.91	5.9e-33	3.28e-29	0.46	0.51	Kawasaki disease;	chr14:106776119	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.556	rs6576222	ENSG00000223648.3	IGHV3-64	12.91	5.9e-33	3.28e-29	0.46	0.51	Kawasaki disease;	chr14:106776442	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.536	rs6576223	ENSG00000223648.3	IGHV3-64	12.91	5.9e-33	3.28e-29	0.46	0.51	Kawasaki disease;	chr14:106776448	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.518	rs8009594	ENSG00000223648.3	IGHV3-64	12.91	5.93e-33	3.3e-29	0.46	0.51	Kawasaki disease;	chr14:106777494	chr14:106643132~106658258:-
LUAD	cis	rs6538678	0.824	rs1436120	ENSG00000199506.1	RNU6-247P	12.91	5.95e-33	3.31e-29	0.72	0.51	Lupus nephritis in systemic lupus erythematosus;	chr12:95826872	chr12:95792529~95792635:-
LUAD	cis	rs3091242	0.933	rs10903130	ENSG00000261349.1	RP3-465N24.5	-12.91	6.28e-33	3.48e-29	-0.56	-0.51	Erythrocyte sedimentation rate;	chr1:25442730	chr1:25266102~25267136:-
LUAD	cis	rs3091242	0.933	rs11249251	ENSG00000261349.1	RP3-465N24.5	-12.91	6.28e-33	3.48e-29	-0.56	-0.51	Erythrocyte sedimentation rate;	chr1:25443697	chr1:25266102~25267136:-
LUAD	cis	rs3091242	0.9	rs4649086	ENSG00000261349.1	RP3-465N24.5	-12.91	6.28e-33	3.48e-29	-0.56	-0.51	Erythrocyte sedimentation rate;	chr1:25452476	chr1:25266102~25267136:-
LUAD	cis	rs858239	0.863	rs466225	ENSG00000230658.1	KLHL7-AS1	12.9	6.4e-33	3.55e-29	0.63	0.51	Cerebrospinal fluid biomarker levels;	chr7:23292784	chr7:23101228~23105703:-
LUAD	cis	rs10129255	0.518	rs8009612	ENSG00000223648.3	IGHV3-64	12.9	6.54e-33	3.63e-29	0.46	0.51	Kawasaki disease;	chr14:106777510	chr14:106643132~106658258:-
LUAD	cis	rs3091242	0.933	rs11249250	ENSG00000261349.1	RP3-465N24.5	-12.9	6.56e-33	3.64e-29	-0.56	-0.51	Erythrocyte sedimentation rate;	chr1:25441118	chr1:25266102~25267136:-
LUAD	cis	rs10129255	0.5	rs4774189	ENSG00000223648.3	IGHV3-64	12.9	6.6e-33	3.66e-29	0.46	0.51	Kawasaki disease;	chr14:106768275	chr14:106643132~106658258:-
LUAD	cis	rs1153858	1	rs56850226	ENSG00000259520.4	CTD-2651B20.3	-12.9	6.61e-33	3.66e-29	-0.68	-0.51	Homoarginine levels;	chr15:45340920	chr15:45251580~45279251:-
LUAD	cis	rs2019137	0.56	rs11123172	ENSG00000274877.1	RP11-65I12.1	12.9	6.75e-33	3.74e-29	0.65	0.51	Lymphocyte counts;	chr2:113226726	chr2:113237595~113240825:+
LUAD	cis	rs9399135	0.967	rs6923827	ENSG00000232876.1	CTA-212D2.2	-12.9	6.77e-33	3.75e-29	-0.57	-0.51	Red blood cell count;	chr6:135014244	chr6:135055033~135060550:+
LUAD	cis	rs7301826	1	rs1609985	ENSG00000256250.1	RP11-989F5.1	-12.89	6.94e-33	3.84e-29	-0.56	-0.51	Plasma plasminogen activator levels;	chr12:130835625	chr12:130810606~130812438:+
LUAD	cis	rs1577917	0.958	rs10944136	ENSG00000203875.9	SNHG5	-12.89	6.96e-33	3.85e-29	-0.69	-0.51	Response to antipsychotic treatment;	chr6:85738781	chr6:85660950~85678736:-
LUAD	cis	rs3091242	0.933	rs35403885	ENSG00000261349.1	RP3-465N24.5	12.89	7.05e-33	3.9e-29	0.56	0.51	Erythrocyte sedimentation rate;	chr1:25458060	chr1:25266102~25267136:-
LUAD	cis	rs992157	0.735	rs12990082	ENSG00000261338.2	RP11-378A13.1	12.89	7.12e-33	3.93e-29	0.51	0.51	Colorectal cancer;	chr2:218237609	chr2:218255319~218257366:+
LUAD	cis	rs3091242	0.933	rs35530120	ENSG00000261349.1	RP3-465N24.5	12.89	7.22e-33	3.99e-29	0.56	0.51	Erythrocyte sedimentation rate;	chr1:25458960	chr1:25266102~25267136:-
LUAD	cis	rs992157	0.735	rs2271541	ENSG00000261338.2	RP11-378A13.1	12.89	7.33e-33	4.05e-29	0.51	0.51	Colorectal cancer;	chr2:218217396	chr2:218255319~218257366:+
LUAD	cis	rs2658782	0.789	rs3020076	ENSG00000279684.1	RP11-755E23.2	-12.89	7.33e-33	4.05e-29	-0.77	-0.51	Pulmonary function decline;	chr11:93407892	chr11:93286629~93288903:-
LUAD	cis	rs3091242	0.935	rs4233043	ENSG00000261349.1	RP3-465N24.5	-12.89	7.42e-33	4.09e-29	-0.56	-0.51	Erythrocyte sedimentation rate;	chr1:25438992	chr1:25266102~25267136:-
LUAD	cis	rs9399135	0.967	rs7766189	ENSG00000232876.1	CTA-212D2.2	-12.88	7.77e-33	4.27e-29	-0.56	-0.51	Red blood cell count;	chr6:135032713	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs9402676	ENSG00000232876.1	CTA-212D2.2	-12.88	7.77e-33	4.27e-29	-0.56	-0.51	Red blood cell count;	chr6:135034369	chr6:135055033~135060550:+
LUAD	cis	rs6538678	0.929	rs7962359	ENSG00000258343.1	RP11-536G4.2	-12.88	7.81e-33	4.3e-29	-0.7	-0.51	Lupus nephritis in systemic lupus erythematosus;	chr12:95862566	chr12:95795345~95858839:-
LUAD	cis	rs1153858	0.725	rs74572151	ENSG00000259520.4	CTD-2651B20.3	-12.88	8.11e-33	4.45e-29	-0.68	-0.51	Homoarginine levels;	chr15:45355328	chr15:45251580~45279251:-
LUAD	cis	rs2739330	0.828	rs2186366	ENSG00000250470.1	AP000351.3	-12.88	8.18e-33	4.49e-29	-0.63	-0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23976904~23977585:-
LUAD	cis	rs73086581	0.687	rs73082600	ENSG00000229539.1	RP11-119B16.2	12.88	8.39e-33	4.6e-29	0.75	0.51	Response to antidepressants in depression;	chr20:3863718	chr20:3888239~3888868:-
LUAD	cis	rs2019137	0.539	rs11123170	ENSG00000274877.1	RP11-65I12.1	-12.87	8.44e-33	4.63e-29	-0.65	-0.51	Lymphocyte counts;	chr2:113221363	chr2:113237595~113240825:+
LUAD	cis	rs2019137	0.56	rs7578633	ENSG00000274877.1	RP11-65I12.1	-12.87	8.54e-33	4.68e-29	-0.65	-0.51	Lymphocyte counts;	chr2:113221073	chr2:113237595~113240825:+
LUAD	cis	rs7617773	0.817	rs936426	ENSG00000229759.1	MRPS18AP1	12.87	8.7e-33	4.77e-29	0.51	0.51	Coronary artery disease;	chr3:48173763	chr3:48256350~48256938:-
LUAD	cis	rs1153858	1	rs67831559	ENSG00000259520.4	CTD-2651B20.3	-12.87	8.85e-33	4.85e-29	-0.68	-0.51	Homoarginine levels;	chr15:45357109	chr15:45251580~45279251:-
LUAD	cis	rs6538678	0.746	rs703693	ENSG00000258343.1	RP11-536G4.2	-12.87	8.92e-33	4.88e-29	-0.74	-0.51	Lupus nephritis in systemic lupus erythematosus;	chr12:95866214	chr12:95795345~95858839:-
LUAD	cis	rs1153858	1	rs4774577	ENSG00000259520.4	CTD-2651B20.3	-12.87	9.13e-33	4.98e-29	-0.68	-0.51	Homoarginine levels;	chr15:45352487	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs11070453	ENSG00000259520.4	CTD-2651B20.3	-12.87	9.13e-33	4.98e-29	-0.68	-0.51	Homoarginine levels;	chr15:45352956	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs4774578	ENSG00000259520.4	CTD-2651B20.3	-12.87	9.13e-33	4.98e-29	-0.68	-0.51	Homoarginine levels;	chr15:45353853	chr15:45251580~45279251:-
LUAD	cis	rs61524473	1	rs61524473	ENSG00000259520.4	CTD-2651B20.3	-12.87	9.13e-33	4.98e-29	-0.68	-0.51	Metabolite levels (small molecules and protein measures);	chr15:45354085	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs10444821	ENSG00000259520.4	CTD-2651B20.3	-12.87	9.13e-33	4.98e-29	-0.68	-0.51	Homoarginine levels;	chr15:45355038	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs72623915	ENSG00000259520.4	CTD-2651B20.3	-12.87	9.13e-33	4.98e-29	-0.68	-0.51	Homoarginine levels;	chr15:45355235	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs66714503	ENSG00000259520.4	CTD-2651B20.3	-12.87	9.13e-33	4.98e-29	-0.68	-0.51	Homoarginine levels;	chr15:45355840	chr15:45251580~45279251:-
LUAD	cis	rs3091242	0.933	rs10903129	ENSG00000224183.1	SDHDP6	-12.86	1.01e-32	5.48e-29	-0.64	-0.51	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25294164~25294643:-
LUAD	cis	rs992157	0.735	rs13430006	ENSG00000261338.2	RP11-378A13.1	-12.86	1.01e-32	5.48e-29	-0.51	-0.51	Colorectal cancer;	chr2:218248366	chr2:218255319~218257366:+
LUAD	cis	rs3091242	0.933	rs34933589	ENSG00000261349.1	RP3-465N24.5	12.85	1.02e-32	5.56e-29	0.56	0.51	Erythrocyte sedimentation rate;	chr1:25461707	chr1:25266102~25267136:-
LUAD	cis	rs875971	0.522	rs6960048	ENSG00000226824.5	RP4-756H11.3	-12.85	1.05e-32	5.71e-29	-0.63	-0.51	Aortic root size;	chr7:65943052	chr7:66654538~66669855:+
LUAD	cis	rs9399135	0.967	rs9389258	ENSG00000232876.1	CTA-212D2.2	-12.85	1.05e-32	5.72e-29	-0.56	-0.51	Red blood cell count;	chr6:135040002	chr6:135055033~135060550:+
LUAD	cis	rs11155671	0.53	rs9371215	ENSG00000231760.4	RP11-350J20.5	12.84	1.13e-32	6.11e-29	0.63	0.51	Testicular germ cell tumor;	chr6:149873162	chr6:149796151~149826294:-
LUAD	cis	rs3091242	0.867	rs602052	ENSG00000224183.1	SDHDP6	-12.84	1.16e-32	6.3e-29	-0.64	-0.51	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25294164~25294643:-
LUAD	cis	rs9326248	0.53	rs7950364	ENSG00000254851.1	RP11-109L13.1	-12.84	1.17e-32	6.35e-29	-0.88	-0.51	Blood protein levels;	chr11:117028170	chr11:117135528~117138582:+
LUAD	cis	rs992157	0.798	rs4996257	ENSG00000261338.2	RP11-378A13.1	12.84	1.2e-32	6.48e-29	0.51	0.51	Colorectal cancer;	chr2:218298113	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.687	rs35271699	ENSG00000261338.2	RP11-378A13.1	12.84	1.22e-32	6.62e-29	0.51	0.51	Colorectal cancer;	chr2:218252759	chr2:218255319~218257366:+
LUAD	cis	rs7301826	1	rs4759787	ENSG00000256299.1	RP11-989F5.3	-12.83	1.25e-32	6.73e-29	-0.55	-0.51	Plasma plasminogen activator levels;	chr12:130805635	chr12:130810821~130812622:-
LUAD	cis	rs7195287	0.826	rs9925824	ENSG00000276791.1	CTD-2270P14.5	-12.83	1.26e-32	6.81e-29	-0.62	-0.51	Eosinophil counts;	chr16:2777972	chr16:2777319~2780568:+
LUAD	cis	rs992157	0.71	rs13026485	ENSG00000261338.2	RP11-378A13.1	-12.83	1.28e-32	6.94e-29	-0.51	-0.5	Colorectal cancer;	chr2:218193261	chr2:218255319~218257366:+
LUAD	cis	rs3091242	0.804	rs631133	ENSG00000224183.1	SDHDP6	-12.83	1.31e-32	7.06e-29	-0.64	-0.5	Erythrocyte sedimentation rate;	chr1:25397655	chr1:25294164~25294643:-
LUAD	cis	rs2658782	0.789	rs2259633	ENSG00000279684.1	RP11-755E23.2	-12.83	1.32e-32	7.15e-29	-0.78	-0.5	Pulmonary function decline;	chr11:93408414	chr11:93286629~93288903:-
LUAD	cis	rs7301826	1	rs7301826	ENSG00000256299.1	RP11-989F5.3	-12.83	1.35e-32	7.28e-29	-0.55	-0.5	Plasma plasminogen activator levels;	chr12:130806556	chr12:130810821~130812622:-
LUAD	cis	rs10256972	0.567	rs2949185	ENSG00000229043.2	AC091729.9	-12.82	1.39e-32	7.51e-29	-0.55	-0.5	Endometriosis;Longevity;	chr7:1169377	chr7:1160374~1165267:+
LUAD	cis	rs6538678	0.746	rs12820313	ENSG00000258343.1	RP11-536G4.2	-12.82	1.4e-32	7.52e-29	-0.71	-0.5	Lupus nephritis in systemic lupus erythematosus;	chr12:95861926	chr12:95795345~95858839:-
LUAD	cis	rs2658782	0.951	rs2608214	ENSG00000279684.1	RP11-755E23.2	-12.82	1.45e-32	7.81e-29	-0.79	-0.5	Pulmonary function decline;	chr11:93415499	chr11:93286629~93288903:-
LUAD	cis	rs2658782	0.901	rs11604909	ENSG00000279684.1	RP11-755E23.2	-12.82	1.45e-32	7.81e-29	-0.81	-0.5	Pulmonary function decline;	chr11:93485189	chr11:93286629~93288903:-
LUAD	cis	rs7301826	1	rs10773822	ENSG00000256299.1	RP11-989F5.3	-12.82	1.48e-32	7.95e-29	-0.55	-0.5	Plasma plasminogen activator levels;	chr12:130804562	chr12:130810821~130812622:-
LUAD	cis	rs7617773	1	rs12496784	ENSG00000229759.1	MRPS18AP1	-12.82	1.48e-32	7.96e-29	-0.5	-0.5	Coronary artery disease;	chr3:48144777	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs11710257	ENSG00000229759.1	MRPS18AP1	12.81	1.51e-32	8.11e-29	0.54	0.5	Coronary artery disease;	chr3:48331724	chr3:48256350~48256938:-
LUAD	cis	rs4853012	0.838	rs72915068	ENSG00000217702.2	RP11-287D1.4	12.81	1.53e-32	8.2e-29	0.78	0.5	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74130583~74135395:+
LUAD	cis	rs10256972	0.552	rs2949195	ENSG00000229043.2	AC091729.9	-12.81	1.56e-32	8.35e-29	-0.55	-0.5	Endometriosis;Longevity;	chr7:1163069	chr7:1160374~1165267:+
LUAD	cis	rs10129255	0.5	rs8004923	ENSG00000223648.3	IGHV3-64	12.81	1.56e-32	8.39e-29	0.45	0.5	Kawasaki disease;	chr14:106785926	chr14:106643132~106658258:-
LUAD	cis	rs7617773	0.78	rs13084616	ENSG00000229759.1	MRPS18AP1	-12.81	1.62e-32	8.67e-29	-0.53	-0.5	Coronary artery disease;	chr3:48298209	chr3:48256350~48256938:-
LUAD	cis	rs12439619	0.693	rs8034801	ENSG00000278603.1	RP13-608F4.5	12.81	1.63e-32	8.73e-29	0.69	0.5	Intelligence (multi-trait analysis);	chr15:82183996	chr15:82472203~82472426:+
LUAD	cis	rs992157	0.71	rs10169718	ENSG00000261338.2	RP11-378A13.1	-12.81	1.65e-32	8.82e-29	-0.5	-0.5	Colorectal cancer;	chr2:218238857	chr2:218255319~218257366:+
LUAD	cis	rs3091242	0.934	rs686631	ENSG00000224183.1	SDHDP6	-12.81	1.65e-32	8.84e-29	-0.63	-0.5	Erythrocyte sedimentation rate;	chr1:25393108	chr1:25294164~25294643:-
LUAD	cis	rs73086581	0.947	rs67356712	ENSG00000229539.1	RP11-119B16.2	12.8	1.66e-32	8.92e-29	0.71	0.5	Response to antidepressants in depression;	chr20:3912239	chr20:3888239~3888868:-
LUAD	cis	rs7617773	0.78	rs71323395	ENSG00000229759.1	MRPS18AP1	12.8	1.68e-32	8.97e-29	0.54	0.5	Coronary artery disease;	chr3:48332587	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.743	rs71323397	ENSG00000229759.1	MRPS18AP1	12.8	1.68e-32	8.97e-29	0.54	0.5	Coronary artery disease;	chr3:48333384	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.778	rs11715776	ENSG00000229759.1	MRPS18AP1	12.8	1.68e-32	8.97e-29	0.54	0.5	Coronary artery disease;	chr3:48336121	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.778	rs11707997	ENSG00000229759.1	MRPS18AP1	12.8	1.68e-32	8.97e-29	0.54	0.5	Coronary artery disease;	chr3:48336385	chr3:48256350~48256938:-
LUAD	cis	rs10129255	0.5	rs6576232	ENSG00000223648.3	IGHV3-64	12.8	1.68e-32	9e-29	0.45	0.5	Kawasaki disease;	chr14:106787090	chr14:106643132~106658258:-
LUAD	cis	rs9399135	0.933	rs9389262	ENSG00000232876.1	CTA-212D2.2	-12.8	1.71e-32	9.09e-29	-0.55	-0.5	Red blood cell count;	chr6:135055271	chr6:135055033~135060550:+
LUAD	cis	rs3091242	0.933	rs9645452	ENSG00000224183.1	SDHDP6	12.8	1.76e-32	9.35e-29	0.64	0.5	Erythrocyte sedimentation rate;	chr1:25341835	chr1:25294164~25294643:-
LUAD	cis	rs858239	0.698	rs4265084	ENSG00000230658.1	KLHL7-AS1	12.8	1.8e-32	9.59e-29	0.62	0.5	Cerebrospinal fluid biomarker levels;	chr7:23367621	chr7:23101228~23105703:-
LUAD	cis	rs3091242	0.933	rs10903129	ENSG00000261349.1	RP3-465N24.5	-12.79	1.82e-32	9.66e-29	-0.55	-0.5	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25266102~25267136:-
LUAD	cis	rs9399135	0.967	rs9321481	ENSG00000232876.1	CTA-212D2.2	12.79	1.82e-32	9.69e-29	0.55	0.5	Red blood cell count;	chr6:135031510	chr6:135055033~135060550:+
LUAD	cis	rs4853012	0.752	rs13413795	ENSG00000217702.2	RP11-287D1.4	12.79	1.84e-32	9.79e-29	0.77	0.5	Gestational age at birth (maternal effect);	chr2:74122712	chr2:74130583~74135395:+
LUAD	cis	rs9399135	0.967	rs59329760	ENSG00000232876.1	CTA-212D2.2	-12.79	1.92e-32	1.02e-28	-0.56	-0.5	Red blood cell count;	chr6:135021299	chr6:135055033~135060550:+
LUAD	cis	rs12439619	0.693	rs17269819	ENSG00000278603.1	RP13-608F4.5	12.79	1.95e-32	1.03e-28	0.69	0.5	Intelligence (multi-trait analysis);	chr15:82174660	chr15:82472203~82472426:+
LUAD	cis	rs9399135	0.967	rs10872427	ENSG00000232876.1	CTA-212D2.2	-12.79	1.95e-32	1.04e-28	-0.55	-0.5	Red blood cell count;	chr6:135032314	chr6:135055033~135060550:+
LUAD	cis	rs4423214	0.65	rs2186777	ENSG00000254682.1	RP11-660L16.2	12.79	1.96e-32	1.04e-28	0.69	0.5	Vitamin D levels;	chr11:71508757	chr11:71448674~71452157:+
LUAD	cis	rs6538678	0.929	rs10777744	ENSG00000258343.1	RP11-536G4.2	-12.79	1.97e-32	1.05e-28	-0.7	-0.5	Lupus nephritis in systemic lupus erythematosus;	chr12:95864561	chr12:95795345~95858839:-
LUAD	cis	rs9399135	0.967	rs6909975	ENSG00000232876.1	CTA-212D2.2	-12.78	2.02e-32	1.07e-28	-0.56	-0.5	Red blood cell count;	chr6:134994432	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs7773126	ENSG00000232876.1	CTA-212D2.2	-12.78	2.02e-32	1.07e-28	-0.56	-0.5	Red blood cell count;	chr6:134997252	chr6:135055033~135060550:+
LUAD	cis	rs1153858	1	rs2066090	ENSG00000259520.4	CTD-2651B20.3	-12.78	2.04e-32	1.08e-28	-0.68	-0.5	Homoarginine levels;	chr15:45357820	chr15:45251580~45279251:-
LUAD	cis	rs3091242	0.933	rs7541095	ENSG00000261349.1	RP3-465N24.5	-12.78	2.18e-32	1.15e-28	-0.55	-0.5	Erythrocyte sedimentation rate;	chr1:25434800	chr1:25266102~25267136:-
LUAD	cis	rs67383717	0.643	rs72756397	ENSG00000175611.10	LINC00476	-12.77	2.23e-32	1.18e-28	-0.53	-0.5	Parkinson's disease (pesticide exposure interaction);	chr9:95790861	chr9:95759231~95875977:-
LUAD	cis	rs6538678	0.929	rs10745733	ENSG00000258343.1	RP11-536G4.2	-12.77	2.27e-32	1.2e-28	-0.7	-0.5	Lupus nephritis in systemic lupus erythematosus;	chr12:95868728	chr12:95795345~95858839:-
LUAD	cis	rs6538678	0.926	rs10745734	ENSG00000258343.1	RP11-536G4.2	-12.77	2.27e-32	1.2e-28	-0.7	-0.5	Lupus nephritis in systemic lupus erythematosus;	chr12:95868936	chr12:95795345~95858839:-
LUAD	cis	rs7617773	0.925	rs6442105	ENSG00000229759.1	MRPS18AP1	-12.77	2.39e-32	1.26e-28	-0.51	-0.5	Coronary artery disease;	chr3:48140836	chr3:48256350~48256938:-
LUAD	cis	rs9399135	0.935	rs4445070	ENSG00000232876.1	CTA-212D2.2	-12.77	2.42e-32	1.27e-28	-0.55	-0.5	Red blood cell count;	chr6:134988074	chr6:135055033~135060550:+
LUAD	cis	rs6538678	0.818	rs7976294	ENSG00000199506.1	RNU6-247P	-12.76	2.52e-32	1.32e-28	-0.71	-0.5	Lupus nephritis in systemic lupus erythematosus;	chr12:95876868	chr12:95792529~95792635:-
LUAD	cis	rs6538678	0.818	rs1036429	ENSG00000199506.1	RNU6-247P	-12.76	2.52e-32	1.32e-28	-0.71	-0.5	Lupus nephritis in systemic lupus erythematosus;	chr12:95877650	chr12:95792529~95792635:-
LUAD	cis	rs7301826	0.967	rs4759792	ENSG00000256299.1	RP11-989F5.3	-12.76	2.52e-32	1.33e-28	-0.55	-0.5	Plasma plasminogen activator levels;	chr12:130812086	chr12:130810821~130812622:-
LUAD	cis	rs6538678	0.864	rs10777747	ENSG00000258343.1	RP11-536G4.2	-12.76	2.54e-32	1.34e-28	-0.68	-0.5	Lupus nephritis in systemic lupus erythematosus;	chr12:95870192	chr12:95795345~95858839:-
LUAD	cis	rs9399135	0.967	rs6919862	ENSG00000232876.1	CTA-212D2.2	-12.76	2.62e-32	1.38e-28	-0.55	-0.5	Red blood cell count;	chr6:135031305	chr6:135055033~135060550:+
LUAD	cis	rs7301826	0.966	rs10734980	ENSG00000256299.1	RP11-989F5.3	-12.76	2.62e-32	1.38e-28	-0.55	-0.5	Plasma plasminogen activator levels;	chr12:130810081	chr12:130810821~130812622:-
LUAD	cis	rs7301826	1	rs4759793	ENSG00000256299.1	RP11-989F5.3	-12.76	2.62e-32	1.38e-28	-0.55	-0.5	Plasma plasminogen activator levels;	chr12:130812693	chr12:130810821~130812622:-
LUAD	cis	rs3091242	0.933	rs909833	ENSG00000261349.1	RP3-465N24.5	-12.76	2.65e-32	1.39e-28	-0.56	-0.5	Erythrocyte sedimentation rate;	chr1:25427649	chr1:25266102~25267136:-
LUAD	cis	rs1153858	1	rs16952714	ENSG00000259520.4	CTD-2651B20.3	-12.75	2.68e-32	1.41e-28	-0.68	-0.5	Homoarginine levels;	chr15:45358160	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs12101539	ENSG00000259520.4	CTD-2651B20.3	-12.75	2.68e-32	1.41e-28	-0.68	-0.5	Homoarginine levels;	chr15:45358468	chr15:45251580~45279251:-
LUAD	cis	rs9399135	0.967	rs9376082	ENSG00000232876.1	CTA-212D2.2	-12.75	2.68e-32	1.41e-28	-0.56	-0.5	Red blood cell count;	chr6:135025251	chr6:135055033~135060550:+
LUAD	cis	rs7301826	1	rs1106369	ENSG00000256299.1	RP11-989F5.3	-12.75	2.85e-32	1.49e-28	-0.54	-0.5	Plasma plasminogen activator levels;	chr12:130815550	chr12:130810821~130812622:-
LUAD	cis	rs2739330	0.892	rs5751776	ENSG00000231271.1	AP000350.8	12.75	2.88e-32	1.51e-28	0.6	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23949918~23954042:+
LUAD	cis	rs7617773	0.707	rs13061269	ENSG00000229759.1	MRPS18AP1	12.75	2.89e-32	1.51e-28	0.54	0.5	Coronary artery disease;	chr3:48331853	chr3:48256350~48256938:-
LUAD	cis	rs3091242	0.933	rs28633797	ENSG00000224183.1	SDHDP6	-12.75	2.89e-32	1.52e-28	-0.64	-0.5	Erythrocyte sedimentation rate;	chr1:25415138	chr1:25294164~25294643:-
LUAD	cis	rs3091242	0.933	rs35497030	ENSG00000224183.1	SDHDP6	12.74	2.96e-32	1.55e-28	0.64	0.5	Erythrocyte sedimentation rate;	chr1:25456575	chr1:25294164~25294643:-
LUAD	cis	rs1153858	0.943	rs28605551	ENSG00000259520.4	CTD-2651B20.3	-12.74	3e-32	1.57e-28	-0.67	-0.5	Homoarginine levels;	chr15:45349522	chr15:45251580~45279251:-
LUAD	cis	rs1799949	0.965	rs4793230	ENSG00000198496.9	NBR2	-12.74	3.05e-32	1.6e-28	-0.52	-0.5	Menopause (age at onset);	chr17:43350035	chr17:43125610~43153671:+
LUAD	cis	rs992157	0.798	rs10932772	ENSG00000261338.2	RP11-378A13.1	12.74	3.07e-32	1.6e-28	0.51	0.5	Colorectal cancer;	chr2:218312425	chr2:218255319~218257366:+
LUAD	cis	rs507080	0.922	rs558781	ENSG00000255422.1	AP002954.4	-12.74	3.12e-32	1.63e-28	-0.64	-0.5	Serum metabolite levels;	chr11:118693688	chr11:118704607~118750263:+
LUAD	cis	rs7617773	0.78	rs13066044	ENSG00000229759.1	MRPS18AP1	12.74	3.22e-32	1.68e-28	0.54	0.5	Coronary artery disease;	chr3:48335786	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.78	rs11716848	ENSG00000229759.1	MRPS18AP1	12.74	3.22e-32	1.68e-28	0.54	0.5	Coronary artery disease;	chr3:48337010	chr3:48256350~48256938:-
LUAD	cis	rs3091242	0.967	rs665372	ENSG00000224183.1	SDHDP6	-12.73	3.26e-32	1.7e-28	-0.64	-0.5	Erythrocyte sedimentation rate;	chr1:25392744	chr1:25294164~25294643:-
LUAD	cis	rs7617773	0.817	rs745116	ENSG00000229759.1	MRPS18AP1	12.73	3.28e-32	1.71e-28	0.51	0.5	Coronary artery disease;	chr3:48231046	chr3:48256350~48256938:-
LUAD	cis	rs55794721	0.509	rs11249248	ENSG00000261349.1	RP3-465N24.5	-12.73	3.36e-32	1.75e-28	-0.55	-0.5	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25266102~25267136:-
LUAD	cis	rs9326248	0.53	rs10732856	ENSG00000254851.1	RP11-109L13.1	-12.73	3.4e-32	1.77e-28	-0.85	-0.5	Blood protein levels;	chr11:117036397	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.53	rs2513095	ENSG00000254851.1	RP11-109L13.1	-12.73	3.49e-32	1.82e-28	-0.88	-0.5	Blood protein levels;	chr11:116935553	chr11:117135528~117138582:+
LUAD	cis	rs7617773	0.78	rs34523942	ENSG00000229759.1	MRPS18AP1	12.72	3.79e-32	1.97e-28	0.52	0.5	Coronary artery disease;	chr3:48301179	chr3:48256350~48256938:-
LUAD	cis	rs7617773	1	rs9832957	ENSG00000229759.1	MRPS18AP1	-12.72	3.8e-32	1.97e-28	-0.51	-0.5	Coronary artery disease;	chr3:48143776	chr3:48256350~48256938:-
LUAD	cis	rs4423214	1	rs4944062	ENSG00000254682.1	RP11-660L16.2	12.72	3.83e-32	1.99e-28	0.66	0.5	Vitamin D levels;	chr11:71476248	chr11:71448674~71452157:+
LUAD	cis	rs10129255	0.556	rs8010005	ENSG00000223648.3	IGHV3-64	12.72	3.86e-32	2e-28	0.46	0.5	Kawasaki disease;	chr14:106777987	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.556	rs6576224	ENSG00000223648.3	IGHV3-64	12.72	3.86e-32	2e-28	0.46	0.5	Kawasaki disease;	chr14:106777997	chr14:106643132~106658258:-
LUAD	cis	rs2739330	0.76	rs5760095	ENSG00000225282.1	AP000350.6	12.72	3.87e-32	2.01e-28	0.59	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23926900~23929574:+
LUAD	cis	rs1153858	1	rs61365925	ENSG00000259520.4	CTD-2651B20.3	-12.72	3.9e-32	2.02e-28	-0.68	-0.5	Homoarginine levels;	chr15:45358113	chr15:45251580~45279251:-
LUAD	cis	rs3091242	0.933	rs61775174	ENSG00000224183.1	SDHDP6	12.71	3.97e-32	2.06e-28	0.64	0.5	Erythrocyte sedimentation rate;	chr1:25460822	chr1:25294164~25294643:-
LUAD	cis	rs12439619	0.693	rs28689861	ENSG00000278603.1	RP13-608F4.5	12.71	3.98e-32	2.06e-28	0.69	0.5	Intelligence (multi-trait analysis);	chr15:82206369	chr15:82472203~82472426:+
LUAD	cis	rs9399135	0.967	rs6902954	ENSG00000232876.1	CTA-212D2.2	-12.71	4e-32	2.07e-28	-0.55	-0.5	Red blood cell count;	chr6:134992856	chr6:135055033~135060550:+
LUAD	cis	rs992157	0.732	rs10932771	ENSG00000261338.2	RP11-378A13.1	12.71	4.15e-32	2.15e-28	0.5	0.5	Colorectal cancer;	chr2:218305513	chr2:218255319~218257366:+
LUAD	cis	rs1153858	1	rs4775909	ENSG00000259520.4	CTD-2651B20.3	-12.71	4.15e-32	2.15e-28	-0.68	-0.5	Homoarginine levels;	chr15:45350844	chr15:45251580~45279251:-
LUAD	cis	rs875971	0.522	rs9530	ENSG00000226824.5	RP4-756H11.3	-12.71	4.16e-32	2.15e-28	-0.63	-0.5	Aortic root size;	chr7:65960907	chr7:66654538~66669855:+
LUAD	cis	rs9399135	1	rs4475342	ENSG00000232876.1	CTA-212D2.2	-12.71	4.21e-32	2.17e-28	-0.56	-0.5	Red blood cell count;	chr6:134962210	chr6:135055033~135060550:+
LUAD	cis	rs3091242	0.933	rs7541095	ENSG00000224183.1	SDHDP6	-12.71	4.26e-32	2.2e-28	-0.63	-0.5	Erythrocyte sedimentation rate;	chr1:25434800	chr1:25294164~25294643:-
LUAD	cis	rs507080	0.883	rs558593	ENSG00000255422.1	AP002954.4	-12.71	4.28e-32	2.21e-28	-0.63	-0.5	Serum metabolite levels;	chr11:118691811	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.922	rs592280	ENSG00000255422.1	AP002954.4	-12.7	4.36e-32	2.25e-28	-0.62	-0.5	Serum metabolite levels;	chr11:118682509	chr11:118704607~118750263:+
LUAD	cis	rs2882667	0.66	rs6894907	ENSG00000253404.1	AC034243.1	12.7	4.4e-32	2.27e-28	0.61	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106815	chr5:138744434~138753309:-
LUAD	cis	rs9399135	0.967	rs4896125	ENSG00000232876.1	CTA-212D2.2	-12.7	4.46e-32	2.3e-28	-0.55	-0.5	Red blood cell count;	chr6:135021431	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.935	rs949547	ENSG00000232876.1	CTA-212D2.2	-12.7	4.46e-32	2.3e-28	-0.55	-0.5	Red blood cell count;	chr6:135022361	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.935	rs2150680	ENSG00000232876.1	CTA-212D2.2	-12.7	4.46e-32	2.3e-28	-0.55	-0.5	Red blood cell count;	chr6:135025993	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs11756988	ENSG00000232876.1	CTA-212D2.2	-12.7	4.46e-32	2.3e-28	-0.55	-0.5	Red blood cell count;	chr6:135026457	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs11754783	ENSG00000232876.1	CTA-212D2.2	-12.7	4.46e-32	2.3e-28	-0.55	-0.5	Red blood cell count;	chr6:135026523	chr6:135055033~135060550:+
LUAD	cis	rs9326248	0.53	rs510988	ENSG00000254851.1	RP11-109L13.1	-12.7	4.55e-32	2.34e-28	-0.88	-0.5	Blood protein levels;	chr11:116943088	chr11:117135528~117138582:+
LUAD	cis	rs7115242	0.669	rs1241658	ENSG00000254851.1	RP11-109L13.1	-12.7	4.55e-32	2.34e-28	-0.88	-0.5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116948901	chr11:117135528~117138582:+
LUAD	cis	rs10129255	0.5	rs11628999	ENSG00000223648.3	IGHV3-64	12.7	4.63e-32	2.38e-28	0.45	0.5	Kawasaki disease;	chr14:106800208	chr14:106643132~106658258:-
LUAD	cis	rs2019137	0.56	rs10206269	ENSG00000274877.1	RP11-65I12.1	-12.7	4.71e-32	2.42e-28	-0.64	-0.5	Lymphocyte counts;	chr2:113232816	chr2:113237595~113240825:+
LUAD	cis	rs10256972	0.552	rs7805591	ENSG00000229043.2	AC091729.9	-12.7	4.73e-32	2.43e-28	-0.55	-0.5	Endometriosis;Longevity;	chr7:1171109	chr7:1160374~1165267:+
LUAD	cis	rs67383717	0.643	rs10759883	ENSG00000175611.10	LINC00476	-12.69	4.83e-32	2.48e-28	-0.54	-0.5	Parkinson's disease (pesticide exposure interaction);	chr9:95790481	chr9:95759231~95875977:-
LUAD	cis	rs7617773	0.78	rs13090538	ENSG00000229759.1	MRPS18AP1	12.69	4.91e-32	2.52e-28	0.53	0.5	Coronary artery disease;	chr3:48329279	chr3:48256350~48256938:-
LUAD	cis	rs7104764	0.778	rs7930823	ENSG00000277290.1	RP11-326C3.16	12.69	4.93e-32	2.53e-28	0.47	0.5	Menarche (age at onset);	chr11:206767	chr11:243099~243483:-
LUAD	cis	rs10256972	0.567	rs2960835	ENSG00000229043.2	AC091729.9	-12.69	4.93e-32	2.53e-28	-0.55	-0.5	Endometriosis;Longevity;	chr7:1163327	chr7:1160374~1165267:+
LUAD	cis	rs1577917	0.958	rs12216074	ENSG00000203875.9	SNHG5	-12.69	4.94e-32	2.54e-28	-0.67	-0.5	Response to antipsychotic treatment;	chr6:85810284	chr6:85660950~85678736:-
LUAD	cis	rs9399135	0.967	rs2297338	ENSG00000232876.1	CTA-212D2.2	-12.69	4.96e-32	2.54e-28	-0.55	-0.5	Red blood cell count;	chr6:135054624	chr6:135055033~135060550:+
LUAD	cis	rs2739330	0.731	rs2000468	ENSG00000231271.1	AP000350.8	12.69	5.03e-32	2.58e-28	0.58	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23949918~23954042:+
LUAD	cis	rs9399135	0.967	rs2297340	ENSG00000232876.1	CTA-212D2.2	-12.69	5.11e-32	2.62e-28	-0.55	-0.5	Red blood cell count;	chr6:135054920	chr6:135055033~135060550:+
LUAD	cis	rs17507216	1	rs17158413	ENSG00000278603.1	RP13-608F4.5	12.68	5.3e-32	2.71e-28	0.67	0.5	Excessive daytime sleepiness;	chr15:82566658	chr15:82472203~82472426:+
LUAD	cis	rs977987	0.868	rs10871313	ENSG00000261783.1	RP11-252K23.2	-12.68	5.3e-32	2.71e-28	-0.69	-0.5	Dupuytren's disease;	chr16:75473196	chr16:75379818~75381260:-
LUAD	cis	rs3091242	0.933	rs10903130	ENSG00000224183.1	SDHDP6	-12.68	5.36e-32	2.74e-28	-0.63	-0.5	Erythrocyte sedimentation rate;	chr1:25442730	chr1:25294164~25294643:-
LUAD	cis	rs3091242	0.933	rs11249251	ENSG00000224183.1	SDHDP6	-12.68	5.36e-32	2.74e-28	-0.63	-0.5	Erythrocyte sedimentation rate;	chr1:25443697	chr1:25294164~25294643:-
LUAD	cis	rs3091242	0.9	rs4649086	ENSG00000224183.1	SDHDP6	-12.68	5.36e-32	2.74e-28	-0.63	-0.5	Erythrocyte sedimentation rate;	chr1:25452476	chr1:25294164~25294643:-
LUAD	cis	rs3091242	0.933	rs9438904	ENSG00000261349.1	RP3-465N24.5	-12.68	5.4e-32	2.76e-28	-0.55	-0.5	Erythrocyte sedimentation rate;	chr1:25430369	chr1:25266102~25267136:-
LUAD	cis	rs9399135	0.904	rs4895438	ENSG00000232876.1	CTA-212D2.2	-12.68	5.48e-32	2.8e-28	-0.55	-0.5	Red blood cell count;	chr6:134996527	chr6:135055033~135060550:+
LUAD	cis	rs1799949	0.965	rs6503727	ENSG00000198496.9	NBR2	-12.68	5.48e-32	2.8e-28	-0.52	-0.5	Menopause (age at onset);	chr17:43160842	chr17:43125610~43153671:+
LUAD	cis	rs9399135	0.967	rs2183709	ENSG00000232876.1	CTA-212D2.2	-12.68	5.66e-32	2.89e-28	-0.55	-0.5	Red blood cell count;	chr6:135055953	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs4142299	ENSG00000232876.1	CTA-212D2.2	-12.68	5.66e-32	2.89e-28	-0.55	-0.5	Red blood cell count;	chr6:135056048	chr6:135055033~135060550:+
LUAD	cis	rs7617773	0.78	rs35297486	ENSG00000229759.1	MRPS18AP1	12.68	5.7e-32	2.91e-28	0.54	0.5	Coronary artery disease;	chr3:48336657	chr3:48256350~48256938:-
LUAD	cis	rs9399135	0.967	rs6915770	ENSG00000232876.1	CTA-212D2.2	-12.67	5.82e-32	2.96e-28	-0.55	-0.5	Red blood cell count;	chr6:135048076	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.935	rs9376086	ENSG00000232876.1	CTA-212D2.2	-12.67	5.82e-32	2.96e-28	-0.55	-0.5	Red blood cell count;	chr6:135050191	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs1041480	ENSG00000232876.1	CTA-212D2.2	-12.67	5.82e-32	2.96e-28	-0.55	-0.5	Red blood cell count;	chr6:135051938	chr6:135055033~135060550:+
LUAD	cis	rs9326248	0.53	rs511676	ENSG00000254851.1	RP11-109L13.1	-12.67	5.85e-32	2.98e-28	-0.88	-0.5	Blood protein levels;	chr11:116954168	chr11:117135528~117138582:+
LUAD	cis	rs2019137	0.56	rs7421852	ENSG00000274877.1	RP11-65I12.1	-12.67	5.89e-32	3e-28	-0.64	-0.5	Lymphocyte counts;	chr2:113232684	chr2:113237595~113240825:+
LUAD	cis	rs10129255	0.518	rs2006284	ENSG00000223648.3	IGHV3-64	12.67	5.91e-32	3.01e-28	0.46	0.5	Kawasaki disease;	chr14:106676185	chr14:106643132~106658258:-
LUAD	cis	rs9399135	0.967	rs2327580	ENSG00000232876.1	CTA-212D2.2	-12.67	5.92e-32	3.01e-28	-0.55	-0.5	Red blood cell count;	chr6:135043279	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.844	rs13209789	ENSG00000232876.1	CTA-212D2.2	-12.67	5.92e-32	3.01e-28	-0.55	-0.5	Red blood cell count;	chr6:135046778	chr6:135055033~135060550:+
LUAD	cis	rs3091242	0.933	rs34006994	ENSG00000224183.1	SDHDP6	12.67	6.07e-32	3.08e-28	0.63	0.5	Erythrocyte sedimentation rate;	chr1:25454177	chr1:25294164~25294643:-
LUAD	cis	rs3091242	0.902	rs36003018	ENSG00000224183.1	SDHDP6	12.67	6.07e-32	3.08e-28	0.63	0.5	Erythrocyte sedimentation rate;	chr1:25457827	chr1:25294164~25294643:-
LUAD	cis	rs3091242	0.933	rs35530120	ENSG00000224183.1	SDHDP6	12.67	6.16e-32	3.13e-28	0.63	0.5	Erythrocyte sedimentation rate;	chr1:25458960	chr1:25294164~25294643:-
LUAD	cis	rs7617773	0.963	rs6766754	ENSG00000229759.1	MRPS18AP1	-12.67	6.27e-32	3.18e-28	-0.5	-0.5	Coronary artery disease;	chr3:48141099	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.832	rs6775114	ENSG00000229759.1	MRPS18AP1	-12.67	6.27e-32	3.18e-28	-0.5	-0.5	Coronary artery disease;	chr3:48141130	chr3:48256350~48256938:-
LUAD	cis	rs992157	0.71	rs12694432	ENSG00000261338.2	RP11-378A13.1	12.67	6.29e-32	3.19e-28	0.5	0.5	Colorectal cancer;	chr2:218217607	chr2:218255319~218257366:+
LUAD	cis	rs2882667	0.824	rs13189485	ENSG00000253404.1	AC034243.1	12.66	6.37e-32	3.23e-28	0.67	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139139712	chr5:138744434~138753309:-
LUAD	cis	rs9326248	0.53	rs562179	ENSG00000254851.1	RP11-109L13.1	-12.66	6.5e-32	3.29e-28	-0.87	-0.5	Blood protein levels;	chr11:116934488	chr11:117135528~117138582:+
LUAD	cis	rs4423214	0.819	rs7938885	ENSG00000254682.1	RP11-660L16.2	12.66	6.53e-32	3.31e-28	0.66	0.5	Vitamin D levels;	chr11:71458997	chr11:71448674~71452157:+
LUAD	cis	rs4423214	0.959	rs12800438	ENSG00000254682.1	RP11-660L16.2	12.66	6.53e-32	3.31e-28	0.66	0.5	Vitamin D levels;	chr11:71459957	chr11:71448674~71452157:+
LUAD	cis	rs4423214	1	rs12807718	ENSG00000254682.1	RP11-660L16.2	12.66	6.53e-32	3.31e-28	0.66	0.5	Vitamin D levels;	chr11:71460124	chr11:71448674~71452157:+
LUAD	cis	rs4423214	1	rs4423214	ENSG00000254682.1	RP11-660L16.2	12.66	6.53e-32	3.31e-28	0.66	0.5	Vitamin D levels;	chr11:71462208	chr11:71448674~71452157:+
LUAD	cis	rs4423214	1	rs2276362	ENSG00000254682.1	RP11-660L16.2	12.66	6.53e-32	3.31e-28	0.66	0.5	Vitamin D levels;	chr11:71463406	chr11:71448674~71452157:+
LUAD	cis	rs7301826	0.967	rs4759790	ENSG00000256299.1	RP11-989F5.3	-12.66	6.55e-32	3.32e-28	-0.54	-0.5	Plasma plasminogen activator levels;	chr12:130811845	chr12:130810821~130812622:-
LUAD	cis	rs3091242	1	rs9689	ENSG00000224183.1	SDHDP6	-12.66	6.61e-32	3.34e-28	-0.62	-0.5	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25294164~25294643:-
LUAD	cis	rs10129255	0.5	rs10131875	ENSG00000223648.3	IGHV3-64	12.66	6.66e-32	3.37e-28	0.45	0.5	Kawasaki disease;	chr14:106792798	chr14:106643132~106658258:-
LUAD	cis	rs9389248	0.5	rs116273677	ENSG00000232876.1	CTA-212D2.2	-12.66	6.84e-32	3.46e-28	-0.55	-0.5	High light scatter reticulocyte percentage of red cells;	chr6:135017997	chr6:135055033~135060550:+
LUAD	cis	rs2739330	0.76	rs5751760	ENSG00000231271.1	AP000350.8	12.66	6.85e-32	3.47e-28	0.58	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23949918~23954042:+
LUAD	cis	rs3091242	0.933	rs35403885	ENSG00000224183.1	SDHDP6	12.66	6.9e-32	3.49e-28	0.63	0.5	Erythrocyte sedimentation rate;	chr1:25458060	chr1:25294164~25294643:-
LUAD	cis	rs7301826	1	rs4759523	ENSG00000256299.1	RP11-989F5.3	-12.66	6.92e-32	3.5e-28	-0.55	-0.5	Plasma plasminogen activator levels;	chr12:130830867	chr12:130810821~130812622:-
LUAD	cis	rs875971	0.577	rs34888281	ENSG00000226824.5	RP4-756H11.3	12.65	7.01e-32	3.54e-28	0.64	0.5	Aortic root size;	chr7:66120784	chr7:66654538~66669855:+
LUAD	cis	rs507080	0.922	rs508640	ENSG00000255422.1	AP002954.4	-12.65	7.03e-32	3.55e-28	-0.63	-0.5	Serum metabolite levels;	chr11:118693704	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.922	rs471227	ENSG00000255422.1	AP002954.4	-12.65	7.03e-32	3.55e-28	-0.63	-0.5	Serum metabolite levels;	chr11:118693892	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.922	rs516153	ENSG00000255422.1	AP002954.4	-12.65	7.03e-32	3.55e-28	-0.63	-0.5	Serum metabolite levels;	chr11:118694053	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.922	rs518028	ENSG00000255422.1	AP002954.4	-12.65	7.03e-32	3.55e-28	-0.63	-0.5	Serum metabolite levels;	chr11:118694273	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.922	rs519982	ENSG00000255422.1	AP002954.4	-12.65	7.03e-32	3.55e-28	-0.63	-0.5	Serum metabolite levels;	chr11:118694522	chr11:118704607~118750263:+
LUAD	cis	rs9399135	0.967	rs9389256	ENSG00000232876.1	CTA-212D2.2	-12.65	7.19e-32	3.63e-28	-0.55	-0.5	Red blood cell count;	chr6:135010116	chr6:135055033~135060550:+
LUAD	cis	rs507080	0.922	rs12788848	ENSG00000255422.1	AP002954.4	-12.65	7.24e-32	3.65e-28	-0.62	-0.5	Serum metabolite levels;	chr11:118683079	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.922	rs4474473	ENSG00000255422.1	AP002954.4	-12.65	7.24e-32	3.65e-28	-0.62	-0.5	Serum metabolite levels;	chr11:118683180	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.922	rs12796373	ENSG00000255422.1	AP002954.4	-12.65	7.24e-32	3.65e-28	-0.62	-0.5	Serum metabolite levels;	chr11:118684230	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.922	rs502601	ENSG00000255422.1	AP002954.4	-12.65	7.31e-32	3.68e-28	-0.63	-0.5	Serum metabolite levels;	chr11:118694970	chr11:118704607~118750263:+
LUAD	cis	rs10129255	0.5	rs7157975	ENSG00000223648.3	IGHV3-64	12.65	7.47e-32	3.76e-28	0.45	0.5	Kawasaki disease;	chr14:106804049	chr14:106643132~106658258:-
LUAD	cis	rs6538678	0.833	rs10859966	ENSG00000258343.1	RP11-536G4.2	12.65	7.53e-32	3.79e-28	0.65	0.5	Lupus nephritis in systemic lupus erythematosus;	chr12:95859597	chr12:95795345~95858839:-
LUAD	cis	rs1577917	0.958	rs6454488	ENSG00000203875.9	SNHG5	-12.65	7.55e-32	3.8e-28	-0.67	-0.5	Response to antipsychotic treatment;	chr6:85741124	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs13207173	ENSG00000203875.9	SNHG5	-12.65	7.56e-32	3.8e-28	-0.69	-0.5	Response to antipsychotic treatment;	chr6:85747804	chr6:85660950~85678736:-
LUAD	cis	rs916888	0.61	rs199530	ENSG00000214401.4	KANSL1-AS1	-12.65	7.57e-32	3.81e-28	-0.67	-0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46193576~46196723:+
LUAD	cis	rs7301826	1	rs4759524	ENSG00000256299.1	RP11-989F5.3	-12.65	7.57e-32	3.81e-28	-0.54	-0.5	Plasma plasminogen activator levels;	chr12:130831065	chr12:130810821~130812622:-
LUAD	cis	rs9322193	0.567	rs7742692	ENSG00000231760.4	RP11-350J20.5	12.64	7.7e-32	3.87e-28	0.62	0.5	Lung cancer;	chr6:149892363	chr6:149796151~149826294:-
LUAD	cis	rs9399135	0.935	rs11759999	ENSG00000232876.1	CTA-212D2.2	-12.64	7.87e-32	3.95e-28	-0.55	-0.5	Red blood cell count;	chr6:135049357	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.935	rs11760000	ENSG00000232876.1	CTA-212D2.2	-12.64	7.87e-32	3.95e-28	-0.55	-0.5	Red blood cell count;	chr6:135049358	chr6:135055033~135060550:+
LUAD	cis	rs10129255	0.5	rs11627315	ENSG00000223648.3	IGHV3-64	12.64	7.87e-32	3.95e-28	0.45	0.5	Kawasaki disease;	chr14:106802182	chr14:106643132~106658258:-
LUAD	cis	rs7617773	0.779	rs11718329	ENSG00000229759.1	MRPS18AP1	12.64	8.01e-32	4.02e-28	0.51	0.5	Coronary artery disease;	chr3:48268338	chr3:48256350~48256938:-
LUAD	cis	rs2882667	0.756	rs11957953	ENSG00000253404.1	AC034243.1	12.64	8.06e-32	4.04e-28	0.67	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139143688	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.828	rs4822454	ENSG00000250470.1	AP000351.3	12.64	8.39e-32	4.2e-28	0.63	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23976904~23977585:-
LUAD	cis	rs1577917	0.917	rs4098044	ENSG00000203875.9	SNHG5	-12.63	8.46e-32	4.23e-28	-0.68	-0.5	Response to antipsychotic treatment;	chr6:85752348	chr6:85660950~85678736:-
LUAD	cis	rs9399135	0.967	rs4896120	ENSG00000232876.1	CTA-212D2.2	-12.63	8.55e-32	4.28e-28	-0.56	-0.5	Red blood cell count;	chr6:134972374	chr6:135055033~135060550:+
LUAD	cis	rs17507216	0.958	rs28648832	ENSG00000278603.1	RP13-608F4.5	12.63	8.56e-32	4.28e-28	0.67	0.5	Excessive daytime sleepiness;	chr15:82567642	chr15:82472203~82472426:+
LUAD	cis	rs2658782	0.789	rs3020057	ENSG00000279684.1	RP11-755E23.2	-12.63	8.97e-32	4.48e-28	-0.74	-0.5	Pulmonary function decline;	chr11:93385349	chr11:93286629~93288903:-
LUAD	cis	rs1577917	0.958	rs12191340	ENSG00000203875.9	SNHG5	-12.63	9e-32	4.49e-28	-0.68	-0.5	Response to antipsychotic treatment;	chr6:85811682	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs1414199	ENSG00000203875.9	SNHG5	-12.63	9e-32	4.49e-28	-0.68	-0.5	Response to antipsychotic treatment;	chr6:85812652	chr6:85660950~85678736:-
LUAD	cis	rs9399135	0.967	rs6925424	ENSG00000232876.1	CTA-212D2.2	-12.63	9.07e-32	4.53e-28	-0.55	-0.5	Red blood cell count;	chr6:134992810	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs17638970	ENSG00000232876.1	CTA-212D2.2	-12.63	9.07e-32	4.53e-28	-0.55	-0.5	Red blood cell count;	chr6:134998925	chr6:135055033~135060550:+
LUAD	cis	rs9402673	0.558	rs9688342	ENSG00000232876.1	CTA-212D2.2	-12.63	9.07e-32	4.53e-28	-0.55	-0.5	High light scatter reticulocyte count;Reticulocyte count;	chr6:135001888	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.933	rs4559100	ENSG00000232876.1	CTA-212D2.2	-12.63	9.07e-32	4.53e-28	-0.55	-0.5	Red blood cell count;	chr6:135002947	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs12527707	ENSG00000232876.1	CTA-212D2.2	-12.63	9.07e-32	4.53e-28	-0.55	-0.5	Red blood cell count;	chr6:135003373	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs9389251	ENSG00000232876.1	CTA-212D2.2	-12.63	9.07e-32	4.53e-28	-0.55	-0.5	Red blood cell count;	chr6:135004579	chr6:135055033~135060550:+
LUAD	cis	rs858239	1	rs199357	ENSG00000230658.1	KLHL7-AS1	-12.62	9.43e-32	4.7e-28	-0.59	-0.5	Cerebrospinal fluid biomarker levels;	chr7:23248690	chr7:23101228~23105703:-
LUAD	cis	rs7617773	0.817	rs9847953	ENSG00000229759.1	MRPS18AP1	12.62	9.47e-32	4.72e-28	0.51	0.5	Coronary artery disease;	chr3:48241205	chr3:48256350~48256938:-
LUAD	cis	rs992157	0.643	rs10191283	ENSG00000261338.2	RP11-378A13.1	12.62	9.62e-32	4.79e-28	0.5	0.5	Colorectal cancer;	chr2:218192032	chr2:218255319~218257366:+
LUAD	cis	rs10129255	0.518	rs10150460	ENSG00000223648.3	IGHV3-64	-12.61	1.04e-31	5.15e-28	-0.45	-0.5	Kawasaki disease;	chr14:106677179	chr14:106643132~106658258:-
LUAD	cis	rs1577917	0.958	rs34795473	ENSG00000203875.9	SNHG5	-12.61	1.04e-31	5.17e-28	-0.68	-0.5	Response to antipsychotic treatment;	chr6:85752081	chr6:85660950~85678736:-
LUAD	cis	rs6538678	0.929	rs10735336	ENSG00000258343.1	RP11-536G4.2	-12.61	1.06e-31	5.26e-28	-0.69	-0.5	Lupus nephritis in systemic lupus erythematosus;	chr12:95869661	chr12:95795345~95858839:-
LUAD	cis	rs7301826	0.934	rs10773826	ENSG00000256250.1	RP11-989F5.1	-12.61	1.06e-31	5.28e-28	-0.55	-0.5	Plasma plasminogen activator levels;	chr12:130836629	chr12:130810606~130812438:+
LUAD	cis	rs9399135	0.967	rs12526055	ENSG00000232876.1	CTA-212D2.2	-12.61	1.07e-31	5.31e-28	-0.55	-0.5	Red blood cell count;	chr6:135004780	chr6:135055033~135060550:+
LUAD	cis	rs992157	0.735	rs13392177	ENSG00000261338.2	RP11-378A13.1	-12.61	1.07e-31	5.32e-28	-0.5	-0.5	Colorectal cancer;	chr2:218248233	chr2:218255319~218257366:+
LUAD	cis	rs1577917	0.837	rs806529	ENSG00000203875.9	SNHG5	-12.61	1.08e-31	5.36e-28	-0.68	-0.5	Response to antipsychotic treatment;	chr6:85757403	chr6:85660950~85678736:-
LUAD	cis	rs3091242	0.933	rs11802413	ENSG00000261349.1	RP3-465N24.5	12.61	1.1e-31	5.46e-28	0.55	0.5	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25266102~25267136:-
LUAD	cis	rs1577917	0.958	rs72907388	ENSG00000203875.9	SNHG5	-12.61	1.12e-31	5.53e-28	-0.7	-0.5	Response to antipsychotic treatment;	chr6:85730489	chr6:85660950~85678736:-
LUAD	cis	rs3091242	0.933	rs11249250	ENSG00000224183.1	SDHDP6	-12.6	1.15e-31	5.68e-28	-0.64	-0.5	Erythrocyte sedimentation rate;	chr1:25441118	chr1:25294164~25294643:-
LUAD	cis	rs9399135	0.967	rs9376077	ENSG00000232876.1	CTA-212D2.2	-12.6	1.18e-31	5.81e-28	-0.55	-0.5	Red blood cell count;	chr6:134978575	chr6:135055033~135060550:+
LUAD	cis	rs9326248	0.53	rs2513093	ENSG00000254851.1	RP11-109L13.1	-12.6	1.18e-31	5.85e-28	-0.88	-0.5	Blood protein levels;	chr11:116935971	chr11:117135528~117138582:+
LUAD	cis	rs9399135	0.967	rs6929661	ENSG00000232876.1	CTA-212D2.2	-12.6	1.19e-31	5.85e-28	-0.55	-0.5	Red blood cell count;	chr6:135007654	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs2327578	ENSG00000232876.1	CTA-212D2.2	-12.6	1.19e-31	5.85e-28	-0.55	-0.5	Red blood cell count;	chr6:135008831	chr6:135055033~135060550:+
LUAD	cis	rs7617773	0.817	rs3937	ENSG00000229759.1	MRPS18AP1	12.6	1.19e-31	5.87e-28	0.52	0.5	Coronary artery disease;	chr3:48270912	chr3:48256350~48256938:-
LUAD	cis	rs3091242	0.933	rs28530483	ENSG00000224183.1	SDHDP6	-12.6	1.19e-31	5.89e-28	-0.64	-0.5	Erythrocyte sedimentation rate;	chr1:25414356	chr1:25294164~25294643:-
LUAD	cis	rs9399135	0.967	rs9399129	ENSG00000232876.1	CTA-212D2.2	-12.59	1.25e-31	6.14e-28	-0.55	-0.5	Red blood cell count;	chr6:134964010	chr6:135055033~135060550:+
LUAD	cis	rs3091242	0.933	rs9438905	ENSG00000224183.1	SDHDP6	-12.59	1.25e-31	6.16e-28	-0.63	-0.5	Erythrocyte sedimentation rate;	chr1:25437686	chr1:25294164~25294643:-
LUAD	cis	rs507080	0.922	rs642662	ENSG00000255422.1	AP002954.4	-12.59	1.26e-31	6.22e-28	-0.64	-0.5	Serum metabolite levels;	chr11:118696311	chr11:118704607~118750263:+
LUAD	cis	rs55794721	0.509	rs909834	ENSG00000224183.1	SDHDP6	-12.59	1.27e-31	6.25e-28	-0.63	-0.5	Mean corpuscular volume;Plateletcrit;	chr1:25431505	chr1:25294164~25294643:-
LUAD	cis	rs55794721	0.509	rs2982358	ENSG00000224183.1	SDHDP6	-12.59	1.28e-31	6.31e-28	-0.64	-0.5	Mean corpuscular volume;Plateletcrit;	chr1:25418713	chr1:25294164~25294643:-
LUAD	cis	rs3091242	0.933	rs61775167	ENSG00000224183.1	SDHDP6	12.59	1.31e-31	6.44e-28	0.63	0.5	Erythrocyte sedimentation rate;	chr1:25454402	chr1:25294164~25294643:-
LUAD	cis	rs3091242	0.935	rs4233043	ENSG00000224183.1	SDHDP6	-12.59	1.31e-31	6.46e-28	-0.64	-0.5	Erythrocyte sedimentation rate;	chr1:25438992	chr1:25294164~25294643:-
LUAD	cis	rs6597981	0.675	rs4963120	ENSG00000279672.1	CMB9-55F22.1	-12.58	1.35e-31	6.65e-28	-0.52	-0.5	Breast cancer;	chr11:825777	chr11:779617~780755:+
LUAD	cis	rs1263173	0.696	rs1263172	ENSG00000254851.1	RP11-109L13.1	-12.58	1.37e-31	6.71e-28	-0.66	-0.5	HDL cholesterol;	chr11:116810202	chr11:117135528~117138582:+
LUAD	cis	rs977987	0.832	rs37597	ENSG00000261783.1	RP11-252K23.2	12.58	1.44e-31	7.07e-28	0.68	0.5	Dupuytren's disease;	chr16:75466377	chr16:75379818~75381260:-
LUAD	cis	rs1153858	1	rs7169587	ENSG00000259520.4	CTD-2651B20.3	-12.58	1.44e-31	7.07e-28	-0.66	-0.5	Homoarginine levels;	chr15:45348181	chr15:45251580~45279251:-
LUAD	cis	rs2658782	0.901	rs7116173	ENSG00000279684.1	RP11-755E23.2	12.57	1.52e-31	7.45e-28	0.78	0.5	Pulmonary function decline;	chr11:93489145	chr11:93286629~93288903:-
LUAD	cis	rs1153858	1	rs28679834	ENSG00000259520.4	CTD-2651B20.3	-12.57	1.53e-31	7.51e-28	-0.69	-0.5	Homoarginine levels;	chr15:45324008	chr15:45251580~45279251:-
LUAD	cis	rs4423214	1	rs7928249	ENSG00000254682.1	RP11-660L16.2	12.57	1.56e-31	7.63e-28	0.66	0.5	Vitamin D levels;	chr11:71450017	chr11:71448674~71452157:+
LUAD	cis	rs3091242	0.933	rs4649084	ENSG00000224183.1	SDHDP6	-12.57	1.56e-31	7.65e-28	-0.63	-0.5	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25294164~25294643:-
LUAD	cis	rs3091242	0.809	rs660129	ENSG00000224183.1	SDHDP6	-12.57	1.61e-31	7.85e-28	-0.64	-0.5	Erythrocyte sedimentation rate;	chr1:25400947	chr1:25294164~25294643:-
LUAD	cis	rs3091242	0.728	rs706845	ENSG00000224183.1	SDHDP6	-12.57	1.61e-31	7.85e-28	-0.64	-0.5	Erythrocyte sedimentation rate;	chr1:25404222	chr1:25294164~25294643:-
LUAD	cis	rs6538678	0.895	rs1436124	ENSG00000258343.1	RP11-536G4.2	-12.57	1.63e-31	7.96e-28	-0.7	-0.5	Lupus nephritis in systemic lupus erythematosus;	chr12:95889654	chr12:95795345~95858839:-
LUAD	cis	rs9399135	0.967	rs7750300	ENSG00000232876.1	CTA-212D2.2	-12.57	1.63e-31	7.96e-28	-0.55	-0.5	Red blood cell count;	chr6:135029812	chr6:135055033~135060550:+
LUAD	cis	rs507080	0.922	rs533646	ENSG00000255422.1	AP002954.4	-12.57	1.63e-31	7.97e-28	-0.63	-0.5	Serum metabolite levels;	chr11:118696037	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.922	rs478371	ENSG00000255422.1	AP002954.4	-12.57	1.64e-31	7.99e-28	-0.63	-0.5	Serum metabolite levels;	chr11:118694627	chr11:118704607~118750263:+
LUAD	cis	rs7301826	0.932	rs1007246	ENSG00000256299.1	RP11-989F5.3	-12.56	1.65e-31	8.05e-28	-0.55	-0.5	Plasma plasminogen activator levels;	chr12:130795585	chr12:130810821~130812622:-
LUAD	cis	rs9399135	1	rs35123050	ENSG00000232876.1	CTA-212D2.2	-12.56	1.66e-31	8.09e-28	-0.56	-0.5	Red blood cell count;	chr6:134981602	chr6:135055033~135060550:+
LUAD	cis	rs507080	0.845	rs667982	ENSG00000255422.1	AP002954.4	-12.56	1.67e-31	8.16e-28	-0.62	-0.5	Serum metabolite levels;	chr11:118692058	chr11:118704607~118750263:+
LUAD	cis	rs11155671	0.53	rs4869763	ENSG00000231760.4	RP11-350J20.5	12.56	1.69e-31	8.25e-28	0.62	0.5	Testicular germ cell tumor;	chr6:149890548	chr6:149796151~149826294:-
LUAD	cis	rs2658782	0.789	rs1456238	ENSG00000279684.1	RP11-755E23.2	-12.56	1.69e-31	8.25e-28	-0.77	-0.5	Pulmonary function decline;	chr11:93384204	chr11:93286629~93288903:-
LUAD	cis	rs2739330	0.929	rs5751777	ENSG00000231271.1	AP000350.8	12.56	1.69e-31	8.26e-28	0.59	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23949918~23954042:+
LUAD	cis	rs2658782	0.789	rs2605580	ENSG00000279684.1	RP11-755E23.2	-12.56	1.74e-31	8.45e-28	-0.73	-0.5	Pulmonary function decline;	chr11:93413888	chr11:93286629~93288903:-
LUAD	cis	rs2658782	0.789	rs3019206	ENSG00000279684.1	RP11-755E23.2	-12.56	1.74e-31	8.47e-28	-0.76	-0.5	Pulmonary function decline;	chr11:93377907	chr11:93286629~93288903:-
LUAD	cis	rs7617773	0.78	rs11720026	ENSG00000229759.1	MRPS18AP1	12.56	1.8e-31	8.74e-28	0.54	0.5	Coronary artery disease;	chr3:48336431	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.743	rs11715876	ENSG00000229759.1	MRPS18AP1	12.56	1.8e-31	8.74e-28	0.54	0.5	Coronary artery disease;	chr3:48336432	chr3:48256350~48256938:-
LUAD	cis	rs2658782	0.901	rs10466368	ENSG00000279684.1	RP11-755E23.2	-12.55	1.83e-31	8.87e-28	-0.82	-0.5	Pulmonary function decline;	chr11:93496590	chr11:93286629~93288903:-
LUAD	cis	rs992157	0.71	rs12612347	ENSG00000261338.2	RP11-378A13.1	-12.55	1.98e-31	9.57e-28	-0.5	-0.5	Colorectal cancer;	chr2:218192615	chr2:218255319~218257366:+
LUAD	cis	rs2739330	0.929	rs5751775	ENSG00000231271.1	AP000350.8	12.54	2.02e-31	9.78e-28	0.59	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23949918~23954042:+
LUAD	cis	rs3091242	0.933	rs12402120	ENSG00000224183.1	SDHDP6	-12.54	2.04e-31	9.88e-28	-0.62	-0.5	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25294164~25294643:-
LUAD	cis	rs929843	1	rs929843	ENSG00000226232.7	RP11-419C5.2	-12.54	2.06e-31	9.94e-28	-0.53	-0.5	Menarche (age at onset);	chr16:70011845	chr16:69976388~69996188:-
LUAD	cis	rs9399135	0.967	rs45544135	ENSG00000232876.1	CTA-212D2.2	-12.54	2.1e-31	1.01e-27	-0.55	-0.5	Red blood cell count;	chr6:135002913	chr6:135055033~135060550:+
LUAD	cis	rs11155671	0.53	rs7758033	ENSG00000231760.4	RP11-350J20.5	12.54	2.1e-31	1.01e-27	0.62	0.5	Testicular germ cell tumor;	chr6:149886999	chr6:149796151~149826294:-
LUAD	cis	rs9399135	1	rs9399135	ENSG00000232876.1	CTA-212D2.2	-12.54	2.14e-31	1.03e-27	-0.55	-0.5	Red blood cell count;	chr6:135047176	chr6:135055033~135060550:+
LUAD	cis	rs9322193	0.543	rs9371533	ENSG00000231760.4	RP11-350J20.5	12.54	2.18e-31	1.05e-27	0.63	0.5	Lung cancer;	chr6:149889545	chr6:149796151~149826294:-
LUAD	cis	rs3091242	0.809	rs660129	ENSG00000261349.1	RP3-465N24.5	-12.53	2.2e-31	1.06e-27	-0.55	-0.5	Erythrocyte sedimentation rate;	chr1:25400947	chr1:25266102~25267136:-
LUAD	cis	rs3091242	0.728	rs706845	ENSG00000261349.1	RP3-465N24.5	-12.53	2.2e-31	1.06e-27	-0.55	-0.5	Erythrocyte sedimentation rate;	chr1:25404222	chr1:25266102~25267136:-
LUAD	cis	rs1577917	0.958	rs12192033	ENSG00000203875.9	SNHG5	-12.53	2.28e-31	1.1e-27	-0.68	-0.5	Response to antipsychotic treatment;	chr6:85762841	chr6:85660950~85678736:-
LUAD	cis	rs11155671	0.53	rs9322228	ENSG00000231760.4	RP11-350J20.5	12.53	2.31e-31	1.11e-27	0.62	0.5	Testicular germ cell tumor;	chr6:149888173	chr6:149796151~149826294:-
LUAD	cis	rs11155671	0.53	rs7774787	ENSG00000231760.4	RP11-350J20.5	12.53	2.31e-31	1.11e-27	0.62	0.5	Testicular germ cell tumor;	chr6:149888296	chr6:149796151~149826294:-
LUAD	cis	rs11155671	0.53	rs2342767	ENSG00000231760.4	RP11-350J20.5	12.53	2.31e-31	1.11e-27	0.62	0.5	Testicular germ cell tumor;	chr6:149888581	chr6:149796151~149826294:-
LUAD	cis	rs11155671	0.53	rs7764376	ENSG00000231760.4	RP11-350J20.5	12.53	2.31e-31	1.11e-27	0.62	0.5	Testicular germ cell tumor;	chr6:149889208	chr6:149796151~149826294:-
LUAD	cis	rs11155671	0.53	rs6933882	ENSG00000231760.4	RP11-350J20.5	12.53	2.31e-31	1.11e-27	0.62	0.5	Testicular germ cell tumor;	chr6:149889666	chr6:149796151~149826294:-
LUAD	cis	rs11155671	0.53	rs6939761	ENSG00000231760.4	RP11-350J20.5	12.53	2.31e-31	1.11e-27	0.62	0.5	Testicular germ cell tumor;	chr6:149889858	chr6:149796151~149826294:-
LUAD	cis	rs11155671	0.53	rs3823021	ENSG00000231760.4	RP11-350J20.5	12.53	2.31e-31	1.11e-27	0.62	0.5	Testicular germ cell tumor;	chr6:149889863	chr6:149796151~149826294:-
LUAD	cis	rs11155671	0.53	rs4869764	ENSG00000231760.4	RP11-350J20.5	12.53	2.31e-31	1.11e-27	0.62	0.5	Testicular germ cell tumor;	chr6:149890692	chr6:149796151~149826294:-
LUAD	cis	rs1577917	0.958	rs2324817	ENSG00000203875.9	SNHG5	-12.53	2.37e-31	1.14e-27	-0.67	-0.5	Response to antipsychotic treatment;	chr6:85752936	chr6:85660950~85678736:-
LUAD	cis	rs7115242	0.8	rs493134	ENSG00000254851.1	RP11-109L13.1	-12.53	2.38e-31	1.14e-27	-0.85	-0.5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116962963	chr11:117135528~117138582:+
LUAD	cis	rs1153858	1	rs11852800	ENSG00000259520.4	CTD-2651B20.3	12.52	2.4e-31	1.15e-27	0.65	0.5	Homoarginine levels;	chr15:45346933	chr15:45251580~45279251:-
LUAD	cis	rs11155671	0.53	rs9397420	ENSG00000231760.4	RP11-350J20.5	-12.52	2.43e-31	1.16e-27	-0.61	-0.5	Testicular germ cell tumor;	chr6:149885645	chr6:149796151~149826294:-
LUAD	cis	rs7617773	0.817	rs11710861	ENSG00000229759.1	MRPS18AP1	12.52	2.43e-31	1.17e-27	0.51	0.5	Coronary artery disease;	chr3:48256070	chr3:48256350~48256938:-
LUAD	cis	rs1153858	1	rs16942000	ENSG00000259520.4	CTD-2651B20.3	-12.52	2.48e-31	1.19e-27	-0.66	-0.5	Homoarginine levels;	chr15:45340805	chr15:45251580~45279251:-
LUAD	cis	rs1153858	0.945	rs7182300	ENSG00000259520.4	CTD-2651B20.3	-12.52	2.48e-31	1.19e-27	-0.66	-0.5	Homoarginine levels;	chr15:45342730	chr15:45251580~45279251:-
LUAD	cis	rs1153858	0.887	rs7171163	ENSG00000259520.4	CTD-2651B20.3	-12.52	2.48e-31	1.19e-27	-0.66	-0.5	Homoarginine levels;	chr15:45344197	chr15:45251580~45279251:-
LUAD	cis	rs992157	0.71	rs12996912	ENSG00000261338.2	RP11-378A13.1	12.52	2.52e-31	1.21e-27	0.5	0.5	Colorectal cancer;	chr2:218245832	chr2:218255319~218257366:+
LUAD	cis	rs4853012	0.838	rs12619982	ENSG00000217702.2	RP11-287D1.4	12.52	2.55e-31	1.22e-27	0.78	0.5	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74130583~74135395:+
LUAD	cis	rs1153858	1	rs7167900	ENSG00000259520.4	CTD-2651B20.3	-12.52	2.55e-31	1.22e-27	-0.66	-0.5	Homoarginine levels;	chr15:45347273	chr15:45251580~45279251:-
LUAD	cis	rs4423214	1	rs12792306	ENSG00000254682.1	RP11-660L16.2	12.51	2.65e-31	1.27e-27	0.65	0.5	Vitamin D levels;	chr11:71455946	chr11:71448674~71452157:+
LUAD	cis	rs4423214	1	rs4944955	ENSG00000254682.1	RP11-660L16.2	12.51	2.65e-31	1.27e-27	0.65	0.5	Vitamin D levels;	chr11:71456631	chr11:71448674~71452157:+
LUAD	cis	rs4423214	1	rs4944956	ENSG00000254682.1	RP11-660L16.2	12.51	2.65e-31	1.27e-27	0.65	0.5	Vitamin D levels;	chr11:71456719	chr11:71448674~71452157:+
LUAD	cis	rs2739330	0.796	rs2154594	ENSG00000250470.1	AP000351.3	-12.51	2.68e-31	1.28e-27	-0.62	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23976904~23977585:-
LUAD	cis	rs11155671	0.53	rs9383577	ENSG00000231760.4	RP11-350J20.5	12.51	2.69e-31	1.29e-27	0.61	0.5	Testicular germ cell tumor;	chr6:149886059	chr6:149796151~149826294:-
LUAD	cis	rs11155671	0.53	rs9383914	ENSG00000231760.4	RP11-350J20.5	12.51	2.69e-31	1.29e-27	0.61	0.5	Testicular germ cell tumor;	chr6:149886098	chr6:149796151~149826294:-
LUAD	cis	rs11155671	0.517	rs9397058	ENSG00000231760.4	RP11-350J20.5	12.51	2.69e-31	1.29e-27	0.61	0.5	Testicular germ cell tumor;	chr6:149886113	chr6:149796151~149826294:-
LUAD	cis	rs11155671	0.53	rs7768626	ENSG00000231760.4	RP11-350J20.5	12.51	2.83e-31	1.35e-27	0.61	0.5	Testicular germ cell tumor;	chr6:149886826	chr6:149796151~149826294:-
LUAD	cis	rs11155671	0.53	rs7768665	ENSG00000231760.4	RP11-350J20.5	12.51	2.83e-31	1.35e-27	0.61	0.5	Testicular germ cell tumor;	chr6:149886888	chr6:149796151~149826294:-
LUAD	cis	rs11155671	0.53	rs7758020	ENSG00000231760.4	RP11-350J20.5	12.51	2.83e-31	1.35e-27	0.61	0.5	Testicular germ cell tumor;	chr6:149886975	chr6:149796151~149826294:-
LUAD	cis	rs1153858	1	rs9783731	ENSG00000259520.4	CTD-2651B20.3	12.51	2.87e-31	1.37e-27	0.65	0.5	Homoarginine levels;	chr15:45350686	chr15:45251580~45279251:-
LUAD	cis	rs3091242	0.933	rs28633797	ENSG00000261349.1	RP3-465N24.5	-12.51	2.87e-31	1.37e-27	-0.55	-0.5	Erythrocyte sedimentation rate;	chr1:25415138	chr1:25266102~25267136:-
LUAD	cis	rs1577917	0.876	rs4618490	ENSG00000203875.9	SNHG5	-12.5	2.93e-31	1.39e-27	-0.68	-0.5	Response to antipsychotic treatment;	chr6:85808685	chr6:85660950~85678736:-
LUAD	cis	rs2658782	0.901	rs2605611	ENSG00000279684.1	RP11-755E23.2	-12.5	2.95e-31	1.4e-27	-0.82	-0.5	Pulmonary function decline;	chr11:93496153	chr11:93286629~93288903:-
LUAD	cis	rs55794721	0.509	rs11249248	ENSG00000224183.1	SDHDP6	-12.5	3e-31	1.43e-27	-0.63	-0.5	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25294164~25294643:-
LUAD	cis	rs1153858	1	rs7163720	ENSG00000259520.4	CTD-2651B20.3	-12.5	3.05e-31	1.45e-27	-0.66	-0.5	Homoarginine levels;	chr15:45347176	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs12591058	ENSG00000259520.4	CTD-2651B20.3	-12.5	3.05e-31	1.45e-27	-0.66	-0.5	Homoarginine levels;	chr15:45347974	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs4775907	ENSG00000259520.4	CTD-2651B20.3	-12.5	3.09e-31	1.47e-27	-0.66	-0.5	Homoarginine levels;	chr15:45346449	chr15:45251580~45279251:-
LUAD	cis	rs7617773	0.784	rs9850672	ENSG00000229759.1	MRPS18AP1	12.5	3.18e-31	1.51e-27	0.51	0.5	Coronary artery disease;	chr3:48259682	chr3:48256350~48256938:-
LUAD	cis	rs4423214	1	rs2040323	ENSG00000254682.1	RP11-660L16.2	12.49	3.33e-31	1.58e-27	0.64	0.49	Vitamin D levels;	chr11:71461737	chr11:71448674~71452157:+
LUAD	cis	rs73086581	0.891	rs11907503	ENSG00000229539.1	RP11-119B16.2	12.49	3.43e-31	1.62e-27	0.7	0.49	Response to antidepressants in depression;	chr20:3906943	chr20:3888239~3888868:-
LUAD	cis	rs2906856	0.526	rs2906852	ENSG00000255733.4	IFNG-AS1	12.49	3.46e-31	1.63e-27	0.47	0.49	Mosquito bite size;	chr12:67985701	chr12:67989445~68234686:+
LUAD	cis	rs4853012	0.838	rs4563249	ENSG00000217702.2	RP11-287D1.4	12.48	3.54e-31	1.68e-27	0.74	0.49	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74130583~74135395:+
LUAD	cis	rs10256972	0.552	rs2960837	ENSG00000229043.2	AC091729.9	-12.48	3.57e-31	1.69e-27	-0.54	-0.49	Endometriosis;Longevity;	chr7:1164321	chr7:1160374~1165267:+
LUAD	cis	rs11155671	0.53	rs9383912	ENSG00000231760.4	RP11-350J20.5	12.47	3.87e-31	1.83e-27	0.61	0.49	Testicular germ cell tumor;	chr6:149885479	chr6:149796151~149826294:-
LUAD	cis	rs7617773	0.817	rs6801801	ENSG00000229759.1	MRPS18AP1	12.47	3.99e-31	1.88e-27	0.51	0.49	Coronary artery disease;	chr3:48284943	chr3:48256350~48256938:-
LUAD	cis	rs1577917	0.57	rs114854865	ENSG00000203875.9	SNHG5	-12.47	3.99e-31	1.88e-27	-0.68	-0.49	Response to antipsychotic treatment;	chr6:85844518	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.916	rs4706252	ENSG00000203875.9	SNHG5	-12.47	3.99e-31	1.88e-27	-0.68	-0.49	Response to antipsychotic treatment;	chr6:85845462	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.917	rs1838959	ENSG00000203875.9	SNHG5	-12.47	3.99e-31	1.88e-27	-0.68	-0.49	Response to antipsychotic treatment;	chr6:85847086	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.917	rs1579886	ENSG00000203875.9	SNHG5	-12.47	3.99e-31	1.88e-27	-0.68	-0.49	Response to antipsychotic treatment;	chr6:85847473	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs1816937	ENSG00000203875.9	SNHG5	-12.47	3.99e-31	1.88e-27	-0.68	-0.49	Response to antipsychotic treatment;	chr6:85847533	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs2324840	ENSG00000203875.9	SNHG5	-12.47	3.99e-31	1.88e-27	-0.68	-0.49	Response to antipsychotic treatment;	chr6:85847902	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs7382798	ENSG00000203875.9	SNHG5	-12.47	3.99e-31	1.88e-27	-0.68	-0.49	Response to antipsychotic treatment;	chr6:85850116	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs12202188	ENSG00000203875.9	SNHG5	-12.47	3.99e-31	1.88e-27	-0.68	-0.49	Response to antipsychotic treatment;	chr6:85852982	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs36035797	ENSG00000203875.9	SNHG5	-12.47	3.99e-31	1.88e-27	-0.68	-0.49	Response to antipsychotic treatment;	chr6:85853162	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs1838958	ENSG00000203875.9	SNHG5	-12.47	3.99e-31	1.88e-27	-0.68	-0.49	Response to antipsychotic treatment;	chr6:85854250	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.917	rs2084293	ENSG00000203875.9	SNHG5	-12.47	3.99e-31	1.88e-27	-0.68	-0.49	Response to antipsychotic treatment;	chr6:85856284	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs12209668	ENSG00000203875.9	SNHG5	-12.47	3.99e-31	1.88e-27	-0.68	-0.49	Response to antipsychotic treatment;	chr6:85856799	chr6:85660950~85678736:-
LUAD	cis	rs3091242	0.933	rs926438	ENSG00000261349.1	RP3-465N24.5	-12.47	4.02e-31	1.89e-27	-0.55	-0.49	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25266102~25267136:-
LUAD	cis	rs1577917	0.917	rs1414201	ENSG00000203875.9	SNHG5	-12.47	4.05e-31	1.9e-27	-0.68	-0.49	Response to antipsychotic treatment;	chr6:85790598	chr6:85660950~85678736:-
LUAD	cis	rs6538678	0.824	rs4762633	ENSG00000199506.1	RNU6-247P	-12.47	4.08e-31	1.92e-27	-0.71	-0.49	Lupus nephritis in systemic lupus erythematosus;	chr12:95860295	chr12:95792529~95792635:-
LUAD	cis	rs55794721	0.509	rs12027135	ENSG00000224183.1	SDHDP6	-12.47	4.12e-31	1.93e-27	-0.62	-0.49	Mean corpuscular volume;Plateletcrit;	chr1:25449242	chr1:25294164~25294643:-
LUAD	cis	rs3096299	0.509	rs4785691	ENSG00000274627.1	RP11-104N10.2	12.47	4.23e-31	1.98e-27	0.47	0.49	Multiple myeloma (IgH translocation);	chr16:89530813	chr16:89516797~89522217:+
LUAD	cis	rs3091242	0.836	rs34997029	ENSG00000224183.1	SDHDP6	12.46	4.39e-31	2.05e-27	0.62	0.49	Erythrocyte sedimentation rate;	chr1:25457332	chr1:25294164~25294643:-
LUAD	cis	rs2658782	0.547	rs3020052	ENSG00000279684.1	RP11-755E23.2	-12.46	4.39e-31	2.05e-27	-0.68	-0.49	Pulmonary function decline;	chr11:93322018	chr11:93286629~93288903:-
LUAD	cis	rs7301826	1	rs10744482	ENSG00000256299.1	RP11-989F5.3	-12.46	4.39e-31	2.05e-27	-0.54	-0.49	Plasma plasminogen activator levels;	chr12:130813650	chr12:130810821~130812622:-
LUAD	cis	rs2658782	0.789	rs3020073	ENSG00000279684.1	RP11-755E23.2	-12.45	4.75e-31	2.21e-27	-0.76	-0.49	Pulmonary function decline;	chr11:93370664	chr11:93286629~93288903:-
LUAD	cis	rs3091242	0.933	rs34933589	ENSG00000224183.1	SDHDP6	12.45	4.75e-31	2.21e-27	0.63	0.49	Erythrocyte sedimentation rate;	chr1:25461707	chr1:25294164~25294643:-
LUAD	cis	rs801193	0.548	rs2659904	ENSG00000226824.5	RP4-756H11.3	-12.45	4.84e-31	2.25e-27	-0.63	-0.49	Aortic root size;	chr7:66713615	chr7:66654538~66669855:+
LUAD	cis	rs1577917	0.917	rs12665464	ENSG00000203875.9	SNHG5	-12.45	4.84e-31	2.25e-27	-0.67	-0.49	Response to antipsychotic treatment;	chr6:85864415	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs6921315	ENSG00000203875.9	SNHG5	-12.45	4.85e-31	2.26e-27	-0.67	-0.49	Response to antipsychotic treatment;	chr6:85761950	chr6:85660950~85678736:-
LUAD	cis	rs875971	0.508	rs10950045	ENSG00000226824.5	RP4-756H11.3	12.45	4.87e-31	2.26e-27	0.61	0.49	Aortic root size;	chr7:66601386	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.839	rs6968619	ENSG00000226824.5	RP4-756H11.3	12.45	4.87e-31	2.26e-27	0.61	0.49	Aortic root size;	chr7:66603880	chr7:66654538~66669855:+
LUAD	cis	rs9399135	0.838	rs4896126	ENSG00000232876.1	CTA-212D2.2	-12.45	4.99e-31	2.32e-27	-0.54	-0.49	Red blood cell count;	chr6:135021648	chr6:135055033~135060550:+
LUAD	cis	rs9402673	0.517	rs978036	ENSG00000232876.1	CTA-212D2.2	-12.45	4.99e-31	2.32e-27	-0.54	-0.49	High light scatter reticulocyte count;Reticulocyte count;	chr6:135021765	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs1023179	ENSG00000232876.1	CTA-212D2.2	-12.45	4.99e-31	2.32e-27	-0.54	-0.49	Red blood cell count;	chr6:135022691	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs952674	ENSG00000232876.1	CTA-212D2.2	-12.45	4.99e-31	2.32e-27	-0.54	-0.49	Red blood cell count;	chr6:135028019	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.935	rs987690	ENSG00000232876.1	CTA-212D2.2	-12.45	4.99e-31	2.32e-27	-0.54	-0.49	Red blood cell count;	chr6:135029241	chr6:135055033~135060550:+
LUAD	cis	rs3091242	0.933	rs909833	ENSG00000224183.1	SDHDP6	-12.45	5e-31	2.32e-27	-0.63	-0.49	Erythrocyte sedimentation rate;	chr1:25427649	chr1:25294164~25294643:-
LUAD	cis	rs916888	0.647	rs199524	ENSG00000214401.4	KANSL1-AS1	-12.44	5.18e-31	2.41e-27	-0.67	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46193576~46196723:+
LUAD	cis	rs507080	0.922	rs585039	ENSG00000255422.1	AP002954.4	-12.44	5.22e-31	2.42e-27	-0.62	-0.49	Serum metabolite levels;	chr11:118692672	chr11:118704607~118750263:+
LUAD	cis	rs9399135	0.967	rs13218642	ENSG00000232876.1	CTA-212D2.2	-12.44	5.49e-31	2.54e-27	-0.54	-0.49	Red blood cell count;	chr6:134988802	chr6:135055033~135060550:+
LUAD	cis	rs3091242	0.933	rs932372	ENSG00000224183.1	SDHDP6	-12.44	5.5e-31	2.55e-27	-0.62	-0.49	Erythrocyte sedimentation rate;	chr1:25428523	chr1:25294164~25294643:-
LUAD	cis	rs1891275	0.513	rs1539041	ENSG00000228701.1	TNKS2-AS1	-12.44	5.56e-31	2.58e-27	-0.71	-0.49	Intelligence (multi-trait analysis);	chr10:91817384	chr10:91782839~91798291:-
LUAD	cis	rs4853012	0.941	rs78128123	ENSG00000217702.2	RP11-287D1.4	12.43	5.67e-31	2.62e-27	0.81	0.49	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74130583~74135395:+
LUAD	cis	rs10129255	0.536	rs6576201	ENSG00000223648.3	IGHV3-64	-12.43	5.68e-31	2.63e-27	-0.44	-0.49	Kawasaki disease;	chr14:106683696	chr14:106643132~106658258:-
LUAD	cis	rs9399135	0.967	rs4451151	ENSG00000232876.1	CTA-212D2.2	-12.43	5.8e-31	2.68e-27	-0.54	-0.49	Red blood cell count;	chr6:134989408	chr6:135055033~135060550:+
LUAD	cis	rs992157	0.71	rs6719789	ENSG00000261338.2	RP11-378A13.1	-12.43	5.83e-31	2.7e-27	-0.49	-0.49	Colorectal cancer;	chr2:218193087	chr2:218255319~218257366:+
LUAD	cis	rs9326248	0.53	rs900012	ENSG00000254851.1	RP11-109L13.1	-12.43	5.88e-31	2.72e-27	-0.83	-0.49	Blood protein levels;	chr11:117095719	chr11:117135528~117138582:+
LUAD	cis	rs1577917	0.958	rs11752180	ENSG00000203875.9	SNHG5	-12.43	5.96e-31	2.75e-27	-0.67	-0.49	Response to antipsychotic treatment;	chr6:85863447	chr6:85660950~85678736:-
LUAD	cis	rs507080	0.922	rs4938524	ENSG00000255239.1	AP002954.6	12.43	5.98e-31	2.76e-27	0.59	0.49	Serum metabolite levels;	chr11:118681365	chr11:118688039~118690600:-
LUAD	cis	rs801193	0.66	rs1962050	ENSG00000226824.5	RP4-756H11.3	12.43	6e-31	2.77e-27	0.62	0.49	Aortic root size;	chr7:66775021	chr7:66654538~66669855:+
LUAD	cis	rs916888	0.647	rs199523	ENSG00000214401.4	KANSL1-AS1	-12.43	6.02e-31	2.78e-27	-0.67	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46193576~46196723:+
LUAD	cis	rs507080	0.922	rs7114458	ENSG00000255422.1	AP002954.4	-12.43	6.06e-31	2.8e-27	-0.63	-0.49	Serum metabolite levels;	chr11:118695466	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.922	rs7114216	ENSG00000255422.1	AP002954.4	-12.43	6.06e-31	2.8e-27	-0.63	-0.49	Serum metabolite levels;	chr11:118695525	chr11:118704607~118750263:+
LUAD	cis	rs7115242	0.8	rs1320668	ENSG00000254851.1	RP11-109L13.1	-12.42	6.26e-31	2.89e-27	-0.84	-0.49	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117096950	chr11:117135528~117138582:+
LUAD	cis	rs3091242	0.933	rs35497030	ENSG00000261349.1	RP3-465N24.5	12.42	6.36e-31	2.93e-27	0.54	0.49	Erythrocyte sedimentation rate;	chr1:25456575	chr1:25266102~25267136:-
LUAD	cis	rs2882667	0.824	rs1560656	ENSG00000253404.1	AC034243.1	-12.42	6.41e-31	2.96e-27	-0.64	-0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135100	chr5:138744434~138753309:-
LUAD	cis	rs62388641	0.802	rs13202504	ENSG00000272279.1	RP11-157J24.2	12.42	6.43e-31	2.97e-27	0.79	0.49	Daytime sleep phenotypes;	chr6:1537640	chr6:1528364~1528911:-
LUAD	cis	rs2882667	0.652	rs6596463	ENSG00000253404.1	AC034243.1	12.42	6.53e-31	3.01e-27	0.63	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139109237	chr5:138744434~138753309:-
LUAD	cis	rs3091242	1	rs646867	ENSG00000224183.1	SDHDP6	-12.42	6.56e-31	3.02e-27	-0.62	-0.49	Erythrocyte sedimentation rate;	chr1:25382767	chr1:25294164~25294643:-
LUAD	cis	rs2658782	0.666	rs2925361	ENSG00000279684.1	RP11-755E23.2	-12.42	6.64e-31	3.06e-27	-0.76	-0.49	Pulmonary function decline;	chr11:93365657	chr11:93286629~93288903:-
LUAD	cis	rs977987	0.654	rs8054194	ENSG00000261783.1	RP11-252K23.2	-12.42	6.72e-31	3.09e-27	-0.67	-0.49	Dupuytren's disease;	chr16:75463262	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.581	rs8056141	ENSG00000261783.1	RP11-252K23.2	-12.42	6.72e-31	3.09e-27	-0.67	-0.49	Dupuytren's disease;	chr16:75463264	chr16:75379818~75381260:-
LUAD	cis	rs875971	1	rs3981131	ENSG00000226824.5	RP4-756H11.3	-12.42	6.76e-31	3.11e-27	-0.62	-0.49	Aortic root size;	chr7:66486690	chr7:66654538~66669855:+
LUAD	cis	rs67383717	0.689	rs62559007	ENSG00000175611.10	LINC00476	-12.42	6.78e-31	3.12e-27	-0.52	-0.49	Parkinson's disease (pesticide exposure interaction);	chr9:95790981	chr9:95759231~95875977:-
LUAD	cis	rs9326248	0.53	rs1351452	ENSG00000254851.1	RP11-109L13.1	12.41	6.9e-31	3.17e-27	0.82	0.49	Blood protein levels;	chr11:117072638	chr11:117135528~117138582:+
LUAD	cis	rs7301826	0.966	rs4759795	ENSG00000256299.1	RP11-989F5.3	-12.41	7.34e-31	3.36e-27	-0.54	-0.49	Plasma plasminogen activator levels;	chr12:130816355	chr12:130810821~130812622:-
LUAD	cis	rs7301826	1	rs4619189	ENSG00000256299.1	RP11-989F5.3	-12.41	7.37e-31	3.38e-27	-0.54	-0.49	Plasma plasminogen activator levels;	chr12:130829252	chr12:130810821~130812622:-
LUAD	cis	rs7195287	0.779	rs2335454	ENSG00000276791.1	CTD-2270P14.5	12.41	7.46e-31	3.42e-27	0.63	0.49	Eosinophil counts;	chr16:2778156	chr16:2777319~2780568:+
LUAD	cis	rs6538678	1	rs6538678	ENSG00000258343.1	RP11-536G4.2	-12.4	7.62e-31	3.49e-27	-0.71	-0.49	Lupus nephritis in systemic lupus erythematosus;	chr12:95867790	chr12:95795345~95858839:-
LUAD	cis	rs1577917	0.958	rs7453105	ENSG00000203875.9	SNHG5	-12.4	7.66e-31	3.51e-27	-0.68	-0.49	Response to antipsychotic treatment;	chr6:85791043	chr6:85660950~85678736:-
LUAD	cis	rs7617773	0.78	rs6442111	ENSG00000229759.1	MRPS18AP1	12.4	7.76e-31	3.55e-27	0.51	0.49	Coronary artery disease;	chr3:48270570	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.851	rs6775179	ENSG00000229759.1	MRPS18AP1	12.4	7.76e-31	3.55e-27	0.51	0.49	Coronary artery disease;	chr3:48271928	chr3:48256350~48256938:-
LUAD	cis	rs1153858	1	rs56669689	ENSG00000259520.4	CTD-2651B20.3	-12.4	7.86e-31	3.59e-27	-0.65	-0.49	Homoarginine levels;	chr15:45345531	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs56806728	ENSG00000259520.4	CTD-2651B20.3	-12.4	7.86e-31	3.59e-27	-0.65	-0.49	Homoarginine levels;	chr15:45345616	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs4775906	ENSG00000259520.4	CTD-2651B20.3	-12.4	7.86e-31	3.59e-27	-0.65	-0.49	Homoarginine levels;	chr15:45346096	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs7179743	ENSG00000259520.4	CTD-2651B20.3	-12.4	7.86e-31	3.59e-27	-0.65	-0.49	Homoarginine levels;	chr15:45346133	chr15:45251580~45279251:-
LUAD	cis	rs11723261	0.621	rs11733385	ENSG00000275426.1	CH17-262A2.1	12.4	7.91e-31	3.61e-27	0.71	0.49	Immune response to smallpox vaccine (IL-6);	chr4:146677	chr4:149738~150317:+
LUAD	cis	rs11723261	0.546	rs4315728	ENSG00000275426.1	CH17-262A2.1	12.4	7.91e-31	3.61e-27	0.71	0.49	Immune response to smallpox vaccine (IL-6);	chr4:147237	chr4:149738~150317:+
LUAD	cis	rs3091242	0.933	rs9438904	ENSG00000224183.1	SDHDP6	-12.4	7.93e-31	3.62e-27	-0.63	-0.49	Erythrocyte sedimentation rate;	chr1:25430369	chr1:25294164~25294643:-
LUAD	cis	rs9322193	0.567	rs7747457	ENSG00000231760.4	RP11-350J20.5	12.4	7.99e-31	3.65e-27	0.62	0.49	Lung cancer;	chr6:149892366	chr6:149796151~149826294:-
LUAD	cis	rs507080	0.885	rs693037	ENSG00000255239.1	AP002954.6	12.4	8.04e-31	3.67e-27	0.59	0.49	Serum metabolite levels;	chr11:118682617	chr11:118688039~118690600:-
LUAD	cis	rs1577917	0.958	rs12195776	ENSG00000203875.9	SNHG5	-12.39	8.25e-31	3.77e-27	-0.68	-0.49	Response to antipsychotic treatment;	chr6:85778881	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs12209259	ENSG00000203875.9	SNHG5	-12.39	8.4e-31	3.83e-27	-0.67	-0.49	Response to antipsychotic treatment;	chr6:85792630	chr6:85660950~85678736:-
LUAD	cis	rs7617773	0.743	rs6804986	ENSG00000229759.1	MRPS18AP1	12.39	8.52e-31	3.89e-27	0.51	0.49	Coronary artery disease;	chr3:48322105	chr3:48256350~48256938:-
LUAD	cis	rs1577917	0.958	rs9647601	ENSG00000203875.9	SNHG5	-12.39	8.61e-31	3.93e-27	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85740109	chr6:85660950~85678736:-
LUAD	cis	rs3091242	0.9	rs35345536	ENSG00000224183.1	SDHDP6	-12.39	8.94e-31	4.07e-27	-0.62	-0.49	Erythrocyte sedimentation rate;	chr1:25439997	chr1:25294164~25294643:-
LUAD	cis	rs11155671	0.53	rs7742993	ENSG00000231760.4	RP11-350J20.5	12.39	8.98e-31	4.09e-27	0.61	0.49	Testicular germ cell tumor;	chr6:149883959	chr6:149796151~149826294:-
LUAD	cis	rs3091242	0.933	rs1534954	ENSG00000224183.1	SDHDP6	-12.38	9.06e-31	4.13e-27	-0.62	-0.49	Erythrocyte sedimentation rate;	chr1:25435433	chr1:25294164~25294643:-
LUAD	cis	rs801193	0.805	rs12532355	ENSG00000226824.5	RP4-756H11.3	12.38	9.27e-31	4.21e-27	0.61	0.49	Aortic root size;	chr7:66605597	chr7:66654538~66669855:+
LUAD	cis	rs507080	0.845	rs613377	ENSG00000255422.1	AP002954.4	-12.38	9.39e-31	4.26e-27	-0.61	-0.49	Serum metabolite levels;	chr11:118685375	chr11:118704607~118750263:+
LUAD	cis	rs4423214	1	rs2276361	ENSG00000254682.1	RP11-660L16.2	12.38	9.54e-31	4.33e-27	0.65	0.49	Vitamin D levels;	chr11:71458602	chr11:71448674~71452157:+
LUAD	cis	rs9399135	0.967	rs7741626	ENSG00000232876.1	CTA-212D2.2	-12.38	9.55e-31	4.33e-27	-0.54	-0.49	Red blood cell count;	chr6:134993044	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs4895439	ENSG00000232876.1	CTA-212D2.2	-12.38	9.55e-31	4.33e-27	-0.54	-0.49	Red blood cell count;	chr6:134997716	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.935	rs11754504	ENSG00000232876.1	CTA-212D2.2	-12.38	9.55e-31	4.33e-27	-0.54	-0.49	Red blood cell count;	chr6:135000371	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.869	rs9402675	ENSG00000232876.1	CTA-212D2.2	-12.38	9.55e-31	4.33e-27	-0.54	-0.49	Red blood cell count;	chr6:135004656	chr6:135055033~135060550:+
LUAD	cis	rs3091242	0.967	rs3093614	ENSG00000261349.1	RP3-465N24.5	12.38	9.56e-31	4.33e-27	0.54	0.49	Erythrocyte sedimentation rate;	chr1:25351353	chr1:25266102~25267136:-
LUAD	cis	rs801193	0.839	rs12534943	ENSG00000226824.5	RP4-756H11.3	12.38	9.61e-31	4.35e-27	0.61	0.49	Aortic root size;	chr7:66605533	chr7:66654538~66669855:+
LUAD	cis	rs1577917	1	rs1962716	ENSG00000203875.9	SNHG5	-12.38	9.84e-31	4.46e-27	-0.65	-0.49	Response to antipsychotic treatment;	chr6:85938718	chr6:85660950~85678736:-
LUAD	cis	rs7617773	0.817	rs9837228	ENSG00000229759.1	MRPS18AP1	-12.38	9.89e-31	4.48e-27	-0.5	-0.49	Coronary artery disease;	chr3:48282976	chr3:48256350~48256938:-
LUAD	cis	rs17507216	0.718	rs72751675	ENSG00000278603.1	RP13-608F4.5	12.37	1e-30	4.54e-27	0.71	0.49	Excessive daytime sleepiness;	chr15:82630452	chr15:82472203~82472426:+
LUAD	cis	rs3091242	0.967	rs1053438	ENSG00000261349.1	RP3-465N24.5	12.37	1.01e-30	4.59e-27	0.54	0.49	Erythrocyte sedimentation rate;	chr1:25361410	chr1:25266102~25267136:-
LUAD	cis	rs1153858	1	rs7171577	ENSG00000259520.4	CTD-2651B20.3	-12.37	1.02e-30	4.6e-27	-0.66	-0.49	Homoarginine levels;	chr15:45335781	chr15:45251580~45279251:-
LUAD	cis	rs11155671	0.53	rs7757984	ENSG00000231760.4	RP11-350J20.5	12.37	1.04e-30	4.72e-27	0.62	0.49	Testicular germ cell tumor;	chr6:149887515	chr6:149796151~149826294:-
LUAD	cis	rs507080	0.922	rs582630	ENSG00000255422.1	AP002954.4	-12.37	1.07e-30	4.83e-27	-0.62	-0.49	Serum metabolite levels;	chr11:118692090	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.883	rs527475	ENSG00000255422.1	AP002954.4	-12.37	1.07e-30	4.83e-27	-0.62	-0.49	Serum metabolite levels;	chr11:118692530	chr11:118704607~118750263:+
LUAD	cis	rs1799949	0.965	rs799917	ENSG00000198496.9	NBR2	-12.37	1.07e-30	4.83e-27	-0.51	-0.49	Menopause (age at onset);	chr17:43092919	chr17:43125610~43153671:+
LUAD	cis	rs2658782	0.547	rs3020054	ENSG00000279684.1	RP11-755E23.2	-12.37	1.07e-30	4.83e-27	-0.65	-0.49	Pulmonary function decline;	chr11:93322390	chr11:93286629~93288903:-
LUAD	cis	rs7617773	0.963	rs9822496	ENSG00000229759.1	MRPS18AP1	12.37	1.08e-30	4.87e-27	0.48	0.49	Coronary artery disease;	chr3:48139843	chr3:48256350~48256938:-
LUAD	cis	rs3091242	0.9	rs1883427	ENSG00000224183.1	SDHDP6	-12.37	1.09e-30	4.91e-27	-0.62	-0.49	Erythrocyte sedimentation rate;	chr1:25417977	chr1:25294164~25294643:-
LUAD	cis	rs992157	0.735	rs10932765	ENSG00000261338.2	RP11-378A13.1	12.37	1.09e-30	4.91e-27	0.49	0.49	Colorectal cancer;	chr2:218234761	chr2:218255319~218257366:+
LUAD	cis	rs1799949	0.929	rs799905	ENSG00000198496.9	NBR2	-12.36	1.11e-30	5e-27	-0.52	-0.49	Menopause (age at onset);	chr17:43125170	chr17:43125610~43153671:+
LUAD	cis	rs7301826	1	rs2001483	ENSG00000256299.1	RP11-989F5.3	-12.36	1.11e-30	5.02e-27	-0.54	-0.49	Plasma plasminogen activator levels;	chr12:130834100	chr12:130810821~130812622:-
LUAD	cis	rs507080	0.922	rs555356	ENSG00000255422.1	AP002954.4	-12.36	1.12e-30	5.03e-27	-0.61	-0.49	Serum metabolite levels;	chr11:118687369	chr11:118704607~118750263:+
LUAD	cis	rs73086581	1	rs73084575	ENSG00000229539.1	RP11-119B16.2	12.36	1.12e-30	5.03e-27	0.7	0.49	Response to antidepressants in depression;	chr20:3926121	chr20:3888239~3888868:-
LUAD	cis	rs1153858	1	rs2467863	ENSG00000259520.4	CTD-2651B20.3	-12.36	1.13e-30	5.09e-27	-0.67	-0.49	Homoarginine levels;	chr15:45349682	chr15:45251580~45279251:-
LUAD	cis	rs3091242	0.933	rs11802413	ENSG00000224183.1	SDHDP6	12.36	1.15e-30	5.19e-27	0.62	0.49	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25294164~25294643:-
LUAD	cis	rs1153858	1	rs10519021	ENSG00000259520.4	CTD-2651B20.3	-12.35	1.21e-30	5.44e-27	-0.66	-0.49	Homoarginine levels;	chr15:45339597	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs4775911	ENSG00000259520.4	CTD-2651B20.3	12.35	1.22e-30	5.45e-27	0.65	0.49	Homoarginine levels;	chr15:45357589	chr15:45251580~45279251:-
LUAD	cis	rs1799949	0.965	rs799912	ENSG00000198496.9	NBR2	-12.35	1.22e-30	5.45e-27	-0.51	-0.49	Menopause (age at onset);	chr17:43105117	chr17:43125610~43153671:+
LUAD	cis	rs7617773	0.815	rs9825637	ENSG00000229759.1	MRPS18AP1	12.35	1.23e-30	5.5e-27	0.51	0.49	Coronary artery disease;	chr3:48330792	chr3:48256350~48256938:-
LUAD	cis	rs1577917	0.916	rs4142546	ENSG00000203875.9	SNHG5	-12.35	1.24e-30	5.55e-27	-0.68	-0.49	Response to antipsychotic treatment;	chr6:85795593	chr6:85660950~85678736:-
LUAD	cis	rs9399135	0.967	rs9389253	ENSG00000232876.1	CTA-212D2.2	-12.35	1.24e-30	5.57e-27	-0.54	-0.49	Red blood cell count;	chr6:135008617	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs9389254	ENSG00000232876.1	CTA-212D2.2	-12.35	1.24e-30	5.57e-27	-0.54	-0.49	Red blood cell count;	chr6:135009571	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs1014020	ENSG00000232876.1	CTA-212D2.2	-12.35	1.25e-30	5.58e-27	-0.54	-0.49	Red blood cell count;	chr6:135013288	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs1041481	ENSG00000232876.1	CTA-212D2.2	-12.35	1.25e-30	5.59e-27	-0.54	-0.49	Red blood cell count;	chr6:135013925	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs6902438	ENSG00000232876.1	CTA-212D2.2	-12.35	1.25e-30	5.59e-27	-0.54	-0.49	Red blood cell count;	chr6:135015449	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.935	rs6908681	ENSG00000232876.1	CTA-212D2.2	-12.35	1.25e-30	5.59e-27	-0.54	-0.49	Red blood cell count;	chr6:135016595	chr6:135055033~135060550:+
LUAD	cis	rs7847628	0.666	rs2031974	ENSG00000226752.6	PSMD5-AS1	-12.35	1.27e-30	5.69e-27	-0.58	-0.49	Birth weight;	chr9:120765243	chr9:120824828~120854385:+
LUAD	cis	rs7617773	0.963	rs12494304	ENSG00000229759.1	MRPS18AP1	-12.35	1.3e-30	5.79e-27	-0.48	-0.49	Coronary artery disease;	chr3:48136539	chr3:48256350~48256938:-
LUAD	cis	rs1577917	0.958	rs12190603	ENSG00000203875.9	SNHG5	-12.35	1.3e-30	5.8e-27	-0.67	-0.49	Response to antipsychotic treatment;	chr6:85766000	chr6:85660950~85678736:-
LUAD	cis	rs3091242	0.804	rs631133	ENSG00000261349.1	RP3-465N24.5	-12.35	1.31e-30	5.84e-27	-0.54	-0.49	Erythrocyte sedimentation rate;	chr1:25397655	chr1:25266102~25267136:-
LUAD	cis	rs507080	0.883	rs12798453	ENSG00000255422.1	AP002954.4	-12.35	1.32e-30	5.87e-27	-0.61	-0.49	Serum metabolite levels;	chr11:118690701	chr11:118704607~118750263:+
LUAD	cis	rs6452524	0.935	rs7718472	ENSG00000249664.1	CTD-2227C6.2	12.34	1.39e-30	6.17e-27	0.56	0.49	Hypertension (SNP x SNP interaction);	chr5:83082603	chr5:83012285~83013109:-
LUAD	cis	rs17507216	0.718	rs72751662	ENSG00000278603.1	RP13-608F4.5	12.34	1.39e-30	6.2e-27	0.71	0.49	Excessive daytime sleepiness;	chr15:82594705	chr15:82472203~82472426:+
LUAD	cis	rs2739330	0.753	rs4822452	ENSG00000250470.1	AP000351.3	12.34	1.42e-30	6.32e-27	0.61	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23976904~23977585:-
LUAD	cis	rs6452524	0.935	rs7703318	ENSG00000249664.1	CTD-2227C6.2	12.34	1.43e-30	6.34e-27	0.56	0.49	Hypertension (SNP x SNP interaction);	chr5:83118234	chr5:83012285~83013109:-
LUAD	cis	rs10129255	0.5	rs10143242	ENSG00000223648.3	IGHV3-64	12.33	1.45e-30	6.44e-27	0.44	0.49	Kawasaki disease;	chr14:106681814	chr14:106643132~106658258:-
LUAD	cis	rs1799949	0.965	rs799910	ENSG00000198496.9	NBR2	-12.33	1.45e-30	6.46e-27	-0.52	-0.49	Menopause (age at onset);	chr17:43127544	chr17:43125610~43153671:+
LUAD	cis	rs507080	0.922	rs546890	ENSG00000255239.1	AP002954.6	12.33	1.48e-30	6.57e-27	0.59	0.49	Serum metabolite levels;	chr11:118686489	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.883	rs693306	ENSG00000255239.1	AP002954.6	12.33	1.48e-30	6.57e-27	0.59	0.49	Serum metabolite levels;	chr11:118687624	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.922	rs558907	ENSG00000255239.1	AP002954.6	12.33	1.48e-30	6.57e-27	0.59	0.49	Serum metabolite levels;	chr11:118687746	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.922	rs561845	ENSG00000255239.1	AP002954.6	12.33	1.48e-30	6.57e-27	0.59	0.49	Serum metabolite levels;	chr11:118688118	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.922	rs638805	ENSG00000255239.1	AP002954.6	12.33	1.48e-30	6.57e-27	0.59	0.49	Serum metabolite levels;	chr11:118688180	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.845	rs510408	ENSG00000255239.1	AP002954.6	12.33	1.48e-30	6.57e-27	0.59	0.49	Serum metabolite levels;	chr11:118688192	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.845	rs509641	ENSG00000255239.1	AP002954.6	12.33	1.48e-30	6.57e-27	0.59	0.49	Serum metabolite levels;	chr11:118688243	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.883	rs563549	ENSG00000255239.1	AP002954.6	12.33	1.48e-30	6.57e-27	0.59	0.49	Serum metabolite levels;	chr11:118688244	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.885	rs533144	ENSG00000255239.1	AP002954.6	12.33	1.48e-30	6.57e-27	0.59	0.49	Serum metabolite levels;	chr11:118688538	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.885	rs4938530	ENSG00000255239.1	AP002954.6	12.33	1.48e-30	6.57e-27	0.59	0.49	Serum metabolite levels;	chr11:118689861	chr11:118688039~118690600:-
LUAD	cis	rs875971	0.508	rs10253883	ENSG00000226824.5	RP4-756H11.3	12.33	1.49e-30	6.6e-27	0.61	0.49	Aortic root size;	chr7:66596151	chr7:66654538~66669855:+
LUAD	cis	rs7301826	0.934	rs10848212	ENSG00000256250.1	RP11-989F5.1	12.33	1.5e-30	6.62e-27	0.53	0.49	Plasma plasminogen activator levels;	chr12:130837455	chr12:130810606~130812438:+
LUAD	cis	rs801193	0.773	rs801207	ENSG00000226824.5	RP4-756H11.3	12.33	1.54e-30	6.8e-27	0.61	0.49	Aortic root size;	chr7:66555603	chr7:66654538~66669855:+
LUAD	cis	rs858239	0.665	rs858305	ENSG00000230658.1	KLHL7-AS1	-12.33	1.58e-30	6.98e-27	-0.58	-0.49	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23101228~23105703:-
LUAD	cis	rs6538678	0.712	rs10777748	ENSG00000258343.1	RP11-536G4.2	-12.33	1.59e-30	7e-27	-0.69	-0.49	Lupus nephritis in systemic lupus erythematosus;	chr12:95880227	chr12:95795345~95858839:-
LUAD	cis	rs858239	0.831	rs7796541	ENSG00000230658.1	KLHL7-AS1	12.32	1.61e-30	7.09e-27	0.59	0.49	Cerebrospinal fluid biomarker levels;	chr7:23349454	chr7:23101228~23105703:-
LUAD	cis	rs7617773	0.817	rs9819094	ENSG00000229759.1	MRPS18AP1	12.32	1.62e-30	7.16e-27	0.5	0.49	Coronary artery disease;	chr3:48278068	chr3:48256350~48256938:-
LUAD	cis	rs1577917	0.958	rs11758508	ENSG00000203875.9	SNHG5	12.32	1.64e-30	7.24e-27	0.67	0.49	Response to antipsychotic treatment;	chr6:85797160	chr6:85660950~85678736:-
LUAD	cis	rs950027	0.62	rs872192	ENSG00000259520.4	CTD-2651B20.3	-12.32	1.65e-30	7.26e-27	-0.59	-0.49	Response to fenofibrate (adiponectin levels);	chr15:45322304	chr15:45251580~45279251:-
LUAD	cis	rs1577917	0.958	rs6900436	ENSG00000203875.9	SNHG5	-12.32	1.66e-30	7.33e-27	-0.68	-0.49	Response to antipsychotic treatment;	chr6:85796570	chr6:85660950~85678736:-
LUAD	cis	rs62388641	1	rs62388641	ENSG00000272279.1	RP11-157J24.2	12.32	1.67e-30	7.35e-27	0.79	0.49	Daytime sleep phenotypes;	chr6:1539849	chr6:1528364~1528911:-
LUAD	cis	rs875971	0.895	rs7788984	ENSG00000226824.5	RP4-756H11.3	-12.32	1.73e-30	7.61e-27	-0.62	-0.49	Aortic root size;	chr7:66450629	chr7:66654538~66669855:+
LUAD	cis	rs1577917	0.687	rs1470531	ENSG00000203875.9	SNHG5	-12.31	1.78e-30	7.81e-27	-0.67	-0.49	Response to antipsychotic treatment;	chr6:85797651	chr6:85660950~85678736:-
LUAD	cis	rs507080	0.922	rs525485	ENSG00000255422.1	AP002954.4	-12.31	1.82e-30	8e-27	-0.61	-0.49	Serum metabolite levels;	chr11:118685045	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.922	rs625513	ENSG00000255422.1	AP002954.4	-12.31	1.83e-30	8.04e-27	-0.61	-0.49	Serum metabolite levels;	chr11:118685010	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.922	rs514143	ENSG00000255422.1	AP002954.4	-12.31	1.83e-30	8.04e-27	-0.61	-0.49	Serum metabolite levels;	chr11:118687740	chr11:118704607~118750263:+
LUAD	cis	rs4423214	0.57	rs7118246	ENSG00000254682.1	RP11-660L16.2	12.31	1.83e-30	8.05e-27	0.67	0.49	Vitamin D levels;	chr11:71520078	chr11:71448674~71452157:+
LUAD	cis	rs7617773	0.963	rs6800730	ENSG00000229759.1	MRPS18AP1	12.31	1.88e-30	8.23e-27	0.49	0.49	Coronary artery disease;	chr3:48132720	chr3:48256350~48256938:-
LUAD	cis	rs1799949	0.965	rs9646418	ENSG00000198496.9	NBR2	-12.31	1.9e-30	8.34e-27	-0.51	-0.49	Menopause (age at onset);	chr17:43348533	chr17:43125610~43153671:+
LUAD	cis	rs3091242	0.933	rs3093584	ENSG00000261349.1	RP3-465N24.5	12.3	1.94e-30	8.5e-27	0.54	0.49	Erythrocyte sedimentation rate;	chr1:25342223	chr1:25266102~25267136:-
LUAD	cis	rs1799949	0.965	rs11080034	ENSG00000198496.9	NBR2	-12.3	2.01e-30	8.8e-27	-0.52	-0.49	Menopause (age at onset);	chr17:43365646	chr17:43125610~43153671:+
LUAD	cis	rs2882667	0.683	rs13188935	ENSG00000253404.1	AC034243.1	12.3	2.09e-30	9.14e-27	0.61	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139116536	chr5:138744434~138753309:-
LUAD	cis	rs875971	1	rs7781698	ENSG00000226824.5	RP4-756H11.3	-12.29	2.12e-30	9.29e-27	-0.62	-0.49	Aortic root size;	chr7:66431325	chr7:66654538~66669855:+
LUAD	cis	rs17507216	0.718	rs4779033	ENSG00000278603.1	RP13-608F4.5	-12.29	2.18e-30	9.52e-27	-0.69	-0.49	Excessive daytime sleepiness;	chr15:82576634	chr15:82472203~82472426:+
LUAD	cis	rs507080	0.961	rs642497	ENSG00000255422.1	AP002954.4	-12.29	2.23e-30	9.74e-27	-0.6	-0.49	Serum metabolite levels;	chr11:118680075	chr11:118704607~118750263:+
LUAD	cis	rs7617773	0.925	rs35942721	ENSG00000229759.1	MRPS18AP1	12.29	2.25e-30	9.81e-27	0.53	0.49	Coronary artery disease;	chr3:48131579	chr3:48256350~48256938:-
LUAD	cis	rs11155671	0.53	rs1334510	ENSG00000231760.4	RP11-350J20.5	12.29	2.26e-30	9.84e-27	0.62	0.49	Testicular germ cell tumor;	chr6:149880043	chr6:149796151~149826294:-
LUAD	cis	rs3091242	0.933	rs926438	ENSG00000224183.1	SDHDP6	-12.29	2.27e-30	9.91e-27	-0.62	-0.49	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25294164~25294643:-
LUAD	cis	rs9399135	0.967	rs4896121	ENSG00000232876.1	CTA-212D2.2	-12.29	2.28e-30	9.95e-27	-0.54	-0.49	Red blood cell count;	chr6:134972507	chr6:135055033~135060550:+
LUAD	cis	rs67383717	0.713	rs1369156	ENSG00000175611.10	LINC00476	-12.29	2.29e-30	9.97e-27	-0.52	-0.49	Parkinson's disease (pesticide exposure interaction);	chr9:95794612	chr9:95759231~95875977:-
LUAD	cis	rs11155671	0.53	rs9371542	ENSG00000231760.4	RP11-350J20.5	12.29	2.3e-30	1e-26	0.62	0.49	Testicular germ cell tumor;	chr6:149891949	chr6:149796151~149826294:-
LUAD	cis	rs11155671	0.53	rs9371223	ENSG00000231760.4	RP11-350J20.5	12.29	2.3e-30	1e-26	0.62	0.49	Testicular germ cell tumor;	chr6:149893670	chr6:149796151~149826294:-
LUAD	cis	rs1577917	0.958	rs1545376	ENSG00000203875.9	SNHG5	12.28	2.33e-30	1.02e-26	0.67	0.49	Response to antipsychotic treatment;	chr6:85794864	chr6:85660950~85678736:-
LUAD	cis	rs507080	0.885	rs693037	ENSG00000255422.1	AP002954.4	-12.28	2.34e-30	1.02e-26	-0.61	-0.49	Serum metabolite levels;	chr11:118682617	chr11:118704607~118750263:+
LUAD	cis	rs73086581	1	rs14047	ENSG00000229539.1	RP11-119B16.2	12.28	2.42e-30	1.05e-26	0.72	0.49	Response to antidepressants in depression;	chr20:3933568	chr20:3888239~3888868:-
LUAD	cis	rs7617773	0.925	rs34513961	ENSG00000229759.1	MRPS18AP1	12.28	2.46e-30	1.07e-26	0.53	0.49	Coronary artery disease;	chr3:48132163	chr3:48256350~48256938:-
LUAD	cis	rs7301826	1	rs10773819	ENSG00000256299.1	RP11-989F5.3	-12.28	2.48e-30	1.08e-26	-0.54	-0.49	Plasma plasminogen activator levels;	chr12:130794477	chr12:130810821~130812622:-
LUAD	cis	rs507080	0.922	rs555356	ENSG00000255239.1	AP002954.6	12.27	2.64e-30	1.14e-26	0.59	0.49	Serum metabolite levels;	chr11:118687369	chr11:118688039~118690600:-
LUAD	cis	rs11723261	0.621	rs61794960	ENSG00000275426.1	CH17-262A2.1	12.27	2.66e-30	1.15e-26	0.71	0.49	Immune response to smallpox vaccine (IL-6);	chr4:156661	chr4:149738~150317:+
LUAD	cis	rs1577917	0.771	rs3812133	ENSG00000203875.9	SNHG5	-12.26	2.82e-30	1.22e-26	-0.71	-0.49	Response to antipsychotic treatment;	chr6:85644693	chr6:85660950~85678736:-
LUAD	cis	rs875971	1	rs6958271	ENSG00000226824.5	RP4-756H11.3	-12.26	2.84e-30	1.23e-26	-0.62	-0.49	Aortic root size;	chr7:66514344	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs6958277	ENSG00000226824.5	RP4-756H11.3	-12.26	2.84e-30	1.23e-26	-0.62	-0.49	Aortic root size;	chr7:66514362	chr7:66654538~66669855:+
LUAD	cis	rs11118620	0.535	rs1389750	ENSG00000238078.1	LINC01352	12.26	2.89e-30	1.25e-26	0.54	0.49	Heart failure;	chr1:220866829	chr1:220829255~220832429:+
LUAD	cis	rs9326248	0.53	rs6589576	ENSG00000254851.1	RP11-109L13.1	12.26	2.92e-30	1.26e-26	0.81	0.49	Blood protein levels;	chr11:116865072	chr11:117135528~117138582:+
LUAD	cis	rs7617773	0.963	rs12493256	ENSG00000229759.1	MRPS18AP1	-12.26	2.97e-30	1.28e-26	-0.48	-0.49	Coronary artery disease;	chr3:48135257	chr3:48256350~48256938:-
LUAD	cis	rs9399135	0.967	rs4895436	ENSG00000232876.1	CTA-212D2.2	-12.26	3.04e-30	1.31e-26	-0.54	-0.49	Red blood cell count;	chr6:134973863	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs4896122	ENSG00000232876.1	CTA-212D2.2	-12.26	3.04e-30	1.31e-26	-0.54	-0.49	Red blood cell count;	chr6:134973943	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs9376075	ENSG00000232876.1	CTA-212D2.2	-12.26	3.04e-30	1.31e-26	-0.54	-0.49	Red blood cell count;	chr6:134975825	chr6:135055033~135060550:+
LUAD	cis	rs1577917	0.958	rs2225754	ENSG00000203875.9	SNHG5	-12.26	3.04e-30	1.31e-26	-0.69	-0.49	Response to antipsychotic treatment;	chr6:85739980	chr6:85660950~85678736:-
LUAD	cis	rs875971	1	rs1981798	ENSG00000226824.5	RP4-756H11.3	-12.26	3.06e-30	1.32e-26	-0.62	-0.49	Aortic root size;	chr7:66489916	chr7:66654538~66669855:+
LUAD	cis	rs11155671	0.53	rs7756850	ENSG00000231760.4	RP11-350J20.5	12.25	3.1e-30	1.34e-26	0.61	0.49	Testicular germ cell tumor;	chr6:149891460	chr6:149796151~149826294:-
LUAD	cis	rs2283792	0.812	rs240066	ENSG00000224086.5	LL22NC03-86G7.1	12.25	3.11e-30	1.34e-26	0.46	0.49	Multiple sclerosis;	chr22:21938623	chr22:21938293~21977632:+
LUAD	cis	rs17507216	0.609	rs1431716	ENSG00000278603.1	RP13-608F4.5	12.25	3.28e-30	1.41e-26	0.7	0.49	Excessive daytime sleepiness;	chr15:82676180	chr15:82472203~82472426:+
LUAD	cis	rs3091242	0.933	rs4649084	ENSG00000261349.1	RP3-465N24.5	-12.24	3.4e-30	1.46e-26	-0.54	-0.49	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25266102~25267136:-
LUAD	cis	rs10129255	0.5	rs8011115	ENSG00000223648.3	IGHV3-64	12.24	3.41e-30	1.47e-26	0.44	0.49	Kawasaki disease;	chr14:106786292	chr14:106643132~106658258:-
LUAD	cis	rs10935480	0.577	rs10804683	ENSG00000239445.4	ST3GAL6-AS1	-12.24	3.48e-30	1.5e-26	-0.61	-0.49	Blood protein levels;	chr3:98661882	chr3:98714330~98732651:-
LUAD	cis	rs11155671	0.53	rs2342769	ENSG00000231760.4	RP11-350J20.5	12.24	3.5e-30	1.51e-26	0.61	0.49	Testicular germ cell tumor;	chr6:149895371	chr6:149796151~149826294:-
LUAD	cis	rs507080	0.922	rs546890	ENSG00000255422.1	AP002954.4	-12.24	3.56e-30	1.53e-26	-0.61	-0.49	Serum metabolite levels;	chr11:118686489	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.883	rs693306	ENSG00000255422.1	AP002954.4	-12.24	3.56e-30	1.53e-26	-0.61	-0.49	Serum metabolite levels;	chr11:118687624	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.922	rs558907	ENSG00000255422.1	AP002954.4	-12.24	3.56e-30	1.53e-26	-0.61	-0.49	Serum metabolite levels;	chr11:118687746	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.922	rs561845	ENSG00000255422.1	AP002954.4	-12.24	3.56e-30	1.53e-26	-0.61	-0.49	Serum metabolite levels;	chr11:118688118	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.922	rs638805	ENSG00000255422.1	AP002954.4	-12.24	3.56e-30	1.53e-26	-0.61	-0.49	Serum metabolite levels;	chr11:118688180	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.845	rs510408	ENSG00000255422.1	AP002954.4	-12.24	3.56e-30	1.53e-26	-0.61	-0.49	Serum metabolite levels;	chr11:118688192	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.845	rs509641	ENSG00000255422.1	AP002954.4	-12.24	3.56e-30	1.53e-26	-0.61	-0.49	Serum metabolite levels;	chr11:118688243	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.883	rs563549	ENSG00000255422.1	AP002954.4	-12.24	3.56e-30	1.53e-26	-0.61	-0.49	Serum metabolite levels;	chr11:118688244	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.885	rs533144	ENSG00000255422.1	AP002954.4	-12.24	3.56e-30	1.53e-26	-0.61	-0.49	Serum metabolite levels;	chr11:118688538	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.885	rs4938530	ENSG00000255422.1	AP002954.4	-12.24	3.56e-30	1.53e-26	-0.61	-0.49	Serum metabolite levels;	chr11:118689861	chr11:118704607~118750263:+
LUAD	cis	rs1577917	0.958	rs36053156	ENSG00000203875.9	SNHG5	-12.24	3.65e-30	1.56e-26	-0.7	-0.49	Response to antipsychotic treatment;	chr6:85865791	chr6:85660950~85678736:-
LUAD	cis	rs875971	0.895	rs12698520	ENSG00000226824.5	RP4-756H11.3	-12.24	3.69e-30	1.58e-26	-0.62	-0.49	Aortic root size;	chr7:66453720	chr7:66654538~66669855:+
LUAD	cis	rs4423214	1	rs11233746	ENSG00000254682.1	RP11-660L16.2	12.24	3.7e-30	1.59e-26	0.63	0.49	Vitamin D levels;	chr11:71460394	chr11:71448674~71452157:+
LUAD	cis	rs875971	0.964	rs60193905	ENSG00000226824.5	RP4-756H11.3	-12.23	3.73e-30	1.6e-26	-0.62	-0.49	Aortic root size;	chr7:66506273	chr7:66654538~66669855:+
LUAD	cis	rs1577917	0.958	rs12196230	ENSG00000203875.9	SNHG5	-12.23	3.76e-30	1.61e-26	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85810242	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs34994386	ENSG00000203875.9	SNHG5	-12.23	3.76e-30	1.61e-26	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85814417	chr6:85660950~85678736:-
LUAD	cis	rs507080	0.961	rs600969	ENSG00000255422.1	AP002954.4	-12.23	3.78e-30	1.62e-26	-0.6	-0.49	Serum metabolite levels;	chr11:118675087	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.961	rs673770	ENSG00000255422.1	AP002954.4	-12.23	3.78e-30	1.62e-26	-0.6	-0.49	Serum metabolite levels;	chr11:118679892	chr11:118704607~118750263:+
LUAD	cis	rs7115242	0.925	rs7925256	ENSG00000254851.1	RP11-109L13.1	-12.23	3.83e-30	1.64e-26	-0.99	-0.49	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117174619	chr11:117135528~117138582:+
LUAD	cis	rs875971	1	rs35149210	ENSG00000226824.5	RP4-756H11.3	-12.23	3.87e-30	1.65e-26	-0.62	-0.49	Aortic root size;	chr7:66464938	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs6460296	ENSG00000226824.5	RP4-756H11.3	-12.23	3.97e-30	1.69e-26	-0.62	-0.49	Aortic root size;	chr7:66430152	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs4717292	ENSG00000226824.5	RP4-756H11.3	-12.23	3.97e-30	1.69e-26	-0.62	-0.49	Aortic root size;	chr7:66430611	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.895	rs4718349	ENSG00000226824.5	RP4-756H11.3	-12.23	3.97e-30	1.69e-26	-0.62	-0.49	Aortic root size;	chr7:66444024	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs2420591	ENSG00000226824.5	RP4-756H11.3	-12.23	3.97e-30	1.69e-26	-0.62	-0.49	Aortic root size;	chr7:66447394	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.895	rs10755833	ENSG00000226824.5	RP4-756H11.3	-12.23	3.97e-30	1.69e-26	-0.62	-0.49	Aortic root size;	chr7:66448930	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.964	rs12668936	ENSG00000226824.5	RP4-756H11.3	-12.23	3.97e-30	1.69e-26	-0.62	-0.49	Aortic root size;	chr7:66449417	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.895	rs1833495	ENSG00000226824.5	RP4-756H11.3	-12.23	3.97e-30	1.69e-26	-0.62	-0.49	Aortic root size;	chr7:66456608	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.964	rs6945032	ENSG00000226824.5	RP4-756H11.3	-12.23	3.97e-30	1.69e-26	-0.62	-0.49	Aortic root size;	chr7:66457499	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.929	rs12673810	ENSG00000226824.5	RP4-756H11.3	-12.23	3.97e-30	1.69e-26	-0.62	-0.49	Aortic root size;	chr7:66458866	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs2042133	ENSG00000226824.5	RP4-756H11.3	-12.23	3.97e-30	1.69e-26	-0.62	-0.49	Aortic root size;	chr7:66466935	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.964	rs2161065	ENSG00000226824.5	RP4-756H11.3	-12.23	3.97e-30	1.69e-26	-0.62	-0.49	Aortic root size;	chr7:66467918	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs6961155	ENSG00000226824.5	RP4-756H11.3	-12.23	3.97e-30	1.69e-26	-0.62	-0.49	Aortic root size;	chr7:66468308	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.895	rs3857684	ENSG00000226824.5	RP4-756H11.3	-12.23	3.97e-30	1.69e-26	-0.62	-0.49	Aortic root size;	chr7:66473171	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs7789768	ENSG00000226824.5	RP4-756H11.3	-12.23	3.97e-30	1.69e-26	-0.62	-0.49	Aortic root size;	chr7:66473993	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs12698521	ENSG00000226824.5	RP4-756H11.3	-12.23	3.97e-30	1.69e-26	-0.62	-0.49	Aortic root size;	chr7:66474502	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs6957199	ENSG00000226824.5	RP4-756H11.3	-12.23	3.99e-30	1.7e-26	-0.61	-0.49	Aortic root size;	chr7:66513532	chr7:66654538~66669855:+
LUAD	cis	rs10256972	0.539	rs2949174	ENSG00000229043.2	AC091729.9	-12.23	4.06e-30	1.73e-26	-0.54	-0.49	Endometriosis;Longevity;	chr7:1174287	chr7:1160374~1165267:+
LUAD	cis	rs11118620	0.535	rs1389750	ENSG00000272823.1	RP11-295M18.6	12.22	4.15e-30	1.77e-26	0.55	0.49	Heart failure;	chr1:220866829	chr1:220828676~220829211:-
LUAD	cis	rs875971	0.543	rs801191	ENSG00000226824.5	RP4-756H11.3	12.22	4.22e-30	1.79e-26	0.6	0.49	Aortic root size;	chr7:66567968	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.929	rs10950041	ENSG00000226824.5	RP4-756H11.3	-12.22	4.22e-30	1.79e-26	-0.61	-0.49	Aortic root size;	chr7:66508888	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.929	rs6970860	ENSG00000226824.5	RP4-756H11.3	-12.22	4.22e-30	1.79e-26	-0.61	-0.49	Aortic root size;	chr7:66511647	chr7:66654538~66669855:+
LUAD	cis	rs997154	0.655	rs8015121	ENSG00000279656.1	RP11-298I3.6	12.22	4.26e-30	1.81e-26	0.7	0.49	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22906042	chr14:23023083~23024217:-
LUAD	cis	rs67383717	0.672	rs589458	ENSG00000175611.10	LINC00476	12.22	4.29e-30	1.82e-26	0.52	0.49	Parkinson's disease (pesticide exposure interaction);	chr9:95878389	chr9:95759231~95875977:-
LUAD	cis	rs2882667	0.788	rs11959691	ENSG00000253404.1	AC034243.1	12.22	4.33e-30	1.83e-26	0.67	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139145399	chr5:138744434~138753309:-
LUAD	cis	rs17507216	0.718	rs7161977	ENSG00000278603.1	RP13-608F4.5	12.22	4.36e-30	1.85e-26	0.7	0.49	Excessive daytime sleepiness;	chr15:82646782	chr15:82472203~82472426:+
LUAD	cis	rs2658782	0.901	rs11601056	ENSG00000279684.1	RP11-755E23.2	12.22	4.37e-30	1.85e-26	0.81	0.49	Pulmonary function decline;	chr11:93495995	chr11:93286629~93288903:-
LUAD	cis	rs3091242	0.967	rs665372	ENSG00000261349.1	RP3-465N24.5	-12.22	4.38e-30	1.86e-26	-0.54	-0.49	Erythrocyte sedimentation rate;	chr1:25392744	chr1:25266102~25267136:-
LUAD	cis	rs9399135	0.967	rs3756799	ENSG00000232876.1	CTA-212D2.2	-12.22	4.4e-30	1.86e-26	-0.54	-0.49	Red blood cell count;	chr6:135019873	chr6:135055033~135060550:+
LUAD	cis	rs2658782	0.756	rs3019222	ENSG00000279684.1	RP11-755E23.2	-12.22	4.41e-30	1.87e-26	-0.78	-0.49	Pulmonary function decline;	chr11:93346552	chr11:93286629~93288903:-
LUAD	cis	rs2739330	0.796	rs1006771	ENSG00000099984.9	GSTT2	-12.21	4.57e-30	1.93e-26	-0.6	-0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23980123~23983911:+
LUAD	cis	rs10262624	0.504	rs4722255	ENSG00000234286.1	AC006026.13	-12.21	4.61e-30	1.95e-26	-0.59	-0.49	Schizophrenia;	chr7:23706453	chr7:23680195~23680786:-
LUAD	cis	rs875971	1	rs2077593	ENSG00000226824.5	RP4-756H11.3	-12.21	4.75e-30	2.01e-26	-0.61	-0.49	Aortic root size;	chr7:66427543	chr7:66654538~66669855:+
LUAD	cis	rs1577917	0.916	rs12198730	ENSG00000203875.9	SNHG5	-12.21	4.84e-30	2.05e-26	-0.68	-0.49	Response to antipsychotic treatment;	chr6:85845420	chr6:85660950~85678736:-
LUAD	cis	rs12439619	0.921	rs56042848	ENSG00000278603.1	RP13-608F4.5	12.2	4.94e-30	2.09e-26	0.62	0.49	Intelligence (multi-trait analysis);	chr15:82235244	chr15:82472203~82472426:+
LUAD	cis	rs9326248	0.53	rs588918	ENSG00000254851.1	RP11-109L13.1	-12.2	4.97e-30	2.1e-26	-0.81	-0.49	Blood protein levels;	chr11:116985926	chr11:117135528~117138582:+
LUAD	cis	rs4853012	0.941	rs4852329	ENSG00000217702.2	RP11-287D1.4	12.2	5.01e-30	2.12e-26	0.79	0.49	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74130583~74135395:+
LUAD	cis	rs9399135	0.935	rs4273704	ENSG00000232876.1	CTA-212D2.2	-12.2	5.04e-30	2.13e-26	-0.53	-0.49	Red blood cell count;	chr6:134976382	chr6:135055033~135060550:+
LUAD	cis	rs73086581	1	rs73084594	ENSG00000229539.1	RP11-119B16.2	12.2	5.15e-30	2.17e-26	0.72	0.49	Response to antidepressants in depression;	chr20:3935733	chr20:3888239~3888868:-
LUAD	cis	rs858239	0.799	rs10279941	ENSG00000230658.1	KLHL7-AS1	12.2	5.16e-30	2.18e-26	0.62	0.49	Cerebrospinal fluid biomarker levels;	chr7:23330889	chr7:23101228~23105703:-
LUAD	cis	rs9399135	0.967	rs4637662	ENSG00000232876.1	CTA-212D2.2	-12.2	5.16e-30	2.18e-26	-0.53	-0.49	Red blood cell count;	chr6:134977020	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs4896119	ENSG00000232876.1	CTA-212D2.2	-12.2	5.2e-30	2.19e-26	-0.53	-0.49	Red blood cell count;	chr6:134972253	chr6:135055033~135060550:+
LUAD	cis	rs11155671	0.53	rs6935829	ENSG00000231760.4	RP11-350J20.5	12.2	5.25e-30	2.21e-26	0.62	0.49	Testicular germ cell tumor;	chr6:149896675	chr6:149796151~149826294:-
LUAD	cis	rs9399135	0.933	rs7755680	ENSG00000232876.1	CTA-212D2.2	-12.2	5.26e-30	2.22e-26	-0.53	-0.49	Red blood cell count;	chr6:134973121	chr6:135055033~135060550:+
LUAD	cis	rs10262624	0.504	rs59865844	ENSG00000234286.1	AC006026.13	12.2	5.39e-30	2.27e-26	0.58	0.49	Schizophrenia;	chr7:23693421	chr7:23680195~23680786:-
LUAD	cis	rs875971	0.895	rs1974769	ENSG00000226824.5	RP4-756H11.3	-12.19	5.43e-30	2.28e-26	-0.61	-0.49	Aortic root size;	chr7:66485627	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.895	rs6460300	ENSG00000226824.5	RP4-756H11.3	-12.19	5.43e-30	2.28e-26	-0.61	-0.49	Aortic root size;	chr7:66487937	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs7803416	ENSG00000226824.5	RP4-756H11.3	-12.19	5.43e-30	2.28e-26	-0.61	-0.49	Aortic root size;	chr7:66489212	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs1981799	ENSG00000226824.5	RP4-756H11.3	-12.19	5.43e-30	2.28e-26	-0.61	-0.49	Aortic root size;	chr7:66490572	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.964	rs2277911	ENSG00000226824.5	RP4-756H11.3	-12.19	5.43e-30	2.28e-26	-0.61	-0.49	Aortic root size;	chr7:66493638	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.964	rs6978429	ENSG00000226824.5	RP4-756H11.3	-12.19	5.43e-30	2.28e-26	-0.61	-0.49	Aortic root size;	chr7:66494889	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs4718357	ENSG00000226824.5	RP4-756H11.3	-12.19	5.43e-30	2.28e-26	-0.61	-0.49	Aortic root size;	chr7:66495891	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.929	rs12535036	ENSG00000226824.5	RP4-756H11.3	-12.19	5.43e-30	2.28e-26	-0.61	-0.49	Aortic root size;	chr7:66499076	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs12533997	ENSG00000226824.5	RP4-756H11.3	-12.19	5.43e-30	2.28e-26	-0.61	-0.49	Aortic root size;	chr7:66500390	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs12698523	ENSG00000226824.5	RP4-756H11.3	-12.19	5.43e-30	2.28e-26	-0.61	-0.49	Aortic root size;	chr7:66503126	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs6970030	ENSG00000226824.5	RP4-756H11.3	-12.19	5.43e-30	2.28e-26	-0.61	-0.49	Aortic root size;	chr7:66503692	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.928	rs6970357	ENSG00000226824.5	RP4-756H11.3	-12.19	5.43e-30	2.28e-26	-0.61	-0.49	Aortic root size;	chr7:66503891	chr7:66654538~66669855:+
LUAD	cis	rs17507216	0.681	rs28877110	ENSG00000278603.1	RP13-608F4.5	12.19	5.65e-30	2.37e-26	0.7	0.49	Excessive daytime sleepiness;	chr15:82672111	chr15:82472203~82472426:+
LUAD	cis	rs507080	0.807	rs7926944	ENSG00000255239.1	AP002954.6	12.19	5.77e-30	2.43e-26	0.58	0.49	Serum metabolite levels;	chr11:118689119	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.922	rs12577485	ENSG00000255422.1	AP002954.4	-12.19	5.82e-30	2.45e-26	-0.6	-0.49	Serum metabolite levels;	chr11:118676793	chr11:118704607~118750263:+
LUAD	cis	rs7301826	1	rs10848205	ENSG00000256299.1	RP11-989F5.3	-12.19	5.83e-30	2.45e-26	-0.54	-0.49	Plasma plasminogen activator levels;	chr12:130796169	chr12:130810821~130812622:-
LUAD	cis	rs3091242	0.934	rs686631	ENSG00000261349.1	RP3-465N24.5	-12.19	5.89e-30	2.47e-26	-0.53	-0.49	Erythrocyte sedimentation rate;	chr1:25393108	chr1:25266102~25267136:-
LUAD	cis	rs3091242	0.933	rs61775174	ENSG00000261349.1	RP3-465N24.5	12.18	5.94e-30	2.5e-26	0.54	0.49	Erythrocyte sedimentation rate;	chr1:25460822	chr1:25266102~25267136:-
LUAD	cis	rs875971	0.508	rs6947808	ENSG00000226824.5	RP4-756H11.3	12.18	6.11e-30	2.56e-26	0.6	0.49	Aortic root size;	chr7:66580095	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.929	rs34406470	ENSG00000226824.5	RP4-756H11.3	-12.18	6.12e-30	2.57e-26	-0.61	-0.49	Aortic root size;	chr7:66464969	chr7:66654538~66669855:+
LUAD	cis	rs507080	0.961	rs34413584	ENSG00000255239.1	AP002954.6	12.18	6.2e-30	2.6e-26	0.58	0.49	Serum metabolite levels;	chr11:118675072	chr11:118688039~118690600:-
LUAD	cis	rs1577917	0.958	rs36042496	ENSG00000203875.9	SNHG5	-12.18	6.34e-30	2.65e-26	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85814496	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.917	rs1584273	ENSG00000203875.9	SNHG5	-12.18	6.34e-30	2.65e-26	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85814859	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs12198971	ENSG00000203875.9	SNHG5	-12.18	6.34e-30	2.65e-26	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85815727	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs34230196	ENSG00000203875.9	SNHG5	-12.18	6.34e-30	2.65e-26	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85816304	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.917	rs4707226	ENSG00000203875.9	SNHG5	-12.18	6.34e-30	2.65e-26	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85818110	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs10455448	ENSG00000203875.9	SNHG5	-12.18	6.34e-30	2.65e-26	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85823893	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.917	rs13196576	ENSG00000203875.9	SNHG5	-12.18	6.34e-30	2.65e-26	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85824348	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.917	rs13213603	ENSG00000203875.9	SNHG5	-12.18	6.34e-30	2.65e-26	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85825040	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs3857480	ENSG00000203875.9	SNHG5	-12.18	6.34e-30	2.65e-26	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85825431	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs2324839	ENSG00000203875.9	SNHG5	-12.18	6.34e-30	2.65e-26	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85827224	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs3900313	ENSG00000203875.9	SNHG5	-12.18	6.34e-30	2.65e-26	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85827436	chr6:85660950~85678736:-
LUAD	cis	rs507080	0.922	rs625513	ENSG00000255239.1	AP002954.6	12.18	6.45e-30	2.7e-26	0.58	0.49	Serum metabolite levels;	chr11:118685010	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.922	rs514143	ENSG00000255239.1	AP002954.6	12.18	6.45e-30	2.7e-26	0.58	0.49	Serum metabolite levels;	chr11:118687740	chr11:118688039~118690600:-
LUAD	cis	rs9399135	0.967	rs4376365	ENSG00000232876.1	CTA-212D2.2	-12.17	6.59e-30	2.76e-26	-0.53	-0.49	Red blood cell count;	chr6:134986602	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs6923765	ENSG00000232876.1	CTA-212D2.2	12.17	6.62e-30	2.77e-26	0.54	0.49	Red blood cell count;	chr6:135014038	chr6:135055033~135060550:+
LUAD	cis	rs801193	0.844	rs732465	ENSG00000226824.5	RP4-756H11.3	-12.17	6.71e-30	2.81e-26	-0.6	-0.49	Aortic root size;	chr7:66533463	chr7:66654538~66669855:+
LUAD	cis	rs9399135	0.967	rs4388304	ENSG00000232876.1	CTA-212D2.2	-12.17	6.78e-30	2.83e-26	-0.53	-0.49	Red blood cell count;	chr6:134988459	chr6:135055033~135060550:+
LUAD	cis	rs6538678	0.864	rs4762249	ENSG00000258343.1	RP11-536G4.2	12.17	6.81e-30	2.85e-26	0.65	0.49	Lupus nephritis in systemic lupus erythematosus;	chr12:95884183	chr12:95795345~95858839:-
LUAD	cis	rs1930961	0.702	rs8141065	ENSG00000272977.1	CTA-390C10.10	12.17	6.97e-30	2.91e-26	0.84	0.49	Bipolar disorder with mood-incongruent psychosis;	chr22:25489221	chr22:25476218~25479971:+
LUAD	cis	rs67383717	0.689	rs1836404	ENSG00000175611.10	LINC00476	-12.17	6.98e-30	2.91e-26	-0.52	-0.49	Parkinson's disease (pesticide exposure interaction);	chr9:95787982	chr9:95759231~95875977:-
LUAD	cis	rs4853012	0.838	rs4429500	ENSG00000217702.2	RP11-287D1.4	12.17	7.02e-30	2.93e-26	0.69	0.49	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74130583~74135395:+
LUAD	cis	rs9399135	0.967	rs6910530	ENSG00000232876.1	CTA-212D2.2	-12.17	7.07e-30	2.95e-26	-0.54	-0.49	Red blood cell count;	chr6:135011632	chr6:135055033~135060550:+
LUAD	cis	rs73086581	1	rs6107393	ENSG00000229539.1	RP11-119B16.2	12.16	7.44e-30	3.1e-26	0.69	0.48	Response to antidepressants in depression;	chr20:4007091	chr20:3888239~3888868:-
LUAD	cis	rs2739330	0.828	rs2330635	ENSG00000250470.1	AP000351.3	12.16	7.6e-30	3.16e-26	0.61	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23976904~23977585:-
LUAD	cis	rs4853012	0.887	rs6737314	ENSG00000217702.2	RP11-287D1.4	12.16	7.77e-30	3.23e-26	0.77	0.48	Gestational age at birth (maternal effect);	chr2:74112459	chr2:74130583~74135395:+
LUAD	cis	rs507080	0.922	rs519848	ENSG00000255422.1	AP002954.4	-12.16	7.82e-30	3.25e-26	-0.61	-0.48	Serum metabolite levels;	chr11:118682006	chr11:118704607~118750263:+
LUAD	cis	rs875971	1	rs12532998	ENSG00000226824.5	RP4-756H11.3	-12.15	7.86e-30	3.27e-26	-0.61	-0.48	Aortic root size;	chr7:66502472	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs3735148	ENSG00000226824.5	RP4-756H11.3	-12.15	7.89e-30	3.28e-26	-0.61	-0.48	Aortic root size;	chr7:66506022	chr7:66654538~66669855:+
LUAD	cis	rs1153858	1	rs8032904	ENSG00000259520.4	CTD-2651B20.3	-12.15	7.9e-30	3.28e-26	-0.65	-0.48	Homoarginine levels;	chr15:45359111	chr15:45251580~45279251:-
LUAD	cis	rs6452524	0.935	rs10076059	ENSG00000249664.1	CTD-2227C6.2	12.15	7.97e-30	3.31e-26	0.55	0.48	Hypertension (SNP x SNP interaction);	chr5:83105698	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.935	rs7736783	ENSG00000249664.1	CTD-2227C6.2	12.15	7.97e-30	3.31e-26	0.55	0.48	Hypertension (SNP x SNP interaction);	chr5:83107050	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.935	rs11951257	ENSG00000249664.1	CTD-2227C6.2	12.15	7.97e-30	3.31e-26	0.55	0.48	Hypertension (SNP x SNP interaction);	chr5:83107492	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.935	rs767771	ENSG00000249664.1	CTD-2227C6.2	12.15	7.97e-30	3.31e-26	0.55	0.48	Hypertension (SNP x SNP interaction);	chr5:83108117	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.935	rs1543847	ENSG00000249664.1	CTD-2227C6.2	12.15	7.97e-30	3.31e-26	0.55	0.48	Hypertension (SNP x SNP interaction);	chr5:83116044	chr5:83012285~83013109:-
LUAD	cis	rs7617773	0.78	rs71323396	ENSG00000229759.1	MRPS18AP1	12.15	8.01e-30	3.33e-26	0.52	0.48	Coronary artery disease;	chr3:48333244	chr3:48256350~48256938:-
LUAD	cis	rs977987	0.671	rs9922008	ENSG00000261783.1	RP11-252K23.2	-12.15	8.16e-30	3.39e-26	-0.67	-0.48	Dupuytren's disease;	chr16:75301508	chr16:75379818~75381260:-
LUAD	cis	rs1577917	1	rs6923148	ENSG00000203875.9	SNHG5	12.15	8.27e-30	3.43e-26	0.66	0.48	Response to antipsychotic treatment;	chr6:86058068	chr6:85660950~85678736:-
LUAD	cis	rs507080	0.883	rs12798453	ENSG00000255239.1	AP002954.6	12.15	8.4e-30	3.48e-26	0.58	0.48	Serum metabolite levels;	chr11:118690701	chr11:118688039~118690600:-
LUAD	cis	rs4423214	1	rs4944957	ENSG00000254682.1	RP11-660L16.2	-12.15	8.41e-30	3.49e-26	-0.63	-0.48	Vitamin D levels;	chr11:71456989	chr11:71448674~71452157:+
LUAD	cis	rs2739330	0.828	rs5760107	ENSG00000250470.1	AP000351.3	12.14	8.8e-30	3.65e-26	0.61	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23976904~23977585:-
LUAD	cis	rs2739330	0.789	rs5760109	ENSG00000250470.1	AP000351.3	12.14	8.8e-30	3.65e-26	0.61	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23976904~23977585:-
LUAD	cis	rs2882667	0.824	rs11748097	ENSG00000253404.1	AC034243.1	12.14	8.85e-30	3.66e-26	0.66	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144198	chr5:138744434~138753309:-
LUAD	cis	rs3091242	0.935	rs3093632	ENSG00000224183.1	SDHDP6	-12.14	8.86e-30	3.67e-26	-0.61	-0.48	Erythrocyte sedimentation rate;	chr1:25357521	chr1:25294164~25294643:-
LUAD	cis	rs875971	0.964	rs6945019	ENSG00000226824.5	RP4-756H11.3	-12.14	8.9e-30	3.68e-26	-0.61	-0.48	Aortic root size;	chr7:66457471	chr7:66654538~66669855:+
LUAD	cis	rs3091242	0.967	rs3091240	ENSG00000224183.1	SDHDP6	-12.14	8.91e-30	3.69e-26	-0.61	-0.48	Erythrocyte sedimentation rate;	chr1:25350444	chr1:25294164~25294643:-
LUAD	cis	rs3091242	1	rs3091242	ENSG00000224183.1	SDHDP6	-12.14	8.92e-30	3.69e-26	-0.61	-0.48	Erythrocyte sedimentation rate;	chr1:25348294	chr1:25294164~25294643:-
LUAD	cis	rs875971	0.508	rs10242423	ENSG00000226824.5	RP4-756H11.3	12.14	8.98e-30	3.71e-26	0.6	0.48	Aortic root size;	chr7:66594188	chr7:66654538~66669855:+
LUAD	cis	rs997154	0.655	rs4981454	ENSG00000279656.1	RP11-298I3.6	12.14	9.08e-30	3.75e-26	0.71	0.48	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22952977	chr14:23023083~23024217:-
LUAD	cis	rs12439619	0.883	rs62012045	ENSG00000278603.1	RP13-608F4.5	12.14	9.08e-30	3.75e-26	0.61	0.48	Intelligence (multi-trait analysis);	chr15:82229366	chr15:82472203~82472426:+
LUAD	cis	rs1153858	1	rs4271549	ENSG00000259520.4	CTD-2651B20.3	-12.14	9.23e-30	3.81e-26	-0.65	-0.48	Homoarginine levels;	chr15:45360532	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs4627277	ENSG00000259520.4	CTD-2651B20.3	-12.14	9.23e-30	3.81e-26	-0.65	-0.48	Homoarginine levels;	chr15:45360570	chr15:45251580~45279251:-
LUAD	cis	rs6452524	0.905	rs1478482	ENSG00000249664.1	CTD-2227C6.2	12.14	9.27e-30	3.82e-26	0.55	0.48	Hypertension (SNP x SNP interaction);	chr5:83111279	chr5:83012285~83013109:-
LUAD	cis	rs10129255	0.509	rs756583	ENSG00000211972.2	IGHV3-66	12.14	9.28e-30	3.83e-26	0.38	0.48	Kawasaki disease;	chr14:106680002	chr14:106675017~106675544:-
LUAD	cis	rs1577917	0.876	rs12212808	ENSG00000203875.9	SNHG5	-12.14	9.32e-30	3.84e-26	-0.66	-0.48	Response to antipsychotic treatment;	chr6:85824254	chr6:85660950~85678736:-
LUAD	cis	rs10129255	0.5	rs988132	ENSG00000223648.3	IGHV3-64	12.13	9.63e-30	3.96e-26	0.45	0.48	Kawasaki disease;	chr14:106776758	chr14:106643132~106658258:-
LUAD	cis	rs6538678	0.824	rs7307510	ENSG00000258343.1	RP11-536G4.2	-12.13	9.87e-30	4.06e-26	-0.73	-0.48	Lupus nephritis in systemic lupus erythematosus;	chr12:95843792	chr12:95795345~95858839:-
LUAD	cis	rs1577917	0.958	rs1591438	ENSG00000203875.9	SNHG5	-12.13	9.93e-30	4.09e-26	-0.68	-0.48	Response to antipsychotic treatment;	chr6:85815496	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs1591437	ENSG00000203875.9	SNHG5	-12.13	9.93e-30	4.09e-26	-0.68	-0.48	Response to antipsychotic treatment;	chr6:85815587	chr6:85660950~85678736:-
LUAD	cis	rs6452524	0.935	rs10045744	ENSG00000249664.1	CTD-2227C6.2	12.13	1.01e-29	4.16e-26	0.55	0.48	Hypertension (SNP x SNP interaction);	chr5:83113688	chr5:83012285~83013109:-
LUAD	cis	rs875971	1	rs1363055	ENSG00000226824.5	RP4-756H11.3	-12.13	1.02e-29	4.19e-26	-0.61	-0.48	Aortic root size;	chr7:66478288	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.964	rs9691480	ENSG00000226824.5	RP4-756H11.3	-12.13	1.02e-29	4.19e-26	-0.61	-0.48	Aortic root size;	chr7:66479319	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs7789554	ENSG00000226824.5	RP4-756H11.3	-12.13	1.02e-29	4.19e-26	-0.61	-0.48	Aortic root size;	chr7:66481051	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs4717300	ENSG00000226824.5	RP4-756H11.3	-12.13	1.02e-29	4.19e-26	-0.61	-0.48	Aortic root size;	chr7:66482393	chr7:66654538~66669855:+
LUAD	cis	rs73086581	1	rs73086505	ENSG00000229539.1	RP11-119B16.2	12.13	1.03e-29	4.22e-26	0.72	0.48	Response to antidepressants in depression;	chr20:3940924	chr20:3888239~3888868:-
LUAD	cis	rs73086581	1	rs73086508	ENSG00000229539.1	RP11-119B16.2	12.13	1.03e-29	4.22e-26	0.72	0.48	Response to antidepressants in depression;	chr20:3941068	chr20:3888239~3888868:-
LUAD	cis	rs73086581	1	rs73086510	ENSG00000229539.1	RP11-119B16.2	12.13	1.03e-29	4.22e-26	0.72	0.48	Response to antidepressants in depression;	chr20:3941484	chr20:3888239~3888868:-
LUAD	cis	rs73086581	1	rs17286768	ENSG00000229539.1	RP11-119B16.2	12.13	1.03e-29	4.22e-26	0.72	0.48	Response to antidepressants in depression;	chr20:3943922	chr20:3888239~3888868:-
LUAD	cis	rs73086581	1	rs17214621	ENSG00000229539.1	RP11-119B16.2	12.13	1.03e-29	4.22e-26	0.72	0.48	Response to antidepressants in depression;	chr20:3945277	chr20:3888239~3888868:-
LUAD	cis	rs950027	0.549	rs11636114	ENSG00000259520.4	CTD-2651B20.3	-12.12	1.08e-29	4.43e-26	-0.6	-0.48	Response to fenofibrate (adiponectin levels);	chr15:45309214	chr15:45251580~45279251:-
LUAD	cis	rs1153858	0.943	rs8038342	ENSG00000259520.4	CTD-2651B20.3	-12.12	1.09e-29	4.48e-26	-0.65	-0.48	Homoarginine levels;	chr15:45359339	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs4774579	ENSG00000259520.4	CTD-2651B20.3	-12.12	1.09e-29	4.48e-26	-0.65	-0.48	Homoarginine levels;	chr15:45359605	chr15:45251580~45279251:-
LUAD	cis	rs6538678	0.833	rs1898178	ENSG00000258343.1	RP11-536G4.2	-12.12	1.1e-29	4.49e-26	-0.65	-0.48	Lupus nephritis in systemic lupus erythematosus;	chr12:95887554	chr12:95795345~95858839:-
LUAD	cis	rs6538678	0.833	rs1898177	ENSG00000258343.1	RP11-536G4.2	-12.12	1.1e-29	4.49e-26	-0.65	-0.48	Lupus nephritis in systemic lupus erythematosus;	chr12:95887568	chr12:95795345~95858839:-
LUAD	cis	rs875971	0.83	rs4718358	ENSG00000226824.5	RP4-756H11.3	-12.12	1.11e-29	4.56e-26	-0.61	-0.48	Aortic root size;	chr7:66508681	chr7:66654538~66669855:+
LUAD	cis	rs4853012	0.838	rs60964317	ENSG00000217702.2	RP11-287D1.4	12.12	1.12e-29	4.61e-26	0.7	0.48	Gestational age at birth (maternal effect);	chr2:74116296	chr2:74130583~74135395:+
LUAD	cis	rs11155671	0.53	rs9397398	ENSG00000231760.4	RP11-350J20.5	12.11	1.15e-29	4.71e-26	0.6	0.48	Testicular germ cell tumor;	chr6:149872467	chr6:149796151~149826294:-
LUAD	cis	rs507080	0.885	rs7926959	ENSG00000255239.1	AP002954.6	12.11	1.16e-29	4.73e-26	0.58	0.48	Serum metabolite levels;	chr11:118689157	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.663	rs7926970	ENSG00000255239.1	AP002954.6	12.11	1.16e-29	4.73e-26	0.58	0.48	Serum metabolite levels;	chr11:118689172	chr11:118688039~118690600:-
LUAD	cis	rs4423214	0.65	rs4245442	ENSG00000254682.1	RP11-660L16.2	12.11	1.17e-29	4.77e-26	0.65	0.48	Vitamin D levels;	chr11:71509863	chr11:71448674~71452157:+
LUAD	cis	rs858239	0.863	rs274054	ENSG00000230658.1	KLHL7-AS1	12.11	1.17e-29	4.79e-26	0.6	0.48	Cerebrospinal fluid biomarker levels;	chr7:23350848	chr7:23101228~23105703:-
LUAD	cis	rs507080	0.961	rs642530	ENSG00000255422.1	AP002954.4	-12.11	1.22e-29	4.97e-26	-0.6	-0.48	Serum metabolite levels;	chr11:118680047	chr11:118704607~118750263:+
LUAD	cis	rs7617773	0.817	rs9830016	ENSG00000229759.1	MRPS18AP1	12.11	1.25e-29	5.1e-26	0.48	0.48	Coronary artery disease;	chr3:48241004	chr3:48256350~48256938:-
LUAD	cis	rs1577917	0.958	rs4707223	ENSG00000203875.9	SNHG5	-12.1	1.3e-29	5.32e-26	-0.66	-0.48	Response to antipsychotic treatment;	chr6:85800084	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.916	rs7759727	ENSG00000203875.9	SNHG5	-12.1	1.33e-29	5.41e-26	-0.66	-0.48	Response to antipsychotic treatment;	chr6:85809160	chr6:85660950~85678736:-
LUAD	cis	rs6538678	0.895	rs7137751	ENSG00000199506.1	RNU6-247P	-12.1	1.35e-29	5.5e-26	-0.65	-0.48	Lupus nephritis in systemic lupus erythematosus;	chr12:95861806	chr12:95792529~95792635:-
LUAD	cis	rs73086581	0.947	rs11906612	ENSG00000229539.1	RP11-119B16.2	12.1	1.36e-29	5.55e-26	0.71	0.48	Response to antidepressants in depression;	chr20:3922987	chr20:3888239~3888868:-
LUAD	cis	rs17507216	0.718	rs72751657	ENSG00000278603.1	RP13-608F4.5	12.1	1.37e-29	5.58e-26	0.7	0.48	Excessive daytime sleepiness;	chr15:82581259	chr15:82472203~82472426:+
LUAD	cis	rs2658782	0.547	rs4753453	ENSG00000279684.1	RP11-755E23.2	-12.09	1.38e-29	5.61e-26	-0.69	-0.48	Pulmonary function decline;	chr11:93308008	chr11:93286629~93288903:-
LUAD	cis	rs9399135	0.967	rs12527683	ENSG00000232876.1	CTA-212D2.2	-12.09	1.4e-29	5.69e-26	-0.53	-0.48	Red blood cell count;	chr6:135003396	chr6:135055033~135060550:+
LUAD	cis	rs9399135	0.967	rs12661423	ENSG00000232876.1	CTA-212D2.2	-12.09	1.43e-29	5.8e-26	-0.53	-0.48	Red blood cell count;	chr6:135028432	chr6:135055033~135060550:+
LUAD	cis	rs1153858	1	rs12439274	ENSG00000259520.4	CTD-2651B20.3	-12.09	1.48e-29	5.99e-26	-0.64	-0.48	Homoarginine levels;	chr15:45344469	chr15:45251580~45279251:-
LUAD	cis	rs2882667	0.824	rs12173085	ENSG00000253404.1	AC034243.1	12.09	1.48e-29	6e-26	0.66	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144336	chr5:138744434~138753309:-
LUAD	cis	rs10256972	0.552	rs2949192	ENSG00000229043.2	AC091729.9	-12.09	1.51e-29	6.1e-26	-0.52	-0.48	Endometriosis;Longevity;	chr7:1164205	chr7:1160374~1165267:+
LUAD	cis	rs507080	0.922	rs519848	ENSG00000255239.1	AP002954.6	12.08	1.51e-29	6.14e-26	0.58	0.48	Serum metabolite levels;	chr11:118682006	chr11:118688039~118690600:-
LUAD	cis	rs997154	0.655	rs2008345	ENSG00000279656.1	RP11-298I3.6	12.08	1.53e-29	6.2e-26	0.7	0.48	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22932233	chr14:23023083~23024217:-
LUAD	cis	rs507080	0.885	rs7926959	ENSG00000255422.1	AP002954.4	-12.08	1.56e-29	6.32e-26	-0.6	-0.48	Serum metabolite levels;	chr11:118689157	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.663	rs7926970	ENSG00000255422.1	AP002954.4	-12.08	1.56e-29	6.32e-26	-0.6	-0.48	Serum metabolite levels;	chr11:118689172	chr11:118704607~118750263:+
LUAD	cis	rs2739330	0.892	rs4822455	ENSG00000231271.1	AP000350.8	12.08	1.57e-29	6.36e-26	0.58	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23949918~23954042:+
LUAD	cis	rs875971	0.929	rs4122249	ENSG00000226824.5	RP4-756H11.3	-12.08	1.59e-29	6.42e-26	-0.62	-0.48	Aortic root size;	chr7:66455949	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs6979382	ENSG00000226824.5	RP4-756H11.3	-12.08	1.6e-29	6.47e-26	-0.61	-0.48	Aortic root size;	chr7:66421388	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs6961990	ENSG00000226824.5	RP4-756H11.3	-12.08	1.6e-29	6.47e-26	-0.61	-0.48	Aortic root size;	chr7:66423583	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs11971949	ENSG00000226824.5	RP4-756H11.3	12.08	1.62e-29	6.55e-26	0.61	0.48	Aortic root size;	chr7:66161027	chr7:66654538~66669855:+
LUAD	cis	rs9545047	0.935	rs1577416	ENSG00000227676.3	LINC01068	-12.08	1.62e-29	6.55e-26	-0.6	-0.48	Schizophrenia;	chr13:79500646	chr13:79566727~79571436:+
LUAD	cis	rs4853012	0.941	rs7571083	ENSG00000217702.2	RP11-287D1.4	12.08	1.62e-29	6.55e-26	0.77	0.48	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74130583~74135395:+
LUAD	cis	rs6452524	0.935	rs1542539	ENSG00000249664.1	CTD-2227C6.2	12.08	1.62e-29	6.55e-26	0.55	0.48	Hypertension (SNP x SNP interaction);	chr5:83116033	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs1564211	ENSG00000249664.1	CTD-2227C6.2	12.08	1.62e-29	6.55e-26	0.55	0.48	Hypertension (SNP x SNP interaction);	chr5:83117014	chr5:83012285~83013109:-
LUAD	cis	rs507080	0.961	rs520543	ENSG00000255239.1	AP002954.6	12.08	1.63e-29	6.57e-26	0.57	0.48	Serum metabolite levels;	chr11:118667448	chr11:118688039~118690600:-
LUAD	cis	rs9545047	0.935	rs4885634	ENSG00000227676.3	LINC01068	-12.08	1.66e-29	6.69e-26	-0.61	-0.48	Schizophrenia;	chr13:79482772	chr13:79566727~79571436:+
LUAD	cis	rs10129255	0.5	rs2027902	ENSG00000223648.3	IGHV3-64	12.07	1.69e-29	6.81e-26	0.43	0.48	Kawasaki disease;	chr14:106807157	chr14:106643132~106658258:-
LUAD	cis	rs9399135	0.967	rs7741515	ENSG00000232876.1	CTA-212D2.2	12.07	1.72e-29	6.94e-26	0.52	0.48	Red blood cell count;	chr6:135053230	chr6:135055033~135060550:+
LUAD	cis	rs801193	0.66	rs2659897	ENSG00000226824.5	RP4-756H11.3	12.07	1.76e-29	7.11e-26	0.61	0.48	Aortic root size;	chr7:66722728	chr7:66654538~66669855:+
LUAD	cis	rs1153858	0.943	rs4774580	ENSG00000259520.4	CTD-2651B20.3	-12.07	1.76e-29	7.12e-26	-0.65	-0.48	Homoarginine levels;	chr15:45359888	chr15:45251580~45279251:-
LUAD	cis	rs4423214	1	rs12419334	ENSG00000254682.1	RP11-660L16.2	12.07	1.76e-29	7.12e-26	0.63	0.48	Vitamin D levels;	chr11:71428426	chr11:71448674~71452157:+
LUAD	cis	rs875971	0.964	rs1643388	ENSG00000226824.5	RP4-756H11.3	-12.07	1.78e-29	7.15e-26	-0.61	-0.48	Aortic root size;	chr7:66379575	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs778722	ENSG00000226824.5	RP4-756H11.3	-12.07	1.78e-29	7.15e-26	-0.61	-0.48	Aortic root size;	chr7:66379841	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.964	rs778721	ENSG00000226824.5	RP4-756H11.3	-12.07	1.78e-29	7.15e-26	-0.61	-0.48	Aortic root size;	chr7:66380410	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.929	rs778712	ENSG00000226824.5	RP4-756H11.3	-12.07	1.78e-29	7.15e-26	-0.61	-0.48	Aortic root size;	chr7:66384991	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs778710	ENSG00000226824.5	RP4-756H11.3	-12.07	1.78e-29	7.15e-26	-0.61	-0.48	Aortic root size;	chr7:66389847	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.964	rs778708	ENSG00000226824.5	RP4-756H11.3	-12.07	1.78e-29	7.15e-26	-0.61	-0.48	Aortic root size;	chr7:66391332	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs778706	ENSG00000226824.5	RP4-756H11.3	-12.07	1.78e-29	7.15e-26	-0.61	-0.48	Aortic root size;	chr7:66395437	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.895	rs778700	ENSG00000226824.5	RP4-756H11.3	-12.07	1.78e-29	7.15e-26	-0.61	-0.48	Aortic root size;	chr7:66401463	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs778699	ENSG00000226824.5	RP4-756H11.3	-12.07	1.78e-29	7.15e-26	-0.61	-0.48	Aortic root size;	chr7:66403303	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs778696	ENSG00000226824.5	RP4-756H11.3	-12.07	1.78e-29	7.15e-26	-0.61	-0.48	Aortic root size;	chr7:66405826	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs778694	ENSG00000226824.5	RP4-756H11.3	-12.07	1.78e-29	7.15e-26	-0.61	-0.48	Aortic root size;	chr7:66406571	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.929	rs778692	ENSG00000226824.5	RP4-756H11.3	-12.07	1.78e-29	7.15e-26	-0.61	-0.48	Aortic root size;	chr7:66407462	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs4718343	ENSG00000226824.5	RP4-756H11.3	-12.07	1.78e-29	7.15e-26	-0.61	-0.48	Aortic root size;	chr7:66409301	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs4718344	ENSG00000226824.5	RP4-756H11.3	-12.07	1.78e-29	7.15e-26	-0.61	-0.48	Aortic root size;	chr7:66409394	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs1968225	ENSG00000226824.5	RP4-756H11.3	-12.07	1.78e-29	7.15e-26	-0.61	-0.48	Aortic root size;	chr7:66409786	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.737	rs7803424	ENSG00000226824.5	RP4-756H11.3	-12.07	1.78e-29	7.15e-26	-0.61	-0.48	Aortic root size;	chr7:66415618	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.83	rs7799834	ENSG00000226824.5	RP4-756H11.3	-12.07	1.78e-29	7.15e-26	-0.61	-0.48	Aortic root size;	chr7:66415707	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs6460295	ENSG00000226824.5	RP4-756H11.3	-12.07	1.78e-29	7.15e-26	-0.61	-0.48	Aortic root size;	chr7:66417741	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.964	rs6978721	ENSG00000226824.5	RP4-756H11.3	-12.07	1.78e-29	7.15e-26	-0.61	-0.48	Aortic root size;	chr7:66418217	chr7:66654538~66669855:+
LUAD	cis	rs1577917	0.958	rs10944147	ENSG00000203875.9	SNHG5	-12.07	1.79e-29	7.2e-26	-0.68	-0.48	Response to antipsychotic treatment;	chr6:85841068	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs13201730	ENSG00000203875.9	SNHG5	-12.07	1.79e-29	7.2e-26	-0.68	-0.48	Response to antipsychotic treatment;	chr6:85846929	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs12196377	ENSG00000203875.9	SNHG5	-12.07	1.79e-29	7.2e-26	-0.68	-0.48	Response to antipsychotic treatment;	chr6:85857057	chr6:85660950~85678736:-
LUAD	cis	rs2486288	0.656	rs1706767	ENSG00000259520.4	CTD-2651B20.3	12.06	1.83e-29	7.36e-26	0.6	0.48	Glomerular filtration rate;	chr15:45276901	chr15:45251580~45279251:-
LUAD	cis	rs9545047	0.905	rs9318644	ENSG00000227676.3	LINC01068	-12.06	1.85e-29	7.44e-26	-0.6	-0.48	Schizophrenia;	chr13:79510042	chr13:79566727~79571436:+
LUAD	cis	rs73086581	1	rs34640283	ENSG00000229539.1	RP11-119B16.2	12.06	1.87e-29	7.49e-26	0.69	0.48	Response to antidepressants in depression;	chr20:4008929	chr20:3888239~3888868:-
LUAD	cis	rs1577917	0.958	rs12665542	ENSG00000203875.9	SNHG5	-12.06	1.88e-29	7.54e-26	-0.68	-0.48	Response to antipsychotic treatment;	chr6:85834725	chr6:85660950~85678736:-
LUAD	cis	rs507080	0.922	rs582630	ENSG00000255239.1	AP002954.6	12.06	1.88e-29	7.55e-26	0.58	0.48	Serum metabolite levels;	chr11:118692090	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.883	rs527475	ENSG00000255239.1	AP002954.6	12.06	1.88e-29	7.55e-26	0.58	0.48	Serum metabolite levels;	chr11:118692530	chr11:118688039~118690600:-
LUAD	cis	rs2658782	0.547	rs10765602	ENSG00000279684.1	RP11-755E23.2	-12.06	1.91e-29	7.67e-26	-0.69	-0.48	Pulmonary function decline;	chr11:93314999	chr11:93286629~93288903:-
LUAD	cis	rs875971	0.54	rs781152	ENSG00000226824.5	RP4-756H11.3	-12.06	1.94e-29	7.76e-26	-0.62	-0.48	Aortic root size;	chr7:66014585	chr7:66654538~66669855:+
LUAD	cis	rs17711722	0.727	rs781151	ENSG00000226824.5	RP4-756H11.3	-12.06	1.94e-29	7.76e-26	-0.62	-0.48	Calcium levels;	chr7:66014891	chr7:66654538~66669855:+
LUAD	cis	rs73086581	1	rs3746666	ENSG00000229539.1	RP11-119B16.2	12.06	1.97e-29	7.91e-26	0.69	0.48	Response to antidepressants in depression;	chr20:3930214	chr20:3888239~3888868:-
LUAD	cis	rs9326248	0.53	rs579890	ENSG00000254851.1	RP11-109L13.1	-12.06	1.97e-29	7.91e-26	-0.88	-0.48	Blood protein levels;	chr11:116928247	chr11:117135528~117138582:+
LUAD	cis	rs10262624	0.528	rs722294	ENSG00000234286.1	AC006026.13	12.05	2.02e-29	8.07e-26	0.59	0.48	Schizophrenia;	chr7:23706966	chr7:23680195~23680786:-
LUAD	cis	rs6452524	0.935	rs6868416	ENSG00000249664.1	CTD-2227C6.2	12.05	2.09e-29	8.37e-26	0.55	0.48	Hypertension (SNP x SNP interaction);	chr5:83084320	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.935	rs1478485	ENSG00000249664.1	CTD-2227C6.2	12.05	2.09e-29	8.37e-26	0.55	0.48	Hypertension (SNP x SNP interaction);	chr5:83084708	chr5:83012285~83013109:-
LUAD	cis	rs507080	0.845	rs613377	ENSG00000255239.1	AP002954.6	12.05	2.19e-29	8.75e-26	0.57	0.48	Serum metabolite levels;	chr11:118685375	chr11:118688039~118690600:-
LUAD	cis	rs1577917	0.958	rs2100109	ENSG00000203875.9	SNHG5	-12.04	2.2e-29	8.76e-26	-0.66	-0.48	Response to antipsychotic treatment;	chr6:85835208	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs1447160	ENSG00000203875.9	SNHG5	-12.04	2.2e-29	8.76e-26	-0.66	-0.48	Response to antipsychotic treatment;	chr6:85836405	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs4707229	ENSG00000203875.9	SNHG5	-12.04	2.2e-29	8.76e-26	-0.66	-0.48	Response to antipsychotic treatment;	chr6:85836519	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs12198061	ENSG00000203875.9	SNHG5	-12.04	2.2e-29	8.76e-26	-0.66	-0.48	Response to antipsychotic treatment;	chr6:85841267	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs1838955	ENSG00000203875.9	SNHG5	-12.04	2.2e-29	8.76e-26	-0.66	-0.48	Response to antipsychotic treatment;	chr6:85855731	chr6:85660950~85678736:-
LUAD	cis	rs10129255	0.536	rs8004835	ENSG00000211972.2	IGHV3-66	12.04	2.21e-29	8.79e-26	0.38	0.48	Kawasaki disease;	chr14:106686361	chr14:106675017~106675544:-
LUAD	cis	rs507080	0.922	rs4589335	ENSG00000255239.1	AP002954.6	12.04	2.21e-29	8.81e-26	0.57	0.48	Serum metabolite levels;	chr11:118668431	chr11:118688039~118690600:-
LUAD	cis	rs10129255	0.556	rs9324093	ENSG00000211972.2	IGHV3-66	12.04	2.21e-29	8.81e-26	0.38	0.48	Kawasaki disease;	chr14:106683893	chr14:106675017~106675544:-
LUAD	cis	rs507080	0.807	rs7926944	ENSG00000255422.1	AP002954.4	-12.04	2.31e-29	9.2e-26	-0.6	-0.48	Serum metabolite levels;	chr11:118689119	chr11:118704607~118750263:+
LUAD	cis	rs73086581	1	rs17286349	ENSG00000229539.1	RP11-119B16.2	12.04	2.34e-29	9.3e-26	0.7	0.48	Response to antidepressants in depression;	chr20:3933655	chr20:3888239~3888868:-
LUAD	cis	rs1577917	0.874	rs1838954	ENSG00000203875.9	SNHG5	-12.04	2.36e-29	9.36e-26	-0.65	-0.48	Response to antipsychotic treatment;	chr6:85855760	chr6:85660950~85678736:-
LUAD	cis	rs10129255	0.536	rs3944157	ENSG00000211972.2	IGHV3-66	12.04	2.4e-29	9.51e-26	0.38	0.48	Kawasaki disease;	chr14:106682286	chr14:106675017~106675544:-
LUAD	cis	rs507080	0.922	rs592280	ENSG00000255239.1	AP002954.6	12.03	2.43e-29	9.64e-26	0.57	0.48	Serum metabolite levels;	chr11:118682509	chr11:118688039~118690600:-
LUAD	cis	rs1577917	0.916	rs12206726	ENSG00000203875.9	SNHG5	-12.03	2.47e-29	9.75e-26	-0.66	-0.48	Response to antipsychotic treatment;	chr6:85789998	chr6:85660950~85678736:-
LUAD	cis	rs3091242	0.933	rs9645452	ENSG00000261349.1	RP3-465N24.5	12.03	2.49e-29	9.83e-26	0.53	0.48	Erythrocyte sedimentation rate;	chr1:25341835	chr1:25266102~25267136:-
LUAD	cis	rs9545047	0.935	rs9530925	ENSG00000227676.3	LINC01068	-12.03	2.52e-29	9.95e-26	-0.6	-0.48	Schizophrenia;	chr13:79492641	chr13:79566727~79571436:+
LUAD	cis	rs11723261	0.621	rs57013142	ENSG00000275426.1	CH17-262A2.1	12.03	2.6e-29	1.02e-25	0.7	0.48	Immune response to smallpox vaccine (IL-6);	chr4:141956	chr4:149738~150317:+
LUAD	cis	rs11723261	0.564	rs61792258	ENSG00000275426.1	CH17-262A2.1	12.03	2.6e-29	1.02e-25	0.7	0.48	Immune response to smallpox vaccine (IL-6);	chr4:143482	chr4:149738~150317:+
LUAD	cis	rs875971	1	rs11974219	ENSG00000226824.5	RP4-756H11.3	12.02	2.67e-29	1.05e-25	0.6	0.48	Aortic root size;	chr7:66182423	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs1565531	ENSG00000226824.5	RP4-756H11.3	12.02	2.68e-29	1.06e-25	0.61	0.48	Aortic root size;	chr7:66198126	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs6956179	ENSG00000226824.5	RP4-756H11.3	12.02	2.69e-29	1.06e-25	0.61	0.48	Aortic root size;	chr7:66341672	chr7:66654538~66669855:+
LUAD	cis	rs1577917	0.958	rs12198876	ENSG00000203875.9	SNHG5	-12.02	2.71e-29	1.07e-25	-0.69	-0.48	Response to antipsychotic treatment;	chr6:85815758	chr6:85660950~85678736:-
LUAD	cis	rs73086581	1	rs6052220	ENSG00000229539.1	RP11-119B16.2	12.02	2.72e-29	1.07e-25	0.65	0.48	Response to antidepressants in depression;	chr20:3989947	chr20:3888239~3888868:-
LUAD	cis	rs507080	0.922	rs585039	ENSG00000255239.1	AP002954.6	12.02	2.78e-29	1.09e-25	0.58	0.48	Serum metabolite levels;	chr11:118692672	chr11:118688039~118690600:-
LUAD	cis	rs875971	1	rs55962648	ENSG00000226824.5	RP4-756H11.3	12.02	2.79e-29	1.1e-25	0.61	0.48	Aortic root size;	chr7:66160764	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs2420168	ENSG00000226824.5	RP4-756H11.3	12.02	2.79e-29	1.1e-25	0.61	0.48	Aortic root size;	chr7:66165644	chr7:66654538~66669855:+
LUAD	cis	rs62229266	0.682	rs2835224	ENSG00000231106.2	LINC01436	12.02	2.81e-29	1.11e-25	0.69	0.48	Mitral valve prolapse;	chr21:35997732	chr21:36005338~36007838:+
LUAD	cis	rs17507216	1	rs3850610	ENSG00000278603.1	RP13-608F4.5	-12.02	2.83e-29	1.11e-25	-0.61	-0.48	Excessive daytime sleepiness;	chr15:82552642	chr15:82472203~82472426:+
LUAD	cis	rs1577917	0.958	rs2084294	ENSG00000203875.9	SNHG5	-12.02	2.89e-29	1.14e-25	-0.65	-0.48	Response to antipsychotic treatment;	chr6:85856225	chr6:85660950~85678736:-
LUAD	cis	rs7617773	0.963	rs12495221	ENSG00000229759.1	MRPS18AP1	-12.01	2.91e-29	1.14e-25	-0.47	-0.48	Coronary artery disease;	chr3:48137688	chr3:48256350~48256938:-
LUAD	cis	rs997154	0.608	rs8007089	ENSG00000279656.1	RP11-298I3.6	12.01	3.02e-29	1.18e-25	0.69	0.48	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22922704	chr14:23023083~23024217:-
LUAD	cis	rs507080	0.922	rs4938524	ENSG00000255422.1	AP002954.4	-12.01	3.17e-29	1.24e-25	-0.6	-0.48	Serum metabolite levels;	chr11:118681365	chr11:118704607~118750263:+
LUAD	cis	rs801193	0.613	rs2659900	ENSG00000226824.5	RP4-756H11.3	-12	3.2e-29	1.25e-25	-0.6	-0.48	Aortic root size;	chr7:66719456	chr7:66654538~66669855:+
LUAD	cis	rs1577917	1	rs12216203	ENSG00000203875.9	SNHG5	-12	3.23e-29	1.26e-25	-0.67	-0.48	Response to antipsychotic treatment;	chr6:85965583	chr6:85660950~85678736:-
LUAD	cis	rs6452524	0.935	rs6880566	ENSG00000249664.1	CTD-2227C6.2	12	3.44e-29	1.34e-25	0.55	0.48	Hypertension (SNP x SNP interaction);	chr5:83086909	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.905	rs6884981	ENSG00000249664.1	CTD-2227C6.2	12	3.44e-29	1.34e-25	0.55	0.48	Hypertension (SNP x SNP interaction);	chr5:83087339	chr5:83012285~83013109:-
LUAD	cis	rs875971	1	rs778726	ENSG00000226824.5	RP4-756H11.3	-12	3.46e-29	1.35e-25	-0.61	-0.48	Aortic root size;	chr7:66363744	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.964	rs778723	ENSG00000226824.5	RP4-756H11.3	-12	3.46e-29	1.35e-25	-0.61	-0.48	Aortic root size;	chr7:66364510	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.767	rs1695815	ENSG00000226824.5	RP4-756H11.3	-12	3.46e-29	1.35e-25	-0.61	-0.48	Aortic root size;	chr7:66366357	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs778685	ENSG00000226824.5	RP4-756H11.3	-12	3.46e-29	1.35e-25	-0.61	-0.48	Aortic root size;	chr7:66371189	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.929	rs778682	ENSG00000226824.5	RP4-756H11.3	-12	3.46e-29	1.35e-25	-0.61	-0.48	Aortic root size;	chr7:66372947	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.964	rs11765965	ENSG00000226824.5	RP4-756H11.3	-12	3.46e-29	1.35e-25	-0.61	-0.48	Aortic root size;	chr7:66377234	chr7:66654538~66669855:+
LUAD	cis	rs858239	0.796	rs433395	ENSG00000230658.1	KLHL7-AS1	11.99	3.53e-29	1.38e-25	0.59	0.48	Cerebrospinal fluid biomarker levels;	chr7:23362336	chr7:23101228~23105703:-
LUAD	cis	rs507080	0.883	rs692750	ENSG00000255422.1	AP002954.4	-11.99	3.56e-29	1.39e-25	-0.6	-0.48	Serum metabolite levels;	chr11:118667599	chr11:118704607~118750263:+
LUAD	cis	rs1577917	0.958	rs2121594	ENSG00000203875.9	SNHG5	-11.99	3.58e-29	1.39e-25	-0.67	-0.48	Response to antipsychotic treatment;	chr6:85867136	chr6:85660950~85678736:-
LUAD	cis	rs6452524	0.935	rs7736296	ENSG00000249664.1	CTD-2227C6.2	-11.99	3.64e-29	1.42e-25	-0.55	-0.48	Hypertension (SNP x SNP interaction);	chr5:83082421	chr5:83012285~83013109:-
LUAD	cis	rs507080	0.922	rs525485	ENSG00000255239.1	AP002954.6	11.99	3.76e-29	1.46e-25	0.58	0.48	Serum metabolite levels;	chr11:118685045	chr11:118688039~118690600:-
LUAD	cis	rs875971	1	rs10244498	ENSG00000226824.5	RP4-756H11.3	-11.97	4.26e-29	1.65e-25	-0.6	-0.48	Aortic root size;	chr7:66651069	chr7:66654538~66669855:+
LUAD	cis	rs507080	0.922	rs12788848	ENSG00000255239.1	AP002954.6	11.97	4.38e-29	1.7e-25	0.57	0.48	Serum metabolite levels;	chr11:118683079	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.922	rs4474473	ENSG00000255239.1	AP002954.6	11.97	4.38e-29	1.7e-25	0.57	0.48	Serum metabolite levels;	chr11:118683180	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.922	rs12796373	ENSG00000255239.1	AP002954.6	11.97	4.38e-29	1.7e-25	0.57	0.48	Serum metabolite levels;	chr11:118684230	chr11:118688039~118690600:-
LUAD	cis	rs801193	0.636	rs2659895	ENSG00000226824.5	RP4-756H11.3	-11.97	4.47e-29	1.73e-25	-0.6	-0.48	Aortic root size;	chr7:66731484	chr7:66654538~66669855:+
LUAD	cis	rs6452524	0.935	rs1017794	ENSG00000249664.1	CTD-2227C6.2	11.97	4.55e-29	1.76e-25	0.55	0.48	Hypertension (SNP x SNP interaction);	chr5:83086236	chr5:83012285~83013109:-
LUAD	cis	rs4853012	0.838	rs6715351	ENSG00000217702.2	RP11-287D1.4	11.97	4.58e-29	1.77e-25	0.7	0.48	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74130583~74135395:+
LUAD	cis	rs5760092	0.618	rs5996631	ENSG00000273295.1	AP000350.5	-11.97	4.59e-29	1.78e-25	-0.62	-0.48	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23901432~23907068:-
LUAD	cis	rs73086581	1	rs73086512	ENSG00000229539.1	RP11-119B16.2	11.97	4.61e-29	1.79e-25	0.7	0.48	Response to antidepressants in depression;	chr20:3942125	chr20:3888239~3888868:-
LUAD	cis	rs1577917	0.958	rs1335442	ENSG00000203875.9	SNHG5	-11.96	4.64e-29	1.8e-25	-0.68	-0.48	Response to antipsychotic treatment;	chr6:85756974	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.917	rs2218594	ENSG00000203875.9	SNHG5	-11.96	4.68e-29	1.81e-25	-0.65	-0.48	Response to antipsychotic treatment;	chr6:85834048	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs2197648	ENSG00000203875.9	SNHG5	-11.96	4.68e-29	1.81e-25	-0.65	-0.48	Response to antipsychotic treatment;	chr6:85834169	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.876	rs11752223	ENSG00000203875.9	SNHG5	-11.96	4.68e-29	1.81e-25	-0.65	-0.48	Response to antipsychotic treatment;	chr6:85863676	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs12660846	ENSG00000203875.9	SNHG5	-11.96	4.68e-29	1.81e-25	-0.65	-0.48	Response to antipsychotic treatment;	chr6:85864091	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.876	rs66986937	ENSG00000203875.9	SNHG5	-11.96	4.7e-29	1.82e-25	-0.68	-0.48	Response to antipsychotic treatment;	chr6:85822473	chr6:85660950~85678736:-
LUAD	cis	rs875971	1	rs709597	ENSG00000226824.5	RP4-756H11.3	11.96	4.7e-29	1.82e-25	0.6	0.48	Aortic root size;	chr7:66360996	chr7:66654538~66669855:+
LUAD	cis	rs1577917	1	rs16876529	ENSG00000203875.9	SNHG5	-11.96	4.72e-29	1.82e-25	-0.65	-0.48	Response to antipsychotic treatment;	chr6:85881484	chr6:85660950~85678736:-
LUAD	cis	rs4423214	0.65	rs7940244	ENSG00000254682.1	RP11-660L16.2	-11.96	4.86e-29	1.88e-25	-0.64	-0.48	Vitamin D levels;	chr11:71510528	chr11:71448674~71452157:+
LUAD	cis	rs2739330	0.76	rs5751761	ENSG00000231271.1	AP000350.8	-11.96	4.86e-29	1.88e-25	-0.54	-0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23949918~23954042:+
LUAD	cis	rs1577917	0.958	rs10944137	ENSG00000203875.9	SNHG5	-11.96	4.88e-29	1.88e-25	-0.69	-0.48	Response to antipsychotic treatment;	chr6:85744596	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs12212480	ENSG00000203875.9	SNHG5	-11.96	4.88e-29	1.88e-25	-0.69	-0.48	Response to antipsychotic treatment;	chr6:85749059	chr6:85660950~85678736:-
LUAD	cis	rs17507216	0.671	rs4779035	ENSG00000278603.1	RP13-608F4.5	11.96	4.9e-29	1.89e-25	0.69	0.48	Excessive daytime sleepiness;	chr15:82591686	chr15:82472203~82472426:+
LUAD	cis	rs507080	1	rs507080	ENSG00000255422.1	AP002954.4	-11.96	5.05e-29	1.95e-25	-0.59	-0.48	Serum metabolite levels;	chr11:118678873	chr11:118704607~118750263:+
LUAD	cis	rs1577917	0.958	rs67024565	ENSG00000203875.9	SNHG5	-11.95	5.07e-29	1.95e-25	-0.69	-0.48	Response to antipsychotic treatment;	chr6:85844279	chr6:85660950~85678736:-
LUAD	cis	rs875971	1	rs7792762	ENSG00000226824.5	RP4-756H11.3	-11.95	5.29e-29	2.03e-25	-0.61	-0.48	Aortic root size;	chr7:66539151	chr7:66654538~66669855:+
LUAD	cis	rs507080	0.961	rs642530	ENSG00000255239.1	AP002954.6	11.95	5.35e-29	2.06e-25	0.57	0.48	Serum metabolite levels;	chr11:118680047	chr11:118688039~118690600:-
LUAD	cis	rs992157	0.661	rs10171839	ENSG00000261338.2	RP11-378A13.1	11.95	5.5e-29	2.11e-25	0.48	0.48	Colorectal cancer;	chr2:218186591	chr2:218255319~218257366:+
LUAD	cis	rs3091242	1	rs646867	ENSG00000261349.1	RP3-465N24.5	-11.95	5.51e-29	2.12e-25	-0.53	-0.48	Erythrocyte sedimentation rate;	chr1:25382767	chr1:25266102~25267136:-
LUAD	cis	rs4853012	0.838	rs61521879	ENSG00000217702.2	RP11-287D1.4	11.95	5.51e-29	2.12e-25	0.69	0.48	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74130583~74135395:+
LUAD	cis	rs507080	0.883	rs656575	ENSG00000255422.1	AP002954.4	-11.95	5.54e-29	2.12e-25	-0.59	-0.48	Serum metabolite levels;	chr11:118679199	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.961	rs656505	ENSG00000255422.1	AP002954.4	-11.95	5.54e-29	2.12e-25	-0.59	-0.48	Serum metabolite levels;	chr11:118679245	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.961	rs660489	ENSG00000255422.1	AP002954.4	-11.95	5.54e-29	2.12e-25	-0.59	-0.48	Serum metabolite levels;	chr11:118679255	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.961	rs543327	ENSG00000255422.1	AP002954.4	-11.95	5.54e-29	2.12e-25	-0.59	-0.48	Serum metabolite levels;	chr11:118679276	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.961	rs543413	ENSG00000255422.1	AP002954.4	-11.95	5.54e-29	2.12e-25	-0.59	-0.48	Serum metabolite levels;	chr11:118679308	chr11:118704607~118750263:+
LUAD	cis	rs10129255	0.536	rs10139058	ENSG00000211972.2	IGHV3-66	11.94	5.57e-29	2.14e-25	0.38	0.48	Kawasaki disease;	chr14:106685899	chr14:106675017~106675544:-
LUAD	cis	rs2658782	0.756	rs3019223	ENSG00000279684.1	RP11-755E23.2	-11.94	5.72e-29	2.19e-25	-0.77	-0.48	Pulmonary function decline;	chr11:93351016	chr11:93286629~93288903:-
LUAD	cis	rs2658782	0.826	rs2925355	ENSG00000279684.1	RP11-755E23.2	-11.94	5.72e-29	2.19e-25	-0.77	-0.48	Pulmonary function decline;	chr11:93357721	chr11:93286629~93288903:-
LUAD	cis	rs1577917	1	rs12208493	ENSG00000203875.9	SNHG5	-11.94	5.75e-29	2.2e-25	-0.66	-0.48	Response to antipsychotic treatment;	chr6:85952549	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs12213149	ENSG00000203875.9	SNHG5	-11.94	5.75e-29	2.2e-25	-0.66	-0.48	Response to antipsychotic treatment;	chr6:85958926	chr6:85660950~85678736:-
LUAD	cis	rs8062405	1	rs2008514	ENSG00000259982.1	CDC37P1	-11.94	6.08e-29	2.33e-25	-0.61	-0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28700294~28701540:-
LUAD	cis	rs1577917	0.958	rs13213899	ENSG00000203875.9	SNHG5	-11.93	6.1e-29	2.33e-25	-0.68	-0.48	Response to antipsychotic treatment;	chr6:85763422	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs10806337	ENSG00000203875.9	SNHG5	-11.93	6.12e-29	2.34e-25	-0.68	-0.48	Response to antipsychotic treatment;	chr6:85764531	chr6:85660950~85678736:-
LUAD	cis	rs507080	0.961	rs642497	ENSG00000255239.1	AP002954.6	11.93	6.3e-29	2.41e-25	0.57	0.48	Serum metabolite levels;	chr11:118680075	chr11:118688039~118690600:-
LUAD	cis	rs17507216	0.718	rs7165690	ENSG00000278603.1	RP13-608F4.5	11.93	6.32e-29	2.42e-25	0.68	0.48	Excessive daytime sleepiness;	chr15:82654804	chr15:82472203~82472426:+
LUAD	cis	rs801193	0.591	rs2707839	ENSG00000226824.5	RP4-756H11.3	-11.93	6.39e-29	2.44e-25	-0.6	-0.48	Aortic root size;	chr7:66728097	chr7:66654538~66669855:+
LUAD	cis	rs6452524	0.868	rs10071617	ENSG00000249664.1	CTD-2227C6.2	11.93	6.43e-29	2.46e-25	0.54	0.48	Hypertension (SNP x SNP interaction);	chr5:83103207	chr5:83012285~83013109:-
LUAD	cis	rs1577917	1	rs2812972	ENSG00000203875.9	SNHG5	-11.93	6.44e-29	2.46e-25	-0.64	-0.48	Response to antipsychotic treatment;	chr6:85960162	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs12213431	ENSG00000203875.9	SNHG5	-11.93	6.56e-29	2.5e-25	-0.64	-0.48	Response to antipsychotic treatment;	chr6:85791238	chr6:85660950~85678736:-
LUAD	cis	rs9545047	0.935	rs6563113	ENSG00000227676.3	LINC01068	-11.92	6.93e-29	2.64e-25	-0.6	-0.48	Schizophrenia;	chr13:79490000	chr13:79566727~79571436:+
LUAD	cis	rs11723261	0.582	rs11248006	ENSG00000275426.1	CH17-262A2.1	11.92	6.95e-29	2.65e-25	0.7	0.48	Immune response to smallpox vaccine (IL-6);	chr4:172914	chr4:149738~150317:+
LUAD	cis	rs950027	0.62	rs1617634	ENSG00000259520.4	CTD-2651B20.3	-11.92	7.17e-29	2.72e-25	-0.58	-0.48	Response to fenofibrate (adiponectin levels);	chr15:45323380	chr15:45251580~45279251:-
LUAD	cis	rs4853012	0.887	rs7570950	ENSG00000217702.2	RP11-287D1.4	11.92	7.2e-29	2.73e-25	0.76	0.48	Gestational age at birth (maternal effect);	chr2:74111815	chr2:74130583~74135395:+
LUAD	cis	rs12439619	0.921	rs4778672	ENSG00000278603.1	RP13-608F4.5	-11.91	7.42e-29	2.81e-25	-0.6	-0.48	Intelligence (multi-trait analysis);	chr15:82245013	chr15:82472203~82472426:+
LUAD	cis	rs7617773	0.925	rs7374376	ENSG00000229759.1	MRPS18AP1	-11.91	7.5e-29	2.84e-25	-0.47	-0.48	Coronary artery disease;	chr3:48131197	chr3:48256350~48256938:-
LUAD	cis	rs507080	0.922	rs7114458	ENSG00000255239.1	AP002954.6	11.91	7.56e-29	2.86e-25	0.58	0.48	Serum metabolite levels;	chr11:118695466	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.922	rs7114216	ENSG00000255239.1	AP002954.6	11.91	7.56e-29	2.86e-25	0.58	0.48	Serum metabolite levels;	chr11:118695525	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.961	rs4457789	ENSG00000255239.1	AP002954.6	11.91	7.6e-29	2.88e-25	0.57	0.48	Serum metabolite levels;	chr11:118668461	chr11:118688039~118690600:-
LUAD	cis	rs1577917	0.917	rs35283633	ENSG00000203875.9	SNHG5	-11.91	7.74e-29	2.93e-25	-0.67	-0.48	Response to antipsychotic treatment;	chr6:85981069	chr6:85660950~85678736:-
LUAD	cis	rs507080	0.961	rs1784298	ENSG00000255422.1	AP002954.4	-11.91	7.92e-29	2.99e-25	-0.59	-0.48	Serum metabolite levels;	chr11:118677956	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.961	rs4938522	ENSG00000255422.1	AP002954.4	-11.91	7.92e-29	2.99e-25	-0.59	-0.48	Serum metabolite levels;	chr11:118677962	chr11:118704607~118750263:+
LUAD	cis	rs507080	1	rs659969	ENSG00000255422.1	AP002954.4	-11.91	7.92e-29	2.99e-25	-0.59	-0.48	Serum metabolite levels;	chr11:118679094	chr11:118704607~118750263:+
LUAD	cis	rs6452524	0.935	rs1382374	ENSG00000249664.1	CTD-2227C6.2	11.9	8.1e-29	3.06e-25	0.54	0.48	Hypertension (SNP x SNP interaction);	chr5:83101010	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.935	rs12109517	ENSG00000249664.1	CTD-2227C6.2	11.9	8.31e-29	3.14e-25	0.54	0.48	Hypertension (SNP x SNP interaction);	chr5:83095947	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.935	rs12109514	ENSG00000249664.1	CTD-2227C6.2	11.9	8.31e-29	3.14e-25	0.54	0.48	Hypertension (SNP x SNP interaction);	chr5:83095965	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.901	rs17284211	ENSG00000249664.1	CTD-2227C6.2	11.9	8.31e-29	3.14e-25	0.54	0.48	Hypertension (SNP x SNP interaction);	chr5:83098706	chr5:83012285~83013109:-
LUAD	cis	rs11155671	0.53	rs1334510	ENSG00000216906.2	RP11-350J20.9	11.9	8.37e-29	3.16e-25	0.59	0.48	Testicular germ cell tumor;	chr6:149880043	chr6:149904243~149906418:+
LUAD	cis	rs9545047	0.935	rs8002042	ENSG00000227676.3	LINC01068	-11.9	8.38e-29	3.16e-25	-0.6	-0.48	Schizophrenia;	chr13:79486552	chr13:79566727~79571436:+
LUAD	cis	rs507080	0.883	rs558593	ENSG00000255239.1	AP002954.6	11.9	8.43e-29	3.18e-25	0.58	0.48	Serum metabolite levels;	chr11:118691811	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.922	rs4589335	ENSG00000255422.1	AP002954.4	-11.9	8.48e-29	3.2e-25	-0.59	-0.48	Serum metabolite levels;	chr11:118668431	chr11:118704607~118750263:+
LUAD	cis	rs1577917	1	rs12201571	ENSG00000203875.9	SNHG5	-11.9	8.61e-29	3.25e-25	-0.66	-0.48	Response to antipsychotic treatment;	chr6:85900032	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs11759855	ENSG00000203875.9	SNHG5	-11.9	8.61e-29	3.25e-25	-0.66	-0.48	Response to antipsychotic treatment;	chr6:85901123	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.798	rs7772384	ENSG00000203875.9	SNHG5	-11.9	8.61e-29	3.25e-25	-0.66	-0.48	Response to antipsychotic treatment;	chr6:85929962	chr6:85660950~85678736:-
LUAD	cis	rs6538678	0.864	rs10777749	ENSG00000258343.1	RP11-536G4.2	-11.9	8.62e-29	3.25e-25	-0.64	-0.48	Lupus nephritis in systemic lupus erythematosus;	chr12:95883182	chr12:95795345~95858839:-
LUAD	cis	rs1577917	0.958	rs13219504	ENSG00000203875.9	SNHG5	-11.9	8.65e-29	3.26e-25	-0.68	-0.48	Response to antipsychotic treatment;	chr6:85847199	chr6:85660950~85678736:-
LUAD	cis	rs2739330	0.828	rs4820572	ENSG00000250470.1	AP000351.3	11.89	8.99e-29	3.38e-25	0.6	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23976904~23977585:-
LUAD	cis	rs507080	0.961	rs4938523	ENSG00000255422.1	AP002954.4	-11.89	9.26e-29	3.48e-25	-0.59	-0.48	Serum metabolite levels;	chr11:118678129	chr11:118704607~118750263:+
LUAD	cis	rs1577917	0.958	rs12213331	ENSG00000203875.9	SNHG5	-11.89	9.36e-29	3.52e-25	-0.67	-0.48	Response to antipsychotic treatment;	chr6:85795079	chr6:85660950~85678736:-
LUAD	cis	rs11723261	0.621	rs6599306	ENSG00000275426.1	CH17-262A2.1	-11.89	9.4e-29	3.53e-25	-0.69	-0.48	Immune response to smallpox vaccine (IL-6);	chr4:149655	chr4:149738~150317:+
LUAD	cis	rs875971	1	rs7801282	ENSG00000226824.5	RP4-756H11.3	11.89	9.41e-29	3.53e-25	0.6	0.48	Aortic root size;	chr7:66148700	chr7:66654538~66669855:+
LUAD	cis	rs1577917	1	rs955227	ENSG00000203875.9	SNHG5	-11.89	9.44e-29	3.54e-25	-0.67	-0.48	Response to antipsychotic treatment;	chr6:85941314	chr6:85660950~85678736:-
LUAD	cis	rs9545047	0.935	rs1475797	ENSG00000227676.3	LINC01068	-11.89	9.46e-29	3.55e-25	-0.58	-0.48	Schizophrenia;	chr13:79519690	chr13:79566727~79571436:+
LUAD	cis	rs6452524	0.836	rs1478484	ENSG00000249664.1	CTD-2227C6.2	11.89	9.48e-29	3.56e-25	0.55	0.48	Hypertension (SNP x SNP interaction);	chr5:83085055	chr5:83012285~83013109:-
LUAD	cis	rs1577917	1	rs34281561	ENSG00000203875.9	SNHG5	-11.89	9.54e-29	3.58e-25	-0.67	-0.48	Response to antipsychotic treatment;	chr6:85992154	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs35419329	ENSG00000203875.9	SNHG5	-11.89	9.54e-29	3.58e-25	-0.67	-0.48	Response to antipsychotic treatment;	chr6:85992573	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs12216328	ENSG00000203875.9	SNHG5	-11.89	9.54e-29	3.58e-25	-0.67	-0.48	Response to antipsychotic treatment;	chr6:85993700	chr6:85660950~85678736:-
LUAD	cis	rs6452524	0.935	rs11750799	ENSG00000249664.1	CTD-2227C6.2	11.89	9.6e-29	3.6e-25	0.55	0.48	Hypertension (SNP x SNP interaction);	chr5:83082983	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.935	rs10942321	ENSG00000249664.1	CTD-2227C6.2	11.89	9.6e-29	3.6e-25	0.55	0.48	Hypertension (SNP x SNP interaction);	chr5:83083200	chr5:83012285~83013109:-
LUAD	cis	rs2739330	0.828	rs2154593	ENSG00000250470.1	AP000351.3	11.88	9.72e-29	3.64e-25	0.59	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23976904~23977585:-
LUAD	cis	rs950027	0.62	rs1617984	ENSG00000259520.4	CTD-2651B20.3	-11.88	1e-28	3.76e-25	-0.58	-0.48	Response to fenofibrate (adiponectin levels);	chr15:45330464	chr15:45251580~45279251:-
LUAD	cis	rs1577917	0.958	rs2660576	ENSG00000203875.9	SNHG5	-11.88	1.01e-28	3.77e-25	-0.64	-0.48	Response to antipsychotic treatment;	chr6:85941885	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs11756615	ENSG00000203875.9	SNHG5	-11.88	1.02e-28	3.81e-25	-0.66	-0.48	Response to antipsychotic treatment;	chr6:85970117	chr6:85660950~85678736:-
LUAD	cis	rs3091242	0.934	rs666686	ENSG00000224183.1	SDHDP6	-11.88	1.04e-28	3.88e-25	-0.6	-0.48	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25294164~25294643:-
LUAD	cis	rs875971	1	rs11974264	ENSG00000226824.5	RP4-756H11.3	11.87	1.08e-28	4.05e-25	0.6	0.48	Aortic root size;	chr7:66182595	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs1540651	ENSG00000226824.5	RP4-756H11.3	11.87	1.08e-28	4.05e-25	0.6	0.48	Aortic root size;	chr7:66185134	chr7:66654538~66669855:+
LUAD	cis	rs62229266	0.654	rs62230787	ENSG00000231106.2	LINC01436	11.87	1.1e-28	4.09e-25	0.68	0.48	Mitral valve prolapse;	chr21:36004182	chr21:36005338~36007838:+
LUAD	cis	rs2739330	0.828	rs5760108	ENSG00000250470.1	AP000351.3	11.87	1.13e-28	4.2e-25	0.59	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23976904~23977585:-
LUAD	cis	rs6452524	0.901	rs10079680	ENSG00000249664.1	CTD-2227C6.2	11.87	1.13e-28	4.21e-25	0.55	0.48	Hypertension (SNP x SNP interaction);	chr5:83082746	chr5:83012285~83013109:-
LUAD	cis	rs1577917	0.958	rs10944144	ENSG00000203875.9	SNHG5	-11.87	1.14e-28	4.26e-25	-0.68	-0.48	Response to antipsychotic treatment;	chr6:85828037	chr6:85660950~85678736:-
LUAD	cis	rs2739330	0.828	rs2877178	ENSG00000250470.1	AP000351.3	11.87	1.15e-28	4.3e-25	0.59	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23976904~23977585:-
LUAD	cis	rs1577917	0.958	rs1337843	ENSG00000203875.9	SNHG5	-11.87	1.16e-28	4.33e-25	-0.64	-0.48	Response to antipsychotic treatment;	chr6:85965827	chr6:85660950~85678736:-
LUAD	cis	rs2658782	0.826	rs1975820	ENSG00000279684.1	RP11-755E23.2	-11.86	1.18e-28	4.41e-25	-0.77	-0.48	Pulmonary function decline;	chr11:93348649	chr11:93286629~93288903:-
LUAD	cis	rs1153858	1	rs7181167	ENSG00000259520.4	CTD-2651B20.3	-11.86	1.2e-28	4.46e-25	-0.64	-0.48	Homoarginine levels;	chr15:45394038	chr15:45251580~45279251:-
LUAD	cis	rs507080	0.883	rs692750	ENSG00000255239.1	AP002954.6	11.86	1.22e-28	4.52e-25	0.57	0.48	Serum metabolite levels;	chr11:118667599	chr11:118688039~118690600:-
LUAD	cis	rs1577917	0.917	rs2197651	ENSG00000203875.9	SNHG5	-11.86	1.23e-28	4.59e-25	-0.68	-0.48	Response to antipsychotic treatment;	chr6:85785724	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs10944163	ENSG00000203875.9	SNHG5	-11.86	1.24e-28	4.61e-25	-0.67	-0.48	Response to antipsychotic treatment;	chr6:85948975	chr6:85660950~85678736:-
LUAD	cis	rs507080	0.922	rs502601	ENSG00000255239.1	AP002954.6	11.85	1.28e-28	4.75e-25	0.58	0.48	Serum metabolite levels;	chr11:118694970	chr11:118688039~118690600:-
LUAD	cis	rs9322193	0.607	rs6925151	ENSG00000231760.4	RP11-350J20.5	11.85	1.29e-28	4.78e-25	0.68	0.48	Lung cancer;	chr6:149889587	chr6:149796151~149826294:-
LUAD	cis	rs1263173	0.566	rs4225	ENSG00000254851.1	RP11-109L13.1	-11.85	1.32e-28	4.89e-25	-0.61	-0.48	HDL cholesterol;	chr11:116832955	chr11:117135528~117138582:+
LUAD	cis	rs7115242	0.858	rs6589592	ENSG00000254851.1	RP11-109L13.1	-11.85	1.33e-28	4.91e-25	-0.95	-0.48	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117087191	chr11:117135528~117138582:+
LUAD	cis	rs507080	0.961	rs34413584	ENSG00000255422.1	AP002954.4	-11.85	1.33e-28	4.92e-25	-0.59	-0.48	Serum metabolite levels;	chr11:118675072	chr11:118704607~118750263:+
LUAD	cis	rs9545047	0.935	rs9530922	ENSG00000227676.3	LINC01068	-11.85	1.33e-28	4.92e-25	-0.61	-0.48	Schizophrenia;	chr13:79469002	chr13:79566727~79571436:+
LUAD	cis	rs1577917	0.958	rs10944168	ENSG00000203875.9	SNHG5	-11.85	1.36e-28	5.02e-25	-0.66	-0.48	Response to antipsychotic treatment;	chr6:85970438	chr6:85660950~85678736:-
LUAD	cis	rs801193	0.66	rs2659914	ENSG00000226824.5	RP4-756H11.3	-11.84	1.4e-28	5.2e-25	-0.6	-0.48	Aortic root size;	chr7:66691927	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.66	rs1016265	ENSG00000226824.5	RP4-756H11.3	-11.84	1.43e-28	5.31e-25	-0.6	-0.48	Aortic root size;	chr7:66749580	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.66	rs4610622	ENSG00000226824.5	RP4-756H11.3	-11.84	1.43e-28	5.31e-25	-0.6	-0.48	Aortic root size;	chr7:66759510	chr7:66654538~66669855:+
LUAD	cis	rs1577917	1	rs13196930	ENSG00000203875.9	SNHG5	-11.84	1.52e-28	5.62e-25	-0.66	-0.47	Response to antipsychotic treatment;	chr6:85942527	chr6:85660950~85678736:-
LUAD	cis	rs1153858	1	rs9788780	ENSG00000259520.4	CTD-2651B20.3	-11.83	1.56e-28	5.77e-25	-0.64	-0.47	Homoarginine levels;	chr15:45393289	chr15:45251580~45279251:-
LUAD	cis	rs6452524	0.935	rs1382376	ENSG00000249664.1	CTD-2227C6.2	11.83	1.58e-28	5.83e-25	0.54	0.47	Hypertension (SNP x SNP interaction);	chr5:83095418	chr5:83012285~83013109:-
LUAD	cis	rs55794721	0.543	rs1293260	ENSG00000224183.1	SDHDP6	-11.83	1.59e-28	5.86e-25	-0.6	-0.47	Mean corpuscular volume;Plateletcrit;	chr1:25382613	chr1:25294164~25294643:-
LUAD	cis	rs1153858	1	rs3759899	ENSG00000259520.4	CTD-2651B20.3	-11.83	1.59e-28	5.87e-25	-0.64	-0.47	Homoarginine levels;	chr15:45363705	chr15:45251580~45279251:-
LUAD	cis	rs11723261	0.621	rs3829	ENSG00000275426.1	CH17-262A2.1	11.83	1.6e-28	5.88e-25	0.69	0.47	Immune response to smallpox vaccine (IL-6);	chr4:141070	chr4:149738~150317:+
LUAD	cis	rs6452524	0.905	rs6896548	ENSG00000249664.1	CTD-2227C6.2	11.83	1.6e-28	5.9e-25	0.54	0.47	Hypertension (SNP x SNP interaction);	chr5:83089247	chr5:83012285~83013109:-
LUAD	cis	rs1153858	1	rs4625670	ENSG00000259520.4	CTD-2651B20.3	-11.83	1.62e-28	5.97e-25	-0.64	-0.47	Homoarginine levels;	chr15:45360728	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs4534782	ENSG00000259520.4	CTD-2651B20.3	-11.83	1.62e-28	5.97e-25	-0.64	-0.47	Homoarginine levels;	chr15:45360735	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs1049503	ENSG00000259520.4	CTD-2651B20.3	-11.83	1.62e-28	5.97e-25	-0.64	-0.47	Homoarginine levels;	chr15:45361509	chr15:45251580~45279251:-
LUAD	cis	rs8062405	1	rs1987472	ENSG00000259982.1	CDC37P1	11.83	1.63e-28	6e-25	0.6	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.895	rs56186137	ENSG00000259982.1	CDC37P1	11.83	1.63e-28	6e-25	0.6	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28700294~28701540:-
LUAD	cis	rs1577917	1	rs12192992	ENSG00000203875.9	SNHG5	-11.83	1.63e-28	6e-25	-0.66	-0.47	Response to antipsychotic treatment;	chr6:85900197	chr6:85660950~85678736:-
LUAD	cis	rs6452524	0.905	rs7736289	ENSG00000249664.1	CTD-2227C6.2	11.83	1.68e-28	6.17e-25	0.55	0.47	Hypertension (SNP x SNP interaction);	chr5:83082401	chr5:83012285~83013109:-
LUAD	cis	rs73086581	1	rs73086535	ENSG00000229539.1	RP11-119B16.2	11.82	1.71e-28	6.28e-25	0.7	0.47	Response to antidepressants in depression;	chr20:3963503	chr20:3888239~3888868:-
LUAD	cis	rs73086581	0.947	rs55794220	ENSG00000229539.1	RP11-119B16.2	11.82	1.71e-28	6.28e-25	0.7	0.47	Response to antidepressants in depression;	chr20:3975755	chr20:3888239~3888868:-
LUAD	cis	rs1577917	1	rs1857964	ENSG00000203875.9	SNHG5	-11.82	1.73e-28	6.36e-25	-0.66	-0.47	Response to antipsychotic treatment;	chr6:85926276	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs35760725	ENSG00000203875.9	SNHG5	-11.82	1.75e-28	6.42e-25	-0.63	-0.47	Response to antipsychotic treatment;	chr6:85939267	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs13194429	ENSG00000203875.9	SNHG5	-11.82	1.76e-28	6.45e-25	-0.66	-0.47	Response to antipsychotic treatment;	chr6:85936987	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs2816821	ENSG00000203875.9	SNHG5	-11.82	1.8e-28	6.59e-25	-0.64	-0.47	Response to antipsychotic treatment;	chr6:85947366	chr6:85660950~85678736:-
LUAD	cis	rs6538678	0.895	rs4762637	ENSG00000258343.1	RP11-536G4.2	-11.82	1.81e-28	6.62e-25	-0.64	-0.47	Lupus nephritis in systemic lupus erythematosus;	chr12:95888877	chr12:95795345~95858839:-
LUAD	cis	rs6452524	0.935	rs1580311	ENSG00000249664.1	CTD-2227C6.2	11.82	1.82e-28	6.67e-25	0.54	0.47	Hypertension (SNP x SNP interaction);	chr5:83091667	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.935	rs7714710	ENSG00000249664.1	CTD-2227C6.2	11.82	1.82e-28	6.68e-25	0.55	0.47	Hypertension (SNP x SNP interaction);	chr5:83085750	chr5:83012285~83013109:-
LUAD	cis	rs1577917	0.958	rs12192546	ENSG00000203875.9	SNHG5	11.82	1.84e-28	6.73e-25	0.67	0.47	Response to antipsychotic treatment;	chr6:85766766	chr6:85660950~85678736:-
LUAD	cis	rs9601248	0.508	rs9601240	ENSG00000227676.3	LINC01068	11.81	1.89e-28	6.91e-25	0.6	0.47	Major depressive disorder;	chr13:79558238	chr13:79566727~79571436:+
LUAD	cis	rs507080	0.922	rs508640	ENSG00000255239.1	AP002954.6	11.81	1.92e-28	7.02e-25	0.58	0.47	Serum metabolite levels;	chr11:118693704	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.922	rs471227	ENSG00000255239.1	AP002954.6	11.81	1.92e-28	7.02e-25	0.58	0.47	Serum metabolite levels;	chr11:118693892	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.922	rs516153	ENSG00000255239.1	AP002954.6	11.81	1.92e-28	7.02e-25	0.58	0.47	Serum metabolite levels;	chr11:118694053	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.922	rs518028	ENSG00000255239.1	AP002954.6	11.81	1.92e-28	7.02e-25	0.58	0.47	Serum metabolite levels;	chr11:118694273	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.922	rs519982	ENSG00000255239.1	AP002954.6	11.81	1.92e-28	7.02e-25	0.58	0.47	Serum metabolite levels;	chr11:118694522	chr11:118688039~118690600:-
LUAD	cis	rs9545047	0.901	rs7982263	ENSG00000227676.3	LINC01068	-11.81	1.95e-28	7.12e-25	-0.6	-0.47	Schizophrenia;	chr13:79486939	chr13:79566727~79571436:+
LUAD	cis	rs1577917	1	rs10455455	ENSG00000203875.9	SNHG5	-11.81	1.96e-28	7.15e-25	-0.66	-0.47	Response to antipsychotic treatment;	chr6:85960496	chr6:85660950~85678736:-
LUAD	cis	rs1153858	1	rs11070456	ENSG00000259520.4	CTD-2651B20.3	-11.81	1.96e-28	7.16e-25	-0.63	-0.47	Homoarginine levels;	chr15:45394637	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs11070457	ENSG00000259520.4	CTD-2651B20.3	-11.81	1.96e-28	7.16e-25	-0.63	-0.47	Homoarginine levels;	chr15:45394745	chr15:45251580~45279251:-
LUAD	cis	rs73086581	0.891	rs55871214	ENSG00000229539.1	RP11-119B16.2	11.81	1.96e-28	7.16e-25	0.7	0.47	Response to antidepressants in depression;	chr20:3985059	chr20:3888239~3888868:-
LUAD	cis	rs73086581	1	rs56069856	ENSG00000229539.1	RP11-119B16.2	11.81	1.96e-28	7.16e-25	0.7	0.47	Response to antidepressants in depression;	chr20:3985062	chr20:3888239~3888868:-
LUAD	cis	rs7301826	0.934	rs10773826	ENSG00000256299.1	RP11-989F5.3	-11.81	1.97e-28	7.19e-25	-0.51	-0.47	Plasma plasminogen activator levels;	chr12:130836629	chr12:130810821~130812622:-
LUAD	cis	rs875971	1	rs709595	ENSG00000226824.5	RP4-756H11.3	-11.81	1.99e-28	7.28e-25	-0.6	-0.47	Aortic root size;	chr7:66352346	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs811880	ENSG00000226824.5	RP4-756H11.3	-11.81	1.99e-28	7.28e-25	-0.6	-0.47	Aortic root size;	chr7:66353659	chr7:66654538~66669855:+
LUAD	cis	rs1153858	1	rs12595087	ENSG00000259520.4	CTD-2651B20.3	-11.8	2.03e-28	7.41e-25	-0.64	-0.47	Homoarginine levels;	chr15:45363034	chr15:45251580~45279251:-
LUAD	cis	rs2739330	0.753	rs4822452	ENSG00000231271.1	AP000350.8	11.8	2.03e-28	7.42e-25	0.57	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23949918~23954042:+
LUAD	cis	rs875971	1	rs9986696	ENSG00000226824.5	RP4-756H11.3	11.8	2.07e-28	7.57e-25	0.6	0.47	Aortic root size;	chr7:66239589	chr7:66654538~66669855:+
LUAD	cis	rs977987	0.735	rs166013	ENSG00000261783.1	RP11-252K23.2	11.8	2.1e-28	7.67e-25	0.64	0.47	Dupuytren's disease;	chr16:75400248	chr16:75379818~75381260:-
LUAD	cis	rs1577917	1	rs12664335	ENSG00000203875.9	SNHG5	11.8	2.12e-28	7.71e-25	0.65	0.47	Response to antipsychotic treatment;	chr6:85888056	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs12200330	ENSG00000203875.9	SNHG5	-11.8	2.19e-28	7.96e-25	-0.66	-0.47	Response to antipsychotic treatment;	chr6:85946935	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs12661204	ENSG00000203875.9	SNHG5	-11.8	2.2e-28	7.99e-25	-0.67	-0.47	Response to antipsychotic treatment;	chr6:85968868	chr6:85660950~85678736:-
LUAD	cis	rs950027	0.62	rs1145093	ENSG00000259520.4	CTD-2651B20.3	-11.79	2.36e-28	8.59e-25	-0.58	-0.47	Response to fenofibrate (adiponectin levels);	chr15:45357615	chr15:45251580~45279251:-
LUAD	cis	rs2739330	0.828	rs4822454	ENSG00000231271.1	AP000350.8	11.79	2.38e-28	8.63e-25	0.58	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23949918~23954042:+
LUAD	cis	rs6782228	0.675	rs6806687	ENSG00000242551.2	POU5F1P6	11.79	2.4e-28	8.7e-25	0.53	0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128672946	chr3:128674735~128677005:-
LUAD	cis	rs507080	0.961	rs607527	ENSG00000255422.1	AP002954.4	11.79	2.41e-28	8.74e-25	0.58	0.47	Serum metabolite levels;	chr11:118667478	chr11:118704607~118750263:+
LUAD	cis	rs1577917	0.958	rs2875456	ENSG00000203875.9	SNHG5	-11.79	2.43e-28	8.82e-25	-0.66	-0.47	Response to antipsychotic treatment;	chr6:85892566	chr6:85660950~85678736:-
LUAD	cis	rs875971	1	rs875971	ENSG00000226824.5	RP4-756H11.3	11.78	2.46e-28	8.93e-25	0.6	0.47	Aortic root size;	chr7:66152608	chr7:66654538~66669855:+
LUAD	cis	rs992157	0.56	rs7605980	ENSG00000261338.2	RP11-378A13.1	11.78	2.48e-28	9.01e-25	0.48	0.47	Colorectal cancer;	chr2:218236146	chr2:218255319~218257366:+
LUAD	cis	rs875971	1	rs6961717	ENSG00000226824.5	RP4-756H11.3	11.78	2.49e-28	9.05e-25	0.59	0.47	Aortic root size;	chr7:66122550	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs2087647	ENSG00000226824.5	RP4-756H11.3	11.78	2.5e-28	9.06e-25	0.59	0.47	Aortic root size;	chr7:66128201	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs6958484	ENSG00000226824.5	RP4-756H11.3	11.78	2.5e-28	9.06e-25	0.59	0.47	Aortic root size;	chr7:66134459	chr7:66654538~66669855:+
LUAD	cis	rs950027	0.62	rs1145089	ENSG00000259520.4	CTD-2651B20.3	-11.78	2.5e-28	9.07e-25	-0.58	-0.47	Response to fenofibrate (adiponectin levels);	chr15:45359856	chr15:45251580~45279251:-
LUAD	cis	rs1577917	1	rs35385043	ENSG00000203875.9	SNHG5	-11.78	2.5e-28	9.08e-25	-0.63	-0.47	Response to antipsychotic treatment;	chr6:85938828	chr6:85660950~85678736:-
LUAD	cis	rs875971	0.597	rs11771318	ENSG00000226824.5	RP4-756H11.3	11.78	2.56e-28	9.26e-25	0.62	0.47	Aortic root size;	chr7:66597493	chr7:66654538~66669855:+
LUAD	cis	rs1153858	1	rs1890565	ENSG00000259520.4	CTD-2651B20.3	-11.78	2.56e-28	9.26e-25	-0.63	-0.47	Homoarginine levels;	chr15:45371101	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs12594857	ENSG00000259520.4	CTD-2651B20.3	-11.78	2.56e-28	9.26e-25	-0.63	-0.47	Homoarginine levels;	chr15:45374980	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs7164602	ENSG00000259520.4	CTD-2651B20.3	-11.78	2.56e-28	9.26e-25	-0.63	-0.47	Homoarginine levels;	chr15:45379127	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs12441971	ENSG00000259520.4	CTD-2651B20.3	-11.78	2.56e-28	9.26e-25	-0.63	-0.47	Homoarginine levels;	chr15:45379759	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs1346268	ENSG00000259520.4	CTD-2651B20.3	-11.78	2.56e-28	9.26e-25	-0.63	-0.47	Homoarginine levels;	chr15:45380831	chr15:45251580~45279251:-
LUAD	cis	rs1153858	0.943	rs67045941	ENSG00000259520.4	CTD-2651B20.3	-11.78	2.56e-28	9.26e-25	-0.63	-0.47	Homoarginine levels;	chr15:45384813	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs67744121	ENSG00000259520.4	CTD-2651B20.3	-11.78	2.56e-28	9.26e-25	-0.63	-0.47	Homoarginine levels;	chr15:45385039	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs16942568	ENSG00000259520.4	CTD-2651B20.3	-11.78	2.56e-28	9.26e-25	-0.63	-0.47	Homoarginine levels;	chr15:45385192	chr15:45251580~45279251:-
LUAD	cis	rs1153858	0.943	rs11070454	ENSG00000259520.4	CTD-2651B20.3	-11.78	2.56e-28	9.26e-25	-0.63	-0.47	Homoarginine levels;	chr15:45388054	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs10519022	ENSG00000259520.4	CTD-2651B20.3	11.78	2.56e-28	9.28e-25	0.63	0.47	Homoarginine levels;	chr15:45371486	chr15:45251580~45279251:-
LUAD	cis	rs801193	0.66	rs10950049	ENSG00000226824.5	RP4-756H11.3	-11.78	2.58e-28	9.33e-25	-0.6	-0.47	Aortic root size;	chr7:66765873	chr7:66654538~66669855:+
LUAD	cis	rs1577917	1	rs34581302	ENSG00000203875.9	SNHG5	-11.78	2.58e-28	9.33e-25	-0.66	-0.47	Response to antipsychotic treatment;	chr6:85996230	chr6:85660950~85678736:-
LUAD	cis	rs6452524	0.935	rs1011979	ENSG00000249664.1	CTD-2227C6.2	11.78	2.59e-28	9.36e-25	0.54	0.47	Hypertension (SNP x SNP interaction);	chr5:83097431	chr5:83012285~83013109:-
LUAD	cis	rs1577917	1	rs12204015	ENSG00000203875.9	SNHG5	-11.78	2.6e-28	9.41e-25	-0.64	-0.47	Response to antipsychotic treatment;	chr6:85888616	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs4707236	ENSG00000203875.9	SNHG5	-11.78	2.63e-28	9.51e-25	-0.64	-0.47	Response to antipsychotic treatment;	chr6:85874249	chr6:85660950~85678736:-
LUAD	cis	rs801193	0.66	rs974239	ENSG00000226824.5	RP4-756H11.3	-11.78	2.63e-28	9.53e-25	-0.6	-0.47	Aortic root size;	chr7:66748504	chr7:66654538~66669855:+
LUAD	cis	rs1577917	1	rs791856	ENSG00000203875.9	SNHG5	11.77	2.68e-28	9.67e-25	0.63	0.47	Response to antipsychotic treatment;	chr6:85972123	chr6:85660950~85678736:-
LUAD	cis	rs6452524	0.935	rs1580310	ENSG00000249664.1	CTD-2227C6.2	11.77	2.69e-28	9.71e-25	0.54	0.47	Hypertension (SNP x SNP interaction);	chr5:83091792	chr5:83012285~83013109:-
LUAD	cis	rs62229266	0.682	rs11700546	ENSG00000231106.2	LINC01436	11.77	2.69e-28	9.72e-25	0.68	0.47	Mitral valve prolapse;	chr21:35998841	chr21:36005338~36007838:+
LUAD	cis	rs2658782	0.547	rs3020064	ENSG00000279684.1	RP11-755E23.2	-11.77	2.87e-28	1.04e-24	-0.67	-0.47	Pulmonary function decline;	chr11:93327685	chr11:93286629~93288903:-
LUAD	cis	rs9545047	0.935	rs2783119	ENSG00000227676.3	LINC01068	11.77	2.87e-28	1.04e-24	0.59	0.47	Schizophrenia;	chr13:79524983	chr13:79566727~79571436:+
LUAD	cis	rs10129255	0.589	rs78599641	ENSG00000211970.3	IGHV4-61	-11.77	2.88e-28	1.04e-24	-0.37	-0.47	Kawasaki disease;	chr14:106637576	chr14:106639119~106639657:-
LUAD	cis	rs2739330	0.828	rs2186366	ENSG00000231271.1	AP000350.8	-11.77	2.88e-28	1.04e-24	-0.57	-0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23949918~23954042:+
LUAD	cis	rs73086581	1	rs11906274	ENSG00000229539.1	RP11-119B16.2	11.77	2.93e-28	1.05e-24	0.69	0.47	Response to antidepressants in depression;	chr20:3964889	chr20:3888239~3888868:-
LUAD	cis	rs73086581	1	rs6052196	ENSG00000229539.1	RP11-119B16.2	11.77	2.93e-28	1.05e-24	0.69	0.47	Response to antidepressants in depression;	chr20:3965177	chr20:3888239~3888868:-
LUAD	cis	rs73086581	1	rs6116130	ENSG00000229539.1	RP11-119B16.2	11.77	2.93e-28	1.05e-24	0.69	0.47	Response to antidepressants in depression;	chr20:3966379	chr20:3888239~3888868:-
LUAD	cis	rs1577917	0.917	rs12202170	ENSG00000203875.9	SNHG5	-11.76	2.93e-28	1.06e-24	-0.67	-0.47	Response to antipsychotic treatment;	chr6:85880668	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs10455449	ENSG00000203875.9	SNHG5	-11.76	2.93e-28	1.06e-24	-0.67	-0.47	Response to antipsychotic treatment;	chr6:85882508	chr6:85660950~85678736:-
LUAD	cis	rs1153858	1	rs3809472	ENSG00000259520.4	CTD-2651B20.3	-11.76	2.95e-28	1.06e-24	-0.63	-0.47	Homoarginine levels;	chr15:45402120	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs1820518	ENSG00000259520.4	CTD-2651B20.3	-11.76	2.95e-28	1.06e-24	-0.63	-0.47	Homoarginine levels;	chr15:45402381	chr15:45251580~45279251:-
LUAD	cis	rs1577917	0.958	rs11756510	ENSG00000203875.9	SNHG5	-11.76	2.99e-28	1.08e-24	-0.66	-0.47	Response to antipsychotic treatment;	chr6:85990076	chr6:85660950~85678736:-
LUAD	cis	rs17507216	0.718	rs28587782	ENSG00000278603.1	RP13-608F4.5	11.76	3.1e-28	1.11e-24	0.66	0.47	Excessive daytime sleepiness;	chr15:82576881	chr15:82472203~82472426:+
LUAD	cis	rs1577917	1	rs6914463	ENSG00000203875.9	SNHG5	-11.76	3.15e-28	1.13e-24	-0.64	-0.47	Response to antipsychotic treatment;	chr6:85943697	chr6:85660950~85678736:-
LUAD	cis	rs875971	0.867	rs1002053	ENSG00000226824.5	RP4-756H11.3	11.75	3.23e-28	1.16e-24	0.6	0.47	Aortic root size;	chr7:66333558	chr7:66654538~66669855:+
LUAD	cis	rs7847628	0.765	rs7026635	ENSG00000226752.6	PSMD5-AS1	11.75	3.26e-28	1.17e-24	0.57	0.47	Birth weight;	chr9:120787749	chr9:120824828~120854385:+
LUAD	cis	rs1577917	0.917	rs35738006	ENSG00000203875.9	SNHG5	-11.75	3.33e-28	1.2e-24	-0.66	-0.47	Response to antipsychotic treatment;	chr6:85936591	chr6:85660950~85678736:-
LUAD	cis	rs73086581	1	rs6052209	ENSG00000229539.1	RP11-119B16.2	11.75	3.34e-28	1.2e-24	0.69	0.47	Response to antidepressants in depression;	chr20:3981100	chr20:3888239~3888868:-
LUAD	cis	rs992157	0.56	rs10932763	ENSG00000261338.2	RP11-378A13.1	-11.75	3.37e-28	1.21e-24	-0.48	-0.47	Colorectal cancer;	chr2:218221140	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.56	rs12992937	ENSG00000261338.2	RP11-378A13.1	-11.75	3.37e-28	1.21e-24	-0.48	-0.47	Colorectal cancer;	chr2:218222349	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.56	rs4674274	ENSG00000261338.2	RP11-378A13.1	-11.75	3.37e-28	1.21e-24	-0.48	-0.47	Colorectal cancer;	chr2:218224408	chr2:218255319~218257366:+
LUAD	cis	rs2382817	0.58	rs6756265	ENSG00000261338.2	RP11-378A13.1	-11.75	3.37e-28	1.21e-24	-0.48	-0.47	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr2:218230831	chr2:218255319~218257366:+
LUAD	cis	rs7301826	1	rs1609985	ENSG00000256299.1	RP11-989F5.3	-11.75	3.4e-28	1.22e-24	-0.52	-0.47	Plasma plasminogen activator levels;	chr12:130835625	chr12:130810821~130812622:-
LUAD	cis	rs9545047	0.901	rs1212082	ENSG00000227676.3	LINC01068	11.75	3.45e-28	1.24e-24	0.6	0.47	Schizophrenia;	chr13:79552633	chr13:79566727~79571436:+
LUAD	cis	rs1153858	0.943	rs12439575	ENSG00000259520.4	CTD-2651B20.3	-11.75	3.45e-28	1.24e-24	-0.63	-0.47	Homoarginine levels;	chr15:45392618	chr15:45251580~45279251:-
LUAD	cis	rs9322193	0.504	rs7771014	ENSG00000231760.4	RP11-350J20.5	11.75	3.46e-28	1.24e-24	0.59	0.47	Lung cancer;	chr6:149884310	chr6:149796151~149826294:-
LUAD	cis	rs507080	0.922	rs478371	ENSG00000255239.1	AP002954.6	11.75	3.49e-28	1.25e-24	0.57	0.47	Serum metabolite levels;	chr11:118694627	chr11:118688039~118690600:-
LUAD	cis	rs3091242	0.9	rs669063	ENSG00000224183.1	SDHDP6	-11.74	3.71e-28	1.33e-24	-0.6	-0.47	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25294164~25294643:-
LUAD	cis	rs875971	1	rs4718307	ENSG00000226824.5	RP4-756H11.3	11.74	3.75e-28	1.34e-24	0.59	0.47	Aortic root size;	chr7:66146001	chr7:66654538~66669855:+
LUAD	cis	rs992157	0.56	rs1514132	ENSG00000261338.2	RP11-378A13.1	-11.74	3.79e-28	1.35e-24	-0.48	-0.47	Colorectal cancer;	chr2:218219359	chr2:218255319~218257366:+
LUAD	cis	rs73086581	0.945	rs6037715	ENSG00000229539.1	RP11-119B16.2	11.74	3.82e-28	1.37e-24	0.67	0.47	Response to antidepressants in depression;	chr20:3991519	chr20:3888239~3888868:-
LUAD	cis	rs2658782	0.547	rs3133454	ENSG00000279684.1	RP11-755E23.2	-11.73	3.94e-28	1.41e-24	-0.67	-0.47	Pulmonary function decline;	chr11:93325853	chr11:93286629~93288903:-
LUAD	cis	rs2739330	0.587	rs4820571	ENSG00000231271.1	AP000350.8	11.73	3.94e-28	1.41e-24	0.56	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23949918~23954042:+
LUAD	cis	rs801193	0.636	rs10233806	ENSG00000226824.5	RP4-756H11.3	11.73	3.95e-28	1.41e-24	0.59	0.47	Aortic root size;	chr7:66653261	chr7:66654538~66669855:+
LUAD	cis	rs950027	0.62	rs2467862	ENSG00000259520.4	CTD-2651B20.3	-11.73	4.03e-28	1.44e-24	-0.57	-0.47	Response to fenofibrate (adiponectin levels);	chr15:45351645	chr15:45251580~45279251:-
LUAD	cis	rs6782228	0.606	rs7613073	ENSG00000242551.2	POU5F1P6	-11.73	4.08e-28	1.45e-24	-0.54	-0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669660	chr3:128674735~128677005:-
LUAD	cis	rs1577917	0.959	rs16876540	ENSG00000203875.9	SNHG5	-11.73	4.18e-28	1.49e-24	-0.67	-0.47	Response to antipsychotic treatment;	chr6:85902801	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs35761942	ENSG00000203875.9	SNHG5	-11.73	4.18e-28	1.49e-24	-0.67	-0.47	Response to antipsychotic treatment;	chr6:85919786	chr6:85660950~85678736:-
LUAD	cis	rs6452524	0.901	rs1580309	ENSG00000249664.1	CTD-2227C6.2	11.73	4.18e-28	1.49e-24	0.54	0.47	Hypertension (SNP x SNP interaction);	chr5:83091948	chr5:83012285~83013109:-
LUAD	cis	rs73086581	1	rs73088416	ENSG00000229539.1	RP11-119B16.2	11.72	4.24e-28	1.51e-24	0.69	0.47	Response to antidepressants in depression;	chr20:4014629	chr20:3888239~3888868:-
LUAD	cis	rs1577917	1	rs12196037	ENSG00000203875.9	SNHG5	-11.72	4.27e-28	1.52e-24	-0.67	-0.47	Response to antipsychotic treatment;	chr6:85984913	chr6:85660950~85678736:-
LUAD	cis	rs6452524	0.935	rs6896953	ENSG00000249664.1	CTD-2227C6.2	-11.72	4.36e-28	1.55e-24	-0.53	-0.47	Hypertension (SNP x SNP interaction);	chr5:83089284	chr5:83012285~83013109:-
LUAD	cis	rs11723261	0.582	rs11732336	ENSG00000275426.1	CH17-262A2.1	11.72	4.41e-28	1.57e-24	0.65	0.47	Immune response to smallpox vaccine (IL-6);	chr4:146728	chr4:149738~150317:+
LUAD	cis	rs11723261	0.582	rs61792238	ENSG00000275426.1	CH17-262A2.1	11.72	4.43e-28	1.57e-24	0.69	0.47	Immune response to smallpox vaccine (IL-6);	chr4:112398	chr4:149738~150317:+
LUAD	cis	rs2739330	0.796	rs5760106	ENSG00000250470.1	AP000351.3	-11.72	4.47e-28	1.59e-24	-0.59	-0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23976904~23977585:-
LUAD	cis	rs507080	0.922	rs642662	ENSG00000255239.1	AP002954.6	11.72	4.51e-28	1.6e-24	0.58	0.47	Serum metabolite levels;	chr11:118696311	chr11:118688039~118690600:-
LUAD	cis	rs73086581	1	rs6052217	ENSG00000229539.1	RP11-119B16.2	11.72	4.51e-28	1.6e-24	0.68	0.47	Response to antidepressants in depression;	chr20:3989564	chr20:3888239~3888868:-
LUAD	cis	rs73086581	1	rs6052218	ENSG00000229539.1	RP11-119B16.2	11.72	4.51e-28	1.6e-24	0.68	0.47	Response to antidepressants in depression;	chr20:3989565	chr20:3888239~3888868:-
LUAD	cis	rs73086581	0.945	rs6052219	ENSG00000229539.1	RP11-119B16.2	11.72	4.51e-28	1.6e-24	0.68	0.47	Response to antidepressants in depression;	chr20:3989660	chr20:3888239~3888868:-
LUAD	cis	rs7115242	0.748	rs1035237	ENSG00000254851.1	RP11-109L13.1	-11.72	4.58e-28	1.63e-24	-0.8	-0.47	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116857134	chr11:117135528~117138582:+
LUAD	cis	rs1153858	1	rs8042786	ENSG00000259520.4	CTD-2651B20.3	-11.72	4.62e-28	1.64e-24	-0.63	-0.47	Homoarginine levels;	chr15:45411341	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs12440038	ENSG00000259520.4	CTD-2651B20.3	-11.72	4.62e-28	1.64e-24	-0.63	-0.47	Homoarginine levels;	chr15:45414541	chr15:45251580~45279251:-
LUAD	cis	rs11155671	0.53	rs4870080	ENSG00000231760.4	RP11-350J20.5	11.72	4.64e-28	1.64e-24	0.58	0.47	Testicular germ cell tumor;	chr6:149881508	chr6:149796151~149826294:-
LUAD	cis	rs507080	0.922	rs533646	ENSG00000255239.1	AP002954.6	11.71	4.65e-28	1.65e-24	0.58	0.47	Serum metabolite levels;	chr11:118696037	chr11:118688039~118690600:-
LUAD	cis	rs2658782	0.789	rs56091149	ENSG00000279684.1	RP11-755E23.2	11.71	4.7e-28	1.66e-24	0.76	0.47	Pulmonary function decline;	chr11:93340474	chr11:93286629~93288903:-
LUAD	cis	rs992157	0.56	rs6738394	ENSG00000261338.2	RP11-378A13.1	-11.71	4.74e-28	1.68e-24	-0.48	-0.47	Colorectal cancer;	chr2:218245902	chr2:218255319~218257366:+
LUAD	cis	rs507080	0.883	rs656575	ENSG00000255239.1	AP002954.6	11.71	4.77e-28	1.69e-24	0.56	0.47	Serum metabolite levels;	chr11:118679199	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.961	rs656505	ENSG00000255239.1	AP002954.6	11.71	4.77e-28	1.69e-24	0.56	0.47	Serum metabolite levels;	chr11:118679245	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.961	rs660489	ENSG00000255239.1	AP002954.6	11.71	4.77e-28	1.69e-24	0.56	0.47	Serum metabolite levels;	chr11:118679255	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.961	rs543327	ENSG00000255239.1	AP002954.6	11.71	4.77e-28	1.69e-24	0.56	0.47	Serum metabolite levels;	chr11:118679276	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.961	rs543413	ENSG00000255239.1	AP002954.6	11.71	4.77e-28	1.69e-24	0.56	0.47	Serum metabolite levels;	chr11:118679308	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.845	rs667982	ENSG00000255239.1	AP002954.6	11.71	4.85e-28	1.72e-24	0.57	0.47	Serum metabolite levels;	chr11:118692058	chr11:118688039~118690600:-
LUAD	cis	rs1577917	0.816	rs9353349	ENSG00000203875.9	SNHG5	11.71	5e-28	1.77e-24	0.64	0.47	Response to antipsychotic treatment;	chr6:85998007	chr6:85660950~85678736:-
LUAD	cis	rs6452524	0.901	rs1600362	ENSG00000249664.1	CTD-2227C6.2	11.71	5.01e-28	1.77e-24	0.54	0.47	Hypertension (SNP x SNP interaction);	chr5:83091354	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.935	rs9293330	ENSG00000249664.1	CTD-2227C6.2	11.71	5.03e-28	1.78e-24	0.53	0.47	Hypertension (SNP x SNP interaction);	chr5:83102299	chr5:83012285~83013109:-
LUAD	cis	rs9545047	0.935	rs2760102	ENSG00000227676.3	LINC01068	11.71	5.03e-28	1.78e-24	0.59	0.47	Schizophrenia;	chr13:79555193	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.901	rs73235963	ENSG00000227676.3	LINC01068	11.71	5.03e-28	1.78e-24	0.59	0.47	Schizophrenia;	chr13:79562805	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.868	rs2476173	ENSG00000227676.3	LINC01068	11.71	5.03e-28	1.78e-24	0.59	0.47	Schizophrenia;	chr13:79565740	chr13:79566727~79571436:+
LUAD	cis	rs73086581	1	rs56324992	ENSG00000229539.1	RP11-119B16.2	11.7	5.17e-28	1.82e-24	0.66	0.47	Response to antidepressants in depression;	chr20:3997506	chr20:3888239~3888868:-
LUAD	cis	rs992157	0.56	rs4674275	ENSG00000261338.2	RP11-378A13.1	-11.7	5.2e-28	1.83e-24	-0.48	-0.47	Colorectal cancer;	chr2:218233015	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.585	rs62182795	ENSG00000261338.2	RP11-378A13.1	-11.7	5.2e-28	1.83e-24	-0.48	-0.47	Colorectal cancer;	chr2:218235479	chr2:218255319~218257366:+
LUAD	cis	rs507080	0.961	rs1784298	ENSG00000255239.1	AP002954.6	11.7	5.28e-28	1.86e-24	0.56	0.47	Serum metabolite levels;	chr11:118677956	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.961	rs4938522	ENSG00000255239.1	AP002954.6	11.7	5.28e-28	1.86e-24	0.56	0.47	Serum metabolite levels;	chr11:118677962	chr11:118688039~118690600:-
LUAD	cis	rs507080	1	rs659969	ENSG00000255239.1	AP002954.6	11.7	5.28e-28	1.86e-24	0.56	0.47	Serum metabolite levels;	chr11:118679094	chr11:118688039~118690600:-
LUAD	cis	rs977987	0.705	rs4888377	ENSG00000261783.1	RP11-252K23.2	-11.7	5.28e-28	1.86e-24	-0.66	-0.47	Dupuytren's disease;	chr16:75291788	chr16:75379818~75381260:-
LUAD	cis	rs875971	1	rs6460292	ENSG00000226824.5	RP4-756H11.3	11.7	5.28e-28	1.86e-24	0.6	0.47	Aortic root size;	chr7:66345088	chr7:66654538~66669855:+
LUAD	cis	rs11155671	0.53	rs9968871	ENSG00000231760.4	RP11-350J20.5	11.7	5.31e-28	1.87e-24	0.6	0.47	Testicular germ cell tumor;	chr6:149888060	chr6:149796151~149826294:-
LUAD	cis	rs11155671	0.53	rs9969044	ENSG00000231760.4	RP11-350J20.5	11.7	5.31e-28	1.87e-24	0.6	0.47	Testicular germ cell tumor;	chr6:149888068	chr6:149796151~149826294:-
LUAD	cis	rs875971	0.965	rs6971509	ENSG00000226824.5	RP4-756H11.3	11.7	5.32e-28	1.88e-24	0.6	0.47	Aortic root size;	chr7:66249983	chr7:66654538~66669855:+
LUAD	cis	rs1153858	1	rs11858495	ENSG00000259520.4	CTD-2651B20.3	11.7	5.37e-28	1.89e-24	0.65	0.47	Homoarginine levels;	chr15:45345464	chr15:45251580~45279251:-
LUAD	cis	rs9545047	0.935	rs2484343	ENSG00000227676.3	LINC01068	11.7	5.4e-28	1.9e-24	0.59	0.47	Schizophrenia;	chr13:79563587	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.868	rs1208049	ENSG00000227676.3	LINC01068	11.7	5.51e-28	1.94e-24	0.59	0.47	Schizophrenia;	chr13:79570220	chr13:79566727~79571436:+
LUAD	cis	rs2658782	0.547	rs4344448	ENSG00000279684.1	RP11-755E23.2	-11.7	5.56e-28	1.96e-24	-0.67	-0.47	Pulmonary function decline;	chr11:93313881	chr11:93286629~93288903:-
LUAD	cis	rs875971	0.964	rs778735	ENSG00000226824.5	RP4-756H11.3	-11.69	5.64e-28	1.99e-24	-0.6	-0.47	Aortic root size;	chr7:66349822	chr7:66654538~66669855:+
LUAD	cis	rs5760092	0.755	rs4585126	ENSG00000250470.1	AP000351.3	-11.69	5.74e-28	2.02e-24	-0.66	-0.47	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23976904~23977585:-
LUAD	cis	rs1153858	1	rs1365610	ENSG00000259520.4	CTD-2651B20.3	-11.69	5.76e-28	2.02e-24	-0.63	-0.47	Homoarginine levels;	chr15:45402412	chr15:45251580~45279251:-
LUAD	cis	rs875971	1	rs6963646	ENSG00000226824.5	RP4-756H11.3	11.69	5.89e-28	2.07e-24	0.59	0.47	Aortic root size;	chr7:66220780	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.965	rs28682868	ENSG00000226824.5	RP4-756H11.3	11.69	5.89e-28	2.07e-24	0.59	0.47	Aortic root size;	chr7:66224822	chr7:66654538~66669855:+
LUAD	cis	rs9545047	0.905	rs7321953	ENSG00000227676.3	LINC01068	-11.69	5.89e-28	2.07e-24	-0.58	-0.47	Schizophrenia;	chr13:79517404	chr13:79566727~79571436:+
LUAD	cis	rs17711722	0.653	rs2460421	ENSG00000226824.5	RP4-756H11.3	11.69	5.93e-28	2.08e-24	0.59	0.47	Calcium levels;	chr7:66026136	chr7:66654538~66669855:+
LUAD	cis	rs4853012	0.838	rs2177707	ENSG00000217702.2	RP11-287D1.4	11.69	6e-28	2.1e-24	0.76	0.47	Gestational age at birth (maternal effect);	chr2:74129723	chr2:74130583~74135395:+
LUAD	cis	rs950027	0.62	rs1719245	ENSG00000259520.4	CTD-2651B20.3	-11.69	6.02e-28	2.11e-24	-0.57	-0.47	Response to fenofibrate (adiponectin levels);	chr15:45331584	chr15:45251580~45279251:-
LUAD	cis	rs858239	0.863	rs274058	ENSG00000230658.1	KLHL7-AS1	11.69	6.02e-28	2.11e-24	0.58	0.47	Cerebrospinal fluid biomarker levels;	chr7:23351890	chr7:23101228~23105703:-
LUAD	cis	rs73086581	1	rs6037708	ENSG00000229539.1	RP11-119B16.2	11.69	6.08e-28	2.13e-24	0.68	0.47	Response to antidepressants in depression;	chr20:3980606	chr20:3888239~3888868:-
LUAD	cis	rs507080	0.961	rs4938523	ENSG00000255239.1	AP002954.6	11.68	6.19e-28	2.17e-24	0.56	0.47	Serum metabolite levels;	chr11:118678129	chr11:118688039~118690600:-
LUAD	cis	rs2658782	0.547	rs3020065	ENSG00000279684.1	RP11-755E23.2	-11.68	6.54e-28	2.29e-24	-0.67	-0.47	Pulmonary function decline;	chr11:93326733	chr11:93286629~93288903:-
LUAD	cis	rs2658782	0.526	rs3020062	ENSG00000279684.1	RP11-755E23.2	-11.68	6.54e-28	2.29e-24	-0.67	-0.47	Pulmonary function decline;	chr11:93327993	chr11:93286629~93288903:-
LUAD	cis	rs1577917	1	rs2324843	ENSG00000203875.9	SNHG5	-11.67	6.74e-28	2.36e-24	-0.66	-0.47	Response to antipsychotic treatment;	chr6:85907783	chr6:85660950~85678736:-
LUAD	cis	rs9322193	0.607	rs10457852	ENSG00000231760.4	RP11-350J20.5	11.67	6.78e-28	2.37e-24	0.71	0.47	Lung cancer;	chr6:149880584	chr6:149796151~149826294:-
LUAD	cis	rs1153858	1	rs7402650	ENSG00000259520.4	CTD-2651B20.3	-11.67	6.94e-28	2.42e-24	-0.63	-0.47	Homoarginine levels;	chr15:45409697	chr15:45251580~45279251:-
LUAD	cis	rs73086581	1	rs73086581	ENSG00000229539.1	RP11-119B16.2	11.67	6.99e-28	2.44e-24	0.69	0.47	Response to antidepressants in depression;	chr20:3996678	chr20:3888239~3888868:-
LUAD	cis	rs9545047	0.901	rs7338530	ENSG00000227676.3	LINC01068	-11.67	7.07e-28	2.47e-24	-0.59	-0.47	Schizophrenia;	chr13:79477715	chr13:79566727~79571436:+
LUAD	cis	rs1153858	1	rs60476496	ENSG00000259520.4	CTD-2651B20.3	-11.67	7.13e-28	2.49e-24	-0.63	-0.47	Homoarginine levels;	chr15:45421603	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs66528868	ENSG00000259520.4	CTD-2651B20.3	-11.67	7.2e-28	2.51e-24	-0.63	-0.47	Homoarginine levels;	chr15:45376349	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs7494956	ENSG00000259520.4	CTD-2651B20.3	-11.67	7.2e-28	2.51e-24	-0.63	-0.47	Homoarginine levels;	chr15:45376367	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs12437840	ENSG00000259520.4	CTD-2651B20.3	-11.67	7.2e-28	2.51e-24	-0.63	-0.47	Homoarginine levels;	chr15:45376857	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs12437887	ENSG00000259520.4	CTD-2651B20.3	-11.67	7.2e-28	2.51e-24	-0.63	-0.47	Homoarginine levels;	chr15:45376896	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs2114501	ENSG00000259520.4	CTD-2651B20.3	-11.67	7.2e-28	2.51e-24	-0.63	-0.47	Homoarginine levels;	chr15:45378118	chr15:45251580~45279251:-
LUAD	cis	rs1153858	0.887	rs7164139	ENSG00000259520.4	CTD-2651B20.3	-11.67	7.2e-28	2.51e-24	-0.63	-0.47	Homoarginine levels;	chr15:45378653	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs67461176	ENSG00000259520.4	CTD-2651B20.3	-11.67	7.2e-28	2.51e-24	-0.63	-0.47	Homoarginine levels;	chr15:45384621	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs66939267	ENSG00000259520.4	CTD-2651B20.3	-11.67	7.2e-28	2.51e-24	-0.63	-0.47	Homoarginine levels;	chr15:45384704	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs4775937	ENSG00000259520.4	CTD-2651B20.3	-11.67	7.2e-28	2.51e-24	-0.63	-0.47	Homoarginine levels;	chr15:45386416	chr15:45251580~45279251:-
LUAD	cis	rs6782228	0.651	rs9289332	ENSG00000242551.2	POU5F1P6	-11.67	7.27e-28	2.54e-24	-0.54	-0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669041	chr3:128674735~128677005:-
LUAD	cis	rs507080	0.961	rs600969	ENSG00000255239.1	AP002954.6	11.66	7.36e-28	2.56e-24	0.56	0.47	Serum metabolite levels;	chr11:118675087	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.961	rs673770	ENSG00000255239.1	AP002954.6	11.66	7.36e-28	2.56e-24	0.56	0.47	Serum metabolite levels;	chr11:118679892	chr11:118688039~118690600:-
LUAD	cis	rs1577917	0.958	rs7739241	ENSG00000203875.9	SNHG5	-11.66	7.43e-28	2.59e-24	-0.64	-0.47	Response to antipsychotic treatment;	chr6:85866078	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs12202712	ENSG00000203875.9	SNHG5	-11.66	7.43e-28	2.59e-24	-0.64	-0.47	Response to antipsychotic treatment;	chr6:85868823	chr6:85660950~85678736:-
LUAD	cis	rs9326248	0.53	rs2075292	ENSG00000254851.1	RP11-109L13.1	-11.66	7.46e-28	2.6e-24	-0.83	-0.47	Blood protein levels;	chr11:116861796	chr11:117135528~117138582:+
LUAD	cis	rs9545047	0.935	rs7339303	ENSG00000227676.3	LINC01068	-11.66	7.5e-28	2.61e-24	-0.58	-0.47	Schizophrenia;	chr13:79516730	chr13:79566727~79571436:+
LUAD	cis	rs507080	0.922	rs558781	ENSG00000255239.1	AP002954.6	11.66	7.53e-28	2.62e-24	0.57	0.47	Serum metabolite levels;	chr11:118693688	chr11:118688039~118690600:-
LUAD	cis	rs1799949	0.965	rs8067269	ENSG00000198496.9	NBR2	-11.66	7.79e-28	2.71e-24	-0.5	-0.47	Menopause (age at onset);	chr17:43083782	chr17:43125610~43153671:+
LUAD	cis	rs7301826	0.934	rs10848212	ENSG00000256299.1	RP11-989F5.3	11.66	7.97e-28	2.77e-24	0.5	0.47	Plasma plasminogen activator levels;	chr12:130837455	chr12:130810821~130812622:-
LUAD	cis	rs11723261	0.621	rs7440274	ENSG00000275426.1	CH17-262A2.1	-11.66	8.01e-28	2.78e-24	-0.65	-0.47	Immune response to smallpox vaccine (IL-6);	chr4:161923	chr4:149738~150317:+
LUAD	cis	rs2581828	0.656	rs2581800	ENSG00000242142.1	SERBP1P3	11.65	8.16e-28	2.84e-24	0.48	0.47	Crohn's disease;	chr3:53075336	chr3:53064283~53065091:-
LUAD	cis	rs875971	1	rs1167411	ENSG00000226824.5	RP4-756H11.3	11.65	8.19e-28	2.85e-24	0.6	0.47	Aortic root size;	chr7:66074277	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.898	rs6977501	ENSG00000226824.5	RP4-756H11.3	11.65	8.23e-28	2.86e-24	0.59	0.47	Aortic root size;	chr7:66228355	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.964	rs55748098	ENSG00000226824.5	RP4-756H11.3	11.65	8.37e-28	2.91e-24	0.6	0.47	Aortic root size;	chr7:66298631	chr7:66654538~66669855:+
LUAD	cis	rs10129255	0.536	rs6576201	ENSG00000211972.2	IGHV3-66	-11.65	8.58e-28	2.98e-24	-0.37	-0.47	Kawasaki disease;	chr14:106683696	chr14:106675017~106675544:-
LUAD	cis	rs9545047	0.935	rs4885633	ENSG00000227676.3	LINC01068	-11.64	9.02e-28	3.13e-24	-0.6	-0.47	Schizophrenia;	chr13:79469720	chr13:79566727~79571436:+
LUAD	cis	rs2882667	0.537	rs6887866	ENSG00000253404.1	AC034243.1	11.64	9.03e-28	3.13e-24	0.57	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139102007	chr5:138744434~138753309:-
LUAD	cis	rs11155671	0.53	rs2342770	ENSG00000231760.4	RP11-350J20.5	11.64	9.22e-28	3.19e-24	0.59	0.47	Testicular germ cell tumor;	chr6:149895549	chr6:149796151~149826294:-
LUAD	cis	rs7115242	1	rs7115242	ENSG00000254851.1	RP11-109L13.1	11.64	9.37e-28	3.25e-24	0.88	0.47	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117037567	chr11:117135528~117138582:+
LUAD	cis	rs9545047	0.837	rs9601242	ENSG00000227676.3	LINC01068	11.64	9.42e-28	3.26e-24	0.59	0.47	Schizophrenia;	chr13:79561543	chr13:79566727~79571436:+
LUAD	cis	rs1153858	1	rs4395020	ENSG00000259520.4	CTD-2651B20.3	-11.64	9.46e-28	3.27e-24	-0.62	-0.47	Homoarginine levels;	chr15:45360691	chr15:45251580~45279251:-
LUAD	cis	rs2739330	0.828	rs5751770	ENSG00000250470.1	AP000351.3	11.64	9.51e-28	3.29e-24	0.58	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23976904~23977585:-
LUAD	cis	rs55794721	0.509	rs6699896	ENSG00000224183.1	SDHDP6	-11.63	9.8e-28	3.39e-24	-0.59	-0.47	Mean corpuscular volume;Plateletcrit;	chr1:25436411	chr1:25294164~25294643:-
LUAD	cis	rs73086581	0.786	rs6037705	ENSG00000229539.1	RP11-119B16.2	11.63	9.8e-28	3.39e-24	0.67	0.47	Response to antidepressants in depression;	chr20:3972183	chr20:3888239~3888868:-
LUAD	cis	rs1577917	0.876	rs1582126	ENSG00000203875.9	SNHG5	-11.63	9.88e-28	3.42e-24	-0.66	-0.47	Response to antipsychotic treatment;	chr6:85987487	chr6:85660950~85678736:-
LUAD	cis	rs3091242	0.9	rs1811832	ENSG00000224183.1	SDHDP6	-11.63	1e-27	3.47e-24	-0.6	-0.47	Erythrocyte sedimentation rate;	chr1:25427074	chr1:25294164~25294643:-
LUAD	cis	rs875971	0.965	rs9969301	ENSG00000226824.5	RP4-756H11.3	11.63	1.01e-27	3.48e-24	0.6	0.47	Aortic root size;	chr7:66316668	chr7:66654538~66669855:+
LUAD	cis	rs507080	0.961	rs4457789	ENSG00000255422.1	AP002954.4	-11.63	1.02e-27	3.54e-24	-0.58	-0.47	Serum metabolite levels;	chr11:118668461	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.961	rs607527	ENSG00000255239.1	AP002954.6	-11.63	1.03e-27	3.55e-24	-0.55	-0.47	Serum metabolite levels;	chr11:118667478	chr11:118688039~118690600:-
LUAD	cis	rs7188445	0.556	rs7203910	ENSG00000261390.4	RP11-345M22.2	-11.63	1.03e-27	3.56e-24	-0.58	-0.47	Urate levels;	chr16:79711722	chr16:79715232~79770563:-
LUAD	cis	rs11155671	0.53	rs9371544	ENSG00000231760.4	RP11-350J20.5	11.63	1.03e-27	3.57e-24	0.59	0.47	Testicular germ cell tumor;	chr6:149896224	chr6:149796151~149826294:-
LUAD	cis	rs507080	1	rs507080	ENSG00000255239.1	AP002954.6	11.63	1.04e-27	3.6e-24	0.56	0.47	Serum metabolite levels;	chr11:118678873	chr11:118688039~118690600:-
LUAD	cis	rs2739330	0.796	rs2154594	ENSG00000231271.1	AP000350.8	-11.63	1.05e-27	3.63e-24	-0.57	-0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23949918~23954042:+
LUAD	cis	rs507080	0.922	rs12577485	ENSG00000255239.1	AP002954.6	11.63	1.06e-27	3.65e-24	0.56	0.47	Serum metabolite levels;	chr11:118676793	chr11:118688039~118690600:-
LUAD	cis	rs950027	0.62	rs1153860	ENSG00000259520.4	CTD-2651B20.3	11.62	1.08e-27	3.71e-24	0.56	0.47	Response to fenofibrate (adiponectin levels);	chr15:45344386	chr15:45251580~45279251:-
LUAD	cis	rs1577917	0.958	rs34765423	ENSG00000203875.9	SNHG5	-11.62	1.08e-27	3.72e-24	-0.67	-0.47	Response to antipsychotic treatment;	chr6:85774730	chr6:85660950~85678736:-
LUAD	cis	rs11723261	0.582	rs11735742	ENSG00000275426.1	CH17-262A2.1	-11.62	1.08e-27	3.74e-24	-0.62	-0.47	Immune response to smallpox vaccine (IL-6);	chr4:148766	chr4:149738~150317:+
LUAD	cis	rs1577917	1	rs1911552	ENSG00000203875.9	SNHG5	-11.62	1.13e-27	3.88e-24	-0.63	-0.47	Response to antipsychotic treatment;	chr6:85928306	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs9647603	ENSG00000203875.9	SNHG5	-11.62	1.13e-27	3.88e-24	-0.63	-0.47	Response to antipsychotic treatment;	chr6:85929623	chr6:85660950~85678736:-
LUAD	cis	rs6782228	0.651	rs9852825	ENSG00000242551.2	POU5F1P6	-11.62	1.14e-27	3.92e-24	-0.54	-0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128668514	chr3:128674735~128677005:-
LUAD	cis	rs6538678	0.777	rs10745736	ENSG00000258343.1	RP11-536G4.2	-11.61	1.16e-27	4e-24	-0.7	-0.47	Lupus nephritis in systemic lupus erythematosus;	chr12:95889308	chr12:95795345~95858839:-
LUAD	cis	rs992157	0.56	rs12987130	ENSG00000261338.2	RP11-378A13.1	-11.61	1.17e-27	4.04e-24	-0.48	-0.47	Colorectal cancer;	chr2:218240267	chr2:218255319~218257366:+
LUAD	cis	rs875971	0.965	rs10267430	ENSG00000226824.5	RP4-756H11.3	11.61	1.22e-27	4.21e-24	0.59	0.47	Aortic root size;	chr7:66278036	chr7:66654538~66669855:+
LUAD	cis	rs1577917	1	rs7747824	ENSG00000203875.9	SNHG5	-11.61	1.24e-27	4.26e-24	-0.63	-0.47	Response to antipsychotic treatment;	chr6:85937388	chr6:85660950~85678736:-
LUAD	cis	rs950027	0.62	rs1145076	ENSG00000259520.4	CTD-2651B20.3	-11.61	1.27e-27	4.35e-24	-0.56	-0.47	Response to fenofibrate (adiponectin levels);	chr15:45392310	chr15:45251580~45279251:-
LUAD	cis	rs73086581	1	rs73086588	ENSG00000229539.1	RP11-119B16.2	11.6	1.28e-27	4.4e-24	0.67	0.47	Response to antidepressants in depression;	chr20:4001577	chr20:3888239~3888868:-
LUAD	cis	rs73086581	1	rs73086595	ENSG00000229539.1	RP11-119B16.2	11.6	1.28e-27	4.4e-24	0.67	0.47	Response to antidepressants in depression;	chr20:4002801	chr20:3888239~3888868:-
LUAD	cis	rs73086581	1	rs73086597	ENSG00000229539.1	RP11-119B16.2	11.6	1.28e-27	4.4e-24	0.67	0.47	Response to antidepressants in depression;	chr20:4002924	chr20:3888239~3888868:-
LUAD	cis	rs9326248	0.53	rs6589575	ENSG00000254851.1	RP11-109L13.1	-11.6	1.3e-27	4.46e-24	-0.83	-0.47	Blood protein levels;	chr11:116862594	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.53	rs718847	ENSG00000254851.1	RP11-109L13.1	-11.6	1.3e-27	4.46e-24	-0.83	-0.47	Blood protein levels;	chr11:116863430	chr11:117135528~117138582:+
LUAD	cis	rs992157	0.56	rs6436047	ENSG00000261338.2	RP11-378A13.1	11.6	1.31e-27	4.49e-24	0.47	0.47	Colorectal cancer;	chr2:218244190	chr2:218255319~218257366:+
LUAD	cis	rs2882667	0.522	rs7731574	ENSG00000253404.1	AC034243.1	-11.6	1.37e-27	4.69e-24	-0.6	-0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139118503	chr5:138744434~138753309:-
LUAD	cis	rs950027	0.62	rs2486274	ENSG00000259520.4	CTD-2651B20.3	-11.6	1.38e-27	4.72e-24	-0.57	-0.47	Response to fenofibrate (adiponectin levels);	chr15:45374030	chr15:45251580~45279251:-
LUAD	cis	rs2739330	0.828	rs4822451	ENSG00000250470.1	AP000351.3	11.6	1.39e-27	4.75e-24	0.59	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23976904~23977585:-
LUAD	cis	rs2739330	0.828	rs5760098	ENSG00000250470.1	AP000351.3	11.6	1.39e-27	4.75e-24	0.59	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23976904~23977585:-
LUAD	cis	rs5760092	0.618	rs5996631	ENSG00000218537.1	MIF-AS1	-11.6	1.39e-27	4.77e-24	-0.68	-0.47	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23894426~23898930:-
LUAD	cis	rs6782228	0.675	rs56141228	ENSG00000242551.2	POU5F1P6	-11.59	1.45e-27	4.95e-24	-0.54	-0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128667199	chr3:128674735~128677005:-
LUAD	cis	rs11723261	0.621	rs11721745	ENSG00000275426.1	CH17-262A2.1	11.59	1.49e-27	5.08e-24	0.67	0.47	Immune response to smallpox vaccine (IL-6);	chr4:115052	chr4:149738~150317:+
LUAD	cis	rs6782228	0.628	rs7641584	ENSG00000242551.2	POU5F1P6	-11.59	1.52e-27	5.2e-24	-0.53	-0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128673787	chr3:128674735~128677005:-
LUAD	cis	rs1577917	0.958	rs11754330	ENSG00000203875.9	SNHG5	-11.58	1.57e-27	5.35e-24	-0.66	-0.47	Response to antipsychotic treatment;	chr6:85745352	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs34622605	ENSG00000203875.9	SNHG5	-11.58	1.57e-27	5.35e-24	-0.66	-0.47	Response to antipsychotic treatment;	chr6:85746801	chr6:85660950~85678736:-
LUAD	cis	rs1799949	0.965	rs6503726	ENSG00000198496.9	NBR2	-11.58	1.62e-27	5.53e-24	-0.5	-0.47	Menopause (age at onset);	chr17:43132725	chr17:43125610~43153671:+
LUAD	cis	rs507080	0.961	rs520543	ENSG00000255422.1	AP002954.4	-11.58	1.67e-27	5.69e-24	-0.58	-0.47	Serum metabolite levels;	chr11:118667448	chr11:118704607~118750263:+
LUAD	cis	rs950027	0.62	rs1049518	ENSG00000259520.4	CTD-2651B20.3	-11.58	1.67e-27	5.69e-24	-0.57	-0.47	Response to fenofibrate (adiponectin levels);	chr15:45361169	chr15:45251580~45279251:-
LUAD	cis	rs950027	0.584	rs1145086	ENSG00000259520.4	CTD-2651B20.3	-11.58	1.67e-27	5.69e-24	-0.57	-0.47	Response to fenofibrate (adiponectin levels);	chr15:45362129	chr15:45251580~45279251:-
LUAD	cis	rs950027	0.62	rs1153857	ENSG00000259520.4	CTD-2651B20.3	-11.58	1.67e-27	5.69e-24	-0.57	-0.47	Response to fenofibrate (adiponectin levels);	chr15:45366897	chr15:45251580~45279251:-
LUAD	cis	rs950027	0.62	rs1153855	ENSG00000259520.4	CTD-2651B20.3	-11.58	1.67e-27	5.69e-24	-0.57	-0.47	Response to fenofibrate (adiponectin levels);	chr15:45368560	chr15:45251580~45279251:-
LUAD	cis	rs950027	0.62	rs1145080	ENSG00000259520.4	CTD-2651B20.3	-11.58	1.67e-27	5.69e-24	-0.57	-0.47	Response to fenofibrate (adiponectin levels);	chr15:45389140	chr15:45251580~45279251:-
LUAD	cis	rs1577917	1	rs955196	ENSG00000203875.9	SNHG5	11.57	1.76e-27	5.97e-24	0.64	0.47	Response to antipsychotic treatment;	chr6:86020233	chr6:85660950~85678736:-
LUAD	cis	rs2658782	0.639	rs2100552	ENSG00000279684.1	RP11-755E23.2	-11.57	1.76e-27	5.98e-24	-0.66	-0.47	Pulmonary function decline;	chr11:93449083	chr11:93286629~93288903:-
LUAD	cis	rs1577917	0.958	rs12193904	ENSG00000203875.9	SNHG5	-11.57	1.78e-27	6.07e-24	-0.66	-0.47	Response to antipsychotic treatment;	chr6:85742985	chr6:85660950~85678736:-
LUAD	cis	rs3091242	0.904	rs6661533	ENSG00000224183.1	SDHDP6	-11.57	1.81e-27	6.16e-24	-0.58	-0.47	Erythrocyte sedimentation rate;	chr1:25445224	chr1:25294164~25294643:-
LUAD	cis	rs55794721	0.509	rs6699113	ENSG00000224183.1	SDHDP6	-11.57	1.81e-27	6.16e-24	-0.58	-0.47	Mean corpuscular volume;Plateletcrit;	chr1:25451252	chr1:25294164~25294643:-
LUAD	cis	rs55794721	0.509	rs7554255	ENSG00000224183.1	SDHDP6	-11.57	1.81e-27	6.16e-24	-0.58	-0.47	Mean corpuscular volume;Plateletcrit;	chr1:25451615	chr1:25294164~25294643:-
LUAD	cis	rs55794721	0.509	rs4649085	ENSG00000224183.1	SDHDP6	-11.57	1.81e-27	6.16e-24	-0.58	-0.47	Mean corpuscular volume;Plateletcrit;	chr1:25452341	chr1:25294164~25294643:-
LUAD	cis	rs2739330	0.828	rs5760099	ENSG00000250470.1	AP000351.3	11.56	1.83e-27	6.23e-24	0.59	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23976904~23977585:-
LUAD	cis	rs11723261	0.509	rs61792240	ENSG00000275426.1	CH17-262A2.1	11.56	1.85e-27	6.29e-24	0.69	0.47	Immune response to smallpox vaccine (IL-6);	chr4:134876	chr4:149738~150317:+
LUAD	cis	rs1153858	1	rs1554521	ENSG00000259520.4	CTD-2651B20.3	11.56	1.88e-27	6.38e-24	0.62	0.47	Homoarginine levels;	chr15:45371991	chr15:45251580~45279251:-
LUAD	cis	rs8062405	1	rs62036617	ENSG00000259982.1	CDC37P1	11.56	1.9e-27	6.44e-24	0.6	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28700294~28701540:-
LUAD	cis	rs11155671	0.53	rs7763849	ENSG00000231760.4	RP11-350J20.5	11.56	1.9e-27	6.44e-24	0.57	0.47	Testicular germ cell tumor;	chr6:149885244	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.796	rs5760097	ENSG00000250470.1	AP000351.3	11.56	1.91e-27	6.48e-24	0.59	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23976904~23977585:-
LUAD	cis	rs6452524	0.934	rs12153179	ENSG00000249664.1	CTD-2227C6.2	11.56	1.93e-27	6.55e-24	0.54	0.47	Hypertension (SNP x SNP interaction);	chr5:83125109	chr5:83012285~83013109:-
LUAD	cis	rs73086581	1	rs6107391	ENSG00000229539.1	RP11-119B16.2	11.56	1.94e-27	6.58e-24	0.67	0.47	Response to antidepressants in depression;	chr20:4002436	chr20:3888239~3888868:-
LUAD	cis	rs1577917	0.958	rs12205492	ENSG00000203875.9	SNHG5	-11.56	1.99e-27	6.73e-24	-0.65	-0.47	Response to antipsychotic treatment;	chr6:85766258	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs884841	ENSG00000203875.9	SNHG5	-11.56	1.99e-27	6.74e-24	-0.63	-0.47	Response to antipsychotic treatment;	chr6:85970582	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs1999852	ENSG00000203875.9	SNHG5	-11.56	2e-27	6.77e-24	-0.64	-0.47	Response to antipsychotic treatment;	chr6:85996020	chr6:85660950~85678736:-
LUAD	cis	rs10262624	0.528	rs5029444	ENSG00000234286.1	AC006026.13	11.55	2.03e-27	6.86e-24	0.56	0.47	Schizophrenia;	chr7:23698176	chr7:23680195~23680786:-
LUAD	cis	rs9322193	0.607	rs3798763	ENSG00000231760.4	RP11-350J20.5	11.55	2.05e-27	6.94e-24	0.72	0.47	Lung cancer;	chr6:149889964	chr6:149796151~149826294:-
LUAD	cis	rs55794721	0.509	rs2375313	ENSG00000224183.1	SDHDP6	-11.55	2.06e-27	6.96e-24	-0.59	-0.47	Mean corpuscular volume;Plateletcrit;	chr1:25421744	chr1:25294164~25294643:-
LUAD	cis	rs2739330	0.828	rs5760102	ENSG00000250470.1	AP000351.3	11.55	2.14e-27	7.21e-24	0.59	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23976904~23977585:-
LUAD	cis	rs8062405	0.964	rs11860513	ENSG00000259982.1	CDC37P1	11.55	2.16e-27	7.3e-24	0.59	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28700294~28701540:-
LUAD	cis	rs3096299	0.658	rs3934737	ENSG00000274627.1	RP11-104N10.2	11.55	2.18e-27	7.34e-24	0.44	0.47	Multiple myeloma (IgH translocation);	chr16:89493801	chr16:89516797~89522217:+
LUAD	cis	rs1577917	1	rs12190604	ENSG00000203875.9	SNHG5	-11.55	2.19e-27	7.4e-24	-0.65	-0.47	Response to antipsychotic treatment;	chr6:86006497	chr6:85660950~85678736:-
LUAD	cis	rs6782228	0.675	rs9841987	ENSG00000242551.2	POU5F1P6	-11.54	2.23e-27	7.5e-24	-0.54	-0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128666299	chr3:128674735~128677005:-
LUAD	cis	rs1577917	0.837	rs10944157	ENSG00000203875.9	SNHG5	-11.54	2.25e-27	7.57e-24	-0.64	-0.47	Response to antipsychotic treatment;	chr6:85867481	chr6:85660950~85678736:-
LUAD	cis	rs6452524	0.905	rs10040244	ENSG00000249664.1	CTD-2227C6.2	11.54	2.25e-27	7.59e-24	0.52	0.47	Hypertension (SNP x SNP interaction);	chr5:83089242	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.935	rs10474081	ENSG00000249664.1	CTD-2227C6.2	11.54	2.25e-27	7.59e-24	0.52	0.47	Hypertension (SNP x SNP interaction);	chr5:83095064	chr5:83012285~83013109:-
LUAD	cis	rs1577917	1	rs1018184	ENSG00000203875.9	SNHG5	11.54	2.26e-27	7.62e-24	0.62	0.47	Response to antipsychotic treatment;	chr6:85938757	chr6:85660950~85678736:-
LUAD	cis	rs950027	0.62	rs2461700	ENSG00000259520.4	CTD-2651B20.3	-11.54	2.28e-27	7.66e-24	-0.56	-0.47	Response to fenofibrate (adiponectin levels);	chr15:45348429	chr15:45251580~45279251:-
LUAD	cis	rs950027	0.62	rs2453533	ENSG00000259520.4	CTD-2651B20.3	-11.54	2.28e-27	7.66e-24	-0.56	-0.47	Response to fenofibrate (adiponectin levels);	chr15:45349027	chr15:45251580~45279251:-
LUAD	cis	rs950027	0.596	rs2467865	ENSG00000259520.4	CTD-2651B20.3	-11.54	2.3e-27	7.74e-24	-0.56	-0.47	Response to fenofibrate (adiponectin levels);	chr15:45346109	chr15:45251580~45279251:-
LUAD	cis	rs1153858	0.723	rs11855527	ENSG00000259520.4	CTD-2651B20.3	11.54	2.36e-27	7.92e-24	0.65	0.47	Homoarginine levels;	chr15:45314487	chr15:45251580~45279251:-
LUAD	cis	rs9322193	0.923	rs9766037	ENSG00000216906.2	RP11-350J20.9	11.53	2.41e-27	8.1e-24	0.56	0.47	Lung cancer;	chr6:149616921	chr6:149904243~149906418:+
LUAD	cis	rs7174755	0.923	rs9672310	ENSG00000260657.2	RP11-315D16.4	11.53	2.46e-27	8.28e-24	0.54	0.47	Major depressive disorder;	chr15:68306578	chr15:68267792~68277994:-
LUAD	cis	rs9545047	0.901	rs314688	ENSG00000227676.3	LINC01068	11.52	2.68e-27	8.99e-24	0.59	0.47	Schizophrenia;	chr13:79449171	chr13:79566727~79571436:+
LUAD	cis	rs875971	0.965	rs7794930	ENSG00000226824.5	RP4-756H11.3	11.52	2.81e-27	9.39e-24	0.59	0.46	Aortic root size;	chr7:66313559	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.567	rs7742692	ENSG00000216906.2	RP11-350J20.9	11.52	2.82e-27	9.43e-24	0.57	0.46	Lung cancer;	chr6:149892363	chr6:149904243~149906418:+
LUAD	cis	rs1577917	1	rs35797755	ENSG00000203875.9	SNHG5	-11.52	2.82e-27	9.45e-24	-0.64	-0.46	Response to antipsychotic treatment;	chr6:85996836	chr6:85660950~85678736:-
LUAD	cis	rs3091242	0.933	rs35148262	ENSG00000224183.1	SDHDP6	-11.51	3.01e-27	1.01e-23	-0.59	-0.46	Erythrocyte sedimentation rate;	chr1:25440132	chr1:25294164~25294643:-
LUAD	cis	rs10129255	0.589	rs78599641	ENSG00000223648.3	IGHV3-64	11.51	3.11e-27	1.04e-23	0.47	0.46	Kawasaki disease;	chr14:106637576	chr14:106643132~106658258:-
LUAD	cis	rs73086581	1	rs6107386	ENSG00000229539.1	RP11-119B16.2	11.5	3.17e-27	1.06e-23	0.67	0.46	Response to antidepressants in depression;	chr20:3992109	chr20:3888239~3888868:-
LUAD	cis	rs11155671	0.53	rs9397420	ENSG00000216906.2	RP11-350J20.9	-11.5	3.25e-27	1.08e-23	-0.56	-0.46	Testicular germ cell tumor;	chr6:149885645	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.543	rs9371533	ENSG00000216906.2	RP11-350J20.9	11.5	3.27e-27	1.09e-23	0.57	0.46	Lung cancer;	chr6:149889545	chr6:149904243~149906418:+
LUAD	cis	rs1577917	1	rs13199006	ENSG00000203875.9	SNHG5	-11.5	3.28e-27	1.09e-23	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85898990	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs4707239	ENSG00000203875.9	SNHG5	-11.5	3.28e-27	1.09e-23	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85900999	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs7766645	ENSG00000203875.9	SNHG5	-11.5	3.28e-27	1.09e-23	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85912520	chr6:85660950~85678736:-
LUAD	cis	rs10129255	0.557	rs4043727	ENSG00000223648.3	IGHV3-64	11.5	3.28e-27	1.09e-23	0.46	0.46	Kawasaki disease;	chr14:106649820	chr14:106643132~106658258:-
LUAD	cis	rs73086581	1	rs17214949	ENSG00000229539.1	RP11-119B16.2	11.5	3.28e-27	1.09e-23	0.69	0.46	Response to antidepressants in depression;	chr20:3960305	chr20:3888239~3888868:-
LUAD	cis	rs73086581	1	rs17215054	ENSG00000229539.1	RP11-119B16.2	11.5	3.28e-27	1.09e-23	0.69	0.46	Response to antidepressants in depression;	chr20:3964132	chr20:3888239~3888868:-
LUAD	cis	rs73086581	1	rs17287486	ENSG00000229539.1	RP11-119B16.2	11.5	3.28e-27	1.09e-23	0.69	0.46	Response to antidepressants in depression;	chr20:3965620	chr20:3888239~3888868:-
LUAD	cis	rs73086581	1	rs73086540	ENSG00000229539.1	RP11-119B16.2	11.5	3.28e-27	1.09e-23	0.69	0.46	Response to antidepressants in depression;	chr20:3970203	chr20:3888239~3888868:-
LUAD	cis	rs73086581	1	rs73086544	ENSG00000229539.1	RP11-119B16.2	11.5	3.28e-27	1.09e-23	0.69	0.46	Response to antidepressants in depression;	chr20:3970281	chr20:3888239~3888868:-
LUAD	cis	rs73086581	1	rs2326289	ENSG00000229539.1	RP11-119B16.2	11.5	3.28e-27	1.09e-23	0.69	0.46	Response to antidepressants in depression;	chr20:3971653	chr20:3888239~3888868:-
LUAD	cis	rs73086581	1	rs73086549	ENSG00000229539.1	RP11-119B16.2	11.5	3.28e-27	1.09e-23	0.69	0.46	Response to antidepressants in depression;	chr20:3974015	chr20:3888239~3888868:-
LUAD	cis	rs875971	1	rs10257427	ENSG00000226824.5	RP4-756H11.3	11.5	3.29e-27	1.1e-23	0.59	0.46	Aortic root size;	chr7:66278221	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs10215948	ENSG00000226824.5	RP4-756H11.3	11.5	3.29e-27	1.1e-23	0.59	0.46	Aortic root size;	chr7:66282799	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.607	rs4869755	ENSG00000231760.4	RP11-350J20.5	11.5	3.34e-27	1.11e-23	0.71	0.46	Lung cancer;	chr6:149886347	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.639	rs4869756	ENSG00000231760.4	RP11-350J20.5	11.5	3.34e-27	1.11e-23	0.71	0.46	Lung cancer;	chr6:149886360	chr6:149796151~149826294:-
LUAD	cis	rs977987	0.931	rs8057084	ENSG00000261783.1	RP11-252K23.2	11.5	3.37e-27	1.12e-23	0.6	0.46	Dupuytren's disease;	chr16:75458808	chr16:75379818~75381260:-
LUAD	cis	rs11155671	0.53	rs9383940	ENSG00000231760.4	RP11-350J20.5	11.5	3.38e-27	1.13e-23	0.59	0.46	Testicular germ cell tumor;	chr6:149904923	chr6:149796151~149826294:-
LUAD	cis	rs10256972	0.567	rs2960850	ENSG00000229043.2	AC091729.9	-11.5	3.39e-27	1.13e-23	-0.52	-0.46	Endometriosis;Longevity;	chr7:1172013	chr7:1160374~1165267:+
LUAD	cis	rs507080	0.769	rs7389	ENSG00000255239.1	AP002954.6	-11.5	3.45e-27	1.15e-23	-0.57	-0.46	Serum metabolite levels;	chr11:118657756	chr11:118688039~118690600:-
LUAD	cis	rs17507216	0.718	rs4779034	ENSG00000278603.1	RP13-608F4.5	11.49	3.51e-27	1.17e-23	0.64	0.46	Excessive daytime sleepiness;	chr15:82576799	chr15:82472203~82472426:+
LUAD	cis	rs2581828	0.656	rs1864367	ENSG00000242142.1	SERBP1P3	11.49	3.59e-27	1.19e-23	0.48	0.46	Crohn's disease;	chr3:53077688	chr3:53064283~53065091:-
LUAD	cis	rs950027	0.62	rs1145084	ENSG00000259520.4	CTD-2651B20.3	-11.49	3.63e-27	1.2e-23	-0.56	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45383242	chr15:45251580~45279251:-
LUAD	cis	rs55794721	0.509	rs873308	ENSG00000224183.1	SDHDP6	11.49	3.65e-27	1.21e-23	0.57	0.46	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25294164~25294643:-
LUAD	cis	rs9660180	0.62	rs3817856	ENSG00000268575.1	RP1-283E3.8	11.49	3.66e-27	1.22e-23	0.41	0.46	Body mass index;	chr1:1732392	chr1:1702736~1737688:-
LUAD	cis	rs73086581	1	rs113812453	ENSG00000229539.1	RP11-119B16.2	11.49	3.74e-27	1.24e-23	0.69	0.46	Response to antidepressants in depression;	chr20:3982546	chr20:3888239~3888868:-
LUAD	cis	rs73086581	0.947	rs17287577	ENSG00000229539.1	RP11-119B16.2	11.49	3.74e-27	1.24e-23	0.69	0.46	Response to antidepressants in depression;	chr20:3985607	chr20:3888239~3888868:-
LUAD	cis	rs875971	0.838	rs2173570	ENSG00000226824.5	RP4-756H11.3	11.48	3.8e-27	1.26e-23	0.59	0.46	Aortic root size;	chr7:66297976	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs2420820	ENSG00000226824.5	RP4-756H11.3	11.48	3.8e-27	1.26e-23	0.59	0.46	Aortic root size;	chr7:66626920	chr7:66654538~66669855:+
LUAD	cis	rs1577917	0.652	rs75593931	ENSG00000203875.9	SNHG5	-11.48	3.81e-27	1.26e-23	-0.65	-0.46	Response to antipsychotic treatment;	chr6:86009821	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.959	rs12201739	ENSG00000203875.9	SNHG5	-11.48	3.81e-27	1.26e-23	-0.65	-0.46	Response to antipsychotic treatment;	chr6:86011021	chr6:85660950~85678736:-
LUAD	cis	rs2658782	0.688	rs2658768	ENSG00000279684.1	RP11-755E23.2	-11.48	3.92e-27	1.3e-23	-0.75	-0.46	Pulmonary function decline;	chr11:93517661	chr11:93286629~93288903:-
LUAD	cis	rs11155671	0.53	rs4869763	ENSG00000216906.2	RP11-350J20.9	11.48	3.93e-27	1.3e-23	0.57	0.46	Testicular germ cell tumor;	chr6:149890548	chr6:149904243~149906418:+
LUAD	cis	rs3096299	0.658	rs4785679	ENSG00000274627.1	RP11-104N10.2	11.48	3.96e-27	1.31e-23	0.44	0.46	Multiple myeloma (IgH translocation);	chr16:89499705	chr16:89516797~89522217:+
LUAD	cis	rs8062405	1	rs7187776	ENSG00000259982.1	CDC37P1	11.48	4.11e-27	1.36e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28700294~28701540:-
LUAD	cis	rs10935480	0.771	rs7634817	ENSG00000239445.4	ST3GAL6-AS1	11.48	4.15e-27	1.37e-23	0.56	0.46	Blood protein levels;	chr3:98743681	chr3:98714330~98732651:-
LUAD	cis	rs875971	1	rs1544549	ENSG00000226824.5	RP4-756H11.3	11.47	4.18e-27	1.38e-23	0.59	0.46	Aortic root size;	chr7:66625676	chr7:66654538~66669855:+
LUAD	cis	rs997154	0.655	rs7147394	ENSG00000279656.1	RP11-298I3.6	11.47	4.24e-27	1.4e-23	0.67	0.46	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22941845	chr14:23023083~23024217:-
LUAD	cis	rs11155671	0.53	rs9322228	ENSG00000216906.2	RP11-350J20.9	11.47	4.32e-27	1.43e-23	0.56	0.46	Testicular germ cell tumor;	chr6:149888173	chr6:149904243~149906418:+
LUAD	cis	rs11155671	0.53	rs7774787	ENSG00000216906.2	RP11-350J20.9	11.47	4.32e-27	1.43e-23	0.56	0.46	Testicular germ cell tumor;	chr6:149888296	chr6:149904243~149906418:+
LUAD	cis	rs11155671	0.53	rs2342767	ENSG00000216906.2	RP11-350J20.9	11.47	4.32e-27	1.43e-23	0.56	0.46	Testicular germ cell tumor;	chr6:149888581	chr6:149904243~149906418:+
LUAD	cis	rs11155671	0.53	rs7764376	ENSG00000216906.2	RP11-350J20.9	11.47	4.32e-27	1.43e-23	0.56	0.46	Testicular germ cell tumor;	chr6:149889208	chr6:149904243~149906418:+
LUAD	cis	rs11155671	0.53	rs6933882	ENSG00000216906.2	RP11-350J20.9	11.47	4.32e-27	1.43e-23	0.56	0.46	Testicular germ cell tumor;	chr6:149889666	chr6:149904243~149906418:+
LUAD	cis	rs11155671	0.53	rs6939761	ENSG00000216906.2	RP11-350J20.9	11.47	4.32e-27	1.43e-23	0.56	0.46	Testicular germ cell tumor;	chr6:149889858	chr6:149904243~149906418:+
LUAD	cis	rs11155671	0.53	rs3823021	ENSG00000216906.2	RP11-350J20.9	11.47	4.32e-27	1.43e-23	0.56	0.46	Testicular germ cell tumor;	chr6:149889863	chr6:149904243~149906418:+
LUAD	cis	rs11155671	0.53	rs4869764	ENSG00000216906.2	RP11-350J20.9	11.47	4.32e-27	1.43e-23	0.56	0.46	Testicular germ cell tumor;	chr6:149890692	chr6:149904243~149906418:+
LUAD	cis	rs11155671	0.53	rs4458704	ENSG00000216906.2	RP11-350J20.9	11.47	4.33e-27	1.43e-23	0.56	0.46	Testicular germ cell tumor;	chr6:149911743	chr6:149904243~149906418:+
LUAD	cis	rs6452524	0.967	rs10065973	ENSG00000249664.1	CTD-2227C6.2	11.47	4.43e-27	1.46e-23	0.53	0.46	Hypertension (SNP x SNP interaction);	chr5:83123181	chr5:83012285~83013109:-
LUAD	cis	rs992157	0.56	rs7578940	ENSG00000261338.2	RP11-378A13.1	-11.47	4.43e-27	1.46e-23	-0.47	-0.46	Colorectal cancer;	chr2:218218595	chr2:218255319~218257366:+
LUAD	cis	rs6452524	0.967	rs6897075	ENSG00000249664.1	CTD-2227C6.2	11.47	4.46e-27	1.47e-23	0.53	0.46	Hypertension (SNP x SNP interaction);	chr5:83122959	chr5:83012285~83013109:-
LUAD	cis	rs7174755	0.924	rs8035431	ENSG00000260657.2	RP11-315D16.4	11.46	4.58e-27	1.51e-23	0.54	0.46	Major depressive disorder;	chr15:68305012	chr15:68267792~68277994:-
LUAD	cis	rs2486288	0.539	rs2433601	ENSG00000259520.4	CTD-2651B20.3	-11.46	4.58e-27	1.51e-23	-0.56	-0.46	Glomerular filtration rate;	chr15:45424227	chr15:45251580~45279251:-
LUAD	cis	rs875971	0.862	rs10256544	ENSG00000226824.5	RP4-756H11.3	-11.46	4.68e-27	1.54e-23	-0.59	-0.46	Aortic root size;	chr7:66210141	chr7:66654538~66669855:+
LUAD	cis	rs2739330	0.828	rs2330635	ENSG00000231271.1	AP000350.8	11.45	5e-27	1.64e-23	0.56	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23949918~23954042:+
LUAD	cis	rs950027	0.62	rs35861938	ENSG00000259520.4	CTD-2651B20.3	-11.45	5.16e-27	1.7e-23	-0.56	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45345145	chr15:45251580~45279251:-
LUAD	cis	rs2658782	0.694	rs3019221	ENSG00000279684.1	RP11-755E23.2	-11.45	5.24e-27	1.72e-23	-0.7	-0.46	Pulmonary function decline;	chr11:93346534	chr11:93286629~93288903:-
LUAD	cis	rs7188445	0.592	rs17767281	ENSG00000261390.4	RP11-345M22.2	-11.45	5.3e-27	1.74e-23	-0.57	-0.46	Urate levels;	chr16:79708544	chr16:79715232~79770563:-
LUAD	cis	rs2455601	0.638	rs3815991	ENSG00000254860.4	TMEM9B-AS1	-11.45	5.32e-27	1.75e-23	-0.62	-0.46	Schizophrenia;	chr11:8986122	chr11:8964675~8977527:+
LUAD	cis	rs950027	0.62	rs1426932	ENSG00000259520.4	CTD-2651B20.3	-11.45	5.41e-27	1.78e-23	-0.56	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45395058	chr15:45251580~45279251:-
LUAD	cis	rs8062405	0.964	rs78613234	ENSG00000259982.1	CDC37P1	11.44	5.46e-27	1.79e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs62036624	ENSG00000259982.1	CDC37P1	11.44	5.46e-27	1.79e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs80275162	ENSG00000259982.1	CDC37P1	11.44	5.5e-27	1.81e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28700294~28701540:-
LUAD	cis	rs6452524	0.967	rs12153441	ENSG00000249664.1	CTD-2227C6.2	11.44	5.55e-27	1.82e-23	0.53	0.46	Hypertension (SNP x SNP interaction);	chr5:83125181	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs12152891	ENSG00000249664.1	CTD-2227C6.2	11.44	5.55e-27	1.82e-23	0.53	0.46	Hypertension (SNP x SNP interaction);	chr5:83125217	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs6452507	ENSG00000249664.1	CTD-2227C6.2	11.44	5.55e-27	1.82e-23	0.53	0.46	Hypertension (SNP x SNP interaction);	chr5:83125537	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs6452508	ENSG00000249664.1	CTD-2227C6.2	11.44	5.55e-27	1.82e-23	0.53	0.46	Hypertension (SNP x SNP interaction);	chr5:83125546	chr5:83012285~83013109:-
LUAD	cis	rs8062405	1	rs4788095	ENSG00000259982.1	CDC37P1	11.44	5.68e-27	1.86e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.964	rs72793809	ENSG00000259982.1	CDC37P1	11.44	5.68e-27	1.86e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs62036620	ENSG00000259982.1	CDC37P1	11.44	5.68e-27	1.86e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs62036621	ENSG00000259982.1	CDC37P1	11.44	5.68e-27	1.86e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28700294~28701540:-
LUAD	cis	rs6452524	0.967	rs7717964	ENSG00000249664.1	CTD-2227C6.2	11.44	5.79e-27	1.9e-23	0.53	0.46	Hypertension (SNP x SNP interaction);	chr5:83126323	chr5:83012285~83013109:-
LUAD	cis	rs7174755	0.923	rs11634149	ENSG00000260657.2	RP11-315D16.4	11.44	5.91e-27	1.93e-23	0.54	0.46	Major depressive disorder;	chr15:68306072	chr15:68267792~68277994:-
LUAD	cis	rs55794721	0.509	rs12027110	ENSG00000224183.1	SDHDP6	-11.44	5.92e-27	1.94e-23	-0.58	-0.46	Mean corpuscular volume;Plateletcrit;	chr1:25449191	chr1:25294164~25294643:-
LUAD	cis	rs875971	1	rs2220626	ENSG00000226824.5	RP4-756H11.3	11.44	5.96e-27	1.95e-23	0.59	0.46	Aortic root size;	chr7:66081075	chr7:66654538~66669855:+
LUAD	cis	rs904251	0.828	rs1757178	ENSG00000279942.1	RP1-153P14.7	11.44	5.97e-27	1.95e-23	0.44	0.46	Cognitive performance;	chr6:37518534	chr6:37567716~37571460:+
LUAD	cis	rs1577917	0.958	rs884842	ENSG00000203875.9	SNHG5	-11.43	6e-27	1.96e-23	-0.63	-0.46	Response to antipsychotic treatment;	chr6:85970679	chr6:85660950~85678736:-
LUAD	cis	rs6452524	0.711	rs1478486	ENSG00000249664.1	CTD-2227C6.2	11.43	6.09e-27	1.99e-23	0.54	0.46	Hypertension (SNP x SNP interaction);	chr5:83081185	chr5:83012285~83013109:-
LUAD	cis	rs950027	0.62	rs1153862	ENSG00000259520.4	CTD-2651B20.3	-11.43	6.1e-27	1.99e-23	-0.56	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45339670	chr15:45251580~45279251:-
LUAD	cis	rs6452524	0.934	rs6452512	ENSG00000249664.1	CTD-2227C6.2	11.42	6.71e-27	2.19e-23	0.53	0.46	Hypertension (SNP x SNP interaction);	chr5:83127523	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs6452514	ENSG00000249664.1	CTD-2227C6.2	11.42	6.71e-27	2.19e-23	0.53	0.46	Hypertension (SNP x SNP interaction);	chr5:83127627	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.935	rs6884543	ENSG00000249664.1	CTD-2227C6.2	11.42	6.71e-27	2.19e-23	0.53	0.46	Hypertension (SNP x SNP interaction);	chr5:83127939	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.934	rs1120477	ENSG00000249664.1	CTD-2227C6.2	11.42	6.9e-27	2.25e-23	0.53	0.46	Hypertension (SNP x SNP interaction);	chr5:83127062	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.934	rs1120478	ENSG00000249664.1	CTD-2227C6.2	11.42	6.9e-27	2.25e-23	0.53	0.46	Hypertension (SNP x SNP interaction);	chr5:83127072	chr5:83012285~83013109:-
LUAD	cis	rs904251	0.861	rs1776456	ENSG00000279942.1	RP1-153P14.7	-11.42	6.92e-27	2.26e-23	-0.44	-0.46	Cognitive performance;	chr6:37516922	chr6:37567716~37571460:+
LUAD	cis	rs1577917	1	rs6454513	ENSG00000203875.9	SNHG5	11.42	7.01e-27	2.28e-23	0.62	0.46	Response to antipsychotic treatment;	chr6:86010331	chr6:85660950~85678736:-
LUAD	cis	rs7188445	0.556	rs7194711	ENSG00000261390.4	RP11-345M22.2	-11.41	7.19e-27	2.34e-23	-0.58	-0.46	Urate levels;	chr16:79715134	chr16:79715232~79770563:-
LUAD	cis	rs950027	0.595	rs2486288	ENSG00000259520.4	CTD-2651B20.3	-11.41	7.26e-27	2.36e-23	-0.56	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45420141	chr15:45251580~45279251:-
LUAD	cis	rs11155671	0.53	rs9397398	ENSG00000216906.2	RP11-350J20.9	11.41	7.26e-27	2.36e-23	0.56	0.46	Testicular germ cell tumor;	chr6:149872467	chr6:149904243~149906418:+
LUAD	cis	rs9545047	0.935	rs7988601	ENSG00000227676.3	LINC01068	-11.41	7.42e-27	2.41e-23	-0.58	-0.46	Schizophrenia;	chr13:79475648	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.935	rs6563110	ENSG00000227676.3	LINC01068	-11.41	7.42e-27	2.41e-23	-0.58	-0.46	Schizophrenia;	chr13:79477137	chr13:79566727~79571436:+
LUAD	cis	rs8062405	1	rs55991577	ENSG00000259982.1	CDC37P1	11.41	7.49e-27	2.43e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs56358680	ENSG00000259982.1	CDC37P1	11.41	7.49e-27	2.43e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs62036626	ENSG00000259982.1	CDC37P1	11.41	7.49e-27	2.43e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs62036657	ENSG00000259982.1	CDC37P1	11.41	7.49e-27	2.43e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs12444171	ENSG00000259982.1	CDC37P1	11.41	7.49e-27	2.43e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs56404918	ENSG00000259982.1	CDC37P1	11.41	7.49e-27	2.43e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs55719896	ENSG00000259982.1	CDC37P1	11.41	7.49e-27	2.43e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs55830740	ENSG00000259982.1	CDC37P1	11.41	7.49e-27	2.43e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28700294~28701540:-
LUAD	cis	rs2739330	0.828	rs5760107	ENSG00000231271.1	AP000350.8	11.41	7.5e-27	2.44e-23	0.56	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23949918~23954042:+
LUAD	cis	rs2739330	0.789	rs5760109	ENSG00000231271.1	AP000350.8	11.41	7.5e-27	2.44e-23	0.56	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23949918~23954042:+
LUAD	cis	rs8040855	0.579	rs28521166	ENSG00000259295.5	CSPG4P12	-11.41	7.53e-27	2.44e-23	-0.53	-0.46	Bulimia nervosa;	chr15:85184801	chr15:85191438~85213905:+
LUAD	cis	rs11155671	0.53	rs4458704	ENSG00000231760.4	RP11-350J20.5	11.41	7.63e-27	2.47e-23	0.57	0.46	Testicular germ cell tumor;	chr6:149911743	chr6:149796151~149826294:-
LUAD	cis	rs4853012	0.887	rs2280642	ENSG00000217702.2	RP11-287D1.4	11.41	7.77e-27	2.52e-23	0.75	0.46	Gestational age at birth (maternal effect);	chr2:74131125	chr2:74130583~74135395:+
LUAD	cis	rs73086581	1	rs3746665	ENSG00000229539.1	RP11-119B16.2	-11.41	7.81e-27	2.53e-23	-0.63	-0.46	Response to antidepressants in depression;	chr20:3929759	chr20:3888239~3888868:-
LUAD	cis	rs875971	1	rs697970	ENSG00000226824.5	RP4-756H11.3	11.4	7.93e-27	2.57e-23	0.59	0.46	Aortic root size;	chr7:66095065	chr7:66654538~66669855:+
LUAD	cis	rs2019137	0.868	rs6755639	ENSG00000189223.12	PAX8-AS1	-11.4	8.5e-27	2.75e-23	-0.61	-0.46	Lymphocyte counts;	chr2:113224233	chr2:113211522~113276581:+
LUAD	cis	rs2739330	0.828	rs2154593	ENSG00000231271.1	AP000350.8	11.4	8.53e-27	2.76e-23	0.55	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23949918~23954042:+
LUAD	cis	rs1577917	1	rs10455456	ENSG00000203875.9	SNHG5	-11.4	8.54e-27	2.76e-23	-0.63	-0.46	Response to antipsychotic treatment;	chr6:85960604	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs11755864	ENSG00000203875.9	SNHG5	-11.39	8.9e-27	2.87e-23	-0.63	-0.46	Response to antipsychotic treatment;	chr6:85982073	chr6:85660950~85678736:-
LUAD	cis	rs875971	0.964	rs697969	ENSG00000226824.5	RP4-756H11.3	11.39	8.98e-27	2.89e-23	0.59	0.46	Aortic root size;	chr7:66093491	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs1182882	ENSG00000226824.5	RP4-756H11.3	11.39	8.98e-27	2.89e-23	0.59	0.46	Aortic root size;	chr7:66097076	chr7:66654538~66669855:+
LUAD	cis	rs1577917	1	rs34106666	ENSG00000203875.9	SNHG5	-11.38	9.47e-27	3.05e-23	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85966540	chr6:85660950~85678736:-
LUAD	cis	rs8062405	1	rs3888190	ENSG00000259982.1	CDC37P1	11.38	9.56e-27	3.08e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28700294~28701540:-
LUAD	cis	rs2739330	0.828	rs5760108	ENSG00000231271.1	AP000350.8	11.38	9.72e-27	3.13e-23	0.55	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23949918~23954042:+
LUAD	cis	rs1972460	0.506	rs62012050	ENSG00000278603.1	RP13-608F4.5	11.38	9.8e-27	3.15e-23	0.58	0.46	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82472203~82472426:+
LUAD	cis	rs950027	0.596	rs2467853	ENSG00000259520.4	CTD-2651B20.3	-11.38	1.02e-26	3.29e-23	-0.56	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45406595	chr15:45251580~45279251:-
LUAD	cis	rs73086581	1	rs17215529	ENSG00000229539.1	RP11-119B16.2	11.37	1.05e-26	3.38e-23	0.66	0.46	Response to antidepressants in depression;	chr20:3994755	chr20:3888239~3888868:-
LUAD	cis	rs875971	1	rs2036264	ENSG00000226824.5	RP4-756H11.3	11.37	1.06e-26	3.39e-23	0.59	0.46	Aortic root size;	chr7:66334917	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs7783613	ENSG00000226824.5	RP4-756H11.3	11.37	1.06e-26	3.39e-23	0.59	0.46	Aortic root size;	chr7:66340274	chr7:66654538~66669855:+
LUAD	cis	rs1577917	1	rs1577917	ENSG00000203875.9	SNHG5	-11.37	1.07e-26	3.42e-23	-0.65	-0.46	Response to antipsychotic treatment;	chr6:85982222	chr6:85660950~85678736:-
LUAD	cis	rs875971	0.965	rs697968	ENSG00000226824.5	RP4-756H11.3	11.37	1.08e-26	3.46e-23	0.59	0.46	Aortic root size;	chr7:66070046	chr7:66654538~66669855:+
LUAD	cis	rs1577917	0.958	rs12215232	ENSG00000203875.9	SNHG5	-11.36	1.15e-26	3.7e-23	-0.66	-0.46	Response to antipsychotic treatment;	chr6:86075712	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs1337844	ENSG00000203875.9	SNHG5	-11.36	1.17e-26	3.75e-23	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85967555	chr6:85660950~85678736:-
LUAD	cis	rs6700559	1	rs10494821	ENSG00000260088.1	RP11-92G12.3	-11.36	1.18e-26	3.76e-23	-0.56	-0.46	Coronary artery disease;	chr1:200673357	chr1:200669507~200694250:+
LUAD	cis	rs6700559	1	rs4311922	ENSG00000260088.1	RP11-92G12.3	-11.36	1.18e-26	3.76e-23	-0.56	-0.46	Coronary artery disease;	chr1:200674257	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.967	rs4447009	ENSG00000260088.1	RP11-92G12.3	-11.36	1.18e-26	3.76e-23	-0.56	-0.46	Coronary artery disease;	chr1:200674278	chr1:200669507~200694250:+
LUAD	cis	rs6700559	1	rs4265457	ENSG00000260088.1	RP11-92G12.3	-11.36	1.18e-26	3.76e-23	-0.56	-0.46	Coronary artery disease;	chr1:200674326	chr1:200669507~200694250:+
LUAD	cis	rs6700559	1	rs6667172	ENSG00000260088.1	RP11-92G12.3	-11.36	1.18e-26	3.76e-23	-0.56	-0.46	Coronary artery disease;	chr1:200674710	chr1:200669507~200694250:+
LUAD	cis	rs2739330	0.828	rs2877178	ENSG00000231271.1	AP000350.8	11.36	1.21e-26	3.87e-23	0.56	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23949918~23954042:+
LUAD	cis	rs73086581	0.945	rs6052222	ENSG00000229539.1	RP11-119B16.2	11.36	1.22e-26	3.9e-23	0.67	0.46	Response to antidepressants in depression;	chr20:3992146	chr20:3888239~3888868:-
LUAD	cis	rs8062405	1	rs8055138	ENSG00000259982.1	CDC37P1	11.36	1.23e-26	3.93e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28700294~28701540:-
LUAD	cis	rs977987	0.866	rs17696831	ENSG00000261783.1	RP11-252K23.2	-11.35	1.23e-26	3.94e-23	-0.6	-0.46	Dupuytren's disease;	chr16:75459400	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.931	rs11641430	ENSG00000261783.1	RP11-252K23.2	-11.35	1.27e-26	4.04e-23	-0.6	-0.46	Dupuytren's disease;	chr16:75461378	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.931	rs7195161	ENSG00000261783.1	RP11-252K23.2	-11.35	1.27e-26	4.04e-23	-0.6	-0.46	Dupuytren's disease;	chr16:75461674	chr16:75379818~75381260:-
LUAD	cis	rs2658782	0.654	rs2605623	ENSG00000279684.1	RP11-755E23.2	-11.35	1.28e-26	4.09e-23	-0.7	-0.46	Pulmonary function decline;	chr11:93516193	chr11:93286629~93288903:-
LUAD	cis	rs1577917	1	rs10498958	ENSG00000203875.9	SNHG5	11.35	1.31e-26	4.18e-23	0.64	0.46	Response to antipsychotic treatment;	chr6:85939987	chr6:85660950~85678736:-
LUAD	cis	rs9399135	0.66	rs9376072	ENSG00000232876.1	CTA-212D2.2	-11.35	1.32e-26	4.21e-23	-0.51	-0.46	Red blood cell count;	chr6:134959381	chr6:135055033~135060550:+
LUAD	cis	rs6782228	0.675	rs9813845	ENSG00000242551.2	POU5F1P6	-11.35	1.33e-26	4.25e-23	-0.53	-0.46	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128680780	chr3:128674735~128677005:-
LUAD	cis	rs1153858	1	rs1613559	ENSG00000259520.4	CTD-2651B20.3	-11.35	1.34e-26	4.27e-23	-0.61	-0.46	Homoarginine levels;	chr15:45329918	chr15:45251580~45279251:-
LUAD	cis	rs6700559	1	rs6700559	ENSG00000260088.1	RP11-92G12.3	11.35	1.34e-26	4.27e-23	0.57	0.46	Coronary artery disease;	chr1:200676945	chr1:200669507~200694250:+
LUAD	cis	rs507080	0.769	rs11603616	ENSG00000255239.1	AP002954.6	11.34	1.37e-26	4.37e-23	0.56	0.46	Serum metabolite levels;	chr11:118625350	chr11:118688039~118690600:-
LUAD	cis	rs875971	1	rs937495	ENSG00000226824.5	RP4-756H11.3	11.34	1.4e-26	4.45e-23	0.58	0.46	Aortic root size;	chr7:66314811	chr7:66654538~66669855:+
LUAD	cis	rs1577917	1	rs1415753	ENSG00000203875.9	SNHG5	-11.34	1.43e-26	4.54e-23	-0.65	-0.46	Response to antipsychotic treatment;	chr6:86043356	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs1577919	ENSG00000203875.9	SNHG5	-11.34	1.43e-26	4.54e-23	-0.65	-0.46	Response to antipsychotic treatment;	chr6:86047578	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs12203493	ENSG00000203875.9	SNHG5	-11.34	1.43e-26	4.54e-23	-0.65	-0.46	Response to antipsychotic treatment;	chr6:86048924	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs12203924	ENSG00000203875.9	SNHG5	-11.34	1.43e-26	4.54e-23	-0.65	-0.46	Response to antipsychotic treatment;	chr6:86066694	chr6:85660950~85678736:-
LUAD	cis	rs9545047	1	rs9545047	ENSG00000227676.3	LINC01068	11.34	1.43e-26	4.54e-23	0.58	0.46	Schizophrenia;	chr13:79285321	chr13:79566727~79571436:+
LUAD	cis	rs1577917	1	rs2166663	ENSG00000203875.9	SNHG5	-11.34	1.44e-26	4.57e-23	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85884178	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs16876530	ENSG00000203875.9	SNHG5	-11.34	1.44e-26	4.57e-23	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85885923	chr6:85660950~85678736:-
LUAD	cis	rs904251	0.737	rs914347	ENSG00000279942.1	RP1-153P14.7	-11.34	1.44e-26	4.57e-23	-0.43	-0.46	Cognitive performance;	chr6:37517194	chr6:37567716~37571460:+
LUAD	cis	rs1577917	1	rs10455158	ENSG00000203875.9	SNHG5	-11.33	1.49e-26	4.71e-23	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85963107	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.959	rs34258068	ENSG00000203875.9	SNHG5	-11.33	1.49e-26	4.71e-23	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85969731	chr6:85660950~85678736:-
LUAD	cis	rs507080	0.769	rs745663	ENSG00000255239.1	AP002954.6	11.33	1.52e-26	4.8e-23	0.56	0.46	Serum metabolite levels;	chr11:118658886	chr11:118688039~118690600:-
LUAD	cis	rs1577917	1	rs12207610	ENSG00000203875.9	SNHG5	-11.33	1.53e-26	4.85e-23	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85978298	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs12203457	ENSG00000203875.9	SNHG5	-11.33	1.53e-26	4.85e-23	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85979559	chr6:85660950~85678736:-
LUAD	cis	rs2658782	0.724	rs2658769	ENSG00000279684.1	RP11-755E23.2	-11.33	1.56e-26	4.94e-23	-0.73	-0.46	Pulmonary function decline;	chr11:93518864	chr11:93286629~93288903:-
LUAD	cis	rs2739330	0.734	rs2000467	ENSG00000099984.9	GSTT2	11.33	1.57e-26	4.95e-23	0.57	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23980123~23983911:+
LUAD	cis	rs17507216	0.718	rs17158403	ENSG00000278603.1	RP13-608F4.5	11.33	1.57e-26	4.97e-23	0.64	0.46	Excessive daytime sleepiness;	chr15:82572478	chr15:82472203~82472426:+
LUAD	cis	rs9326248	0.569	rs4938315	ENSG00000254851.1	RP11-109L13.1	-11.33	1.57e-26	4.97e-23	-0.77	-0.46	Blood protein levels;	chr11:116860489	chr11:117135528~117138582:+
LUAD	cis	rs875971	1	rs1183245	ENSG00000226824.5	RP4-756H11.3	11.33	1.58e-26	4.98e-23	0.59	0.46	Aortic root size;	chr7:66076198	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs1144895	ENSG00000226824.5	RP4-756H11.3	11.33	1.58e-26	4.98e-23	0.59	0.46	Aortic root size;	chr7:66076320	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs1144894	ENSG00000226824.5	RP4-756H11.3	11.33	1.58e-26	4.98e-23	0.59	0.46	Aortic root size;	chr7:66077907	chr7:66654538~66669855:+
LUAD	cis	rs1577917	1	rs12212733	ENSG00000203875.9	SNHG5	-11.33	1.58e-26	5e-23	-0.64	-0.46	Response to antipsychotic treatment;	chr6:86016295	chr6:85660950~85678736:-
LUAD	cis	rs2882667	0.537	rs10057545	ENSG00000253404.1	AC034243.1	11.33	1.59e-26	5.01e-23	0.56	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095319	chr5:138744434~138753309:-
LUAD	cis	rs6700559	1	rs7527499	ENSG00000260088.1	RP11-92G12.3	-11.32	1.63e-26	5.15e-23	-0.56	-0.46	Coronary artery disease;	chr1:200676217	chr1:200669507~200694250:+
LUAD	cis	rs6700559	1	rs6427838	ENSG00000260088.1	RP11-92G12.3	-11.32	1.63e-26	5.15e-23	-0.56	-0.46	Coronary artery disease;	chr1:200676519	chr1:200669507~200694250:+
LUAD	cis	rs6700559	1	rs12061346	ENSG00000260088.1	RP11-92G12.3	-11.32	1.63e-26	5.15e-23	-0.56	-0.46	Coronary artery disease;	chr1:200677648	chr1:200669507~200694250:+
LUAD	cis	rs6700559	1	rs7533971	ENSG00000260088.1	RP11-92G12.3	-11.32	1.63e-26	5.15e-23	-0.56	-0.46	Coronary artery disease;	chr1:200678243	chr1:200669507~200694250:+
LUAD	cis	rs6700559	1	rs10919998	ENSG00000260088.1	RP11-92G12.3	-11.32	1.63e-26	5.15e-23	-0.56	-0.46	Coronary artery disease;	chr1:200679182	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.967	rs4072552	ENSG00000260088.1	RP11-92G12.3	-11.32	1.63e-26	5.15e-23	-0.56	-0.46	Coronary artery disease;	chr1:200680003	chr1:200669507~200694250:+
LUAD	cis	rs6452524	0.934	rs10473870	ENSG00000249664.1	CTD-2227C6.2	11.32	1.66e-26	5.24e-23	0.52	0.46	Hypertension (SNP x SNP interaction);	chr5:83199768	chr5:83012285~83013109:-
LUAD	cis	rs9399135	0.636	rs4646871	ENSG00000232876.1	CTA-212D2.2	11.32	1.69e-26	5.32e-23	0.51	0.46	Red blood cell count;	chr6:134944479	chr6:135055033~135060550:+
LUAD	cis	rs2739330	0.828	rs5751770	ENSG00000231271.1	AP000350.8	11.32	1.69e-26	5.33e-23	0.55	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23949918~23954042:+
LUAD	cis	rs2581828	0.694	rs2336725	ENSG00000242142.1	SERBP1P3	11.32	1.73e-26	5.44e-23	0.47	0.46	Crohn's disease;	chr3:53084723	chr3:53064283~53065091:-
LUAD	cis	rs8062405	1	rs11861174	ENSG00000259982.1	CDC37P1	11.31	1.77e-26	5.57e-23	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs4788102	ENSG00000259982.1	CDC37P1	11.31	1.77e-26	5.57e-23	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs62037367	ENSG00000259982.1	CDC37P1	11.31	1.77e-26	5.57e-23	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs7198606	ENSG00000259982.1	CDC37P1	11.31	1.77e-26	5.57e-23	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.929	rs11864750	ENSG00000259982.1	CDC37P1	11.31	1.77e-26	5.57e-23	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.964	rs7193733	ENSG00000259982.1	CDC37P1	11.31	1.77e-26	5.57e-23	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs8055982	ENSG00000259982.1	CDC37P1	11.31	1.77e-26	5.57e-23	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs7498665	ENSG00000259982.1	CDC37P1	11.31	1.77e-26	5.57e-23	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.964	rs11864107	ENSG00000259982.1	CDC37P1	11.31	1.77e-26	5.57e-23	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs62037371	ENSG00000259982.1	CDC37P1	11.31	1.77e-26	5.57e-23	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28700294~28701540:-
LUAD	cis	rs3091242	0.806	rs35189848	ENSG00000224183.1	SDHDP6	11.31	1.77e-26	5.57e-23	0.59	0.46	Erythrocyte sedimentation rate;	chr1:25461931	chr1:25294164~25294643:-
LUAD	cis	rs3091242	0.836	rs35346083	ENSG00000224183.1	SDHDP6	11.31	1.77e-26	5.57e-23	0.59	0.46	Erythrocyte sedimentation rate;	chr1:25461934	chr1:25294164~25294643:-
LUAD	cis	rs507080	0.769	rs2077173	ENSG00000255239.1	AP002954.6	11.31	1.79e-26	5.62e-23	0.55	0.46	Serum metabolite levels;	chr11:118621876	chr11:118688039~118690600:-
LUAD	cis	rs11155671	0.53	rs7742993	ENSG00000216906.2	RP11-350J20.9	11.31	1.83e-26	5.76e-23	0.56	0.46	Testicular germ cell tumor;	chr6:149883959	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs12175504	ENSG00000216906.2	RP11-350J20.9	11.31	1.84e-26	5.79e-23	0.56	0.46	Lung cancer;	chr6:149664079	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs62439843	ENSG00000216906.2	RP11-350J20.9	11.31	1.84e-26	5.79e-23	0.56	0.46	Lung cancer;	chr6:149676521	chr6:149904243~149906418:+
LUAD	cis	rs2581828	0.656	rs2336723	ENSG00000242142.1	SERBP1P3	11.31	1.88e-26	5.89e-23	0.47	0.46	Crohn's disease;	chr3:53072031	chr3:53064283~53065091:-
LUAD	cis	rs1577917	1	rs4706254	ENSG00000203875.9	SNHG5	-11.3	1.93e-26	6.06e-23	-0.61	-0.46	Response to antipsychotic treatment;	chr6:85893095	chr6:85660950~85678736:-
LUAD	cis	rs6700559	0.804	rs11588318	ENSG00000260088.1	RP11-92G12.3	-11.3	1.94e-26	6.08e-23	-0.56	-0.46	Coronary artery disease;	chr1:200669534	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.903	rs6661240	ENSG00000260088.1	RP11-92G12.3	-11.3	1.94e-26	6.08e-23	-0.56	-0.46	Coronary artery disease;	chr1:200669719	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.967	rs6688581	ENSG00000260088.1	RP11-92G12.3	-11.3	1.94e-26	6.08e-23	-0.56	-0.46	Coronary artery disease;	chr1:200670028	chr1:200669507~200694250:+
LUAD	cis	rs6700559	1	rs3806358	ENSG00000260088.1	RP11-92G12.3	-11.3	1.94e-26	6.08e-23	-0.56	-0.46	Coronary artery disease;	chr1:200670555	chr1:200669507~200694250:+
LUAD	cis	rs8062405	1	rs3088215	ENSG00000259982.1	CDC37P1	11.3	1.94e-26	6.09e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs28403629	ENSG00000259982.1	CDC37P1	11.3	1.94e-26	6.09e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs61737565	ENSG00000259982.1	CDC37P1	11.3	1.94e-26	6.09e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs4788099	ENSG00000259982.1	CDC37P1	11.3	1.94e-26	6.09e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28700294~28701540:-
LUAD	cis	rs7174755	1	rs68069953	ENSG00000260657.2	RP11-315D16.4	11.3	2e-26	6.27e-23	0.54	0.46	Major depressive disorder;	chr15:68304235	chr15:68267792~68277994:-
LUAD	cis	rs6700559	0.683	rs4915450	ENSG00000260088.1	RP11-92G12.3	-11.3	2.01e-26	6.28e-23	-0.56	-0.46	Coronary artery disease;	chr1:200672461	chr1:200669507~200694250:+
LUAD	cis	rs1577917	0.876	rs1582127	ENSG00000203875.9	SNHG5	-11.3	2.03e-26	6.36e-23	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85987486	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs34852683	ENSG00000203875.9	SNHG5	-11.3	2.03e-26	6.36e-23	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85992612	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs12213740	ENSG00000203875.9	SNHG5	-11.3	2.03e-26	6.36e-23	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85947015	chr6:85660950~85678736:-
LUAD	cis	rs977987	0.902	rs34539062	ENSG00000261783.1	RP11-252K23.2	-11.3	2.05e-26	6.4e-23	-0.6	-0.46	Dupuytren's disease;	chr16:75459381	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.898	rs12918797	ENSG00000261783.1	RP11-252K23.2	-11.3	2.05e-26	6.4e-23	-0.6	-0.46	Dupuytren's disease;	chr16:75459912	chr16:75379818~75381260:-
LUAD	cis	rs8062405	1	rs4451951	ENSG00000259982.1	CDC37P1	11.3	2.07e-26	6.48e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28700294~28701540:-
LUAD	cis	rs977987	0.931	rs1424013	ENSG00000261783.1	RP11-252K23.2	-11.3	2.1e-26	6.56e-23	-0.6	-0.46	Dupuytren's disease;	chr16:75462088	chr16:75379818~75381260:-
LUAD	cis	rs3091242	0.866	rs11249249	ENSG00000224183.1	SDHDP6	-11.3	2.1e-26	6.57e-23	-0.58	-0.46	Erythrocyte sedimentation rate;	chr1:25431643	chr1:25294164~25294643:-
LUAD	cis	rs1577917	0.958	rs11755642	ENSG00000203875.9	SNHG5	-11.3	2.1e-26	6.57e-23	-0.64	-0.46	Response to antipsychotic treatment;	chr6:85740348	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs36096931	ENSG00000203875.9	SNHG5	-11.3	2.11e-26	6.59e-23	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85983416	chr6:85660950~85678736:-
LUAD	cis	rs2337406	0.852	rs12050239	ENSG00000274576.2	IGHV2-70	-11.3	2.11e-26	6.59e-23	-0.49	-0.46	Alzheimer's disease (late onset);	chr14:106781132	chr14:106770577~106771020:-
LUAD	cis	rs977987	0.898	rs12918974	ENSG00000261783.1	RP11-252K23.2	-11.29	2.16e-26	6.75e-23	-0.6	-0.46	Dupuytren's disease;	chr16:75460045	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.866	rs12932606	ENSG00000261783.1	RP11-252K23.2	-11.29	2.16e-26	6.75e-23	-0.6	-0.46	Dupuytren's disease;	chr16:75460046	chr16:75379818~75381260:-
LUAD	cis	rs11155671	0.53	rs9371215	ENSG00000216906.2	RP11-350J20.9	11.29	2.17e-26	6.77e-23	0.56	0.46	Testicular germ cell tumor;	chr6:149873162	chr6:149904243~149906418:+
LUAD	cis	rs9601248	0.529	rs2783125	ENSG00000227676.3	LINC01068	11.29	2.25e-26	7.01e-23	0.58	0.46	Major depressive disorder;	chr13:79583755	chr13:79566727~79571436:+
LUAD	cis	rs992157	0.764	rs62183964	ENSG00000261338.2	RP11-378A13.1	11.29	2.28e-26	7.11e-23	0.47	0.46	Colorectal cancer;	chr2:218321869	chr2:218255319~218257366:+
LUAD	cis	rs507080	0.769	rs571001	ENSG00000255239.1	AP002954.6	11.29	2.29e-26	7.13e-23	0.56	0.46	Serum metabolite levels;	chr11:118629457	chr11:118688039~118690600:-
LUAD	cis	rs8062405	0.792	rs12446550	ENSG00000259982.1	CDC37P1	11.28	2.34e-26	7.28e-23	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28700294~28701540:-
LUAD	cis	rs8040855	0.599	rs2342123	ENSG00000259295.5	CSPG4P12	11.28	2.35e-26	7.32e-23	0.53	0.46	Bulimia nervosa;	chr15:85181918	chr15:85191438~85213905:+
LUAD	cis	rs11155671	0.53	rs9383577	ENSG00000216906.2	RP11-350J20.9	11.28	2.37e-26	7.37e-23	0.55	0.46	Testicular germ cell tumor;	chr6:149886059	chr6:149904243~149906418:+
LUAD	cis	rs11155671	0.53	rs9383914	ENSG00000216906.2	RP11-350J20.9	11.28	2.37e-26	7.37e-23	0.55	0.46	Testicular germ cell tumor;	chr6:149886098	chr6:149904243~149906418:+
LUAD	cis	rs11155671	0.517	rs9397058	ENSG00000216906.2	RP11-350J20.9	11.28	2.37e-26	7.37e-23	0.55	0.46	Testicular germ cell tumor;	chr6:149886113	chr6:149904243~149906418:+
LUAD	cis	rs1577917	1	rs12215903	ENSG00000203875.9	SNHG5	-11.28	2.43e-26	7.56e-23	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85965310	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs12199832	ENSG00000203875.9	SNHG5	-11.28	2.43e-26	7.57e-23	-0.63	-0.46	Response to antipsychotic treatment;	chr6:85943030	chr6:85660950~85678736:-
LUAD	cis	rs2581828	0.656	rs2253209	ENSG00000242142.1	SERBP1P3	11.28	2.48e-26	7.7e-23	0.47	0.46	Crohn's disease;	chr3:53081144	chr3:53064283~53065091:-
LUAD	cis	rs8062405	0.679	rs72793818	ENSG00000259982.1	CDC37P1	11.28	2.48e-26	7.71e-23	0.59	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28700294~28701540:-
LUAD	cis	rs11155671	0.53	rs7758033	ENSG00000216906.2	RP11-350J20.9	11.28	2.5e-26	7.78e-23	0.56	0.46	Testicular germ cell tumor;	chr6:149886999	chr6:149904243~149906418:+
LUAD	cis	rs1577917	1	rs6940458	ENSG00000203875.9	SNHG5	-11.27	2.54e-26	7.89e-23	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85935274	chr6:85660950~85678736:-
LUAD	cis	rs858239	0.614	rs10229956	ENSG00000230658.1	KLHL7-AS1	-11.27	2.55e-26	7.91e-23	-0.52	-0.46	Cerebrospinal fluid biomarker levels;	chr7:23363317	chr7:23101228~23105703:-
LUAD	cis	rs1577917	1	rs68171315	ENSG00000203875.9	SNHG5	-11.27	2.56e-26	7.93e-23	-0.64	-0.46	Response to antipsychotic treatment;	chr6:85997682	chr6:85660950~85678736:-
LUAD	cis	rs8062405	0.824	rs28698667	ENSG00000259982.1	CDC37P1	11.27	2.59e-26	8.02e-23	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28700294~28701540:-
LUAD	cis	rs9322193	0.607	rs12204653	ENSG00000231760.4	RP11-350J20.5	11.27	2.74e-26	8.49e-23	0.71	0.46	Lung cancer;	chr6:149891885	chr6:149796151~149826294:-
LUAD	cis	rs7188445	0.592	rs7196490	ENSG00000261390.4	RP11-345M22.2	-11.27	2.76e-26	8.54e-23	-0.58	-0.46	Urate levels;	chr16:79718572	chr16:79715232~79770563:-
LUAD	cis	rs875971	0.658	rs432667	ENSG00000226824.5	RP4-756H11.3	-11.26	2.79e-26	8.63e-23	-0.58	-0.46	Aortic root size;	chr7:66049646	chr7:66654538~66669855:+
LUAD	cis	rs11155671	0.53	rs9383912	ENSG00000216906.2	RP11-350J20.9	11.26	2.89e-26	8.94e-23	0.55	0.46	Testicular germ cell tumor;	chr6:149885479	chr6:149904243~149906418:+
LUAD	cis	rs6700559	1	rs6656619	ENSG00000260088.1	RP11-92G12.3	11.26	2.94e-26	9.08e-23	0.56	0.46	Coronary artery disease;	chr1:200671664	chr1:200669507~200694250:+
LUAD	cis	rs2882667	0.537	rs13181793	ENSG00000253404.1	AC034243.1	11.26	2.94e-26	9.08e-23	0.56	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139073267	chr5:138744434~138753309:-
LUAD	cis	rs875971	0.564	rs313804	ENSG00000226824.5	RP4-756H11.3	-11.26	2.96e-26	9.14e-23	-0.58	-0.46	Aortic root size;	chr7:66049635	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.662	rs448725	ENSG00000226824.5	RP4-756H11.3	-11.26	2.96e-26	9.14e-23	-0.58	-0.46	Aortic root size;	chr7:66049641	chr7:66654538~66669855:+
LUAD	cis	rs1577917	1	rs955197	ENSG00000203875.9	SNHG5	-11.25	3.12e-26	9.63e-23	-0.64	-0.46	Response to antipsychotic treatment;	chr6:86019957	chr6:85660950~85678736:-
LUAD	cis	rs904251	0.797	rs1776460	ENSG00000279942.1	RP1-153P14.7	-11.25	3.14e-26	9.68e-23	-0.43	-0.46	Cognitive performance;	chr6:37517708	chr6:37567716~37571460:+
LUAD	cis	rs8062405	1	rs9972693	ENSG00000259982.1	CDC37P1	11.25	3.14e-26	9.68e-23	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.964	rs9972768	ENSG00000259982.1	CDC37P1	11.25	3.14e-26	9.68e-23	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.965	rs56040780	ENSG00000259982.1	CDC37P1	11.25	3.14e-26	9.68e-23	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.965	rs62037363	ENSG00000259982.1	CDC37P1	11.25	3.14e-26	9.68e-23	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs7205323	ENSG00000259982.1	CDC37P1	11.25	3.14e-26	9.68e-23	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs4788101	ENSG00000259982.1	CDC37P1	11.25	3.14e-26	9.68e-23	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs62037365	ENSG00000259982.1	CDC37P1	11.25	3.14e-26	9.68e-23	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.929	rs11150609	ENSG00000259982.1	CDC37P1	11.25	3.14e-26	9.68e-23	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28700294~28701540:-
LUAD	cis	rs1577917	0.958	rs13207354	ENSG00000203875.9	SNHG5	-11.25	3.15e-26	9.71e-23	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85990545	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs12204365	ENSG00000203875.9	SNHG5	-11.25	3.15e-26	9.71e-23	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85990814	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs12663651	ENSG00000203875.9	SNHG5	-11.25	3.15e-26	9.71e-23	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85991937	chr6:85660950~85678736:-
LUAD	cis	rs7174755	0.923	rs9672383	ENSG00000260657.2	RP11-315D16.4	11.25	3.16e-26	9.74e-23	0.53	0.46	Major depressive disorder;	chr15:68306731	chr15:68267792~68277994:-
LUAD	cis	rs9322193	0.923	rs9479810	ENSG00000216906.2	RP11-350J20.9	11.25	3.23e-26	9.93e-23	0.56	0.46	Lung cancer;	chr6:149751359	chr6:149904243~149906418:+
LUAD	cis	rs11089937	0.963	rs2226943	ENSG00000211639.2	IGLV4-60	11.25	3.25e-26	1e-22	0.47	0.46	Periodontitis (PAL4Q3);	chr22:22143100	chr22:22162199~22162681:+
LUAD	cis	rs1577917	0.958	rs12207374	ENSG00000203875.9	SNHG5	-11.24	3.32e-26	1.02e-22	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85946927	chr6:85660950~85678736:-
LUAD	cis	rs507080	0.769	rs570952	ENSG00000255239.1	AP002954.6	11.24	3.33e-26	1.02e-22	0.55	0.46	Serum metabolite levels;	chr11:118629477	chr11:118688039~118690600:-
LUAD	cis	rs2882667	0.518	rs10041986	ENSG00000253404.1	AC034243.1	11.24	3.61e-26	1.11e-22	0.54	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139088748	chr5:138744434~138753309:-
LUAD	cis	rs1577917	1	rs12201735	ENSG00000203875.9	SNHG5	-11.23	3.68e-26	1.13e-22	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85947221	chr6:85660950~85678736:-
LUAD	cis	rs10129255	0.557	rs4043727	ENSG00000211970.3	IGHV4-61	-11.23	3.72e-26	1.14e-22	-0.36	-0.46	Kawasaki disease;	chr14:106649820	chr14:106639119~106639657:-
LUAD	cis	rs5760092	0.755	rs915589	ENSG00000273295.1	AP000350.5	-11.23	3.74e-26	1.15e-22	-0.63	-0.46	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23901432~23907068:-
LUAD	cis	rs2882667	0.537	rs11743534	ENSG00000253404.1	AC034243.1	11.23	3.77e-26	1.16e-22	0.56	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139073318	chr5:138744434~138753309:-
LUAD	cis	rs2658782	0.547	rs2085334	ENSG00000279684.1	RP11-755E23.2	-11.23	3.78e-26	1.16e-22	-0.63	-0.46	Pulmonary function decline;	chr11:93447884	chr11:93286629~93288903:-
LUAD	cis	rs2581828	0.656	rs11242	ENSG00000242142.1	SERBP1P3	-11.23	3.83e-26	1.17e-22	-0.47	-0.46	Crohn's disease;	chr3:53091906	chr3:53064283~53065091:-
LUAD	cis	rs7617773	0.851	rs13068288	ENSG00000229759.1	MRPS18AP1	11.23	3.86e-26	1.18e-22	0.51	0.46	Coronary artery disease;	chr3:48290261	chr3:48256350~48256938:-
LUAD	cis	rs875971	1	rs6945843	ENSG00000226824.5	RP4-756H11.3	11.23	3.9e-26	1.19e-22	0.58	0.46	Aortic root size;	chr7:66269796	chr7:66654538~66669855:+
LUAD	cis	rs507080	0.769	rs483283	ENSG00000255239.1	AP002954.6	11.23	3.91e-26	1.2e-22	0.56	0.46	Serum metabolite levels;	chr11:118635684	chr11:118688039~118690600:-
LUAD	cis	rs8062405	1	rs62037364	ENSG00000259982.1	CDC37P1	11.23	3.92e-26	1.2e-22	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.737	rs11861132	ENSG00000259982.1	CDC37P1	11.22	3.96e-26	1.21e-22	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28700294~28701540:-
LUAD	cis	rs507080	0.769	rs527290	ENSG00000255239.1	AP002954.6	11.22	3.97e-26	1.21e-22	0.56	0.46	Serum metabolite levels;	chr11:118644898	chr11:118688039~118690600:-
LUAD	cis	rs8062405	0.824	rs62034326	ENSG00000259982.1	CDC37P1	11.22	3.99e-26	1.22e-22	0.57	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.824	rs4788084	ENSG00000259982.1	CDC37P1	11.22	3.99e-26	1.22e-22	0.57	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28700294~28701540:-
LUAD	cis	rs6452524	0.935	rs1478480	ENSG00000249664.1	CTD-2227C6.2	11.22	4e-26	1.22e-22	0.53	0.46	Hypertension (SNP x SNP interaction);	chr5:83112117	chr5:83012285~83013109:-
LUAD	cis	rs2882667	0.556	rs6873733	ENSG00000253404.1	AC034243.1	11.22	4.01e-26	1.23e-22	0.55	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139067628	chr5:138744434~138753309:-
LUAD	cis	rs11155671	0.53	rs7768626	ENSG00000216906.2	RP11-350J20.9	11.22	4.03e-26	1.23e-22	0.55	0.46	Testicular germ cell tumor;	chr6:149886826	chr6:149904243~149906418:+
LUAD	cis	rs11155671	0.53	rs7768665	ENSG00000216906.2	RP11-350J20.9	11.22	4.03e-26	1.23e-22	0.55	0.46	Testicular germ cell tumor;	chr6:149886888	chr6:149904243~149906418:+
LUAD	cis	rs11155671	0.53	rs7758020	ENSG00000216906.2	RP11-350J20.9	11.22	4.03e-26	1.23e-22	0.55	0.46	Testicular germ cell tumor;	chr6:149886975	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs9322206	ENSG00000216906.2	RP11-350J20.9	11.22	4.03e-26	1.23e-22	0.56	0.46	Lung cancer;	chr6:149641481	chr6:149904243~149906418:+
LUAD	cis	rs8062405	0.754	rs62034323	ENSG00000259982.1	CDC37P1	11.22	4.07e-26	1.24e-22	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.824	rs62034324	ENSG00000259982.1	CDC37P1	11.22	4.07e-26	1.24e-22	0.58	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28700294~28701540:-
LUAD	cis	rs17507216	0.628	rs4627310	ENSG00000278603.1	RP13-608F4.5	11.22	4.15e-26	1.27e-22	0.65	0.46	Excessive daytime sleepiness;	chr15:82708330	chr15:82472203~82472426:+
LUAD	cis	rs9322193	0.923	rs35830138	ENSG00000216906.2	RP11-350J20.9	11.22	4.24e-26	1.29e-22	0.55	0.46	Lung cancer;	chr6:149668635	chr6:149904243~149906418:+
LUAD	cis	rs2581828	0.656	rs2253656	ENSG00000242142.1	SERBP1P3	11.21	4.36e-26	1.33e-22	0.47	0.46	Crohn's disease;	chr3:53085083	chr3:53064283~53065091:-
LUAD	cis	rs8040855	0.894	rs6496770	ENSG00000259295.5	CSPG4P12	-11.21	4.36e-26	1.33e-22	-0.55	-0.46	Bulimia nervosa;	chr15:85161890	chr15:85191438~85213905:+
LUAD	cis	rs17507216	0.588	rs28864981	ENSG00000278603.1	RP13-608F4.5	11.21	4.39e-26	1.34e-22	0.64	0.46	Excessive daytime sleepiness;	chr15:82695420	chr15:82472203~82472426:+
LUAD	cis	rs17507216	0.628	rs8032321	ENSG00000278603.1	RP13-608F4.5	11.21	4.39e-26	1.34e-22	0.64	0.46	Excessive daytime sleepiness;	chr15:82698956	chr15:82472203~82472426:+
LUAD	cis	rs17507216	0.628	rs8040488	ENSG00000278603.1	RP13-608F4.5	11.21	4.39e-26	1.34e-22	0.64	0.46	Excessive daytime sleepiness;	chr15:82699081	chr15:82472203~82472426:+
LUAD	cis	rs6504950	0.705	rs17745123	ENSG00000275710.1	RP11-257O5.4	11.21	4.44e-26	1.35e-22	0.58	0.46	Breast cancer;	chr17:54910871	chr17:54964474~54964679:+
LUAD	cis	rs9322193	0.923	rs9322196	ENSG00000216906.2	RP11-350J20.9	11.21	4.5e-26	1.37e-22	0.55	0.46	Lung cancer;	chr6:149619645	chr6:149904243~149906418:+
LUAD	cis	rs950027	0.62	rs1719246	ENSG00000259520.4	CTD-2651B20.3	-11.21	4.51e-26	1.37e-22	-0.55	-0.46	Response to fenofibrate (adiponectin levels);	chr15:45333281	chr15:45251580~45279251:-
LUAD	cis	rs2729354	0.909	rs2729374	ENSG00000265566.2	RN7SL605P	-11.21	4.52e-26	1.38e-22	-0.71	-0.46	Blood protein levels;	chr11:57559454	chr11:57528085~57528365:-
LUAD	cis	rs9322193	0.607	rs12527391	ENSG00000231760.4	RP11-350J20.5	11.21	4.61e-26	1.4e-22	0.69	0.46	Lung cancer;	chr6:149882156	chr6:149796151~149826294:-
LUAD	cis	rs6452524	0.967	rs11741420	ENSG00000249664.1	CTD-2227C6.2	11.21	4.68e-26	1.42e-22	0.52	0.46	Hypertension (SNP x SNP interaction);	chr5:83174913	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs4401555	ENSG00000249664.1	CTD-2227C6.2	11.21	4.68e-26	1.42e-22	0.52	0.46	Hypertension (SNP x SNP interaction);	chr5:83175267	chr5:83012285~83013109:-
LUAD	cis	rs1577917	0.874	rs11756621	ENSG00000203875.9	SNHG5	-11.21	4.68e-26	1.42e-22	-0.65	-0.46	Response to antipsychotic treatment;	chr6:86030345	chr6:85660950~85678736:-
LUAD	cis	rs11155671	0.53	rs7757984	ENSG00000216906.2	RP11-350J20.9	11.21	4.72e-26	1.43e-22	0.56	0.45	Testicular germ cell tumor;	chr6:149887515	chr6:149904243~149906418:+
LUAD	cis	rs1577917	1	rs12205336	ENSG00000203875.9	SNHG5	-11.2	4.77e-26	1.45e-22	-0.64	-0.45	Response to antipsychotic treatment;	chr6:86012649	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs12209127	ENSG00000203875.9	SNHG5	-11.2	4.77e-26	1.45e-22	-0.64	-0.45	Response to antipsychotic treatment;	chr6:86014709	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs1337850	ENSG00000203875.9	SNHG5	-11.2	4.77e-26	1.45e-22	-0.64	-0.45	Response to antipsychotic treatment;	chr6:86019385	chr6:85660950~85678736:-
LUAD	cis	rs3096299	0.658	rs4291902	ENSG00000274627.1	RP11-104N10.2	11.2	4.89e-26	1.49e-22	0.43	0.45	Multiple myeloma (IgH translocation);	chr16:89493907	chr16:89516797~89522217:+
LUAD	cis	rs9322193	0.923	rs9322197	ENSG00000216906.2	RP11-350J20.9	11.2	4.95e-26	1.5e-22	0.55	0.45	Lung cancer;	chr6:149622577	chr6:149904243~149906418:+
LUAD	cis	rs1577917	1	rs12196411	ENSG00000203875.9	SNHG5	-11.2	5.15e-26	1.56e-22	-0.65	-0.45	Response to antipsychotic treatment;	chr6:86070044	chr6:85660950~85678736:-
LUAD	cis	rs8040855	0.93	rs6496767	ENSG00000259295.5	CSPG4P12	-11.19	5.31e-26	1.61e-22	-0.55	-0.45	Bulimia nervosa;	chr15:85159522	chr15:85191438~85213905:+
LUAD	cis	rs9322193	0.923	rs9767554	ENSG00000216906.2	RP11-350J20.9	11.19	5.35e-26	1.62e-22	0.55	0.45	Lung cancer;	chr6:149616860	chr6:149904243~149906418:+
LUAD	cis	rs6452524	0.967	rs11949474	ENSG00000249664.1	CTD-2227C6.2	11.19	5.36e-26	1.62e-22	0.52	0.45	Hypertension (SNP x SNP interaction);	chr5:83179759	chr5:83012285~83013109:-
LUAD	cis	rs9399135	0.66	rs4472368	ENSG00000232876.1	CTA-212D2.2	-11.19	5.36e-26	1.62e-22	-0.51	-0.45	Red blood cell count;	chr6:134953094	chr6:135055033~135060550:+
LUAD	cis	rs1577917	0.958	rs7747897	ENSG00000203875.9	SNHG5	-11.19	5.51e-26	1.67e-22	-0.62	-0.45	Response to antipsychotic treatment;	chr6:85937631	chr6:85660950~85678736:-
LUAD	cis	rs73086581	1	rs73088421	ENSG00000229539.1	RP11-119B16.2	11.19	5.56e-26	1.68e-22	0.67	0.45	Response to antidepressants in depression;	chr20:4017224	chr20:3888239~3888868:-
LUAD	cis	rs9322193	0.923	rs12660304	ENSG00000216906.2	RP11-350J20.9	11.18	5.71e-26	1.73e-22	0.56	0.45	Lung cancer;	chr6:149739647	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.847	rs62439808	ENSG00000216906.2	RP11-350J20.9	11.18	5.86e-26	1.77e-22	0.55	0.45	Lung cancer;	chr6:149629690	chr6:149904243~149906418:+
LUAD	cis	rs507080	0.845	rs481903	ENSG00000255239.1	AP002954.6	11.18	5.9e-26	1.78e-22	0.55	0.45	Serum metabolite levels;	chr11:118697024	chr11:118688039~118690600:-
LUAD	cis	rs1577917	0.958	rs13213551	ENSG00000203875.9	SNHG5	-11.18	5.9e-26	1.78e-22	-0.61	-0.45	Response to antipsychotic treatment;	chr6:85898983	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs34622557	ENSG00000203875.9	SNHG5	-11.18	5.9e-26	1.78e-22	-0.61	-0.45	Response to antipsychotic treatment;	chr6:85921134	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs1911553	ENSG00000203875.9	SNHG5	-11.18	5.9e-26	1.78e-22	-0.61	-0.45	Response to antipsychotic treatment;	chr6:85921174	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs1995688	ENSG00000203875.9	SNHG5	-11.18	5.9e-26	1.78e-22	-0.61	-0.45	Response to antipsychotic treatment;	chr6:85922601	chr6:85660950~85678736:-
LUAD	cis	rs977987	0.806	rs4146809	ENSG00000261783.1	RP11-252K23.2	11.18	5.97e-26	1.8e-22	0.6	0.45	Dupuytren's disease;	chr16:75381877	chr16:75379818~75381260:-
LUAD	cis	rs3096299	0.685	rs4785676	ENSG00000274627.1	RP11-104N10.2	11.18	6.13e-26	1.85e-22	0.43	0.45	Multiple myeloma (IgH translocation);	chr16:89487216	chr16:89516797~89522217:+
LUAD	cis	rs8062405	0.823	rs7202948	ENSG00000259982.1	CDC37P1	11.17	6.21e-26	1.87e-22	0.57	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28700294~28701540:-
LUAD	cis	rs2658782	0.526	rs7131487	ENSG00000279684.1	RP11-755E23.2	-11.17	6.35e-26	1.91e-22	-0.63	-0.45	Pulmonary function decline;	chr11:93452786	chr11:93286629~93288903:-
LUAD	cis	rs992157	0.56	rs6436048	ENSG00000261338.2	RP11-378A13.1	11.17	6.39e-26	1.93e-22	0.46	0.45	Colorectal cancer;	chr2:218244310	chr2:218255319~218257366:+
LUAD	cis	rs1577917	1	rs10944170	ENSG00000203875.9	SNHG5	-11.17	6.42e-26	1.93e-22	-0.62	-0.45	Response to antipsychotic treatment;	chr6:85975751	chr6:85660950~85678736:-
LUAD	cis	rs9322193	0.884	rs9688858	ENSG00000216906.2	RP11-350J20.9	11.17	6.46e-26	1.95e-22	0.55	0.45	Lung cancer;	chr6:149637911	chr6:149904243~149906418:+
LUAD	cis	rs5760092	0.755	rs4585126	ENSG00000231271.1	AP000350.8	-11.17	6.65e-26	2e-22	-0.62	-0.45	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23949918~23954042:+
LUAD	cis	rs507080	0.769	rs570836	ENSG00000255239.1	AP002954.6	11.17	6.66e-26	2e-22	0.55	0.45	Serum metabolite levels;	chr11:118641444	chr11:118688039~118690600:-
LUAD	cis	rs6452524	0.935	rs7718284	ENSG00000249664.1	CTD-2227C6.2	-11.17	6.69e-26	2.01e-22	-0.52	-0.45	Hypertension (SNP x SNP interaction);	chr5:83082488	chr5:83012285~83013109:-
LUAD	cis	rs9322193	0.923	rs9377230	ENSG00000216906.2	RP11-350J20.9	11.17	6.69e-26	2.01e-22	0.55	0.45	Lung cancer;	chr6:149613607	chr6:149904243~149906418:+
LUAD	cis	rs507080	0.769	rs645637	ENSG00000255239.1	AP002954.6	11.17	6.73e-26	2.03e-22	0.55	0.45	Serum metabolite levels;	chr11:118634373	chr11:118688039~118690600:-
LUAD	cis	rs1577917	1	rs12199516	ENSG00000203875.9	SNHG5	-11.16	6.89e-26	2.07e-22	-0.63	-0.45	Response to antipsychotic treatment;	chr6:86016503	chr6:85660950~85678736:-
LUAD	cis	rs992157	0.73	rs4280446	ENSG00000261338.2	RP11-378A13.1	11.16	6.89e-26	2.07e-22	0.47	0.45	Colorectal cancer;	chr2:218319998	chr2:218255319~218257366:+
LUAD	cis	rs7174755	1	rs7174755	ENSG00000260657.2	RP11-315D16.4	-11.16	6.89e-26	2.07e-22	-0.52	-0.45	Major depressive disorder;	chr15:68304789	chr15:68267792~68277994:-
LUAD	cis	rs977987	0.8	rs3784935	ENSG00000261783.1	RP11-252K23.2	-11.16	6.93e-26	2.08e-22	-0.6	-0.45	Dupuytren's disease;	chr16:75302532	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.8	rs11645329	ENSG00000261783.1	RP11-252K23.2	-11.16	6.93e-26	2.08e-22	-0.6	-0.45	Dupuytren's disease;	chr16:75302781	chr16:75379818~75381260:-
LUAD	cis	rs1577917	0.916	rs12203358	ENSG00000203875.9	SNHG5	-11.16	7.03e-26	2.11e-22	-0.62	-0.45	Response to antipsychotic treatment;	chr6:85893506	chr6:85660950~85678736:-
LUAD	cis	rs1153858	1	rs1719247	ENSG00000259520.4	CTD-2651B20.3	-11.16	7.06e-26	2.12e-22	-0.6	-0.45	Homoarginine levels;	chr15:45328787	chr15:45251580~45279251:-
LUAD	cis	rs992157	0.672	rs2382829	ENSG00000261338.2	RP11-378A13.1	11.16	7.11e-26	2.13e-22	0.47	0.45	Colorectal cancer;	chr2:218319894	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.764	rs4552182	ENSG00000261338.2	RP11-378A13.1	11.16	7.11e-26	2.13e-22	0.47	0.45	Colorectal cancer;	chr2:218320149	chr2:218255319~218257366:+
LUAD	cis	rs992157	0.764	rs4423579	ENSG00000261338.2	RP11-378A13.1	11.16	7.11e-26	2.13e-22	0.47	0.45	Colorectal cancer;	chr2:218320310	chr2:218255319~218257366:+
LUAD	cis	rs977987	0.742	rs34624768	ENSG00000261783.1	RP11-252K23.2	-11.16	7.22e-26	2.17e-22	-0.6	-0.45	Dupuytren's disease;	chr16:75297674	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.8	rs4888378	ENSG00000261783.1	RP11-252K23.2	-11.16	7.22e-26	2.17e-22	-0.6	-0.45	Dupuytren's disease;	chr16:75298143	chr16:75379818~75381260:-
LUAD	cis	rs9322193	0.923	rs9322200	ENSG00000216906.2	RP11-350J20.9	11.16	7.29e-26	2.19e-22	0.55	0.45	Lung cancer;	chr6:149630078	chr6:149904243~149906418:+
LUAD	cis	rs11118620	0.81	rs4587570	ENSG00000272823.1	RP11-295M18.6	11.16	7.38e-26	2.21e-22	0.57	0.45	Heart failure;	chr1:220860693	chr1:220828676~220829211:-
LUAD	cis	rs11089937	0.929	rs2236727	ENSG00000211639.2	IGLV4-60	11.15	7.44e-26	2.23e-22	0.47	0.45	Periodontitis (PAL4Q3);	chr22:22156654	chr22:22162199~22162681:+
LUAD	cis	rs1577917	0.917	rs35038582	ENSG00000203875.9	SNHG5	-11.15	7.52e-26	2.26e-22	-0.62	-0.45	Response to antipsychotic treatment;	chr6:86011587	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs7760207	ENSG00000203875.9	SNHG5	-11.15	7.52e-26	2.26e-22	-0.62	-0.45	Response to antipsychotic treatment;	chr6:86011982	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs12207305	ENSG00000203875.9	SNHG5	-11.15	7.52e-26	2.26e-22	-0.62	-0.45	Response to antipsychotic treatment;	chr6:86013784	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs12199784	ENSG00000203875.9	SNHG5	-11.15	7.52e-26	2.26e-22	-0.62	-0.45	Response to antipsychotic treatment;	chr6:86017090	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs12205548	ENSG00000203875.9	SNHG5	-11.15	7.59e-26	2.27e-22	-0.65	-0.45	Response to antipsychotic treatment;	chr6:86050052	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs12665321	ENSG00000203875.9	SNHG5	-11.15	7.59e-26	2.27e-22	-0.65	-0.45	Response to antipsychotic treatment;	chr6:86059571	chr6:85660950~85678736:-
LUAD	cis	rs1577917	0.958	rs12196175	ENSG00000203875.9	SNHG5	-11.15	7.59e-26	2.27e-22	-0.65	-0.45	Response to antipsychotic treatment;	chr6:86069652	chr6:85660950~85678736:-
LUAD	cis	rs875971	1	rs1167612	ENSG00000226824.5	RP4-756H11.3	11.15	7.63e-26	2.29e-22	0.58	0.45	Aortic root size;	chr7:66102989	chr7:66654538~66669855:+
LUAD	cis	rs4423214	1	rs1044482	ENSG00000254682.1	RP11-660L16.2	11.15	7.65e-26	2.29e-22	0.59	0.45	Vitamin D levels;	chr11:71444125	chr11:71448674~71452157:+
LUAD	cis	rs6452524	0.935	rs3901654	ENSG00000249664.1	CTD-2227C6.2	11.15	7.67e-26	2.3e-22	0.53	0.45	Hypertension (SNP x SNP interaction);	chr5:83110519	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs2974445	ENSG00000249664.1	CTD-2227C6.2	-11.15	7.68e-26	2.3e-22	-0.51	-0.45	Hypertension (SNP x SNP interaction);	chr5:83185561	chr5:83012285~83013109:-
LUAD	cis	rs9322193	0.923	rs7767622	ENSG00000216906.2	RP11-350J20.9	11.15	7.7e-26	2.31e-22	0.55	0.45	Lung cancer;	chr6:149681766	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs4421206	ENSG00000216906.2	RP11-350J20.9	11.15	7.7e-26	2.31e-22	0.55	0.45	Lung cancer;	chr6:149682891	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs3798761	ENSG00000216906.2	RP11-350J20.9	11.15	7.7e-26	2.31e-22	0.55	0.45	Lung cancer;	chr6:149683643	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs35961297	ENSG00000216906.2	RP11-350J20.9	11.15	7.82e-26	2.34e-22	0.55	0.45	Lung cancer;	chr6:149667929	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs35967444	ENSG00000216906.2	RP11-350J20.9	11.15	7.82e-26	2.34e-22	0.55	0.45	Lung cancer;	chr6:149675588	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs62439842	ENSG00000216906.2	RP11-350J20.9	11.15	7.82e-26	2.34e-22	0.55	0.45	Lung cancer;	chr6:149675847	chr6:149904243~149906418:+
LUAD	cis	rs2882667	0.627	rs1549203	ENSG00000253404.1	AC034243.1	-11.15	7.85e-26	2.35e-22	-0.56	-0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139132655	chr5:138744434~138753309:-
LUAD	cis	rs9399135	0.66	rs4440481	ENSG00000232876.1	CTA-212D2.2	-11.15	8.08e-26	2.42e-22	-0.5	-0.45	Red blood cell count;	chr6:134955558	chr6:135055033~135060550:+
LUAD	cis	rs992157	0.644	rs6741757	ENSG00000261338.2	RP11-378A13.1	11.14	8.16e-26	2.44e-22	0.47	0.45	Colorectal cancer;	chr2:218318025	chr2:218255319~218257366:+
LUAD	cis	rs9322193	0.923	rs9322209	ENSG00000216906.2	RP11-350J20.9	11.14	8.17e-26	2.44e-22	0.55	0.45	Lung cancer;	chr6:149691226	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs9479094	ENSG00000216906.2	RP11-350J20.9	11.14	8.21e-26	2.45e-22	0.55	0.45	Lung cancer;	chr6:149725083	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs9404048	ENSG00000216906.2	RP11-350J20.9	11.14	8.44e-26	2.52e-22	0.55	0.45	Lung cancer;	chr6:149616188	chr6:149904243~149906418:+
LUAD	cis	rs801193	0.569	rs35070132	ENSG00000226824.5	RP4-756H11.3	-11.14	8.5e-26	2.54e-22	-0.58	-0.45	Aortic root size;	chr7:66773096	chr7:66654538~66669855:+
LUAD	cis	rs992157	0.764	rs2891079	ENSG00000261338.2	RP11-378A13.1	11.14	8.53e-26	2.55e-22	0.47	0.45	Colorectal cancer;	chr2:218319968	chr2:218255319~218257366:+
LUAD	cis	rs9322193	0.884	rs10872646	ENSG00000216906.2	RP11-350J20.9	11.14	8.62e-26	2.57e-22	0.55	0.45	Lung cancer;	chr6:149746539	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.884	rs12528279	ENSG00000216906.2	RP11-350J20.9	11.14	8.62e-26	2.57e-22	0.55	0.45	Lung cancer;	chr6:149750892	chr6:149904243~149906418:+
LUAD	cis	rs2739330	0.828	rs4820572	ENSG00000231271.1	AP000350.8	11.14	8.65e-26	2.58e-22	0.55	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23949918~23954042:+
LUAD	cis	rs1577917	1	rs6936048	ENSG00000203875.9	SNHG5	-11.14	8.71e-26	2.6e-22	-0.63	-0.45	Response to antipsychotic treatment;	chr6:85992890	chr6:85660950~85678736:-
LUAD	cis	rs8062405	1	rs8062405	ENSG00000259982.1	CDC37P1	-11.14	8.72e-26	2.6e-22	-0.58	-0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28700294~28701540:-
LUAD	cis	rs2581828	0.656	rs2564940	ENSG00000242142.1	SERBP1P3	11.13	9.07e-26	2.7e-22	0.47	0.45	Crohn's disease;	chr3:53073553	chr3:53064283~53065091:-
LUAD	cis	rs977987	0.8	rs12935787	ENSG00000261783.1	RP11-252K23.2	-11.13	9.13e-26	2.72e-22	-0.6	-0.45	Dupuytren's disease;	chr16:75298437	chr16:75379818~75381260:-
LUAD	cis	rs2019137	0.868	rs3748916	ENSG00000189223.12	PAX8-AS1	11.13	9.57e-26	2.85e-22	0.6	0.45	Lymphocyte counts;	chr2:113226456	chr2:113211522~113276581:+
LUAD	cis	rs9322193	0.923	rs9688350	ENSG00000216906.2	RP11-350J20.9	11.13	9.63e-26	2.86e-22	0.55	0.45	Lung cancer;	chr6:149730977	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs9767652	ENSG00000216906.2	RP11-350J20.9	11.13	9.63e-26	2.86e-22	0.55	0.45	Lung cancer;	chr6:149734502	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs35031906	ENSG00000216906.2	RP11-350J20.9	11.12	9.74e-26	2.9e-22	0.55	0.45	Lung cancer;	chr6:149677438	chr6:149904243~149906418:+
LUAD	cis	rs7188445	0.615	rs4340340	ENSG00000261390.4	RP11-345M22.2	-11.12	9.76e-26	2.9e-22	-0.57	-0.45	Urate levels;	chr16:79716720	chr16:79715232~79770563:-
LUAD	cis	rs2019137	0.901	rs4849176	ENSG00000189223.12	PAX8-AS1	11.12	9.79e-26	2.91e-22	0.6	0.45	Lymphocyte counts;	chr2:113220359	chr2:113211522~113276581:+
LUAD	cis	rs801193	0.569	rs2659908	ENSG00000226824.5	RP4-756H11.3	-11.12	9.82e-26	2.92e-22	-0.58	-0.45	Aortic root size;	chr7:66695835	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.83	rs427973	ENSG00000226824.5	RP4-756H11.3	-11.12	9.83e-26	2.92e-22	-0.57	-0.45	Aortic root size;	chr7:66061661	chr7:66654538~66669855:+
LUAD	cis	rs2658782	0.724	rs2605627	ENSG00000279684.1	RP11-755E23.2	-11.12	1e-25	2.98e-22	-0.72	-0.45	Pulmonary function decline;	chr11:93526349	chr11:93286629~93288903:-
LUAD	cis	rs9322193	0.809	rs9479808	ENSG00000216906.2	RP11-350J20.9	11.12	1.02e-25	3.03e-22	0.54	0.45	Lung cancer;	chr6:149751328	chr6:149904243~149906418:+
LUAD	cis	rs11089937	0.963	rs5757098	ENSG00000211639.2	IGLV4-60	-11.12	1.05e-25	3.1e-22	-0.46	-0.45	Periodontitis (PAL4Q3);	chr22:22154322	chr22:22162199~22162681:+
LUAD	cis	rs1153858	1	rs1618874	ENSG00000259520.4	CTD-2651B20.3	-11.12	1.05e-25	3.13e-22	-0.6	-0.45	Homoarginine levels;	chr15:45330588	chr15:45251580~45279251:-
LUAD	cis	rs6452524	0.967	rs2974443	ENSG00000249664.1	CTD-2227C6.2	11.11	1.08e-25	3.19e-22	0.51	0.45	Hypertension (SNP x SNP interaction);	chr5:83184595	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs2974441	ENSG00000249664.1	CTD-2227C6.2	11.11	1.08e-25	3.2e-22	0.51	0.45	Hypertension (SNP x SNP interaction);	chr5:83193330	chr5:83012285~83013109:-
LUAD	cis	rs9322193	0.923	rs10872644	ENSG00000216906.2	RP11-350J20.9	11.11	1.08e-25	3.2e-22	0.54	0.45	Lung cancer;	chr6:149741819	chr6:149904243~149906418:+
LUAD	cis	rs2712381	0.797	rs62270806	ENSG00000242551.2	POU5F1P6	-11.11	1.09e-25	3.23e-22	-0.51	-0.45	Monocyte count;	chr3:128657426	chr3:128674735~128677005:-
LUAD	cis	rs3096299	0.685	rs4238830	ENSG00000274627.1	RP11-104N10.2	11.11	1.09e-25	3.23e-22	0.43	0.45	Multiple myeloma (IgH translocation);	chr16:89473833	chr16:89516797~89522217:+
LUAD	cis	rs875971	0.862	rs11773628	ENSG00000226824.5	RP4-756H11.3	11.11	1.1e-25	3.25e-22	0.59	0.45	Aortic root size;	chr7:66517644	chr7:66654538~66669855:+
LUAD	cis	rs2658782	0.654	rs2605622	ENSG00000279684.1	RP11-755E23.2	-11.11	1.11e-25	3.3e-22	-0.69	-0.45	Pulmonary function decline;	chr11:93515076	chr11:93286629~93288903:-
LUAD	cis	rs7688540	0.511	rs4522818	ENSG00000275426.1	CH17-262A2.1	11.11	1.12e-25	3.31e-22	0.69	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:187973	chr4:149738~150317:+
LUAD	cis	rs2882667	0.537	rs7701116	ENSG00000253404.1	AC034243.1	11.11	1.12e-25	3.31e-22	0.55	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070389	chr5:138744434~138753309:-
LUAD	cis	rs7688540	0.547	rs11728864	ENSG00000275426.1	CH17-262A2.1	11.11	1.12e-25	3.32e-22	0.68	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:197518	chr4:149738~150317:+
LUAD	cis	rs1577917	1	rs12201741	ENSG00000203875.9	SNHG5	-11.11	1.12e-25	3.32e-22	-0.61	-0.45	Response to antipsychotic treatment;	chr6:85892901	chr6:85660950~85678736:-
LUAD	cis	rs2739330	0.828	rs5760102	ENSG00000231271.1	AP000350.8	11.11	1.13e-25	3.35e-22	0.55	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23949918~23954042:+
LUAD	cis	rs7208859	0.673	rs79541516	ENSG00000263531.1	RP13-753N3.1	11.11	1.14e-25	3.38e-22	0.97	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913565	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs9895684	ENSG00000263531.1	RP13-753N3.1	11.11	1.14e-25	3.38e-22	0.97	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30915582	chr17:30863921~30864940:-
LUAD	cis	rs3096299	0.685	rs4785675	ENSG00000274627.1	RP11-104N10.2	11.11	1.15e-25	3.38e-22	0.43	0.45	Multiple myeloma (IgH translocation);	chr16:89473566	chr16:89516797~89522217:+
LUAD	cis	rs8062405	0.824	rs62034319	ENSG00000259982.1	CDC37P1	11.11	1.15e-25	3.38e-22	0.57	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28700294~28701540:-
LUAD	cis	rs904251	0.861	rs1757180	ENSG00000279942.1	RP1-153P14.7	-11.1	1.16e-25	3.42e-22	-0.43	-0.45	Cognitive performance;	chr6:37518369	chr6:37567716~37571460:+
LUAD	cis	rs875971	0.793	rs460678	ENSG00000226824.5	RP4-756H11.3	-11.1	1.16e-25	3.43e-22	-0.57	-0.45	Aortic root size;	chr7:66062213	chr7:66654538~66669855:+
LUAD	cis	rs55879323	1	rs55879323	ENSG00000237975.5	FLG-AS1	-11.1	1.16e-25	3.43e-22	-0.55	-0.45	Inflammatory skin disease;	chr1:152196264	chr1:152168125~152445456:+
LUAD	cis	rs2455601	0.638	rs2742484	ENSG00000254860.4	TMEM9B-AS1	11.1	1.16e-25	3.43e-22	0.6	0.45	Schizophrenia;	chr11:8966536	chr11:8964675~8977527:+
LUAD	cis	rs2455601	0.638	rs2248245	ENSG00000254860.4	TMEM9B-AS1	11.1	1.16e-25	3.43e-22	0.6	0.45	Schizophrenia;	chr11:8966803	chr11:8964675~8977527:+
LUAD	cis	rs10129255	0.53	rs11624912	ENSG00000211972.2	IGHV3-66	11.1	1.16e-25	3.43e-22	0.36	0.45	Kawasaki disease;	chr14:106673891	chr14:106675017~106675544:-
LUAD	cis	rs801193	0.742	rs9969300	ENSG00000226824.5	RP4-756H11.3	11.1	1.17e-25	3.46e-22	0.58	0.45	Aortic root size;	chr7:66316659	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.923	rs9478291	ENSG00000216906.2	RP11-350J20.9	11.1	1.2e-25	3.53e-22	0.54	0.45	Lung cancer;	chr6:149729434	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs3924871	ENSG00000216906.2	RP11-350J20.9	11.1	1.2e-25	3.55e-22	0.55	0.45	Lung cancer;	chr6:149662080	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs10782315	ENSG00000216906.2	RP11-350J20.9	11.1	1.21e-25	3.56e-22	0.55	0.45	Lung cancer;	chr6:149743093	chr6:149904243~149906418:+
LUAD	cis	rs7174755	0.923	rs4777033	ENSG00000260657.2	RP11-315D16.4	-11.1	1.23e-25	3.63e-22	-0.53	-0.45	Major depressive disorder;	chr15:68308010	chr15:68267792~68277994:-
LUAD	cis	rs17507216	0.628	rs28371837	ENSG00000278603.1	RP13-608F4.5	11.1	1.23e-25	3.64e-22	0.65	0.45	Excessive daytime sleepiness;	chr15:82714435	chr15:82472203~82472426:+
LUAD	cis	rs10256972	0.568	rs1133043	ENSG00000229043.2	AC091729.9	-11.1	1.24e-25	3.65e-22	-0.49	-0.45	Endometriosis;Longevity;	chr7:1093669	chr7:1160374~1165267:+
LUAD	cis	rs9322193	0.923	rs9505823	ENSG00000216906.2	RP11-350J20.9	11.1	1.24e-25	3.66e-22	0.55	0.45	Lung cancer;	chr6:149628899	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs9689599	ENSG00000216906.2	RP11-350J20.9	11.1	1.24e-25	3.66e-22	0.55	0.45	Lung cancer;	chr6:149631973	chr6:149904243~149906418:+
LUAD	cis	rs7174755	0.961	rs12148843	ENSG00000260657.2	RP11-315D16.4	11.1	1.24e-25	3.66e-22	0.54	0.45	Major depressive disorder;	chr15:68302184	chr15:68267792~68277994:-
LUAD	cis	rs875971	0.83	rs6950137	ENSG00000226824.5	RP4-756H11.3	-11.1	1.25e-25	3.67e-22	-0.58	-0.45	Aortic root size;	chr7:66511623	chr7:66654538~66669855:+
LUAD	cis	rs1577917	0.876	rs12201992	ENSG00000203875.9	SNHG5	-11.1	1.26e-25	3.71e-22	-0.61	-0.45	Response to antipsychotic treatment;	chr6:85908501	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs12201880	ENSG00000203875.9	SNHG5	-11.1	1.26e-25	3.71e-22	-0.61	-0.45	Response to antipsychotic treatment;	chr6:85917289	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs7756203	ENSG00000203875.9	SNHG5	-11.1	1.26e-25	3.71e-22	-0.61	-0.45	Response to antipsychotic treatment;	chr6:85917989	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs10944161	ENSG00000203875.9	SNHG5	-11.1	1.26e-25	3.71e-22	-0.61	-0.45	Response to antipsychotic treatment;	chr6:85920658	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs1857965	ENSG00000203875.9	SNHG5	-11.1	1.26e-25	3.71e-22	-0.61	-0.45	Response to antipsychotic treatment;	chr6:85921058	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs7771342	ENSG00000203875.9	SNHG5	-11.1	1.26e-25	3.71e-22	-0.61	-0.45	Response to antipsychotic treatment;	chr6:85922218	chr6:85660950~85678736:-
LUAD	cis	rs1577917	1	rs12154056	ENSG00000203875.9	SNHG5	-11.1	1.26e-25	3.71e-22	-0.61	-0.45	Response to antipsychotic treatment;	chr6:85924376	chr6:85660950~85678736:-
LUAD	cis	rs8040855	0.86	rs6496775	ENSG00000259295.5	CSPG4P12	-11.09	1.29e-25	3.8e-22	-0.57	-0.45	Bulimia nervosa;	chr15:85164910	chr15:85191438~85213905:+
LUAD	cis	rs950027	0.62	rs1346267	ENSG00000259520.4	CTD-2651B20.3	-11.09	1.29e-25	3.81e-22	-0.55	-0.45	Response to fenofibrate (adiponectin levels);	chr15:45398791	chr15:45251580~45279251:-
LUAD	cis	rs6452524	0.967	rs10051542	ENSG00000249664.1	CTD-2227C6.2	11.09	1.31e-25	3.85e-22	0.52	0.45	Hypertension (SNP x SNP interaction);	chr5:83178268	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs10051557	ENSG00000249664.1	CTD-2227C6.2	11.09	1.31e-25	3.85e-22	0.52	0.45	Hypertension (SNP x SNP interaction);	chr5:83178307	chr5:83012285~83013109:-
LUAD	cis	rs748404	0.56	rs1869258	ENSG00000205771.5	CATSPER2P1	-11.09	1.32e-25	3.88e-22	-0.58	-0.45	Lung cancer;	chr15:43511423	chr15:43726918~43747094:-
LUAD	cis	rs73086581	1	rs56141565	ENSG00000229539.1	RP11-119B16.2	11.09	1.33e-25	3.92e-22	0.66	0.45	Response to antidepressants in depression;	chr20:4017956	chr20:3888239~3888868:-
LUAD	cis	rs6504950	0.83	rs12949538	ENSG00000275710.1	RP11-257O5.4	-11.09	1.34e-25	3.93e-22	-0.59	-0.45	Breast cancer;	chr17:54933309	chr17:54964474~54964679:+
LUAD	cis	rs7115242	0.702	rs672058	ENSG00000254851.1	RP11-109L13.1	-11.09	1.34e-25	3.94e-22	-0.77	-0.45	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116893305	chr11:117135528~117138582:+
LUAD	cis	rs7104764	0.507	rs6598056	ENSG00000277290.1	RP11-326C3.16	11.09	1.34e-25	3.94e-22	0.47	0.45	Menarche (age at onset);	chr11:252283	chr11:243099~243483:-
LUAD	cis	rs6452524	0.967	rs62374400	ENSG00000249664.1	CTD-2227C6.2	11.09	1.34e-25	3.94e-22	0.52	0.45	Hypertension (SNP x SNP interaction);	chr5:83177053	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs10040363	ENSG00000249664.1	CTD-2227C6.2	11.09	1.34e-25	3.94e-22	0.52	0.45	Hypertension (SNP x SNP interaction);	chr5:83177826	chr5:83012285~83013109:-
LUAD	cis	rs2739330	0.828	rs4822451	ENSG00000231271.1	AP000350.8	11.09	1.36e-25	4e-22	0.55	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23949918~23954042:+
LUAD	cis	rs2739330	0.828	rs5760098	ENSG00000231271.1	AP000350.8	11.09	1.36e-25	4e-22	0.55	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23949918~23954042:+
LUAD	cis	rs977987	0.872	rs4887816	ENSG00000261783.1	RP11-252K23.2	-11.09	1.36e-25	4e-22	-0.6	-0.45	Dupuytren's disease;	chr16:75285818	chr16:75379818~75381260:-
LUAD	cis	rs7688540	0.511	rs11731927	ENSG00000275426.1	CH17-262A2.1	11.09	1.36e-25	4.01e-22	0.69	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:180316	chr4:149738~150317:+
LUAD	cis	rs9545047	0.967	rs9574402	ENSG00000227676.3	LINC01068	11.08	1.39e-25	4.09e-22	0.57	0.45	Schizophrenia;	chr13:79298392	chr13:79566727~79571436:+
LUAD	cis	rs875971	0.798	rs6460304	ENSG00000226824.5	RP4-756H11.3	-11.08	1.4e-25	4.09e-22	-0.58	-0.45	Aortic root size;	chr7:66499741	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs6945775	ENSG00000226824.5	RP4-756H11.3	-11.08	1.4e-25	4.09e-22	-0.58	-0.45	Aortic root size;	chr7:66503987	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.566	rs4870118	ENSG00000231760.4	RP11-350J20.5	-11.08	1.42e-25	4.15e-22	-0.67	-0.45	Lung cancer;	chr6:149923877	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.566	rs4869767	ENSG00000231760.4	RP11-350J20.5	-11.08	1.42e-25	4.15e-22	-0.67	-0.45	Lung cancer;	chr6:149923974	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.566	rs4869768	ENSG00000231760.4	RP11-350J20.5	-11.08	1.42e-25	4.15e-22	-0.67	-0.45	Lung cancer;	chr6:149924067	chr6:149796151~149826294:-
LUAD	cis	rs67383717	0.527	rs12004422	ENSG00000175611.10	LINC00476	11.08	1.42e-25	4.16e-22	0.46	0.45	Parkinson's disease (pesticide exposure interaction);	chr9:95873393	chr9:95759231~95875977:-
LUAD	cis	rs9322193	0.884	rs9322210	ENSG00000216906.2	RP11-350J20.9	11.08	1.44e-25	4.22e-22	0.55	0.45	Lung cancer;	chr6:149695440	chr6:149904243~149906418:+
LUAD	cis	rs1799949	0.757	rs9915489	ENSG00000198496.9	NBR2	-11.08	1.46e-25	4.27e-22	-0.48	-0.45	Menopause (age at onset);	chr17:43021209	chr17:43125610~43153671:+
LUAD	cis	rs992157	0.764	rs2015863	ENSG00000261338.2	RP11-378A13.1	-11.08	1.47e-25	4.3e-22	-0.47	-0.45	Colorectal cancer;	chr2:218320438	chr2:218255319~218257366:+
LUAD	cis	rs6452524	0.967	rs4616871	ENSG00000249664.1	CTD-2227C6.2	11.08	1.49e-25	4.36e-22	0.52	0.45	Hypertension (SNP x SNP interaction);	chr5:83175271	chr5:83012285~83013109:-
LUAD	cis	rs1577917	1	rs13217384	ENSG00000203875.9	SNHG5	-11.07	1.51e-25	4.43e-22	-0.61	-0.45	Response to antipsychotic treatment;	chr6:86010282	chr6:85660950~85678736:-
LUAD	cis	rs801193	0.569	rs7782587	ENSG00000226824.5	RP4-756H11.3	-11.07	1.52e-25	4.44e-22	-0.57	-0.45	Aortic root size;	chr7:66701485	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.569	rs4717315	ENSG00000226824.5	RP4-756H11.3	-11.07	1.52e-25	4.44e-22	-0.57	-0.45	Aortic root size;	chr7:66713338	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.527	rs2707837	ENSG00000226824.5	RP4-756H11.3	-11.07	1.52e-25	4.44e-22	-0.57	-0.45	Aortic root size;	chr7:66716086	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.964	rs160635	ENSG00000226824.5	RP4-756H11.3	-11.07	1.53e-25	4.46e-22	-0.57	-0.45	Aortic root size;	chr7:66063931	chr7:66654538~66669855:+
LUAD	cis	rs2739330	0.796	rs5760097	ENSG00000231271.1	AP000350.8	11.07	1.53e-25	4.48e-22	0.55	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23949918~23954042:+
LUAD	cis	rs5760092	0.755	rs915589	ENSG00000218537.1	MIF-AS1	-11.07	1.54e-25	4.51e-22	-0.7	-0.45	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23894426~23898930:-
LUAD	cis	rs4814920	0.818	rs4813377	ENSG00000275142.1	RP5-999L4.2	-11.07	1.55e-25	4.53e-22	-0.7	-0.45	Bipolar disorder (body mass index interaction);	chr20:19870822	chr20:19871891~19872284:+
LUAD	cis	rs1153858	0.943	rs7402632	ENSG00000259520.4	CTD-2651B20.3	-11.07	1.57e-25	4.58e-22	-0.62	-0.45	Homoarginine levels;	chr15:45409715	chr15:45251580~45279251:-
LUAD	cis	rs9322193	0.923	rs12174716	ENSG00000216906.2	RP11-350J20.9	11.07	1.58e-25	4.62e-22	0.55	0.45	Lung cancer;	chr6:149644487	chr6:149904243~149906418:+
LUAD	cis	rs3096299	0.632	rs4399533	ENSG00000274627.1	RP11-104N10.2	11.07	1.6e-25	4.68e-22	0.43	0.45	Multiple myeloma (IgH translocation);	chr16:89472974	chr16:89516797~89522217:+
LUAD	cis	rs9322193	0.923	rs9505982	ENSG00000216906.2	RP11-350J20.9	11.07	1.61e-25	4.68e-22	0.55	0.45	Lung cancer;	chr6:149618465	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs10782310	ENSG00000216906.2	RP11-350J20.9	11.07	1.61e-25	4.68e-22	0.55	0.45	Lung cancer;	chr6:149622458	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs10782311	ENSG00000216906.2	RP11-350J20.9	11.07	1.61e-25	4.68e-22	0.55	0.45	Lung cancer;	chr6:149622592	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs10747275	ENSG00000216906.2	RP11-350J20.9	11.07	1.61e-25	4.68e-22	0.55	0.45	Lung cancer;	chr6:149622782	chr6:149904243~149906418:+
LUAD	cis	rs2739330	0.828	rs5760099	ENSG00000231271.1	AP000350.8	11.07	1.62e-25	4.72e-22	0.55	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23949918~23954042:+
LUAD	cis	rs9322193	0.923	rs10872645	ENSG00000216906.2	RP11-350J20.9	11.07	1.64e-25	4.79e-22	0.55	0.45	Lung cancer;	chr6:149742840	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs12211511	ENSG00000216906.2	RP11-350J20.9	11.07	1.64e-25	4.79e-22	0.55	0.45	Lung cancer;	chr6:149745206	chr6:149904243~149906418:+
LUAD	cis	rs6538678	0.895	rs1436124	ENSG00000199506.1	RNU6-247P	-11.07	1.64e-25	4.79e-22	-0.59	-0.45	Lupus nephritis in systemic lupus erythematosus;	chr12:95889654	chr12:95792529~95792635:-
LUAD	cis	rs9660180	0.62	rs34298494	ENSG00000268575.1	RP1-283E3.8	11.06	1.65e-25	4.82e-22	0.41	0.45	Body mass index;	chr1:1731963	chr1:1702736~1737688:-
LUAD	cis	rs1577917	1	rs12215037	ENSG00000203875.9	SNHG5	-11.06	1.66e-25	4.83e-22	-0.63	-0.45	Response to antipsychotic treatment;	chr6:86017913	chr6:85660950~85678736:-
LUAD	cis	rs2658782	0.724	rs2248655	ENSG00000279684.1	RP11-755E23.2	-11.06	1.66e-25	4.84e-22	-0.71	-0.45	Pulmonary function decline;	chr11:93521446	chr11:93286629~93288903:-
LUAD	cis	rs6504950	0.83	rs56175787	ENSG00000275710.1	RP11-257O5.4	11.06	1.67e-25	4.86e-22	0.59	0.45	Breast cancer;	chr17:54940386	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.83	rs17817847	ENSG00000275710.1	RP11-257O5.4	11.06	1.67e-25	4.86e-22	0.59	0.45	Breast cancer;	chr17:54940920	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.83	rs35097996	ENSG00000275710.1	RP11-257O5.4	11.06	1.67e-25	4.86e-22	0.59	0.45	Breast cancer;	chr17:54944562	chr17:54964474~54964679:+
LUAD	cis	rs3096299	0.685	rs4329923	ENSG00000274627.1	RP11-104N10.2	11.06	1.67e-25	4.87e-22	0.43	0.45	Multiple myeloma (IgH translocation);	chr16:89493770	chr16:89516797~89522217:+
LUAD	cis	rs9322193	0.884	rs62439836	ENSG00000216906.2	RP11-350J20.9	11.06	1.68e-25	4.88e-22	0.54	0.45	Lung cancer;	chr6:149669173	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs4869812	ENSG00000216906.2	RP11-350J20.9	11.06	1.68e-25	4.88e-22	0.54	0.45	Lung cancer;	chr6:149669447	chr6:149904243~149906418:+
LUAD	cis	rs17507216	0.671	rs28582623	ENSG00000278603.1	RP13-608F4.5	11.06	1.69e-25	4.93e-22	0.62	0.45	Excessive daytime sleepiness;	chr15:82577381	chr15:82472203~82472426:+
LUAD	cis	rs3096299	0.658	rs12443705	ENSG00000274627.1	RP11-104N10.2	11.06	1.71e-25	4.98e-22	0.43	0.45	Multiple myeloma (IgH translocation);	chr16:89480646	chr16:89516797~89522217:+
LUAD	cis	rs2581828	0.656	rs891368	ENSG00000242142.1	SERBP1P3	11.06	1.72e-25	5e-22	0.46	0.45	Crohn's disease;	chr3:53089257	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.656	rs1078968	ENSG00000242142.1	SERBP1P3	11.06	1.72e-25	5e-22	0.46	0.45	Crohn's disease;	chr3:53089470	chr3:53064283~53065091:-
LUAD	cis	rs7688540	0.511	rs76125013	ENSG00000275426.1	CH17-262A2.1	11.06	1.73e-25	5.03e-22	0.67	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:201493	chr4:149738~150317:+
LUAD	cis	rs11723261	0.545	rs6812799	ENSG00000275426.1	CH17-262A2.1	11.06	1.73e-25	5.03e-22	0.67	0.45	Immune response to smallpox vaccine (IL-6);	chr4:203545	chr4:149738~150317:+
LUAD	cis	rs7688540	0.511	rs75433628	ENSG00000275426.1	CH17-262A2.1	11.06	1.74e-25	5.05e-22	0.68	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:184563	chr4:149738~150317:+
LUAD	cis	rs875971	0.651	rs2420596	ENSG00000226824.5	RP4-756H11.3	-11.06	1.74e-25	5.06e-22	-0.58	-0.45	Aortic root size;	chr7:66450996	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.52	rs2420597	ENSG00000226824.5	RP4-756H11.3	-11.06	1.74e-25	5.06e-22	-0.58	-0.45	Aortic root size;	chr7:66450999	chr7:66654538~66669855:+
LUAD	cis	rs11089937	0.929	rs5757155	ENSG00000211639.2	IGLV4-60	11.06	1.75e-25	5.07e-22	0.46	0.45	Periodontitis (PAL4Q3);	chr22:22165378	chr22:22162199~22162681:+
LUAD	cis	rs2581828	0.656	rs2253685	ENSG00000242142.1	SERBP1P3	11.06	1.77e-25	5.14e-22	0.46	0.45	Crohn's disease;	chr3:53085687	chr3:53064283~53065091:-
LUAD	cis	rs6452524	0.836	rs10041617	ENSG00000249664.1	CTD-2227C6.2	11.06	1.77e-25	5.15e-22	0.52	0.45	Hypertension (SNP x SNP interaction);	chr5:83096535	chr5:83012285~83013109:-
LUAD	cis	rs7188445	0.614	rs62043313	ENSG00000261390.4	RP11-345M22.2	-11.06	1.78e-25	5.16e-22	-0.57	-0.45	Urate levels;	chr16:79710237	chr16:79715232~79770563:-
LUAD	cis	rs8062405	0.824	rs4788083	ENSG00000259982.1	CDC37P1	11.06	1.79e-25	5.19e-22	0.56	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.824	rs7191618	ENSG00000259982.1	CDC37P1	11.06	1.79e-25	5.2e-22	0.57	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28700294~28701540:-
LUAD	cis	rs9322193	0.923	rs12174349	ENSG00000216906.2	RP11-350J20.9	11.05	1.81e-25	5.27e-22	0.54	0.45	Lung cancer;	chr6:149718012	chr6:149904243~149906418:+
LUAD	cis	rs2581828	0.646	rs2564923	ENSG00000242142.1	SERBP1P3	11.05	1.81e-25	5.27e-22	0.47	0.45	Crohn's disease;	chr3:53069246	chr3:53064283~53065091:-
LUAD	cis	rs9399135	0.684	rs1135205	ENSG00000232876.1	CTA-212D2.2	-11.05	1.86e-25	5.38e-22	-0.51	-0.45	Red blood cell count;	chr6:134960657	chr6:135055033~135060550:+
LUAD	cis	rs12130219	0.5	rs1552991	ENSG00000237975.5	FLG-AS1	-11.05	1.86e-25	5.38e-22	-0.54	-0.45	Inflammatory skin disease;	chr1:152193402	chr1:152168125~152445456:+
LUAD	cis	rs875971	0.861	rs801215	ENSG00000226824.5	RP4-756H11.3	11.05	1.87e-25	5.41e-22	0.58	0.45	Aortic root size;	chr7:66546951	chr7:66654538~66669855:+
LUAD	cis	rs7688540	0.511	rs61794969	ENSG00000275426.1	CH17-262A2.1	11.05	1.87e-25	5.41e-22	0.68	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:194242	chr4:149738~150317:+
LUAD	cis	rs2581828	0.656	rs2253796	ENSG00000242142.1	SERBP1P3	11.05	1.88e-25	5.44e-22	0.46	0.45	Crohn's disease;	chr3:53086082	chr3:53064283~53065091:-
LUAD	cis	rs801193	0.569	rs2707824	ENSG00000226824.5	RP4-756H11.3	-11.05	1.88e-25	5.46e-22	-0.57	-0.45	Aortic root size;	chr7:66724256	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.83	rs427575	ENSG00000226824.5	RP4-756H11.3	-11.05	1.89e-25	5.47e-22	-0.57	-0.45	Aortic root size;	chr7:66054232	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.8	rs427557	ENSG00000226824.5	RP4-756H11.3	-11.05	1.89e-25	5.47e-22	-0.57	-0.45	Aortic root size;	chr7:66054263	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.83	rs587360	ENSG00000226824.5	RP4-756H11.3	-11.05	1.89e-25	5.47e-22	-0.57	-0.45	Aortic root size;	chr7:66057711	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.798	rs57739047	ENSG00000226824.5	RP4-756H11.3	-11.05	1.89e-25	5.48e-22	-0.58	-0.45	Aortic root size;	chr7:66507579	chr7:66654538~66669855:+
LUAD	cis	rs11098499	0.954	rs12510138	ENSG00000245958.5	RP11-33B1.1	-11.05	1.91e-25	5.52e-22	-0.42	-0.45	Corneal astigmatism;	chr4:119502780	chr4:119454791~119552025:+
LUAD	cis	rs9322193	0.847	rs12234128	ENSG00000216906.2	RP11-350J20.9	11.05	1.91e-25	5.52e-22	0.54	0.45	Lung cancer;	chr6:149627553	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs57012784	ENSG00000216906.2	RP11-350J20.9	11.05	1.91e-25	5.52e-22	0.54	0.45	Lung cancer;	chr6:149627691	chr6:149904243~149906418:+
LUAD	cis	rs11118620	0.853	rs12037861	ENSG00000272823.1	RP11-295M18.6	11.05	1.92e-25	5.55e-22	0.56	0.45	Heart failure;	chr1:220864835	chr1:220828676~220829211:-
LUAD	cis	rs875971	0.862	rs778720	ENSG00000226824.5	RP4-756H11.3	11.05	1.92e-25	5.55e-22	0.58	0.45	Aortic root size;	chr7:66381288	chr7:66654538~66669855:+
LUAD	cis	rs6782228	0.675	rs4443194	ENSG00000242551.2	POU5F1P6	-11.05	1.93e-25	5.57e-22	-0.52	-0.45	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664603	chr3:128674735~128677005:-
LUAD	cis	rs11723261	0.582	rs6830247	ENSG00000275426.1	CH17-262A2.1	11.05	1.94e-25	5.61e-22	0.61	0.45	Immune response to smallpox vaccine (IL-6);	chr4:156885	chr4:149738~150317:+
LUAD	cis	rs1577917	1	rs2816815	ENSG00000203875.9	SNHG5	-11.05	1.95e-25	5.64e-22	-0.6	-0.45	Response to antipsychotic treatment;	chr6:85981938	chr6:85660950~85678736:-
LUAD	cis	rs9322193	0.923	rs1572229	ENSG00000216906.2	RP11-350J20.9	11.05	1.97e-25	5.69e-22	0.54	0.45	Lung cancer;	chr6:149743841	chr6:149904243~149906418:+
LUAD	cis	rs2581828	0.656	rs11130338	ENSG00000242142.1	SERBP1P3	11.04	2e-25	5.77e-22	0.46	0.45	Crohn's disease;	chr3:53086908	chr3:53064283~53065091:-
LUAD	cis	rs748404	0.56	rs529611	ENSG00000205771.5	CATSPER2P1	-11.04	2.04e-25	5.9e-22	-0.58	-0.45	Lung cancer;	chr15:43513790	chr15:43726918~43747094:-
LUAD	cis	rs2739330	0.796	rs5760106	ENSG00000231271.1	AP000350.8	-11.04	2.05e-25	5.93e-22	-0.54	-0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23949918~23954042:+
LUAD	cis	rs9322193	0.884	rs9689702	ENSG00000216906.2	RP11-350J20.9	11.04	2.05e-25	5.93e-22	0.55	0.45	Lung cancer;	chr6:149740720	chr6:149904243~149906418:+
LUAD	cis	rs7688540	0.511	rs61794991	ENSG00000275426.1	CH17-262A2.1	11.04	2.06e-25	5.94e-22	0.67	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:204418	chr4:149738~150317:+
LUAD	cis	rs977987	0.902	rs4888430	ENSG00000261783.1	RP11-252K23.2	-11.04	2.06e-25	5.96e-22	-0.6	-0.45	Dupuytren's disease;	chr16:75460526	chr16:75379818~75381260:-
LUAD	cis	rs11098499	0.909	rs6842762	ENSG00000245958.5	RP11-33B1.1	-11.04	2.08e-25	6.01e-22	-0.42	-0.45	Corneal astigmatism;	chr4:119477081	chr4:119454791~119552025:+
LUAD	cis	rs6782228	0.675	rs4857918	ENSG00000242551.2	POU5F1P6	-11.04	2.09e-25	6.03e-22	-0.52	-0.45	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128665117	chr3:128674735~128677005:-
LUAD	cis	rs6504950	0.79	rs8066833	ENSG00000275710.1	RP11-257O5.4	11.04	2.11e-25	6.07e-22	0.59	0.45	Breast cancer;	chr17:54948114	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.821	rs8066588	ENSG00000275710.1	RP11-257O5.4	11.04	2.11e-25	6.07e-22	0.59	0.45	Breast cancer;	chr17:54948328	chr17:54964474~54964679:+
LUAD	cis	rs7688540	0.511	rs61794965	ENSG00000275426.1	CH17-262A2.1	11.04	2.12e-25	6.1e-22	0.68	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:177880	chr4:149738~150317:+
LUAD	cis	rs11098499	0.954	rs9993199	ENSG00000245958.5	RP11-33B1.1	11.04	2.13e-25	6.14e-22	0.42	0.45	Corneal astigmatism;	chr4:119471718	chr4:119454791~119552025:+
LUAD	cis	rs12130219	0.5	rs4845737	ENSG00000237975.5	FLG-AS1	-11.03	2.17e-25	6.26e-22	-0.55	-0.45	Inflammatory skin disease;	chr1:152205063	chr1:152168125~152445456:+
LUAD	cis	rs6504950	0.76	rs7214573	ENSG00000275710.1	RP11-257O5.4	11.03	2.18e-25	6.27e-22	0.59	0.45	Breast cancer;	chr17:54929293	chr17:54964474~54964679:+
LUAD	cis	rs2455601	0.638	rs2742485	ENSG00000254860.4	TMEM9B-AS1	11.03	2.27e-25	6.53e-22	0.61	0.45	Schizophrenia;	chr11:8965240	chr11:8964675~8977527:+
LUAD	cis	rs9322193	0.886	rs9485408	ENSG00000216906.2	RP11-350J20.9	11.03	2.28e-25	6.56e-22	0.54	0.45	Lung cancer;	chr6:149618888	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs1080670	ENSG00000216906.2	RP11-350J20.9	11.03	2.28e-25	6.56e-22	0.54	0.45	Lung cancer;	chr6:149620161	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.884	rs10782312	ENSG00000216906.2	RP11-350J20.9	11.03	2.28e-25	6.56e-22	0.54	0.45	Lung cancer;	chr6:149622669	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.886	rs9322198	ENSG00000216906.2	RP11-350J20.9	11.03	2.28e-25	6.56e-22	0.54	0.45	Lung cancer;	chr6:149623772	chr6:149904243~149906418:+
LUAD	cis	rs2581828	0.541	rs2115781	ENSG00000242142.1	SERBP1P3	11.03	2.29e-25	6.59e-22	0.47	0.45	Crohn's disease;	chr3:53097813	chr3:53064283~53065091:-
LUAD	cis	rs9322193	0.923	rs9689716	ENSG00000216906.2	RP11-350J20.9	11.03	2.31e-25	6.64e-22	0.55	0.45	Lung cancer;	chr6:149655662	chr6:149904243~149906418:+
LUAD	cis	rs10256972	0.641	rs12702017	ENSG00000229043.2	AC091729.9	-11.03	2.33e-25	6.69e-22	-0.5	-0.45	Endometriosis;Longevity;	chr7:1089777	chr7:1160374~1165267:+
LUAD	cis	rs977987	0.966	rs6564261	ENSG00000261783.1	RP11-252K23.2	-11.02	2.37e-25	6.79e-22	-0.59	-0.45	Dupuytren's disease;	chr16:75458344	chr16:75379818~75381260:-
LUAD	cis	rs875971	0.862	rs1695820	ENSG00000226824.5	RP4-756H11.3	-11.02	2.37e-25	6.79e-22	-0.57	-0.45	Aortic root size;	chr7:66379576	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.83	rs778715	ENSG00000226824.5	RP4-756H11.3	-11.02	2.37e-25	6.79e-22	-0.57	-0.45	Aortic root size;	chr7:66384222	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.83	rs809025	ENSG00000226824.5	RP4-756H11.3	-11.02	2.37e-25	6.79e-22	-0.57	-0.45	Aortic root size;	chr7:66384832	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs778702	ENSG00000226824.5	RP4-756H11.3	-11.02	2.37e-25	6.79e-22	-0.57	-0.45	Aortic root size;	chr7:66399848	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs1643375	ENSG00000226824.5	RP4-756H11.3	-11.02	2.37e-25	6.79e-22	-0.57	-0.45	Aortic root size;	chr7:66407690	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs6962717	ENSG00000226824.5	RP4-756H11.3	-11.02	2.37e-25	6.79e-22	-0.57	-0.45	Aortic root size;	chr7:66418748	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.923	rs9689084	ENSG00000216906.2	RP11-350J20.9	11.02	2.39e-25	6.86e-22	0.54	0.45	Lung cancer;	chr6:149639648	chr6:149904243~149906418:+
LUAD	cis	rs2455601	0.638	rs2568092	ENSG00000254860.4	TMEM9B-AS1	-11.02	2.4e-25	6.87e-22	-0.58	-0.45	Schizophrenia;	chr11:8965891	chr11:8964675~8977527:+
LUAD	cis	rs9322193	0.923	rs9688517	ENSG00000216906.2	RP11-350J20.9	11.02	2.44e-25	6.99e-22	0.54	0.45	Lung cancer;	chr6:149740655	chr6:149904243~149906418:+
LUAD	cis	rs8062405	0.789	rs240704	ENSG00000259982.1	CDC37P1	11.02	2.46e-25	7.04e-22	0.57	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28518628	chr16:28700294~28701540:-
LUAD	cis	rs2581828	0.656	rs2163167	ENSG00000242142.1	SERBP1P3	11.02	2.46e-25	7.04e-22	0.47	0.45	Crohn's disease;	chr3:53097756	chr3:53064283~53065091:-
LUAD	cis	rs2658782	0.724	rs2605626	ENSG00000279684.1	RP11-755E23.2	-11.02	2.5e-25	7.15e-22	-0.71	-0.45	Pulmonary function decline;	chr11:93520737	chr11:93286629~93288903:-
LUAD	cis	rs2581828	0.656	rs2581786	ENSG00000242142.1	SERBP1P3	11.02	2.5e-25	7.17e-22	0.46	0.45	Crohn's disease;	chr3:53092127	chr3:53064283~53065091:-
LUAD	cis	rs1577917	0.958	rs28442244	ENSG00000203875.9	SNHG5	11.01	2.58e-25	7.39e-22	0.62	0.45	Response to antipsychotic treatment;	chr6:85991518	chr6:85660950~85678736:-
LUAD	cis	rs9322193	0.884	rs9688794	ENSG00000216906.2	RP11-350J20.9	11.01	2.59e-25	7.41e-22	0.54	0.45	Lung cancer;	chr6:149632121	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs9322204	ENSG00000216906.2	RP11-350J20.9	11.01	2.59e-25	7.41e-22	0.54	0.45	Lung cancer;	chr6:149636047	chr6:149904243~149906418:+
LUAD	cis	rs11155671	0.53	rs4870080	ENSG00000216906.2	RP11-350J20.9	11.01	2.59e-25	7.42e-22	0.54	0.45	Testicular germ cell tumor;	chr6:149881508	chr6:149904243~149906418:+
LUAD	cis	rs7208859	0.614	rs73265646	ENSG00000263531.1	RP13-753N3.1	11.01	2.6e-25	7.42e-22	0.95	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917005	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs58908911	ENSG00000263531.1	RP13-753N3.1	11.01	2.6e-25	7.42e-22	0.95	0.45	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917540	chr17:30863921~30864940:-
LUAD	cis	rs1729407	0.647	rs2727791	ENSG00000254851.1	RP11-109L13.1	-11.01	2.6e-25	7.44e-22	-0.57	-0.45	Apolipoprotein A-IV levels;	chr11:116813846	chr11:117135528~117138582:+
LUAD	cis	rs11723261	0.546	rs57839456	ENSG00000275426.1	CH17-262A2.1	11.01	2.6e-25	7.44e-22	0.62	0.45	Immune response to smallpox vaccine (IL-6);	chr4:154494	chr4:149738~150317:+
LUAD	cis	rs694739	1	rs646153	ENSG00000236935.1	AP003774.1	11.01	2.62e-25	7.49e-22	0.44	0.45	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64322116	chr11:64325050~64329504:-
LUAD	cis	rs875971	0.862	rs778724	ENSG00000226824.5	RP4-756H11.3	-11.01	2.63e-25	7.5e-22	-0.57	-0.45	Aortic root size;	chr7:66364304	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.923	rs11155671	ENSG00000216906.2	RP11-350J20.9	11.01	2.64e-25	7.55e-22	0.54	0.45	Lung cancer;	chr6:149650996	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.516	rs1999632	ENSG00000231760.4	RP11-350J20.5	11.01	2.65e-25	7.57e-22	0.69	0.45	Lung cancer;	chr6:149866737	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs56397000	ENSG00000216906.2	RP11-350J20.9	11.01	2.66e-25	7.58e-22	0.55	0.45	Lung cancer;	chr6:149739347	chr6:149904243~149906418:+
LUAD	cis	rs992157	0.73	rs2382828	ENSG00000261338.2	RP11-378A13.1	11.01	2.66e-25	7.59e-22	0.47	0.45	Colorectal cancer;	chr2:218319769	chr2:218255319~218257366:+
LUAD	cis	rs7688540	0.511	rs11731623	ENSG00000275426.1	CH17-262A2.1	11.01	2.67e-25	7.63e-22	0.67	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:207221	chr4:149738~150317:+
LUAD	cis	rs2658782	0.654	rs2605617	ENSG00000279684.1	RP11-755E23.2	-11.01	2.69e-25	7.67e-22	-0.68	-0.45	Pulmonary function decline;	chr11:93510167	chr11:93286629~93288903:-
LUAD	cis	rs7688540	0.511	rs6841415	ENSG00000275426.1	CH17-262A2.1	11.01	2.7e-25	7.71e-22	0.67	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:203594	chr4:149738~150317:+
LUAD	cis	rs11118620	1	rs11118620	ENSG00000272823.1	RP11-295M18.6	11	2.83e-25	8.06e-22	0.57	0.45	Heart failure;	chr1:220855166	chr1:220828676~220829211:-
LUAD	cis	rs6452524	0.934	rs12153440	ENSG00000249664.1	CTD-2227C6.2	11	2.9e-25	8.26e-22	0.52	0.45	Hypertension (SNP x SNP interaction);	chr5:83125097	chr5:83012285~83013109:-
LUAD	cis	rs9322193	0.962	rs4380763	ENSG00000216906.2	RP11-350J20.9	11	2.91e-25	8.28e-22	0.54	0.45	Lung cancer;	chr6:149678086	chr6:149904243~149906418:+
LUAD	cis	rs8040855	0.794	rs4843024	ENSG00000259295.5	CSPG4P12	-11	2.91e-25	8.3e-22	-0.56	-0.45	Bulimia nervosa;	chr15:85162669	chr15:85191438~85213905:+
LUAD	cis	rs1577917	1	rs10944169	ENSG00000203875.9	SNHG5	-11	2.95e-25	8.39e-22	-0.61	-0.45	Response to antipsychotic treatment;	chr6:85973318	chr6:85660950~85678736:-
LUAD	cis	rs11098499	0.954	rs9998585	ENSG00000245958.5	RP11-33B1.1	-11	2.96e-25	8.43e-22	-0.42	-0.45	Corneal astigmatism;	chr4:119475647	chr4:119454791~119552025:+
LUAD	cis	rs9322193	0.923	rs9479494	ENSG00000216906.2	RP11-350J20.9	11	3.05e-25	8.67e-22	0.54	0.45	Lung cancer;	chr6:149739108	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs9800806	ENSG00000216906.2	RP11-350J20.9	11	3.05e-25	8.67e-22	0.54	0.45	Lung cancer;	chr6:149740350	chr6:149904243~149906418:+
LUAD	cis	rs11155671	0.53	rs9968871	ENSG00000216906.2	RP11-350J20.9	11	3.06e-25	8.71e-22	0.56	0.45	Testicular germ cell tumor;	chr6:149888060	chr6:149904243~149906418:+
LUAD	cis	rs11155671	0.53	rs9969044	ENSG00000216906.2	RP11-350J20.9	11	3.06e-25	8.71e-22	0.56	0.45	Testicular germ cell tumor;	chr6:149888068	chr6:149904243~149906418:+
LUAD	cis	rs12439619	0.739	rs4778988	ENSG00000278603.1	RP13-608F4.5	11	3.07e-25	8.73e-22	0.56	0.45	Intelligence (multi-trait analysis);	chr15:82247996	chr15:82472203~82472426:+
LUAD	cis	rs17507216	0.628	rs28737193	ENSG00000278603.1	RP13-608F4.5	10.99	3.09e-25	8.78e-22	0.62	0.45	Excessive daytime sleepiness;	chr15:82701318	chr15:82472203~82472426:+
LUAD	cis	rs904251	0.766	rs1757175	ENSG00000279942.1	RP1-153P14.7	-10.99	3.14e-25	8.93e-22	-0.43	-0.45	Cognitive performance;	chr6:37518918	chr6:37567716~37571460:+
LUAD	cis	rs904251	0.828	rs1757174	ENSG00000279942.1	RP1-153P14.7	-10.99	3.14e-25	8.93e-22	-0.43	-0.45	Cognitive performance;	chr6:37518919	chr6:37567716~37571460:+
LUAD	cis	rs904251	0.861	rs1757173	ENSG00000279942.1	RP1-153P14.7	-10.99	3.14e-25	8.93e-22	-0.43	-0.45	Cognitive performance;	chr6:37519176	chr6:37567716~37571460:+
LUAD	cis	rs7174755	0.962	rs1020842	ENSG00000260657.2	RP11-315D16.4	-10.99	3.15e-25	8.95e-22	-0.52	-0.45	Major depressive disorder;	chr15:68309840	chr15:68267792~68277994:-
LUAD	cis	rs7188445	0.592	rs4404082	ENSG00000261390.4	RP11-345M22.2	10.99	3.22e-25	9.15e-22	0.56	0.45	Urate levels;	chr16:79716615	chr16:79715232~79770563:-
LUAD	cis	rs11098499	0.954	rs10518328	ENSG00000245958.5	RP11-33B1.1	-10.99	3.27e-25	9.27e-22	-0.42	-0.45	Corneal astigmatism;	chr4:119480624	chr4:119454791~119552025:+
LUAD	cis	rs977987	0.931	rs1834013	ENSG00000261783.1	RP11-252K23.2	-10.99	3.31e-25	9.38e-22	-0.6	-0.45	Dupuytren's disease;	chr16:75462265	chr16:75379818~75381260:-
LUAD	cis	rs7688540	0.511	rs77815676	ENSG00000275426.1	CH17-262A2.1	10.99	3.31e-25	9.4e-22	0.67	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:196080	chr4:149738~150317:+
LUAD	cis	rs801193	0.569	rs2659907	ENSG00000226824.5	RP4-756H11.3	-10.99	3.32e-25	9.42e-22	-0.57	-0.45	Aortic root size;	chr7:66699045	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.923	rs9322207	ENSG00000216906.2	RP11-350J20.9	10.99	3.33e-25	9.43e-22	0.55	0.45	Lung cancer;	chr6:149657185	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs9322208	ENSG00000216906.2	RP11-350J20.9	10.99	3.33e-25	9.43e-22	0.55	0.45	Lung cancer;	chr6:149658547	chr6:149904243~149906418:+
LUAD	cis	rs6504950	0.76	rs17745189	ENSG00000275710.1	RP11-257O5.4	10.98	3.42e-25	9.69e-22	0.59	0.45	Breast cancer;	chr17:54936619	chr17:54964474~54964679:+
LUAD	cis	rs9322193	0.923	rs9767123	ENSG00000216906.2	RP11-350J20.9	10.98	3.42e-25	9.7e-22	0.54	0.45	Lung cancer;	chr6:149660323	chr6:149904243~149906418:+
LUAD	cis	rs3096299	0.685	rs12446145	ENSG00000274627.1	RP11-104N10.2	10.98	3.46e-25	9.8e-22	0.43	0.45	Multiple myeloma (IgH translocation);	chr16:89476287	chr16:89516797~89522217:+
LUAD	cis	rs11098499	0.954	rs12499324	ENSG00000245958.5	RP11-33B1.1	-10.98	3.49e-25	9.89e-22	-0.42	-0.45	Corneal astigmatism;	chr4:119472631	chr4:119454791~119552025:+
LUAD	cis	rs9545047	0.967	rs9593396	ENSG00000227676.3	LINC01068	10.98	3.58e-25	1.01e-21	0.57	0.45	Schizophrenia;	chr13:79396164	chr13:79566727~79571436:+
LUAD	cis	rs9545047	1	rs9545101	ENSG00000227676.3	LINC01068	10.98	3.58e-25	1.01e-21	0.57	0.45	Schizophrenia;	chr13:79399806	chr13:79566727~79571436:+
LUAD	cis	rs904251	0.861	rs2776875	ENSG00000279942.1	RP1-153P14.7	-10.98	3.58e-25	1.01e-21	-0.43	-0.45	Cognitive performance;	chr6:37519020	chr6:37567716~37571460:+
LUAD	cis	rs62388641	0.813	rs34114087	ENSG00000272279.1	RP11-157J24.2	10.98	3.59e-25	1.02e-21	0.67	0.45	Daytime sleep phenotypes;	chr6:1553203	chr6:1528364~1528911:-
LUAD	cis	rs875971	0.83	rs6976714	ENSG00000226824.5	RP4-756H11.3	-10.98	3.65e-25	1.03e-21	-0.57	-0.45	Aortic root size;	chr7:66426474	chr7:66654538~66669855:+
LUAD	cis	rs11155671	0.53	rs9383940	ENSG00000216906.2	RP11-350J20.9	10.97	3.7e-25	1.04e-21	0.55	0.45	Testicular germ cell tumor;	chr6:149904923	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs57938011	ENSG00000216906.2	RP11-350J20.9	10.97	3.71e-25	1.05e-21	0.56	0.45	Lung cancer;	chr6:149642969	chr6:149904243~149906418:+
LUAD	cis	rs875971	0.862	rs778686	ENSG00000226824.5	RP4-756H11.3	-10.97	3.84e-25	1.08e-21	-0.57	-0.45	Aortic root size;	chr7:66370923	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs778684	ENSG00000226824.5	RP4-756H11.3	-10.97	3.84e-25	1.08e-21	-0.57	-0.45	Aortic root size;	chr7:66371416	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs778680	ENSG00000226824.5	RP4-756H11.3	-10.97	3.84e-25	1.08e-21	-0.57	-0.45	Aortic root size;	chr7:66375427	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs11769079	ENSG00000226824.5	RP4-756H11.3	-10.97	3.84e-25	1.08e-21	-0.57	-0.45	Aortic root size;	chr7:66377141	chr7:66654538~66669855:+
LUAD	cis	rs4423214	0.798	rs12224205	ENSG00000254682.1	RP11-660L16.2	-10.97	3.84e-25	1.08e-21	-0.64	-0.45	Vitamin D levels;	chr11:71469946	chr11:71448674~71452157:+
LUAD	cis	rs9545047	0.869	rs3742119	ENSG00000227676.3	LINC01068	10.97	3.84e-25	1.08e-21	0.56	0.45	Schizophrenia;	chr13:79342859	chr13:79566727~79571436:+
LUAD	cis	rs9545047	1	rs9318626	ENSG00000227676.3	LINC01068	10.97	3.84e-25	1.08e-21	0.56	0.45	Schizophrenia;	chr13:79351820	chr13:79566727~79571436:+
LUAD	cis	rs9545047	1	rs56911077	ENSG00000227676.3	LINC01068	10.97	3.84e-25	1.08e-21	0.56	0.45	Schizophrenia;	chr13:79354126	chr13:79566727~79571436:+
LUAD	cis	rs9399135	0.66	rs4267967	ENSG00000232876.1	CTA-212D2.2	-10.97	3.84e-25	1.08e-21	-0.5	-0.45	Red blood cell count;	chr6:134951339	chr6:135055033~135060550:+
LUAD	cis	rs2581828	0.656	rs2581782	ENSG00000242142.1	SERBP1P3	10.97	3.88e-25	1.09e-21	0.46	0.45	Crohn's disease;	chr3:53088241	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.656	rs2581783	ENSG00000242142.1	SERBP1P3	10.97	3.88e-25	1.09e-21	0.46	0.45	Crohn's disease;	chr3:53088242	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.607	rs2581784	ENSG00000242142.1	SERBP1P3	10.97	3.88e-25	1.09e-21	0.46	0.45	Crohn's disease;	chr3:53088354	chr3:53064283~53065091:-
LUAD	cis	rs9322193	0.923	rs10782316	ENSG00000216906.2	RP11-350J20.9	10.97	3.88e-25	1.09e-21	0.54	0.45	Lung cancer;	chr6:149752755	chr6:149904243~149906418:+
LUAD	cis	rs858239	0.676	rs3807459	ENSG00000230658.1	KLHL7-AS1	10.97	3.94e-25	1.11e-21	0.56	0.45	Cerebrospinal fluid biomarker levels;	chr7:23350132	chr7:23101228~23105703:-
LUAD	cis	rs9322193	0.923	rs9688861	ENSG00000216906.2	RP11-350J20.9	10.97	3.97e-25	1.12e-21	0.54	0.45	Lung cancer;	chr6:149637924	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs7740278	ENSG00000216906.2	RP11-350J20.9	10.97	3.97e-25	1.12e-21	0.54	0.45	Lung cancer;	chr6:149640116	chr6:149904243~149906418:+
LUAD	cis	rs6504950	0.751	rs12937760	ENSG00000275710.1	RP11-257O5.4	10.96	4.03e-25	1.13e-21	0.59	0.45	Breast cancer;	chr17:54938769	chr17:54964474~54964679:+
LUAD	cis	rs904251	0.861	rs1757169	ENSG00000279942.1	RP1-153P14.7	-10.96	4.07e-25	1.14e-21	-0.43	-0.45	Cognitive performance;	chr6:37519300	chr6:37567716~37571460:+
LUAD	cis	rs11155671	0.53	rs6557133	ENSG00000216906.2	RP11-350J20.9	10.96	4.1e-25	1.15e-21	0.53	0.45	Testicular germ cell tumor;	chr6:149874248	chr6:149904243~149906418:+
LUAD	cis	rs2658782	0.724	rs1563445	ENSG00000279684.1	RP11-755E23.2	-10.96	4.1e-25	1.15e-21	-0.71	-0.45	Pulmonary function decline;	chr11:93512876	chr11:93286629~93288903:-
LUAD	cis	rs4728142	0.625	rs4731533	ENSG00000275106.1	RP11-309L24.10	-10.96	4.12e-25	1.16e-21	-0.54	-0.45	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128962088	chr7:128952527~128953316:-
LUAD	cis	rs904251	0.861	rs1757183	ENSG00000279942.1	RP1-153P14.7	10.96	4.13e-25	1.16e-21	0.42	0.45	Cognitive performance;	chr6:37517014	chr6:37567716~37571460:+
LUAD	cis	rs2581828	0.656	rs2564921	ENSG00000242142.1	SERBP1P3	-10.96	4.2e-25	1.18e-21	-0.47	-0.45	Crohn's disease;	chr3:53091569	chr3:53064283~53065091:-
LUAD	cis	rs9322193	0.962	rs35443312	ENSG00000216906.2	RP11-350J20.9	10.96	4.2e-25	1.18e-21	0.55	0.45	Lung cancer;	chr6:149670625	chr6:149904243~149906418:+
LUAD	cis	rs2739330	0.587	rs4820571	ENSG00000225282.1	AP000350.6	10.96	4.21e-25	1.18e-21	0.52	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23926900~23929574:+
LUAD	cis	rs6964833	1	rs17515241	ENSG00000277053.3	GTF2IP1	10.96	4.23e-25	1.19e-21	0.63	0.45	Menarche (age at onset);	chr7:74717695	chr7:75185385~75237696:-
LUAD	cis	rs9322193	0.923	rs11155674	ENSG00000216906.2	RP11-350J20.9	10.96	4.24e-25	1.19e-21	0.54	0.45	Lung cancer;	chr6:149711111	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs2185352	ENSG00000216906.2	RP11-350J20.9	10.96	4.24e-25	1.19e-21	0.54	0.45	Lung cancer;	chr6:149714640	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs2297932	ENSG00000216906.2	RP11-350J20.9	10.96	4.24e-25	1.19e-21	0.54	0.45	Lung cancer;	chr6:149718225	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs2297930	ENSG00000216906.2	RP11-350J20.9	10.96	4.24e-25	1.19e-21	0.54	0.45	Lung cancer;	chr6:149718360	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.576	rs7452592	ENSG00000231760.4	RP11-350J20.5	10.96	4.26e-25	1.2e-21	0.72	0.45	Lung cancer;	chr6:149875445	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs6913486	ENSG00000216906.2	RP11-350J20.9	-10.96	4.28e-25	1.2e-21	-0.55	-0.45	Lung cancer;	chr6:149705060	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs9800580	ENSG00000216906.2	RP11-350J20.9	10.96	4.3e-25	1.21e-21	0.54	0.45	Lung cancer;	chr6:149632845	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.884	rs11155669	ENSG00000216906.2	RP11-350J20.9	10.96	4.3e-25	1.21e-21	0.54	0.45	Lung cancer;	chr6:149633501	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.887	rs9505824	ENSG00000216906.2	RP11-350J20.9	10.96	4.3e-25	1.21e-21	0.54	0.45	Lung cancer;	chr6:149633663	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs9505826	ENSG00000216906.2	RP11-350J20.9	10.96	4.3e-25	1.21e-21	0.54	0.45	Lung cancer;	chr6:149633912	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs9766886	ENSG00000216906.2	RP11-350J20.9	10.96	4.3e-25	1.21e-21	0.54	0.45	Lung cancer;	chr6:149637048	chr6:149904243~149906418:+
LUAD	cis	rs2337406	0.866	rs988130	ENSG00000274576.2	IGHV2-70	-10.96	4.37e-25	1.23e-21	-0.48	-0.45	Alzheimer's disease (late onset);	chr14:106777154	chr14:106770577~106771020:-
LUAD	cis	rs801193	0.548	rs2109297	ENSG00000226824.5	RP4-756H11.3	10.95	4.38e-25	1.23e-21	0.57	0.45	Aortic root size;	chr7:66657397	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.591	rs721717	ENSG00000226824.5	RP4-756H11.3	10.95	4.38e-25	1.23e-21	0.57	0.45	Aortic root size;	chr7:66665305	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.569	rs6951302	ENSG00000226824.5	RP4-756H11.3	10.95	4.38e-25	1.23e-21	0.57	0.45	Aortic root size;	chr7:66667525	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.923	rs4870267	ENSG00000216906.2	RP11-350J20.9	10.95	4.39e-25	1.23e-21	0.54	0.45	Lung cancer;	chr6:149671572	chr6:149904243~149906418:+
LUAD	cis	rs2283792	0.812	rs5995269	ENSG00000224086.5	LL22NC03-86G7.1	-10.95	4.4e-25	1.23e-21	-0.41	-0.45	Multiple sclerosis;	chr22:21935025	chr22:21938293~21977632:+
LUAD	cis	rs9322193	0.923	rs2297928	ENSG00000216906.2	RP11-350J20.9	10.95	4.42e-25	1.24e-21	0.54	0.45	Lung cancer;	chr6:149718584	chr6:149904243~149906418:+
LUAD	cis	rs875971	0.862	rs1983372	ENSG00000226824.5	RP4-756H11.3	10.95	4.51e-25	1.26e-21	0.57	0.45	Aortic root size;	chr7:66146364	chr7:66654538~66669855:+
LUAD	cis	rs2581828	0.656	rs34530577	ENSG00000242142.1	SERBP1P3	10.95	4.52e-25	1.27e-21	0.47	0.45	Crohn's disease;	chr3:53069780	chr3:53064283~53065091:-
LUAD	cis	rs6452524	0.967	rs4541638	ENSG00000249664.1	CTD-2227C6.2	10.95	4.59e-25	1.28e-21	0.51	0.45	Hypertension (SNP x SNP interaction);	chr5:83181325	chr5:83012285~83013109:-
LUAD	cis	rs2929278	0.546	rs686666	ENSG00000205771.5	CATSPER2P1	-10.95	4.73e-25	1.32e-21	-0.56	-0.45	Schizophrenia;	chr15:43869352	chr15:43726918~43747094:-
LUAD	cis	rs875971	0.862	rs7786892	ENSG00000226824.5	RP4-756H11.3	10.95	4.77e-25	1.33e-21	0.57	0.45	Aortic root size;	chr7:66163889	chr7:66654538~66669855:+
LUAD	cis	rs6452524	0.967	rs28360104	ENSG00000249664.1	CTD-2227C6.2	10.95	4.78e-25	1.33e-21	0.51	0.45	Hypertension (SNP x SNP interaction);	chr5:83181525	chr5:83012285~83013109:-
LUAD	cis	rs6782228	0.675	rs2253151	ENSG00000242551.2	POU5F1P6	-10.95	4.78e-25	1.34e-21	-0.51	-0.45	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611294	chr3:128674735~128677005:-
LUAD	cis	rs8062405	0.754	rs3859172	ENSG00000259982.1	CDC37P1	10.94	4.85e-25	1.35e-21	0.56	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28700294~28701540:-
LUAD	cis	rs3096299	0.685	rs4785571	ENSG00000274627.1	RP11-104N10.2	10.94	4.88e-25	1.36e-21	0.43	0.45	Multiple myeloma (IgH translocation);	chr16:89498761	chr16:89516797~89522217:+
LUAD	cis	rs73086581	0.838	rs73088424	ENSG00000229539.1	RP11-119B16.2	10.94	4.88e-25	1.36e-21	0.65	0.45	Response to antidepressants in depression;	chr20:4020359	chr20:3888239~3888868:-
LUAD	cis	rs9322193	0.923	rs10782314	ENSG00000216906.2	RP11-350J20.9	10.94	4.89e-25	1.37e-21	0.55	0.45	Lung cancer;	chr6:149735527	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.504	rs7771014	ENSG00000216906.2	RP11-350J20.9	10.94	4.97e-25	1.39e-21	0.54	0.45	Lung cancer;	chr6:149884310	chr6:149904243~149906418:+
LUAD	cis	rs801193	0.548	rs6975044	ENSG00000226824.5	RP4-756H11.3	-10.94	4.99e-25	1.39e-21	-0.57	-0.45	Aortic root size;	chr7:66762495	chr7:66654538~66669855:+
LUAD	cis	rs7174755	0.961	rs11631030	ENSG00000260657.2	RP11-315D16.4	10.94	5.08e-25	1.42e-21	0.53	0.45	Major depressive disorder;	chr15:68303463	chr15:68267792~68277994:-
LUAD	cis	rs9545047	0.967	rs3903388	ENSG00000227676.3	LINC01068	10.94	5.12e-25	1.43e-21	0.56	0.45	Schizophrenia;	chr13:79330686	chr13:79566727~79571436:+
LUAD	cis	rs9545047	1	rs9545073	ENSG00000227676.3	LINC01068	10.94	5.12e-25	1.43e-21	0.56	0.45	Schizophrenia;	chr13:79334872	chr13:79566727~79571436:+
LUAD	cis	rs9545047	1	rs9545078	ENSG00000227676.3	LINC01068	10.94	5.12e-25	1.43e-21	0.56	0.45	Schizophrenia;	chr13:79339216	chr13:79566727~79571436:+
LUAD	cis	rs9322193	0.566	rs5024811	ENSG00000231760.4	RP11-350J20.5	-10.94	5.21e-25	1.45e-21	-0.65	-0.45	Lung cancer;	chr6:149924898	chr6:149796151~149826294:-
LUAD	cis	rs8062405	1	rs8061590	ENSG00000259982.1	CDC37P1	10.93	5.31e-25	1.48e-21	0.57	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28883809	chr16:28700294~28701540:-
LUAD	cis	rs977987	0.645	rs34904236	ENSG00000261783.1	RP11-252K23.2	-10.93	5.34e-25	1.49e-21	-0.6	-0.45	Dupuytren's disease;	chr16:75464355	chr16:75379818~75381260:-
LUAD	cis	rs6452524	1	rs10474093	ENSG00000249664.1	CTD-2227C6.2	10.93	5.36e-25	1.49e-21	0.51	0.45	Hypertension (SNP x SNP interaction);	chr5:83141612	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.935	rs10473868	ENSG00000249664.1	CTD-2227C6.2	10.93	5.36e-25	1.49e-21	0.51	0.45	Hypertension (SNP x SNP interaction);	chr5:83141628	chr5:83012285~83013109:-
LUAD	cis	rs11723261	0.582	rs4634177	ENSG00000275426.1	CH17-262A2.1	10.93	5.4e-25	1.5e-21	0.62	0.45	Immune response to smallpox vaccine (IL-6);	chr4:143055	chr4:149738~150317:+
LUAD	cis	rs3096299	0.563	rs4600467	ENSG00000274627.1	RP11-104N10.2	10.93	5.43e-25	1.51e-21	0.43	0.45	Multiple myeloma (IgH translocation);	chr16:89496108	chr16:89516797~89522217:+
LUAD	cis	rs11723261	0.582	rs6814287	ENSG00000275426.1	CH17-262A2.1	10.93	5.44e-25	1.51e-21	0.63	0.45	Immune response to smallpox vaccine (IL-6);	chr4:122443	chr4:149738~150317:+
LUAD	cis	rs9322193	0.962	rs3805748	ENSG00000216906.2	RP11-350J20.9	10.93	5.45e-25	1.51e-21	0.54	0.45	Lung cancer;	chr6:149772542	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.886	rs12525871	ENSG00000216906.2	RP11-350J20.9	10.93	5.45e-25	1.51e-21	0.54	0.45	Lung cancer;	chr6:149775882	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.81	rs62439811	ENSG00000216906.2	RP11-350J20.9	10.93	5.45e-25	1.51e-21	0.56	0.45	Lung cancer;	chr6:149640416	chr6:149904243~149906418:+
LUAD	cis	rs977987	0.933	rs1834014	ENSG00000261783.1	RP11-252K23.2	-10.93	5.49e-25	1.52e-21	-0.6	-0.45	Dupuytren's disease;	chr16:75467376	chr16:75379818~75381260:-
LUAD	cis	rs8062405	0.824	rs240702	ENSG00000259982.1	CDC37P1	10.93	5.52e-25	1.53e-21	0.56	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520032	chr16:28700294~28701540:-
LUAD	cis	rs6504950	0.83	rs8073158	ENSG00000275710.1	RP11-257O5.4	10.93	5.67e-25	1.57e-21	0.59	0.45	Breast cancer;	chr17:54951254	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.83	rs3087650	ENSG00000275710.1	RP11-257O5.4	10.93	5.67e-25	1.57e-21	0.59	0.45	Breast cancer;	chr17:54951967	chr17:54964474~54964679:+
LUAD	cis	rs2337406	0.866	rs8003852	ENSG00000274576.2	IGHV2-70	-10.93	5.68e-25	1.58e-21	-0.48	-0.45	Alzheimer's disease (late onset);	chr14:106776648	chr14:106770577~106771020:-
LUAD	cis	rs2337406	0.866	rs988131	ENSG00000274576.2	IGHV2-70	-10.93	5.68e-25	1.58e-21	-0.48	-0.45	Alzheimer's disease (late onset);	chr14:106776833	chr14:106770577~106771020:-
LUAD	cis	rs2337406	0.866	rs8005518	ENSG00000274576.2	IGHV2-70	-10.93	5.68e-25	1.58e-21	-0.48	-0.45	Alzheimer's disease (late onset);	chr14:106777009	chr14:106770577~106771020:-
LUAD	cis	rs2337406	0.866	rs57684263	ENSG00000274576.2	IGHV2-70	-10.93	5.68e-25	1.58e-21	-0.48	-0.45	Alzheimer's disease (late onset);	chr14:106777263	chr14:106770577~106771020:-
LUAD	cis	rs2337406	0.866	rs7152809	ENSG00000274576.2	IGHV2-70	-10.93	5.68e-25	1.58e-21	-0.48	-0.45	Alzheimer's disease (late onset);	chr14:106778385	chr14:106770577~106771020:-
LUAD	cis	rs2337406	0.866	rs7152832	ENSG00000274576.2	IGHV2-70	-10.93	5.68e-25	1.58e-21	-0.48	-0.45	Alzheimer's disease (late onset);	chr14:106778427	chr14:106770577~106771020:-
LUAD	cis	rs2337406	0.5	rs7152934	ENSG00000274576.2	IGHV2-70	-10.93	5.68e-25	1.58e-21	-0.48	-0.45	Alzheimer's disease (late onset);	chr14:106778702	chr14:106770577~106771020:-
LUAD	cis	rs2337406	0.789	rs12050392	ENSG00000274576.2	IGHV2-70	-10.93	5.68e-25	1.58e-21	-0.48	-0.45	Alzheimer's disease (late onset);	chr14:106779073	chr14:106770577~106771020:-
LUAD	cis	rs2337406	0.866	rs74092505	ENSG00000274576.2	IGHV2-70	-10.93	5.68e-25	1.58e-21	-0.48	-0.45	Alzheimer's disease (late onset);	chr14:106779163	chr14:106770577~106771020:-
LUAD	cis	rs2337406	0.789	rs74092507	ENSG00000274576.2	IGHV2-70	-10.93	5.68e-25	1.58e-21	-0.48	-0.45	Alzheimer's disease (late onset);	chr14:106779174	chr14:106770577~106771020:-
LUAD	cis	rs2337406	0.866	rs74092511	ENSG00000274576.2	IGHV2-70	-10.93	5.68e-25	1.58e-21	-0.48	-0.45	Alzheimer's disease (late onset);	chr14:106779234	chr14:106770577~106771020:-
LUAD	cis	rs6452524	1	rs62374374	ENSG00000249664.1	CTD-2227C6.2	10.92	5.72e-25	1.59e-21	0.51	0.45	Hypertension (SNP x SNP interaction);	chr5:83144838	chr5:83012285~83013109:-
LUAD	cis	rs11723261	0.582	rs7679573	ENSG00000275426.1	CH17-262A2.1	10.92	5.74e-25	1.59e-21	0.62	0.45	Immune response to smallpox vaccine (IL-6);	chr4:157810	chr4:149738~150317:+
LUAD	cis	rs11118620	0.81	rs1603047	ENSG00000272823.1	RP11-295M18.6	10.92	5.78e-25	1.6e-21	0.55	0.45	Heart failure;	chr1:220849953	chr1:220828676~220829211:-
LUAD	cis	rs9322193	0.962	rs9688750	ENSG00000216906.2	RP11-350J20.9	10.92	5.81e-25	1.61e-21	0.55	0.45	Lung cancer;	chr6:149657633	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs9689723	ENSG00000216906.2	RP11-350J20.9	10.92	5.83e-25	1.62e-21	0.54	0.45	Lung cancer;	chr6:149655935	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs62439840	ENSG00000216906.2	RP11-350J20.9	10.92	5.89e-25	1.63e-21	0.56	0.45	Lung cancer;	chr6:149674639	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs9393175	ENSG00000216906.2	RP11-350J20.9	10.92	5.89e-25	1.63e-21	0.56	0.45	Lung cancer;	chr6:149677587	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs62441284	ENSG00000216906.2	RP11-350J20.9	10.92	5.9e-25	1.63e-21	0.54	0.45	Lung cancer;	chr6:149751542	chr6:149904243~149906418:+
LUAD	cis	rs7174755	0.962	rs4777034	ENSG00000260657.2	RP11-315D16.4	-10.92	5.95e-25	1.65e-21	-0.52	-0.45	Major depressive disorder;	chr15:68309546	chr15:68267792~68277994:-
LUAD	cis	rs11098499	0.954	rs28685688	ENSG00000245958.5	RP11-33B1.1	-10.92	5.97e-25	1.65e-21	-0.42	-0.45	Corneal astigmatism;	chr4:119499179	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs7687843	ENSG00000245958.5	RP11-33B1.1	-10.92	5.97e-25	1.65e-21	-0.42	-0.45	Corneal astigmatism;	chr4:119500056	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs2306455	ENSG00000245958.5	RP11-33B1.1	-10.92	5.97e-25	1.65e-21	-0.42	-0.45	Corneal astigmatism;	chr4:119500814	chr4:119454791~119552025:+
LUAD	cis	rs8040855	0.599	rs6496791	ENSG00000259295.5	CSPG4P12	-10.92	5.97e-25	1.65e-21	-0.52	-0.45	Bulimia nervosa;	chr15:85182428	chr15:85191438~85213905:+
LUAD	cis	rs9545047	0.967	rs9545097	ENSG00000227676.3	LINC01068	10.92	6.02e-25	1.67e-21	0.57	0.45	Schizophrenia;	chr13:79387352	chr13:79566727~79571436:+
LUAD	cis	rs11098499	0.954	rs13145352	ENSG00000245958.5	RP11-33B1.1	10.92	6.03e-25	1.67e-21	0.42	0.45	Corneal astigmatism;	chr4:119488808	chr4:119454791~119552025:+
LUAD	cis	rs801193	0.591	rs4506088	ENSG00000226824.5	RP4-756H11.3	10.92	6.08e-25	1.68e-21	0.57	0.45	Aortic root size;	chr7:66670470	chr7:66654538~66669855:+
LUAD	cis	rs9601248	0.529	rs2783126	ENSG00000227676.3	LINC01068	10.91	6.38e-25	1.76e-21	0.56	0.45	Major depressive disorder;	chr13:79584566	chr13:79566727~79571436:+
LUAD	cis	rs9601248	0.529	rs9545142	ENSG00000227676.3	LINC01068	10.91	6.38e-25	1.76e-21	0.56	0.45	Major depressive disorder;	chr13:79588420	chr13:79566727~79571436:+
LUAD	cis	rs507080	0.733	rs601318	ENSG00000255239.1	AP002954.6	10.91	6.47e-25	1.79e-21	0.55	0.45	Serum metabolite levels;	chr11:118648845	chr11:118688039~118690600:-
LUAD	cis	rs748404	0.646	rs2253268	ENSG00000205771.5	CATSPER2P1	-10.91	6.5e-25	1.79e-21	-0.57	-0.45	Lung cancer;	chr15:43508770	chr15:43726918~43747094:-
LUAD	cis	rs11098499	0.954	rs6822679	ENSG00000245958.5	RP11-33B1.1	-10.91	6.51e-25	1.8e-21	-0.42	-0.45	Corneal astigmatism;	chr4:119481547	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs4577559	ENSG00000245958.5	RP11-33B1.1	-10.91	6.51e-25	1.8e-21	-0.42	-0.45	Corneal astigmatism;	chr4:119482888	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs7656252	ENSG00000245958.5	RP11-33B1.1	-10.91	6.51e-25	1.8e-21	-0.42	-0.45	Corneal astigmatism;	chr4:119483113	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.865	rs28845498	ENSG00000245958.5	RP11-33B1.1	-10.91	6.51e-25	1.8e-21	-0.42	-0.45	Corneal astigmatism;	chr4:119484031	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs56270433	ENSG00000245958.5	RP11-33B1.1	-10.91	6.51e-25	1.8e-21	-0.42	-0.45	Corneal astigmatism;	chr4:119484875	chr4:119454791~119552025:+
LUAD	cis	rs6452524	1	rs6868817	ENSG00000249664.1	CTD-2227C6.2	10.91	6.57e-25	1.81e-21	0.51	0.45	Hypertension (SNP x SNP interaction);	chr5:83142287	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs10042018	ENSG00000249664.1	CTD-2227C6.2	10.91	6.57e-25	1.81e-21	0.51	0.45	Hypertension (SNP x SNP interaction);	chr5:83142490	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs10036418	ENSG00000249664.1	CTD-2227C6.2	10.91	6.57e-25	1.81e-21	0.51	0.45	Hypertension (SNP x SNP interaction);	chr5:83142493	chr5:83012285~83013109:-
LUAD	cis	rs4423214	0.959	rs11606033	ENSG00000254682.1	RP11-660L16.2	10.91	6.65e-25	1.84e-21	0.58	0.45	Vitamin D levels;	chr11:71443158	chr11:71448674~71452157:+
LUAD	cis	rs6452524	1	rs10055948	ENSG00000249664.1	CTD-2227C6.2	10.91	6.7e-25	1.85e-21	0.51	0.45	Hypertension (SNP x SNP interaction);	chr5:83143437	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs10037872	ENSG00000249664.1	CTD-2227C6.2	10.91	6.7e-25	1.85e-21	0.51	0.45	Hypertension (SNP x SNP interaction);	chr5:83144101	chr5:83012285~83013109:-
LUAD	cis	rs12439619	1	rs35152457	ENSG00000278603.1	RP13-608F4.5	10.91	6.75e-25	1.86e-21	0.55	0.45	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82472203~82472426:+
LUAD	cis	rs11098499	0.954	rs7681544	ENSG00000245958.5	RP11-33B1.1	-10.91	6.76e-25	1.86e-21	-0.42	-0.45	Corneal astigmatism;	chr4:119490100	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs11940028	ENSG00000245958.5	RP11-33B1.1	-10.91	6.76e-25	1.86e-21	-0.42	-0.45	Corneal astigmatism;	chr4:119490752	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs11935596	ENSG00000245958.5	RP11-33B1.1	-10.91	6.76e-25	1.86e-21	-0.42	-0.45	Corneal astigmatism;	chr4:119491302	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs12507964	ENSG00000245958.5	RP11-33B1.1	-10.91	6.76e-25	1.86e-21	-0.42	-0.45	Corneal astigmatism;	chr4:119491906	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.909	rs11098530	ENSG00000245958.5	RP11-33B1.1	-10.91	6.76e-25	1.86e-21	-0.42	-0.45	Corneal astigmatism;	chr4:119491999	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs6834796	ENSG00000245958.5	RP11-33B1.1	-10.91	6.76e-25	1.86e-21	-0.42	-0.45	Corneal astigmatism;	chr4:119493538	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs11734241	ENSG00000245958.5	RP11-33B1.1	-10.91	6.76e-25	1.86e-21	-0.42	-0.45	Corneal astigmatism;	chr4:119495717	chr4:119454791~119552025:+
LUAD	cis	rs9322193	0.884	rs7450246	ENSG00000216906.2	RP11-350J20.9	10.91	6.77e-25	1.86e-21	0.54	0.45	Lung cancer;	chr6:149702517	chr6:149904243~149906418:+
LUAD	cis	rs2882667	0.638	rs2351905	ENSG00000253404.1	AC034243.1	10.91	6.78e-25	1.87e-21	0.56	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135641	chr5:138744434~138753309:-
LUAD	cis	rs7688540	0.511	rs6845131	ENSG00000275426.1	CH17-262A2.1	10.9	6.88e-25	1.89e-21	0.66	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:206358	chr4:149738~150317:+
LUAD	cis	rs9322193	0.923	rs12174035	ENSG00000216906.2	RP11-350J20.9	10.9	6.91e-25	1.9e-21	0.54	0.45	Lung cancer;	chr6:149763311	chr6:149904243~149906418:+
LUAD	cis	rs2739330	0.828	rs5760107	ENSG00000099984.9	GSTT2	-10.9	6.95e-25	1.91e-21	-0.54	-0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23980123~23983911:+
LUAD	cis	rs2739330	0.789	rs5760109	ENSG00000099984.9	GSTT2	-10.9	6.95e-25	1.91e-21	-0.54	-0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23980123~23983911:+
LUAD	cis	rs2283792	0.812	rs94194	ENSG00000224086.5	LL22NC03-86G7.1	-10.9	6.98e-25	1.92e-21	-0.41	-0.45	Multiple sclerosis;	chr22:21933937	chr22:21938293~21977632:+
LUAD	cis	rs11098499	0.954	rs6848389	ENSG00000245958.5	RP11-33B1.1	-10.9	7.14e-25	1.96e-21	-0.42	-0.45	Corneal astigmatism;	chr4:119481467	chr4:119454791~119552025:+
LUAD	cis	rs801193	0.569	rs6978178	ENSG00000226824.5	RP4-756H11.3	10.9	7.16e-25	1.97e-21	0.57	0.45	Aortic root size;	chr7:66658097	chr7:66654538~66669855:+
LUAD	cis	rs904251	0.828	rs2797803	ENSG00000279942.1	RP1-153P14.7	-10.9	7.19e-25	1.98e-21	-0.43	-0.45	Cognitive performance;	chr6:37519564	chr6:37567716~37571460:+
LUAD	cis	rs875971	0.862	rs908915	ENSG00000226824.5	RP4-756H11.3	10.9	7.22e-25	1.98e-21	0.56	0.45	Aortic root size;	chr7:66149664	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs7809814	ENSG00000226824.5	RP4-756H11.3	10.9	7.22e-25	1.98e-21	0.56	0.45	Aortic root size;	chr7:66150410	chr7:66654538~66669855:+
LUAD	cis	rs11098499	0.697	rs4560394	ENSG00000245958.5	RP11-33B1.1	-10.9	7.25e-25	1.99e-21	-0.42	-0.44	Corneal astigmatism;	chr4:119392280	chr4:119454791~119552025:+
LUAD	cis	rs9322193	0.923	rs9800686	ENSG00000216906.2	RP11-350J20.9	10.9	7.27e-25	2e-21	0.56	0.44	Lung cancer;	chr6:149634464	chr6:149904243~149906418:+
LUAD	cis	rs9399135	0.66	rs4646868	ENSG00000232876.1	CTA-212D2.2	-10.9	7.3e-25	2e-21	-0.5	-0.44	Red blood cell count;	chr6:134950808	chr6:135055033~135060550:+
LUAD	cis	rs6538678	0.864	rs7308921	ENSG00000199506.1	RNU6-247P	10.9	7.35e-25	2.02e-21	0.56	0.44	Lupus nephritis in systemic lupus erythematosus;	chr12:95870757	chr12:95792529~95792635:-
LUAD	cis	rs875971	0.862	rs709596	ENSG00000226824.5	RP4-756H11.3	-10.9	7.41e-25	2.03e-21	-0.57	-0.44	Aortic root size;	chr7:66360926	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs880166	ENSG00000226824.5	RP4-756H11.3	10.89	7.58e-25	2.08e-21	0.57	0.44	Aortic root size;	chr7:66205775	chr7:66654538~66669855:+
LUAD	cis	rs10129255	0.536	rs17113249	ENSG00000211972.2	IGHV3-66	10.89	7.77e-25	2.13e-21	0.35	0.44	Kawasaki disease;	chr14:106678273	chr14:106675017~106675544:-
LUAD	cis	rs9322193	0.923	rs7753812	ENSG00000216906.2	RP11-350J20.9	10.89	7.82e-25	2.14e-21	0.55	0.44	Lung cancer;	chr6:149690150	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs17745062	ENSG00000216906.2	RP11-350J20.9	10.89	7.82e-25	2.14e-21	0.54	0.44	Lung cancer;	chr6:149721079	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs62441279	ENSG00000216906.2	RP11-350J20.9	10.89	7.82e-25	2.14e-21	0.54	0.44	Lung cancer;	chr6:149721194	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs11155677	ENSG00000216906.2	RP11-350J20.9	10.89	7.91e-25	2.17e-21	0.53	0.44	Lung cancer;	chr6:149756953	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs12195866	ENSG00000216906.2	RP11-350J20.9	10.89	7.94e-25	2.18e-21	0.55	0.44	Lung cancer;	chr6:149693334	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.954	rs12502423	ENSG00000245958.5	RP11-33B1.1	-10.89	7.95e-25	2.18e-21	-0.42	-0.44	Corneal astigmatism;	chr4:119503017	chr4:119454791~119552025:+
LUAD	cis	rs875971	0.767	rs1643394	ENSG00000226824.5	RP4-756H11.3	-10.89	7.98e-25	2.19e-21	-0.57	-0.44	Aortic root size;	chr7:66371107	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.569	rs11772819	ENSG00000226824.5	RP4-756H11.3	-10.89	7.99e-25	2.19e-21	-0.57	-0.44	Aortic root size;	chr7:66752983	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.569	rs7800620	ENSG00000226824.5	RP4-756H11.3	-10.89	7.99e-25	2.19e-21	-0.57	-0.44	Aortic root size;	chr7:66758701	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.923	rs12529698	ENSG00000216906.2	RP11-350J20.9	10.89	8.02e-25	2.2e-21	0.54	0.44	Lung cancer;	chr6:149650951	chr6:149904243~149906418:+
LUAD	cis	rs904251	0.861	rs2776877	ENSG00000279942.1	RP1-153P14.7	-10.89	8.04e-25	2.2e-21	-0.43	-0.44	Cognitive performance;	chr6:37519359	chr6:37567716~37571460:+
LUAD	cis	rs904251	0.864	rs2797801	ENSG00000279942.1	RP1-153P14.7	-10.89	8.04e-25	2.2e-21	-0.43	-0.44	Cognitive performance;	chr6:37519385	chr6:37567716~37571460:+
LUAD	cis	rs904251	0.797	rs2776878	ENSG00000279942.1	RP1-153P14.7	-10.89	8.04e-25	2.2e-21	-0.43	-0.44	Cognitive performance;	chr6:37519497	chr6:37567716~37571460:+
LUAD	cis	rs9322193	0.923	rs9285524	ENSG00000216906.2	RP11-350J20.9	10.89	8.07e-25	2.21e-21	0.55	0.44	Lung cancer;	chr6:149694122	chr6:149904243~149906418:+
LUAD	cis	rs875971	0.862	rs2420174	ENSG00000226824.5	RP4-756H11.3	10.88	8.14e-25	2.23e-21	0.57	0.44	Aortic root size;	chr7:66180374	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs2420173	ENSG00000226824.5	RP4-756H11.3	10.88	8.14e-25	2.23e-21	0.57	0.44	Aortic root size;	chr7:66180412	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs4718319	ENSG00000226824.5	RP4-756H11.3	10.88	8.14e-25	2.23e-21	0.57	0.44	Aortic root size;	chr7:66187797	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.723	rs28391294	ENSG00000226824.5	RP4-756H11.3	10.88	8.14e-25	2.23e-21	0.57	0.44	Aortic root size;	chr7:66189328	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.83	rs6967708	ENSG00000226824.5	RP4-756H11.3	10.88	8.14e-25	2.23e-21	0.57	0.44	Aortic root size;	chr7:66192326	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.895	rs7782806	ENSG00000226824.5	RP4-756H11.3	10.88	8.14e-25	2.23e-21	0.57	0.44	Aortic root size;	chr7:66192910	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.566	rs3922947	ENSG00000231760.4	RP11-350J20.5	-10.88	8.22e-25	2.25e-21	-0.65	-0.44	Lung cancer;	chr6:149924856	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs9968911	ENSG00000216906.2	RP11-350J20.9	10.88	8.26e-25	2.26e-21	0.54	0.44	Lung cancer;	chr6:149657419	chr6:149904243~149906418:+
LUAD	cis	rs6452524	0.901	rs1842020	ENSG00000249664.1	CTD-2227C6.2	10.88	8.28e-25	2.27e-21	0.52	0.44	Hypertension (SNP x SNP interaction);	chr5:83125814	chr5:83012285~83013109:-
LUAD	cis	rs4423214	0.765	rs2002064	ENSG00000254682.1	RP11-660L16.2	-10.88	8.29e-25	2.27e-21	-0.64	-0.44	Vitamin D levels;	chr11:71452374	chr11:71448674~71452157:+
LUAD	cis	rs6782228	0.606	rs2811500	ENSG00000242551.2	POU5F1P6	-10.88	8.34e-25	2.28e-21	-0.5	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128647413	chr3:128674735~128677005:-
LUAD	cis	rs8040855	0.599	rs8037195	ENSG00000259295.5	CSPG4P12	-10.88	8.34e-25	2.28e-21	-0.52	-0.44	Bulimia nervosa;	chr15:85181455	chr15:85191438~85213905:+
LUAD	cis	rs6504950	0.83	rs12937006	ENSG00000275710.1	RP11-257O5.4	10.88	8.36e-25	2.29e-21	0.59	0.44	Breast cancer;	chr17:54953100	chr17:54964474~54964679:+
LUAD	cis	rs11098499	0.954	rs11729521	ENSG00000245958.5	RP11-33B1.1	-10.88	8.51e-25	2.33e-21	-0.42	-0.44	Corneal astigmatism;	chr4:119495633	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.865	rs28753180	ENSG00000245958.5	RP11-33B1.1	-10.88	8.6e-25	2.35e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119484212	chr4:119454791~119552025:+
LUAD	cis	rs507080	0.697	rs653008	ENSG00000255239.1	AP002954.6	10.88	8.61e-25	2.35e-21	0.55	0.44	Serum metabolite levels;	chr11:118649775	chr11:118688039~118690600:-
LUAD	cis	rs9322193	0.923	rs4354168	ENSG00000216906.2	RP11-350J20.9	10.88	8.62e-25	2.35e-21	0.54	0.44	Lung cancer;	chr6:149696642	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs4455682	ENSG00000216906.2	RP11-350J20.9	10.88	8.62e-25	2.35e-21	0.54	0.44	Lung cancer;	chr6:149700161	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.779	rs10011097	ENSG00000245958.5	RP11-33B1.1	-10.88	8.64e-25	2.36e-21	-0.42	-0.44	Corneal astigmatism;	chr4:119389204	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.908	rs2017057	ENSG00000245958.5	RP11-33B1.1	-10.88	8.66e-25	2.37e-21	-0.42	-0.44	Corneal astigmatism;	chr4:119336556	chr4:119454791~119552025:+
LUAD	cis	rs875971	0.893	rs62465470	ENSG00000226824.5	RP4-756H11.3	10.87	8.88e-25	2.42e-21	0.56	0.44	Aortic root size;	chr7:66136231	chr7:66654538~66669855:+
LUAD	cis	rs4728142	0.604	rs10229001	ENSG00000275106.1	RP11-309L24.10	-10.87	8.97e-25	2.45e-21	-0.54	-0.44	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128959343	chr7:128952527~128953316:-
LUAD	cis	rs9545047	1	rs2484345	ENSG00000227676.3	LINC01068	-10.87	8.99e-25	2.45e-21	-0.57	-0.44	Schizophrenia;	chr13:79427913	chr13:79566727~79571436:+
LUAD	cis	rs8040855	0.599	rs6496792	ENSG00000259295.5	CSPG4P12	-10.87	9.02e-25	2.46e-21	-0.52	-0.44	Bulimia nervosa;	chr15:85182514	chr15:85191438~85213905:+
LUAD	cis	rs8040855	0.599	rs6496793	ENSG00000259295.5	CSPG4P12	-10.87	9.02e-25	2.46e-21	-0.52	-0.44	Bulimia nervosa;	chr15:85182515	chr15:85191438~85213905:+
LUAD	cis	rs8040855	0.599	rs6496795	ENSG00000259295.5	CSPG4P12	-10.87	9.02e-25	2.46e-21	-0.52	-0.44	Bulimia nervosa;	chr15:85182622	chr15:85191438~85213905:+
LUAD	cis	rs8040855	0.599	rs4577058	ENSG00000259295.5	CSPG4P12	-10.87	9.02e-25	2.46e-21	-0.52	-0.44	Bulimia nervosa;	chr15:85183227	chr15:85191438~85213905:+
LUAD	cis	rs8040855	0.599	rs1964724	ENSG00000259295.5	CSPG4P12	-10.87	9.07e-25	2.47e-21	-0.52	-0.44	Bulimia nervosa;	chr15:85183269	chr15:85191438~85213905:+
LUAD	cis	rs2658782	0.526	rs7127240	ENSG00000279684.1	RP11-755E23.2	-10.87	9.21e-25	2.51e-21	-0.62	-0.44	Pulmonary function decline;	chr11:93451726	chr11:93286629~93288903:-
LUAD	cis	rs11098499	0.954	rs7436506	ENSG00000245958.5	RP11-33B1.1	-10.87	9.28e-25	2.52e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119472614	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.909	rs2127821	ENSG00000245958.5	RP11-33B1.1	-10.87	9.28e-25	2.52e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119473380	chr4:119454791~119552025:+
LUAD	cis	rs6452524	1	rs6452519	ENSG00000249664.1	CTD-2227C6.2	10.87	9.47e-25	2.58e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83133429	chr5:83012285~83013109:-
LUAD	cis	rs875971	0.862	rs11763189	ENSG00000226824.5	RP4-756H11.3	-10.87	9.51e-25	2.59e-21	-0.57	-0.44	Aortic root size;	chr7:66518542	chr7:66654538~66669855:+
LUAD	cis	rs4423214	0.84	rs1792235	ENSG00000254682.1	RP11-660L16.2	-10.87	9.52e-25	2.59e-21	-0.64	-0.44	Vitamin D levels;	chr11:71470427	chr11:71448674~71452157:+
LUAD	cis	rs4423214	0.84	rs1619577	ENSG00000254682.1	RP11-660L16.2	-10.87	9.52e-25	2.59e-21	-0.64	-0.44	Vitamin D levels;	chr11:71470439	chr11:71448674~71452157:+
LUAD	cis	rs4423214	0.84	rs1792234	ENSG00000254682.1	RP11-660L16.2	-10.87	9.52e-25	2.59e-21	-0.64	-0.44	Vitamin D levels;	chr11:71470972	chr11:71448674~71452157:+
LUAD	cis	rs977987	0.836	rs17685540	ENSG00000261783.1	RP11-252K23.2	-10.87	9.6e-25	2.61e-21	-0.59	-0.44	Dupuytren's disease;	chr16:75289942	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.836	rs4888376	ENSG00000261783.1	RP11-252K23.2	-10.87	9.62e-25	2.62e-21	-0.59	-0.44	Dupuytren's disease;	chr16:75288675	chr16:75379818~75381260:-
LUAD	cis	rs6452524	0.934	rs2940543	ENSG00000249664.1	CTD-2227C6.2	10.86	9.88e-25	2.68e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83187297	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs2974450	ENSG00000249664.1	CTD-2227C6.2	10.86	9.88e-25	2.68e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83187323	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs2974449	ENSG00000249664.1	CTD-2227C6.2	10.86	9.88e-25	2.68e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83187465	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs2662241	ENSG00000249664.1	CTD-2227C6.2	10.86	9.88e-25	2.68e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83188774	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.935	rs2940544	ENSG00000249664.1	CTD-2227C6.2	10.86	9.88e-25	2.68e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83189785	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs2731865	ENSG00000249664.1	CTD-2227C6.2	10.86	9.88e-25	2.68e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83190570	chr5:83012285~83013109:-
LUAD	cis	rs8040855	0.579	rs4843029	ENSG00000259295.5	CSPG4P12	-10.86	9.96e-25	2.71e-21	-0.52	-0.44	Bulimia nervosa;	chr15:85182164	chr15:85191438~85213905:+
LUAD	cis	rs1577917	0.958	rs11755048	ENSG00000203875.9	SNHG5	-10.86	1.01e-24	2.73e-21	-0.66	-0.44	Response to antipsychotic treatment;	chr6:85804616	chr6:85660950~85678736:-
LUAD	cis	rs7174755	0.961	rs1122247	ENSG00000260657.2	RP11-315D16.4	10.86	1.02e-24	2.76e-21	0.53	0.44	Major depressive disorder;	chr15:68302523	chr15:68267792~68277994:-
LUAD	cis	rs11098499	0.954	rs10008459	ENSG00000245958.5	RP11-33B1.1	-10.86	1.02e-24	2.76e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119473076	chr4:119454791~119552025:+
LUAD	cis	rs9322193	0.567	rs7747457	ENSG00000216906.2	RP11-350J20.9	10.86	1.02e-24	2.76e-21	0.55	0.44	Lung cancer;	chr6:149892366	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.618	rs28491261	ENSG00000245958.5	RP11-33B1.1	-10.86	1.02e-24	2.76e-21	-0.42	-0.44	Corneal astigmatism;	chr4:119373745	chr4:119454791~119552025:+
LUAD	cis	rs875971	0.862	rs13232191	ENSG00000226824.5	RP4-756H11.3	-10.86	1.02e-24	2.78e-21	-0.57	-0.44	Aortic root size;	chr7:66521661	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.923	rs55849538	ENSG00000216906.2	RP11-350J20.9	10.86	1.03e-24	2.78e-21	0.56	0.44	Lung cancer;	chr6:149635330	chr6:149904243~149906418:+
LUAD	cis	rs992157	0.764	rs4672886	ENSG00000261338.2	RP11-378A13.1	-10.86	1.03e-24	2.8e-21	-0.45	-0.44	Colorectal cancer;	chr2:218320822	chr2:218255319~218257366:+
LUAD	cis	rs9322193	0.607	rs915140	ENSG00000231760.4	RP11-350J20.5	10.86	1.03e-24	2.8e-21	0.68	0.44	Lung cancer;	chr6:149899674	chr6:149796151~149826294:-
LUAD	cis	rs6452524	1	rs6452526	ENSG00000249664.1	CTD-2227C6.2	10.86	1.03e-24	2.8e-21	0.51	0.44	Hypertension (SNP x SNP interaction);	chr5:83140992	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs6452527	ENSG00000249664.1	CTD-2227C6.2	10.86	1.03e-24	2.8e-21	0.51	0.44	Hypertension (SNP x SNP interaction);	chr5:83141021	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs10055844	ENSG00000249664.1	CTD-2227C6.2	10.86	1.03e-24	2.8e-21	0.51	0.44	Hypertension (SNP x SNP interaction);	chr5:83141276	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs10077862	ENSG00000249664.1	CTD-2227C6.2	10.86	1.03e-24	2.8e-21	0.51	0.44	Hypertension (SNP x SNP interaction);	chr5:83141322	chr5:83012285~83013109:-
LUAD	cis	rs2455601	0.638	rs11042148	ENSG00000254860.4	TMEM9B-AS1	10.86	1.04e-24	2.82e-21	0.6	0.44	Schizophrenia;	chr11:8987127	chr11:8964675~8977527:+
LUAD	cis	rs875971	0.862	rs9791712	ENSG00000226824.5	RP4-756H11.3	10.86	1.04e-24	2.82e-21	0.57	0.44	Aortic root size;	chr7:66640176	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs9791713	ENSG00000226824.5	RP4-756H11.3	10.86	1.04e-24	2.82e-21	0.57	0.44	Aortic root size;	chr7:66640211	chr7:66654538~66669855:+
LUAD	cis	rs977987	0.966	rs8055490	ENSG00000261783.1	RP11-252K23.2	-10.85	1.08e-24	2.92e-21	-0.6	-0.44	Dupuytren's disease;	chr16:75463237	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs7204984	ENSG00000261783.1	RP11-252K23.2	-10.85	1.09e-24	2.94e-21	-0.6	-0.44	Dupuytren's disease;	chr16:75441622	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.778	rs35214308	ENSG00000261783.1	RP11-252K23.2	-10.85	1.09e-24	2.94e-21	-0.6	-0.44	Dupuytren's disease;	chr16:75442190	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs4888425	ENSG00000261783.1	RP11-252K23.2	-10.85	1.09e-24	2.94e-21	-0.6	-0.44	Dupuytren's disease;	chr16:75442465	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.778	rs4888426	ENSG00000261783.1	RP11-252K23.2	-10.85	1.09e-24	2.94e-21	-0.6	-0.44	Dupuytren's disease;	chr16:75442553	chr16:75379818~75381260:-
LUAD	cis	rs6782228	0.585	rs2811492	ENSG00000242551.2	POU5F1P6	-10.85	1.1e-24	2.97e-21	-0.5	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128637436	chr3:128674735~128677005:-
LUAD	cis	rs4423214	0.84	rs1792315	ENSG00000254682.1	RP11-660L16.2	-10.85	1.1e-24	2.97e-21	-0.63	-0.44	Vitamin D levels;	chr11:71454501	chr11:71448674~71452157:+
LUAD	cis	rs9322193	0.923	rs66516768	ENSG00000216906.2	RP11-350J20.9	10.85	1.11e-24	3e-21	0.54	0.44	Lung cancer;	chr6:149671999	chr6:149904243~149906418:+
LUAD	cis	rs2581828	0.656	rs2581787	ENSG00000242142.1	SERBP1P3	10.85	1.11e-24	3e-21	0.46	0.44	Crohn's disease;	chr3:53093661	chr3:53064283~53065091:-
LUAD	cis	rs801193	0.569	rs2659893	ENSG00000226824.5	RP4-756H11.3	-10.85	1.11e-24	3.01e-21	-0.57	-0.44	Aortic root size;	chr7:66735006	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.569	rs2659892	ENSG00000226824.5	RP4-756H11.3	-10.85	1.11e-24	3.01e-21	-0.57	-0.44	Aortic root size;	chr7:66735318	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.548	rs2659891	ENSG00000226824.5	RP4-756H11.3	-10.85	1.11e-24	3.01e-21	-0.57	-0.44	Aortic root size;	chr7:66736127	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.569	rs2707847	ENSG00000226824.5	RP4-756H11.3	-10.85	1.11e-24	3.01e-21	-0.57	-0.44	Aortic root size;	chr7:66737884	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.548	rs7805152	ENSG00000226824.5	RP4-756H11.3	-10.85	1.11e-24	3.01e-21	-0.57	-0.44	Aortic root size;	chr7:66744266	chr7:66654538~66669855:+
LUAD	cis	rs2739330	0.734	rs2000467	ENSG00000250470.1	AP000351.3	-10.85	1.12e-24	3.03e-21	-0.57	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23976904~23977585:-
LUAD	cis	rs2882667	0.505	rs6596465	ENSG00000253404.1	AC034243.1	-10.85	1.14e-24	3.08e-21	-0.55	-0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139147337	chr5:138744434~138753309:-
LUAD	cis	rs2337406	0.81	rs7161739	ENSG00000274576.2	IGHV2-70	-10.85	1.14e-24	3.08e-21	-0.49	-0.44	Alzheimer's disease (late onset);	chr14:106776118	chr14:106770577~106771020:-
LUAD	cis	rs8040855	0.825	rs4843021	ENSG00000259295.5	CSPG4P12	-10.85	1.15e-24	3.09e-21	-0.57	-0.44	Bulimia nervosa;	chr15:85151317	chr15:85191438~85213905:+
LUAD	cis	rs9322193	0.884	rs9480009	ENSG00000216906.2	RP11-350J20.9	10.84	1.16e-24	3.13e-21	0.53	0.44	Lung cancer;	chr6:149758502	chr6:149904243~149906418:+
LUAD	cis	rs6452524	1	rs9986131	ENSG00000249664.1	CTD-2227C6.2	10.84	1.17e-24	3.14e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83149037	chr5:83012285~83013109:-
LUAD	cis	rs9322193	0.923	rs9383812	ENSG00000216906.2	RP11-350J20.9	10.84	1.18e-24	3.17e-21	0.54	0.44	Lung cancer;	chr6:149712355	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.847	rs9383844	ENSG00000216906.2	RP11-350J20.9	10.84	1.18e-24	3.17e-21	0.54	0.44	Lung cancer;	chr6:149716268	chr6:149904243~149906418:+
LUAD	cis	rs7688540	0.511	rs11735723	ENSG00000275426.1	CH17-262A2.1	10.84	1.18e-24	3.19e-21	0.68	0.44	Facial morphology (factor 6, height of vermillion lower lip);	chr4:205848	chr4:149738~150317:+
LUAD	cis	rs4423214	0.84	rs1792233	ENSG00000254682.1	RP11-660L16.2	-10.84	1.19e-24	3.19e-21	-0.64	-0.44	Vitamin D levels;	chr11:71471133	chr11:71448674~71452157:+
LUAD	cis	rs17507216	0.667	rs13379724	ENSG00000278603.1	RP13-608F4.5	10.84	1.19e-24	3.2e-21	0.6	0.44	Excessive daytime sleepiness;	chr15:82619892	chr15:82472203~82472426:+
LUAD	cis	rs977987	0.836	rs7200053	ENSG00000261783.1	RP11-252K23.2	-10.84	1.2e-24	3.22e-21	-0.6	-0.44	Dupuytren's disease;	chr16:75440720	chr16:75379818~75381260:-
LUAD	cis	rs6452524	1	rs1382372	ENSG00000249664.1	CTD-2227C6.2	10.84	1.21e-24	3.25e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83145237	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs1382371	ENSG00000249664.1	CTD-2227C6.2	10.84	1.21e-24	3.25e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83145300	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs2386240	ENSG00000249664.1	CTD-2227C6.2	10.84	1.21e-24	3.25e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83147192	chr5:83012285~83013109:-
LUAD	cis	rs9322193	1	rs9377229	ENSG00000216906.2	RP11-350J20.9	10.84	1.22e-24	3.28e-21	0.54	0.44	Lung cancer;	chr6:149607655	chr6:149904243~149906418:+
LUAD	cis	rs6538678	1	rs6538678	ENSG00000199506.1	RNU6-247P	-10.84	1.23e-24	3.29e-21	-0.6	-0.44	Lupus nephritis in systemic lupus erythematosus;	chr12:95867790	chr12:95792529~95792635:-
LUAD	cis	rs9322193	0.884	rs11155675	ENSG00000216906.2	RP11-350J20.9	10.84	1.23e-24	3.3e-21	0.57	0.44	Lung cancer;	chr6:149742883	chr6:149904243~149906418:+
LUAD	cis	rs3096299	0.685	rs8050512	ENSG00000274627.1	RP11-104N10.2	10.84	1.24e-24	3.32e-21	0.42	0.44	Multiple myeloma (IgH translocation);	chr16:89485912	chr16:89516797~89522217:+
LUAD	cis	rs9322193	0.962	rs12175575	ENSG00000216906.2	RP11-350J20.9	10.84	1.25e-24	3.36e-21	0.54	0.44	Lung cancer;	chr6:149763351	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs4869966	ENSG00000216906.2	RP11-350J20.9	10.84	1.25e-24	3.36e-21	0.54	0.44	Lung cancer;	chr6:149763714	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs1112730	ENSG00000216906.2	RP11-350J20.9	10.84	1.25e-24	3.36e-21	0.54	0.44	Lung cancer;	chr6:149766383	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs1112729	ENSG00000216906.2	RP11-350J20.9	10.84	1.25e-24	3.36e-21	0.54	0.44	Lung cancer;	chr6:149766491	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs10452626	ENSG00000216906.2	RP11-350J20.9	10.84	1.25e-24	3.36e-21	0.54	0.44	Lung cancer;	chr6:149767481	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs62441303	ENSG00000216906.2	RP11-350J20.9	10.84	1.25e-24	3.36e-21	0.54	0.44	Lung cancer;	chr6:149767547	chr6:149904243~149906418:+
LUAD	cis	rs977987	0.836	rs34673655	ENSG00000261783.1	RP11-252K23.2	-10.84	1.25e-24	3.36e-21	-0.59	-0.44	Dupuytren's disease;	chr16:75289661	chr16:75379818~75381260:-
LUAD	cis	rs11098499	0.954	rs3733523	ENSG00000245958.5	RP11-33B1.1	-10.84	1.25e-24	3.37e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119502564	chr4:119454791~119552025:+
LUAD	cis	rs904251	0.861	rs914349	ENSG00000279942.1	RP1-153P14.7	-10.84	1.26e-24	3.37e-21	-0.4	-0.44	Cognitive performance;	chr6:37516939	chr6:37567716~37571460:+
LUAD	cis	rs875971	0.862	rs10274883	ENSG00000226824.5	RP4-756H11.3	10.83	1.27e-24	3.42e-21	0.56	0.44	Aortic root size;	chr7:66651104	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.569	rs881285	ENSG00000226824.5	RP4-756H11.3	10.83	1.27e-24	3.42e-21	0.56	0.44	Aortic root size;	chr7:66654433	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.569	rs3846973	ENSG00000226824.5	RP4-756H11.3	10.83	1.27e-24	3.42e-21	0.56	0.44	Aortic root size;	chr7:66655048	chr7:66654538~66669855:+
LUAD	cis	rs801193	0.569	rs2013908	ENSG00000226824.5	RP4-756H11.3	10.83	1.27e-24	3.42e-21	0.56	0.44	Aortic root size;	chr7:66656082	chr7:66654538~66669855:+
LUAD	cis	rs6782228	0.606	rs2811497	ENSG00000242551.2	POU5F1P6	-10.83	1.29e-24	3.46e-21	-0.5	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128644489	chr3:128674735~128677005:-
LUAD	cis	rs2929278	0.617	rs575082	ENSG00000205771.5	CATSPER2P1	10.83	1.29e-24	3.47e-21	0.56	0.44	Schizophrenia;	chr15:43817944	chr15:43726918~43747094:-
LUAD	cis	rs2929278	0.617	rs2955969	ENSG00000205771.5	CATSPER2P1	10.83	1.29e-24	3.47e-21	0.56	0.44	Schizophrenia;	chr15:43822329	chr15:43726918~43747094:-
LUAD	cis	rs11155671	0.53	rs6557133	ENSG00000231760.4	RP11-350J20.5	10.83	1.31e-24	3.5e-21	0.54	0.44	Testicular germ cell tumor;	chr6:149874248	chr6:149796151~149826294:-
LUAD	cis	rs11098499	0.908	rs11098527	ENSG00000245958.5	RP11-33B1.1	-10.83	1.32e-24	3.54e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119478751	chr4:119454791~119552025:+
LUAD	cis	rs977987	0.933	rs4888431	ENSG00000261783.1	RP11-252K23.2	-10.83	1.33e-24	3.55e-21	-0.6	-0.44	Dupuytren's disease;	chr16:75466801	chr16:75379818~75381260:-
LUAD	cis	rs977987	1	rs62060550	ENSG00000261783.1	RP11-252K23.2	-10.83	1.33e-24	3.55e-21	-0.6	-0.44	Dupuytren's disease;	chr16:75468354	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.966	rs62060551	ENSG00000261783.1	RP11-252K23.2	-10.83	1.33e-24	3.55e-21	-0.6	-0.44	Dupuytren's disease;	chr16:75468414	chr16:75379818~75381260:-
LUAD	cis	rs9322193	0.924	rs9498382	ENSG00000216906.2	RP11-350J20.9	10.83	1.34e-24	3.59e-21	0.54	0.44	Lung cancer;	chr6:149610982	chr6:149904243~149906418:+
LUAD	cis	rs977987	0.806	rs12933281	ENSG00000261783.1	RP11-252K23.2	-10.83	1.36e-24	3.64e-21	-0.6	-0.44	Dupuytren's disease;	chr16:75449166	chr16:75379818~75381260:-
LUAD	cis	rs9322193	0.923	rs55993747	ENSG00000216906.2	RP11-350J20.9	10.83	1.37e-24	3.66e-21	0.54	0.44	Lung cancer;	chr6:149622016	chr6:149904243~149906418:+
LUAD	cis	rs2455601	0.638	rs2742478	ENSG00000254860.4	TMEM9B-AS1	10.83	1.37e-24	3.66e-21	0.59	0.44	Schizophrenia;	chr11:8974552	chr11:8964675~8977527:+
LUAD	cis	rs7208859	0.673	rs11657270	ENSG00000263531.1	RP13-753N3.1	10.83	1.37e-24	3.67e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887369	chr17:30863921~30864940:-
LUAD	cis	rs17507216	0.628	rs4513065	ENSG00000278603.1	RP13-608F4.5	10.82	1.38e-24	3.69e-21	0.64	0.44	Excessive daytime sleepiness;	chr15:82712096	chr15:82472203~82472426:+
LUAD	cis	rs11098499	0.954	rs10031483	ENSG00000245958.5	RP11-33B1.1	-10.82	1.38e-24	3.69e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119501481	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs10031665	ENSG00000245958.5	RP11-33B1.1	-10.82	1.38e-24	3.69e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119501697	chr4:119454791~119552025:+
LUAD	cis	rs10129255	0.5	rs2105991	ENSG00000211972.2	IGHV3-66	10.82	1.4e-24	3.73e-21	0.35	0.44	Kawasaki disease;	chr14:106682022	chr14:106675017~106675544:-
LUAD	cis	rs9322193	1	rs58189451	ENSG00000216906.2	RP11-350J20.9	10.82	1.4e-24	3.75e-21	0.55	0.44	Lung cancer;	chr6:149600252	chr6:149904243~149906418:+
LUAD	cis	rs7208859	0.673	rs9889968	ENSG00000263531.1	RP13-753N3.1	10.82	1.41e-24	3.76e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30893110	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs61348930	ENSG00000263531.1	RP13-753N3.1	10.82	1.41e-24	3.76e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30894745	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.614	rs28758251	ENSG00000263531.1	RP13-753N3.1	10.82	1.41e-24	3.76e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896294	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs9899943	ENSG00000263531.1	RP13-753N3.1	10.82	1.41e-24	3.76e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896907	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs11080138	ENSG00000263531.1	RP13-753N3.1	10.82	1.41e-24	3.76e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30897524	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs73265612	ENSG00000263531.1	RP13-753N3.1	10.82	1.41e-24	3.76e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30898965	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs2433	ENSG00000263531.1	RP13-753N3.1	10.82	1.41e-24	3.76e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30899210	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs11658435	ENSG00000263531.1	RP13-753N3.1	10.82	1.41e-24	3.76e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30901543	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs73265624	ENSG00000263531.1	RP13-753N3.1	10.82	1.41e-24	3.76e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905048	chr17:30863921~30864940:-
LUAD	cis	rs12130219	0.5	rs4845743	ENSG00000237975.5	FLG-AS1	-10.82	1.41e-24	3.77e-21	-0.53	-0.44	Inflammatory skin disease;	chr1:152211673	chr1:152168125~152445456:+
LUAD	cis	rs9322193	0.923	rs9371207	ENSG00000216906.2	RP11-350J20.9	10.82	1.41e-24	3.77e-21	0.57	0.44	Lung cancer;	chr6:149858087	chr6:149904243~149906418:+
LUAD	cis	rs2487048	0.725	rs2246293	ENSG00000226334.1	RP11-217B7.2	10.82	1.41e-24	3.78e-21	0.57	0.44	Intraocular pressure;	chr9:104928557	chr9:104927553~104928892:+
LUAD	cis	rs1729407	0.774	rs2849167	ENSG00000254851.1	RP11-109L13.1	10.82	1.43e-24	3.83e-21	0.55	0.44	Apolipoprotein A-IV levels;	chr11:116814028	chr11:117135528~117138582:+
LUAD	cis	rs6452524	0.508	rs40214	ENSG00000249664.1	CTD-2227C6.2	-10.82	1.45e-24	3.86e-21	-0.52	-0.44	Hypertension (SNP x SNP interaction);	chr5:83000359	chr5:83012285~83013109:-
LUAD	cis	rs11155671	0.53	rs9371542	ENSG00000216906.2	RP11-350J20.9	10.82	1.45e-24	3.88e-21	0.54	0.44	Testicular germ cell tumor;	chr6:149891949	chr6:149904243~149906418:+
LUAD	cis	rs11155671	0.53	rs9371223	ENSG00000216906.2	RP11-350J20.9	10.82	1.45e-24	3.88e-21	0.54	0.44	Testicular germ cell tumor;	chr6:149893670	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs2880436	ENSG00000216906.2	RP11-350J20.9	10.82	1.47e-24	3.91e-21	0.57	0.44	Lung cancer;	chr6:149859123	chr6:149904243~149906418:+
LUAD	cis	rs977987	0.8	rs1011121	ENSG00000261783.1	RP11-252K23.2	-10.82	1.47e-24	3.91e-21	-0.59	-0.44	Dupuytren's disease;	chr16:75292035	chr16:75379818~75381260:-
LUAD	cis	rs9545047	0.967	rs9318627	ENSG00000227676.3	LINC01068	10.82	1.47e-24	3.92e-21	0.57	0.44	Schizophrenia;	chr13:79355944	chr13:79566727~79571436:+
LUAD	cis	rs9545047	1	rs9574418	ENSG00000227676.3	LINC01068	10.82	1.47e-24	3.93e-21	0.57	0.44	Schizophrenia;	chr13:79393874	chr13:79566727~79571436:+
LUAD	cis	rs977987	0.966	rs11643207	ENSG00000261783.1	RP11-252K23.2	-10.82	1.48e-24	3.94e-21	-0.6	-0.44	Dupuytren's disease;	chr16:75464895	chr16:75379818~75381260:-
LUAD	cis	rs801193	0.569	rs11761542	ENSG00000226824.5	RP4-756H11.3	-10.82	1.48e-24	3.95e-21	-0.57	-0.44	Aortic root size;	chr7:66753209	chr7:66654538~66669855:+
LUAD	cis	rs6782228	0.606	rs1697	ENSG00000242551.2	POU5F1P6	-10.82	1.48e-24	3.95e-21	-0.5	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128638009	chr3:128674735~128677005:-
LUAD	cis	rs6782228	0.585	rs3122175	ENSG00000242551.2	POU5F1P6	-10.82	1.48e-24	3.95e-21	-0.5	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642433	chr3:128674735~128677005:-
LUAD	cis	rs10129255	0.518	rs10150460	ENSG00000211972.2	IGHV3-66	-10.82	1.48e-24	3.96e-21	-0.35	-0.44	Kawasaki disease;	chr14:106677179	chr14:106675017~106675544:-
LUAD	cis	rs11098499	0.865	rs9994730	ENSG00000245958.5	RP11-33B1.1	-10.82	1.5e-24	4e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119460409	chr4:119454791~119552025:+
LUAD	cis	rs11723261	0.582	rs3747693	ENSG00000275426.1	CH17-262A2.1	10.81	1.51e-24	4.02e-21	0.63	0.44	Immune response to smallpox vaccine (IL-6);	chr4:124493	chr4:149738~150317:+
LUAD	cis	rs875971	0.862	rs13536	ENSG00000226824.5	RP4-756H11.3	10.81	1.52e-24	4.04e-21	0.57	0.44	Aortic root size;	chr7:66554203	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs801209	ENSG00000226824.5	RP4-756H11.3	10.81	1.52e-24	4.04e-21	0.57	0.44	Aortic root size;	chr7:66554403	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs801206	ENSG00000226824.5	RP4-756H11.3	10.81	1.52e-24	4.04e-21	0.57	0.44	Aortic root size;	chr7:66556979	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs801204	ENSG00000226824.5	RP4-756H11.3	10.81	1.52e-24	4.04e-21	0.57	0.44	Aortic root size;	chr7:66557934	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs801203	ENSG00000226824.5	RP4-756H11.3	10.81	1.52e-24	4.04e-21	0.57	0.44	Aortic root size;	chr7:66558025	chr7:66654538~66669855:+
LUAD	cis	rs694739	1	rs11231757	ENSG00000236935.1	AP003774.1	10.81	1.52e-24	4.04e-21	0.43	0.44	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64338845	chr11:64325050~64329504:-
LUAD	cis	rs6538678	0.833	rs10859966	ENSG00000199506.1	RNU6-247P	10.81	1.52e-24	4.05e-21	0.54	0.44	Lupus nephritis in systemic lupus erythematosus;	chr12:95859597	chr12:95792529~95792635:-
LUAD	cis	rs875971	0.825	rs28480509	ENSG00000226824.5	RP4-756H11.3	10.81	1.53e-24	4.06e-21	0.57	0.44	Aortic root size;	chr7:66634237	chr7:66654538~66669855:+
LUAD	cis	rs8062405	0.965	rs8049439	ENSG00000259982.1	CDC37P1	10.81	1.54e-24	4.09e-21	0.56	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28700294~28701540:-
LUAD	cis	rs6504950	0.705	rs9899602	ENSG00000275710.1	RP11-257O5.4	-10.81	1.55e-24	4.14e-21	-0.57	-0.44	Breast cancer;	chr17:54909547	chr17:54964474~54964679:+
LUAD	cis	rs7208859	0.673	rs73277967	ENSG00000263531.1	RP13-753N3.1	10.81	1.57e-24	4.17e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30857148	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs60020217	ENSG00000263531.1	RP13-753N3.1	10.81	1.57e-24	4.17e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30858036	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.573	rs73277974	ENSG00000263531.1	RP13-753N3.1	10.81	1.57e-24	4.17e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862851	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs73277978	ENSG00000263531.1	RP13-753N3.1	10.81	1.57e-24	4.17e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864431	chr17:30863921~30864940:-
LUAD	cis	rs17826219	0.706	rs9905827	ENSG00000263531.1	RP13-753N3.1	10.81	1.57e-24	4.17e-21	0.93	0.44	Body mass index;	chr17:30865150	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs11657391	ENSG00000263531.1	RP13-753N3.1	10.81	1.57e-24	4.17e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30867269	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs58089675	ENSG00000263531.1	RP13-753N3.1	10.81	1.57e-24	4.17e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869746	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs73263755	ENSG00000263531.1	RP13-753N3.1	10.81	1.57e-24	4.17e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30871954	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs9899349	ENSG00000263531.1	RP13-753N3.1	10.81	1.57e-24	4.17e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30873104	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs11652358	ENSG00000263531.1	RP13-753N3.1	10.81	1.57e-24	4.17e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30878462	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs11656845	ENSG00000263531.1	RP13-753N3.1	10.81	1.57e-24	4.17e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30879146	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs9891179	ENSG00000263531.1	RP13-753N3.1	10.81	1.57e-24	4.17e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881142	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs9891413	ENSG00000263531.1	RP13-753N3.1	10.81	1.57e-24	4.17e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881191	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs73263776	ENSG00000263531.1	RP13-753N3.1	10.81	1.57e-24	4.17e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30884313	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs11650271	ENSG00000263531.1	RP13-753N3.1	10.81	1.57e-24	4.17e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30886925	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs73263785	ENSG00000263531.1	RP13-753N3.1	10.81	1.57e-24	4.17e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887790	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs55904046	ENSG00000263531.1	RP13-753N3.1	10.81	1.57e-24	4.17e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888373	chr17:30863921~30864940:-
LUAD	cis	rs6504950	0.8	rs35647022	ENSG00000275710.1	RP11-257O5.4	10.81	1.57e-24	4.17e-21	0.59	0.44	Breast cancer;	chr17:54930710	chr17:54964474~54964679:+
LUAD	cis	rs3096299	0.719	rs2965817	ENSG00000274627.1	RP11-104N10.2	10.81	1.58e-24	4.18e-21	0.42	0.44	Multiple myeloma (IgH translocation);	chr16:89446826	chr16:89516797~89522217:+
LUAD	cis	rs7208859	0.673	rs2269915	ENSG00000263531.1	RP13-753N3.1	10.81	1.58e-24	4.19e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906326	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs2269916	ENSG00000263531.1	RP13-753N3.1	10.81	1.58e-24	4.19e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906745	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs11649765	ENSG00000263531.1	RP13-753N3.1	10.81	1.58e-24	4.19e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906870	chr17:30863921~30864940:-
LUAD	cis	rs2739330	0.828	rs4822454	ENSG00000099984.9	GSTT2	-10.81	1.59e-24	4.21e-21	-0.54	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23980123~23983911:+
LUAD	cis	rs9322193	0.923	rs4870529	ENSG00000216906.2	RP11-350J20.9	10.81	1.59e-24	4.21e-21	0.53	0.44	Lung cancer;	chr6:149716436	chr6:149904243~149906418:+
LUAD	cis	rs4423214	0.879	rs1792283	ENSG00000254682.1	RP11-660L16.2	-10.81	1.59e-24	4.22e-21	-0.62	-0.44	Vitamin D levels;	chr11:71424090	chr11:71448674~71452157:+
LUAD	cis	rs4423214	0.879	rs1792282	ENSG00000254682.1	RP11-660L16.2	-10.81	1.59e-24	4.22e-21	-0.62	-0.44	Vitamin D levels;	chr11:71424120	chr11:71448674~71452157:+
LUAD	cis	rs7396835	0.741	rs7396851	ENSG00000254851.1	RP11-109L13.1	10.81	1.6e-24	4.24e-21	0.71	0.44	Quantitative traits;	chr11:116813448	chr11:117135528~117138582:+
LUAD	cis	rs801193	0.569	rs13226966	ENSG00000226824.5	RP4-756H11.3	-10.81	1.62e-24	4.3e-21	-0.57	-0.44	Aortic root size;	chr7:66768636	chr7:66654538~66669855:+
LUAD	cis	rs8040855	0.599	rs6496800	ENSG00000259295.5	CSPG4P12	-10.8	1.65e-24	4.37e-21	-0.51	-0.44	Bulimia nervosa;	chr15:85185055	chr15:85191438~85213905:+
LUAD	cis	rs73086581	0.617	rs2300213	ENSG00000229539.1	RP11-119B16.2	-10.8	1.66e-24	4.38e-21	-0.53	-0.44	Response to antidepressants in depression;	chr20:4006076	chr20:3888239~3888868:-
LUAD	cis	rs10129255	0.5	rs10143242	ENSG00000211972.2	IGHV3-66	10.8	1.68e-24	4.43e-21	0.35	0.44	Kawasaki disease;	chr14:106681814	chr14:106675017~106675544:-
LUAD	cis	rs4423214	1	rs3750997	ENSG00000254682.1	RP11-660L16.2	10.8	1.69e-24	4.47e-21	0.58	0.44	Vitamin D levels;	chr11:71447795	chr11:71448674~71452157:+
LUAD	cis	rs9322193	0.884	rs9688699	ENSG00000216906.2	RP11-350J20.9	10.8	1.7e-24	4.49e-21	0.54	0.44	Lung cancer;	chr6:149733680	chr6:149904243~149906418:+
LUAD	cis	rs694739	0.894	rs887314	ENSG00000236935.1	AP003774.1	10.8	1.7e-24	4.51e-21	0.44	0.44	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64285685	chr11:64325050~64329504:-
LUAD	cis	rs11098499	0.954	rs10006525	ENSG00000245958.5	RP11-33B1.1	-10.8	1.71e-24	4.51e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119487776	chr4:119454791~119552025:+
LUAD	cis	rs748404	0.66	rs518288	ENSG00000205771.5	CATSPER2P1	-10.8	1.72e-24	4.56e-21	-0.56	-0.44	Lung cancer;	chr15:43471801	chr15:43726918~43747094:-
LUAD	cis	rs977987	0.835	rs8046109	ENSG00000261783.1	RP11-252K23.2	-10.8	1.73e-24	4.57e-21	-0.58	-0.44	Dupuytren's disease;	chr16:75326198	chr16:75379818~75381260:-
LUAD	cis	rs3096299	0.642	rs12934829	ENSG00000274627.1	RP11-104N10.2	10.8	1.73e-24	4.58e-21	0.42	0.44	Multiple myeloma (IgH translocation);	chr16:89456941	chr16:89516797~89522217:+
LUAD	cis	rs2739330	0.929	rs5751775	ENSG00000099984.9	GSTT2	-10.8	1.76e-24	4.65e-21	-0.53	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23980123~23983911:+
LUAD	cis	rs6504950	0.72	rs9914596	ENSG00000275710.1	RP11-257O5.4	10.8	1.78e-24	4.69e-21	0.57	0.44	Breast cancer;	chr17:54919190	chr17:54964474~54964679:+
LUAD	cis	rs11155671	0.53	rs2342769	ENSG00000216906.2	RP11-350J20.9	10.8	1.78e-24	4.69e-21	0.54	0.44	Testicular germ cell tumor;	chr6:149895371	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.954	rs17006190	ENSG00000245958.5	RP11-33B1.1	-10.79	1.8e-24	4.74e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119497683	chr4:119454791~119552025:+
LUAD	cis	rs4853012	1	rs2280643	ENSG00000217702.2	RP11-287D1.4	10.79	1.82e-24	4.8e-21	0.71	0.44	Gestational age at birth (maternal effect);	chr2:74131159	chr2:74130583~74135395:+
LUAD	cis	rs4853012	0.887	rs2280644	ENSG00000217702.2	RP11-287D1.4	10.79	1.82e-24	4.8e-21	0.71	0.44	Gestational age at birth (maternal effect);	chr2:74131284	chr2:74130583~74135395:+
LUAD	cis	rs10256972	0.567	rs7782651	ENSG00000229043.2	AC091729.9	-10.79	1.83e-24	4.83e-21	-0.49	-0.44	Endometriosis;Longevity;	chr7:1120259	chr7:1160374~1165267:+
LUAD	cis	rs6504950	0.83	rs12936860	ENSG00000275710.1	RP11-257O5.4	10.79	1.83e-24	4.83e-21	0.57	0.44	Breast cancer;	chr17:54952865	chr17:54964474~54964679:+
LUAD	cis	rs62229266	0.771	rs11701590	ENSG00000231106.2	LINC01436	10.79	1.84e-24	4.85e-21	0.61	0.44	Mitral valve prolapse;	chr21:36012432	chr21:36005338~36007838:+
LUAD	cis	rs507080	0.697	rs653008	ENSG00000255422.1	AP002954.4	-10.79	1.85e-24	4.87e-21	-0.57	-0.44	Serum metabolite levels;	chr11:118649775	chr11:118704607~118750263:+
LUAD	cis	rs2739330	0.796	rs5760097	ENSG00000099984.9	GSTT2	-10.79	1.85e-24	4.89e-21	-0.54	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23980123~23983911:+
LUAD	cis	rs7208859	0.673	rs12103759	ENSG00000263531.1	RP13-753N3.1	10.79	1.87e-24	4.92e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908669	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs59029591	ENSG00000263531.1	RP13-753N3.1	10.79	1.87e-24	4.92e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908728	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs73265633	ENSG00000263531.1	RP13-753N3.1	10.79	1.87e-24	4.92e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30909288	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs9911989	ENSG00000263531.1	RP13-753N3.1	-10.79	1.87e-24	4.93e-21	-0.91	-0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30863921~30864940:-
LUAD	cis	rs3096299	0.632	rs8051537	ENSG00000274627.1	RP11-104N10.2	10.79	1.88e-24	4.95e-21	0.42	0.44	Multiple myeloma (IgH translocation);	chr16:89477976	chr16:89516797~89522217:+
LUAD	cis	rs9322193	0.566	rs6912330	ENSG00000231760.4	RP11-350J20.5	-10.79	1.9e-24	5e-21	-0.66	-0.44	Lung cancer;	chr6:149908811	chr6:149796151~149826294:-
LUAD	cis	rs1577917	1	rs11758849	ENSG00000203875.9	SNHG5	-10.79	1.9e-24	5.01e-21	-0.62	-0.44	Response to antipsychotic treatment;	chr6:85998544	chr6:85660950~85678736:-
LUAD	cis	rs7208859	0.673	rs17826219	ENSG00000263531.1	RP13-753N3.1	10.79	1.92e-24	5.05e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834827	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs61223749	ENSG00000263531.1	RP13-753N3.1	10.79	1.92e-24	5.05e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30836729	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs3764420	ENSG00000263531.1	RP13-753N3.1	10.79	1.92e-24	5.05e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837136	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs3764421	ENSG00000263531.1	RP13-753N3.1	10.79	1.92e-24	5.05e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30840635	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs11651858	ENSG00000263531.1	RP13-753N3.1	10.79	1.92e-24	5.05e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843700	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs36056619	ENSG00000263531.1	RP13-753N3.1	10.79	1.92e-24	5.05e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30845266	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs9909497	ENSG00000263531.1	RP13-753N3.1	10.79	1.92e-24	5.05e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846210	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs11080135	ENSG00000263531.1	RP13-753N3.1	10.79	1.92e-24	5.05e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30849463	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs9894876	ENSG00000263531.1	RP13-753N3.1	10.79	1.92e-24	5.05e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855002	chr17:30863921~30864940:-
LUAD	cis	rs2739330	0.828	rs5760102	ENSG00000099984.9	GSTT2	-10.79	1.94e-24	5.09e-21	-0.54	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23980123~23983911:+
LUAD	cis	rs6782228	0.509	rs2811495	ENSG00000242551.2	POU5F1P6	-10.79	1.95e-24	5.12e-21	-0.5	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641114	chr3:128674735~128677005:-
LUAD	cis	rs6782228	0.565	rs2811496	ENSG00000242551.2	POU5F1P6	-10.79	1.95e-24	5.12e-21	-0.5	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641115	chr3:128674735~128677005:-
LUAD	cis	rs62388641	0.813	rs62390562	ENSG00000272279.1	RP11-157J24.2	10.79	1.95e-24	5.13e-21	0.66	0.44	Daytime sleep phenotypes;	chr6:1551467	chr6:1528364~1528911:-
LUAD	cis	rs4728142	0.604	rs10239340	ENSG00000275106.1	RP11-309L24.10	-10.78	1.96e-24	5.15e-21	-0.53	-0.44	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129028456	chr7:128952527~128953316:-
LUAD	cis	rs8062405	0.824	rs4788085	ENSG00000259982.1	CDC37P1	10.78	1.97e-24	5.17e-21	0.55	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.824	rs28772958	ENSG00000259982.1	CDC37P1	10.78	1.97e-24	5.17e-21	0.55	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28700294~28701540:-
LUAD	cis	rs875971	0.756	rs2901210	ENSG00000226824.5	RP4-756H11.3	10.78	1.97e-24	5.18e-21	0.57	0.44	Aortic root size;	chr7:66552518	chr7:66654538~66669855:+
LUAD	cis	rs6964833	1	rs34324835	ENSG00000277053.3	GTF2IP1	-10.78	1.99e-24	5.23e-21	-0.64	-0.44	Menarche (age at onset);	chr7:74717986	chr7:75185385~75237696:-
LUAD	cis	rs977987	0.778	rs4243112	ENSG00000261783.1	RP11-252K23.2	-10.78	1.99e-24	5.23e-21	-0.59	-0.44	Dupuytren's disease;	chr16:75287133	chr16:75379818~75381260:-
LUAD	cis	rs2739330	0.828	rs4822451	ENSG00000099984.9	GSTT2	-10.78	2.01e-24	5.27e-21	-0.54	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23980123~23983911:+
LUAD	cis	rs2739330	0.828	rs5760098	ENSG00000099984.9	GSTT2	-10.78	2.01e-24	5.27e-21	-0.54	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23980123~23983911:+
LUAD	cis	rs748404	0.66	rs548704	ENSG00000205771.5	CATSPER2P1	-10.78	2.01e-24	5.27e-21	-0.56	-0.44	Lung cancer;	chr15:43499508	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.69	rs2924369	ENSG00000205771.5	CATSPER2P1	10.78	2.01e-24	5.28e-21	0.56	0.44	Lung cancer;	chr15:43485787	chr15:43726918~43747094:-
LUAD	cis	rs73086581	0.898	rs11906452	ENSG00000229539.1	RP11-119B16.2	10.78	2.02e-24	5.3e-21	0.61	0.44	Response to antidepressants in depression;	chr20:4000912	chr20:3888239~3888868:-
LUAD	cis	rs6452524	0.967	rs2974444	ENSG00000249664.1	CTD-2227C6.2	10.78	2.03e-24	5.33e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83185174	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs2940542	ENSG00000249664.1	CTD-2227C6.2	10.78	2.03e-24	5.33e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83185734	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs2731861	ENSG00000249664.1	CTD-2227C6.2	10.78	2.03e-24	5.33e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83189445	chr5:83012285~83013109:-
LUAD	cis	rs11098499	0.954	rs10017543	ENSG00000245958.5	RP11-33B1.1	-10.78	2.06e-24	5.39e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119400265	chr4:119454791~119552025:+
LUAD	cis	rs748404	0.66	rs690446	ENSG00000205771.5	CATSPER2P1	-10.78	2.07e-24	5.42e-21	-0.56	-0.44	Lung cancer;	chr15:43469066	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.631	rs560191	ENSG00000205771.5	CATSPER2P1	-10.78	2.07e-24	5.42e-21	-0.56	-0.44	Lung cancer;	chr15:43475576	chr15:43726918~43747094:-
LUAD	cis	rs9322193	0.923	rs9767309	ENSG00000216906.2	RP11-350J20.9	10.78	2.08e-24	5.45e-21	0.53	0.44	Lung cancer;	chr6:149716807	chr6:149904243~149906418:+
LUAD	cis	rs4423214	0.84	rs1790339	ENSG00000254682.1	RP11-660L16.2	-10.78	2.1e-24	5.5e-21	-0.63	-0.44	Vitamin D levels;	chr11:71471715	chr11:71448674~71452157:+
LUAD	cis	rs977987	0.836	rs7198873	ENSG00000261783.1	RP11-252K23.2	-10.78	2.13e-24	5.57e-21	-0.59	-0.44	Dupuytren's disease;	chr16:75440856	chr16:75379818~75381260:-
LUAD	cis	rs11098499	0.954	rs10034623	ENSG00000245958.5	RP11-33B1.1	-10.78	2.13e-24	5.57e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119476674	chr4:119454791~119552025:+
LUAD	cis	rs11155671	0.53	rs7756850	ENSG00000216906.2	RP11-350J20.9	10.77	2.15e-24	5.62e-21	0.54	0.44	Testicular germ cell tumor;	chr6:149891460	chr6:149904243~149906418:+
LUAD	cis	rs4728142	0.564	rs10954213	ENSG00000275106.1	RP11-309L24.10	-10.77	2.17e-24	5.67e-21	-0.54	-0.44	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128949373	chr7:128952527~128953316:-
LUAD	cis	rs4728142	0.604	rs13242262	ENSG00000275106.1	RP11-309L24.10	-10.77	2.17e-24	5.67e-21	-0.54	-0.44	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128951310	chr7:128952527~128953316:-
LUAD	cis	rs875971	0.862	rs6947339	ENSG00000226824.5	RP4-756H11.3	-10.77	2.19e-24	5.72e-21	-0.57	-0.44	Aortic root size;	chr7:66423483	chr7:66654538~66669855:+
LUAD	cis	rs748404	0.69	rs2244981	ENSG00000205771.5	CATSPER2P1	-10.77	2.2e-24	5.76e-21	-0.56	-0.44	Lung cancer;	chr15:43460553	chr15:43726918~43747094:-
LUAD	cis	rs73086581	0.838	rs41398349	ENSG00000229539.1	RP11-119B16.2	-10.77	2.22e-24	5.79e-21	-0.63	-0.44	Response to antidepressants in depression;	chr20:4043792	chr20:3888239~3888868:-
LUAD	cis	rs875971	0.862	rs778734	ENSG00000226824.5	RP4-756H11.3	-10.77	2.22e-24	5.79e-21	-0.57	-0.44	Aortic root size;	chr7:66349862	chr7:66654538~66669855:+
LUAD	cis	rs8062405	0.789	rs2106480	ENSG00000259982.1	CDC37P1	10.77	2.23e-24	5.83e-21	0.55	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.824	rs153106	ENSG00000259982.1	CDC37P1	10.77	2.25e-24	5.87e-21	0.56	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28700294~28701540:-
LUAD	cis	rs11098499	0.954	rs3890049	ENSG00000245958.5	RP11-33B1.1	-10.77	2.25e-24	5.88e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119405128	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs71629403	ENSG00000245958.5	RP11-33B1.1	-10.77	2.25e-24	5.88e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119451412	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.909	rs28571712	ENSG00000245958.5	RP11-33B1.1	-10.77	2.25e-24	5.88e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119454825	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.909	rs9759478	ENSG00000245958.5	RP11-33B1.1	-10.77	2.27e-24	5.92e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119446843	chr4:119454791~119552025:+
LUAD	cis	rs875971	0.862	rs4368860	ENSG00000226824.5	RP4-756H11.3	10.77	2.28e-24	5.94e-21	0.56	0.44	Aortic root size;	chr7:66143495	chr7:66654538~66669855:+
LUAD	cis	rs7208859	0.673	rs9913782	ENSG00000263531.1	RP13-753N3.1	10.77	2.28e-24	5.94e-21	0.93	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910366	chr17:30863921~30864940:-
LUAD	cis	rs6538678	0.824	rs7307510	ENSG00000199506.1	RNU6-247P	-10.77	2.31e-24	6.01e-21	-0.63	-0.44	Lupus nephritis in systemic lupus erythematosus;	chr12:95843792	chr12:95792529~95792635:-
LUAD	cis	rs6504950	0.72	rs28564882	ENSG00000275710.1	RP11-257O5.4	10.76	2.4e-24	6.25e-21	0.57	0.44	Breast cancer;	chr17:54912237	chr17:54964474~54964679:+
LUAD	cis	rs875971	0.862	rs7783779	ENSG00000226824.5	RP4-756H11.3	10.76	2.41e-24	6.27e-21	0.57	0.44	Aortic root size;	chr7:66331639	chr7:66654538~66669855:+
LUAD	cis	rs6782228	0.527	rs7426806	ENSG00000242551.2	POU5F1P6	-10.76	2.42e-24	6.29e-21	-0.49	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694087	chr3:128674735~128677005:-
LUAD	cis	rs9322193	0.847	rs12191643	ENSG00000216906.2	RP11-350J20.9	10.76	2.43e-24	6.31e-21	0.54	0.44	Lung cancer;	chr6:149628912	chr6:149904243~149906418:+
LUAD	cis	rs2455601	0.671	rs2568091	ENSG00000254860.4	TMEM9B-AS1	10.76	2.43e-24	6.32e-21	0.6	0.44	Schizophrenia;	chr11:8964501	chr11:8964675~8977527:+
LUAD	cis	rs9322193	0.566	rs9397070	ENSG00000231760.4	RP11-350J20.5	-10.76	2.44e-24	6.34e-21	-0.65	-0.44	Lung cancer;	chr6:149922073	chr6:149796151~149826294:-
LUAD	cis	rs2739330	0.828	rs5760099	ENSG00000099984.9	GSTT2	-10.76	2.44e-24	6.34e-21	-0.54	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23980123~23983911:+
LUAD	cis	rs6452524	1	rs2126990	ENSG00000249664.1	CTD-2227C6.2	10.76	2.47e-24	6.42e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83161351	chr5:83012285~83013109:-
LUAD	cis	rs11118620	0.853	rs11118622	ENSG00000238078.1	LINC01352	10.75	2.54e-24	6.61e-21	0.54	0.44	Heart failure;	chr1:220868833	chr1:220829255~220832429:+
LUAD	cis	rs992157	0.764	rs10932774	ENSG00000261338.2	RP11-378A13.1	10.75	2.69e-24	6.97e-21	0.46	0.44	Colorectal cancer;	chr2:218326846	chr2:218255319~218257366:+
LUAD	cis	rs2739330	0.929	rs5751777	ENSG00000099984.9	GSTT2	-10.75	2.7e-24	7e-21	-0.52	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23980123~23983911:+
LUAD	cis	rs801193	0.569	rs13242290	ENSG00000226824.5	RP4-756H11.3	10.75	2.77e-24	7.17e-21	0.56	0.44	Aortic root size;	chr7:66656898	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.607	rs9371228	ENSG00000231760.4	RP11-350J20.5	-10.74	2.79e-24	7.22e-21	-0.65	-0.44	Lung cancer;	chr6:149921977	chr6:149796151~149826294:-
LUAD	cis	rs6452524	1	rs4591730	ENSG00000249664.1	CTD-2227C6.2	10.74	2.79e-24	7.24e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83151983	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs1031902	ENSG00000249664.1	CTD-2227C6.2	10.74	2.79e-24	7.24e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83152308	chr5:83012285~83013109:-
LUAD	cis	rs9322193	0.923	rs9800871	ENSG00000216906.2	RP11-350J20.9	10.74	2.79e-24	7.24e-21	0.54	0.44	Lung cancer;	chr6:149644540	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs9800614	ENSG00000216906.2	RP11-350J20.9	10.74	2.79e-24	7.24e-21	0.54	0.44	Lung cancer;	chr6:149644604	chr6:149904243~149906418:+
LUAD	cis	rs3096299	0.685	rs3803682	ENSG00000274627.1	RP11-104N10.2	10.74	2.82e-24	7.3e-21	0.42	0.44	Multiple myeloma (IgH translocation);	chr16:89478228	chr16:89516797~89522217:+
LUAD	cis	rs3096299	0.685	rs3803681	ENSG00000274627.1	RP11-104N10.2	10.74	2.83e-24	7.32e-21	0.42	0.44	Multiple myeloma (IgH translocation);	chr16:89478348	chr16:89516797~89522217:+
LUAD	cis	rs73086581	0.68	rs11908158	ENSG00000229539.1	RP11-119B16.2	10.74	2.83e-24	7.32e-21	0.64	0.44	Response to antidepressants in depression;	chr20:3956025	chr20:3888239~3888868:-
LUAD	cis	rs2739330	0.796	rs1006771	ENSG00000250470.1	AP000351.3	10.74	2.83e-24	7.33e-21	0.56	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23976904~23977585:-
LUAD	cis	rs11098499	0.58	rs12509234	ENSG00000245958.5	RP11-33B1.1	-10.74	2.84e-24	7.36e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119398279	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.909	rs10014719	ENSG00000245958.5	RP11-33B1.1	-10.74	2.84e-24	7.36e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119399560	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.908	rs7696649	ENSG00000245958.5	RP11-33B1.1	-10.74	2.84e-24	7.36e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119401022	chr4:119454791~119552025:+
LUAD	cis	rs4423214	0.84	rs1792231	ENSG00000254682.1	RP11-660L16.2	-10.74	2.85e-24	7.39e-21	-0.63	-0.44	Vitamin D levels;	chr11:71471635	chr11:71448674~71452157:+
LUAD	cis	rs9322193	0.923	rs9480031	ENSG00000216906.2	RP11-350J20.9	10.74	2.88e-24	7.45e-21	0.53	0.44	Lung cancer;	chr6:149758875	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs10872649	ENSG00000216906.2	RP11-350J20.9	10.74	2.88e-24	7.45e-21	0.53	0.44	Lung cancer;	chr6:149759454	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs10872650	ENSG00000216906.2	RP11-350J20.9	10.74	2.88e-24	7.45e-21	0.53	0.44	Lung cancer;	chr6:149760959	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.697	rs28655325	ENSG00000245958.5	RP11-33B1.1	-10.74	2.88e-24	7.46e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119451844	chr4:119454791~119552025:+
LUAD	cis	rs8040855	0.579	rs6496797	ENSG00000259295.5	CSPG4P12	-10.74	2.89e-24	7.47e-21	-0.51	-0.44	Bulimia nervosa;	chr15:85183624	chr15:85191438~85213905:+
LUAD	cis	rs6504950	0.745	rs1962045	ENSG00000275710.1	RP11-257O5.4	10.74	2.89e-24	7.47e-21	0.57	0.44	Breast cancer;	chr17:54918789	chr17:54964474~54964679:+
LUAD	cis	rs875971	0.825	rs801202	ENSG00000226824.5	RP4-756H11.3	10.74	2.91e-24	7.52e-21	0.57	0.44	Aortic root size;	chr7:66558942	chr7:66654538~66669855:+
LUAD	cis	rs6452524	0.934	rs1120476	ENSG00000249664.1	CTD-2227C6.2	10.74	2.91e-24	7.54e-21	0.51	0.44	Hypertension (SNP x SNP interaction);	chr5:83126824	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.934	rs6452510	ENSG00000249664.1	CTD-2227C6.2	10.74	2.91e-24	7.54e-21	0.51	0.44	Hypertension (SNP x SNP interaction);	chr5:83127401	chr5:83012285~83013109:-
LUAD	cis	rs2487048	1	rs2487046	ENSG00000226334.1	RP11-217B7.2	-10.74	2.93e-24	7.56e-21	-0.58	-0.44	Intraocular pressure;	chr9:104929948	chr9:104927553~104928892:+
LUAD	cis	rs9322193	0.926	rs9383546	ENSG00000216906.2	RP11-350J20.9	10.74	2.94e-24	7.59e-21	0.54	0.44	Lung cancer;	chr6:149822743	chr6:149904243~149906418:+
LUAD	cis	rs875971	0.83	rs778711	ENSG00000226824.5	RP4-756H11.3	-10.74	2.96e-24	7.63e-21	-0.57	-0.44	Aortic root size;	chr7:66386670	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs1083554	ENSG00000226824.5	RP4-756H11.3	-10.74	2.96e-24	7.63e-21	-0.57	-0.44	Aortic root size;	chr7:66387354	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs778707	ENSG00000226824.5	RP4-756H11.3	-10.74	2.96e-24	7.63e-21	-0.57	-0.44	Aortic root size;	chr7:66392040	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs778705	ENSG00000226824.5	RP4-756H11.3	-10.74	2.96e-24	7.63e-21	-0.57	-0.44	Aortic root size;	chr7:66396128	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs778697	ENSG00000226824.5	RP4-756H11.3	-10.74	2.96e-24	7.63e-21	-0.57	-0.44	Aortic root size;	chr7:66405439	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.798	rs7789615	ENSG00000226824.5	RP4-756H11.3	-10.74	2.96e-24	7.63e-21	-0.57	-0.44	Aortic root size;	chr7:66413674	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs6978028	ENSG00000226824.5	RP4-756H11.3	-10.74	2.96e-24	7.63e-21	-0.57	-0.44	Aortic root size;	chr7:66421313	chr7:66654538~66669855:+
LUAD	cis	rs9545047	0.613	rs79774056	ENSG00000227676.3	LINC01068	10.74	2.98e-24	7.7e-21	0.56	0.44	Schizophrenia;	chr13:79421486	chr13:79566727~79571436:+
LUAD	cis	rs1577917	1	rs12663690	ENSG00000203875.9	SNHG5	10.74	3e-24	7.75e-21	0.6	0.44	Response to antipsychotic treatment;	chr6:85930444	chr6:85660950~85678736:-
LUAD	cis	rs8040855	0.756	rs2342118	ENSG00000259295.5	CSPG4P12	-10.74	3.02e-24	7.79e-21	-0.55	-0.44	Bulimia nervosa;	chr15:85149785	chr15:85191438~85213905:+
LUAD	cis	rs2882667	0.505	rs7721110	ENSG00000253404.1	AC034243.1	10.73	3.03e-24	7.82e-21	0.55	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139146817	chr5:138744434~138753309:-
LUAD	cis	rs11098499	0.954	rs12505469	ENSG00000245958.5	RP11-33B1.1	-10.73	3.04e-24	7.84e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119328430	chr4:119454791~119552025:+
LUAD	cis	rs3096299	0.754	rs2965816	ENSG00000274627.1	RP11-104N10.2	-10.73	3.05e-24	7.87e-21	-0.42	-0.44	Multiple myeloma (IgH translocation);	chr16:89447775	chr16:89516797~89522217:+
LUAD	cis	rs6782228	0.606	rs7650156	ENSG00000242551.2	POU5F1P6	-10.73	3.06e-24	7.89e-21	-0.49	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642712	chr3:128674735~128677005:-
LUAD	cis	rs8062405	0.72	rs9926245	ENSG00000259982.1	CDC37P1	10.73	3.07e-24	7.92e-21	0.55	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28700294~28701540:-
LUAD	cis	rs3096299	0.719	rs2353581	ENSG00000274627.1	RP11-104N10.2	10.73	3.09e-24	7.97e-21	0.42	0.44	Multiple myeloma (IgH translocation);	chr16:89452500	chr16:89516797~89522217:+
LUAD	cis	rs11098499	0.954	rs10017371	ENSG00000245958.5	RP11-33B1.1	-10.73	3.1e-24	7.99e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119372621	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs17005535	ENSG00000245958.5	RP11-33B1.1	-10.73	3.12e-24	8.05e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119490407	chr4:119454791~119552025:+
LUAD	cis	rs6782228	0.527	rs6767383	ENSG00000242551.2	POU5F1P6	-10.73	3.12e-24	8.05e-21	-0.49	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694744	chr3:128674735~128677005:-
LUAD	cis	rs11155671	0.53	rs6935829	ENSG00000216906.2	RP11-350J20.9	10.73	3.13e-24	8.06e-21	0.55	0.44	Testicular germ cell tumor;	chr6:149896675	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.779	rs7699346	ENSG00000245958.5	RP11-33B1.1	-10.73	3.14e-24	8.09e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119389387	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs13107475	ENSG00000245958.5	RP11-33B1.1	-10.73	3.2e-24	8.23e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119471856	chr4:119454791~119552025:+
LUAD	cis	rs9322193	0.884	rs62439837	ENSG00000216906.2	RP11-350J20.9	10.73	3.22e-24	8.29e-21	0.55	0.44	Lung cancer;	chr6:149670380	chr6:149904243~149906418:+
LUAD	cis	rs6452524	1	rs9293332	ENSG00000249664.1	CTD-2227C6.2	10.73	3.23e-24	8.31e-21	0.49	0.44	Hypertension (SNP x SNP interaction);	chr5:83141546	chr5:83012285~83013109:-
LUAD	cis	rs6782228	0.606	rs4857861	ENSG00000242551.2	POU5F1P6	-10.73	3.26e-24	8.4e-21	-0.49	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687924	chr3:128674735~128677005:-
LUAD	cis	rs6782228	0.606	rs4857919	ENSG00000242551.2	POU5F1P6	-10.73	3.26e-24	8.4e-21	-0.49	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128688652	chr3:128674735~128677005:-
LUAD	cis	rs9322193	0.923	rs4870509	ENSG00000216906.2	RP11-350J20.9	10.72	3.33e-24	8.55e-21	0.55	0.44	Lung cancer;	chr6:149702212	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.566	rs12528243	ENSG00000231760.4	RP11-350J20.5	10.72	3.37e-24	8.68e-21	0.67	0.44	Lung cancer;	chr6:149898491	chr6:149796151~149826294:-
LUAD	cis	rs11098499	0.69	rs34818745	ENSG00000245958.5	RP11-33B1.1	-10.72	3.38e-24	8.68e-21	-0.42	-0.44	Corneal astigmatism;	chr4:119335900	chr4:119454791~119552025:+
LUAD	cis	rs507080	0.733	rs601318	ENSG00000255422.1	AP002954.4	-10.72	3.38e-24	8.7e-21	-0.56	-0.44	Serum metabolite levels;	chr11:118648845	chr11:118704607~118750263:+
LUAD	cis	rs9322193	0.923	rs9800736	ENSG00000216906.2	RP11-350J20.9	10.72	3.4e-24	8.74e-21	0.53	0.44	Lung cancer;	chr6:149661281	chr6:149904243~149906418:+
LUAD	cis	rs4423214	0.84	rs4435028	ENSG00000254682.1	RP11-660L16.2	-10.72	3.41e-24	8.75e-21	-0.63	-0.44	Vitamin D levels;	chr11:71472644	chr11:71448674~71452157:+
LUAD	cis	rs4423214	0.802	rs4616066	ENSG00000254682.1	RP11-660L16.2	-10.72	3.41e-24	8.75e-21	-0.63	-0.44	Vitamin D levels;	chr11:71472800	chr11:71448674~71452157:+
LUAD	cis	rs4423214	0.802	rs4402322	ENSG00000254682.1	RP11-660L16.2	-10.72	3.41e-24	8.75e-21	-0.63	-0.44	Vitamin D levels;	chr11:71472969	chr11:71448674~71452157:+
LUAD	cis	rs4423214	0.802	rs2276358	ENSG00000254682.1	RP11-660L16.2	-10.72	3.41e-24	8.75e-21	-0.63	-0.44	Vitamin D levels;	chr11:71473452	chr11:71448674~71452157:+
LUAD	cis	rs4423214	0.84	rs3794057	ENSG00000254682.1	RP11-660L16.2	-10.72	3.41e-24	8.75e-21	-0.63	-0.44	Vitamin D levels;	chr11:71475698	chr11:71448674~71452157:+
LUAD	cis	rs4423214	0.84	rs2017686	ENSG00000254682.1	RP11-660L16.2	-10.72	3.41e-24	8.75e-21	-0.63	-0.44	Vitamin D levels;	chr11:71476015	chr11:71448674~71452157:+
LUAD	cis	rs9322193	1	rs9399693	ENSG00000216906.2	RP11-350J20.9	10.72	3.43e-24	8.8e-21	0.53	0.44	Lung cancer;	chr6:149612718	chr6:149904243~149906418:+
LUAD	cis	rs1757171	0.504	rs11969056	ENSG00000279942.1	RP1-153P14.7	-10.72	3.43e-24	8.81e-21	-0.41	-0.44	Cognitive performance;	chr6:37516509	chr6:37567716~37571460:+
LUAD	cis	rs748404	0.66	rs2467738	ENSG00000205771.5	CATSPER2P1	-10.72	3.45e-24	8.87e-21	-0.56	-0.44	Lung cancer;	chr15:43447738	chr15:43726918~43747094:-
LUAD	cis	rs11098499	0.954	rs6849171	ENSG00000245958.5	RP11-33B1.1	-10.72	3.46e-24	8.88e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119488394	chr4:119454791~119552025:+
LUAD	cis	rs6452524	0.967	rs4290995	ENSG00000249664.1	CTD-2227C6.2	10.72	3.48e-24	8.92e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83182177	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs965674	ENSG00000249664.1	CTD-2227C6.2	10.72	3.48e-24	8.92e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83186765	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs2662242	ENSG00000249664.1	CTD-2227C6.2	10.72	3.48e-24	8.92e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83189066	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs2731844	ENSG00000249664.1	CTD-2227C6.2	10.72	3.48e-24	8.92e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83192627	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.901	rs2940540	ENSG00000249664.1	CTD-2227C6.2	10.72	3.48e-24	8.92e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83193004	chr5:83012285~83013109:-
LUAD	cis	rs3096299	0.719	rs12934708	ENSG00000274627.1	RP11-104N10.2	10.72	3.48e-24	8.93e-21	0.42	0.44	Multiple myeloma (IgH translocation);	chr16:89457382	chr16:89516797~89522217:+
LUAD	cis	rs11118620	0.81	rs1603047	ENSG00000238078.1	LINC01352	10.72	3.5e-24	8.98e-21	0.53	0.44	Heart failure;	chr1:220849953	chr1:220829255~220832429:+
LUAD	cis	rs11118620	0.81	rs4587570	ENSG00000238078.1	LINC01352	10.72	3.54e-24	9.08e-21	0.54	0.44	Heart failure;	chr1:220860693	chr1:220829255~220832429:+
LUAD	cis	rs977987	0.843	rs59155720	ENSG00000261783.1	RP11-252K23.2	-10.72	3.6e-24	9.22e-21	-0.59	-0.44	Dupuytren's disease;	chr16:75449908	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.736	rs11865296	ENSG00000261783.1	RP11-252K23.2	-10.71	3.61e-24	9.24e-21	-0.59	-0.44	Dupuytren's disease;	chr16:75439795	chr16:75379818~75381260:-
LUAD	cis	rs11118620	1	rs11118620	ENSG00000238078.1	LINC01352	10.71	3.62e-24	9.27e-21	0.54	0.44	Heart failure;	chr1:220855166	chr1:220829255~220832429:+
LUAD	cis	rs11098499	0.954	rs67265404	ENSG00000245958.5	RP11-33B1.1	-10.71	3.63e-24	9.29e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119438115	chr4:119454791~119552025:+
LUAD	cis	rs11723261	0.621	rs7692530	ENSG00000275426.1	CH17-262A2.1	10.71	3.68e-24	9.42e-21	0.61	0.44	Immune response to smallpox vaccine (IL-6);	chr4:123563	chr4:149738~150317:+
LUAD	cis	rs6782228	0.509	rs6780447	ENSG00000242551.2	POU5F1P6	-10.71	3.7e-24	9.48e-21	-0.49	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694965	chr3:128674735~128677005:-
LUAD	cis	rs11098499	0.954	rs1480931	ENSG00000245958.5	RP11-33B1.1	-10.71	3.72e-24	9.53e-21	-0.4	-0.44	Corneal astigmatism;	chr4:119474654	chr4:119454791~119552025:+
LUAD	cis	rs875971	0.862	rs1860469	ENSG00000226824.5	RP4-756H11.3	10.71	3.79e-24	9.71e-21	0.57	0.44	Aortic root size;	chr7:66641888	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.756	rs4718328	ENSG00000226824.5	RP4-756H11.3	10.71	3.82e-24	9.76e-21	0.56	0.44	Aortic root size;	chr7:66228350	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.923	rs11155670	ENSG00000216906.2	RP11-350J20.9	10.71	3.83e-24	9.79e-21	0.53	0.44	Lung cancer;	chr6:149644992	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs10782317	ENSG00000216906.2	RP11-350J20.9	-10.71	3.83e-24	9.8e-21	-0.52	-0.44	Lung cancer;	chr6:149753911	chr6:149904243~149906418:+
LUAD	cis	rs748404	0.66	rs2439846	ENSG00000205771.5	CATSPER2P1	-10.71	3.86e-24	9.85e-21	-0.55	-0.44	Lung cancer;	chr15:43448772	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.66	rs2467741	ENSG00000205771.5	CATSPER2P1	-10.71	3.86e-24	9.85e-21	-0.55	-0.44	Lung cancer;	chr15:43450428	chr15:43726918~43747094:-
LUAD	cis	rs7396835	0.8	rs6589572	ENSG00000254851.1	RP11-109L13.1	-10.71	3.87e-24	9.88e-21	-0.74	-0.44	Quantitative traits;	chr11:116810847	chr11:117135528~117138582:+
LUAD	cis	rs9322193	0.736	rs10457851	ENSG00000216906.2	RP11-350J20.9	10.71	3.88e-24	9.91e-21	0.54	0.44	Lung cancer;	chr6:149775216	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.886	rs10872652	ENSG00000216906.2	RP11-350J20.9	10.71	3.88e-24	9.91e-21	0.54	0.44	Lung cancer;	chr6:149775303	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.886	rs17672976	ENSG00000216906.2	RP11-350J20.9	10.71	3.88e-24	9.91e-21	0.54	0.44	Lung cancer;	chr6:149776207	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs2184369	ENSG00000216906.2	RP11-350J20.9	10.71	3.88e-24	9.91e-21	0.54	0.44	Lung cancer;	chr6:149776681	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs2342861	ENSG00000216906.2	RP11-350J20.9	10.71	3.88e-24	9.91e-21	0.54	0.44	Lung cancer;	chr6:149777561	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.926	rs2342860	ENSG00000216906.2	RP11-350J20.9	10.71	3.88e-24	9.91e-21	0.54	0.44	Lung cancer;	chr6:149777641	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs10872653	ENSG00000216906.2	RP11-350J20.9	10.71	3.88e-24	9.91e-21	0.54	0.44	Lung cancer;	chr6:149778907	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.657	rs71614442	ENSG00000245958.5	RP11-33B1.1	-10.71	3.89e-24	9.91e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119458191	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs2892848	ENSG00000245958.5	RP11-33B1.1	-10.71	3.89e-24	9.91e-21	-0.41	-0.44	Corneal astigmatism;	chr4:119460186	chr4:119454791~119552025:+
LUAD	cis	rs6452524	1	rs11958314	ENSG00000249664.1	CTD-2227C6.2	10.71	3.89e-24	9.91e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83132929	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.686	rs6452517	ENSG00000249664.1	CTD-2227C6.2	10.71	3.89e-24	9.91e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83133041	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs10069402	ENSG00000249664.1	CTD-2227C6.2	10.71	3.89e-24	9.91e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83133776	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs10076271	ENSG00000249664.1	CTD-2227C6.2	10.71	3.89e-24	9.91e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83133875	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs10076274	ENSG00000249664.1	CTD-2227C6.2	10.71	3.89e-24	9.91e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83133908	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs10061521	ENSG00000249664.1	CTD-2227C6.2	10.71	3.89e-24	9.91e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83133936	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.686	rs6452518	ENSG00000249664.1	CTD-2227C6.2	10.71	3.91e-24	9.96e-21	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83133043	chr5:83012285~83013109:-
LUAD	cis	rs7396835	0.866	rs7927820	ENSG00000254851.1	RP11-109L13.1	-10.71	3.92e-24	9.97e-21	-0.74	-0.44	Quantitative traits;	chr11:116811440	chr11:117135528~117138582:+
LUAD	cis	rs875971	0.862	rs2909688	ENSG00000226824.5	RP4-756H11.3	-10.7	3.94e-24	1e-20	-0.56	-0.44	Aortic root size;	chr7:66376625	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs35378740	ENSG00000226824.5	RP4-756H11.3	-10.7	3.94e-24	1e-20	-0.56	-0.44	Aortic root size;	chr7:66522725	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs10950043	ENSG00000226824.5	RP4-756H11.3	-10.7	3.94e-24	1e-20	-0.56	-0.44	Aortic root size;	chr7:66523623	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs17747530	ENSG00000226824.5	RP4-756H11.3	-10.7	3.94e-24	1e-20	-0.56	-0.44	Aortic root size;	chr7:66529742	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs13226170	ENSG00000226824.5	RP4-756H11.3	-10.7	3.94e-24	1e-20	-0.56	-0.44	Aortic root size;	chr7:66534311	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs2420611	ENSG00000226824.5	RP4-756H11.3	-10.7	3.94e-24	1e-20	-0.56	-0.44	Aortic root size;	chr7:66534333	chr7:66654538~66669855:+
LUAD	cis	rs6452524	1	rs1382369	ENSG00000249664.1	CTD-2227C6.2	10.7	3.94e-24	1e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83145610	chr5:83012285~83013109:-
LUAD	cis	rs6782228	0.606	rs7627549	ENSG00000242551.2	POU5F1P6	-10.7	3.94e-24	1e-20	-0.49	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128634236	chr3:128674735~128677005:-
LUAD	cis	rs2487048	0.725	rs2422493	ENSG00000226334.1	RP11-217B7.2	-10.7	3.97e-24	1.01e-20	-0.57	-0.44	Intraocular pressure;	chr9:104928714	chr9:104927553~104928892:+
LUAD	cis	rs10256972	0.63	rs13235747	ENSG00000229043.2	AC091729.9	-10.7	3.97e-24	1.01e-20	-0.48	-0.44	Endometriosis;Longevity;	chr7:1089487	chr7:1160374~1165267:+
LUAD	cis	rs694739	0.93	rs574087	ENSG00000236935.1	AP003774.1	10.7	3.99e-24	1.02e-20	0.43	0.44	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64335476	chr11:64325050~64329504:-
LUAD	cis	rs904251	0.797	rs1757181	ENSG00000279942.1	RP1-153P14.7	10.7	4e-24	1.02e-20	0.41	0.44	Cognitive performance;	chr6:37517952	chr6:37567716~37571460:+
LUAD	cis	rs11098499	0.954	rs11098526	ENSG00000245958.5	RP11-33B1.1	-10.7	4.02e-24	1.02e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119469204	chr4:119454791~119552025:+
LUAD	cis	rs6782228	0.509	rs4481172	ENSG00000242551.2	POU5F1P6	-10.7	4.04e-24	1.03e-20	-0.49	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128653814	chr3:128674735~128677005:-
LUAD	cis	rs11098499	0.865	rs11098513	ENSG00000245958.5	RP11-33B1.1	-10.7	4.05e-24	1.03e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119394920	chr4:119454791~119552025:+
LUAD	cis	rs6452524	0.934	rs7700253	ENSG00000249664.1	CTD-2227C6.2	10.7	4.05e-24	1.03e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83135510	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs10067439	ENSG00000249664.1	CTD-2227C6.2	10.7	4.05e-24	1.03e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83136274	chr5:83012285~83013109:-
LUAD	cis	rs4423214	0.84	rs1629220	ENSG00000254682.1	RP11-660L16.2	-10.7	4.09e-24	1.04e-20	-0.63	-0.44	Vitamin D levels;	chr11:71463507	chr11:71448674~71452157:+
LUAD	cis	rs4423214	0.84	rs1792224	ENSG00000254682.1	RP11-660L16.2	-10.7	4.09e-24	1.04e-20	-0.63	-0.44	Vitamin D levels;	chr11:71465095	chr11:71448674~71452157:+
LUAD	cis	rs4423214	0.84	rs1792226	ENSG00000254682.1	RP11-660L16.2	-10.7	4.09e-24	1.04e-20	-0.63	-0.44	Vitamin D levels;	chr11:71465528	chr11:71448674~71452157:+
LUAD	cis	rs4423214	0.84	rs1790344	ENSG00000254682.1	RP11-660L16.2	-10.7	4.09e-24	1.04e-20	-0.63	-0.44	Vitamin D levels;	chr11:71465851	chr11:71448674~71452157:+
LUAD	cis	rs4423214	0.84	rs1790343	ENSG00000254682.1	RP11-660L16.2	-10.7	4.09e-24	1.04e-20	-0.63	-0.44	Vitamin D levels;	chr11:71466161	chr11:71448674~71452157:+
LUAD	cis	rs6504950	0.615	rs66898273	ENSG00000275710.1	RP11-257O5.4	10.7	4.09e-24	1.04e-20	0.57	0.44	Breast cancer;	chr17:54916595	chr17:54964474~54964679:+
LUAD	cis	rs507080	0.922	rs4936433	ENSG00000255422.1	AP002954.4	10.7	4.1e-24	1.04e-20	0.58	0.44	Serum metabolite levels;	chr11:118681711	chr11:118704607~118750263:+
LUAD	cis	rs9322193	0.607	rs9383941	ENSG00000231760.4	RP11-350J20.5	-10.7	4.13e-24	1.05e-20	-0.65	-0.44	Lung cancer;	chr6:149912100	chr6:149796151~149826294:-
LUAD	cis	rs2729354	0.953	rs1846567	ENSG00000265566.2	RN7SL605P	-10.7	4.14e-24	1.05e-20	-0.7	-0.44	Blood protein levels;	chr11:57590120	chr11:57528085~57528365:-
LUAD	cis	rs6452524	1	rs7733151	ENSG00000249664.1	CTD-2227C6.2	10.7	4.15e-24	1.05e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83134655	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs7733330	ENSG00000249664.1	CTD-2227C6.2	10.7	4.15e-24	1.05e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83134774	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs7733354	ENSG00000249664.1	CTD-2227C6.2	10.7	4.15e-24	1.05e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83134859	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs4634330	ENSG00000249664.1	CTD-2227C6.2	10.7	4.15e-24	1.05e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83134963	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs2386238	ENSG00000249664.1	CTD-2227C6.2	10.7	4.15e-24	1.05e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83135266	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs2386239	ENSG00000249664.1	CTD-2227C6.2	10.7	4.15e-24	1.05e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83135339	chr5:83012285~83013109:-
LUAD	cis	rs11098499	0.954	rs4345162	ENSG00000245958.5	RP11-33B1.1	-10.7	4.18e-24	1.06e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119391804	chr4:119454791~119552025:+
LUAD	cis	rs9322193	0.923	rs9322214	ENSG00000216906.2	RP11-350J20.9	10.7	4.2e-24	1.07e-20	0.54	0.44	Lung cancer;	chr6:149703986	chr6:149904243~149906418:+
LUAD	cis	rs977987	0.806	rs4887818	ENSG00000261783.1	RP11-252K23.2	-10.7	4.2e-24	1.07e-20	-0.57	-0.44	Dupuytren's disease;	chr16:75328097	chr16:75379818~75381260:-
LUAD	cis	rs11098499	0.954	rs3733519	ENSG00000245958.5	RP11-33B1.1	-10.7	4.22e-24	1.07e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119502293	chr4:119454791~119552025:+
LUAD	cis	rs2739330	0.828	rs2877178	ENSG00000099984.9	GSTT2	-10.7	4.25e-24	1.08e-20	-0.53	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23980123~23983911:+
LUAD	cis	rs6452524	1	rs7710900	ENSG00000249664.1	CTD-2227C6.2	10.7	4.25e-24	1.08e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83137201	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs62374373	ENSG00000249664.1	CTD-2227C6.2	10.7	4.25e-24	1.08e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83137389	chr5:83012285~83013109:-
LUAD	cis	rs73086581	0.592	rs6037702	ENSG00000229539.1	RP11-119B16.2	-10.7	4.28e-24	1.08e-20	-0.54	-0.44	Response to antidepressants in depression;	chr20:3955745	chr20:3888239~3888868:-
LUAD	cis	rs11098499	0.909	rs11723757	ENSG00000245958.5	RP11-33B1.1	-10.69	4.34e-24	1.1e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119378514	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs10014845	ENSG00000245958.5	RP11-33B1.1	-10.69	4.34e-24	1.1e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119379922	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.779	rs7674500	ENSG00000245958.5	RP11-33B1.1	-10.69	4.34e-24	1.1e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119382438	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.909	rs28884220	ENSG00000245958.5	RP11-33B1.1	-10.69	4.34e-24	1.1e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119386056	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.909	rs28793658	ENSG00000245958.5	RP11-33B1.1	-10.69	4.34e-24	1.1e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119386059	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.865	rs4507344	ENSG00000245958.5	RP11-33B1.1	-10.69	4.34e-24	1.1e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119386330	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.697	rs4373140	ENSG00000245958.5	RP11-33B1.1	-10.69	4.34e-24	1.1e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119386543	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs13113483	ENSG00000245958.5	RP11-33B1.1	-10.69	4.34e-24	1.1e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119387884	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.542	rs10440343	ENSG00000245958.5	RP11-33B1.1	-10.69	4.34e-24	1.1e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119388632	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.909	rs28668716	ENSG00000245958.5	RP11-33B1.1	-10.69	4.34e-24	1.1e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119388720	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.542	rs7677836	ENSG00000245958.5	RP11-33B1.1	-10.69	4.34e-24	1.1e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119389483	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.909	rs10002083	ENSG00000245958.5	RP11-33B1.1	-10.69	4.34e-24	1.1e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119389997	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs10024844	ENSG00000245958.5	RP11-33B1.1	-10.69	4.34e-24	1.1e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119390373	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.657	rs4463052	ENSG00000245958.5	RP11-33B1.1	-10.69	4.34e-24	1.1e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119392103	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs13151285	ENSG00000245958.5	RP11-33B1.1	-10.69	4.34e-24	1.1e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119393586	chr4:119454791~119552025:+
LUAD	cis	rs9322193	0.923	rs10747276	ENSG00000216906.2	RP11-350J20.9	10.69	4.36e-24	1.1e-20	0.53	0.44	Lung cancer;	chr6:149758739	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs9688452	ENSG00000216906.2	RP11-350J20.9	10.69	4.37e-24	1.1e-20	0.54	0.44	Lung cancer;	chr6:149658764	chr6:149904243~149906418:+
LUAD	cis	rs4728142	0.584	rs6965542	ENSG00000275106.1	RP11-309L24.10	-10.69	4.37e-24	1.1e-20	-0.53	-0.44	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129015864	chr7:128952527~128953316:-
LUAD	cis	rs9322193	0.607	rs12209310	ENSG00000231760.4	RP11-350J20.5	10.69	4.38e-24	1.11e-20	0.67	0.44	Lung cancer;	chr6:149904882	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.607	rs12210822	ENSG00000231760.4	RP11-350J20.5	10.69	4.39e-24	1.11e-20	0.67	0.44	Lung cancer;	chr6:149905356	chr6:149796151~149826294:-
LUAD	cis	rs977987	0.835	rs4888380	ENSG00000261783.1	RP11-252K23.2	-10.69	4.41e-24	1.11e-20	-0.57	-0.44	Dupuytren's disease;	chr16:75313792	chr16:75379818~75381260:-
LUAD	cis	rs2739330	0.828	rs2330635	ENSG00000099984.9	GSTT2	-10.69	4.43e-24	1.12e-20	-0.53	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23980123~23983911:+
LUAD	cis	rs11098499	0.954	rs66506550	ENSG00000245958.5	RP11-33B1.1	-10.69	4.44e-24	1.12e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119450290	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs10008392	ENSG00000245958.5	RP11-33B1.1	-10.69	4.49e-24	1.13e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119397684	chr4:119454791~119552025:+
LUAD	cis	rs6782228	0.606	rs6439135	ENSG00000242551.2	POU5F1P6	-10.69	4.5e-24	1.13e-20	-0.49	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128639790	chr3:128674735~128677005:-
LUAD	cis	rs4853012	0.775	rs12465641	ENSG00000217702.2	RP11-287D1.4	-10.69	4.53e-24	1.14e-20	-0.72	-0.44	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74130583~74135395:+
LUAD	cis	rs748404	0.69	rs1079309	ENSG00000205771.5	CATSPER2P1	-10.69	4.58e-24	1.15e-20	-0.55	-0.44	Lung cancer;	chr15:43490966	chr15:43726918~43747094:-
LUAD	cis	rs4814920	0.818	rs4813376	ENSG00000275142.1	RP5-999L4.2	10.69	4.59e-24	1.16e-20	0.74	0.44	Bipolar disorder (body mass index interaction);	chr20:19870811	chr20:19871891~19872284:+
LUAD	cis	rs875971	0.798	rs12698522	ENSG00000226824.5	RP4-756H11.3	-10.69	4.59e-24	1.16e-20	-0.57	-0.44	Aortic root size;	chr7:66502354	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.83	rs28714531	ENSG00000226824.5	RP4-756H11.3	-10.69	4.59e-24	1.16e-20	-0.57	-0.44	Aortic root size;	chr7:66503250	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs12698526	ENSG00000226824.5	RP4-756H11.3	-10.69	4.59e-24	1.16e-20	-0.57	-0.44	Aortic root size;	chr7:66504118	chr7:66654538~66669855:+
LUAD	cis	rs977987	0.806	rs4993969	ENSG00000261783.1	RP11-252K23.2	-10.69	4.61e-24	1.16e-20	-0.58	-0.44	Dupuytren's disease;	chr16:75377623	chr16:75379818~75381260:-
LUAD	cis	rs875971	0.767	rs12668005	ENSG00000226824.5	RP4-756H11.3	-10.69	4.64e-24	1.17e-20	-0.57	-0.44	Aortic root size;	chr7:66444034	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs11765791	ENSG00000226824.5	RP4-756H11.3	-10.69	4.64e-24	1.17e-20	-0.57	-0.44	Aortic root size;	chr7:66471587	chr7:66654538~66669855:+
LUAD	cis	rs6452524	1	rs10043018	ENSG00000249664.1	CTD-2227C6.2	10.69	4.66e-24	1.17e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83138498	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.935	rs10037501	ENSG00000249664.1	CTD-2227C6.2	10.69	4.66e-24	1.17e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83138722	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.904	rs6452525	ENSG00000249664.1	CTD-2227C6.2	10.69	4.66e-24	1.17e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83138752	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs7716931	ENSG00000249664.1	CTD-2227C6.2	10.69	4.66e-24	1.17e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83138856	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs7721416	ENSG00000249664.1	CTD-2227C6.2	10.69	4.66e-24	1.17e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83139174	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs6882220	ENSG00000249664.1	CTD-2227C6.2	10.69	4.66e-24	1.17e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83139715	chr5:83012285~83013109:-
LUAD	cis	rs11098499	0.909	rs11723839	ENSG00000245958.5	RP11-33B1.1	-10.69	4.66e-24	1.17e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119378518	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs11098525	ENSG00000245958.5	RP11-33B1.1	-10.69	4.67e-24	1.17e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119468997	chr4:119454791~119552025:+
LUAD	cis	rs748404	0.66	rs690472	ENSG00000205771.5	CATSPER2P1	-10.68	4.68e-24	1.18e-20	-0.55	-0.44	Lung cancer;	chr15:43472170	chr15:43726918~43747094:-
LUAD	cis	rs4423214	0.84	rs1792227	ENSG00000254682.1	RP11-660L16.2	-10.68	4.72e-24	1.19e-20	-0.63	-0.44	Vitamin D levels;	chr11:71466366	chr11:71448674~71452157:+
LUAD	cis	rs4423214	0.84	rs1790341	ENSG00000254682.1	RP11-660L16.2	-10.68	4.72e-24	1.19e-20	-0.63	-0.44	Vitamin D levels;	chr11:71466532	chr11:71448674~71452157:+
LUAD	cis	rs4423214	0.84	rs1540127	ENSG00000254682.1	RP11-660L16.2	-10.68	4.72e-24	1.19e-20	-0.63	-0.44	Vitamin D levels;	chr11:71467992	chr11:71448674~71452157:+
LUAD	cis	rs8040855	0.557	rs9744503	ENSG00000259295.5	CSPG4P12	-10.68	4.75e-24	1.19e-20	-0.51	-0.44	Bulimia nervosa;	chr15:85180986	chr15:85191438~85213905:+
LUAD	cis	rs10256972	0.681	rs12702016	ENSG00000229043.2	AC091729.9	-10.68	4.78e-24	1.2e-20	-0.48	-0.44	Endometriosis;Longevity;	chr7:1089756	chr7:1160374~1165267:+
LUAD	cis	rs6538678	0.963	rs11108310	ENSG00000199506.1	RNU6-247P	-10.68	4.79e-24	1.2e-20	-0.57	-0.44	Lupus nephritis in systemic lupus erythematosus;	chr12:95864164	chr12:95792529~95792635:-
LUAD	cis	rs875971	0.895	rs6460278	ENSG00000226824.5	RP4-756H11.3	10.68	4.8e-24	1.21e-20	0.56	0.44	Aortic root size;	chr7:66197749	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs6460279	ENSG00000226824.5	RP4-756H11.3	10.68	4.8e-24	1.21e-20	0.56	0.44	Aortic root size;	chr7:66197774	chr7:66654538~66669855:+
LUAD	cis	rs9322193	1	rs9377228	ENSG00000216906.2	RP11-350J20.9	10.68	4.82e-24	1.21e-20	0.53	0.44	Lung cancer;	chr6:149600862	chr6:149904243~149906418:+
LUAD	cis	rs11118620	0.853	rs12037861	ENSG00000238078.1	LINC01352	10.68	4.84e-24	1.22e-20	0.54	0.44	Heart failure;	chr1:220864835	chr1:220829255~220832429:+
LUAD	cis	rs9322193	0.886	rs9767555	ENSG00000216906.2	RP11-350J20.9	10.68	4.87e-24	1.22e-20	0.55	0.44	Lung cancer;	chr6:149647022	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.954	rs10006706	ENSG00000245958.5	RP11-33B1.1	-10.68	4.92e-24	1.23e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119487997	chr4:119454791~119552025:+
LUAD	cis	rs6782228	0.606	rs2811490	ENSG00000242551.2	POU5F1P6	-10.68	4.93e-24	1.24e-20	-0.49	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128632912	chr3:128674735~128677005:-
LUAD	cis	rs977987	0.806	rs12444589	ENSG00000261783.1	RP11-252K23.2	10.68	4.94e-24	1.24e-20	0.57	0.44	Dupuytren's disease;	chr16:75420506	chr16:75379818~75381260:-
LUAD	cis	rs748404	0.66	rs2444251	ENSG00000205771.5	CATSPER2P1	-10.68	4.95e-24	1.24e-20	-0.55	-0.44	Lung cancer;	chr15:43496397	chr15:43726918~43747094:-
LUAD	cis	rs6452524	1	rs17284288	ENSG00000249664.1	CTD-2227C6.2	10.68	4.95e-24	1.24e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83148997	chr5:83012285~83013109:-
LUAD	cis	rs748404	0.66	rs2467742	ENSG00000205771.5	CATSPER2P1	-10.68	5.07e-24	1.27e-20	-0.55	-0.44	Lung cancer;	chr15:43458039	chr15:43726918~43747094:-
LUAD	cis	rs6538678	0.864	rs10777747	ENSG00000199506.1	RNU6-247P	-10.68	5.09e-24	1.27e-20	-0.56	-0.44	Lupus nephritis in systemic lupus erythematosus;	chr12:95870192	chr12:95792529~95792635:-
LUAD	cis	rs2337406	0.866	rs79901786	ENSG00000274576.2	IGHV2-70	-10.68	5.09e-24	1.28e-20	-0.47	-0.44	Alzheimer's disease (late onset);	chr14:106777623	chr14:106770577~106771020:-
LUAD	cis	rs4423214	0.84	rs1792229	ENSG00000254682.1	RP11-660L16.2	-10.67	5.14e-24	1.29e-20	-0.63	-0.44	Vitamin D levels;	chr11:71468349	chr11:71448674~71452157:+
LUAD	cis	rs6504950	0.79	rs8076984	ENSG00000275710.1	RP11-257O5.4	10.67	5.16e-24	1.29e-20	0.58	0.44	Breast cancer;	chr17:54958067	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.83	rs17745231	ENSG00000275710.1	RP11-257O5.4	10.67	5.16e-24	1.29e-20	0.58	0.44	Breast cancer;	chr17:54959168	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.83	rs12938118	ENSG00000275710.1	RP11-257O5.4	10.67	5.16e-24	1.29e-20	0.58	0.44	Breast cancer;	chr17:54959998	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.83	rs1802212	ENSG00000275710.1	RP11-257O5.4	10.67	5.16e-24	1.29e-20	0.58	0.44	Breast cancer;	chr17:54961293	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.83	rs17817901	ENSG00000275710.1	RP11-257O5.4	10.67	5.16e-24	1.29e-20	0.58	0.44	Breast cancer;	chr17:54961384	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.83	rs12150038	ENSG00000275710.1	RP11-257O5.4	10.67	5.16e-24	1.29e-20	0.58	0.44	Breast cancer;	chr17:54964159	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.83	rs12951542	ENSG00000275710.1	RP11-257O5.4	10.67	5.16e-24	1.29e-20	0.58	0.44	Breast cancer;	chr17:54964604	chr17:54964474~54964679:+
LUAD	cis	rs11098499	0.909	rs10020034	ENSG00000245958.5	RP11-33B1.1	-10.67	5.18e-24	1.29e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119373176	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs7437420	ENSG00000245958.5	RP11-33B1.1	-10.67	5.18e-24	1.3e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119391748	chr4:119454791~119552025:+
LUAD	cis	rs6782228	0.585	rs6774515	ENSG00000242551.2	POU5F1P6	-10.67	5.22e-24	1.31e-20	-0.49	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128697035	chr3:128674735~128677005:-
LUAD	cis	rs6782228	0.565	rs12695509	ENSG00000242551.2	POU5F1P6	-10.67	5.22e-24	1.31e-20	-0.49	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128698201	chr3:128674735~128677005:-
LUAD	cis	rs977987	0.872	rs2161648	ENSG00000261783.1	RP11-252K23.2	-10.67	5.22e-24	1.31e-20	-0.58	-0.44	Dupuytren's disease;	chr16:75280731	chr16:75379818~75381260:-
LUAD	cis	rs748404	0.69	rs2467737	ENSG00000205771.5	CATSPER2P1	-10.67	5.29e-24	1.32e-20	-0.55	-0.44	Lung cancer;	chr15:43444990	chr15:43726918~43747094:-
LUAD	cis	rs11723261	0.582	rs4582104	ENSG00000275426.1	CH17-262A2.1	10.67	5.31e-24	1.33e-20	0.59	0.44	Immune response to smallpox vaccine (IL-6);	chr4:143160	chr4:149738~150317:+
LUAD	cis	rs11098499	0.954	rs28572238	ENSG00000245958.5	RP11-33B1.1	-10.67	5.34e-24	1.33e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119395531	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.909	rs28714195	ENSG00000245958.5	RP11-33B1.1	-10.67	5.34e-24	1.33e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119395795	chr4:119454791~119552025:+
LUAD	cis	rs10129255	0.518	rs7143784	ENSG00000211972.2	IGHV3-66	10.67	5.35e-24	1.34e-20	0.35	0.44	Kawasaki disease;	chr14:106687277	chr14:106675017~106675544:-
LUAD	cis	rs977987	0.835	rs8057535	ENSG00000261783.1	RP11-252K23.2	-10.67	5.41e-24	1.35e-20	-0.57	-0.44	Dupuytren's disease;	chr16:75314043	chr16:75379818~75381260:-
LUAD	cis	rs694739	1	rs1783521	ENSG00000236935.1	AP003774.1	10.67	5.51e-24	1.37e-20	0.42	0.44	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64338819	chr11:64325050~64329504:-
LUAD	cis	rs9322193	0.923	rs10872651	ENSG00000216906.2	RP11-350J20.9	10.67	5.57e-24	1.39e-20	0.55	0.44	Lung cancer;	chr6:149768273	chr6:149904243~149906418:+
LUAD	cis	rs694739	0.964	rs2510066	ENSG00000236935.1	AP003774.1	10.66	5.65e-24	1.41e-20	0.43	0.44	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64284975	chr11:64325050~64329504:-
LUAD	cis	rs2929278	0.588	rs1975364	ENSG00000205771.5	CATSPER2P1	-10.66	5.7e-24	1.42e-20	-0.55	-0.44	Schizophrenia;	chr15:43857991	chr15:43726918~43747094:-
LUAD	cis	rs8062405	0.755	rs111693583	ENSG00000259982.1	CDC37P1	10.66	5.84e-24	1.46e-20	0.55	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28700294~28701540:-
LUAD	cis	rs6504950	0.745	rs35079296	ENSG00000275710.1	RP11-257O5.4	10.66	5.87e-24	1.46e-20	0.56	0.44	Breast cancer;	chr17:54916849	chr17:54964474~54964679:+
LUAD	cis	rs6782228	0.527	rs2712371	ENSG00000242551.2	POU5F1P6	-10.66	5.88e-24	1.47e-20	-0.49	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128627371	chr3:128674735~128677005:-
LUAD	cis	rs11098499	0.954	rs13133522	ENSG00000245958.5	RP11-33B1.1	-10.66	5.92e-24	1.47e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119403269	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs35091806	ENSG00000245958.5	RP11-33B1.1	-10.66	5.92e-24	1.47e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119404374	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.909	rs35165976	ENSG00000245958.5	RP11-33B1.1	-10.66	5.92e-24	1.47e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119404475	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs2389802	ENSG00000245958.5	RP11-33B1.1	-10.66	5.92e-24	1.47e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119404577	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs6846442	ENSG00000245958.5	RP11-33B1.1	-10.66	5.92e-24	1.47e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119405168	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.738	rs34566984	ENSG00000245958.5	RP11-33B1.1	-10.66	5.92e-24	1.47e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119440115	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs17009122	ENSG00000245958.5	RP11-33B1.1	-10.66	5.92e-24	1.47e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119441248	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs9685777	ENSG00000245958.5	RP11-33B1.1	-10.66	5.92e-24	1.47e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119444810	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs71614438	ENSG00000245958.5	RP11-33B1.1	-10.66	5.92e-24	1.47e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119450097	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.909	rs7659501	ENSG00000245958.5	RP11-33B1.1	-10.66	5.92e-24	1.47e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119450397	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.779	rs28495013	ENSG00000245958.5	RP11-33B1.1	-10.66	5.92e-24	1.47e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119454676	chr4:119454791~119552025:+
LUAD	cis	rs977987	0.8	rs12922951	ENSG00000261783.1	RP11-252K23.2	-10.66	5.94e-24	1.48e-20	-0.57	-0.44	Dupuytren's disease;	chr16:75321198	chr16:75379818~75381260:-
LUAD	cis	rs8062405	0.755	rs12447461	ENSG00000259982.1	CDC37P1	10.66	5.98e-24	1.49e-20	0.55	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28700294~28701540:-
LUAD	cis	rs4728142	0.525	rs4731534	ENSG00000275106.1	RP11-309L24.10	-10.66	6.02e-24	1.5e-20	-0.53	-0.44	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128965540	chr7:128952527~128953316:-
LUAD	cis	rs11098499	0.908	rs7695996	ENSG00000245958.5	RP11-33B1.1	-10.66	6.05e-24	1.5e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119400878	chr4:119454791~119552025:+
LUAD	cis	rs3096299	0.692	rs4785565	ENSG00000274627.1	RP11-104N10.2	10.66	6.06e-24	1.5e-20	0.42	0.44	Multiple myeloma (IgH translocation);	chr16:89449351	chr16:89516797~89522217:+
LUAD	cis	rs11098499	0.954	rs59394118	ENSG00000245958.5	RP11-33B1.1	-10.66	6.07e-24	1.51e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119374396	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.865	rs9996417	ENSG00000245958.5	RP11-33B1.1	-10.66	6.07e-24	1.51e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119374707	chr4:119454791~119552025:+
LUAD	cis	rs6452524	1	rs6887846	ENSG00000249664.1	CTD-2227C6.2	-10.65	6.09e-24	1.51e-20	-0.5	-0.44	Hypertension (SNP x SNP interaction);	chr5:83140542	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs7718278	ENSG00000249664.1	CTD-2227C6.2	10.65	6.1e-24	1.51e-20	0.51	0.44	Hypertension (SNP x SNP interaction);	chr5:83126600	chr5:83012285~83013109:-
LUAD	cis	rs11098499	0.954	rs59866101	ENSG00000245958.5	RP11-33B1.1	-10.65	6.11e-24	1.51e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119375436	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.618	rs6858383	ENSG00000245958.5	RP11-33B1.1	-10.65	6.11e-24	1.51e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119375617	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.697	rs6832410	ENSG00000245958.5	RP11-33B1.1	-10.65	6.11e-24	1.51e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119375645	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.865	rs1112817	ENSG00000245958.5	RP11-33B1.1	-10.65	6.11e-24	1.51e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119376645	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.779	rs10016060	ENSG00000245958.5	RP11-33B1.1	-10.65	6.11e-24	1.51e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119377257	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs10005644	ENSG00000245958.5	RP11-33B1.1	-10.65	6.11e-24	1.51e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119377322	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.697	rs10016448	ENSG00000245958.5	RP11-33B1.1	-10.65	6.11e-24	1.51e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119377690	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.657	rs9996569	ENSG00000245958.5	RP11-33B1.1	-10.65	6.11e-24	1.51e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119377849	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.908	rs11729050	ENSG00000245958.5	RP11-33B1.1	-10.65	6.11e-24	1.51e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119378911	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs28429722	ENSG00000245958.5	RP11-33B1.1	-10.65	6.11e-24	1.51e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119378938	chr4:119454791~119552025:+
LUAD	cis	rs1577917	1	rs12190598	ENSG00000203875.9	SNHG5	-10.65	6.12e-24	1.52e-20	-0.62	-0.44	Response to antipsychotic treatment;	chr6:85976356	chr6:85660950~85678736:-
LUAD	cis	rs11098499	0.863	rs12508173	ENSG00000245958.5	RP11-33B1.1	-10.65	6.17e-24	1.53e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119397371	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.908	rs12504149	ENSG00000245958.5	RP11-33B1.1	-10.65	6.17e-24	1.53e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119397422	chr4:119454791~119552025:+
LUAD	cis	rs977987	0.806	rs2161684	ENSG00000261783.1	RP11-252K23.2	-10.65	6.2e-24	1.54e-20	-0.58	-0.44	Dupuytren's disease;	chr16:75445255	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs34996006	ENSG00000261783.1	RP11-252K23.2	-10.65	6.2e-24	1.54e-20	-0.58	-0.44	Dupuytren's disease;	chr16:75445536	chr16:75379818~75381260:-
LUAD	cis	rs9322193	0.884	rs10872647	ENSG00000216906.2	RP11-350J20.9	10.65	6.21e-24	1.54e-20	0.56	0.44	Lung cancer;	chr6:149758687	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.884	rs10872648	ENSG00000216906.2	RP11-350J20.9	10.65	6.21e-24	1.54e-20	0.56	0.44	Lung cancer;	chr6:149758699	chr6:149904243~149906418:+
LUAD	cis	rs12439619	1	rs12439619	ENSG00000278603.1	RP13-608F4.5	10.65	6.23e-24	1.54e-20	0.53	0.44	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82472203~82472426:+
LUAD	cis	rs875971	0.862	rs4718383	ENSG00000226824.5	RP4-756H11.3	10.65	6.25e-24	1.55e-20	0.57	0.44	Aortic root size;	chr7:66643422	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.607	rs9322229	ENSG00000231760.4	RP11-350J20.5	10.65	6.27e-24	1.55e-20	0.62	0.44	Lung cancer;	chr6:149908949	chr6:149796151~149826294:-
LUAD	cis	rs2564921	0.765	rs2581799	ENSG00000242142.1	SERBP1P3	-10.65	6.33e-24	1.57e-20	-0.45	-0.44	Height;	chr3:53074760	chr3:53064283~53065091:-
LUAD	cis	rs11098499	0.954	rs878373	ENSG00000245958.5	RP11-33B1.1	-10.65	6.51e-24	1.61e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119316329	chr4:119454791~119552025:+
LUAD	cis	rs7115242	0.92	rs6589574	ENSG00000254851.1	RP11-109L13.1	-10.65	6.52e-24	1.61e-20	-0.87	-0.44	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116859922	chr11:117135528~117138582:+
LUAD	cis	rs11098499	0.909	rs1546504	ENSG00000245958.5	RP11-33B1.1	-10.65	6.53e-24	1.61e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119320024	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs10006877	ENSG00000245958.5	RP11-33B1.1	-10.65	6.53e-24	1.61e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119321638	chr4:119454791~119552025:+
LUAD	cis	rs2470135	1	rs2470135	ENSG00000205771.5	CATSPER2P1	-10.64	6.66e-24	1.65e-20	-0.55	-0.44	Diastolic blood pressure;	chr15:43703591	chr15:43726918~43747094:-
LUAD	cis	rs875971	0.862	rs28491091	ENSG00000226824.5	RP4-756H11.3	10.64	6.68e-24	1.65e-20	0.56	0.44	Aortic root size;	chr7:66204077	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.887	rs9767113	ENSG00000216906.2	RP11-350J20.9	10.64	6.71e-24	1.66e-20	0.54	0.44	Lung cancer;	chr6:149718157	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.954	rs12506546	ENSG00000245958.5	RP11-33B1.1	-10.64	6.73e-24	1.66e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119380463	chr4:119454791~119552025:+
LUAD	cis	rs9322193	1	rs9322193	ENSG00000216906.2	RP11-350J20.9	10.64	6.78e-24	1.67e-20	0.53	0.44	Lung cancer;	chr6:149598007	chr6:149904243~149906418:+
LUAD	cis	rs11723261	0.582	rs11248005	ENSG00000275426.1	CH17-262A2.1	10.64	6.85e-24	1.69e-20	0.61	0.44	Immune response to smallpox vaccine (IL-6);	chr4:172826	chr4:149738~150317:+
LUAD	cis	rs11723261	0.582	rs11733927	ENSG00000275426.1	CH17-262A2.1	10.64	6.85e-24	1.69e-20	0.61	0.44	Immune response to smallpox vaccine (IL-6);	chr4:173039	chr4:149738~150317:+
LUAD	cis	rs6452524	1	rs6452520	ENSG00000249664.1	CTD-2227C6.2	10.64	6.97e-24	1.72e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83133452	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs6452521	ENSG00000249664.1	CTD-2227C6.2	10.64	6.97e-24	1.72e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83133453	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.935	rs6452522	ENSG00000249664.1	CTD-2227C6.2	10.64	6.97e-24	1.72e-20	0.5	0.44	Hypertension (SNP x SNP interaction);	chr5:83133471	chr5:83012285~83013109:-
LUAD	cis	rs694739	0.894	rs11601860	ENSG00000236935.1	AP003774.1	10.64	6.98e-24	1.72e-20	0.43	0.44	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64342950	chr11:64325050~64329504:-
LUAD	cis	rs10256972	0.591	rs6968988	ENSG00000229043.2	AC091729.9	-10.64	7.06e-24	1.74e-20	-0.48	-0.44	Endometriosis;Longevity;	chr7:1129983	chr7:1160374~1165267:+
LUAD	cis	rs11098499	0.865	rs2389809	ENSG00000245958.5	RP11-33B1.1	-10.64	7.08e-24	1.75e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119456244	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs3733520	ENSG00000245958.5	RP11-33B1.1	-10.64	7.1e-24	1.75e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119502325	chr4:119454791~119552025:+
LUAD	cis	rs694739	0.796	rs479777	ENSG00000236935.1	AP003774.1	10.63	7.31e-24	1.8e-20	0.43	0.44	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64340005	chr11:64325050~64329504:-
LUAD	cis	rs6782228	0.606	rs1127030	ENSG00000242551.2	POU5F1P6	-10.63	7.37e-24	1.81e-20	-0.49	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128620110	chr3:128674735~128677005:-
LUAD	cis	rs6782228	0.606	rs2712419	ENSG00000242551.2	POU5F1P6	-10.63	7.37e-24	1.81e-20	-0.49	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128622053	chr3:128674735~128677005:-
LUAD	cis	rs6782228	0.606	rs2712417	ENSG00000242551.2	POU5F1P6	-10.63	7.37e-24	1.81e-20	-0.49	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128626336	chr3:128674735~128677005:-
LUAD	cis	rs977987	0.836	rs8055974	ENSG00000261783.1	RP11-252K23.2	-10.63	7.43e-24	1.83e-20	-0.59	-0.44	Dupuytren's disease;	chr16:75437088	chr16:75379818~75381260:-
LUAD	cis	rs62229266	0.804	rs62230788	ENSG00000231106.2	LINC01436	10.63	7.44e-24	1.83e-20	0.61	0.44	Mitral valve prolapse;	chr21:36008039	chr21:36005338~36007838:+
LUAD	cis	rs875971	0.767	rs61348003	ENSG00000226824.5	RP4-756H11.3	-10.63	7.49e-24	1.84e-20	-0.56	-0.44	Aortic root size;	chr7:66540947	chr7:66654538~66669855:+
LUAD	cis	rs2729354	0.953	rs2848625	ENSG00000265566.2	RN7SL605P	-10.63	7.5e-24	1.85e-20	-0.67	-0.44	Blood protein levels;	chr11:57563177	chr11:57528085~57528365:-
LUAD	cis	rs6504950	0.83	rs17817877	ENSG00000275710.1	RP11-257O5.4	10.63	7.59e-24	1.87e-20	0.58	0.44	Breast cancer;	chr17:54957267	chr17:54964474~54964679:+
LUAD	cis	rs748404	0.588	rs506120	ENSG00000205771.5	CATSPER2P1	-10.63	7.7e-24	1.89e-20	-0.56	-0.44	Lung cancer;	chr15:43509826	chr15:43726918~43747094:-
LUAD	cis	rs11098499	0.909	rs1809406	ENSG00000245958.5	RP11-33B1.1	-10.62	7.89e-24	1.94e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119455967	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.909	rs9994810	ENSG00000245958.5	RP11-33B1.1	-10.62	7.89e-24	1.94e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119460435	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.697	rs10020027	ENSG00000245958.5	RP11-33B1.1	-10.62	7.89e-24	1.94e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119460724	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.779	rs7356491	ENSG00000245958.5	RP11-33B1.1	-10.62	7.89e-24	1.94e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119460819	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs10518331	ENSG00000245958.5	RP11-33B1.1	-10.62	8.04e-24	1.97e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119402440	chr4:119454791~119552025:+
LUAD	cis	rs10129255	0.5	rs1024350	ENSG00000211972.2	IGHV3-66	10.62	8.08e-24	1.98e-20	0.35	0.44	Kawasaki disease;	chr14:106685105	chr14:106675017~106675544:-
LUAD	cis	rs4423214	0.592	rs7120029	ENSG00000254682.1	RP11-660L16.2	-10.62	8.19e-24	2.01e-20	-0.64	-0.44	Vitamin D levels;	chr11:71487911	chr11:71448674~71452157:+
LUAD	cis	rs694739	1	rs499425	ENSG00000236935.1	AP003774.1	-10.62	8.23e-24	2.02e-20	-0.42	-0.44	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64338457	chr11:64325050~64329504:-
LUAD	cis	rs11155671	0.53	rs9371544	ENSG00000216906.2	RP11-350J20.9	10.62	8.27e-24	2.03e-20	0.54	0.44	Testicular germ cell tumor;	chr6:149896224	chr6:149904243~149906418:+
LUAD	cis	rs6782228	0.606	rs58977394	ENSG00000242551.2	POU5F1P6	-10.62	8.28e-24	2.03e-20	-0.49	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619074	chr3:128674735~128677005:-
LUAD	cis	rs6782228	0.606	rs2712381	ENSG00000242551.2	POU5F1P6	-10.62	8.28e-24	2.03e-20	-0.49	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619757	chr3:128674735~128677005:-
LUAD	cis	rs904251	0.861	rs1757171	ENSG00000279942.1	RP1-153P14.7	-10.62	8.32e-24	2.04e-20	-0.42	-0.44	Cognitive performance;	chr6:37519268	chr6:37567716~37571460:+
LUAD	cis	rs1577917	0.958	rs12208227	ENSG00000203875.9	SNHG5	-10.62	8.35e-24	2.05e-20	-0.61	-0.44	Response to antipsychotic treatment;	chr6:85961226	chr6:85660950~85678736:-
LUAD	cis	rs1757171	0.542	rs1757186	ENSG00000279942.1	RP1-153P14.7	-10.62	8.39e-24	2.06e-20	-0.4	-0.44	Cognitive performance;	chr6:37516335	chr6:37567716~37571460:+
LUAD	cis	rs694739	1	rs694739	ENSG00000236935.1	AP003774.1	10.62	8.4e-24	2.06e-20	0.43	0.44	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64329761	chr11:64325050~64329504:-
LUAD	cis	rs6782228	0.606	rs6807019	ENSG00000242551.2	POU5F1P6	-10.62	8.45e-24	2.07e-20	-0.48	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687091	chr3:128674735~128677005:-
LUAD	cis	rs875971	0.862	rs801195	ENSG00000226824.5	RP4-756H11.3	10.61	8.65e-24	2.12e-20	0.56	0.44	Aortic root size;	chr7:66561128	chr7:66654538~66669855:+
LUAD	cis	rs11098499	0.909	rs1546502	ENSG00000245958.5	RP11-33B1.1	-10.61	8.67e-24	2.12e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119314743	chr4:119454791~119552025:+
LUAD	cis	rs2929278	0.617	rs693919	ENSG00000205771.5	CATSPER2P1	10.61	8.77e-24	2.15e-20	0.54	0.44	Schizophrenia;	chr15:43810130	chr15:43726918~43747094:-
LUAD	cis	rs2658782	0.724	rs2658770	ENSG00000279684.1	RP11-755E23.2	-10.61	8.81e-24	2.16e-20	-0.7	-0.44	Pulmonary function decline;	chr11:93528720	chr11:93286629~93288903:-
LUAD	cis	rs11098499	0.821	rs10032151	ENSG00000245958.5	RP11-33B1.1	-10.61	8.82e-24	2.16e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119470473	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.865	rs10032158	ENSG00000245958.5	RP11-33B1.1	-10.61	8.82e-24	2.16e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119470477	chr4:119454791~119552025:+
LUAD	cis	rs7208859	0.673	rs11651802	ENSG00000263531.1	RP13-753N3.1	10.61	8.87e-24	2.17e-20	0.92	0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832642	chr17:30863921~30864940:-
LUAD	cis	rs9322193	0.886	rs2065663	ENSG00000216906.2	RP11-350J20.9	10.61	8.96e-24	2.19e-20	0.54	0.44	Lung cancer;	chr6:149760331	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs12205092	ENSG00000216906.2	RP11-350J20.9	10.61	8.96e-24	2.19e-20	0.54	0.44	Lung cancer;	chr6:149761375	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.908	rs1002152	ENSG00000245958.5	RP11-33B1.1	-10.61	8.98e-24	2.2e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119352232	chr4:119454791~119552025:+
LUAD	cis	rs1153858	1	rs1145091	ENSG00000259520.4	CTD-2651B20.3	-10.61	9.03e-24	2.21e-20	-0.58	-0.44	Homoarginine levels;	chr15:45357798	chr15:45251580~45279251:-
LUAD	cis	rs2882667	0.537	rs7701338	ENSG00000253404.1	AC034243.1	10.61	9.11e-24	2.23e-20	0.53	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070305	chr5:138744434~138753309:-
LUAD	cis	rs2739330	0.892	rs5751776	ENSG00000099984.9	GSTT2	-10.61	9.12e-24	2.23e-20	-0.52	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23980123~23983911:+
LUAD	cis	rs9322193	0.923	rs12526675	ENSG00000216906.2	RP11-350J20.9	-10.61	9.32e-24	2.28e-20	-0.54	-0.44	Lung cancer;	chr6:149729540	chr6:149904243~149906418:+
LUAD	cis	rs2739330	0.828	rs2154593	ENSG00000099984.9	GSTT2	-10.6	9.45e-24	2.31e-20	-0.52	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23980123~23983911:+
LUAD	cis	rs11098499	0.909	rs71614422	ENSG00000245958.5	RP11-33B1.1	-10.6	9.48e-24	2.32e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119438185	chr4:119454791~119552025:+
LUAD	cis	rs977987	0.741	rs10514393	ENSG00000261783.1	RP11-252K23.2	-10.6	9.56e-24	2.34e-20	-0.57	-0.44	Dupuytren's disease;	chr16:75310578	chr16:75379818~75381260:-
LUAD	cis	rs62229266	0.771	rs62230790	ENSG00000231106.2	LINC01436	10.6	9.61e-24	2.35e-20	0.6	0.44	Mitral valve prolapse;	chr21:36016613	chr21:36005338~36007838:+
LUAD	cis	rs11098499	0.954	rs3733524	ENSG00000245958.5	RP11-33B1.1	-10.6	9.63e-24	2.35e-20	-0.41	-0.44	Corneal astigmatism;	chr4:119502574	chr4:119454791~119552025:+
LUAD	cis	rs6452524	0.967	rs12186460	ENSG00000249664.1	CTD-2227C6.2	10.6	9.7e-24	2.37e-20	0.51	0.44	Hypertension (SNP x SNP interaction);	chr5:83123950	chr5:83012285~83013109:-
LUAD	cis	rs4728142	0.604	rs6467222	ENSG00000275106.1	RP11-309L24.10	-10.6	9.7e-24	2.37e-20	-0.53	-0.44	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129034365	chr7:128952527~128953316:-
LUAD	cis	rs9322193	0.962	rs9765929	ENSG00000216906.2	RP11-350J20.9	10.6	9.86e-24	2.41e-20	0.53	0.44	Lung cancer;	chr6:149769680	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs4870048	ENSG00000216906.2	RP11-350J20.9	10.6	9.96e-24	2.43e-20	0.54	0.44	Lung cancer;	chr6:149834324	chr6:149904243~149906418:+
LUAD	cis	rs2729354	0.953	rs2649650	ENSG00000265566.2	RN7SL605P	-10.6	1e-23	2.44e-20	-0.67	-0.44	Blood protein levels;	chr11:57560094	chr11:57528085~57528365:-
LUAD	cis	rs8040855	0.599	rs4643289	ENSG00000259295.5	CSPG4P12	-10.6	1.02e-23	2.47e-20	-0.5	-0.44	Bulimia nervosa;	chr15:85183483	chr15:85191438~85213905:+
LUAD	cis	rs977987	0.771	rs12929673	ENSG00000261783.1	RP11-252K23.2	-10.6	1.02e-23	2.48e-20	-0.58	-0.44	Dupuytren's disease;	chr16:75436397	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.836	rs35209155	ENSG00000261783.1	RP11-252K23.2	-10.6	1.02e-23	2.48e-20	-0.58	-0.44	Dupuytren's disease;	chr16:75436598	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.872	rs4887825	ENSG00000261783.1	RP11-252K23.2	-10.6	1.02e-23	2.48e-20	-0.58	-0.44	Dupuytren's disease;	chr16:75438524	chr16:75379818~75381260:-
LUAD	cis	rs7186831	1	rs7186831	ENSG00000261783.1	RP11-252K23.2	-10.6	1.02e-23	2.48e-20	-0.58	-0.44	Chronic obstructive pulmonary disease;	chr16:75439257	chr16:75379818~75381260:-
LUAD	cis	rs11098499	0.697	rs11941899	ENSG00000245958.5	RP11-33B1.1	-10.6	1.02e-23	2.49e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119461603	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.909	rs7681978	ENSG00000245958.5	RP11-33B1.1	-10.6	1.02e-23	2.49e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119462620	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.821	rs28665282	ENSG00000245958.5	RP11-33B1.1	-10.6	1.02e-23	2.49e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119463031	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.738	rs10026493	ENSG00000245958.5	RP11-33B1.1	-10.6	1.02e-23	2.49e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119463039	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.909	rs7681214	ENSG00000245958.5	RP11-33B1.1	-10.6	1.02e-23	2.49e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119464165	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.908	rs71614449	ENSG00000245958.5	RP11-33B1.1	-10.6	1.02e-23	2.49e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119465900	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs35063680	ENSG00000245958.5	RP11-33B1.1	-10.6	1.02e-23	2.49e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119465947	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs34858317	ENSG00000245958.5	RP11-33B1.1	-10.6	1.02e-23	2.49e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119465955	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs17046116	ENSG00000245958.5	RP11-33B1.1	-10.6	1.02e-23	2.49e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119466104	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.909	rs17046118	ENSG00000245958.5	RP11-33B1.1	-10.6	1.02e-23	2.49e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119466341	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs7654587	ENSG00000245958.5	RP11-33B1.1	-10.6	1.02e-23	2.49e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119467251	chr4:119454791~119552025:+
LUAD	cis	rs6452524	1	rs9293334	ENSG00000249664.1	CTD-2227C6.2	10.59	1.02e-23	2.49e-20	0.5	0.43	Hypertension (SNP x SNP interaction);	chr5:83156984	chr5:83012285~83013109:-
LUAD	cis	rs11098499	0.779	rs80242894	ENSG00000245958.5	RP11-33B1.1	-10.59	1.02e-23	2.49e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119454597	chr4:119454791~119552025:+
LUAD	cis	rs9322193	0.961	rs9027	ENSG00000216906.2	RP11-350J20.9	10.59	1.03e-23	2.49e-20	0.53	0.43	Lung cancer;	chr6:149594921	chr6:149904243~149906418:+
LUAD	cis	rs11089937	1	rs6001121	ENSG00000211639.2	IGLV4-60	10.59	1.03e-23	2.51e-20	0.45	0.43	Periodontitis (PAL4Q3);	chr22:22149505	chr22:22162199~22162681:+
LUAD	cis	rs11098499	0.954	rs6838814	ENSG00000245958.5	RP11-33B1.1	-10.59	1.04e-23	2.52e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119471288	chr4:119454791~119552025:+
LUAD	cis	rs2019137	1	rs2019137	ENSG00000189223.12	PAX8-AS1	10.59	1.04e-23	2.53e-20	0.58	0.43	Lymphocyte counts;	chr2:113216055	chr2:113211522~113276581:+
LUAD	cis	rs2019137	0.967	rs895412	ENSG00000189223.12	PAX8-AS1	10.59	1.04e-23	2.53e-20	0.58	0.43	Lymphocyte counts;	chr2:113216387	chr2:113211522~113276581:+
LUAD	cis	rs977987	0.806	rs34021527	ENSG00000261783.1	RP11-252K23.2	-10.59	1.04e-23	2.53e-20	-0.58	-0.43	Dupuytren's disease;	chr16:75440192	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.751	rs56004344	ENSG00000261783.1	RP11-252K23.2	-10.59	1.04e-23	2.53e-20	-0.58	-0.43	Dupuytren's disease;	chr16:75440291	chr16:75379818~75381260:-
LUAD	cis	rs5769707	0.846	rs5770610	ENSG00000188511.11	C22orf34	10.59	1.05e-23	2.54e-20	0.49	0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49643249	chr22:49414524~49657542:-
LUAD	cis	rs6452524	0.508	rs256795	ENSG00000249664.1	CTD-2227C6.2	-10.59	1.05e-23	2.56e-20	-0.5	-0.43	Hypertension (SNP x SNP interaction);	chr5:83001543	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs11740478	ENSG00000249664.1	CTD-2227C6.2	10.59	1.05e-23	2.56e-20	0.49	0.43	Hypertension (SNP x SNP interaction);	chr5:83150567	chr5:83012285~83013109:-
LUAD	cis	rs748404	0.516	rs523156	ENSG00000205771.5	CATSPER2P1	10.59	1.06e-23	2.57e-20	0.56	0.43	Lung cancer;	chr15:43519645	chr15:43726918~43747094:-
LUAD	cis	rs9545047	1	rs9545086	ENSG00000227676.3	LINC01068	10.59	1.08e-23	2.62e-20	0.55	0.43	Schizophrenia;	chr13:79364233	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.967	rs9545087	ENSG00000227676.3	LINC01068	10.59	1.08e-23	2.62e-20	0.55	0.43	Schizophrenia;	chr13:79364440	chr13:79566727~79571436:+
LUAD	cis	rs6538678	0.895	rs4762637	ENSG00000199506.1	RNU6-247P	-10.59	1.09e-23	2.63e-20	-0.55	-0.43	Lupus nephritis in systemic lupus erythematosus;	chr12:95888877	chr12:95792529~95792635:-
LUAD	cis	rs694739	0.857	rs574835	ENSG00000236935.1	AP003774.1	10.59	1.1e-23	2.67e-20	0.43	0.43	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64343196	chr11:64325050~64329504:-
LUAD	cis	rs2729354	1	rs2848630	ENSG00000265566.2	RN7SL605P	-10.59	1.1e-23	2.67e-20	-0.68	-0.43	Blood protein levels;	chr11:57589434	chr11:57528085~57528365:-
LUAD	cis	rs4423214	0.592	rs10898186	ENSG00000254682.1	RP11-660L16.2	-10.59	1.11e-23	2.69e-20	-0.65	-0.43	Vitamin D levels;	chr11:71477754	chr11:71448674~71452157:+
LUAD	cis	rs11098499	0.908	rs28559989	ENSG00000245958.5	RP11-33B1.1	-10.58	1.12e-23	2.71e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119465472	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.909	rs28632018	ENSG00000245958.5	RP11-33B1.1	-10.58	1.12e-23	2.71e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119465575	chr4:119454791~119552025:+
LUAD	cis	rs977987	0.806	rs766521	ENSG00000261783.1	RP11-252K23.2	10.58	1.12e-23	2.71e-20	0.57	0.43	Dupuytren's disease;	chr16:75390256	chr16:75379818~75381260:-
LUAD	cis	rs4728142	0.604	rs12155080	ENSG00000275106.1	RP11-309L24.10	-10.58	1.12e-23	2.72e-20	-0.52	-0.43	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129018685	chr7:128952527~128953316:-
LUAD	cis	rs875971	0.862	rs4718330	ENSG00000226824.5	RP4-756H11.3	10.58	1.13e-23	2.73e-20	0.56	0.43	Aortic root size;	chr7:66250256	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.923	rs2342765	ENSG00000216906.2	RP11-350J20.9	10.58	1.14e-23	2.76e-20	0.54	0.43	Lung cancer;	chr6:149858873	chr6:149904243~149906418:+
LUAD	cis	rs2929278	0.588	rs688009	ENSG00000205771.5	CATSPER2P1	-10.58	1.15e-23	2.77e-20	-0.55	-0.43	Schizophrenia;	chr15:43864104	chr15:43726918~43747094:-
LUAD	cis	rs11098499	0.618	rs35265692	ENSG00000245958.5	RP11-33B1.1	-10.58	1.15e-23	2.79e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119403980	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.908	rs9995234	ENSG00000245958.5	RP11-33B1.1	-10.58	1.19e-23	2.87e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119400672	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.954	rs1022145	ENSG00000245958.5	RP11-33B1.1	-10.58	1.19e-23	2.88e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119309824	chr4:119454791~119552025:+
LUAD	cis	rs1153858	1	rs2453541	ENSG00000259520.4	CTD-2651B20.3	-10.58	1.19e-23	2.88e-20	-0.58	-0.43	Homoarginine levels;	chr15:45353180	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs2461702	ENSG00000259520.4	CTD-2651B20.3	-10.58	1.19e-23	2.88e-20	-0.58	-0.43	Homoarginine levels;	chr15:45355229	chr15:45251580~45279251:-
LUAD	cis	rs11098499	0.738	rs28408407	ENSG00000245958.5	RP11-33B1.1	-10.58	1.19e-23	2.88e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119454875	chr4:119454791~119552025:+
LUAD	cis	rs2739330	0.828	rs4820572	ENSG00000099984.9	GSTT2	-10.58	1.2e-23	2.89e-20	-0.53	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23980123~23983911:+
LUAD	cis	rs11723261	0.582	rs6599293	ENSG00000275426.1	CH17-262A2.1	10.58	1.21e-23	2.91e-20	0.6	0.43	Immune response to smallpox vaccine (IL-6);	chr4:139246	chr4:149738~150317:+
LUAD	cis	rs2455601	0.574	rs2568094	ENSG00000254860.4	TMEM9B-AS1	10.58	1.21e-23	2.92e-20	0.58	0.43	Schizophrenia;	chr11:8970671	chr11:8964675~8977527:+
LUAD	cis	rs8062405	0.755	rs4788073	ENSG00000259982.1	CDC37P1	10.57	1.24e-23	2.98e-20	0.55	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28700294~28701540:-
LUAD	cis	rs4728142	0.604	rs7783384	ENSG00000275106.1	RP11-309L24.10	-10.57	1.24e-23	2.99e-20	-0.53	-0.43	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129041243	chr7:128952527~128953316:-
LUAD	cis	rs11690935	1	rs11678984	ENSG00000228389.1	AC068039.4	-10.57	1.24e-23	3e-20	-0.51	-0.43	Schizophrenia;	chr2:171679338	chr2:171773482~171775844:+
LUAD	cis	rs9322193	0.923	rs4869750	ENSG00000216906.2	RP11-350J20.9	10.57	1.25e-23	3e-20	0.53	0.43	Lung cancer;	chr6:149855996	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.738	rs34965784	ENSG00000245958.5	RP11-33B1.1	-10.57	1.26e-23	3.03e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119440431	chr4:119454791~119552025:+
LUAD	cis	rs2581828	0.656	rs4687701	ENSG00000242142.1	SERBP1P3	-10.57	1.27e-23	3.07e-20	-0.45	-0.43	Crohn's disease;	chr3:53087260	chr3:53064283~53065091:-
LUAD	cis	rs748404	0.588	rs2255410	ENSG00000205771.5	CATSPER2P1	-10.57	1.28e-23	3.09e-20	-0.55	-0.43	Lung cancer;	chr15:43538899	chr15:43726918~43747094:-
LUAD	cis	rs11690935	1	rs6433311	ENSG00000228389.1	AC068039.4	-10.57	1.28e-23	3.09e-20	-0.51	-0.43	Schizophrenia;	chr2:171692738	chr2:171773482~171775844:+
LUAD	cis	rs875971	0.862	rs6460302	ENSG00000226824.5	RP4-756H11.3	-10.57	1.28e-23	3.09e-20	-0.56	-0.43	Aortic root size;	chr7:66495270	chr7:66654538~66669855:+
LUAD	cis	rs6452524	1	rs13436667	ENSG00000249664.1	CTD-2227C6.2	10.57	1.29e-23	3.1e-20	0.49	0.43	Hypertension (SNP x SNP interaction);	chr5:83168948	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs7726564	ENSG00000249664.1	CTD-2227C6.2	10.57	1.29e-23	3.1e-20	0.49	0.43	Hypertension (SNP x SNP interaction);	chr5:83170274	chr5:83012285~83013109:-
LUAD	cis	rs2337406	0.866	rs4280141	ENSG00000274576.2	IGHV2-70	10.57	1.3e-23	3.13e-20	0.46	0.43	Alzheimer's disease (late onset);	chr14:106780476	chr14:106770577~106771020:-
LUAD	cis	rs5769707	0.967	rs739248	ENSG00000188511.11	C22orf34	10.56	1.33e-23	3.19e-20	0.49	0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49631557	chr22:49414524~49657542:-
LUAD	cis	rs5769707	0.967	rs9616701	ENSG00000188511.11	C22orf34	10.56	1.33e-23	3.19e-20	0.49	0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49631898	chr22:49414524~49657542:-
LUAD	cis	rs904251	0.797	rs1757177	ENSG00000279942.1	RP1-153P14.7	-10.56	1.35e-23	3.25e-20	-0.41	-0.43	Cognitive performance;	chr6:37518594	chr6:37567716~37571460:+
LUAD	cis	rs9322193	0.962	rs1413655	ENSG00000216906.2	RP11-350J20.9	10.56	1.35e-23	3.25e-20	0.54	0.43	Lung cancer;	chr6:149821815	chr6:149904243~149906418:+
LUAD	cis	rs904251	0.522	rs882322	ENSG00000279942.1	RP1-153P14.7	-10.56	1.36e-23	3.26e-20	-0.4	-0.43	Cognitive performance;	chr6:37516327	chr6:37567716~37571460:+
LUAD	cis	rs977987	0.806	rs35937717	ENSG00000261783.1	RP11-252K23.2	-10.56	1.36e-23	3.27e-20	-0.57	-0.43	Dupuytren's disease;	chr16:75297669	chr16:75379818~75381260:-
LUAD	cis	rs6538678	0.746	rs12820313	ENSG00000199506.1	RNU6-247P	-10.56	1.36e-23	3.27e-20	-0.57	-0.43	Lupus nephritis in systemic lupus erythematosus;	chr12:95861926	chr12:95792529~95792635:-
LUAD	cis	rs6452524	1	rs6452531	ENSG00000249664.1	CTD-2227C6.2	10.56	1.37e-23	3.28e-20	0.49	0.43	Hypertension (SNP x SNP interaction);	chr5:83170355	chr5:83012285~83013109:-
LUAD	cis	rs977987	0.843	rs10871312	ENSG00000261783.1	RP11-252K23.2	-10.56	1.38e-23	3.31e-20	-0.58	-0.43	Dupuytren's disease;	chr16:75452304	chr16:75379818~75381260:-
LUAD	cis	rs9545047	1	rs9574422	ENSG00000227676.3	LINC01068	10.56	1.4e-23	3.35e-20	0.56	0.43	Schizophrenia;	chr13:79415246	chr13:79566727~79571436:+
LUAD	cis	rs9322193	0.962	rs4869730	ENSG00000216906.2	RP11-350J20.9	10.56	1.41e-23	3.38e-20	0.53	0.43	Lung cancer;	chr6:149808187	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs2151913	ENSG00000216906.2	RP11-350J20.9	10.56	1.41e-23	3.38e-20	0.53	0.43	Lung cancer;	chr6:149809506	chr6:149904243~149906418:+
LUAD	cis	rs6782228	0.565	rs11719239	ENSG00000242551.2	POU5F1P6	-10.56	1.41e-23	3.38e-20	-0.49	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700211	chr3:128674735~128677005:-
LUAD	cis	rs6782228	0.606	rs2001950	ENSG00000242551.2	POU5F1P6	-10.56	1.41e-23	3.38e-20	-0.49	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700913	chr3:128674735~128677005:-
LUAD	cis	rs2658782	0.724	rs2605629	ENSG00000279684.1	RP11-755E23.2	10.56	1.41e-23	3.39e-20	0.69	0.43	Pulmonary function decline;	chr11:93530871	chr11:93286629~93288903:-
LUAD	cis	rs7396835	1	rs7396835	ENSG00000254851.1	RP11-109L13.1	-10.56	1.44e-23	3.44e-20	-0.72	-0.43	Quantitative traits;	chr11:116813312	chr11:117135528~117138582:+
LUAD	cis	rs62229266	0.804	rs2835259	ENSG00000231106.2	LINC01436	10.56	1.44e-23	3.44e-20	0.59	0.43	Mitral valve prolapse;	chr21:36053004	chr21:36005338~36007838:+
LUAD	cis	rs8062405	0.755	rs55792032	ENSG00000259982.1	CDC37P1	10.55	1.46e-23	3.49e-20	0.54	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28700294~28701540:-
LUAD	cis	rs977987	0.835	rs1010630	ENSG00000261783.1	RP11-252K23.2	-10.55	1.46e-23	3.51e-20	-0.57	-0.43	Dupuytren's disease;	chr16:75294693	chr16:75379818~75381260:-
LUAD	cis	rs9322193	0.962	rs2065664	ENSG00000216906.2	RP11-350J20.9	10.55	1.49e-23	3.57e-20	0.54	0.43	Lung cancer;	chr6:149762485	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.505	rs75122014	ENSG00000245958.5	RP11-33B1.1	-10.55	1.51e-23	3.61e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119441271	chr4:119454791~119552025:+
LUAD	cis	rs875971	0.862	rs1167390	ENSG00000226824.5	RP4-756H11.3	10.55	1.53e-23	3.67e-20	0.56	0.43	Aortic root size;	chr7:66110906	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs35034167	ENSG00000226824.5	RP4-756H11.3	10.55	1.53e-23	3.67e-20	0.56	0.43	Aortic root size;	chr7:66115179	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.926	rs3805751	ENSG00000216906.2	RP11-350J20.9	10.55	1.55e-23	3.7e-20	0.53	0.43	Lung cancer;	chr6:149791193	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs10872656	ENSG00000216906.2	RP11-350J20.9	10.55	1.55e-23	3.7e-20	0.53	0.43	Lung cancer;	chr6:149799444	chr6:149904243~149906418:+
LUAD	cis	rs904251	0.861	rs1776456	ENSG00000204110.6	RP1-153P14.8	-10.55	1.55e-23	3.71e-20	-0.45	-0.43	Cognitive performance;	chr6:37516922	chr6:37507348~37535616:+
LUAD	cis	rs950027	0.62	rs1145077	ENSG00000259520.4	CTD-2651B20.3	10.55	1.55e-23	3.71e-20	0.54	0.43	Response to fenofibrate (adiponectin levels);	chr15:45391597	chr15:45251580~45279251:-
LUAD	cis	rs2739330	0.828	rs5760108	ENSG00000099984.9	GSTT2	-10.55	1.56e-23	3.72e-20	-0.52	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23980123~23983911:+
LUAD	cis	rs11690935	1	rs12053003	ENSG00000228389.1	AC068039.4	-10.55	1.56e-23	3.73e-20	-0.51	-0.43	Schizophrenia;	chr2:171680840	chr2:171773482~171775844:+
LUAD	cis	rs6452524	1	rs2126988	ENSG00000249664.1	CTD-2227C6.2	10.54	1.58e-23	3.78e-20	0.49	0.43	Hypertension (SNP x SNP interaction);	chr5:83146496	chr5:83012285~83013109:-
LUAD	cis	rs11098499	0.738	rs72918577	ENSG00000245958.5	RP11-33B1.1	-10.54	1.58e-23	3.78e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119405546	chr4:119454791~119552025:+
LUAD	cis	rs507080	0.733	rs7108144	ENSG00000255239.1	AP002954.6	10.54	1.58e-23	3.78e-20	0.53	0.43	Serum metabolite levels;	chr11:118698985	chr11:118688039~118690600:-
LUAD	cis	rs2929278	0.589	rs2411284	ENSG00000205771.5	CATSPER2P1	10.54	1.58e-23	3.78e-20	0.55	0.43	Schizophrenia;	chr15:43746701	chr15:43726918~43747094:-
LUAD	cis	rs6504950	0.83	rs72831295	ENSG00000275710.1	RP11-257O5.4	10.54	1.59e-23	3.8e-20	0.57	0.43	Breast cancer;	chr17:54966443	chr17:54964474~54964679:+
LUAD	cis	rs977987	0.843	rs12927562	ENSG00000261783.1	RP11-252K23.2	-10.54	1.61e-23	3.84e-20	-0.58	-0.43	Dupuytren's disease;	chr16:75448962	chr16:75379818~75381260:-
LUAD	cis	rs2019137	0.936	rs12612729	ENSG00000189223.12	PAX8-AS1	10.54	1.61e-23	3.85e-20	0.58	0.43	Lymphocyte counts;	chr2:113199471	chr2:113211522~113276581:+
LUAD	cis	rs2019137	0.936	rs731834	ENSG00000189223.12	PAX8-AS1	10.54	1.61e-23	3.85e-20	0.58	0.43	Lymphocyte counts;	chr2:113199621	chr2:113211522~113276581:+
LUAD	cis	rs875971	0.862	rs6460293	ENSG00000226824.5	RP4-756H11.3	10.54	1.62e-23	3.86e-20	0.55	0.43	Aortic root size;	chr7:66345205	chr7:66654538~66669855:+
LUAD	cis	rs977987	0.806	rs4888389	ENSG00000261783.1	RP11-252K23.2	-10.54	1.63e-23	3.88e-20	-0.58	-0.43	Dupuytren's disease;	chr16:75361330	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs11865004	ENSG00000261783.1	RP11-252K23.2	-10.54	1.63e-23	3.88e-20	-0.58	-0.43	Dupuytren's disease;	chr16:75361879	chr16:75379818~75381260:-
LUAD	cis	rs9322193	0.923	rs14314	ENSG00000216906.2	RP11-350J20.9	10.54	1.63e-23	3.89e-20	0.53	0.43	Lung cancer;	chr6:149820395	chr6:149904243~149906418:+
LUAD	cis	rs977987	0.806	rs4888405	ENSG00000261783.1	RP11-252K23.2	-10.54	1.63e-23	3.89e-20	-0.57	-0.43	Dupuytren's disease;	chr16:75394298	chr16:75379818~75381260:-
LUAD	cis	rs748404	0.56	rs689797	ENSG00000205771.5	CATSPER2P1	-10.54	1.64e-23	3.9e-20	-0.55	-0.43	Lung cancer;	chr15:43534359	chr15:43726918~43747094:-
LUAD	cis	rs2019137	0.936	rs2305133	ENSG00000189223.12	PAX8-AS1	10.54	1.66e-23	3.95e-20	0.58	0.43	Lymphocyte counts;	chr2:113199244	chr2:113211522~113276581:+
LUAD	cis	rs904251	0.504	rs12202664	ENSG00000279942.1	RP1-153P14.7	-10.54	1.67e-23	3.97e-20	-0.41	-0.43	Cognitive performance;	chr6:37513422	chr6:37567716~37571460:+
LUAD	cis	rs507080	0.663	rs523793	ENSG00000255239.1	AP002954.6	10.54	1.68e-23	4e-20	0.53	0.43	Serum metabolite levels;	chr11:118699988	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.736	rs659564	ENSG00000255239.1	AP002954.6	10.54	1.68e-23	4e-20	0.53	0.43	Serum metabolite levels;	chr11:118700205	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.736	rs642224	ENSG00000255239.1	AP002954.6	10.54	1.68e-23	4e-20	0.53	0.43	Serum metabolite levels;	chr11:118700210	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.733	rs541631	ENSG00000255239.1	AP002954.6	10.54	1.68e-23	4e-20	0.53	0.43	Serum metabolite levels;	chr11:118700314	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.736	rs658676	ENSG00000255239.1	AP002954.6	10.54	1.68e-23	4e-20	0.53	0.43	Serum metabolite levels;	chr11:118700414	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.733	rs488141	ENSG00000255239.1	AP002954.6	10.54	1.68e-23	4e-20	0.53	0.43	Serum metabolite levels;	chr11:118700459	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.733	rs657769	ENSG00000255239.1	AP002954.6	10.54	1.68e-23	4e-20	0.53	0.43	Serum metabolite levels;	chr11:118700607	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.733	rs544452	ENSG00000255239.1	AP002954.6	10.54	1.68e-23	4e-20	0.53	0.43	Serum metabolite levels;	chr11:118700648	chr11:118688039~118690600:-
LUAD	cis	rs2019137	0.936	rs12620738	ENSG00000189223.12	PAX8-AS1	10.54	1.7e-23	4.05e-20	0.58	0.43	Lymphocyte counts;	chr2:113206162	chr2:113211522~113276581:+
LUAD	cis	rs9322193	0.962	rs4552	ENSG00000216906.2	RP11-350J20.9	10.54	1.7e-23	4.05e-20	0.53	0.43	Lung cancer;	chr6:149811183	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.865	rs11722183	ENSG00000245958.5	RP11-33B1.1	-10.54	1.71e-23	4.07e-20	-0.4	-0.43	Corneal astigmatism;	chr4:119359442	chr4:119454791~119552025:+
LUAD	cis	rs2019137	0.967	rs902695	ENSG00000189223.12	PAX8-AS1	10.54	1.71e-23	4.07e-20	0.58	0.43	Lymphocyte counts;	chr2:113197497	chr2:113211522~113276581:+
LUAD	cis	rs2019137	0.905	rs2276561	ENSG00000189223.12	PAX8-AS1	10.54	1.71e-23	4.07e-20	0.58	0.43	Lymphocyte counts;	chr2:113198794	chr2:113211522~113276581:+
LUAD	cis	rs977987	0.778	rs7203157	ENSG00000261783.1	RP11-252K23.2	-10.54	1.72e-23	4.08e-20	-0.58	-0.43	Dupuytren's disease;	chr16:75384022	chr16:75379818~75381260:-
LUAD	cis	rs7688540	0.511	rs10003260	ENSG00000275426.1	CH17-262A2.1	10.54	1.72e-23	4.09e-20	0.66	0.43	Facial morphology (factor 6, height of vermillion lower lip);	chr4:191053	chr4:149738~150317:+
LUAD	cis	rs748404	0.56	rs570933	ENSG00000205771.5	CATSPER2P1	-10.53	1.73e-23	4.11e-20	-0.55	-0.43	Lung cancer;	chr15:43531832	chr15:43726918~43747094:-
LUAD	cis	rs875971	0.825	rs1000464	ENSG00000226824.5	RP4-756H11.3	10.53	1.73e-23	4.11e-20	0.56	0.43	Aortic root size;	chr7:66312922	chr7:66654538~66669855:+
LUAD	cis	rs694739	0.734	rs663743	ENSG00000236935.1	AP003774.1	10.53	1.73e-23	4.12e-20	0.44	0.43	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64340263	chr11:64325050~64329504:-
LUAD	cis	rs2019137	0.936	rs902696	ENSG00000189223.12	PAX8-AS1	-10.53	1.74e-23	4.13e-20	-0.58	-0.43	Lymphocyte counts;	chr2:113197302	chr2:113211522~113276581:+
LUAD	cis	rs5769707	0.935	rs5770594	ENSG00000188511.11	C22orf34	10.53	1.75e-23	4.15e-20	0.49	0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49624849	chr22:49414524~49657542:-
LUAD	cis	rs5769707	0.967	rs4524218	ENSG00000188511.11	C22orf34	10.53	1.75e-23	4.15e-20	0.49	0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49624991	chr22:49414524~49657542:-
LUAD	cis	rs62229266	0.773	rs878606	ENSG00000231106.2	LINC01436	10.53	1.75e-23	4.17e-20	0.6	0.43	Mitral valve prolapse;	chr21:36034394	chr21:36005338~36007838:+
LUAD	cis	rs9322193	0.884	rs1125	ENSG00000216906.2	RP11-350J20.9	10.53	1.76e-23	4.18e-20	0.56	0.43	Lung cancer;	chr6:149658280	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs1934534	ENSG00000216906.2	RP11-350J20.9	10.53	1.76e-23	4.19e-20	0.52	0.43	Lung cancer;	chr6:149711896	chr6:149904243~149906418:+
LUAD	cis	rs2019137	0.936	rs3811059	ENSG00000189223.12	PAX8-AS1	10.53	1.79e-23	4.24e-20	0.58	0.43	Lymphocyte counts;	chr2:113204494	chr2:113211522~113276581:+
LUAD	cis	rs875971	0.862	rs6971059	ENSG00000226824.5	RP4-756H11.3	10.53	1.79e-23	4.26e-20	0.55	0.43	Aortic root size;	chr7:66602045	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs6958294	ENSG00000226824.5	RP4-756H11.3	10.53	1.81e-23	4.3e-20	0.55	0.43	Aortic root size;	chr7:66329809	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs2088655	ENSG00000226824.5	RP4-756H11.3	10.53	1.81e-23	4.3e-20	0.55	0.43	Aortic root size;	chr7:66330724	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.895	rs10447522	ENSG00000226824.5	RP4-756H11.3	10.53	1.81e-23	4.3e-20	0.55	0.43	Aortic root size;	chr7:66331087	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs2088653	ENSG00000226824.5	RP4-756H11.3	10.53	1.81e-23	4.3e-20	0.55	0.43	Aortic root size;	chr7:66343621	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs778736	ENSG00000226824.5	RP4-756H11.3	-10.53	1.81e-23	4.3e-20	-0.55	-0.43	Aortic root size;	chr7:66348861	chr7:66654538~66669855:+
LUAD	cis	rs6452524	0.935	rs2731846	ENSG00000249664.1	CTD-2227C6.2	10.53	1.83e-23	4.34e-20	0.5	0.43	Hypertension (SNP x SNP interaction);	chr5:83193781	chr5:83012285~83013109:-
LUAD	cis	rs875971	0.862	rs2901152	ENSG00000226824.5	RP4-756H11.3	10.53	1.83e-23	4.35e-20	0.56	0.43	Aortic root size;	chr7:66300017	chr7:66654538~66669855:+
LUAD	cis	rs2658782	0.593	rs2243410	ENSG00000279684.1	RP11-755E23.2	-10.53	1.84e-23	4.36e-20	-0.66	-0.43	Pulmonary function decline;	chr11:93522353	chr11:93286629~93288903:-
LUAD	cis	rs6538678	0.746	rs703693	ENSG00000199506.1	RNU6-247P	-10.53	1.85e-23	4.39e-20	-0.59	-0.43	Lupus nephritis in systemic lupus erythematosus;	chr12:95866214	chr12:95792529~95792635:-
LUAD	cis	rs9322193	0.884	rs1108889	ENSG00000216906.2	RP11-350J20.9	10.53	1.86e-23	4.41e-20	0.55	0.43	Lung cancer;	chr6:149845433	chr6:149904243~149906418:+
LUAD	cis	rs7104764	0.507	rs6598054	ENSG00000277290.1	RP11-326C3.16	10.53	1.86e-23	4.41e-20	0.48	0.43	Menarche (age at onset);	chr11:254010	chr11:243099~243483:-
LUAD	cis	rs2188561	0.697	rs6947099	ENSG00000241764.3	AC002467.7	10.52	1.88e-23	4.46e-20	0.59	0.43	Alcohol consumption;	chr7:107720471	chr7:107742817~107744581:-
LUAD	cis	rs11690935	1	rs35549875	ENSG00000228389.1	AC068039.4	-10.52	1.89e-23	4.48e-20	-0.51	-0.43	Schizophrenia;	chr2:171675882	chr2:171773482~171775844:+
LUAD	cis	rs858239	0.712	rs200717	ENSG00000230658.1	KLHL7-AS1	10.52	1.9e-23	4.49e-20	0.53	0.43	Cerebrospinal fluid biomarker levels;	chr7:23352652	chr7:23101228~23105703:-
LUAD	cis	rs9399135	0.66	rs9389248	ENSG00000232876.1	CTA-212D2.2	-10.52	1.91e-23	4.52e-20	-0.49	-0.43	Red blood cell count;	chr6:134961518	chr6:135055033~135060550:+
LUAD	cis	rs3096299	0.728	rs1011749	ENSG00000274627.1	RP11-104N10.2	10.52	1.91e-23	4.52e-20	0.42	0.43	Multiple myeloma (IgH translocation);	chr16:89444461	chr16:89516797~89522217:+
LUAD	cis	rs904251	0.523	rs1776454	ENSG00000279942.1	RP1-153P14.7	-10.52	1.93e-23	4.56e-20	-0.4	-0.43	Cognitive performance;	chr6:37514323	chr6:37567716~37571460:+
LUAD	cis	rs507080	0.733	rs4486664	ENSG00000255239.1	AP002954.6	10.52	1.95e-23	4.62e-20	0.52	0.43	Serum metabolite levels;	chr11:118698358	chr11:118688039~118690600:-
LUAD	cis	rs4728142	0.604	rs10954215	ENSG00000275106.1	RP11-309L24.10	-10.52	1.99e-23	4.7e-20	-0.52	-0.43	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129005459	chr7:128952527~128953316:-
LUAD	cis	rs875971	0.862	rs6460290	ENSG00000226824.5	RP4-756H11.3	10.52	2e-23	4.72e-20	0.55	0.43	Aortic root size;	chr7:66344119	chr7:66654538~66669855:+
LUAD	cis	rs11690935	0.959	rs12692973	ENSG00000228389.1	AC068039.4	-10.52	2e-23	4.72e-20	-0.51	-0.43	Schizophrenia;	chr2:171785547	chr2:171773482~171775844:+
LUAD	cis	rs875971	0.862	rs28470208	ENSG00000226824.5	RP4-756H11.3	10.52	2e-23	4.73e-20	0.55	0.43	Aortic root size;	chr7:66119713	chr7:66654538~66669855:+
LUAD	cis	rs6452524	0.71	rs7708124	ENSG00000249664.1	CTD-2227C6.2	10.52	2.02e-23	4.76e-20	0.5	0.43	Hypertension (SNP x SNP interaction);	chr5:83132035	chr5:83012285~83013109:-
LUAD	cis	rs6782228	0.606	rs6775270	ENSG00000242551.2	POU5F1P6	-10.52	2.02e-23	4.77e-20	-0.48	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128684655	chr3:128674735~128677005:-
LUAD	cis	rs4814920	0.756	rs6075586	ENSG00000275142.1	RP5-999L4.2	-10.52	2.02e-23	4.77e-20	-0.77	-0.43	Bipolar disorder (body mass index interaction);	chr20:19874650	chr20:19871891~19872284:+
LUAD	cis	rs748404	0.66	rs493377	ENSG00000205771.5	CATSPER2P1	-10.52	2.03e-23	4.79e-20	-0.55	-0.43	Lung cancer;	chr15:43481269	chr15:43726918~43747094:-
LUAD	cis	rs11098499	0.865	rs28634456	ENSG00000245958.5	RP11-33B1.1	-10.51	2.05e-23	4.84e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119454623	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.909	rs78332141	ENSG00000245958.5	RP11-33B1.1	-10.51	2.05e-23	4.84e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119454627	chr4:119454791~119552025:+
LUAD	cis	rs4423214	0.592	rs10898193	ENSG00000254682.1	RP11-660L16.2	10.51	2.05e-23	4.84e-20	0.64	0.43	Vitamin D levels;	chr11:71486037	chr11:71448674~71452157:+
LUAD	cis	rs62229266	0.74	rs4817759	ENSG00000231106.2	LINC01436	10.51	2.08e-23	4.91e-20	0.6	0.43	Mitral valve prolapse;	chr21:36017261	chr21:36005338~36007838:+
LUAD	cis	rs62229266	0.771	rs2835232	ENSG00000231106.2	LINC01436	10.51	2.08e-23	4.91e-20	0.6	0.43	Mitral valve prolapse;	chr21:36021129	chr21:36005338~36007838:+
LUAD	cis	rs62229266	0.74	rs2835233	ENSG00000231106.2	LINC01436	10.51	2.08e-23	4.91e-20	0.6	0.43	Mitral valve prolapse;	chr21:36021284	chr21:36005338~36007838:+
LUAD	cis	rs8062405	0.755	rs17640009	ENSG00000259982.1	CDC37P1	10.51	2.09e-23	4.94e-20	0.54	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28700294~28701540:-
LUAD	cis	rs11098499	0.863	rs3775841	ENSG00000245958.5	RP11-33B1.1	-10.51	2.1e-23	4.95e-20	-0.4	-0.43	Corneal astigmatism;	chr4:119504622	chr4:119454791~119552025:+
LUAD	cis	rs875971	1	rs6946143	ENSG00000226824.5	RP4-756H11.3	-10.51	2.1e-23	4.97e-20	-0.55	-0.43	Aortic root size;	chr7:66114735	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.962	rs3805753	ENSG00000216906.2	RP11-350J20.9	10.51	2.14e-23	5.05e-20	0.53	0.43	Lung cancer;	chr6:149795662	chr6:149904243~149906418:+
LUAD	cis	rs11690935	0.959	rs6754817	ENSG00000228389.1	AC068039.4	10.51	2.15e-23	5.06e-20	0.52	0.43	Schizophrenia;	chr2:171806884	chr2:171773482~171775844:+
LUAD	cis	rs875971	0.825	rs1129531	ENSG00000226824.5	RP4-756H11.3	10.51	2.16e-23	5.08e-20	0.56	0.43	Aortic root size;	chr7:66154117	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.923	rs11155683	ENSG00000216906.2	RP11-350J20.9	10.5	2.23e-23	5.25e-20	0.53	0.43	Lung cancer;	chr6:149779341	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs9372044	ENSG00000216906.2	RP11-350J20.9	10.5	2.23e-23	5.25e-20	0.53	0.43	Lung cancer;	chr6:149780867	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs11155685	ENSG00000216906.2	RP11-350J20.9	10.5	2.23e-23	5.25e-20	0.53	0.43	Lung cancer;	chr6:149781649	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs9689269	ENSG00000216906.2	RP11-350J20.9	10.5	2.23e-23	5.25e-20	0.53	0.43	Lung cancer;	chr6:149791861	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs62441335	ENSG00000216906.2	RP11-350J20.9	10.5	2.23e-23	5.25e-20	0.53	0.43	Lung cancer;	chr6:149792658	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs4816	ENSG00000216906.2	RP11-350J20.9	10.5	2.23e-23	5.25e-20	0.53	0.43	Lung cancer;	chr6:149793609	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.926	rs952166	ENSG00000216906.2	RP11-350J20.9	10.5	2.23e-23	5.25e-20	0.53	0.43	Lung cancer;	chr6:149798774	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs952165	ENSG00000216906.2	RP11-350J20.9	10.5	2.23e-23	5.25e-20	0.53	0.43	Lung cancer;	chr6:149798900	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.926	rs9285525	ENSG00000216906.2	RP11-350J20.9	10.5	2.23e-23	5.25e-20	0.53	0.43	Lung cancer;	chr6:149801253	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.884	rs2342858	ENSG00000216906.2	RP11-350J20.9	10.5	2.23e-23	5.25e-20	0.53	0.43	Lung cancer;	chr6:149805967	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.884	rs2095375	ENSG00000216906.2	RP11-350J20.9	10.5	2.23e-23	5.25e-20	0.53	0.43	Lung cancer;	chr6:149807037	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.908	rs28499576	ENSG00000245958.5	RP11-33B1.1	-10.5	2.24e-23	5.28e-20	-0.41	-0.43	Corneal astigmatism;	chr4:119465522	chr4:119454791~119552025:+
LUAD	cis	rs11690935	1	rs3795999	ENSG00000228389.1	AC068039.4	-10.5	2.27e-23	5.33e-20	-0.51	-0.43	Schizophrenia;	chr2:171687973	chr2:171773482~171775844:+
LUAD	cis	rs9322193	0.886	rs4870055	ENSG00000216906.2	RP11-350J20.9	10.5	2.27e-23	5.35e-20	0.53	0.43	Lung cancer;	chr6:149848433	chr6:149904243~149906418:+
LUAD	cis	rs2929278	0.617	rs12908467	ENSG00000205771.5	CATSPER2P1	10.5	2.28e-23	5.37e-20	0.55	0.43	Schizophrenia;	chr15:43755232	chr15:43726918~43747094:-
LUAD	cis	rs11690935	1	rs1554166	ENSG00000228389.1	AC068039.4	10.5	2.3e-23	5.42e-20	0.5	0.43	Schizophrenia;	chr2:171685099	chr2:171773482~171775844:+
LUAD	cis	rs11118620	0.853	rs11118622	ENSG00000272823.1	RP11-295M18.6	10.5	2.33e-23	5.47e-20	0.53	0.43	Heart failure;	chr1:220868833	chr1:220828676~220829211:-
LUAD	cis	rs875971	0.862	rs10263690	ENSG00000226824.5	RP4-756H11.3	10.5	2.33e-23	5.48e-20	0.55	0.43	Aortic root size;	chr7:66301466	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs10250544	ENSG00000226824.5	RP4-756H11.3	10.5	2.33e-23	5.48e-20	0.55	0.43	Aortic root size;	chr7:66301574	chr7:66654538~66669855:+
LUAD	cis	rs2283792	0.687	rs381849	ENSG00000224086.5	LL22NC03-86G7.1	-10.5	2.34e-23	5.49e-20	-0.4	-0.43	Multiple sclerosis;	chr22:21951341	chr22:21938293~21977632:+
LUAD	cis	rs16828019	0.929	rs1032728	ENSG00000235358.1	RP11-399E6.1	10.5	2.35e-23	5.51e-20	0.75	0.43	Intelligence (multi-trait analysis);	chr1:41213894	chr1:41242373~41284861:+
LUAD	cis	rs904251	0.504	rs9380677	ENSG00000279942.1	RP1-153P14.7	-10.5	2.35e-23	5.52e-20	-0.4	-0.43	Cognitive performance;	chr6:37512590	chr6:37567716~37571460:+
LUAD	cis	rs8062405	0.755	rs7186573	ENSG00000259982.1	CDC37P1	10.5	2.38e-23	5.59e-20	0.54	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28700294~28701540:-
LUAD	cis	rs2929278	0.617	rs3087657	ENSG00000205771.5	CATSPER2P1	-10.5	2.39e-23	5.61e-20	-0.53	-0.43	Schizophrenia;	chr15:43771661	chr15:43726918~43747094:-
LUAD	cis	rs4728142	0.584	rs7796963	ENSG00000275106.1	RP11-309L24.10	-10.49	2.44e-23	5.72e-20	-0.52	-0.43	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128988947	chr7:128952527~128953316:-
LUAD	cis	rs6538678	0.929	rs10735336	ENSG00000199506.1	RNU6-247P	-10.49	2.45e-23	5.75e-20	-0.56	-0.43	Lupus nephritis in systemic lupus erythematosus;	chr12:95869661	chr12:95792529~95792635:-
LUAD	cis	rs6504950	0.72	rs9914836	ENSG00000275710.1	RP11-257O5.4	10.49	2.45e-23	5.75e-20	0.56	0.43	Breast cancer;	chr17:54920514	chr17:54964474~54964679:+
LUAD	cis	rs6452524	0.967	rs2974448	ENSG00000249664.1	CTD-2227C6.2	10.49	2.46e-23	5.77e-20	0.48	0.43	Hypertension (SNP x SNP interaction);	chr5:83190937	chr5:83012285~83013109:-
LUAD	cis	rs748404	0.66	rs542898	ENSG00000205771.5	CATSPER2P1	-10.49	2.48e-23	5.82e-20	-0.54	-0.43	Lung cancer;	chr15:43427194	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.66	rs690012	ENSG00000205771.5	CATSPER2P1	-10.49	2.48e-23	5.82e-20	-0.54	-0.43	Lung cancer;	chr15:43427557	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.66	rs689767	ENSG00000205771.5	CATSPER2P1	-10.49	2.48e-23	5.82e-20	-0.54	-0.43	Lung cancer;	chr15:43429879	chr15:43726918~43747094:-
LUAD	cis	rs8040855	0.756	rs12909477	ENSG00000259295.5	CSPG4P12	-10.49	2.5e-23	5.87e-20	-0.58	-0.43	Bulimia nervosa;	chr15:85146644	chr15:85191438~85213905:+
LUAD	cis	rs6452524	1	rs10474094	ENSG00000249664.1	CTD-2227C6.2	10.49	2.57e-23	6.02e-20	0.49	0.43	Hypertension (SNP x SNP interaction);	chr5:83154678	chr5:83012285~83013109:-
LUAD	cis	rs11098499	0.954	rs4309825	ENSG00000245958.5	RP11-33B1.1	10.49	2.59e-23	6.06e-20	0.4	0.43	Corneal astigmatism;	chr4:119393726	chr4:119454791~119552025:+
LUAD	cis	rs6964833	1	rs36044436	ENSG00000123965.13	PMS2P5	10.49	2.6e-23	6.09e-20	0.69	0.43	Menarche (age at onset);	chr7:74675495	chr7:74894116~74897835:+
LUAD	cis	rs507080	0.769	rs527290	ENSG00000255422.1	AP002954.4	-10.49	2.64e-23	6.17e-20	-0.55	-0.43	Serum metabolite levels;	chr11:118644898	chr11:118704607~118750263:+
LUAD	cis	rs2929278	0.617	rs663214	ENSG00000205771.5	CATSPER2P1	10.48	2.65e-23	6.2e-20	0.54	0.43	Schizophrenia;	chr15:43821584	chr15:43726918~43747094:-
LUAD	cis	rs6452524	1	rs1382364	ENSG00000249664.1	CTD-2227C6.2	10.48	2.66e-23	6.21e-20	0.49	0.43	Hypertension (SNP x SNP interaction);	chr5:83156677	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs1382363	ENSG00000249664.1	CTD-2227C6.2	10.48	2.66e-23	6.21e-20	0.49	0.43	Hypertension (SNP x SNP interaction);	chr5:83156753	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs11741897	ENSG00000249664.1	CTD-2227C6.2	10.48	2.66e-23	6.21e-20	0.49	0.43	Hypertension (SNP x SNP interaction);	chr5:83157246	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs10076000	ENSG00000249664.1	CTD-2227C6.2	10.48	2.66e-23	6.21e-20	0.49	0.43	Hypertension (SNP x SNP interaction);	chr5:83161629	chr5:83012285~83013109:-
LUAD	cis	rs904251	0.523	rs2776872	ENSG00000279942.1	RP1-153P14.7	-10.48	2.69e-23	6.28e-20	-0.4	-0.43	Cognitive performance;	chr6:37515011	chr6:37567716~37571460:+
LUAD	cis	rs904251	0.523	rs1757191	ENSG00000279942.1	RP1-153P14.7	-10.48	2.69e-23	6.28e-20	-0.4	-0.43	Cognitive performance;	chr6:37515095	chr6:37567716~37571460:+
LUAD	cis	rs2658782	0.654	rs2605620	ENSG00000279684.1	RP11-755E23.2	-10.48	2.69e-23	6.29e-20	-0.65	-0.43	Pulmonary function decline;	chr11:93514480	chr11:93286629~93288903:-
LUAD	cis	rs904251	0.523	rs2797799	ENSG00000279942.1	RP1-153P14.7	-10.48	2.69e-23	6.29e-20	-0.4	-0.43	Cognitive performance;	chr6:37515844	chr6:37567716~37571460:+
LUAD	cis	rs875971	0.862	rs7798630	ENSG00000226824.5	RP4-756H11.3	10.48	2.7e-23	6.32e-20	0.55	0.43	Aortic root size;	chr7:66306492	chr7:66654538~66669855:+
LUAD	cis	rs977987	0.778	rs2113232	ENSG00000261783.1	RP11-252K23.2	-10.48	2.73e-23	6.36e-20	-0.58	-0.43	Dupuytren's disease;	chr16:75357287	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs7185640	ENSG00000261783.1	RP11-252K23.2	-10.48	2.73e-23	6.36e-20	-0.58	-0.43	Dupuytren's disease;	chr16:75360501	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs11640674	ENSG00000261783.1	RP11-252K23.2	-10.48	2.73e-23	6.36e-20	-0.58	-0.43	Dupuytren's disease;	chr16:75361046	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs35552529	ENSG00000261783.1	RP11-252K23.2	-10.48	2.73e-23	6.37e-20	-0.58	-0.43	Dupuytren's disease;	chr16:75371981	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs56343285	ENSG00000261783.1	RP11-252K23.2	-10.48	2.73e-23	6.37e-20	-0.58	-0.43	Dupuytren's disease;	chr16:75375899	chr16:75379818~75381260:-
LUAD	cis	rs875971	0.862	rs1612452	ENSG00000226824.5	RP4-756H11.3	10.48	2.73e-23	6.38e-20	0.56	0.43	Aortic root size;	chr7:66108909	chr7:66654538~66669855:+
LUAD	cis	rs62229266	0.804	rs12483151	ENSG00000231106.2	LINC01436	10.48	2.74e-23	6.4e-20	0.59	0.43	Mitral valve prolapse;	chr21:36047280	chr21:36005338~36007838:+
LUAD	cis	rs62229266	0.804	rs880221	ENSG00000231106.2	LINC01436	10.48	2.74e-23	6.4e-20	0.59	0.43	Mitral valve prolapse;	chr21:36048487	chr21:36005338~36007838:+
LUAD	cis	rs977987	0.835	rs3851733	ENSG00000261783.1	RP11-252K23.2	-10.48	2.75e-23	6.4e-20	-0.58	-0.43	Dupuytren's disease;	chr16:75336365	chr16:75379818~75381260:-
LUAD	cis	rs6452524	1	rs6864479	ENSG00000249664.1	CTD-2227C6.2	10.48	2.77e-23	6.45e-20	0.49	0.43	Hypertension (SNP x SNP interaction);	chr5:83166421	chr5:83012285~83013109:-
LUAD	cis	rs875971	0.928	rs2036263	ENSG00000226824.5	RP4-756H11.3	10.48	2.79e-23	6.51e-20	0.55	0.43	Aortic root size;	chr7:66335210	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs10240949	ENSG00000226824.5	RP4-756H11.3	10.48	2.79e-23	6.51e-20	0.55	0.43	Aortic root size;	chr7:66339430	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs7782704	ENSG00000226824.5	RP4-756H11.3	10.48	2.79e-23	6.51e-20	0.55	0.43	Aortic root size;	chr7:66340379	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs6959268	ENSG00000226824.5	RP4-756H11.3	10.48	2.79e-23	6.51e-20	0.55	0.43	Aortic root size;	chr7:66347979	chr7:66654538~66669855:+
LUAD	cis	rs5760092	0.755	rs4585126	ENSG00000225282.1	AP000350.6	-10.48	2.8e-23	6.51e-20	-0.57	-0.43	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23926900~23929574:+
LUAD	cis	rs4423214	0.84	rs1123007	ENSG00000254682.1	RP11-660L16.2	-10.48	2.8e-23	6.52e-20	-0.63	-0.43	Vitamin D levels;	chr11:71474311	chr11:71448674~71452157:+
LUAD	cis	rs11098499	0.954	rs11722872	ENSG00000245958.5	RP11-33B1.1	-10.48	2.82e-23	6.58e-20	-0.4	-0.43	Corneal astigmatism;	chr4:119311875	chr4:119454791~119552025:+
LUAD	cis	rs1729407	0.933	rs1729405	ENSG00000254851.1	RP11-109L13.1	-10.48	2.83e-23	6.59e-20	-0.55	-0.43	Apolipoprotein A-IV levels;	chr11:116808044	chr11:117135528~117138582:+
LUAD	cis	rs977987	0.806	rs2865530	ENSG00000261783.1	RP11-252K23.2	-10.48	2.83e-23	6.6e-20	-0.57	-0.43	Dupuytren's disease;	chr16:75380478	chr16:75379818~75381260:-
LUAD	cis	rs6452524	0.967	rs2662243	ENSG00000249664.1	CTD-2227C6.2	10.48	2.84e-23	6.61e-20	0.49	0.43	Hypertension (SNP x SNP interaction);	chr5:83192630	chr5:83012285~83013109:-
LUAD	cis	rs16828019	0.929	rs35286837	ENSG00000235358.1	RP11-399E6.1	10.48	2.86e-23	6.65e-20	0.74	0.43	Intelligence (multi-trait analysis);	chr1:41217326	chr1:41242373~41284861:+
LUAD	cis	rs6452524	0.804	rs1478481	ENSG00000249664.1	CTD-2227C6.2	10.47	2.9e-23	6.76e-20	0.51	0.43	Hypertension (SNP x SNP interaction);	chr5:83111286	chr5:83012285~83013109:-
LUAD	cis	rs2188561	0.638	rs3735609	ENSG00000241764.3	AC002467.7	10.47	2.91e-23	6.77e-20	0.58	0.43	Alcohol consumption;	chr7:107743299	chr7:107742817~107744581:-
LUAD	cis	rs2188561	0.697	rs10808154	ENSG00000241764.3	AC002467.7	10.47	2.91e-23	6.77e-20	0.58	0.43	Alcohol consumption;	chr7:107745951	chr7:107742817~107744581:-
LUAD	cis	rs9322193	0.962	rs6914319	ENSG00000216906.2	RP11-350J20.9	10.47	2.95e-23	6.86e-20	0.53	0.43	Lung cancer;	chr6:149806304	chr6:149904243~149906418:+
LUAD	cis	rs748404	0.578	rs2278856	ENSG00000205771.5	CATSPER2P1	-10.47	2.97e-23	6.91e-20	-0.54	-0.43	Lung cancer;	chr15:43339158	chr15:43726918~43747094:-
LUAD	cis	rs6452524	0.868	rs1564379	ENSG00000249664.1	CTD-2227C6.2	10.47	2.97e-23	6.91e-20	0.51	0.43	Hypertension (SNP x SNP interaction);	chr5:83082143	chr5:83012285~83013109:-
LUAD	cis	rs904251	0.523	rs914348	ENSG00000279942.1	RP1-153P14.7	-10.47	3e-23	6.97e-20	-0.4	-0.43	Cognitive performance;	chr6:37516953	chr6:37567716~37571460:+
LUAD	cis	rs875971	0.862	rs6460282	ENSG00000226824.5	RP4-756H11.3	10.47	3.03e-23	7.05e-20	0.55	0.43	Aortic root size;	chr7:66226259	chr7:66654538~66669855:+
LUAD	cis	rs2412819	0.599	rs2470120	ENSG00000205771.5	CATSPER2P1	-10.47	3.04e-23	7.07e-20	-0.55	-0.43	Lung cancer;	chr15:43636872	chr15:43726918~43747094:-
LUAD	cis	rs62229266	0.804	rs2255858	ENSG00000231106.2	LINC01436	10.47	3.07e-23	7.13e-20	0.59	0.43	Mitral valve prolapse;	chr21:36040454	chr21:36005338~36007838:+
LUAD	cis	rs62229266	0.804	rs62230821	ENSG00000231106.2	LINC01436	10.47	3.09e-23	7.18e-20	0.59	0.43	Mitral valve prolapse;	chr21:36052818	chr21:36005338~36007838:+
LUAD	cis	rs9322193	0.884	rs11155679	ENSG00000216906.2	RP11-350J20.9	10.46	3.16e-23	7.33e-20	0.56	0.43	Lung cancer;	chr6:149758881	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs3805749	ENSG00000216906.2	RP11-350J20.9	10.46	3.17e-23	7.35e-20	0.54	0.43	Lung cancer;	chr6:149772546	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.847	rs9505972	ENSG00000216906.2	RP11-350J20.9	10.46	3.17e-23	7.35e-20	0.54	0.43	Lung cancer;	chr6:149775255	chr6:149904243~149906418:+
LUAD	cis	rs2729354	1	rs2511983	ENSG00000265566.2	RN7SL605P	-10.46	3.18e-23	7.38e-20	-0.65	-0.43	Blood protein levels;	chr11:57579401	chr11:57528085~57528365:-
LUAD	cis	rs748404	0.518	rs480108	ENSG00000205771.5	CATSPER2P1	-10.46	3.18e-23	7.38e-20	-0.55	-0.43	Lung cancer;	chr15:43525208	chr15:43726918~43747094:-
LUAD	cis	rs9322193	0.962	rs9478848	ENSG00000216906.2	RP11-350J20.9	10.46	3.18e-23	7.38e-20	0.53	0.43	Lung cancer;	chr6:149825080	chr6:149904243~149906418:+
LUAD	cis	rs2739330	0.796	rs5760106	ENSG00000099984.9	GSTT2	10.46	3.2e-23	7.43e-20	0.52	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23980123~23983911:+
LUAD	cis	rs9322193	0.962	rs9689447	ENSG00000216906.2	RP11-350J20.9	10.46	3.21e-23	7.45e-20	0.53	0.43	Lung cancer;	chr6:149789350	chr6:149904243~149906418:+
LUAD	cis	rs5769707	0.967	rs2071904	ENSG00000188511.11	C22orf34	10.46	3.28e-23	7.58e-20	0.49	0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49640829	chr22:49414524~49657542:-
LUAD	cis	rs875971	0.755	rs10228885	ENSG00000226824.5	RP4-756H11.3	10.46	3.28e-23	7.59e-20	0.55	0.43	Aortic root size;	chr7:66315542	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs3893216	ENSG00000226824.5	RP4-756H11.3	10.46	3.28e-23	7.59e-20	0.55	0.43	Aortic root size;	chr7:66325720	chr7:66654538~66669855:+
LUAD	cis	rs11098499	0.865	rs4001305	ENSG00000245958.5	RP11-33B1.1	-10.46	3.34e-23	7.73e-20	-0.4	-0.43	Corneal astigmatism;	chr4:119438081	chr4:119454791~119552025:+
LUAD	cis	rs16828019	0.852	rs12742803	ENSG00000235358.1	RP11-399E6.1	10.46	3.35e-23	7.74e-20	0.74	0.43	Intelligence (multi-trait analysis);	chr1:41182459	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.852	rs12408956	ENSG00000235358.1	RP11-399E6.1	10.46	3.35e-23	7.74e-20	0.74	0.43	Intelligence (multi-trait analysis);	chr1:41186280	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.852	rs35992757	ENSG00000235358.1	RP11-399E6.1	10.46	3.35e-23	7.74e-20	0.74	0.43	Intelligence (multi-trait analysis);	chr1:41187190	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.852	rs12759050	ENSG00000235358.1	RP11-399E6.1	10.46	3.35e-23	7.74e-20	0.74	0.43	Intelligence (multi-trait analysis);	chr1:41198532	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.789	rs34216154	ENSG00000235358.1	RP11-399E6.1	10.46	3.35e-23	7.74e-20	0.74	0.43	Intelligence (multi-trait analysis);	chr1:41205235	chr1:41242373~41284861:+
LUAD	cis	rs11155671	0.53	rs7763849	ENSG00000216906.2	RP11-350J20.9	10.46	3.35e-23	7.74e-20	0.51	0.43	Testicular germ cell tumor;	chr6:149885244	chr6:149904243~149906418:+
LUAD	cis	rs6538678	0.712	rs10777748	ENSG00000199506.1	RNU6-247P	-10.46	3.37e-23	7.79e-20	-0.57	-0.43	Lupus nephritis in systemic lupus erythematosus;	chr12:95880227	chr12:95792529~95792635:-
LUAD	cis	rs11089937	0.929	rs5750624	ENSG00000211639.2	IGLV4-60	10.46	3.38e-23	7.81e-20	0.43	0.43	Periodontitis (PAL4Q3);	chr22:22165354	chr22:22162199~22162681:+
LUAD	cis	rs9322193	0.962	rs3805752	ENSG00000216906.2	RP11-350J20.9	10.46	3.4e-23	7.85e-20	0.54	0.43	Lung cancer;	chr6:149795490	chr6:149904243~149906418:+
LUAD	cis	rs10875746	0.855	rs73102067	ENSG00000240399.1	RP1-228P16.1	-10.46	3.41e-23	7.87e-20	-0.53	-0.43	Longevity (90 years and older);	chr12:48100643	chr12:48054813~48055591:-
LUAD	cis	rs67180937	0.582	rs71524942	ENSG00000272750.1	RP11-378J18.8	-10.46	3.42e-23	7.9e-20	-0.45	-0.43	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222689650	chr1:222658867~222661512:-
LUAD	cis	rs7208859	0.673	rs28588622	ENSG00000263531.1	RP13-753N3.1	10.45	3.44e-23	7.95e-20	0.9	0.43	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30918681	chr17:30863921~30864940:-
LUAD	cis	rs9322193	0.923	rs10782318	ENSG00000216906.2	RP11-350J20.9	10.45	3.47e-23	8e-20	0.54	0.43	Lung cancer;	chr6:149754137	chr6:149904243~149906418:+
LUAD	cis	rs6452524	1	rs10042854	ENSG00000249664.1	CTD-2227C6.2	-10.45	3.49e-23	8.05e-20	-0.49	-0.43	Hypertension (SNP x SNP interaction);	chr5:83143876	chr5:83012285~83013109:-
LUAD	cis	rs977987	0.806	rs4888388	ENSG00000261783.1	RP11-252K23.2	-10.45	3.49e-23	8.05e-20	-0.57	-0.43	Dupuytren's disease;	chr16:75360250	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs1364077	ENSG00000261783.1	RP11-252K23.2	-10.45	3.5e-23	8.07e-20	-0.57	-0.43	Dupuytren's disease;	chr16:75363093	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.843	rs4887820	ENSG00000261783.1	RP11-252K23.2	-10.45	3.5e-23	8.07e-20	-0.57	-0.43	Dupuytren's disease;	chr16:75363389	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.778	rs34222958	ENSG00000261783.1	RP11-252K23.2	-10.45	3.5e-23	8.07e-20	-0.57	-0.43	Dupuytren's disease;	chr16:75364354	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.778	rs4887821	ENSG00000261783.1	RP11-252K23.2	-10.45	3.5e-23	8.07e-20	-0.57	-0.43	Dupuytren's disease;	chr16:75364676	chr16:75379818~75381260:-
LUAD	cis	rs62229266	0.804	rs11088331	ENSG00000231106.2	LINC01436	10.45	3.52e-23	8.12e-20	0.59	0.43	Mitral valve prolapse;	chr21:36049574	chr21:36005338~36007838:+
LUAD	cis	rs875971	0.862	rs11984115	ENSG00000226824.5	RP4-756H11.3	10.45	3.52e-23	8.12e-20	0.55	0.43	Aortic root size;	chr7:66308872	chr7:66654538~66669855:+
LUAD	cis	rs2658782	0.738	rs2605628	ENSG00000279684.1	RP11-755E23.2	-10.45	3.56e-23	8.2e-20	-0.69	-0.43	Pulmonary function decline;	chr11:93528394	chr11:93286629~93288903:-
LUAD	cis	rs875971	0.789	rs7808013	ENSG00000226824.5	RP4-756H11.3	10.45	3.57e-23	8.23e-20	0.55	0.43	Aortic root size;	chr7:66606209	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.825	rs7384021	ENSG00000226824.5	RP4-756H11.3	10.45	3.57e-23	8.23e-20	0.55	0.43	Aortic root size;	chr7:66612917	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.825	rs66981195	ENSG00000226824.5	RP4-756H11.3	10.45	3.57e-23	8.23e-20	0.55	0.43	Aortic root size;	chr7:66614048	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs3926380	ENSG00000226824.5	RP4-756H11.3	10.45	3.57e-23	8.23e-20	0.55	0.43	Aortic root size;	chr7:66615658	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.962	rs3763162	ENSG00000216906.2	RP11-350J20.9	-10.45	3.57e-23	8.23e-20	-0.53	-0.43	Lung cancer;	chr6:149819674	chr6:149904243~149906418:+
LUAD	cis	rs7044106	0.791	rs7036196	ENSG00000226752.6	PSMD5-AS1	-10.45	3.57e-23	8.23e-20	-0.48	-0.43	Hip circumference adjusted for BMI;	chr9:120717179	chr9:120824828~120854385:+
LUAD	cis	rs7044106	0.791	rs7036766	ENSG00000226752.6	PSMD5-AS1	-10.45	3.57e-23	8.23e-20	-0.48	-0.43	Hip circumference adjusted for BMI;	chr9:120717343	chr9:120824828~120854385:+
LUAD	cis	rs11690935	0.959	rs10803863	ENSG00000228389.1	AC068039.4	-10.45	3.62e-23	8.33e-20	-0.51	-0.43	Schizophrenia;	chr2:171678827	chr2:171773482~171775844:+
LUAD	cis	rs8062405	0.698	rs7188071	ENSG00000259982.1	CDC37P1	-10.45	3.69e-23	8.5e-20	-0.56	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28906323	chr16:28700294~28701540:-
LUAD	cis	rs2564921	0.765	rs35333155	ENSG00000242142.1	SERBP1P3	10.45	3.69e-23	8.5e-20	0.44	0.43	Height;	chr3:53073764	chr3:53064283~53065091:-
LUAD	cis	rs8062405	0.755	rs56209193	ENSG00000259982.1	CDC37P1	10.45	3.71e-23	8.55e-20	0.55	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28700294~28701540:-
LUAD	cis	rs875971	0.895	rs12531677	ENSG00000226824.5	RP4-756H11.3	10.45	3.72e-23	8.56e-20	0.55	0.43	Aortic root size;	chr7:66304099	chr7:66654538~66669855:+
LUAD	cis	rs11690935	1	rs34542126	ENSG00000228389.1	AC068039.4	-10.44	3.76e-23	8.66e-20	-0.51	-0.43	Schizophrenia;	chr2:171686195	chr2:171773482~171775844:+
LUAD	cis	rs748404	0.66	rs2439845	ENSG00000205771.5	CATSPER2P1	-10.44	3.77e-23	8.67e-20	-0.54	-0.43	Lung cancer;	chr15:43430412	chr15:43726918~43747094:-
LUAD	cis	rs2188561	0.615	rs13226711	ENSG00000241764.3	AC002467.7	10.44	3.77e-23	8.67e-20	0.58	0.43	Alcohol consumption;	chr7:107754897	chr7:107742817~107744581:-
LUAD	cis	rs977987	0.843	rs11641801	ENSG00000261783.1	RP11-252K23.2	-10.44	3.85e-23	8.85e-20	-0.57	-0.43	Dupuytren's disease;	chr16:75421550	chr16:75379818~75381260:-
LUAD	cis	rs748404	0.56	rs572837	ENSG00000205771.5	CATSPER2P1	-10.44	3.86e-23	8.87e-20	-0.54	-0.43	Lung cancer;	chr15:43531615	chr15:43726918~43747094:-
LUAD	cis	rs11098499	0.863	rs3775843	ENSG00000245958.5	RP11-33B1.1	-10.44	3.89e-23	8.95e-20	-0.4	-0.43	Corneal astigmatism;	chr4:119506689	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs3775844	ENSG00000245958.5	RP11-33B1.1	-10.44	3.89e-23	8.95e-20	-0.4	-0.43	Corneal astigmatism;	chr4:119506878	chr4:119454791~119552025:+
LUAD	cis	rs4423214	0.61	rs12793607	ENSG00000254682.1	RP11-660L16.2	-10.44	3.99e-23	9.16e-20	-0.53	-0.43	Vitamin D levels;	chr11:71418270	chr11:71448674~71452157:+
LUAD	cis	rs9322193	0.847	rs868375	ENSG00000216906.2	RP11-350J20.9	10.44	3.99e-23	9.17e-20	0.53	0.43	Lung cancer;	chr6:149844905	chr6:149904243~149906418:+
LUAD	cis	rs5769707	0.967	rs5770585	ENSG00000188511.11	C22orf34	10.44	4.01e-23	9.21e-20	0.48	0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49614226	chr22:49414524~49657542:-
LUAD	cis	rs7174755	0.884	rs11634026	ENSG00000260657.2	RP11-315D16.4	10.44	4.05e-23	9.3e-20	0.51	0.43	Major depressive disorder;	chr15:68305668	chr15:68267792~68277994:-
LUAD	cis	rs16828019	0.929	rs12029321	ENSG00000235358.1	RP11-399E6.1	10.43	4.08e-23	9.36e-20	0.74	0.43	Intelligence (multi-trait analysis);	chr1:41216858	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.929	rs11209734	ENSG00000235358.1	RP11-399E6.1	10.43	4.08e-23	9.36e-20	0.74	0.43	Intelligence (multi-trait analysis);	chr1:41232402	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.929	rs12037037	ENSG00000235358.1	RP11-399E6.1	10.43	4.08e-23	9.36e-20	0.74	0.43	Intelligence (multi-trait analysis);	chr1:41232584	chr1:41242373~41284861:+
LUAD	cis	rs9322193	0.884	rs9397036	ENSG00000216906.2	RP11-350J20.9	10.43	4.08e-23	9.36e-20	0.54	0.43	Lung cancer;	chr6:149851787	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.884	rs9383864	ENSG00000216906.2	RP11-350J20.9	10.43	4.08e-23	9.36e-20	0.54	0.43	Lung cancer;	chr6:149851969	chr6:149904243~149906418:+
LUAD	cis	rs977987	0.806	rs1544810	ENSG00000261783.1	RP11-252K23.2	-10.43	4.09e-23	9.38e-20	-0.57	-0.43	Dupuytren's disease;	chr16:75377265	chr16:75379818~75381260:-
LUAD	cis	rs6538678	0.864	rs4762249	ENSG00000199506.1	RNU6-247P	10.43	4.1e-23	9.4e-20	0.54	0.43	Lupus nephritis in systemic lupus erythematosus;	chr12:95884183	chr12:95792529~95792635:-
LUAD	cis	rs11098499	0.866	rs72676074	ENSG00000245958.5	RP11-33B1.1	-10.43	4.14e-23	9.49e-20	-0.4	-0.43	Corneal astigmatism;	chr4:119438686	chr4:119454791~119552025:+
LUAD	cis	rs977987	0.806	rs8050769	ENSG00000261783.1	RP11-252K23.2	-10.43	4.14e-23	9.49e-20	-0.57	-0.43	Dupuytren's disease;	chr16:75354536	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs6564252	ENSG00000261783.1	RP11-252K23.2	-10.43	4.14e-23	9.49e-20	-0.57	-0.43	Dupuytren's disease;	chr16:75355042	chr16:75379818~75381260:-
LUAD	cis	rs3096299	0.658	rs34590044	ENSG00000274627.1	RP11-104N10.2	10.43	4.17e-23	9.56e-20	0.41	0.43	Multiple myeloma (IgH translocation);	chr16:89476749	chr16:89516797~89522217:+
LUAD	cis	rs2929278	0.617	rs4617832	ENSG00000205771.5	CATSPER2P1	10.43	4.19e-23	9.6e-20	0.55	0.43	Schizophrenia;	chr15:43738381	chr15:43726918~43747094:-
LUAD	cis	rs904251	0.504	rs1757188	ENSG00000279942.1	RP1-153P14.7	-10.43	4.23e-23	9.69e-20	-0.4	-0.43	Cognitive performance;	chr6:37516032	chr6:37567716~37571460:+
LUAD	cis	rs11690935	1	rs6757773	ENSG00000228389.1	AC068039.4	-10.43	4.28e-23	9.81e-20	-0.5	-0.43	Schizophrenia;	chr2:171693120	chr2:171773482~171775844:+
LUAD	cis	rs6782228	0.527	rs2811491	ENSG00000242551.2	POU5F1P6	-10.43	4.3e-23	9.86e-20	-0.49	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128635107	chr3:128674735~128677005:-
LUAD	cis	rs6538678	0.929	rs10745733	ENSG00000199506.1	RNU6-247P	-10.43	4.34e-23	9.94e-20	-0.56	-0.43	Lupus nephritis in systemic lupus erythematosus;	chr12:95868728	chr12:95792529~95792635:-
LUAD	cis	rs6538678	0.926	rs10745734	ENSG00000199506.1	RNU6-247P	-10.43	4.34e-23	9.94e-20	-0.56	-0.43	Lupus nephritis in systemic lupus erythematosus;	chr12:95868936	chr12:95792529~95792635:-
LUAD	cis	rs977987	0.806	rs4888383	ENSG00000261783.1	RP11-252K23.2	-10.43	4.38e-23	1e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75352451	chr16:75379818~75381260:-
LUAD	cis	rs3096299	0.719	rs2911262	ENSG00000274627.1	RP11-104N10.2	10.43	4.39e-23	1e-19	0.4	0.43	Multiple myeloma (IgH translocation);	chr16:89448633	chr16:89516797~89522217:+
LUAD	cis	rs4728142	0.604	rs4731541	ENSG00000275106.1	RP11-309L24.10	-10.43	4.41e-23	1.01e-19	-0.52	-0.43	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129038182	chr7:128952527~128953316:-
LUAD	cis	rs2487048	0.905	rs2437812	ENSG00000226334.1	RP11-217B7.2	-10.42	4.44e-23	1.02e-19	-0.57	-0.43	Intraocular pressure;	chr9:104930920	chr9:104927553~104928892:+
LUAD	cis	rs73086581	1	rs17287822	ENSG00000229539.1	RP11-119B16.2	10.42	4.49e-23	1.03e-19	0.59	0.43	Response to antidepressants in depression;	chr20:3997889	chr20:3888239~3888868:-
LUAD	cis	rs4728142	0.564	rs11767711	ENSG00000275106.1	RP11-309L24.10	-10.42	4.55e-23	1.04e-19	-0.51	-0.43	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129011778	chr7:128952527~128953316:-
LUAD	cis	rs8062405	0.755	rs62034325	ENSG00000259982.1	CDC37P1	10.42	4.59e-23	1.05e-19	0.54	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28700294~28701540:-
LUAD	cis	rs5769707	0.967	rs5769698	ENSG00000188511.11	C22orf34	10.42	4.61e-23	1.05e-19	0.47	0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49604058	chr22:49414524~49657542:-
LUAD	cis	rs6782228	0.606	rs4634140	ENSG00000242551.2	POU5F1P6	10.42	4.62e-23	1.06e-19	0.49	0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705613	chr3:128674735~128677005:-
LUAD	cis	rs875971	0.825	rs1860472	ENSG00000226824.5	RP4-756H11.3	10.42	4.62e-23	1.06e-19	0.55	0.43	Aortic root size;	chr7:66617736	chr7:66654538~66669855:+
LUAD	cis	rs11089937	0.963	rs2073454	ENSG00000211639.2	IGLV4-60	10.42	4.66e-23	1.07e-19	0.44	0.43	Periodontitis (PAL4Q3);	chr22:22163086	chr22:22162199~22162681:+
LUAD	cis	rs977987	0.778	rs4888400	ENSG00000261783.1	RP11-252K23.2	-10.42	4.67e-23	1.07e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75391698	chr16:75379818~75381260:-
LUAD	cis	rs16828019	0.852	rs12759023	ENSG00000235358.1	RP11-399E6.1	10.42	4.67e-23	1.07e-19	0.74	0.43	Intelligence (multi-trait analysis);	chr1:41138306	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.852	rs34286980	ENSG00000235358.1	RP11-399E6.1	10.42	4.67e-23	1.07e-19	0.74	0.43	Intelligence (multi-trait analysis);	chr1:41142717	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.852	rs71648534	ENSG00000235358.1	RP11-399E6.1	10.42	4.67e-23	1.07e-19	0.74	0.43	Intelligence (multi-trait analysis);	chr1:41148075	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.852	rs71648535	ENSG00000235358.1	RP11-399E6.1	10.42	4.67e-23	1.07e-19	0.74	0.43	Intelligence (multi-trait analysis);	chr1:41148078	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.852	rs12048187	ENSG00000235358.1	RP11-399E6.1	10.42	4.67e-23	1.07e-19	0.74	0.43	Intelligence (multi-trait analysis);	chr1:41150511	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.852	rs71648536	ENSG00000235358.1	RP11-399E6.1	10.42	4.67e-23	1.07e-19	0.74	0.43	Intelligence (multi-trait analysis);	chr1:41166336	chr1:41242373~41284861:+
LUAD	cis	rs875971	0.862	rs6944374	ENSG00000226824.5	RP4-756H11.3	10.42	4.68e-23	1.07e-19	0.55	0.43	Aortic root size;	chr7:66221942	chr7:66654538~66669855:+
LUAD	cis	rs10129255	0.5	rs2027902	ENSG00000280411.1	IGHV1-69-2	-10.42	4.68e-23	1.07e-19	-0.29	-0.43	Kawasaki disease;	chr14:106807157	chr14:106762092~106762588:-
LUAD	cis	rs5769707	0.967	rs9616327	ENSG00000188511.11	C22orf34	10.42	4.7e-23	1.07e-19	0.48	0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49617243	chr22:49414524~49657542:-
LUAD	cis	rs977987	0.806	rs11860284	ENSG00000261783.1	RP11-252K23.2	-10.42	4.71e-23	1.07e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75379009	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.736	rs4888392	ENSG00000261783.1	RP11-252K23.2	-10.41	4.85e-23	1.11e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75378364	chr16:75379818~75381260:-
LUAD	cis	rs7044106	0.791	rs2416799	ENSG00000226752.6	PSMD5-AS1	-10.41	4.85e-23	1.11e-19	-0.47	-0.43	Hip circumference adjusted for BMI;	chr9:120718588	chr9:120824828~120854385:+
LUAD	cis	rs7044106	0.791	rs10984998	ENSG00000226752.6	PSMD5-AS1	-10.41	4.85e-23	1.11e-19	-0.47	-0.43	Hip circumference adjusted for BMI;	chr9:120719238	chr9:120824828~120854385:+
LUAD	cis	rs73086581	0.838	rs11907416	ENSG00000229539.1	RP11-119B16.2	10.41	4.88e-23	1.11e-19	0.63	0.43	Response to antidepressants in depression;	chr20:4024972	chr20:3888239~3888868:-
LUAD	cis	rs4423214	0.592	rs10898211	ENSG00000254682.1	RP11-660L16.2	-10.41	4.91e-23	1.12e-19	-0.65	-0.43	Vitamin D levels;	chr11:71499631	chr11:71448674~71452157:+
LUAD	cis	rs7174755	0.961	rs58175526	ENSG00000260657.2	RP11-315D16.4	10.41	4.97e-23	1.13e-19	0.52	0.43	Major depressive disorder;	chr15:68300789	chr15:68267792~68277994:-
LUAD	cis	rs11690935	0.959	rs12185567	ENSG00000228389.1	AC068039.4	-10.41	4.98e-23	1.13e-19	-0.51	-0.43	Schizophrenia;	chr2:171704219	chr2:171773482~171775844:+
LUAD	cis	rs2019137	0.936	rs4849169	ENSG00000189223.12	PAX8-AS1	10.41	4.98e-23	1.13e-19	0.57	0.43	Lymphocyte counts;	chr2:113196080	chr2:113211522~113276581:+
LUAD	cis	rs2019137	0.836	rs4848318	ENSG00000189223.12	PAX8-AS1	10.41	4.98e-23	1.13e-19	0.57	0.43	Lymphocyte counts;	chr2:113196375	chr2:113211522~113276581:+
LUAD	cis	rs2019137	0.936	rs2241978	ENSG00000189223.12	PAX8-AS1	10.41	4.98e-23	1.13e-19	0.57	0.43	Lymphocyte counts;	chr2:113196429	chr2:113211522~113276581:+
LUAD	cis	rs2019137	0.936	rs3828188	ENSG00000189223.12	PAX8-AS1	10.41	4.98e-23	1.13e-19	0.57	0.43	Lymphocyte counts;	chr2:113196670	chr2:113211522~113276581:+
LUAD	cis	rs2019137	0.936	rs3828189	ENSG00000189223.12	PAX8-AS1	10.41	4.98e-23	1.13e-19	0.57	0.43	Lymphocyte counts;	chr2:113196919	chr2:113211522~113276581:+
LUAD	cis	rs5769707	1	rs5769707	ENSG00000188511.11	C22orf34	10.41	5.02e-23	1.14e-19	0.49	0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49619754	chr22:49414524~49657542:-
LUAD	cis	rs977987	0.778	rs11858992	ENSG00000261783.1	RP11-252K23.2	-10.41	5.03e-23	1.15e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75377547	chr16:75379818~75381260:-
LUAD	cis	rs9322193	0.884	rs2064521	ENSG00000216906.2	RP11-350J20.9	-10.41	5.03e-23	1.15e-19	-0.52	-0.43	Lung cancer;	chr6:149625336	chr6:149904243~149906418:+
LUAD	cis	rs2581828	0.965	rs2581829	ENSG00000242142.1	SERBP1P3	-10.41	5.03e-23	1.15e-19	-0.44	-0.43	Crohn's disease;	chr3:53099510	chr3:53064283~53065091:-
LUAD	cis	rs904251	0.523	rs2797794	ENSG00000279942.1	RP1-153P14.7	-10.41	5.05e-23	1.15e-19	-0.4	-0.43	Cognitive performance;	chr6:37512828	chr6:37567716~37571460:+
LUAD	cis	rs904251	0.523	rs2776920	ENSG00000279942.1	RP1-153P14.7	-10.41	5.05e-23	1.15e-19	-0.4	-0.43	Cognitive performance;	chr6:37512829	chr6:37567716~37571460:+
LUAD	cis	rs904251	0.504	rs2797795	ENSG00000279942.1	RP1-153P14.7	-10.41	5.05e-23	1.15e-19	-0.4	-0.43	Cognitive performance;	chr6:37512907	chr6:37567716~37571460:+
LUAD	cis	rs904251	0.523	rs2797796	ENSG00000279942.1	RP1-153P14.7	-10.41	5.05e-23	1.15e-19	-0.4	-0.43	Cognitive performance;	chr6:37513110	chr6:37567716~37571460:+
LUAD	cis	rs904251	0.523	rs2776870	ENSG00000279942.1	RP1-153P14.7	-10.41	5.05e-23	1.15e-19	-0.4	-0.43	Cognitive performance;	chr6:37513588	chr6:37567716~37571460:+
LUAD	cis	rs904251	0.523	rs2797798	ENSG00000279942.1	RP1-153P14.7	-10.41	5.05e-23	1.15e-19	-0.4	-0.43	Cognitive performance;	chr6:37513661	chr6:37567716~37571460:+
LUAD	cis	rs904251	0.523	rs2776871	ENSG00000279942.1	RP1-153P14.7	-10.41	5.05e-23	1.15e-19	-0.4	-0.43	Cognitive performance;	chr6:37513983	chr6:37567716~37571460:+
LUAD	cis	rs977987	0.806	rs4993970	ENSG00000261783.1	RP11-252K23.2	-10.41	5.15e-23	1.17e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75377721	chr16:75379818~75381260:-
LUAD	cis	rs875971	0.862	rs4236208	ENSG00000226824.5	RP4-756H11.3	10.41	5.2e-23	1.18e-19	0.55	0.43	Aortic root size;	chr7:66284091	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs10261398	ENSG00000226824.5	RP4-756H11.3	10.41	5.2e-23	1.18e-19	0.55	0.43	Aortic root size;	chr7:66285177	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs10224872	ENSG00000226824.5	RP4-756H11.3	10.41	5.2e-23	1.18e-19	0.55	0.43	Aortic root size;	chr7:66294786	chr7:66654538~66669855:+
LUAD	cis	rs2729354	0.903	rs2729371	ENSG00000265566.2	RN7SL605P	-10.41	5.22e-23	1.18e-19	-0.69	-0.43	Blood protein levels;	chr11:57553849	chr11:57528085~57528365:-
LUAD	cis	rs10256972	0.591	rs10229680	ENSG00000229043.2	AC091729.9	-10.41	5.25e-23	1.19e-19	-0.47	-0.43	Endometriosis;Longevity;	chr7:1118929	chr7:1160374~1165267:+
LUAD	cis	rs16828019	0.777	rs35044078	ENSG00000235358.1	RP11-399E6.1	10.4	5.27e-23	1.19e-19	0.73	0.43	Intelligence (multi-trait analysis);	chr1:41008728	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.704	rs4996176	ENSG00000235358.1	RP11-399E6.1	10.4	5.27e-23	1.19e-19	0.73	0.43	Intelligence (multi-trait analysis);	chr1:41022496	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.777	rs35496942	ENSG00000235358.1	RP11-399E6.1	10.4	5.27e-23	1.19e-19	0.73	0.43	Intelligence (multi-trait analysis);	chr1:41023232	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.704	rs12031277	ENSG00000235358.1	RP11-399E6.1	10.4	5.27e-23	1.19e-19	0.73	0.43	Intelligence (multi-trait analysis);	chr1:41026129	chr1:41242373~41284861:+
LUAD	cis	rs6452524	0.967	rs6452509	ENSG00000249664.1	CTD-2227C6.2	10.4	5.27e-23	1.19e-19	0.5	0.43	Hypertension (SNP x SNP interaction);	chr5:83125564	chr5:83012285~83013109:-
LUAD	cis	rs875971	0.862	rs6964437	ENSG00000226824.5	RP4-756H11.3	10.4	5.32e-23	1.2e-19	0.55	0.43	Aortic root size;	chr7:66221457	chr7:66654538~66669855:+
LUAD	cis	rs16828019	0.777	rs3738369	ENSG00000235358.1	RP11-399E6.1	10.4	5.34e-23	1.21e-19	0.73	0.43	Intelligence (multi-trait analysis);	chr1:41020736	chr1:41242373~41284861:+
LUAD	cis	rs7044106	0.791	rs10985004	ENSG00000226752.6	PSMD5-AS1	-10.4	5.44e-23	1.23e-19	-0.48	-0.43	Hip circumference adjusted for BMI;	chr9:120722659	chr9:120824828~120854385:+
LUAD	cis	rs977987	0.771	rs8048527	ENSG00000261783.1	RP11-252K23.2	-10.4	5.5e-23	1.24e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75388156	chr16:75379818~75381260:-
LUAD	cis	rs4774565	0.762	rs34565064	ENSG00000244879.4	GABPB1-AS1	-10.4	5.52e-23	1.25e-19	-0.38	-0.43	Breast cancer;	chr15:50371706	chr15:50354959~50372202:+
LUAD	cis	rs6538678	0.929	rs7962359	ENSG00000199506.1	RNU6-247P	-10.4	5.52e-23	1.25e-19	-0.56	-0.43	Lupus nephritis in systemic lupus erythematosus;	chr12:95862566	chr12:95792529~95792635:-
LUAD	cis	rs875971	0.862	rs949930	ENSG00000226824.5	RP4-756H11.3	10.4	5.59e-23	1.26e-19	0.55	0.43	Aortic root size;	chr7:66301835	chr7:66654538~66669855:+
LUAD	cis	rs11098499	0.863	rs13134665	ENSG00000245958.5	RP11-33B1.1	-10.4	5.61e-23	1.27e-19	-0.4	-0.43	Corneal astigmatism;	chr4:119505275	chr4:119454791~119552025:+
LUAD	cis	rs977987	0.835	rs11641532	ENSG00000261783.1	RP11-252K23.2	-10.4	5.64e-23	1.27e-19	-0.56	-0.43	Dupuytren's disease;	chr16:75295582	chr16:75379818~75381260:-
LUAD	cis	rs11098499	0.954	rs12508504	ENSG00000245958.5	RP11-33B1.1	-10.4	5.66e-23	1.28e-19	-0.4	-0.43	Corneal astigmatism;	chr4:119489452	chr4:119454791~119552025:+
LUAD	cis	rs17837474	0.656	rs17273	ENSG00000276597.1	TRBV11-3	10.4	5.67e-23	1.28e-19	0.63	0.43	Cancer;	chr7:142407435	chr7:142554836~142555318:+
LUAD	cis	rs977987	0.815	rs11149821	ENSG00000261783.1	RP11-252K23.2	-10.39	5.77e-23	1.3e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75388919	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs1895490	ENSG00000261783.1	RP11-252K23.2	-10.39	5.83e-23	1.32e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75358908	chr16:75379818~75381260:-
LUAD	cis	rs9322193	0.962	rs13215691	ENSG00000216906.2	RP11-350J20.9	10.39	5.84e-23	1.32e-19	0.53	0.43	Lung cancer;	chr6:149792666	chr6:149904243~149906418:+
LUAD	cis	rs977987	0.806	rs11640473	ENSG00000261783.1	RP11-252K23.2	-10.39	5.84e-23	1.32e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75369391	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs8057203	ENSG00000261783.1	RP11-252K23.2	-10.39	5.84e-23	1.32e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75371076	chr16:75379818~75381260:-
LUAD	cis	rs875971	0.862	rs10282433	ENSG00000226824.5	RP4-756H11.3	10.39	5.87e-23	1.32e-19	0.55	0.43	Aortic root size;	chr7:66256452	chr7:66654538~66669855:+
LUAD	cis	rs67180937	0.922	rs17465982	ENSG00000272750.1	RP11-378J18.8	-10.39	5.88e-23	1.32e-19	-0.45	-0.43	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222664597	chr1:222658867~222661512:-
LUAD	cis	rs977987	0.806	rs1109342	ENSG00000261783.1	RP11-252K23.2	10.39	5.9e-23	1.33e-19	0.57	0.43	Dupuytren's disease;	chr16:75411777	chr16:75379818~75381260:-
LUAD	cis	rs748404	0.66	rs693510	ENSG00000205771.5	CATSPER2P1	-10.39	5.9e-23	1.33e-19	-0.54	-0.43	Lung cancer;	chr15:43422427	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.66	rs509306	ENSG00000205771.5	CATSPER2P1	-10.39	5.9e-23	1.33e-19	-0.54	-0.43	Lung cancer;	chr15:43422973	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.66	rs690512	ENSG00000205771.5	CATSPER2P1	-10.39	5.9e-23	1.33e-19	-0.54	-0.43	Lung cancer;	chr15:43425480	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.66	rs2249952	ENSG00000205771.5	CATSPER2P1	-10.39	5.9e-23	1.33e-19	-0.54	-0.43	Lung cancer;	chr15:43428335	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.631	rs2467745	ENSG00000205771.5	CATSPER2P1	-10.39	5.9e-23	1.33e-19	-0.54	-0.43	Lung cancer;	chr15:43430544	chr15:43726918~43747094:-
LUAD	cis	rs4423214	0.592	rs10898234	ENSG00000254682.1	RP11-660L16.2	-10.39	5.93e-23	1.34e-19	-0.64	-0.43	Vitamin D levels;	chr11:71525638	chr11:71448674~71452157:+
LUAD	cis	rs875971	0.862	rs10276077	ENSG00000226824.5	RP4-756H11.3	10.39	5.94e-23	1.34e-19	0.55	0.43	Aortic root size;	chr7:66263424	chr7:66654538~66669855:+
LUAD	cis	rs3096299	0.685	rs12935112	ENSG00000274627.1	RP11-104N10.2	-10.39	5.97e-23	1.34e-19	-0.4	-0.43	Multiple myeloma (IgH translocation);	chr16:89476450	chr16:89516797~89522217:+
LUAD	cis	rs977987	0.806	rs2865531	ENSG00000261783.1	RP11-252K23.2	-10.39	6.01e-23	1.35e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75356418	chr16:75379818~75381260:-
LUAD	cis	rs9481169	0.85	rs13210247	ENSG00000255389.1	C6orf3	-10.39	6.04e-23	1.36e-19	-0.81	-0.43	Inflammatory skin disease;	chr6:111601517	chr6:111599875~111602295:+
LUAD	cis	rs2283792	0.745	rs5756306	ENSG00000224086.5	LL22NC03-86G7.1	10.39	6.16e-23	1.39e-19	0.39	0.43	Multiple sclerosis;	chr22:21978846	chr22:21938293~21977632:+
LUAD	cis	rs9322193	0.962	rs9505974	ENSG00000216906.2	RP11-350J20.9	10.39	6.2e-23	1.39e-19	0.52	0.43	Lung cancer;	chr6:149779294	chr6:149904243~149906418:+
LUAD	cis	rs11690935	0.959	rs7604918	ENSG00000228389.1	AC068039.4	10.39	6.22e-23	1.4e-19	0.51	0.43	Schizophrenia;	chr2:171731584	chr2:171773482~171775844:+
LUAD	cis	rs875971	0.862	rs6952182	ENSG00000226824.5	RP4-756H11.3	10.39	6.22e-23	1.4e-19	0.55	0.43	Aortic root size;	chr7:66218330	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.923	rs4242279	ENSG00000216906.2	RP11-350J20.9	10.38	6.25e-23	1.41e-19	0.53	0.43	Lung cancer;	chr6:149839815	chr6:149904243~149906418:+
LUAD	cis	rs977987	0.806	rs2903033	ENSG00000261783.1	RP11-252K23.2	-10.38	6.26e-23	1.41e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75355708	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.771	rs4888387	ENSG00000261783.1	RP11-252K23.2	-10.38	6.26e-23	1.41e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75355857	chr16:75379818~75381260:-
LUAD	cis	rs5769707	0.967	rs1018812	ENSG00000188511.11	C22orf34	10.38	6.28e-23	1.41e-19	0.49	0.43	Monocyte percentage of white cells;Monocyte count;	chr22:49616425	chr22:49414524~49657542:-
LUAD	cis	rs62229266	0.804	rs56279140	ENSG00000231106.2	LINC01436	10.38	6.32e-23	1.42e-19	0.59	0.43	Mitral valve prolapse;	chr21:36052063	chr21:36005338~36007838:+
LUAD	cis	rs6782228	0.585	rs2712392	ENSG00000242551.2	POU5F1P6	-10.38	6.44e-23	1.45e-19	-0.49	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705414	chr3:128674735~128677005:-
LUAD	cis	rs10129255	0.518	rs2006284	ENSG00000211972.2	IGHV3-66	10.38	6.48e-23	1.46e-19	0.34	0.43	Kawasaki disease;	chr14:106676185	chr14:106675017~106675544:-
LUAD	cis	rs1823913	1	rs6749232	ENSG00000280083.1	RP11-317J9.1	10.38	6.5e-23	1.46e-19	0.53	0.43	Obesity-related traits;	chr2:191250326	chr2:191154118~191156070:-
LUAD	cis	rs875971	0.862	rs1167408	ENSG00000226824.5	RP4-756H11.3	10.38	6.53e-23	1.46e-19	0.55	0.43	Aortic root size;	chr7:66091121	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.83	rs1167406	ENSG00000226824.5	RP4-756H11.3	10.38	6.53e-23	1.46e-19	0.55	0.43	Aortic root size;	chr7:66091949	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs709609	ENSG00000226824.5	RP4-756H11.3	10.38	6.53e-23	1.46e-19	0.55	0.43	Aortic root size;	chr7:66095574	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs1167399	ENSG00000226824.5	RP4-756H11.3	10.38	6.53e-23	1.46e-19	0.55	0.43	Aortic root size;	chr7:66096890	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs57866200	ENSG00000226824.5	RP4-756H11.3	10.38	6.53e-23	1.46e-19	0.55	0.43	Aortic root size;	chr7:66100405	chr7:66654538~66669855:+
LUAD	cis	rs10256972	0.706	rs12701969	ENSG00000229043.2	AC091729.9	-10.38	6.53e-23	1.47e-19	-0.48	-0.43	Endometriosis;Longevity;	chr7:1082213	chr7:1160374~1165267:+
LUAD	cis	rs9322193	0.962	rs7740784	ENSG00000216906.2	RP11-350J20.9	10.38	6.62e-23	1.48e-19	0.54	0.43	Lung cancer;	chr6:149833364	chr6:149904243~149906418:+
LUAD	cis	rs1061377	0.965	rs7690465	ENSG00000249207.1	RP11-360F5.1	-10.38	6.63e-23	1.49e-19	-0.49	-0.43	Uric acid levels;	chr4:39147015	chr4:39112677~39126818:-
LUAD	cis	rs875971	0.755	rs76288834	ENSG00000226824.5	RP4-756H11.3	10.38	6.64e-23	1.49e-19	0.55	0.43	Aortic root size;	chr7:66604815	chr7:66654538~66669855:+
LUAD	cis	rs11690935	1	rs6721680	ENSG00000228389.1	AC068039.4	-10.38	6.72e-23	1.51e-19	-0.5	-0.43	Schizophrenia;	chr2:171687403	chr2:171773482~171775844:+
LUAD	cis	rs748404	0.587	rs690276	ENSG00000205771.5	CATSPER2P1	-10.38	6.72e-23	1.51e-19	-0.54	-0.43	Lung cancer;	chr15:43412360	chr15:43726918~43747094:-
LUAD	cis	rs10256972	0.516	rs12702081	ENSG00000229043.2	AC091729.9	-10.37	6.8e-23	1.53e-19	-0.47	-0.43	Endometriosis;Longevity;	chr7:1101892	chr7:1160374~1165267:+
LUAD	cis	rs62229266	0.633	rs743420	ENSG00000231106.2	LINC01436	10.37	6.86e-23	1.54e-19	0.58	0.43	Mitral valve prolapse;	chr21:36015104	chr21:36005338~36007838:+
LUAD	cis	rs4423214	0.547	rs11234030	ENSG00000254682.1	RP11-660L16.2	-10.37	6.9e-23	1.55e-19	-0.64	-0.43	Vitamin D levels;	chr11:71525921	chr11:71448674~71452157:+
LUAD	cis	rs507080	0.697	rs656287	ENSG00000255239.1	AP002954.6	10.37	6.95e-23	1.56e-19	0.52	0.43	Serum metabolite levels;	chr11:118701081	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.733	rs570949	ENSG00000255239.1	AP002954.6	10.37	6.95e-23	1.56e-19	0.52	0.43	Serum metabolite levels;	chr11:118701202	chr11:118688039~118690600:-
LUAD	cis	rs11098499	0.954	rs6849561	ENSG00000245958.5	RP11-33B1.1	10.37	6.97e-23	1.56e-19	0.41	0.43	Corneal astigmatism;	chr4:119488539	chr4:119454791~119552025:+
LUAD	cis	rs9322193	0.962	rs7752089	ENSG00000216906.2	RP11-350J20.9	10.37	7.06e-23	1.58e-19	0.53	0.43	Lung cancer;	chr6:149839298	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.884	rs9383865	ENSG00000216906.2	RP11-350J20.9	10.37	7.13e-23	1.6e-19	0.54	0.43	Lung cancer;	chr6:149852043	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs4870050	ENSG00000216906.2	RP11-350J20.9	10.37	7.13e-23	1.6e-19	0.53	0.43	Lung cancer;	chr6:149838917	chr6:149904243~149906418:+
LUAD	cis	rs11690935	0.959	rs2292815	ENSG00000228389.1	AC068039.4	10.37	7.21e-23	1.61e-19	0.51	0.43	Schizophrenia;	chr2:171730141	chr2:171773482~171775844:+
LUAD	cis	rs1061377	0.965	rs7669376	ENSG00000249207.1	RP11-360F5.1	-10.37	7.26e-23	1.62e-19	-0.47	-0.43	Uric acid levels;	chr4:39116717	chr4:39112677~39126818:-
LUAD	cis	rs62229266	0.804	rs2835263	ENSG00000231106.2	LINC01436	-10.37	7.37e-23	1.65e-19	-0.58	-0.43	Mitral valve prolapse;	chr21:36057947	chr21:36005338~36007838:+
LUAD	cis	rs977987	0.835	rs4888379	ENSG00000261783.1	RP11-252K23.2	-10.36	7.42e-23	1.66e-19	-0.56	-0.43	Dupuytren's disease;	chr16:75306333	chr16:75379818~75381260:-
LUAD	cis	rs904251	0.523	rs9369005	ENSG00000279942.1	RP1-153P14.7	-10.36	7.57e-23	1.69e-19	-0.39	-0.43	Cognitive performance;	chr6:37515333	chr6:37567716~37571460:+
LUAD	cis	rs9322193	0.847	rs880246	ENSG00000216906.2	RP11-350J20.9	10.36	7.57e-23	1.69e-19	0.54	0.43	Lung cancer;	chr6:149845972	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.961	rs2064520	ENSG00000216906.2	RP11-350J20.9	10.36	7.57e-23	1.69e-19	0.51	0.43	Lung cancer;	chr6:149603650	chr6:149904243~149906418:+
LUAD	cis	rs977987	0.75	rs4888414	ENSG00000261783.1	RP11-252K23.2	-10.36	7.65e-23	1.71e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75413335	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs6564258	ENSG00000261783.1	RP11-252K23.2	-10.36	7.65e-23	1.71e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75413465	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.843	rs6564259	ENSG00000261783.1	RP11-252K23.2	-10.36	7.65e-23	1.71e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75413495	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.843	rs6564260	ENSG00000261783.1	RP11-252K23.2	-10.36	7.65e-23	1.71e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75413528	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs8056236	ENSG00000261783.1	RP11-252K23.2	-10.36	7.65e-23	1.71e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75414375	chr16:75379818~75381260:-
LUAD	cis	rs11098499	0.954	rs6857105	ENSG00000245958.5	RP11-33B1.1	-10.36	7.68e-23	1.71e-19	-0.4	-0.43	Corneal astigmatism;	chr4:119301143	chr4:119454791~119552025:+
LUAD	cis	rs11690935	0.959	rs4667694	ENSG00000228389.1	AC068039.4	10.36	7.69e-23	1.72e-19	0.51	0.43	Schizophrenia;	chr2:171748889	chr2:171773482~171775844:+
LUAD	cis	rs748404	0.66	rs694725	ENSG00000205771.5	CATSPER2P1	-10.36	7.77e-23	1.73e-19	-0.54	-0.43	Lung cancer;	chr15:43464012	chr15:43726918~43747094:-
LUAD	cis	rs977987	0.806	rs8051407	ENSG00000261783.1	RP11-252K23.2	-10.36	7.82e-23	1.74e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75414761	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs4888416	ENSG00000261783.1	RP11-252K23.2	-10.36	7.82e-23	1.74e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75415278	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs7199132	ENSG00000261783.1	RP11-252K23.2	-10.36	7.82e-23	1.74e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75416141	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs7188604	ENSG00000261783.1	RP11-252K23.2	-10.36	7.82e-23	1.74e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75417272	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.843	rs12149063	ENSG00000261783.1	RP11-252K23.2	-10.36	7.82e-23	1.74e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75417860	chr16:75379818~75381260:-
LUAD	cis	rs8062405	0.723	rs113208333	ENSG00000259982.1	CDC37P1	10.36	7.86e-23	1.75e-19	0.55	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28594839	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.691	rs743590	ENSG00000259982.1	CDC37P1	10.36	7.86e-23	1.75e-19	0.55	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28596909	chr16:28700294~28701540:-
LUAD	cis	rs9322193	0.632	rs3828700	ENSG00000216906.2	RP11-350J20.9	10.36	7.86e-23	1.75e-19	0.52	0.43	Lung cancer;	chr6:149791033	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs2275046	ENSG00000216906.2	RP11-350J20.9	10.36	7.87e-23	1.75e-19	0.53	0.43	Lung cancer;	chr6:149835865	chr6:149904243~149906418:+
LUAD	cis	rs1061377	0.722	rs34803689	ENSG00000249207.1	RP11-360F5.1	-10.36	7.9e-23	1.76e-19	-0.48	-0.43	Uric acid levels;	chr4:39116665	chr4:39112677~39126818:-
LUAD	cis	rs8040855	0.659	rs8037886	ENSG00000259295.5	CSPG4P12	-10.36	7.92e-23	1.77e-19	-0.57	-0.43	Bulimia nervosa;	chr15:85143533	chr15:85191438~85213905:+
LUAD	cis	rs9322193	0.884	rs880245	ENSG00000216906.2	RP11-350J20.9	-10.36	8.04e-23	1.79e-19	-0.54	-0.43	Lung cancer;	chr6:149846262	chr6:149904243~149906418:+
LUAD	cis	rs7044106	0.791	rs10760116	ENSG00000226752.6	PSMD5-AS1	-10.35	8.13e-23	1.81e-19	-0.48	-0.43	Hip circumference adjusted for BMI;	chr9:120732403	chr9:120824828~120854385:+
LUAD	cis	rs17507216	0.667	rs72753916	ENSG00000278603.1	RP13-608F4.5	10.35	8.17e-23	1.82e-19	0.57	0.43	Excessive daytime sleepiness;	chr15:82684001	chr15:82472203~82472426:+
LUAD	cis	rs977987	0.806	rs11642572	ENSG00000261783.1	RP11-252K23.2	-10.35	8.2e-23	1.83e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75418884	chr16:75379818~75381260:-
LUAD	cis	rs507080	0.769	rs7389	ENSG00000255422.1	AP002954.4	10.35	8.22e-23	1.83e-19	0.54	0.43	Serum metabolite levels;	chr11:118657756	chr11:118704607~118750263:+
LUAD	cis	rs977987	0.872	rs4243111	ENSG00000261783.1	RP11-252K23.2	-10.35	8.22e-23	1.83e-19	-0.56	-0.43	Dupuytren's disease;	chr16:75286929	chr16:75379818~75381260:-
LUAD	cis	rs3096299	0.719	rs2911265	ENSG00000274627.1	RP11-104N10.2	10.35	8.31e-23	1.85e-19	0.41	0.43	Multiple myeloma (IgH translocation);	chr16:89444920	chr16:89516797~89522217:+
LUAD	cis	rs977987	0.806	rs8050059	ENSG00000261783.1	RP11-252K23.2	-10.35	8.32e-23	1.85e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75354833	chr16:75379818~75381260:-
LUAD	cis	rs10875746	0.903	rs886588	ENSG00000240399.1	RP1-228P16.1	-10.35	8.36e-23	1.86e-19	-0.53	-0.43	Longevity (90 years and older);	chr12:48083639	chr12:48054813~48055591:-
LUAD	cis	rs62388641	0.813	rs55821127	ENSG00000272279.1	RP11-157J24.2	10.35	8.37e-23	1.86e-19	0.63	0.43	Daytime sleep phenotypes;	chr6:1550635	chr6:1528364~1528911:-
LUAD	cis	rs507080	0.733	rs489126	ENSG00000255239.1	AP002954.6	10.35	8.43e-23	1.87e-19	0.52	0.43	Serum metabolite levels;	chr11:118702038	chr11:118688039~118690600:-
LUAD	cis	rs977987	0.843	rs11860231	ENSG00000261783.1	RP11-252K23.2	-10.35	8.44e-23	1.88e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75351261	chr16:75379818~75381260:-
LUAD	cis	rs875971	0.862	rs2460432	ENSG00000226824.5	RP4-756H11.3	10.35	8.45e-23	1.88e-19	0.55	0.43	Aortic root size;	chr7:66089398	chr7:66654538~66669855:+
LUAD	cis	rs1153858	1	rs7169818	ENSG00000259520.4	CTD-2651B20.3	-10.35	8.45e-23	1.88e-19	-0.56	-0.43	Homoarginine levels;	chr15:45347993	chr15:45251580~45279251:-
LUAD	cis	rs977987	0.806	rs35263058	ENSG00000261783.1	RP11-252K23.2	-10.35	8.5e-23	1.89e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75358039	chr16:75379818~75381260:-
LUAD	cis	rs6504950	0.705	rs9899545	ENSG00000275710.1	RP11-257O5.4	10.35	8.53e-23	1.9e-19	0.55	0.43	Breast cancer;	chr17:54909484	chr17:54964474~54964679:+
LUAD	cis	rs6538678	0.777	rs10745736	ENSG00000199506.1	RNU6-247P	-10.35	8.54e-23	1.9e-19	-0.59	-0.43	Lupus nephritis in systemic lupus erythematosus;	chr12:95889308	chr12:95792529~95792635:-
LUAD	cis	rs11690935	1	rs312925	ENSG00000228389.1	AC068039.4	10.35	8.55e-23	1.9e-19	0.5	0.43	Schizophrenia;	chr2:171707412	chr2:171773482~171775844:+
LUAD	cis	rs9322193	0.924	rs9322189	ENSG00000216906.2	RP11-350J20.9	10.35	8.66e-23	1.92e-19	0.52	0.43	Lung cancer;	chr6:149588797	chr6:149904243~149906418:+
LUAD	cis	rs977987	0.645	rs10871311	ENSG00000261783.1	RP11-252K23.2	-10.35	8.68e-23	1.93e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75417014	chr16:75379818~75381260:-
LUAD	cis	rs6452524	1	rs6452528	ENSG00000249664.1	CTD-2227C6.2	10.35	8.74e-23	1.94e-19	0.48	0.43	Hypertension (SNP x SNP interaction);	chr5:83162560	chr5:83012285~83013109:-
LUAD	cis	rs2019137	0.868	rs6755639	ENSG00000274877.1	RP11-65I12.1	-10.34	8.79e-23	1.95e-19	-0.53	-0.43	Lymphocyte counts;	chr2:113224233	chr2:113237595~113240825:+
LUAD	cis	rs8040855	0.69	rs8041189	ENSG00000259295.5	CSPG4P12	-10.34	8.92e-23	1.98e-19	-0.57	-0.43	Bulimia nervosa;	chr15:85143096	chr15:85191438~85213905:+
LUAD	cis	rs875971	0.825	rs6951503	ENSG00000226824.5	RP4-756H11.3	10.34	8.96e-23	1.99e-19	0.55	0.43	Aortic root size;	chr7:66253949	chr7:66654538~66669855:+
LUAD	cis	rs977987	0.843	rs11644741	ENSG00000261783.1	RP11-252K23.2	-10.34	8.99e-23	1.99e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75432535	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs12917651	ENSG00000261783.1	RP11-252K23.2	-10.34	8.99e-23	1.99e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75432798	chr16:75379818~75381260:-
LUAD	cis	rs7044106	0.791	rs3904196	ENSG00000226752.6	PSMD5-AS1	-10.34	8.99e-23	1.99e-19	-0.47	-0.43	Hip circumference adjusted for BMI;	chr9:120718091	chr9:120824828~120854385:+
LUAD	cis	rs507080	0.733	rs611733	ENSG00000255239.1	AP002954.6	10.34	9.04e-23	2e-19	0.52	0.43	Serum metabolite levels;	chr11:118702051	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.733	rs552079	ENSG00000255239.1	AP002954.6	10.34	9.04e-23	2e-19	0.52	0.43	Serum metabolite levels;	chr11:118702313	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.733	rs673547	ENSG00000255239.1	AP002954.6	10.34	9.04e-23	2e-19	0.52	0.43	Serum metabolite levels;	chr11:118702630	chr11:118688039~118690600:-
LUAD	cis	rs9326248	1	rs9326248	ENSG00000280143.1	AP000892.6	10.34	9.06e-23	2.01e-19	0.52	0.43	Blood protein levels;	chr11:117128509	chr11:117204967~117210292:+
LUAD	cis	rs875971	0.862	rs2024192	ENSG00000226824.5	RP4-756H11.3	10.34	9.11e-23	2.02e-19	0.54	0.43	Aortic root size;	chr7:66576460	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs4718377	ENSG00000226824.5	RP4-756H11.3	10.34	9.11e-23	2.02e-19	0.54	0.43	Aortic root size;	chr7:66584691	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs10278014	ENSG00000226824.5	RP4-756H11.3	10.34	9.11e-23	2.02e-19	0.54	0.43	Aortic root size;	chr7:66586277	chr7:66654538~66669855:+
LUAD	cis	rs2188561	0.697	rs6956243	ENSG00000241764.3	AC002467.7	10.34	9.24e-23	2.05e-19	0.57	0.43	Alcohol consumption;	chr7:107748466	chr7:107742817~107744581:-
LUAD	cis	rs2188561	0.666	rs13231387	ENSG00000241764.3	AC002467.7	10.34	9.24e-23	2.05e-19	0.57	0.43	Alcohol consumption;	chr7:107749534	chr7:107742817~107744581:-
LUAD	cis	rs3829251	0.786	rs7103591	ENSG00000254682.1	RP11-660L16.2	-10.34	9.25e-23	2.05e-19	-0.64	-0.43	Vitamin D levels;	chr11:71526573	chr11:71448674~71452157:+
LUAD	cis	rs6452524	1	rs1382368	ENSG00000249664.1	CTD-2227C6.2	10.34	9.29e-23	2.06e-19	0.48	0.43	Hypertension (SNP x SNP interaction);	chr5:83155256	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs1382366	ENSG00000249664.1	CTD-2227C6.2	10.34	9.29e-23	2.06e-19	0.48	0.43	Hypertension (SNP x SNP interaction);	chr5:83156352	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs13358361	ENSG00000249664.1	CTD-2227C6.2	10.34	9.29e-23	2.06e-19	0.48	0.43	Hypertension (SNP x SNP interaction);	chr5:83160237	chr5:83012285~83013109:-
LUAD	cis	rs2188561	0.697	rs3735607	ENSG00000241764.3	AC002467.7	10.34	9.34e-23	2.07e-19	0.57	0.43	Alcohol consumption;	chr7:107743833	chr7:107742817~107744581:-
LUAD	cis	rs3096299	0.719	rs2965945	ENSG00000274627.1	RP11-104N10.2	10.34	9.35e-23	2.07e-19	0.4	0.43	Multiple myeloma (IgH translocation);	chr16:89447609	chr16:89516797~89522217:+
LUAD	cis	rs9322193	0.884	rs11155689	ENSG00000216906.2	RP11-350J20.9	10.34	9.49e-23	2.1e-19	0.52	0.43	Lung cancer;	chr6:149808470	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.884	rs933055	ENSG00000216906.2	RP11-350J20.9	10.34	9.49e-23	2.1e-19	0.52	0.43	Lung cancer;	chr6:149809701	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs4869731	ENSG00000216906.2	RP11-350J20.9	10.34	9.49e-23	2.1e-19	0.52	0.43	Lung cancer;	chr6:149810072	chr6:149904243~149906418:+
LUAD	cis	rs4774565	0.762	rs11634585	ENSG00000244879.4	GABPB1-AS1	10.34	9.52e-23	2.1e-19	0.38	0.43	Breast cancer;	chr15:50364252	chr15:50354959~50372202:+
LUAD	cis	rs5760092	0.755	rs915589	ENSG00000250470.1	AP000351.3	-10.34	9.53e-23	2.11e-19	-0.64	-0.43	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23976904~23977585:-
LUAD	cis	rs10875746	0.903	rs11168420	ENSG00000240399.1	RP1-228P16.1	-10.33	9.58e-23	2.12e-19	-0.52	-0.43	Longevity (90 years and older);	chr12:48122113	chr12:48054813~48055591:-
LUAD	cis	rs507080	0.733	rs517445	ENSG00000255239.1	AP002954.6	10.33	9.59e-23	2.12e-19	0.52	0.43	Serum metabolite levels;	chr11:118702826	chr11:118688039~118690600:-
LUAD	cis	rs9322193	0.962	rs9322220	ENSG00000216906.2	RP11-350J20.9	10.33	9.59e-23	2.12e-19	0.52	0.43	Lung cancer;	chr6:149782897	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs10214845	ENSG00000216906.2	RP11-350J20.9	10.33	9.59e-23	2.12e-19	0.52	0.43	Lung cancer;	chr6:149783124	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs9767122	ENSG00000216906.2	RP11-350J20.9	10.33	9.59e-23	2.12e-19	0.52	0.43	Lung cancer;	chr6:149783553	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs1413654	ENSG00000216906.2	RP11-350J20.9	10.33	9.59e-23	2.12e-19	0.52	0.43	Lung cancer;	chr6:149783956	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs9688809	ENSG00000216906.2	RP11-350J20.9	10.33	9.59e-23	2.12e-19	0.52	0.43	Lung cancer;	chr6:149787920	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs9689242	ENSG00000216906.2	RP11-350J20.9	10.33	9.59e-23	2.12e-19	0.52	0.43	Lung cancer;	chr6:149787970	chr6:149904243~149906418:+
LUAD	cis	rs9322193	1	rs9767077	ENSG00000216906.2	RP11-350J20.9	10.33	9.59e-23	2.12e-19	0.52	0.43	Lung cancer;	chr6:149788479	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs9688938	ENSG00000216906.2	RP11-350J20.9	10.33	9.59e-23	2.12e-19	0.52	0.43	Lung cancer;	chr6:149788941	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs9688940	ENSG00000216906.2	RP11-350J20.9	10.33	9.59e-23	2.12e-19	0.52	0.43	Lung cancer;	chr6:149788977	chr6:149904243~149906418:+
LUAD	cis	rs11690935	0.959	rs2674484	ENSG00000228389.1	AC068039.4	10.33	9.59e-23	2.12e-19	0.5	0.43	Schizophrenia;	chr2:171718102	chr2:171773482~171775844:+
LUAD	cis	rs11690935	0.959	rs11897196	ENSG00000228389.1	AC068039.4	10.33	9.59e-23	2.12e-19	0.5	0.43	Schizophrenia;	chr2:171729085	chr2:171773482~171775844:+
LUAD	cis	rs11690935	0.959	rs10207085	ENSG00000228389.1	AC068039.4	10.33	9.59e-23	2.12e-19	0.5	0.43	Schizophrenia;	chr2:171729375	chr2:171773482~171775844:+
LUAD	cis	rs2929278	0.562	rs8033846	ENSG00000205771.5	CATSPER2P1	10.33	9.63e-23	2.13e-19	0.55	0.43	Schizophrenia;	chr15:43743165	chr15:43726918~43747094:-
LUAD	cis	rs2929278	0.589	rs7174732	ENSG00000205771.5	CATSPER2P1	10.33	9.63e-23	2.13e-19	0.55	0.43	Schizophrenia;	chr15:43746265	chr15:43726918~43747094:-
LUAD	cis	rs11690935	0.959	rs66835971	ENSG00000228389.1	AC068039.4	10.33	9.75e-23	2.15e-19	0.5	0.43	Schizophrenia;	chr2:171820949	chr2:171773482~171775844:+
LUAD	cis	rs9322193	0.851	rs9322194	ENSG00000216906.2	RP11-350J20.9	10.33	9.81e-23	2.17e-19	0.52	0.43	Lung cancer;	chr6:149599113	chr6:149904243~149906418:+
LUAD	cis	rs67180937	0.961	rs17465940	ENSG00000272750.1	RP11-378J18.8	-10.33	9.86e-23	2.18e-19	-0.45	-0.43	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222663654	chr1:222658867~222661512:-
LUAD	cis	rs9322193	0.962	rs2151912	ENSG00000216906.2	RP11-350J20.9	10.33	9.87e-23	2.18e-19	0.53	0.43	Lung cancer;	chr6:149831772	chr6:149904243~149906418:+
LUAD	cis	rs16828019	0.852	rs12742379	ENSG00000235358.1	RP11-399E6.1	10.33	1e-22	2.21e-19	0.72	0.43	Intelligence (multi-trait analysis);	chr1:41060709	chr1:41242373~41284861:+
LUAD	cis	rs977987	0.843	rs4888427	ENSG00000261783.1	RP11-252K23.2	-10.33	1.01e-22	2.22e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75444549	chr16:75379818~75381260:-
LUAD	cis	rs10875746	0.903	rs11168427	ENSG00000240399.1	RP1-228P16.1	-10.33	1.01e-22	2.22e-19	-0.52	-0.43	Longevity (90 years and older);	chr12:48145196	chr12:48054813~48055591:-
LUAD	cis	rs6452524	0.901	rs72767146	ENSG00000249664.1	CTD-2227C6.2	10.33	1.01e-22	2.22e-19	0.5	0.43	Hypertension (SNP x SNP interaction);	chr5:83126365	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs6452524	ENSG00000249664.1	CTD-2227C6.2	-10.33	1.01e-22	2.23e-19	-0.48	-0.43	Hypertension (SNP x SNP interaction);	chr5:83137962	chr5:83012285~83013109:-
LUAD	cis	rs9322193	0.923	rs9766004	ENSG00000216906.2	RP11-350J20.9	10.33	1.02e-22	2.25e-19	0.5	0.43	Lung cancer;	chr6:149754363	chr6:149904243~149906418:+
LUAD	cis	rs1153858	1	rs2668747	ENSG00000259520.4	CTD-2651B20.3	-10.33	1.03e-22	2.27e-19	-0.57	-0.43	Homoarginine levels;	chr15:45325018	chr15:45251580~45279251:-
LUAD	cis	rs977987	0.778	rs35415181	ENSG00000261783.1	RP11-252K23.2	-10.33	1.03e-22	2.27e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75369226	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs1549306	ENSG00000261783.1	RP11-252K23.2	-10.33	1.03e-22	2.28e-19	-0.56	-0.43	Dupuytren's disease;	chr16:75381443	chr16:75379818~75381260:-
LUAD	cis	rs11098499	0.863	rs7664986	ENSG00000245958.5	RP11-33B1.1	-10.33	1.04e-22	2.28e-19	-0.4	-0.43	Corneal astigmatism;	chr4:119508797	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.818	rs10008791	ENSG00000245958.5	RP11-33B1.1	-10.33	1.04e-22	2.28e-19	-0.4	-0.43	Corneal astigmatism;	chr4:119510314	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs11736416	ENSG00000245958.5	RP11-33B1.1	-10.33	1.04e-22	2.28e-19	-0.4	-0.43	Corneal astigmatism;	chr4:119510506	chr4:119454791~119552025:+
LUAD	cis	rs2929278	0.561	rs3099045	ENSG00000205771.5	CATSPER2P1	-10.33	1.04e-22	2.28e-19	-0.54	-0.43	Schizophrenia;	chr15:43631757	chr15:43726918~43747094:-
LUAD	cis	rs6538678	0.929	rs10777744	ENSG00000199506.1	RNU6-247P	-10.33	1.04e-22	2.28e-19	-0.55	-0.43	Lupus nephritis in systemic lupus erythematosus;	chr12:95864561	chr12:95792529~95792635:-
LUAD	cis	rs2658782	0.724	rs2248020	ENSG00000279684.1	RP11-755E23.2	-10.33	1.04e-22	2.29e-19	-0.66	-0.43	Pulmonary function decline;	chr11:93526799	chr11:93286629~93288903:-
LUAD	cis	rs2188561	0.697	rs12539555	ENSG00000241764.3	AC002467.7	10.33	1.04e-22	2.29e-19	0.57	0.43	Alcohol consumption;	chr7:107764028	chr7:107742817~107744581:-
LUAD	cis	rs875971	0.79	rs10257911	ENSG00000226824.5	RP4-756H11.3	10.32	1.04e-22	2.29e-19	0.55	0.43	Aortic root size;	chr7:66278783	chr7:66654538~66669855:+
LUAD	cis	rs11098499	0.863	rs3775845	ENSG00000245958.5	RP11-33B1.1	-10.32	1.05e-22	2.31e-19	-0.4	-0.43	Corneal astigmatism;	chr4:119511292	chr4:119454791~119552025:+
LUAD	cis	rs904251	0.861	rs914349	ENSG00000204110.6	RP1-153P14.8	-10.32	1.06e-22	2.33e-19	-0.42	-0.43	Cognitive performance;	chr6:37516939	chr6:37507348~37535616:+
LUAD	cis	rs10875746	0.903	rs12306451	ENSG00000240399.1	RP1-228P16.1	-10.32	1.06e-22	2.34e-19	-0.53	-0.43	Longevity (90 years and older);	chr12:48089458	chr12:48054813~48055591:-
LUAD	cis	rs977987	0.806	rs35787595	ENSG00000261783.1	RP11-252K23.2	-10.32	1.07e-22	2.34e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75432949	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs12448947	ENSG00000261783.1	RP11-252K23.2	-10.32	1.07e-22	2.35e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75429056	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs4888420	ENSG00000261783.1	RP11-252K23.2	-10.32	1.07e-22	2.35e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75429100	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs12449170	ENSG00000261783.1	RP11-252K23.2	-10.32	1.07e-22	2.35e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75429114	chr16:75379818~75381260:-
LUAD	cis	rs10875746	0.855	rs10875730	ENSG00000240399.1	RP1-228P16.1	-10.32	1.08e-22	2.36e-19	-0.53	-0.43	Longevity (90 years and older);	chr12:48034092	chr12:48054813~48055591:-
LUAD	cis	rs62229266	0.804	rs2835231	ENSG00000231106.2	LINC01436	10.32	1.09e-22	2.39e-19	0.59	0.43	Mitral valve prolapse;	chr21:36018300	chr21:36005338~36007838:+
LUAD	cis	rs977987	0.843	rs4146810	ENSG00000261783.1	RP11-252K23.2	-10.32	1.1e-22	2.42e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75381933	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs17696696	ENSG00000261783.1	RP11-252K23.2	10.32	1.11e-22	2.44e-19	0.57	0.43	Dupuytren's disease;	chr16:75359454	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.815	rs11861810	ENSG00000261783.1	RP11-252K23.2	-10.32	1.11e-22	2.44e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75427931	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs11149832	ENSG00000261783.1	RP11-252K23.2	-10.32	1.11e-22	2.44e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75428815	chr16:75379818~75381260:-
LUAD	cis	rs11690935	0.959	rs10184866	ENSG00000228389.1	AC068039.4	10.32	1.12e-22	2.45e-19	0.5	0.43	Schizophrenia;	chr2:171752446	chr2:171773482~171775844:+
LUAD	cis	rs977987	0.806	rs4888418	ENSG00000261783.1	RP11-252K23.2	-10.32	1.13e-22	2.47e-19	-0.57	-0.43	Dupuytren's disease;	chr16:75426408	chr16:75379818~75381260:-
LUAD	cis	rs7396835	0.866	rs6589571	ENSG00000254851.1	RP11-109L13.1	-10.32	1.13e-22	2.48e-19	-0.75	-0.43	Quantitative traits;	chr11:116809702	chr11:117135528~117138582:+
LUAD	cis	rs10256972	0.591	rs6950319	ENSG00000229043.2	AC091729.9	-10.31	1.14e-22	2.49e-19	-0.46	-0.43	Endometriosis;Longevity;	chr7:1121688	chr7:1160374~1165267:+
LUAD	cis	rs16828019	0.852	rs12729448	ENSG00000235358.1	RP11-399E6.1	10.31	1.14e-22	2.49e-19	0.72	0.43	Intelligence (multi-trait analysis);	chr1:41044162	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.852	rs2268678	ENSG00000235358.1	RP11-399E6.1	10.31	1.14e-22	2.49e-19	0.72	0.43	Intelligence (multi-trait analysis);	chr1:41045381	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.852	rs10489520	ENSG00000235358.1	RP11-399E6.1	10.31	1.14e-22	2.49e-19	0.72	0.43	Intelligence (multi-trait analysis);	chr1:41046083	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.852	rs12406620	ENSG00000235358.1	RP11-399E6.1	10.31	1.14e-22	2.49e-19	0.72	0.43	Intelligence (multi-trait analysis);	chr1:41046992	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.852	rs12729586	ENSG00000235358.1	RP11-399E6.1	10.31	1.14e-22	2.49e-19	0.72	0.43	Intelligence (multi-trait analysis);	chr1:41056705	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.704	rs34486565	ENSG00000235358.1	RP11-399E6.1	10.31	1.14e-22	2.49e-19	0.72	0.43	Intelligence (multi-trait analysis);	chr1:41056838	chr1:41242373~41284861:+
LUAD	cis	rs2487048	0.761	rs2980083	ENSG00000226334.1	RP11-217B7.2	-10.31	1.15e-22	2.51e-19	-0.55	-0.43	Intraocular pressure;	chr9:104929081	chr9:104927553~104928892:+
LUAD	cis	rs904251	0.828	rs1757178	ENSG00000204110.6	RP1-153P14.8	10.31	1.15e-22	2.52e-19	0.44	0.43	Cognitive performance;	chr6:37518534	chr6:37507348~37535616:+
LUAD	cis	rs875971	0.825	rs59466412	ENSG00000226824.5	RP4-756H11.3	10.31	1.17e-22	2.55e-19	0.55	0.43	Aortic root size;	chr7:66100371	chr7:66654538~66669855:+
LUAD	cis	rs6782228	0.606	rs9828893	ENSG00000242551.2	POU5F1P6	-10.31	1.17e-22	2.55e-19	-0.48	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128614082	chr3:128674735~128677005:-
LUAD	cis	rs2188561	0.697	rs12705421	ENSG00000241764.3	AC002467.7	10.31	1.17e-22	2.55e-19	0.57	0.43	Alcohol consumption;	chr7:107760984	chr7:107742817~107744581:-
LUAD	cis	rs10129255	0.5	rs2027902	ENSG00000211972.2	IGHV3-66	10.31	1.17e-22	2.56e-19	0.34	0.43	Kawasaki disease;	chr14:106807157	chr14:106675017~106675544:-
LUAD	cis	rs2188561	0.638	rs28690459	ENSG00000241764.3	AC002467.7	10.31	1.17e-22	2.56e-19	0.57	0.43	Alcohol consumption;	chr7:107740258	chr7:107742817~107744581:-
LUAD	cis	rs10875746	0.859	rs4760680	ENSG00000240399.1	RP1-228P16.1	-10.31	1.18e-22	2.58e-19	-0.53	-0.43	Longevity (90 years and older);	chr12:48072914	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.903	rs11168386	ENSG00000240399.1	RP1-228P16.1	-10.31	1.18e-22	2.58e-19	-0.53	-0.43	Longevity (90 years and older);	chr12:48074194	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.807	rs12313300	ENSG00000240399.1	RP1-228P16.1	-10.31	1.18e-22	2.58e-19	-0.53	-0.43	Longevity (90 years and older);	chr12:48076934	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.903	rs12315625	ENSG00000240399.1	RP1-228P16.1	-10.31	1.18e-22	2.58e-19	-0.53	-0.43	Longevity (90 years and older);	chr12:48078670	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.903	rs10875738	ENSG00000240399.1	RP1-228P16.1	-10.31	1.18e-22	2.58e-19	-0.53	-0.43	Longevity (90 years and older);	chr12:48079956	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.903	rs12301339	ENSG00000240399.1	RP1-228P16.1	-10.31	1.18e-22	2.58e-19	-0.53	-0.43	Longevity (90 years and older);	chr12:48081450	chr12:48054813~48055591:-
LUAD	cis	rs73086581	0.838	rs56401022	ENSG00000229539.1	RP11-119B16.2	10.31	1.19e-22	2.6e-19	0.62	0.43	Response to antidepressants in depression;	chr20:4043634	chr20:3888239~3888868:-
LUAD	cis	rs11089937	1	rs11089937	ENSG00000211639.2	IGLV4-60	10.31	1.19e-22	2.61e-19	0.44	0.43	Periodontitis (PAL4Q3);	chr22:22152176	chr22:22162199~22162681:+
LUAD	cis	rs16828019	0.852	rs12044539	ENSG00000235358.1	RP11-399E6.1	10.31	1.2e-22	2.61e-19	0.73	0.43	Intelligence (multi-trait analysis);	chr1:41196060	chr1:41242373~41284861:+
LUAD	cis	rs507080	0.922	rs654792	ENSG00000255422.1	AP002954.4	10.31	1.2e-22	2.62e-19	0.54	0.43	Serum metabolite levels;	chr11:118682287	chr11:118704607~118750263:+
LUAD	cis	rs748404	0.66	rs690367	ENSG00000205771.5	CATSPER2P1	10.31	1.21e-22	2.64e-19	0.55	0.43	Lung cancer;	chr15:43456106	chr15:43726918~43747094:-
LUAD	cis	rs4728142	0.604	rs7807018	ENSG00000275106.1	RP11-309L24.10	-10.31	1.21e-22	2.64e-19	-0.51	-0.43	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129000134	chr7:128952527~128953316:-
LUAD	cis	rs10875746	0.903	rs11168401	ENSG00000240399.1	RP1-228P16.1	-10.31	1.23e-22	2.67e-19	-0.53	-0.43	Longevity (90 years and older);	chr12:48087736	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.903	rs12304476	ENSG00000240399.1	RP1-228P16.1	-10.31	1.23e-22	2.67e-19	-0.53	-0.43	Longevity (90 years and older);	chr12:48088370	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.903	rs989144	ENSG00000240399.1	RP1-228P16.1	-10.31	1.23e-22	2.67e-19	-0.53	-0.43	Longevity (90 years and older);	chr12:48090190	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.903	rs61918806	ENSG00000240399.1	RP1-228P16.1	-10.31	1.23e-22	2.67e-19	-0.53	-0.43	Longevity (90 years and older);	chr12:48090650	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.903	rs11168403	ENSG00000240399.1	RP1-228P16.1	-10.31	1.23e-22	2.67e-19	-0.53	-0.43	Longevity (90 years and older);	chr12:48091175	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.903	rs10875740	ENSG00000240399.1	RP1-228P16.1	-10.31	1.23e-22	2.67e-19	-0.53	-0.43	Longevity (90 years and older);	chr12:48095334	chr12:48054813~48055591:-
LUAD	cis	rs4423214	0.592	rs7130829	ENSG00000254682.1	RP11-660L16.2	-10.31	1.23e-22	2.68e-19	-0.63	-0.43	Vitamin D levels;	chr11:71526656	chr11:71448674~71452157:+
LUAD	cis	rs11690935	0.959	rs1474074	ENSG00000228389.1	AC068039.4	10.3	1.24e-22	2.7e-19	0.51	0.43	Schizophrenia;	chr2:171803342	chr2:171773482~171775844:+
LUAD	cis	rs11690935	0.959	rs6705200	ENSG00000228389.1	AC068039.4	10.3	1.24e-22	2.71e-19	0.5	0.43	Schizophrenia;	chr2:171781090	chr2:171773482~171775844:+
LUAD	cis	rs9322193	0.884	rs7743823	ENSG00000216906.2	RP11-350J20.9	10.3	1.25e-22	2.72e-19	0.53	0.43	Lung cancer;	chr6:149849744	chr6:149904243~149906418:+
LUAD	cis	rs1061377	1	rs7685468	ENSG00000249207.1	RP11-360F5.1	-10.3	1.25e-22	2.73e-19	-0.46	-0.43	Uric acid levels;	chr4:39116649	chr4:39112677~39126818:-
LUAD	cis	rs6782228	0.606	rs2811488	ENSG00000242551.2	POU5F1P6	-10.3	1.26e-22	2.74e-19	-0.48	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617674	chr3:128674735~128677005:-
LUAD	cis	rs67180937	0.921	rs2291834	ENSG00000272750.1	RP11-378J18.8	-10.3	1.27e-22	2.76e-19	-0.45	-0.43	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222658953	chr1:222658867~222661512:-
LUAD	cis	rs67180937	0.922	rs1133220	ENSG00000272750.1	RP11-378J18.8	-10.3	1.27e-22	2.76e-19	-0.45	-0.43	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222661461	chr1:222658867~222661512:-
LUAD	cis	rs875971	0.862	rs12537823	ENSG00000226824.5	RP4-756H11.3	-10.3	1.27e-22	2.77e-19	-0.55	-0.43	Aortic root size;	chr7:66255897	chr7:66654538~66669855:+
LUAD	cis	rs16828019	0.632	rs12749196	ENSG00000235358.1	RP11-399E6.1	10.3	1.28e-22	2.78e-19	0.76	0.43	Intelligence (multi-trait analysis);	chr1:40995111	chr1:41242373~41284861:+
LUAD	cis	rs2739330	0.734	rs2000467	ENSG00000231271.1	AP000350.8	-10.3	1.29e-22	2.81e-19	-0.53	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23949918~23954042:+
LUAD	cis	rs2487048	0.761	rs1800976	ENSG00000226334.1	RP11-217B7.2	-10.3	1.3e-22	2.82e-19	-0.55	-0.43	Intraocular pressure;	chr9:104928428	chr9:104927553~104928892:+
LUAD	cis	rs4423214	0.592	rs10898191	ENSG00000254682.1	RP11-660L16.2	-10.3	1.3e-22	2.83e-19	-0.63	-0.43	Vitamin D levels;	chr11:71483555	chr11:71448674~71452157:+
LUAD	cis	rs62229266	0.804	rs62230822	ENSG00000231106.2	LINC01436	10.3	1.31e-22	2.84e-19	0.58	0.43	Mitral valve prolapse;	chr21:36057647	chr21:36005338~36007838:+
LUAD	cis	rs2882667	0.537	rs7704790	ENSG00000253404.1	AC034243.1	10.3	1.32e-22	2.87e-19	0.52	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139074407	chr5:138744434~138753309:-
LUAD	cis	rs6452524	0.839	rs28745307	ENSG00000249664.1	CTD-2227C6.2	10.3	1.33e-22	2.88e-19	0.51	0.42	Hypertension (SNP x SNP interaction);	chr5:83122099	chr5:83012285~83013109:-
LUAD	cis	rs2455601	0.573	rs2653573	ENSG00000254860.4	TMEM9B-AS1	10.3	1.33e-22	2.88e-19	0.54	0.42	Schizophrenia;	chr11:8968327	chr11:8964675~8977527:+
LUAD	cis	rs875971	0.862	rs801194	ENSG00000226824.5	RP4-756H11.3	10.3	1.33e-22	2.89e-19	0.54	0.42	Aortic root size;	chr7:66563508	chr7:66654538~66669855:+
LUAD	cis	rs2739330	0.828	rs2186366	ENSG00000099984.9	GSTT2	10.3	1.34e-22	2.9e-19	0.51	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23980123~23983911:+
LUAD	cis	rs875971	0.862	rs1875057	ENSG00000226824.5	RP4-756H11.3	10.3	1.34e-22	2.91e-19	0.54	0.42	Aortic root size;	chr7:66266868	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs6960446	ENSG00000226824.5	RP4-756H11.3	10.3	1.34e-22	2.91e-19	0.54	0.42	Aortic root size;	chr7:66268272	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.789	rs10260426	ENSG00000226824.5	RP4-756H11.3	10.3	1.34e-22	2.91e-19	0.54	0.42	Aortic root size;	chr7:66271055	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs7796162	ENSG00000226824.5	RP4-756H11.3	10.3	1.34e-22	2.91e-19	0.54	0.42	Aortic root size;	chr7:66280771	chr7:66654538~66669855:+
LUAD	cis	rs4423214	0.559	rs10898228	ENSG00000254682.1	RP11-660L16.2	-10.29	1.35e-22	2.92e-19	-0.63	-0.42	Vitamin D levels;	chr11:71517312	chr11:71448674~71452157:+
LUAD	cis	rs748404	0.56	rs2255663	ENSG00000205771.5	CATSPER2P1	10.29	1.35e-22	2.94e-19	0.53	0.42	Lung cancer;	chr15:43536810	chr15:43726918~43747094:-
LUAD	cis	rs67180937	0.961	rs17011681	ENSG00000272750.1	RP11-378J18.8	-10.29	1.36e-22	2.95e-19	-0.45	-0.42	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222651746	chr1:222658867~222661512:-
LUAD	cis	rs16828019	0.929	rs2363805	ENSG00000235358.1	RP11-399E6.1	10.29	1.36e-22	2.96e-19	0.73	0.42	Intelligence (multi-trait analysis);	chr1:41253762	chr1:41242373~41284861:+
LUAD	cis	rs9322193	0.926	rs9689036	ENSG00000216906.2	RP11-350J20.9	10.29	1.37e-22	2.97e-19	0.52	0.42	Lung cancer;	chr6:149780563	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs9322218	ENSG00000216906.2	RP11-350J20.9	10.29	1.37e-22	2.97e-19	0.52	0.42	Lung cancer;	chr6:149782183	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs9322219	ENSG00000216906.2	RP11-350J20.9	10.29	1.37e-22	2.97e-19	0.52	0.42	Lung cancer;	chr6:149782263	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs9322223	ENSG00000216906.2	RP11-350J20.9	10.29	1.37e-22	2.97e-19	0.52	0.42	Lung cancer;	chr6:149801509	chr6:149904243~149906418:+
LUAD	cis	rs8040855	0.791	rs8042888	ENSG00000259295.5	CSPG4P12	-10.29	1.37e-22	2.98e-19	-0.53	-0.42	Bulimia nervosa;	chr15:85152360	chr15:85191438~85213905:+
LUAD	cis	rs10875746	0.903	rs2158516	ENSG00000240399.1	RP1-228P16.1	-10.29	1.37e-22	2.98e-19	-0.53	-0.42	Longevity (90 years and older);	chr12:48097051	chr12:48054813~48055591:-
LUAD	cis	rs7044106	0.791	rs10985009	ENSG00000226752.6	PSMD5-AS1	10.29	1.38e-22	2.99e-19	0.47	0.42	Hip circumference adjusted for BMI;	chr9:120730761	chr9:120824828~120854385:+
LUAD	cis	rs11690935	0.959	rs3770451	ENSG00000228389.1	AC068039.4	10.29	1.38e-22	2.99e-19	0.5	0.42	Schizophrenia;	chr2:171812205	chr2:171773482~171775844:+
LUAD	cis	rs10875746	0.903	rs3782911	ENSG00000240399.1	RP1-228P16.1	-10.29	1.39e-22	3.01e-19	-0.53	-0.42	Longevity (90 years and older);	chr12:48089709	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.859	rs3782910	ENSG00000240399.1	RP1-228P16.1	-10.29	1.39e-22	3.01e-19	-0.53	-0.42	Longevity (90 years and older);	chr12:48089724	chr12:48054813~48055591:-
LUAD	cis	rs16828019	0.852	rs71648540	ENSG00000235358.1	RP11-399E6.1	10.29	1.39e-22	3.01e-19	0.73	0.42	Intelligence (multi-trait analysis);	chr1:41256623	chr1:41242373~41284861:+
LUAD	cis	rs10875746	0.903	rs10875735	ENSG00000240399.1	RP1-228P16.1	-10.29	1.4e-22	3.03e-19	-0.53	-0.42	Longevity (90 years and older);	chr12:48070023	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.855	rs17122620	ENSG00000240399.1	RP1-228P16.1	-10.29	1.4e-22	3.03e-19	-0.53	-0.42	Longevity (90 years and older);	chr12:48070692	chr12:48054813~48055591:-
LUAD	cis	rs9322193	0.683	rs113281309	ENSG00000216906.2	RP11-350J20.9	10.29	1.41e-22	3.05e-19	0.52	0.42	Lung cancer;	chr6:149787289	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.961	rs9767713	ENSG00000216906.2	RP11-350J20.9	10.29	1.42e-22	3.07e-19	0.53	0.42	Lung cancer;	chr6:149588241	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs6899661	ENSG00000216906.2	RP11-350J20.9	10.29	1.42e-22	3.08e-19	0.52	0.42	Lung cancer;	chr6:149818093	chr6:149904243~149906418:+
LUAD	cis	rs10256972	0.706	rs4285396	ENSG00000229043.2	AC091729.9	-10.29	1.42e-22	3.08e-19	-0.46	-0.42	Endometriosis;Longevity;	chr7:1084102	chr7:1160374~1165267:+
LUAD	cis	rs11690935	0.959	rs7608403	ENSG00000228389.1	AC068039.4	10.29	1.44e-22	3.11e-19	0.5	0.42	Schizophrenia;	chr2:171790255	chr2:171773482~171775844:+
LUAD	cis	rs3096299	0.503	rs9940093	ENSG00000274627.1	RP11-104N10.2	10.29	1.44e-22	3.12e-19	0.41	0.42	Multiple myeloma (IgH translocation);	chr16:89492297	chr16:89516797~89522217:+
LUAD	cis	rs1823913	1	rs11691372	ENSG00000280083.1	RP11-317J9.1	10.29	1.44e-22	3.12e-19	0.53	0.42	Obesity-related traits;	chr2:191249952	chr2:191154118~191156070:-
LUAD	cis	rs977987	0.872	rs7206665	ENSG00000261783.1	RP11-252K23.2	-10.29	1.44e-22	3.13e-19	-0.57	-0.42	Dupuytren's disease;	chr16:75441389	chr16:75379818~75381260:-
LUAD	cis	rs1823913	1	rs12623832	ENSG00000280083.1	RP11-317J9.1	10.29	1.45e-22	3.13e-19	0.53	0.42	Obesity-related traits;	chr2:191260918	chr2:191154118~191156070:-
LUAD	cis	rs17507216	0.591	rs7163848	ENSG00000278603.1	RP13-608F4.5	10.29	1.45e-22	3.14e-19	0.61	0.42	Excessive daytime sleepiness;	chr15:82729563	chr15:82472203~82472426:+
LUAD	cis	rs977987	0.806	rs4888404	ENSG00000261783.1	RP11-252K23.2	-10.28	1.47e-22	3.18e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75394199	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs11643410	ENSG00000261783.1	RP11-252K23.2	-10.28	1.47e-22	3.18e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75394408	chr16:75379818~75381260:-
LUAD	cis	rs507080	0.769	rs745663	ENSG00000255422.1	AP002954.4	-10.28	1.48e-22	3.21e-19	-0.54	-0.42	Serum metabolite levels;	chr11:118658886	chr11:118704607~118750263:+
LUAD	cis	rs1061377	1	rs13182	ENSG00000249207.1	RP11-360F5.1	-10.28	1.53e-22	3.3e-19	-0.47	-0.42	Uric acid levels;	chr4:39121293	chr4:39112677~39126818:-
LUAD	cis	rs977987	0.806	rs11862684	ENSG00000261783.1	RP11-252K23.2	-10.28	1.53e-22	3.31e-19	-0.57	-0.42	Dupuytren's disease;	chr16:75427848	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs11149833	ENSG00000261783.1	RP11-252K23.2	-10.28	1.54e-22	3.32e-19	-0.57	-0.42	Dupuytren's disease;	chr16:75430104	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs11641587	ENSG00000261783.1	RP11-252K23.2	-10.28	1.54e-22	3.32e-19	-0.57	-0.42	Dupuytren's disease;	chr16:75430521	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs12930768	ENSG00000261783.1	RP11-252K23.2	-10.28	1.54e-22	3.32e-19	-0.57	-0.42	Dupuytren's disease;	chr16:75430602	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.778	rs12445726	ENSG00000261783.1	RP11-252K23.2	-10.28	1.54e-22	3.32e-19	-0.57	-0.42	Dupuytren's disease;	chr16:75431677	chr16:75379818~75381260:-
LUAD	cis	rs10256972	0.616	rs4585652	ENSG00000229043.2	AC091729.9	-10.28	1.54e-22	3.33e-19	-0.47	-0.42	Endometriosis;Longevity;	chr7:1105760	chr7:1160374~1165267:+
LUAD	cis	rs507080	0.771	rs687664	ENSG00000255239.1	AP002954.6	10.28	1.55e-22	3.35e-19	0.51	0.42	Serum metabolite levels;	chr11:118703476	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.771	rs523715	ENSG00000255239.1	AP002954.6	10.28	1.55e-22	3.35e-19	0.51	0.42	Serum metabolite levels;	chr11:118703479	chr11:118688039~118690600:-
LUAD	cis	rs977987	0.836	rs7199062	ENSG00000261783.1	RP11-252K23.2	-10.28	1.56e-22	3.37e-19	-0.57	-0.42	Dupuytren's disease;	chr16:75440929	chr16:75379818~75381260:-
LUAD	cis	rs11098499	0.909	rs73842633	ENSG00000245958.5	RP11-33B1.1	-10.28	1.58e-22	3.42e-19	-0.4	-0.42	Corneal astigmatism;	chr4:119454309	chr4:119454791~119552025:+
LUAD	cis	rs977987	0.872	rs1559339	ENSG00000261783.1	RP11-252K23.2	-10.28	1.58e-22	3.42e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75284748	chr16:75379818~75381260:-
LUAD	cis	rs9322193	0.926	rs9766562	ENSG00000216906.2	RP11-350J20.9	10.28	1.59e-22	3.42e-19	0.52	0.42	Lung cancer;	chr6:149788709	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.909	rs10026736	ENSG00000245958.5	RP11-33B1.1	-10.27	1.6e-22	3.44e-19	-0.4	-0.42	Corneal astigmatism;	chr4:119463167	chr4:119454791~119552025:+
LUAD	cis	rs6504950	0.8	rs12952253	ENSG00000275710.1	RP11-257O5.4	10.27	1.6e-22	3.45e-19	0.54	0.42	Breast cancer;	chr17:54928355	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.8	rs7208123	ENSG00000275710.1	RP11-257O5.4	10.27	1.6e-22	3.45e-19	0.54	0.42	Breast cancer;	chr17:54928978	chr17:54964474~54964679:+
LUAD	cis	rs2929278	0.589	rs11638972	ENSG00000205771.5	CATSPER2P1	10.27	1.6e-22	3.46e-19	0.52	0.42	Schizophrenia;	chr15:43782493	chr15:43726918~43747094:-
LUAD	cis	rs11098499	0.954	rs6847248	ENSG00000245958.5	RP11-33B1.1	-10.27	1.61e-22	3.48e-19	-0.41	-0.42	Corneal astigmatism;	chr4:119304800	chr4:119454791~119552025:+
LUAD	cis	rs11690935	0.959	rs6724337	ENSG00000228389.1	AC068039.4	10.27	1.62e-22	3.5e-19	0.5	0.42	Schizophrenia;	chr2:171878819	chr2:171773482~171775844:+
LUAD	cis	rs11690935	0.959	rs7586207	ENSG00000228389.1	AC068039.4	10.27	1.65e-22	3.56e-19	0.5	0.42	Schizophrenia;	chr2:171814584	chr2:171773482~171775844:+
LUAD	cis	rs11690935	0.959	rs6745143	ENSG00000228389.1	AC068039.4	10.27	1.65e-22	3.56e-19	0.5	0.42	Schizophrenia;	chr2:171793872	chr2:171773482~171775844:+
LUAD	cis	rs11690935	0.959	rs6758704	ENSG00000228389.1	AC068039.4	10.27	1.65e-22	3.56e-19	0.5	0.42	Schizophrenia;	chr2:171798587	chr2:171773482~171775844:+
LUAD	cis	rs6964833	1	rs34324835	ENSG00000123965.13	PMS2P5	10.27	1.66e-22	3.57e-19	0.68	0.42	Menarche (age at onset);	chr7:74717986	chr7:74894116~74897835:+
LUAD	cis	rs9326248	1	rs3736120	ENSG00000280143.1	AP000892.6	10.27	1.67e-22	3.59e-19	0.51	0.42	Blood protein levels;	chr11:117161409	chr11:117204967~117210292:+
LUAD	cis	rs9322193	0.923	rs7769101	ENSG00000216906.2	RP11-350J20.9	10.27	1.68e-22	3.61e-19	0.53	0.42	Lung cancer;	chr6:149848768	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.82	rs11737395	ENSG00000245958.5	RP11-33B1.1	-10.27	1.68e-22	3.61e-19	-0.4	-0.42	Corneal astigmatism;	chr4:119599549	chr4:119454791~119552025:+
LUAD	cis	rs16828019	0.929	rs10524	ENSG00000235358.1	RP11-399E6.1	10.27	1.68e-22	3.62e-19	0.73	0.42	Intelligence (multi-trait analysis);	chr1:41260801	chr1:41242373~41284861:+
LUAD	cis	rs67180937	0.849	rs4575092	ENSG00000272750.1	RP11-378J18.8	-10.27	1.68e-22	3.63e-19	-0.45	-0.42	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222661161	chr1:222658867~222661512:-
LUAD	cis	rs1153858	1	rs1145085	ENSG00000259520.4	CTD-2651B20.3	-10.27	1.68e-22	3.63e-19	-0.56	-0.42	Homoarginine levels;	chr15:45365606	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs1288775	ENSG00000259520.4	CTD-2651B20.3	-10.27	1.68e-22	3.63e-19	-0.56	-0.42	Homoarginine levels;	chr15:45369480	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs1049508	ENSG00000259520.4	CTD-2651B20.3	-10.27	1.69e-22	3.63e-19	-0.56	-0.42	Homoarginine levels;	chr15:45361394	chr15:45251580~45279251:-
LUAD	cis	rs2729354	0.779	rs2511984	ENSG00000265566.2	RN7SL605P	-10.27	1.7e-22	3.65e-19	-0.64	-0.42	Blood protein levels;	chr11:57511260	chr11:57528085~57528365:-
LUAD	cis	rs875971	0.862	rs6955837	ENSG00000226824.5	RP4-756H11.3	10.27	1.72e-22	3.7e-19	0.54	0.42	Aortic root size;	chr7:66578155	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.825	rs10281499	ENSG00000226824.5	RP4-756H11.3	10.27	1.72e-22	3.7e-19	0.54	0.42	Aortic root size;	chr7:66583979	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.884	rs7744105	ENSG00000216906.2	RP11-350J20.9	10.26	1.76e-22	3.78e-19	0.53	0.42	Lung cancer;	chr6:149849308	chr6:149904243~149906418:+
LUAD	cis	rs10875746	0.855	rs11168369	ENSG00000240399.1	RP1-228P16.1	-10.26	1.77e-22	3.8e-19	-0.52	-0.42	Longevity (90 years and older);	chr12:48037385	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.855	rs10875731	ENSG00000240399.1	RP1-228P16.1	-10.26	1.77e-22	3.8e-19	-0.52	-0.42	Longevity (90 years and older);	chr12:48038960	chr12:48054813~48055591:-
LUAD	cis	rs11690935	0.959	rs10166005	ENSG00000228389.1	AC068039.4	10.26	1.78e-22	3.82e-19	0.5	0.42	Schizophrenia;	chr2:171750784	chr2:171773482~171775844:+
LUAD	cis	rs1061377	1	rs2381284	ENSG00000249207.1	RP11-360F5.1	-10.26	1.78e-22	3.82e-19	-0.47	-0.42	Uric acid levels;	chr4:39117976	chr4:39112677~39126818:-
LUAD	cis	rs1061377	0.803	rs6857761	ENSG00000249207.1	RP11-360F5.1	-10.26	1.78e-22	3.82e-19	-0.47	-0.42	Uric acid levels;	chr4:39118353	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs9997089	ENSG00000249207.1	RP11-360F5.1	-10.26	1.78e-22	3.82e-19	-0.47	-0.42	Uric acid levels;	chr4:39119263	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs28465556	ENSG00000249207.1	RP11-360F5.1	-10.26	1.78e-22	3.82e-19	-0.47	-0.42	Uric acid levels;	chr4:39119569	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs10027813	ENSG00000249207.1	RP11-360F5.1	-10.26	1.78e-22	3.82e-19	-0.47	-0.42	Uric acid levels;	chr4:39119818	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs9990755	ENSG00000249207.1	RP11-360F5.1	-10.26	1.78e-22	3.82e-19	-0.47	-0.42	Uric acid levels;	chr4:39119819	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs7676008	ENSG00000249207.1	RP11-360F5.1	-10.26	1.78e-22	3.82e-19	-0.47	-0.42	Uric acid levels;	chr4:39120154	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs7655122	ENSG00000249207.1	RP11-360F5.1	-10.26	1.78e-22	3.82e-19	-0.47	-0.42	Uric acid levels;	chr4:39120396	chr4:39112677~39126818:-
LUAD	cis	rs1061377	0.965	rs3733275	ENSG00000249207.1	RP11-360F5.1	-10.26	1.78e-22	3.82e-19	-0.47	-0.42	Uric acid levels;	chr4:39121077	chr4:39112677~39126818:-
LUAD	cis	rs6452524	0.775	rs10071579	ENSG00000249664.1	CTD-2227C6.2	10.26	1.79e-22	3.84e-19	0.5	0.42	Hypertension (SNP x SNP interaction);	chr5:83113925	chr5:83012285~83013109:-
LUAD	cis	rs11690935	0.959	rs10204622	ENSG00000228389.1	AC068039.4	10.26	1.8e-22	3.86e-19	0.5	0.42	Schizophrenia;	chr2:171732472	chr2:171773482~171775844:+
LUAD	cis	rs1061377	1	rs9998867	ENSG00000249207.1	RP11-360F5.1	-10.26	1.82e-22	3.91e-19	-0.47	-0.42	Uric acid levels;	chr4:39117542	chr4:39112677~39126818:-
LUAD	cis	rs9326248	0.954	rs4938349	ENSG00000280143.1	AP000892.6	10.26	1.82e-22	3.91e-19	0.51	0.42	Blood protein levels;	chr11:117151207	chr11:117204967~117210292:+
LUAD	cis	rs977987	0.843	rs11649638	ENSG00000261783.1	RP11-252K23.2	-10.26	1.86e-22	3.99e-19	-0.57	-0.42	Dupuytren's disease;	chr16:75454387	chr16:75379818~75381260:-
LUAD	cis	rs1061377	1	rs10026775	ENSG00000249207.1	RP11-360F5.1	-10.26	1.87e-22	4.01e-19	-0.47	-0.42	Uric acid levels;	chr4:39115155	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs3733276	ENSG00000249207.1	RP11-360F5.1	-10.26	1.87e-22	4.01e-19	-0.47	-0.42	Uric acid levels;	chr4:39115291	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs3733277	ENSG00000249207.1	RP11-360F5.1	-10.26	1.87e-22	4.01e-19	-0.47	-0.42	Uric acid levels;	chr4:39115483	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs3733278	ENSG00000249207.1	RP11-360F5.1	-10.26	1.87e-22	4.01e-19	-0.47	-0.42	Uric acid levels;	chr4:39115615	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs3733279	ENSG00000249207.1	RP11-360F5.1	-10.26	1.87e-22	4.01e-19	-0.47	-0.42	Uric acid levels;	chr4:39115625	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs10018049	ENSG00000249207.1	RP11-360F5.1	-10.26	1.87e-22	4.01e-19	-0.47	-0.42	Uric acid levels;	chr4:39115781	chr4:39112677~39126818:-
LUAD	cis	rs9322193	0.962	rs9688412	ENSG00000216906.2	RP11-350J20.9	-10.26	1.89e-22	4.04e-19	-0.52	-0.42	Lung cancer;	chr6:149803147	chr6:149904243~149906418:+
LUAD	cis	rs10875746	0.951	rs61918826	ENSG00000240399.1	RP1-228P16.1	-10.25	1.9e-22	4.06e-19	-0.52	-0.42	Longevity (90 years and older);	chr12:48150195	chr12:48054813~48055591:-
LUAD	cis	rs9322193	0.923	rs2342857	ENSG00000216906.2	RP11-350J20.9	10.25	1.9e-22	4.07e-19	0.52	0.42	Lung cancer;	chr6:149809537	chr6:149904243~149906418:+
LUAD	cis	rs2283792	0.718	rs239918	ENSG00000224086.5	LL22NC03-86G7.1	-10.25	1.9e-22	4.07e-19	-0.39	-0.42	Multiple sclerosis;	chr22:21959457	chr22:21938293~21977632:+
LUAD	cis	rs10129255	0.5	rs8011115	ENSG00000211972.2	IGHV3-66	10.25	1.91e-22	4.09e-19	0.34	0.42	Kawasaki disease;	chr14:106786292	chr14:106675017~106675544:-
LUAD	cis	rs1061377	1	rs1036037	ENSG00000249207.1	RP11-360F5.1	-10.25	1.92e-22	4.11e-19	-0.47	-0.42	Uric acid levels;	chr4:39111272	chr4:39112677~39126818:-
LUAD	cis	rs6782228	0.606	rs2811489	ENSG00000242551.2	POU5F1P6	10.25	1.93e-22	4.13e-19	0.48	0.42	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128618528	chr3:128674735~128677005:-
LUAD	cis	rs748404	0.66	rs2602141	ENSG00000205771.5	CATSPER2P1	-10.25	1.93e-22	4.14e-19	-0.52	-0.42	Lung cancer;	chr15:43432448	chr15:43726918~43747094:-
LUAD	cis	rs11098499	0.863	rs1480940	ENSG00000245958.5	RP11-33B1.1	-10.25	1.94e-22	4.14e-19	-0.4	-0.42	Corneal astigmatism;	chr4:119536527	chr4:119454791~119552025:+
LUAD	cis	rs875971	0.825	rs4587224	ENSG00000226824.5	RP4-756H11.3	10.25	1.94e-22	4.15e-19	0.54	0.42	Aortic root size;	chr7:66271195	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.792	rs6971752	ENSG00000226824.5	RP4-756H11.3	10.25	1.94e-22	4.15e-19	0.54	0.42	Aortic root size;	chr7:66272999	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs10950033	ENSG00000226824.5	RP4-756H11.3	10.25	1.94e-22	4.15e-19	0.54	0.42	Aortic root size;	chr7:66274686	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs11760844	ENSG00000226824.5	RP4-756H11.3	10.25	1.94e-22	4.15e-19	0.54	0.42	Aortic root size;	chr7:66274896	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.862	rs4149461	ENSG00000226824.5	RP4-756H11.3	10.25	1.94e-22	4.15e-19	0.54	0.42	Aortic root size;	chr7:66279745	chr7:66654538~66669855:+
LUAD	cis	rs143626010	1	rs143626010	ENSG00000259982.1	CDC37P1	10.25	1.96e-22	4.2e-19	0.53	0.42	Mosquito bite size;	chr16:28528081	chr16:28700294~28701540:-
LUAD	cis	rs11690935	0.959	rs7597387	ENSG00000228389.1	AC068039.4	10.25	1.97e-22	4.2e-19	0.5	0.42	Schizophrenia;	chr2:171720606	chr2:171773482~171775844:+
LUAD	cis	rs1061377	1	rs36090629	ENSG00000249207.1	RP11-360F5.1	-10.25	1.97e-22	4.22e-19	-0.47	-0.42	Uric acid levels;	chr4:39137195	chr4:39112677~39126818:-
LUAD	cis	rs1061377	0.87	rs73238544	ENSG00000249207.1	RP11-360F5.1	-10.25	1.97e-22	4.22e-19	-0.47	-0.42	Uric acid levels;	chr4:39137343	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs7675782	ENSG00000249207.1	RP11-360F5.1	-10.25	1.98e-22	4.22e-19	-0.47	-0.42	Uric acid levels;	chr4:39120048	chr4:39112677~39126818:-
LUAD	cis	rs67180937	0.884	rs2291832	ENSG00000272750.1	RP11-378J18.8	-10.25	1.98e-22	4.23e-19	-0.45	-0.42	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222653139	chr1:222658867~222661512:-
LUAD	cis	rs35158675	1	rs35158675	ENSG00000272750.1	RP11-378J18.8	-10.25	2.01e-22	4.29e-19	-0.45	-0.42	Coronary artery disease;	chr1:222656208	chr1:222658867~222661512:-
LUAD	cis	rs6782228	0.606	rs10048945	ENSG00000242551.2	POU5F1P6	-10.25	2.01e-22	4.29e-19	-0.47	-0.42	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128690837	chr3:128674735~128677005:-
LUAD	cis	rs7044106	0.791	rs10985008	ENSG00000226752.6	PSMD5-AS1	-10.25	2.04e-22	4.36e-19	-0.48	-0.42	Hip circumference adjusted for BMI;	chr9:120730682	chr9:120824828~120854385:+
LUAD	cis	rs4774565	0.762	rs8041193	ENSG00000244879.4	GABPB1-AS1	-10.25	2.05e-22	4.38e-19	-0.38	-0.42	Breast cancer;	chr15:50369960	chr15:50354959~50372202:+
LUAD	cis	rs6504950	0.8	rs17745183	ENSG00000275710.1	RP11-257O5.4	10.24	2.07e-22	4.42e-19	0.54	0.42	Breast cancer;	chr17:54936234	chr17:54964474~54964679:+
LUAD	cis	rs16828019	0.85	rs12027691	ENSG00000235358.1	RP11-399E6.1	10.24	2.09e-22	4.47e-19	0.75	0.42	Intelligence (multi-trait analysis);	chr1:40996360	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.777	rs12047078	ENSG00000235358.1	RP11-399E6.1	10.24	2.09e-22	4.47e-19	0.75	0.42	Intelligence (multi-trait analysis);	chr1:40997314	chr1:41242373~41284861:+
LUAD	cis	rs2739330	0.796	rs2154594	ENSG00000099984.9	GSTT2	10.24	2.1e-22	4.48e-19	0.52	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23980123~23983911:+
LUAD	cis	rs977987	0.815	rs11149818	ENSG00000261783.1	RP11-252K23.2	-10.24	2.13e-22	4.55e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75385475	chr16:75379818~75381260:-
LUAD	cis	rs6504950	0.8	rs72829484	ENSG00000275710.1	RP11-257O5.4	10.24	2.13e-22	4.55e-19	0.54	0.42	Breast cancer;	chr17:54931919	chr17:54964474~54964679:+
LUAD	cis	rs977987	0.806	rs35683383	ENSG00000261783.1	RP11-252K23.2	-10.24	2.14e-22	4.56e-19	-0.57	-0.42	Dupuytren's disease;	chr16:75445379	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs7202596	ENSG00000261783.1	RP11-252K23.2	-10.24	2.14e-22	4.56e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75457174	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs4888390	ENSG00000261783.1	RP11-252K23.2	-10.24	2.18e-22	4.65e-19	-0.57	-0.42	Dupuytren's disease;	chr16:75366422	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs4888391	ENSG00000261783.1	RP11-252K23.2	-10.24	2.18e-22	4.65e-19	-0.57	-0.42	Dupuytren's disease;	chr16:75366848	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs8054769	ENSG00000261783.1	RP11-252K23.2	-10.24	2.18e-22	4.65e-19	-0.57	-0.42	Dupuytren's disease;	chr16:75367215	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.778	rs12930452	ENSG00000261783.1	RP11-252K23.2	-10.24	2.18e-22	4.65e-19	-0.57	-0.42	Dupuytren's disease;	chr16:75428157	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.778	rs12929908	ENSG00000261783.1	RP11-252K23.2	-10.24	2.18e-22	4.65e-19	-0.57	-0.42	Dupuytren's disease;	chr16:75428173	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.742	rs12928898	ENSG00000261783.1	RP11-252K23.2	-10.24	2.18e-22	4.65e-19	-0.57	-0.42	Dupuytren's disease;	chr16:75428183	chr16:75379818~75381260:-
LUAD	cis	rs4423214	0.84	rs1790340	ENSG00000254682.1	RP11-660L16.2	-10.24	2.19e-22	4.66e-19	-0.63	-0.42	Vitamin D levels;	chr11:71471543	chr11:71448674~71452157:+
LUAD	cis	rs11723261	0.564	rs60994255	ENSG00000275426.1	CH17-262A2.1	10.24	2.19e-22	4.68e-19	0.64	0.42	Immune response to smallpox vaccine (IL-6);	chr4:77554	chr4:149738~150317:+
LUAD	cis	rs977987	0.836	rs11646044	ENSG00000261783.1	RP11-252K23.2	-10.24	2.21e-22	4.71e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75278650	chr16:75379818~75381260:-
LUAD	cis	rs62388641	0.813	rs34779492	ENSG00000272279.1	RP11-157J24.2	10.24	2.21e-22	4.71e-19	0.62	0.42	Daytime sleep phenotypes;	chr6:1547737	chr6:1528364~1528911:-
LUAD	cis	rs62388641	0.774	rs13212794	ENSG00000272279.1	RP11-157J24.2	10.24	2.21e-22	4.71e-19	0.62	0.42	Daytime sleep phenotypes;	chr6:1548349	chr6:1528364~1528911:-
LUAD	cis	rs1061377	0.861	rs35739603	ENSG00000249207.1	RP11-360F5.1	-10.24	2.24e-22	4.77e-19	-0.47	-0.42	Uric acid levels;	chr4:39107938	chr4:39112677~39126818:-
LUAD	cis	rs10875746	0.904	rs10875750	ENSG00000240399.1	RP1-228P16.1	-10.23	2.24e-22	4.78e-19	-0.52	-0.42	Longevity (90 years and older);	chr12:48151847	chr12:48054813~48055591:-
LUAD	cis	rs6504950	0.679	rs9897646	ENSG00000275710.1	RP11-257O5.4	10.23	2.27e-22	4.84e-19	0.56	0.42	Breast cancer;	chr17:54907990	chr17:54964474~54964679:+
LUAD	cis	rs16828019	0.777	rs12047657	ENSG00000235358.1	RP11-399E6.1	10.23	2.28e-22	4.84e-19	0.75	0.42	Intelligence (multi-trait analysis);	chr1:40995841	chr1:41242373~41284861:+
LUAD	cis	rs9322193	0.886	rs9718079	ENSG00000216906.2	RP11-350J20.9	10.23	2.28e-22	4.85e-19	0.52	0.42	Lung cancer;	chr6:149645947	chr6:149904243~149906418:+
LUAD	cis	rs2188561	0.697	rs66560125	ENSG00000241764.3	AC002467.7	10.23	2.29e-22	4.86e-19	0.57	0.42	Alcohol consumption;	chr7:107729589	chr7:107742817~107744581:-
LUAD	cis	rs9322193	0.962	rs3763163	ENSG00000216906.2	RP11-350J20.9	10.23	2.3e-22	4.89e-19	0.52	0.42	Lung cancer;	chr6:149819770	chr6:149904243~149906418:+
LUAD	cis	rs1061377	1	rs9990742	ENSG00000249207.1	RP11-360F5.1	-10.23	2.3e-22	4.89e-19	-0.47	-0.42	Uric acid levels;	chr4:39119794	chr4:39112677~39126818:-
LUAD	cis	rs9918079	0.56	rs4698406	ENSG00000273133.1	RP11-799M12.2	-10.23	2.31e-22	4.91e-19	-0.6	-0.42	Obesity-related traits;	chr4:15638994	chr4:15563698~15564253:-
LUAD	cis	rs11098499	0.863	rs1155576	ENSG00000245958.5	RP11-33B1.1	-10.23	2.31e-22	4.92e-19	-0.39	-0.42	Corneal astigmatism;	chr4:119529004	chr4:119454791~119552025:+
LUAD	cis	rs9322193	0.962	rs7818	ENSG00000216906.2	RP11-350J20.9	10.23	2.32e-22	4.93e-19	0.5	0.42	Lung cancer;	chr6:149810956	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.863	rs6858592	ENSG00000245958.5	RP11-33B1.1	-10.23	2.32e-22	4.94e-19	-0.39	-0.42	Corneal astigmatism;	chr4:119537537	chr4:119454791~119552025:+
LUAD	cis	rs6452524	0.868	rs62372714	ENSG00000249664.1	CTD-2227C6.2	10.23	2.36e-22	5.02e-19	0.5	0.42	Hypertension (SNP x SNP interaction);	chr5:83095449	chr5:83012285~83013109:-
LUAD	cis	rs9532669	0.926	rs4942007	ENSG00000176268.5	CYCSP34	10.23	2.36e-22	5.02e-19	0.41	0.42	Cervical cancer;	chr13:40871887	chr13:40863599~40863902:-
LUAD	cis	rs3096299	0.667	rs2965947	ENSG00000274627.1	RP11-104N10.2	10.23	2.36e-22	5.02e-19	0.4	0.42	Multiple myeloma (IgH translocation);	chr16:89452262	chr16:89516797~89522217:+
LUAD	cis	rs2739330	0.753	rs4822452	ENSG00000099984.9	GSTT2	-10.23	2.37e-22	5.04e-19	-0.51	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23980123~23983911:+
LUAD	cis	rs1153858	1	rs1153858	ENSG00000259520.4	CTD-2651B20.3	10.23	2.39e-22	5.07e-19	0.56	0.42	Homoarginine levels;	chr15:45360505	chr15:45251580~45279251:-
LUAD	cis	rs2929278	0.561	rs2927071	ENSG00000205771.5	CATSPER2P1	-10.23	2.41e-22	5.11e-19	-0.54	-0.42	Schizophrenia;	chr15:43626883	chr15:43726918~43747094:-
LUAD	cis	rs11690935	0.959	rs6759575	ENSG00000228389.1	AC068039.4	10.22	2.44e-22	5.18e-19	0.5	0.42	Schizophrenia;	chr2:171832558	chr2:171773482~171775844:+
LUAD	cis	rs9322193	0.962	rs7745915	ENSG00000216906.2	RP11-350J20.9	10.22	2.45e-22	5.21e-19	0.52	0.42	Lung cancer;	chr6:149834111	chr6:149904243~149906418:+
LUAD	cis	rs9918079	0.643	rs35414597	ENSG00000273133.1	RP11-799M12.2	10.22	2.47e-22	5.24e-19	0.6	0.42	Obesity-related traits;	chr4:15564113	chr4:15563698~15564253:-
LUAD	cis	rs9322193	0.962	rs1889473	ENSG00000216906.2	RP11-350J20.9	10.22	2.51e-22	5.32e-19	0.52	0.42	Lung cancer;	chr6:149825485	chr6:149904243~149906418:+
LUAD	cis	rs11690935	0.921	rs7355523	ENSG00000228389.1	AC068039.4	10.22	2.52e-22	5.34e-19	0.51	0.42	Schizophrenia;	chr2:171887911	chr2:171773482~171775844:+
LUAD	cis	rs1061377	0.965	rs7677729	ENSG00000249207.1	RP11-360F5.1	-10.22	2.53e-22	5.37e-19	-0.47	-0.42	Uric acid levels;	chr4:39120370	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs3796511	ENSG00000249207.1	RP11-360F5.1	-10.22	2.53e-22	5.37e-19	-0.47	-0.42	Uric acid levels;	chr4:39120586	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs3733274	ENSG00000249207.1	RP11-360F5.1	-10.22	2.53e-22	5.37e-19	-0.47	-0.42	Uric acid levels;	chr4:39120957	chr4:39112677~39126818:-
LUAD	cis	rs904251	0.523	rs1776455	ENSG00000279942.1	RP1-153P14.7	-10.22	2.54e-22	5.38e-19	-0.39	-0.42	Cognitive performance;	chr6:37515147	chr6:37567716~37571460:+
LUAD	cis	rs1153858	1	rs1145081	ENSG00000259520.4	CTD-2651B20.3	-10.22	2.55e-22	5.39e-19	-0.56	-0.42	Homoarginine levels;	chr15:45387469	chr15:45251580~45279251:-
LUAD	cis	rs1153858	0.943	rs1145079	ENSG00000259520.4	CTD-2651B20.3	-10.22	2.55e-22	5.39e-19	-0.56	-0.42	Homoarginine levels;	chr15:45389563	chr15:45251580~45279251:-
LUAD	cis	rs11690935	0.959	rs1113389	ENSG00000228389.1	AC068039.4	10.22	2.55e-22	5.41e-19	0.5	0.42	Schizophrenia;	chr2:171778855	chr2:171773482~171775844:+
LUAD	cis	rs1823913	1	rs4853561	ENSG00000280083.1	RP11-317J9.1	10.22	2.58e-22	5.47e-19	0.54	0.42	Obesity-related traits;	chr2:191242980	chr2:191154118~191156070:-
LUAD	cis	rs1823913	1	rs6704784	ENSG00000280083.1	RP11-317J9.1	10.22	2.58e-22	5.47e-19	0.54	0.42	Obesity-related traits;	chr2:191244832	chr2:191154118~191156070:-
LUAD	cis	rs6452524	0.868	rs11746977	ENSG00000249664.1	CTD-2227C6.2	10.22	2.59e-22	5.48e-19	0.5	0.42	Hypertension (SNP x SNP interaction);	chr5:83085581	chr5:83012285~83013109:-
LUAD	cis	rs4728142	0.604	rs4731536	ENSG00000275106.1	RP11-309L24.10	-10.22	2.59e-22	5.48e-19	-0.5	-0.42	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129000239	chr7:128952527~128953316:-
LUAD	cis	rs1061377	1	rs7685082	ENSG00000249207.1	RP11-360F5.1	-10.22	2.59e-22	5.49e-19	-0.47	-0.42	Uric acid levels;	chr4:39116472	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs7664078	ENSG00000249207.1	RP11-360F5.1	-10.22	2.59e-22	5.49e-19	-0.47	-0.42	Uric acid levels;	chr4:39116583	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs9998481	ENSG00000249207.1	RP11-360F5.1	-10.22	2.59e-22	5.49e-19	-0.47	-0.42	Uric acid levels;	chr4:39117215	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs4974997	ENSG00000249207.1	RP11-360F5.1	-10.22	2.6e-22	5.49e-19	-0.47	-0.42	Uric acid levels;	chr4:39109151	chr4:39112677~39126818:-
LUAD	cis	rs10875746	0.855	rs12310999	ENSG00000240399.1	RP1-228P16.1	-10.22	2.6e-22	5.49e-19	-0.52	-0.42	Longevity (90 years and older);	chr12:48053875	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.903	rs61918774	ENSG00000240399.1	RP1-228P16.1	-10.22	2.6e-22	5.49e-19	-0.52	-0.42	Longevity (90 years and older);	chr12:48054351	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.807	rs12297004	ENSG00000240399.1	RP1-228P16.1	-10.22	2.6e-22	5.49e-19	-0.52	-0.42	Longevity (90 years and older);	chr12:48060037	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.903	rs58952582	ENSG00000240399.1	RP1-228P16.1	-10.22	2.6e-22	5.49e-19	-0.52	-0.42	Longevity (90 years and older);	chr12:48064665	chr12:48054813~48055591:-
LUAD	cis	rs11690935	0.959	rs973889	ENSG00000228389.1	AC068039.4	10.22	2.6e-22	5.51e-19	0.5	0.42	Schizophrenia;	chr2:171723444	chr2:171773482~171775844:+
LUAD	cis	rs4728142	0.604	rs6969930	ENSG00000275106.1	RP11-309L24.10	-10.22	2.61e-22	5.52e-19	-0.5	-0.42	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128990259	chr7:128952527~128953316:-
LUAD	cis	rs16828019	0.777	rs11209363	ENSG00000235358.1	RP11-399E6.1	10.22	2.61e-22	5.52e-19	0.71	0.42	Intelligence (multi-trait analysis);	chr1:41019405	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.64	rs1140227	ENSG00000235358.1	RP11-399E6.1	10.22	2.61e-22	5.52e-19	0.71	0.42	Intelligence (multi-trait analysis);	chr1:41028139	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.777	rs16911	ENSG00000235358.1	RP11-399E6.1	10.22	2.61e-22	5.52e-19	0.71	0.42	Intelligence (multi-trait analysis);	chr1:41032349	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.777	rs2300658	ENSG00000235358.1	RP11-399E6.1	10.22	2.61e-22	5.52e-19	0.71	0.42	Intelligence (multi-trait analysis);	chr1:41039350	chr1:41242373~41284861:+
LUAD	cis	rs5769707	0.967	rs2051626	ENSG00000188511.11	C22orf34	10.22	2.61e-22	5.53e-19	0.48	0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49615325	chr22:49414524~49657542:-
LUAD	cis	rs73086581	0.592	rs2300217	ENSG00000229539.1	RP11-119B16.2	10.22	2.62e-22	5.53e-19	0.5	0.42	Response to antidepressants in depression;	chr20:3957928	chr20:3888239~3888868:-
LUAD	cis	rs227275	0.554	rs223467	ENSG00000246560.2	RP11-10L12.4	10.22	2.62e-22	5.55e-19	0.52	0.42	Allergic disease (asthma, hay fever or eczema);	chr4:102779721	chr4:102828055~102844075:+
LUAD	cis	rs11690935	0.838	rs10432423	ENSG00000228389.1	AC068039.4	10.22	2.63e-22	5.56e-19	0.49	0.42	Schizophrenia;	chr2:171896785	chr2:171773482~171775844:+
LUAD	cis	rs8040855	0.576	rs62022528	ENSG00000259295.5	CSPG4P12	10.22	2.64e-22	5.57e-19	0.57	0.42	Bulimia nervosa;	chr15:84992030	chr15:85191438~85213905:+
LUAD	cis	rs977987	0.815	rs4887829	ENSG00000261783.1	RP11-252K23.2	-10.22	2.64e-22	5.58e-19	-0.57	-0.42	Dupuytren's disease;	chr16:75455037	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.843	rs28655617	ENSG00000261783.1	RP11-252K23.2	-10.22	2.64e-22	5.58e-19	-0.57	-0.42	Dupuytren's disease;	chr16:75455744	chr16:75379818~75381260:-
LUAD	cis	rs1823913	1	rs1454749	ENSG00000280083.1	RP11-317J9.1	-10.21	2.68e-22	5.67e-19	-0.54	-0.42	Obesity-related traits;	chr2:191240909	chr2:191154118~191156070:-
LUAD	cis	rs1061377	1	rs1036036	ENSG00000249207.1	RP11-360F5.1	-10.21	2.69e-22	5.68e-19	-0.47	-0.42	Uric acid levels;	chr4:39111104	chr4:39112677~39126818:-
LUAD	cis	rs8040855	0.627	rs11632658	ENSG00000259295.5	CSPG4P12	-10.21	2.7e-22	5.7e-19	-0.56	-0.42	Bulimia nervosa;	chr15:85062982	chr15:85191438~85213905:+
LUAD	cis	rs1153858	1	rs1346266	ENSG00000259520.4	CTD-2651B20.3	-10.21	2.7e-22	5.71e-19	-0.56	-0.42	Homoarginine levels;	chr15:45402318	chr15:45251580~45279251:-
LUAD	cis	rs11098499	0.863	rs1383533	ENSG00000245958.5	RP11-33B1.1	-10.21	2.74e-22	5.77e-19	-0.39	-0.42	Corneal astigmatism;	chr4:119513421	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs2291185	ENSG00000245958.5	RP11-33B1.1	-10.21	2.74e-22	5.77e-19	-0.39	-0.42	Corneal astigmatism;	chr4:119513678	chr4:119454791~119552025:+
LUAD	cis	rs977987	0.778	rs62059846	ENSG00000261783.1	RP11-252K23.2	-10.21	2.78e-22	5.87e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75396911	chr16:75379818~75381260:-
LUAD	cis	rs9326248	0.911	rs11216284	ENSG00000280143.1	AP000892.6	10.21	2.79e-22	5.88e-19	0.51	0.42	Blood protein levels;	chr11:117132344	chr11:117204967~117210292:+
LUAD	cis	rs67180937	0.922	rs10495198	ENSG00000272750.1	RP11-378J18.8	-10.21	2.82e-22	5.93e-19	-0.45	-0.42	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222652375	chr1:222658867~222661512:-
LUAD	cis	rs3096299	0.719	rs2965818	ENSG00000274627.1	RP11-104N10.2	10.21	2.82e-22	5.93e-19	0.41	0.42	Multiple myeloma (IgH translocation);	chr16:89444086	chr16:89516797~89522217:+
LUAD	cis	rs67180937	0.885	rs2133187	ENSG00000272750.1	RP11-378J18.8	-10.21	2.83e-22	5.97e-19	-0.44	-0.42	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222640383	chr1:222658867~222661512:-
LUAD	cis	rs11098499	0.821	rs3775852	ENSG00000245958.5	RP11-33B1.1	-10.21	2.83e-22	5.97e-19	-0.4	-0.42	Corneal astigmatism;	chr4:119533401	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.82	rs6534140	ENSG00000245958.5	RP11-33B1.1	-10.21	2.83e-22	5.97e-19	-0.4	-0.42	Corneal astigmatism;	chr4:119534156	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs7657849	ENSG00000245958.5	RP11-33B1.1	-10.21	2.83e-22	5.97e-19	-0.4	-0.42	Corneal astigmatism;	chr4:119534339	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs10034450	ENSG00000245958.5	RP11-33B1.1	-10.21	2.83e-22	5.97e-19	-0.4	-0.42	Corneal astigmatism;	chr4:119534494	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs1480939	ENSG00000245958.5	RP11-33B1.1	-10.21	2.83e-22	5.97e-19	-0.4	-0.42	Corneal astigmatism;	chr4:119535772	chr4:119454791~119552025:+
LUAD	cis	rs11690935	1	rs2138348	ENSG00000228389.1	AC068039.4	-10.21	2.83e-22	5.97e-19	-0.5	-0.42	Schizophrenia;	chr2:171701662	chr2:171773482~171775844:+
LUAD	cis	rs977987	0.806	rs11648176	ENSG00000261783.1	RP11-252K23.2	-10.21	2.84e-22	5.99e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75422525	chr16:75379818~75381260:-
LUAD	cis	rs2729354	0.768	rs1001956	ENSG00000265566.2	RN7SL605P	-10.21	2.86e-22	6.02e-19	-0.61	-0.42	Blood protein levels;	chr11:57499476	chr11:57528085~57528365:-
LUAD	cis	rs1061377	1	rs28607301	ENSG00000249207.1	RP11-360F5.1	-10.21	2.87e-22	6.04e-19	-0.47	-0.42	Uric acid levels;	chr4:39136460	chr4:39112677~39126818:-
LUAD	cis	rs11098499	0.909	rs10017335	ENSG00000245958.5	RP11-33B1.1	10.21	2.88e-22	6.06e-19	0.39	0.42	Corneal astigmatism;	chr4:119460368	chr4:119454791~119552025:+
LUAD	cis	rs73086581	0.735	rs6037730	ENSG00000229539.1	RP11-119B16.2	10.2	2.89e-22	6.09e-19	0.61	0.42	Response to antidepressants in depression;	chr20:4046171	chr20:3888239~3888868:-
LUAD	cis	rs73086581	0.838	rs6052265	ENSG00000229539.1	RP11-119B16.2	10.2	2.89e-22	6.09e-19	0.61	0.42	Response to antidepressants in depression;	chr20:4046188	chr20:3888239~3888868:-
LUAD	cis	rs9326248	1	rs585849	ENSG00000280143.1	AP000892.6	10.2	2.9e-22	6.1e-19	0.51	0.42	Blood protein levels;	chr11:117198345	chr11:117204967~117210292:+
LUAD	cis	rs10875746	0.855	rs12296244	ENSG00000240399.1	RP1-228P16.1	-10.2	2.9e-22	6.11e-19	-0.52	-0.42	Longevity (90 years and older);	chr12:48047696	chr12:48054813~48055591:-
LUAD	cis	rs1061377	1	rs1061377	ENSG00000249207.1	RP11-360F5.1	-10.2	2.93e-22	6.17e-19	-0.47	-0.42	Uric acid levels;	chr4:39123130	chr4:39112677~39126818:-
LUAD	cis	rs11098499	0.818	rs7688802	ENSG00000245958.5	RP11-33B1.1	-10.2	2.94e-22	6.18e-19	-0.4	-0.42	Corneal astigmatism;	chr4:119530513	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs7695620	ENSG00000245958.5	RP11-33B1.1	-10.2	2.94e-22	6.18e-19	-0.4	-0.42	Corneal astigmatism;	chr4:119531621	chr4:119454791~119552025:+
LUAD	cis	rs8062405	0.755	rs4788076	ENSG00000259982.1	CDC37P1	10.2	2.94e-22	6.19e-19	0.53	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28700294~28701540:-
LUAD	cis	rs11098499	0.863	rs12502389	ENSG00000245958.5	RP11-33B1.1	-10.2	2.95e-22	6.2e-19	-0.4	-0.42	Corneal astigmatism;	chr4:119533036	chr4:119454791~119552025:+
LUAD	cis	rs1061377	1	rs13109200	ENSG00000249207.1	RP11-360F5.1	-10.2	2.96e-22	6.22e-19	-0.47	-0.42	Uric acid levels;	chr4:39124396	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs13144374	ENSG00000249207.1	RP11-360F5.1	-10.2	2.96e-22	6.22e-19	-0.47	-0.42	Uric acid levels;	chr4:39128859	chr4:39112677~39126818:-
LUAD	cis	rs2188561	0.697	rs34986332	ENSG00000241764.3	AC002467.7	10.2	2.98e-22	6.26e-19	0.56	0.42	Alcohol consumption;	chr7:107739010	chr7:107742817~107744581:-
LUAD	cis	rs9918079	0.524	rs4235379	ENSG00000273133.1	RP11-799M12.2	-10.2	3.04e-22	6.38e-19	-0.59	-0.42	Obesity-related traits;	chr4:15657655	chr4:15563698~15564253:-
LUAD	cis	rs11690935	0.694	rs312921	ENSG00000228389.1	AC068039.4	10.2	3.06e-22	6.43e-19	0.5	0.42	Schizophrenia;	chr2:171710715	chr2:171773482~171775844:+
LUAD	cis	rs11098499	0.863	rs10013305	ENSG00000245958.5	RP11-33B1.1	-10.2	3.06e-22	6.43e-19	-0.4	-0.42	Corneal astigmatism;	chr4:119529269	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs3775849	ENSG00000245958.5	RP11-33B1.1	-10.2	3.06e-22	6.43e-19	-0.4	-0.42	Corneal astigmatism;	chr4:119529753	chr4:119454791~119552025:+
LUAD	cis	rs11690935	0.959	rs6709156	ENSG00000228389.1	AC068039.4	10.2	3.06e-22	6.43e-19	0.5	0.42	Schizophrenia;	chr2:171735434	chr2:171773482~171775844:+
LUAD	cis	rs9322193	0.847	rs56103941	ENSG00000216906.2	RP11-350J20.9	10.2	3.07e-22	6.45e-19	0.53	0.42	Lung cancer;	chr6:149816095	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.863	rs1383532	ENSG00000245958.5	RP11-33B1.1	10.2	3.1e-22	6.51e-19	0.39	0.42	Corneal astigmatism;	chr4:119513249	chr4:119454791~119552025:+
LUAD	cis	rs2739330	0.796	rs1006771	ENSG00000231271.1	AP000350.8	10.2	3.12e-22	6.54e-19	0.52	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23949918~23954042:+
LUAD	cis	rs67180937	1	rs67180937	ENSG00000272750.1	RP11-378J18.8	-10.2	3.12e-22	6.54e-19	-0.45	-0.42	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222650401	chr1:222658867~222661512:-
LUAD	cis	rs904251	0.828	rs2797803	ENSG00000204110.6	RP1-153P14.8	-10.2	3.13e-22	6.57e-19	-0.44	-0.42	Cognitive performance;	chr6:37519564	chr6:37507348~37535616:+
LUAD	cis	rs1061377	1	rs35437629	ENSG00000249207.1	RP11-360F5.1	-10.2	3.14e-22	6.58e-19	-0.46	-0.42	Uric acid levels;	chr4:39131712	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs7657926	ENSG00000249207.1	RP11-360F5.1	-10.2	3.14e-22	6.58e-19	-0.46	-0.42	Uric acid levels;	chr4:39132443	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs11096982	ENSG00000249207.1	RP11-360F5.1	-10.2	3.14e-22	6.58e-19	-0.46	-0.42	Uric acid levels;	chr4:39133247	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs11727875	ENSG00000249207.1	RP11-360F5.1	-10.2	3.14e-22	6.58e-19	-0.46	-0.42	Uric acid levels;	chr4:39133699	chr4:39112677~39126818:-
LUAD	cis	rs10129255	0.5	rs8006888	ENSG00000280411.1	IGHV1-69-2	-10.2	3.14e-22	6.58e-19	-0.29	-0.42	Kawasaki disease;	chr14:106782219	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.536	rs10142951	ENSG00000280411.1	IGHV1-69-2	-10.2	3.14e-22	6.58e-19	-0.29	-0.42	Kawasaki disease;	chr14:106782337	chr14:106762092~106762588:-
LUAD	cis	rs67180937	0.961	rs17163363	ENSG00000272750.1	RP11-378J18.8	-10.2	3.14e-22	6.59e-19	-0.45	-0.42	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222655362	chr1:222658867~222661512:-
LUAD	cis	rs11690935	1	rs312918	ENSG00000228389.1	AC068039.4	10.2	3.15e-22	6.6e-19	0.48	0.42	Schizophrenia;	chr2:171713077	chr2:171773482~171775844:+
LUAD	cis	rs2188561	0.708	rs9718496	ENSG00000241764.3	AC002467.7	10.19	3.16e-22	6.63e-19	0.57	0.42	Alcohol consumption;	chr7:107730187	chr7:107742817~107744581:-
LUAD	cis	rs10129255	0.5	rs8022547	ENSG00000280411.1	IGHV1-69-2	-10.19	3.18e-22	6.66e-19	-0.29	-0.42	Kawasaki disease;	chr14:106781985	chr14:106762092~106762588:-
LUAD	cis	rs977987	0.806	rs11862095	ENSG00000261783.1	RP11-252K23.2	-10.19	3.2e-22	6.71e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75351520	chr16:75379818~75381260:-
LUAD	cis	rs11723261	0.621	rs6599307	ENSG00000275426.1	CH17-262A2.1	10.19	3.21e-22	6.73e-19	0.55	0.42	Immune response to smallpox vaccine (IL-6);	chr4:149993	chr4:149738~150317:+
LUAD	cis	rs9322193	0.923	rs12176034	ENSG00000216906.2	RP11-350J20.9	10.19	3.25e-22	6.81e-19	0.53	0.42	Lung cancer;	chr6:149800557	chr6:149904243~149906418:+
LUAD	cis	rs1061377	1	rs4974998	ENSG00000249207.1	RP11-360F5.1	-10.19	3.28e-22	6.86e-19	-0.47	-0.42	Uric acid levels;	chr4:39109129	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs7673299	ENSG00000249207.1	RP11-360F5.1	-10.19	3.28e-22	6.86e-19	-0.47	-0.42	Uric acid levels;	chr4:39109138	chr4:39112677~39126818:-
LUAD	cis	rs1153858	1	rs1153849	ENSG00000259520.4	CTD-2651B20.3	-10.19	3.3e-22	6.91e-19	-0.56	-0.42	Homoarginine levels;	chr15:45403497	chr15:45251580~45279251:-
LUAD	cis	rs11690935	0.918	rs11757	ENSG00000228389.1	AC068039.4	10.19	3.33e-22	6.97e-19	0.5	0.42	Schizophrenia;	chr2:171784535	chr2:171773482~171775844:+
LUAD	cis	rs748404	0.631	rs1133395	ENSG00000205771.5	CATSPER2P1	-10.19	3.34e-22	6.98e-19	-0.54	-0.42	Lung cancer;	chr15:43358186	chr15:43726918~43747094:-
LUAD	cis	rs2188561	0.697	rs13242107	ENSG00000241764.3	AC002467.7	10.19	3.35e-22	7e-19	0.57	0.42	Alcohol consumption;	chr7:107734800	chr7:107742817~107744581:-
LUAD	cis	rs875971	0.862	rs1968126	ENSG00000226824.5	RP4-756H11.3	10.19	3.38e-22	7.07e-19	0.54	0.42	Aortic root size;	chr7:66592017	chr7:66654538~66669855:+
LUAD	cis	rs11690935	0.959	rs6433314	ENSG00000228389.1	AC068039.4	10.19	3.4e-22	7.1e-19	0.5	0.42	Schizophrenia;	chr2:171804461	chr2:171773482~171775844:+
LUAD	cis	rs11098499	0.863	rs1010739	ENSG00000245958.5	RP11-33B1.1	-10.19	3.4e-22	7.1e-19	-0.39	-0.42	Corneal astigmatism;	chr4:119542316	chr4:119454791~119552025:+
LUAD	cis	rs11690935	0.959	rs6722757	ENSG00000228389.1	AC068039.4	10.18	3.45e-22	7.2e-19	0.51	0.42	Schizophrenia;	chr2:171735453	chr2:171773482~171775844:+
LUAD	cis	rs6504950	0.745	rs9914088	ENSG00000275710.1	RP11-257O5.4	10.18	3.45e-22	7.21e-19	0.54	0.42	Breast cancer;	chr17:54902624	chr17:54964474~54964679:+
LUAD	cis	rs9322193	0.923	rs1984111	ENSG00000216906.2	RP11-350J20.9	10.18	3.5e-22	7.32e-19	0.52	0.42	Lung cancer;	chr6:149831720	chr6:149904243~149906418:+
LUAD	cis	rs904251	0.523	rs10807184	ENSG00000279942.1	RP1-153P14.7	-10.18	3.51e-22	7.33e-19	-0.39	-0.42	Cognitive performance;	chr6:37515937	chr6:37567716~37571460:+
LUAD	cis	rs9322193	0.962	rs6903998	ENSG00000216906.2	RP11-350J20.9	10.18	3.51e-22	7.34e-19	0.52	0.42	Lung cancer;	chr6:149831357	chr6:149904243~149906418:+
LUAD	cis	rs2337406	0.866	rs4773949	ENSG00000274576.2	IGHV2-70	10.18	3.51e-22	7.34e-19	0.43	0.42	Alzheimer's disease (late onset);	chr14:106808070	chr14:106770577~106771020:-
LUAD	cis	rs11690935	0.959	rs3770452	ENSG00000228389.1	AC068039.4	10.18	3.53e-22	7.36e-19	0.49	0.42	Schizophrenia;	chr2:171812172	chr2:171773482~171775844:+
LUAD	cis	rs8040855	0.627	rs12904238	ENSG00000259295.5	CSPG4P12	10.18	3.6e-22	7.52e-19	0.54	0.42	Bulimia nervosa;	chr15:85096610	chr15:85191438~85213905:+
LUAD	cis	rs11690935	0.921	rs4668414	ENSG00000228389.1	AC068039.4	10.18	3.64e-22	7.6e-19	0.5	0.42	Schizophrenia;	chr2:171847781	chr2:171773482~171775844:+
LUAD	cis	rs10129255	0.518	rs8010020	ENSG00000280411.1	IGHV1-69-2	-10.18	3.66e-22	7.62e-19	-0.29	-0.42	Kawasaki disease;	chr14:106778016	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.5	rs6576225	ENSG00000280411.1	IGHV1-69-2	-10.18	3.66e-22	7.62e-19	-0.29	-0.42	Kawasaki disease;	chr14:106778120	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.5	rs6576226	ENSG00000280411.1	IGHV1-69-2	-10.18	3.66e-22	7.62e-19	-0.29	-0.42	Kawasaki disease;	chr14:106778135	chr14:106762092~106762588:-
LUAD	cis	rs16828019	0.929	rs111309254	ENSG00000235358.1	RP11-399E6.1	10.18	3.67e-22	7.64e-19	0.73	0.42	Intelligence (multi-trait analysis);	chr1:41270328	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.929	rs4131949	ENSG00000235358.1	RP11-399E6.1	10.18	3.67e-22	7.64e-19	0.73	0.42	Intelligence (multi-trait analysis);	chr1:41272965	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.929	rs35813191	ENSG00000235358.1	RP11-399E6.1	10.18	3.67e-22	7.64e-19	0.73	0.42	Intelligence (multi-trait analysis);	chr1:41277128	chr1:41242373~41284861:+
LUAD	cis	rs977987	0.806	rs4638613	ENSG00000261783.1	RP11-252K23.2	-10.18	3.72e-22	7.74e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75391655	chr16:75379818~75381260:-
LUAD	cis	rs16828019	0.852	rs16827876	ENSG00000235358.1	RP11-399E6.1	10.17	3.78e-22	7.87e-19	0.71	0.42	Intelligence (multi-trait analysis);	chr1:41073864	chr1:41242373~41284861:+
LUAD	cis	rs9322193	0.923	rs9371486	ENSG00000216906.2	RP11-350J20.9	10.17	3.8e-22	7.9e-19	0.55	0.42	Lung cancer;	chr6:149832090	chr6:149904243~149906418:+
LUAD	cis	rs9326248	1	rs4938344	ENSG00000280143.1	AP000892.6	10.17	3.85e-22	8.01e-19	0.51	0.42	Blood protein levels;	chr11:117133033	chr11:117204967~117210292:+
LUAD	cis	rs9322193	0.887	rs3777949	ENSG00000216906.2	RP11-350J20.9	10.17	3.87e-22	8.05e-19	0.51	0.42	Lung cancer;	chr6:149596021	chr6:149904243~149906418:+
LUAD	cis	rs6964833	1	rs17515241	ENSG00000123965.13	PMS2P5	-10.17	3.89e-22	8.09e-19	-0.66	-0.42	Menarche (age at onset);	chr7:74717695	chr7:74894116~74897835:+
LUAD	cis	rs10129255	0.5	rs7161740	ENSG00000280411.1	IGHV1-69-2	-10.17	3.91e-22	8.13e-19	-0.29	-0.42	Kawasaki disease;	chr14:106776119	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.556	rs6576222	ENSG00000280411.1	IGHV1-69-2	-10.17	3.91e-22	8.13e-19	-0.29	-0.42	Kawasaki disease;	chr14:106776442	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.536	rs6576223	ENSG00000280411.1	IGHV1-69-2	-10.17	3.91e-22	8.13e-19	-0.29	-0.42	Kawasaki disease;	chr14:106776448	chr14:106762092~106762588:-
LUAD	cis	rs6452524	0.836	rs62372713	ENSG00000249664.1	CTD-2227C6.2	10.17	3.91e-22	8.14e-19	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83090635	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.868	rs17205699	ENSG00000249664.1	CTD-2227C6.2	10.17	3.91e-22	8.14e-19	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83098479	chr5:83012285~83013109:-
LUAD	cis	rs6782228	0.585	rs9841161	ENSG00000242551.2	POU5F1P6	-10.17	3.95e-22	8.22e-19	-0.48	-0.42	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613027	chr3:128674735~128677005:-
LUAD	cis	rs6782228	0.606	rs2712405	ENSG00000242551.2	POU5F1P6	-10.17	3.95e-22	8.22e-19	-0.48	-0.42	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613239	chr3:128674735~128677005:-
LUAD	cis	rs2929278	0.617	rs11070410	ENSG00000205771.5	CATSPER2P1	10.17	3.96e-22	8.24e-19	0.54	0.42	Schizophrenia;	chr15:43764847	chr15:43726918~43747094:-
LUAD	cis	rs1061377	1	rs34771104	ENSG00000249207.1	RP11-360F5.1	-10.17	4e-22	8.32e-19	-0.47	-0.42	Uric acid levels;	chr4:39127432	chr4:39112677~39126818:-
LUAD	cis	rs10129255	0.5	rs34326748	ENSG00000280411.1	IGHV1-69-2	-10.16	4.09e-22	8.5e-19	-0.29	-0.42	Kawasaki disease;	chr14:106782523	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.5	rs10143385	ENSG00000280411.1	IGHV1-69-2	-10.16	4.09e-22	8.5e-19	-0.29	-0.42	Kawasaki disease;	chr14:106782559	chr14:106762092~106762588:-
LUAD	cis	rs977987	0.778	rs11149825	ENSG00000261783.1	RP11-252K23.2	-10.16	4.11e-22	8.54e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75400980	chr16:75379818~75381260:-
LUAD	cis	rs67180937	0.961	rs2133189	ENSG00000272750.1	RP11-378J18.8	-10.16	4.11e-22	8.54e-19	-0.44	-0.42	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222641100	chr1:222658867~222661512:-
LUAD	cis	rs5760092	0.618	rs5996631	ENSG00000250470.1	AP000351.3	-10.16	4.12e-22	8.55e-19	-0.59	-0.42	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23976904~23977585:-
LUAD	cis	rs1061377	1	rs9999327	ENSG00000249207.1	RP11-360F5.1	-10.16	4.17e-22	8.65e-19	-0.46	-0.42	Uric acid levels;	chr4:39110111	chr4:39112677~39126818:-
LUAD	cis	rs1061377	0.965	rs6833654	ENSG00000249207.1	RP11-360F5.1	-10.16	4.17e-22	8.65e-19	-0.46	-0.42	Uric acid levels;	chr4:39110701	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs1036038	ENSG00000249207.1	RP11-360F5.1	-10.16	4.17e-22	8.65e-19	-0.46	-0.42	Uric acid levels;	chr4:39111383	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs1560396	ENSG00000249207.1	RP11-360F5.1	-10.16	4.17e-22	8.65e-19	-0.46	-0.42	Uric acid levels;	chr4:39112092	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs1560397	ENSG00000249207.1	RP11-360F5.1	-10.16	4.17e-22	8.65e-19	-0.46	-0.42	Uric acid levels;	chr4:39112265	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs2381285	ENSG00000249207.1	RP11-360F5.1	-10.16	4.17e-22	8.65e-19	-0.46	-0.42	Uric acid levels;	chr4:39112775	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs2163272	ENSG00000249207.1	RP11-360F5.1	-10.16	4.17e-22	8.65e-19	-0.46	-0.42	Uric acid levels;	chr4:39112790	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs2163273	ENSG00000249207.1	RP11-360F5.1	-10.16	4.17e-22	8.65e-19	-0.46	-0.42	Uric acid levels;	chr4:39112835	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs62310332	ENSG00000249207.1	RP11-360F5.1	-10.16	4.17e-22	8.65e-19	-0.46	-0.42	Uric acid levels;	chr4:39112939	chr4:39112677~39126818:-
LUAD	cis	rs1061377	0.965	rs3796510	ENSG00000249207.1	RP11-360F5.1	-10.16	4.17e-22	8.65e-19	-0.46	-0.42	Uric acid levels;	chr4:39113309	chr4:39112677~39126818:-
LUAD	cis	rs1061377	0.932	rs6855118	ENSG00000249207.1	RP11-360F5.1	-10.16	4.17e-22	8.65e-19	-0.46	-0.42	Uric acid levels;	chr4:39114322	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs6829234	ENSG00000249207.1	RP11-360F5.1	-10.16	4.17e-22	8.65e-19	-0.46	-0.42	Uric acid levels;	chr4:39114586	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs6812540	ENSG00000249207.1	RP11-360F5.1	-10.16	4.17e-22	8.65e-19	-0.46	-0.42	Uric acid levels;	chr4:39114803	chr4:39112677~39126818:-
LUAD	cis	rs11098499	0.863	rs3733525	ENSG00000245958.5	RP11-33B1.1	-10.16	4.2e-22	8.72e-19	-0.39	-0.42	Corneal astigmatism;	chr4:119525893	chr4:119454791~119552025:+
LUAD	cis	rs73086581	0.838	rs73088426	ENSG00000229539.1	RP11-119B16.2	10.16	4.21e-22	8.73e-19	0.63	0.42	Response to antidepressants in depression;	chr20:4022636	chr20:3888239~3888868:-
LUAD	cis	rs10875746	0.903	rs4760681	ENSG00000240399.1	RP1-228P16.1	-10.16	4.22e-22	8.75e-19	-0.5	-0.42	Longevity (90 years and older);	chr12:48111447	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.903	rs11168414	ENSG00000240399.1	RP1-228P16.1	-10.16	4.24e-22	8.8e-19	-0.51	-0.42	Longevity (90 years and older);	chr12:48118548	chr12:48054813~48055591:-
LUAD	cis	rs10129255	0.518	rs8009612	ENSG00000280411.1	IGHV1-69-2	-10.16	4.25e-22	8.81e-19	-0.29	-0.42	Kawasaki disease;	chr14:106777510	chr14:106762092~106762588:-
LUAD	cis	rs9918079	0.6	rs61021642	ENSG00000273133.1	RP11-799M12.2	10.16	4.26e-22	8.82e-19	0.59	0.42	Obesity-related traits;	chr4:15575702	chr4:15563698~15564253:-
LUAD	cis	rs9918079	0.6	rs12500587	ENSG00000273133.1	RP11-799M12.2	10.16	4.26e-22	8.82e-19	0.59	0.42	Obesity-related traits;	chr4:15579131	chr4:15563698~15564253:-
LUAD	cis	rs10129255	0.5	rs988134	ENSG00000280411.1	IGHV1-69-2	-10.16	4.33e-22	8.97e-19	-0.29	-0.42	Kawasaki disease;	chr14:106776698	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.5	rs988133	ENSG00000280411.1	IGHV1-69-2	-10.16	4.33e-22	8.97e-19	-0.29	-0.42	Kawasaki disease;	chr14:106776724	chr14:106762092~106762588:-
LUAD	cis	rs11098499	0.863	rs11098532	ENSG00000245958.5	RP11-33B1.1	-10.16	4.33e-22	8.97e-19	-0.39	-0.42	Corneal astigmatism;	chr4:119569571	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs13140391	ENSG00000245958.5	RP11-33B1.1	-10.16	4.33e-22	8.97e-19	-0.39	-0.42	Corneal astigmatism;	chr4:119582282	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs13140409	ENSG00000245958.5	RP11-33B1.1	-10.16	4.33e-22	8.97e-19	-0.39	-0.42	Corneal astigmatism;	chr4:119582305	chr4:119454791~119552025:+
LUAD	cis	rs977987	0.806	rs4887824	ENSG00000261783.1	RP11-252K23.2	-10.16	4.33e-22	8.97e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75407715	chr16:75379818~75381260:-
LUAD	cis	rs904251	0.523	rs2776874	ENSG00000279942.1	RP1-153P14.7	-10.16	4.35e-22	9e-19	-0.38	-0.42	Cognitive performance;	chr6:37515421	chr6:37567716~37571460:+
LUAD	cis	rs977987	0.585	rs62059845	ENSG00000261783.1	RP11-252K23.2	-10.16	4.35e-22	9e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75396815	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs12051136	ENSG00000261783.1	RP11-252K23.2	-10.16	4.37e-22	9.04e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75401833	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.778	rs4888409	ENSG00000261783.1	RP11-252K23.2	-10.16	4.37e-22	9.04e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75402333	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.778	rs7206541	ENSG00000261783.1	RP11-252K23.2	-10.16	4.37e-22	9.04e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75402815	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.843	rs12443834	ENSG00000261783.1	RP11-252K23.2	-10.16	4.37e-22	9.04e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75404571	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs12924920	ENSG00000261783.1	RP11-252K23.2	-10.16	4.37e-22	9.04e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75406235	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs12051326	ENSG00000261783.1	RP11-252K23.2	-10.16	4.37e-22	9.04e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75403989	chr16:75379818~75381260:-
LUAD	cis	rs875971	0.895	rs4145009	ENSG00000226824.5	RP4-756H11.3	10.16	4.38e-22	9.05e-19	0.55	0.42	Aortic root size;	chr7:66261628	chr7:66654538~66669855:+
LUAD	cis	rs11098499	0.863	rs3775847	ENSG00000245958.5	RP11-33B1.1	-10.16	4.38e-22	9.07e-19	-0.39	-0.42	Corneal astigmatism;	chr4:119526487	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs3775848	ENSG00000245958.5	RP11-33B1.1	-10.16	4.38e-22	9.07e-19	-0.39	-0.42	Corneal astigmatism;	chr4:119526569	chr4:119454791~119552025:+
LUAD	cis	rs4774565	0.762	rs17431095	ENSG00000244879.4	GABPB1-AS1	-10.15	4.42e-22	9.14e-19	-0.38	-0.42	Breast cancer;	chr15:50369252	chr15:50354959~50372202:+
LUAD	cis	rs11690935	0.959	rs10206062	ENSG00000228389.1	AC068039.4	10.15	4.43e-22	9.17e-19	0.5	0.42	Schizophrenia;	chr2:171720766	chr2:171773482~171775844:+
LUAD	cis	rs16828019	0.789	rs36084778	ENSG00000235358.1	RP11-399E6.1	10.15	4.44e-22	9.18e-19	0.71	0.42	Intelligence (multi-trait analysis);	chr1:41013866	chr1:41242373~41284861:+
LUAD	cis	rs10129255	0.518	rs8009594	ENSG00000280411.1	IGHV1-69-2	-10.15	4.45e-22	9.2e-19	-0.29	-0.42	Kawasaki disease;	chr14:106777494	chr14:106762092~106762588:-
LUAD	cis	rs1061377	1	rs1897136	ENSG00000249207.1	RP11-360F5.1	-10.15	4.46e-22	9.22e-19	-0.46	-0.42	Uric acid levels;	chr4:39131242	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs1897137	ENSG00000249207.1	RP11-360F5.1	-10.15	4.46e-22	9.22e-19	-0.46	-0.42	Uric acid levels;	chr4:39131387	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs7681116	ENSG00000249207.1	RP11-360F5.1	-10.15	4.46e-22	9.22e-19	-0.46	-0.42	Uric acid levels;	chr4:39133015	chr4:39112677~39126818:-
LUAD	cis	rs1061377	0.965	rs10018622	ENSG00000249207.1	RP11-360F5.1	-10.15	4.46e-22	9.22e-19	-0.46	-0.42	Uric acid levels;	chr4:39133944	chr4:39112677~39126818:-
LUAD	cis	rs1823913	1	rs4853562	ENSG00000280083.1	RP11-317J9.1	10.15	4.48e-22	9.25e-19	0.53	0.42	Obesity-related traits;	chr2:191253696	chr2:191154118~191156070:-
LUAD	cis	rs1823913	1	rs4853461	ENSG00000280083.1	RP11-317J9.1	10.15	4.48e-22	9.25e-19	0.53	0.42	Obesity-related traits;	chr2:191254572	chr2:191154118~191156070:-
LUAD	cis	rs858239	0.676	rs274032	ENSG00000230658.1	KLHL7-AS1	10.15	4.48e-22	9.26e-19	0.52	0.42	Cerebrospinal fluid biomarker levels;	chr7:23334940	chr7:23101228~23105703:-
LUAD	cis	rs2455601	0.744	rs2163626	ENSG00000254860.4	TMEM9B-AS1	10.15	4.5e-22	9.3e-19	0.58	0.42	Schizophrenia;	chr11:8962000	chr11:8964675~8977527:+
LUAD	cis	rs10875746	0.855	rs2269936	ENSG00000240399.1	RP1-228P16.1	-10.15	4.51e-22	9.32e-19	-0.52	-0.42	Longevity (90 years and older);	chr12:48031452	chr12:48054813~48055591:-
LUAD	cis	rs1061377	1	rs4974931	ENSG00000249207.1	RP11-360F5.1	-10.15	4.52e-22	9.33e-19	-0.47	-0.42	Uric acid levels;	chr4:39108896	chr4:39112677~39126818:-
LUAD	cis	rs977987	0.806	rs12599361	ENSG00000261783.1	RP11-252K23.2	-10.15	4.53e-22	9.36e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75401075	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs11864102	ENSG00000261783.1	RP11-252K23.2	-10.15	4.54e-22	9.38e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75408462	chr16:75379818~75381260:-
LUAD	cis	rs9322193	0.847	rs12210605	ENSG00000216906.2	RP11-350J20.9	10.15	4.59e-22	9.45e-19	0.53	0.42	Lung cancer;	chr6:149817267	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.923	rs9371199	ENSG00000216906.2	RP11-350J20.9	10.15	4.59e-22	9.45e-19	0.53	0.42	Lung cancer;	chr6:149817526	chr6:149904243~149906418:+
LUAD	cis	rs801193	0.569	rs10950050	ENSG00000226824.5	RP4-756H11.3	-10.15	4.62e-22	9.52e-19	-0.52	-0.42	Aortic root size;	chr7:66774601	chr7:66654538~66669855:+
LUAD	cis	rs11690935	0.959	rs10167419	ENSG00000228389.1	AC068039.4	10.15	4.63e-22	9.54e-19	0.49	0.42	Schizophrenia;	chr2:171793316	chr2:171773482~171775844:+
LUAD	cis	rs11098499	0.863	rs58452170	ENSG00000245958.5	RP11-33B1.1	-10.15	4.65e-22	9.57e-19	-0.4	-0.42	Corneal astigmatism;	chr4:119538519	chr4:119454791~119552025:+
LUAD	cis	rs1061377	1	rs2890659	ENSG00000249207.1	RP11-360F5.1	-10.15	4.65e-22	9.57e-19	-0.46	-0.42	Uric acid levels;	chr4:39125401	chr4:39112677~39126818:-
LUAD	cis	rs1061377	0.932	rs35464499	ENSG00000249207.1	RP11-360F5.1	-10.15	4.65e-22	9.57e-19	-0.46	-0.42	Uric acid levels;	chr4:39127670	chr4:39112677~39126818:-
LUAD	cis	rs11690935	0.959	rs67204065	ENSG00000228389.1	AC068039.4	10.15	4.69e-22	9.65e-19	0.5	0.42	Schizophrenia;	chr2:171816114	chr2:171773482~171775844:+
LUAD	cis	rs977987	0.778	rs11862719	ENSG00000261783.1	RP11-252K23.2	-10.15	4.73e-22	9.74e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75397810	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.843	rs11149824	ENSG00000261783.1	RP11-252K23.2	-10.15	4.73e-22	9.74e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75397932	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs4887823	ENSG00000261783.1	RP11-252K23.2	-10.15	4.73e-22	9.74e-19	-0.56	-0.42	Dupuytren's disease;	chr16:75399176	chr16:75379818~75381260:-
LUAD	cis	rs1061377	1	rs3796509	ENSG00000249207.1	RP11-360F5.1	-10.15	4.74e-22	9.74e-19	-0.47	-0.42	Uric acid levels;	chr4:39108566	chr4:39112677~39126818:-
LUAD	cis	rs8040855	0.576	rs62022527	ENSG00000259295.5	CSPG4P12	10.15	4.78e-22	9.83e-19	0.56	0.42	Bulimia nervosa;	chr15:84988022	chr15:85191438~85213905:+
LUAD	cis	rs10875746	0.951	rs8804	ENSG00000240399.1	RP1-228P16.1	-10.14	4.8e-22	9.87e-19	-0.52	-0.42	Longevity (90 years and older);	chr12:48147974	chr12:48054813~48055591:-
LUAD	cis	rs977987	0.835	rs7200616	ENSG00000261783.1	RP11-252K23.2	-10.14	4.88e-22	1e-18	-0.55	-0.42	Dupuytren's disease;	chr16:75332191	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs2285225	ENSG00000261783.1	RP11-252K23.2	-10.14	4.91e-22	1.01e-18	-0.55	-0.42	Dupuytren's disease;	chr16:75395354	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.527	rs62059844	ENSG00000261783.1	RP11-252K23.2	-10.14	4.91e-22	1.01e-18	-0.55	-0.42	Dupuytren's disease;	chr16:75395839	chr16:75379818~75381260:-
LUAD	cis	rs11690935	0.959	rs10204501	ENSG00000228389.1	AC068039.4	10.14	4.92e-22	1.01e-18	0.5	0.42	Schizophrenia;	chr2:171732355	chr2:171773482~171775844:+
LUAD	cis	rs11690935	0.959	rs10204502	ENSG00000228389.1	AC068039.4	10.14	4.92e-22	1.01e-18	0.5	0.42	Schizophrenia;	chr2:171732356	chr2:171773482~171775844:+
LUAD	cis	rs11098499	0.863	rs3822190	ENSG00000245958.5	RP11-33B1.1	-10.14	4.94e-22	1.01e-18	-0.4	-0.42	Corneal astigmatism;	chr4:119506943	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs3822191	ENSG00000245958.5	RP11-33B1.1	-10.14	4.94e-22	1.01e-18	-0.4	-0.42	Corneal astigmatism;	chr4:119506946	chr4:119454791~119552025:+
LUAD	cis	rs2739330	0.828	rs5751770	ENSG00000099984.9	GSTT2	-10.14	4.96e-22	1.02e-18	-0.5	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23980123~23983911:+
LUAD	cis	rs11098499	0.863	rs2127823	ENSG00000245958.5	RP11-33B1.1	-10.14	4.97e-22	1.02e-18	-0.4	-0.42	Corneal astigmatism;	chr4:119564515	chr4:119454791~119552025:+
LUAD	cis	rs748404	0.604	rs2278857	ENSG00000205771.5	CATSPER2P1	-10.14	5.01e-22	1.03e-18	-0.52	-0.42	Lung cancer;	chr15:43340351	chr15:43726918~43747094:-
LUAD	cis	rs904251	0.965	rs62406516	ENSG00000279942.1	RP1-153P14.7	-10.14	5.06e-22	1.04e-18	-0.4	-0.42	Cognitive performance;	chr6:37471588	chr6:37567716~37571460:+
LUAD	cis	rs9322193	0.847	rs4870054	ENSG00000216906.2	RP11-350J20.9	10.14	5.1e-22	1.05e-18	0.54	0.42	Lung cancer;	chr6:149848402	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.863	rs10004484	ENSG00000245958.5	RP11-33B1.1	-10.14	5.1e-22	1.05e-18	-0.39	-0.42	Corneal astigmatism;	chr4:119521273	chr4:119454791~119552025:+
LUAD	cis	rs6452524	0.901	rs4571449	ENSG00000249664.1	CTD-2227C6.2	10.14	5.12e-22	1.05e-18	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83175392	chr5:83012285~83013109:-
LUAD	cis	rs1823913	1	rs4853563	ENSG00000280083.1	RP11-317J9.1	10.14	5.2e-22	1.07e-18	0.53	0.42	Obesity-related traits;	chr2:191254808	chr2:191154118~191156070:-
LUAD	cis	rs11690935	0.959	rs12692974	ENSG00000228389.1	AC068039.4	10.14	5.22e-22	1.07e-18	0.5	0.42	Schizophrenia;	chr2:171806746	chr2:171773482~171775844:+
LUAD	cis	rs6452524	0.87	rs2174976	ENSG00000249664.1	CTD-2227C6.2	10.14	5.22e-22	1.07e-18	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83197136	chr5:83012285~83013109:-
LUAD	cis	rs11098499	0.863	rs28718422	ENSG00000245958.5	RP11-33B1.1	-10.13	5.23e-22	1.07e-18	-0.4	-0.42	Corneal astigmatism;	chr4:119545149	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.818	rs12498599	ENSG00000245958.5	RP11-33B1.1	-10.13	5.23e-22	1.07e-18	-0.4	-0.42	Corneal astigmatism;	chr4:119547348	chr4:119454791~119552025:+
LUAD	cis	rs8062405	0.755	rs17707300	ENSG00000259982.1	CDC37P1	10.13	5.24e-22	1.07e-18	0.53	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28700294~28701540:-
LUAD	cis	rs2019137	0.868	rs3748916	ENSG00000274877.1	RP11-65I12.1	10.13	5.26e-22	1.08e-18	0.53	0.42	Lymphocyte counts;	chr2:113226456	chr2:113237595~113240825:+
LUAD	cis	rs16828019	0.852	rs34979067	ENSG00000235358.1	RP11-399E6.1	10.13	5.27e-22	1.08e-18	0.71	0.42	Intelligence (multi-trait analysis);	chr1:41077412	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.852	rs35190461	ENSG00000235358.1	RP11-399E6.1	10.13	5.27e-22	1.08e-18	0.71	0.42	Intelligence (multi-trait analysis);	chr1:41077463	chr1:41242373~41284861:+
LUAD	cis	rs748404	0.631	rs7163288	ENSG00000205771.5	CATSPER2P1	-10.13	5.31e-22	1.09e-18	-0.52	-0.42	Lung cancer;	chr15:43379157	chr15:43726918~43747094:-
LUAD	cis	rs1061377	0.76	rs7678457	ENSG00000249207.1	RP11-360F5.1	-10.13	5.35e-22	1.1e-18	-0.46	-0.42	Uric acid levels;	chr4:39136041	chr4:39112677~39126818:-
LUAD	cis	rs694739	0.595	rs11606015	ENSG00000236935.1	AP003774.1	10.13	5.35e-22	1.1e-18	0.41	0.42	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64369405	chr11:64325050~64329504:-
LUAD	cis	rs9918079	0.542	rs7688984	ENSG00000273133.1	RP11-799M12.2	-10.13	5.42e-22	1.11e-18	-0.59	-0.42	Obesity-related traits;	chr4:15655630	chr4:15563698~15564253:-
LUAD	cis	rs3096299	0.504	rs4785574	ENSG00000274627.1	RP11-104N10.2	10.13	5.45e-22	1.12e-18	0.4	0.42	Multiple myeloma (IgH translocation);	chr16:89502467	chr16:89516797~89522217:+
LUAD	cis	rs10129255	0.5	rs8011115	ENSG00000280411.1	IGHV1-69-2	-10.13	5.47e-22	1.12e-18	-0.29	-0.42	Kawasaki disease;	chr14:106786292	chr14:106762092~106762588:-
LUAD	cis	rs2564921	0.73	rs2564929	ENSG00000242142.1	SERBP1P3	-10.13	5.5e-22	1.13e-18	-0.47	-0.42	Height;	chr3:53084188	chr3:53064283~53065091:-
LUAD	cis	rs9322193	0.736	rs3828701	ENSG00000216906.2	RP11-350J20.9	10.13	5.52e-22	1.13e-18	0.51	0.42	Lung cancer;	chr6:149791063	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.736	rs3805750	ENSG00000216906.2	RP11-350J20.9	10.13	5.52e-22	1.13e-18	0.51	0.42	Lung cancer;	chr6:149791065	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.863	rs11098531	ENSG00000245958.5	RP11-33B1.1	-10.13	5.57e-22	1.14e-18	-0.4	-0.42	Corneal astigmatism;	chr4:119543846	chr4:119454791~119552025:+
LUAD	cis	rs507080	0.922	rs4936433	ENSG00000255239.1	AP002954.6	-10.13	5.57e-22	1.14e-18	-0.53	-0.42	Serum metabolite levels;	chr11:118681711	chr11:118688039~118690600:-
LUAD	cis	rs8062405	0.755	rs4787455	ENSG00000259982.1	CDC37P1	10.13	5.59e-22	1.14e-18	0.53	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28700294~28701540:-
LUAD	cis	rs10875746	0.903	rs725454	ENSG00000240399.1	RP1-228P16.1	-10.13	5.64e-22	1.15e-18	-0.5	-0.42	Longevity (90 years and older);	chr12:48108317	chr12:48054813~48055591:-
LUAD	cis	rs1061377	1	rs10030904	ENSG00000249207.1	RP11-360F5.1	-10.13	5.65e-22	1.16e-18	-0.46	-0.42	Uric acid levels;	chr4:39113603	chr4:39112677~39126818:-
LUAD	cis	rs694739	0.726	rs17857342	ENSG00000236935.1	AP003774.1	10.12	5.77e-22	1.18e-18	0.41	0.42	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64371433	chr11:64325050~64329504:-
LUAD	cis	rs904251	0.861	rs2776877	ENSG00000204110.6	RP1-153P14.8	-10.12	5.89e-22	1.2e-18	-0.44	-0.42	Cognitive performance;	chr6:37519359	chr6:37507348~37535616:+
LUAD	cis	rs904251	0.864	rs2797801	ENSG00000204110.6	RP1-153P14.8	-10.12	5.89e-22	1.2e-18	-0.44	-0.42	Cognitive performance;	chr6:37519385	chr6:37507348~37535616:+
LUAD	cis	rs904251	0.797	rs2776878	ENSG00000204110.6	RP1-153P14.8	-10.12	5.89e-22	1.2e-18	-0.44	-0.42	Cognitive performance;	chr6:37519497	chr6:37507348~37535616:+
LUAD	cis	rs9322193	0.962	rs2342764	ENSG00000216906.2	RP11-350J20.9	10.12	5.9e-22	1.2e-18	0.52	0.42	Lung cancer;	chr6:149835068	chr6:149904243~149906418:+
LUAD	cis	rs10256972	0.758	rs7799391	ENSG00000229043.2	AC091729.9	-10.12	6.02e-22	1.23e-18	-0.45	-0.42	Endometriosis;Longevity;	chr7:1042930	chr7:1160374~1165267:+
LUAD	cis	rs11098499	0.818	rs55825515	ENSG00000245958.5	RP11-33B1.1	-10.12	6.02e-22	1.23e-18	-0.4	-0.42	Corneal astigmatism;	chr4:119565247	chr4:119454791~119552025:+
LUAD	cis	rs1757171	0.542	rs3818985	ENSG00000279942.1	RP1-153P14.7	-10.12	6.08e-22	1.24e-18	-0.39	-0.42	Cognitive performance;	chr6:37516438	chr6:37567716~37571460:+
LUAD	cis	rs748404	0.631	rs3809482	ENSG00000205771.5	CATSPER2P1	-10.12	6.1e-22	1.24e-18	-0.53	-0.42	Lung cancer;	chr15:43369604	chr15:43726918~43747094:-
LUAD	cis	rs875971	0.83	rs12673450	ENSG00000226824.5	RP4-756H11.3	-10.12	6.1e-22	1.24e-18	-0.55	-0.42	Aortic root size;	chr7:66544233	chr7:66654538~66669855:+
LUAD	cis	rs2006771	0.846	rs6518754	ENSG00000236132.1	CTA-440B3.1	-10.12	6.11e-22	1.24e-18	-0.47	-0.42	Nonsyndromic cleft lip with cleft palate;	chr22:31701789	chr22:31816379~31817491:-
LUAD	cis	rs9326248	0.906	rs171052	ENSG00000280143.1	AP000892.6	-10.12	6.15e-22	1.25e-18	-0.5	-0.42	Blood protein levels;	chr11:117211047	chr11:117204967~117210292:+
LUAD	cis	rs10129255	0.556	rs8010005	ENSG00000280411.1	IGHV1-69-2	-10.12	6.16e-22	1.25e-18	-0.29	-0.42	Kawasaki disease;	chr14:106777987	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.556	rs6576224	ENSG00000280411.1	IGHV1-69-2	-10.12	6.16e-22	1.25e-18	-0.29	-0.42	Kawasaki disease;	chr14:106777997	chr14:106762092~106762588:-
LUAD	cis	rs1153858	0.832	rs1145078	ENSG00000259520.4	CTD-2651B20.3	-10.11	6.2e-22	1.26e-18	-0.56	-0.42	Homoarginine levels;	chr15:45390079	chr15:45251580~45279251:-
LUAD	cis	rs11098499	0.863	rs9997631	ENSG00000245958.5	RP11-33B1.1	-10.11	6.25e-22	1.27e-18	-0.39	-0.42	Corneal astigmatism;	chr4:119548840	chr4:119454791~119552025:+
LUAD	cis	rs6782228	0.606	rs6787559	ENSG00000242551.2	POU5F1P6	-10.11	6.27e-22	1.28e-18	-0.48	-0.42	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662243	chr3:128674735~128677005:-
LUAD	cis	rs6782228	0.606	rs2001703	ENSG00000242551.2	POU5F1P6	-10.11	6.27e-22	1.28e-18	-0.48	-0.42	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664254	chr3:128674735~128677005:-
LUAD	cis	rs875971	0.862	rs6460306	ENSG00000226824.5	RP4-756H11.3	10.11	6.29e-22	1.28e-18	0.53	0.42	Aortic root size;	chr7:66595806	chr7:66654538~66669855:+
LUAD	cis	rs1823913	1	rs1840377	ENSG00000280083.1	RP11-317J9.1	10.11	6.33e-22	1.29e-18	0.53	0.42	Obesity-related traits;	chr2:191257992	chr2:191154118~191156070:-
LUAD	cis	rs1823913	1	rs4853564	ENSG00000280083.1	RP11-317J9.1	10.11	6.33e-22	1.29e-18	0.53	0.42	Obesity-related traits;	chr2:191258939	chr2:191154118~191156070:-
LUAD	cis	rs1823913	1	rs4853565	ENSG00000280083.1	RP11-317J9.1	10.11	6.33e-22	1.29e-18	0.53	0.42	Obesity-related traits;	chr2:191259020	chr2:191154118~191156070:-
LUAD	cis	rs1823913	1	rs4853462	ENSG00000280083.1	RP11-317J9.1	10.11	6.33e-22	1.29e-18	0.53	0.42	Obesity-related traits;	chr2:191259078	chr2:191154118~191156070:-
LUAD	cis	rs10875746	0.903	rs17122666	ENSG00000240399.1	RP1-228P16.1	-10.11	6.37e-22	1.29e-18	-0.5	-0.42	Longevity (90 years and older);	chr12:48108791	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.951	rs11168433	ENSG00000240399.1	RP1-228P16.1	-10.11	6.43e-22	1.31e-18	-0.51	-0.42	Longevity (90 years and older);	chr12:48164281	chr12:48054813~48055591:-
LUAD	cis	rs904251	0.561	rs1757189	ENSG00000279942.1	RP1-153P14.7	-10.11	6.43e-22	1.31e-18	-0.39	-0.42	Cognitive performance;	chr6:37515951	chr6:37567716~37571460:+
LUAD	cis	rs904251	0.523	rs10947675	ENSG00000279942.1	RP1-153P14.7	-10.11	6.46e-22	1.31e-18	-0.39	-0.42	Cognitive performance;	chr6:37512196	chr6:37567716~37571460:+
LUAD	cis	rs977987	0.806	rs1030262	ENSG00000261783.1	RP11-252K23.2	-10.11	6.48e-22	1.32e-18	-0.55	-0.42	Dupuytren's disease;	chr16:75457429	chr16:75379818~75381260:-
LUAD	cis	rs11690935	0.959	rs7355594	ENSG00000228389.1	AC068039.4	10.11	6.49e-22	1.32e-18	0.49	0.42	Schizophrenia;	chr2:171782938	chr2:171773482~171775844:+
LUAD	cis	rs11690935	0.959	rs10497374	ENSG00000228389.1	AC068039.4	10.11	6.49e-22	1.32e-18	0.49	0.42	Schizophrenia;	chr2:171784113	chr2:171773482~171775844:+
LUAD	cis	rs1061377	1	rs1982009	ENSG00000249207.1	RP11-360F5.1	-10.11	6.53e-22	1.33e-18	-0.46	-0.42	Uric acid levels;	chr4:39123253	chr4:39112677~39126818:-
LUAD	cis	rs1061377	0.965	rs1138494	ENSG00000249207.1	RP11-360F5.1	-10.11	6.53e-22	1.33e-18	-0.46	-0.42	Uric acid levels;	chr4:39123315	chr4:39112677~39126818:-
LUAD	cis	rs4814920	0.756	rs6046400	ENSG00000275142.1	RP5-999L4.2	-10.11	6.55e-22	1.33e-18	-0.74	-0.42	Bipolar disorder (body mass index interaction);	chr20:19878482	chr20:19871891~19872284:+
LUAD	cis	rs4814920	0.818	rs6035467	ENSG00000275142.1	RP5-999L4.2	-10.11	6.55e-22	1.33e-18	-0.74	-0.42	Bipolar disorder (body mass index interaction);	chr20:19879602	chr20:19871891~19872284:+
LUAD	cis	rs694739	0.628	rs538147	ENSG00000236935.1	AP003774.1	10.11	6.6e-22	1.34e-18	0.4	0.42	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64362250	chr11:64325050~64329504:-
LUAD	cis	rs1061377	0.965	rs1046655	ENSG00000249207.1	RP11-360F5.1	-10.11	6.6e-22	1.34e-18	-0.46	-0.42	Uric acid levels;	chr4:39126127	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs7694760	ENSG00000249207.1	RP11-360F5.1	-10.11	6.6e-22	1.34e-18	-0.46	-0.42	Uric acid levels;	chr4:39126481	chr4:39112677~39126818:-
LUAD	cis	rs1061377	0.965	rs11728058	ENSG00000249207.1	RP11-360F5.1	-10.11	6.6e-22	1.34e-18	-0.46	-0.42	Uric acid levels;	chr4:39128224	chr4:39112677~39126818:-
LUAD	cis	rs1061377	1	rs17508864	ENSG00000249207.1	RP11-360F5.1	-10.11	6.6e-22	1.34e-18	-0.46	-0.42	Uric acid levels;	chr4:39129025	chr4:39112677~39126818:-
LUAD	cis	rs10129255	0.5	rs59939897	ENSG00000280411.1	IGHV1-69-2	-10.11	6.61e-22	1.34e-18	-0.29	-0.42	Kawasaki disease;	chr14:106783414	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.5	rs8014529	ENSG00000280411.1	IGHV1-69-2	-10.11	6.61e-22	1.34e-18	-0.29	-0.42	Kawasaki disease;	chr14:106784065	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.5	rs12101190	ENSG00000280411.1	IGHV1-69-2	-10.11	6.61e-22	1.34e-18	-0.29	-0.42	Kawasaki disease;	chr14:106784149	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.518	rs8004895	ENSG00000280411.1	IGHV1-69-2	-10.11	6.61e-22	1.34e-18	-0.29	-0.42	Kawasaki disease;	chr14:106785139	chr14:106762092~106762588:-
LUAD	cis	rs904251	0.861	rs2776875	ENSG00000204110.6	RP1-153P14.8	-10.11	6.62e-22	1.34e-18	-0.44	-0.42	Cognitive performance;	chr6:37519020	chr6:37507348~37535616:+
LUAD	cis	rs6964833	0.935	rs34630792	ENSG00000123965.13	PMS2P5	10.11	6.63e-22	1.35e-18	0.64	0.42	Menarche (age at onset);	chr7:74646869	chr7:74894116~74897835:+
LUAD	cis	rs11690935	0.959	rs7562356	ENSG00000228389.1	AC068039.4	10.11	6.7e-22	1.36e-18	0.49	0.42	Schizophrenia;	chr2:171770101	chr2:171773482~171775844:+
LUAD	cis	rs11098499	0.863	rs34868248	ENSG00000245958.5	RP11-33B1.1	-10.11	6.72e-22	1.36e-18	-0.39	-0.42	Corneal astigmatism;	chr4:119521275	chr4:119454791~119552025:+
LUAD	cis	rs4423214	0.592	rs11234027	ENSG00000254682.1	RP11-660L16.2	-10.1	6.77e-22	1.37e-18	-0.63	-0.42	Vitamin D levels;	chr11:71523061	chr11:71448674~71452157:+
LUAD	cis	rs977987	0.843	rs10431974	ENSG00000261783.1	RP11-252K23.2	-10.1	6.77e-22	1.37e-18	-0.56	-0.42	Dupuytren's disease;	chr16:75401563	chr16:75379818~75381260:-
LUAD	cis	rs2455601	0.529	rs2653569	ENSG00000254860.4	TMEM9B-AS1	10.1	6.86e-22	1.39e-18	0.54	0.42	Schizophrenia;	chr11:8965431	chr11:8964675~8977527:+
LUAD	cis	rs62229266	0.804	rs2835241	ENSG00000231106.2	LINC01436	-10.1	6.86e-22	1.39e-18	-0.57	-0.42	Mitral valve prolapse;	chr21:36039082	chr21:36005338~36007838:+
LUAD	cis	rs694739	0.628	rs11606081	ENSG00000236935.1	AP003774.1	10.1	6.97e-22	1.41e-18	0.41	0.42	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64370403	chr11:64325050~64329504:-
LUAD	cis	rs6538678	0.864	rs10777749	ENSG00000199506.1	RNU6-247P	-10.1	7.1e-22	1.44e-18	-0.53	-0.42	Lupus nephritis in systemic lupus erythematosus;	chr12:95883182	chr12:95792529~95792635:-
LUAD	cis	rs9322193	0.923	rs4870052	ENSG00000216906.2	RP11-350J20.9	10.1	7.16e-22	1.45e-18	0.53	0.42	Lung cancer;	chr6:149839978	chr6:149904243~149906418:+
LUAD	cis	rs11690935	0.851	rs9808259	ENSG00000228389.1	AC068039.4	10.1	7.24e-22	1.47e-18	0.49	0.42	Schizophrenia;	chr2:171792464	chr2:171773482~171775844:+
LUAD	cis	rs7044106	0.791	rs10984994	ENSG00000226752.6	PSMD5-AS1	10.1	7.27e-22	1.47e-18	0.47	0.42	Hip circumference adjusted for BMI;	chr9:120716491	chr9:120824828~120854385:+
LUAD	cis	rs7044106	0.708	rs10760113	ENSG00000226752.6	PSMD5-AS1	-10.09	7.33e-22	1.48e-18	-0.46	-0.42	Hip circumference adjusted for BMI;	chr9:120711772	chr9:120824828~120854385:+
LUAD	cis	rs11098499	0.82	rs6829903	ENSG00000245958.5	RP11-33B1.1	-10.09	7.33e-22	1.48e-18	-0.39	-0.42	Corneal astigmatism;	chr4:119585729	chr4:119454791~119552025:+
LUAD	cis	rs10256972	0.591	rs11766651	ENSG00000229043.2	AC091729.9	-10.09	7.37e-22	1.49e-18	-0.46	-0.42	Endometriosis;Longevity;	chr7:1122010	chr7:1160374~1165267:+
LUAD	cis	rs5769707	0.967	rs763127	ENSG00000188511.11	C22orf34	10.09	7.38e-22	1.49e-18	0.46	0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49612430	chr22:49414524~49657542:-
LUAD	cis	rs10129255	0.5	rs4774189	ENSG00000280411.1	IGHV1-69-2	-10.09	7.42e-22	1.5e-18	-0.29	-0.42	Kawasaki disease;	chr14:106768275	chr14:106762092~106762588:-
LUAD	cis	rs3096299	0.503	rs4785677	ENSG00000274627.1	RP11-104N10.2	10.09	7.42e-22	1.5e-18	0.4	0.42	Multiple myeloma (IgH translocation);	chr16:89488693	chr16:89516797~89522217:+
LUAD	cis	rs11098499	0.863	rs10018280	ENSG00000245958.5	RP11-33B1.1	-10.09	7.46e-22	1.51e-18	-0.39	-0.42	Corneal astigmatism;	chr4:119556984	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs6534141	ENSG00000245958.5	RP11-33B1.1	-10.09	7.46e-22	1.51e-18	-0.39	-0.42	Corneal astigmatism;	chr4:119564068	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs3775858	ENSG00000245958.5	RP11-33B1.1	-10.09	7.46e-22	1.51e-18	-0.39	-0.42	Corneal astigmatism;	chr4:119564873	chr4:119454791~119552025:+
LUAD	cis	rs1061377	1	rs12646251	ENSG00000249207.1	RP11-360F5.1	-10.09	7.6e-22	1.54e-18	-0.46	-0.42	Uric acid levels;	chr4:39132751	chr4:39112677~39126818:-
LUAD	cis	rs4423214	0.559	rs11234042	ENSG00000254682.1	RP11-660L16.2	-10.09	7.63e-22	1.54e-18	-0.63	-0.42	Vitamin D levels;	chr11:71528040	chr11:71448674~71452157:+
LUAD	cis	rs977987	0.806	rs4888411	ENSG00000261783.1	RP11-252K23.2	-10.09	7.66e-22	1.55e-18	-0.55	-0.42	Dupuytren's disease;	chr16:75409285	chr16:75379818~75381260:-
LUAD	cis	rs6452524	0.806	rs10078084	ENSG00000249664.1	CTD-2227C6.2	10.09	7.68e-22	1.55e-18	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83106588	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.868	rs11750836	ENSG00000249664.1	CTD-2227C6.2	10.09	7.68e-22	1.55e-18	0.49	0.42	Hypertension (SNP x SNP interaction);	chr5:83107368	chr5:83012285~83013109:-
LUAD	cis	rs11098499	0.863	rs9884402	ENSG00000245958.5	RP11-33B1.1	-10.09	7.7e-22	1.55e-18	-0.39	-0.42	Corneal astigmatism;	chr4:119568827	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.731	rs9995026	ENSG00000245958.5	RP11-33B1.1	-10.09	7.7e-22	1.55e-18	-0.39	-0.42	Corneal astigmatism;	chr4:119569344	chr4:119454791~119552025:+
LUAD	cis	rs1891275	0.515	rs1080496	ENSG00000228701.1	TNKS2-AS1	10.09	7.74e-22	1.56e-18	0.52	0.42	Intelligence (multi-trait analysis);	chr10:91684505	chr10:91782839~91798291:-
LUAD	cis	rs228614	0.536	rs223484	ENSG00000246560.2	RP11-10L12.4	10.09	7.8e-22	1.57e-18	0.52	0.42	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102764314	chr4:102828055~102844075:+
LUAD	cis	rs904251	0.766	rs1757175	ENSG00000204110.6	RP1-153P14.8	-10.09	7.8e-22	1.57e-18	-0.43	-0.42	Cognitive performance;	chr6:37518918	chr6:37507348~37535616:+
LUAD	cis	rs904251	0.828	rs1757174	ENSG00000204110.6	RP1-153P14.8	-10.09	7.8e-22	1.57e-18	-0.43	-0.42	Cognitive performance;	chr6:37518919	chr6:37507348~37535616:+
LUAD	cis	rs904251	0.861	rs1757173	ENSG00000204110.6	RP1-153P14.8	-10.09	7.8e-22	1.57e-18	-0.43	-0.42	Cognitive performance;	chr6:37519176	chr6:37507348~37535616:+
LUAD	cis	rs7044106	0.5	rs56725168	ENSG00000226752.6	PSMD5-AS1	-10.09	7.84e-22	1.58e-18	-0.47	-0.42	Hip circumference adjusted for BMI;	chr9:120730298	chr9:120824828~120854385:+
LUAD	cis	rs9322193	0.884	rs9371201	ENSG00000216906.2	RP11-350J20.9	10.09	7.88e-22	1.59e-18	0.55	0.42	Lung cancer;	chr6:149823865	chr6:149904243~149906418:+
LUAD	cis	rs7044106	0.791	rs4617229	ENSG00000226752.6	PSMD5-AS1	-10.08	7.99e-22	1.61e-18	-0.46	-0.42	Hip circumference adjusted for BMI;	chr9:120718418	chr9:120824828~120854385:+
LUAD	cis	rs6964833	0.786	rs35633336	ENSG00000123965.13	PMS2P5	10.08	8.02e-22	1.62e-18	0.63	0.42	Menarche (age at onset);	chr7:74643961	chr7:74894116~74897835:+
LUAD	cis	rs6964833	0.935	rs35735900	ENSG00000123965.13	PMS2P5	10.08	8.02e-22	1.62e-18	0.63	0.42	Menarche (age at onset);	chr7:74651887	chr7:74894116~74897835:+
LUAD	cis	rs11098499	0.955	rs35434465	ENSG00000245958.5	RP11-33B1.1	-10.08	8.05e-22	1.62e-18	-0.38	-0.42	Corneal astigmatism;	chr4:119248223	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs6833334	ENSG00000245958.5	RP11-33B1.1	-10.08	8.09e-22	1.63e-18	-0.39	-0.42	Corneal astigmatism;	chr4:119583072	chr4:119454791~119552025:+
LUAD	cis	rs977987	0.843	rs8056080	ENSG00000261783.1	RP11-252K23.2	-10.08	8.16e-22	1.64e-18	-0.56	-0.42	Dupuytren's disease;	chr16:75376900	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.778	rs4888412	ENSG00000261783.1	RP11-252K23.2	-10.08	8.21e-22	1.65e-18	-0.55	-0.42	Dupuytren's disease;	chr16:75409298	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.778	rs4888413	ENSG00000261783.1	RP11-252K23.2	-10.08	8.21e-22	1.65e-18	-0.55	-0.42	Dupuytren's disease;	chr16:75409325	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.778	rs8057849	ENSG00000261783.1	RP11-252K23.2	-10.08	8.21e-22	1.65e-18	-0.55	-0.42	Dupuytren's disease;	chr16:75409918	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs72787160	ENSG00000261783.1	RP11-252K23.2	-10.08	8.21e-22	1.65e-18	-0.55	-0.42	Dupuytren's disease;	chr16:75411264	chr16:75379818~75381260:-
LUAD	cis	rs11098499	0.863	rs10009626	ENSG00000245958.5	RP11-33B1.1	-10.08	8.24e-22	1.66e-18	-0.4	-0.42	Corneal astigmatism;	chr4:119548850	chr4:119454791~119552025:+
LUAD	cis	rs977987	0.843	rs11149820	ENSG00000261783.1	RP11-252K23.2	-10.08	8.35e-22	1.68e-18	-0.55	-0.42	Dupuytren's disease;	chr16:75388862	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.843	rs10514396	ENSG00000261783.1	RP11-252K23.2	-10.08	8.35e-22	1.68e-18	-0.55	-0.42	Dupuytren's disease;	chr16:75389005	chr16:75379818~75381260:-
LUAD	cis	rs10256972	0.721	rs2030959	ENSG00000229043.2	AC091729.9	-10.08	8.38e-22	1.69e-18	-0.44	-0.42	Endometriosis;Longevity;	chr7:1036270	chr7:1160374~1165267:+
LUAD	cis	rs7044106	0.791	rs4836831	ENSG00000226752.6	PSMD5-AS1	-10.08	8.39e-22	1.69e-18	-0.47	-0.42	Hip circumference adjusted for BMI;	chr9:120734292	chr9:120824828~120854385:+
LUAD	cis	rs7044106	0.791	rs4836829	ENSG00000226752.6	PSMD5-AS1	-10.08	8.44e-22	1.7e-18	-0.47	-0.42	Hip circumference adjusted for BMI;	chr9:120720469	chr9:120824828~120854385:+
LUAD	cis	rs904251	0.861	rs1757169	ENSG00000204110.6	RP1-153P14.8	-10.08	8.47e-22	1.7e-18	-0.43	-0.42	Cognitive performance;	chr6:37519300	chr6:37507348~37535616:+
LUAD	cis	rs11098499	0.863	rs1552095	ENSG00000245958.5	RP11-33B1.1	-10.08	8.47e-22	1.7e-18	-0.4	-0.42	Corneal astigmatism;	chr4:119539151	chr4:119454791~119552025:+
LUAD	cis	rs748404	0.587	rs9920879	ENSG00000205771.5	CATSPER2P1	-10.08	8.59e-22	1.73e-18	-0.53	-0.42	Lung cancer;	chr15:43347572	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.631	rs7166812	ENSG00000205771.5	CATSPER2P1	-10.08	8.59e-22	1.73e-18	-0.53	-0.42	Lung cancer;	chr15:43352562	chr15:43726918~43747094:-
LUAD	cis	rs2729354	0.768	rs2848640	ENSG00000265566.2	RN7SL605P	-10.08	8.63e-22	1.73e-18	-0.61	-0.42	Blood protein levels;	chr11:57495207	chr11:57528085~57528365:-
LUAD	cis	rs6964833	1	rs4717906	ENSG00000123965.13	PMS2P5	10.07	8.66e-22	1.74e-18	0.63	0.42	Menarche (age at onset);	chr7:74671923	chr7:74894116~74897835:+
LUAD	cis	rs321358	0.895	rs17457430	ENSG00000271584.1	RP11-89C3.4	10.07	8.7e-22	1.75e-18	0.66	0.42	Body mass index;	chr11:111085279	chr11:111091932~111097357:-
LUAD	cis	rs6822297	0.542	rs35499018	ENSG00000240005.4	RP11-293A21.1	-10.07	8.72e-22	1.75e-18	-0.5	-0.42	Obesity-related traits;	chr4:27004489	chr4:26859806~26860599:-
LUAD	cis	rs2658782	0.654	rs2248531	ENSG00000279684.1	RP11-755E23.2	-10.07	8.85e-22	1.78e-18	-0.63	-0.42	Pulmonary function decline;	chr11:93522197	chr11:93286629~93288903:-
LUAD	cis	rs10256972	0.758	rs9801444	ENSG00000229043.2	AC091729.9	10.07	9.12e-22	1.83e-18	0.44	0.42	Endometriosis;Longevity;	chr7:1040808	chr7:1160374~1165267:+
LUAD	cis	rs6504950	0.745	rs9915913	ENSG00000275710.1	RP11-257O5.4	10.07	9.16e-22	1.84e-18	0.54	0.42	Breast cancer;	chr17:54920807	chr17:54964474~54964679:+
LUAD	cis	rs5769707	0.967	rs763126	ENSG00000188511.11	C22orf34	-10.07	9.2e-22	1.85e-18	-0.47	-0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49594926	chr22:49414524~49657542:-
LUAD	cis	rs321358	0.895	rs17535942	ENSG00000271584.1	RP11-89C3.4	10.07	9.24e-22	1.85e-18	0.66	0.42	Body mass index;	chr11:111085233	chr11:111091932~111097357:-
LUAD	cis	rs11098499	0.955	rs1511019	ENSG00000245958.5	RP11-33B1.1	-10.07	9.33e-22	1.87e-18	-0.38	-0.42	Corneal astigmatism;	chr4:119244852	chr4:119454791~119552025:+
LUAD	cis	rs67180937	0.921	rs17163360	ENSG00000272750.1	RP11-378J18.8	-10.07	9.33e-22	1.87e-18	-0.44	-0.42	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647448	chr1:222658867~222661512:-
LUAD	cis	rs2006771	0.81	rs2006648	ENSG00000236132.1	CTA-440B3.1	10.07	9.4e-22	1.88e-18	0.46	0.42	Nonsyndromic cleft lip with cleft palate;	chr22:31685943	chr22:31816379~31817491:-
LUAD	cis	rs11690935	0.921	rs908670	ENSG00000228389.1	AC068039.4	10.06	9.47e-22	1.9e-18	0.49	0.42	Schizophrenia;	chr2:171833670	chr2:171773482~171775844:+
LUAD	cis	rs11098499	0.863	rs12498539	ENSG00000245958.5	RP11-33B1.1	-10.06	9.54e-22	1.91e-18	-0.39	-0.42	Corneal astigmatism;	chr4:119547215	chr4:119454791~119552025:+
LUAD	cis	rs694739	0.657	rs11231770	ENSG00000236935.1	AP003774.1	10.06	9.62e-22	1.93e-18	0.41	0.42	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64373153	chr11:64325050~64329504:-
LUAD	cis	rs694739	0.687	rs11231771	ENSG00000236935.1	AP003774.1	10.06	9.62e-22	1.93e-18	0.41	0.42	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64373170	chr11:64325050~64329504:-
LUAD	cis	rs694739	0.628	rs10897487	ENSG00000236935.1	AP003774.1	10.06	9.62e-22	1.93e-18	0.41	0.42	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64373232	chr11:64325050~64329504:-
LUAD	cis	rs694739	0.654	rs10897488	ENSG00000236935.1	AP003774.1	10.06	9.62e-22	1.93e-18	0.41	0.42	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64373334	chr11:64325050~64329504:-
LUAD	cis	rs11690935	0.959	rs4668412	ENSG00000228389.1	AC068039.4	10.06	9.64e-22	1.93e-18	0.5	0.42	Schizophrenia;	chr2:171763260	chr2:171773482~171775844:+
LUAD	cis	rs11690935	0.959	rs13419987	ENSG00000228389.1	AC068039.4	10.06	9.64e-22	1.93e-18	0.5	0.42	Schizophrenia;	chr2:171767404	chr2:171773482~171775844:+
LUAD	cis	rs11098499	0.863	rs2306456	ENSG00000245958.5	RP11-33B1.1	-10.06	9.72e-22	1.94e-18	-0.4	-0.42	Corneal astigmatism;	chr4:119551267	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs11947234	ENSG00000245958.5	RP11-33B1.1	-10.06	9.72e-22	1.94e-18	-0.4	-0.42	Corneal astigmatism;	chr4:119553704	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs11933966	ENSG00000245958.5	RP11-33B1.1	-10.06	9.72e-22	1.94e-18	-0.4	-0.42	Corneal astigmatism;	chr4:119555560	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs36040693	ENSG00000245958.5	RP11-33B1.1	-10.06	9.72e-22	1.94e-18	-0.4	-0.42	Corneal astigmatism;	chr4:119556461	chr4:119454791~119552025:+
LUAD	cis	rs6782228	0.565	rs67445542	ENSG00000242551.2	POU5F1P6	-10.06	9.74e-22	1.95e-18	-0.47	-0.42	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611683	chr3:128674735~128677005:-
LUAD	cis	rs321358	0.895	rs73015171	ENSG00000271584.1	RP11-89C3.4	10.06	9.8e-22	1.96e-18	0.66	0.42	Body mass index;	chr11:111087535	chr11:111091932~111097357:-
LUAD	cis	rs977987	0.788	rs7184525	ENSG00000261783.1	RP11-252K23.2	-10.06	9.89e-22	1.98e-18	-0.55	-0.42	Dupuytren's disease;	chr16:75403288	chr16:75379818~75381260:-
LUAD	cis	rs16828019	0.777	rs34502739	ENSG00000235358.1	RP11-399E6.1	10.06	9.92e-22	1.98e-18	0.73	0.42	Intelligence (multi-trait analysis);	chr1:40993474	chr1:41242373~41284861:+
LUAD	cis	rs507080	0.501	rs626645	ENSG00000255422.1	AP002954.4	-10.06	9.97e-22	1.99e-18	-0.5	-0.42	Serum metabolite levels;	chr11:118704471	chr11:118704607~118750263:+
LUAD	cis	rs6964833	0.935	rs34762099	ENSG00000123965.13	PMS2P5	10.06	9.98e-22	1.99e-18	0.63	0.42	Menarche (age at onset);	chr7:74636378	chr7:74894116~74897835:+
LUAD	cis	rs10875746	0.903	rs11168418	ENSG00000240399.1	RP1-228P16.1	-10.06	1e-21	2e-18	-0.5	-0.42	Longevity (90 years and older);	chr12:48121971	chr12:48054813~48055591:-
LUAD	cis	rs11690935	0.879	rs908671	ENSG00000228389.1	AC068039.4	10.06	1e-21	2e-18	0.5	0.42	Schizophrenia;	chr2:171833755	chr2:171773482~171775844:+
LUAD	cis	rs2929278	0.561	rs62018952	ENSG00000205771.5	CATSPER2P1	10.06	1.01e-21	2.02e-18	0.53	0.42	Schizophrenia;	chr15:43788539	chr15:43726918~43747094:-
LUAD	cis	rs8040855	0.627	rs3816105	ENSG00000259295.5	CSPG4P12	10.06	1.01e-21	2.03e-18	0.54	0.42	Bulimia nervosa;	chr15:85097680	chr15:85191438~85213905:+
LUAD	cis	rs8040855	0.627	rs2304418	ENSG00000259295.5	CSPG4P12	10.06	1.01e-21	2.03e-18	0.54	0.42	Bulimia nervosa;	chr15:85097752	chr15:85191438~85213905:+
LUAD	cis	rs227275	0.525	rs223332	ENSG00000246560.2	RP11-10L12.4	10.05	1.03e-21	2.05e-18	0.51	0.42	Allergic disease (asthma, hay fever or eczema);	chr4:102869029	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.536	rs223327	ENSG00000246560.2	RP11-10L12.4	10.05	1.03e-21	2.05e-18	0.51	0.42	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873560	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.51	rs223326	ENSG00000246560.2	RP11-10L12.4	10.05	1.03e-21	2.05e-18	0.51	0.42	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873770	chr4:102828055~102844075:+
LUAD	cis	rs11690935	0.959	rs35391289	ENSG00000228389.1	AC068039.4	10.05	1.03e-21	2.06e-18	0.5	0.42	Schizophrenia;	chr2:171778473	chr2:171773482~171775844:+
LUAD	cis	rs11098499	1	rs7659194	ENSG00000245958.5	RP11-33B1.1	-10.05	1.03e-21	2.06e-18	-0.38	-0.42	Corneal astigmatism;	chr4:119285992	chr4:119454791~119552025:+
LUAD	cis	rs9322193	0.962	rs17673294	ENSG00000216906.2	RP11-350J20.9	10.05	1.04e-21	2.07e-18	0.51	0.42	Lung cancer;	chr6:149813857	chr6:149904243~149906418:+
LUAD	cis	rs11690935	0.959	rs11904009	ENSG00000228389.1	AC068039.4	10.05	1.05e-21	2.09e-18	0.5	0.42	Schizophrenia;	chr2:171770833	chr2:171773482~171775844:+
LUAD	cis	rs34779708	0.966	rs17591163	ENSG00000230534.5	RP11-297A16.2	10.05	1.06e-21	2.1e-18	0.51	0.42	Inflammatory bowel disease;Crohn's disease;	chr10:35176351	chr10:35098006~35127020:-
LUAD	cis	rs10875746	0.903	rs12313404	ENSG00000240399.1	RP1-228P16.1	-10.05	1.07e-21	2.14e-18	-0.52	-0.42	Longevity (90 years and older);	chr12:48098265	chr12:48054813~48055591:-
LUAD	cis	rs694739	0.541	rs61886926	ENSG00000236935.1	AP003774.1	10.05	1.08e-21	2.15e-18	0.4	0.42	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64366080	chr11:64325050~64329504:-
LUAD	cis	rs694739	0.628	rs617051	ENSG00000236935.1	AP003774.1	10.05	1.08e-21	2.15e-18	0.4	0.42	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64366166	chr11:64325050~64329504:-
LUAD	cis	rs904251	0.525	rs12200378	ENSG00000279942.1	RP1-153P14.7	-10.05	1.08e-21	2.15e-18	-0.39	-0.42	Cognitive performance;	chr6:37457528	chr6:37567716~37571460:+
LUAD	cis	rs11098499	0.955	rs1511018	ENSG00000245958.5	RP11-33B1.1	-10.05	1.09e-21	2.17e-18	-0.38	-0.42	Corneal astigmatism;	chr4:119240425	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs10030660	ENSG00000245958.5	RP11-33B1.1	-10.05	1.09e-21	2.17e-18	-0.39	-0.42	Corneal astigmatism;	chr4:119515549	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs13149407	ENSG00000245958.5	RP11-33B1.1	-10.05	1.09e-21	2.17e-18	-0.39	-0.42	Corneal astigmatism;	chr4:119516670	chr4:119454791~119552025:+
LUAD	cis	rs7044106	0.791	rs10818473	ENSG00000226752.6	PSMD5-AS1	-10.05	1.09e-21	2.18e-18	-0.47	-0.42	Hip circumference adjusted for BMI;	chr9:120721877	chr9:120824828~120854385:+
LUAD	cis	rs11098499	0.863	rs7678400	ENSG00000245958.5	RP11-33B1.1	-10.05	1.1e-21	2.2e-18	-0.4	-0.42	Corneal astigmatism;	chr4:119540802	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs1480936	ENSG00000245958.5	RP11-33B1.1	-10.05	1.1e-21	2.2e-18	-0.4	-0.42	Corneal astigmatism;	chr4:119541706	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs59732491	ENSG00000245958.5	RP11-33B1.1	-10.04	1.12e-21	2.23e-18	-0.39	-0.42	Corneal astigmatism;	chr4:119568433	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs11723090	ENSG00000245958.5	RP11-33B1.1	-10.04	1.12e-21	2.23e-18	-0.39	-0.42	Corneal astigmatism;	chr4:119569437	chr4:119454791~119552025:+
LUAD	cis	rs8062405	0.755	rs7193402	ENSG00000259982.1	CDC37P1	10.04	1.12e-21	2.24e-18	0.52	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28700294~28701540:-
LUAD	cis	rs10129255	0.518	rs10136903	ENSG00000280411.1	IGHV1-69-2	-10.04	1.13e-21	2.24e-18	-0.29	-0.42	Kawasaki disease;	chr14:106778866	chr14:106762092~106762588:-
LUAD	cis	rs11098499	1	rs6837898	ENSG00000245958.5	RP11-33B1.1	-10.04	1.13e-21	2.25e-18	-0.38	-0.42	Corneal astigmatism;	chr4:119257999	chr4:119454791~119552025:+
LUAD	cis	rs904251	0.6	rs2270687	ENSG00000279942.1	RP1-153P14.7	-10.04	1.13e-21	2.25e-18	-0.39	-0.42	Cognitive performance;	chr6:37450487	chr6:37567716~37571460:+
LUAD	cis	rs494459	0.929	rs627391	ENSG00000255422.1	AP002954.4	-10.04	1.14e-21	2.27e-18	-0.5	-0.42	Height;	chr11:118703207	chr11:118704607~118750263:+
LUAD	cis	rs10875746	0.951	rs10875747	ENSG00000240399.1	RP1-228P16.1	-10.04	1.14e-21	2.27e-18	-0.51	-0.42	Longevity (90 years and older);	chr12:48132078	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.951	rs10875748	ENSG00000240399.1	RP1-228P16.1	-10.04	1.14e-21	2.27e-18	-0.51	-0.42	Longevity (90 years and older);	chr12:48132577	chr12:48054813~48055591:-
LUAD	cis	rs8062405	0.723	rs12445744	ENSG00000259982.1	CDC37P1	10.04	1.14e-21	2.27e-18	0.52	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28700294~28701540:-
LUAD	cis	rs507080	0.733	rs4393358	ENSG00000255239.1	AP002954.6	10.04	1.15e-21	2.28e-18	0.5	0.42	Serum metabolite levels;	chr11:118698388	chr11:118688039~118690600:-
LUAD	cis	rs321358	0.895	rs17457375	ENSG00000271584.1	RP11-89C3.4	10.04	1.15e-21	2.29e-18	0.66	0.42	Body mass index;	chr11:111085100	chr11:111091932~111097357:-
LUAD	cis	rs11098499	0.863	rs3822192	ENSG00000245958.5	RP11-33B1.1	-10.04	1.15e-21	2.29e-18	-0.39	-0.42	Corneal astigmatism;	chr4:119524565	chr4:119454791~119552025:+
LUAD	cis	rs10875746	0.951	rs7485355	ENSG00000240399.1	RP1-228P16.1	-10.04	1.17e-21	2.32e-18	-0.52	-0.42	Longevity (90 years and older);	chr12:48154559	chr12:48054813~48055591:-
LUAD	cis	rs977987	0.843	rs12928036	ENSG00000261783.1	RP11-252K23.2	-10.04	1.17e-21	2.33e-18	-0.56	-0.42	Dupuytren's disease;	chr16:75449234	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.843	rs59465235	ENSG00000261783.1	RP11-252K23.2	-10.04	1.17e-21	2.33e-18	-0.56	-0.42	Dupuytren's disease;	chr16:75449912	chr16:75379818~75381260:-
LUAD	cis	rs16828019	0.777	rs67450703	ENSG00000235358.1	RP11-399E6.1	10.04	1.18e-21	2.33e-18	0.73	0.42	Intelligence (multi-trait analysis);	chr1:40994457	chr1:41242373~41284861:+
LUAD	cis	rs694739	0.628	rs508168	ENSG00000236935.1	AP003774.1	10.04	1.18e-21	2.34e-18	0.4	0.42	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64367963	chr11:64325050~64329504:-
LUAD	cis	rs10875746	0.951	rs2228500	ENSG00000240399.1	RP1-228P16.1	10.04	1.2e-21	2.38e-18	0.51	0.42	Longevity (90 years and older);	chr12:48132929	chr12:48054813~48055591:-
LUAD	cis	rs9326248	0.798	rs10892079	ENSG00000280143.1	AP000892.6	10.04	1.21e-21	2.4e-18	0.5	0.42	Blood protein levels;	chr11:117146108	chr11:117204967~117210292:+
LUAD	cis	rs11098499	0.863	rs1552092	ENSG00000245958.5	RP11-33B1.1	-10.03	1.21e-21	2.4e-18	-0.4	-0.42	Corneal astigmatism;	chr4:119567341	chr4:119454791~119552025:+
LUAD	cis	rs8062405	0.755	rs4788074	ENSG00000259982.1	CDC37P1	-10.03	1.22e-21	2.41e-18	-0.52	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28700294~28701540:-
LUAD	cis	rs1823913	0.927	rs13025919	ENSG00000280083.1	RP11-317J9.1	-10.03	1.23e-21	2.44e-18	-0.53	-0.42	Obesity-related traits;	chr2:191260175	chr2:191154118~191156070:-
LUAD	cis	rs507080	0.769	rs11603616	ENSG00000255422.1	AP002954.4	-10.03	1.24e-21	2.46e-18	-0.53	-0.42	Serum metabolite levels;	chr11:118625350	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.769	rs645637	ENSG00000255422.1	AP002954.4	-10.03	1.25e-21	2.48e-18	-0.53	-0.42	Serum metabolite levels;	chr11:118634373	chr11:118704607~118750263:+
LUAD	cis	rs10129255	0.5	rs6576230	ENSG00000280411.1	IGHV1-69-2	-10.03	1.25e-21	2.48e-18	-0.29	-0.42	Kawasaki disease;	chr14:106778539	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.518	rs11847766	ENSG00000280411.1	IGHV1-69-2	-10.03	1.25e-21	2.48e-18	-0.29	-0.42	Kawasaki disease;	chr14:106779186	chr14:106762092~106762588:-
LUAD	cis	rs977987	0.806	rs4888386	ENSG00000261783.1	RP11-252K23.2	-10.03	1.25e-21	2.48e-18	-0.56	-0.42	Dupuytren's disease;	chr16:75355842	chr16:75379818~75381260:-
LUAD	cis	rs35955747	0.539	rs738685	ENSG00000236132.1	CTA-440B3.1	10.03	1.25e-21	2.48e-18	0.46	0.42	Neutrophil count;Sum basophil neutrophil counts;	chr22:31636292	chr22:31816379~31817491:-
LUAD	cis	rs2188561	0.697	rs739518	ENSG00000241764.3	AC002467.7	10.03	1.27e-21	2.52e-18	0.55	0.42	Alcohol consumption;	chr7:107743682	chr7:107742817~107744581:-
LUAD	cis	rs9326248	1	rs4938354	ENSG00000280143.1	AP000892.6	10.03	1.28e-21	2.53e-18	0.5	0.42	Blood protein levels;	chr11:117180449	chr11:117204967~117210292:+
LUAD	cis	rs9326248	1	rs7946257	ENSG00000280143.1	AP000892.6	10.03	1.28e-21	2.53e-18	0.5	0.42	Blood protein levels;	chr11:117182449	chr11:117204967~117210292:+
LUAD	cis	rs11690935	0.959	rs7572215	ENSG00000228389.1	AC068039.4	10.03	1.29e-21	2.55e-18	0.49	0.42	Schizophrenia;	chr2:171777718	chr2:171773482~171775844:+
LUAD	cis	rs6452524	0.868	rs1011981	ENSG00000249664.1	CTD-2227C6.2	10.03	1.3e-21	2.56e-18	0.48	0.42	Hypertension (SNP x SNP interaction);	chr5:83097869	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.868	rs17284218	ENSG00000249664.1	CTD-2227C6.2	10.03	1.3e-21	2.56e-18	0.48	0.42	Hypertension (SNP x SNP interaction);	chr5:83099530	chr5:83012285~83013109:-
LUAD	cis	rs9322193	0.884	rs7769115	ENSG00000216906.2	RP11-350J20.9	10.03	1.3e-21	2.58e-18	0.52	0.42	Lung cancer;	chr6:149848796	chr6:149904243~149906418:+
LUAD	cis	rs1799949	0.602	rs8176257	ENSG00000198496.9	NBR2	-10.02	1.32e-21	2.61e-18	-0.49	-0.42	Menopause (age at onset);	chr17:43064188	chr17:43125610~43153671:+
LUAD	cis	rs2729354	0.817	rs2467327	ENSG00000265566.2	RN7SL605P	-10.02	1.32e-21	2.62e-18	-0.62	-0.42	Blood protein levels;	chr11:57511755	chr11:57528085~57528365:-
LUAD	cis	rs6452524	1	rs4590162	ENSG00000249664.1	CTD-2227C6.2	10.02	1.34e-21	2.65e-18	0.47	0.42	Hypertension (SNP x SNP interaction);	chr5:83145621	chr5:83012285~83013109:-
LUAD	cis	rs5760092	0.755	rs915589	ENSG00000231271.1	AP000350.8	-10.02	1.34e-21	2.65e-18	-0.61	-0.42	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23949918~23954042:+
LUAD	cis	rs5769707	0.904	rs7288869	ENSG00000188511.11	C22orf34	10.02	1.34e-21	2.65e-18	0.47	0.42	Monocyte percentage of white cells;Monocyte count;	chr22:49621679	chr22:49414524~49657542:-
LUAD	cis	rs1577917	1	rs6933377	ENSG00000203875.9	SNHG5	10.02	1.35e-21	2.67e-18	0.52	0.42	Response to antipsychotic treatment;	chr6:85995537	chr6:85660950~85678736:-
LUAD	cis	rs977987	0.586	rs12920883	ENSG00000261783.1	RP11-252K23.2	-10.02	1.35e-21	2.67e-18	-0.55	-0.42	Dupuytren's disease;	chr16:75398783	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.624	rs59867374	ENSG00000261783.1	RP11-252K23.2	-10.02	1.35e-21	2.67e-18	-0.55	-0.42	Dupuytren's disease;	chr16:75398784	chr16:75379818~75381260:-
LUAD	cis	rs10875746	0.951	rs2286021	ENSG00000240399.1	RP1-228P16.1	-10.02	1.36e-21	2.68e-18	-0.51	-0.42	Longevity (90 years and older);	chr12:48134437	chr12:48054813~48055591:-
LUAD	cis	rs977987	0.762	rs1364079	ENSG00000261783.1	RP11-252K23.2	-10.02	1.36e-21	2.69e-18	-0.55	-0.42	Dupuytren's disease;	chr16:75359233	chr16:75379818~75381260:-
LUAD	cis	rs67180937	0.961	rs17163358	ENSG00000272750.1	RP11-378J18.8	-10.02	1.37e-21	2.71e-18	-0.44	-0.42	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647297	chr1:222658867~222661512:-
LUAD	cis	rs875971	0.862	rs6460307	ENSG00000226824.5	RP4-756H11.3	-10.02	1.38e-21	2.72e-18	-0.53	-0.42	Aortic root size;	chr7:66595884	chr7:66654538~66669855:+
LUAD	cis	rs977987	0.815	rs11646677	ENSG00000261783.1	RP11-252K23.2	-10.02	1.39e-21	2.73e-18	-0.55	-0.42	Dupuytren's disease;	chr16:75375083	chr16:75379818~75381260:-
LUAD	cis	rs904251	0.797	rs1757181	ENSG00000204110.6	RP1-153P14.8	10.02	1.4e-21	2.75e-18	0.42	0.42	Cognitive performance;	chr6:37517952	chr6:37507348~37535616:+
LUAD	cis	rs748404	0.586	rs2584700	ENSG00000205771.5	CATSPER2P1	-10.02	1.4e-21	2.75e-18	-0.53	-0.42	Lung cancer;	chr15:43393134	chr15:43726918~43747094:-
LUAD	cis	rs9309711	0.621	rs12993215	ENSG00000225234.1	TRAPPC12-AS1	-10.02	1.4e-21	2.75e-18	-0.48	-0.42	Neurofibrillary tangles;	chr2:3469956	chr2:3481242~3482409:-
LUAD	cis	rs1823913	0.895	rs10931491	ENSG00000280083.1	RP11-317J9.1	10.02	1.41e-21	2.79e-18	0.52	0.42	Obesity-related traits;	chr2:191256087	chr2:191154118~191156070:-
LUAD	cis	rs977987	0.806	rs11644306	ENSG00000261783.1	RP11-252K23.2	-10.02	1.42e-21	2.8e-18	-0.56	-0.42	Dupuytren's disease;	chr16:75456155	chr16:75379818~75381260:-
LUAD	cis	rs9326248	0.954	rs10790177	ENSG00000280143.1	AP000892.6	10.01	1.43e-21	2.83e-18	0.5	0.42	Blood protein levels;	chr11:117177701	chr11:117204967~117210292:+
LUAD	cis	rs748404	0.56	rs1060939	ENSG00000205771.5	CATSPER2P1	-10.01	1.44e-21	2.83e-18	-0.52	-0.42	Lung cancer;	chr15:43524719	chr15:43726918~43747094:-
LUAD	cis	rs1823913	1	rs1823913	ENSG00000280083.1	RP11-317J9.1	-10.01	1.46e-21	2.87e-18	-0.52	-0.42	Obesity-related traits;	chr2:191253321	chr2:191154118~191156070:-
LUAD	cis	rs748404	0.631	rs2412781	ENSG00000205771.5	CATSPER2P1	10.01	1.46e-21	2.88e-18	0.52	0.42	Lung cancer;	chr15:43375702	chr15:43726918~43747094:-
LUAD	cis	rs4728142	0.604	rs2272347	ENSG00000275106.1	RP11-309L24.10	10.01	1.47e-21	2.89e-18	0.49	0.42	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128979361	chr7:128952527~128953316:-
LUAD	cis	rs9545047	0.735	rs314690	ENSG00000227676.3	LINC01068	10.01	1.48e-21	2.91e-18	0.55	0.42	Schizophrenia;	chr13:79434822	chr13:79566727~79571436:+
LUAD	cis	rs494459	0.964	rs576283	ENSG00000255422.1	AP002954.4	-10.01	1.48e-21	2.92e-18	-0.5	-0.42	Height;	chr11:118703185	chr11:118704607~118750263:+
LUAD	cis	rs507080	0.524	rs524409	ENSG00000255422.1	AP002954.4	-10.01	1.48e-21	2.92e-18	-0.5	-0.42	Serum metabolite levels;	chr11:118703602	chr11:118704607~118750263:+
LUAD	cis	rs7044106	0.762	rs7044226	ENSG00000226752.6	PSMD5-AS1	-10.01	1.48e-21	2.92e-18	-0.46	-0.42	Hip circumference adjusted for BMI;	chr9:120704050	chr9:120824828~120854385:+
LUAD	cis	rs228614	0.51	rs223356	ENSG00000246560.2	RP11-10L12.4	10.01	1.48e-21	2.92e-18	0.51	0.42	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102852344	chr4:102828055~102844075:+
LUAD	cis	rs6452524	1	rs7732092	ENSG00000249664.1	CTD-2227C6.2	10.01	1.49e-21	2.93e-18	0.47	0.42	Hypertension (SNP x SNP interaction);	chr5:83141110	chr5:83012285~83013109:-
LUAD	cis	rs977987	0.778	rs1109341	ENSG00000261783.1	RP11-252K23.2	-10.01	1.49e-21	2.94e-18	-0.55	-0.42	Dupuytren's disease;	chr16:75411707	chr16:75379818~75381260:-
LUAD	cis	rs904251	0.6	rs11756241	ENSG00000279942.1	RP1-153P14.7	-10.01	1.52e-21	2.99e-18	-0.39	-0.42	Cognitive performance;	chr6:37477325	chr6:37567716~37571460:+
LUAD	cis	rs227275	0.527	rs223338	ENSG00000246560.2	RP11-10L12.4	10.01	1.52e-21	2.99e-18	0.51	0.42	Allergic disease (asthma, hay fever or eczema);	chr4:102864959	chr4:102828055~102844075:+
LUAD	cis	rs6964833	0.872	rs4717903	ENSG00000123965.13	PMS2P5	10.01	1.52e-21	2.99e-18	0.63	0.42	Menarche (age at onset);	chr7:74653827	chr7:74894116~74897835:+
LUAD	cis	rs9322193	0.962	rs9397022	ENSG00000216906.2	RP11-350J20.9	10.01	1.54e-21	3.03e-18	0.51	0.42	Lung cancer;	chr6:149812052	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs9397357	ENSG00000216906.2	RP11-350J20.9	10.01	1.54e-21	3.03e-18	0.51	0.42	Lung cancer;	chr6:149812465	chr6:149904243~149906418:+
LUAD	cis	rs11690935	0.921	rs6710698	ENSG00000228389.1	AC068039.4	10.01	1.55e-21	3.04e-18	0.49	0.42	Schizophrenia;	chr2:171739568	chr2:171773482~171775844:+
LUAD	cis	rs507080	0.769	rs571001	ENSG00000255422.1	AP002954.4	-10	1.56e-21	3.07e-18	-0.53	-0.42	Serum metabolite levels;	chr11:118629457	chr11:118704607~118750263:+
LUAD	cis	rs8062405	0.756	rs151182	ENSG00000259982.1	CDC37P1	10	1.56e-21	3.07e-18	0.54	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28484431	chr16:28700294~28701540:-
LUAD	cis	rs4774565	0.762	rs1056682	ENSG00000244879.4	GABPB1-AS1	-10	1.6e-21	3.14e-18	-0.37	-0.41	Breast cancer;	chr15:50368004	chr15:50354959~50372202:+
LUAD	cis	rs904251	0.6	rs1874736	ENSG00000279942.1	RP1-153P14.7	-10	1.6e-21	3.14e-18	-0.39	-0.41	Cognitive performance;	chr6:37480218	chr6:37567716~37571460:+
LUAD	cis	rs904251	1	rs10947673	ENSG00000279942.1	RP1-153P14.7	-10	1.61e-21	3.16e-18	-0.39	-0.41	Cognitive performance;	chr6:37477303	chr6:37567716~37571460:+
LUAD	cis	rs1153858	0.945	rs2467854	ENSG00000259520.4	CTD-2651B20.3	-10	1.62e-21	3.18e-18	-0.55	-0.41	Homoarginine levels;	chr15:45409399	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs2461701	ENSG00000259520.4	CTD-2651B20.3	-10	1.62e-21	3.18e-18	-0.55	-0.41	Homoarginine levels;	chr15:45411193	chr15:45251580~45279251:-
LUAD	cis	rs1153858	1	rs2467858	ENSG00000259520.4	CTD-2651B20.3	-10	1.62e-21	3.18e-18	-0.55	-0.41	Homoarginine levels;	chr15:45419294	chr15:45251580~45279251:-
LUAD	cis	rs6452524	0.967	rs1031901	ENSG00000249664.1	CTD-2227C6.2	10	1.64e-21	3.22e-18	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83147904	chr5:83012285~83013109:-
LUAD	cis	rs694739	0.726	rs516124	ENSG00000236935.1	AP003774.1	10	1.65e-21	3.23e-18	0.4	0.41	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64360951	chr11:64325050~64329504:-
LUAD	cis	rs1823913	1	rs11681777	ENSG00000280083.1	RP11-317J9.1	10	1.65e-21	3.23e-18	0.52	0.41	Obesity-related traits;	chr2:191256741	chr2:191154118~191156070:-
LUAD	cis	rs2729354	0.953	rs2649663	ENSG00000265566.2	RN7SL605P	-10	1.65e-21	3.24e-18	-0.63	-0.41	Blood protein levels;	chr11:57589832	chr11:57528085~57528365:-
LUAD	cis	rs7044106	0.762	rs1470307	ENSG00000226752.6	PSMD5-AS1	-10	1.65e-21	3.24e-18	-0.45	-0.41	Hip circumference adjusted for BMI;	chr9:120670761	chr9:120824828~120854385:+
LUAD	cis	rs11098499	1	rs11726229	ENSG00000245958.5	RP11-33B1.1	-10	1.66e-21	3.26e-18	-0.38	-0.41	Corneal astigmatism;	chr4:119290425	chr4:119454791~119552025:+
LUAD	cis	rs1823913	1	rs4853568	ENSG00000280083.1	RP11-317J9.1	10	1.67e-21	3.27e-18	0.53	0.41	Obesity-related traits;	chr2:191261464	chr2:191154118~191156070:-
LUAD	cis	rs977987	0.843	rs2059256	ENSG00000261783.1	RP11-252K23.2	-10	1.68e-21	3.29e-18	-0.55	-0.41	Dupuytren's disease;	chr16:75361937	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.815	rs1364078	ENSG00000261783.1	RP11-252K23.2	-10	1.68e-21	3.3e-18	-0.55	-0.41	Dupuytren's disease;	chr16:75362983	chr16:75379818~75381260:-
LUAD	cis	rs507080	0.769	rs570952	ENSG00000255422.1	AP002954.4	-9.99	1.7e-21	3.34e-18	-0.52	-0.41	Serum metabolite levels;	chr11:118629477	chr11:118704607~118750263:+
LUAD	cis	rs977987	0.843	rs4888372	ENSG00000261783.1	RP11-252K23.2	-9.99	1.72e-21	3.37e-18	-0.55	-0.41	Dupuytren's disease;	chr16:75279587	chr16:75379818~75381260:-
LUAD	cis	rs321358	0.895	rs7101466	ENSG00000271584.1	RP11-89C3.4	9.99	1.73e-21	3.38e-18	0.66	0.41	Body mass index;	chr11:111085729	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.895	rs7101576	ENSG00000271584.1	RP11-89C3.4	9.99	1.73e-21	3.38e-18	0.66	0.41	Body mass index;	chr11:111085795	chr11:111091932~111097357:-
LUAD	cis	rs507080	0.501	rs637563	ENSG00000255422.1	AP002954.4	-9.99	1.74e-21	3.42e-18	-0.5	-0.41	Serum metabolite levels;	chr11:118704770	chr11:118704607~118750263:+
LUAD	cis	rs11098499	0.863	rs3822195	ENSG00000245958.5	RP11-33B1.1	-9.99	1.75e-21	3.43e-18	-0.39	-0.41	Corneal astigmatism;	chr4:119550505	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs3775854	ENSG00000245958.5	RP11-33B1.1	-9.99	1.75e-21	3.43e-18	-0.39	-0.41	Corneal astigmatism;	chr4:119550816	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs2306457	ENSG00000245958.5	RP11-33B1.1	-9.99	1.75e-21	3.43e-18	-0.39	-0.41	Corneal astigmatism;	chr4:119551684	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs6853998	ENSG00000245958.5	RP11-33B1.1	-9.99	1.75e-21	3.43e-18	-0.39	-0.41	Corneal astigmatism;	chr4:119554705	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs6858777	ENSG00000245958.5	RP11-33B1.1	-9.99	1.75e-21	3.43e-18	-0.39	-0.41	Corneal astigmatism;	chr4:119554811	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs11731756	ENSG00000245958.5	RP11-33B1.1	-9.99	1.75e-21	3.43e-18	-0.39	-0.41	Corneal astigmatism;	chr4:119557541	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs34308924	ENSG00000245958.5	RP11-33B1.1	-9.99	1.75e-21	3.43e-18	-0.39	-0.41	Corneal astigmatism;	chr4:119560276	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs2170276	ENSG00000245958.5	RP11-33B1.1	-9.99	1.75e-21	3.43e-18	-0.39	-0.41	Corneal astigmatism;	chr4:119564669	chr4:119454791~119552025:+
LUAD	cis	rs6538678	0.833	rs1898178	ENSG00000199506.1	RNU6-247P	-9.99	1.75e-21	3.43e-18	-0.52	-0.41	Lupus nephritis in systemic lupus erythematosus;	chr12:95887554	chr12:95792529~95792635:-
LUAD	cis	rs6538678	0.833	rs1898177	ENSG00000199506.1	RNU6-247P	-9.99	1.75e-21	3.43e-18	-0.52	-0.41	Lupus nephritis in systemic lupus erythematosus;	chr12:95887568	chr12:95792529~95792635:-
LUAD	cis	rs10256972	0.553	rs4236381	ENSG00000229043.2	AC091729.9	-9.99	1.76e-21	3.44e-18	-0.46	-0.41	Endometriosis;Longevity;	chr7:1126087	chr7:1160374~1165267:+
LUAD	cis	rs67180937	0.844	rs35626308	ENSG00000272750.1	RP11-378J18.8	-9.99	1.76e-21	3.44e-18	-0.44	-0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222643014	chr1:222658867~222661512:-
LUAD	cis	rs11690935	0.959	rs10194102	ENSG00000228389.1	AC068039.4	9.99	1.77e-21	3.46e-18	0.49	0.41	Schizophrenia;	chr2:171769633	chr2:171773482~171775844:+
LUAD	cis	rs9595066	0.564	rs12869383	ENSG00000227258.4	SMIM2-AS1	-9.99	1.79e-21	3.51e-18	-0.54	-0.41	Schizophrenia;	chr13:44131305	chr13:44110451~44240517:+
LUAD	cis	rs7044106	0.762	rs10984972	ENSG00000226752.6	PSMD5-AS1	-9.99	1.81e-21	3.54e-18	-0.45	-0.41	Hip circumference adjusted for BMI;	chr9:120647586	chr9:120824828~120854385:+
LUAD	cis	rs10875746	0.81	rs10875732	ENSG00000240399.1	RP1-228P16.1	-9.99	1.82e-21	3.56e-18	-0.52	-0.41	Longevity (90 years and older);	chr12:48048322	chr12:48054813~48055591:-
LUAD	cis	rs11098499	1	rs11098499	ENSG00000245958.5	RP11-33B1.1	-9.99	1.83e-21	3.57e-18	-0.38	-0.41	Corneal astigmatism;	chr4:119266456	chr4:119454791~119552025:+
LUAD	cis	rs67180937	0.733	rs61824331	ENSG00000272750.1	RP11-378J18.8	-9.99	1.83e-21	3.59e-18	-0.43	-0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222708030	chr1:222658867~222661512:-
LUAD	cis	rs6782228	0.606	rs2712404	ENSG00000242551.2	POU5F1P6	9.98	1.85e-21	3.61e-18	0.47	0.41	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613836	chr3:128674735~128677005:-
LUAD	cis	rs1891275	0.515	rs7093728	ENSG00000228701.1	TNKS2-AS1	-9.98	1.85e-21	3.62e-18	-0.51	-0.41	Intelligence (multi-trait analysis);	chr10:91683860	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.515	rs10786010	ENSG00000228701.1	TNKS2-AS1	-9.98	1.85e-21	3.62e-18	-0.51	-0.41	Intelligence (multi-trait analysis);	chr10:91684016	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.515	rs1986941	ENSG00000228701.1	TNKS2-AS1	-9.98	1.85e-21	3.62e-18	-0.51	-0.41	Intelligence (multi-trait analysis);	chr10:91684586	chr10:91782839~91798291:-
LUAD	cis	rs11098499	0.909	rs28555550	ENSG00000245958.5	RP11-33B1.1	-9.98	1.86e-21	3.62e-18	-0.38	-0.41	Corneal astigmatism;	chr4:119289885	chr4:119454791~119552025:+
LUAD	cis	rs11098499	1	rs28419773	ENSG00000245958.5	RP11-33B1.1	-9.98	1.86e-21	3.62e-18	-0.38	-0.41	Corneal astigmatism;	chr4:119289906	chr4:119454791~119552025:+
LUAD	cis	rs977987	0.835	rs3863445	ENSG00000261783.1	RP11-252K23.2	-9.98	1.86e-21	3.63e-18	-0.55	-0.41	Dupuytren's disease;	chr16:75337846	chr16:75379818~75381260:-
LUAD	cis	rs11098499	0.909	rs79026312	ENSG00000245958.5	RP11-33B1.1	-9.98	1.86e-21	3.63e-18	-0.39	-0.41	Corneal astigmatism;	chr4:119519522	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.909	rs35111518	ENSG00000245958.5	RP11-33B1.1	-9.98	1.86e-21	3.63e-18	-0.39	-0.41	Corneal astigmatism;	chr4:119519527	chr4:119454791~119552025:+
LUAD	cis	rs11155671	0.53	rs2342770	ENSG00000216906.2	RP11-350J20.9	9.98	1.86e-21	3.64e-18	0.51	0.41	Testicular germ cell tumor;	chr6:149895549	chr6:149904243~149906418:+
LUAD	cis	rs11098499	0.863	rs17050695	ENSG00000245958.5	RP11-33B1.1	-9.98	1.88e-21	3.67e-18	-0.38	-0.41	Corneal astigmatism;	chr4:119568372	chr4:119454791~119552025:+
LUAD	cis	rs16828019	0.929	rs8179465	ENSG00000235358.1	RP11-399E6.1	9.98	1.89e-21	3.68e-18	0.7	0.41	Intelligence (multi-trait analysis);	chr1:41236075	chr1:41242373~41284861:+
LUAD	cis	rs977987	0.872	rs10781976	ENSG00000261783.1	RP11-252K23.2	-9.98	1.9e-21	3.71e-18	-0.54	-0.41	Dupuytren's disease;	chr16:75280940	chr16:75379818~75381260:-
LUAD	cis	rs67180937	0.733	rs35725247	ENSG00000272750.1	RP11-378J18.8	-9.98	1.93e-21	3.77e-18	-0.43	-0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222706825	chr1:222658867~222661512:-
LUAD	cis	rs6452524	0.967	rs62374399	ENSG00000249664.1	CTD-2227C6.2	9.98	1.94e-21	3.78e-18	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83176051	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.967	rs62374401	ENSG00000249664.1	CTD-2227C6.2	9.98	1.94e-21	3.78e-18	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83177159	chr5:83012285~83013109:-
LUAD	cis	rs8062405	0.721	rs151303	ENSG00000259982.1	CDC37P1	9.98	1.95e-21	3.81e-18	0.53	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28481189	chr16:28700294~28701540:-
LUAD	cis	rs4423214	0.61	rs3763856	ENSG00000254682.1	RP11-660L16.2	9.98	1.96e-21	3.82e-18	0.51	0.41	Vitamin D levels;	chr11:71414299	chr11:71448674~71452157:+
LUAD	cis	rs321358	0.895	rs73015151	ENSG00000271584.1	RP11-89C3.4	9.98	1.97e-21	3.83e-18	0.66	0.41	Body mass index;	chr11:111084669	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.895	rs17535886	ENSG00000271584.1	RP11-89C3.4	9.98	1.97e-21	3.83e-18	0.66	0.41	Body mass index;	chr11:111084852	chr11:111091932~111097357:-
LUAD	cis	rs6452524	0.868	rs10079372	ENSG00000249664.1	CTD-2227C6.2	9.98	1.97e-21	3.85e-18	0.49	0.41	Hypertension (SNP x SNP interaction);	chr5:83117113	chr5:83012285~83013109:-
LUAD	cis	rs3096299	0.685	rs2911244	ENSG00000274627.1	RP11-104N10.2	9.98	1.99e-21	3.88e-18	0.4	0.41	Multiple myeloma (IgH translocation);	chr16:89455452	chr16:89516797~89522217:+
LUAD	cis	rs16828019	0.777	rs12739052	ENSG00000235358.1	RP11-399E6.1	9.97	2e-21	3.9e-18	0.73	0.41	Intelligence (multi-trait analysis);	chr1:40998783	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.777	rs12748235	ENSG00000235358.1	RP11-399E6.1	9.97	2e-21	3.9e-18	0.73	0.41	Intelligence (multi-trait analysis);	chr1:41000549	chr1:41242373~41284861:+
LUAD	cis	rs2729354	1	rs2729354	ENSG00000265566.2	RN7SL605P	-9.97	2.01e-21	3.91e-18	-0.63	-0.41	Blood protein levels;	chr11:57588497	chr11:57528085~57528365:-
LUAD	cis	rs1891275	0.515	rs7098763	ENSG00000228701.1	TNKS2-AS1	-9.97	2.02e-21	3.93e-18	-0.51	-0.41	Intelligence (multi-trait analysis);	chr10:91685070	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.508	rs7099557	ENSG00000228701.1	TNKS2-AS1	-9.97	2.02e-21	3.93e-18	-0.51	-0.41	Intelligence (multi-trait analysis);	chr10:91685607	chr10:91782839~91798291:-
LUAD	cis	rs1061377	0.965	rs12504238	ENSG00000249207.1	RP11-360F5.1	-9.97	2.02e-21	3.94e-18	-0.47	-0.41	Uric acid levels;	chr4:39142824	chr4:39112677~39126818:-
LUAD	cis	rs977987	0.843	rs28558946	ENSG00000261783.1	RP11-252K23.2	-9.97	2.03e-21	3.95e-18	-0.55	-0.41	Dupuytren's disease;	chr16:75455424	chr16:75379818~75381260:-
LUAD	cis	rs4423214	0.879	rs1792264	ENSG00000254682.1	RP11-660L16.2	-9.97	2.05e-21	3.99e-18	-0.58	-0.41	Vitamin D levels;	chr11:71439201	chr11:71448674~71452157:+
LUAD	cis	rs11690935	0.959	rs12692970	ENSG00000228389.1	AC068039.4	9.97	2.06e-21	4e-18	0.49	0.41	Schizophrenia;	chr2:171737687	chr2:171773482~171775844:+
LUAD	cis	rs9326248	0.953	rs634960	ENSG00000280143.1	AP000892.6	-9.97	2.06e-21	4.01e-18	-0.49	-0.41	Blood protein levels;	chr11:117202247	chr11:117204967~117210292:+
LUAD	cis	rs11690935	0.921	rs3770445	ENSG00000228389.1	AC068039.4	9.97	2.09e-21	4.06e-18	0.49	0.41	Schizophrenia;	chr2:171852409	chr2:171773482~171775844:+
LUAD	cis	rs11098499	0.863	rs7669520	ENSG00000245958.5	RP11-33B1.1	-9.97	2.09e-21	4.07e-18	-0.39	-0.41	Corneal astigmatism;	chr4:119594123	chr4:119454791~119552025:+
LUAD	cis	rs1757171	0.542	rs3818986	ENSG00000279942.1	RP1-153P14.7	-9.97	2.12e-21	4.11e-18	-0.39	-0.41	Cognitive performance;	chr6:37516573	chr6:37567716~37571460:+
LUAD	cis	rs904251	0.797	rs1757177	ENSG00000204110.6	RP1-153P14.8	-9.97	2.13e-21	4.15e-18	-0.42	-0.41	Cognitive performance;	chr6:37518594	chr6:37507348~37535616:+
LUAD	cis	rs8040855	0.627	rs4843019	ENSG00000259295.5	CSPG4P12	-9.97	2.14e-21	4.15e-18	-0.54	-0.41	Bulimia nervosa;	chr15:85101228	chr15:85191438~85213905:+
LUAD	cis	rs11098499	1	rs3749591	ENSG00000245958.5	RP11-33B1.1	-9.97	2.15e-21	4.17e-18	-0.38	-0.41	Corneal astigmatism;	chr4:119292875	chr4:119454791~119552025:+
LUAD	cis	rs904251	0.523	rs9369005	ENSG00000204110.6	RP1-153P14.8	-9.97	2.16e-21	4.2e-18	-0.42	-0.41	Cognitive performance;	chr6:37515333	chr6:37507348~37535616:+
LUAD	cis	rs6964833	1	rs4717907	ENSG00000123965.13	PMS2P5	9.97	2.16e-21	4.2e-18	0.61	0.41	Menarche (age at onset);	chr7:74672169	chr7:74894116~74897835:+
LUAD	cis	rs6452524	0.87	rs12152892	ENSG00000249664.1	CTD-2227C6.2	9.97	2.17e-21	4.21e-18	0.49	0.41	Hypertension (SNP x SNP interaction);	chr5:83125110	chr5:83012285~83013109:-
LUAD	cis	rs4423214	0.592	rs11233977	ENSG00000254682.1	RP11-660L16.2	-9.96	2.2e-21	4.26e-18	-0.62	-0.41	Vitamin D levels;	chr11:71510559	chr11:71448674~71452157:+
LUAD	cis	rs16828019	0.852	rs12022978	ENSG00000235358.1	RP11-399E6.1	9.96	2.2e-21	4.27e-18	0.7	0.41	Intelligence (multi-trait analysis);	chr1:41088416	chr1:41242373~41284861:+
LUAD	cis	rs2564921	0.73	rs930122	ENSG00000242142.1	SERBP1P3	9.96	2.23e-21	4.33e-18	0.46	0.41	Height;	chr3:53085313	chr3:53064283~53065091:-
LUAD	cis	rs977987	0.835	rs3851734	ENSG00000261783.1	RP11-252K23.2	-9.96	2.24e-21	4.35e-18	-0.56	-0.41	Dupuytren's disease;	chr16:75338022	chr16:75379818~75381260:-
LUAD	cis	rs6504950	0.745	rs12949718	ENSG00000275710.1	RP11-257O5.4	-9.96	2.25e-21	4.35e-18	-0.51	-0.41	Breast cancer;	chr17:54904492	chr17:54964474~54964679:+
LUAD	cis	rs6964833	1	rs36044436	ENSG00000277053.3	GTF2IP1	-9.96	2.25e-21	4.36e-18	-0.6	-0.41	Menarche (age at onset);	chr7:74675495	chr7:75185385~75237696:-
LUAD	cis	rs228614	0.51	rs223358	ENSG00000246560.2	RP11-10L12.4	9.96	2.25e-21	4.36e-18	0.51	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102849637	chr4:102828055~102844075:+
LUAD	cis	rs10256972	0.706	rs12701970	ENSG00000229043.2	AC091729.9	-9.96	2.26e-21	4.38e-18	-0.45	-0.41	Endometriosis;Longevity;	chr7:1082322	chr7:1160374~1165267:+
LUAD	cis	rs11098499	0.863	rs3822194	ENSG00000245958.5	RP11-33B1.1	-9.96	2.29e-21	4.43e-18	-0.39	-0.41	Corneal astigmatism;	chr4:119550493	chr4:119454791~119552025:+
LUAD	cis	rs321358	0.895	rs7131434	ENSG00000271584.1	RP11-89C3.4	9.96	2.3e-21	4.45e-18	0.67	0.41	Body mass index;	chr11:111085693	chr11:111091932~111097357:-
LUAD	cis	rs694739	0.595	rs11542299	ENSG00000236935.1	AP003774.1	9.96	2.3e-21	4.46e-18	0.4	0.41	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64371333	chr11:64325050~64329504:-
LUAD	cis	rs7044106	0.791	rs4837793	ENSG00000226752.6	PSMD5-AS1	-9.96	2.34e-21	4.54e-18	-0.47	-0.41	Hip circumference adjusted for BMI;	chr9:120721343	chr9:120824828~120854385:+
LUAD	cis	rs11098499	0.82	rs13128602	ENSG00000245958.5	RP11-33B1.1	9.96	2.35e-21	4.55e-18	0.39	0.41	Corneal astigmatism;	chr4:119538211	chr4:119454791~119552025:+
LUAD	cis	rs2729354	0.903	rs1846568	ENSG00000265566.2	RN7SL605P	-9.95	2.4e-21	4.64e-18	-0.65	-0.41	Blood protein levels;	chr11:57590241	chr11:57528085~57528365:-
LUAD	cis	rs507080	0.769	rs570836	ENSG00000255422.1	AP002954.4	-9.95	2.41e-21	4.67e-18	-0.52	-0.41	Serum metabolite levels;	chr11:118641444	chr11:118704607~118750263:+
LUAD	cis	rs11098499	0.954	rs2389803	ENSG00000245958.5	RP11-33B1.1	9.95	2.43e-21	4.71e-18	0.39	0.41	Corneal astigmatism;	chr4:119472356	chr4:119454791~119552025:+
LUAD	cis	rs9918079	0.56	rs6449153	ENSG00000273133.1	RP11-799M12.2	-9.95	2.45e-21	4.73e-18	-0.59	-0.41	Obesity-related traits;	chr4:15629593	chr4:15563698~15564253:-
LUAD	cis	rs2581828	0.965	rs2581830	ENSG00000242142.1	SERBP1P3	9.95	2.45e-21	4.73e-18	0.43	0.41	Crohn's disease;	chr3:53100082	chr3:53064283~53065091:-
LUAD	cis	rs7208859	0.623	rs9914242	ENSG00000263531.1	RP13-753N3.1	9.95	2.49e-21	4.82e-18	0.86	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889227	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs75142521	ENSG00000263531.1	RP13-753N3.1	9.95	2.53e-21	4.88e-18	0.83	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913519	chr17:30863921~30864940:-
LUAD	cis	rs904251	0.861	rs1757171	ENSG00000204110.6	RP1-153P14.8	-9.95	2.54e-21	4.91e-18	-0.43	-0.41	Cognitive performance;	chr6:37519268	chr6:37507348~37535616:+
LUAD	cis	rs7044106	0.762	rs3904197	ENSG00000226752.6	PSMD5-AS1	-9.95	2.55e-21	4.93e-18	-0.46	-0.41	Hip circumference adjusted for BMI;	chr9:120718100	chr9:120824828~120854385:+
LUAD	cis	rs9481169	0.557	rs33980500	ENSG00000255389.1	C6orf3	-9.94	2.59e-21	5.01e-18	-0.81	-0.41	Inflammatory skin disease;	chr6:111592059	chr6:111599875~111602295:+
LUAD	cis	rs11690935	0.921	rs10200608	ENSG00000228389.1	AC068039.4	9.94	2.6e-21	5.01e-18	0.49	0.41	Schizophrenia;	chr2:171741419	chr2:171773482~171775844:+
LUAD	cis	rs9322193	0.772	rs7738696	ENSG00000216906.2	RP11-350J20.9	9.94	2.62e-21	5.05e-18	0.52	0.41	Lung cancer;	chr6:149848985	chr6:149904243~149906418:+
LUAD	cis	rs1153858	0.945	rs16943246	ENSG00000259520.4	CTD-2651B20.3	-9.94	2.62e-21	5.06e-18	-0.56	-0.41	Homoarginine levels;	chr15:45428399	chr15:45251580~45279251:-
LUAD	cis	rs3096299	0.503	rs9925045	ENSG00000274627.1	RP11-104N10.2	9.94	2.64e-21	5.1e-18	0.39	0.41	Multiple myeloma (IgH translocation);	chr16:89490068	chr16:89516797~89522217:+
LUAD	cis	rs4423214	0.592	rs7114252	ENSG00000254682.1	RP11-660L16.2	-9.94	2.65e-21	5.12e-18	-0.62	-0.41	Vitamin D levels;	chr11:71526560	chr11:71448674~71452157:+
LUAD	cis	rs9532669	0.89	rs9532627	ENSG00000176268.5	CYCSP34	9.94	2.69e-21	5.17e-18	0.4	0.41	Cervical cancer;	chr13:40874811	chr13:40863599~40863902:-
LUAD	cis	rs9326248	0.817	rs1242127	ENSG00000280143.1	AP000892.6	-9.94	2.69e-21	5.18e-18	-0.49	-0.41	Blood protein levels;	chr11:117205848	chr11:117204967~117210292:+
LUAD	cis	rs3096299	0.559	rs9931073	ENSG00000274627.1	RP11-104N10.2	9.94	2.69e-21	5.19e-18	0.39	0.41	Multiple myeloma (IgH translocation);	chr16:89502105	chr16:89516797~89522217:+
LUAD	cis	rs11098499	0.863	rs6534139	ENSG00000245958.5	RP11-33B1.1	9.94	2.73e-21	5.25e-18	0.39	0.41	Corneal astigmatism;	chr4:119528301	chr4:119454791~119552025:+
LUAD	cis	rs10129255	0.5	rs6576231	ENSG00000280411.1	IGHV1-69-2	-9.94	2.74e-21	5.27e-18	-0.29	-0.41	Kawasaki disease;	chr14:106783693	chr14:106762092~106762588:-
LUAD	cis	rs6452524	1	rs7738033	ENSG00000249664.1	CTD-2227C6.2	9.94	2.76e-21	5.32e-18	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83135470	chr5:83012285~83013109:-
LUAD	cis	rs6452524	1	rs6860239	ENSG00000249664.1	CTD-2227C6.2	9.94	2.76e-21	5.32e-18	0.48	0.41	Hypertension (SNP x SNP interaction);	chr5:83136022	chr5:83012285~83013109:-
LUAD	cis	rs73086581	0.645	rs2103659	ENSG00000229539.1	RP11-119B16.2	-9.94	2.77e-21	5.33e-18	-0.49	-0.41	Response to antidepressants in depression;	chr20:4001925	chr20:3888239~3888868:-
LUAD	cis	rs228614	0.51	rs223472	ENSG00000246560.2	RP11-10L12.4	9.94	2.78e-21	5.35e-18	0.51	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102774327	chr4:102828055~102844075:+
LUAD	cis	rs507080	0.501	rs494459	ENSG00000255422.1	AP002954.4	9.93	2.8e-21	5.39e-18	0.49	0.41	Serum metabolite levels;	chr11:118703966	chr11:118704607~118750263:+
LUAD	cis	rs11098499	0.954	rs1546505	ENSG00000245958.5	RP11-33B1.1	-9.93	2.81e-21	5.4e-18	-0.38	-0.41	Corneal astigmatism;	chr4:119320069	chr4:119454791~119552025:+
LUAD	cis	rs2581828	0.965	rs35783750	ENSG00000242142.1	SERBP1P3	9.93	2.81e-21	5.41e-18	0.43	0.41	Crohn's disease;	chr3:53100847	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.965	rs34454739	ENSG00000242142.1	SERBP1P3	9.93	2.81e-21	5.41e-18	0.43	0.41	Crohn's disease;	chr3:53100955	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.965	rs2564961	ENSG00000242142.1	SERBP1P3	9.93	2.81e-21	5.41e-18	0.43	0.41	Crohn's disease;	chr3:53102445	chr3:53064283~53065091:-
LUAD	cis	rs1799949	0.602	rs8176235	ENSG00000198496.9	NBR2	-9.93	2.86e-21	5.5e-18	-0.48	-0.41	Menopause (age at onset);	chr17:43067543	chr17:43125610~43153671:+
LUAD	cis	rs11098499	0.863	rs3736115	ENSG00000245958.5	RP11-33B1.1	9.93	2.88e-21	5.53e-18	0.39	0.41	Corneal astigmatism;	chr4:119567548	chr4:119454791~119552025:+
LUAD	cis	rs228614	0.536	rs150897	ENSG00000246560.2	RP11-10L12.4	9.93	2.88e-21	5.53e-18	0.51	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769309	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.536	rs223475	ENSG00000246560.2	RP11-10L12.4	9.93	2.88e-21	5.53e-18	0.51	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771986	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.536	rs223474	ENSG00000246560.2	RP11-10L12.4	9.93	2.88e-21	5.53e-18	0.51	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102772007	chr4:102828055~102844075:+
LUAD	cis	rs7044106	0.791	rs7043969	ENSG00000226752.6	PSMD5-AS1	-9.93	2.93e-21	5.63e-18	-0.46	-0.41	Hip circumference adjusted for BMI;	chr9:120731711	chr9:120824828~120854385:+
LUAD	cis	rs9309711	0.643	rs4535074	ENSG00000225234.1	TRAPPC12-AS1	-9.93	2.97e-21	5.71e-18	-0.47	-0.41	Neurofibrillary tangles;	chr2:3477866	chr2:3481242~3482409:-
LUAD	cis	rs7208859	0.673	rs78799101	ENSG00000263531.1	RP13-753N3.1	9.92	3.09e-21	5.92e-18	0.84	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888142	chr17:30863921~30864940:-
LUAD	cis	rs1061377	1	rs12499266	ENSG00000249207.1	RP11-360F5.1	9.92	3.1e-21	5.94e-18	0.46	0.41	Uric acid levels;	chr4:39118133	chr4:39112677~39126818:-
LUAD	cis	rs9326248	0.954	rs8521	ENSG00000280143.1	AP000892.6	9.92	3.15e-21	6.04e-18	0.5	0.41	Blood protein levels;	chr11:117196983	chr11:117204967~117210292:+
LUAD	cis	rs228614	0.51	rs223324	ENSG00000246560.2	RP11-10L12.4	9.92	3.18e-21	6.09e-18	0.51	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102876177	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.543	rs223330	ENSG00000246560.2	RP11-10L12.4	9.92	3.2e-21	6.14e-18	0.51	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102872502	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.51	rs223329	ENSG00000246560.2	RP11-10L12.4	9.92	3.2e-21	6.14e-18	0.51	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873031	chr4:102828055~102844075:+
LUAD	cis	rs11098499	0.863	rs10019674	ENSG00000245958.5	RP11-33B1.1	9.92	3.28e-21	6.28e-18	0.39	0.41	Corneal astigmatism;	chr4:119522334	chr4:119454791~119552025:+
LUAD	cis	rs8040855	0.627	rs17540307	ENSG00000259295.5	CSPG4P12	9.92	3.28e-21	6.28e-18	0.54	0.41	Bulimia nervosa;	chr15:85090614	chr15:85191438~85213905:+
LUAD	cis	rs748404	0.631	rs7167882	ENSG00000205771.5	CATSPER2P1	-9.92	3.29e-21	6.29e-18	-0.51	-0.41	Lung cancer;	chr15:43386465	chr15:43726918~43747094:-
LUAD	cis	rs858239	0.712	rs199650	ENSG00000230658.1	KLHL7-AS1	-9.91	3.32e-21	6.36e-18	-0.51	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23327570	chr7:23101228~23105703:-
LUAD	cis	rs10875746	0.855	rs73102065	ENSG00000240399.1	RP1-228P16.1	-9.91	3.33e-21	6.38e-18	-0.52	-0.41	Longevity (90 years and older);	chr12:48098824	chr12:48054813~48055591:-
LUAD	cis	rs6452524	0.967	rs62372752	ENSG00000249664.1	CTD-2227C6.2	9.91	3.34e-21	6.38e-18	0.47	0.41	Hypertension (SNP x SNP interaction);	chr5:83134239	chr5:83012285~83013109:-
LUAD	cis	rs8046696	1	rs8046696	ENSG00000261783.1	RP11-252K23.2	-9.91	3.34e-21	6.39e-18	-0.55	-0.41	Coronary artery disease;	chr16:75408245	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.737	rs8046697	ENSG00000261783.1	RP11-252K23.2	-9.91	3.34e-21	6.39e-18	-0.55	-0.41	Dupuytren's disease;	chr16:75408246	chr16:75379818~75381260:-
LUAD	cis	rs9322193	0.886	rs4870049	ENSG00000216906.2	RP11-350J20.9	9.91	3.35e-21	6.41e-18	0.51	0.41	Lung cancer;	chr6:149837058	chr6:149904243~149906418:+
LUAD	cis	rs1061377	0.674	rs34506243	ENSG00000249207.1	RP11-360F5.1	-9.91	3.37e-21	6.45e-18	-0.45	-0.41	Uric acid levels;	chr4:39082702	chr4:39112677~39126818:-
LUAD	cis	rs904251	1	rs12212090	ENSG00000279942.1	RP1-153P14.7	-9.91	3.4e-21	6.5e-18	-0.39	-0.41	Cognitive performance;	chr6:37464032	chr6:37567716~37571460:+
LUAD	cis	rs227275	0.556	rs4455413	ENSG00000246560.2	RP11-10L12.4	9.91	3.42e-21	6.54e-18	0.51	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102971925	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.556	rs223398	ENSG00000246560.2	RP11-10L12.4	9.91	3.43e-21	6.55e-18	0.51	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102821256	chr4:102828055~102844075:+
LUAD	cis	rs748404	0.578	rs4547312	ENSG00000205771.5	CATSPER2P1	-9.91	3.43e-21	6.56e-18	-0.51	-0.41	Lung cancer;	chr15:43339940	chr15:43726918~43747094:-
LUAD	cis	rs2729354	1	rs2729355	ENSG00000265566.2	RN7SL605P	-9.91	3.5e-21	6.69e-18	-0.64	-0.41	Blood protein levels;	chr11:57586510	chr11:57528085~57528365:-
LUAD	cis	rs507080	0.769	rs483283	ENSG00000255422.1	AP002954.4	-9.91	3.52e-21	6.71e-18	-0.52	-0.41	Serum metabolite levels;	chr11:118635684	chr11:118704607~118750263:+
LUAD	cis	rs67180937	0.961	rs17465637	ENSG00000272750.1	RP11-378J18.8	9.91	3.55e-21	6.78e-18	0.43	0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222650187	chr1:222658867~222661512:-
LUAD	cis	rs10256972	0.681	rs6979076	ENSG00000229043.2	AC091729.9	9.9	3.59e-21	6.86e-18	0.45	0.41	Endometriosis;Longevity;	chr7:1076611	chr7:1160374~1165267:+
LUAD	cis	rs10875746	0.951	rs2269935	ENSG00000240399.1	RP1-228P16.1	-9.9	3.7e-21	7.05e-18	-0.52	-0.41	Longevity (90 years and older);	chr12:48122681	chr12:48054813~48055591:-
LUAD	cis	rs67180937	0.621	rs2068814	ENSG00000272750.1	RP11-378J18.8	-9.9	3.74e-21	7.12e-18	-0.43	-0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222749659	chr1:222658867~222661512:-
LUAD	cis	rs2929278	0.617	rs533143	ENSG00000205771.5	CATSPER2P1	-9.9	3.79e-21	7.23e-18	-0.51	-0.41	Schizophrenia;	chr15:43896656	chr15:43726918~43747094:-
LUAD	cis	rs4774565	0.724	rs606118	ENSG00000244879.4	GABPB1-AS1	-9.89	3.9e-21	7.42e-18	-0.37	-0.41	Breast cancer;	chr15:50362974	chr15:50354959~50372202:+
LUAD	cis	rs10875746	0.855	rs10875729	ENSG00000240399.1	RP1-228P16.1	-9.89	3.91e-21	7.44e-18	-0.5	-0.41	Longevity (90 years and older);	chr12:48032943	chr12:48054813~48055591:-
LUAD	cis	rs2188561	0.697	rs13224313	ENSG00000241764.3	AC002467.7	9.89	3.97e-21	7.55e-18	0.54	0.41	Alcohol consumption;	chr7:107741907	chr7:107742817~107744581:-
LUAD	cis	rs977987	0.75	rs4888407	ENSG00000261783.1	RP11-252K23.2	-9.89	4e-21	7.61e-18	-0.54	-0.41	Dupuytren's disease;	chr16:75398492	chr16:75379818~75381260:-
LUAD	cis	rs10875746	0.855	rs10875728	ENSG00000240399.1	RP1-228P16.1	-9.89	4.04e-21	7.68e-18	-0.49	-0.41	Longevity (90 years and older);	chr12:48032609	chr12:48054813~48055591:-
LUAD	cis	rs2929278	0.617	rs694461	ENSG00000205771.5	CATSPER2P1	9.89	4.13e-21	7.85e-18	0.53	0.41	Schizophrenia;	chr15:43803865	chr15:43726918~43747094:-
LUAD	cis	rs1061377	1	rs9996285	ENSG00000249207.1	RP11-360F5.1	-9.89	4.15e-21	7.89e-18	-0.45	-0.41	Uric acid levels;	chr4:39130556	chr4:39112677~39126818:-
LUAD	cis	rs228614	0.536	rs223477	ENSG00000246560.2	RP11-10L12.4	9.89	4.15e-21	7.89e-18	0.51	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769099	chr4:102828055~102844075:+
LUAD	cis	rs10875746	0.951	rs4760690	ENSG00000240399.1	RP1-228P16.1	-9.89	4.18e-21	7.94e-18	-0.51	-0.41	Longevity (90 years and older);	chr12:48169870	chr12:48054813~48055591:-
LUAD	cis	rs11089937	0.857	rs5750578	ENSG00000211639.2	IGLV4-60	9.89	4.2e-21	7.97e-18	0.41	0.41	Periodontitis (PAL4Q3);	chr22:22136444	chr22:22162199~22162681:+
LUAD	cis	rs8062405	0.69	rs7187604	ENSG00000259982.1	CDC37P1	9.89	4.2e-21	7.98e-18	0.52	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28700294~28701540:-
LUAD	cis	rs944289	0.616	rs1742867	ENSG00000257826.1	RP11-116N8.4	9.89	4.21e-21	8e-18	0.43	0.41	Thyroid cancer;	chr14:36067937	chr14:36061026~36067190:-
LUAD	cis	rs8040855	0.627	rs12913859	ENSG00000259295.5	CSPG4P12	9.88	4.23e-21	8.03e-18	0.54	0.41	Bulimia nervosa;	chr15:85095187	chr15:85191438~85213905:+
LUAD	cis	rs2188561	0.697	rs4730258	ENSG00000241764.3	AC002467.7	9.88	4.25e-21	8.06e-18	0.54	0.41	Alcohol consumption;	chr7:107755787	chr7:107742817~107744581:-
LUAD	cis	rs2019137	0.901	rs4849176	ENSG00000274877.1	RP11-65I12.1	9.88	4.25e-21	8.06e-18	0.52	0.41	Lymphocyte counts;	chr2:113220359	chr2:113237595~113240825:+
LUAD	cis	rs11098499	0.954	rs11098524	ENSG00000245958.5	RP11-33B1.1	-9.88	4.35e-21	8.25e-18	-0.39	-0.41	Corneal astigmatism;	chr4:119468877	chr4:119454791~119552025:+
LUAD	cis	rs6504950	0.8	rs8065361	ENSG00000275710.1	RP11-257O5.4	9.88	4.35e-21	8.25e-18	0.51	0.41	Breast cancer;	chr17:54931492	chr17:54964474~54964679:+
LUAD	cis	rs10875746	0.951	rs10875756	ENSG00000240399.1	RP1-228P16.1	-9.88	4.36e-21	8.28e-18	-0.51	-0.41	Longevity (90 years and older);	chr12:48168521	chr12:48054813~48055591:-
LUAD	cis	rs9322193	0.923	rs9767105	ENSG00000216906.2	RP11-350J20.9	9.88	4.39e-21	8.32e-18	0.5	0.41	Lung cancer;	chr6:149659591	chr6:149904243~149906418:+
LUAD	cis	rs321358	0.895	rs17457658	ENSG00000271584.1	RP11-89C3.4	9.88	4.4e-21	8.34e-18	0.66	0.41	Body mass index;	chr11:111089448	chr11:111091932~111097357:-
LUAD	cis	rs904251	0.861	rs1757180	ENSG00000204110.6	RP1-153P14.8	-9.88	4.43e-21	8.39e-18	-0.43	-0.41	Cognitive performance;	chr6:37518369	chr6:37507348~37535616:+
LUAD	cis	rs67180937	0.621	rs2378607	ENSG00000272750.1	RP11-378J18.8	-9.88	4.43e-21	8.4e-18	-0.43	-0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222746553	chr1:222658867~222661512:-
LUAD	cis	rs228614	0.51	rs223468	ENSG00000246560.2	RP11-10L12.4	9.88	4.5e-21	8.52e-18	0.5	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102779265	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.51	rs223465	ENSG00000246560.2	RP11-10L12.4	9.88	4.5e-21	8.52e-18	0.5	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780174	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.51	rs223464	ENSG00000246560.2	RP11-10L12.4	9.88	4.5e-21	8.52e-18	0.5	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780603	chr4:102828055~102844075:+
LUAD	cis	rs17608059	0.504	rs11656981	ENSG00000141028.6	CDRT15P1	-9.88	4.51e-21	8.54e-18	-0.47	-0.41	Temperament;	chr17:14075460	chr17:14024514~14025488:+
LUAD	cis	rs904251	0.797	rs1776460	ENSG00000204110.6	RP1-153P14.8	-9.88	4.52e-21	8.55e-18	-0.42	-0.41	Cognitive performance;	chr6:37517708	chr6:37507348~37535616:+
LUAD	cis	rs228614	0.51	rs223349	ENSG00000246560.2	RP11-10L12.4	9.88	4.53e-21	8.58e-18	0.51	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102857277	chr4:102828055~102844075:+
LUAD	cis	rs8040855	0.627	rs11630697	ENSG00000259295.5	CSPG4P12	9.88	4.54e-21	8.6e-18	0.54	0.41	Bulimia nervosa;	chr15:85063214	chr15:85191438~85213905:+
LUAD	cis	rs10129255	0.957	rs6576233	ENSG00000211970.3	IGHV4-61	-9.88	4.55e-21	8.61e-18	-0.31	-0.41	Kawasaki disease;	chr14:106787239	chr14:106639119~106639657:-
LUAD	cis	rs11098499	0.69	rs7674713	ENSG00000245958.5	RP11-33B1.1	-9.88	4.57e-21	8.65e-18	-0.38	-0.41	Corneal astigmatism;	chr4:119401102	chr4:119454791~119552025:+
LUAD	cis	rs5769707	0.837	rs5769709	ENSG00000188511.11	C22orf34	9.88	4.57e-21	8.66e-18	0.47	0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49628109	chr22:49414524~49657542:-
LUAD	cis	rs228614	0.51	rs223353	ENSG00000246560.2	RP11-10L12.4	9.87	4.6e-21	8.71e-18	0.51	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102854547	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.51	rs223352	ENSG00000246560.2	RP11-10L12.4	9.87	4.6e-21	8.71e-18	0.51	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102855710	chr4:102828055~102844075:+
LUAD	cis	rs5769707	0.837	rs1573726	ENSG00000188511.11	C22orf34	9.87	4.62e-21	8.73e-18	0.47	0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49639224	chr22:49414524~49657542:-
LUAD	cis	rs10875746	0.903	rs11168370	ENSG00000240399.1	RP1-228P16.1	-9.87	4.63e-21	8.76e-18	-0.49	-0.41	Longevity (90 years and older);	chr12:48041497	chr12:48054813~48055591:-
LUAD	cis	rs2006771	0.618	rs470072	ENSG00000236132.1	CTA-440B3.1	-9.87	4.77e-21	9.01e-18	-0.47	-0.41	Nonsyndromic cleft lip with cleft palate;	chr22:31867145	chr22:31816379~31817491:-
LUAD	cis	rs2658782	0.654	rs2248524	ENSG00000279684.1	RP11-755E23.2	-9.87	4.78e-21	9.04e-18	-0.62	-0.41	Pulmonary function decline;	chr11:93522549	chr11:93286629~93288903:-
LUAD	cis	rs10256972	0.684	rs2363279	ENSG00000229043.2	AC091729.9	-9.87	4.8e-21	9.06e-18	-0.45	-0.41	Endometriosis;Longevity;	chr7:1056507	chr7:1160374~1165267:+
LUAD	cis	rs977987	0.843	rs17696749	ENSG00000261783.1	RP11-252K23.2	-9.87	4.81e-21	9.1e-18	-0.55	-0.41	Dupuytren's disease;	chr16:75369164	chr16:75379818~75381260:-
LUAD	cis	rs10875746	0.951	rs4760689	ENSG00000240399.1	RP1-228P16.1	-9.87	4.93e-21	9.31e-18	-0.51	-0.41	Longevity (90 years and older);	chr12:48169861	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.951	rs58865997	ENSG00000240399.1	RP1-228P16.1	-9.87	4.93e-21	9.31e-18	-0.51	-0.41	Longevity (90 years and older);	chr12:48173090	chr12:48054813~48055591:-
LUAD	cis	rs11098499	0.826	rs4472123	ENSG00000245958.5	RP11-33B1.1	-9.87	4.95e-21	9.34e-18	-0.37	-0.41	Corneal astigmatism;	chr4:119315475	chr4:119454791~119552025:+
LUAD	cis	rs8040855	0.627	rs11637512	ENSG00000259295.5	CSPG4P12	9.87	4.95e-21	9.34e-18	0.54	0.41	Bulimia nervosa;	chr15:85105528	chr15:85191438~85213905:+
LUAD	cis	rs8040855	0.627	rs17541051	ENSG00000259295.5	CSPG4P12	9.87	4.95e-21	9.34e-18	0.54	0.41	Bulimia nervosa;	chr15:85106122	chr15:85191438~85213905:+
LUAD	cis	rs8040855	0.627	rs35668291	ENSG00000259295.5	CSPG4P12	9.87	4.95e-21	9.34e-18	0.54	0.41	Bulimia nervosa;	chr15:85109582	chr15:85191438~85213905:+
LUAD	cis	rs6452524	0.746	rs28745311	ENSG00000249664.1	CTD-2227C6.2	9.87	4.96e-21	9.36e-18	0.49	0.41	Hypertension (SNP x SNP interaction);	chr5:83123030	chr5:83012285~83013109:-
LUAD	cis	rs8040855	0.658	rs11634877	ENSG00000259295.5	CSPG4P12	9.86	5.12e-21	9.65e-18	0.54	0.41	Bulimia nervosa;	chr15:85068246	chr15:85191438~85213905:+
LUAD	cis	rs8040855	0.627	rs11632175	ENSG00000259295.5	CSPG4P12	9.86	5.12e-21	9.65e-18	0.54	0.41	Bulimia nervosa;	chr15:85068449	chr15:85191438~85213905:+
LUAD	cis	rs8040855	0.627	rs62019482	ENSG00000259295.5	CSPG4P12	9.86	5.12e-21	9.65e-18	0.54	0.41	Bulimia nervosa;	chr15:85071796	chr15:85191438~85213905:+
LUAD	cis	rs6504950	0.8	rs9916547	ENSG00000275710.1	RP11-257O5.4	9.86	5.15e-21	9.7e-18	0.51	0.41	Breast cancer;	chr17:54929529	chr17:54964474~54964679:+
LUAD	cis	rs9322193	0.607	rs7764677	ENSG00000231760.4	RP11-350J20.5	9.86	5.21e-21	9.81e-18	0.6	0.41	Lung cancer;	chr6:149906197	chr6:149796151~149826294:-
LUAD	cis	rs8062405	0.755	rs62034358	ENSG00000259982.1	CDC37P1	9.86	5.22e-21	9.83e-18	0.52	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.755	rs12445823	ENSG00000259982.1	CDC37P1	9.86	5.22e-21	9.83e-18	0.52	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28700294~28701540:-
LUAD	cis	rs11089937	0.864	rs5757041	ENSG00000211639.2	IGLV4-60	9.86	5.23e-21	9.86e-18	0.41	0.41	Periodontitis (PAL4Q3);	chr22:22140538	chr22:22162199~22162681:+
LUAD	cis	rs6504950	0.72	rs12602751	ENSG00000275710.1	RP11-257O5.4	9.86	5.27e-21	9.92e-18	0.51	0.41	Breast cancer;	chr17:54916813	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.72	rs7216138	ENSG00000275710.1	RP11-257O5.4	9.86	5.27e-21	9.92e-18	0.51	0.41	Breast cancer;	chr17:54918303	chr17:54964474~54964679:+
LUAD	cis	rs10256972	0.721	rs6975972	ENSG00000229043.2	AC091729.9	-9.86	5.28e-21	9.94e-18	-0.45	-0.41	Endometriosis;Longevity;	chr7:1030832	chr7:1160374~1165267:+
LUAD	cis	rs7044106	0.791	rs4836830	ENSG00000226752.6	PSMD5-AS1	-9.86	5.33e-21	1e-17	-0.46	-0.41	Hip circumference adjusted for BMI;	chr9:120721390	chr9:120824828~120854385:+
LUAD	cis	rs16828019	0.852	rs2300649	ENSG00000235358.1	RP11-399E6.1	9.86	5.35e-21	1.01e-17	0.69	0.41	Intelligence (multi-trait analysis);	chr1:41103531	chr1:41242373~41284861:+
LUAD	cis	rs11098499	0.863	rs6835635	ENSG00000245958.5	RP11-33B1.1	-9.86	5.37e-21	1.01e-17	-0.39	-0.41	Corneal astigmatism;	chr4:119537712	chr4:119454791~119552025:+
LUAD	cis	rs16828019	0.704	rs12024115	ENSG00000235358.1	RP11-399E6.1	9.86	5.39e-21	1.01e-17	0.68	0.41	Intelligence (multi-trait analysis);	chr1:41068685	chr1:41242373~41284861:+
LUAD	cis	rs6504950	0.745	rs12603899	ENSG00000275710.1	RP11-257O5.4	9.85	5.45e-21	1.02e-17	0.51	0.41	Breast cancer;	chr17:54932737	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.8	rs9891704	ENSG00000275710.1	RP11-257O5.4	9.85	5.45e-21	1.02e-17	0.51	0.41	Breast cancer;	chr17:54933394	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.8	rs9900816	ENSG00000275710.1	RP11-257O5.4	9.85	5.45e-21	1.02e-17	0.51	0.41	Breast cancer;	chr17:54934696	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.8	rs9907961	ENSG00000275710.1	RP11-257O5.4	9.85	5.45e-21	1.02e-17	0.51	0.41	Breast cancer;	chr17:54935566	chr17:54964474~54964679:+
LUAD	cis	rs10129255	0.518	rs12590732	ENSG00000280411.1	IGHV1-69-2	9.85	5.48e-21	1.03e-17	0.28	0.41	Kawasaki disease;	chr14:106779612	chr14:106762092~106762588:-
LUAD	cis	rs11722779	0.844	rs10003326	ENSG00000246560.2	RP11-10L12.4	9.85	5.51e-21	1.03e-17	0.51	0.41	Schizophrenia;	chr4:102948193	chr4:102828055~102844075:+
LUAD	cis	rs321358	0.848	rs78087740	ENSG00000271584.1	RP11-89C3.4	9.85	5.55e-21	1.04e-17	0.67	0.41	Body mass index;	chr11:111079016	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.848	rs73015146	ENSG00000271584.1	RP11-89C3.4	9.85	5.55e-21	1.04e-17	0.67	0.41	Body mass index;	chr11:111079143	chr11:111091932~111097357:-
LUAD	cis	rs1061377	1	rs35116118	ENSG00000249207.1	RP11-360F5.1	-9.85	5.56e-21	1.04e-17	-0.45	-0.41	Uric acid levels;	chr4:39127293	chr4:39112677~39126818:-
LUAD	cis	rs8040855	0.627	rs11631548	ENSG00000259295.5	CSPG4P12	9.85	5.71e-21	1.07e-17	0.54	0.41	Bulimia nervosa;	chr15:85076017	chr15:85191438~85213905:+
LUAD	cis	rs8040855	0.627	rs1532776	ENSG00000259295.5	CSPG4P12	9.85	5.71e-21	1.07e-17	0.54	0.41	Bulimia nervosa;	chr15:85081383	chr15:85191438~85213905:+
LUAD	cis	rs748404	0.676	rs4401024	ENSG00000205771.5	CATSPER2P1	-9.85	5.73e-21	1.07e-17	-0.52	-0.41	Lung cancer;	chr15:43358137	chr15:43726918~43747094:-
LUAD	cis	rs11722779	0.787	rs6533040	ENSG00000246560.2	RP11-10L12.4	9.85	5.74e-21	1.08e-17	0.51	0.41	Schizophrenia;	chr4:102951421	chr4:102828055~102844075:+
LUAD	cis	rs977987	0.843	rs4888415	ENSG00000261783.1	RP11-252K23.2	-9.85	5.77e-21	1.08e-17	-0.54	-0.41	Dupuytren's disease;	chr16:75415023	chr16:75379818~75381260:-
LUAD	cis	rs7429990	0.901	rs9825114	ENSG00000229759.1	MRPS18AP1	-9.85	5.81e-21	1.09e-17	-0.43	-0.41	Educational attainment (years of education);	chr3:48096592	chr3:48256350~48256938:-
LUAD	cis	rs2283792	0.812	rs240064	ENSG00000224086.5	LL22NC03-86G7.1	9.85	5.82e-21	1.09e-17	0.38	0.41	Multiple sclerosis;	chr22:21927265	chr22:21938293~21977632:+
LUAD	cis	rs1153858	1	rs2467864	ENSG00000259520.4	CTD-2651B20.3	9.85	5.87e-21	1.1e-17	0.54	0.41	Homoarginine levels;	chr15:45348900	chr15:45251580~45279251:-
LUAD	cis	rs11098499	0.954	rs6820115	ENSG00000245958.5	RP11-33B1.1	-9.84	5.89e-21	1.1e-17	-0.36	-0.41	Corneal astigmatism;	chr4:119477027	chr4:119454791~119552025:+
LUAD	cis	rs62229266	0.659	rs62230814	ENSG00000231106.2	LINC01436	9.84	5.94e-21	1.11e-17	0.55	0.41	Mitral valve prolapse;	chr21:36031248	chr21:36005338~36007838:+
LUAD	cis	rs5769707	0.872	rs5770604	ENSG00000188511.11	C22orf34	9.84	5.98e-21	1.12e-17	0.47	0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49637024	chr22:49414524~49657542:-
LUAD	cis	rs111321694	1	rs111321694	ENSG00000271584.1	RP11-89C3.4	9.84	6.01e-21	1.13e-17	0.67	0.41	Educational attainment (years of education);	chr11:111079662	chr11:111091932~111097357:-
LUAD	cis	rs227275	0.524	rs223337	ENSG00000246560.2	RP11-10L12.4	9.84	6.05e-21	1.13e-17	0.5	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102865214	chr4:102828055~102844075:+
LUAD	cis	rs11089937	0.825	rs5757012	ENSG00000211639.2	IGLV4-60	9.84	6.12e-21	1.15e-17	0.41	0.41	Periodontitis (PAL4Q3);	chr22:22135515	chr22:22162199~22162681:+
LUAD	cis	rs904251	0.737	rs914347	ENSG00000204110.6	RP1-153P14.8	-9.84	6.12e-21	1.15e-17	-0.42	-0.41	Cognitive performance;	chr6:37517194	chr6:37507348~37535616:+
LUAD	cis	rs9326248	0.954	rs521171	ENSG00000280143.1	AP000892.6	9.84	6.14e-21	1.15e-17	0.49	0.41	Blood protein levels;	chr11:117193977	chr11:117204967~117210292:+
LUAD	cis	rs321358	0.895	rs7950087	ENSG00000271584.1	RP11-89C3.4	-9.84	6.25e-21	1.17e-17	-0.66	-0.41	Body mass index;	chr11:111082536	chr11:111091932~111097357:-
LUAD	cis	rs6452524	1	rs6882179	ENSG00000249664.1	CTD-2227C6.2	9.84	6.27e-21	1.17e-17	0.47	0.41	Hypertension (SNP x SNP interaction);	chr5:83139582	chr5:83012285~83013109:-
LUAD	cis	rs10129255	0.5	rs6576232	ENSG00000280411.1	IGHV1-69-2	-9.84	6.32e-21	1.18e-17	-0.28	-0.41	Kawasaki disease;	chr14:106787090	chr14:106762092~106762588:-
LUAD	cis	rs2581828	1	rs2581828	ENSG00000242142.1	SERBP1P3	9.84	6.32e-21	1.18e-17	0.43	0.41	Crohn's disease;	chr3:53099133	chr3:53064283~53065091:-
LUAD	cis	rs977987	0.843	rs62062564	ENSG00000261783.1	RP11-252K23.2	-9.84	6.34e-21	1.18e-17	-0.54	-0.41	Dupuytren's disease;	chr16:75408724	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.806	rs7188231	ENSG00000261783.1	RP11-252K23.2	-9.84	6.36e-21	1.19e-17	-0.54	-0.41	Dupuytren's disease;	chr16:75402663	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.843	rs12443904	ENSG00000261783.1	RP11-252K23.2	-9.84	6.36e-21	1.19e-17	-0.54	-0.41	Dupuytren's disease;	chr16:75404872	chr16:75379818~75381260:-
LUAD	cis	rs4814920	0.818	rs6081790	ENSG00000275142.1	RP5-999L4.2	-9.83	6.43e-21	1.2e-17	-0.74	-0.41	Bipolar disorder (body mass index interaction);	chr20:19882273	chr20:19871891~19872284:+
LUAD	cis	rs977987	0.843	rs7499872	ENSG00000261783.1	RP11-252K23.2	-9.83	6.45e-21	1.21e-17	-0.54	-0.41	Dupuytren's disease;	chr16:75392631	chr16:75379818~75381260:-
LUAD	cis	rs7044106	0.762	rs10760112	ENSG00000226752.6	PSMD5-AS1	-9.83	6.48e-21	1.21e-17	-0.45	-0.41	Hip circumference adjusted for BMI;	chr9:120705292	chr9:120824828~120854385:+
LUAD	cis	rs10170846	0.924	rs3768973	ENSG00000261428.2	RP11-16P6.1	9.83	6.5e-21	1.21e-17	0.51	0.41	Schizophrenia (inflammation and infection response interaction);	chr2:222571683	chr2:222566899~222569719:-
LUAD	cis	rs10129255	0.5	rs8004923	ENSG00000280411.1	IGHV1-69-2	-9.83	6.54e-21	1.22e-17	-0.28	-0.41	Kawasaki disease;	chr14:106785926	chr14:106762092~106762588:-
LUAD	cis	rs7044106	0.762	rs966396	ENSG00000226752.6	PSMD5-AS1	-9.83	6.57e-21	1.23e-17	-0.45	-0.41	Hip circumference adjusted for BMI;	chr9:120691003	chr9:120824828~120854385:+
LUAD	cis	rs1061377	1	rs56119980	ENSG00000249207.1	RP11-360F5.1	-9.83	6.65e-21	1.24e-17	-0.46	-0.41	Uric acid levels;	chr4:39139390	chr4:39112677~39126818:-
LUAD	cis	rs7044106	0.791	rs10984995	ENSG00000226752.6	PSMD5-AS1	-9.83	6.68e-21	1.25e-17	-0.45	-0.41	Hip circumference adjusted for BMI;	chr9:120716932	chr9:120824828~120854385:+
LUAD	cis	rs4774565	0.762	rs17431150	ENSG00000244879.4	GABPB1-AS1	-9.83	6.77e-21	1.26e-17	-0.37	-0.41	Breast cancer;	chr15:50371385	chr15:50354959~50372202:+
LUAD	cis	rs4774565	0.762	rs17431171	ENSG00000244879.4	GABPB1-AS1	-9.83	6.77e-21	1.26e-17	-0.37	-0.41	Breast cancer;	chr15:50371424	chr15:50354959~50372202:+
LUAD	cis	rs977987	0.843	rs60730309	ENSG00000261783.1	RP11-252K23.2	-9.83	6.8e-21	1.27e-17	-0.54	-0.41	Dupuytren's disease;	chr16:75397871	chr16:75379818~75381260:-
LUAD	cis	rs977987	0.75	rs4888406	ENSG00000261783.1	RP11-252K23.2	-9.83	6.8e-21	1.27e-17	-0.54	-0.41	Dupuytren's disease;	chr16:75398436	chr16:75379818~75381260:-
LUAD	cis	rs10256972	0.758	rs11979275	ENSG00000229043.2	AC091729.9	-9.83	6.85e-21	1.28e-17	-0.44	-0.41	Endometriosis;Longevity;	chr7:1029699	chr7:1160374~1165267:+
LUAD	cis	rs10256972	0.758	rs11980081	ENSG00000229043.2	AC091729.9	-9.83	6.85e-21	1.28e-17	-0.44	-0.41	Endometriosis;Longevity;	chr7:1029736	chr7:1160374~1165267:+
LUAD	cis	rs67180937	0.921	rs35700460	ENSG00000272750.1	RP11-378J18.8	-9.83	6.85e-21	1.28e-17	-0.43	-0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222638065	chr1:222658867~222661512:-
LUAD	cis	rs10853057	0.541	rs77675516	ENSG00000214174.7	AMZ2P1	9.83	6.88e-21	1.28e-17	0.77	0.41	White matter microstructure (global fractional anisotropy);	chr17:65050690	chr17:64966550~64975576:-
LUAD	cis	rs7044106	0.762	rs10760115	ENSG00000226752.6	PSMD5-AS1	-9.83	6.89e-21	1.28e-17	-0.45	-0.41	Hip circumference adjusted for BMI;	chr9:120714674	chr9:120824828~120854385:+
LUAD	cis	rs507080	0.769	rs2077173	ENSG00000255422.1	AP002954.4	-9.82	6.95e-21	1.3e-17	-0.51	-0.41	Serum metabolite levels;	chr11:118621876	chr11:118704607~118750263:+
LUAD	cis	rs2455601	0.786	rs11042127	ENSG00000254860.4	TMEM9B-AS1	9.82	7.03e-21	1.31e-17	0.59	0.41	Schizophrenia;	chr11:8926039	chr11:8964675~8977527:+
LUAD	cis	rs228614	0.51	rs223378	ENSG00000246560.2	RP11-10L12.4	9.82	7.03e-21	1.31e-17	0.51	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102833488	chr4:102828055~102844075:+
LUAD	cis	rs7044106	0.762	rs7849566	ENSG00000226752.6	PSMD5-AS1	-9.82	7.24e-21	1.35e-17	-0.45	-0.41	Hip circumference adjusted for BMI;	chr9:120698491	chr9:120824828~120854385:+
LUAD	cis	rs10853057	0.541	rs8076716	ENSG00000214174.7	AMZ2P1	9.82	7.26e-21	1.35e-17	0.77	0.41	White matter microstructure (global fractional anisotropy);	chr17:65051891	chr17:64966550~64975576:-
LUAD	cis	rs8040855	0.627	rs4980357	ENSG00000259295.5	CSPG4P12	9.82	7.29e-21	1.35e-17	0.53	0.41	Bulimia nervosa;	chr15:85064878	chr15:85191438~85213905:+
LUAD	cis	rs8040855	0.627	rs4980356	ENSG00000259295.5	CSPG4P12	9.82	7.29e-21	1.35e-17	0.53	0.41	Bulimia nervosa;	chr15:85064901	chr15:85191438~85213905:+
LUAD	cis	rs748404	0.631	rs6493083	ENSG00000205771.5	CATSPER2P1	-9.82	7.32e-21	1.36e-17	-0.53	-0.41	Lung cancer;	chr15:43345787	chr15:43726918~43747094:-
LUAD	cis	rs1153858	1	rs1145074	ENSG00000259520.4	CTD-2651B20.3	-9.82	7.39e-21	1.37e-17	-0.55	-0.41	Homoarginine levels;	chr15:45411626	chr15:45251580~45279251:-
LUAD	cis	rs7044106	0.708	rs10984992	ENSG00000226752.6	PSMD5-AS1	-9.82	7.41e-21	1.38e-17	-0.45	-0.41	Hip circumference adjusted for BMI;	chr9:120711138	chr9:120824828~120854385:+
LUAD	cis	rs8040855	0.627	rs12905036	ENSG00000259295.5	CSPG4P12	9.82	7.42e-21	1.38e-17	0.54	0.41	Bulimia nervosa;	chr15:85094557	chr15:85191438~85213905:+
LUAD	cis	rs4423214	0.879	rs1790345	ENSG00000254682.1	RP11-660L16.2	-9.82	7.42e-21	1.38e-17	-0.58	-0.41	Vitamin D levels;	chr11:71434895	chr11:71448674~71452157:+
LUAD	cis	rs904251	0.6	rs4714068	ENSG00000279942.1	RP1-153P14.7	-9.82	7.49e-21	1.39e-17	-0.38	-0.41	Cognitive performance;	chr6:37487866	chr6:37567716~37571460:+
LUAD	cis	rs6452524	0.868	rs10045104	ENSG00000249664.1	CTD-2227C6.2	9.81	7.56e-21	1.4e-17	0.49	0.41	Hypertension (SNP x SNP interaction);	chr5:83116543	chr5:83012285~83013109:-
LUAD	cis	rs10129255	0.5	rs7157975	ENSG00000280411.1	IGHV1-69-2	-9.81	7.59e-21	1.41e-17	-0.28	-0.41	Kawasaki disease;	chr14:106804049	chr14:106762092~106762588:-
LUAD	cis	rs904251	0.523	rs12202055	ENSG00000279942.1	RP1-153P14.7	-9.81	7.79e-21	1.45e-17	-0.38	-0.41	Cognitive performance;	chr6:37518304	chr6:37567716~37571460:+
LUAD	cis	rs67180937	0.7	rs4282830	ENSG00000272750.1	RP11-378J18.8	-9.81	7.95e-21	1.47e-17	-0.42	-0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222738618	chr1:222658867~222661512:-
LUAD	cis	rs228614	0.51	rs223470	ENSG00000246560.2	RP11-10L12.4	9.81	8.08e-21	1.5e-17	0.5	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102778004	chr4:102828055~102844075:+
LUAD	cis	rs17507216	0.628	rs17158396	ENSG00000278603.1	RP13-608F4.5	9.81	8.13e-21	1.51e-17	0.54	0.41	Excessive daytime sleepiness;	chr15:82615688	chr15:82472203~82472426:+
LUAD	cis	rs977987	0.872	rs1542864	ENSG00000261783.1	RP11-252K23.2	-9.81	8.16e-21	1.51e-17	-0.55	-0.41	Dupuytren's disease;	chr16:75437480	chr16:75379818~75381260:-
LUAD	cis	rs8040855	0.657	rs6496733	ENSG00000259295.5	CSPG4P12	-9.81	8.17e-21	1.51e-17	-0.53	-0.41	Bulimia nervosa;	chr15:85129945	chr15:85191438~85213905:+
LUAD	cis	rs227275	0.554	rs223316	ENSG00000246560.2	RP11-10L12.4	9.81	8.18e-21	1.52e-17	0.5	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102881949	chr4:102828055~102844075:+
LUAD	cis	rs11098499	0.955	rs35197422	ENSG00000245958.5	RP11-33B1.1	-9.8	8.35e-21	1.55e-17	-0.37	-0.41	Corneal astigmatism;	chr4:119248159	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.955	rs1511015	ENSG00000245958.5	RP11-33B1.1	-9.8	8.35e-21	1.55e-17	-0.37	-0.41	Corneal astigmatism;	chr4:119249318	chr4:119454791~119552025:+
LUAD	cis	rs11098499	1	rs10029750	ENSG00000245958.5	RP11-33B1.1	-9.8	8.35e-21	1.55e-17	-0.37	-0.41	Corneal astigmatism;	chr4:119251388	chr4:119454791~119552025:+
LUAD	cis	rs228614	0.51	rs50034	ENSG00000246560.2	RP11-10L12.4	9.8	8.38e-21	1.55e-17	0.5	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102832214	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.556	rs223380	ENSG00000246560.2	RP11-10L12.4	9.8	8.38e-21	1.55e-17	0.5	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102833343	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.556	rs223379	ENSG00000246560.2	RP11-10L12.4	9.8	8.38e-21	1.55e-17	0.5	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102833434	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.536	rs223375	ENSG00000246560.2	RP11-10L12.4	9.8	8.38e-21	1.55e-17	0.5	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102836484	chr4:102828055~102844075:+
LUAD	cis	rs67180937	0.733	rs17532708	ENSG00000272750.1	RP11-378J18.8	-9.8	8.38e-21	1.55e-17	-0.42	-0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222726085	chr1:222658867~222661512:-
LUAD	cis	rs2188561	0.697	rs2072064	ENSG00000241764.3	AC002467.7	9.8	8.4e-21	1.56e-17	0.56	0.41	Alcohol consumption;	chr7:107694068	chr7:107742817~107744581:-
LUAD	cis	rs11098499	1	rs58601355	ENSG00000245958.5	RP11-33B1.1	-9.8	8.41e-21	1.56e-17	-0.38	-0.41	Corneal astigmatism;	chr4:119265212	chr4:119454791~119552025:+
LUAD	cis	rs7208859	0.623	rs9906957	ENSG00000263531.1	RP13-753N3.1	9.8	8.41e-21	1.56e-17	0.83	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30830737	chr17:30863921~30864940:-
LUAD	cis	rs10129255	0.5	rs11628999	ENSG00000280411.1	IGHV1-69-2	-9.8	8.61e-21	1.59e-17	-0.28	-0.41	Kawasaki disease;	chr14:106800208	chr14:106762092~106762588:-
LUAD	cis	rs904251	1	rs904251	ENSG00000279942.1	RP1-153P14.7	-9.8	8.66e-21	1.6e-17	-0.39	-0.41	Cognitive performance;	chr6:37483920	chr6:37567716~37571460:+
LUAD	cis	rs11722779	0.935	rs7681629	ENSG00000246560.2	RP11-10L12.4	9.8	8.68e-21	1.6e-17	0.5	0.41	Schizophrenia;	chr4:102974407	chr4:102828055~102844075:+
LUAD	cis	rs11722779	0.844	rs17033381	ENSG00000246560.2	RP11-10L12.4	9.8	8.68e-21	1.6e-17	0.5	0.41	Schizophrenia;	chr4:102974952	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.556	rs4699044	ENSG00000246560.2	RP11-10L12.4	9.8	8.68e-21	1.6e-17	0.5	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102976939	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.556	rs4699045	ENSG00000246560.2	RP11-10L12.4	9.8	8.68e-21	1.6e-17	0.5	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102977009	chr4:102828055~102844075:+
LUAD	cis	rs62229266	0.618	rs11088334	ENSG00000231106.2	LINC01436	9.8	8.7e-21	1.61e-17	0.56	0.41	Mitral valve prolapse;	chr21:36094531	chr21:36005338~36007838:+
LUAD	cis	rs904251	0.523	rs12202055	ENSG00000204110.6	RP1-153P14.8	-9.8	8.72e-21	1.61e-17	-0.42	-0.41	Cognitive performance;	chr6:37518304	chr6:37507348~37535616:+
LUAD	cis	rs10256972	0.721	rs4720249	ENSG00000229043.2	AC091729.9	-9.8	8.81e-21	1.63e-17	-0.44	-0.41	Endometriosis;Longevity;	chr7:1032927	chr7:1160374~1165267:+
LUAD	cis	rs1061377	0.748	rs11096977	ENSG00000249207.1	RP11-360F5.1	-9.8	8.82e-21	1.63e-17	-0.45	-0.41	Uric acid levels;	chr4:39106186	chr4:39112677~39126818:-
LUAD	cis	rs11098499	1	rs35643470	ENSG00000245958.5	RP11-33B1.1	-9.8	8.85e-21	1.63e-17	-0.37	-0.41	Corneal astigmatism;	chr4:119263793	chr4:119454791~119552025:+
LUAD	cis	rs62229266	0.835	rs998384	ENSG00000231106.2	LINC01436	9.8	8.86e-21	1.64e-17	0.56	0.41	Mitral valve prolapse;	chr21:36073228	chr21:36005338~36007838:+
LUAD	cis	rs904251	0.861	rs1757183	ENSG00000204110.6	RP1-153P14.8	9.79	8.95e-21	1.65e-17	0.42	0.41	Cognitive performance;	chr6:37517014	chr6:37507348~37535616:+
LUAD	cis	rs16828019	0.852	rs34386859	ENSG00000235358.1	RP11-399E6.1	9.79	8.95e-21	1.65e-17	0.69	0.41	Intelligence (multi-trait analysis);	chr1:41098352	chr1:41242373~41284861:+
LUAD	cis	rs9481169	0.85	rs60962769	ENSG00000255389.1	C6orf3	-9.79	8.96e-21	1.65e-17	-0.84	-0.41	Inflammatory skin disease;	chr6:111598221	chr6:111599875~111602295:+
LUAD	cis	rs2108622	0.785	rs3093199	ENSG00000267453.5	AC004791.2	-9.79	9.01e-21	1.66e-17	-0.5	-0.41	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15879061	chr19:15851993~15864904:-
LUAD	cis	rs62229266	0.659	rs7275820	ENSG00000231106.2	LINC01436	9.79	9.01e-21	1.66e-17	0.55	0.41	Mitral valve prolapse;	chr21:36037116	chr21:36005338~36007838:+
LUAD	cis	rs7208859	0.623	rs73271869	ENSG00000263531.1	RP13-753N3.1	9.79	9.06e-21	1.67e-17	0.83	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825203	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs73271872	ENSG00000263531.1	RP13-753N3.1	9.79	9.06e-21	1.67e-17	0.83	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825210	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs56146117	ENSG00000263531.1	RP13-753N3.1	9.79	9.06e-21	1.67e-17	0.83	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826307	chr17:30863921~30864940:-
LUAD	cis	rs17826219	0.568	rs9907834	ENSG00000263531.1	RP13-753N3.1	9.79	9.06e-21	1.67e-17	0.83	0.41	Body mass index;	chr17:30826995	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs73271887	ENSG00000263531.1	RP13-753N3.1	9.79	9.06e-21	1.67e-17	0.83	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827917	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs9898858	ENSG00000263531.1	RP13-753N3.1	9.79	9.06e-21	1.67e-17	0.83	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829193	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs55658077	ENSG00000263531.1	RP13-753N3.1	9.79	9.06e-21	1.67e-17	0.83	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829501	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs9899692	ENSG00000263531.1	RP13-753N3.1	9.79	9.06e-21	1.67e-17	0.83	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829921	chr17:30863921~30864940:-
LUAD	cis	rs227275	0.554	rs223466	ENSG00000246560.2	RP11-10L12.4	9.79	9.08e-21	1.67e-17	0.5	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102780039	chr4:102828055~102844075:+
LUAD	cis	rs1061377	0.748	rs6810770	ENSG00000249207.1	RP11-360F5.1	-9.79	9.08e-21	1.68e-17	-0.45	-0.41	Uric acid levels;	chr4:39106545	chr4:39112677~39126818:-
LUAD	cis	rs1061377	0.748	rs6812316	ENSG00000249207.1	RP11-360F5.1	-9.79	9.08e-21	1.68e-17	-0.45	-0.41	Uric acid levels;	chr4:39106617	chr4:39112677~39126818:-
LUAD	cis	rs4774565	0.724	rs2555486	ENSG00000244879.4	GABPB1-AS1	9.79	9.16e-21	1.69e-17	0.37	0.41	Breast cancer;	chr15:50363924	chr15:50354959~50372202:+
LUAD	cis	rs4774565	0.762	rs7182201	ENSG00000244879.4	GABPB1-AS1	-9.79	9.16e-21	1.69e-17	-0.37	-0.41	Breast cancer;	chr15:50364377	chr15:50354959~50372202:+
LUAD	cis	rs10129255	0.5	rs10142931	ENSG00000280411.1	IGHV1-69-2	-9.79	9.18e-21	1.69e-17	-0.28	-0.41	Kawasaki disease;	chr14:106782288	chr14:106762092~106762588:-
LUAD	cis	rs11098499	1	rs13116504	ENSG00000245958.5	RP11-33B1.1	-9.79	9.19e-21	1.69e-17	-0.37	-0.41	Corneal astigmatism;	chr4:119288257	chr4:119454791~119552025:+
LUAD	cis	rs950027	0.787	rs1547487	ENSG00000259520.4	CTD-2651B20.3	-9.79	9.19e-21	1.69e-17	-0.5	-0.41	Response to fenofibrate (adiponectin levels);	chr15:45431785	chr15:45251580~45279251:-
LUAD	cis	rs10129255	0.5	rs8021941	ENSG00000280411.1	IGHV1-69-2	-9.79	9.27e-21	1.71e-17	-0.28	-0.41	Kawasaki disease;	chr14:106781490	chr14:106762092~106762588:-
LUAD	cis	rs2188561	0.697	rs2237679	ENSG00000241764.3	AC002467.7	9.79	9.34e-21	1.72e-17	0.56	0.41	Alcohol consumption;	chr7:107693581	chr7:107742817~107744581:-
LUAD	cis	rs1061377	0.965	rs12511857	ENSG00000249207.1	RP11-360F5.1	-9.79	9.54e-21	1.76e-17	-0.47	-0.41	Uric acid levels;	chr4:39143252	chr4:39112677~39126818:-
LUAD	cis	rs67180937	0.7	rs12043288	ENSG00000272750.1	RP11-378J18.8	-9.79	9.54e-21	1.76e-17	-0.42	-0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222732952	chr1:222658867~222661512:-
LUAD	cis	rs11690935	0.959	rs76324055	ENSG00000228389.1	AC068039.4	9.79	9.59e-21	1.76e-17	0.49	0.41	Schizophrenia;	chr2:171763640	chr2:171773482~171775844:+
LUAD	cis	rs11690935	0.959	rs77280952	ENSG00000228389.1	AC068039.4	9.79	9.59e-21	1.76e-17	0.49	0.41	Schizophrenia;	chr2:171763641	chr2:171773482~171775844:+
LUAD	cis	rs11690935	0.959	rs75922913	ENSG00000228389.1	AC068039.4	9.79	9.59e-21	1.76e-17	0.49	0.41	Schizophrenia;	chr2:171763642	chr2:171773482~171775844:+
LUAD	cis	rs228614	0.51	rs223362	ENSG00000246560.2	RP11-10L12.4	9.79	9.62e-21	1.77e-17	0.5	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102848077	chr4:102828055~102844075:+
LUAD	cis	rs10129255	0.5	rs10131875	ENSG00000280411.1	IGHV1-69-2	-9.79	9.62e-21	1.77e-17	-0.28	-0.41	Kawasaki disease;	chr14:106792798	chr14:106762092~106762588:-
LUAD	cis	rs228614	0.51	rs223455	ENSG00000246560.2	RP11-10L12.4	9.78	9.7e-21	1.78e-17	0.5	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789026	chr4:102828055~102844075:+
LUAD	cis	rs5769707	0.837	rs5770599	ENSG00000188511.11	C22orf34	9.78	9.85e-21	1.81e-17	0.47	0.41	Monocyte percentage of white cells;Monocyte count;	chr22:49626333	chr22:49414524~49657542:-
LUAD	cis	rs228614	0.509	rs223480	ENSG00000246560.2	RP11-10L12.4	9.78	9.85e-21	1.81e-17	0.51	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766881	chr4:102828055~102844075:+
LUAD	cis	rs7104764	0.507	rs7121085	ENSG00000277290.1	RP11-326C3.16	-9.78	9.88e-21	1.82e-17	-0.46	-0.41	Menarche (age at onset);	chr11:258523	chr11:243099~243483:-
LUAD	cis	rs321358	0.895	rs73015175	ENSG00000271584.1	RP11-89C3.4	9.78	9.96e-21	1.83e-17	0.67	0.41	Body mass index;	chr11:111088593	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.895	rs17536143	ENSG00000271584.1	RP11-89C3.4	9.78	9.96e-21	1.83e-17	0.67	0.41	Body mass index;	chr11:111088619	chr11:111091932~111097357:-
LUAD	cis	rs2455601	0.786	rs3763914	ENSG00000254860.4	TMEM9B-AS1	9.78	9.97e-21	1.83e-17	0.57	0.41	Schizophrenia;	chr11:8919156	chr11:8964675~8977527:+
LUAD	cis	rs1155848	0.892	rs9565509	ENSG00000227354.5	RBM26-AS1	9.78	9.99e-21	1.84e-17	0.92	0.41	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79483696	chr13:79406309~79424328:+
LUAD	cis	rs2929278	0.638	rs2016840	ENSG00000205771.5	CATSPER2P1	9.78	1e-20	1.85e-17	0.49	0.41	Schizophrenia;	chr15:43919670	chr15:43726918~43747094:-
LUAD	cis	rs2455601	0.766	rs1109304	ENSG00000254860.4	TMEM9B-AS1	9.78	1.01e-20	1.85e-17	0.59	0.41	Schizophrenia;	chr11:8933908	chr11:8964675~8977527:+
LUAD	cis	rs977987	0.806	rs11862582	ENSG00000261783.1	RP11-252K23.2	-9.78	1.01e-20	1.85e-17	-0.54	-0.41	Dupuytren's disease;	chr16:75397397	chr16:75379818~75381260:-
LUAD	cis	rs73086581	0.568	rs6084541	ENSG00000229539.1	RP11-119B16.2	-9.78	1.03e-20	1.88e-17	-0.49	-0.41	Response to antidepressants in depression;	chr20:3982084	chr20:3888239~3888868:-
LUAD	cis	rs228614	0.51	rs223463	ENSG00000246560.2	RP11-10L12.4	9.78	1.03e-20	1.89e-17	0.5	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780620	chr4:102828055~102844075:+
LUAD	cis	rs4423214	0.879	rs1630498	ENSG00000254682.1	RP11-660L16.2	-9.78	1.03e-20	1.89e-17	-0.56	-0.41	Vitamin D levels;	chr11:71439739	chr11:71448674~71452157:+
LUAD	cis	rs7208859	0.623	rs3752019	ENSG00000263531.1	RP13-753N3.1	9.78	1.03e-20	1.9e-17	0.83	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824687	chr17:30863921~30864940:-
LUAD	cis	rs977987	0.843	rs10459859	ENSG00000261783.1	RP11-252K23.2	-9.78	1.04e-20	1.92e-17	-0.54	-0.41	Dupuytren's disease;	chr16:75348052	chr16:75379818~75381260:-
LUAD	cis	rs228614	0.51	rs223392	ENSG00000246560.2	RP11-10L12.4	9.77	1.05e-20	1.93e-17	0.5	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102824599	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.554	rs223390	ENSG00000246560.2	RP11-10L12.4	9.77	1.05e-20	1.93e-17	0.5	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102827640	chr4:102828055~102844075:+
LUAD	cis	rs62229266	0.609	rs12482541	ENSG00000231106.2	LINC01436	9.77	1.06e-20	1.94e-17	0.54	0.41	Mitral valve prolapse;	chr21:36047445	chr21:36005338~36007838:+
LUAD	cis	rs62229266	0.609	rs2835253	ENSG00000231106.2	LINC01436	9.77	1.06e-20	1.94e-17	0.54	0.41	Mitral valve prolapse;	chr21:36047447	chr21:36005338~36007838:+
LUAD	cis	rs16828019	0.852	rs3766324	ENSG00000235358.1	RP11-399E6.1	9.77	1.06e-20	1.94e-17	0.69	0.41	Intelligence (multi-trait analysis);	chr1:41122981	chr1:41242373~41284861:+
LUAD	cis	rs227275	0.554	rs223485	ENSG00000246560.2	RP11-10L12.4	9.77	1.07e-20	1.95e-17	0.5	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102764018	chr4:102828055~102844075:+
LUAD	cis	rs34779708	0.931	rs11010077	ENSG00000230534.5	RP11-297A16.2	-9.77	1.08e-20	1.98e-17	-0.47	-0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35039160	chr10:35098006~35127020:-
LUAD	cis	rs1823913	0.927	rs13013390	ENSG00000280083.1	RP11-317J9.1	-9.77	1.09e-20	2e-17	-0.49	-0.41	Obesity-related traits;	chr2:191262001	chr2:191154118~191156070:-
LUAD	cis	rs321358	0.895	rs17457076	ENSG00000271584.1	RP11-89C3.4	9.77	1.1e-20	2.01e-17	0.66	0.41	Body mass index;	chr11:111081030	chr11:111091932~111097357:-
LUAD	cis	rs10875746	0.859	rs4760622	ENSG00000240399.1	RP1-228P16.1	-9.77	1.1e-20	2.01e-17	-0.47	-0.41	Longevity (90 years and older);	chr12:48198177	chr12:48054813~48055591:-
LUAD	cis	rs4814920	0.818	rs6046403	ENSG00000275142.1	RP5-999L4.2	-9.77	1.11e-20	2.03e-17	-0.72	-0.41	Bipolar disorder (body mass index interaction);	chr20:19882329	chr20:19871891~19872284:+
LUAD	cis	rs6991838	0.584	rs14213	ENSG00000200714.1	Y_RNA	9.77	1.11e-20	2.04e-17	0.5	0.41	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65592731~65592820:+
LUAD	cis	rs944289	0.646	rs375095	ENSG00000257826.1	RP11-116N8.4	9.77	1.12e-20	2.05e-17	0.42	0.41	Thyroid cancer;	chr14:36066043	chr14:36061026~36067190:-
LUAD	cis	rs944289	0.646	rs394246	ENSG00000257826.1	RP11-116N8.4	9.77	1.12e-20	2.05e-17	0.42	0.41	Thyroid cancer;	chr14:36066074	chr14:36061026~36067190:-
LUAD	cis	rs1823913	0.892	rs35596292	ENSG00000280083.1	RP11-317J9.1	-9.77	1.12e-20	2.05e-17	-0.52	-0.41	Obesity-related traits;	chr2:191246890	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.927	rs35530564	ENSG00000280083.1	RP11-317J9.1	-9.77	1.12e-20	2.05e-17	-0.52	-0.41	Obesity-related traits;	chr2:191247324	chr2:191154118~191156070:-
LUAD	cis	rs11098499	0.955	rs1397608	ENSG00000245958.5	RP11-33B1.1	-9.77	1.12e-20	2.05e-17	-0.37	-0.41	Corneal astigmatism;	chr4:119240589	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.955	rs7685268	ENSG00000245958.5	RP11-33B1.1	-9.77	1.12e-20	2.05e-17	-0.37	-0.41	Corneal astigmatism;	chr4:119241033	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.955	rs7684942	ENSG00000245958.5	RP11-33B1.1	-9.77	1.12e-20	2.05e-17	-0.37	-0.41	Corneal astigmatism;	chr4:119241046	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.913	rs10010696	ENSG00000245958.5	RP11-33B1.1	-9.77	1.12e-20	2.06e-17	-0.37	-0.41	Corneal astigmatism;	chr4:119243148	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.863	rs7699064	ENSG00000245958.5	RP11-33B1.1	9.77	1.13e-20	2.07e-17	0.38	0.41	Corneal astigmatism;	chr4:119507154	chr4:119454791~119552025:+
LUAD	cis	rs321358	0.895	rs12419745	ENSG00000271584.1	RP11-89C3.4	9.77	1.13e-20	2.07e-17	0.67	0.41	Body mass index;	chr11:111090741	chr11:111091932~111097357:-
LUAD	cis	rs11098499	1	rs28374891	ENSG00000245958.5	RP11-33B1.1	-9.77	1.13e-20	2.07e-17	-0.37	-0.41	Corneal astigmatism;	chr4:119262395	chr4:119454791~119552025:+
LUAD	cis	rs977987	0.843	rs35737321	ENSG00000261783.1	RP11-252K23.2	-9.76	1.15e-20	2.11e-17	-0.54	-0.41	Dupuytren's disease;	chr16:75405287	chr16:75379818~75381260:-
LUAD	cis	rs7044106	0.734	rs12553070	ENSG00000226752.6	PSMD5-AS1	-9.76	1.16e-20	2.12e-17	-0.46	-0.41	Hip circumference adjusted for BMI;	chr9:120722988	chr9:120824828~120854385:+
LUAD	cis	rs4774565	0.762	rs720599	ENSG00000244879.4	GABPB1-AS1	-9.76	1.17e-20	2.14e-17	-0.37	-0.41	Breast cancer;	chr15:50372318	chr15:50354959~50372202:+
LUAD	cis	rs1823913	0.927	rs56209234	ENSG00000280083.1	RP11-317J9.1	-9.76	1.17e-20	2.14e-17	-0.52	-0.41	Obesity-related traits;	chr2:191261748	chr2:191154118~191156070:-
LUAD	cis	rs1757171	0.542	rs3818986	ENSG00000204110.6	RP1-153P14.8	-9.76	1.18e-20	2.16e-17	-0.42	-0.41	Cognitive performance;	chr6:37516573	chr6:37507348~37535616:+
LUAD	cis	rs6504950	0.72	rs9895901	ENSG00000275710.1	RP11-257O5.4	9.76	1.18e-20	2.16e-17	0.52	0.41	Breast cancer;	chr17:54907524	chr17:54964474~54964679:+
LUAD	cis	rs9326248	0.953	rs488962	ENSG00000280143.1	AP000892.6	-9.76	1.19e-20	2.17e-17	-0.48	-0.41	Blood protein levels;	chr11:117201809	chr11:117204967~117210292:+
LUAD	cis	rs228614	0.51	rs223397	ENSG00000246560.2	RP11-10L12.4	9.76	1.19e-20	2.18e-17	0.5	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102821494	chr4:102828055~102844075:+
LUAD	cis	rs8062405	0.755	rs4788080	ENSG00000259982.1	CDC37P1	9.76	1.19e-20	2.18e-17	0.51	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28700294~28701540:-
LUAD	cis	rs62229266	0.652	rs7280551	ENSG00000231106.2	LINC01436	9.76	1.2e-20	2.18e-17	0.54	0.41	Mitral valve prolapse;	chr21:36037311	chr21:36005338~36007838:+
LUAD	cis	rs367615	0.512	rs414724	ENSG00000249476.1	CTD-2587M2.1	9.76	1.2e-20	2.19e-17	0.48	0.41	Colorectal cancer (SNP x SNP interaction);	chr5:109334720	chr5:109237120~109326369:-
LUAD	cis	rs8062405	0.691	rs11646653	ENSG00000259982.1	CDC37P1	-9.76	1.2e-20	2.19e-17	-0.52	-0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.754	rs151179	ENSG00000259982.1	CDC37P1	9.76	1.2e-20	2.19e-17	0.52	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28700294~28701540:-
LUAD	cis	rs228614	0.51	rs223311	ENSG00000246560.2	RP11-10L12.4	9.76	1.21e-20	2.21e-17	0.5	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888757	chr4:102828055~102844075:+
LUAD	cis	rs16828019	0.852	rs11209531	ENSG00000235358.1	RP11-399E6.1	9.76	1.22e-20	2.23e-17	0.68	0.41	Intelligence (multi-trait analysis);	chr1:41105349	chr1:41242373~41284861:+
LUAD	cis	rs7429990	0.932	rs6766641	ENSG00000229759.1	MRPS18AP1	-9.76	1.22e-20	2.23e-17	-0.43	-0.41	Educational attainment (years of education);	chr3:48103734	chr3:48256350~48256938:-
LUAD	cis	rs227275	0.554	rs223339	ENSG00000246560.2	RP11-10L12.4	9.76	1.23e-20	2.24e-17	0.5	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102864700	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.554	rs223333	ENSG00000246560.2	RP11-10L12.4	9.76	1.23e-20	2.24e-17	0.5	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102868653	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.51	rs223328	ENSG00000246560.2	RP11-10L12.4	9.76	1.23e-20	2.24e-17	0.5	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873379	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.536	rs223325	ENSG00000246560.2	RP11-10L12.4	9.76	1.23e-20	2.24e-17	0.5	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102875751	chr4:102828055~102844075:+
LUAD	cis	rs1823913	0.927	rs35339956	ENSG00000280083.1	RP11-317J9.1	-9.75	1.24e-20	2.26e-17	-0.52	-0.41	Obesity-related traits;	chr2:191261668	chr2:191154118~191156070:-
LUAD	cis	rs748404	0.631	rs6493084	ENSG00000205771.5	CATSPER2P1	-9.75	1.25e-20	2.28e-17	-0.51	-0.41	Lung cancer;	chr15:43355429	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.631	rs12905772	ENSG00000205771.5	CATSPER2P1	-9.75	1.25e-20	2.28e-17	-0.51	-0.41	Lung cancer;	chr15:43356246	chr15:43726918~43747094:-
LUAD	cis	rs4423214	0.569	rs12806918	ENSG00000254682.1	RP11-660L16.2	9.75	1.26e-20	2.29e-17	0.5	0.41	Vitamin D levels;	chr11:71407972	chr11:71448674~71452157:+
LUAD	cis	rs6452524	1	rs6863300	ENSG00000249664.1	CTD-2227C6.2	9.75	1.26e-20	2.29e-17	0.46	0.41	Hypertension (SNP x SNP interaction);	chr5:83139629	chr5:83012285~83013109:-
LUAD	cis	rs904251	0.6	rs12211110	ENSG00000279942.1	RP1-153P14.7	-9.75	1.27e-20	2.32e-17	-0.38	-0.41	Cognitive performance;	chr6:37498456	chr6:37567716~37571460:+
LUAD	cis	rs9326248	1	rs664922	ENSG00000280143.1	AP000892.6	9.75	1.29e-20	2.35e-17	0.48	0.41	Blood protein levels;	chr11:117200179	chr11:117204967~117210292:+
LUAD	cis	rs9326248	1	rs664082	ENSG00000280143.1	AP000892.6	9.75	1.29e-20	2.35e-17	0.48	0.41	Blood protein levels;	chr11:117200354	chr11:117204967~117210292:+
LUAD	cis	rs11098499	0.863	rs1010740	ENSG00000245958.5	RP11-33B1.1	9.75	1.29e-20	2.36e-17	0.38	0.41	Corneal astigmatism;	chr4:119542254	chr4:119454791~119552025:+
LUAD	cis	rs9918079	0.56	rs7685083	ENSG00000273133.1	RP11-799M12.2	9.75	1.29e-20	2.36e-17	0.56	0.41	Obesity-related traits;	chr4:15609148	chr4:15563698~15564253:-
LUAD	cis	rs10875746	0.859	rs12305511	ENSG00000240399.1	RP1-228P16.1	9.75	1.31e-20	2.38e-17	0.47	0.41	Longevity (90 years and older);	chr12:48188933	chr12:48054813~48055591:-
LUAD	cis	rs11098499	0.82	rs28394116	ENSG00000245958.5	RP11-33B1.1	-9.75	1.31e-20	2.39e-17	-0.38	-0.41	Corneal astigmatism;	chr4:119603128	chr4:119454791~119552025:+
LUAD	cis	rs10129255	0.5	rs1024350	ENSG00000280411.1	IGHV1-69-2	-9.75	1.32e-20	2.4e-17	-0.28	-0.41	Kawasaki disease;	chr14:106685105	chr14:106762092~106762588:-
LUAD	cis	rs7044106	0.791	rs12554440	ENSG00000226752.6	PSMD5-AS1	-9.75	1.32e-20	2.4e-17	-0.46	-0.41	Hip circumference adjusted for BMI;	chr9:120723055	chr9:120824828~120854385:+
LUAD	cis	rs904251	0.6	rs9380673	ENSG00000279942.1	RP1-153P14.7	-9.75	1.32e-20	2.41e-17	-0.38	-0.41	Cognitive performance;	chr6:37447349	chr6:37567716~37571460:+
LUAD	cis	rs172166	0.516	rs1225710	ENSG00000216901.1	AL022393.7	-9.75	1.33e-20	2.42e-17	-0.47	-0.41	Cardiac Troponin-T levels;	chr6:28132862	chr6:28176188~28176674:+
LUAD	cis	rs7044106	0.791	rs10984997	ENSG00000226752.6	PSMD5-AS1	-9.75	1.33e-20	2.42e-17	-0.46	-0.41	Hip circumference adjusted for BMI;	chr9:120718928	chr9:120824828~120854385:+
LUAD	cis	rs6452524	1	rs7716962	ENSG00000249664.1	CTD-2227C6.2	9.74	1.36e-20	2.47e-17	0.46	0.41	Hypertension (SNP x SNP interaction);	chr5:83138913	chr5:83012285~83013109:-
LUAD	cis	rs11098499	0.78	rs7680914	ENSG00000245958.5	RP11-33B1.1	-9.74	1.36e-20	2.47e-17	-0.38	-0.41	Corneal astigmatism;	chr4:119641898	chr4:119454791~119552025:+
LUAD	cis	rs8062405	0.755	rs4787456	ENSG00000259982.1	CDC37P1	9.74	1.36e-20	2.48e-17	0.51	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.755	rs4788078	ENSG00000259982.1	CDC37P1	9.74	1.36e-20	2.48e-17	0.51	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28700294~28701540:-
LUAD	cis	rs62229266	0.633	rs34259635	ENSG00000231106.2	LINC01436	9.74	1.37e-20	2.5e-17	0.55	0.41	Mitral valve prolapse;	chr21:36031272	chr21:36005338~36007838:+
LUAD	cis	rs7044106	0.762	rs1411158	ENSG00000226752.6	PSMD5-AS1	-9.74	1.38e-20	2.5e-17	-0.44	-0.41	Hip circumference adjusted for BMI;	chr9:120702526	chr9:120824828~120854385:+
LUAD	cis	rs34779708	0.931	rs17591135	ENSG00000230534.5	RP11-297A16.2	9.74	1.39e-20	2.52e-17	0.5	0.41	Inflammatory bowel disease;Crohn's disease;	chr10:35176262	chr10:35098006~35127020:-
LUAD	cis	rs7044106	0.791	rs2416797	ENSG00000226752.6	PSMD5-AS1	-9.74	1.41e-20	2.55e-17	-0.46	-0.41	Hip circumference adjusted for BMI;	chr9:120718322	chr9:120824828~120854385:+
LUAD	cis	rs7044106	0.791	rs2416798	ENSG00000226752.6	PSMD5-AS1	-9.74	1.41e-20	2.55e-17	-0.46	-0.41	Hip circumference adjusted for BMI;	chr9:120718325	chr9:120824828~120854385:+
LUAD	cis	rs2564921	0.73	rs56386026	ENSG00000242142.1	SERBP1P3	-9.74	1.41e-20	2.55e-17	-0.45	-0.41	Height;	chr3:53080524	chr3:53064283~53065091:-
LUAD	cis	rs2108622	0.559	rs7252638	ENSG00000267453.5	AC004791.2	-9.74	1.42e-20	2.58e-17	-0.49	-0.41	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870215	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.727	rs7253684	ENSG00000267453.5	AC004791.2	-9.74	1.42e-20	2.58e-17	-0.49	-0.41	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870316	chr19:15851993~15864904:-
LUAD	cis	rs11722779	0.903	rs6830193	ENSG00000246560.2	RP11-10L12.4	9.74	1.42e-20	2.58e-17	0.5	0.41	Schizophrenia;	chr4:102955457	chr4:102828055~102844075:+
LUAD	cis	rs11722779	0.935	rs6533046	ENSG00000246560.2	RP11-10L12.4	9.74	1.42e-20	2.58e-17	0.5	0.41	Schizophrenia;	chr4:102965917	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.556	rs12508069	ENSG00000246560.2	RP11-10L12.4	9.74	1.43e-20	2.6e-17	0.5	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102983598	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.556	rs9999303	ENSG00000246560.2	RP11-10L12.4	9.74	1.44e-20	2.6e-17	0.5	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102986881	chr4:102828055~102844075:+
LUAD	cis	rs6452524	1	rs10080123	ENSG00000249664.1	CTD-2227C6.2	-9.74	1.45e-20	2.63e-17	-0.46	-0.41	Hypertension (SNP x SNP interaction);	chr5:83165447	chr5:83012285~83013109:-
LUAD	cis	rs73086581	0.524	rs2253977	ENSG00000229539.1	RP11-119B16.2	-9.73	1.46e-20	2.65e-17	-0.48	-0.41	Response to antidepressants in depression;	chr20:3958493	chr20:3888239~3888868:-
LUAD	cis	rs748404	0.631	rs11070399	ENSG00000205771.5	CATSPER2P1	-9.73	1.46e-20	2.65e-17	-0.51	-0.41	Lung cancer;	chr15:43354149	chr15:43726918~43747094:-
LUAD	cis	rs228614	0.509	rs223486	ENSG00000246560.2	RP11-10L12.4	9.73	1.46e-20	2.65e-17	0.5	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102763796	chr4:102828055~102844075:+
LUAD	cis	rs1891275	0.515	rs4244930	ENSG00000228701.1	TNKS2-AS1	-9.73	1.48e-20	2.68e-17	-0.5	-0.41	Intelligence (multi-trait analysis);	chr10:91707092	chr10:91782839~91798291:-
LUAD	cis	rs62229266	0.625	rs62230813	ENSG00000231106.2	LINC01436	9.73	1.48e-20	2.68e-17	0.55	0.41	Mitral valve prolapse;	chr21:36031134	chr21:36005338~36007838:+
LUAD	cis	rs11098499	0.866	rs3756156	ENSG00000245958.5	RP11-33B1.1	-9.73	1.49e-20	2.7e-17	-0.38	-0.41	Corneal astigmatism;	chr4:119603686	chr4:119454791~119552025:+
LUAD	cis	rs227275	0.527	rs12500379	ENSG00000246560.2	RP11-10L12.4	9.73	1.49e-20	2.71e-17	0.51	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102983665	chr4:102828055~102844075:+
LUAD	cis	rs1891275	0.515	rs7092884	ENSG00000228701.1	TNKS2-AS1	9.73	1.49e-20	2.71e-17	0.49	0.41	Intelligence (multi-trait analysis);	chr10:91724115	chr10:91782839~91798291:-
LUAD	cis	rs227275	0.556	rs223449	ENSG00000246560.2	RP11-10L12.4	9.73	1.5e-20	2.71e-17	0.5	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102791180	chr4:102828055~102844075:+
LUAD	cis	rs10256972	0.758	rs2280724	ENSG00000229043.2	AC091729.9	-9.73	1.51e-20	2.73e-17	-0.44	-0.41	Endometriosis;Longevity;	chr7:1025084	chr7:1160374~1165267:+
LUAD	cis	rs7044106	0.762	rs1886337	ENSG00000226752.6	PSMD5-AS1	-9.73	1.51e-20	2.73e-17	-0.44	-0.41	Hip circumference adjusted for BMI;	chr9:120681498	chr9:120824828~120854385:+
LUAD	cis	rs227275	0.554	rs223382	ENSG00000246560.2	RP11-10L12.4	9.73	1.51e-20	2.74e-17	0.5	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102831145	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.51	rs223377	ENSG00000246560.2	RP11-10L12.4	9.73	1.51e-20	2.74e-17	0.5	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102834919	chr4:102828055~102844075:+
LUAD	cis	rs7044106	0.762	rs13291660	ENSG00000226752.6	PSMD5-AS1	-9.73	1.51e-20	2.74e-17	-0.44	-0.41	Hip circumference adjusted for BMI;	chr9:120630470	chr9:120824828~120854385:+
LUAD	cis	rs7044106	0.718	rs1981021	ENSG00000226752.6	PSMD5-AS1	-9.73	1.51e-20	2.74e-17	-0.44	-0.41	Hip circumference adjusted for BMI;	chr9:120626115	chr9:120824828~120854385:+
LUAD	cis	rs7044106	0.734	rs1981020	ENSG00000226752.6	PSMD5-AS1	-9.73	1.51e-20	2.74e-17	-0.44	-0.41	Hip circumference adjusted for BMI;	chr9:120626186	chr9:120824828~120854385:+
LUAD	cis	rs7044106	0.708	rs920745	ENSG00000226752.6	PSMD5-AS1	-9.73	1.51e-20	2.74e-17	-0.44	-0.41	Hip circumference adjusted for BMI;	chr9:120667665	chr9:120824828~120854385:+
LUAD	cis	rs7044106	0.734	rs10491784	ENSG00000226752.6	PSMD5-AS1	-9.73	1.51e-20	2.74e-17	-0.44	-0.41	Hip circumference adjusted for BMI;	chr9:120670011	chr9:120824828~120854385:+
LUAD	cis	rs11098499	1	rs12506395	ENSG00000245958.5	RP11-33B1.1	-9.73	1.52e-20	2.75e-17	-0.37	-0.41	Corneal astigmatism;	chr4:119263939	chr4:119454791~119552025:+
LUAD	cis	rs228614	0.51	rs223446	ENSG00000246560.2	RP11-10L12.4	9.73	1.54e-20	2.78e-17	0.5	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793025	chr4:102828055~102844075:+
LUAD	cis	rs8062405	0.755	rs4787457	ENSG00000259982.1	CDC37P1	9.73	1.54e-20	2.79e-17	0.51	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28700294~28701540:-
LUAD	cis	rs227275	0.556	rs28367331	ENSG00000246560.2	RP11-10L12.4	9.73	1.55e-20	2.8e-17	0.5	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102900734	chr4:102828055~102844075:+
LUAD	cis	rs10129255	0.536	rs17113249	ENSG00000280411.1	IGHV1-69-2	-9.73	1.55e-20	2.8e-17	-0.28	-0.41	Kawasaki disease;	chr14:106678273	chr14:106762092~106762588:-
LUAD	cis	rs228614	0.51	rs3774987	ENSG00000246560.2	RP11-10L12.4	9.73	1.55e-20	2.8e-17	0.5	0.41	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799709	chr4:102828055~102844075:+
LUAD	cis	rs11098499	1	rs11098500	ENSG00000245958.5	RP11-33B1.1	-9.73	1.55e-20	2.8e-17	-0.37	-0.41	Corneal astigmatism;	chr4:119298084	chr4:119454791~119552025:+
LUAD	cis	rs2581828	0.965	rs4337632	ENSG00000242142.1	SERBP1P3	9.73	1.56e-20	2.82e-17	0.42	0.41	Crohn's disease;	chr3:53103295	chr3:53064283~53065091:-
LUAD	cis	rs10129255	0.518	rs7143784	ENSG00000280411.1	IGHV1-69-2	-9.73	1.56e-20	2.82e-17	-0.28	-0.41	Kawasaki disease;	chr14:106687277	chr14:106762092~106762588:-
LUAD	cis	rs8062405	0.755	rs62034350	ENSG00000259982.1	CDC37P1	9.73	1.57e-20	2.84e-17	0.51	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28700294~28701540:-
LUAD	cis	rs11098499	0.955	rs11944880	ENSG00000245958.5	RP11-33B1.1	9.73	1.58e-20	2.85e-17	0.36	0.41	Corneal astigmatism;	chr4:119238179	chr4:119454791~119552025:+
LUAD	cis	rs10875746	0.859	rs12305647	ENSG00000240399.1	RP1-228P16.1	-9.73	1.58e-20	2.85e-17	-0.48	-0.41	Longevity (90 years and older);	chr12:48189178	chr12:48054813~48055591:-
LUAD	cis	rs11722779	0.869	rs223323	ENSG00000246560.2	RP11-10L12.4	9.72	1.58e-20	2.86e-17	0.5	0.41	Schizophrenia;	chr4:102878412	chr4:102828055~102844075:+
LUAD	cis	rs11098499	0.866	rs6847778	ENSG00000245958.5	RP11-33B1.1	-9.72	1.61e-20	2.9e-17	-0.36	-0.41	Corneal astigmatism;	chr4:119372427	chr4:119454791~119552025:+
LUAD	cis	rs507080	0.501	rs625735	ENSG00000255422.1	AP002954.4	-9.72	1.63e-20	2.94e-17	-0.49	-0.41	Serum metabolite levels;	chr11:118704710	chr11:118704607~118750263:+
LUAD	cis	rs11098499	0.78	rs12504773	ENSG00000245958.5	RP11-33B1.1	-9.72	1.63e-20	2.94e-17	-0.38	-0.41	Corneal astigmatism;	chr4:119640994	chr4:119454791~119552025:+
LUAD	cis	rs2729354	1	rs2649662	ENSG00000265566.2	RN7SL605P	9.72	1.63e-20	2.95e-17	0.6	0.41	Blood protein levels;	chr11:57585089	chr11:57528085~57528365:-
LUAD	cis	rs694739	0.628	rs645078	ENSG00000236935.1	AP003774.1	9.72	1.64e-20	2.96e-17	0.39	0.41	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64367826	chr11:64325050~64329504:-
LUAD	cis	rs4423214	0.879	rs10898144	ENSG00000254682.1	RP11-660L16.2	-9.72	1.66e-20	2.99e-17	-0.57	-0.41	Vitamin D levels;	chr11:71440494	chr11:71448674~71452157:+
LUAD	cis	rs2455601	0.786	rs3751064	ENSG00000254860.4	TMEM9B-AS1	9.72	1.67e-20	3.01e-17	0.58	0.41	Schizophrenia;	chr11:8937356	chr11:8964675~8977527:+
LUAD	cis	rs9326248	0.817	rs6589598	ENSG00000280143.1	AP000892.6	9.72	1.68e-20	3.03e-17	0.51	0.41	Blood protein levels;	chr11:117131687	chr11:117204967~117210292:+
LUAD	cis	rs227275	0.554	rs223381	ENSG00000246560.2	RP11-10L12.4	9.72	1.71e-20	3.07e-17	0.5	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102832578	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.554	rs223357	ENSG00000246560.2	RP11-10L12.4	9.71	1.72e-20	3.1e-17	0.5	0.41	Allergic disease (asthma, hay fever or eczema);	chr4:102851095	chr4:102828055~102844075:+
LUAD	cis	rs10170846	1	rs10170846	ENSG00000261428.2	RP11-16P6.1	-9.71	1.72e-20	3.1e-17	-0.5	-0.41	Schizophrenia (inflammation and infection response interaction);	chr2:222652986	chr2:222566899~222569719:-
LUAD	cis	rs62229266	0.659	rs2255734	ENSG00000231106.2	LINC01436	9.71	1.72e-20	3.1e-17	0.54	0.4	Mitral valve prolapse;	chr21:36039611	chr21:36005338~36007838:+
LUAD	cis	rs62229266	0.659	rs2835242	ENSG00000231106.2	LINC01436	9.71	1.72e-20	3.1e-17	0.54	0.4	Mitral valve prolapse;	chr21:36041234	chr21:36005338~36007838:+
LUAD	cis	rs62229266	0.659	rs2835243	ENSG00000231106.2	LINC01436	9.71	1.72e-20	3.1e-17	0.54	0.4	Mitral valve prolapse;	chr21:36041648	chr21:36005338~36007838:+
LUAD	cis	rs4423214	0.61	rs12789253	ENSG00000254682.1	RP11-660L16.2	9.71	1.77e-20	3.18e-17	0.5	0.4	Vitamin D levels;	chr11:71414719	chr11:71448674~71452157:+
LUAD	cis	rs10875746	0.859	rs4760695	ENSG00000240399.1	RP1-228P16.1	-9.71	1.77e-20	3.19e-17	-0.48	-0.4	Longevity (90 years and older);	chr12:48198065	chr12:48054813~48055591:-
LUAD	cis	rs11098499	0.913	rs11098496	ENSG00000245958.5	RP11-33B1.1	-9.71	1.77e-20	3.19e-17	-0.37	-0.4	Corneal astigmatism;	chr4:119246311	chr4:119454791~119552025:+
LUAD	cis	rs62388641	0.539	rs56304710	ENSG00000272279.1	RP11-157J24.2	9.71	1.78e-20	3.19e-17	0.51	0.4	Daytime sleep phenotypes;	chr6:1542341	chr6:1528364~1528911:-
LUAD	cis	rs228614	0.51	rs223438	ENSG00000246560.2	RP11-10L12.4	-9.71	1.78e-20	3.19e-17	-0.5	-0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798584	chr4:102828055~102844075:+
LUAD	cis	rs5760092	0.618	rs5996631	ENSG00000231271.1	AP000350.8	-9.71	1.78e-20	3.2e-17	-0.55	-0.4	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23949918~23954042:+
LUAD	cis	rs7208859	0.673	rs12949860	ENSG00000263531.1	RP13-753N3.1	9.71	1.81e-20	3.25e-17	0.8	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896014	chr17:30863921~30864940:-
LUAD	cis	rs944289	0.646	rs367883	ENSG00000257826.1	RP11-116N8.4	9.71	1.83e-20	3.29e-17	0.42	0.4	Thyroid cancer;	chr14:36063400	chr14:36061026~36067190:-
LUAD	cis	rs944289	0.646	rs368181	ENSG00000257826.1	RP11-116N8.4	9.71	1.83e-20	3.29e-17	0.42	0.4	Thyroid cancer;	chr14:36065621	chr14:36061026~36067190:-
LUAD	cis	rs6452524	0.935	rs10043698	ENSG00000249664.1	CTD-2227C6.2	9.71	1.84e-20	3.3e-17	0.47	0.4	Hypertension (SNP x SNP interaction);	chr5:83169100	chr5:83012285~83013109:-
LUAD	cis	rs904251	0.523	rs10807184	ENSG00000204110.6	RP1-153P14.8	-9.71	1.86e-20	3.33e-17	-0.41	-0.4	Cognitive performance;	chr6:37515937	chr6:37507348~37535616:+
LUAD	cis	rs62229266	0.659	rs2026259	ENSG00000231106.2	LINC01436	9.71	1.86e-20	3.34e-17	0.53	0.4	Mitral valve prolapse;	chr21:36058329	chr21:36005338~36007838:+
LUAD	cis	rs7044106	0.762	rs10760107	ENSG00000226752.6	PSMD5-AS1	-9.7	1.88e-20	3.37e-17	-0.44	-0.4	Hip circumference adjusted for BMI;	chr9:120621352	chr9:120824828~120854385:+
LUAD	cis	rs10129255	0.5	rs11627315	ENSG00000280411.1	IGHV1-69-2	-9.7	1.88e-20	3.38e-17	-0.28	-0.4	Kawasaki disease;	chr14:106802182	chr14:106762092~106762588:-
LUAD	cis	rs7044106	0.791	rs10985000	ENSG00000226752.6	PSMD5-AS1	-9.7	1.89e-20	3.39e-17	-0.45	-0.4	Hip circumference adjusted for BMI;	chr9:120721837	chr9:120824828~120854385:+
LUAD	cis	rs1891275	0.515	rs7092745	ENSG00000228701.1	TNKS2-AS1	-9.7	1.9e-20	3.42e-17	-0.49	-0.4	Intelligence (multi-trait analysis);	chr10:91724063	chr10:91782839~91798291:-
LUAD	cis	rs7208859	0.673	rs11656462	ENSG00000263531.1	RP13-753N3.1	9.7	1.93e-20	3.47e-17	0.79	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30833682	chr17:30863921~30864940:-
LUAD	cis	rs321358	0.79	rs73015129	ENSG00000271584.1	RP11-89C3.4	9.7	1.94e-20	3.47e-17	0.67	0.4	Body mass index;	chr11:111076157	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.79	rs73015134	ENSG00000271584.1	RP11-89C3.4	9.7	1.94e-20	3.47e-17	0.67	0.4	Body mass index;	chr11:111076520	chr11:111091932~111097357:-
LUAD	cis	rs10256972	0.732	rs12701856	ENSG00000229043.2	AC091729.9	-9.7	1.94e-20	3.48e-17	-0.44	-0.4	Endometriosis;Longevity;	chr7:1068071	chr7:1160374~1165267:+
LUAD	cis	rs227275	0.554	rs223395	ENSG00000246560.2	RP11-10L12.4	9.7	1.98e-20	3.54e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102823801	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.554	rs223388	ENSG00000246560.2	RP11-10L12.4	9.7	1.98e-20	3.54e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102828287	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.554	rs223386	ENSG00000246560.2	RP11-10L12.4	9.7	1.98e-20	3.54e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102829111	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.554	rs223385	ENSG00000246560.2	RP11-10L12.4	9.7	1.98e-20	3.54e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102829159	chr4:102828055~102844075:+
LUAD	cis	rs11722779	0.873	rs223384	ENSG00000246560.2	RP11-10L12.4	9.7	1.98e-20	3.54e-17	0.5	0.4	Schizophrenia;	chr4:102829976	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.554	rs223383	ENSG00000246560.2	RP11-10L12.4	9.7	1.98e-20	3.54e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102830094	chr4:102828055~102844075:+
LUAD	cis	rs4423214	0.569	rs4944044	ENSG00000254682.1	RP11-660L16.2	9.7	1.98e-20	3.55e-17	0.49	0.4	Vitamin D levels;	chr11:71409167	chr11:71448674~71452157:+
LUAD	cis	rs7044106	0.762	rs12003646	ENSG00000226752.6	PSMD5-AS1	-9.7	1.98e-20	3.55e-17	-0.45	-0.4	Hip circumference adjusted for BMI;	chr9:120708343	chr9:120824828~120854385:+
LUAD	cis	rs9322193	0.607	rs6557165	ENSG00000231760.4	RP11-350J20.5	-9.7	1.99e-20	3.56e-17	-0.59	-0.4	Lung cancer;	chr6:149906883	chr6:149796151~149826294:-
LUAD	cis	rs7208859	0.673	rs11650305	ENSG00000263531.1	RP13-753N3.1	9.7	2e-20	3.59e-17	0.8	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902343	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs11654914	ENSG00000263531.1	RP13-753N3.1	9.7	2e-20	3.59e-17	0.8	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902406	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs9914271	ENSG00000263531.1	RP13-753N3.1	9.7	2e-20	3.59e-17	0.8	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905607	chr17:30863921~30864940:-
LUAD	cis	rs3931020	0.72	rs927904	ENSG00000272864.1	RP11-17E13.2	-9.7	2e-20	3.59e-17	-0.51	-0.4	Resistin levels;	chr1:74794644	chr1:74698769~74699333:-
LUAD	cis	rs7208859	0.623	rs73263788	ENSG00000263531.1	RP13-753N3.1	9.7	2.01e-20	3.59e-17	0.8	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889472	chr17:30863921~30864940:-
LUAD	cis	rs1891275	0.509	rs34190234	ENSG00000228701.1	TNKS2-AS1	-9.69	2.03e-20	3.62e-17	-0.51	-0.4	Intelligence (multi-trait analysis);	chr10:91683317	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.509	rs76313529	ENSG00000228701.1	TNKS2-AS1	-9.69	2.03e-20	3.62e-17	-0.51	-0.4	Intelligence (multi-trait analysis);	chr10:91683319	chr10:91782839~91798291:-
LUAD	cis	rs10256972	0.758	rs4723649	ENSG00000229043.2	AC091729.9	-9.69	2.05e-20	3.66e-17	-0.44	-0.4	Endometriosis;Longevity;	chr7:1032269	chr7:1160374~1165267:+
LUAD	cis	rs62229266	0.659	rs2835245	ENSG00000231106.2	LINC01436	9.69	2.05e-20	3.66e-17	0.54	0.4	Mitral valve prolapse;	chr21:36044410	chr21:36005338~36007838:+
LUAD	cis	rs6142102	0.625	rs1883707	ENSG00000276073.1	RP5-1125A11.7	9.69	2.1e-20	3.74e-17	0.41	0.4	Skin pigmentation;	chr20:33964781	chr20:33985617~33988989:-
LUAD	cis	rs10129255	0.5	rs2027903	ENSG00000280411.1	IGHV1-69-2	-9.69	2.1e-20	3.75e-17	-0.28	-0.4	Kawasaki disease;	chr14:106807047	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.518	rs28378320	ENSG00000280411.1	IGHV1-69-2	-9.69	2.1e-20	3.75e-17	-0.28	-0.4	Kawasaki disease;	chr14:106808609	chr14:106762092~106762588:-
LUAD	cis	rs62229266	0.659	rs2835258	ENSG00000231106.2	LINC01436	9.69	2.1e-20	3.75e-17	0.54	0.4	Mitral valve prolapse;	chr21:36052067	chr21:36005338~36007838:+
LUAD	cis	rs7044106	0.791	rs10985001	ENSG00000226752.6	PSMD5-AS1	-9.69	2.11e-20	3.77e-17	-0.45	-0.4	Hip circumference adjusted for BMI;	chr9:120721954	chr9:120824828~120854385:+
LUAD	cis	rs2564921	0.704	rs12053904	ENSG00000242142.1	SERBP1P3	-9.69	2.15e-20	3.83e-17	-0.45	-0.4	Height;	chr3:52991821	chr3:53064283~53065091:-
LUAD	cis	rs2108622	0.727	rs62106155	ENSG00000267453.5	AC004791.2	-9.69	2.18e-20	3.88e-17	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869550	chr19:15851993~15864904:-
LUAD	cis	rs6452524	0.87	rs6452511	ENSG00000249664.1	CTD-2227C6.2	9.69	2.19e-20	3.89e-17	0.48	0.4	Hypertension (SNP x SNP interaction);	chr5:83127403	chr5:83012285~83013109:-
LUAD	cis	rs228614	0.534	rs223387	ENSG00000246560.2	RP11-10L12.4	9.69	2.19e-20	3.9e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102828359	chr4:102828055~102844075:+
LUAD	cis	rs8062405	0.722	rs3785354	ENSG00000259982.1	CDC37P1	9.69	2.19e-20	3.9e-17	0.51	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28700294~28701540:-
LUAD	cis	rs2108622	0.727	rs62106157	ENSG00000267453.5	AC004791.2	-9.69	2.19e-20	3.9e-17	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869638	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.727	rs62106158	ENSG00000267453.5	AC004791.2	-9.69	2.19e-20	3.9e-17	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869682	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.727	rs7256877	ENSG00000267453.5	AC004791.2	-9.69	2.19e-20	3.9e-17	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869873	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.727	rs7253873	ENSG00000267453.5	AC004791.2	-9.69	2.19e-20	3.9e-17	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870090	chr19:15851993~15864904:-
LUAD	cis	rs8040855	0.965	rs4843027	ENSG00000259295.5	CSPG4P12	-9.69	2.19e-20	3.91e-17	-0.48	-0.4	Bulimia nervosa;	chr15:85171892	chr15:85191438~85213905:+
LUAD	cis	rs4423214	0.879	rs1790330	ENSG00000254682.1	RP11-660L16.2	-9.68	2.21e-20	3.94e-17	-0.57	-0.4	Vitamin D levels;	chr11:71436779	chr11:71448674~71452157:+
LUAD	cis	rs4423214	0.84	rs1790328	ENSG00000254682.1	RP11-660L16.2	-9.68	2.21e-20	3.94e-17	-0.57	-0.4	Vitamin D levels;	chr11:71436992	chr11:71448674~71452157:+
LUAD	cis	rs7208859	0.614	rs9914534	ENSG00000263531.1	RP13-753N3.1	9.68	2.22e-20	3.95e-17	0.8	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30875646	chr17:30863921~30864940:-
LUAD	cis	rs9918079	0.56	rs4698409	ENSG00000273133.1	RP11-799M12.2	-9.68	2.22e-20	3.95e-17	-0.56	-0.4	Obesity-related traits;	chr4:15658143	chr4:15563698~15564253:-
LUAD	cis	rs7208859	0.673	rs9896095	ENSG00000263531.1	RP13-753N3.1	9.68	2.22e-20	3.95e-17	0.8	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30860479	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.573	rs58920731	ENSG00000263531.1	RP13-753N3.1	9.68	2.22e-20	3.95e-17	0.8	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864728	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs73277984	ENSG00000263531.1	RP13-753N3.1	9.68	2.22e-20	3.95e-17	0.8	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869115	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs73277986	ENSG00000263531.1	RP13-753N3.1	9.68	2.22e-20	3.95e-17	0.8	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869179	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs12103588	ENSG00000263531.1	RP13-753N3.1	9.68	2.22e-20	3.95e-17	0.8	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30870442	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs4131618	ENSG00000263531.1	RP13-753N3.1	9.68	2.22e-20	3.95e-17	0.8	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30877783	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs11658344	ENSG00000263531.1	RP13-753N3.1	9.68	2.22e-20	3.95e-17	0.8	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30880727	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs9900144	ENSG00000263531.1	RP13-753N3.1	9.68	2.22e-20	3.95e-17	0.8	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881371	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.573	rs11656121	ENSG00000263531.1	RP13-753N3.1	9.68	2.22e-20	3.95e-17	0.8	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887025	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs11650973	ENSG00000263531.1	RP13-753N3.1	9.68	2.22e-20	3.95e-17	0.8	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887027	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs56085216	ENSG00000263531.1	RP13-753N3.1	9.68	2.22e-20	3.95e-17	0.8	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30890216	chr17:30863921~30864940:-
LUAD	cis	rs9918079	0.506	rs10214	ENSG00000273133.1	RP11-799M12.2	9.68	2.23e-20	3.97e-17	0.56	0.4	Obesity-related traits;	chr4:15604808	chr4:15563698~15564253:-
LUAD	cis	rs7044106	0.762	rs3903886	ENSG00000226752.6	PSMD5-AS1	9.68	2.23e-20	3.97e-17	0.43	0.4	Hip circumference adjusted for BMI;	chr9:120621368	chr9:120824828~120854385:+
LUAD	cis	rs16828019	0.852	rs3904243	ENSG00000235358.1	RP11-399E6.1	9.68	2.24e-20	3.97e-17	0.68	0.4	Intelligence (multi-trait analysis);	chr1:41109180	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.852	rs11209545	ENSG00000235358.1	RP11-399E6.1	9.68	2.24e-20	3.97e-17	0.68	0.4	Intelligence (multi-trait analysis);	chr1:41110685	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.852	rs11209576	ENSG00000235358.1	RP11-399E6.1	9.68	2.24e-20	3.97e-17	0.68	0.4	Intelligence (multi-trait analysis);	chr1:41120357	chr1:41242373~41284861:+
LUAD	cis	rs16828019	0.777	rs12023079	ENSG00000235358.1	RP11-399E6.1	9.68	2.26e-20	4.01e-17	0.7	0.4	Intelligence (multi-trait analysis);	chr1:41004439	chr1:41242373~41284861:+
LUAD	cis	rs62388641	0.547	rs2745610	ENSG00000272279.1	RP11-157J24.2	-9.68	2.26e-20	4.02e-17	-0.52	-0.4	Daytime sleep phenotypes;	chr6:1553741	chr6:1528364~1528911:-
LUAD	cis	rs7044106	0.762	rs1867254	ENSG00000226752.6	PSMD5-AS1	-9.68	2.27e-20	4.03e-17	-0.45	-0.4	Hip circumference adjusted for BMI;	chr9:120666800	chr9:120824828~120854385:+
LUAD	cis	rs6452524	0.868	rs2386235	ENSG00000249664.1	CTD-2227C6.2	9.68	2.27e-20	4.03e-17	0.48	0.4	Hypertension (SNP x SNP interaction);	chr5:83101452	chr5:83012285~83013109:-
LUAD	cis	rs6504950	0.72	rs2877634	ENSG00000275710.1	RP11-257O5.4	9.68	2.27e-20	4.03e-17	0.5	0.4	Breast cancer;	chr17:54910184	chr17:54964474~54964679:+
LUAD	cis	rs11098499	0.687	rs71610270	ENSG00000245958.5	RP11-33B1.1	-9.68	2.28e-20	4.05e-17	-0.36	-0.4	Corneal astigmatism;	chr4:119366281	chr4:119454791~119552025:+
LUAD	cis	rs9918079	0.56	rs7438356	ENSG00000273133.1	RP11-799M12.2	-9.68	2.29e-20	4.06e-17	-0.55	-0.4	Obesity-related traits;	chr4:15623147	chr4:15563698~15564253:-
LUAD	cis	rs944289	0.646	rs1742868	ENSG00000257826.1	RP11-116N8.4	-9.68	2.29e-20	4.07e-17	-0.42	-0.4	Thyroid cancer;	chr14:36067743	chr14:36061026~36067190:-
LUAD	cis	rs7044106	0.762	rs10818471	ENSG00000226752.6	PSMD5-AS1	-9.68	2.3e-20	4.08e-17	-0.44	-0.4	Hip circumference adjusted for BMI;	chr9:120631767	chr9:120824828~120854385:+
LUAD	cis	rs9660180	0.967	rs6603803	ENSG00000231050.1	RP1-140A9.1	9.68	2.3e-20	4.08e-17	0.45	0.4	Body mass index;	chr1:1881249	chr1:1891471~1892658:+
LUAD	cis	rs11155671	0.546	rs1999633	ENSG00000231760.4	RP11-350J20.5	9.68	2.3e-20	4.09e-17	0.59	0.4	Testicular germ cell tumor;	chr6:149866576	chr6:149796151~149826294:-
LUAD	cis	rs10256972	0.732	rs1574108	ENSG00000229043.2	AC091729.9	-9.68	2.32e-20	4.11e-17	-0.44	-0.4	Endometriosis;Longevity;	chr7:1066169	chr7:1160374~1165267:+
LUAD	cis	rs6452524	0.901	rs12188673	ENSG00000249664.1	CTD-2227C6.2	9.68	2.34e-20	4.14e-17	0.48	0.4	Hypertension (SNP x SNP interaction);	chr5:83126268	chr5:83012285~83013109:-
LUAD	cis	rs34779708	0.931	rs7079498	ENSG00000230534.5	RP11-297A16.2	9.68	2.34e-20	4.15e-17	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35086416	chr10:35098006~35127020:-
LUAD	cis	rs8062405	0.723	rs62031562	ENSG00000259982.1	CDC37P1	9.68	2.36e-20	4.19e-17	0.52	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28598008	chr16:28700294~28701540:-
LUAD	cis	rs11098499	0.78	rs10013652	ENSG00000245958.5	RP11-33B1.1	-9.68	2.39e-20	4.23e-17	-0.36	-0.4	Corneal astigmatism;	chr4:119371101	chr4:119454791~119552025:+
LUAD	cis	rs6142102	0.625	rs6141436	ENSG00000276073.1	RP5-1125A11.7	-9.67	2.4e-20	4.25e-17	-0.41	-0.4	Skin pigmentation;	chr20:33966765	chr20:33985617~33988989:-
LUAD	cis	rs5769707	0.967	rs17182154	ENSG00000188511.11	C22orf34	9.67	2.4e-20	4.25e-17	0.45	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49596822	chr22:49414524~49657542:-
LUAD	cis	rs7208859	0.573	rs73277960	ENSG00000263531.1	RP13-753N3.1	9.67	2.41e-20	4.26e-17	0.79	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30850423	chr17:30863921~30864940:-
LUAD	cis	rs11098499	0.754	rs1814813	ENSG00000245958.5	RP11-33B1.1	9.67	2.41e-20	4.26e-17	0.34	0.4	Corneal astigmatism;	chr4:119337052	chr4:119454791~119552025:+
LUAD	cis	rs8062405	0.723	rs4788079	ENSG00000259982.1	CDC37P1	9.67	2.41e-20	4.27e-17	0.51	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28700294~28701540:-
LUAD	cis	rs34779708	0.931	rs55724039	ENSG00000230534.5	RP11-297A16.2	9.67	2.43e-20	4.3e-17	0.49	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35176469	chr10:35098006~35127020:-
LUAD	cis	rs904251	0.561	rs1757189	ENSG00000204110.6	RP1-153P14.8	-9.67	2.43e-20	4.31e-17	-0.41	-0.4	Cognitive performance;	chr6:37515951	chr6:37507348~37535616:+
LUAD	cis	rs227275	0.556	rs6815526	ENSG00000246560.2	RP11-10L12.4	9.67	2.44e-20	4.32e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102899729	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.556	rs6824070	ENSG00000246560.2	RP11-10L12.4	9.67	2.44e-20	4.32e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102901676	chr4:102828055~102844075:+
LUAD	cis	rs11722779	0.935	rs6856176	ENSG00000246560.2	RP11-10L12.4	9.67	2.44e-20	4.32e-17	0.5	0.4	Schizophrenia;	chr4:102902574	chr4:102828055~102844075:+
LUAD	cis	rs2729354	0.817	rs2649667	ENSG00000265566.2	RN7SL605P	-9.67	2.45e-20	4.33e-17	-0.57	-0.4	Blood protein levels;	chr11:57503036	chr11:57528085~57528365:-
LUAD	cis	rs11690935	0.798	rs13018768	ENSG00000228389.1	AC068039.4	9.67	2.45e-20	4.34e-17	0.48	0.4	Schizophrenia;	chr2:171742082	chr2:171773482~171775844:+
LUAD	cis	rs904251	0.504	rs12202664	ENSG00000204110.6	RP1-153P14.8	-9.67	2.45e-20	4.34e-17	-0.41	-0.4	Cognitive performance;	chr6:37513422	chr6:37507348~37535616:+
LUAD	cis	rs10129255	0.5	rs1974468	ENSG00000280411.1	IGHV1-69-2	-9.67	2.48e-20	4.38e-17	-0.28	-0.4	Kawasaki disease;	chr14:106686149	chr14:106762092~106762588:-
LUAD	cis	rs11098499	0.863	rs13136462	ENSG00000245958.5	RP11-33B1.1	-9.67	2.51e-20	4.43e-17	-0.38	-0.4	Corneal astigmatism;	chr4:119622018	chr4:119454791~119552025:+
LUAD	cis	rs3096299	0.738	rs9929606	ENSG00000274627.1	RP11-104N10.2	9.67	2.51e-20	4.43e-17	0.39	0.4	Multiple myeloma (IgH translocation);	chr16:89461129	chr16:89516797~89522217:+
LUAD	cis	rs227275	0.554	rs223314	ENSG00000246560.2	RP11-10L12.4	9.67	2.51e-20	4.44e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102884642	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.51	rs7254	ENSG00000246560.2	RP11-10L12.4	9.67	2.51e-20	4.44e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888488	chr4:102828055~102844075:+
LUAD	cis	rs11722779	0.566	rs6822658	ENSG00000246560.2	RP11-10L12.4	9.67	2.51e-20	4.44e-17	0.5	0.4	Schizophrenia;	chr4:102891964	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.51	rs6823625	ENSG00000246560.2	RP11-10L12.4	9.67	2.51e-20	4.44e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892437	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.51	rs6846762	ENSG00000246560.2	RP11-10L12.4	9.67	2.51e-20	4.44e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892577	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.51	rs4699032	ENSG00000246560.2	RP11-10L12.4	9.67	2.51e-20	4.44e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892724	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.51	rs6830407	ENSG00000246560.2	RP11-10L12.4	9.67	2.51e-20	4.44e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102895366	chr4:102828055~102844075:+
LUAD	cis	rs1061377	0.748	rs35904472	ENSG00000249207.1	RP11-360F5.1	-9.67	2.53e-20	4.47e-17	-0.45	-0.4	Uric acid levels;	chr4:39094901	chr4:39112677~39126818:-
LUAD	cis	rs1061377	0.748	rs10856841	ENSG00000249207.1	RP11-360F5.1	-9.67	2.53e-20	4.47e-17	-0.45	-0.4	Uric acid levels;	chr4:39095240	chr4:39112677~39126818:-
LUAD	cis	rs11098499	0.604	rs12642411	ENSG00000245958.5	RP11-33B1.1	-9.67	2.54e-20	4.48e-17	-0.38	-0.4	Corneal astigmatism;	chr4:119659370	chr4:119454791~119552025:+
LUAD	cis	rs748404	0.631	rs6493086	ENSG00000205771.5	CATSPER2P1	-9.67	2.54e-20	4.49e-17	-0.51	-0.4	Lung cancer;	chr15:43363196	chr15:43726918~43747094:-
LUAD	cis	rs9918079	0.506	rs7696127	ENSG00000273133.1	RP11-799M12.2	-9.67	2.55e-20	4.49e-17	-0.56	-0.4	Obesity-related traits;	chr4:15641330	chr4:15563698~15564253:-
LUAD	cis	rs6142102	0.58	rs4911139	ENSG00000276073.1	RP5-1125A11.7	-9.67	2.55e-20	4.51e-17	-0.41	-0.4	Skin pigmentation;	chr20:33963729	chr20:33985617~33988989:-
LUAD	cis	rs227275	0.554	rs223367	ENSG00000246560.2	RP11-10L12.4	9.67	2.55e-20	4.51e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102843836	chr4:102828055~102844075:+
LUAD	cis	rs2108622	0.727	rs62106156	ENSG00000267453.5	AC004791.2	-9.67	2.55e-20	4.51e-17	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869614	chr19:15851993~15864904:-
LUAD	cis	rs2564921	0.679	rs2115779	ENSG00000242142.1	SERBP1P3	-9.67	2.56e-20	4.52e-17	-0.45	-0.4	Height;	chr3:52992698	chr3:53064283~53065091:-
LUAD	cis	rs227275	0.554	rs223371	ENSG00000246560.2	RP11-10L12.4	9.67	2.57e-20	4.54e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102838032	chr4:102828055~102844075:+
LUAD	cis	rs8062405	0.723	rs35175818	ENSG00000259982.1	CDC37P1	9.67	2.57e-20	4.54e-17	0.52	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597425	chr16:28700294~28701540:-
LUAD	cis	rs9660180	0.934	rs12729990	ENSG00000231050.1	RP1-140A9.1	9.66	2.61e-20	4.6e-17	0.46	0.4	Body mass index;	chr1:1880596	chr1:1891471~1892658:+
LUAD	cis	rs73086581	1	rs17215340	ENSG00000229539.1	RP11-119B16.2	-9.66	2.64e-20	4.65e-17	-0.55	-0.4	Response to antidepressants in depression;	chr20:3989526	chr20:3888239~3888868:-
LUAD	cis	rs8040855	0.575	rs12912860	ENSG00000259295.5	CSPG4P12	9.66	2.64e-20	4.65e-17	0.53	0.4	Bulimia nervosa;	chr15:85030267	chr15:85191438~85213905:+
LUAD	cis	rs7208859	0.673	rs11654331	ENSG00000263531.1	RP13-753N3.1	9.66	2.65e-20	4.67e-17	0.79	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837999	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs73277964	ENSG00000263531.1	RP13-753N3.1	9.66	2.65e-20	4.67e-17	0.79	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30852183	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs11652409	ENSG00000263531.1	RP13-753N3.1	9.66	2.65e-20	4.67e-17	0.79	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855689	chr17:30863921~30864940:-
LUAD	cis	rs6452524	0.868	rs10057303	ENSG00000249664.1	CTD-2227C6.2	9.66	2.65e-20	4.67e-17	0.48	0.4	Hypertension (SNP x SNP interaction);	chr5:83098564	chr5:83012285~83013109:-
LUAD	cis	rs367615	0.537	rs17161729	ENSG00000249476.1	CTD-2587M2.1	-9.66	2.68e-20	4.71e-17	-0.47	-0.4	Colorectal cancer (SNP x SNP interaction);	chr5:109324827	chr5:109237120~109326369:-
LUAD	cis	rs8062405	0.931	rs12928404	ENSG00000259982.1	CDC37P1	9.66	2.71e-20	4.77e-17	0.52	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835925	chr16:28700294~28701540:-
LUAD	cis	rs367615	0.512	rs814153	ENSG00000249476.1	CTD-2587M2.1	9.66	2.72e-20	4.79e-17	0.48	0.4	Colorectal cancer (SNP x SNP interaction);	chr5:109332128	chr5:109237120~109326369:-
LUAD	cis	rs1891275	0.515	rs11186666	ENSG00000228701.1	TNKS2-AS1	-9.66	2.73e-20	4.8e-17	-0.49	-0.4	Intelligence (multi-trait analysis);	chr10:91718162	chr10:91782839~91798291:-
LUAD	cis	rs1789	0.903	rs6850422	ENSG00000273133.1	RP11-799M12.2	-9.66	2.73e-20	4.81e-17	-0.56	-0.4	Blood protein levels;	chr4:15680814	chr4:15563698~15564253:-
LUAD	cis	rs7044106	0.791	rs10739572	ENSG00000226752.6	PSMD5-AS1	-9.66	2.75e-20	4.83e-17	-0.45	-0.4	Hip circumference adjusted for BMI;	chr9:120727537	chr9:120824828~120854385:+
LUAD	cis	rs7044106	0.791	rs4837792	ENSG00000226752.6	PSMD5-AS1	-9.66	2.75e-20	4.83e-17	-0.45	-0.4	Hip circumference adjusted for BMI;	chr9:120721281	chr9:120824828~120854385:+
LUAD	cis	rs2108622	0.649	rs113055956	ENSG00000267453.5	AC004791.2	-9.66	2.81e-20	4.94e-17	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866502	chr19:15851993~15864904:-
LUAD	cis	rs73086581	0.838	rs11906481	ENSG00000229539.1	RP11-119B16.2	9.65	2.82e-20	4.95e-17	0.58	0.4	Response to antidepressants in depression;	chr20:4048059	chr20:3888239~3888868:-
LUAD	cis	rs10256972	0.786	rs3735686	ENSG00000229043.2	AC091729.9	-9.65	2.83e-20	4.97e-17	-0.43	-0.4	Endometriosis;Longevity;	chr7:1022891	chr7:1160374~1165267:+
LUAD	cis	rs6142102	0.625	rs4911138	ENSG00000276073.1	RP5-1125A11.7	-9.65	2.84e-20	4.99e-17	-0.41	-0.4	Skin pigmentation;	chr20:33959893	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.625	rs4243974	ENSG00000276073.1	RP5-1125A11.7	-9.65	2.84e-20	4.99e-17	-0.41	-0.4	Skin pigmentation;	chr20:33960062	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.625	rs6142062	ENSG00000276073.1	RP5-1125A11.7	-9.65	2.84e-20	4.99e-17	-0.41	-0.4	Skin pigmentation;	chr20:33960706	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.625	rs6141432	ENSG00000276073.1	RP5-1125A11.7	-9.65	2.84e-20	4.99e-17	-0.41	-0.4	Skin pigmentation;	chr20:33960791	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.602	rs6141433	ENSG00000276073.1	RP5-1125A11.7	-9.65	2.84e-20	4.99e-17	-0.41	-0.4	Skin pigmentation;	chr20:33961056	chr20:33985617~33988989:-
LUAD	cis	rs8062405	0.723	rs762633	ENSG00000259982.1	CDC37P1	9.65	2.86e-20	5.02e-17	0.52	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597020	chr16:28700294~28701540:-
LUAD	cis	rs6142102	0.625	rs6142061	ENSG00000276073.1	RP5-1125A11.7	-9.65	2.93e-20	5.13e-17	-0.41	-0.4	Skin pigmentation;	chr20:33960529	chr20:33985617~33988989:-
LUAD	cis	rs9918079	0.56	rs10008376	ENSG00000273133.1	RP11-799M12.2	9.65	2.95e-20	5.17e-17	0.56	0.4	Obesity-related traits;	chr4:15622332	chr4:15563698~15564253:-
LUAD	cis	rs11098499	0.82	rs13122709	ENSG00000245958.5	RP11-33B1.1	-9.65	2.96e-20	5.18e-17	-0.38	-0.4	Corneal astigmatism;	chr4:119634201	chr4:119454791~119552025:+
LUAD	cis	rs8040855	0.597	rs12902942	ENSG00000259295.5	CSPG4P12	9.65	2.98e-20	5.22e-17	0.53	0.4	Bulimia nervosa;	chr15:85041573	chr15:85191438~85213905:+
LUAD	cis	rs8062405	0.755	rs2077031	ENSG00000259982.1	CDC37P1	9.65	2.98e-20	5.22e-17	0.51	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28591847	chr16:28700294~28701540:-
LUAD	cis	rs6452524	0.78	rs2386237	ENSG00000249664.1	CTD-2227C6.2	9.65	2.99e-20	5.23e-17	0.48	0.4	Hypertension (SNP x SNP interaction);	chr5:83101852	chr5:83012285~83013109:-
LUAD	cis	rs227275	0.525	rs223461	ENSG00000246560.2	RP11-10L12.4	9.65	3e-20	5.25e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102782372	chr4:102828055~102844075:+
LUAD	cis	rs7044106	0.762	rs1547268	ENSG00000226752.6	PSMD5-AS1	-9.65	3.02e-20	5.28e-17	-0.44	-0.4	Hip circumference adjusted for BMI;	chr9:120646410	chr9:120824828~120854385:+
LUAD	cis	rs7044106	0.762	rs1547267	ENSG00000226752.6	PSMD5-AS1	-9.65	3.02e-20	5.28e-17	-0.44	-0.4	Hip circumference adjusted for BMI;	chr9:120646458	chr9:120824828~120854385:+
LUAD	cis	rs7044106	0.762	rs4142158	ENSG00000226752.6	PSMD5-AS1	-9.65	3.02e-20	5.28e-17	-0.44	-0.4	Hip circumference adjusted for BMI;	chr9:120648541	chr9:120824828~120854385:+
LUAD	cis	rs10129255	0.5	rs2105991	ENSG00000280411.1	IGHV1-69-2	-9.65	3.02e-20	5.29e-17	-0.28	-0.4	Kawasaki disease;	chr14:106682022	chr14:106762092~106762588:-
LUAD	cis	rs321358	1	rs321352	ENSG00000271584.1	RP11-89C3.4	9.65	3.02e-20	5.29e-17	0.68	0.4	Body mass index;	chr11:111123001	chr11:111091932~111097357:-
LUAD	cis	rs321358	1	rs167683	ENSG00000271584.1	RP11-89C3.4	9.65	3.02e-20	5.29e-17	0.68	0.4	Body mass index;	chr11:111123131	chr11:111091932~111097357:-
LUAD	cis	rs5769707	0.777	rs739243	ENSG00000188511.11	C22orf34	9.65	3.02e-20	5.29e-17	0.45	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49663563	chr22:49414524~49657542:-
LUAD	cis	rs6142102	0.625	rs1883706	ENSG00000276073.1	RP5-1125A11.7	-9.65	3.04e-20	5.32e-17	-0.41	-0.4	Skin pigmentation;	chr20:33965071	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.625	rs1883705	ENSG00000276073.1	RP5-1125A11.7	-9.65	3.04e-20	5.32e-17	-0.41	-0.4	Skin pigmentation;	chr20:33965072	chr20:33985617~33988989:-
LUAD	cis	rs321358	0.895	rs7110930	ENSG00000271584.1	RP11-89C3.4	-9.64	3.07e-20	5.37e-17	-0.65	-0.4	Body mass index;	chr11:111088556	chr11:111091932~111097357:-
LUAD	cis	rs748404	0.631	rs4296223	ENSG00000205771.5	CATSPER2P1	-9.64	3.11e-20	5.43e-17	-0.51	-0.4	Lung cancer;	chr15:43353048	chr15:43726918~43747094:-
LUAD	cis	rs1789	0.903	rs4470622	ENSG00000273133.1	RP11-799M12.2	-9.64	3.12e-20	5.45e-17	-0.56	-0.4	Blood protein levels;	chr4:15672552	chr4:15563698~15564253:-
LUAD	cis	rs227275	0.556	rs11722779	ENSG00000246560.2	RP11-10L12.4	9.64	3.12e-20	5.45e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102906331	chr4:102828055~102844075:+
LUAD	cis	rs8040855	0.547	rs17611171	ENSG00000259295.5	CSPG4P12	9.64	3.13e-20	5.46e-17	0.53	0.4	Bulimia nervosa;	chr15:85029468	chr15:85191438~85213905:+
LUAD	cis	rs9309711	0.643	rs4264589	ENSG00000225234.1	TRAPPC12-AS1	-9.64	3.13e-20	5.47e-17	-0.47	-0.4	Neurofibrillary tangles;	chr2:3477327	chr2:3481242~3482409:-
LUAD	cis	rs227275	0.525	rs28845922	ENSG00000246560.2	RP11-10L12.4	9.64	3.15e-20	5.5e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102981959	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.51	rs223451	ENSG00000246560.2	RP11-10L12.4	9.64	3.16e-20	5.51e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791032	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.51	rs223450	ENSG00000246560.2	RP11-10L12.4	9.64	3.16e-20	5.51e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791052	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs10032234	ENSG00000246560.2	RP11-10L12.4	9.64	3.17e-20	5.52e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102980538	chr4:102828055~102844075:+
LUAD	cis	rs2564921	0.666	rs62253656	ENSG00000242142.1	SERBP1P3	-9.64	3.17e-20	5.53e-17	-0.45	-0.4	Height;	chr3:52989412	chr3:53064283~53065091:-
LUAD	cis	rs228614	0.51	rs223459	ENSG00000246560.2	RP11-10L12.4	9.64	3.18e-20	5.54e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102788229	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs223462	ENSG00000246560.2	RP11-10L12.4	9.64	3.18e-20	5.55e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102780661	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.531	rs223460	ENSG00000246560.2	RP11-10L12.4	9.64	3.18e-20	5.55e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102782903	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.588	rs223458	ENSG00000246560.2	RP11-10L12.4	9.64	3.18e-20	5.55e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102788414	chr4:102828055~102844075:+
LUAD	cis	rs2108622	0.727	rs55954696	ENSG00000267453.5	AC004791.2	-9.64	3.19e-20	5.56e-17	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870995	chr19:15851993~15864904:-
LUAD	cis	rs944289	0.675	rs398745	ENSG00000257826.1	RP11-116N8.4	9.64	3.19e-20	5.57e-17	0.42	0.4	Thyroid cancer;	chr14:36066975	chr14:36061026~36067190:-
LUAD	cis	rs228614	0.51	rs223313	ENSG00000246560.2	RP11-10L12.4	9.64	3.2e-20	5.59e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102886563	chr4:102828055~102844075:+
LUAD	cis	rs977987	0.872	rs3743609	ENSG00000261783.1	RP11-252K23.2	-9.64	3.21e-20	5.59e-17	-0.54	-0.4	Dupuytren's disease;	chr16:75433123	chr16:75379818~75381260:-
LUAD	cis	rs11098499	0.731	rs6846966	ENSG00000245958.5	RP11-33B1.1	-9.64	3.24e-20	5.65e-17	-0.36	-0.4	Corneal astigmatism;	chr4:119372053	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.82	rs2389885	ENSG00000245958.5	RP11-33B1.1	-9.64	3.27e-20	5.71e-17	-0.38	-0.4	Corneal astigmatism;	chr4:119612776	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs9991959	ENSG00000245958.5	RP11-33B1.1	9.64	3.3e-20	5.74e-17	0.36	0.4	Corneal astigmatism;	chr4:119332618	chr4:119454791~119552025:+
LUAD	cis	rs62229266	0.804	rs998383	ENSG00000231106.2	LINC01436	9.64	3.31e-20	5.76e-17	0.55	0.4	Mitral valve prolapse;	chr21:36073441	chr21:36005338~36007838:+
LUAD	cis	rs7208859	0.673	rs11655623	ENSG00000263531.1	RP13-753N3.1	9.63	3.32e-20	5.78e-17	0.79	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30835155	chr17:30863921~30864940:-
LUAD	cis	rs1153858	0.887	rs28569043	ENSG00000259520.4	CTD-2651B20.3	-9.63	3.34e-20	5.82e-17	-0.55	-0.4	Homoarginine levels;	chr15:45438728	chr15:45251580~45279251:-
LUAD	cis	rs9918079	0.56	rs13147590	ENSG00000273133.1	RP11-799M12.2	9.63	3.35e-20	5.83e-17	0.56	0.4	Obesity-related traits;	chr4:15619565	chr4:15563698~15564253:-
LUAD	cis	rs34779708	0.966	rs12769484	ENSG00000230534.5	RP11-297A16.2	9.63	3.41e-20	5.94e-17	0.49	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35176818	chr10:35098006~35127020:-
LUAD	cis	rs10129255	0.5	rs4774008	ENSG00000280411.1	IGHV1-69-2	-9.63	3.41e-20	5.94e-17	-0.28	-0.4	Kawasaki disease;	chr14:106681273	chr14:106762092~106762588:-
LUAD	cis	rs6142102	0.625	rs4012234	ENSG00000276073.1	RP5-1125A11.7	-9.63	3.43e-20	5.96e-17	-0.41	-0.4	Skin pigmentation;	chr20:33965241	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.649	rs4911382	ENSG00000276073.1	RP5-1125A11.7	-9.63	3.43e-20	5.96e-17	-0.41	-0.4	Skin pigmentation;	chr20:33965289	chr20:33985617~33988989:-
LUAD	cis	rs6504950	0.8	rs7209926	ENSG00000275710.1	RP11-257O5.4	-9.63	3.43e-20	5.96e-17	-0.49	-0.4	Breast cancer;	chr17:54928963	chr17:54964474~54964679:+
LUAD	cis	rs9918079	0.58	rs13120905	ENSG00000273133.1	RP11-799M12.2	9.63	3.43e-20	5.98e-17	0.56	0.4	Obesity-related traits;	chr4:15610665	chr4:15563698~15564253:-
LUAD	cis	rs34779708	0.966	rs11010135	ENSG00000230534.5	RP11-297A16.2	9.63	3.44e-20	5.98e-17	0.49	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35229135	chr10:35098006~35127020:-
LUAD	cis	rs2564921	0.791	rs36033494	ENSG00000242142.1	SERBP1P3	9.63	3.47e-20	6.03e-17	0.42	0.4	Height;	chr3:53082835	chr3:53064283~53065091:-
LUAD	cis	rs9918079	0.542	rs12499412	ENSG00000273133.1	RP11-799M12.2	9.63	3.48e-20	6.05e-17	0.56	0.4	Obesity-related traits;	chr4:15600629	chr4:15563698~15564253:-
LUAD	cis	rs9918079	0.542	rs6414765	ENSG00000273133.1	RP11-799M12.2	-9.63	3.49e-20	6.07e-17	-0.56	-0.4	Obesity-related traits;	chr4:15624870	chr4:15563698~15564253:-
LUAD	cis	rs2564921	0.704	rs35671032	ENSG00000242142.1	SERBP1P3	-9.63	3.5e-20	6.08e-17	-0.45	-0.4	Height;	chr3:52972039	chr3:53064283~53065091:-
LUAD	cis	rs944289	0.616	rs408783	ENSG00000257826.1	RP11-116N8.4	9.63	3.52e-20	6.11e-17	0.42	0.4	Thyroid cancer;	chr14:36065667	chr14:36061026~36067190:-
LUAD	cis	rs367615	0.512	rs246105	ENSG00000249476.1	CTD-2587M2.1	9.63	3.53e-20	6.14e-17	0.47	0.4	Colorectal cancer (SNP x SNP interaction);	chr5:109337245	chr5:109237120~109326369:-
LUAD	cis	rs2729354	0.817	rs2250673	ENSG00000265566.2	RN7SL605P	-9.63	3.54e-20	6.16e-17	-0.57	-0.4	Blood protein levels;	chr11:57500697	chr11:57528085~57528365:-
LUAD	cis	rs2108622	0.727	rs8102532	ENSG00000267453.5	AC004791.2	-9.63	3.57e-20	6.21e-17	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869250	chr19:15851993~15864904:-
LUAD	cis	rs4273100	0.646	rs6587216	ENSG00000262319.1	CTC-457L16.2	9.63	3.58e-20	6.22e-17	0.48	0.4	Schizophrenia;	chr17:19321084	chr17:19141017~19143689:-
LUAD	cis	rs9918079	0.542	rs1789	ENSG00000273133.1	RP11-799M12.2	-9.62	3.6e-20	6.25e-17	-0.56	-0.4	Obesity-related traits;	chr4:15662912	chr4:15563698~15564253:-
LUAD	cis	rs228614	0.51	rs223400	ENSG00000246560.2	RP11-10L12.4	9.62	3.62e-20	6.27e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102820439	chr4:102828055~102844075:+
LUAD	cis	rs34779708	0.966	rs2045917	ENSG00000230534.5	RP11-297A16.2	9.62	3.62e-20	6.29e-17	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35129598	chr10:35098006~35127020:-
LUAD	cis	rs62229266	0.839	rs11702763	ENSG00000231106.2	LINC01436	9.62	3.64e-20	6.32e-17	0.55	0.4	Mitral valve prolapse;	chr21:36098406	chr21:36005338~36007838:+
LUAD	cis	rs977987	0.843	rs62062568	ENSG00000261783.1	RP11-252K23.2	-9.62	3.64e-20	6.32e-17	-0.53	-0.4	Dupuytren's disease;	chr16:75411426	chr16:75379818~75381260:-
LUAD	cis	rs904251	0.523	rs914348	ENSG00000204110.6	RP1-153P14.8	-9.62	3.65e-20	6.33e-17	-0.4	-0.4	Cognitive performance;	chr6:37516953	chr6:37507348~37535616:+
LUAD	cis	rs227275	0.556	rs10015289	ENSG00000246560.2	RP11-10L12.4	9.62	3.66e-20	6.34e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102984956	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.556	rs6852141	ENSG00000246560.2	RP11-10L12.4	9.62	3.66e-20	6.34e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102986439	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.509	rs4455415	ENSG00000246560.2	RP11-10L12.4	9.62	3.66e-20	6.34e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102993663	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs6853193	ENSG00000246560.2	RP11-10L12.4	9.62	3.66e-20	6.34e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102994888	chr4:102828055~102844075:+
LUAD	cis	rs9309711	0.666	rs6723126	ENSG00000225234.1	TRAPPC12-AS1	-9.62	3.67e-20	6.37e-17	-0.46	-0.4	Neurofibrillary tangles;	chr2:3480729	chr2:3481242~3482409:-
LUAD	cis	rs10129255	0.518	rs2006284	ENSG00000280411.1	IGHV1-69-2	-9.62	3.68e-20	6.38e-17	-0.28	-0.4	Kawasaki disease;	chr14:106676185	chr14:106762092~106762588:-
LUAD	cis	rs748404	0.631	rs8042688	ENSG00000205771.5	CATSPER2P1	-9.62	3.69e-20	6.39e-17	-0.51	-0.4	Lung cancer;	chr15:43346327	chr15:43726918~43747094:-
LUAD	cis	rs1757171	0.542	rs3818985	ENSG00000204110.6	RP1-153P14.8	-9.62	3.74e-20	6.48e-17	-0.41	-0.4	Cognitive performance;	chr6:37516438	chr6:37507348~37535616:+
LUAD	cis	rs950027	0.787	rs2433616	ENSG00000259520.4	CTD-2651B20.3	-9.62	3.74e-20	6.49e-17	-0.48	-0.4	Response to fenofibrate (adiponectin levels);	chr15:45436401	chr15:45251580~45279251:-
LUAD	cis	rs6452524	0.869	rs10051155	ENSG00000249664.1	CTD-2227C6.2	9.62	3.76e-20	6.51e-17	0.47	0.4	Hypertension (SNP x SNP interaction);	chr5:83160851	chr5:83012285~83013109:-
LUAD	cis	rs7044106	0.762	rs10739570	ENSG00000226752.6	PSMD5-AS1	-9.62	3.78e-20	6.54e-17	-0.44	-0.4	Hip circumference adjusted for BMI;	chr9:120618944	chr9:120824828~120854385:+
LUAD	cis	rs228614	0.51	rs4699033	ENSG00000246560.2	RP11-10L12.4	9.62	3.78e-20	6.55e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102897577	chr4:102828055~102844075:+
LUAD	cis	rs8040855	0.627	rs12909130	ENSG00000259295.5	CSPG4P12	9.62	3.79e-20	6.56e-17	0.52	0.4	Bulimia nervosa;	chr15:85047270	chr15:85191438~85213905:+
LUAD	cis	rs2455601	0.786	rs3763913	ENSG00000254860.4	TMEM9B-AS1	9.62	3.8e-20	6.58e-17	0.58	0.4	Schizophrenia;	chr11:8929683	chr11:8964675~8977527:+
LUAD	cis	rs12468226	1	rs116635509	ENSG00000273456.1	RP11-686O6.2	9.62	3.81e-20	6.59e-17	0.61	0.4	Urate levels;	chr2:202460027	chr2:202374932~202375604:-
LUAD	cis	rs228614	0.509	rs223482	ENSG00000246560.2	RP11-10L12.4	9.62	3.86e-20	6.67e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766051	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.536	rs223478	ENSG00000246560.2	RP11-10L12.4	9.62	3.86e-20	6.67e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102768648	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.536	rs150898	ENSG00000246560.2	RP11-10L12.4	9.62	3.86e-20	6.67e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769234	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.509	rs223476	ENSG00000246560.2	RP11-10L12.4	9.62	3.86e-20	6.67e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771000	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.509	rs150896	ENSG00000246560.2	RP11-10L12.4	9.62	3.86e-20	6.67e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771186	chr4:102828055~102844075:+
LUAD	cis	rs10875746	0.904	rs11168422	ENSG00000240399.1	RP1-228P16.1	-9.62	3.87e-20	6.7e-17	-0.49	-0.4	Longevity (90 years and older);	chr12:48125722	chr12:48054813~48055591:-
LUAD	cis	rs12468226	0.872	rs115187557	ENSG00000273456.1	RP11-686O6.2	9.61	3.96e-20	6.85e-17	0.61	0.4	Urate levels;	chr2:202495351	chr2:202374932~202375604:-
LUAD	cis	rs34779708	0.966	rs35814343	ENSG00000230534.5	RP11-297A16.2	9.61	3.98e-20	6.88e-17	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35138786	chr10:35098006~35127020:-
LUAD	cis	rs367615	0.537	rs1965670	ENSG00000249476.1	CTD-2587M2.1	-9.61	4.05e-20	7e-17	-0.46	-0.4	Colorectal cancer (SNP x SNP interaction);	chr5:109314097	chr5:109237120~109326369:-
LUAD	cis	rs11098499	0.866	rs11098506	ENSG00000245958.5	RP11-33B1.1	-9.61	4.08e-20	7.04e-17	-0.36	-0.4	Corneal astigmatism;	chr4:119363816	chr4:119454791~119552025:+
LUAD	cis	rs944289	0.646	rs396043	ENSG00000257826.1	RP11-116N8.4	9.61	4.11e-20	7.1e-17	0.42	0.4	Thyroid cancer;	chr14:36071815	chr14:36061026~36067190:-
LUAD	cis	rs944289	0.646	rs429041	ENSG00000257826.1	RP11-116N8.4	9.61	4.11e-20	7.1e-17	0.42	0.4	Thyroid cancer;	chr14:36071930	chr14:36061026~36067190:-
LUAD	cis	rs944289	0.646	rs368772	ENSG00000257826.1	RP11-116N8.4	9.61	4.11e-20	7.1e-17	0.42	0.4	Thyroid cancer;	chr14:36071955	chr14:36061026~36067190:-
LUAD	cis	rs944289	0.646	rs4981320	ENSG00000257826.1	RP11-116N8.4	9.61	4.11e-20	7.1e-17	0.42	0.4	Thyroid cancer;	chr14:36072456	chr14:36061026~36067190:-
LUAD	cis	rs2564921	0.704	rs56155510	ENSG00000242142.1	SERBP1P3	-9.61	4.12e-20	7.11e-17	-0.45	-0.4	Height;	chr3:53009621	chr3:53064283~53065091:-
LUAD	cis	rs694739	0.628	rs475032	ENSG00000236935.1	AP003774.1	-9.61	4.12e-20	7.12e-17	-0.38	-0.4	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64373265	chr11:64325050~64329504:-
LUAD	cis	rs8062405	1	rs62036616	ENSG00000259982.1	CDC37P1	9.61	4.13e-20	7.13e-17	0.52	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28700294~28701540:-
LUAD	cis	rs2108622	0.727	rs3093193	ENSG00000267453.5	AC004791.2	-9.61	4.18e-20	7.21e-17	-0.5	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15881104	chr19:15851993~15864904:-
LUAD	cis	rs2729354	0.768	rs2584856	ENSG00000265566.2	RN7SL605P	-9.61	4.2e-20	7.25e-17	-0.57	-0.4	Blood protein levels;	chr11:57499839	chr11:57528085~57528365:-
LUAD	cis	rs228614	0.51	rs223447	ENSG00000246560.2	RP11-10L12.4	9.61	4.22e-20	7.29e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102792202	chr4:102828055~102844075:+
LUAD	cis	rs9660180	0.967	rs6603802	ENSG00000231050.1	RP1-140A9.1	9.6	4.23e-20	7.3e-17	0.45	0.4	Body mass index;	chr1:1881082	chr1:1891471~1892658:+
LUAD	cis	rs507080	0.501	rs516503	ENSG00000255422.1	AP002954.4	-9.6	4.3e-20	7.42e-17	-0.49	-0.4	Serum metabolite levels;	chr11:118709639	chr11:118704607~118750263:+
LUAD	cis	rs2108622	0.701	rs118144071	ENSG00000267453.5	AC004791.2	-9.6	4.32e-20	7.46e-17	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15868384	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.683	rs56228205	ENSG00000267453.5	AC004791.2	-9.6	4.35e-20	7.49e-17	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871163	chr19:15851993~15864904:-
LUAD	cis	rs944289	0.616	rs410546	ENSG00000257826.1	RP11-116N8.4	9.6	4.44e-20	7.65e-17	0.41	0.4	Thyroid cancer;	chr14:36071858	chr14:36061026~36067190:-
LUAD	cis	rs6504950	0.695	rs9904377	ENSG00000275710.1	RP11-257O5.4	9.6	4.48e-20	7.7e-17	0.5	0.4	Breast cancer;	chr17:54908621	chr17:54964474~54964679:+
LUAD	cis	rs11098499	0.738	rs28687057	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119359657	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.775	rs67281037	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119360002	chr4:119454791~119552025:+
LUAD	cis	rs10028773	0.506	rs12374346	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Educational attainment;	chr4:119360550	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.866	rs12374244	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119360817	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.866	rs12374352	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119360822	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.775	rs10021601	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119361408	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.866	rs6857892	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119361541	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.909	rs28581362	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119362393	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.82	rs12503082	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119363162	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.866	rs12499602	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119363232	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.774	rs11098505	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119363472	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.866	rs13105020	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119364533	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.866	rs6824111	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119364813	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.775	rs10029303	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119365600	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.866	rs9995136	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119365690	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.866	rs13125526	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119366864	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.866	rs12513310	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119366884	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.564	rs11098507	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119367131	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.866	rs12510451	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119367988	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.774	rs73842616	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119369528	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.645	rs72676059	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119369673	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.569	rs55845118	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119369758	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.866	rs7677068	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119370549	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.866	rs9991221	ENSG00000245958.5	RP11-33B1.1	-9.6	4.48e-20	7.7e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119370952	chr4:119454791~119552025:+
LUAD	cis	rs6452524	1	rs67683443	ENSG00000249664.1	CTD-2227C6.2	9.6	4.53e-20	7.78e-17	0.46	0.4	Hypertension (SNP x SNP interaction);	chr5:83167884	chr5:83012285~83013109:-
LUAD	cis	rs11098499	0.866	rs7665125	ENSG00000245958.5	RP11-33B1.1	-9.6	4.56e-20	7.83e-17	-0.35	-0.4	Corneal astigmatism;	chr4:119480924	chr4:119454791~119552025:+
LUAD	cis	rs2337406	0.925	rs2011167	ENSG00000274576.2	IGHV2-70	-9.6	4.57e-20	7.84e-17	-0.46	-0.4	Alzheimer's disease (late onset);	chr14:106680831	chr14:106770577~106771020:-
LUAD	cis	rs2108622	0.727	rs12609468	ENSG00000267453.5	AC004791.2	-9.59	4.61e-20	7.91e-17	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867004	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.727	rs12610967	ENSG00000267453.5	AC004791.2	-9.59	4.61e-20	7.91e-17	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867119	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.711	rs12609820	ENSG00000267453.5	AC004791.2	-9.59	4.61e-20	7.91e-17	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867247	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.668	rs62106153	ENSG00000267453.5	AC004791.2	-9.59	4.61e-20	7.91e-17	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867697	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.727	rs12611242	ENSG00000267453.5	AC004791.2	-9.59	4.61e-20	7.91e-17	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867754	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.727	rs12611308	ENSG00000267453.5	AC004791.2	-9.59	4.61e-20	7.91e-17	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867776	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.727	rs12610189	ENSG00000267453.5	AC004791.2	-9.59	4.61e-20	7.91e-17	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867831	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.711	rs113343664	ENSG00000267453.5	AC004791.2	-9.59	4.61e-20	7.91e-17	-0.49	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15868183	chr19:15851993~15864904:-
LUAD	cis	rs11098499	0.82	rs28535956	ENSG00000245958.5	RP11-33B1.1	9.59	4.64e-20	7.96e-17	0.38	0.4	Corneal astigmatism;	chr4:119615703	chr4:119454791~119552025:+
LUAD	cis	rs9660180	0.837	rs915292	ENSG00000231050.1	RP1-140A9.1	9.59	4.65e-20	7.98e-17	0.45	0.4	Body mass index;	chr1:1860718	chr1:1891471~1892658:+
LUAD	cis	rs11722779	0.935	rs3974481	ENSG00000246560.2	RP11-10L12.4	9.59	4.65e-20	7.98e-17	0.49	0.4	Schizophrenia;	chr4:102956834	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.554	rs9307281	ENSG00000246560.2	RP11-10L12.4	9.59	4.66e-20	7.98e-17	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102934971	chr4:102828055~102844075:+
LUAD	cis	rs11722779	0.903	rs6533037	ENSG00000246560.2	RP11-10L12.4	9.59	4.66e-20	7.98e-17	0.49	0.4	Schizophrenia;	chr4:102935865	chr4:102828055~102844075:+
LUAD	cis	rs11722779	0.903	rs4530634	ENSG00000246560.2	RP11-10L12.4	9.59	4.66e-20	7.98e-17	0.49	0.4	Schizophrenia;	chr4:102937924	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs7676943	ENSG00000246560.2	RP11-10L12.4	9.59	4.66e-20	7.98e-17	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102938135	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs6419160	ENSG00000246560.2	RP11-10L12.4	9.59	4.66e-20	7.98e-17	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102938648	chr4:102828055~102844075:+
LUAD	cis	rs11722779	0.901	rs28674656	ENSG00000246560.2	RP11-10L12.4	9.59	4.66e-20	7.98e-17	0.49	0.4	Schizophrenia;	chr4:102944396	chr4:102828055~102844075:+
LUAD	cis	rs11722779	0.838	rs3974494	ENSG00000246560.2	RP11-10L12.4	9.59	4.66e-20	7.98e-17	0.49	0.4	Schizophrenia;	chr4:102945323	chr4:102828055~102844075:+
LUAD	cis	rs11722779	0.873	rs6533041	ENSG00000246560.2	RP11-10L12.4	9.59	4.66e-20	7.98e-17	0.49	0.4	Schizophrenia;	chr4:102951615	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs4699037	ENSG00000246560.2	RP11-10L12.4	9.59	4.66e-20	7.98e-17	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102957010	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.556	rs3857198	ENSG00000246560.2	RP11-10L12.4	9.59	4.66e-20	7.98e-17	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102957720	chr4:102828055~102844075:+
LUAD	cis	rs11722779	0.935	rs3857199	ENSG00000246560.2	RP11-10L12.4	9.59	4.66e-20	7.98e-17	0.49	0.4	Schizophrenia;	chr4:102957991	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs4699039	ENSG00000246560.2	RP11-10L12.4	9.59	4.66e-20	7.98e-17	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102958354	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs5028609	ENSG00000246560.2	RP11-10L12.4	9.59	4.66e-20	7.98e-17	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102959294	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs6815540	ENSG00000246560.2	RP11-10L12.4	9.59	4.66e-20	7.98e-17	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102959922	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs4698867	ENSG00000246560.2	RP11-10L12.4	9.59	4.66e-20	7.98e-17	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102961049	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs7663876	ENSG00000246560.2	RP11-10L12.4	9.59	4.66e-20	7.98e-17	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102966174	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.556	rs6821173	ENSG00000246560.2	RP11-10L12.4	9.59	4.66e-20	7.98e-17	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102966404	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs6533050	ENSG00000246560.2	RP11-10L12.4	9.59	4.67e-20	8e-17	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102979044	chr4:102828055~102844075:+
LUAD	cis	rs12468226	0.873	rs59293950	ENSG00000273456.1	RP11-686O6.2	9.59	4.72e-20	8.09e-17	0.64	0.4	Urate levels;	chr2:202214069	chr2:202374932~202375604:-
LUAD	cis	rs748404	0.631	rs28702649	ENSG00000205771.5	CATSPER2P1	-9.59	4.73e-20	8.11e-17	-0.51	-0.4	Lung cancer;	chr15:43356431	chr15:43726918~43747094:-
LUAD	cis	rs11098499	0.73	rs12505735	ENSG00000245958.5	RP11-33B1.1	-9.59	4.75e-20	8.13e-17	-0.38	-0.4	Corneal astigmatism;	chr4:119611801	chr4:119454791~119552025:+
LUAD	cis	rs977987	0.778	rs2865528	ENSG00000261783.1	RP11-252K23.2	-9.59	4.79e-20	8.19e-17	-0.53	-0.4	Dupuytren's disease;	chr16:75422044	chr16:75379818~75381260:-
LUAD	cis	rs228614	0.51	rs223435	ENSG00000246560.2	RP11-10L12.4	9.59	4.81e-20	8.23e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799826	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.556	rs223426	ENSG00000246560.2	RP11-10L12.4	9.59	4.81e-20	8.23e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102801330	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.51	rs223445	ENSG00000246560.2	RP11-10L12.4	9.59	4.81e-20	8.24e-17	0.49	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793337	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.536	rs223437	ENSG00000246560.2	RP11-10L12.4	9.59	4.81e-20	8.24e-17	0.49	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798736	chr4:102828055~102844075:+
LUAD	cis	rs62229266	0.625	rs2051395	ENSG00000231106.2	LINC01436	-9.59	4.92e-20	8.42e-17	-0.53	-0.4	Mitral valve prolapse;	chr21:36058967	chr21:36005338~36007838:+
LUAD	cis	rs321358	0.732	rs17535419	ENSG00000271584.1	RP11-89C3.4	9.59	4.95e-20	8.46e-17	0.65	0.4	Body mass index;	chr11:111075357	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.79	rs77820525	ENSG00000271584.1	RP11-89C3.4	9.59	4.95e-20	8.46e-17	0.65	0.4	Body mass index;	chr11:111076697	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.848	rs73015141	ENSG00000271584.1	RP11-89C3.4	9.59	4.95e-20	8.46e-17	0.65	0.4	Body mass index;	chr11:111077556	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.848	rs73015142	ENSG00000271584.1	RP11-89C3.4	9.59	4.95e-20	8.46e-17	0.65	0.4	Body mass index;	chr11:111078647	chr11:111091932~111097357:-
LUAD	cis	rs34779708	0.931	rs11010101	ENSG00000230534.5	RP11-297A16.2	9.58	4.98e-20	8.5e-17	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35122117	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs11010102	ENSG00000230534.5	RP11-297A16.2	9.58	4.98e-20	8.5e-17	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35122138	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs12765038	ENSG00000230534.5	RP11-297A16.2	9.58	4.98e-20	8.5e-17	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35127585	chr10:35098006~35127020:-
LUAD	cis	rs1577917	0.876	rs12190735	ENSG00000203875.9	SNHG5	-9.58	5e-20	8.53e-17	-0.54	-0.4	Response to antipsychotic treatment;	chr6:85976749	chr6:85660950~85678736:-
LUAD	cis	rs228614	0.51	rs223443	ENSG00000246560.2	RP11-10L12.4	9.58	5e-20	8.54e-17	0.49	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793629	chr4:102828055~102844075:+
LUAD	cis	rs1061377	1	rs6829450	ENSG00000249207.1	RP11-360F5.1	-9.58	5.01e-20	8.56e-17	-0.44	-0.4	Uric acid levels;	chr4:39114721	chr4:39112677~39126818:-
LUAD	cis	rs227275	0.554	rs223359	ENSG00000246560.2	RP11-10L12.4	9.58	5.02e-20	8.57e-17	0.5	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102849422	chr4:102828055~102844075:+
LUAD	cis	rs2564921	0.73	rs2564922	ENSG00000242142.1	SERBP1P3	9.58	5.04e-20	8.6e-17	0.45	0.4	Height;	chr3:53091453	chr3:53064283~53065091:-
LUAD	cis	rs12468226	1	rs76528043	ENSG00000273456.1	RP11-686O6.2	9.58	5.09e-20	8.69e-17	0.61	0.4	Urate levels;	chr2:202466116	chr2:202374932~202375604:-
LUAD	cis	rs2564921	0.615	rs56129941	ENSG00000242142.1	SERBP1P3	-9.58	5.1e-20	8.7e-17	-0.45	-0.4	Height;	chr3:53007328	chr3:53064283~53065091:-
LUAD	cis	rs34779708	0.966	rs35146199	ENSG00000230534.5	RP11-297A16.2	9.58	5.11e-20	8.71e-17	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35172011	chr10:35098006~35127020:-
LUAD	cis	rs494459	0.691	rs607472	ENSG00000255422.1	AP002954.4	-9.58	5.14e-20	8.76e-17	-0.5	-0.4	Height;	chr11:118809363	chr11:118704607~118750263:+
LUAD	cis	rs7044106	0.791	rs735109	ENSG00000226752.6	PSMD5-AS1	-9.58	5.14e-20	8.77e-17	-0.45	-0.4	Hip circumference adjusted for BMI;	chr9:120726601	chr9:120824828~120854385:+
LUAD	cis	rs11723261	0.664	rs4627799	ENSG00000275426.1	CH17-262A2.1	9.58	5.14e-20	8.77e-17	0.54	0.4	Immune response to smallpox vaccine (IL-6);	chr4:138608	chr4:149738~150317:+
LUAD	cis	rs944289	0.616	rs448145	ENSG00000257826.1	RP11-116N8.4	9.58	5.15e-20	8.79e-17	0.41	0.4	Thyroid cancer;	chr14:36069722	chr14:36061026~36067190:-
LUAD	cis	rs228614	0.51	rs170565	ENSG00000246560.2	RP11-10L12.4	9.58	5.17e-20	8.81e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798277	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.51	rs223405	ENSG00000246560.2	RP11-10L12.4	9.58	5.19e-20	8.86e-17	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102815894	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs3974604	ENSG00000246560.2	RP11-10L12.4	9.58	5.25e-20	8.95e-17	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102928601	chr4:102828055~102844075:+
LUAD	cis	rs34779708	0.733	rs11597184	ENSG00000230534.5	RP11-297A16.2	9.58	5.26e-20	8.95e-17	0.49	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35108468	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs12257770	ENSG00000230534.5	RP11-297A16.2	9.58	5.3e-20	9.03e-17	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35228306	chr10:35098006~35127020:-
LUAD	cis	rs1061377	0.748	rs13117988	ENSG00000249207.1	RP11-360F5.1	-9.58	5.31e-20	9.03e-17	-0.44	-0.4	Uric acid levels;	chr4:39092219	chr4:39112677~39126818:-
LUAD	cis	rs2564921	0.666	rs11130335	ENSG00000242142.1	SERBP1P3	-9.58	5.31e-20	9.05e-17	-0.45	-0.4	Height;	chr3:52989619	chr3:53064283~53065091:-
LUAD	cis	rs8040855	0.627	rs12909971	ENSG00000259295.5	CSPG4P12	9.57	5.42e-20	9.22e-17	0.51	0.4	Bulimia nervosa;	chr15:85045767	chr15:85191438~85213905:+
LUAD	cis	rs10129255	0.5	rs4774189	ENSG00000211972.2	IGHV3-66	9.57	5.42e-20	9.22e-17	0.32	0.4	Kawasaki disease;	chr14:106768275	chr14:106675017~106675544:-
LUAD	cis	rs11098499	0.604	rs2389886	ENSG00000245958.5	RP11-33B1.1	-9.57	5.44e-20	9.26e-17	-0.38	-0.4	Corneal astigmatism;	chr4:119649267	chr4:119454791~119552025:+
LUAD	cis	rs228614	0.51	rs223453	ENSG00000246560.2	RP11-10L12.4	9.57	5.46e-20	9.28e-17	0.49	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789895	chr4:102828055~102844075:+
LUAD	cis	rs1150668	0.835	rs203869	ENSG00000216901.1	AL022393.7	9.57	5.51e-20	9.38e-17	0.47	0.4	Pubertal anthropometrics;	chr6:28073041	chr6:28176188~28176674:+
LUAD	cis	rs9660180	0.967	rs9660106	ENSG00000231050.1	RP1-140A9.1	9.57	5.52e-20	9.39e-17	0.45	0.4	Body mass index;	chr1:1866508	chr1:1891471~1892658:+
LUAD	cis	rs367615	0.537	rs431669	ENSG00000249476.1	CTD-2587M2.1	9.57	5.56e-20	9.46e-17	0.47	0.4	Colorectal cancer (SNP x SNP interaction);	chr5:109327414	chr5:109237120~109326369:-
LUAD	cis	rs367615	0.537	rs10463600	ENSG00000249476.1	CTD-2587M2.1	9.57	5.56e-20	9.46e-17	0.47	0.4	Colorectal cancer (SNP x SNP interaction);	chr5:109327935	chr5:109237120~109326369:-
LUAD	cis	rs9918079	0.56	rs10008975	ENSG00000273133.1	RP11-799M12.2	-9.57	5.6e-20	9.51e-17	-0.55	-0.4	Obesity-related traits;	chr4:15622948	chr4:15563698~15564253:-
LUAD	cis	rs10129255	1	rs10129407	ENSG00000211970.3	IGHV4-61	-9.57	5.63e-20	9.57e-17	-0.31	-0.4	Kawasaki disease;	chr14:106767956	chr14:106639119~106639657:-
LUAD	cis	rs34779708	0.658	rs4934715	ENSG00000230534.5	RP11-297A16.2	9.57	5.64e-20	9.59e-17	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35076064	chr10:35098006~35127020:-
LUAD	cis	rs6142102	0.625	rs4911381	ENSG00000276073.1	RP5-1125A11.7	9.57	5.66e-20	9.61e-17	0.4	0.4	Skin pigmentation;	chr20:33962539	chr20:33985617~33988989:-
LUAD	cis	rs12468226	0.873	rs12472035	ENSG00000273456.1	RP11-686O6.2	9.57	5.66e-20	9.62e-17	0.64	0.4	Urate levels;	chr2:202221970	chr2:202374932~202375604:-
LUAD	cis	rs7044106	0.762	rs10984974	ENSG00000226752.6	PSMD5-AS1	-9.57	5.67e-20	9.63e-17	-0.43	-0.4	Hip circumference adjusted for BMI;	chr9:120659278	chr9:120824828~120854385:+
LUAD	cis	rs6504950	0.72	rs9913784	ENSG00000275710.1	RP11-257O5.4	9.57	5.71e-20	9.69e-17	0.5	0.4	Breast cancer;	chr17:54911710	chr17:54964474~54964679:+
LUAD	cis	rs904251	0.523	rs1776455	ENSG00000204110.6	RP1-153P14.8	-9.57	5.72e-20	9.71e-17	-0.4	-0.4	Cognitive performance;	chr6:37515147	chr6:37507348~37535616:+
LUAD	cis	rs6782228	0.606	rs2253144	ENSG00000242551.2	POU5F1P6	9.57	5.76e-20	9.78e-17	0.45	0.4	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611077	chr3:128674735~128677005:-
LUAD	cis	rs321358	1	rs321355	ENSG00000271584.1	RP11-89C3.4	9.57	5.76e-20	9.78e-17	0.67	0.4	Body mass index;	chr11:111124273	chr11:111091932~111097357:-
LUAD	cis	rs9309711	0.689	rs4535075	ENSG00000225234.1	TRAPPC12-AS1	-9.57	5.79e-20	9.82e-17	-0.46	-0.4	Neurofibrillary tangles;	chr2:3477945	chr2:3481242~3482409:-
LUAD	cis	rs9309711	0.666	rs6767	ENSG00000225234.1	TRAPPC12-AS1	-9.57	5.79e-20	9.82e-17	-0.46	-0.4	Neurofibrillary tangles;	chr2:3479434	chr2:3481242~3482409:-
LUAD	cis	rs9309711	0.623	rs7569694	ENSG00000225234.1	TRAPPC12-AS1	-9.57	5.79e-20	9.82e-17	-0.46	-0.4	Neurofibrillary tangles;	chr2:3479619	chr2:3481242~3482409:-
LUAD	cis	rs227275	0.554	rs223457	ENSG00000246560.2	RP11-10L12.4	9.56	5.91e-20	1e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102788506	chr4:102828055~102844075:+
LUAD	cis	rs34779708	0.966	rs10827487	ENSG00000230534.5	RP11-297A16.2	9.56	5.95e-20	1.01e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35117950	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs4294520	ENSG00000230534.5	RP11-297A16.2	9.56	6.01e-20	1.02e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35133578	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs34876468	ENSG00000230534.5	RP11-297A16.2	9.56	6.01e-20	1.02e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35135522	chr10:35098006~35127020:-
LUAD	cis	rs11722779	0.844	rs3974602	ENSG00000246560.2	RP11-10L12.4	9.56	6.1e-20	1.03e-16	0.49	0.4	Schizophrenia;	chr4:102928840	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs13113923	ENSG00000246560.2	RP11-10L12.4	9.56	6.11e-20	1.04e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102918936	chr4:102828055~102844075:+
LUAD	cis	rs34779708	0.931	rs4934721	ENSG00000230534.5	RP11-297A16.2	9.56	6.14e-20	1.04e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35088787	chr10:35098006~35127020:-
LUAD	cis	rs1757171	0.504	rs11969056	ENSG00000204110.6	RP1-153P14.8	-9.56	6.2e-20	1.05e-16	-0.4	-0.4	Cognitive performance;	chr6:37516509	chr6:37507348~37535616:+
LUAD	cis	rs228614	0.536	rs223420	ENSG00000246560.2	RP11-10L12.4	9.56	6.26e-20	1.06e-16	0.49	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102806853	chr4:102828055~102844075:+
LUAD	cis	rs904251	0.523	rs10947675	ENSG00000204110.6	RP1-153P14.8	-9.56	6.27e-20	1.06e-16	-0.41	-0.4	Cognitive performance;	chr6:37512196	chr6:37507348~37535616:+
LUAD	cis	rs228614	0.51	rs223410	ENSG00000246560.2	RP11-10L12.4	9.56	6.31e-20	1.07e-16	0.49	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102813568	chr4:102828055~102844075:+
LUAD	cis	rs4774565	0.762	rs7164848	ENSG00000244879.4	GABPB1-AS1	9.56	6.31e-20	1.07e-16	0.35	0.4	Breast cancer;	chr15:50370833	chr15:50354959~50372202:+
LUAD	cis	rs34779708	0.966	rs4934536	ENSG00000230534.5	RP11-297A16.2	9.56	6.33e-20	1.07e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35152241	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs4934537	ENSG00000230534.5	RP11-297A16.2	9.56	6.33e-20	1.07e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35152584	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs12784482	ENSG00000230534.5	RP11-297A16.2	9.56	6.33e-20	1.07e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35157937	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs113170867	ENSG00000230534.5	RP11-297A16.2	9.56	6.33e-20	1.07e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35161219	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs17499811	ENSG00000230534.5	RP11-297A16.2	9.56	6.33e-20	1.07e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35167287	chr10:35098006~35127020:-
LUAD	cis	rs6142102	0.625	rs2050208	ENSG00000276073.1	RP5-1125A11.7	-9.55	6.37e-20	1.08e-16	-0.41	-0.4	Skin pigmentation;	chr20:33955767	chr20:33985617~33988989:-
LUAD	cis	rs7684446	1	rs7684446	ENSG00000273133.1	RP11-799M12.2	9.55	6.43e-20	1.09e-16	0.52	0.4	Red blood cell count;	chr4:15591241	chr4:15563698~15564253:-
LUAD	cis	rs1789	0.653	rs13142069	ENSG00000273133.1	RP11-799M12.2	9.55	6.43e-20	1.09e-16	0.52	0.4	Blood protein levels;	chr4:15592069	chr4:15563698~15564253:-
LUAD	cis	rs694739	0.892	rs647152	ENSG00000236935.1	AP003774.1	9.55	6.56e-20	1.11e-16	0.39	0.4	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64341646	chr11:64325050~64329504:-
LUAD	cis	rs9918079	0.56	rs4557256	ENSG00000273133.1	RP11-799M12.2	-9.55	6.56e-20	1.11e-16	-0.55	-0.4	Obesity-related traits;	chr4:15625024	chr4:15563698~15564253:-
LUAD	cis	rs9918079	0.56	rs4698402	ENSG00000273133.1	RP11-799M12.2	-9.55	6.56e-20	1.11e-16	-0.55	-0.4	Obesity-related traits;	chr4:15628180	chr4:15563698~15564253:-
LUAD	cis	rs9918079	0.56	rs7662032	ENSG00000273133.1	RP11-799M12.2	-9.55	6.56e-20	1.11e-16	-0.55	-0.4	Obesity-related traits;	chr4:15633791	chr4:15563698~15564253:-
LUAD	cis	rs9918079	0.56	rs12651550	ENSG00000273133.1	RP11-799M12.2	-9.55	6.56e-20	1.11e-16	-0.55	-0.4	Obesity-related traits;	chr4:15639395	chr4:15563698~15564253:-
LUAD	cis	rs1789	0.839	rs9997068	ENSG00000273133.1	RP11-799M12.2	-9.55	6.56e-20	1.11e-16	-0.55	-0.4	Blood protein levels;	chr4:15649367	chr4:15563698~15564253:-
LUAD	cis	rs9918079	0.56	rs6414767	ENSG00000273133.1	RP11-799M12.2	-9.55	6.56e-20	1.11e-16	-0.55	-0.4	Obesity-related traits;	chr4:15654098	chr4:15563698~15564253:-
LUAD	cis	rs228614	0.536	rs223419	ENSG00000246560.2	RP11-10L12.4	9.55	6.57e-20	1.11e-16	0.49	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102808586	chr4:102828055~102844075:+
LUAD	cis	rs34779708	0.931	rs79749947	ENSG00000230534.5	RP11-297A16.2	9.55	6.6e-20	1.11e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:34988153	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs9663401	ENSG00000230534.5	RP11-297A16.2	9.55	6.6e-20	1.11e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:34989921	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.897	rs9787566	ENSG00000230534.5	RP11-297A16.2	9.55	6.6e-20	1.11e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:34990527	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs4351760	ENSG00000230534.5	RP11-297A16.2	9.55	6.6e-20	1.11e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:34991326	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.898	rs4934695	ENSG00000230534.5	RP11-297A16.2	9.55	6.6e-20	1.11e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:34991677	chr10:35098006~35127020:-
LUAD	cis	rs11098499	0.779	rs10857066	ENSG00000245958.5	RP11-33B1.1	-9.55	6.62e-20	1.12e-16	-0.35	-0.4	Corneal astigmatism;	chr4:119365441	chr4:119454791~119552025:+
LUAD	cis	rs494459	0.838	rs567680	ENSG00000255422.1	AP002954.4	-9.55	6.64e-20	1.12e-16	-0.49	-0.4	Height;	chr11:118737823	chr11:118704607~118750263:+
LUAD	cis	rs7044106	0.762	rs10491783	ENSG00000226752.6	PSMD5-AS1	-9.55	6.65e-20	1.12e-16	-0.44	-0.4	Hip circumference adjusted for BMI;	chr9:120687877	chr9:120824828~120854385:+
LUAD	cis	rs7044106	0.762	rs966397	ENSG00000226752.6	PSMD5-AS1	-9.55	6.65e-20	1.12e-16	-0.44	-0.4	Hip circumference adjusted for BMI;	chr9:120691034	chr9:120824828~120854385:+
LUAD	cis	rs6142102	0.602	rs1054534	ENSG00000276073.1	RP5-1125A11.7	-9.55	6.69e-20	1.13e-16	-0.4	-0.4	Skin pigmentation;	chr20:34017521	chr20:33985617~33988989:-
LUAD	cis	rs7044106	0.762	rs1158553	ENSG00000226752.6	PSMD5-AS1	-9.55	6.7e-20	1.13e-16	-0.44	-0.4	Hip circumference adjusted for BMI;	chr9:120638696	chr9:120824828~120854385:+
LUAD	cis	rs6504950	0.72	rs9910653	ENSG00000275710.1	RP11-257O5.4	9.55	6.72e-20	1.13e-16	0.5	0.4	Breast cancer;	chr17:54914907	chr17:54964474~54964679:+
LUAD	cis	rs9309711	0.666	rs6723101	ENSG00000225234.1	TRAPPC12-AS1	-9.55	6.74e-20	1.14e-16	-0.46	-0.4	Neurofibrillary tangles;	chr2:3480672	chr2:3481242~3482409:-
LUAD	cis	rs494459	0.726	rs1784300	ENSG00000255422.1	AP002954.4	-9.55	6.86e-20	1.16e-16	-0.5	-0.4	Height;	chr11:118808920	chr11:118704607~118750263:+
LUAD	cis	rs7044106	0.762	rs1158554	ENSG00000226752.6	PSMD5-AS1	-9.55	6.87e-20	1.16e-16	-0.43	-0.4	Hip circumference adjusted for BMI;	chr9:120638620	chr9:120824828~120854385:+
LUAD	cis	rs16828019	0.777	rs13376450	ENSG00000235358.1	RP11-399E6.1	9.54	6.94e-20	1.17e-16	0.68	0.4	Intelligence (multi-trait analysis);	chr1:41003371	chr1:41242373~41284861:+
LUAD	cis	rs8062405	1	rs12443881	ENSG00000259982.1	CDC37P1	9.54	6.96e-20	1.17e-16	0.52	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28700294~28701540:-
LUAD	cis	rs1153858	0.945	rs1974981	ENSG00000259520.4	CTD-2651B20.3	9.54	7.11e-20	1.19e-16	0.54	0.4	Homoarginine levels;	chr15:45436925	chr15:45251580~45279251:-
LUAD	cis	rs367615	0.552	rs2963010	ENSG00000249476.1	CTD-2587M2.1	-9.54	7.15e-20	1.2e-16	-0.47	-0.4	Colorectal cancer (SNP x SNP interaction);	chr5:109401342	chr5:109237120~109326369:-
LUAD	cis	rs8040855	0.965	rs1961276	ENSG00000259295.5	CSPG4P12	9.54	7.16e-20	1.2e-16	0.47	0.4	Bulimia nervosa;	chr15:85170986	chr15:85191438~85213905:+
LUAD	cis	rs9660180	0.967	rs2272908	ENSG00000231050.1	RP1-140A9.1	-9.54	7.17e-20	1.2e-16	-0.45	-0.4	Body mass index;	chr1:1790040	chr1:1891471~1892658:+
LUAD	cis	rs34779708	0.897	rs7897827	ENSG00000230534.5	RP11-297A16.2	9.54	7.18e-20	1.21e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35097309	chr10:35098006~35127020:-
LUAD	cis	rs321358	0.79	rs4635115	ENSG00000271584.1	RP11-89C3.4	9.54	7.18e-20	1.21e-16	0.64	0.4	Body mass index;	chr11:111076352	chr11:111091932~111097357:-
LUAD	cis	rs34779708	0.931	rs4934724	ENSG00000230534.5	RP11-297A16.2	9.54	7.27e-20	1.22e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35104741	chr10:35098006~35127020:-
LUAD	cis	rs12468226	1	rs12468226	ENSG00000273456.1	RP11-686O6.2	9.54	7.27e-20	1.22e-16	0.61	0.4	Urate levels;	chr2:202472278	chr2:202374932~202375604:-
LUAD	cis	rs12468226	1	rs74508472	ENSG00000273456.1	RP11-686O6.2	9.54	7.27e-20	1.22e-16	0.61	0.4	Urate levels;	chr2:202517290	chr2:202374932~202375604:-
LUAD	cis	rs11098499	0.604	rs2389887	ENSG00000245958.5	RP11-33B1.1	-9.54	7.3e-20	1.23e-16	-0.37	-0.4	Corneal astigmatism;	chr4:119649489	chr4:119454791~119552025:+
LUAD	cis	rs7044106	0.762	rs1324473	ENSG00000226752.6	PSMD5-AS1	9.54	7.32e-20	1.23e-16	0.43	0.4	Hip circumference adjusted for BMI;	chr9:120642332	chr9:120824828~120854385:+
LUAD	cis	rs1891275	0.515	rs6583784	ENSG00000228701.1	TNKS2-AS1	9.54	7.34e-20	1.23e-16	0.49	0.4	Intelligence (multi-trait analysis);	chr10:91731819	chr10:91782839~91798291:-
LUAD	cis	rs34779708	0.966	rs4934734	ENSG00000230534.5	RP11-297A16.2	9.54	7.41e-20	1.24e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35145445	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs12769575	ENSG00000230534.5	RP11-297A16.2	9.54	7.41e-20	1.24e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35146999	chr10:35098006~35127020:-
LUAD	cis	rs228614	0.51	rs223434	ENSG00000246560.2	RP11-10L12.4	9.54	7.46e-20	1.25e-16	0.49	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799902	chr4:102828055~102844075:+
LUAD	cis	rs7188445	0.592	rs7199794	ENSG00000261390.4	RP11-345M22.2	9.53	7.46e-20	1.25e-16	0.49	0.4	Urate levels;	chr16:79708296	chr16:79715232~79770563:-
LUAD	cis	rs12468226	0.873	rs12470401	ENSG00000273456.1	RP11-686O6.2	9.53	7.49e-20	1.25e-16	0.64	0.4	Urate levels;	chr2:202236436	chr2:202374932~202375604:-
LUAD	cis	rs8062405	0.964	rs62036614	ENSG00000259982.1	CDC37P1	9.53	7.49e-20	1.26e-16	0.51	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28700294~28701540:-
LUAD	cis	rs11098499	0.78	rs7692994	ENSG00000245958.5	RP11-33B1.1	-9.53	7.5e-20	1.26e-16	-0.35	-0.4	Corneal astigmatism;	chr4:119506334	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.82	rs28578366	ENSG00000245958.5	RP11-33B1.1	9.53	7.51e-20	1.26e-16	0.37	0.4	Corneal astigmatism;	chr4:119615750	chr4:119454791~119552025:+
LUAD	cis	rs6142102	0.602	rs6141435	ENSG00000276073.1	RP5-1125A11.7	-9.53	7.6e-20	1.27e-16	-0.4	-0.4	Skin pigmentation;	chr20:33963473	chr20:33985617~33988989:-
LUAD	cis	rs34779708	0.966	rs2045918	ENSG00000230534.5	RP11-297A16.2	9.53	7.65e-20	1.28e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35129589	chr10:35098006~35127020:-
LUAD	cis	rs321358	1	rs321356	ENSG00000271584.1	RP11-89C3.4	-9.53	7.71e-20	1.29e-16	-0.67	-0.4	Body mass index;	chr11:111124957	chr11:111091932~111097357:-
LUAD	cis	rs34779708	0.931	rs11010130	ENSG00000230534.5	RP11-297A16.2	9.53	7.93e-20	1.33e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35224379	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.897	rs11010131	ENSG00000230534.5	RP11-297A16.2	9.53	7.93e-20	1.33e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35224388	chr10:35098006~35127020:-
LUAD	cis	rs10129255	0.5	rs10143242	ENSG00000280411.1	IGHV1-69-2	-9.53	8e-20	1.34e-16	-0.27	-0.4	Kawasaki disease;	chr14:106681814	chr14:106762092~106762588:-
LUAD	cis	rs11098499	1	rs6849889	ENSG00000245958.5	RP11-33B1.1	-9.53	8.01e-20	1.34e-16	-0.37	-0.4	Corneal astigmatism;	chr4:119265193	chr4:119454791~119552025:+
LUAD	cis	rs7208859	0.673	rs3816780	ENSG00000263531.1	RP13-753N3.1	9.53	8.06e-20	1.35e-16	0.78	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834340	chr17:30863921~30864940:-
LUAD	cis	rs3096299	0.586	rs4572400	ENSG00000274627.1	RP11-104N10.2	9.52	8.12e-20	1.36e-16	0.39	0.4	Multiple myeloma (IgH translocation);	chr16:89467108	chr16:89516797~89522217:+
LUAD	cis	rs9532669	0.926	rs4254182	ENSG00000176268.5	CYCSP34	9.52	8.14e-20	1.36e-16	0.38	0.4	Cervical cancer;	chr13:40879120	chr13:40863599~40863902:-
LUAD	cis	rs10129255	0.5	rs2105989	ENSG00000211972.2	IGHV3-66	9.52	8.17e-20	1.36e-16	0.32	0.4	Kawasaki disease;	chr14:106682199	chr14:106675017~106675544:-
LUAD	cis	rs34779708	0.931	rs11597483	ENSG00000230534.5	RP11-297A16.2	9.52	8.18e-20	1.37e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:34996189	chr10:35098006~35127020:-
LUAD	cis	rs2564921	0.704	rs56058643	ENSG00000242142.1	SERBP1P3	-9.52	8.24e-20	1.38e-16	-0.45	-0.4	Height;	chr3:53093751	chr3:53064283~53065091:-
LUAD	cis	rs6142102	0.602	rs4911399	ENSG00000276073.1	RP5-1125A11.7	-9.52	8.27e-20	1.38e-16	-0.4	-0.4	Skin pigmentation;	chr20:34035612	chr20:33985617~33988989:-
LUAD	cis	rs227275	0.554	rs223319	ENSG00000246560.2	RP11-10L12.4	9.52	8.34e-20	1.39e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102881157	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.509	rs223318	ENSG00000246560.2	RP11-10L12.4	9.52	8.34e-20	1.39e-16	0.49	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102881422	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.554	rs223315	ENSG00000246560.2	RP11-10L12.4	9.52	8.36e-20	1.39e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102884286	chr4:102828055~102844075:+
LUAD	cis	rs34779708	0.931	rs4934535	ENSG00000230534.5	RP11-297A16.2	9.52	8.38e-20	1.4e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35143793	chr10:35098006~35127020:-
LUAD	cis	rs2019137	1	rs2019137	ENSG00000274877.1	RP11-65I12.1	9.52	8.43e-20	1.41e-16	0.5	0.4	Lymphocyte counts;	chr2:113216055	chr2:113237595~113240825:+
LUAD	cis	rs2019137	0.967	rs895412	ENSG00000274877.1	RP11-65I12.1	9.52	8.43e-20	1.41e-16	0.5	0.4	Lymphocyte counts;	chr2:113216387	chr2:113237595~113240825:+
LUAD	cis	rs227275	0.556	rs4235407	ENSG00000246560.2	RP11-10L12.4	9.52	8.43e-20	1.41e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102897427	chr4:102828055~102844075:+
LUAD	cis	rs6991838	0.584	rs1053088	ENSG00000200714.1	Y_RNA	9.52	8.44e-20	1.41e-16	0.49	0.4	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65592731~65592820:+
LUAD	cis	rs34779708	0.966	rs1545757	ENSG00000230534.5	RP11-297A16.2	9.52	8.52e-20	1.42e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35156660	chr10:35098006~35127020:-
LUAD	cis	rs5769707	0.749	rs7286706	ENSG00000188511.11	C22orf34	9.52	8.53e-20	1.42e-16	0.45	0.4	Monocyte percentage of white cells;Monocyte count;	chr22:49664698	chr22:49414524~49657542:-
LUAD	cis	rs7044106	0.762	rs7024046	ENSG00000226752.6	PSMD5-AS1	-9.52	8.54e-20	1.42e-16	-0.44	-0.4	Hip circumference adjusted for BMI;	chr9:120656900	chr9:120824828~120854385:+
LUAD	cis	rs950027	0.787	rs1153845	ENSG00000259520.4	CTD-2651B20.3	9.52	8.57e-20	1.43e-16	0.5	0.4	Response to fenofibrate (adiponectin levels);	chr15:45432531	chr15:45251580~45279251:-
LUAD	cis	rs11098499	0.866	rs12501602	ENSG00000245958.5	RP11-33B1.1	-9.52	8.61e-20	1.43e-16	-0.35	-0.4	Corneal astigmatism;	chr4:119366780	chr4:119454791~119552025:+
LUAD	cis	rs7104764	0.507	rs7111364	ENSG00000277290.1	RP11-326C3.16	-9.52	8.65e-20	1.44e-16	-0.45	-0.4	Menarche (age at onset);	chr11:258542	chr11:243099~243483:-
LUAD	cis	rs6142102	0.602	rs4911402	ENSG00000276073.1	RP5-1125A11.7	-9.52	8.66e-20	1.44e-16	-0.39	-0.4	Skin pigmentation;	chr20:34079839	chr20:33985617~33988989:-
LUAD	cis	rs12468226	1	rs74766638	ENSG00000273456.1	RP11-686O6.2	9.51	8.89e-20	1.48e-16	0.61	0.4	Urate levels;	chr2:202445168	chr2:202374932~202375604:-
LUAD	cis	rs1891275	0.515	rs1592051	ENSG00000228701.1	TNKS2-AS1	9.51	8.92e-20	1.48e-16	0.48	0.4	Intelligence (multi-trait analysis);	chr10:91782429	chr10:91782839~91798291:-
LUAD	cis	rs11098499	0.754	rs7689729	ENSG00000245958.5	RP11-33B1.1	-9.51	8.96e-20	1.49e-16	-0.36	-0.4	Corneal astigmatism;	chr4:119335037	chr4:119454791~119552025:+
LUAD	cis	rs10028773	0.7	rs7690338	ENSG00000245958.5	RP11-33B1.1	-9.51	8.96e-20	1.49e-16	-0.36	-0.4	Educational attainment;	chr4:119335313	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.865	rs3956464	ENSG00000245958.5	RP11-33B1.1	-9.51	8.96e-20	1.49e-16	-0.36	-0.4	Corneal astigmatism;	chr4:119335609	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.619	rs28502463	ENSG00000245958.5	RP11-33B1.1	-9.51	8.96e-20	1.49e-16	-0.36	-0.4	Corneal astigmatism;	chr4:119335868	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.648	rs2002047	ENSG00000245958.5	RP11-33B1.1	-9.51	8.96e-20	1.49e-16	-0.36	-0.4	Corneal astigmatism;	chr4:119336073	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.775	rs2002049	ENSG00000245958.5	RP11-33B1.1	-9.51	8.96e-20	1.49e-16	-0.36	-0.4	Corneal astigmatism;	chr4:119336262	chr4:119454791~119552025:+
LUAD	cis	rs1155848	0.892	rs1023293	ENSG00000227354.5	RBM26-AS1	9.51	8.99e-20	1.49e-16	0.86	0.4	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79480285	chr13:79406309~79424328:+
LUAD	cis	rs6452524	0.904	rs10473867	ENSG00000249664.1	CTD-2227C6.2	9.51	8.99e-20	1.49e-16	0.46	0.4	Hypertension (SNP x SNP interaction);	chr5:83141613	chr5:83012285~83013109:-
LUAD	cis	rs6452524	0.904	rs10474095	ENSG00000249664.1	CTD-2227C6.2	9.51	9e-20	1.5e-16	0.47	0.4	Hypertension (SNP x SNP interaction);	chr5:83154887	chr5:83012285~83013109:-
LUAD	cis	rs2739330	0.627	rs9608219	ENSG00000099984.9	GSTT2	-9.51	9.04e-20	1.5e-16	-0.48	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23980123~23983911:+
LUAD	cis	rs227275	0.554	rs150895	ENSG00000246560.2	RP11-10L12.4	9.51	9.05e-20	1.5e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102791432	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.554	rs223442	ENSG00000246560.2	RP11-10L12.4	9.51	9.05e-20	1.5e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102793960	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.554	rs223441	ENSG00000246560.2	RP11-10L12.4	9.51	9.05e-20	1.5e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102794228	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.554	rs223439	ENSG00000246560.2	RP11-10L12.4	9.51	9.05e-20	1.5e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102798377	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.554	rs223436	ENSG00000246560.2	RP11-10L12.4	9.51	9.05e-20	1.5e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102798749	chr4:102828055~102844075:+
LUAD	cis	rs6452524	1	rs10068099	ENSG00000249664.1	CTD-2227C6.2	9.51	9.13e-20	1.52e-16	0.45	0.4	Hypertension (SNP x SNP interaction);	chr5:83161373	chr5:83012285~83013109:-
LUAD	cis	rs10129255	0.518	rs10150460	ENSG00000280411.1	IGHV1-69-2	9.51	9.15e-20	1.52e-16	0.27	0.4	Kawasaki disease;	chr14:106677179	chr14:106762092~106762588:-
LUAD	cis	rs2455601	0.786	rs56680262	ENSG00000254860.4	TMEM9B-AS1	9.51	9.21e-20	1.53e-16	0.57	0.4	Schizophrenia;	chr11:8950008	chr11:8964675~8977527:+
LUAD	cis	rs1155848	0.892	rs28546558	ENSG00000227354.5	RBM26-AS1	9.51	9.24e-20	1.53e-16	0.9	0.4	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79516024	chr13:79406309~79424328:+
LUAD	cis	rs11722779	0.658	rs6533044	ENSG00000246560.2	RP11-10L12.4	9.51	9.27e-20	1.54e-16	0.49	0.4	Schizophrenia;	chr4:102965261	chr4:102828055~102844075:+
LUAD	cis	rs34779708	0.966	rs11592567	ENSG00000230534.5	RP11-297A16.2	9.51	9.27e-20	1.54e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35120441	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs4934538	ENSG00000230534.5	RP11-297A16.2	9.51	9.27e-20	1.54e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35183222	chr10:35098006~35127020:-
LUAD	cis	rs9326248	0.911	rs474339	ENSG00000280143.1	AP000892.6	9.51	9.3e-20	1.54e-16	0.48	0.4	Blood protein levels;	chr11:117188836	chr11:117204967~117210292:+
LUAD	cis	rs11098499	0.866	rs10518329	ENSG00000245958.5	RP11-33B1.1	-9.51	9.35e-20	1.55e-16	-0.34	-0.4	Corneal astigmatism;	chr4:119480680	chr4:119454791~119552025:+
LUAD	cis	rs10875746	0.859	rs11558768	ENSG00000240399.1	RP1-228P16.1	-9.51	9.41e-20	1.56e-16	-0.47	-0.4	Longevity (90 years and older);	chr12:48184006	chr12:48054813~48055591:-
LUAD	cis	rs6142102	0.602	rs2300209	ENSG00000276073.1	RP5-1125A11.7	-9.51	9.49e-20	1.57e-16	-0.39	-0.4	Skin pigmentation;	chr20:34055294	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.602	rs932388	ENSG00000276073.1	RP5-1125A11.7	-9.51	9.49e-20	1.57e-16	-0.39	-0.4	Skin pigmentation;	chr20:34069572	chr20:33985617~33988989:-
LUAD	cis	rs2455601	0.744	rs11042133	ENSG00000254860.4	TMEM9B-AS1	9.5	9.6e-20	1.59e-16	0.57	0.4	Schizophrenia;	chr11:8944964	chr11:8964675~8977527:+
LUAD	cis	rs11723261	0.527	rs11731581	ENSG00000275426.1	CH17-262A2.1	9.5	9.61e-20	1.59e-16	0.54	0.4	Immune response to smallpox vaccine (IL-6);	chr4:88044	chr4:149738~150317:+
LUAD	cis	rs11098499	0.657	rs10434028	ENSG00000245958.5	RP11-33B1.1	-9.5	9.71e-20	1.61e-16	-0.35	-0.4	Corneal astigmatism;	chr4:119373309	chr4:119454791~119552025:+
LUAD	cis	rs494459	0.838	rs12796102	ENSG00000255422.1	AP002954.4	-9.5	9.8e-20	1.62e-16	-0.5	-0.4	Height;	chr11:118791319	chr11:118704607~118750263:+
LUAD	cis	rs9481169	0.85	rs4947128	ENSG00000255389.1	C6orf3	-9.5	9.83e-20	1.63e-16	-0.77	-0.4	Inflammatory skin disease;	chr6:111597665	chr6:111599875~111602295:+
LUAD	cis	rs9660180	0.967	rs11260623	ENSG00000231050.1	RP1-140A9.1	9.5	9.87e-20	1.63e-16	0.45	0.4	Body mass index;	chr1:1850017	chr1:1891471~1892658:+
LUAD	cis	rs6452524	1	rs7349753	ENSG00000249664.1	CTD-2227C6.2	9.5	9.89e-20	1.64e-16	0.45	0.4	Hypertension (SNP x SNP interaction);	chr5:83165632	chr5:83012285~83013109:-
LUAD	cis	rs7044106	0.762	rs4837789	ENSG00000226752.6	PSMD5-AS1	-9.5	9.96e-20	1.65e-16	-0.44	-0.4	Hip circumference adjusted for BMI;	chr9:120663978	chr9:120824828~120854385:+
LUAD	cis	rs228614	0.51	rs65671	ENSG00000246560.2	RP11-10L12.4	9.5	9.96e-20	1.65e-16	0.49	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102801081	chr4:102828055~102844075:+
LUAD	cis	rs2564921	0.679	rs12635933	ENSG00000242142.1	SERBP1P3	-9.5	1e-19	1.66e-16	-0.45	-0.4	Height;	chr3:53015087	chr3:53064283~53065091:-
LUAD	cis	rs227275	0.525	rs10028116	ENSG00000246560.2	RP11-10L12.4	9.5	1.01e-19	1.67e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102931421	chr4:102828055~102844075:+
LUAD	cis	rs1061377	0.748	rs4974933	ENSG00000249207.1	RP11-360F5.1	-9.5	1.03e-19	1.7e-16	-0.44	-0.4	Uric acid levels;	chr4:39105636	chr4:39112677~39126818:-
LUAD	cis	rs748404	0.578	rs512628	ENSG00000205771.5	CATSPER2P1	-9.5	1.03e-19	1.7e-16	-0.51	-0.4	Lung cancer;	chr15:43326536	chr15:43726918~43747094:-
LUAD	cis	rs2019137	0.936	rs12612729	ENSG00000274877.1	RP11-65I12.1	9.49	1.04e-19	1.71e-16	0.5	0.4	Lymphocyte counts;	chr2:113199471	chr2:113237595~113240825:+
LUAD	cis	rs2019137	0.936	rs731834	ENSG00000274877.1	RP11-65I12.1	9.49	1.04e-19	1.71e-16	0.5	0.4	Lymphocyte counts;	chr2:113199621	chr2:113237595~113240825:+
LUAD	cis	rs10129255	0.5	rs988132	ENSG00000280411.1	IGHV1-69-2	-9.49	1.04e-19	1.71e-16	-0.28	-0.4	Kawasaki disease;	chr14:106776758	chr14:106762092~106762588:-
LUAD	cis	rs11098499	0.697	rs35280960	ENSG00000245958.5	RP11-33B1.1	-9.49	1.04e-19	1.71e-16	-0.36	-0.4	Corneal astigmatism;	chr4:119335904	chr4:119454791~119552025:+
LUAD	cis	rs34779708	0.966	rs4934730	ENSG00000230534.5	RP11-297A16.2	9.49	1.05e-19	1.73e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35126627	chr10:35098006~35127020:-
LUAD	cis	rs227275	0.525	rs7672319	ENSG00000246560.2	RP11-10L12.4	9.49	1.05e-19	1.73e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102990002	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs6533051	ENSG00000246560.2	RP11-10L12.4	9.49	1.05e-19	1.73e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102990065	chr4:102828055~102844075:+
LUAD	cis	rs6142102	0.538	rs6142058	ENSG00000276073.1	RP5-1125A11.7	-9.49	1.06e-19	1.74e-16	-0.4	-0.4	Skin pigmentation;	chr20:33954995	chr20:33985617~33988989:-
LUAD	cis	rs367615	0.552	rs7720036	ENSG00000249476.1	CTD-2587M2.1	-9.49	1.06e-19	1.75e-16	-0.47	-0.4	Colorectal cancer (SNP x SNP interaction);	chr5:109374998	chr5:109237120~109326369:-
LUAD	cis	rs7208859	0.623	rs56325146	ENSG00000263531.1	RP13-753N3.1	9.49	1.06e-19	1.75e-16	0.78	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824006	chr17:30863921~30864940:-
LUAD	cis	rs227275	0.556	rs11731885	ENSG00000246560.2	RP11-10L12.4	9.49	1.07e-19	1.77e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:103010913	chr4:102828055~102844075:+
LUAD	cis	rs7044106	0.762	rs7357638	ENSG00000226752.6	PSMD5-AS1	-9.49	1.07e-19	1.77e-16	-0.44	-0.4	Hip circumference adjusted for BMI;	chr9:120626926	chr9:120824828~120854385:+
LUAD	cis	rs7044106	0.718	rs1960421	ENSG00000226752.6	PSMD5-AS1	-9.49	1.07e-19	1.77e-16	-0.44	-0.4	Hip circumference adjusted for BMI;	chr9:120632616	chr9:120824828~120854385:+
LUAD	cis	rs2019137	0.936	rs2305133	ENSG00000274877.1	RP11-65I12.1	9.49	1.07e-19	1.77e-16	0.5	0.4	Lymphocyte counts;	chr2:113199244	chr2:113237595~113240825:+
LUAD	cis	rs1155848	0.892	rs3759438	ENSG00000227354.5	RBM26-AS1	9.49	1.09e-19	1.79e-16	0.86	0.4	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79566863	chr13:79406309~79424328:+
LUAD	cis	rs16828019	0.852	rs12045171	ENSG00000235358.1	RP11-399E6.1	9.49	1.09e-19	1.8e-16	0.64	0.4	Intelligence (multi-trait analysis);	chr1:41063133	chr1:41242373~41284861:+
LUAD	cis	rs6142102	0.602	rs4911380	ENSG00000276073.1	RP5-1125A11.7	-9.49	1.09e-19	1.8e-16	-0.4	-0.4	Skin pigmentation;	chr20:33958418	chr20:33985617~33988989:-
LUAD	cis	rs2019137	0.967	rs902695	ENSG00000274877.1	RP11-65I12.1	9.49	1.1e-19	1.81e-16	0.5	0.4	Lymphocyte counts;	chr2:113197497	chr2:113237595~113240825:+
LUAD	cis	rs2019137	0.905	rs2276561	ENSG00000274877.1	RP11-65I12.1	9.49	1.1e-19	1.81e-16	0.5	0.4	Lymphocyte counts;	chr2:113198794	chr2:113237595~113240825:+
LUAD	cis	rs34779708	0.897	rs16935880	ENSG00000230534.5	RP11-297A16.2	9.49	1.1e-19	1.81e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35126540	chr10:35098006~35127020:-
LUAD	cis	rs11098499	0.754	rs938056	ENSG00000245958.5	RP11-33B1.1	-9.49	1.1e-19	1.81e-16	-0.36	-0.4	Corneal astigmatism;	chr4:119316298	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs878376	ENSG00000245958.5	RP11-33B1.1	-9.49	1.1e-19	1.81e-16	-0.36	-0.4	Corneal astigmatism;	chr4:119316547	chr4:119454791~119552025:+
LUAD	cis	rs62229266	0.839	rs11088335	ENSG00000231106.2	LINC01436	9.49	1.1e-19	1.82e-16	0.53	0.4	Mitral valve prolapse;	chr21:36098037	chr21:36005338~36007838:+
LUAD	cis	rs10129255	0.5	rs9324092	ENSG00000211972.2	IGHV3-66	-9.49	1.11e-19	1.82e-16	-0.31	-0.4	Kawasaki disease;	chr14:106683806	chr14:106675017~106675544:-
LUAD	cis	rs7044106	0.762	rs4837790	ENSG00000226752.6	PSMD5-AS1	-9.49	1.11e-19	1.82e-16	-0.43	-0.4	Hip circumference adjusted for BMI;	chr9:120684047	chr9:120824828~120854385:+
LUAD	cis	rs11722779	0.935	rs3857200	ENSG00000246560.2	RP11-10L12.4	9.49	1.12e-19	1.84e-16	0.49	0.4	Schizophrenia;	chr4:103001864	chr4:102828055~102844075:+
LUAD	cis	rs4423214	0.879	rs1790324	ENSG00000254682.1	RP11-660L16.2	-9.48	1.13e-19	1.86e-16	-0.55	-0.4	Vitamin D levels;	chr11:71439474	chr11:71448674~71452157:+
LUAD	cis	rs12134133	1	rs28371614	ENSG00000274245.1	RP11-357P18.2	9.48	1.14e-19	1.88e-16	0.53	0.4	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207331929	chr1:207372559~207373252:+
LUAD	cis	rs34779708	0.966	rs12782948	ENSG00000230534.5	RP11-297A16.2	9.48	1.14e-19	1.88e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35161679	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs10827493	ENSG00000230534.5	RP11-297A16.2	9.48	1.14e-19	1.88e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35166048	chr10:35098006~35127020:-
LUAD	cis	rs748404	0.578	rs510108	ENSG00000205771.5	CATSPER2P1	-9.48	1.14e-19	1.88e-16	-0.51	-0.4	Lung cancer;	chr15:43313241	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.578	rs507178	ENSG00000205771.5	CATSPER2P1	-9.48	1.14e-19	1.88e-16	-0.51	-0.4	Lung cancer;	chr15:43317937	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.578	rs576557	ENSG00000205771.5	CATSPER2P1	-9.48	1.16e-19	1.9e-16	-0.51	-0.4	Lung cancer;	chr15:43305539	chr15:43726918~43747094:-
LUAD	cis	rs11098499	0.604	rs34278750	ENSG00000245958.5	RP11-33B1.1	-9.48	1.17e-19	1.92e-16	-0.37	-0.4	Corneal astigmatism;	chr4:119649981	chr4:119454791~119552025:+
LUAD	cis	rs5760092	0.572	rs738806	ENSG00000273295.1	AP000350.5	9.48	1.17e-19	1.92e-16	0.53	0.4	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23901432~23907068:-
LUAD	cis	rs67180937	0.621	rs34885880	ENSG00000272750.1	RP11-378J18.8	-9.48	1.18e-19	1.93e-16	-0.42	-0.4	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222752593	chr1:222658867~222661512:-
LUAD	cis	rs977987	0.843	rs67409275	ENSG00000261783.1	RP11-252K23.2	-9.48	1.19e-19	1.95e-16	-0.53	-0.4	Dupuytren's disease;	chr16:75423314	chr16:75379818~75381260:-
LUAD	cis	rs2729354	0.768	rs2729384	ENSG00000265566.2	RN7SL605P	-9.48	1.19e-19	1.96e-16	-0.56	-0.4	Blood protein levels;	chr11:57491144	chr11:57528085~57528365:-
LUAD	cis	rs1799949	0.602	rs8176199	ENSG00000198496.9	NBR2	-9.48	1.19e-19	1.96e-16	-0.48	-0.4	Menopause (age at onset);	chr17:43078507	chr17:43125610~43153671:+
LUAD	cis	rs1891275	0.515	rs7911755	ENSG00000228701.1	TNKS2-AS1	-9.48	1.2e-19	1.98e-16	-0.49	-0.4	Intelligence (multi-trait analysis);	chr10:91730060	chr10:91782839~91798291:-
LUAD	cis	rs34779708	0.966	rs4934539	ENSG00000230534.5	RP11-297A16.2	9.47	1.22e-19	2.01e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35183271	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs1478463	ENSG00000230534.5	RP11-297A16.2	9.47	1.22e-19	2.01e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35184107	chr10:35098006~35127020:-
LUAD	cis	rs2019137	0.936	rs902696	ENSG00000274877.1	RP11-65I12.1	-9.47	1.22e-19	2.01e-16	-0.5	-0.4	Lymphocyte counts;	chr2:113197302	chr2:113237595~113240825:+
LUAD	cis	rs321358	1	rs73019214	ENSG00000271584.1	RP11-89C3.4	9.47	1.23e-19	2.01e-16	0.67	0.4	Body mass index;	chr11:111131680	chr11:111091932~111097357:-
LUAD	cis	rs10262624	0.935	rs6966641	ENSG00000234286.1	AC006026.13	-9.47	1.23e-19	2.01e-16	-0.47	-0.4	Schizophrenia;	chr7:23866979	chr7:23680195~23680786:-
LUAD	cis	rs321358	1	rs321361	ENSG00000271584.1	RP11-89C3.4	9.47	1.23e-19	2.02e-16	0.66	0.4	Body mass index;	chr11:111125495	chr11:111091932~111097357:-
LUAD	cis	rs321358	1	rs321362	ENSG00000271584.1	RP11-89C3.4	9.47	1.23e-19	2.02e-16	0.66	0.4	Body mass index;	chr11:111125754	chr11:111091932~111097357:-
LUAD	cis	rs321358	1	rs321363	ENSG00000271584.1	RP11-89C3.4	9.47	1.23e-19	2.02e-16	0.66	0.4	Body mass index;	chr11:111125929	chr11:111091932~111097357:-
LUAD	cis	rs494459	0.838	rs607125	ENSG00000255422.1	AP002954.4	-9.47	1.23e-19	2.02e-16	-0.49	-0.4	Height;	chr11:118746590	chr11:118704607~118750263:+
LUAD	cis	rs11098499	0.955	rs11931312	ENSG00000245958.5	RP11-33B1.1	-9.47	1.24e-19	2.03e-16	-0.36	-0.4	Corneal astigmatism;	chr4:119237868	chr4:119454791~119552025:+
LUAD	cis	rs228614	0.509	rs223481	ENSG00000246560.2	RP11-10L12.4	9.47	1.25e-19	2.04e-16	0.5	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766860	chr4:102828055~102844075:+
LUAD	cis	rs12468226	1	rs75040639	ENSG00000273456.1	RP11-686O6.2	9.47	1.25e-19	2.04e-16	0.6	0.4	Urate levels;	chr2:202486973	chr2:202374932~202375604:-
LUAD	cis	rs9389248	0.69	rs728030	ENSG00000232876.1	CTA-212D2.2	9.47	1.25e-19	2.05e-16	0.45	0.4	High light scatter reticulocyte percentage of red cells;	chr6:134925156	chr6:135055033~135060550:+
LUAD	cis	rs34779708	0.931	rs11596502	ENSG00000230534.5	RP11-297A16.2	9.47	1.26e-19	2.06e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35098259	chr10:35098006~35127020:-
LUAD	cis	rs227275	0.555	rs223403	ENSG00000246560.2	RP11-10L12.4	9.47	1.26e-19	2.07e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102817086	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.555	rs223402	ENSG00000246560.2	RP11-10L12.4	9.47	1.26e-19	2.07e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102817198	chr4:102828055~102844075:+
LUAD	cis	rs34779708	0.966	rs4934725	ENSG00000230534.5	RP11-297A16.2	9.47	1.27e-19	2.07e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35109308	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs12774834	ENSG00000230534.5	RP11-297A16.2	9.47	1.27e-19	2.07e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35111142	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs12775759	ENSG00000230534.5	RP11-297A16.2	9.47	1.27e-19	2.07e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35111255	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs34296409	ENSG00000230534.5	RP11-297A16.2	9.47	1.27e-19	2.07e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35115685	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs35777088	ENSG00000230534.5	RP11-297A16.2	9.47	1.27e-19	2.07e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35120120	chr10:35098006~35127020:-
LUAD	cis	rs8040855	0.931	rs11855471	ENSG00000259295.5	CSPG4P12	-9.47	1.27e-19	2.07e-16	-0.47	-0.4	Bulimia nervosa;	chr15:85175976	chr15:85191438~85213905:+
LUAD	cis	rs227275	0.554	rs223425	ENSG00000246560.2	RP11-10L12.4	9.47	1.27e-19	2.08e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102802836	chr4:102828055~102844075:+
LUAD	cis	rs2564921	0.73	rs73079924	ENSG00000242142.1	SERBP1P3	-9.47	1.27e-19	2.08e-16	-0.45	-0.4	Height;	chr3:53034139	chr3:53064283~53065091:-
LUAD	cis	rs6142102	0.502	rs58393429	ENSG00000276073.1	RP5-1125A11.7	-9.47	1.27e-19	2.08e-16	-0.4	-0.4	Skin pigmentation;	chr20:33957996	chr20:33985617~33988989:-
LUAD	cis	rs2564921	0.73	rs12633064	ENSG00000242142.1	SERBP1P3	-9.47	1.27e-19	2.08e-16	-0.45	-0.4	Height;	chr3:53027361	chr3:53064283~53065091:-
LUAD	cis	rs227275	0.525	rs11737544	ENSG00000246560.2	RP11-10L12.4	9.47	1.28e-19	2.08e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102983877	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs7685399	ENSG00000246560.2	RP11-10L12.4	9.47	1.28e-19	2.08e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102991926	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs3974485	ENSG00000246560.2	RP11-10L12.4	9.47	1.28e-19	2.08e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102993283	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs2866417	ENSG00000246560.2	RP11-10L12.4	9.47	1.28e-19	2.08e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102993481	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs7688940	ENSG00000246560.2	RP11-10L12.4	9.47	1.28e-19	2.08e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102994153	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs1383733	ENSG00000246560.2	RP11-10L12.4	9.47	1.28e-19	2.08e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102995297	chr4:102828055~102844075:+
LUAD	cis	rs12468226	1	rs57080353	ENSG00000273456.1	RP11-686O6.2	9.47	1.28e-19	2.09e-16	0.61	0.4	Urate levels;	chr2:202511824	chr2:202374932~202375604:-
LUAD	cis	rs12468226	0.81	rs3736578	ENSG00000273456.1	RP11-686O6.2	9.47	1.28e-19	2.09e-16	0.61	0.4	Urate levels;	chr2:202519989	chr2:202374932~202375604:-
LUAD	cis	rs12468226	1	rs116439150	ENSG00000273456.1	RP11-686O6.2	9.47	1.28e-19	2.09e-16	0.61	0.4	Urate levels;	chr2:202523814	chr2:202374932~202375604:-
LUAD	cis	rs12468226	1	rs12467409	ENSG00000273456.1	RP11-686O6.2	9.47	1.28e-19	2.09e-16	0.61	0.4	Urate levels;	chr2:202529625	chr2:202374932~202375604:-
LUAD	cis	rs12468226	0.81	rs77090459	ENSG00000273456.1	RP11-686O6.2	9.47	1.28e-19	2.09e-16	0.61	0.4	Urate levels;	chr2:202542132	chr2:202374932~202375604:-
LUAD	cis	rs11098499	0.566	rs7664440	ENSG00000245958.5	RP11-33B1.1	-9.47	1.28e-19	2.1e-16	-0.37	-0.4	Corneal astigmatism;	chr4:119657385	chr4:119454791~119552025:+
LUAD	cis	rs2564921	0.704	rs2336720	ENSG00000242142.1	SERBP1P3	-9.47	1.28e-19	2.1e-16	-0.41	-0.4	Height;	chr3:52994045	chr3:53064283~53065091:-
LUAD	cis	rs2564921	0.73	rs56384586	ENSG00000242142.1	SERBP1P3	-9.47	1.28e-19	2.1e-16	-0.41	-0.4	Height;	chr3:52994990	chr3:53064283~53065091:-
LUAD	cis	rs227275	0.556	rs3886723	ENSG00000246560.2	RP11-10L12.4	9.47	1.29e-19	2.11e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102983013	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.517	rs3886722	ENSG00000246560.2	RP11-10L12.4	9.47	1.29e-19	2.11e-16	0.49	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102983084	chr4:102828055~102844075:+
LUAD	cis	rs34779708	1	rs12769189	ENSG00000230534.5	RP11-297A16.2	9.47	1.29e-19	2.11e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35110740	chr10:35098006~35127020:-
LUAD	cis	rs8062405	1	rs72793811	ENSG00000259982.1	CDC37P1	9.47	1.29e-19	2.11e-16	0.52	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28700294~28701540:-
LUAD	cis	rs321358	1	rs321368	ENSG00000271584.1	RP11-89C3.4	9.47	1.3e-19	2.12e-16	0.66	0.4	Body mass index;	chr11:111129033	chr11:111091932~111097357:-
LUAD	cis	rs321358	1	rs321369	ENSG00000271584.1	RP11-89C3.4	9.47	1.3e-19	2.12e-16	0.66	0.4	Body mass index;	chr11:111129797	chr11:111091932~111097357:-
LUAD	cis	rs321358	1	rs321370	ENSG00000271584.1	RP11-89C3.4	9.47	1.3e-19	2.12e-16	0.66	0.4	Body mass index;	chr11:111129959	chr11:111091932~111097357:-
LUAD	cis	rs10129255	0.5	rs7161740	ENSG00000211972.2	IGHV3-66	9.47	1.3e-19	2.12e-16	0.32	0.4	Kawasaki disease;	chr14:106776119	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.556	rs6576222	ENSG00000211972.2	IGHV3-66	9.47	1.3e-19	2.12e-16	0.32	0.4	Kawasaki disease;	chr14:106776442	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.536	rs6576223	ENSG00000211972.2	IGHV3-66	9.47	1.3e-19	2.12e-16	0.32	0.4	Kawasaki disease;	chr14:106776448	chr14:106675017~106675544:-
LUAD	cis	rs11722779	0.81	rs223417	ENSG00000246560.2	RP11-10L12.4	9.47	1.3e-19	2.13e-16	0.49	0.4	Schizophrenia;	chr4:102810568	chr4:102828055~102844075:+
LUAD	cis	rs11722779	0.805	rs223416	ENSG00000246560.2	RP11-10L12.4	9.47	1.3e-19	2.13e-16	0.49	0.4	Schizophrenia;	chr4:102810580	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.51	rs223415	ENSG00000246560.2	RP11-10L12.4	9.47	1.31e-19	2.13e-16	0.49	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102811016	chr4:102828055~102844075:+
LUAD	cis	rs34779708	0.931	rs11010132	ENSG00000230534.5	RP11-297A16.2	9.47	1.31e-19	2.14e-16	0.47	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35228337	chr10:35098006~35127020:-
LUAD	cis	rs1891275	0.515	rs1418161	ENSG00000228701.1	TNKS2-AS1	-9.46	1.34e-19	2.18e-16	-0.49	-0.4	Intelligence (multi-trait analysis);	chr10:91724898	chr10:91782839~91798291:-
LUAD	cis	rs321358	0.895	rs6589210	ENSG00000271584.1	RP11-89C3.4	9.46	1.34e-19	2.18e-16	0.62	0.4	Body mass index;	chr11:111088408	chr11:111091932~111097357:-
LUAD	cis	rs227275	0.554	rs223399	ENSG00000246560.2	RP11-10L12.4	9.46	1.35e-19	2.2e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:102820800	chr4:102828055~102844075:+
LUAD	cis	rs10129255	1	rs11627342	ENSG00000223648.3	IGHV3-64	9.46	1.36e-19	2.21e-16	0.4	0.4	Kawasaki disease;	chr14:106675823	chr14:106643132~106658258:-
LUAD	cis	rs2729354	0.768	rs2581922	ENSG00000265566.2	RN7SL605P	-9.46	1.36e-19	2.21e-16	-0.56	-0.4	Blood protein levels;	chr11:57497927	chr11:57528085~57528365:-
LUAD	cis	rs34779708	0.931	rs12776390	ENSG00000230534.5	RP11-297A16.2	9.46	1.36e-19	2.21e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35102607	chr10:35098006~35127020:-
LUAD	cis	rs11098499	0.754	rs17049949	ENSG00000245958.5	RP11-33B1.1	-9.46	1.36e-19	2.22e-16	-0.36	-0.4	Corneal astigmatism;	chr4:119334135	chr4:119454791~119552025:+
LUAD	cis	rs494459	0.756	rs570806	ENSG00000255422.1	AP002954.4	-9.46	1.37e-19	2.23e-16	-0.49	-0.4	Height;	chr11:118786602	chr11:118704607~118750263:+
LUAD	cis	rs11098499	0.955	rs13113112	ENSG00000245958.5	RP11-33B1.1	-9.46	1.39e-19	2.26e-16	-0.37	-0.4	Corneal astigmatism;	chr4:119234885	chr4:119454791~119552025:+
LUAD	cis	rs904251	0.523	rs2776872	ENSG00000204110.6	RP1-153P14.8	-9.46	1.42e-19	2.31e-16	-0.4	-0.4	Cognitive performance;	chr6:37515011	chr6:37507348~37535616:+
LUAD	cis	rs904251	0.523	rs1757191	ENSG00000204110.6	RP1-153P14.8	-9.46	1.42e-19	2.31e-16	-0.4	-0.4	Cognitive performance;	chr6:37515095	chr6:37507348~37535616:+
LUAD	cis	rs10129255	0.5	rs988134	ENSG00000211972.2	IGHV3-66	9.46	1.42e-19	2.31e-16	0.32	0.4	Kawasaki disease;	chr14:106776698	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.5	rs988133	ENSG00000211972.2	IGHV3-66	9.46	1.42e-19	2.31e-16	0.32	0.4	Kawasaki disease;	chr14:106776724	chr14:106675017~106675544:-
LUAD	cis	rs16828019	0.777	rs67460888	ENSG00000235358.1	RP11-399E6.1	9.46	1.42e-19	2.31e-16	0.68	0.4	Intelligence (multi-trait analysis);	chr1:41003665	chr1:41242373~41284861:+
LUAD	cis	rs227275	0.525	rs4623004	ENSG00000246560.2	RP11-10L12.4	9.46	1.42e-19	2.31e-16	0.49	0.4	Allergic disease (asthma, hay fever or eczema);	chr4:103000141	chr4:102828055~102844075:+
LUAD	cis	rs56163509	1	rs56163509	ENSG00000259982.1	CDC37P1	9.46	1.42e-19	2.31e-16	0.51	0.4	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.964	rs7187333	ENSG00000259982.1	CDC37P1	9.46	1.42e-19	2.31e-16	0.51	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28700294~28701540:-
LUAD	cis	rs8062405	1	rs62037369	ENSG00000259982.1	CDC37P1	9.46	1.42e-19	2.31e-16	0.51	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.965	rs7359397	ENSG00000259982.1	CDC37P1	9.46	1.42e-19	2.31e-16	0.51	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28700294~28701540:-
LUAD	cis	rs10129255	0.5	rs9324092	ENSG00000280411.1	IGHV1-69-2	9.45	1.43e-19	2.32e-16	0.27	0.4	Kawasaki disease;	chr14:106683806	chr14:106762092~106762588:-
LUAD	cis	rs6142102	0.625	rs4911384	ENSG00000276073.1	RP5-1125A11.7	-9.45	1.43e-19	2.33e-16	-0.4	-0.4	Skin pigmentation;	chr20:33968001	chr20:33985617~33988989:-
LUAD	cis	rs10129255	0.518	rs8010020	ENSG00000211972.2	IGHV3-66	9.45	1.46e-19	2.36e-16	0.32	0.4	Kawasaki disease;	chr14:106778016	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.5	rs6576225	ENSG00000211972.2	IGHV3-66	9.45	1.46e-19	2.36e-16	0.32	0.4	Kawasaki disease;	chr14:106778120	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.5	rs6576226	ENSG00000211972.2	IGHV3-66	9.45	1.46e-19	2.36e-16	0.32	0.4	Kawasaki disease;	chr14:106778135	chr14:106675017~106675544:-
LUAD	cis	rs10256972	0.521	rs7811577	ENSG00000229043.2	AC091729.9	-9.45	1.46e-19	2.38e-16	-0.42	-0.4	Endometriosis;Longevity;	chr7:1063193	chr7:1160374~1165267:+
LUAD	cis	rs10875746	0.859	rs11168371	ENSG00000240399.1	RP1-228P16.1	-9.45	1.47e-19	2.38e-16	-0.47	-0.4	Longevity (90 years and older);	chr12:48043903	chr12:48054813~48055591:-
LUAD	cis	rs7044106	0.791	rs747819	ENSG00000226752.6	PSMD5-AS1	-9.45	1.47e-19	2.38e-16	-0.45	-0.4	Hip circumference adjusted for BMI;	chr9:120726163	chr9:120824828~120854385:+
LUAD	cis	rs34779708	0.897	rs12764820	ENSG00000230534.5	RP11-297A16.2	9.45	1.48e-19	2.4e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35097393	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs67261877	ENSG00000230534.5	RP11-297A16.2	9.45	1.48e-19	2.4e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35097412	chr10:35098006~35127020:-
LUAD	cis	rs9660180	0.967	rs6687065	ENSG00000231050.1	RP1-140A9.1	9.45	1.49e-19	2.42e-16	0.45	0.4	Body mass index;	chr1:1847030	chr1:1891471~1892658:+
LUAD	cis	rs8040855	0.627	rs4842863	ENSG00000259295.5	CSPG4P12	9.45	1.49e-19	2.42e-16	0.51	0.4	Bulimia nervosa;	chr15:85098974	chr15:85191438~85213905:+
LUAD	cis	rs11098499	0.73	rs78971550	ENSG00000245958.5	RP11-33B1.1	-9.45	1.49e-19	2.42e-16	-0.35	-0.4	Corneal astigmatism;	chr4:119359886	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.645	rs78422072	ENSG00000245958.5	RP11-33B1.1	-9.45	1.49e-19	2.42e-16	-0.35	-0.4	Corneal astigmatism;	chr4:119359887	chr4:119454791~119552025:+
LUAD	cis	rs34779708	0.966	rs10827492	ENSG00000230534.5	RP11-297A16.2	-9.45	1.5e-19	2.43e-16	-0.47	-0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35140897	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs12260130	ENSG00000230534.5	RP11-297A16.2	9.45	1.5e-19	2.44e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35178743	chr10:35098006~35127020:-
LUAD	cis	rs10129255	0.53	rs11624912	ENSG00000280411.1	IGHV1-69-2	-9.45	1.51e-19	2.45e-16	-0.27	-0.4	Kawasaki disease;	chr14:106673891	chr14:106762092~106762588:-
LUAD	cis	rs12468226	1	rs76021735	ENSG00000273456.1	RP11-686O6.2	9.45	1.52e-19	2.46e-16	0.6	0.4	Urate levels;	chr2:202511476	chr2:202374932~202375604:-
LUAD	cis	rs11098499	0.662	rs13108589	ENSG00000245958.5	RP11-33B1.1	-9.45	1.52e-19	2.47e-16	-0.35	-0.4	Corneal astigmatism;	chr4:119346947	chr4:119454791~119552025:+
LUAD	cis	rs6142102	0.602	rs4911395	ENSG00000276073.1	RP5-1125A11.7	-9.45	1.52e-19	2.47e-16	-0.39	-0.4	Skin pigmentation;	chr20:33992095	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.602	rs2268079	ENSG00000276073.1	RP5-1125A11.7	-9.45	1.52e-19	2.47e-16	-0.39	-0.4	Skin pigmentation;	chr20:34008944	chr20:33985617~33988989:-
LUAD	cis	rs9660180	0.967	rs61422524	ENSG00000231050.1	RP1-140A9.1	9.45	1.53e-19	2.48e-16	0.44	0.4	Body mass index;	chr1:1836126	chr1:1891471~1892658:+
LUAD	cis	rs228614	0.514	rs59550147	ENSG00000246560.2	RP11-10L12.4	9.45	1.53e-19	2.49e-16	0.49	0.4	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102914239	chr4:102828055~102844075:+
LUAD	cis	rs2337406	1	rs17095456	ENSG00000274576.2	IGHV2-70	-9.44	1.54e-19	2.5e-16	-0.45	-0.4	Alzheimer's disease (late onset);	chr14:106676559	chr14:106770577~106771020:-
LUAD	cis	rs10129255	0.518	rs8009594	ENSG00000211972.2	IGHV3-66	9.44	1.55e-19	2.51e-16	0.32	0.4	Kawasaki disease;	chr14:106777494	chr14:106675017~106675544:-
LUAD	cis	rs8062405	1	rs72793812	ENSG00000259982.1	CDC37P1	9.44	1.55e-19	2.51e-16	0.51	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28700294~28701540:-
LUAD	cis	rs6142102	0.602	rs4911396	ENSG00000276073.1	RP5-1125A11.7	-9.44	1.55e-19	2.51e-16	-0.39	-0.4	Skin pigmentation;	chr20:33992139	chr20:33985617~33988989:-
LUAD	cis	rs1757171	0.542	rs1757186	ENSG00000204110.6	RP1-153P14.8	-9.44	1.55e-19	2.51e-16	-0.4	-0.4	Cognitive performance;	chr6:37516335	chr6:37507348~37535616:+
LUAD	cis	rs6142102	0.602	rs2268086	ENSG00000276073.1	RP5-1125A11.7	9.44	1.58e-19	2.56e-16	0.39	0.4	Skin pigmentation;	chr20:34060932	chr20:33985617~33988989:-
LUAD	cis	rs2564921	0.704	rs55950520	ENSG00000242142.1	SERBP1P3	-9.44	1.58e-19	2.56e-16	-0.44	-0.4	Height;	chr3:53094335	chr3:53064283~53065091:-
LUAD	cis	rs11098499	0.789	rs1980024	ENSG00000245958.5	RP11-33B1.1	-9.44	1.61e-19	2.6e-16	-0.36	-0.4	Corneal astigmatism;	chr4:119331892	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs34425882	ENSG00000245958.5	RP11-33B1.1	-9.44	1.61e-19	2.6e-16	-0.36	-0.4	Corneal astigmatism;	chr4:119332022	chr4:119454791~119552025:+
LUAD	cis	rs3096299	0.781	rs2965819	ENSG00000274627.1	RP11-104N10.2	-9.44	1.61e-19	2.6e-16	-0.38	-0.4	Multiple myeloma (IgH translocation);	chr16:89434622	chr16:89516797~89522217:+
LUAD	cis	rs1061377	0.862	rs12508577	ENSG00000249207.1	RP11-360F5.1	-9.44	1.61e-19	2.6e-16	-0.44	-0.4	Uric acid levels;	chr4:39107779	chr4:39112677~39126818:-
LUAD	cis	rs904251	0.522	rs882322	ENSG00000204110.6	RP1-153P14.8	-9.44	1.61e-19	2.61e-16	-0.4	-0.4	Cognitive performance;	chr6:37516327	chr6:37507348~37535616:+
LUAD	cis	rs12468226	1	rs2350809	ENSG00000273456.1	RP11-686O6.2	9.44	1.62e-19	2.62e-16	0.6	0.4	Urate levels;	chr2:202464210	chr2:202374932~202375604:-
LUAD	cis	rs10129255	0.518	rs8009612	ENSG00000211972.2	IGHV3-66	9.44	1.62e-19	2.62e-16	0.32	0.4	Kawasaki disease;	chr14:106777510	chr14:106675017~106675544:-
LUAD	cis	rs9326248	1	rs10790175	ENSG00000280143.1	AP000892.6	9.44	1.63e-19	2.63e-16	0.46	0.4	Blood protein levels;	chr11:117164013	chr11:117204967~117210292:+
LUAD	cis	rs367615	0.512	rs246104	ENSG00000249476.1	CTD-2587M2.1	-9.44	1.63e-19	2.63e-16	-0.48	-0.4	Colorectal cancer (SNP x SNP interaction);	chr5:109365281	chr5:109237120~109326369:-
LUAD	cis	rs3096299	0.582	rs12935119	ENSG00000274627.1	RP11-104N10.2	9.44	1.63e-19	2.64e-16	0.38	0.4	Multiple myeloma (IgH translocation);	chr16:89476466	chr16:89516797~89522217:+
LUAD	cis	rs904251	0.504	rs9380677	ENSG00000204110.6	RP1-153P14.8	-9.44	1.64e-19	2.66e-16	-0.4	-0.4	Cognitive performance;	chr6:37512590	chr6:37507348~37535616:+
LUAD	cis	rs748404	0.578	rs478028	ENSG00000205771.5	CATSPER2P1	-9.44	1.64e-19	2.66e-16	-0.51	-0.4	Lung cancer;	chr15:43318574	chr15:43726918~43747094:-
LUAD	cis	rs7044106	0.762	rs1530370	ENSG00000226752.6	PSMD5-AS1	-9.44	1.65e-19	2.66e-16	-0.44	-0.4	Hip circumference adjusted for BMI;	chr9:120662274	chr9:120824828~120854385:+
LUAD	cis	rs1891275	0.515	rs1361552	ENSG00000228701.1	TNKS2-AS1	-9.44	1.66e-19	2.68e-16	-0.48	-0.4	Intelligence (multi-trait analysis);	chr10:91774867	chr10:91782839~91798291:-
LUAD	cis	rs9309711	0.643	rs10188449	ENSG00000225234.1	TRAPPC12-AS1	-9.43	1.68e-19	2.7e-16	-0.46	-0.4	Neurofibrillary tangles;	chr2:3476595	chr2:3481242~3482409:-
LUAD	cis	rs4423214	0.515	rs4944042	ENSG00000254682.1	RP11-660L16.2	9.43	1.71e-19	2.75e-16	0.49	0.4	Vitamin D levels;	chr11:71407742	chr11:71448674~71452157:+
LUAD	cis	rs2581828	0.931	rs2564942	ENSG00000242142.1	SERBP1P3	9.43	1.72e-19	2.77e-16	0.42	0.4	Crohn's disease;	chr3:53105490	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.931	rs2581774	ENSG00000242142.1	SERBP1P3	9.43	1.72e-19	2.77e-16	0.42	0.4	Crohn's disease;	chr3:53105491	chr3:53064283~53065091:-
LUAD	cis	rs34779708	0.897	rs34481177	ENSG00000230534.5	RP11-297A16.2	9.43	1.72e-19	2.77e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35091985	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs4934723	ENSG00000230534.5	RP11-297A16.2	9.43	1.72e-19	2.77e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35092835	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs72789690	ENSG00000230534.5	RP11-297A16.2	9.43	1.72e-19	2.77e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35093889	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs68039650	ENSG00000230534.5	RP11-297A16.2	9.43	1.72e-19	2.77e-16	0.48	0.4	Inflammatory bowel disease;Crohn's disease;	chr10:35096571	chr10:35098006~35127020:-
LUAD	cis	rs2564921	0.704	rs62253606	ENSG00000242142.1	SERBP1P3	-9.43	1.72e-19	2.78e-16	-0.45	-0.4	Height;	chr3:52949886	chr3:53064283~53065091:-
LUAD	cis	rs67180937	0.882	rs17163345	ENSG00000272750.1	RP11-378J18.8	-9.43	1.73e-19	2.78e-16	-0.41	-0.4	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222632876	chr1:222658867~222661512:-
LUAD	cis	rs8062405	1	rs12446589	ENSG00000259982.1	CDC37P1	9.43	1.75e-19	2.83e-16	0.51	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28700294~28701540:-
LUAD	cis	rs227275	0.556	rs7676765	ENSG00000246560.2	RP11-10L12.4	-9.43	1.77e-19	2.85e-16	-0.49	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:103016776	chr4:102828055~102844075:+
LUAD	cis	rs321358	1	rs321360	ENSG00000271584.1	RP11-89C3.4	9.43	1.78e-19	2.86e-16	0.65	0.39	Body mass index;	chr11:111125346	chr11:111091932~111097357:-
LUAD	cis	rs2108622	0.701	rs3093209	ENSG00000267453.5	AC004791.2	-9.43	1.79e-19	2.87e-16	-0.48	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15877610	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.727	rs3093207	ENSG00000267453.5	AC004791.2	-9.43	1.79e-19	2.87e-16	-0.48	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15877848	chr19:15851993~15864904:-
LUAD	cis	rs5769707	0.933	rs2157444	ENSG00000188511.11	C22orf34	9.43	1.79e-19	2.88e-16	0.44	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49600644	chr22:49414524~49657542:-
LUAD	cis	rs2581828	0.896	rs12637287	ENSG00000242142.1	SERBP1P3	9.43	1.81e-19	2.9e-16	0.42	0.39	Crohn's disease;	chr3:53105425	chr3:53064283~53065091:-
LUAD	cis	rs34779708	0.966	rs11010129	ENSG00000230534.5	RP11-297A16.2	9.43	1.81e-19	2.91e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35221894	chr10:35098006~35127020:-
LUAD	cis	rs10129255	0.957	rs10150241	ENSG00000223648.3	IGHV3-64	-9.42	1.83e-19	2.93e-16	-0.38	-0.39	Kawasaki disease;	chr14:106775945	chr14:106643132~106658258:-
LUAD	cis	rs10262624	0.901	rs6977550	ENSG00000234286.1	AC006026.13	-9.42	1.84e-19	2.96e-16	-0.48	-0.39	Schizophrenia;	chr7:23865825	chr7:23680195~23680786:-
LUAD	cis	rs8062405	1	rs12325113	ENSG00000259982.1	CDC37P1	9.42	1.85e-19	2.98e-16	0.51	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28700294~28701540:-
LUAD	cis	rs34779708	0.966	rs4934737	ENSG00000230534.5	RP11-297A16.2	9.42	1.86e-19	2.98e-16	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35223871	chr10:35098006~35127020:-
LUAD	cis	rs11098499	0.754	rs1511017	ENSG00000245958.5	RP11-33B1.1	-9.42	1.86e-19	2.99e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119329650	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.789	rs12498994	ENSG00000245958.5	RP11-33B1.1	-9.42	1.86e-19	2.99e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119329663	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs12507565	ENSG00000245958.5	RP11-33B1.1	-9.42	1.86e-19	2.99e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119329966	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.826	rs12511640	ENSG00000245958.5	RP11-33B1.1	-9.42	1.86e-19	2.99e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119330093	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs1980026	ENSG00000245958.5	RP11-33B1.1	-9.42	1.86e-19	2.99e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119330488	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.743	rs11098501	ENSG00000245958.5	RP11-33B1.1	-9.42	1.86e-19	2.99e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119330862	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs11098502	ENSG00000245958.5	RP11-33B1.1	-9.42	1.86e-19	2.99e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119330908	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.708	rs11732686	ENSG00000245958.5	RP11-33B1.1	-9.42	1.86e-19	2.99e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119331175	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs11724409	ENSG00000245958.5	RP11-33B1.1	-9.42	1.86e-19	2.99e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119331206	chr4:119454791~119552025:+
LUAD	cis	rs12468226	0.873	rs78798541	ENSG00000273456.1	RP11-686O6.2	9.42	1.87e-19	3e-16	0.64	0.39	Urate levels;	chr2:202194708	chr2:202374932~202375604:-
LUAD	cis	rs227275	0.525	rs6533052	ENSG00000246560.2	RP11-10L12.4	9.42	1.88e-19	3.01e-16	0.49	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102990624	chr4:102828055~102844075:+
LUAD	cis	rs12594515	1	rs12594515	ENSG00000273972.1	CTD-2306A12.1	9.42	1.88e-19	3.01e-16	0.43	0.39	Weight;Waist circumference;	chr15:45692873	chr15:45702640~45703183:+
LUAD	cis	rs12468226	1	rs115170232	ENSG00000273456.1	RP11-686O6.2	9.42	1.89e-19	3.03e-16	0.6	0.39	Urate levels;	chr2:202416790	chr2:202374932~202375604:-
LUAD	cis	rs12468226	1	rs16839149	ENSG00000273456.1	RP11-686O6.2	9.42	1.89e-19	3.03e-16	0.6	0.39	Urate levels;	chr2:202427621	chr2:202374932~202375604:-
LUAD	cis	rs9898641	1	rs9898641	ENSG00000266992.1	DHX40P1	9.42	1.9e-19	3.04e-16	0.49	0.39	Interleukin-1-beta levels;	chr17:59493672	chr17:59976009~60002384:-
LUAD	cis	rs6452524	0.935	rs6887915	ENSG00000249664.1	CTD-2227C6.2	9.42	1.9e-19	3.04e-16	0.46	0.39	Hypertension (SNP x SNP interaction);	chr5:83170837	chr5:83012285~83013109:-
LUAD	cis	rs11722779	0.935	rs11938650	ENSG00000246560.2	RP11-10L12.4	9.42	1.91e-19	3.06e-16	0.49	0.39	Schizophrenia;	chr4:103021639	chr4:102828055~102844075:+
LUAD	cis	rs34779708	0.966	rs4934540	ENSG00000230534.5	RP11-297A16.2	9.42	1.91e-19	3.06e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35185771	chr10:35098006~35127020:-
LUAD	cis	rs10129255	0.5	rs6576231	ENSG00000211972.2	IGHV3-66	9.42	1.92e-19	3.07e-16	0.32	0.39	Kawasaki disease;	chr14:106783693	chr14:106675017~106675544:-
LUAD	cis	rs34779708	0.931	rs35997236	ENSG00000230534.5	RP11-297A16.2	9.42	1.92e-19	3.08e-16	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35087762	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs4934719	ENSG00000230534.5	RP11-297A16.2	9.42	1.92e-19	3.08e-16	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35087841	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs4934720	ENSG00000230534.5	RP11-297A16.2	9.42	1.92e-19	3.08e-16	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35087872	chr10:35098006~35127020:-
LUAD	cis	rs10129255	0.957	rs11846893	ENSG00000223648.3	IGHV3-64	9.42	1.92e-19	3.08e-16	0.38	0.39	Kawasaki disease;	chr14:106779068	chr14:106643132~106658258:-
LUAD	cis	rs944289	0.616	rs395212	ENSG00000257826.1	RP11-116N8.4	-9.42	1.93e-19	3.09e-16	-0.41	-0.39	Thyroid cancer;	chr14:36065759	chr14:36061026~36067190:-
LUAD	cis	rs34779708	0.931	rs35317849	ENSG00000230534.5	RP11-297A16.2	9.42	1.93e-19	3.1e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:34996793	chr10:35098006~35127020:-
LUAD	cis	rs228614	0.51	rs223452	ENSG00000246560.2	RP11-10L12.4	9.42	1.94e-19	3.1e-16	0.49	0.39	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102790277	chr4:102828055~102844075:+
LUAD	cis	rs11722779	0.838	rs4533776	ENSG00000246560.2	RP11-10L12.4	9.42	1.94e-19	3.1e-16	0.48	0.39	Schizophrenia;	chr4:102912732	chr4:102828055~102844075:+
LUAD	cis	rs11722779	0.838	rs6821247	ENSG00000246560.2	RP11-10L12.4	9.42	1.94e-19	3.1e-16	0.48	0.39	Schizophrenia;	chr4:102913483	chr4:102828055~102844075:+
LUAD	cis	rs7617773	0.539	rs1471217	ENSG00000229759.1	MRPS18AP1	9.42	1.94e-19	3.11e-16	0.39	0.39	Coronary artery disease;	chr3:48343405	chr3:48256350~48256938:-
LUAD	cis	rs227275	0.525	rs9917919	ENSG00000246560.2	RP11-10L12.4	9.42	1.94e-19	3.11e-16	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102918497	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs3974608	ENSG00000246560.2	RP11-10L12.4	9.42	1.94e-19	3.11e-16	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102925641	chr4:102828055~102844075:+
LUAD	cis	rs977987	0.872	rs4888422	ENSG00000261783.1	RP11-252K23.2	-9.42	1.94e-19	3.11e-16	-0.53	-0.39	Dupuytren's disease;	chr16:75436678	chr16:75379818~75381260:-
LUAD	cis	rs2564921	0.654	rs73087044	ENSG00000242142.1	SERBP1P3	-9.42	1.95e-19	3.11e-16	-0.45	-0.39	Height;	chr3:52975027	chr3:53064283~53065091:-
LUAD	cis	rs228614	0.536	rs223418	ENSG00000246560.2	RP11-10L12.4	9.41	1.97e-19	3.15e-16	0.49	0.39	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102809336	chr4:102828055~102844075:+
LUAD	cis	rs6142102	0.625	rs6142068	ENSG00000276073.1	RP5-1125A11.7	9.41	1.98e-19	3.16e-16	0.39	0.39	Skin pigmentation;	chr20:33969366	chr20:33985617~33988989:-
LUAD	cis	rs11098499	0.754	rs28643450	ENSG00000245958.5	RP11-33B1.1	-9.41	1.98e-19	3.16e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119324087	chr4:119454791~119552025:+
LUAD	cis	rs9918079	0.56	rs4270584	ENSG00000273133.1	RP11-799M12.2	9.41	1.98e-19	3.16e-16	0.55	0.39	Obesity-related traits;	chr4:15599176	chr4:15563698~15564253:-
LUAD	cis	rs11722779	0.692	rs223414	ENSG00000246560.2	RP11-10L12.4	9.41	1.99e-19	3.18e-16	0.49	0.39	Schizophrenia;	chr4:102811688	chr4:102828055~102844075:+
LUAD	cis	rs11098499	0.722	rs28713555	ENSG00000245958.5	RP11-33B1.1	-9.41	1.99e-19	3.19e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119330840	chr4:119454791~119552025:+
LUAD	cis	rs11722779	0.869	rs223350	ENSG00000246560.2	RP11-10L12.4	9.41	1.99e-19	3.19e-16	0.49	0.39	Schizophrenia;	chr4:102856899	chr4:102828055~102844075:+
LUAD	cis	rs2019137	0.936	rs12620738	ENSG00000274877.1	RP11-65I12.1	9.41	2e-19	3.19e-16	0.5	0.39	Lymphocyte counts;	chr2:113206162	chr2:113237595~113240825:+
LUAD	cis	rs7174755	0.772	rs80187654	ENSG00000260657.2	RP11-315D16.4	9.41	2.02e-19	3.23e-16	0.51	0.39	Major depressive disorder;	chr15:68082833	chr15:68267792~68277994:-
LUAD	cis	rs2564921	0.704	rs62253649	ENSG00000242142.1	SERBP1P3	-9.41	2.02e-19	3.23e-16	-0.45	-0.39	Height;	chr3:52967831	chr3:53064283~53065091:-
LUAD	cis	rs2564921	0.704	rs57916015	ENSG00000242142.1	SERBP1P3	-9.41	2.02e-19	3.23e-16	-0.45	-0.39	Height;	chr3:52971094	chr3:53064283~53065091:-
LUAD	cis	rs526231	0.543	rs158244	ENSG00000175749.11	EIF3KP1	9.41	2.03e-19	3.24e-16	0.55	0.39	Primary biliary cholangitis;	chr5:103075062	chr5:103032376~103033031:+
LUAD	cis	rs7617773	0.539	rs13082217	ENSG00000229759.1	MRPS18AP1	9.41	2.04e-19	3.26e-16	0.39	0.39	Coronary artery disease;	chr3:48341774	chr3:48256350~48256938:-
LUAD	cis	rs11098499	0.754	rs12513083	ENSG00000245958.5	RP11-33B1.1	-9.41	2.06e-19	3.29e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119328457	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs12509621	ENSG00000245958.5	RP11-33B1.1	-9.41	2.06e-19	3.29e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119328505	chr4:119454791~119552025:+
LUAD	cis	rs2108622	0.683	rs111388185	ENSG00000267453.5	AC004791.2	-9.41	2.07e-19	3.3e-16	-0.48	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866604	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.683	rs112571591	ENSG00000267453.5	AC004791.2	-9.41	2.07e-19	3.3e-16	-0.48	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866635	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.647	rs111427692	ENSG00000267453.5	AC004791.2	-9.41	2.07e-19	3.3e-16	-0.48	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866669	chr19:15851993~15864904:-
LUAD	cis	rs11098499	0.754	rs2036860	ENSG00000245958.5	RP11-33B1.1	-9.41	2.08e-19	3.31e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119327779	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs2036857	ENSG00000245958.5	RP11-33B1.1	-9.41	2.08e-19	3.31e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119328085	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs2036856	ENSG00000245958.5	RP11-33B1.1	-9.41	2.08e-19	3.31e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119328133	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs4443261	ENSG00000245958.5	RP11-33B1.1	-9.41	2.08e-19	3.31e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119328146	chr4:119454791~119552025:+
LUAD	cis	rs321358	1	rs321357	ENSG00000271584.1	RP11-89C3.4	9.41	2.08e-19	3.32e-16	0.64	0.39	Body mass index;	chr11:111125002	chr11:111091932~111097357:-
LUAD	cis	rs34779708	0.931	rs4934524	ENSG00000230534.5	RP11-297A16.2	9.41	2.09e-19	3.32e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:34981993	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs4934693	ENSG00000230534.5	RP11-297A16.2	9.41	2.09e-19	3.32e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:34982916	chr10:35098006~35127020:-
LUAD	cis	rs2564921	0.693	rs2581798	ENSG00000242142.1	SERBP1P3	9.41	2.09e-19	3.32e-16	0.44	0.39	Height;	chr3:53073584	chr3:53064283~53065091:-
LUAD	cis	rs1757171	0.534	rs2797793	ENSG00000279942.1	RP1-153P14.7	9.41	2.11e-19	3.35e-16	0.36	0.39	Cognitive performance;	chr6:37509486	chr6:37567716~37571460:+
LUAD	cis	rs2019137	0.936	rs3811059	ENSG00000274877.1	RP11-65I12.1	9.41	2.12e-19	3.37e-16	0.5	0.39	Lymphocyte counts;	chr2:113204494	chr2:113237595~113240825:+
LUAD	cis	rs10129255	0.556	rs8010005	ENSG00000211972.2	IGHV3-66	9.41	2.13e-19	3.38e-16	0.32	0.39	Kawasaki disease;	chr14:106777987	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.556	rs6576224	ENSG00000211972.2	IGHV3-66	9.41	2.13e-19	3.38e-16	0.32	0.39	Kawasaki disease;	chr14:106777997	chr14:106675017~106675544:-
LUAD	cis	rs227275	0.527	rs223308	ENSG00000246560.2	RP11-10L12.4	9.4	2.14e-19	3.4e-16	0.49	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102891342	chr4:102828055~102844075:+
LUAD	cis	rs62229266	0.693	rs2835264	ENSG00000231106.2	LINC01436	9.4	2.15e-19	3.41e-16	0.53	0.39	Mitral valve prolapse;	chr21:36063667	chr21:36005338~36007838:+
LUAD	cis	rs7567389	0.704	rs4662714	ENSG00000236682.1	AC068282.3	9.4	2.19e-19	3.48e-16	0.52	0.39	Self-rated health;	chr2:127237637	chr2:127389130~127400580:+
LUAD	cis	rs7617773	0.539	rs13087050	ENSG00000229759.1	MRPS18AP1	9.4	2.21e-19	3.51e-16	0.39	0.39	Coronary artery disease;	chr3:48351310	chr3:48256350~48256938:-
LUAD	cis	rs10028773	0.7	rs7671797	ENSG00000245958.5	RP11-33B1.1	-9.4	2.22e-19	3.52e-16	-0.36	-0.39	Educational attainment;	chr4:119327002	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs7672594	ENSG00000245958.5	RP11-33B1.1	-9.4	2.22e-19	3.52e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119327388	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs7672778	ENSG00000245958.5	RP11-33B1.1	-9.4	2.22e-19	3.52e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119327430	chr4:119454791~119552025:+
LUAD	cis	rs2729354	0.779	rs2454663	ENSG00000265566.2	RN7SL605P	-9.4	2.24e-19	3.55e-16	-0.64	-0.39	Blood protein levels;	chr11:57590610	chr11:57528085~57528365:-
LUAD	cis	rs11098499	0.754	rs1980027	ENSG00000245958.5	RP11-33B1.1	-9.4	2.24e-19	3.55e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119330422	chr4:119454791~119552025:+
LUAD	cis	rs11690935	0.851	rs7573003	ENSG00000228389.1	AC068039.4	9.4	2.24e-19	3.55e-16	0.46	0.39	Schizophrenia;	chr2:171884905	chr2:171773482~171775844:+
LUAD	cis	rs34779708	0.931	rs11592404	ENSG00000230534.5	RP11-297A16.2	9.4	2.24e-19	3.55e-16	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:34984548	chr10:35098006~35127020:-
LUAD	cis	rs8062405	1	rs7498555	ENSG00000259982.1	CDC37P1	9.4	2.25e-19	3.57e-16	0.51	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28882250	chr16:28700294~28701540:-
LUAD	cis	rs321358	0.945	rs17537367	ENSG00000271584.1	RP11-89C3.4	9.4	2.25e-19	3.57e-16	0.65	0.39	Body mass index;	chr11:111117008	chr11:111091932~111097357:-
LUAD	cis	rs62388641	0.539	rs56016631	ENSG00000272279.1	RP11-157J24.2	9.4	2.26e-19	3.59e-16	0.5	0.39	Daytime sleep phenotypes;	chr6:1542340	chr6:1528364~1528911:-
LUAD	cis	rs11098499	0.754	rs66900435	ENSG00000245958.5	RP11-33B1.1	-9.4	2.27e-19	3.6e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119328270	chr4:119454791~119552025:+
LUAD	cis	rs227275	0.554	rs223424	ENSG00000246560.2	RP11-10L12.4	9.39	2.31e-19	3.66e-16	0.49	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102804177	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.524	rs223423	ENSG00000246560.2	RP11-10L12.4	9.39	2.31e-19	3.66e-16	0.49	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102804737	chr4:102828055~102844075:+
LUAD	cis	rs1061377	0.748	rs12649085	ENSG00000249207.1	RP11-360F5.1	-9.39	2.31e-19	3.67e-16	-0.44	-0.39	Uric acid levels;	chr4:39106459	chr4:39112677~39126818:-
LUAD	cis	rs7617773	0.539	rs11706939	ENSG00000229759.1	MRPS18AP1	9.39	2.34e-19	3.7e-16	0.39	0.39	Coronary artery disease;	chr3:48342502	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.539	rs11130165	ENSG00000229759.1	MRPS18AP1	9.39	2.34e-19	3.7e-16	0.39	0.39	Coronary artery disease;	chr3:48343231	chr3:48256350~48256938:-
LUAD	cis	rs34779708	0.931	rs12768019	ENSG00000230534.5	RP11-297A16.2	9.39	2.34e-19	3.71e-16	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35100915	chr10:35098006~35127020:-
LUAD	cis	rs227275	0.554	rs223404	ENSG00000246560.2	RP11-10L12.4	9.39	2.35e-19	3.72e-16	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102816951	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.586	rs223448	ENSG00000246560.2	RP11-10L12.4	9.39	2.38e-19	3.77e-16	0.49	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102792189	chr4:102828055~102844075:+
LUAD	cis	rs1061377	0.71	rs12503506	ENSG00000249207.1	RP11-360F5.1	-9.39	2.38e-19	3.78e-16	-0.44	-0.39	Uric acid levels;	chr4:39082553	chr4:39112677~39126818:-
LUAD	cis	rs2108622	0.711	rs113059233	ENSG00000267453.5	AC004791.2	-9.39	2.39e-19	3.78e-16	-0.48	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866558	chr19:15851993~15864904:-
LUAD	cis	rs227275	0.524	rs150894	ENSG00000246560.2	RP11-10L12.4	9.39	2.39e-19	3.79e-16	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102811541	chr4:102828055~102844075:+
LUAD	cis	rs7617773	0.539	rs13069884	ENSG00000229759.1	MRPS18AP1	9.39	2.4e-19	3.8e-16	0.39	0.39	Coronary artery disease;	chr3:48339658	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.539	rs2017859	ENSG00000229759.1	MRPS18AP1	9.39	2.4e-19	3.8e-16	0.39	0.39	Coronary artery disease;	chr3:48340771	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.539	rs2017858	ENSG00000229759.1	MRPS18AP1	9.39	2.4e-19	3.8e-16	0.39	0.39	Coronary artery disease;	chr3:48340792	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.501	rs12185901	ENSG00000229759.1	MRPS18AP1	9.39	2.4e-19	3.8e-16	0.39	0.39	Coronary artery disease;	chr3:48341429	chr3:48256350~48256938:-
LUAD	cis	rs10256972	0.713	rs10435026	ENSG00000229043.2	AC091729.9	-9.39	2.42e-19	3.83e-16	-0.43	-0.39	Endometriosis;Longevity;	chr7:1026312	chr7:1160374~1165267:+
LUAD	cis	rs11098499	0.955	rs6815725	ENSG00000245958.5	RP11-33B1.1	-9.39	2.42e-19	3.83e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119237255	chr4:119454791~119552025:+
LUAD	cis	rs9309711	0.623	rs4641971	ENSG00000225234.1	TRAPPC12-AS1	9.39	2.44e-19	3.85e-16	0.46	0.39	Neurofibrillary tangles;	chr2:3478086	chr2:3481242~3482409:-
LUAD	cis	rs321358	1	rs321365	ENSG00000271584.1	RP11-89C3.4	9.39	2.44e-19	3.85e-16	0.65	0.39	Body mass index;	chr11:111126676	chr11:111091932~111097357:-
LUAD	cis	rs526231	0.543	rs257310	ENSG00000175749.11	EIF3KP1	9.39	2.47e-19	3.9e-16	0.55	0.39	Primary biliary cholangitis;	chr5:103083149	chr5:103032376~103033031:+
LUAD	cis	rs1061377	0.748	rs12642261	ENSG00000249207.1	RP11-360F5.1	-9.39	2.48e-19	3.92e-16	-0.44	-0.39	Uric acid levels;	chr4:39096278	chr4:39112677~39126818:-
LUAD	cis	rs4853012	0.539	rs9789534	ENSG00000217702.2	RP11-287D1.4	9.39	2.49e-19	3.93e-16	0.63	0.39	Gestational age at birth (maternal effect);	chr2:74135863	chr2:74130583~74135395:+
LUAD	cis	rs321358	1	rs321366	ENSG00000271584.1	RP11-89C3.4	9.39	2.5e-19	3.95e-16	0.65	0.39	Body mass index;	chr11:111128003	chr11:111091932~111097357:-
LUAD	cis	rs9326248	1	rs664971	ENSG00000280143.1	AP000892.6	-9.38	2.5e-19	3.95e-16	-0.45	-0.39	Blood protein levels;	chr11:117200141	chr11:117204967~117210292:+
LUAD	cis	rs2564921	0.73	rs73082047	ENSG00000242142.1	SERBP1P3	-9.38	2.52e-19	3.97e-16	-0.44	-0.39	Height;	chr3:53070344	chr3:53064283~53065091:-
LUAD	cis	rs8062405	1	rs62036622	ENSG00000259982.1	CDC37P1	9.38	2.52e-19	3.98e-16	0.51	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28700294~28701540:-
LUAD	cis	rs2564921	0.73	rs2253675	ENSG00000242142.1	SERBP1P3	-9.38	2.52e-19	3.99e-16	-0.44	-0.39	Height;	chr3:53085518	chr3:53064283~53065091:-
LUAD	cis	rs11098499	0.754	rs7672372	ENSG00000245958.5	RP11-33B1.1	-9.38	2.54e-19	4.01e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119327251	chr4:119454791~119552025:+
LUAD	cis	rs1155848	0.892	rs953005	ENSG00000227354.5	RBM26-AS1	9.38	2.54e-19	4.01e-16	0.84	0.39	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79480544	chr13:79406309~79424328:+
LUAD	cis	rs7924176	0.601	rs10824107	ENSG00000213731.2	RAB5CP1	-9.38	2.54e-19	4.01e-16	-0.42	-0.39	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74202041	chr10:74423435~74424014:-
LUAD	cis	rs2108622	0.727	rs3093216	ENSG00000267453.5	AC004791.2	-9.38	2.55e-19	4.02e-16	-0.48	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15876927	chr19:15851993~15864904:-
LUAD	cis	rs8062405	0.721	rs151181	ENSG00000259982.1	CDC37P1	9.38	2.57e-19	4.05e-16	0.5	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28700294~28701540:-
LUAD	cis	rs34779708	0.931	rs12771399	ENSG00000230534.5	RP11-297A16.2	9.38	2.6e-19	4.11e-16	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35163449	chr10:35098006~35127020:-
LUAD	cis	rs5769707	0.935	rs1109320	ENSG00000188511.11	C22orf34	9.38	2.61e-19	4.12e-16	0.44	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49595458	chr22:49414524~49657542:-
LUAD	cis	rs6142102	0.602	rs6142069	ENSG00000276073.1	RP5-1125A11.7	-9.38	2.62e-19	4.13e-16	-0.39	-0.39	Skin pigmentation;	chr20:33972736	chr20:33985617~33988989:-
LUAD	cis	rs11098499	0.604	rs17051352	ENSG00000245958.5	RP11-33B1.1	-9.38	2.63e-19	4.14e-16	-0.37	-0.39	Corneal astigmatism;	chr4:119660272	chr4:119454791~119552025:+
LUAD	cis	rs9595066	0.941	rs9533777	ENSG00000227258.4	SMIM2-AS1	-9.38	2.63e-19	4.14e-16	-0.56	-0.39	Schizophrenia;	chr13:44134584	chr13:44110451~44240517:+
LUAD	cis	rs228614	0.51	rs223412	ENSG00000246560.2	RP11-10L12.4	9.38	2.63e-19	4.15e-16	0.48	0.39	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102812443	chr4:102828055~102844075:+
LUAD	cis	rs10463554	0.927	rs7717343	ENSG00000175749.11	EIF3KP1	9.38	2.63e-19	4.15e-16	0.54	0.39	Parkinson's disease;	chr5:103026279	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.963	rs7721530	ENSG00000175749.11	EIF3KP1	9.38	2.63e-19	4.15e-16	0.54	0.39	Parkinson's disease;	chr5:103026488	chr5:103032376~103033031:+
LUAD	cis	rs34779708	0.966	rs11599606	ENSG00000230534.5	RP11-297A16.2	9.38	2.66e-19	4.19e-16	0.48	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35117698	chr10:35098006~35127020:-
LUAD	cis	rs9326248	1	rs7107152	ENSG00000280143.1	AP000892.6	-9.38	2.67e-19	4.21e-16	-0.46	-0.39	Blood protein levels;	chr11:117185364	chr11:117204967~117210292:+
LUAD	cis	rs321358	0.945	rs10502130	ENSG00000271584.1	RP11-89C3.4	9.38	2.68e-19	4.22e-16	0.65	0.39	Body mass index;	chr11:111107437	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.945	rs73017109	ENSG00000271584.1	RP11-89C3.4	9.38	2.68e-19	4.22e-16	0.65	0.39	Body mass index;	chr11:111108484	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.887	rs1470537	ENSG00000271584.1	RP11-89C3.4	9.38	2.68e-19	4.22e-16	0.65	0.39	Body mass index;	chr11:111109328	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.945	rs12421769	ENSG00000271584.1	RP11-89C3.4	9.38	2.68e-19	4.22e-16	0.65	0.39	Body mass index;	chr11:111109500	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.945	rs73017114	ENSG00000271584.1	RP11-89C3.4	9.38	2.68e-19	4.22e-16	0.65	0.39	Body mass index;	chr11:111111582	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.945	rs17458493	ENSG00000271584.1	RP11-89C3.4	9.38	2.68e-19	4.22e-16	0.65	0.39	Body mass index;	chr11:111112156	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.945	rs17458541	ENSG00000271584.1	RP11-89C3.4	9.38	2.68e-19	4.22e-16	0.65	0.39	Body mass index;	chr11:111113182	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.836	rs17458597	ENSG00000271584.1	RP11-89C3.4	9.38	2.68e-19	4.22e-16	0.65	0.39	Body mass index;	chr11:111113599	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.945	rs73017176	ENSG00000271584.1	RP11-89C3.4	9.38	2.68e-19	4.22e-16	0.65	0.39	Body mass index;	chr11:111113879	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.887	rs80221187	ENSG00000271584.1	RP11-89C3.4	9.38	2.68e-19	4.22e-16	0.65	0.39	Body mass index;	chr11:111113977	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.945	rs73017177	ENSG00000271584.1	RP11-89C3.4	9.38	2.68e-19	4.22e-16	0.65	0.39	Body mass index;	chr11:111114034	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.895	rs73017179	ENSG00000271584.1	RP11-89C3.4	9.38	2.68e-19	4.22e-16	0.65	0.39	Body mass index;	chr11:111114037	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.945	rs1356411	ENSG00000271584.1	RP11-89C3.4	9.38	2.68e-19	4.22e-16	0.65	0.39	Body mass index;	chr11:111115371	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.945	rs17537360	ENSG00000271584.1	RP11-89C3.4	9.38	2.68e-19	4.22e-16	0.65	0.39	Body mass index;	chr11:111116921	chr11:111091932~111097357:-
LUAD	cis	rs11089937	0.857	rs5750580	ENSG00000211639.2	IGLV4-60	9.38	2.69e-19	4.23e-16	0.39	0.39	Periodontitis (PAL4Q3);	chr22:22137471	chr22:22162199~22162681:+
LUAD	cis	rs321358	1	rs321359	ENSG00000271584.1	RP11-89C3.4	9.38	2.69e-19	4.23e-16	0.65	0.39	Body mass index;	chr11:111125257	chr11:111091932~111097357:-
LUAD	cis	rs62229266	0.563	rs6517325	ENSG00000231106.2	LINC01436	9.38	2.7e-19	4.25e-16	0.53	0.39	Mitral valve prolapse;	chr21:36062680	chr21:36005338~36007838:+
LUAD	cis	rs34779708	0.931	rs11593858	ENSG00000230534.5	RP11-297A16.2	9.37	2.71e-19	4.27e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35092445	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs35136660	ENSG00000230534.5	RP11-297A16.2	9.37	2.71e-19	4.27e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35097045	chr10:35098006~35127020:-
LUAD	cis	rs11098499	0.535	rs7671759	ENSG00000245958.5	RP11-33B1.1	-9.37	2.71e-19	4.27e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119326939	chr4:119454791~119552025:+
LUAD	cis	rs5769707	0.839	rs73176988	ENSG00000188511.11	C22orf34	9.37	2.72e-19	4.29e-16	0.44	0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49596001	chr22:49414524~49657542:-
LUAD	cis	rs227275	0.554	rs223363	ENSG00000246560.2	RP11-10L12.4	9.37	2.72e-19	4.29e-16	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102846182	chr4:102828055~102844075:+
LUAD	cis	rs904251	0.523	rs2797799	ENSG00000204110.6	RP1-153P14.8	-9.37	2.74e-19	4.31e-16	-0.39	-0.39	Cognitive performance;	chr6:37515844	chr6:37507348~37535616:+
LUAD	cis	rs34779708	0.966	rs878264	ENSG00000230534.5	RP11-297A16.2	9.37	2.77e-19	4.36e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35151653	chr10:35098006~35127020:-
LUAD	cis	rs7617773	0.563	rs62263035	ENSG00000229759.1	MRPS18AP1	9.37	2.78e-19	4.37e-16	0.39	0.39	Coronary artery disease;	chr3:48350079	chr3:48256350~48256938:-
LUAD	cis	rs321358	0.945	rs73015196	ENSG00000271584.1	RP11-89C3.4	9.37	2.79e-19	4.39e-16	0.65	0.39	Body mass index;	chr11:111104608	chr11:111091932~111097357:-
LUAD	cis	rs11098499	0.691	rs9996644	ENSG00000245958.5	RP11-33B1.1	-9.37	2.79e-19	4.39e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119317722	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.691	rs9996494	ENSG00000245958.5	RP11-33B1.1	-9.37	2.79e-19	4.39e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119317725	chr4:119454791~119552025:+
LUAD	cis	rs10129255	1	rs10129255	ENSG00000211970.3	IGHV4-61	9.37	2.8e-19	4.4e-16	0.3	0.39	Kawasaki disease;	chr14:106767970	chr14:106639119~106639657:-
LUAD	cis	rs10256972	0.616	rs6463001	ENSG00000229043.2	AC091729.9	-9.37	2.8e-19	4.41e-16	-0.42	-0.39	Endometriosis;Longevity;	chr7:1068636	chr7:1160374~1165267:+
LUAD	cis	rs12468226	0.935	rs75597391	ENSG00000273456.1	RP11-686O6.2	9.37	2.82e-19	4.43e-16	0.6	0.39	Urate levels;	chr2:202398850	chr2:202374932~202375604:-
LUAD	cis	rs2929278	0.617	rs524908	ENSG00000205771.5	CATSPER2P1	9.37	2.84e-19	4.46e-16	0.48	0.39	Schizophrenia;	chr15:43895793	chr15:43726918~43747094:-
LUAD	cis	rs494459	0.838	rs1784543	ENSG00000255422.1	AP002954.4	-9.37	2.84e-19	4.47e-16	-0.48	-0.39	Height;	chr11:118760944	chr11:118704607~118750263:+
LUAD	cis	rs494459	0.838	rs632124	ENSG00000255422.1	AP002954.4	-9.37	2.85e-19	4.47e-16	-0.48	-0.39	Height;	chr11:118742526	chr11:118704607~118750263:+
LUAD	cis	rs2564921	0.73	rs2564939	ENSG00000242142.1	SERBP1P3	9.37	2.86e-19	4.49e-16	0.45	0.39	Height;	chr3:53072864	chr3:53064283~53065091:-
LUAD	cis	rs11098499	1	rs1011054	ENSG00000245958.5	RP11-33B1.1	9.37	2.87e-19	4.51e-16	0.36	0.39	Corneal astigmatism;	chr4:119281232	chr4:119454791~119552025:+
LUAD	cis	rs8062405	0.755	rs4149398	ENSG00000259982.1	CDC37P1	9.37	2.87e-19	4.51e-16	0.5	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597617	chr16:28700294~28701540:-
LUAD	cis	rs34779708	0.931	rs58159560	ENSG00000230534.5	RP11-297A16.2	9.37	2.88e-19	4.52e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35062321	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs17591857	ENSG00000230534.5	RP11-297A16.2	-9.37	2.88e-19	4.52e-16	-0.47	-0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35210115	chr10:35098006~35127020:-
LUAD	cis	rs10129255	0.5	rs4774008	ENSG00000211972.2	IGHV3-66	9.37	2.89e-19	4.53e-16	0.31	0.39	Kawasaki disease;	chr14:106681273	chr14:106675017~106675544:-
LUAD	cis	rs11098499	0.754	rs17595608	ENSG00000245958.5	RP11-33B1.1	-9.37	2.9e-19	4.55e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119329351	chr4:119454791~119552025:+
LUAD	cis	rs494459	0.688	rs1048040	ENSG00000255422.1	AP002954.4	-9.37	2.91e-19	4.56e-16	-0.48	-0.39	Height;	chr11:118747911	chr11:118704607~118750263:+
LUAD	cis	rs494459	0.838	rs566733	ENSG00000255422.1	AP002954.4	-9.37	2.93e-19	4.6e-16	-0.48	-0.39	Height;	chr11:118737916	chr11:118704607~118750263:+
LUAD	cis	rs11098499	0.789	rs9991166	ENSG00000245958.5	RP11-33B1.1	-9.36	2.94e-19	4.62e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119316696	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.708	rs10005237	ENSG00000245958.5	RP11-33B1.1	-9.36	2.94e-19	4.62e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119316742	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs878372	ENSG00000245958.5	RP11-33B1.1	-9.36	2.94e-19	4.62e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119317625	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs10213267	ENSG00000245958.5	RP11-33B1.1	-9.36	2.94e-19	4.62e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119317919	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs10212775	ENSG00000245958.5	RP11-33B1.1	-9.36	2.94e-19	4.62e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119318089	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs11732087	ENSG00000245958.5	RP11-33B1.1	-9.36	2.94e-19	4.62e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119318676	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs2964	ENSG00000245958.5	RP11-33B1.1	-9.36	2.94e-19	4.62e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119318976	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs1511025	ENSG00000245958.5	RP11-33B1.1	-9.36	2.94e-19	4.62e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119319083	chr4:119454791~119552025:+
LUAD	cis	rs34779708	0.966	rs7077242	ENSG00000230534.5	RP11-297A16.2	-9.36	2.97e-19	4.66e-16	-0.47	-0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35193037	chr10:35098006~35127020:-
LUAD	cis	rs321358	1	rs321353	ENSG00000271584.1	RP11-89C3.4	-9.36	2.99e-19	4.69e-16	-0.64	-0.39	Body mass index;	chr11:111123841	chr11:111091932~111097357:-
LUAD	cis	rs11098499	0.754	rs12506610	ENSG00000245958.5	RP11-33B1.1	-9.36	3e-19	4.7e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119320504	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.743	rs10003567	ENSG00000245958.5	RP11-33B1.1	-9.36	3e-19	4.7e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119320519	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs10006259	ENSG00000245958.5	RP11-33B1.1	-9.36	3e-19	4.7e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119320990	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs28652763	ENSG00000245958.5	RP11-33B1.1	-9.36	3e-19	4.7e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119321157	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs12711071	ENSG00000245958.5	RP11-33B1.1	-9.36	3.02e-19	4.73e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119319779	chr4:119454791~119552025:+
LUAD	cis	rs8040855	0.627	rs12900012	ENSG00000259295.5	CSPG4P12	9.36	3.02e-19	4.73e-16	0.51	0.39	Bulimia nervosa;	chr15:85046955	chr15:85191438~85213905:+
LUAD	cis	rs8040855	0.627	rs72757059	ENSG00000259295.5	CSPG4P12	9.36	3.02e-19	4.73e-16	0.51	0.39	Bulimia nervosa;	chr15:85059918	chr15:85191438~85213905:+
LUAD	cis	rs8040855	0.627	rs11634975	ENSG00000259295.5	CSPG4P12	9.36	3.02e-19	4.73e-16	0.51	0.39	Bulimia nervosa;	chr15:85063247	chr15:85191438~85213905:+
LUAD	cis	rs10262624	0.901	rs6966655	ENSG00000234286.1	AC006026.13	-9.36	3.03e-19	4.75e-16	-0.47	-0.39	Schizophrenia;	chr7:23867010	chr7:23680195~23680786:-
LUAD	cis	rs6142102	0.581	rs4911148	ENSG00000276073.1	RP5-1125A11.7	-9.36	3.06e-19	4.79e-16	-0.39	-0.39	Skin pigmentation;	chr20:34080438	chr20:33985617~33988989:-
LUAD	cis	rs12468226	0.872	rs1061157	ENSG00000273456.1	RP11-686O6.2	9.36	3.06e-19	4.79e-16	0.61	0.39	Urate levels;	chr2:202556476	chr2:202374932~202375604:-
LUAD	cis	rs17608059	0.518	rs4792436	ENSG00000141028.6	CDRT15P1	9.36	3.07e-19	4.81e-16	0.44	0.39	Temperament;	chr17:14068990	chr17:14024514~14025488:+
LUAD	cis	rs11098499	0.955	rs1551	ENSG00000245958.5	RP11-33B1.1	-9.36	3.08e-19	4.82e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119237345	chr4:119454791~119552025:+
LUAD	cis	rs7567389	0.74	rs1604817	ENSG00000236682.1	AC068282.3	9.36	3.09e-19	4.83e-16	0.52	0.39	Self-rated health;	chr2:127242345	chr2:127389130~127400580:+
LUAD	cis	rs34779708	0.931	rs7099036	ENSG00000230534.5	RP11-297A16.2	9.36	3.09e-19	4.84e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35060646	chr10:35098006~35127020:-
LUAD	cis	rs2739330	0.892	rs4822455	ENSG00000099984.9	GSTT2	-9.36	3.12e-19	4.89e-16	-0.47	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23980123~23983911:+
LUAD	cis	rs944289	0.646	rs408283	ENSG00000257826.1	RP11-116N8.4	-9.36	3.14e-19	4.9e-16	-0.41	-0.39	Thyroid cancer;	chr14:36073503	chr14:36061026~36067190:-
LUAD	cis	rs2108622	0.527	rs67617968	ENSG00000267453.5	AC004791.2	-9.36	3.14e-19	4.91e-16	-0.46	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866755	chr19:15851993~15864904:-
LUAD	cis	rs6452524	0.935	rs5000997	ENSG00000249664.1	CTD-2227C6.2	9.36	3.17e-19	4.96e-16	0.46	0.39	Hypertension (SNP x SNP interaction);	chr5:83164248	chr5:83012285~83013109:-
LUAD	cis	rs34779708	0.966	rs34776628	ENSG00000230534.5	RP11-297A16.2	9.35	3.18e-19	4.98e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35137396	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs17499247	ENSG00000230534.5	RP11-297A16.2	9.35	3.18e-19	4.98e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35137827	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs10827491	ENSG00000230534.5	RP11-297A16.2	9.35	3.18e-19	4.98e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35138467	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs4934732	ENSG00000230534.5	RP11-297A16.2	9.35	3.18e-19	4.98e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35142756	chr10:35098006~35127020:-
LUAD	cis	rs321358	0.945	rs17458885	ENSG00000271584.1	RP11-89C3.4	9.35	3.21e-19	5.01e-16	0.65	0.39	Body mass index;	chr11:111117222	chr11:111091932~111097357:-
LUAD	cis	rs494459	0.657	rs614554	ENSG00000255422.1	AP002954.4	-9.35	3.21e-19	5.02e-16	-0.48	-0.39	Height;	chr11:118764443	chr11:118704607~118750263:+
LUAD	cis	rs12468226	1	rs76284304	ENSG00000273456.1	RP11-686O6.2	9.35	3.22e-19	5.03e-16	0.6	0.39	Urate levels;	chr2:202427116	chr2:202374932~202375604:-
LUAD	cis	rs227275	0.554	rs223421	ENSG00000246560.2	RP11-10L12.4	9.35	3.22e-19	5.03e-16	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102805861	chr4:102828055~102844075:+
LUAD	cis	rs172166	0.56	rs203878	ENSG00000216901.1	AL022393.7	9.35	3.26e-19	5.09e-16	0.46	0.39	Cardiac Troponin-T levels;	chr6:28081218	chr6:28176188~28176674:+
LUAD	cis	rs11098499	0.754	rs4107728	ENSG00000245958.5	RP11-33B1.1	-9.35	3.27e-19	5.1e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119332755	chr4:119454791~119552025:+
LUAD	cis	rs12468226	0.873	rs79071680	ENSG00000273456.1	RP11-686O6.2	9.35	3.28e-19	5.12e-16	0.64	0.39	Urate levels;	chr2:202191520	chr2:202374932~202375604:-
LUAD	cis	rs12468226	0.873	rs79860867	ENSG00000273456.1	RP11-686O6.2	9.35	3.28e-19	5.12e-16	0.64	0.39	Urate levels;	chr2:202192397	chr2:202374932~202375604:-
LUAD	cis	rs11098499	0.754	rs9999724	ENSG00000245958.5	RP11-33B1.1	-9.35	3.29e-19	5.13e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119318789	chr4:119454791~119552025:+
LUAD	cis	rs944289	0.589	rs63360860	ENSG00000257826.1	RP11-116N8.4	9.35	3.32e-19	5.18e-16	0.41	0.39	Thyroid cancer;	chr14:36068846	chr14:36061026~36067190:-
LUAD	cis	rs9532669	0.926	rs2039119	ENSG00000176268.5	CYCSP34	-9.35	3.34e-19	5.21e-16	-0.38	-0.39	Cervical cancer;	chr13:40872432	chr13:40863599~40863902:-
LUAD	cis	rs11098499	0.754	rs714899	ENSG00000245958.5	RP11-33B1.1	-9.35	3.35e-19	5.22e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119321880	chr4:119454791~119552025:+
LUAD	cis	rs494459	0.838	rs488219	ENSG00000255422.1	AP002954.4	-9.35	3.36e-19	5.24e-16	-0.48	-0.39	Height;	chr11:118749988	chr11:118704607~118750263:+
LUAD	cis	rs7617773	0.539	rs6779517	ENSG00000229759.1	MRPS18AP1	9.35	3.37e-19	5.26e-16	0.38	0.39	Coronary artery disease;	chr3:48342898	chr3:48256350~48256938:-
LUAD	cis	rs7044106	0.762	rs10760110	ENSG00000226752.6	PSMD5-AS1	9.35	3.37e-19	5.26e-16	0.43	0.39	Hip circumference adjusted for BMI;	chr9:120650285	chr9:120824828~120854385:+
LUAD	cis	rs9326248	0.861	rs4938343	ENSG00000280143.1	AP000892.6	9.35	3.43e-19	5.35e-16	0.54	0.39	Blood protein levels;	chr11:117132812	chr11:117204967~117210292:+
LUAD	cis	rs227275	0.554	rs223409	ENSG00000246560.2	RP11-10L12.4	9.34	3.46e-19	5.39e-16	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102815023	chr4:102828055~102844075:+
LUAD	cis	rs10129255	0.5	rs2027903	ENSG00000211972.2	IGHV3-66	9.34	3.47e-19	5.4e-16	0.31	0.39	Kawasaki disease;	chr14:106807047	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.518	rs28378320	ENSG00000211972.2	IGHV3-66	9.34	3.47e-19	5.4e-16	0.31	0.39	Kawasaki disease;	chr14:106808609	chr14:106675017~106675544:-
LUAD	cis	rs34779708	0.966	rs7070427	ENSG00000230534.5	RP11-297A16.2	9.34	3.47e-19	5.4e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35196761	chr10:35098006~35127020:-
LUAD	cis	rs11690935	0.921	rs7594711	ENSG00000228389.1	AC068039.4	9.34	3.49e-19	5.43e-16	0.46	0.39	Schizophrenia;	chr2:172030734	chr2:171773482~171775844:+
LUAD	cis	rs34779708	0.897	rs9665538	ENSG00000230534.5	RP11-297A16.2	9.34	3.51e-19	5.46e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35172110	chr10:35098006~35127020:-
LUAD	cis	rs7617773	0.539	rs13094496	ENSG00000229759.1	MRPS18AP1	9.34	3.51e-19	5.46e-16	0.39	0.39	Coronary artery disease;	chr3:48345560	chr3:48256350~48256938:-
LUAD	cis	rs16828019	0.852	rs3820090	ENSG00000235358.1	RP11-399E6.1	9.34	3.55e-19	5.52e-16	0.66	0.39	Intelligence (multi-trait analysis);	chr1:41107980	chr1:41242373~41284861:+
LUAD	cis	rs10129255	0.5	rs6576230	ENSG00000211972.2	IGHV3-66	9.34	3.56e-19	5.53e-16	0.31	0.39	Kawasaki disease;	chr14:106778539	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.518	rs11847766	ENSG00000211972.2	IGHV3-66	9.34	3.56e-19	5.53e-16	0.31	0.39	Kawasaki disease;	chr14:106779186	chr14:106675017~106675544:-
LUAD	cis	rs2108622	0.727	rs62107770	ENSG00000267453.5	AC004791.2	-9.34	3.57e-19	5.55e-16	-0.48	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15874615	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.727	rs2158511	ENSG00000267453.5	AC004791.2	-9.34	3.57e-19	5.55e-16	-0.48	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15875837	chr19:15851993~15864904:-
LUAD	cis	rs227275	0.554	rs223422	ENSG00000246560.2	RP11-10L12.4	9.34	3.57e-19	5.56e-16	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102805616	chr4:102828055~102844075:+
LUAD	cis	rs10129255	0.5	rs59939897	ENSG00000211972.2	IGHV3-66	9.34	3.64e-19	5.66e-16	0.31	0.39	Kawasaki disease;	chr14:106783414	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.5	rs8014529	ENSG00000211972.2	IGHV3-66	9.34	3.64e-19	5.66e-16	0.31	0.39	Kawasaki disease;	chr14:106784065	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.5	rs12101190	ENSG00000211972.2	IGHV3-66	9.34	3.64e-19	5.66e-16	0.31	0.39	Kawasaki disease;	chr14:106784149	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.518	rs8004895	ENSG00000211972.2	IGHV3-66	9.34	3.64e-19	5.66e-16	0.31	0.39	Kawasaki disease;	chr14:106785139	chr14:106675017~106675544:-
LUAD	cis	rs227275	0.554	rs6810668	ENSG00000246560.2	RP11-10L12.4	9.34	3.68e-19	5.72e-16	0.49	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102987574	chr4:102828055~102844075:+
LUAD	cis	rs10262624	0.564	rs58051142	ENSG00000234286.1	AC006026.13	-9.34	3.72e-19	5.77e-16	-0.47	-0.39	Schizophrenia;	chr7:23866047	chr7:23680195~23680786:-
LUAD	cis	rs10256972	0.616	rs6957733	ENSG00000229043.2	AC091729.9	-9.33	3.73e-19	5.8e-16	-0.41	-0.39	Endometriosis;Longevity;	chr7:1066691	chr7:1160374~1165267:+
LUAD	cis	rs7208859	0.673	rs999797	ENSG00000263531.1	RP13-753N3.1	9.33	3.75e-19	5.82e-16	0.8	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832311	chr17:30863921~30864940:-
LUAD	cis	rs10129255	1	rs10134517	ENSG00000211970.3	IGHV4-61	-9.33	3.76e-19	5.83e-16	-0.3	-0.39	Kawasaki disease;	chr14:106718498	chr14:106639119~106639657:-
LUAD	cis	rs11098499	0.754	rs1546503	ENSG00000245958.5	RP11-33B1.1	-9.33	3.76e-19	5.83e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119320012	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.708	rs1546506	ENSG00000245958.5	RP11-33B1.1	-9.33	3.76e-19	5.83e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119320085	chr4:119454791~119552025:+
LUAD	cis	rs227275	0.525	rs10029073	ENSG00000246560.2	RP11-10L12.4	9.33	3.76e-19	5.84e-16	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:103006991	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs724446	ENSG00000246560.2	RP11-10L12.4	9.33	3.76e-19	5.84e-16	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:103010206	chr4:102828055~102844075:+
LUAD	cis	rs34779708	0.897	rs4934527	ENSG00000230534.5	RP11-297A16.2	9.33	3.78e-19	5.86e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:34992190	chr10:35098006~35127020:-
LUAD	cis	rs227275	0.525	rs11097796	ENSG00000246560.2	RP11-10L12.4	9.33	3.81e-19	5.9e-16	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:103002401	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs11097797	ENSG00000246560.2	RP11-10L12.4	9.33	3.81e-19	5.9e-16	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:103002507	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs13117110	ENSG00000246560.2	RP11-10L12.4	9.33	3.81e-19	5.9e-16	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:103003981	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs13144033	ENSG00000246560.2	RP11-10L12.4	9.33	3.81e-19	5.9e-16	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:103004032	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs4699046	ENSG00000246560.2	RP11-10L12.4	9.33	3.81e-19	5.9e-16	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:103004514	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs4699047	ENSG00000246560.2	RP11-10L12.4	9.33	3.81e-19	5.9e-16	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:103005385	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs28778380	ENSG00000246560.2	RP11-10L12.4	9.33	3.81e-19	5.9e-16	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:103006416	chr4:102828055~102844075:+
LUAD	cis	rs2108622	0.727	rs7254940	ENSG00000267453.5	AC004791.2	-9.33	3.84e-19	5.94e-16	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15873698	chr19:15851993~15864904:-
LUAD	cis	rs34779708	0.966	rs34630580	ENSG00000230534.5	RP11-297A16.2	9.33	3.86e-19	5.98e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35160300	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs35126129	ENSG00000230534.5	RP11-297A16.2	9.33	3.86e-19	5.98e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35163213	chr10:35098006~35127020:-
LUAD	cis	rs6991838	0.584	rs1053087	ENSG00000200714.1	Y_RNA	-9.33	3.87e-19	5.99e-16	-0.48	-0.39	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65592731~65592820:+
LUAD	cis	rs321358	1	rs321358	ENSG00000271584.1	RP11-89C3.4	9.33	3.88e-19	6e-16	0.65	0.39	Body mass index;	chr11:111125247	chr11:111091932~111097357:-
LUAD	cis	rs11098499	0.575	rs907204	ENSG00000245958.5	RP11-33B1.1	-9.33	3.88e-19	6.01e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119317499	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.575	rs907205	ENSG00000245958.5	RP11-33B1.1	-9.33	3.88e-19	6.01e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119317509	chr4:119454791~119552025:+
LUAD	cis	rs6142102	0.58	rs6142101	ENSG00000276073.1	RP5-1125A11.7	-9.33	3.89e-19	6.03e-16	-0.38	-0.39	Skin pigmentation;	chr20:34110039	chr20:33985617~33988989:-
LUAD	cis	rs12468226	0.938	rs12463937	ENSG00000273456.1	RP11-686O6.2	9.33	3.91e-19	6.05e-16	0.62	0.39	Urate levels;	chr2:202246543	chr2:202374932~202375604:-
LUAD	cis	rs11123170	0.65	rs2289897	ENSG00000189223.12	PAX8-AS1	-9.33	3.93e-19	6.08e-16	-0.59	-0.39	Renal function-related traits (BUN);	chr2:113219877	chr2:113211522~113276581:+
LUAD	cis	rs7617773	0.539	rs17593974	ENSG00000229759.1	MRPS18AP1	9.33	3.93e-19	6.08e-16	0.39	0.39	Coronary artery disease;	chr3:48345844	chr3:48256350~48256938:-
LUAD	cis	rs7617773	0.514	rs11130166	ENSG00000229759.1	MRPS18AP1	9.33	3.93e-19	6.08e-16	0.39	0.39	Coronary artery disease;	chr3:48346566	chr3:48256350~48256938:-
LUAD	cis	rs9326248	0.861	rs1871757	ENSG00000280143.1	AP000892.6	9.33	3.96e-19	6.12e-16	0.52	0.39	Blood protein levels;	chr11:117159865	chr11:117204967~117210292:+
LUAD	cis	rs11098499	0.865	rs10213221	ENSG00000245958.5	RP11-33B1.1	-9.33	3.97e-19	6.14e-16	-0.35	-0.39	Corneal astigmatism;	chr4:119334771	chr4:119454791~119552025:+
LUAD	cis	rs9660180	0.967	rs10907191	ENSG00000231050.1	RP1-140A9.1	9.33	4e-19	6.18e-16	0.44	0.39	Body mass index;	chr1:1843381	chr1:1891471~1892658:+
LUAD	cis	rs3931020	0.53	rs12125889	ENSG00000272864.1	RP11-17E13.2	-9.33	4.02e-19	6.22e-16	-0.47	-0.39	Resistin levels;	chr1:74776287	chr1:74698769~74699333:-
LUAD	cis	rs2729354	0.729	rs2848634	ENSG00000265566.2	RN7SL605P	-9.33	4.03e-19	6.23e-16	-0.56	-0.39	Blood protein levels;	chr11:57484855	chr11:57528085~57528365:-
LUAD	cis	rs227275	0.554	rs223334	ENSG00000246560.2	RP11-10L12.4	-9.32	4.06e-19	6.28e-16	-0.48	-0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102867054	chr4:102828055~102844075:+
LUAD	cis	rs2108622	0.727	rs62107763	ENSG00000267453.5	AC004791.2	-9.32	4.14e-19	6.4e-16	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871788	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.727	rs62107764	ENSG00000267453.5	AC004791.2	-9.32	4.14e-19	6.4e-16	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871848	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.727	rs76984410	ENSG00000267453.5	AC004791.2	-9.32	4.14e-19	6.4e-16	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871890	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.727	rs77780918	ENSG00000267453.5	AC004791.2	-9.32	4.14e-19	6.4e-16	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871897	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.727	rs8104311	ENSG00000267453.5	AC004791.2	-9.32	4.14e-19	6.4e-16	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871950	chr19:15851993~15864904:-
LUAD	cis	rs2108622	0.727	rs8101038	ENSG00000267453.5	AC004791.2	-9.32	4.14e-19	6.4e-16	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872054	chr19:15851993~15864904:-
LUAD	cis	rs2729354	0.729	rs2581923	ENSG00000265566.2	RN7SL605P	-9.32	4.17e-19	6.43e-16	-0.56	-0.39	Blood protein levels;	chr11:57482518	chr11:57528085~57528365:-
LUAD	cis	rs2108622	0.727	rs12609900	ENSG00000267453.5	AC004791.2	-9.32	4.17e-19	6.44e-16	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871604	chr19:15851993~15864904:-
LUAD	cis	rs6142102	0.602	rs10485503	ENSG00000276073.1	RP5-1125A11.7	-9.32	4.21e-19	6.51e-16	-0.39	-0.39	Skin pigmentation;	chr20:33970036	chr20:33985617~33988989:-
LUAD	cis	rs7044106	0.708	rs959558	ENSG00000226752.6	PSMD5-AS1	-9.32	4.21e-19	6.51e-16	-0.42	-0.39	Hip circumference adjusted for BMI;	chr9:120606633	chr9:120824828~120854385:+
LUAD	cis	rs321358	0.945	rs10502129	ENSG00000271584.1	RP11-89C3.4	9.32	4.32e-19	6.67e-16	0.65	0.39	Body mass index;	chr11:111107405	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.945	rs12420595	ENSG00000271584.1	RP11-89C3.4	9.32	4.32e-19	6.67e-16	0.65	0.39	Body mass index;	chr11:111115871	chr11:111091932~111097357:-
LUAD	cis	rs4423214	0.879	rs1790353	ENSG00000254682.1	RP11-660L16.2	-9.32	4.32e-19	6.67e-16	-0.55	-0.39	Vitamin D levels;	chr11:71425684	chr11:71448674~71452157:+
LUAD	cis	rs10129255	0.5	rs34326748	ENSG00000211972.2	IGHV3-66	9.32	4.33e-19	6.68e-16	0.31	0.39	Kawasaki disease;	chr14:106782523	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.5	rs10143385	ENSG00000211972.2	IGHV3-66	9.32	4.33e-19	6.68e-16	0.31	0.39	Kawasaki disease;	chr14:106782559	chr14:106675017~106675544:-
LUAD	cis	rs494459	0.838	rs2510897	ENSG00000255422.1	AP002954.4	-9.31	4.41e-19	6.8e-16	-0.48	-0.39	Height;	chr11:118773873	chr11:118704607~118750263:+
LUAD	cis	rs6142102	0.602	rs11696338	ENSG00000276073.1	RP5-1125A11.7	-9.31	4.45e-19	6.86e-16	-0.38	-0.39	Skin pigmentation;	chr20:34099805	chr20:33985617~33988989:-
LUAD	cis	rs6964833	0.873	rs4717905	ENSG00000123965.13	PMS2P5	9.31	4.49e-19	6.92e-16	0.61	0.39	Menarche (age at onset);	chr7:74668903	chr7:74894116~74897835:+
LUAD	cis	rs2337406	0.714	rs115401799	ENSG00000274576.2	IGHV2-70	-9.31	4.5e-19	6.93e-16	-0.46	-0.39	Alzheimer's disease (late onset);	chr14:106813739	chr14:106770577~106771020:-
LUAD	cis	rs9399135	0.622	rs3817776	ENSG00000232876.1	CTA-212D2.2	9.31	4.51e-19	6.95e-16	0.43	0.39	Red blood cell count;	chr6:134935618	chr6:135055033~135060550:+
LUAD	cis	rs34779708	0.931	rs34087268	ENSG00000230534.5	RP11-297A16.2	9.31	4.51e-19	6.95e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35057796	chr10:35098006~35127020:-
LUAD	cis	rs1891275	0.515	rs2421694	ENSG00000228701.1	TNKS2-AS1	-9.31	4.52e-19	6.95e-16	-0.49	-0.39	Intelligence (multi-trait analysis);	chr10:91756347	chr10:91782839~91798291:-
LUAD	cis	rs10129255	0.957	rs61997760	ENSG00000211970.3	IGHV4-61	-9.31	4.57e-19	7.02e-16	-0.31	-0.39	Kawasaki disease;	chr14:106716993	chr14:106639119~106639657:-
LUAD	cis	rs321358	0.945	rs7112932	ENSG00000271584.1	RP11-89C3.4	9.31	4.58e-19	7.04e-16	0.65	0.39	Body mass index;	chr11:111101099	chr11:111091932~111097357:-
LUAD	cis	rs11098499	0.604	rs10022185	ENSG00000245958.5	RP11-33B1.1	-9.31	4.61e-19	7.08e-16	-0.36	-0.39	Corneal astigmatism;	chr4:119650610	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.691	rs10028773	ENSG00000245958.5	RP11-33B1.1	9.31	4.72e-19	7.26e-16	0.33	0.39	Corneal astigmatism;	chr4:119344104	chr4:119454791~119552025:+
LUAD	cis	rs227275	0.554	rs149576	ENSG00000246560.2	RP11-10L12.4	9.3	4.8e-19	7.38e-16	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:102811411	chr4:102828055~102844075:+
LUAD	cis	rs2564921	0.704	rs62255931	ENSG00000242142.1	SERBP1P3	-9.3	4.82e-19	7.4e-16	-0.44	-0.39	Height;	chr3:53097932	chr3:53064283~53065091:-
LUAD	cis	rs7617773	0.563	rs13082269	ENSG00000229759.1	MRPS18AP1	9.3	4.82e-19	7.4e-16	0.39	0.39	Coronary artery disease;	chr3:48350784	chr3:48256350~48256938:-
LUAD	cis	rs904251	0.504	rs1757188	ENSG00000204110.6	RP1-153P14.8	-9.3	4.82e-19	7.41e-16	-0.39	-0.39	Cognitive performance;	chr6:37516032	chr6:37507348~37535616:+
LUAD	cis	rs2564921	0.73	rs60579898	ENSG00000242142.1	SERBP1P3	-9.3	4.9e-19	7.52e-16	-0.44	-0.39	Height;	chr3:53069965	chr3:53064283~53065091:-
LUAD	cis	rs1976403	0.659	rs10799701	ENSG00000227001.3	NBPF2P	9.3	4.94e-19	7.58e-16	0.45	0.39	Liver enzyme levels (alkaline phosphatase);	chr1:21494497	chr1:21424625~21427967:-
LUAD	cis	rs10129255	0.5	rs8006888	ENSG00000211972.2	IGHV3-66	9.3	4.97e-19	7.62e-16	0.31	0.39	Kawasaki disease;	chr14:106782219	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.536	rs10142951	ENSG00000211972.2	IGHV3-66	9.3	4.97e-19	7.62e-16	0.31	0.39	Kawasaki disease;	chr14:106782337	chr14:106675017~106675544:-
LUAD	cis	rs7924176	0.564	rs11000920	ENSG00000213731.2	RAB5CP1	-9.3	4.99e-19	7.65e-16	-0.41	-0.39	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74208443	chr10:74423435~74424014:-
LUAD	cis	rs733592	0.723	rs10875766	ENSG00000240399.1	RP1-228P16.1	9.3	5.03e-19	7.71e-16	0.37	0.39	Plateletcrit;	chr12:48199797	chr12:48054813~48055591:-
LUAD	cis	rs12468226	1	rs7587234	ENSG00000273456.1	RP11-686O6.2	9.3	5.09e-19	7.79e-16	0.61	0.39	Urate levels;	chr2:202351699	chr2:202374932~202375604:-
LUAD	cis	rs4273100	1	rs12602286	ENSG00000262319.1	CTC-457L16.2	9.3	5.1e-19	7.81e-16	0.51	0.39	Schizophrenia;	chr17:19333641	chr17:19141017~19143689:-
LUAD	cis	rs2019137	0.936	rs4849169	ENSG00000274877.1	RP11-65I12.1	9.3	5.1e-19	7.82e-16	0.49	0.39	Lymphocyte counts;	chr2:113196080	chr2:113237595~113240825:+
LUAD	cis	rs2019137	0.836	rs4848318	ENSG00000274877.1	RP11-65I12.1	9.3	5.1e-19	7.82e-16	0.49	0.39	Lymphocyte counts;	chr2:113196375	chr2:113237595~113240825:+
LUAD	cis	rs2019137	0.936	rs2241978	ENSG00000274877.1	RP11-65I12.1	9.3	5.1e-19	7.82e-16	0.49	0.39	Lymphocyte counts;	chr2:113196429	chr2:113237595~113240825:+
LUAD	cis	rs2019137	0.936	rs3828188	ENSG00000274877.1	RP11-65I12.1	9.3	5.1e-19	7.82e-16	0.49	0.39	Lymphocyte counts;	chr2:113196670	chr2:113237595~113240825:+
LUAD	cis	rs2019137	0.936	rs3828189	ENSG00000274877.1	RP11-65I12.1	9.3	5.1e-19	7.82e-16	0.49	0.39	Lymphocyte counts;	chr2:113196919	chr2:113237595~113240825:+
LUAD	cis	rs34779708	0.966	rs4934736	ENSG00000230534.5	RP11-297A16.2	9.3	5.12e-19	7.84e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35207940	chr10:35098006~35127020:-
LUAD	cis	rs321358	0.945	rs7931995	ENSG00000271584.1	RP11-89C3.4	9.29	5.17e-19	7.92e-16	0.65	0.39	Body mass index;	chr11:111117691	chr11:111091932~111097357:-
LUAD	cis	rs9532669	0.926	rs9594450	ENSG00000176268.5	CYCSP34	9.29	5.22e-19	7.99e-16	0.42	0.39	Cervical cancer;	chr13:40880067	chr13:40863599~40863902:-
LUAD	cis	rs4423214	0.879	rs1792281	ENSG00000254682.1	RP11-660L16.2	-9.29	5.29e-19	8.08e-16	-0.55	-0.39	Vitamin D levels;	chr11:71424450	chr11:71448674~71452157:+
LUAD	cis	rs10129255	0.5	rs8022547	ENSG00000211972.2	IGHV3-66	9.29	5.29e-19	8.09e-16	0.31	0.39	Kawasaki disease;	chr14:106781985	chr14:106675017~106675544:-
LUAD	cis	rs10875746	0.768	rs4760609	ENSG00000240399.1	RP1-228P16.1	9.29	5.33e-19	8.15e-16	0.43	0.39	Longevity (90 years and older);	chr12:48021974	chr12:48054813~48055591:-
LUAD	cis	rs10129255	0.5	rs11627315	ENSG00000211972.2	IGHV3-66	9.29	5.34e-19	8.16e-16	0.31	0.39	Kawasaki disease;	chr14:106802182	chr14:106675017~106675544:-
LUAD	cis	rs172166	0.516	rs1225618	ENSG00000216901.1	AL022393.7	9.29	5.35e-19	8.17e-16	0.46	0.39	Cardiac Troponin-T levels;	chr6:28161935	chr6:28176188~28176674:+
LUAD	cis	rs34779708	0.833	rs12777517	ENSG00000230534.5	RP11-297A16.2	9.29	5.37e-19	8.21e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35184999	chr10:35098006~35127020:-
LUAD	cis	rs732716	0.785	rs62130979	ENSG00000267769.1	CTB-50L17.9	-9.29	5.38e-19	8.22e-16	-0.44	-0.39	Mean corpuscular volume;	chr19:4432447	chr19:4454014~4455286:+
LUAD	cis	rs10463554	0.963	rs17154959	ENSG00000175749.11	EIF3KP1	9.29	5.41e-19	8.26e-16	0.55	0.39	Parkinson's disease;	chr5:103020587	chr5:103032376~103033031:+
LUAD	cis	rs4423214	0.879	rs736894	ENSG00000254682.1	RP11-660L16.2	9.29	5.44e-19	8.31e-16	0.55	0.39	Vitamin D levels;	chr11:71441212	chr11:71448674~71452157:+
LUAD	cis	rs6964833	1	rs4717907	ENSG00000277053.3	GTF2IP1	-9.29	5.46e-19	8.34e-16	-0.52	-0.39	Menarche (age at onset);	chr7:74672169	chr7:75185385~75237696:-
LUAD	cis	rs7174755	0.772	rs75395345	ENSG00000260657.2	RP11-315D16.4	9.29	5.53e-19	8.44e-16	0.49	0.39	Major depressive disorder;	chr15:68081380	chr15:68267792~68277994:-
LUAD	cis	rs10262624	0.935	rs6955725	ENSG00000234286.1	AC006026.13	-9.28	5.65e-19	8.61e-16	-0.48	-0.39	Schizophrenia;	chr7:23865523	chr7:23680195~23680786:-
LUAD	cis	rs17023223	0.537	rs10923767	ENSG00000231365.4	RP11-418J17.1	-9.28	5.68e-19	8.67e-16	-0.51	-0.39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119189724	chr1:119140396~119275973:+
LUAD	cis	rs10262624	0.935	rs6955884	ENSG00000234286.1	AC006026.13	-9.28	5.72e-19	8.73e-16	-0.48	-0.39	Schizophrenia;	chr7:23865654	chr7:23680195~23680786:-
LUAD	cis	rs7924176	0.54	rs61866073	ENSG00000213731.2	RAB5CP1	-9.28	5.74e-19	8.75e-16	-0.41	-0.39	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74347856	chr10:74423435~74424014:-
LUAD	cis	rs11098499	0.722	rs1814814	ENSG00000245958.5	RP11-33B1.1	-9.28	5.78e-19	8.81e-16	-0.33	-0.39	Corneal astigmatism;	chr4:119336969	chr4:119454791~119552025:+
LUAD	cis	rs35160687	0.862	rs13023154	ENSG00000273080.1	RP11-301O19.1	-9.28	5.79e-19	8.83e-16	-0.44	-0.39	Night sleep phenotypes;	chr2:86289861	chr2:86195590~86196049:+
LUAD	cis	rs1976403	0.659	rs10799699	ENSG00000227001.3	NBPF2P	9.28	5.83e-19	8.88e-16	0.46	0.39	Liver enzyme levels (alkaline phosphatase);	chr1:21494468	chr1:21424625~21427967:-
LUAD	cis	rs11690935	0.885	rs6725388	ENSG00000228389.1	AC068039.4	9.28	5.88e-19	8.96e-16	0.45	0.39	Schizophrenia;	chr2:171873505	chr2:171773482~171775844:+
LUAD	cis	rs34779708	0.931	rs6481935	ENSG00000230534.5	RP11-297A16.2	9.28	5.9e-19	8.98e-16	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35054031	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs12242882	ENSG00000230534.5	RP11-297A16.2	9.28	5.9e-19	8.98e-16	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35058932	chr10:35098006~35127020:-
LUAD	cis	rs200895692	1	rs200895692	ENSG00000227533.4	SLC2A1-AS1	9.28	5.92e-19	9.02e-16	0.58	0.39	Monocyte count;	chr1:42956299	chr1:42959049~42983358:+
LUAD	cis	rs34779708	0.966	rs17591781	ENSG00000230534.5	RP11-297A16.2	9.27	6.04e-19	9.19e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35209610	chr10:35098006~35127020:-
LUAD	cis	rs321358	0.945	rs73015199	ENSG00000271584.1	RP11-89C3.4	9.27	6.05e-19	9.21e-16	0.64	0.39	Body mass index;	chr11:111104952	chr11:111091932~111097357:-
LUAD	cis	rs34779708	0.897	rs12830	ENSG00000230534.5	RP11-297A16.2	9.27	6.13e-19	9.32e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35013777	chr10:35098006~35127020:-
LUAD	cis	rs6142102	0.602	rs4911145	ENSG00000276073.1	RP5-1125A11.7	9.27	6.19e-19	9.42e-16	0.38	0.39	Skin pigmentation;	chr20:34027417	chr20:33985617~33988989:-
LUAD	cis	rs6452524	0.935	rs72767160	ENSG00000249664.1	CTD-2227C6.2	9.27	6.25e-19	9.5e-16	0.46	0.39	Hypertension (SNP x SNP interaction);	chr5:83161102	chr5:83012285~83013109:-
LUAD	cis	rs34779708	0.931	rs67976880	ENSG00000230534.5	RP11-297A16.2	9.27	6.26e-19	9.51e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35083333	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs72789687	ENSG00000230534.5	RP11-297A16.2	9.27	6.26e-19	9.51e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35083561	chr10:35098006~35127020:-
LUAD	cis	rs12468226	1	rs79919139	ENSG00000273456.1	RP11-686O6.2	9.27	6.27e-19	9.52e-16	0.59	0.39	Urate levels;	chr2:202382786	chr2:202374932~202375604:-
LUAD	cis	rs321358	0.79	rs10502128	ENSG00000271584.1	RP11-89C3.4	9.27	6.3e-19	9.56e-16	0.62	0.39	Body mass index;	chr11:111076827	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.848	rs57168185	ENSG00000271584.1	RP11-89C3.4	9.27	6.3e-19	9.56e-16	0.62	0.39	Body mass index;	chr11:111078120	chr11:111091932~111097357:-
LUAD	cis	rs34779708	0.931	rs4007289	ENSG00000230534.5	RP11-297A16.2	9.27	6.34e-19	9.63e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:34980862	chr10:35098006~35127020:-
LUAD	cis	rs7617773	0.539	rs12486935	ENSG00000229759.1	MRPS18AP1	9.27	6.37e-19	9.68e-16	0.38	0.39	Coronary artery disease;	chr3:48348674	chr3:48256350~48256938:-
LUAD	cis	rs227275	0.556	rs6842179	ENSG00000246560.2	RP11-10L12.4	9.27	6.39e-19	9.7e-16	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:103018363	chr4:102828055~102844075:+
LUAD	cis	rs367615	0.552	rs2963023	ENSG00000249476.1	CTD-2587M2.1	-9.27	6.44e-19	9.77e-16	-0.46	-0.39	Colorectal cancer (SNP x SNP interaction);	chr5:109394369	chr5:109237120~109326369:-
LUAD	cis	rs34779708	0.931	rs11010125	ENSG00000230534.5	RP11-297A16.2	9.27	6.44e-19	9.77e-16	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35214025	chr10:35098006~35127020:-
LUAD	cis	rs2929278	0.617	rs4617832	ENSG00000249839.1	AC011330.5	9.26	6.53e-19	9.92e-16	0.52	0.39	Schizophrenia;	chr15:43738381	chr15:43663654~43684339:-
LUAD	cis	rs3931020	0.53	rs6668736	ENSG00000272864.1	RP11-17E13.2	-9.26	6.54e-19	9.93e-16	-0.46	-0.39	Resistin levels;	chr1:74768866	chr1:74698769~74699333:-
LUAD	cis	rs9309711	0.666	rs11127429	ENSG00000225234.1	TRAPPC12-AS1	-9.26	6.58e-19	9.98e-16	-0.46	-0.39	Neurofibrillary tangles;	chr2:3481453	chr2:3481242~3482409:-
LUAD	cis	rs9309711	0.666	rs11127430	ENSG00000225234.1	TRAPPC12-AS1	-9.26	6.58e-19	9.98e-16	-0.46	-0.39	Neurofibrillary tangles;	chr2:3481471	chr2:3481242~3482409:-
LUAD	cis	rs748404	0.578	rs552701	ENSG00000205771.5	CATSPER2P1	-9.26	6.59e-19	9.99e-16	-0.5	-0.39	Lung cancer;	chr15:43321612	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.578	rs573615	ENSG00000205771.5	CATSPER2P1	-9.26	6.59e-19	9.99e-16	-0.5	-0.39	Lung cancer;	chr15:43322083	chr15:43726918~43747094:-
LUAD	cis	rs12130219	1	rs1552994	ENSG00000237975.5	FLG-AS1	9.26	6.6e-19	1e-15	0.54	0.39	Inflammatory skin disease;	chr1:152198985	chr1:152168125~152445456:+
LUAD	cis	rs12130219	1	rs12733173	ENSG00000237975.5	FLG-AS1	9.26	6.6e-19	1e-15	0.54	0.39	Inflammatory skin disease;	chr1:152201496	chr1:152168125~152445456:+
LUAD	cis	rs9326248	0.861	rs4938352	ENSG00000280143.1	AP000892.6	9.26	6.62e-19	1e-15	0.52	0.39	Blood protein levels;	chr11:117156765	chr11:117204967~117210292:+
LUAD	cis	rs7044106	0.791	rs735110	ENSG00000226752.6	PSMD5-AS1	-9.26	6.63e-19	1.01e-15	-0.44	-0.39	Hip circumference adjusted for BMI;	chr9:120726662	chr9:120824828~120854385:+
LUAD	cis	rs10256972	0.521	rs10280960	ENSG00000229043.2	AC091729.9	-9.26	6.68e-19	1.01e-15	-0.41	-0.39	Endometriosis;Longevity;	chr7:1064061	chr7:1160374~1165267:+
LUAD	cis	rs34779708	0.966	rs35079558	ENSG00000230534.5	RP11-297A16.2	9.26	6.68e-19	1.01e-15	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35190958	chr10:35098006~35127020:-
LUAD	cis	rs6782228	1	rs11711038	ENSG00000242551.2	POU5F1P6	9.26	6.68e-19	1.01e-15	0.5	0.39	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128675467	chr3:128674735~128677005:-
LUAD	cis	rs2564921	0.73	rs1811351	ENSG00000242142.1	SERBP1P3	-9.26	6.71e-19	1.02e-15	-0.43	-0.39	Height;	chr3:53064759	chr3:53064283~53065091:-
LUAD	cis	rs9399137	0.507	rs13197750	ENSG00000232876.1	CTA-212D2.2	-9.26	6.74e-19	1.02e-15	-0.45	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134991242	chr6:135055033~135060550:+
LUAD	cis	rs9399137	0.507	rs12663447	ENSG00000232876.1	CTA-212D2.2	-9.26	6.74e-19	1.02e-15	-0.45	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995888	chr6:135055033~135060550:+
LUAD	cis	rs9399137	0.507	rs4895437	ENSG00000232876.1	CTA-212D2.2	-9.26	6.74e-19	1.02e-15	-0.45	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134996216	chr6:135055033~135060550:+
LUAD	cis	rs904251	0.6	rs12211110	ENSG00000204110.6	RP1-153P14.8	-9.26	6.78e-19	1.03e-15	-0.4	-0.39	Cognitive performance;	chr6:37498456	chr6:37507348~37535616:+
LUAD	cis	rs1789	0.903	rs4453929	ENSG00000273133.1	RP11-799M12.2	-9.26	6.85e-19	1.04e-15	-0.54	-0.39	Blood protein levels;	chr4:15670550	chr4:15563698~15564253:-
LUAD	cis	rs1789	0.868	rs4631041	ENSG00000273133.1	RP11-799M12.2	-9.26	6.85e-19	1.04e-15	-0.54	-0.39	Blood protein levels;	chr4:15671772	chr4:15563698~15564253:-
LUAD	cis	rs34779708	0.931	rs12773169	ENSG00000230534.5	RP11-297A16.2	9.26	6.86e-19	1.04e-15	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35077534	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs7084196	ENSG00000230534.5	RP11-297A16.2	9.26	6.86e-19	1.04e-15	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35078233	chr10:35098006~35127020:-
LUAD	cis	rs526231	0.578	rs34794	ENSG00000175749.11	EIF3KP1	9.26	6.88e-19	1.04e-15	0.55	0.39	Primary biliary cholangitis;	chr5:103087664	chr5:103032376~103033031:+
LUAD	cis	rs34779708	0.966	rs1057108	ENSG00000230534.5	RP11-297A16.2	9.26	6.92e-19	1.05e-15	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35196021	chr10:35098006~35127020:-
LUAD	cis	rs526231	0.543	rs158395	ENSG00000175749.11	EIF3KP1	9.26	6.95e-19	1.05e-15	0.54	0.39	Primary biliary cholangitis;	chr5:103075685	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.543	rs158400	ENSG00000175749.11	EIF3KP1	9.26	6.95e-19	1.05e-15	0.54	0.39	Primary biliary cholangitis;	chr5:103077628	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.543	rs257302	ENSG00000175749.11	EIF3KP1	9.26	6.95e-19	1.05e-15	0.54	0.39	Primary biliary cholangitis;	chr5:103080426	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.543	rs257303	ENSG00000175749.11	EIF3KP1	9.26	6.95e-19	1.05e-15	0.54	0.39	Primary biliary cholangitis;	chr5:103081023	chr5:103032376~103033031:+
LUAD	cis	rs321358	0.945	rs7111445	ENSG00000271584.1	RP11-89C3.4	-9.26	6.97e-19	1.05e-15	-0.64	-0.39	Body mass index;	chr11:111105787	chr11:111091932~111097357:-
LUAD	cis	rs9660180	0.868	rs72634846	ENSG00000231050.1	RP1-140A9.1	9.26	6.99e-19	1.06e-15	0.44	0.39	Body mass index;	chr1:1773476	chr1:1891471~1892658:+
LUAD	cis	rs62229266	0.771	rs7280136	ENSG00000231106.2	LINC01436	-9.26	6.99e-19	1.06e-15	-0.53	-0.39	Mitral valve prolapse;	chr21:36060612	chr21:36005338~36007838:+
LUAD	cis	rs732716	0.785	rs55660045	ENSG00000267769.1	CTB-50L17.9	-9.26	7e-19	1.06e-15	-0.42	-0.39	Mean corpuscular volume;	chr19:4425308	chr19:4454014~4455286:+
LUAD	cis	rs904251	0.58	rs62408367	ENSG00000279942.1	RP1-153P14.7	-9.25	7.08e-19	1.07e-15	-0.36	-0.39	Cognitive performance;	chr6:37477037	chr6:37567716~37571460:+
LUAD	cis	rs2564921	0.73	rs6781896	ENSG00000242142.1	SERBP1P3	-9.25	7.1e-19	1.07e-15	-0.43	-0.39	Height;	chr3:53047596	chr3:53064283~53065091:-
LUAD	cis	rs10129255	0.828	rs10140989	ENSG00000223648.3	IGHV3-64	9.25	7.12e-19	1.07e-15	0.39	0.39	Kawasaki disease;	chr14:106668657	chr14:106643132~106658258:-
LUAD	cis	rs34779708	0.966	rs34605125	ENSG00000230534.5	RP11-297A16.2	9.25	7.14e-19	1.08e-15	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35122318	chr10:35098006~35127020:-
LUAD	cis	rs1155848	0.892	rs9565508	ENSG00000227354.5	RBM26-AS1	9.25	7.18e-19	1.08e-15	0.84	0.39	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79482451	chr13:79406309~79424328:+
LUAD	cis	rs4423214	0.879	rs1792284	ENSG00000254682.1	RP11-660L16.2	9.25	7.2e-19	1.09e-15	0.54	0.39	Vitamin D levels;	chr11:71423920	chr11:71448674~71452157:+
LUAD	cis	rs6991838	0.584	rs1053088	ENSG00000272010.1	CTD-3025N20.3	9.25	7.32e-19	1.11e-15	0.43	0.39	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65591850~65592472:-
LUAD	cis	rs34779708	1	rs34779708	ENSG00000230534.5	RP11-297A16.2	9.25	7.34e-19	1.11e-15	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35177257	chr10:35098006~35127020:-
LUAD	cis	rs10129255	0.912	rs67410411	ENSG00000223648.3	IGHV3-64	9.25	7.35e-19	1.11e-15	0.39	0.39	Kawasaki disease;	chr14:106680324	chr14:106643132~106658258:-
LUAD	cis	rs4423214	0.535	rs1540129	ENSG00000254682.1	RP11-660L16.2	9.25	7.46e-19	1.12e-15	0.51	0.39	Vitamin D levels;	chr11:71418477	chr11:71448674~71452157:+
LUAD	cis	rs6991838	0.584	rs6994213	ENSG00000200714.1	Y_RNA	-9.25	7.54e-19	1.14e-15	-0.48	-0.39	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65592731~65592820:+
LUAD	cis	rs9660180	0.935	rs2180311	ENSG00000231050.1	RP1-140A9.1	9.24	7.65e-19	1.15e-15	0.44	0.39	Body mass index;	chr1:1817295	chr1:1891471~1892658:+
LUAD	cis	rs9660180	0.967	rs6664664	ENSG00000231050.1	RP1-140A9.1	9.24	7.65e-19	1.15e-15	0.44	0.39	Body mass index;	chr1:1819825	chr1:1891471~1892658:+
LUAD	cis	rs4423214	0.625	rs78685409	ENSG00000254682.1	RP11-660L16.2	-9.24	7.65e-19	1.15e-15	-0.55	-0.39	Vitamin D levels;	chr11:71426337	chr11:71448674~71452157:+
LUAD	cis	rs4423214	0.879	rs1792277	ENSG00000254682.1	RP11-660L16.2	-9.24	7.65e-19	1.15e-15	-0.55	-0.39	Vitamin D levels;	chr11:71427872	chr11:71448674~71452157:+
LUAD	cis	rs6142102	0.58	rs761233	ENSG00000276073.1	RP5-1125A11.7	-9.24	7.68e-19	1.16e-15	-0.39	-0.39	Skin pigmentation;	chr20:33981080	chr20:33985617~33988989:-
LUAD	cis	rs9399137	0.507	rs6569986	ENSG00000232876.1	CTA-212D2.2	-9.24	7.69e-19	1.16e-15	-0.45	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134990503	chr6:135055033~135060550:+
LUAD	cis	rs2337406	1	rs4774173	ENSG00000274576.2	IGHV2-70	-9.24	7.74e-19	1.17e-15	-0.42	-0.39	Alzheimer's disease (late onset);	chr14:106682029	chr14:106770577~106771020:-
LUAD	cis	rs11098499	0.789	rs10212719	ENSG00000245958.5	RP11-33B1.1	-9.24	7.77e-19	1.17e-15	-0.35	-0.39	Corneal astigmatism;	chr4:119333282	chr4:119454791~119552025:+
LUAD	cis	rs2283792	0.633	rs240068	ENSG00000224086.5	LL22NC03-86G7.1	-9.24	7.84e-19	1.18e-15	-0.36	-0.39	Multiple sclerosis;	chr22:21936031	chr22:21938293~21977632:+
LUAD	cis	rs6991838	0.584	rs34494846	ENSG00000200714.1	Y_RNA	-9.24	7.91e-19	1.19e-15	-0.48	-0.39	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65592731~65592820:+
LUAD	cis	rs35160687	0.64	rs13015186	ENSG00000273080.1	RP11-301O19.1	9.24	7.92e-19	1.19e-15	0.45	0.39	Night sleep phenotypes;	chr2:86258455	chr2:86195590~86196049:+
LUAD	cis	rs2564921	0.704	rs11130333	ENSG00000242142.1	SERBP1P3	-9.24	8e-19	1.2e-15	-0.44	-0.39	Height;	chr3:52977358	chr3:53064283~53065091:-
LUAD	cis	rs321358	1	rs419633	ENSG00000271584.1	RP11-89C3.4	9.24	8.01e-19	1.2e-15	0.65	0.39	Body mass index;	chr11:111132187	chr11:111091932~111097357:-
LUAD	cis	rs321358	1	rs429803	ENSG00000271584.1	RP11-89C3.4	9.24	8.01e-19	1.2e-15	0.65	0.39	Body mass index;	chr11:111132263	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.943	rs402820	ENSG00000271584.1	RP11-89C3.4	9.24	8.01e-19	1.2e-15	0.65	0.39	Body mass index;	chr11:111132480	chr11:111091932~111097357:-
LUAD	cis	rs10463554	0.927	rs158396	ENSG00000175749.11	EIF3KP1	9.24	8.17e-19	1.23e-15	0.54	0.39	Parkinson's disease;	chr5:103076015	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.892	rs158401	ENSG00000175749.11	EIF3KP1	9.24	8.17e-19	1.23e-15	0.54	0.39	Parkinson's disease;	chr5:103079764	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs257304	ENSG00000175749.11	EIF3KP1	9.24	8.17e-19	1.23e-15	0.54	0.39	Parkinson's disease;	chr5:103081114	chr5:103032376~103033031:+
LUAD	cis	rs12468226	1	rs16839090	ENSG00000273456.1	RP11-686O6.2	9.24	8.2e-19	1.23e-15	0.61	0.39	Urate levels;	chr2:202348338	chr2:202374932~202375604:-
LUAD	cis	rs34779708	0.966	rs12775799	ENSG00000230534.5	RP11-297A16.2	9.24	8.21e-19	1.23e-15	0.47	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35199336	chr10:35098006~35127020:-
LUAD	cis	rs11098499	0.754	rs12510269	ENSG00000245958.5	RP11-33B1.1	-9.24	8.21e-19	1.23e-15	-0.35	-0.39	Corneal astigmatism;	chr4:119320491	chr4:119454791~119552025:+
LUAD	cis	rs12468226	1	rs13389798	ENSG00000273456.1	RP11-686O6.2	9.24	8.23e-19	1.24e-15	0.6	0.39	Urate levels;	chr2:202348370	chr2:202374932~202375604:-
LUAD	cis	rs34779708	0.9	rs73262807	ENSG00000230534.5	RP11-297A16.2	9.24	8.26e-19	1.24e-15	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35207458	chr10:35098006~35127020:-
LUAD	cis	rs904251	0.523	rs2797794	ENSG00000204110.6	RP1-153P14.8	-9.23	8.3e-19	1.25e-15	-0.39	-0.39	Cognitive performance;	chr6:37512828	chr6:37507348~37535616:+
LUAD	cis	rs904251	0.523	rs2776920	ENSG00000204110.6	RP1-153P14.8	-9.23	8.3e-19	1.25e-15	-0.39	-0.39	Cognitive performance;	chr6:37512829	chr6:37507348~37535616:+
LUAD	cis	rs904251	0.504	rs2797795	ENSG00000204110.6	RP1-153P14.8	-9.23	8.3e-19	1.25e-15	-0.39	-0.39	Cognitive performance;	chr6:37512907	chr6:37507348~37535616:+
LUAD	cis	rs904251	0.523	rs2797796	ENSG00000204110.6	RP1-153P14.8	-9.23	8.3e-19	1.25e-15	-0.39	-0.39	Cognitive performance;	chr6:37513110	chr6:37507348~37535616:+
LUAD	cis	rs904251	0.523	rs2776870	ENSG00000204110.6	RP1-153P14.8	-9.23	8.3e-19	1.25e-15	-0.39	-0.39	Cognitive performance;	chr6:37513588	chr6:37507348~37535616:+
LUAD	cis	rs904251	0.523	rs2797798	ENSG00000204110.6	RP1-153P14.8	-9.23	8.3e-19	1.25e-15	-0.39	-0.39	Cognitive performance;	chr6:37513661	chr6:37507348~37535616:+
LUAD	cis	rs904251	0.523	rs2776871	ENSG00000204110.6	RP1-153P14.8	-9.23	8.3e-19	1.25e-15	-0.39	-0.39	Cognitive performance;	chr6:37513983	chr6:37507348~37535616:+
LUAD	cis	rs10129255	0.83	rs61997609	ENSG00000223648.3	IGHV3-64	9.23	8.36e-19	1.25e-15	0.39	0.39	Kawasaki disease;	chr14:106692376	chr14:106643132~106658258:-
LUAD	cis	rs7567389	0.74	rs4536600	ENSG00000236682.1	AC068282.3	-9.23	8.46e-19	1.27e-15	-0.5	-0.39	Self-rated health;	chr2:127244996	chr2:127389130~127400580:+
LUAD	cis	rs7188445	0.932	rs17767383	ENSG00000261390.4	RP11-345M22.2	-9.23	8.59e-19	1.29e-15	-0.51	-0.39	Urate levels;	chr16:79710504	chr16:79715232~79770563:-
LUAD	cis	rs10129255	1	rs10129319	ENSG00000211970.3	IGHV4-61	-9.23	8.67e-19	1.3e-15	-0.3	-0.39	Kawasaki disease;	chr14:106767996	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.957	rs11846893	ENSG00000211970.3	IGHV4-61	-9.23	8.72e-19	1.31e-15	-0.29	-0.39	Kawasaki disease;	chr14:106779068	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.719	rs7156660	ENSG00000223648.3	IGHV3-64	9.23	8.73e-19	1.31e-15	0.38	0.39	Kawasaki disease;	chr14:106673171	chr14:106643132~106658258:-
LUAD	cis	rs1976403	0.659	rs10799700	ENSG00000227001.3	NBPF2P	9.23	8.74e-19	1.31e-15	0.46	0.39	Liver enzyme levels (alkaline phosphatase);	chr1:21494475	chr1:21424625~21427967:-
LUAD	cis	rs7044106	0.708	rs2416760	ENSG00000226752.6	PSMD5-AS1	-9.23	8.75e-19	1.31e-15	-0.42	-0.39	Hip circumference adjusted for BMI;	chr9:120612361	chr9:120824828~120854385:+
LUAD	cis	rs10256972	0.621	rs10951594	ENSG00000229043.2	AC091729.9	-9.23	8.84e-19	1.32e-15	-0.4	-0.39	Endometriosis;Longevity;	chr7:1048971	chr7:1160374~1165267:+
LUAD	cis	rs2739330	0.732	rs5760175	ENSG00000099984.9	GSTT2	-9.23	8.86e-19	1.33e-15	-0.48	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23980123~23983911:+
LUAD	cis	rs944289	0.561	rs371191	ENSG00000257826.1	RP11-116N8.4	9.23	8.91e-19	1.33e-15	0.41	0.39	Thyroid cancer;	chr14:36064000	chr14:36061026~36067190:-
LUAD	cis	rs7617773	0.539	rs35460860	ENSG00000229759.1	MRPS18AP1	9.23	8.92e-19	1.33e-15	0.39	0.39	Coronary artery disease;	chr3:48350595	chr3:48256350~48256938:-
LUAD	cis	rs34779708	0.931	rs13377158	ENSG00000230534.5	RP11-297A16.2	-9.23	8.94e-19	1.34e-15	-0.46	-0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35081537	chr10:35098006~35127020:-
LUAD	cis	rs26232	0.521	rs11958562	ENSG00000175749.11	EIF3KP1	9.22	8.96e-19	1.34e-15	0.53	0.39	Rheumatoid arthritis;	chr5:103027357	chr5:103032376~103033031:+
LUAD	cis	rs11690935	1	rs312924	ENSG00000228389.1	AC068039.4	-9.22	8.97e-19	1.34e-15	-0.45	-0.39	Schizophrenia;	chr2:171707511	chr2:171773482~171775844:+
LUAD	cis	rs7044106	0.664	rs7861679	ENSG00000226752.6	PSMD5-AS1	9.22	9.03e-19	1.35e-15	0.42	0.39	Hip circumference adjusted for BMI;	chr9:120613311	chr9:120824828~120854385:+
LUAD	cis	rs10129255	0.957	rs10141052	ENSG00000211970.3	IGHV4-61	-9.22	9.05e-19	1.35e-15	-0.29	-0.39	Kawasaki disease;	chr14:106776528	chr14:106639119~106639657:-
LUAD	cis	rs11690935	0.851	rs6433319	ENSG00000228389.1	AC068039.4	9.22	9.1e-19	1.36e-15	0.44	0.39	Schizophrenia;	chr2:171974442	chr2:171773482~171775844:+
LUAD	cis	rs10129255	0.701	rs2005643	ENSG00000211970.3	IGHV4-61	-9.22	9.15e-19	1.37e-15	-0.3	-0.39	Kawasaki disease;	chr14:106676288	chr14:106639119~106639657:-
LUAD	cis	rs801193	0.613	rs2016325	ENSG00000226824.5	RP4-756H11.3	9.22	9.15e-19	1.37e-15	0.49	0.39	Aortic root size;	chr7:66858513	chr7:66654538~66669855:+
LUAD	cis	rs11676348	0.755	rs62183956	ENSG00000261338.2	RP11-378A13.1	9.22	9.29e-19	1.39e-15	0.41	0.39	Ulcerative colitis;	chr2:218181399	chr2:218255319~218257366:+
LUAD	cis	rs904251	0.523	rs1776454	ENSG00000204110.6	RP1-153P14.8	-9.22	9.3e-19	1.39e-15	-0.39	-0.39	Cognitive performance;	chr6:37514323	chr6:37507348~37535616:+
LUAD	cis	rs10875746	1	rs10875746	ENSG00000240399.1	RP1-228P16.1	-9.22	9.32e-19	1.39e-15	-0.44	-0.39	Longevity (90 years and older);	chr12:48124481	chr12:48054813~48055591:-
LUAD	cis	rs172166	0.538	rs1150686	ENSG00000216901.1	AL022393.7	9.22	9.36e-19	1.4e-15	0.45	0.39	Cardiac Troponin-T levels;	chr6:28193493	chr6:28176188~28176674:+
LUAD	cis	rs9326248	0.813	rs474488	ENSG00000280143.1	AP000892.6	9.22	9.37e-19	1.4e-15	0.53	0.39	Blood protein levels;	chr11:117198261	chr11:117204967~117210292:+
LUAD	cis	rs10262624	0.935	rs4722283	ENSG00000234286.1	AC006026.13	9.22	9.38e-19	1.4e-15	0.46	0.39	Schizophrenia;	chr7:23866595	chr7:23680195~23680786:-
LUAD	cis	rs6964833	1	rs4717906	ENSG00000277053.3	GTF2IP1	-9.22	9.38e-19	1.4e-15	-0.53	-0.39	Menarche (age at onset);	chr7:74671923	chr7:75185385~75237696:-
LUAD	cis	rs34779708	0.966	rs12775548	ENSG00000230534.5	RP11-297A16.2	9.22	9.38e-19	1.4e-15	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35190576	chr10:35098006~35127020:-
LUAD	cis	rs11098499	0.913	rs68128210	ENSG00000245958.5	RP11-33B1.1	-9.22	9.4e-19	1.4e-15	-0.36	-0.39	Corneal astigmatism;	chr4:119216664	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.913	rs13126596	ENSG00000245958.5	RP11-33B1.1	-9.22	9.4e-19	1.4e-15	-0.36	-0.39	Corneal astigmatism;	chr4:119219574	chr4:119454791~119552025:+
LUAD	cis	rs526231	0.543	rs34808	ENSG00000175749.11	EIF3KP1	9.22	9.42e-19	1.4e-15	0.55	0.39	Primary biliary cholangitis;	chr5:103093484	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.543	rs34809	ENSG00000175749.11	EIF3KP1	9.22	9.42e-19	1.4e-15	0.55	0.39	Primary biliary cholangitis;	chr5:103094413	chr5:103032376~103033031:+
LUAD	cis	rs1799949	0.628	rs4474733	ENSG00000198496.9	NBR2	-9.22	9.44e-19	1.41e-15	-0.46	-0.39	Menopause (age at onset);	chr17:43356292	chr17:43125610~43153671:+
LUAD	cis	rs733592	0.524	rs10875741	ENSG00000240399.1	RP1-228P16.1	-9.22	9.47e-19	1.41e-15	-0.36	-0.39	Plateletcrit;	chr12:48099139	chr12:48054813~48055591:-
LUAD	cis	rs10463554	0.927	rs257312	ENSG00000175749.11	EIF3KP1	9.22	9.51e-19	1.42e-15	0.54	0.39	Parkinson's disease;	chr5:103083923	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs185387	ENSG00000175749.11	EIF3KP1	9.22	9.51e-19	1.42e-15	0.54	0.39	Parkinson's disease;	chr5:103084315	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.892	rs257313	ENSG00000175749.11	EIF3KP1	9.22	9.51e-19	1.42e-15	0.54	0.39	Parkinson's disease;	chr5:103084943	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs257315	ENSG00000175749.11	EIF3KP1	9.22	9.51e-19	1.42e-15	0.54	0.39	Parkinson's disease;	chr5:103085725	chr5:103032376~103033031:+
LUAD	cis	rs11098499	0.913	rs10006304	ENSG00000245958.5	RP11-33B1.1	-9.22	9.54e-19	1.42e-15	-0.36	-0.39	Corneal astigmatism;	chr4:119203150	chr4:119454791~119552025:+
LUAD	cis	rs8040855	1	rs8040855	ENSG00000259295.5	CSPG4P12	-9.22	9.55e-19	1.42e-15	-0.46	-0.39	Bulimia nervosa;	chr15:85155976	chr15:85191438~85213905:+
LUAD	cis	rs733592	0.507	rs56129148	ENSG00000240399.1	RP1-228P16.1	-9.22	9.62e-19	1.43e-15	-0.36	-0.39	Plateletcrit;	chr12:48091747	chr12:48054813~48055591:-
LUAD	cis	rs1185460	0.967	rs11217137	ENSG00000271751.1	RP11-110I1.14	-9.22	9.67e-19	1.44e-15	-0.48	-0.39	Coronary artery disease;	chr11:119060319	chr11:119065263~119065677:-
LUAD	cis	rs34779708	0.931	rs12240347	ENSG00000230534.5	RP11-297A16.2	9.22	9.69e-19	1.44e-15	0.45	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35070547	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs4934533	ENSG00000230534.5	RP11-297A16.2	9.22	9.69e-19	1.44e-15	0.45	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35070691	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs12248333	ENSG00000230534.5	RP11-297A16.2	9.22	9.69e-19	1.44e-15	0.45	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35074049	chr10:35098006~35127020:-
LUAD	cis	rs10129255	0.872	rs8015406	ENSG00000223648.3	IGHV3-64	9.21	9.73e-19	1.45e-15	0.39	0.39	Kawasaki disease;	chr14:106670611	chr14:106643132~106658258:-
LUAD	cis	rs9389248	0.708	rs7750574	ENSG00000232876.1	CTA-212D2.2	-9.21	9.76e-19	1.45e-15	-0.45	-0.39	High light scatter reticulocyte percentage of red cells;	chr6:135029794	chr6:135055033~135060550:+
LUAD	cis	rs2188561	0.673	rs2712218	ENSG00000241764.3	AC002467.7	9.21	9.77e-19	1.45e-15	0.58	0.39	Alcohol consumption;	chr7:107716314	chr7:107742817~107744581:-
LUAD	cis	rs367615	0.552	rs2963025	ENSG00000249476.1	CTD-2587M2.1	-9.21	9.8e-19	1.46e-15	-0.45	-0.39	Colorectal cancer (SNP x SNP interaction);	chr5:109397555	chr5:109237120~109326369:-
LUAD	cis	rs34779708	0.966	rs17500582	ENSG00000230534.5	RP11-297A16.2	9.21	9.83e-19	1.46e-15	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35209860	chr10:35098006~35127020:-
LUAD	cis	rs9660180	0.836	rs72634845	ENSG00000231050.1	RP1-140A9.1	9.21	9.92e-19	1.48e-15	0.44	0.39	Body mass index;	chr1:1773460	chr1:1891471~1892658:+
LUAD	cis	rs9660180	0.839	rs12040826	ENSG00000231050.1	RP1-140A9.1	9.21	9.94e-19	1.48e-15	0.44	0.39	Body mass index;	chr1:1773848	chr1:1891471~1892658:+
LUAD	cis	rs7924176	0.521	rs11516630	ENSG00000213731.2	RAB5CP1	-9.21	1.01e-18	1.5e-15	-0.41	-0.39	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74351195	chr10:74423435~74424014:-
LUAD	cis	rs7924176	0.521	rs10509347	ENSG00000213731.2	RAB5CP1	-9.21	1.01e-18	1.5e-15	-0.41	-0.39	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74358782	chr10:74423435~74424014:-
LUAD	cis	rs12468226	1	rs12472408	ENSG00000273456.1	RP11-686O6.2	9.21	1.01e-18	1.5e-15	0.59	0.39	Urate levels;	chr2:202413973	chr2:202374932~202375604:-
LUAD	cis	rs2564921	0.73	rs62255895	ENSG00000242142.1	SERBP1P3	-9.21	1.01e-18	1.5e-15	-0.44	-0.39	Height;	chr3:53027969	chr3:53064283~53065091:-
LUAD	cis	rs2564921	0.73	rs62255898	ENSG00000242142.1	SERBP1P3	-9.21	1.01e-18	1.5e-15	-0.44	-0.39	Height;	chr3:53029908	chr3:53064283~53065091:-
LUAD	cis	rs526231	0.511	rs3776861	ENSG00000175749.11	EIF3KP1	9.21	1.01e-18	1.5e-15	0.55	0.39	Primary biliary cholangitis;	chr5:103013958	chr5:103032376~103033031:+
LUAD	cis	rs12134133	1	rs2802235	ENSG00000274245.1	RP11-357P18.2	9.21	1.01e-18	1.51e-15	0.5	0.39	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207298454	chr1:207372559~207373252:+
LUAD	cis	rs526231	0.512	rs34797	ENSG00000175749.11	EIF3KP1	9.21	1.02e-18	1.51e-15	0.55	0.39	Primary biliary cholangitis;	chr5:103090023	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.543	rs34801	ENSG00000175749.11	EIF3KP1	9.21	1.02e-18	1.51e-15	0.55	0.39	Primary biliary cholangitis;	chr5:103090809	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.543	rs40092	ENSG00000175749.11	EIF3KP1	9.21	1.02e-18	1.51e-15	0.55	0.39	Primary biliary cholangitis;	chr5:103088509	chr5:103032376~103033031:+
LUAD	cis	rs6991838	0.584	rs7823840	ENSG00000200714.1	Y_RNA	-9.21	1.02e-18	1.51e-15	-0.48	-0.39	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65592731~65592820:+
LUAD	cis	rs11722779	0.815	rs223347	ENSG00000246560.2	RP11-10L12.4	9.21	1.02e-18	1.51e-15	0.48	0.39	Schizophrenia;	chr4:102858815	chr4:102828055~102844075:+
LUAD	cis	rs11722779	0.873	rs223346	ENSG00000246560.2	RP11-10L12.4	9.21	1.02e-18	1.51e-15	0.48	0.39	Schizophrenia;	chr4:102859339	chr4:102828055~102844075:+
LUAD	cis	rs10256972	0.616	rs7806746	ENSG00000229043.2	AC091729.9	-9.21	1.03e-18	1.53e-15	-0.4	-0.39	Endometriosis;Longevity;	chr7:1035937	chr7:1160374~1165267:+
LUAD	cis	rs944289	0.557	rs8016147	ENSG00000257826.1	RP11-116N8.4	-9.21	1.04e-18	1.54e-15	-0.41	-0.39	Thyroid cancer;	chr14:36111685	chr14:36061026~36067190:-
LUAD	cis	rs9326248	0.813	rs588534	ENSG00000280143.1	AP000892.6	9.21	1.04e-18	1.55e-15	0.52	0.39	Blood protein levels;	chr11:117197788	chr11:117204967~117210292:+
LUAD	cis	rs34779708	0.931	rs7099593	ENSG00000230534.5	RP11-297A16.2	9.21	1.05e-18	1.55e-15	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35077950	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs13376801	ENSG00000230534.5	RP11-297A16.2	9.21	1.05e-18	1.55e-15	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35081515	chr10:35098006~35127020:-
LUAD	cis	rs12468226	0.938	rs3731700	ENSG00000273456.1	RP11-686O6.2	9.2	1.06e-18	1.57e-15	0.62	0.39	Urate levels;	chr2:202291213	chr2:202374932~202375604:-
LUAD	cis	rs12468226	0.938	rs12471060	ENSG00000273456.1	RP11-686O6.2	9.2	1.06e-18	1.57e-15	0.62	0.39	Urate levels;	chr2:202309597	chr2:202374932~202375604:-
LUAD	cis	rs34779708	0.966	rs12773647	ENSG00000230534.5	RP11-297A16.2	9.2	1.07e-18	1.59e-15	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35151399	chr10:35098006~35127020:-
LUAD	cis	rs733592	0.507	rs7304428	ENSG00000240399.1	RP1-228P16.1	-9.2	1.08e-18	1.6e-15	-0.36	-0.39	Plateletcrit;	chr12:48100492	chr12:48054813~48055591:-
LUAD	cis	rs227275	0.525	rs13150426	ENSG00000246560.2	RP11-10L12.4	9.2	1.1e-18	1.62e-15	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:103013743	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs28445579	ENSG00000246560.2	RP11-10L12.4	9.2	1.1e-18	1.62e-15	0.48	0.39	Allergic disease (asthma, hay fever or eczema);	chr4:103016438	chr4:102828055~102844075:+
LUAD	cis	rs11722779	0.935	rs7676736	ENSG00000246560.2	RP11-10L12.4	9.2	1.1e-18	1.63e-15	0.48	0.39	Schizophrenia;	chr4:103016729	chr4:102828055~102844075:+
LUAD	cis	rs34779708	0.931	rs11010083	ENSG00000230534.5	RP11-297A16.2	9.2	1.1e-18	1.63e-15	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35062603	chr10:35098006~35127020:-
LUAD	cis	rs10129255	0.518	rs10136903	ENSG00000211972.2	IGHV3-66	9.2	1.11e-18	1.64e-15	0.31	0.39	Kawasaki disease;	chr14:106778866	chr14:106675017~106675544:-
LUAD	cis	rs1789	0.903	rs4616746	ENSG00000273133.1	RP11-799M12.2	-9.2	1.11e-18	1.64e-15	-0.53	-0.39	Blood protein levels;	chr4:15671475	chr4:15563698~15564253:-
LUAD	cis	rs9399137	0.507	rs13209780	ENSG00000232876.1	CTA-212D2.2	-9.2	1.11e-18	1.64e-15	-0.45	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135023657	chr6:135055033~135060550:+
LUAD	cis	rs9399137	0.507	rs4896129	ENSG00000232876.1	CTA-212D2.2	-9.2	1.11e-18	1.64e-15	-0.45	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028707	chr6:135055033~135060550:+
LUAD	cis	rs11098499	0.955	rs56386062	ENSG00000245958.5	RP11-33B1.1	-9.2	1.13e-18	1.67e-15	-0.35	-0.39	Corneal astigmatism;	chr4:119233980	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.955	rs4145951	ENSG00000245958.5	RP11-33B1.1	-9.2	1.13e-18	1.67e-15	-0.35	-0.39	Corneal astigmatism;	chr4:119234662	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.955	rs35916640	ENSG00000245958.5	RP11-33B1.1	-9.2	1.13e-18	1.67e-15	-0.35	-0.39	Corneal astigmatism;	chr4:119234697	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.955	rs13114751	ENSG00000245958.5	RP11-33B1.1	-9.2	1.13e-18	1.67e-15	-0.35	-0.39	Corneal astigmatism;	chr4:119235462	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.913	rs35271032	ENSG00000245958.5	RP11-33B1.1	-9.2	1.13e-18	1.67e-15	-0.35	-0.39	Corneal astigmatism;	chr4:119235504	chr4:119454791~119552025:+
LUAD	cis	rs10129255	1	rs9324091	ENSG00000223648.3	IGHV3-64	9.2	1.13e-18	1.67e-15	0.39	0.39	Kawasaki disease;	chr14:106676625	chr14:106643132~106658258:-
LUAD	cis	rs34779708	0.931	rs7897457	ENSG00000230534.5	RP11-297A16.2	9.19	1.14e-18	1.69e-15	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35097112	chr10:35098006~35127020:-
LUAD	cis	rs367615	0.552	rs2963022	ENSG00000249476.1	CTD-2587M2.1	-9.19	1.15e-18	1.7e-15	-0.46	-0.39	Colorectal cancer (SNP x SNP interaction);	chr5:109391484	chr5:109237120~109326369:-
LUAD	cis	rs10129255	0.957	rs10141009	ENSG00000211970.3	IGHV4-61	-9.19	1.16e-18	1.72e-15	-0.29	-0.39	Kawasaki disease;	chr14:106776695	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.912	rs6576227	ENSG00000211970.3	IGHV4-61	-9.19	1.16e-18	1.72e-15	-0.29	-0.39	Kawasaki disease;	chr14:106778202	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.957	rs6576228	ENSG00000211970.3	IGHV4-61	-9.19	1.16e-18	1.72e-15	-0.29	-0.39	Kawasaki disease;	chr14:106778401	chr14:106639119~106639657:-
LUAD	cis	rs9660180	0.935	rs9786942	ENSG00000231050.1	RP1-140A9.1	9.19	1.18e-18	1.74e-15	0.43	0.39	Body mass index;	chr1:1827774	chr1:1891471~1892658:+
LUAD	cis	rs9660180	0.934	rs34849348	ENSG00000231050.1	RP1-140A9.1	9.19	1.18e-18	1.74e-15	0.43	0.39	Body mass index;	chr1:1831318	chr1:1891471~1892658:+
LUAD	cis	rs321358	0.945	rs17458235	ENSG00000271584.1	RP11-89C3.4	-9.19	1.18e-18	1.74e-15	-0.62	-0.39	Body mass index;	chr11:111106114	chr11:111091932~111097357:-
LUAD	cis	rs367615	0.552	rs3828603	ENSG00000249476.1	CTD-2587M2.1	-9.19	1.18e-18	1.74e-15	-0.46	-0.39	Colorectal cancer (SNP x SNP interaction);	chr5:109376367	chr5:109237120~109326369:-
LUAD	cis	rs10463554	0.892	rs13340345	ENSG00000175749.11	EIF3KP1	9.19	1.19e-18	1.76e-15	0.54	0.39	Parkinson's disease;	chr5:103003518	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.963	rs3776860	ENSG00000175749.11	EIF3KP1	9.19	1.19e-18	1.76e-15	0.54	0.39	Parkinson's disease;	chr5:103014266	chr5:103032376~103033031:+
LUAD	cis	rs11722779	0.903	rs13130741	ENSG00000246560.2	RP11-10L12.4	9.19	1.21e-18	1.77e-15	0.49	0.39	Schizophrenia;	chr4:103035799	chr4:102828055~102844075:+
LUAD	cis	rs944289	0.617	rs1958614	ENSG00000257826.1	RP11-116N8.4	-9.19	1.21e-18	1.79e-15	-0.41	-0.39	Thyroid cancer;	chr14:36118107	chr14:36061026~36067190:-
LUAD	cis	rs34779708	0.931	rs34954932	ENSG00000230534.5	RP11-297A16.2	9.19	1.22e-18	1.79e-15	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35121879	chr10:35098006~35127020:-
LUAD	cis	rs9326248	0.768	rs4936366	ENSG00000280143.1	AP000892.6	9.19	1.23e-18	1.81e-15	0.52	0.39	Blood protein levels;	chr11:117156169	chr11:117204967~117210292:+
LUAD	cis	rs34779708	0.897	rs4934716	ENSG00000230534.5	RP11-297A16.2	9.18	1.23e-18	1.81e-15	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35080371	chr10:35098006~35127020:-
LUAD	cis	rs2564921	0.73	rs62253602	ENSG00000242142.1	SERBP1P3	-9.18	1.23e-18	1.82e-15	-0.44	-0.39	Height;	chr3:52936861	chr3:53064283~53065091:-
LUAD	cis	rs2564921	0.704	rs62253603	ENSG00000242142.1	SERBP1P3	-9.18	1.23e-18	1.82e-15	-0.44	-0.39	Height;	chr3:52938846	chr3:53064283~53065091:-
LUAD	cis	rs8040855	0.894	rs4843023	ENSG00000259295.5	CSPG4P12	-9.18	1.24e-18	1.82e-15	-0.45	-0.39	Bulimia nervosa;	chr15:85162641	chr15:85191438~85213905:+
LUAD	cis	rs12468226	0.938	rs80315897	ENSG00000273456.1	RP11-686O6.2	9.18	1.25e-18	1.83e-15	0.62	0.39	Urate levels;	chr2:202318044	chr2:202374932~202375604:-
LUAD	cis	rs507080	0.922	rs654792	ENSG00000255239.1	AP002954.6	-9.18	1.26e-18	1.85e-15	-0.47	-0.39	Serum metabolite levels;	chr11:118682287	chr11:118688039~118690600:-
LUAD	cis	rs2108622	0.727	rs9305069	ENSG00000267453.5	AC004791.2	-9.18	1.26e-18	1.85e-15	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872576	chr19:15851993~15864904:-
LUAD	cis	rs526231	0.511	rs11951374	ENSG00000175749.11	EIF3KP1	9.18	1.26e-18	1.86e-15	0.55	0.39	Primary biliary cholangitis;	chr5:103020094	chr5:103032376~103033031:+
LUAD	cis	rs11098499	0.754	rs1980025	ENSG00000245958.5	RP11-33B1.1	9.18	1.26e-18	1.86e-15	0.35	0.39	Corneal astigmatism;	chr4:119331651	chr4:119454791~119552025:+
LUAD	cis	rs12468226	0.938	rs56684065	ENSG00000273456.1	RP11-686O6.2	9.18	1.27e-18	1.86e-15	0.61	0.39	Urate levels;	chr2:202289528	chr2:202374932~202375604:-
LUAD	cis	rs12468226	0.938	rs1474001	ENSG00000273456.1	RP11-686O6.2	9.18	1.27e-18	1.86e-15	0.61	0.39	Urate levels;	chr2:202290230	chr2:202374932~202375604:-
LUAD	cis	rs12468226	0.938	rs76664732	ENSG00000273456.1	RP11-686O6.2	9.18	1.27e-18	1.86e-15	0.61	0.39	Urate levels;	chr2:202296298	chr2:202374932~202375604:-
LUAD	cis	rs12468226	0.938	rs16841867	ENSG00000273456.1	RP11-686O6.2	9.18	1.27e-18	1.86e-15	0.61	0.39	Urate levels;	chr2:202303512	chr2:202374932~202375604:-
LUAD	cis	rs12468226	0.938	rs16839065	ENSG00000273456.1	RP11-686O6.2	9.18	1.27e-18	1.86e-15	0.61	0.39	Urate levels;	chr2:202308774	chr2:202374932~202375604:-
LUAD	cis	rs2564921	0.73	rs58492539	ENSG00000242142.1	SERBP1P3	-9.18	1.28e-18	1.88e-15	-0.43	-0.39	Height;	chr3:53052712	chr3:53064283~53065091:-
LUAD	cis	rs9660180	0.967	rs12044597	ENSG00000231050.1	RP1-140A9.1	9.18	1.28e-18	1.88e-15	0.43	0.39	Body mass index;	chr1:1777362	chr1:1891471~1892658:+
LUAD	cis	rs526231	0.578	rs42860	ENSG00000175749.11	EIF3KP1	9.18	1.28e-18	1.88e-15	0.54	0.39	Primary biliary cholangitis;	chr5:103092414	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs34806	ENSG00000175749.11	EIF3KP1	9.18	1.28e-18	1.88e-15	0.54	0.39	Parkinson's disease;	chr5:103092733	chr5:103032376~103033031:+
LUAD	cis	rs367615	0.552	rs2115511	ENSG00000249476.1	CTD-2587M2.1	-9.18	1.28e-18	1.88e-15	-0.45	-0.39	Colorectal cancer (SNP x SNP interaction);	chr5:109389702	chr5:109237120~109326369:-
LUAD	cis	rs11690935	0.851	rs10201430	ENSG00000228389.1	AC068039.4	9.18	1.29e-18	1.9e-15	0.44	0.39	Schizophrenia;	chr2:171956715	chr2:171773482~171775844:+
LUAD	cis	rs12468226	0.938	rs12464254	ENSG00000273456.1	RP11-686O6.2	9.18	1.3e-18	1.9e-15	0.62	0.39	Urate levels;	chr2:202301641	chr2:202374932~202375604:-
LUAD	cis	rs34779708	0.966	rs11010122	ENSG00000230534.5	RP11-297A16.2	9.18	1.32e-18	1.94e-15	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35204590	chr10:35098006~35127020:-
LUAD	cis	rs8040855	1	rs6496768	ENSG00000259295.5	CSPG4P12	-9.18	1.32e-18	1.94e-15	-0.46	-0.39	Bulimia nervosa;	chr15:85159701	chr15:85191438~85213905:+
LUAD	cis	rs944289	0.561	rs395660	ENSG00000257826.1	RP11-116N8.4	9.18	1.32e-18	1.94e-15	0.41	0.39	Thyroid cancer;	chr14:36063593	chr14:36061026~36067190:-
LUAD	cis	rs9326248	0.652	rs7128382	ENSG00000280143.1	AP000892.6	9.18	1.33e-18	1.95e-15	0.52	0.39	Blood protein levels;	chr11:117152771	chr11:117204967~117210292:+
LUAD	cis	rs10129255	0.957	rs12590799	ENSG00000211970.3	IGHV4-61	-9.17	1.35e-18	1.98e-15	-0.29	-0.39	Kawasaki disease;	chr14:106779713	chr14:106639119~106639657:-
LUAD	cis	rs944289	0.589	rs847516	ENSG00000257826.1	RP11-116N8.4	9.17	1.36e-18	1.99e-15	0.4	0.39	Thyroid cancer;	chr14:36060593	chr14:36061026~36067190:-
LUAD	cis	rs11690935	0.851	rs6731562	ENSG00000228389.1	AC068039.4	9.17	1.36e-18	1.99e-15	0.44	0.39	Schizophrenia;	chr2:171941742	chr2:171773482~171775844:+
LUAD	cis	rs6991838	0.584	rs6993876	ENSG00000200714.1	Y_RNA	9.17	1.38e-18	2.01e-15	0.47	0.39	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65592731~65592820:+
LUAD	cis	rs1891275	0.515	rs7475294	ENSG00000228701.1	TNKS2-AS1	-9.17	1.39e-18	2.03e-15	-0.48	-0.39	Intelligence (multi-trait analysis);	chr10:91748442	chr10:91782839~91798291:-
LUAD	cis	rs12468226	1	rs16839077	ENSG00000273456.1	RP11-686O6.2	9.17	1.39e-18	2.03e-15	0.61	0.39	Urate levels;	chr2:202343970	chr2:202374932~202375604:-
LUAD	cis	rs10129255	0.912	rs8009135	ENSG00000211970.3	IGHV4-61	-9.17	1.4e-18	2.05e-15	-0.29	-0.39	Kawasaki disease;	chr14:106777528	chr14:106639119~106639657:-
LUAD	cis	rs12130219	1	rs34428306	ENSG00000237975.5	FLG-AS1	9.17	1.41e-18	2.06e-15	0.54	0.39	Inflammatory skin disease;	chr1:152211840	chr1:152168125~152445456:+
LUAD	cis	rs2283792	0.73	rs2083565	ENSG00000224086.5	LL22NC03-86G7.1	-9.17	1.41e-18	2.06e-15	-0.36	-0.39	Multiple sclerosis;	chr22:21929985	chr22:21938293~21977632:+
LUAD	cis	rs10129255	0.5	rs10142931	ENSG00000211972.2	IGHV3-66	9.17	1.41e-18	2.07e-15	0.31	0.39	Kawasaki disease;	chr14:106782288	chr14:106675017~106675544:-
LUAD	cis	rs2188561	1	rs2712207	ENSG00000241764.3	AC002467.7	9.17	1.41e-18	2.07e-15	0.57	0.39	Alcohol consumption;	chr7:107711672	chr7:107742817~107744581:-
LUAD	cis	rs494459	0.838	rs581045	ENSG00000255422.1	AP002954.4	-9.17	1.42e-18	2.07e-15	-0.47	-0.39	Height;	chr11:118761813	chr11:118704607~118750263:+
LUAD	cis	rs7174755	0.923	rs4777036	ENSG00000260657.2	RP11-315D16.4	-9.17	1.42e-18	2.07e-15	-0.45	-0.39	Major depressive disorder;	chr15:68313230	chr15:68267792~68277994:-
LUAD	cis	rs11722779	0.775	rs223341	ENSG00000246560.2	RP11-10L12.4	9.17	1.43e-18	2.08e-15	0.47	0.39	Schizophrenia;	chr4:102862343	chr4:102828055~102844075:+
LUAD	cis	rs2564921	0.73	rs62255897	ENSG00000242142.1	SERBP1P3	-9.16	1.44e-18	2.1e-15	-0.44	-0.39	Height;	chr3:53029854	chr3:53064283~53065091:-
LUAD	cis	rs10256972	0.621	rs2280725	ENSG00000229043.2	AC091729.9	-9.16	1.44e-18	2.11e-15	-0.4	-0.39	Endometriosis;Longevity;	chr7:1047790	chr7:1160374~1165267:+
LUAD	cis	rs11098499	0.874	rs17839089	ENSG00000245958.5	RP11-33B1.1	-9.16	1.46e-18	2.13e-15	-0.36	-0.39	Corneal astigmatism;	chr4:119189914	chr4:119454791~119552025:+
LUAD	cis	rs7924176	0.521	rs12359775	ENSG00000213731.2	RAB5CP1	-9.16	1.48e-18	2.16e-15	-0.41	-0.39	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74330115	chr10:74423435~74424014:-
LUAD	cis	rs6991838	0.584	rs34226237	ENSG00000200714.1	Y_RNA	-9.16	1.48e-18	2.16e-15	-0.47	-0.39	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65592731~65592820:+
LUAD	cis	rs10129255	0.5	rs8021941	ENSG00000211972.2	IGHV3-66	9.16	1.48e-18	2.16e-15	0.31	0.39	Kawasaki disease;	chr14:106781490	chr14:106675017~106675544:-
LUAD	cis	rs34779708	0.897	rs4934529	ENSG00000230534.5	RP11-297A16.2	9.16	1.48e-18	2.16e-15	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35013448	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs7920095	ENSG00000230534.5	RP11-297A16.2	9.16	1.48e-18	2.16e-15	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35014406	chr10:35098006~35127020:-
LUAD	cis	rs12468226	0.938	rs115418918	ENSG00000273456.1	RP11-686O6.2	9.16	1.49e-18	2.17e-15	0.61	0.39	Urate levels;	chr2:202315145	chr2:202374932~202375604:-
LUAD	cis	rs12468226	0.938	rs114922024	ENSG00000273456.1	RP11-686O6.2	9.16	1.49e-18	2.17e-15	0.61	0.39	Urate levels;	chr2:202315958	chr2:202374932~202375604:-
LUAD	cis	rs12468226	0.938	rs77261109	ENSG00000273456.1	RP11-686O6.2	9.16	1.49e-18	2.17e-15	0.61	0.39	Urate levels;	chr2:202316233	chr2:202374932~202375604:-
LUAD	cis	rs12468226	0.938	rs12466003	ENSG00000273456.1	RP11-686O6.2	9.16	1.49e-18	2.17e-15	0.61	0.39	Urate levels;	chr2:202317317	chr2:202374932~202375604:-
LUAD	cis	rs12468226	0.938	rs76501067	ENSG00000273456.1	RP11-686O6.2	9.16	1.49e-18	2.17e-15	0.61	0.39	Urate levels;	chr2:202318042	chr2:202374932~202375604:-
LUAD	cis	rs11098499	1	rs13435802	ENSG00000245958.5	RP11-33B1.1	9.16	1.49e-18	2.17e-15	0.34	0.39	Corneal astigmatism;	chr4:119256805	chr4:119454791~119552025:+
LUAD	cis	rs8040855	0.86	rs7172266	ENSG00000259295.5	CSPG4P12	-9.16	1.51e-18	2.19e-15	-0.47	-0.39	Bulimia nervosa;	chr15:85172982	chr15:85191438~85213905:+
LUAD	cis	rs7924176	0.521	rs11000986	ENSG00000213731.2	RAB5CP1	-9.16	1.51e-18	2.2e-15	-0.4	-0.39	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74312877	chr10:74423435~74424014:-
LUAD	cis	rs7924176	0.521	rs10824147	ENSG00000213731.2	RAB5CP1	-9.16	1.51e-18	2.2e-15	-0.4	-0.39	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74317528	chr10:74423435~74424014:-
LUAD	cis	rs34779708	0.931	rs12268745	ENSG00000230534.5	RP11-297A16.2	9.16	1.53e-18	2.22e-15	0.45	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35017061	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs7923172	ENSG00000230534.5	RP11-297A16.2	9.16	1.53e-18	2.22e-15	0.45	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35020439	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs3740083	ENSG00000230534.5	RP11-297A16.2	9.16	1.53e-18	2.22e-15	0.45	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:35031455	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs4934697	ENSG00000230534.5	RP11-297A16.2	9.16	1.53e-18	2.22e-15	0.46	0.39	Inflammatory bowel disease;Crohn's disease;	chr10:34998264	chr10:35098006~35127020:-
LUAD	cis	rs11118620	0.622	rs11118618	ENSG00000238078.1	LINC01352	9.16	1.54e-18	2.23e-15	0.52	0.39	Heart failure;	chr1:220838204	chr1:220829255~220832429:+
LUAD	cis	rs172166	0.561	rs149971	ENSG00000204709.4	LINC01556	9.15	1.56e-18	2.26e-15	0.47	0.39	Cardiac Troponin-T levels;	chr6:28014374	chr6:28943877~28944537:+
LUAD	cis	rs8040855	0.965	rs6496766	ENSG00000259295.5	CSPG4P12	-9.15	1.57e-18	2.27e-15	-0.46	-0.39	Bulimia nervosa;	chr15:85159144	chr15:85191438~85213905:+
LUAD	cis	rs172166	0.516	rs2622322	ENSG00000216901.1	AL022393.7	9.15	1.58e-18	2.29e-15	0.45	0.39	Cardiac Troponin-T levels;	chr6:28149665	chr6:28176188~28176674:+
LUAD	cis	rs12468226	0.873	rs60722019	ENSG00000273456.1	RP11-686O6.2	9.15	1.59e-18	2.3e-15	0.61	0.39	Urate levels;	chr2:202282060	chr2:202374932~202375604:-
LUAD	cis	rs10129255	0.957	rs1024349	ENSG00000223648.3	IGHV3-64	9.15	1.59e-18	2.31e-15	0.38	0.39	Kawasaki disease;	chr14:106689997	chr14:106643132~106658258:-
LUAD	cis	rs1150688	1	rs1150688	ENSG00000216901.1	AL022393.7	9.15	1.6e-18	2.31e-15	0.45	0.39	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28176188~28176674:+
LUAD	cis	rs9399137	0.507	rs7761964	ENSG00000232876.1	CTA-212D2.2	-9.15	1.6e-18	2.33e-15	-0.45	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134993127	chr6:135055033~135060550:+
LUAD	cis	rs9399137	0.507	rs11753673	ENSG00000232876.1	CTA-212D2.2	-9.15	1.6e-18	2.33e-15	-0.45	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995338	chr6:135055033~135060550:+
LUAD	cis	rs10129255	0.536	rs10139058	ENSG00000280411.1	IGHV1-69-2	-9.15	1.62e-18	2.35e-15	-0.27	-0.39	Kawasaki disease;	chr14:106685899	chr14:106762092~106762588:-
LUAD	cis	rs7044106	0.537	rs4434680	ENSG00000226752.6	PSMD5-AS1	-9.15	1.64e-18	2.37e-15	-0.47	-0.38	Hip circumference adjusted for BMI;	chr9:120727410	chr9:120824828~120854385:+
LUAD	cis	rs6991838	0.584	rs1053085	ENSG00000200714.1	Y_RNA	-9.15	1.64e-18	2.38e-15	-0.48	-0.38	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65592731~65592820:+
LUAD	cis	rs34779708	0.931	rs11597392	ENSG00000230534.5	RP11-297A16.2	9.15	1.65e-18	2.39e-15	0.46	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:34999647	chr10:35098006~35127020:-
LUAD	cis	rs10463554	0.963	rs13340364	ENSG00000175749.11	EIF3KP1	9.15	1.65e-18	2.39e-15	0.54	0.38	Parkinson's disease;	chr5:103003406	chr5:103032376~103033031:+
LUAD	cis	rs7924176	0.521	rs10824137	ENSG00000213731.2	RAB5CP1	9.15	1.65e-18	2.39e-15	0.41	0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74273396	chr10:74423435~74424014:-
LUAD	cis	rs10129255	0.912	rs8011090	ENSG00000223648.3	IGHV3-64	9.15	1.66e-18	2.4e-15	0.38	0.38	Kawasaki disease;	chr14:106678896	chr14:106643132~106658258:-
LUAD	cis	rs10129255	1	rs61997605	ENSG00000223648.3	IGHV3-64	9.15	1.67e-18	2.41e-15	0.38	0.38	Kawasaki disease;	chr14:106678368	chr14:106643132~106658258:-
LUAD	cis	rs10129255	1	rs8012033	ENSG00000223648.3	IGHV3-64	9.15	1.67e-18	2.41e-15	0.38	0.38	Kawasaki disease;	chr14:106678854	chr14:106643132~106658258:-
LUAD	cis	rs6991838	0.584	rs1053087	ENSG00000272010.1	CTD-3025N20.3	-9.15	1.68e-18	2.43e-15	-0.42	-0.38	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65591850~65592472:-
LUAD	cis	rs172166	0.538	rs149956	ENSG00000216901.1	AL022393.7	9.15	1.68e-18	2.44e-15	0.45	0.38	Cardiac Troponin-T levels;	chr6:28068473	chr6:28176188~28176674:+
LUAD	cis	rs9326248	0.727	rs4938347	ENSG00000280143.1	AP000892.6	9.14	1.69e-18	2.45e-15	0.51	0.38	Blood protein levels;	chr11:117151043	chr11:117204967~117210292:+
LUAD	cis	rs9326248	0.813	rs4938350	ENSG00000280143.1	AP000892.6	9.14	1.69e-18	2.45e-15	0.51	0.38	Blood protein levels;	chr11:117151560	chr11:117204967~117210292:+
LUAD	cis	rs12468226	0.679	rs6435133	ENSG00000273456.1	RP11-686O6.2	-9.14	1.69e-18	2.45e-15	-0.59	-0.38	Urate levels;	chr2:202209237	chr2:202374932~202375604:-
LUAD	cis	rs10463554	0.963	rs3776857	ENSG00000175749.11	EIF3KP1	9.14	1.69e-18	2.45e-15	0.54	0.38	Parkinson's disease;	chr5:103022456	chr5:103032376~103033031:+
LUAD	cis	rs10129255	0.518	rs12590732	ENSG00000211972.2	IGHV3-66	-9.14	1.71e-18	2.47e-15	-0.31	-0.38	Kawasaki disease;	chr14:106779612	chr14:106675017~106675544:-
LUAD	cis	rs34779708	0.771	rs12098283	ENSG00000230534.5	RP11-297A16.2	9.14	1.71e-18	2.47e-15	0.46	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35189187	chr10:35098006~35127020:-
LUAD	cis	rs7924176	0.521	rs11001022	ENSG00000213731.2	RAB5CP1	-9.14	1.71e-18	2.47e-15	-0.4	-0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74380110	chr10:74423435~74424014:-
LUAD	cis	rs2929278	0.561	rs62018952	ENSG00000249839.1	AC011330.5	9.14	1.71e-18	2.47e-15	0.51	0.38	Schizophrenia;	chr15:43788539	chr15:43663654~43684339:-
LUAD	cis	rs34779708	0.931	rs10508815	ENSG00000230534.5	RP11-297A16.2	9.14	1.72e-18	2.49e-15	0.45	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35043693	chr10:35098006~35127020:-
LUAD	cis	rs7924176	0.521	rs10762599	ENSG00000213731.2	RAB5CP1	-9.14	1.72e-18	2.49e-15	-0.41	-0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74339162	chr10:74423435~74424014:-
LUAD	cis	rs34779708	0.897	rs35784065	ENSG00000230534.5	RP11-297A16.2	9.14	1.73e-18	2.5e-15	0.46	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35064646	chr10:35098006~35127020:-
LUAD	cis	rs10129255	0.828	rs10140989	ENSG00000211970.3	IGHV4-61	-9.14	1.74e-18	2.51e-15	-0.3	-0.38	Kawasaki disease;	chr14:106668657	chr14:106639119~106639657:-
LUAD	cis	rs12130219	1	rs12130219	ENSG00000237975.5	FLG-AS1	9.14	1.75e-18	2.53e-15	0.54	0.38	Inflammatory skin disease;	chr1:152189630	chr1:152168125~152445456:+
LUAD	cis	rs944289	0.533	rs2780313	ENSG00000257826.1	RP11-116N8.4	9.14	1.77e-18	2.55e-15	0.39	0.38	Thyroid cancer;	chr14:36059216	chr14:36061026~36067190:-
LUAD	cis	rs2283792	0.73	rs2329884	ENSG00000224086.5	LL22NC03-86G7.1	-9.14	1.79e-18	2.58e-15	-0.36	-0.38	Multiple sclerosis;	chr22:21927890	chr22:21938293~21977632:+
LUAD	cis	rs10129255	0.719	rs7156660	ENSG00000211970.3	IGHV4-61	-9.14	1.79e-18	2.59e-15	-0.3	-0.38	Kawasaki disease;	chr14:106673171	chr14:106639119~106639657:-
LUAD	cis	rs2929278	0.589	rs11638972	ENSG00000249839.1	AC011330.5	9.14	1.8e-18	2.6e-15	0.49	0.38	Schizophrenia;	chr15:43782493	chr15:43663654~43684339:-
LUAD	cis	rs34779708	0.931	rs2384283	ENSG00000230534.5	RP11-297A16.2	9.14	1.82e-18	2.62e-15	0.46	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35037861	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs66887762	ENSG00000230534.5	RP11-297A16.2	9.14	1.82e-18	2.62e-15	0.46	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35041649	chr10:35098006~35127020:-
LUAD	cis	rs172166	0.516	rs2791333	ENSG00000216901.1	AL022393.7	9.14	1.82e-18	2.63e-15	0.45	0.38	Cardiac Troponin-T levels;	chr6:28143336	chr6:28176188~28176674:+
LUAD	cis	rs9660180	1	rs9660180	ENSG00000231050.1	RP1-140A9.1	9.13	1.83e-18	2.63e-15	0.43	0.38	Body mass index;	chr1:1791592	chr1:1891471~1892658:+
LUAD	cis	rs8040855	0.597	rs994989	ENSG00000259295.5	CSPG4P12	9.13	1.83e-18	2.64e-15	0.52	0.38	Bulimia nervosa;	chr15:85117485	chr15:85191438~85213905:+
LUAD	cis	rs12468226	0.873	rs3181153	ENSG00000273456.1	RP11-686O6.2	-9.13	1.84e-18	2.65e-15	-0.59	-0.38	Urate levels;	chr2:202205155	chr2:202374932~202375604:-
LUAD	cis	rs732716	0.819	rs12459919	ENSG00000267769.1	CTB-50L17.9	-9.13	1.85e-18	2.66e-15	-0.42	-0.38	Mean corpuscular volume;	chr19:4434506	chr19:4454014~4455286:+
LUAD	cis	rs11168351	0.591	rs4258439	ENSG00000240399.1	RP1-228P16.1	-9.13	1.85e-18	2.66e-15	-0.36	-0.38	Bipolar disorder and schizophrenia;	chr12:48074869	chr12:48054813~48055591:-
LUAD	cis	rs733592	0.507	rs10747529	ENSG00000240399.1	RP1-228P16.1	-9.13	1.85e-18	2.66e-15	-0.36	-0.38	Plateletcrit;	chr12:48079586	chr12:48054813~48055591:-
LUAD	cis	rs34779708	0.931	rs4934709	ENSG00000230534.5	RP11-297A16.2	-9.13	1.86e-18	2.68e-15	-0.45	-0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35050396	chr10:35098006~35127020:-
LUAD	cis	rs367615	0.552	rs10042721	ENSG00000249476.1	CTD-2587M2.1	-9.13	1.87e-18	2.69e-15	-0.45	-0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109378269	chr5:109237120~109326369:-
LUAD	cis	rs10129255	0.957	rs10141052	ENSG00000223648.3	IGHV3-64	9.13	1.87e-18	2.69e-15	0.37	0.38	Kawasaki disease;	chr14:106776528	chr14:106643132~106658258:-
LUAD	cis	rs367615	0.552	rs2416210	ENSG00000249476.1	CTD-2587M2.1	-9.13	1.87e-18	2.7e-15	-0.45	-0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109405436	chr5:109237120~109326369:-
LUAD	cis	rs6142102	0.625	rs6142067	ENSG00000276073.1	RP5-1125A11.7	-9.13	1.88e-18	2.71e-15	-0.38	-0.38	Skin pigmentation;	chr20:33968766	chr20:33985617~33988989:-
LUAD	cis	rs11098499	0.754	rs10213554	ENSG00000245958.5	RP11-33B1.1	9.13	1.9e-18	2.73e-15	0.35	0.38	Corneal astigmatism;	chr4:119339630	chr4:119454791~119552025:+
LUAD	cis	rs17608059	1	rs17608059	ENSG00000141028.6	CDRT15P1	-9.13	1.92e-18	2.76e-15	-0.43	-0.38	Temperament;	chr17:14007232	chr17:14024514~14025488:+
LUAD	cis	rs526231	0.543	rs34807	ENSG00000175749.11	EIF3KP1	9.13	1.93e-18	2.77e-15	0.54	0.38	Primary biliary cholangitis;	chr5:103092818	chr5:103032376~103033031:+
LUAD	cis	rs2337406	1	rs11845269	ENSG00000274576.2	IGHV2-70	-9.13	1.93e-18	2.78e-15	-0.42	-0.38	Alzheimer's disease (late onset);	chr14:106683851	chr14:106770577~106771020:-
LUAD	cis	rs321358	0.943	rs17537987	ENSG00000271584.1	RP11-89C3.4	9.13	1.94e-18	2.79e-15	0.64	0.38	Body mass index;	chr11:111134144	chr11:111091932~111097357:-
LUAD	cis	rs321358	1	rs73019218	ENSG00000271584.1	RP11-89C3.4	9.13	1.94e-18	2.79e-15	0.64	0.38	Body mass index;	chr11:111134521	chr11:111091932~111097357:-
LUAD	cis	rs11722779	0.844	rs223345	ENSG00000246560.2	RP11-10L12.4	9.13	1.95e-18	2.81e-15	0.47	0.38	Schizophrenia;	chr4:102859366	chr4:102828055~102844075:+
LUAD	cis	rs11722779	0.873	rs223344	ENSG00000246560.2	RP11-10L12.4	9.13	1.95e-18	2.81e-15	0.47	0.38	Schizophrenia;	chr4:102859765	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs7698608	ENSG00000246560.2	RP11-10L12.4	9.13	1.97e-18	2.83e-15	0.47	0.38	Allergic disease (asthma, hay fever or eczema);	chr4:103016817	chr4:102828055~102844075:+
LUAD	cis	rs11098499	0.663	rs9996501	ENSG00000245958.5	RP11-33B1.1	-9.13	1.97e-18	2.83e-15	-0.35	-0.38	Corneal astigmatism;	chr4:119317763	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.697	rs28458294	ENSG00000245958.5	RP11-33B1.1	-9.13	1.97e-18	2.83e-15	-0.35	-0.38	Corneal astigmatism;	chr4:119317769	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.663	rs28369503	ENSG00000245958.5	RP11-33B1.1	-9.13	1.97e-18	2.83e-15	-0.35	-0.38	Corneal astigmatism;	chr4:119317770	chr4:119454791~119552025:+
LUAD	cis	rs732716	0.785	rs62130978	ENSG00000267769.1	CTB-50L17.9	-9.12	1.97e-18	2.83e-15	-0.42	-0.38	Mean corpuscular volume;	chr19:4429010	chr19:4454014~4455286:+
LUAD	cis	rs367615	0.552	rs2963024	ENSG00000249476.1	CTD-2587M2.1	-9.12	1.99e-18	2.85e-15	-0.44	-0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109395072	chr5:109237120~109326369:-
LUAD	cis	rs526231	0.543	rs152134	ENSG00000175749.11	EIF3KP1	9.12	1.99e-18	2.85e-15	0.53	0.38	Primary biliary cholangitis;	chr5:103176745	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs158250	ENSG00000175749.11	EIF3KP1	9.12	2.01e-18	2.88e-15	0.53	0.38	Parkinson's disease;	chr5:103071075	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs464702	ENSG00000175749.11	EIF3KP1	9.12	2.01e-18	2.88e-15	0.53	0.38	Parkinson's disease;	chr5:103071180	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs464720	ENSG00000175749.11	EIF3KP1	9.12	2.01e-18	2.88e-15	0.53	0.38	Parkinson's disease;	chr5:103071183	chr5:103032376~103033031:+
LUAD	cis	rs6782228	1	rs6801509	ENSG00000242551.2	POU5F1P6	9.12	2.04e-18	2.92e-15	0.48	0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645426	chr3:128674735~128677005:-
LUAD	cis	rs10256972	0.684	rs4724039	ENSG00000229043.2	AC091729.9	-9.12	2.05e-18	2.93e-15	-0.41	-0.38	Endometriosis;Longevity;	chr7:1071997	chr7:1160374~1165267:+
LUAD	cis	rs7924176	0.521	rs11000999	ENSG00000213731.2	RAB5CP1	-9.12	2.05e-18	2.94e-15	-0.4	-0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74332933	chr10:74423435~74424014:-
LUAD	cis	rs10129255	0.957	rs10132367	ENSG00000223648.3	IGHV3-64	9.12	2.07e-18	2.97e-15	0.38	0.38	Kawasaki disease;	chr14:106690981	chr14:106643132~106658258:-
LUAD	cis	rs2487048	0.773	rs2472493	ENSG00000226334.1	RP11-217B7.2	-9.12	2.08e-18	2.98e-15	-0.52	-0.38	Intraocular pressure;	chr9:104933567	chr9:104927553~104928892:+
LUAD	cis	rs528808	1	rs528808	ENSG00000219755.1	RP1-199J3.5	9.12	2.13e-18	3.04e-15	0.6	0.38	Age-related hearing impairment;	chr6:99656413	chr6:99575712~99576456:+
LUAD	cis	rs7188445	0.736	rs11642757	ENSG00000261390.4	RP11-345M22.2	-9.12	2.13e-18	3.06e-15	-0.51	-0.38	Urate levels;	chr16:79719570	chr16:79715232~79770563:-
LUAD	cis	rs10463554	0.963	rs1595553	ENSG00000175749.11	EIF3KP1	9.11	2.15e-18	3.08e-15	0.53	0.38	Parkinson's disease;	chr5:103043164	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.963	rs12655592	ENSG00000175749.11	EIF3KP1	9.11	2.15e-18	3.08e-15	0.53	0.38	Parkinson's disease;	chr5:103043715	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.963	rs12054848	ENSG00000175749.11	EIF3KP1	9.11	2.15e-18	3.08e-15	0.53	0.38	Parkinson's disease;	chr5:103044736	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.963	rs11242484	ENSG00000175749.11	EIF3KP1	9.11	2.15e-18	3.08e-15	0.53	0.38	Parkinson's disease;	chr5:103046172	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.963	rs11242485	ENSG00000175749.11	EIF3KP1	9.11	2.15e-18	3.08e-15	0.53	0.38	Parkinson's disease;	chr5:103046330	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.892	rs10434791	ENSG00000175749.11	EIF3KP1	9.11	2.15e-18	3.08e-15	0.53	0.38	Parkinson's disease;	chr5:103053768	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.963	rs34382	ENSG00000175749.11	EIF3KP1	9.11	2.15e-18	3.08e-15	0.53	0.38	Parkinson's disease;	chr5:103060521	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.963	rs34380	ENSG00000175749.11	EIF3KP1	9.11	2.15e-18	3.08e-15	0.53	0.38	Parkinson's disease;	chr5:103061245	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs12055075	ENSG00000175749.11	EIF3KP1	9.11	2.17e-18	3.11e-15	0.53	0.38	Parkinson's disease;	chr5:103044553	chr5:103032376~103033031:+
LUAD	cis	rs7429990	0.901	rs7431567	ENSG00000229759.1	MRPS18AP1	-9.11	2.18e-18	3.11e-15	-0.42	-0.38	Educational attainment (years of education);	chr3:47986342	chr3:48256350~48256938:-
LUAD	cis	rs11123170	0.64	rs1015754	ENSG00000189223.12	PAX8-AS1	9.11	2.18e-18	3.11e-15	0.55	0.38	Renal function-related traits (BUN);	chr2:113210413	chr2:113211522~113276581:+
LUAD	cis	rs9399137	0.507	rs6923512	ENSG00000232876.1	CTA-212D2.2	9.11	2.18e-18	3.12e-15	0.44	0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135014130	chr6:135055033~135060550:+
LUAD	cis	rs2929278	0.736	rs2412823	ENSG00000205771.5	CATSPER2P1	9.11	2.19e-18	3.14e-15	0.46	0.38	Schizophrenia;	chr15:43935072	chr15:43726918~43747094:-
LUAD	cis	rs34779708	0.931	rs2384287	ENSG00000230534.5	RP11-297A16.2	9.11	2.2e-18	3.14e-15	0.45	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35051631	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs1926556	ENSG00000230534.5	RP11-297A16.2	9.11	2.2e-18	3.15e-15	0.46	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35055979	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs1926554	ENSG00000230534.5	RP11-297A16.2	9.11	2.2e-18	3.15e-15	0.46	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35056041	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs4934710	ENSG00000230534.5	RP11-297A16.2	9.11	2.2e-18	3.15e-15	0.46	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35061488	chr10:35098006~35127020:-
LUAD	cis	rs35160687	0.862	rs13024964	ENSG00000273080.1	RP11-301O19.1	9.11	2.26e-18	3.23e-15	0.45	0.38	Night sleep phenotypes;	chr2:86284745	chr2:86195590~86196049:+
LUAD	cis	rs1185460	0.967	rs1784459	ENSG00000271751.1	RP11-110I1.14	-9.11	2.27e-18	3.24e-15	-0.47	-0.38	Coronary artery disease;	chr11:119067677	chr11:119065263~119065677:-
LUAD	cis	rs1185460	0.967	rs1786684	ENSG00000271751.1	RP11-110I1.14	-9.11	2.27e-18	3.24e-15	-0.47	-0.38	Coronary artery disease;	chr11:119067724	chr11:119065263~119065677:-
LUAD	cis	rs34779708	0.931	rs4934700	ENSG00000230534.5	RP11-297A16.2	9.11	2.27e-18	3.24e-15	0.46	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35021914	chr10:35098006~35127020:-
LUAD	cis	rs3931020	0.72	rs1327090	ENSG00000272864.1	RP11-17E13.2	-9.11	2.27e-18	3.24e-15	-0.48	-0.38	Resistin levels;	chr1:74800795	chr1:74698769~74699333:-
LUAD	cis	rs4423214	0.798	rs1894100	ENSG00000254682.1	RP11-660L16.2	-9.11	2.28e-18	3.25e-15	-0.54	-0.38	Vitamin D levels;	chr11:71419297	chr11:71448674~71452157:+
LUAD	cis	rs2283792	0.73	rs2027790	ENSG00000224086.5	LL22NC03-86G7.1	-9.11	2.28e-18	3.25e-15	-0.36	-0.38	Multiple sclerosis;	chr22:21933592	chr22:21938293~21977632:+
LUAD	cis	rs2188561	0.697	rs7782475	ENSG00000241764.3	AC002467.7	-9.11	2.28e-18	3.26e-15	-0.48	-0.38	Alcohol consumption;	chr7:107745806	chr7:107742817~107744581:-
LUAD	cis	rs7188445	0.932	rs73575076	ENSG00000261390.4	RP11-345M22.2	-9.11	2.28e-18	3.26e-15	-0.5	-0.38	Urate levels;	chr16:79710251	chr16:79715232~79770563:-
LUAD	cis	rs10463554	0.926	rs3776858	ENSG00000175749.11	EIF3KP1	9.11	2.3e-18	3.28e-15	0.54	0.38	Parkinson's disease;	chr5:103021790	chr5:103032376~103033031:+
LUAD	cis	rs2564921	0.704	rs62253604	ENSG00000242142.1	SERBP1P3	-9.11	2.3e-18	3.28e-15	-0.44	-0.38	Height;	chr3:52941053	chr3:53064283~53065091:-
LUAD	cis	rs1185460	0.967	rs1784460	ENSG00000271751.1	RP11-110I1.14	9.11	2.3e-18	3.29e-15	0.46	0.38	Coronary artery disease;	chr11:119067660	chr11:119065263~119065677:-
LUAD	cis	rs7188445	0.932	rs73575079	ENSG00000261390.4	RP11-345M22.2	-9.1	2.31e-18	3.3e-15	-0.5	-0.38	Urate levels;	chr16:79711344	chr16:79715232~79770563:-
LUAD	cis	rs2337406	0.714	rs2337463	ENSG00000274576.2	IGHV2-70	-9.1	2.32e-18	3.31e-15	-0.43	-0.38	Alzheimer's disease (late onset);	chr14:106816066	chr14:106770577~106771020:-
LUAD	cis	rs227275	0.525	rs17215211	ENSG00000246560.2	RP11-10L12.4	9.1	2.33e-18	3.32e-15	0.48	0.38	Allergic disease (asthma, hay fever or eczema);	chr4:103025961	chr4:102828055~102844075:+
LUAD	cis	rs11096990	0.634	rs2276888	ENSG00000249207.1	RP11-360F5.1	9.1	2.33e-18	3.32e-15	0.42	0.38	Cognitive function;	chr4:39278287	chr4:39112677~39126818:-
LUAD	cis	rs6991838	0.584	rs3765205	ENSG00000200714.1	Y_RNA	-9.1	2.34e-18	3.33e-15	-0.47	-0.38	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65592731~65592820:+
LUAD	cis	rs34779708	0.931	rs12261654	ENSG00000230534.5	RP11-297A16.2	9.1	2.34e-18	3.34e-15	0.45	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35033096	chr10:35098006~35127020:-
LUAD	cis	rs11690935	0.885	rs6727017	ENSG00000228389.1	AC068039.4	9.1	2.36e-18	3.37e-15	0.45	0.38	Schizophrenia;	chr2:171910337	chr2:171773482~171775844:+
LUAD	cis	rs34779708	0.931	rs2505631	ENSG00000230534.5	RP11-297A16.2	-9.1	2.38e-18	3.39e-15	-0.44	-0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35079457	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs7913615	ENSG00000230534.5	RP11-297A16.2	9.1	2.39e-18	3.41e-15	0.46	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35134029	chr10:35098006~35127020:-
LUAD	cis	rs10463554	0.927	rs34373	ENSG00000175749.11	EIF3KP1	9.1	2.41e-18	3.43e-15	0.53	0.38	Parkinson's disease;	chr5:103068590	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs158253	ENSG00000175749.11	EIF3KP1	9.1	2.41e-18	3.43e-15	0.53	0.38	Parkinson's disease;	chr5:103069502	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.892	rs158252	ENSG00000175749.11	EIF3KP1	9.1	2.41e-18	3.43e-15	0.53	0.38	Parkinson's disease;	chr5:103070546	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs154369	ENSG00000175749.11	EIF3KP1	9.1	2.41e-18	3.43e-15	0.53	0.38	Parkinson's disease;	chr5:103071140	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.892	rs158246	ENSG00000175749.11	EIF3KP1	9.1	2.41e-18	3.43e-15	0.53	0.38	Parkinson's disease;	chr5:103073145	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs158245	ENSG00000175749.11	EIF3KP1	9.1	2.41e-18	3.43e-15	0.53	0.38	Parkinson's disease;	chr5:103073801	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.857	rs158397	ENSG00000175749.11	EIF3KP1	9.1	2.41e-18	3.43e-15	0.53	0.38	Parkinson's disease;	chr5:103076497	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs158399	ENSG00000175749.11	EIF3KP1	9.1	2.41e-18	3.43e-15	0.53	0.38	Parkinson's disease;	chr5:103077564	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs158403	ENSG00000175749.11	EIF3KP1	9.1	2.41e-18	3.43e-15	0.53	0.38	Parkinson's disease;	chr5:103080064	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs158404	ENSG00000175749.11	EIF3KP1	9.1	2.41e-18	3.43e-15	0.53	0.38	Parkinson's disease;	chr5:103080206	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.892	rs257305	ENSG00000175749.11	EIF3KP1	9.1	2.41e-18	3.43e-15	0.53	0.38	Parkinson's disease;	chr5:103081533	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs257306	ENSG00000175749.11	EIF3KP1	9.1	2.41e-18	3.43e-15	0.53	0.38	Parkinson's disease;	chr5:103081770	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.892	rs257307	ENSG00000175749.11	EIF3KP1	9.1	2.41e-18	3.43e-15	0.53	0.38	Parkinson's disease;	chr5:103081805	chr5:103032376~103033031:+
LUAD	cis	rs11098499	0.874	rs10022508	ENSG00000245958.5	RP11-33B1.1	-9.1	2.42e-18	3.45e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119194073	chr4:119454791~119552025:+
LUAD	cis	rs367615	0.506	rs246102	ENSG00000249476.1	CTD-2587M2.1	-9.1	2.42e-18	3.45e-15	-0.45	-0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109363994	chr5:109237120~109326369:-
LUAD	cis	rs10129255	0.957	rs10141009	ENSG00000223648.3	IGHV3-64	9.1	2.44e-18	3.47e-15	0.37	0.38	Kawasaki disease;	chr14:106776695	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.912	rs6576227	ENSG00000223648.3	IGHV3-64	9.1	2.44e-18	3.47e-15	0.37	0.38	Kawasaki disease;	chr14:106778202	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.957	rs6576228	ENSG00000223648.3	IGHV3-64	9.1	2.44e-18	3.47e-15	0.37	0.38	Kawasaki disease;	chr14:106778401	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.957	rs56134540	ENSG00000223648.3	IGHV3-64	9.1	2.45e-18	3.48e-15	0.38	0.38	Kawasaki disease;	chr14:106691290	chr14:106643132~106658258:-
LUAD	cis	rs10463554	0.963	rs6883113	ENSG00000175749.11	EIF3KP1	9.1	2.45e-18	3.48e-15	0.53	0.38	Parkinson's disease;	chr5:103042185	chr5:103032376~103033031:+
LUAD	cis	rs11098499	0.644	rs2389880	ENSG00000245958.5	RP11-33B1.1	-9.1	2.46e-18	3.49e-15	-0.35	-0.38	Corneal astigmatism;	chr4:119638715	chr4:119454791~119552025:+
LUAD	cis	rs227275	0.525	rs2086499	ENSG00000246560.2	RP11-10L12.4	9.1	2.46e-18	3.49e-15	0.48	0.38	Allergic disease (asthma, hay fever or eczema);	chr4:103008672	chr4:102828055~102844075:+
LUAD	cis	rs10463554	0.927	rs34811	ENSG00000175749.11	EIF3KP1	9.1	2.49e-18	3.54e-15	0.54	0.38	Parkinson's disease;	chr5:103096117	chr5:103032376~103033031:+
LUAD	cis	rs7188445	0.787	rs7189954	ENSG00000261390.4	RP11-345M22.2	9.1	2.5e-18	3.55e-15	0.48	0.38	Urate levels;	chr16:79701150	chr16:79715232~79770563:-
LUAD	cis	rs35160687	0.862	rs17737955	ENSG00000273080.1	RP11-301O19.1	9.09	2.51e-18	3.57e-15	0.45	0.38	Night sleep phenotypes;	chr2:86280891	chr2:86195590~86196049:+
LUAD	cis	rs10463554	0.927	rs468844	ENSG00000175749.11	EIF3KP1	9.09	2.52e-18	3.57e-15	0.54	0.38	Parkinson's disease;	chr5:103087872	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs469094	ENSG00000175749.11	EIF3KP1	9.09	2.52e-18	3.57e-15	0.54	0.38	Parkinson's disease;	chr5:103087875	chr5:103032376~103033031:+
LUAD	cis	rs494459	0.838	rs555639	ENSG00000255422.1	AP002954.4	9.09	2.52e-18	3.58e-15	0.47	0.38	Height;	chr11:118758322	chr11:118704607~118750263:+
LUAD	cis	rs6991838	0.584	rs73236948	ENSG00000200714.1	Y_RNA	-9.09	2.52e-18	3.58e-15	-0.48	-0.38	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65592731~65592820:+
LUAD	cis	rs10129255	0.957	rs17113284	ENSG00000211970.3	IGHV4-61	9.09	2.53e-18	3.59e-15	0.3	0.38	Kawasaki disease;	chr14:106684476	chr14:106639119~106639657:-
LUAD	cis	rs7429990	0.932	rs12493348	ENSG00000229759.1	MRPS18AP1	-9.09	2.53e-18	3.59e-15	-0.38	-0.38	Educational attainment (years of education);	chr3:48102048	chr3:48256350~48256938:-
LUAD	cis	rs6452524	0.904	rs10076056	ENSG00000249664.1	CTD-2227C6.2	-9.09	2.53e-18	3.59e-15	-0.44	-0.38	Hypertension (SNP x SNP interaction);	chr5:83161702	chr5:83012285~83013109:-
LUAD	cis	rs7924176	0.58	rs12360119	ENSG00000213731.2	RAB5CP1	-9.09	2.54e-18	3.6e-15	-0.4	-0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74255558	chr10:74423435~74424014:-
LUAD	cis	rs7924176	0.521	rs10824142	ENSG00000213731.2	RAB5CP1	-9.09	2.55e-18	3.61e-15	-0.4	-0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74290249	chr10:74423435~74424014:-
LUAD	cis	rs7924176	0.521	rs11000965	ENSG00000213731.2	RAB5CP1	-9.09	2.55e-18	3.61e-15	-0.4	-0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74294019	chr10:74423435~74424014:-
LUAD	cis	rs7924176	0.521	rs12357370	ENSG00000213731.2	RAB5CP1	-9.09	2.55e-18	3.61e-15	-0.4	-0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74296329	chr10:74423435~74424014:-
LUAD	cis	rs4423214	0.592	rs79634040	ENSG00000254682.1	RP11-660L16.2	-9.09	2.55e-18	3.62e-15	-0.59	-0.38	Vitamin D levels;	chr11:71519123	chr11:71448674~71452157:+
LUAD	cis	rs10129255	0.957	rs12590799	ENSG00000223648.3	IGHV3-64	9.09	2.58e-18	3.66e-15	0.37	0.38	Kawasaki disease;	chr14:106779713	chr14:106643132~106658258:-
LUAD	cis	rs9660180	0.78	rs12038111	ENSG00000231050.1	RP1-140A9.1	9.09	2.62e-18	3.71e-15	0.44	0.38	Body mass index;	chr1:1772410	chr1:1891471~1892658:+
LUAD	cis	rs9660180	0.836	rs12038134	ENSG00000231050.1	RP1-140A9.1	9.09	2.62e-18	3.71e-15	0.44	0.38	Body mass index;	chr1:1772426	chr1:1891471~1892658:+
LUAD	cis	rs26232	0.526	rs61654927	ENSG00000175749.11	EIF3KP1	9.09	2.62e-18	3.72e-15	0.53	0.38	Rheumatoid arthritis;	chr5:103047021	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.892	rs59292735	ENSG00000175749.11	EIF3KP1	9.09	2.62e-18	3.72e-15	0.53	0.38	Parkinson's disease;	chr5:103047047	chr5:103032376~103033031:+
LUAD	cis	rs9326248	0.813	rs7115562	ENSG00000280143.1	AP000892.6	9.09	2.63e-18	3.73e-15	0.51	0.38	Blood protein levels;	chr11:117149754	chr11:117204967~117210292:+
LUAD	cis	rs12134133	1	rs2490261	ENSG00000274245.1	RP11-357P18.2	9.09	2.65e-18	3.75e-15	0.49	0.38	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207304124	chr1:207372559~207373252:+
LUAD	cis	rs1150668	0.835	rs1233696	ENSG00000216901.1	AL022393.7	9.09	2.65e-18	3.76e-15	0.45	0.38	Pubertal anthropometrics;	chr6:28175232	chr6:28176188~28176674:+
LUAD	cis	rs6991838	0.557	rs57419568	ENSG00000200714.1	Y_RNA	-9.09	2.65e-18	3.76e-15	-0.47	-0.38	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs16932250	ENSG00000200714.1	Y_RNA	-9.09	2.65e-18	3.76e-15	-0.47	-0.38	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65592731~65592820:+
LUAD	cis	rs7924176	0.601	rs2131957	ENSG00000213731.2	RAB5CP1	-9.09	2.67e-18	3.79e-15	-0.41	-0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74107171	chr10:74423435~74424014:-
LUAD	cis	rs172166	0.516	rs1225618	ENSG00000204709.4	LINC01556	9.09	2.68e-18	3.8e-15	0.48	0.38	Cardiac Troponin-T levels;	chr6:28161935	chr6:28943877~28944537:+
LUAD	cis	rs34779708	0.931	rs4934704	ENSG00000230534.5	RP11-297A16.2	9.08	2.73e-18	3.87e-15	0.45	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35043236	chr10:35098006~35127020:-
LUAD	cis	rs6991838	0.53	rs35038843	ENSG00000200714.1	Y_RNA	-9.08	2.74e-18	3.88e-15	-0.47	-0.38	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs4737748	ENSG00000200714.1	Y_RNA	9.08	2.74e-18	3.88e-15	0.47	0.38	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.55	rs12335006	ENSG00000200714.1	Y_RNA	9.08	2.74e-18	3.88e-15	0.47	0.38	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs10957361	ENSG00000200714.1	Y_RNA	9.08	2.74e-18	3.88e-15	0.47	0.38	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.612	rs12335276	ENSG00000200714.1	Y_RNA	9.08	2.74e-18	3.88e-15	0.47	0.38	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65592731~65592820:+
LUAD	cis	rs17507216	0.56	rs2871011	ENSG00000278603.1	RP13-608F4.5	9.08	2.75e-18	3.89e-15	0.44	0.38	Excessive daytime sleepiness;	chr15:82560792	chr15:82472203~82472426:+
LUAD	cis	rs10129255	1	rs4612959	ENSG00000223648.3	IGHV3-64	9.08	2.75e-18	3.89e-15	0.37	0.38	Kawasaki disease;	chr14:106767055	chr14:106643132~106658258:-
LUAD	cis	rs7924176	0.521	rs7899920	ENSG00000213731.2	RAB5CP1	9.08	2.76e-18	3.9e-15	0.4	0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74329365	chr10:74423435~74424014:-
LUAD	cis	rs11690935	0.802	rs34636594	ENSG00000228389.1	AC068039.4	9.08	2.78e-18	3.93e-15	0.46	0.38	Schizophrenia;	chr2:172046366	chr2:171773482~171775844:+
LUAD	cis	rs10129255	0.957	rs2013423	ENSG00000223648.3	IGHV3-64	9.08	2.79e-18	3.94e-15	0.38	0.38	Kawasaki disease;	chr14:106690675	chr14:106643132~106658258:-
LUAD	cis	rs2470135	1	rs2470135	ENSG00000249839.1	AC011330.5	-9.08	2.79e-18	3.95e-15	-0.5	-0.38	Diastolic blood pressure;	chr15:43703591	chr15:43663654~43684339:-
LUAD	cis	rs1891275	0.515	rs2153653	ENSG00000228701.1	TNKS2-AS1	-9.08	2.8e-18	3.95e-15	-0.47	-0.38	Intelligence (multi-trait analysis);	chr10:91736169	chr10:91782839~91798291:-
LUAD	cis	rs10129255	0.957	rs8009638	ENSG00000211970.3	IGHV4-61	-9.08	2.8e-18	3.95e-15	-0.29	-0.38	Kawasaki disease;	chr14:106777570	chr14:106639119~106639657:-
LUAD	cis	rs11098499	0.722	rs7673476	ENSG00000245958.5	RP11-33B1.1	-9.08	2.82e-18	3.98e-15	-0.34	-0.38	Corneal astigmatism;	chr4:119327528	chr4:119454791~119552025:+
LUAD	cis	rs26232	0.521	rs40508	ENSG00000175749.11	EIF3KP1	9.08	2.83e-18	4e-15	0.54	0.38	Rheumatoid arthritis;	chr5:103108234	chr5:103032376~103033031:+
LUAD	cis	rs7924176	0.521	rs61863363	ENSG00000213731.2	RAB5CP1	-9.08	2.84e-18	4.01e-15	-0.4	-0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74380493	chr10:74423435~74424014:-
LUAD	cis	rs7188445	0.932	rs56738967	ENSG00000261390.4	RP11-345M22.2	-9.08	2.85e-18	4.03e-15	-0.5	-0.38	Urate levels;	chr16:79706644	chr16:79715232~79770563:-
LUAD	cis	rs904251	0.965	rs62406516	ENSG00000204110.6	RP1-153P14.8	-9.08	2.85e-18	4.03e-15	-0.4	-0.38	Cognitive performance;	chr6:37471588	chr6:37507348~37535616:+
LUAD	cis	rs12468226	1	rs6739198	ENSG00000273456.1	RP11-686O6.2	9.08	2.85e-18	4.03e-15	0.55	0.38	Urate levels;	chr2:202492273	chr2:202374932~202375604:-
LUAD	cis	rs172166	0.516	rs1150670	ENSG00000216901.1	AL022393.7	9.08	2.87e-18	4.04e-15	0.45	0.38	Cardiac Troponin-T levels;	chr6:28162781	chr6:28176188~28176674:+
LUAD	cis	rs172166	0.516	rs2021826	ENSG00000216901.1	AL022393.7	9.08	2.87e-18	4.04e-15	0.45	0.38	Cardiac Troponin-T levels;	chr6:28164978	chr6:28176188~28176674:+
LUAD	cis	rs10463554	0.927	rs257308	ENSG00000175749.11	EIF3KP1	9.08	2.87e-18	4.05e-15	0.53	0.38	Parkinson's disease;	chr5:103082557	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs257311	ENSG00000175749.11	EIF3KP1	9.08	2.87e-18	4.05e-15	0.53	0.38	Parkinson's disease;	chr5:103083394	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs257314	ENSG00000175749.11	EIF3KP1	9.08	2.87e-18	4.05e-15	0.53	0.38	Parkinson's disease;	chr5:103085391	chr5:103032376~103033031:+
LUAD	cis	rs10129255	0.957	rs10150241	ENSG00000211970.3	IGHV4-61	9.08	2.88e-18	4.06e-15	0.29	0.38	Kawasaki disease;	chr14:106775945	chr14:106639119~106639657:-
LUAD	cis	rs172166	0.561	rs149973	ENSG00000204709.4	LINC01556	9.07	2.93e-18	4.13e-15	0.46	0.38	Cardiac Troponin-T levels;	chr6:28015835	chr6:28943877~28944537:+
LUAD	cis	rs172166	0.561	rs149974	ENSG00000204709.4	LINC01556	9.07	2.93e-18	4.13e-15	0.46	0.38	Cardiac Troponin-T levels;	chr6:28017318	chr6:28943877~28944537:+
LUAD	cis	rs733592	0.507	rs3825403	ENSG00000240399.1	RP1-228P16.1	-9.07	2.93e-18	4.13e-15	-0.36	-0.38	Plateletcrit;	chr12:48063376	chr12:48054813~48055591:-
LUAD	cis	rs6991838	0.584	rs6994213	ENSG00000272010.1	CTD-3025N20.3	-9.07	2.94e-18	4.14e-15	-0.42	-0.38	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs4737747	ENSG00000200714.1	Y_RNA	-9.07	2.94e-18	4.15e-15	-0.47	-0.38	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65592731~65592820:+
LUAD	cis	rs7924176	0.564	rs6480727	ENSG00000213731.2	RAB5CP1	-9.07	2.96e-18	4.17e-15	-0.4	-0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74243315	chr10:74423435~74424014:-
LUAD	cis	rs10129255	0.789	rs61997796	ENSG00000223648.3	IGHV3-64	9.07	2.98e-18	4.2e-15	0.39	0.38	Kawasaki disease;	chr14:106813798	chr14:106643132~106658258:-
LUAD	cis	rs1150668	0.699	rs2394049	ENSG00000216901.1	AL022393.7	9.07	2.99e-18	4.2e-15	0.44	0.38	Pubertal anthropometrics;	chr6:28271903	chr6:28176188~28176674:+
LUAD	cis	rs7924176	0.521	rs11000960	ENSG00000213731.2	RAB5CP1	-9.07	3e-18	4.22e-15	-0.4	-0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74288349	chr10:74423435~74424014:-
LUAD	cis	rs526231	0.543	rs34832	ENSG00000175749.11	EIF3KP1	9.07	3e-18	4.22e-15	0.54	0.38	Primary biliary cholangitis;	chr5:103108891	chr5:103032376~103033031:+
LUAD	cis	rs7924176	0.521	rs7098200	ENSG00000213731.2	RAB5CP1	9.07	3e-18	4.23e-15	0.4	0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74339799	chr10:74423435~74424014:-
LUAD	cis	rs7429990	0.965	rs4296617	ENSG00000229759.1	MRPS18AP1	-9.07	3.04e-18	4.27e-15	-0.41	-0.38	Educational attainment (years of education);	chr3:48026818	chr3:48256350~48256938:-
LUAD	cis	rs7924176	0.521	rs1904062	ENSG00000213731.2	RAB5CP1	-9.07	3.04e-18	4.27e-15	-0.4	-0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74309665	chr10:74423435~74424014:-
LUAD	cis	rs733592	0.507	rs7299704	ENSG00000240399.1	RP1-228P16.1	9.07	3.05e-18	4.29e-15	0.36	0.38	Plateletcrit;	chr12:48050705	chr12:48054813~48055591:-
LUAD	cis	rs172166	0.543	rs1150691	ENSG00000204709.4	LINC01556	9.07	3.05e-18	4.29e-15	0.48	0.38	Cardiac Troponin-T levels;	chr6:28200255	chr6:28943877~28944537:+
LUAD	cis	rs6964833	0.935	rs34630792	ENSG00000277053.3	GTF2IP1	-9.07	3.05e-18	4.29e-15	-0.53	-0.38	Menarche (age at onset);	chr7:74646869	chr7:75185385~75237696:-
LUAD	cis	rs10129255	1	rs4612959	ENSG00000211970.3	IGHV4-61	-9.07	3.06e-18	4.31e-15	-0.29	-0.38	Kawasaki disease;	chr14:106767055	chr14:106639119~106639657:-
LUAD	cis	rs11098499	0.644	rs10012252	ENSG00000245958.5	RP11-33B1.1	-9.07	3.07e-18	4.32e-15	-0.35	-0.38	Corneal astigmatism;	chr4:119637984	chr4:119454791~119552025:+
LUAD	cis	rs11722779	0.933	rs7695096	ENSG00000246560.2	RP11-10L12.4	9.07	3.08e-18	4.33e-15	0.47	0.38	Schizophrenia;	chr4:103011399	chr4:102828055~102844075:+
LUAD	cis	rs733592	0.524	rs10875744	ENSG00000240399.1	RP1-228P16.1	9.07	3.1e-18	4.36e-15	0.36	0.38	Plateletcrit;	chr12:48104657	chr12:48054813~48055591:-
LUAD	cis	rs732716	0.785	rs56272533	ENSG00000267769.1	CTB-50L17.9	-9.07	3.11e-18	4.36e-15	-0.42	-0.38	Mean corpuscular volume;	chr19:4420045	chr19:4454014~4455286:+
LUAD	cis	rs7429990	0.901	rs6442091	ENSG00000229759.1	MRPS18AP1	-9.07	3.11e-18	4.37e-15	-0.41	-0.38	Educational attainment (years of education);	chr3:48001568	chr3:48256350~48256938:-
LUAD	cis	rs1891275	0.508	rs2096079	ENSG00000228701.1	TNKS2-AS1	-9.07	3.12e-18	4.38e-15	-0.47	-0.38	Intelligence (multi-trait analysis);	chr10:91736910	chr10:91782839~91798291:-
LUAD	cis	rs34779708	0.966	rs1213392	ENSG00000230534.5	RP11-297A16.2	9.07	3.12e-18	4.39e-15	0.44	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35141357	chr10:35098006~35127020:-
LUAD	cis	rs6991838	0.584	rs7841652	ENSG00000200714.1	Y_RNA	-9.07	3.16e-18	4.43e-15	-0.47	-0.38	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65592731~65592820:+
LUAD	cis	rs11098499	0.874	rs6822498	ENSG00000245958.5	RP11-33B1.1	-9.07	3.16e-18	4.44e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119199028	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.874	rs9995277	ENSG00000245958.5	RP11-33B1.1	-9.06	3.22e-18	4.52e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119187448	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.874	rs6826823	ENSG00000245958.5	RP11-33B1.1	-9.06	3.22e-18	4.52e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119190943	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.874	rs12509054	ENSG00000245958.5	RP11-33B1.1	-9.06	3.22e-18	4.52e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119193920	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.874	rs12502503	ENSG00000245958.5	RP11-33B1.1	-9.06	3.22e-18	4.52e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119195100	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.874	rs6832670	ENSG00000245958.5	RP11-33B1.1	-9.06	3.22e-18	4.52e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119197637	chr4:119454791~119552025:+
LUAD	cis	rs12468226	0.873	rs76552560	ENSG00000273456.1	RP11-686O6.2	9.06	3.22e-18	4.52e-15	0.61	0.38	Urate levels;	chr2:202173123	chr2:202374932~202375604:-
LUAD	cis	rs10129255	0.5	rs988132	ENSG00000211972.2	IGHV3-66	9.06	3.26e-18	4.57e-15	0.31	0.38	Kawasaki disease;	chr14:106776758	chr14:106675017~106675544:-
LUAD	cis	rs10463554	0.526	rs114525197	ENSG00000175749.11	EIF3KP1	9.06	3.31e-18	4.64e-15	0.54	0.38	Parkinson's disease;	chr5:103107341	chr5:103032376~103033031:+
LUAD	cis	rs227275	0.554	rs223454	ENSG00000246560.2	RP11-10L12.4	9.06	3.31e-18	4.64e-15	0.46	0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102789773	chr4:102828055~102844075:+
LUAD	cis	rs2283792	0.73	rs738858	ENSG00000224086.5	LL22NC03-86G7.1	-9.06	3.32e-18	4.66e-15	-0.36	-0.38	Multiple sclerosis;	chr22:21926544	chr22:21938293~21977632:+
LUAD	cis	rs1185460	0.904	rs1003081	ENSG00000271751.1	RP11-110I1.14	9.06	3.36e-18	4.71e-15	0.47	0.38	Coronary artery disease;	chr11:119043282	chr11:119065263~119065677:-
LUAD	cis	rs1061377	0.585	rs2163271	ENSG00000249207.1	RP11-360F5.1	-9.06	3.38e-18	4.74e-15	-0.42	-0.38	Uric acid levels;	chr4:39076525	chr4:39112677~39126818:-
LUAD	cis	rs2487048	0.773	rs2472494	ENSG00000226334.1	RP11-217B7.2	-9.06	3.39e-18	4.75e-15	-0.51	-0.38	Intraocular pressure;	chr9:104933258	chr9:104927553~104928892:+
LUAD	cis	rs2929278	0.589	rs2411284	ENSG00000249839.1	AC011330.5	9.06	3.41e-18	4.78e-15	0.5	0.38	Schizophrenia;	chr15:43746701	chr15:43663654~43684339:-
LUAD	cis	rs2337406	1	rs3858878	ENSG00000274576.2	IGHV2-70	-9.06	3.41e-18	4.78e-15	-0.42	-0.38	Alzheimer's disease (late onset);	chr14:106688061	chr14:106770577~106771020:-
LUAD	cis	rs7429990	0.965	rs4858810	ENSG00000229759.1	MRPS18AP1	-9.06	3.42e-18	4.79e-15	-0.41	-0.38	Educational attainment (years of education);	chr3:48002247	chr3:48256350~48256938:-
LUAD	cis	rs10463554	0.926	rs5855	ENSG00000175749.11	EIF3KP1	-9.05	3.42e-18	4.79e-15	-0.52	-0.38	Parkinson's disease;	chr5:103029482	chr5:103032376~103033031:+
LUAD	cis	rs12468226	0.938	rs79117531	ENSG00000273456.1	RP11-686O6.2	9.05	3.43e-18	4.8e-15	0.6	0.38	Urate levels;	chr2:202307690	chr2:202374932~202375604:-
LUAD	cis	rs6142102	0.625	rs6142056	ENSG00000276073.1	RP5-1125A11.7	-9.05	3.45e-18	4.83e-15	-0.39	-0.38	Skin pigmentation;	chr20:33953349	chr20:33985617~33988989:-
LUAD	cis	rs62229266	0.557	rs4817760	ENSG00000231106.2	LINC01436	9.05	3.45e-18	4.84e-15	0.54	0.38	Mitral valve prolapse;	chr21:36023003	chr21:36005338~36007838:+
LUAD	cis	rs228614	0.51	rs150893	ENSG00000246560.2	RP11-10L12.4	-9.05	3.46e-18	4.84e-15	-0.46	-0.38	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102817075	chr4:102828055~102844075:+
LUAD	cis	rs10129255	1	rs10129407	ENSG00000223648.3	IGHV3-64	9.05	3.49e-18	4.88e-15	0.37	0.38	Kawasaki disease;	chr14:106767956	chr14:106643132~106658258:-
LUAD	cis	rs944289	0.617	rs12431579	ENSG00000257826.1	RP11-116N8.4	-9.05	3.57e-18	5e-15	-0.39	-0.38	Thyroid cancer;	chr14:36125191	chr14:36061026~36067190:-
LUAD	cis	rs10129255	0.957	rs10136781	ENSG00000223648.3	IGHV3-64	9.05	3.58e-18	5e-15	0.37	0.38	Kawasaki disease;	chr14:106780451	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.957	rs8022165	ENSG00000223648.3	IGHV3-64	9.05	3.58e-18	5e-15	0.37	0.38	Kawasaki disease;	chr14:106781682	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.917	rs8022493	ENSG00000223648.3	IGHV3-64	9.05	3.58e-18	5e-15	0.37	0.38	Kawasaki disease;	chr14:106781820	chr14:106643132~106658258:-
LUAD	cis	rs11098499	0.913	rs56122576	ENSG00000245958.5	RP11-33B1.1	-9.05	3.58e-18	5.01e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119208181	chr4:119454791~119552025:+
LUAD	cis	rs6142102	0.625	rs9753690	ENSG00000276073.1	RP5-1125A11.7	-9.05	3.59e-18	5.02e-15	-0.39	-0.38	Skin pigmentation;	chr20:33952995	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.625	rs7263727	ENSG00000276073.1	RP5-1125A11.7	-9.05	3.59e-18	5.02e-15	-0.39	-0.38	Skin pigmentation;	chr20:33953133	chr20:33985617~33988989:-
LUAD	cis	rs34779708	0.897	rs7900480	ENSG00000230534.5	RP11-297A16.2	-9.05	3.59e-18	5.02e-15	-0.45	-0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35049771	chr10:35098006~35127020:-
LUAD	cis	rs2929278	0.617	rs11070410	ENSG00000249839.1	AC011330.5	9.05	3.63e-18	5.07e-15	0.51	0.38	Schizophrenia;	chr15:43764847	chr15:43663654~43684339:-
LUAD	cis	rs10463554	0.927	rs34799	ENSG00000175749.11	EIF3KP1	9.05	3.65e-18	5.09e-15	0.54	0.38	Parkinson's disease;	chr5:103090498	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs34800	ENSG00000175749.11	EIF3KP1	9.05	3.65e-18	5.09e-15	0.54	0.38	Parkinson's disease;	chr5:103090799	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs34802	ENSG00000175749.11	EIF3KP1	9.05	3.65e-18	5.09e-15	0.54	0.38	Parkinson's disease;	chr5:103091301	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.508	rs34805	ENSG00000175749.11	EIF3KP1	9.05	3.65e-18	5.09e-15	0.54	0.38	Primary biliary cholangitis;	chr5:103092608	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs34810	ENSG00000175749.11	EIF3KP1	9.05	3.65e-18	5.09e-15	0.54	0.38	Parkinson's disease;	chr5:103095045	chr5:103032376~103033031:+
LUAD	cis	rs10129255	0.912	rs8009135	ENSG00000223648.3	IGHV3-64	9.05	3.69e-18	5.15e-15	0.37	0.38	Kawasaki disease;	chr14:106777528	chr14:106643132~106658258:-
LUAD	cis	rs227275	0.525	rs4698874	ENSG00000246560.2	RP11-10L12.4	9.04	3.7e-18	5.16e-15	0.47	0.38	Allergic disease (asthma, hay fever or eczema);	chr4:103009354	chr4:102828055~102844075:+
LUAD	cis	rs12468226	1	rs58288071	ENSG00000273456.1	RP11-686O6.2	9.04	3.7e-18	5.16e-15	0.6	0.38	Urate levels;	chr2:202350016	chr2:202374932~202375604:-
LUAD	cis	rs11098499	0.955	rs13129661	ENSG00000245958.5	RP11-33B1.1	-9.04	3.71e-18	5.17e-15	-0.35	-0.38	Corneal astigmatism;	chr4:119231754	chr4:119454791~119552025:+
LUAD	cis	rs9399135	0.773	rs949895	ENSG00000232876.1	CTA-212D2.2	-9.04	3.72e-18	5.18e-15	-0.43	-0.38	Red blood cell count;	chr6:135084221	chr6:135055033~135060550:+
LUAD	cis	rs3931020	0.745	rs1969111	ENSG00000272864.1	RP11-17E13.2	9.04	3.73e-18	5.19e-15	0.47	0.38	Resistin levels;	chr1:74797801	chr1:74698769~74699333:-
LUAD	cis	rs12468226	0.817	rs12693965	ENSG00000273456.1	RP11-686O6.2	-9.04	3.73e-18	5.2e-15	-0.59	-0.38	Urate levels;	chr2:202210188	chr2:202374932~202375604:-
LUAD	cis	rs10463554	0.824	rs34818	ENSG00000175749.11	EIF3KP1	9.04	3.74e-18	5.21e-15	0.53	0.38	Parkinson's disease;	chr5:103100407	chr5:103032376~103033031:+
LUAD	cis	rs34779708	0.931	rs34375045	ENSG00000230534.5	RP11-297A16.2	9.04	3.75e-18	5.22e-15	0.45	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35073428	chr10:35098006~35127020:-
LUAD	cis	rs1150668	0.745	rs213238	ENSG00000204709.4	LINC01556	9.04	3.76e-18	5.24e-15	0.47	0.38	Pubertal anthropometrics;	chr6:28354216	chr6:28943877~28944537:+
LUAD	cis	rs6142102	0.517	rs6142046	ENSG00000276073.1	RP5-1125A11.7	-9.04	3.78e-18	5.27e-15	-0.38	-0.38	Skin pigmentation;	chr20:33926255	chr20:33985617~33988989:-
LUAD	cis	rs227275	0.525	rs4596243	ENSG00000246560.2	RP11-10L12.4	9.04	3.82e-18	5.32e-15	0.48	0.38	Allergic disease (asthma, hay fever or eczema);	chr4:102964411	chr4:102828055~102844075:+
LUAD	cis	rs7188445	0.932	rs17689455	ENSG00000261390.4	RP11-345M22.2	-9.04	3.84e-18	5.34e-15	-0.5	-0.38	Urate levels;	chr16:79712438	chr16:79715232~79770563:-
LUAD	cis	rs10129255	0.872	rs1858683	ENSG00000223648.3	IGHV3-64	9.04	3.84e-18	5.34e-15	0.38	0.38	Kawasaki disease;	chr14:106670217	chr14:106643132~106658258:-
LUAD	cis	rs6991838	0.584	rs7812446	ENSG00000200714.1	Y_RNA	-9.04	3.84e-18	5.35e-15	-0.47	-0.38	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.557	rs7812390	ENSG00000200714.1	Y_RNA	-9.04	3.84e-18	5.35e-15	-0.47	-0.38	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs16932245	ENSG00000200714.1	Y_RNA	-9.04	3.84e-18	5.35e-15	-0.47	-0.38	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65592731~65592820:+
LUAD	cis	rs9532669	0.889	rs7333447	ENSG00000176268.5	CYCSP34	9.04	3.86e-18	5.37e-15	0.36	0.38	Cervical cancer;	chr13:40917586	chr13:40863599~40863902:-
LUAD	cis	rs6991838	0.584	rs34226237	ENSG00000272010.1	CTD-3025N20.3	-9.04	3.88e-18	5.39e-15	-0.42	-0.38	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65591850~65592472:-
LUAD	cis	rs2283792	0.622	rs381523	ENSG00000224086.5	LL22NC03-86G7.1	-9.04	3.9e-18	5.42e-15	-0.36	-0.38	Multiple sclerosis;	chr22:21951257	chr22:21938293~21977632:+
LUAD	cis	rs10463554	0.963	rs6596530	ENSG00000175749.11	EIF3KP1	9.04	3.9e-18	5.42e-15	0.52	0.38	Parkinson's disease;	chr5:103035736	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs34795	ENSG00000175749.11	EIF3KP1	9.04	3.93e-18	5.46e-15	0.54	0.38	Parkinson's disease;	chr5:103088716	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs34796	ENSG00000175749.11	EIF3KP1	9.04	3.93e-18	5.46e-15	0.54	0.38	Parkinson's disease;	chr5:103088725	chr5:103032376~103033031:+
LUAD	cis	rs34779708	0.931	rs59418206	ENSG00000230534.5	RP11-297A16.2	9.04	3.96e-18	5.5e-15	0.46	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35042696	chr10:35098006~35127020:-
LUAD	cis	rs7429990	0.965	rs1060407	ENSG00000229759.1	MRPS18AP1	9.04	3.96e-18	5.5e-15	0.4	0.38	Educational attainment (years of education);	chr3:47916547	chr3:48256350~48256938:-
LUAD	cis	rs9660180	1	rs3737628	ENSG00000231050.1	RP1-140A9.1	9.04	3.98e-18	5.53e-15	0.42	0.38	Body mass index;	chr1:1791493	chr1:1891471~1892658:+
LUAD	cis	rs526231	0.543	rs42431	ENSG00000175749.11	EIF3KP1	-9.03	4e-18	5.56e-15	-0.55	-0.38	Primary biliary cholangitis;	chr5:103064359	chr5:103032376~103033031:+
LUAD	cis	rs10256972	0.521	rs871019	ENSG00000229043.2	AC091729.9	-9.03	4.03e-18	5.59e-15	-0.4	-0.38	Endometriosis;Longevity;	chr7:1065594	chr7:1160374~1165267:+
LUAD	cis	rs6991838	0.584	rs34494846	ENSG00000272010.1	CTD-3025N20.3	-9.03	4.03e-18	5.59e-15	-0.42	-0.38	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65591850~65592472:-
LUAD	cis	rs2929278	0.562	rs8033846	ENSG00000249839.1	AC011330.5	9.03	4.04e-18	5.6e-15	0.5	0.38	Schizophrenia;	chr15:43743165	chr15:43663654~43684339:-
LUAD	cis	rs2929278	0.589	rs7174732	ENSG00000249839.1	AC011330.5	9.03	4.04e-18	5.6e-15	0.5	0.38	Schizophrenia;	chr15:43746265	chr15:43663654~43684339:-
LUAD	cis	rs2929278	0.617	rs12908467	ENSG00000249839.1	AC011330.5	9.03	4.04e-18	5.6e-15	0.5	0.38	Schizophrenia;	chr15:43755232	chr15:43663654~43684339:-
LUAD	cis	rs2188561	0.697	rs3735606	ENSG00000241764.3	AC002467.7	9.03	4.04e-18	5.6e-15	0.48	0.38	Alcohol consumption;	chr7:107743864	chr7:107742817~107744581:-
LUAD	cis	rs10129255	0.5	rs1974468	ENSG00000211972.2	IGHV3-66	9.03	4.04e-18	5.61e-15	0.3	0.38	Kawasaki disease;	chr14:106686149	chr14:106675017~106675544:-
LUAD	cis	rs10463554	0.927	rs34824	ENSG00000175749.11	EIF3KP1	9.03	4.07e-18	5.64e-15	0.53	0.38	Parkinson's disease;	chr5:103103227	chr5:103032376~103033031:+
LUAD	cis	rs7188445	0.899	rs17689024	ENSG00000261390.4	RP11-345M22.2	-9.03	4.15e-18	5.75e-15	-0.5	-0.38	Urate levels;	chr16:79706081	chr16:79715232~79770563:-
LUAD	cis	rs10129255	1	rs11621409	ENSG00000211970.3	IGHV4-61	-9.03	4.16e-18	5.76e-15	-0.3	-0.38	Kawasaki disease;	chr14:106695603	chr14:106639119~106639657:-
LUAD	cis	rs11123170	0.64	rs931472	ENSG00000189223.12	PAX8-AS1	9.03	4.17e-18	5.77e-15	0.55	0.38	Renal function-related traits (BUN);	chr2:113212371	chr2:113211522~113276581:+
LUAD	cis	rs7429990	0.965	rs7649981	ENSG00000229759.1	MRPS18AP1	9.03	4.18e-18	5.79e-15	0.39	0.38	Educational attainment (years of education);	chr3:47957847	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.965	rs2053767	ENSG00000229759.1	MRPS18AP1	9.03	4.18e-18	5.79e-15	0.39	0.38	Educational attainment (years of education);	chr3:47958184	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.965	rs6770467	ENSG00000229759.1	MRPS18AP1	-9.03	4.18e-18	5.79e-15	-0.39	-0.38	Educational attainment (years of education);	chr3:47977742	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.932	rs6770477	ENSG00000229759.1	MRPS18AP1	-9.03	4.18e-18	5.79e-15	-0.39	-0.38	Educational attainment (years of education);	chr3:47977768	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.965	rs28637561	ENSG00000229759.1	MRPS18AP1	-9.03	4.18e-18	5.79e-15	-0.39	-0.38	Educational attainment (years of education);	chr3:47979528	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.965	rs7431572	ENSG00000229759.1	MRPS18AP1	-9.03	4.18e-18	5.79e-15	-0.39	-0.38	Educational attainment (years of education);	chr3:47986361	chr3:48256350~48256938:-
LUAD	cis	rs7924176	0.521	rs12415957	ENSG00000213731.2	RAB5CP1	9.03	4.2e-18	5.81e-15	0.4	0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74342225	chr10:74423435~74424014:-
LUAD	cis	rs35160687	0.829	rs13017143	ENSG00000273080.1	RP11-301O19.1	-9.03	4.2e-18	5.81e-15	-0.44	-0.38	Night sleep phenotypes;	chr2:86239426	chr2:86195590~86196049:+
LUAD	cis	rs526231	0.543	rs34770	ENSG00000175749.11	EIF3KP1	9.03	4.24e-18	5.87e-15	0.54	0.38	Primary biliary cholangitis;	chr5:103111942	chr5:103032376~103033031:+
LUAD	cis	rs34779708	0.931	rs2001893	ENSG00000230534.5	RP11-297A16.2	9.03	4.25e-18	5.88e-15	0.44	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35011695	chr10:35098006~35127020:-
LUAD	cis	rs172166	0.516	rs1150670	ENSG00000204709.4	LINC01556	9.03	4.28e-18	5.92e-15	0.47	0.38	Cardiac Troponin-T levels;	chr6:28162781	chr6:28943877~28944537:+
LUAD	cis	rs172166	0.516	rs2021826	ENSG00000204709.4	LINC01556	9.03	4.28e-18	5.92e-15	0.47	0.38	Cardiac Troponin-T levels;	chr6:28164978	chr6:28943877~28944537:+
LUAD	cis	rs34779708	0.931	rs2148482	ENSG00000230534.5	RP11-297A16.2	9.03	4.31e-18	5.96e-15	0.46	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35059982	chr10:35098006~35127020:-
LUAD	cis	rs904251	0.6	rs2270687	ENSG00000204110.6	RP1-153P14.8	-9.03	4.32e-18	5.97e-15	-0.39	-0.38	Cognitive performance;	chr6:37450487	chr6:37507348~37535616:+
LUAD	cis	rs10463554	0.824	rs427430	ENSG00000175749.11	EIF3KP1	9.03	4.32e-18	5.97e-15	0.54	0.38	Parkinson's disease;	chr5:103096320	chr5:103032376~103033031:+
LUAD	cis	rs9389248	0.737	rs56358308	ENSG00000232876.1	CTA-212D2.2	-9.02	4.34e-18	5.99e-15	-0.45	-0.38	High light scatter reticulocyte percentage of red cells;	chr6:134985842	chr6:135055033~135060550:+
LUAD	cis	rs12468226	0.873	rs3769817	ENSG00000273456.1	RP11-686O6.2	-9.02	4.34e-18	6e-15	-0.59	-0.38	Urate levels;	chr2:202214584	chr2:202374932~202375604:-
LUAD	cis	rs12468226	0.873	rs6435134	ENSG00000273456.1	RP11-686O6.2	-9.02	4.34e-18	6e-15	-0.59	-0.38	Urate levels;	chr2:202214857	chr2:202374932~202375604:-
LUAD	cis	rs26232	0.521	rs3776855	ENSG00000175749.11	EIF3KP1	9.02	4.38e-18	6.06e-15	0.55	0.38	Rheumatoid arthritis;	chr5:103023111	chr5:103032376~103033031:+
LUAD	cis	rs7924176	0.521	rs7477710	ENSG00000213731.2	RAB5CP1	-9.02	4.41e-18	6.1e-15	-0.4	-0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74275444	chr10:74423435~74424014:-
LUAD	cis	rs10129255	1	rs10129255	ENSG00000223648.3	IGHV3-64	-9.02	4.42e-18	6.1e-15	-0.37	-0.38	Kawasaki disease;	chr14:106767970	chr14:106643132~106658258:-
LUAD	cis	rs12468226	1	rs16824599	ENSG00000273456.1	RP11-686O6.2	9.02	4.44e-18	6.12e-15	0.61	0.38	Urate levels;	chr2:202358243	chr2:202374932~202375604:-
LUAD	cis	rs904251	0.772	rs1812186	ENSG00000204110.6	RP1-153P14.8	-9.02	4.44e-18	6.13e-15	-0.43	-0.38	Cognitive performance;	chr6:37498140	chr6:37507348~37535616:+
LUAD	cis	rs7429990	0.965	rs11707679	ENSG00000229759.1	MRPS18AP1	9.02	4.47e-18	6.17e-15	0.41	0.38	Educational attainment (years of education);	chr3:47915016	chr3:48256350~48256938:-
LUAD	cis	rs62229266	0.557	rs4817761	ENSG00000231106.2	LINC01436	9.02	4.48e-18	6.18e-15	0.53	0.38	Mitral valve prolapse;	chr21:36023258	chr21:36005338~36007838:+
LUAD	cis	rs35955747	0.601	rs5749302	ENSG00000236132.1	CTA-440B3.1	-9.02	4.55e-18	6.27e-15	-0.44	-0.38	Neutrophil count;Sum basophil neutrophil counts;	chr22:31554632	chr22:31816379~31817491:-
LUAD	cis	rs6964833	0.786	rs35633336	ENSG00000277053.3	GTF2IP1	-9.02	4.57e-18	6.3e-15	-0.52	-0.38	Menarche (age at onset);	chr7:74643961	chr7:75185385~75237696:-
LUAD	cis	rs6964833	0.935	rs35735900	ENSG00000277053.3	GTF2IP1	-9.02	4.57e-18	6.3e-15	-0.52	-0.38	Menarche (age at onset);	chr7:74651887	chr7:75185385~75237696:-
LUAD	cis	rs1185460	0.934	rs1006195	ENSG00000271751.1	RP11-110I1.14	9.02	4.57e-18	6.3e-15	0.46	0.38	Coronary artery disease;	chr11:119088159	chr11:119065263~119065677:-
LUAD	cis	rs10463554	0.927	rs40061	ENSG00000175749.11	EIF3KP1	9.02	4.57e-18	6.31e-15	0.53	0.38	Parkinson's disease;	chr5:103067412	chr5:103032376~103033031:+
LUAD	cis	rs7188445	0.932	rs17767419	ENSG00000261390.4	RP11-345M22.2	-9.02	4.58e-18	6.31e-15	-0.5	-0.38	Urate levels;	chr16:79710651	chr16:79715232~79770563:-
LUAD	cis	rs1150668	0.835	rs1233696	ENSG00000204709.4	LINC01556	9.02	4.58e-18	6.32e-15	0.47	0.38	Pubertal anthropometrics;	chr6:28175232	chr6:28943877~28944537:+
LUAD	cis	rs10875746	0.729	rs11168357	ENSG00000240399.1	RP1-228P16.1	-9.02	4.61e-18	6.35e-15	-0.44	-0.38	Longevity (90 years and older);	chr12:48018355	chr12:48054813~48055591:-
LUAD	cis	rs172166	0.561	rs149976	ENSG00000204709.4	LINC01556	-9.02	4.62e-18	6.37e-15	-0.46	-0.38	Cardiac Troponin-T levels;	chr6:28019998	chr6:28943877~28944537:+
LUAD	cis	rs10256972	0.524	rs6945202	ENSG00000229043.2	AC091729.9	-9.02	4.63e-18	6.38e-15	-0.42	-0.38	Endometriosis;Longevity;	chr7:1076922	chr7:1160374~1165267:+
LUAD	cis	rs2337406	0.925	rs76288499	ENSG00000274576.2	IGHV2-70	-9.02	4.65e-18	6.4e-15	-0.43	-0.38	Alzheimer's disease (late onset);	chr14:106686309	chr14:106770577~106771020:-
LUAD	cis	rs9660180	0.967	rs12040325	ENSG00000231050.1	RP1-140A9.1	9.02	4.65e-18	6.41e-15	0.44	0.38	Body mass index;	chr1:1770997	chr1:1891471~1892658:+
LUAD	cis	rs11690935	0.885	rs6752812	ENSG00000228389.1	AC068039.4	9.02	4.66e-18	6.41e-15	0.44	0.38	Schizophrenia;	chr2:171986588	chr2:171773482~171775844:+
LUAD	cis	rs1061377	0.56	rs6531690	ENSG00000249207.1	RP11-360F5.1	-9.01	4.68e-18	6.45e-15	-0.42	-0.38	Uric acid levels;	chr4:39072583	chr4:39112677~39126818:-
LUAD	cis	rs733592	0.524	rs10875726	ENSG00000240399.1	RP1-228P16.1	-9.01	4.75e-18	6.53e-15	-0.35	-0.38	Plateletcrit;	chr12:48032209	chr12:48054813~48055591:-
LUAD	cis	rs733592	0.524	rs10875727	ENSG00000240399.1	RP1-228P16.1	-9.01	4.75e-18	6.53e-15	-0.35	-0.38	Plateletcrit;	chr12:48032360	chr12:48054813~48055591:-
LUAD	cis	rs1976403	0.633	rs1780324	ENSG00000227001.3	NBPF2P	9.01	4.77e-18	6.57e-15	0.45	0.38	Liver enzyme levels (alkaline phosphatase);	chr1:21495264	chr1:21424625~21427967:-
LUAD	cis	rs11098499	0.874	rs6851169	ENSG00000245958.5	RP11-33B1.1	-9.01	4.84e-18	6.66e-15	-0.36	-0.38	Corneal astigmatism;	chr4:119196355	chr4:119454791~119552025:+
LUAD	cis	rs10129255	0.536	rs8004835	ENSG00000280411.1	IGHV1-69-2	-9.01	4.85e-18	6.67e-15	-0.26	-0.38	Kawasaki disease;	chr14:106686361	chr14:106762092~106762588:-
LUAD	cis	rs7188445	0.932	rs17689625	ENSG00000261390.4	RP11-345M22.2	-9.01	4.87e-18	6.7e-15	-0.5	-0.38	Urate levels;	chr16:79715065	chr16:79715232~79770563:-
LUAD	cis	rs1185460	0.967	rs1784302	ENSG00000271751.1	RP11-110I1.14	-9.01	4.89e-18	6.72e-15	-0.47	-0.38	Coronary artery disease;	chr11:119070247	chr11:119065263~119065677:-
LUAD	cis	rs733592	0.56	rs2158515	ENSG00000240399.1	RP1-228P16.1	-9.01	4.89e-18	6.73e-15	-0.36	-0.38	Plateletcrit;	chr12:48113885	chr12:48054813~48055591:-
LUAD	cis	rs34779708	0.931	rs72789609	ENSG00000230534.5	RP11-297A16.2	9.01	4.9e-18	6.74e-15	0.45	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35017278	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs7908573	ENSG00000230534.5	RP11-297A16.2	9.01	4.9e-18	6.74e-15	0.45	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35020585	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs34304999	ENSG00000230534.5	RP11-297A16.2	9.01	4.91e-18	6.75e-15	0.45	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35076777	chr10:35098006~35127020:-
LUAD	cis	rs172166	0.538	rs1150686	ENSG00000204709.4	LINC01556	9.01	4.92e-18	6.76e-15	0.47	0.38	Cardiac Troponin-T levels;	chr6:28193493	chr6:28943877~28944537:+
LUAD	cis	rs10129255	0.833	rs7156689	ENSG00000223648.3	IGHV3-64	9.01	4.92e-18	6.76e-15	0.38	0.38	Kawasaki disease;	chr14:106816039	chr14:106643132~106658258:-
LUAD	cis	rs10463554	0.963	rs1011454	ENSG00000175749.11	EIF3KP1	9.01	4.95e-18	6.81e-15	0.53	0.38	Parkinson's disease;	chr5:103032551	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs34821	ENSG00000175749.11	EIF3KP1	9.01	4.96e-18	6.81e-15	0.53	0.38	Parkinson's disease;	chr5:103101913	chr5:103032376~103033031:+
LUAD	cis	rs720475	1	rs720475	ENSG00000204959.4	ARHGEF34P	-9.01	5e-18	6.87e-15	-0.49	-0.38	Breast cancer;	chr7:144377836	chr7:144272445~144286966:-
LUAD	cis	rs10256972	0.685	rs10263665	ENSG00000229043.2	AC091729.9	-9.01	5.02e-18	6.9e-15	-0.41	-0.38	Endometriosis;Longevity;	chr7:1070992	chr7:1160374~1165267:+
LUAD	cis	rs2086824	0.538	rs4785673	ENSG00000274627.1	RP11-104N10.2	9	5.06e-18	6.94e-15	0.37	0.38	Multiple myeloma (IgH translocation);	chr16:89470137	chr16:89516797~89522217:+
LUAD	cis	rs7044106	0.708	rs991121	ENSG00000226752.6	PSMD5-AS1	-9	5.08e-18	6.98e-15	-0.41	-0.38	Hip circumference adjusted for BMI;	chr9:120608067	chr9:120824828~120854385:+
LUAD	cis	rs11690935	0.959	rs6738445	ENSG00000228389.1	AC068039.4	-9	5.1e-18	7e-15	-0.45	-0.38	Schizophrenia;	chr2:171743105	chr2:171773482~171775844:+
LUAD	cis	rs10129255	0.957	rs12589190	ENSG00000223648.3	IGHV3-64	9	5.1e-18	7e-15	0.37	0.38	Kawasaki disease;	chr14:106783079	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.957	rs7493713	ENSG00000223648.3	IGHV3-64	9	5.1e-18	7e-15	0.37	0.38	Kawasaki disease;	chr14:106783685	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.912	rs35468694	ENSG00000223648.3	IGHV3-64	9	5.1e-18	7e-15	0.37	0.38	Kawasaki disease;	chr14:106784199	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.957	rs8019272	ENSG00000223648.3	IGHV3-64	9	5.1e-18	7e-15	0.37	0.38	Kawasaki disease;	chr14:106784709	chr14:106643132~106658258:-
LUAD	cis	rs34779708	0.931	rs4934702	ENSG00000230534.5	RP11-297A16.2	9	5.13e-18	7.04e-15	0.44	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35034146	chr10:35098006~35127020:-
LUAD	cis	rs10129255	1	rs11621409	ENSG00000223648.3	IGHV3-64	9	5.14e-18	7.05e-15	0.38	0.38	Kawasaki disease;	chr14:106695603	chr14:106643132~106658258:-
LUAD	cis	rs10463554	0.963	rs62362546	ENSG00000175749.11	EIF3KP1	9	5.14e-18	7.06e-15	0.53	0.38	Parkinson's disease;	chr5:103015615	chr5:103032376~103033031:+
LUAD	cis	rs1789	0.592	rs6812708	ENSG00000273133.1	RP11-799M12.2	-9	5.15e-18	7.07e-15	-0.57	-0.38	Blood protein levels;	chr4:15539986	chr4:15563698~15564253:-
LUAD	cis	rs4888378	0.6	rs729109	ENSG00000261783.1	RP11-252K23.2	9	5.18e-18	7.1e-15	0.57	0.38	Coronary artery disease;	chr16:75282176	chr16:75379818~75381260:-
LUAD	cis	rs904251	0.525	rs12200378	ENSG00000204110.6	RP1-153P14.8	-9	5.2e-18	7.14e-15	-0.39	-0.38	Cognitive performance;	chr6:37457528	chr6:37507348~37535616:+
LUAD	cis	rs5760092	0.572	rs738806	ENSG00000218537.1	MIF-AS1	9	5.24e-18	7.18e-15	0.57	0.38	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23894426~23898930:-
LUAD	cis	rs34779708	0.931	rs2384275	ENSG00000230534.5	RP11-297A16.2	9	5.24e-18	7.19e-15	0.44	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35008214	chr10:35098006~35127020:-
LUAD	cis	rs526231	0.511	rs73179850	ENSG00000175749.11	EIF3KP1	9	5.27e-18	7.22e-15	0.55	0.38	Primary biliary cholangitis;	chr5:103012873	chr5:103032376~103033031:+
LUAD	cis	rs11098499	0.644	rs3806808	ENSG00000245958.5	RP11-33B1.1	-9	5.3e-18	7.26e-15	-0.35	-0.38	Corneal astigmatism;	chr4:119629930	chr4:119454791~119552025:+
LUAD	cis	rs904251	0.6	rs1874736	ENSG00000204110.6	RP1-153P14.8	-9	5.3e-18	7.27e-15	-0.39	-0.38	Cognitive performance;	chr6:37480218	chr6:37507348~37535616:+
LUAD	cis	rs1185460	0.967	rs1786685	ENSG00000271751.1	RP11-110I1.14	-9	5.32e-18	7.29e-15	-0.47	-0.38	Coronary artery disease;	chr11:119068246	chr11:119065263~119065677:-
LUAD	cis	rs172166	0.516	rs2791333	ENSG00000204709.4	LINC01556	9	5.34e-18	7.31e-15	0.47	0.38	Cardiac Troponin-T levels;	chr6:28143336	chr6:28943877~28944537:+
LUAD	cis	rs5769707	0.749	rs8137251	ENSG00000188511.11	C22orf34	9	5.36e-18	7.34e-15	0.46	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49643021	chr22:49414524~49657542:-
LUAD	cis	rs9399135	0.773	rs1331308	ENSG00000232876.1	CTA-212D2.2	9	5.38e-18	7.37e-15	0.43	0.38	Red blood cell count;	chr6:135083984	chr6:135055033~135060550:+
LUAD	cis	rs7924176	0.601	rs10824072	ENSG00000213731.2	RAB5CP1	-9	5.42e-18	7.42e-15	-0.4	-0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74114134	chr10:74423435~74424014:-
LUAD	cis	rs12468226	0.817	rs6435135	ENSG00000273456.1	RP11-686O6.2	-9	5.45e-18	7.46e-15	-0.58	-0.38	Urate levels;	chr2:202217469	chr2:202374932~202375604:-
LUAD	cis	rs7924176	0.564	rs10762588	ENSG00000213731.2	RAB5CP1	-8.99	5.48e-18	7.5e-15	-0.4	-0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74226087	chr10:74423435~74424014:-
LUAD	cis	rs7924176	0.564	rs4564273	ENSG00000213731.2	RAB5CP1	-8.99	5.48e-18	7.5e-15	-0.4	-0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74230154	chr10:74423435~74424014:-
LUAD	cis	rs3931020	0.548	rs17618340	ENSG00000272864.1	RP11-17E13.2	-8.99	5.54e-18	7.57e-15	-0.45	-0.38	Resistin levels;	chr1:74781933	chr1:74698769~74699333:-
LUAD	cis	rs34779708	0.931	rs35886556	ENSG00000230534.5	RP11-297A16.2	8.99	5.56e-18	7.61e-15	0.45	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35046057	chr10:35098006~35127020:-
LUAD	cis	rs904251	1	rs904251	ENSG00000204110.6	RP1-153P14.8	-8.99	5.58e-18	7.63e-15	-0.39	-0.38	Cognitive performance;	chr6:37483920	chr6:37507348~37535616:+
LUAD	cis	rs7429990	0.932	rs6442101	ENSG00000229759.1	MRPS18AP1	-8.99	5.58e-18	7.63e-15	-0.4	-0.38	Educational attainment (years of education);	chr3:48089403	chr3:48256350~48256938:-
LUAD	cis	rs227275	0.525	rs1080081	ENSG00000246560.2	RP11-10L12.4	8.99	5.6e-18	7.65e-15	0.48	0.38	Allergic disease (asthma, hay fever or eczema);	chr4:103029268	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.525	rs4699049	ENSG00000246560.2	RP11-10L12.4	8.99	5.6e-18	7.65e-15	0.48	0.38	Allergic disease (asthma, hay fever or eczema);	chr4:103030467	chr4:102828055~102844075:+
LUAD	cis	rs12468226	1	rs112306637	ENSG00000273456.1	RP11-686O6.2	8.99	5.8e-18	7.91e-15	0.6	0.38	Urate levels;	chr2:202334195	chr2:202374932~202375604:-
LUAD	cis	rs12468226	1	rs111252524	ENSG00000273456.1	RP11-686O6.2	8.99	5.8e-18	7.91e-15	0.6	0.38	Urate levels;	chr2:202334465	chr2:202374932~202375604:-
LUAD	cis	rs12468226	1	rs112753638	ENSG00000273456.1	RP11-686O6.2	8.99	5.8e-18	7.91e-15	0.6	0.38	Urate levels;	chr2:202334496	chr2:202374932~202375604:-
LUAD	cis	rs12468226	0.935	rs113188021	ENSG00000273456.1	RP11-686O6.2	8.99	5.8e-18	7.91e-15	0.6	0.38	Urate levels;	chr2:202336237	chr2:202374932~202375604:-
LUAD	cis	rs12468226	1	rs6731027	ENSG00000273456.1	RP11-686O6.2	8.99	5.8e-18	7.91e-15	0.6	0.38	Urate levels;	chr2:202337443	chr2:202374932~202375604:-
LUAD	cis	rs10129255	0.957	rs11847726	ENSG00000223648.3	IGHV3-64	8.99	5.8e-18	7.91e-15	0.37	0.38	Kawasaki disease;	chr14:106779116	chr14:106643132~106658258:-
LUAD	cis	rs494459	0.838	rs555649	ENSG00000255422.1	AP002954.4	-8.99	5.82e-18	7.94e-15	-0.46	-0.38	Height;	chr11:118781100	chr11:118704607~118750263:+
LUAD	cis	rs6964833	0.935	rs34762099	ENSG00000277053.3	GTF2IP1	-8.99	5.83e-18	7.95e-15	-0.52	-0.38	Menarche (age at onset);	chr7:74636378	chr7:75185385~75237696:-
LUAD	cis	rs12468226	1	rs113877751	ENSG00000273456.1	RP11-686O6.2	8.99	5.84e-18	7.96e-15	0.6	0.38	Urate levels;	chr2:202329998	chr2:202374932~202375604:-
LUAD	cis	rs12468226	0.935	rs113021930	ENSG00000273456.1	RP11-686O6.2	8.99	5.84e-18	7.96e-15	0.6	0.38	Urate levels;	chr2:202330448	chr2:202374932~202375604:-
LUAD	cis	rs12468226	1	rs113491584	ENSG00000273456.1	RP11-686O6.2	8.99	5.84e-18	7.96e-15	0.6	0.38	Urate levels;	chr2:202331724	chr2:202374932~202375604:-
LUAD	cis	rs9399137	0.507	rs11754021	ENSG00000232876.1	CTA-212D2.2	-8.98	5.97e-18	8.14e-15	-0.44	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134987237	chr6:135055033~135060550:+
LUAD	cis	rs7429990	0.965	rs9811277	ENSG00000229759.1	MRPS18AP1	8.98	6.01e-18	8.19e-15	0.39	0.38	Educational attainment (years of education);	chr3:47970148	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.965	rs9814961	ENSG00000229759.1	MRPS18AP1	8.98	6.01e-18	8.19e-15	0.39	0.38	Educational attainment (years of education);	chr3:47976127	chr3:48256350~48256938:-
LUAD	cis	rs6142102	0.625	rs6141431	ENSG00000276073.1	RP5-1125A11.7	-8.98	6.02e-18	8.21e-15	-0.39	-0.38	Skin pigmentation;	chr20:33952508	chr20:33985617~33988989:-
LUAD	cis	rs1891275	0.55	rs4933694	ENSG00000228701.1	TNKS2-AS1	-8.98	6.05e-18	8.24e-15	-0.47	-0.38	Intelligence (multi-trait analysis);	chr10:91739456	chr10:91782839~91798291:-
LUAD	cis	rs1185460	0.967	rs4454730	ENSG00000271751.1	RP11-110I1.14	-8.98	6.09e-18	8.3e-15	-0.47	-0.38	Coronary artery disease;	chr11:119066733	chr11:119065263~119065677:-
LUAD	cis	rs1185460	0.967	rs4545564	ENSG00000271751.1	RP11-110I1.14	-8.98	6.09e-18	8.3e-15	-0.47	-0.38	Coronary artery disease;	chr11:119066807	chr11:119065263~119065677:-
LUAD	cis	rs11676348	0.811	rs13027120	ENSG00000261338.2	RP11-378A13.1	8.98	6.11e-18	8.32e-15	0.39	0.38	Ulcerative colitis;	chr2:218156191	chr2:218255319~218257366:+
LUAD	cis	rs2283792	0.622	rs239917	ENSG00000224086.5	LL22NC03-86G7.1	-8.98	6.11e-18	8.33e-15	-0.36	-0.38	Multiple sclerosis;	chr22:21960091	chr22:21938293~21977632:+
LUAD	cis	rs227275	0.556	rs724447	ENSG00000246560.2	RP11-10L12.4	-8.98	6.12e-18	8.34e-15	-0.46	-0.38	Allergic disease (asthma, hay fever or eczema);	chr4:103010149	chr4:102828055~102844075:+
LUAD	cis	rs11690935	0.885	rs6750058	ENSG00000228389.1	AC068039.4	8.98	6.22e-18	8.47e-15	0.44	0.38	Schizophrenia;	chr2:171930399	chr2:171773482~171775844:+
LUAD	cis	rs34779708	0.931	rs17583009	ENSG00000230534.5	RP11-297A16.2	8.98	6.23e-18	8.48e-15	0.45	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35031987	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.898	rs11595898	ENSG00000230534.5	RP11-297A16.2	8.98	6.23e-18	8.48e-15	0.45	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35037335	chr10:35098006~35127020:-
LUAD	cis	rs11098499	0.604	rs2389882	ENSG00000245958.5	RP11-33B1.1	-8.98	6.27e-18	8.53e-15	-0.35	-0.38	Corneal astigmatism;	chr4:119645578	chr4:119454791~119552025:+
LUAD	cis	rs1185460	0.967	rs1784461	ENSG00000271751.1	RP11-110I1.14	-8.98	6.29e-18	8.55e-15	-0.47	-0.38	Coronary artery disease;	chr11:119067274	chr11:119065263~119065677:-
LUAD	cis	rs9660180	0.967	rs12034740	ENSG00000231050.1	RP1-140A9.1	8.98	6.3e-18	8.57e-15	0.43	0.38	Body mass index;	chr1:1797530	chr1:1891471~1892658:+
LUAD	cis	rs10463554	0.927	rs34825	ENSG00000175749.11	EIF3KP1	8.98	6.36e-18	8.64e-15	0.53	0.38	Parkinson's disease;	chr5:103103614	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.963	rs34826	ENSG00000175749.11	EIF3KP1	8.98	6.36e-18	8.64e-15	0.53	0.38	Parkinson's disease;	chr5:103106044	chr5:103032376~103033031:+
LUAD	cis	rs1061377	0.585	rs1367296	ENSG00000249207.1	RP11-360F5.1	-8.97	6.46e-18	8.77e-15	-0.42	-0.38	Uric acid levels;	chr4:39066895	chr4:39112677~39126818:-
LUAD	cis	rs11098499	0.874	rs7661020	ENSG00000245958.5	RP11-33B1.1	-8.97	6.49e-18	8.82e-15	-0.35	-0.38	Corneal astigmatism;	chr4:119185827	chr4:119454791~119552025:+
LUAD	cis	rs34779708	0.931	rs35388511	ENSG00000230534.5	RP11-297A16.2	8.97	6.58e-18	8.93e-15	0.44	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35007688	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs34815241	ENSG00000230534.5	RP11-297A16.2	8.97	6.58e-18	8.93e-15	0.44	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35007748	chr10:35098006~35127020:-
LUAD	cis	rs8062405	0.895	rs62036658	ENSG00000259982.1	CDC37P1	8.97	6.59e-18	8.94e-15	0.5	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28839050	chr16:28700294~28701540:-
LUAD	cis	rs904251	0.6	rs11756241	ENSG00000204110.6	RP1-153P14.8	-8.97	6.6e-18	8.95e-15	-0.39	-0.38	Cognitive performance;	chr6:37477325	chr6:37507348~37535616:+
LUAD	cis	rs10129255	0.5	rs2105989	ENSG00000280411.1	IGHV1-69-2	-8.97	6.6e-18	8.96e-15	-0.26	-0.38	Kawasaki disease;	chr14:106682199	chr14:106762092~106762588:-
LUAD	cis	rs6964833	0.872	rs4717903	ENSG00000277053.3	GTF2IP1	-8.97	6.63e-18	8.99e-15	-0.52	-0.38	Menarche (age at onset);	chr7:74653827	chr7:75185385~75237696:-
LUAD	cis	rs2929278	0.617	rs663214	ENSG00000249839.1	AC011330.5	8.97	6.65e-18	9.03e-15	0.49	0.38	Schizophrenia;	chr15:43821584	chr15:43663654~43684339:-
LUAD	cis	rs10463554	0.759	rs34815	ENSG00000175749.11	EIF3KP1	8.97	6.68e-18	9.06e-15	0.54	0.38	Parkinson's disease;	chr5:103098561	chr5:103032376~103033031:+
LUAD	cis	rs62229266	1	rs62229266	ENSG00000231106.2	LINC01436	8.97	6.7e-18	9.09e-15	0.52	0.38	Mitral valve prolapse;	chr21:36087973	chr21:36005338~36007838:+
LUAD	cis	rs7208859	0.623	rs55724095	ENSG00000263531.1	RP13-753N3.1	8.97	6.72e-18	9.11e-15	0.75	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826040	chr17:30863921~30864940:-
LUAD	cis	rs17826219	0.568	rs9903854	ENSG00000263531.1	RP13-753N3.1	8.97	6.72e-18	9.11e-15	0.75	0.38	Body mass index;	chr17:30826980	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs80355557	ENSG00000263531.1	RP13-753N3.1	8.97	6.72e-18	9.11e-15	0.75	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827403	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs9911173	ENSG00000263531.1	RP13-753N3.1	8.97	6.72e-18	9.11e-15	0.75	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827732	chr17:30863921~30864940:-
LUAD	cis	rs7924176	0.601	rs7099026	ENSG00000213731.2	RAB5CP1	-8.97	6.74e-18	9.13e-15	-0.4	-0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74128770	chr10:74423435~74424014:-
LUAD	cis	rs34779708	0.931	rs35848945	ENSG00000230534.5	RP11-297A16.2	8.97	6.76e-18	9.17e-15	0.45	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:34998633	chr10:35098006~35127020:-
LUAD	cis	rs10463554	0.759	rs461609	ENSG00000175749.11	EIF3KP1	8.97	6.77e-18	9.18e-15	0.54	0.38	Parkinson's disease;	chr5:103111601	chr5:103032376~103033031:+
LUAD	cis	rs1061377	0.608	rs35168672	ENSG00000249207.1	RP11-360F5.1	-8.97	6.79e-18	9.2e-15	-0.42	-0.38	Uric acid levels;	chr4:39078902	chr4:39112677~39126818:-
LUAD	cis	rs34779708	0.931	rs2490663	ENSG00000230534.5	RP11-297A16.2	-8.97	6.81e-18	9.22e-15	-0.44	-0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35040807	chr10:35098006~35127020:-
LUAD	cis	rs9399137	0.507	rs12663810	ENSG00000232876.1	CTA-212D2.2	-8.96	6.9e-18	9.35e-15	-0.44	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134968644	chr6:135055033~135060550:+
LUAD	cis	rs34779708	0.75	rs35032841	ENSG00000230534.5	RP11-297A16.2	8.96	7e-18	9.47e-15	0.44	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35023759	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.742	rs35912711	ENSG00000230534.5	RP11-297A16.2	8.96	7e-18	9.47e-15	0.44	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35024068	chr10:35098006~35127020:-
LUAD	cis	rs11690935	0.686	rs10165126	ENSG00000228389.1	AC068039.4	8.96	7.02e-18	9.5e-15	0.43	0.38	Schizophrenia;	chr2:171963793	chr2:171773482~171775844:+
LUAD	cis	rs1150668	0.699	rs1531681	ENSG00000216901.1	AL022393.7	8.96	7.04e-18	9.52e-15	0.44	0.38	Pubertal anthropometrics;	chr6:28259100	chr6:28176188~28176674:+
LUAD	cis	rs10129255	1	rs8010605	ENSG00000223648.3	IGHV3-64	8.96	7.05e-18	9.53e-15	0.38	0.38	Kawasaki disease;	chr14:106678742	chr14:106643132~106658258:-
LUAD	cis	rs6991838	0.612	rs7832407	ENSG00000200714.1	Y_RNA	8.96	7.06e-18	9.53e-15	0.46	0.38	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.551	rs7007505	ENSG00000200714.1	Y_RNA	8.96	7.06e-18	9.53e-15	0.46	0.38	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs7012856	ENSG00000200714.1	Y_RNA	8.96	7.06e-18	9.53e-15	0.46	0.38	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.55	rs7817112	ENSG00000200714.1	Y_RNA	8.96	7.06e-18	9.53e-15	0.46	0.38	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs2048650	ENSG00000200714.1	Y_RNA	8.96	7.06e-18	9.53e-15	0.46	0.38	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs4737749	ENSG00000200714.1	Y_RNA	8.96	7.06e-18	9.53e-15	0.46	0.38	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs10092109	ENSG00000200714.1	Y_RNA	8.96	7.06e-18	9.53e-15	0.46	0.38	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs6997959	ENSG00000200714.1	Y_RNA	8.96	7.06e-18	9.53e-15	0.46	0.38	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs7814841	ENSG00000200714.1	Y_RNA	8.96	7.06e-18	9.53e-15	0.46	0.38	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs11985628	ENSG00000200714.1	Y_RNA	8.96	7.06e-18	9.53e-15	0.46	0.38	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.557	rs13266834	ENSG00000200714.1	Y_RNA	8.96	7.06e-18	9.53e-15	0.46	0.38	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs13268343	ENSG00000200714.1	Y_RNA	8.96	7.06e-18	9.53e-15	0.46	0.38	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs7835313	ENSG00000200714.1	Y_RNA	8.96	7.06e-18	9.53e-15	0.46	0.38	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs3812412	ENSG00000200714.1	Y_RNA	8.96	7.06e-18	9.53e-15	0.46	0.38	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.53	rs6472217	ENSG00000200714.1	Y_RNA	8.96	7.06e-18	9.53e-15	0.46	0.38	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs6472218	ENSG00000200714.1	Y_RNA	8.96	7.06e-18	9.53e-15	0.46	0.38	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs1533285	ENSG00000200714.1	Y_RNA	8.96	7.06e-18	9.53e-15	0.46	0.38	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65592731~65592820:+
LUAD	cis	rs10129255	0.509	rs756583	ENSG00000280411.1	IGHV1-69-2	-8.96	7.06e-18	9.54e-15	-0.26	-0.38	Kawasaki disease;	chr14:106680002	chr14:106762092~106762588:-
LUAD	cis	rs7924176	0.502	rs1874151	ENSG00000213731.2	RAB5CP1	-8.96	7.12e-18	9.61e-15	-0.4	-0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74107856	chr10:74423435~74424014:-
LUAD	cis	rs944289	0.589	rs847514	ENSG00000257826.1	RP11-116N8.4	8.96	7.22e-18	9.74e-15	0.4	0.38	Thyroid cancer;	chr14:36060904	chr14:36061026~36067190:-
LUAD	cis	rs2739330	0.761	rs5760176	ENSG00000228039.3	KB-1125A3.10	-8.96	7.25e-18	9.78e-15	-0.45	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23963780~23964374:+
LUAD	cis	rs7429990	0.895	rs35790549	ENSG00000229759.1	MRPS18AP1	8.96	7.27e-18	9.8e-15	0.44	0.38	Educational attainment (years of education);	chr3:48029998	chr3:48256350~48256938:-
LUAD	cis	rs526231	0.543	rs34377	ENSG00000175749.11	EIF3KP1	8.96	7.37e-18	9.93e-15	0.52	0.38	Primary biliary cholangitis;	chr5:103064852	chr5:103032376~103033031:+
LUAD	cis	rs8062405	0.754	rs149299	ENSG00000259982.1	CDC37P1	8.96	7.39e-18	9.95e-15	0.49	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28473820	chr16:28700294~28701540:-
LUAD	cis	rs11098499	0.874	rs13123591	ENSG00000245958.5	RP11-33B1.1	-8.96	7.41e-18	9.98e-15	-0.35	-0.38	Corneal astigmatism;	chr4:119184835	chr4:119454791~119552025:+
LUAD	cis	rs321358	1	rs12419222	ENSG00000271584.1	RP11-89C3.4	8.95	7.47e-18	1.01e-14	0.64	0.38	Body mass index;	chr11:111128439	chr11:111091932~111097357:-
LUAD	cis	rs9309711	0.621	rs7586472	ENSG00000225234.1	TRAPPC12-AS1	-8.95	7.49e-18	1.01e-14	-0.44	-0.38	Neurofibrillary tangles;	chr2:3469899	chr2:3481242~3482409:-
LUAD	cis	rs11118620	0.622	rs11118618	ENSG00000272823.1	RP11-295M18.6	8.95	7.5e-18	1.01e-14	0.52	0.38	Heart failure;	chr1:220838204	chr1:220828676~220829211:-
LUAD	cis	rs12468226	0.938	rs114177656	ENSG00000273456.1	RP11-686O6.2	8.95	7.52e-18	1.01e-14	0.6	0.38	Urate levels;	chr2:202291596	chr2:202374932~202375604:-
LUAD	cis	rs9399137	0.507	rs28384513	ENSG00000232876.1	CTA-212D2.2	-8.95	7.55e-18	1.02e-14	-0.44	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135055071	chr6:135055033~135060550:+
LUAD	cis	rs8040855	0.52	rs11629963	ENSG00000259295.5	CSPG4P12	-8.95	7.58e-18	1.02e-14	-0.51	-0.38	Bulimia nervosa;	chr15:84986808	chr15:85191438~85213905:+
LUAD	cis	rs12468226	1	rs7565875	ENSG00000273456.1	RP11-686O6.2	8.95	7.59e-18	1.02e-14	0.54	0.38	Urate levels;	chr2:202516412	chr2:202374932~202375604:-
LUAD	cis	rs2487048	0.804	rs2472496	ENSG00000226334.1	RP11-217B7.2	-8.95	7.66e-18	1.03e-14	-0.49	-0.38	Intraocular pressure;	chr9:104933072	chr9:104927553~104928892:+
LUAD	cis	rs944289	0.617	rs1958617	ENSG00000257826.1	RP11-116N8.4	-8.95	7.71e-18	1.04e-14	-0.4	-0.38	Thyroid cancer;	chr14:36118418	chr14:36061026~36067190:-
LUAD	cis	rs13392177	0.672	rs4674270	ENSG00000261338.2	RP11-378A13.1	-8.95	7.77e-18	1.04e-14	-0.39	-0.38	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218188418	chr2:218255319~218257366:+
LUAD	cis	rs172166	0.516	rs2622322	ENSG00000204709.4	LINC01556	8.95	7.77e-18	1.04e-14	0.47	0.38	Cardiac Troponin-T levels;	chr6:28149665	chr6:28943877~28944537:+
LUAD	cis	rs6991838	0.557	rs57419568	ENSG00000272010.1	CTD-3025N20.3	-8.95	7.83e-18	1.05e-14	-0.42	-0.38	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs16932250	ENSG00000272010.1	CTD-3025N20.3	-8.95	7.83e-18	1.05e-14	-0.42	-0.38	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65591850~65592472:-
LUAD	cis	rs34779708	0.931	rs7079205	ENSG00000230534.5	RP11-297A16.2	8.95	7.84e-18	1.05e-14	0.45	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35035691	chr10:35098006~35127020:-
LUAD	cis	rs5769707	0.732	rs135865	ENSG00000188511.11	C22orf34	8.95	7.93e-18	1.06e-14	0.45	0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49611181	chr22:49414524~49657542:-
LUAD	cis	rs9399137	0.507	rs10484496	ENSG00000232876.1	CTA-212D2.2	-8.95	7.97e-18	1.07e-14	-0.44	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978544	chr6:135055033~135060550:+
LUAD	cis	rs9399137	0.507	rs13214669	ENSG00000232876.1	CTA-212D2.2	-8.95	7.97e-18	1.07e-14	-0.44	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978821	chr6:135055033~135060550:+
LUAD	cis	rs34779708	0.966	rs1148245	ENSG00000230534.5	RP11-297A16.2	8.95	7.97e-18	1.07e-14	0.44	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35222966	chr10:35098006~35127020:-
LUAD	cis	rs7617773	0.539	rs12486944	ENSG00000229759.1	MRPS18AP1	8.95	7.98e-18	1.07e-14	0.37	0.38	Coronary artery disease;	chr3:48348526	chr3:48256350~48256938:-
LUAD	cis	rs11123170	0.64	rs2863240	ENSG00000189223.12	PAX8-AS1	8.94	8.1e-18	1.09e-14	0.55	0.38	Renal function-related traits (BUN);	chr2:113212539	chr2:113211522~113276581:+
LUAD	cis	rs904251	0.523	rs2776874	ENSG00000204110.6	RP1-153P14.8	-8.94	8.12e-18	1.09e-14	-0.37	-0.38	Cognitive performance;	chr6:37515421	chr6:37507348~37535616:+
LUAD	cis	rs11098499	0.566	rs17051356	ENSG00000245958.5	RP11-33B1.1	-8.94	8.15e-18	1.09e-14	-0.36	-0.38	Corneal astigmatism;	chr4:119664153	chr4:119454791~119552025:+
LUAD	cis	rs1891275	0.515	rs10881957	ENSG00000228701.1	TNKS2-AS1	-8.94	8.22e-18	1.1e-14	-0.47	-0.38	Intelligence (multi-trait analysis);	chr10:91742119	chr10:91782839~91798291:-
LUAD	cis	rs10129255	0.957	rs8005468	ENSG00000223648.3	IGHV3-64	8.94	8.31e-18	1.11e-14	0.37	0.38	Kawasaki disease;	chr14:106686431	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.556	rs9324093	ENSG00000280411.1	IGHV1-69-2	-8.94	8.32e-18	1.11e-14	-0.26	-0.38	Kawasaki disease;	chr14:106683893	chr14:106762092~106762588:-
LUAD	cis	rs12594515	1	rs12595137	ENSG00000273972.1	CTD-2306A12.1	-8.94	8.35e-18	1.12e-14	-0.41	-0.38	Weight;Waist circumference;	chr15:45693907	chr15:45702640~45703183:+
LUAD	cis	rs12594515	0.967	rs12595138	ENSG00000273972.1	CTD-2306A12.1	-8.94	8.35e-18	1.12e-14	-0.41	-0.38	Weight;Waist circumference;	chr15:45693910	chr15:45702640~45703183:+
LUAD	cis	rs1150668	0.799	rs1736891	ENSG00000216901.1	AL022393.7	8.94	8.49e-18	1.14e-14	0.45	0.38	Pubertal anthropometrics;	chr6:28219323	chr6:28176188~28176674:+
LUAD	cis	rs10129255	0.833	rs61997797	ENSG00000223648.3	IGHV3-64	8.94	8.53e-18	1.14e-14	0.37	0.38	Kawasaki disease;	chr14:106815190	chr14:106643132~106658258:-
LUAD	cis	rs904251	1	rs10947673	ENSG00000204110.6	RP1-153P14.8	-8.94	8.54e-18	1.14e-14	-0.39	-0.38	Cognitive performance;	chr6:37477303	chr6:37507348~37535616:+
LUAD	cis	rs9326248	0.861	rs7931335	ENSG00000280143.1	AP000892.6	8.94	8.56e-18	1.14e-14	0.5	0.38	Blood protein levels;	chr11:117166089	chr11:117204967~117210292:+
LUAD	cis	rs7429990	0.965	rs7642590	ENSG00000229759.1	MRPS18AP1	-8.94	8.57e-18	1.15e-14	-0.41	-0.38	Educational attainment (years of education);	chr3:48058260	chr3:48256350~48256938:-
LUAD	cis	rs507080	0.501	rs516503	ENSG00000255239.1	AP002954.6	8.94	8.59e-18	1.15e-14	0.44	0.38	Serum metabolite levels;	chr11:118709639	chr11:118688039~118690600:-
LUAD	cis	rs7429990	0.932	rs936428	ENSG00000229759.1	MRPS18AP1	-8.94	8.6e-18	1.15e-14	-0.38	-0.38	Educational attainment (years of education);	chr3:48125791	chr3:48256350~48256938:-
LUAD	cis	rs526231	0.511	rs158402	ENSG00000175749.11	EIF3KP1	8.94	8.7e-18	1.16e-14	0.52	0.38	Primary biliary cholangitis;	chr5:103079821	chr5:103032376~103033031:+
LUAD	cis	rs6991838	0.584	rs3765205	ENSG00000272010.1	CTD-3025N20.3	-8.93	8.73e-18	1.17e-14	-0.41	-0.38	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65591850~65592472:-
LUAD	cis	rs1976403	0.633	rs1697422	ENSG00000227001.3	NBPF2P	8.93	8.88e-18	1.19e-14	0.45	0.38	Liver enzyme levels (alkaline phosphatase);	chr1:21495404	chr1:21424625~21427967:-
LUAD	cis	rs6991838	0.584	rs7459944	ENSG00000272010.1	CTD-3025N20.3	-8.93	8.9e-18	1.19e-14	-0.42	-0.38	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65591850~65592472:-
LUAD	cis	rs1799949	0.587	rs1824890	ENSG00000198496.9	NBR2	-8.93	8.91e-18	1.19e-14	-0.47	-0.38	Menopause (age at onset);	chr17:43344536	chr17:43125610~43153671:+
LUAD	cis	rs12134133	1	rs4844590	ENSG00000274245.1	RP11-357P18.2	8.93	9.04e-18	1.21e-14	0.51	0.38	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207322784	chr1:207372559~207373252:+
LUAD	cis	rs10129255	1	rs10129319	ENSG00000223648.3	IGHV3-64	8.93	9.15e-18	1.22e-14	0.37	0.38	Kawasaki disease;	chr14:106767996	chr14:106643132~106658258:-
LUAD	cis	rs526231	0.511	rs17154965	ENSG00000175749.11	EIF3KP1	8.93	9.15e-18	1.22e-14	0.54	0.38	Primary biliary cholangitis;	chr5:103023862	chr5:103032376~103033031:+
LUAD	cis	rs7429990	0.965	rs4599334	ENSG00000229759.1	MRPS18AP1	-8.93	9.21e-18	1.23e-14	-0.4	-0.38	Educational attainment (years of education);	chr3:48024910	chr3:48256350~48256938:-
LUAD	cis	rs6991838	0.557	rs7012578	ENSG00000200714.1	Y_RNA	-8.93	9.24e-18	1.23e-14	-0.47	-0.38	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65592731~65592820:+
LUAD	cis	rs10129255	0.957	rs8009464	ENSG00000223648.3	IGHV3-64	8.93	9.27e-18	1.23e-14	0.37	0.38	Kawasaki disease;	chr14:106777611	chr14:106643132~106658258:-
LUAD	cis	rs6991838	0.584	rs1053085	ENSG00000272010.1	CTD-3025N20.3	-8.93	9.28e-18	1.24e-14	-0.42	-0.38	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65591850~65592472:-
LUAD	cis	rs1185460	0.967	rs1786141	ENSG00000271751.1	RP11-110I1.14	-8.92	9.42e-18	1.25e-14	-0.47	-0.38	Coronary artery disease;	chr11:119067604	chr11:119065263~119065677:-
LUAD	cis	rs11690935	0.885	rs10202823	ENSG00000228389.1	AC068039.4	8.92	9.43e-18	1.26e-14	0.44	0.38	Schizophrenia;	chr2:171923622	chr2:171773482~171775844:+
LUAD	cis	rs34779708	0.868	rs2384352	ENSG00000230534.5	RP11-297A16.2	8.92	9.43e-18	1.26e-14	0.46	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35203904	chr10:35098006~35127020:-
LUAD	cis	rs172166	0.61	rs276369	ENSG00000204709.4	LINC01556	8.92	9.46e-18	1.26e-14	0.45	0.38	Cardiac Troponin-T levels;	chr6:27951465	chr6:28943877~28944537:+
LUAD	cis	rs2337406	0.866	rs8003852	ENSG00000254174.1	IGHV1-12	8.92	9.55e-18	1.27e-14	0.34	0.38	Alzheimer's disease (late onset);	chr14:106776648	chr14:106122420~106122709:-
LUAD	cis	rs2337406	0.866	rs988131	ENSG00000254174.1	IGHV1-12	8.92	9.55e-18	1.27e-14	0.34	0.38	Alzheimer's disease (late onset);	chr14:106776833	chr14:106122420~106122709:-
LUAD	cis	rs2337406	0.866	rs8005518	ENSG00000254174.1	IGHV1-12	8.92	9.55e-18	1.27e-14	0.34	0.38	Alzheimer's disease (late onset);	chr14:106777009	chr14:106122420~106122709:-
LUAD	cis	rs2337406	0.866	rs57684263	ENSG00000254174.1	IGHV1-12	8.92	9.55e-18	1.27e-14	0.34	0.38	Alzheimer's disease (late onset);	chr14:106777263	chr14:106122420~106122709:-
LUAD	cis	rs2337406	0.866	rs7152809	ENSG00000254174.1	IGHV1-12	8.92	9.55e-18	1.27e-14	0.34	0.38	Alzheimer's disease (late onset);	chr14:106778385	chr14:106122420~106122709:-
LUAD	cis	rs2337406	0.866	rs7152832	ENSG00000254174.1	IGHV1-12	8.92	9.55e-18	1.27e-14	0.34	0.38	Alzheimer's disease (late onset);	chr14:106778427	chr14:106122420~106122709:-
LUAD	cis	rs2337406	0.5	rs7152934	ENSG00000254174.1	IGHV1-12	8.92	9.55e-18	1.27e-14	0.34	0.38	Alzheimer's disease (late onset);	chr14:106778702	chr14:106122420~106122709:-
LUAD	cis	rs2337406	0.789	rs12050392	ENSG00000254174.1	IGHV1-12	8.92	9.55e-18	1.27e-14	0.34	0.38	Alzheimer's disease (late onset);	chr14:106779073	chr14:106122420~106122709:-
LUAD	cis	rs2337406	0.866	rs74092505	ENSG00000254174.1	IGHV1-12	8.92	9.55e-18	1.27e-14	0.34	0.38	Alzheimer's disease (late onset);	chr14:106779163	chr14:106122420~106122709:-
LUAD	cis	rs2337406	0.789	rs74092507	ENSG00000254174.1	IGHV1-12	8.92	9.55e-18	1.27e-14	0.34	0.38	Alzheimer's disease (late onset);	chr14:106779174	chr14:106122420~106122709:-
LUAD	cis	rs2337406	0.866	rs74092511	ENSG00000254174.1	IGHV1-12	8.92	9.55e-18	1.27e-14	0.34	0.38	Alzheimer's disease (late onset);	chr14:106779234	chr14:106122420~106122709:-
LUAD	cis	rs11098499	0.754	rs10518300	ENSG00000245958.5	RP11-33B1.1	8.92	9.6e-18	1.28e-14	0.35	0.38	Corneal astigmatism;	chr4:119328344	chr4:119454791~119552025:+
LUAD	cis	rs6991838	0.612	rs7832407	ENSG00000272010.1	CTD-3025N20.3	8.92	9.63e-18	1.28e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.551	rs7007505	ENSG00000272010.1	CTD-3025N20.3	8.92	9.63e-18	1.28e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs7012856	ENSG00000272010.1	CTD-3025N20.3	8.92	9.63e-18	1.28e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.55	rs7817112	ENSG00000272010.1	CTD-3025N20.3	8.92	9.63e-18	1.28e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs2048650	ENSG00000272010.1	CTD-3025N20.3	8.92	9.63e-18	1.28e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs4737749	ENSG00000272010.1	CTD-3025N20.3	8.92	9.63e-18	1.28e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs10092109	ENSG00000272010.1	CTD-3025N20.3	8.92	9.63e-18	1.28e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs6997959	ENSG00000272010.1	CTD-3025N20.3	8.92	9.63e-18	1.28e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs7814841	ENSG00000272010.1	CTD-3025N20.3	8.92	9.63e-18	1.28e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs11985628	ENSG00000272010.1	CTD-3025N20.3	8.92	9.63e-18	1.28e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.557	rs13266834	ENSG00000272010.1	CTD-3025N20.3	8.92	9.63e-18	1.28e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs13268343	ENSG00000272010.1	CTD-3025N20.3	8.92	9.63e-18	1.28e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs7835313	ENSG00000272010.1	CTD-3025N20.3	8.92	9.63e-18	1.28e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs3812412	ENSG00000272010.1	CTD-3025N20.3	8.92	9.63e-18	1.28e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.53	rs6472217	ENSG00000272010.1	CTD-3025N20.3	8.92	9.63e-18	1.28e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs6472218	ENSG00000272010.1	CTD-3025N20.3	8.92	9.63e-18	1.28e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs1533285	ENSG00000272010.1	CTD-3025N20.3	8.92	9.63e-18	1.28e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65591850~65592472:-
LUAD	cis	rs3931020	0.745	rs1980851	ENSG00000272864.1	RP11-17E13.2	-8.92	9.67e-18	1.28e-14	-0.47	-0.38	Resistin levels;	chr1:74803287	chr1:74698769~74699333:-
LUAD	cis	rs7188445	0.932	rs17767742	ENSG00000261390.4	RP11-345M22.2	-8.92	9.74e-18	1.29e-14	-0.5	-0.38	Urate levels;	chr16:79715108	chr16:79715232~79770563:-
LUAD	cis	rs10256972	0.967	rs1881122	ENSG00000229043.2	AC091729.9	-8.92	9.74e-18	1.29e-14	-0.41	-0.38	Endometriosis;Longevity;	chr7:1001310	chr7:1160374~1165267:+
LUAD	cis	rs12594515	1	rs6493170	ENSG00000273972.1	CTD-2306A12.1	-8.92	9.81e-18	1.3e-14	-0.4	-0.38	Weight;Waist circumference;	chr15:45694821	chr15:45702640~45703183:+
LUAD	cis	rs2739330	0.685	rs4822453	ENSG00000099984.9	GSTT2	-8.92	9.83e-18	1.31e-14	-0.44	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23980123~23983911:+
LUAD	cis	rs526231	0.511	rs55810112	ENSG00000175749.11	EIF3KP1	8.92	9.84e-18	1.31e-14	0.54	0.38	Primary biliary cholangitis;	chr5:103026645	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.892	rs34830	ENSG00000175749.11	EIF3KP1	8.92	9.95e-18	1.32e-14	0.53	0.38	Parkinson's disease;	chr5:103108349	chr5:103032376~103033031:+
LUAD	cis	rs12468226	0.938	rs80282360	ENSG00000273456.1	RP11-686O6.2	8.92	1.01e-17	1.34e-14	0.61	0.38	Urate levels;	chr2:202275121	chr2:202374932~202375604:-
LUAD	cis	rs1185460	0.967	rs11217133	ENSG00000271751.1	RP11-110I1.14	-8.92	1.01e-17	1.34e-14	-0.47	-0.38	Coronary artery disease;	chr11:119057538	chr11:119065263~119065677:-
LUAD	cis	rs10262624	1	rs7792262	ENSG00000234286.1	AC006026.13	8.91	1.02e-17	1.35e-14	0.45	0.38	Schizophrenia;	chr7:23876124	chr7:23680195~23680786:-
LUAD	cis	rs26232	0.521	rs3776856	ENSG00000175749.11	EIF3KP1	8.91	1.03e-17	1.36e-14	0.54	0.38	Rheumatoid arthritis;	chr5:103023102	chr5:103032376~103033031:+
LUAD	cis	rs10129255	0.957	rs10136781	ENSG00000211970.3	IGHV4-61	-8.91	1.03e-17	1.37e-14	-0.28	-0.38	Kawasaki disease;	chr14:106780451	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.957	rs8022165	ENSG00000211970.3	IGHV4-61	-8.91	1.03e-17	1.37e-14	-0.28	-0.38	Kawasaki disease;	chr14:106781682	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.917	rs8022493	ENSG00000211970.3	IGHV4-61	-8.91	1.03e-17	1.37e-14	-0.28	-0.38	Kawasaki disease;	chr14:106781820	chr14:106639119~106639657:-
LUAD	cis	rs34779708	0.966	rs6481941	ENSG00000230534.5	RP11-297A16.2	8.91	1.03e-17	1.37e-14	0.44	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35151213	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs2505639	ENSG00000230534.5	RP11-297A16.2	-8.91	1.04e-17	1.37e-14	-0.44	-0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35185493	chr10:35098006~35127020:-
LUAD	cis	rs9399137	0.507	rs4594969	ENSG00000232876.1	CTA-212D2.2	-8.91	1.04e-17	1.38e-14	-0.44	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134964448	chr6:135055033~135060550:+
LUAD	cis	rs8040855	0.603	rs10520585	ENSG00000259295.5	CSPG4P12	-8.91	1.04e-17	1.38e-14	-0.52	-0.38	Bulimia nervosa;	chr15:85118275	chr15:85191438~85213905:+
LUAD	cis	rs1150668	0.799	rs9301	ENSG00000204709.4	LINC01556	8.91	1.05e-17	1.39e-14	0.47	0.38	Pubertal anthropometrics;	chr6:28324929	chr6:28943877~28944537:+
LUAD	cis	rs67383717	0.527	rs10760718	ENSG00000175611.10	LINC00476	8.91	1.05e-17	1.39e-14	0.39	0.38	Parkinson's disease (pesticide exposure interaction);	chr9:96032397	chr9:95759231~95875977:-
LUAD	cis	rs10129255	0.957	rs8009638	ENSG00000223648.3	IGHV3-64	8.91	1.05e-17	1.39e-14	0.37	0.38	Kawasaki disease;	chr14:106777570	chr14:106643132~106658258:-
LUAD	cis	rs526231	0.511	rs1011453	ENSG00000175749.11	EIF3KP1	8.91	1.05e-17	1.39e-14	0.53	0.38	Primary biliary cholangitis;	chr5:103032323	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.511	rs62362558	ENSG00000175749.11	EIF3KP1	8.91	1.05e-17	1.39e-14	0.53	0.38	Primary biliary cholangitis;	chr5:103032789	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.511	rs4421079	ENSG00000175749.11	EIF3KP1	8.91	1.05e-17	1.39e-14	0.53	0.38	Primary biliary cholangitis;	chr5:103033372	chr5:103032376~103033031:+
LUAD	cis	rs3823536	0.583	rs10236569	ENSG00000275106.1	RP11-309L24.10	-8.91	1.05e-17	1.39e-14	-0.48	-0.38	Sjögren's syndrome;	chr7:128957533	chr7:128952527~128953316:-
LUAD	cis	rs11098499	0.644	rs10009566	ENSG00000245958.5	RP11-33B1.1	-8.91	1.05e-17	1.39e-14	-0.34	-0.38	Corneal astigmatism;	chr4:119637453	chr4:119454791~119552025:+
LUAD	cis	rs12468226	0.873	rs6435138	ENSG00000273456.1	RP11-686O6.2	-8.91	1.06e-17	1.41e-14	-0.58	-0.38	Urate levels;	chr2:202234310	chr2:202374932~202375604:-
LUAD	cis	rs10875746	0.729	rs11168355	ENSG00000240399.1	RP1-228P16.1	8.91	1.06e-17	1.41e-14	0.43	0.38	Longevity (90 years and older);	chr12:48017195	chr12:48054813~48055591:-
LUAD	cis	rs7429990	0.965	rs7430913	ENSG00000229759.1	MRPS18AP1	-8.91	1.07e-17	1.42e-14	-0.39	-0.38	Educational attainment (years of education);	chr3:47990867	chr3:48256350~48256938:-
LUAD	cis	rs7924176	0.564	rs12572820	ENSG00000213731.2	RAB5CP1	-8.91	1.08e-17	1.43e-14	-0.4	-0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74117387	chr10:74423435~74424014:-
LUAD	cis	rs9399137	0.507	rs4451150	ENSG00000232876.1	CTA-212D2.2	-8.91	1.09e-17	1.44e-14	-0.43	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957925	chr6:135055033~135060550:+
LUAD	cis	rs12468226	0.938	rs116109808	ENSG00000273456.1	RP11-686O6.2	8.91	1.09e-17	1.44e-14	0.6	0.38	Urate levels;	chr2:202287356	chr2:202374932~202375604:-
LUAD	cis	rs12468226	0.873	rs78175596	ENSG00000273456.1	RP11-686O6.2	8.91	1.09e-17	1.44e-14	0.6	0.38	Urate levels;	chr2:202287993	chr2:202374932~202375604:-
LUAD	cis	rs12468226	0.938	rs74454549	ENSG00000273456.1	RP11-686O6.2	8.91	1.09e-17	1.44e-14	0.6	0.38	Urate levels;	chr2:202288044	chr2:202374932~202375604:-
LUAD	cis	rs9326248	0.861	rs7120309	ENSG00000280143.1	AP000892.6	8.9	1.1e-17	1.45e-14	0.5	0.38	Blood protein levels;	chr11:117172100	chr11:117204967~117210292:+
LUAD	cis	rs9326248	0.861	rs7120449	ENSG00000280143.1	AP000892.6	8.9	1.1e-17	1.45e-14	0.5	0.38	Blood protein levels;	chr11:117172183	chr11:117204967~117210292:+
LUAD	cis	rs7174755	0.637	rs113002386	ENSG00000260657.2	RP11-315D16.4	8.9	1.1e-17	1.45e-14	0.45	0.38	Major depressive disorder;	chr15:68172375	chr15:68267792~68277994:-
LUAD	cis	rs1150688	1	rs1150688	ENSG00000204709.4	LINC01556	8.9	1.11e-17	1.46e-14	0.47	0.38	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28943877~28944537:+
LUAD	cis	rs4423214	0.592	rs10898223	ENSG00000254682.1	RP11-660L16.2	-8.9	1.13e-17	1.49e-14	-0.58	-0.38	Vitamin D levels;	chr11:71508218	chr11:71448674~71452157:+
LUAD	cis	rs2739330	0.731	rs5751792	ENSG00000228039.3	KB-1125A3.10	8.9	1.13e-17	1.49e-14	0.45	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23963780~23964374:+
LUAD	cis	rs6142102	0.58	rs9753679	ENSG00000276073.1	RP5-1125A11.7	-8.9	1.13e-17	1.49e-14	-0.38	-0.38	Skin pigmentation;	chr20:33953054	chr20:33985617~33988989:-
LUAD	cis	rs4927850	1	rs10881563	ENSG00000231464.1	AC024937.4	8.9	1.14e-17	1.5e-14	0.45	0.38	Pancreatic cancer;	chr3:196023354	chr3:195996738~195998233:+
LUAD	cis	rs733592	0.507	rs7138917	ENSG00000240399.1	RP1-228P16.1	-8.9	1.14e-17	1.51e-14	-0.36	-0.38	Plateletcrit;	chr12:48061472	chr12:48054813~48055591:-
LUAD	cis	rs7429990	0.932	rs11130155	ENSG00000229759.1	MRPS18AP1	-8.9	1.14e-17	1.51e-14	-0.38	-0.38	Educational attainment (years of education);	chr3:48098938	chr3:48256350~48256938:-
LUAD	cis	rs526231	0.543	rs34804	ENSG00000175749.11	EIF3KP1	8.9	1.15e-17	1.51e-14	0.56	0.38	Primary biliary cholangitis;	chr5:103092535	chr5:103032376~103033031:+
LUAD	cis	rs8040855	0.52	rs67613323	ENSG00000259295.5	CSPG4P12	8.9	1.15e-17	1.52e-14	0.52	0.38	Bulimia nervosa;	chr15:84986541	chr15:85191438~85213905:+
LUAD	cis	rs8040855	0.52	rs11629962	ENSG00000259295.5	CSPG4P12	8.9	1.15e-17	1.52e-14	0.52	0.38	Bulimia nervosa;	chr15:84986797	chr15:85191438~85213905:+
LUAD	cis	rs6991838	0.584	rs7841652	ENSG00000272010.1	CTD-3025N20.3	-8.9	1.15e-17	1.52e-14	-0.41	-0.38	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65591850~65592472:-
LUAD	cis	rs11690935	0.885	rs7602037	ENSG00000228389.1	AC068039.4	8.9	1.16e-17	1.52e-14	0.43	0.38	Schizophrenia;	chr2:171961268	chr2:171773482~171775844:+
LUAD	cis	rs12468226	0.938	rs77062060	ENSG00000273456.1	RP11-686O6.2	8.9	1.17e-17	1.54e-14	0.6	0.38	Urate levels;	chr2:202285639	chr2:202374932~202375604:-
LUAD	cis	rs4423214	0.592	rs11233933	ENSG00000254682.1	RP11-660L16.2	-8.9	1.18e-17	1.55e-14	-0.58	-0.38	Vitamin D levels;	chr11:71499024	chr11:71448674~71452157:+
LUAD	cis	rs34779708	0.966	rs4934735	ENSG00000230534.5	RP11-297A16.2	-8.89	1.19e-17	1.57e-14	-0.45	-0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35207802	chr10:35098006~35127020:-
LUAD	cis	rs9399137	0.507	rs4580893	ENSG00000232876.1	CTA-212D2.2	-8.89	1.19e-17	1.57e-14	-0.44	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134976524	chr6:135055033~135060550:+
LUAD	cis	rs9326248	0.861	rs4938348	ENSG00000280143.1	AP000892.6	8.89	1.2e-17	1.58e-14	0.51	0.38	Blood protein levels;	chr11:117151161	chr11:117204967~117210292:+
LUAD	cis	rs12134133	1	rs28371597	ENSG00000274245.1	RP11-357P18.2	8.89	1.2e-17	1.58e-14	0.51	0.38	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207323551	chr1:207372559~207373252:+
LUAD	cis	rs12468226	0.938	rs116601501	ENSG00000273456.1	RP11-686O6.2	8.89	1.21e-17	1.59e-14	0.6	0.38	Urate levels;	chr2:202274567	chr2:202374932~202375604:-
LUAD	cis	rs12468226	0.938	rs76658848	ENSG00000273456.1	RP11-686O6.2	8.89	1.21e-17	1.59e-14	0.6	0.38	Urate levels;	chr2:202275548	chr2:202374932~202375604:-
LUAD	cis	rs12468226	0.938	rs57571703	ENSG00000273456.1	RP11-686O6.2	8.89	1.21e-17	1.59e-14	0.6	0.38	Urate levels;	chr2:202281997	chr2:202374932~202375604:-
LUAD	cis	rs12468226	0.938	rs78928733	ENSG00000273456.1	RP11-686O6.2	8.89	1.21e-17	1.59e-14	0.6	0.38	Urate levels;	chr2:202283787	chr2:202374932~202375604:-
LUAD	cis	rs2739330	0.731	rs5751792	ENSG00000099984.9	GSTT2	-8.89	1.22e-17	1.61e-14	-0.45	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23980123~23983911:+
LUAD	cis	rs12468226	0.873	rs6761131	ENSG00000273456.1	RP11-686O6.2	-8.89	1.23e-17	1.61e-14	-0.58	-0.38	Urate levels;	chr2:202237675	chr2:202374932~202375604:-
LUAD	cis	rs7044106	0.537	rs10739573	ENSG00000226752.6	PSMD5-AS1	-8.89	1.23e-17	1.62e-14	-0.46	-0.38	Hip circumference adjusted for BMI;	chr9:120727540	chr9:120824828~120854385:+
LUAD	cis	rs9322193	0.651	rs9322188	ENSG00000216906.2	RP11-350J20.9	-8.89	1.23e-17	1.62e-14	-0.45	-0.38	Lung cancer;	chr6:149588355	chr6:149904243~149906418:+
LUAD	cis	rs3823536	0.583	rs10954214	ENSG00000275106.1	RP11-309L24.10	-8.89	1.24e-17	1.62e-14	-0.48	-0.38	Sjögren's syndrome;	chr7:128949579	chr7:128952527~128953316:-
LUAD	cis	rs3823536	0.505	rs3925323	ENSG00000275106.1	RP11-309L24.10	-8.89	1.24e-17	1.62e-14	-0.48	-0.38	Sjögren's syndrome;	chr7:128952187	chr7:128952527~128953316:-
LUAD	cis	rs6991838	0.53	rs35038843	ENSG00000272010.1	CTD-3025N20.3	-8.89	1.26e-17	1.66e-14	-0.41	-0.38	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs4737748	ENSG00000272010.1	CTD-3025N20.3	8.89	1.26e-17	1.66e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.55	rs12335006	ENSG00000272010.1	CTD-3025N20.3	8.89	1.26e-17	1.66e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs10957361	ENSG00000272010.1	CTD-3025N20.3	8.89	1.26e-17	1.66e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.612	rs12335276	ENSG00000272010.1	CTD-3025N20.3	8.89	1.26e-17	1.66e-14	0.41	0.38	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65591850~65592472:-
LUAD	cis	rs34779708	0.931	rs4934711	ENSG00000230534.5	RP11-297A16.2	8.89	1.26e-17	1.66e-14	0.45	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35071382	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs13376871	ENSG00000230534.5	RP11-297A16.2	8.89	1.26e-17	1.66e-14	0.45	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35080128	chr10:35098006~35127020:-
LUAD	cis	rs12468226	0.817	rs6722588	ENSG00000273456.1	RP11-686O6.2	-8.89	1.27e-17	1.66e-14	-0.58	-0.38	Urate levels;	chr2:202187163	chr2:202374932~202375604:-
LUAD	cis	rs904251	0.802	rs2646933	ENSG00000204110.6	RP1-153P14.8	-8.89	1.28e-17	1.68e-14	-0.43	-0.38	Cognitive performance;	chr6:37434294	chr6:37507348~37535616:+
LUAD	cis	rs904251	1	rs12212090	ENSG00000204110.6	RP1-153P14.8	-8.88	1.28e-17	1.68e-14	-0.39	-0.38	Cognitive performance;	chr6:37464032	chr6:37507348~37535616:+
LUAD	cis	rs4423214	0.592	rs3829251	ENSG00000254682.1	RP11-660L16.2	-8.88	1.29e-17	1.69e-14	-0.58	-0.38	Vitamin D levels;	chr11:71483513	chr11:71448674~71452157:+
LUAD	cis	rs9399137	0.507	rs4289677	ENSG00000232876.1	CTA-212D2.2	-8.88	1.3e-17	1.7e-14	-0.43	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954347	chr6:135055033~135060550:+
LUAD	cis	rs2337406	0.866	rs988130	ENSG00000254174.1	IGHV1-12	8.88	1.3e-17	1.7e-14	0.33	0.38	Alzheimer's disease (late onset);	chr14:106777154	chr14:106122420~106122709:-
LUAD	cis	rs10129255	0.744	rs28517388	ENSG00000211970.3	IGHV4-61	-8.88	1.31e-17	1.72e-14	-0.3	-0.38	Kawasaki disease;	chr14:106704323	chr14:106639119~106639657:-
LUAD	cis	rs7188445	1	rs11150189	ENSG00000261390.4	RP11-345M22.2	-8.88	1.32e-17	1.73e-14	-0.49	-0.38	Urate levels;	chr16:79700330	chr16:79715232~79770563:-
LUAD	cis	rs10262624	1	rs17347505	ENSG00000234286.1	AC006026.13	-8.88	1.33e-17	1.74e-14	-0.45	-0.38	Schizophrenia;	chr7:23875664	chr7:23680195~23680786:-
LUAD	cis	rs10262624	1	rs12671584	ENSG00000234286.1	AC006026.13	-8.88	1.33e-17	1.74e-14	-0.45	-0.38	Schizophrenia;	chr7:23875803	chr7:23680195~23680786:-
LUAD	cis	rs12134133	1	rs28371583	ENSG00000274245.1	RP11-357P18.2	8.88	1.33e-17	1.75e-14	0.5	0.38	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207321334	chr1:207372559~207373252:+
LUAD	cis	rs526231	0.511	rs55896090	ENSG00000175749.11	EIF3KP1	8.88	1.34e-17	1.76e-14	0.53	0.38	Primary biliary cholangitis;	chr5:103026300	chr5:103032376~103033031:+
LUAD	cis	rs11098499	0.739	rs6534130	ENSG00000245958.5	RP11-33B1.1	8.87	1.4e-17	1.83e-14	0.35	0.38	Corneal astigmatism;	chr4:119210184	chr4:119454791~119552025:+
LUAD	cis	rs732716	0.719	rs56088814	ENSG00000267769.1	CTB-50L17.9	-8.87	1.44e-17	1.88e-14	-0.41	-0.37	Mean corpuscular volume;	chr19:4422181	chr19:4454014~4455286:+
LUAD	cis	rs11098499	0.691	rs12510133	ENSG00000245958.5	RP11-33B1.1	-8.87	1.44e-17	1.89e-14	-0.32	-0.37	Corneal astigmatism;	chr4:119350189	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs12506487	ENSG00000245958.5	RP11-33B1.1	-8.87	1.44e-17	1.89e-14	-0.32	-0.37	Corneal astigmatism;	chr4:119350206	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.691	rs12502524	ENSG00000245958.5	RP11-33B1.1	-8.87	1.44e-17	1.89e-14	-0.32	-0.37	Corneal astigmatism;	chr4:119350259	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.691	rs28396837	ENSG00000245958.5	RP11-33B1.1	-8.87	1.44e-17	1.89e-14	-0.32	-0.37	Corneal astigmatism;	chr4:119350386	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.629	rs28369518	ENSG00000245958.5	RP11-33B1.1	-8.87	1.44e-17	1.89e-14	-0.32	-0.37	Corneal astigmatism;	chr4:119350475	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.722	rs10025925	ENSG00000245958.5	RP11-33B1.1	-8.87	1.44e-17	1.89e-14	-0.32	-0.37	Corneal astigmatism;	chr4:119350589	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.731	rs10015579	ENSG00000245958.5	RP11-33B1.1	-8.87	1.44e-17	1.89e-14	-0.32	-0.37	Corneal astigmatism;	chr4:119350647	chr4:119454791~119552025:+
LUAD	cis	rs172166	0.538	rs149956	ENSG00000204709.4	LINC01556	8.87	1.45e-17	1.89e-14	0.46	0.37	Cardiac Troponin-T levels;	chr6:28068473	chr6:28943877~28944537:+
LUAD	cis	rs10463554	0.927	rs257316	ENSG00000175749.11	EIF3KP1	-8.87	1.46e-17	1.9e-14	-0.51	-0.37	Parkinson's disease;	chr5:103086739	chr5:103032376~103033031:+
LUAD	cis	rs9399137	0.507	rs7745289	ENSG00000232876.1	CTA-212D2.2	-8.87	1.48e-17	1.93e-14	-0.44	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135059189	chr6:135055033~135060550:+
LUAD	cis	rs9399137	0.507	rs11759062	ENSG00000232876.1	CTA-212D2.2	-8.87	1.48e-17	1.93e-14	-0.44	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060110	chr6:135055033~135060550:+
LUAD	cis	rs9399137	0.507	rs11759077	ENSG00000232876.1	CTA-212D2.2	-8.87	1.48e-17	1.93e-14	-0.44	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060213	chr6:135055033~135060550:+
LUAD	cis	rs2188561	1	rs2712208	ENSG00000241764.3	AC002467.7	8.87	1.49e-17	1.94e-14	0.55	0.37	Alcohol consumption;	chr7:107703317	chr7:107742817~107744581:-
LUAD	cis	rs526231	0.511	rs7731395	ENSG00000175749.11	EIF3KP1	8.87	1.49e-17	1.94e-14	0.52	0.37	Primary biliary cholangitis;	chr5:103026057	chr5:103032376~103033031:+
LUAD	cis	rs1789	0.592	rs1558572	ENSG00000273133.1	RP11-799M12.2	-8.86	1.5e-17	1.95e-14	-0.56	-0.37	Blood protein levels;	chr4:15537121	chr4:15563698~15564253:-
LUAD	cis	rs10129255	0.957	rs2007467	ENSG00000223648.3	IGHV3-64	-8.86	1.5e-17	1.96e-14	-0.38	-0.37	Kawasaki disease;	chr14:106771605	chr14:106643132~106658258:-
LUAD	cis	rs10463554	0.857	rs34376	ENSG00000175749.11	EIF3KP1	8.86	1.5e-17	1.96e-14	0.52	0.37	Parkinson's disease;	chr5:103065409	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs34375	ENSG00000175749.11	EIF3KP1	8.86	1.5e-17	1.96e-14	0.52	0.37	Parkinson's disease;	chr5:103065419	chr5:103032376~103033031:+
LUAD	cis	rs11098499	0.874	rs13139045	ENSG00000245958.5	RP11-33B1.1	-8.86	1.52e-17	1.98e-14	-0.32	-0.37	Corneal astigmatism;	chr4:119247433	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.754	rs1849457	ENSG00000245958.5	RP11-33B1.1	-8.86	1.53e-17	1.99e-14	-0.35	-0.37	Corneal astigmatism;	chr4:119333200	chr4:119454791~119552025:+
LUAD	cis	rs3823536	0.583	rs2280714	ENSG00000275106.1	RP11-309L24.10	-8.86	1.53e-17	1.99e-14	-0.47	-0.37	Sjögren's syndrome;	chr7:128954671	chr7:128952527~128953316:-
LUAD	cis	rs9399137	0.507	rs4520025	ENSG00000232876.1	CTA-212D2.2	-8.86	1.53e-17	1.99e-14	-0.43	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957481	chr6:135055033~135060550:+
LUAD	cis	rs6991838	0.584	rs14213	ENSG00000272010.1	CTD-3025N20.3	8.86	1.53e-17	1.99e-14	0.41	0.37	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65591850~65592472:-
LUAD	cis	rs4888378	0.535	rs9319483	ENSG00000261783.1	RP11-252K23.2	8.86	1.53e-17	1.99e-14	0.53	0.37	Coronary artery disease;	chr16:75311893	chr16:75379818~75381260:-
LUAD	cis	rs7174755	0.608	rs62004789	ENSG00000260657.2	RP11-315D16.4	8.86	1.54e-17	2e-14	0.45	0.37	Major depressive disorder;	chr15:68148268	chr15:68267792~68277994:-
LUAD	cis	rs34779708	0.966	rs57081218	ENSG00000230534.5	RP11-297A16.2	8.86	1.54e-17	2.01e-14	0.44	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35145680	chr10:35098006~35127020:-
LUAD	cis	rs1150668	0.799	rs853684	ENSG00000204709.4	LINC01556	8.86	1.55e-17	2.02e-14	0.47	0.37	Pubertal anthropometrics;	chr6:28326773	chr6:28943877~28944537:+
LUAD	cis	rs4423214	0.592	rs78300366	ENSG00000254682.1	RP11-660L16.2	-8.86	1.57e-17	2.04e-14	-0.59	-0.37	Vitamin D levels;	chr11:71494468	chr11:71448674~71452157:+
LUAD	cis	rs10129255	0.913	rs10140943	ENSG00000223648.3	IGHV3-64	8.86	1.57e-17	2.04e-14	0.38	0.37	Kawasaki disease;	chr14:106767441	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.536	rs3944157	ENSG00000280411.1	IGHV1-69-2	-8.86	1.57e-17	2.04e-14	-0.26	-0.37	Kawasaki disease;	chr14:106682286	chr14:106762092~106762588:-
LUAD	cis	rs7429990	0.965	rs7427418	ENSG00000229759.1	MRPS18AP1	-8.86	1.59e-17	2.06e-14	-0.39	-0.37	Educational attainment (years of education);	chr3:47981217	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.965	rs13074973	ENSG00000229759.1	MRPS18AP1	-8.86	1.59e-17	2.06e-14	-0.39	-0.37	Educational attainment (years of education);	chr3:47986654	chr3:48256350~48256938:-
LUAD	cis	rs11214589	0.747	rs11214582	ENSG00000270179.1	RP11-159N11.4	-8.86	1.6e-17	2.08e-14	-0.38	-0.37	Neuroticism;	chr11:113347328	chr11:113368478~113369117:+
LUAD	cis	rs10463554	0.963	rs257319	ENSG00000175749.11	EIF3KP1	8.86	1.6e-17	2.08e-14	0.53	0.37	Parkinson's disease;	chr5:103110123	chr5:103032376~103033031:+
LUAD	cis	rs10129255	0.957	rs1024349	ENSG00000211970.3	IGHV4-61	-8.86	1.61e-17	2.09e-14	-0.29	-0.37	Kawasaki disease;	chr14:106689997	chr14:106639119~106639657:-
LUAD	cis	rs7188445	0.932	rs7203756	ENSG00000261390.4	RP11-345M22.2	8.86	1.61e-17	2.09e-14	0.49	0.37	Urate levels;	chr16:79711709	chr16:79715232~79770563:-
LUAD	cis	rs9545047	0.716	rs943710	ENSG00000227676.3	LINC01068	8.85	1.62e-17	2.1e-14	0.46	0.37	Schizophrenia;	chr13:79282987	chr13:79566727~79571436:+
LUAD	cis	rs10875746	0.68	rs4760610	ENSG00000240399.1	RP1-228P16.1	-8.85	1.62e-17	2.11e-14	-0.45	-0.37	Longevity (90 years and older);	chr12:48024442	chr12:48054813~48055591:-
LUAD	cis	rs7188445	0.932	rs73575083	ENSG00000261390.4	RP11-345M22.2	-8.85	1.62e-17	2.11e-14	-0.49	-0.37	Urate levels;	chr16:79713958	chr16:79715232~79770563:-
LUAD	cis	rs7188445	0.932	rs73575085	ENSG00000261390.4	RP11-345M22.2	-8.85	1.62e-17	2.11e-14	-0.49	-0.37	Urate levels;	chr16:79714179	chr16:79715232~79770563:-
LUAD	cis	rs172166	0.516	rs1225715	ENSG00000216901.1	AL022393.7	-8.85	1.63e-17	2.11e-14	-0.44	-0.37	Cardiac Troponin-T levels;	chr6:28145595	chr6:28176188~28176674:+
LUAD	cis	rs34779708	0.966	rs12761675	ENSG00000230534.5	RP11-297A16.2	-8.85	1.64e-17	2.13e-14	-0.45	-0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35149409	chr10:35098006~35127020:-
LUAD	cis	rs7924176	0.58	rs7912162	ENSG00000213731.2	RAB5CP1	-8.85	1.65e-17	2.14e-14	-0.4	-0.37	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74162005	chr10:74423435~74424014:-
LUAD	cis	rs56046484	0.871	rs7177110	ENSG00000259295.5	CSPG4P12	8.85	1.66e-17	2.15e-14	0.53	0.37	Testicular germ cell tumor;	chr15:85128524	chr15:85191438~85213905:+
LUAD	cis	rs10262624	1	rs10257777	ENSG00000234286.1	AC006026.13	-8.85	1.66e-17	2.15e-14	-0.44	-0.37	Schizophrenia;	chr7:23871362	chr7:23680195~23680786:-
LUAD	cis	rs11214589	0.747	rs10891536	ENSG00000270179.1	RP11-159N11.4	-8.85	1.66e-17	2.16e-14	-0.37	-0.37	Neuroticism;	chr11:113338706	chr11:113368478~113369117:+
LUAD	cis	rs673078	0.607	rs7305647	ENSG00000275759.1	RP11-131L12.3	-8.85	1.67e-17	2.16e-14	-0.53	-0.37	Glucose homeostasis traits;	chr12:118417761	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs61943444	ENSG00000275759.1	RP11-131L12.3	-8.85	1.67e-17	2.16e-14	-0.53	-0.37	Glucose homeostasis traits;	chr12:118421641	chr12:118428281~118428870:+
LUAD	cis	rs2739330	0.791	rs4822458	ENSG00000099984.9	GSTT2	-8.85	1.68e-17	2.18e-14	-0.44	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23980123~23983911:+
LUAD	cis	rs1150668	0.835	rs203869	ENSG00000204709.4	LINC01556	8.85	1.69e-17	2.19e-14	0.46	0.37	Pubertal anthropometrics;	chr6:28073041	chr6:28943877~28944537:+
LUAD	cis	rs9532669	0.926	rs9525418	ENSG00000176268.5	CYCSP34	-8.85	1.69e-17	2.19e-14	-0.36	-0.37	Cervical cancer;	chr13:40879081	chr13:40863599~40863902:-
LUAD	cis	rs7429990	0.932	rs7630685	ENSG00000229759.1	MRPS18AP1	-8.85	1.69e-17	2.19e-14	-0.4	-0.37	Educational attainment (years of education);	chr3:48089680	chr3:48256350~48256938:-
LUAD	cis	rs11098499	0.739	rs9884728	ENSG00000245958.5	RP11-33B1.1	8.85	1.69e-17	2.19e-14	0.34	0.37	Corneal astigmatism;	chr4:119205924	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.739	rs2203039	ENSG00000245958.5	RP11-33B1.1	8.85	1.69e-17	2.19e-14	0.34	0.37	Corneal astigmatism;	chr4:119211192	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.739	rs7441137	ENSG00000245958.5	RP11-33B1.1	8.85	1.69e-17	2.19e-14	0.34	0.37	Corneal astigmatism;	chr4:119212066	chr4:119454791~119552025:+
LUAD	cis	rs10129255	1	rs10141557	ENSG00000223648.3	IGHV3-64	8.85	1.69e-17	2.19e-14	0.38	0.37	Kawasaki disease;	chr14:106767990	chr14:106643132~106658258:-
LUAD	cis	rs13423976	0.663	rs7559097	ENSG00000231367.4	AC016995.3	-8.85	1.7e-17	2.2e-14	-0.47	-0.37	Gut microbiome composition (summer);	chr2:38517625	chr2:38406719~38515740:-
LUAD	cis	rs9545047	0.716	rs9545053	ENSG00000227676.3	LINC01068	8.85	1.71e-17	2.21e-14	0.46	0.37	Schizophrenia;	chr13:79296079	chr13:79566727~79571436:+
LUAD	cis	rs10463554	0.963	rs67068617	ENSG00000175749.11	EIF3KP1	8.85	1.71e-17	2.21e-14	0.52	0.37	Parkinson's disease;	chr5:103039977	chr5:103032376~103033031:+
LUAD	cis	rs9545047	0.645	rs9635027	ENSG00000227676.3	LINC01068	8.85	1.72e-17	2.23e-14	0.46	0.37	Schizophrenia;	chr13:79295538	chr13:79566727~79571436:+
LUAD	cis	rs944289	0.706	rs11156904	ENSG00000257826.1	RP11-116N8.4	-8.85	1.73e-17	2.24e-14	-0.39	-0.37	Thyroid cancer;	chr14:36085688	chr14:36061026~36067190:-
LUAD	cis	rs526231	0.511	rs17155009	ENSG00000175749.11	EIF3KP1	8.85	1.74e-17	2.25e-14	0.52	0.37	Primary biliary cholangitis;	chr5:103038440	chr5:103032376~103033031:+
LUAD	cis	rs26232	0.521	rs67019105	ENSG00000175749.11	EIF3KP1	8.85	1.74e-17	2.25e-14	0.52	0.37	Rheumatoid arthritis;	chr5:103038459	chr5:103032376~103033031:+
LUAD	cis	rs26232	0.583	rs26430	ENSG00000175749.11	EIF3KP1	-8.84	1.75e-17	2.26e-14	-0.51	-0.37	Rheumatoid arthritis;	chr5:103030228	chr5:103032376~103033031:+
LUAD	cis	rs7924176	0.564	rs12569971	ENSG00000213731.2	RAB5CP1	-8.84	1.76e-17	2.27e-14	-0.4	-0.37	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74194617	chr10:74423435~74424014:-
LUAD	cis	rs6964833	0.873	rs4717905	ENSG00000277053.3	GTF2IP1	-8.84	1.76e-17	2.27e-14	-0.53	-0.37	Menarche (age at onset);	chr7:74668903	chr7:75185385~75237696:-
LUAD	cis	rs7044106	0.718	rs10616	ENSG00000226752.6	PSMD5-AS1	-8.84	1.76e-17	2.28e-14	-0.41	-0.37	Hip circumference adjusted for BMI;	chr9:120601255	chr9:120824828~120854385:+
LUAD	cis	rs904251	0.6	rs9380673	ENSG00000204110.6	RP1-153P14.8	-8.84	1.76e-17	2.28e-14	-0.38	-0.37	Cognitive performance;	chr6:37447349	chr6:37507348~37535616:+
LUAD	cis	rs673078	0.607	rs73207504	ENSG00000275759.1	RP11-131L12.3	-8.84	1.77e-17	2.29e-14	-0.53	-0.37	Glucose homeostasis traits;	chr12:118427914	chr12:118428281~118428870:+
LUAD	cis	rs1150668	0.768	rs1150716	ENSG00000204709.4	LINC01556	8.84	1.78e-17	2.31e-14	0.46	0.37	Pubertal anthropometrics;	chr6:28294921	chr6:28943877~28944537:+
LUAD	cis	rs12468226	0.817	rs2350360	ENSG00000273456.1	RP11-686O6.2	-8.84	1.78e-17	2.31e-14	-0.58	-0.37	Urate levels;	chr2:202222980	chr2:202374932~202375604:-
LUAD	cis	rs3931020	0.745	rs10874274	ENSG00000272864.1	RP11-17E13.2	-8.84	1.8e-17	2.32e-14	-0.45	-0.37	Resistin levels;	chr1:74786450	chr1:74698769~74699333:-
LUAD	cis	rs6991838	0.584	rs4737747	ENSG00000272010.1	CTD-3025N20.3	-8.84	1.81e-17	2.34e-14	-0.41	-0.37	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65591850~65592472:-
LUAD	cis	rs2739330	0.761	rs5760176	ENSG00000099984.9	GSTT2	8.84	1.82e-17	2.35e-14	0.44	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23980123~23983911:+
LUAD	cis	rs2739330	0.732	rs5760175	ENSG00000228039.3	KB-1125A3.10	8.84	1.85e-17	2.39e-14	0.46	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23963780~23964374:+
LUAD	cis	rs12468226	1	rs7597469	ENSG00000273456.1	RP11-686O6.2	8.84	1.85e-17	2.39e-14	0.59	0.37	Urate levels;	chr2:202329547	chr2:202374932~202375604:-
LUAD	cis	rs1789	0.592	rs1125378	ENSG00000273133.1	RP11-799M12.2	-8.84	1.86e-17	2.4e-14	-0.56	-0.37	Blood protein levels;	chr4:15538867	chr4:15563698~15564253:-
LUAD	cis	rs11098499	0.675	rs11098534	ENSG00000245958.5	RP11-33B1.1	-8.84	1.86e-17	2.4e-14	-0.34	-0.37	Corneal astigmatism;	chr4:119635617	chr4:119454791~119552025:+
LUAD	cis	rs7188445	0.836	rs3813580	ENSG00000261390.4	RP11-345M22.2	-8.84	1.87e-17	2.41e-14	-0.49	-0.37	Urate levels;	chr16:79715383	chr16:79715232~79770563:-
LUAD	cis	rs1185460	0.967	rs2509121	ENSG00000271751.1	RP11-110I1.14	-8.84	1.87e-17	2.41e-14	-0.46	-0.37	Coronary artery disease;	chr11:119057542	chr11:119065263~119065677:-
LUAD	cis	rs34779708	0.931	rs4934731	ENSG00000230534.5	RP11-297A16.2	8.84	1.87e-17	2.41e-14	0.44	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35142708	chr10:35098006~35127020:-
LUAD	cis	rs2108622	0.727	rs7251296	ENSG00000267453.5	AC004791.2	-8.83	1.89e-17	2.44e-14	-0.44	-0.37	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872926	chr19:15851993~15864904:-
LUAD	cis	rs11096990	0.634	rs2381372	ENSG00000249207.1	RP11-360F5.1	-8.83	1.89e-17	2.44e-14	-0.41	-0.37	Cognitive function;	chr4:39271471	chr4:39112677~39126818:-
LUAD	cis	rs1150668	0.83	rs213240	ENSG00000204709.4	LINC01556	8.83	1.89e-17	2.44e-14	0.46	0.37	Pubertal anthropometrics;	chr6:28348098	chr6:28943877~28944537:+
LUAD	cis	rs733592	0.894	rs886589	ENSG00000240399.1	RP1-228P16.1	-8.83	1.9e-17	2.45e-14	-0.36	-0.37	Plateletcrit;	chr12:48083414	chr12:48054813~48055591:-
LUAD	cis	rs9326248	0.689	rs4516002	ENSG00000280143.1	AP000892.6	8.83	1.91e-17	2.47e-14	0.54	0.37	Blood protein levels;	chr11:117128343	chr11:117204967~117210292:+
LUAD	cis	rs1150668	0.799	rs853684	ENSG00000216901.1	AL022393.7	8.83	1.92e-17	2.47e-14	0.44	0.37	Pubertal anthropometrics;	chr6:28326773	chr6:28176188~28176674:+
LUAD	cis	rs11098499	0.644	rs34835603	ENSG00000245958.5	RP11-33B1.1	-8.83	1.92e-17	2.47e-14	-0.34	-0.37	Corneal astigmatism;	chr4:119632273	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.615	rs28850368	ENSG00000245958.5	RP11-33B1.1	-8.83	1.92e-17	2.47e-14	-0.34	-0.37	Corneal astigmatism;	chr4:119633158	chr4:119454791~119552025:+
LUAD	cis	rs507080	0.501	rs626645	ENSG00000255239.1	AP002954.6	8.83	1.94e-17	2.5e-14	0.43	0.37	Serum metabolite levels;	chr11:118704471	chr11:118688039~118690600:-
LUAD	cis	rs7429990	0.965	rs35199727	ENSG00000229759.1	MRPS18AP1	8.83	1.94e-17	2.5e-14	0.4	0.37	Educational attainment (years of education);	chr3:47905218	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.965	rs13075795	ENSG00000229759.1	MRPS18AP1	-8.83	1.94e-17	2.5e-14	-0.39	-0.37	Educational attainment (years of education);	chr3:47983139	chr3:48256350~48256938:-
LUAD	cis	rs6496044	0.507	rs2467096	ENSG00000202081.1	RNU6-1280P	-8.83	1.94e-17	2.51e-14	-0.43	-0.37	Interstitial lung disease;	chr15:85667447	chr15:85651522~85651628:-
LUAD	cis	rs2337406	0.81	rs7161739	ENSG00000254174.1	IGHV1-12	8.83	1.94e-17	2.51e-14	0.34	0.37	Alzheimer's disease (late onset);	chr14:106776118	chr14:106122420~106122709:-
LUAD	cis	rs11098499	0.754	rs10212714	ENSG00000245958.5	RP11-33B1.1	-8.83	1.97e-17	2.54e-14	-0.35	-0.37	Corneal astigmatism;	chr4:119333147	chr4:119454791~119552025:+
LUAD	cis	rs34779708	0.966	rs10508816	ENSG00000230534.5	RP11-297A16.2	8.83	1.98e-17	2.56e-14	0.44	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35171048	chr10:35098006~35127020:-
LUAD	cis	rs11096990	0.634	rs12651217	ENSG00000249207.1	RP11-360F5.1	-8.83	1.99e-17	2.56e-14	-0.41	-0.37	Cognitive function;	chr4:39271964	chr4:39112677~39126818:-
LUAD	cis	rs6991838	0.584	rs73236948	ENSG00000272010.1	CTD-3025N20.3	-8.83	2e-17	2.57e-14	-0.41	-0.37	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65591850~65592472:-
LUAD	cis	rs56046484	0.797	rs907260	ENSG00000259295.5	CSPG4P12	-8.83	2e-17	2.58e-14	-0.53	-0.37	Testicular germ cell tumor;	chr15:85133526	chr15:85191438~85213905:+
LUAD	cis	rs26232	0.52	rs26432	ENSG00000175749.11	EIF3KP1	-8.83	2e-17	2.58e-14	-0.51	-0.37	Rheumatoid arthritis;	chr5:103030006	chr5:103032376~103033031:+
LUAD	cis	rs10262624	1	rs4722286	ENSG00000234286.1	AC006026.13	8.83	2.02e-17	2.6e-14	0.44	0.37	Schizophrenia;	chr7:23874005	chr7:23680195~23680786:-
LUAD	cis	rs1150668	0.796	rs2531832	ENSG00000204709.4	LINC01556	8.83	2.02e-17	2.6e-14	0.46	0.37	Pubertal anthropometrics;	chr6:28421445	chr6:28943877~28944537:+
LUAD	cis	rs526231	0.543	rs4386712	ENSG00000175749.11	EIF3KP1	8.83	2.03e-17	2.62e-14	0.52	0.37	Primary biliary cholangitis;	chr5:103033530	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.511	rs56235607	ENSG00000175749.11	EIF3KP1	8.83	2.03e-17	2.62e-14	0.52	0.37	Primary biliary cholangitis;	chr5:103036902	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.511	rs55741939	ENSG00000175749.11	EIF3KP1	8.83	2.03e-17	2.62e-14	0.52	0.37	Primary biliary cholangitis;	chr5:103036984	chr5:103032376~103033031:+
LUAD	cis	rs4713118	0.505	rs156740	ENSG00000204709.4	LINC01556	8.83	2.04e-17	2.62e-14	0.46	0.37	Parkinson's disease;	chr6:27992657	chr6:28943877~28944537:+
LUAD	cis	rs6782228	1	rs7429360	ENSG00000242551.2	POU5F1P6	8.82	2.04e-17	2.62e-14	0.45	0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645954	chr3:128674735~128677005:-
LUAD	cis	rs6991838	0.584	rs6993876	ENSG00000272010.1	CTD-3025N20.3	8.82	2.06e-17	2.64e-14	0.41	0.37	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65591850~65592472:-
LUAD	cis	rs9399137	0.507	rs6940258	ENSG00000232876.1	CTA-212D2.2	-8.82	2.06e-17	2.65e-14	-0.43	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135044994	chr6:135055033~135060550:+
LUAD	cis	rs11098499	0.739	rs4833612	ENSG00000245958.5	RP11-33B1.1	8.82	2.06e-17	2.65e-14	0.34	0.37	Corneal astigmatism;	chr4:119226441	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.739	rs10013032	ENSG00000245958.5	RP11-33B1.1	8.82	2.06e-17	2.65e-14	0.34	0.37	Corneal astigmatism;	chr4:119228264	chr4:119454791~119552025:+
LUAD	cis	rs10262624	1	rs2106748	ENSG00000234286.1	AC006026.13	-8.82	2.11e-17	2.71e-14	-0.45	-0.37	Schizophrenia;	chr7:23871694	chr7:23680195~23680786:-
LUAD	cis	rs10262624	1	rs2390847	ENSG00000234286.1	AC006026.13	-8.82	2.11e-17	2.71e-14	-0.45	-0.37	Schizophrenia;	chr7:23872082	chr7:23680195~23680786:-
LUAD	cis	rs10262624	1	rs2023786	ENSG00000234286.1	AC006026.13	-8.82	2.11e-17	2.71e-14	-0.45	-0.37	Schizophrenia;	chr7:23875534	chr7:23680195~23680786:-
LUAD	cis	rs944289	0.617	rs1537428	ENSG00000257826.1	RP11-116N8.4	8.82	2.11e-17	2.72e-14	0.39	0.37	Thyroid cancer;	chr14:36117579	chr14:36061026~36067190:-
LUAD	cis	rs9389248	0.728	rs1022491	ENSG00000232876.1	CTA-212D2.2	8.82	2.12e-17	2.72e-14	0.44	0.37	High light scatter reticulocyte percentage of red cells;	chr6:134938228	chr6:135055033~135060550:+
LUAD	cis	rs9399137	0.507	rs11154791	ENSG00000232876.1	CTA-212D2.2	-8.82	2.12e-17	2.73e-14	-0.44	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135058010	chr6:135055033~135060550:+
LUAD	cis	rs1150668	0.799	rs2142730	ENSG00000216901.1	AL022393.7	8.82	2.13e-17	2.74e-14	0.43	0.37	Pubertal anthropometrics;	chr6:28298372	chr6:28176188~28176674:+
LUAD	cis	rs1799810	0.899	rs7599210	ENSG00000236682.1	AC068282.3	-8.82	2.15e-17	2.77e-14	-0.48	-0.37	Self-rated health;	chr2:127406601	chr2:127389130~127400580:+
LUAD	cis	rs6991838	0.584	rs7812446	ENSG00000272010.1	CTD-3025N20.3	-8.82	2.16e-17	2.77e-14	-0.41	-0.37	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.557	rs7812390	ENSG00000272010.1	CTD-3025N20.3	-8.82	2.16e-17	2.77e-14	-0.41	-0.37	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs16932245	ENSG00000272010.1	CTD-3025N20.3	-8.82	2.16e-17	2.77e-14	-0.41	-0.37	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65591850~65592472:-
LUAD	cis	rs172166	0.585	rs149963	ENSG00000204709.4	LINC01556	8.82	2.16e-17	2.78e-14	0.45	0.37	Cardiac Troponin-T levels;	chr6:28049354	chr6:28943877~28944537:+
LUAD	cis	rs9399137	0.507	rs13064	ENSG00000232876.1	CTA-212D2.2	-8.81	2.2e-17	2.82e-14	-0.44	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134966395	chr6:135055033~135060550:+
LUAD	cis	rs904251	0.965	rs1317563	ENSG00000279942.1	RP1-153P14.7	-8.81	2.21e-17	2.83e-14	-0.35	-0.37	Cognitive performance;	chr6:37484078	chr6:37567716~37571460:+
LUAD	cis	rs3823536	0.583	rs7800687	ENSG00000275106.1	RP11-309L24.10	-8.81	2.21e-17	2.84e-14	-0.47	-0.37	Sjögren's syndrome;	chr7:128953665	chr7:128952527~128953316:-
LUAD	cis	rs10463554	0.927	rs39666	ENSG00000175749.11	EIF3KP1	8.81	2.25e-17	2.89e-14	0.53	0.37	Parkinson's disease;	chr5:103111423	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs34769	ENSG00000175749.11	EIF3KP1	8.81	2.25e-17	2.89e-14	0.53	0.37	Parkinson's disease;	chr5:103111523	chr5:103032376~103033031:+
LUAD	cis	rs6782228	1	rs12495411	ENSG00000242551.2	POU5F1P6	8.81	2.26e-17	2.9e-14	0.47	0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128676852	chr3:128674735~128677005:-
LUAD	cis	rs7429990	0.965	rs34750113	ENSG00000229759.1	MRPS18AP1	8.81	2.27e-17	2.91e-14	0.4	0.37	Educational attainment (years of education);	chr3:47944902	chr3:48256350~48256938:-
LUAD	cis	rs7945705	0.747	rs1123936	ENSG00000254860.4	TMEM9B-AS1	8.81	2.28e-17	2.92e-14	0.41	0.37	Hemoglobin concentration;	chr11:8981759	chr11:8964675~8977527:+
LUAD	cis	rs7945705	0.692	rs2742470	ENSG00000254860.4	TMEM9B-AS1	8.81	2.28e-17	2.92e-14	0.41	0.37	Hemoglobin concentration;	chr11:8982455	chr11:8964675~8977527:+
LUAD	cis	rs2188561	1	rs2188561	ENSG00000241764.3	AC002467.7	8.81	2.3e-17	2.94e-14	0.55	0.37	Alcohol consumption;	chr7:107695613	chr7:107742817~107744581:-
LUAD	cis	rs10129255	0.872	rs1858683	ENSG00000211970.3	IGHV4-61	-8.81	2.3e-17	2.95e-14	-0.29	-0.37	Kawasaki disease;	chr14:106670217	chr14:106639119~106639657:-
LUAD	cis	rs12594515	1	rs6493167	ENSG00000273972.1	CTD-2306A12.1	-8.81	2.31e-17	2.96e-14	-0.4	-0.37	Weight;Waist circumference;	chr15:45694611	chr15:45702640~45703183:+
LUAD	cis	rs12594515	1	rs6493168	ENSG00000273972.1	CTD-2306A12.1	-8.81	2.31e-17	2.96e-14	-0.4	-0.37	Weight;Waist circumference;	chr15:45694613	chr15:45702640~45703183:+
LUAD	cis	rs10129255	0.957	rs12590667	ENSG00000223648.3	IGHV3-64	-8.81	2.32e-17	2.97e-14	-0.35	-0.37	Kawasaki disease;	chr14:106779223	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.83	rs61997609	ENSG00000211970.3	IGHV4-61	-8.81	2.33e-17	2.99e-14	-0.29	-0.37	Kawasaki disease;	chr14:106692376	chr14:106639119~106639657:-
LUAD	cis	rs8005677	0.798	rs4982711	ENSG00000279656.1	RP11-298I3.6	8.81	2.35e-17	3.01e-14	0.45	0.37	Cognitive ability (multi-trait analysis);	chr14:22929781	chr14:23023083~23024217:-
LUAD	cis	rs13392177	0.684	rs6720449	ENSG00000261338.2	RP11-378A13.1	-8.81	2.36e-17	3.02e-14	-0.38	-0.37	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218216255	chr2:218255319~218257366:+
LUAD	cis	rs11098499	0.691	rs17009144	ENSG00000245958.5	RP11-33B1.1	8.81	2.37e-17	3.03e-14	0.32	0.37	Corneal astigmatism;	chr4:119349640	chr4:119454791~119552025:+
LUAD	cis	rs10463554	0.963	rs62364874	ENSG00000175749.11	EIF3KP1	8.8	2.38e-17	3.04e-14	0.51	0.37	Parkinson's disease;	chr5:103056475	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.963	rs62364876	ENSG00000175749.11	EIF3KP1	8.8	2.38e-17	3.04e-14	0.51	0.37	Parkinson's disease;	chr5:103058454	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.963	rs158254	ENSG00000175749.11	EIF3KP1	8.8	2.38e-17	3.04e-14	0.51	0.37	Parkinson's disease;	chr5:103059179	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.963	rs34381	ENSG00000175749.11	EIF3KP1	8.8	2.38e-17	3.04e-14	0.51	0.37	Parkinson's disease;	chr5:103060852	chr5:103032376~103033031:+
LUAD	cis	rs6782228	1	rs6775011	ENSG00000242551.2	POU5F1P6	8.8	2.38e-17	3.05e-14	0.47	0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128677640	chr3:128674735~128677005:-
LUAD	cis	rs10129255	1	rs10141557	ENSG00000211970.3	IGHV4-61	-8.8	2.39e-17	3.05e-14	-0.29	-0.37	Kawasaki disease;	chr14:106767990	chr14:106639119~106639657:-
LUAD	cis	rs34779708	0.966	rs12762493	ENSG00000230534.5	RP11-297A16.2	8.8	2.39e-17	3.06e-14	0.44	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35182945	chr10:35098006~35127020:-
LUAD	cis	rs494459	0.838	rs567680	ENSG00000255239.1	AP002954.6	8.8	2.4e-17	3.07e-14	0.44	0.37	Height;	chr11:118737823	chr11:118688039~118690600:-
LUAD	cis	rs904251	0.772	rs10692	ENSG00000204110.6	RP1-153P14.8	-8.8	2.41e-17	3.08e-14	-0.42	-0.37	Cognitive performance;	chr6:37483138	chr6:37507348~37535616:+
LUAD	cis	rs6991838	0.584	rs7823840	ENSG00000272010.1	CTD-3025N20.3	-8.8	2.44e-17	3.12e-14	-0.41	-0.37	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65591850~65592472:-
LUAD	cis	rs10463554	0.892	rs464591	ENSG00000175749.11	EIF3KP1	8.8	2.45e-17	3.13e-14	0.53	0.37	Parkinson's disease;	chr5:103111600	chr5:103032376~103033031:+
LUAD	cis	rs172166	0.561	rs149976	ENSG00000216901.1	AL022393.7	-8.8	2.46e-17	3.14e-14	-0.43	-0.37	Cardiac Troponin-T levels;	chr6:28019998	chr6:28176188~28176674:+
LUAD	cis	rs11676348	0.755	rs13410318	ENSG00000261338.2	RP11-378A13.1	8.8	2.47e-17	3.15e-14	0.39	0.37	Ulcerative colitis;	chr2:218158187	chr2:218255319~218257366:+
LUAD	cis	rs944289	0.617	rs2415314	ENSG00000257826.1	RP11-116N8.4	-8.8	2.47e-17	3.16e-14	-0.39	-0.37	Thyroid cancer;	chr14:36115335	chr14:36061026~36067190:-
LUAD	cis	rs13392177	0.672	rs1877715	ENSG00000261338.2	RP11-378A13.1	8.8	2.47e-17	3.16e-14	0.38	0.37	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218187823	chr2:218255319~218257366:+
LUAD	cis	rs35160687	0.862	rs12476706	ENSG00000273080.1	RP11-301O19.1	8.8	2.47e-17	3.16e-14	0.43	0.37	Night sleep phenotypes;	chr2:86301247	chr2:86195590~86196049:+
LUAD	cis	rs944289	0.617	rs7156229	ENSG00000257826.1	RP11-116N8.4	-8.8	2.49e-17	3.18e-14	-0.4	-0.37	Thyroid cancer;	chr14:36114780	chr14:36061026~36067190:-
LUAD	cis	rs56080343	0.808	rs1045552	ENSG00000275759.1	RP11-131L12.3	-8.8	2.49e-17	3.18e-14	-0.53	-0.37	Neuroticism;	chr12:118417678	chr12:118428281~118428870:+
LUAD	cis	rs34779708	0.931	rs2384289	ENSG00000230534.5	RP11-297A16.2	8.8	2.51e-17	3.2e-14	0.44	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35054597	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.931	rs11010082	ENSG00000230534.5	RP11-297A16.2	8.8	2.51e-17	3.2e-14	0.44	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35062227	chr10:35098006~35127020:-
LUAD	cis	rs10262624	1	rs13244265	ENSG00000234286.1	AC006026.13	-8.8	2.51e-17	3.21e-14	-0.45	-0.37	Schizophrenia;	chr7:23878284	chr7:23680195~23680786:-
LUAD	cis	rs10262624	1	rs10238070	ENSG00000234286.1	AC006026.13	-8.8	2.52e-17	3.22e-14	-0.45	-0.37	Schizophrenia;	chr7:23870172	chr7:23680195~23680786:-
LUAD	cis	rs35955747	0.633	rs1916	ENSG00000236132.1	CTA-440B3.1	-8.8	2.52e-17	3.22e-14	-0.42	-0.37	Neutrophil count;Sum basophil neutrophil counts;	chr22:31496135	chr22:31816379~31817491:-
LUAD	cis	rs9399137	0.529	rs7739722	ENSG00000232876.1	CTA-212D2.2	-8.8	2.55e-17	3.25e-14	-0.43	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134961087	chr6:135055033~135060550:+
LUAD	cis	rs11676348	0.846	rs7607437	ENSG00000261338.2	RP11-378A13.1	-8.8	2.55e-17	3.25e-14	-0.39	-0.37	Ulcerative colitis;	chr2:218143669	chr2:218255319~218257366:+
LUAD	cis	rs732716	0.785	rs11085073	ENSG00000267769.1	CTB-50L17.9	8.79	2.57e-17	3.27e-14	0.4	0.37	Mean corpuscular volume;	chr19:4375165	chr19:4454014~4455286:+
LUAD	cis	rs7429990	0.965	rs2166770	ENSG00000229759.1	MRPS18AP1	8.79	2.62e-17	3.34e-14	0.38	0.37	Educational attainment (years of education);	chr3:47964183	chr3:48256350~48256938:-
LUAD	cis	rs10463554	0.963	rs72785733	ENSG00000175749.11	EIF3KP1	8.79	2.63e-17	3.35e-14	0.52	0.37	Parkinson's disease;	chr5:103038488	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.963	rs61418746	ENSG00000175749.11	EIF3KP1	8.79	2.64e-17	3.36e-14	0.51	0.37	Parkinson's disease;	chr5:103043914	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.963	rs62364875	ENSG00000175749.11	EIF3KP1	8.79	2.64e-17	3.36e-14	0.51	0.37	Parkinson's disease;	chr5:103056486	chr5:103032376~103033031:+
LUAD	cis	rs2337406	0.866	rs79901786	ENSG00000254174.1	IGHV1-12	8.79	2.64e-17	3.36e-14	0.33	0.37	Alzheimer's disease (late onset);	chr14:106777623	chr14:106122420~106122709:-
LUAD	cis	rs10262624	0.967	rs2390848	ENSG00000234286.1	AC006026.13	-8.79	2.65e-17	3.38e-14	-0.44	-0.37	Schizophrenia;	chr7:23872755	chr7:23680195~23680786:-
LUAD	cis	rs10262624	1	rs2023787	ENSG00000234286.1	AC006026.13	-8.79	2.65e-17	3.38e-14	-0.44	-0.37	Schizophrenia;	chr7:23875521	chr7:23680195~23680786:-
LUAD	cis	rs10262624	1	rs12671624	ENSG00000234286.1	AC006026.13	-8.79	2.65e-17	3.38e-14	-0.44	-0.37	Schizophrenia;	chr7:23875794	chr7:23680195~23680786:-
LUAD	cis	rs10262624	1	rs10262624	ENSG00000234286.1	AC006026.13	-8.79	2.65e-17	3.38e-14	-0.44	-0.37	Schizophrenia;	chr7:23876057	chr7:23680195~23680786:-
LUAD	cis	rs10262624	0.967	rs7792734	ENSG00000234286.1	AC006026.13	-8.79	2.65e-17	3.38e-14	-0.44	-0.37	Schizophrenia;	chr7:23876429	chr7:23680195~23680786:-
LUAD	cis	rs11123170	0.542	rs11123169	ENSG00000189223.12	PAX8-AS1	8.79	2.68e-17	3.41e-14	0.51	0.37	Renal function-related traits (BUN);	chr2:113209498	chr2:113211522~113276581:+
LUAD	cis	rs7429990	0.93	rs71323371	ENSG00000229759.1	MRPS18AP1	8.79	2.68e-17	3.41e-14	0.39	0.37	Educational attainment (years of education);	chr3:47904327	chr3:48256350~48256938:-
LUAD	cis	rs9322193	0.607	rs4870078	ENSG00000231760.4	RP11-350J20.5	-8.79	2.69e-17	3.43e-14	-0.53	-0.37	Lung cancer;	chr6:149880676	chr6:149796151~149826294:-
LUAD	cis	rs172166	0.56	rs203878	ENSG00000204709.4	LINC01556	8.79	2.71e-17	3.45e-14	0.46	0.37	Cardiac Troponin-T levels;	chr6:28081218	chr6:28943877~28944537:+
LUAD	cis	rs12468226	0.938	rs3843338	ENSG00000273456.1	RP11-686O6.2	-8.79	2.72e-17	3.46e-14	-0.57	-0.37	Urate levels;	chr2:202246102	chr2:202374932~202375604:-
LUAD	cis	rs11690935	0.851	rs7581072	ENSG00000228389.1	AC068039.4	8.79	2.75e-17	3.5e-14	0.43	0.37	Schizophrenia;	chr2:171994938	chr2:171773482~171775844:+
LUAD	cis	rs7188445	0.899	rs58722186	ENSG00000261390.4	RP11-345M22.2	-8.79	2.75e-17	3.5e-14	-0.49	-0.37	Urate levels;	chr16:79717694	chr16:79715232~79770563:-
LUAD	cis	rs34779708	0.966	rs2045915	ENSG00000230534.5	RP11-297A16.2	8.78	2.78e-17	3.53e-14	0.44	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35129688	chr10:35098006~35127020:-
LUAD	cis	rs1150668	0.83	rs2023493	ENSG00000204709.4	LINC01556	8.78	2.78e-17	3.54e-14	0.46	0.37	Pubertal anthropometrics;	chr6:28432385	chr6:28943877~28944537:+
LUAD	cis	rs1150668	0.796	rs1124132	ENSG00000204709.4	LINC01556	8.78	2.79e-17	3.54e-14	0.46	0.37	Pubertal anthropometrics;	chr6:28412544	chr6:28943877~28944537:+
LUAD	cis	rs9399137	0.507	rs13196486	ENSG00000232876.1	CTA-212D2.2	-8.78	2.79e-17	3.55e-14	-0.43	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134962736	chr6:135055033~135060550:+
LUAD	cis	rs9399137	0.507	rs6918512	ENSG00000232876.1	CTA-212D2.2	-8.78	2.79e-17	3.55e-14	-0.43	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134963701	chr6:135055033~135060550:+
LUAD	cis	rs9399137	0.507	rs12664898	ENSG00000232876.1	CTA-212D2.2	-8.78	2.79e-17	3.55e-14	-0.43	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134967525	chr6:135055033~135060550:+
LUAD	cis	rs9399137	0.507	rs35571217	ENSG00000232876.1	CTA-212D2.2	-8.78	2.79e-17	3.55e-14	-0.43	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134969217	chr6:135055033~135060550:+
LUAD	cis	rs1155848	0.892	rs9574424	ENSG00000227354.5	RBM26-AS1	-8.78	2.79e-17	3.55e-14	-0.78	-0.37	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79448541	chr13:79406309~79424328:+
LUAD	cis	rs9399137	0.507	rs56164974	ENSG00000232876.1	CTA-212D2.2	-8.78	2.8e-17	3.56e-14	-0.43	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134967578	chr6:135055033~135060550:+
LUAD	cis	rs10129255	0.872	rs8015406	ENSG00000211970.3	IGHV4-61	-8.78	2.82e-17	3.59e-14	-0.29	-0.37	Kawasaki disease;	chr14:106670611	chr14:106639119~106639657:-
LUAD	cis	rs11214589	0.747	rs11214577	ENSG00000270179.1	RP11-159N11.4	8.78	2.83e-17	3.59e-14	0.37	0.37	Neuroticism;	chr11:113333544	chr11:113368478~113369117:+
LUAD	cis	rs4908760	0.811	rs301806	ENSG00000232912.4	RP5-1115A15.1	8.78	2.83e-17	3.59e-14	0.34	0.37	Vitiligo;	chr1:8422018	chr1:8424645~8434838:+
LUAD	cis	rs6496044	0.507	rs410522	ENSG00000202081.1	RNU6-1280P	-8.78	2.84e-17	3.6e-14	-0.43	-0.37	Interstitial lung disease;	chr15:85663813	chr15:85651522~85651628:-
LUAD	cis	rs9322193	0.923	rs9766037	ENSG00000223701.3	RAET1E-AS1	8.78	2.84e-17	3.61e-14	0.43	0.37	Lung cancer;	chr6:149616921	chr6:149884431~149919508:+
LUAD	cis	rs10129255	0.957	rs12589190	ENSG00000211970.3	IGHV4-61	-8.78	2.88e-17	3.65e-14	-0.28	-0.37	Kawasaki disease;	chr14:106783079	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.957	rs7493713	ENSG00000211970.3	IGHV4-61	-8.78	2.88e-17	3.65e-14	-0.28	-0.37	Kawasaki disease;	chr14:106783685	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.912	rs35468694	ENSG00000211970.3	IGHV4-61	-8.78	2.88e-17	3.65e-14	-0.28	-0.37	Kawasaki disease;	chr14:106784199	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.957	rs8019272	ENSG00000211970.3	IGHV4-61	-8.78	2.88e-17	3.65e-14	-0.28	-0.37	Kawasaki disease;	chr14:106784709	chr14:106639119~106639657:-
LUAD	cis	rs7188445	0.899	rs7195321	ENSG00000261390.4	RP11-345M22.2	-8.78	2.89e-17	3.68e-14	-0.48	-0.37	Urate levels;	chr16:79701065	chr16:79715232~79770563:-
LUAD	cis	rs34779708	0.931	rs11010067	ENSG00000230534.5	RP11-297A16.2	-8.78	2.93e-17	3.72e-14	-0.43	-0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35006503	chr10:35098006~35127020:-
LUAD	cis	rs2188561	0.697	rs7787927	ENSG00000241764.3	AC002467.7	8.78	2.93e-17	3.72e-14	0.47	0.37	Alcohol consumption;	chr7:107763915	chr7:107742817~107744581:-
LUAD	cis	rs10463554	0.89	rs26428	ENSG00000175749.11	EIF3KP1	-8.78	2.94e-17	3.72e-14	-0.5	-0.37	Parkinson's disease;	chr5:103030780	chr5:103032376~103033031:+
LUAD	cis	rs34779708	0.931	rs2244100	ENSG00000230534.5	RP11-297A16.2	-8.78	2.94e-17	3.73e-14	-0.43	-0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35034708	chr10:35098006~35127020:-
LUAD	cis	rs10129255	0.957	rs2013423	ENSG00000211970.3	IGHV4-61	-8.78	2.95e-17	3.75e-14	-0.29	-0.37	Kawasaki disease;	chr14:106690675	chr14:106639119~106639657:-
LUAD	cis	rs172166	0.561	rs149973	ENSG00000216901.1	AL022393.7	8.78	2.96e-17	3.76e-14	0.43	0.37	Cardiac Troponin-T levels;	chr6:28015835	chr6:28176188~28176674:+
LUAD	cis	rs172166	0.561	rs149974	ENSG00000216901.1	AL022393.7	8.78	2.96e-17	3.76e-14	0.43	0.37	Cardiac Troponin-T levels;	chr6:28017318	chr6:28176188~28176674:+
LUAD	cis	rs7924176	0.564	rs12359146	ENSG00000213731.2	RAB5CP1	-8.78	2.97e-17	3.76e-14	-0.4	-0.37	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74205914	chr10:74423435~74424014:-
LUAD	cis	rs1061377	0.621	rs11096974	ENSG00000249207.1	RP11-360F5.1	-8.78	2.98e-17	3.78e-14	-0.41	-0.37	Uric acid levels;	chr4:39062039	chr4:39112677~39126818:-
LUAD	cis	rs9399137	0.507	rs6904897	ENSG00000232876.1	CTA-212D2.2	-8.78	2.98e-17	3.78e-14	-0.43	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135061842	chr6:135055033~135060550:+
LUAD	cis	rs6700559	1	rs10800720	ENSG00000260088.1	RP11-92G12.3	-8.78	2.99e-17	3.79e-14	-0.48	-0.37	Coronary artery disease;	chr1:200679441	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.935	rs4072553	ENSG00000260088.1	RP11-92G12.3	-8.78	2.99e-17	3.79e-14	-0.48	-0.37	Coronary artery disease;	chr1:200680036	chr1:200669507~200694250:+
LUAD	cis	rs9399137	0.507	rs11758774	ENSG00000232876.1	CTA-212D2.2	-8.77	3e-17	3.8e-14	-0.44	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135062651	chr6:135055033~135060550:+
LUAD	cis	rs9389248	0.737	rs12664956	ENSG00000232876.1	CTA-212D2.2	-8.77	3e-17	3.8e-14	-0.44	-0.37	High light scatter reticulocyte percentage of red cells;	chr6:135063050	chr6:135055033~135060550:+
LUAD	cis	rs2929278	0.617	rs3087657	ENSG00000249839.1	AC011330.5	-8.77	3e-17	3.81e-14	-0.47	-0.37	Schizophrenia;	chr15:43771661	chr15:43663654~43684339:-
LUAD	cis	rs7188445	0.899	rs57652769	ENSG00000261390.4	RP11-345M22.2	-8.77	3.02e-17	3.82e-14	-0.49	-0.37	Urate levels;	chr16:79720079	chr16:79715232~79770563:-
LUAD	cis	rs10129255	0.957	rs56134540	ENSG00000211970.3	IGHV4-61	-8.77	3.03e-17	3.84e-14	-0.29	-0.37	Kawasaki disease;	chr14:106691290	chr14:106639119~106639657:-
LUAD	cis	rs11846409	0.587	rs1806881	ENSG00000274576.2	IGHV2-70	8.77	3.07e-17	3.88e-14	0.4	0.37	Rheumatic heart disease;	chr14:106650770	chr14:106770577~106771020:-
LUAD	cis	rs7188445	1	rs7188445	ENSG00000261390.4	RP11-345M22.2	-8.77	3.07e-17	3.89e-14	-0.48	-0.37	Urate levels;	chr16:79701090	chr16:79715232~79770563:-
LUAD	cis	rs3931020	0.548	rs2134836	ENSG00000272864.1	RP11-17E13.2	-8.77	3.07e-17	3.89e-14	-0.45	-0.37	Resistin levels;	chr1:74805962	chr1:74698769~74699333:-
LUAD	cis	rs3931020	0.548	rs12145183	ENSG00000272864.1	RP11-17E13.2	-8.77	3.07e-17	3.89e-14	-0.45	-0.37	Resistin levels;	chr1:74806796	chr1:74698769~74699333:-
LUAD	cis	rs3931020	0.566	rs1409782	ENSG00000272864.1	RP11-17E13.2	-8.77	3.07e-17	3.89e-14	-0.45	-0.37	Resistin levels;	chr1:74807251	chr1:74698769~74699333:-
LUAD	cis	rs733592	0.965	rs1978161	ENSG00000240399.1	RP1-228P16.1	-8.77	3.07e-17	3.89e-14	-0.36	-0.37	Plateletcrit;	chr12:48073938	chr12:48054813~48055591:-
LUAD	cis	rs2929278	0.617	rs693919	ENSG00000249839.1	AC011330.5	8.77	3.08e-17	3.89e-14	0.48	0.37	Schizophrenia;	chr15:43810130	chr15:43663654~43684339:-
LUAD	cis	rs10129255	0.957	rs8009464	ENSG00000211970.3	IGHV4-61	-8.77	3.1e-17	3.92e-14	-0.28	-0.37	Kawasaki disease;	chr14:106777611	chr14:106639119~106639657:-
LUAD	cis	rs172166	0.561	rs149971	ENSG00000216901.1	AL022393.7	8.77	3.11e-17	3.94e-14	0.43	0.37	Cardiac Troponin-T levels;	chr6:28014374	chr6:28176188~28176674:+
LUAD	cis	rs7188445	0.932	rs11150191	ENSG00000261390.4	RP11-345M22.2	-8.77	3.11e-17	3.94e-14	-0.48	-0.37	Urate levels;	chr16:79700390	chr16:79715232~79770563:-
LUAD	cis	rs904251	0.772	rs2776906	ENSG00000204110.6	RP1-153P14.8	-8.77	3.12e-17	3.95e-14	-0.41	-0.37	Cognitive performance;	chr6:37463981	chr6:37507348~37535616:+
LUAD	cis	rs944289	0.617	rs12432682	ENSG00000257826.1	RP11-116N8.4	-8.77	3.14e-17	3.97e-14	-0.39	-0.37	Thyroid cancer;	chr14:36114058	chr14:36061026~36067190:-
LUAD	cis	rs944289	0.617	rs7156269	ENSG00000257826.1	RP11-116N8.4	-8.77	3.14e-17	3.97e-14	-0.39	-0.37	Thyroid cancer;	chr14:36114849	chr14:36061026~36067190:-
LUAD	cis	rs7429990	0.93	rs7374516	ENSG00000229759.1	MRPS18AP1	8.77	3.15e-17	3.98e-14	0.38	0.37	Educational attainment (years of education);	chr3:47961150	chr3:48256350~48256938:-
LUAD	cis	rs9389248	0.69	rs6939543	ENSG00000232876.1	CTA-212D2.2	8.77	3.16e-17	4e-14	0.42	0.37	High light scatter reticulocyte percentage of red cells;	chr6:134934005	chr6:135055033~135060550:+
LUAD	cis	rs1150668	0.799	rs9301	ENSG00000216901.1	AL022393.7	8.77	3.18e-17	4.02e-14	0.44	0.37	Pubertal anthropometrics;	chr6:28324929	chr6:28176188~28176674:+
LUAD	cis	rs7188445	0.932	rs73575086	ENSG00000261390.4	RP11-345M22.2	-8.77	3.18e-17	4.03e-14	-0.49	-0.37	Urate levels;	chr16:79714588	chr16:79715232~79770563:-
LUAD	cis	rs3823536	0.544	rs12532542	ENSG00000275106.1	RP11-309L24.10	-8.77	3.19e-17	4.04e-14	-0.47	-0.37	Sjögren's syndrome;	chr7:129027358	chr7:128952527~128953316:-
LUAD	cis	rs3823536	0.583	rs4731540	ENSG00000275106.1	RP11-309L24.10	-8.77	3.19e-17	4.04e-14	-0.47	-0.37	Sjögren's syndrome;	chr7:129028196	chr7:128952527~128953316:-
LUAD	cis	rs10463554	0.667	rs57714862	ENSG00000175749.11	EIF3KP1	8.77	3.21e-17	4.06e-14	0.51	0.37	Parkinson's disease;	chr5:103047025	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.511	rs6881612	ENSG00000175749.11	EIF3KP1	8.77	3.21e-17	4.06e-14	0.52	0.37	Primary biliary cholangitis;	chr5:103041309	chr5:103032376~103033031:+
LUAD	cis	rs7924176	0.601	rs7089391	ENSG00000213731.2	RAB5CP1	-8.77	3.21e-17	4.06e-14	-0.39	-0.37	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74177762	chr10:74423435~74424014:-
LUAD	cis	rs11098499	0.71	rs6851130	ENSG00000245958.5	RP11-33B1.1	8.77	3.22e-17	4.06e-14	0.34	0.37	Corneal astigmatism;	chr4:119212557	chr4:119454791~119552025:+
LUAD	cis	rs1150668	0.83	rs2023493	ENSG00000216901.1	AL022393.7	8.77	3.22e-17	4.06e-14	0.44	0.37	Pubertal anthropometrics;	chr6:28432385	chr6:28176188~28176674:+
LUAD	cis	rs11096990	0.613	rs4974996	ENSG00000249207.1	RP11-360F5.1	-8.77	3.22e-17	4.07e-14	-0.4	-0.37	Cognitive function;	chr4:39225928	chr4:39112677~39126818:-
LUAD	cis	rs944289	0.617	rs1475715	ENSG00000257826.1	RP11-116N8.4	-8.76	3.23e-17	4.08e-14	-0.39	-0.37	Thyroid cancer;	chr14:36116017	chr14:36061026~36067190:-
LUAD	cis	rs10129255	0.5	rs11628999	ENSG00000211972.2	IGHV3-66	8.76	3.24e-17	4.1e-14	0.29	0.37	Kawasaki disease;	chr14:106800208	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.5	rs7157975	ENSG00000211972.2	IGHV3-66	8.76	3.25e-17	4.1e-14	0.29	0.37	Kawasaki disease;	chr14:106804049	chr14:106675017~106675544:-
LUAD	cis	rs732716	0.785	rs34080966	ENSG00000267769.1	CTB-50L17.9	8.76	3.25e-17	4.11e-14	0.39	0.37	Mean corpuscular volume;	chr19:4417848	chr19:4454014~4455286:+
LUAD	cis	rs1150668	0.799	rs7206	ENSG00000204709.4	LINC01556	8.76	3.27e-17	4.13e-14	0.46	0.37	Pubertal anthropometrics;	chr6:28233360	chr6:28943877~28944537:+
LUAD	cis	rs10256972	0.967	rs4723338	ENSG00000229043.2	AC091729.9	-8.76	3.3e-17	4.17e-14	-0.4	-0.37	Endometriosis;Longevity;	chr7:996605	chr7:1160374~1165267:+
LUAD	cis	rs11096990	0.634	rs11096988	ENSG00000249207.1	RP11-360F5.1	-8.76	3.31e-17	4.18e-14	-0.4	-0.37	Cognitive function;	chr4:39264081	chr4:39112677~39126818:-
LUAD	cis	rs1150668	0.768	rs1233713	ENSG00000204709.4	LINC01556	8.76	3.34e-17	4.22e-14	0.46	0.37	Pubertal anthropometrics;	chr6:28230503	chr6:28943877~28944537:+
LUAD	cis	rs7188445	0.932	rs73575095	ENSG00000261390.4	RP11-345M22.2	-8.76	3.36e-17	4.24e-14	-0.49	-0.37	Urate levels;	chr16:79716435	chr16:79715232~79770563:-
LUAD	cis	rs1061377	0.585	rs12648581	ENSG00000249207.1	RP11-360F5.1	-8.76	3.37e-17	4.25e-14	-0.41	-0.37	Uric acid levels;	chr4:39054024	chr4:39112677~39126818:-
LUAD	cis	rs12468226	0.938	rs4675274	ENSG00000273456.1	RP11-686O6.2	-8.76	3.38e-17	4.27e-14	-0.57	-0.37	Urate levels;	chr2:202243145	chr2:202374932~202375604:-
LUAD	cis	rs6504622	0.693	rs12952596	ENSG00000262879.4	RP11-156P1.3	-8.76	3.39e-17	4.28e-14	-0.42	-0.37	Orofacial clefts;	chr17:46994319	chr17:46984045~47100323:-
LUAD	cis	rs944289	0.616	rs6571735	ENSG00000257826.1	RP11-116N8.4	-8.76	3.41e-17	4.3e-14	-0.38	-0.37	Thyroid cancer;	chr14:36089428	chr14:36061026~36067190:-
LUAD	cis	rs2337406	1	rs17113276	ENSG00000274576.2	IGHV2-70	8.76	3.42e-17	4.31e-14	0.4	0.37	Alzheimer's disease (late onset);	chr14:106683485	chr14:106770577~106771020:-
LUAD	cis	rs6991838	0.584	rs10089708	ENSG00000272010.1	CTD-3025N20.3	8.76	3.42e-17	4.31e-14	0.42	0.37	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs6991731	ENSG00000272010.1	CTD-3025N20.3	8.76	3.42e-17	4.31e-14	0.42	0.37	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65591850~65592472:-
LUAD	cis	rs10262624	1	rs2106747	ENSG00000234286.1	AC006026.13	-8.76	3.44e-17	4.33e-14	-0.44	-0.37	Schizophrenia;	chr7:23871880	chr7:23680195~23680786:-
LUAD	cis	rs11098499	0.644	rs10050092	ENSG00000245958.5	RP11-33B1.1	-8.76	3.44e-17	4.34e-14	-0.34	-0.37	Corneal astigmatism;	chr4:119610930	chr4:119454791~119552025:+
LUAD	cis	rs7188445	0.932	rs17689159	ENSG00000261390.4	RP11-345M22.2	-8.76	3.46e-17	4.37e-14	-0.49	-0.37	Urate levels;	chr16:79708493	chr16:79715232~79770563:-
LUAD	cis	rs10129255	0.5	rs8004923	ENSG00000211972.2	IGHV3-66	8.76	3.47e-17	4.37e-14	0.29	0.37	Kawasaki disease;	chr14:106785926	chr14:106675017~106675544:-
LUAD	cis	rs7429990	0.932	rs34025851	ENSG00000229759.1	MRPS18AP1	8.76	3.48e-17	4.38e-14	0.39	0.37	Educational attainment (years of education);	chr3:47912243	chr3:48256350~48256938:-
LUAD	cis	rs6782228	1	rs6782407	ENSG00000242551.2	POU5F1P6	8.76	3.48e-17	4.39e-14	0.47	0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619905	chr3:128674735~128677005:-
LUAD	cis	rs3931020	0.772	rs1409785	ENSG00000272864.1	RP11-17E13.2	-8.76	3.48e-17	4.39e-14	-0.45	-0.37	Resistin levels;	chr1:74782438	chr1:74698769~74699333:-
LUAD	cis	rs7945705	0.714	rs2653570	ENSG00000254860.4	TMEM9B-AS1	8.76	3.48e-17	4.39e-14	0.4	0.37	Hemoglobin concentration;	chr11:8966276	chr11:8964675~8977527:+
LUAD	cis	rs16863064	0.66	rs1007308	ENSG00000279891.1	FLJ42393	-8.75	3.49e-17	4.41e-14	-0.49	-0.37	Schizophrenia;	chr3:188171935	chr3:188178543~188180812:+
LUAD	cis	rs7188445	0.932	rs17767904	ENSG00000261390.4	RP11-345M22.2	-8.75	3.5e-17	4.41e-14	-0.49	-0.37	Urate levels;	chr16:79716078	chr16:79715232~79770563:-
LUAD	cis	rs4908760	0.811	rs301802	ENSG00000232912.4	RP5-1115A15.1	8.75	3.5e-17	4.41e-14	0.33	0.37	Vitiligo;	chr1:8437247	chr1:8424645~8434838:+
LUAD	cis	rs1185460	0.967	rs1307145	ENSG00000271751.1	RP11-110I1.14	-8.75	3.5e-17	4.42e-14	-0.46	-0.37	Coronary artery disease;	chr11:119079507	chr11:119065263~119065677:-
LUAD	cis	rs10740039	0.583	rs2127352	ENSG00000254271.1	RP11-131N11.4	-8.75	3.52e-17	4.43e-14	-0.41	-0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60742129	chr10:60734342~60741828:+
LUAD	cis	rs11096990	0.572	rs35040563	ENSG00000249207.1	RP11-360F5.1	-8.75	3.53e-17	4.45e-14	-0.41	-0.37	Cognitive function;	chr4:39154262	chr4:39112677~39126818:-
LUAD	cis	rs1150668	0.768	rs1150716	ENSG00000216901.1	AL022393.7	8.75	3.56e-17	4.48e-14	0.43	0.37	Pubertal anthropometrics;	chr6:28294921	chr6:28176188~28176674:+
LUAD	cis	rs13392177	0.684	rs6720105	ENSG00000261338.2	RP11-378A13.1	-8.75	3.56e-17	4.48e-14	-0.38	-0.37	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218215995	chr2:218255319~218257366:+
LUAD	cis	rs10129255	0.5	rs6576232	ENSG00000211972.2	IGHV3-66	8.75	3.56e-17	4.48e-14	0.29	0.37	Kawasaki disease;	chr14:106787090	chr14:106675017~106675544:-
LUAD	cis	rs6504622	0.702	rs11079747	ENSG00000262879.4	RP11-156P1.3	-8.75	3.59e-17	4.52e-14	-0.42	-0.37	Orofacial clefts;	chr17:47001484	chr17:46984045~47100323:-
LUAD	cis	rs10256972	0.933	rs35696159	ENSG00000229043.2	AC091729.9	-8.75	3.59e-17	4.53e-14	-0.4	-0.37	Endometriosis;Longevity;	chr7:1007558	chr7:1160374~1165267:+
LUAD	cis	rs9399137	0.507	rs7748708	ENSG00000232876.1	CTA-212D2.2	-8.75	3.6e-17	4.54e-14	-0.43	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954004	chr6:135055033~135060550:+
LUAD	cis	rs6991838	0.584	rs7463649	ENSG00000272010.1	CTD-3025N20.3	-8.75	3.61e-17	4.54e-14	-0.41	-0.37	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs66467166	ENSG00000272010.1	CTD-3025N20.3	-8.75	3.61e-17	4.54e-14	-0.41	-0.37	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.557	rs67685675	ENSG00000272010.1	CTD-3025N20.3	-8.75	3.61e-17	4.54e-14	-0.41	-0.37	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs66486920	ENSG00000272010.1	CTD-3025N20.3	-8.75	3.61e-17	4.54e-14	-0.41	-0.37	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs60023200	ENSG00000272010.1	CTD-3025N20.3	-8.75	3.61e-17	4.54e-14	-0.41	-0.37	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs61083799	ENSG00000272010.1	CTD-3025N20.3	-8.75	3.61e-17	4.54e-14	-0.41	-0.37	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs4449837	ENSG00000272010.1	CTD-3025N20.3	-8.75	3.61e-17	4.54e-14	-0.41	-0.37	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs57042777	ENSG00000272010.1	CTD-3025N20.3	-8.75	3.61e-17	4.54e-14	-0.41	-0.37	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs4275254	ENSG00000200714.1	Y_RNA	-8.75	3.61e-17	4.55e-14	-0.45	-0.37	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65592731~65592820:+
LUAD	cis	rs7945705	0.747	rs2742480	ENSG00000254860.4	TMEM9B-AS1	8.75	3.62e-17	4.55e-14	0.41	0.37	Hemoglobin concentration;	chr11:8971583	chr11:8964675~8977527:+
LUAD	cis	rs7688540	0.723	rs17521834	ENSG00000275426.1	CH17-262A2.1	-8.75	3.62e-17	4.56e-14	-0.52	-0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231660	chr4:149738~150317:+
LUAD	cis	rs10129255	0.957	rs17113284	ENSG00000223648.3	IGHV3-64	-8.75	3.64e-17	4.58e-14	-0.37	-0.37	Kawasaki disease;	chr14:106684476	chr14:106643132~106658258:-
LUAD	cis	rs526231	0.511	rs10434792	ENSG00000175749.11	EIF3KP1	8.75	3.66e-17	4.61e-14	0.52	0.37	Primary biliary cholangitis;	chr5:103053898	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.511	rs10434793	ENSG00000175749.11	EIF3KP1	8.75	3.66e-17	4.61e-14	0.52	0.37	Primary biliary cholangitis;	chr5:103054111	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.511	rs12109860	ENSG00000175749.11	EIF3KP1	8.75	3.66e-17	4.61e-14	0.52	0.37	Primary biliary cholangitis;	chr5:103057408	chr5:103032376~103033031:+
LUAD	cis	rs7429990	0.965	rs6772396	ENSG00000229759.1	MRPS18AP1	8.75	3.67e-17	4.61e-14	0.38	0.37	Educational attainment (years of education);	chr3:47918280	chr3:48256350~48256938:-
LUAD	cis	rs10262624	0.967	rs35988560	ENSG00000234286.1	AC006026.13	-8.75	3.67e-17	4.62e-14	-0.45	-0.37	Schizophrenia;	chr7:23878561	chr7:23680195~23680786:-
LUAD	cis	rs12594515	1	rs12911309	ENSG00000273972.1	CTD-2306A12.1	-8.75	3.7e-17	4.65e-14	-0.4	-0.37	Weight;Waist circumference;	chr15:45693521	chr15:45702640~45703183:+
LUAD	cis	rs10129255	0.957	rs10132367	ENSG00000211970.3	IGHV4-61	-8.75	3.7e-17	4.65e-14	-0.29	-0.37	Kawasaki disease;	chr14:106690981	chr14:106639119~106639657:-
LUAD	cis	rs12594515	1	rs8025258	ENSG00000273972.1	CTD-2306A12.1	-8.75	3.71e-17	4.66e-14	-0.4	-0.37	Weight;Waist circumference;	chr15:45695356	chr15:45702640~45703183:+
LUAD	cis	rs12594515	1	rs8027000	ENSG00000273972.1	CTD-2306A12.1	-8.75	3.71e-17	4.66e-14	-0.4	-0.37	Weight;Waist circumference;	chr15:45695597	chr15:45702640~45703183:+
LUAD	cis	rs12594515	1	rs8039974	ENSG00000273972.1	CTD-2306A12.1	-8.75	3.72e-17	4.67e-14	-0.4	-0.37	Weight;Waist circumference;	chr15:45694467	chr15:45702640~45703183:+
LUAD	cis	rs904251	0.772	rs756202	ENSG00000204110.6	RP1-153P14.8	-8.75	3.72e-17	4.68e-14	-0.41	-0.37	Cognitive performance;	chr6:37492574	chr6:37507348~37535616:+
LUAD	cis	rs494459	0.964	rs576283	ENSG00000255239.1	AP002954.6	8.74	3.76e-17	4.73e-14	0.43	0.37	Height;	chr11:118703185	chr11:118688039~118690600:-
LUAD	cis	rs507080	0.524	rs524409	ENSG00000255239.1	AP002954.6	8.74	3.76e-17	4.73e-14	0.43	0.37	Serum metabolite levels;	chr11:118703602	chr11:118688039~118690600:-
LUAD	cis	rs7924176	0.601	rs12414280	ENSG00000213731.2	RAB5CP1	-8.74	3.77e-17	4.73e-14	-0.39	-0.37	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74174642	chr10:74423435~74424014:-
LUAD	cis	rs11098499	0.644	rs17517414	ENSG00000245958.5	RP11-33B1.1	-8.74	3.77e-17	4.73e-14	-0.31	-0.37	Corneal astigmatism;	chr4:119340946	chr4:119454791~119552025:+
LUAD	cis	rs10028773	0.666	rs12498657	ENSG00000245958.5	RP11-33B1.1	-8.74	3.77e-17	4.73e-14	-0.31	-0.37	Educational attainment;	chr4:119341711	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.722	rs10006192	ENSG00000245958.5	RP11-33B1.1	-8.74	3.77e-17	4.73e-14	-0.31	-0.37	Corneal astigmatism;	chr4:119341867	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.615	rs28551750	ENSG00000245958.5	RP11-33B1.1	-8.74	3.77e-17	4.73e-14	-0.31	-0.37	Corneal astigmatism;	chr4:119343746	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.691	rs9995716	ENSG00000245958.5	RP11-33B1.1	-8.74	3.77e-17	4.73e-14	-0.31	-0.37	Corneal astigmatism;	chr4:119343841	chr4:119454791~119552025:+
LUAD	cis	rs10129255	0.785	rs10150044	ENSG00000211970.3	IGHV4-61	-8.74	3.77e-17	4.74e-14	-0.29	-0.37	Kawasaki disease;	chr14:106775695	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.957	rs10137980	ENSG00000211970.3	IGHV4-61	-8.74	3.77e-17	4.74e-14	-0.29	-0.37	Kawasaki disease;	chr14:106775735	chr14:106639119~106639657:-
LUAD	cis	rs12134133	1	rs6673333	ENSG00000274245.1	RP11-357P18.2	8.74	3.81e-17	4.79e-14	0.49	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285802	chr1:207372559~207373252:+
LUAD	cis	rs11096990	0.593	rs4580660	ENSG00000249207.1	RP11-360F5.1	-8.74	3.81e-17	4.79e-14	-0.41	-0.37	Cognitive function;	chr4:39152216	chr4:39112677~39126818:-
LUAD	cis	rs10129255	0.957	rs10140904	ENSG00000223648.3	IGHV3-64	8.74	3.82e-17	4.79e-14	0.37	0.37	Kawasaki disease;	chr14:106776558	chr14:106643132~106658258:-
LUAD	cis	rs9399137	0.507	rs6940878	ENSG00000232876.1	CTA-212D2.2	-8.74	3.83e-17	4.81e-14	-0.44	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135045171	chr6:135055033~135060550:+
LUAD	cis	rs34779708	0.966	rs11010095	ENSG00000230534.5	RP11-297A16.2	8.74	3.86e-17	4.84e-14	0.44	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35107020	chr10:35098006~35127020:-
LUAD	cis	rs904251	0.6	rs4714068	ENSG00000204110.6	RP1-153P14.8	-8.74	3.87e-17	4.86e-14	-0.37	-0.37	Cognitive performance;	chr6:37487866	chr6:37507348~37535616:+
LUAD	cis	rs9545047	0.716	rs9545063	ENSG00000227676.3	LINC01068	8.74	3.9e-17	4.89e-14	0.45	0.37	Schizophrenia;	chr13:79316989	chr13:79566727~79571436:+
LUAD	cis	rs494459	0.838	rs566733	ENSG00000255239.1	AP002954.6	8.74	3.98e-17	4.99e-14	0.44	0.37	Height;	chr11:118737916	chr11:118688039~118690600:-
LUAD	cis	rs944289	0.617	rs1159048	ENSG00000257826.1	RP11-116N8.4	-8.74	3.99e-17	5e-14	-0.39	-0.37	Thyroid cancer;	chr14:36115428	chr14:36061026~36067190:-
LUAD	cis	rs10129255	0.701	rs2005643	ENSG00000223648.3	IGHV3-64	8.74	3.99e-17	5.01e-14	0.36	0.37	Kawasaki disease;	chr14:106676288	chr14:106643132~106658258:-
LUAD	cis	rs7429990	0.965	rs184388	ENSG00000229759.1	MRPS18AP1	8.74	4.03e-17	5.05e-14	0.39	0.37	Educational attainment (years of education);	chr3:47898136	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.965	rs319696	ENSG00000229759.1	MRPS18AP1	8.74	4.03e-17	5.05e-14	0.39	0.37	Educational attainment (years of education);	chr3:47902371	chr3:48256350~48256938:-
LUAD	cis	rs10129255	0.957	rs8009073	ENSG00000223648.3	IGHV3-64	8.74	4.04e-17	5.06e-14	0.37	0.37	Kawasaki disease;	chr14:106777278	chr14:106643132~106658258:-
LUAD	cis	rs7924176	0.549	rs2395076	ENSG00000213731.2	RAB5CP1	-8.74	4.05e-17	5.08e-14	-0.39	-0.37	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74172081	chr10:74423435~74424014:-
LUAD	cis	rs10740039	0.583	rs2127348	ENSG00000254271.1	RP11-131N11.4	-8.73	4.06e-17	5.09e-14	-0.41	-0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740945	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.583	rs2127349	ENSG00000254271.1	RP11-131N11.4	-8.73	4.06e-17	5.09e-14	-0.41	-0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740947	chr10:60734342~60741828:+
LUAD	cis	rs2283792	0.622	rs5756323	ENSG00000224086.5	LL22NC03-86G7.1	8.73	4.08e-17	5.11e-14	0.35	0.37	Multiple sclerosis;	chr22:21980398	chr22:21938293~21977632:+
LUAD	cis	rs7945705	0.719	rs2012680	ENSG00000254860.4	TMEM9B-AS1	8.73	4.08e-17	5.11e-14	0.4	0.37	Hemoglobin concentration;	chr11:8974512	chr11:8964675~8977527:+
LUAD	cis	rs16928809	0.52	rs74050440	ENSG00000183562.3	CTC-343N3.1	8.73	4.09e-17	5.12e-14	0.57	0.37	Bilirubin levels;	chr11:2941213	chr11:2989863~2991344:+
LUAD	cis	rs12594515	1	rs12906442	ENSG00000273972.1	CTD-2306A12.1	-8.73	4.1e-17	5.14e-14	-0.39	-0.37	Weight;Waist circumference;	chr15:45693056	chr15:45702640~45703183:+
LUAD	cis	rs6991838	0.557	rs7012578	ENSG00000272010.1	CTD-3025N20.3	-8.73	4.12e-17	5.16e-14	-0.41	-0.37	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65591850~65592472:-
LUAD	cis	rs944289	0.617	rs7151738	ENSG00000257826.1	RP11-116N8.4	-8.73	4.12e-17	5.16e-14	-0.39	-0.37	Thyroid cancer;	chr14:36114670	chr14:36061026~36067190:-
LUAD	cis	rs904251	0.772	rs1224127	ENSG00000204110.6	RP1-153P14.8	-8.73	4.18e-17	5.23e-14	-0.42	-0.37	Cognitive performance;	chr6:37449780	chr6:37507348~37535616:+
LUAD	cis	rs4423214	0.559	rs10898201	ENSG00000254682.1	RP11-660L16.2	-8.73	4.21e-17	5.27e-14	-0.57	-0.37	Vitamin D levels;	chr11:71490481	chr11:71448674~71452157:+
LUAD	cis	rs7945705	0.747	rs2568020	ENSG00000254860.4	TMEM9B-AS1	8.73	4.22e-17	5.28e-14	0.4	0.37	Hemoglobin concentration;	chr11:8973168	chr11:8964675~8977527:+
LUAD	cis	rs10463554	0.926	rs26429	ENSG00000175749.11	EIF3KP1	-8.73	4.22e-17	5.28e-14	-0.5	-0.37	Parkinson's disease;	chr5:103030349	chr5:103032376~103033031:+
LUAD	cis	rs12594515	1	rs6493169	ENSG00000273972.1	CTD-2306A12.1	8.73	4.23e-17	5.29e-14	0.4	0.37	Weight;Waist circumference;	chr15:45694796	chr15:45702640~45703183:+
LUAD	cis	rs9389248	0.69	rs1028314	ENSG00000232876.1	CTA-212D2.2	8.73	4.26e-17	5.33e-14	0.42	0.37	High light scatter reticulocyte percentage of red cells;	chr6:134934572	chr6:135055033~135060550:+
LUAD	cis	rs10740039	0.583	rs2127350	ENSG00000254271.1	RP11-131N11.4	-8.73	4.35e-17	5.43e-14	-0.41	-0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741079	chr10:60734342~60741828:+
LUAD	cis	rs10129255	1	rs10134517	ENSG00000223648.3	IGHV3-64	8.73	4.37e-17	5.46e-14	0.36	0.37	Kawasaki disease;	chr14:106718498	chr14:106643132~106658258:-
LUAD	cis	rs10463554	0.892	rs34816	ENSG00000175749.11	EIF3KP1	8.73	4.38e-17	5.47e-14	0.53	0.37	Parkinson's disease;	chr5:103098941	chr5:103032376~103033031:+
LUAD	cis	rs6142102	0.517	rs6142050	ENSG00000276073.1	RP5-1125A11.7	-8.73	4.38e-17	5.47e-14	-0.38	-0.37	Skin pigmentation;	chr20:33939322	chr20:33985617~33988989:-
LUAD	cis	rs496547	0.719	rs476246	ENSG00000278376.1	RP11-158I9.8	8.72	4.4e-17	5.5e-14	0.4	0.37	Hip minimal joint space width;	chr11:118747211	chr11:118791254~118793137:+
LUAD	cis	rs10262624	0.935	rs8180700	ENSG00000234286.1	AC006026.13	-8.72	4.4e-17	5.5e-14	-0.44	-0.37	Schizophrenia;	chr7:23870323	chr7:23680195~23680786:-
LUAD	cis	rs10262624	1	rs9769098	ENSG00000234286.1	AC006026.13	-8.72	4.42e-17	5.52e-14	-0.44	-0.37	Schizophrenia;	chr7:23877113	chr7:23680195~23680786:-
LUAD	cis	rs10262624	0.967	rs12333669	ENSG00000234286.1	AC006026.13	-8.72	4.42e-17	5.52e-14	-0.44	-0.37	Schizophrenia;	chr7:23877267	chr7:23680195~23680786:-
LUAD	cis	rs10262624	0.935	rs10487596	ENSG00000234286.1	AC006026.13	-8.72	4.42e-17	5.52e-14	-0.44	-0.37	Schizophrenia;	chr7:23877458	chr7:23680195~23680786:-
LUAD	cis	rs10262624	1	rs10950973	ENSG00000234286.1	AC006026.13	-8.72	4.42e-17	5.52e-14	-0.44	-0.37	Schizophrenia;	chr7:23877658	chr7:23680195~23680786:-
LUAD	cis	rs10262624	1	rs10950974	ENSG00000234286.1	AC006026.13	-8.72	4.42e-17	5.52e-14	-0.44	-0.37	Schizophrenia;	chr7:23877661	chr7:23680195~23680786:-
LUAD	cis	rs10262624	1	rs10950975	ENSG00000234286.1	AC006026.13	-8.72	4.42e-17	5.52e-14	-0.44	-0.37	Schizophrenia;	chr7:23877861	chr7:23680195~23680786:-
LUAD	cis	rs10262624	0.967	rs13244145	ENSG00000234286.1	AC006026.13	-8.72	4.42e-17	5.52e-14	-0.44	-0.37	Schizophrenia;	chr7:23878123	chr7:23680195~23680786:-
LUAD	cis	rs526231	0.511	rs3756582	ENSG00000175749.11	EIF3KP1	8.72	4.43e-17	5.53e-14	0.53	0.37	Primary biliary cholangitis;	chr5:103003848	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.511	rs45518833	ENSG00000175749.11	EIF3KP1	8.72	4.43e-17	5.53e-14	0.53	0.37	Primary biliary cholangitis;	chr5:103007286	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.511	rs1826673	ENSG00000175749.11	EIF3KP1	8.72	4.43e-17	5.53e-14	0.53	0.37	Primary biliary cholangitis;	chr5:103010212	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.511	rs62362545	ENSG00000175749.11	EIF3KP1	8.72	4.43e-17	5.53e-14	0.53	0.37	Primary biliary cholangitis;	chr5:103011748	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.511	rs3910557	ENSG00000175749.11	EIF3KP1	8.72	4.43e-17	5.53e-14	0.53	0.37	Primary biliary cholangitis;	chr5:103014767	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.511	rs2288389	ENSG00000175749.11	EIF3KP1	8.72	4.43e-17	5.53e-14	0.53	0.37	Primary biliary cholangitis;	chr5:103018104	chr5:103032376~103033031:+
LUAD	cis	rs6504622	0.702	rs2316758	ENSG00000262879.4	RP11-156P1.3	-8.72	4.45e-17	5.55e-14	-0.42	-0.37	Orofacial clefts;	chr17:46988999	chr17:46984045~47100323:-
LUAD	cis	rs7924176	0.601	rs7093532	ENSG00000213731.2	RAB5CP1	-8.72	4.47e-17	5.57e-14	-0.39	-0.37	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74178282	chr10:74423435~74424014:-
LUAD	cis	rs10740039	0.583	rs2127351	ENSG00000254271.1	RP11-131N11.4	-8.72	4.56e-17	5.68e-14	-0.41	-0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741425	chr10:60734342~60741828:+
LUAD	cis	rs7188445	0.932	rs3813582	ENSG00000261390.4	RP11-345M22.2	-8.72	4.63e-17	5.77e-14	-0.47	-0.37	Urate levels;	chr16:79715456	chr16:79715232~79770563:-
LUAD	cis	rs733592	1	rs733592	ENSG00000240399.1	RP1-228P16.1	-8.72	4.67e-17	5.82e-14	-0.35	-0.37	Plateletcrit;	chr12:48035993	chr12:48054813~48055591:-
LUAD	cis	rs733592	0.931	rs765260	ENSG00000240399.1	RP1-228P16.1	-8.72	4.67e-17	5.82e-14	-0.35	-0.37	Plateletcrit;	chr12:48038153	chr12:48054813~48055591:-
LUAD	cis	rs526231	0.511	rs58344084	ENSG00000175749.11	EIF3KP1	8.72	4.68e-17	5.83e-14	0.52	0.37	Primary biliary cholangitis;	chr5:103042508	chr5:103032376~103033031:+
LUAD	cis	rs1150668	0.796	rs1005125	ENSG00000204709.4	LINC01556	8.72	4.69e-17	5.84e-14	0.46	0.37	Pubertal anthropometrics;	chr6:28399578	chr6:28943877~28944537:+
LUAD	cis	rs2929278	0.561	rs2927071	ENSG00000249839.1	AC011330.5	-8.72	4.7e-17	5.86e-14	-0.49	-0.37	Schizophrenia;	chr15:43626883	chr15:43663654~43684339:-
LUAD	cis	rs10740039	0.583	rs2170005	ENSG00000254271.1	RP11-131N11.4	8.72	4.71e-17	5.87e-14	0.41	0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740842	chr10:60734342~60741828:+
LUAD	cis	rs11096990	0.634	rs2381371	ENSG00000249207.1	RP11-360F5.1	-8.72	4.72e-17	5.88e-14	-0.4	-0.37	Cognitive function;	chr4:39271414	chr4:39112677~39126818:-
LUAD	cis	rs10129255	0.957	rs10138532	ENSG00000223648.3	IGHV3-64	8.71	4.77e-17	5.94e-14	0.37	0.37	Kawasaki disease;	chr14:106803901	chr14:106643132~106658258:-
LUAD	cis	rs3823536	0.583	rs1874327	ENSG00000275106.1	RP11-309L24.10	-8.71	4.79e-17	5.97e-14	-0.47	-0.37	Sjögren's syndrome;	chr7:128945322	chr7:128952527~128953316:-
LUAD	cis	rs10256972	0.869	rs1007766	ENSG00000229043.2	AC091729.9	-8.71	4.8e-17	5.98e-14	-0.4	-0.37	Endometriosis;Longevity;	chr7:995267	chr7:1160374~1165267:+
LUAD	cis	rs1150668	0.699	rs1736895	ENSG00000216901.1	AL022393.7	8.71	4.83e-17	6.02e-14	0.43	0.37	Pubertal anthropometrics;	chr6:28252048	chr6:28176188~28176674:+
LUAD	cis	rs10262624	1	rs17347692	ENSG00000234286.1	AC006026.13	-8.71	4.86e-17	6.05e-14	-0.44	-0.37	Schizophrenia;	chr7:23878748	chr7:23680195~23680786:-
LUAD	cis	rs10740039	0.583	rs1904401	ENSG00000254271.1	RP11-131N11.4	-8.71	4.86e-17	6.05e-14	-0.41	-0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741809	chr10:60734342~60741828:+
LUAD	cis	rs9545047	0.716	rs6563096	ENSG00000227676.3	LINC01068	-8.71	4.9e-17	6.09e-14	-0.44	-0.37	Schizophrenia;	chr13:79284100	chr13:79566727~79571436:+
LUAD	cis	rs34779708	0.931	rs10466072	ENSG00000230534.5	RP11-297A16.2	8.71	4.9e-17	6.09e-14	0.43	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35113828	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.966	rs998658	ENSG00000230534.5	RP11-297A16.2	8.71	4.9e-17	6.09e-14	0.43	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35119726	chr10:35098006~35127020:-
LUAD	cis	rs4908760	0.757	rs301807	ENSG00000232912.4	RP5-1115A15.1	8.71	4.91e-17	6.1e-14	0.34	0.37	Vitiligo;	chr1:8424763	chr1:8424645~8434838:+
LUAD	cis	rs2108622	0.683	rs6512067	ENSG00000267453.5	AC004791.2	-8.71	4.91e-17	6.11e-14	-0.44	-0.37	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872141	chr19:15851993~15864904:-
LUAD	cis	rs10262624	1	rs17347733	ENSG00000234286.1	AC006026.13	-8.71	4.96e-17	6.16e-14	-0.44	-0.37	Schizophrenia;	chr7:23878891	chr7:23680195~23680786:-
LUAD	cis	rs6565180	0.507	rs4471699	ENSG00000183604.13	SMG1P5	-8.71	4.98e-17	6.19e-14	-0.37	-0.37	Tonsillectomy;	chr16:30308986	chr16:30267553~30335374:-
LUAD	cis	rs9399137	0.507	rs61738647	ENSG00000232876.1	CTA-212D2.2	-8.71	4.99e-17	6.21e-14	-0.43	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134961597	chr6:135055033~135060550:+
LUAD	cis	rs34779708	0.931	rs12767414	ENSG00000230534.5	RP11-297A16.2	8.71	5.01e-17	6.23e-14	0.43	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35101265	chr10:35098006~35127020:-
LUAD	cis	rs13392177	0.66	rs62185964	ENSG00000261338.2	RP11-378A13.1	-8.71	5.04e-17	6.26e-14	-0.38	-0.37	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209022	chr2:218255319~218257366:+
LUAD	cis	rs13392177	0.684	rs62185965	ENSG00000261338.2	RP11-378A13.1	-8.71	5.04e-17	6.26e-14	-0.38	-0.37	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209056	chr2:218255319~218257366:+
LUAD	cis	rs13392177	0.66	rs10932762	ENSG00000261338.2	RP11-378A13.1	-8.71	5.04e-17	6.26e-14	-0.38	-0.37	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218211490	chr2:218255319~218257366:+
LUAD	cis	rs13392177	0.684	rs11682371	ENSG00000261338.2	RP11-378A13.1	-8.71	5.04e-17	6.26e-14	-0.38	-0.37	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218214790	chr2:218255319~218257366:+
LUAD	cis	rs9399137	0.507	rs11757723	ENSG00000232876.1	CTA-212D2.2	-8.71	5.04e-17	6.26e-14	-0.43	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134970155	chr6:135055033~135060550:+
LUAD	cis	rs11214589	0.747	rs7939992	ENSG00000270179.1	RP11-159N11.4	-8.71	5.09e-17	6.32e-14	-0.37	-0.37	Neuroticism;	chr11:113358943	chr11:113368478~113369117:+
LUAD	cis	rs11098499	0.644	rs7676296	ENSG00000245958.5	RP11-33B1.1	-8.71	5.09e-17	6.33e-14	-0.34	-0.37	Corneal astigmatism;	chr4:119634532	chr4:119454791~119552025:+
LUAD	cis	rs10875746	0.768	rs12305182	ENSG00000240399.1	RP1-228P16.1	-8.7	5.13e-17	6.37e-14	-0.43	-0.37	Longevity (90 years and older);	chr12:48027624	chr12:48054813~48055591:-
LUAD	cis	rs1061377	0.585	rs3733271	ENSG00000249207.1	RP11-360F5.1	-8.7	5.14e-17	6.38e-14	-0.41	-0.37	Uric acid levels;	chr4:39047948	chr4:39112677~39126818:-
LUAD	cis	rs904251	0.62	rs883372	ENSG00000204110.6	RP1-153P14.8	-8.7	5.15e-17	6.4e-14	-0.45	-0.37	Cognitive performance;	chr6:37509829	chr6:37507348~37535616:+
LUAD	cis	rs12134133	1	rs7526831	ENSG00000274245.1	RP11-357P18.2	8.7	5.3e-17	6.57e-14	0.49	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207265261	chr1:207372559~207373252:+
LUAD	cis	rs4927850	1	rs4927850	ENSG00000231464.1	AC024937.4	-8.7	5.33e-17	6.61e-14	-0.42	-0.37	Pancreatic cancer;	chr3:196024759	chr3:195996738~195998233:+
LUAD	cis	rs6991838	0.55	rs4737750	ENSG00000200714.1	Y_RNA	8.7	5.34e-17	6.62e-14	0.45	0.37	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65592731~65592820:+
LUAD	cis	rs673078	0.66	rs17512609	ENSG00000275759.1	RP11-131L12.3	-8.7	5.35e-17	6.63e-14	-0.52	-0.37	Glucose homeostasis traits;	chr12:118354072	chr12:118428281~118428870:+
LUAD	cis	rs9481169	0.85	rs35815577	ENSG00000255389.1	C6orf3	-8.7	5.37e-17	6.65e-14	-0.84	-0.37	Inflammatory skin disease;	chr6:111603527	chr6:111599875~111602295:+
LUAD	cis	rs944289	0.617	rs1952708	ENSG00000257826.1	RP11-116N8.4	-8.7	5.41e-17	6.7e-14	-0.39	-0.37	Thyroid cancer;	chr14:36113126	chr14:36061026~36067190:-
LUAD	cis	rs1075265	0.584	rs1833497	ENSG00000233266.1	HMGB1P31	8.7	5.41e-17	6.7e-14	0.48	0.37	Chronotype;Morning vs. evening chronotype;	chr2:54052186	chr2:54051334~54051760:+
LUAD	cis	rs673078	0.607	rs61943443	ENSG00000275759.1	RP11-131L12.3	-8.7	5.41e-17	6.7e-14	-0.51	-0.37	Glucose homeostasis traits;	chr12:118416602	chr12:118428281~118428870:+
LUAD	cis	rs7188445	1	rs11150190	ENSG00000261390.4	RP11-345M22.2	-8.7	5.42e-17	6.71e-14	-0.47	-0.37	Urate levels;	chr16:79700352	chr16:79715232~79770563:-
LUAD	cis	rs12594515	1	rs6493172	ENSG00000273972.1	CTD-2306A12.1	-8.7	5.42e-17	6.72e-14	-0.4	-0.37	Weight;Waist circumference;	chr15:45695015	chr15:45702640~45703183:+
LUAD	cis	rs11098499	0.698	rs4422403	ENSG00000245958.5	RP11-33B1.1	-8.7	5.46e-17	6.76e-14	-0.32	-0.37	Corneal astigmatism;	chr4:119337039	chr4:119454791~119552025:+
LUAD	cis	rs4718428	1	rs1830070	ENSG00000226824.5	RP4-756H11.3	-8.7	5.49e-17	6.8e-14	-0.47	-0.37	Corneal structure;	chr7:66884684	chr7:66654538~66669855:+
LUAD	cis	rs3931020	0.772	rs11485555	ENSG00000272864.1	RP11-17E13.2	-8.69	5.51e-17	6.82e-14	-0.45	-0.37	Resistin levels;	chr1:74720825	chr1:74698769~74699333:-
LUAD	cis	rs9309711	0.544	rs9752130	ENSG00000225234.1	TRAPPC12-AS1	-8.69	5.53e-17	6.84e-14	-0.43	-0.37	Neurofibrillary tangles;	chr2:3484731	chr2:3481242~3482409:-
LUAD	cis	rs11098499	0.661	rs10015965	ENSG00000245958.5	RP11-33B1.1	-8.69	5.55e-17	6.87e-14	-0.31	-0.37	Corneal astigmatism;	chr4:119347082	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.535	rs10005542	ENSG00000245958.5	RP11-33B1.1	-8.69	5.55e-17	6.87e-14	-0.31	-0.37	Corneal astigmatism;	chr4:119347147	chr4:119454791~119552025:+
LUAD	cis	rs7429990	0.965	rs4858887	ENSG00000229759.1	MRPS18AP1	-8.69	5.59e-17	6.92e-14	-0.4	-0.37	Educational attainment (years of education);	chr3:48050527	chr3:48256350~48256938:-
LUAD	cis	rs10129255	0.957	rs8014696	ENSG00000223648.3	IGHV3-64	-8.69	5.59e-17	6.92e-14	-0.36	-0.37	Kawasaki disease;	chr14:106769752	chr14:106643132~106658258:-
LUAD	cis	rs2283792	0.73	rs894095	ENSG00000224086.5	LL22NC03-86G7.1	-8.69	5.62e-17	6.95e-14	-0.34	-0.37	Multiple sclerosis;	chr22:21928404	chr22:21938293~21977632:+
LUAD	cis	rs6504622	0.755	rs12938690	ENSG00000262879.4	RP11-156P1.3	-8.69	5.62e-17	6.96e-14	-0.42	-0.37	Orofacial clefts;	chr17:46997999	chr17:46984045~47100323:-
LUAD	cis	rs1150668	0.799	rs1150705	ENSG00000216901.1	AL022393.7	8.69	5.65e-17	6.99e-14	0.43	0.37	Pubertal anthropometrics;	chr6:28226008	chr6:28176188~28176674:+
LUAD	cis	rs7429990	0.965	rs9846062	ENSG00000229759.1	MRPS18AP1	8.69	5.72e-17	7.08e-14	0.38	0.37	Educational attainment (years of education);	chr3:47957476	chr3:48256350~48256938:-
LUAD	cis	rs2337406	0.925	rs11851094	ENSG00000274576.2	IGHV2-70	-8.69	5.75e-17	7.11e-14	-0.4	-0.37	Alzheimer's disease (late onset);	chr14:106688967	chr14:106770577~106771020:-
LUAD	cis	rs1185460	0.967	rs1168568	ENSG00000271751.1	RP11-110I1.14	-8.69	5.75e-17	7.12e-14	-0.46	-0.37	Coronary artery disease;	chr11:119079089	chr11:119065263~119065677:-
LUAD	cis	rs11098499	0.569	rs10023641	ENSG00000245958.5	RP11-33B1.1	-8.69	5.77e-17	7.14e-14	-0.32	-0.37	Corneal astigmatism;	chr4:119337255	chr4:119454791~119552025:+
LUAD	cis	rs1150668	0.768	rs1233713	ENSG00000216901.1	AL022393.7	8.69	5.79e-17	7.17e-14	0.43	0.37	Pubertal anthropometrics;	chr6:28230503	chr6:28176188~28176674:+
LUAD	cis	rs6991838	0.584	rs7459944	ENSG00000200714.1	Y_RNA	-8.69	5.8e-17	7.18e-14	-0.46	-0.37	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65592731~65592820:+
LUAD	cis	rs17023223	0.537	rs12092807	ENSG00000231365.4	RP11-418J17.1	8.69	5.84e-17	7.22e-14	0.51	0.37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119208021	chr1:119140396~119275973:+
LUAD	cis	rs9399137	0.561	rs11753985	ENSG00000232876.1	CTA-212D2.2	-8.69	5.85e-17	7.24e-14	-0.43	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134959300	chr6:135055033~135060550:+
LUAD	cis	rs1185460	0.967	rs1177563	ENSG00000271751.1	RP11-110I1.14	-8.69	5.86e-17	7.24e-14	-0.45	-0.37	Coronary artery disease;	chr11:119078373	chr11:119065263~119065677:-
LUAD	cis	rs944289	0.646	rs8007617	ENSG00000257826.1	RP11-116N8.4	-8.69	5.87e-17	7.26e-14	-0.38	-0.37	Thyroid cancer;	chr14:36088883	chr14:36061026~36067190:-
LUAD	cis	rs6991838	0.584	rs4388482	ENSG00000200714.1	Y_RNA	-8.69	5.9e-17	7.29e-14	-0.45	-0.37	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs4637885	ENSG00000200714.1	Y_RNA	-8.69	5.9e-17	7.29e-14	-0.45	-0.37	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.556	rs7846527	ENSG00000200714.1	Y_RNA	-8.69	5.9e-17	7.29e-14	-0.45	-0.37	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs4320587	ENSG00000200714.1	Y_RNA	-8.69	5.9e-17	7.29e-14	-0.45	-0.37	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs35941313	ENSG00000200714.1	Y_RNA	-8.69	5.9e-17	7.29e-14	-0.45	-0.37	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.557	rs4737222	ENSG00000200714.1	Y_RNA	-8.69	5.9e-17	7.29e-14	-0.45	-0.37	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65592731~65592820:+
LUAD	cis	rs11676348	0.755	rs1008562	ENSG00000261338.2	RP11-378A13.1	8.69	5.92e-17	7.32e-14	0.39	0.37	Ulcerative colitis;	chr2:218162249	chr2:218255319~218257366:+
LUAD	cis	rs10028773	0.6	rs4001390	ENSG00000245958.5	RP11-33B1.1	-8.69	5.93e-17	7.32e-14	-0.31	-0.37	Educational attainment;	chr4:119344628	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.691	rs2136911	ENSG00000245958.5	RP11-33B1.1	-8.69	5.93e-17	7.32e-14	-0.31	-0.37	Corneal astigmatism;	chr4:119344704	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.554	rs2175381	ENSG00000245958.5	RP11-33B1.1	-8.69	5.93e-17	7.32e-14	-0.31	-0.37	Corneal astigmatism;	chr4:119344812	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.599	rs3864142	ENSG00000245958.5	RP11-33B1.1	-8.69	5.93e-17	7.32e-14	-0.31	-0.37	Corneal astigmatism;	chr4:119345036	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.605	rs6833140	ENSG00000245958.5	RP11-33B1.1	-8.69	5.93e-17	7.32e-14	-0.31	-0.37	Corneal astigmatism;	chr4:119345667	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.779	rs6815934	ENSG00000245958.5	RP11-33B1.1	-8.69	5.93e-17	7.32e-14	-0.31	-0.37	Corneal astigmatism;	chr4:119346155	chr4:119454791~119552025:+
LUAD	cis	rs2739330	0.703	rs5760112	ENSG00000099984.9	GSTT2	-8.68	5.95e-17	7.34e-14	-0.44	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23980123~23983911:+
LUAD	cis	rs9532669	0.89	rs4941999	ENSG00000176268.5	CYCSP34	8.68	5.96e-17	7.35e-14	0.36	0.37	Cervical cancer;	chr13:40859926	chr13:40863599~40863902:-
LUAD	cis	rs1150668	0.799	rs2142730	ENSG00000204709.4	LINC01556	8.68	6.02e-17	7.44e-14	0.45	0.37	Pubertal anthropometrics;	chr6:28298372	chr6:28943877~28944537:+
LUAD	cis	rs8005677	0.828	rs4981450	ENSG00000279656.1	RP11-298I3.6	8.68	6.07e-17	7.49e-14	0.44	0.37	Cognitive ability (multi-trait analysis);	chr14:22920095	chr14:23023083~23024217:-
LUAD	cis	rs13392177	0.647	rs6718220	ENSG00000261338.2	RP11-378A13.1	-8.68	6.12e-17	7.55e-14	-0.38	-0.37	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218201795	chr2:218255319~218257366:+
LUAD	cis	rs507080	0.501	rs494459	ENSG00000255239.1	AP002954.6	-8.68	6.15e-17	7.59e-14	-0.42	-0.37	Serum metabolite levels;	chr11:118703966	chr11:118688039~118690600:-
LUAD	cis	rs13392177	0.543	rs12623716	ENSG00000261338.2	RP11-378A13.1	-8.68	6.15e-17	7.59e-14	-0.38	-0.37	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218208295	chr2:218255319~218257366:+
LUAD	cis	rs56046484	0.871	rs35000527	ENSG00000259295.5	CSPG4P12	8.68	6.16e-17	7.6e-14	0.57	0.37	Testicular germ cell tumor;	chr15:85010550	chr15:85191438~85213905:+
LUAD	cis	rs56046484	0.826	rs35816571	ENSG00000259295.5	CSPG4P12	8.68	6.16e-17	7.6e-14	0.57	0.37	Testicular germ cell tumor;	chr15:85010891	chr15:85191438~85213905:+
LUAD	cis	rs11098499	0.644	rs7693919	ENSG00000245958.5	RP11-33B1.1	-8.68	6.21e-17	7.66e-14	-0.34	-0.37	Corneal astigmatism;	chr4:119619416	chr4:119454791~119552025:+
LUAD	cis	rs6504622	0.702	rs3851796	ENSG00000262879.4	RP11-156P1.3	-8.68	6.28e-17	7.73e-14	-0.41	-0.37	Orofacial clefts;	chr17:46983809	chr17:46984045~47100323:-
LUAD	cis	rs4927850	0.881	rs7624638	ENSG00000231464.1	AC024937.4	8.68	6.28e-17	7.74e-14	0.43	0.37	Pancreatic cancer;	chr3:196021858	chr3:195996738~195998233:+
LUAD	cis	rs56046484	0.871	rs12900736	ENSG00000259295.5	CSPG4P12	8.68	6.29e-17	7.75e-14	0.57	0.37	Testicular germ cell tumor;	chr15:85014909	chr15:85191438~85213905:+
LUAD	cis	rs56046484	0.871	rs12904958	ENSG00000259295.5	CSPG4P12	8.68	6.29e-17	7.75e-14	0.57	0.37	Testicular germ cell tumor;	chr15:85014956	chr15:85191438~85213905:+
LUAD	cis	rs56046484	0.871	rs34493704	ENSG00000259295.5	CSPG4P12	8.68	6.29e-17	7.75e-14	0.57	0.37	Testicular germ cell tumor;	chr15:85015539	chr15:85191438~85213905:+
LUAD	cis	rs56046484	0.871	rs71397837	ENSG00000259295.5	CSPG4P12	8.68	6.29e-17	7.75e-14	0.57	0.37	Testicular germ cell tumor;	chr15:85020330	chr15:85191438~85213905:+
LUAD	cis	rs56046484	0.871	rs62021203	ENSG00000259295.5	CSPG4P12	8.68	6.29e-17	7.75e-14	0.57	0.37	Testicular germ cell tumor;	chr15:85020846	chr15:85191438~85213905:+
LUAD	cis	rs7188445	1	rs7190187	ENSG00000261390.4	RP11-345M22.2	-8.68	6.31e-17	7.77e-14	-0.47	-0.37	Urate levels;	chr16:79701281	chr16:79715232~79770563:-
LUAD	cis	rs34779708	0.931	rs10437420	ENSG00000230534.5	RP11-297A16.2	-8.68	6.31e-17	7.78e-14	-0.43	-0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35046116	chr10:35098006~35127020:-
LUAD	cis	rs1075265	0.584	rs7558126	ENSG00000233266.1	HMGB1P31	8.68	6.36e-17	7.83e-14	0.48	0.37	Chronotype;Morning vs. evening chronotype;	chr2:54053847	chr2:54051334~54051760:+
LUAD	cis	rs10256972	1	rs10256972	ENSG00000229043.2	AC091729.9	8.68	6.37e-17	7.84e-14	0.39	0.37	Endometriosis;Longevity;	chr7:999367	chr7:1160374~1165267:+
LUAD	cis	rs62034325	0.697	rs710410	ENSG00000259982.1	CDC37P1	8.67	6.42e-17	7.9e-14	0.48	0.37	Body mass index;	chr16:28592021	chr16:28700294~28701540:-
LUAD	cis	rs2283792	0.622	rs2266979	ENSG00000224086.5	LL22NC03-86G7.1	-8.67	6.48e-17	7.98e-14	-0.35	-0.37	Multiple sclerosis;	chr22:21977447	chr22:21938293~21977632:+
LUAD	cis	rs1789	0.872	rs4333182	ENSG00000273133.1	RP11-799M12.2	-8.67	6.51e-17	8.01e-14	-0.53	-0.37	Blood protein levels;	chr4:15683089	chr4:15563698~15564253:-
LUAD	cis	rs12594515	1	rs8026221	ENSG00000273972.1	CTD-2306A12.1	-8.67	6.53e-17	8.04e-14	-0.39	-0.37	Weight;Waist circumference;	chr15:45695712	chr15:45702640~45703183:+
LUAD	cis	rs12594515	1	rs8031128	ENSG00000273972.1	CTD-2306A12.1	-8.67	6.53e-17	8.04e-14	-0.39	-0.37	Weight;Waist circumference;	chr15:45696330	chr15:45702640~45703183:+
LUAD	cis	rs12594515	1	rs8032361	ENSG00000273972.1	CTD-2306A12.1	-8.67	6.53e-17	8.04e-14	-0.39	-0.37	Weight;Waist circumference;	chr15:45696355	chr15:45702640~45703183:+
LUAD	cis	rs12594515	0.967	rs71405295	ENSG00000273972.1	CTD-2306A12.1	-8.67	6.53e-17	8.04e-14	-0.39	-0.37	Weight;Waist circumference;	chr15:45696723	chr15:45702640~45703183:+
LUAD	cis	rs673078	0.607	rs61943391	ENSG00000275759.1	RP11-131L12.3	-8.67	6.55e-17	8.05e-14	-0.51	-0.37	Glucose homeostasis traits;	chr12:118382603	chr12:118428281~118428870:+
LUAD	cis	rs10463554	0.963	rs34772	ENSG00000175749.11	EIF3KP1	8.67	6.6e-17	8.11e-14	0.52	0.37	Parkinson's disease;	chr5:103114808	chr5:103032376~103033031:+
LUAD	cis	rs10262624	1	rs11767124	ENSG00000234286.1	AC006026.13	-8.67	6.6e-17	8.12e-14	-0.45	-0.37	Schizophrenia;	chr7:23879461	chr7:23680195~23680786:-
LUAD	cis	rs10262624	0.967	rs10229233	ENSG00000234286.1	AC006026.13	-8.67	6.62e-17	8.14e-14	-0.44	-0.37	Schizophrenia;	chr7:23867900	chr7:23680195~23680786:-
LUAD	cis	rs10262624	1	rs10245161	ENSG00000234286.1	AC006026.13	-8.67	6.62e-17	8.14e-14	-0.44	-0.37	Schizophrenia;	chr7:23868073	chr7:23680195~23680786:-
LUAD	cis	rs2739330	0.587	rs4820571	ENSG00000099984.9	GSTT2	-8.67	6.62e-17	8.15e-14	-0.44	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23980123~23983911:+
LUAD	cis	rs10129255	0.957	rs10142918	ENSG00000223648.3	IGHV3-64	8.67	6.64e-17	8.16e-14	0.36	0.37	Kawasaki disease;	chr14:106782206	chr14:106643132~106658258:-
LUAD	cis	rs11098499	0.644	rs28787668	ENSG00000245958.5	RP11-33B1.1	-8.67	6.72e-17	8.26e-14	-0.34	-0.37	Corneal astigmatism;	chr4:119633532	chr4:119454791~119552025:+
LUAD	cis	rs9326248	0.861	rs4938353	ENSG00000280143.1	AP000892.6	8.67	6.73e-17	8.27e-14	0.49	0.37	Blood protein levels;	chr11:117175481	chr11:117204967~117210292:+
LUAD	cis	rs6504622	0.702	rs3851799	ENSG00000262879.4	RP11-156P1.3	-8.67	6.78e-17	8.32e-14	-0.42	-0.37	Orofacial clefts;	chr17:46989122	chr17:46984045~47100323:-
LUAD	cis	rs6504622	0.667	rs11653589	ENSG00000262879.4	RP11-156P1.3	-8.67	6.78e-17	8.32e-14	-0.42	-0.37	Orofacial clefts;	chr17:46990299	chr17:46984045~47100323:-
LUAD	cis	rs6504622	0.634	rs8068715	ENSG00000262879.4	RP11-156P1.3	-8.67	6.78e-17	8.32e-14	-0.42	-0.37	Orofacial clefts;	chr17:46991022	chr17:46984045~47100323:-
LUAD	cis	rs6504622	0.514	rs60611133	ENSG00000262879.4	RP11-156P1.3	-8.67	6.78e-17	8.32e-14	-0.42	-0.37	Orofacial clefts;	chr17:46993027	chr17:46984045~47100323:-
LUAD	cis	rs10129255	0.785	rs10150044	ENSG00000223648.3	IGHV3-64	8.67	6.79e-17	8.34e-14	0.36	0.37	Kawasaki disease;	chr14:106775695	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.957	rs10137980	ENSG00000223648.3	IGHV3-64	8.67	6.79e-17	8.34e-14	0.36	0.37	Kawasaki disease;	chr14:106775735	chr14:106643132~106658258:-
LUAD	cis	rs3823536	0.583	rs1072767	ENSG00000275106.1	RP11-309L24.10	-8.67	6.84e-17	8.4e-14	-0.47	-0.37	Sjögren's syndrome;	chr7:129033151	chr7:128952527~128953316:-
LUAD	cis	rs11098499	0.644	rs3986377	ENSG00000245958.5	RP11-33B1.1	-8.67	6.9e-17	8.47e-14	-0.31	-0.37	Corneal astigmatism;	chr4:119339115	chr4:119454791~119552025:+
LUAD	cis	rs10028773	0.556	rs4473640	ENSG00000245958.5	RP11-33B1.1	-8.67	6.9e-17	8.47e-14	-0.31	-0.37	Educational attainment;	chr4:119339282	chr4:119454791~119552025:+
LUAD	cis	rs9322193	0.923	rs55993747	ENSG00000223701.3	RAET1E-AS1	8.66	6.92e-17	8.49e-14	0.43	0.37	Lung cancer;	chr6:149622016	chr6:149884431~149919508:+
LUAD	cis	rs7429990	0.965	rs7430879	ENSG00000229759.1	MRPS18AP1	-8.66	6.93e-17	8.5e-14	-0.38	-0.37	Educational attainment (years of education);	chr3:47997224	chr3:48256350~48256938:-
LUAD	cis	rs11214589	0.719	rs10891535	ENSG00000270179.1	RP11-159N11.4	-8.66	6.94e-17	8.52e-14	-0.37	-0.37	Neuroticism;	chr11:113330558	chr11:113368478~113369117:+
LUAD	cis	rs10129255	1	rs11627342	ENSG00000211970.3	IGHV4-61	-8.66	6.95e-17	8.52e-14	-0.29	-0.37	Kawasaki disease;	chr14:106675823	chr14:106639119~106639657:-
LUAD	cis	rs7429990	0.965	rs11130154	ENSG00000229759.1	MRPS18AP1	-8.66	7.01e-17	8.6e-14	-0.38	-0.37	Educational attainment (years of education);	chr3:48027752	chr3:48256350~48256938:-
LUAD	cis	rs12594515	0.967	rs11856523	ENSG00000273972.1	CTD-2306A12.1	-8.66	7.04e-17	8.63e-14	-0.39	-0.37	Weight;Waist circumference;	chr15:45697297	chr15:45702640~45703183:+
LUAD	cis	rs17711722	0.522	rs4642526	ENSG00000164669.11	INTS4P1	-8.66	7.1e-17	8.7e-14	-0.43	-0.37	Calcium levels;	chr7:65751755	chr7:65141225~65234216:+
LUAD	cis	rs11690935	0.843	rs9784070	ENSG00000228389.1	AC068039.4	8.66	7.1e-17	8.71e-14	0.43	0.37	Schizophrenia;	chr2:171928497	chr2:171773482~171775844:+
LUAD	cis	rs9545047	0.716	rs7140027	ENSG00000227676.3	LINC01068	8.66	7.11e-17	8.72e-14	0.44	0.37	Schizophrenia;	chr13:79281162	chr13:79566727~79571436:+
LUAD	cis	rs1150668	0.799	rs7206	ENSG00000216901.1	AL022393.7	8.66	7.17e-17	8.78e-14	0.43	0.37	Pubertal anthropometrics;	chr6:28233360	chr6:28176188~28176674:+
LUAD	cis	rs7688540	0.61	rs6830496	ENSG00000275426.1	CH17-262A2.1	8.66	7.26e-17	8.89e-14	0.48	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:221985	chr4:149738~150317:+
LUAD	cis	rs9545047	0.716	rs418150	ENSG00000227676.3	LINC01068	-8.66	7.39e-17	9.05e-14	-0.44	-0.37	Schizophrenia;	chr13:79432675	chr13:79566727~79571436:+
LUAD	cis	rs7174755	0.608	rs10162905	ENSG00000260657.2	RP11-315D16.4	8.66	7.42e-17	9.08e-14	0.44	0.37	Major depressive disorder;	chr15:68103709	chr15:68267792~68277994:-
LUAD	cis	rs10256972	0.869	rs4720158	ENSG00000229043.2	AC091729.9	-8.66	7.44e-17	9.11e-14	-0.39	-0.37	Endometriosis;Longevity;	chr7:1000689	chr7:1160374~1165267:+
LUAD	cis	rs9399137	0.507	rs7768278	ENSG00000232876.1	CTA-212D2.2	-8.65	7.49e-17	9.16e-14	-0.42	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134953819	chr6:135055033~135060550:+
LUAD	cis	rs12468226	0.938	rs10931993	ENSG00000273456.1	RP11-686O6.2	8.65	7.5e-17	9.18e-14	0.56	0.37	Urate levels;	chr2:202243017	chr2:202374932~202375604:-
LUAD	cis	rs12594515	1	rs8038058	ENSG00000273972.1	CTD-2306A12.1	-8.65	7.55e-17	9.23e-14	-0.39	-0.37	Weight;Waist circumference;	chr15:45698074	chr15:45702640~45703183:+
LUAD	cis	rs673078	0.607	rs61943389	ENSG00000275759.1	RP11-131L12.3	-8.65	7.56e-17	9.25e-14	-0.52	-0.37	Glucose homeostasis traits;	chr12:118377467	chr12:118428281~118428870:+
LUAD	cis	rs853679	0.506	rs1150711	ENSG00000216901.1	AL022393.7	8.65	7.6e-17	9.29e-14	0.44	0.37	Depression;	chr6:28240757	chr6:28176188~28176674:+
LUAD	cis	rs1185460	0.967	rs1184902	ENSG00000271751.1	RP11-110I1.14	-8.65	7.6e-17	9.29e-14	-0.45	-0.37	Coronary artery disease;	chr11:119074627	chr11:119065263~119065677:-
LUAD	cis	rs8005677	0.828	rs12589539	ENSG00000279656.1	RP11-298I3.6	8.65	7.67e-17	9.38e-14	0.44	0.37	Cognitive ability (multi-trait analysis);	chr14:22927471	chr14:23023083~23024217:-
LUAD	cis	rs12594515	1	rs6493175	ENSG00000273972.1	CTD-2306A12.1	-8.65	7.74e-17	9.46e-14	-0.39	-0.37	Weight;Waist circumference;	chr15:45697700	chr15:45702640~45703183:+
LUAD	cis	rs12594515	1	rs6493176	ENSG00000273972.1	CTD-2306A12.1	-8.65	7.74e-17	9.46e-14	-0.39	-0.37	Weight;Waist circumference;	chr15:45697828	chr15:45702640~45703183:+
LUAD	cis	rs12594515	0.967	rs8039088	ENSG00000273972.1	CTD-2306A12.1	-8.65	7.74e-17	9.46e-14	-0.39	-0.37	Weight;Waist circumference;	chr15:45697980	chr15:45702640~45703183:+
LUAD	cis	rs12594515	1	rs8038320	ENSG00000273972.1	CTD-2306A12.1	-8.65	7.74e-17	9.46e-14	-0.39	-0.37	Weight;Waist circumference;	chr15:45698069	chr15:45702640~45703183:+
LUAD	cis	rs12594515	0.967	rs67854274	ENSG00000273972.1	CTD-2306A12.1	-8.65	7.74e-17	9.46e-14	-0.39	-0.37	Weight;Waist circumference;	chr15:45698320	chr15:45702640~45703183:+
LUAD	cis	rs12594515	1	rs58368732	ENSG00000273972.1	CTD-2306A12.1	-8.65	7.74e-17	9.46e-14	-0.39	-0.37	Weight;Waist circumference;	chr15:45698333	chr15:45702640~45703183:+
LUAD	cis	rs12594515	1	rs7172161	ENSG00000273972.1	CTD-2306A12.1	-8.65	7.74e-17	9.46e-14	-0.39	-0.37	Weight;Waist circumference;	chr15:45698582	chr15:45702640~45703183:+
LUAD	cis	rs12594515	1	rs7173144	ENSG00000273972.1	CTD-2306A12.1	-8.65	7.74e-17	9.46e-14	-0.39	-0.37	Weight;Waist circumference;	chr15:45698998	chr15:45702640~45703183:+
LUAD	cis	rs1185460	0.934	rs10892328	ENSG00000271751.1	RP11-110I1.14	-8.65	7.76e-17	9.48e-14	-0.45	-0.37	Coronary artery disease;	chr11:119071944	chr11:119065263~119065677:-
LUAD	cis	rs1185460	0.967	rs3825061	ENSG00000271751.1	RP11-110I1.14	-8.65	7.76e-17	9.48e-14	-0.45	-0.37	Coronary artery disease;	chr11:119073965	chr11:119065263~119065677:-
LUAD	cis	rs11098499	0.691	rs10010355	ENSG00000245958.5	RP11-33B1.1	-8.65	7.78e-17	9.5e-14	-0.31	-0.37	Corneal astigmatism;	chr4:119339888	chr4:119454791~119552025:+
LUAD	cis	rs4718428	1	rs4718428	ENSG00000226824.5	RP4-756H11.3	-8.65	7.8e-17	9.52e-14	-0.47	-0.37	Corneal structure;	chr7:66956459	chr7:66654538~66669855:+
LUAD	cis	rs13423976	0.6	rs35776111	ENSG00000231367.4	AC016995.3	8.65	7.83e-17	9.56e-14	0.48	0.37	Gut microbiome composition (summer);	chr2:38515087	chr2:38406719~38515740:-
LUAD	cis	rs4927850	0.958	rs1975582	ENSG00000231464.1	AC024937.4	8.65	7.87e-17	9.61e-14	0.42	0.37	Pancreatic cancer;	chr3:196024568	chr3:195996738~195998233:+
LUAD	cis	rs4423214	0.559	rs10898203	ENSG00000254682.1	RP11-660L16.2	-8.65	7.89e-17	9.63e-14	-0.58	-0.37	Vitamin D levels;	chr11:71492390	chr11:71448674~71452157:+
LUAD	cis	rs7429990	0.965	rs5012971	ENSG00000229759.1	MRPS18AP1	-8.65	7.91e-17	9.66e-14	-0.38	-0.37	Educational attainment (years of education);	chr3:48033057	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.965	rs7653368	ENSG00000229759.1	MRPS18AP1	8.65	7.95e-17	9.71e-14	0.38	0.37	Educational attainment (years of education);	chr3:47943871	chr3:48256350~48256938:-
LUAD	cis	rs10129255	0.957	rs8009948	ENSG00000223648.3	IGHV3-64	8.65	7.96e-17	9.71e-14	0.37	0.37	Kawasaki disease;	chr14:106805607	chr14:106643132~106658258:-
LUAD	cis	rs9322193	0.847	rs12191643	ENSG00000223701.3	RAET1E-AS1	8.65	8e-17	9.76e-14	0.43	0.37	Lung cancer;	chr6:149628912	chr6:149884431~149919508:+
LUAD	cis	rs6142102	0.625	rs6142051	ENSG00000276073.1	RP5-1125A11.7	-8.65	8.03e-17	9.8e-14	-0.37	-0.37	Skin pigmentation;	chr20:33945212	chr20:33985617~33988989:-
LUAD	cis	rs11096990	0.551	rs11724855	ENSG00000249207.1	RP11-360F5.1	-8.64	8.07e-17	9.84e-14	-0.41	-0.37	Cognitive function;	chr4:39163379	chr4:39112677~39126818:-
LUAD	cis	rs7429990	0.93	rs11130152	ENSG00000229759.1	MRPS18AP1	-8.64	8.11e-17	9.89e-14	-0.38	-0.37	Educational attainment (years of education);	chr3:48014919	chr3:48256350~48256938:-
LUAD	cis	rs10256972	0.967	rs7799110	ENSG00000229043.2	AC091729.9	-8.64	8.14e-17	9.93e-14	-0.39	-0.37	Endometriosis;Longevity;	chr7:999429	chr7:1160374~1165267:+
LUAD	cis	rs4888378	0.576	rs8050367	ENSG00000261783.1	RP11-252K23.2	8.64	8.2e-17	9.99e-14	0.55	0.37	Coronary artery disease;	chr16:75279360	chr16:75379818~75381260:-
LUAD	cis	rs673078	0.607	rs17440942	ENSG00000275759.1	RP11-131L12.3	8.64	8.2e-17	1e-13	0.51	0.37	Glucose homeostasis traits;	chr12:118394030	chr12:118428281~118428870:+
LUAD	cis	rs11098499	0.691	rs9307471	ENSG00000245958.5	RP11-33B1.1	-8.64	8.21e-17	1e-13	-0.31	-0.37	Corneal astigmatism;	chr4:119340107	chr4:119454791~119552025:+
LUAD	cis	rs1075265	0.568	rs7604357	ENSG00000233266.1	HMGB1P31	8.64	8.22e-17	1e-13	0.48	0.37	Chronotype;Morning vs. evening chronotype;	chr2:54074026	chr2:54051334~54051760:+
LUAD	cis	rs10262624	0.967	rs13235406	ENSG00000234286.1	AC006026.13	-8.64	8.24e-17	1e-13	-0.44	-0.37	Schizophrenia;	chr7:23879212	chr7:23680195~23680786:-
LUAD	cis	rs4718428	1	rs12534637	ENSG00000226824.5	RP4-756H11.3	-8.64	8.25e-17	1.01e-13	-0.47	-0.37	Corneal structure;	chr7:66862667	chr7:66654538~66669855:+
LUAD	cis	rs11098499	0.722	rs17595727	ENSG00000245958.5	RP11-33B1.1	8.64	8.29e-17	1.01e-13	0.31	0.37	Corneal astigmatism;	chr4:119340919	chr4:119454791~119552025:+
LUAD	cis	rs732716	0.785	rs11667543	ENSG00000267769.1	CTB-50L17.9	-8.64	8.34e-17	1.02e-13	-0.41	-0.37	Mean corpuscular volume;	chr19:4374853	chr19:4454014~4455286:+
LUAD	cis	rs11098499	0.739	rs951570	ENSG00000245958.5	RP11-33B1.1	8.64	8.37e-17	1.02e-13	0.34	0.37	Corneal astigmatism;	chr4:119229312	chr4:119454791~119552025:+
LUAD	cis	rs11690935	0.843	rs9784123	ENSG00000228389.1	AC068039.4	8.64	8.37e-17	1.02e-13	0.43	0.37	Schizophrenia;	chr2:171928495	chr2:171773482~171775844:+
LUAD	cis	rs6991838	0.584	rs35790435	ENSG00000200714.1	Y_RNA	-8.64	8.43e-17	1.03e-13	-0.45	-0.37	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65592731~65592820:+
LUAD	cis	rs7924176	0.668	rs7895133	ENSG00000213731.2	RAB5CP1	-8.64	8.51e-17	1.04e-13	-0.39	-0.37	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74247697	chr10:74423435~74424014:-
LUAD	cis	rs1789	0.786	rs6449161	ENSG00000273133.1	RP11-799M12.2	-8.64	8.52e-17	1.04e-13	-0.52	-0.37	Blood protein levels;	chr4:15691331	chr4:15563698~15564253:-
LUAD	cis	rs1150668	0.799	rs1150707	ENSG00000204709.4	LINC01556	8.64	8.53e-17	1.04e-13	0.46	0.37	Pubertal anthropometrics;	chr6:28229827	chr6:28943877~28944537:+
LUAD	cis	rs494459	0.929	rs627391	ENSG00000255239.1	AP002954.6	8.64	8.6e-17	1.05e-13	0.42	0.37	Height;	chr11:118703207	chr11:118688039~118690600:-
LUAD	cis	rs673078	0.607	rs7299040	ENSG00000275759.1	RP11-131L12.3	-8.64	8.6e-17	1.05e-13	-0.52	-0.37	Glucose homeostasis traits;	chr12:118380660	chr12:118428281~118428870:+
LUAD	cis	rs3931020	0.679	rs28671241	ENSG00000272864.1	RP11-17E13.2	-8.64	8.64e-17	1.05e-13	-0.46	-0.37	Resistin levels;	chr1:74716197	chr1:74698769~74699333:-
LUAD	cis	rs9399137	0.507	rs7772031	ENSG00000232876.1	CTA-212D2.2	8.64	8.66e-17	1.05e-13	0.43	0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134938596	chr6:135055033~135060550:+
LUAD	cis	rs6991838	0.612	rs7842162	ENSG00000272010.1	CTD-3025N20.3	8.64	8.67e-17	1.05e-13	0.41	0.37	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65591850~65592472:-
LUAD	cis	rs9399135	0.527	rs61738492	ENSG00000232876.1	CTA-212D2.2	-8.63	8.75e-17	1.06e-13	-0.43	-0.37	Red blood cell count;	chr6:134961633	chr6:135055033~135060550:+
LUAD	cis	rs12594515	1	rs8039622	ENSG00000273972.1	CTD-2306A12.1	-8.63	8.75e-17	1.06e-13	-0.39	-0.37	Weight;Waist circumference;	chr15:45694233	chr15:45702640~45703183:+
LUAD	cis	rs3823536	0.583	rs11760442	ENSG00000275106.1	RP11-309L24.10	-8.63	8.75e-17	1.06e-13	-0.46	-0.37	Sjögren's syndrome;	chr7:129016066	chr7:128952527~128953316:-
LUAD	cis	rs3823536	0.583	rs3847099	ENSG00000275106.1	RP11-309L24.10	-8.63	8.75e-17	1.06e-13	-0.46	-0.37	Sjögren's syndrome;	chr7:129016777	chr7:128952527~128953316:-
LUAD	cis	rs3823536	0.604	rs3857852	ENSG00000275106.1	RP11-309L24.10	-8.63	8.75e-17	1.06e-13	-0.46	-0.37	Sjögren's syndrome;	chr7:129017223	chr7:128952527~128953316:-
LUAD	cis	rs10129255	0.957	rs10142859	ENSG00000223648.3	IGHV3-64	8.63	8.81e-17	1.07e-13	0.36	0.37	Kawasaki disease;	chr14:106782238	chr14:106643132~106658258:-
LUAD	cis	rs11098499	0.57	rs6832740	ENSG00000245958.5	RP11-33B1.1	-8.63	8.82e-17	1.07e-13	-0.33	-0.37	Corneal astigmatism;	chr4:119624981	chr4:119454791~119552025:+
LUAD	cis	rs11098499	0.644	rs6855918	ENSG00000245958.5	RP11-33B1.1	-8.63	8.82e-17	1.07e-13	-0.33	-0.37	Corneal astigmatism;	chr4:119625144	chr4:119454791~119552025:+
LUAD	cis	rs4927850	1	rs7625570	ENSG00000231464.1	AC024937.4	8.63	8.83e-17	1.07e-13	0.42	0.37	Pancreatic cancer;	chr3:196020527	chr3:195996738~195998233:+
LUAD	cis	rs10129255	0.913	rs10140943	ENSG00000211970.3	IGHV4-61	-8.63	8.85e-17	1.07e-13	-0.29	-0.37	Kawasaki disease;	chr14:106767441	chr14:106639119~106639657:-
LUAD	cis	rs9660180	0.846	rs10907195	ENSG00000268575.1	RP1-283E3.8	8.63	8.87e-17	1.08e-13	0.32	0.37	Body mass index;	chr1:1781909	chr1:1702736~1737688:-
LUAD	cis	rs8062405	0.755	rs1074631	ENSG00000259982.1	CDC37P1	-8.63	8.92e-17	1.08e-13	-0.46	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28700294~28701540:-
LUAD	cis	rs10262624	0.967	rs2188845	ENSG00000234286.1	AC006026.13	-8.63	8.93e-17	1.08e-13	-0.44	-0.37	Schizophrenia;	chr7:23882391	chr7:23680195~23680786:-
LUAD	cis	rs9807989	0.507	rs13021177	ENSG00000234389.1	AC007278.3	8.63	8.95e-17	1.09e-13	0.33	0.37	Asthma;	chr2:102440033	chr2:102438713~102440475:+
LUAD	cis	rs10740039	0.583	rs1904399	ENSG00000254271.1	RP11-131N11.4	-8.63	8.96e-17	1.09e-13	-0.4	-0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739240	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.583	rs1904400	ENSG00000254271.1	RP11-131N11.4	-8.63	8.96e-17	1.09e-13	-0.4	-0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739361	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.515	rs9414742	ENSG00000254271.1	RP11-131N11.4	-8.63	8.96e-17	1.09e-13	-0.4	-0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739769	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.583	rs9415609	ENSG00000254271.1	RP11-131N11.4	-8.63	8.96e-17	1.09e-13	-0.4	-0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739832	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.583	rs4948263	ENSG00000254271.1	RP11-131N11.4	-8.63	8.96e-17	1.09e-13	-0.4	-0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740132	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.583	rs4948264	ENSG00000254271.1	RP11-131N11.4	-8.63	8.96e-17	1.09e-13	-0.4	-0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740484	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.583	rs4948265	ENSG00000254271.1	RP11-131N11.4	-8.63	8.96e-17	1.09e-13	-0.4	-0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740495	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.583	rs7917700	ENSG00000254271.1	RP11-131N11.4	-8.63	8.96e-17	1.09e-13	-0.4	-0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740596	chr10:60734342~60741828:+
LUAD	cis	rs2280018	0.526	rs2966128	ENSG00000260735.1	RP11-72I8.1	-8.63	8.98e-17	1.09e-13	-0.42	-0.37	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059532	chr16:15094411~15109197:+
LUAD	cis	rs2929278	0.617	rs575082	ENSG00000249839.1	AC011330.5	8.63	8.98e-17	1.09e-13	0.48	0.37	Schizophrenia;	chr15:43817944	chr15:43663654~43684339:-
LUAD	cis	rs2929278	0.617	rs2955969	ENSG00000249839.1	AC011330.5	8.63	8.98e-17	1.09e-13	0.48	0.37	Schizophrenia;	chr15:43822329	chr15:43663654~43684339:-
LUAD	cis	rs62388641	0.547	rs9391923	ENSG00000272279.1	RP11-157J24.2	-8.63	8.99e-17	1.09e-13	-0.45	-0.37	Daytime sleep phenotypes;	chr6:1554089	chr6:1528364~1528911:-
LUAD	cis	rs673078	0.607	rs61943388	ENSG00000275759.1	RP11-131L12.3	-8.63	9.09e-17	1.1e-13	-0.52	-0.37	Glucose homeostasis traits;	chr12:118374590	chr12:118428281~118428870:+
LUAD	cis	rs10129255	0.536	rs6576201	ENSG00000280411.1	IGHV1-69-2	8.63	9.12e-17	1.11e-13	0.25	0.37	Kawasaki disease;	chr14:106683696	chr14:106762092~106762588:-
LUAD	cis	rs17023223	0.537	rs10923759	ENSG00000231365.4	RP11-418J17.1	8.63	9.18e-17	1.11e-13	0.48	0.37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119149571	chr1:119140396~119275973:+
LUAD	cis	rs1150668	0.796	rs1005125	ENSG00000216901.1	AL022393.7	8.63	9.18e-17	1.11e-13	0.43	0.37	Pubertal anthropometrics;	chr6:28399578	chr6:28176188~28176674:+
LUAD	cis	rs12594515	1	rs8029209	ENSG00000273972.1	CTD-2306A12.1	-8.63	9.19e-17	1.11e-13	-0.4	-0.37	Weight;Waist circumference;	chr15:45701291	chr15:45702640~45703183:+
LUAD	cis	rs12594515	1	rs7162201	ENSG00000273972.1	CTD-2306A12.1	-8.63	9.26e-17	1.12e-13	-0.39	-0.37	Weight;Waist circumference;	chr15:45700460	chr15:45702640~45703183:+
LUAD	cis	rs2337406	0.925	rs11851094	ENSG00000254174.1	IGHV1-12	8.63	9.31e-17	1.13e-13	0.33	0.37	Alzheimer's disease (late onset);	chr14:106688967	chr14:106122420~106122709:-
LUAD	cis	rs6991838	0.584	rs4737221	ENSG00000272010.1	CTD-3025N20.3	-8.63	9.34e-17	1.13e-13	-0.41	-0.37	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65591850~65592472:-
LUAD	cis	rs1150668	0.699	rs12214383	ENSG00000216901.1	AL022393.7	-8.62	9.4e-17	1.14e-13	-0.42	-0.37	Pubertal anthropometrics;	chr6:28255953	chr6:28176188~28176674:+
LUAD	cis	rs733592	0.929	rs4760678	ENSG00000240399.1	RP1-228P16.1	-8.62	9.43e-17	1.14e-13	-0.36	-0.37	Plateletcrit;	chr12:48067798	chr12:48054813~48055591:-
LUAD	cis	rs7429990	0.932	rs4293721	ENSG00000229759.1	MRPS18AP1	-8.62	9.52e-17	1.15e-13	-0.38	-0.37	Educational attainment (years of education);	chr3:48003647	chr3:48256350~48256938:-
LUAD	cis	rs9399137	0.507	rs7754722	ENSG00000232876.1	CTA-212D2.2	8.62	9.55e-17	1.16e-13	0.43	0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134939165	chr6:135055033~135060550:+
LUAD	cis	rs9322193	0.923	rs9404048	ENSG00000223701.3	RAET1E-AS1	8.62	9.57e-17	1.16e-13	0.43	0.37	Lung cancer;	chr6:149616188	chr6:149884431~149919508:+
LUAD	cis	rs11690935	0.851	rs10174055	ENSG00000228389.1	AC068039.4	8.62	9.66e-17	1.17e-13	0.43	0.37	Schizophrenia;	chr2:171993303	chr2:171773482~171775844:+
LUAD	cis	rs10463554	0.75	rs26257	ENSG00000175749.11	EIF3KP1	8.62	9.66e-17	1.17e-13	0.52	0.37	Parkinson's disease;	chr5:103214830	chr5:103032376~103033031:+
LUAD	cis	rs1185460	0.967	rs1177562	ENSG00000271751.1	RP11-110I1.14	-8.62	9.71e-17	1.17e-13	-0.45	-0.37	Coronary artery disease;	chr11:119078621	chr11:119065263~119065677:-
LUAD	cis	rs494459	0.688	rs1048040	ENSG00000255239.1	AP002954.6	8.62	9.8e-17	1.18e-13	0.43	0.37	Height;	chr11:118747911	chr11:118688039~118690600:-
LUAD	cis	rs6991838	0.557	rs67046768	ENSG00000272010.1	CTD-3025N20.3	-8.62	1e-16	1.21e-13	-0.4	-0.37	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65591850~65592472:-
LUAD	cis	rs6782228	1	rs35871360	ENSG00000242551.2	POU5F1P6	8.62	1e-16	1.21e-13	0.46	0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617286	chr3:128674735~128677005:-
LUAD	cis	rs673078	0.607	rs7968011	ENSG00000275759.1	RP11-131L12.3	-8.61	1.02e-16	1.23e-13	-0.52	-0.37	Glucose homeostasis traits;	chr12:118382001	chr12:118428281~118428870:+
LUAD	cis	rs380904	0.926	rs7842979	ENSG00000254859.1	RP11-661A12.5	-8.61	1.02e-16	1.23e-13	-0.52	-0.37	Venous thromboembolism (SNP x SNP interaction);	chr8:143519726	chr8:143541973~143549729:-
LUAD	cis	rs10129255	0.957	rs12590735	ENSG00000223648.3	IGHV3-64	8.61	1.02e-16	1.23e-13	0.36	0.37	Kawasaki disease;	chr14:106779660	chr14:106643132~106658258:-
LUAD	cis	rs9545047	0.716	rs9565500	ENSG00000227676.3	LINC01068	-8.61	1.03e-16	1.24e-13	-0.45	-0.37	Schizophrenia;	chr13:79433416	chr13:79566727~79571436:+
LUAD	cis	rs34779708	0.931	rs7923217	ENSG00000230534.5	RP11-297A16.2	8.61	1.03e-16	1.25e-13	0.42	0.37	Inflammatory bowel disease;Crohn's disease;	chr10:35020661	chr10:35098006~35127020:-
LUAD	cis	rs673078	0.607	rs61943392	ENSG00000275759.1	RP11-131L12.3	-8.61	1.03e-16	1.25e-13	-0.52	-0.37	Glucose homeostasis traits;	chr12:118382618	chr12:118428281~118428870:+
LUAD	cis	rs11123170	0.64	rs1015754	ENSG00000274877.1	RP11-65I12.1	8.61	1.03e-16	1.25e-13	0.5	0.37	Renal function-related traits (BUN);	chr2:113210413	chr2:113237595~113240825:+
LUAD	cis	rs3823536	0.583	rs6948928	ENSG00000275106.1	RP11-309L24.10	-8.61	1.03e-16	1.25e-13	-0.46	-0.37	Sjögren's syndrome;	chr7:128983043	chr7:128952527~128953316:-
LUAD	cis	rs4927850	0.918	rs4361313	ENSG00000231464.1	AC024937.4	8.61	1.04e-16	1.25e-13	0.42	0.37	Pancreatic cancer;	chr3:196025389	chr3:195996738~195998233:+
LUAD	cis	rs1789	0.786	rs6414768	ENSG00000273133.1	RP11-799M12.2	-8.61	1.04e-16	1.25e-13	-0.52	-0.37	Blood protein levels;	chr4:15693740	chr4:15563698~15564253:-
LUAD	cis	rs6991838	0.584	rs7463740	ENSG00000272010.1	CTD-3025N20.3	-8.61	1.04e-16	1.26e-13	-0.4	-0.37	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65591850~65592472:-
LUAD	cis	rs4423214	0.559	rs7949129	ENSG00000254682.1	RP11-660L16.2	-8.61	1.05e-16	1.26e-13	-0.57	-0.37	Vitamin D levels;	chr11:71482089	chr11:71448674~71452157:+
LUAD	cis	rs4927850	0.957	rs4927851	ENSG00000231464.1	AC024937.4	8.61	1.06e-16	1.27e-13	0.42	0.37	Pancreatic cancer;	chr3:196024982	chr3:195996738~195998233:+
LUAD	cis	rs1075265	0.584	rs7590846	ENSG00000233266.1	HMGB1P31	8.61	1.06e-16	1.27e-13	0.47	0.37	Chronotype;Morning vs. evening chronotype;	chr2:54051530	chr2:54051334~54051760:+
LUAD	cis	rs3931020	0.548	rs969435	ENSG00000272864.1	RP11-17E13.2	8.61	1.08e-16	1.3e-13	0.44	0.37	Resistin levels;	chr1:74808182	chr1:74698769~74699333:-
LUAD	cis	rs526231	0.511	rs28062	ENSG00000175749.11	EIF3KP1	8.61	1.08e-16	1.3e-13	0.52	0.37	Primary biliary cholangitis;	chr5:103204500	chr5:103032376~103033031:+
LUAD	cis	rs17711722	0.565	rs4275112	ENSG00000164669.11	INTS4P1	8.61	1.08e-16	1.3e-13	0.43	0.37	Calcium levels;	chr7:65733651	chr7:65141225~65234216:+
LUAD	cis	rs9807989	0.507	rs10208196	ENSG00000234389.1	AC007278.3	8.61	1.08e-16	1.31e-13	0.33	0.37	Asthma;	chr2:102379885	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs7584093	ENSG00000234389.1	AC007278.3	8.61	1.08e-16	1.31e-13	0.33	0.37	Asthma;	chr2:102381261	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs3213732	ENSG00000234389.1	AC007278.3	8.61	1.08e-16	1.31e-13	0.33	0.37	Asthma;	chr2:102381819	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs10204757	ENSG00000234389.1	AC007278.3	8.61	1.08e-16	1.31e-13	0.33	0.37	Asthma;	chr2:102382514	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.524	rs7591246	ENSG00000234389.1	AC007278.3	8.61	1.08e-16	1.31e-13	0.33	0.37	Asthma;	chr2:102382943	chr2:102438713~102440475:+
LUAD	cis	rs4988958	0.565	rs6760621	ENSG00000234389.1	AC007278.3	8.61	1.08e-16	1.31e-13	0.33	0.37	Asthma (childhood onset);	chr2:102383492	chr2:102438713~102440475:+
LUAD	cis	rs4988958	0.527	rs11465641	ENSG00000234389.1	AC007278.3	8.61	1.08e-16	1.31e-13	0.33	0.37	Asthma (childhood onset);	chr2:102384408	chr2:102438713~102440475:+
LUAD	cis	rs4988958	0.525	rs3771159	ENSG00000234389.1	AC007278.3	8.61	1.08e-16	1.31e-13	0.33	0.37	Asthma (childhood onset);	chr2:102388498	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.501	rs11903946	ENSG00000234389.1	AC007278.3	8.61	1.08e-16	1.31e-13	0.33	0.37	Asthma;	chr2:102388870	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs6706002	ENSG00000234389.1	AC007278.3	8.61	1.08e-16	1.31e-13	0.33	0.37	Asthma;	chr2:102389644	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs6749014	ENSG00000234389.1	AC007278.3	8.61	1.08e-16	1.31e-13	0.33	0.37	Asthma;	chr2:102389988	chr2:102438713~102440475:+
LUAD	cis	rs4988958	0.565	rs12712146	ENSG00000234389.1	AC007278.3	8.61	1.08e-16	1.31e-13	0.33	0.37	Asthma (childhood onset);	chr2:102392254	chr2:102438713~102440475:+
LUAD	cis	rs4988958	0.565	rs6732138	ENSG00000234389.1	AC007278.3	8.61	1.09e-16	1.31e-13	0.33	0.37	Asthma (childhood onset);	chr2:102393202	chr2:102438713~102440475:+
LUAD	cis	rs10875746	0.579	rs10875778	ENSG00000240399.1	RP1-228P16.1	-8.61	1.09e-16	1.31e-13	-0.45	-0.37	Longevity (90 years and older);	chr12:48230872	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.669	rs10875779	ENSG00000240399.1	RP1-228P16.1	-8.61	1.09e-16	1.31e-13	-0.45	-0.37	Longevity (90 years and older);	chr12:48236086	chr12:48054813~48055591:-
LUAD	cis	rs673078	0.607	rs4767669	ENSG00000275759.1	RP11-131L12.3	-8.6	1.1e-16	1.33e-13	-0.51	-0.37	Glucose homeostasis traits;	chr12:118390651	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs4767670	ENSG00000275759.1	RP11-131L12.3	-8.6	1.1e-16	1.33e-13	-0.51	-0.37	Glucose homeostasis traits;	chr12:118390737	chr12:118428281~118428870:+
LUAD	cis	rs10129255	0.957	rs12590667	ENSG00000211970.3	IGHV4-61	8.6	1.11e-16	1.33e-13	0.27	0.37	Kawasaki disease;	chr14:106779223	chr14:106639119~106639657:-
LUAD	cis	rs1075265	0.584	rs1862122	ENSG00000233266.1	HMGB1P31	-8.6	1.11e-16	1.33e-13	-0.47	-0.37	Chronotype;Morning vs. evening chronotype;	chr2:54052992	chr2:54051334~54051760:+
LUAD	cis	rs1150668	0.764	rs9368565	ENSG00000204709.4	LINC01556	-8.6	1.11e-16	1.34e-13	-0.45	-0.37	Pubertal anthropometrics;	chr6:28377433	chr6:28943877~28944537:+
LUAD	cis	rs1150668	0.796	rs1052215	ENSG00000204709.4	LINC01556	-8.6	1.11e-16	1.34e-13	-0.45	-0.37	Pubertal anthropometrics;	chr6:28380381	chr6:28943877~28944537:+
LUAD	cis	rs12134133	1	rs11584921	ENSG00000274245.1	RP11-357P18.2	8.6	1.11e-16	1.34e-13	0.47	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207268630	chr1:207372559~207373252:+
LUAD	cis	rs11096990	0.634	rs3733281	ENSG00000249207.1	RP11-360F5.1	8.6	1.12e-16	1.35e-13	0.4	0.37	Cognitive function;	chr4:39270293	chr4:39112677~39126818:-
LUAD	cis	rs6991838	0.584	rs4388482	ENSG00000272010.1	CTD-3025N20.3	-8.6	1.12e-16	1.35e-13	-0.4	-0.37	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs4637885	ENSG00000272010.1	CTD-3025N20.3	-8.6	1.12e-16	1.35e-13	-0.4	-0.37	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.556	rs7846527	ENSG00000272010.1	CTD-3025N20.3	-8.6	1.12e-16	1.35e-13	-0.4	-0.37	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs4320587	ENSG00000272010.1	CTD-3025N20.3	-8.6	1.12e-16	1.35e-13	-0.4	-0.37	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.584	rs35941313	ENSG00000272010.1	CTD-3025N20.3	-8.6	1.12e-16	1.35e-13	-0.4	-0.37	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.557	rs4737222	ENSG00000272010.1	CTD-3025N20.3	-8.6	1.12e-16	1.35e-13	-0.4	-0.37	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65591850~65592472:-
LUAD	cis	rs10875746	0.768	rs4760676	ENSG00000240399.1	RP1-228P16.1	-8.6	1.13e-16	1.36e-13	-0.43	-0.37	Longevity (90 years and older);	chr12:48027880	chr12:48054813~48055591:-
LUAD	cis	rs904251	0.772	rs2252920	ENSG00000204110.6	RP1-153P14.8	-8.6	1.14e-16	1.36e-13	-0.42	-0.37	Cognitive performance;	chr6:37450551	chr6:37507348~37535616:+
LUAD	cis	rs9322193	0.923	rs12174716	ENSG00000223701.3	RAET1E-AS1	8.6	1.14e-16	1.37e-13	0.43	0.37	Lung cancer;	chr6:149644487	chr6:149884431~149919508:+
LUAD	cis	rs7044106	0.615	rs10818470	ENSG00000226752.6	PSMD5-AS1	-8.6	1.14e-16	1.37e-13	-0.4	-0.37	Hip circumference adjusted for BMI;	chr9:120596926	chr9:120824828~120854385:+
LUAD	cis	rs6700559	0.967	rs12041320	ENSG00000260088.1	RP11-92G12.3	-8.6	1.14e-16	1.37e-13	-0.47	-0.37	Coronary artery disease;	chr1:200652107	chr1:200669507~200694250:+
LUAD	cis	rs6782228	0.883	rs6439142	ENSG00000242551.2	POU5F1P6	8.6	1.15e-16	1.38e-13	0.45	0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701714	chr3:128674735~128677005:-
LUAD	cis	rs732716	0.785	rs62129354	ENSG00000267769.1	CTB-50L17.9	-8.6	1.15e-16	1.38e-13	-0.4	-0.36	Mean corpuscular volume;	chr19:4396508	chr19:4454014~4455286:+
LUAD	cis	rs9322193	0.607	rs10457852	ENSG00000216906.2	RP11-350J20.9	8.6	1.15e-16	1.38e-13	0.54	0.36	Lung cancer;	chr6:149880584	chr6:149904243~149906418:+
LUAD	cis	rs172166	0.585	rs149963	ENSG00000216901.1	AL022393.7	8.6	1.15e-16	1.38e-13	0.42	0.36	Cardiac Troponin-T levels;	chr6:28049354	chr6:28176188~28176674:+
LUAD	cis	rs9545047	0.716	rs9545061	ENSG00000227676.3	LINC01068	8.6	1.15e-16	1.38e-13	0.44	0.36	Schizophrenia;	chr13:79310695	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.716	rs9545067	ENSG00000227676.3	LINC01068	8.6	1.15e-16	1.38e-13	0.44	0.36	Schizophrenia;	chr13:79323429	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.68	rs9574405	ENSG00000227676.3	LINC01068	8.6	1.15e-16	1.38e-13	0.44	0.36	Schizophrenia;	chr13:79328943	chr13:79566727~79571436:+
LUAD	cis	rs7429990	0.813	rs7637622	ENSG00000229759.1	MRPS18AP1	-8.6	1.16e-16	1.39e-13	-0.38	-0.36	Educational attainment (years of education);	chr3:48051561	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.965	rs7627645	ENSG00000229759.1	MRPS18AP1	-8.6	1.16e-16	1.39e-13	-0.38	-0.36	Educational attainment (years of education);	chr3:48051643	chr3:48256350~48256938:-
LUAD	cis	rs6782228	0.848	rs3935016	ENSG00000242551.2	POU5F1P6	8.6	1.16e-16	1.39e-13	0.45	0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701591	chr3:128674735~128677005:-
LUAD	cis	rs6782228	0.848	rs6439141	ENSG00000242551.2	POU5F1P6	8.6	1.16e-16	1.39e-13	0.45	0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701691	chr3:128674735~128677005:-
LUAD	cis	rs9322193	0.923	rs9377230	ENSG00000223701.3	RAET1E-AS1	8.6	1.16e-16	1.4e-13	0.43	0.36	Lung cancer;	chr6:149613607	chr6:149884431~149919508:+
LUAD	cis	rs9545047	0.68	rs7987769	ENSG00000227676.3	LINC01068	8.6	1.17e-16	1.4e-13	0.44	0.36	Schizophrenia;	chr13:79343965	chr13:79566727~79571436:+
LUAD	cis	rs9389248	0.69	rs6569982	ENSG00000232876.1	CTA-212D2.2	-8.6	1.17e-16	1.41e-13	-0.41	-0.36	High light scatter reticulocyte percentage of red cells;	chr6:134935357	chr6:135055033~135060550:+
LUAD	cis	rs10129255	0.5	rs10131875	ENSG00000211972.2	IGHV3-66	8.59	1.18e-16	1.41e-13	0.29	0.36	Kawasaki disease;	chr14:106792798	chr14:106675017~106675544:-
LUAD	cis	rs2581828	0.632	rs891369	ENSG00000242142.1	SERBP1P3	-8.59	1.18e-16	1.42e-13	-0.41	-0.36	Crohn's disease;	chr3:53102535	chr3:53064283~53065091:-
LUAD	cis	rs9545047	0.716	rs314693	ENSG00000227676.3	LINC01068	-8.59	1.19e-16	1.42e-13	-0.45	-0.36	Schizophrenia;	chr13:79432792	chr13:79566727~79571436:+
LUAD	cis	rs17023223	0.537	rs61806983	ENSG00000231365.4	RP11-418J17.1	-8.59	1.2e-16	1.43e-13	-0.48	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119188901	chr1:119140396~119275973:+
LUAD	cis	rs1075265	0.584	rs1862121	ENSG00000233266.1	HMGB1P31	8.59	1.2e-16	1.43e-13	0.47	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54058102	chr2:54051334~54051760:+
LUAD	cis	rs526231	0.543	rs34379	ENSG00000175749.11	EIF3KP1	-8.59	1.2e-16	1.43e-13	-0.5	-0.36	Primary biliary cholangitis;	chr5:103062994	chr5:103032376~103033031:+
LUAD	cis	rs12594515	0.935	rs8042519	ENSG00000273972.1	CTD-2306A12.1	-8.59	1.2e-16	1.44e-13	-0.4	-0.36	Weight;Waist circumference;	chr15:45704143	chr15:45702640~45703183:+
LUAD	cis	rs7945705	0.747	rs1980428	ENSG00000254860.4	TMEM9B-AS1	-8.59	1.21e-16	1.45e-13	-0.4	-0.36	Hemoglobin concentration;	chr11:8988950	chr11:8964675~8977527:+
LUAD	cis	rs12594515	0.506	rs74199860	ENSG00000273972.1	CTD-2306A12.1	-8.59	1.21e-16	1.45e-13	-0.39	-0.36	Weight;Waist circumference;	chr15:45696992	chr15:45702640~45703183:+
LUAD	cis	rs494459	0.838	rs607125	ENSG00000255239.1	AP002954.6	8.59	1.21e-16	1.45e-13	0.43	0.36	Height;	chr11:118746590	chr11:118688039~118690600:-
LUAD	cis	rs10129255	0.784	rs7147210	ENSG00000223648.3	IGHV3-64	8.59	1.22e-16	1.46e-13	0.37	0.36	Kawasaki disease;	chr14:106705271	chr14:106643132~106658258:-
LUAD	cis	rs10875746	0.669	rs1021313	ENSG00000240399.1	RP1-228P16.1	-8.59	1.23e-16	1.48e-13	-0.43	-0.36	Longevity (90 years and older);	chr12:48244258	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.625	rs2898065	ENSG00000240399.1	RP1-228P16.1	-8.59	1.23e-16	1.48e-13	-0.43	-0.36	Longevity (90 years and older);	chr12:48250836	chr12:48054813~48055591:-
LUAD	cis	rs6991838	0.612	rs7842162	ENSG00000200714.1	Y_RNA	8.59	1.23e-16	1.48e-13	0.46	0.36	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65592731~65592820:+
LUAD	cis	rs10463554	0.927	rs34820	ENSG00000175749.11	EIF3KP1	8.59	1.24e-16	1.48e-13	0.5	0.36	Parkinson's disease;	chr5:103101164	chr5:103032376~103033031:+
LUAD	cis	rs494459	0.838	rs632124	ENSG00000255239.1	AP002954.6	8.59	1.24e-16	1.48e-13	0.43	0.36	Height;	chr11:118742526	chr11:118688039~118690600:-
LUAD	cis	rs7429990	0.965	rs9854454	ENSG00000229759.1	MRPS18AP1	-8.59	1.24e-16	1.48e-13	-0.38	-0.36	Educational attainment (years of education);	chr3:47971307	chr3:48256350~48256938:-
LUAD	cis	rs9545047	0.716	rs314692	ENSG00000227676.3	LINC01068	-8.59	1.25e-16	1.49e-13	-0.45	-0.36	Schizophrenia;	chr13:79433091	chr13:79566727~79571436:+
LUAD	cis	rs9322193	0.884	rs2064521	ENSG00000223701.3	RAET1E-AS1	-8.59	1.26e-16	1.5e-13	-0.43	-0.36	Lung cancer;	chr6:149625336	chr6:149884431~149919508:+
LUAD	cis	rs10875746	0.669	rs61941003	ENSG00000240399.1	RP1-228P16.1	-8.59	1.26e-16	1.5e-13	-0.45	-0.36	Longevity (90 years and older);	chr12:48225842	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.669	rs11168487	ENSG00000240399.1	RP1-228P16.1	-8.59	1.26e-16	1.5e-13	-0.45	-0.36	Longevity (90 years and older);	chr12:48246926	chr12:48054813~48055591:-
LUAD	cis	rs673078	0.607	rs17512763	ENSG00000275759.1	RP11-131L12.3	-8.59	1.27e-16	1.51e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118400974	chr12:118428281~118428870:+
LUAD	cis	rs10129255	0.869	rs7150549	ENSG00000223648.3	IGHV3-64	8.59	1.27e-16	1.51e-13	0.37	0.36	Kawasaki disease;	chr14:106705441	chr14:106643132~106658258:-
LUAD	cis	rs7208859	0.673	rs9915139	ENSG00000263531.1	RP13-753N3.1	8.58	1.27e-16	1.52e-13	0.7	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831497	chr17:30863921~30864940:-
LUAD	cis	rs7847628	0.566	rs10739575	ENSG00000226752.6	PSMD5-AS1	8.58	1.27e-16	1.52e-13	0.51	0.36	Birth weight;	chr9:120843823	chr9:120824828~120854385:+
LUAD	cis	rs2412819	0.599	rs2470120	ENSG00000249839.1	AC011330.5	-8.58	1.28e-16	1.52e-13	-0.48	-0.36	Lung cancer;	chr15:43636872	chr15:43663654~43684339:-
LUAD	cis	rs5769707	0.681	rs9616329	ENSG00000188511.11	C22orf34	8.58	1.28e-16	1.53e-13	0.45	0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49632666	chr22:49414524~49657542:-
LUAD	cis	rs11096990	0.593	rs1026235	ENSG00000249207.1	RP11-360F5.1	-8.58	1.29e-16	1.54e-13	-0.39	-0.36	Cognitive function;	chr4:39226629	chr4:39112677~39126818:-
LUAD	cis	rs9322193	0.923	rs9505982	ENSG00000223701.3	RAET1E-AS1	8.58	1.29e-16	1.54e-13	0.42	0.36	Lung cancer;	chr6:149618465	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs10782310	ENSG00000223701.3	RAET1E-AS1	8.58	1.29e-16	1.54e-13	0.42	0.36	Lung cancer;	chr6:149622458	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs10782311	ENSG00000223701.3	RAET1E-AS1	8.58	1.29e-16	1.54e-13	0.42	0.36	Lung cancer;	chr6:149622592	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs10747275	ENSG00000223701.3	RAET1E-AS1	8.58	1.29e-16	1.54e-13	0.42	0.36	Lung cancer;	chr6:149622782	chr6:149884431~149919508:+
LUAD	cis	rs526231	0.512	rs28022	ENSG00000175749.11	EIF3KP1	8.58	1.29e-16	1.54e-13	0.52	0.36	Primary biliary cholangitis;	chr5:103128663	chr5:103032376~103033031:+
LUAD	cis	rs12468226	0.808	rs77251002	ENSG00000273456.1	RP11-686O6.2	8.58	1.3e-16	1.55e-13	0.57	0.36	Urate levels;	chr2:202150236	chr2:202374932~202375604:-
LUAD	cis	rs732716	0.74	rs78869060	ENSG00000267769.1	CTB-50L17.9	-8.58	1.3e-16	1.55e-13	-0.4	-0.36	Mean corpuscular volume;	chr19:4444745	chr19:4454014~4455286:+
LUAD	cis	rs1075265	0.584	rs34769118	ENSG00000233266.1	HMGB1P31	8.58	1.31e-16	1.56e-13	0.48	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54102173	chr2:54051334~54051760:+
LUAD	cis	rs6991838	0.55	rs4737750	ENSG00000272010.1	CTD-3025N20.3	8.58	1.33e-16	1.59e-13	0.4	0.36	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65591850~65592472:-
LUAD	cis	rs9545047	0.74	rs9574409	ENSG00000227676.3	LINC01068	8.58	1.33e-16	1.59e-13	0.44	0.36	Schizophrenia;	chr13:79341844	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.716	rs7327386	ENSG00000227676.3	LINC01068	8.58	1.33e-16	1.59e-13	0.44	0.36	Schizophrenia;	chr13:79347901	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.644	rs9318624	ENSG00000227676.3	LINC01068	8.58	1.33e-16	1.59e-13	0.44	0.36	Schizophrenia;	chr13:79350915	chr13:79566727~79571436:+
LUAD	cis	rs6782228	0.848	rs6439140	ENSG00000242551.2	POU5F1P6	8.58	1.34e-16	1.6e-13	0.45	0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128699917	chr3:128674735~128677005:-
LUAD	cis	rs6991838	0.557	rs67046768	ENSG00000200714.1	Y_RNA	-8.58	1.35e-16	1.6e-13	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65592731~65592820:+
LUAD	cis	rs10129255	0.784	rs7147210	ENSG00000211970.3	IGHV4-61	-8.58	1.35e-16	1.61e-13	-0.29	-0.36	Kawasaki disease;	chr14:106705271	chr14:106639119~106639657:-
LUAD	cis	rs944289	0.646	rs8003253	ENSG00000257826.1	RP11-116N8.4	-8.58	1.35e-16	1.61e-13	-0.38	-0.36	Thyroid cancer;	chr14:36088485	chr14:36061026~36067190:-
LUAD	cis	rs12594515	1	rs12185095	ENSG00000273972.1	CTD-2306A12.1	-8.58	1.36e-16	1.62e-13	-0.4	-0.36	Weight;Waist circumference;	chr15:45702437	chr15:45702640~45703183:+
LUAD	cis	rs8062405	0.698	rs8046545	ENSG00000259982.1	CDC37P1	-8.58	1.36e-16	1.62e-13	-0.49	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28903896	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.698	rs10499	ENSG00000259982.1	CDC37P1	-8.58	1.36e-16	1.62e-13	-0.49	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28904206	chr16:28700294~28701540:-
LUAD	cis	rs10129255	0.917	rs7142373	ENSG00000223648.3	IGHV3-64	8.57	1.37e-16	1.63e-13	0.37	0.36	Kawasaki disease;	chr14:106708947	chr14:106643132~106658258:-
LUAD	cis	rs12594515	1	rs12592190	ENSG00000273972.1	CTD-2306A12.1	-8.57	1.37e-16	1.63e-13	-0.39	-0.36	Weight;Waist circumference;	chr15:45701830	chr15:45702640~45703183:+
LUAD	cis	rs12594515	1	rs11854554	ENSG00000273972.1	CTD-2306A12.1	-8.57	1.37e-16	1.63e-13	-0.39	-0.36	Weight;Waist circumference;	chr15:45702348	chr15:45702640~45703183:+
LUAD	cis	rs12594515	1	rs35182335	ENSG00000273972.1	CTD-2306A12.1	-8.57	1.37e-16	1.63e-13	-0.39	-0.36	Weight;Waist circumference;	chr15:45702986	chr15:45702640~45703183:+
LUAD	cis	rs12594515	1	rs11855509	ENSG00000273972.1	CTD-2306A12.1	-8.57	1.37e-16	1.63e-13	-0.39	-0.36	Weight;Waist circumference;	chr15:45703276	chr15:45702640~45703183:+
LUAD	cis	rs12594515	1	rs11855562	ENSG00000273972.1	CTD-2306A12.1	-8.57	1.37e-16	1.63e-13	-0.39	-0.36	Weight;Waist circumference;	chr15:45703461	chr15:45702640~45703183:+
LUAD	cis	rs12594515	1	rs8043291	ENSG00000273972.1	CTD-2306A12.1	-8.57	1.37e-16	1.63e-13	-0.39	-0.36	Weight;Waist circumference;	chr15:45704049	chr15:45702640~45703183:+
LUAD	cis	rs12594515	1	rs56412446	ENSG00000273972.1	CTD-2306A12.1	-8.57	1.37e-16	1.63e-13	-0.39	-0.36	Weight;Waist circumference;	chr15:45704226	chr15:45702640~45703183:+
LUAD	cis	rs12594515	1	rs57299255	ENSG00000273972.1	CTD-2306A12.1	-8.57	1.37e-16	1.63e-13	-0.39	-0.36	Weight;Waist circumference;	chr15:45704334	chr15:45702640~45703183:+
LUAD	cis	rs12134133	0.962	rs2039543	ENSG00000274245.1	RP11-357P18.2	8.57	1.38e-16	1.64e-13	0.47	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207294228	chr1:207372559~207373252:+
LUAD	cis	rs12134133	1	rs2802232	ENSG00000274245.1	RP11-357P18.2	8.57	1.38e-16	1.64e-13	0.47	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207294806	chr1:207372559~207373252:+
LUAD	cis	rs12134133	0.962	rs2782847	ENSG00000274245.1	RP11-357P18.2	8.57	1.38e-16	1.64e-13	0.47	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207295766	chr1:207372559~207373252:+
LUAD	cis	rs6504950	1	rs17745344	ENSG00000275710.1	RP11-257O5.4	8.57	1.38e-16	1.64e-13	0.48	0.36	Breast cancer;	chr17:54970958	chr17:54964474~54964679:+
LUAD	cis	rs11096990	0.613	rs6829660	ENSG00000249207.1	RP11-360F5.1	-8.57	1.38e-16	1.65e-13	-0.4	-0.36	Cognitive function;	chr4:39280943	chr4:39112677~39126818:-
LUAD	cis	rs11676348	0.776	rs11690316	ENSG00000261338.2	RP11-378A13.1	-8.57	1.39e-16	1.66e-13	-0.38	-0.36	Ulcerative colitis;	chr2:218152739	chr2:218255319~218257366:+
LUAD	cis	rs9545047	0.716	rs416660	ENSG00000227676.3	LINC01068	-8.57	1.4e-16	1.66e-13	-0.44	-0.36	Schizophrenia;	chr13:79432726	chr13:79566727~79571436:+
LUAD	cis	rs12468226	0.873	rs1474267	ENSG00000273456.1	RP11-686O6.2	-8.57	1.4e-16	1.66e-13	-0.57	-0.36	Urate levels;	chr2:202178596	chr2:202374932~202375604:-
LUAD	cis	rs8005677	0.798	rs61977741	ENSG00000279656.1	RP11-298I3.6	8.57	1.4e-16	1.66e-13	0.43	0.36	Cognitive ability (multi-trait analysis);	chr14:22931770	chr14:23023083~23024217:-
LUAD	cis	rs9322193	0.923	rs9689084	ENSG00000223701.3	RAET1E-AS1	8.57	1.41e-16	1.67e-13	0.42	0.36	Lung cancer;	chr6:149639648	chr6:149884431~149919508:+
LUAD	cis	rs673078	0.607	rs7136676	ENSG00000275759.1	RP11-131L12.3	-8.57	1.41e-16	1.67e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118403605	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs17441033	ENSG00000275759.1	RP11-131L12.3	-8.57	1.41e-16	1.67e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118404101	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.562	rs61943405	ENSG00000275759.1	RP11-131L12.3	-8.57	1.41e-16	1.67e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118405030	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs61943406	ENSG00000275759.1	RP11-131L12.3	-8.57	1.41e-16	1.67e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118405767	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs17441075	ENSG00000275759.1	RP11-131L12.3	-8.57	1.41e-16	1.67e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118410542	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs965524	ENSG00000275759.1	RP11-131L12.3	-8.57	1.41e-16	1.67e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118412361	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs74685643	ENSG00000275759.1	RP11-131L12.3	-8.57	1.41e-16	1.67e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118412761	chr12:118428281~118428870:+
LUAD	cis	rs2337406	1	rs74090714	ENSG00000274576.2	IGHV2-70	-8.57	1.41e-16	1.68e-13	-0.41	-0.36	Alzheimer's disease (late onset);	chr14:106691225	chr14:106770577~106771020:-
LUAD	cis	rs2337406	0.852	rs12050239	ENSG00000254174.1	IGHV1-12	8.57	1.42e-16	1.69e-13	0.32	0.36	Alzheimer's disease (late onset);	chr14:106781132	chr14:106122420~106122709:-
LUAD	cis	rs2108622	0.958	rs56340170	ENSG00000267453.5	AC004791.2	-8.57	1.42e-16	1.69e-13	-0.48	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871067	chr19:15851993~15864904:-
LUAD	cis	rs526231	0.543	rs27361	ENSG00000175749.11	EIF3KP1	8.57	1.43e-16	1.69e-13	0.52	0.36	Primary biliary cholangitis;	chr5:103213266	chr5:103032376~103033031:+
LUAD	cis	rs7924176	0.502	rs12784355	ENSG00000213731.2	RAB5CP1	-8.57	1.44e-16	1.71e-13	-0.38	-0.36	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74386487	chr10:74423435~74424014:-
LUAD	cis	rs12468226	1	rs11899836	ENSG00000273456.1	RP11-686O6.2	8.57	1.44e-16	1.71e-13	0.55	0.36	Urate levels;	chr2:202371316	chr2:202374932~202375604:-
LUAD	cis	rs9322193	0.884	rs9688794	ENSG00000223701.3	RAET1E-AS1	8.57	1.45e-16	1.72e-13	0.42	0.36	Lung cancer;	chr6:149632121	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs9322204	ENSG00000223701.3	RAET1E-AS1	8.57	1.45e-16	1.72e-13	0.42	0.36	Lung cancer;	chr6:149636047	chr6:149884431~149919508:+
LUAD	cis	rs1075265	0.584	rs1559037	ENSG00000233266.1	HMGB1P31	8.57	1.45e-16	1.72e-13	0.47	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54051448	chr2:54051334~54051760:+
LUAD	cis	rs494459	0.838	rs488219	ENSG00000255239.1	AP002954.6	8.57	1.45e-16	1.72e-13	0.43	0.36	Height;	chr11:118749988	chr11:118688039~118690600:-
LUAD	cis	rs13392177	0.684	rs11695527	ENSG00000261338.2	RP11-378A13.1	8.57	1.45e-16	1.72e-13	0.37	0.36	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218203380	chr2:218255319~218257366:+
LUAD	cis	rs11096990	0.634	rs4975001	ENSG00000249207.1	RP11-360F5.1	8.57	1.45e-16	1.72e-13	0.4	0.36	Cognitive function;	chr4:39264844	chr4:39112677~39126818:-
LUAD	cis	rs507080	0.501	rs637563	ENSG00000255239.1	AP002954.6	8.57	1.46e-16	1.73e-13	0.42	0.36	Serum metabolite levels;	chr11:118704770	chr11:118688039~118690600:-
LUAD	cis	rs1150668	0.699	rs13408	ENSG00000216901.1	AL022393.7	8.57	1.47e-16	1.74e-13	0.43	0.36	Pubertal anthropometrics;	chr6:28244970	chr6:28176188~28176674:+
LUAD	cis	rs12134133	1	rs1429904	ENSG00000274245.1	RP11-357P18.2	8.57	1.47e-16	1.74e-13	0.46	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207288539	chr1:207372559~207373252:+
LUAD	cis	rs12134133	1	rs2782854	ENSG00000274245.1	RP11-357P18.2	8.57	1.47e-16	1.74e-13	0.46	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207289369	chr1:207372559~207373252:+
LUAD	cis	rs12134133	1	rs2782850	ENSG00000274245.1	RP11-357P18.2	8.57	1.47e-16	1.74e-13	0.46	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207292092	chr1:207372559~207373252:+
LUAD	cis	rs7429990	0.965	rs34380889	ENSG00000229759.1	MRPS18AP1	8.56	1.48e-16	1.75e-13	0.38	0.36	Educational attainment (years of education);	chr3:47905692	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.965	rs4858871	ENSG00000229759.1	MRPS18AP1	8.56	1.48e-16	1.75e-13	0.38	0.36	Educational attainment (years of education);	chr3:47911915	chr3:48256350~48256938:-
LUAD	cis	rs2337406	0.925	rs2011167	ENSG00000254174.1	IGHV1-12	8.56	1.49e-16	1.77e-13	0.34	0.36	Alzheimer's disease (late onset);	chr14:106680831	chr14:106122420~106122709:-
LUAD	cis	rs6991838	0.584	rs7463649	ENSG00000200714.1	Y_RNA	-8.56	1.5e-16	1.77e-13	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs66467166	ENSG00000200714.1	Y_RNA	-8.56	1.5e-16	1.77e-13	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.557	rs67685675	ENSG00000200714.1	Y_RNA	-8.56	1.5e-16	1.77e-13	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs66486920	ENSG00000200714.1	Y_RNA	-8.56	1.5e-16	1.77e-13	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs60023200	ENSG00000200714.1	Y_RNA	-8.56	1.5e-16	1.77e-13	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs61083799	ENSG00000200714.1	Y_RNA	-8.56	1.5e-16	1.77e-13	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs4449837	ENSG00000200714.1	Y_RNA	-8.56	1.5e-16	1.77e-13	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs57042777	ENSG00000200714.1	Y_RNA	-8.56	1.5e-16	1.77e-13	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65592731~65592820:+
LUAD	cis	rs673078	0.562	rs4767672	ENSG00000275759.1	RP11-131L12.3	-8.56	1.5e-16	1.77e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118397048	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs73205594	ENSG00000275759.1	RP11-131L12.3	-8.56	1.5e-16	1.77e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118397168	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs61943400	ENSG00000275759.1	RP11-131L12.3	-8.56	1.5e-16	1.77e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118398236	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs61943401	ENSG00000275759.1	RP11-131L12.3	-8.56	1.5e-16	1.77e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118398527	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs61943402	ENSG00000275759.1	RP11-131L12.3	-8.56	1.5e-16	1.77e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118398808	chr12:118428281~118428870:+
LUAD	cis	rs13423976	0.546	rs10184164	ENSG00000231367.4	AC016995.3	8.56	1.51e-16	1.78e-13	0.47	0.36	Gut microbiome composition (summer);	chr2:38514411	chr2:38406719~38515740:-
LUAD	cis	rs13423976	0.586	rs12617556	ENSG00000231367.4	AC016995.3	8.56	1.51e-16	1.78e-13	0.47	0.36	Gut microbiome composition (summer);	chr2:38514972	chr2:38406719~38515740:-
LUAD	cis	rs12134133	1	rs2782848	ENSG00000274245.1	RP11-357P18.2	8.56	1.51e-16	1.78e-13	0.47	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207293407	chr1:207372559~207373252:+
LUAD	cis	rs9309711	0.666	rs4321399	ENSG00000225234.1	TRAPPC12-AS1	-8.56	1.51e-16	1.79e-13	-0.42	-0.36	Neurofibrillary tangles;	chr2:3477888	chr2:3481242~3482409:-
LUAD	cis	rs17023223	0.537	rs12087987	ENSG00000231365.4	RP11-418J17.1	-8.56	1.51e-16	1.79e-13	-0.48	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119192198	chr1:119140396~119275973:+
LUAD	cis	rs1075265	0.528	rs2018747	ENSG00000233266.1	HMGB1P31	8.56	1.52e-16	1.79e-13	0.48	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54082487	chr2:54051334~54051760:+
LUAD	cis	rs12134133	1	rs7553157	ENSG00000274245.1	RP11-357P18.2	8.56	1.54e-16	1.82e-13	0.46	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207283922	chr1:207372559~207373252:+
LUAD	cis	rs733592	1	rs1859440	ENSG00000240399.1	RP1-228P16.1	-8.56	1.55e-16	1.83e-13	-0.35	-0.36	Plateletcrit;	chr12:48033546	chr12:48054813~48055591:-
LUAD	cis	rs11098499	0.874	rs28452522	ENSG00000245958.5	RP11-33B1.1	-8.56	1.55e-16	1.84e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119189629	chr4:119454791~119552025:+
LUAD	cis	rs526231	0.511	rs34823	ENSG00000175749.11	EIF3KP1	-8.56	1.55e-16	1.84e-13	-0.5	-0.36	Primary biliary cholangitis;	chr5:103102587	chr5:103032376~103033031:+
LUAD	cis	rs77204473	0.549	rs12280210	ENSG00000254851.1	RP11-109L13.1	8.56	1.56e-16	1.84e-13	0.69	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117069733	chr11:117135528~117138582:+
LUAD	cis	rs7429990	0.965	rs7426976	ENSG00000229759.1	MRPS18AP1	-8.56	1.56e-16	1.84e-13	-0.37	-0.36	Educational attainment (years of education);	chr3:47981083	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.965	rs1013431	ENSG00000229759.1	MRPS18AP1	-8.56	1.56e-16	1.84e-13	-0.37	-0.36	Educational attainment (years of education);	chr3:47987628	chr3:48256350~48256938:-
LUAD	cis	rs3931020	0.772	rs1475396	ENSG00000272864.1	RP11-17E13.2	-8.56	1.56e-16	1.85e-13	-0.44	-0.36	Resistin levels;	chr1:74776712	chr1:74698769~74699333:-
LUAD	cis	rs10129255	0.957	rs4387509	ENSG00000211970.3	IGHV4-61	-8.56	1.57e-16	1.85e-13	-0.29	-0.36	Kawasaki disease;	chr14:106704386	chr14:106639119~106639657:-
LUAD	cis	rs13392177	0.637	rs61041183	ENSG00000261338.2	RP11-378A13.1	8.56	1.57e-16	1.85e-13	0.36	0.36	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218191657	chr2:218255319~218257366:+
LUAD	cis	rs11676348	0.846	rs7594532	ENSG00000261338.2	RP11-378A13.1	-8.56	1.57e-16	1.86e-13	-0.38	-0.36	Ulcerative colitis;	chr2:218143277	chr2:218255319~218257366:+
LUAD	cis	rs9545047	0.716	rs7333904	ENSG00000227676.3	LINC01068	8.56	1.58e-16	1.86e-13	0.44	0.36	Schizophrenia;	chr13:79281413	chr13:79566727~79571436:+
LUAD	cis	rs2729354	0.768	rs2848635	ENSG00000265566.2	RN7SL605P	-8.55	1.6e-16	1.89e-13	-0.53	-0.36	Blood protein levels;	chr11:57486458	chr11:57528085~57528365:-
LUAD	cis	rs10463554	0.963	rs34829	ENSG00000175749.11	EIF3KP1	8.55	1.61e-16	1.9e-13	0.49	0.36	Parkinson's disease;	chr5:103108260	chr5:103032376~103033031:+
LUAD	cis	rs7924176	0.601	rs10824073	ENSG00000213731.2	RAB5CP1	-8.55	1.62e-16	1.91e-13	-0.38	-0.36	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74115458	chr10:74423435~74424014:-
LUAD	cis	rs1150668	0.764	rs9368565	ENSG00000216901.1	AL022393.7	-8.55	1.63e-16	1.92e-13	-0.43	-0.36	Pubertal anthropometrics;	chr6:28377433	chr6:28176188~28176674:+
LUAD	cis	rs1150668	0.796	rs1052215	ENSG00000216901.1	AL022393.7	-8.55	1.63e-16	1.92e-13	-0.43	-0.36	Pubertal anthropometrics;	chr6:28380381	chr6:28176188~28176674:+
LUAD	cis	rs1075265	0.584	rs4671178	ENSG00000233266.1	HMGB1P31	-8.55	1.63e-16	1.93e-13	-0.47	-0.36	Chronotype;Morning vs. evening chronotype;	chr2:54056356	chr2:54051334~54051760:+
LUAD	cis	rs12468226	0.938	rs6435139	ENSG00000273456.1	RP11-686O6.2	-8.55	1.64e-16	1.93e-13	-0.56	-0.36	Urate levels;	chr2:202255145	chr2:202374932~202375604:-
LUAD	cis	rs10875746	0.768	rs10875724	ENSG00000240399.1	RP1-228P16.1	-8.55	1.64e-16	1.94e-13	-0.42	-0.36	Longevity (90 years and older);	chr12:48026470	chr12:48054813~48055591:-
LUAD	cis	rs2729354	0.52	rs2729377	ENSG00000265566.2	RN7SL605P	-8.55	1.64e-16	1.94e-13	-0.53	-0.36	Blood protein levels;	chr11:57482611	chr11:57528085~57528365:-
LUAD	cis	rs10875746	0.669	rs10875772	ENSG00000240399.1	RP1-228P16.1	-8.55	1.65e-16	1.94e-13	-0.44	-0.36	Longevity (90 years and older);	chr12:48215770	chr12:48054813~48055591:-
LUAD	cis	rs4908760	0.773	rs301805	ENSG00000232912.4	RP5-1115A15.1	8.55	1.65e-16	1.95e-13	0.33	0.36	Vitiligo;	chr1:8420956	chr1:8424645~8434838:+
LUAD	cis	rs11096990	0.634	rs12648082	ENSG00000249207.1	RP11-360F5.1	8.55	1.65e-16	1.95e-13	0.4	0.36	Cognitive function;	chr4:39278104	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.634	rs6531703	ENSG00000249207.1	RP11-360F5.1	8.55	1.65e-16	1.95e-13	0.4	0.36	Cognitive function;	chr4:39281786	chr4:39112677~39126818:-
LUAD	cis	rs3823536	0.604	rs13221560	ENSG00000275106.1	RP11-309L24.10	-8.55	1.67e-16	1.97e-13	-0.45	-0.36	Sjögren's syndrome;	chr7:129023121	chr7:128952527~128953316:-
LUAD	cis	rs6142102	0.602	rs68051854	ENSG00000276073.1	RP5-1125A11.7	-8.55	1.67e-16	1.97e-13	-0.36	-0.36	Skin pigmentation;	chr20:34114150	chr20:33985617~33988989:-
LUAD	cis	rs6504950	1	rs17818028	ENSG00000275710.1	RP11-257O5.4	-8.55	1.67e-16	1.97e-13	-0.48	-0.36	Breast cancer;	chr17:54985394	chr17:54964474~54964679:+
LUAD	cis	rs9399137	0.507	rs4896128	ENSG00000232876.1	CTA-212D2.2	8.55	1.68e-16	1.97e-13	0.42	0.36	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028618	chr6:135055033~135060550:+
LUAD	cis	rs4927850	1	rs10881564	ENSG00000231464.1	AC024937.4	8.55	1.68e-16	1.98e-13	0.42	0.36	Pancreatic cancer;	chr3:196023455	chr3:195996738~195998233:+
LUAD	cis	rs944289	0.615	rs1333312	ENSG00000257826.1	RP11-116N8.4	-8.55	1.68e-16	1.98e-13	-0.38	-0.36	Thyroid cancer;	chr14:36093396	chr14:36061026~36067190:-
LUAD	cis	rs2337406	0.539	rs2583292	ENSG00000274576.2	IGHV2-70	-8.55	1.69e-16	1.98e-13	-0.38	-0.36	Alzheimer's disease (late onset);	chr14:106649040	chr14:106770577~106771020:-
LUAD	cis	rs10256972	0.9	rs7812072	ENSG00000229043.2	AC091729.9	-8.55	1.71e-16	2.01e-13	-0.39	-0.36	Endometriosis;Longevity;	chr7:1014226	chr7:1160374~1165267:+
LUAD	cis	rs6504622	0.677	rs12949446	ENSG00000262879.4	RP11-156P1.3	-8.54	1.71e-16	2.02e-13	-0.42	-0.36	Orofacial clefts;	chr17:46994311	chr17:46984045~47100323:-
LUAD	cis	rs6504950	1	rs7221223	ENSG00000275710.1	RP11-257O5.4	8.54	1.72e-16	2.02e-13	0.48	0.36	Breast cancer;	chr17:54981646	chr17:54964474~54964679:+
LUAD	cis	rs11096990	0.634	rs17431358	ENSG00000249207.1	RP11-360F5.1	8.54	1.73e-16	2.03e-13	0.4	0.36	Cognitive function;	chr4:39275676	chr4:39112677~39126818:-
LUAD	cis	rs9545047	0.604	rs9545048	ENSG00000227676.3	LINC01068	8.54	1.73e-16	2.03e-13	0.43	0.36	Schizophrenia;	chr13:79285593	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs1626333	ENSG00000227676.3	LINC01068	8.54	1.73e-16	2.03e-13	0.43	0.36	Schizophrenia;	chr13:79286932	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.567	rs1856996	ENSG00000227676.3	LINC01068	8.54	1.73e-16	2.03e-13	0.43	0.36	Schizophrenia;	chr13:79287453	chr13:79566727~79571436:+
LUAD	cis	rs7044106	0.708	rs1324472	ENSG00000226752.6	PSMD5-AS1	-8.54	1.74e-16	2.05e-13	-0.39	-0.36	Hip circumference adjusted for BMI;	chr9:120612832	chr9:120824828~120854385:+
LUAD	cis	rs11676348	0.846	rs13009946	ENSG00000261338.2	RP11-378A13.1	-8.54	1.75e-16	2.06e-13	-0.37	-0.36	Ulcerative colitis;	chr2:218143029	chr2:218255319~218257366:+
LUAD	cis	rs9545047	0.604	rs4885625	ENSG00000227676.3	LINC01068	8.54	1.75e-16	2.06e-13	0.43	0.36	Schizophrenia;	chr13:79290355	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs1324873	ENSG00000227676.3	LINC01068	8.54	1.75e-16	2.06e-13	0.43	0.36	Schizophrenia;	chr13:79292246	chr13:79566727~79571436:+
LUAD	cis	rs11098499	0.739	rs9996382	ENSG00000245958.5	RP11-33B1.1	-8.54	1.76e-16	2.07e-13	-0.33	-0.36	Corneal astigmatism;	chr4:119229857	chr4:119454791~119552025:+
LUAD	cis	rs673078	0.607	rs61943399	ENSG00000275759.1	RP11-131L12.3	-8.54	1.76e-16	2.07e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118393628	chr12:118428281~118428870:+
LUAD	cis	rs4927850	1	rs7630875	ENSG00000231464.1	AC024937.4	8.54	1.78e-16	2.09e-13	0.41	0.36	Pancreatic cancer;	chr3:196026895	chr3:195996738~195998233:+
LUAD	cis	rs10129255	0.956	rs10137268	ENSG00000223648.3	IGHV3-64	8.54	1.78e-16	2.1e-13	0.37	0.36	Kawasaki disease;	chr14:106697402	chr14:106643132~106658258:-
LUAD	cis	rs944289	0.646	rs8008989	ENSG00000257826.1	RP11-116N8.4	-8.54	1.79e-16	2.1e-13	-0.38	-0.36	Thyroid cancer;	chr14:36088871	chr14:36061026~36067190:-
LUAD	cis	rs944289	0.74	rs404131	ENSG00000257826.1	RP11-116N8.4	8.54	1.8e-16	2.12e-13	0.38	0.36	Thyroid cancer;	chr14:36075287	chr14:36061026~36067190:-
LUAD	cis	rs10129255	0.557	rs4043727	ENSG00000280411.1	IGHV1-69-2	-8.54	1.82e-16	2.14e-13	-0.28	-0.36	Kawasaki disease;	chr14:106649820	chr14:106762092~106762588:-
LUAD	cis	rs526231	0.511	rs27896	ENSG00000175749.11	EIF3KP1	8.54	1.83e-16	2.15e-13	0.51	0.36	Primary biliary cholangitis;	chr5:103152867	chr5:103032376~103033031:+
LUAD	cis	rs9487094	0.689	rs9480949	ENSG00000260273.1	RP11-425D10.10	8.54	1.84e-16	2.16e-13	0.46	0.36	Height;	chr6:109407238	chr6:109382795~109383666:+
LUAD	cis	rs7429990	0.965	rs2882668	ENSG00000229759.1	MRPS18AP1	8.54	1.84e-16	2.16e-13	0.38	0.36	Educational attainment (years of education);	chr3:47938816	chr3:48256350~48256938:-
LUAD	cis	rs9545047	0.604	rs9530891	ENSG00000227676.3	LINC01068	8.54	1.84e-16	2.16e-13	0.43	0.36	Schizophrenia;	chr13:79284750	chr13:79566727~79571436:+
LUAD	cis	rs944289	0.617	rs11156905	ENSG00000257826.1	RP11-116N8.4	-8.54	1.84e-16	2.16e-13	-0.38	-0.36	Thyroid cancer;	chr14:36100314	chr14:36061026~36067190:-
LUAD	cis	rs7945705	0.747	rs2568045	ENSG00000254860.4	TMEM9B-AS1	8.54	1.85e-16	2.17e-13	0.39	0.36	Hemoglobin concentration;	chr11:8982513	chr11:8964675~8977527:+
LUAD	cis	rs7945705	0.747	rs2653605	ENSG00000254860.4	TMEM9B-AS1	8.53	1.85e-16	2.17e-13	0.39	0.36	Hemoglobin concentration;	chr11:8971762	chr11:8964675~8977527:+
LUAD	cis	rs6142102	0.646	rs2223553	ENSG00000276073.1	RP5-1125A11.7	-8.53	1.85e-16	2.17e-13	-0.36	-0.36	Skin pigmentation;	chr20:34121638	chr20:33985617~33988989:-
LUAD	cis	rs2455601	0.882	rs11042116	ENSG00000254860.4	TMEM9B-AS1	8.53	1.86e-16	2.18e-13	0.54	0.36	Schizophrenia;	chr11:8906925	chr11:8964675~8977527:+
LUAD	cis	rs2455601	0.882	rs11042118	ENSG00000254860.4	TMEM9B-AS1	8.53	1.86e-16	2.18e-13	0.54	0.36	Schizophrenia;	chr11:8907244	chr11:8964675~8977527:+
LUAD	cis	rs10129255	0.869	rs7150549	ENSG00000211970.3	IGHV4-61	-8.53	1.86e-16	2.18e-13	-0.29	-0.36	Kawasaki disease;	chr14:106705441	chr14:106639119~106639657:-
LUAD	cis	rs673078	0.607	rs61943404	ENSG00000275759.1	RP11-131L12.3	-8.53	1.87e-16	2.19e-13	-0.5	-0.36	Glucose homeostasis traits;	chr12:118402062	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs17441061	ENSG00000275759.1	RP11-131L12.3	-8.53	1.88e-16	2.2e-13	-0.5	-0.36	Glucose homeostasis traits;	chr12:118409847	chr12:118428281~118428870:+
LUAD	cis	rs7174755	0.558	rs11071975	ENSG00000260657.2	RP11-315D16.4	-8.53	1.89e-16	2.22e-13	-0.46	-0.36	Major depressive disorder;	chr15:68037106	chr15:68267792~68277994:-
LUAD	cis	rs4988958	0.565	rs3755265	ENSG00000234389.1	AC007278.3	8.53	1.9e-16	2.22e-13	0.33	0.36	Asthma (childhood onset);	chr2:102436356	chr2:102438713~102440475:+
LUAD	cis	rs3823536	0.583	rs7789423	ENSG00000275106.1	RP11-309L24.10	-8.53	1.9e-16	2.23e-13	-0.45	-0.36	Sjögren's syndrome;	chr7:128981150	chr7:128952527~128953316:-
LUAD	cis	rs1075265	0.633	rs4671190	ENSG00000233266.1	HMGB1P31	8.53	1.9e-16	2.23e-13	0.47	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54085604	chr2:54051334~54051760:+
LUAD	cis	rs9807989	0.507	rs1420094	ENSG00000234389.1	AC007278.3	8.53	1.92e-16	2.25e-13	0.33	0.36	Asthma;	chr2:102399227	chr2:102438713~102440475:+
LUAD	cis	rs34779708	0.966	rs2126984	ENSG00000230534.5	RP11-297A16.2	8.53	1.92e-16	2.25e-13	0.42	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35121363	chr10:35098006~35127020:-
LUAD	cis	rs673078	0.607	rs61943367	ENSG00000275759.1	RP11-131L12.3	-8.53	1.92e-16	2.25e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118366316	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs61943368	ENSG00000275759.1	RP11-131L12.3	-8.53	1.92e-16	2.25e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118366568	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs61943385	ENSG00000275759.1	RP11-131L12.3	-8.53	1.92e-16	2.25e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118370339	chr12:118428281~118428870:+
LUAD	cis	rs7924176	0.601	rs17676126	ENSG00000213731.2	RAB5CP1	-8.53	1.93e-16	2.26e-13	-0.39	-0.36	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74145440	chr10:74423435~74424014:-
LUAD	cis	rs9807989	0.507	rs4851571	ENSG00000234389.1	AC007278.3	8.53	1.93e-16	2.26e-13	0.33	0.36	Asthma;	chr2:102402540	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs4851572	ENSG00000234389.1	AC007278.3	8.53	1.93e-16	2.26e-13	0.33	0.36	Asthma;	chr2:102402571	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs1035129	ENSG00000234389.1	AC007278.3	8.53	1.93e-16	2.26e-13	0.33	0.36	Asthma;	chr2:102403325	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.524	rs2110662	ENSG00000234389.1	AC007278.3	8.53	1.93e-16	2.26e-13	0.33	0.36	Asthma;	chr2:102403679	chr2:102438713~102440475:+
LUAD	cis	rs673078	0.607	rs7309484	ENSG00000275759.1	RP11-131L12.3	-8.53	1.93e-16	2.26e-13	-0.5	-0.36	Glucose homeostasis traits;	chr12:118400833	chr12:118428281~118428870:+
LUAD	cis	rs56046484	0.956	rs17540501	ENSG00000259295.5	CSPG4P12	8.53	1.94e-16	2.27e-13	0.55	0.36	Testicular germ cell tumor;	chr15:85094870	chr15:85191438~85213905:+
LUAD	cis	rs673078	0.607	rs950288	ENSG00000275759.1	RP11-131L12.3	-8.53	1.96e-16	2.29e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118392201	chr12:118428281~118428870:+
LUAD	cis	rs10129255	0.957	rs10136817	ENSG00000223648.3	IGHV3-64	8.53	1.96e-16	2.29e-13	0.37	0.36	Kawasaki disease;	chr14:106787730	chr14:106643132~106658258:-
LUAD	cis	rs17608059	0.71	rs8080167	ENSG00000141028.6	CDRT15P1	-8.53	1.96e-16	2.29e-13	-0.4	-0.36	Temperament;	chr17:14046511	chr17:14024514~14025488:+
LUAD	cis	rs17608059	0.679	rs9898056	ENSG00000141028.6	CDRT15P1	-8.53	1.96e-16	2.29e-13	-0.4	-0.36	Temperament;	chr17:14048649	chr17:14024514~14025488:+
LUAD	cis	rs11214589	0.747	rs10891537	ENSG00000270179.1	RP11-159N11.4	-8.53	1.96e-16	2.3e-13	-0.37	-0.36	Neuroticism;	chr11:113340648	chr11:113368478~113369117:+
LUAD	cis	rs7201929	1	rs7201929	ENSG00000259982.1	CDC37P1	8.53	1.97e-16	2.3e-13	0.5	0.36	QT interval;	chr16:28860645	chr16:28700294~28701540:-
LUAD	cis	rs526231	0.543	rs34783	ENSG00000175749.11	EIF3KP1	8.52	2e-16	2.34e-13	0.52	0.36	Primary biliary cholangitis;	chr5:103121337	chr5:103032376~103033031:+
LUAD	cis	rs11098499	0.913	rs67073020	ENSG00000245958.5	RP11-33B1.1	-8.52	2.01e-16	2.35e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119231402	chr4:119454791~119552025:+
LUAD	cis	rs367615	0.506	rs2963021	ENSG00000249476.1	CTD-2587M2.1	8.52	2.02e-16	2.36e-13	0.4	0.36	Colorectal cancer (SNP x SNP interaction);	chr5:109464664	chr5:109237120~109326369:-
LUAD	cis	rs4908760	0.783	rs301799	ENSG00000232912.4	RP5-1115A15.1	8.52	2.03e-16	2.37e-13	0.33	0.36	Vitiligo;	chr1:8429242	chr1:8424645~8434838:+
LUAD	cis	rs9399137	0.507	rs7771310	ENSG00000232876.1	CTA-212D2.2	-8.52	2.03e-16	2.37e-13	-0.42	-0.36	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134951397	chr6:135055033~135060550:+
LUAD	cis	rs3823536	0.583	rs3778750	ENSG00000275106.1	RP11-309L24.10	-8.52	2.05e-16	2.4e-13	-0.45	-0.36	Sjögren's syndrome;	chr7:128977035	chr7:128952527~128953316:-
LUAD	cis	rs9807989	0.507	rs6734762	ENSG00000234389.1	AC007278.3	8.52	2.06e-16	2.41e-13	0.33	0.36	Asthma;	chr2:102446466	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs11465721	ENSG00000234389.1	AC007278.3	8.52	2.06e-16	2.41e-13	0.33	0.36	Asthma;	chr2:102446780	chr2:102438713~102440475:+
LUAD	cis	rs12922040	0.701	rs12149912	ENSG00000263335.1	AF001548.5	-8.52	2.07e-16	2.42e-13	-0.44	-0.36	Serum uric acid levels in response to allopurinol in gout;	chr16:15774798	chr16:15726674~15732993:+
LUAD	cis	rs6700559	0.967	rs10919992	ENSG00000260088.1	RP11-92G12.3	-8.52	2.07e-16	2.42e-13	-0.46	-0.36	Coronary artery disease;	chr1:200638338	chr1:200669507~200694250:+
LUAD	cis	rs9545047	0.692	rs314694	ENSG00000227676.3	LINC01068	-8.52	2.11e-16	2.46e-13	-0.44	-0.36	Schizophrenia;	chr13:79432467	chr13:79566727~79571436:+
LUAD	cis	rs10463554	0.727	rs34768	ENSG00000175749.11	EIF3KP1	8.52	2.12e-16	2.47e-13	0.51	0.36	Parkinson's disease;	chr5:103155798	chr5:103032376~103033031:+
LUAD	cis	rs673078	0.607	rs17440893	ENSG00000275759.1	RP11-131L12.3	-8.52	2.12e-16	2.47e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118362532	chr12:118428281~118428870:+
LUAD	cis	rs9807989	0.507	rs2041739	ENSG00000234389.1	AC007278.3	-8.52	2.13e-16	2.49e-13	-0.33	-0.36	Asthma;	chr2:102377873	chr2:102438713~102440475:+
LUAD	cis	rs9545047	0.716	rs643778	ENSG00000227676.3	LINC01068	-8.52	2.14e-16	2.5e-13	-0.45	-0.36	Schizophrenia;	chr13:79423937	chr13:79566727~79571436:+
LUAD	cis	rs7945705	0.747	rs10840158	ENSG00000254860.4	TMEM9B-AS1	8.51	2.15e-16	2.5e-13	0.4	0.36	Hemoglobin concentration;	chr11:8999350	chr11:8964675~8977527:+
LUAD	cis	rs8062405	0.69	rs762634	ENSG00000259982.1	CDC37P1	8.51	2.16e-16	2.52e-13	0.47	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28700294~28701540:-
LUAD	cis	rs732716	0.785	rs56033249	ENSG00000267769.1	CTB-50L17.9	-8.51	2.16e-16	2.52e-13	-0.4	-0.36	Mean corpuscular volume;	chr19:4369450	chr19:4454014~4455286:+
LUAD	cis	rs7429990	0.965	rs777015	ENSG00000229759.1	MRPS18AP1	8.51	2.17e-16	2.53e-13	0.38	0.36	Educational attainment (years of education);	chr3:47895582	chr3:48256350~48256938:-
LUAD	cis	rs5760092	0.618	rs5996631	ENSG00000225282.1	AP000350.6	-8.51	2.17e-16	2.53e-13	-0.48	-0.36	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23926900~23929574:+
LUAD	cis	rs7429990	0.932	rs9862913	ENSG00000229759.1	MRPS18AP1	8.51	2.17e-16	2.53e-13	0.37	0.36	Educational attainment (years of education);	chr3:47974682	chr3:48256350~48256938:-
LUAD	cis	rs10129255	0.826	rs7150693	ENSG00000223648.3	IGHV3-64	8.51	2.18e-16	2.54e-13	0.37	0.36	Kawasaki disease;	chr14:106705382	chr14:106643132~106658258:-
LUAD	cis	rs673078	0.607	rs17512644	ENSG00000275759.1	RP11-131L12.3	-8.51	2.18e-16	2.54e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118359963	chr12:118428281~118428870:+
LUAD	cis	rs2455601	1	rs11042114	ENSG00000254860.4	TMEM9B-AS1	8.51	2.19e-16	2.55e-13	0.55	0.36	Schizophrenia;	chr11:8898342	chr11:8964675~8977527:+
LUAD	cis	rs9322193	0.923	rs12529698	ENSG00000223701.3	RAET1E-AS1	8.51	2.2e-16	2.56e-13	0.42	0.36	Lung cancer;	chr6:149650951	chr6:149884431~149919508:+
LUAD	cis	rs673078	0.607	rs7132753	ENSG00000275759.1	RP11-131L12.3	-8.51	2.2e-16	2.57e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118420383	chr12:118428281~118428870:+
LUAD	cis	rs10875746	0.669	rs11168496	ENSG00000240399.1	RP1-228P16.1	-8.51	2.21e-16	2.57e-13	-0.43	-0.36	Longevity (90 years and older);	chr12:48257072	chr12:48054813~48055591:-
LUAD	cis	rs526231	0.543	rs7714539	ENSG00000175749.11	EIF3KP1	8.51	2.22e-16	2.59e-13	0.52	0.36	Primary biliary cholangitis;	chr5:102993174	chr5:103032376~103033031:+
LUAD	cis	rs10129255	0.826	rs7150693	ENSG00000211970.3	IGHV4-61	-8.51	2.22e-16	2.59e-13	-0.29	-0.36	Kawasaki disease;	chr14:106705382	chr14:106639119~106639657:-
LUAD	cis	rs1150668	0.799	rs1150707	ENSG00000216901.1	AL022393.7	8.51	2.24e-16	2.61e-13	0.43	0.36	Pubertal anthropometrics;	chr6:28229827	chr6:28176188~28176674:+
LUAD	cis	rs526231	0.543	rs26523	ENSG00000175749.11	EIF3KP1	8.51	2.25e-16	2.62e-13	0.52	0.36	Primary biliary cholangitis;	chr5:103120550	chr5:103032376~103033031:+
LUAD	cis	rs9807989	0.507	rs2058659	ENSG00000234389.1	AC007278.3	-8.51	2.25e-16	2.62e-13	-0.32	-0.36	Asthma;	chr2:102438096	chr2:102438713~102440475:+
LUAD	cis	rs1150668	0.796	rs1124132	ENSG00000216901.1	AL022393.7	8.51	2.25e-16	2.62e-13	0.42	0.36	Pubertal anthropometrics;	chr6:28412544	chr6:28176188~28176674:+
LUAD	cis	rs10740039	0.549	rs9414741	ENSG00000254271.1	RP11-131N11.4	-8.51	2.26e-16	2.63e-13	-0.4	-0.36	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60738510	chr10:60734342~60741828:+
LUAD	cis	rs10129255	1	rs9324091	ENSG00000211970.3	IGHV4-61	-8.51	2.26e-16	2.63e-13	-0.28	-0.36	Kawasaki disease;	chr14:106676625	chr14:106639119~106639657:-
LUAD	cis	rs12594515	0.967	rs11070465	ENSG00000273972.1	CTD-2306A12.1	-8.51	2.26e-16	2.63e-13	-0.39	-0.36	Weight;Waist circumference;	chr15:45692701	chr15:45702640~45703183:+
LUAD	cis	rs9322193	0.923	rs11155671	ENSG00000223701.3	RAET1E-AS1	8.51	2.27e-16	2.64e-13	0.42	0.36	Lung cancer;	chr6:149650996	chr6:149884431~149919508:+
LUAD	cis	rs7044106	0.648	rs2031369	ENSG00000226752.6	PSMD5-AS1	-8.51	2.28e-16	2.66e-13	-0.39	-0.36	Hip circumference adjusted for BMI;	chr9:120598016	chr9:120824828~120854385:+
LUAD	cis	rs526231	0.543	rs32851	ENSG00000175749.11	EIF3KP1	8.51	2.29e-16	2.66e-13	0.52	0.36	Primary biliary cholangitis;	chr5:103132967	chr5:103032376~103033031:+
LUAD	cis	rs494459	0.838	rs1784543	ENSG00000255239.1	AP002954.6	8.5	2.32e-16	2.7e-13	0.42	0.36	Height;	chr11:118760944	chr11:118688039~118690600:-
LUAD	cis	rs1075265	0.547	rs11125520	ENSG00000233266.1	HMGB1P31	8.5	2.32e-16	2.7e-13	0.47	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54076696	chr2:54051334~54051760:+
LUAD	cis	rs526231	0.543	rs34779	ENSG00000175749.11	EIF3KP1	8.5	2.35e-16	2.73e-13	0.52	0.36	Primary biliary cholangitis;	chr5:103117064	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.547	rs34780	ENSG00000175749.11	EIF3KP1	8.5	2.35e-16	2.73e-13	0.52	0.36	Primary biliary cholangitis;	chr5:103117853	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.759	rs34781	ENSG00000175749.11	EIF3KP1	8.5	2.35e-16	2.73e-13	0.52	0.36	Parkinson's disease;	chr5:103118735	chr5:103032376~103033031:+
LUAD	cis	rs9807989	0.507	rs1420105	ENSG00000234389.1	AC007278.3	8.5	2.38e-16	2.76e-13	0.33	0.36	Asthma;	chr2:102418659	chr2:102438713~102440475:+
LUAD	cis	rs10256972	0.521	rs7457418	ENSG00000229043.2	AC091729.9	-8.5	2.38e-16	2.76e-13	-0.38	-0.36	Endometriosis;Longevity;	chr7:1070619	chr7:1160374~1165267:+
LUAD	cis	rs10875746	0.624	rs11168498	ENSG00000240399.1	RP1-228P16.1	-8.5	2.38e-16	2.76e-13	-0.45	-0.36	Longevity (90 years and older);	chr12:48261305	chr12:48054813~48055591:-
LUAD	cis	rs638893	0.53	rs1961138	ENSG00000278376.1	RP11-158I9.8	-8.5	2.4e-16	2.79e-13	-0.54	-0.36	Vitiligo;	chr11:118748714	chr11:118791254~118793137:+
LUAD	cis	rs2455601	0.882	rs11042115	ENSG00000254860.4	TMEM9B-AS1	8.5	2.4e-16	2.79e-13	0.55	0.36	Schizophrenia;	chr11:8905132	chr11:8964675~8977527:+
LUAD	cis	rs9487094	0.517	rs3778474	ENSG00000260273.1	RP11-425D10.10	8.5	2.41e-16	2.8e-13	0.46	0.36	Height;	chr6:109374782	chr6:109382795~109383666:+
LUAD	cis	rs9481169	0.557	rs73534579	ENSG00000255389.1	C6orf3	-8.5	2.42e-16	2.81e-13	-0.85	-0.36	Inflammatory skin disease;	chr6:111589486	chr6:111599875~111602295:+
LUAD	cis	rs8005677	0.77	rs56180741	ENSG00000279656.1	RP11-298I3.6	8.5	2.42e-16	2.81e-13	0.43	0.36	Cognitive ability (multi-trait analysis);	chr14:22908037	chr14:23023083~23024217:-
LUAD	cis	rs8005677	0.828	rs3794452	ENSG00000279656.1	RP11-298I3.6	8.5	2.42e-16	2.81e-13	0.43	0.36	Cognitive ability (multi-trait analysis);	chr14:22917473	chr14:23023083~23024217:-
LUAD	cis	rs7945705	0.747	rs1980429	ENSG00000254860.4	TMEM9B-AS1	8.5	2.42e-16	2.81e-13	0.39	0.36	Hemoglobin concentration;	chr11:8988927	chr11:8964675~8977527:+
LUAD	cis	rs13423976	0.6	rs2373404	ENSG00000231367.4	AC016995.3	8.5	2.42e-16	2.81e-13	0.47	0.36	Gut microbiome composition (summer);	chr2:38512959	chr2:38406719~38515740:-
LUAD	cis	rs13423976	0.631	rs2373405	ENSG00000231367.4	AC016995.3	8.5	2.42e-16	2.81e-13	0.47	0.36	Gut microbiome composition (summer);	chr2:38513072	chr2:38406719~38515740:-
LUAD	cis	rs10129255	0.912	rs8011090	ENSG00000211970.3	IGHV4-61	-8.5	2.43e-16	2.82e-13	-0.28	-0.36	Kawasaki disease;	chr14:106678896	chr14:106639119~106639657:-
LUAD	cis	rs638893	0.636	rs6589687	ENSG00000278376.1	RP11-158I9.8	-8.5	2.43e-16	2.82e-13	-0.54	-0.36	Vitiligo;	chr11:118744951	chr11:118791254~118793137:+
LUAD	cis	rs10129255	0.957	rs4387509	ENSG00000223648.3	IGHV3-64	8.5	2.44e-16	2.83e-13	0.37	0.36	Kawasaki disease;	chr14:106704386	chr14:106643132~106658258:-
LUAD	cis	rs17023223	0.537	rs3934789	ENSG00000231365.4	RP11-418J17.1	-8.5	2.44e-16	2.83e-13	-0.48	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119140440	chr1:119140396~119275973:+
LUAD	cis	rs6700559	1	rs12076877	ENSG00000260088.1	RP11-92G12.3	-8.5	2.46e-16	2.85e-13	-0.46	-0.36	Coronary artery disease;	chr1:200674277	chr1:200669507~200694250:+
LUAD	cis	rs9807989	0.524	rs7594402	ENSG00000234389.1	AC007278.3	8.5	2.49e-16	2.88e-13	0.33	0.36	Asthma;	chr2:102404807	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs6710034	ENSG00000234389.1	AC007278.3	8.5	2.49e-16	2.88e-13	0.33	0.36	Asthma;	chr2:102407218	chr2:102438713~102440475:+
LUAD	cis	rs2108622	1	rs2108622	ENSG00000267453.5	AC004791.2	-8.49	2.5e-16	2.89e-13	-0.48	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15879621	chr19:15851993~15864904:-
LUAD	cis	rs2337406	0.587	rs916547	ENSG00000274576.2	IGHV2-70	-8.49	2.5e-16	2.89e-13	-0.39	-0.36	Alzheimer's disease (late onset);	chr14:106646735	chr14:106770577~106771020:-
LUAD	cis	rs10875746	0.669	rs61941006	ENSG00000240399.1	RP1-228P16.1	-8.49	2.5e-16	2.89e-13	-0.44	-0.36	Longevity (90 years and older);	chr12:48237350	chr12:48054813~48055591:-
LUAD	cis	rs9807989	0.507	rs1420096	ENSG00000234389.1	AC007278.3	8.49	2.5e-16	2.89e-13	0.33	0.36	Asthma;	chr2:102394452	chr2:102438713~102440475:+
LUAD	cis	rs7924176	0.601	rs767809	ENSG00000213731.2	RAB5CP1	-8.49	2.52e-16	2.91e-13	-0.39	-0.36	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74105307	chr10:74423435~74424014:-
LUAD	cis	rs6991838	0.584	rs10089708	ENSG00000200714.1	Y_RNA	8.49	2.53e-16	2.93e-13	0.46	0.36	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.584	rs6991731	ENSG00000200714.1	Y_RNA	8.49	2.53e-16	2.93e-13	0.46	0.36	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65592731~65592820:+
LUAD	cis	rs733592	0.507	rs10875739	ENSG00000240399.1	RP1-228P16.1	8.49	2.53e-16	2.93e-13	0.34	0.36	Plateletcrit;	chr12:48087136	chr12:48054813~48055591:-
LUAD	cis	rs10129255	0.912	rs67410411	ENSG00000211970.3	IGHV4-61	-8.49	2.54e-16	2.94e-13	-0.28	-0.36	Kawasaki disease;	chr14:106680324	chr14:106639119~106639657:-
LUAD	cis	rs10129255	1	rs61997605	ENSG00000211970.3	IGHV4-61	-8.49	2.56e-16	2.96e-13	-0.28	-0.36	Kawasaki disease;	chr14:106678368	chr14:106639119~106639657:-
LUAD	cis	rs10129255	1	rs8012033	ENSG00000211970.3	IGHV4-61	-8.49	2.56e-16	2.96e-13	-0.28	-0.36	Kawasaki disease;	chr14:106678854	chr14:106639119~106639657:-
LUAD	cis	rs526231	0.543	rs60633061	ENSG00000175749.11	EIF3KP1	8.49	2.56e-16	2.96e-13	0.52	0.36	Primary biliary cholangitis;	chr5:102994345	chr5:103032376~103033031:+
LUAD	cis	rs12134133	1	rs10494889	ENSG00000274245.1	RP11-357P18.2	8.49	2.57e-16	2.97e-13	0.46	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207286963	chr1:207372559~207373252:+
LUAD	cis	rs12134133	0.962	rs2564970	ENSG00000274245.1	RP11-357P18.2	8.49	2.57e-16	2.97e-13	0.46	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207290696	chr1:207372559~207373252:+
LUAD	cis	rs12134133	1	rs2782851	ENSG00000274245.1	RP11-357P18.2	8.49	2.57e-16	2.97e-13	0.46	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207291717	chr1:207372559~207373252:+
LUAD	cis	rs10129255	1	rs10137758	ENSG00000223648.3	IGHV3-64	8.49	2.58e-16	2.98e-13	0.37	0.36	Kawasaki disease;	chr14:106697673	chr14:106643132~106658258:-
LUAD	cis	rs7945705	0.837	rs2742474	ENSG00000254860.4	TMEM9B-AS1	8.49	2.58e-16	2.98e-13	0.4	0.36	Hemoglobin concentration;	chr11:8980542	chr11:8964675~8977527:+
LUAD	cis	rs7945705	0.869	rs2742471	ENSG00000254860.4	TMEM9B-AS1	8.49	2.58e-16	2.98e-13	0.4	0.36	Hemoglobin concentration;	chr11:8982406	chr11:8964675~8977527:+
LUAD	cis	rs8062405	0.69	rs4787458	ENSG00000259982.1	CDC37P1	8.49	2.6e-16	3.01e-13	0.47	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28519966	chr16:28700294~28701540:-
LUAD	cis	rs10875746	0.669	rs10875770	ENSG00000240399.1	RP1-228P16.1	-8.49	2.61e-16	3.02e-13	-0.42	-0.36	Longevity (90 years and older);	chr12:48206737	chr12:48054813~48055591:-
LUAD	cis	rs17023223	0.581	rs10923750	ENSG00000231365.4	RP11-418J17.1	-8.49	2.62e-16	3.03e-13	-0.48	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119108172	chr1:119140396~119275973:+
LUAD	cis	rs2739330	0.76	rs1002286	ENSG00000099984.9	GSTT2	8.49	2.64e-16	3.05e-13	0.43	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23980123~23983911:+
LUAD	cis	rs12134133	1	rs6660557	ENSG00000274245.1	RP11-357P18.2	8.48	2.7e-16	3.12e-13	0.46	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207281251	chr1:207372559~207373252:+
LUAD	cis	rs12134133	1	rs7521457	ENSG00000274245.1	RP11-357P18.2	8.48	2.7e-16	3.12e-13	0.46	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207283802	chr1:207372559~207373252:+
LUAD	cis	rs12134133	1	rs7553339	ENSG00000274245.1	RP11-357P18.2	8.48	2.7e-16	3.12e-13	0.46	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207284075	chr1:207372559~207373252:+
LUAD	cis	rs12134133	1	rs6668683	ENSG00000274245.1	RP11-357P18.2	8.48	2.7e-16	3.12e-13	0.46	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285846	chr1:207372559~207373252:+
LUAD	cis	rs7429990	0.932	rs2166772	ENSG00000229759.1	MRPS18AP1	-8.48	2.7e-16	3.12e-13	-0.37	-0.36	Educational attainment (years of education);	chr3:48006384	chr3:48256350~48256938:-
LUAD	cis	rs9322193	0.886	rs9485408	ENSG00000223701.3	RAET1E-AS1	8.48	2.7e-16	3.12e-13	0.42	0.36	Lung cancer;	chr6:149618888	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs1080670	ENSG00000223701.3	RAET1E-AS1	8.48	2.7e-16	3.12e-13	0.42	0.36	Lung cancer;	chr6:149620161	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.884	rs10782312	ENSG00000223701.3	RAET1E-AS1	8.48	2.7e-16	3.12e-13	0.42	0.36	Lung cancer;	chr6:149622669	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.886	rs9322198	ENSG00000223701.3	RAET1E-AS1	8.48	2.7e-16	3.12e-13	0.42	0.36	Lung cancer;	chr6:149623772	chr6:149884431~149919508:+
LUAD	cis	rs10028773	0.568	rs6838457	ENSG00000245958.5	RP11-33B1.1	-8.48	2.72e-16	3.13e-13	-0.31	-0.36	Educational attainment;	chr4:119346212	chr4:119454791~119552025:+
LUAD	cis	rs4927850	1	rs7614767	ENSG00000231464.1	AC024937.4	8.48	2.72e-16	3.14e-13	0.41	0.36	Pancreatic cancer;	chr3:196026580	chr3:195996738~195998233:+
LUAD	cis	rs13392177	0.66	rs12988046	ENSG00000261338.2	RP11-378A13.1	-8.48	2.72e-16	3.14e-13	-0.37	-0.36	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209081	chr2:218255319~218257366:+
LUAD	cis	rs732716	0.785	rs9973266	ENSG00000267769.1	CTB-50L17.9	-8.48	2.72e-16	3.14e-13	-0.4	-0.36	Mean corpuscular volume;	chr19:4392718	chr19:4454014~4455286:+
LUAD	cis	rs950169	0.84	rs62019457	ENSG00000225151.9	GOLGA2P7	-8.48	2.75e-16	3.17e-13	-0.5	-0.36	Schizophrenia;	chr15:84558911	chr15:84199311~84230136:-
LUAD	cis	rs9322193	0.923	rs9688861	ENSG00000223701.3	RAET1E-AS1	8.48	2.76e-16	3.18e-13	0.42	0.36	Lung cancer;	chr6:149637924	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs7740278	ENSG00000223701.3	RAET1E-AS1	8.48	2.76e-16	3.18e-13	0.42	0.36	Lung cancer;	chr6:149640116	chr6:149884431~149919508:+
LUAD	cis	rs6782228	1	rs35604103	ENSG00000242551.2	POU5F1P6	8.48	2.77e-16	3.19e-13	0.44	0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128616009	chr3:128674735~128677005:-
LUAD	cis	rs11123170	0.542	rs11123169	ENSG00000274877.1	RP11-65I12.1	8.48	2.77e-16	3.2e-13	0.47	0.36	Renal function-related traits (BUN);	chr2:113209498	chr2:113237595~113240825:+
LUAD	cis	rs7429990	0.932	rs6803741	ENSG00000229759.1	MRPS18AP1	-8.48	2.78e-16	3.2e-13	-0.37	-0.36	Educational attainment (years of education);	chr3:48082050	chr3:48256350~48256938:-
LUAD	cis	rs673078	0.607	rs8467	ENSG00000275759.1	RP11-131L12.3	-8.48	2.79e-16	3.21e-13	-0.5	-0.36	Glucose homeostasis traits;	chr12:118417479	chr12:118428281~118428870:+
LUAD	cis	rs7044106	0.537	rs10818474	ENSG00000226752.6	PSMD5-AS1	-8.48	2.79e-16	3.22e-13	-0.42	-0.36	Hip circumference adjusted for BMI;	chr9:120727686	chr9:120824828~120854385:+
LUAD	cis	rs10129255	0.957	rs6576233	ENSG00000223648.3	IGHV3-64	8.48	2.8e-16	3.22e-13	0.35	0.36	Kawasaki disease;	chr14:106787239	chr14:106643132~106658258:-
LUAD	cis	rs2280018	0.526	rs1510148	ENSG00000260735.1	RP11-72I8.1	-8.48	2.81e-16	3.23e-13	-0.4	-0.36	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15073522	chr16:15094411~15109197:+
LUAD	cis	rs17711722	0.522	rs6957759	ENSG00000164669.11	INTS4P1	-8.48	2.81e-16	3.23e-13	-0.43	-0.36	Calcium levels;	chr7:65806798	chr7:65141225~65234216:+
LUAD	cis	rs17711722	0.522	rs62469933	ENSG00000164669.11	INTS4P1	-8.48	2.81e-16	3.23e-13	-0.42	-0.36	Calcium levels;	chr7:65800652	chr7:65141225~65234216:+
LUAD	cis	rs6991838	0.584	rs7463740	ENSG00000200714.1	Y_RNA	-8.48	2.81e-16	3.24e-13	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65592731~65592820:+
LUAD	cis	rs9322193	0.923	rs9800580	ENSG00000223701.3	RAET1E-AS1	8.48	2.83e-16	3.26e-13	0.42	0.36	Lung cancer;	chr6:149632845	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.884	rs11155669	ENSG00000223701.3	RAET1E-AS1	8.48	2.83e-16	3.26e-13	0.42	0.36	Lung cancer;	chr6:149633501	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.887	rs9505824	ENSG00000223701.3	RAET1E-AS1	8.48	2.83e-16	3.26e-13	0.42	0.36	Lung cancer;	chr6:149633663	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs9505826	ENSG00000223701.3	RAET1E-AS1	8.48	2.83e-16	3.26e-13	0.42	0.36	Lung cancer;	chr6:149633912	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs9766886	ENSG00000223701.3	RAET1E-AS1	8.48	2.83e-16	3.26e-13	0.42	0.36	Lung cancer;	chr6:149637048	chr6:149884431~149919508:+
LUAD	cis	rs17711722	0.523	rs365896	ENSG00000164669.11	INTS4P1	8.48	2.84e-16	3.26e-13	0.42	0.36	Calcium levels;	chr7:66045710	chr7:65141225~65234216:+
LUAD	cis	rs17023223	0.537	rs12081198	ENSG00000231365.4	RP11-418J17.1	-8.48	2.84e-16	3.26e-13	-0.48	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143481	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs12081327	ENSG00000231365.4	RP11-418J17.1	-8.48	2.84e-16	3.26e-13	-0.48	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143735	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs12086686	ENSG00000231365.4	RP11-418J17.1	-8.48	2.84e-16	3.26e-13	-0.48	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146461	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs12085616	ENSG00000231365.4	RP11-418J17.1	-8.48	2.84e-16	3.26e-13	-0.48	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146525	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs12097967	ENSG00000231365.4	RP11-418J17.1	-8.48	2.84e-16	3.26e-13	-0.48	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119160290	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs10923756	ENSG00000231365.4	RP11-418J17.1	-8.48	2.84e-16	3.27e-13	-0.48	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119132025	chr1:119140396~119275973:+
LUAD	cis	rs3823536	0.583	rs921403	ENSG00000275106.1	RP11-309L24.10	-8.48	2.86e-16	3.29e-13	-0.45	-0.36	Sjögren's syndrome;	chr7:129036670	chr7:128952527~128953316:-
LUAD	cis	rs11098499	0.913	rs12186259	ENSG00000245958.5	RP11-33B1.1	-8.48	2.89e-16	3.32e-13	-0.34	-0.36	Corneal astigmatism;	chr4:119230884	chr4:119454791~119552025:+
LUAD	cis	rs10875746	0.624	rs10875777	ENSG00000240399.1	RP1-228P16.1	-8.48	2.89e-16	3.32e-13	-0.43	-0.36	Longevity (90 years and older);	chr12:48228288	chr12:48054813~48055591:-
LUAD	cis	rs10463554	0.892	rs158408	ENSG00000175749.11	EIF3KP1	8.47	2.92e-16	3.35e-13	0.49	0.36	Parkinson's disease;	chr5:103071670	chr5:103032376~103033031:+
LUAD	cis	rs11690935	0.788	rs10201053	ENSG00000228389.1	AC068039.4	8.47	2.95e-16	3.39e-13	0.43	0.36	Schizophrenia;	chr2:172024653	chr2:171773482~171775844:+
LUAD	cis	rs9545047	0.604	rs943712	ENSG00000227676.3	LINC01068	8.47	2.98e-16	3.42e-13	0.42	0.36	Schizophrenia;	chr13:79282671	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs943711	ENSG00000227676.3	LINC01068	8.47	2.98e-16	3.42e-13	0.42	0.36	Schizophrenia;	chr13:79282886	chr13:79566727~79571436:+
LUAD	cis	rs7688540	0.771	rs11248009	ENSG00000275426.1	CH17-262A2.1	8.47	2.98e-16	3.42e-13	0.52	0.36	Facial morphology (factor 6, height of vermillion lower lip);	chr4:226360	chr4:149738~150317:+
LUAD	cis	rs7688540	0.771	rs61794997	ENSG00000275426.1	CH17-262A2.1	8.47	2.98e-16	3.42e-13	0.52	0.36	Facial morphology (factor 6, height of vermillion lower lip);	chr4:228314	chr4:149738~150317:+
LUAD	cis	rs7688540	0.771	rs11724417	ENSG00000275426.1	CH17-262A2.1	8.47	2.98e-16	3.42e-13	0.52	0.36	Facial morphology (factor 6, height of vermillion lower lip);	chr4:229563	chr4:149738~150317:+
LUAD	cis	rs7688540	0.771	rs11724176	ENSG00000275426.1	CH17-262A2.1	8.47	2.98e-16	3.42e-13	0.52	0.36	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231112	chr4:149738~150317:+
LUAD	cis	rs7688540	0.723	rs1986386	ENSG00000275426.1	CH17-262A2.1	8.47	2.98e-16	3.42e-13	0.52	0.36	Facial morphology (factor 6, height of vermillion lower lip);	chr4:235020	chr4:149738~150317:+
LUAD	cis	rs26232	0.551	rs26431	ENSG00000175749.11	EIF3KP1	-8.47	3e-16	3.44e-13	-0.5	-0.36	Rheumatoid arthritis;	chr5:103030090	chr5:103032376~103033031:+
LUAD	cis	rs2337406	0.925	rs76288499	ENSG00000254174.1	IGHV1-12	8.47	3.01e-16	3.45e-13	0.34	0.36	Alzheimer's disease (late onset);	chr14:106686309	chr14:106122420~106122709:-
LUAD	cis	rs12134133	1	rs2782846	ENSG00000274245.1	RP11-357P18.2	8.47	3.02e-16	3.46e-13	0.47	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207300495	chr1:207372559~207373252:+
LUAD	cis	rs4853012	0.793	rs6707619	ENSG00000257800.1	FNBP1P1	8.47	3.08e-16	3.53e-13	0.44	0.36	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74120680~74123218:+
LUAD	cis	rs7924176	0.601	rs7896660	ENSG00000213731.2	RAB5CP1	-8.47	3.09e-16	3.54e-13	-0.39	-0.36	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74170399	chr10:74423435~74424014:-
LUAD	cis	rs3823536	0.583	rs6973975	ENSG00000275106.1	RP11-309L24.10	-8.47	3.11e-16	3.56e-13	-0.45	-0.36	Sjögren's syndrome;	chr7:129035495	chr7:128952527~128953316:-
LUAD	cis	rs1789	0.706	rs7696938	ENSG00000273133.1	RP11-799M12.2	8.46	3.16e-16	3.62e-13	0.53	0.36	Blood protein levels;	chr4:15701954	chr4:15563698~15564253:-
LUAD	cis	rs2929278	0.561	rs3099045	ENSG00000249839.1	AC011330.5	-8.46	3.16e-16	3.62e-13	-0.47	-0.36	Schizophrenia;	chr15:43631757	chr15:43663654~43684339:-
LUAD	cis	rs12594515	1	rs8032835	ENSG00000273972.1	CTD-2306A12.1	-8.46	3.16e-16	3.62e-13	-0.39	-0.36	Weight;Waist circumference;	chr15:45705699	chr15:45702640~45703183:+
LUAD	cis	rs12594515	1	rs8033148	ENSG00000273972.1	CTD-2306A12.1	-8.46	3.16e-16	3.62e-13	-0.39	-0.36	Weight;Waist circumference;	chr15:45705731	chr15:45702640~45703183:+
LUAD	cis	rs12594515	0.904	rs8032875	ENSG00000273972.1	CTD-2306A12.1	-8.46	3.16e-16	3.62e-13	-0.39	-0.36	Weight;Waist circumference;	chr15:45705812	chr15:45702640~45703183:+
LUAD	cis	rs12594515	0.874	rs8032878	ENSG00000273972.1	CTD-2306A12.1	-8.46	3.16e-16	3.62e-13	-0.39	-0.36	Weight;Waist circumference;	chr15:45705817	chr15:45702640~45703183:+
LUAD	cis	rs367615	0.506	rs2963013	ENSG00000249476.1	CTD-2587M2.1	-8.46	3.17e-16	3.63e-13	-0.4	-0.36	Colorectal cancer (SNP x SNP interaction);	chr5:109440110	chr5:109237120~109326369:-
LUAD	cis	rs638893	0.588	rs529717	ENSG00000278376.1	RP11-158I9.8	-8.46	3.18e-16	3.64e-13	-0.54	-0.36	Vitiligo;	chr11:118769372	chr11:118791254~118793137:+
LUAD	cis	rs2455601	0.507	rs2568044	ENSG00000254860.4	TMEM9B-AS1	-8.46	3.18e-16	3.64e-13	-0.45	-0.36	Schizophrenia;	chr11:8980930	chr11:8964675~8977527:+
LUAD	cis	rs9545047	0.604	rs9545052	ENSG00000227676.3	LINC01068	8.46	3.18e-16	3.64e-13	0.42	0.36	Schizophrenia;	chr13:79294875	chr13:79566727~79571436:+
LUAD	cis	rs17023223	0.537	rs10923754	ENSG00000231365.4	RP11-418J17.1	-8.46	3.18e-16	3.64e-13	-0.48	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119126017	chr1:119140396~119275973:+
LUAD	cis	rs2455601	1	rs72632952	ENSG00000254860.4	TMEM9B-AS1	8.46	3.19e-16	3.65e-13	0.54	0.36	Schizophrenia;	chr11:8896429	chr11:8964675~8977527:+
LUAD	cis	rs10129255	0.957	rs28887506	ENSG00000223648.3	IGHV3-64	8.46	3.2e-16	3.66e-13	0.36	0.36	Kawasaki disease;	chr14:106785589	chr14:106643132~106658258:-
LUAD	cis	rs1075265	0.568	rs10865277	ENSG00000233266.1	HMGB1P31	8.46	3.2e-16	3.66e-13	0.47	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54074865	chr2:54051334~54051760:+
LUAD	cis	rs77204473	0.655	rs11216183	ENSG00000254851.1	RP11-109L13.1	8.46	3.2e-16	3.66e-13	0.76	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116910829	chr11:117135528~117138582:+
LUAD	cis	rs673078	0.607	rs2055534	ENSG00000275759.1	RP11-131L12.3	-8.46	3.21e-16	3.68e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118386527	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs56157623	ENSG00000275759.1	RP11-131L12.3	-8.46	3.21e-16	3.68e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118388162	chr12:118428281~118428870:+
LUAD	cis	rs10129255	0.957	rs10136560	ENSG00000223648.3	IGHV3-64	8.46	3.22e-16	3.68e-13	0.36	0.36	Kawasaki disease;	chr14:106787630	chr14:106643132~106658258:-
LUAD	cis	rs321358	1	rs73003511	ENSG00000271584.1	RP11-89C3.4	8.46	3.24e-16	3.7e-13	0.62	0.36	Body mass index;	chr11:111160478	chr11:111091932~111097357:-
LUAD	cis	rs321358	1	rs73003514	ENSG00000271584.1	RP11-89C3.4	8.46	3.24e-16	3.7e-13	0.62	0.36	Body mass index;	chr11:111160605	chr11:111091932~111097357:-
LUAD	cis	rs2280018	0.526	rs2941257	ENSG00000260735.1	RP11-72I8.1	-8.46	3.24e-16	3.7e-13	-0.4	-0.36	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072588	chr16:15094411~15109197:+
LUAD	cis	rs17023223	0.537	rs12083510	ENSG00000231365.4	RP11-418J17.1	-8.46	3.25e-16	3.71e-13	-0.48	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119203997	chr1:119140396~119275973:+
LUAD	cis	rs1061377	0.501	rs62308278	ENSG00000249207.1	RP11-360F5.1	-8.46	3.28e-16	3.75e-13	-0.4	-0.36	Uric acid levels;	chr4:39161038	chr4:39112677~39126818:-
LUAD	cis	rs673078	0.571	rs17440823	ENSG00000275759.1	RP11-131L12.3	-8.46	3.29e-16	3.76e-13	-0.5	-0.36	Glucose homeostasis traits;	chr12:118353023	chr12:118428281~118428870:+
LUAD	cis	rs10463554	0.927	rs257317	ENSG00000175749.11	EIF3KP1	8.46	3.3e-16	3.76e-13	0.49	0.36	Parkinson's disease;	chr5:103086881	chr5:103032376~103033031:+
LUAD	cis	rs7924176	0.601	rs10824091	ENSG00000213731.2	RAB5CP1	-8.46	3.31e-16	3.78e-13	-0.38	-0.36	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74169750	chr10:74423435~74424014:-
LUAD	cis	rs7429990	0.932	rs7620736	ENSG00000229759.1	MRPS18AP1	-8.46	3.32e-16	3.78e-13	-0.37	-0.36	Educational attainment (years of education);	chr3:48068479	chr3:48256350~48256938:-
LUAD	cis	rs6991838	0.584	rs4737221	ENSG00000200714.1	Y_RNA	-8.45	3.4e-16	3.87e-13	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65592731~65592820:+
LUAD	cis	rs10129255	0.957	rs61997760	ENSG00000223648.3	IGHV3-64	8.45	3.4e-16	3.88e-13	0.36	0.36	Kawasaki disease;	chr14:106716993	chr14:106643132~106658258:-
LUAD	cis	rs494459	0.838	rs555649	ENSG00000255239.1	AP002954.6	8.45	3.44e-16	3.91e-13	0.42	0.36	Height;	chr11:118781100	chr11:118688039~118690600:-
LUAD	cis	rs11096990	0.613	rs2060805	ENSG00000249207.1	RP11-360F5.1	-8.45	3.45e-16	3.93e-13	-0.39	-0.36	Cognitive function;	chr4:39232788	chr4:39112677~39126818:-
LUAD	cis	rs2337406	1	rs17095456	ENSG00000254174.1	IGHV1-12	8.45	3.47e-16	3.95e-13	0.34	0.36	Alzheimer's disease (late onset);	chr14:106676559	chr14:106122420~106122709:-
LUAD	cis	rs6991838	0.584	rs2175810	ENSG00000272010.1	CTD-3025N20.3	-8.45	3.48e-16	3.96e-13	-0.39	-0.36	Intelligence (multi-trait analysis);	chr8:65643583	chr8:65591850~65592472:-
LUAD	cis	rs11096990	0.634	rs1451818	ENSG00000249207.1	RP11-360F5.1	-8.45	3.48e-16	3.96e-13	-0.39	-0.36	Cognitive function;	chr4:39257151	chr4:39112677~39126818:-
LUAD	cis	rs6991838	0.584	rs4275254	ENSG00000272010.1	CTD-3025N20.3	-8.45	3.5e-16	3.98e-13	-0.39	-0.36	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65591850~65592472:-
LUAD	cis	rs12134133	1	rs12134133	ENSG00000274245.1	RP11-357P18.2	8.45	3.5e-16	3.99e-13	0.46	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207284500	chr1:207372559~207373252:+
LUAD	cis	rs26232	0.583	rs154258	ENSG00000175749.11	EIF3KP1	-8.45	3.5e-16	3.99e-13	-0.5	-0.36	Rheumatoid arthritis;	chr5:103027919	chr5:103032376~103033031:+
LUAD	cis	rs12594515	1	rs56220882	ENSG00000273972.1	CTD-2306A12.1	-8.45	3.55e-16	4.03e-13	-0.39	-0.36	Weight;Waist circumference;	chr15:45704877	chr15:45702640~45703183:+
LUAD	cis	rs9322193	0.923	rs11155670	ENSG00000223701.3	RAET1E-AS1	8.45	3.56e-16	4.05e-13	0.42	0.36	Lung cancer;	chr6:149644992	chr6:149884431~149919508:+
LUAD	cis	rs9807989	0.507	rs6758936	ENSG00000234389.1	AC007278.3	-8.45	3.57e-16	4.06e-13	-0.33	-0.36	Asthma;	chr2:102374909	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs4479442	ENSG00000234389.1	AC007278.3	8.45	3.58e-16	4.07e-13	0.32	0.36	Asthma;	chr2:102437614	chr2:102438713~102440475:+
LUAD	cis	rs12134133	1	rs61822697	ENSG00000274245.1	RP11-357P18.2	8.45	3.58e-16	4.07e-13	0.49	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207311819	chr1:207372559~207373252:+
LUAD	cis	rs494459	0.657	rs614554	ENSG00000255239.1	AP002954.6	8.45	3.58e-16	4.07e-13	0.42	0.36	Height;	chr11:118764443	chr11:118688039~118690600:-
LUAD	cis	rs732716	0.74	rs62129356	ENSG00000267769.1	CTB-50L17.9	-8.45	3.6e-16	4.09e-13	-0.4	-0.36	Mean corpuscular volume;	chr19:4400317	chr19:4454014~4455286:+
LUAD	cis	rs71403859	0.73	rs12931191	ENSG00000260886.1	TAT-AS1	-8.45	3.62e-16	4.11e-13	-0.6	-0.36	Post bronchodilator FEV1;	chr16:71587470	chr16:71565789~71578187:+
LUAD	cis	rs10129255	0.917	rs7142373	ENSG00000211970.3	IGHV4-61	-8.44	3.63e-16	4.13e-13	-0.29	-0.36	Kawasaki disease;	chr14:106708947	chr14:106639119~106639657:-
LUAD	cis	rs7924176	0.601	rs4638254	ENSG00000213731.2	RAB5CP1	-8.44	3.65e-16	4.15e-13	-0.38	-0.36	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74152974	chr10:74423435~74424014:-
LUAD	cis	rs11096990	0.593	rs35937374	ENSG00000249207.1	RP11-360F5.1	-8.44	3.66e-16	4.16e-13	-0.39	-0.36	Cognitive function;	chr4:39184735	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.574	rs34070258	ENSG00000249207.1	RP11-360F5.1	-8.44	3.66e-16	4.16e-13	-0.39	-0.36	Cognitive function;	chr4:39188132	chr4:39112677~39126818:-
LUAD	cis	rs8040855	0.965	rs11073990	ENSG00000259295.5	CSPG4P12	8.44	3.66e-16	4.16e-13	0.42	0.36	Bulimia nervosa;	chr15:85168070	chr15:85191438~85213905:+
LUAD	cis	rs2337406	1	rs3858878	ENSG00000254174.1	IGHV1-12	8.44	3.68e-16	4.18e-13	0.33	0.36	Alzheimer's disease (late onset);	chr14:106688061	chr14:106122420~106122709:-
LUAD	cis	rs526231	0.543	rs62362544	ENSG00000175749.11	EIF3KP1	8.44	3.69e-16	4.19e-13	0.51	0.36	Primary biliary cholangitis;	chr5:102998543	chr5:103032376~103033031:+
LUAD	cis	rs2739330	0.791	rs4822458	ENSG00000206090.4	AP000350.7	8.44	3.71e-16	4.21e-13	0.4	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23939998~23942798:+
LUAD	cis	rs9807989	0.507	rs6745614	ENSG00000234389.1	AC007278.3	8.44	3.72e-16	4.22e-13	0.33	0.36	Asthma;	chr2:102374753	chr2:102438713~102440475:+
LUAD	cis	rs2929278	0.617	rs524908	ENSG00000249839.1	AC011330.5	8.44	3.72e-16	4.23e-13	0.45	0.36	Schizophrenia;	chr15:43895793	chr15:43663654~43684339:-
LUAD	cis	rs34779708	0.931	rs17582416	ENSG00000230534.5	RP11-297A16.2	8.44	3.73e-16	4.24e-13	0.41	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:34998722	chr10:35098006~35127020:-
LUAD	cis	rs526231	0.578	rs17154821	ENSG00000175749.11	EIF3KP1	8.44	3.77e-16	4.28e-13	0.49	0.36	Primary biliary cholangitis;	chr5:102905637	chr5:103032376~103033031:+
LUAD	cis	rs6991838	0.584	rs35790435	ENSG00000272010.1	CTD-3025N20.3	-8.44	3.8e-16	4.31e-13	-0.39	-0.36	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65591850~65592472:-
LUAD	cis	rs11096990	0.593	rs6531700	ENSG00000249207.1	RP11-360F5.1	8.44	3.8e-16	4.32e-13	0.39	0.36	Cognitive function;	chr4:39269265	chr4:39112677~39126818:-
LUAD	cis	rs944289	0.74	rs2780302	ENSG00000257826.1	RP11-116N8.4	-8.44	3.81e-16	4.32e-13	-0.38	-0.36	Thyroid cancer;	chr14:36079456	chr14:36061026~36067190:-
LUAD	cis	rs7688540	0.771	rs61794996	ENSG00000275426.1	CH17-262A2.1	8.44	3.82e-16	4.33e-13	0.52	0.36	Facial morphology (factor 6, height of vermillion lower lip);	chr4:215539	chr4:149738~150317:+
LUAD	cis	rs17023223	0.537	rs12085308	ENSG00000231365.4	RP11-418J17.1	-8.44	3.84e-16	4.35e-13	-0.48	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119134930	chr1:119140396~119275973:+
LUAD	cis	rs11168351	0.517	rs10875754	ENSG00000240399.1	RP1-228P16.1	8.44	3.84e-16	4.36e-13	0.34	0.36	Bipolar disorder and schizophrenia;	chr12:48164139	chr12:48054813~48055591:-
LUAD	cis	rs673078	0.607	rs17512652	ENSG00000275759.1	RP11-131L12.3	-8.44	3.86e-16	4.37e-13	-0.51	-0.36	Glucose homeostasis traits;	chr12:118361278	chr12:118428281~118428870:+
LUAD	cis	rs2549794	0.511	rs27645	ENSG00000248734.2	CTD-2260A17.1	8.44	3.86e-16	4.38e-13	0.36	0.36	Crohn's disease;	chr5:96827736	chr5:96784777~96785999:+
LUAD	cis	rs13423976	0.631	rs7582463	ENSG00000231367.4	AC016995.3	-8.44	3.87e-16	4.39e-13	-0.46	-0.36	Gut microbiome composition (summer);	chr2:38511226	chr2:38406719~38515740:-
LUAD	cis	rs10463554	0.963	rs28301	ENSG00000175749.11	EIF3KP1	8.44	3.88e-16	4.39e-13	0.5	0.36	Parkinson's disease;	chr5:103105778	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.963	rs34828	ENSG00000175749.11	EIF3KP1	8.44	3.88e-16	4.39e-13	0.5	0.36	Parkinson's disease;	chr5:103107209	chr5:103032376~103033031:+
LUAD	cis	rs7945705	0.692	rs11042149	ENSG00000254860.4	TMEM9B-AS1	8.44	3.88e-16	4.4e-13	0.39	0.36	Hemoglobin concentration;	chr11:8989190	chr11:8964675~8977527:+
LUAD	cis	rs7945705	0.747	rs11042150	ENSG00000254860.4	TMEM9B-AS1	8.44	3.88e-16	4.4e-13	0.39	0.36	Hemoglobin concentration;	chr11:8989272	chr11:8964675~8977527:+
LUAD	cis	rs9322193	0.923	rs9689716	ENSG00000223701.3	RAET1E-AS1	8.44	3.89e-16	4.4e-13	0.42	0.36	Lung cancer;	chr6:149655662	chr6:149884431~149919508:+
LUAD	cis	rs526231	0.575	rs55652053	ENSG00000175749.11	EIF3KP1	8.43	3.9e-16	4.42e-13	0.52	0.36	Primary biliary cholangitis;	chr5:103001466	chr5:103032376~103033031:+
LUAD	cis	rs8005677	0.828	rs8016027	ENSG00000279656.1	RP11-298I3.6	8.43	3.93e-16	4.46e-13	0.43	0.36	Cognitive ability (multi-trait analysis);	chr14:22950944	chr14:23023083~23024217:-
LUAD	cis	rs10129255	0.957	rs8009073	ENSG00000211970.3	IGHV4-61	-8.43	3.94e-16	4.46e-13	-0.28	-0.36	Kawasaki disease;	chr14:106777278	chr14:106639119~106639657:-
LUAD	cis	rs732716	0.785	rs11666453	ENSG00000267769.1	CTB-50L17.9	-8.43	3.94e-16	4.47e-13	-0.4	-0.36	Mean corpuscular volume;	chr19:4368800	chr19:4454014~4455286:+
LUAD	cis	rs673078	0.607	rs4766900	ENSG00000275759.1	RP11-131L12.3	-8.43	3.96e-16	4.49e-13	-0.5	-0.36	Glucose homeostasis traits;	chr12:118375139	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs884844	ENSG00000275759.1	RP11-131L12.3	-8.43	3.96e-16	4.49e-13	-0.5	-0.36	Glucose homeostasis traits;	chr12:118377033	chr12:118428281~118428870:+
LUAD	cis	rs9326248	0.861	rs11216172	ENSG00000280143.1	AP000892.6	8.43	3.96e-16	4.49e-13	0.45	0.36	Blood protein levels;	chr11:116879162	chr11:117204967~117210292:+
LUAD	cis	rs9322193	0.923	rs9322196	ENSG00000223701.3	RAET1E-AS1	8.43	3.99e-16	4.51e-13	0.42	0.36	Lung cancer;	chr6:149619645	chr6:149884431~149919508:+
LUAD	cis	rs8005677	0.828	rs35085068	ENSG00000279656.1	RP11-298I3.6	8.43	4.01e-16	4.54e-13	0.43	0.36	Cognitive ability (multi-trait analysis);	chr14:22940700	chr14:23023083~23024217:-
LUAD	cis	rs8005677	0.828	rs57822749	ENSG00000279656.1	RP11-298I3.6	8.43	4.01e-16	4.54e-13	0.43	0.36	Cognitive ability (multi-trait analysis);	chr14:22940758	chr14:23023083~23024217:-
LUAD	cis	rs8005677	0.828	rs4981451	ENSG00000279656.1	RP11-298I3.6	8.43	4.01e-16	4.54e-13	0.43	0.36	Cognitive ability (multi-trait analysis);	chr14:22941072	chr14:23023083~23024217:-
LUAD	cis	rs8005677	0.798	rs4536383	ENSG00000279656.1	RP11-298I3.6	8.43	4.01e-16	4.54e-13	0.43	0.36	Cognitive ability (multi-trait analysis);	chr14:22941717	chr14:23023083~23024217:-
LUAD	cis	rs8005677	0.828	rs34584578	ENSG00000279656.1	RP11-298I3.6	8.43	4.01e-16	4.54e-13	0.43	0.36	Cognitive ability (multi-trait analysis);	chr14:22942481	chr14:23023083~23024217:-
LUAD	cis	rs2929278	0.588	rs1975364	ENSG00000249839.1	AC011330.5	-8.43	4.03e-16	4.56e-13	-0.47	-0.36	Schizophrenia;	chr15:43857991	chr15:43663654~43684339:-
LUAD	cis	rs9545047	0.604	rs4573813	ENSG00000227676.3	LINC01068	8.43	4.04e-16	4.58e-13	0.42	0.36	Schizophrenia;	chr13:79293357	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs2147566	ENSG00000227676.3	LINC01068	8.43	4.04e-16	4.58e-13	0.42	0.36	Schizophrenia;	chr13:79296580	chr13:79566727~79571436:+
LUAD	cis	rs9487094	0.689	rs699700	ENSG00000260273.1	RP11-425D10.10	8.43	4.05e-16	4.59e-13	0.45	0.36	Height;	chr6:109367528	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.689	rs11251	ENSG00000260273.1	RP11-425D10.10	8.43	4.05e-16	4.59e-13	0.45	0.36	Height;	chr6:109368704	chr6:109382795~109383666:+
LUAD	cis	rs11123170	0.65	rs2289897	ENSG00000274877.1	RP11-65I12.1	-8.43	4.06e-16	4.59e-13	-0.51	-0.36	Renal function-related traits (BUN);	chr2:113219877	chr2:113237595~113240825:+
LUAD	cis	rs526231	0.543	rs32849	ENSG00000175749.11	EIF3KP1	8.43	4.06e-16	4.6e-13	0.51	0.36	Primary biliary cholangitis;	chr5:103134339	chr5:103032376~103033031:+
LUAD	cis	rs2455601	0.935	rs12049908	ENSG00000254860.4	TMEM9B-AS1	8.43	4.06e-16	4.6e-13	0.54	0.36	Schizophrenia;	chr11:8897762	chr11:8964675~8977527:+
LUAD	cis	rs2108622	1	rs55744319	ENSG00000267453.5	AC004791.2	-8.43	4.07e-16	4.6e-13	-0.47	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871011	chr19:15851993~15864904:-
LUAD	cis	rs10463554	0.927	rs62362489	ENSG00000175749.11	EIF3KP1	8.43	4.1e-16	4.63e-13	0.49	0.36	Parkinson's disease;	chr5:102909841	chr5:103032376~103033031:+
LUAD	cis	rs6142102	0.625	rs4911137	ENSG00000276073.1	RP5-1125A11.7	-8.43	4.11e-16	4.64e-13	-0.36	-0.36	Skin pigmentation;	chr20:33947657	chr20:33985617~33988989:-
LUAD	cis	rs1150668	0.796	rs2531832	ENSG00000216901.1	AL022393.7	8.43	4.14e-16	4.68e-13	0.42	0.36	Pubertal anthropometrics;	chr6:28421445	chr6:28176188~28176674:+
LUAD	cis	rs526231	0.543	rs34785	ENSG00000175749.11	EIF3KP1	8.43	4.16e-16	4.7e-13	0.51	0.36	Primary biliary cholangitis;	chr5:103122399	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.578	rs34786	ENSG00000175749.11	EIF3KP1	8.43	4.16e-16	4.7e-13	0.51	0.36	Primary biliary cholangitis;	chr5:103122409	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.543	rs34787	ENSG00000175749.11	EIF3KP1	8.43	4.16e-16	4.7e-13	0.51	0.36	Primary biliary cholangitis;	chr5:103123199	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.543	rs34789	ENSG00000175749.11	EIF3KP1	8.43	4.16e-16	4.7e-13	0.51	0.36	Primary biliary cholangitis;	chr5:103125035	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.543	rs34791	ENSG00000175749.11	EIF3KP1	8.43	4.16e-16	4.7e-13	0.51	0.36	Primary biliary cholangitis;	chr5:103126400	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.543	rs26525	ENSG00000175749.11	EIF3KP1	8.43	4.16e-16	4.7e-13	0.51	0.36	Primary biliary cholangitis;	chr5:103129219	chr5:103032376~103033031:+
LUAD	cis	rs4988958	0.584	rs7589142	ENSG00000234389.1	AC007278.3	8.43	4.16e-16	4.7e-13	0.32	0.36	Asthma (childhood onset);	chr2:102408200	chr2:102438713~102440475:+
LUAD	cis	rs638893	0.947	rs515707	ENSG00000278376.1	RP11-158I9.8	-8.43	4.18e-16	4.72e-13	-0.5	-0.36	Vitiligo;	chr11:118814772	chr11:118791254~118793137:+
LUAD	cis	rs638893	0.578	rs500254	ENSG00000278376.1	RP11-158I9.8	8.43	4.18e-16	4.72e-13	0.52	0.36	Vitiligo;	chr11:118808071	chr11:118791254~118793137:+
LUAD	cis	rs11098499	0.739	rs10031033	ENSG00000245958.5	RP11-33B1.1	-8.43	4.18e-16	4.72e-13	-0.32	-0.36	Corneal astigmatism;	chr4:119230297	chr4:119454791~119552025:+
LUAD	cis	rs7924176	0.601	rs11000882	ENSG00000213731.2	RAB5CP1	-8.42	4.22e-16	4.77e-13	-0.38	-0.36	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74130145	chr10:74423435~74424014:-
LUAD	cis	rs13423976	0.631	rs4670876	ENSG00000231367.4	AC016995.3	8.42	4.26e-16	4.81e-13	0.46	0.36	Gut microbiome composition (summer);	chr2:38508948	chr2:38406719~38515740:-
LUAD	cis	rs1150668	0.83	rs213240	ENSG00000216901.1	AL022393.7	8.42	4.28e-16	4.83e-13	0.42	0.36	Pubertal anthropometrics;	chr6:28348098	chr6:28176188~28176674:+
LUAD	cis	rs17023223	0.537	rs6677107	ENSG00000231365.4	RP11-418J17.1	-8.42	4.29e-16	4.84e-13	-0.47	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166142	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs12064033	ENSG00000231365.4	RP11-418J17.1	-8.42	4.29e-16	4.84e-13	-0.47	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166935	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs12064137	ENSG00000231365.4	RP11-418J17.1	-8.42	4.29e-16	4.84e-13	-0.47	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119167126	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.509	rs61806978	ENSG00000231365.4	RP11-418J17.1	-8.42	4.29e-16	4.84e-13	-0.47	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119170592	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.509	rs56195272	ENSG00000231365.4	RP11-418J17.1	-8.42	4.29e-16	4.84e-13	-0.47	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119171374	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs12065809	ENSG00000231365.4	RP11-418J17.1	-8.42	4.29e-16	4.84e-13	-0.47	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119181912	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.553	rs11484962	ENSG00000231365.4	RP11-418J17.1	-8.42	4.29e-16	4.84e-13	-0.47	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182563	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs55836852	ENSG00000231365.4	RP11-418J17.1	-8.42	4.29e-16	4.84e-13	-0.47	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182778	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs66715579	ENSG00000231365.4	RP11-418J17.1	-8.42	4.29e-16	4.84e-13	-0.47	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182809	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs11487668	ENSG00000231365.4	RP11-418J17.1	-8.42	4.29e-16	4.84e-13	-0.47	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184173	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs10923766	ENSG00000231365.4	RP11-418J17.1	-8.42	4.29e-16	4.84e-13	-0.47	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184309	chr1:119140396~119275973:+
LUAD	cis	rs4853012	0.838	rs6707729	ENSG00000257800.1	FNBP1P1	8.42	4.3e-16	4.85e-13	0.44	0.36	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74120680~74123218:+
LUAD	cis	rs11096990	0.576	rs2008679	ENSG00000249207.1	RP11-360F5.1	8.42	4.32e-16	4.88e-13	0.39	0.36	Cognitive function;	chr4:39266385	chr4:39112677~39126818:-
LUAD	cis	rs9595066	1	rs66786230	ENSG00000227258.4	SMIM2-AS1	8.42	4.33e-16	4.88e-13	0.59	0.36	Schizophrenia;	chr13:44137489	chr13:44110451~44240517:+
LUAD	cis	rs6782228	1	rs12635488	ENSG00000242551.2	POU5F1P6	8.42	4.33e-16	4.88e-13	0.47	0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128633535	chr3:128674735~128677005:-
LUAD	cis	rs673078	0.607	rs17441172	ENSG00000275759.1	RP11-131L12.3	8.42	4.35e-16	4.91e-13	0.5	0.36	Glucose homeostasis traits;	chr12:118430456	chr12:118428281~118428870:+
LUAD	cis	rs10129255	0.957	rs8005468	ENSG00000211970.3	IGHV4-61	-8.42	4.36e-16	4.91e-13	-0.28	-0.36	Kawasaki disease;	chr14:106686431	chr14:106639119~106639657:-
LUAD	cis	rs7924176	0.601	rs10824071	ENSG00000213731.2	RAB5CP1	-8.42	4.39e-16	4.95e-13	-0.38	-0.36	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74113881	chr10:74423435~74424014:-
LUAD	cis	rs6142102	0.517	rs8119076	ENSG00000276073.1	RP5-1125A11.7	-8.42	4.43e-16	4.99e-13	-0.37	-0.36	Skin pigmentation;	chr20:33937909	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.517	rs6059577	ENSG00000276073.1	RP5-1125A11.7	-8.42	4.43e-16	4.99e-13	-0.37	-0.36	Skin pigmentation;	chr20:33939880	chr20:33985617~33988989:-
LUAD	cis	rs9322193	0.847	rs62439808	ENSG00000223701.3	RAET1E-AS1	8.42	4.44e-16	5e-13	0.42	0.36	Lung cancer;	chr6:149629690	chr6:149884431~149919508:+
LUAD	cis	rs11096990	0.634	rs11736790	ENSG00000249207.1	RP11-360F5.1	-8.42	4.44e-16	5e-13	-0.39	-0.36	Cognitive function;	chr4:39254704	chr4:39112677~39126818:-
LUAD	cis	rs9322193	0.923	rs9322200	ENSG00000223701.3	RAET1E-AS1	8.42	4.44e-16	5.01e-13	0.42	0.36	Lung cancer;	chr6:149630078	chr6:149884431~149919508:+
LUAD	cis	rs673078	0.607	rs7137055	ENSG00000275759.1	RP11-131L12.3	-8.42	4.45e-16	5.02e-13	-0.5	-0.36	Glucose homeostasis traits;	chr12:118395030	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs7137184	ENSG00000275759.1	RP11-131L12.3	-8.42	4.45e-16	5.02e-13	-0.5	-0.36	Glucose homeostasis traits;	chr12:118395163	chr12:118428281~118428870:+
LUAD	cis	rs1075265	0.547	rs6741891	ENSG00000233266.1	HMGB1P31	8.42	4.46e-16	5.02e-13	0.47	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54088529	chr2:54051334~54051760:+
LUAD	cis	rs7429990	1	rs1684942	ENSG00000229759.1	MRPS18AP1	8.42	4.48e-16	5.05e-13	0.37	0.36	Educational attainment (years of education);	chr3:47859213	chr3:48256350~48256938:-
LUAD	cis	rs5769707	0.967	rs2187891	ENSG00000188511.11	C22orf34	8.41	4.56e-16	5.13e-13	0.4	0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49600446	chr22:49414524~49657542:-
LUAD	cis	rs10129255	0.957	rs10140904	ENSG00000211970.3	IGHV4-61	-8.41	4.56e-16	5.13e-13	-0.28	-0.36	Kawasaki disease;	chr14:106776558	chr14:106639119~106639657:-
LUAD	cis	rs638893	0.578	rs485901	ENSG00000278376.1	RP11-158I9.8	-8.41	4.57e-16	5.14e-13	-0.54	-0.36	Vitiligo;	chr11:118751536	chr11:118791254~118793137:+
LUAD	cis	rs638893	0.578	rs580079	ENSG00000278376.1	RP11-158I9.8	-8.41	4.57e-16	5.14e-13	-0.54	-0.36	Vitiligo;	chr11:118754900	chr11:118791254~118793137:+
LUAD	cis	rs638893	0.588	rs2508929	ENSG00000278376.1	RP11-158I9.8	-8.41	4.57e-16	5.14e-13	-0.54	-0.36	Vitiligo;	chr11:118770742	chr11:118791254~118793137:+
LUAD	cis	rs673078	0.607	rs73207564	ENSG00000275759.1	RP11-131L12.3	-8.41	4.58e-16	5.15e-13	-0.5	-0.36	Glucose homeostasis traits;	chr12:118429566	chr12:118428281~118428870:+
LUAD	cis	rs4927850	1	rs7627868	ENSG00000231464.1	AC024937.4	8.41	4.62e-16	5.19e-13	0.41	0.36	Pancreatic cancer;	chr3:196026602	chr3:195996738~195998233:+
LUAD	cis	rs11096990	0.551	rs2060005	ENSG00000249207.1	RP11-360F5.1	-8.41	4.65e-16	5.22e-13	-0.4	-0.36	Cognitive function;	chr4:39160901	chr4:39112677~39126818:-
LUAD	cis	rs9322193	0.923	rs12660304	ENSG00000223701.3	RAET1E-AS1	8.41	4.67e-16	5.24e-13	0.42	0.36	Lung cancer;	chr6:149739647	chr6:149884431~149919508:+
LUAD	cis	rs56046484	0.956	rs35204319	ENSG00000259295.5	CSPG4P12	8.41	4.67e-16	5.25e-13	0.54	0.36	Testicular germ cell tumor;	chr15:85107246	chr15:85191438~85213905:+
LUAD	cis	rs494459	0.838	rs2510897	ENSG00000255239.1	AP002954.6	8.41	4.75e-16	5.33e-13	0.42	0.36	Height;	chr11:118773873	chr11:118688039~118690600:-
LUAD	cis	rs12134133	1	rs2564973	ENSG00000274245.1	RP11-357P18.2	8.41	4.76e-16	5.34e-13	0.47	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207306759	chr1:207372559~207373252:+
LUAD	cis	rs9595066	1	rs7981575	ENSG00000227258.4	SMIM2-AS1	8.41	4.78e-16	5.37e-13	0.56	0.36	Schizophrenia;	chr13:44136811	chr13:44110451~44240517:+
LUAD	cis	rs2337406	1	rs10459466	ENSG00000274576.2	IGHV2-70	-8.41	4.79e-16	5.37e-13	-0.44	-0.36	Alzheimer's disease (late onset);	chr14:106689255	chr14:106770577~106771020:-
LUAD	cis	rs1150668	0.799	rs1736891	ENSG00000204709.4	LINC01556	8.41	4.83e-16	5.42e-13	0.45	0.36	Pubertal anthropometrics;	chr6:28219323	chr6:28943877~28944537:+
LUAD	cis	rs6991838	0.584	rs7842085	ENSG00000272010.1	CTD-3025N20.3	8.41	4.85e-16	5.43e-13	0.41	0.36	Intelligence (multi-trait analysis);	chr8:65636787	chr8:65591850~65592472:-
LUAD	cis	rs11096990	0.634	rs746678	ENSG00000249207.1	RP11-360F5.1	8.41	4.85e-16	5.44e-13	0.39	0.36	Cognitive function;	chr4:39279035	chr4:39112677~39126818:-
LUAD	cis	rs9322193	0.884	rs9689702	ENSG00000223701.3	RAET1E-AS1	8.41	4.87e-16	5.46e-13	0.42	0.36	Lung cancer;	chr6:149740720	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs9322207	ENSG00000223701.3	RAET1E-AS1	8.41	4.87e-16	5.46e-13	0.42	0.36	Lung cancer;	chr6:149657185	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs9322208	ENSG00000223701.3	RAET1E-AS1	8.41	4.87e-16	5.46e-13	0.42	0.36	Lung cancer;	chr6:149658547	chr6:149884431~149919508:+
LUAD	cis	rs3823536	0.583	rs3807302	ENSG00000275106.1	RP11-309L24.10	-8.4	4.9e-16	5.49e-13	-0.45	-0.36	Sjögren's syndrome;	chr7:129004803	chr7:128952527~128953316:-
LUAD	cis	rs1185460	0.804	rs13929	ENSG00000271751.1	RP11-110I1.14	-8.4	4.9e-16	5.49e-13	-0.44	-0.36	Coronary artery disease;	chr11:119045044	chr11:119065263~119065677:-
LUAD	cis	rs4927850	1	rs7627706	ENSG00000231464.1	AC024937.4	8.4	4.99e-16	5.59e-13	0.41	0.36	Pancreatic cancer;	chr3:196026482	chr3:195996738~195998233:+
LUAD	cis	rs673078	0.607	rs73207578	ENSG00000275759.1	RP11-131L12.3	-8.4	5.02e-16	5.62e-13	-0.5	-0.36	Glucose homeostasis traits;	chr12:118447080	chr12:118428281~118428870:+
LUAD	cis	rs10129255	0.589	rs78599641	ENSG00000280411.1	IGHV1-69-2	-8.4	5.03e-16	5.63e-13	-0.27	-0.36	Kawasaki disease;	chr14:106637576	chr14:106762092~106762588:-
LUAD	cis	rs6504622	0.702	rs3851798	ENSG00000262879.4	RP11-156P1.3	8.4	5.05e-16	5.65e-13	0.4	0.36	Orofacial clefts;	chr17:46988901	chr17:46984045~47100323:-
LUAD	cis	rs7188445	0.966	rs8053589	ENSG00000261390.4	RP11-345M22.2	-8.4	5.05e-16	5.65e-13	-0.47	-0.36	Urate levels;	chr16:79693093	chr16:79715232~79770563:-
LUAD	cis	rs507080	0.501	rs625735	ENSG00000255239.1	AP002954.6	8.4	5.06e-16	5.66e-13	0.41	0.36	Serum metabolite levels;	chr11:118704710	chr11:118688039~118690600:-
LUAD	cis	rs1322639	0.571	rs13204417	ENSG00000261039.2	RP11-417E7.2	8.4	5.1e-16	5.71e-13	0.46	0.36	Pulse pressure;	chr6:169175260	chr6:169175304~169182740:-
LUAD	cis	rs11096990	0.613	rs12505690	ENSG00000249207.1	RP11-360F5.1	-8.4	5.11e-16	5.71e-13	-0.39	-0.36	Cognitive function;	chr4:39167425	chr4:39112677~39126818:-
LUAD	cis	rs12280210	0.557	rs12284696	ENSG00000254851.1	RP11-109L13.1	8.4	5.11e-16	5.72e-13	0.71	0.36	Lobe attachment (rater-scored or self-reported);	chr11:117008803	chr11:117135528~117138582:+
LUAD	cis	rs10129255	0.744	rs28517388	ENSG00000223648.3	IGHV3-64	8.4	5.14e-16	5.75e-13	0.36	0.36	Kawasaki disease;	chr14:106704323	chr14:106643132~106658258:-
LUAD	cis	rs950169	0.686	rs12906474	ENSG00000225151.9	GOLGA2P7	-8.4	5.14e-16	5.75e-13	-0.49	-0.36	Schizophrenia;	chr15:84566006	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.81	rs2879976	ENSG00000225151.9	GOLGA2P7	-8.4	5.14e-16	5.75e-13	-0.49	-0.36	Schizophrenia;	chr15:84566347	chr15:84199311~84230136:-
LUAD	cis	rs12594515	0.967	rs11070466	ENSG00000273972.1	CTD-2306A12.1	-8.4	5.15e-16	5.75e-13	-0.38	-0.36	Weight;Waist circumference;	chr15:45692757	chr15:45702640~45703183:+
LUAD	cis	rs26232	0.583	rs26434	ENSG00000175749.11	EIF3KP1	-8.4	5.16e-16	5.76e-13	-0.49	-0.36	Rheumatoid arthritis;	chr5:103027698	chr5:103032376~103033031:+
LUAD	cis	rs4927850	0.881	rs7630489	ENSG00000231464.1	AC024937.4	8.4	5.17e-16	5.77e-13	0.41	0.36	Pancreatic cancer;	chr3:196026530	chr3:195996738~195998233:+
LUAD	cis	rs7567389	0.744	rs6430934	ENSG00000236682.1	AC068282.3	8.4	5.17e-16	5.77e-13	0.48	0.36	Self-rated health;	chr2:127243257	chr2:127389130~127400580:+
LUAD	cis	rs526231	0.511	rs17154942	ENSG00000175749.11	EIF3KP1	-8.4	5.19e-16	5.79e-13	-0.52	-0.36	Primary biliary cholangitis;	chr5:103017014	chr5:103032376~103033031:+
LUAD	cis	rs8005677	0.828	rs2295682	ENSG00000279656.1	RP11-298I3.6	8.4	5.22e-16	5.82e-13	0.43	0.36	Cognitive ability (multi-trait analysis);	chr14:22905653	chr14:23023083~23024217:-
LUAD	cis	rs732716	0.889	rs11666856	ENSG00000267769.1	CTB-50L17.9	-8.4	5.23e-16	5.83e-13	-0.39	-0.36	Mean corpuscular volume;	chr19:4437453	chr19:4454014~4455286:+
LUAD	cis	rs2280018	0.609	rs2941253	ENSG00000260735.1	RP11-72I8.1	-8.39	5.28e-16	5.89e-13	-0.39	-0.36	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15079889	chr16:15094411~15109197:+
LUAD	cis	rs11123170	0.64	rs931472	ENSG00000274877.1	RP11-65I12.1	8.39	5.31e-16	5.92e-13	0.49	0.36	Renal function-related traits (BUN);	chr2:113212371	chr2:113237595~113240825:+
LUAD	cis	rs7924176	0.601	rs3750862	ENSG00000213731.2	RAB5CP1	-8.39	5.33e-16	5.95e-13	-0.39	-0.36	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74091491	chr10:74423435~74424014:-
LUAD	cis	rs8005677	0.798	rs4982713	ENSG00000279656.1	RP11-298I3.6	8.39	5.35e-16	5.97e-13	0.43	0.36	Cognitive ability (multi-trait analysis);	chr14:22934893	chr14:23023083~23024217:-
LUAD	cis	rs8005677	0.798	rs35615180	ENSG00000279656.1	RP11-298I3.6	8.39	5.35e-16	5.97e-13	0.43	0.36	Cognitive ability (multi-trait analysis);	chr14:22935180	chr14:23023083~23024217:-
LUAD	cis	rs10463554	0.927	rs6862616	ENSG00000175749.11	EIF3KP1	8.39	5.36e-16	5.98e-13	0.49	0.36	Parkinson's disease;	chr5:102910334	chr5:103032376~103033031:+
LUAD	cis	rs673078	0.607	rs61943447	ENSG00000275759.1	RP11-131L12.3	-8.39	5.37e-16	5.99e-13	-0.5	-0.36	Glucose homeostasis traits;	chr12:118430598	chr12:118428281~118428870:+
LUAD	cis	rs12594515	1	rs11070467	ENSG00000273972.1	CTD-2306A12.1	8.39	5.44e-16	6.06e-13	0.38	0.36	Weight;Waist circumference;	chr15:45692803	chr15:45702640~45703183:+
LUAD	cis	rs7429990	0.965	rs319682	ENSG00000229759.1	MRPS18AP1	8.39	5.49e-16	6.12e-13	0.37	0.36	Educational attainment (years of education);	chr3:47873628	chr3:48256350~48256938:-
LUAD	cis	rs17608059	0.611	rs62052300	ENSG00000141028.6	CDRT15P1	-8.39	5.51e-16	6.14e-13	-0.39	-0.36	Temperament;	chr17:14013482	chr17:14024514~14025488:+
LUAD	cis	rs9322193	0.923	rs56397000	ENSG00000223701.3	RAET1E-AS1	8.39	5.54e-16	6.17e-13	0.42	0.36	Lung cancer;	chr6:149739347	chr6:149884431~149919508:+
LUAD	cis	rs494459	0.838	rs555639	ENSG00000255239.1	AP002954.6	-8.39	5.64e-16	6.28e-13	-0.42	-0.36	Height;	chr11:118758322	chr11:118688039~118690600:-
LUAD	cis	rs35955747	0.633	rs7287937	ENSG00000236132.1	CTA-440B3.1	8.38	5.68e-16	6.32e-13	0.4	0.36	Neutrophil count;Sum basophil neutrophil counts;	chr22:31624759	chr22:31816379~31817491:-
LUAD	cis	rs7924176	0.601	rs3180427	ENSG00000213731.2	RAB5CP1	-8.38	5.68e-16	6.32e-13	-0.38	-0.36	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74121589	chr10:74423435~74424014:-
LUAD	cis	rs9807989	0.507	rs1420097	ENSG00000234389.1	AC007278.3	-8.38	5.7e-16	6.34e-13	-0.33	-0.36	Asthma;	chr2:102392894	chr2:102438713~102440475:+
LUAD	cis	rs944289	0.74	rs1742869	ENSG00000257826.1	RP11-116N8.4	8.38	5.72e-16	6.36e-13	0.38	0.36	Thyroid cancer;	chr14:36067601	chr14:36061026~36067190:-
LUAD	cis	rs7429990	0.813	rs7627568	ENSG00000229759.1	MRPS18AP1	-8.38	5.73e-16	6.38e-13	-0.37	-0.36	Educational attainment (years of education);	chr3:48051562	chr3:48256350~48256938:-
LUAD	cis	rs9545047	0.604	rs943709	ENSG00000227676.3	LINC01068	8.38	5.74e-16	6.38e-13	0.42	0.36	Schizophrenia;	chr13:79282990	chr13:79566727~79571436:+
LUAD	cis	rs9322193	0.923	rs10782315	ENSG00000223701.3	RAET1E-AS1	8.38	5.76e-16	6.41e-13	0.42	0.36	Lung cancer;	chr6:149743093	chr6:149884431~149919508:+
LUAD	cis	rs2280018	0.526	rs2966129	ENSG00000260735.1	RP11-72I8.1	8.38	5.79e-16	6.44e-13	0.41	0.36	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059070	chr16:15094411~15109197:+
LUAD	cis	rs526231	0.543	rs75913944	ENSG00000175749.11	EIF3KP1	8.38	5.84e-16	6.49e-13	0.51	0.36	Primary biliary cholangitis;	chr5:103143799	chr5:103032376~103033031:+
LUAD	cis	rs17023223	0.537	rs4590715	ENSG00000231365.4	RP11-418J17.1	-8.38	5.85e-16	6.51e-13	-0.48	-0.36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119207578	chr1:119140396~119275973:+
LUAD	cis	rs638893	0.685	rs486651	ENSG00000278376.1	RP11-158I9.8	-8.38	5.9e-16	6.56e-13	-0.54	-0.36	Vitiligo;	chr11:118779150	chr11:118791254~118793137:+
LUAD	cis	rs321358	1	rs73021573	ENSG00000271584.1	RP11-89C3.4	8.38	5.93e-16	6.59e-13	0.61	0.36	Body mass index;	chr11:111155508	chr11:111091932~111097357:-
LUAD	cis	rs673078	0.607	rs61943403	ENSG00000275759.1	RP11-131L12.3	-8.38	5.94e-16	6.6e-13	-0.49	-0.36	Glucose homeostasis traits;	chr12:118399887	chr12:118428281~118428870:+
LUAD	cis	rs4853012	0.752	rs13413795	ENSG00000257800.1	FNBP1P1	8.38	5.96e-16	6.63e-13	0.44	0.36	Gestational age at birth (maternal effect);	chr2:74122712	chr2:74120680~74123218:+
LUAD	cis	rs6504950	1	rs9902718	ENSG00000275710.1	RP11-257O5.4	8.38	5.97e-16	6.63e-13	0.45	0.36	Breast cancer;	chr17:54984261	chr17:54964474~54964679:+
LUAD	cis	rs526231	0.578	rs35100629	ENSG00000175749.11	EIF3KP1	8.38	5.97e-16	6.63e-13	0.5	0.36	Primary biliary cholangitis;	chr5:102910381	chr5:103032376~103033031:+
LUAD	cis	rs4853012	0.838	rs60705299	ENSG00000257800.1	FNBP1P1	8.38	5.98e-16	6.64e-13	0.44	0.36	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74120680~74123218:+
LUAD	cis	rs7429990	0.965	rs1550914	ENSG00000229759.1	MRPS18AP1	8.38	5.99e-16	6.65e-13	0.37	0.36	Educational attainment (years of education);	chr3:47953678	chr3:48256350~48256938:-
LUAD	cis	rs2455601	0.786	rs2568068	ENSG00000254860.4	TMEM9B-AS1	8.38	6.02e-16	6.69e-13	0.48	0.36	Schizophrenia;	chr11:8956283	chr11:8964675~8977527:+
LUAD	cis	rs9287719	0.781	rs6714413	ENSG00000234818.1	AC092687.5	8.38	6.03e-16	6.69e-13	0.43	0.36	Prostate cancer;	chr2:10618733	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.746	rs6742448	ENSG00000234818.1	AC092687.5	8.38	6.03e-16	6.69e-13	0.43	0.36	Prostate cancer;	chr2:10619000	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.781	rs6732671	ENSG00000234818.1	AC092687.5	8.38	6.03e-16	6.69e-13	0.43	0.36	Prostate cancer;	chr2:10619023	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.753	rs2018512	ENSG00000234818.1	AC092687.5	8.38	6.03e-16	6.69e-13	0.43	0.36	Prostate cancer;	chr2:10619153	chr2:10589166~10604830:+
LUAD	cis	rs11690935	0.851	rs10930502	ENSG00000228389.1	AC068039.4	8.38	6.04e-16	6.7e-13	0.42	0.36	Schizophrenia;	chr2:172025679	chr2:171773482~171775844:+
LUAD	cis	rs7945705	0.869	rs7925728	ENSG00000254860.4	TMEM9B-AS1	8.37	6.14e-16	6.81e-13	0.39	0.36	Hemoglobin concentration;	chr11:8991455	chr11:8964675~8977527:+
LUAD	cis	rs4853012	0.838	rs4452177	ENSG00000257800.1	FNBP1P1	8.37	6.25e-16	6.93e-13	0.44	0.36	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74120680~74123218:+
LUAD	cis	rs6991838	0.584	rs7836349	ENSG00000200714.1	Y_RNA	-8.37	6.29e-16	6.97e-13	-0.43	-0.36	Intelligence (multi-trait analysis);	chr8:65591328	chr8:65592731~65592820:+
LUAD	cis	rs638893	0.528	rs521910	ENSG00000278376.1	RP11-158I9.8	8.37	6.29e-16	6.97e-13	0.51	0.36	Vitiligo;	chr11:118739920	chr11:118791254~118793137:+
LUAD	cis	rs11096990	0.613	rs1451821	ENSG00000249207.1	RP11-360F5.1	8.37	6.3e-16	6.98e-13	0.39	0.36	Cognitive function;	chr4:39178797	chr4:39112677~39126818:-
LUAD	cis	rs7188445	1	rs11864901	ENSG00000261390.4	RP11-345M22.2	-8.37	6.31e-16	7e-13	-0.47	-0.36	Urate levels;	chr16:79697908	chr16:79715232~79770563:-
LUAD	cis	rs35955747	0.659	rs11704494	ENSG00000236132.1	CTA-440B3.1	8.37	6.35e-16	7.04e-13	0.4	0.36	Neutrophil count;Sum basophil neutrophil counts;	chr22:31517285	chr22:31816379~31817491:-
LUAD	cis	rs17711722	0.565	rs4717276	ENSG00000164669.11	INTS4P1	-8.37	6.35e-16	7.04e-13	-0.42	-0.36	Calcium levels;	chr7:65829754	chr7:65141225~65234216:+
LUAD	cis	rs10875746	0.669	rs11168508	ENSG00000240399.1	RP1-228P16.1	-8.37	6.35e-16	7.04e-13	-0.42	-0.36	Longevity (90 years and older);	chr12:48289728	chr12:48054813~48055591:-
LUAD	cis	rs2799081	1	rs2799081	ENSG00000204709.4	LINC01556	8.37	6.38e-16	7.07e-13	0.47	0.36	Myopia;	chr6:28302807	chr6:28943877~28944537:+
LUAD	cis	rs4273100	1	rs16960499	ENSG00000262319.1	CTC-457L16.2	-8.37	6.39e-16	7.08e-13	-0.5	-0.36	Schizophrenia;	chr17:19299719	chr17:19141017~19143689:-
LUAD	cis	rs10740039	0.583	rs1904404	ENSG00000254271.1	RP11-131N11.4	-8.37	6.41e-16	7.1e-13	-0.39	-0.36	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60742428	chr10:60734342~60741828:+
LUAD	cis	rs9807989	0.507	rs3732124	ENSG00000234389.1	AC007278.3	-8.37	6.42e-16	7.11e-13	-0.32	-0.36	Asthma;	chr2:102401592	chr2:102438713~102440475:+
LUAD	cis	rs944289	0.718	rs12878623	ENSG00000257826.1	RP11-116N8.4	-8.37	6.43e-16	7.12e-13	-0.38	-0.36	Thyroid cancer;	chr14:36081499	chr14:36061026~36067190:-
LUAD	cis	rs2337406	1	rs4774173	ENSG00000254174.1	IGHV1-12	8.37	6.43e-16	7.12e-13	0.32	0.36	Alzheimer's disease (late onset);	chr14:106682029	chr14:106122420~106122709:-
LUAD	cis	rs10129255	0.957	rs10136817	ENSG00000211970.3	IGHV4-61	-8.37	6.43e-16	7.12e-13	-0.28	-0.36	Kawasaki disease;	chr14:106787730	chr14:106639119~106639657:-
LUAD	cis	rs8177876	0.749	rs10459871	ENSG00000261838.4	RP11-303E16.6	8.37	6.46e-16	7.15e-13	0.82	0.36	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81059462	chr16:81069854~81076598:+
LUAD	cis	rs6504622	0.702	rs3851792	ENSG00000262879.4	RP11-156P1.3	8.37	6.48e-16	7.18e-13	0.4	0.36	Orofacial clefts;	chr17:46982458	chr17:46984045~47100323:-
LUAD	cis	rs6782228	1	rs11718130	ENSG00000242551.2	POU5F1P6	8.37	6.49e-16	7.18e-13	0.47	0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611184	chr3:128674735~128677005:-
LUAD	cis	rs71403859	0.73	rs12922775	ENSG00000260886.1	TAT-AS1	8.37	6.5e-16	7.2e-13	0.6	0.36	Post bronchodilator FEV1;	chr16:71550451	chr16:71565789~71578187:+
LUAD	cis	rs9322193	0.923	rs9767554	ENSG00000223701.3	RAET1E-AS1	8.37	6.5e-16	7.2e-13	0.42	0.36	Lung cancer;	chr6:149616860	chr6:149884431~149919508:+
LUAD	cis	rs7188445	1	rs61221126	ENSG00000261390.4	RP11-345M22.2	-8.36	6.56e-16	7.26e-13	-0.47	-0.36	Urate levels;	chr16:79699377	chr16:79715232~79770563:-
LUAD	cis	rs35955747	0.633	rs4541328	ENSG00000236132.1	CTA-440B3.1	8.36	6.59e-16	7.29e-13	0.4	0.36	Neutrophil count;Sum basophil neutrophil counts;	chr22:31500186	chr22:31816379~31817491:-
LUAD	cis	rs13423976	0.572	rs11893988	ENSG00000231367.4	AC016995.3	8.36	6.66e-16	7.36e-13	0.46	0.36	Gut microbiome composition (summer);	chr2:38515630	chr2:38406719~38515740:-
LUAD	cis	rs7429990	0.93	rs13075457	ENSG00000229759.1	MRPS18AP1	-8.36	6.68e-16	7.38e-13	-0.37	-0.36	Educational attainment (years of education);	chr3:48013063	chr3:48256350~48256938:-
LUAD	cis	rs1075265	0.588	rs1477258	ENSG00000233266.1	HMGB1P31	8.36	6.77e-16	7.48e-13	0.44	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54000031	chr2:54051334~54051760:+
LUAD	cis	rs673078	0.607	rs7304342	ENSG00000275759.1	RP11-131L12.3	-8.36	6.78e-16	7.49e-13	-0.49	-0.36	Glucose homeostasis traits;	chr12:118390166	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.615	rs61943397	ENSG00000275759.1	RP11-131L12.3	-8.36	6.78e-16	7.49e-13	-0.49	-0.36	Glucose homeostasis traits;	chr12:118390996	chr12:118428281~118428870:+
LUAD	cis	rs5769707	0.632	rs135871	ENSG00000188511.11	C22orf34	8.36	6.82e-16	7.54e-13	0.45	0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49615321	chr22:49414524~49657542:-
LUAD	cis	rs638893	0.636	rs548167	ENSG00000278376.1	RP11-158I9.8	-8.36	6.88e-16	7.6e-13	-0.54	-0.36	Vitiligo;	chr11:118777687	chr11:118791254~118793137:+
LUAD	cis	rs638893	0.578	rs4508234	ENSG00000278376.1	RP11-158I9.8	-8.36	6.9e-16	7.62e-13	-0.54	-0.36	Vitiligo;	chr11:118791494	chr11:118791254~118793137:+
LUAD	cis	rs9322193	0.576	rs7452592	ENSG00000216906.2	RP11-350J20.9	8.36	6.95e-16	7.68e-13	0.56	0.36	Lung cancer;	chr6:149875445	chr6:149904243~149906418:+
LUAD	cis	rs638893	0.527	rs7933859	ENSG00000278376.1	RP11-158I9.8	-8.36	6.97e-16	7.7e-13	-0.54	-0.36	Vitiligo;	chr11:118791336	chr11:118791254~118793137:+
LUAD	cis	rs638893	0.578	rs5006102	ENSG00000278376.1	RP11-158I9.8	-8.36	6.97e-16	7.7e-13	-0.54	-0.36	Vitiligo;	chr11:118791631	chr11:118791254~118793137:+
LUAD	cis	rs2337406	1	rs17112416	ENSG00000274576.2	IGHV2-70	8.36	7.03e-16	7.76e-13	0.4	0.36	Alzheimer's disease (late onset);	chr14:106686773	chr14:106770577~106771020:-
LUAD	cis	rs7429990	0.901	rs7433678	ENSG00000229759.1	MRPS18AP1	-8.36	7.05e-16	7.79e-13	-0.36	-0.36	Educational attainment (years of education);	chr3:47995588	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.965	rs7619882	ENSG00000229759.1	MRPS18AP1	8.35	7.08e-16	7.82e-13	0.37	0.36	Educational attainment (years of education);	chr3:47943334	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.965	rs4858881	ENSG00000229759.1	MRPS18AP1	-8.35	7.09e-16	7.82e-13	-0.36	-0.36	Educational attainment (years of education);	chr3:48082306	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.965	rs6791834	ENSG00000229759.1	MRPS18AP1	-8.35	7.11e-16	7.85e-13	-0.36	-0.36	Educational attainment (years of education);	chr3:48073598	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.965	rs35689209	ENSG00000229759.1	MRPS18AP1	-8.35	7.11e-16	7.85e-13	-0.36	-0.36	Educational attainment (years of education);	chr3:48078273	chr3:48256350~48256938:-
LUAD	cis	rs526231	0.543	rs34767	ENSG00000175749.11	EIF3KP1	8.35	7.18e-16	7.92e-13	0.5	0.36	Primary biliary cholangitis;	chr5:103153807	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.553	rs72785712	ENSG00000175749.11	EIF3KP1	8.35	7.19e-16	7.94e-13	0.51	0.36	Parkinson's disease;	chr5:102988693	chr5:103032376~103033031:+
LUAD	cis	rs4853012	0.838	rs59570457	ENSG00000257800.1	FNBP1P1	8.35	7.25e-16	7.99e-13	0.44	0.36	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74120680~74123218:+
LUAD	cis	rs12468226	0.808	rs73992849	ENSG00000273456.1	RP11-686O6.2	8.35	7.27e-16	8.01e-13	0.53	0.36	Urate levels;	chr2:202152444	chr2:202374932~202375604:-
LUAD	cis	rs732716	0.853	rs1127888	ENSG00000267769.1	CTB-50L17.9	-8.35	7.31e-16	8.06e-13	-0.39	-0.36	Mean corpuscular volume;	chr19:4454086	chr19:4454014~4455286:+
LUAD	cis	rs732716	0.853	rs12459922	ENSG00000267769.1	CTB-50L17.9	-8.35	7.31e-16	8.06e-13	-0.39	-0.36	Mean corpuscular volume;	chr19:4455865	chr19:4454014~4455286:+
LUAD	cis	rs11214589	0.747	rs1893695	ENSG00000270179.1	RP11-159N11.4	-8.35	7.35e-16	8.1e-13	-0.36	-0.36	Neuroticism;	chr11:113335363	chr11:113368478~113369117:+
LUAD	cis	rs12594515	1	rs11070464	ENSG00000273972.1	CTD-2306A12.1	-8.35	7.4e-16	8.15e-13	-0.38	-0.36	Weight;Waist circumference;	chr15:45692578	chr15:45702640~45703183:+
LUAD	cis	rs673078	0.607	rs76809232	ENSG00000275759.1	RP11-131L12.3	-8.35	7.4e-16	8.15e-13	-0.49	-0.36	Glucose homeostasis traits;	chr12:118444979	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs61944660	ENSG00000275759.1	RP11-131L12.3	-8.35	7.4e-16	8.15e-13	-0.49	-0.36	Glucose homeostasis traits;	chr12:118445326	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs61944662	ENSG00000275759.1	RP11-131L12.3	-8.35	7.4e-16	8.15e-13	-0.49	-0.36	Glucose homeostasis traits;	chr12:118445520	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs4254101	ENSG00000275759.1	RP11-131L12.3	-8.35	7.4e-16	8.15e-13	-0.49	-0.36	Glucose homeostasis traits;	chr12:118445877	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs4622305	ENSG00000275759.1	RP11-131L12.3	-8.35	7.4e-16	8.15e-13	-0.49	-0.36	Glucose homeostasis traits;	chr12:118445912	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs73207575	ENSG00000275759.1	RP11-131L12.3	-8.35	7.4e-16	8.15e-13	-0.49	-0.36	Glucose homeostasis traits;	chr12:118446711	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs61944663	ENSG00000275759.1	RP11-131L12.3	-8.35	7.4e-16	8.15e-13	-0.49	-0.36	Glucose homeostasis traits;	chr12:118446886	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs73207577	ENSG00000275759.1	RP11-131L12.3	-8.35	7.4e-16	8.15e-13	-0.49	-0.36	Glucose homeostasis traits;	chr12:118447012	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs73207579	ENSG00000275759.1	RP11-131L12.3	-8.35	7.4e-16	8.15e-13	-0.49	-0.36	Glucose homeostasis traits;	chr12:118447123	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs61944664	ENSG00000275759.1	RP11-131L12.3	-8.35	7.4e-16	8.15e-13	-0.49	-0.36	Glucose homeostasis traits;	chr12:118447145	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs7969871	ENSG00000275759.1	RP11-131L12.3	-8.35	7.4e-16	8.15e-13	-0.49	-0.36	Glucose homeostasis traits;	chr12:118447331	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.56	rs7970361	ENSG00000275759.1	RP11-131L12.3	-8.35	7.4e-16	8.15e-13	-0.49	-0.36	Glucose homeostasis traits;	chr12:118447723	chr12:118428281~118428870:+
LUAD	cis	rs526231	0.543	rs183752	ENSG00000175749.11	EIF3KP1	8.35	7.41e-16	8.17e-13	0.5	0.36	Primary biliary cholangitis;	chr5:103172108	chr5:103032376~103033031:+
LUAD	cis	rs9545047	0.704	rs3742120	ENSG00000227676.3	LINC01068	8.35	7.51e-16	8.27e-13	0.44	0.36	Schizophrenia;	chr13:79386700	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.716	rs3742122	ENSG00000227676.3	LINC01068	8.35	7.51e-16	8.27e-13	0.44	0.36	Schizophrenia;	chr13:79387061	chr13:79566727~79571436:+
LUAD	cis	rs8040855	0.658	rs4842864	ENSG00000259295.5	CSPG4P12	8.35	7.53e-16	8.29e-13	0.45	0.36	Bulimia nervosa;	chr15:85101315	chr15:85191438~85213905:+
LUAD	cis	rs10463554	0.927	rs34831	ENSG00000175749.11	EIF3KP1	8.35	7.55e-16	8.32e-13	0.49	0.36	Parkinson's disease;	chr5:103108385	chr5:103032376~103033031:+
LUAD	cis	rs35955747	0.633	rs5998012	ENSG00000236132.1	CTA-440B3.1	8.35	7.58e-16	8.35e-13	0.4	0.36	Neutrophil count;Sum basophil neutrophil counts;	chr22:31493858	chr22:31816379~31817491:-
LUAD	cis	rs4988958	0.565	rs10206291	ENSG00000234389.1	AC007278.3	8.34	7.64e-16	8.41e-13	0.32	0.36	Asthma (childhood onset);	chr2:102422403	chr2:102438713~102440475:+
LUAD	cis	rs4988958	0.565	rs3771154	ENSG00000234389.1	AC007278.3	8.34	7.64e-16	8.41e-13	0.32	0.36	Asthma (childhood onset);	chr2:102422900	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.524	rs6759479	ENSG00000234389.1	AC007278.3	8.34	7.64e-16	8.41e-13	0.32	0.36	Asthma;	chr2:102423587	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs6543133	ENSG00000234389.1	AC007278.3	8.34	7.64e-16	8.41e-13	0.32	0.36	Asthma;	chr2:102423717	chr2:102438713~102440475:+
LUAD	cis	rs496547	0.719	rs472641	ENSG00000278376.1	RP11-158I9.8	-8.34	7.71e-16	8.48e-13	-0.39	-0.36	Hip minimal joint space width;	chr11:118746835	chr11:118791254~118793137:+
LUAD	cis	rs2929278	0.546	rs686666	ENSG00000249839.1	AC011330.5	-8.34	7.77e-16	8.55e-13	-0.46	-0.36	Schizophrenia;	chr15:43869352	chr15:43663654~43684339:-
LUAD	cis	rs673078	0.607	rs61944661	ENSG00000275759.1	RP11-131L12.3	-8.34	7.77e-16	8.55e-13	-0.49	-0.36	Glucose homeostasis traits;	chr12:118445514	chr12:118428281~118428870:+
LUAD	cis	rs10463554	0.889	rs34775	ENSG00000175749.11	EIF3KP1	8.34	7.85e-16	8.63e-13	0.51	0.36	Parkinson's disease;	chr5:103115572	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs34776	ENSG00000175749.11	EIF3KP1	8.34	7.85e-16	8.63e-13	0.51	0.36	Parkinson's disease;	chr5:103116090	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.667	rs34782	ENSG00000175749.11	EIF3KP1	8.34	7.85e-16	8.63e-13	0.51	0.36	Parkinson's disease;	chr5:103118766	chr5:103032376~103033031:+
LUAD	cis	rs10740039	0.583	rs9415612	ENSG00000254271.1	RP11-131N11.4	-8.34	7.94e-16	8.72e-13	-0.4	-0.36	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60746638	chr10:60734342~60741828:+
LUAD	cis	rs732716	0.853	rs72990643	ENSG00000267769.1	CTB-50L17.9	-8.34	8e-16	8.77e-13	-0.39	-0.36	Mean corpuscular volume;	chr19:4454739	chr19:4454014~4455286:+
LUAD	cis	rs321358	1	rs73003503	ENSG00000271584.1	RP11-89C3.4	8.34	8.04e-16	8.81e-13	0.62	0.36	Body mass index;	chr11:111158360	chr11:111091932~111097357:-
LUAD	cis	rs10129255	0.834	rs10139893	ENSG00000223648.3	IGHV3-64	8.34	8.04e-16	8.82e-13	0.36	0.36	Kawasaki disease;	chr14:106711377	chr14:106643132~106658258:-
LUAD	cis	rs526231	0.543	rs62362541	ENSG00000175749.11	EIF3KP1	8.34	8.16e-16	8.94e-13	0.5	0.36	Primary biliary cholangitis;	chr5:102986744	chr5:103032376~103033031:+
LUAD	cis	rs11123170	0.64	rs2863240	ENSG00000274877.1	RP11-65I12.1	8.33	8.32e-16	9.11e-13	0.48	0.36	Renal function-related traits (BUN);	chr2:113212539	chr2:113237595~113240825:+
LUAD	cis	rs12134133	1	rs2782840	ENSG00000274245.1	RP11-357P18.2	8.33	8.41e-16	9.2e-13	0.46	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310838	chr1:207372559~207373252:+
LUAD	cis	rs9322193	0.923	rs9322209	ENSG00000223701.3	RAET1E-AS1	8.33	8.42e-16	9.21e-13	0.41	0.36	Lung cancer;	chr6:149691226	chr6:149884431~149919508:+
LUAD	cis	rs7429990	0.866	rs3732529	ENSG00000229759.1	MRPS18AP1	8.33	8.42e-16	9.21e-13	0.36	0.36	Educational attainment (years of education);	chr3:47928619	chr3:48256350~48256938:-
LUAD	cis	rs9807989	0.524	rs6543126	ENSG00000234389.1	AC007278.3	8.33	8.43e-16	9.22e-13	0.32	0.36	Asthma;	chr2:102410644	chr2:102438713~102440475:+
LUAD	cis	rs11214589	0.747	rs11493880	ENSG00000270179.1	RP11-159N11.4	-8.33	8.52e-16	9.32e-13	-0.36	-0.36	Neuroticism;	chr11:113354422	chr11:113368478~113369117:+
LUAD	cis	rs10740039	0.583	rs9415608	ENSG00000254271.1	RP11-131N11.4	-8.33	8.55e-16	9.35e-13	-0.4	-0.36	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60737680	chr10:60734342~60741828:+
LUAD	cis	rs673078	0.607	rs73207573	ENSG00000275759.1	RP11-131L12.3	-8.33	8.57e-16	9.37e-13	-0.49	-0.36	Glucose homeostasis traits;	chr12:118444664	chr12:118428281~118428870:+
LUAD	cis	rs9322193	0.923	rs9505823	ENSG00000223701.3	RAET1E-AS1	8.33	8.64e-16	9.44e-13	0.41	0.35	Lung cancer;	chr6:149628899	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs9689599	ENSG00000223701.3	RAET1E-AS1	8.33	8.64e-16	9.44e-13	0.41	0.35	Lung cancer;	chr6:149631973	chr6:149884431~149919508:+
LUAD	cis	rs17023223	0.537	rs61319010	ENSG00000231365.4	RP11-418J17.1	-8.33	8.67e-16	9.47e-13	-0.48	-0.35	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119200388	chr1:119140396~119275973:+
LUAD	cis	rs11214589	0.747	rs10502172	ENSG00000270179.1	RP11-159N11.4	-8.33	8.75e-16	9.56e-13	-0.36	-0.35	Neuroticism;	chr11:113328424	chr11:113368478~113369117:+
LUAD	cis	rs7429990	0.965	rs4392441	ENSG00000229759.1	MRPS18AP1	-8.33	8.79e-16	9.6e-13	-0.36	-0.35	Educational attainment (years of education);	chr3:48036211	chr3:48256350~48256938:-
LUAD	cis	rs526231	0.543	rs34765	ENSG00000175749.11	EIF3KP1	8.33	8.79e-16	9.61e-13	0.5	0.35	Primary biliary cholangitis;	chr5:103171160	chr5:103032376~103033031:+
LUAD	cis	rs11214589	0.747	rs2155462	ENSG00000270179.1	RP11-159N11.4	-8.33	8.81e-16	9.62e-13	-0.36	-0.35	Neuroticism;	chr11:113336077	chr11:113368478~113369117:+
LUAD	cis	rs7429990	0.965	rs4858880	ENSG00000229759.1	MRPS18AP1	-8.32	8.86e-16	9.68e-13	-0.37	-0.35	Educational attainment (years of education);	chr3:48062959	chr3:48256350~48256938:-
LUAD	cis	rs11676348	0.846	rs4674259	ENSG00000261338.2	RP11-378A13.1	-8.32	8.87e-16	9.69e-13	-0.38	-0.35	Ulcerative colitis;	chr2:218126282	chr2:218255319~218257366:+
LUAD	cis	rs7429990	0.932	rs60446735	ENSG00000229759.1	MRPS18AP1	8.32	8.94e-16	9.76e-13	0.37	0.35	Educational attainment (years of education);	chr3:47929958	chr3:48256350~48256938:-
LUAD	cis	rs494459	0.838	rs581045	ENSG00000255239.1	AP002954.6	8.32	8.99e-16	9.81e-13	0.42	0.35	Height;	chr11:118761813	chr11:118688039~118690600:-
LUAD	cis	rs673078	0.607	rs882927	ENSG00000275759.1	RP11-131L12.3	-8.32	9.06e-16	9.89e-13	-0.48	-0.35	Glucose homeostasis traits;	chr12:118406737	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs11068926	ENSG00000275759.1	RP11-131L12.3	-8.32	9.07e-16	9.89e-13	-0.48	-0.35	Glucose homeostasis traits;	chr12:118367320	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs4442583	ENSG00000275759.1	RP11-131L12.3	-8.32	9.07e-16	9.89e-13	-0.48	-0.35	Glucose homeostasis traits;	chr12:118367914	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs61943370	ENSG00000275759.1	RP11-131L12.3	-8.32	9.07e-16	9.89e-13	-0.48	-0.35	Glucose homeostasis traits;	chr12:118369469	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs61943371	ENSG00000275759.1	RP11-131L12.3	-8.32	9.07e-16	9.89e-13	-0.48	-0.35	Glucose homeostasis traits;	chr12:118369600	chr12:118428281~118428870:+
LUAD	cis	rs9807989	0.507	rs4851004	ENSG00000234389.1	AC007278.3	-8.32	9.19e-16	1e-12	-0.32	-0.35	Asthma;	chr2:102393077	chr2:102438713~102440475:+
LUAD	cis	rs17023223	0.553	rs56234947	ENSG00000231365.4	RP11-418J17.1	-8.32	9.24e-16	1.01e-12	-0.47	-0.35	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119165121	chr1:119140396~119275973:+
LUAD	cis	rs56046484	0.956	rs34054841	ENSG00000259295.5	CSPG4P12	8.32	9.25e-16	1.01e-12	0.53	0.35	Testicular germ cell tumor;	chr15:85058115	chr15:85191438~85213905:+
LUAD	cis	rs56046484	0.956	rs12908535	ENSG00000259295.5	CSPG4P12	8.32	9.25e-16	1.01e-12	0.53	0.35	Testicular germ cell tumor;	chr15:85058294	chr15:85191438~85213905:+
LUAD	cis	rs9322193	0.847	rs12234128	ENSG00000223701.3	RAET1E-AS1	8.32	9.3e-16	1.01e-12	0.41	0.35	Lung cancer;	chr6:149627553	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs57012784	ENSG00000223701.3	RAET1E-AS1	8.32	9.3e-16	1.01e-12	0.41	0.35	Lung cancer;	chr6:149627691	chr6:149884431~149919508:+
LUAD	cis	rs2337406	0.538	rs10141701	ENSG00000274576.2	IGHV2-70	-8.32	9.31e-16	1.01e-12	-0.36	-0.35	Alzheimer's disease (late onset);	chr14:106633467	chr14:106770577~106771020:-
LUAD	cis	rs11676348	0.818	rs7425447	ENSG00000261338.2	RP11-378A13.1	-8.32	9.37e-16	1.02e-12	-0.38	-0.35	Ulcerative colitis;	chr2:218115460	chr2:218255319~218257366:+
LUAD	cis	rs11096990	0.634	rs6854358	ENSG00000249207.1	RP11-360F5.1	8.32	9.39e-16	1.02e-12	0.39	0.35	Cognitive function;	chr4:39281492	chr4:39112677~39126818:-
LUAD	cis	rs526231	0.543	rs7709726	ENSG00000175749.11	EIF3KP1	-8.32	9.42e-16	1.03e-12	-0.48	-0.35	Primary biliary cholangitis;	chr5:102991759	chr5:103032376~103033031:+
LUAD	cis	rs17711722	0.523	rs313812	ENSG00000164669.11	INTS4P1	8.32	9.47e-16	1.03e-12	0.42	0.35	Calcium levels;	chr7:66040056	chr7:65141225~65234216:+
LUAD	cis	rs10875746	0.669	rs10783244	ENSG00000240399.1	RP1-228P16.1	-8.32	9.48e-16	1.03e-12	-0.42	-0.35	Longevity (90 years and older);	chr12:48271206	chr12:48054813~48055591:-
LUAD	cis	rs12468226	1	rs7597156	ENSG00000273456.1	RP11-686O6.2	8.31	9.51e-16	1.04e-12	0.52	0.35	Urate levels;	chr2:202329339	chr2:202374932~202375604:-
LUAD	cis	rs9545047	0.669	rs2095477	ENSG00000227676.3	LINC01068	-8.31	9.61e-16	1.05e-12	-0.44	-0.35	Schizophrenia;	chr13:79427869	chr13:79566727~79571436:+
LUAD	cis	rs56046484	0.956	rs35885781	ENSG00000259295.5	CSPG4P12	8.31	9.66e-16	1.05e-12	0.53	0.35	Testicular germ cell tumor;	chr15:85047852	chr15:85191438~85213905:+
LUAD	cis	rs56046484	0.956	rs34105012	ENSG00000259295.5	CSPG4P12	8.31	9.66e-16	1.05e-12	0.53	0.35	Testicular germ cell tumor;	chr15:85048455	chr15:85191438~85213905:+
LUAD	cis	rs9287719	0.781	rs6714795	ENSG00000234818.1	AC092687.5	8.31	9.68e-16	1.05e-12	0.43	0.35	Prostate cancer;	chr2:10619008	chr2:10589166~10604830:+
LUAD	cis	rs2549794	0.537	rs34755	ENSG00000248734.2	CTD-2260A17.1	-8.31	9.98e-16	1.08e-12	-0.35	-0.35	Crohn's disease;	chr5:96816057	chr5:96784777~96785999:+
LUAD	cis	rs13423976	0.631	rs11888984	ENSG00000231367.4	AC016995.3	-8.31	1.01e-15	1.09e-12	-0.45	-0.35	Gut microbiome composition (summer);	chr2:38517250	chr2:38406719~38515740:-
LUAD	cis	rs6782228	0.876	rs34198449	ENSG00000242551.2	POU5F1P6	8.31	1.01e-15	1.1e-12	0.45	0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662427	chr3:128674735~128677005:-
LUAD	cis	rs6782228	0.883	rs11712115	ENSG00000242551.2	POU5F1P6	8.31	1.01e-15	1.1e-12	0.43	0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128685426	chr3:128674735~128677005:-
LUAD	cis	rs10463554	0.963	rs26817	ENSG00000175749.11	EIF3KP1	-8.31	1.01e-15	1.1e-12	-0.48	-0.35	Parkinson's disease;	chr5:103204665	chr5:103032376~103033031:+
LUAD	cis	rs12439619	0.508	rs8023960	ENSG00000255769.6	GOLGA2P10	-8.31	1.01e-15	1.1e-12	-0.37	-0.35	Intelligence (multi-trait analysis);	chr15:82206704	chr15:82472993~82513950:-
LUAD	cis	rs673078	0.607	rs61944669	ENSG00000275759.1	RP11-131L12.3	-8.31	1.02e-15	1.1e-12	-0.49	-0.35	Glucose homeostasis traits;	chr12:118448530	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs61944670	ENSG00000275759.1	RP11-131L12.3	-8.31	1.02e-15	1.1e-12	-0.49	-0.35	Glucose homeostasis traits;	chr12:118448697	chr12:118428281~118428870:+
LUAD	cis	rs2980436	1	rs2980436	ENSG00000253981.4	ALG1L13P	-8.31	1.02e-15	1.11e-12	-0.42	-0.35	Schizophrenia;	chr8:8234503	chr8:8236003~8244667:-
LUAD	cis	rs367615	0.506	rs2914684	ENSG00000249476.1	CTD-2587M2.1	-8.3	1.02e-15	1.11e-12	-0.4	-0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109439409	chr5:109237120~109326369:-
LUAD	cis	rs673078	0.607	rs61943398	ENSG00000275759.1	RP11-131L12.3	-8.3	1.03e-15	1.12e-12	-0.49	-0.35	Glucose homeostasis traits;	chr12:118393280	chr12:118428281~118428870:+
LUAD	cis	rs10170846	0.8	rs10194743	ENSG00000261428.2	RP11-16P6.1	8.3	1.05e-15	1.13e-12	0.42	0.35	Schizophrenia (inflammation and infection response interaction);	chr2:222653432	chr2:222566899~222569719:-
LUAD	cis	rs11676348	0.846	rs3890158	ENSG00000261338.2	RP11-378A13.1	-8.3	1.06e-15	1.15e-12	-0.38	-0.35	Ulcerative colitis;	chr2:218125569	chr2:218255319~218257366:+
LUAD	cis	rs944289	0.74	rs368187	ENSG00000257826.1	RP11-116N8.4	8.3	1.06e-15	1.15e-12	0.37	0.35	Thyroid cancer;	chr14:36063370	chr14:36061026~36067190:-
LUAD	cis	rs9322193	0.923	rs10747276	ENSG00000223701.3	RAET1E-AS1	8.3	1.08e-15	1.17e-12	0.41	0.35	Lung cancer;	chr6:149758739	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.607	rs7764677	ENSG00000216906.2	RP11-350J20.9	8.3	1.09e-15	1.18e-12	0.51	0.35	Lung cancer;	chr6:149906197	chr6:149904243~149906418:+
LUAD	cis	rs5769707	0.706	rs2071903	ENSG00000188511.11	C22orf34	8.3	1.09e-15	1.18e-12	0.45	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49640869	chr22:49414524~49657542:-
LUAD	cis	rs10129255	1	rs10137758	ENSG00000211970.3	IGHV4-61	-8.3	1.09e-15	1.18e-12	-0.28	-0.35	Kawasaki disease;	chr14:106697673	chr14:106639119~106639657:-
LUAD	cis	rs638893	0.898	rs587816	ENSG00000278376.1	RP11-158I9.8	-8.3	1.09e-15	1.18e-12	-0.49	-0.35	Vitiligo;	chr11:118819162	chr11:118791254~118793137:+
LUAD	cis	rs11676348	0.818	rs6436031	ENSG00000261338.2	RP11-378A13.1	-8.3	1.09e-15	1.18e-12	-0.38	-0.35	Ulcerative colitis;	chr2:218114536	chr2:218255319~218257366:+
LUAD	cis	rs638893	0.636	rs583213	ENSG00000278376.1	RP11-158I9.8	-8.29	1.1e-15	1.19e-12	-0.53	-0.35	Vitiligo;	chr11:118798469	chr11:118791254~118793137:+
LUAD	cis	rs9326248	0.773	rs1060211	ENSG00000280143.1	AP000892.6	8.29	1.11e-15	1.2e-12	0.48	0.35	Blood protein levels;	chr11:117169081	chr11:117204967~117210292:+
LUAD	cis	rs526231	0.578	rs10463553	ENSG00000175749.11	EIF3KP1	8.29	1.11e-15	1.2e-12	0.49	0.35	Primary biliary cholangitis;	chr5:102913503	chr5:103032376~103033031:+
LUAD	cis	rs9807989	0.507	rs1592459	ENSG00000234389.1	AC007278.3	8.29	1.11e-15	1.2e-12	0.32	0.35	Asthma;	chr2:102415109	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs1592458	ENSG00000234389.1	AC007278.3	8.29	1.11e-15	1.2e-12	0.32	0.35	Asthma;	chr2:102415289	chr2:102438713~102440475:+
LUAD	cis	rs4988958	0.565	rs1035125	ENSG00000234389.1	AC007278.3	8.29	1.11e-15	1.2e-12	0.32	0.35	Asthma (childhood onset);	chr2:102417379	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs2160201	ENSG00000234389.1	AC007278.3	8.29	1.11e-15	1.2e-12	0.32	0.35	Asthma;	chr2:102417501	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs1833174	ENSG00000234389.1	AC007278.3	8.29	1.11e-15	1.2e-12	0.32	0.35	Asthma;	chr2:102418383	chr2:102438713~102440475:+
LUAD	cis	rs5769707	0.632	rs6009782	ENSG00000188511.11	C22orf34	8.29	1.11e-15	1.2e-12	0.44	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49617164	chr22:49414524~49657542:-
LUAD	cis	rs526231	0.543	rs34784	ENSG00000175749.11	EIF3KP1	8.29	1.12e-15	1.21e-12	0.51	0.35	Primary biliary cholangitis;	chr5:103121626	chr5:103032376~103033031:+
LUAD	cis	rs7429990	0.965	rs319685	ENSG00000229759.1	MRPS18AP1	8.29	1.12e-15	1.21e-12	0.37	0.35	Educational attainment (years of education);	chr3:47890494	chr3:48256350~48256938:-
LUAD	cis	rs2581828	0.618	rs1560332	ENSG00000242142.1	SERBP1P3	8.29	1.12e-15	1.22e-12	0.39	0.35	Crohn's disease;	chr3:53130787	chr3:53064283~53065091:-
LUAD	cis	rs172166	0.516	rs1225710	ENSG00000204709.4	LINC01556	-8.29	1.13e-15	1.22e-12	-0.44	-0.35	Cardiac Troponin-T levels;	chr6:28132862	chr6:28943877~28944537:+
LUAD	cis	rs526231	0.543	rs8488	ENSG00000175749.11	EIF3KP1	8.29	1.13e-15	1.22e-12	0.5	0.35	Primary biliary cholangitis;	chr5:103203051	chr5:103032376~103033031:+
LUAD	cis	rs7188445	0.932	rs17767491	ENSG00000261390.4	RP11-345M22.2	-8.29	1.14e-15	1.23e-12	-0.47	-0.35	Urate levels;	chr16:79711590	chr16:79715232~79770563:-
LUAD	cis	rs11123170	0.543	rs4849178	ENSG00000189223.12	PAX8-AS1	-8.29	1.14e-15	1.23e-12	-0.56	-0.35	Renal function-related traits (BUN);	chr2:113225031	chr2:113211522~113276581:+
LUAD	cis	rs950880	0.71	rs3732123	ENSG00000234389.1	AC007278.3	-8.29	1.14e-15	1.23e-12	-0.35	-0.35	Serum protein levels (sST2);	chr2:102401617	chr2:102438713~102440475:+
LUAD	cis	rs5769707	0.632	rs135876	ENSG00000188511.11	C22orf34	8.29	1.15e-15	1.24e-12	0.45	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49619925	chr22:49414524~49657542:-
LUAD	cis	rs4273100	0.834	rs59415593	ENSG00000262319.1	CTC-457L16.2	-8.29	1.15e-15	1.25e-12	-0.5	-0.35	Schizophrenia;	chr17:19319911	chr17:19141017~19143689:-
LUAD	cis	rs1891275	0.551	rs7071844	ENSG00000228701.1	TNKS2-AS1	-8.29	1.15e-15	1.25e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91644092	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.551	rs4933684	ENSG00000228701.1	TNKS2-AS1	-8.29	1.15e-15	1.25e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91647805	chr10:91782839~91798291:-
LUAD	cis	rs7688540	0.771	rs2353605	ENSG00000275426.1	CH17-262A2.1	8.29	1.16e-15	1.25e-12	0.49	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:225749	chr4:149738~150317:+
LUAD	cis	rs9545047	0.704	rs9530904	ENSG00000227676.3	LINC01068	8.29	1.16e-15	1.26e-12	0.43	0.35	Schizophrenia;	chr13:79370157	chr13:79566727~79571436:+
LUAD	cis	rs8177876	0.822	rs79926943	ENSG00000261838.4	RP11-303E16.6	8.29	1.17e-15	1.26e-12	0.82	0.35	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81072005	chr16:81069854~81076598:+
LUAD	cis	rs1075265	0.568	rs10865278	ENSG00000233266.1	HMGB1P31	8.29	1.18e-15	1.27e-12	0.46	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54074902	chr2:54051334~54051760:+
LUAD	cis	rs10875746	0.669	rs10431526	ENSG00000240399.1	RP1-228P16.1	-8.28	1.19e-15	1.28e-12	-0.42	-0.35	Longevity (90 years and older);	chr12:48296360	chr12:48054813~48055591:-
LUAD	cis	rs12439619	0.508	rs8042665	ENSG00000255769.6	GOLGA2P10	-8.28	1.19e-15	1.29e-12	-0.37	-0.35	Intelligence (multi-trait analysis);	chr15:82189008	chr15:82472993~82513950:-
LUAD	cis	rs7429990	0.965	rs1061003	ENSG00000229759.1	MRPS18AP1	8.28	1.2e-15	1.29e-12	0.37	0.35	Educational attainment (years of education);	chr3:47851089	chr3:48256350~48256938:-
LUAD	cis	rs526231	0.543	rs28025	ENSG00000175749.11	EIF3KP1	8.28	1.2e-15	1.29e-12	0.5	0.35	Primary biliary cholangitis;	chr5:103201678	chr5:103032376~103033031:+
LUAD	cis	rs11676348	0.818	rs4674256	ENSG00000261338.2	RP11-378A13.1	-8.28	1.21e-15	1.31e-12	-0.37	-0.35	Ulcerative colitis;	chr2:218123170	chr2:218255319~218257366:+
LUAD	cis	rs11676348	0.846	rs4674257	ENSG00000261338.2	RP11-378A13.1	-8.28	1.21e-15	1.31e-12	-0.37	-0.35	Ulcerative colitis;	chr2:218124051	chr2:218255319~218257366:+
LUAD	cis	rs638893	0.898	rs577121	ENSG00000278376.1	RP11-158I9.8	-8.28	1.21e-15	1.31e-12	-0.49	-0.35	Vitiligo;	chr11:118819841	chr11:118791254~118793137:+
LUAD	cis	rs944289	0.74	rs414755	ENSG00000257826.1	RP11-116N8.4	8.28	1.22e-15	1.31e-12	0.37	0.35	Thyroid cancer;	chr14:36073387	chr14:36061026~36067190:-
LUAD	cis	rs638893	0.636	rs1784295	ENSG00000278376.1	RP11-158I9.8	-8.28	1.22e-15	1.31e-12	-0.54	-0.35	Vitiligo;	chr11:118790223	chr11:118791254~118793137:+
LUAD	cis	rs9807989	0.507	rs10439410	ENSG00000234389.1	AC007278.3	-8.28	1.23e-15	1.32e-12	-0.32	-0.35	Asthma;	chr2:102374328	chr2:102438713~102440475:+
LUAD	cis	rs7665090	0.51	rs223498	ENSG00000246560.2	RP11-10L12.4	-8.28	1.25e-15	1.34e-12	-0.44	-0.35	Primary biliary cholangitis;	chr4:102730805	chr4:102828055~102844075:+
LUAD	cis	rs950169	0.922	rs67804993	ENSG00000225151.9	GOLGA2P7	-8.28	1.25e-15	1.35e-12	-0.49	-0.35	Schizophrenia;	chr15:84560799	chr15:84199311~84230136:-
LUAD	cis	rs2919917	0.915	rs3899796	ENSG00000254352.1	RP11-578O24.2	8.28	1.26e-15	1.35e-12	0.42	0.35	Lymphocyte counts;	chr8:78655847	chr8:78723796~78724136:-
LUAD	cis	rs9322193	0.923	rs9800871	ENSG00000223701.3	RAET1E-AS1	8.28	1.27e-15	1.37e-12	0.41	0.35	Lung cancer;	chr6:149644540	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs9800614	ENSG00000223701.3	RAET1E-AS1	8.28	1.27e-15	1.37e-12	0.41	0.35	Lung cancer;	chr6:149644604	chr6:149884431~149919508:+
LUAD	cis	rs1150668	0.799	rs1150705	ENSG00000204709.4	LINC01556	8.28	1.27e-15	1.37e-12	0.44	0.35	Pubertal anthropometrics;	chr6:28226008	chr6:28943877~28944537:+
LUAD	cis	rs5769707	0.605	rs9616702	ENSG00000188511.11	C22orf34	8.27	1.28e-15	1.37e-12	0.46	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49632290	chr22:49414524~49657542:-
LUAD	cis	rs9807989	0.524	rs4851576	ENSG00000234389.1	AC007278.3	8.27	1.28e-15	1.37e-12	0.32	0.35	Asthma;	chr2:102412435	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs4851577	ENSG00000234389.1	AC007278.3	8.27	1.28e-15	1.37e-12	0.32	0.35	Asthma;	chr2:102412461	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs4851579	ENSG00000234389.1	AC007278.3	8.27	1.28e-15	1.37e-12	0.32	0.35	Asthma;	chr2:102412524	chr2:102438713~102440475:+
LUAD	cis	rs11096990	0.634	rs7666632	ENSG00000249207.1	RP11-360F5.1	-8.27	1.28e-15	1.38e-12	-0.38	-0.35	Cognitive function;	chr4:39238568	chr4:39112677~39126818:-
LUAD	cis	rs2108622	0.958	rs79400241	ENSG00000267453.5	AC004791.2	-8.27	1.28e-15	1.38e-12	-0.47	-0.35	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15873592	chr19:15851993~15864904:-
LUAD	cis	rs673078	0.607	rs11068919	ENSG00000275759.1	RP11-131L12.3	-8.27	1.28e-15	1.38e-12	-0.47	-0.35	Glucose homeostasis traits;	chr12:118354925	chr12:118428281~118428870:+
LUAD	cis	rs526231	0.578	rs17154825	ENSG00000175749.11	EIF3KP1	8.27	1.29e-15	1.38e-12	0.49	0.35	Primary biliary cholangitis;	chr5:102910365	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.578	rs6876278	ENSG00000175749.11	EIF3KP1	8.27	1.29e-15	1.38e-12	0.49	0.35	Primary biliary cholangitis;	chr5:102913842	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.543	rs6880911	ENSG00000175749.11	EIF3KP1	8.27	1.29e-15	1.38e-12	0.51	0.35	Primary biliary cholangitis;	chr5:102971767	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.963	rs1552916	ENSG00000175749.11	EIF3KP1	8.27	1.31e-15	1.4e-12	0.49	0.35	Parkinson's disease;	chr5:103002036	chr5:103032376~103033031:+
LUAD	cis	rs10875746	0.669	rs9634261	ENSG00000240399.1	RP1-228P16.1	-8.27	1.31e-15	1.41e-12	-0.41	-0.35	Longevity (90 years and older);	chr12:48293088	chr12:48054813~48055591:-
LUAD	cis	rs150992	0.742	rs34495	ENSG00000248489.1	CTD-2007H13.3	8.27	1.31e-15	1.41e-12	0.38	0.35	Body mass index;	chr5:98930103	chr5:98929171~98995013:+
LUAD	cis	rs11123170	0.543	rs12472361	ENSG00000189223.12	PAX8-AS1	-8.27	1.31e-15	1.41e-12	-0.57	-0.35	Renal function-related traits (BUN);	chr2:113223068	chr2:113211522~113276581:+
LUAD	cis	rs7429990	0.965	rs319686	ENSG00000229759.1	MRPS18AP1	8.27	1.31e-15	1.41e-12	0.37	0.35	Educational attainment (years of education);	chr3:47888930	chr3:48256350~48256938:-
LUAD	cis	rs12468226	0.752	rs79058237	ENSG00000273456.1	RP11-686O6.2	8.27	1.34e-15	1.44e-12	0.54	0.35	Urate levels;	chr2:202140247	chr2:202374932~202375604:-
LUAD	cis	rs7688540	0.723	rs61794999	ENSG00000275426.1	CH17-262A2.1	8.27	1.35e-15	1.44e-12	0.51	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238578	chr4:149738~150317:+
LUAD	cis	rs950169	0.887	rs35986397	ENSG00000225151.9	GOLGA2P7	-8.27	1.35e-15	1.44e-12	-0.5	-0.35	Schizophrenia;	chr15:84400409	chr15:84199311~84230136:-
LUAD	cis	rs10463554	0.892	rs1438687	ENSG00000175749.11	EIF3KP1	8.27	1.35e-15	1.45e-12	0.49	0.35	Parkinson's disease;	chr5:102968792	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.963	rs11242483	ENSG00000175749.11	EIF3KP1	8.27	1.35e-15	1.45e-12	0.48	0.35	Parkinson's disease;	chr5:102988062	chr5:103032376~103033031:+
LUAD	cis	rs11676348	0.811	rs4674255	ENSG00000261338.2	RP11-378A13.1	-8.27	1.36e-15	1.46e-12	-0.37	-0.35	Ulcerative colitis;	chr2:218122602	chr2:218255319~218257366:+
LUAD	cis	rs11123170	0.543	rs35222158	ENSG00000189223.12	PAX8-AS1	-8.27	1.37e-15	1.46e-12	-0.57	-0.35	Renal function-related traits (BUN);	chr2:113229052	chr2:113211522~113276581:+
LUAD	cis	rs12468226	0.702	rs114634431	ENSG00000273456.1	RP11-686O6.2	8.26	1.38e-15	1.48e-12	0.54	0.35	Urate levels;	chr2:202142530	chr2:202374932~202375604:-
LUAD	cis	rs944289	0.774	rs34081947	ENSG00000257826.1	RP11-116N8.4	-8.26	1.41e-15	1.5e-12	-0.37	-0.35	Thyroid cancer;	chr14:36090325	chr14:36061026~36067190:-
LUAD	cis	rs56046484	1	rs12911330	ENSG00000259295.5	CSPG4P12	8.26	1.42e-15	1.52e-12	0.53	0.35	Testicular germ cell tumor;	chr15:85087103	chr15:85191438~85213905:+
LUAD	cis	rs56046484	0.956	rs34919315	ENSG00000259295.5	CSPG4P12	8.26	1.42e-15	1.52e-12	0.53	0.35	Testicular germ cell tumor;	chr15:85088675	chr15:85191438~85213905:+
LUAD	cis	rs12220777	0.786	rs2342607	ENSG00000230091.5	TMEM254-AS1	8.26	1.42e-15	1.52e-12	0.71	0.35	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80061733	chr10:80046860~80078912:-
LUAD	cis	rs673078	0.607	rs2036314	ENSG00000275759.1	RP11-131L12.3	-8.26	1.43e-15	1.53e-12	-0.47	-0.35	Glucose homeostasis traits;	chr12:118367132	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs61943369	ENSG00000275759.1	RP11-131L12.3	-8.26	1.43e-15	1.53e-12	-0.47	-0.35	Glucose homeostasis traits;	chr12:118368145	chr12:118428281~118428870:+
LUAD	cis	rs11098499	0.562	rs13101722	ENSG00000245958.5	RP11-33B1.1	8.26	1.43e-15	1.53e-12	0.3	0.35	Corneal astigmatism;	chr4:119634820	chr4:119454791~119552025:+
LUAD	cis	rs10463554	0.824	rs3776868	ENSG00000175749.11	EIF3KP1	8.26	1.44e-15	1.54e-12	0.49	0.35	Parkinson's disease;	chr5:102963012	chr5:103032376~103033031:+
LUAD	cis	rs7688540	0.771	rs11730202	ENSG00000275426.1	CH17-262A2.1	8.26	1.45e-15	1.55e-12	0.5	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:216307	chr4:149738~150317:+
LUAD	cis	rs1075265	0.568	rs959286	ENSG00000233266.1	HMGB1P31	8.26	1.46e-15	1.56e-12	0.46	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54078941	chr2:54051334~54051760:+
LUAD	cis	rs7174755	0.743	rs4777035	ENSG00000260657.2	RP11-315D16.4	-8.26	1.47e-15	1.57e-12	-0.4	-0.35	Major depressive disorder;	chr15:68312831	chr15:68267792~68277994:-
LUAD	cis	rs494459	0.838	rs12796102	ENSG00000255239.1	AP002954.6	8.25	1.48e-15	1.57e-12	0.42	0.35	Height;	chr11:118791319	chr11:118688039~118690600:-
LUAD	cis	rs9287719	0.81	rs1990612	ENSG00000234818.1	AC092687.5	8.25	1.49e-15	1.59e-12	0.42	0.35	Prostate cancer;	chr2:10641818	chr2:10589166~10604830:+
LUAD	cis	rs9660180	0.783	rs1107910	ENSG00000268575.1	RP1-283E3.8	-8.25	1.49e-15	1.59e-12	-0.31	-0.35	Body mass index;	chr1:1760882	chr1:1702736~1737688:-
LUAD	cis	rs6452524	0.935	rs2386241	ENSG00000249664.1	CTD-2227C6.2	-8.25	1.49e-15	1.59e-12	-0.41	-0.35	Hypertension (SNP x SNP interaction);	chr5:83149872	chr5:83012285~83013109:-
LUAD	cis	rs526231	0.543	rs26819	ENSG00000175749.11	EIF3KP1	8.25	1.49e-15	1.59e-12	0.5	0.35	Primary biliary cholangitis;	chr5:103193700	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.615	rs26818	ENSG00000175749.11	EIF3KP1	8.25	1.49e-15	1.59e-12	0.5	0.35	Primary biliary cholangitis;	chr5:103194018	chr5:103032376~103033031:+
LUAD	cis	rs4988958	0.565	rs885088	ENSG00000234389.1	AC007278.3	8.25	1.49e-15	1.59e-12	0.32	0.35	Asthma (childhood onset);	chr2:102422584	chr2:102438713~102440475:+
LUAD	cis	rs7688540	0.771	rs61795001	ENSG00000275426.1	CH17-262A2.1	8.25	1.5e-15	1.6e-12	0.51	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:248268	chr4:149738~150317:+
LUAD	cis	rs7688540	0.771	rs61795002	ENSG00000275426.1	CH17-262A2.1	8.25	1.5e-15	1.6e-12	0.51	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:249008	chr4:149738~150317:+
LUAD	cis	rs11089937	0.626	rs5757056	ENSG00000211639.2	IGLV4-60	8.25	1.51e-15	1.61e-12	0.4	0.35	Periodontitis (PAL4Q3);	chr22:22142491	chr22:22162199~22162681:+
LUAD	cis	rs7429990	0.965	rs800762	ENSG00000229759.1	MRPS18AP1	8.25	1.51e-15	1.61e-12	0.36	0.35	Educational attainment (years of education);	chr3:47864080	chr3:48256350~48256938:-
LUAD	cis	rs12220777	0.681	rs117394476	ENSG00000230091.5	TMEM254-AS1	8.25	1.51e-15	1.61e-12	0.68	0.35	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80103000	chr10:80046860~80078912:-
LUAD	cis	rs1891275	0.551	rs2421621	ENSG00000228701.1	TNKS2-AS1	-8.25	1.52e-15	1.62e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91640344	chr10:91782839~91798291:-
LUAD	cis	rs9287719	0.967	rs1541573	ENSG00000234818.1	AC092687.5	8.25	1.52e-15	1.62e-12	0.42	0.35	Prostate cancer;	chr2:10633259	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs1541574	ENSG00000234818.1	AC092687.5	8.25	1.52e-15	1.62e-12	0.42	0.35	Prostate cancer;	chr2:10633382	chr2:10589166~10604830:+
LUAD	cis	rs1185460	0.547	rs666741	ENSG00000271751.1	RP11-110I1.14	8.25	1.56e-15	1.67e-12	0.44	0.35	Coronary artery disease;	chr11:119040640	chr11:119065263~119065677:-
LUAD	cis	rs11676348	0.783	rs4674252	ENSG00000261338.2	RP11-378A13.1	-8.25	1.57e-15	1.67e-12	-0.37	-0.35	Ulcerative colitis;	chr2:218119755	chr2:218255319~218257366:+
LUAD	cis	rs11676348	0.818	rs7423433	ENSG00000261338.2	RP11-378A13.1	-8.25	1.57e-15	1.67e-12	-0.37	-0.35	Ulcerative colitis;	chr2:218120361	chr2:218255319~218257366:+
LUAD	cis	rs11676348	0.714	rs4674254	ENSG00000261338.2	RP11-378A13.1	-8.25	1.57e-15	1.67e-12	-0.37	-0.35	Ulcerative colitis;	chr2:218121354	chr2:218255319~218257366:+
LUAD	cis	rs526231	0.543	rs6881225	ENSG00000175749.11	EIF3KP1	8.25	1.58e-15	1.68e-12	0.51	0.35	Primary biliary cholangitis;	chr5:102971888	chr5:103032376~103033031:+
LUAD	cis	rs950169	0.922	rs11630507	ENSG00000225151.9	GOLGA2P7	-8.25	1.58e-15	1.68e-12	-0.49	-0.35	Schizophrenia;	chr15:84552494	chr15:84199311~84230136:-
LUAD	cis	rs11096990	0.634	rs60016848	ENSG00000249207.1	RP11-360F5.1	8.24	1.61e-15	1.71e-12	0.39	0.35	Cognitive function;	chr4:39281436	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.577	rs6830736	ENSG00000249207.1	RP11-360F5.1	8.24	1.61e-15	1.71e-12	0.39	0.35	Cognitive function;	chr4:39281467	chr4:39112677~39126818:-
LUAD	cis	rs9322193	0.923	rs9479094	ENSG00000223701.3	RAET1E-AS1	8.24	1.61e-15	1.71e-12	0.41	0.35	Lung cancer;	chr6:149725083	chr6:149884431~149919508:+
LUAD	cis	rs11096990	0.634	rs745642	ENSG00000249207.1	RP11-360F5.1	8.24	1.61e-15	1.71e-12	0.39	0.35	Cognitive function;	chr4:39279642	chr4:39112677~39126818:-
LUAD	cis	rs10129255	0.834	rs10139893	ENSG00000211970.3	IGHV4-61	-8.24	1.62e-15	1.72e-12	-0.28	-0.35	Kawasaki disease;	chr14:106711377	chr14:106639119~106639657:-
LUAD	cis	rs9322193	0.923	rs9322197	ENSG00000223701.3	RAET1E-AS1	8.24	1.62e-15	1.72e-12	0.41	0.35	Lung cancer;	chr6:149622577	chr6:149884431~149919508:+
LUAD	cis	rs10740039	0.583	rs9415611	ENSG00000254271.1	RP11-131N11.4	-8.24	1.62e-15	1.73e-12	-0.39	-0.35	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60743440	chr10:60734342~60741828:+
LUAD	cis	rs526231	0.543	rs62362521	ENSG00000175749.11	EIF3KP1	8.24	1.63e-15	1.73e-12	0.51	0.35	Primary biliary cholangitis;	chr5:102970357	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.575	rs12652973	ENSG00000175749.11	EIF3KP1	8.24	1.63e-15	1.73e-12	0.51	0.35	Primary biliary cholangitis;	chr5:102970618	chr5:103032376~103033031:+
LUAD	cis	rs494459	0.756	rs570806	ENSG00000255239.1	AP002954.6	8.24	1.63e-15	1.74e-12	0.42	0.35	Height;	chr11:118786602	chr11:118688039~118690600:-
LUAD	cis	rs465969	1	rs4509157	ENSG00000255389.1	C6orf3	-8.24	1.63e-15	1.74e-12	-0.66	-0.35	Psoriasis;	chr6:111513875	chr6:111599875~111602295:+
LUAD	cis	rs10740039	0.548	rs9415607	ENSG00000254271.1	RP11-131N11.4	-8.24	1.64e-15	1.74e-12	-0.4	-0.35	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60737616	chr10:60734342~60741828:+
LUAD	cis	rs2739330	0.761	rs5760176	ENSG00000206090.4	AP000350.7	-8.24	1.64e-15	1.74e-12	-0.4	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23939998~23942798:+
LUAD	cis	rs9545047	0.604	rs1028770	ENSG00000227676.3	LINC01068	-8.24	1.65e-15	1.75e-12	-0.41	-0.35	Schizophrenia;	chr13:79297346	chr13:79566727~79571436:+
LUAD	cis	rs12134133	1	rs2802237	ENSG00000274245.1	RP11-357P18.2	8.24	1.65e-15	1.76e-12	0.46	0.35	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207300825	chr1:207372559~207373252:+
LUAD	cis	rs12134133	1	rs2782842	ENSG00000274245.1	RP11-357P18.2	8.24	1.66e-15	1.76e-12	0.45	0.35	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310231	chr1:207372559~207373252:+
LUAD	cis	rs112990264	0.568	rs3006239	ENSG00000198468.6	FLVCR1-AS1	8.24	1.66e-15	1.76e-12	0.64	0.35	Itch intensity from mosquito bite;	chr1:212812498	chr1:212852108~212858088:-
LUAD	cis	rs4988958	0.548	rs6543127	ENSG00000234389.1	AC007278.3	8.24	1.66e-15	1.76e-12	0.32	0.35	Asthma (childhood onset);	chr2:102411841	chr2:102438713~102440475:+
LUAD	cis	rs5769707	0.656	rs135875	ENSG00000188511.11	C22orf34	8.24	1.66e-15	1.76e-12	0.44	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49618771	chr22:49414524~49657542:-
LUAD	cis	rs9807989	0.507	rs10203558	ENSG00000234389.1	AC007278.3	8.24	1.66e-15	1.77e-12	0.32	0.35	Asthma;	chr2:102411180	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs10200952	ENSG00000234389.1	AC007278.3	8.24	1.66e-15	1.77e-12	0.32	0.35	Asthma;	chr2:102411191	chr2:102438713~102440475:+
LUAD	cis	rs5769707	0.681	rs135879	ENSG00000188511.11	C22orf34	8.24	1.67e-15	1.77e-12	0.44	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49625003	chr22:49414524~49657542:-
LUAD	cis	rs5769707	0.642	rs135880	ENSG00000188511.11	C22orf34	8.24	1.67e-15	1.77e-12	0.44	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49625006	chr22:49414524~49657542:-
LUAD	cis	rs9807989	0.507	rs2293224	ENSG00000234389.1	AC007278.3	8.24	1.67e-15	1.77e-12	0.32	0.35	Asthma;	chr2:102419319	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs6743516	ENSG00000234389.1	AC007278.3	8.24	1.67e-15	1.77e-12	0.32	0.35	Asthma;	chr2:102419875	chr2:102438713~102440475:+
LUAD	cis	rs4988958	0.565	rs1420100	ENSG00000234389.1	AC007278.3	8.24	1.67e-15	1.77e-12	0.32	0.35	Asthma (childhood onset);	chr2:102420542	chr2:102438713~102440475:+
LUAD	cis	rs4988958	0.527	rs3771155	ENSG00000234389.1	AC007278.3	8.24	1.67e-15	1.77e-12	0.32	0.35	Asthma (childhood onset);	chr2:102421366	chr2:102438713~102440475:+
LUAD	cis	rs673078	0.607	rs61943393	ENSG00000275759.1	RP11-131L12.3	-8.24	1.67e-15	1.78e-12	-0.51	-0.35	Glucose homeostasis traits;	chr12:118383650	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs73205576	ENSG00000275759.1	RP11-131L12.3	-8.24	1.67e-15	1.78e-12	-0.51	-0.35	Glucose homeostasis traits;	chr12:118384268	chr12:118428281~118428870:+
LUAD	cis	rs11098499	0.588	rs6534149	ENSG00000245958.5	RP11-33B1.1	8.24	1.68e-15	1.78e-12	0.3	0.35	Corneal astigmatism;	chr4:119638137	chr4:119454791~119552025:+
LUAD	cis	rs11846409	0.86	rs17112419	ENSG00000274576.2	IGHV2-70	-8.24	1.68e-15	1.78e-12	-0.36	-0.35	Rheumatic heart disease;	chr14:106633260	chr14:106770577~106771020:-
LUAD	cis	rs526231	0.543	rs34766	ENSG00000175749.11	EIF3KP1	8.24	1.69e-15	1.79e-12	0.5	0.35	Primary biliary cholangitis;	chr5:103175219	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.892	rs66505956	ENSG00000175749.11	EIF3KP1	8.24	1.69e-15	1.79e-12	0.48	0.35	Parkinson's disease;	chr5:102943853	chr5:103032376~103033031:+
LUAD	cis	rs3823536	0.583	rs10279821	ENSG00000275106.1	RP11-309L24.10	-8.24	1.69e-15	1.8e-12	-0.44	-0.35	Sjögren's syndrome;	chr7:129043493	chr7:128952527~128953316:-
LUAD	cis	rs2729354	0.729	rs2258835	ENSG00000265566.2	RN7SL605P	-8.24	1.7e-15	1.8e-12	-0.52	-0.35	Blood protein levels;	chr11:57476115	chr11:57528085~57528365:-
LUAD	cis	rs11098499	0.562	rs58583086	ENSG00000245958.5	RP11-33B1.1	8.24	1.7e-15	1.81e-12	0.3	0.35	Corneal astigmatism;	chr4:119635207	chr4:119454791~119552025:+
LUAD	cis	rs9322193	0.884	rs9688858	ENSG00000223701.3	RAET1E-AS1	8.23	1.71e-15	1.81e-12	0.41	0.35	Lung cancer;	chr6:149637911	chr6:149884431~149919508:+
LUAD	cis	rs11096990	0.634	rs2086752	ENSG00000249207.1	RP11-360F5.1	8.23	1.71e-15	1.81e-12	0.39	0.35	Cognitive function;	chr4:39280486	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.594	rs2381373	ENSG00000249207.1	RP11-360F5.1	8.23	1.71e-15	1.81e-12	0.39	0.35	Cognitive function;	chr4:39280683	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.6	rs6835337	ENSG00000249207.1	RP11-360F5.1	8.23	1.71e-15	1.81e-12	0.39	0.35	Cognitive function;	chr4:39281189	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.634	rs6531704	ENSG00000249207.1	RP11-360F5.1	8.23	1.71e-15	1.81e-12	0.39	0.35	Cognitive function;	chr4:39282126	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.634	rs7654501	ENSG00000249207.1	RP11-360F5.1	8.23	1.71e-15	1.81e-12	0.39	0.35	Cognitive function;	chr4:39282364	chr4:39112677~39126818:-
LUAD	cis	rs2581828	0.646	rs9878875	ENSG00000242142.1	SERBP1P3	-8.23	1.72e-15	1.82e-12	-0.39	-0.35	Crohn's disease;	chr3:53122851	chr3:53064283~53065091:-
LUAD	cis	rs673078	0.607	rs7967900	ENSG00000275759.1	RP11-131L12.3	8.23	1.72e-15	1.82e-12	0.49	0.35	Glucose homeostasis traits;	chr12:118381902	chr12:118428281~118428870:+
LUAD	cis	rs1322639	0.614	rs9689800	ENSG00000261039.2	RP11-417E7.2	8.23	1.72e-15	1.82e-12	0.44	0.35	Pulse pressure;	chr6:169172850	chr6:169175304~169182740:-
LUAD	cis	rs5769707	0.592	rs6009783	ENSG00000188511.11	C22orf34	8.23	1.72e-15	1.82e-12	0.43	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49617353	chr22:49414524~49657542:-
LUAD	cis	rs10875746	0.537	rs4760625	ENSG00000240399.1	RP1-228P16.1	-8.23	1.73e-15	1.83e-12	-0.43	-0.35	Longevity (90 years and older);	chr12:48279960	chr12:48054813~48055591:-
LUAD	cis	rs17023223	0.508	rs12096448	ENSG00000231365.4	RP11-418J17.1	-8.23	1.73e-15	1.83e-12	-0.46	-0.35	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119140767	chr1:119140396~119275973:+
LUAD	cis	rs9322193	0.962	rs9322206	ENSG00000223701.3	RAET1E-AS1	8.23	1.73e-15	1.84e-12	0.41	0.35	Lung cancer;	chr6:149641481	chr6:149884431~149919508:+
LUAD	cis	rs150992	0.886	rs161948	ENSG00000248489.1	CTD-2007H13.3	8.23	1.73e-15	1.84e-12	0.39	0.35	Body mass index;	chr5:98932333	chr5:98929171~98995013:+
LUAD	cis	rs10463554	0.889	rs34822	ENSG00000175749.11	EIF3KP1	8.23	1.74e-15	1.84e-12	0.48	0.35	Parkinson's disease;	chr5:103102007	chr5:103032376~103033031:+
LUAD	cis	rs673078	0.607	rs17513013	ENSG00000275759.1	RP11-131L12.3	-8.23	1.74e-15	1.84e-12	-0.49	-0.35	Glucose homeostasis traits;	chr12:118442070	chr12:118428281~118428870:+
LUAD	cis	rs10875746	0.669	rs17122812	ENSG00000240399.1	RP1-228P16.1	-8.23	1.74e-15	1.85e-12	-0.43	-0.35	Longevity (90 years and older);	chr12:48203270	chr12:48054813~48055591:-
LUAD	cis	rs673078	0.607	rs111607725	ENSG00000275759.1	RP11-131L12.3	-8.23	1.75e-15	1.85e-12	-0.49	-0.35	Glucose homeostasis traits;	chr12:118442957	chr12:118428281~118428870:+
LUAD	cis	rs1891275	0.54	rs10732773	ENSG00000228701.1	TNKS2-AS1	-8.23	1.75e-15	1.85e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91656468	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.551	rs2421624	ENSG00000228701.1	TNKS2-AS1	-8.23	1.75e-15	1.85e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91656659	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.551	rs2421625	ENSG00000228701.1	TNKS2-AS1	-8.23	1.75e-15	1.85e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91656744	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.576	rs7900117	ENSG00000228701.1	TNKS2-AS1	-8.23	1.75e-15	1.85e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91657530	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.551	rs4933213	ENSG00000228701.1	TNKS2-AS1	-8.23	1.75e-15	1.85e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91657947	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.506	rs4933214	ENSG00000228701.1	TNKS2-AS1	-8.23	1.75e-15	1.85e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91658004	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.515	rs7358148	ENSG00000228701.1	TNKS2-AS1	-8.23	1.75e-15	1.85e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91658775	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.551	rs7908547	ENSG00000228701.1	TNKS2-AS1	-8.23	1.75e-15	1.85e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91659230	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.515	rs7908980	ENSG00000228701.1	TNKS2-AS1	-8.23	1.75e-15	1.85e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91659545	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.551	rs4933690	ENSG00000228701.1	TNKS2-AS1	-8.23	1.75e-15	1.85e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91659810	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.576	rs4933216	ENSG00000228701.1	TNKS2-AS1	-8.23	1.75e-15	1.85e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91659825	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.551	rs4933691	ENSG00000228701.1	TNKS2-AS1	-8.23	1.75e-15	1.85e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91660200	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.551	rs2421626	ENSG00000228701.1	TNKS2-AS1	-8.23	1.75e-15	1.85e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91661177	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.551	rs2421627	ENSG00000228701.1	TNKS2-AS1	-8.23	1.75e-15	1.85e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91662226	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.551	rs2421628	ENSG00000228701.1	TNKS2-AS1	-8.23	1.75e-15	1.85e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91662412	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.515	rs10881945	ENSG00000228701.1	TNKS2-AS1	-8.23	1.75e-15	1.85e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91663826	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.551	rs2421629	ENSG00000228701.1	TNKS2-AS1	-8.23	1.75e-15	1.85e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91664018	chr10:91782839~91798291:-
LUAD	cis	rs526231	0.543	rs3776863	ENSG00000175749.11	EIF3KP1	8.23	1.76e-15	1.86e-12	0.49	0.35	Primary biliary cholangitis;	chr5:102992165	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.543	rs17154913	ENSG00000175749.11	EIF3KP1	8.23	1.76e-15	1.86e-12	0.49	0.35	Primary biliary cholangitis;	chr5:102992786	chr5:103032376~103033031:+
LUAD	cis	rs673078	0.607	rs2393418	ENSG00000275759.1	RP11-131L12.3	-8.23	1.76e-15	1.86e-12	-0.48	-0.35	Glucose homeostasis traits;	chr12:118445995	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.562	rs56347775	ENSG00000275759.1	RP11-131L12.3	-8.23	1.77e-15	1.87e-12	-0.49	-0.35	Glucose homeostasis traits;	chr12:118438002	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs2393416	ENSG00000275759.1	RP11-131L12.3	-8.23	1.77e-15	1.87e-12	-0.49	-0.35	Glucose homeostasis traits;	chr12:118439968	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.56	rs4406856	ENSG00000275759.1	RP11-131L12.3	-8.23	1.77e-15	1.87e-12	-0.49	-0.35	Glucose homeostasis traits;	chr12:118440094	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs4457791	ENSG00000275759.1	RP11-131L12.3	-8.23	1.77e-15	1.87e-12	-0.49	-0.35	Glucose homeostasis traits;	chr12:118440144	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs61943456	ENSG00000275759.1	RP11-131L12.3	-8.23	1.77e-15	1.87e-12	-0.49	-0.35	Glucose homeostasis traits;	chr12:118440326	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs17513006	ENSG00000275759.1	RP11-131L12.3	-8.23	1.77e-15	1.87e-12	-0.49	-0.35	Glucose homeostasis traits;	chr12:118440383	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.56	rs61943457	ENSG00000275759.1	RP11-131L12.3	-8.23	1.77e-15	1.87e-12	-0.49	-0.35	Glucose homeostasis traits;	chr12:118440487	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.562	rs55883417	ENSG00000275759.1	RP11-131L12.3	-8.23	1.77e-15	1.87e-12	-0.49	-0.35	Glucose homeostasis traits;	chr12:118440801	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs55842338	ENSG00000275759.1	RP11-131L12.3	-8.23	1.77e-15	1.87e-12	-0.49	-0.35	Glucose homeostasis traits;	chr12:118441259	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.518	rs17441251	ENSG00000275759.1	RP11-131L12.3	-8.23	1.77e-15	1.87e-12	-0.49	-0.35	Glucose homeostasis traits;	chr12:118441361	chr12:118428281~118428870:+
LUAD	cis	rs11098499	0.615	rs59867181	ENSG00000245958.5	RP11-33B1.1	8.23	1.77e-15	1.87e-12	0.3	0.35	Corneal astigmatism;	chr4:119635312	chr4:119454791~119552025:+
LUAD	cis	rs367615	0.506	rs1428932	ENSG00000249476.1	CTD-2587M2.1	-8.23	1.79e-15	1.89e-12	-0.4	-0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109456778	chr5:109237120~109326369:-
LUAD	cis	rs673078	0.607	rs61944671	ENSG00000275759.1	RP11-131L12.3	-8.23	1.81e-15	1.91e-12	-0.49	-0.35	Glucose homeostasis traits;	chr12:118450046	chr12:118428281~118428870:+
LUAD	cis	rs526231	0.575	rs26822	ENSG00000175749.11	EIF3KP1	8.23	1.82e-15	1.92e-12	0.51	0.35	Primary biliary cholangitis;	chr5:103183094	chr5:103032376~103033031:+
LUAD	cis	rs944289	0.774	rs7147401	ENSG00000257826.1	RP11-116N8.4	-8.23	1.83e-15	1.94e-12	-0.37	-0.35	Thyroid cancer;	chr14:36089461	chr14:36061026~36067190:-
LUAD	cis	rs1891275	0.551	rs7088831	ENSG00000228701.1	TNKS2-AS1	-8.23	1.84e-15	1.94e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91652695	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.576	rs2000178	ENSG00000228701.1	TNKS2-AS1	-8.23	1.84e-15	1.94e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91653287	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.551	rs2027486	ENSG00000228701.1	TNKS2-AS1	-8.23	1.84e-15	1.94e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91654229	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.551	rs2421623	ENSG00000228701.1	TNKS2-AS1	-8.23	1.84e-15	1.94e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91654700	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.551	rs10881941	ENSG00000228701.1	TNKS2-AS1	-8.23	1.84e-15	1.94e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91655154	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.576	rs10881942	ENSG00000228701.1	TNKS2-AS1	-8.23	1.84e-15	1.94e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91655263	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.516	rs10881943	ENSG00000228701.1	TNKS2-AS1	-8.23	1.84e-15	1.94e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91655373	chr10:91782839~91798291:-
LUAD	cis	rs10463554	1	rs11949145	ENSG00000175749.11	EIF3KP1	8.23	1.84e-15	1.94e-12	0.48	0.35	Parkinson's disease;	chr5:102994552	chr5:103032376~103033031:+
LUAD	cis	rs732716	0.813	rs760369	ENSG00000267769.1	CTB-50L17.9	8.22	1.84e-15	1.94e-12	0.38	0.35	Mean corpuscular volume;	chr19:4449290	chr19:4454014~4455286:+
LUAD	cis	rs8005677	0.828	rs12437151	ENSG00000279656.1	RP11-298I3.6	8.22	1.85e-15	1.95e-12	0.42	0.35	Cognitive ability (multi-trait analysis);	chr14:22903704	chr14:23023083~23024217:-
LUAD	cis	rs2581828	0.646	rs9867023	ENSG00000242142.1	SERBP1P3	8.22	1.86e-15	1.96e-12	0.39	0.35	Crohn's disease;	chr3:53126116	chr3:53064283~53065091:-
LUAD	cis	rs17608059	0.545	rs736261	ENSG00000141028.6	CDRT15P1	-8.22	1.87e-15	1.98e-12	-0.39	-0.35	Temperament;	chr17:14033087	chr17:14024514~14025488:+
LUAD	cis	rs2929278	0.588	rs688009	ENSG00000249839.1	AC011330.5	-8.22	1.89e-15	1.99e-12	-0.46	-0.35	Schizophrenia;	chr15:43864104	chr15:43663654~43684339:-
LUAD	cis	rs17023223	0.581	rs11811859	ENSG00000231365.4	RP11-418J17.1	-8.22	1.89e-15	1.99e-12	-0.46	-0.35	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119165057	chr1:119140396~119275973:+
LUAD	cis	rs10463554	1	rs12656131	ENSG00000175749.11	EIF3KP1	-8.22	1.9e-15	2e-12	-0.49	-0.35	Parkinson's disease;	chr5:102990174	chr5:103032376~103033031:+
LUAD	cis	rs944289	0.774	rs12589124	ENSG00000257826.1	RP11-116N8.4	-8.22	1.91e-15	2.01e-12	-0.37	-0.35	Thyroid cancer;	chr14:36094718	chr14:36061026~36067190:-
LUAD	cis	rs944289	0.74	rs2183451	ENSG00000257826.1	RP11-116N8.4	-8.22	1.91e-15	2.01e-12	-0.37	-0.35	Thyroid cancer;	chr14:36095227	chr14:36061026~36067190:-
LUAD	cis	rs944289	0.774	rs884090	ENSG00000257826.1	RP11-116N8.4	-8.22	1.91e-15	2.01e-12	-0.37	-0.35	Thyroid cancer;	chr14:36095741	chr14:36061026~36067190:-
LUAD	cis	rs1075265	0.584	rs11896781	ENSG00000233266.1	HMGB1P31	8.22	1.92e-15	2.02e-12	0.46	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54096987	chr2:54051334~54051760:+
LUAD	cis	rs12134133	1	rs1782468	ENSG00000274245.1	RP11-357P18.2	8.22	1.93e-15	2.04e-12	0.45	0.35	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207297070	chr1:207372559~207373252:+
LUAD	cis	rs5769707	0.616	rs135869	ENSG00000188511.11	C22orf34	8.22	1.96e-15	2.06e-12	0.46	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49614718	chr22:49414524~49657542:-
LUAD	cis	rs11096990	0.634	rs6852967	ENSG00000249207.1	RP11-360F5.1	8.22	1.97e-15	2.07e-12	0.39	0.35	Cognitive function;	chr4:39281526	chr4:39112677~39126818:-
LUAD	cis	rs321358	0.895	rs17536059	ENSG00000271584.1	RP11-89C3.4	-8.22	1.98e-15	2.08e-12	-0.55	-0.35	Body mass index;	chr11:111086611	chr11:111091932~111097357:-
LUAD	cis	rs904251	0.62	rs883372	ENSG00000279942.1	RP1-153P14.7	-8.21	1.98e-15	2.08e-12	-0.39	-0.35	Cognitive performance;	chr6:37509829	chr6:37567716~37571460:+
LUAD	cis	rs10463554	1	rs3776864	ENSG00000175749.11	EIF3KP1	8.21	2e-15	2.1e-12	0.49	0.35	Parkinson's disease;	chr5:102992164	chr5:103032376~103033031:+
LUAD	cis	rs11096990	0.593	rs35552004	ENSG00000249207.1	RP11-360F5.1	-8.21	2e-15	2.1e-12	-0.39	-0.35	Cognitive function;	chr4:39170914	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.552	rs7655170	ENSG00000249207.1	RP11-360F5.1	-8.21	2e-15	2.1e-12	-0.39	-0.35	Cognitive function;	chr4:39171984	chr4:39112677~39126818:-
LUAD	cis	rs950169	0.887	rs12903946	ENSG00000225151.9	GOLGA2P7	-8.21	2.01e-15	2.12e-12	-0.49	-0.35	Schizophrenia;	chr15:84399732	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.887	rs62029593	ENSG00000225151.9	GOLGA2P7	-8.21	2.01e-15	2.12e-12	-0.49	-0.35	Schizophrenia;	chr15:84400482	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.81	rs62029594	ENSG00000225151.9	GOLGA2P7	-8.21	2.01e-15	2.12e-12	-0.49	-0.35	Schizophrenia;	chr15:84400554	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.881	rs62029596	ENSG00000225151.9	GOLGA2P7	-8.21	2.01e-15	2.12e-12	-0.49	-0.35	Schizophrenia;	chr15:84400736	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.881	rs4081123	ENSG00000225151.9	GOLGA2P7	-8.21	2.01e-15	2.12e-12	-0.49	-0.35	Schizophrenia;	chr15:84401537	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.881	rs62029599	ENSG00000225151.9	GOLGA2P7	-8.21	2.01e-15	2.12e-12	-0.49	-0.35	Schizophrenia;	chr15:84401867	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.8	rs4099846	ENSG00000225151.9	GOLGA2P7	-8.21	2.01e-15	2.12e-12	-0.49	-0.35	Schizophrenia;	chr15:84402196	chr15:84199311~84230136:-
LUAD	cis	rs9287719	0.901	rs55861579	ENSG00000234818.1	AC092687.5	8.21	2.02e-15	2.13e-12	0.42	0.35	Prostate cancer;	chr2:10623214	chr2:10589166~10604830:+
LUAD	cis	rs1150668	0.745	rs213238	ENSG00000216901.1	AL022393.7	8.21	2.03e-15	2.14e-12	0.4	0.35	Pubertal anthropometrics;	chr6:28354216	chr6:28176188~28176674:+
LUAD	cis	rs7688540	0.623	rs11735968	ENSG00000275426.1	CH17-262A2.1	8.21	2.03e-15	2.14e-12	0.51	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245031	chr4:149738~150317:+
LUAD	cis	rs7688540	0.771	rs7686546	ENSG00000275426.1	CH17-262A2.1	8.21	2.03e-15	2.14e-12	0.51	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:246825	chr4:149738~150317:+
LUAD	cis	rs2108622	1	rs62107762	ENSG00000267453.5	AC004791.2	-8.21	2.05e-15	2.16e-12	-0.46	-0.35	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871728	chr19:15851993~15864904:-
LUAD	cis	rs7688540	0.771	rs7665727	ENSG00000275426.1	CH17-262A2.1	8.21	2.05e-15	2.16e-12	0.5	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:283268	chr4:149738~150317:+
LUAD	cis	rs150992	0.673	rs330419	ENSG00000248489.1	CTD-2007H13.3	-8.21	2.06e-15	2.16e-12	-0.38	-0.35	Body mass index;	chr5:98857460	chr5:98929171~98995013:+
LUAD	cis	rs17608059	0.901	rs11078215	ENSG00000141028.6	CDRT15P1	-8.21	2.06e-15	2.16e-12	-0.39	-0.35	Temperament;	chr17:14003617	chr17:14024514~14025488:+
LUAD	cis	rs8005677	0.828	rs712486	ENSG00000279656.1	RP11-298I3.6	8.21	2.06e-15	2.17e-12	0.42	0.35	Cognitive ability (multi-trait analysis);	chr14:22955832	chr14:23023083~23024217:-
LUAD	cis	rs55894132	1	rs55894132	ENSG00000279656.1	RP11-298I3.6	8.21	2.06e-15	2.17e-12	0.42	0.35	Intelligence (multi-trait analysis);	chr14:22939628	chr14:23023083~23024217:-
LUAD	cis	rs11846409	0.932	rs2015469	ENSG00000274576.2	IGHV2-70	-8.21	2.07e-15	2.17e-12	-0.36	-0.35	Rheumatic heart disease;	chr14:106631857	chr14:106770577~106771020:-
LUAD	cis	rs11846409	0.932	rs56167903	ENSG00000274576.2	IGHV2-70	-8.21	2.07e-15	2.17e-12	-0.36	-0.35	Rheumatic heart disease;	chr14:106632070	chr14:106770577~106771020:-
LUAD	cis	rs10129255	0.913	rs28861466	ENSG00000223648.3	IGHV3-64	8.21	2.07e-15	2.18e-12	0.35	0.35	Kawasaki disease;	chr14:106718572	chr14:106643132~106658258:-
LUAD	cis	rs75045569	1	rs75045569	ENSG00000229153.4	EPHA1-AS1	8.21	2.07e-15	2.18e-12	0.6	0.35	Alzheimer's disease in APOE e4- carriers;	chr7:143412115	chr7:143407813~143523449:+
LUAD	cis	rs1891275	0.527	rs35812291	ENSG00000228701.1	TNKS2-AS1	-8.21	2.09e-15	2.19e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91642584	chr10:91782839~91798291:-
LUAD	cis	rs526231	0.543	rs152123	ENSG00000175749.11	EIF3KP1	-8.21	2.1e-15	2.21e-12	-0.53	-0.35	Primary biliary cholangitis;	chr5:103196218	chr5:103032376~103033031:+
LUAD	cis	rs2581828	0.609	rs73088342	ENSG00000242142.1	SERBP1P3	-8.21	2.11e-15	2.21e-12	-0.39	-0.35	Crohn's disease;	chr3:53117648	chr3:53064283~53065091:-
LUAD	cis	rs11676348	0.846	rs11677534	ENSG00000261338.2	RP11-378A13.1	-8.21	2.11e-15	2.21e-12	-0.36	-0.35	Ulcerative colitis;	chr2:218142337	chr2:218255319~218257366:+
LUAD	cis	rs9287719	0.781	rs12472807	ENSG00000234818.1	AC092687.5	8.2	2.13e-15	2.24e-12	0.42	0.35	Prostate cancer;	chr2:10641479	chr2:10589166~10604830:+
LUAD	cis	rs148406912	1	rs148406912	ENSG00000254851.1	RP11-109L13.1	8.2	2.14e-15	2.24e-12	0.66	0.35	Lobe attachment (rater-scored or self-reported);	chr11:116967001	chr11:117135528~117138582:+
LUAD	cis	rs10129255	0.957	rs8009948	ENSG00000211970.3	IGHV4-61	-8.2	2.15e-15	2.25e-12	-0.28	-0.35	Kawasaki disease;	chr14:106805607	chr14:106639119~106639657:-
LUAD	cis	rs1075265	0.527	rs959285	ENSG00000233266.1	HMGB1P31	8.2	2.17e-15	2.28e-12	0.46	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54078964	chr2:54051334~54051760:+
LUAD	cis	rs11690935	0.788	rs6715929	ENSG00000228389.1	AC068039.4	8.2	2.18e-15	2.28e-12	0.39	0.35	Schizophrenia;	chr2:172012600	chr2:171773482~171775844:+
LUAD	cis	rs673078	0.66	rs17619932	ENSG00000275759.1	RP11-131L12.3	-8.2	2.18e-15	2.28e-12	-0.46	-0.35	Glucose homeostasis traits;	chr12:118352228	chr12:118428281~118428870:+
LUAD	cis	rs11846409	0.86	rs10150951	ENSG00000274576.2	IGHV2-70	-8.2	2.2e-15	2.31e-12	-0.36	-0.35	Rheumatic heart disease;	chr14:106632988	chr14:106770577~106771020:-
LUAD	cis	rs11846409	0.932	rs2583329	ENSG00000274576.2	IGHV2-70	8.2	2.2e-15	2.31e-12	0.36	0.35	Rheumatic heart disease;	chr14:106632971	chr14:106770577~106771020:-
LUAD	cis	rs2739330	0.732	rs5760175	ENSG00000206090.4	AP000350.7	8.2	2.2e-15	2.31e-12	0.41	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23939998~23942798:+
LUAD	cis	rs11096990	0.656	rs2123028	ENSG00000249207.1	RP11-360F5.1	8.2	2.22e-15	2.32e-12	0.38	0.35	Cognitive function;	chr4:39301859	chr4:39112677~39126818:-
LUAD	cis	rs526231	0.543	rs27698	ENSG00000175749.11	EIF3KP1	-8.2	2.22e-15	2.32e-12	-0.49	-0.35	Primary biliary cholangitis;	chr5:103190474	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.963	rs40093	ENSG00000175749.11	EIF3KP1	8.2	2.23e-15	2.33e-12	0.48	0.35	Parkinson's disease;	chr5:103104121	chr5:103032376~103033031:+
LUAD	cis	rs7688540	0.609	rs77700883	ENSG00000275426.1	CH17-262A2.1	8.2	2.25e-15	2.35e-12	0.51	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238743	chr4:149738~150317:+
LUAD	cis	rs7688540	0.609	rs78896226	ENSG00000275426.1	CH17-262A2.1	8.2	2.25e-15	2.35e-12	0.51	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238744	chr4:149738~150317:+
LUAD	cis	rs8059260	0.604	rs9302458	ENSG00000274038.1	RP11-66H6.4	-8.2	2.27e-15	2.37e-12	-0.6	-0.35	Alcohol consumption over the past year;	chr16:11050352	chr16:11056556~11057034:+
LUAD	cis	rs950169	0.763	rs35372971	ENSG00000225151.9	GOLGA2P7	-8.2	2.27e-15	2.38e-12	-0.49	-0.35	Schizophrenia;	chr15:84387097	chr15:84199311~84230136:-
LUAD	cis	rs11098499	0.562	rs2389879	ENSG00000245958.5	RP11-33B1.1	8.2	2.28e-15	2.38e-12	0.3	0.35	Corneal astigmatism;	chr4:119636529	chr4:119454791~119552025:+
LUAD	cis	rs3823536	0.583	rs10156169	ENSG00000275106.1	RP11-309L24.10	-8.2	2.28e-15	2.38e-12	-0.44	-0.35	Sjögren's syndrome;	chr7:129044517	chr7:128952527~128953316:-
LUAD	cis	rs2337406	0.641	rs10133227	ENSG00000274576.2	IGHV2-70	8.19	2.3e-15	2.4e-12	0.38	0.35	Alzheimer's disease (late onset);	chr14:106814260	chr14:106770577~106771020:-
LUAD	cis	rs526231	0.575	rs66730942	ENSG00000175749.11	EIF3KP1	8.19	2.31e-15	2.41e-12	0.5	0.35	Primary biliary cholangitis;	chr5:102971075	chr5:103032376~103033031:+
LUAD	cis	rs6991838	0.584	rs7836349	ENSG00000272010.1	CTD-3025N20.3	-8.19	2.31e-15	2.42e-12	-0.38	-0.35	Intelligence (multi-trait analysis);	chr8:65591328	chr8:65591850~65592472:-
LUAD	cis	rs1891275	0.551	rs7087959	ENSG00000228701.1	TNKS2-AS1	-8.19	2.32e-15	2.42e-12	-0.47	-0.35	Intelligence (multi-trait analysis);	chr10:91656160	chr10:91782839~91798291:-
LUAD	cis	rs11096990	0.613	rs35391082	ENSG00000249207.1	RP11-360F5.1	-8.19	2.32e-15	2.43e-12	-0.38	-0.35	Cognitive function;	chr4:39191033	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.613	rs4974990	ENSG00000249207.1	RP11-360F5.1	-8.19	2.32e-15	2.43e-12	-0.38	-0.35	Cognitive function;	chr4:39191645	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.613	rs6840578	ENSG00000249207.1	RP11-360F5.1	-8.19	2.32e-15	2.43e-12	-0.38	-0.35	Cognitive function;	chr4:39206996	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.613	rs7690414	ENSG00000249207.1	RP11-360F5.1	-8.19	2.32e-15	2.43e-12	-0.38	-0.35	Cognitive function;	chr4:39210669	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.593	rs7685619	ENSG00000249207.1	RP11-360F5.1	-8.19	2.32e-15	2.43e-12	-0.38	-0.35	Cognitive function;	chr4:39211779	chr4:39112677~39126818:-
LUAD	cis	rs1891275	0.551	rs2000177	ENSG00000228701.1	TNKS2-AS1	-8.19	2.33e-15	2.43e-12	-0.47	-0.35	Intelligence (multi-trait analysis);	chr10:91653237	chr10:91782839~91798291:-
LUAD	cis	rs2919917	0.915	rs2953477	ENSG00000254352.1	RP11-578O24.2	8.19	2.33e-15	2.44e-12	0.43	0.35	Lymphocyte counts;	chr8:78712370	chr8:78723796~78724136:-
LUAD	cis	rs950169	0.84	rs62029595	ENSG00000225151.9	GOLGA2P7	-8.19	2.33e-15	2.44e-12	-0.49	-0.35	Schizophrenia;	chr15:84400603	chr15:84199311~84230136:-
LUAD	cis	rs13423976	0.631	rs4566347	ENSG00000231367.4	AC016995.3	8.19	2.33e-15	2.44e-12	0.45	0.35	Gut microbiome composition (summer);	chr2:38515498	chr2:38406719~38515740:-
LUAD	cis	rs950880	0.71	rs17027060	ENSG00000234389.1	AC007278.3	-8.19	2.35e-15	2.46e-12	-0.35	-0.35	Serum protein levels (sST2);	chr2:102391107	chr2:102438713~102440475:+
LUAD	cis	rs950880	0.71	rs66919607	ENSG00000234389.1	AC007278.3	-8.19	2.35e-15	2.46e-12	-0.35	-0.35	Serum protein levels (sST2);	chr2:102392509	chr2:102438713~102440475:+
LUAD	cis	rs4853012	0.838	rs72911122	ENSG00000257800.1	FNBP1P1	8.19	2.36e-15	2.46e-12	0.43	0.35	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74120680~74123218:+
LUAD	cis	rs9322193	0.607	rs4869755	ENSG00000216906.2	RP11-350J20.9	8.19	2.36e-15	2.46e-12	0.52	0.35	Lung cancer;	chr6:149886347	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.639	rs4869756	ENSG00000216906.2	RP11-350J20.9	8.19	2.36e-15	2.46e-12	0.52	0.35	Lung cancer;	chr6:149886360	chr6:149904243~149906418:+
LUAD	cis	rs7429990	0.965	rs796566	ENSG00000229759.1	MRPS18AP1	8.19	2.36e-15	2.46e-12	0.36	0.35	Educational attainment (years of education);	chr3:47896864	chr3:48256350~48256938:-
LUAD	cis	rs11155671	0.53	rs7742993	ENSG00000223701.3	RAET1E-AS1	8.19	2.37e-15	2.47e-12	0.41	0.35	Testicular germ cell tumor;	chr6:149883959	chr6:149884431~149919508:+
LUAD	cis	rs638893	0.636	rs6421569	ENSG00000278376.1	RP11-158I9.8	-8.19	2.37e-15	2.47e-12	-0.53	-0.35	Vitiligo;	chr11:118785066	chr11:118791254~118793137:+
LUAD	cis	rs638893	0.578	rs1790188	ENSG00000278376.1	RP11-158I9.8	-8.19	2.37e-15	2.47e-12	-0.53	-0.35	Vitiligo;	chr11:118790346	chr11:118791254~118793137:+
LUAD	cis	rs2337406	1	rs11845269	ENSG00000254174.1	IGHV1-12	8.19	2.38e-15	2.48e-12	0.32	0.35	Alzheimer's disease (late onset);	chr14:106683851	chr14:106122420~106122709:-
LUAD	cis	rs10463554	0.892	rs6871715	ENSG00000175749.11	EIF3KP1	8.19	2.38e-15	2.48e-12	0.48	0.35	Parkinson's disease;	chr5:102930398	chr5:103032376~103033031:+
LUAD	cis	rs71403859	0.803	rs8063455	ENSG00000260886.1	TAT-AS1	8.19	2.39e-15	2.48e-12	0.58	0.35	Post bronchodilator FEV1;	chr16:71566074	chr16:71565789~71578187:+
LUAD	cis	rs10463554	1	rs12659870	ENSG00000175749.11	EIF3KP1	8.19	2.39e-15	2.49e-12	0.48	0.35	Parkinson's disease;	chr5:103000867	chr5:103032376~103033031:+
LUAD	cis	rs9807989	0.507	rs3755266	ENSG00000234389.1	AC007278.3	8.19	2.4e-15	2.49e-12	0.32	0.35	Asthma;	chr2:102426252	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs2110659	ENSG00000234389.1	AC007278.3	8.19	2.4e-15	2.49e-12	0.32	0.35	Asthma;	chr2:102427407	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs7605284	ENSG00000234389.1	AC007278.3	8.19	2.4e-15	2.49e-12	0.32	0.35	Asthma;	chr2:102427715	chr2:102438713~102440475:+
LUAD	cis	rs4988958	0.584	rs12712149	ENSG00000234389.1	AC007278.3	8.19	2.4e-15	2.49e-12	0.32	0.35	Asthma (childhood onset);	chr2:102428733	chr2:102438713~102440475:+
LUAD	cis	rs4988958	0.584	rs7559845	ENSG00000234389.1	AC007278.3	8.19	2.4e-15	2.49e-12	0.32	0.35	Asthma (childhood onset);	chr2:102429754	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs6755905	ENSG00000234389.1	AC007278.3	8.19	2.4e-15	2.49e-12	0.32	0.35	Asthma;	chr2:102431747	chr2:102438713~102440475:+
LUAD	cis	rs4988958	0.527	rs6756161	ENSG00000234389.1	AC007278.3	8.19	2.4e-15	2.49e-12	0.32	0.35	Asthma (childhood onset);	chr2:102431957	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs6726985	ENSG00000234389.1	AC007278.3	8.19	2.4e-15	2.49e-12	0.32	0.35	Asthma;	chr2:102432120	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs2310300	ENSG00000234389.1	AC007278.3	8.19	2.4e-15	2.49e-12	0.32	0.35	Asthma;	chr2:102432614	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.507	rs7581119	ENSG00000234389.1	AC007278.3	8.19	2.4e-15	2.49e-12	0.32	0.35	Asthma;	chr2:102433405	chr2:102438713~102440475:+
LUAD	cis	rs950169	0.887	rs220333	ENSG00000225151.9	GOLGA2P7	-8.19	2.41e-15	2.51e-12	-0.49	-0.35	Schizophrenia;	chr15:84547902	chr15:84199311~84230136:-
LUAD	cis	rs7429990	0.965	rs2631721	ENSG00000229759.1	MRPS18AP1	8.19	2.41e-15	2.51e-12	0.36	0.35	Educational attainment (years of education);	chr3:47881807	chr3:48256350~48256938:-
LUAD	cis	rs9399137	0.507	rs4896118	ENSG00000232876.1	CTA-212D2.2	8.19	2.42e-15	2.52e-12	0.4	0.35	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954927	chr6:135055033~135060550:+
LUAD	cis	rs465969	0.744	rs71562296	ENSG00000255389.1	C6orf3	-8.19	2.42e-15	2.52e-12	-0.7	-0.35	Psoriasis;	chr6:111521444	chr6:111599875~111602295:+
LUAD	cis	rs27432	0.608	rs2927619	ENSG00000248734.2	CTD-2260A17.1	8.19	2.43e-15	2.53e-12	0.37	0.35	Psoriasis vulgaris;	chr5:96847014	chr5:96784777~96785999:+
LUAD	cis	rs9322193	0.923	rs57938011	ENSG00000223701.3	RAET1E-AS1	8.19	2.43e-15	2.53e-12	0.42	0.35	Lung cancer;	chr6:149642969	chr6:149884431~149919508:+
LUAD	cis	rs950880	0.71	rs55742125	ENSG00000234389.1	AC007278.3	-8.19	2.44e-15	2.54e-12	-0.35	-0.35	Serum protein levels (sST2);	chr2:102403322	chr2:102438713~102440475:+
LUAD	cis	rs4853012	0.838	rs72915068	ENSG00000257800.1	FNBP1P1	8.19	2.45e-15	2.54e-12	0.45	0.35	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74120680~74123218:+
LUAD	cis	rs150992	0.673	rs692832	ENSG00000248489.1	CTD-2007H13.3	8.19	2.45e-15	2.55e-12	0.38	0.35	Body mass index;	chr5:98856761	chr5:98929171~98995013:+
LUAD	cis	rs35955747	0.533	rs5998004	ENSG00000236132.1	CTA-440B3.1	8.18	2.47e-15	2.57e-12	0.4	0.35	Neutrophil count;Sum basophil neutrophil counts;	chr22:31485843	chr22:31816379~31817491:-
LUAD	cis	rs9487094	0.689	rs7754650	ENSG00000260273.1	RP11-425D10.10	8.18	2.48e-15	2.57e-12	0.43	0.35	Height;	chr6:109405536	chr6:109382795~109383666:+
LUAD	cis	rs10129255	1	rs8010605	ENSG00000211970.3	IGHV4-61	-8.18	2.48e-15	2.58e-12	-0.27	-0.35	Kawasaki disease;	chr14:106678742	chr14:106639119~106639657:-
LUAD	cis	rs62388641	0.547	rs4513844	ENSG00000272279.1	RP11-157J24.2	-8.18	2.49e-15	2.58e-12	-0.43	-0.35	Daytime sleep phenotypes;	chr6:1551747	chr6:1528364~1528911:-
LUAD	cis	rs11096990	0.634	rs10010352	ENSG00000249207.1	RP11-360F5.1	-8.18	2.49e-15	2.59e-12	-0.38	-0.35	Cognitive function;	chr4:39240657	chr4:39112677~39126818:-
LUAD	cis	rs11676348	0.818	rs6436033	ENSG00000261338.2	RP11-378A13.1	-8.18	2.53e-15	2.62e-12	-0.37	-0.35	Ulcerative colitis;	chr2:218119040	chr2:218255319~218257366:+
LUAD	cis	rs10463554	0.927	rs56361326	ENSG00000175749.11	EIF3KP1	8.18	2.53e-15	2.62e-12	0.47	0.35	Parkinson's disease;	chr5:103054184	chr5:103032376~103033031:+
LUAD	cis	rs11089937	0.626	rs4820337	ENSG00000211639.2	IGLV4-60	-8.18	2.54e-15	2.64e-12	-0.41	-0.35	Periodontitis (PAL4Q3);	chr22:22164374	chr22:22162199~22162681:+
LUAD	cis	rs6504622	0.721	rs11079748	ENSG00000262879.4	RP11-156P1.3	-8.18	2.55e-15	2.65e-12	-0.4	-0.35	Orofacial clefts;	chr17:47055097	chr17:46984045~47100323:-
LUAD	cis	rs9322193	0.607	rs6925151	ENSG00000216906.2	RP11-350J20.9	8.18	2.55e-15	2.65e-12	0.49	0.35	Lung cancer;	chr6:149889587	chr6:149904243~149906418:+
LUAD	cis	rs10129255	1	rs11627342	ENSG00000211972.2	IGHV3-66	8.18	2.57e-15	2.66e-12	0.31	0.35	Kawasaki disease;	chr14:106675823	chr14:106675017~106675544:-
LUAD	cis	rs6496044	0.507	rs8034676	ENSG00000202081.1	RNU6-1280P	8.18	2.57e-15	2.66e-12	0.4	0.35	Interstitial lung disease;	chr15:85616031	chr15:85651522~85651628:-
LUAD	cis	rs1891275	0.551	rs4933681	ENSG00000228701.1	TNKS2-AS1	-8.18	2.57e-15	2.67e-12	-0.47	-0.35	Intelligence (multi-trait analysis);	chr10:91643365	chr10:91782839~91798291:-
LUAD	cis	rs950169	0.881	rs34117475	ENSG00000225151.9	GOLGA2P7	-8.18	2.58e-15	2.68e-12	-0.48	-0.35	Schizophrenia;	chr15:84565212	chr15:84199311~84230136:-
LUAD	cis	rs526231	0.575	rs62362523	ENSG00000175749.11	EIF3KP1	8.18	2.59e-15	2.69e-12	0.5	0.35	Primary biliary cholangitis;	chr5:102977979	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.575	rs62362524	ENSG00000175749.11	EIF3KP1	8.18	2.59e-15	2.69e-12	0.5	0.35	Primary biliary cholangitis;	chr5:102978523	chr5:103032376~103033031:+
LUAD	cis	rs12134133	1	rs61822669	ENSG00000274245.1	RP11-357P18.2	8.18	2.6e-15	2.69e-12	0.46	0.35	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207247869	chr1:207372559~207373252:+
LUAD	cis	rs5769707	0.706	rs763128	ENSG00000188511.11	C22orf34	8.18	2.6e-15	2.69e-12	0.43	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49624397	chr22:49414524~49657542:-
LUAD	cis	rs17711722	0.565	rs73372653	ENSG00000164669.11	INTS4P1	-8.18	2.61e-15	2.7e-12	-0.42	-0.35	Calcium levels;	chr7:65977808	chr7:65141225~65234216:+
LUAD	cis	rs9807989	0.507	rs6710528	ENSG00000234389.1	AC007278.3	-8.18	2.61e-15	2.7e-12	-0.31	-0.35	Asthma;	chr2:102399682	chr2:102438713~102440475:+
LUAD	cis	rs1891275	0.601	rs7358034	ENSG00000228701.1	TNKS2-AS1	-8.18	2.63e-15	2.73e-12	-0.47	-0.35	Intelligence (multi-trait analysis);	chr10:91659007	chr10:91782839~91798291:-
LUAD	cis	rs12594515	0.967	rs11857628	ENSG00000273972.1	CTD-2306A12.1	-8.18	2.64e-15	2.74e-12	-0.37	-0.35	Weight;Waist circumference;	chr15:45706008	chr15:45702640~45703183:+
LUAD	cis	rs71403859	0.803	rs7203606	ENSG00000260886.1	TAT-AS1	8.17	2.65e-15	2.74e-12	0.58	0.35	Post bronchodilator FEV1;	chr16:71556608	chr16:71565789~71578187:+
LUAD	cis	rs944289	0.745	rs1537427	ENSG00000257826.1	RP11-116N8.4	8.17	2.66e-15	2.75e-12	0.37	0.35	Thyroid cancer;	chr14:36117640	chr14:36061026~36067190:-
LUAD	cis	rs4853012	0.941	rs60291089	ENSG00000257800.1	FNBP1P1	8.17	2.67e-15	2.76e-12	0.44	0.35	Gestational age at birth (maternal effect);	chr2:74117763	chr2:74120680~74123218:+
LUAD	cis	rs4853012	0.838	rs58759652	ENSG00000257800.1	FNBP1P1	8.17	2.67e-15	2.76e-12	0.44	0.35	Gestational age at birth (maternal effect);	chr2:74117775	chr2:74120680~74123218:+
LUAD	cis	rs944289	0.774	rs7150539	ENSG00000257826.1	RP11-116N8.4	-8.17	2.67e-15	2.76e-12	-0.37	-0.35	Thyroid cancer;	chr14:36086408	chr14:36061026~36067190:-
LUAD	cis	rs12134133	1	rs2661357	ENSG00000274245.1	RP11-357P18.2	8.17	2.67e-15	2.76e-12	0.45	0.35	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310593	chr1:207372559~207373252:+
LUAD	cis	rs9807989	0.507	rs2287033	ENSG00000234389.1	AC007278.3	-8.17	2.69e-15	2.78e-12	-0.31	-0.35	Asthma;	chr2:102394777	chr2:102438713~102440475:+
LUAD	cis	rs10129255	0.957	rs10142918	ENSG00000211970.3	IGHV4-61	-8.17	2.71e-15	2.8e-12	-0.27	-0.35	Kawasaki disease;	chr14:106782206	chr14:106639119~106639657:-
LUAD	cis	rs9322193	1	rs9399693	ENSG00000223701.3	RAET1E-AS1	8.17	2.71e-15	2.8e-12	0.41	0.35	Lung cancer;	chr6:149612718	chr6:149884431~149919508:+
LUAD	cis	rs1185460	0.565	rs10892325	ENSG00000271751.1	RP11-110I1.14	8.17	2.72e-15	2.8e-12	0.44	0.35	Coronary artery disease;	chr11:119041992	chr11:119065263~119065677:-
LUAD	cis	rs465969	0.744	rs6939657	ENSG00000255389.1	C6orf3	-8.17	2.73e-15	2.81e-12	-0.7	-0.35	Psoriasis;	chr6:111521822	chr6:111599875~111602295:+
LUAD	cis	rs11676348	0.846	rs6723449	ENSG00000261338.2	RP11-378A13.1	8.17	2.75e-15	2.83e-12	0.37	0.35	Ulcerative colitis;	chr2:218132857	chr2:218255319~218257366:+
LUAD	cis	rs9322193	0.81	rs62439811	ENSG00000223701.3	RAET1E-AS1	8.17	2.76e-15	2.84e-12	0.42	0.35	Lung cancer;	chr6:149640416	chr6:149884431~149919508:+
LUAD	cis	rs6496044	0.507	rs62022863	ENSG00000202081.1	RNU6-1280P	-8.17	2.76e-15	2.85e-12	-0.4	-0.35	Interstitial lung disease;	chr15:85618822	chr15:85651522~85651628:-
LUAD	cis	rs526231	0.543	rs246900	ENSG00000175749.11	EIF3KP1	8.17	2.77e-15	2.85e-12	0.5	0.35	Primary biliary cholangitis;	chr5:103198928	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.927	rs11952361	ENSG00000175749.11	EIF3KP1	8.17	2.78e-15	2.86e-12	0.48	0.35	Parkinson's disease;	chr5:102952216	chr5:103032376~103033031:+
LUAD	cis	rs5769707	0.632	rs135877	ENSG00000188511.11	C22orf34	8.17	2.78e-15	2.86e-12	0.44	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49620354	chr22:49414524~49657542:-
LUAD	cis	rs950169	0.922	rs11635505	ENSG00000225151.9	GOLGA2P7	8.17	2.78e-15	2.87e-12	0.48	0.35	Schizophrenia;	chr15:84553803	chr15:84199311~84230136:-
LUAD	cis	rs673078	0.607	rs7958551	ENSG00000275759.1	RP11-131L12.3	-8.17	2.8e-15	2.88e-12	-0.48	-0.35	Glucose homeostasis traits;	chr12:118442585	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs7958652	ENSG00000275759.1	RP11-131L12.3	-8.17	2.8e-15	2.88e-12	-0.48	-0.35	Glucose homeostasis traits;	chr12:118442630	chr12:118428281~118428870:+
LUAD	cis	rs1322639	0.531	rs11751421	ENSG00000261039.2	RP11-417E7.2	8.17	2.82e-15	2.9e-12	0.43	0.35	Pulse pressure;	chr6:169174898	chr6:169175304~169182740:-
LUAD	cis	rs11123170	0.543	rs4849180	ENSG00000189223.12	PAX8-AS1	-8.17	2.82e-15	2.9e-12	-0.56	-0.35	Renal function-related traits (BUN);	chr2:113227609	chr2:113211522~113276581:+
LUAD	cis	rs11096990	0.634	rs12648793	ENSG00000249207.1	RP11-360F5.1	8.17	2.83e-15	2.91e-12	0.38	0.35	Cognitive function;	chr4:39284473	chr4:39112677~39126818:-
LUAD	cis	rs1150668	0.796	rs213236	ENSG00000204709.4	LINC01556	8.17	2.83e-15	2.91e-12	0.43	0.35	Pubertal anthropometrics;	chr6:28356620	chr6:28943877~28944537:+
LUAD	cis	rs56046484	0.913	rs17611290	ENSG00000259295.5	CSPG4P12	8.16	2.86e-15	2.94e-12	0.53	0.35	Testicular germ cell tumor;	chr15:85031188	chr15:85191438~85213905:+
LUAD	cis	rs56046484	0.913	rs12906544	ENSG00000259295.5	CSPG4P12	8.16	2.86e-15	2.94e-12	0.53	0.35	Testicular germ cell tumor;	chr15:85032832	chr15:85191438~85213905:+
LUAD	cis	rs56046484	0.871	rs34978449	ENSG00000259295.5	CSPG4P12	8.16	2.86e-15	2.94e-12	0.53	0.35	Testicular germ cell tumor;	chr15:85036917	chr15:85191438~85213905:+
LUAD	cis	rs950880	0.71	rs4851570	ENSG00000234389.1	AC007278.3	-8.16	2.87e-15	2.95e-12	-0.35	-0.35	Serum protein levels (sST2);	chr2:102389927	chr2:102438713~102440475:+
LUAD	cis	rs1075265	0.547	rs41385746	ENSG00000233266.1	HMGB1P31	-8.16	2.87e-15	2.95e-12	-0.45	-0.35	Chronotype;Morning vs. evening chronotype;	chr2:54077893	chr2:54051334~54051760:+
LUAD	cis	rs1167827	1	rs1167827	ENSG00000127957.15	PMS2P3	-8.16	2.91e-15	2.99e-12	-0.33	-0.35	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75502930~75528148:-
LUAD	cis	rs9322193	0.923	rs9688350	ENSG00000223701.3	RAET1E-AS1	8.16	2.92e-15	3e-12	0.41	0.35	Lung cancer;	chr6:149730977	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs9767652	ENSG00000223701.3	RAET1E-AS1	8.16	2.92e-15	3e-12	0.41	0.35	Lung cancer;	chr6:149734502	chr6:149884431~149919508:+
LUAD	cis	rs7688540	0.771	rs17164747	ENSG00000275426.1	CH17-262A2.1	8.16	2.93e-15	3.01e-12	0.5	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:266798	chr4:149738~150317:+
LUAD	cis	rs10463554	1	rs1593842	ENSG00000175749.11	EIF3KP1	8.16	2.94e-15	3.02e-12	0.48	0.35	Parkinson's disease;	chr5:102999018	chr5:103032376~103033031:+
LUAD	cis	rs9322193	0.923	rs9800686	ENSG00000223701.3	RAET1E-AS1	8.16	2.96e-15	3.04e-12	0.42	0.35	Lung cancer;	chr6:149634464	chr6:149884431~149919508:+
LUAD	cis	rs11089937	0.54	rs9622920	ENSG00000211639.2	IGLV4-60	-8.16	2.97e-15	3.04e-12	-0.4	-0.35	Periodontitis (PAL4Q3);	chr22:22133024	chr22:22162199~22162681:+
LUAD	cis	rs10875746	0.669	rs10467101	ENSG00000240399.1	RP1-228P16.1	-8.16	2.97e-15	3.05e-12	-0.42	-0.35	Longevity (90 years and older);	chr12:48213954	chr12:48054813~48055591:-
LUAD	cis	rs7188445	0.898	rs11644758	ENSG00000261390.4	RP11-345M22.2	-8.16	2.98e-15	3.06e-12	-0.46	-0.35	Urate levels;	chr16:79675094	chr16:79715232~79770563:-
LUAD	cis	rs5769707	0.656	rs135878	ENSG00000188511.11	C22orf34	8.16	2.98e-15	3.06e-12	0.46	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49620721	chr22:49414524~49657542:-
LUAD	cis	rs11676348	0.818	rs1126579	ENSG00000261338.2	RP11-378A13.1	-8.16	2.98e-15	3.06e-12	-0.37	-0.35	Ulcerative colitis;	chr2:218136011	chr2:218255319~218257366:+
LUAD	cis	rs11676348	0.846	rs4674260	ENSG00000261338.2	RP11-378A13.1	-8.16	2.98e-15	3.06e-12	-0.37	-0.35	Ulcerative colitis;	chr2:218137653	chr2:218255319~218257366:+
LUAD	cis	rs9660180	0.783	rs1107910	ENSG00000231050.1	RP1-140A9.1	8.16	3e-15	3.08e-12	0.38	0.35	Body mass index;	chr1:1760882	chr1:1891471~1892658:+
LUAD	cis	rs9322193	0.607	rs9322229	ENSG00000216906.2	RP11-350J20.9	8.16	3.01e-15	3.09e-12	0.49	0.35	Lung cancer;	chr6:149908949	chr6:149904243~149906418:+
LUAD	cis	rs10129255	0.957	rs8014696	ENSG00000211970.3	IGHV4-61	8.16	3.04e-15	3.12e-12	0.27	0.35	Kawasaki disease;	chr14:106769752	chr14:106639119~106639657:-
LUAD	cis	rs11096990	0.634	rs2839765	ENSG00000249207.1	RP11-360F5.1	8.16	3.05e-15	3.12e-12	0.38	0.35	Cognitive function;	chr4:39293933	chr4:39112677~39126818:-
LUAD	cis	rs1891275	0.551	rs4933692	ENSG00000228701.1	TNKS2-AS1	-8.16	3.06e-15	3.13e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91664876	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.551	rs7900863	ENSG00000228701.1	TNKS2-AS1	-8.16	3.06e-15	3.13e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91665737	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.588	rs6583782	ENSG00000228701.1	TNKS2-AS1	-8.16	3.06e-15	3.13e-12	-0.48	-0.35	Intelligence (multi-trait analysis);	chr10:91666022	chr10:91782839~91798291:-
LUAD	cis	rs673078	0.607	rs61943451	ENSG00000275759.1	RP11-131L12.3	-8.16	3.06e-15	3.13e-12	-0.48	-0.35	Glucose homeostasis traits;	chr12:118438929	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.518	rs61943452	ENSG00000275759.1	RP11-131L12.3	-8.16	3.06e-15	3.13e-12	-0.48	-0.35	Glucose homeostasis traits;	chr12:118438990	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs61943454	ENSG00000275759.1	RP11-131L12.3	-8.16	3.06e-15	3.13e-12	-0.48	-0.35	Glucose homeostasis traits;	chr12:118439140	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.517	rs61943455	ENSG00000275759.1	RP11-131L12.3	-8.16	3.06e-15	3.13e-12	-0.48	-0.35	Glucose homeostasis traits;	chr12:118439414	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs73207566	ENSG00000275759.1	RP11-131L12.3	-8.16	3.06e-15	3.13e-12	-0.48	-0.35	Glucose homeostasis traits;	chr12:118439471	chr12:118428281~118428870:+
LUAD	cis	rs9322193	0.923	rs35830138	ENSG00000223701.3	RAET1E-AS1	8.16	3.06e-15	3.13e-12	0.41	0.35	Lung cancer;	chr6:149668635	chr6:149884431~149919508:+
LUAD	cis	rs7201929	1	rs11644151	ENSG00000259982.1	CDC37P1	-8.16	3.06e-15	3.13e-12	-0.5	-0.35	QT interval;	chr16:28884339	chr16:28700294~28701540:-
LUAD	cis	rs9487094	0.666	rs13219952	ENSG00000260273.1	RP11-425D10.10	8.15	3.08e-15	3.15e-12	0.44	0.35	Height;	chr6:109391084	chr6:109382795~109383666:+
LUAD	cis	rs10875746	0.669	rs11168510	ENSG00000240399.1	RP1-228P16.1	-8.15	3.08e-15	3.15e-12	-0.42	-0.35	Longevity (90 years and older);	chr12:48291772	chr12:48054813~48055591:-
LUAD	cis	rs17023223	0.537	rs4508058	ENSG00000231365.4	RP11-418J17.1	-8.15	3.08e-15	3.16e-12	-0.46	-0.35	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119141627	chr1:119140396~119275973:+
LUAD	cis	rs7429990	0.965	rs62260764	ENSG00000229759.1	MRPS18AP1	8.15	3.1e-15	3.17e-12	0.42	0.35	Educational attainment (years of education);	chr3:47949010	chr3:48256350~48256938:-
LUAD	cis	rs8059260	0.604	rs12928945	ENSG00000274038.1	RP11-66H6.4	-8.15	3.11e-15	3.18e-12	-0.71	-0.35	Alcohol consumption over the past year;	chr16:11106309	chr16:11056556~11057034:+
LUAD	cis	rs5769707	0.681	rs4824068	ENSG00000188511.11	C22orf34	8.15	3.13e-15	3.2e-12	0.44	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49631153	chr22:49414524~49657542:-
LUAD	cis	rs10875746	0.669	rs2279464	ENSG00000240399.1	RP1-228P16.1	-8.15	3.15e-15	3.22e-12	-0.43	-0.35	Longevity (90 years and older);	chr12:48296626	chr12:48054813~48055591:-
LUAD	cis	rs9322193	0.884	rs11155675	ENSG00000223701.3	RAET1E-AS1	8.15	3.15e-15	3.22e-12	0.43	0.35	Lung cancer;	chr6:149742883	chr6:149884431~149919508:+
LUAD	cis	rs2337406	1	rs17113276	ENSG00000254174.1	IGHV1-12	-8.15	3.17e-15	3.24e-12	-0.31	-0.35	Alzheimer's disease (late onset);	chr14:106683485	chr14:106122420~106122709:-
LUAD	cis	rs9660180	0.875	rs4648727	ENSG00000231050.1	RP1-140A9.1	-8.15	3.17e-15	3.25e-12	-0.38	-0.35	Body mass index;	chr1:1844830	chr1:1891471~1892658:+
LUAD	cis	rs77204473	0.557	rs9971422	ENSG00000254851.1	RP11-109L13.1	8.15	3.19e-15	3.26e-12	0.65	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116966657	chr11:117135528~117138582:+
LUAD	cis	rs10129255	0.957	rs11847726	ENSG00000211970.3	IGHV4-61	-8.15	3.2e-15	3.27e-12	-0.27	-0.35	Kawasaki disease;	chr14:106779116	chr14:106639119~106639657:-
LUAD	cis	rs673078	0.607	rs4767671	ENSG00000275759.1	RP11-131L12.3	-8.15	3.23e-15	3.31e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118396038	chr12:118428281~118428870:+
LUAD	cis	rs9322193	0.923	rs11155677	ENSG00000223701.3	RAET1E-AS1	8.15	3.24e-15	3.31e-12	0.4	0.35	Lung cancer;	chr6:149756953	chr6:149884431~149919508:+
LUAD	cis	rs5769707	0.616	rs6009786	ENSG00000188511.11	C22orf34	8.15	3.24e-15	3.31e-12	0.43	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49621497	chr22:49414524~49657542:-
LUAD	cis	rs6504950	1	rs8078550	ENSG00000275710.1	RP11-257O5.4	8.15	3.25e-15	3.32e-12	0.44	0.35	Breast cancer;	chr17:54976018	chr17:54964474~54964679:+
LUAD	cis	rs950880	0.71	rs1135354	ENSG00000234389.1	AC007278.3	-8.15	3.25e-15	3.32e-12	-0.35	-0.35	Serum protein levels (sST2);	chr2:102397842	chr2:102438713~102440475:+
LUAD	cis	rs11096990	0.634	rs3733287	ENSG00000249207.1	RP11-360F5.1	-8.15	3.26e-15	3.33e-12	-0.38	-0.35	Cognitive function;	chr4:39215732	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.656	rs4580661	ENSG00000249207.1	RP11-360F5.1	8.15	3.27e-15	3.34e-12	0.38	0.35	Cognitive function;	chr4:39294730	chr4:39112677~39126818:-
LUAD	cis	rs9322193	0.923	rs9689723	ENSG00000223701.3	RAET1E-AS1	8.15	3.29e-15	3.36e-12	0.41	0.35	Lung cancer;	chr6:149655935	chr6:149884431~149919508:+
LUAD	cis	rs77204473	0.557	rs7111854	ENSG00000254851.1	RP11-109L13.1	8.15	3.29e-15	3.36e-12	0.66	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116906110	chr11:117135528~117138582:+
LUAD	cis	rs7182621	0.512	rs71403471	ENSG00000182397.13	DNM1P46	8.15	3.29e-15	3.36e-12	0.49	0.35	Colonoscopy-negative controls vs population controls;	chr15:99870656	chr15:99790156~99806927:-
LUAD	cis	rs10129255	0.719	rs7156660	ENSG00000280411.1	IGHV1-69-2	-8.14	3.33e-15	3.39e-12	-0.26	-0.35	Kawasaki disease;	chr14:106673171	chr14:106762092~106762588:-
LUAD	cis	rs950169	0.922	rs11631096	ENSG00000225151.9	GOLGA2P7	-8.14	3.33e-15	3.4e-12	-0.49	-0.35	Schizophrenia;	chr15:84557698	chr15:84199311~84230136:-
LUAD	cis	rs6504950	1	rs12940106	ENSG00000275710.1	RP11-257O5.4	8.14	3.34e-15	3.41e-12	0.47	0.35	Breast cancer;	chr17:54990322	chr17:54964474~54964679:+
LUAD	cis	rs10463554	0.927	rs55641526	ENSG00000175749.11	EIF3KP1	8.14	3.37e-15	3.43e-12	0.48	0.35	Parkinson's disease;	chr5:102915301	chr5:103032376~103033031:+
LUAD	cis	rs11089937	0.589	rs4239891	ENSG00000211639.2	IGLV4-60	8.14	3.38e-15	3.45e-12	0.39	0.35	Periodontitis (PAL4Q3);	chr22:22165674	chr22:22162199~22162681:+
LUAD	cis	rs526231	0.578	rs3776870	ENSG00000175749.11	EIF3KP1	8.14	3.38e-15	3.45e-12	0.49	0.35	Primary biliary cholangitis;	chr5:102959366	chr5:103032376~103033031:+
LUAD	cis	rs4718428	0.705	rs12698547	ENSG00000226824.5	RP4-756H11.3	-8.14	3.39e-15	3.46e-12	-0.47	-0.35	Corneal structure;	chr7:66813271	chr7:66654538~66669855:+
LUAD	cis	rs10463554	0.927	rs34798	ENSG00000175749.11	EIF3KP1	8.14	3.39e-15	3.46e-12	0.56	0.35	Parkinson's disease;	chr5:103090047	chr5:103032376~103033031:+
LUAD	cis	rs7688540	0.771	rs4582105	ENSG00000275426.1	CH17-262A2.1	8.14	3.4e-15	3.47e-12	0.51	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:252553	chr4:149738~150317:+
LUAD	cis	rs950169	0.922	rs2033284	ENSG00000225151.9	GOLGA2P7	-8.14	3.4e-15	3.47e-12	-0.49	-0.35	Schizophrenia;	chr15:84391575	chr15:84199311~84230136:-
LUAD	cis	rs1185460	0.565	rs657685	ENSG00000271751.1	RP11-110I1.14	8.14	3.42e-15	3.49e-12	0.44	0.35	Coronary artery disease;	chr11:119042272	chr11:119065263~119065677:-
LUAD	cis	rs1150668	0.699	rs2394049	ENSG00000204709.4	LINC01556	8.14	3.42e-15	3.49e-12	0.43	0.35	Pubertal anthropometrics;	chr6:28271903	chr6:28943877~28944537:+
LUAD	cis	rs56046484	0.871	rs62021230	ENSG00000259295.5	CSPG4P12	8.14	3.43e-15	3.49e-12	0.53	0.35	Testicular germ cell tumor;	chr15:85040721	chr15:85191438~85213905:+
LUAD	cis	rs11096990	0.634	rs6531706	ENSG00000249207.1	RP11-360F5.1	8.14	3.44e-15	3.51e-12	0.38	0.35	Cognitive function;	chr4:39294547	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.634	rs6815855	ENSG00000249207.1	RP11-360F5.1	8.14	3.44e-15	3.51e-12	0.38	0.35	Cognitive function;	chr4:39294926	chr4:39112677~39126818:-
LUAD	cis	rs10463554	0.892	rs11952337	ENSG00000175749.11	EIF3KP1	8.14	3.45e-15	3.52e-12	0.48	0.35	Parkinson's disease;	chr5:102928043	chr5:103032376~103033031:+
LUAD	cis	rs9487094	0.67	rs749517	ENSG00000260273.1	RP11-425D10.10	-8.14	3.45e-15	3.52e-12	-0.45	-0.35	Height;	chr6:109531713	chr6:109382795~109383666:+
LUAD	cis	rs10129255	0.957	rs10142859	ENSG00000211970.3	IGHV4-61	-8.14	3.46e-15	3.53e-12	-0.27	-0.35	Kawasaki disease;	chr14:106782238	chr14:106639119~106639657:-
LUAD	cis	rs17482078	0.959	rs10062964	ENSG00000248734.2	CTD-2260A17.1	8.14	3.47e-15	3.53e-12	0.43	0.35	Behcet's disease;Blood protein levels;	chr5:96803363	chr5:96784777~96785999:+
LUAD	cis	rs1891275	0.551	rs4933687	ENSG00000228701.1	TNKS2-AS1	-8.14	3.47e-15	3.53e-12	-0.47	-0.35	Intelligence (multi-trait analysis);	chr10:91650642	chr10:91782839~91798291:-
LUAD	cis	rs9322193	0.566	rs6912330	ENSG00000216906.2	RP11-350J20.9	-8.14	3.48e-15	3.54e-12	-0.51	-0.35	Lung cancer;	chr6:149908811	chr6:149904243~149906418:+
LUAD	cis	rs526231	0.575	rs10463990	ENSG00000175749.11	EIF3KP1	8.14	3.48e-15	3.55e-12	0.5	0.35	Primary biliary cholangitis;	chr5:102981714	chr5:103032376~103033031:+
LUAD	cis	rs2919917	1	rs13269243	ENSG00000254352.1	RP11-578O24.2	8.14	3.49e-15	3.55e-12	0.42	0.35	Lymphocyte counts;	chr8:78669501	chr8:78723796~78724136:-
LUAD	cis	rs5769707	0.568	rs2011097	ENSG00000188511.11	C22orf34	8.14	3.49e-15	3.55e-12	0.43	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49624421	chr22:49414524~49657542:-
LUAD	cis	rs1185460	0.547	rs667584	ENSG00000271751.1	RP11-110I1.14	8.14	3.5e-15	3.57e-12	0.44	0.35	Coronary artery disease;	chr11:119040834	chr11:119065263~119065677:-
LUAD	cis	rs9322193	0.923	rs3924871	ENSG00000223701.3	RAET1E-AS1	8.14	3.5e-15	3.57e-12	0.4	0.35	Lung cancer;	chr6:149662080	chr6:149884431~149919508:+
LUAD	cis	rs10129255	1	rs8010605	ENSG00000211972.2	IGHV3-66	8.14	3.51e-15	3.57e-12	0.3	0.35	Kawasaki disease;	chr14:106678742	chr14:106675017~106675544:-
LUAD	cis	rs5769707	0.609	rs2071890	ENSG00000188511.11	C22orf34	8.14	3.52e-15	3.58e-12	0.43	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49607643	chr22:49414524~49657542:-
LUAD	cis	rs11098499	0.532	rs4504231	ENSG00000245958.5	RP11-33B1.1	-8.14	3.52e-15	3.58e-12	-0.32	-0.35	Corneal astigmatism;	chr4:119665736	chr4:119454791~119552025:+
LUAD	cis	rs526231	0.578	rs6860588	ENSG00000175749.11	EIF3KP1	-8.14	3.53e-15	3.59e-12	-0.49	-0.35	Primary biliary cholangitis;	chr5:102944598	chr5:103032376~103033031:+
LUAD	cis	rs6991838	0.584	rs2175810	ENSG00000200714.1	Y_RNA	-8.13	3.55e-15	3.61e-12	-0.42	-0.35	Intelligence (multi-trait analysis);	chr8:65643583	chr8:65592731~65592820:+
LUAD	cis	rs319690	1	rs319690	ENSG00000229759.1	MRPS18AP1	8.13	3.55e-15	3.61e-12	0.36	0.35	Diastolic blood pressure;Systolic blood pressure;Blood pressure;	chr3:47885994	chr3:48256350~48256938:-
LUAD	cis	rs10875746	0.669	rs10875767	ENSG00000240399.1	RP1-228P16.1	-8.13	3.55e-15	3.61e-12	-0.42	-0.35	Longevity (90 years and older);	chr12:48205474	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.669	rs10875792	ENSG00000240399.1	RP1-228P16.1	-8.13	3.61e-15	3.67e-12	-0.42	-0.35	Longevity (90 years and older);	chr12:48303640	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.623	rs10875793	ENSG00000240399.1	RP1-228P16.1	-8.13	3.61e-15	3.67e-12	-0.42	-0.35	Longevity (90 years and older);	chr12:48303647	chr12:48054813~48055591:-
LUAD	cis	rs2919917	1	rs2953475	ENSG00000254352.1	RP11-578O24.2	-8.13	3.62e-15	3.68e-12	-0.42	-0.35	Lymphocyte counts;	chr8:78725903	chr8:78723796~78724136:-
LUAD	cis	rs10256972	0.621	rs2363285	ENSG00000229043.2	AC091729.9	-8.13	3.63e-15	3.68e-12	-0.36	-0.35	Endometriosis;Longevity;	chr7:1052008	chr7:1160374~1165267:+
LUAD	cis	rs11096990	0.593	rs7662880	ENSG00000249207.1	RP11-360F5.1	8.13	3.63e-15	3.69e-12	0.38	0.35	Cognitive function;	chr4:39283604	chr4:39112677~39126818:-
LUAD	cis	rs673078	0.607	rs7295288	ENSG00000275759.1	RP11-131L12.3	-8.13	3.64e-15	3.7e-12	-0.47	-0.35	Glucose homeostasis traits;	chr12:118418008	chr12:118428281~118428870:+
LUAD	cis	rs8059260	0.604	rs34573672	ENSG00000274038.1	RP11-66H6.4	-8.13	3.64e-15	3.7e-12	-0.7	-0.35	Alcohol consumption over the past year;	chr16:11111882	chr16:11056556~11057034:+
LUAD	cis	rs1075265	0.547	rs10865279	ENSG00000233266.1	HMGB1P31	8.13	3.65e-15	3.7e-12	0.46	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54097564	chr2:54051334~54051760:+
LUAD	cis	rs526231	0.511	rs10515341	ENSG00000175749.11	EIF3KP1	8.13	3.67e-15	3.73e-12	0.5	0.35	Primary biliary cholangitis;	chr5:102981413	chr5:103032376~103033031:+
LUAD	cis	rs2581828	0.646	rs3796351	ENSG00000242142.1	SERBP1P3	8.13	3.69e-15	3.75e-12	0.39	0.35	Crohn's disease;	chr3:53122049	chr3:53064283~53065091:-
LUAD	cis	rs7429990	0.965	rs319684	ENSG00000229759.1	MRPS18AP1	8.13	3.73e-15	3.78e-12	0.36	0.35	Educational attainment (years of education);	chr3:47890784	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.932	rs810334	ENSG00000229759.1	MRPS18AP1	8.13	3.73e-15	3.78e-12	0.36	0.35	Educational attainment (years of education);	chr3:47893813	chr3:48256350~48256938:-
LUAD	cis	rs673078	0.66	rs11068917	ENSG00000275759.1	RP11-131L12.3	-8.13	3.77e-15	3.82e-12	-0.46	-0.35	Glucose homeostasis traits;	chr12:118353315	chr12:118428281~118428870:+
LUAD	cis	rs7208859	0.725	rs9897673	ENSG00000263531.1	RP13-753N3.1	8.13	3.78e-15	3.83e-12	0.61	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916348	chr17:30863921~30864940:-
LUAD	cis	rs12134133	1	rs6658718	ENSG00000274245.1	RP11-357P18.2	8.13	3.79e-15	3.84e-12	0.43	0.35	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285561	chr1:207372559~207373252:+
LUAD	cis	rs12550612	0.561	rs11784599	ENSG00000253616.4	RP11-875O11.3	8.13	3.79e-15	3.84e-12	0.55	0.35	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23074609	chr8:23071377~23074488:-
LUAD	cis	rs10463554	0.963	rs257318	ENSG00000175749.11	EIF3KP1	8.13	3.79e-15	3.85e-12	0.47	0.35	Parkinson's disease;	chr5:103109766	chr5:103032376~103033031:+
LUAD	cis	rs71403859	0.803	rs17282500	ENSG00000260886.1	TAT-AS1	8.13	3.8e-15	3.85e-12	0.59	0.35	Post bronchodilator FEV1;	chr16:71599750	chr16:71565789~71578187:+
LUAD	cis	rs11089937	0.597	rs4145535	ENSG00000211639.2	IGLV4-60	8.12	3.81e-15	3.86e-12	0.42	0.35	Periodontitis (PAL4Q3);	chr22:22143981	chr22:22162199~22162681:+
LUAD	cis	rs12280210	0.557	rs11216225	ENSG00000254851.1	RP11-109L13.1	8.12	3.83e-15	3.88e-12	0.65	0.35	Lobe attachment (rater-scored or self-reported);	chr11:117007298	chr11:117135528~117138582:+
LUAD	cis	rs12280210	0.557	rs7112937	ENSG00000254851.1	RP11-109L13.1	8.12	3.83e-15	3.88e-12	0.65	0.35	Lobe attachment (rater-scored or self-reported);	chr11:117009740	chr11:117135528~117138582:+
LUAD	cis	rs6504950	1	rs9915183	ENSG00000275710.1	RP11-257O5.4	8.12	3.88e-15	3.93e-12	0.43	0.35	Breast cancer;	chr17:54969776	chr17:54964474~54964679:+
LUAD	cis	rs2929278	0.617	rs533143	ENSG00000249839.1	AC011330.5	-8.12	3.88e-15	3.93e-12	-0.45	-0.35	Schizophrenia;	chr15:43896656	chr15:43663654~43684339:-
LUAD	cis	rs10129255	0.957	rs12590735	ENSG00000211970.3	IGHV4-61	-8.12	3.89e-15	3.94e-12	-0.27	-0.35	Kawasaki disease;	chr14:106779660	chr14:106639119~106639657:-
LUAD	cis	rs526231	0.543	rs26820	ENSG00000175749.11	EIF3KP1	8.12	3.91e-15	3.96e-12	0.49	0.35	Primary biliary cholangitis;	chr5:103192391	chr5:103032376~103033031:+
LUAD	cis	rs11098499	0.532	rs4833624	ENSG00000245958.5	RP11-33B1.1	-8.12	3.91e-15	3.96e-12	-0.32	-0.35	Corneal astigmatism;	chr4:119664342	chr4:119454791~119552025:+
LUAD	cis	rs944289	0.774	rs12050449	ENSG00000257826.1	RP11-116N8.4	-8.12	3.92e-15	3.97e-12	-0.37	-0.35	Thyroid cancer;	chr14:36101949	chr14:36061026~36067190:-
LUAD	cis	rs10463554	0.963	rs26262	ENSG00000175749.11	EIF3KP1	8.12	3.93e-15	3.98e-12	0.48	0.35	Parkinson's disease;	chr5:103209462	chr5:103032376~103033031:+
LUAD	cis	rs5769707	0.609	rs2007024	ENSG00000188511.11	C22orf34	8.12	3.93e-15	3.98e-12	0.42	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49595167	chr22:49414524~49657542:-
LUAD	cis	rs10853057	0.717	rs62062479	ENSG00000214174.7	AMZ2P1	8.12	3.94e-15	3.98e-12	0.77	0.35	White matter microstructure (global fractional anisotropy);	chr17:65060017	chr17:64966550~64975576:-
LUAD	cis	rs2581828	0.646	rs6769931	ENSG00000242142.1	SERBP1P3	-8.12	3.95e-15	3.99e-12	-0.38	-0.35	Crohn's disease;	chr3:53126177	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.646	rs6809973	ENSG00000242142.1	SERBP1P3	-8.12	3.95e-15	3.99e-12	-0.38	-0.35	Crohn's disease;	chr3:53126200	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.608	rs6769944	ENSG00000242142.1	SERBP1P3	-8.12	3.95e-15	3.99e-12	-0.38	-0.35	Crohn's disease;	chr3:53126227	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.646	rs9858469	ENSG00000242142.1	SERBP1P3	-8.12	3.95e-15	3.99e-12	-0.38	-0.35	Crohn's disease;	chr3:53128390	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.646	rs9820324	ENSG00000242142.1	SERBP1P3	-8.12	3.95e-15	3.99e-12	-0.38	-0.35	Crohn's disease;	chr3:53128429	chr3:53064283~53065091:-
LUAD	cis	rs5769707	0.681	rs2071902	ENSG00000188511.11	C22orf34	8.12	3.96e-15	4e-12	0.44	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49640890	chr22:49414524~49657542:-
LUAD	cis	rs2581828	0.618	rs6792345	ENSG00000242142.1	SERBP1P3	-8.12	3.99e-15	4.03e-12	-0.4	-0.35	Crohn's disease;	chr3:53131178	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.618	rs6792363	ENSG00000242142.1	SERBP1P3	-8.12	3.99e-15	4.03e-12	-0.4	-0.35	Crohn's disease;	chr3:53131247	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.618	rs6445565	ENSG00000242142.1	SERBP1P3	-8.12	3.99e-15	4.03e-12	-0.4	-0.35	Crohn's disease;	chr3:53131448	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.591	rs6445566	ENSG00000242142.1	SERBP1P3	-8.12	3.99e-15	4.03e-12	-0.4	-0.35	Crohn's disease;	chr3:53131611	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.618	rs13319872	ENSG00000242142.1	SERBP1P3	-8.12	3.99e-15	4.03e-12	-0.4	-0.35	Crohn's disease;	chr3:53132082	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.618	rs6784207	ENSG00000242142.1	SERBP1P3	-8.12	3.99e-15	4.03e-12	-0.4	-0.35	Crohn's disease;	chr3:53133458	chr3:53064283~53065091:-
LUAD	cis	rs80285556	1	rs17605685	ENSG00000161643.11	SIGLEC16	8.12	3.99e-15	4.04e-12	0.8	0.35	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49983484	chr19:49969673~49975814:+
LUAD	cis	rs765787	0.53	rs11636410	ENSG00000259520.4	CTD-2651B20.3	-8.12	4e-15	4.04e-12	-0.45	-0.35	Uric acid levels;	chr15:45243715	chr15:45251580~45279251:-
LUAD	cis	rs5769707	0.554	rs10854876	ENSG00000188511.11	C22orf34	8.12	4e-15	4.04e-12	0.45	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49616922	chr22:49414524~49657542:-
LUAD	cis	rs5769707	0.605	rs6009791	ENSG00000188511.11	C22orf34	8.12	4.02e-15	4.07e-12	0.44	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49631617	chr22:49414524~49657542:-
LUAD	cis	rs5769707	0.667	rs4824069	ENSG00000188511.11	C22orf34	8.12	4.02e-15	4.07e-12	0.44	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49636677	chr22:49414524~49657542:-
LUAD	cis	rs9322193	0.923	rs9968911	ENSG00000223701.3	RAET1E-AS1	8.12	4.06e-15	4.1e-12	0.41	0.35	Lung cancer;	chr6:149657419	chr6:149884431~149919508:+
LUAD	cis	rs2739330	0.731	rs5751792	ENSG00000206090.4	AP000350.7	8.12	4.06e-15	4.11e-12	0.39	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23939998~23942798:+
LUAD	cis	rs7688540	0.723	rs80316648	ENSG00000275426.1	CH17-262A2.1	8.12	4.08e-15	4.12e-12	0.49	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238426	chr4:149738~150317:+
LUAD	cis	rs9322193	0.607	rs3798763	ENSG00000216906.2	RP11-350J20.9	8.11	4.11e-15	4.15e-12	0.52	0.35	Lung cancer;	chr6:149889964	chr6:149904243~149906418:+
LUAD	cis	rs9287719	0.967	rs6744599	ENSG00000234818.1	AC092687.5	-8.11	4.12e-15	4.16e-12	-0.41	-0.35	Prostate cancer;	chr2:10606887	chr2:10589166~10604830:+
LUAD	cis	rs7429990	1	rs1665982	ENSG00000229759.1	MRPS18AP1	-8.11	4.15e-15	4.19e-12	-0.4	-0.35	Educational attainment (years of education);	chr3:47863589	chr3:48256350~48256938:-
LUAD	cis	rs10463554	0.963	rs11955683	ENSG00000175749.11	EIF3KP1	8.11	4.16e-15	4.2e-12	0.48	0.35	Parkinson's disease;	chr5:102990992	chr5:103032376~103033031:+
LUAD	cis	rs9287719	0.934	rs6727884	ENSG00000234818.1	AC092687.5	-8.11	4.18e-15	4.22e-12	-0.41	-0.35	Prostate cancer;	chr2:10617431	chr2:10589166~10604830:+
LUAD	cis	rs950169	0.84	rs2896002	ENSG00000225151.9	GOLGA2P7	-8.11	4.21e-15	4.25e-12	-0.49	-0.35	Schizophrenia;	chr15:84390423	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.8	rs34302901	ENSG00000225151.9	GOLGA2P7	-8.11	4.23e-15	4.27e-12	-0.48	-0.35	Schizophrenia;	chr15:84567712	chr15:84199311~84230136:-
LUAD	cis	rs2581828	0.646	rs12630819	ENSG00000242142.1	SERBP1P3	-8.11	4.23e-15	4.27e-12	-0.38	-0.35	Crohn's disease;	chr3:53123286	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.618	rs9824325	ENSG00000242142.1	SERBP1P3	-8.11	4.29e-15	4.33e-12	-0.4	-0.35	Crohn's disease;	chr3:53132494	chr3:53064283~53065091:-
LUAD	cis	rs10129255	0.957	rs10132367	ENSG00000211972.2	IGHV3-66	8.11	4.31e-15	4.34e-12	0.3	0.35	Kawasaki disease;	chr14:106690981	chr14:106675017~106675544:-
LUAD	cis	rs10129255	1	rs9324091	ENSG00000211972.2	IGHV3-66	8.11	4.32e-15	4.35e-12	0.3	0.35	Kawasaki disease;	chr14:106676625	chr14:106675017~106675544:-
LUAD	cis	rs9322193	0.923	rs10782314	ENSG00000223701.3	RAET1E-AS1	8.11	4.34e-15	4.38e-12	0.41	0.35	Lung cancer;	chr6:149735527	chr6:149884431~149919508:+
LUAD	cis	rs80285556	1	rs79633979	ENSG00000161643.11	SIGLEC16	8.11	4.37e-15	4.4e-12	0.8	0.35	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49985355	chr19:49969673~49975814:+
LUAD	cis	rs9487094	0.689	rs9487069	ENSG00000260273.1	RP11-425D10.10	8.11	4.39e-15	4.42e-12	0.43	0.35	Height;	chr6:109358652	chr6:109382795~109383666:+
LUAD	cis	rs8040855	0.825	rs3964197	ENSG00000259295.5	CSPG4P12	8.11	4.4e-15	4.43e-12	0.43	0.35	Bulimia nervosa;	chr15:85178681	chr15:85191438~85213905:+
LUAD	cis	rs35955747	0.633	rs2006771	ENSG00000236132.1	CTA-440B3.1	8.1	4.4e-15	4.43e-12	0.39	0.35	Neutrophil count;Sum basophil neutrophil counts;	chr22:31602626	chr22:31816379~31817491:-
LUAD	cis	rs8062405	0.688	rs3924376	ENSG00000259982.1	CDC37P1	-8.1	4.41e-15	4.44e-12	-0.46	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28700294~28701540:-
LUAD	cis	rs950169	0.922	rs12910334	ENSG00000225151.9	GOLGA2P7	-8.1	4.42e-15	4.45e-12	-0.49	-0.35	Schizophrenia;	chr15:84403620	chr15:84199311~84230136:-
LUAD	cis	rs2919917	1	rs1384804	ENSG00000254352.1	RP11-578O24.2	8.1	4.44e-15	4.47e-12	0.41	0.35	Lymphocyte counts;	chr8:78659987	chr8:78723796~78724136:-
LUAD	cis	rs6504950	1	rs9895808	ENSG00000275710.1	RP11-257O5.4	8.1	4.46e-15	4.49e-12	0.43	0.35	Breast cancer;	chr17:54971081	chr17:54964474~54964679:+
LUAD	cis	rs1757171	0.534	rs2797793	ENSG00000204110.6	RP1-153P14.8	8.1	4.46e-15	4.49e-12	0.35	0.35	Cognitive performance;	chr6:37509486	chr6:37507348~37535616:+
LUAD	cis	rs11098499	0.532	rs12512646	ENSG00000245958.5	RP11-33B1.1	-8.1	4.48e-15	4.5e-12	-0.32	-0.35	Corneal astigmatism;	chr4:119664578	chr4:119454791~119552025:+
LUAD	cis	rs10875746	0.669	rs11168459	ENSG00000240399.1	RP1-228P16.1	-8.1	4.51e-15	4.54e-12	-0.42	-0.35	Longevity (90 years and older);	chr12:48202458	chr12:48054813~48055591:-
LUAD	cis	rs10129255	1	rs61997605	ENSG00000211972.2	IGHV3-66	8.1	4.57e-15	4.59e-12	0.3	0.35	Kawasaki disease;	chr14:106678368	chr14:106675017~106675544:-
LUAD	cis	rs10129255	1	rs8012033	ENSG00000211972.2	IGHV3-66	8.1	4.57e-15	4.59e-12	0.3	0.35	Kawasaki disease;	chr14:106678854	chr14:106675017~106675544:-
LUAD	cis	rs950169	0.84	rs4842854	ENSG00000225151.9	GOLGA2P7	-8.1	4.57e-15	4.59e-12	-0.49	-0.35	Schizophrenia;	chr15:84387641	chr15:84199311~84230136:-
LUAD	cis	rs944289	0.51	rs2780314	ENSG00000257826.1	RP11-116N8.4	-8.1	4.59e-15	4.62e-12	-0.36	-0.35	Thyroid cancer;	chr14:36059286	chr14:36061026~36067190:-
LUAD	cis	rs2581828	0.646	rs6783748	ENSG00000242142.1	SERBP1P3	-8.1	4.61e-15	4.63e-12	-0.38	-0.35	Crohn's disease;	chr3:53119415	chr3:53064283~53065091:-
LUAD	cis	rs7174755	0.637	rs10152713	ENSG00000260657.2	RP11-315D16.4	-8.1	4.61e-15	4.63e-12	-0.41	-0.35	Major depressive disorder;	chr15:68179553	chr15:68267792~68277994:-
LUAD	cis	rs2581828	0.539	rs114317830	ENSG00000242142.1	SERBP1P3	-8.1	4.66e-15	4.68e-12	-0.38	-0.35	Crohn's disease;	chr3:53126253	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.539	rs114670283	ENSG00000242142.1	SERBP1P3	-8.1	4.66e-15	4.68e-12	-0.38	-0.35	Crohn's disease;	chr3:53126254	chr3:53064283~53065091:-
LUAD	cis	rs673078	0.607	rs7312555	ENSG00000275759.1	RP11-131L12.3	-8.1	4.69e-15	4.71e-12	-0.5	-0.35	Glucose homeostasis traits;	chr12:118414120	chr12:118428281~118428870:+
LUAD	cis	rs8062405	0.655	rs7184597	ENSG00000259982.1	CDC37P1	-8.1	4.71e-15	4.73e-12	-0.46	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28700294~28701540:-
LUAD	cis	rs9545047	0.716	rs8001795	ENSG00000227676.3	LINC01068	8.1	4.72e-15	4.74e-12	0.43	0.35	Schizophrenia;	chr13:79421402	chr13:79566727~79571436:+
LUAD	cis	rs7188445	0.933	rs12449161	ENSG00000261390.4	RP11-345M22.2	-8.1	4.73e-15	4.75e-12	-0.45	-0.35	Urate levels;	chr16:79682409	chr16:79715232~79770563:-
LUAD	cis	rs35955747	0.633	rs5998002	ENSG00000236132.1	CTA-440B3.1	8.1	4.73e-15	4.75e-12	0.4	0.35	Neutrophil count;Sum basophil neutrophil counts;	chr22:31485183	chr22:31816379~31817491:-
LUAD	cis	rs5769707	0.632	rs135872	ENSG00000188511.11	C22orf34	8.09	4.73e-15	4.75e-12	0.43	0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49615652	chr22:49414524~49657542:-
LUAD	cis	rs9601248	0.838	rs2783130	ENSG00000227676.3	LINC01068	-8.09	4.73e-15	4.75e-12	-0.43	-0.35	Major depressive disorder;	chr13:79596025	chr13:79566727~79571436:+
LUAD	cis	rs1150668	0.83	rs2531831	ENSG00000216901.1	AL022393.7	8.09	4.73e-15	4.75e-12	0.39	0.35	Pubertal anthropometrics;	chr6:28420988	chr6:28176188~28176674:+
LUAD	cis	rs2337406	0.866	rs4280141	ENSG00000254174.1	IGHV1-12	-8.09	4.78e-15	4.79e-12	-0.3	-0.35	Alzheimer's disease (late onset);	chr14:106780476	chr14:106122420~106122709:-
LUAD	cis	rs7688540	0.771	rs77234191	ENSG00000275426.1	CH17-262A2.1	8.09	4.79e-15	4.8e-12	0.5	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:264505	chr4:149738~150317:+
LUAD	cis	rs950169	0.881	rs4842852	ENSG00000225151.9	GOLGA2P7	-8.09	4.8e-15	4.82e-12	-0.49	-0.35	Schizophrenia;	chr15:84387263	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.84	rs4842853	ENSG00000225151.9	GOLGA2P7	-8.09	4.8e-15	4.82e-12	-0.49	-0.35	Schizophrenia;	chr15:84387606	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.922	rs4842946	ENSG00000225151.9	GOLGA2P7	-8.09	4.8e-15	4.82e-12	-0.49	-0.35	Schizophrenia;	chr15:84387633	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.887	rs3860265	ENSG00000225151.9	GOLGA2P7	-8.09	4.8e-15	4.82e-12	-0.49	-0.35	Schizophrenia;	chr15:84390487	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.881	rs34591918	ENSG00000225151.9	GOLGA2P7	-8.09	4.83e-15	4.84e-12	-0.48	-0.35	Schizophrenia;	chr15:84396135	chr15:84199311~84230136:-
LUAD	cis	rs9322193	0.923	rs9800736	ENSG00000223701.3	RAET1E-AS1	8.09	4.84e-15	4.86e-12	0.4	0.35	Lung cancer;	chr6:149661281	chr6:149884431~149919508:+
LUAD	cis	rs8177876	0.731	rs76093926	ENSG00000261838.4	RP11-303E16.6	8.09	4.84e-15	4.86e-12	0.82	0.35	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078920	chr16:81069854~81076598:+
LUAD	cis	rs9287719	0.967	rs12467642	ENSG00000234818.1	AC092687.5	8.09	4.88e-15	4.89e-12	0.41	0.35	Prostate cancer;	chr2:10621358	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs12464908	ENSG00000234818.1	AC092687.5	8.09	4.88e-15	4.89e-12	0.41	0.35	Prostate cancer;	chr2:10621370	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs7563816	ENSG00000234818.1	AC092687.5	8.09	4.88e-15	4.89e-12	0.41	0.35	Prostate cancer;	chr2:10623274	chr2:10589166~10604830:+
LUAD	cis	rs2880765	0.566	rs17553249	ENSG00000259295.5	CSPG4P12	8.09	4.88e-15	4.89e-12	0.41	0.35	Coronary artery disease;	chr15:85463463	chr15:85191438~85213905:+
LUAD	cis	rs9287719	0.967	rs6721739	ENSG00000234818.1	AC092687.5	-8.09	4.88e-15	4.89e-12	-0.41	-0.35	Prostate cancer;	chr2:10611120	chr2:10589166~10604830:+
LUAD	cis	rs7188445	0.933	rs74637523	ENSG00000261390.4	RP11-345M22.2	-8.09	4.88e-15	4.89e-12	-0.45	-0.35	Urate levels;	chr16:79677400	chr16:79715232~79770563:-
LUAD	cis	rs150992	0.673	rs161953	ENSG00000248489.1	CTD-2007H13.3	8.09	4.9e-15	4.92e-12	0.37	0.35	Body mass index;	chr5:98921201	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.673	rs161952	ENSG00000248489.1	CTD-2007H13.3	8.09	4.9e-15	4.92e-12	0.37	0.35	Body mass index;	chr5:98921665	chr5:98929171~98995013:+
LUAD	cis	rs10853057	0.717	rs62062478	ENSG00000214174.7	AMZ2P1	8.09	4.95e-15	4.96e-12	0.75	0.35	White matter microstructure (global fractional anisotropy);	chr17:65059458	chr17:64966550~64975576:-
LUAD	cis	rs9545047	0.716	rs586219	ENSG00000227676.3	LINC01068	-8.09	5.01e-15	5.02e-12	-0.43	-0.35	Schizophrenia;	chr13:79425177	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.716	rs2265377	ENSG00000227676.3	LINC01068	-8.09	5.01e-15	5.02e-12	-0.43	-0.35	Schizophrenia;	chr13:79425485	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.716	rs2265378	ENSG00000227676.3	LINC01068	-8.09	5.01e-15	5.02e-12	-0.43	-0.35	Schizophrenia;	chr13:79425581	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.716	rs8002838	ENSG00000227676.3	LINC01068	8.09	5.01e-15	5.02e-12	0.43	0.35	Schizophrenia;	chr13:79421681	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.669	rs9545113	ENSG00000227676.3	LINC01068	8.09	5.01e-15	5.02e-12	0.43	0.35	Schizophrenia;	chr13:79422017	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.68	rs9545114	ENSG00000227676.3	LINC01068	8.09	5.01e-15	5.02e-12	0.43	0.35	Schizophrenia;	chr13:79423744	chr13:79566727~79571436:+
LUAD	cis	rs11676348	0.818	rs7426289	ENSG00000261338.2	RP11-378A13.1	-8.09	5.01e-15	5.02e-12	-0.37	-0.35	Ulcerative colitis;	chr2:218101592	chr2:218255319~218257366:+
LUAD	cis	rs10875746	0.729	rs1990028	ENSG00000240399.1	RP1-228P16.1	-8.09	5.01e-15	5.02e-12	-0.4	-0.35	Longevity (90 years and older);	chr12:48014230	chr12:48054813~48055591:-
LUAD	cis	rs9545047	0.604	rs9565483	ENSG00000227676.3	LINC01068	-8.09	5.04e-15	5.04e-12	-0.41	-0.35	Schizophrenia;	chr13:79294001	chr13:79566727~79571436:+
LUAD	cis	rs2739330	0.627	rs9608219	ENSG00000206090.4	AP000350.7	8.09	5.04e-15	5.05e-12	0.39	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23939998~23942798:+
LUAD	cis	rs9545047	0.625	rs7338170	ENSG00000227676.3	LINC01068	-8.09	5.05e-15	5.05e-12	-0.41	-0.35	Schizophrenia;	chr13:79286030	chr13:79566727~79571436:+
LUAD	cis	rs10875746	0.669	rs11168499	ENSG00000240399.1	RP1-228P16.1	-8.09	5.06e-15	5.07e-12	-0.42	-0.35	Longevity (90 years and older);	chr12:48268887	chr12:48054813~48055591:-
LUAD	cis	rs367615	0.704	rs6889301	ENSG00000249476.1	CTD-2587M2.1	8.09	5.07e-15	5.08e-12	0.4	0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109499480	chr5:109237120~109326369:-
LUAD	cis	rs367615	0.704	rs4286723	ENSG00000249476.1	CTD-2587M2.1	8.09	5.07e-15	5.08e-12	0.4	0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109500258	chr5:109237120~109326369:-
LUAD	cis	rs367615	0.661	rs9326775	ENSG00000249476.1	CTD-2587M2.1	8.09	5.07e-15	5.08e-12	0.4	0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109501224	chr5:109237120~109326369:-
LUAD	cis	rs9322193	0.923	rs9383812	ENSG00000223701.3	RAET1E-AS1	8.09	5.07e-15	5.08e-12	0.4	0.35	Lung cancer;	chr6:149712355	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.847	rs9383844	ENSG00000223701.3	RAET1E-AS1	8.09	5.07e-15	5.08e-12	0.4	0.35	Lung cancer;	chr6:149716268	chr6:149884431~149919508:+
LUAD	cis	rs10129255	0.957	rs8005468	ENSG00000211972.2	IGHV3-66	8.09	5.08e-15	5.08e-12	0.3	0.35	Kawasaki disease;	chr14:106686431	chr14:106675017~106675544:-
LUAD	cis	rs950880	0.71	rs17027071	ENSG00000234389.1	AC007278.3	-8.08	5.13e-15	5.13e-12	-0.35	-0.35	Serum protein levels (sST2);	chr2:102396214	chr2:102438713~102440475:+
LUAD	cis	rs9322193	0.884	rs1125	ENSG00000223701.3	RAET1E-AS1	8.08	5.16e-15	5.16e-12	0.43	0.35	Lung cancer;	chr6:149658280	chr6:149884431~149919508:+
LUAD	cis	rs11096990	0.656	rs2066786	ENSG00000249207.1	RP11-360F5.1	-8.08	5.17e-15	5.17e-12	-0.38	-0.35	Cognitive function;	chr4:39300409	chr4:39112677~39126818:-
LUAD	cis	rs1823913	0.927	rs35339956	ENSG00000227542.1	AC092614.2	8.08	5.19e-15	5.19e-12	0.46	0.35	Obesity-related traits;	chr2:191261668	chr2:191229165~191246172:-
LUAD	cis	rs56046484	0.956	rs2174218	ENSG00000259295.5	CSPG4P12	-8.08	5.2e-15	5.2e-12	-0.51	-0.35	Testicular germ cell tumor;	chr15:85081425	chr15:85191438~85213905:+
LUAD	cis	rs56046484	0.956	rs35045545	ENSG00000259295.5	CSPG4P12	8.08	5.22e-15	5.22e-12	0.52	0.35	Testicular germ cell tumor;	chr15:85121720	chr15:85191438~85213905:+
LUAD	cis	rs6504950	1	rs10468513	ENSG00000275710.1	RP11-257O5.4	8.08	5.23e-15	5.23e-12	0.44	0.35	Breast cancer;	chr17:54985542	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs1990674	ENSG00000275710.1	RP11-257O5.4	8.08	5.23e-15	5.23e-12	0.43	0.35	Breast cancer;	chr17:54983714	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs9897447	ENSG00000275710.1	RP11-257O5.4	8.08	5.24e-15	5.23e-12	0.44	0.35	Breast cancer;	chr17:54971108	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs9902687	ENSG00000275710.1	RP11-257O5.4	8.08	5.24e-15	5.23e-12	0.44	0.35	Breast cancer;	chr17:54971563	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs8080491	ENSG00000275710.1	RP11-257O5.4	8.08	5.24e-15	5.23e-12	0.44	0.35	Breast cancer;	chr17:54972508	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs6504948	ENSG00000275710.1	RP11-257O5.4	8.08	5.24e-15	5.23e-12	0.44	0.35	Breast cancer;	chr17:54972626	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs6504949	ENSG00000275710.1	RP11-257O5.4	8.08	5.24e-15	5.23e-12	0.44	0.35	Breast cancer;	chr17:54972772	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs9914732	ENSG00000275710.1	RP11-257O5.4	8.08	5.24e-15	5.23e-12	0.44	0.35	Breast cancer;	chr17:54977006	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs9916642	ENSG00000275710.1	RP11-257O5.4	8.08	5.24e-15	5.23e-12	0.44	0.35	Breast cancer;	chr17:54977136	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs9915832	ENSG00000275710.1	RP11-257O5.4	8.08	5.24e-15	5.23e-12	0.44	0.35	Breast cancer;	chr17:54977336	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs9893306	ENSG00000275710.1	RP11-257O5.4	8.08	5.24e-15	5.23e-12	0.44	0.35	Breast cancer;	chr17:54977388	chr17:54964474~54964679:+
LUAD	cis	rs950169	0.922	rs12915832	ENSG00000225151.9	GOLGA2P7	-8.08	5.25e-15	5.24e-12	-0.48	-0.35	Schizophrenia;	chr15:84568226	chr15:84199311~84230136:-
LUAD	cis	rs9322193	0.923	rs7767622	ENSG00000223701.3	RAET1E-AS1	8.08	5.27e-15	5.26e-12	0.4	0.35	Lung cancer;	chr6:149681766	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs4421206	ENSG00000223701.3	RAET1E-AS1	8.08	5.27e-15	5.26e-12	0.4	0.35	Lung cancer;	chr6:149682891	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs3798761	ENSG00000223701.3	RAET1E-AS1	8.08	5.27e-15	5.26e-12	0.4	0.35	Lung cancer;	chr6:149683643	chr6:149884431~149919508:+
LUAD	cis	rs496547	0.686	rs487728	ENSG00000278376.1	RP11-158I9.8	-8.08	5.27e-15	5.26e-12	-0.38	-0.35	Hip minimal joint space width;	chr11:118750785	chr11:118791254~118793137:+
LUAD	cis	rs10463554	0.963	rs40322	ENSG00000175749.11	EIF3KP1	8.08	5.29e-15	5.29e-12	0.47	0.35	Parkinson's disease;	chr5:103111253	chr5:103032376~103033031:+
LUAD	cis	rs7188445	0.933	rs12449109	ENSG00000261390.4	RP11-345M22.2	-8.08	5.3e-15	5.29e-12	-0.45	-0.35	Urate levels;	chr16:79682146	chr16:79715232~79770563:-
LUAD	cis	rs2919917	1	rs10093654	ENSG00000254352.1	RP11-578O24.2	8.08	5.32e-15	5.31e-12	0.41	0.35	Lymphocyte counts;	chr8:78660360	chr8:78723796~78724136:-
LUAD	cis	rs2919917	1	rs10093797	ENSG00000254352.1	RP11-578O24.2	8.08	5.32e-15	5.31e-12	0.41	0.35	Lymphocyte counts;	chr8:78660478	chr8:78723796~78724136:-
LUAD	cis	rs6504622	0.755	rs4074249	ENSG00000262879.4	RP11-156P1.3	-8.08	5.35e-15	5.35e-12	-0.39	-0.35	Orofacial clefts;	chr17:47072043	chr17:46984045~47100323:-
LUAD	cis	rs11846409	0.932	rs61233250	ENSG00000274576.2	IGHV2-70	-8.08	5.36e-15	5.35e-12	-0.36	-0.35	Rheumatic heart disease;	chr14:106634072	chr14:106770577~106771020:-
LUAD	cis	rs11089937	0.597	rs4821770	ENSG00000211639.2	IGLV4-60	8.08	5.38e-15	5.37e-12	0.41	0.35	Periodontitis (PAL4Q3);	chr22:22131281	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.568	rs4821771	ENSG00000211639.2	IGLV4-60	8.08	5.38e-15	5.37e-12	0.41	0.35	Periodontitis (PAL4Q3);	chr22:22131287	chr22:22162199~22162681:+
LUAD	cis	rs2919917	1	rs3736169	ENSG00000254352.1	RP11-578O24.2	8.08	5.42e-15	5.41e-12	0.42	0.35	Lymphocyte counts;	chr8:78675620	chr8:78723796~78724136:-
LUAD	cis	rs11123170	0.542	rs28522253	ENSG00000189223.12	PAX8-AS1	-8.08	5.43e-15	5.42e-12	-0.57	-0.35	Renal function-related traits (BUN);	chr2:113209810	chr2:113211522~113276581:+
LUAD	cis	rs465969	0.546	rs77990243	ENSG00000255389.1	C6orf3	-8.08	5.44e-15	5.43e-12	-0.68	-0.35	Psoriasis;	chr6:111513183	chr6:111599875~111602295:+
LUAD	cis	rs2919917	1	rs3808619	ENSG00000254352.1	RP11-578O24.2	8.08	5.45e-15	5.44e-12	0.42	0.35	Lymphocyte counts;	chr8:78665491	chr8:78723796~78724136:-
LUAD	cis	rs6496044	0.507	rs7175731	ENSG00000202081.1	RNU6-1280P	-8.08	5.46e-15	5.45e-12	-0.39	-0.35	Interstitial lung disease;	chr15:85611115	chr15:85651522~85651628:-
LUAD	cis	rs6496044	0.507	rs1471455	ENSG00000202081.1	RNU6-1280P	-8.08	5.46e-15	5.45e-12	-0.39	-0.35	Interstitial lung disease;	chr15:85611496	chr15:85651522~85651628:-
LUAD	cis	rs8059260	0.544	rs34846673	ENSG00000274038.1	RP11-66H6.4	-8.07	5.47e-15	5.46e-12	-0.7	-0.35	Alcohol consumption over the past year;	chr16:11102829	chr16:11056556~11057034:+
LUAD	cis	rs8059260	0.604	rs12929596	ENSG00000274038.1	RP11-66H6.4	-8.07	5.47e-15	5.46e-12	-0.7	-0.35	Alcohol consumption over the past year;	chr16:11105495	chr16:11056556~11057034:+
LUAD	cis	rs2919917	1	rs13280202	ENSG00000254352.1	RP11-578O24.2	-8.07	5.49e-15	5.47e-12	-0.42	-0.35	Lymphocyte counts;	chr8:78700238	chr8:78723796~78724136:-
LUAD	cis	rs9322193	0.923	rs55849538	ENSG00000223701.3	RAET1E-AS1	8.07	5.51e-15	5.49e-12	0.42	0.35	Lung cancer;	chr6:149635330	chr6:149884431~149919508:+
LUAD	cis	rs6700559	0.873	rs7526367	ENSG00000260088.1	RP11-92G12.3	-8.07	5.53e-15	5.51e-12	-0.45	-0.35	Coronary artery disease;	chr1:200688025	chr1:200669507~200694250:+
LUAD	cis	rs1150668	0.796	rs9468372	ENSG00000204709.4	LINC01556	8.07	5.54e-15	5.52e-12	0.42	0.35	Pubertal anthropometrics;	chr6:28411584	chr6:28943877~28944537:+
LUAD	cis	rs11089937	0.626	rs5757051	ENSG00000211639.2	IGLV4-60	-8.07	5.55e-15	5.53e-12	-0.4	-0.35	Periodontitis (PAL4Q3);	chr22:22141753	chr22:22162199~22162681:+
LUAD	cis	rs2581828	0.646	rs12638996	ENSG00000242142.1	SERBP1P3	-8.07	5.56e-15	5.54e-12	-0.38	-0.35	Crohn's disease;	chr3:53123530	chr3:53064283~53065091:-
LUAD	cis	rs904251	0.772	rs1224127	ENSG00000279942.1	RP1-153P14.7	-8.07	5.6e-15	5.58e-12	-0.36	-0.35	Cognitive performance;	chr6:37449780	chr6:37567716~37571460:+
LUAD	cis	rs4853012	0.838	rs12619982	ENSG00000257800.1	FNBP1P1	8.07	5.63e-15	5.61e-12	0.45	0.35	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74120680~74123218:+
LUAD	cis	rs10463554	0.856	rs26427	ENSG00000175749.11	EIF3KP1	-8.07	5.63e-15	5.61e-12	-0.46	-0.35	Parkinson's disease;	chr5:103031079	chr5:103032376~103033031:+
LUAD	cis	rs950169	0.881	rs150965	ENSG00000225151.9	GOLGA2P7	-8.07	5.64e-15	5.61e-12	-0.49	-0.35	Schizophrenia;	chr15:84537296	chr15:84199311~84230136:-
LUAD	cis	rs1150668	0.83	rs2859365	ENSG00000204709.4	LINC01556	-8.07	5.65e-15	5.63e-12	-0.42	-0.35	Pubertal anthropometrics;	chr6:28423688	chr6:28943877~28944537:+
LUAD	cis	rs6504950	1	rs9896044	ENSG00000275710.1	RP11-257O5.4	8.07	5.68e-15	5.65e-12	0.43	0.35	Breast cancer;	chr17:54971181	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs9894529	ENSG00000275710.1	RP11-257O5.4	8.07	5.68e-15	5.65e-12	0.43	0.35	Breast cancer;	chr17:54977885	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs56348638	ENSG00000275710.1	RP11-257O5.4	8.07	5.69e-15	5.66e-12	0.43	0.35	Breast cancer;	chr17:54987189	chr17:54964474~54964679:+
LUAD	cis	rs10463554	0.963	rs17154953	ENSG00000175749.11	EIF3KP1	8.07	5.69e-15	5.67e-12	0.47	0.35	Parkinson's disease;	chr5:103019557	chr5:103032376~103033031:+
LUAD	cis	rs10875746	0.551	rs12322347	ENSG00000240399.1	RP1-228P16.1	-8.07	5.69e-15	5.67e-12	-0.42	-0.35	Longevity (90 years and older);	chr12:48313915	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.551	rs12322348	ENSG00000240399.1	RP1-228P16.1	-8.07	5.69e-15	5.67e-12	-0.42	-0.35	Longevity (90 years and older);	chr12:48313916	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.551	rs1471998	ENSG00000240399.1	RP1-228P16.1	-8.07	5.69e-15	5.67e-12	-0.42	-0.35	Longevity (90 years and older);	chr12:48318219	chr12:48054813~48055591:-
LUAD	cis	rs10875746	0.669	rs61940962	ENSG00000240399.1	RP1-228P16.1	-8.07	5.7e-15	5.67e-12	-0.42	-0.35	Longevity (90 years and older);	chr12:48201694	chr12:48054813~48055591:-
LUAD	cis	rs10463554	1	rs3776862	ENSG00000175749.11	EIF3KP1	8.07	5.7e-15	5.68e-12	0.47	0.35	Parkinson's disease;	chr5:102996017	chr5:103032376~103033031:+
LUAD	cis	rs10129255	0.912	rs8011090	ENSG00000211972.2	IGHV3-66	8.07	5.72e-15	5.69e-12	0.3	0.35	Kawasaki disease;	chr14:106678896	chr14:106675017~106675544:-
LUAD	cis	rs56046484	0.912	rs12914674	ENSG00000259295.5	CSPG4P12	8.07	5.75e-15	5.72e-12	0.52	0.35	Testicular germ cell tumor;	chr15:85119829	chr15:85191438~85213905:+
LUAD	cis	rs56046484	0.956	rs34889576	ENSG00000259295.5	CSPG4P12	8.07	5.75e-15	5.72e-12	0.52	0.35	Testicular germ cell tumor;	chr15:85121445	chr15:85191438~85213905:+
LUAD	cis	rs56046484	0.956	rs34076898	ENSG00000259295.5	CSPG4P12	8.07	5.75e-15	5.72e-12	0.52	0.35	Testicular germ cell tumor;	chr15:85121569	chr15:85191438~85213905:+
LUAD	cis	rs56046484	0.956	rs35533990	ENSG00000259295.5	CSPG4P12	8.07	5.75e-15	5.72e-12	0.52	0.35	Testicular germ cell tumor;	chr15:85121590	chr15:85191438~85213905:+
LUAD	cis	rs7188445	0.933	rs11644082	ENSG00000261390.4	RP11-345M22.2	-8.07	5.76e-15	5.73e-12	-0.45	-0.35	Urate levels;	chr16:79680519	chr16:79715232~79770563:-
LUAD	cis	rs17608059	0.545	rs9944522	ENSG00000141028.6	CDRT15P1	-8.07	5.78e-15	5.75e-12	-0.39	-0.35	Temperament;	chr17:14015466	chr17:14024514~14025488:+
LUAD	cis	rs10463554	1	rs10463554	ENSG00000175749.11	EIF3KP1	8.07	5.79e-15	5.76e-12	0.47	0.35	Parkinson's disease;	chr5:102983270	chr5:103032376~103033031:+
LUAD	cis	rs2188561	0.806	rs2712210	ENSG00000241764.3	AC002467.7	8.07	5.79e-15	5.76e-12	0.46	0.35	Alcohol consumption;	chr7:107687407	chr7:107742817~107744581:-
LUAD	cis	rs465969	1	rs13208890	ENSG00000255389.1	C6orf3	-8.07	5.82e-15	5.79e-12	-0.68	-0.35	Psoriasis;	chr6:111500620	chr6:111599875~111602295:+
LUAD	cis	rs465969	0.744	rs36007392	ENSG00000255389.1	C6orf3	-8.07	5.82e-15	5.79e-12	-0.68	-0.35	Psoriasis;	chr6:111509287	chr6:111599875~111602295:+
LUAD	cis	rs465969	1	rs13197107	ENSG00000255389.1	C6orf3	-8.07	5.82e-15	5.79e-12	-0.68	-0.35	Psoriasis;	chr6:111512031	chr6:111599875~111602295:+
LUAD	cis	rs8059260	0.604	rs35715760	ENSG00000274038.1	RP11-66H6.4	-8.07	5.82e-15	5.79e-12	-0.7	-0.35	Alcohol consumption over the past year;	chr16:11102091	chr16:11056556~11057034:+
LUAD	cis	rs944289	0.74	rs1537425	ENSG00000257826.1	RP11-116N8.4	8.07	5.83e-15	5.79e-12	0.36	0.35	Thyroid cancer;	chr14:36098954	chr14:36061026~36067190:-
LUAD	cis	rs9322193	0.923	rs35961297	ENSG00000223701.3	RAET1E-AS1	8.06	5.9e-15	5.86e-12	0.4	0.35	Lung cancer;	chr6:149667929	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs35967444	ENSG00000223701.3	RAET1E-AS1	8.06	5.9e-15	5.86e-12	0.4	0.35	Lung cancer;	chr6:149675588	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs62439842	ENSG00000223701.3	RAET1E-AS1	8.06	5.9e-15	5.86e-12	0.4	0.35	Lung cancer;	chr6:149675847	chr6:149884431~149919508:+
LUAD	cis	rs10463554	0.963	rs3776859	ENSG00000175749.11	EIF3KP1	8.06	5.9e-15	5.86e-12	0.47	0.35	Parkinson's disease;	chr5:103016330	chr5:103032376~103033031:+
LUAD	cis	rs9322193	0.923	rs12174349	ENSG00000223701.3	RAET1E-AS1	8.06	5.91e-15	5.87e-12	0.4	0.35	Lung cancer;	chr6:149718012	chr6:149884431~149919508:+
LUAD	cis	rs12922040	0.651	rs35288467	ENSG00000263335.1	AF001548.5	-8.06	5.92e-15	5.88e-12	-0.42	-0.35	Serum uric acid levels in response to allopurinol in gout;	chr16:15773097	chr16:15726674~15732993:+
LUAD	cis	rs9322193	0.884	rs9480009	ENSG00000223701.3	RAET1E-AS1	8.06	5.93e-15	5.89e-12	0.4	0.35	Lung cancer;	chr6:149758502	chr6:149884431~149919508:+
LUAD	cis	rs11096990	0.634	rs1057807	ENSG00000249207.1	RP11-360F5.1	8.06	5.94e-15	5.9e-12	0.38	0.35	Cognitive function;	chr4:39287853	chr4:39112677~39126818:-
LUAD	cis	rs10463554	1	rs56372231	ENSG00000175749.11	EIF3KP1	8.06	5.94e-15	5.9e-12	0.47	0.35	Parkinson's disease;	chr5:102986201	chr5:103032376~103033031:+
LUAD	cis	rs6504950	1	rs9903146	ENSG00000275710.1	RP11-257O5.4	8.06	6.03e-15	5.98e-12	0.43	0.34	Breast cancer;	chr17:54980386	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.962	rs9902950	ENSG00000275710.1	RP11-257O5.4	8.06	6.03e-15	5.98e-12	0.43	0.34	Breast cancer;	chr17:54980403	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs9903220	ENSG00000275710.1	RP11-257O5.4	8.06	6.03e-15	5.98e-12	0.43	0.34	Breast cancer;	chr17:54980504	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs9903444	ENSG00000275710.1	RP11-257O5.4	8.06	6.03e-15	5.98e-12	0.43	0.34	Breast cancer;	chr17:54980532	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs9903825	ENSG00000275710.1	RP11-257O5.4	8.06	6.03e-15	5.98e-12	0.43	0.34	Breast cancer;	chr17:54980553	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs16955471	ENSG00000275710.1	RP11-257O5.4	8.06	6.03e-15	5.98e-12	0.43	0.34	Breast cancer;	chr17:54981446	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs9891865	ENSG00000275710.1	RP11-257O5.4	8.06	6.03e-15	5.98e-12	0.43	0.34	Breast cancer;	chr17:54982672	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs9892173	ENSG00000275710.1	RP11-257O5.4	8.06	6.03e-15	5.98e-12	0.43	0.34	Breast cancer;	chr17:54982853	chr17:54964474~54964679:+
LUAD	cis	rs9532669	0.926	rs9562254	ENSG00000176268.5	CYCSP34	-8.06	6.04e-15	5.98e-12	-0.34	-0.34	Cervical cancer;	chr13:40960902	chr13:40863599~40863902:-
LUAD	cis	rs950169	0.724	rs11632668	ENSG00000225151.9	GOLGA2P7	-8.06	6.09e-15	6.04e-12	-0.48	-0.34	Schizophrenia;	chr15:84393989	chr15:84199311~84230136:-
LUAD	cis	rs526231	0.547	rs72783895	ENSG00000175749.11	EIF3KP1	8.06	6.11e-15	6.05e-12	0.5	0.34	Primary biliary cholangitis;	chr5:102951792	chr5:103032376~103033031:+
LUAD	cis	rs11089937	0.568	rs35626600	ENSG00000211639.2	IGLV4-60	8.06	6.13e-15	6.07e-12	0.41	0.34	Periodontitis (PAL4Q3);	chr22:22130811	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.539	rs34228957	ENSG00000211639.2	IGLV4-60	8.06	6.13e-15	6.07e-12	0.41	0.34	Periodontitis (PAL4Q3);	chr22:22130838	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.512	rs13054756	ENSG00000211639.2	IGLV4-60	8.06	6.13e-15	6.07e-12	0.41	0.34	Periodontitis (PAL4Q3);	chr22:22130948	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.597	rs4821768	ENSG00000211639.2	IGLV4-60	8.06	6.13e-15	6.07e-12	0.41	0.34	Periodontitis (PAL4Q3);	chr22:22131047	chr22:22162199~22162681:+
LUAD	cis	rs9487094	0.67	rs729888	ENSG00000260273.1	RP11-425D10.10	-8.06	6.13e-15	6.07e-12	-0.45	-0.34	Height;	chr6:109636120	chr6:109382795~109383666:+
LUAD	cis	rs496547	0.686	rs524590	ENSG00000278376.1	RP11-158I9.8	-8.06	6.15e-15	6.09e-12	-0.38	-0.34	Hip minimal joint space width;	chr11:118769354	chr11:118791254~118793137:+
LUAD	cis	rs1891275	0.576	rs1891272	ENSG00000228701.1	TNKS2-AS1	-8.06	6.16e-15	6.1e-12	-0.47	-0.34	Intelligence (multi-trait analysis);	chr10:91666306	chr10:91782839~91798291:-
LUAD	cis	rs1891275	0.551	rs1891271	ENSG00000228701.1	TNKS2-AS1	-8.06	6.16e-15	6.1e-12	-0.47	-0.34	Intelligence (multi-trait analysis);	chr10:91666566	chr10:91782839~91798291:-
LUAD	cis	rs11676348	0.783	rs13035513	ENSG00000261338.2	RP11-378A13.1	-8.06	6.16e-15	6.1e-12	-0.37	-0.34	Ulcerative colitis;	chr2:218095957	chr2:218255319~218257366:+
LUAD	cis	rs11098499	0.588	rs2389874	ENSG00000245958.5	RP11-33B1.1	8.06	6.16e-15	6.1e-12	0.3	0.34	Corneal astigmatism;	chr4:119633836	chr4:119454791~119552025:+
LUAD	cis	rs9322193	0.923	rs9688517	ENSG00000223701.3	RAET1E-AS1	8.06	6.16e-15	6.11e-12	0.4	0.34	Lung cancer;	chr6:149740655	chr6:149884431~149919508:+
LUAD	cis	rs11096990	0.634	rs7659894	ENSG00000249207.1	RP11-360F5.1	8.06	6.19e-15	6.13e-12	0.38	0.34	Cognitive function;	chr4:39282815	chr4:39112677~39126818:-
LUAD	cis	rs9322193	0.884	rs10872646	ENSG00000223701.3	RAET1E-AS1	8.06	6.19e-15	6.13e-12	0.4	0.34	Lung cancer;	chr6:149746539	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.884	rs12528279	ENSG00000223701.3	RAET1E-AS1	8.06	6.19e-15	6.13e-12	0.4	0.34	Lung cancer;	chr6:149750892	chr6:149884431~149919508:+
LUAD	cis	rs2919917	1	rs10093127	ENSG00000254352.1	RP11-578O24.2	8.06	6.24e-15	6.18e-12	0.42	0.34	Lymphocyte counts;	chr8:78686869	chr8:78723796~78724136:-
LUAD	cis	rs2980436	1	rs2980436	ENSG00000173295.6	FAM86B3P	-8.06	6.29e-15	6.23e-12	-0.37	-0.34	Schizophrenia;	chr8:8234503	chr8:8228595~8244865:+
LUAD	cis	rs8177876	0.749	rs12444969	ENSG00000261838.4	RP11-303E16.6	8.05	6.34e-15	6.27e-12	0.82	0.34	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81050211	chr16:81069854~81076598:+
LUAD	cis	rs6504622	0.72	rs4968304	ENSG00000262879.4	RP11-156P1.3	-8.05	6.34e-15	6.27e-12	-0.39	-0.34	Orofacial clefts;	chr17:47063235	chr17:46984045~47100323:-
LUAD	cis	rs9322193	0.923	rs11155674	ENSG00000223701.3	RAET1E-AS1	8.05	6.37e-15	6.3e-12	0.4	0.34	Lung cancer;	chr6:149711111	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs2185352	ENSG00000223701.3	RAET1E-AS1	8.05	6.37e-15	6.3e-12	0.4	0.34	Lung cancer;	chr6:149714640	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs2297932	ENSG00000223701.3	RAET1E-AS1	8.05	6.37e-15	6.3e-12	0.4	0.34	Lung cancer;	chr6:149718225	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs2297930	ENSG00000223701.3	RAET1E-AS1	8.05	6.37e-15	6.3e-12	0.4	0.34	Lung cancer;	chr6:149718360	chr6:149884431~149919508:+
LUAD	cis	rs9287719	0.967	rs6432126	ENSG00000234818.1	AC092687.5	8.05	6.37e-15	6.3e-12	0.41	0.34	Prostate cancer;	chr2:10616975	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.904	rs55738250	ENSG00000234818.1	AC092687.5	8.05	6.37e-15	6.3e-12	0.41	0.34	Prostate cancer;	chr2:10617006	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6727768	ENSG00000234818.1	AC092687.5	8.05	6.37e-15	6.3e-12	0.41	0.34	Prostate cancer;	chr2:10617353	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs10167129	ENSG00000234818.1	AC092687.5	8.05	6.37e-15	6.3e-12	0.41	0.34	Prostate cancer;	chr2:10618449	chr2:10589166~10604830:+
LUAD	cis	rs9322193	0.923	rs9688452	ENSG00000223701.3	RAET1E-AS1	8.05	6.42e-15	6.35e-12	0.41	0.34	Lung cancer;	chr6:149658764	chr6:149884431~149919508:+
LUAD	cis	rs6700559	0.81	rs7521550	ENSG00000260088.1	RP11-92G12.3	-8.05	6.49e-15	6.41e-12	-0.44	-0.34	Coronary artery disease;	chr1:200623235	chr1:200669507~200694250:+
LUAD	cis	rs10129255	0.912	rs61997792	ENSG00000223648.3	IGHV3-64	8.05	6.54e-15	6.46e-12	0.35	0.34	Kawasaki disease;	chr14:106799304	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.957	rs56134540	ENSG00000211972.2	IGHV3-66	8.05	6.55e-15	6.48e-12	0.3	0.34	Kawasaki disease;	chr14:106691290	chr14:106675017~106675544:-
LUAD	cis	rs7188445	0.932	rs4575545	ENSG00000261390.4	RP11-345M22.2	-8.05	6.6e-15	6.53e-12	-0.47	-0.34	Urate levels;	chr16:79721549	chr16:79715232~79770563:-
LUAD	cis	rs7688540	0.665	rs11731933	ENSG00000275426.1	CH17-262A2.1	8.05	6.61e-15	6.53e-12	0.48	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245370	chr4:149738~150317:+
LUAD	cis	rs2929278	0.638	rs2016840	ENSG00000249839.1	AC011330.5	8.05	6.61e-15	6.53e-12	0.43	0.34	Schizophrenia;	chr15:43919670	chr15:43663654~43684339:-
LUAD	cis	rs9287719	0.967	rs10206225	ENSG00000234818.1	AC092687.5	8.05	6.62e-15	6.54e-12	0.41	0.34	Prostate cancer;	chr2:10618531	chr2:10589166~10604830:+
LUAD	cis	rs7429990	0.864	rs4858863	ENSG00000229759.1	MRPS18AP1	-8.05	6.62e-15	6.54e-12	-0.36	-0.34	Educational attainment (years of education);	chr3:47814143	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs7629850	ENSG00000229759.1	MRPS18AP1	-8.05	6.62e-15	6.54e-12	-0.36	-0.34	Educational attainment (years of education);	chr3:47815592	chr3:48256350~48256938:-
LUAD	cis	rs12220777	1	rs75913297	ENSG00000230091.5	TMEM254-AS1	8.05	6.62e-15	6.54e-12	0.67	0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80030089	chr10:80046860~80078912:-
LUAD	cis	rs11089937	0.597	rs4821773	ENSG00000211639.2	IGLV4-60	8.05	6.69e-15	6.6e-12	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22131434	chr22:22162199~22162681:+
LUAD	cis	rs10129255	0.957	rs10138532	ENSG00000211970.3	IGHV4-61	-8.05	6.7e-15	6.62e-12	-0.27	-0.34	Kawasaki disease;	chr14:106803901	chr14:106639119~106639657:-
LUAD	cis	rs9322193	0.923	rs66516768	ENSG00000223701.3	RAET1E-AS1	8.05	6.7e-15	6.62e-12	0.4	0.34	Lung cancer;	chr6:149671999	chr6:149884431~149919508:+
LUAD	cis	rs7429990	0.803	rs6776963	ENSG00000229759.1	MRPS18AP1	-8.04	6.79e-15	6.7e-12	-0.36	-0.34	Educational attainment (years of education);	chr3:47789251	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs13077230	ENSG00000229759.1	MRPS18AP1	-8.04	6.8e-15	6.71e-12	-0.35	-0.34	Educational attainment (years of education);	chr3:47832232	chr3:48256350~48256938:-
LUAD	cis	rs9309711	0.544	rs9309712	ENSG00000225234.1	TRAPPC12-AS1	-8.04	6.84e-15	6.74e-12	-0.39	-0.34	Neurofibrillary tangles;	chr2:3487556	chr2:3481242~3482409:-
LUAD	cis	rs6504950	1	rs6504950	ENSG00000275710.1	RP11-257O5.4	8.04	6.85e-15	6.75e-12	0.43	0.34	Breast cancer;	chr17:54979110	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs6504951	ENSG00000275710.1	RP11-257O5.4	8.04	6.85e-15	6.75e-12	0.43	0.34	Breast cancer;	chr17:54979614	chr17:54964474~54964679:+
LUAD	cis	rs71403859	0.614	rs12935422	ENSG00000260886.1	TAT-AS1	8.04	6.85e-15	6.76e-12	0.56	0.34	Post bronchodilator FEV1;	chr16:71630322	chr16:71565789~71578187:+
LUAD	cis	rs9322193	0.923	rs9479494	ENSG00000223701.3	RAET1E-AS1	8.04	6.86e-15	6.77e-12	0.4	0.34	Lung cancer;	chr6:149739108	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs9800806	ENSG00000223701.3	RAET1E-AS1	8.04	6.86e-15	6.77e-12	0.4	0.34	Lung cancer;	chr6:149740350	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs2297928	ENSG00000223701.3	RAET1E-AS1	8.04	6.87e-15	6.78e-12	0.4	0.34	Lung cancer;	chr6:149718584	chr6:149884431~149919508:+
LUAD	cis	rs7044106	0.69	rs10739569	ENSG00000226752.6	PSMD5-AS1	-8.04	6.91e-15	6.81e-12	-0.37	-0.34	Hip circumference adjusted for BMI;	chr9:120598749	chr9:120824828~120854385:+
LUAD	cis	rs7188445	0.898	rs74037508	ENSG00000261390.4	RP11-345M22.2	-8.04	6.92e-15	6.82e-12	-0.45	-0.34	Urate levels;	chr16:79677439	chr16:79715232~79770563:-
LUAD	cis	rs6597981	0.592	rs10902218	ENSG00000255142.1	AP006621.6	-8.04	6.92e-15	6.82e-12	-0.27	-0.34	Breast cancer;	chr11:743813	chr11:781645~782105:+
LUAD	cis	rs2929278	0.617	rs694461	ENSG00000249839.1	AC011330.5	8.04	6.93e-15	6.83e-12	0.46	0.34	Schizophrenia;	chr15:43803865	chr15:43663654~43684339:-
LUAD	cis	rs2581828	0.646	rs9861233	ENSG00000242142.1	SERBP1P3	-8.04	6.94e-15	6.84e-12	-0.38	-0.34	Crohn's disease;	chr3:53124815	chr3:53064283~53065091:-
LUAD	cis	rs7688540	0.739	rs11729659	ENSG00000275426.1	CH17-262A2.1	8.04	6.94e-15	6.84e-12	0.48	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:243495	chr4:149738~150317:+
LUAD	cis	rs11089937	0.626	rs5757017	ENSG00000211639.2	IGLV4-60	8.04	6.97e-15	6.86e-12	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22135947	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.568	rs59356111	ENSG00000211639.2	IGLV4-60	8.04	6.97e-15	6.86e-12	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22136175	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.626	rs5757019	ENSG00000211639.2	IGLV4-60	8.04	6.97e-15	6.86e-12	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22136286	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.597	rs5750579	ENSG00000211639.2	IGLV4-60	8.04	6.97e-15	6.86e-12	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22136581	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.597	rs11089925	ENSG00000211639.2	IGLV4-60	8.04	6.97e-15	6.86e-12	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22137267	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.597	rs5757024	ENSG00000211639.2	IGLV4-60	8.04	6.97e-15	6.86e-12	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22137415	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.597	rs5757026	ENSG00000211639.2	IGLV4-60	8.04	6.97e-15	6.86e-12	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22137556	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.597	rs2213156	ENSG00000211639.2	IGLV4-60	8.04	6.97e-15	6.86e-12	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22137852	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.626	rs9622955	ENSG00000211639.2	IGLV4-60	8.04	6.97e-15	6.86e-12	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22138343	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.626	rs4821781	ENSG00000211639.2	IGLV4-60	8.04	6.97e-15	6.86e-12	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22138845	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.626	rs5750589	ENSG00000211639.2	IGLV4-60	8.04	6.97e-15	6.86e-12	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22139655	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.626	rs5757038	ENSG00000211639.2	IGLV4-60	8.04	6.97e-15	6.86e-12	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22140149	chr22:22162199~22162681:+
LUAD	cis	rs71403859	0.685	rs12444890	ENSG00000260886.1	TAT-AS1	8.04	6.98e-15	6.87e-12	0.59	0.34	Post bronchodilator FEV1;	chr16:71602123	chr16:71565789~71578187:+
LUAD	cis	rs2337406	1	rs10459466	ENSG00000254174.1	IGHV1-12	8.04	7e-15	6.89e-12	0.35	0.34	Alzheimer's disease (late onset);	chr14:106689255	chr14:106122420~106122709:-
LUAD	cis	rs2919917	1	rs7839152	ENSG00000254352.1	RP11-578O24.2	8.04	7.02e-15	6.9e-12	0.42	0.34	Lymphocyte counts;	chr8:78677777	chr8:78723796~78724136:-
LUAD	cis	rs2919917	1	rs28429528	ENSG00000254352.1	RP11-578O24.2	8.04	7.02e-15	6.9e-12	0.42	0.34	Lymphocyte counts;	chr8:78678782	chr8:78723796~78724136:-
LUAD	cis	rs2919917	1	rs9298316	ENSG00000254352.1	RP11-578O24.2	8.04	7.02e-15	6.9e-12	0.42	0.34	Lymphocyte counts;	chr8:78680191	chr8:78723796~78724136:-
LUAD	cis	rs2919917	1	rs7842142	ENSG00000254352.1	RP11-578O24.2	8.04	7.02e-15	6.9e-12	0.42	0.34	Lymphocyte counts;	chr8:78681501	chr8:78723796~78724136:-
LUAD	cis	rs2919917	1	rs11785966	ENSG00000254352.1	RP11-578O24.2	8.04	7.02e-15	6.9e-12	0.42	0.34	Lymphocyte counts;	chr8:78681851	chr8:78723796~78724136:-
LUAD	cis	rs2919917	1	rs10092335	ENSG00000254352.1	RP11-578O24.2	8.04	7.02e-15	6.9e-12	0.42	0.34	Lymphocyte counts;	chr8:78686218	chr8:78723796~78724136:-
LUAD	cis	rs6504950	1	rs28558726	ENSG00000275710.1	RP11-257O5.4	8.04	7.03e-15	6.91e-12	0.43	0.34	Breast cancer;	chr17:54981315	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs9892976	ENSG00000275710.1	RP11-257O5.4	8.04	7.03e-15	6.91e-12	0.43	0.34	Breast cancer;	chr17:54982968	chr17:54964474~54964679:+
LUAD	cis	rs9322193	0.884	rs7450246	ENSG00000223701.3	RAET1E-AS1	8.04	7.09e-15	6.97e-12	0.4	0.34	Lung cancer;	chr6:149702517	chr6:149884431~149919508:+
LUAD	cis	rs34081947	0.5	rs1930766	ENSG00000257826.1	RP11-116N8.4	-8.04	7.16e-15	7.03e-12	-0.37	-0.34	Papillary thyroid cancer;Differentiated thyroid cancer;	chr14:36081037	chr14:36061026~36067190:-
LUAD	cis	rs11123170	0.543	rs2863242	ENSG00000189223.12	PAX8-AS1	-8.04	7.16e-15	7.04e-12	-0.56	-0.34	Renal function-related traits (BUN);	chr2:113231659	chr2:113211522~113276581:+
LUAD	cis	rs77505915	0.512	rs12921808	ENSG00000261783.1	RP11-252K23.2	8.04	7.19e-15	7.06e-12	0.49	0.34	Migraine;	chr16:75350086	chr16:75379818~75381260:-
LUAD	cis	rs904251	0.686	rs2776911	ENSG00000279942.1	RP1-153P14.7	-8.04	7.23e-15	7.1e-12	-0.37	-0.34	Cognitive performance;	chr6:37472174	chr6:37567716~37571460:+
LUAD	cis	rs950880	0.71	rs2270298	ENSG00000234389.1	AC007278.3	-8.04	7.28e-15	7.14e-12	-0.35	-0.34	Serum protein levels (sST2);	chr2:102375619	chr2:102438713~102440475:+
LUAD	cis	rs950880	0.71	rs17027037	ENSG00000234389.1	AC007278.3	-8.04	7.28e-15	7.14e-12	-0.35	-0.34	Serum protein levels (sST2);	chr2:102378424	chr2:102438713~102440475:+
LUAD	cis	rs950880	0.71	rs2080289	ENSG00000234389.1	AC007278.3	-8.04	7.28e-15	7.14e-12	-0.35	-0.34	Serum protein levels (sST2);	chr2:102378560	chr2:102438713~102440475:+
LUAD	cis	rs950880	0.71	rs3821203	ENSG00000234389.1	AC007278.3	-8.04	7.28e-15	7.14e-12	-0.35	-0.34	Serum protein levels (sST2);	chr2:102380412	chr2:102438713~102440475:+
LUAD	cis	rs950880	0.71	rs3771162	ENSG00000234389.1	AC007278.3	-8.04	7.28e-15	7.14e-12	-0.35	-0.34	Serum protein levels (sST2);	chr2:102380714	chr2:102438713~102440475:+
LUAD	cis	rs950880	0.71	rs11465633	ENSG00000234389.1	AC007278.3	-8.04	7.28e-15	7.14e-12	-0.35	-0.34	Serum protein levels (sST2);	chr2:102381273	chr2:102438713~102440475:+
LUAD	cis	rs950880	0.71	rs1035130	ENSG00000234389.1	AC007278.3	-8.04	7.28e-15	7.14e-12	-0.35	-0.34	Serum protein levels (sST2);	chr2:102384942	chr2:102438713~102440475:+
LUAD	cis	rs7688540	0.771	rs11722521	ENSG00000275426.1	CH17-262A2.1	8.03	7.34e-15	7.2e-12	0.49	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:282976	chr4:149738~150317:+
LUAD	cis	rs526231	0.578	rs59323174	ENSG00000175749.11	EIF3KP1	8.03	7.34e-15	7.21e-12	0.48	0.34	Primary biliary cholangitis;	chr5:102932165	chr5:103032376~103033031:+
LUAD	cis	rs8177876	0.822	rs56166222	ENSG00000261838.4	RP11-303E16.6	8.03	7.34e-15	7.21e-12	0.78	0.34	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81067920	chr16:81069854~81076598:+
LUAD	cis	rs11089937	0.597	rs9619812	ENSG00000211639.2	IGLV4-60	8.03	7.41e-15	7.27e-12	0.41	0.34	Periodontitis (PAL4Q3);	chr22:22163945	chr22:22162199~22162681:+
LUAD	cis	rs2283792	0.567	rs2027789	ENSG00000224086.5	LL22NC03-86G7.1	-8.03	7.42e-15	7.28e-12	-0.33	-0.34	Multiple sclerosis;	chr22:21933490	chr22:21938293~21977632:+
LUAD	cis	rs71403859	0.73	rs12923781	ENSG00000260886.1	TAT-AS1	8.03	7.42e-15	7.28e-12	0.6	0.34	Post bronchodilator FEV1;	chr16:71619561	chr16:71565789~71578187:+
LUAD	cis	rs9322193	0.607	rs12204653	ENSG00000216906.2	RP11-350J20.9	8.03	7.45e-15	7.3e-12	0.52	0.34	Lung cancer;	chr6:149891885	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.962	rs9688750	ENSG00000223701.3	RAET1E-AS1	8.03	7.45e-15	7.31e-12	0.41	0.34	Lung cancer;	chr6:149657633	chr6:149884431~149919508:+
LUAD	cis	rs10463554	0.892	rs10463988	ENSG00000175749.11	EIF3KP1	8.03	7.48e-15	7.33e-12	0.47	0.34	Parkinson's disease;	chr5:102913595	chr5:103032376~103033031:+
LUAD	cis	rs1823913	0.927	rs56209234	ENSG00000227542.1	AC092614.2	8.03	7.49e-15	7.35e-12	0.45	0.34	Obesity-related traits;	chr2:191261748	chr2:191229165~191246172:-
LUAD	cis	rs9322193	0.809	rs9479808	ENSG00000223701.3	RAET1E-AS1	8.03	7.5e-15	7.35e-12	0.4	0.34	Lung cancer;	chr6:149751328	chr6:149884431~149919508:+
LUAD	cis	rs2284378	0.506	rs6142059	ENSG00000276073.1	RP5-1125A11.7	-8.03	7.52e-15	7.37e-12	-0.34	-0.34	Breast cancer;	chr20:33956521	chr20:33985617~33988989:-
LUAD	cis	rs904251	0.714	rs2776910	ENSG00000279942.1	RP1-153P14.7	-8.03	7.57e-15	7.41e-12	-0.37	-0.34	Cognitive performance;	chr6:37468508	chr6:37567716~37571460:+
LUAD	cis	rs7188445	0.898	rs74247468	ENSG00000261390.4	RP11-345M22.2	-8.03	7.58e-15	7.42e-12	-0.45	-0.34	Urate levels;	chr16:79679188	chr16:79715232~79770563:-
LUAD	cis	rs9322193	0.884	rs11155679	ENSG00000223701.3	RAET1E-AS1	8.03	7.6e-15	7.44e-12	0.43	0.34	Lung cancer;	chr6:149758881	chr6:149884431~149919508:+
LUAD	cis	rs2880765	0.566	rs55899824	ENSG00000259295.5	CSPG4P12	8.03	7.62e-15	7.46e-12	0.42	0.34	Coronary artery disease;	chr15:85460860	chr15:85191438~85213905:+
LUAD	cis	rs2880765	0.631	rs55767890	ENSG00000259295.5	CSPG4P12	8.03	7.62e-15	7.46e-12	0.42	0.34	Coronary artery disease;	chr15:85460911	chr15:85191438~85213905:+
LUAD	cis	rs10463554	0.963	rs10463555	ENSG00000175749.11	EIF3KP1	8.03	7.66e-15	7.5e-12	0.47	0.34	Parkinson's disease;	chr5:102983333	chr5:103032376~103033031:+
LUAD	cis	rs7688540	0.771	rs6599318	ENSG00000275426.1	CH17-262A2.1	8.03	7.7e-15	7.54e-12	0.49	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:250179	chr4:149738~150317:+
LUAD	cis	rs8040855	0.658	rs12909111	ENSG00000259295.5	CSPG4P12	8.03	7.7e-15	7.54e-12	0.43	0.34	Bulimia nervosa;	chr15:85061095	chr15:85191438~85213905:+
LUAD	cis	rs9322193	0.516	rs1999632	ENSG00000216906.2	RP11-350J20.9	8.03	7.76e-15	7.59e-12	0.52	0.34	Lung cancer;	chr6:149866737	chr6:149904243~149906418:+
LUAD	cis	rs904251	0.605	rs4257849	ENSG00000204110.6	RP1-153P14.8	-8.03	7.76e-15	7.59e-12	-0.41	-0.34	Cognitive performance;	chr6:37443193	chr6:37507348~37535616:+
LUAD	cis	rs11089937	0.597	rs4821774	ENSG00000211639.2	IGLV4-60	8.02	7.84e-15	7.67e-12	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22131536	chr22:22162199~22162681:+
LUAD	cis	rs10875746	0.551	rs11168536	ENSG00000240399.1	RP1-228P16.1	-8.02	7.88e-15	7.71e-12	-0.42	-0.34	Longevity (90 years and older);	chr12:48351268	chr12:48054813~48055591:-
LUAD	cis	rs71403859	0.73	rs17347255	ENSG00000260886.1	TAT-AS1	8.02	7.91e-15	7.73e-12	0.59	0.34	Post bronchodilator FEV1;	chr16:71553322	chr16:71565789~71578187:+
LUAD	cis	rs6504622	0.755	rs34038545	ENSG00000262879.4	RP11-156P1.3	-8.02	7.92e-15	7.74e-12	-0.38	-0.34	Orofacial clefts;	chr17:47067541	chr17:46984045~47100323:-
LUAD	cis	rs11089937	0.597	rs5757027	ENSG00000211639.2	IGLV4-60	8.02	7.95e-15	7.78e-12	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22137683	chr22:22162199~22162681:+
LUAD	cis	rs1789	0.706	rs8180240	ENSG00000273133.1	RP11-799M12.2	-8.02	7.95e-15	7.78e-12	-0.52	-0.34	Blood protein levels;	chr4:15699952	chr4:15563698~15564253:-
LUAD	cis	rs71403859	0.614	rs12447033	ENSG00000260886.1	TAT-AS1	8.02	7.96e-15	7.78e-12	0.54	0.34	Post bronchodilator FEV1;	chr16:71549752	chr16:71565789~71578187:+
LUAD	cis	rs1823913	0.927	rs13025919	ENSG00000227542.1	AC092614.2	8.02	7.96e-15	7.78e-12	0.45	0.34	Obesity-related traits;	chr2:191260175	chr2:191229165~191246172:-
LUAD	cis	rs7201929	1	rs7499878	ENSG00000259982.1	CDC37P1	-8.02	7.97e-15	7.79e-12	-0.5	-0.34	QT interval;	chr16:28857143	chr16:28700294~28701540:-
LUAD	cis	rs950880	0.71	rs1474309	ENSG00000234389.1	AC007278.3	-8.02	7.97e-15	7.79e-12	-0.35	-0.34	Serum protein levels (sST2);	chr2:102474542	chr2:102438713~102440475:+
LUAD	cis	rs8177876	0.822	rs77475047	ENSG00000261838.4	RP11-303E16.6	8.02	7.98e-15	7.79e-12	0.8	0.34	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81073355	chr16:81069854~81076598:+
LUAD	cis	rs10129255	0.589	rs78599641	ENSG00000224373.3	IGHV4-59	8.02	8.01e-15	7.82e-12	0.23	0.34	Kawasaki disease;	chr14:106637576	chr14:106627249~106627825:-
LUAD	cis	rs34976449	1	rs34976449	ENSG00000232912.4	RP5-1115A15.1	8.02	8.01e-15	7.83e-12	0.31	0.34	Lymphocyte counts;	chr1:8438266	chr1:8424645~8434838:+
LUAD	cis	rs950880	0.71	rs11694360	ENSG00000234389.1	AC007278.3	-8.02	8.01e-15	7.83e-12	-0.34	-0.34	Serum protein levels (sST2);	chr2:102444687	chr2:102438713~102440475:+
LUAD	cis	rs950880	0.71	rs7597017	ENSG00000234389.1	AC007278.3	-8.02	8.01e-15	7.83e-12	-0.34	-0.34	Serum protein levels (sST2);	chr2:102445656	chr2:102438713~102440475:+
LUAD	cis	rs950880	0.677	rs4851585	ENSG00000234389.1	AC007278.3	-8.02	8.01e-15	7.83e-12	-0.34	-0.34	Serum protein levels (sST2);	chr2:102446294	chr2:102438713~102440475:+
LUAD	cis	rs2455601	0.744	rs7938995	ENSG00000254860.4	TMEM9B-AS1	8.02	8.04e-15	7.86e-12	0.47	0.34	Schizophrenia;	chr11:8954128	chr11:8964675~8977527:+
LUAD	cis	rs8177876	0.749	rs79834398	ENSG00000261838.4	RP11-303E16.6	8.02	8.05e-15	7.86e-12	0.77	0.34	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81057033	chr16:81069854~81076598:+
LUAD	cis	rs1537424	0.513	rs944845	ENSG00000257826.1	RP11-116N8.4	-8.02	8.06e-15	7.87e-12	-0.37	-0.34	Thyroid hormone levels;	chr14:36081480	chr14:36061026~36067190:-
LUAD	cis	rs8040855	0.624	rs12903975	ENSG00000259295.5	CSPG4P12	8.02	8.07e-15	7.88e-12	0.41	0.34	Bulimia nervosa;	chr15:85006004	chr15:85191438~85213905:+
LUAD	cis	rs2919917	1	rs1872072	ENSG00000254352.1	RP11-578O24.2	8.02	8.1e-15	7.91e-12	0.42	0.34	Lymphocyte counts;	chr8:78689185	chr8:78723796~78724136:-
LUAD	cis	rs2919917	1	rs2717539	ENSG00000254352.1	RP11-578O24.2	8.02	8.14e-15	7.95e-12	0.42	0.34	Lymphocyte counts;	chr8:78716804	chr8:78723796~78724136:-
LUAD	cis	rs2919917	0.793	rs2625664	ENSG00000254352.1	RP11-578O24.2	8.02	8.14e-15	7.95e-12	0.42	0.34	Lymphocyte counts;	chr8:78718373	chr8:78723796~78724136:-
LUAD	cis	rs2581828	0.58	rs9872260	ENSG00000242142.1	SERBP1P3	-8.02	8.15e-15	7.95e-12	-0.39	-0.34	Crohn's disease;	chr3:53136158	chr3:53064283~53065091:-
LUAD	cis	rs2919917	1	rs1026920	ENSG00000254352.1	RP11-578O24.2	8.02	8.2e-15	8e-12	0.42	0.34	Lymphocyte counts;	chr8:78719775	chr8:78723796~78724136:-
LUAD	cis	rs2919917	1	rs2717538	ENSG00000254352.1	RP11-578O24.2	8.02	8.2e-15	8e-12	0.42	0.34	Lymphocyte counts;	chr8:78720914	chr8:78723796~78724136:-
LUAD	cis	rs12468226	1	rs111542497	ENSG00000273456.1	RP11-686O6.2	8.02	8.25e-15	8.05e-12	0.47	0.34	Urate levels;	chr2:202330369	chr2:202374932~202375604:-
LUAD	cis	rs9322193	0.923	rs9480031	ENSG00000223701.3	RAET1E-AS1	8.02	8.27e-15	8.06e-12	0.4	0.34	Lung cancer;	chr6:149758875	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs10872649	ENSG00000223701.3	RAET1E-AS1	8.02	8.27e-15	8.06e-12	0.4	0.34	Lung cancer;	chr6:149759454	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs10872650	ENSG00000223701.3	RAET1E-AS1	8.02	8.27e-15	8.06e-12	0.4	0.34	Lung cancer;	chr6:149760959	chr6:149884431~149919508:+
LUAD	cis	rs2581828	0.58	rs57514626	ENSG00000242142.1	SERBP1P3	-8.02	8.27e-15	8.07e-12	-0.39	-0.34	Crohn's disease;	chr3:53135286	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.58	rs61296683	ENSG00000242142.1	SERBP1P3	-8.02	8.27e-15	8.07e-12	-0.39	-0.34	Crohn's disease;	chr3:53135307	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.58	rs9867590	ENSG00000242142.1	SERBP1P3	-8.02	8.27e-15	8.07e-12	-0.39	-0.34	Crohn's disease;	chr3:53135635	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.58	rs9834111	ENSG00000242142.1	SERBP1P3	-8.02	8.27e-15	8.07e-12	-0.39	-0.34	Crohn's disease;	chr3:53136028	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.58	rs9817467	ENSG00000242142.1	SERBP1P3	-8.02	8.27e-15	8.07e-12	-0.39	-0.34	Crohn's disease;	chr3:53136609	chr3:53064283~53065091:-
LUAD	cis	rs9322193	0.884	rs9322210	ENSG00000223701.3	RAET1E-AS1	8.01	8.46e-15	8.25e-12	0.4	0.34	Lung cancer;	chr6:149695440	chr6:149884431~149919508:+
LUAD	cis	rs4718428	0.705	rs11028	ENSG00000226824.5	RP4-756H11.3	-8.01	8.5e-15	8.28e-12	-0.46	-0.34	Corneal structure;	chr7:66811230	chr7:66654538~66669855:+
LUAD	cis	rs7688540	0.771	rs11729365	ENSG00000275426.1	CH17-262A2.1	8.01	8.51e-15	8.29e-12	0.49	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:278735	chr4:149738~150317:+
LUAD	cis	rs8059260	0.604	rs16957984	ENSG00000274038.1	RP11-66H6.4	-8.01	8.54e-15	8.32e-12	-0.65	-0.34	Alcohol consumption over the past year;	chr16:11051105	chr16:11056556~11057034:+
LUAD	cis	rs5769707	0.609	rs135861	ENSG00000188511.11	C22orf34	8.01	8.57e-15	8.35e-12	0.42	0.34	Monocyte percentage of white cells;Monocyte count;	chr22:49604470	chr22:49414524~49657542:-
LUAD	cis	rs10875746	0.551	rs10875799	ENSG00000240399.1	RP1-228P16.1	-8.01	8.58e-15	8.36e-12	-0.41	-0.34	Longevity (90 years and older);	chr12:48347096	chr12:48054813~48055591:-
LUAD	cis	rs7688540	0.771	rs4549329	ENSG00000275426.1	CH17-262A2.1	8.01	8.6e-15	8.38e-12	0.48	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245996	chr4:149738~150317:+
LUAD	cis	rs2581828	0.618	rs9828221	ENSG00000242142.1	SERBP1P3	-8.01	8.63e-15	8.4e-12	-0.39	-0.34	Crohn's disease;	chr3:53132643	chr3:53064283~53065091:-
LUAD	cis	rs9545047	0.604	rs9574416	ENSG00000227676.3	LINC01068	-8.01	8.65e-15	8.42e-12	-0.41	-0.34	Schizophrenia;	chr13:79388577	chr13:79566727~79571436:+
LUAD	cis	rs10129255	0.956	rs10137268	ENSG00000211970.3	IGHV4-61	-8.01	8.67e-15	8.44e-12	-0.27	-0.34	Kawasaki disease;	chr14:106697402	chr14:106639119~106639657:-
LUAD	cis	rs950880	0.71	rs17027255	ENSG00000234389.1	AC007278.3	-8.01	8.71e-15	8.48e-12	-0.35	-0.34	Serum protein levels (sST2);	chr2:102473668	chr2:102438713~102440475:+
LUAD	cis	rs950880	0.71	rs17027258	ENSG00000234389.1	AC007278.3	-8.01	8.71e-15	8.48e-12	-0.35	-0.34	Serum protein levels (sST2);	chr2:102475081	chr2:102438713~102440475:+
LUAD	cis	rs9545047	0.716	rs9545108	ENSG00000227676.3	LINC01068	8.01	8.72e-15	8.49e-12	0.42	0.34	Schizophrenia;	chr13:79411175	chr13:79566727~79571436:+
LUAD	cis	rs1823913	0.892	rs35596292	ENSG00000227542.1	AC092614.2	8.01	8.75e-15	8.52e-12	0.45	0.34	Obesity-related traits;	chr2:191246890	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.927	rs35530564	ENSG00000227542.1	AC092614.2	8.01	8.75e-15	8.52e-12	0.45	0.34	Obesity-related traits;	chr2:191247324	chr2:191229165~191246172:-
LUAD	cis	rs1891275	0.516	rs10881935	ENSG00000228701.1	TNKS2-AS1	-8.01	8.76e-15	8.52e-12	-0.47	-0.34	Intelligence (multi-trait analysis);	chr10:91637944	chr10:91782839~91798291:-
LUAD	cis	rs6700559	0.935	rs10920001	ENSG00000260088.1	RP11-92G12.3	-8.01	8.8e-15	8.56e-12	-0.45	-0.34	Coronary artery disease;	chr1:200682420	chr1:200669507~200694250:+
LUAD	cis	rs11089937	0.597	rs9619794	ENSG00000211639.2	IGLV4-60	8.01	8.88e-15	8.63e-12	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22132999	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.626	rs9619800	ENSG00000211639.2	IGLV4-60	8.01	8.9e-15	8.65e-12	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22141088	chr22:22162199~22162681:+
LUAD	cis	rs8177876	0.749	rs76892049	ENSG00000261838.4	RP11-303E16.6	8.01	8.9e-15	8.66e-12	0.77	0.34	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81055736	chr16:81069854~81076598:+
LUAD	cis	rs944289	0.868	rs2415316	ENSG00000257826.1	RP11-116N8.4	-8.01	8.91e-15	8.66e-12	-0.37	-0.34	Thyroid cancer;	chr14:36139806	chr14:36061026~36067190:-
LUAD	cis	rs2581828	0.608	rs9868263	ENSG00000242142.1	SERBP1P3	-8.01	8.92e-15	8.67e-12	-0.39	-0.34	Crohn's disease;	chr3:53130078	chr3:53064283~53065091:-
LUAD	cis	rs4660456	0.913	rs12743517	ENSG00000237899.1	RP4-739H11.3	8.01	8.95e-15	8.7e-12	0.46	0.34	Platelet count;	chr1:40759682	chr1:40669089~40687588:-
LUAD	cis	rs10129255	0.913	rs28861466	ENSG00000211970.3	IGHV4-61	-8.01	8.95e-15	8.7e-12	-0.27	-0.34	Kawasaki disease;	chr14:106718572	chr14:106639119~106639657:-
LUAD	cis	rs673078	0.607	rs55929628	ENSG00000275759.1	RP11-131L12.3	-8.01	8.96e-15	8.71e-12	-0.5	-0.34	Glucose homeostasis traits;	chr12:118371332	chr12:118428281~118428870:+
LUAD	cis	rs9287719	0.967	rs10929688	ENSG00000234818.1	AC092687.5	8.01	8.98e-15	8.72e-12	0.41	0.34	Prostate cancer;	chr2:10616524	chr2:10589166~10604830:+
LUAD	cis	rs9545047	0.604	rs1856997	ENSG00000227676.3	LINC01068	8.01	8.99e-15	8.74e-12	0.42	0.34	Schizophrenia;	chr13:79287487	chr13:79566727~79571436:+
LUAD	cis	rs944289	0.774	rs2415313	ENSG00000257826.1	RP11-116N8.4	-8.01	9.01e-15	8.76e-12	-0.36	-0.34	Thyroid cancer;	chr14:36115246	chr14:36061026~36067190:-
LUAD	cis	rs638893	1	rs583905	ENSG00000278376.1	RP11-158I9.8	-8.01	9.03e-15	8.77e-12	-0.5	-0.34	Vitiligo;	chr11:118825199	chr11:118791254~118793137:+
LUAD	cis	rs10875746	0.551	rs3751273	ENSG00000240399.1	RP1-228P16.1	-8	9.11e-15	8.84e-12	-0.41	-0.34	Longevity (90 years and older);	chr12:48345655	chr12:48054813~48055591:-
LUAD	cis	rs2284378	0.515	rs6059579	ENSG00000276073.1	RP5-1125A11.7	-8	9.11e-15	8.84e-12	-0.35	-0.34	Breast cancer;	chr20:33940059	chr20:33985617~33988989:-
LUAD	cis	rs2919917	0.956	rs10112388	ENSG00000254352.1	RP11-578O24.2	8	9.15e-15	8.88e-12	0.42	0.34	Lymphocyte counts;	chr8:78691512	chr8:78723796~78724136:-
LUAD	cis	rs2919917	1	rs6980663	ENSG00000254352.1	RP11-578O24.2	8	9.15e-15	8.88e-12	0.42	0.34	Lymphocyte counts;	chr8:78691589	chr8:78723796~78724136:-
LUAD	cis	rs2919917	1	rs7001074	ENSG00000254352.1	RP11-578O24.2	8	9.15e-15	8.88e-12	0.42	0.34	Lymphocyte counts;	chr8:78691689	chr8:78723796~78724136:-
LUAD	cis	rs950169	0.922	rs4338765	ENSG00000225151.9	GOLGA2P7	-8	9.16e-15	8.9e-12	-0.49	-0.34	Schizophrenia;	chr15:84248084	chr15:84199311~84230136:-
LUAD	cis	rs10463554	0.963	rs34771	ENSG00000175749.11	EIF3KP1	8	9.28e-15	9e-12	0.47	0.34	Parkinson's disease;	chr5:103114713	chr5:103032376~103033031:+
LUAD	cis	rs12134133	1	rs1583090	ENSG00000274245.1	RP11-357P18.2	8	9.35e-15	9.07e-12	0.45	0.34	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207262438	chr1:207372559~207373252:+
LUAD	cis	rs150992	0.638	rs466340	ENSG00000248489.1	CTD-2007H13.3	8	9.37e-15	9.09e-12	0.37	0.34	Body mass index;	chr5:98904318	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.673	rs326463	ENSG00000248489.1	CTD-2007H13.3	8	9.37e-15	9.09e-12	0.37	0.34	Body mass index;	chr5:98905785	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.673	rs327792	ENSG00000248489.1	CTD-2007H13.3	8	9.37e-15	9.09e-12	0.37	0.34	Body mass index;	chr5:98909802	chr5:98929171~98995013:+
LUAD	cis	rs6504622	0.755	rs7216950	ENSG00000262879.4	RP11-156P1.3	-8	9.4e-15	9.11e-12	-0.39	-0.34	Orofacial clefts;	chr17:47011089	chr17:46984045~47100323:-
LUAD	cis	rs8177876	0.749	rs78707250	ENSG00000261838.4	RP11-303E16.6	8	9.4e-15	9.12e-12	0.79	0.34	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046757	chr16:81069854~81076598:+
LUAD	cis	rs7201929	0.801	rs9933198	ENSG00000259982.1	CDC37P1	-8	9.44e-15	9.15e-12	-0.49	-0.34	QT interval;	chr16:28877088	chr16:28700294~28701540:-
LUAD	cis	rs9287719	0.967	rs7355649	ENSG00000234818.1	AC092687.5	8	9.47e-15	9.18e-12	0.41	0.34	Prostate cancer;	chr2:10607968	chr2:10589166~10604830:+
LUAD	cis	rs2337406	1	rs74090714	ENSG00000254174.1	IGHV1-12	8	9.47e-15	9.18e-12	0.32	0.34	Alzheimer's disease (late onset);	chr14:106691225	chr14:106122420~106122709:-
LUAD	cis	rs7044106	0.578	rs4837788	ENSG00000226752.6	PSMD5-AS1	-8	9.47e-15	9.18e-12	-0.46	-0.34	Hip circumference adjusted for BMI;	chr9:120634523	chr9:120824828~120854385:+
LUAD	cis	rs7429990	0.864	rs6442081	ENSG00000229759.1	MRPS18AP1	-8	9.5e-15	9.21e-12	-0.35	-0.34	Educational attainment (years of education);	chr3:47728890	chr3:48256350~48256938:-
LUAD	cis	rs9322193	0.923	rs1572229	ENSG00000223701.3	RAET1E-AS1	8	9.52e-15	9.23e-12	0.4	0.34	Lung cancer;	chr6:149743841	chr6:149884431~149919508:+
LUAD	cis	rs7188445	0.933	rs56892402	ENSG00000261390.4	RP11-345M22.2	-8	9.6e-15	9.3e-12	-0.44	-0.34	Urate levels;	chr16:79682728	chr16:79715232~79770563:-
LUAD	cis	rs9545047	0.604	rs9601217	ENSG00000227676.3	LINC01068	-8	9.63e-15	9.33e-12	-0.4	-0.34	Schizophrenia;	chr13:79359797	chr13:79566727~79571436:+
LUAD	cis	rs950880	0.71	rs11693955	ENSG00000234389.1	AC007278.3	-8	9.68e-15	9.37e-12	-0.35	-0.34	Serum protein levels (sST2);	chr2:102412705	chr2:102438713~102440475:+
LUAD	cis	rs2581828	0.646	rs9757079	ENSG00000242142.1	SERBP1P3	-8	9.71e-15	9.4e-12	-0.38	-0.34	Crohn's disease;	chr3:53121142	chr3:53064283~53065091:-
LUAD	cis	rs9287719	0.839	rs11683335	ENSG00000234818.1	AC092687.5	7.99	9.78e-15	9.46e-12	0.41	0.34	Prostate cancer;	chr2:10616539	chr2:10589166~10604830:+
LUAD	cis	rs9595066	1	rs4942281	ENSG00000227258.4	SMIM2-AS1	7.99	9.78e-15	9.47e-12	0.56	0.34	Schizophrenia;	chr13:44133990	chr13:44110451~44240517:+
LUAD	cis	rs9595066	1	rs4942282	ENSG00000227258.4	SMIM2-AS1	7.99	9.78e-15	9.47e-12	0.56	0.34	Schizophrenia;	chr13:44134280	chr13:44110451~44240517:+
LUAD	cis	rs7924176	0.564	rs2270551	ENSG00000213731.2	RAB5CP1	-7.99	9.84e-15	9.52e-12	-0.37	-0.34	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74109307	chr10:74423435~74424014:-
LUAD	cis	rs10129255	0.83	rs61997609	ENSG00000211972.2	IGHV3-66	7.99	9.85e-15	9.53e-12	0.3	0.34	Kawasaki disease;	chr14:106692376	chr14:106675017~106675544:-
LUAD	cis	rs10463554	0.963	rs6889592	ENSG00000175749.11	EIF3KP1	7.99	9.85e-15	9.54e-12	0.47	0.34	Parkinson's disease;	chr5:102978235	chr5:103032376~103033031:+
LUAD	cis	rs12220777	1	rs11201660	ENSG00000230091.5	TMEM254-AS1	-7.99	9.87e-15	9.55e-12	-0.65	-0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80094775	chr10:80046860~80078912:-
LUAD	cis	rs950169	0.922	rs12912934	ENSG00000225151.9	GOLGA2P7	-7.99	9.97e-15	9.64e-12	-0.48	-0.34	Schizophrenia;	chr15:84571216	chr15:84199311~84230136:-
LUAD	cis	rs12468226	1	rs77435512	ENSG00000273456.1	RP11-686O6.2	7.99	9.97e-15	9.64e-12	0.47	0.34	Urate levels;	chr2:202334165	chr2:202374932~202375604:-
LUAD	cis	rs9287719	0.934	rs6710033	ENSG00000234818.1	AC092687.5	7.99	1e-14	9.67e-12	0.41	0.34	Prostate cancer;	chr2:10617551	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs4669598	ENSG00000234818.1	AC092687.5	7.99	1e-14	9.67e-12	0.41	0.34	Prostate cancer;	chr2:10617712	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs4669599	ENSG00000234818.1	AC092687.5	7.99	1e-14	9.67e-12	0.41	0.34	Prostate cancer;	chr2:10617903	chr2:10589166~10604830:+
LUAD	cis	rs950880	0.71	rs11123927	ENSG00000234389.1	AC007278.3	-7.99	1.01e-14	9.72e-12	-0.35	-0.34	Serum protein levels (sST2);	chr2:102442343	chr2:102438713~102440475:+
LUAD	cis	rs950880	0.71	rs10490203	ENSG00000234389.1	AC007278.3	-7.99	1.01e-14	9.72e-12	-0.35	-0.34	Serum protein levels (sST2);	chr2:102442777	chr2:102438713~102440475:+
LUAD	cis	rs950880	0.71	rs4851583	ENSG00000234389.1	AC007278.3	-7.99	1.01e-14	9.72e-12	-0.35	-0.34	Serum protein levels (sST2);	chr2:102443840	chr2:102438713~102440475:+
LUAD	cis	rs11123694	1	rs11123694	ENSG00000214184.3	AC012487.2	-7.99	1.01e-14	9.72e-12	-0.41	-0.34	Mean platelet volume;	chr2:108448107	chr2:108507515~108534196:-
LUAD	cis	rs7688540	0.68	rs77762064	ENSG00000275426.1	CH17-262A2.1	7.99	1.01e-14	9.74e-12	0.49	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:281154	chr4:149738~150317:+
LUAD	cis	rs526231	0.543	rs72785717	ENSG00000175749.11	EIF3KP1	7.99	1.01e-14	9.76e-12	0.52	0.34	Primary biliary cholangitis;	chr5:102997401	chr5:103032376~103033031:+
LUAD	cis	rs9322193	0.923	rs9478291	ENSG00000223701.3	RAET1E-AS1	7.99	1.01e-14	9.77e-12	0.39	0.34	Lung cancer;	chr6:149729434	chr6:149884431~149919508:+
LUAD	cis	rs2581828	0.646	rs13433700	ENSG00000242142.1	SERBP1P3	-7.99	1.01e-14	9.79e-12	-0.38	-0.34	Crohn's disease;	chr3:53113870	chr3:53064283~53065091:-
LUAD	cis	rs10129255	0.957	rs10140904	ENSG00000280411.1	IGHV1-69-2	-7.99	1.01e-14	9.8e-12	-0.26	-0.34	Kawasaki disease;	chr14:106776558	chr14:106762092~106762588:-
LUAD	cis	rs8177876	0.822	rs55939311	ENSG00000261838.4	RP11-303E16.6	7.99	1.02e-14	9.81e-12	0.79	0.34	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81075493	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.822	rs12444137	ENSG00000261838.4	RP11-303E16.6	7.99	1.02e-14	9.81e-12	0.79	0.34	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81076746	chr16:81069854~81076598:+
LUAD	cis	rs11089937	0.568	rs5756989	ENSG00000211639.2	IGLV4-60	7.99	1.02e-14	9.82e-12	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22132415	chr22:22162199~22162681:+
LUAD	cis	rs7188445	0.933	rs74037509	ENSG00000261390.4	RP11-345M22.2	-7.99	1.02e-14	9.84e-12	-0.45	-0.34	Urate levels;	chr16:79679107	chr16:79715232~79770563:-
LUAD	cis	rs7188445	0.933	rs76390413	ENSG00000261390.4	RP11-345M22.2	-7.99	1.02e-14	9.84e-12	-0.45	-0.34	Urate levels;	chr16:79680019	chr16:79715232~79770563:-
LUAD	cis	rs9287719	0.967	rs6759714	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10607081	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6744854	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10607120	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6759740	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10607145	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6709466	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10608131	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6719701	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10608157	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.934	rs6432115	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10608217	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6432116	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10608489	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs2110776	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10608684	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs2110778	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10608844	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6432117	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10609233	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6432118	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10609315	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.935	rs728283	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10609964	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs728282	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10610177	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs728281	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10610229	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.934	rs6721510	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10610920	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6721514	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10610936	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.934	rs6706763	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10611281	chr2:10589166~10604830:+
LUAD	cis	rs9287719	1	rs9679122	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10611584	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs9679581	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10611610	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs10203664	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10612251	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.934	rs10201077	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10612300	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs10203785	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10612382	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs9287720	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10612538	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.87	rs10167676	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10613014	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs12995159	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10613197	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs12995602	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10613416	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6432119	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10613561	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6432120	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10613645	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6432122	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10613718	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6712304	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10614249	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6712406	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10614294	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs10195802	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10614406	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs7566875	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10614666	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.934	rs4371336	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10615597	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs4405729	ENSG00000234818.1	AC092687.5	7.99	1.03e-14	9.89e-12	0.41	0.34	Prostate cancer;	chr2:10615653	chr2:10589166~10604830:+
LUAD	cis	rs4718428	0.705	rs62465692	ENSG00000226824.5	RP4-756H11.3	-7.99	1.03e-14	9.91e-12	-0.47	-0.34	Corneal structure;	chr7:66830758	chr7:66654538~66669855:+
LUAD	cis	rs4718428	0.662	rs34577323	ENSG00000226824.5	RP4-756H11.3	-7.99	1.03e-14	9.94e-12	-0.47	-0.34	Corneal structure;	chr7:66845054	chr7:66654538~66669855:+
LUAD	cis	rs7188445	0.933	rs7187128	ENSG00000261390.4	RP11-345M22.2	-7.99	1.04e-14	1e-11	-0.45	-0.34	Urate levels;	chr16:79675606	chr16:79715232~79770563:-
LUAD	cis	rs9287719	0.967	rs6748036	ENSG00000234818.1	AC092687.5	7.98	1.05e-14	1.01e-11	0.41	0.34	Prostate cancer;	chr2:10577363	chr2:10589166~10604830:+
LUAD	cis	rs6700559	0.873	rs6427840	ENSG00000260088.1	RP11-92G12.3	-7.98	1.05e-14	1.01e-11	-0.44	-0.34	Coronary artery disease;	chr1:200685659	chr1:200669507~200694250:+
LUAD	cis	rs950169	0.84	rs12905223	ENSG00000225151.9	GOLGA2P7	-7.98	1.06e-14	1.02e-11	-0.48	-0.34	Schizophrenia;	chr15:84571037	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.8	rs4842847	ENSG00000225151.9	GOLGA2P7	-7.98	1.06e-14	1.02e-11	-0.49	-0.34	Schizophrenia;	chr15:84262447	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.922	rs11630760	ENSG00000225151.9	GOLGA2P7	-7.98	1.06e-14	1.02e-11	-0.48	-0.34	Schizophrenia;	chr15:84570106	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.887	rs71395453	ENSG00000225151.9	GOLGA2P7	-7.98	1.06e-14	1.02e-11	-0.48	-0.34	Schizophrenia;	chr15:84570259	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.922	rs11633075	ENSG00000225151.9	GOLGA2P7	-7.98	1.06e-14	1.02e-11	-0.48	-0.34	Schizophrenia;	chr15:84570741	chr15:84199311~84230136:-
LUAD	cis	rs9322193	0.923	rs10872644	ENSG00000223701.3	RAET1E-AS1	7.98	1.07e-14	1.03e-11	0.39	0.34	Lung cancer;	chr6:149741819	chr6:149884431~149919508:+
LUAD	cis	rs10129255	0.957	rs2013423	ENSG00000211972.2	IGHV3-66	7.98	1.07e-14	1.03e-11	0.3	0.34	Kawasaki disease;	chr14:106690675	chr14:106675017~106675544:-
LUAD	cis	rs9287719	0.967	rs7563894	ENSG00000234818.1	AC092687.5	7.98	1.07e-14	1.03e-11	0.41	0.34	Prostate cancer;	chr2:10614523	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs7566767	ENSG00000234818.1	AC092687.5	7.98	1.07e-14	1.03e-11	0.41	0.34	Prostate cancer;	chr2:10614537	chr2:10589166~10604830:+
LUAD	cis	rs1150668	0.796	rs728122	ENSG00000216901.1	AL022393.7	7.98	1.08e-14	1.04e-11	0.4	0.34	Pubertal anthropometrics;	chr6:28431347	chr6:28176188~28176674:+
LUAD	cis	rs9322193	0.923	rs10782316	ENSG00000223701.3	RAET1E-AS1	7.98	1.08e-14	1.04e-11	0.39	0.34	Lung cancer;	chr6:149752755	chr6:149884431~149919508:+
LUAD	cis	rs150992	0.678	rs327793	ENSG00000248489.1	CTD-2007H13.3	7.98	1.09e-14	1.05e-11	0.37	0.34	Body mass index;	chr5:98913717	chr5:98929171~98995013:+
LUAD	cis	rs944289	0.708	rs2755194	ENSG00000257826.1	RP11-116N8.4	-7.98	1.09e-14	1.05e-11	-0.36	-0.34	Thyroid cancer;	chr14:36079176	chr14:36061026~36067190:-
LUAD	cis	rs12439619	0.508	rs11856561	ENSG00000255769.6	GOLGA2P10	-7.98	1.1e-14	1.06e-11	-0.35	-0.34	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82472993~82513950:-
LUAD	cis	rs34375054	0.738	rs10846834	ENSG00000279233.1	RP11-158L12.4	7.98	1.11e-14	1.07e-11	0.27	0.34	Post bronchodilator FEV1/FVC ratio;	chr12:125141024	chr12:125138245~125141711:+
LUAD	cis	rs950169	0.922	rs62028133	ENSG00000225151.9	GOLGA2P7	-7.98	1.11e-14	1.07e-11	-0.48	-0.34	Schizophrenia;	chr15:84250623	chr15:84199311~84230136:-
LUAD	cis	rs11089937	0.512	rs34963809	ENSG00000211639.2	IGLV4-60	7.98	1.11e-14	1.07e-11	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22130737	chr22:22162199~22162681:+
LUAD	cis	rs10129255	0.557	rs4043727	ENSG00000224373.3	IGHV4-59	7.98	1.11e-14	1.07e-11	0.22	0.34	Kawasaki disease;	chr14:106649820	chr14:106627249~106627825:-
LUAD	cis	rs944289	0.74	rs11156902	ENSG00000257826.1	RP11-116N8.4	-7.98	1.11e-14	1.07e-11	-0.36	-0.34	Thyroid cancer;	chr14:36080016	chr14:36061026~36067190:-
LUAD	cis	rs7688540	0.771	rs79366248	ENSG00000275426.1	CH17-262A2.1	7.98	1.12e-14	1.07e-11	0.49	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:272870	chr4:149738~150317:+
LUAD	cis	rs7688540	0.771	rs78343340	ENSG00000275426.1	CH17-262A2.1	7.98	1.12e-14	1.07e-11	0.49	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:273648	chr4:149738~150317:+
LUAD	cis	rs9487094	0.666	rs4946967	ENSG00000260273.1	RP11-425D10.10	7.98	1.12e-14	1.07e-11	0.43	0.34	Height;	chr6:109357369	chr6:109382795~109383666:+
LUAD	cis	rs4660456	0.913	rs657149	ENSG00000237899.1	RP4-739H11.3	7.98	1.12e-14	1.07e-11	0.46	0.34	Platelet count;	chr1:40692486	chr1:40669089~40687588:-
LUAD	cis	rs944289	0.74	rs1617130	ENSG00000257826.1	RP11-116N8.4	7.97	1.12e-14	1.08e-11	0.36	0.34	Thyroid cancer;	chr14:36077059	chr14:36061026~36067190:-
LUAD	cis	rs9322193	0.886	rs9767555	ENSG00000223701.3	RAET1E-AS1	7.97	1.12e-14	1.08e-11	0.41	0.34	Lung cancer;	chr6:149647022	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs62441284	ENSG00000223701.3	RAET1E-AS1	7.97	1.12e-14	1.08e-11	0.4	0.34	Lung cancer;	chr6:149751542	chr6:149884431~149919508:+
LUAD	cis	rs904251	0.772	rs10692	ENSG00000279942.1	RP1-153P14.7	-7.97	1.12e-14	1.08e-11	-0.35	-0.34	Cognitive performance;	chr6:37483138	chr6:37567716~37571460:+
LUAD	cis	rs10875746	0.551	rs1471997	ENSG00000240399.1	RP1-228P16.1	-7.97	1.13e-14	1.08e-11	-0.41	-0.34	Longevity (90 years and older);	chr12:48329812	chr12:48054813~48055591:-
LUAD	cis	rs9545047	0.541	rs36152718	ENSG00000227676.3	LINC01068	7.97	1.13e-14	1.08e-11	0.42	0.34	Schizophrenia;	chr13:79306069	chr13:79566727~79571436:+
LUAD	cis	rs11089937	0.597	rs5756991	ENSG00000211639.2	IGLV4-60	7.97	1.13e-14	1.08e-11	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22132541	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.54	rs5756992	ENSG00000211639.2	IGLV4-60	7.97	1.13e-14	1.08e-11	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22132636	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.597	rs9622919	ENSG00000211639.2	IGLV4-60	7.97	1.13e-14	1.08e-11	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22132863	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.597	rs9619793	ENSG00000211639.2	IGLV4-60	7.97	1.13e-14	1.08e-11	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22132952	chr22:22162199~22162681:+
LUAD	cis	rs944289	0.74	rs56400346	ENSG00000257826.1	RP11-116N8.4	-7.97	1.13e-14	1.08e-11	-0.36	-0.34	Thyroid cancer;	chr14:36114681	chr14:36061026~36067190:-
LUAD	cis	rs6504622	0.755	rs11653838	ENSG00000262879.4	RP11-156P1.3	-7.97	1.14e-14	1.09e-11	-0.39	-0.34	Orofacial clefts;	chr17:47006317	chr17:46984045~47100323:-
LUAD	cis	rs12594515	0.967	rs11854477	ENSG00000273972.1	CTD-2306A12.1	-7.97	1.14e-14	1.09e-11	-0.37	-0.34	Weight;Waist circumference;	chr15:45706147	chr15:45702640~45703183:+
LUAD	cis	rs6903823	0.508	rs1778484	ENSG00000216901.1	AL022393.7	7.97	1.15e-14	1.1e-11	0.4	0.34	Pulmonary function;	chr6:28273021	chr6:28176188~28176674:+
LUAD	cis	rs9322193	0.884	rs10872647	ENSG00000223701.3	RAET1E-AS1	7.97	1.15e-14	1.1e-11	0.42	0.34	Lung cancer;	chr6:149758687	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.884	rs10872648	ENSG00000223701.3	RAET1E-AS1	7.97	1.15e-14	1.1e-11	0.42	0.34	Lung cancer;	chr6:149758699	chr6:149884431~149919508:+
LUAD	cis	rs9309711	0.506	rs9284794	ENSG00000225234.1	TRAPPC12-AS1	-7.97	1.16e-14	1.11e-11	-0.39	-0.34	Neurofibrillary tangles;	chr2:3488281	chr2:3481242~3482409:-
LUAD	cis	rs526231	0.578	rs2112886	ENSG00000175749.11	EIF3KP1	-7.97	1.17e-14	1.12e-11	-0.49	-0.34	Primary biliary cholangitis;	chr5:102915678	chr5:103032376~103033031:+
LUAD	cis	rs11846409	0.932	rs60659763	ENSG00000274576.2	IGHV2-70	-7.97	1.17e-14	1.12e-11	-0.36	-0.34	Rheumatic heart disease;	chr14:106634172	chr14:106770577~106771020:-
LUAD	cis	rs11846409	0.932	rs57080270	ENSG00000274576.2	IGHV2-70	-7.97	1.17e-14	1.12e-11	-0.36	-0.34	Rheumatic heart disease;	chr14:106634215	chr14:106770577~106771020:-
LUAD	cis	rs11846409	0.932	rs60917084	ENSG00000274576.2	IGHV2-70	-7.97	1.17e-14	1.12e-11	-0.36	-0.34	Rheumatic heart disease;	chr14:106634621	chr14:106770577~106771020:-
LUAD	cis	rs367615	0.704	rs4320313	ENSG00000249476.1	CTD-2587M2.1	7.97	1.17e-14	1.12e-11	0.39	0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109492986	chr5:109237120~109326369:-
LUAD	cis	rs7688540	0.771	rs74984113	ENSG00000275426.1	CH17-262A2.1	7.97	1.17e-14	1.12e-11	0.5	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:256733	chr4:149738~150317:+
LUAD	cis	rs367615	0.704	rs60538082	ENSG00000249476.1	CTD-2587M2.1	7.97	1.18e-14	1.13e-11	0.39	0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109493400	chr5:109237120~109326369:-
LUAD	cis	rs950169	0.723	rs17589320	ENSG00000225151.9	GOLGA2P7	-7.97	1.18e-14	1.13e-11	-0.48	-0.34	Schizophrenia;	chr15:84251244	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.845	rs4502182	ENSG00000225151.9	GOLGA2P7	-7.97	1.18e-14	1.13e-11	-0.48	-0.34	Schizophrenia;	chr15:84254768	chr15:84199311~84230136:-
LUAD	cis	rs9322193	0.884	rs9688699	ENSG00000223701.3	RAET1E-AS1	7.97	1.18e-14	1.13e-11	0.4	0.34	Lung cancer;	chr6:149733680	chr6:149884431~149919508:+
LUAD	cis	rs10129255	0.957	rs8009073	ENSG00000280411.1	IGHV1-69-2	-7.97	1.19e-14	1.14e-11	-0.26	-0.34	Kawasaki disease;	chr14:106777278	chr14:106762092~106762588:-
LUAD	cis	rs9326248	0.861	rs494356	ENSG00000280143.1	AP000892.6	7.97	1.19e-14	1.14e-11	0.5	0.34	Blood protein levels;	chr11:117201254	chr11:117204967~117210292:+
LUAD	cis	rs950880	0.71	rs56043441	ENSG00000234389.1	AC007278.3	-7.97	1.2e-14	1.15e-11	-0.35	-0.34	Serum protein levels (sST2);	chr2:102470923	chr2:102438713~102440475:+
LUAD	cis	rs1150668	0.796	rs213237	ENSG00000204709.4	LINC01556	7.96	1.22e-14	1.16e-11	0.42	0.34	Pubertal anthropometrics;	chr6:28356161	chr6:28943877~28944537:+
LUAD	cis	rs8040855	0.694	rs12908400	ENSG00000259295.5	CSPG4P12	7.96	1.22e-14	1.17e-11	0.43	0.34	Bulimia nervosa;	chr15:85029945	chr15:85191438~85213905:+
LUAD	cis	rs1150668	0.796	rs2247002	ENSG00000204709.4	LINC01556	7.96	1.23e-14	1.18e-11	0.42	0.34	Pubertal anthropometrics;	chr6:28430174	chr6:28943877~28944537:+
LUAD	cis	rs2337406	0.866	rs4773949	ENSG00000254174.1	IGHV1-12	-7.96	1.23e-14	1.18e-11	-0.29	-0.34	Alzheimer's disease (late onset);	chr14:106808070	chr14:106122420~106122709:-
LUAD	cis	rs638893	0.636	rs61901411	ENSG00000278376.1	RP11-158I9.8	7.96	1.24e-14	1.18e-11	0.54	0.34	Vitiligo;	chr11:118794615	chr11:118791254~118793137:+
LUAD	cis	rs2283792	1	rs5999521	ENSG00000224086.5	LL22NC03-86G7.1	-7.96	1.26e-14	1.2e-11	-0.32	-0.34	Multiple sclerosis;	chr22:21792110	chr22:21938293~21977632:+
LUAD	cis	rs35160687	0.798	rs11127029	ENSG00000273080.1	RP11-301O19.1	-7.96	1.26e-14	1.2e-11	-0.39	-0.34	Night sleep phenotypes;	chr2:86327502	chr2:86195590~86196049:+
LUAD	cis	rs9545047	0.604	rs1324870	ENSG00000227676.3	LINC01068	-7.96	1.26e-14	1.21e-11	-0.39	-0.34	Schizophrenia;	chr13:79297911	chr13:79566727~79571436:+
LUAD	cis	rs6504950	0.925	rs244317	ENSG00000275710.1	RP11-257O5.4	-7.96	1.26e-14	1.21e-11	-0.45	-0.34	Breast cancer;	chr17:55139624	chr17:54964474~54964679:+
LUAD	cis	rs4718428	0.672	rs36038499	ENSG00000226824.5	RP4-756H11.3	-7.96	1.27e-14	1.21e-11	-0.46	-0.34	Corneal structure;	chr7:66824628	chr7:66654538~66669855:+
LUAD	cis	rs638893	1	rs28827279	ENSG00000278376.1	RP11-158I9.8	-7.96	1.27e-14	1.22e-11	-0.49	-0.34	Vitiligo;	chr11:118830054	chr11:118791254~118793137:+
LUAD	cis	rs10463554	0.892	rs32842	ENSG00000175749.11	EIF3KP1	7.96	1.28e-14	1.22e-11	0.48	0.34	Parkinson's disease;	chr5:103142298	chr5:103032376~103033031:+
LUAD	cis	rs4718428	0.705	rs3800817	ENSG00000226824.5	RP4-756H11.3	-7.96	1.28e-14	1.22e-11	-0.47	-0.34	Corneal structure;	chr7:66798563	chr7:66654538~66669855:+
LUAD	cis	rs10129255	0.912	rs67410411	ENSG00000211972.2	IGHV3-66	7.96	1.28e-14	1.23e-11	0.3	0.34	Kawasaki disease;	chr14:106680324	chr14:106675017~106675544:-
LUAD	cis	rs7429990	0.864	rs3915654	ENSG00000229759.1	MRPS18AP1	-7.96	1.29e-14	1.23e-11	-0.34	-0.34	Educational attainment (years of education);	chr3:47827132	chr3:48256350~48256938:-
LUAD	cis	rs7429990	1	rs7429990	ENSG00000229759.1	MRPS18AP1	7.95	1.3e-14	1.24e-11	0.37	0.34	Educational attainment (years of education);	chr3:47860313	chr3:48256350~48256938:-
LUAD	cis	rs11089937	0.553	rs35336247	ENSG00000211639.2	IGLV4-60	7.95	1.31e-14	1.25e-11	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22131593	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.553	rs34088081	ENSG00000211639.2	IGLV4-60	7.95	1.31e-14	1.25e-11	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22131601	chr22:22162199~22162681:+
LUAD	cis	rs11123170	0.503	rs28679654	ENSG00000189223.12	PAX8-AS1	-7.95	1.32e-14	1.26e-11	-0.55	-0.34	Renal function-related traits (BUN);	chr2:113210040	chr2:113211522~113276581:+
LUAD	cis	rs8059260	0.541	rs16958028	ENSG00000274038.1	RP11-66H6.4	-7.95	1.32e-14	1.26e-11	-0.78	-0.34	Alcohol consumption over the past year;	chr16:11082811	chr16:11056556~11057034:+
LUAD	cis	rs10875746	0.587	rs9788082	ENSG00000240399.1	RP1-228P16.1	-7.95	1.32e-14	1.26e-11	-0.42	-0.34	Longevity (90 years and older);	chr12:48358273	chr12:48054813~48055591:-
LUAD	cis	rs673078	0.517	rs73205578	ENSG00000275759.1	RP11-131L12.3	-7.95	1.33e-14	1.27e-11	-0.51	-0.34	Glucose homeostasis traits;	chr12:118385113	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.66	rs73205579	ENSG00000275759.1	RP11-131L12.3	-7.95	1.33e-14	1.27e-11	-0.51	-0.34	Glucose homeostasis traits;	chr12:118385125	chr12:118428281~118428870:+
LUAD	cis	rs11089937	0.626	rs9619811	ENSG00000211639.2	IGLV4-60	7.95	1.34e-14	1.28e-11	0.41	0.34	Periodontitis (PAL4Q3);	chr22:22159186	chr22:22162199~22162681:+
LUAD	cis	rs2919917	1	rs11986947	ENSG00000254352.1	RP11-578O24.2	7.95	1.34e-14	1.28e-11	0.42	0.34	Lymphocyte counts;	chr8:78708957	chr8:78723796~78724136:-
LUAD	cis	rs8059260	0.544	rs35347079	ENSG00000274038.1	RP11-66H6.4	-7.95	1.35e-14	1.29e-11	-0.68	-0.34	Alcohol consumption over the past year;	chr16:11099696	chr16:11056556~11057034:+
LUAD	cis	rs944289	0.74	rs1623766	ENSG00000257826.1	RP11-116N8.4	7.95	1.37e-14	1.3e-11	0.36	0.34	Thyroid cancer;	chr14:36075632	chr14:36061026~36067190:-
LUAD	cis	rs944289	0.74	rs416664	ENSG00000257826.1	RP11-116N8.4	7.95	1.37e-14	1.3e-11	0.36	0.34	Thyroid cancer;	chr14:36076319	chr14:36061026~36067190:-
LUAD	cis	rs9322193	0.886	rs9718079	ENSG00000223701.3	RAET1E-AS1	7.95	1.37e-14	1.3e-11	0.4	0.34	Lung cancer;	chr6:149645947	chr6:149884431~149919508:+
LUAD	cis	rs944289	0.74	rs1467794	ENSG00000257826.1	RP11-116N8.4	7.95	1.37e-14	1.3e-11	0.36	0.34	Thyroid cancer;	chr14:36097617	chr14:36061026~36067190:-
LUAD	cis	rs10463554	0.963	rs34773	ENSG00000175749.11	EIF3KP1	7.95	1.37e-14	1.3e-11	0.47	0.34	Parkinson's disease;	chr5:103114872	chr5:103032376~103033031:+
LUAD	cis	rs3096299	0.967	rs2965937	ENSG00000274627.1	RP11-104N10.2	7.95	1.38e-14	1.31e-11	0.33	0.34	Multiple myeloma (IgH translocation);	chr16:89422371	chr16:89516797~89522217:+
LUAD	cis	rs367615	0.66	rs10061221	ENSG00000249476.1	CTD-2587M2.1	7.95	1.38e-14	1.32e-11	0.39	0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109503337	chr5:109237120~109326369:-
LUAD	cis	rs6903823	0.508	rs1150726	ENSG00000216901.1	AL022393.7	7.95	1.38e-14	1.32e-11	0.4	0.34	Pulmonary function;	chr6:28275265	chr6:28176188~28176674:+
LUAD	cis	rs9287719	0.967	rs4284804	ENSG00000234818.1	AC092687.5	7.95	1.39e-14	1.32e-11	0.41	0.34	Prostate cancer;	chr2:10581998	chr2:10589166~10604830:+
LUAD	cis	rs8062405	0.723	rs4788077	ENSG00000259982.1	CDC37P1	7.94	1.39e-14	1.32e-11	0.44	0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28700294~28701540:-
LUAD	cis	rs944289	0.74	rs414155	ENSG00000257826.1	RP11-116N8.4	7.94	1.39e-14	1.32e-11	0.36	0.34	Thyroid cancer;	chr14:36076300	chr14:36061026~36067190:-
LUAD	cis	rs1563304	1	rs1563304	ENSG00000262539.1	RP11-259G18.3	7.94	1.4e-14	1.33e-11	0.6	0.34	Neuroticism;	chr17:46797087	chr17:46259551~46260606:-
LUAD	cis	rs11089937	0.597	rs6001072	ENSG00000211639.2	IGLV4-60	7.94	1.41e-14	1.34e-11	0.39	0.34	Periodontitis (PAL4Q3);	chr22:22133629	chr22:22162199~22162681:+
LUAD	cis	rs6844153	0.752	rs58968032	ENSG00000240005.4	RP11-293A21.1	-7.94	1.41e-14	1.35e-11	-0.51	-0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26884674	chr4:26859806~26860599:-
LUAD	cis	rs10463554	0.892	rs1837256	ENSG00000175749.11	EIF3KP1	7.94	1.41e-14	1.35e-11	0.48	0.34	Parkinson's disease;	chr5:102968852	chr5:103032376~103033031:+
LUAD	cis	rs4141404	0.582	rs5753630	ENSG00000236132.1	CTA-440B3.1	-7.94	1.42e-14	1.35e-11	-0.39	-0.34	Paclitaxel-induced neuropathy;	chr22:31465964	chr22:31816379~31817491:-
LUAD	cis	rs8005677	0.828	rs2295680	ENSG00000279656.1	RP11-298I3.6	-7.94	1.43e-14	1.36e-11	-0.41	-0.34	Cognitive ability (multi-trait analysis);	chr14:22905226	chr14:23023083~23024217:-
LUAD	cis	rs10129255	0.701	rs2005643	ENSG00000280411.1	IGHV1-69-2	-7.94	1.43e-14	1.36e-11	-0.25	-0.34	Kawasaki disease;	chr14:106676288	chr14:106762092~106762588:-
LUAD	cis	rs7688540	0.771	rs11722197	ENSG00000275426.1	CH17-262A2.1	7.94	1.44e-14	1.36e-11	0.49	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:287918	chr4:149738~150317:+
LUAD	cis	rs7688540	0.771	rs11723261	ENSG00000275426.1	CH17-262A2.1	7.94	1.44e-14	1.36e-11	0.49	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:288710	chr4:149738~150317:+
LUAD	cis	rs1537424	0.513	rs1615453	ENSG00000257826.1	RP11-116N8.4	7.94	1.44e-14	1.37e-11	0.37	0.34	Thyroid hormone levels;	chr14:36077246	chr14:36061026~36067190:-
LUAD	cis	rs6700559	0.873	rs7526031	ENSG00000260088.1	RP11-92G12.3	-7.94	1.44e-14	1.37e-11	-0.43	-0.34	Coronary artery disease;	chr1:200695174	chr1:200669507~200694250:+
LUAD	cis	rs494459	0.691	rs607472	ENSG00000255239.1	AP002954.6	7.94	1.44e-14	1.37e-11	0.41	0.34	Height;	chr11:118809363	chr11:118688039~118690600:-
LUAD	cis	rs5769707	0.681	rs2319346	ENSG00000188511.11	C22orf34	7.94	1.45e-14	1.38e-11	0.44	0.34	Monocyte percentage of white cells;Monocyte count;	chr22:49635992	chr22:49414524~49657542:-
LUAD	cis	rs7429990	0.864	rs319693	ENSG00000229759.1	MRPS18AP1	7.94	1.45e-14	1.38e-11	0.36	0.34	Educational attainment (years of education);	chr3:47845090	chr3:48256350~48256938:-
LUAD	cis	rs9660180	0.875	rs4648727	ENSG00000268575.1	RP1-283E3.8	7.94	1.45e-14	1.38e-11	0.3	0.34	Body mass index;	chr1:1844830	chr1:1702736~1737688:-
LUAD	cis	rs2015599	0.563	rs11050168	ENSG00000257176.2	RP11-996F15.2	7.94	1.46e-14	1.38e-11	0.37	0.34	Platelet count;Mean platelet volume;	chr12:29273760	chr12:29280418~29317848:-
LUAD	cis	rs8059260	0.604	rs16958021	ENSG00000274038.1	RP11-66H6.4	-7.94	1.46e-14	1.39e-11	-0.7	-0.34	Alcohol consumption over the past year;	chr16:11076190	chr16:11056556~11057034:+
LUAD	cis	rs673078	0.607	rs4766899	ENSG00000275759.1	RP11-131L12.3	-7.94	1.46e-14	1.39e-11	-0.43	-0.34	Glucose homeostasis traits;	chr12:118374888	chr12:118428281~118428870:+
LUAD	cis	rs11123170	0.529	rs1015755	ENSG00000189223.12	PAX8-AS1	-7.94	1.46e-14	1.39e-11	-0.56	-0.34	Renal function-related traits (BUN);	chr2:113210730	chr2:113211522~113276581:+
LUAD	cis	rs7188445	0.866	rs11644799	ENSG00000261390.4	RP11-345M22.2	-7.94	1.46e-14	1.39e-11	-0.45	-0.34	Urate levels;	chr16:79675212	chr16:79715232~79770563:-
LUAD	cis	rs526231	0.543	rs246906	ENSG00000175749.11	EIF3KP1	7.94	1.46e-14	1.39e-11	0.5	0.34	Primary biliary cholangitis;	chr5:103230770	chr5:103032376~103033031:+
LUAD	cis	rs765787	0.53	rs2668737	ENSG00000259520.4	CTD-2651B20.3	7.94	1.47e-14	1.4e-11	0.45	0.34	Uric acid levels;	chr15:45230601	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs1706764	ENSG00000259520.4	CTD-2651B20.3	7.94	1.47e-14	1.4e-11	0.45	0.34	Uric acid levels;	chr15:45232058	chr15:45251580~45279251:-
LUAD	cis	rs7429990	0.965	rs7651237	ENSG00000229759.1	MRPS18AP1	-7.94	1.48e-14	1.4e-11	-0.38	-0.34	Educational attainment (years of education);	chr3:48064038	chr3:48256350~48256938:-
LUAD	cis	rs6700559	0.873	rs7542210	ENSG00000260088.1	RP11-92G12.3	-7.94	1.48e-14	1.4e-11	-0.43	-0.34	Coronary artery disease;	chr1:200693087	chr1:200669507~200694250:+
LUAD	cis	rs9322193	0.924	rs9498382	ENSG00000223701.3	RAET1E-AS1	7.94	1.48e-14	1.4e-11	0.4	0.34	Lung cancer;	chr6:149610982	chr6:149884431~149919508:+
LUAD	cis	rs10463554	0.892	rs1561404	ENSG00000175749.11	EIF3KP1	7.94	1.48e-14	1.4e-11	0.47	0.34	Parkinson's disease;	chr5:102963647	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.892	rs1560040	ENSG00000175749.11	EIF3KP1	7.94	1.48e-14	1.4e-11	0.47	0.34	Parkinson's disease;	chr5:102964363	chr5:103032376~103033031:+
LUAD	cis	rs6504622	0.721	rs8077021	ENSG00000262879.4	RP11-156P1.3	-7.94	1.48e-14	1.41e-11	-0.38	-0.34	Orofacial clefts;	chr17:47061937	chr17:46984045~47100323:-
LUAD	cis	rs11089937	0.626	rs2213157	ENSG00000211639.2	IGLV4-60	7.94	1.48e-14	1.41e-11	0.39	0.34	Periodontitis (PAL4Q3);	chr22:22137997	chr22:22162199~22162681:+
LUAD	cis	rs9322193	0.566	rs12528243	ENSG00000216906.2	RP11-350J20.9	7.93	1.49e-14	1.42e-11	0.5	0.34	Lung cancer;	chr6:149898491	chr6:149904243~149906418:+
LUAD	cis	rs11096990	0.634	rs4975002	ENSG00000249207.1	RP11-360F5.1	7.93	1.49e-14	1.42e-11	0.37	0.34	Cognitive function;	chr4:39286733	chr4:39112677~39126818:-
LUAD	cis	rs638893	0.842	rs480791	ENSG00000278376.1	RP11-158I9.8	-7.93	1.49e-14	1.42e-11	-0.48	-0.34	Vitiligo;	chr11:118833546	chr11:118791254~118793137:+
LUAD	cis	rs9322193	0.923	rs4870050	ENSG00000223701.3	RAET1E-AS1	7.93	1.5e-14	1.42e-11	0.4	0.34	Lung cancer;	chr6:149838917	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs4242279	ENSG00000223701.3	RAET1E-AS1	7.93	1.5e-14	1.42e-11	0.4	0.34	Lung cancer;	chr6:149839815	chr6:149884431~149919508:+
LUAD	cis	rs10463554	0.892	rs62362519	ENSG00000175749.11	EIF3KP1	7.93	1.51e-14	1.43e-11	0.47	0.34	Parkinson's disease;	chr5:102965759	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.853	rs2241565	ENSG00000175749.11	EIF3KP1	7.93	1.51e-14	1.43e-11	0.47	0.34	Parkinson's disease;	chr5:102966233	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.818	rs2241564	ENSG00000175749.11	EIF3KP1	7.93	1.51e-14	1.43e-11	0.47	0.34	Parkinson's disease;	chr5:102966547	chr5:103032376~103033031:+
LUAD	cis	rs944289	0.774	rs1537423	ENSG00000257826.1	RP11-116N8.4	7.93	1.52e-14	1.44e-11	0.36	0.34	Thyroid cancer;	chr14:36104863	chr14:36061026~36067190:-
LUAD	cis	rs8062405	0.755	rs62031607	ENSG00000259982.1	CDC37P1	7.93	1.53e-14	1.45e-11	0.44	0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620209	chr16:28700294~28701540:-
LUAD	cis	rs55757919	1	rs55757919	ENSG00000231742.4	LINC01273	7.93	1.53e-14	1.45e-11	0.49	0.34	Monocyte percentage of white cells;	chr20:50132011	chr20:50172550~50176671:+
LUAD	cis	rs4853012	0.838	rs4563249	ENSG00000257800.1	FNBP1P1	7.93	1.54e-14	1.46e-11	0.42	0.34	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74120680~74123218:+
LUAD	cis	rs765787	0.53	rs2413786	ENSG00000259520.4	CTD-2651B20.3	7.93	1.55e-14	1.47e-11	0.44	0.34	Uric acid levels;	chr15:45233196	chr15:45251580~45279251:-
LUAD	cis	rs2581828	0.618	rs9868406	ENSG00000242142.1	SERBP1P3	-7.93	1.56e-14	1.47e-11	-0.39	-0.34	Crohn's disease;	chr3:53130177	chr3:53064283~53065091:-
LUAD	cis	rs944289	0.712	rs35736442	ENSG00000257826.1	RP11-116N8.4	-7.93	1.56e-14	1.47e-11	-0.36	-0.34	Thyroid cancer;	chr14:36081119	chr14:36061026~36067190:-
LUAD	cis	rs11155671	0.53	rs6935829	ENSG00000223701.3	RAET1E-AS1	7.93	1.56e-14	1.48e-11	0.41	0.34	Testicular germ cell tumor;	chr6:149896675	chr6:149884431~149919508:+
LUAD	cis	rs7945705	0.774	rs6486060	ENSG00000254860.4	TMEM9B-AS1	-7.93	1.56e-14	1.48e-11	-0.39	-0.34	Hemoglobin concentration;	chr11:9003083	chr11:8964675~8977527:+
LUAD	cis	rs944289	0.74	rs884384	ENSG00000257826.1	RP11-116N8.4	-7.93	1.56e-14	1.48e-11	-0.36	-0.34	Thyroid cancer;	chr14:36081801	chr14:36061026~36067190:-
LUAD	cis	rs944289	0.74	rs884383	ENSG00000257826.1	RP11-116N8.4	-7.93	1.56e-14	1.48e-11	-0.36	-0.34	Thyroid cancer;	chr14:36081936	chr14:36061026~36067190:-
LUAD	cis	rs9322193	0.851	rs9322194	ENSG00000223701.3	RAET1E-AS1	7.93	1.59e-14	1.5e-11	0.4	0.34	Lung cancer;	chr6:149599113	chr6:149884431~149919508:+
LUAD	cis	rs904251	0.686	rs1224128	ENSG00000204110.6	RP1-153P14.8	-7.93	1.59e-14	1.51e-11	-0.4	-0.34	Cognitive performance;	chr6:37447900	chr6:37507348~37535616:+
LUAD	cis	rs9322193	0.962	rs7752089	ENSG00000223701.3	RAET1E-AS1	7.93	1.6e-14	1.51e-11	0.4	0.34	Lung cancer;	chr6:149839298	chr6:149884431~149919508:+
LUAD	cis	rs6504622	0.755	rs11079750	ENSG00000262879.4	RP11-156P1.3	-7.92	1.6e-14	1.52e-11	-0.38	-0.34	Orofacial clefts;	chr17:47072149	chr17:46984045~47100323:-
LUAD	cis	rs10899021	1	rs11236190	ENSG00000279353.1	RP11-864N7.4	7.92	1.6e-14	1.52e-11	0.69	0.34	Response to metformin (IC50);	chr11:74655710	chr11:74698231~74699658:-
LUAD	cis	rs9287719	0.967	rs6432121	ENSG00000234818.1	AC092687.5	7.92	1.61e-14	1.52e-11	0.4	0.34	Prostate cancer;	chr2:10613678	chr2:10589166~10604830:+
LUAD	cis	rs11096990	0.634	rs7564	ENSG00000249207.1	RP11-360F5.1	7.92	1.62e-14	1.53e-11	0.37	0.34	Cognitive function;	chr4:39285702	chr4:39112677~39126818:-
LUAD	cis	rs944289	0.74	rs398501	ENSG00000257826.1	RP11-116N8.4	-7.92	1.62e-14	1.53e-11	-0.36	-0.34	Thyroid cancer;	chr14:36078452	chr14:36061026~36067190:-
LUAD	cis	rs904251	0.714	rs2776910	ENSG00000204110.6	RP1-153P14.8	-7.92	1.63e-14	1.54e-11	-0.4	-0.34	Cognitive performance;	chr6:37468508	chr6:37507348~37535616:+
LUAD	cis	rs9322193	0.607	rs12527391	ENSG00000216906.2	RP11-350J20.9	7.92	1.63e-14	1.54e-11	0.51	0.34	Lung cancer;	chr6:149882156	chr6:149904243~149906418:+
LUAD	cis	rs11096990	0.613	rs9997015	ENSG00000249207.1	RP11-360F5.1	7.92	1.63e-14	1.54e-11	0.37	0.34	Cognitive function;	chr4:39222677	chr4:39112677~39126818:-
LUAD	cis	rs10875746	0.551	rs3185921	ENSG00000240399.1	RP1-228P16.1	-7.92	1.63e-14	1.54e-11	-0.41	-0.34	Longevity (90 years and older);	chr12:48340948	chr12:48054813~48055591:-
LUAD	cis	rs11155671	0.53	rs9397420	ENSG00000223701.3	RAET1E-AS1	-7.92	1.64e-14	1.55e-11	-0.4	-0.34	Testicular germ cell tumor;	chr6:149885645	chr6:149884431~149919508:+
LUAD	cis	rs11096990	0.656	rs7686161	ENSG00000249207.1	RP11-360F5.1	7.92	1.64e-14	1.55e-11	0.37	0.34	Cognitive function;	chr4:39283201	chr4:39112677~39126818:-
LUAD	cis	rs10129255	0.957	rs1024349	ENSG00000211972.2	IGHV3-66	7.92	1.64e-14	1.55e-11	0.3	0.34	Kawasaki disease;	chr14:106689997	chr14:106675017~106675544:-
LUAD	cis	rs9287719	0.81	rs7601748	ENSG00000234818.1	AC092687.5	7.92	1.65e-14	1.56e-11	0.41	0.34	Prostate cancer;	chr2:10645320	chr2:10589166~10604830:+
LUAD	cis	rs904251	0.58	rs62408367	ENSG00000204110.6	RP1-153P14.8	-7.92	1.67e-14	1.57e-11	-0.35	-0.34	Cognitive performance;	chr6:37477037	chr6:37507348~37535616:+
LUAD	cis	rs2919917	1	rs7010897	ENSG00000254352.1	RP11-578O24.2	7.92	1.67e-14	1.58e-11	0.42	0.34	Lymphocyte counts;	chr8:78708119	chr8:78723796~78724136:-
LUAD	cis	rs10463554	1	rs17154893	ENSG00000175749.11	EIF3KP1	7.92	1.68e-14	1.58e-11	0.46	0.34	Parkinson's disease;	chr5:102980902	chr5:103032376~103033031:+
LUAD	cis	rs10463554	1	rs6596529	ENSG00000175749.11	EIF3KP1	7.92	1.68e-14	1.58e-11	0.46	0.34	Parkinson's disease;	chr5:102981338	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.543	rs62362884	ENSG00000175749.11	EIF3KP1	7.92	1.68e-14	1.59e-11	0.5	0.34	Primary biliary cholangitis;	chr5:103231754	chr5:103032376~103033031:+
LUAD	cis	rs10200159	0.793	rs13383352	ENSG00000272606.1	RP11-554J4.1	7.92	1.68e-14	1.59e-11	0.57	0.34	Vitiligo;	chr2:55643692	chr2:55617909~55618373:+
LUAD	cis	rs8059260	0.604	rs741176	ENSG00000274038.1	RP11-66H6.4	7.92	1.69e-14	1.59e-11	0.58	0.34	Alcohol consumption over the past year;	chr16:11051953	chr16:11056556~11057034:+
LUAD	cis	rs8059260	0.604	rs11863415	ENSG00000274038.1	RP11-66H6.4	-7.92	1.69e-14	1.6e-11	-0.56	-0.34	Alcohol consumption over the past year;	chr16:11053237	chr16:11056556~11057034:+
LUAD	cis	rs7429990	1	rs319680	ENSG00000229759.1	MRPS18AP1	7.92	1.69e-14	1.6e-11	0.37	0.34	Educational attainment (years of education);	chr3:47856817	chr3:48256350~48256938:-
LUAD	cis	rs3096299	0.967	rs2911253	ENSG00000274627.1	RP11-104N10.2	7.92	1.69e-14	1.6e-11	0.33	0.34	Multiple myeloma (IgH translocation);	chr16:89422179	chr16:89516797~89522217:+
LUAD	cis	rs35160687	0.798	rs6547674	ENSG00000273080.1	RP11-301O19.1	-7.92	1.69e-14	1.6e-11	-0.39	-0.34	Night sleep phenotypes;	chr2:86325796	chr2:86195590~86196049:+
LUAD	cis	rs9287719	1	rs9287719	ENSG00000234818.1	AC092687.5	7.92	1.69e-14	1.6e-11	0.41	0.34	Prostate cancer;	chr2:10570604	chr2:10589166~10604830:+
LUAD	cis	rs1167827	0.805	rs809439	ENSG00000127957.15	PMS2P3	7.92	1.71e-14	1.61e-11	0.32	0.34	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75531992	chr7:75502930~75528148:-
LUAD	cis	rs9287719	0.935	rs10803723	ENSG00000234818.1	AC092687.5	7.92	1.71e-14	1.61e-11	0.41	0.34	Prostate cancer;	chr2:10582751	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.935	rs6751075	ENSG00000234818.1	AC092687.5	7.92	1.71e-14	1.61e-11	0.41	0.34	Prostate cancer;	chr2:10583420	chr2:10589166~10604830:+
LUAD	cis	rs7208859	0.725	rs9910051	ENSG00000263531.1	RP13-753N3.1	7.91	1.73e-14	1.63e-11	0.59	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834184	chr17:30863921~30864940:-
LUAD	cis	rs4660456	0.913	rs2361651	ENSG00000237899.1	RP4-739H11.3	7.91	1.73e-14	1.64e-11	0.47	0.34	Platelet count;	chr1:40764542	chr1:40669089~40687588:-
LUAD	cis	rs638893	0.636	rs61901410	ENSG00000278376.1	RP11-158I9.8	7.91	1.74e-14	1.64e-11	0.54	0.34	Vitiligo;	chr11:118790488	chr11:118791254~118793137:+
LUAD	cis	rs638893	1	rs638893	ENSG00000278376.1	RP11-158I9.8	-7.91	1.74e-14	1.64e-11	-0.49	-0.34	Vitiligo;	chr11:118827828	chr11:118791254~118793137:+
LUAD	cis	rs950880	0.71	rs2287034	ENSG00000234389.1	AC007278.3	7.91	1.75e-14	1.65e-11	0.34	0.34	Serum protein levels (sST2);	chr2:102394128	chr2:102438713~102440475:+
LUAD	cis	rs7429990	0.864	rs17290490	ENSG00000229759.1	MRPS18AP1	-7.91	1.75e-14	1.65e-11	-0.34	-0.34	Educational attainment (years of education);	chr3:47841237	chr3:48256350~48256938:-
LUAD	cis	rs7188445	0.933	rs28773265	ENSG00000261390.4	RP11-345M22.2	-7.91	1.75e-14	1.65e-11	-0.45	-0.34	Urate levels;	chr16:79678864	chr16:79715232~79770563:-
LUAD	cis	rs10899021	1	rs11236201	ENSG00000279353.1	RP11-864N7.4	7.91	1.76e-14	1.66e-11	0.7	0.34	Response to metformin (IC50);	chr11:74664588	chr11:74698231~74699658:-
LUAD	cis	rs10899021	1	rs11236202	ENSG00000279353.1	RP11-864N7.4	7.91	1.76e-14	1.66e-11	0.7	0.34	Response to metformin (IC50);	chr11:74665647	chr11:74698231~74699658:-
LUAD	cis	rs11096990	0.613	rs4974995	ENSG00000249207.1	RP11-360F5.1	7.91	1.77e-14	1.67e-11	0.37	0.34	Cognitive function;	chr4:39216503	chr4:39112677~39126818:-
LUAD	cis	rs2581828	0.58	rs6799837	ENSG00000242142.1	SERBP1P3	-7.91	1.77e-14	1.67e-11	-0.39	-0.34	Crohn's disease;	chr3:53133838	chr3:53064283~53065091:-
LUAD	cis	rs11123170	0.543	rs2166421	ENSG00000189223.12	PAX8-AS1	-7.91	1.77e-14	1.67e-11	-0.56	-0.34	Renal function-related traits (BUN);	chr2:113232665	chr2:113211522~113276581:+
LUAD	cis	rs6903823	0.508	rs1150721	ENSG00000216901.1	AL022393.7	7.91	1.77e-14	1.67e-11	0.39	0.34	Pulmonary function;	chr6:28287263	chr6:28176188~28176674:+
LUAD	cis	rs9532669	0.926	rs7329302	ENSG00000176268.5	CYCSP34	-7.91	1.78e-14	1.67e-11	-0.33	-0.34	Cervical cancer;	chr13:40962396	chr13:40863599~40863902:-
LUAD	cis	rs3096299	0.967	rs2911255	ENSG00000274627.1	RP11-104N10.2	7.91	1.78e-14	1.68e-11	0.32	0.34	Multiple myeloma (IgH translocation);	chr16:89420729	chr16:89516797~89522217:+
LUAD	cis	rs950169	0.922	rs11633534	ENSG00000225151.9	GOLGA2P7	-7.91	1.79e-14	1.68e-11	-0.48	-0.34	Schizophrenia;	chr15:84581411	chr15:84199311~84230136:-
LUAD	cis	rs9287719	0.649	rs58633964	ENSG00000234818.1	AC092687.5	7.91	1.79e-14	1.69e-11	0.41	0.34	Prostate cancer;	chr2:10596256	chr2:10589166~10604830:+
LUAD	cis	rs9481169	0.557	rs13194006	ENSG00000255389.1	C6orf3	-7.91	1.79e-14	1.69e-11	-0.77	-0.34	Inflammatory skin disease;	chr6:111575051	chr6:111599875~111602295:+
LUAD	cis	rs7945705	0.712	rs61876274	ENSG00000254860.4	TMEM9B-AS1	-7.91	1.8e-14	1.69e-11	-0.38	-0.34	Hemoglobin concentration;	chr11:8997643	chr11:8964675~8977527:+
LUAD	cis	rs9287719	0.967	rs10929682	ENSG00000234818.1	AC092687.5	7.91	1.8e-14	1.7e-11	0.41	0.34	Prostate cancer;	chr2:10592063	chr2:10589166~10604830:+
LUAD	cis	rs8059260	0.736	rs80207136	ENSG00000274038.1	RP11-66H6.4	-7.91	1.81e-14	1.7e-11	-0.63	-0.34	Alcohol consumption over the past year;	chr16:11015480	chr16:11056556~11057034:+
LUAD	cis	rs944289	0.74	rs12891345	ENSG00000257826.1	RP11-116N8.4	-7.91	1.82e-14	1.71e-11	-0.36	-0.34	Thyroid cancer;	chr14:36126977	chr14:36061026~36067190:-
LUAD	cis	rs10170846	0.893	rs10932967	ENSG00000261428.2	RP11-16P6.1	7.91	1.82e-14	1.72e-11	0.4	0.34	Schizophrenia (inflammation and infection response interaction);	chr2:222679392	chr2:222566899~222569719:-
LUAD	cis	rs9322193	0.923	rs17745062	ENSG00000223701.3	RAET1E-AS1	7.91	1.83e-14	1.72e-11	0.4	0.34	Lung cancer;	chr6:149721079	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs62441279	ENSG00000223701.3	RAET1E-AS1	7.91	1.83e-14	1.72e-11	0.4	0.34	Lung cancer;	chr6:149721194	chr6:149884431~149919508:+
LUAD	cis	rs9287719	0.967	rs12464817	ENSG00000234818.1	AC092687.5	7.91	1.84e-14	1.73e-11	0.41	0.34	Prostate cancer;	chr2:10567086	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs4669593	ENSG00000234818.1	AC092687.5	7.91	1.84e-14	1.73e-11	0.41	0.34	Prostate cancer;	chr2:10561782	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs3814388	ENSG00000234818.1	AC092687.5	7.91	1.84e-14	1.73e-11	0.41	0.34	Prostate cancer;	chr2:10561973	chr2:10589166~10604830:+
LUAD	cis	rs4718428	0.672	rs13241598	ENSG00000226824.5	RP4-756H11.3	-7.91	1.84e-14	1.73e-11	-0.46	-0.34	Corneal structure;	chr7:66835665	chr7:66654538~66669855:+
LUAD	cis	rs3096299	0.933	rs2965939	ENSG00000274627.1	RP11-104N10.2	7.9	1.87e-14	1.75e-11	0.32	0.34	Multiple myeloma (IgH translocation);	chr16:89426635	chr16:89516797~89522217:+
LUAD	cis	rs10463554	0.963	rs32850	ENSG00000175749.11	EIF3KP1	7.9	1.87e-14	1.75e-11	0.47	0.34	Parkinson's disease;	chr5:103134325	chr5:103032376~103033031:+
LUAD	cis	rs465969	0.744	rs3851228	ENSG00000255389.1	C6orf3	7.9	1.87e-14	1.76e-11	0.6	0.34	Psoriasis;	chr6:111526988	chr6:111599875~111602295:+
LUAD	cis	rs765787	0.53	rs2554455	ENSG00000259520.4	CTD-2651B20.3	7.9	1.88e-14	1.77e-11	0.44	0.34	Uric acid levels;	chr15:45229106	chr15:45251580~45279251:-
LUAD	cis	rs10200159	1	rs13430684	ENSG00000272606.1	RP11-554J4.1	7.9	1.88e-14	1.77e-11	0.57	0.34	Vitiligo;	chr2:55642709	chr2:55617909~55618373:+
LUAD	cis	rs765787	0.53	rs3759893	ENSG00000259520.4	CTD-2651B20.3	7.9	1.89e-14	1.77e-11	0.44	0.34	Uric acid levels;	chr15:45250752	chr15:45251580~45279251:-
LUAD	cis	rs673078	0.607	rs6490177	ENSG00000275759.1	RP11-131L12.3	-7.9	1.89e-14	1.77e-11	-0.44	-0.34	Glucose homeostasis traits;	chr12:118358280	chr12:118428281~118428870:+
LUAD	cis	rs904251	0.605	rs4257849	ENSG00000279942.1	RP1-153P14.7	-7.9	1.89e-14	1.77e-11	-0.37	-0.34	Cognitive performance;	chr6:37443193	chr6:37567716~37571460:+
LUAD	cis	rs80285556	0.51	rs75463146	ENSG00000161643.11	SIGLEC16	7.9	1.89e-14	1.78e-11	0.76	0.34	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49989087	chr19:49969673~49975814:+
LUAD	cis	rs80285556	1	rs80202648	ENSG00000161643.11	SIGLEC16	7.9	1.89e-14	1.78e-11	0.76	0.34	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49991129	chr19:49969673~49975814:+
LUAD	cis	rs1891275	0.601	rs1970506	ENSG00000228701.1	TNKS2-AS1	-7.9	1.89e-14	1.78e-11	-0.47	-0.34	Intelligence (multi-trait analysis);	chr10:91668529	chr10:91782839~91798291:-
LUAD	cis	rs9322193	0.923	rs12526675	ENSG00000223701.3	RAET1E-AS1	-7.9	1.9e-14	1.79e-11	-0.4	-0.34	Lung cancer;	chr6:149729540	chr6:149884431~149919508:+
LUAD	cis	rs10200159	1	rs7558127	ENSG00000272606.1	RP11-554J4.1	7.9	1.91e-14	1.79e-11	0.56	0.34	Vitiligo;	chr2:55639470	chr2:55617909~55618373:+
LUAD	cis	rs367615	0.704	rs72802966	ENSG00000249476.1	CTD-2587M2.1	7.9	1.91e-14	1.79e-11	0.38	0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109511053	chr5:109237120~109326369:-
LUAD	cis	rs2919917	0.915	rs2046339	ENSG00000254352.1	RP11-578O24.2	7.9	1.92e-14	1.8e-11	0.41	0.34	Lymphocyte counts;	chr8:78724283	chr8:78723796~78724136:-
LUAD	cis	rs5769707	0.642	rs4824070	ENSG00000188511.11	C22orf34	7.9	1.94e-14	1.82e-11	0.44	0.34	Monocyte percentage of white cells;Monocyte count;	chr22:49637873	chr22:49414524~49657542:-
LUAD	cis	rs6700559	0.683	rs7548530	ENSG00000260088.1	RP11-92G12.3	-7.9	1.95e-14	1.83e-11	-0.44	-0.34	Coronary artery disease;	chr1:200687904	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.683	rs7526136	ENSG00000260088.1	RP11-92G12.3	-7.9	1.95e-14	1.83e-11	-0.44	-0.34	Coronary artery disease;	chr1:200687911	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.733	rs7526265	ENSG00000260088.1	RP11-92G12.3	-7.9	1.95e-14	1.83e-11	-0.44	-0.34	Coronary artery disease;	chr1:200687916	chr1:200669507~200694250:+
LUAD	cis	rs1563304	1	rs1563304	ENSG00000214401.4	KANSL1-AS1	7.9	1.95e-14	1.83e-11	0.6	0.34	Neuroticism;	chr17:46797087	chr17:46193576~46196723:+
LUAD	cis	rs4660456	0.913	rs16827532	ENSG00000237899.1	RP4-739H11.3	-7.9	1.95e-14	1.83e-11	-0.46	-0.34	Platelet count;	chr1:40755064	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.913	rs12729696	ENSG00000237899.1	RP4-739H11.3	-7.9	1.95e-14	1.83e-11	-0.46	-0.34	Platelet count;	chr1:40755099	chr1:40669089~40687588:-
LUAD	cis	rs1075265	0.633	rs28653587	ENSG00000233266.1	HMGB1P31	7.9	1.96e-14	1.83e-11	0.43	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53992435	chr2:54051334~54051760:+
LUAD	cis	rs950169	0.922	rs62029585	ENSG00000225151.9	GOLGA2P7	-7.9	1.97e-14	1.85e-11	-0.48	-0.34	Schizophrenia;	chr15:84397176	chr15:84199311~84230136:-
LUAD	cis	rs11155671	0.53	rs7758033	ENSG00000223701.3	RAET1E-AS1	7.9	1.97e-14	1.85e-11	0.4	0.34	Testicular germ cell tumor;	chr6:149886999	chr6:149884431~149919508:+
LUAD	cis	rs4660456	0.913	rs16827552	ENSG00000237899.1	RP4-739H11.3	-7.9	1.97e-14	1.85e-11	-0.47	-0.34	Platelet count;	chr1:40758336	chr1:40669089~40687588:-
LUAD	cis	rs35955747	0.714	rs5997989	ENSG00000236132.1	CTA-440B3.1	7.89	1.98e-14	1.86e-11	0.38	0.34	Neutrophil count;Sum basophil neutrophil counts;	chr22:31443964	chr22:31816379~31817491:-
LUAD	cis	rs944289	0.74	rs379426	ENSG00000257826.1	RP11-116N8.4	7.89	1.99e-14	1.86e-11	0.36	0.34	Thyroid cancer;	chr14:36075253	chr14:36061026~36067190:-
LUAD	cis	rs6700559	0.81	rs10919990	ENSG00000260088.1	RP11-92G12.3	-7.89	1.99e-14	1.86e-11	-0.43	-0.34	Coronary artery disease;	chr1:200627076	chr1:200669507~200694250:+
LUAD	cis	rs950880	0.71	rs17027166	ENSG00000234389.1	AC007278.3	-7.89	1.99e-14	1.87e-11	-0.35	-0.34	Serum protein levels (sST2);	chr2:102438960	chr2:102438713~102440475:+
LUAD	cis	rs673078	0.66	rs17512574	ENSG00000275759.1	RP11-131L12.3	-7.89	1.99e-14	1.87e-11	-0.47	-0.34	Glucose homeostasis traits;	chr12:118350198	chr12:118428281~118428870:+
LUAD	cis	rs11089937	0.597	rs5750582	ENSG00000211639.2	IGLV4-60	7.89	1.99e-14	1.87e-11	0.39	0.34	Periodontitis (PAL4Q3);	chr22:22137690	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.626	rs5757028	ENSG00000211639.2	IGLV4-60	7.89	1.99e-14	1.87e-11	0.39	0.34	Periodontitis (PAL4Q3);	chr22:22137699	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.54	rs2329931	ENSG00000211639.2	IGLV4-60	7.89	2e-14	1.87e-11	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22131994	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.568	rs2876996	ENSG00000211639.2	IGLV4-60	7.89	2e-14	1.87e-11	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22132006	chr22:22162199~22162681:+
LUAD	cis	rs950880	0.677	rs17027087	ENSG00000234389.1	AC007278.3	-7.89	2e-14	1.88e-11	-0.34	-0.34	Serum protein levels (sST2);	chr2:102399458	chr2:102438713~102440475:+
LUAD	cis	rs8031584	0.651	rs28664821	ENSG00000260382.1	RP11-540B6.2	-7.89	2.02e-14	1.89e-11	-0.41	-0.34	Huntington's disease progression;	chr15:30880120	chr15:30882267~30883231:-
LUAD	cis	rs10875746	0.551	rs2054904	ENSG00000240399.1	RP1-228P16.1	-7.89	2.02e-14	1.89e-11	-0.41	-0.34	Longevity (90 years and older);	chr12:48330571	chr12:48054813~48055591:-
LUAD	cis	rs9322193	0.923	rs10872651	ENSG00000223701.3	RAET1E-AS1	7.89	2.02e-14	1.89e-11	0.41	0.34	Lung cancer;	chr6:149768273	chr6:149884431~149919508:+
LUAD	cis	rs9287719	0.837	rs4233883	ENSG00000234818.1	AC092687.5	7.89	2.02e-14	1.89e-11	0.4	0.34	Prostate cancer;	chr2:10615470	chr2:10589166~10604830:+
LUAD	cis	rs6700559	0.873	rs7542840	ENSG00000260088.1	RP11-92G12.3	-7.89	2.04e-14	1.91e-11	-0.43	-0.34	Coronary artery disease;	chr1:200686558	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.815	rs7526365	ENSG00000260088.1	RP11-92G12.3	-7.89	2.04e-14	1.91e-11	-0.43	-0.34	Coronary artery disease;	chr1:200688020	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.873	rs7526482	ENSG00000260088.1	RP11-92G12.3	-7.89	2.04e-14	1.91e-11	-0.43	-0.34	Coronary artery disease;	chr1:200688310	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.873	rs7526853	ENSG00000260088.1	RP11-92G12.3	-7.89	2.04e-14	1.91e-11	-0.43	-0.34	Coronary artery disease;	chr1:200688529	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.844	rs61825137	ENSG00000260088.1	RP11-92G12.3	-7.89	2.04e-14	1.91e-11	-0.43	-0.34	Coronary artery disease;	chr1:200689267	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.873	rs7545177	ENSG00000260088.1	RP11-92G12.3	-7.89	2.04e-14	1.91e-11	-0.43	-0.34	Coronary artery disease;	chr1:200690727	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.873	rs7539646	ENSG00000260088.1	RP11-92G12.3	-7.89	2.04e-14	1.91e-11	-0.43	-0.34	Coronary artery disease;	chr1:200692534	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.873	rs7519383	ENSG00000260088.1	RP11-92G12.3	-7.89	2.04e-14	1.91e-11	-0.43	-0.34	Coronary artery disease;	chr1:200692968	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.815	rs12141497	ENSG00000260088.1	RP11-92G12.3	-7.89	2.04e-14	1.91e-11	-0.43	-0.34	Coronary artery disease;	chr1:200693389	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.873	rs12126708	ENSG00000260088.1	RP11-92G12.3	-7.89	2.04e-14	1.91e-11	-0.43	-0.34	Coronary artery disease;	chr1:200693397	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.873	rs10920008	ENSG00000260088.1	RP11-92G12.3	-7.89	2.04e-14	1.91e-11	-0.43	-0.34	Coronary artery disease;	chr1:200694546	chr1:200669507~200694250:+
LUAD	cis	rs1150668	0.796	rs2247002	ENSG00000216901.1	AL022393.7	7.89	2.05e-14	1.92e-11	0.39	0.34	Pubertal anthropometrics;	chr6:28430174	chr6:28176188~28176674:+
LUAD	cis	rs367615	0.506	rs2914680	ENSG00000249476.1	CTD-2587M2.1	-7.89	2.05e-14	1.92e-11	-0.39	-0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109451445	chr5:109237120~109326369:-
LUAD	cis	rs10170846	0.893	rs1447108	ENSG00000261428.2	RP11-16P6.1	7.89	2.06e-14	1.92e-11	0.4	0.34	Schizophrenia (inflammation and infection response interaction);	chr2:222677512	chr2:222566899~222569719:-
LUAD	cis	rs10170846	0.893	rs12614976	ENSG00000261428.2	RP11-16P6.1	7.89	2.06e-14	1.92e-11	0.4	0.34	Schizophrenia (inflammation and infection response interaction);	chr2:222678177	chr2:222566899~222569719:-
LUAD	cis	rs12468226	0.873	rs2350358	ENSG00000273456.1	RP11-686O6.2	-7.89	2.06e-14	1.93e-11	-0.5	-0.34	Urate levels;	chr2:202199771	chr2:202374932~202375604:-
LUAD	cis	rs1150668	0.796	rs728122	ENSG00000204709.4	LINC01556	7.89	2.07e-14	1.94e-11	0.42	0.34	Pubertal anthropometrics;	chr6:28431347	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.527	rs853683	ENSG00000216901.1	AL022393.7	7.89	2.08e-14	1.94e-11	0.39	0.34	Depression;	chr6:28327262	chr6:28176188~28176674:+
LUAD	cis	rs2919917	1	rs1021156	ENSG00000254352.1	RP11-578O24.2	7.89	2.09e-14	1.96e-11	0.41	0.34	Lymphocyte counts;	chr8:78663569	chr8:78723796~78724136:-
LUAD	cis	rs904251	0.686	rs931649	ENSG00000204110.6	RP1-153P14.8	-7.89	2.1e-14	1.96e-11	-0.4	-0.34	Cognitive performance;	chr6:37498303	chr6:37507348~37535616:+
LUAD	cis	rs9545047	0.604	rs12875039	ENSG00000227676.3	LINC01068	-7.89	2.1e-14	1.96e-11	-0.4	-0.34	Schizophrenia;	chr13:79327449	chr13:79566727~79571436:+
LUAD	cis	rs11096990	0.656	rs2123027	ENSG00000249207.1	RP11-360F5.1	7.89	2.1e-14	1.96e-11	0.37	0.34	Cognitive function;	chr4:39289493	chr4:39112677~39126818:-
LUAD	cis	rs56046484	0.703	rs12439802	ENSG00000259295.5	CSPG4P12	7.89	2.11e-14	1.97e-11	0.55	0.34	Testicular germ cell tumor;	chr15:84977098	chr15:85191438~85213905:+
LUAD	cis	rs11096990	0.656	rs9993224	ENSG00000249207.1	RP11-360F5.1	7.89	2.11e-14	1.97e-11	0.37	0.34	Cognitive function;	chr4:39298578	chr4:39112677~39126818:-
LUAD	cis	rs10463554	0.963	rs26261	ENSG00000175749.11	EIF3KP1	7.89	2.12e-14	1.98e-11	0.46	0.34	Parkinson's disease;	chr5:103209992	chr5:103032376~103033031:+
LUAD	cis	rs12550612	0.614	rs4268128	ENSG00000253616.4	RP11-875O11.3	7.89	2.12e-14	1.98e-11	0.5	0.34	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23080343	chr8:23071377~23074488:-
LUAD	cis	rs9287719	0.967	rs7570118	ENSG00000234818.1	AC092687.5	7.89	2.12e-14	1.98e-11	0.41	0.34	Prostate cancer;	chr2:10577881	chr2:10589166~10604830:+
LUAD	cis	rs4718428	1	rs4718421	ENSG00000226824.5	RP4-756H11.3	-7.88	2.14e-14	1.99e-11	-0.43	-0.34	Corneal structure;	chr7:66885313	chr7:66654538~66669855:+
LUAD	cis	rs6700559	0.873	rs7524025	ENSG00000260088.1	RP11-92G12.3	-7.88	2.14e-14	2e-11	-0.43	-0.34	Coronary artery disease;	chr1:200687859	chr1:200669507~200694250:+
LUAD	cis	rs2455601	0.882	rs10840139	ENSG00000254860.4	TMEM9B-AS1	7.88	2.15e-14	2.01e-11	0.52	0.34	Schizophrenia;	chr11:8873291	chr11:8964675~8977527:+
LUAD	cis	rs71403859	0.73	rs12927768	ENSG00000260886.1	TAT-AS1	7.88	2.15e-14	2.01e-11	0.59	0.34	Post bronchodilator FEV1;	chr16:71611360	chr16:71565789~71578187:+
LUAD	cis	rs2243480	1	rs10807702	ENSG00000273142.1	RP11-458F8.4	-7.88	2.16e-14	2.02e-11	-0.34	-0.34	Diabetic kidney disease;	chr7:66302856	chr7:66902857~66906297:+
LUAD	cis	rs11089937	0.626	rs2213161	ENSG00000211639.2	IGLV4-60	7.88	2.16e-14	2.02e-11	0.42	0.34	Periodontitis (PAL4Q3);	chr22:22143005	chr22:22162199~22162681:+
LUAD	cis	rs7429990	0.833	rs35582375	ENSG00000229759.1	MRPS18AP1	-7.88	2.17e-14	2.02e-11	-0.34	-0.34	Educational attainment (years of education);	chr3:47829639	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs11130150	ENSG00000229759.1	MRPS18AP1	-7.88	2.17e-14	2.02e-11	-0.34	-0.34	Educational attainment (years of education);	chr3:47832449	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs11710199	ENSG00000229759.1	MRPS18AP1	-7.88	2.17e-14	2.02e-11	-0.34	-0.34	Educational attainment (years of education);	chr3:47836588	chr3:48256350~48256938:-
LUAD	cis	rs11089937	0.568	rs12160318	ENSG00000211639.2	IGLV4-60	7.88	2.17e-14	2.02e-11	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22131627	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.568	rs12159174	ENSG00000211639.2	IGLV4-60	7.88	2.17e-14	2.02e-11	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22131639	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.568	rs11089919	ENSG00000211639.2	IGLV4-60	7.88	2.17e-14	2.02e-11	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22131648	chr22:22162199~22162681:+
LUAD	cis	rs765787	0.53	rs2458224	ENSG00000259520.4	CTD-2651B20.3	7.88	2.17e-14	2.03e-11	0.45	0.34	Uric acid levels;	chr15:45229932	chr15:45251580~45279251:-
LUAD	cis	rs4660456	0.913	rs2223486	ENSG00000237899.1	RP4-739H11.3	-7.88	2.2e-14	2.05e-11	-0.46	-0.34	Platelet count;	chr1:40693557	chr1:40669089~40687588:-
LUAD	cis	rs10954213	0.525	rs11770589	ENSG00000275106.1	RP11-309L24.10	-7.88	2.21e-14	2.06e-11	-0.41	-0.34	Sjögren's syndrome;	chr7:128949434	chr7:128952527~128953316:-
LUAD	cis	rs673078	0.607	rs17440956	ENSG00000275759.1	RP11-131L12.3	7.88	2.22e-14	2.07e-11	0.47	0.34	Glucose homeostasis traits;	chr12:118394639	chr12:118428281~118428870:+
LUAD	cis	rs7188445	0.583	rs80170002	ENSG00000261390.4	RP11-345M22.2	-7.88	2.23e-14	2.08e-11	-0.44	-0.34	Urate levels;	chr16:79677817	chr16:79715232~79770563:-
LUAD	cis	rs950880	0.71	rs17027179	ENSG00000234389.1	AC007278.3	-7.88	2.23e-14	2.08e-11	-0.34	-0.34	Serum protein levels (sST2);	chr2:102440699	chr2:102438713~102440475:+
LUAD	cis	rs9322193	0.923	rs4870052	ENSG00000223701.3	RAET1E-AS1	7.88	2.24e-14	2.09e-11	0.41	0.34	Lung cancer;	chr6:149839978	chr6:149884431~149919508:+
LUAD	cis	rs380904	1	rs12543128	ENSG00000254859.1	RP11-661A12.5	-7.88	2.24e-14	2.09e-11	-0.47	-0.34	Venous thromboembolism (SNP x SNP interaction);	chr8:143512872	chr8:143541973~143549729:-
LUAD	cis	rs765787	0.53	rs2554457	ENSG00000259520.4	CTD-2651B20.3	7.87	2.28e-14	2.13e-11	0.44	0.34	Uric acid levels;	chr15:45228728	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs2554456	ENSG00000259520.4	CTD-2651B20.3	7.87	2.28e-14	2.13e-11	0.44	0.34	Uric acid levels;	chr15:45228940	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs10467979	ENSG00000259520.4	CTD-2651B20.3	7.87	2.28e-14	2.13e-11	0.44	0.34	Uric acid levels;	chr15:45229072	chr15:45251580~45279251:-
LUAD	cis	rs227275	0.526	rs223497	ENSG00000246560.2	RP11-10L12.4	7.87	2.29e-14	2.13e-11	0.42	0.34	Allergic disease (asthma, hay fever or eczema);	chr4:102732819	chr4:102828055~102844075:+
LUAD	cis	rs4660456	0.564	rs34320811	ENSG00000237899.1	RP4-739H11.3	-7.87	2.29e-14	2.13e-11	-0.47	-0.34	Platelet count;	chr1:40763288	chr1:40669089~40687588:-
LUAD	cis	rs765787	0.53	rs7165889	ENSG00000259520.4	CTD-2651B20.3	7.87	2.31e-14	2.15e-11	0.44	0.34	Uric acid levels;	chr15:45239442	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs11070451	ENSG00000259520.4	CTD-2651B20.3	7.87	2.31e-14	2.15e-11	0.44	0.34	Uric acid levels;	chr15:45241343	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs28897155	ENSG00000259520.4	CTD-2651B20.3	7.87	2.31e-14	2.15e-11	0.44	0.34	Uric acid levels;	chr15:45241776	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs4775831	ENSG00000259520.4	CTD-2651B20.3	7.87	2.31e-14	2.15e-11	0.44	0.34	Uric acid levels;	chr15:45242524	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs4775832	ENSG00000259520.4	CTD-2651B20.3	7.87	2.31e-14	2.15e-11	0.44	0.34	Uric acid levels;	chr15:45242630	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs4442750	ENSG00000259520.4	CTD-2651B20.3	7.87	2.31e-14	2.15e-11	0.44	0.34	Uric acid levels;	chr15:45243130	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs4270107	ENSG00000259520.4	CTD-2651B20.3	7.87	2.31e-14	2.15e-11	0.44	0.34	Uric acid levels;	chr15:45243152	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs4544188	ENSG00000259520.4	CTD-2651B20.3	7.87	2.31e-14	2.15e-11	0.44	0.34	Uric acid levels;	chr15:45243195	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs11636440	ENSG00000259520.4	CTD-2651B20.3	7.87	2.31e-14	2.15e-11	0.44	0.34	Uric acid levels;	chr15:45243784	chr15:45251580~45279251:-
LUAD	cis	rs8177876	0.731	rs10514512	ENSG00000261838.4	RP11-303E16.6	7.87	2.32e-14	2.15e-11	0.79	0.34	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080350	chr16:81069854~81076598:+
LUAD	cis	rs2581828	0.58	rs9845021	ENSG00000242142.1	SERBP1P3	-7.87	2.32e-14	2.16e-11	-0.39	-0.34	Crohn's disease;	chr3:53138096	chr3:53064283~53065091:-
LUAD	cis	rs8031584	0.678	rs4779790	ENSG00000260382.1	RP11-540B6.2	7.87	2.33e-14	2.17e-11	0.42	0.34	Huntington's disease progression;	chr15:30872392	chr15:30882267~30883231:-
LUAD	cis	rs4713118	0.662	rs9393881	ENSG00000219392.1	RP1-265C24.5	-7.87	2.33e-14	2.17e-11	-0.45	-0.34	Parkinson's disease;	chr6:28055973	chr6:28115628~28116551:+
LUAD	cis	rs150992	0.547	rs325217	ENSG00000248489.1	CTD-2007H13.3	7.87	2.33e-14	2.17e-11	0.38	0.34	Body mass index;	chr5:98844109	chr5:98929171~98995013:+
LUAD	cis	rs62388641	0.547	rs2317966	ENSG00000272279.1	RP11-157J24.2	-7.87	2.34e-14	2.18e-11	-0.41	-0.34	Daytime sleep phenotypes;	chr6:1550651	chr6:1528364~1528911:-
LUAD	cis	rs2243480	1	rs1618893	ENSG00000226824.5	RP4-756H11.3	-7.87	2.34e-14	2.18e-11	-0.58	-0.34	Diabetic kidney disease;	chr7:66631132	chr7:66654538~66669855:+
LUAD	cis	rs950880	0.71	rs17027230	ENSG00000234389.1	AC007278.3	-7.87	2.35e-14	2.18e-11	-0.34	-0.34	Serum protein levels (sST2);	chr2:102462870	chr2:102438713~102440475:+
LUAD	cis	rs150992	0.673	rs331929	ENSG00000248489.1	CTD-2007H13.3	7.87	2.35e-14	2.18e-11	0.38	0.34	Body mass index;	chr5:98830528	chr5:98929171~98995013:+
LUAD	cis	rs12468226	0.752	rs77319662	ENSG00000273456.1	RP11-686O6.2	7.87	2.35e-14	2.19e-11	0.51	0.34	Urate levels;	chr2:202126928	chr2:202374932~202375604:-
LUAD	cis	rs673078	0.615	rs56324376	ENSG00000275759.1	RP11-131L12.3	-7.87	2.35e-14	2.19e-11	-0.42	-0.34	Glucose homeostasis traits;	chr12:118372134	chr12:118428281~118428870:+
LUAD	cis	rs950880	0.71	rs55883125	ENSG00000234389.1	AC007278.3	-7.87	2.36e-14	2.19e-11	-0.34	-0.34	Serum protein levels (sST2);	chr2:102407871	chr2:102438713~102440475:+
LUAD	cis	rs367615	0.704	rs72804385	ENSG00000249476.1	CTD-2587M2.1	7.87	2.36e-14	2.19e-11	0.38	0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109512442	chr5:109237120~109326369:-
LUAD	cis	rs765787	0.53	rs2554453	ENSG00000259520.4	CTD-2651B20.3	7.87	2.37e-14	2.2e-11	0.44	0.34	Uric acid levels;	chr15:45229909	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs11858988	ENSG00000259520.4	CTD-2651B20.3	7.87	2.37e-14	2.2e-11	0.44	0.34	Uric acid levels;	chr15:45229916	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs11855435	ENSG00000259520.4	CTD-2651B20.3	7.87	2.37e-14	2.2e-11	0.44	0.34	Uric acid levels;	chr15:45229919	chr15:45251580~45279251:-
LUAD	cis	rs10740039	0.583	rs2127353	ENSG00000254271.1	RP11-131N11.4	-7.87	2.37e-14	2.2e-11	-0.39	-0.34	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60750206	chr10:60734342~60741828:+
LUAD	cis	rs11846409	0.932	rs28378201	ENSG00000274576.2	IGHV2-70	-7.87	2.37e-14	2.2e-11	-0.36	-0.34	Rheumatic heart disease;	chr14:106637262	chr14:106770577~106771020:-
LUAD	cis	rs11846409	0.86	rs74091720	ENSG00000274576.2	IGHV2-70	-7.87	2.37e-14	2.2e-11	-0.36	-0.34	Rheumatic heart disease;	chr14:106638192	chr14:106770577~106771020:-
LUAD	cis	rs9545047	0.604	rs9318623	ENSG00000227676.3	LINC01068	-7.87	2.38e-14	2.21e-11	-0.4	-0.34	Schizophrenia;	chr13:79346913	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.564	rs7998837	ENSG00000227676.3	LINC01068	-7.87	2.38e-14	2.21e-11	-0.4	-0.34	Schizophrenia;	chr13:79349190	chr13:79566727~79571436:+
LUAD	cis	rs11089937	0.568	rs12160317	ENSG00000211639.2	IGLV4-60	7.87	2.38e-14	2.21e-11	0.4	0.34	Periodontitis (PAL4Q3);	chr22:22131619	chr22:22162199~22162681:+
LUAD	cis	rs11155671	0.53	rs1334510	ENSG00000223701.3	RAET1E-AS1	7.87	2.39e-14	2.22e-11	0.4	0.34	Testicular germ cell tumor;	chr6:149880043	chr6:149884431~149919508:+
LUAD	cis	rs11096990	0.656	rs3796513	ENSG00000249207.1	RP11-360F5.1	7.87	2.4e-14	2.23e-11	0.37	0.34	Cognitive function;	chr4:39289462	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.634	rs10029074	ENSG00000249207.1	RP11-360F5.1	7.87	2.4e-14	2.23e-11	0.37	0.34	Cognitive function;	chr4:39290882	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.634	rs1564710	ENSG00000249207.1	RP11-360F5.1	7.87	2.4e-14	2.23e-11	0.37	0.34	Cognitive function;	chr4:39291178	chr4:39112677~39126818:-
LUAD	cis	rs10129255	0.957	rs10136560	ENSG00000211970.3	IGHV4-61	-7.87	2.41e-14	2.24e-11	-0.26	-0.34	Kawasaki disease;	chr14:106787630	chr14:106639119~106639657:-
LUAD	cis	rs11096990	0.679	rs6531707	ENSG00000249207.1	RP11-360F5.1	7.87	2.41e-14	2.24e-11	0.37	0.34	Cognitive function;	chr4:39296064	chr4:39112677~39126818:-
LUAD	cis	rs1729407	0.625	rs2727789	ENSG00000254851.1	RP11-109L13.1	-7.87	2.42e-14	2.25e-11	-0.42	-0.34	Apolipoprotein A-IV levels;	chr11:116826171	chr11:117135528~117138582:+
LUAD	cis	rs9322193	0.923	rs12176034	ENSG00000223701.3	RAET1E-AS1	7.87	2.44e-14	2.27e-11	0.41	0.34	Lung cancer;	chr6:149800557	chr6:149884431~149919508:+
LUAD	cis	rs71403859	0.803	rs10500562	ENSG00000260886.1	TAT-AS1	7.87	2.44e-14	2.27e-11	0.57	0.34	Post bronchodilator FEV1;	chr16:71593828	chr16:71565789~71578187:+
LUAD	cis	rs2919917	1	rs2046338	ENSG00000254352.1	RP11-578O24.2	7.87	2.45e-14	2.27e-11	0.41	0.34	Lymphocyte counts;	chr8:78723734	chr8:78723796~78724136:-
LUAD	cis	rs10853057	0.717	rs58524282	ENSG00000214174.7	AMZ2P1	7.86	2.45e-14	2.28e-11	0.73	0.34	White matter microstructure (global fractional anisotropy);	chr17:65060479	chr17:64966550~64975576:-
LUAD	cis	rs9287719	0.935	rs61424402	ENSG00000234818.1	AC092687.5	7.86	2.45e-14	2.28e-11	0.4	0.34	Prostate cancer;	chr2:10618245	chr2:10589166~10604830:+
LUAD	cis	rs4927850	0.709	rs6783079	ENSG00000231464.1	AC024937.4	7.86	2.46e-14	2.28e-11	0.41	0.34	Pancreatic cancer;	chr3:195925837	chr3:195996738~195998233:+
LUAD	cis	rs4927850	0.709	rs6765762	ENSG00000231464.1	AC024937.4	7.86	2.46e-14	2.28e-11	0.41	0.34	Pancreatic cancer;	chr3:195925980	chr3:195996738~195998233:+
LUAD	cis	rs11096990	0.634	rs6531702	ENSG00000249207.1	RP11-360F5.1	-7.86	2.47e-14	2.29e-11	-0.37	-0.34	Cognitive function;	chr4:39273774	chr4:39112677~39126818:-
LUAD	cis	rs950880	0.645	rs4851006	ENSG00000234389.1	AC007278.3	-7.86	2.47e-14	2.29e-11	-0.34	-0.34	Serum protein levels (sST2);	chr2:102408278	chr2:102438713~102440475:+
LUAD	cis	rs10463554	0.963	rs34774	ENSG00000175749.11	EIF3KP1	7.86	2.48e-14	2.3e-11	0.47	0.34	Parkinson's disease;	chr5:103115116	chr5:103032376~103033031:+
LUAD	cis	rs2455601	0.786	rs2568070	ENSG00000254860.4	TMEM9B-AS1	7.86	2.48e-14	2.3e-11	0.46	0.34	Schizophrenia;	chr11:8955346	chr11:8964675~8977527:+
LUAD	cis	rs4853012	0.838	rs60964317	ENSG00000257800.1	FNBP1P1	7.86	2.49e-14	2.31e-11	0.4	0.34	Gestational age at birth (maternal effect);	chr2:74116296	chr2:74120680~74123218:+
LUAD	cis	rs9545047	0.604	rs9545068	ENSG00000227676.3	LINC01068	7.86	2.49e-14	2.31e-11	0.39	0.34	Schizophrenia;	chr13:79324101	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs7322167	ENSG00000227676.3	LINC01068	7.86	2.49e-14	2.31e-11	0.39	0.34	Schizophrenia;	chr13:79325931	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs9285309	ENSG00000227676.3	LINC01068	7.86	2.49e-14	2.31e-11	0.39	0.34	Schizophrenia;	chr13:79326707	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.584	rs9545069	ENSG00000227676.3	LINC01068	7.86	2.49e-14	2.31e-11	0.39	0.34	Schizophrenia;	chr13:79328065	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.647	rs7317416	ENSG00000227676.3	LINC01068	7.86	2.49e-14	2.31e-11	0.39	0.34	Schizophrenia;	chr13:79328400	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.588	rs1408658	ENSG00000227676.3	LINC01068	7.86	2.49e-14	2.31e-11	0.39	0.34	Schizophrenia;	chr13:79329294	chr13:79566727~79571436:+
LUAD	cis	rs6903823	0.508	rs1150724	ENSG00000216901.1	AL022393.7	7.86	2.49e-14	2.31e-11	0.39	0.34	Pulmonary function;	chr6:28282459	chr6:28176188~28176674:+
LUAD	cis	rs494459	0.726	rs1784300	ENSG00000255239.1	AP002954.6	7.86	2.51e-14	2.33e-11	0.4	0.34	Height;	chr11:118808920	chr11:118688039~118690600:-
LUAD	cis	rs765787	0.53	rs28396110	ENSG00000259520.4	CTD-2651B20.3	7.86	2.55e-14	2.36e-11	0.44	0.34	Uric acid levels;	chr15:45244711	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs4775834	ENSG00000259520.4	CTD-2651B20.3	7.86	2.55e-14	2.36e-11	0.44	0.34	Uric acid levels;	chr15:45245313	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs4775835	ENSG00000259520.4	CTD-2651B20.3	7.86	2.55e-14	2.36e-11	0.44	0.34	Uric acid levels;	chr15:45245355	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs4775836	ENSG00000259520.4	CTD-2651B20.3	7.86	2.55e-14	2.36e-11	0.44	0.34	Uric acid levels;	chr15:45245466	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs4775837	ENSG00000259520.4	CTD-2651B20.3	7.86	2.55e-14	2.36e-11	0.44	0.34	Uric acid levels;	chr15:45245486	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs12917187	ENSG00000259520.4	CTD-2651B20.3	7.86	2.55e-14	2.36e-11	0.44	0.34	Uric acid levels;	chr15:45246099	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs11639403	ENSG00000259520.4	CTD-2651B20.3	7.86	2.55e-14	2.36e-11	0.44	0.34	Uric acid levels;	chr15:45246152	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs2413782	ENSG00000259520.4	CTD-2651B20.3	7.86	2.55e-14	2.36e-11	0.44	0.34	Uric acid levels;	chr15:45246292	chr15:45251580~45279251:-
LUAD	cis	rs3096299	0.809	rs2911264	ENSG00000274627.1	RP11-104N10.2	7.86	2.56e-14	2.37e-11	0.32	0.34	Multiple myeloma (IgH translocation);	chr16:89432864	chr16:89516797~89522217:+
LUAD	cis	rs9287719	0.967	rs12622765	ENSG00000234818.1	AC092687.5	7.86	2.56e-14	2.37e-11	0.41	0.34	Prostate cancer;	chr2:10588205	chr2:10589166~10604830:+
LUAD	cis	rs9545047	0.604	rs3187338	ENSG00000227676.3	LINC01068	7.86	2.56e-14	2.37e-11	0.39	0.34	Schizophrenia;	chr13:79320601	chr13:79566727~79571436:+
LUAD	cis	rs9322193	0.887	rs3777949	ENSG00000223701.3	RAET1E-AS1	7.86	2.57e-14	2.37e-11	0.4	0.34	Lung cancer;	chr6:149596021	chr6:149884431~149919508:+
LUAD	cis	rs367615	0.513	rs11741087	ENSG00000249476.1	CTD-2587M2.1	7.86	2.57e-14	2.38e-11	0.39	0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109472059	chr5:109237120~109326369:-
LUAD	cis	rs9545047	0.604	rs12865187	ENSG00000227676.3	LINC01068	-7.86	2.57e-14	2.38e-11	-0.4	-0.34	Schizophrenia;	chr13:79316469	chr13:79566727~79571436:+
LUAD	cis	rs2280018	1	rs2280017	ENSG00000260735.1	RP11-72I8.1	7.86	2.58e-14	2.39e-11	0.36	0.34	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15057504	chr16:15094411~15109197:+
LUAD	cis	rs10200159	1	rs6739788	ENSG00000272606.1	RP11-554J4.1	7.86	2.61e-14	2.42e-11	0.56	0.34	Vitiligo;	chr2:55635220	chr2:55617909~55618373:+
LUAD	cis	rs11155671	0.53	rs9383577	ENSG00000223701.3	RAET1E-AS1	7.86	2.62e-14	2.42e-11	0.39	0.34	Testicular germ cell tumor;	chr6:149886059	chr6:149884431~149919508:+
LUAD	cis	rs11155671	0.53	rs9383914	ENSG00000223701.3	RAET1E-AS1	7.86	2.62e-14	2.42e-11	0.39	0.34	Testicular germ cell tumor;	chr6:149886098	chr6:149884431~149919508:+
LUAD	cis	rs11155671	0.517	rs9397058	ENSG00000223701.3	RAET1E-AS1	7.86	2.62e-14	2.42e-11	0.39	0.34	Testicular germ cell tumor;	chr6:149886113	chr6:149884431~149919508:+
LUAD	cis	rs11155671	0.53	rs4869763	ENSG00000223701.3	RAET1E-AS1	7.86	2.62e-14	2.42e-11	0.4	0.34	Testicular germ cell tumor;	chr6:149890548	chr6:149884431~149919508:+
LUAD	cis	rs1729407	0.709	rs2098453	ENSG00000254851.1	RP11-109L13.1	-7.86	2.62e-14	2.42e-11	-0.42	-0.34	Apolipoprotein A-IV levels;	chr11:116825964	chr11:117135528~117138582:+
LUAD	cis	rs9326248	0.648	rs11216257	ENSG00000280143.1	AP000892.6	7.86	2.62e-14	2.43e-11	0.44	0.34	Blood protein levels;	chr11:117061845	chr11:117204967~117210292:+
LUAD	cis	rs1150668	0.699	rs1736895	ENSG00000204709.4	LINC01556	7.86	2.63e-14	2.43e-11	0.41	0.34	Pubertal anthropometrics;	chr6:28252048	chr6:28943877~28944537:+
LUAD	cis	rs8062405	0.69	rs62034351	ENSG00000259982.1	CDC37P1	7.86	2.63e-14	2.43e-11	0.43	0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28700294~28701540:-
LUAD	cis	rs9287719	0.967	rs7592691	ENSG00000234818.1	AC092687.5	7.86	2.63e-14	2.43e-11	0.4	0.34	Prostate cancer;	chr2:10597300	chr2:10589166~10604830:+
LUAD	cis	rs765787	0.53	rs11636367	ENSG00000259520.4	CTD-2651B20.3	7.85	2.63e-14	2.43e-11	0.44	0.34	Uric acid levels;	chr15:45243664	chr15:45251580~45279251:-
LUAD	cis	rs11096990	0.634	rs6829064	ENSG00000249207.1	RP11-360F5.1	7.85	2.64e-14	2.44e-11	0.37	0.34	Cognitive function;	chr4:39290192	chr4:39112677~39126818:-
LUAD	cis	rs9287719	0.967	rs4669596	ENSG00000234818.1	AC092687.5	7.85	2.64e-14	2.44e-11	0.4	0.34	Prostate cancer;	chr2:10580446	chr2:10589166~10604830:+
LUAD	cis	rs9545047	0.604	rs9530900	ENSG00000227676.3	LINC01068	7.85	2.65e-14	2.44e-11	0.39	0.34	Schizophrenia;	chr13:79355048	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs9530901	ENSG00000227676.3	LINC01068	7.85	2.65e-14	2.44e-11	0.39	0.34	Schizophrenia;	chr13:79355191	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs4328330	ENSG00000227676.3	LINC01068	7.85	2.65e-14	2.44e-11	0.39	0.34	Schizophrenia;	chr13:79355503	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.567	rs4497554	ENSG00000227676.3	LINC01068	7.85	2.65e-14	2.44e-11	0.39	0.34	Schizophrenia;	chr13:79355651	chr13:79566727~79571436:+
LUAD	cis	rs9287719	0.967	rs759402	ENSG00000234818.1	AC092687.5	7.85	2.65e-14	2.45e-11	0.4	0.34	Prostate cancer;	chr2:10589428	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs759403	ENSG00000234818.1	AC092687.5	7.85	2.65e-14	2.45e-11	0.4	0.34	Prostate cancer;	chr2:10589771	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs11674433	ENSG00000234818.1	AC092687.5	7.85	2.65e-14	2.45e-11	0.4	0.34	Prostate cancer;	chr2:10590713	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs2024431	ENSG00000234818.1	AC092687.5	7.85	2.65e-14	2.45e-11	0.4	0.34	Prostate cancer;	chr2:10591201	chr2:10589166~10604830:+
LUAD	cis	rs9640161	0.702	rs1962004	ENSG00000261305.1	RP4-584D14.7	7.85	2.66e-14	2.46e-11	0.51	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150323292	chr7:150341771~150342607:+
LUAD	cis	rs732716	0.889	rs55637375	ENSG00000267769.1	CTB-50L17.9	-7.85	2.67e-14	2.46e-11	-0.37	-0.34	Mean corpuscular volume;	chr19:4386848	chr19:4454014~4455286:+
LUAD	cis	rs12439619	0.53	rs7162177	ENSG00000278603.1	RP13-608F4.5	7.85	2.67e-14	2.46e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr15:82181728	chr15:82472203~82472426:+
LUAD	cis	rs2739330	0.587	rs4820571	ENSG00000228039.3	KB-1125A3.10	7.85	2.68e-14	2.47e-11	0.41	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23963780~23964374:+
LUAD	cis	rs2739330	0.76	rs5760095	ENSG00000099984.9	GSTT2	-7.85	2.69e-14	2.48e-11	-0.41	-0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23980123~23983911:+
LUAD	cis	rs9287719	0.967	rs715247	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10596165	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs715246	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10596229	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs2010073	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10596352	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs2010080	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10596426	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.901	rs6432109	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10596695	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.934	rs6432110	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10597892	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs7605461	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10598008	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs7593496	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10598050	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs7608498	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10598302	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs7582775	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10598323	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6750891	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10598437	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6733416	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10598558	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6751398	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10598846	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.901	rs13034017	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10599466	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs13034061	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10599525	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.935	rs7600495	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10599674	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs7600587	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10599725	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.839	rs7600695	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10599819	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs7587114	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10599837	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs7600728	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10599873	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs7600820	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10599918	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs7587231	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10599967	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs4668691	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10600368	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.934	rs10181806	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10601015	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs11687023	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10601286	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs10454738	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10601923	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6706542	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10602365	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs2287061	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10603027	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs2287062	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10603065	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.935	rs1309	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10603420	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs3815521	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10603528	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs10929686	ENSG00000234818.1	AC092687.5	7.85	2.69e-14	2.48e-11	0.4	0.34	Prostate cancer;	chr2:10603579	chr2:10589166~10604830:+
LUAD	cis	rs765787	0.53	rs28815867	ENSG00000259520.4	CTD-2651B20.3	7.85	2.69e-14	2.48e-11	0.44	0.34	Uric acid levels;	chr15:45234607	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs4775822	ENSG00000259520.4	CTD-2651B20.3	7.85	2.69e-14	2.48e-11	0.44	0.34	Uric acid levels;	chr15:45234929	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs11854294	ENSG00000259520.4	CTD-2651B20.3	7.85	2.69e-14	2.48e-11	0.44	0.34	Uric acid levels;	chr15:45235798	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs2413785	ENSG00000259520.4	CTD-2651B20.3	7.85	2.69e-14	2.48e-11	0.44	0.34	Uric acid levels;	chr15:45238183	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs2413784	ENSG00000259520.4	CTD-2651B20.3	7.85	2.69e-14	2.48e-11	0.44	0.34	Uric acid levels;	chr15:45238318	chr15:45251580~45279251:-
LUAD	cis	rs367615	0.704	rs55956735	ENSG00000249476.1	CTD-2587M2.1	7.85	2.71e-14	2.49e-11	0.39	0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109509341	chr5:109237120~109326369:-
LUAD	cis	rs367615	0.679	rs4259216	ENSG00000249476.1	CTD-2587M2.1	7.85	2.71e-14	2.5e-11	0.38	0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109506116	chr5:109237120~109326369:-
LUAD	cis	rs9287719	0.967	rs4613248	ENSG00000234818.1	AC092687.5	7.85	2.71e-14	2.5e-11	0.4	0.34	Prostate cancer;	chr2:10603925	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs10191883	ENSG00000234818.1	AC092687.5	7.85	2.71e-14	2.5e-11	0.4	0.34	Prostate cancer;	chr2:10604010	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.934	rs4629131	ENSG00000234818.1	AC092687.5	7.85	2.71e-14	2.5e-11	0.4	0.34	Prostate cancer;	chr2:10604033	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.901	rs4555317	ENSG00000234818.1	AC092687.5	7.85	2.71e-14	2.5e-11	0.4	0.34	Prostate cancer;	chr2:10604121	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs4555318	ENSG00000234818.1	AC092687.5	7.85	2.71e-14	2.5e-11	0.4	0.34	Prostate cancer;	chr2:10604169	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.934	rs4622695	ENSG00000234818.1	AC092687.5	7.85	2.71e-14	2.5e-11	0.4	0.34	Prostate cancer;	chr2:10604201	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.934	rs6432111	ENSG00000234818.1	AC092687.5	7.85	2.71e-14	2.5e-11	0.4	0.34	Prostate cancer;	chr2:10604494	chr2:10589166~10604830:+
LUAD	cis	rs9322193	1	rs9377228	ENSG00000223701.3	RAET1E-AS1	7.85	2.73e-14	2.51e-11	0.39	0.34	Lung cancer;	chr6:149600862	chr6:149884431~149919508:+
LUAD	cis	rs9545047	0.625	rs7319320	ENSG00000227676.3	LINC01068	7.85	2.74e-14	2.52e-11	0.39	0.34	Schizophrenia;	chr13:79343072	chr13:79566727~79571436:+
LUAD	cis	rs1075265	0.633	rs7564912	ENSG00000233266.1	HMGB1P31	7.85	2.74e-14	2.52e-11	0.42	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53995048	chr2:54051334~54051760:+
LUAD	cis	rs1075265	0.61	rs6746965	ENSG00000233266.1	HMGB1P31	7.85	2.74e-14	2.52e-11	0.42	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53996388	chr2:54051334~54051760:+
LUAD	cis	rs8177876	0.658	rs2278022	ENSG00000261838.4	RP11-303E16.6	7.85	2.74e-14	2.52e-11	0.77	0.34	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81043216	chr16:81069854~81076598:+
LUAD	cis	rs6782228	1	rs34890930	ENSG00000242551.2	POU5F1P6	7.85	2.74e-14	2.53e-11	0.41	0.34	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128610380	chr3:128674735~128677005:-
LUAD	cis	rs944289	0.74	rs376927	ENSG00000257826.1	RP11-116N8.4	-7.85	2.76e-14	2.54e-11	-0.36	-0.34	Thyroid cancer;	chr14:36078725	chr14:36061026~36067190:-
LUAD	cis	rs2919917	1	rs2919936	ENSG00000254352.1	RP11-578O24.2	7.85	2.77e-14	2.55e-11	0.41	0.34	Lymphocyte counts;	chr8:78721772	chr8:78723796~78724136:-
LUAD	cis	rs9287719	0.967	rs4519489	ENSG00000234818.1	AC092687.5	7.85	2.77e-14	2.55e-11	0.4	0.34	Prostate cancer;	chr2:10598961	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs4453662	ENSG00000234818.1	AC092687.5	7.85	2.77e-14	2.55e-11	0.4	0.34	Prostate cancer;	chr2:10599002	chr2:10589166~10604830:+
LUAD	cis	rs10129255	0.957	rs2007467	ENSG00000211970.3	IGHV4-61	7.85	2.78e-14	2.56e-11	0.27	0.34	Kawasaki disease;	chr14:106771605	chr14:106639119~106639657:-
LUAD	cis	rs853679	0.517	rs9380052	ENSG00000219392.1	RP1-265C24.5	-7.85	2.78e-14	2.56e-11	-0.46	-0.34	Depression;	chr6:28096845	chr6:28115628~28116551:+
LUAD	cis	rs944289	0.708	rs2899845	ENSG00000257826.1	RP11-116N8.4	-7.85	2.81e-14	2.58e-11	-0.36	-0.34	Thyroid cancer;	chr14:36116632	chr14:36061026~36067190:-
LUAD	cis	rs7208859	0.725	rs9891656	ENSG00000263531.1	RP13-753N3.1	7.85	2.82e-14	2.59e-11	0.58	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916337	chr17:30863921~30864940:-
LUAD	cis	rs8059260	0.604	rs12102345	ENSG00000274038.1	RP11-66H6.4	-7.85	2.82e-14	2.59e-11	-0.58	-0.34	Alcohol consumption over the past year;	chr16:11053863	chr16:11056556~11057034:+
LUAD	cis	rs2412819	0.571	rs2930529	ENSG00000205771.5	CATSPER2P1	7.84	2.83e-14	2.6e-11	0.5	0.34	Lung cancer;	chr15:43819467	chr15:43726918~43747094:-
LUAD	cis	rs2412819	0.571	rs2930530	ENSG00000205771.5	CATSPER2P1	7.84	2.83e-14	2.6e-11	0.5	0.34	Lung cancer;	chr15:43823268	chr15:43726918~43747094:-
LUAD	cis	rs2919917	0.628	rs10111658	ENSG00000254352.1	RP11-578O24.2	7.84	2.83e-14	2.6e-11	0.43	0.34	Lymphocyte counts;	chr8:78652834	chr8:78723796~78724136:-
LUAD	cis	rs2919917	0.59	rs10098472	ENSG00000254352.1	RP11-578O24.2	7.84	2.83e-14	2.6e-11	0.43	0.34	Lymphocyte counts;	chr8:78652955	chr8:78723796~78724136:-
LUAD	cis	rs2919917	0.628	rs13251931	ENSG00000254352.1	RP11-578O24.2	7.84	2.83e-14	2.6e-11	0.43	0.34	Lymphocyte counts;	chr8:78653990	chr8:78723796~78724136:-
LUAD	cis	rs2919917	0.628	rs1351742	ENSG00000254352.1	RP11-578O24.2	7.84	2.83e-14	2.6e-11	0.43	0.34	Lymphocyte counts;	chr8:78655823	chr8:78723796~78724136:-
LUAD	cis	rs2919917	0.666	rs982032	ENSG00000254352.1	RP11-578O24.2	7.84	2.83e-14	2.6e-11	0.43	0.34	Lymphocyte counts;	chr8:78655825	chr8:78723796~78724136:-
LUAD	cis	rs1150668	0.796	rs9468372	ENSG00000216901.1	AL022393.7	7.84	2.83e-14	2.6e-11	0.39	0.34	Pubertal anthropometrics;	chr6:28411584	chr6:28176188~28176674:+
LUAD	cis	rs950169	0.922	rs62021167	ENSG00000225151.9	GOLGA2P7	-7.84	2.83e-14	2.6e-11	-0.48	-0.34	Schizophrenia;	chr15:84574820	chr15:84199311~84230136:-
LUAD	cis	rs9287719	0.967	rs6432114	ENSG00000234818.1	AC092687.5	7.84	2.84e-14	2.61e-11	0.4	0.34	Prostate cancer;	chr2:10604804	chr2:10589166~10604830:+
LUAD	cis	rs11096990	0.634	rs17754	ENSG00000249207.1	RP11-360F5.1	-7.84	2.84e-14	2.61e-11	-0.36	-0.34	Cognitive function;	chr4:39287688	chr4:39112677~39126818:-
LUAD	cis	rs150992	0.673	rs331545	ENSG00000248489.1	CTD-2007H13.3	-7.84	2.85e-14	2.61e-11	-0.37	-0.34	Body mass index;	chr5:98810402	chr5:98929171~98995013:+
LUAD	cis	rs9322193	0.607	rs12210822	ENSG00000216906.2	RP11-350J20.9	7.84	2.85e-14	2.62e-11	0.5	0.34	Lung cancer;	chr6:149905356	chr6:149904243~149906418:+
LUAD	cis	rs11096990	0.634	rs10019594	ENSG00000249207.1	RP11-360F5.1	7.84	2.86e-14	2.63e-11	0.37	0.34	Cognitive function;	chr4:39287127	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.656	rs3733284	ENSG00000249207.1	RP11-360F5.1	7.84	2.88e-14	2.65e-11	0.37	0.34	Cognitive function;	chr4:39299714	chr4:39112677~39126818:-
LUAD	cis	rs17482078	0.959	rs35983588	ENSG00000248734.2	CTD-2260A17.1	7.84	2.88e-14	2.65e-11	0.43	0.34	Behcet's disease;Blood protein levels;	chr5:96787726	chr5:96784777~96785999:+
LUAD	cis	rs150992	0.585	rs331931	ENSG00000248489.1	CTD-2007H13.3	7.84	2.9e-14	2.66e-11	0.38	0.34	Body mass index;	chr5:98834012	chr5:98929171~98995013:+
LUAD	cis	rs7201929	1	rs8061877	ENSG00000259982.1	CDC37P1	-7.84	2.91e-14	2.68e-11	-0.49	-0.34	QT interval;	chr16:28845498	chr16:28700294~28701540:-
LUAD	cis	rs9322193	0.923	rs12174035	ENSG00000223701.3	RAET1E-AS1	7.84	2.92e-14	2.68e-11	0.4	0.34	Lung cancer;	chr6:149763311	chr6:149884431~149919508:+
LUAD	cis	rs2880765	0.545	rs11631739	ENSG00000259295.5	CSPG4P12	7.84	2.93e-14	2.69e-11	0.42	0.34	Coronary artery disease;	chr15:85469347	chr15:85191438~85213905:+
LUAD	cis	rs150992	0.711	rs326489	ENSG00000248489.1	CTD-2007H13.3	7.84	2.93e-14	2.69e-11	0.38	0.34	Body mass index;	chr5:98841105	chr5:98929171~98995013:+
LUAD	cis	rs1537424	0.513	rs1953119	ENSG00000257826.1	RP11-116N8.4	-7.84	2.94e-14	2.7e-11	-0.37	-0.34	Thyroid hormone levels;	chr14:36091618	chr14:36061026~36067190:-
LUAD	cis	rs7188445	1	rs16950982	ENSG00000261390.4	RP11-345M22.2	-7.84	2.94e-14	2.7e-11	-0.44	-0.34	Urate levels;	chr16:79668474	chr16:79715232~79770563:-
LUAD	cis	rs11098499	0.71	rs4145952	ENSG00000245958.5	RP11-33B1.1	-7.84	2.94e-14	2.7e-11	-0.29	-0.34	Corneal astigmatism;	chr4:119234651	chr4:119454791~119552025:+
LUAD	cis	rs10200159	1	rs10172506	ENSG00000272606.1	RP11-554J4.1	7.84	2.94e-14	2.7e-11	0.57	0.34	Vitiligo;	chr2:55638334	chr2:55617909~55618373:+
LUAD	cis	rs367615	0.66	rs10477972	ENSG00000249476.1	CTD-2587M2.1	7.84	2.96e-14	2.72e-11	0.39	0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109496250	chr5:109237120~109326369:-
LUAD	cis	rs367615	0.66	rs4632850	ENSG00000249476.1	CTD-2587M2.1	7.84	2.96e-14	2.72e-11	0.39	0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109497182	chr5:109237120~109326369:-
LUAD	cis	rs1976403	0.51	rs1697421	ENSG00000227001.3	NBPF2P	7.84	2.97e-14	2.73e-11	0.39	0.34	Liver enzyme levels (alkaline phosphatase);	chr1:21496799	chr1:21424625~21427967:-
LUAD	cis	rs7429990	0.965	rs319692	ENSG00000229759.1	MRPS18AP1	7.84	2.99e-14	2.74e-11	0.35	0.34	Educational attainment (years of education);	chr3:47882827	chr3:48256350~48256938:-
LUAD	cis	rs3096299	0.933	rs2930219	ENSG00000274627.1	RP11-104N10.2	7.84	2.99e-14	2.74e-11	0.32	0.34	Multiple myeloma (IgH translocation);	chr16:89425641	chr16:89516797~89522217:+
LUAD	cis	rs950169	0.922	rs4586394	ENSG00000225151.9	GOLGA2P7	7.84	2.99e-14	2.74e-11	0.47	0.34	Schizophrenia;	chr15:84153633	chr15:84199311~84230136:-
LUAD	cis	rs765787	0.53	rs7167389	ENSG00000259520.4	CTD-2651B20.3	7.84	2.99e-14	2.74e-11	0.44	0.34	Uric acid levels;	chr15:45243485	chr15:45251580~45279251:-
LUAD	cis	rs7615952	0.673	rs9821905	ENSG00000171084.14	FAM86JP	-7.84	3e-14	2.75e-11	-0.59	-0.34	Blood pressure (smoking interaction);	chr3:125902007	chr3:125916620~125930024:+
LUAD	cis	rs2919917	0.628	rs13265305	ENSG00000254352.1	RP11-578O24.2	7.84	3e-14	2.75e-11	0.43	0.34	Lymphocyte counts;	chr8:78656575	chr8:78723796~78724136:-
LUAD	cis	rs2919917	0.628	rs2887482	ENSG00000254352.1	RP11-578O24.2	7.84	3e-14	2.75e-11	0.43	0.34	Lymphocyte counts;	chr8:78659633	chr8:78723796~78724136:-
LUAD	cis	rs2919917	0.628	rs1905364	ENSG00000254352.1	RP11-578O24.2	7.84	3e-14	2.75e-11	0.43	0.34	Lymphocyte counts;	chr8:78660244	chr8:78723796~78724136:-
LUAD	cis	rs11123170	0.529	rs1015753	ENSG00000189223.12	PAX8-AS1	-7.84	3e-14	2.75e-11	-0.54	-0.34	Renal function-related traits (BUN);	chr2:113211226	chr2:113211522~113276581:+
LUAD	cis	rs4660456	0.913	rs2361650	ENSG00000237899.1	RP4-739H11.3	-7.84	3.01e-14	2.76e-11	-0.46	-0.34	Platelet count;	chr1:40764678	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.913	rs954654	ENSG00000237899.1	RP4-739H11.3	-7.84	3.01e-14	2.76e-11	-0.46	-0.34	Platelet count;	chr1:40764979	chr1:40669089~40687588:-
LUAD	cis	rs7487637	0.566	rs875023	ENSG00000276691.1	RP5-1057I20.5	-7.84	3.02e-14	2.77e-11	-0.37	-0.34	Mononucleosis;	chr12:47800652	chr12:47788426~47788971:+
LUAD	cis	rs765787	0.53	rs2413780	ENSG00000259520.4	CTD-2651B20.3	7.84	3.03e-14	2.77e-11	0.44	0.34	Uric acid levels;	chr15:45246668	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs11636018	ENSG00000259520.4	CTD-2651B20.3	7.84	3.03e-14	2.77e-11	0.44	0.34	Uric acid levels;	chr15:45246939	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.556	rs2413778	ENSG00000259520.4	CTD-2651B20.3	7.84	3.03e-14	2.77e-11	0.44	0.34	Uric acid levels;	chr15:45247199	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs28756676	ENSG00000259520.4	CTD-2651B20.3	7.84	3.03e-14	2.77e-11	0.44	0.34	Uric acid levels;	chr15:45248162	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs55771002	ENSG00000259520.4	CTD-2651B20.3	7.84	3.03e-14	2.77e-11	0.44	0.34	Uric acid levels;	chr15:45249368	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs55920042	ENSG00000259520.4	CTD-2651B20.3	7.84	3.03e-14	2.77e-11	0.44	0.34	Uric acid levels;	chr15:45249379	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs4238376	ENSG00000259520.4	CTD-2651B20.3	7.84	3.03e-14	2.77e-11	0.44	0.34	Uric acid levels;	chr15:45249689	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs4238377	ENSG00000259520.4	CTD-2651B20.3	7.84	3.03e-14	2.77e-11	0.44	0.34	Uric acid levels;	chr15:45249783	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs4775844	ENSG00000259520.4	CTD-2651B20.3	7.84	3.03e-14	2.77e-11	0.44	0.34	Uric acid levels;	chr15:45249850	chr15:45251580~45279251:-
LUAD	cis	rs17608059	0.524	rs9897978	ENSG00000141028.6	CDRT15P1	7.83	3.04e-14	2.78e-11	0.4	0.34	Temperament;	chr17:13996939	chr17:14024514~14025488:+
LUAD	cis	rs3779195	0.929	rs10953259	ENSG00000272950.1	RP11-307C18.1	-7.83	3.04e-14	2.79e-11	-0.57	-0.34	Sex hormone-binding globulin levels;	chr7:98383795	chr7:98322853~98323430:+
LUAD	cis	rs6504950	1	rs7222197	ENSG00000275710.1	RP11-257O5.4	-7.83	3.05e-14	2.79e-11	-0.42	-0.34	Breast cancer;	chr17:54970138	chr17:54964474~54964679:+
LUAD	cis	rs9287719	0.87	rs728135	ENSG00000234818.1	AC092687.5	7.83	3.05e-14	2.79e-11	0.4	0.34	Prostate cancer;	chr2:10605006	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs963831	ENSG00000234818.1	AC092687.5	7.83	3.05e-14	2.79e-11	0.4	0.34	Prostate cancer;	chr2:10605058	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs728134	ENSG00000234818.1	AC092687.5	7.83	3.05e-14	2.79e-11	0.4	0.34	Prostate cancer;	chr2:10605061	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs2884233	ENSG00000234818.1	AC092687.5	7.83	3.05e-14	2.79e-11	0.4	0.34	Prostate cancer;	chr2:10605177	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.839	rs12692415	ENSG00000234818.1	AC092687.5	7.83	3.05e-14	2.79e-11	0.4	0.34	Prostate cancer;	chr2:10605348	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.934	rs12692416	ENSG00000234818.1	AC092687.5	7.83	3.05e-14	2.79e-11	0.4	0.34	Prostate cancer;	chr2:10605501	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs12692417	ENSG00000234818.1	AC092687.5	7.83	3.05e-14	2.79e-11	0.4	0.34	Prostate cancer;	chr2:10605592	chr2:10589166~10604830:+
LUAD	cis	rs11096990	0.634	rs11947159	ENSG00000249207.1	RP11-360F5.1	7.83	3.06e-14	2.8e-11	0.37	0.34	Cognitive function;	chr4:39286900	chr4:39112677~39126818:-
LUAD	cis	rs1789	0.558	rs10021522	ENSG00000273133.1	RP11-799M12.2	-7.83	3.06e-14	2.8e-11	-0.46	-0.34	Blood protein levels;	chr4:15522985	chr4:15563698~15564253:-
LUAD	cis	rs9545047	0.604	rs28579970	ENSG00000227676.3	LINC01068	-7.83	3.08e-14	2.82e-11	-0.39	-0.34	Schizophrenia;	chr13:79308726	chr13:79566727~79571436:+
LUAD	cis	rs9287719	0.934	rs12692418	ENSG00000234818.1	AC092687.5	7.83	3.08e-14	2.82e-11	0.4	0.34	Prostate cancer;	chr2:10605744	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6755548	ENSG00000234818.1	AC092687.5	7.83	3.08e-14	2.82e-11	0.4	0.34	Prostate cancer;	chr2:10606000	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6761678	ENSG00000234818.1	AC092687.5	7.83	3.08e-14	2.82e-11	0.4	0.34	Prostate cancer;	chr2:10606215	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.967	rs6759100	ENSG00000234818.1	AC092687.5	7.83	3.08e-14	2.82e-11	0.4	0.34	Prostate cancer;	chr2:10606584	chr2:10589166~10604830:+
LUAD	cis	rs11089937	0.667	rs9622981	ENSG00000211639.2	IGLV4-60	7.83	3.11e-14	2.84e-11	0.41	0.34	Periodontitis (PAL4Q3);	chr22:22150100	chr22:22162199~22162681:+
LUAD	cis	rs6142102	0.517	rs6059580	ENSG00000276073.1	RP5-1125A11.7	-7.83	3.12e-14	2.85e-11	-0.34	-0.34	Skin pigmentation;	chr20:33940067	chr20:33985617~33988989:-
LUAD	cis	rs9322193	0.886	rs2065663	ENSG00000223701.3	RAET1E-AS1	7.83	3.15e-14	2.88e-11	0.4	0.34	Lung cancer;	chr6:149760331	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs12205092	ENSG00000223701.3	RAET1E-AS1	7.83	3.15e-14	2.88e-11	0.4	0.34	Lung cancer;	chr6:149761375	chr6:149884431~149919508:+
LUAD	cis	rs2880765	0.566	rs12911430	ENSG00000259295.5	CSPG4P12	7.83	3.15e-14	2.88e-11	0.42	0.34	Coronary artery disease;	chr15:85468033	chr15:85191438~85213905:+
LUAD	cis	rs7615952	0.932	rs13065725	ENSG00000171084.14	FAM86JP	7.83	3.16e-14	2.89e-11	0.51	0.34	Blood pressure (smoking interaction);	chr3:125913446	chr3:125916620~125930024:+
LUAD	cis	rs2581828	0.646	rs28501212	ENSG00000242142.1	SERBP1P3	-7.83	3.16e-14	2.89e-11	-0.38	-0.34	Crohn's disease;	chr3:53129041	chr3:53064283~53065091:-
LUAD	cis	rs673078	0.66	rs61945190	ENSG00000275759.1	RP11-131L12.3	-7.83	3.17e-14	2.9e-11	-0.48	-0.34	Glucose homeostasis traits;	chr12:118231345	chr12:118428281~118428870:+
LUAD	cis	rs9545047	0.625	rs9565489	ENSG00000227676.3	LINC01068	7.83	3.19e-14	2.91e-11	0.39	0.34	Schizophrenia;	chr13:79342106	chr13:79566727~79571436:+
LUAD	cis	rs11155671	0.53	rs9383912	ENSG00000223701.3	RAET1E-AS1	7.83	3.2e-14	2.93e-11	0.39	0.34	Testicular germ cell tumor;	chr6:149885479	chr6:149884431~149919508:+
LUAD	cis	rs9640161	0.75	rs73170185	ENSG00000261305.1	RP4-584D14.7	7.83	3.22e-14	2.94e-11	0.5	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150333102	chr7:150341771~150342607:+
LUAD	cis	rs7301826	0.627	rs7315707	ENSG00000256250.1	RP11-989F5.1	7.83	3.23e-14	2.95e-11	0.44	0.34	Plasma plasminogen activator levels;	chr12:130788274	chr12:130810606~130812438:+
LUAD	cis	rs2581828	0.659	rs9845352	ENSG00000242142.1	SERBP1P3	-7.83	3.23e-14	2.95e-11	-0.37	-0.34	Crohn's disease;	chr3:53108205	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.659	rs9845484	ENSG00000242142.1	SERBP1P3	-7.83	3.23e-14	2.95e-11	-0.37	-0.34	Crohn's disease;	chr3:53108240	chr3:53064283~53065091:-
LUAD	cis	rs673078	0.607	rs17441214	ENSG00000275759.1	RP11-131L12.3	-7.83	3.23e-14	2.95e-11	-0.49	-0.34	Glucose homeostasis traits;	chr12:118436721	chr12:118428281~118428870:+
LUAD	cis	rs10463554	0.892	rs66759661	ENSG00000175749.11	EIF3KP1	7.83	3.24e-14	2.96e-11	0.47	0.34	Parkinson's disease;	chr5:102925894	chr5:103032376~103033031:+
LUAD	cis	rs11089937	0.626	rs4821784	ENSG00000211639.2	IGLV4-60	7.83	3.24e-14	2.96e-11	0.42	0.34	Periodontitis (PAL4Q3);	chr22:22143513	chr22:22162199~22162681:+
LUAD	cis	rs2337406	1	rs17112416	ENSG00000254174.1	IGHV1-12	-7.83	3.25e-14	2.96e-11	-0.31	-0.34	Alzheimer's disease (late onset);	chr14:106686773	chr14:106122420~106122709:-
LUAD	cis	rs904251	0.647	rs2776908	ENSG00000279942.1	RP1-153P14.7	-7.83	3.25e-14	2.97e-11	-0.37	-0.34	Cognitive performance;	chr6:37467081	chr6:37567716~37571460:+
LUAD	cis	rs11089937	0.667	rs10483108	ENSG00000211639.2	IGLV4-60	7.83	3.25e-14	2.97e-11	0.42	0.34	Periodontitis (PAL4Q3);	chr22:22152664	chr22:22162199~22162681:+
LUAD	cis	rs2919917	0.915	rs10957897	ENSG00000254352.1	RP11-578O24.2	7.83	3.25e-14	2.97e-11	0.42	0.34	Lymphocyte counts;	chr8:78695658	chr8:78723796~78724136:-
LUAD	cis	rs9326248	0.53	rs7940310	ENSG00000280143.1	AP000892.6	7.82	3.27e-14	2.98e-11	0.53	0.34	Blood protein levels;	chr11:117153765	chr11:117204967~117210292:+
LUAD	cis	rs34779708	0.832	rs6481946	ENSG00000230534.5	RP11-297A16.2	7.82	3.27e-14	2.98e-11	0.41	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35240186	chr10:35098006~35127020:-
LUAD	cis	rs3096299	0.967	rs2965935	ENSG00000274627.1	RP11-104N10.2	-7.82	3.27e-14	2.99e-11	-0.32	-0.34	Multiple myeloma (IgH translocation);	chr16:89414866	chr16:89516797~89522217:+
LUAD	cis	rs673078	0.66	rs7977403	ENSG00000275759.1	RP11-131L12.3	-7.82	3.28e-14	2.99e-11	-0.48	-0.34	Glucose homeostasis traits;	chr12:118233446	chr12:118428281~118428870:+
LUAD	cis	rs904251	0.772	rs2252920	ENSG00000279942.1	RP1-153P14.7	-7.82	3.28e-14	2.99e-11	-0.35	-0.34	Cognitive performance;	chr6:37450551	chr6:37567716~37571460:+
LUAD	cis	rs9322193	0.566	rs5024811	ENSG00000216906.2	RP11-350J20.9	-7.82	3.29e-14	3e-11	-0.47	-0.34	Lung cancer;	chr6:149924898	chr6:149904243~149906418:+
LUAD	cis	rs150992	0.673	rs331934	ENSG00000248489.1	CTD-2007H13.3	-7.82	3.31e-14	3.02e-11	-0.37	-0.34	Body mass index;	chr5:98804016	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.673	rs331549	ENSG00000248489.1	CTD-2007H13.3	-7.82	3.31e-14	3.02e-11	-0.37	-0.34	Body mass index;	chr5:98805731	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.673	rs992775	ENSG00000248489.1	CTD-2007H13.3	-7.82	3.31e-14	3.02e-11	-0.37	-0.34	Body mass index;	chr5:98807754	chr5:98929171~98995013:+
LUAD	cis	rs11155671	0.53	rs9322228	ENSG00000223701.3	RAET1E-AS1	7.82	3.32e-14	3.02e-11	0.39	0.34	Testicular germ cell tumor;	chr6:149888173	chr6:149884431~149919508:+
LUAD	cis	rs11155671	0.53	rs7774787	ENSG00000223701.3	RAET1E-AS1	7.82	3.32e-14	3.02e-11	0.39	0.34	Testicular germ cell tumor;	chr6:149888296	chr6:149884431~149919508:+
LUAD	cis	rs11155671	0.53	rs2342767	ENSG00000223701.3	RAET1E-AS1	7.82	3.32e-14	3.02e-11	0.39	0.34	Testicular germ cell tumor;	chr6:149888581	chr6:149884431~149919508:+
LUAD	cis	rs11155671	0.53	rs7764376	ENSG00000223701.3	RAET1E-AS1	7.82	3.32e-14	3.02e-11	0.39	0.34	Testicular germ cell tumor;	chr6:149889208	chr6:149884431~149919508:+
LUAD	cis	rs11155671	0.53	rs6933882	ENSG00000223701.3	RAET1E-AS1	7.82	3.32e-14	3.02e-11	0.39	0.34	Testicular germ cell tumor;	chr6:149889666	chr6:149884431~149919508:+
LUAD	cis	rs11155671	0.53	rs6939761	ENSG00000223701.3	RAET1E-AS1	7.82	3.32e-14	3.02e-11	0.39	0.34	Testicular germ cell tumor;	chr6:149889858	chr6:149884431~149919508:+
LUAD	cis	rs11155671	0.53	rs3823021	ENSG00000223701.3	RAET1E-AS1	7.82	3.32e-14	3.02e-11	0.39	0.34	Testicular germ cell tumor;	chr6:149889863	chr6:149884431~149919508:+
LUAD	cis	rs11155671	0.53	rs4869764	ENSG00000223701.3	RAET1E-AS1	7.82	3.32e-14	3.02e-11	0.39	0.34	Testicular germ cell tumor;	chr6:149890692	chr6:149884431~149919508:+
LUAD	cis	rs10463554	0.963	rs26816	ENSG00000175749.11	EIF3KP1	7.82	3.34e-14	3.04e-11	0.46	0.34	Parkinson's disease;	chr5:103204821	chr5:103032376~103033031:+
LUAD	cis	rs11089937	0.637	rs988200	ENSG00000211639.2	IGLV4-60	7.82	3.35e-14	3.06e-11	0.42	0.34	Periodontitis (PAL4Q3);	chr22:22154715	chr22:22162199~22162681:+
LUAD	cis	rs10740039	0.583	rs9415613	ENSG00000254271.1	RP11-131N11.4	-7.82	3.37e-14	3.07e-11	-0.4	-0.34	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60747636	chr10:60734342~60741828:+
LUAD	cis	rs944289	0.774	rs1958623	ENSG00000257826.1	RP11-116N8.4	-7.82	3.37e-14	3.08e-11	-0.35	-0.34	Thyroid cancer;	chr14:36128417	chr14:36061026~36067190:-
LUAD	cis	rs10129255	0.957	rs17113284	ENSG00000211972.2	IGHV3-66	-7.82	3.39e-14	3.09e-11	-0.3	-0.34	Kawasaki disease;	chr14:106684476	chr14:106675017~106675544:-
LUAD	cis	rs765787	0.53	rs1706835	ENSG00000259520.4	CTD-2651B20.3	7.82	3.4e-14	3.1e-11	0.44	0.34	Uric acid levels;	chr15:45225686	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs1631533	ENSG00000259520.4	CTD-2651B20.3	7.82	3.4e-14	3.1e-11	0.44	0.34	Uric acid levels;	chr15:45226430	chr15:45251580~45279251:-
LUAD	cis	rs9287719	0.901	rs10210859	ENSG00000234818.1	AC092687.5	7.82	3.4e-14	3.1e-11	0.4	0.34	Prostate cancer;	chr2:10593803	chr2:10589166~10604830:+
LUAD	cis	rs35955747	0.633	rs5998021	ENSG00000236132.1	CTA-440B3.1	7.82	3.41e-14	3.11e-11	0.38	0.34	Neutrophil count;Sum basophil neutrophil counts;	chr22:31511441	chr22:31816379~31817491:-
LUAD	cis	rs9322193	0.923	rs10782317	ENSG00000223701.3	RAET1E-AS1	-7.82	3.41e-14	3.11e-11	-0.38	-0.34	Lung cancer;	chr6:149753911	chr6:149884431~149919508:+
LUAD	cis	rs11155671	0.53	rs7768626	ENSG00000223701.3	RAET1E-AS1	7.82	3.43e-14	3.12e-11	0.39	0.34	Testicular germ cell tumor;	chr6:149886826	chr6:149884431~149919508:+
LUAD	cis	rs11155671	0.53	rs7768665	ENSG00000223701.3	RAET1E-AS1	7.82	3.43e-14	3.12e-11	0.39	0.34	Testicular germ cell tumor;	chr6:149886888	chr6:149884431~149919508:+
LUAD	cis	rs11155671	0.53	rs7758020	ENSG00000223701.3	RAET1E-AS1	7.82	3.43e-14	3.12e-11	0.39	0.34	Testicular germ cell tumor;	chr6:149886975	chr6:149884431~149919508:+
LUAD	cis	rs944289	0.774	rs8013429	ENSG00000257826.1	RP11-116N8.4	-7.82	3.43e-14	3.12e-11	-0.35	-0.34	Thyroid cancer;	chr14:36131855	chr14:36061026~36067190:-
LUAD	cis	rs2739330	0.703	rs5760112	ENSG00000206090.4	AP000350.7	7.82	3.44e-14	3.14e-11	0.38	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23939998~23942798:+
LUAD	cis	rs71403859	1	rs71403859	ENSG00000260886.1	TAT-AS1	7.82	3.46e-14	3.15e-11	0.58	0.34	Post bronchodilator FEV1;	chr16:71606304	chr16:71565789~71578187:+
LUAD	cis	rs71403859	0.803	rs34381861	ENSG00000260886.1	TAT-AS1	7.82	3.46e-14	3.15e-11	0.58	0.34	Post bronchodilator FEV1;	chr16:71606327	chr16:71565789~71578187:+
LUAD	cis	rs2880765	0.566	rs11630381	ENSG00000259295.5	CSPG4P12	7.82	3.47e-14	3.16e-11	0.42	0.34	Coronary artery disease;	chr15:85469272	chr15:85191438~85213905:+
LUAD	cis	rs950169	0.84	rs72748702	ENSG00000225151.9	GOLGA2P7	-7.81	3.49e-14	3.18e-11	-0.47	-0.34	Schizophrenia;	chr15:84246494	chr15:84199311~84230136:-
LUAD	cis	rs7201929	1	rs12920514	ENSG00000259982.1	CDC37P1	-7.81	3.5e-14	3.18e-11	-0.48	-0.34	QT interval;	chr16:28824579	chr16:28700294~28701540:-
LUAD	cis	rs8091660	0.929	rs11082685	ENSG00000278983.1	RP11-426J5.3	7.81	3.5e-14	3.18e-11	0.38	0.34	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48566806	chr18:48564795~48568342:+
LUAD	cis	rs1891275	0.551	rs7908678	ENSG00000228701.1	TNKS2-AS1	7.81	3.52e-14	3.2e-11	0.45	0.34	Intelligence (multi-trait analysis);	chr10:91659253	chr10:91782839~91798291:-
LUAD	cis	rs9545047	0.604	rs3752994	ENSG00000227676.3	LINC01068	7.81	3.52e-14	3.2e-11	0.39	0.34	Schizophrenia;	chr13:79345076	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.567	rs4884129	ENSG00000227676.3	LINC01068	7.81	3.52e-14	3.2e-11	0.39	0.34	Schizophrenia;	chr13:79346448	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.567	rs1410336	ENSG00000227676.3	LINC01068	7.81	3.52e-14	3.2e-11	0.39	0.34	Schizophrenia;	chr13:79347598	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs9565492	ENSG00000227676.3	LINC01068	7.81	3.52e-14	3.2e-11	0.39	0.34	Schizophrenia;	chr13:79348554	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs9318625	ENSG00000227676.3	LINC01068	7.81	3.52e-14	3.2e-11	0.39	0.34	Schizophrenia;	chr13:79351429	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs9530899	ENSG00000227676.3	LINC01068	7.81	3.52e-14	3.2e-11	0.39	0.34	Schizophrenia;	chr13:79352461	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs7338677	ENSG00000227676.3	LINC01068	7.81	3.52e-14	3.2e-11	0.39	0.34	Schizophrenia;	chr13:79352580	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs7322744	ENSG00000227676.3	LINC01068	7.81	3.52e-14	3.2e-11	0.39	0.34	Schizophrenia;	chr13:79354070	chr13:79566727~79571436:+
LUAD	cis	rs4718428	0.705	rs4717328	ENSG00000226824.5	RP4-756H11.3	-7.81	3.52e-14	3.21e-11	-0.45	-0.34	Corneal structure;	chr7:66887678	chr7:66654538~66669855:+
LUAD	cis	rs9545047	0.604	rs7996652	ENSG00000227676.3	LINC01068	7.81	3.53e-14	3.21e-11	0.39	0.34	Schizophrenia;	chr13:79341474	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs9565488	ENSG00000227676.3	LINC01068	7.81	3.53e-14	3.21e-11	0.39	0.34	Schizophrenia;	chr13:79341604	chr13:79566727~79571436:+
LUAD	cis	rs4718428	0.607	rs66954441	ENSG00000226824.5	RP4-756H11.3	-7.81	3.54e-14	3.22e-11	-0.45	-0.34	Corneal structure;	chr7:66904222	chr7:66654538~66669855:+
LUAD	cis	rs3096299	0.967	rs2911257	ENSG00000274627.1	RP11-104N10.2	7.81	3.54e-14	3.22e-11	0.32	0.34	Multiple myeloma (IgH translocation);	chr16:89417726	chr16:89516797~89522217:+
LUAD	cis	rs56080343	0.688	rs10083190	ENSG00000275759.1	RP11-131L12.3	-7.81	3.55e-14	3.22e-11	-0.42	-0.34	Neuroticism;	chr12:118365385	chr12:118428281~118428870:+
LUAD	cis	rs6921919	0.848	rs9468350	ENSG00000204709.4	LINC01556	7.81	3.55e-14	3.22e-11	0.46	0.34	Autism spectrum disorder or schizophrenia;	chr6:28351330	chr6:28943877~28944537:+
LUAD	cis	rs4660456	1	rs4660456	ENSG00000237899.1	RP4-739H11.3	-7.81	3.57e-14	3.24e-11	-0.46	-0.34	Platelet count;	chr1:40773839	chr1:40669089~40687588:-
LUAD	cis	rs7429990	0.864	rs35698005	ENSG00000229759.1	MRPS18AP1	-7.81	3.57e-14	3.24e-11	-0.34	-0.34	Educational attainment (years of education);	chr3:47800558	chr3:48256350~48256938:-
LUAD	cis	rs17482078	0.959	rs13173167	ENSG00000248734.2	CTD-2260A17.1	7.81	3.58e-14	3.25e-11	0.43	0.34	Behcet's disease;Blood protein levels;	chr5:96795780	chr5:96784777~96785999:+
LUAD	cis	rs17482078	0.959	rs2013717	ENSG00000248734.2	CTD-2260A17.1	7.81	3.58e-14	3.25e-11	0.43	0.34	Behcet's disease;Blood protein levels;	chr5:96798472	chr5:96784777~96785999:+
LUAD	cis	rs17482078	0.918	rs2013671	ENSG00000248734.2	CTD-2260A17.1	7.81	3.58e-14	3.25e-11	0.43	0.34	Behcet's disease;Blood protein levels;	chr5:96798580	chr5:96784777~96785999:+
LUAD	cis	rs17482078	0.959	rs2013633	ENSG00000248734.2	CTD-2260A17.1	7.81	3.58e-14	3.25e-11	0.43	0.34	Behcet's disease;Blood protein levels;	chr5:96798603	chr5:96784777~96785999:+
LUAD	cis	rs17482078	0.959	rs10074694	ENSG00000248734.2	CTD-2260A17.1	7.81	3.58e-14	3.25e-11	0.43	0.34	Behcet's disease;Blood protein levels;	chr5:96801437	chr5:96784777~96785999:+
LUAD	cis	rs17482078	0.959	rs10074708	ENSG00000248734.2	CTD-2260A17.1	7.81	3.58e-14	3.25e-11	0.43	0.34	Behcet's disease;Blood protein levels;	chr5:96801501	chr5:96784777~96785999:+
LUAD	cis	rs9545047	0.604	rs7981067	ENSG00000227676.3	LINC01068	7.81	3.6e-14	3.27e-11	0.39	0.34	Schizophrenia;	chr13:79341254	chr13:79566727~79571436:+
LUAD	cis	rs673078	0.607	rs2062519	ENSG00000275759.1	RP11-131L12.3	-7.81	3.6e-14	3.27e-11	-0.42	-0.34	Glucose homeostasis traits;	chr12:118367577	chr12:118428281~118428870:+
LUAD	cis	rs35955747	0.689	rs5997988	ENSG00000236132.1	CTA-440B3.1	7.81	3.62e-14	3.29e-11	0.38	0.34	Neutrophil count;Sum basophil neutrophil counts;	chr22:31442099	chr22:31816379~31817491:-
LUAD	cis	rs131777	0.577	rs131748	ENSG00000205559.3	CHKB-AS1	7.81	3.63e-14	3.3e-11	0.37	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586408	chr22:50583026~50583877:+
LUAD	cis	rs765787	0.53	rs2433228	ENSG00000259520.4	CTD-2651B20.3	7.81	3.65e-14	3.31e-11	0.44	0.34	Uric acid levels;	chr15:45223173	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs11854690	ENSG00000259520.4	CTD-2651B20.3	7.81	3.65e-14	3.31e-11	0.44	0.34	Uric acid levels;	chr15:45223818	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs28733848	ENSG00000259520.4	CTD-2651B20.3	7.81	3.65e-14	3.31e-11	0.44	0.34	Uric acid levels;	chr15:45223849	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs11854689	ENSG00000259520.4	CTD-2651B20.3	7.81	3.65e-14	3.31e-11	0.44	0.34	Uric acid levels;	chr15:45223854	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs1706830	ENSG00000259520.4	CTD-2651B20.3	7.81	3.65e-14	3.31e-11	0.44	0.34	Uric acid levels;	chr15:45224031	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs1706831	ENSG00000259520.4	CTD-2651B20.3	7.81	3.65e-14	3.31e-11	0.44	0.34	Uric acid levels;	chr15:45224032	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs2433227	ENSG00000259520.4	CTD-2651B20.3	7.81	3.65e-14	3.31e-11	0.44	0.34	Uric acid levels;	chr15:45224921	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs1648286	ENSG00000259520.4	CTD-2651B20.3	7.81	3.65e-14	3.31e-11	0.44	0.34	Uric acid levels;	chr15:45225188	chr15:45251580~45279251:-
LUAD	cis	rs9322193	0.962	rs9505974	ENSG00000223701.3	RAET1E-AS1	7.81	3.65e-14	3.31e-11	0.39	0.34	Lung cancer;	chr6:149779294	chr6:149884431~149919508:+
LUAD	cis	rs9545047	0.604	rs9574411	ENSG00000227676.3	LINC01068	-7.81	3.65e-14	3.31e-11	-0.39	-0.34	Schizophrenia;	chr13:79354342	chr13:79566727~79571436:+
LUAD	cis	rs2581828	0.646	rs2564944	ENSG00000242142.1	SERBP1P3	7.81	3.65e-14	3.31e-11	0.36	0.34	Crohn's disease;	chr3:53114439	chr3:53064283~53065091:-
LUAD	cis	rs11089937	0.597	rs4821772	ENSG00000211639.2	IGLV4-60	-7.81	3.66e-14	3.32e-11	-0.39	-0.34	Periodontitis (PAL4Q3);	chr22:22131383	chr22:22162199~22162681:+
LUAD	cis	rs9287719	0.753	rs1990613	ENSG00000234818.1	AC092687.5	-7.81	3.67e-14	3.33e-11	-0.39	-0.34	Prostate cancer;	chr2:10641849	chr2:10589166~10604830:+
LUAD	cis	rs4660456	0.913	rs569159	ENSG00000237899.1	RP4-739H11.3	-7.81	3.67e-14	3.33e-11	-0.46	-0.34	Platelet count;	chr1:40701862	chr1:40669089~40687588:-
LUAD	cis	rs944289	0.74	rs950319	ENSG00000257826.1	RP11-116N8.4	-7.81	3.68e-14	3.33e-11	-0.35	-0.34	Thyroid cancer;	chr14:36096786	chr14:36061026~36067190:-
LUAD	cis	rs7208859	0.725	rs7342938	ENSG00000263531.1	RP13-753N3.1	7.81	3.68e-14	3.34e-11	0.58	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862812	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.725	rs6505215	ENSG00000263531.1	RP13-753N3.1	7.81	3.68e-14	3.34e-11	0.58	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862885	chr17:30863921~30864940:-
LUAD	cis	rs950027	1	rs950027	ENSG00000259520.4	CTD-2651B20.3	7.81	3.69e-14	3.34e-11	0.39	0.34	Response to fenofibrate (adiponectin levels);	chr15:45508837	chr15:45251580~45279251:-
LUAD	cis	rs2455601	0.882	rs11042105	ENSG00000254860.4	TMEM9B-AS1	7.81	3.7e-14	3.36e-11	0.51	0.34	Schizophrenia;	chr11:8872963	chr11:8964675~8977527:+
LUAD	cis	rs35955747	0.714	rs4820048	ENSG00000236132.1	CTA-440B3.1	7.81	3.7e-14	3.36e-11	0.38	0.34	Neutrophil count;Sum basophil neutrophil counts;	chr22:31458384	chr22:31816379~31817491:-
LUAD	cis	rs4660456	0.913	rs2780950	ENSG00000237899.1	RP4-739H11.3	7.81	3.71e-14	3.36e-11	0.46	0.34	Platelet count;	chr1:40686937	chr1:40669089~40687588:-
LUAD	cis	rs9322193	0.926	rs9689036	ENSG00000223701.3	RAET1E-AS1	7.81	3.71e-14	3.36e-11	0.39	0.34	Lung cancer;	chr6:149780563	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs9322218	ENSG00000223701.3	RAET1E-AS1	7.81	3.71e-14	3.36e-11	0.39	0.34	Lung cancer;	chr6:149782183	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs9322219	ENSG00000223701.3	RAET1E-AS1	7.81	3.71e-14	3.36e-11	0.39	0.34	Lung cancer;	chr6:149782263	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs9322223	ENSG00000223701.3	RAET1E-AS1	7.81	3.71e-14	3.36e-11	0.39	0.34	Lung cancer;	chr6:149801509	chr6:149884431~149919508:+
LUAD	cis	rs2739330	0.76	rs1002286	ENSG00000206090.4	AP000350.7	-7.81	3.71e-14	3.37e-11	-0.38	-0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23939998~23942798:+
LUAD	cis	rs732716	0.853	rs62129349	ENSG00000267769.1	CTB-50L17.9	-7.81	3.71e-14	3.37e-11	-0.37	-0.34	Mean corpuscular volume;	chr19:4385662	chr19:4454014~4455286:+
LUAD	cis	rs732716	0.889	rs11085074	ENSG00000267769.1	CTB-50L17.9	-7.81	3.71e-14	3.37e-11	-0.37	-0.34	Mean corpuscular volume;	chr19:4386355	chr19:4454014~4455286:+
LUAD	cis	rs2739330	0.791	rs4822458	ENSG00000228039.3	KB-1125A3.10	7.81	3.72e-14	3.37e-11	0.4	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23963780~23964374:+
LUAD	cis	rs11089937	0.626	rs11704092	ENSG00000211639.2	IGLV4-60	7.81	3.72e-14	3.37e-11	0.41	0.34	Periodontitis (PAL4Q3);	chr22:22135815	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.667	rs78549985	ENSG00000211639.2	IGLV4-60	7.81	3.72e-14	3.37e-11	0.41	0.34	Periodontitis (PAL4Q3);	chr22:22139152	chr22:22162199~22162681:+
LUAD	cis	rs10129255	0.956	rs10137268	ENSG00000211972.2	IGHV3-66	7.81	3.73e-14	3.38e-11	0.3	0.34	Kawasaki disease;	chr14:106697402	chr14:106675017~106675544:-
LUAD	cis	rs80285556	1	rs111902838	ENSG00000161643.11	SIGLEC16	7.81	3.73e-14	3.38e-11	0.78	0.34	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:49993357	chr19:49969673~49975814:+
LUAD	cis	rs10875746	0.551	rs2054903	ENSG00000240399.1	RP1-228P16.1	-7.8	3.77e-14	3.42e-11	-0.4	-0.34	Longevity (90 years and older);	chr12:48330710	chr12:48054813~48055591:-
LUAD	cis	rs4660456	0.871	rs7549789	ENSG00000237899.1	RP4-739H11.3	-7.8	3.78e-14	3.43e-11	-0.46	-0.34	Platelet count;	chr1:40759362	chr1:40669089~40687588:-
LUAD	cis	rs2919917	1	rs2919917	ENSG00000254352.1	RP11-578O24.2	-7.8	3.81e-14	3.45e-11	-0.41	-0.34	Lymphocyte counts;	chr8:78745028	chr8:78723796~78724136:-
LUAD	cis	rs673078	0.66	rs61943524	ENSG00000275759.1	RP11-131L12.3	-7.8	3.81e-14	3.45e-11	-0.5	-0.34	Glucose homeostasis traits;	chr12:118151530	chr12:118428281~118428870:+
LUAD	cis	rs496547	0.557	rs516719	ENSG00000278376.1	RP11-158I9.8	-7.8	3.82e-14	3.45e-11	-0.37	-0.34	Hip minimal joint space width;	chr11:118808736	chr11:118791254~118793137:+
LUAD	cis	rs10463554	1	rs6879788	ENSG00000175749.11	EIF3KP1	7.8	3.82e-14	3.46e-11	0.45	0.34	Parkinson's disease;	chr5:102978353	chr5:103032376~103033031:+
LUAD	cis	rs9322193	0.607	rs12209310	ENSG00000216906.2	RP11-350J20.9	7.8	3.82e-14	3.46e-11	0.5	0.34	Lung cancer;	chr6:149904882	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.566	rs9397070	ENSG00000216906.2	RP11-350J20.9	-7.8	3.84e-14	3.47e-11	-0.48	-0.34	Lung cancer;	chr6:149922073	chr6:149904243~149906418:+
LUAD	cis	rs950880	0.71	rs56166614	ENSG00000234389.1	AC007278.3	-7.8	3.87e-14	3.5e-11	-0.34	-0.34	Serum protein levels (sST2);	chr2:102439636	chr2:102438713~102440475:+
LUAD	cis	rs9545047	0.604	rs2057573	ENSG00000227676.3	LINC01068	-7.8	3.87e-14	3.5e-11	-0.39	-0.34	Schizophrenia;	chr13:79357736	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.625	rs1408657	ENSG00000227676.3	LINC01068	7.8	3.88e-14	3.51e-11	0.39	0.34	Schizophrenia;	chr13:79329315	chr13:79566727~79571436:+
LUAD	cis	rs367615	0.679	rs10070786	ENSG00000249476.1	CTD-2587M2.1	7.8	3.9e-14	3.52e-11	0.39	0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109479380	chr5:109237120~109326369:-
LUAD	cis	rs2919917	1	rs1054283	ENSG00000254352.1	RP11-578O24.2	7.8	3.9e-14	3.53e-11	0.41	0.34	Lymphocyte counts;	chr8:78698475	chr8:78723796~78724136:-
LUAD	cis	rs9545047	0.604	rs1749988	ENSG00000227676.3	LINC01068	7.8	3.9e-14	3.53e-11	0.39	0.34	Schizophrenia;	chr13:79333103	chr13:79566727~79571436:+
LUAD	cis	rs944289	0.708	rs1958615	ENSG00000257826.1	RP11-116N8.4	-7.8	3.91e-14	3.53e-11	-0.35	-0.34	Thyroid cancer;	chr14:36118282	chr14:36061026~36067190:-
LUAD	cis	rs9545047	0.584	rs9565485	ENSG00000227676.3	LINC01068	-7.8	3.91e-14	3.54e-11	-0.39	-0.34	Schizophrenia;	chr13:79307428	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs1007569	ENSG00000227676.3	LINC01068	7.8	3.93e-14	3.55e-11	0.39	0.34	Schizophrenia;	chr13:79306752	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.584	rs4885626	ENSG00000227676.3	LINC01068	7.8	3.93e-14	3.55e-11	0.39	0.34	Schizophrenia;	chr13:79309765	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs4885627	ENSG00000227676.3	LINC01068	7.8	3.93e-14	3.55e-11	0.39	0.34	Schizophrenia;	chr13:79309786	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs4885628	ENSG00000227676.3	LINC01068	7.8	3.93e-14	3.55e-11	0.39	0.34	Schizophrenia;	chr13:79309830	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.554	rs4885629	ENSG00000227676.3	LINC01068	7.8	3.93e-14	3.55e-11	0.39	0.34	Schizophrenia;	chr13:79309855	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs1927506	ENSG00000227676.3	LINC01068	7.8	3.93e-14	3.55e-11	0.39	0.34	Schizophrenia;	chr13:79311350	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs1409019	ENSG00000227676.3	LINC01068	7.8	3.93e-14	3.55e-11	0.39	0.34	Schizophrenia;	chr13:79312431	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs7317343	ENSG00000227676.3	LINC01068	7.8	3.93e-14	3.55e-11	0.39	0.34	Schizophrenia;	chr13:79312542	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs6563098	ENSG00000227676.3	LINC01068	7.8	3.93e-14	3.55e-11	0.39	0.34	Schizophrenia;	chr13:79313102	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.532	rs1748768	ENSG00000227676.3	LINC01068	7.8	3.93e-14	3.55e-11	0.39	0.34	Schizophrenia;	chr13:79313276	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs1748767	ENSG00000227676.3	LINC01068	7.8	3.93e-14	3.55e-11	0.39	0.34	Schizophrenia;	chr13:79313381	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.567	rs1409018	ENSG00000227676.3	LINC01068	7.8	3.93e-14	3.55e-11	0.39	0.34	Schizophrenia;	chr13:79313403	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs1410332	ENSG00000227676.3	LINC01068	7.8	3.93e-14	3.55e-11	0.39	0.34	Schizophrenia;	chr13:79315171	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs9545065	ENSG00000227676.3	LINC01068	7.8	3.93e-14	3.55e-11	0.39	0.34	Schizophrenia;	chr13:79317034	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs3818563	ENSG00000227676.3	LINC01068	7.8	3.93e-14	3.55e-11	0.39	0.34	Schizophrenia;	chr13:79318587	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.625	rs9318621	ENSG00000227676.3	LINC01068	7.8	3.93e-14	3.55e-11	0.39	0.34	Schizophrenia;	chr13:79325662	chr13:79566727~79571436:+
LUAD	cis	rs673078	0.66	rs16948193	ENSG00000275759.1	RP11-131L12.3	-7.8	3.93e-14	3.55e-11	-0.48	-0.34	Glucose homeostasis traits;	chr12:118227115	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.66	rs61945187	ENSG00000275759.1	RP11-131L12.3	-7.8	3.93e-14	3.55e-11	-0.48	-0.34	Glucose homeostasis traits;	chr12:118228989	chr12:118428281~118428870:+
LUAD	cis	rs12468226	1	rs13426118	ENSG00000273456.1	RP11-686O6.2	7.8	3.95e-14	3.57e-11	0.44	0.33	Urate levels;	chr2:202390762	chr2:202374932~202375604:-
LUAD	cis	rs367615	0.704	rs7726991	ENSG00000249476.1	CTD-2587M2.1	7.8	3.96e-14	3.58e-11	0.38	0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109511733	chr5:109237120~109326369:-
LUAD	cis	rs7429990	0.828	rs55823596	ENSG00000229759.1	MRPS18AP1	7.8	3.98e-14	3.6e-11	0.35	0.33	Educational attainment (years of education);	chr3:47758541	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs4858853	ENSG00000229759.1	MRPS18AP1	7.8	3.98e-14	3.6e-11	0.35	0.33	Educational attainment (years of education);	chr3:47760605	chr3:48256350~48256938:-
LUAD	cis	rs4660456	0.869	rs7518344	ENSG00000237899.1	RP4-739H11.3	7.8	3.99e-14	3.6e-11	0.46	0.33	Platelet count;	chr1:40708327	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.827	rs10736404	ENSG00000237899.1	RP4-739H11.3	7.8	3.99e-14	3.6e-11	0.46	0.33	Platelet count;	chr1:40710331	chr1:40669089~40687588:-
LUAD	cis	rs8005677	1	rs1956880	ENSG00000279656.1	RP11-298I3.6	7.8	3.99e-14	3.6e-11	0.4	0.33	Cognitive ability (multi-trait analysis);	chr14:22924798	chr14:23023083~23024217:-
LUAD	cis	rs367615	0.704	rs7705399	ENSG00000249476.1	CTD-2587M2.1	7.8	3.99e-14	3.6e-11	0.38	0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109514650	chr5:109237120~109326369:-
LUAD	cis	rs950169	0.922	rs12906983	ENSG00000225151.9	GOLGA2P7	-7.8	4e-14	3.61e-11	-0.48	-0.33	Schizophrenia;	chr15:84262270	chr15:84199311~84230136:-
LUAD	cis	rs150992	0.678	rs161950	ENSG00000248489.1	CTD-2007H13.3	-7.79	4.04e-14	3.65e-11	-0.36	-0.33	Body mass index;	chr5:98924533	chr5:98929171~98995013:+
LUAD	cis	rs5769707	0.632	rs5770601	ENSG00000188511.11	C22orf34	7.79	4.05e-14	3.66e-11	0.43	0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49628255	chr22:49414524~49657542:-
LUAD	cis	rs4660456	0.913	rs2780952	ENSG00000237899.1	RP4-739H11.3	7.79	4.06e-14	3.66e-11	0.46	0.33	Platelet count;	chr1:40689711	chr1:40669089~40687588:-
LUAD	cis	rs765787	0.53	rs28414644	ENSG00000259520.4	CTD-2651B20.3	7.79	4.07e-14	3.68e-11	0.44	0.33	Uric acid levels;	chr15:45244523	chr15:45251580~45279251:-
LUAD	cis	rs2581828	0.618	rs6777975	ENSG00000242142.1	SERBP1P3	-7.79	4.08e-14	3.68e-11	-0.38	-0.33	Crohn's disease;	chr3:53132119	chr3:53064283~53065091:-
LUAD	cis	rs4660456	0.913	rs7551747	ENSG00000237899.1	RP4-739H11.3	7.79	4.09e-14	3.69e-11	0.46	0.33	Platelet count;	chr1:40699407	chr1:40669089~40687588:-
LUAD	cis	rs8081395	0.836	rs2063353	ENSG00000266992.1	DHX40P1	-7.79	4.1e-14	3.7e-11	-0.38	-0.33	White blood cell count;	chr17:59811831	chr17:59976009~60002384:-
LUAD	cis	rs4853012	0.838	rs4429500	ENSG00000257800.1	FNBP1P1	7.79	4.11e-14	3.71e-11	0.39	0.33	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74120680~74123218:+
LUAD	cis	rs2880765	0.545	rs17553734	ENSG00000259295.5	CSPG4P12	-7.79	4.13e-14	3.72e-11	-0.41	-0.33	Coronary artery disease;	chr15:85469828	chr15:85191438~85213905:+
LUAD	cis	rs765787	0.53	rs2899381	ENSG00000259520.4	CTD-2651B20.3	7.79	4.14e-14	3.73e-11	0.44	0.33	Uric acid levels;	chr15:45237432	chr15:45251580~45279251:-
LUAD	cis	rs673078	0.607	rs2036489	ENSG00000275759.1	RP11-131L12.3	-7.79	4.15e-14	3.74e-11	-0.42	-0.33	Glucose homeostasis traits;	chr12:118364643	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs10082823	ENSG00000275759.1	RP11-131L12.3	-7.79	4.15e-14	3.74e-11	-0.42	-0.33	Glucose homeostasis traits;	chr12:118365386	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.66	rs76842574	ENSG00000275759.1	RP11-131L12.3	-7.79	4.16e-14	3.75e-11	-0.42	-0.33	Glucose homeostasis traits;	chr12:118371789	chr12:118428281~118428870:+
LUAD	cis	rs765787	0.53	rs2413776	ENSG00000259520.4	CTD-2651B20.3	7.79	4.17e-14	3.76e-11	0.43	0.33	Uric acid levels;	chr15:45251972	chr15:45251580~45279251:-
LUAD	cis	rs944289	0.684	rs8016315	ENSG00000257826.1	RP11-116N8.4	-7.79	4.18e-14	3.76e-11	-0.35	-0.33	Thyroid cancer;	chr14:36101158	chr14:36061026~36067190:-
LUAD	cis	rs944289	0.74	rs4982334	ENSG00000257826.1	RP11-116N8.4	-7.79	4.18e-14	3.76e-11	-0.35	-0.33	Thyroid cancer;	chr14:36101396	chr14:36061026~36067190:-
LUAD	cis	rs8059260	0.604	rs76969865	ENSG00000274038.1	RP11-66H6.4	-7.79	4.19e-14	3.77e-11	-0.63	-0.33	Alcohol consumption over the past year;	chr16:11050092	chr16:11056556~11057034:+
LUAD	cis	rs9287719	0.967	rs6432112	ENSG00000234818.1	AC092687.5	-7.79	4.2e-14	3.78e-11	-0.4	-0.33	Prostate cancer;	chr2:10604748	chr2:10589166~10604830:+
LUAD	cis	rs765787	0.53	rs4331289	ENSG00000259520.4	CTD-2651B20.3	7.79	4.2e-14	3.78e-11	0.44	0.33	Uric acid levels;	chr15:45223140	chr15:45251580~45279251:-
LUAD	cis	rs9545047	0.604	rs9285310	ENSG00000227676.3	LINC01068	-7.79	4.21e-14	3.79e-11	-0.39	-0.33	Schizophrenia;	chr13:79328340	chr13:79566727~79571436:+
LUAD	cis	rs9322193	0.923	rs9767123	ENSG00000223701.3	RAET1E-AS1	7.79	4.21e-14	3.79e-11	0.39	0.33	Lung cancer;	chr6:149660323	chr6:149884431~149919508:+
LUAD	cis	rs950169	0.881	rs72750843	ENSG00000225151.9	GOLGA2P7	-7.79	4.21e-14	3.79e-11	-0.47	-0.33	Schizophrenia;	chr15:84592552	chr15:84199311~84230136:-
LUAD	cis	rs12439619	0.53	rs7162177	ENSG00000255769.6	GOLGA2P10	-7.79	4.21e-14	3.8e-11	-0.35	-0.33	Intelligence (multi-trait analysis);	chr15:82181728	chr15:82472993~82513950:-
LUAD	cis	rs7429990	0.864	rs11712464	ENSG00000229759.1	MRPS18AP1	7.79	4.23e-14	3.8e-11	0.35	0.33	Educational attainment (years of education);	chr3:47724057	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs56376646	ENSG00000229759.1	MRPS18AP1	7.79	4.23e-14	3.8e-11	0.35	0.33	Educational attainment (years of education);	chr3:47732588	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs11927129	ENSG00000229759.1	MRPS18AP1	7.79	4.23e-14	3.8e-11	0.35	0.33	Educational attainment (years of education);	chr3:47745413	chr3:48256350~48256938:-
LUAD	cis	rs950169	0.922	rs4842940	ENSG00000225151.9	GOLGA2P7	7.79	4.23e-14	3.81e-11	0.47	0.33	Schizophrenia;	chr15:84162473	chr15:84199311~84230136:-
LUAD	cis	rs56046484	0.956	rs12904410	ENSG00000259295.5	CSPG4P12	7.79	4.25e-14	3.82e-11	0.5	0.33	Testicular germ cell tumor;	chr15:85066557	chr15:85191438~85213905:+
LUAD	cis	rs7208859	0.673	rs9889755	ENSG00000263531.1	RP13-753N3.1	-7.79	4.25e-14	3.82e-11	-0.6	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30907487	chr17:30863921~30864940:-
LUAD	cis	rs9287719	0.967	rs6432113	ENSG00000234818.1	AC092687.5	-7.79	4.25e-14	3.82e-11	-0.4	-0.33	Prostate cancer;	chr2:10604763	chr2:10589166~10604830:+
LUAD	cis	rs9545047	0.625	rs9593391	ENSG00000227676.3	LINC01068	-7.79	4.28e-14	3.85e-11	-0.39	-0.33	Schizophrenia;	chr13:79329168	chr13:79566727~79571436:+
LUAD	cis	rs9322193	0.923	rs9322214	ENSG00000223701.3	RAET1E-AS1	7.79	4.28e-14	3.85e-11	0.4	0.33	Lung cancer;	chr6:149703986	chr6:149884431~149919508:+
LUAD	cis	rs10028773	0.515	rs9994488	ENSG00000245958.5	RP11-33B1.1	-7.78	4.32e-14	3.89e-11	-0.29	-0.33	Educational attainment;	chr4:119666626	chr4:119454791~119552025:+
LUAD	cis	rs9545047	0.604	rs7988784	ENSG00000227676.3	LINC01068	-7.78	4.34e-14	3.9e-11	-0.39	-0.33	Schizophrenia;	chr13:79335337	chr13:79566727~79571436:+
LUAD	cis	rs11089937	0.512	rs6001073	ENSG00000211639.2	IGLV4-60	7.78	4.35e-14	3.91e-11	0.39	0.33	Periodontitis (PAL4Q3);	chr22:22133650	chr22:22162199~22162681:+
LUAD	cis	rs9545047	0.604	rs9545054	ENSG00000227676.3	LINC01068	7.78	4.35e-14	3.91e-11	0.39	0.33	Schizophrenia;	chr13:79298833	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.547	rs2876739	ENSG00000227676.3	LINC01068	7.78	4.35e-14	3.91e-11	0.39	0.33	Schizophrenia;	chr13:79299057	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.567	rs7988331	ENSG00000227676.3	LINC01068	7.78	4.35e-14	3.91e-11	0.39	0.33	Schizophrenia;	chr13:79299745	chr13:79566727~79571436:+
LUAD	cis	rs4718428	0.705	rs28648401	ENSG00000226824.5	RP4-756H11.3	-7.78	4.38e-14	3.94e-11	-0.45	-0.33	Corneal structure;	chr7:66902145	chr7:66654538~66669855:+
LUAD	cis	rs367615	0.704	rs11747622	ENSG00000249476.1	CTD-2587M2.1	7.78	4.39e-14	3.94e-11	0.38	0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109509019	chr5:109237120~109326369:-
LUAD	cis	rs8177876	0.749	rs2278024	ENSG00000261838.4	RP11-303E16.6	7.78	4.41e-14	3.97e-11	0.73	0.33	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81045628	chr16:81069854~81076598:+
LUAD	cis	rs4718428	0.672	rs12530806	ENSG00000226824.5	RP4-756H11.3	-7.78	4.43e-14	3.98e-11	-0.45	-0.33	Corneal structure;	chr7:66925737	chr7:66654538~66669855:+
LUAD	cis	rs4718428	0.705	rs10267335	ENSG00000226824.5	RP4-756H11.3	-7.78	4.43e-14	3.98e-11	-0.45	-0.33	Corneal structure;	chr7:66938233	chr7:66654538~66669855:+
LUAD	cis	rs240993	0.909	rs11153279	ENSG00000230177.1	RP5-1112D6.4	7.78	4.44e-14	3.99e-11	0.32	0.33	Inflammatory skin disease;Psoriasis;	chr6:111266063	chr6:111277932~111278742:+
LUAD	cis	rs2919917	1	rs1441438	ENSG00000254352.1	RP11-578O24.2	-7.78	4.46e-14	4.01e-11	-0.41	-0.33	Lymphocyte counts;	chr8:78729534	chr8:78723796~78724136:-
LUAD	cis	rs71403859	0.73	rs17355804	ENSG00000260886.1	TAT-AS1	7.78	4.49e-14	4.03e-11	0.57	0.33	Post bronchodilator FEV1;	chr16:71683311	chr16:71565789~71578187:+
LUAD	cis	rs4660456	0.913	rs3767950	ENSG00000237899.1	RP4-739H11.3	-7.78	4.51e-14	4.05e-11	-0.46	-0.33	Platelet count;	chr1:40767541	chr1:40669089~40687588:-
LUAD	cis	rs1150668	0.796	rs2531825	ENSG00000216901.1	AL022393.7	7.78	4.53e-14	4.06e-11	0.39	0.33	Pubertal anthropometrics;	chr6:28381487	chr6:28176188~28176674:+
LUAD	cis	rs10129255	0.872	rs8015406	ENSG00000211972.2	IGHV3-66	7.78	4.53e-14	4.07e-11	0.29	0.33	Kawasaki disease;	chr14:106670611	chr14:106675017~106675544:-
LUAD	cis	rs11155671	0.53	rs9371544	ENSG00000223701.3	RAET1E-AS1	7.78	4.59e-14	4.11e-11	0.4	0.33	Testicular germ cell tumor;	chr6:149896224	chr6:149884431~149919508:+
LUAD	cis	rs3096299	0.967	rs2911256	ENSG00000274627.1	RP11-104N10.2	7.78	4.59e-14	4.11e-11	0.32	0.33	Multiple myeloma (IgH translocation);	chr16:89418688	chr16:89516797~89522217:+
LUAD	cis	rs8031584	0.678	rs8035703	ENSG00000260382.1	RP11-540B6.2	7.78	4.6e-14	4.13e-11	0.41	0.33	Huntington's disease progression;	chr15:30876269	chr15:30882267~30883231:-
LUAD	cis	rs6504950	0.85	rs2541242	ENSG00000275710.1	RP11-257O5.4	-7.78	4.6e-14	4.13e-11	-0.43	-0.33	Breast cancer;	chr17:55012326	chr17:54964474~54964679:+
LUAD	cis	rs4660456	0.913	rs34212676	ENSG00000237899.1	RP4-739H11.3	-7.78	4.61e-14	4.14e-11	-0.46	-0.33	Platelet count;	chr1:40766522	chr1:40669089~40687588:-
LUAD	cis	rs9545047	0.604	rs3742117	ENSG00000227676.3	LINC01068	7.77	4.63e-14	4.15e-11	0.39	0.33	Schizophrenia;	chr13:79342498	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.647	rs3742118	ENSG00000227676.3	LINC01068	7.77	4.63e-14	4.15e-11	0.39	0.33	Schizophrenia;	chr13:79342838	chr13:79566727~79571436:+
LUAD	cis	rs4660456	0.913	rs489222	ENSG00000237899.1	RP4-739H11.3	7.77	4.63e-14	4.15e-11	0.46	0.33	Platelet count;	chr1:40683422	chr1:40669089~40687588:-
LUAD	cis	rs1150668	0.83	rs2531831	ENSG00000204709.4	LINC01556	7.77	4.64e-14	4.16e-11	0.4	0.33	Pubertal anthropometrics;	chr6:28420988	chr6:28943877~28944537:+
LUAD	cis	rs4660456	0.956	rs4660457	ENSG00000237899.1	RP4-739H11.3	-7.77	4.64e-14	4.16e-11	-0.46	-0.33	Platelet count;	chr1:40774121	chr1:40669089~40687588:-
LUAD	cis	rs1537424	0.513	rs944290	ENSG00000257826.1	RP11-116N8.4	-7.77	4.65e-14	4.17e-11	-0.36	-0.33	Thyroid hormone levels;	chr14:36095493	chr14:36061026~36067190:-
LUAD	cis	rs9322193	0.962	rs3805749	ENSG00000223701.3	RAET1E-AS1	7.77	4.66e-14	4.18e-11	0.4	0.33	Lung cancer;	chr6:149772546	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.847	rs9505972	ENSG00000223701.3	RAET1E-AS1	7.77	4.66e-14	4.18e-11	0.4	0.33	Lung cancer;	chr6:149775255	chr6:149884431~149919508:+
LUAD	cis	rs9287719	0.967	rs6735074	ENSG00000234818.1	AC092687.5	-7.77	4.66e-14	4.18e-11	-0.39	-0.33	Prostate cancer;	chr2:10594640	chr2:10589166~10604830:+
LUAD	cis	rs765787	0.53	rs16941017	ENSG00000259520.4	CTD-2651B20.3	7.77	4.67e-14	4.18e-11	0.43	0.33	Uric acid levels;	chr15:45251083	chr15:45251580~45279251:-
LUAD	cis	rs7429990	0.864	rs13086149	ENSG00000229759.1	MRPS18AP1	-7.77	4.68e-14	4.2e-11	-0.34	-0.33	Educational attainment (years of education);	chr3:47784158	chr3:48256350~48256938:-
LUAD	cis	rs950880	0.71	rs55645612	ENSG00000234389.1	AC007278.3	-7.77	4.69e-14	4.2e-11	-0.34	-0.33	Serum protein levels (sST2);	chr2:102439201	chr2:102438713~102440475:+
LUAD	cis	rs1501911	0.509	rs330421	ENSG00000248489.1	CTD-2007H13.3	7.77	4.69e-14	4.2e-11	0.36	0.33	Lung function (FEV1/FVC);	chr5:98859077	chr5:98929171~98995013:+
LUAD	cis	rs5760092	0.755	rs915589	ENSG00000225282.1	AP000350.6	-7.77	4.69e-14	4.21e-11	-0.48	-0.33	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23926900~23929574:+
LUAD	cis	rs9545047	0.604	rs9574410	ENSG00000227676.3	LINC01068	-7.77	4.72e-14	4.22e-11	-0.39	-0.33	Schizophrenia;	chr13:79343091	chr13:79566727~79571436:+
LUAD	cis	rs950169	0.922	rs4842941	ENSG00000225151.9	GOLGA2P7	7.77	4.74e-14	4.25e-11	0.47	0.33	Schizophrenia;	chr15:84162560	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.922	rs12911223	ENSG00000225151.9	GOLGA2P7	7.77	4.74e-14	4.25e-11	0.47	0.33	Schizophrenia;	chr15:84162919	chr15:84199311~84230136:-
LUAD	cis	rs10463554	0.963	rs257294	ENSG00000175749.11	EIF3KP1	7.77	4.75e-14	4.25e-11	0.47	0.33	Parkinson's disease;	chr5:103131563	chr5:103032376~103033031:+
LUAD	cis	rs11155671	0.53	rs2342769	ENSG00000223701.3	RAET1E-AS1	7.77	4.75e-14	4.25e-11	0.39	0.33	Testicular germ cell tumor;	chr6:149895371	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.607	rs915140	ENSG00000216906.2	RP11-350J20.9	7.77	4.76e-14	4.26e-11	0.5	0.33	Lung cancer;	chr6:149899674	chr6:149904243~149906418:+
LUAD	cis	rs7688540	0.771	rs7674560	ENSG00000275426.1	CH17-262A2.1	7.77	4.76e-14	4.27e-11	0.47	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:269530	chr4:149738~150317:+
LUAD	cis	rs9595908	0.9	rs9591137	ENSG00000212293.1	SNORA16	7.77	4.78e-14	4.28e-11	0.37	0.33	Body mass index;	chr13:32578345	chr13:32420390~32420516:-
LUAD	cis	rs10463554	0.926	rs26433	ENSG00000175749.11	EIF3KP1	7.77	4.78e-14	4.28e-11	0.44	0.33	Parkinson's disease;	chr5:103028154	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.963	rs34777	ENSG00000175749.11	EIF3KP1	7.77	4.8e-14	4.3e-11	0.47	0.33	Parkinson's disease;	chr5:103116554	chr5:103032376~103033031:+
LUAD	cis	rs35160687	0.798	rs2367233	ENSG00000273080.1	RP11-301O19.1	-7.77	4.81e-14	4.3e-11	-0.38	-0.33	Night sleep phenotypes;	chr2:86314543	chr2:86195590~86196049:+
LUAD	cis	rs71403859	0.667	rs12924650	ENSG00000260886.1	TAT-AS1	7.77	4.81e-14	4.31e-11	0.55	0.33	Post bronchodilator FEV1;	chr16:71672005	chr16:71565789~71578187:+
LUAD	cis	rs2919917	1	rs1483573	ENSG00000254352.1	RP11-578O24.2	7.77	4.86e-14	4.35e-11	0.41	0.33	Lymphocyte counts;	chr8:78711382	chr8:78723796~78724136:-
LUAD	cis	rs17482078	0.959	rs13154629	ENSG00000248734.2	CTD-2260A17.1	7.77	4.9e-14	4.38e-11	0.42	0.33	Behcet's disease;Blood protein levels;	chr5:96786754	chr5:96784777~96785999:+
LUAD	cis	rs944289	0.774	rs1958624	ENSG00000257826.1	RP11-116N8.4	7.77	4.91e-14	4.4e-11	0.35	0.33	Thyroid cancer;	chr14:36128692	chr14:36061026~36067190:-
LUAD	cis	rs8177876	0.658	rs77874075	ENSG00000261838.4	RP11-303E16.6	7.77	4.92e-14	4.4e-11	0.77	0.33	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81032734	chr16:81069854~81076598:+
LUAD	cis	rs950169	0.922	rs11638445	ENSG00000225151.9	GOLGA2P7	-7.77	4.92e-14	4.4e-11	-0.47	-0.33	Schizophrenia;	chr15:84594463	chr15:84199311~84230136:-
LUAD	cis	rs56046484	0.956	rs17541572	ENSG00000259295.5	CSPG4P12	-7.77	4.94e-14	4.42e-11	-0.5	-0.33	Testicular germ cell tumor;	chr15:85122016	chr15:85191438~85213905:+
LUAD	cis	rs2581828	0.632	rs73088322	ENSG00000242142.1	SERBP1P3	-7.77	4.95e-14	4.43e-11	-0.37	-0.33	Crohn's disease;	chr3:53107500	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.659	rs73088327	ENSG00000242142.1	SERBP1P3	-7.77	4.95e-14	4.43e-11	-0.37	-0.33	Crohn's disease;	chr3:53107533	chr3:53064283~53065091:-
LUAD	cis	rs2581828	0.659	rs4282053	ENSG00000242142.1	SERBP1P3	-7.77	4.95e-14	4.43e-11	-0.37	-0.33	Crohn's disease;	chr3:53107949	chr3:53064283~53065091:-
LUAD	cis	rs11096990	0.634	rs2062229	ENSG00000249207.1	RP11-360F5.1	-7.76	4.96e-14	4.44e-11	-0.36	-0.33	Cognitive function;	chr4:39285146	chr4:39112677~39126818:-
LUAD	cis	rs9545047	0.604	rs9530897	ENSG00000227676.3	LINC01068	7.76	4.98e-14	4.45e-11	0.39	0.33	Schizophrenia;	chr13:79336420	chr13:79566727~79571436:+
LUAD	cis	rs150992	0.711	rs331918	ENSG00000248489.1	CTD-2007H13.3	7.76	5e-14	4.47e-11	0.38	0.33	Body mass index;	chr5:98823040	chr5:98929171~98995013:+
LUAD	cis	rs4660456	0.913	rs3767951	ENSG00000237899.1	RP4-739H11.3	-7.76	5.01e-14	4.48e-11	-0.46	-0.33	Platelet count;	chr1:40767359	chr1:40669089~40687588:-
LUAD	cis	rs9545047	0.588	rs9530894	ENSG00000227676.3	LINC01068	7.76	5.01e-14	4.48e-11	0.39	0.33	Schizophrenia;	chr13:79334020	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs9530895	ENSG00000227676.3	LINC01068	7.76	5.01e-14	4.48e-11	0.39	0.33	Schizophrenia;	chr13:79334877	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.567	rs9530896	ENSG00000227676.3	LINC01068	7.76	5.01e-14	4.48e-11	0.39	0.33	Schizophrenia;	chr13:79335507	chr13:79566727~79571436:+
LUAD	cis	rs9322193	0.962	rs12175575	ENSG00000223701.3	RAET1E-AS1	7.76	5.04e-14	4.5e-11	0.39	0.33	Lung cancer;	chr6:149763351	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs4869966	ENSG00000223701.3	RAET1E-AS1	7.76	5.04e-14	4.5e-11	0.39	0.33	Lung cancer;	chr6:149763714	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs1112730	ENSG00000223701.3	RAET1E-AS1	7.76	5.04e-14	4.5e-11	0.39	0.33	Lung cancer;	chr6:149766383	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs1112729	ENSG00000223701.3	RAET1E-AS1	7.76	5.04e-14	4.5e-11	0.39	0.33	Lung cancer;	chr6:149766491	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs10452626	ENSG00000223701.3	RAET1E-AS1	7.76	5.04e-14	4.5e-11	0.39	0.33	Lung cancer;	chr6:149767481	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs62441303	ENSG00000223701.3	RAET1E-AS1	7.76	5.04e-14	4.5e-11	0.39	0.33	Lung cancer;	chr6:149767547	chr6:149884431~149919508:+
LUAD	cis	rs950880	0.71	rs56258475	ENSG00000234389.1	AC007278.3	-7.76	5.05e-14	4.51e-11	-0.35	-0.33	Serum protein levels (sST2);	chr2:102382852	chr2:102438713~102440475:+
LUAD	cis	rs17482078	0.959	rs71630754	ENSG00000248734.2	CTD-2260A17.1	7.76	5.06e-14	4.52e-11	0.42	0.33	Behcet's disease;Blood protein levels;	chr5:96791235	chr5:96784777~96785999:+
LUAD	cis	rs9322193	0.887	rs9767113	ENSG00000223701.3	RAET1E-AS1	7.76	5.08e-14	4.53e-11	0.4	0.33	Lung cancer;	chr6:149718157	chr6:149884431~149919508:+
LUAD	cis	rs9545047	0.604	rs1752649	ENSG00000227676.3	LINC01068	7.76	5.08e-14	4.54e-11	0.39	0.33	Schizophrenia;	chr13:79331980	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs1749983	ENSG00000227676.3	LINC01068	7.76	5.08e-14	4.54e-11	0.39	0.33	Schizophrenia;	chr13:79332077	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.567	rs1752648	ENSG00000227676.3	LINC01068	7.76	5.08e-14	4.54e-11	0.39	0.33	Schizophrenia;	chr13:79332124	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs1752647	ENSG00000227676.3	LINC01068	7.76	5.08e-14	4.54e-11	0.39	0.33	Schizophrenia;	chr13:79332741	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.532	rs1752646	ENSG00000227676.3	LINC01068	7.76	5.08e-14	4.54e-11	0.39	0.33	Schizophrenia;	chr13:79332752	chr13:79566727~79571436:+
LUAD	cis	rs904251	0.686	rs1224128	ENSG00000279942.1	RP1-153P14.7	-7.76	5.09e-14	4.54e-11	-0.36	-0.33	Cognitive performance;	chr6:37447900	chr6:37567716~37571460:+
LUAD	cis	rs80285556	1	rs77187281	ENSG00000161643.11	SIGLEC16	7.76	5.11e-14	4.56e-11	0.78	0.33	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50004410	chr19:49969673~49975814:+
LUAD	cis	rs80285556	1	rs10500303	ENSG00000161643.11	SIGLEC16	7.76	5.11e-14	4.56e-11	0.78	0.33	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50008776	chr19:49969673~49975814:+
LUAD	cis	rs9532669	0.926	rs9532691	ENSG00000176268.5	CYCSP34	-7.76	5.12e-14	4.57e-11	-0.32	-0.33	Cervical cancer;	chr13:40969358	chr13:40863599~40863902:-
LUAD	cis	rs950169	0.922	rs6603022	ENSG00000225151.9	GOLGA2P7	7.76	5.15e-14	4.59e-11	0.47	0.33	Schizophrenia;	chr15:84161418	chr15:84199311~84230136:-
LUAD	cis	rs944289	0.74	rs7145145	ENSG00000257826.1	RP11-116N8.4	-7.76	5.15e-14	4.6e-11	-0.35	-0.33	Thyroid cancer;	chr14:36110724	chr14:36061026~36067190:-
LUAD	cis	rs944289	0.708	rs7145311	ENSG00000257826.1	RP11-116N8.4	-7.76	5.15e-14	4.6e-11	-0.35	-0.33	Thyroid cancer;	chr14:36110738	chr14:36061026~36067190:-
LUAD	cis	rs950169	0.65	rs12902052	ENSG00000225151.9	GOLGA2P7	-7.76	5.15e-14	4.6e-11	-0.47	-0.33	Schizophrenia;	chr15:84582607	chr15:84199311~84230136:-
LUAD	cis	rs9322193	0.566	rs4870118	ENSG00000216906.2	RP11-350J20.9	-7.76	5.15e-14	4.6e-11	-0.48	-0.33	Lung cancer;	chr6:149923877	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.566	rs4869767	ENSG00000216906.2	RP11-350J20.9	-7.76	5.15e-14	4.6e-11	-0.48	-0.33	Lung cancer;	chr6:149923974	chr6:149904243~149906418:+
LUAD	cis	rs9322193	0.566	rs4869768	ENSG00000216906.2	RP11-350J20.9	-7.76	5.15e-14	4.6e-11	-0.48	-0.33	Lung cancer;	chr6:149924067	chr6:149904243~149906418:+
LUAD	cis	rs150992	0.512	rs161954	ENSG00000248489.1	CTD-2007H13.3	7.76	5.18e-14	4.62e-11	0.36	0.33	Body mass index;	chr5:98920833	chr5:98929171~98995013:+
LUAD	cis	rs1155848	0.571	rs7983556	ENSG00000227354.5	RBM26-AS1	7.76	5.18e-14	4.62e-11	0.65	0.33	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79608777	chr13:79406309~79424328:+
LUAD	cis	rs904251	0.772	rs2776906	ENSG00000279942.1	RP1-153P14.7	-7.76	5.18e-14	4.62e-11	-0.34	-0.33	Cognitive performance;	chr6:37463981	chr6:37567716~37571460:+
LUAD	cis	rs6844153	0.823	rs12642922	ENSG00000240005.4	RP11-293A21.1	-7.76	5.23e-14	4.67e-11	-0.53	-0.33	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:27025996	chr4:26859806~26860599:-
LUAD	cis	rs9545047	0.604	rs9565487	ENSG00000227676.3	LINC01068	-7.76	5.24e-14	4.67e-11	-0.39	-0.33	Schizophrenia;	chr13:79332742	chr13:79566727~79571436:+
LUAD	cis	rs7429990	0.864	rs13098128	ENSG00000229759.1	MRPS18AP1	-7.76	5.25e-14	4.68e-11	-0.34	-0.33	Educational attainment (years of education);	chr3:47756066	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs6442085	ENSG00000229759.1	MRPS18AP1	-7.76	5.25e-14	4.68e-11	-0.34	-0.33	Educational attainment (years of education);	chr3:47760080	chr3:48256350~48256938:-
LUAD	cis	rs11155671	0.53	rs9371542	ENSG00000223701.3	RAET1E-AS1	7.76	5.26e-14	4.69e-11	0.39	0.33	Testicular germ cell tumor;	chr6:149891949	chr6:149884431~149919508:+
LUAD	cis	rs11155671	0.53	rs9371223	ENSG00000223701.3	RAET1E-AS1	7.76	5.26e-14	4.69e-11	0.39	0.33	Testicular germ cell tumor;	chr6:149893670	chr6:149884431~149919508:+
LUAD	cis	rs35160687	0.901	rs7571424	ENSG00000273080.1	RP11-301O19.1	7.76	5.26e-14	4.69e-11	0.36	0.33	Night sleep phenotypes;	chr2:86312037	chr2:86195590~86196049:+
LUAD	cis	rs9545047	0.532	rs9545079	ENSG00000227676.3	LINC01068	7.76	5.27e-14	4.69e-11	0.39	0.33	Schizophrenia;	chr13:79346044	chr13:79566727~79571436:+
LUAD	cis	rs950880	0.71	rs11683700	ENSG00000234389.1	AC007278.3	-7.76	5.27e-14	4.7e-11	-0.35	-0.33	Serum protein levels (sST2);	chr2:102380345	chr2:102438713~102440475:+
LUAD	cis	rs950880	0.71	rs11123929	ENSG00000234389.1	AC007278.3	-7.76	5.28e-14	4.7e-11	-0.34	-0.33	Serum protein levels (sST2);	chr2:102450683	chr2:102438713~102440475:+
LUAD	cis	rs11155671	0.53	rs7756850	ENSG00000223701.3	RAET1E-AS1	7.76	5.3e-14	4.72e-11	0.39	0.33	Testicular germ cell tumor;	chr6:149891460	chr6:149884431~149919508:+
LUAD	cis	rs9640161	0.673	rs11773351	ENSG00000261305.1	RP4-584D14.7	7.76	5.31e-14	4.73e-11	0.51	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150333874	chr7:150341771~150342607:+
LUAD	cis	rs4718428	0.705	rs4718422	ENSG00000226824.5	RP4-756H11.3	-7.75	5.32e-14	4.73e-11	-0.45	-0.33	Corneal structure;	chr7:66894282	chr7:66654538~66669855:+
LUAD	cis	rs4718428	0.705	rs13231140	ENSG00000226824.5	RP4-756H11.3	-7.75	5.32e-14	4.73e-11	-0.45	-0.33	Corneal structure;	chr7:66896631	chr7:66654538~66669855:+
LUAD	cis	rs11089937	0.626	rs737840	ENSG00000211639.2	IGLV4-60	7.75	5.39e-14	4.79e-11	0.41	0.33	Periodontitis (PAL4Q3);	chr22:22162743	chr22:22162199~22162681:+
LUAD	cis	rs7688540	0.771	rs11723615	ENSG00000275426.1	CH17-262A2.1	7.75	5.4e-14	4.8e-11	0.47	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:283194	chr4:149738~150317:+
LUAD	cis	rs2243480	1	rs4718317	ENSG00000226824.5	RP4-756H11.3	7.75	5.46e-14	4.85e-11	0.61	0.33	Diabetic kidney disease;	chr7:66183914	chr7:66654538~66669855:+
LUAD	cis	rs7684253	0.55	rs4566710	ENSG00000269949.1	RP11-738E22.3	-7.75	5.51e-14	4.9e-11	-0.45	-0.33	Migraine;	chr4:56879297	chr4:56960927~56961373:-
LUAD	cis	rs6142102	0.961	rs6119447	ENSG00000276073.1	RP5-1125A11.7	-7.75	5.52e-14	4.9e-11	-0.34	-0.33	Skin pigmentation;	chr20:34080770	chr20:33985617~33988989:-
LUAD	cis	rs673078	0.66	rs10507286	ENSG00000275759.1	RP11-131L12.3	-7.75	5.53e-14	4.91e-11	-0.48	-0.33	Glucose homeostasis traits;	chr12:118197101	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.66	rs61945180	ENSG00000275759.1	RP11-131L12.3	-7.75	5.53e-14	4.91e-11	-0.48	-0.33	Glucose homeostasis traits;	chr12:118216335	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.66	rs61945181	ENSG00000275759.1	RP11-131L12.3	-7.75	5.53e-14	4.91e-11	-0.48	-0.33	Glucose homeostasis traits;	chr12:118216651	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.66	rs61945183	ENSG00000275759.1	RP11-131L12.3	-7.75	5.53e-14	4.91e-11	-0.48	-0.33	Glucose homeostasis traits;	chr12:118221966	chr12:118428281~118428870:+
LUAD	cis	rs9322193	0.923	rs6913486	ENSG00000223701.3	RAET1E-AS1	-7.75	5.57e-14	4.94e-11	-0.39	-0.33	Lung cancer;	chr6:149705060	chr6:149884431~149919508:+
LUAD	cis	rs853679	0.527	rs1997660	ENSG00000216901.1	AL022393.7	7.75	5.58e-14	4.95e-11	0.39	0.33	Depression;	chr6:28301886	chr6:28176188~28176674:+
LUAD	cis	rs2283792	0.935	rs5750113	ENSG00000224086.5	LL22NC03-86G7.1	-7.75	5.59e-14	4.96e-11	-0.31	-0.33	Multiple sclerosis;	chr22:21865784	chr22:21938293~21977632:+
LUAD	cis	rs1150668	0.699	rs12214383	ENSG00000204709.4	LINC01556	-7.75	5.59e-14	4.97e-11	-0.41	-0.33	Pubertal anthropometrics;	chr6:28255953	chr6:28943877~28944537:+
LUAD	cis	rs4718428	0.705	rs12536410	ENSG00000226824.5	RP4-756H11.3	-7.75	5.6e-14	4.97e-11	-0.45	-0.33	Corneal structure;	chr7:66789303	chr7:66654538~66669855:+
LUAD	cis	rs11096990	0.656	rs7693837	ENSG00000249207.1	RP11-360F5.1	-7.75	5.61e-14	4.98e-11	-0.36	-0.33	Cognitive function;	chr4:39301481	chr4:39112677~39126818:-
LUAD	cis	rs496547	0.686	rs540180	ENSG00000278376.1	RP11-158I9.8	-7.75	5.62e-14	4.99e-11	-0.37	-0.33	Hip minimal joint space width;	chr11:118782920	chr11:118791254~118793137:+
LUAD	cis	rs496547	0.686	rs2508916	ENSG00000278376.1	RP11-158I9.8	-7.75	5.62e-14	4.99e-11	-0.37	-0.33	Hip minimal joint space width;	chr11:118783942	chr11:118791254~118793137:+
LUAD	cis	rs11676348	0.755	rs6436026	ENSG00000261338.2	RP11-378A13.1	-7.75	5.64e-14	5.01e-11	-0.35	-0.33	Ulcerative colitis;	chr2:218087015	chr2:218255319~218257366:+
LUAD	cis	rs496547	0.721	rs2508570	ENSG00000278376.1	RP11-158I9.8	-7.75	5.69e-14	5.05e-11	-0.36	-0.33	Hip minimal joint space width;	chr11:118807900	chr11:118791254~118793137:+
LUAD	cis	rs11155671	0.53	rs7757984	ENSG00000223701.3	RAET1E-AS1	7.75	5.69e-14	5.05e-11	0.4	0.33	Testicular germ cell tumor;	chr6:149887515	chr6:149884431~149919508:+
LUAD	cis	rs6142102	0.961	rs2268089	ENSG00000276073.1	RP5-1125A11.7	-7.75	5.7e-14	5.06e-11	-0.34	-0.33	Skin pigmentation;	chr20:34079492	chr20:33985617~33988989:-
LUAD	cis	rs9322193	0.923	rs4870509	ENSG00000223701.3	RAET1E-AS1	7.74	5.71e-14	5.06e-11	0.4	0.33	Lung cancer;	chr6:149702212	chr6:149884431~149919508:+
LUAD	cis	rs2739330	0.76	rs1007888	ENSG00000099984.9	GSTT2	-7.74	5.72e-14	5.07e-11	-0.39	-0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23980123~23983911:+
LUAD	cis	rs8059260	0.604	rs78753859	ENSG00000274038.1	RP11-66H6.4	-7.74	5.73e-14	5.09e-11	-0.63	-0.33	Alcohol consumption over the past year;	chr16:11052774	chr16:11056556~11057034:+
LUAD	cis	rs765787	0.53	rs4444275	ENSG00000259520.4	CTD-2651B20.3	7.74	5.76e-14	5.1e-11	0.43	0.33	Uric acid levels;	chr15:45243149	chr15:45251580~45279251:-
LUAD	cis	rs4660456	0.913	rs656230	ENSG00000237899.1	RP4-739H11.3	7.74	5.77e-14	5.12e-11	0.45	0.33	Platelet count;	chr1:40692701	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.913	rs2780953	ENSG00000237899.1	RP4-739H11.3	7.74	5.77e-14	5.12e-11	0.45	0.33	Platelet count;	chr1:40694105	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.83	rs12566786	ENSG00000237899.1	RP4-739H11.3	-7.74	5.78e-14	5.12e-11	-0.46	-0.33	Platelet count;	chr1:40742709	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.871	rs2274957	ENSG00000237899.1	RP4-739H11.3	-7.74	5.78e-14	5.12e-11	-0.46	-0.33	Platelet count;	chr1:40747290	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.913	rs4660173	ENSG00000237899.1	RP4-739H11.3	-7.74	5.78e-14	5.12e-11	-0.46	-0.33	Platelet count;	chr1:40747876	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.913	rs4660452	ENSG00000237899.1	RP4-739H11.3	-7.74	5.78e-14	5.12e-11	-0.46	-0.33	Platelet count;	chr1:40748519	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.913	rs12567925	ENSG00000237899.1	RP4-739H11.3	-7.74	5.78e-14	5.12e-11	-0.46	-0.33	Platelet count;	chr1:40751428	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.913	rs12728776	ENSG00000237899.1	RP4-739H11.3	-7.74	5.78e-14	5.12e-11	-0.46	-0.33	Platelet count;	chr1:40751718	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.913	rs12567755	ENSG00000237899.1	RP4-739H11.3	-7.74	5.78e-14	5.12e-11	-0.46	-0.33	Platelet count;	chr1:40751813	chr1:40669089~40687588:-
LUAD	cis	rs6921919	0.789	rs13210258	ENSG00000204709.4	LINC01556	7.74	5.85e-14	5.18e-11	0.47	0.33	Autism spectrum disorder or schizophrenia;	chr6:28340894	chr6:28943877~28944537:+
LUAD	cis	rs2283792	1	rs6928	ENSG00000224086.5	LL22NC03-86G7.1	-7.74	5.85e-14	5.19e-11	-0.32	-0.33	Multiple sclerosis;	chr22:21760715	chr22:21938293~21977632:+
LUAD	cis	rs4660456	0.913	rs556875	ENSG00000237899.1	RP4-739H11.3	-7.74	5.86e-14	5.19e-11	-0.46	-0.33	Platelet count;	chr1:40688571	chr1:40669089~40687588:-
LUAD	cis	rs9322193	0.923	rs9479810	ENSG00000223701.3	RAET1E-AS1	7.74	5.86e-14	5.19e-11	0.39	0.33	Lung cancer;	chr6:149751359	chr6:149884431~149919508:+
LUAD	cis	rs8177876	0.749	rs1035541	ENSG00000261838.4	RP11-303E16.6	7.74	5.86e-14	5.19e-11	0.76	0.33	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81065249	chr16:81069854~81076598:+
LUAD	cis	rs4660456	0.913	rs7542019	ENSG00000237899.1	RP4-739H11.3	7.74	5.87e-14	5.2e-11	0.46	0.33	Platelet count;	chr1:40704039	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.913	rs1494	ENSG00000237899.1	RP4-739H11.3	7.74	5.87e-14	5.2e-11	0.46	0.33	Platelet count;	chr1:40706176	chr1:40669089~40687588:-
LUAD	cis	rs7429990	0.864	rs6786001	ENSG00000229759.1	MRPS18AP1	-7.74	5.88e-14	5.21e-11	-0.34	-0.33	Educational attainment (years of education);	chr3:47718500	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs35148469	ENSG00000229759.1	MRPS18AP1	-7.74	5.88e-14	5.21e-11	-0.34	-0.33	Educational attainment (years of education);	chr3:47739873	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs6442082	ENSG00000229759.1	MRPS18AP1	-7.74	5.88e-14	5.21e-11	-0.34	-0.33	Educational attainment (years of education);	chr3:47743991	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.747	rs6442083	ENSG00000229759.1	MRPS18AP1	-7.74	5.88e-14	5.21e-11	-0.34	-0.33	Educational attainment (years of education);	chr3:47744305	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.786	rs13064183	ENSG00000229759.1	MRPS18AP1	-7.74	5.88e-14	5.21e-11	-0.34	-0.33	Educational attainment (years of education);	chr3:47745405	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.833	rs6777632	ENSG00000229759.1	MRPS18AP1	-7.74	5.88e-14	5.21e-11	-0.34	-0.33	Educational attainment (years of education);	chr3:47748775	chr3:48256350~48256938:-
LUAD	cis	rs673078	0.66	rs17512177	ENSG00000275759.1	RP11-131L12.3	-7.74	5.88e-14	5.21e-11	-0.48	-0.33	Glucose homeostasis traits;	chr12:118192335	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.66	rs17512198	ENSG00000275759.1	RP11-131L12.3	-7.74	5.88e-14	5.21e-11	-0.48	-0.33	Glucose homeostasis traits;	chr12:118194217	chr12:118428281~118428870:+
LUAD	cis	rs7188445	0.966	rs79193369	ENSG00000261390.4	RP11-345M22.2	-7.74	5.88e-14	5.21e-11	-0.45	-0.33	Urate levels;	chr16:79691119	chr16:79715232~79770563:-
LUAD	cis	rs10759883	0.563	rs689738	ENSG00000175611.10	LINC00476	7.74	5.89e-14	5.22e-11	0.38	0.33	Nicotine dependence;	chr9:95939738	chr9:95759231~95875977:-
LUAD	cis	rs465969	1	rs1407644	ENSG00000255389.1	C6orf3	7.74	5.9e-14	5.22e-11	0.67	0.33	Psoriasis;	chr6:111480895	chr6:111599875~111602295:+
LUAD	cis	rs11676348	0.791	rs4133195	ENSG00000261338.2	RP11-378A13.1	7.74	5.91e-14	5.23e-11	0.35	0.33	Ulcerative colitis;	chr2:218086522	chr2:218255319~218257366:+
LUAD	cis	rs950880	0.645	rs56044378	ENSG00000234389.1	AC007278.3	-7.74	5.94e-14	5.25e-11	-0.34	-0.33	Serum protein levels (sST2);	chr2:102448907	chr2:102438713~102440475:+
LUAD	cis	rs6504950	1	rs8082471	ENSG00000275710.1	RP11-257O5.4	7.74	5.94e-14	5.26e-11	0.42	0.33	Breast cancer;	chr17:54990632	chr17:54964474~54964679:+
LUAD	cis	rs6504950	1	rs7219874	ENSG00000275710.1	RP11-257O5.4	7.74	5.95e-14	5.27e-11	0.42	0.33	Breast cancer;	chr17:54988446	chr17:54964474~54964679:+
LUAD	cis	rs17608059	0.566	rs17676459	ENSG00000141028.6	CDRT15P1	-7.74	5.96e-14	5.27e-11	-0.37	-0.33	Temperament;	chr17:14007198	chr17:14024514~14025488:+
LUAD	cis	rs950880	0.71	rs4851011	ENSG00000234389.1	AC007278.3	7.74	5.96e-14	5.27e-11	0.34	0.33	Serum protein levels (sST2);	chr2:102473219	chr2:102438713~102440475:+
LUAD	cis	rs2919917	1	rs1545228	ENSG00000254352.1	RP11-578O24.2	-7.74	5.96e-14	5.28e-11	-0.41	-0.33	Lymphocyte counts;	chr8:78732202	chr8:78723796~78724136:-
LUAD	cis	rs2919917	1	rs894221	ENSG00000254352.1	RP11-578O24.2	-7.74	5.96e-14	5.28e-11	-0.41	-0.33	Lymphocyte counts;	chr8:78736822	chr8:78723796~78724136:-
LUAD	cis	rs9545047	0.604	rs9545082	ENSG00000227676.3	LINC01068	7.74	5.96e-14	5.28e-11	0.38	0.33	Schizophrenia;	chr13:79358994	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs7332913	ENSG00000227676.3	LINC01068	7.74	5.96e-14	5.28e-11	0.38	0.33	Schizophrenia;	chr13:79359149	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs9545083	ENSG00000227676.3	LINC01068	7.74	5.96e-14	5.28e-11	0.38	0.33	Schizophrenia;	chr13:79360695	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs7322756	ENSG00000227676.3	LINC01068	7.74	5.96e-14	5.28e-11	0.38	0.33	Schizophrenia;	chr13:79361120	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs7324006	ENSG00000227676.3	LINC01068	7.74	5.96e-14	5.28e-11	0.38	0.33	Schizophrenia;	chr13:79361225	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs7322673	ENSG00000227676.3	LINC01068	7.74	5.96e-14	5.28e-11	0.38	0.33	Schizophrenia;	chr13:79361266	chr13:79566727~79571436:+
LUAD	cis	rs673078	0.66	rs73205512	ENSG00000275759.1	RP11-131L12.3	-7.74	5.99e-14	5.29e-11	-0.48	-0.33	Glucose homeostasis traits;	chr12:118235770	chr12:118428281~118428870:+
LUAD	cis	rs367615	0.704	rs17161885	ENSG00000249476.1	CTD-2587M2.1	7.74	6.01e-14	5.31e-11	0.39	0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109516941	chr5:109237120~109326369:-
LUAD	cis	rs4718428	0.924	rs6971897	ENSG00000226824.5	RP4-756H11.3	-7.74	6.01e-14	5.31e-11	-0.42	-0.33	Corneal structure;	chr7:66947787	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.923	rs4870529	ENSG00000223701.3	RAET1E-AS1	7.74	6.02e-14	5.32e-11	0.39	0.33	Lung cancer;	chr6:149716436	chr6:149884431~149919508:+
LUAD	cis	rs496547	0.686	rs477014	ENSG00000278376.1	RP11-158I9.8	-7.74	6.04e-14	5.34e-11	-0.37	-0.33	Hip minimal joint space width;	chr11:118808277	chr11:118791254~118793137:+
LUAD	cis	rs9545047	0.604	rs2274555	ENSG00000227676.3	LINC01068	-7.74	6.07e-14	5.36e-11	-0.39	-0.33	Schizophrenia;	chr13:79344188	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs9565491	ENSG00000227676.3	LINC01068	-7.74	6.07e-14	5.36e-11	-0.39	-0.33	Schizophrenia;	chr13:79346037	chr13:79566727~79571436:+
LUAD	cis	rs6903823	0.508	rs1150718	ENSG00000216901.1	AL022393.7	7.74	6.08e-14	5.37e-11	0.39	0.33	Pulmonary function;	chr6:28289170	chr6:28176188~28176674:+
LUAD	cis	rs6903823	0.508	rs1233660	ENSG00000216901.1	AL022393.7	7.74	6.08e-14	5.37e-11	0.39	0.33	Pulmonary function;	chr6:28292472	chr6:28176188~28176674:+
LUAD	cis	rs950169	1	rs1818950	ENSG00000225151.9	GOLGA2P7	-7.74	6.09e-14	5.38e-11	-0.47	-0.33	Schizophrenia;	chr15:84053769	chr15:84199311~84230136:-
LUAD	cis	rs950880	0.668	rs3732126	ENSG00000234389.1	AC007278.3	-7.74	6.09e-14	5.38e-11	-0.35	-0.33	Serum protein levels (sST2);	chr2:102397502	chr2:102438713~102440475:+
LUAD	cis	rs950880	0.71	rs3732125	ENSG00000234389.1	AC007278.3	-7.74	6.09e-14	5.38e-11	-0.35	-0.33	Serum protein levels (sST2);	chr2:102397503	chr2:102438713~102440475:+
LUAD	cis	rs9545047	0.604	rs9574406	ENSG00000227676.3	LINC01068	-7.74	6.11e-14	5.39e-11	-0.39	-0.33	Schizophrenia;	chr13:79338982	chr13:79566727~79571436:+
LUAD	cis	rs17482078	0.959	rs2287987	ENSG00000248734.2	CTD-2260A17.1	7.73	6.14e-14	5.42e-11	0.42	0.33	Behcet's disease;Blood protein levels;	chr5:96793832	chr5:96784777~96785999:+
LUAD	cis	rs17482078	0.959	rs13168673	ENSG00000248734.2	CTD-2260A17.1	7.73	6.14e-14	5.42e-11	0.42	0.33	Behcet's disease;Blood protein levels;	chr5:96794486	chr5:96784777~96785999:+
LUAD	cis	rs944289	0.712	rs12050121	ENSG00000257826.1	RP11-116N8.4	-7.73	6.18e-14	5.45e-11	-0.35	-0.33	Thyroid cancer;	chr14:36103742	chr14:36061026~36067190:-
LUAD	cis	rs2739330	0.685	rs4822453	ENSG00000228039.3	KB-1125A3.10	7.73	6.18e-14	5.46e-11	0.4	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23963780~23964374:+
LUAD	cis	rs17482078	0.879	rs2124921	ENSG00000248734.2	CTD-2260A17.1	7.73	6.19e-14	5.47e-11	0.42	0.33	Behcet's disease;Blood protein levels;	chr5:96783635	chr5:96784777~96785999:+
LUAD	cis	rs8177876	0.731	rs74878296	ENSG00000261838.4	RP11-303E16.6	7.73	6.25e-14	5.51e-11	0.85	0.33	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81071940	chr16:81069854~81076598:+
LUAD	cis	rs8005677	1	rs10148215	ENSG00000279656.1	RP11-298I3.6	7.73	6.25e-14	5.52e-11	0.4	0.33	Cognitive ability (multi-trait analysis);	chr14:22913136	chr14:23023083~23024217:-
LUAD	cis	rs17608059	0.566	rs5005684	ENSG00000141028.6	CDRT15P1	-7.73	6.25e-14	5.52e-11	-0.37	-0.33	Temperament;	chr17:14007316	chr17:14024514~14025488:+
LUAD	cis	rs10129255	0.789	rs61997796	ENSG00000211970.3	IGHV4-61	-7.73	6.28e-14	5.54e-11	-0.27	-0.33	Kawasaki disease;	chr14:106813798	chr14:106639119~106639657:-
LUAD	cis	rs8177876	0.658	rs75422577	ENSG00000261838.4	RP11-303E16.6	7.73	6.31e-14	5.56e-11	0.76	0.33	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81054561	chr16:81069854~81076598:+
LUAD	cis	rs950169	0.845	rs4106951	ENSG00000225151.9	GOLGA2P7	-7.73	6.32e-14	5.58e-11	-0.47	-0.33	Schizophrenia;	chr15:84164642	chr15:84199311~84230136:-
LUAD	cis	rs9322193	0.884	rs62439836	ENSG00000223701.3	RAET1E-AS1	7.73	6.36e-14	5.6e-11	0.38	0.33	Lung cancer;	chr6:149669173	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs4869812	ENSG00000223701.3	RAET1E-AS1	7.73	6.36e-14	5.6e-11	0.38	0.33	Lung cancer;	chr6:149669447	chr6:149884431~149919508:+
LUAD	cis	rs2439831	0.681	rs1095386	ENSG00000205771.5	CATSPER2P1	-7.73	6.36e-14	5.61e-11	-0.56	-0.33	Lung cancer in ever smokers;	chr15:43317311	chr15:43726918~43747094:-
LUAD	cis	rs5769707	0.521	rs5769719	ENSG00000188511.11	C22orf34	7.73	6.37e-14	5.62e-11	0.41	0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49668453	chr22:49414524~49657542:-
LUAD	cis	rs5769707	0.521	rs5769720	ENSG00000188511.11	C22orf34	7.73	6.37e-14	5.62e-11	0.41	0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49668485	chr22:49414524~49657542:-
LUAD	cis	rs5769707	0.521	rs5770633	ENSG00000188511.11	C22orf34	7.73	6.37e-14	5.62e-11	0.41	0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49668779	chr22:49414524~49657542:-
LUAD	cis	rs8059260	0.668	rs75637865	ENSG00000274038.1	RP11-66H6.4	-7.73	6.37e-14	5.62e-11	-0.61	-0.33	Alcohol consumption over the past year;	chr16:10982439	chr16:11056556~11057034:+
LUAD	cis	rs1185460	0.547	rs34150933	ENSG00000271751.1	RP11-110I1.14	7.73	6.43e-14	5.67e-11	0.42	0.33	Coronary artery disease;	chr11:119040329	chr11:119065263~119065677:-
LUAD	cis	rs71403859	0.667	rs35538253	ENSG00000260886.1	TAT-AS1	7.73	6.45e-14	5.68e-11	0.55	0.33	Post bronchodilator FEV1;	chr16:71644072	chr16:71565789~71578187:+
LUAD	cis	rs7688540	0.771	rs77078697	ENSG00000275426.1	CH17-262A2.1	7.73	6.49e-14	5.71e-11	0.47	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:258259	chr4:149738~150317:+
LUAD	cis	rs7688540	0.771	rs61795006	ENSG00000275426.1	CH17-262A2.1	7.73	6.49e-14	5.71e-11	0.47	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:259812	chr4:149738~150317:+
LUAD	cis	rs7688540	0.771	rs61795007	ENSG00000275426.1	CH17-262A2.1	7.73	6.49e-14	5.71e-11	0.47	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:261475	chr4:149738~150317:+
LUAD	cis	rs8081395	0.801	rs2665405	ENSG00000266992.1	DHX40P1	-7.73	6.52e-14	5.74e-11	-0.38	-0.33	White blood cell count;	chr17:59797931	chr17:59976009~60002384:-
LUAD	cis	rs10129255	0.957	rs28887506	ENSG00000211970.3	IGHV4-61	-7.73	6.54e-14	5.76e-11	-0.26	-0.33	Kawasaki disease;	chr14:106785589	chr14:106639119~106639657:-
LUAD	cis	rs904251	0.965	rs1317563	ENSG00000204110.6	RP1-153P14.8	-7.73	6.55e-14	5.77e-11	-0.34	-0.33	Cognitive performance;	chr6:37484078	chr6:37507348~37535616:+
LUAD	cis	rs9545047	0.604	rs2182873	ENSG00000227676.3	LINC01068	7.72	6.56e-14	5.78e-11	0.38	0.33	Schizophrenia;	chr13:79356846	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs2025913	ENSG00000227676.3	LINC01068	7.72	6.56e-14	5.78e-11	0.38	0.33	Schizophrenia;	chr13:79357315	chr13:79566727~79571436:+
LUAD	cis	rs5769707	0.609	rs739247	ENSG00000188511.11	C22orf34	7.72	6.56e-14	5.78e-11	0.41	0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49603009	chr22:49414524~49657542:-
LUAD	cis	rs7208859	0.725	rs7210904	ENSG00000263531.1	RP13-753N3.1	7.72	6.57e-14	5.78e-11	0.58	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843187	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.725	rs9915802	ENSG00000263531.1	RP13-753N3.1	7.72	6.57e-14	5.78e-11	0.58	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846040	chr17:30863921~30864940:-
LUAD	cis	rs9545047	0.604	rs1980883	ENSG00000227676.3	LINC01068	-7.72	6.65e-14	5.85e-11	-0.39	-0.33	Schizophrenia;	chr13:79310629	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs9565486	ENSG00000227676.3	LINC01068	-7.72	6.65e-14	5.85e-11	-0.39	-0.33	Schizophrenia;	chr13:79317469	chr13:79566727~79571436:+
LUAD	cis	rs4718428	0.705	rs68168107	ENSG00000226824.5	RP4-756H11.3	-7.72	6.67e-14	5.87e-11	-0.45	-0.33	Corneal structure;	chr7:66790251	chr7:66654538~66669855:+
LUAD	cis	rs7615952	0.932	rs13325495	ENSG00000171084.14	FAM86JP	7.72	6.69e-14	5.89e-11	0.51	0.33	Blood pressure (smoking interaction);	chr3:125918573	chr3:125916620~125930024:+
LUAD	cis	rs11155671	0.53	rs4458704	ENSG00000223701.3	RAET1E-AS1	7.72	6.73e-14	5.92e-11	0.38	0.33	Testicular germ cell tumor;	chr6:149911743	chr6:149884431~149919508:+
LUAD	cis	rs526231	0.543	rs246909	ENSG00000175749.11	EIF3KP1	7.72	6.74e-14	5.93e-11	0.49	0.33	Primary biliary cholangitis;	chr5:103227976	chr5:103032376~103033031:+
LUAD	cis	rs904251	0.772	rs1812186	ENSG00000279942.1	RP1-153P14.7	-7.72	6.75e-14	5.94e-11	-0.34	-0.33	Cognitive performance;	chr6:37498140	chr6:37567716~37571460:+
LUAD	cis	rs11096990	0.656	rs6531709	ENSG00000249207.1	RP11-360F5.1	7.72	6.77e-14	5.95e-11	0.36	0.33	Cognitive function;	chr4:39300629	chr4:39112677~39126818:-
LUAD	cis	rs12439619	0.508	rs8023960	ENSG00000278603.1	RP13-608F4.5	7.72	6.81e-14	5.98e-11	0.38	0.33	Intelligence (multi-trait analysis);	chr15:82206704	chr15:82472203~82472426:+
LUAD	cis	rs2015599	0.623	rs7964831	ENSG00000257176.2	RP11-996F15.2	-7.72	6.83e-14	6e-11	-0.35	-0.33	Platelet count;Mean platelet volume;	chr12:29286655	chr12:29280418~29317848:-
LUAD	cis	rs8040855	0.627	rs11632899	ENSG00000259295.5	CSPG4P12	7.72	6.83e-14	6.01e-11	0.42	0.33	Bulimia nervosa;	chr15:85057609	chr15:85191438~85213905:+
LUAD	cis	rs496547	0.686	rs591756	ENSG00000278376.1	RP11-158I9.8	-7.72	6.85e-14	6.02e-11	-0.36	-0.33	Hip minimal joint space width;	chr11:118808172	chr11:118791254~118793137:+
LUAD	cis	rs2015599	0.54	rs12301475	ENSG00000257176.2	RP11-996F15.2	7.72	6.86e-14	6.03e-11	0.36	0.33	Platelet count;Mean platelet volume;	chr12:29253144	chr12:29280418~29317848:-
LUAD	cis	rs673078	0.607	rs59594854	ENSG00000275759.1	RP11-131L12.3	-7.72	6.88e-14	6.04e-11	-0.42	-0.33	Glucose homeostasis traits;	chr12:118374000	chr12:118428281~118428870:+
LUAD	cis	rs950169	0.922	rs11639244	ENSG00000225151.9	GOLGA2P7	-7.72	6.9e-14	6.06e-11	-0.47	-0.33	Schizophrenia;	chr15:84163898	chr15:84199311~84230136:-
LUAD	cis	rs9322193	0.923	rs62439840	ENSG00000223701.3	RAET1E-AS1	7.72	6.9e-14	6.06e-11	0.4	0.33	Lung cancer;	chr6:149674639	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs9393175	ENSG00000223701.3	RAET1E-AS1	7.72	6.9e-14	6.06e-11	0.4	0.33	Lung cancer;	chr6:149677587	chr6:149884431~149919508:+
LUAD	cis	rs11676348	0.703	rs6737563	ENSG00000261338.2	RP11-378A13.1	-7.72	6.9e-14	6.06e-11	-0.36	-0.33	Ulcerative colitis;	chr2:218080951	chr2:218255319~218257366:+
LUAD	cis	rs4853012	0.941	rs78128123	ENSG00000257800.1	FNBP1P1	7.72	6.91e-14	6.07e-11	0.45	0.33	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74120680~74123218:+
LUAD	cis	rs9640161	0.636	rs56190213	ENSG00000261305.1	RP4-584D14.7	7.72	6.92e-14	6.07e-11	0.5	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150328631	chr7:150341771~150342607:+
LUAD	cis	rs673078	0.66	rs61945206	ENSG00000275759.1	RP11-131L12.3	-7.72	6.93e-14	6.08e-11	-0.47	-0.33	Glucose homeostasis traits;	chr12:118238295	chr12:118428281~118428870:+
LUAD	cis	rs9322193	0.923	rs4870267	ENSG00000223701.3	RAET1E-AS1	7.72	6.99e-14	6.13e-11	0.38	0.33	Lung cancer;	chr6:149671572	chr6:149884431~149919508:+
LUAD	cis	rs950880	0.71	rs11123928	ENSG00000234389.1	AC007278.3	-7.72	7e-14	6.14e-11	-0.34	-0.33	Serum protein levels (sST2);	chr2:102444826	chr2:102438713~102440475:+
LUAD	cis	rs10129255	1	rs11627342	ENSG00000280411.1	IGHV1-69-2	-7.72	7.03e-14	6.17e-11	-0.25	-0.33	Kawasaki disease;	chr14:106675823	chr14:106762092~106762588:-
LUAD	cis	rs765787	0.53	rs2433229	ENSG00000259520.4	CTD-2651B20.3	7.71	7.04e-14	6.17e-11	0.44	0.33	Uric acid levels;	chr15:45223037	chr15:45251580~45279251:-
LUAD	cis	rs9660180	0.967	rs12040325	ENSG00000268575.1	RP1-283E3.8	-7.71	7.04e-14	6.18e-11	-0.31	-0.33	Body mass index;	chr1:1770997	chr1:1702736~1737688:-
LUAD	cis	rs12439619	0.508	rs8042665	ENSG00000278603.1	RP13-608F4.5	7.71	7.06e-14	6.2e-11	0.38	0.33	Intelligence (multi-trait analysis);	chr15:82189008	chr15:82472203~82472426:+
LUAD	cis	rs11089937	0.626	rs5757014	ENSG00000211639.2	IGLV4-60	7.71	7.09e-14	6.22e-11	0.39	0.33	Periodontitis (PAL4Q3);	chr22:22135612	chr22:22162199~22162681:+
LUAD	cis	rs904251	0.772	rs756202	ENSG00000279942.1	RP1-153P14.7	-7.71	7.12e-14	6.24e-11	-0.34	-0.33	Cognitive performance;	chr6:37492574	chr6:37567716~37571460:+
LUAD	cis	rs2412819	0.597	rs2412821	ENSG00000205771.5	CATSPER2P1	-7.71	7.12e-14	6.25e-11	-0.5	-0.33	Lung cancer;	chr15:43864966	chr15:43726918~43747094:-
LUAD	cis	rs673078	0.66	rs73220119	ENSG00000275759.1	RP11-131L12.3	-7.71	7.14e-14	6.26e-11	-0.49	-0.33	Glucose homeostasis traits;	chr12:118159864	chr12:118428281~118428870:+
LUAD	cis	rs8059260	0.736	rs7202408	ENSG00000274038.1	RP11-66H6.4	-7.71	7.15e-14	6.27e-11	-0.62	-0.33	Alcohol consumption over the past year;	chr16:10984758	chr16:11056556~11057034:+
LUAD	cis	rs6504950	0.889	rs2628301	ENSG00000275710.1	RP11-257O5.4	-7.71	7.17e-14	6.29e-11	-0.43	-0.33	Breast cancer;	chr17:55081912	chr17:54964474~54964679:+
LUAD	cis	rs9322193	0.962	rs3805748	ENSG00000223701.3	RAET1E-AS1	7.71	7.18e-14	6.3e-11	0.39	0.33	Lung cancer;	chr6:149772542	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.886	rs12525871	ENSG00000223701.3	RAET1E-AS1	7.71	7.18e-14	6.3e-11	0.39	0.33	Lung cancer;	chr6:149775882	chr6:149884431~149919508:+
LUAD	cis	rs17608059	0.566	rs6502327	ENSG00000141028.6	CDRT15P1	-7.71	7.21e-14	6.32e-11	-0.38	-0.33	Temperament;	chr17:14042870	chr17:14024514~14025488:+
LUAD	cis	rs11317778	1	rs11317778	ENSG00000248489.1	CTD-2007H13.3	7.71	7.22e-14	6.32e-11	0.36	0.33	Eosinophil percentage of white cells;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr5:98905525	chr5:98929171~98995013:+
LUAD	cis	rs11098499	0.866	rs6847778	ENSG00000248280.1	RP11-33B1.2	7.71	7.23e-14	6.33e-11	0.4	0.33	Corneal astigmatism;	chr4:119372427	chr4:119440561~119450157:-
LUAD	cis	rs1537424	0.513	rs1333313	ENSG00000257826.1	RP11-116N8.4	-7.71	7.28e-14	6.38e-11	-0.36	-0.33	Thyroid hormone levels;	chr14:36093440	chr14:36061026~36067190:-
LUAD	cis	rs673078	0.607	rs10850967	ENSG00000275759.1	RP11-131L12.3	-7.71	7.29e-14	6.38e-11	-0.42	-0.33	Glucose homeostasis traits;	chr12:118380072	chr12:118428281~118428870:+
LUAD	cis	rs4853012	0.941	rs2421752	ENSG00000257800.1	FNBP1P1	7.71	7.29e-14	6.39e-11	0.44	0.33	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74120680~74123218:+
LUAD	cis	rs7208859	0.673	rs999796	ENSG00000263531.1	RP13-753N3.1	7.71	7.34e-14	6.42e-11	0.58	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832386	chr17:30863921~30864940:-
LUAD	cis	rs10899021	0.92	rs76121309	ENSG00000279353.1	RP11-864N7.4	7.71	7.35e-14	6.43e-11	0.65	0.33	Response to metformin (IC50);	chr11:74632876	chr11:74698231~74699658:-
LUAD	cis	rs944289	0.708	rs2415315	ENSG00000257826.1	RP11-116N8.4	-7.71	7.4e-14	6.47e-11	-0.35	-0.33	Thyroid cancer;	chr14:36115338	chr14:36061026~36067190:-
LUAD	cis	rs7899628	1	rs7899628	ENSG00000226864.1	ATE1-AS1	-7.71	7.4e-14	6.48e-11	-0.45	-0.33	Breast cancer;	chr10:121904429	chr10:121928312~121951965:+
LUAD	cis	rs1729407	0.649	rs2849176	ENSG00000254851.1	RP11-109L13.1	7.71	7.43e-14	6.49e-11	0.41	0.33	Apolipoprotein A-IV levels;	chr11:116826205	chr11:117135528~117138582:+
LUAD	cis	rs9322193	0.962	rs3805752	ENSG00000223701.3	RAET1E-AS1	7.71	7.45e-14	6.52e-11	0.4	0.33	Lung cancer;	chr6:149795490	chr6:149884431~149919508:+
LUAD	cis	rs11089937	0.597	rs11704434	ENSG00000211639.2	IGLV4-60	7.71	7.5e-14	6.56e-11	0.41	0.33	Periodontitis (PAL4Q3);	chr22:22131715	chr22:22162199~22162681:+
LUAD	cis	rs10170846	0.893	rs11692810	ENSG00000261428.2	RP11-16P6.1	-7.71	7.53e-14	6.58e-11	-0.39	-0.33	Schizophrenia (inflammation and infection response interaction);	chr2:222679377	chr2:222566899~222569719:-
LUAD	cis	rs9322193	0.923	rs4354168	ENSG00000223701.3	RAET1E-AS1	7.7	7.56e-14	6.6e-11	0.39	0.33	Lung cancer;	chr6:149696642	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs4455682	ENSG00000223701.3	RAET1E-AS1	7.7	7.56e-14	6.6e-11	0.39	0.33	Lung cancer;	chr6:149700161	chr6:149884431~149919508:+
LUAD	cis	rs8177876	0.822	rs12443549	ENSG00000261838.4	RP11-303E16.6	-7.7	7.57e-14	6.61e-11	-0.74	-0.33	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81070596	chr16:81069854~81076598:+
LUAD	cis	rs11676348	0.791	rs6726126	ENSG00000261338.2	RP11-378A13.1	-7.7	7.58e-14	6.62e-11	-0.35	-0.33	Ulcerative colitis;	chr2:218087510	chr2:218255319~218257366:+
LUAD	cis	rs9326248	0.53	rs7123517	ENSG00000280143.1	AP000892.6	7.7	7.61e-14	6.64e-11	0.53	0.33	Blood protein levels;	chr11:117157039	chr11:117204967~117210292:+
LUAD	cis	rs9487094	0.644	rs13201430	ENSG00000260273.1	RP11-425D10.10	7.7	7.62e-14	6.65e-11	0.42	0.33	Height;	chr6:109634847	chr6:109382795~109383666:+
LUAD	cis	rs673078	0.607	rs1060964	ENSG00000275759.1	RP11-131L12.3	-7.7	7.63e-14	6.66e-11	-0.44	-0.33	Glucose homeostasis traits;	chr12:118414906	chr12:118428281~118428870:+
LUAD	cis	rs950880	0.71	rs4851582	ENSG00000234389.1	AC007278.3	-7.7	7.66e-14	6.69e-11	-0.34	-0.33	Serum protein levels (sST2);	chr2:102435098	chr2:102438713~102440475:+
LUAD	cis	rs9322193	0.607	rs9371228	ENSG00000216906.2	RP11-350J20.9	-7.7	7.72e-14	6.73e-11	-0.48	-0.33	Lung cancer;	chr6:149921977	chr6:149904243~149906418:+
LUAD	cis	rs1150668	0.699	rs1531681	ENSG00000204709.4	LINC01556	7.7	7.78e-14	6.79e-11	0.4	0.33	Pubertal anthropometrics;	chr6:28259100	chr6:28943877~28944537:+
LUAD	cis	rs7429990	0.864	rs3772399	ENSG00000229759.1	MRPS18AP1	-7.7	7.79e-14	6.79e-11	-0.34	-0.33	Educational attainment (years of education);	chr3:47826237	chr3:48256350~48256938:-
LUAD	cis	rs6504950	0.925	rs2787483	ENSG00000275710.1	RP11-257O5.4	7.7	7.81e-14	6.81e-11	0.43	0.33	Breast cancer;	chr17:55132953	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.925	rs2628317	ENSG00000275710.1	RP11-257O5.4	7.7	7.81e-14	6.81e-11	0.43	0.33	Breast cancer;	chr17:55135212	chr17:54964474~54964679:+
LUAD	cis	rs80285556	1	rs79602855	ENSG00000161643.11	SIGLEC16	7.7	7.81e-14	6.81e-11	0.76	0.33	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50022468	chr19:49969673~49975814:+
LUAD	cis	rs10754283	0.756	rs17441836	ENSG00000231613.1	RP5-943J3.1	7.7	7.85e-14	6.84e-11	0.34	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89669874	chr1:89788914~89790492:+
LUAD	cis	rs7688540	0.771	rs4129956	ENSG00000275426.1	CH17-262A2.1	7.7	7.87e-14	6.86e-11	0.48	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:308219	chr4:149738~150317:+
LUAD	cis	rs9545047	0.604	rs1616547	ENSG00000227676.3	LINC01068	7.7	7.87e-14	6.86e-11	0.4	0.33	Schizophrenia;	chr13:79411901	chr13:79566727~79571436:+
LUAD	cis	rs9322193	0.923	rs10872645	ENSG00000223701.3	RAET1E-AS1	7.7	7.88e-14	6.87e-11	0.39	0.33	Lung cancer;	chr6:149742840	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs12211511	ENSG00000223701.3	RAET1E-AS1	7.7	7.88e-14	6.87e-11	0.39	0.33	Lung cancer;	chr6:149745206	chr6:149884431~149919508:+
LUAD	cis	rs35160687	0.901	rs10520415	ENSG00000273080.1	RP11-301O19.1	-7.7	7.91e-14	6.89e-11	-0.37	-0.33	Night sleep phenotypes;	chr2:86271615	chr2:86195590~86196049:+
LUAD	cis	rs4660456	0.871	rs669072	ENSG00000237899.1	RP4-739H11.3	7.7	7.98e-14	6.95e-11	0.46	0.33	Platelet count;	chr1:40679946	chr1:40669089~40687588:-
LUAD	cis	rs7429990	0.864	rs7637950	ENSG00000229759.1	MRPS18AP1	-7.7	7.99e-14	6.96e-11	-0.33	-0.33	Educational attainment (years of education);	chr3:47758204	chr3:48256350~48256938:-
LUAD	cis	rs4660456	0.913	rs4660448	ENSG00000237899.1	RP4-739H11.3	-7.7	7.99e-14	6.96e-11	-0.46	-0.33	Platelet count;	chr1:40724682	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.913	rs7532802	ENSG00000237899.1	RP4-739H11.3	-7.7	7.99e-14	6.96e-11	-0.46	-0.33	Platelet count;	chr1:40725528	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.913	rs2361648	ENSG00000237899.1	RP4-739H11.3	-7.7	7.99e-14	6.96e-11	-0.46	-0.33	Platelet count;	chr1:40726825	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.913	rs6675886	ENSG00000237899.1	RP4-739H11.3	-7.7	7.99e-14	6.96e-11	-0.46	-0.33	Platelet count;	chr1:40727955	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.913	rs6668453	ENSG00000237899.1	RP4-739H11.3	-7.7	7.99e-14	6.96e-11	-0.46	-0.33	Platelet count;	chr1:40733299	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.913	rs35881320	ENSG00000237899.1	RP4-739H11.3	-7.7	7.99e-14	6.96e-11	-0.46	-0.33	Platelet count;	chr1:40733893	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.871	rs34512220	ENSG00000237899.1	RP4-739H11.3	-7.7	7.99e-14	6.96e-11	-0.46	-0.33	Platelet count;	chr1:40733912	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.913	rs6664044	ENSG00000237899.1	RP4-739H11.3	-7.7	7.99e-14	6.96e-11	-0.46	-0.33	Platelet count;	chr1:40735089	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.913	rs6702983	ENSG00000237899.1	RP4-739H11.3	-7.7	7.99e-14	6.96e-11	-0.46	-0.33	Platelet count;	chr1:40735585	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.913	rs12566733	ENSG00000237899.1	RP4-739H11.3	-7.7	7.99e-14	6.96e-11	-0.46	-0.33	Platelet count;	chr1:40736067	chr1:40669089~40687588:-
LUAD	cis	rs944289	0.74	rs7150440	ENSG00000257826.1	RP11-116N8.4	-7.7	8.01e-14	6.97e-11	-0.35	-0.33	Thyroid cancer;	chr14:36114691	chr14:36061026~36067190:-
LUAD	cis	rs944289	0.74	rs7150768	ENSG00000257826.1	RP11-116N8.4	-7.7	8.01e-14	6.97e-11	-0.35	-0.33	Thyroid cancer;	chr14:36114699	chr14:36061026~36067190:-
LUAD	cis	rs11098499	0.657	rs10434028	ENSG00000248280.1	RP11-33B1.2	7.7	8.03e-14	6.99e-11	0.4	0.33	Corneal astigmatism;	chr4:119373309	chr4:119440561~119450157:-
LUAD	cis	rs9640161	0.789	rs2373751	ENSG00000261305.1	RP4-584D14.7	7.7	8.07e-14	7.03e-11	0.5	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150324510	chr7:150341771~150342607:+
LUAD	cis	rs4927850	0.501	rs9881504	ENSG00000231464.1	AC024937.4	7.7	8.08e-14	7.03e-11	0.39	0.33	Pancreatic cancer;	chr3:195929743	chr3:195996738~195998233:+
LUAD	cis	rs9545047	0.584	rs7995243	ENSG00000227676.3	LINC01068	-7.69	8.2e-14	7.13e-11	-0.38	-0.33	Schizophrenia;	chr13:79358645	chr13:79566727~79571436:+
LUAD	cis	rs8177876	0.749	rs75923695	ENSG00000261838.4	RP11-303E16.6	7.69	8.21e-14	7.14e-11	0.73	0.33	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81060289	chr16:81069854~81076598:+
LUAD	cis	rs7429990	0.694	rs7645846	ENSG00000229759.1	MRPS18AP1	-7.69	8.22e-14	7.15e-11	-0.33	-0.33	Educational attainment (years of education);	chr3:47740829	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs12495520	ENSG00000229759.1	MRPS18AP1	-7.69	8.26e-14	7.18e-11	-0.34	-0.33	Educational attainment (years of education);	chr3:47766269	chr3:48256350~48256938:-
LUAD	cis	rs8005677	1	rs8006409	ENSG00000279656.1	RP11-298I3.6	7.69	8.28e-14	7.2e-11	0.39	0.33	Cognitive ability (multi-trait analysis);	chr14:22927302	chr14:23023083~23024217:-
LUAD	cis	rs10129255	0.872	rs1858683	ENSG00000211972.2	IGHV3-66	7.69	8.29e-14	7.21e-11	0.29	0.33	Kawasaki disease;	chr14:106670217	chr14:106675017~106675544:-
LUAD	cis	rs34375054	0.735	rs34961756	ENSG00000279233.1	RP11-158L12.4	7.69	8.33e-14	7.24e-11	0.26	0.33	Post bronchodilator FEV1/FVC ratio;	chr12:125144052	chr12:125138245~125141711:+
LUAD	cis	rs4660456	0.913	rs3754179	ENSG00000237899.1	RP4-739H11.3	-7.69	8.34e-14	7.25e-11	-0.46	-0.33	Platelet count;	chr1:40768464	chr1:40669089~40687588:-
LUAD	cis	rs9595908	0.965	rs7335710	ENSG00000212293.1	SNORA16	7.69	8.36e-14	7.27e-11	0.37	0.33	Body mass index;	chr13:32561287	chr13:32420390~32420516:-
LUAD	cis	rs9322193	0.567	rs7742692	ENSG00000223701.3	RAET1E-AS1	7.69	8.4e-14	7.3e-11	0.39	0.33	Lung cancer;	chr6:149892363	chr6:149884431~149919508:+
LUAD	cis	rs1150668	0.83	rs2859365	ENSG00000216901.1	AL022393.7	-7.69	8.4e-14	7.3e-11	-0.38	-0.33	Pubertal anthropometrics;	chr6:28423688	chr6:28176188~28176674:+
LUAD	cis	rs1729407	0.565	rs2849173	ENSG00000254851.1	RP11-109L13.1	-7.69	8.42e-14	7.32e-11	-0.41	-0.33	Apolipoprotein A-IV levels;	chr11:116826605	chr11:117135528~117138582:+
LUAD	cis	rs2455601	0.786	rs10279	ENSG00000254860.4	TMEM9B-AS1	7.69	8.52e-14	7.4e-11	0.46	0.33	Schizophrenia;	chr11:8947762	chr11:8964675~8977527:+
LUAD	cis	rs950169	0.922	rs8037078	ENSG00000225151.9	GOLGA2P7	7.69	8.53e-14	7.41e-11	0.47	0.33	Schizophrenia;	chr15:84150119	chr15:84199311~84230136:-
LUAD	cis	rs2919917	0.628	rs9298314	ENSG00000254352.1	RP11-578O24.2	7.69	8.56e-14	7.44e-11	0.42	0.33	Lymphocyte counts;	chr8:78660874	chr8:78723796~78724136:-
LUAD	cis	rs2248020	0.501	rs2263368	ENSG00000279684.1	RP11-755E23.2	-7.69	8.57e-14	7.44e-11	-0.42	-0.33	Insulin levels in response to oral glucose tolerance test (30 minutes);	chr11:93531514	chr11:93286629~93288903:-
LUAD	cis	rs9326248	0.689	rs236916	ENSG00000280143.1	AP000892.6	-7.69	8.59e-14	7.46e-11	-0.5	-0.33	Blood protein levels;	chr11:117218912	chr11:117204967~117210292:+
LUAD	cis	rs11089937	0.568	rs6001078	ENSG00000211639.2	IGLV4-60	7.69	8.63e-14	7.49e-11	0.39	0.33	Periodontitis (PAL4Q3);	chr22:22134365	chr22:22162199~22162681:+
LUAD	cis	rs1501911	0.53	rs162149	ENSG00000248489.1	CTD-2007H13.3	7.68	8.67e-14	7.53e-11	0.36	0.33	Lung function (FEV1/FVC);	chr5:98913851	chr5:98929171~98995013:+
LUAD	cis	rs730566	0.64	rs6442112	ENSG00000229759.1	MRPS18AP1	7.68	8.68e-14	7.54e-11	0.35	0.33	Prion diseases;	chr3:48274544	chr3:48256350~48256938:-
LUAD	cis	rs10129255	0.912	rs61997792	ENSG00000211970.3	IGHV4-61	-7.68	8.69e-14	7.54e-11	-0.26	-0.33	Kawasaki disease;	chr14:106799304	chr14:106639119~106639657:-
LUAD	cis	rs9322193	0.543	rs9371533	ENSG00000223701.3	RAET1E-AS1	7.68	8.72e-14	7.56e-11	0.39	0.33	Lung cancer;	chr6:149889545	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs13215691	ENSG00000223701.3	RAET1E-AS1	7.68	8.73e-14	7.58e-11	0.39	0.33	Lung cancer;	chr6:149792666	chr6:149884431~149919508:+
LUAD	cis	rs9287719	0.967	rs4470306	ENSG00000234818.1	AC092687.5	7.68	8.79e-14	7.62e-11	0.4	0.33	Prostate cancer;	chr2:10603872	chr2:10589166~10604830:+
LUAD	cis	rs944289	0.708	rs1475716	ENSG00000257826.1	RP11-116N8.4	-7.68	8.84e-14	7.67e-11	-0.35	-0.33	Thyroid cancer;	chr14:36116033	chr14:36061026~36067190:-
LUAD	cis	rs7429990	0.864	rs6768699	ENSG00000229759.1	MRPS18AP1	-7.68	8.84e-14	7.67e-11	-0.33	-0.33	Educational attainment (years of education);	chr3:47711258	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs12495204	ENSG00000229759.1	MRPS18AP1	-7.68	8.84e-14	7.67e-11	-0.33	-0.33	Educational attainment (years of education);	chr3:47720540	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs7612219	ENSG00000229759.1	MRPS18AP1	-7.68	8.84e-14	7.67e-11	-0.33	-0.33	Educational attainment (years of education);	chr3:47739676	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs7637372	ENSG00000229759.1	MRPS18AP1	-7.68	8.84e-14	7.67e-11	-0.33	-0.33	Educational attainment (years of education);	chr3:47750385	chr3:48256350~48256938:-
LUAD	cis	rs904251	0.686	rs931649	ENSG00000279942.1	RP1-153P14.7	-7.68	8.85e-14	7.67e-11	-0.36	-0.33	Cognitive performance;	chr6:37498303	chr6:37567716~37571460:+
LUAD	cis	rs9322193	0.923	rs10782318	ENSG00000223701.3	RAET1E-AS1	7.68	8.86e-14	7.68e-11	0.4	0.33	Lung cancer;	chr6:149754137	chr6:149884431~149919508:+
LUAD	cis	rs2919917	0.628	rs1021157	ENSG00000254352.1	RP11-578O24.2	7.68	8.87e-14	7.69e-11	0.43	0.33	Lymphocyte counts;	chr8:78662938	chr8:78723796~78724136:-
LUAD	cis	rs1150668	0.796	rs2531825	ENSG00000204709.4	LINC01556	7.68	8.9e-14	7.71e-11	0.41	0.33	Pubertal anthropometrics;	chr6:28381487	chr6:28943877~28944537:+
LUAD	cis	rs2153535	0.58	rs9328484	ENSG00000230939.1	RP11-314C16.1	-7.68	8.9e-14	7.72e-11	-0.39	-0.33	Motion sickness;	chr6:8524610	chr6:8784178~8785445:+
LUAD	cis	rs7429990	0.864	rs6806860	ENSG00000229759.1	MRPS18AP1	-7.68	8.91e-14	7.72e-11	-0.33	-0.33	Educational attainment (years of education);	chr3:47708218	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs17079785	ENSG00000229759.1	MRPS18AP1	-7.68	8.91e-14	7.72e-11	-0.33	-0.33	Educational attainment (years of education);	chr3:47743160	chr3:48256350~48256938:-
LUAD	cis	rs673078	0.66	rs17440315	ENSG00000275759.1	RP11-131L12.3	-7.68	8.93e-14	7.74e-11	-0.49	-0.33	Glucose homeostasis traits;	chr12:118158819	chr12:118428281~118428870:+
LUAD	cis	rs80285556	0.655	rs17311832	ENSG00000161643.11	SIGLEC16	7.68	8.94e-14	7.74e-11	0.76	0.33	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50022059	chr19:49969673~49975814:+
LUAD	cis	rs80285556	1	rs80314222	ENSG00000161643.11	SIGLEC16	7.68	8.94e-14	7.74e-11	0.76	0.33	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50022257	chr19:49969673~49975814:+
LUAD	cis	rs4660456	0.913	rs16827569	ENSG00000237899.1	RP4-739H11.3	-7.68	8.94e-14	7.74e-11	-0.46	-0.33	Platelet count;	chr1:40761655	chr1:40669089~40687588:-
LUAD	cis	rs496547	0.719	rs1790189	ENSG00000278376.1	RP11-158I9.8	-7.68	8.97e-14	7.77e-11	-0.37	-0.33	Hip minimal joint space width;	chr11:118781617	chr11:118791254~118793137:+
LUAD	cis	rs237743	1	rs238200	ENSG00000222365.1	SNORD12B	-7.68	8.99e-14	7.78e-11	-0.37	-0.33	Height;	chr20:49283115	chr20:49280319~49280409:+
LUAD	cis	rs2283792	0.967	rs5755099	ENSG00000224086.5	LL22NC03-86G7.1	-7.68	8.99e-14	7.79e-11	-0.31	-0.33	Multiple sclerosis;	chr22:21770751	chr22:21938293~21977632:+
LUAD	cis	rs150992	0.711	rs170734	ENSG00000248489.1	CTD-2007H13.3	7.68	9.06e-14	7.84e-11	0.36	0.33	Body mass index;	chr5:98811337	chr5:98929171~98995013:+
LUAD	cis	rs17482078	0.959	rs13185488	ENSG00000248734.2	CTD-2260A17.1	7.68	9.07e-14	7.85e-11	0.41	0.33	Behcet's disease;Blood protein levels;	chr5:96785480	chr5:96784777~96785999:+
LUAD	cis	rs17482078	0.959	rs13186739	ENSG00000248734.2	CTD-2260A17.1	7.68	9.07e-14	7.85e-11	0.41	0.33	Behcet's disease;Blood protein levels;	chr5:96785539	chr5:96784777~96785999:+
LUAD	cis	rs638893	0.947	rs1170396	ENSG00000278376.1	RP11-158I9.8	-7.68	9.1e-14	7.88e-11	-0.48	-0.33	Vitiligo;	chr11:118833108	chr11:118791254~118793137:+
LUAD	cis	rs6142102	0.961	rs2284389	ENSG00000276073.1	RP5-1125A11.7	-7.68	9.11e-14	7.89e-11	-0.34	-0.33	Skin pigmentation;	chr20:34069035	chr20:33985617~33988989:-
LUAD	cis	rs8005677	0.962	rs10130756	ENSG00000279656.1	RP11-298I3.6	7.68	9.13e-14	7.9e-11	0.39	0.33	Cognitive ability (multi-trait analysis);	chr14:22927391	chr14:23023083~23024217:-
LUAD	cis	rs8005677	1	rs2295685	ENSG00000279656.1	RP11-298I3.6	7.68	9.13e-14	7.9e-11	0.39	0.33	Cognitive ability (multi-trait analysis);	chr14:22928944	chr14:23023083~23024217:-
LUAD	cis	rs8005677	1	rs7145494	ENSG00000279656.1	RP11-298I3.6	7.68	9.13e-14	7.9e-11	0.39	0.33	Cognitive ability (multi-trait analysis);	chr14:22930581	chr14:23023083~23024217:-
LUAD	cis	rs10463554	0.892	rs1898673	ENSG00000175749.11	EIF3KP1	7.68	9.13e-14	7.9e-11	0.46	0.33	Parkinson's disease;	chr5:102957676	chr5:103032376~103033031:+
LUAD	cis	rs9595908	0.965	rs11840502	ENSG00000212293.1	SNORA16	7.68	9.16e-14	7.93e-11	0.36	0.33	Body mass index;	chr13:32624572	chr13:32420390~32420516:-
LUAD	cis	rs7615952	0.551	rs6438945	ENSG00000171084.14	FAM86JP	7.68	9.18e-14	7.94e-11	0.51	0.33	Blood pressure (smoking interaction);	chr3:125915630	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.673	rs7632557	ENSG00000171084.14	FAM86JP	7.68	9.18e-14	7.94e-11	0.51	0.33	Blood pressure (smoking interaction);	chr3:125916038	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.932	rs9841157	ENSG00000171084.14	FAM86JP	7.68	9.18e-14	7.94e-11	0.51	0.33	Blood pressure (smoking interaction);	chr3:125916812	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.551	rs12695470	ENSG00000171084.14	FAM86JP	7.68	9.18e-14	7.94e-11	0.51	0.33	Blood pressure (smoking interaction);	chr3:125916875	chr3:125916620~125930024:+
LUAD	cis	rs10129255	0.826	rs7150693	ENSG00000211972.2	IGHV3-66	7.68	9.23e-14	7.98e-11	0.29	0.33	Kawasaki disease;	chr14:106705382	chr14:106675017~106675544:-
LUAD	cis	rs8005677	1	rs4982710	ENSG00000279656.1	RP11-298I3.6	7.68	9.26e-14	8.01e-11	0.39	0.33	Cognitive ability (multi-trait analysis);	chr14:22929693	chr14:23023083~23024217:-
LUAD	cis	rs10463554	0.892	rs2195272	ENSG00000175749.11	EIF3KP1	7.68	9.27e-14	8.01e-11	0.45	0.33	Parkinson's disease;	chr5:102959800	chr5:103032376~103033031:+
LUAD	cis	rs11089937	0.609	rs9622980	ENSG00000211639.2	IGLV4-60	7.68	9.27e-14	8.01e-11	0.41	0.33	Periodontitis (PAL4Q3);	chr22:22149888	chr22:22162199~22162681:+
LUAD	cis	rs10129255	0.957	rs8009073	ENSG00000211972.2	IGHV3-66	7.67	9.32e-14	8.06e-11	0.29	0.33	Kawasaki disease;	chr14:106777278	chr14:106675017~106675544:-
LUAD	cis	rs944289	0.708	rs1958622	ENSG00000257826.1	RP11-116N8.4	-7.67	9.34e-14	8.07e-11	-0.35	-0.33	Thyroid cancer;	chr14:36127289	chr14:36061026~36067190:-
LUAD	cis	rs8059260	0.668	rs4781029	ENSG00000274038.1	RP11-66H6.4	-7.67	9.43e-14	8.14e-11	-0.61	-0.33	Alcohol consumption over the past year;	chr16:10983717	chr16:11056556~11057034:+
LUAD	cis	rs11089937	0.626	rs737841	ENSG00000211639.2	IGLV4-60	7.67	9.45e-14	8.17e-11	0.4	0.33	Periodontitis (PAL4Q3);	chr22:22162769	chr22:22162199~22162681:+
LUAD	cis	rs150992	0.962	rs327811	ENSG00000248489.1	CTD-2007H13.3	7.67	9.46e-14	8.17e-11	0.37	0.33	Body mass index;	chr5:98935471	chr5:98929171~98995013:+
LUAD	cis	rs11123170	0.529	rs35606997	ENSG00000189223.12	PAX8-AS1	-7.67	9.47e-14	8.18e-11	-0.52	-0.33	Renal function-related traits (BUN);	chr2:113215773	chr2:113211522~113276581:+
LUAD	cis	rs1729407	0.659	rs2542050	ENSG00000254851.1	RP11-109L13.1	-7.67	9.47e-14	8.18e-11	-0.41	-0.33	Apolipoprotein A-IV levels;	chr11:116826401	chr11:117135528~117138582:+
LUAD	cis	rs1729407	0.632	rs2071523	ENSG00000254851.1	RP11-109L13.1	-7.67	9.53e-14	8.24e-11	-0.42	-0.33	Apolipoprotein A-IV levels;	chr11:116826628	chr11:117135528~117138582:+
LUAD	cis	rs34375054	0.738	rs3751181	ENSG00000279233.1	RP11-158L12.4	7.67	9.56e-14	8.26e-11	0.26	0.33	Post bronchodilator FEV1/FVC ratio;	chr12:125141989	chr12:125138245~125141711:+
LUAD	cis	rs4718428	0.705	rs4717331	ENSG00000226824.5	RP4-756H11.3	-7.67	9.58e-14	8.28e-11	-0.44	-0.33	Corneal structure;	chr7:66913899	chr7:66654538~66669855:+
LUAD	cis	rs8059260	0.668	rs78573173	ENSG00000274038.1	RP11-66H6.4	-7.67	9.69e-14	8.37e-11	-0.6	-0.33	Alcohol consumption over the past year;	chr16:11017642	chr16:11056556~11057034:+
LUAD	cis	rs10129255	0.872	rs1858683	ENSG00000280411.1	IGHV1-69-2	-7.67	9.76e-14	8.43e-11	-0.25	-0.33	Kawasaki disease;	chr14:106670217	chr14:106762092~106762588:-
LUAD	cis	rs8059260	0.604	rs71381192	ENSG00000274038.1	RP11-66H6.4	-7.67	9.8e-14	8.45e-11	-0.68	-0.33	Alcohol consumption over the past year;	chr16:11075528	chr16:11056556~11057034:+
LUAD	cis	rs11089937	0.597	rs5757005	ENSG00000211639.2	IGLV4-60	7.67	9.82e-14	8.47e-11	0.39	0.33	Periodontitis (PAL4Q3);	chr22:22134775	chr22:22162199~22162681:+
LUAD	cis	rs7188445	1	rs76819459	ENSG00000261390.4	RP11-345M22.2	-7.67	9.87e-14	8.51e-11	-0.45	-0.33	Urate levels;	chr16:79685020	chr16:79715232~79770563:-
LUAD	cis	rs150992	0.64	rs326485	ENSG00000248489.1	CTD-2007H13.3	7.67	9.87e-14	8.52e-11	0.37	0.33	Body mass index;	chr5:98845717	chr5:98929171~98995013:+
LUAD	cis	rs6142102	0.961	rs6120519	ENSG00000276073.1	RP5-1125A11.7	-7.67	9.88e-14	8.52e-11	-0.33	-0.33	Skin pigmentation;	chr20:34100307	chr20:33985617~33988989:-
LUAD	cis	rs1501911	0.53	rs331926	ENSG00000248489.1	CTD-2007H13.3	7.67	9.9e-14	8.54e-11	0.37	0.33	Lung function (FEV1/FVC);	chr5:98828697	chr5:98929171~98995013:+
LUAD	cis	rs11089937	0.667	rs10483107	ENSG00000211639.2	IGLV4-60	7.67	9.91e-14	8.55e-11	0.41	0.33	Periodontitis (PAL4Q3);	chr22:22151036	chr22:22162199~22162681:+
LUAD	cis	rs9309711	0.56	rs6548164	ENSG00000225234.1	TRAPPC12-AS1	7.67	9.93e-14	8.56e-11	0.37	0.33	Neurofibrillary tangles;	chr2:3468894	chr2:3481242~3482409:-
LUAD	cis	rs9322193	0.962	rs2342764	ENSG00000223701.3	RAET1E-AS1	7.67	9.93e-14	8.56e-11	0.4	0.33	Lung cancer;	chr6:149835068	chr6:149884431~149919508:+
LUAD	cis	rs10129255	0.957	rs11847726	ENSG00000280411.1	IGHV1-69-2	-7.67	9.93e-14	8.56e-11	-0.25	-0.33	Kawasaki disease;	chr14:106779116	chr14:106762092~106762588:-
LUAD	cis	rs11089937	0.667	rs11704024	ENSG00000211639.2	IGLV4-60	7.67	9.95e-14	8.58e-11	0.41	0.33	Periodontitis (PAL4Q3);	chr22:22151195	chr22:22162199~22162681:+
LUAD	cis	rs8062405	0.755	rs56272201	ENSG00000259982.1	CDC37P1	7.66	9.96e-14	8.58e-11	0.43	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.755	rs62034355	ENSG00000259982.1	CDC37P1	7.66	9.96e-14	8.58e-11	0.43	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28700294~28701540:-
LUAD	cis	rs150992	0.517	rs326464	ENSG00000248489.1	CTD-2007H13.3	7.66	9.97e-14	8.59e-11	0.36	0.33	Body mass index;	chr5:98906499	chr5:98929171~98995013:+
LUAD	cis	rs6142102	0.961	rs2284386	ENSG00000276073.1	RP5-1125A11.7	-7.66	9.97e-14	8.59e-11	-0.34	-0.33	Skin pigmentation;	chr20:34056590	chr20:33985617~33988989:-
LUAD	cis	rs9545047	0.604	rs2876740	ENSG00000227676.3	LINC01068	-7.66	1e-13	8.61e-11	-0.38	-0.33	Schizophrenia;	chr13:79409829	chr13:79566727~79571436:+
LUAD	cis	rs1075265	0.554	rs10168293	ENSG00000233266.1	HMGB1P31	7.66	1.01e-13	8.72e-11	0.41	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53973793	chr2:54051334~54051760:+
LUAD	cis	rs1075265	0.567	rs66773232	ENSG00000233266.1	HMGB1P31	7.66	1.01e-13	8.72e-11	0.41	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53973970	chr2:54051334~54051760:+
LUAD	cis	rs10853057	0.541	rs11656396	ENSG00000214174.7	AMZ2P1	7.66	1.01e-13	8.74e-11	0.55	0.33	White matter microstructure (global fractional anisotropy);	chr17:65049958	chr17:64966550~64975576:-
LUAD	cis	rs35160687	0.901	rs6713456	ENSG00000273080.1	RP11-301O19.1	7.66	1.02e-13	8.76e-11	0.37	0.33	Night sleep phenotypes;	chr2:86280530	chr2:86195590~86196049:+
LUAD	cis	rs11089937	0.626	rs5757013	ENSG00000211639.2	IGLV4-60	7.66	1.02e-13	8.76e-11	0.39	0.33	Periodontitis (PAL4Q3);	chr22:22135544	chr22:22162199~22162681:+
LUAD	cis	rs8059260	0.668	rs75811377	ENSG00000274038.1	RP11-66H6.4	-7.66	1.02e-13	8.8e-11	-0.6	-0.33	Alcohol consumption over the past year;	chr16:11023451	chr16:11056556~11057034:+
LUAD	cis	rs7615952	0.673	rs35955861	ENSG00000171084.14	FAM86JP	7.66	1.03e-13	8.87e-11	0.59	0.33	Blood pressure (smoking interaction);	chr3:125907358	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.673	rs35001498	ENSG00000171084.14	FAM86JP	7.66	1.03e-13	8.87e-11	0.59	0.33	Blood pressure (smoking interaction);	chr3:125909801	chr3:125916620~125930024:+
LUAD	cis	rs7188445	1	rs11644836	ENSG00000261390.4	RP11-345M22.2	-7.66	1.04e-13	8.93e-11	-0.45	-0.33	Urate levels;	chr16:79678758	chr16:79715232~79770563:-
LUAD	cis	rs1150668	0.699	rs13408	ENSG00000204709.4	LINC01556	7.66	1.04e-13	8.93e-11	0.41	0.33	Pubertal anthropometrics;	chr6:28244970	chr6:28943877~28944537:+
LUAD	cis	rs6504950	0.925	rs181727	ENSG00000275710.1	RP11-257O5.4	7.66	1.04e-13	8.95e-11	0.42	0.33	Breast cancer;	chr17:55113634	chr17:54964474~54964679:+
LUAD	cis	rs638893	0.717	rs622690	ENSG00000278376.1	RP11-158I9.8	-7.66	1.04e-13	8.96e-11	-0.47	-0.33	Vitiligo;	chr11:118833556	chr11:118791254~118793137:+
LUAD	cis	rs10463554	0.963	rs32840	ENSG00000175749.11	EIF3KP1	7.66	1.05e-13	9.01e-11	0.45	0.33	Parkinson's disease;	chr5:103143446	chr5:103032376~103033031:+
LUAD	cis	rs7208859	0.623	rs9895785	ENSG00000263531.1	RP13-753N3.1	-7.66	1.05e-13	9.02e-11	-0.67	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30863921~30864940:-
LUAD	cis	rs7429990	0.864	rs7618758	ENSG00000229759.1	MRPS18AP1	-7.66	1.05e-13	9.05e-11	-0.33	-0.33	Educational attainment (years of education);	chr3:47720993	chr3:48256350~48256938:-
LUAD	cis	rs7182621	0.639	rs12906068	ENSG00000182397.13	DNM1P46	7.66	1.05e-13	9.06e-11	0.46	0.33	Colonoscopy-negative controls vs population controls;	chr15:99873422	chr15:99790156~99806927:-
LUAD	cis	rs10463554	0.926	rs34778	ENSG00000175749.11	EIF3KP1	7.66	1.05e-13	9.07e-11	0.45	0.33	Parkinson's disease;	chr5:103116852	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.963	rs26524	ENSG00000175749.11	EIF3KP1	7.66	1.05e-13	9.07e-11	0.45	0.33	Parkinson's disease;	chr5:103120600	chr5:103032376~103033031:+
LUAD	cis	rs11089937	0.626	rs5757011	ENSG00000211639.2	IGLV4-60	7.66	1.06e-13	9.09e-11	0.39	0.33	Periodontitis (PAL4Q3);	chr22:22135336	chr22:22162199~22162681:+
LUAD	cis	rs2283792	1	rs2283792	ENSG00000224086.5	LL22NC03-86G7.1	-7.65	1.07e-13	9.18e-11	-0.31	-0.33	Multiple sclerosis;	chr22:21776836	chr22:21938293~21977632:+
LUAD	cis	rs496547	0.654	rs688161	ENSG00000278376.1	RP11-158I9.8	-7.65	1.07e-13	9.21e-11	-0.36	-0.33	Hip minimal joint space width;	chr11:118807001	chr11:118791254~118793137:+
LUAD	cis	rs56046484	0.711	rs71397835	ENSG00000259295.5	CSPG4P12	7.65	1.08e-13	9.25e-11	0.55	0.33	Testicular germ cell tumor;	chr15:84987540	chr15:85191438~85213905:+
LUAD	cis	rs7182621	0.639	rs35049216	ENSG00000182397.13	DNM1P46	7.65	1.08e-13	9.31e-11	0.46	0.33	Colonoscopy-negative controls vs population controls;	chr15:99872562	chr15:99790156~99806927:-
LUAD	cis	rs11920570	0.526	rs3828362	ENSG00000272758.4	RP11-299J3.8	7.65	1.09e-13	9.36e-11	0.32	0.33	Resting heart rate;	chr3:122412930	chr3:122416207~122443180:+
LUAD	cis	rs6504622	0.755	rs36056466	ENSG00000262879.4	RP11-156P1.3	-7.65	1.09e-13	9.37e-11	-0.38	-0.33	Orofacial clefts;	chr17:47006017	chr17:46984045~47100323:-
LUAD	cis	rs7429990	0.864	rs3888	ENSG00000229759.1	MRPS18AP1	-7.65	1.1e-13	9.48e-11	-0.33	-0.33	Educational attainment (years of education);	chr3:47816085	chr3:48256350~48256938:-
LUAD	cis	rs853679	0.517	rs1947863	ENSG00000219392.1	RP1-265C24.5	-7.65	1.11e-13	9.53e-11	-0.46	-0.33	Depression;	chr6:28131566	chr6:28115628~28116551:+
LUAD	cis	rs10129255	1	rs9324091	ENSG00000280411.1	IGHV1-69-2	-7.65	1.11e-13	9.53e-11	-0.25	-0.33	Kawasaki disease;	chr14:106676625	chr14:106762092~106762588:-
LUAD	cis	rs8059260	0.542	rs6498148	ENSG00000274038.1	RP11-66H6.4	-7.65	1.12e-13	9.6e-11	-0.6	-0.33	Alcohol consumption over the past year;	chr16:11018374	chr16:11056556~11057034:+
LUAD	cis	rs1501911	0.53	rs326468	ENSG00000248489.1	CTD-2007H13.3	7.65	1.12e-13	9.61e-11	0.36	0.33	Lung function (FEV1/FVC);	chr5:98897105	chr5:98929171~98995013:+
LUAD	cis	rs2412819	0.571	rs2729494	ENSG00000205771.5	CATSPER2P1	7.65	1.12e-13	9.64e-11	0.49	0.33	Lung cancer;	chr15:43837395	chr15:43726918~43747094:-
LUAD	cis	rs2412819	0.571	rs528764	ENSG00000205771.5	CATSPER2P1	7.65	1.12e-13	9.64e-11	0.49	0.33	Lung cancer;	chr15:43838650	chr15:43726918~43747094:-
LUAD	cis	rs10028773	0.515	rs9994651	ENSG00000245958.5	RP11-33B1.1	-7.65	1.12e-13	9.64e-11	-0.29	-0.33	Educational attainment;	chr4:119666648	chr4:119454791~119552025:+
LUAD	cis	rs6504622	0.755	rs7219544	ENSG00000262879.4	RP11-156P1.3	-7.65	1.13e-13	9.7e-11	-0.37	-0.33	Orofacial clefts;	chr17:47089562	chr17:46984045~47100323:-
LUAD	cis	rs8059260	0.736	rs78121798	ENSG00000274038.1	RP11-66H6.4	-7.65	1.13e-13	9.73e-11	-0.61	-0.33	Alcohol consumption over the past year;	chr16:10984224	chr16:11056556~11057034:+
LUAD	cis	rs904251	0.686	rs2776911	ENSG00000204110.6	RP1-153P14.8	-7.65	1.14e-13	9.75e-11	-0.39	-0.33	Cognitive performance;	chr6:37472174	chr6:37507348~37535616:+
LUAD	cis	rs9322193	0.962	rs4380763	ENSG00000223701.3	RAET1E-AS1	7.65	1.14e-13	9.78e-11	0.38	0.33	Lung cancer;	chr6:149678086	chr6:149884431~149919508:+
LUAD	cis	rs1501911	0.53	rs162150	ENSG00000248489.1	CTD-2007H13.3	7.64	1.15e-13	9.81e-11	0.36	0.33	Lung function (FEV1/FVC);	chr5:98913909	chr5:98929171~98995013:+
LUAD	cis	rs6700559	0.742	rs10399790	ENSG00000260088.1	RP11-92G12.3	-7.64	1.15e-13	9.82e-11	-0.42	-0.33	Coronary artery disease;	chr1:200626241	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.81	rs10919991	ENSG00000260088.1	RP11-92G12.3	-7.64	1.15e-13	9.82e-11	-0.42	-0.33	Coronary artery disease;	chr1:200627217	chr1:200669507~200694250:+
LUAD	cis	rs10463554	0.963	rs187427	ENSG00000175749.11	EIF3KP1	7.64	1.15e-13	9.82e-11	0.45	0.33	Parkinson's disease;	chr5:103177102	chr5:103032376~103033031:+
LUAD	cis	rs7044106	0.512	rs7873848	ENSG00000226752.6	PSMD5-AS1	-7.64	1.15e-13	9.84e-11	-0.37	-0.33	Hip circumference adjusted for BMI;	chr9:120591944	chr9:120824828~120854385:+
LUAD	cis	rs673078	0.66	rs7136216	ENSG00000275759.1	RP11-131L12.3	-7.64	1.15e-13	9.86e-11	-0.43	-0.33	Glucose homeostasis traits;	chr12:118170475	chr12:118428281~118428870:+
LUAD	cis	rs9532669	0.926	rs9532690	ENSG00000176268.5	CYCSP34	7.64	1.15e-13	9.86e-11	0.31	0.33	Cervical cancer;	chr13:40968654	chr13:40863599~40863902:-
LUAD	cis	rs6504950	0.925	rs244358	ENSG00000275710.1	RP11-257O5.4	7.64	1.15e-13	9.88e-11	0.42	0.33	Breast cancer;	chr17:55114870	chr17:54964474~54964679:+
LUAD	cis	rs2929278	0.736	rs2412823	ENSG00000249839.1	AC011330.5	7.64	1.16e-13	9.89e-11	0.41	0.33	Schizophrenia;	chr15:43935072	chr15:43663654~43684339:-
LUAD	cis	rs1075265	0.633	rs10183655	ENSG00000233266.1	HMGB1P31	7.64	1.16e-13	9.91e-11	0.41	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53983644	chr2:54051334~54051760:+
LUAD	cis	rs10129255	0.5	rs9324092	ENSG00000211970.3	IGHV4-61	7.64	1.16e-13	9.92e-11	0.23	0.33	Kawasaki disease;	chr14:106683806	chr14:106639119~106639657:-
LUAD	cis	rs9545047	0.604	rs7983344	ENSG00000227676.3	LINC01068	-7.64	1.16e-13	9.93e-11	-0.38	-0.33	Schizophrenia;	chr13:79299295	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.584	rs12871015	ENSG00000227676.3	LINC01068	-7.64	1.16e-13	9.95e-11	-0.38	-0.33	Schizophrenia;	chr13:79333564	chr13:79566727~79571436:+
LUAD	cis	rs9487094	0.67	rs4490694	ENSG00000260273.1	RP11-425D10.10	7.64	1.17e-13	9.97e-11	0.43	0.33	Height;	chr6:109571489	chr6:109382795~109383666:+
LUAD	cis	rs9322193	1	rs9377229	ENSG00000223701.3	RAET1E-AS1	7.64	1.17e-13	9.97e-11	0.39	0.33	Lung cancer;	chr6:149607655	chr6:149884431~149919508:+
LUAD	cis	rs765787	0.53	rs4775819	ENSG00000259520.4	CTD-2651B20.3	7.64	1.17e-13	9.99e-11	0.43	0.33	Uric acid levels;	chr15:45233768	chr15:45251580~45279251:-
LUAD	cis	rs4718428	0.705	rs4718424	ENSG00000226824.5	RP4-756H11.3	-7.64	1.17e-13	9.99e-11	-0.44	-0.33	Corneal structure;	chr7:66911108	chr7:66654538~66669855:+
LUAD	cis	rs7567389	0.6	rs72845979	ENSG00000236682.1	AC068282.3	-7.64	1.17e-13	1e-10	-0.45	-0.33	Self-rated health;	chr2:127338178	chr2:127389130~127400580:+
LUAD	cis	rs7567389	0.534	rs72845982	ENSG00000236682.1	AC068282.3	-7.64	1.17e-13	1e-10	-0.45	-0.33	Self-rated health;	chr2:127340994	chr2:127389130~127400580:+
LUAD	cis	rs71403859	0.73	rs12447672	ENSG00000260886.1	TAT-AS1	7.64	1.17e-13	1e-10	0.57	0.33	Post bronchodilator FEV1;	chr16:71681228	chr16:71565789~71578187:+
LUAD	cis	rs10740039	0.729	rs6479728	ENSG00000254271.1	RP11-131N11.4	-7.64	1.17e-13	1e-10	-0.35	-0.33	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60731043	chr10:60734342~60741828:+
LUAD	cis	rs6504950	0.679	rs2628298	ENSG00000275710.1	RP11-257O5.4	-7.64	1.18e-13	1.01e-10	-0.45	-0.33	Breast cancer;	chr17:55086117	chr17:54964474~54964679:+
LUAD	cis	rs9595908	0.865	rs497255	ENSG00000212293.1	SNORA16	-7.64	1.18e-13	1.01e-10	-0.37	-0.33	Body mass index;	chr13:32424754	chr13:32420390~32420516:-
LUAD	cis	rs4853012	0.838	rs6715351	ENSG00000257800.1	FNBP1P1	7.64	1.18e-13	1.01e-10	0.39	0.33	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74120680~74123218:+
LUAD	cis	rs2739330	0.731	rs4822450	ENSG00000228039.3	KB-1125A3.10	7.64	1.18e-13	1.01e-10	0.39	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23963780~23964374:+
LUAD	cis	rs56205728	0.601	rs3784399	ENSG00000273855.1	RP11-133K1.12	-7.64	1.18e-13	1.01e-10	-0.43	-0.33	Schizophrenia;	chr15:40306093	chr15:40285468~40285909:-
LUAD	cis	rs9595908	0.9	rs9595850	ENSG00000212293.1	SNORA16	7.64	1.19e-13	1.02e-10	0.35	0.33	Body mass index;	chr13:32579773	chr13:32420390~32420516:-
LUAD	cis	rs8059260	0.544	rs7205916	ENSG00000274038.1	RP11-66H6.4	-7.64	1.19e-13	1.02e-10	-0.62	-0.33	Alcohol consumption over the past year;	chr16:11095399	chr16:11056556~11057034:+
LUAD	cis	rs10256972	0.63	rs10282584	ENSG00000229043.2	AC091729.9	-7.64	1.19e-13	1.02e-10	-0.35	-0.33	Endometriosis;Longevity;	chr7:1041806	chr7:1160374~1165267:+
LUAD	cis	rs9322193	0.736	rs10457851	ENSG00000223701.3	RAET1E-AS1	7.64	1.2e-13	1.02e-10	0.39	0.33	Lung cancer;	chr6:149775216	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.886	rs10872652	ENSG00000223701.3	RAET1E-AS1	7.64	1.2e-13	1.02e-10	0.39	0.33	Lung cancer;	chr6:149775303	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.886	rs17672976	ENSG00000223701.3	RAET1E-AS1	7.64	1.2e-13	1.02e-10	0.39	0.33	Lung cancer;	chr6:149776207	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs2184369	ENSG00000223701.3	RAET1E-AS1	7.64	1.2e-13	1.02e-10	0.39	0.33	Lung cancer;	chr6:149776681	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs2342861	ENSG00000223701.3	RAET1E-AS1	7.64	1.2e-13	1.02e-10	0.39	0.33	Lung cancer;	chr6:149777561	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.926	rs2342860	ENSG00000223701.3	RAET1E-AS1	7.64	1.2e-13	1.02e-10	0.39	0.33	Lung cancer;	chr6:149777641	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs10872653	ENSG00000223701.3	RAET1E-AS1	7.64	1.2e-13	1.02e-10	0.39	0.33	Lung cancer;	chr6:149778907	chr6:149884431~149919508:+
LUAD	cis	rs9660180	0.78	rs12038111	ENSG00000268575.1	RP1-283E3.8	-7.64	1.2e-13	1.03e-10	-0.3	-0.33	Body mass index;	chr1:1772410	chr1:1702736~1737688:-
LUAD	cis	rs9660180	0.836	rs12038134	ENSG00000268575.1	RP1-283E3.8	-7.64	1.2e-13	1.03e-10	-0.3	-0.33	Body mass index;	chr1:1772426	chr1:1702736~1737688:-
LUAD	cis	rs11089937	0.609	rs2213158	ENSG00000211639.2	IGLV4-60	7.64	1.2e-13	1.03e-10	0.39	0.33	Periodontitis (PAL4Q3);	chr22:22138099	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.637	rs2213159	ENSG00000211639.2	IGLV4-60	7.64	1.2e-13	1.03e-10	0.39	0.33	Periodontitis (PAL4Q3);	chr22:22138100	chr22:22162199~22162681:+
LUAD	cis	rs950880	0.593	rs887971	ENSG00000234389.1	AC007278.3	-7.64	1.2e-13	1.03e-10	-0.33	-0.33	Serum protein levels (sST2);	chr2:102424707	chr2:102438713~102440475:+
LUAD	cis	rs2283792	0.935	rs8141851	ENSG00000224086.5	LL22NC03-86G7.1	-7.64	1.21e-13	1.03e-10	-0.31	-0.33	Multiple sclerosis;	chr22:21812161	chr22:21938293~21977632:+
LUAD	cis	rs673078	0.66	rs17440433	ENSG00000275759.1	RP11-131L12.3	-7.64	1.21e-13	1.03e-10	-0.48	-0.33	Glucose homeostasis traits;	chr12:118201507	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.66	rs17512219	ENSG00000275759.1	RP11-131L12.3	-7.64	1.21e-13	1.03e-10	-0.48	-0.33	Glucose homeostasis traits;	chr12:118211468	chr12:118428281~118428870:+
LUAD	cis	rs35955747	0.677	rs4820974	ENSG00000236132.1	CTA-440B3.1	7.64	1.22e-13	1.04e-10	0.38	0.33	Neutrophil count;Sum basophil neutrophil counts;	chr22:31473481	chr22:31816379~31817491:-
LUAD	cis	rs2455601	0.882	rs11042106	ENSG00000254860.4	TMEM9B-AS1	-7.64	1.22e-13	1.04e-10	-0.49	-0.33	Schizophrenia;	chr11:8874536	chr11:8964675~8977527:+
LUAD	cis	rs1185460	0.565	rs584115	ENSG00000271751.1	RP11-110I1.14	7.63	1.24e-13	1.06e-10	0.42	0.33	Coronary artery disease;	chr11:119068169	chr11:119065263~119065677:-
LUAD	cis	rs904251	0.647	rs2776908	ENSG00000204110.6	RP1-153P14.8	-7.63	1.25e-13	1.07e-10	-0.39	-0.33	Cognitive performance;	chr6:37467081	chr6:37507348~37535616:+
LUAD	cis	rs8059260	0.668	rs7206753	ENSG00000274038.1	RP11-66H6.4	-7.63	1.26e-13	1.07e-10	-0.53	-0.33	Alcohol consumption over the past year;	chr16:10974987	chr16:11056556~11057034:+
LUAD	cis	rs1075265	0.597	rs11694711	ENSG00000233266.1	HMGB1P31	7.63	1.26e-13	1.07e-10	0.41	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53971924	chr2:54051334~54051760:+
LUAD	cis	rs6921919	0.789	rs1119211	ENSG00000204709.4	LINC01556	-7.63	1.26e-13	1.07e-10	-0.45	-0.33	Autism spectrum disorder or schizophrenia;	chr6:28341359	chr6:28943877~28944537:+
LUAD	cis	rs2946504	0.705	rs1879487	ENSG00000251468.2	RP11-369K16.1	-7.63	1.27e-13	1.08e-10	-0.4	-0.33	Type 2 diabetes;	chr8:12947413	chr8:12958387~12962200:+
LUAD	cis	rs4853012	0.838	rs2177707	ENSG00000257800.1	FNBP1P1	7.63	1.27e-13	1.08e-10	0.43	0.33	Gestational age at birth (maternal effect);	chr2:74129723	chr2:74120680~74123218:+
LUAD	cis	rs7646881	1	rs61558956	ENSG00000240207.5	RP11-379F4.4	-7.63	1.27e-13	1.08e-10	-0.39	-0.33	Tetralogy of Fallot;	chr3:158734866	chr3:158732263~158784070:+
LUAD	cis	rs17711722	0.523	rs313812	ENSG00000226824.5	RP4-756H11.3	7.63	1.27e-13	1.09e-10	0.41	0.33	Calcium levels;	chr7:66040056	chr7:66654538~66669855:+
LUAD	cis	rs9487605	1	rs9487605	ENSG00000230177.1	RP5-1112D6.4	-7.63	1.28e-13	1.09e-10	-0.32	-0.33	Inflammatory skin disease;	chr6:111261682	chr6:111277932~111278742:+
LUAD	cis	rs10129255	0.912	rs8011090	ENSG00000280411.1	IGHV1-69-2	-7.63	1.28e-13	1.09e-10	-0.25	-0.33	Kawasaki disease;	chr14:106678896	chr14:106762092~106762588:-
LUAD	cis	rs783540	0.846	rs2099259	ENSG00000278603.1	RP13-608F4.5	7.63	1.28e-13	1.09e-10	0.38	0.33	Schizophrenia;	chr15:82654937	chr15:82472203~82472426:+
LUAD	cis	rs2283792	1	rs3810610	ENSG00000224086.5	LL22NC03-86G7.1	-7.63	1.28e-13	1.09e-10	-0.31	-0.33	Multiple sclerosis;	chr22:21761209	chr22:21938293~21977632:+
LUAD	cis	rs4718428	0.96	rs6460317	ENSG00000226824.5	RP4-756H11.3	-7.63	1.28e-13	1.09e-10	-0.42	-0.33	Corneal structure;	chr7:66925268	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.962	rs9765929	ENSG00000223701.3	RAET1E-AS1	7.63	1.29e-13	1.1e-10	0.38	0.33	Lung cancer;	chr6:149769680	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.567	rs7747457	ENSG00000223701.3	RAET1E-AS1	7.63	1.29e-13	1.1e-10	0.39	0.33	Lung cancer;	chr6:149892366	chr6:149884431~149919508:+
LUAD	cis	rs4660456	0.913	rs4660449	ENSG00000237899.1	RP4-739H11.3	7.63	1.3e-13	1.1e-10	0.45	0.33	Platelet count;	chr1:40739780	chr1:40669089~40687588:-
LUAD	cis	rs526231	0.578	rs1898672	ENSG00000175749.11	EIF3KP1	-7.63	1.3e-13	1.11e-10	-0.45	-0.33	Primary biliary cholangitis;	chr5:102958149	chr5:103032376~103033031:+
LUAD	cis	rs2283792	0.967	rs5999823	ENSG00000224086.5	LL22NC03-86G7.1	-7.63	1.3e-13	1.11e-10	-0.31	-0.33	Multiple sclerosis;	chr22:21856587	chr22:21938293~21977632:+
LUAD	cis	rs9487094	0.67	rs12194061	ENSG00000260273.1	RP11-425D10.10	7.63	1.31e-13	1.11e-10	0.43	0.33	Height;	chr6:109546439	chr6:109382795~109383666:+
LUAD	cis	rs6920372	0.731	rs2357124	ENSG00000260273.1	RP11-425D10.10	7.63	1.31e-13	1.11e-10	0.43	0.33	Height;	chr6:109551060	chr6:109382795~109383666:+
LUAD	cis	rs4853012	0.887	rs77148265	ENSG00000257800.1	FNBP1P1	7.63	1.31e-13	1.12e-10	0.43	0.33	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74120680~74123218:+
LUAD	cis	rs1075265	0.633	rs3731967	ENSG00000233266.1	HMGB1P31	-7.62	1.32e-13	1.12e-10	-0.41	-0.33	Chronotype;Morning vs. evening chronotype;	chr2:53975311	chr2:54051334~54051760:+
LUAD	cis	rs2919917	0.955	rs1441850	ENSG00000254352.1	RP11-578O24.2	-7.62	1.33e-13	1.13e-10	-0.4	-0.33	Lymphocyte counts;	chr8:78745431	chr8:78723796~78724136:-
LUAD	cis	rs8059260	0.668	rs79389789	ENSG00000274038.1	RP11-66H6.4	-7.62	1.33e-13	1.13e-10	-0.59	-0.33	Alcohol consumption over the past year;	chr16:11015168	chr16:11056556~11057034:+
LUAD	cis	rs2581828	0.608	rs9830353	ENSG00000242142.1	SERBP1P3	-7.62	1.33e-13	1.13e-10	-0.37	-0.33	Crohn's disease;	chr3:53129937	chr3:53064283~53065091:-
LUAD	cis	rs9640161	0.789	rs2098053	ENSG00000261305.1	RP4-584D14.7	7.62	1.33e-13	1.13e-10	0.5	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150346116	chr7:150341771~150342607:+
LUAD	cis	rs765787	0.53	rs3759895	ENSG00000259520.4	CTD-2651B20.3	7.62	1.33e-13	1.13e-10	0.43	0.33	Uric acid levels;	chr15:45251672	chr15:45251580~45279251:-
LUAD	cis	rs2153535	0.58	rs1360054	ENSG00000230939.1	RP11-314C16.1	-7.62	1.35e-13	1.14e-10	-0.39	-0.33	Motion sickness;	chr6:8520144	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9328483	ENSG00000230939.1	RP11-314C16.1	-7.62	1.35e-13	1.14e-10	-0.39	-0.33	Motion sickness;	chr6:8521062	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9393033	ENSG00000230939.1	RP11-314C16.1	-7.62	1.35e-13	1.14e-10	-0.39	-0.33	Motion sickness;	chr6:8521213	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.541	rs6938688	ENSG00000230939.1	RP11-314C16.1	-7.62	1.35e-13	1.14e-10	-0.39	-0.33	Motion sickness;	chr6:8521396	chr6:8784178~8785445:+
LUAD	cis	rs62229266	0.626	rs2835268	ENSG00000231106.2	LINC01436	7.62	1.35e-13	1.15e-10	0.44	0.33	Mitral valve prolapse;	chr21:36076838	chr21:36005338~36007838:+
LUAD	cis	rs11676348	0.729	rs13013361	ENSG00000261338.2	RP11-378A13.1	-7.62	1.35e-13	1.15e-10	-0.34	-0.33	Ulcerative colitis;	chr2:218082792	chr2:218255319~218257366:+
LUAD	cis	rs4853012	0.838	rs61521879	ENSG00000257800.1	FNBP1P1	7.62	1.36e-13	1.15e-10	0.39	0.33	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74120680~74123218:+
LUAD	cis	rs9322193	0.607	rs9383941	ENSG00000216906.2	RP11-350J20.9	-7.62	1.36e-13	1.15e-10	-0.47	-0.33	Lung cancer;	chr6:149912100	chr6:149904243~149906418:+
LUAD	cis	rs10129255	0.957	rs4387509	ENSG00000211972.2	IGHV3-66	7.62	1.36e-13	1.15e-10	0.29	0.33	Kawasaki disease;	chr14:106704386	chr14:106675017~106675544:-
LUAD	cis	rs7429990	0.931	rs62262084	ENSG00000229759.1	MRPS18AP1	7.62	1.36e-13	1.16e-10	0.39	0.33	Educational attainment (years of education);	chr3:47612332	chr3:48256350~48256938:-
LUAD	cis	rs2153535	0.58	rs9505467	ENSG00000230939.1	RP11-314C16.1	-7.62	1.36e-13	1.16e-10	-0.39	-0.33	Motion sickness;	chr6:8519986	chr6:8784178~8785445:+
LUAD	cis	rs7684253	0.565	rs13108570	ENSG00000269949.1	RP11-738E22.3	-7.62	1.37e-13	1.16e-10	-0.44	-0.33	Migraine;	chr4:56940917	chr4:56960927~56961373:-
LUAD	cis	rs2283792	0.935	rs2283794	ENSG00000224086.5	LL22NC03-86G7.1	-7.62	1.37e-13	1.17e-10	-0.31	-0.33	Multiple sclerosis;	chr22:21858180	chr22:21938293~21977632:+
LUAD	cis	rs4660456	0.826	rs507914	ENSG00000237899.1	RP4-739H11.3	7.62	1.38e-13	1.17e-10	0.46	0.33	Platelet count;	chr1:40686529	chr1:40669089~40687588:-
LUAD	cis	rs11089937	0.539	rs6001075	ENSG00000211639.2	IGLV4-60	7.62	1.38e-13	1.17e-10	0.39	0.33	Periodontitis (PAL4Q3);	chr22:22133765	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.597	rs6001076	ENSG00000211639.2	IGLV4-60	7.62	1.38e-13	1.17e-10	0.39	0.33	Periodontitis (PAL4Q3);	chr22:22133873	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.597	rs5995560	ENSG00000211639.2	IGLV4-60	7.62	1.38e-13	1.17e-10	0.39	0.33	Periodontitis (PAL4Q3);	chr22:22133989	chr22:22162199~22162681:+
LUAD	cis	rs2739330	0.703	rs5760112	ENSG00000228039.3	KB-1125A3.10	7.62	1.39e-13	1.18e-10	0.4	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23963780~23964374:+
LUAD	cis	rs9640161	0.673	rs34489187	ENSG00000261305.1	RP4-584D14.7	7.62	1.39e-13	1.18e-10	0.5	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150347290	chr7:150341771~150342607:+
LUAD	cis	rs2919917	0.628	rs6990105	ENSG00000254352.1	RP11-578O24.2	7.62	1.39e-13	1.18e-10	0.43	0.33	Lymphocyte counts;	chr8:78689652	chr8:78723796~78724136:-
LUAD	cis	rs9640161	0.75	rs3735167	ENSG00000261305.1	RP4-584D14.7	7.62	1.39e-13	1.18e-10	0.51	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150342466	chr7:150341771~150342607:+
LUAD	cis	rs9322193	0.926	rs9383546	ENSG00000223701.3	RAET1E-AS1	7.62	1.39e-13	1.18e-10	0.39	0.33	Lung cancer;	chr6:149822743	chr6:149884431~149919508:+
LUAD	cis	rs9640161	0.75	rs11765644	ENSG00000261305.1	RP4-584D14.7	7.62	1.4e-13	1.18e-10	0.49	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150329250	chr7:150341771~150342607:+
LUAD	cis	rs9545047	0.604	rs7322901	ENSG00000227676.3	LINC01068	7.62	1.4e-13	1.19e-10	0.38	0.33	Schizophrenia;	chr13:79383505	chr13:79566727~79571436:+
LUAD	cis	rs526231	0.543	rs171558	ENSG00000175749.11	EIF3KP1	7.62	1.41e-13	1.19e-10	0.48	0.33	Primary biliary cholangitis;	chr5:103242193	chr5:103032376~103033031:+
LUAD	cis	rs150992	0.711	rs2617507	ENSG00000248489.1	CTD-2007H13.3	7.62	1.41e-13	1.19e-10	0.36	0.33	Body mass index;	chr5:98912548	chr5:98929171~98995013:+
LUAD	cis	rs2283792	1	rs13943	ENSG00000224086.5	LL22NC03-86G7.1	-7.62	1.41e-13	1.19e-10	-0.31	-0.33	Multiple sclerosis;	chr22:21761913	chr22:21938293~21977632:+
LUAD	cis	rs7688540	0.771	rs12505835	ENSG00000275426.1	CH17-262A2.1	7.62	1.41e-13	1.19e-10	0.48	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:303736	chr4:149738~150317:+
LUAD	cis	rs8059260	0.736	rs113120936	ENSG00000274038.1	RP11-66H6.4	-7.61	1.42e-13	1.2e-10	-0.6	-0.33	Alcohol consumption over the past year;	chr16:10989474	chr16:11056556~11057034:+
LUAD	cis	rs950880	0.71	rs66566526	ENSG00000234389.1	AC007278.3	-7.61	1.42e-13	1.2e-10	-0.33	-0.33	Serum protein levels (sST2);	chr2:102431342	chr2:102438713~102440475:+
LUAD	cis	rs3931020	0.508	rs11485298	ENSG00000272864.1	RP11-17E13.2	-7.61	1.42e-13	1.2e-10	-0.42	-0.33	Resistin levels;	chr1:74752068	chr1:74698769~74699333:-
LUAD	cis	rs3931020	0.508	rs4145871	ENSG00000272864.1	RP11-17E13.2	-7.61	1.42e-13	1.2e-10	-0.42	-0.33	Resistin levels;	chr1:74753020	chr1:74698769~74699333:-
LUAD	cis	rs11676348	1	rs11676348	ENSG00000261338.2	RP11-378A13.1	-7.61	1.43e-13	1.21e-10	-0.35	-0.33	Ulcerative colitis;	chr2:218145423	chr2:218255319~218257366:+
LUAD	cis	rs237743	1	rs6648	ENSG00000222365.1	SNORD12B	-7.61	1.43e-13	1.21e-10	-0.37	-0.33	Height;	chr20:49278705	chr20:49280319~49280409:+
LUAD	cis	rs237743	1	rs238198	ENSG00000222365.1	SNORD12B	-7.61	1.43e-13	1.21e-10	-0.37	-0.33	Height;	chr20:49282523	chr20:49280319~49280409:+
LUAD	cis	rs237743	1	rs237741	ENSG00000222365.1	SNORD12B	-7.61	1.43e-13	1.21e-10	-0.37	-0.33	Height;	chr20:49287143	chr20:49280319~49280409:+
LUAD	cis	rs237743	1	rs13038621	ENSG00000222365.1	SNORD12B	-7.61	1.43e-13	1.21e-10	-0.37	-0.33	Height;	chr20:49291523	chr20:49280319~49280409:+
LUAD	cis	rs9545047	0.716	rs9530920	ENSG00000227676.3	LINC01068	7.61	1.43e-13	1.21e-10	0.41	0.33	Schizophrenia;	chr13:79423254	chr13:79566727~79571436:+
LUAD	cis	rs9487094	0.67	rs10782163	ENSG00000260273.1	RP11-425D10.10	7.61	1.44e-13	1.21e-10	0.43	0.33	Height;	chr6:109533040	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.67	rs10457195	ENSG00000260273.1	RP11-425D10.10	7.61	1.44e-13	1.21e-10	0.43	0.33	Height;	chr6:109534269	chr6:109382795~109383666:+
LUAD	cis	rs10129255	1	rs61997605	ENSG00000280411.1	IGHV1-69-2	-7.61	1.44e-13	1.22e-10	-0.25	-0.33	Kawasaki disease;	chr14:106678368	chr14:106762092~106762588:-
LUAD	cis	rs10129255	1	rs8012033	ENSG00000280411.1	IGHV1-69-2	-7.61	1.44e-13	1.22e-10	-0.25	-0.33	Kawasaki disease;	chr14:106678854	chr14:106762092~106762588:-
LUAD	cis	rs9595908	1	rs718444	ENSG00000212293.1	SNORA16	7.61	1.44e-13	1.22e-10	0.37	0.33	Body mass index;	chr13:32572915	chr13:32420390~32420516:-
LUAD	cis	rs9595908	1	rs7332115	ENSG00000212293.1	SNORA16	7.61	1.44e-13	1.22e-10	0.37	0.33	Body mass index;	chr13:32573411	chr13:32420390~32420516:-
LUAD	cis	rs9595908	1	rs7332763	ENSG00000212293.1	SNORA16	7.61	1.44e-13	1.22e-10	0.37	0.33	Body mass index;	chr13:32573751	chr13:32420390~32420516:-
LUAD	cis	rs9595908	1	rs9591134	ENSG00000212293.1	SNORA16	7.61	1.44e-13	1.22e-10	0.37	0.33	Body mass index;	chr13:32574079	chr13:32420390~32420516:-
LUAD	cis	rs5769707	0.632	rs1476037	ENSG00000188511.11	C22orf34	7.61	1.45e-13	1.22e-10	0.4	0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49597729	chr22:49414524~49657542:-
LUAD	cis	rs8005677	1	rs8014936	ENSG00000279656.1	RP11-298I3.6	7.61	1.45e-13	1.22e-10	0.39	0.33	Cognitive ability (multi-trait analysis);	chr14:22905936	chr14:23023083~23024217:-
LUAD	cis	rs8005677	1	rs8016061	ENSG00000279656.1	RP11-298I3.6	7.61	1.45e-13	1.22e-10	0.39	0.33	Cognitive ability (multi-trait analysis);	chr14:22906600	chr14:23023083~23024217:-
LUAD	cis	rs8005677	1	rs8005677	ENSG00000279656.1	RP11-298I3.6	7.61	1.45e-13	1.22e-10	0.39	0.33	Cognitive ability (multi-trait analysis);	chr14:22907469	chr14:23023083~23024217:-
LUAD	cis	rs8005677	1	rs8006396	ENSG00000279656.1	RP11-298I3.6	7.61	1.45e-13	1.22e-10	0.39	0.33	Cognitive ability (multi-trait analysis);	chr14:22911641	chr14:23023083~23024217:-
LUAD	cis	rs8005677	1	rs4981446	ENSG00000279656.1	RP11-298I3.6	7.61	1.45e-13	1.22e-10	0.39	0.33	Cognitive ability (multi-trait analysis);	chr14:22912204	chr14:23023083~23024217:-
LUAD	cis	rs8005677	1	rs4982706	ENSG00000279656.1	RP11-298I3.6	7.61	1.45e-13	1.22e-10	0.39	0.33	Cognitive ability (multi-trait analysis);	chr14:22912488	chr14:23023083~23024217:-
LUAD	cis	rs8005677	0.926	rs34344888	ENSG00000279656.1	RP11-298I3.6	7.61	1.45e-13	1.22e-10	0.39	0.33	Cognitive ability (multi-trait analysis);	chr14:22918376	chr14:23023083~23024217:-
LUAD	cis	rs8005677	0.962	rs34917191	ENSG00000279656.1	RP11-298I3.6	7.61	1.45e-13	1.22e-10	0.39	0.33	Cognitive ability (multi-trait analysis);	chr14:22918419	chr14:23023083~23024217:-
LUAD	cis	rs8005677	1	rs1951119	ENSG00000279656.1	RP11-298I3.6	7.61	1.45e-13	1.22e-10	0.39	0.33	Cognitive ability (multi-trait analysis);	chr14:22919117	chr14:23023083~23024217:-
LUAD	cis	rs8005677	1	rs2295683	ENSG00000279656.1	RP11-298I3.6	7.61	1.45e-13	1.22e-10	0.39	0.33	Cognitive ability (multi-trait analysis);	chr14:22919173	chr14:23023083~23024217:-
LUAD	cis	rs8005677	1	rs4981449	ENSG00000279656.1	RP11-298I3.6	7.61	1.45e-13	1.22e-10	0.39	0.33	Cognitive ability (multi-trait analysis);	chr14:22919662	chr14:23023083~23024217:-
LUAD	cis	rs7646881	0.812	rs75267618	ENSG00000240207.5	RP11-379F4.4	-7.61	1.45e-13	1.22e-10	-0.42	-0.33	Tetralogy of Fallot;	chr3:158726027	chr3:158732263~158784070:+
LUAD	cis	rs1185460	0.565	rs1182922	ENSG00000271751.1	RP11-110I1.14	7.61	1.46e-13	1.24e-10	0.42	0.33	Coronary artery disease;	chr11:119062148	chr11:119065263~119065677:-
LUAD	cis	rs8177876	0.749	rs10459872	ENSG00000261838.4	RP11-303E16.6	-7.61	1.47e-13	1.24e-10	-0.68	-0.33	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81061346	chr16:81069854~81076598:+
LUAD	cis	rs10463554	0.857	rs3776871	ENSG00000175749.11	EIF3KP1	7.61	1.48e-13	1.25e-10	0.45	0.33	Parkinson's disease;	chr5:102956507	chr5:103032376~103033031:+
LUAD	cis	rs853679	0.517	rs6932109	ENSG00000219392.1	RP1-265C24.5	7.61	1.48e-13	1.25e-10	0.45	0.33	Depression;	chr6:28110525	chr6:28115628~28116551:+
LUAD	cis	rs8005677	1	rs1956881	ENSG00000279656.1	RP11-298I3.6	7.61	1.48e-13	1.25e-10	0.39	0.33	Cognitive ability (multi-trait analysis);	chr14:22924860	chr14:23023083~23024217:-
LUAD	cis	rs7684253	0.565	rs6830774	ENSG00000269949.1	RP11-738E22.3	-7.61	1.48e-13	1.25e-10	-0.44	-0.33	Migraine;	chr4:56950140	chr4:56960927~56961373:-
LUAD	cis	rs944289	0.74	rs4982333	ENSG00000257826.1	RP11-116N8.4	-7.61	1.48e-13	1.25e-10	-0.35	-0.33	Thyroid cancer;	chr14:36100842	chr14:36061026~36067190:-
LUAD	cis	rs4660456	0.826	rs2744802	ENSG00000237899.1	RP4-739H11.3	7.61	1.48e-13	1.25e-10	0.45	0.33	Platelet count;	chr1:40687577	chr1:40669089~40687588:-
LUAD	cis	rs6142102	0.923	rs3787230	ENSG00000276073.1	RP5-1125A11.7	-7.61	1.49e-13	1.26e-10	-0.33	-0.33	Skin pigmentation;	chr20:34052466	chr20:33985617~33988989:-
LUAD	cis	rs732716	0.889	rs62129355	ENSG00000267769.1	CTB-50L17.9	-7.61	1.5e-13	1.27e-10	-0.35	-0.33	Mean corpuscular volume;	chr19:4397037	chr19:4454014~4455286:+
LUAD	cis	rs9487094	0.696	rs11153188	ENSG00000260273.1	RP11-425D10.10	7.6	1.51e-13	1.27e-10	0.43	0.33	Height;	chr6:109558247	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.67	rs11752791	ENSG00000260273.1	RP11-425D10.10	7.6	1.51e-13	1.27e-10	0.43	0.33	Height;	chr6:109564443	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.67	rs12214639	ENSG00000260273.1	RP11-425D10.10	7.6	1.51e-13	1.27e-10	0.43	0.33	Height;	chr6:109576414	chr6:109382795~109383666:+
LUAD	cis	rs2015599	0.549	rs7134796	ENSG00000257176.2	RP11-996F15.2	7.6	1.51e-13	1.27e-10	0.35	0.33	Platelet count;Mean platelet volume;	chr12:29294361	chr12:29280418~29317848:-
LUAD	cis	rs8031584	0.678	rs3122	ENSG00000260382.1	RP11-540B6.2	-7.6	1.51e-13	1.28e-10	-0.4	-0.33	Huntington's disease progression;	chr15:30878087	chr15:30882267~30883231:-
LUAD	cis	rs9487094	0.67	rs2277114	ENSG00000260273.1	RP11-425D10.10	7.6	1.51e-13	1.28e-10	0.41	0.33	Height;	chr6:109506513	chr6:109382795~109383666:+
LUAD	cis	rs6452524	0.766	rs2252179	ENSG00000249664.1	CTD-2227C6.2	-7.6	1.52e-13	1.28e-10	-0.39	-0.33	Hypertension (SNP x SNP interaction);	chr5:83145630	chr5:83012285~83013109:-
LUAD	cis	rs9487094	0.67	rs34928881	ENSG00000260273.1	RP11-425D10.10	7.6	1.52e-13	1.28e-10	0.43	0.33	Height;	chr6:109526846	chr6:109382795~109383666:+
LUAD	cis	rs1729407	0.695	rs1263176	ENSG00000254851.1	RP11-109L13.1	-7.6	1.52e-13	1.28e-10	-0.41	-0.33	Apolipoprotein A-IV levels;	chr11:116819407	chr11:117135528~117138582:+
LUAD	cis	rs2153535	0.58	rs6421948	ENSG00000230939.1	RP11-314C16.1	-7.6	1.52e-13	1.29e-10	-0.39	-0.33	Motion sickness;	chr6:8530787	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs6421949	ENSG00000230939.1	RP11-314C16.1	-7.6	1.53e-13	1.29e-10	-0.39	-0.33	Motion sickness;	chr6:8531536	chr6:8784178~8785445:+
LUAD	cis	rs9322193	0.923	rs9767105	ENSG00000223701.3	RAET1E-AS1	7.6	1.53e-13	1.29e-10	0.39	0.33	Lung cancer;	chr6:149659591	chr6:149884431~149919508:+
LUAD	cis	rs12468226	0.752	rs116078354	ENSG00000273456.1	RP11-686O6.2	7.6	1.53e-13	1.29e-10	0.5	0.33	Urate levels;	chr2:202136356	chr2:202374932~202375604:-
LUAD	cis	rs2581828	0.618	rs9838517	ENSG00000242142.1	SERBP1P3	-7.6	1.54e-13	1.3e-10	-0.36	-0.33	Crohn's disease;	chr3:53110347	chr3:53064283~53065091:-
LUAD	cis	rs9322193	0.926	rs3805751	ENSG00000223701.3	RAET1E-AS1	7.6	1.54e-13	1.3e-10	0.38	0.33	Lung cancer;	chr6:149791193	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs10872656	ENSG00000223701.3	RAET1E-AS1	7.6	1.54e-13	1.3e-10	0.38	0.33	Lung cancer;	chr6:149799444	chr6:149884431~149919508:+
LUAD	cis	rs13423976	1	rs13423976	ENSG00000231367.4	AC016995.3	-7.6	1.54e-13	1.3e-10	-0.43	-0.33	Gut microbiome composition (summer);	chr2:38518482	chr2:38406719~38515740:-
LUAD	cis	rs2015599	0.623	rs2288128	ENSG00000257176.2	RP11-996F15.2	7.6	1.54e-13	1.3e-10	0.35	0.33	Platelet count;Mean platelet volume;	chr12:29316054	chr12:29280418~29317848:-
LUAD	cis	rs2015599	0.584	rs2288129	ENSG00000257176.2	RP11-996F15.2	7.6	1.54e-13	1.3e-10	0.35	0.33	Platelet count;Mean platelet volume;	chr12:29316355	chr12:29280418~29317848:-
LUAD	cis	rs8005677	1	rs7155857	ENSG00000279656.1	RP11-298I3.6	7.6	1.54e-13	1.3e-10	0.39	0.33	Cognitive ability (multi-trait analysis);	chr14:22930850	chr14:23023083~23024217:-
LUAD	cis	rs944289	0.708	rs1953120	ENSG00000257826.1	RP11-116N8.4	-7.6	1.56e-13	1.31e-10	-0.34	-0.33	Thyroid cancer;	chr14:36105724	chr14:36061026~36067190:-
LUAD	cis	rs7429990	0.965	rs34507589	ENSG00000229759.1	MRPS18AP1	7.6	1.57e-13	1.32e-10	0.39	0.33	Educational attainment (years of education);	chr3:47832552	chr3:48256350~48256938:-
LUAD	cis	rs9326248	0.53	rs2127905	ENSG00000280143.1	AP000892.6	7.6	1.57e-13	1.32e-10	0.52	0.33	Blood protein levels;	chr11:117155658	chr11:117204967~117210292:+
LUAD	cis	rs765787	0.53	rs2668751	ENSG00000259520.4	CTD-2651B20.3	7.6	1.57e-13	1.32e-10	0.43	0.33	Uric acid levels;	chr15:45225095	chr15:45251580~45279251:-
LUAD	cis	rs9322193	0.962	rs9689447	ENSG00000223701.3	RAET1E-AS1	7.6	1.57e-13	1.32e-10	0.39	0.33	Lung cancer;	chr6:149789350	chr6:149884431~149919508:+
LUAD	cis	rs1501911	0.53	rs751878	ENSG00000248489.1	CTD-2007H13.3	7.6	1.57e-13	1.33e-10	0.37	0.33	Lung function (FEV1/FVC);	chr5:98827240	chr5:98929171~98995013:+
LUAD	cis	rs853679	0.527	rs853690	ENSG00000216901.1	AL022393.7	7.6	1.58e-13	1.33e-10	0.39	0.33	Depression;	chr6:28317705	chr6:28176188~28176674:+
LUAD	cis	rs10200159	1	rs12616982	ENSG00000272606.1	RP11-554J4.1	7.6	1.59e-13	1.34e-10	0.54	0.33	Vitiligo;	chr2:55647676	chr2:55617909~55618373:+
LUAD	cis	rs10200159	1	rs13407344	ENSG00000272606.1	RP11-554J4.1	7.6	1.59e-13	1.34e-10	0.54	0.33	Vitiligo;	chr2:55648233	chr2:55617909~55618373:+
LUAD	cis	rs10200159	1	rs13382187	ENSG00000272606.1	RP11-554J4.1	7.6	1.59e-13	1.34e-10	0.54	0.33	Vitiligo;	chr2:55648611	chr2:55617909~55618373:+
LUAD	cis	rs10129255	0.789	rs61997796	ENSG00000280411.1	IGHV1-69-2	-7.6	1.59e-13	1.34e-10	-0.26	-0.33	Kawasaki disease;	chr14:106813798	chr14:106762092~106762588:-
LUAD	cis	rs8005677	1	rs1043209	ENSG00000279656.1	RP11-298I3.6	-7.6	1.6e-13	1.35e-10	-0.39	-0.33	Cognitive ability (multi-trait analysis);	chr14:22904777	chr14:23023083~23024217:-
LUAD	cis	rs853679	0.527	rs707907	ENSG00000216901.1	AL022393.7	7.6	1.61e-13	1.35e-10	0.39	0.33	Depression;	chr6:28323463	chr6:28176188~28176674:+
LUAD	cis	rs9595908	0.865	rs499966	ENSG00000212293.1	SNORA16	-7.6	1.62e-13	1.36e-10	-0.36	-0.33	Body mass index;	chr13:32424473	chr13:32420390~32420516:-
LUAD	cis	rs7684253	0.565	rs7697176	ENSG00000269949.1	RP11-738E22.3	-7.6	1.62e-13	1.36e-10	-0.44	-0.33	Migraine;	chr4:56956882	chr4:56960927~56961373:-
LUAD	cis	rs7684253	0.565	rs7680140	ENSG00000269949.1	RP11-738E22.3	-7.59	1.62e-13	1.36e-10	-0.44	-0.33	Migraine;	chr4:56957291	chr4:56960927~56961373:-
LUAD	cis	rs6700559	0.81	rs10399615	ENSG00000260088.1	RP11-92G12.3	7.59	1.62e-13	1.36e-10	0.42	0.33	Coronary artery disease;	chr1:200626145	chr1:200669507~200694250:+
LUAD	cis	rs9326248	0.53	rs7112513	ENSG00000280143.1	AP000892.6	7.59	1.62e-13	1.36e-10	0.52	0.33	Blood protein levels;	chr11:117166645	chr11:117204967~117210292:+
LUAD	cis	rs1501911	0.53	rs161942	ENSG00000248489.1	CTD-2007H13.3	7.59	1.62e-13	1.36e-10	0.36	0.33	Lung function (FEV1/FVC);	chr5:98868016	chr5:98929171~98995013:+
LUAD	cis	rs9322193	0.962	rs1413655	ENSG00000223701.3	RAET1E-AS1	7.59	1.63e-13	1.37e-10	0.39	0.33	Lung cancer;	chr6:149821815	chr6:149884431~149919508:+
LUAD	cis	rs638893	0.636	rs7119702	ENSG00000278376.1	RP11-158I9.8	-7.59	1.64e-13	1.38e-10	-0.5	-0.33	Vitiligo;	chr11:118736985	chr11:118791254~118793137:+
LUAD	cis	rs9532669	0.926	rs9532689	ENSG00000176268.5	CYCSP34	7.59	1.64e-13	1.38e-10	0.31	0.33	Cervical cancer;	chr13:40957990	chr13:40863599~40863902:-
LUAD	cis	rs944289	0.774	rs1958625	ENSG00000257826.1	RP11-116N8.4	-7.59	1.66e-13	1.39e-10	-0.34	-0.33	Thyroid cancer;	chr14:36133470	chr14:36061026~36067190:-
LUAD	cis	rs11155671	0.53	rs4870080	ENSG00000223701.3	RAET1E-AS1	7.59	1.66e-13	1.39e-10	0.38	0.33	Testicular germ cell tumor;	chr6:149881508	chr6:149884431~149919508:+
LUAD	cis	rs9287719	0.837	rs4233882	ENSG00000234818.1	AC092687.5	7.59	1.66e-13	1.4e-10	0.39	0.33	Prostate cancer;	chr2:10615438	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.837	rs4331474	ENSG00000234818.1	AC092687.5	7.59	1.66e-13	1.4e-10	0.39	0.33	Prostate cancer;	chr2:10615457	chr2:10589166~10604830:+
LUAD	cis	rs17608059	0.611	rs2108591	ENSG00000141028.6	CDRT15P1	-7.59	1.67e-13	1.4e-10	-0.37	-0.33	Temperament;	chr17:14019308	chr17:14024514~14025488:+
LUAD	cis	rs9322193	0.566	rs3922947	ENSG00000216906.2	RP11-350J20.9	-7.59	1.67e-13	1.4e-10	-0.47	-0.33	Lung cancer;	chr6:149924856	chr6:149904243~149906418:+
LUAD	cis	rs9545047	0.604	rs7331872	ENSG00000227676.3	LINC01068	-7.59	1.68e-13	1.41e-10	-0.39	-0.33	Schizophrenia;	chr13:79388717	chr13:79566727~79571436:+
LUAD	cis	rs853679	0.542	rs6934769	ENSG00000219392.1	RP1-265C24.5	-7.59	1.69e-13	1.41e-10	-0.46	-0.33	Depression;	chr6:28123153	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs17711801	ENSG00000219392.1	RP1-265C24.5	-7.59	1.69e-13	1.41e-10	-0.46	-0.33	Depression;	chr6:28124529	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs6922063	ENSG00000219392.1	RP1-265C24.5	-7.59	1.69e-13	1.41e-10	-0.46	-0.33	Depression;	chr6:28126588	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs2275508	ENSG00000219392.1	RP1-265C24.5	-7.59	1.69e-13	1.41e-10	-0.46	-0.33	Depression;	chr6:28126953	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.527	rs9461433	ENSG00000219392.1	RP1-265C24.5	-7.59	1.69e-13	1.41e-10	-0.46	-0.33	Parkinson's disease;	chr6:28127394	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9468292	ENSG00000219392.1	RP1-265C24.5	-7.59	1.69e-13	1.41e-10	-0.46	-0.33	Depression;	chr6:28127577	chr6:28115628~28116551:+
LUAD	cis	rs6504622	0.755	rs12942936	ENSG00000262879.4	RP11-156P1.3	-7.59	1.69e-13	1.42e-10	-0.37	-0.33	Orofacial clefts;	chr17:47075062	chr17:46984045~47100323:-
LUAD	cis	rs3096299	0.933	rs2965938	ENSG00000274627.1	RP11-104N10.2	7.59	1.69e-13	1.42e-10	0.31	0.33	Multiple myeloma (IgH translocation);	chr16:89424928	chr16:89516797~89522217:+
LUAD	cis	rs944289	0.708	rs11622885	ENSG00000257826.1	RP11-116N8.4	-7.59	1.69e-13	1.42e-10	-0.35	-0.33	Thyroid cancer;	chr14:36095036	chr14:36061026~36067190:-
LUAD	cis	rs6921919	0.789	rs6456814	ENSG00000204709.4	LINC01556	7.59	1.69e-13	1.42e-10	0.46	0.33	Autism spectrum disorder or schizophrenia;	chr6:28338035	chr6:28943877~28944537:+
LUAD	cis	rs12134133	0.752	rs4844579	ENSG00000274245.1	RP11-357P18.2	7.59	1.7e-13	1.42e-10	0.47	0.33	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207204546	chr1:207372559~207373252:+
LUAD	cis	rs10463554	0.857	rs3776873	ENSG00000175749.11	EIF3KP1	7.59	1.7e-13	1.42e-10	0.45	0.33	Parkinson's disease;	chr5:102946768	chr5:103032376~103033031:+
LUAD	cis	rs2283792	1	rs3788332	ENSG00000224086.5	LL22NC03-86G7.1	-7.59	1.71e-13	1.43e-10	-0.31	-0.33	Multiple sclerosis;	chr22:21817278	chr22:21938293~21977632:+
LUAD	cis	rs1322639	0.614	rs4708414	ENSG00000261039.2	RP11-417E7.2	-7.59	1.71e-13	1.43e-10	-0.41	-0.33	Pulse pressure;	chr6:169174049	chr6:169175304~169182740:-
LUAD	cis	rs2739330	0.76	rs5760095	ENSG00000206090.4	AP000350.7	7.59	1.71e-13	1.44e-10	0.37	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23939998~23942798:+
LUAD	cis	rs2412819	0.571	rs495880	ENSG00000205771.5	CATSPER2P1	7.59	1.71e-13	1.44e-10	0.49	0.33	Lung cancer;	chr15:43855067	chr15:43726918~43747094:-
LUAD	cis	rs4660456	0.912	rs658806	ENSG00000237899.1	RP4-739H11.3	7.59	1.72e-13	1.44e-10	0.45	0.33	Platelet count;	chr1:40683312	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.871	rs671704	ENSG00000237899.1	RP4-739H11.3	7.59	1.72e-13	1.44e-10	0.45	0.33	Platelet count;	chr1:40683974	chr1:40669089~40687588:-
LUAD	cis	rs7182621	0.639	rs1561048	ENSG00000182397.13	DNM1P46	7.59	1.72e-13	1.44e-10	0.44	0.33	Colonoscopy-negative controls vs population controls;	chr15:99875369	chr15:99790156~99806927:-
LUAD	cis	rs9549367	0.713	rs510160	ENSG00000269125.1	RP11-98F14.11	7.59	1.72e-13	1.44e-10	0.41	0.33	Platelet distribution width;	chr13:113168167	chr13:113165002~113165183:-
LUAD	cis	rs4927850	0.521	rs4927679	ENSG00000231464.1	AC024937.4	-7.59	1.73e-13	1.44e-10	-0.34	-0.33	Pancreatic cancer;	chr3:195931489	chr3:195996738~195998233:+
LUAD	cis	rs6504950	0.785	rs2628304	ENSG00000275710.1	RP11-257O5.4	-7.59	1.73e-13	1.45e-10	-0.41	-0.33	Breast cancer;	chr17:55079828	chr17:54964474~54964679:+
LUAD	cis	rs2283792	1	rs6518986	ENSG00000224086.5	LL22NC03-86G7.1	-7.59	1.73e-13	1.45e-10	-0.31	-0.33	Multiple sclerosis;	chr22:21831058	chr22:21938293~21977632:+
LUAD	cis	rs2283792	1	rs1892846	ENSG00000224086.5	LL22NC03-86G7.1	-7.59	1.73e-13	1.45e-10	-0.31	-0.33	Multiple sclerosis;	chr22:21832190	chr22:21938293~21977632:+
LUAD	cis	rs2283792	1	rs1892848	ENSG00000224086.5	LL22NC03-86G7.1	-7.59	1.73e-13	1.45e-10	-0.31	-0.33	Multiple sclerosis;	chr22:21832273	chr22:21938293~21977632:+
LUAD	cis	rs2283792	1	rs5999750	ENSG00000224086.5	LL22NC03-86G7.1	-7.59	1.73e-13	1.45e-10	-0.31	-0.33	Multiple sclerosis;	chr22:21833720	chr22:21938293~21977632:+
LUAD	cis	rs4718428	0.672	rs4718412	ENSG00000226824.5	RP4-756H11.3	7.58	1.74e-13	1.45e-10	0.44	0.33	Corneal structure;	chr7:66821880	chr7:66654538~66669855:+
LUAD	cis	rs4660456	0.826	rs3767952	ENSG00000237899.1	RP4-739H11.3	-7.58	1.74e-13	1.46e-10	-0.46	-0.33	Platelet count;	chr1:40765360	chr1:40669089~40687588:-
LUAD	cis	rs9595908	1	rs9595905	ENSG00000212293.1	SNORA16	7.58	1.74e-13	1.46e-10	0.35	0.33	Body mass index;	chr13:32609266	chr13:32420390~32420516:-
LUAD	cis	rs6700559	0.81	rs7529962	ENSG00000260088.1	RP11-92G12.3	-7.58	1.74e-13	1.46e-10	-0.4	-0.33	Coronary artery disease;	chr1:200627849	chr1:200669507~200694250:+
LUAD	cis	rs34375054	0.738	rs10773145	ENSG00000279233.1	RP11-158L12.4	-7.58	1.77e-13	1.48e-10	-0.26	-0.33	Post bronchodilator FEV1/FVC ratio;	chr12:125141057	chr12:125138245~125141711:+
LUAD	cis	rs9322193	0.884	rs62439837	ENSG00000223701.3	RAET1E-AS1	7.58	1.77e-13	1.48e-10	0.39	0.33	Lung cancer;	chr6:149670380	chr6:149884431~149919508:+
LUAD	cis	rs17482078	0.959	rs10043309	ENSG00000248734.2	CTD-2260A17.1	7.58	1.78e-13	1.49e-10	0.41	0.33	Behcet's disease;Blood protein levels;	chr5:96804163	chr5:96784777~96785999:+
LUAD	cis	rs17482078	0.959	rs10041240	ENSG00000248734.2	CTD-2260A17.1	7.58	1.78e-13	1.49e-10	0.41	0.33	Behcet's disease;Blood protein levels;	chr5:96805037	chr5:96784777~96785999:+
LUAD	cis	rs9322193	0.962	rs6914319	ENSG00000223701.3	RAET1E-AS1	7.58	1.79e-13	1.5e-10	0.38	0.33	Lung cancer;	chr6:149806304	chr6:149884431~149919508:+
LUAD	cis	rs7567389	0.6	rs3732209	ENSG00000236682.1	AC068282.3	-7.58	1.79e-13	1.5e-10	-0.45	-0.33	Self-rated health;	chr2:127322230	chr2:127389130~127400580:+
LUAD	cis	rs9640161	0.75	rs11538922	ENSG00000261305.1	RP4-584D14.7	7.58	1.8e-13	1.5e-10	0.5	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150338094	chr7:150341771~150342607:+
LUAD	cis	rs8177876	0.749	rs2287995	ENSG00000261838.4	RP11-303E16.6	7.58	1.81e-13	1.51e-10	0.72	0.33	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81061494	chr16:81069854~81076598:+
LUAD	cis	rs6142102	0.961	rs1055857	ENSG00000276073.1	RP5-1125A11.7	-7.58	1.81e-13	1.51e-10	-0.33	-0.33	Skin pigmentation;	chr20:34026067	chr20:33985617~33988989:-
LUAD	cis	rs9595908	0.865	rs2761365	ENSG00000212293.1	SNORA16	-7.58	1.82e-13	1.52e-10	-0.38	-0.33	Body mass index;	chr13:32437687	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.827	rs2761366	ENSG00000212293.1	SNORA16	-7.58	1.82e-13	1.52e-10	-0.38	-0.33	Body mass index;	chr13:32437735	chr13:32420390~32420516:-
LUAD	cis	rs875971	0.66	rs2191268	ENSG00000226824.5	RP4-756H11.3	-7.58	1.83e-13	1.53e-10	-0.38	-0.33	Aortic root size;	chr7:66645237	chr7:66654538~66669855:+
LUAD	cis	rs8177876	0.658	rs12444747	ENSG00000261838.4	RP11-303E16.6	7.58	1.83e-13	1.53e-10	0.77	0.33	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81041299	chr16:81069854~81076598:+
LUAD	cis	rs853679	0.517	rs1947862	ENSG00000219392.1	RP1-265C24.5	-7.58	1.84e-13	1.53e-10	-0.46	-0.33	Depression;	chr6:28137418	chr6:28115628~28116551:+
LUAD	cis	rs11676348	0.935	rs4674250	ENSG00000261338.2	RP11-378A13.1	-7.58	1.84e-13	1.53e-10	-0.35	-0.33	Ulcerative colitis;	chr2:218112808	chr2:218255319~218257366:+
LUAD	cis	rs2564921	0.57	rs3821831	ENSG00000242142.1	SERBP1P3	-7.58	1.85e-13	1.55e-10	-0.36	-0.33	Height;	chr3:52819385	chr3:53064283~53065091:-
LUAD	cis	rs2337406	0.587	rs2583291	ENSG00000274576.2	IGHV2-70	7.58	1.86e-13	1.55e-10	0.34	0.33	Alzheimer's disease (late onset);	chr14:106649293	chr14:106770577~106771020:-
LUAD	cis	rs35955747	0.601	rs7289941	ENSG00000236132.1	CTA-440B3.1	-7.57	1.87e-13	1.56e-10	-0.38	-0.33	Neutrophil count;Sum basophil neutrophil counts;	chr22:31488419	chr22:31816379~31817491:-
LUAD	cis	rs765787	0.53	rs4774542	ENSG00000259520.4	CTD-2651B20.3	-7.57	1.87e-13	1.56e-10	-0.42	-0.33	Uric acid levels;	chr15:45233828	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs4774550	ENSG00000259520.4	CTD-2651B20.3	7.57	1.88e-13	1.57e-10	0.42	0.33	Uric acid levels;	chr15:45250114	chr15:45251580~45279251:-
LUAD	cis	rs9545047	0.547	rs1590465	ENSG00000227676.3	LINC01068	-7.57	1.88e-13	1.57e-10	-0.39	-0.33	Schizophrenia;	chr13:79393998	chr13:79566727~79571436:+
LUAD	cis	rs2919917	1	rs2717547	ENSG00000254352.1	RP11-578O24.2	-7.57	1.9e-13	1.58e-10	-0.4	-0.33	Lymphocyte counts;	chr8:78744754	chr8:78723796~78724136:-
LUAD	cis	rs944289	0.74	rs885535	ENSG00000257826.1	RP11-116N8.4	-7.57	1.9e-13	1.58e-10	-0.34	-0.33	Thyroid cancer;	chr14:36082574	chr14:36061026~36067190:-
LUAD	cis	rs950880	0.614	rs60038017	ENSG00000234389.1	AC007278.3	-7.57	1.9e-13	1.58e-10	-0.33	-0.33	Serum protein levels (sST2);	chr2:102459541	chr2:102438713~102440475:+
LUAD	cis	rs6504950	0.889	rs2541237	ENSG00000275710.1	RP11-257O5.4	-7.57	1.9e-13	1.58e-10	-0.42	-0.33	Breast cancer;	chr17:55086676	chr17:54964474~54964679:+
LUAD	cis	rs11096990	0.656	rs6531710	ENSG00000249207.1	RP11-360F5.1	7.57	1.9e-13	1.58e-10	0.36	0.33	Cognitive function;	chr4:39300658	chr4:39112677~39126818:-
LUAD	cis	rs35955747	0.738	rs2012451	ENSG00000236132.1	CTA-440B3.1	7.57	1.9e-13	1.58e-10	0.36	0.33	Neutrophil count;Sum basophil neutrophil counts;	chr22:31448387	chr22:31816379~31817491:-
LUAD	cis	rs9322193	0.961	rs9767713	ENSG00000223701.3	RAET1E-AS1	7.57	1.91e-13	1.59e-10	0.39	0.33	Lung cancer;	chr6:149588241	chr6:149884431~149919508:+
LUAD	cis	rs8177876	0.749	rs58144189	ENSG00000261838.4	RP11-303E16.6	7.57	1.91e-13	1.59e-10	0.73	0.33	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81064478	chr16:81069854~81076598:+
LUAD	cis	rs2337406	0.587	rs2516889	ENSG00000274576.2	IGHV2-70	7.57	1.92e-13	1.6e-10	0.34	0.33	Alzheimer's disease (late onset);	chr14:106648903	chr14:106770577~106771020:-
LUAD	cis	rs950880	0.71	rs12469506	ENSG00000234389.1	AC007278.3	-7.57	1.92e-13	1.6e-10	-0.34	-0.33	Serum protein levels (sST2);	chr2:102349411	chr2:102438713~102440475:+
LUAD	cis	rs6142102	0.961	rs2300204	ENSG00000276073.1	RP5-1125A11.7	-7.57	1.93e-13	1.61e-10	-0.34	-0.33	Skin pigmentation;	chr20:34000967	chr20:33985617~33988989:-
LUAD	cis	rs853679	0.517	rs4713145	ENSG00000219392.1	RP1-265C24.5	-7.57	1.93e-13	1.61e-10	-0.46	-0.33	Depression;	chr6:28139049	chr6:28115628~28116551:+
LUAD	cis	rs367615	0.731	rs58241713	ENSG00000249476.1	CTD-2587M2.1	7.57	1.93e-13	1.61e-10	0.38	0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109517963	chr5:109237120~109326369:-
LUAD	cis	rs765787	0.53	rs1648285	ENSG00000259520.4	CTD-2651B20.3	7.57	1.94e-13	1.62e-10	0.42	0.33	Uric acid levels;	chr15:45225307	chr15:45251580~45279251:-
LUAD	cis	rs3779195	0.627	rs6950023	ENSG00000272950.1	RP11-307C18.1	7.57	1.96e-13	1.64e-10	0.56	0.33	Sex hormone-binding globulin levels;	chr7:98286323	chr7:98322853~98323430:+
LUAD	cis	rs3779195	0.627	rs6967728	ENSG00000272950.1	RP11-307C18.1	7.57	1.96e-13	1.64e-10	0.56	0.33	Sex hormone-binding globulin levels;	chr7:98286325	chr7:98322853~98323430:+
LUAD	cis	rs9545047	0.604	rs7986306	ENSG00000227676.3	LINC01068	7.57	1.97e-13	1.64e-10	0.38	0.33	Schizophrenia;	chr13:79392530	chr13:79566727~79571436:+
LUAD	cis	rs673078	0.66	rs2280711	ENSG00000275759.1	RP11-131L12.3	-7.57	1.97e-13	1.64e-10	-0.44	-0.33	Glucose homeostasis traits;	chr12:118212149	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.615	rs73222058	ENSG00000275759.1	RP11-131L12.3	-7.57	1.97e-13	1.64e-10	-0.44	-0.33	Glucose homeostasis traits;	chr12:118221066	chr12:118428281~118428870:+
LUAD	cis	rs11155671	0.53	rs7763849	ENSG00000223701.3	RAET1E-AS1	7.57	1.98e-13	1.65e-10	0.37	0.33	Testicular germ cell tumor;	chr6:149885244	chr6:149884431~149919508:+
LUAD	cis	rs7567389	0.6	rs11691088	ENSG00000236682.1	AC068282.3	-7.57	1.98e-13	1.65e-10	-0.45	-0.33	Self-rated health;	chr2:127374277	chr2:127389130~127400580:+
LUAD	cis	rs62229266	0.682	rs2835224	ENSG00000214914.3	RPL23AP3	7.57	1.98e-13	1.65e-10	0.42	0.33	Mitral valve prolapse;	chr21:35997732	chr21:36016079~36016546:-
LUAD	cis	rs944289	0.708	rs1537426	ENSG00000257826.1	RP11-116N8.4	7.56	2.01e-13	1.67e-10	0.34	0.33	Thyroid cancer;	chr14:36117961	chr14:36061026~36067190:-
LUAD	cis	rs9322193	0.884	rs9371201	ENSG00000223701.3	RAET1E-AS1	7.56	2.01e-13	1.67e-10	0.41	0.33	Lung cancer;	chr6:149823865	chr6:149884431~149919508:+
LUAD	cis	rs9287719	0.774	rs4997811	ENSG00000234818.1	AC092687.5	7.56	2.01e-13	1.67e-10	0.39	0.33	Prostate cancer;	chr2:10615412	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.745	rs4997810	ENSG00000234818.1	AC092687.5	7.56	2.01e-13	1.67e-10	0.39	0.33	Prostate cancer;	chr2:10615414	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.745	rs4997809	ENSG00000234818.1	AC092687.5	7.56	2.01e-13	1.67e-10	0.39	0.33	Prostate cancer;	chr2:10615416	chr2:10589166~10604830:+
LUAD	cis	rs237743	1	rs238174	ENSG00000222365.1	SNORD12B	-7.56	2.02e-13	1.68e-10	-0.37	-0.33	Height;	chr20:49262572	chr20:49280319~49280409:+
LUAD	cis	rs7567389	0.6	rs7590030	ENSG00000236682.1	AC068282.3	7.56	2.02e-13	1.68e-10	0.45	0.33	Self-rated health;	chr2:127298391	chr2:127389130~127400580:+
LUAD	cis	rs9545047	0.604	rs6563100	ENSG00000227676.3	LINC01068	7.56	2.03e-13	1.69e-10	0.38	0.33	Schizophrenia;	chr13:79382978	chr13:79566727~79571436:+
LUAD	cis	rs10463554	0.853	rs257309	ENSG00000175749.11	EIF3KP1	7.56	2.04e-13	1.7e-10	0.43	0.33	Parkinson's disease;	chr5:103082900	chr5:103032376~103033031:+
LUAD	cis	rs9322193	0.962	rs3805753	ENSG00000223701.3	RAET1E-AS1	7.56	2.04e-13	1.7e-10	0.38	0.33	Lung cancer;	chr6:149795662	chr6:149884431~149919508:+
LUAD	cis	rs4853012	0.941	rs4852329	ENSG00000257800.1	FNBP1P1	7.56	2.04e-13	1.7e-10	0.44	0.33	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74120680~74123218:+
LUAD	cis	rs7429990	0.965	rs5016900	ENSG00000229759.1	MRPS18AP1	7.56	2.05e-13	1.71e-10	0.39	0.33	Educational attainment (years of education);	chr3:47781387	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.896	rs34448818	ENSG00000229759.1	MRPS18AP1	7.56	2.05e-13	1.71e-10	0.39	0.33	Educational attainment (years of education);	chr3:47799822	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.93	rs13072132	ENSG00000229759.1	MRPS18AP1	7.56	2.05e-13	1.71e-10	0.39	0.33	Educational attainment (years of education);	chr3:47824671	chr3:48256350~48256938:-
LUAD	cis	rs62229266	0.647	rs59397717	ENSG00000231106.2	LINC01436	7.56	2.07e-13	1.72e-10	0.43	0.33	Mitral valve prolapse;	chr21:36079427	chr21:36005338~36007838:+
LUAD	cis	rs11098499	0.731	rs6846966	ENSG00000248280.1	RP11-33B1.2	7.56	2.07e-13	1.72e-10	0.4	0.33	Corneal astigmatism;	chr4:119372053	chr4:119440561~119450157:-
LUAD	cis	rs17711722	0.523	rs365896	ENSG00000226824.5	RP4-756H11.3	7.56	2.08e-13	1.73e-10	0.4	0.33	Calcium levels;	chr7:66045710	chr7:66654538~66669855:+
LUAD	cis	rs8059260	0.524	rs1122185	ENSG00000274038.1	RP11-66H6.4	-7.56	2.08e-13	1.73e-10	-0.48	-0.33	Alcohol consumption over the past year;	chr16:11104119	chr16:11056556~11057034:+
LUAD	cis	rs2337406	0.587	rs2516886	ENSG00000274576.2	IGHV2-70	7.56	2.09e-13	1.74e-10	0.34	0.33	Alzheimer's disease (late onset);	chr14:106649674	chr14:106770577~106771020:-
LUAD	cis	rs12134133	1	rs6660254	ENSG00000274245.1	RP11-357P18.2	7.56	2.1e-13	1.74e-10	0.43	0.33	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207272746	chr1:207372559~207373252:+
LUAD	cis	rs748404	0.723	rs573169	ENSG00000205771.5	CATSPER2P1	-7.56	2.1e-13	1.74e-10	-0.4	-0.33	Lung cancer;	chr15:43258383	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.697	rs524547	ENSG00000205771.5	CATSPER2P1	-7.56	2.1e-13	1.74e-10	-0.4	-0.33	Lung cancer;	chr15:43258825	chr15:43726918~43747094:-
LUAD	cis	rs9322193	0.923	rs11155683	ENSG00000223701.3	RAET1E-AS1	7.56	2.1e-13	1.74e-10	0.38	0.33	Lung cancer;	chr6:149779341	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs9372044	ENSG00000223701.3	RAET1E-AS1	7.56	2.1e-13	1.74e-10	0.38	0.33	Lung cancer;	chr6:149780867	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs11155685	ENSG00000223701.3	RAET1E-AS1	7.56	2.1e-13	1.74e-10	0.38	0.33	Lung cancer;	chr6:149781649	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs9689269	ENSG00000223701.3	RAET1E-AS1	7.56	2.1e-13	1.74e-10	0.38	0.33	Lung cancer;	chr6:149791861	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs62441335	ENSG00000223701.3	RAET1E-AS1	7.56	2.1e-13	1.74e-10	0.38	0.33	Lung cancer;	chr6:149792658	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs4816	ENSG00000223701.3	RAET1E-AS1	7.56	2.1e-13	1.74e-10	0.38	0.33	Lung cancer;	chr6:149793609	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.926	rs952166	ENSG00000223701.3	RAET1E-AS1	7.56	2.1e-13	1.74e-10	0.38	0.33	Lung cancer;	chr6:149798774	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs952165	ENSG00000223701.3	RAET1E-AS1	7.56	2.1e-13	1.74e-10	0.38	0.33	Lung cancer;	chr6:149798900	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.926	rs9285525	ENSG00000223701.3	RAET1E-AS1	7.56	2.1e-13	1.74e-10	0.38	0.33	Lung cancer;	chr6:149801253	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.884	rs2342858	ENSG00000223701.3	RAET1E-AS1	7.56	2.1e-13	1.74e-10	0.38	0.33	Lung cancer;	chr6:149805967	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.884	rs2095375	ENSG00000223701.3	RAET1E-AS1	7.56	2.1e-13	1.74e-10	0.38	0.33	Lung cancer;	chr6:149807037	chr6:149884431~149919508:+
LUAD	cis	rs9532669	0.926	rs7799	ENSG00000176268.5	CYCSP34	7.56	2.1e-13	1.74e-10	0.32	0.33	Cervical cancer;	chr13:40958916	chr13:40863599~40863902:-
LUAD	cis	rs9545047	0.604	rs7336581	ENSG00000227676.3	LINC01068	7.56	2.11e-13	1.75e-10	0.38	0.33	Schizophrenia;	chr13:79385739	chr13:79566727~79571436:+
LUAD	cis	rs6504950	0.886	rs2541236	ENSG00000275710.1	RP11-257O5.4	-7.56	2.12e-13	1.76e-10	-0.41	-0.33	Breast cancer;	chr17:55082471	chr17:54964474~54964679:+
LUAD	cis	rs2919917	1	rs2369440	ENSG00000254352.1	RP11-578O24.2	7.56	2.13e-13	1.77e-10	0.38	0.33	Lymphocyte counts;	chr8:78709474	chr8:78723796~78724136:-
LUAD	cis	rs9545047	0.604	rs314695	ENSG00000227676.3	LINC01068	-7.56	2.13e-13	1.77e-10	-0.38	-0.33	Schizophrenia;	chr13:79432206	chr13:79566727~79571436:+
LUAD	cis	rs35160687	0.901	rs17738096	ENSG00000273080.1	RP11-301O19.1	7.55	2.13e-13	1.77e-10	0.37	0.33	Night sleep phenotypes;	chr2:86286770	chr2:86195590~86196049:+
LUAD	cis	rs1729407	0.814	rs2542051	ENSG00000254851.1	RP11-109L13.1	7.55	2.14e-13	1.78e-10	0.42	0.33	Apolipoprotein A-IV levels;	chr11:116827022	chr11:117135528~117138582:+
LUAD	cis	rs853679	0.517	rs1340004	ENSG00000219392.1	RP1-265C24.5	-7.55	2.15e-13	1.78e-10	-0.46	-0.33	Depression;	chr6:28135913	chr6:28115628~28116551:+
LUAD	cis	rs7208859	0.524	rs8069400	ENSG00000263531.1	RP13-753N3.1	7.55	2.15e-13	1.78e-10	0.68	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748949	chr17:30863921~30864940:-
LUAD	cis	rs8059260	0.736	rs16957883	ENSG00000274038.1	RP11-66H6.4	-7.55	2.15e-13	1.79e-10	-0.6	-0.33	Alcohol consumption over the past year;	chr16:10994788	chr16:11056556~11057034:+
LUAD	cis	rs6504622	0.755	rs34774205	ENSG00000262879.4	RP11-156P1.3	-7.55	2.16e-13	1.79e-10	-0.37	-0.33	Orofacial clefts;	chr17:47083453	chr17:46984045~47100323:-
LUAD	cis	rs8177876	0.822	rs56198248	ENSG00000261838.4	RP11-303E16.6	7.55	2.17e-13	1.8e-10	0.81	0.33	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074869	chr16:81069854~81076598:+
LUAD	cis	rs11155671	0.53	rs9371215	ENSG00000223701.3	RAET1E-AS1	7.55	2.17e-13	1.8e-10	0.38	0.33	Testicular germ cell tumor;	chr6:149873162	chr6:149884431~149919508:+
LUAD	cis	rs9487094	0.6	rs10457193	ENSG00000260273.1	RP11-425D10.10	7.55	2.17e-13	1.8e-10	0.42	0.33	Height;	chr6:109507364	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.558	rs10457194	ENSG00000260273.1	RP11-425D10.10	7.55	2.17e-13	1.8e-10	0.42	0.33	Height;	chr6:109507366	chr6:109382795~109383666:+
LUAD	cis	rs367615	0.679	rs11241021	ENSG00000249476.1	CTD-2587M2.1	7.55	2.17e-13	1.8e-10	0.38	0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109476389	chr5:109237120~109326369:-
LUAD	cis	rs7615952	0.604	rs9837847	ENSG00000171084.14	FAM86JP	7.55	2.17e-13	1.8e-10	0.59	0.33	Blood pressure (smoking interaction);	chr3:125905076	chr3:125916620~125930024:+
LUAD	cis	rs7397814	0.558	rs4764447	ENSG00000278635.1	CTD-2318O12.1	7.55	2.18e-13	1.81e-10	0.3	0.33	IgG glycosylation;	chr12:9426513	chr12:9415641~9416718:+
LUAD	cis	rs10463554	0.892	rs6872442	ENSG00000175749.11	EIF3KP1	7.55	2.19e-13	1.81e-10	0.45	0.33	Parkinson's disease;	chr5:102930818	chr5:103032376~103033031:+
LUAD	cis	rs227275	0.53	rs3960788	ENSG00000246560.2	RP11-10L12.4	7.55	2.19e-13	1.81e-10	0.39	0.33	Allergic disease (asthma, hay fever or eczema);	chr4:102994461	chr4:102828055~102844075:+
LUAD	cis	rs237743	1	rs34580798	ENSG00000222365.1	SNORD12B	-7.55	2.19e-13	1.81e-10	-0.38	-0.33	Height;	chr20:49283420	chr20:49280319~49280409:+
LUAD	cis	rs10129255	0.83	rs61997609	ENSG00000280411.1	IGHV1-69-2	-7.55	2.19e-13	1.81e-10	-0.25	-0.33	Kawasaki disease;	chr14:106692376	chr14:106762092~106762588:-
LUAD	cis	rs6142102	0.961	rs6087557	ENSG00000276073.1	RP5-1125A11.7	-7.55	2.19e-13	1.82e-10	-0.33	-0.33	Skin pigmentation;	chr20:34110469	chr20:33985617~33988989:-
LUAD	cis	rs496547	0.588	rs473298	ENSG00000278376.1	RP11-158I9.8	-7.55	2.21e-13	1.83e-10	-0.36	-0.33	Hip minimal joint space width;	chr11:118808678	chr11:118791254~118793137:+
LUAD	cis	rs944289	0.708	rs34613409	ENSG00000257826.1	RP11-116N8.4	-7.55	2.21e-13	1.83e-10	-0.34	-0.33	Thyroid cancer;	chr14:36096489	chr14:36061026~36067190:-
LUAD	cis	rs944289	0.774	rs2415312	ENSG00000257826.1	RP11-116N8.4	-7.55	2.21e-13	1.83e-10	-0.34	-0.33	Thyroid cancer;	chr14:36097145	chr14:36061026~36067190:-
LUAD	cis	rs801193	0.591	rs9986881	ENSG00000226824.5	RP4-756H11.3	-7.55	2.21e-13	1.83e-10	-0.4	-0.33	Aortic root size;	chr7:66708053	chr7:66654538~66669855:+
LUAD	cis	rs62229266	0.626	rs7280896	ENSG00000231106.2	LINC01436	7.55	2.22e-13	1.84e-10	0.43	0.33	Mitral valve prolapse;	chr21:36088608	chr21:36005338~36007838:+
LUAD	cis	rs17711722	0.565	rs4275112	ENSG00000226824.5	RP4-756H11.3	7.55	2.22e-13	1.84e-10	0.4	0.33	Calcium levels;	chr7:65733651	chr7:66654538~66669855:+
LUAD	cis	rs2280018	0.963	rs4985147	ENSG00000260735.1	RP11-72I8.1	-7.55	2.22e-13	1.84e-10	-0.35	-0.33	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15074903	chr16:15094411~15109197:+
LUAD	cis	rs7684253	0.565	rs12641030	ENSG00000269949.1	RP11-738E22.3	-7.55	2.24e-13	1.85e-10	-0.44	-0.33	Migraine;	chr4:56937339	chr4:56960927~56961373:-
LUAD	cis	rs6142102	0.886	rs6142098	ENSG00000276073.1	RP5-1125A11.7	-7.55	2.24e-13	1.86e-10	-0.33	-0.33	Skin pigmentation;	chr20:34100488	chr20:33985617~33988989:-
LUAD	cis	rs748404	0.697	rs555001	ENSG00000205771.5	CATSPER2P1	-7.55	2.24e-13	1.86e-10	-0.4	-0.33	Lung cancer;	chr15:43253530	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.697	rs475261	ENSG00000205771.5	CATSPER2P1	-7.55	2.24e-13	1.86e-10	-0.4	-0.33	Lung cancer;	chr15:43254258	chr15:43726918~43747094:-
LUAD	cis	rs853679	0.517	rs9380056	ENSG00000219392.1	RP1-265C24.5	-7.55	2.24e-13	1.86e-10	-0.46	-0.33	Depression;	chr6:28136698	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9380057	ENSG00000219392.1	RP1-265C24.5	-7.55	2.24e-13	1.86e-10	-0.46	-0.33	Depression;	chr6:28136856	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs6941992	ENSG00000219392.1	RP1-265C24.5	-7.55	2.24e-13	1.86e-10	-0.46	-0.33	Depression;	chr6:28138363	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.516	rs4713142	ENSG00000219392.1	RP1-265C24.5	-7.55	2.24e-13	1.86e-10	-0.46	-0.33	Parkinson's disease;	chr6:28138569	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs4713143	ENSG00000219392.1	RP1-265C24.5	-7.55	2.24e-13	1.86e-10	-0.46	-0.33	Depression;	chr6:28138981	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs4713144	ENSG00000219392.1	RP1-265C24.5	-7.55	2.24e-13	1.86e-10	-0.46	-0.33	Depression;	chr6:28139012	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.621	rs10484403	ENSG00000219392.1	RP1-265C24.5	-7.55	2.25e-13	1.86e-10	-0.45	-0.33	Parkinson's disease;	chr6:28065745	chr6:28115628~28116551:+
LUAD	cis	rs638893	1	rs113641235	ENSG00000278376.1	RP11-158I9.8	7.55	2.27e-13	1.88e-10	0.5	0.33	Vitiligo;	chr11:118829555	chr11:118791254~118793137:+
LUAD	cis	rs6142102	0.961	rs1883524	ENSG00000276073.1	RP5-1125A11.7	-7.55	2.28e-13	1.88e-10	-0.33	-0.33	Skin pigmentation;	chr20:34038301	chr20:33985617~33988989:-
LUAD	cis	rs10129255	0.872	rs8015406	ENSG00000280411.1	IGHV1-69-2	-7.55	2.28e-13	1.89e-10	-0.25	-0.33	Kawasaki disease;	chr14:106670611	chr14:106762092~106762588:-
LUAD	cis	rs1075265	0.527	rs10167891	ENSG00000233266.1	HMGB1P31	7.54	2.28e-13	1.89e-10	0.41	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54003658	chr2:54051334~54051760:+
LUAD	cis	rs7429990	0.864	rs883662	ENSG00000229759.1	MRPS18AP1	7.54	2.29e-13	1.89e-10	0.34	0.33	Educational attainment (years of education);	chr3:47619342	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.828	rs11712152	ENSG00000229759.1	MRPS18AP1	7.54	2.29e-13	1.89e-10	0.34	0.33	Educational attainment (years of education);	chr3:47655314	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs12635438	ENSG00000229759.1	MRPS18AP1	7.54	2.29e-13	1.89e-10	0.34	0.33	Educational attainment (years of education);	chr3:47693210	chr3:48256350~48256938:-
LUAD	cis	rs9595908	1	rs9591165	ENSG00000212293.1	SNORA16	7.54	2.29e-13	1.89e-10	0.35	0.33	Body mass index;	chr13:32611016	chr13:32420390~32420516:-
LUAD	cis	rs2919917	0.628	rs6981103	ENSG00000254352.1	RP11-578O24.2	7.54	2.3e-13	1.9e-10	0.43	0.33	Lymphocyte counts;	chr8:78691702	chr8:78723796~78724136:-
LUAD	cis	rs10129255	1	rs11621409	ENSG00000280411.1	IGHV1-69-2	-7.54	2.3e-13	1.91e-10	-0.25	-0.33	Kawasaki disease;	chr14:106695603	chr14:106762092~106762588:-
LUAD	cis	rs6504950	0.889	rs1484769	ENSG00000275710.1	RP11-257O5.4	-7.54	2.33e-13	1.92e-10	-0.41	-0.33	Breast cancer;	chr17:55089290	chr17:54964474~54964679:+
LUAD	cis	rs9322193	0.923	rs1934534	ENSG00000223701.3	RAET1E-AS1	7.54	2.33e-13	1.92e-10	0.37	0.33	Lung cancer;	chr6:149711896	chr6:149884431~149919508:+
LUAD	cis	rs950169	0.922	rs4842939	ENSG00000225151.9	GOLGA2P7	7.54	2.33e-13	1.93e-10	0.42	0.33	Schizophrenia;	chr15:84159214	chr15:84199311~84230136:-
LUAD	cis	rs9322193	0.923	rs9767309	ENSG00000223701.3	RAET1E-AS1	7.54	2.34e-13	1.93e-10	0.38	0.33	Lung cancer;	chr6:149716807	chr6:149884431~149919508:+
LUAD	cis	rs673078	0.66	rs61945212	ENSG00000275759.1	RP11-131L12.3	-7.54	2.35e-13	1.94e-10	-0.47	-0.33	Glucose homeostasis traits;	chr12:118252351	chr12:118428281~118428870:+
LUAD	cis	rs7688540	0.713	rs12511388	ENSG00000275426.1	CH17-262A2.1	7.54	2.35e-13	1.94e-10	0.45	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:303758	chr4:149738~150317:+
LUAD	cis	rs9322193	0.961	rs2064520	ENSG00000223701.3	RAET1E-AS1	7.54	2.36e-13	1.95e-10	0.38	0.33	Lung cancer;	chr6:149603650	chr6:149884431~149919508:+
LUAD	cis	rs950880	0.71	rs17027006	ENSG00000234389.1	AC007278.3	7.54	2.36e-13	1.95e-10	0.34	0.33	Serum protein levels (sST2);	chr2:102348872	chr2:102438713~102440475:+
LUAD	cis	rs7615952	0.673	rs16834637	ENSG00000171084.14	FAM86JP	7.54	2.37e-13	1.96e-10	0.56	0.33	Blood pressure (smoking interaction);	chr3:125886628	chr3:125916620~125930024:+
LUAD	cis	rs673078	0.66	rs75752792	ENSG00000275759.1	RP11-131L12.3	-7.54	2.38e-13	1.96e-10	-0.47	-0.33	Glucose homeostasis traits;	chr12:118187005	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.66	rs75571641	ENSG00000275759.1	RP11-131L12.3	-7.54	2.38e-13	1.96e-10	-0.47	-0.33	Glucose homeostasis traits;	chr12:118187012	chr12:118428281~118428870:+
LUAD	cis	rs9545047	0.716	rs9318638	ENSG00000227676.3	LINC01068	-7.54	2.38e-13	1.96e-10	-0.4	-0.33	Schizophrenia;	chr13:79412018	chr13:79566727~79571436:+
LUAD	cis	rs11690935	0.632	rs12052246	ENSG00000228389.1	AC068039.4	-7.54	2.39e-13	1.97e-10	-0.34	-0.33	Schizophrenia;	chr2:172030703	chr2:171773482~171775844:+
LUAD	cis	rs7182621	0.639	rs12906050	ENSG00000182397.13	DNM1P46	7.54	2.4e-13	1.98e-10	0.44	0.33	Colonoscopy-negative controls vs population controls;	chr15:99873384	chr15:99790156~99806927:-
LUAD	cis	rs7182621	0.639	rs35248328	ENSG00000182397.13	DNM1P46	7.54	2.4e-13	1.98e-10	0.44	0.33	Colonoscopy-negative controls vs population controls;	chr15:99873399	chr15:99790156~99806927:-
LUAD	cis	rs9545047	0.604	rs7327603	ENSG00000227676.3	LINC01068	7.54	2.41e-13	1.99e-10	0.38	0.32	Schizophrenia;	chr13:79366676	chr13:79566727~79571436:+
LUAD	cis	rs9322193	0.924	rs9322189	ENSG00000223701.3	RAET1E-AS1	7.54	2.42e-13	2e-10	0.38	0.32	Lung cancer;	chr6:149588797	chr6:149884431~149919508:+
LUAD	cis	rs34779708	0.801	rs12242110	ENSG00000230534.5	RP11-297A16.2	7.54	2.43e-13	2e-10	0.39	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35246767	chr10:35098006~35127020:-
LUAD	cis	rs17482078	0.959	rs13170045	ENSG00000248734.2	CTD-2260A17.1	7.54	2.43e-13	2.01e-10	0.4	0.32	Behcet's disease;Blood protein levels;	chr5:96790082	chr5:96784777~96785999:+
LUAD	cis	rs6700559	0.81	rs2808248	ENSG00000260088.1	RP11-92G12.3	7.54	2.44e-13	2.01e-10	0.4	0.32	Coronary artery disease;	chr1:200623147	chr1:200669507~200694250:+
LUAD	cis	rs10463554	0.892	rs72783889	ENSG00000175749.11	EIF3KP1	7.53	2.44e-13	2.01e-10	0.45	0.32	Parkinson's disease;	chr5:102938835	chr5:103032376~103033031:+
LUAD	cis	rs10463554	0.892	rs72783890	ENSG00000175749.11	EIF3KP1	7.53	2.44e-13	2.01e-10	0.45	0.32	Parkinson's disease;	chr5:102938836	chr5:103032376~103033031:+
LUAD	cis	rs7182621	0.639	rs34701806	ENSG00000182397.13	DNM1P46	7.53	2.45e-13	2.02e-10	0.44	0.32	Colonoscopy-negative controls vs population controls;	chr15:99872953	chr15:99790156~99806927:-
LUAD	cis	rs71403859	0.667	rs12149264	ENSG00000260886.1	TAT-AS1	7.53	2.45e-13	2.02e-10	0.54	0.32	Post bronchodilator FEV1;	chr16:71687018	chr16:71565789~71578187:+
LUAD	cis	rs8059260	0.542	rs80000109	ENSG00000274038.1	RP11-66H6.4	-7.53	2.47e-13	2.03e-10	-0.57	-0.32	Alcohol consumption over the past year;	chr16:11031457	chr16:11056556~11057034:+
LUAD	cis	rs56046484	0.62	rs34585903	ENSG00000259295.5	CSPG4P12	7.53	2.47e-13	2.04e-10	0.54	0.32	Testicular germ cell tumor;	chr15:84984893	chr15:85191438~85213905:+
LUAD	cis	rs35160687	0.865	rs10189492	ENSG00000273080.1	RP11-301O19.1	7.53	2.47e-13	2.04e-10	0.36	0.32	Night sleep phenotypes;	chr2:86251779	chr2:86195590~86196049:+
LUAD	cis	rs9326248	0.569	rs10892082	ENSG00000280143.1	AP000892.6	7.53	2.49e-13	2.05e-10	0.49	0.32	Blood protein levels;	chr11:117168609	chr11:117204967~117210292:+
LUAD	cis	rs10463554	0.892	rs3776874	ENSG00000175749.11	EIF3KP1	7.53	2.5e-13	2.06e-10	0.45	0.32	Parkinson's disease;	chr5:102946613	chr5:103032376~103033031:+
LUAD	cis	rs10129255	0.5	rs1974468	ENSG00000211970.3	IGHV4-61	-7.53	2.5e-13	2.06e-10	-0.23	-0.32	Kawasaki disease;	chr14:106686149	chr14:106639119~106639657:-
LUAD	cis	rs4423214	0.592	rs1790349	ENSG00000254682.1	RP11-660L16.2	-7.53	2.53e-13	2.08e-10	-0.5	-0.32	Vitamin D levels;	chr11:71431304	chr11:71448674~71452157:+
LUAD	cis	rs950169	1	rs12903820	ENSG00000225151.9	GOLGA2P7	-7.53	2.53e-13	2.08e-10	-0.46	-0.32	Schizophrenia;	chr15:84055068	chr15:84199311~84230136:-
LUAD	cis	rs367615	0.661	rs9326773	ENSG00000249476.1	CTD-2587M2.1	7.53	2.54e-13	2.09e-10	0.38	0.32	Colorectal cancer (SNP x SNP interaction);	chr5:109497822	chr5:109237120~109326369:-
LUAD	cis	rs765787	0.53	rs1706837	ENSG00000259520.4	CTD-2651B20.3	7.53	2.54e-13	2.09e-10	0.42	0.32	Uric acid levels;	chr15:45226838	chr15:45251580~45279251:-
LUAD	cis	rs2919917	0.578	rs11783804	ENSG00000254352.1	RP11-578O24.2	7.53	2.54e-13	2.09e-10	0.42	0.32	Lymphocyte counts;	chr8:78652776	chr8:78723796~78724136:-
LUAD	cis	rs9545047	0.604	rs11620233	ENSG00000227676.3	LINC01068	-7.53	2.55e-13	2.09e-10	-0.38	-0.32	Schizophrenia;	chr13:79373871	chr13:79566727~79571436:+
LUAD	cis	rs10463554	0.963	rs154355	ENSG00000175749.11	EIF3KP1	7.53	2.56e-13	2.1e-10	0.44	0.32	Parkinson's disease;	chr5:103163177	chr5:103032376~103033031:+
LUAD	cis	rs26232	0.517	rs154356	ENSG00000175749.11	EIF3KP1	7.53	2.56e-13	2.1e-10	0.44	0.32	Rheumatoid arthritis;	chr5:103163440	chr5:103032376~103033031:+
LUAD	cis	rs17711722	0.565	rs73372653	ENSG00000226824.5	RP4-756H11.3	-7.53	2.56e-13	2.11e-10	-0.41	-0.32	Calcium levels;	chr7:65977808	chr7:66654538~66669855:+
LUAD	cis	rs34779708	0.771	rs3867218	ENSG00000230534.5	RP11-297A16.2	7.53	2.57e-13	2.11e-10	0.39	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35238615	chr10:35098006~35127020:-
LUAD	cis	rs7615952	0.673	rs9289270	ENSG00000171084.14	FAM86JP	7.53	2.57e-13	2.11e-10	0.58	0.32	Blood pressure (smoking interaction);	chr3:125918136	chr3:125916620~125930024:+
LUAD	cis	rs11098499	0.863	rs6835635	ENSG00000248280.1	RP11-33B1.2	7.53	2.58e-13	2.12e-10	0.43	0.32	Corneal astigmatism;	chr4:119537712	chr4:119440561~119450157:-
LUAD	cis	rs7429990	0.965	rs11709289	ENSG00000229759.1	MRPS18AP1	7.53	2.58e-13	2.12e-10	0.39	0.32	Educational attainment (years of education);	chr3:47765159	chr3:48256350~48256938:-
LUAD	cis	rs526231	0.578	rs10515337	ENSG00000175749.11	EIF3KP1	-7.53	2.58e-13	2.12e-10	-0.45	-0.32	Primary biliary cholangitis;	chr5:102965664	chr5:103032376~103033031:+
LUAD	cis	rs950169	0.919	rs17300292	ENSG00000225151.9	GOLGA2P7	-7.53	2.58e-13	2.12e-10	-0.46	-0.32	Schizophrenia;	chr15:84093816	chr15:84199311~84230136:-
LUAD	cis	rs2280018	1	rs2280018	ENSG00000260735.1	RP11-72I8.1	-7.53	2.6e-13	2.14e-10	-0.35	-0.32	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056976	chr16:15094411~15109197:+
LUAD	cis	rs17482078	1	rs17482078	ENSG00000248734.2	CTD-2260A17.1	7.53	2.6e-13	2.14e-10	0.41	0.32	Behcet's disease;Blood protein levels;	chr5:96783162	chr5:96784777~96785999:+
LUAD	cis	rs11155671	0.53	rs9383940	ENSG00000223701.3	RAET1E-AS1	7.52	2.63e-13	2.16e-10	0.39	0.32	Testicular germ cell tumor;	chr6:149904923	chr6:149884431~149919508:+
LUAD	cis	rs10129255	1	rs10137758	ENSG00000211972.2	IGHV3-66	7.52	2.63e-13	2.16e-10	0.29	0.32	Kawasaki disease;	chr14:106697673	chr14:106675017~106675544:-
LUAD	cis	rs6504950	0.889	rs2541245	ENSG00000275710.1	RP11-257O5.4	-7.52	2.63e-13	2.16e-10	-0.42	-0.32	Breast cancer;	chr17:55023839	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.889	rs2787505	ENSG00000275710.1	RP11-257O5.4	-7.52	2.63e-13	2.16e-10	-0.42	-0.32	Breast cancer;	chr17:55030071	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.85	rs2787507	ENSG00000275710.1	RP11-257O5.4	-7.52	2.63e-13	2.16e-10	-0.42	-0.32	Breast cancer;	chr17:55050563	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.813	rs9889687	ENSG00000275710.1	RP11-257O5.4	-7.52	2.63e-13	2.16e-10	-0.42	-0.32	Breast cancer;	chr17:55055050	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.85	rs17745534	ENSG00000275710.1	RP11-257O5.4	-7.52	2.63e-13	2.16e-10	-0.42	-0.32	Breast cancer;	chr17:55060145	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.889	rs9303363	ENSG00000275710.1	RP11-257O5.4	-7.52	2.63e-13	2.16e-10	-0.42	-0.32	Breast cancer;	chr17:55060613	chr17:54964474~54964679:+
LUAD	cis	rs1501911	0.53	rs193072	ENSG00000248489.1	CTD-2007H13.3	7.52	2.63e-13	2.16e-10	0.36	0.32	Lung function (FEV1/FVC);	chr5:98822171	chr5:98929171~98995013:+
LUAD	cis	rs6504950	0.925	rs2787497	ENSG00000275710.1	RP11-257O5.4	-7.52	2.63e-13	2.16e-10	-0.42	-0.32	Breast cancer;	chr17:55098850	chr17:54964474~54964679:+
LUAD	cis	rs9660180	0.846	rs10907195	ENSG00000231050.1	RP1-140A9.1	-7.52	2.65e-13	2.17e-10	-0.36	-0.32	Body mass index;	chr1:1781909	chr1:1891471~1892658:+
LUAD	cis	rs6504950	0.925	rs2787481	ENSG00000275710.1	RP11-257O5.4	-7.52	2.66e-13	2.18e-10	-0.42	-0.32	Breast cancer;	chr17:55133749	chr17:54964474~54964679:+
LUAD	cis	rs7429990	0.864	rs4858860	ENSG00000229759.1	MRPS18AP1	-7.52	2.68e-13	2.19e-10	-0.33	-0.32	Educational attainment (years of education);	chr3:47817344	chr3:48256350~48256938:-
LUAD	cis	rs904251	0.802	rs2646933	ENSG00000279942.1	RP1-153P14.7	-7.52	2.68e-13	2.2e-10	-0.34	-0.32	Cognitive performance;	chr6:37434294	chr6:37567716~37571460:+
LUAD	cis	rs7811142	0.83	rs6955367	ENSG00000242294.5	STAG3L5P	7.52	2.73e-13	2.24e-10	0.27	0.32	Platelet count;	chr7:100363571	chr7:100336079~100351900:+
LUAD	cis	rs172166	0.61	rs276369	ENSG00000216901.1	AL022393.7	7.52	2.73e-13	2.24e-10	0.37	0.32	Cardiac Troponin-T levels;	chr6:27951465	chr6:28176188~28176674:+
LUAD	cis	rs75422866	0.867	rs73102188	ENSG00000274902.1	RP1-197B17.4	7.52	2.74e-13	2.25e-10	0.75	0.32	Pneumonia;	chr12:47662993	chr12:47731908~47732351:+
LUAD	cis	rs9595908	0.9	rs731413	ENSG00000212293.1	SNORA16	7.52	2.74e-13	2.25e-10	0.34	0.32	Body mass index;	chr13:32601519	chr13:32420390~32420516:-
LUAD	cis	rs367615	0.704	rs7704824	ENSG00000249476.1	CTD-2587M2.1	7.52	2.75e-13	2.25e-10	0.36	0.32	Colorectal cancer (SNP x SNP interaction);	chr5:109514577	chr5:109237120~109326369:-
LUAD	cis	rs7674212	0.507	rs10516495	ENSG00000246560.2	RP11-10L12.4	7.52	2.75e-13	2.25e-10	0.44	0.32	Type 2 diabetes;	chr4:102978933	chr4:102828055~102844075:+
LUAD	cis	rs7429990	0.828	rs6792350	ENSG00000229759.1	MRPS18AP1	-7.52	2.75e-13	2.25e-10	-0.33	-0.32	Educational attainment (years of education);	chr3:47797451	chr3:48256350~48256938:-
LUAD	cis	rs8177876	0.597	rs1048194	ENSG00000261838.4	RP11-303E16.6	-7.52	2.75e-13	2.25e-10	-0.76	-0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81031097	chr16:81069854~81076598:+
LUAD	cis	rs10129255	1	rs11621409	ENSG00000211972.2	IGHV3-66	7.52	2.76e-13	2.26e-10	0.29	0.32	Kawasaki disease;	chr14:106695603	chr14:106675017~106675544:-
LUAD	cis	rs1185460	1	rs1784305	ENSG00000271751.1	RP11-110I1.14	-7.52	2.76e-13	2.26e-10	-0.4	-0.32	Coronary artery disease;	chr11:119071338	chr11:119065263~119065677:-
LUAD	cis	rs7684253	0.565	rs13130605	ENSG00000269949.1	RP11-738E22.3	-7.52	2.78e-13	2.28e-10	-0.43	-0.32	Migraine;	chr4:56943905	chr4:56960927~56961373:-
LUAD	cis	rs10129255	0.833	rs61997797	ENSG00000280411.1	IGHV1-69-2	-7.52	2.79e-13	2.28e-10	-0.24	-0.32	Kawasaki disease;	chr14:106815190	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.957	rs8009948	ENSG00000211972.2	IGHV3-66	7.52	2.79e-13	2.28e-10	0.29	0.32	Kawasaki disease;	chr14:106805607	chr14:106675017~106675544:-
LUAD	cis	rs6700559	0.81	rs2808250	ENSG00000260088.1	RP11-92G12.3	-7.52	2.79e-13	2.28e-10	-0.4	-0.32	Coronary artery disease;	chr1:200623419	chr1:200669507~200694250:+
LUAD	cis	rs1075265	0.633	rs7591431	ENSG00000233266.1	HMGB1P31	7.52	2.79e-13	2.28e-10	0.42	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53995028	chr2:54051334~54051760:+
LUAD	cis	rs7811142	0.83	rs7341507	ENSG00000242294.5	STAG3L5P	7.52	2.79e-13	2.29e-10	0.29	0.32	Platelet count;	chr7:100353692	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.667	rs3873746	ENSG00000242294.5	STAG3L5P	7.51	2.83e-13	2.32e-10	0.27	0.32	Platelet count;	chr7:100337474	chr7:100336079~100351900:+
LUAD	cis	rs2239557	0.5	rs7157723	ENSG00000259065.1	RP5-1021I20.1	7.51	2.84e-13	2.32e-10	0.36	0.32	Common traits (Other);	chr14:73999497	chr14:73787360~73803270:+
LUAD	cis	rs9545047	0.604	rs9318634	ENSG00000227676.3	LINC01068	-7.51	2.85e-13	2.33e-10	-0.38	-0.32	Schizophrenia;	chr13:79369303	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs9545076	ENSG00000227676.3	LINC01068	-7.51	2.87e-13	2.35e-10	-0.37	-0.32	Schizophrenia;	chr13:79335983	chr13:79566727~79571436:+
LUAD	cis	rs8177876	0.749	rs754429	ENSG00000261838.4	RP11-303E16.6	7.51	2.89e-13	2.36e-10	0.72	0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81062574	chr16:81069854~81076598:+
LUAD	cis	rs10463554	0.856	rs26260	ENSG00000175749.11	EIF3KP1	7.51	2.89e-13	2.36e-10	0.44	0.32	Parkinson's disease;	chr5:103211493	chr5:103032376~103033031:+
LUAD	cis	rs7945705	0.902	rs7479407	ENSG00000254860.4	TMEM9B-AS1	-7.51	2.9e-13	2.37e-10	-0.36	-0.32	Hemoglobin concentration;	chr11:9001874	chr11:8964675~8977527:+
LUAD	cis	rs4713118	0.516	rs6931858	ENSG00000219392.1	RP1-265C24.5	-7.51	2.92e-13	2.38e-10	-0.44	-0.32	Parkinson's disease;	chr6:28110633	chr6:28115628~28116551:+
LUAD	cis	rs8177876	0.554	rs56286107	ENSG00000261838.4	RP11-303E16.6	7.51	2.93e-13	2.39e-10	0.84	0.32	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81084227	chr16:81069854~81076598:+
LUAD	cis	rs4273100	1	rs4924986	ENSG00000262319.1	CTC-457L16.2	7.51	2.93e-13	2.39e-10	0.43	0.32	Schizophrenia;	chr17:19339154	chr17:19141017~19143689:-
LUAD	cis	rs2412819	0.597	rs514311	ENSG00000205771.5	CATSPER2P1	-7.51	2.93e-13	2.39e-10	-0.48	-0.32	Lung cancer;	chr15:43869376	chr15:43726918~43747094:-
LUAD	cis	rs7811142	0.775	rs1059129	ENSG00000242294.5	STAG3L5P	7.51	2.94e-13	2.4e-10	0.27	0.32	Platelet count;	chr7:100328899	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.562	rs7786844	ENSG00000242294.5	STAG3L5P	7.51	2.94e-13	2.4e-10	0.27	0.32	Platelet count;	chr7:100336385	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.83	rs6979910	ENSG00000242294.5	STAG3L5P	7.51	2.94e-13	2.4e-10	0.27	0.32	Platelet count;	chr7:100343007	chr7:100336079~100351900:+
LUAD	cis	rs6844153	0.938	rs77926313	ENSG00000240005.4	RP11-293A21.1	-7.51	2.94e-13	2.4e-10	-0.55	-0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26965420	chr4:26859806~26860599:-
LUAD	cis	rs950169	1	rs12916348	ENSG00000225151.9	GOLGA2P7	-7.51	2.94e-13	2.4e-10	-0.46	-0.32	Schizophrenia;	chr15:84096775	chr15:84199311~84230136:-
LUAD	cis	rs10129255	0.869	rs7150549	ENSG00000211972.2	IGHV3-66	7.51	2.96e-13	2.41e-10	0.29	0.32	Kawasaki disease;	chr14:106705441	chr14:106675017~106675544:-
LUAD	cis	rs9549367	0.673	rs575453	ENSG00000269125.1	RP11-98F14.11	7.51	2.96e-13	2.42e-10	0.41	0.32	Platelet distribution width;	chr13:113183557	chr13:113165002~113165183:-
LUAD	cis	rs9322193	1	rs9322193	ENSG00000223701.3	RAET1E-AS1	7.51	2.97e-13	2.42e-10	0.38	0.32	Lung cancer;	chr6:149598007	chr6:149884431~149919508:+
LUAD	cis	rs673078	0.571	rs61945220	ENSG00000275759.1	RP11-131L12.3	-7.51	2.97e-13	2.42e-10	-0.47	-0.32	Glucose homeostasis traits;	chr12:118272924	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.571	rs61945221	ENSG00000275759.1	RP11-131L12.3	-7.51	2.97e-13	2.42e-10	-0.47	-0.32	Glucose homeostasis traits;	chr12:118272926	chr12:118428281~118428870:+
LUAD	cis	rs2524005	1	rs2524005	ENSG00000227766.1	HCG4P5	-7.51	2.97e-13	2.42e-10	-0.47	-0.32	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29942075~29943067:-
LUAD	cis	rs2842992	0.872	rs2758315	ENSG00000237927.1	RP3-393E18.2	-7.51	2.98e-13	2.43e-10	-0.46	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159737608	chr6:159586955~159589169:-
LUAD	cis	rs8059260	0.736	rs8049278	ENSG00000274038.1	RP11-66H6.4	-7.51	2.98e-13	2.43e-10	-0.61	-0.32	Alcohol consumption over the past year;	chr16:10968766	chr16:11056556~11057034:+
LUAD	cis	rs8059260	0.736	rs12149904	ENSG00000274038.1	RP11-66H6.4	-7.51	2.98e-13	2.43e-10	-0.59	-0.32	Alcohol consumption over the past year;	chr16:10991789	chr16:11056556~11057034:+
LUAD	cis	rs12468226	0.938	rs10166594	ENSG00000273456.1	RP11-686O6.2	7.51	2.99e-13	2.43e-10	0.47	0.32	Urate levels;	chr2:202250262	chr2:202374932~202375604:-
LUAD	cis	rs1891275	0.551	rs11186640	ENSG00000228701.1	TNKS2-AS1	-7.51	2.99e-13	2.44e-10	-0.44	-0.32	Intelligence (multi-trait analysis);	chr10:91640674	chr10:91782839~91798291:-
LUAD	cis	rs9640161	0.711	rs55881542	ENSG00000261305.1	RP4-584D14.7	7.51	2.99e-13	2.44e-10	0.48	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150328645	chr7:150341771~150342607:+
LUAD	cis	rs9640161	0.742	rs2108852	ENSG00000261305.1	RP4-584D14.7	7.51	3e-13	2.44e-10	0.47	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150322539	chr7:150341771~150342607:+
LUAD	cis	rs9640161	0.742	rs2108851	ENSG00000261305.1	RP4-584D14.7	7.51	3e-13	2.44e-10	0.47	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150322545	chr7:150341771~150342607:+
LUAD	cis	rs9322193	0.961	rs9027	ENSG00000223701.3	RAET1E-AS1	7.51	3e-13	2.44e-10	0.38	0.32	Lung cancer;	chr6:149594921	chr6:149884431~149919508:+
LUAD	cis	rs9487094	0.67	rs12193719	ENSG00000260273.1	RP11-425D10.10	7.5	3e-13	2.44e-10	0.42	0.32	Height;	chr6:109589051	chr6:109382795~109383666:+
LUAD	cis	rs7646881	1	rs7646881	ENSG00000240207.5	RP11-379F4.4	-7.5	3e-13	2.44e-10	-0.39	-0.32	Tetralogy of Fallot;	chr3:158735490	chr3:158732263~158784070:+
LUAD	cis	rs1501911	0.53	rs161933	ENSG00000248489.1	CTD-2007H13.3	7.5	3.01e-13	2.45e-10	0.35	0.32	Lung function (FEV1/FVC);	chr5:98874643	chr5:98929171~98995013:+
LUAD	cis	rs1501911	0.53	rs161938	ENSG00000248489.1	CTD-2007H13.3	7.5	3.01e-13	2.45e-10	0.35	0.32	Lung function (FEV1/FVC);	chr5:98875501	chr5:98929171~98995013:+
LUAD	cis	rs2153535	0.58	rs1410766	ENSG00000230939.1	RP11-314C16.1	-7.5	3.01e-13	2.45e-10	-0.39	-0.32	Motion sickness;	chr6:8525127	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.601	rs1928183	ENSG00000230939.1	RP11-314C16.1	-7.5	3.01e-13	2.45e-10	-0.39	-0.32	Motion sickness;	chr6:8529785	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1328862	ENSG00000230939.1	RP11-314C16.1	-7.5	3.02e-13	2.46e-10	-0.39	-0.32	Motion sickness;	chr6:8526448	chr6:8784178~8785445:+
LUAD	cis	rs8059260	0.545	rs2286972	ENSG00000274038.1	RP11-66H6.4	-7.5	3.03e-13	2.47e-10	-0.58	-0.32	Alcohol consumption over the past year;	chr16:11061141	chr16:11056556~11057034:+
LUAD	cis	rs7811142	0.83	rs11761253	ENSG00000242294.5	STAG3L5P	7.5	3.05e-13	2.48e-10	0.29	0.32	Platelet count;	chr7:100341698	chr7:100336079~100351900:+
LUAD	cis	rs6504950	0.85	rs2628309	ENSG00000275710.1	RP11-257O5.4	-7.5	3.05e-13	2.48e-10	-0.42	-0.32	Breast cancer;	chr17:55038058	chr17:54964474~54964679:+
LUAD	cis	rs35160687	0.901	rs12472390	ENSG00000273080.1	RP11-301O19.1	7.5	3.05e-13	2.49e-10	0.36	0.32	Night sleep phenotypes;	chr2:86247960	chr2:86195590~86196049:+
LUAD	cis	rs7567389	1	rs7567389	ENSG00000236682.1	AC068282.3	7.5	3.06e-13	2.49e-10	0.44	0.32	Self-rated health;	chr2:127225069	chr2:127389130~127400580:+
LUAD	cis	rs9322193	0.884	rs880245	ENSG00000223701.3	RAET1E-AS1	-7.5	3.07e-13	2.5e-10	-0.4	-0.32	Lung cancer;	chr6:149846262	chr6:149884431~149919508:+
LUAD	cis	rs9326248	0.53	rs2471884	ENSG00000280143.1	AP000892.6	7.5	3.07e-13	2.5e-10	0.51	0.32	Blood protein levels;	chr11:117139604	chr11:117204967~117210292:+
LUAD	cis	rs9322193	0.962	rs4869730	ENSG00000223701.3	RAET1E-AS1	7.5	3.09e-13	2.51e-10	0.38	0.32	Lung cancer;	chr6:149808187	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs2151913	ENSG00000223701.3	RAET1E-AS1	7.5	3.09e-13	2.51e-10	0.38	0.32	Lung cancer;	chr6:149809506	chr6:149884431~149919508:+
LUAD	cis	rs6991838	0.584	rs7842085	ENSG00000200714.1	Y_RNA	7.5	3.09e-13	2.51e-10	0.41	0.32	Intelligence (multi-trait analysis);	chr8:65636787	chr8:65592731~65592820:+
LUAD	cis	rs673078	0.66	rs61943535	ENSG00000275759.1	RP11-131L12.3	-7.5	3.1e-13	2.52e-10	-0.47	-0.32	Glucose homeostasis traits;	chr12:118168307	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.66	rs76621503	ENSG00000275759.1	RP11-131L12.3	-7.5	3.1e-13	2.52e-10	-0.47	-0.32	Glucose homeostasis traits;	chr12:118179370	chr12:118428281~118428870:+
LUAD	cis	rs7646881	1	rs73015655	ENSG00000240207.5	RP11-379F4.4	-7.5	3.1e-13	2.53e-10	-0.39	-0.32	Tetralogy of Fallot;	chr3:158734093	chr3:158732263~158784070:+
LUAD	cis	rs7646881	0.904	rs112493023	ENSG00000240207.5	RP11-379F4.4	-7.5	3.11e-13	2.53e-10	-0.38	-0.32	Tetralogy of Fallot;	chr3:158730487	chr3:158732263~158784070:+
LUAD	cis	rs12468226	0.689	rs73989733	ENSG00000273456.1	RP11-686O6.2	7.5	3.11e-13	2.53e-10	0.47	0.32	Urate levels;	chr2:202115241	chr2:202374932~202375604:-
LUAD	cis	rs6142102	0.923	rs6059635	ENSG00000276073.1	RP5-1125A11.7	-7.5	3.12e-13	2.54e-10	-0.34	-0.32	Skin pigmentation;	chr20:34025687	chr20:33985617~33988989:-
LUAD	cis	rs2946504	0.501	rs2977092	ENSG00000251468.2	RP11-369K16.1	-7.5	3.13e-13	2.54e-10	-0.39	-0.32	Type 2 diabetes;	chr8:12949867	chr8:12958387~12962200:+
LUAD	cis	rs10129255	0.828	rs10140989	ENSG00000280411.1	IGHV1-69-2	-7.5	3.13e-13	2.55e-10	-0.25	-0.32	Kawasaki disease;	chr14:106668657	chr14:106762092~106762588:-
LUAD	cis	rs4660456	0.913	rs2744808	ENSG00000237899.1	RP4-739H11.3	-7.5	3.14e-13	2.55e-10	-0.45	-0.32	Platelet count;	chr1:40712271	chr1:40669089~40687588:-
LUAD	cis	rs8059260	0.736	rs16957872	ENSG00000274038.1	RP11-66H6.4	-7.5	3.14e-13	2.56e-10	-0.59	-0.32	Alcohol consumption over the past year;	chr16:10988835	chr16:11056556~11057034:+
LUAD	cis	rs2283792	0.967	rs743409	ENSG00000224086.5	LL22NC03-86G7.1	-7.5	3.16e-13	2.56e-10	-0.31	-0.32	Multiple sclerosis;	chr22:21774926	chr22:21938293~21977632:+
LUAD	cis	rs11690935	0.527	rs7586556	ENSG00000228389.1	AC068039.4	-7.5	3.16e-13	2.57e-10	-0.35	-0.32	Schizophrenia;	chr2:172036983	chr2:171773482~171775844:+
LUAD	cis	rs9487094	0.626	rs1980591	ENSG00000260273.1	RP11-425D10.10	7.5	3.18e-13	2.58e-10	0.42	0.32	Height;	chr6:109618620	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.696	rs12191353	ENSG00000260273.1	RP11-425D10.10	7.5	3.18e-13	2.58e-10	0.42	0.32	Height;	chr6:109620772	chr6:109382795~109383666:+
LUAD	cis	rs10875746	0.556	rs4760619	ENSG00000240399.1	RP1-228P16.1	-7.5	3.2e-13	2.6e-10	-0.5	-0.32	Longevity (90 years and older);	chr12:48106148	chr12:48054813~48055591:-
LUAD	cis	rs9322193	0.632	rs3828700	ENSG00000223701.3	RAET1E-AS1	7.49	3.21e-13	2.61e-10	0.38	0.32	Lung cancer;	chr6:149791033	chr6:149884431~149919508:+
LUAD	cis	rs9545047	0.604	rs7329331	ENSG00000227676.3	LINC01068	7.49	3.24e-13	2.62e-10	0.38	0.32	Schizophrenia;	chr13:79384986	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs7330479	ENSG00000227676.3	LINC01068	7.49	3.24e-13	2.62e-10	0.38	0.32	Schizophrenia;	chr13:79385058	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs6563104	ENSG00000227676.3	LINC01068	7.49	3.24e-13	2.62e-10	0.38	0.32	Schizophrenia;	chr13:79389718	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs7981500	ENSG00000227676.3	LINC01068	7.49	3.24e-13	2.62e-10	0.38	0.32	Schizophrenia;	chr13:79391461	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs57821487	ENSG00000227676.3	LINC01068	7.49	3.24e-13	2.62e-10	0.38	0.32	Schizophrenia;	chr13:79392810	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs7323246	ENSG00000227676.3	LINC01068	7.49	3.24e-13	2.62e-10	0.38	0.32	Schizophrenia;	chr13:79392903	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs7331766	ENSG00000227676.3	LINC01068	7.49	3.24e-13	2.62e-10	0.38	0.32	Schizophrenia;	chr13:79394076	chr13:79566727~79571436:+
LUAD	cis	rs7208859	0.623	rs9899268	ENSG00000263531.1	RP13-753N3.1	7.49	3.25e-13	2.63e-10	0.65	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30823237	chr17:30863921~30864940:-
LUAD	cis	rs9545047	0.588	rs9530913	ENSG00000227676.3	LINC01068	7.49	3.25e-13	2.63e-10	0.38	0.32	Schizophrenia;	chr13:79384539	chr13:79566727~79571436:+
LUAD	cis	rs1577917	0.545	rs9294338	ENSG00000203875.9	SNHG5	7.49	3.27e-13	2.65e-10	0.42	0.32	Response to antipsychotic treatment;	chr6:85764650	chr6:85660950~85678736:-
LUAD	cis	rs10200159	0.744	rs6725101	ENSG00000272606.1	RP11-554J4.1	7.49	3.27e-13	2.65e-10	0.53	0.32	Vitiligo;	chr2:55659736	chr2:55617909~55618373:+
LUAD	cis	rs10200159	0.744	rs10496044	ENSG00000272606.1	RP11-554J4.1	7.49	3.27e-13	2.65e-10	0.53	0.32	Vitiligo;	chr2:55660614	chr2:55617909~55618373:+
LUAD	cis	rs34779708	0.801	rs12255409	ENSG00000230534.5	RP11-297A16.2	7.49	3.28e-13	2.66e-10	0.39	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35246497	chr10:35098006~35127020:-
LUAD	cis	rs7429990	0.833	rs1486915	ENSG00000229759.1	MRPS18AP1	-7.49	3.32e-13	2.68e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47781053	chr3:48256350~48256938:-
LUAD	cis	rs2739330	0.76	rs1002286	ENSG00000228039.3	KB-1125A3.10	-7.49	3.32e-13	2.69e-10	-0.39	-0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23963780~23964374:+
LUAD	cis	rs237743	1	rs67733885	ENSG00000222365.1	SNORD12B	-7.49	3.32e-13	2.69e-10	-0.37	-0.32	Height;	chr20:49280020	chr20:49280319~49280409:+
LUAD	cis	rs237743	0.963	rs35772539	ENSG00000222365.1	SNORD12B	-7.49	3.32e-13	2.69e-10	-0.37	-0.32	Height;	chr20:49282748	chr20:49280319~49280409:+
LUAD	cis	rs172166	0.61	rs156737	ENSG00000216901.1	AL022393.7	7.49	3.34e-13	2.7e-10	0.37	0.32	Cardiac Troponin-T levels;	chr6:27927435	chr6:28176188~28176674:+
LUAD	cis	rs2919917	0.628	rs2717544	ENSG00000254352.1	RP11-578O24.2	-7.49	3.34e-13	2.7e-10	-0.42	-0.32	Lymphocyte counts;	chr8:78724307	chr8:78723796~78724136:-
LUAD	cis	rs950880	0.71	rs56331791	ENSG00000234389.1	AC007278.3	-7.49	3.34e-13	2.7e-10	-0.34	-0.32	Serum protein levels (sST2);	chr2:102431697	chr2:102438713~102440475:+
LUAD	cis	rs7044106	0.791	rs12554440	ENSG00000238181.2	AHCYP2	-7.49	3.34e-13	2.7e-10	-0.43	-0.32	Hip circumference adjusted for BMI;	chr9:120723055	chr9:120720673~120721972:+
LUAD	cis	rs950169	1	rs12915234	ENSG00000225151.9	GOLGA2P7	-7.49	3.35e-13	2.71e-10	-0.46	-0.32	Schizophrenia;	chr15:84089549	chr15:84199311~84230136:-
LUAD	cis	rs950169	1	rs34751999	ENSG00000225151.9	GOLGA2P7	-7.49	3.35e-13	2.71e-10	-0.46	-0.32	Schizophrenia;	chr15:84089667	chr15:84199311~84230136:-
LUAD	cis	rs8059260	0.668	rs16957894	ENSG00000274038.1	RP11-66H6.4	-7.49	3.37e-13	2.72e-10	-0.59	-0.32	Alcohol consumption over the past year;	chr16:10996501	chr16:11056556~11057034:+
LUAD	cis	rs7208859	0.623	rs7208441	ENSG00000263531.1	RP13-753N3.1	7.49	3.39e-13	2.74e-10	0.65	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30863921~30864940:-
LUAD	cis	rs944289	0.708	rs7158599	ENSG00000257826.1	RP11-116N8.4	-7.49	3.39e-13	2.74e-10	-0.34	-0.32	Thyroid cancer;	chr14:36111976	chr14:36061026~36067190:-
LUAD	cis	rs7208859	0.623	rs7219361	ENSG00000263531.1	RP13-753N3.1	7.49	3.39e-13	2.75e-10	0.66	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30863921~30864940:-
LUAD	cis	rs9640161	0.711	rs3735170	ENSG00000261305.1	RP4-584D14.7	7.49	3.41e-13	2.75e-10	0.48	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150337095	chr7:150341771~150342607:+
LUAD	cis	rs9640161	0.75	rs3735169	ENSG00000261305.1	RP4-584D14.7	7.49	3.41e-13	2.75e-10	0.48	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150337289	chr7:150341771~150342607:+
LUAD	cis	rs12468226	0.689	rs17651413	ENSG00000273456.1	RP11-686O6.2	7.49	3.42e-13	2.77e-10	0.5	0.32	Urate levels;	chr2:202104086	chr2:202374932~202375604:-
LUAD	cis	rs35160687	0.901	rs6714362	ENSG00000273080.1	RP11-301O19.1	-7.49	3.44e-13	2.78e-10	-0.36	-0.32	Night sleep phenotypes;	chr2:86249465	chr2:86195590~86196049:+
LUAD	cis	rs11155671	0.53	rs9968871	ENSG00000223701.3	RAET1E-AS1	7.48	3.46e-13	2.79e-10	0.39	0.32	Testicular germ cell tumor;	chr6:149888060	chr6:149884431~149919508:+
LUAD	cis	rs11155671	0.53	rs9969044	ENSG00000223701.3	RAET1E-AS1	7.48	3.46e-13	2.79e-10	0.39	0.32	Testicular germ cell tumor;	chr6:149888068	chr6:149884431~149919508:+
LUAD	cis	rs10200159	1	rs7594497	ENSG00000272606.1	RP11-554J4.1	7.48	3.46e-13	2.8e-10	0.52	0.32	Vitiligo;	chr2:55645403	chr2:55617909~55618373:+
LUAD	cis	rs9322193	1	rs58189451	ENSG00000223701.3	RAET1E-AS1	7.48	3.48e-13	2.81e-10	0.38	0.32	Lung cancer;	chr6:149600252	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.884	rs1108889	ENSG00000223701.3	RAET1E-AS1	7.48	3.48e-13	2.81e-10	0.4	0.32	Lung cancer;	chr6:149845433	chr6:149884431~149919508:+
LUAD	cis	rs638893	0.853	rs4938549	ENSG00000278376.1	RP11-158I9.8	-7.48	3.49e-13	2.82e-10	-0.47	-0.32	Vitiligo;	chr11:118830888	chr11:118791254~118793137:+
LUAD	cis	rs638893	0.898	rs530646	ENSG00000278376.1	RP11-158I9.8	-7.48	3.49e-13	2.82e-10	-0.47	-0.32	Vitiligo;	chr11:118830959	chr11:118791254~118793137:+
LUAD	cis	rs7429990	0.965	rs17785248	ENSG00000229759.1	MRPS18AP1	7.48	3.51e-13	2.83e-10	0.39	0.32	Educational attainment (years of education);	chr3:47631425	chr3:48256350~48256938:-
LUAD	cis	rs733592	0.504	rs2261608	ENSG00000240399.1	RP1-228P16.1	7.48	3.53e-13	2.85e-10	0.31	0.32	Plateletcrit;	chr12:48327851	chr12:48054813~48055591:-
LUAD	cis	rs2283792	0.967	rs3810609	ENSG00000224086.5	LL22NC03-86G7.1	-7.48	3.54e-13	2.86e-10	-0.3	-0.32	Multiple sclerosis;	chr22:21758513	chr22:21938293~21977632:+
LUAD	cis	rs9322193	0.962	rs9478848	ENSG00000223701.3	RAET1E-AS1	7.48	3.54e-13	2.86e-10	0.38	0.32	Lung cancer;	chr6:149825080	chr6:149884431~149919508:+
LUAD	cis	rs6142102	0.961	rs4911392	ENSG00000276073.1	RP5-1125A11.7	-7.48	3.54e-13	2.86e-10	-0.33	-0.32	Skin pigmentation;	chr20:33982712	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.961	rs4911393	ENSG00000276073.1	RP5-1125A11.7	-7.48	3.54e-13	2.86e-10	-0.33	-0.32	Skin pigmentation;	chr20:33983120	chr20:33985617~33988989:-
LUAD	cis	rs7615952	0.611	rs7632305	ENSG00000171084.14	FAM86JP	7.48	3.58e-13	2.89e-10	0.58	0.32	Blood pressure (smoking interaction);	chr3:125915924	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.673	rs9841194	ENSG00000171084.14	FAM86JP	7.48	3.58e-13	2.89e-10	0.58	0.32	Blood pressure (smoking interaction);	chr3:125916896	chr3:125916620~125930024:+
LUAD	cis	rs4660456	0.711	rs12409109	ENSG00000237899.1	RP4-739H11.3	-7.48	3.58e-13	2.89e-10	-0.45	-0.32	Platelet count;	chr1:40727216	chr1:40669089~40687588:-
LUAD	cis	rs10129255	0.834	rs10139893	ENSG00000211972.2	IGHV3-66	7.48	3.6e-13	2.9e-10	0.29	0.32	Kawasaki disease;	chr14:106711377	chr14:106675017~106675544:-
LUAD	cis	rs4660456	0.913	rs552147	ENSG00000237899.1	RP4-739H11.3	-7.48	3.6e-13	2.91e-10	-0.44	-0.32	Platelet count;	chr1:40689141	chr1:40669089~40687588:-
LUAD	cis	rs9322193	0.886	rs4870049	ENSG00000223701.3	RAET1E-AS1	7.48	3.62e-13	2.92e-10	0.38	0.32	Lung cancer;	chr6:149837058	chr6:149884431~149919508:+
LUAD	cis	rs9532669	0.926	rs4942014	ENSG00000176268.5	CYCSP34	7.48	3.62e-13	2.92e-10	0.31	0.32	Cervical cancer;	chr13:40966366	chr13:40863599~40863902:-
LUAD	cis	rs6504950	0.889	rs1156287	ENSG00000275710.1	RP11-257O5.4	-7.48	3.64e-13	2.93e-10	-0.42	-0.32	Breast cancer;	chr17:54999438	chr17:54964474~54964679:+
LUAD	cis	rs6095360	0.517	rs237700	ENSG00000222365.1	SNORD12B	-7.48	3.65e-13	2.94e-10	-0.36	-0.32	Intelligence (multi-trait analysis);	chr20:49293285	chr20:49280319~49280409:+
LUAD	cis	rs2439831	0.717	rs2470132	ENSG00000205771.5	CATSPER2P1	-7.48	3.67e-13	2.96e-10	-0.56	-0.32	Lung cancer in ever smokers;	chr15:43543283	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.867	rs2255051	ENSG00000205771.5	CATSPER2P1	-7.48	3.67e-13	2.96e-10	-0.56	-0.32	Lung cancer in ever smokers;	chr15:43553963	chr15:43726918~43747094:-
LUAD	cis	rs35160687	0.901	rs35762338	ENSG00000273080.1	RP11-301O19.1	7.47	3.7e-13	2.98e-10	0.36	0.32	Night sleep phenotypes;	chr2:86286430	chr2:86195590~86196049:+
LUAD	cis	rs9595908	1	rs7992980	ENSG00000212293.1	SNORA16	7.47	3.7e-13	2.98e-10	0.35	0.32	Body mass index;	chr13:32607005	chr13:32420390~32420516:-
LUAD	cis	rs6921919	0.697	rs758398	ENSG00000216901.1	AL022393.7	7.47	3.7e-13	2.98e-10	0.39	0.32	Autism spectrum disorder or schizophrenia;	chr6:28352897	chr6:28176188~28176674:+
LUAD	cis	rs7688540	0.723	rs7687112	ENSG00000275426.1	CH17-262A2.1	7.47	3.72e-13	2.99e-10	0.43	0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:249767	chr4:149738~150317:+
LUAD	cis	rs3779195	0.697	rs13232861	ENSG00000272950.1	RP11-307C18.1	7.47	3.72e-13	3e-10	0.54	0.32	Sex hormone-binding globulin levels;	chr7:98299769	chr7:98322853~98323430:+
LUAD	cis	rs853679	0.517	rs4713141	ENSG00000219392.1	RP1-265C24.5	-7.47	3.75e-13	3.02e-10	-0.46	-0.32	Depression;	chr6:28133900	chr6:28115628~28116551:+
LUAD	cis	rs673078	0.66	rs7973455	ENSG00000275759.1	RP11-131L12.3	-7.47	3.75e-13	3.02e-10	-0.46	-0.32	Glucose homeostasis traits;	chr12:118247490	chr12:118428281~118428870:+
LUAD	cis	rs7945705	0.902	rs2016942	ENSG00000254860.4	TMEM9B-AS1	-7.47	3.75e-13	3.02e-10	-0.36	-0.32	Hemoglobin concentration;	chr11:8917240	chr11:8964675~8977527:+
LUAD	cis	rs6844153	0.715	rs73813220	ENSG00000240005.4	RP11-293A21.1	-7.47	3.76e-13	3.03e-10	-0.46	-0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26920224	chr4:26859806~26860599:-
LUAD	cis	rs944289	0.708	rs34232378	ENSG00000257826.1	RP11-116N8.4	-7.47	3.76e-13	3.03e-10	-0.34	-0.32	Thyroid cancer;	chr14:36102879	chr14:36061026~36067190:-
LUAD	cis	rs2842992	0.83	rs2758312	ENSG00000237927.1	RP3-393E18.2	-7.47	3.77e-13	3.03e-10	-0.46	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159732420	chr6:159586955~159589169:-
LUAD	cis	rs17711722	0.522	rs4642526	ENSG00000226824.5	RP4-756H11.3	-7.47	3.78e-13	3.04e-10	-0.4	-0.32	Calcium levels;	chr7:65751755	chr7:66654538~66669855:+
LUAD	cis	rs10129255	0.957	rs28887506	ENSG00000280411.1	IGHV1-69-2	-7.47	3.78e-13	3.04e-10	-0.25	-0.32	Kawasaki disease;	chr14:106785589	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.957	rs10142918	ENSG00000280411.1	IGHV1-69-2	-7.47	3.79e-13	3.05e-10	-0.24	-0.32	Kawasaki disease;	chr14:106782206	chr14:106762092~106762588:-
LUAD	cis	rs7044106	0.655	rs1359329	ENSG00000226752.6	PSMD5-AS1	-7.47	3.8e-13	3.05e-10	-0.43	-0.32	Hip circumference adjusted for BMI;	chr9:120608707	chr9:120824828~120854385:+
LUAD	cis	rs7688540	0.656	rs79657896	ENSG00000275426.1	CH17-262A2.1	7.47	3.81e-13	3.06e-10	0.48	0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:305472	chr4:149738~150317:+
LUAD	cis	rs6844153	0.938	rs111946747	ENSG00000240005.4	RP11-293A21.1	-7.47	3.82e-13	3.07e-10	-0.56	-0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26988996	chr4:26859806~26860599:-
LUAD	cis	rs9545047	0.604	rs9545085	ENSG00000227676.3	LINC01068	7.47	3.82e-13	3.07e-10	0.38	0.32	Schizophrenia;	chr13:79363969	chr13:79566727~79571436:+
LUAD	cis	rs10129255	0.912	rs67410411	ENSG00000280411.1	IGHV1-69-2	-7.47	3.85e-13	3.09e-10	-0.25	-0.32	Kawasaki disease;	chr14:106680324	chr14:106762092~106762588:-
LUAD	cis	rs638893	0.947	rs12808822	ENSG00000278376.1	RP11-158I9.8	-7.47	3.86e-13	3.1e-10	-0.47	-0.32	Vitiligo;	chr11:118831560	chr11:118791254~118793137:+
LUAD	cis	rs6504950	0.889	rs2628305	ENSG00000275710.1	RP11-257O5.4	7.47	3.86e-13	3.1e-10	0.4	0.32	Breast cancer;	chr17:55063066	chr17:54964474~54964679:+
LUAD	cis	rs950169	0.959	rs12911210	ENSG00000225151.9	GOLGA2P7	-7.47	3.88e-13	3.12e-10	-0.44	-0.32	Schizophrenia;	chr15:84123331	chr15:84199311~84230136:-
LUAD	cis	rs10129255	0.833	rs7156689	ENSG00000280411.1	IGHV1-69-2	-7.47	3.88e-13	3.12e-10	-0.24	-0.32	Kawasaki disease;	chr14:106816039	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.957	rs12590735	ENSG00000280411.1	IGHV1-69-2	-7.47	3.89e-13	3.13e-10	-0.25	-0.32	Kawasaki disease;	chr14:106779660	chr14:106762092~106762588:-
LUAD	cis	rs944289	0.708	rs6571736	ENSG00000257826.1	RP11-116N8.4	-7.47	3.92e-13	3.15e-10	-0.34	-0.32	Thyroid cancer;	chr14:36111271	chr14:36061026~36067190:-
LUAD	cis	rs1729407	0.741	rs1263177	ENSG00000254851.1	RP11-109L13.1	-7.47	3.92e-13	3.15e-10	-0.41	-0.32	Apolipoprotein A-IV levels;	chr11:116819996	chr11:117135528~117138582:+
LUAD	cis	rs9640161	0.742	rs2108853	ENSG00000261305.1	RP4-584D14.7	7.47	3.92e-13	3.15e-10	0.47	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150320500	chr7:150341771~150342607:+
LUAD	cis	rs7208859	0.623	rs7220999	ENSG00000263531.1	RP13-753N3.1	7.47	3.94e-13	3.16e-10	0.65	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822280	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs55638872	ENSG00000263531.1	RP13-753N3.1	7.47	3.94e-13	3.16e-10	0.65	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822534	chr17:30863921~30864940:-
LUAD	cis	rs9487094	0.67	rs12197950	ENSG00000260273.1	RP11-425D10.10	7.47	3.94e-13	3.16e-10	0.42	0.32	Height;	chr6:109642186	chr6:109382795~109383666:+
LUAD	cis	rs6504950	0.889	rs1484776	ENSG00000275710.1	RP11-257O5.4	-7.47	3.94e-13	3.16e-10	-0.4	-0.32	Breast cancer;	chr17:55034022	chr17:54964474~54964679:+
LUAD	cis	rs6504622	0.721	rs7215903	ENSG00000262879.4	RP11-156P1.3	-7.46	3.94e-13	3.17e-10	-0.37	-0.32	Orofacial clefts;	chr17:47097100	chr17:46984045~47100323:-
LUAD	cis	rs2946504	0.501	rs2946509	ENSG00000251468.2	RP11-369K16.1	-7.46	3.96e-13	3.18e-10	-0.4	-0.32	Type 2 diabetes;	chr8:12950782	chr8:12958387~12962200:+
LUAD	cis	rs240993	0.809	rs11153277	ENSG00000230177.1	RP5-1112D6.4	-7.46	3.96e-13	3.18e-10	-0.31	-0.32	Inflammatory skin disease;Psoriasis;	chr6:111259358	chr6:111277932~111278742:+
LUAD	cis	rs2880765	0.566	rs17553790	ENSG00000259295.5	CSPG4P12	-7.46	3.97e-13	3.19e-10	-0.39	-0.32	Coronary artery disease;	chr15:85470434	chr15:85191438~85213905:+
LUAD	cis	rs638893	1	rs649338	ENSG00000278376.1	RP11-158I9.8	-7.46	3.98e-13	3.2e-10	-0.47	-0.32	Vitiligo;	chr11:118834945	chr11:118791254~118793137:+
LUAD	cis	rs10200159	1	rs3748955	ENSG00000272606.1	RP11-554J4.1	7.46	3.99e-13	3.2e-10	0.56	0.32	Vitiligo;	chr2:55626335	chr2:55617909~55618373:+
LUAD	cis	rs944289	0.679	rs8016148	ENSG00000257826.1	RP11-116N8.4	-7.46	3.99e-13	3.2e-10	-0.34	-0.32	Thyroid cancer;	chr14:36111688	chr14:36061026~36067190:-
LUAD	cis	rs11155671	0.53	rs9397398	ENSG00000223701.3	RAET1E-AS1	7.46	3.99e-13	3.2e-10	0.37	0.32	Testicular germ cell tumor;	chr6:149872467	chr6:149884431~149919508:+
LUAD	cis	rs9487094	0.67	rs11754340	ENSG00000260273.1	RP11-425D10.10	7.46	4e-13	3.21e-10	0.42	0.32	Height;	chr6:109584789	chr6:109382795~109383666:+
LUAD	cis	rs4713118	0.505	rs276371	ENSG00000216901.1	AL022393.7	7.46	4e-13	3.21e-10	0.36	0.32	Parkinson's disease;	chr6:27942930	chr6:28176188~28176674:+
LUAD	cis	rs2015599	0.601	rs17715086	ENSG00000257176.2	RP11-996F15.2	-7.46	4.01e-13	3.22e-10	-0.35	-0.32	Platelet count;Mean platelet volume;	chr12:29329073	chr12:29280418~29317848:-
LUAD	cis	rs11089937	0.597	rs5757007	ENSG00000211639.2	IGLV4-60	7.46	4.02e-13	3.22e-10	0.39	0.32	Periodontitis (PAL4Q3);	chr22:22135167	chr22:22162199~22162681:+
LUAD	cis	rs12468226	0.689	rs17656903	ENSG00000273456.1	RP11-686O6.2	-7.46	4.03e-13	3.23e-10	-0.49	-0.32	Urate levels;	chr2:202106312	chr2:202374932~202375604:-
LUAD	cis	rs9545047	0.604	rs9530915	ENSG00000227676.3	LINC01068	7.46	4.03e-13	3.23e-10	0.38	0.32	Schizophrenia;	chr13:79396512	chr13:79566727~79571436:+
LUAD	cis	rs9640161	0.789	rs1464751	ENSG00000261305.1	RP4-584D14.7	7.46	4.04e-13	3.24e-10	0.47	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150324193	chr7:150341771~150342607:+
LUAD	cis	rs11089937	0.524	rs2877021	ENSG00000211639.2	IGLV4-60	7.46	4.04e-13	3.24e-10	0.36	0.32	Periodontitis (PAL4Q3);	chr22:22165909	chr22:22162199~22162681:+
LUAD	cis	rs8059260	0.542	rs7184915	ENSG00000274038.1	RP11-66H6.4	-7.46	4.05e-13	3.25e-10	-0.56	-0.32	Alcohol consumption over the past year;	chr16:11034509	chr16:11056556~11057034:+
LUAD	cis	rs237743	1	rs238217	ENSG00000222365.1	SNORD12B	-7.46	4.05e-13	3.25e-10	-0.36	-0.32	Height;	chr20:49254902	chr20:49280319~49280409:+
LUAD	cis	rs7811142	0.83	rs11768967	ENSG00000242294.5	STAG3L5P	7.46	4.07e-13	3.26e-10	0.27	0.32	Platelet count;	chr7:100370021	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.83	rs6975660	ENSG00000242294.5	STAG3L5P	7.46	4.07e-13	3.26e-10	0.27	0.32	Platelet count;	chr7:100377643	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.83	rs73401443	ENSG00000242294.5	STAG3L5P	7.46	4.07e-13	3.26e-10	0.27	0.32	Platelet count;	chr7:100379959	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.83	rs10085549	ENSG00000242294.5	STAG3L5P	7.46	4.07e-13	3.26e-10	0.27	0.32	Platelet count;	chr7:100385512	chr7:100336079~100351900:+
LUAD	cis	rs6844153	0.68	rs6833053	ENSG00000240005.4	RP11-293A21.1	-7.46	4.07e-13	3.26e-10	-0.47	-0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26870838	chr4:26859806~26860599:-
LUAD	cis	rs673078	0.66	rs58113338	ENSG00000275759.1	RP11-131L12.3	-7.46	4.08e-13	3.27e-10	-0.46	-0.32	Glucose homeostasis traits;	chr12:118251335	chr12:118428281~118428870:+
LUAD	cis	rs10129255	0.828	rs10140989	ENSG00000211972.2	IGHV3-66	7.46	4.08e-13	3.27e-10	0.28	0.32	Kawasaki disease;	chr14:106668657	chr14:106675017~106675544:-
LUAD	cis	rs11123170	0.529	rs112692022	ENSG00000189223.12	PAX8-AS1	-7.46	4.08e-13	3.27e-10	-0.52	-0.32	Renal function-related traits (BUN);	chr2:113212605	chr2:113211522~113276581:+
LUAD	cis	rs9545047	0.589	rs9545090	ENSG00000227676.3	LINC01068	7.46	4.08e-13	3.27e-10	0.38	0.32	Schizophrenia;	chr13:79367276	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs9530902	ENSG00000227676.3	LINC01068	7.46	4.08e-13	3.27e-10	0.38	0.32	Schizophrenia;	chr13:79367748	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs9545092	ENSG00000227676.3	LINC01068	7.46	4.08e-13	3.27e-10	0.38	0.32	Schizophrenia;	chr13:79369809	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.611	rs9545093	ENSG00000227676.3	LINC01068	7.46	4.08e-13	3.27e-10	0.38	0.32	Schizophrenia;	chr13:79371969	chr13:79566727~79571436:+
LUAD	cis	rs7208859	0.524	rs77498725	ENSG00000263531.1	RP13-753N3.1	7.46	4.11e-13	3.29e-10	0.66	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30736968	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.573	rs73267865	ENSG00000263531.1	RP13-753N3.1	7.46	4.11e-13	3.29e-10	0.66	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737186	chr17:30863921~30864940:-
LUAD	cis	rs7115242	0.8	rs7131536	ENSG00000280143.1	AP000892.6	7.46	4.11e-13	3.29e-10	0.51	0.32	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117128730	chr11:117204967~117210292:+
LUAD	cis	rs9322193	0.962	rs7740784	ENSG00000223701.3	RAET1E-AS1	7.46	4.12e-13	3.3e-10	0.39	0.32	Lung cancer;	chr6:149833364	chr6:149884431~149919508:+
LUAD	cis	rs75422866	0.867	rs73102125	ENSG00000274902.1	RP1-197B17.4	7.46	4.13e-13	3.3e-10	0.7	0.32	Pneumonia;	chr12:47637869	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs12426849	ENSG00000274902.1	RP1-197B17.4	7.46	4.13e-13	3.3e-10	0.7	0.32	Pneumonia;	chr12:47638975	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs117950951	ENSG00000274902.1	RP1-197B17.4	7.46	4.13e-13	3.3e-10	0.7	0.32	Pneumonia;	chr12:47639794	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs7954764	ENSG00000274902.1	RP1-197B17.4	7.46	4.13e-13	3.3e-10	0.7	0.32	Pneumonia;	chr12:47641136	chr12:47731908~47732351:+
LUAD	cis	rs9640161	0.75	rs11769348	ENSG00000261305.1	RP4-584D14.7	-7.46	4.13e-13	3.31e-10	-0.47	-0.32	Blood protein levels;Circulating chemerin levels;	chr7:150329664	chr7:150341771~150342607:+
LUAD	cis	rs7208859	0.524	rs59923796	ENSG00000263531.1	RP13-753N3.1	7.46	4.15e-13	3.32e-10	0.66	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737901	chr17:30863921~30864940:-
LUAD	cis	rs17826219	0.5	rs57005940	ENSG00000263531.1	RP13-753N3.1	7.46	4.15e-13	3.32e-10	0.66	0.32	Body mass index;	chr17:30739311	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.573	rs73267872	ENSG00000263531.1	RP13-753N3.1	7.46	4.15e-13	3.32e-10	0.66	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30740189	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs56812022	ENSG00000263531.1	RP13-753N3.1	7.46	4.15e-13	3.32e-10	0.66	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741715	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.524	rs57670615	ENSG00000263531.1	RP13-753N3.1	7.46	4.15e-13	3.32e-10	0.66	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30742480	chr17:30863921~30864940:-
LUAD	cis	rs17826219	0.5	rs2874724	ENSG00000263531.1	RP13-753N3.1	7.46	4.15e-13	3.32e-10	0.66	0.32	Body mass index;	chr17:30745415	chr17:30863921~30864940:-
LUAD	cis	rs17826219	0.568	rs9898097	ENSG00000263531.1	RP13-753N3.1	7.46	4.15e-13	3.32e-10	0.66	0.32	Body mass index;	chr17:30745654	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs9911490	ENSG00000263531.1	RP13-753N3.1	7.46	4.15e-13	3.32e-10	0.66	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30745995	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs7503542	ENSG00000263531.1	RP13-753N3.1	7.46	4.15e-13	3.32e-10	0.66	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746812	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.573	rs11656278	ENSG00000263531.1	RP13-753N3.1	7.46	4.15e-13	3.32e-10	0.66	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748170	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs6505207	ENSG00000263531.1	RP13-753N3.1	7.46	4.15e-13	3.32e-10	0.66	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749553	chr17:30863921~30864940:-
LUAD	cis	rs10129255	0.957	rs10142859	ENSG00000280411.1	IGHV1-69-2	-7.46	4.16e-13	3.33e-10	-0.24	-0.32	Kawasaki disease;	chr14:106782238	chr14:106762092~106762588:-
LUAD	cis	rs6504622	0.693	rs12950276	ENSG00000262879.4	RP11-156P1.3	-7.46	4.17e-13	3.33e-10	-0.37	-0.32	Orofacial clefts;	chr17:47095819	chr17:46984045~47100323:-
LUAD	cis	rs6504622	0.755	rs12950699	ENSG00000262879.4	RP11-156P1.3	-7.46	4.17e-13	3.33e-10	-0.37	-0.32	Orofacial clefts;	chr17:47096296	chr17:46984045~47100323:-
LUAD	cis	rs6504622	0.748	rs7215573	ENSG00000262879.4	RP11-156P1.3	-7.46	4.17e-13	3.33e-10	-0.37	-0.32	Orofacial clefts;	chr17:47096887	chr17:46984045~47100323:-
LUAD	cis	rs62229266	0.839	rs11088335	ENSG00000214914.3	RPL23AP3	7.46	4.18e-13	3.34e-10	0.38	0.32	Mitral valve prolapse;	chr21:36098037	chr21:36016079~36016546:-
LUAD	cis	rs7615952	0.611	rs9681518	ENSG00000171084.14	FAM86JP	7.46	4.18e-13	3.34e-10	0.59	0.32	Blood pressure (smoking interaction);	chr3:125896287	chr3:125916620~125930024:+
LUAD	cis	rs6504950	0.886	rs2787500	ENSG00000275710.1	RP11-257O5.4	-7.46	4.19e-13	3.35e-10	-0.39	-0.32	Breast cancer;	chr17:55092445	chr17:54964474~54964679:+
LUAD	cis	rs7208859	0.623	rs73267858	ENSG00000263531.1	RP13-753N3.1	7.46	4.2e-13	3.35e-10	0.65	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732719	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs56095789	ENSG00000263531.1	RP13-753N3.1	7.46	4.2e-13	3.35e-10	0.65	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733152	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs11656844	ENSG00000263531.1	RP13-753N3.1	7.46	4.2e-13	3.35e-10	0.65	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733579	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs11652533	ENSG00000263531.1	RP13-753N3.1	7.46	4.2e-13	3.35e-10	0.65	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733583	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs11652631	ENSG00000263531.1	RP13-753N3.1	7.46	4.2e-13	3.35e-10	0.65	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733748	chr17:30863921~30864940:-
LUAD	cis	rs10129255	0.917	rs7142373	ENSG00000211972.2	IGHV3-66	7.46	4.21e-13	3.36e-10	0.29	0.32	Kawasaki disease;	chr14:106708947	chr14:106675017~106675544:-
LUAD	cis	rs8059260	0.604	rs741177	ENSG00000274038.1	RP11-66H6.4	-7.46	4.21e-13	3.36e-10	-0.59	-0.32	Alcohol consumption over the past year;	chr16:11051791	chr16:11056556~11057034:+
LUAD	cis	rs9322193	0.923	rs9766004	ENSG00000223701.3	RAET1E-AS1	7.45	4.24e-13	3.38e-10	0.37	0.32	Lung cancer;	chr6:149754363	chr6:149884431~149919508:+
LUAD	cis	rs2286503	0.966	rs6949233	ENSG00000228649.7	AC005682.5	7.45	4.25e-13	3.39e-10	0.4	0.32	Fibrinogen;	chr7:22818572	chr7:22854178~22861579:+
LUAD	cis	rs2153535	0.58	rs6597337	ENSG00000230939.1	RP11-314C16.1	-7.45	4.26e-13	3.4e-10	-0.38	-0.32	Motion sickness;	chr6:8531419	chr6:8784178~8785445:+
LUAD	cis	rs10129255	0.784	rs7147210	ENSG00000211972.2	IGHV3-66	7.45	4.27e-13	3.41e-10	0.29	0.32	Kawasaki disease;	chr14:106705271	chr14:106675017~106675544:-
LUAD	cis	rs12134133	0.962	rs6682586	ENSG00000274245.1	RP11-357P18.2	7.45	4.27e-13	3.41e-10	0.43	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207243122	chr1:207372559~207373252:+
LUAD	cis	rs12134133	0.962	rs6668560	ENSG00000274245.1	RP11-357P18.2	7.45	4.27e-13	3.41e-10	0.43	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207243462	chr1:207372559~207373252:+
LUAD	cis	rs11155671	0.546	rs1999633	ENSG00000216906.2	RP11-350J20.9	7.45	4.28e-13	3.41e-10	0.46	0.32	Testicular germ cell tumor;	chr6:149866576	chr6:149904243~149906418:+
LUAD	cis	rs9487094	0.666	rs7748669	ENSG00000260273.1	RP11-425D10.10	7.45	4.28e-13	3.42e-10	0.41	0.32	Height;	chr6:109424139	chr6:109382795~109383666:+
LUAD	cis	rs10129255	0.556	rs8010005	ENSG00000211970.3	IGHV4-61	-7.45	4.29e-13	3.42e-10	-0.23	-0.32	Kawasaki disease;	chr14:106777987	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.556	rs6576224	ENSG00000211970.3	IGHV4-61	-7.45	4.29e-13	3.42e-10	-0.23	-0.32	Kawasaki disease;	chr14:106777997	chr14:106639119~106639657:-
LUAD	cis	rs6921919	0.638	rs9468344	ENSG00000216901.1	AL022393.7	7.45	4.29e-13	3.42e-10	0.38	0.32	Autism spectrum disorder or schizophrenia;	chr6:28341792	chr6:28176188~28176674:+
LUAD	cis	rs950880	0.744	rs3771156	ENSG00000234389.1	AC007278.3	-7.45	4.29e-13	3.42e-10	-0.34	-0.32	Serum protein levels (sST2);	chr2:102420217	chr2:102438713~102440475:+
LUAD	cis	rs9322193	0.923	rs1984111	ENSG00000223701.3	RAET1E-AS1	7.45	4.29e-13	3.42e-10	0.38	0.32	Lung cancer;	chr6:149831720	chr6:149884431~149919508:+
LUAD	cis	rs2439831	0.681	rs526450	ENSG00000205771.5	CATSPER2P1	-7.45	4.3e-13	3.43e-10	-0.54	-0.32	Lung cancer in ever smokers;	chr15:43307127	chr15:43726918~43747094:-
LUAD	cis	rs9545047	0.564	rs7336186	ENSG00000227676.3	LINC01068	-7.45	4.3e-13	3.43e-10	-0.38	-0.32	Schizophrenia;	chr13:79385497	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs2182009	ENSG00000227676.3	LINC01068	-7.45	4.3e-13	3.43e-10	-0.38	-0.32	Schizophrenia;	chr13:79397781	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs4605023	ENSG00000227676.3	LINC01068	-7.45	4.3e-13	3.43e-10	-0.38	-0.32	Schizophrenia;	chr13:79398700	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs9565496	ENSG00000227676.3	LINC01068	-7.45	4.3e-13	3.43e-10	-0.38	-0.32	Schizophrenia;	chr13:79398751	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs12877507	ENSG00000227676.3	LINC01068	-7.45	4.3e-13	3.43e-10	-0.38	-0.32	Schizophrenia;	chr13:79401822	chr13:79566727~79571436:+
LUAD	cis	rs9640161	0.789	rs2159234	ENSG00000261305.1	RP4-584D14.7	7.45	4.31e-13	3.43e-10	0.47	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150323333	chr7:150341771~150342607:+
LUAD	cis	rs9640161	0.702	rs3735175	ENSG00000261305.1	RP4-584D14.7	7.45	4.31e-13	3.43e-10	0.47	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150323368	chr7:150341771~150342607:+
LUAD	cis	rs10463554	0.853	rs246907	ENSG00000175749.11	EIF3KP1	7.45	4.31e-13	3.44e-10	0.46	0.32	Parkinson's disease;	chr5:103230577	chr5:103032376~103033031:+
LUAD	cis	rs950169	1	rs35297609	ENSG00000225151.9	GOLGA2P7	-7.45	4.32e-13	3.45e-10	-0.46	-0.32	Schizophrenia;	chr15:84104144	chr15:84199311~84230136:-
LUAD	cis	rs950169	1	rs62026530	ENSG00000225151.9	GOLGA2P7	-7.45	4.32e-13	3.45e-10	-0.46	-0.32	Schizophrenia;	chr15:84107088	chr15:84199311~84230136:-
LUAD	cis	rs6991838	0.67	rs869151	ENSG00000272010.1	CTD-3025N20.3	7.45	4.34e-13	3.46e-10	0.34	0.32	Intelligence (multi-trait analysis);	chr8:65726487	chr8:65591850~65592472:-
LUAD	cis	rs7182621	0.546	rs11632596	ENSG00000182397.13	DNM1P46	7.45	4.35e-13	3.47e-10	0.44	0.32	Colonoscopy-negative controls vs population controls;	chr15:99834385	chr15:99790156~99806927:-
LUAD	cis	rs9545047	0.584	rs1886494	ENSG00000227676.3	LINC01068	-7.45	4.4e-13	3.5e-10	-0.38	-0.32	Schizophrenia;	chr13:79403005	chr13:79566727~79571436:+
LUAD	cis	rs11098499	0.73	rs78971550	ENSG00000248280.1	RP11-33B1.2	7.45	4.42e-13	3.52e-10	0.39	0.32	Corneal astigmatism;	chr4:119359886	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.645	rs78422072	ENSG00000248280.1	RP11-33B1.2	7.45	4.42e-13	3.52e-10	0.39	0.32	Corneal astigmatism;	chr4:119359887	chr4:119440561~119450157:-
LUAD	cis	rs11690935	0.549	rs62183819	ENSG00000228389.1	AC068039.4	-7.45	4.47e-13	3.55e-10	-0.35	-0.32	Schizophrenia;	chr2:172039610	chr2:171773482~171775844:+
LUAD	cis	rs2439831	0.681	rs11858152	ENSG00000205771.5	CATSPER2P1	-7.45	4.48e-13	3.56e-10	-0.53	-0.32	Lung cancer in ever smokers;	chr15:43341998	chr15:43726918~43747094:-
LUAD	cis	rs7615952	0.8	rs11915699	ENSG00000171084.14	FAM86JP	7.45	4.48e-13	3.57e-10	0.47	0.32	Blood pressure (smoking interaction);	chr3:125913841	chr3:125916620~125930024:+
LUAD	cis	rs10200159	1	rs6712314	ENSG00000272606.1	RP11-554J4.1	7.45	4.49e-13	3.57e-10	0.55	0.32	Vitiligo;	chr2:55626901	chr2:55617909~55618373:+
LUAD	cis	rs6504950	0.889	rs2628296	ENSG00000275710.1	RP11-257O5.4	-7.45	4.51e-13	3.58e-10	-0.4	-0.32	Breast cancer;	chr17:55089134	chr17:54964474~54964679:+
LUAD	cis	rs944289	0.74	rs10498332	ENSG00000257826.1	RP11-116N8.4	-7.44	4.52e-13	3.6e-10	-0.33	-0.32	Thyroid cancer;	chr14:36102348	chr14:36061026~36067190:-
LUAD	cis	rs9595908	0.865	rs743760	ENSG00000212293.1	SNORA16	-7.44	4.53e-13	3.6e-10	-0.39	-0.32	Body mass index;	chr13:32496990	chr13:32420390~32420516:-
LUAD	cis	rs673078	0.615	rs61943528	ENSG00000275759.1	RP11-131L12.3	-7.44	4.53e-13	3.6e-10	-0.47	-0.32	Glucose homeostasis traits;	chr12:118163134	chr12:118428281~118428870:+
LUAD	cis	rs11089937	0.568	rs5756988	ENSG00000211639.2	IGLV4-60	-7.44	4.53e-13	3.6e-10	-0.37	-0.32	Periodontitis (PAL4Q3);	chr22:22132397	chr22:22162199~22162681:+
LUAD	cis	rs638893	1	rs73005500	ENSG00000278376.1	RP11-158I9.8	7.44	4.54e-13	3.61e-10	0.5	0.32	Vitiligo;	chr11:118826666	chr11:118791254~118793137:+
LUAD	cis	rs10129255	0.833	rs61997797	ENSG00000211970.3	IGHV4-61	-7.44	4.55e-13	3.62e-10	-0.25	-0.32	Kawasaki disease;	chr14:106815190	chr14:106639119~106639657:-
LUAD	cis	rs9595908	0.965	rs8000071	ENSG00000212293.1	SNORA16	7.44	4.56e-13	3.62e-10	0.37	0.32	Body mass index;	chr13:32551236	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.965	rs7984903	ENSG00000212293.1	SNORA16	7.44	4.56e-13	3.62e-10	0.37	0.32	Body mass index;	chr13:32552002	chr13:32420390~32420516:-
LUAD	cis	rs7429990	0.965	rs35012836	ENSG00000229759.1	MRPS18AP1	7.44	4.58e-13	3.64e-10	0.38	0.32	Educational attainment (years of education);	chr3:47670000	chr3:48256350~48256938:-
LUAD	cis	rs6504950	0.925	rs244336	ENSG00000275710.1	RP11-257O5.4	7.44	4.58e-13	3.64e-10	0.4	0.32	Breast cancer;	chr17:55124141	chr17:54964474~54964679:+
LUAD	cis	rs9322193	0.923	rs9371486	ENSG00000223701.3	RAET1E-AS1	7.44	4.59e-13	3.64e-10	0.4	0.32	Lung cancer;	chr6:149832090	chr6:149884431~149919508:+
LUAD	cis	rs7208859	0.623	rs11657662	ENSG00000263531.1	RP13-753N3.1	-7.44	4.59e-13	3.65e-10	-0.65	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30863921~30864940:-
LUAD	cis	rs2153535	0.58	rs7745043	ENSG00000230939.1	RP11-314C16.1	-7.44	4.59e-13	3.65e-10	-0.38	-0.32	Motion sickness;	chr6:8513274	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9406170	ENSG00000230939.1	RP11-314C16.1	-7.44	4.59e-13	3.65e-10	-0.38	-0.32	Motion sickness;	chr6:8513920	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9379222	ENSG00000230939.1	RP11-314C16.1	-7.44	4.59e-13	3.65e-10	-0.38	-0.32	Motion sickness;	chr6:8514555	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9406172	ENSG00000230939.1	RP11-314C16.1	-7.44	4.59e-13	3.65e-10	-0.38	-0.32	Motion sickness;	chr6:8515231	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9406174	ENSG00000230939.1	RP11-314C16.1	-7.44	4.59e-13	3.65e-10	-0.38	-0.32	Motion sickness;	chr6:8516531	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs2143356	ENSG00000230939.1	RP11-314C16.1	-7.44	4.59e-13	3.65e-10	-0.38	-0.32	Motion sickness;	chr6:8517442	chr6:8784178~8785445:+
LUAD	cis	rs10129255	0.957	rs1024349	ENSG00000280411.1	IGHV1-69-2	-7.44	4.61e-13	3.66e-10	-0.24	-0.32	Kawasaki disease;	chr14:106689997	chr14:106762092~106762588:-
LUAD	cis	rs2283792	1	rs2266967	ENSG00000224086.5	LL22NC03-86G7.1	-7.44	4.63e-13	3.67e-10	-0.3	-0.32	Multiple sclerosis;	chr22:21802500	chr22:21938293~21977632:+
LUAD	cis	rs7811142	0.83	rs7792959	ENSG00000242294.5	STAG3L5P	7.44	4.65e-13	3.69e-10	0.27	0.32	Platelet count;	chr7:100374780	chr7:100336079~100351900:+
LUAD	cis	rs10875746	0.669	rs4760701	ENSG00000240399.1	RP1-228P16.1	-7.44	4.67e-13	3.7e-10	-0.37	-0.32	Longevity (90 years and older);	chr12:48304735	chr12:48054813~48055591:-
LUAD	cis	rs17482078	0.879	rs10050860	ENSG00000248734.2	CTD-2260A17.1	-7.44	4.67e-13	3.7e-10	-0.4	-0.32	Behcet's disease;Blood protein levels;	chr5:96786506	chr5:96784777~96785999:+
LUAD	cis	rs6991838	0.702	rs13274205	ENSG00000272010.1	CTD-3025N20.3	7.44	4.68e-13	3.71e-10	0.33	0.32	Intelligence (multi-trait analysis);	chr8:65708124	chr8:65591850~65592472:-
LUAD	cis	rs673078	0.66	rs16948197	ENSG00000275759.1	RP11-131L12.3	7.44	4.68e-13	3.72e-10	0.45	0.32	Glucose homeostasis traits;	chr12:118239135	chr12:118428281~118428870:+
LUAD	cis	rs2153535	0.58	rs2327067	ENSG00000230939.1	RP11-314C16.1	-7.44	4.7e-13	3.73e-10	-0.38	-0.32	Motion sickness;	chr6:8518249	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.541	rs9328477	ENSG00000230939.1	RP11-314C16.1	-7.44	4.7e-13	3.73e-10	-0.38	-0.32	Motion sickness;	chr6:8518876	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9328478	ENSG00000230939.1	RP11-314C16.1	-7.44	4.7e-13	3.73e-10	-0.38	-0.32	Motion sickness;	chr6:8518950	chr6:8784178~8785445:+
LUAD	cis	rs4660456	0.913	rs6661855	ENSG00000237899.1	RP4-739H11.3	7.44	4.7e-13	3.73e-10	0.45	0.32	Platelet count;	chr1:40703245	chr1:40669089~40687588:-
LUAD	cis	rs2280018	0.963	rs12928424	ENSG00000260735.1	RP11-72I8.1	-7.44	4.73e-13	3.75e-10	-0.34	-0.32	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056916	chr16:15094411~15109197:+
LUAD	cis	rs150992	0.711	rs161735	ENSG00000248489.1	CTD-2007H13.3	7.44	4.73e-13	3.76e-10	0.36	0.32	Body mass index;	chr5:98862026	chr5:98929171~98995013:+
LUAD	cis	rs7208859	0.623	rs59447372	ENSG00000263531.1	RP13-753N3.1	7.44	4.75e-13	3.77e-10	0.65	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30730567	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs8079891	ENSG00000263531.1	RP13-753N3.1	7.44	4.75e-13	3.77e-10	0.65	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30731845	chr17:30863921~30864940:-
LUAD	cis	rs9595908	0.931	rs55645971	ENSG00000212293.1	SNORA16	7.44	4.8e-13	3.81e-10	0.35	0.32	Body mass index;	chr13:32615452	chr13:32420390~32420516:-
LUAD	cis	rs950169	1	rs12902672	ENSG00000225151.9	GOLGA2P7	-7.44	4.8e-13	3.81e-10	-0.45	-0.32	Schizophrenia;	chr15:84048234	chr15:84199311~84230136:-
LUAD	cis	rs673078	0.607	rs17440669	ENSG00000275759.1	RP11-131L12.3	-7.44	4.81e-13	3.81e-10	-0.48	-0.32	Glucose homeostasis traits;	chr12:118310397	chr12:118428281~118428870:+
LUAD	cis	rs7208859	0.573	rs7223803	ENSG00000263531.1	RP13-753N3.1	7.44	4.82e-13	3.82e-10	0.66	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750175	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs55814012	ENSG00000263531.1	RP13-753N3.1	7.44	4.82e-13	3.82e-10	0.66	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750679	chr17:30863921~30864940:-
LUAD	cis	rs17826219	0.5	rs2449749	ENSG00000263531.1	RP13-753N3.1	7.44	4.82e-13	3.82e-10	0.66	0.32	Body mass index;	chr17:30751280	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs9894709	ENSG00000263531.1	RP13-753N3.1	7.44	4.82e-13	3.82e-10	0.66	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751436	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs9896603	ENSG00000263531.1	RP13-753N3.1	7.44	4.82e-13	3.82e-10	0.66	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751494	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs8080882	ENSG00000263531.1	RP13-753N3.1	7.44	4.82e-13	3.82e-10	0.66	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30754128	chr17:30863921~30864940:-
LUAD	cis	rs8040855	0.559	rs6496801	ENSG00000259774.1	RP11-182J1.13	-7.43	4.84e-13	3.83e-10	-0.39	-0.32	Bulimia nervosa;	chr15:85185168	chr15:84422618~84425882:+
LUAD	cis	rs10463554	0.889	rs246908	ENSG00000175749.11	EIF3KP1	7.43	4.85e-13	3.84e-10	0.46	0.32	Parkinson's disease;	chr5:103228476	chr5:103032376~103033031:+
LUAD	cis	rs8005677	0.962	rs8003934	ENSG00000279656.1	RP11-298I3.6	7.43	4.86e-13	3.85e-10	0.38	0.32	Cognitive ability (multi-trait analysis);	chr14:22931933	chr14:23023083~23024217:-
LUAD	cis	rs56046484	0.75	rs12900078	ENSG00000259295.5	CSPG4P12	7.43	4.87e-13	3.85e-10	0.54	0.32	Testicular germ cell tumor;	chr15:84980738	chr15:85191438~85213905:+
LUAD	cis	rs17826219	0.5	rs28452421	ENSG00000263531.1	RP13-753N3.1	7.43	4.9e-13	3.87e-10	0.65	0.32	Body mass index;	chr17:30756962	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.573	rs28779471	ENSG00000263531.1	RP13-753N3.1	7.43	4.9e-13	3.87e-10	0.65	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30863921~30864940:-
LUAD	cis	rs17826219	0.5	rs61685770	ENSG00000263531.1	RP13-753N3.1	7.43	4.9e-13	3.87e-10	0.65	0.32	Body mass index;	chr17:30758695	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs57486336	ENSG00000263531.1	RP13-753N3.1	7.43	4.9e-13	3.87e-10	0.65	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs12103440	ENSG00000263531.1	RP13-753N3.1	7.43	4.9e-13	3.87e-10	0.65	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs11657777	ENSG00000263531.1	RP13-753N3.1	7.43	4.9e-13	3.87e-10	0.65	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30863921~30864940:-
LUAD	cis	rs9545047	0.604	rs1853830	ENSG00000227676.3	LINC01068	-7.43	4.93e-13	3.9e-10	-0.38	-0.32	Schizophrenia;	chr13:79406877	chr13:79566727~79571436:+
LUAD	cis	rs944289	0.746	rs7145546	ENSG00000257826.1	RP11-116N8.4	-7.43	4.94e-13	3.91e-10	-0.35	-0.32	Thyroid cancer;	chr14:36089040	chr14:36061026~36067190:-
LUAD	cis	rs9640161	0.789	rs1464752	ENSG00000261305.1	RP4-584D14.7	7.43	4.97e-13	3.93e-10	0.47	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150324195	chr7:150341771~150342607:+
LUAD	cis	rs9640161	0.789	rs1464753	ENSG00000261305.1	RP4-584D14.7	7.43	4.97e-13	3.93e-10	0.47	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150324261	chr7:150341771~150342607:+
LUAD	cis	rs944289	0.746	rs7145211	ENSG00000257826.1	RP11-116N8.4	-7.43	4.97e-13	3.93e-10	-0.35	-0.32	Thyroid cancer;	chr14:36089060	chr14:36061026~36067190:-
LUAD	cis	rs2153535	0.505	rs1737583	ENSG00000230939.1	RP11-314C16.1	-7.43	4.98e-13	3.94e-10	-0.38	-0.32	Motion sickness;	chr6:8536579	chr6:8784178~8785445:+
LUAD	cis	rs56046484	0.75	rs62022525	ENSG00000259295.5	CSPG4P12	7.43	4.99e-13	3.94e-10	0.54	0.32	Testicular germ cell tumor;	chr15:84980447	chr15:85191438~85213905:+
LUAD	cis	rs9326248	0.53	rs7122944	ENSG00000280143.1	AP000892.6	7.43	4.99e-13	3.94e-10	0.51	0.32	Blood protein levels;	chr11:117163903	chr11:117204967~117210292:+
LUAD	cis	rs7115242	0.514	rs4936367	ENSG00000280143.1	AP000892.6	7.43	4.99e-13	3.94e-10	0.51	0.32	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117171661	chr11:117204967~117210292:+
LUAD	cis	rs9326248	0.53	rs4604928	ENSG00000280143.1	AP000892.6	7.43	4.99e-13	3.94e-10	0.51	0.32	Blood protein levels;	chr11:117173487	chr11:117204967~117210292:+
LUAD	cis	rs1185460	0.565	rs538478	ENSG00000271751.1	RP11-110I1.14	7.43	5.01e-13	3.96e-10	0.4	0.32	Coronary artery disease;	chr11:119054629	chr11:119065263~119065677:-
LUAD	cis	rs9545047	0.604	rs8001392	ENSG00000227676.3	LINC01068	7.43	5.01e-13	3.96e-10	0.37	0.32	Schizophrenia;	chr13:79374211	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs4146473	ENSG00000227676.3	LINC01068	7.43	5.01e-13	3.96e-10	0.37	0.32	Schizophrenia;	chr13:79374548	chr13:79566727~79571436:+
LUAD	cis	rs2280018	0.963	rs11075255	ENSG00000260735.1	RP11-72I8.1	-7.43	5.02e-13	3.96e-10	-0.34	-0.32	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072375	chr16:15094411~15109197:+
LUAD	cis	rs2412819	0.597	rs541871	ENSG00000205771.5	CATSPER2P1	-7.43	5.03e-13	3.97e-10	-0.48	-0.32	Lung cancer;	chr15:43868656	chr15:43726918~43747094:-
LUAD	cis	rs9640161	0.789	rs3735174	ENSG00000261305.1	RP4-584D14.7	7.43	5.04e-13	3.98e-10	0.46	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150323400	chr7:150341771~150342607:+
LUAD	cis	rs9640161	0.75	rs3735173	ENSG00000261305.1	RP4-584D14.7	7.43	5.04e-13	3.98e-10	0.46	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150323437	chr7:150341771~150342607:+
LUAD	cis	rs6142102	0.961	rs2377957	ENSG00000276073.1	RP5-1125A11.7	-7.43	5.06e-13	3.99e-10	-0.33	-0.32	Skin pigmentation;	chr20:33966667	chr20:33985617~33988989:-
LUAD	cis	rs853679	0.517	rs9393891	ENSG00000219392.1	RP1-265C24.5	-7.43	5.06e-13	3.99e-10	-0.45	-0.32	Depression;	chr6:28111382	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9468286	ENSG00000219392.1	RP1-265C24.5	-7.43	5.06e-13	3.99e-10	-0.45	-0.32	Depression;	chr6:28111650	chr6:28115628~28116551:+
LUAD	cis	rs11690935	0.688	rs7600835	ENSG00000228389.1	AC068039.4	7.43	5.07e-13	4e-10	0.36	0.32	Schizophrenia;	chr2:171665317	chr2:171773482~171775844:+
LUAD	cis	rs9322193	0.884	rs11155689	ENSG00000223701.3	RAET1E-AS1	7.43	5.07e-13	4e-10	0.38	0.32	Lung cancer;	chr6:149808470	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.884	rs933055	ENSG00000223701.3	RAET1E-AS1	7.43	5.07e-13	4e-10	0.38	0.32	Lung cancer;	chr6:149809701	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs4869731	ENSG00000223701.3	RAET1E-AS1	7.43	5.07e-13	4e-10	0.38	0.32	Lung cancer;	chr6:149810072	chr6:149884431~149919508:+
LUAD	cis	rs9595908	0.897	rs10083285	ENSG00000212293.1	SNORA16	7.43	5.07e-13	4e-10	0.35	0.32	Body mass index;	chr13:32557205	chr13:32420390~32420516:-
LUAD	cis	rs7684253	0.587	rs4339274	ENSG00000269949.1	RP11-738E22.3	7.43	5.09e-13	4.01e-10	0.42	0.32	Migraine;	chr4:56881468	chr4:56960927~56961373:-
LUAD	cis	rs1185460	0.546	rs17075	ENSG00000271751.1	RP11-110I1.14	7.43	5.09e-13	4.02e-10	0.39	0.32	Coronary artery disease;	chr11:119088621	chr11:119065263~119065677:-
LUAD	cis	rs7301826	0.627	rs7315707	ENSG00000256299.1	RP11-989F5.3	7.43	5.11e-13	4.03e-10	0.41	0.32	Plasma plasminogen activator levels;	chr12:130788274	chr12:130810821~130812622:-
LUAD	cis	rs7811142	0.775	rs1636980	ENSG00000242294.5	STAG3L5P	-7.43	5.11e-13	4.03e-10	-0.28	-0.32	Platelet count;	chr7:100341241	chr7:100336079~100351900:+
LUAD	cis	rs4591358	0.648	rs7557471	ENSG00000223466.1	AC064834.2	-7.43	5.13e-13	4.05e-10	-0.45	-0.32	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195520713	chr2:195533035~195538681:+
LUAD	cis	rs9322193	0.504	rs7771014	ENSG00000223701.3	RAET1E-AS1	7.43	5.13e-13	4.05e-10	0.37	0.32	Lung cancer;	chr6:149884310	chr6:149884431~149919508:+
LUAD	cis	rs150992	0.525	rs331930	ENSG00000248489.1	CTD-2007H13.3	7.43	5.13e-13	4.05e-10	0.36	0.32	Body mass index;	chr5:98833559	chr5:98929171~98995013:+
LUAD	cis	rs7044106	0.887	rs1359328	ENSG00000226752.6	PSMD5-AS1	-7.43	5.14e-13	4.05e-10	-0.38	-0.32	Hip circumference adjusted for BMI;	chr9:120608544	chr9:120824828~120854385:+
LUAD	cis	rs75422866	0.867	rs73104163	ENSG00000274902.1	RP1-197B17.4	7.43	5.14e-13	4.05e-10	0.75	0.32	Pneumonia;	chr12:47706187	chr12:47731908~47732351:+
LUAD	cis	rs75422866	1	rs12423045	ENSG00000274902.1	RP1-197B17.4	7.43	5.14e-13	4.05e-10	0.75	0.32	Pneumonia;	chr12:47706275	chr12:47731908~47732351:+
LUAD	cis	rs10129255	0.957	rs2013423	ENSG00000280411.1	IGHV1-69-2	-7.43	5.14e-13	4.06e-10	-0.24	-0.32	Kawasaki disease;	chr14:106690675	chr14:106762092~106762588:-
LUAD	cis	rs2015599	0.623	rs3782505	ENSG00000257176.2	RP11-996F15.2	7.42	5.19e-13	4.09e-10	0.35	0.32	Platelet count;Mean platelet volume;	chr12:29292236	chr12:29280418~29317848:-
LUAD	cis	rs9322193	0.962	rs3763163	ENSG00000223701.3	RAET1E-AS1	7.42	5.19e-13	4.09e-10	0.38	0.32	Lung cancer;	chr6:149819770	chr6:149884431~149919508:+
LUAD	cis	rs6142102	0.961	rs6120487	ENSG00000276073.1	RP5-1125A11.7	-7.42	5.22e-13	4.11e-10	-0.33	-0.32	Skin pigmentation;	chr20:34034802	chr20:33985617~33988989:-
LUAD	cis	rs2739330	0.76	rs1007888	ENSG00000228039.3	KB-1125A3.10	7.42	5.23e-13	4.11e-10	0.38	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23963780~23964374:+
LUAD	cis	rs4423214	0.524	rs4944046	ENSG00000254682.1	RP11-660L16.2	7.42	5.23e-13	4.12e-10	0.41	0.32	Vitamin D levels;	chr11:71412748	chr11:71448674~71452157:+
LUAD	cis	rs7188445	1	rs12444166	ENSG00000261390.4	RP11-345M22.2	-7.42	5.25e-13	4.13e-10	-0.43	-0.32	Urate levels;	chr16:79676053	chr16:79715232~79770563:-
LUAD	cis	rs7646881	0.767	rs58152433	ENSG00000240207.5	RP11-379F4.4	-7.42	5.25e-13	4.14e-10	-0.42	-0.32	Tetralogy of Fallot;	chr3:158738851	chr3:158732263~158784070:+
LUAD	cis	rs673078	0.66	rs17586342	ENSG00000275759.1	RP11-131L12.3	-7.42	5.28e-13	4.16e-10	-0.43	-0.32	Glucose homeostasis traits;	chr12:118162399	chr12:118428281~118428870:+
LUAD	cis	rs7396835	0.551	rs10750098	ENSG00000254851.1	RP11-109L13.1	-7.42	5.29e-13	4.16e-10	-0.57	-0.32	Quantitative traits;	chr11:116834852	chr11:117135528~117138582:+
LUAD	cis	rs10129255	0.5	rs4774008	ENSG00000211970.3	IGHV4-61	-7.42	5.29e-13	4.17e-10	-0.23	-0.32	Kawasaki disease;	chr14:106681273	chr14:106639119~106639657:-
LUAD	cis	rs9322193	0.607	rs6557165	ENSG00000216906.2	RP11-350J20.9	-7.42	5.33e-13	4.19e-10	-0.45	-0.32	Lung cancer;	chr6:149906883	chr6:149904243~149906418:+
LUAD	cis	rs2153535	0.521	rs6939827	ENSG00000230939.1	RP11-314C16.1	-7.42	5.34e-13	4.2e-10	-0.39	-0.32	Motion sickness;	chr6:8461127	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9393019	ENSG00000230939.1	RP11-314C16.1	-7.42	5.34e-13	4.2e-10	-0.39	-0.32	Motion sickness;	chr6:8461858	chr6:8784178~8785445:+
LUAD	cis	rs9322193	0.962	rs1889473	ENSG00000223701.3	RAET1E-AS1	7.42	5.35e-13	4.21e-10	0.38	0.32	Lung cancer;	chr6:149825485	chr6:149884431~149919508:+
LUAD	cis	rs9487094	0.67	rs11755641	ENSG00000260273.1	RP11-425D10.10	7.42	5.35e-13	4.21e-10	0.42	0.32	Height;	chr6:109586733	chr6:109382795~109383666:+
LUAD	cis	rs9322193	0.962	rs6903998	ENSG00000223701.3	RAET1E-AS1	7.42	5.35e-13	4.21e-10	0.38	0.32	Lung cancer;	chr6:149831357	chr6:149884431~149919508:+
LUAD	cis	rs10129255	0.5	rs988132	ENSG00000211970.3	IGHV4-61	-7.42	5.38e-13	4.23e-10	-0.23	-0.32	Kawasaki disease;	chr14:106776758	chr14:106639119~106639657:-
LUAD	cis	rs17023223	0.581	rs61808932	ENSG00000231365.4	RP11-418J17.1	-7.42	5.39e-13	4.24e-10	-0.44	-0.32	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119101197	chr1:119140396~119275973:+
LUAD	cis	rs1185460	0.546	rs2508948	ENSG00000271751.1	RP11-110I1.14	7.42	5.42e-13	4.27e-10	0.41	0.32	Coronary artery disease;	chr11:119080932	chr11:119065263~119065677:-
LUAD	cis	rs673078	0.66	rs7970481	ENSG00000275759.1	RP11-131L12.3	-7.42	5.43e-13	4.27e-10	-0.46	-0.32	Glucose homeostasis traits;	chr12:118242112	chr12:118428281~118428870:+
LUAD	cis	rs9322193	0.923	rs12175504	ENSG00000223701.3	RAET1E-AS1	7.42	5.45e-13	4.28e-10	0.37	0.32	Lung cancer;	chr6:149664079	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs62439843	ENSG00000223701.3	RAET1E-AS1	7.42	5.45e-13	4.28e-10	0.37	0.32	Lung cancer;	chr6:149676521	chr6:149884431~149919508:+
LUAD	cis	rs853679	0.517	rs9393896	ENSG00000219392.1	RP1-265C24.5	-7.42	5.45e-13	4.29e-10	-0.46	-0.32	Depression;	chr6:28159925	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9393897	ENSG00000219392.1	RP1-265C24.5	-7.42	5.45e-13	4.29e-10	-0.46	-0.32	Depression;	chr6:28159932	chr6:28115628~28116551:+
LUAD	cis	rs4660456	0.913	rs6667368	ENSG00000237899.1	RP4-739H11.3	7.42	5.46e-13	4.29e-10	0.44	0.32	Platelet count;	chr1:40694887	chr1:40669089~40687588:-
LUAD	cis	rs4713118	0.516	rs7739216	ENSG00000219392.1	RP1-265C24.5	-7.42	5.49e-13	4.31e-10	-0.45	-0.32	Parkinson's disease;	chr6:28112168	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs35512245	ENSG00000219392.1	RP1-265C24.5	-7.42	5.49e-13	4.31e-10	-0.45	-0.32	Depression;	chr6:28112175	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9380055	ENSG00000219392.1	RP1-265C24.5	-7.42	5.49e-13	4.31e-10	-0.45	-0.32	Depression;	chr6:28113851	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9368553	ENSG00000219392.1	RP1-265C24.5	-7.42	5.49e-13	4.31e-10	-0.45	-0.32	Depression;	chr6:28114487	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9368554	ENSG00000219392.1	RP1-265C24.5	-7.42	5.49e-13	4.31e-10	-0.45	-0.32	Depression;	chr6:28114933	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs4713137	ENSG00000219392.1	RP1-265C24.5	-7.42	5.49e-13	4.31e-10	-0.45	-0.32	Depression;	chr6:28115743	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9348793	ENSG00000219392.1	RP1-265C24.5	-7.42	5.49e-13	4.31e-10	-0.45	-0.32	Depression;	chr6:28116411	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.586	rs6905516	ENSG00000219392.1	RP1-265C24.5	-7.42	5.49e-13	4.31e-10	-0.45	-0.32	Parkinson's disease;	chr6:28118700	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.586	rs6905522	ENSG00000219392.1	RP1-265C24.5	-7.42	5.49e-13	4.31e-10	-0.45	-0.32	Parkinson's disease;	chr6:28118701	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.586	rs9468290	ENSG00000219392.1	RP1-265C24.5	-7.42	5.49e-13	4.31e-10	-0.45	-0.32	Parkinson's disease;	chr6:28119896	chr6:28115628~28116551:+
LUAD	cis	rs11155671	0.53	rs6557133	ENSG00000223701.3	RAET1E-AS1	7.42	5.5e-13	4.32e-10	0.37	0.32	Testicular germ cell tumor;	chr6:149874248	chr6:149884431~149919508:+
LUAD	cis	rs853679	0.517	rs2281588	ENSG00000219392.1	RP1-265C24.5	-7.42	5.51e-13	4.33e-10	-0.45	-0.32	Depression;	chr6:28104824	chr6:28115628~28116551:+
LUAD	cis	rs950169	0.922	rs17531523	ENSG00000225151.9	GOLGA2P7	-7.42	5.52e-13	4.33e-10	-0.45	-0.32	Schizophrenia;	chr15:84589218	chr15:84199311~84230136:-
LUAD	cis	rs11214589	0.87	rs10789942	ENSG00000270179.1	RP11-159N11.4	7.42	5.52e-13	4.33e-10	0.32	0.32	Neuroticism;	chr11:113365477	chr11:113368478~113369117:+
LUAD	cis	rs2153535	0.601	rs2143352	ENSG00000230939.1	RP11-314C16.1	-7.41	5.54e-13	4.35e-10	-0.38	-0.32	Motion sickness;	chr6:8530015	chr6:8784178~8785445:+
LUAD	cis	rs7945705	0.869	rs4909952	ENSG00000254860.4	TMEM9B-AS1	-7.41	5.56e-13	4.36e-10	-0.36	-0.32	Hemoglobin concentration;	chr11:8942399	chr11:8964675~8977527:+
LUAD	cis	rs9487094	0.67	rs12194157	ENSG00000260273.1	RP11-425D10.10	7.41	5.58e-13	4.38e-10	0.42	0.32	Height;	chr6:109640141	chr6:109382795~109383666:+
LUAD	cis	rs35160687	0.901	rs12620833	ENSG00000273080.1	RP11-301O19.1	7.41	5.58e-13	4.38e-10	0.36	0.32	Night sleep phenotypes;	chr2:86245747	chr2:86195590~86196049:+
LUAD	cis	rs7811142	0.83	rs1063945	ENSG00000242294.5	STAG3L5P	7.41	5.59e-13	4.38e-10	0.28	0.32	Platelet count;	chr7:100332824	chr7:100336079~100351900:+
LUAD	cis	rs2153535	0.58	rs6597335	ENSG00000230939.1	RP11-314C16.1	-7.41	5.6e-13	4.39e-10	-0.38	-0.32	Motion sickness;	chr6:8527481	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9328486	ENSG00000230939.1	RP11-314C16.1	-7.41	5.6e-13	4.39e-10	-0.38	-0.32	Motion sickness;	chr6:8527775	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs2183112	ENSG00000230939.1	RP11-314C16.1	-7.41	5.6e-13	4.39e-10	-0.38	-0.32	Motion sickness;	chr6:8527979	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.601	rs2143353	ENSG00000230939.1	RP11-314C16.1	-7.41	5.6e-13	4.39e-10	-0.38	-0.32	Motion sickness;	chr6:8529878	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.601	rs7741024	ENSG00000230939.1	RP11-314C16.1	-7.41	5.6e-13	4.39e-10	-0.38	-0.32	Motion sickness;	chr6:8530080	chr6:8784178~8785445:+
LUAD	cis	rs2286503	1	rs2286503	ENSG00000228649.7	AC005682.5	7.41	5.6e-13	4.39e-10	0.39	0.32	Fibrinogen;	chr7:22816987	chr7:22854178~22861579:+
LUAD	cis	rs9601248	0.874	rs2093621	ENSG00000227676.3	LINC01068	7.41	5.61e-13	4.4e-10	0.41	0.32	Major depressive disorder;	chr13:79613953	chr13:79566727~79571436:+
LUAD	cis	rs9601248	0.874	rs2093620	ENSG00000227676.3	LINC01068	7.41	5.61e-13	4.4e-10	0.41	0.32	Major depressive disorder;	chr13:79613954	chr13:79566727~79571436:+
LUAD	cis	rs673078	0.66	rs61945176	ENSG00000275759.1	RP11-131L12.3	-7.41	5.61e-13	4.4e-10	-0.43	-0.32	Glucose homeostasis traits;	chr12:118204735	chr12:118428281~118428870:+
LUAD	cis	rs9487094	0.67	rs12192268	ENSG00000260273.1	RP11-425D10.10	7.41	5.63e-13	4.41e-10	0.43	0.32	Height;	chr6:109690255	chr6:109382795~109383666:+
LUAD	cis	rs2842992	0.714	rs2475564	ENSG00000237927.1	RP3-393E18.2	-7.41	5.65e-13	4.43e-10	-0.45	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159702641	chr6:159586955~159589169:-
LUAD	cis	rs2283792	1	rs9607287	ENSG00000224086.5	LL22NC03-86G7.1	-7.41	5.68e-13	4.45e-10	-0.31	-0.32	Multiple sclerosis;	chr22:21809136	chr22:21938293~21977632:+
LUAD	cis	rs113835537	0.529	rs11821155	ENSG00000255517.5	CTD-3074O7.5	7.41	5.69e-13	4.45e-10	0.37	0.32	Airway imaging phenotypes;	chr11:66478866	chr11:66473490~66480233:-
LUAD	cis	rs8005677	1	rs11157930	ENSG00000279656.1	RP11-298I3.6	7.41	5.69e-13	4.46e-10	0.38	0.32	Cognitive ability (multi-trait analysis);	chr14:22933962	chr14:23023083~23024217:-
LUAD	cis	rs8005677	0.962	rs11157931	ENSG00000279656.1	RP11-298I3.6	7.41	5.69e-13	4.46e-10	0.38	0.32	Cognitive ability (multi-trait analysis);	chr14:22933984	chr14:23023083~23024217:-
LUAD	cis	rs9545047	0.553	rs7332004	ENSG00000227676.3	LINC01068	-7.41	5.74e-13	4.49e-10	-0.37	-0.32	Schizophrenia;	chr13:79364128	chr13:79566727~79571436:+
LUAD	cis	rs75422866	0.867	rs73113143	ENSG00000280054.1	RP1-197B17.7	7.41	5.74e-13	4.5e-10	0.73	0.32	Pneumonia;	chr12:47623060	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs75568526	ENSG00000280054.1	RP1-197B17.7	7.41	5.74e-13	4.5e-10	0.73	0.32	Pneumonia;	chr12:47649718	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs116302411	ENSG00000280054.1	RP1-197B17.7	7.41	5.74e-13	4.5e-10	0.73	0.32	Pneumonia;	chr12:47649788	chr12:47728151~47730598:-
LUAD	cis	rs8031584	0.736	rs11635775	ENSG00000260382.1	RP11-540B6.2	7.41	5.77e-13	4.52e-10	0.41	0.32	Huntington's disease progression;	chr15:30868437	chr15:30882267~30883231:-
LUAD	cis	rs1075265	0.548	rs805448	ENSG00000233266.1	HMGB1P31	7.41	5.8e-13	4.54e-10	0.41	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53950055	chr2:54051334~54051760:+
LUAD	cis	rs7811142	0.83	rs11771936	ENSG00000242294.5	STAG3L5P	7.41	5.8e-13	4.54e-10	0.28	0.32	Platelet count;	chr7:100345660	chr7:100336079~100351900:+
LUAD	cis	rs950880	0.71	rs4140785	ENSG00000234389.1	AC007278.3	-7.41	5.84e-13	4.57e-10	-0.33	-0.32	Serum protein levels (sST2);	chr2:102472057	chr2:102438713~102440475:+
LUAD	cis	rs748404	0.697	rs564946	ENSG00000205771.5	CATSPER2P1	-7.41	5.84e-13	4.57e-10	-0.39	-0.32	Lung cancer;	chr15:43264074	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.723	rs565658	ENSG00000205771.5	CATSPER2P1	-7.41	5.84e-13	4.57e-10	-0.39	-0.32	Lung cancer;	chr15:43264109	chr15:43726918~43747094:-
LUAD	cis	rs34779708	0.733	rs61449529	ENSG00000230534.5	RP11-297A16.2	7.41	5.86e-13	4.58e-10	0.38	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35254986	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.733	rs59287215	ENSG00000230534.5	RP11-297A16.2	7.41	5.86e-13	4.58e-10	0.38	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35255066	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.702	rs35969476	ENSG00000230534.5	RP11-297A16.2	7.41	5.86e-13	4.58e-10	0.38	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35255390	chr10:35098006~35127020:-
LUAD	cis	rs62229266	0.654	rs62230787	ENSG00000214914.3	RPL23AP3	7.41	5.88e-13	4.6e-10	0.41	0.32	Mitral valve prolapse;	chr21:36004182	chr21:36016079~36016546:-
LUAD	cis	rs7208859	0.573	rs79505916	ENSG00000263531.1	RP13-753N3.1	7.41	5.88e-13	4.6e-10	0.65	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30735308	chr17:30863921~30864940:-
LUAD	cis	rs9595908	0.965	rs2239748	ENSG00000212293.1	SNORA16	7.41	5.91e-13	4.62e-10	0.38	0.32	Body mass index;	chr13:32527680	chr13:32420390~32420516:-
LUAD	cis	rs9601248	0.874	rs9545158	ENSG00000227676.3	LINC01068	7.41	5.92e-13	4.63e-10	0.41	0.32	Major depressive disorder;	chr13:79618771	chr13:79566727~79571436:+
LUAD	cis	rs2439831	0.867	rs2251844	ENSG00000205771.5	CATSPER2P1	-7.4	5.92e-13	4.63e-10	-0.56	-0.32	Lung cancer in ever smokers;	chr15:43544280	chr15:43726918~43747094:-
LUAD	cis	rs4853012	0.941	rs7571083	ENSG00000257800.1	FNBP1P1	7.4	5.93e-13	4.64e-10	0.42	0.32	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74120680~74123218:+
LUAD	cis	rs9545047	0.604	rs9318640	ENSG00000227676.3	LINC01068	-7.4	5.97e-13	4.66e-10	-0.38	-0.32	Schizophrenia;	chr13:79426527	chr13:79566727~79571436:+
LUAD	cis	rs10463554	0.963	rs27970	ENSG00000175749.11	EIF3KP1	7.4	5.97e-13	4.67e-10	0.44	0.32	Parkinson's disease;	chr5:103151019	chr5:103032376~103033031:+
LUAD	cis	rs2980439	0.783	rs2955587	ENSG00000253893.2	FAM85B	-7.4	5.99e-13	4.68e-10	-0.41	-0.32	Neuroticism;	chr8:8240557	chr8:8167819~8226614:-
LUAD	cis	rs6504950	0.886	rs2787501	ENSG00000275710.1	RP11-257O5.4	7.4	5.99e-13	4.68e-10	0.38	0.32	Breast cancer;	chr17:55016604	chr17:54964474~54964679:+
LUAD	cis	rs237743	1	rs68014903	ENSG00000222365.1	SNORD12B	-7.4	6.02e-13	4.7e-10	-0.37	-0.32	Height;	chr20:49295502	chr20:49280319~49280409:+
LUAD	cis	rs237743	1	rs67375757	ENSG00000222365.1	SNORD12B	-7.4	6.02e-13	4.7e-10	-0.37	-0.32	Height;	chr20:49299758	chr20:49280319~49280409:+
LUAD	cis	rs1729407	0.706	rs595049	ENSG00000254851.1	RP11-109L13.1	-7.4	6.02e-13	4.7e-10	-0.4	-0.32	Apolipoprotein A-IV levels;	chr11:116828729	chr11:117135528~117138582:+
LUAD	cis	rs9595908	0.965	rs9595893	ENSG00000212293.1	SNORA16	7.4	6.04e-13	4.71e-10	0.35	0.32	Body mass index;	chr13:32601656	chr13:32420390~32420516:-
LUAD	cis	rs944289	0.708	rs1537424	ENSG00000257826.1	RP11-116N8.4	-7.4	6.06e-13	4.73e-10	-0.34	-0.32	Thyroid cancer;	chr14:36104812	chr14:36061026~36067190:-
LUAD	cis	rs12439619	0.693	rs9944185	ENSG00000255769.6	GOLGA2P10	-7.4	6.07e-13	4.74e-10	-0.39	-0.32	Intelligence (multi-trait analysis);	chr15:82157927	chr15:82472993~82513950:-
LUAD	cis	rs9601248	0.845	rs1932197	ENSG00000227676.3	LINC01068	7.4	6.08e-13	4.75e-10	0.41	0.32	Major depressive disorder;	chr13:79609218	chr13:79566727~79571436:+
LUAD	cis	rs8059260	0.736	rs7195509	ENSG00000274038.1	RP11-66H6.4	-7.4	6.09e-13	4.75e-10	-0.58	-0.32	Alcohol consumption over the past year;	chr16:10951572	chr16:11056556~11057034:+
LUAD	cis	rs944289	0.679	rs12050116	ENSG00000257826.1	RP11-116N8.4	-7.4	6.11e-13	4.77e-10	-0.34	-0.32	Thyroid cancer;	chr14:36103725	chr14:36061026~36067190:-
LUAD	cis	rs75422866	0.867	rs73104115	ENSG00000280054.1	RP1-197B17.7	7.4	6.15e-13	4.8e-10	0.72	0.32	Pneumonia;	chr12:47684843	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs73104116	ENSG00000280054.1	RP1-197B17.7	7.4	6.15e-13	4.8e-10	0.72	0.32	Pneumonia;	chr12:47685023	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs73104138	ENSG00000280054.1	RP1-197B17.7	7.4	6.15e-13	4.8e-10	0.72	0.32	Pneumonia;	chr12:47692302	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.717	rs73104143	ENSG00000280054.1	RP1-197B17.7	7.4	6.15e-13	4.8e-10	0.72	0.32	Pneumonia;	chr12:47693449	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs73104144	ENSG00000280054.1	RP1-197B17.7	7.4	6.15e-13	4.8e-10	0.72	0.32	Pneumonia;	chr12:47694390	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs73104148	ENSG00000280054.1	RP1-197B17.7	7.4	6.15e-13	4.8e-10	0.72	0.32	Pneumonia;	chr12:47696732	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs73104152	ENSG00000280054.1	RP1-197B17.7	7.4	6.15e-13	4.8e-10	0.72	0.32	Pneumonia;	chr12:47699091	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs73104155	ENSG00000280054.1	RP1-197B17.7	7.4	6.15e-13	4.8e-10	0.72	0.32	Pneumonia;	chr12:47700790	chr12:47728151~47730598:-
LUAD	cis	rs2919917	0.628	rs4739135	ENSG00000254352.1	RP11-578O24.2	7.4	6.16e-13	4.8e-10	0.41	0.32	Lymphocyte counts;	chr8:78656057	chr8:78723796~78724136:-
LUAD	cis	rs4713118	0.621	rs9295756	ENSG00000219392.1	RP1-265C24.5	-7.4	6.16e-13	4.8e-10	-0.45	-0.32	Parkinson's disease;	chr6:28065618	chr6:28115628~28116551:+
LUAD	cis	rs9487094	0.67	rs12197180	ENSG00000260273.1	RP11-425D10.10	7.4	6.2e-13	4.84e-10	0.41	0.32	Height;	chr6:109500687	chr6:109382795~109383666:+
LUAD	cis	rs9545047	0.604	rs9574419	ENSG00000227676.3	LINC01068	-7.4	6.22e-13	4.85e-10	-0.38	-0.32	Schizophrenia;	chr13:79402337	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs9601226	ENSG00000227676.3	LINC01068	-7.4	6.22e-13	4.85e-10	-0.38	-0.32	Schizophrenia;	chr13:79403400	chr13:79566727~79571436:+
LUAD	cis	rs9322193	0.847	rs4870054	ENSG00000223701.3	RAET1E-AS1	7.4	6.25e-13	4.87e-10	0.4	0.32	Lung cancer;	chr6:149848402	chr6:149884431~149919508:+
LUAD	cis	rs2919917	0.628	rs2625663	ENSG00000254352.1	RP11-578O24.2	7.4	6.25e-13	4.87e-10	0.42	0.32	Lymphocyte counts;	chr8:78718106	chr8:78723796~78724136:-
LUAD	cis	rs2015599	0.514	rs10843376	ENSG00000257176.2	RP11-996F15.2	7.4	6.27e-13	4.88e-10	0.35	0.32	Platelet count;Mean platelet volume;	chr12:29283651	chr12:29280418~29317848:-
LUAD	cis	rs10129255	0.833	rs61997797	ENSG00000211972.2	IGHV3-66	7.4	6.27e-13	4.89e-10	0.28	0.32	Kawasaki disease;	chr14:106815190	chr14:106675017~106675544:-
LUAD	cis	rs950169	0.92	rs17300048	ENSG00000225151.9	GOLGA2P7	-7.4	6.28e-13	4.89e-10	-0.46	-0.32	Schizophrenia;	chr15:84080725	chr15:84199311~84230136:-
LUAD	cis	rs496547	0.719	rs598373	ENSG00000278376.1	RP11-158I9.8	-7.4	6.29e-13	4.9e-10	-0.35	-0.32	Hip minimal joint space width;	chr11:118793668	chr11:118791254~118793137:+
LUAD	cis	rs2412819	0.571	rs678084	ENSG00000205771.5	CATSPER2P1	7.4	6.3e-13	4.91e-10	0.48	0.32	Lung cancer;	chr15:43828361	chr15:43726918~43747094:-
LUAD	cis	rs75422866	0.867	rs78912815	ENSG00000280054.1	RP1-197B17.7	7.4	6.31e-13	4.92e-10	0.72	0.32	Pneumonia;	chr12:47612065	chr12:47728151~47730598:-
LUAD	cis	rs2283792	0.967	rs5999550	ENSG00000224086.5	LL22NC03-86G7.1	-7.4	6.33e-13	4.93e-10	-0.3	-0.32	Multiple sclerosis;	chr22:21796997	chr22:21938293~21977632:+
LUAD	cis	rs9595908	1	rs9591143	ENSG00000212293.1	SNORA16	7.39	6.34e-13	4.94e-10	0.35	0.32	Body mass index;	chr13:32585301	chr13:32420390~32420516:-
LUAD	cis	rs2015599	0.623	rs7358667	ENSG00000257176.2	RP11-996F15.2	7.39	6.35e-13	4.95e-10	0.35	0.32	Platelet count;Mean platelet volume;	chr12:29290236	chr12:29280418~29317848:-
LUAD	cis	rs7646881	1	rs59918529	ENSG00000240207.5	RP11-379F4.4	-7.39	6.36e-13	4.96e-10	-0.37	-0.32	Tetralogy of Fallot;	chr3:158734916	chr3:158732263~158784070:+
LUAD	cis	rs75422866	0.867	rs73102195	ENSG00000280054.1	RP1-197B17.7	7.39	6.37e-13	4.96e-10	0.72	0.32	Pneumonia;	chr12:47666309	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs73102201	ENSG00000280054.1	RP1-197B17.7	7.39	6.37e-13	4.96e-10	0.72	0.32	Pneumonia;	chr12:47669269	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs73104104	ENSG00000280054.1	RP1-197B17.7	7.39	6.37e-13	4.96e-10	0.72	0.32	Pneumonia;	chr12:47671986	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs73104111	ENSG00000280054.1	RP1-197B17.7	7.39	6.37e-13	4.96e-10	0.72	0.32	Pneumonia;	chr12:47673994	chr12:47728151~47730598:-
LUAD	cis	rs9545047	0.584	rs1619669	ENSG00000227676.3	LINC01068	7.39	6.37e-13	4.96e-10	0.37	0.32	Schizophrenia;	chr13:79378363	chr13:79566727~79571436:+
LUAD	cis	rs2712431	0.554	rs2010054	ENSG00000242551.2	POU5F1P6	-7.39	6.4e-13	4.98e-10	-0.36	-0.32	Monocyte chemoattractant protein-1 levels;	chr3:128586459	chr3:128674735~128677005:-
LUAD	cis	rs2919917	0.628	rs979564	ENSG00000254352.1	RP11-578O24.2	7.39	6.41e-13	4.99e-10	0.42	0.32	Lymphocyte counts;	chr8:78663924	chr8:78723796~78724136:-
LUAD	cis	rs7182621	0.512	rs12903892	ENSG00000182397.13	DNM1P46	7.39	6.43e-13	5.01e-10	0.44	0.32	Colonoscopy-negative controls vs population controls;	chr15:99869662	chr15:99790156~99806927:-
LUAD	cis	rs7811142	0.779	rs77370288	ENSG00000242294.5	STAG3L5P	7.39	6.43e-13	5.01e-10	0.28	0.32	Platelet count;	chr7:100350274	chr7:100336079~100351900:+
LUAD	cis	rs9549367	0.601	rs558869	ENSG00000269125.1	RP11-98F14.11	7.39	6.45e-13	5.02e-10	0.4	0.32	Platelet distribution width;	chr13:113195618	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.713	rs2480949	ENSG00000269125.1	RP11-98F14.11	7.39	6.45e-13	5.02e-10	0.4	0.32	Platelet distribution width;	chr13:113198835	chr13:113165002~113165183:-
LUAD	cis	rs7188445	0.835	rs1424231	ENSG00000261390.4	RP11-345M22.2	-7.39	6.45e-13	5.02e-10	-0.41	-0.32	Urate levels;	chr16:79672854	chr16:79715232~79770563:-
LUAD	cis	rs9545047	0.567	rs9574420	ENSG00000227676.3	LINC01068	-7.39	6.46e-13	5.03e-10	-0.38	-0.32	Schizophrenia;	chr13:79404342	chr13:79566727~79571436:+
LUAD	cis	rs2337406	0.714	rs2337463	ENSG00000254174.1	IGHV1-12	7.39	6.49e-13	5.05e-10	0.3	0.32	Alzheimer's disease (late onset);	chr14:106816066	chr14:106122420~106122709:-
LUAD	cis	rs6844153	0.68	rs11729927	ENSG00000240005.4	RP11-293A21.1	-7.39	6.49e-13	5.05e-10	-0.46	-0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26922178	chr4:26859806~26860599:-
LUAD	cis	rs7429990	0.833	rs869508	ENSG00000229759.1	MRPS18AP1	7.39	6.51e-13	5.06e-10	0.34	0.32	Educational attainment (years of education);	chr3:47571812	chr3:48256350~48256938:-
LUAD	cis	rs35160687	0.901	rs12622200	ENSG00000273080.1	RP11-301O19.1	-7.39	6.51e-13	5.07e-10	-0.36	-0.32	Night sleep phenotypes;	chr2:86271472	chr2:86195590~86196049:+
LUAD	cis	rs3931020	0.508	rs28568334	ENSG00000272864.1	RP11-17E13.2	-7.39	6.51e-13	5.07e-10	-0.42	-0.32	Resistin levels;	chr1:74733615	chr1:74698769~74699333:-
LUAD	cis	rs7688540	0.771	rs61792114	ENSG00000275426.1	CH17-262A2.1	7.39	6.53e-13	5.08e-10	0.45	0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:295350	chr4:149738~150317:+
LUAD	cis	rs10129255	0.957	rs11847726	ENSG00000211972.2	IGHV3-66	7.39	6.55e-13	5.09e-10	0.28	0.32	Kawasaki disease;	chr14:106779116	chr14:106675017~106675544:-
LUAD	cis	rs9487094	0.626	rs10457192	ENSG00000260273.1	RP11-425D10.10	7.39	6.56e-13	5.1e-10	0.42	0.32	Height;	chr6:109507271	chr6:109382795~109383666:+
LUAD	cis	rs2439831	0.867	rs2255042	ENSG00000205771.5	CATSPER2P1	7.39	6.56e-13	5.1e-10	0.55	0.32	Lung cancer in ever smokers;	chr15:43542120	chr15:43726918~43747094:-
LUAD	cis	rs10129255	0.5	rs7157975	ENSG00000211970.3	IGHV4-61	-7.39	6.57e-13	5.11e-10	-0.23	-0.32	Kawasaki disease;	chr14:106804049	chr14:106639119~106639657:-
LUAD	cis	rs7945705	0.902	rs10769980	ENSG00000254860.4	TMEM9B-AS1	-7.39	6.58e-13	5.12e-10	-0.36	-0.32	Hemoglobin concentration;	chr11:8992633	chr11:8964675~8977527:+
LUAD	cis	rs3931020	0.508	rs2345436	ENSG00000272864.1	RP11-17E13.2	-7.39	6.6e-13	5.13e-10	-0.42	-0.32	Resistin levels;	chr1:74733056	chr1:74698769~74699333:-
LUAD	cis	rs7811142	0.72	rs7795656	ENSG00000242294.5	STAG3L5P	7.39	6.61e-13	5.14e-10	0.28	0.32	Platelet count;	chr7:100352674	chr7:100336079~100351900:+
LUAD	cis	rs35955747	0.902	rs7288735	ENSG00000236132.1	CTA-440B3.1	7.39	6.61e-13	5.14e-10	0.36	0.32	Neutrophil count;Sum basophil neutrophil counts;	chr22:31283560	chr22:31816379~31817491:-
LUAD	cis	rs673078	0.607	rs7309671	ENSG00000275759.1	RP11-131L12.3	-7.39	6.61e-13	5.14e-10	-0.47	-0.32	Glucose homeostasis traits;	chr12:118313188	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs17512525	ENSG00000275759.1	RP11-131L12.3	-7.39	6.61e-13	5.14e-10	-0.47	-0.32	Glucose homeostasis traits;	chr12:118315467	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs17440774	ENSG00000275759.1	RP11-131L12.3	-7.39	6.61e-13	5.14e-10	-0.47	-0.32	Glucose homeostasis traits;	chr12:118316155	chr12:118428281~118428870:+
LUAD	cis	rs9487094	0.67	rs2024850	ENSG00000260273.1	RP11-425D10.10	-7.39	6.61e-13	5.14e-10	-0.43	-0.32	Height;	chr6:109497253	chr6:109382795~109383666:+
LUAD	cis	rs881375	0.967	rs1014529	ENSG00000226752.6	PSMD5-AS1	-7.39	6.65e-13	5.17e-10	-0.35	-0.32	Rheumatoid arthritis;	chr9:120922665	chr9:120824828~120854385:+
LUAD	cis	rs7811142	0.83	rs78256546	ENSG00000242294.5	STAG3L5P	7.39	6.67e-13	5.18e-10	0.28	0.32	Platelet count;	chr7:100355347	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.83	rs41280971	ENSG00000242294.5	STAG3L5P	7.39	6.67e-13	5.18e-10	0.28	0.32	Platelet count;	chr7:100356834	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.83	rs3087502	ENSG00000242294.5	STAG3L5P	7.39	6.67e-13	5.18e-10	0.28	0.32	Platelet count;	chr7:100357741	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.83	rs61735533	ENSG00000242294.5	STAG3L5P	7.39	6.67e-13	5.18e-10	0.28	0.32	Platelet count;	chr7:100358243	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.83	rs11761426	ENSG00000242294.5	STAG3L5P	7.39	6.67e-13	5.18e-10	0.28	0.32	Platelet count;	chr7:100359270	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.83	rs77861211	ENSG00000242294.5	STAG3L5P	7.39	6.67e-13	5.18e-10	0.28	0.32	Platelet count;	chr7:100364473	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.83	rs11769057	ENSG00000242294.5	STAG3L5P	7.39	6.67e-13	5.18e-10	0.28	0.32	Platelet count;	chr7:100367038	chr7:100336079~100351900:+
LUAD	cis	rs2015599	0.623	rs1072724	ENSG00000257176.2	RP11-996F15.2	7.39	6.68e-13	5.19e-10	0.35	0.32	Platelet count;Mean platelet volume;	chr12:29289205	chr12:29280418~29317848:-
LUAD	cis	rs7684253	0.587	rs2002154	ENSG00000269949.1	RP11-738E22.3	-7.39	6.68e-13	5.19e-10	-0.43	-0.32	Migraine;	chr4:56879851	chr4:56960927~56961373:-
LUAD	cis	rs7684253	0.587	rs7670313	ENSG00000269949.1	RP11-738E22.3	-7.39	6.68e-13	5.19e-10	-0.43	-0.32	Migraine;	chr4:56880007	chr4:56960927~56961373:-
LUAD	cis	rs7684253	0.587	rs2170074	ENSG00000269949.1	RP11-738E22.3	-7.39	6.68e-13	5.19e-10	-0.43	-0.32	Migraine;	chr4:56880190	chr4:56960927~56961373:-
LUAD	cis	rs10129255	0.5	rs4774189	ENSG00000211970.3	IGHV4-61	-7.39	6.69e-13	5.2e-10	-0.23	-0.32	Kawasaki disease;	chr14:106768275	chr14:106639119~106639657:-
LUAD	cis	rs9640161	0.711	rs3800781	ENSG00000261305.1	RP4-584D14.7	7.39	6.7e-13	5.2e-10	0.47	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150330235	chr7:150341771~150342607:+
LUAD	cis	rs17818399	0.888	rs2346419	ENSG00000279254.1	RP11-536C12.1	-7.39	6.71e-13	5.21e-10	-0.36	-0.32	Height;	chr2:46617930	chr2:46668870~46670778:+
LUAD	cis	rs10129255	0.957	rs28887506	ENSG00000211972.2	IGHV3-66	7.39	6.72e-13	5.22e-10	0.28	0.32	Kawasaki disease;	chr14:106785589	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.5	rs8022547	ENSG00000211970.3	IGHV4-61	-7.39	6.72e-13	5.22e-10	-0.23	-0.32	Kawasaki disease;	chr14:106781985	chr14:106639119~106639657:-
LUAD	cis	rs9549367	0.713	rs553316	ENSG00000269125.1	RP11-98F14.11	7.39	6.73e-13	5.22e-10	0.4	0.32	Platelet distribution width;	chr13:113183701	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.713	rs556990	ENSG00000269125.1	RP11-98F14.11	7.39	6.73e-13	5.22e-10	0.4	0.32	Platelet distribution width;	chr13:113190745	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.713	rs576463	ENSG00000269125.1	RP11-98F14.11	7.39	6.73e-13	5.22e-10	0.4	0.32	Platelet distribution width;	chr13:113192300	chr13:113165002~113165183:-
LUAD	cis	rs9487094	0.67	rs13199135	ENSG00000260273.1	RP11-425D10.10	7.39	6.73e-13	5.22e-10	0.42	0.32	Height;	chr6:109588639	chr6:109382795~109383666:+
LUAD	cis	rs12439619	0.693	rs7165536	ENSG00000255769.6	GOLGA2P10	-7.39	6.75e-13	5.24e-10	-0.4	-0.32	Intelligence (multi-trait analysis);	chr15:82273743	chr15:82472993~82513950:-
LUAD	cis	rs853679	0.527	rs853683	ENSG00000204709.4	LINC01556	7.39	6.75e-13	5.24e-10	0.39	0.32	Depression;	chr6:28327262	chr6:28943877~28944537:+
LUAD	cis	rs75422866	0.867	rs73102188	ENSG00000280054.1	RP1-197B17.7	7.38	6.78e-13	5.26e-10	0.74	0.32	Pneumonia;	chr12:47662993	chr12:47728151~47730598:-
LUAD	cis	rs6046396	1	rs6046396	ENSG00000275142.1	RP5-999L4.2	7.38	6.78e-13	5.26e-10	0.42	0.32	Bipolar disorder and schizophrenia;	chr20:19871859	chr20:19871891~19872284:+
LUAD	cis	rs2283792	0.967	rs11704205	ENSG00000224086.5	LL22NC03-86G7.1	-7.38	6.81e-13	5.28e-10	-0.3	-0.32	Multiple sclerosis;	chr22:21790964	chr22:21938293~21977632:+
LUAD	cis	rs8062405	0.573	rs6565300	ENSG00000259982.1	CDC37P1	7.38	6.81e-13	5.28e-10	0.42	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28981728	chr16:28700294~28701540:-
LUAD	cis	rs2739330	0.627	rs9608219	ENSG00000228039.3	KB-1125A3.10	7.38	6.82e-13	5.29e-10	0.39	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23963780~23964374:+
LUAD	cis	rs75422866	0.867	rs73104163	ENSG00000280054.1	RP1-197B17.7	7.38	6.83e-13	5.3e-10	0.76	0.32	Pneumonia;	chr12:47706187	chr12:47728151~47730598:-
LUAD	cis	rs75422866	1	rs12423045	ENSG00000280054.1	RP1-197B17.7	7.38	6.83e-13	5.3e-10	0.76	0.32	Pneumonia;	chr12:47706275	chr12:47728151~47730598:-
LUAD	cis	rs11603023	0.804	rs527619	ENSG00000255422.1	AP002954.4	7.38	6.83e-13	5.3e-10	0.39	0.32	Cholesterol, total;	chr11:118692577	chr11:118704607~118750263:+
LUAD	cis	rs950169	0.92	rs2135551	ENSG00000225151.9	GOLGA2P7	-7.38	6.83e-13	5.3e-10	-0.45	-0.32	Schizophrenia;	chr15:84039099	chr15:84199311~84230136:-
LUAD	cis	rs7684253	0.587	rs2170073	ENSG00000269949.1	RP11-738E22.3	-7.38	6.84e-13	5.3e-10	-0.43	-0.32	Migraine;	chr4:56880659	chr4:56960927~56961373:-
LUAD	cis	rs2919917	0.628	rs10113703	ENSG00000254352.1	RP11-578O24.2	7.38	6.84e-13	5.3e-10	0.42	0.32	Lymphocyte counts;	chr8:78688404	chr8:78723796~78724136:-
LUAD	cis	rs35955747	0.902	rs7287402	ENSG00000236132.1	CTA-440B3.1	-7.38	6.85e-13	5.31e-10	-0.35	-0.32	Neutrophil count;Sum basophil neutrophil counts;	chr22:31258837	chr22:31816379~31817491:-
LUAD	cis	rs765787	0.53	rs2554454	ENSG00000259520.4	CTD-2651B20.3	7.38	6.89e-13	5.34e-10	0.41	0.32	Uric acid levels;	chr15:45229338	chr15:45251580~45279251:-
LUAD	cis	rs9545047	0.604	rs9318633	ENSG00000227676.3	LINC01068	-7.38	6.91e-13	5.35e-10	-0.37	-0.32	Schizophrenia;	chr13:79369113	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs12872328	ENSG00000227676.3	LINC01068	-7.38	6.91e-13	5.35e-10	-0.37	-0.32	Schizophrenia;	chr13:79370489	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs2182010	ENSG00000227676.3	LINC01068	-7.38	6.91e-13	5.35e-10	-0.37	-0.32	Schizophrenia;	chr13:79370618	chr13:79566727~79571436:+
LUAD	cis	rs9595908	0.9	rs7994229	ENSG00000212293.1	SNORA16	7.38	6.91e-13	5.36e-10	0.34	0.32	Body mass index;	chr13:32586568	chr13:32420390~32420516:-
LUAD	cis	rs75422866	0.867	rs73102166	ENSG00000274902.1	RP1-197B17.4	7.38	6.93e-13	5.37e-10	0.73	0.32	Pneumonia;	chr12:47653769	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs73102168	ENSG00000274902.1	RP1-197B17.4	7.38	6.93e-13	5.37e-10	0.73	0.32	Pneumonia;	chr12:47654010	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs73102171	ENSG00000274902.1	RP1-197B17.4	7.38	6.93e-13	5.37e-10	0.73	0.32	Pneumonia;	chr12:47656077	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs76100981	ENSG00000274902.1	RP1-197B17.4	7.38	6.93e-13	5.37e-10	0.73	0.32	Pneumonia;	chr12:47660092	chr12:47731908~47732351:+
LUAD	cis	rs5769707	0.521	rs7285764	ENSG00000188511.11	C22orf34	7.38	6.94e-13	5.38e-10	0.39	0.32	Monocyte percentage of white cells;Monocyte count;	chr22:49664913	chr22:49414524~49657542:-
LUAD	cis	rs5769707	0.521	rs9616715	ENSG00000188511.11	C22orf34	7.38	6.94e-13	5.38e-10	0.39	0.32	Monocyte percentage of white cells;Monocyte count;	chr22:49664934	chr22:49414524~49657542:-
LUAD	cis	rs5769707	0.521	rs6009805	ENSG00000188511.11	C22orf34	7.38	6.94e-13	5.38e-10	0.39	0.32	Monocyte percentage of white cells;Monocyte count;	chr22:49665067	chr22:49414524~49657542:-
LUAD	cis	rs5769707	0.521	rs6009807	ENSG00000188511.11	C22orf34	7.38	6.94e-13	5.38e-10	0.39	0.32	Monocyte percentage of white cells;Monocyte count;	chr22:49665274	chr22:49414524~49657542:-
LUAD	cis	rs34779708	0.801	rs12246600	ENSG00000230534.5	RP11-297A16.2	7.38	6.95e-13	5.38e-10	0.38	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35249193	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.801	rs12098720	ENSG00000230534.5	RP11-297A16.2	7.38	6.95e-13	5.38e-10	0.38	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35249755	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.801	rs34592588	ENSG00000230534.5	RP11-297A16.2	7.38	6.95e-13	5.38e-10	0.38	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35251206	chr10:35098006~35127020:-
LUAD	cis	rs2739330	0.76	rs5751760	ENSG00000206090.4	AP000350.7	7.38	6.95e-13	5.38e-10	0.35	0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23939998~23942798:+
LUAD	cis	rs17301013	0.507	rs57953555	ENSG00000227373.4	RP11-160H22.5	7.38	6.96e-13	5.39e-10	0.47	0.32	Systemic lupus erythematosus;	chr1:174384958	chr1:174115300~174160004:-
LUAD	cis	rs9595908	0.9	rs731414	ENSG00000212293.1	SNORA16	7.38	6.99e-13	5.41e-10	0.34	0.32	Body mass index;	chr13:32601160	chr13:32420390~32420516:-
LUAD	cis	rs9322193	0.923	rs2342857	ENSG00000223701.3	RAET1E-AS1	7.38	7e-13	5.42e-10	0.38	0.32	Lung cancer;	chr6:149809537	chr6:149884431~149919508:+
LUAD	cis	rs673078	0.66	rs61943525	ENSG00000275759.1	RP11-131L12.3	-7.38	7e-13	5.42e-10	-0.51	-0.32	Glucose homeostasis traits;	chr12:118152927	chr12:118428281~118428870:+
LUAD	cis	rs8059260	0.668	rs16957855	ENSG00000274038.1	RP11-66H6.4	-7.38	7.01e-13	5.43e-10	-0.58	-0.32	Alcohol consumption over the past year;	chr16:10977116	chr16:11056556~11057034:+
LUAD	cis	rs9322193	0.923	rs7753812	ENSG00000223701.3	RAET1E-AS1	7.38	7.1e-13	5.5e-10	0.38	0.32	Lung cancer;	chr6:149690150	chr6:149884431~149919508:+
LUAD	cis	rs35160687	0.901	rs13017338	ENSG00000273080.1	RP11-301O19.1	7.38	7.11e-13	5.5e-10	0.36	0.32	Night sleep phenotypes;	chr2:86274430	chr2:86195590~86196049:+
LUAD	cis	rs9595066	0.715	rs9567366	ENSG00000227258.4	SMIM2-AS1	-7.38	7.11e-13	5.5e-10	-0.48	-0.32	Schizophrenia;	chr13:44108837	chr13:44110451~44240517:+
LUAD	cis	rs1185460	0.546	rs474201	ENSG00000271751.1	RP11-110I1.14	-7.38	7.11e-13	5.51e-10	-0.41	-0.32	Coronary artery disease;	chr11:119087519	chr11:119065263~119065677:-
LUAD	cis	rs9545047	0.604	rs9565497	ENSG00000227676.3	LINC01068	-7.38	7.12e-13	5.51e-10	-0.38	-0.32	Schizophrenia;	chr13:79406330	chr13:79566727~79571436:+
LUAD	cis	rs237743	1	rs34804433	ENSG00000222365.1	SNORD12B	-7.38	7.14e-13	5.52e-10	-0.37	-0.32	Height;	chr20:49279650	chr20:49280319~49280409:+
LUAD	cis	rs237743	1	rs67214274	ENSG00000222365.1	SNORD12B	-7.38	7.14e-13	5.52e-10	-0.37	-0.32	Height;	chr20:49282024	chr20:49280319~49280409:+
LUAD	cis	rs237743	1	rs35387764	ENSG00000222365.1	SNORD12B	-7.38	7.14e-13	5.52e-10	-0.37	-0.32	Height;	chr20:49286304	chr20:49280319~49280409:+
LUAD	cis	rs10129255	0.833	rs7156689	ENSG00000211970.3	IGHV4-61	-7.38	7.15e-13	5.53e-10	-0.25	-0.32	Kawasaki disease;	chr14:106816039	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.5	rs8006888	ENSG00000211970.3	IGHV4-61	-7.38	7.15e-13	5.53e-10	-0.23	-0.32	Kawasaki disease;	chr14:106782219	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.536	rs10142951	ENSG00000211970.3	IGHV4-61	-7.38	7.15e-13	5.53e-10	-0.23	-0.32	Kawasaki disease;	chr14:106782337	chr14:106639119~106639657:-
LUAD	cis	rs7429990	0.864	rs1403578	ENSG00000229759.1	MRPS18AP1	-7.38	7.17e-13	5.55e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47617997	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs868255	ENSG00000229759.1	MRPS18AP1	-7.38	7.17e-13	5.55e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47619074	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs4858842	ENSG00000229759.1	MRPS18AP1	-7.38	7.17e-13	5.55e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47619574	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs12636863	ENSG00000229759.1	MRPS18AP1	-7.38	7.17e-13	5.55e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47638629	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs7621236	ENSG00000229759.1	MRPS18AP1	-7.38	7.17e-13	5.55e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47646677	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs7624474	ENSG00000229759.1	MRPS18AP1	-7.38	7.17e-13	5.55e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47647786	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs4858846	ENSG00000229759.1	MRPS18AP1	-7.38	7.17e-13	5.55e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47654591	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.803	rs11130145	ENSG00000229759.1	MRPS18AP1	-7.38	7.17e-13	5.55e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47661780	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs6772301	ENSG00000229759.1	MRPS18AP1	-7.38	7.17e-13	5.55e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47682366	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs2133601	ENSG00000229759.1	MRPS18AP1	-7.38	7.17e-13	5.55e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47692525	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs6792497	ENSG00000229759.1	MRPS18AP1	-7.38	7.17e-13	5.55e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47693684	chr3:48256350~48256938:-
LUAD	cis	rs1062177	1	rs41494545	ENSG00000213433.5	RPLP1P6	7.38	7.19e-13	5.56e-10	0.41	0.32	Preschool internalizing problems;	chr5:151855533	chr5:151765859~151766378:-
LUAD	cis	rs75422866	0.867	rs73104103	ENSG00000280054.1	RP1-197B17.7	7.38	7.2e-13	5.57e-10	0.72	0.32	Pneumonia;	chr12:47669604	chr12:47728151~47730598:-
LUAD	cis	rs9494142	0.592	rs1547247	ENSG00000232876.1	CTA-212D2.2	-7.38	7.2e-13	5.57e-10	-0.39	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;Lymphocyte counts;	chr6:135069698	chr6:135055033~135060550:+
LUAD	cis	rs944289	0.624	rs55775461	ENSG00000257826.1	RP11-116N8.4	-7.38	7.2e-13	5.57e-10	-0.34	-0.32	Thyroid cancer;	chr14:36108166	chr14:36061026~36067190:-
LUAD	cis	rs9322193	0.962	rs2275046	ENSG00000223701.3	RAET1E-AS1	7.38	7.21e-13	5.57e-10	0.38	0.32	Lung cancer;	chr6:149835865	chr6:149884431~149919508:+
LUAD	cis	rs2919917	0.628	rs1384803	ENSG00000254352.1	RP11-578O24.2	-7.38	7.23e-13	5.59e-10	-0.41	-0.32	Lymphocyte counts;	chr8:78669393	chr8:78723796~78724136:-
LUAD	cis	rs7674212	0.556	rs6533039	ENSG00000246560.2	RP11-10L12.4	7.38	7.25e-13	5.6e-10	0.41	0.32	Type 2 diabetes;	chr4:102938381	chr4:102828055~102844075:+
LUAD	cis	rs673078	0.66	rs7965350	ENSG00000275759.1	RP11-131L12.3	-7.37	7.25e-13	5.6e-10	-0.45	-0.32	Glucose homeostasis traits;	chr12:118266710	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.66	rs73205531	ENSG00000275759.1	RP11-131L12.3	-7.37	7.25e-13	5.61e-10	-0.47	-0.32	Glucose homeostasis traits;	chr12:118282063	chr12:118428281~118428870:+
LUAD	cis	rs853679	0.542	rs9393892	ENSG00000219392.1	RP1-265C24.5	-7.37	7.26e-13	5.61e-10	-0.45	-0.32	Depression;	chr6:28113616	chr6:28115628~28116551:+
LUAD	cis	rs7208859	0.623	rs9912440	ENSG00000263531.1	RP13-753N3.1	7.37	7.29e-13	5.63e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30821754	chr17:30863921~30864940:-
LUAD	cis	rs5769707	0.542	rs739242	ENSG00000188511.11	C22orf34	7.37	7.31e-13	5.64e-10	0.39	0.32	Monocyte percentage of white cells;Monocyte count;	chr22:49663468	chr22:49414524~49657542:-
LUAD	cis	rs7208859	0.623	rs11658022	ENSG00000263531.1	RP13-753N3.1	7.37	7.32e-13	5.65e-10	0.65	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30863921~30864940:-
LUAD	cis	rs35160687	1	rs35160687	ENSG00000273080.1	RP11-301O19.1	7.37	7.38e-13	5.7e-10	0.36	0.32	Night sleep phenotypes;	chr2:86244991	chr2:86195590~86196049:+
LUAD	cis	rs755249	1	rs17513135	ENSG00000228060.1	RP11-69E11.8	-7.37	7.4e-13	5.71e-10	-0.32	-0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39570014	chr1:39565160~39573203:+
LUAD	cis	rs12134133	0.962	rs17258843	ENSG00000274245.1	RP11-357P18.2	7.37	7.41e-13	5.72e-10	0.42	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241387	chr1:207372559~207373252:+
LUAD	cis	rs9549367	0.713	rs2476328	ENSG00000269125.1	RP11-98F14.11	7.37	7.44e-13	5.74e-10	0.4	0.32	Platelet distribution width;	chr13:113175036	chr13:113165002~113165183:-
LUAD	cis	rs201673768	1	rs201673768	ENSG00000240399.1	RP1-228P16.1	7.37	7.47e-13	5.76e-10	0.31	0.32	Platelet count;	chr12:48305834	chr12:48054813~48055591:-
LUAD	cis	rs35955747	0.838	rs7285171	ENSG00000236132.1	CTA-440B3.1	7.37	7.47e-13	5.76e-10	0.36	0.32	Neutrophil count;Sum basophil neutrophil counts;	chr22:31202381	chr22:31816379~31817491:-
LUAD	cis	rs7182621	0.512	rs34151878	ENSG00000182397.13	DNM1P46	7.37	7.48e-13	5.77e-10	0.44	0.32	Colonoscopy-negative controls vs population controls;	chr15:99869179	chr15:99790156~99806927:-
LUAD	cis	rs10875746	0.624	rs7297298	ENSG00000240399.1	RP1-228P16.1	-7.37	7.48e-13	5.77e-10	-0.39	-0.32	Longevity (90 years and older);	chr12:48278523	chr12:48054813~48055591:-
LUAD	cis	rs2015599	0.623	rs7313552	ENSG00000257176.2	RP11-996F15.2	7.37	7.49e-13	5.78e-10	0.35	0.32	Platelet count;Mean platelet volume;	chr12:29277302	chr12:29280418~29317848:-
LUAD	cis	rs2015599	0.584	rs7299283	ENSG00000257176.2	RP11-996F15.2	7.37	7.49e-13	5.78e-10	0.35	0.32	Platelet count;Mean platelet volume;	chr12:29277442	chr12:29280418~29317848:-
LUAD	cis	rs673078	0.607	rs56080343	ENSG00000275759.1	RP11-131L12.3	-7.37	7.49e-13	5.78e-10	-0.4	-0.32	Glucose homeostasis traits;	chr12:118439113	chr12:118428281~118428870:+
LUAD	cis	rs10129255	0.957	rs56134540	ENSG00000280411.1	IGHV1-69-2	-7.37	7.5e-13	5.79e-10	-0.24	-0.32	Kawasaki disease;	chr14:106691290	chr14:106762092~106762588:-
LUAD	cis	rs4660456	0.913	rs12727412	ENSG00000237899.1	RP4-739H11.3	-7.37	7.5e-13	5.79e-10	-0.44	-0.32	Platelet count;	chr1:40723243	chr1:40669089~40687588:-
LUAD	cis	rs150992	0.711	rs1069182	ENSG00000248489.1	CTD-2007H13.3	-7.37	7.52e-13	5.8e-10	-0.35	-0.32	Body mass index;	chr5:98806512	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.673	rs992773	ENSG00000248489.1	CTD-2007H13.3	-7.37	7.52e-13	5.8e-10	-0.35	-0.32	Body mass index;	chr5:98808169	chr5:98929171~98995013:+
LUAD	cis	rs9640161	0.617	rs73170169	ENSG00000261305.1	RP4-584D14.7	7.37	7.52e-13	5.8e-10	0.48	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150310947	chr7:150341771~150342607:+
LUAD	cis	rs2243480	0.908	rs313822	ENSG00000273142.1	RP11-458F8.4	-7.37	7.54e-13	5.81e-10	-0.33	-0.32	Diabetic kidney disease;	chr7:66108952	chr7:66902857~66906297:+
LUAD	cis	rs867371	1	rs7181655	ENSG00000255769.6	GOLGA2P10	-7.37	7.56e-13	5.83e-10	-0.34	-0.32	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163275	chr15:82472993~82513950:-
LUAD	cis	rs867371	1	rs7180584	ENSG00000255769.6	GOLGA2P10	-7.37	7.56e-13	5.83e-10	-0.34	-0.32	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163493	chr15:82472993~82513950:-
LUAD	cis	rs867371	1	rs6495642	ENSG00000255769.6	GOLGA2P10	-7.37	7.56e-13	5.83e-10	-0.34	-0.32	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82165156	chr15:82472993~82513950:-
LUAD	cis	rs6991838	0.765	rs4424306	ENSG00000272010.1	CTD-3025N20.3	7.37	7.56e-13	5.83e-10	0.33	0.32	Intelligence (multi-trait analysis);	chr8:65618674	chr8:65591850~65592472:-
LUAD	cis	rs9322193	0.962	rs9688412	ENSG00000223701.3	RAET1E-AS1	-7.37	7.58e-13	5.84e-10	-0.38	-0.32	Lung cancer;	chr6:149803147	chr6:149884431~149919508:+
LUAD	cis	rs12468226	0.689	rs60584169	ENSG00000273456.1	RP11-686O6.2	7.37	7.58e-13	5.85e-10	0.46	0.32	Urate levels;	chr2:202111695	chr2:202374932~202375604:-
LUAD	cis	rs9487094	0.67	rs1476388	ENSG00000260273.1	RP11-425D10.10	7.37	7.59e-13	5.85e-10	0.42	0.32	Height;	chr6:109518783	chr6:109382795~109383666:+
LUAD	cis	rs1185460	1	rs1614264	ENSG00000271751.1	RP11-110I1.14	-7.37	7.61e-13	5.87e-10	-0.39	-0.32	Coronary artery disease;	chr11:119071928	chr11:119065263~119065677:-
LUAD	cis	rs950880	0.71	rs10490204	ENSG00000234389.1	AC007278.3	-7.37	7.61e-13	5.87e-10	-0.33	-0.32	Serum protein levels (sST2);	chr2:102440074	chr2:102438713~102440475:+
LUAD	cis	rs7945705	0.902	rs2012696	ENSG00000254860.4	TMEM9B-AS1	-7.37	7.66e-13	5.9e-10	-0.36	-0.32	Hemoglobin concentration;	chr11:8974271	chr11:8964675~8977527:+
LUAD	cis	rs2153535	0.58	rs1414342	ENSG00000230939.1	RP11-314C16.1	-7.37	7.67e-13	5.91e-10	-0.39	-0.32	Motion sickness;	chr6:8462319	chr6:8784178~8785445:+
LUAD	cis	rs35160687	0.814	rs7563887	ENSG00000273080.1	RP11-301O19.1	7.37	7.68e-13	5.92e-10	0.35	0.32	Night sleep phenotypes;	chr2:86288998	chr2:86195590~86196049:+
LUAD	cis	rs748404	0.631	rs7163288	ENSG00000249839.1	AC011330.5	-7.37	7.69e-13	5.92e-10	-0.41	-0.32	Lung cancer;	chr15:43379157	chr15:43663654~43684339:-
LUAD	cis	rs3779195	0.697	rs1688606	ENSG00000272950.1	RP11-307C18.1	7.37	7.69e-13	5.92e-10	0.52	0.32	Sex hormone-binding globulin levels;	chr7:98345539	chr7:98322853~98323430:+
LUAD	cis	rs9322193	0.923	rs9285524	ENSG00000223701.3	RAET1E-AS1	7.37	7.72e-13	5.95e-10	0.38	0.32	Lung cancer;	chr6:149694122	chr6:149884431~149919508:+
LUAD	cis	rs12439619	0.693	rs4778989	ENSG00000255769.6	GOLGA2P10	-7.37	7.73e-13	5.96e-10	-0.4	-0.32	Intelligence (multi-trait analysis);	chr15:82276963	chr15:82472993~82513950:-
LUAD	cis	rs9545047	0.604	rs9530906	ENSG00000227676.3	LINC01068	7.36	7.78e-13	5.99e-10	0.37	0.32	Schizophrenia;	chr13:79372401	chr13:79566727~79571436:+
LUAD	cis	rs7188445	0.871	rs7202770	ENSG00000261390.4	RP11-345M22.2	-7.36	7.8e-13	6.01e-10	-0.41	-0.32	Urate levels;	chr16:79672643	chr16:79715232~79770563:-
LUAD	cis	rs10129255	0.744	rs28517388	ENSG00000211972.2	IGHV3-66	7.36	7.81e-13	6.01e-10	0.29	0.32	Kawasaki disease;	chr14:106704323	chr14:106675017~106675544:-
LUAD	cis	rs748404	0.697	rs1095389	ENSG00000205771.5	CATSPER2P1	-7.36	7.81e-13	6.01e-10	-0.39	-0.32	Lung cancer;	chr15:43274473	chr15:43726918~43747094:-
LUAD	cis	rs2337406	0.641	rs10133227	ENSG00000254174.1	IGHV1-12	-7.36	7.82e-13	6.02e-10	-0.29	-0.32	Alzheimer's disease (late onset);	chr14:106814260	chr14:106122420~106122709:-
LUAD	cis	rs8059260	0.668	rs74737820	ENSG00000274038.1	RP11-66H6.4	-7.36	7.82e-13	6.02e-10	-0.59	-0.32	Alcohol consumption over the past year;	chr16:10972240	chr16:11056556~11057034:+
LUAD	cis	rs8091660	0.929	rs4939780	ENSG00000278983.1	RP11-426J5.3	7.36	7.84e-13	6.03e-10	0.37	0.32	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48568873	chr18:48564795~48568342:+
LUAD	cis	rs2919917	0.628	rs2170732	ENSG00000254352.1	RP11-578O24.2	7.36	7.85e-13	6.04e-10	0.41	0.32	Lymphocyte counts;	chr8:78684261	chr8:78723796~78724136:-
LUAD	cis	rs7188445	0.871	rs16950997	ENSG00000261390.4	RP11-345M22.2	-7.36	7.86e-13	6.05e-10	-0.41	-0.32	Urate levels;	chr16:79673733	chr16:79715232~79770563:-
LUAD	cis	rs6991838	0.8	rs28547533	ENSG00000272010.1	CTD-3025N20.3	7.36	7.91e-13	6.09e-10	0.33	0.32	Intelligence (multi-trait analysis);	chr8:65559318	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.8	rs28626262	ENSG00000272010.1	CTD-3025N20.3	7.36	7.91e-13	6.09e-10	0.33	0.32	Intelligence (multi-trait analysis);	chr8:65559335	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.8	rs28709439	ENSG00000272010.1	CTD-3025N20.3	7.36	7.91e-13	6.09e-10	0.33	0.32	Intelligence (multi-trait analysis);	chr8:65559337	chr8:65591850~65592472:-
LUAD	cis	rs748404	0.697	rs531910	ENSG00000205771.5	CATSPER2P1	-7.36	7.94e-13	6.11e-10	-0.39	-0.32	Lung cancer;	chr15:43268409	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.697	rs491804	ENSG00000205771.5	CATSPER2P1	-7.36	7.94e-13	6.11e-10	-0.39	-0.32	Lung cancer;	chr15:43268627	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.697	rs492743	ENSG00000205771.5	CATSPER2P1	-7.36	7.94e-13	6.11e-10	-0.39	-0.32	Lung cancer;	chr15:43268747	chr15:43726918~43747094:-
LUAD	cis	rs12468226	0.689	rs73989731	ENSG00000273456.1	RP11-686O6.2	7.36	7.95e-13	6.11e-10	0.46	0.32	Urate levels;	chr2:202109309	chr2:202374932~202375604:-
LUAD	cis	rs9322193	0.923	rs12195866	ENSG00000223701.3	RAET1E-AS1	7.36	7.95e-13	6.12e-10	0.38	0.32	Lung cancer;	chr6:149693334	chr6:149884431~149919508:+
LUAD	cis	rs853679	0.517	rs4713150	ENSG00000219392.1	RP1-265C24.5	-7.36	7.97e-13	6.13e-10	-0.45	-0.32	Depression;	chr6:28168434	chr6:28115628~28116551:+
LUAD	cis	rs755249	1	rs2293476	ENSG00000228060.1	RP11-69E11.8	7.36	7.98e-13	6.14e-10	0.31	0.32	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39571175	chr1:39565160~39573203:+
LUAD	cis	rs9640161	0.75	rs1983440	ENSG00000261305.1	RP4-584D14.7	7.36	7.99e-13	6.14e-10	0.47	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150326852	chr7:150341771~150342607:+
LUAD	cis	rs1577917	0.545	rs7755958	ENSG00000203875.9	SNHG5	7.36	8.01e-13	6.16e-10	0.41	0.32	Response to antipsychotic treatment;	chr6:85778793	chr6:85660950~85678736:-
LUAD	cis	rs6844153	0.877	rs10939146	ENSG00000240005.4	RP11-293A21.1	-7.36	8.04e-13	6.18e-10	-0.51	-0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26978399	chr4:26859806~26860599:-
LUAD	cis	rs4591358	0.689	rs16837051	ENSG00000223466.1	AC064834.2	-7.36	8.07e-13	6.2e-10	-0.45	-0.32	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195536281	chr2:195533035~195538681:+
LUAD	cis	rs7208859	0.573	rs55661352	ENSG00000263531.1	RP13-753N3.1	7.36	8.07e-13	6.2e-10	0.65	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30863921~30864940:-
LUAD	cis	rs6504622	0.755	rs4968253	ENSG00000262879.4	RP11-156P1.3	-7.36	8.1e-13	6.22e-10	-0.36	-0.32	Orofacial clefts;	chr17:47093553	chr17:46984045~47100323:-
LUAD	cis	rs11098499	0.738	rs28687057	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119359657	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.775	rs67281037	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119360002	chr4:119440561~119450157:-
LUAD	cis	rs10028773	0.506	rs12374346	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Educational attainment;	chr4:119360550	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.866	rs12374244	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119360817	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.866	rs12374352	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119360822	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.775	rs10021601	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119361408	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.866	rs6857892	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119361541	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.909	rs28581362	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119362393	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.82	rs12503082	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119363162	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.866	rs12499602	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119363232	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.774	rs11098505	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119363472	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.866	rs13105020	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119364533	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.866	rs6824111	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119364813	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.775	rs10029303	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119365600	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.866	rs9995136	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119365690	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.866	rs13125526	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119366864	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.866	rs12513310	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119366884	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.564	rs11098507	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119367131	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.866	rs12510451	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119367988	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.774	rs73842616	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119369528	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.645	rs72676059	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119369673	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.569	rs55845118	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119369758	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.866	rs7677068	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119370549	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.866	rs9991221	ENSG00000248280.1	RP11-33B1.2	7.36	8.11e-13	6.23e-10	0.39	0.32	Corneal astigmatism;	chr4:119370952	chr4:119440561~119450157:-
LUAD	cis	rs9601248	0.874	rs4141825	ENSG00000227676.3	LINC01068	7.36	8.11e-13	6.23e-10	0.4	0.32	Major depressive disorder;	chr13:79616713	chr13:79566727~79571436:+
LUAD	cis	rs17301013	0.507	rs6701911	ENSG00000227373.4	RP11-160H22.5	7.36	8.12e-13	6.23e-10	0.47	0.32	Systemic lupus erythematosus;	chr1:174364755	chr1:174115300~174160004:-
LUAD	cis	rs6504950	1	rs9892848	ENSG00000275710.1	RP11-257O5.4	7.36	8.15e-13	6.26e-10	0.42	0.32	Breast cancer;	chr17:54982414	chr17:54964474~54964679:+
LUAD	cis	rs748404	0.697	rs473016	ENSG00000205771.5	CATSPER2P1	-7.36	8.15e-13	6.26e-10	-0.39	-0.32	Lung cancer;	chr15:43266625	chr15:43726918~43747094:-
LUAD	cis	rs10463554	0.784	rs187424	ENSG00000175749.11	EIF3KP1	7.36	8.16e-13	6.26e-10	0.44	0.32	Parkinson's disease;	chr5:103251882	chr5:103032376~103033031:+
LUAD	cis	rs9595908	1	rs9591145	ENSG00000212293.1	SNORA16	7.36	8.17e-13	6.27e-10	0.35	0.32	Body mass index;	chr13:32587322	chr13:32420390~32420516:-
LUAD	cis	rs9595908	1	rs3742320	ENSG00000212293.1	SNORA16	7.36	8.17e-13	6.27e-10	0.35	0.32	Body mass index;	chr13:32590281	chr13:32420390~32420516:-
LUAD	cis	rs17826219	0.636	rs4055314	ENSG00000263531.1	RP13-753N3.1	7.36	8.18e-13	6.28e-10	0.65	0.32	Body mass index;	chr17:30752751	chr17:30863921~30864940:-
LUAD	cis	rs34779708	0.733	rs16935945	ENSG00000230534.5	RP11-297A16.2	7.36	8.21e-13	6.3e-10	0.38	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35251392	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.733	rs12777960	ENSG00000230534.5	RP11-297A16.2	7.36	8.21e-13	6.3e-10	0.38	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35252098	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.733	rs60553075	ENSG00000230534.5	RP11-297A16.2	7.36	8.21e-13	6.3e-10	0.38	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35253534	chr10:35098006~35127020:-
LUAD	cis	rs9640161	0.75	rs3800780	ENSG00000261305.1	RP4-584D14.7	7.36	8.23e-13	6.31e-10	0.47	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150330195	chr7:150341771~150342607:+
LUAD	cis	rs950169	1	rs1848093	ENSG00000225151.9	GOLGA2P7	-7.36	8.25e-13	6.33e-10	-0.46	-0.32	Schizophrenia;	chr15:84086775	chr15:84199311~84230136:-
LUAD	cis	rs9322193	0.962	rs4552	ENSG00000223701.3	RAET1E-AS1	7.36	8.25e-13	6.33e-10	0.37	0.32	Lung cancer;	chr6:149811183	chr6:149884431~149919508:+
LUAD	cis	rs2015599	0.623	rs10843385	ENSG00000257176.2	RP11-996F15.2	-7.36	8.26e-13	6.33e-10	-0.35	-0.32	Platelet count;Mean platelet volume;	chr12:29323100	chr12:29280418~29317848:-
LUAD	cis	rs7429990	0.864	rs2047559	ENSG00000229759.1	MRPS18AP1	-7.36	8.27e-13	6.34e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47704695	chr3:48256350~48256938:-
LUAD	cis	rs9595908	0.965	rs7318297	ENSG00000212293.1	SNORA16	7.36	8.29e-13	6.36e-10	0.37	0.32	Body mass index;	chr13:32563835	chr13:32420390~32420516:-
LUAD	cis	rs6991838	0.733	rs13281981	ENSG00000272010.1	CTD-3025N20.3	7.35	8.3e-13	6.36e-10	0.33	0.32	Intelligence (multi-trait analysis);	chr8:65611649	chr8:65591850~65592472:-
LUAD	cis	rs7615952	0.609	rs13088451	ENSG00000171084.14	FAM86JP	7.35	8.31e-13	6.37e-10	0.46	0.32	Blood pressure (smoking interaction);	chr3:125834656	chr3:125916620~125930024:+
LUAD	cis	rs9322193	0.962	rs2065664	ENSG00000223701.3	RAET1E-AS1	7.35	8.33e-13	6.38e-10	0.38	0.32	Lung cancer;	chr6:149762485	chr6:149884431~149919508:+
LUAD	cis	rs7923609	0.578	rs10740138	ENSG00000232075.1	MRPL35P2	-7.35	8.35e-13	6.4e-10	-0.38	-0.32	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63635373	chr10:63634317~63634827:-
LUAD	cis	rs9487094	0.696	rs1853330	ENSG00000260273.1	RP11-425D10.10	7.35	8.35e-13	6.4e-10	0.39	0.32	Height;	chr6:109375548	chr6:109382795~109383666:+
LUAD	cis	rs17301013	0.507	rs61218633	ENSG00000227373.4	RP11-160H22.5	7.35	8.38e-13	6.42e-10	0.47	0.32	Systemic lupus erythematosus;	chr1:174375955	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs56148594	ENSG00000227373.4	RP11-160H22.5	7.35	8.38e-13	6.42e-10	0.47	0.32	Systemic lupus erythematosus;	chr1:174383932	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12091056	ENSG00000227373.4	RP11-160H22.5	7.35	8.38e-13	6.42e-10	0.47	0.32	Systemic lupus erythematosus;	chr1:174384470	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs4651019	ENSG00000227373.4	RP11-160H22.5	7.35	8.38e-13	6.42e-10	0.47	0.32	Systemic lupus erythematosus;	chr1:174385079	chr1:174115300~174160004:-
LUAD	cis	rs7182621	0.639	rs1561047	ENSG00000182397.13	DNM1P46	7.35	8.39e-13	6.43e-10	0.44	0.32	Colonoscopy-negative controls vs population controls;	chr15:99874606	chr15:99790156~99806927:-
LUAD	cis	rs2286503	1	rs2286501	ENSG00000228649.7	AC005682.5	7.35	8.4e-13	6.43e-10	0.39	0.32	Fibrinogen;	chr7:22817166	chr7:22854178~22861579:+
LUAD	cis	rs9660180	0.836	rs72634845	ENSG00000268575.1	RP1-283E3.8	-7.35	8.41e-13	6.44e-10	-0.29	-0.32	Body mass index;	chr1:1773460	chr1:1702736~1737688:-
LUAD	cis	rs10129255	0.957	rs10132367	ENSG00000280411.1	IGHV1-69-2	-7.35	8.42e-13	6.45e-10	-0.24	-0.32	Kawasaki disease;	chr14:106690981	chr14:106762092~106762588:-
LUAD	cis	rs2286503	0.839	rs2270105	ENSG00000228649.7	AC005682.5	7.35	8.43e-13	6.46e-10	0.4	0.32	Fibrinogen;	chr7:22822848	chr7:22854178~22861579:+
LUAD	cis	rs9545047	0.604	rs7319212	ENSG00000227676.3	LINC01068	-7.35	8.47e-13	6.48e-10	-0.37	-0.32	Schizophrenia;	chr13:79365404	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs7319252	ENSG00000227676.3	LINC01068	-7.35	8.47e-13	6.48e-10	-0.37	-0.32	Schizophrenia;	chr13:79365471	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs35476664	ENSG00000227676.3	LINC01068	-7.35	8.47e-13	6.48e-10	-0.37	-0.32	Schizophrenia;	chr13:79375462	chr13:79566727~79571436:+
LUAD	cis	rs3096299	0.9	rs3114867	ENSG00000274627.1	RP11-104N10.2	7.35	8.48e-13	6.49e-10	0.3	0.32	Multiple myeloma (IgH translocation);	chr16:89362559	chr16:89516797~89522217:+
LUAD	cis	rs11098499	0.866	rs11098506	ENSG00000248280.1	RP11-33B1.2	7.35	8.48e-13	6.49e-10	0.39	0.32	Corneal astigmatism;	chr4:119363816	chr4:119440561~119450157:-
LUAD	cis	rs7688540	0.771	rs61792116	ENSG00000275426.1	CH17-262A2.1	7.35	8.49e-13	6.5e-10	0.47	0.32	Facial morphology (factor 6, height of vermillion lower lip);	chr4:307288	chr4:149738~150317:+
LUAD	cis	rs6142102	0.812	rs6120440	ENSG00000276073.1	RP5-1125A11.7	7.35	8.51e-13	6.52e-10	0.35	0.32	Skin pigmentation;	chr20:33929779	chr20:33985617~33988989:-
LUAD	cis	rs10200159	0.744	rs6545510	ENSG00000272606.1	RP11-554J4.1	7.35	8.52e-13	6.52e-10	0.54	0.32	Vitiligo;	chr2:55607591	chr2:55617909~55618373:+
LUAD	cis	rs7811142	0.83	rs7792525	ENSG00000242294.5	STAG3L5P	7.35	8.56e-13	6.55e-10	0.28	0.32	Platelet count;	chr7:100374499	chr7:100336079~100351900:+
LUAD	cis	rs673078	0.66	rs17440364	ENSG00000275759.1	RP11-131L12.3	-7.35	8.58e-13	6.57e-10	-0.46	-0.32	Glucose homeostasis traits;	chr12:118186613	chr12:118428281~118428870:+
LUAD	cis	rs1499614	1	rs2659913	ENSG00000273142.1	RP11-458F8.4	-7.35	8.59e-13	6.58e-10	-0.33	-0.32	Gout;	chr7:66692349	chr7:66902857~66906297:+
LUAD	cis	rs1499614	1	rs2659911	ENSG00000273142.1	RP11-458F8.4	-7.35	8.59e-13	6.58e-10	-0.33	-0.32	Gout;	chr7:66693433	chr7:66902857~66906297:+
LUAD	cis	rs1499614	1	rs2707838	ENSG00000273142.1	RP11-458F8.4	-7.35	8.59e-13	6.58e-10	-0.33	-0.32	Gout;	chr7:66694214	chr7:66902857~66906297:+
LUAD	cis	rs1499614	1	rs60326618	ENSG00000273142.1	RP11-458F8.4	-7.35	8.59e-13	6.58e-10	-0.33	-0.32	Gout;	chr7:66701371	chr7:66902857~66906297:+
LUAD	cis	rs1499614	1	rs2707830	ENSG00000273142.1	RP11-458F8.4	-7.35	8.59e-13	6.58e-10	-0.33	-0.32	Gout;	chr7:66702658	chr7:66902857~66906297:+
LUAD	cis	rs1499614	1	rs2707828	ENSG00000273142.1	RP11-458F8.4	-7.35	8.59e-13	6.58e-10	-0.33	-0.32	Gout;	chr7:66706390	chr7:66902857~66906297:+
LUAD	cis	rs1499614	0.803	rs1922723	ENSG00000273142.1	RP11-458F8.4	-7.35	8.59e-13	6.58e-10	-0.33	-0.32	Gout;	chr7:66710076	chr7:66902857~66906297:+
LUAD	cis	rs1499614	1	rs2659903	ENSG00000273142.1	RP11-458F8.4	-7.35	8.59e-13	6.58e-10	-0.33	-0.32	Gout;	chr7:66715944	chr7:66902857~66906297:+
LUAD	cis	rs1499614	1	rs2141924	ENSG00000273142.1	RP11-458F8.4	-7.35	8.59e-13	6.58e-10	-0.33	-0.32	Gout;	chr7:66721259	chr7:66902857~66906297:+
LUAD	cis	rs6504950	0.85	rs2628308	ENSG00000275710.1	RP11-257O5.4	-7.35	8.6e-13	6.58e-10	-0.4	-0.32	Breast cancer;	chr17:55046212	chr17:54964474~54964679:+
LUAD	cis	rs11098499	0.779	rs10857066	ENSG00000248280.1	RP11-33B1.2	7.35	8.6e-13	6.58e-10	0.39	0.32	Corneal astigmatism;	chr4:119365441	chr4:119440561~119450157:-
LUAD	cis	rs638893	0.636	rs493720	ENSG00000278376.1	RP11-158I9.8	-7.35	8.62e-13	6.59e-10	-0.47	-0.32	Vitiligo;	chr11:118733969	chr11:118791254~118793137:+
LUAD	cis	rs638893	0.636	rs526850	ENSG00000278376.1	RP11-158I9.8	-7.35	8.62e-13	6.59e-10	-0.47	-0.32	Vitiligo;	chr11:118734418	chr11:118791254~118793137:+
LUAD	cis	rs9640161	0.871	rs56156367	ENSG00000261305.1	RP4-584D14.7	7.35	8.63e-13	6.6e-10	0.46	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150350112	chr7:150341771~150342607:+
LUAD	cis	rs3096299	0.933	rs2965934	ENSG00000274627.1	RP11-104N10.2	7.35	8.64e-13	6.61e-10	0.3	0.32	Multiple myeloma (IgH translocation);	chr16:89414821	chr16:89516797~89522217:+
LUAD	cis	rs748404	0.697	rs579651	ENSG00000205771.5	CATSPER2P1	-7.35	8.66e-13	6.62e-10	-0.39	-0.32	Lung cancer;	chr15:43266178	chr15:43726918~43747094:-
LUAD	cis	rs2153535	0.58	rs6921036	ENSG00000230939.1	RP11-314C16.1	-7.35	8.67e-13	6.63e-10	-0.38	-0.32	Motion sickness;	chr6:8455167	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs6926759	ENSG00000230939.1	RP11-314C16.1	-7.35	8.67e-13	6.63e-10	-0.38	-0.32	Motion sickness;	chr6:8455943	chr6:8784178~8785445:+
LUAD	cis	rs9545047	0.604	rs7987193	ENSG00000227676.3	LINC01068	-7.35	8.68e-13	6.64e-10	-0.37	-0.32	Schizophrenia;	chr13:79408449	chr13:79566727~79571436:+
LUAD	cis	rs867371	1	rs13380317	ENSG00000255769.6	GOLGA2P10	7.35	8.69e-13	6.64e-10	0.33	0.32	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214449	chr15:82472993~82513950:-
LUAD	cis	rs853679	0.517	rs4713146	ENSG00000219392.1	RP1-265C24.5	-7.35	8.69e-13	6.65e-10	-0.46	-0.32	Depression;	chr6:28143758	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9393894	ENSG00000219392.1	RP1-265C24.5	-7.35	8.69e-13	6.65e-10	-0.46	-0.32	Depression;	chr6:28144784	chr6:28115628~28116551:+
LUAD	cis	rs2919917	0.628	rs9643739	ENSG00000254352.1	RP11-578O24.2	7.35	8.7e-13	6.65e-10	0.41	0.32	Lymphocyte counts;	chr8:78679535	chr8:78723796~78724136:-
LUAD	cis	rs6504950	1	rs9890971	ENSG00000275710.1	RP11-257O5.4	7.35	8.72e-13	6.66e-10	0.43	0.32	Breast cancer;	chr17:54982415	chr17:54964474~54964679:+
LUAD	cis	rs11089937	0.651	rs2330015	ENSG00000211639.2	IGLV4-60	-7.35	8.72e-13	6.67e-10	-0.33	-0.32	Periodontitis (PAL4Q3);	chr22:22182566	chr22:22162199~22162681:+
LUAD	cis	rs8091660	0.929	rs2175564	ENSG00000278983.1	RP11-426J5.3	7.35	8.75e-13	6.69e-10	0.36	0.32	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48570838	chr18:48564795~48568342:+
LUAD	cis	rs7208859	0.673	rs8077116	ENSG00000263531.1	RP13-753N3.1	7.35	8.77e-13	6.7e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30863921~30864940:-
LUAD	cis	rs7044106	0.5	rs56725168	ENSG00000238181.2	AHCYP2	-7.35	8.77e-13	6.7e-10	-0.42	-0.32	Hip circumference adjusted for BMI;	chr9:120730298	chr9:120720673~120721972:+
LUAD	cis	rs10129255	0.784	rs7147210	ENSG00000280411.1	IGHV1-69-2	-7.35	8.79e-13	6.71e-10	-0.25	-0.32	Kawasaki disease;	chr14:106705271	chr14:106762092~106762588:-
LUAD	cis	rs7945705	0.87	rs1109305	ENSG00000254860.4	TMEM9B-AS1	-7.35	8.79e-13	6.71e-10	-0.36	-0.32	Hemoglobin concentration;	chr11:8933725	chr11:8964675~8977527:+
LUAD	cis	rs950880	0.71	rs67723747	ENSG00000234389.1	AC007278.3	-7.35	8.81e-13	6.73e-10	-0.33	-0.32	Serum protein levels (sST2);	chr2:102353347	chr2:102438713~102440475:+
LUAD	cis	rs950880	0.71	rs56386507	ENSG00000234389.1	AC007278.3	-7.35	8.81e-13	6.73e-10	-0.33	-0.32	Serum protein levels (sST2);	chr2:102354705	chr2:102438713~102440475:+
LUAD	cis	rs10129255	0.5	rs6576230	ENSG00000211970.3	IGHV4-61	-7.35	8.81e-13	6.73e-10	-0.22	-0.32	Kawasaki disease;	chr14:106778539	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.518	rs11847766	ENSG00000211970.3	IGHV4-61	-7.35	8.81e-13	6.73e-10	-0.22	-0.32	Kawasaki disease;	chr14:106779186	chr14:106639119~106639657:-
LUAD	cis	rs9487094	0.644	rs1960325	ENSG00000260273.1	RP11-425D10.10	7.35	8.82e-13	6.74e-10	0.42	0.32	Height;	chr6:109592105	chr6:109382795~109383666:+
LUAD	cis	rs7044106	0.791	rs4836829	ENSG00000238181.2	AHCYP2	-7.35	8.82e-13	6.74e-10	-0.42	-0.32	Hip circumference adjusted for BMI;	chr9:120720469	chr9:120720673~120721972:+
LUAD	cis	rs9595908	0.965	rs9337	ENSG00000212293.1	SNORA16	7.35	8.83e-13	6.75e-10	0.38	0.32	Body mass index;	chr13:32517104	chr13:32420390~32420516:-
LUAD	cis	rs2283792	1	rs5749986	ENSG00000224086.5	LL22NC03-86G7.1	7.35	8.84e-13	6.75e-10	0.3	0.32	Multiple sclerosis;	chr22:21803372	chr22:21938293~21977632:+
LUAD	cis	rs853679	0.517	rs4713135	ENSG00000219392.1	RP1-265C24.5	-7.35	8.85e-13	6.76e-10	-0.45	-0.32	Depression;	chr6:28071808	chr6:28115628~28116551:+
LUAD	cis	rs75422866	0.867	rs73102166	ENSG00000280054.1	RP1-197B17.7	7.34	8.89e-13	6.78e-10	0.73	0.32	Pneumonia;	chr12:47653769	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs73102168	ENSG00000280054.1	RP1-197B17.7	7.34	8.89e-13	6.78e-10	0.73	0.32	Pneumonia;	chr12:47654010	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs73102171	ENSG00000280054.1	RP1-197B17.7	7.34	8.89e-13	6.78e-10	0.73	0.32	Pneumonia;	chr12:47656077	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs76100981	ENSG00000280054.1	RP1-197B17.7	7.34	8.89e-13	6.78e-10	0.73	0.32	Pneumonia;	chr12:47660092	chr12:47728151~47730598:-
LUAD	cis	rs853679	0.517	rs4713152	ENSG00000219392.1	RP1-265C24.5	-7.34	8.89e-13	6.79e-10	-0.45	-0.32	Depression;	chr6:28169676	chr6:28115628~28116551:+
LUAD	cis	rs673078	0.66	rs17433217	ENSG00000275759.1	RP11-131L12.3	-7.34	8.9e-13	6.8e-10	-0.45	-0.32	Glucose homeostasis traits;	chr12:118269076	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.607	rs61946067	ENSG00000275759.1	RP11-131L12.3	-7.34	8.91e-13	6.8e-10	-0.47	-0.32	Glucose homeostasis traits;	chr12:118303152	chr12:118428281~118428870:+
LUAD	cis	rs7811142	0.83	rs6948685	ENSG00000242294.5	STAG3L5P	7.34	8.96e-13	6.84e-10	0.28	0.32	Platelet count;	chr7:100372565	chr7:100336079~100351900:+
LUAD	cis	rs8059260	0.668	rs7199305	ENSG00000274038.1	RP11-66H6.4	7.34	8.96e-13	6.84e-10	0.54	0.32	Alcohol consumption over the past year;	chr16:11006476	chr16:11056556~11057034:+
LUAD	cis	rs9595908	0.965	rs9595903	ENSG00000212293.1	SNORA16	7.34	8.98e-13	6.85e-10	0.36	0.32	Body mass index;	chr13:32608003	chr13:32420390~32420516:-
LUAD	cis	rs9487094	0.67	rs6911700	ENSG00000260273.1	RP11-425D10.10	7.34	8.98e-13	6.85e-10	0.42	0.32	Height;	chr6:109676091	chr6:109382795~109383666:+
LUAD	cis	rs10129255	0.5	rs34326748	ENSG00000211970.3	IGHV4-61	-7.34	8.98e-13	6.85e-10	-0.23	-0.32	Kawasaki disease;	chr14:106782523	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.5	rs10143385	ENSG00000211970.3	IGHV4-61	-7.34	8.98e-13	6.85e-10	-0.23	-0.32	Kawasaki disease;	chr14:106782559	chr14:106639119~106639657:-
LUAD	cis	rs8059260	0.668	rs7198089	ENSG00000274038.1	RP11-66H6.4	-7.34	8.99e-13	6.86e-10	-0.57	-0.32	Alcohol consumption over the past year;	chr16:11027199	chr16:11056556~11057034:+
LUAD	cis	rs35955747	0.838	rs5997900	ENSG00000236132.1	CTA-440B3.1	7.34	9.03e-13	6.88e-10	0.35	0.32	Neutrophil count;Sum basophil neutrophil counts;	chr22:31184360	chr22:31816379~31817491:-
LUAD	cis	rs853679	0.517	rs9393890	ENSG00000219392.1	RP1-265C24.5	-7.34	9.11e-13	6.95e-10	-0.45	-0.32	Depression;	chr6:28096077	chr6:28115628~28116551:+
LUAD	cis	rs638893	0.636	rs2186781	ENSG00000278376.1	RP11-158I9.8	-7.34	9.12e-13	6.95e-10	-0.48	-0.32	Vitiligo;	chr11:118734738	chr11:118791254~118793137:+
LUAD	cis	rs75422866	0.717	rs73113159	ENSG00000274902.1	RP1-197B17.4	7.34	9.14e-13	6.96e-10	0.73	0.32	Pneumonia;	chr12:47631318	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.717	rs73113161	ENSG00000274902.1	RP1-197B17.4	7.34	9.14e-13	6.96e-10	0.73	0.32	Pneumonia;	chr12:47632361	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs117022227	ENSG00000274902.1	RP1-197B17.4	7.34	9.14e-13	6.96e-10	0.73	0.32	Pneumonia;	chr12:47633282	chr12:47731908~47732351:+
LUAD	cis	rs75422866	1	rs73102120	ENSG00000274902.1	RP1-197B17.4	7.34	9.14e-13	6.96e-10	0.73	0.32	Pneumonia;	chr12:47637280	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs12422974	ENSG00000274902.1	RP1-197B17.4	7.34	9.14e-13	6.96e-10	0.73	0.32	Pneumonia;	chr12:47644559	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs73102127	ENSG00000274902.1	RP1-197B17.4	7.34	9.14e-13	6.96e-10	0.73	0.32	Pneumonia;	chr12:47645341	chr12:47731908~47732351:+
LUAD	cis	rs673078	0.615	rs16948204	ENSG00000275759.1	RP11-131L12.3	-7.34	9.16e-13	6.98e-10	-0.45	-0.32	Glucose homeostasis traits;	chr12:118258252	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.66	rs7303417	ENSG00000275759.1	RP11-131L12.3	-7.34	9.16e-13	6.98e-10	-0.45	-0.32	Glucose homeostasis traits;	chr12:118258859	chr12:118428281~118428870:+
LUAD	cis	rs2015599	0.623	rs1006410	ENSG00000257176.2	RP11-996F15.2	7.34	9.17e-13	6.99e-10	0.35	0.32	Platelet count;Mean platelet volume;	chr12:29282682	chr12:29280418~29317848:-
LUAD	cis	rs34779708	0.733	rs7083266	ENSG00000230534.5	RP11-297A16.2	7.34	9.18e-13	6.99e-10	0.38	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35252704	chr10:35098006~35127020:-
LUAD	cis	rs9322193	0.962	rs4870048	ENSG00000223701.3	RAET1E-AS1	7.34	9.2e-13	7.01e-10	0.38	0.32	Lung cancer;	chr6:149834324	chr6:149884431~149919508:+
LUAD	cis	rs2439831	0.681	rs7168940	ENSG00000205771.5	CATSPER2P1	-7.34	9.22e-13	7.02e-10	-0.53	-0.32	Lung cancer in ever smokers;	chr15:43341136	chr15:43726918~43747094:-
LUAD	cis	rs7429990	0.864	rs13085978	ENSG00000229759.1	MRPS18AP1	7.34	9.27e-13	7.06e-10	0.33	0.32	Educational attainment (years of education);	chr3:47608585	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.727	rs61675361	ENSG00000229759.1	MRPS18AP1	7.34	9.27e-13	7.06e-10	0.33	0.32	Educational attainment (years of education);	chr3:47610630	chr3:48256350~48256938:-
LUAD	cis	rs10129255	0.518	rs8009612	ENSG00000211970.3	IGHV4-61	-7.34	9.32e-13	7.1e-10	-0.23	-0.32	Kawasaki disease;	chr14:106777510	chr14:106639119~106639657:-
LUAD	cis	rs11214589	0.905	rs10891539	ENSG00000270179.1	RP11-159N11.4	-7.34	9.32e-13	7.1e-10	-0.31	-0.32	Neuroticism;	chr11:113365770	chr11:113368478~113369117:+
LUAD	cis	rs2739330	0.76	rs5751760	ENSG00000099984.9	GSTT2	-7.34	9.34e-13	7.11e-10	-0.37	-0.32	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23980123~23983911:+
LUAD	cis	rs9545047	0.604	rs2265382	ENSG00000227676.3	LINC01068	-7.34	9.41e-13	7.17e-10	-0.37	-0.32	Schizophrenia;	chr13:79426196	chr13:79566727~79571436:+
LUAD	cis	rs853679	0.517	rs2273564	ENSG00000219392.1	RP1-265C24.5	-7.34	9.43e-13	7.17e-10	-0.45	-0.32	Depression;	chr6:28089816	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs1853097	ENSG00000219392.1	RP1-265C24.5	-7.34	9.43e-13	7.17e-10	-0.45	-0.32	Depression;	chr6:28090857	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9393887	ENSG00000219392.1	RP1-265C24.5	-7.34	9.43e-13	7.17e-10	-0.45	-0.32	Depression;	chr6:28091242	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9393888	ENSG00000219392.1	RP1-265C24.5	-7.34	9.43e-13	7.17e-10	-0.45	-0.32	Depression;	chr6:28091439	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs3734573	ENSG00000219392.1	RP1-265C24.5	-7.34	9.43e-13	7.17e-10	-0.45	-0.32	Depression;	chr6:28091659	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9357063	ENSG00000219392.1	RP1-265C24.5	-7.34	9.43e-13	7.17e-10	-0.45	-0.32	Depression;	chr6:28092227	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs3823180	ENSG00000219392.1	RP1-265C24.5	-7.34	9.43e-13	7.17e-10	-0.45	-0.32	Depression;	chr6:28093966	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9368551	ENSG00000219392.1	RP1-265C24.5	-7.34	9.43e-13	7.17e-10	-0.45	-0.32	Depression;	chr6:28094014	chr6:28115628~28116551:+
LUAD	cis	rs17711722	0.565	rs4717276	ENSG00000226824.5	RP4-756H11.3	-7.34	9.45e-13	7.19e-10	-0.39	-0.32	Calcium levels;	chr7:65829754	chr7:66654538~66669855:+
LUAD	cis	rs4660456	0.83	rs12742219	ENSG00000237899.1	RP4-739H11.3	-7.33	9.49e-13	7.21e-10	-0.44	-0.32	Platelet count;	chr1:40728665	chr1:40669089~40687588:-
LUAD	cis	rs10200159	1	rs13428382	ENSG00000272606.1	RP11-554J4.1	7.33	9.5e-13	7.22e-10	0.52	0.32	Vitiligo;	chr2:55636929	chr2:55617909~55618373:+
LUAD	cis	rs1501911	0.53	rs162611	ENSG00000248489.1	CTD-2007H13.3	-7.33	9.51e-13	7.23e-10	-0.35	-0.32	Lung function (FEV1/FVC);	chr5:98809801	chr5:98929171~98995013:+
LUAD	cis	rs11098499	0.863	rs7678400	ENSG00000248280.1	RP11-33B1.2	7.33	9.54e-13	7.24e-10	0.41	0.32	Corneal astigmatism;	chr4:119540802	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs1480936	ENSG00000248280.1	RP11-33B1.2	7.33	9.54e-13	7.24e-10	0.41	0.32	Corneal astigmatism;	chr4:119541706	chr4:119440561~119450157:-
LUAD	cis	rs9545047	0.604	rs2477395	ENSG00000227676.3	LINC01068	-7.33	9.55e-13	7.25e-10	-0.37	-0.32	Schizophrenia;	chr13:79427679	chr13:79566727~79571436:+
LUAD	cis	rs2842992	0.83	rs2025190	ENSG00000237927.1	RP3-393E18.2	-7.33	9.55e-13	7.25e-10	-0.45	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159717209	chr6:159586955~159589169:-
LUAD	cis	rs10129255	0.5	rs11628999	ENSG00000211970.3	IGHV4-61	-7.33	9.55e-13	7.25e-10	-0.22	-0.32	Kawasaki disease;	chr14:106800208	chr14:106639119~106639657:-
LUAD	cis	rs1729407	0.814	rs2071521	ENSG00000254851.1	RP11-109L13.1	7.33	9.57e-13	7.27e-10	0.39	0.32	Apolipoprotein A-IV levels;	chr11:116827132	chr11:117135528~117138582:+
LUAD	cis	rs10129255	0.518	rs8009594	ENSG00000211970.3	IGHV4-61	-7.33	9.59e-13	7.28e-10	-0.23	-0.32	Kawasaki disease;	chr14:106777494	chr14:106639119~106639657:-
LUAD	cis	rs1729407	0.786	rs5096	ENSG00000254851.1	RP11-109L13.1	-7.33	9.6e-13	7.28e-10	-0.4	-0.32	Apolipoprotein A-IV levels;	chr11:116822379	chr11:117135528~117138582:+
LUAD	cis	rs2286503	0.839	rs2270108	ENSG00000228649.7	AC005682.5	7.33	9.64e-13	7.31e-10	0.4	0.32	Fibrinogen;	chr7:22822512	chr7:22854178~22861579:+
LUAD	cis	rs2286503	0.839	rs2270107	ENSG00000228649.7	AC005682.5	7.33	9.64e-13	7.31e-10	0.4	0.32	Fibrinogen;	chr7:22822564	chr7:22854178~22861579:+
LUAD	cis	rs2286503	0.839	rs2270103	ENSG00000228649.7	AC005682.5	7.33	9.64e-13	7.31e-10	0.4	0.32	Fibrinogen;	chr7:22823103	chr7:22854178~22861579:+
LUAD	cis	rs2286503	0.839	rs10276099	ENSG00000228649.7	AC005682.5	7.33	9.64e-13	7.31e-10	0.4	0.32	Fibrinogen;	chr7:22823331	chr7:22854178~22861579:+
LUAD	cis	rs9545047	0.604	rs9545104	ENSG00000227676.3	LINC01068	7.33	9.64e-13	7.32e-10	0.37	0.32	Schizophrenia;	chr13:79404000	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs9545106	ENSG00000227676.3	LINC01068	7.33	9.64e-13	7.32e-10	0.37	0.32	Schizophrenia;	chr13:79404130	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs2763810	ENSG00000227676.3	LINC01068	7.33	9.64e-13	7.32e-10	0.37	0.32	Schizophrenia;	chr13:79405544	chr13:79566727~79571436:+
LUAD	cis	rs7208859	0.524	rs8065744	ENSG00000263531.1	RP13-753N3.1	7.33	9.66e-13	7.33e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30772431	chr17:30863921~30864940:-
LUAD	cis	rs17826219	0.706	rs8071236	ENSG00000263531.1	RP13-753N3.1	7.33	9.66e-13	7.33e-10	0.64	0.32	Body mass index;	chr17:30772984	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs56163556	ENSG00000263531.1	RP13-753N3.1	7.33	9.66e-13	7.33e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774850	chr17:30863921~30864940:-
LUAD	cis	rs2286503	0.839	rs4722189	ENSG00000228649.7	AC005682.5	7.33	9.7e-13	7.35e-10	0.4	0.32	Fibrinogen;	chr7:22820855	chr7:22854178~22861579:+
LUAD	cis	rs2286503	0.809	rs4719716	ENSG00000228649.7	AC005682.5	7.33	9.7e-13	7.35e-10	0.4	0.32	Fibrinogen;	chr7:22821750	chr7:22854178~22861579:+
LUAD	cis	rs2286503	0.78	rs981792	ENSG00000228649.7	AC005682.5	7.33	9.7e-13	7.35e-10	0.4	0.32	Fibrinogen;	chr7:22822020	chr7:22854178~22861579:+
LUAD	cis	rs9322193	0.736	rs3828701	ENSG00000223701.3	RAET1E-AS1	7.33	9.71e-13	7.36e-10	0.37	0.32	Lung cancer;	chr6:149791063	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.736	rs3805750	ENSG00000223701.3	RAET1E-AS1	7.33	9.71e-13	7.36e-10	0.37	0.32	Lung cancer;	chr6:149791065	chr6:149884431~149919508:+
LUAD	cis	rs11676348	0.935	rs2230054	ENSG00000261338.2	RP11-378A13.1	-7.33	9.72e-13	7.37e-10	-0.34	-0.32	Ulcerative colitis;	chr2:218135587	chr2:218255319~218257366:+
LUAD	cis	rs10129255	0.833	rs7156689	ENSG00000211972.2	IGHV3-66	7.33	9.75e-13	7.39e-10	0.28	0.32	Kawasaki disease;	chr14:106816039	chr14:106675017~106675544:-
LUAD	cis	rs4591358	0.648	rs16836855	ENSG00000223466.1	AC064834.2	-7.33	9.76e-13	7.4e-10	-0.44	-0.32	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195522267	chr2:195533035~195538681:+
LUAD	cis	rs6142102	0.812	rs4911375	ENSG00000276073.1	RP5-1125A11.7	-7.33	9.76e-13	7.4e-10	-0.33	-0.32	Skin pigmentation;	chr20:33928216	chr20:33985617~33988989:-
LUAD	cis	rs10200159	0.744	rs6545513	ENSG00000272606.1	RP11-554J4.1	7.33	9.77e-13	7.41e-10	0.51	0.32	Vitiligo;	chr2:55657729	chr2:55617909~55618373:+
LUAD	cis	rs950169	0.919	rs12915589	ENSG00000225151.9	GOLGA2P7	-7.33	9.85e-13	7.47e-10	-0.45	-0.32	Schizophrenia;	chr15:84065712	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.959	rs66801143	ENSG00000225151.9	GOLGA2P7	-7.33	9.85e-13	7.47e-10	-0.45	-0.32	Schizophrenia;	chr15:84067905	chr15:84199311~84230136:-
LUAD	cis	rs950169	1	rs35648189	ENSG00000225151.9	GOLGA2P7	-7.33	9.85e-13	7.47e-10	-0.45	-0.32	Schizophrenia;	chr15:84071996	chr15:84199311~84230136:-
LUAD	cis	rs6504950	0.886	rs12449538	ENSG00000275710.1	RP11-257O5.4	-7.33	9.88e-13	7.49e-10	-0.38	-0.32	Breast cancer;	chr17:55033760	chr17:54964474~54964679:+
LUAD	cis	rs6504622	0.728	rs7222781	ENSG00000262879.4	RP11-156P1.3	-7.33	9.88e-13	7.49e-10	-0.36	-0.32	Orofacial clefts;	chr17:47100059	chr17:46984045~47100323:-
LUAD	cis	rs950169	1	rs35658069	ENSG00000225151.9	GOLGA2P7	-7.33	9.92e-13	7.51e-10	-0.45	-0.32	Schizophrenia;	chr15:84111394	chr15:84199311~84230136:-
LUAD	cis	rs1167827	0.805	rs809439	ENSG00000278416.1	PMS2L2	-7.33	9.94e-13	7.53e-10	-0.4	-0.32	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75531992	chr7:75344015~75359550:-
LUAD	cis	rs950880	0.71	rs55927292	ENSG00000234389.1	AC007278.3	-7.33	9.97e-13	7.55e-10	-0.32	-0.32	Serum protein levels (sST2);	chr2:102348401	chr2:102438713~102440475:+
LUAD	cis	rs9322193	0.847	rs880246	ENSG00000223701.3	RAET1E-AS1	7.33	9.98e-13	7.56e-10	0.38	0.32	Lung cancer;	chr6:149845972	chr6:149884431~149919508:+
LUAD	cis	rs35160687	0.901	rs12714179	ENSG00000273080.1	RP11-301O19.1	7.33	9.99e-13	7.56e-10	0.36	0.32	Night sleep phenotypes;	chr2:86287835	chr2:86195590~86196049:+
LUAD	cis	rs7208859	0.623	rs216445	ENSG00000263531.1	RP13-753N3.1	7.33	1e-12	7.57e-10	0.65	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606558	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs216446	ENSG00000263531.1	RP13-753N3.1	7.33	1e-12	7.57e-10	0.65	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606700	chr17:30863921~30864940:-
LUAD	cis	rs10463554	0.963	rs26821	ENSG00000175749.11	EIF3KP1	7.33	1e-12	7.6e-10	0.44	0.32	Parkinson's disease;	chr5:103184699	chr5:103032376~103033031:+
LUAD	cis	rs7811142	0.83	rs11765869	ENSG00000242294.5	STAG3L5P	7.33	1e-12	7.61e-10	0.28	0.32	Platelet count;	chr7:100367166	chr7:100336079~100351900:+
LUAD	cis	rs9545047	0.604	rs2477397	ENSG00000227676.3	LINC01068	-7.33	1.01e-12	7.62e-10	-0.37	-0.32	Schizophrenia;	chr13:79428211	chr13:79566727~79571436:+
LUAD	cis	rs10129255	0.518	rs8010020	ENSG00000211970.3	IGHV4-61	-7.33	1.01e-12	7.64e-10	-0.23	-0.32	Kawasaki disease;	chr14:106778016	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.5	rs6576225	ENSG00000211970.3	IGHV4-61	-7.33	1.01e-12	7.64e-10	-0.23	-0.32	Kawasaki disease;	chr14:106778120	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.5	rs6576226	ENSG00000211970.3	IGHV4-61	-7.33	1.01e-12	7.64e-10	-0.23	-0.32	Kawasaki disease;	chr14:106778135	chr14:106639119~106639657:-
LUAD	cis	rs944289	0.708	rs8016762	ENSG00000257826.1	RP11-116N8.4	-7.33	1.01e-12	7.64e-10	-0.33	-0.32	Thyroid cancer;	chr14:36108538	chr14:36061026~36067190:-
LUAD	cis	rs34779708	0.733	rs11010146	ENSG00000230534.5	RP11-297A16.2	7.33	1.01e-12	7.65e-10	0.38	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35252633	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.733	rs7086715	ENSG00000230534.5	RP11-297A16.2	7.33	1.01e-12	7.65e-10	0.38	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35252912	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.702	rs7087150	ENSG00000230534.5	RP11-297A16.2	7.33	1.01e-12	7.65e-10	0.38	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35253210	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.733	rs12249814	ENSG00000230534.5	RP11-297A16.2	7.33	1.01e-12	7.65e-10	0.38	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35253829	chr10:35098006~35127020:-
LUAD	cis	rs748404	0.697	rs471122	ENSG00000205771.5	CATSPER2P1	7.33	1.01e-12	7.66e-10	0.39	0.32	Lung cancer;	chr15:43266376	chr15:43726918~43747094:-
LUAD	cis	rs9640161	0.75	rs11764936	ENSG00000261305.1	RP4-584D14.7	7.33	1.01e-12	7.66e-10	0.46	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150328826	chr7:150341771~150342607:+
LUAD	cis	rs237743	1	rs8117111	ENSG00000222365.1	SNORD12B	-7.33	1.01e-12	7.66e-10	-0.37	-0.32	Height;	chr20:49267648	chr20:49280319~49280409:+
LUAD	cis	rs75422866	0.867	rs73113117	ENSG00000280054.1	RP1-197B17.7	7.33	1.01e-12	7.67e-10	0.72	0.32	Pneumonia;	chr12:47617299	chr12:47728151~47730598:-
LUAD	cis	rs1729407	0.786	rs5100	ENSG00000254851.1	RP11-109L13.1	-7.32	1.02e-12	7.7e-10	-0.4	-0.32	Apolipoprotein A-IV levels;	chr11:116821978	chr11:117135528~117138582:+
LUAD	cis	rs950169	1	rs11638394	ENSG00000225151.9	GOLGA2P7	-7.32	1.02e-12	7.75e-10	-0.45	-0.32	Schizophrenia;	chr15:84110176	chr15:84199311~84230136:-
LUAD	cis	rs1499614	1	rs1638731	ENSG00000273142.1	RP11-458F8.4	-7.32	1.03e-12	7.8e-10	-0.33	-0.32	Gout;	chr7:66679692	chr7:66902857~66906297:+
LUAD	cis	rs1499614	1	rs1882655	ENSG00000273142.1	RP11-458F8.4	7.32	1.03e-12	7.8e-10	0.33	0.32	Gout;	chr7:66682070	chr7:66902857~66906297:+
LUAD	cis	rs1499614	0.831	rs3800822	ENSG00000273142.1	RP11-458F8.4	7.32	1.03e-12	7.8e-10	0.33	0.32	Gout;	chr7:66682162	chr7:66902857~66906297:+
LUAD	cis	rs11089937	0.559	rs2330014	ENSG00000211639.2	IGLV4-60	7.32	1.03e-12	7.8e-10	0.35	0.32	Periodontitis (PAL4Q3);	chr22:22166155	chr22:22162199~22162681:+
LUAD	cis	rs8059260	0.668	rs8055893	ENSG00000274038.1	RP11-66H6.4	-7.32	1.04e-12	7.83e-10	-0.58	-0.32	Alcohol consumption over the past year;	chr16:10977938	chr16:11056556~11057034:+
LUAD	cis	rs11098499	0.954	rs6847248	ENSG00000248280.1	RP11-33B1.2	7.32	1.04e-12	7.83e-10	0.42	0.32	Corneal astigmatism;	chr4:119304800	chr4:119440561~119450157:-
LUAD	cis	rs7429990	0.833	rs870622	ENSG00000229759.1	MRPS18AP1	-7.32	1.04e-12	7.85e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47618683	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs11130144	ENSG00000229759.1	MRPS18AP1	-7.32	1.04e-12	7.85e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47626444	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs12492915	ENSG00000229759.1	MRPS18AP1	-7.32	1.04e-12	7.85e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47636545	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs7613934	ENSG00000229759.1	MRPS18AP1	-7.32	1.04e-12	7.85e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47640681	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.803	rs13081356	ENSG00000229759.1	MRPS18AP1	-7.32	1.04e-12	7.85e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47660067	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs11130146	ENSG00000229759.1	MRPS18AP1	-7.32	1.04e-12	7.85e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47666322	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs12633604	ENSG00000229759.1	MRPS18AP1	-7.32	1.04e-12	7.85e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47673308	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs13063042	ENSG00000229759.1	MRPS18AP1	-7.32	1.04e-12	7.85e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47683825	chr3:48256350~48256938:-
LUAD	cis	rs1501911	0.53	rs161941	ENSG00000248489.1	CTD-2007H13.3	-7.32	1.04e-12	7.85e-10	-0.34	-0.32	Lung function (FEV1/FVC);	chr5:98863500	chr5:98929171~98995013:+
LUAD	cis	rs75422866	0.867	rs73113139	ENSG00000274902.1	RP1-197B17.4	7.32	1.04e-12	7.85e-10	0.73	0.32	Pneumonia;	chr12:47622826	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs73102140	ENSG00000274902.1	RP1-197B17.4	7.32	1.04e-12	7.85e-10	0.73	0.32	Pneumonia;	chr12:47647497	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs73102148	ENSG00000274902.1	RP1-197B17.4	7.32	1.04e-12	7.85e-10	0.73	0.32	Pneumonia;	chr12:47648013	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs73102151	ENSG00000274902.1	RP1-197B17.4	7.32	1.04e-12	7.85e-10	0.73	0.32	Pneumonia;	chr12:47648023	chr12:47731908~47732351:+
LUAD	cis	rs2243480	1	rs160639	ENSG00000273142.1	RP11-458F8.4	-7.32	1.04e-12	7.86e-10	-0.33	-0.32	Diabetic kidney disease;	chr7:66115000	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs313824	ENSG00000273142.1	RP11-458F8.4	-7.32	1.04e-12	7.86e-10	-0.33	-0.32	Diabetic kidney disease;	chr7:66116220	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs186378	ENSG00000273142.1	RP11-458F8.4	-7.32	1.04e-12	7.86e-10	-0.33	-0.32	Diabetic kidney disease;	chr7:66117071	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs160637	ENSG00000273142.1	RP11-458F8.4	-7.32	1.04e-12	7.86e-10	-0.33	-0.32	Diabetic kidney disease;	chr7:66119331	chr7:66902857~66906297:+
LUAD	cis	rs853679	0.517	rs36078605	ENSG00000219392.1	RP1-265C24.5	-7.32	1.04e-12	7.87e-10	-0.45	-0.32	Depression;	chr6:28110254	chr6:28115628~28116551:+
LUAD	cis	rs10200159	1	rs10204169	ENSG00000272606.1	RP11-554J4.1	7.32	1.04e-12	7.88e-10	0.52	0.32	Vitiligo;	chr2:55663468	chr2:55617909~55618373:+
LUAD	cis	rs11690935	0.571	rs13020884	ENSG00000228389.1	AC068039.4	-7.32	1.05e-12	7.89e-10	-0.34	-0.32	Schizophrenia;	chr2:172036795	chr2:171773482~171775844:+
LUAD	cis	rs4853012	0.887	rs6737314	ENSG00000257800.1	FNBP1P1	7.32	1.05e-12	7.9e-10	0.41	0.32	Gestational age at birth (maternal effect);	chr2:74112459	chr2:74120680~74123218:+
LUAD	cis	rs881375	1	rs10760118	ENSG00000226752.6	PSMD5-AS1	-7.32	1.05e-12	7.9e-10	-0.34	-0.32	Rheumatoid arthritis;	chr9:120879338	chr9:120824828~120854385:+
LUAD	cis	rs8059260	0.604	rs9940096	ENSG00000274038.1	RP11-66H6.4	-7.32	1.05e-12	7.91e-10	-0.6	-0.32	Alcohol consumption over the past year;	chr16:11045737	chr16:11056556~11057034:+
LUAD	cis	rs9487094	0.67	rs1406899	ENSG00000260273.1	RP11-425D10.10	7.32	1.05e-12	7.91e-10	0.41	0.32	Height;	chr6:109495102	chr6:109382795~109383666:+
LUAD	cis	rs7429990	0.833	rs883661	ENSG00000229759.1	MRPS18AP1	-7.32	1.05e-12	7.92e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47618611	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.833	rs2030596	ENSG00000229759.1	MRPS18AP1	-7.32	1.05e-12	7.92e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47701712	chr3:48256350~48256938:-
LUAD	cis	rs853679	0.517	rs12174753	ENSG00000219392.1	RP1-265C24.5	-7.32	1.05e-12	7.92e-10	-0.45	-0.32	Depression;	chr6:28074687	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs55747925	ENSG00000219392.1	RP1-265C24.5	-7.32	1.05e-12	7.92e-10	-0.45	-0.32	Depression;	chr6:28076559	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs56310871	ENSG00000219392.1	RP1-265C24.5	-7.32	1.05e-12	7.92e-10	-0.45	-0.32	Depression;	chr6:28076704	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs34716816	ENSG00000219392.1	RP1-265C24.5	-7.32	1.05e-12	7.92e-10	-0.45	-0.32	Depression;	chr6:28078391	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9393884	ENSG00000219392.1	RP1-265C24.5	-7.32	1.05e-12	7.92e-10	-0.45	-0.32	Depression;	chr6:28079011	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9380049	ENSG00000219392.1	RP1-265C24.5	-7.32	1.05e-12	7.92e-10	-0.45	-0.32	Depression;	chr6:28080757	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9380050	ENSG00000219392.1	RP1-265C24.5	-7.32	1.05e-12	7.92e-10	-0.45	-0.32	Depression;	chr6:28080760	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9393885	ENSG00000219392.1	RP1-265C24.5	-7.32	1.05e-12	7.92e-10	-0.45	-0.32	Depression;	chr6:28082231	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9393886	ENSG00000219392.1	RP1-265C24.5	-7.32	1.05e-12	7.92e-10	-0.45	-0.32	Depression;	chr6:28082261	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.515	rs9368549	ENSG00000219392.1	RP1-265C24.5	-7.32	1.05e-12	7.92e-10	-0.45	-0.32	Parkinson's disease;	chr6:28082269	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs56364346	ENSG00000219392.1	RP1-265C24.5	-7.32	1.05e-12	7.92e-10	-0.45	-0.32	Depression;	chr6:28082984	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9357061	ENSG00000219392.1	RP1-265C24.5	-7.32	1.05e-12	7.92e-10	-0.45	-0.32	Depression;	chr6:28083994	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9368550	ENSG00000219392.1	RP1-265C24.5	-7.32	1.05e-12	7.92e-10	-0.45	-0.32	Depression;	chr6:28084025	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.542	rs2295594	ENSG00000219392.1	RP1-265C24.5	-7.32	1.05e-12	7.92e-10	-0.45	-0.32	Depression;	chr6:28085319	chr6:28115628~28116551:+
LUAD	cis	rs7567389	0.6	rs11679414	ENSG00000236682.1	AC068282.3	-7.32	1.05e-12	7.92e-10	-0.44	-0.32	Self-rated health;	chr2:127393427	chr2:127389130~127400580:+
LUAD	cis	rs748404	0.697	rs572959	ENSG00000205771.5	CATSPER2P1	-7.32	1.05e-12	7.93e-10	-0.39	-0.32	Lung cancer;	chr15:43258304	chr15:43726918~43747094:-
LUAD	cis	rs11332131	1	rs11332131	ENSG00000266992.1	DHX40P1	7.32	1.05e-12	7.94e-10	0.36	0.32	Platelet distribution width;	chr17:59849031	chr17:59976009~60002384:-
LUAD	cis	rs10129255	1	rs8010605	ENSG00000280411.1	IGHV1-69-2	-7.32	1.05e-12	7.94e-10	-0.24	-0.32	Kawasaki disease;	chr14:106678742	chr14:106762092~106762588:-
LUAD	cis	rs7945705	0.902	rs10769979	ENSG00000254860.4	TMEM9B-AS1	-7.32	1.05e-12	7.94e-10	-0.36	-0.32	Hemoglobin concentration;	chr11:8989112	chr11:8964675~8977527:+
LUAD	cis	rs11676348	0.967	rs4674258	ENSG00000261338.2	RP11-378A13.1	-7.32	1.06e-12	7.95e-10	-0.34	-0.32	Ulcerative colitis;	chr2:218125863	chr2:218255319~218257366:+
LUAD	cis	rs7208859	0.623	rs8075163	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30863921~30864940:-
LUAD	cis	rs17826219	0.706	rs8075107	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Body mass index;	chr17:30779631	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs7223209	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs7223404	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs9916725	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs9916727	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs73269945	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs9897728	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs1054400	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs1054397	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs9890558	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs3752020	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs9890855	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs9893422	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs9891166	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs73269974	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs34756112	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.573	rs60724269	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs76633166	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs1061346	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs1061343	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs73269988	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs9899525	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs9911784	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs9911997	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs9890862	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs78071511	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs2035494	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs9915566	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.573	rs8064686	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs11657369	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs8075341	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs73271842	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.524	rs28760584	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs7212991	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs28627615	ENSG00000263531.1	RP13-753N3.1	7.32	1.06e-12	7.95e-10	0.64	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30863921~30864940:-
LUAD	cis	rs11098499	0.954	rs6849561	ENSG00000248280.1	RP11-33B1.2	-7.32	1.06e-12	7.95e-10	-0.42	-0.32	Corneal astigmatism;	chr4:119488539	chr4:119440561~119450157:-
LUAD	cis	rs10200159	1	rs9309267	ENSG00000272606.1	RP11-554J4.1	-7.32	1.06e-12	7.96e-10	-0.55	-0.32	Vitiligo;	chr2:55623198	chr2:55617909~55618373:+
LUAD	cis	rs673078	0.66	rs7974718	ENSG00000275759.1	RP11-131L12.3	-7.32	1.06e-12	7.96e-10	-0.42	-0.32	Glucose homeostasis traits;	chr12:118243258	chr12:118428281~118428870:+
LUAD	cis	rs237743	1	rs36016605	ENSG00000222365.1	SNORD12B	-7.32	1.06e-12	7.98e-10	-0.37	-0.32	Height;	chr20:49279608	chr20:49280319~49280409:+
LUAD	cis	rs71403859	0.73	rs17356206	ENSG00000260886.1	TAT-AS1	7.32	1.06e-12	7.98e-10	0.56	0.32	Post bronchodilator FEV1;	chr16:71702456	chr16:71565789~71578187:+
LUAD	cis	rs2980439	0.818	rs2945249	ENSG00000253893.2	FAM85B	-7.32	1.06e-12	7.99e-10	-0.41	-0.32	Neuroticism;	chr8:8237204	chr8:8167819~8226614:-
LUAD	cis	rs9487094	0.626	rs12192776	ENSG00000260273.1	RP11-425D10.10	7.32	1.06e-12	8e-10	0.41	0.32	Height;	chr6:109634150	chr6:109382795~109383666:+
LUAD	cis	rs10256972	0.626	rs62433138	ENSG00000229043.2	AC091729.9	-7.32	1.06e-12	8e-10	-0.34	-0.32	Endometriosis;Longevity;	chr7:1011241	chr7:1160374~1165267:+
LUAD	cis	rs2286503	1	rs2286498	ENSG00000228649.7	AC005682.5	-7.32	1.07e-12	8.06e-10	-0.39	-0.32	Fibrinogen;	chr7:22817885	chr7:22854178~22861579:+
LUAD	cis	rs9545047	0.604	rs2265381	ENSG00000227676.3	LINC01068	-7.32	1.07e-12	8.08e-10	-0.37	-0.32	Schizophrenia;	chr13:79425903	chr13:79566727~79571436:+
LUAD	cis	rs853679	0.517	rs9468298	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Depression;	chr6:28154567	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9295759	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Depression;	chr6:28156691	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9348796	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Depression;	chr6:28158424	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs11552219	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Depression;	chr6:28159056	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9380058	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Depression;	chr6:28159666	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9393895	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Depression;	chr6:28159843	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9357066	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Depression;	chr6:28162053	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9393898	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Depression;	chr6:28162598	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9368556	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Depression;	chr6:28163375	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9368557	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Depression;	chr6:28163759	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9380059	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Depression;	chr6:28164580	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9380060	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Depression;	chr6:28164825	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs35227624	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Depression;	chr6:28164948	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9380061	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Depression;	chr6:28165025	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9368558	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Depression;	chr6:28165528	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.587	rs9393899	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Parkinson's disease;	chr6:28165750	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.527	rs4713151	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Parkinson's disease;	chr6:28168578	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9393901	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Depression;	chr6:28169019	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs3173443	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Depression;	chr6:28169249	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9348797	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Depression;	chr6:28169755	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9380062	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Depression;	chr6:28169791	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.542	rs9380063	ENSG00000219392.1	RP1-265C24.5	-7.32	1.08e-12	8.09e-10	-0.45	-0.32	Depression;	chr6:28170075	chr6:28115628~28116551:+
LUAD	cis	rs748404	0.697	rs530188	ENSG00000205771.5	CATSPER2P1	-7.32	1.08e-12	8.09e-10	-0.39	-0.32	Lung cancer;	chr15:43253116	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.697	rs475227	ENSG00000205771.5	CATSPER2P1	-7.32	1.08e-12	8.09e-10	-0.39	-0.32	Lung cancer;	chr15:43254248	chr15:43726918~43747094:-
LUAD	cis	rs2153535	0.58	rs2327053	ENSG00000230939.1	RP11-314C16.1	-7.32	1.08e-12	8.12e-10	-0.37	-0.32	Motion sickness;	chr6:8442894	chr6:8784178~8785445:+
LUAD	cis	rs2243480	0.908	rs2460431	ENSG00000273142.1	RP11-458F8.4	7.32	1.08e-12	8.16e-10	0.33	0.32	Diabetic kidney disease;	chr7:66157859	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs4718309	ENSG00000273142.1	RP11-458F8.4	7.32	1.08e-12	8.16e-10	0.33	0.32	Diabetic kidney disease;	chr7:66162777	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs6460274	ENSG00000273142.1	RP11-458F8.4	7.32	1.08e-12	8.16e-10	0.33	0.32	Diabetic kidney disease;	chr7:66163497	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs7787230	ENSG00000273142.1	RP11-458F8.4	7.32	1.08e-12	8.16e-10	0.33	0.32	Diabetic kidney disease;	chr7:66164112	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs2465120	ENSG00000273142.1	RP11-458F8.4	-7.32	1.08e-12	8.16e-10	-0.33	-0.32	Diabetic kidney disease;	chr7:66155987	chr7:66902857~66906297:+
LUAD	cis	rs2153535	0.58	rs1119688	ENSG00000230939.1	RP11-314C16.1	-7.31	1.09e-12	8.16e-10	-0.38	-0.32	Motion sickness;	chr6:8460617	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.541	rs6923558	ENSG00000230939.1	RP11-314C16.1	-7.31	1.09e-12	8.16e-10	-0.38	-0.32	Motion sickness;	chr6:8461234	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1577470	ENSG00000230939.1	RP11-314C16.1	-7.31	1.09e-12	8.16e-10	-0.38	-0.32	Motion sickness;	chr6:8462193	chr6:8784178~8785445:+
LUAD	cis	rs2439831	0.867	rs3213990	ENSG00000205771.5	CATSPER2P1	-7.31	1.09e-12	8.16e-10	-0.55	-0.32	Lung cancer in ever smokers;	chr15:43378028	chr15:43726918~43747094:-
LUAD	cis	rs10129255	1	rs10141557	ENSG00000280411.1	IGHV1-69-2	-7.31	1.09e-12	8.19e-10	-0.24	-0.32	Kawasaki disease;	chr14:106767990	chr14:106762092~106762588:-
LUAD	cis	rs7811142	0.83	rs75636500	ENSG00000242294.5	STAG3L5P	7.31	1.09e-12	8.19e-10	0.28	0.32	Platelet count;	chr7:100350034	chr7:100336079~100351900:+
LUAD	cis	rs3931020	0.962	rs2185695	ENSG00000272864.1	RP11-17E13.2	-7.31	1.09e-12	8.2e-10	-0.41	-0.32	Resistin levels;	chr1:74792197	chr1:74698769~74699333:-
LUAD	cis	rs950880	0.71	rs56117144	ENSG00000234389.1	AC007278.3	-7.31	1.09e-12	8.2e-10	-0.33	-0.32	Serum protein levels (sST2);	chr2:102458191	chr2:102438713~102440475:+
LUAD	cis	rs950880	0.71	rs57081652	ENSG00000234389.1	AC007278.3	-7.31	1.09e-12	8.2e-10	-0.33	-0.32	Serum protein levels (sST2);	chr2:102458921	chr2:102438713~102440475:+
LUAD	cis	rs8059260	0.604	rs16957966	ENSG00000274038.1	RP11-66H6.4	-7.31	1.09e-12	8.22e-10	-0.56	-0.32	Alcohol consumption over the past year;	chr16:11046280	chr16:11056556~11057034:+
LUAD	cis	rs10200159	0.793	rs6545512	ENSG00000272606.1	RP11-554J4.1	7.31	1.09e-12	8.22e-10	0.51	0.32	Vitiligo;	chr2:55656896	chr2:55617909~55618373:+
LUAD	cis	rs11098499	0.687	rs71610270	ENSG00000248280.1	RP11-33B1.2	7.31	1.1e-12	8.25e-10	0.39	0.32	Corneal astigmatism;	chr4:119366281	chr4:119440561~119450157:-
LUAD	cis	rs7646881	1	rs59217052	ENSG00000240207.5	RP11-379F4.4	-7.31	1.1e-12	8.26e-10	-0.38	-0.32	Tetralogy of Fallot;	chr3:158734667	chr3:158732263~158784070:+
LUAD	cis	rs2153535	0.58	rs1928184	ENSG00000230939.1	RP11-314C16.1	-7.31	1.1e-12	8.27e-10	-0.38	-0.32	Motion sickness;	chr6:8531875	chr6:8784178~8785445:+
LUAD	cis	rs9595908	0.965	rs9595877	ENSG00000212293.1	SNORA16	7.31	1.1e-12	8.28e-10	0.36	0.32	Body mass index;	chr13:32589512	chr13:32420390~32420516:-
LUAD	cis	rs9309711	0.922	rs13385119	ENSG00000225234.1	TRAPPC12-AS1	-7.31	1.11e-12	8.31e-10	-0.4	-0.32	Neurofibrillary tangles;	chr2:3480750	chr2:3481242~3482409:-
LUAD	cis	rs2842992	0.724	rs9347340	ENSG00000237927.1	RP3-393E18.2	7.31	1.11e-12	8.31e-10	0.44	0.32	Age-related macular degeneration (geographic atrophy);	chr6:159767859	chr6:159586955~159589169:-
LUAD	cis	rs9595908	0.929	rs34916533	ENSG00000212293.1	SNORA16	7.31	1.11e-12	8.31e-10	0.37	0.32	Body mass index;	chr13:32500537	chr13:32420390~32420516:-
LUAD	cis	rs7429990	0.864	rs6785669	ENSG00000229759.1	MRPS18AP1	-7.31	1.11e-12	8.32e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47715771	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.833	rs6442079	ENSG00000229759.1	MRPS18AP1	-7.31	1.11e-12	8.32e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47721044	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs13094264	ENSG00000229759.1	MRPS18AP1	-7.31	1.11e-12	8.32e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47722723	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs4858851	ENSG00000229759.1	MRPS18AP1	-7.31	1.11e-12	8.32e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47724165	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.833	rs34777284	ENSG00000229759.1	MRPS18AP1	-7.31	1.11e-12	8.32e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47726585	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.833	rs7649393	ENSG00000229759.1	MRPS18AP1	-7.31	1.11e-12	8.32e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47727501	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs7638103	ENSG00000229759.1	MRPS18AP1	-7.31	1.11e-12	8.32e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47727585	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs11130148	ENSG00000229759.1	MRPS18AP1	-7.31	1.11e-12	8.32e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47729797	chr3:48256350~48256938:-
LUAD	cis	rs1789	0.503	rs13133213	ENSG00000273133.1	RP11-799M12.2	-7.31	1.11e-12	8.32e-10	-0.43	-0.32	Blood protein levels;	chr4:15645171	chr4:15563698~15564253:-
LUAD	cis	rs7674212	0.531	rs2866416	ENSG00000246560.2	RP11-10L12.4	7.31	1.11e-12	8.33e-10	0.42	0.32	Type 2 diabetes;	chr4:102959554	chr4:102828055~102844075:+
LUAD	cis	rs9549367	0.636	rs486407	ENSG00000269125.1	RP11-98F14.11	7.31	1.12e-12	8.38e-10	0.4	0.32	Platelet distribution width;	chr13:113179185	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.713	rs2476319	ENSG00000269125.1	RP11-98F14.11	7.31	1.12e-12	8.38e-10	0.4	0.32	Platelet distribution width;	chr13:113182205	chr13:113165002~113165183:-
LUAD	cis	rs2286503	0.752	rs6461669	ENSG00000228649.7	AC005682.5	7.31	1.12e-12	8.41e-10	0.4	0.32	Fibrinogen;	chr7:22818447	chr7:22854178~22861579:+
LUAD	cis	rs10129255	0.826	rs7150693	ENSG00000280411.1	IGHV1-69-2	-7.31	1.12e-12	8.41e-10	-0.24	-0.32	Kawasaki disease;	chr14:106705382	chr14:106762092~106762588:-
LUAD	cis	rs1501911	0.53	rs162473	ENSG00000248489.1	CTD-2007H13.3	-7.31	1.12e-12	8.42e-10	-0.35	-0.32	Lung function (FEV1/FVC);	chr5:98805276	chr5:98929171~98995013:+
LUAD	cis	rs7208859	0.573	rs216443	ENSG00000263531.1	RP13-753N3.1	7.31	1.12e-12	8.42e-10	0.66	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30863921~30864940:-
LUAD	cis	rs950027	0.967	rs2643718	ENSG00000259520.4	CTD-2651B20.3	-7.31	1.12e-12	8.43e-10	-0.37	-0.32	Response to fenofibrate (adiponectin levels);	chr15:45502464	chr15:45251580~45279251:-
LUAD	cis	rs6142102	0.961	rs2235596	ENSG00000276073.1	RP5-1125A11.7	7.31	1.13e-12	8.44e-10	0.32	0.32	Skin pigmentation;	chr20:34096503	chr20:33985617~33988989:-
LUAD	cis	rs10129255	0.5	rs988134	ENSG00000211970.3	IGHV4-61	-7.31	1.13e-12	8.45e-10	-0.22	-0.32	Kawasaki disease;	chr14:106776698	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.5	rs988133	ENSG00000211970.3	IGHV4-61	-7.31	1.13e-12	8.45e-10	-0.22	-0.32	Kawasaki disease;	chr14:106776724	chr14:106639119~106639657:-
LUAD	cis	rs9487094	0.67	rs12528781	ENSG00000260273.1	RP11-425D10.10	7.31	1.13e-12	8.47e-10	0.41	0.32	Height;	chr6:109608105	chr6:109382795~109383666:+
LUAD	cis	rs11155671	0.53	rs2342770	ENSG00000223701.3	RAET1E-AS1	7.31	1.14e-12	8.52e-10	0.37	0.32	Testicular germ cell tumor;	chr6:149895549	chr6:149884431~149919508:+
LUAD	cis	rs950880	0.71	rs3771150	ENSG00000234389.1	AC007278.3	-7.31	1.14e-12	8.52e-10	-0.33	-0.32	Serum protein levels (sST2);	chr2:102444391	chr2:102438713~102440475:+
LUAD	cis	rs9549367	0.713	rs4907598	ENSG00000269125.1	RP11-98F14.11	7.31	1.14e-12	8.52e-10	0.4	0.32	Platelet distribution width;	chr13:113207071	chr13:113165002~113165183:-
LUAD	cis	rs853679	0.527	rs707907	ENSG00000204709.4	LINC01556	7.31	1.14e-12	8.52e-10	0.4	0.32	Depression;	chr6:28323463	chr6:28943877~28944537:+
LUAD	cis	rs7811142	0.83	rs76798830	ENSG00000242294.5	STAG3L5P	7.31	1.14e-12	8.55e-10	0.28	0.32	Platelet count;	chr7:100355205	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.775	rs6946768	ENSG00000242294.5	STAG3L5P	7.31	1.14e-12	8.55e-10	0.28	0.32	Platelet count;	chr7:100356770	chr7:100336079~100351900:+
LUAD	cis	rs881375	0.967	rs1930778	ENSG00000226752.6	PSMD5-AS1	-7.31	1.14e-12	8.57e-10	-0.34	-0.32	Rheumatoid arthritis;	chr9:120879091	chr9:120824828~120854385:+
LUAD	cis	rs10463554	0.856	rs257293	ENSG00000175749.11	EIF3KP1	7.31	1.14e-12	8.58e-10	0.43	0.32	Parkinson's disease;	chr5:103159824	chr5:103032376~103033031:+
LUAD	cis	rs3198697	1	rs3198697	ENSG00000207425.1	Y_RNA	7.31	1.15e-12	8.59e-10	0.36	0.32	Triglycerides;	chr16:15036083	chr16:14915457~14915556:-
LUAD	cis	rs673078	0.607	rs7307393	ENSG00000275759.1	RP11-131L12.3	-7.31	1.15e-12	8.59e-10	-0.47	-0.32	Glucose homeostasis traits;	chr12:118308537	chr12:118428281~118428870:+
LUAD	cis	rs9322193	0.962	rs9322220	ENSG00000223701.3	RAET1E-AS1	7.31	1.15e-12	8.6e-10	0.37	0.32	Lung cancer;	chr6:149782897	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs10214845	ENSG00000223701.3	RAET1E-AS1	7.31	1.15e-12	8.6e-10	0.37	0.32	Lung cancer;	chr6:149783124	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs9767122	ENSG00000223701.3	RAET1E-AS1	7.31	1.15e-12	8.6e-10	0.37	0.32	Lung cancer;	chr6:149783553	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs1413654	ENSG00000223701.3	RAET1E-AS1	7.31	1.15e-12	8.6e-10	0.37	0.32	Lung cancer;	chr6:149783956	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs9688809	ENSG00000223701.3	RAET1E-AS1	7.31	1.15e-12	8.6e-10	0.37	0.32	Lung cancer;	chr6:149787920	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs9689242	ENSG00000223701.3	RAET1E-AS1	7.31	1.15e-12	8.6e-10	0.37	0.32	Lung cancer;	chr6:149787970	chr6:149884431~149919508:+
LUAD	cis	rs9322193	1	rs9767077	ENSG00000223701.3	RAET1E-AS1	7.31	1.15e-12	8.6e-10	0.37	0.32	Lung cancer;	chr6:149788479	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs9688938	ENSG00000223701.3	RAET1E-AS1	7.31	1.15e-12	8.6e-10	0.37	0.32	Lung cancer;	chr6:149788941	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs9688940	ENSG00000223701.3	RAET1E-AS1	7.31	1.15e-12	8.6e-10	0.37	0.32	Lung cancer;	chr6:149788977	chr6:149884431~149919508:+
LUAD	cis	rs2439831	0.681	rs2278859	ENSG00000205771.5	CATSPER2P1	-7.31	1.15e-12	8.6e-10	-0.53	-0.32	Lung cancer in ever smokers;	chr15:43340762	chr15:43726918~43747094:-
LUAD	cis	rs783540	0.846	rs783539	ENSG00000278603.1	RP13-608F4.5	-7.31	1.15e-12	8.62e-10	-0.37	-0.32	Schizophrenia;	chr15:82585320	chr15:82472203~82472426:+
LUAD	cis	rs10129255	0.5	rs8004923	ENSG00000211970.3	IGHV4-61	-7.31	1.15e-12	8.63e-10	-0.22	-0.32	Kawasaki disease;	chr14:106785926	chr14:106639119~106639657:-
LUAD	cis	rs7646881	1	rs59313096	ENSG00000240207.5	RP11-379F4.4	-7.31	1.16e-12	8.67e-10	-0.38	-0.32	Tetralogy of Fallot;	chr3:158734453	chr3:158732263~158784070:+
LUAD	cis	rs2153535	0.542	rs9505465	ENSG00000230939.1	RP11-314C16.1	-7.31	1.16e-12	8.67e-10	-0.38	-0.32	Motion sickness;	chr6:8510613	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.541	rs945304	ENSG00000230939.1	RP11-314C16.1	-7.31	1.16e-12	8.68e-10	-0.37	-0.32	Motion sickness;	chr6:8442659	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1889715	ENSG00000230939.1	RP11-314C16.1	-7.31	1.16e-12	8.68e-10	-0.37	-0.32	Motion sickness;	chr6:8443242	chr6:8784178~8785445:+
LUAD	cis	rs10129255	0.5	rs6576232	ENSG00000211970.3	IGHV4-61	-7.31	1.16e-12	8.68e-10	-0.22	-0.32	Kawasaki disease;	chr14:106787090	chr14:106639119~106639657:-
LUAD	cis	rs950169	1	rs950169	ENSG00000225151.9	GOLGA2P7	-7.3	1.17e-12	8.73e-10	-0.45	-0.32	Schizophrenia;	chr15:84037709	chr15:84199311~84230136:-
LUAD	cis	rs2153535	0.563	rs1796688	ENSG00000230939.1	RP11-314C16.1	-7.3	1.17e-12	8.73e-10	-0.38	-0.32	Motion sickness;	chr6:8536190	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.526	rs1796689	ENSG00000230939.1	RP11-314C16.1	-7.3	1.17e-12	8.73e-10	-0.38	-0.32	Motion sickness;	chr6:8536200	chr6:8784178~8785445:+
LUAD	cis	rs9640161	0.789	rs4554381	ENSG00000261305.1	RP4-584D14.7	7.3	1.17e-12	8.74e-10	0.45	0.32	Blood protein levels;Circulating chemerin levels;	chr7:150328478	chr7:150341771~150342607:+
LUAD	cis	rs8031584	0.678	rs4779496	ENSG00000260382.1	RP11-540B6.2	7.3	1.17e-12	8.74e-10	0.4	0.32	Huntington's disease progression;	chr15:30858851	chr15:30882267~30883231:-
LUAD	cis	rs8031584	0.678	rs4779497	ENSG00000260382.1	RP11-540B6.2	7.3	1.17e-12	8.74e-10	0.4	0.32	Huntington's disease progression;	chr15:30859162	chr15:30882267~30883231:-
LUAD	cis	rs8031584	0.678	rs8028173	ENSG00000260382.1	RP11-540B6.2	7.3	1.17e-12	8.74e-10	0.4	0.32	Huntington's disease progression;	chr15:30863546	chr15:30882267~30883231:-
LUAD	cis	rs8031584	0.706	rs2177670	ENSG00000260382.1	RP11-540B6.2	7.3	1.17e-12	8.74e-10	0.4	0.32	Huntington's disease progression;	chr15:30865548	chr15:30882267~30883231:-
LUAD	cis	rs8031584	0.678	rs36047941	ENSG00000260382.1	RP11-540B6.2	7.3	1.17e-12	8.74e-10	0.4	0.32	Huntington's disease progression;	chr15:30867032	chr15:30882267~30883231:-
LUAD	cis	rs853679	0.517	rs9380047	ENSG00000219392.1	RP1-265C24.5	-7.3	1.17e-12	8.75e-10	-0.45	-0.32	Depression;	chr6:28070115	chr6:28115628~28116551:+
LUAD	cis	rs10129255	0.913	rs10140943	ENSG00000211972.2	IGHV3-66	7.3	1.17e-12	8.77e-10	0.28	0.32	Kawasaki disease;	chr14:106767441	chr14:106675017~106675544:-
LUAD	cis	rs853679	0.517	rs9366715	ENSG00000219392.1	RP1-265C24.5	-7.3	1.17e-12	8.78e-10	-0.44	-0.32	Depression;	chr6:28096855	chr6:28115628~28116551:+
LUAD	cis	rs2153535	0.58	rs7761937	ENSG00000230939.1	RP11-314C16.1	-7.3	1.17e-12	8.79e-10	-0.38	-0.32	Motion sickness;	chr6:8459201	chr6:8784178~8785445:+
LUAD	cis	rs13056815	1	rs13056815	ENSG00000236132.1	CTA-440B3.1	7.3	1.17e-12	8.79e-10	0.35	0.32	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr22:31272264	chr22:31816379~31817491:-
LUAD	cis	rs9545047	0.604	rs9601227	ENSG00000227676.3	LINC01068	-7.3	1.18e-12	8.84e-10	-0.38	-0.32	Schizophrenia;	chr13:79420805	chr13:79566727~79571436:+
LUAD	cis	rs1185460	0.565	rs540261	ENSG00000271751.1	RP11-110I1.14	7.3	1.18e-12	8.84e-10	0.41	0.32	Coronary artery disease;	chr11:119076924	chr11:119065263~119065677:-
LUAD	cis	rs2842992	0.915	rs2842985	ENSG00000237927.1	RP3-393E18.2	-7.3	1.18e-12	8.85e-10	-0.44	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159664402	chr6:159586955~159589169:-
LUAD	cis	rs4713118	0.629	rs149899	ENSG00000219392.1	RP1-265C24.5	-7.3	1.18e-12	8.85e-10	-0.43	-0.32	Parkinson's disease;	chr6:28052201	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.629	rs172165	ENSG00000219392.1	RP1-265C24.5	-7.3	1.18e-12	8.85e-10	-0.43	-0.32	Parkinson's disease;	chr6:28053036	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.597	rs172166	ENSG00000219392.1	RP1-265C24.5	-7.3	1.18e-12	8.85e-10	-0.43	-0.32	Parkinson's disease;	chr6:28053042	chr6:28115628~28116551:+
LUAD	cis	rs9322193	0.607	rs4870078	ENSG00000216906.2	RP11-350J20.9	-7.3	1.19e-12	8.87e-10	-0.44	-0.32	Lung cancer;	chr6:149880676	chr6:149904243~149906418:+
LUAD	cis	rs2153535	0.58	rs7743995	ENSG00000230939.1	RP11-314C16.1	-7.3	1.19e-12	8.88e-10	-0.37	-0.32	Motion sickness;	chr6:8495979	chr6:8784178~8785445:+
LUAD	cis	rs35955747	0.669	rs878718	ENSG00000236132.1	CTA-440B3.1	-7.3	1.19e-12	8.88e-10	-0.35	-0.32	Neutrophil count;Sum basophil neutrophil counts;	chr22:31156716	chr22:31816379~31817491:-
LUAD	cis	rs17608059	0.634	rs10852819	ENSG00000141028.6	CDRT15P1	-7.3	1.19e-12	8.91e-10	-0.35	-0.32	Temperament;	chr17:14018109	chr17:14024514~14025488:+
LUAD	cis	rs2243480	1	rs313820	ENSG00000273142.1	RP11-458F8.4	-7.3	1.19e-12	8.92e-10	-0.33	-0.32	Diabetic kidney disease;	chr7:66109479	chr7:66902857~66906297:+
LUAD	cis	rs748404	0.697	rs530683	ENSG00000205771.5	CATSPER2P1	7.3	1.19e-12	8.92e-10	0.39	0.32	Lung cancer;	chr15:43276801	chr15:43726918~43747094:-
LUAD	cis	rs853679	0.598	rs9380054	ENSG00000219392.1	RP1-265C24.5	-7.3	1.19e-12	8.92e-10	-0.44	-0.32	Depression;	chr6:28099759	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.547	rs2116981	ENSG00000219392.1	RP1-265C24.5	-7.3	1.19e-12	8.92e-10	-0.44	-0.32	Parkinson's disease;	chr6:28100173	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9368552	ENSG00000219392.1	RP1-265C24.5	-7.3	1.19e-12	8.92e-10	-0.44	-0.32	Depression;	chr6:28100648	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.542	rs34131763	ENSG00000219392.1	RP1-265C24.5	-7.3	1.19e-12	8.92e-10	-0.44	-0.32	Depression;	chr6:28107222	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs35193936	ENSG00000219392.1	RP1-265C24.5	-7.3	1.19e-12	8.92e-10	-0.44	-0.32	Depression;	chr6:28108492	chr6:28115628~28116551:+
LUAD	cis	rs7945705	0.902	rs7930026	ENSG00000254860.4	TMEM9B-AS1	-7.3	1.2e-12	8.94e-10	-0.36	-0.32	Hemoglobin concentration;	chr11:8992092	chr11:8964675~8977527:+
LUAD	cis	rs7829975	0.536	rs2980439	ENSG00000253981.4	ALG1L13P	7.3	1.2e-12	8.94e-10	0.37	0.32	Mood instability;	chr8:8237348	chr8:8236003~8244667:-
LUAD	cis	rs9545047	0.604	rs912639	ENSG00000227676.3	LINC01068	-7.3	1.2e-12	8.94e-10	-0.37	-0.32	Schizophrenia;	chr13:79409788	chr13:79566727~79571436:+
LUAD	cis	rs7429990	0.864	rs13091913	ENSG00000229759.1	MRPS18AP1	-7.3	1.2e-12	8.95e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47762307	chr3:48256350~48256938:-
LUAD	cis	rs8091660	0.929	rs3744827	ENSG00000278983.1	RP11-426J5.3	-7.3	1.2e-12	8.95e-10	-0.36	-0.32	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48569572	chr18:48564795~48568342:+
LUAD	cis	rs71403859	0.614	rs12149533	ENSG00000260886.1	TAT-AS1	7.3	1.21e-12	9.04e-10	0.56	0.32	Post bronchodilator FEV1;	chr16:71768043	chr16:71565789~71578187:+
LUAD	cis	rs9487094	0.67	rs12212476	ENSG00000260273.1	RP11-425D10.10	7.3	1.22e-12	9.08e-10	0.42	0.32	Height;	chr6:109501402	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.67	rs12198938	ENSG00000260273.1	RP11-425D10.10	7.3	1.22e-12	9.08e-10	0.42	0.32	Height;	chr6:109501429	chr6:109382795~109383666:+
LUAD	cis	rs10129255	0.869	rs7150549	ENSG00000280411.1	IGHV1-69-2	-7.3	1.22e-12	9.09e-10	-0.24	-0.32	Kawasaki disease;	chr14:106705441	chr14:106762092~106762588:-
LUAD	cis	rs6597981	0.675	rs4963120	ENSG00000255142.1	AP006621.6	-7.3	1.24e-12	9.22e-10	-0.25	-0.32	Breast cancer;	chr11:825777	chr11:781645~782105:+
LUAD	cis	rs7429990	0.864	rs2140335	ENSG00000229759.1	MRPS18AP1	-7.29	1.24e-12	9.25e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47663625	chr3:48256350~48256938:-
LUAD	cis	rs10129255	0.957	rs4387509	ENSG00000280411.1	IGHV1-69-2	-7.29	1.24e-12	9.26e-10	-0.24	-0.32	Kawasaki disease;	chr14:106704386	chr14:106762092~106762588:-
LUAD	cis	rs237743	1	rs8123912	ENSG00000222365.1	SNORD12B	-7.29	1.24e-12	9.27e-10	-0.37	-0.32	Height;	chr20:49246745	chr20:49280319~49280409:+
LUAD	cis	rs6142102	0.886	rs4911147	ENSG00000276073.1	RP5-1125A11.7	-7.29	1.24e-12	9.28e-10	-0.33	-0.32	Skin pigmentation;	chr20:34079801	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.659	rs6057945	ENSG00000276073.1	RP5-1125A11.7	-7.29	1.25e-12	9.28e-10	-0.33	-0.32	Skin pigmentation;	chr20:33929374	chr20:33985617~33988989:-
LUAD	cis	rs7429990	0.864	rs7631950	ENSG00000229759.1	MRPS18AP1	-7.29	1.25e-12	9.32e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47591865	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.833	rs4858801	ENSG00000229759.1	MRPS18AP1	-7.29	1.25e-12	9.35e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47599432	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs61620099	ENSG00000229759.1	MRPS18AP1	-7.29	1.25e-12	9.35e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47600755	chr3:48256350~48256938:-
LUAD	cis	rs75422866	0.717	rs73113159	ENSG00000280054.1	RP1-197B17.7	7.29	1.25e-12	9.35e-10	0.73	0.32	Pneumonia;	chr12:47631318	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.717	rs73113161	ENSG00000280054.1	RP1-197B17.7	7.29	1.25e-12	9.35e-10	0.73	0.32	Pneumonia;	chr12:47632361	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs117022227	ENSG00000280054.1	RP1-197B17.7	7.29	1.25e-12	9.35e-10	0.73	0.32	Pneumonia;	chr12:47633282	chr12:47728151~47730598:-
LUAD	cis	rs75422866	1	rs73102120	ENSG00000280054.1	RP1-197B17.7	7.29	1.25e-12	9.35e-10	0.73	0.32	Pneumonia;	chr12:47637280	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs12422974	ENSG00000280054.1	RP1-197B17.7	7.29	1.25e-12	9.35e-10	0.73	0.32	Pneumonia;	chr12:47644559	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs73102127	ENSG00000280054.1	RP1-197B17.7	7.29	1.25e-12	9.35e-10	0.73	0.32	Pneumonia;	chr12:47645341	chr12:47728151~47730598:-
LUAD	cis	rs8059260	1	rs6498138	ENSG00000274038.1	RP11-66H6.4	7.29	1.26e-12	9.36e-10	0.49	0.32	Alcohol consumption over the past year;	chr16:10951421	chr16:11056556~11057034:+
LUAD	cis	rs853679	0.527	rs9468333	ENSG00000216901.1	AL022393.7	7.29	1.26e-12	9.37e-10	0.37	0.32	Depression;	chr6:28303421	chr6:28176188~28176674:+
LUAD	cis	rs904251	0.698	rs2646926	ENSG00000204110.6	RP1-153P14.8	-7.29	1.26e-12	9.39e-10	-0.34	-0.32	Cognitive performance;	chr6:37457212	chr6:37507348~37535616:+
LUAD	cis	rs7429990	0.52	rs78838427	ENSG00000229759.1	MRPS18AP1	-7.29	1.27e-12	9.45e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47595561	chr3:48256350~48256938:-
LUAD	cis	rs9601248	0.874	rs9545154	ENSG00000227676.3	LINC01068	7.29	1.27e-12	9.47e-10	0.4	0.32	Major depressive disorder;	chr13:79617682	chr13:79566727~79571436:+
LUAD	cis	rs9601248	0.874	rs9545155	ENSG00000227676.3	LINC01068	7.29	1.27e-12	9.47e-10	0.4	0.32	Major depressive disorder;	chr13:79617738	chr13:79566727~79571436:+
LUAD	cis	rs2243480	0.831	rs57294491	ENSG00000273142.1	RP11-458F8.4	7.29	1.28e-12	9.49e-10	0.33	0.32	Diabetic kidney disease;	chr7:66219914	chr7:66902857~66906297:+
LUAD	cis	rs6142102	0.961	rs4911405	ENSG00000276073.1	RP5-1125A11.7	-7.29	1.28e-12	9.49e-10	-0.34	-0.32	Skin pigmentation;	chr20:34087161	chr20:33985617~33988989:-
LUAD	cis	rs10129255	0.5	rs59939897	ENSG00000211970.3	IGHV4-61	-7.29	1.28e-12	9.5e-10	-0.23	-0.32	Kawasaki disease;	chr14:106783414	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.5	rs8014529	ENSG00000211970.3	IGHV4-61	-7.29	1.28e-12	9.5e-10	-0.23	-0.32	Kawasaki disease;	chr14:106784065	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.5	rs12101190	ENSG00000211970.3	IGHV4-61	-7.29	1.28e-12	9.5e-10	-0.23	-0.32	Kawasaki disease;	chr14:106784149	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.518	rs8004895	ENSG00000211970.3	IGHV4-61	-7.29	1.28e-12	9.5e-10	-0.23	-0.32	Kawasaki disease;	chr14:106785139	chr14:106639119~106639657:-
LUAD	cis	rs35160687	0.901	rs12999029	ENSG00000273080.1	RP11-301O19.1	7.29	1.28e-12	9.5e-10	0.36	0.32	Night sleep phenotypes;	chr2:86275790	chr2:86195590~86196049:+
LUAD	cis	rs6142102	0.961	rs8123521	ENSG00000276073.1	RP5-1125A11.7	-7.29	1.28e-12	9.51e-10	-0.33	-0.32	Skin pigmentation;	chr20:34081079	chr20:33985617~33988989:-
LUAD	cis	rs7429990	0.864	rs12497826	ENSG00000229759.1	MRPS18AP1	-7.29	1.28e-12	9.51e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47628059	chr3:48256350~48256938:-
LUAD	cis	rs4713118	0.662	rs149970	ENSG00000219392.1	RP1-265C24.5	-7.29	1.28e-12	9.53e-10	-0.43	-0.32	Parkinson's disease;	chr6:28012442	chr6:28115628~28116551:+
LUAD	cis	rs10129255	0.5	rs9324092	ENSG00000224373.3	IGHV4-59	-7.29	1.28e-12	9.54e-10	-0.19	-0.32	Kawasaki disease;	chr14:106683806	chr14:106627249~106627825:-
LUAD	cis	rs2153535	0.563	rs1737585	ENSG00000230939.1	RP11-314C16.1	7.29	1.28e-12	9.54e-10	0.37	0.32	Motion sickness;	chr6:8536361	chr6:8784178~8785445:+
LUAD	cis	rs2842992	0.83	rs1998365	ENSG00000237927.1	RP3-393E18.2	-7.29	1.28e-12	9.56e-10	-0.45	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159758503	chr6:159586955~159589169:-
LUAD	cis	rs944289	0.598	rs56359141	ENSG00000257826.1	RP11-116N8.4	-7.29	1.29e-12	9.58e-10	-0.34	-0.32	Thyroid cancer;	chr14:36108167	chr14:36061026~36067190:-
LUAD	cis	rs748404	0.697	rs493177	ENSG00000205771.5	CATSPER2P1	-7.29	1.29e-12	9.61e-10	-0.39	-0.32	Lung cancer;	chr15:43251060	chr15:43726918~43747094:-
LUAD	cis	rs853679	0.517	rs9357065	ENSG00000219392.1	RP1-265C24.5	-7.29	1.29e-12	9.63e-10	-0.45	-0.32	Depression;	chr6:28161802	chr6:28115628~28116551:+
LUAD	cis	rs944289	0.899	rs1169125	ENSG00000257826.1	RP11-116N8.4	-7.29	1.3e-12	9.66e-10	-0.34	-0.32	Thyroid cancer;	chr14:36150560	chr14:36061026~36067190:-
LUAD	cis	rs853679	0.517	rs3757187	ENSG00000219392.1	RP1-265C24.5	-7.29	1.31e-12	9.7e-10	-0.45	-0.32	Depression;	chr6:28139876	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs3757185	ENSG00000219392.1	RP1-265C24.5	-7.29	1.31e-12	9.7e-10	-0.45	-0.32	Depression;	chr6:28139998	chr6:28115628~28116551:+
LUAD	cis	rs1729407	0.706	rs1268354	ENSG00000254851.1	RP11-109L13.1	-7.29	1.31e-12	9.72e-10	-0.4	-0.32	Apolipoprotein A-IV levels;	chr11:116819862	chr11:117135528~117138582:+
LUAD	cis	rs7811142	0.83	rs705866	ENSG00000242294.5	STAG3L5P	7.29	1.31e-12	9.77e-10	0.28	0.32	Platelet count;	chr7:100367662	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.83	rs6965458	ENSG00000242294.5	STAG3L5P	7.29	1.31e-12	9.77e-10	0.28	0.32	Platelet count;	chr7:100375779	chr7:100336079~100351900:+
LUAD	cis	rs7674212	0.581	rs13150953	ENSG00000246560.2	RP11-10L12.4	7.29	1.32e-12	9.79e-10	0.41	0.32	Type 2 diabetes;	chr4:103021341	chr4:102828055~102844075:+
LUAD	cis	rs7674212	0.556	rs13151569	ENSG00000246560.2	RP11-10L12.4	7.29	1.32e-12	9.79e-10	0.41	0.32	Type 2 diabetes;	chr4:103021633	chr4:102828055~102844075:+
LUAD	cis	rs1150668	0.796	rs213236	ENSG00000216901.1	AL022393.7	7.29	1.32e-12	9.79e-10	0.37	0.32	Pubertal anthropometrics;	chr6:28356620	chr6:28176188~28176674:+
LUAD	cis	rs853679	0.517	rs9393893	ENSG00000219392.1	RP1-265C24.5	-7.29	1.32e-12	9.8e-10	-0.45	-0.32	Depression;	chr6:28141484	chr6:28115628~28116551:+
LUAD	cis	rs7567389	0.677	rs6757492	ENSG00000236682.1	AC068282.3	7.29	1.32e-12	9.81e-10	0.44	0.32	Self-rated health;	chr2:127237756	chr2:127389130~127400580:+
LUAD	cis	rs10200159	1	rs17047119	ENSG00000272606.1	RP11-554J4.1	7.29	1.32e-12	9.81e-10	0.54	0.32	Vitiligo;	chr2:55599979	chr2:55617909~55618373:+
LUAD	cis	rs1345301	1	rs1345301	ENSG00000234389.1	AC007278.3	-7.29	1.32e-12	9.82e-10	-0.29	-0.32	Waist circumference;	chr2:102259127	chr2:102438713~102440475:+
LUAD	cis	rs1345301	1	rs11686567	ENSG00000234389.1	AC007278.3	-7.29	1.32e-12	9.82e-10	-0.29	-0.32	Waist circumference;	chr2:102260149	chr2:102438713~102440475:+
LUAD	cis	rs1345301	0.935	rs11691721	ENSG00000234389.1	AC007278.3	-7.29	1.32e-12	9.82e-10	-0.29	-0.32	Waist circumference;	chr2:102260219	chr2:102438713~102440475:+
LUAD	cis	rs9487094	0.67	rs13220915	ENSG00000260273.1	RP11-425D10.10	7.29	1.33e-12	9.85e-10	0.42	0.32	Height;	chr6:109503623	chr6:109382795~109383666:+
LUAD	cis	rs9595908	0.965	rs35193668	ENSG00000212293.1	SNORA16	7.28	1.33e-12	9.86e-10	0.37	0.32	Body mass index;	chr13:32518792	chr13:32420390~32420516:-
LUAD	cis	rs75422866	0.867	rs73104103	ENSG00000274902.1	RP1-197B17.4	7.28	1.33e-12	9.86e-10	0.7	0.32	Pneumonia;	chr12:47669604	chr12:47731908~47732351:+
LUAD	cis	rs9545047	0.567	rs2296287	ENSG00000227676.3	LINC01068	7.28	1.33e-12	9.89e-10	0.37	0.32	Schizophrenia;	chr13:79407045	chr13:79566727~79571436:+
LUAD	cis	rs950880	0.71	rs11681718	ENSG00000234389.1	AC007278.3	-7.28	1.33e-12	9.9e-10	-0.33	-0.32	Serum protein levels (sST2);	chr2:102434684	chr2:102438713~102440475:+
LUAD	cis	rs9322193	0.926	rs9766562	ENSG00000223701.3	RAET1E-AS1	7.28	1.34e-12	9.91e-10	0.37	0.32	Lung cancer;	chr6:149788709	chr6:149884431~149919508:+
LUAD	cis	rs77204473	0.793	rs11216206	ENSG00000254851.1	RP11-109L13.1	7.28	1.34e-12	9.92e-10	0.68	0.32	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116972709	chr11:117135528~117138582:+
LUAD	cis	rs237743	1	rs238164	ENSG00000222365.1	SNORD12B	-7.28	1.34e-12	9.94e-10	-0.35	-0.32	Height;	chr20:49227804	chr20:49280319~49280409:+
LUAD	cis	rs2729354	0.502	rs2848641	ENSG00000265566.2	RN7SL605P	-7.28	1.34e-12	9.95e-10	-0.39	-0.32	Blood protein levels;	chr11:57495595	chr11:57528085~57528365:-
LUAD	cis	rs7429990	0.833	rs11716582	ENSG00000229759.1	MRPS18AP1	-7.28	1.34e-12	9.96e-10	-0.32	-0.32	Educational attainment (years of education);	chr3:47592269	chr3:48256350~48256938:-
LUAD	cis	rs6991838	0.8	rs11786598	ENSG00000272010.1	CTD-3025N20.3	-7.28	1.34e-12	9.97e-10	-0.33	-0.32	Intelligence (multi-trait analysis);	chr8:65559944	chr8:65591850~65592472:-
LUAD	cis	rs2243480	1	rs316332	ENSG00000273142.1	RP11-458F8.4	-7.28	1.34e-12	9.98e-10	-0.33	-0.32	Diabetic kidney disease;	chr7:66139312	chr7:66902857~66906297:+
LUAD	cis	rs17301013	0.507	rs10912775	ENSG00000227373.4	RP11-160H22.5	7.28	1.35e-12	1e-09	0.47	0.32	Systemic lupus erythematosus;	chr1:174388034	chr1:174115300~174160004:-
LUAD	cis	rs2842992	0.83	rs2758313	ENSG00000237927.1	RP3-393E18.2	-7.28	1.35e-12	1e-09	-0.44	-0.32	Age-related macular degeneration (geographic atrophy);	chr6:159733067	chr6:159586955~159589169:-
LUAD	cis	rs10129255	0.518	rs10136903	ENSG00000211970.3	IGHV4-61	-7.28	1.35e-12	1e-09	-0.22	-0.32	Kawasaki disease;	chr14:106778866	chr14:106639119~106639657:-
LUAD	cis	rs237743	1	rs11905214	ENSG00000222365.1	SNORD12B	-7.28	1.35e-12	1e-09	-0.37	-0.32	Height;	chr20:49272073	chr20:49280319~49280409:+
LUAD	cis	rs7208859	0.623	rs9912283	ENSG00000263531.1	RP13-753N3.1	7.28	1.35e-12	1e-09	0.63	0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30863921~30864940:-
LUAD	cis	rs748404	0.697	rs473554	ENSG00000205771.5	CATSPER2P1	-7.28	1.36e-12	1.01e-09	-0.39	-0.32	Lung cancer;	chr15:43276009	chr15:43726918~43747094:-
LUAD	cis	rs3762637	0.882	rs9818537	ENSG00000272758.4	RP11-299J3.8	-7.28	1.36e-12	1.01e-09	-0.49	-0.32	LDL cholesterol levels;	chr3:122367610	chr3:122416207~122443180:+
LUAD	cis	rs2153535	0.58	rs718502	ENSG00000230939.1	RP11-314C16.1	-7.28	1.36e-12	1.01e-09	-0.37	-0.32	Motion sickness;	chr6:8527167	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs718503	ENSG00000230939.1	RP11-314C16.1	-7.28	1.36e-12	1.01e-09	-0.37	-0.32	Motion sickness;	chr6:8527230	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9378556	ENSG00000230939.1	RP11-314C16.1	-7.28	1.36e-12	1.01e-09	-0.37	-0.32	Motion sickness;	chr6:8514462	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9406171	ENSG00000230939.1	RP11-314C16.1	-7.28	1.36e-12	1.01e-09	-0.37	-0.32	Motion sickness;	chr6:8515129	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.54	rs9378557	ENSG00000230939.1	RP11-314C16.1	-7.28	1.36e-12	1.01e-09	-0.37	-0.32	Motion sickness;	chr6:8517148	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs2143355	ENSG00000230939.1	RP11-314C16.1	-7.28	1.36e-12	1.01e-09	-0.37	-0.32	Motion sickness;	chr6:8517623	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs2143354	ENSG00000230939.1	RP11-314C16.1	-7.28	1.36e-12	1.01e-09	-0.37	-0.32	Motion sickness;	chr6:8517674	chr6:8784178~8785445:+
LUAD	cis	rs9545047	0.604	rs1748761	ENSG00000227676.3	LINC01068	7.28	1.38e-12	1.02e-09	0.37	0.32	Schizophrenia;	chr13:79407491	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs2763809	ENSG00000227676.3	LINC01068	7.28	1.38e-12	1.02e-09	0.37	0.32	Schizophrenia;	chr13:79407544	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs1748763	ENSG00000227676.3	LINC01068	7.28	1.38e-12	1.02e-09	0.37	0.32	Schizophrenia;	chr13:79407965	chr13:79566727~79571436:+
LUAD	cis	rs7429990	0.864	rs11130143	ENSG00000229759.1	MRPS18AP1	-7.28	1.38e-12	1.02e-09	-0.31	-0.32	Educational attainment (years of education);	chr3:47614943	chr3:48256350~48256938:-
LUAD	cis	rs72772090	0.539	rs72773989	ENSG00000248734.2	CTD-2260A17.1	-7.28	1.38e-12	1.02e-09	-0.5	-0.32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96827910	chr5:96784777~96785999:+
LUAD	cis	rs4853012	0.887	rs7570950	ENSG00000257800.1	FNBP1P1	7.28	1.39e-12	1.03e-09	0.41	0.31	Gestational age at birth (maternal effect);	chr2:74111815	chr2:74120680~74123218:+
LUAD	cis	rs2015599	0.56	rs3948497	ENSG00000257176.2	RP11-996F15.2	-7.28	1.39e-12	1.03e-09	-0.35	-0.31	Platelet count;Mean platelet volume;	chr12:29247552	chr12:29280418~29317848:-
LUAD	cis	rs2153535	0.601	rs9393030	ENSG00000230939.1	RP11-314C16.1	-7.28	1.39e-12	1.03e-09	-0.37	-0.31	Motion sickness;	chr6:8516256	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9328479	ENSG00000230939.1	RP11-314C16.1	-7.28	1.39e-12	1.03e-09	-0.37	-0.31	Motion sickness;	chr6:8519413	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs6927589	ENSG00000230939.1	RP11-314C16.1	7.28	1.39e-12	1.03e-09	0.38	0.31	Motion sickness;	chr6:8456399	chr6:8784178~8785445:+
LUAD	cis	rs11098499	0.866	rs12501602	ENSG00000248280.1	RP11-33B1.2	7.28	1.39e-12	1.03e-09	0.38	0.31	Corneal astigmatism;	chr4:119366780	chr4:119440561~119450157:-
LUAD	cis	rs7182621	0.546	rs11635811	ENSG00000182397.13	DNM1P46	7.28	1.39e-12	1.03e-09	0.43	0.31	Colonoscopy-negative controls vs population controls;	chr15:99839918	chr15:99790156~99806927:-
LUAD	cis	rs10200159	1	rs6545507	ENSG00000272606.1	RP11-554J4.1	7.28	1.39e-12	1.03e-09	0.54	0.31	Vitiligo;	chr2:55588756	chr2:55617909~55618373:+
LUAD	cis	rs2842992	0.789	rs2475566	ENSG00000237927.1	RP3-393E18.2	-7.28	1.39e-12	1.03e-09	-0.46	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159727709	chr6:159586955~159589169:-
LUAD	cis	rs9545047	0.604	rs1748762	ENSG00000227676.3	LINC01068	7.28	1.4e-12	1.04e-09	0.37	0.31	Schizophrenia;	chr13:79407914	chr13:79566727~79571436:+
LUAD	cis	rs75422866	0.867	rs35044089	ENSG00000280054.1	RP1-197B17.7	7.28	1.4e-12	1.04e-09	0.72	0.31	Pneumonia;	chr12:47610881	chr12:47728151~47730598:-
LUAD	cis	rs11098499	0.954	rs11098526	ENSG00000248280.1	RP11-33B1.2	7.28	1.41e-12	1.04e-09	0.4	0.31	Corneal astigmatism;	chr4:119469204	chr4:119440561~119450157:-
LUAD	cis	rs944289	0.708	rs1930765	ENSG00000257826.1	RP11-116N8.4	-7.28	1.41e-12	1.04e-09	-0.33	-0.31	Thyroid cancer;	chr14:36110053	chr14:36061026~36067190:-
LUAD	cis	rs2842992	0.789	rs4235925	ENSG00000237927.1	RP3-393E18.2	-7.28	1.41e-12	1.04e-09	-0.45	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159781828	chr6:159586955~159589169:-
LUAD	cis	rs2153535	0.563	rs3117071	ENSG00000230939.1	RP11-314C16.1	-7.28	1.41e-12	1.05e-09	-0.38	-0.31	Motion sickness;	chr6:8537675	chr6:8784178~8785445:+
LUAD	cis	rs2286503	0.839	rs4722188	ENSG00000228649.7	AC005682.5	7.27	1.42e-12	1.05e-09	0.4	0.31	Fibrinogen;	chr7:22820592	chr7:22854178~22861579:+
LUAD	cis	rs9640161	0.742	rs2159236	ENSG00000261305.1	RP4-584D14.7	7.27	1.42e-12	1.05e-09	0.46	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150320125	chr7:150341771~150342607:+
LUAD	cis	rs11089937	0.523	rs4821832	ENSG00000211639.2	IGLV4-60	7.27	1.43e-12	1.05e-09	0.32	0.31	Periodontitis (PAL4Q3);	chr22:22188499	chr22:22162199~22162681:+
LUAD	cis	rs1577917	0.545	rs9344548	ENSG00000203875.9	SNHG5	7.27	1.43e-12	1.06e-09	0.4	0.31	Response to antipsychotic treatment;	chr6:85777619	chr6:85660950~85678736:-
LUAD	cis	rs853679	0.517	rs9295761	ENSG00000219392.1	RP1-265C24.5	-7.27	1.43e-12	1.06e-09	-0.45	-0.31	Depression;	chr6:28180209	chr6:28115628~28116551:+
LUAD	cis	rs9545047	0.604	rs7332367	ENSG00000227676.3	LINC01068	-7.27	1.43e-12	1.06e-09	-0.37	-0.31	Schizophrenia;	chr13:79339816	chr13:79566727~79571436:+
LUAD	cis	rs881375	0.967	rs2109896	ENSG00000226752.6	PSMD5-AS1	-7.27	1.43e-12	1.06e-09	-0.34	-0.31	Rheumatoid arthritis;	chr9:120920828	chr9:120824828~120854385:+
LUAD	cis	rs881375	0.9	rs1008383	ENSG00000226752.6	PSMD5-AS1	-7.27	1.43e-12	1.06e-09	-0.34	-0.31	Rheumatoid arthritis;	chr9:120921301	chr9:120824828~120854385:+
LUAD	cis	rs2153535	0.563	rs1737584	ENSG00000230939.1	RP11-314C16.1	-7.27	1.43e-12	1.06e-09	-0.37	-0.31	Motion sickness;	chr6:8536509	chr6:8784178~8785445:+
LUAD	cis	rs881375	0.934	rs2159778	ENSG00000226752.6	PSMD5-AS1	-7.27	1.43e-12	1.06e-09	-0.34	-0.31	Rheumatoid arthritis;	chr9:120915851	chr9:120824828~120854385:+
LUAD	cis	rs17301013	0.507	rs4651008	ENSG00000227373.4	RP11-160H22.5	7.27	1.43e-12	1.06e-09	0.47	0.31	Systemic lupus erythematosus;	chr1:174342681	chr1:174115300~174160004:-
LUAD	cis	rs748404	0.723	rs512431	ENSG00000205771.5	CATSPER2P1	7.27	1.43e-12	1.06e-09	0.39	0.31	Lung cancer;	chr15:43249741	chr15:43726918~43747094:-
LUAD	cis	rs10463554	0.963	rs257115	ENSG00000175749.11	EIF3KP1	7.27	1.44e-12	1.06e-09	0.42	0.31	Parkinson's disease;	chr5:103196107	chr5:103032376~103033031:+
LUAD	cis	rs9549367	0.713	rs1755690	ENSG00000269125.1	RP11-98F14.11	7.27	1.44e-12	1.06e-09	0.4	0.31	Platelet distribution width;	chr13:113169952	chr13:113165002~113165183:-
LUAD	cis	rs944289	0.966	rs1182929	ENSG00000257826.1	RP11-116N8.4	-7.27	1.44e-12	1.06e-09	-0.34	-0.31	Thyroid cancer;	chr14:36165946	chr14:36061026~36067190:-
LUAD	cis	rs11089937	0.523	rs4820352	ENSG00000211639.2	IGLV4-60	7.27	1.44e-12	1.07e-09	0.32	0.31	Periodontitis (PAL4Q3);	chr22:22189203	chr22:22162199~22162681:+
LUAD	cis	rs9640161	0.702	rs11765692	ENSG00000261305.1	RP4-584D14.7	7.27	1.44e-12	1.07e-09	0.46	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150329478	chr7:150341771~150342607:+
LUAD	cis	rs944289	0.966	rs1169124	ENSG00000257826.1	RP11-116N8.4	-7.27	1.46e-12	1.08e-09	-0.34	-0.31	Thyroid cancer;	chr14:36150082	chr14:36061026~36067190:-
LUAD	cis	rs944289	0.966	rs1169129	ENSG00000257826.1	RP11-116N8.4	-7.27	1.46e-12	1.08e-09	-0.34	-0.31	Thyroid cancer;	chr14:36152619	chr14:36061026~36067190:-
LUAD	cis	rs7208859	0.623	rs73269923	ENSG00000263531.1	RP13-753N3.1	7.27	1.46e-12	1.08e-09	0.64	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30863921~30864940:-
LUAD	cis	rs853679	0.517	rs1904841	ENSG00000219392.1	RP1-265C24.5	-7.27	1.46e-12	1.08e-09	-0.45	-0.31	Depression;	chr6:28140307	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs1904840	ENSG00000219392.1	RP1-265C24.5	-7.27	1.46e-12	1.08e-09	-0.45	-0.31	Depression;	chr6:28140454	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9368555	ENSG00000219392.1	RP1-265C24.5	-7.27	1.46e-12	1.08e-09	-0.45	-0.31	Depression;	chr6:28141189	chr6:28115628~28116551:+
LUAD	cis	rs2153535	0.601	rs9328487	ENSG00000230939.1	RP11-314C16.1	-7.27	1.46e-12	1.08e-09	-0.38	-0.31	Motion sickness;	chr6:8529145	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9328488	ENSG00000230939.1	RP11-314C16.1	-7.27	1.46e-12	1.08e-09	-0.38	-0.31	Motion sickness;	chr6:8529178	chr6:8784178~8785445:+
LUAD	cis	rs10129255	0.5	rs10131875	ENSG00000211970.3	IGHV4-61	-7.27	1.47e-12	1.08e-09	-0.22	-0.31	Kawasaki disease;	chr14:106792798	chr14:106639119~106639657:-
LUAD	cis	rs34081947	0.521	rs11623102	ENSG00000257826.1	RP11-116N8.4	-7.27	1.47e-12	1.08e-09	-0.34	-0.31	Papillary thyroid cancer;Differentiated thyroid cancer;	chr14:36130459	chr14:36061026~36067190:-
LUAD	cis	rs4591358	0.689	rs16836990	ENSG00000223466.1	AC064834.2	-7.27	1.47e-12	1.09e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195532968	chr2:195533035~195538681:+
LUAD	cis	rs4713118	0.621	rs4713132	ENSG00000219392.1	RP1-265C24.5	-7.27	1.47e-12	1.09e-09	-0.43	-0.31	Parkinson's disease;	chr6:28066257	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.621	rs4713133	ENSG00000219392.1	RP1-265C24.5	-7.27	1.47e-12	1.09e-09	-0.43	-0.31	Parkinson's disease;	chr6:28066263	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.621	rs4713134	ENSG00000219392.1	RP1-265C24.5	-7.27	1.47e-12	1.09e-09	-0.43	-0.31	Parkinson's disease;	chr6:28066343	chr6:28115628~28116551:+
LUAD	cis	rs9322193	0.923	rs9371207	ENSG00000223701.3	RAET1E-AS1	7.27	1.47e-12	1.09e-09	0.39	0.31	Lung cancer;	chr6:149858087	chr6:149884431~149919508:+
LUAD	cis	rs2153535	0.58	rs7743686	ENSG00000230939.1	RP11-314C16.1	-7.27	1.47e-12	1.09e-09	-0.38	-0.31	Motion sickness;	chr6:8525878	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.601	rs718504	ENSG00000230939.1	RP11-314C16.1	-7.27	1.47e-12	1.09e-09	-0.38	-0.31	Motion sickness;	chr6:8527279	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.601	rs7775274	ENSG00000230939.1	RP11-314C16.1	-7.27	1.47e-12	1.09e-09	-0.38	-0.31	Motion sickness;	chr6:8530070	chr6:8784178~8785445:+
LUAD	cis	rs7188445	0.871	rs8047723	ENSG00000261390.4	RP11-345M22.2	7.27	1.47e-12	1.09e-09	0.4	0.31	Urate levels;	chr16:79671018	chr16:79715232~79770563:-
LUAD	cis	rs9487094	0.67	rs2024853	ENSG00000260273.1	RP11-425D10.10	7.27	1.47e-12	1.09e-09	0.41	0.31	Height;	chr6:109498751	chr6:109382795~109383666:+
LUAD	cis	rs9322193	0.886	rs4870055	ENSG00000223701.3	RAET1E-AS1	7.27	1.48e-12	1.09e-09	0.37	0.31	Lung cancer;	chr6:149848433	chr6:149884431~149919508:+
LUAD	cis	rs6903823	0.527	rs4713158	ENSG00000216901.1	AL022393.7	7.27	1.48e-12	1.09e-09	0.38	0.31	Pulmonary function;	chr6:28309994	chr6:28176188~28176674:+
LUAD	cis	rs7208859	0.623	rs7214570	ENSG00000263531.1	RP13-753N3.1	7.27	1.48e-12	1.09e-09	0.63	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30820146	chr17:30863921~30864940:-
LUAD	cis	rs4591358	0.689	rs55876968	ENSG00000223466.1	AC064834.2	-7.27	1.48e-12	1.09e-09	-0.46	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195549015	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs55974440	ENSG00000223466.1	AC064834.2	-7.27	1.48e-12	1.09e-09	-0.46	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195549056	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs12471810	ENSG00000223466.1	AC064834.2	-7.27	1.48e-12	1.09e-09	-0.46	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195549969	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs2133860	ENSG00000223466.1	AC064834.2	-7.27	1.48e-12	1.09e-09	-0.46	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195551243	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs6759817	ENSG00000223466.1	AC064834.2	-7.27	1.48e-12	1.09e-09	-0.46	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195553739	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs6760142	ENSG00000223466.1	AC064834.2	-7.27	1.48e-12	1.09e-09	-0.46	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195553911	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs6434785	ENSG00000223466.1	AC064834.2	-7.27	1.48e-12	1.09e-09	-0.46	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195554142	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.638	rs16837243	ENSG00000223466.1	AC064834.2	-7.27	1.48e-12	1.09e-09	-0.46	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195556458	chr2:195533035~195538681:+
LUAD	cis	rs2243480	1	rs410128	ENSG00000273142.1	RP11-458F8.4	-7.27	1.49e-12	1.1e-09	-0.33	-0.31	Diabetic kidney disease;	chr7:66138186	chr7:66902857~66906297:+
LUAD	cis	rs1577917	0.545	rs1832070	ENSG00000203875.9	SNHG5	7.27	1.49e-12	1.1e-09	0.41	0.31	Response to antipsychotic treatment;	chr6:85773454	chr6:85660950~85678736:-
LUAD	cis	rs7646881	0.812	rs73017541	ENSG00000240207.5	RP11-379F4.4	-7.27	1.49e-12	1.1e-09	-0.42	-0.31	Tetralogy of Fallot;	chr3:158743007	chr3:158732263~158784070:+
LUAD	cis	rs867371	1	rs13380319	ENSG00000255769.6	GOLGA2P10	-7.27	1.5e-12	1.1e-09	-0.33	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214526	chr15:82472993~82513950:-
LUAD	cis	rs10759883	0.603	rs10985156	ENSG00000175611.10	LINC00476	7.27	1.5e-12	1.11e-09	0.38	0.31	Nicotine dependence;	chr9:95831462	chr9:95759231~95875977:-
LUAD	cis	rs2712431	0.554	rs9864772	ENSG00000242551.2	POU5F1P6	-7.27	1.5e-12	1.11e-09	-0.35	-0.31	Monocyte chemoattractant protein-1 levels;	chr3:128598096	chr3:128674735~128677005:-
LUAD	cis	rs4591358	0.689	rs72927794	ENSG00000223466.1	AC064834.2	-7.27	1.5e-12	1.11e-09	-0.46	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195558607	chr2:195533035~195538681:+
LUAD	cis	rs17301013	0.507	rs12074107	ENSG00000227373.4	RP11-160H22.5	-7.27	1.5e-12	1.11e-09	-0.45	-0.31	Systemic lupus erythematosus;	chr1:174307926	chr1:174115300~174160004:-
LUAD	cis	rs2337406	0.587	rs916547	ENSG00000211974.3	IGHV2-70	-7.27	1.5e-12	1.11e-09	-0.4	-0.31	Alzheimer's disease (late onset);	chr14:106646735	chr14:106723574~106724093:-
LUAD	cis	rs11098499	0.954	rs3733524	ENSG00000248280.1	RP11-33B1.2	7.27	1.51e-12	1.11e-09	0.41	0.31	Corneal astigmatism;	chr4:119502574	chr4:119440561~119450157:-
LUAD	cis	rs9322193	0.923	rs2880436	ENSG00000223701.3	RAET1E-AS1	7.27	1.51e-12	1.11e-09	0.39	0.31	Lung cancer;	chr6:149859123	chr6:149884431~149919508:+
LUAD	cis	rs2919917	0.628	rs7010299	ENSG00000254352.1	RP11-578O24.2	7.27	1.51e-12	1.11e-09	0.41	0.31	Lymphocyte counts;	chr8:78707786	chr8:78723796~78724136:-
LUAD	cis	rs2919917	0.554	rs2086755	ENSG00000254352.1	RP11-578O24.2	7.26	1.52e-12	1.12e-09	0.42	0.31	Lymphocyte counts;	chr8:78701809	chr8:78723796~78724136:-
LUAD	cis	rs11098499	0.863	rs11098531	ENSG00000248280.1	RP11-33B1.2	7.26	1.52e-12	1.12e-09	0.41	0.31	Corneal astigmatism;	chr4:119543846	chr4:119440561~119450157:-
LUAD	cis	rs12439619	0.508	rs11856561	ENSG00000278603.1	RP13-608F4.5	7.26	1.52e-12	1.12e-09	0.36	0.31	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82472203~82472426:+
LUAD	cis	rs9487094	0.67	rs11754455	ENSG00000260273.1	RP11-425D10.10	7.26	1.52e-12	1.12e-09	0.41	0.31	Height;	chr6:109496680	chr6:109382795~109383666:+
LUAD	cis	rs2739330	0.76	rs5751761	ENSG00000228039.3	KB-1125A3.10	-7.26	1.53e-12	1.12e-09	-0.36	-0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23963780~23964374:+
LUAD	cis	rs11089937	0.651	rs6001217	ENSG00000211639.2	IGLV4-60	7.26	1.53e-12	1.13e-09	0.32	0.31	Periodontitis (PAL4Q3);	chr22:22183804	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.521	rs6001221	ENSG00000211639.2	IGLV4-60	7.26	1.53e-12	1.13e-09	0.32	0.31	Periodontitis (PAL4Q3);	chr22:22185176	chr22:22162199~22162681:+
LUAD	cis	rs10129255	0.957	rs8005468	ENSG00000280411.1	IGHV1-69-2	-7.26	1.53e-12	1.13e-09	-0.24	-0.31	Kawasaki disease;	chr14:106686431	chr14:106762092~106762588:-
LUAD	cis	rs11089937	0.584	rs6001213	ENSG00000211639.2	IGLV4-60	7.26	1.53e-12	1.13e-09	0.33	0.31	Periodontitis (PAL4Q3);	chr22:22182108	chr22:22162199~22162681:+
LUAD	cis	rs17301013	0.507	rs7517516	ENSG00000227373.4	RP11-160H22.5	7.26	1.53e-12	1.13e-09	0.47	0.31	Systemic lupus erythematosus;	chr1:174346187	chr1:174115300~174160004:-
LUAD	cis	rs2006771	0.818	rs8142376	ENSG00000236132.1	CTA-440B3.1	7.26	1.54e-12	1.13e-09	0.35	0.31	Nonsyndromic cleft lip with cleft palate;	chr22:31605051	chr22:31816379~31817491:-
LUAD	cis	rs12922040	1	rs2075516	ENSG00000263335.1	AF001548.5	7.26	1.54e-12	1.14e-09	0.39	0.31	Serum uric acid levels in response to allopurinol in gout;	chr16:15775668	chr16:15726674~15732993:+
LUAD	cis	rs6142102	0.961	rs6059587	ENSG00000276073.1	RP5-1125A11.7	-7.26	1.55e-12	1.14e-09	-0.33	-0.31	Skin pigmentation;	chr20:33955120	chr20:33985617~33988989:-
LUAD	cis	rs75422866	0.867	rs73102195	ENSG00000274902.1	RP1-197B17.4	7.26	1.55e-12	1.14e-09	0.7	0.31	Pneumonia;	chr12:47666309	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs73102201	ENSG00000274902.1	RP1-197B17.4	7.26	1.55e-12	1.14e-09	0.7	0.31	Pneumonia;	chr12:47669269	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs73104104	ENSG00000274902.1	RP1-197B17.4	7.26	1.55e-12	1.14e-09	0.7	0.31	Pneumonia;	chr12:47671986	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs73104111	ENSG00000274902.1	RP1-197B17.4	7.26	1.55e-12	1.14e-09	0.7	0.31	Pneumonia;	chr12:47673994	chr12:47731908~47732351:+
LUAD	cis	rs4713118	0.505	rs156740	ENSG00000216901.1	AL022393.7	7.26	1.55e-12	1.14e-09	0.36	0.31	Parkinson's disease;	chr6:27992657	chr6:28176188~28176674:+
LUAD	cis	rs8059260	0.736	rs2302558	ENSG00000274038.1	RP11-66H6.4	-7.26	1.55e-12	1.14e-09	-0.55	-0.31	Alcohol consumption over the past year;	chr16:10969154	chr16:11056556~11057034:+
LUAD	cis	rs11089937	0.651	rs6001216	ENSG00000211639.2	IGLV4-60	7.26	1.55e-12	1.14e-09	0.32	0.31	Periodontitis (PAL4Q3);	chr22:22183755	chr22:22162199~22162681:+
LUAD	cis	rs2111504	0.945	rs1861780	ENSG00000267213.4	AC007773.2	-7.26	1.55e-12	1.14e-09	-0.48	-0.31	Bipolar disorder;	chr19:32372138	chr19:32390050~32405560:-
LUAD	cis	rs12134133	0.719	rs6696142	ENSG00000274245.1	RP11-357P18.2	7.26	1.56e-12	1.15e-09	0.45	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207228898	chr1:207372559~207373252:+
LUAD	cis	rs12134133	0.752	rs57003024	ENSG00000274245.1	RP11-357P18.2	7.26	1.56e-12	1.15e-09	0.45	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207230999	chr1:207372559~207373252:+
LUAD	cis	rs150992	0.574	rs2927655	ENSG00000248489.1	CTD-2007H13.3	7.26	1.56e-12	1.15e-09	0.36	0.31	Body mass index;	chr5:98839049	chr5:98929171~98995013:+
LUAD	cis	rs4591358	0.689	rs72927705	ENSG00000223466.1	AC064834.2	-7.26	1.56e-12	1.15e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195518341	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs72927707	ENSG00000223466.1	AC064834.2	-7.26	1.56e-12	1.15e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195518526	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs16836823	ENSG00000223466.1	AC064834.2	-7.26	1.56e-12	1.15e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195518785	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs57244991	ENSG00000223466.1	AC064834.2	-7.26	1.56e-12	1.15e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195519331	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs72927708	ENSG00000223466.1	AC064834.2	-7.26	1.56e-12	1.15e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195519789	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs72927711	ENSG00000223466.1	AC064834.2	-7.26	1.56e-12	1.15e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195520309	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs72927717	ENSG00000223466.1	AC064834.2	-7.26	1.56e-12	1.15e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195520887	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs72927725	ENSG00000223466.1	AC064834.2	-7.26	1.56e-12	1.15e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195529140	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs7574191	ENSG00000223466.1	AC064834.2	-7.26	1.56e-12	1.15e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195529995	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs1500605	ENSG00000223466.1	AC064834.2	-7.26	1.56e-12	1.15e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195530584	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.648	rs1515877	ENSG00000223466.1	AC064834.2	-7.26	1.56e-12	1.15e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195530995	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs16837006	ENSG00000223466.1	AC064834.2	-7.26	1.56e-12	1.15e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195533245	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs16837010	ENSG00000223466.1	AC064834.2	-7.26	1.56e-12	1.15e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195533302	chr2:195533035~195538681:+
LUAD	cis	rs8059260	0.542	rs11860777	ENSG00000274038.1	RP11-66H6.4	-7.26	1.56e-12	1.15e-09	-0.55	-0.31	Alcohol consumption over the past year;	chr16:11033718	chr16:11056556~11057034:+
LUAD	cis	rs8059260	0.542	rs16957948	ENSG00000274038.1	RP11-66H6.4	-7.26	1.56e-12	1.15e-09	-0.55	-0.31	Alcohol consumption over the past year;	chr16:11034208	chr16:11056556~11057034:+
LUAD	cis	rs4660456	0.913	rs545218	ENSG00000237899.1	RP4-739H11.3	7.26	1.57e-12	1.15e-09	0.43	0.31	Platelet count;	chr1:40675313	chr1:40669089~40687588:-
LUAD	cis	rs75422866	0.867	rs73104115	ENSG00000274902.1	RP1-197B17.4	7.26	1.57e-12	1.15e-09	0.7	0.31	Pneumonia;	chr12:47684843	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs73104116	ENSG00000274902.1	RP1-197B17.4	7.26	1.57e-12	1.15e-09	0.7	0.31	Pneumonia;	chr12:47685023	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs73104138	ENSG00000274902.1	RP1-197B17.4	7.26	1.57e-12	1.15e-09	0.7	0.31	Pneumonia;	chr12:47692302	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.717	rs73104143	ENSG00000274902.1	RP1-197B17.4	7.26	1.57e-12	1.15e-09	0.7	0.31	Pneumonia;	chr12:47693449	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs73104144	ENSG00000274902.1	RP1-197B17.4	7.26	1.57e-12	1.15e-09	0.7	0.31	Pneumonia;	chr12:47694390	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs73104148	ENSG00000274902.1	RP1-197B17.4	7.26	1.57e-12	1.15e-09	0.7	0.31	Pneumonia;	chr12:47696732	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs73104152	ENSG00000274902.1	RP1-197B17.4	7.26	1.57e-12	1.15e-09	0.7	0.31	Pneumonia;	chr12:47699091	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs73104155	ENSG00000274902.1	RP1-197B17.4	7.26	1.57e-12	1.15e-09	0.7	0.31	Pneumonia;	chr12:47700790	chr12:47731908~47732351:+
LUAD	cis	rs4591358	0.689	rs2173773	ENSG00000223466.1	AC064834.2	-7.26	1.57e-12	1.16e-09	-0.46	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195549701	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs72927784	ENSG00000223466.1	AC064834.2	-7.26	1.57e-12	1.16e-09	-0.46	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195550329	chr2:195533035~195538681:+
LUAD	cis	rs2919917	0.628	rs10109359	ENSG00000254352.1	RP11-578O24.2	7.26	1.57e-12	1.16e-09	0.41	0.31	Lymphocyte counts;	chr8:78694369	chr8:78723796~78724136:-
LUAD	cis	rs10256972	0.669	rs10229964	ENSG00000229043.2	AC091729.9	-7.26	1.58e-12	1.16e-09	-0.34	-0.31	Endometriosis;Longevity;	chr7:1012140	chr7:1160374~1165267:+
LUAD	cis	rs2842992	0.83	rs1535475	ENSG00000237927.1	RP3-393E18.2	-7.26	1.58e-12	1.16e-09	-0.45	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159727903	chr6:159586955~159589169:-
LUAD	cis	rs7208859	0.573	rs11654035	ENSG00000263531.1	RP13-753N3.1	7.26	1.58e-12	1.16e-09	0.63	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30863921~30864940:-
LUAD	cis	rs950880	0.71	rs3771172	ENSG00000234389.1	AC007278.3	-7.26	1.59e-12	1.17e-09	-0.33	-0.31	Serum protein levels (sST2);	chr2:102369352	chr2:102438713~102440475:+
LUAD	cis	rs12134133	0.688	rs6540875	ENSG00000274245.1	RP11-357P18.2	7.26	1.59e-12	1.17e-09	0.45	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207221686	chr1:207372559~207373252:+
LUAD	cis	rs11676348	0.967	rs4672873	ENSG00000261338.2	RP11-378A13.1	-7.26	1.59e-12	1.17e-09	-0.33	-0.31	Ulcerative colitis;	chr2:218140487	chr2:218255319~218257366:+
LUAD	cis	rs2919917	0.628	rs7823970	ENSG00000254352.1	RP11-578O24.2	7.26	1.59e-12	1.17e-09	0.4	0.31	Lymphocyte counts;	chr8:78681364	chr8:78723796~78724136:-
LUAD	cis	rs2919917	0.616	rs7823723	ENSG00000254352.1	RP11-578O24.2	7.26	1.59e-12	1.17e-09	0.4	0.31	Lymphocyte counts;	chr8:78681390	chr8:78723796~78724136:-
LUAD	cis	rs4660456	0.913	rs2744799	ENSG00000237899.1	RP4-739H11.3	7.26	1.59e-12	1.17e-09	0.44	0.31	Platelet count;	chr1:40719862	chr1:40669089~40687588:-
LUAD	cis	rs11089937	0.651	rs1543779	ENSG00000211639.2	IGLV4-60	-7.26	1.59e-12	1.17e-09	-0.32	-0.31	Periodontitis (PAL4Q3);	chr22:22194092	chr22:22162199~22162681:+
LUAD	cis	rs2739330	0.929	rs5751777	ENSG00000206090.4	AP000350.7	7.26	1.6e-12	1.17e-09	0.35	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23939998~23942798:+
LUAD	cis	rs9322193	0.884	rs7744105	ENSG00000223701.3	RAET1E-AS1	7.26	1.6e-12	1.17e-09	0.38	0.31	Lung cancer;	chr6:149849308	chr6:149884431~149919508:+
LUAD	cis	rs7646881	0.951	rs6441222	ENSG00000240207.5	RP11-379F4.4	-7.26	1.6e-12	1.17e-09	-0.37	-0.31	Tetralogy of Fallot;	chr3:158731978	chr3:158732263~158784070:+
LUAD	cis	rs7646881	1	rs73015652	ENSG00000240207.5	RP11-379F4.4	-7.26	1.6e-12	1.17e-09	-0.37	-0.31	Tetralogy of Fallot;	chr3:158733594	chr3:158732263~158784070:+
LUAD	cis	rs853679	0.517	rs12332979	ENSG00000219392.1	RP1-265C24.5	-7.26	1.6e-12	1.17e-09	-0.45	-0.31	Depression;	chr6:28173770	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs67878650	ENSG00000219392.1	RP1-265C24.5	-7.26	1.6e-12	1.17e-09	-0.45	-0.31	Depression;	chr6:28174809	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.569	rs9348798	ENSG00000219392.1	RP1-265C24.5	-7.26	1.6e-12	1.17e-09	-0.45	-0.31	Depression;	chr6:28175233	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9380065	ENSG00000219392.1	RP1-265C24.5	-7.26	1.6e-12	1.17e-09	-0.45	-0.31	Depression;	chr6:28176973	chr6:28115628~28116551:+
LUAD	cis	rs2243480	1	rs316304	ENSG00000273142.1	RP11-458F8.4	-7.26	1.6e-12	1.18e-09	-0.33	-0.31	Diabetic kidney disease;	chr7:66151907	chr7:66902857~66906297:+
LUAD	cis	rs2842992	0.915	rs2758350	ENSG00000237927.1	RP3-393E18.2	-7.26	1.6e-12	1.18e-09	-0.44	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159697024	chr6:159586955~159589169:-
LUAD	cis	rs9640161	0.789	rs3735172	ENSG00000261305.1	RP4-584D14.7	-7.26	1.61e-12	1.18e-09	-0.45	-0.31	Blood protein levels;Circulating chemerin levels;	chr7:150331869	chr7:150341771~150342607:+
LUAD	cis	rs75422866	0.867	rs78912815	ENSG00000274902.1	RP1-197B17.4	7.26	1.61e-12	1.18e-09	0.7	0.31	Pneumonia;	chr12:47612065	chr12:47731908~47732351:+
LUAD	cis	rs237743	1	rs35759030	ENSG00000222365.1	SNORD12B	-7.26	1.61e-12	1.18e-09	-0.36	-0.31	Height;	chr20:49241753	chr20:49280319~49280409:+
LUAD	cis	rs7208859	0.623	rs3794796	ENSG00000263531.1	RP13-753N3.1	7.26	1.61e-12	1.18e-09	0.63	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30863921~30864940:-
LUAD	cis	rs34779708	0.733	rs12240638	ENSG00000230534.5	RP11-297A16.2	7.26	1.62e-12	1.19e-09	0.38	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35253682	chr10:35098006~35127020:-
LUAD	cis	rs7500321	1	rs7500321	ENSG00000259982.1	CDC37P1	-7.26	1.62e-12	1.19e-09	-0.43	-0.31	Intelligence (multi-trait analysis);	chr16:28965699	chr16:28700294~28701540:-
LUAD	cis	rs7688014	1	rs7688014	ENSG00000246560.2	RP11-10L12.4	7.25	1.62e-12	1.19e-09	0.41	0.31	Schizophrenia;	chr4:103053903	chr4:102828055~102844075:+
LUAD	cis	rs853679	0.517	rs7755442	ENSG00000219392.1	RP1-265C24.5	-7.25	1.62e-12	1.19e-09	-0.44	-0.31	Depression;	chr6:28071237	chr6:28115628~28116551:+
LUAD	cis	rs2842992	0.789	rs9365093	ENSG00000237927.1	RP3-393E18.2	-7.25	1.62e-12	1.19e-09	-0.45	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159754787	chr6:159586955~159589169:-
LUAD	cis	rs950880	0.593	rs887972	ENSG00000234389.1	AC007278.3	-7.25	1.62e-12	1.19e-09	-0.33	-0.31	Serum protein levels (sST2);	chr2:102424485	chr2:102438713~102440475:+
LUAD	cis	rs2243480	1	rs1039664	ENSG00000273142.1	RP11-458F8.4	-7.25	1.63e-12	1.19e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:65984729	chr7:66902857~66906297:+
LUAD	cis	rs1577917	0.545	rs1335443	ENSG00000203875.9	SNHG5	-7.25	1.63e-12	1.19e-09	-0.4	-0.31	Response to antipsychotic treatment;	chr6:85769019	chr6:85660950~85678736:-
LUAD	cis	rs2153535	0.58	rs2225766	ENSG00000230939.1	RP11-314C16.1	-7.25	1.63e-12	1.2e-09	-0.37	-0.31	Motion sickness;	chr6:8481600	chr6:8784178~8785445:+
LUAD	cis	rs62229266	0.682	rs11700546	ENSG00000214914.3	RPL23AP3	7.25	1.64e-12	1.2e-09	0.4	0.31	Mitral valve prolapse;	chr21:35998841	chr21:36016079~36016546:-
LUAD	cis	rs6700559	0.81	rs2809344	ENSG00000260088.1	RP11-92G12.3	7.25	1.64e-12	1.2e-09	0.39	0.31	Coronary artery disease;	chr1:200627478	chr1:200669507~200694250:+
LUAD	cis	rs12134133	0.752	rs61821050	ENSG00000274245.1	RP11-357P18.2	7.25	1.64e-12	1.21e-09	0.45	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207235253	chr1:207372559~207373252:+
LUAD	cis	rs12134133	0.752	rs61821051	ENSG00000274245.1	RP11-357P18.2	7.25	1.64e-12	1.21e-09	0.45	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207235624	chr1:207372559~207373252:+
LUAD	cis	rs11098499	0.954	rs7681544	ENSG00000248280.1	RP11-33B1.2	7.25	1.65e-12	1.21e-09	0.4	0.31	Corneal astigmatism;	chr4:119490100	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs11940028	ENSG00000248280.1	RP11-33B1.2	7.25	1.65e-12	1.21e-09	0.4	0.31	Corneal astigmatism;	chr4:119490752	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs11935596	ENSG00000248280.1	RP11-33B1.2	7.25	1.65e-12	1.21e-09	0.4	0.31	Corneal astigmatism;	chr4:119491302	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs12507964	ENSG00000248280.1	RP11-33B1.2	7.25	1.65e-12	1.21e-09	0.4	0.31	Corneal astigmatism;	chr4:119491906	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.909	rs11098530	ENSG00000248280.1	RP11-33B1.2	7.25	1.65e-12	1.21e-09	0.4	0.31	Corneal astigmatism;	chr4:119491999	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs6834796	ENSG00000248280.1	RP11-33B1.2	7.25	1.65e-12	1.21e-09	0.4	0.31	Corneal astigmatism;	chr4:119493538	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs11734241	ENSG00000248280.1	RP11-33B1.2	7.25	1.65e-12	1.21e-09	0.4	0.31	Corneal astigmatism;	chr4:119495717	chr4:119440561~119450157:-
LUAD	cis	rs765787	0.53	rs1706832	ENSG00000259520.4	CTD-2651B20.3	7.25	1.65e-12	1.21e-09	0.4	0.31	Uric acid levels;	chr15:45224975	chr15:45251580~45279251:-
LUAD	cis	rs2243480	1	rs316322	ENSG00000273142.1	RP11-458F8.4	-7.25	1.65e-12	1.21e-09	-0.33	-0.31	Diabetic kidney disease;	chr7:66146246	chr7:66902857~66906297:+
LUAD	cis	rs9595908	0.9	rs7981943	ENSG00000212293.1	SNORA16	7.25	1.65e-12	1.21e-09	0.33	0.31	Body mass index;	chr13:32593754	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.9	rs7327429	ENSG00000212293.1	SNORA16	7.25	1.65e-12	1.21e-09	0.33	0.31	Body mass index;	chr13:32595259	chr13:32420390~32420516:-
LUAD	cis	rs2739330	0.731	rs4822450	ENSG00000099984.9	GSTT2	-7.25	1.65e-12	1.21e-09	-0.37	-0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23980123~23983911:+
LUAD	cis	rs950880	0.71	rs11678975	ENSG00000234389.1	AC007278.3	-7.25	1.66e-12	1.22e-09	-0.33	-0.31	Serum protein levels (sST2);	chr2:102427279	chr2:102438713~102440475:+
LUAD	cis	rs1134634	1	rs1134634	ENSG00000273133.1	RP11-799M12.2	7.25	1.67e-12	1.22e-09	0.41	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15601446	chr4:15563698~15564253:-
LUAD	cis	rs10129255	0.5	rs6576231	ENSG00000211970.3	IGHV4-61	-7.25	1.67e-12	1.23e-09	-0.22	-0.31	Kawasaki disease;	chr14:106783693	chr14:106639119~106639657:-
LUAD	cis	rs9487094	0.67	rs7767525	ENSG00000260273.1	RP11-425D10.10	7.25	1.68e-12	1.23e-09	0.41	0.31	Height;	chr6:109646187	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.504	rs71541003	ENSG00000260273.1	RP11-425D10.10	7.25	1.68e-12	1.23e-09	0.41	0.31	Height;	chr6:109652694	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.67	rs3899233	ENSG00000260273.1	RP11-425D10.10	7.25	1.68e-12	1.23e-09	0.41	0.31	Height;	chr6:109655791	chr6:109382795~109383666:+
LUAD	cis	rs2243480	1	rs316321	ENSG00000273142.1	RP11-458F8.4	-7.25	1.69e-12	1.24e-09	-0.33	-0.31	Diabetic kidney disease;	chr7:66146626	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs316318	ENSG00000273142.1	RP11-458F8.4	-7.25	1.69e-12	1.24e-09	-0.33	-0.31	Diabetic kidney disease;	chr7:66147917	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs316317	ENSG00000273142.1	RP11-458F8.4	-7.25	1.69e-12	1.24e-09	-0.33	-0.31	Diabetic kidney disease;	chr7:66148650	chr7:66902857~66906297:+
LUAD	cis	rs35160687	0.901	rs12472676	ENSG00000273080.1	RP11-301O19.1	7.25	1.69e-12	1.24e-09	0.36	0.31	Night sleep phenotypes;	chr2:86283692	chr2:86195590~86196049:+
LUAD	cis	rs4728142	0.593	rs7808907	ENSG00000275106.1	RP11-309L24.10	7.25	1.69e-12	1.24e-09	0.36	0.31	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128944030	chr7:128952527~128953316:-
LUAD	cis	rs71403859	0.502	rs12919417	ENSG00000260886.1	TAT-AS1	-7.25	1.69e-12	1.24e-09	-0.52	-0.31	Post bronchodilator FEV1;	chr16:71545808	chr16:71565789~71578187:+
LUAD	cis	rs673078	0.607	rs16948230	ENSG00000275759.1	RP11-131L12.3	-7.25	1.69e-12	1.24e-09	-0.43	-0.31	Glucose homeostasis traits;	chr12:118277086	chr12:118428281~118428870:+
LUAD	cis	rs783540	0.874	rs10468217	ENSG00000278603.1	RP13-608F4.5	-7.25	1.7e-12	1.24e-09	-0.36	-0.31	Schizophrenia;	chr15:82579329	chr15:82472203~82472426:+
LUAD	cis	rs2243480	0.711	rs2460426	ENSG00000273142.1	RP11-458F8.4	7.25	1.7e-12	1.24e-09	0.33	0.31	Diabetic kidney disease;	chr7:66158142	chr7:66902857~66906297:+
LUAD	cis	rs950169	0.96	rs35159785	ENSG00000225151.9	GOLGA2P7	-7.25	1.7e-12	1.25e-09	-0.45	-0.31	Schizophrenia;	chr15:84135262	chr15:84199311~84230136:-
LUAD	cis	rs66486766	1	rs66486766	ENSG00000225151.9	GOLGA2P7	-7.25	1.7e-12	1.25e-09	-0.45	-0.31	Bipolar disorder lithium response (categorical) or schizophrenia;	chr15:84137308	chr15:84199311~84230136:-
LUAD	cis	rs5769707	0.521	rs739244	ENSG00000188511.11	C22orf34	7.25	1.7e-12	1.25e-09	0.38	0.31	Monocyte percentage of white cells;Monocyte count;	chr22:49666510	chr22:49414524~49657542:-
LUAD	cis	rs9322193	0.923	rs14314	ENSG00000223701.3	RAET1E-AS1	7.25	1.71e-12	1.25e-09	0.37	0.31	Lung cancer;	chr6:149820395	chr6:149884431~149919508:+
LUAD	cis	rs9660180	0.967	rs12044597	ENSG00000268575.1	RP1-283E3.8	-7.25	1.71e-12	1.25e-09	-0.28	-0.31	Body mass index;	chr1:1777362	chr1:1702736~1737688:-
LUAD	cis	rs6504950	0.925	rs244315	ENSG00000275710.1	RP11-257O5.4	7.25	1.71e-12	1.25e-09	0.4	0.31	Breast cancer;	chr17:55137293	chr17:54964474~54964679:+
LUAD	cis	rs11846409	0.799	rs10467899	ENSG00000274576.2	IGHV2-70	-7.25	1.72e-12	1.26e-09	-0.33	-0.31	Rheumatic heart disease;	chr14:106644012	chr14:106770577~106771020:-
LUAD	cis	rs11098499	0.82	rs2389885	ENSG00000248280.1	RP11-33B1.2	7.25	1.72e-12	1.26e-09	0.41	0.31	Corneal astigmatism;	chr4:119612776	chr4:119440561~119450157:-
LUAD	cis	rs9309711	0.922	rs13431788	ENSG00000225234.1	TRAPPC12-AS1	-7.25	1.73e-12	1.26e-09	-0.39	-0.31	Neurofibrillary tangles;	chr2:3479141	chr2:3481242~3482409:-
LUAD	cis	rs10200159	1	rs10172181	ENSG00000272606.1	RP11-554J4.1	7.25	1.73e-12	1.26e-09	0.54	0.31	Vitiligo;	chr2:55664005	chr2:55617909~55618373:+
LUAD	cis	rs7429990	0.833	rs3755638	ENSG00000229759.1	MRPS18AP1	-7.25	1.73e-12	1.26e-09	-0.32	-0.31	Educational attainment (years of education);	chr3:47580841	chr3:48256350~48256938:-
LUAD	cis	rs17818399	0.708	rs1531133	ENSG00000279254.1	RP11-536C12.1	-7.25	1.73e-12	1.27e-09	-0.32	-0.31	Height;	chr2:46616492	chr2:46668870~46670778:+
LUAD	cis	rs8059260	0.668	rs76212701	ENSG00000274038.1	RP11-66H6.4	-7.24	1.73e-12	1.27e-09	-0.55	-0.31	Alcohol consumption over the past year;	chr16:11023634	chr16:11056556~11057034:+
LUAD	cis	rs2243480	1	rs316326	ENSG00000273142.1	RP11-458F8.4	-7.24	1.74e-12	1.27e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66144466	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs316325	ENSG00000273142.1	RP11-458F8.4	-7.24	1.74e-12	1.27e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66144531	chr7:66902857~66906297:+
LUAD	cis	rs7811142	0.666	rs28401739	ENSG00000242294.5	STAG3L5P	7.24	1.74e-12	1.27e-09	0.27	0.31	Platelet count;	chr7:100308061	chr7:100336079~100351900:+
LUAD	cis	rs10200159	1	rs6760959	ENSG00000272606.1	RP11-554J4.1	7.24	1.74e-12	1.27e-09	0.54	0.31	Vitiligo;	chr2:55594365	chr2:55617909~55618373:+
LUAD	cis	rs10200159	1	rs111707510	ENSG00000272606.1	RP11-554J4.1	7.24	1.74e-12	1.27e-09	0.54	0.31	Vitiligo;	chr2:55597100	chr2:55617909~55618373:+
LUAD	cis	rs2153535	0.526	rs9406179	ENSG00000230939.1	RP11-314C16.1	-7.24	1.75e-12	1.28e-09	-0.38	-0.31	Motion sickness;	chr6:8537991	chr6:8784178~8785445:+
LUAD	cis	rs12439619	0.693	rs17269819	ENSG00000255769.6	GOLGA2P10	-7.24	1.75e-12	1.28e-09	-0.39	-0.31	Intelligence (multi-trait analysis);	chr15:82174660	chr15:82472993~82513950:-
LUAD	cis	rs853679	0.527	rs1997660	ENSG00000204709.4	LINC01556	7.24	1.75e-12	1.28e-09	0.39	0.31	Depression;	chr6:28301886	chr6:28943877~28944537:+
LUAD	cis	rs11098499	0.954	rs12508504	ENSG00000248280.1	RP11-33B1.2	7.24	1.75e-12	1.28e-09	0.4	0.31	Corneal astigmatism;	chr4:119489452	chr4:119440561~119450157:-
LUAD	cis	rs9640161	0.789	rs10952250	ENSG00000261305.1	RP4-584D14.7	7.24	1.76e-12	1.28e-09	0.45	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150328877	chr7:150341771~150342607:+
LUAD	cis	rs17608059	0.545	rs9915045	ENSG00000141028.6	CDRT15P1	-7.24	1.76e-12	1.28e-09	-0.35	-0.31	Temperament;	chr17:13999319	chr17:14024514~14025488:+
LUAD	cis	rs9595908	0.863	rs11616287	ENSG00000212293.1	SNORA16	7.24	1.76e-12	1.29e-09	0.34	0.31	Body mass index;	chr13:32580139	chr13:32420390~32420516:-
LUAD	cis	rs9322193	0.962	rs9397022	ENSG00000223701.3	RAET1E-AS1	7.24	1.76e-12	1.29e-09	0.37	0.31	Lung cancer;	chr6:149812052	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.962	rs9397357	ENSG00000223701.3	RAET1E-AS1	7.24	1.76e-12	1.29e-09	0.37	0.31	Lung cancer;	chr6:149812465	chr6:149884431~149919508:+
LUAD	cis	rs2919917	0.617	rs4641056	ENSG00000254352.1	RP11-578O24.2	7.24	1.77e-12	1.29e-09	0.4	0.31	Lymphocyte counts;	chr8:78670261	chr8:78723796~78724136:-
LUAD	cis	rs12134133	0.888	rs11580394	ENSG00000274245.1	RP11-357P18.2	7.24	1.77e-12	1.29e-09	0.41	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207238567	chr1:207372559~207373252:+
LUAD	cis	rs237743	0.928	rs237714	ENSG00000222365.1	SNORD12B	-7.24	1.77e-12	1.3e-09	-0.36	-0.31	Height;	chr20:49306363	chr20:49280319~49280409:+
LUAD	cis	rs638893	1	rs636736	ENSG00000278376.1	RP11-158I9.8	-7.24	1.78e-12	1.3e-09	-0.45	-0.31	Vitiligo;	chr11:118834436	chr11:118791254~118793137:+
LUAD	cis	rs10463554	0.892	rs17154859	ENSG00000175749.11	EIF3KP1	-7.24	1.78e-12	1.3e-09	-0.43	-0.31	Parkinson's disease;	chr5:102955208	chr5:103032376~103033031:+
LUAD	cis	rs4591358	0.689	rs72927780	ENSG00000223466.1	AC064834.2	-7.24	1.78e-12	1.3e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195548569	chr2:195533035~195538681:+
LUAD	cis	rs8031584	0.678	rs798086	ENSG00000260382.1	RP11-540B6.2	-7.24	1.78e-12	1.3e-09	-0.4	-0.31	Huntington's disease progression;	chr15:30837008	chr15:30882267~30883231:-
LUAD	cis	rs237743	1	rs6512577	ENSG00000222365.1	SNORD12B	-7.24	1.79e-12	1.3e-09	-0.36	-0.31	Height;	chr20:49249247	chr20:49280319~49280409:+
LUAD	cis	rs11676348	0.774	rs57545959	ENSG00000261338.2	RP11-378A13.1	7.24	1.8e-12	1.31e-09	0.33	0.31	Ulcerative colitis;	chr2:218182995	chr2:218255319~218257366:+
LUAD	cis	rs4910157	1	rs4910157	ENSG00000254860.4	TMEM9B-AS1	-7.24	1.8e-12	1.31e-09	-0.35	-0.31	Tonsillectomy;	chr11:8919668	chr11:8964675~8977527:+
LUAD	cis	rs9545047	0.511	rs1624537	ENSG00000227676.3	LINC01068	7.24	1.8e-12	1.32e-09	0.37	0.31	Schizophrenia;	chr13:79411686	chr13:79566727~79571436:+
LUAD	cis	rs8081395	0.801	rs2645479	ENSG00000266992.1	DHX40P1	7.24	1.81e-12	1.32e-09	0.36	0.31	White blood cell count;	chr17:59843171	chr17:59976009~60002384:-
LUAD	cis	rs17818399	0.633	rs2242033	ENSG00000279254.1	RP11-536C12.1	-7.24	1.81e-12	1.32e-09	-0.32	-0.31	Height;	chr2:46615271	chr2:46668870~46670778:+
LUAD	cis	rs2337406	0.714	rs115401799	ENSG00000254174.1	IGHV1-12	7.24	1.81e-12	1.32e-09	0.31	0.31	Alzheimer's disease (late onset);	chr14:106813739	chr14:106122420~106122709:-
LUAD	cis	rs9322193	0.847	rs868375	ENSG00000223701.3	RAET1E-AS1	7.24	1.82e-12	1.33e-09	0.37	0.31	Lung cancer;	chr6:149844905	chr6:149884431~149919508:+
LUAD	cis	rs75422866	0.867	rs7303895	ENSG00000280054.1	RP1-197B17.7	7.24	1.82e-12	1.33e-09	0.67	0.31	Pneumonia;	chr12:47683290	chr12:47728151~47730598:-
LUAD	cis	rs4853012	0.887	rs2280642	ENSG00000257800.1	FNBP1P1	7.24	1.82e-12	1.33e-09	0.42	0.31	Gestational age at birth (maternal effect);	chr2:74131125	chr2:74120680~74123218:+
LUAD	cis	rs11098499	0.863	rs58452170	ENSG00000248280.1	RP11-33B1.2	7.24	1.82e-12	1.33e-09	0.41	0.31	Corneal astigmatism;	chr4:119538519	chr4:119440561~119450157:-
LUAD	cis	rs2842992	0.915	rs1967802	ENSG00000237927.1	RP3-393E18.2	-7.24	1.82e-12	1.33e-09	-0.44	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159676759	chr6:159586955~159589169:-
LUAD	cis	rs10129255	1	rs10141557	ENSG00000211972.2	IGHV3-66	7.24	1.82e-12	1.33e-09	0.28	0.31	Kawasaki disease;	chr14:106767990	chr14:106675017~106675544:-
LUAD	cis	rs150992	1	rs150992	ENSG00000248489.1	CTD-2007H13.3	7.24	1.83e-12	1.33e-09	0.35	0.31	Body mass index;	chr5:98939493	chr5:98929171~98995013:+
LUAD	cis	rs9322193	0.962	rs7818	ENSG00000223701.3	RAET1E-AS1	7.24	1.83e-12	1.33e-09	0.36	0.31	Lung cancer;	chr6:149810956	chr6:149884431~149919508:+
LUAD	cis	rs75422866	0.867	rs35044089	ENSG00000274902.1	RP1-197B17.4	7.24	1.83e-12	1.33e-09	0.7	0.31	Pneumonia;	chr12:47610881	chr12:47731908~47732351:+
LUAD	cis	rs35955747	0.902	rs5997938	ENSG00000236132.1	CTA-440B3.1	7.24	1.84e-12	1.34e-09	0.35	0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31281006	chr22:31816379~31817491:-
LUAD	cis	rs1150668	0.768	rs1150709	ENSG00000216901.1	AL022393.7	-7.24	1.85e-12	1.34e-09	-0.36	-0.31	Pubertal anthropometrics;	chr6:28239585	chr6:28176188~28176674:+
LUAD	cis	rs6142102	0.961	rs4911401	ENSG00000276073.1	RP5-1125A11.7	-7.24	1.85e-12	1.35e-09	-0.33	-0.31	Skin pigmentation;	chr20:34066756	chr20:33985617~33988989:-
LUAD	cis	rs673078	0.66	rs56708462	ENSG00000275759.1	RP11-131L12.3	-7.23	1.85e-12	1.35e-09	-0.45	-0.31	Glucose homeostasis traits;	chr12:118284135	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.66	rs7962185	ENSG00000275759.1	RP11-131L12.3	-7.23	1.85e-12	1.35e-09	-0.45	-0.31	Glucose homeostasis traits;	chr12:118287842	chr12:118428281~118428870:+
LUAD	cis	rs12439619	0.693	rs28689861	ENSG00000255769.6	GOLGA2P10	-7.23	1.86e-12	1.35e-09	-0.39	-0.31	Intelligence (multi-trait analysis);	chr15:82206369	chr15:82472993~82513950:-
LUAD	cis	rs2153535	0.563	rs7739249	ENSG00000230939.1	RP11-314C16.1	-7.23	1.86e-12	1.36e-09	-0.36	-0.31	Motion sickness;	chr6:8534357	chr6:8784178~8785445:+
LUAD	cis	rs8100891	0.537	rs58591218	ENSG00000267213.4	AC007773.2	-7.23	1.86e-12	1.36e-09	-0.5	-0.31	Neuroticism;	chr19:32399876	chr19:32390050~32405560:-
LUAD	cis	rs2153535	0.58	rs7767780	ENSG00000230939.1	RP11-314C16.1	-7.23	1.86e-12	1.36e-09	-0.37	-0.31	Motion sickness;	chr6:8453229	chr6:8784178~8785445:+
LUAD	cis	rs4591358	0.648	rs6732306	ENSG00000223466.1	AC064834.2	-7.23	1.87e-12	1.36e-09	-0.46	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195541396	chr2:195533035~195538681:+
LUAD	cis	rs7674212	0.581	rs10516496	ENSG00000246560.2	RP11-10L12.4	7.23	1.87e-12	1.36e-09	0.41	0.31	Type 2 diabetes;	chr4:103021008	chr4:102828055~102844075:+
LUAD	cis	rs6504950	0.925	rs244348	ENSG00000275710.1	RP11-257O5.4	7.23	1.88e-12	1.37e-09	0.39	0.31	Breast cancer;	chr17:55118930	chr17:54964474~54964679:+
LUAD	cis	rs8081395	0.836	rs1295926	ENSG00000266992.1	DHX40P1	-7.23	1.88e-12	1.37e-09	-0.35	-0.31	White blood cell count;	chr17:59832012	chr17:59976009~60002384:-
LUAD	cis	rs2439831	0.681	rs511673	ENSG00000205771.5	CATSPER2P1	-7.23	1.88e-12	1.37e-09	-0.54	-0.31	Lung cancer in ever smokers;	chr15:43326665	chr15:43726918~43747094:-
LUAD	cis	rs7615952	0.611	rs35321002	ENSG00000171084.14	FAM86JP	7.23	1.88e-12	1.37e-09	0.53	0.31	Blood pressure (smoking interaction);	chr3:125893222	chr3:125916620~125930024:+
LUAD	cis	rs2337406	0.587	rs10150642	ENSG00000274576.2	IGHV2-70	7.23	1.88e-12	1.37e-09	0.32	0.31	Alzheimer's disease (late onset);	chr14:106647269	chr14:106770577~106771020:-
LUAD	cis	rs8081395	0.801	rs12938273	ENSG00000266992.1	DHX40P1	-7.23	1.89e-12	1.37e-09	-0.35	-0.31	White blood cell count;	chr17:59824291	chr17:59976009~60002384:-
LUAD	cis	rs4938303	0.718	rs10892023	ENSG00000254851.1	RP11-109L13.1	-7.23	1.89e-12	1.38e-09	-0.49	-0.31	Triglycerides;	chr11:116727532	chr11:117135528~117138582:+
LUAD	cis	rs2439831	0.681	rs498837	ENSG00000205771.5	CATSPER2P1	-7.23	1.9e-12	1.38e-09	-0.54	-0.31	Lung cancer in ever smokers;	chr15:43315826	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.681	rs540031	ENSG00000205771.5	CATSPER2P1	-7.23	1.9e-12	1.38e-09	-0.54	-0.31	Lung cancer in ever smokers;	chr15:43316657	chr15:43726918~43747094:-
LUAD	cis	rs2243480	1	rs431076	ENSG00000273142.1	RP11-458F8.4	-7.23	1.9e-12	1.38e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66135333	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs2257790	ENSG00000273142.1	RP11-458F8.4	-7.23	1.9e-12	1.38e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66135463	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs2460422	ENSG00000273142.1	RP11-458F8.4	-7.23	1.9e-12	1.38e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66136518	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs316334	ENSG00000273142.1	RP11-458F8.4	-7.23	1.9e-12	1.38e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66137139	chr7:66902857~66906297:+
LUAD	cis	rs2439831	0.867	rs3809481	ENSG00000205771.5	CATSPER2P1	-7.23	1.9e-12	1.38e-09	-0.59	-0.31	Lung cancer in ever smokers;	chr15:43370631	chr15:43726918~43747094:-
LUAD	cis	rs35955747	0.807	rs9619169	ENSG00000236132.1	CTA-440B3.1	7.23	1.91e-12	1.39e-09	0.34	0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31141356	chr22:31816379~31817491:-
LUAD	cis	rs2842992	0.872	rs2758330	ENSG00000237927.1	RP3-393E18.2	-7.23	1.91e-12	1.39e-09	-0.44	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159683812	chr6:159586955~159589169:-
LUAD	cis	rs8091660	0.929	rs12456253	ENSG00000278983.1	RP11-426J5.3	-7.23	1.91e-12	1.39e-09	-0.36	-0.31	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48550603	chr18:48564795~48568342:+
LUAD	cis	rs8081395	0.836	rs1292061	ENSG00000266992.1	DHX40P1	-7.23	1.91e-12	1.39e-09	-0.35	-0.31	White blood cell count;	chr17:59833869	chr17:59976009~60002384:-
LUAD	cis	rs35955747	0.902	rs5997932	ENSG00000236132.1	CTA-440B3.1	7.23	1.92e-12	1.39e-09	0.35	0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31272168	chr22:31816379~31817491:-
LUAD	cis	rs7208859	0.673	rs999798	ENSG00000263531.1	RP13-753N3.1	7.23	1.92e-12	1.4e-09	0.54	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831822	chr17:30863921~30864940:-
LUAD	cis	rs748404	0.697	rs1814323	ENSG00000205771.5	CATSPER2P1	7.23	1.93e-12	1.4e-09	0.39	0.31	Lung cancer;	chr15:43271039	chr15:43726918~43747094:-
LUAD	cis	rs950880	0.71	rs3771171	ENSG00000234389.1	AC007278.3	-7.23	1.93e-12	1.4e-09	-0.33	-0.31	Serum protein levels (sST2);	chr2:102369490	chr2:102438713~102440475:+
LUAD	cis	rs950880	0.71	rs2160202	ENSG00000234389.1	AC007278.3	-7.23	1.93e-12	1.4e-09	-0.33	-0.31	Serum protein levels (sST2);	chr2:102369694	chr2:102438713~102440475:+
LUAD	cis	rs35955747	0.902	rs5997929	ENSG00000236132.1	CTA-440B3.1	7.23	1.94e-12	1.41e-09	0.35	0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31268046	chr22:31816379~31817491:-
LUAD	cis	rs10463554	0.889	rs246911	ENSG00000175749.11	EIF3KP1	7.23	1.94e-12	1.41e-09	0.45	0.31	Parkinson's disease;	chr5:103227502	chr5:103032376~103033031:+
LUAD	cis	rs2980439	0.818	rs2948294	ENSG00000253981.4	ALG1L13P	7.23	1.94e-12	1.41e-09	0.37	0.31	Neuroticism;	chr8:8237439	chr8:8236003~8244667:-
LUAD	cis	rs7615952	0.673	rs34209763	ENSG00000171084.14	FAM86JP	7.23	1.94e-12	1.41e-09	0.53	0.31	Blood pressure (smoking interaction);	chr3:125880752	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.8	rs35390120	ENSG00000171084.14	FAM86JP	7.23	1.94e-12	1.41e-09	0.53	0.31	Blood pressure (smoking interaction);	chr3:125880966	chr3:125916620~125930024:+
LUAD	cis	rs9322193	0.962	rs35031906	ENSG00000223701.3	RAET1E-AS1	7.23	1.94e-12	1.41e-09	0.37	0.31	Lung cancer;	chr6:149677438	chr6:149884431~149919508:+
LUAD	cis	rs1345301	1	rs13405355	ENSG00000234389.1	AC007278.3	-7.23	1.94e-12	1.41e-09	-0.28	-0.31	Waist circumference;	chr2:102261746	chr2:102438713~102440475:+
LUAD	cis	rs6991838	0.702	rs34496943	ENSG00000272010.1	CTD-3025N20.3	7.23	1.94e-12	1.41e-09	0.33	0.31	Intelligence (multi-trait analysis);	chr8:65676978	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.733	rs13281090	ENSG00000272010.1	CTD-3025N20.3	7.23	1.94e-12	1.41e-09	0.33	0.31	Intelligence (multi-trait analysis);	chr8:65678244	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.701	rs17395275	ENSG00000272010.1	CTD-3025N20.3	7.23	1.94e-12	1.41e-09	0.33	0.31	Intelligence (multi-trait analysis);	chr8:65679003	chr8:65591850~65592472:-
LUAD	cis	rs4141404	0.604	rs5753625	ENSG00000236132.1	CTA-440B3.1	7.23	1.94e-12	1.41e-09	0.36	0.31	Paclitaxel-induced neuropathy;	chr22:31458860	chr22:31816379~31817491:-
LUAD	cis	rs2153535	0.58	rs1414344	ENSG00000230939.1	RP11-314C16.1	-7.23	1.94e-12	1.41e-09	-0.37	-0.31	Motion sickness;	chr6:8471132	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs2152348	ENSG00000230939.1	RP11-314C16.1	-7.23	1.94e-12	1.41e-09	-0.37	-0.31	Motion sickness;	chr6:8474068	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9505454	ENSG00000230939.1	RP11-314C16.1	-7.23	1.94e-12	1.41e-09	-0.37	-0.31	Motion sickness;	chr6:8478299	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.541	rs9505456	ENSG00000230939.1	RP11-314C16.1	-7.23	1.94e-12	1.41e-09	-0.37	-0.31	Motion sickness;	chr6:8478768	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9505458	ENSG00000230939.1	RP11-314C16.1	-7.23	1.94e-12	1.41e-09	-0.37	-0.31	Motion sickness;	chr6:8478982	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9379215	ENSG00000230939.1	RP11-314C16.1	-7.23	1.94e-12	1.41e-09	-0.37	-0.31	Motion sickness;	chr6:8480992	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs6597326	ENSG00000230939.1	RP11-314C16.1	-7.23	1.94e-12	1.41e-09	-0.37	-0.31	Motion sickness;	chr6:8481786	chr6:8784178~8785445:+
LUAD	cis	rs9549367	0.713	rs3024743	ENSG00000269125.1	RP11-98F14.11	-7.23	1.95e-12	1.42e-09	-0.41	-0.31	Platelet distribution width;	chr13:113167116	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.713	rs3024744	ENSG00000269125.1	RP11-98F14.11	-7.23	1.95e-12	1.42e-09	-0.41	-0.31	Platelet distribution width;	chr13:113167163	chr13:113165002~113165183:-
LUAD	cis	rs6142102	0.961	rs2284387	ENSG00000276073.1	RP5-1125A11.7	-7.23	1.95e-12	1.42e-09	-0.33	-0.31	Skin pigmentation;	chr20:34056782	chr20:33985617~33988989:-
LUAD	cis	rs35955747	0.902	rs7288643	ENSG00000236132.1	CTA-440B3.1	7.23	1.96e-12	1.42e-09	0.35	0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31283683	chr22:31816379~31817491:-
LUAD	cis	rs2153535	0.58	rs6912193	ENSG00000230939.1	RP11-314C16.1	-7.23	1.96e-12	1.42e-09	-0.37	-0.31	Motion sickness;	chr6:8456073	chr6:8784178~8785445:+
LUAD	cis	rs9322193	0.923	rs7769101	ENSG00000223701.3	RAET1E-AS1	7.23	1.96e-12	1.42e-09	0.37	0.31	Lung cancer;	chr6:149848768	chr6:149884431~149919508:+
LUAD	cis	rs9640161	0.75	rs4395803	ENSG00000261305.1	RP4-584D14.7	7.23	1.96e-12	1.43e-09	0.46	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150328278	chr7:150341771~150342607:+
LUAD	cis	rs9834970	0.566	rs4328757	ENSG00000234073.1	AC011816.1	-7.23	1.97e-12	1.43e-09	-0.34	-0.31	Bipolar disorder with mood-incongruent psychosis;Bipolar disorder;Schizophrenia or bipolar disorder;Subjective response to lithium treatment;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr3:36896689	chr3:36880184~36880729:-
LUAD	cis	rs7429990	0.833	rs2293226	ENSG00000229759.1	MRPS18AP1	7.23	1.97e-12	1.43e-09	0.31	0.31	Educational attainment (years of education);	chr3:47585292	chr3:48256350~48256938:-
LUAD	cis	rs7208859	0.524	rs11653098	ENSG00000263531.1	RP13-753N3.1	7.23	1.97e-12	1.43e-09	0.63	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30863921~30864940:-
LUAD	cis	rs10129255	0.5	rs7161740	ENSG00000211970.3	IGHV4-61	-7.23	1.97e-12	1.43e-09	-0.22	-0.31	Kawasaki disease;	chr14:106776119	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.556	rs6576222	ENSG00000211970.3	IGHV4-61	-7.23	1.97e-12	1.43e-09	-0.22	-0.31	Kawasaki disease;	chr14:106776442	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.536	rs6576223	ENSG00000211970.3	IGHV4-61	-7.23	1.97e-12	1.43e-09	-0.22	-0.31	Kawasaki disease;	chr14:106776448	chr14:106639119~106639657:-
LUAD	cis	rs11214589	0.651	rs11214596	ENSG00000270179.1	RP11-159N11.4	-7.23	1.98e-12	1.43e-09	-0.31	-0.31	Neuroticism;	chr11:113393789	chr11:113368478~113369117:+
LUAD	cis	rs783540	0.774	rs28415133	ENSG00000278603.1	RP13-608F4.5	-7.23	1.98e-12	1.43e-09	-0.36	-0.31	Schizophrenia;	chr15:82595963	chr15:82472203~82472426:+
LUAD	cis	rs11098499	0.863	rs2306456	ENSG00000248280.1	RP11-33B1.2	7.22	1.98e-12	1.44e-09	0.41	0.31	Corneal astigmatism;	chr4:119551267	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs11947234	ENSG00000248280.1	RP11-33B1.2	7.22	1.98e-12	1.44e-09	0.41	0.31	Corneal astigmatism;	chr4:119553704	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs11933966	ENSG00000248280.1	RP11-33B1.2	7.22	1.98e-12	1.44e-09	0.41	0.31	Corneal astigmatism;	chr4:119555560	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs36040693	ENSG00000248280.1	RP11-33B1.2	7.22	1.98e-12	1.44e-09	0.41	0.31	Corneal astigmatism;	chr4:119556461	chr4:119440561~119450157:-
LUAD	cis	rs8177876	0.57	rs11863158	ENSG00000261838.4	RP11-303E16.6	7.22	1.98e-12	1.44e-09	0.67	0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81034525	chr16:81069854~81076598:+
LUAD	cis	rs7429990	0.864	rs6774170	ENSG00000229759.1	MRPS18AP1	-7.22	1.98e-12	1.44e-09	-0.31	-0.31	Educational attainment (years of education);	chr3:47615977	chr3:48256350~48256938:-
LUAD	cis	rs11098499	0.954	rs1546505	ENSG00000248280.1	RP11-33B1.2	7.22	1.98e-12	1.44e-09	0.39	0.31	Corneal astigmatism;	chr4:119320069	chr4:119440561~119450157:-
LUAD	cis	rs10129255	0.5	rs2105989	ENSG00000211970.3	IGHV4-61	-7.22	1.98e-12	1.44e-09	-0.22	-0.31	Kawasaki disease;	chr14:106682199	chr14:106639119~106639657:-
LUAD	cis	rs867371	1	rs2088858	ENSG00000255769.6	GOLGA2P10	-7.22	1.99e-12	1.45e-09	-0.33	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182408	chr15:82472993~82513950:-
LUAD	cis	rs867371	1	rs4778982	ENSG00000255769.6	GOLGA2P10	-7.22	1.99e-12	1.45e-09	-0.33	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182931	chr15:82472993~82513950:-
LUAD	cis	rs867371	1	rs2867579	ENSG00000255769.6	GOLGA2P10	-7.22	1.99e-12	1.45e-09	-0.33	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183043	chr15:82472993~82513950:-
LUAD	cis	rs867371	1	rs881308	ENSG00000255769.6	GOLGA2P10	-7.22	1.99e-12	1.45e-09	-0.33	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183456	chr15:82472993~82513950:-
LUAD	cis	rs2153535	0.623	rs2152346	ENSG00000230939.1	RP11-314C16.1	-7.22	2e-12	1.45e-09	-0.37	-0.31	Motion sickness;	chr6:8454419	chr6:8784178~8785445:+
LUAD	cis	rs35955747	0.869	rs5997909	ENSG00000236132.1	CTA-440B3.1	7.22	2e-12	1.45e-09	0.35	0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31195242	chr22:31816379~31817491:-
LUAD	cis	rs35955747	0.871	rs2013254	ENSG00000236132.1	CTA-440B3.1	7.22	2e-12	1.45e-09	0.35	0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31294817	chr22:31816379~31817491:-
LUAD	cis	rs35955747	0.902	rs12167361	ENSG00000236132.1	CTA-440B3.1	7.22	2e-12	1.45e-09	0.35	0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31300292	chr22:31816379~31817491:-
LUAD	cis	rs9595908	0.965	rs4941612	ENSG00000212293.1	SNORA16	7.22	2e-12	1.45e-09	0.36	0.31	Body mass index;	chr13:32549791	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.965	rs12323094	ENSG00000212293.1	SNORA16	7.22	2e-12	1.45e-09	0.36	0.31	Body mass index;	chr13:32569227	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.965	rs12323101	ENSG00000212293.1	SNORA16	7.22	2e-12	1.45e-09	0.36	0.31	Body mass index;	chr13:32569269	chr13:32420390~32420516:-
LUAD	cis	rs9487094	0.67	rs2024849	ENSG00000260273.1	RP11-425D10.10	7.22	2e-12	1.45e-09	0.41	0.31	Height;	chr6:109497088	chr6:109382795~109383666:+
LUAD	cis	rs2153535	0.58	rs2327051	ENSG00000230939.1	RP11-314C16.1	7.22	2e-12	1.45e-09	0.36	0.31	Motion sickness;	chr6:8440917	chr6:8784178~8785445:+
LUAD	cis	rs10256972	0.647	rs10233430	ENSG00000229043.2	AC091729.9	-7.22	2.01e-12	1.46e-09	-0.34	-0.31	Endometriosis;Longevity;	chr7:1012028	chr7:1160374~1165267:+
LUAD	cis	rs673078	0.66	rs61945224	ENSG00000275759.1	RP11-131L12.3	-7.22	2.01e-12	1.46e-09	-0.48	-0.31	Glucose homeostasis traits;	chr12:118288623	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.66	rs61945225	ENSG00000275759.1	RP11-131L12.3	-7.22	2.01e-12	1.46e-09	-0.48	-0.31	Glucose homeostasis traits;	chr12:118288960	chr12:118428281~118428870:+
LUAD	cis	rs2153535	0.58	rs1932283	ENSG00000230939.1	RP11-314C16.1	-7.22	2.01e-12	1.46e-09	-0.37	-0.31	Motion sickness;	chr6:8477428	chr6:8784178~8785445:+
LUAD	cis	rs7829975	0.536	rs2980439	ENSG00000253893.2	FAM85B	-7.22	2.01e-12	1.46e-09	-0.39	-0.31	Mood instability;	chr8:8237348	chr8:8167819~8226614:-
LUAD	cis	rs8100891	0.537	rs4805758	ENSG00000267213.4	AC007773.2	-7.22	2.02e-12	1.46e-09	-0.48	-0.31	Neuroticism;	chr19:32375518	chr19:32390050~32405560:-
LUAD	cis	rs6991838	0.701	rs7829434	ENSG00000272010.1	CTD-3025N20.3	7.22	2.02e-12	1.46e-09	0.33	0.31	Intelligence (multi-trait analysis);	chr8:65716909	chr8:65591850~65592472:-
LUAD	cis	rs1499614	1	rs2707832	ENSG00000273142.1	RP11-458F8.4	-7.22	2.02e-12	1.46e-09	-0.32	-0.31	Gout;	chr7:66671562	chr7:66902857~66906297:+
LUAD	cis	rs8100891	0.537	rs73034207	ENSG00000267213.4	AC007773.2	-7.22	2.02e-12	1.46e-09	-0.49	-0.31	Neuroticism;	chr19:32384863	chr19:32390050~32405560:-
LUAD	cis	rs10129255	0.5	rs10143242	ENSG00000224373.3	IGHV4-59	7.22	2.02e-12	1.47e-09	0.19	0.31	Kawasaki disease;	chr14:106681814	chr14:106627249~106627825:-
LUAD	cis	rs11603023	0.772	rs540800	ENSG00000255422.1	AP002954.4	-7.22	2.03e-12	1.47e-09	-0.38	-0.31	Cholesterol, total;	chr11:118694942	chr11:118704607~118750263:+
LUAD	cis	rs2153535	0.623	rs6597338	ENSG00000230939.1	RP11-314C16.1	-7.22	2.04e-12	1.48e-09	-0.37	-0.31	Motion sickness;	chr6:8533275	chr6:8784178~8785445:+
LUAD	cis	rs75422866	0.867	rs73111258	ENSG00000280054.1	RP1-197B17.7	7.22	2.04e-12	1.48e-09	0.71	0.31	Pneumonia;	chr12:47597313	chr12:47728151~47730598:-
LUAD	cis	rs673078	0.571	rs7963464	ENSG00000275759.1	RP11-131L12.3	-7.22	2.04e-12	1.48e-09	-0.42	-0.31	Glucose homeostasis traits;	chr12:118264924	chr12:118428281~118428870:+
LUAD	cis	rs10899021	0.92	rs7122710	ENSG00000279353.1	RP11-864N7.4	7.22	2.05e-12	1.48e-09	0.56	0.31	Response to metformin (IC50);	chr11:74612130	chr11:74698231~74699658:-
LUAD	cis	rs950880	0.71	rs17026974	ENSG00000234389.1	AC007278.3	7.22	2.06e-12	1.49e-09	0.32	0.31	Serum protein levels (sST2);	chr2:102335900	chr2:102438713~102440475:+
LUAD	cis	rs2842992	0.872	rs2758328	ENSG00000237927.1	RP3-393E18.2	-7.22	2.06e-12	1.49e-09	-0.44	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159669699	chr6:159586955~159589169:-
LUAD	cis	rs673078	0.571	rs7954330	ENSG00000275759.1	RP11-131L12.3	-7.22	2.07e-12	1.5e-09	-0.44	-0.31	Glucose homeostasis traits;	chr12:118275284	chr12:118428281~118428870:+
LUAD	cis	rs2842992	0.724	rs4709368	ENSG00000237927.1	RP3-393E18.2	7.22	2.07e-12	1.5e-09	0.43	0.31	Age-related macular degeneration (geographic atrophy);	chr6:159783095	chr6:159586955~159589169:-
LUAD	cis	rs2243480	1	rs4149468	ENSG00000273142.1	RP11-458F8.4	-7.22	2.07e-12	1.5e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66360703	chr7:66902857~66906297:+
LUAD	cis	rs2842992	0.83	rs2842974	ENSG00000237927.1	RP3-393E18.2	-7.22	2.07e-12	1.5e-09	-0.43	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159738002	chr6:159586955~159589169:-
LUAD	cis	rs6504950	0.85	rs11658717	ENSG00000275710.1	RP11-257O5.4	-7.22	2.07e-12	1.5e-09	-0.39	-0.31	Breast cancer;	chr17:54999625	chr17:54964474~54964679:+
LUAD	cis	rs11098499	0.863	rs10009626	ENSG00000248280.1	RP11-33B1.2	7.22	2.08e-12	1.5e-09	0.41	0.31	Corneal astigmatism;	chr4:119548850	chr4:119440561~119450157:-
LUAD	cis	rs9595908	0.965	rs1123462	ENSG00000212293.1	SNORA16	7.22	2.08e-12	1.5e-09	0.36	0.31	Body mass index;	chr13:32571325	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.897	rs12429688	ENSG00000212293.1	SNORA16	7.22	2.08e-12	1.5e-09	0.36	0.31	Body mass index;	chr13:32572075	chr13:32420390~32420516:-
LUAD	cis	rs11098499	0.82	rs28394116	ENSG00000248280.1	RP11-33B1.2	7.22	2.08e-12	1.51e-09	0.4	0.31	Corneal astigmatism;	chr4:119603128	chr4:119440561~119450157:-
LUAD	cis	rs1799949	1	rs8176126	ENSG00000267681.1	CTD-3199J23.6	7.22	2.08e-12	1.51e-09	0.36	0.31	Menopause (age at onset);	chr17:43107032	chr17:43144956~43145255:+
LUAD	cis	rs35955747	0.87	rs7289189	ENSG00000236132.1	CTA-440B3.1	7.22	2.08e-12	1.51e-09	0.35	0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31261196	chr22:31816379~31817491:-
LUAD	cis	rs11676348	0.751	rs6715591	ENSG00000261338.2	RP11-378A13.1	-7.22	2.09e-12	1.51e-09	-0.32	-0.31	Ulcerative colitis;	chr2:218155148	chr2:218255319~218257366:+
LUAD	cis	rs2153535	0.58	rs2327061	ENSG00000230939.1	RP11-314C16.1	-7.22	2.09e-12	1.51e-09	-0.37	-0.31	Motion sickness;	chr6:8446998	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs7453115	ENSG00000230939.1	RP11-314C16.1	-7.22	2.09e-12	1.51e-09	-0.37	-0.31	Motion sickness;	chr6:8447028	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs6910742	ENSG00000230939.1	RP11-314C16.1	-7.22	2.09e-12	1.51e-09	-0.37	-0.31	Motion sickness;	chr6:8448095	chr6:8784178~8785445:+
LUAD	cis	rs10759883	0.587	rs10818899	ENSG00000175611.10	LINC00476	7.22	2.09e-12	1.51e-09	0.38	0.31	Nicotine dependence;	chr9:95860129	chr9:95759231~95875977:-
LUAD	cis	rs2842992	0.915	rs2842958	ENSG00000237927.1	RP3-393E18.2	-7.22	2.09e-12	1.51e-09	-0.44	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159687393	chr6:159586955~159589169:-
LUAD	cis	rs6504950	0.925	rs244377	ENSG00000275710.1	RP11-257O5.4	-7.22	2.09e-12	1.51e-09	-0.39	-0.31	Breast cancer;	chr17:55105718	chr17:54964474~54964679:+
LUAD	cis	rs9487094	0.67	rs7755941	ENSG00000260273.1	RP11-425D10.10	7.22	2.09e-12	1.52e-09	0.41	0.31	Height;	chr6:109494148	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.626	rs12195904	ENSG00000260273.1	RP11-425D10.10	7.22	2.09e-12	1.52e-09	0.41	0.31	Height;	chr6:109494760	chr6:109382795~109383666:+
LUAD	cis	rs5753618	0.504	rs5749295	ENSG00000236132.1	CTA-440B3.1	-7.22	2.09e-12	1.52e-09	-0.37	-0.31	Colorectal cancer;	chr22:31536909	chr22:31816379~31817491:-
LUAD	cis	rs10129255	0.957	rs17113284	ENSG00000280411.1	IGHV1-69-2	7.22	2.1e-12	1.52e-09	0.24	0.31	Kawasaki disease;	chr14:106684476	chr14:106762092~106762588:-
LUAD	cis	rs673078	0.66	rs61945219	ENSG00000275759.1	RP11-131L12.3	-7.22	2.1e-12	1.52e-09	-0.42	-0.31	Glucose homeostasis traits;	chr12:118272916	chr12:118428281~118428870:+
LUAD	cis	rs62229266	0.659	rs2026259	ENSG00000214914.3	RPL23AP3	7.22	2.11e-12	1.52e-09	0.36	0.31	Mitral valve prolapse;	chr21:36058329	chr21:36016079~36016546:-
LUAD	cis	rs10129255	0.913	rs10140943	ENSG00000280411.1	IGHV1-69-2	-7.22	2.11e-12	1.52e-09	-0.24	-0.31	Kawasaki disease;	chr14:106767441	chr14:106762092~106762588:-
LUAD	cis	rs6142102	0.961	rs2235597	ENSG00000276073.1	RP5-1125A11.7	-7.22	2.11e-12	1.53e-09	-0.33	-0.31	Skin pigmentation;	chr20:34077808	chr20:33985617~33988989:-
LUAD	cis	rs2243480	1	rs73150014	ENSG00000273142.1	RP11-458F8.4	-7.21	2.12e-12	1.53e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:65985932	chr7:66902857~66906297:+
LUAD	cis	rs10200159	1	rs10195281	ENSG00000272606.1	RP11-554J4.1	7.21	2.13e-12	1.54e-09	0.54	0.31	Vitiligo;	chr2:55620886	chr2:55617909~55618373:+
LUAD	cis	rs11676348	0.901	rs7562334	ENSG00000261338.2	RP11-378A13.1	-7.21	2.13e-12	1.54e-09	-0.33	-0.31	Ulcerative colitis;	chr2:218138637	chr2:218255319~218257366:+
LUAD	cis	rs2919917	0.628	rs2717540	ENSG00000254352.1	RP11-578O24.2	7.21	2.13e-12	1.54e-09	0.41	0.31	Lymphocyte counts;	chr8:78710128	chr8:78723796~78724136:-
LUAD	cis	rs7429990	0.965	rs319689	ENSG00000229759.1	MRPS18AP1	7.21	2.13e-12	1.54e-09	0.31	0.31	Educational attainment (years of education);	chr3:47886677	chr3:48256350~48256938:-
LUAD	cis	rs10129255	0.5	rs8021941	ENSG00000211970.3	IGHV4-61	-7.21	2.13e-12	1.54e-09	-0.22	-0.31	Kawasaki disease;	chr14:106781490	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.957	rs10136817	ENSG00000280411.1	IGHV1-69-2	-7.21	2.14e-12	1.54e-09	-0.24	-0.31	Kawasaki disease;	chr14:106787730	chr14:106762092~106762588:-
LUAD	cis	rs10200159	0.744	rs75365186	ENSG00000272606.1	RP11-554J4.1	7.21	2.14e-12	1.55e-09	0.55	0.31	Vitiligo;	chr2:55575834	chr2:55617909~55618373:+
LUAD	cis	rs6142102	0.961	rs1555075	ENSG00000276073.1	RP5-1125A11.7	-7.21	2.15e-12	1.55e-09	-0.33	-0.31	Skin pigmentation;	chr20:34022595	chr20:33985617~33988989:-
LUAD	cis	rs12134133	1	rs7522618	ENSG00000274245.1	RP11-357P18.2	7.21	2.16e-12	1.56e-09	0.41	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207244081	chr1:207372559~207373252:+
LUAD	cis	rs12134133	1	rs11580382	ENSG00000274245.1	RP11-357P18.2	7.21	2.16e-12	1.56e-09	0.41	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207245047	chr1:207372559~207373252:+
LUAD	cis	rs12134133	1	rs11580387	ENSG00000274245.1	RP11-357P18.2	7.21	2.16e-12	1.56e-09	0.41	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207245063	chr1:207372559~207373252:+
LUAD	cis	rs12134133	1	rs7518565	ENSG00000274245.1	RP11-357P18.2	7.21	2.16e-12	1.56e-09	0.41	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207246998	chr1:207372559~207373252:+
LUAD	cis	rs867371	1	rs8041924	ENSG00000255769.6	GOLGA2P10	-7.21	2.16e-12	1.56e-09	-0.33	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82181320	chr15:82472993~82513950:-
LUAD	cis	rs17826219	0.568	rs11658027	ENSG00000263531.1	RP13-753N3.1	-7.21	2.17e-12	1.57e-09	-0.62	-0.31	Body mass index;	chr17:30767864	chr17:30863921~30864940:-
LUAD	cis	rs2153535	0.58	rs6912374	ENSG00000230939.1	RP11-314C16.1	-7.21	2.17e-12	1.57e-09	-0.37	-0.31	Motion sickness;	chr6:8456190	chr6:8784178~8785445:+
LUAD	cis	rs11098499	0.863	rs1552092	ENSG00000248280.1	RP11-33B1.2	7.21	2.17e-12	1.57e-09	0.41	0.31	Corneal astigmatism;	chr4:119567341	chr4:119440561~119450157:-
LUAD	cis	rs10899021	0.92	rs11236171	ENSG00000279353.1	RP11-864N7.4	7.21	2.18e-12	1.57e-09	0.56	0.31	Response to metformin (IC50);	chr11:74606473	chr11:74698231~74699658:-
LUAD	cis	rs673078	0.66	rs73205526	ENSG00000275759.1	RP11-131L12.3	-7.21	2.18e-12	1.57e-09	-0.44	-0.31	Glucose homeostasis traits;	chr12:118273172	chr12:118428281~118428870:+
LUAD	cis	rs35160687	0.901	rs67903513	ENSG00000273080.1	RP11-301O19.1	7.21	2.18e-12	1.57e-09	0.35	0.31	Night sleep phenotypes;	chr2:86284976	chr2:86195590~86196049:+
LUAD	cis	rs7208859	0.623	rs55811708	ENSG00000263531.1	RP13-753N3.1	7.21	2.18e-12	1.58e-09	0.63	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30863921~30864940:-
LUAD	cis	rs2153535	0.562	rs6901765	ENSG00000230939.1	RP11-314C16.1	-7.21	2.18e-12	1.58e-09	-0.37	-0.31	Motion sickness;	chr6:8455203	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.601	rs9502715	ENSG00000230939.1	RP11-314C16.1	-7.21	2.18e-12	1.58e-09	-0.37	-0.31	Motion sickness;	chr6:8455476	chr6:8784178~8785445:+
LUAD	cis	rs11098499	0.863	rs28718422	ENSG00000248280.1	RP11-33B1.2	7.21	2.21e-12	1.6e-09	0.41	0.31	Corneal astigmatism;	chr4:119545149	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.818	rs12498599	ENSG00000248280.1	RP11-33B1.2	7.21	2.21e-12	1.6e-09	0.41	0.31	Corneal astigmatism;	chr4:119547348	chr4:119440561~119450157:-
LUAD	cis	rs6844153	0.627	rs11730235	ENSG00000240005.4	RP11-293A21.1	-7.21	2.22e-12	1.6e-09	-0.46	-0.31	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26922822	chr4:26859806~26860599:-
LUAD	cis	rs3762637	0.941	rs6788746	ENSG00000272758.4	RP11-299J3.8	-7.21	2.22e-12	1.6e-09	-0.49	-0.31	LDL cholesterol levels;	chr3:122387896	chr3:122416207~122443180:+
LUAD	cis	rs34779708	0.733	rs7087099	ENSG00000230534.5	RP11-297A16.2	7.21	2.22e-12	1.6e-09	0.37	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35253054	chr10:35098006~35127020:-
LUAD	cis	rs9545047	0.519	rs8001281	ENSG00000227676.3	LINC01068	7.21	2.22e-12	1.6e-09	0.37	0.31	Schizophrenia;	chr13:79410707	chr13:79566727~79571436:+
LUAD	cis	rs4713118	0.621	rs9368548	ENSG00000219392.1	RP1-265C24.5	-7.21	2.22e-12	1.61e-09	-0.44	-0.31	Parkinson's disease;	chr6:28066959	chr6:28115628~28116551:+
LUAD	cis	rs34779708	0.733	rs7070778	ENSG00000230534.5	RP11-297A16.2	7.21	2.23e-12	1.61e-09	0.37	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35252760	chr10:35098006~35127020:-
LUAD	cis	rs10899021	0.92	rs61901540	ENSG00000279353.1	RP11-864N7.4	7.21	2.23e-12	1.61e-09	0.56	0.31	Response to metformin (IC50);	chr11:74603820	chr11:74698231~74699658:-
LUAD	cis	rs10899021	0.92	rs61901541	ENSG00000279353.1	RP11-864N7.4	7.21	2.23e-12	1.61e-09	0.56	0.31	Response to metformin (IC50);	chr11:74606940	chr11:74698231~74699658:-
LUAD	cis	rs10200159	1	rs6717574	ENSG00000272606.1	RP11-554J4.1	7.21	2.24e-12	1.61e-09	0.54	0.31	Vitiligo;	chr2:55594710	chr2:55617909~55618373:+
LUAD	cis	rs11098499	0.954	rs10031483	ENSG00000248280.1	RP11-33B1.2	7.21	2.24e-12	1.62e-09	0.4	0.31	Corneal astigmatism;	chr4:119501481	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs10031665	ENSG00000248280.1	RP11-33B1.2	7.21	2.24e-12	1.62e-09	0.4	0.31	Corneal astigmatism;	chr4:119501697	chr4:119440561~119450157:-
LUAD	cis	rs10129255	0.5	rs10142931	ENSG00000211970.3	IGHV4-61	-7.21	2.24e-12	1.62e-09	-0.22	-0.31	Kawasaki disease;	chr14:106782288	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.789	rs61997796	ENSG00000211972.2	IGHV3-66	7.21	2.24e-12	1.62e-09	0.28	0.31	Kawasaki disease;	chr14:106813798	chr14:106675017~106675544:-
LUAD	cis	rs9545047	0.567	rs7321186	ENSG00000227676.3	LINC01068	7.21	2.24e-12	1.62e-09	0.37	0.31	Schizophrenia;	chr13:79383403	chr13:79566727~79571436:+
LUAD	cis	rs783540	0.9	rs4778686	ENSG00000278603.1	RP13-608F4.5	-7.21	2.24e-12	1.62e-09	-0.36	-0.31	Schizophrenia;	chr15:82642084	chr15:82472203~82472426:+
LUAD	cis	rs1426063	0.8	rs28861517	ENSG00000249717.1	RP11-44F21.3	7.21	2.25e-12	1.62e-09	0.45	0.31	QT interval;	chr4:75092995	chr4:74955974~74970362:-
LUAD	cis	rs9322193	0.683	rs113281309	ENSG00000223701.3	RAET1E-AS1	7.21	2.25e-12	1.62e-09	0.37	0.31	Lung cancer;	chr6:149787289	chr6:149884431~149919508:+
LUAD	cis	rs6991838	0.733	rs7822627	ENSG00000272010.1	CTD-3025N20.3	7.21	2.25e-12	1.62e-09	0.32	0.31	Intelligence (multi-trait analysis);	chr8:65714139	chr8:65591850~65592472:-
LUAD	cis	rs62229266	0.804	rs2835263	ENSG00000214914.3	RPL23AP3	-7.2	2.26e-12	1.63e-09	-0.38	-0.31	Mitral valve prolapse;	chr21:36057947	chr21:36016079~36016546:-
LUAD	cis	rs11098499	0.908	rs9995234	ENSG00000248280.1	RP11-33B1.2	7.2	2.27e-12	1.63e-09	0.4	0.31	Corneal astigmatism;	chr4:119400672	chr4:119440561~119450157:-
LUAD	cis	rs6142102	0.961	rs4911146	ENSG00000276073.1	RP5-1125A11.7	-7.2	2.27e-12	1.63e-09	-0.33	-0.31	Skin pigmentation;	chr20:34052241	chr20:33985617~33988989:-
LUAD	cis	rs2153535	0.542	rs915354	ENSG00000230939.1	RP11-314C16.1	-7.2	2.27e-12	1.64e-09	-0.36	-0.31	Motion sickness;	chr6:8440124	chr6:8784178~8785445:+
LUAD	cis	rs35955747	0.902	rs2413048	ENSG00000236132.1	CTA-440B3.1	7.2	2.28e-12	1.64e-09	0.35	0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31290116	chr22:31816379~31817491:-
LUAD	cis	rs6142102	0.961	rs6059649	ENSG00000276073.1	RP5-1125A11.7	-7.2	2.28e-12	1.64e-09	-0.33	-0.31	Skin pigmentation;	chr20:34056071	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.961	rs6059651	ENSG00000276073.1	RP5-1125A11.7	-7.2	2.28e-12	1.64e-09	-0.33	-0.31	Skin pigmentation;	chr20:34057246	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.961	rs909884	ENSG00000276073.1	RP5-1125A11.7	-7.2	2.28e-12	1.64e-09	-0.33	-0.31	Skin pigmentation;	chr20:34058257	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.961	rs2268088	ENSG00000276073.1	RP5-1125A11.7	-7.2	2.28e-12	1.64e-09	-0.33	-0.31	Skin pigmentation;	chr20:34061258	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.961	rs2284388	ENSG00000276073.1	RP5-1125A11.7	-7.2	2.28e-12	1.64e-09	-0.33	-0.31	Skin pigmentation;	chr20:34067935	chr20:33985617~33988989:-
LUAD	cis	rs1322639	1	rs1322639	ENSG00000261039.2	RP11-417E7.2	7.2	2.29e-12	1.65e-09	0.44	0.31	Pulse pressure;	chr6:169187008	chr6:169175304~169182740:-
LUAD	cis	rs1322639	1	rs9689079	ENSG00000261039.2	RP11-417E7.2	7.2	2.29e-12	1.65e-09	0.44	0.31	Pulse pressure;	chr6:169187053	chr6:169175304~169182740:-
LUAD	cis	rs853679	0.517	rs868987	ENSG00000219392.1	RP1-265C24.5	7.2	2.3e-12	1.66e-09	0.44	0.31	Depression;	chr6:28142370	chr6:28115628~28116551:+
LUAD	cis	rs10759883	0.627	rs13294931	ENSG00000175611.10	LINC00476	-7.2	2.3e-12	1.66e-09	-0.37	-0.31	Nicotine dependence;	chr9:95833220	chr9:95759231~95875977:-
LUAD	cis	rs4713118	0.662	rs149961	ENSG00000219392.1	RP1-265C24.5	-7.2	2.3e-12	1.66e-09	-0.42	-0.31	Parkinson's disease;	chr6:28047791	chr6:28115628~28116551:+
LUAD	cis	rs8091660	0.893	rs1567656	ENSG00000278983.1	RP11-426J5.3	-7.2	2.31e-12	1.66e-09	-0.36	-0.31	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48568420	chr18:48564795~48568342:+
LUAD	cis	rs9487094	0.666	rs9480958	ENSG00000260273.1	RP11-425D10.10	-7.2	2.31e-12	1.66e-09	-0.38	-0.31	Height;	chr6:109432968	chr6:109382795~109383666:+
LUAD	cis	rs2153535	0.601	rs9379224	ENSG00000230939.1	RP11-314C16.1	-7.2	2.31e-12	1.66e-09	-0.38	-0.31	Motion sickness;	chr6:8538180	chr6:8784178~8785445:+
LUAD	cis	rs7923609	0.578	rs10761789	ENSG00000232075.1	MRPL35P2	-7.2	2.31e-12	1.66e-09	-0.38	-0.31	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63636804	chr10:63634317~63634827:-
LUAD	cis	rs237743	1	rs237711	ENSG00000222365.1	SNORD12B	-7.2	2.32e-12	1.67e-09	-0.35	-0.31	Height;	chr20:49310319	chr20:49280319~49280409:+
LUAD	cis	rs8059260	0.604	rs8052325	ENSG00000274038.1	RP11-66H6.4	-7.2	2.32e-12	1.67e-09	-0.54	-0.31	Alcohol consumption over the past year;	chr16:11044121	chr16:11056556~11057034:+
LUAD	cis	rs853679	0.513	rs9468296	ENSG00000219392.1	RP1-265C24.5	-7.2	2.33e-12	1.67e-09	-0.45	-0.31	Depression;	chr6:28145952	chr6:28115628~28116551:+
LUAD	cis	rs7646881	1	rs73015649	ENSG00000240207.5	RP11-379F4.4	-7.2	2.33e-12	1.67e-09	-0.38	-0.31	Tetralogy of Fallot;	chr3:158732509	chr3:158732263~158784070:+
LUAD	cis	rs2439831	0.867	rs7170489	ENSG00000205771.5	CATSPER2P1	-7.2	2.34e-12	1.68e-09	-0.55	-0.31	Lung cancer in ever smokers;	chr15:43344453	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.867	rs16957630	ENSG00000205771.5	CATSPER2P1	-7.2	2.34e-12	1.68e-09	-0.55	-0.31	Lung cancer in ever smokers;	chr15:43350582	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.867	rs16957632	ENSG00000205771.5	CATSPER2P1	-7.2	2.34e-12	1.68e-09	-0.55	-0.31	Lung cancer in ever smokers;	chr15:43350699	chr15:43726918~43747094:-
LUAD	cis	rs10200159	1	rs10200159	ENSG00000272606.1	RP11-554J4.1	7.2	2.34e-12	1.68e-09	0.53	0.31	Vitiligo;	chr2:55617974	chr2:55617909~55618373:+
LUAD	cis	rs11098499	0.697	rs4560394	ENSG00000248280.1	RP11-33B1.2	7.2	2.34e-12	1.68e-09	0.4	0.31	Corneal astigmatism;	chr4:119392280	chr4:119440561~119450157:-
LUAD	cis	rs10129255	0.912	rs61997792	ENSG00000280411.1	IGHV1-69-2	-7.2	2.34e-12	1.69e-09	-0.24	-0.31	Kawasaki disease;	chr14:106799304	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.957	rs10136560	ENSG00000280411.1	IGHV1-69-2	-7.2	2.35e-12	1.69e-09	-0.24	-0.31	Kawasaki disease;	chr14:106787630	chr14:106762092~106762588:-
LUAD	cis	rs2153535	0.541	rs1414353	ENSG00000230939.1	RP11-314C16.1	-7.2	2.35e-12	1.69e-09	-0.37	-0.31	Motion sickness;	chr6:8485409	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.525	rs1335644	ENSG00000230939.1	RP11-314C16.1	-7.2	2.35e-12	1.69e-09	-0.37	-0.31	Motion sickness;	chr6:8487808	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9393025	ENSG00000230939.1	RP11-314C16.1	-7.2	2.35e-12	1.69e-09	-0.37	-0.31	Motion sickness;	chr6:8490385	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1414340	ENSG00000230939.1	RP11-314C16.1	-7.2	2.35e-12	1.69e-09	-0.37	-0.31	Motion sickness;	chr6:8490906	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1335628	ENSG00000230939.1	RP11-314C16.1	-7.2	2.35e-12	1.69e-09	-0.37	-0.31	Motion sickness;	chr6:8491509	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs6597330	ENSG00000230939.1	RP11-314C16.1	-7.2	2.35e-12	1.69e-09	-0.37	-0.31	Motion sickness;	chr6:8491843	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs6941771	ENSG00000230939.1	RP11-314C16.1	-7.2	2.35e-12	1.69e-09	-0.37	-0.31	Motion sickness;	chr6:8494219	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs6937186	ENSG00000230939.1	RP11-314C16.1	-7.2	2.35e-12	1.69e-09	-0.37	-0.31	Motion sickness;	chr6:8494260	chr6:8784178~8785445:+
LUAD	cis	rs8081395	0.651	rs1292067	ENSG00000266992.1	DHX40P1	-7.2	2.37e-12	1.7e-09	-0.36	-0.31	White blood cell count;	chr17:59853285	chr17:59976009~60002384:-
LUAD	cis	rs11098499	0.618	rs35265692	ENSG00000248280.1	RP11-33B1.2	7.2	2.37e-12	1.7e-09	0.4	0.31	Corneal astigmatism;	chr4:119403980	chr4:119440561~119450157:-
LUAD	cis	rs10129255	0.913	rs28861466	ENSG00000211972.2	IGHV3-66	7.2	2.38e-12	1.71e-09	0.28	0.31	Kawasaki disease;	chr14:106718572	chr14:106675017~106675544:-
LUAD	cis	rs2946504	0.52	rs2272624	ENSG00000251468.2	RP11-369K16.1	-7.2	2.39e-12	1.72e-09	-0.38	-0.31	Type 2 diabetes;	chr8:12952158	chr8:12958387~12962200:+
LUAD	cis	rs172166	0.516	rs1225715	ENSG00000204709.4	LINC01556	-7.2	2.39e-12	1.72e-09	-0.39	-0.31	Cardiac Troponin-T levels;	chr6:28145595	chr6:28943877~28944537:+
LUAD	cis	rs2153535	0.58	rs5001130	ENSG00000230939.1	RP11-314C16.1	-7.2	2.39e-12	1.72e-09	-0.36	-0.31	Motion sickness;	chr6:8442065	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs2327057	ENSG00000230939.1	RP11-314C16.1	-7.2	2.39e-12	1.72e-09	-0.36	-0.31	Motion sickness;	chr6:8443086	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1577466	ENSG00000230939.1	RP11-314C16.1	-7.2	2.39e-12	1.72e-09	-0.36	-0.31	Motion sickness;	chr6:8443959	chr6:8784178~8785445:+
LUAD	cis	rs6142102	0.812	rs6059558	ENSG00000276073.1	RP5-1125A11.7	-7.2	2.39e-12	1.72e-09	-0.32	-0.31	Skin pigmentation;	chr20:33929024	chr20:33985617~33988989:-
LUAD	cis	rs2739330	0.731	rs2000468	ENSG00000099984.9	GSTT2	-7.2	2.4e-12	1.72e-09	-0.36	-0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23980123~23983911:+
LUAD	cis	rs867371	1	rs8041868	ENSG00000255769.6	GOLGA2P10	-7.2	2.4e-12	1.72e-09	-0.33	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82179985	chr15:82472993~82513950:-
LUAD	cis	rs237743	1	rs3021	ENSG00000222365.1	SNORD12B	-7.2	2.4e-12	1.72e-09	-0.36	-0.31	Height;	chr20:49257468	chr20:49280319~49280409:+
LUAD	cis	rs2739330	0.892	rs5751776	ENSG00000206090.4	AP000350.7	7.2	2.4e-12	1.73e-09	0.35	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23939998~23942798:+
LUAD	cis	rs950880	0.71	rs12905	ENSG00000234389.1	AC007278.3	-7.2	2.41e-12	1.73e-09	-0.33	-0.31	Serum protein levels (sST2);	chr2:102343547	chr2:102438713~102440475:+
LUAD	cis	rs4591358	0.53	rs72927723	ENSG00000223466.1	AC064834.2	-7.19	2.41e-12	1.73e-09	-0.46	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195522498	chr2:195533035~195538681:+
LUAD	cis	rs2739330	0.76	rs5760095	ENSG00000228039.3	KB-1125A3.10	7.19	2.42e-12	1.73e-09	0.38	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23963780~23964374:+
LUAD	cis	rs10899021	0.92	rs10899014	ENSG00000279353.1	RP11-864N7.4	7.19	2.42e-12	1.73e-09	0.56	0.31	Response to metformin (IC50);	chr11:74614064	chr11:74698231~74699658:-
LUAD	cis	rs2283792	0.967	rs5749998	ENSG00000224086.5	LL22NC03-86G7.1	-7.19	2.42e-12	1.74e-09	-0.3	-0.31	Multiple sclerosis;	chr22:21808085	chr22:21938293~21977632:+
LUAD	cis	rs9595908	0.827	rs7321262	ENSG00000212293.1	SNORA16	7.19	2.43e-12	1.74e-09	0.33	0.31	Body mass index;	chr13:32597942	chr13:32420390~32420516:-
LUAD	cis	rs62229266	0.804	rs62230788	ENSG00000214914.3	RPL23AP3	7.19	2.43e-12	1.75e-09	0.39	0.31	Mitral valve prolapse;	chr21:36008039	chr21:36016079~36016546:-
LUAD	cis	rs72772090	0.539	rs72773923	ENSG00000248734.2	CTD-2260A17.1	-7.19	2.44e-12	1.75e-09	-0.48	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96781875	chr5:96784777~96785999:+
LUAD	cis	rs72772090	0.539	rs114006288	ENSG00000248734.2	CTD-2260A17.1	-7.19	2.44e-12	1.75e-09	-0.48	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782300	chr5:96784777~96785999:+
LUAD	cis	rs72772090	0.539	rs72773932	ENSG00000248734.2	CTD-2260A17.1	-7.19	2.44e-12	1.75e-09	-0.48	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782444	chr5:96784777~96785999:+
LUAD	cis	rs72772090	0.539	rs11750934	ENSG00000248734.2	CTD-2260A17.1	-7.19	2.44e-12	1.75e-09	-0.48	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782783	chr5:96784777~96785999:+
LUAD	cis	rs72772090	0.539	rs11738810	ENSG00000248734.2	CTD-2260A17.1	-7.19	2.44e-12	1.75e-09	-0.48	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96783351	chr5:96784777~96785999:+
LUAD	cis	rs72772090	0.539	rs11748519	ENSG00000248734.2	CTD-2260A17.1	-7.19	2.44e-12	1.75e-09	-0.48	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96783624	chr5:96784777~96785999:+
LUAD	cis	rs17023223	0.537	rs2361272	ENSG00000231365.4	RP11-418J17.1	-7.19	2.45e-12	1.75e-09	-0.41	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060794	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs1343723	ENSG00000231365.4	RP11-418J17.1	-7.19	2.45e-12	1.75e-09	-0.41	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119062431	chr1:119140396~119275973:+
LUAD	cis	rs3779195	0.86	rs12704986	ENSG00000272950.1	RP11-307C18.1	7.19	2.46e-12	1.76e-09	0.51	0.31	Sex hormone-binding globulin levels;	chr7:98357118	chr7:98322853~98323430:+
LUAD	cis	rs3779195	0.858	rs3779196	ENSG00000272950.1	RP11-307C18.1	7.19	2.46e-12	1.76e-09	0.51	0.31	Sex hormone-binding globulin levels;	chr7:98360794	chr7:98322853~98323430:+
LUAD	cis	rs3779195	0.789	rs6965424	ENSG00000272950.1	RP11-307C18.1	7.19	2.46e-12	1.76e-09	0.51	0.31	Sex hormone-binding globulin levels;	chr7:98361813	chr7:98322853~98323430:+
LUAD	cis	rs7688540	0.771	rs10027325	ENSG00000275426.1	CH17-262A2.1	7.19	2.46e-12	1.76e-09	0.43	0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:288819	chr4:149738~150317:+
LUAD	cis	rs7688540	0.771	rs1986557	ENSG00000275426.1	CH17-262A2.1	7.19	2.46e-12	1.76e-09	0.43	0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:289329	chr4:149738~150317:+
LUAD	cis	rs11098499	0.863	rs6534139	ENSG00000248280.1	RP11-33B1.2	-7.19	2.46e-12	1.77e-09	-0.4	-0.31	Corneal astigmatism;	chr4:119528301	chr4:119440561~119450157:-
LUAD	cis	rs1499614	0.803	rs1796229	ENSG00000273142.1	RP11-458F8.4	-7.19	2.46e-12	1.77e-09	-0.32	-0.31	Gout;	chr7:66654674	chr7:66902857~66906297:+
LUAD	cis	rs1499614	0.901	rs3936	ENSG00000273142.1	RP11-458F8.4	-7.19	2.46e-12	1.77e-09	-0.32	-0.31	Gout;	chr7:66661502	chr7:66902857~66906297:+
LUAD	cis	rs2153535	0.58	rs6914276	ENSG00000230939.1	RP11-314C16.1	7.19	2.46e-12	1.77e-09	0.37	0.31	Motion sickness;	chr6:8450202	chr6:8784178~8785445:+
LUAD	cis	rs10129255	0.917	rs7142373	ENSG00000280411.1	IGHV1-69-2	-7.19	2.47e-12	1.77e-09	-0.24	-0.31	Kawasaki disease;	chr14:106708947	chr14:106762092~106762588:-
LUAD	cis	rs2153535	0.58	rs9406167	ENSG00000230939.1	RP11-314C16.1	-7.19	2.47e-12	1.77e-09	-0.37	-0.31	Motion sickness;	chr6:8502619	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs6597334	ENSG00000230939.1	RP11-314C16.1	-7.19	2.47e-12	1.77e-09	-0.37	-0.31	Motion sickness;	chr6:8504546	chr6:8784178~8785445:+
LUAD	cis	rs2842992	0.915	rs2758335	ENSG00000237927.1	RP3-393E18.2	-7.19	2.48e-12	1.78e-09	-0.44	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159689979	chr6:159586955~159589169:-
LUAD	cis	rs2842992	0.872	rs1570318	ENSG00000237927.1	RP3-393E18.2	-7.19	2.48e-12	1.78e-09	-0.44	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159690441	chr6:159586955~159589169:-
LUAD	cis	rs8031584	0.678	rs798125	ENSG00000260382.1	RP11-540B6.2	-7.19	2.48e-12	1.78e-09	-0.39	-0.31	Huntington's disease progression;	chr15:30824597	chr15:30882267~30883231:-
LUAD	cis	rs783540	0.746	rs7165125	ENSG00000278603.1	RP13-608F4.5	-7.19	2.48e-12	1.78e-09	-0.37	-0.31	Schizophrenia;	chr15:82629185	chr15:82472203~82472426:+
LUAD	cis	rs7208859	0.623	rs216439	ENSG00000263531.1	RP13-753N3.1	7.19	2.48e-12	1.78e-09	0.64	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30600866	chr17:30863921~30864940:-
LUAD	cis	rs6487679	1	rs7298108	ENSG00000111788.10	RP11-22B23.1	-7.19	2.49e-12	1.78e-09	-0.31	-0.31	Non-alcoholic fatty liver disease histology (AST);	chr12:9223572	chr12:9277235~9313241:+
LUAD	cis	rs7044106	0.791	rs10985008	ENSG00000238181.2	AHCYP2	-7.19	2.49e-12	1.78e-09	-0.41	-0.31	Hip circumference adjusted for BMI;	chr9:120730682	chr9:120720673~120721972:+
LUAD	cis	rs8177876	0.658	rs11150337	ENSG00000261838.4	RP11-303E16.6	7.19	2.49e-12	1.78e-09	0.66	0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81035712	chr16:81069854~81076598:+
LUAD	cis	rs2243480	0.764	rs2460423	ENSG00000273142.1	RP11-458F8.4	-7.19	2.49e-12	1.79e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66136229	chr7:66902857~66906297:+
LUAD	cis	rs237743	1	rs238150	ENSG00000222365.1	SNORD12B	-7.19	2.5e-12	1.79e-09	-0.35	-0.31	Height;	chr20:49235382	chr20:49280319~49280409:+
LUAD	cis	rs1577917	0.545	rs9450325	ENSG00000203875.9	SNHG5	7.19	2.5e-12	1.79e-09	0.4	0.31	Response to antipsychotic treatment;	chr6:85766096	chr6:85660950~85678736:-
LUAD	cis	rs11098499	0.779	rs10011097	ENSG00000248280.1	RP11-33B1.2	7.19	2.5e-12	1.79e-09	0.4	0.31	Corneal astigmatism;	chr4:119389204	chr4:119440561~119450157:-
LUAD	cis	rs2243480	1	rs313799	ENSG00000273142.1	RP11-458F8.4	-7.19	2.51e-12	1.79e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66029343	chr7:66902857~66906297:+
LUAD	cis	rs2739330	0.929	rs5751775	ENSG00000206090.4	AP000350.7	7.19	2.51e-12	1.79e-09	0.35	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23939998~23942798:+
LUAD	cis	rs7188445	0.871	rs11150187	ENSG00000261390.4	RP11-345M22.2	7.19	2.51e-12	1.8e-09	0.4	0.31	Urate levels;	chr16:79670515	chr16:79715232~79770563:-
LUAD	cis	rs71403859	0.73	rs12446333	ENSG00000260886.1	TAT-AS1	7.19	2.51e-12	1.8e-09	0.56	0.31	Post bronchodilator FEV1;	chr16:71718254	chr16:71565789~71578187:+
LUAD	cis	rs7646881	1	rs73015654	ENSG00000240207.5	RP11-379F4.4	-7.19	2.51e-12	1.8e-09	-0.38	-0.31	Tetralogy of Fallot;	chr3:158733865	chr3:158732263~158784070:+
LUAD	cis	rs7646881	0.953	rs73015657	ENSG00000240207.5	RP11-379F4.4	-7.19	2.51e-12	1.8e-09	-0.38	-0.31	Tetralogy of Fallot;	chr3:158734143	chr3:158732263~158784070:+
LUAD	cis	rs8040855	0.644	rs4635318	ENSG00000259774.1	RP11-182J1.13	-7.19	2.52e-12	1.8e-09	-0.37	-0.31	Bulimia nervosa;	chr15:85183506	chr15:84422618~84425882:+
LUAD	cis	rs10170846	0.861	rs6740452	ENSG00000261428.2	RP11-16P6.1	7.19	2.52e-12	1.8e-09	0.36	0.31	Schizophrenia (inflammation and infection response interaction);	chr2:222653733	chr2:222566899~222569719:-
LUAD	cis	rs7208859	0.573	rs216442	ENSG00000263531.1	RP13-753N3.1	7.19	2.53e-12	1.81e-09	0.64	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604179	chr17:30863921~30864940:-
LUAD	cis	rs17684571	0.938	rs56101897	ENSG00000231441.1	RP11-472M19.2	7.19	2.54e-12	1.82e-09	0.43	0.31	Schizophrenia;	chr6:56687628	chr6:56844002~56864078:+
LUAD	cis	rs10129255	0.957	rs12590735	ENSG00000211972.2	IGHV3-66	7.19	2.55e-12	1.82e-09	0.27	0.31	Kawasaki disease;	chr14:106779660	chr14:106675017~106675544:-
LUAD	cis	rs8031584	0.578	rs1088473	ENSG00000260382.1	RP11-540B6.2	-7.19	2.55e-12	1.83e-09	-0.39	-0.31	Huntington's disease progression;	chr15:30847095	chr15:30882267~30883231:-
LUAD	cis	rs35955747	0.869	rs9621216	ENSG00000236132.1	CTA-440B3.1	7.19	2.56e-12	1.83e-09	0.35	0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31194222	chr22:31816379~31817491:-
LUAD	cis	rs10129255	0.957	rs10138532	ENSG00000280411.1	IGHV1-69-2	-7.19	2.56e-12	1.83e-09	-0.24	-0.31	Kawasaki disease;	chr14:106803901	chr14:106762092~106762588:-
LUAD	cis	rs9660180	0.839	rs12040826	ENSG00000268575.1	RP1-283E3.8	-7.19	2.56e-12	1.83e-09	-0.28	-0.31	Body mass index;	chr1:1773848	chr1:1702736~1737688:-
LUAD	cis	rs72772090	0.539	rs17481856	ENSG00000248734.2	CTD-2260A17.1	-7.19	2.56e-12	1.83e-09	-0.47	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96781104	chr5:96784777~96785999:+
LUAD	cis	rs9660180	0.868	rs72634846	ENSG00000268575.1	RP1-283E3.8	-7.19	2.57e-12	1.83e-09	-0.28	-0.31	Body mass index;	chr1:1773476	chr1:1702736~1737688:-
LUAD	cis	rs1185460	0.546	rs7114961	ENSG00000271751.1	RP11-110I1.14	7.19	2.57e-12	1.84e-09	0.4	0.31	Coronary artery disease;	chr11:119043677	chr11:119065263~119065677:-
LUAD	cis	rs2581828	0.618	rs7615099	ENSG00000242142.1	SERBP1P3	-7.19	2.57e-12	1.84e-09	-0.34	-0.31	Crohn's disease;	chr3:53109885	chr3:53064283~53065091:-
LUAD	cis	rs7811142	0.83	rs6945952	ENSG00000242294.5	STAG3L5P	7.19	2.58e-12	1.84e-09	0.27	0.31	Platelet count;	chr7:100384152	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.83	rs73401451	ENSG00000242294.5	STAG3L5P	7.19	2.58e-12	1.84e-09	0.27	0.31	Platelet count;	chr7:100384272	chr7:100336079~100351900:+
LUAD	cis	rs7246657	0.943	rs4801803	ENSG00000276846.1	CTD-3220F14.3	-7.18	2.58e-12	1.85e-09	-0.42	-0.31	Coronary artery calcification;	chr19:37476021	chr19:37314868~37315620:-
LUAD	cis	rs10129255	0.957	rs10140904	ENSG00000211972.2	IGHV3-66	7.18	2.59e-12	1.85e-09	0.27	0.31	Kawasaki disease;	chr14:106776558	chr14:106675017~106675544:-
LUAD	cis	rs72772090	0.539	rs3335	ENSG00000248734.2	CTD-2260A17.1	-7.18	2.59e-12	1.85e-09	-0.48	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779366	chr5:96784777~96785999:+
LUAD	cis	rs72772090	0.539	rs3334	ENSG00000248734.2	CTD-2260A17.1	-7.18	2.59e-12	1.85e-09	-0.48	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779381	chr5:96784777~96785999:+
LUAD	cis	rs12134133	0.962	rs11120512	ENSG00000274245.1	RP11-357P18.2	-7.18	2.59e-12	1.85e-09	-0.4	-0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207240370	chr1:207372559~207373252:+
LUAD	cis	rs12439619	0.693	rs8034801	ENSG00000255769.6	GOLGA2P10	-7.18	2.59e-12	1.85e-09	-0.39	-0.31	Intelligence (multi-trait analysis);	chr15:82183996	chr15:82472993~82513950:-
LUAD	cis	rs867371	1	rs7166570	ENSG00000255769.6	GOLGA2P10	-7.18	2.6e-12	1.85e-09	-0.33	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173880	chr15:82472993~82513950:-
LUAD	cis	rs2153535	0.58	rs1119690	ENSG00000230939.1	RP11-314C16.1	-7.18	2.6e-12	1.86e-09	-0.37	-0.31	Motion sickness;	chr6:8460427	chr6:8784178~8785445:+
LUAD	cis	rs7188445	0.966	rs11150188	ENSG00000261390.4	RP11-345M22.2	-7.18	2.6e-12	1.86e-09	-0.41	-0.31	Urate levels;	chr16:79673401	chr16:79715232~79770563:-
LUAD	cis	rs11098499	0.954	rs28685688	ENSG00000248280.1	RP11-33B1.2	7.18	2.6e-12	1.86e-09	0.4	0.31	Corneal astigmatism;	chr4:119499179	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs7687843	ENSG00000248280.1	RP11-33B1.2	7.18	2.6e-12	1.86e-09	0.4	0.31	Corneal astigmatism;	chr4:119500056	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs2306455	ENSG00000248280.1	RP11-33B1.2	7.18	2.6e-12	1.86e-09	0.4	0.31	Corneal astigmatism;	chr4:119500814	chr4:119440561~119450157:-
LUAD	cis	rs748404	0.697	rs498227	ENSG00000205771.5	CATSPER2P1	-7.18	2.61e-12	1.86e-09	-0.38	-0.31	Lung cancer;	chr15:43280854	chr15:43726918~43747094:-
LUAD	cis	rs673078	0.66	rs117091919	ENSG00000275759.1	RP11-131L12.3	-7.18	2.61e-12	1.86e-09	-0.48	-0.31	Glucose homeostasis traits;	chr12:118273228	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.66	rs7314987	ENSG00000275759.1	RP11-131L12.3	-7.18	2.61e-12	1.86e-09	-0.48	-0.31	Glucose homeostasis traits;	chr12:118274072	chr12:118428281~118428870:+
LUAD	cis	rs2243480	1	rs383402	ENSG00000226824.5	RP4-756H11.3	7.18	2.61e-12	1.86e-09	0.57	0.31	Diabetic kidney disease;	chr7:66121666	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.962	rs7745915	ENSG00000223701.3	RAET1E-AS1	7.18	2.63e-12	1.88e-09	0.37	0.31	Lung cancer;	chr6:149834111	chr6:149884431~149919508:+
LUAD	cis	rs72772090	0.539	rs3333	ENSG00000248734.2	CTD-2260A17.1	-7.18	2.63e-12	1.88e-09	-0.48	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779407	chr5:96784777~96785999:+
LUAD	cis	rs72772090	0.539	rs11749811	ENSG00000248734.2	CTD-2260A17.1	-7.18	2.63e-12	1.88e-09	-0.48	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96780221	chr5:96784777~96785999:+
LUAD	cis	rs72772090	0.539	rs67140788	ENSG00000248734.2	CTD-2260A17.1	-7.18	2.63e-12	1.88e-09	-0.48	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96780582	chr5:96784777~96785999:+
LUAD	cis	rs11690935	0.595	rs788166	ENSG00000228389.1	AC068039.4	-7.18	2.64e-12	1.88e-09	-0.33	-0.31	Schizophrenia;	chr2:172050761	chr2:171773482~171775844:+
LUAD	cis	rs9549367	0.713	rs9549357	ENSG00000269125.1	RP11-98F14.11	-7.18	2.65e-12	1.89e-09	-0.41	-0.31	Platelet distribution width;	chr13:113205807	chr13:113165002~113165183:-
LUAD	cis	rs11690935	0.595	rs788170	ENSG00000228389.1	AC068039.4	-7.18	2.65e-12	1.89e-09	-0.33	-0.31	Schizophrenia;	chr2:172055230	chr2:171773482~171775844:+
LUAD	cis	rs4660456	0.869	rs616954	ENSG00000237899.1	RP4-739H11.3	7.18	2.65e-12	1.89e-09	0.45	0.31	Platelet count;	chr1:40669947	chr1:40669089~40687588:-
LUAD	cis	rs853679	0.517	rs16893666	ENSG00000219392.1	RP1-265C24.5	7.18	2.65e-12	1.89e-09	0.44	0.31	Depression;	chr6:28086929	chr6:28115628~28116551:+
LUAD	cis	rs6504950	0.925	rs8082622	ENSG00000275710.1	RP11-257O5.4	-7.18	2.65e-12	1.89e-09	-0.39	-0.31	Breast cancer;	chr17:55100206	chr17:54964474~54964679:+
LUAD	cis	rs7208859	0.51	rs216402	ENSG00000263531.1	RP13-753N3.1	7.18	2.67e-12	1.9e-09	0.64	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30590108	chr17:30863921~30864940:-
LUAD	cis	rs9326248	0.731	rs90192	ENSG00000280143.1	AP000892.6	7.18	2.67e-12	1.9e-09	0.45	0.31	Blood protein levels;	chr11:117188631	chr11:117204967~117210292:+
LUAD	cis	rs10759883	0.603	rs13299166	ENSG00000175611.10	LINC00476	7.18	2.67e-12	1.91e-09	0.37	0.31	Nicotine dependence;	chr9:95833249	chr9:95759231~95875977:-
LUAD	cis	rs673078	0.66	rs61945217	ENSG00000275759.1	RP11-131L12.3	-7.18	2.67e-12	1.91e-09	-0.48	-0.31	Glucose homeostasis traits;	chr12:118261194	chr12:118428281~118428870:+
LUAD	cis	rs11098499	0.954	rs3733519	ENSG00000248280.1	RP11-33B1.2	7.18	2.68e-12	1.91e-09	0.4	0.31	Corneal astigmatism;	chr4:119502293	chr4:119440561~119450157:-
LUAD	cis	rs7646881	1	rs7646987	ENSG00000240207.5	RP11-379F4.4	7.18	2.68e-12	1.91e-09	0.37	0.31	Tetralogy of Fallot;	chr3:158735653	chr3:158732263~158784070:+
LUAD	cis	rs2439831	0.867	rs8039638	ENSG00000205771.5	CATSPER2P1	-7.18	2.68e-12	1.91e-09	-0.54	-0.31	Lung cancer in ever smokers;	chr15:43342207	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.867	rs28415933	ENSG00000205771.5	CATSPER2P1	-7.18	2.68e-12	1.91e-09	-0.54	-0.31	Lung cancer in ever smokers;	chr15:43343602	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.867	rs12324572	ENSG00000205771.5	CATSPER2P1	-7.18	2.68e-12	1.91e-09	-0.54	-0.31	Lung cancer in ever smokers;	chr15:43344002	chr15:43726918~43747094:-
LUAD	cis	rs9326248	0.53	rs900012	ENSG00000280143.1	AP000892.6	7.18	2.68e-12	1.91e-09	0.47	0.31	Blood protein levels;	chr11:117095719	chr11:117204967~117210292:+
LUAD	cis	rs6142102	0.961	rs6088355	ENSG00000276073.1	RP5-1125A11.7	-7.18	2.69e-12	1.92e-09	-0.32	-0.31	Skin pigmentation;	chr20:33958081	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.961	rs6057957	ENSG00000276073.1	RP5-1125A11.7	-7.18	2.69e-12	1.92e-09	-0.32	-0.31	Skin pigmentation;	chr20:33962052	chr20:33985617~33988989:-
LUAD	cis	rs8100891	0.537	rs10417152	ENSG00000267213.4	AC007773.2	-7.18	2.69e-12	1.92e-09	-0.49	-0.31	Neuroticism;	chr19:32397994	chr19:32390050~32405560:-
LUAD	cis	rs11098499	0.818	rs55825515	ENSG00000248280.1	RP11-33B1.2	7.18	2.7e-12	1.92e-09	0.41	0.31	Corneal astigmatism;	chr4:119565247	chr4:119440561~119450157:-
LUAD	cis	rs7811142	0.83	rs73401450	ENSG00000242294.5	STAG3L5P	7.18	2.71e-12	1.94e-09	0.27	0.31	Platelet count;	chr7:100384236	chr7:100336079~100351900:+
LUAD	cis	rs748404	0.56	rs1060939	ENSG00000249839.1	AC011330.5	-7.18	2.72e-12	1.94e-09	-0.41	-0.31	Lung cancer;	chr15:43524719	chr15:43663654~43684339:-
LUAD	cis	rs72772090	0.539	rs111237997	ENSG00000248734.2	CTD-2260A17.1	-7.18	2.72e-12	1.94e-09	-0.47	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96779249	chr5:96784777~96785999:+
LUAD	cis	rs35955747	0.869	rs34873968	ENSG00000236132.1	CTA-440B3.1	7.18	2.72e-12	1.94e-09	0.35	0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31185787	chr22:31816379~31817491:-
LUAD	cis	rs4591358	0.689	rs2102745	ENSG00000223466.1	AC064834.2	-7.18	2.73e-12	1.94e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195559315	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.638	rs6704955	ENSG00000223466.1	AC064834.2	-7.18	2.73e-12	1.94e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195559393	chr2:195533035~195538681:+
LUAD	cis	rs7945705	0.837	rs10769981	ENSG00000254860.4	TMEM9B-AS1	-7.18	2.73e-12	1.94e-09	-0.36	-0.31	Hemoglobin concentration;	chr11:9002913	chr11:8964675~8977527:+
LUAD	cis	rs2243480	1	rs4718333	ENSG00000273142.1	RP11-458F8.4	7.18	2.73e-12	1.95e-09	0.32	0.31	Diabetic kidney disease;	chr7:66307771	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs7792391	ENSG00000273142.1	RP11-458F8.4	7.18	2.73e-12	1.95e-09	0.32	0.31	Diabetic kidney disease;	chr7:66308442	chr7:66902857~66906297:+
LUAD	cis	rs10463554	0.895	rs12656561	ENSG00000175749.11	EIF3KP1	7.18	2.73e-12	1.95e-09	0.41	0.31	Parkinson's disease;	chr5:102989988	chr5:103032376~103033031:+
LUAD	cis	rs7487637	0.529	rs11168244	ENSG00000276691.1	RP5-1057I20.5	7.18	2.74e-12	1.95e-09	0.33	0.31	Mononucleosis;	chr12:47809158	chr12:47788426~47788971:+
LUAD	cis	rs8040855	0.644	rs7495437	ENSG00000259774.1	RP11-182J1.13	-7.18	2.74e-12	1.95e-09	-0.37	-0.31	Bulimia nervosa;	chr15:85183059	chr15:84422618~84425882:+
LUAD	cis	rs1185460	0.565	rs1043314	ENSG00000271751.1	RP11-110I1.14	7.18	2.75e-12	1.96e-09	0.4	0.31	Coronary artery disease;	chr11:119045232	chr11:119065263~119065677:-
LUAD	cis	rs10129255	1	rs10137758	ENSG00000280411.1	IGHV1-69-2	-7.18	2.75e-12	1.96e-09	-0.24	-0.31	Kawasaki disease;	chr14:106697673	chr14:106762092~106762588:-
LUAD	cis	rs75422866	0.867	rs117388682	ENSG00000274902.1	RP1-197B17.4	7.18	2.75e-12	1.96e-09	0.7	0.31	Pneumonia;	chr12:47599713	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs79113930	ENSG00000274902.1	RP1-197B17.4	7.18	2.75e-12	1.96e-09	0.7	0.31	Pneumonia;	chr12:47600628	chr12:47731908~47732351:+
LUAD	cis	rs1322639	0.806	rs1322640	ENSG00000261039.2	RP11-417E7.2	7.17	2.75e-12	1.96e-09	0.44	0.31	Pulse pressure;	chr6:169186792	chr6:169175304~169182740:-
LUAD	cis	rs950880	0.71	rs873022	ENSG00000234389.1	AC007278.3	-7.17	2.76e-12	1.97e-09	-0.32	-0.31	Serum protein levels (sST2);	chr2:102339223	chr2:102438713~102440475:+
LUAD	cis	rs11098499	0.863	rs13136462	ENSG00000248280.1	RP11-33B1.2	7.17	2.76e-12	1.97e-09	0.4	0.31	Corneal astigmatism;	chr4:119622018	chr4:119440561~119450157:-
LUAD	cis	rs4141404	0.757	rs5749272	ENSG00000236132.1	CTA-440B3.1	7.17	2.76e-12	1.97e-09	0.35	0.31	Paclitaxel-induced neuropathy;	chr22:31434365	chr22:31816379~31817491:-
LUAD	cis	rs10463554	0.892	rs17154860	ENSG00000175749.11	EIF3KP1	7.17	2.78e-12	1.98e-09	0.43	0.31	Parkinson's disease;	chr5:102955441	chr5:103032376~103033031:+
LUAD	cis	rs11098499	0.909	rs9759478	ENSG00000248280.1	RP11-33B1.2	7.17	2.78e-12	1.98e-09	0.4	0.31	Corneal astigmatism;	chr4:119446843	chr4:119440561~119450157:-
LUAD	cis	rs72772090	0.539	rs72773969	ENSG00000248734.2	CTD-2260A17.1	-7.17	2.78e-12	1.98e-09	-0.48	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96809493	chr5:96784777~96785999:+
LUAD	cis	rs7429990	0.864	rs1464614	ENSG00000229759.1	MRPS18AP1	7.17	2.79e-12	1.98e-09	0.31	0.31	Educational attainment (years of education);	chr3:47612885	chr3:48256350~48256938:-
LUAD	cis	rs6142102	0.961	rs4911389	ENSG00000276073.1	RP5-1125A11.7	-7.17	2.8e-12	1.99e-09	-0.33	-0.31	Skin pigmentation;	chr20:33977235	chr20:33985617~33988989:-
LUAD	cis	rs10129255	0.834	rs10139893	ENSG00000280411.1	IGHV1-69-2	-7.17	2.8e-12	1.99e-09	-0.24	-0.31	Kawasaki disease;	chr14:106711377	chr14:106762092~106762588:-
LUAD	cis	rs867371	1	rs1501372	ENSG00000255769.6	GOLGA2P10	-7.17	2.8e-12	1.99e-09	-0.33	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176114	chr15:82472993~82513950:-
LUAD	cis	rs867371	1	rs1846911	ENSG00000255769.6	GOLGA2P10	-7.17	2.8e-12	1.99e-09	-0.33	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176309	chr15:82472993~82513950:-
LUAD	cis	rs3762637	0.941	rs79493664	ENSG00000272758.4	RP11-299J3.8	-7.17	2.8e-12	1.99e-09	-0.49	-0.31	LDL cholesterol levels;	chr3:122390699	chr3:122416207~122443180:+
LUAD	cis	rs2712381	0.517	rs62273237	ENSG00000242551.2	POU5F1P6	-7.17	2.81e-12	2e-09	-0.35	-0.31	Monocyte count;	chr3:128591264	chr3:128674735~128677005:-
LUAD	cis	rs867371	1	rs8037224	ENSG00000255769.6	GOLGA2P10	-7.17	2.81e-12	2e-09	-0.33	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82172189	chr15:82472993~82513950:-
LUAD	cis	rs75422866	0.867	rs73113139	ENSG00000280054.1	RP1-197B17.7	7.17	2.82e-12	2e-09	0.72	0.31	Pneumonia;	chr12:47622826	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs73102140	ENSG00000280054.1	RP1-197B17.7	7.17	2.82e-12	2e-09	0.72	0.31	Pneumonia;	chr12:47647497	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs73102148	ENSG00000280054.1	RP1-197B17.7	7.17	2.82e-12	2e-09	0.72	0.31	Pneumonia;	chr12:47648013	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs73102151	ENSG00000280054.1	RP1-197B17.7	7.17	2.82e-12	2e-09	0.72	0.31	Pneumonia;	chr12:47648023	chr12:47728151~47730598:-
LUAD	cis	rs172166	0.694	rs1631552	ENSG00000219392.1	RP1-265C24.5	-7.17	2.82e-12	2.01e-09	-0.41	-0.31	Cardiac Troponin-T levels;	chr6:28121921	chr6:28115628~28116551:+
LUAD	cis	rs659580	1	rs659580	ENSG00000271811.1	RP1-79C4.4	-7.17	2.82e-12	2.01e-09	-0.38	-0.31	Response to angiotensin II receptor blocker therapy;Lobe attachment (rater-scored or self-reported);	chr1:170664755	chr1:170667381~170669425:+
LUAD	cis	rs7246657	0.943	rs10407084	ENSG00000276846.1	CTD-3220F14.3	7.17	2.82e-12	2.01e-09	0.43	0.31	Coronary artery calcification;	chr19:37416890	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs7252099	ENSG00000276846.1	CTD-3220F14.3	7.17	2.82e-12	2.01e-09	0.43	0.31	Coronary artery calcification;	chr19:37442878	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs7255972	ENSG00000276846.1	CTD-3220F14.3	7.17	2.82e-12	2.01e-09	0.43	0.31	Coronary artery calcification;	chr19:37442939	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs1015849	ENSG00000276846.1	CTD-3220F14.3	7.17	2.82e-12	2.01e-09	0.43	0.31	Coronary artery calcification;	chr19:37455278	chr19:37314868~37315620:-
LUAD	cis	rs867371	0.896	rs6495647	ENSG00000255769.6	GOLGA2P10	-7.17	2.82e-12	2.01e-09	-0.33	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82244708	chr15:82472993~82513950:-
LUAD	cis	rs9487094	0.67	rs12201356	ENSG00000260273.1	RP11-425D10.10	7.17	2.83e-12	2.02e-09	0.42	0.31	Height;	chr6:109694672	chr6:109382795~109383666:+
LUAD	cis	rs35955747	0.869	rs8143002	ENSG00000236132.1	CTA-440B3.1	7.17	2.84e-12	2.02e-09	0.35	0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31191205	chr22:31816379~31817491:-
LUAD	cis	rs35160687	0.901	rs12478653	ENSG00000273080.1	RP11-301O19.1	-7.17	2.84e-12	2.02e-09	-0.34	-0.31	Night sleep phenotypes;	chr2:86308271	chr2:86195590~86196049:+
LUAD	cis	rs9326248	0.53	rs511676	ENSG00000280143.1	AP000892.6	7.17	2.84e-12	2.02e-09	0.49	0.31	Blood protein levels;	chr11:116954168	chr11:117204967~117210292:+
LUAD	cis	rs9545047	0.604	rs9318641	ENSG00000227676.3	LINC01068	-7.17	2.84e-12	2.02e-09	-0.37	-0.31	Schizophrenia;	chr13:79426545	chr13:79566727~79571436:+
LUAD	cis	rs72772090	0.539	rs72773922	ENSG00000248734.2	CTD-2260A17.1	-7.17	2.84e-12	2.02e-09	-0.47	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96780956	chr5:96784777~96785999:+
LUAD	cis	rs8031584	0.697	rs798080	ENSG00000260382.1	RP11-540B6.2	-7.17	2.85e-12	2.02e-09	-0.39	-0.31	Huntington's disease progression;	chr15:30829966	chr15:30882267~30883231:-
LUAD	cis	rs62229266	0.839	rs11702763	ENSG00000214914.3	RPL23AP3	7.17	2.85e-12	2.02e-09	0.38	0.31	Mitral valve prolapse;	chr21:36098406	chr21:36016079~36016546:-
LUAD	cis	rs9487094	0.626	rs11153213	ENSG00000260273.1	RP11-425D10.10	7.17	2.85e-12	2.02e-09	0.42	0.31	Height;	chr6:109693890	chr6:109382795~109383666:+
LUAD	cis	rs11098499	0.908	rs7695996	ENSG00000248280.1	RP11-33B1.2	7.17	2.85e-12	2.03e-09	0.4	0.31	Corneal astigmatism;	chr4:119400878	chr4:119440561~119450157:-
LUAD	cis	rs9487094	0.626	rs2025148	ENSG00000260273.1	RP11-425D10.10	7.17	2.85e-12	2.03e-09	0.41	0.31	Height;	chr6:109706740	chr6:109382795~109383666:+
LUAD	cis	rs3096299	0.9	rs2911258	ENSG00000274627.1	RP11-104N10.2	7.17	2.85e-12	2.03e-09	0.3	0.31	Multiple myeloma (IgH translocation);	chr16:89414352	chr16:89516797~89522217:+
LUAD	cis	rs904251	0.507	rs11756941	ENSG00000204110.6	RP1-153P14.8	-7.17	2.86e-12	2.03e-09	-0.39	-0.31	Cognitive performance;	chr6:37448443	chr6:37507348~37535616:+
LUAD	cis	rs4713118	0.587	rs61471148	ENSG00000219392.1	RP1-265C24.5	-7.17	2.86e-12	2.03e-09	-0.44	-0.31	Parkinson's disease;	chr6:28069254	chr6:28115628~28116551:+
LUAD	cis	rs10899021	1	rs61900636	ENSG00000279353.1	RP11-864N7.4	7.17	2.86e-12	2.03e-09	0.57	0.31	Response to metformin (IC50);	chr11:74648546	chr11:74698231~74699658:-
LUAD	cis	rs1345301	0.905	rs2310243	ENSG00000234389.1	AC007278.3	-7.17	2.86e-12	2.03e-09	-0.28	-0.31	Waist circumference;	chr2:102261100	chr2:102438713~102440475:+
LUAD	cis	rs2404602	0.598	rs11855999	ENSG00000259422.1	RP11-593F23.1	-7.17	2.86e-12	2.04e-09	-0.43	-0.31	Blood metabolite levels;	chr15:76334992	chr15:76174891~76181486:-
LUAD	cis	rs35955747	0.869	rs131213	ENSG00000236132.1	CTA-440B3.1	-7.17	2.87e-12	2.04e-09	-0.34	-0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31357863	chr22:31816379~31817491:-
LUAD	cis	rs2153535	0.58	rs6597325	ENSG00000230939.1	RP11-314C16.1	-7.17	2.87e-12	2.04e-09	-0.37	-0.31	Motion sickness;	chr6:8460820	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs6918391	ENSG00000230939.1	RP11-314C16.1	-7.17	2.87e-12	2.04e-09	-0.37	-0.31	Motion sickness;	chr6:8460945	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9379210	ENSG00000230939.1	RP11-314C16.1	-7.17	2.87e-12	2.04e-09	-0.37	-0.31	Motion sickness;	chr6:8461695	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.563	rs1737586	ENSG00000230939.1	RP11-314C16.1	-7.17	2.87e-12	2.04e-09	-0.36	-0.31	Motion sickness;	chr6:8535664	chr6:8784178~8785445:+
LUAD	cis	rs9532669	0.926	rs9525438	ENSG00000176268.5	CYCSP34	7.17	2.87e-12	2.04e-09	0.3	0.31	Cervical cancer;	chr13:40964123	chr13:40863599~40863902:-
LUAD	cis	rs4713118	0.621	rs9295755	ENSG00000219392.1	RP1-265C24.5	7.17	2.89e-12	2.06e-09	0.43	0.31	Parkinson's disease;	chr6:28065396	chr6:28115628~28116551:+
LUAD	cis	rs9640161	0.636	rs3735171	ENSG00000261305.1	RP4-584D14.7	7.17	2.9e-12	2.06e-09	0.45	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150336793	chr7:150341771~150342607:+
LUAD	cis	rs9368481	0.743	rs9368480	ENSG00000241549.7	GUSBP2	7.17	2.91e-12	2.07e-09	0.36	0.31	Autism spectrum disorder or schizophrenia;	chr6:26987971	chr6:26871484~26956554:-
LUAD	cis	rs2439831	0.867	rs2412780	ENSG00000205771.5	CATSPER2P1	-7.17	2.92e-12	2.07e-09	-0.54	-0.31	Lung cancer in ever smokers;	chr15:43363596	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.867	rs2412779	ENSG00000205771.5	CATSPER2P1	-7.17	2.92e-12	2.07e-09	-0.54	-0.31	Lung cancer in ever smokers;	chr15:43363729	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.867	rs2899082	ENSG00000205771.5	CATSPER2P1	-7.17	2.92e-12	2.07e-09	-0.54	-0.31	Lung cancer in ever smokers;	chr15:43363845	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.867	rs4583210	ENSG00000205771.5	CATSPER2P1	-7.17	2.92e-12	2.07e-09	-0.54	-0.31	Lung cancer in ever smokers;	chr15:43368727	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.867	rs28461955	ENSG00000205771.5	CATSPER2P1	-7.17	2.92e-12	2.07e-09	-0.54	-0.31	Lung cancer in ever smokers;	chr15:43369261	chr15:43726918~43747094:-
LUAD	cis	rs867371	0.929	rs7176075	ENSG00000255769.6	GOLGA2P10	-7.17	2.92e-12	2.07e-09	-0.33	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82178998	chr15:82472993~82513950:-
LUAD	cis	rs3096299	0.967	rs16965692	ENSG00000274627.1	RP11-104N10.2	7.17	2.93e-12	2.08e-09	0.29	0.31	Multiple myeloma (IgH translocation);	chr16:89405074	chr16:89516797~89522217:+
LUAD	cis	rs9532669	0.511	rs3783164	ENSG00000176268.5	CYCSP34	-7.17	2.93e-12	2.08e-09	-0.32	-0.31	Cervical cancer;	chr13:40806227	chr13:40863599~40863902:-
LUAD	cis	rs11098499	0.954	rs6838814	ENSG00000248280.1	RP11-33B1.2	7.17	2.94e-12	2.09e-09	0.4	0.31	Corneal astigmatism;	chr4:119471288	chr4:119440561~119450157:-
LUAD	cis	rs2153535	0.58	rs6597332	ENSG00000230939.1	RP11-314C16.1	-7.16	2.94e-12	2.09e-09	-0.37	-0.31	Motion sickness;	chr6:8504515	chr6:8784178~8785445:+
LUAD	cis	rs71403859	0.73	rs35390364	ENSG00000260886.1	TAT-AS1	7.16	2.94e-12	2.09e-09	0.56	0.31	Post bronchodilator FEV1;	chr16:71706146	chr16:71565789~71578187:+
LUAD	cis	rs72772090	0.539	rs116360011	ENSG00000248734.2	CTD-2260A17.1	-7.16	2.96e-12	2.1e-09	-0.47	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96782093	chr5:96784777~96785999:+
LUAD	cis	rs7246657	0.653	rs4805208	ENSG00000276846.1	CTD-3220F14.3	7.16	2.98e-12	2.11e-09	0.48	0.31	Coronary artery calcification;	chr19:37183357	chr19:37314868~37315620:-
LUAD	cis	rs2337406	0.587	rs10129888	ENSG00000274576.2	IGHV2-70	-7.16	2.98e-12	2.12e-09	-0.33	-0.31	Alzheimer's disease (late onset);	chr14:106647421	chr14:106770577~106771020:-
LUAD	cis	rs2439831	0.681	rs528517	ENSG00000205771.5	CATSPER2P1	-7.16	2.99e-12	2.12e-09	-0.54	-0.31	Lung cancer in ever smokers;	chr15:43320727	chr15:43726918~43747094:-
LUAD	cis	rs17711722	0.522	rs62469933	ENSG00000226824.5	RP4-756H11.3	-7.16	2.99e-12	2.12e-09	-0.38	-0.31	Calcium levels;	chr7:65800652	chr7:66654538~66669855:+
LUAD	cis	rs7188445	0.871	rs8048928	ENSG00000261390.4	RP11-345M22.2	-7.16	3e-12	2.13e-09	-0.4	-0.31	Urate levels;	chr16:79671039	chr16:79715232~79770563:-
LUAD	cis	rs35955747	0.902	rs4820961	ENSG00000236132.1	CTA-440B3.1	7.16	3e-12	2.13e-09	0.34	0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31283463	chr22:31816379~31817491:-
LUAD	cis	rs11690935	0.571	rs1008151	ENSG00000228389.1	AC068039.4	-7.16	3.02e-12	2.14e-09	-0.33	-0.31	Schizophrenia;	chr2:172047370	chr2:171773482~171775844:+
LUAD	cis	rs9487094	0.67	rs12199154	ENSG00000260273.1	RP11-425D10.10	-7.16	3.02e-12	2.14e-09	-0.4	-0.31	Height;	chr6:109501793	chr6:109382795~109383666:+
LUAD	cis	rs7688540	0.771	rs10021364	ENSG00000275426.1	CH17-262A2.1	-7.16	3.02e-12	2.14e-09	-0.45	-0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:316902	chr4:149738~150317:+
LUAD	cis	rs3738443	0.645	rs55768801	ENSG00000259865.1	RP11-488L18.10	7.16	3.02e-12	2.14e-09	0.28	0.31	Alcohol dependence;	chr1:247199688	chr1:247187281~247188526:-
LUAD	cis	rs10899021	0.92	rs11236172	ENSG00000279353.1	RP11-864N7.4	7.16	3.03e-12	2.15e-09	0.55	0.31	Response to metformin (IC50);	chr11:74619843	chr11:74698231~74699658:-
LUAD	cis	rs673078	0.66	rs61946068	ENSG00000275759.1	RP11-131L12.3	-7.16	3.03e-12	2.15e-09	-0.46	-0.31	Glucose homeostasis traits;	chr12:118305861	chr12:118428281~118428870:+
LUAD	cis	rs7208859	0.623	rs7220289	ENSG00000263531.1	RP13-753N3.1	7.16	3.04e-12	2.15e-09	0.62	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30776744	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs60890550	ENSG00000263531.1	RP13-753N3.1	7.16	3.04e-12	2.15e-09	0.64	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30703843	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs11653955	ENSG00000263531.1	RP13-753N3.1	7.16	3.04e-12	2.15e-09	0.64	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30706274	chr17:30863921~30864940:-
LUAD	cis	rs2153535	0.563	rs6942177	ENSG00000230939.1	RP11-314C16.1	7.16	3.04e-12	2.16e-09	0.37	0.31	Motion sickness;	chr6:8534227	chr6:8784178~8785445:+
LUAD	cis	rs7945705	0.902	rs11042152	ENSG00000254860.4	TMEM9B-AS1	-7.16	3.04e-12	2.16e-09	-0.35	-0.31	Hemoglobin concentration;	chr11:8999440	chr11:8964675~8977527:+
LUAD	cis	rs9595908	0.931	rs7998440	ENSG00000212293.1	SNORA16	7.16	3.05e-12	2.16e-09	0.35	0.31	Body mass index;	chr13:32551069	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.965	rs7991314	ENSG00000212293.1	SNORA16	7.16	3.05e-12	2.16e-09	0.35	0.31	Body mass index;	chr13:32551937	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.965	rs7328733	ENSG00000212293.1	SNORA16	7.16	3.05e-12	2.16e-09	0.35	0.31	Body mass index;	chr13:32552600	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.929	rs7328939	ENSG00000212293.1	SNORA16	7.16	3.05e-12	2.16e-09	0.35	0.31	Body mass index;	chr13:32552711	chr13:32420390~32420516:-
LUAD	cis	rs9322193	0.884	rs9397036	ENSG00000223701.3	RAET1E-AS1	7.16	3.05e-12	2.16e-09	0.37	0.31	Lung cancer;	chr6:149851787	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.884	rs9383864	ENSG00000223701.3	RAET1E-AS1	7.16	3.05e-12	2.16e-09	0.37	0.31	Lung cancer;	chr6:149851969	chr6:149884431~149919508:+
LUAD	cis	rs11098499	0.697	rs28655325	ENSG00000248280.1	RP11-33B1.2	7.16	3.06e-12	2.17e-09	0.4	0.31	Corneal astigmatism;	chr4:119451844	chr4:119440561~119450157:-
LUAD	cis	rs9834970	0.588	rs4296548	ENSG00000234073.1	AC011816.1	-7.16	3.06e-12	2.17e-09	-0.34	-0.31	Bipolar disorder with mood-incongruent psychosis;Bipolar disorder;Schizophrenia or bipolar disorder;Subjective response to lithium treatment;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr3:36874323	chr3:36880184~36880729:-
LUAD	cis	rs9322193	0.847	rs12210605	ENSG00000223701.3	RAET1E-AS1	7.16	3.06e-12	2.17e-09	0.37	0.31	Lung cancer;	chr6:149817267	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.923	rs9371199	ENSG00000223701.3	RAET1E-AS1	7.16	3.06e-12	2.17e-09	0.37	0.31	Lung cancer;	chr6:149817526	chr6:149884431~149919508:+
LUAD	cis	rs150992	0.673	rs161747	ENSG00000248489.1	CTD-2007H13.3	-7.16	3.07e-12	2.17e-09	-0.33	-0.31	Body mass index;	chr5:98920433	chr5:98929171~98995013:+
LUAD	cis	rs673078	0.607	rs17512483	ENSG00000275759.1	RP11-131L12.3	7.16	3.08e-12	2.18e-09	0.5	0.31	Glucose homeostasis traits;	chr12:118312380	chr12:118428281~118428870:+
LUAD	cis	rs7811142	0.72	rs112622797	ENSG00000242294.5	STAG3L5P	7.16	3.08e-12	2.18e-09	0.28	0.31	Platelet count;	chr7:100319793	chr7:100336079~100351900:+
LUAD	cis	rs9487094	0.67	rs12197838	ENSG00000260273.1	RP11-425D10.10	7.16	3.1e-12	2.19e-09	0.41	0.31	Height;	chr6:109672088	chr6:109382795~109383666:+
LUAD	cis	rs6142102	0.961	rs4911144	ENSG00000276073.1	RP5-1125A11.7	-7.16	3.1e-12	2.19e-09	-0.33	-0.31	Skin pigmentation;	chr20:34026565	chr20:33985617~33988989:-
LUAD	cis	rs71403859	0.73	rs17356316	ENSG00000260886.1	TAT-AS1	7.16	3.1e-12	2.2e-09	0.56	0.31	Post bronchodilator FEV1;	chr16:71713018	chr16:71565789~71578187:+
LUAD	cis	rs11098499	0.821	rs10032151	ENSG00000248280.1	RP11-33B1.2	7.16	3.1e-12	2.2e-09	0.4	0.31	Corneal astigmatism;	chr4:119470473	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.865	rs10032158	ENSG00000248280.1	RP11-33B1.2	7.16	3.1e-12	2.2e-09	0.4	0.31	Corneal astigmatism;	chr4:119470477	chr4:119440561~119450157:-
LUAD	cis	rs3762637	0.882	rs9856011	ENSG00000272758.4	RP11-299J3.8	-7.16	3.1e-12	2.2e-09	-0.49	-0.31	LDL cholesterol levels;	chr3:122374723	chr3:122416207~122443180:+
LUAD	cis	rs1345301	1	rs12474199	ENSG00000234389.1	AC007278.3	-7.16	3.1e-12	2.2e-09	-0.28	-0.31	Waist circumference;	chr2:102252520	chr2:102438713~102440475:+
LUAD	cis	rs1345301	1	rs1420093	ENSG00000234389.1	AC007278.3	-7.16	3.1e-12	2.2e-09	-0.28	-0.31	Waist circumference;	chr2:102253998	chr2:102438713~102440475:+
LUAD	cis	rs1345301	1	rs10200410	ENSG00000234389.1	AC007278.3	-7.16	3.1e-12	2.2e-09	-0.28	-0.31	Waist circumference;	chr2:102254411	chr2:102438713~102440475:+
LUAD	cis	rs7115242	0.8	rs519794	ENSG00000280143.1	AP000892.6	7.16	3.11e-12	2.2e-09	0.47	0.31	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116988737	chr11:117204967~117210292:+
LUAD	cis	rs11098499	0.954	rs17006190	ENSG00000248280.1	RP11-33B1.2	7.16	3.11e-12	2.2e-09	0.4	0.31	Corneal astigmatism;	chr4:119497683	chr4:119440561~119450157:-
LUAD	cis	rs867371	0.964	rs7169961	ENSG00000255769.6	GOLGA2P10	-7.16	3.11e-12	2.2e-09	-0.33	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186588	chr15:82472993~82513950:-
LUAD	cis	rs867371	1	rs6495643	ENSG00000255769.6	GOLGA2P10	-7.16	3.11e-12	2.2e-09	-0.33	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186913	chr15:82472993~82513950:-
LUAD	cis	rs7674212	0.507	rs223322	ENSG00000246560.2	RP11-10L12.4	7.16	3.11e-12	2.2e-09	0.4	0.31	Type 2 diabetes;	chr4:102879037	chr4:102828055~102844075:+
LUAD	cis	rs2842992	0.83	rs2758320	ENSG00000237927.1	RP3-393E18.2	-7.16	3.13e-12	2.22e-09	-0.43	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159649644	chr6:159586955~159589169:-
LUAD	cis	rs7567389	0.638	rs12105051	ENSG00000236682.1	AC068282.3	7.16	3.14e-12	2.22e-09	0.44	0.31	Self-rated health;	chr2:127232601	chr2:127389130~127400580:+
LUAD	cis	rs9322193	0.962	rs2151912	ENSG00000223701.3	RAET1E-AS1	7.16	3.14e-12	2.22e-09	0.37	0.31	Lung cancer;	chr6:149831772	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.847	rs56103941	ENSG00000223701.3	RAET1E-AS1	7.15	3.15e-12	2.23e-09	0.37	0.31	Lung cancer;	chr6:149816095	chr6:149884431~149919508:+
LUAD	cis	rs77204473	0.744	rs12273536	ENSG00000254851.1	RP11-109L13.1	7.15	3.16e-12	2.24e-09	0.76	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117040255	chr11:117135528~117138582:+
LUAD	cis	rs2919917	0.628	rs6997255	ENSG00000254352.1	RP11-578O24.2	7.15	3.16e-12	2.24e-09	0.41	0.31	Lymphocyte counts;	chr8:78694850	chr8:78723796~78724136:-
LUAD	cis	rs2919917	0.628	rs7017898	ENSG00000254352.1	RP11-578O24.2	7.15	3.16e-12	2.24e-09	0.41	0.31	Lymphocyte counts;	chr8:78697147	chr8:78723796~78724136:-
LUAD	cis	rs67311347	1	rs6801859	ENSG00000223797.4	ENTPD3-AS1	-7.15	3.17e-12	2.24e-09	-0.33	-0.31	Renal cell carcinoma;	chr3:40451727	chr3:40313802~40453329:-
LUAD	cis	rs17711722	0.522	rs6957759	ENSG00000226824.5	RP4-756H11.3	-7.15	3.17e-12	2.24e-09	-0.38	-0.31	Calcium levels;	chr7:65806798	chr7:66654538~66669855:+
LUAD	cis	rs12134133	0.962	rs7526658	ENSG00000274245.1	RP11-357P18.2	7.15	3.18e-12	2.25e-09	0.41	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207240098	chr1:207372559~207373252:+
LUAD	cis	rs12134133	0.962	rs7516416	ENSG00000274245.1	RP11-357P18.2	7.15	3.18e-12	2.25e-09	0.41	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241050	chr1:207372559~207373252:+
LUAD	cis	rs12134133	0.962	rs6673890	ENSG00000274245.1	RP11-357P18.2	7.15	3.18e-12	2.25e-09	0.41	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241788	chr1:207372559~207373252:+
LUAD	cis	rs2243480	1	rs778679	ENSG00000273142.1	RP11-458F8.4	-7.15	3.18e-12	2.25e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66375924	chr7:66902857~66906297:+
LUAD	cis	rs6860806	0.507	rs272872	ENSG00000233006.5	AC034220.3	-7.15	3.18e-12	2.25e-09	-0.3	-0.31	Breast cancer;	chr5:132340171	chr5:132311285~132369916:-
LUAD	cis	rs11098499	0.866	rs3756156	ENSG00000248280.1	RP11-33B1.2	7.15	3.19e-12	2.25e-09	0.4	0.31	Corneal astigmatism;	chr4:119603686	chr4:119440561~119450157:-
LUAD	cis	rs2243480	1	rs1499614	ENSG00000273142.1	RP11-458F8.4	-7.15	3.19e-12	2.26e-09	-0.31	-0.31	Diabetic kidney disease;	chr7:66265811	chr7:66902857~66906297:+
LUAD	cis	rs7246657	0.823	rs4802236	ENSG00000276846.1	CTD-3220F14.3	7.15	3.2e-12	2.26e-09	0.43	0.31	Coronary artery calcification;	chr19:37428344	chr19:37314868~37315620:-
LUAD	cis	rs72772090	0.539	rs11739020	ENSG00000248734.2	CTD-2260A17.1	7.15	3.2e-12	2.26e-09	0.46	0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96778134	chr5:96784777~96785999:+
LUAD	cis	rs6142102	0.961	rs2056990	ENSG00000276073.1	RP5-1125A11.7	-7.15	3.21e-12	2.27e-09	-0.33	-0.31	Skin pigmentation;	chr20:34035658	chr20:33985617~33988989:-
LUAD	cis	rs75422866	0.867	rs73102188	ENSG00000257433.4	RP1-197B17.3	7.15	3.22e-12	2.28e-09	0.67	0.31	Pneumonia;	chr12:47662993	chr12:47706085~47742294:+
LUAD	cis	rs12220777	0.892	rs7083787	ENSG00000230091.5	TMEM254-AS1	7.15	3.22e-12	2.28e-09	0.58	0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80029185	chr10:80046860~80078912:-
LUAD	cis	rs11098499	0.863	rs11098532	ENSG00000248280.1	RP11-33B1.2	7.15	3.24e-12	2.29e-09	0.4	0.31	Corneal astigmatism;	chr4:119569571	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs13140391	ENSG00000248280.1	RP11-33B1.2	7.15	3.24e-12	2.29e-09	0.4	0.31	Corneal astigmatism;	chr4:119582282	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs13140409	ENSG00000248280.1	RP11-33B1.2	7.15	3.24e-12	2.29e-09	0.4	0.31	Corneal astigmatism;	chr4:119582305	chr4:119440561~119450157:-
LUAD	cis	rs867371	1	rs1174543	ENSG00000255769.6	GOLGA2P10	7.15	3.24e-12	2.29e-09	0.33	0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82155732	chr15:82472993~82513950:-
LUAD	cis	rs8081395	0.801	rs2777895	ENSG00000266992.1	DHX40P1	-7.15	3.24e-12	2.29e-09	-0.35	-0.31	White blood cell count;	chr17:59802249	chr17:59976009~60002384:-
LUAD	cis	rs8081395	0.769	rs12449331	ENSG00000266992.1	DHX40P1	-7.15	3.24e-12	2.29e-09	-0.35	-0.31	White blood cell count;	chr17:59806285	chr17:59976009~60002384:-
LUAD	cis	rs748404	0.578	rs510108	ENSG00000249839.1	AC011330.5	-7.15	3.24e-12	2.29e-09	-0.41	-0.31	Lung cancer;	chr15:43313241	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.578	rs507178	ENSG00000249839.1	AC011330.5	-7.15	3.24e-12	2.29e-09	-0.41	-0.31	Lung cancer;	chr15:43317937	chr15:43663654~43684339:-
LUAD	cis	rs867371	1	rs11855089	ENSG00000255769.6	GOLGA2P10	-7.15	3.26e-12	2.3e-09	-0.33	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82154924	chr15:82472993~82513950:-
LUAD	cis	rs2337406	0.81	rs7161739	ENSG00000211974.3	IGHV2-70	-7.15	3.27e-12	2.31e-09	-0.41	-0.31	Alzheimer's disease (late onset);	chr14:106776118	chr14:106723574~106724093:-
LUAD	cis	rs748404	0.646	rs2253268	ENSG00000249839.1	AC011330.5	-7.15	3.28e-12	2.32e-09	-0.41	-0.31	Lung cancer;	chr15:43508770	chr15:43663654~43684339:-
LUAD	cis	rs9595908	0.965	rs9595795	ENSG00000212293.1	SNORA16	7.15	3.3e-12	2.33e-09	0.36	0.31	Body mass index;	chr13:32548658	chr13:32420390~32420516:-
LUAD	cis	rs8059260	0.736	rs7200623	ENSG00000274038.1	RP11-66H6.4	-7.15	3.31e-12	2.34e-09	-0.57	-0.31	Alcohol consumption over the past year;	chr16:11001188	chr16:11056556~11057034:+
LUAD	cis	rs9660180	1	rs9660180	ENSG00000268575.1	RP1-283E3.8	-7.15	3.32e-12	2.35e-09	-0.28	-0.31	Body mass index;	chr1:1791592	chr1:1702736~1737688:-
LUAD	cis	rs9640161	0.789	rs28432021	ENSG00000261305.1	RP4-584D14.7	7.15	3.33e-12	2.35e-09	0.45	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150349146	chr7:150341771~150342607:+
LUAD	cis	rs2286503	0.901	rs10950922	ENSG00000228649.7	AC005682.5	7.15	3.33e-12	2.35e-09	0.38	0.31	Fibrinogen;	chr7:22814387	chr7:22854178~22861579:+
LUAD	cis	rs8005677	1	rs4982709	ENSG00000279656.1	RP11-298I3.6	7.15	3.33e-12	2.35e-09	0.37	0.31	Cognitive ability (multi-trait analysis);	chr14:22925490	chr14:23023083~23024217:-
LUAD	cis	rs7044106	0.791	rs4837793	ENSG00000238181.2	AHCYP2	-7.15	3.33e-12	2.35e-09	-0.41	-0.31	Hip circumference adjusted for BMI;	chr9:120721343	chr9:120720673~120721972:+
LUAD	cis	rs11098499	0.82	rs13122709	ENSG00000248280.1	RP11-33B1.2	7.15	3.33e-12	2.35e-09	0.4	0.31	Corneal astigmatism;	chr4:119634201	chr4:119440561~119450157:-
LUAD	cis	rs2243480	1	rs4718334	ENSG00000273142.1	RP11-458F8.4	7.15	3.34e-12	2.35e-09	0.32	0.31	Diabetic kidney disease;	chr7:66324467	chr7:66902857~66906297:+
LUAD	cis	rs7688540	0.771	rs11248013	ENSG00000275426.1	CH17-262A2.1	7.15	3.34e-12	2.36e-09	0.46	0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:317636	chr4:149738~150317:+
LUAD	cis	rs748404	0.518	rs480108	ENSG00000249839.1	AC011330.5	-7.15	3.34e-12	2.36e-09	-0.41	-0.31	Lung cancer;	chr15:43525208	chr15:43663654~43684339:-
LUAD	cis	rs6142102	0.961	rs1007090	ENSG00000276073.1	RP5-1125A11.7	-7.15	3.34e-12	2.36e-09	-0.33	-0.31	Skin pigmentation;	chr20:33995065	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.923	rs2284377	ENSG00000276073.1	RP5-1125A11.7	-7.15	3.34e-12	2.36e-09	-0.33	-0.31	Skin pigmentation;	chr20:33998876	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.961	rs2284378	ENSG00000276073.1	RP5-1125A11.7	-7.15	3.34e-12	2.36e-09	-0.33	-0.31	Skin pigmentation;	chr20:34000289	chr20:33985617~33988989:-
LUAD	cis	rs2300206	1	rs2300206	ENSG00000276073.1	RP5-1125A11.7	-7.15	3.34e-12	2.36e-09	-0.33	-0.31	Cancer (pleiotropy);Cancer;	chr20:34002002	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.961	rs2284379	ENSG00000276073.1	RP5-1125A11.7	-7.15	3.34e-12	2.36e-09	-0.33	-0.31	Skin pigmentation;	chr20:34006836	chr20:33985617~33988989:-
LUAD	cis	rs6142102	0.961	rs2268080	ENSG00000276073.1	RP5-1125A11.7	-7.15	3.34e-12	2.36e-09	-0.33	-0.31	Skin pigmentation;	chr20:34009910	chr20:33985617~33988989:-
LUAD	cis	rs7246657	0.653	rs10414983	ENSG00000276846.1	CTD-3220F14.3	7.15	3.35e-12	2.36e-09	0.48	0.31	Coronary artery calcification;	chr19:37174830	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.598	rs10405372	ENSG00000276846.1	CTD-3220F14.3	7.15	3.35e-12	2.36e-09	0.48	0.31	Coronary artery calcification;	chr19:37177873	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.653	rs10425441	ENSG00000276846.1	CTD-3220F14.3	7.15	3.35e-12	2.36e-09	0.48	0.31	Coronary artery calcification;	chr19:37179746	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.653	rs4805207	ENSG00000276846.1	CTD-3220F14.3	7.15	3.35e-12	2.36e-09	0.48	0.31	Coronary artery calcification;	chr19:37182831	chr19:37314868~37315620:-
LUAD	cis	rs67311347	1	rs2276870	ENSG00000223797.4	ENTPD3-AS1	-7.14	3.35e-12	2.37e-09	-0.33	-0.31	Renal cell carcinoma;	chr3:40457691	chr3:40313802~40453329:-
LUAD	cis	rs12134133	1	rs10494890	ENSG00000274245.1	RP11-357P18.2	-7.14	3.36e-12	2.37e-09	-0.4	-0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207251041	chr1:207372559~207373252:+
LUAD	cis	rs2153535	0.58	rs4960433	ENSG00000230939.1	RP11-314C16.1	-7.14	3.36e-12	2.37e-09	-0.36	-0.31	Motion sickness;	chr6:8523464	chr6:8784178~8785445:+
LUAD	cis	rs2243480	1	rs427044	ENSG00000273142.1	RP11-458F8.4	-7.14	3.36e-12	2.37e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66043558	chr7:66902857~66906297:+
LUAD	cis	rs7017914	0.967	rs13257800	ENSG00000223220.1	Y_RNA	7.14	3.36e-12	2.37e-09	0.34	0.31	Bone mineral density;	chr8:70801898	chr8:70780914~70781008:-
LUAD	cis	rs1167827	1	rs1167827	ENSG00000278416.1	PMS2L2	7.14	3.37e-12	2.37e-09	0.38	0.31	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75344015~75359550:-
LUAD	cis	rs6504950	0.924	rs244338	ENSG00000275710.1	RP11-257O5.4	7.14	3.37e-12	2.38e-09	0.37	0.31	Breast cancer;	chr17:55123057	chr17:54964474~54964679:+
LUAD	cis	rs6991838	0.733	rs10111844	ENSG00000272010.1	CTD-3025N20.3	7.14	3.38e-12	2.39e-09	0.32	0.31	Intelligence (multi-trait analysis);	chr8:65690374	chr8:65591850~65592472:-
LUAD	cis	rs12922040	1	rs12922040	ENSG00000263335.1	AF001548.5	-7.14	3.38e-12	2.39e-09	-0.39	-0.31	Serum uric acid levels in response to allopurinol in gout;	chr16:15775609	chr16:15726674~15732993:+
LUAD	cis	rs8031584	0.652	rs2691683	ENSG00000260382.1	RP11-540B6.2	-7.14	3.39e-12	2.39e-09	-0.39	-0.31	Huntington's disease progression;	chr15:30842857	chr15:30882267~30883231:-
LUAD	cis	rs11098499	0.865	rs9994730	ENSG00000248280.1	RP11-33B1.2	7.14	3.39e-12	2.39e-09	0.4	0.31	Corneal astigmatism;	chr4:119460409	chr4:119440561~119450157:-
LUAD	cis	rs2153535	0.601	rs9502719	ENSG00000230939.1	RP11-314C16.1	-7.14	3.4e-12	2.39e-09	-0.37	-0.31	Motion sickness;	chr6:8540799	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.547	rs9502720	ENSG00000230939.1	RP11-314C16.1	-7.14	3.4e-12	2.39e-09	-0.37	-0.31	Motion sickness;	chr6:8541129	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.547	rs9505475	ENSG00000230939.1	RP11-314C16.1	-7.14	3.4e-12	2.39e-09	-0.37	-0.31	Motion sickness;	chr6:8542657	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.601	rs6906170	ENSG00000230939.1	RP11-314C16.1	-7.14	3.4e-12	2.39e-09	-0.37	-0.31	Motion sickness;	chr6:8542895	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.601	rs330105	ENSG00000230939.1	RP11-314C16.1	-7.14	3.4e-12	2.39e-09	-0.37	-0.31	Motion sickness;	chr6:8543748	chr6:8784178~8785445:+
LUAD	cis	rs11089937	0.651	rs928894	ENSG00000211639.2	IGLV4-60	7.14	3.4e-12	2.39e-09	0.32	0.31	Periodontitis (PAL4Q3);	chr22:22185882	chr22:22162199~22162681:+
LUAD	cis	rs11098499	0.954	rs11098525	ENSG00000248280.1	RP11-33B1.2	7.14	3.41e-12	2.4e-09	0.4	0.31	Corneal astigmatism;	chr4:119468997	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs3733523	ENSG00000248280.1	RP11-33B1.2	7.14	3.41e-12	2.41e-09	0.4	0.31	Corneal astigmatism;	chr4:119502564	chr4:119440561~119450157:-
LUAD	cis	rs9601248	0.838	rs6563121	ENSG00000227676.3	LINC01068	-7.14	3.42e-12	2.41e-09	-0.38	-0.31	Major depressive disorder;	chr13:79600865	chr13:79566727~79571436:+
LUAD	cis	rs11098499	0.954	rs3890049	ENSG00000248280.1	RP11-33B1.2	7.14	3.43e-12	2.42e-09	0.4	0.31	Corneal astigmatism;	chr4:119405128	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs71629403	ENSG00000248280.1	RP11-33B1.2	7.14	3.43e-12	2.42e-09	0.4	0.31	Corneal astigmatism;	chr4:119451412	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.909	rs28571712	ENSG00000248280.1	RP11-33B1.2	7.14	3.43e-12	2.42e-09	0.4	0.31	Corneal astigmatism;	chr4:119454825	chr4:119440561~119450157:-
LUAD	cis	rs2153535	0.58	rs1119689	ENSG00000230939.1	RP11-314C16.1	-7.14	3.44e-12	2.42e-09	-0.37	-0.31	Motion sickness;	chr6:8460521	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs2327060	ENSG00000230939.1	RP11-314C16.1	-7.14	3.44e-12	2.42e-09	-0.36	-0.31	Motion sickness;	chr6:8446878	chr6:8784178~8785445:+
LUAD	cis	rs11098499	0.909	rs73842633	ENSG00000248280.1	RP11-33B1.2	7.14	3.44e-12	2.43e-09	0.4	0.31	Corneal astigmatism;	chr4:119454309	chr4:119440561~119450157:-
LUAD	cis	rs748404	0.697	rs493444	ENSG00000205771.5	CATSPER2P1	-7.14	3.45e-12	2.43e-09	-0.39	-0.31	Lung cancer;	chr15:43274272	chr15:43726918~43747094:-
LUAD	cis	rs12439619	1	rs35152457	ENSG00000255769.6	GOLGA2P10	-7.14	3.46e-12	2.43e-09	-0.35	-0.31	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82472993~82513950:-
LUAD	cis	rs17818399	0.62	rs1080871	ENSG00000279254.1	RP11-536C12.1	-7.14	3.46e-12	2.44e-09	-0.32	-0.31	Height;	chr2:46627569	chr2:46668870~46670778:+
LUAD	cis	rs9322193	0.962	rs35443312	ENSG00000223701.3	RAET1E-AS1	7.14	3.47e-12	2.44e-09	0.36	0.31	Lung cancer;	chr6:149670625	chr6:149884431~149919508:+
LUAD	cis	rs2283792	1	rs2006893	ENSG00000224086.5	LL22NC03-86G7.1	-7.14	3.48e-12	2.45e-09	-0.3	-0.31	Multiple sclerosis;	chr22:21774389	chr22:21938293~21977632:+
LUAD	cis	rs8040855	0.542	rs2342122	ENSG00000259774.1	RP11-182J1.13	-7.14	3.49e-12	2.45e-09	-0.37	-0.31	Bulimia nervosa;	chr15:85185304	chr15:84422618~84425882:+
LUAD	cis	rs8040855	0.644	rs2342120	ENSG00000259774.1	RP11-182J1.13	-7.14	3.49e-12	2.45e-09	-0.37	-0.31	Bulimia nervosa;	chr15:85185589	chr15:84422618~84425882:+
LUAD	cis	rs950880	0.71	rs3821204	ENSG00000234389.1	AC007278.3	-7.14	3.49e-12	2.46e-09	-0.32	-0.31	Serum protein levels (sST2);	chr2:102343821	chr2:102438713~102440475:+
LUAD	cis	rs9309711	0.922	rs11679058	ENSG00000225234.1	TRAPPC12-AS1	-7.14	3.5e-12	2.46e-09	-0.39	-0.31	Neurofibrillary tangles;	chr2:3480042	chr2:3481242~3482409:-
LUAD	cis	rs1345301	1	rs1345302	ENSG00000234389.1	AC007278.3	-7.14	3.5e-12	2.46e-09	-0.28	-0.31	Waist circumference;	chr2:102256909	chr2:102438713~102440475:+
LUAD	cis	rs1345301	1	rs13431601	ENSG00000234389.1	AC007278.3	-7.14	3.5e-12	2.46e-09	-0.28	-0.31	Waist circumference;	chr2:102257253	chr2:102438713~102440475:+
LUAD	cis	rs2243480	1	rs6964245	ENSG00000273142.1	RP11-458F8.4	7.14	3.51e-12	2.47e-09	0.32	0.31	Diabetic kidney disease;	chr7:66253730	chr7:66902857~66906297:+
LUAD	cis	rs9487094	0.689	rs4636056	ENSG00000260273.1	RP11-425D10.10	7.14	3.54e-12	2.49e-09	0.38	0.31	Height;	chr6:109409679	chr6:109382795~109383666:+
LUAD	cis	rs748404	0.697	rs546170	ENSG00000205771.5	CATSPER2P1	-7.14	3.55e-12	2.5e-09	-0.39	-0.31	Lung cancer;	chr15:43272651	chr15:43726918~43747094:-
LUAD	cis	rs944289	0.966	rs2415317	ENSG00000257826.1	RP11-116N8.4	7.14	3.55e-12	2.5e-09	0.33	0.31	Thyroid cancer;	chr14:36140472	chr14:36061026~36067190:-
LUAD	cis	rs11676348	0.774	rs13397673	ENSG00000261338.2	RP11-378A13.1	-7.14	3.56e-12	2.5e-09	-0.32	-0.31	Ulcerative colitis;	chr2:218183059	chr2:218255319~218257366:+
LUAD	cis	rs11098499	0.954	rs11729521	ENSG00000248280.1	RP11-33B1.2	7.14	3.56e-12	2.5e-09	0.4	0.31	Corneal astigmatism;	chr4:119495633	chr4:119440561~119450157:-
LUAD	cis	rs2243480	1	rs316327	ENSG00000273142.1	RP11-458F8.4	7.14	3.57e-12	2.51e-09	0.31	0.31	Diabetic kidney disease;	chr7:66144214	chr7:66902857~66906297:+
LUAD	cis	rs748404	0.697	rs554001	ENSG00000205771.5	CATSPER2P1	-7.14	3.58e-12	2.51e-09	-0.39	-0.31	Lung cancer;	chr15:43259721	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.697	rs501884	ENSG00000205771.5	CATSPER2P1	-7.14	3.58e-12	2.51e-09	-0.39	-0.31	Lung cancer;	chr15:43261784	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.697	rs504417	ENSG00000205771.5	CATSPER2P1	-7.14	3.58e-12	2.51e-09	-0.39	-0.31	Lung cancer;	chr15:43262028	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.723	rs560134	ENSG00000205771.5	CATSPER2P1	-7.14	3.58e-12	2.51e-09	-0.39	-0.31	Lung cancer;	chr15:43263501	chr15:43726918~43747094:-
LUAD	cis	rs2842992	0.75	rs2758354	ENSG00000237927.1	RP3-393E18.2	-7.13	3.58e-12	2.52e-09	-0.44	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159704822	chr6:159586955~159589169:-
LUAD	cis	rs9660180	1	rs3737628	ENSG00000268575.1	RP1-283E3.8	-7.13	3.58e-12	2.52e-09	-0.27	-0.31	Body mass index;	chr1:1791493	chr1:1702736~1737688:-
LUAD	cis	rs10759883	0.627	rs10760189	ENSG00000175611.10	LINC00476	7.13	3.59e-12	2.52e-09	0.37	0.31	Nicotine dependence;	chr9:95838543	chr9:95759231~95875977:-
LUAD	cis	rs2153535	0.601	rs9505472	ENSG00000230939.1	RP11-314C16.1	-7.13	3.6e-12	2.53e-09	-0.37	-0.31	Motion sickness;	chr6:8538532	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.601	rs9505473	ENSG00000230939.1	RP11-314C16.1	-7.13	3.6e-12	2.53e-09	-0.37	-0.31	Motion sickness;	chr6:8538544	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1832101	ENSG00000230939.1	RP11-314C16.1	-7.13	3.61e-12	2.54e-09	-0.37	-0.31	Motion sickness;	chr6:8459944	chr6:8784178~8785445:+
LUAD	cis	rs12134133	0.927	rs4844589	ENSG00000274245.1	RP11-357P18.2	7.13	3.62e-12	2.54e-09	0.4	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207259285	chr1:207372559~207373252:+
LUAD	cis	rs12134133	1	rs6684804	ENSG00000274245.1	RP11-357P18.2	7.13	3.62e-12	2.54e-09	0.4	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207265670	chr1:207372559~207373252:+
LUAD	cis	rs2153535	0.58	rs7748455	ENSG00000230939.1	RP11-314C16.1	-7.13	3.62e-12	2.55e-09	-0.36	-0.31	Motion sickness;	chr6:8453392	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs7743418	ENSG00000230939.1	RP11-314C16.1	-7.13	3.63e-12	2.55e-09	-0.36	-0.31	Motion sickness;	chr6:8437895	chr6:8784178~8785445:+
LUAD	cis	rs11098499	0.865	rs28634456	ENSG00000248280.1	RP11-33B1.2	7.13	3.63e-12	2.55e-09	0.4	0.31	Corneal astigmatism;	chr4:119454623	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.909	rs78332141	ENSG00000248280.1	RP11-33B1.2	7.13	3.63e-12	2.55e-09	0.4	0.31	Corneal astigmatism;	chr4:119454627	chr4:119440561~119450157:-
LUAD	cis	rs867371	1	rs9944197	ENSG00000255769.6	GOLGA2P10	-7.13	3.64e-12	2.56e-09	-0.33	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82158261	chr15:82472993~82513950:-
LUAD	cis	rs867371	1	rs1392976	ENSG00000255769.6	GOLGA2P10	7.13	3.64e-12	2.56e-09	0.33	0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82153834	chr15:82472993~82513950:-
LUAD	cis	rs113835537	0.529	rs4930378	ENSG00000255517.5	CTD-3074O7.5	-7.13	3.64e-12	2.56e-09	-0.36	-0.31	Airway imaging phenotypes;	chr11:66488044	chr11:66473490~66480233:-
LUAD	cis	rs67311347	0.955	rs2123999	ENSG00000223797.4	ENTPD3-AS1	7.13	3.64e-12	2.56e-09	0.32	0.31	Renal cell carcinoma;	chr3:40337247	chr3:40313802~40453329:-
LUAD	cis	rs34779708	0.643	rs4275563	ENSG00000230534.5	RP11-297A16.2	7.13	3.65e-12	2.56e-09	0.37	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35256358	chr10:35098006~35127020:-
LUAD	cis	rs2286503	0.901	rs2286505	ENSG00000228649.7	AC005682.5	7.13	3.65e-12	2.56e-09	0.38	0.31	Fibrinogen;	chr7:22815221	chr7:22854178~22861579:+
LUAD	cis	rs2153535	0.58	rs9406158	ENSG00000230939.1	RP11-314C16.1	-7.13	3.65e-12	2.56e-09	-0.36	-0.31	Motion sickness;	chr6:8463919	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9406159	ENSG00000230939.1	RP11-314C16.1	-7.13	3.65e-12	2.56e-09	-0.36	-0.31	Motion sickness;	chr6:8464626	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1335637	ENSG00000230939.1	RP11-314C16.1	-7.13	3.65e-12	2.56e-09	-0.36	-0.31	Motion sickness;	chr6:8464868	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9406162	ENSG00000230939.1	RP11-314C16.1	-7.13	3.65e-12	2.56e-09	-0.36	-0.31	Motion sickness;	chr6:8465963	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.541	rs9392222	ENSG00000230939.1	RP11-314C16.1	-7.13	3.65e-12	2.56e-09	-0.36	-0.31	Motion sickness;	chr6:8467416	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.541	rs6932434	ENSG00000230939.1	RP11-314C16.1	-7.13	3.65e-12	2.56e-09	-0.36	-0.31	Motion sickness;	chr6:8467446	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1034273	ENSG00000230939.1	RP11-314C16.1	-7.13	3.65e-12	2.56e-09	-0.36	-0.31	Motion sickness;	chr6:8467912	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.541	rs9328471	ENSG00000230939.1	RP11-314C16.1	-7.13	3.65e-12	2.56e-09	-0.36	-0.31	Motion sickness;	chr6:8468609	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.601	rs9505451	ENSG00000230939.1	RP11-314C16.1	-7.13	3.65e-12	2.56e-09	-0.36	-0.31	Motion sickness;	chr6:8469717	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9393023	ENSG00000230939.1	RP11-314C16.1	-7.13	3.65e-12	2.56e-09	-0.36	-0.31	Motion sickness;	chr6:8469761	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1414346	ENSG00000230939.1	RP11-314C16.1	-7.13	3.65e-12	2.56e-09	-0.36	-0.31	Motion sickness;	chr6:8471341	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1855769	ENSG00000230939.1	RP11-314C16.1	-7.13	3.65e-12	2.56e-09	-0.36	-0.31	Motion sickness;	chr6:8472862	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1932279	ENSG00000230939.1	RP11-314C16.1	-7.13	3.65e-12	2.56e-09	-0.36	-0.31	Motion sickness;	chr6:8473420	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs2152347	ENSG00000230939.1	RP11-314C16.1	-7.13	3.65e-12	2.56e-09	-0.36	-0.31	Motion sickness;	chr6:8474048	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9379213	ENSG00000230939.1	RP11-314C16.1	-7.13	3.65e-12	2.56e-09	-0.36	-0.31	Motion sickness;	chr6:8474712	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9505457	ENSG00000230939.1	RP11-314C16.1	-7.13	3.65e-12	2.56e-09	-0.36	-0.31	Motion sickness;	chr6:8478909	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.56	rs9379214	ENSG00000230939.1	RP11-314C16.1	-7.13	3.65e-12	2.56e-09	-0.36	-0.31	Motion sickness;	chr6:8480637	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs2225765	ENSG00000230939.1	RP11-314C16.1	-7.13	3.65e-12	2.56e-09	-0.36	-0.31	Motion sickness;	chr6:8481552	chr6:8784178~8785445:+
LUAD	cis	rs2243480	0.901	rs313808	ENSG00000273142.1	RP11-458F8.4	-7.13	3.65e-12	2.56e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66034886	chr7:66902857~66906297:+
LUAD	cis	rs853679	0.527	rs9468333	ENSG00000204709.4	LINC01556	7.13	3.65e-12	2.57e-09	0.39	0.31	Depression;	chr6:28303421	chr6:28943877~28944537:+
LUAD	cis	rs11098499	0.954	rs12499324	ENSG00000248280.1	RP11-33B1.2	7.13	3.66e-12	2.57e-09	0.39	0.31	Corneal astigmatism;	chr4:119472631	chr4:119440561~119450157:-
LUAD	cis	rs755249	1	rs61779359	ENSG00000228060.1	RP11-69E11.8	-7.13	3.68e-12	2.58e-09	-0.3	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39544563	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.959	rs61781363	ENSG00000228060.1	RP11-69E11.8	-7.13	3.68e-12	2.58e-09	-0.3	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39546761	chr1:39565160~39573203:+
LUAD	cis	rs755249	1	rs4660808	ENSG00000228060.1	RP11-69E11.8	-7.13	3.68e-12	2.58e-09	-0.3	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39552837	chr1:39565160~39573203:+
LUAD	cis	rs755249	1	rs61781364	ENSG00000228060.1	RP11-69E11.8	-7.13	3.68e-12	2.58e-09	-0.3	-0.31	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39553919	chr1:39565160~39573203:+
LUAD	cis	rs11098499	0.863	rs59732491	ENSG00000248280.1	RP11-33B1.2	7.13	3.68e-12	2.58e-09	0.4	0.31	Corneal astigmatism;	chr4:119568433	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs11723090	ENSG00000248280.1	RP11-33B1.2	7.13	3.68e-12	2.58e-09	0.4	0.31	Corneal astigmatism;	chr4:119569437	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs6822679	ENSG00000248280.1	RP11-33B1.2	7.13	3.68e-12	2.58e-09	0.4	0.31	Corneal astigmatism;	chr4:119481547	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs4577559	ENSG00000248280.1	RP11-33B1.2	7.13	3.68e-12	2.58e-09	0.4	0.31	Corneal astigmatism;	chr4:119482888	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs7656252	ENSG00000248280.1	RP11-33B1.2	7.13	3.68e-12	2.58e-09	0.4	0.31	Corneal astigmatism;	chr4:119483113	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.865	rs28845498	ENSG00000248280.1	RP11-33B1.2	7.13	3.68e-12	2.58e-09	0.4	0.31	Corneal astigmatism;	chr4:119484031	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs56270433	ENSG00000248280.1	RP11-33B1.2	7.13	3.68e-12	2.58e-09	0.4	0.31	Corneal astigmatism;	chr4:119484875	chr4:119440561~119450157:-
LUAD	cis	rs11214589	0.62	rs34601878	ENSG00000270179.1	RP11-159N11.4	-7.13	3.7e-12	2.6e-09	-0.31	-0.31	Neuroticism;	chr11:113390176	chr11:113368478~113369117:+
LUAD	cis	rs11098499	0.863	rs6833334	ENSG00000248280.1	RP11-33B1.2	7.13	3.72e-12	2.61e-09	0.4	0.31	Corneal astigmatism;	chr4:119583072	chr4:119440561~119450157:-
LUAD	cis	rs2286503	0.966	rs2286507	ENSG00000228649.7	AC005682.5	7.13	3.73e-12	2.62e-09	0.38	0.31	Fibrinogen;	chr7:22815141	chr7:22854178~22861579:+
LUAD	cis	rs2243480	0.901	rs778687	ENSG00000273142.1	RP11-458F8.4	-7.13	3.75e-12	2.63e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66370832	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs778704	ENSG00000273142.1	RP11-458F8.4	-7.13	3.75e-12	2.63e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66398480	chr7:66902857~66906297:+
LUAD	cis	rs2243480	0.901	rs778693	ENSG00000273142.1	RP11-458F8.4	-7.13	3.75e-12	2.63e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66407358	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs778691	ENSG00000273142.1	RP11-458F8.4	-7.13	3.75e-12	2.63e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66408105	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs13235972	ENSG00000273142.1	RP11-458F8.4	-7.13	3.75e-12	2.63e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66418618	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs34192067	ENSG00000273142.1	RP11-458F8.4	-7.13	3.75e-12	2.63e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66422670	chr7:66902857~66906297:+
LUAD	cis	rs6964833	0.554	rs112506907	ENSG00000123965.13	PMS2P5	7.13	3.78e-12	2.65e-09	0.43	0.31	Menarche (age at onset);	chr7:74654407	chr7:74894116~74897835:+
LUAD	cis	rs2303759	0.918	rs4802597	ENSG00000268686.1	AC010524.2	-7.13	3.79e-12	2.66e-09	-0.42	-0.31	Multiple sclerosis;	chr19:49368828	chr19:49368705~49388081:-
LUAD	cis	rs9549367	0.713	rs4907599	ENSG00000269125.1	RP11-98F14.11	7.13	3.8e-12	2.66e-09	0.38	0.31	Platelet distribution width;	chr13:113207127	chr13:113165002~113165183:-
LUAD	cis	rs9595908	0.9	rs9595890	ENSG00000212293.1	SNORA16	7.13	3.8e-12	2.66e-09	0.33	0.31	Body mass index;	chr13:32597518	chr13:32420390~32420516:-
LUAD	cis	rs10170846	0.861	rs7571732	ENSG00000261428.2	RP11-16P6.1	-7.13	3.8e-12	2.66e-09	-0.36	-0.31	Schizophrenia (inflammation and infection response interaction);	chr2:222673597	chr2:222566899~222569719:-
LUAD	cis	rs7246657	0.943	rs8106839	ENSG00000276846.1	CTD-3220F14.3	7.13	3.81e-12	2.67e-09	0.42	0.31	Coronary artery calcification;	chr19:37467573	chr19:37314868~37315620:-
LUAD	cis	rs748404	0.697	rs574065	ENSG00000205771.5	CATSPER2P1	7.13	3.81e-12	2.67e-09	0.38	0.31	Lung cancer;	chr15:43258457	chr15:43726918~43747094:-
LUAD	cis	rs8031584	0.723	rs711224	ENSG00000260382.1	RP11-540B6.2	-7.13	3.81e-12	2.67e-09	-0.39	-0.31	Huntington's disease progression;	chr15:30835718	chr15:30882267~30883231:-
LUAD	cis	rs10129255	0.957	rs8009464	ENSG00000280411.1	IGHV1-69-2	-7.13	3.82e-12	2.67e-09	-0.23	-0.31	Kawasaki disease;	chr14:106777611	chr14:106762092~106762588:-
LUAD	cis	rs748404	0.66	rs2602141	ENSG00000249839.1	AC011330.5	-7.13	3.82e-12	2.67e-09	-0.39	-0.31	Lung cancer;	chr15:43432448	chr15:43663654~43684339:-
LUAD	cis	rs2243480	1	rs316313	ENSG00000273142.1	RP11-458F8.4	-7.13	3.83e-12	2.68e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66128561	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs316312	ENSG00000273142.1	RP11-458F8.4	-7.13	3.83e-12	2.68e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66131504	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs419603	ENSG00000273142.1	RP11-458F8.4	-7.13	3.83e-12	2.68e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66132354	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs387676	ENSG00000273142.1	RP11-458F8.4	-7.13	3.83e-12	2.68e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66133233	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs13310597	ENSG00000273142.1	RP11-458F8.4	-7.13	3.83e-12	2.68e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66133553	chr7:66902857~66906297:+
LUAD	cis	rs10170846	0.789	rs972650	ENSG00000261428.2	RP11-16P6.1	7.12	3.84e-12	2.69e-09	0.36	0.31	Schizophrenia (inflammation and infection response interaction);	chr2:222655568	chr2:222566899~222569719:-
LUAD	cis	rs10170846	0.861	rs12694582	ENSG00000261428.2	RP11-16P6.1	7.12	3.84e-12	2.69e-09	0.36	0.31	Schizophrenia (inflammation and infection response interaction);	chr2:222657236	chr2:222566899~222569719:-
LUAD	cis	rs10170846	0.731	rs10180632	ENSG00000261428.2	RP11-16P6.1	7.12	3.84e-12	2.69e-09	0.36	0.31	Schizophrenia (inflammation and infection response interaction);	chr2:222661665	chr2:222566899~222569719:-
LUAD	cis	rs10170846	0.8	rs10180462	ENSG00000261428.2	RP11-16P6.1	7.12	3.84e-12	2.69e-09	0.36	0.31	Schizophrenia (inflammation and infection response interaction);	chr2:222661666	chr2:222566899~222569719:-
LUAD	cis	rs7246657	0.598	rs28660259	ENSG00000276846.1	CTD-3220F14.3	7.12	3.84e-12	2.69e-09	0.48	0.31	Coronary artery calcification;	chr19:37167779	chr19:37314868~37315620:-
LUAD	cis	rs9545047	0.604	rs2765078	ENSG00000227676.3	LINC01068	7.12	3.84e-12	2.69e-09	0.37	0.31	Schizophrenia;	chr13:79420604	chr13:79566727~79571436:+
LUAD	cis	rs748404	0.65	rs556851	ENSG00000205771.5	CATSPER2P1	-7.12	3.84e-12	2.69e-09	-0.39	-0.31	Lung cancer;	chr15:43279021	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.697	rs567357	ENSG00000205771.5	CATSPER2P1	-7.12	3.84e-12	2.69e-09	-0.39	-0.31	Lung cancer;	chr15:43279192	chr15:43726918~43747094:-
LUAD	cis	rs2243480	1	rs10247526	ENSG00000273142.1	RP11-458F8.4	7.12	3.85e-12	2.69e-09	0.32	0.31	Diabetic kidney disease;	chr7:66315709	chr7:66902857~66906297:+
LUAD	cis	rs7044106	0.791	rs2416799	ENSG00000238181.2	AHCYP2	-7.12	3.85e-12	2.7e-09	-0.4	-0.31	Hip circumference adjusted for BMI;	chr9:120718588	chr9:120720673~120721972:+
LUAD	cis	rs7044106	0.791	rs10984998	ENSG00000238181.2	AHCYP2	-7.12	3.85e-12	2.7e-09	-0.4	-0.31	Hip circumference adjusted for BMI;	chr9:120719238	chr9:120720673~120721972:+
LUAD	cis	rs11098499	0.865	rs28753180	ENSG00000248280.1	RP11-33B1.2	7.12	3.85e-12	2.7e-09	0.4	0.31	Corneal astigmatism;	chr4:119484212	chr4:119440561~119450157:-
LUAD	cis	rs9487094	0.626	rs3799845	ENSG00000260273.1	RP11-425D10.10	7.12	3.87e-12	2.71e-09	0.42	0.31	Height;	chr6:109706514	chr6:109382795~109383666:+
LUAD	cis	rs10759883	0.627	rs690528	ENSG00000175611.10	LINC00476	7.12	3.88e-12	2.72e-09	0.36	0.31	Nicotine dependence;	chr9:95876006	chr9:95759231~95875977:-
LUAD	cis	rs9595908	1	rs9595908	ENSG00000212293.1	SNORA16	7.12	3.89e-12	2.72e-09	0.34	0.31	Body mass index;	chr13:32610151	chr13:32420390~32420516:-
LUAD	cis	rs7208859	0.623	rs11651857	ENSG00000263531.1	RP13-753N3.1	7.12	3.9e-12	2.73e-09	0.64	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30599344	chr17:30863921~30864940:-
LUAD	cis	rs7246657	0.943	rs2303131	ENSG00000276846.1	CTD-3220F14.3	7.12	3.92e-12	2.74e-09	0.43	0.31	Coronary artery calcification;	chr19:37445123	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.882	rs10422667	ENSG00000276846.1	CTD-3220F14.3	7.12	3.92e-12	2.74e-09	0.43	0.31	Coronary artery calcification;	chr19:37446974	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs1015848	ENSG00000276846.1	CTD-3220F14.3	7.12	3.92e-12	2.74e-09	0.43	0.31	Coronary artery calcification;	chr19:37454372	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs4801759	ENSG00000276846.1	CTD-3220F14.3	7.12	3.92e-12	2.74e-09	0.43	0.31	Coronary artery calcification;	chr19:37464083	chr19:37314868~37315620:-
LUAD	cis	rs75422866	0.867	rs117388682	ENSG00000280054.1	RP1-197B17.7	7.12	3.93e-12	2.75e-09	0.7	0.31	Pneumonia;	chr12:47599713	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs79113930	ENSG00000280054.1	RP1-197B17.7	7.12	3.93e-12	2.75e-09	0.7	0.31	Pneumonia;	chr12:47600628	chr12:47728151~47730598:-
LUAD	cis	rs5753618	0.583	rs5749279	ENSG00000236132.1	CTA-440B3.1	-7.12	3.93e-12	2.75e-09	-0.36	-0.31	Colorectal cancer;	chr22:31458223	chr22:31816379~31817491:-
LUAD	cis	rs2153535	0.58	rs9393022	ENSG00000230939.1	RP11-314C16.1	-7.12	3.93e-12	2.75e-09	-0.36	-0.31	Motion sickness;	chr6:8466355	chr6:8784178~8785445:+
LUAD	cis	rs11098499	0.738	rs34965784	ENSG00000248280.1	RP11-33B1.2	7.12	3.94e-12	2.75e-09	0.4	0.31	Corneal astigmatism;	chr4:119440431	chr4:119440561~119450157:-
LUAD	cis	rs6142102	0.961	rs4911407	ENSG00000276073.1	RP5-1125A11.7	-7.12	3.94e-12	2.75e-09	-0.32	-0.31	Skin pigmentation;	chr20:34095759	chr20:33985617~33988989:-
LUAD	cis	rs2842992	0.83	rs2758352	ENSG00000237927.1	RP3-393E18.2	-7.12	3.94e-12	2.75e-09	-0.44	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159701889	chr6:159586955~159589169:-
LUAD	cis	rs8040855	0.621	rs6496796	ENSG00000259774.1	RP11-182J1.13	-7.12	3.94e-12	2.75e-09	-0.37	-0.31	Bulimia nervosa;	chr15:85183617	chr15:84422618~84425882:+
LUAD	cis	rs9595908	1	rs7999125	ENSG00000212293.1	SNORA16	7.12	3.94e-12	2.75e-09	0.35	0.31	Body mass index;	chr13:32571858	chr13:32420390~32420516:-
LUAD	cis	rs2243480	1	rs10807701	ENSG00000273142.1	RP11-458F8.4	7.12	3.95e-12	2.76e-09	0.32	0.31	Diabetic kidney disease;	chr7:66259699	chr7:66902857~66906297:+
LUAD	cis	rs2439831	0.867	rs2245715	ENSG00000205771.5	CATSPER2P1	-7.12	3.95e-12	2.76e-09	-0.53	-0.31	Lung cancer in ever smokers;	chr15:43525854	chr15:43726918~43747094:-
LUAD	cis	rs950880	0.553	rs2241116	ENSG00000234389.1	AC007278.3	-7.12	3.96e-12	2.77e-09	-0.34	-0.31	Serum protein levels (sST2);	chr2:102386805	chr2:102438713~102440475:+
LUAD	cis	rs950880	0.71	rs3771177	ENSG00000234389.1	AC007278.3	-7.12	3.97e-12	2.78e-09	-0.32	-0.31	Serum protein levels (sST2);	chr2:102339400	chr2:102438713~102440475:+
LUAD	cis	rs6921919	0.789	rs17301128	ENSG00000204709.4	LINC01556	7.12	3.98e-12	2.78e-09	0.44	0.31	Autism spectrum disorder or schizophrenia;	chr6:28340257	chr6:28943877~28944537:+
LUAD	cis	rs2455601	0.744	rs2568085	ENSG00000254860.4	TMEM9B-AS1	-7.12	3.98e-12	2.78e-09	-0.4	-0.31	Schizophrenia;	chr11:8954201	chr11:8964675~8977527:+
LUAD	cis	rs2243480	1	rs35396113	ENSG00000273142.1	RP11-458F8.4	-7.12	3.98e-12	2.78e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66030474	chr7:66902857~66906297:+
LUAD	cis	rs7811142	0.779	rs28680963	ENSG00000242294.5	STAG3L5P	7.12	3.98e-12	2.78e-09	0.27	0.31	Platelet count;	chr7:100307852	chr7:100336079~100351900:+
LUAD	cis	rs9322193	0.884	rs9383865	ENSG00000223701.3	RAET1E-AS1	7.12	4e-12	2.8e-09	0.37	0.31	Lung cancer;	chr6:149852043	chr6:149884431~149919508:+
LUAD	cis	rs748404	0.697	rs513970	ENSG00000205771.5	CATSPER2P1	-7.12	4.01e-12	2.8e-09	-0.39	-0.31	Lung cancer;	chr15:43287368	chr15:43726918~43747094:-
LUAD	cis	rs6903823	0.527	rs4713158	ENSG00000204709.4	LINC01556	7.12	4.01e-12	2.8e-09	0.39	0.31	Pulmonary function;	chr6:28309994	chr6:28943877~28944537:+
LUAD	cis	rs172166	0.694	rs536704	ENSG00000219392.1	RP1-265C24.5	-7.12	4.03e-12	2.81e-09	-0.4	-0.31	Cardiac Troponin-T levels;	chr6:28124825	chr6:28115628~28116551:+
LUAD	cis	rs2243480	1	rs316331	ENSG00000273142.1	RP11-458F8.4	7.12	4.03e-12	2.81e-09	0.32	0.31	Diabetic kidney disease;	chr7:66139635	chr7:66902857~66906297:+
LUAD	cis	rs7646881	0.812	rs73015644	ENSG00000240207.5	RP11-379F4.4	-7.12	4.03e-12	2.81e-09	-0.41	-0.31	Tetralogy of Fallot;	chr3:158729955	chr3:158732263~158784070:+
LUAD	cis	rs853679	0.517	rs4711164	ENSG00000219392.1	RP1-265C24.5	-7.12	4.04e-12	2.82e-09	-0.44	-0.31	Depression;	chr6:28147378	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs4711165	ENSG00000219392.1	RP1-265C24.5	-7.12	4.04e-12	2.82e-09	-0.44	-0.31	Depression;	chr6:28147406	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs4713148	ENSG00000219392.1	RP1-265C24.5	-7.12	4.04e-12	2.82e-09	-0.44	-0.31	Depression;	chr6:28148143	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9348794	ENSG00000219392.1	RP1-265C24.5	-7.12	4.04e-12	2.82e-09	-0.44	-0.31	Depression;	chr6:28149979	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9468297	ENSG00000219392.1	RP1-265C24.5	-7.12	4.04e-12	2.82e-09	-0.44	-0.31	Depression;	chr6:28151096	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs9295758	ENSG00000219392.1	RP1-265C24.5	-7.12	4.04e-12	2.82e-09	-0.44	-0.31	Depression;	chr6:28152885	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs17774663	ENSG00000219392.1	RP1-265C24.5	-7.12	4.04e-12	2.82e-09	-0.44	-0.31	Depression;	chr6:28153120	chr6:28115628~28116551:+
LUAD	cis	rs7646881	0.812	rs7624161	ENSG00000240207.5	RP11-379F4.4	-7.12	4.04e-12	2.82e-09	-0.39	-0.31	Tetralogy of Fallot;	chr3:158742125	chr3:158732263~158784070:+
LUAD	cis	rs7646881	0.812	rs113166116	ENSG00000240207.5	RP11-379F4.4	-7.12	4.04e-12	2.82e-09	-0.39	-0.31	Tetralogy of Fallot;	chr3:158742467	chr3:158732263~158784070:+
LUAD	cis	rs748404	0.586	rs2584700	ENSG00000249839.1	AC011330.5	-7.12	4.04e-12	2.82e-09	-0.4	-0.31	Lung cancer;	chr15:43393134	chr15:43663654~43684339:-
LUAD	cis	rs8031584	0.723	rs11632229	ENSG00000260382.1	RP11-540B6.2	-7.12	4.05e-12	2.82e-09	-0.36	-0.31	Huntington's disease progression;	chr15:30887331	chr15:30882267~30883231:-
LUAD	cis	rs11098499	0.697	rs11941899	ENSG00000248280.1	RP11-33B1.2	7.12	4.05e-12	2.82e-09	0.4	0.31	Corneal astigmatism;	chr4:119461603	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.909	rs7681978	ENSG00000248280.1	RP11-33B1.2	7.12	4.05e-12	2.82e-09	0.4	0.31	Corneal astigmatism;	chr4:119462620	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.821	rs28665282	ENSG00000248280.1	RP11-33B1.2	7.12	4.05e-12	2.82e-09	0.4	0.31	Corneal astigmatism;	chr4:119463031	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.738	rs10026493	ENSG00000248280.1	RP11-33B1.2	7.12	4.05e-12	2.82e-09	0.4	0.31	Corneal astigmatism;	chr4:119463039	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.909	rs7681214	ENSG00000248280.1	RP11-33B1.2	7.12	4.05e-12	2.82e-09	0.4	0.31	Corneal astigmatism;	chr4:119464165	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.908	rs71614449	ENSG00000248280.1	RP11-33B1.2	7.12	4.05e-12	2.82e-09	0.4	0.31	Corneal astigmatism;	chr4:119465900	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs35063680	ENSG00000248280.1	RP11-33B1.2	7.12	4.05e-12	2.82e-09	0.4	0.31	Corneal astigmatism;	chr4:119465947	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs34858317	ENSG00000248280.1	RP11-33B1.2	7.12	4.05e-12	2.82e-09	0.4	0.31	Corneal astigmatism;	chr4:119465955	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs17046116	ENSG00000248280.1	RP11-33B1.2	7.12	4.05e-12	2.82e-09	0.4	0.31	Corneal astigmatism;	chr4:119466104	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.909	rs17046118	ENSG00000248280.1	RP11-33B1.2	7.12	4.05e-12	2.82e-09	0.4	0.31	Corneal astigmatism;	chr4:119466341	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs7654587	ENSG00000248280.1	RP11-33B1.2	7.12	4.05e-12	2.82e-09	0.4	0.31	Corneal astigmatism;	chr4:119467251	chr4:119440561~119450157:-
LUAD	cis	rs2739330	0.76	rs5751760	ENSG00000228039.3	KB-1125A3.10	7.12	4.05e-12	2.82e-09	0.37	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23963780~23964374:+
LUAD	cis	rs10759883	0.563	rs624075	ENSG00000175611.10	LINC00476	7.12	4.07e-12	2.84e-09	0.36	0.31	Nicotine dependence;	chr9:95902665	chr9:95759231~95875977:-
LUAD	cis	rs7811142	0.779	rs111312383	ENSG00000242294.5	STAG3L5P	7.12	4.08e-12	2.84e-09	0.28	0.31	Platelet count;	chr7:100307702	chr7:100336079~100351900:+
LUAD	cis	rs2286503	0.78	rs1304431	ENSG00000228649.7	AC005682.5	7.12	4.08e-12	2.85e-09	0.39	0.31	Fibrinogen;	chr7:22825793	chr7:22854178~22861579:+
LUAD	cis	rs950880	0.71	rs2287035	ENSG00000234389.1	AC007278.3	-7.11	4.09e-12	2.85e-09	-0.32	-0.31	Serum protein levels (sST2);	chr2:102394070	chr2:102438713~102440475:+
LUAD	cis	rs10170846	0.861	rs4674677	ENSG00000261428.2	RP11-16P6.1	7.11	4.09e-12	2.85e-09	0.36	0.31	Schizophrenia (inflammation and infection response interaction);	chr2:222664939	chr2:222566899~222569719:-
LUAD	cis	rs2153535	0.58	rs6929206	ENSG00000230939.1	RP11-314C16.1	-7.11	4.1e-12	2.86e-09	-0.36	-0.31	Motion sickness;	chr6:8447728	chr6:8784178~8785445:+
LUAD	cis	rs10759883	0.627	rs689804	ENSG00000175611.10	LINC00476	7.11	4.11e-12	2.87e-09	0.36	0.31	Nicotine dependence;	chr9:95868574	chr9:95759231~95875977:-
LUAD	cis	rs11098499	0.58	rs12509234	ENSG00000248280.1	RP11-33B1.2	7.11	4.12e-12	2.87e-09	0.4	0.31	Corneal astigmatism;	chr4:119398279	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.909	rs10014719	ENSG00000248280.1	RP11-33B1.2	7.11	4.12e-12	2.87e-09	0.4	0.31	Corneal astigmatism;	chr4:119399560	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.908	rs7696649	ENSG00000248280.1	RP11-33B1.2	7.11	4.12e-12	2.87e-09	0.4	0.31	Corneal astigmatism;	chr4:119401022	chr4:119440561~119450157:-
LUAD	cis	rs2739330	0.731	rs4822450	ENSG00000206090.4	AP000350.7	7.11	4.13e-12	2.87e-09	0.34	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23939998~23942798:+
LUAD	cis	rs2153535	0.58	rs2143357	ENSG00000230939.1	RP11-314C16.1	-7.11	4.14e-12	2.88e-09	-0.37	-0.31	Motion sickness;	chr6:8496963	chr6:8784178~8785445:+
LUAD	cis	rs10800713	0.954	rs4623737	ENSG00000260088.1	RP11-92G12.3	-7.11	4.15e-12	2.89e-09	-0.37	-0.31	Tandem gait;	chr1:200594578	chr1:200669507~200694250:+
LUAD	cis	rs35955747	0.84	rs9621221	ENSG00000236132.1	CTA-440B3.1	7.11	4.16e-12	2.9e-09	0.34	0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31220183	chr22:31816379~31817491:-
LUAD	cis	rs10759883	0.587	rs2405134	ENSG00000175611.10	LINC00476	-7.11	4.17e-12	2.9e-09	-0.37	-0.31	Nicotine dependence;	chr9:95795179	chr9:95759231~95875977:-
LUAD	cis	rs950169	0.881	rs150965	ENSG00000259728.4	LINC00933	7.11	4.18e-12	2.91e-09	0.47	0.31	Schizophrenia;	chr15:84537296	chr15:84570649~84580175:+
LUAD	cis	rs7208859	0.562	rs11650923	ENSG00000263531.1	RP13-753N3.1	7.11	4.18e-12	2.91e-09	0.64	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30681149	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs56378576	ENSG00000263531.1	RP13-753N3.1	7.11	4.18e-12	2.91e-09	0.64	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30683102	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs35916850	ENSG00000263531.1	RP13-753N3.1	7.11	4.18e-12	2.91e-09	0.64	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30684155	chr17:30863921~30864940:-
LUAD	cis	rs10463554	0.895	rs3756583	ENSG00000175749.11	EIF3KP1	7.11	4.19e-12	2.92e-09	0.4	0.31	Parkinson's disease;	chr5:102998340	chr5:103032376~103033031:+
LUAD	cis	rs8081395	0.836	rs2150879	ENSG00000266992.1	DHX40P1	-7.11	4.19e-12	2.92e-09	-0.35	-0.31	White blood cell count;	chr17:59781849	chr17:59976009~60002384:-
LUAD	cis	rs12458462	0.892	rs2007483	ENSG00000274828.1	RP11-567M16.6	7.11	4.2e-12	2.92e-09	0.32	0.31	Monocyte count;	chr18:79716131	chr18:79677287~79679358:-
LUAD	cis	rs2337406	0.587	rs2583291	ENSG00000254174.1	IGHV1-12	-7.11	4.22e-12	2.93e-09	-0.27	-0.31	Alzheimer's disease (late onset);	chr14:106649293	chr14:106122420~106122709:-
LUAD	cis	rs8028182	0.537	rs4371118	ENSG00000260269.4	CTD-2323K18.1	-7.11	4.22e-12	2.94e-09	-0.48	-0.31	Sudden cardiac arrest;	chr15:75606549	chr15:75527150~75601205:-
LUAD	cis	rs904251	0.734	rs2797790	ENSG00000204110.6	RP1-153P14.8	7.11	4.22e-12	2.94e-09	0.33	0.31	Cognitive performance;	chr6:37479299	chr6:37507348~37535616:+
LUAD	cis	rs9640161	0.742	rs2159235	ENSG00000261305.1	RP4-584D14.7	7.11	4.23e-12	2.94e-09	0.44	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150320139	chr7:150341771~150342607:+
LUAD	cis	rs35955747	0.902	rs5997919	ENSG00000236132.1	CTA-440B3.1	7.11	4.25e-12	2.95e-09	0.34	0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31227456	chr22:31816379~31817491:-
LUAD	cis	rs11098499	0.908	rs28559989	ENSG00000248280.1	RP11-33B1.2	7.11	4.26e-12	2.96e-09	0.4	0.31	Corneal astigmatism;	chr4:119465472	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.909	rs28632018	ENSG00000248280.1	RP11-33B1.2	7.11	4.26e-12	2.96e-09	0.4	0.31	Corneal astigmatism;	chr4:119465575	chr4:119440561~119450157:-
LUAD	cis	rs6991838	0.67	rs13275168	ENSG00000272010.1	CTD-3025N20.3	7.11	4.27e-12	2.97e-09	0.32	0.31	Intelligence (multi-trait analysis);	chr8:65685107	chr8:65591850~65592472:-
LUAD	cis	rs9487094	0.67	rs13203587	ENSG00000260273.1	RP11-425D10.10	7.11	4.27e-12	2.97e-09	0.41	0.31	Height;	chr6:109499759	chr6:109382795~109383666:+
LUAD	cis	rs4964805	0.594	rs3812805	ENSG00000257681.1	RP11-341G23.4	7.11	4.28e-12	2.97e-09	0.36	0.31	Attention deficit hyperactivity disorder;	chr12:103777094	chr12:103746315~103768858:-
LUAD	cis	rs34779708	0.733	rs7081597	ENSG00000230534.5	RP11-297A16.2	7.11	4.28e-12	2.98e-09	0.37	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35257403	chr10:35098006~35127020:-
LUAD	cis	rs748404	0.697	rs546722	ENSG00000205771.5	CATSPER2P1	-7.11	4.29e-12	2.98e-09	-0.39	-0.31	Lung cancer;	chr15:43288621	chr15:43726918~43747094:-
LUAD	cis	rs6142102	0.961	rs6088360	ENSG00000276073.1	RP5-1125A11.7	-7.11	4.29e-12	2.98e-09	-0.33	-0.31	Skin pigmentation;	chr20:33969383	chr20:33985617~33988989:-
LUAD	cis	rs7246657	0.653	rs10401525	ENSG00000276846.1	CTD-3220F14.3	7.11	4.3e-12	2.99e-09	0.48	0.31	Coronary artery calcification;	chr19:37168077	chr19:37314868~37315620:-
LUAD	cis	rs1499614	0.901	rs2178742	ENSG00000273142.1	RP11-458F8.4	-7.11	4.3e-12	2.99e-09	-0.33	-0.31	Gout;	chr7:66732812	chr7:66902857~66906297:+
LUAD	cis	rs7646881	0.812	rs7635704	ENSG00000240207.5	RP11-379F4.4	-7.11	4.3e-12	2.99e-09	-0.39	-0.31	Tetralogy of Fallot;	chr3:158741931	chr3:158732263~158784070:+
LUAD	cis	rs2919917	0.628	rs1036751	ENSG00000254352.1	RP11-578O24.2	-7.11	4.31e-12	2.99e-09	-0.41	-0.31	Lymphocyte counts;	chr8:78729671	chr8:78723796~78724136:-
LUAD	cis	rs2153535	0.601	rs4140584	ENSG00000230939.1	RP11-314C16.1	7.11	4.31e-12	2.99e-09	0.37	0.31	Motion sickness;	chr6:8540381	chr6:8784178~8785445:+
LUAD	cis	rs3096299	0.967	rs28644774	ENSG00000274627.1	RP11-104N10.2	7.11	4.31e-12	3e-09	0.29	0.31	Multiple myeloma (IgH translocation);	chr16:89405773	chr16:89516797~89522217:+
LUAD	cis	rs2439831	0.681	rs1549523	ENSG00000205771.5	CATSPER2P1	-7.11	4.32e-12	3e-09	-0.52	-0.31	Lung cancer in ever smokers;	chr15:43331991	chr15:43726918~43747094:-
LUAD	cis	rs12220777	1	rs11201799	ENSG00000230091.5	TMEM254-AS1	-7.11	4.33e-12	3.01e-09	-0.57	-0.31	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80122198	chr10:80046860~80078912:-
LUAD	cis	rs10759883	0.627	rs689697	ENSG00000175611.10	LINC00476	7.11	4.33e-12	3.01e-09	0.36	0.31	Nicotine dependence;	chr9:95876560	chr9:95759231~95875977:-
LUAD	cis	rs950880	0.71	rs3732129	ENSG00000234389.1	AC007278.3	-7.11	4.34e-12	3.01e-09	-0.32	-0.31	Serum protein levels (sST2);	chr2:102341072	chr2:102438713~102440475:+
LUAD	cis	rs1501911	0.509	rs330422	ENSG00000248489.1	CTD-2007H13.3	7.11	4.34e-12	3.02e-09	0.33	0.31	Lung function (FEV1/FVC);	chr5:98859184	chr5:98929171~98995013:+
LUAD	cis	rs748404	0.66	rs542898	ENSG00000249839.1	AC011330.5	-7.11	4.35e-12	3.02e-09	-0.4	-0.31	Lung cancer;	chr15:43427194	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.66	rs690012	ENSG00000249839.1	AC011330.5	-7.11	4.35e-12	3.02e-09	-0.4	-0.31	Lung cancer;	chr15:43427557	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.66	rs689767	ENSG00000249839.1	AC011330.5	-7.11	4.35e-12	3.02e-09	-0.4	-0.31	Lung cancer;	chr15:43429879	chr15:43663654~43684339:-
LUAD	cis	rs10463554	0.856	rs257292	ENSG00000175749.11	EIF3KP1	7.1	4.37e-12	3.03e-09	0.42	0.31	Parkinson's disease;	chr5:103159047	chr5:103032376~103033031:+
LUAD	cis	rs2243480	1	rs12698509	ENSG00000273142.1	RP11-458F8.4	-7.1	4.37e-12	3.03e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:65953889	chr7:66902857~66906297:+
LUAD	cis	rs10129255	0.957	rs8009638	ENSG00000280411.1	IGHV1-69-2	-7.1	4.38e-12	3.04e-09	-0.23	-0.31	Kawasaki disease;	chr14:106777570	chr14:106762092~106762588:-
LUAD	cis	rs2243480	1	rs6958420	ENSG00000273142.1	RP11-458F8.4	7.1	4.38e-12	3.04e-09	0.32	0.31	Diabetic kidney disease;	chr7:66286184	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs1392104	ENSG00000273142.1	RP11-458F8.4	7.1	4.38e-12	3.04e-09	0.32	0.31	Diabetic kidney disease;	chr7:66294120	chr7:66902857~66906297:+
LUAD	cis	rs2153535	0.58	rs1577472	ENSG00000230939.1	RP11-314C16.1	-7.1	4.38e-12	3.04e-09	-0.36	-0.31	Motion sickness;	chr6:8485982	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.542	rs1120393	ENSG00000230939.1	RP11-314C16.1	-7.1	4.38e-12	3.04e-09	-0.36	-0.31	Motion sickness;	chr6:8486657	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.563	rs4428546	ENSG00000230939.1	RP11-314C16.1	-7.1	4.38e-12	3.04e-09	-0.36	-0.31	Motion sickness;	chr6:8490143	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.505	rs1335629	ENSG00000230939.1	RP11-314C16.1	-7.1	4.38e-12	3.04e-09	-0.36	-0.31	Motion sickness;	chr6:8491630	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs763376	ENSG00000230939.1	RP11-314C16.1	-7.1	4.38e-12	3.04e-09	-0.36	-0.31	Motion sickness;	chr6:8492543	chr6:8784178~8785445:+
LUAD	cis	rs11098499	0.863	rs1010740	ENSG00000248280.1	RP11-33B1.2	-7.1	4.38e-12	3.04e-09	-0.4	-0.31	Corneal astigmatism;	chr4:119542254	chr4:119440561~119450157:-
LUAD	cis	rs2153535	0.58	rs4365970	ENSG00000230939.1	RP11-314C16.1	7.1	4.38e-12	3.04e-09	0.36	0.31	Motion sickness;	chr6:8453580	chr6:8784178~8785445:+
LUAD	cis	rs11118620	0.535	rs1389750	ENSG00000257551.1	HLX-AS1	7.1	4.38e-12	3.04e-09	0.34	0.31	Heart failure;	chr1:220866829	chr1:220832763~220880140:-
LUAD	cis	rs2153535	0.58	rs7341381	ENSG00000230939.1	RP11-314C16.1	-7.1	4.39e-12	3.04e-09	-0.37	-0.31	Motion sickness;	chr6:8470304	chr6:8784178~8785445:+
LUAD	cis	rs748404	0.56	rs572837	ENSG00000249839.1	AC011330.5	-7.1	4.4e-12	3.05e-09	-0.4	-0.31	Lung cancer;	chr15:43531615	chr15:43663654~43684339:-
LUAD	cis	rs71403859	0.502	rs12927006	ENSG00000260886.1	TAT-AS1	7.1	4.4e-12	3.06e-09	0.5	0.31	Post bronchodilator FEV1;	chr16:71516008	chr16:71565789~71578187:+
LUAD	cis	rs2153535	0.58	rs7741403	ENSG00000230939.1	RP11-314C16.1	7.1	4.4e-12	3.06e-09	0.36	0.31	Motion sickness;	chr6:8530345	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs4451187	ENSG00000230939.1	RP11-314C16.1	-7.1	4.41e-12	3.06e-09	-0.37	-0.31	Motion sickness;	chr6:8473677	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.504	rs4493781	ENSG00000230939.1	RP11-314C16.1	-7.1	4.41e-12	3.06e-09	-0.37	-0.31	Motion sickness;	chr6:8473708	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.541	rs5026687	ENSG00000230939.1	RP11-314C16.1	-7.1	4.41e-12	3.06e-09	-0.37	-0.31	Motion sickness;	chr6:8473724	chr6:8784178~8785445:+
LUAD	cis	rs2280018	0.526	rs2966129	ENSG00000188599.16	NPIPP1	7.1	4.41e-12	3.06e-09	0.28	0.31	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059070	chr16:15104312~15123498:-
LUAD	cis	rs673078	0.607	rs11068906	ENSG00000275759.1	RP11-131L12.3	-7.1	4.42e-12	3.07e-09	-0.43	-0.31	Glucose homeostasis traits;	chr12:118315098	chr12:118428281~118428870:+
LUAD	cis	rs17818399	0.597	rs13385693	ENSG00000279254.1	RP11-536C12.1	-7.1	4.45e-12	3.09e-09	-0.32	-0.31	Height;	chr2:46640019	chr2:46668870~46670778:+
LUAD	cis	rs9487094	0.67	rs2024852	ENSG00000260273.1	RP11-425D10.10	7.1	4.45e-12	3.09e-09	0.41	0.31	Height;	chr6:109498586	chr6:109382795~109383666:+
LUAD	cis	rs35160687	0.871	rs2278105	ENSG00000273080.1	RP11-301O19.1	7.1	4.46e-12	3.09e-09	0.35	0.31	Night sleep phenotypes;	chr2:86239393	chr2:86195590~86196049:+
LUAD	cis	rs2243480	1	rs7804223	ENSG00000273142.1	RP11-458F8.4	7.1	4.48e-12	3.1e-09	0.32	0.31	Diabetic kidney disease;	chr7:66199572	chr7:66902857~66906297:+
LUAD	cis	rs4660456	0.827	rs617413	ENSG00000237899.1	RP4-739H11.3	7.1	4.48e-12	3.1e-09	0.44	0.31	Platelet count;	chr1:40669846	chr1:40669089~40687588:-
LUAD	cis	rs10129255	0.957	rs8014696	ENSG00000280411.1	IGHV1-69-2	7.1	4.48e-12	3.11e-09	0.23	0.31	Kawasaki disease;	chr14:106769752	chr14:106762092~106762588:-
LUAD	cis	rs2243480	0.901	rs12530490	ENSG00000273142.1	RP11-458F8.4	7.1	4.5e-12	3.12e-09	0.32	0.31	Diabetic kidney disease;	chr7:66226660	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs7778911	ENSG00000273142.1	RP11-458F8.4	7.1	4.5e-12	3.12e-09	0.32	0.31	Diabetic kidney disease;	chr7:66229519	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs1979823	ENSG00000273142.1	RP11-458F8.4	7.1	4.5e-12	3.12e-09	0.32	0.31	Diabetic kidney disease;	chr7:66239626	chr7:66902857~66906297:+
LUAD	cis	rs62229266	0.605	rs11701331	ENSG00000231106.2	LINC01436	7.1	4.51e-12	3.12e-09	0.41	0.31	Mitral valve prolapse;	chr21:36086094	chr21:36005338~36007838:+
LUAD	cis	rs11603023	0.805	rs687190	ENSG00000255422.1	AP002954.4	-7.1	4.51e-12	3.12e-09	-0.37	-0.31	Cholesterol, total;	chr11:118671674	chr11:118704607~118750263:+
LUAD	cis	rs9545047	0.604	rs7331867	ENSG00000227676.3	LINC01068	-7.1	4.51e-12	3.12e-09	-0.37	-0.31	Schizophrenia;	chr13:79418791	chr13:79566727~79571436:+
LUAD	cis	rs2243480	0.908	rs1532573	ENSG00000273142.1	RP11-458F8.4	7.1	4.51e-12	3.12e-09	0.32	0.31	Diabetic kidney disease;	chr7:66333815	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs422164	ENSG00000273142.1	RP11-458F8.4	-7.1	4.51e-12	3.12e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66121618	chr7:66902857~66906297:+
LUAD	cis	rs6142102	0.923	rs4911394	ENSG00000276073.1	RP5-1125A11.7	-7.1	4.52e-12	3.13e-09	-0.33	-0.31	Skin pigmentation;	chr20:33989521	chr20:33985617~33988989:-
LUAD	cis	rs7017914	0.967	rs6993170	ENSG00000223220.1	Y_RNA	7.1	4.53e-12	3.14e-09	0.34	0.31	Bone mineral density;	chr8:70781284	chr8:70780914~70781008:-
LUAD	cis	rs673078	0.66	rs17512407	ENSG00000275759.1	RP11-131L12.3	-7.1	4.53e-12	3.14e-09	-0.48	-0.31	Glucose homeostasis traits;	chr12:118292705	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.66	rs61946064	ENSG00000275759.1	RP11-131L12.3	-7.1	4.53e-12	3.14e-09	-0.48	-0.31	Glucose homeostasis traits;	chr12:118294495	chr12:118428281~118428870:+
LUAD	cis	rs11123170	0.543	rs35222158	ENSG00000274877.1	RP11-65I12.1	-7.1	4.54e-12	3.14e-09	-0.47	-0.31	Renal function-related traits (BUN);	chr2:113229052	chr2:113237595~113240825:+
LUAD	cis	rs2337406	0.587	rs10139664	ENSG00000274576.2	IGHV2-70	-7.1	4.54e-12	3.14e-09	-0.33	-0.31	Alzheimer's disease (late onset);	chr14:106647254	chr14:106770577~106771020:-
LUAD	cis	rs72772090	0.539	rs17481759	ENSG00000248734.2	CTD-2260A17.1	-7.1	4.56e-12	3.15e-09	-0.47	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96778991	chr5:96784777~96785999:+
LUAD	cis	rs11123170	0.542	rs28522253	ENSG00000274877.1	RP11-65I12.1	-7.1	4.56e-12	3.16e-09	-0.48	-0.31	Renal function-related traits (BUN);	chr2:113209810	chr2:113237595~113240825:+
LUAD	cis	rs11676348	0.808	rs4674267	ENSG00000261338.2	RP11-378A13.1	-7.1	4.56e-12	3.16e-09	-0.32	-0.31	Ulcerative colitis;	chr2:218181714	chr2:218255319~218257366:+
LUAD	cis	rs10759883	0.627	rs12349742	ENSG00000175611.10	LINC00476	7.1	4.57e-12	3.16e-09	0.36	0.31	Nicotine dependence;	chr9:95857698	chr9:95759231~95875977:-
LUAD	cis	rs10759883	0.58	rs2026031	ENSG00000175611.10	LINC00476	7.1	4.57e-12	3.16e-09	0.36	0.31	Nicotine dependence;	chr9:95859068	chr9:95759231~95875977:-
LUAD	cis	rs950880	0.645	rs11679889	ENSG00000234389.1	AC007278.3	-7.1	4.58e-12	3.17e-09	-0.32	-0.31	Serum protein levels (sST2);	chr2:102324549	chr2:102438713~102440475:+
LUAD	cis	rs10129255	0.957	rs10138532	ENSG00000211972.2	IGHV3-66	7.1	4.58e-12	3.17e-09	0.27	0.31	Kawasaki disease;	chr14:106803901	chr14:106675017~106675544:-
LUAD	cis	rs6142102	0.778	rs4911374	ENSG00000276073.1	RP5-1125A11.7	-7.1	4.59e-12	3.18e-09	-0.32	-0.31	Skin pigmentation;	chr20:33928195	chr20:33985617~33988989:-
LUAD	cis	rs321358	0.731	rs516177	ENSG00000271584.1	RP11-89C3.4	7.1	4.6e-12	3.18e-09	0.48	0.31	Body mass index;	chr11:111138173	chr11:111091932~111097357:-
LUAD	cis	rs7044106	0.791	rs10818473	ENSG00000238181.2	AHCYP2	-7.1	4.6e-12	3.18e-09	-0.41	-0.31	Hip circumference adjusted for BMI;	chr9:120721877	chr9:120720673~120721972:+
LUAD	cis	rs2283792	0.871	rs8136867	ENSG00000224086.5	LL22NC03-86G7.1	-7.1	4.6e-12	3.18e-09	-0.29	-0.31	Multiple sclerosis;	chr22:21850504	chr22:21938293~21977632:+
LUAD	cis	rs12134133	1	rs7532664	ENSG00000274245.1	RP11-357P18.2	7.1	4.61e-12	3.19e-09	0.4	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207253598	chr1:207372559~207373252:+
LUAD	cis	rs12134133	1	rs55638602	ENSG00000274245.1	RP11-357P18.2	7.1	4.61e-12	3.19e-09	0.4	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207255597	chr1:207372559~207373252:+
LUAD	cis	rs12134133	1	rs4844588	ENSG00000274245.1	RP11-357P18.2	7.1	4.61e-12	3.19e-09	0.4	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207256323	chr1:207372559~207373252:+
LUAD	cis	rs10759883	0.627	rs689986	ENSG00000175611.10	LINC00476	7.1	4.62e-12	3.2e-09	0.36	0.31	Nicotine dependence;	chr9:95866867	chr9:95759231~95875977:-
LUAD	cis	rs8177876	0.822	rs9925940	ENSG00000261838.4	RP11-303E16.6	7.1	4.64e-12	3.21e-09	0.67	0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077379	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.822	rs9925943	ENSG00000261838.4	RP11-303E16.6	7.1	4.64e-12	3.21e-09	0.67	0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077402	chr16:81069854~81076598:+
LUAD	cis	rs321358	0.731	rs7926634	ENSG00000271584.1	RP11-89C3.4	-7.1	4.64e-12	3.21e-09	-0.48	-0.31	Body mass index;	chr11:111149618	chr11:111091932~111097357:-
LUAD	cis	rs11098499	0.954	rs2389803	ENSG00000248280.1	RP11-33B1.2	-7.1	4.64e-12	3.21e-09	-0.4	-0.31	Corneal astigmatism;	chr4:119472356	chr4:119440561~119450157:-
LUAD	cis	rs7208859	0.623	rs216434	ENSG00000263531.1	RP13-753N3.1	7.1	4.64e-12	3.21e-09	0.64	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595317	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs216436	ENSG00000263531.1	RP13-753N3.1	7.1	4.64e-12	3.21e-09	0.64	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595882	chr17:30863921~30864940:-
LUAD	cis	rs17023223	0.537	rs1057991	ENSG00000231365.4	RP11-418J17.1	-7.1	4.64e-12	3.21e-09	-0.4	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119032547	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs1057990	ENSG00000231365.4	RP11-418J17.1	-7.1	4.64e-12	3.21e-09	-0.4	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119032609	chr1:119140396~119275973:+
LUAD	cis	rs9487094	0.666	rs736830	ENSG00000260273.1	RP11-425D10.10	7.09	4.66e-12	3.22e-09	0.38	0.31	Height;	chr6:109392096	chr6:109382795~109383666:+
LUAD	cis	rs950169	0.96	rs12905475	ENSG00000225151.9	GOLGA2P7	-7.09	4.66e-12	3.23e-09	-0.45	-0.31	Schizophrenia;	chr15:84131743	chr15:84199311~84230136:-
LUAD	cis	rs17818399	0.62	rs6544906	ENSG00000279254.1	RP11-536C12.1	-7.09	4.67e-12	3.23e-09	-0.32	-0.31	Height;	chr2:46636733	chr2:46668870~46670778:+
LUAD	cis	rs62229266	0.804	rs2835259	ENSG00000214914.3	RPL23AP3	7.09	4.67e-12	3.23e-09	0.37	0.31	Mitral valve prolapse;	chr21:36053004	chr21:36016079~36016546:-
LUAD	cis	rs2153535	0.541	rs6908504	ENSG00000230939.1	RP11-314C16.1	-7.09	4.67e-12	3.23e-09	-0.37	-0.31	Motion sickness;	chr6:8456545	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs7755284	ENSG00000230939.1	RP11-314C16.1	-7.09	4.67e-12	3.23e-09	-0.37	-0.31	Motion sickness;	chr6:8457246	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs7769020	ENSG00000230939.1	RP11-314C16.1	-7.09	4.67e-12	3.23e-09	-0.37	-0.31	Motion sickness;	chr6:8457491	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9392220	ENSG00000230939.1	RP11-314C16.1	-7.09	4.67e-12	3.23e-09	-0.37	-0.31	Motion sickness;	chr6:8457713	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9379206	ENSG00000230939.1	RP11-314C16.1	-7.09	4.67e-12	3.23e-09	-0.37	-0.31	Motion sickness;	chr6:8457788	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.541	rs9379207	ENSG00000230939.1	RP11-314C16.1	-7.09	4.67e-12	3.23e-09	-0.37	-0.31	Motion sickness;	chr6:8457953	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9393016	ENSG00000230939.1	RP11-314C16.1	-7.09	4.67e-12	3.23e-09	-0.37	-0.31	Motion sickness;	chr6:8458340	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs4960421	ENSG00000230939.1	RP11-314C16.1	-7.09	4.67e-12	3.23e-09	-0.37	-0.31	Motion sickness;	chr6:8459059	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs4960422	ENSG00000230939.1	RP11-314C16.1	-7.09	4.67e-12	3.23e-09	-0.37	-0.31	Motion sickness;	chr6:8459076	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs7742794	ENSG00000230939.1	RP11-314C16.1	-7.09	4.67e-12	3.23e-09	-0.37	-0.31	Motion sickness;	chr6:8459490	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9505448	ENSG00000230939.1	RP11-314C16.1	-7.09	4.67e-12	3.23e-09	-0.37	-0.31	Motion sickness;	chr6:8459571	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9406169	ENSG00000230939.1	RP11-314C16.1	-7.09	4.68e-12	3.23e-09	-0.35	-0.31	Motion sickness;	chr6:8509237	chr6:8784178~8785445:+
LUAD	cis	rs72772090	0.539	rs56319744	ENSG00000248734.2	CTD-2260A17.1	-7.09	4.68e-12	3.23e-09	-0.47	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96806235	chr5:96784777~96785999:+
LUAD	cis	rs11098499	0.818	rs7688802	ENSG00000248280.1	RP11-33B1.2	7.09	4.68e-12	3.24e-09	0.4	0.31	Corneal astigmatism;	chr4:119530513	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs7695620	ENSG00000248280.1	RP11-33B1.2	7.09	4.68e-12	3.24e-09	0.4	0.31	Corneal astigmatism;	chr4:119531621	chr4:119440561~119450157:-
LUAD	cis	rs9326248	0.53	rs562179	ENSG00000280143.1	AP000892.6	7.09	4.69e-12	3.24e-09	0.48	0.31	Blood protein levels;	chr11:116934488	chr11:117204967~117210292:+
LUAD	cis	rs10129255	0.957	rs2007467	ENSG00000211972.2	IGHV3-66	-7.09	4.69e-12	3.24e-09	-0.28	-0.31	Kawasaki disease;	chr14:106771605	chr14:106675017~106675544:-
LUAD	cis	rs11098499	0.954	rs10006706	ENSG00000248280.1	RP11-33B1.2	7.09	4.69e-12	3.24e-09	0.4	0.31	Corneal astigmatism;	chr4:119487997	chr4:119440561~119450157:-
LUAD	cis	rs9640161	0.789	rs60283368	ENSG00000261305.1	RP4-584D14.7	7.09	4.7e-12	3.25e-09	0.44	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150326169	chr7:150341771~150342607:+
LUAD	cis	rs7208859	0.623	rs170051	ENSG00000263531.1	RP13-753N3.1	7.09	4.7e-12	3.25e-09	0.64	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587135	chr17:30863921~30864940:-
LUAD	cis	rs11098499	0.821	rs3775852	ENSG00000248280.1	RP11-33B1.2	7.09	4.7e-12	3.25e-09	0.4	0.31	Corneal astigmatism;	chr4:119533401	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.82	rs6534140	ENSG00000248280.1	RP11-33B1.2	7.09	4.7e-12	3.25e-09	0.4	0.31	Corneal astigmatism;	chr4:119534156	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs7657849	ENSG00000248280.1	RP11-33B1.2	7.09	4.7e-12	3.25e-09	0.4	0.31	Corneal astigmatism;	chr4:119534339	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs10034450	ENSG00000248280.1	RP11-33B1.2	7.09	4.7e-12	3.25e-09	0.4	0.31	Corneal astigmatism;	chr4:119534494	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs1480939	ENSG00000248280.1	RP11-33B1.2	7.09	4.7e-12	3.25e-09	0.4	0.31	Corneal astigmatism;	chr4:119535772	chr4:119440561~119450157:-
LUAD	cis	rs6142102	0.961	rs6088361	ENSG00000276073.1	RP5-1125A11.7	-7.09	4.7e-12	3.25e-09	-0.32	-0.31	Skin pigmentation;	chr20:33969520	chr20:33985617~33988989:-
LUAD	cis	rs17818399	0.62	rs7598578	ENSG00000279254.1	RP11-536C12.1	-7.09	4.73e-12	3.27e-09	-0.32	-0.31	Height;	chr2:46629946	chr2:46668870~46670778:+
LUAD	cis	rs17818399	0.62	rs1598517	ENSG00000279254.1	RP11-536C12.1	-7.09	4.73e-12	3.27e-09	-0.32	-0.31	Height;	chr2:46630262	chr2:46668870~46670778:+
LUAD	cis	rs67180937	0.645	rs2270707	ENSG00000272750.1	RP11-378J18.8	7.09	4.75e-12	3.28e-09	0.34	0.31	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222664252	chr1:222658867~222661512:-
LUAD	cis	rs2153535	0.541	rs9405386	ENSG00000230939.1	RP11-314C16.1	-7.09	4.75e-12	3.28e-09	-0.37	-0.31	Motion sickness;	chr6:8457834	chr6:8784178~8785445:+
LUAD	cis	rs9287719	0.674	rs759399	ENSG00000234818.1	AC092687.5	-7.09	4.77e-12	3.3e-09	-0.37	-0.31	Prostate cancer;	chr2:10656757	chr2:10589166~10604830:+
LUAD	cis	rs8177876	0.822	rs9923732	ENSG00000261838.4	RP11-303E16.6	7.09	4.78e-12	3.3e-09	0.67	0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077298	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.822	rs9933184	ENSG00000261838.4	RP11-303E16.6	7.09	4.78e-12	3.3e-09	0.67	0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077571	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.822	rs9926174	ENSG00000261838.4	RP11-303E16.6	7.09	4.78e-12	3.3e-09	0.67	0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077831	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.642	rs8052490	ENSG00000261838.4	RP11-303E16.6	7.09	4.78e-12	3.3e-09	0.67	0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078251	chr16:81069854~81076598:+
LUAD	cis	rs7246657	0.943	rs10409204	ENSG00000276846.1	CTD-3220F14.3	7.09	4.78e-12	3.3e-09	0.43	0.31	Coronary artery calcification;	chr19:37426790	chr19:37314868~37315620:-
LUAD	cis	rs11098499	0.78	rs10013652	ENSG00000248280.1	RP11-33B1.2	7.09	4.8e-12	3.31e-09	0.37	0.31	Corneal astigmatism;	chr4:119371101	chr4:119440561~119450157:-
LUAD	cis	rs2734839	0.964	rs1107162	ENSG00000270179.1	RP11-159N11.4	7.09	4.81e-12	3.32e-09	0.31	0.31	Information processing speed;	chr11:113418315	chr11:113368478~113369117:+
LUAD	cis	rs4660456	0.913	rs12040422	ENSG00000237899.1	RP4-739H11.3	7.09	4.83e-12	3.33e-09	0.44	0.31	Platelet count;	chr1:40669239	chr1:40669089~40687588:-
LUAD	cis	rs72772090	0.539	rs2042386	ENSG00000248734.2	CTD-2260A17.1	-7.09	4.83e-12	3.33e-09	-0.48	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96821080	chr5:96784777~96785999:+
LUAD	cis	rs10463554	0.856	rs26522	ENSG00000175749.11	EIF3KP1	-7.09	4.84e-12	3.34e-09	-0.41	-0.31	Parkinson's disease;	chr5:103148695	chr5:103032376~103033031:+
LUAD	cis	rs9595908	0.965	rs9591180	ENSG00000212293.1	SNORA16	7.09	4.85e-12	3.35e-09	0.34	0.31	Body mass index;	chr13:32622864	chr13:32420390~32420516:-
LUAD	cis	rs9487094	0.644	rs9320286	ENSG00000260273.1	RP11-425D10.10	7.09	4.86e-12	3.35e-09	0.39	0.31	Height;	chr6:109403734	chr6:109382795~109383666:+
LUAD	cis	rs11098499	0.954	rs67265404	ENSG00000248280.1	RP11-33B1.2	7.09	4.87e-12	3.36e-09	0.4	0.31	Corneal astigmatism;	chr4:119438115	chr4:119440561~119450157:-
LUAD	cis	rs1150668	0.796	rs213237	ENSG00000216901.1	AL022393.7	7.09	4.88e-12	3.36e-09	0.36	0.31	Pubertal anthropometrics;	chr6:28356161	chr6:28176188~28176674:+
LUAD	cis	rs2243480	1	rs313807	ENSG00000273142.1	RP11-458F8.4	-7.09	4.88e-12	3.36e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66034494	chr7:66902857~66906297:+
LUAD	cis	rs2153535	0.58	rs7766852	ENSG00000230939.1	RP11-314C16.1	-7.09	4.89e-12	3.37e-09	-0.37	-0.31	Motion sickness;	chr6:8472184	chr6:8784178~8785445:+
LUAD	cis	rs11098499	0.505	rs75122014	ENSG00000248280.1	RP11-33B1.2	7.09	4.89e-12	3.38e-09	0.4	0.31	Corneal astigmatism;	chr4:119441271	chr4:119440561~119450157:-
LUAD	cis	rs8031584	0.678	rs798127	ENSG00000260382.1	RP11-540B6.2	-7.09	4.9e-12	3.38e-09	-0.39	-0.31	Huntington's disease progression;	chr15:30825200	chr15:30882267~30883231:-
LUAD	cis	rs7429990	0.864	rs1014228	ENSG00000229759.1	MRPS18AP1	-7.09	4.93e-12	3.4e-09	-0.31	-0.31	Educational attainment (years of education);	chr3:47611149	chr3:48256350~48256938:-
LUAD	cis	rs71403859	0.667	rs12920890	ENSG00000260886.1	TAT-AS1	7.09	4.93e-12	3.4e-09	0.52	0.31	Post bronchodilator FEV1;	chr16:71753685	chr16:71565789~71578187:+
LUAD	cis	rs7688540	0.771	rs11737268	ENSG00000275426.1	CH17-262A2.1	7.09	4.94e-12	3.41e-09	0.42	0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:230663	chr4:149738~150317:+
LUAD	cis	rs7688540	0.771	rs11726829	ENSG00000275426.1	CH17-262A2.1	7.09	4.94e-12	3.41e-09	0.42	0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231159	chr4:149738~150317:+
LUAD	cis	rs11098499	0.909	rs1546504	ENSG00000248280.1	RP11-33B1.2	7.09	4.95e-12	3.41e-09	0.39	0.31	Corneal astigmatism;	chr4:119320024	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs10006877	ENSG00000248280.1	RP11-33B1.2	7.09	4.95e-12	3.41e-09	0.39	0.31	Corneal astigmatism;	chr4:119321638	chr4:119440561~119450157:-
LUAD	cis	rs9640161	0.663	rs1916932	ENSG00000261305.1	RP4-584D14.7	7.09	4.95e-12	3.41e-09	0.44	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150324555	chr7:150341771~150342607:+
LUAD	cis	rs9640161	0.75	rs59211922	ENSG00000261305.1	RP4-584D14.7	7.09	4.95e-12	3.41e-09	0.44	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150326701	chr7:150341771~150342607:+
LUAD	cis	rs9640161	0.711	rs60268791	ENSG00000261305.1	RP4-584D14.7	7.09	4.95e-12	3.41e-09	0.44	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150326711	chr7:150341771~150342607:+
LUAD	cis	rs7927592	0.913	rs12283755	ENSG00000212093.1	AP000807.1	7.09	4.97e-12	3.43e-09	0.34	0.31	Total body bone mineral density;	chr11:68604190	chr11:68506083~68506166:-
LUAD	cis	rs2439831	0.867	rs12443102	ENSG00000205771.5	CATSPER2P1	-7.09	4.97e-12	3.43e-09	-0.56	-0.31	Lung cancer in ever smokers;	chr15:43639905	chr15:43726918~43747094:-
LUAD	cis	rs11098499	0.908	rs11098527	ENSG00000248280.1	RP11-33B1.2	7.08	4.98e-12	3.43e-09	0.39	0.31	Corneal astigmatism;	chr4:119478751	chr4:119440561~119450157:-
LUAD	cis	rs496547	0.756	rs562059	ENSG00000278376.1	RP11-158I9.8	-7.08	4.98e-12	3.43e-09	-0.34	-0.31	Hip minimal joint space width;	chr11:118731349	chr11:118791254~118793137:+
LUAD	cis	rs17818399	0.51	rs12105801	ENSG00000279254.1	RP11-536C12.1	-7.08	4.99e-12	3.44e-09	-0.32	-0.31	Height;	chr2:46572204	chr2:46668870~46670778:+
LUAD	cis	rs4713118	0.513	rs149972	ENSG00000219392.1	RP1-265C24.5	-7.08	5e-12	3.44e-09	-0.39	-0.31	Parkinson's disease;	chr6:28015449	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.513	rs149975	ENSG00000219392.1	RP1-265C24.5	-7.08	5e-12	3.44e-09	-0.39	-0.31	Parkinson's disease;	chr6:28018562	chr6:28115628~28116551:+
LUAD	cis	rs10759883	0.563	rs1327997	ENSG00000175611.10	LINC00476	7.08	5e-12	3.45e-09	0.35	0.31	Nicotine dependence;	chr9:95913600	chr9:95759231~95875977:-
LUAD	cis	rs10759883	0.563	rs1327996	ENSG00000175611.10	LINC00476	7.08	5e-12	3.45e-09	0.35	0.31	Nicotine dependence;	chr9:95913710	chr9:95759231~95875977:-
LUAD	cis	rs10759883	0.563	rs617187	ENSG00000175611.10	LINC00476	7.08	5e-12	3.45e-09	0.35	0.31	Nicotine dependence;	chr9:95917359	chr9:95759231~95875977:-
LUAD	cis	rs10759883	0.563	rs689619	ENSG00000175611.10	LINC00476	7.08	5e-12	3.45e-09	0.35	0.31	Nicotine dependence;	chr9:95921689	chr9:95759231~95875977:-
LUAD	cis	rs10759883	0.563	rs10512245	ENSG00000175611.10	LINC00476	7.08	5e-12	3.45e-09	0.35	0.31	Nicotine dependence;	chr9:95929529	chr9:95759231~95875977:-
LUAD	cis	rs11123170	0.503	rs28679654	ENSG00000274877.1	RP11-65I12.1	-7.08	5.01e-12	3.45e-09	-0.47	-0.31	Renal function-related traits (BUN);	chr2:113210040	chr2:113237595~113240825:+
LUAD	cis	rs6142102	0.961	rs4911408	ENSG00000276073.1	RP5-1125A11.7	-7.08	5.02e-12	3.45e-09	-0.32	-0.31	Skin pigmentation;	chr20:34112760	chr20:33985617~33988989:-
LUAD	cis	rs7044106	0.791	rs10985009	ENSG00000238181.2	AHCYP2	7.08	5.02e-12	3.46e-09	0.4	0.31	Hip circumference adjusted for BMI;	chr9:120730761	chr9:120720673~120721972:+
LUAD	cis	rs2337406	0.587	rs2516889	ENSG00000254174.1	IGHV1-12	-7.08	5.02e-12	3.46e-09	-0.27	-0.31	Alzheimer's disease (late onset);	chr14:106648903	chr14:106122420~106122709:-
LUAD	cis	rs2243480	1	rs1499613	ENSG00000273142.1	RP11-458F8.4	7.08	5.05e-12	3.47e-09	0.32	0.31	Diabetic kidney disease;	chr7:66265873	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs1553174	ENSG00000273142.1	RP11-458F8.4	7.08	5.05e-12	3.47e-09	0.32	0.31	Diabetic kidney disease;	chr7:66266207	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs10950032	ENSG00000273142.1	RP11-458F8.4	7.08	5.05e-12	3.47e-09	0.32	0.31	Diabetic kidney disease;	chr7:66273604	chr7:66902857~66906297:+
LUAD	cis	rs6142102	0.778	rs6059555	ENSG00000276073.1	RP5-1125A11.7	-7.08	5.06e-12	3.48e-09	-0.32	-0.31	Skin pigmentation;	chr20:33926518	chr20:33985617~33988989:-
LUAD	cis	rs7849270	0.84	rs12346996	ENSG00000268707.1	RP11-247A12.7	-7.08	5.06e-12	3.48e-09	-0.38	-0.31	Blood metabolite ratios;	chr9:129078577	chr9:129170434~129170940:+
LUAD	cis	rs11098499	0.954	rs17005535	ENSG00000248280.1	RP11-33B1.2	7.08	5.06e-12	3.48e-09	0.39	0.31	Corneal astigmatism;	chr4:119490407	chr4:119440561~119450157:-
LUAD	cis	rs3762637	0.941	rs74467988	ENSG00000272758.4	RP11-299J3.8	-7.08	5.09e-12	3.5e-09	-0.48	-0.31	LDL cholesterol levels;	chr3:122364293	chr3:122416207~122443180:+
LUAD	cis	rs2243480	1	rs2420170	ENSG00000273142.1	RP11-458F8.4	7.08	5.09e-12	3.5e-09	0.32	0.31	Diabetic kidney disease;	chr7:66191066	chr7:66902857~66906297:+
LUAD	cis	rs11676348	0.808	rs61700947	ENSG00000261338.2	RP11-378A13.1	7.08	5.1e-12	3.51e-09	0.32	0.31	Ulcerative colitis;	chr2:218181448	chr2:218255319~218257366:+
LUAD	cis	rs17818399	0.548	rs1989720	ENSG00000279254.1	RP11-536C12.1	-7.08	5.1e-12	3.51e-09	-0.31	-0.31	Height;	chr2:46627225	chr2:46668870~46670778:+
LUAD	cis	rs17818399	0.62	rs6739397	ENSG00000279254.1	RP11-536C12.1	-7.08	5.1e-12	3.51e-09	-0.31	-0.31	Height;	chr2:46631182	chr2:46668870~46670778:+
LUAD	cis	rs11123170	0.543	rs12472361	ENSG00000274877.1	RP11-65I12.1	-7.08	5.1e-12	3.51e-09	-0.47	-0.31	Renal function-related traits (BUN);	chr2:113223068	chr2:113237595~113240825:+
LUAD	cis	rs3931020	1	rs10874122	ENSG00000272864.1	RP11-17E13.2	-7.08	5.12e-12	3.52e-09	-0.39	-0.31	Resistin levels;	chr1:74770182	chr1:74698769~74699333:-
LUAD	cis	rs11214589	0.651	rs11214594	ENSG00000270179.1	RP11-159N11.4	-7.08	5.12e-12	3.52e-09	-0.31	-0.31	Neuroticism;	chr11:113388610	chr11:113368478~113369117:+
LUAD	cis	rs7017914	0.902	rs1373480	ENSG00000223220.1	Y_RNA	7.08	5.13e-12	3.53e-09	0.34	0.31	Bone mineral density;	chr8:70774732	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs10448014	ENSG00000223220.1	Y_RNA	7.08	5.13e-12	3.53e-09	0.34	0.31	Bone mineral density;	chr8:70775930	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs7000647	ENSG00000223220.1	Y_RNA	7.08	5.13e-12	3.53e-09	0.34	0.31	Bone mineral density;	chr8:70776173	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs13254801	ENSG00000223220.1	Y_RNA	7.08	5.13e-12	3.53e-09	0.34	0.31	Bone mineral density;	chr8:70776749	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.783	rs13252584	ENSG00000223220.1	Y_RNA	7.08	5.13e-12	3.53e-09	0.34	0.31	Bone mineral density;	chr8:70776796	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.84	rs13254851	ENSG00000223220.1	Y_RNA	7.08	5.13e-12	3.53e-09	0.34	0.31	Bone mineral density;	chr8:70776799	chr8:70780914~70781008:-
LUAD	cis	rs7429990	0.864	rs883663	ENSG00000229759.1	MRPS18AP1	-7.08	5.14e-12	3.53e-09	-0.31	-0.31	Educational attainment (years of education);	chr3:47619306	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.833	rs6442072	ENSG00000229759.1	MRPS18AP1	-7.08	5.14e-12	3.53e-09	-0.31	-0.31	Educational attainment (years of education);	chr3:47642960	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs2882611	ENSG00000229759.1	MRPS18AP1	-7.08	5.14e-12	3.53e-09	-0.31	-0.31	Educational attainment (years of education);	chr3:47651532	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.803	rs6773732	ENSG00000229759.1	MRPS18AP1	-7.08	5.14e-12	3.53e-09	-0.31	-0.31	Educational attainment (years of education);	chr3:47677772	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs2049301	ENSG00000229759.1	MRPS18AP1	-7.08	5.14e-12	3.53e-09	-0.31	-0.31	Educational attainment (years of education);	chr3:47681369	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs7429162	ENSG00000229759.1	MRPS18AP1	-7.08	5.14e-12	3.53e-09	-0.31	-0.31	Educational attainment (years of education);	chr3:47683845	chr3:48256350~48256938:-
LUAD	cis	rs7429990	0.864	rs4410463	ENSG00000229759.1	MRPS18AP1	-7.08	5.14e-12	3.53e-09	-0.31	-0.31	Educational attainment (years of education);	chr3:47693907	chr3:48256350~48256938:-
LUAD	cis	rs9487094	0.67	rs1885691	ENSG00000260273.1	RP11-425D10.10	7.08	5.14e-12	3.53e-09	0.38	0.31	Height;	chr6:109382188	chr6:109382795~109383666:+
LUAD	cis	rs2153535	0.601	rs2327091	ENSG00000230939.1	RP11-314C16.1	-7.08	5.17e-12	3.55e-09	-0.37	-0.31	Motion sickness;	chr6:8540136	chr6:8784178~8785445:+
LUAD	cis	rs8059260	0.673	rs74985998	ENSG00000274038.1	RP11-66H6.4	-7.08	5.17e-12	3.55e-09	-0.57	-0.31	Alcohol consumption over the past year;	chr16:10967208	chr16:11056556~11057034:+
LUAD	cis	rs2337406	0.587	rs2516886	ENSG00000254174.1	IGHV1-12	-7.08	5.18e-12	3.56e-09	-0.27	-0.31	Alzheimer's disease (late onset);	chr14:106649674	chr14:106122420~106122709:-
LUAD	cis	rs10463554	0.895	rs3733939	ENSG00000175749.11	EIF3KP1	7.08	5.18e-12	3.56e-09	0.41	0.31	Parkinson's disease;	chr5:102974462	chr5:103032376~103033031:+
LUAD	cis	rs9487094	0.67	rs11153183	ENSG00000260273.1	RP11-425D10.10	7.08	5.18e-12	3.56e-09	0.41	0.31	Height;	chr6:109496073	chr6:109382795~109383666:+
LUAD	cis	rs113835537	0.529	rs7943327	ENSG00000255517.5	CTD-3074O7.5	-7.08	5.2e-12	3.58e-09	-0.36	-0.31	Airway imaging phenotypes;	chr11:66489110	chr11:66473490~66480233:-
LUAD	cis	rs9487094	0.689	rs3818933	ENSG00000260273.1	RP11-425D10.10	7.08	5.22e-12	3.58e-09	0.38	0.31	Height;	chr6:109370741	chr6:109382795~109383666:+
LUAD	cis	rs7626444	0.625	rs9826214	ENSG00000272359.1	U4	-7.08	5.22e-12	3.59e-09	-0.33	-0.31	Monocyte count;	chr3:196751342	chr3:196747192~196747324:-
LUAD	cis	rs11214589	0.651	rs12360992	ENSG00000270179.1	RP11-159N11.4	-7.08	5.22e-12	3.59e-09	-0.31	-0.31	Neuroticism;	chr11:113392178	chr11:113368478~113369117:+
LUAD	cis	rs9487094	0.689	rs9487076	ENSG00000260273.1	RP11-425D10.10	7.08	5.25e-12	3.6e-09	0.38	0.31	Height;	chr6:109371524	chr6:109382795~109383666:+
LUAD	cis	rs10129255	0.5	rs11627315	ENSG00000211970.3	IGHV4-61	-7.08	5.27e-12	3.62e-09	-0.22	-0.31	Kawasaki disease;	chr14:106802182	chr14:106639119~106639657:-
LUAD	cis	rs4713118	0.629	rs203887	ENSG00000204709.4	LINC01556	7.08	5.27e-12	3.62e-09	0.42	0.31	Parkinson's disease;	chr6:28053491	chr6:28943877~28944537:+
LUAD	cis	rs9903692	0.954	rs6847	ENSG00000278765.1	RP5-890E16.5	-7.08	5.27e-12	3.62e-09	-0.4	-0.31	Pulse pressure;	chr17:48070445	chr17:48066704~48067293:-
LUAD	cis	rs7044106	0.791	rs7036196	ENSG00000238181.2	AHCYP2	-7.08	5.28e-12	3.63e-09	-0.4	-0.31	Hip circumference adjusted for BMI;	chr9:120717179	chr9:120720673~120721972:+
LUAD	cis	rs7044106	0.791	rs7036766	ENSG00000238181.2	AHCYP2	-7.08	5.28e-12	3.63e-09	-0.4	-0.31	Hip circumference adjusted for BMI;	chr9:120717343	chr9:120720673~120721972:+
LUAD	cis	rs2842992	0.789	rs2277072	ENSG00000237927.1	RP3-393E18.2	-7.08	5.3e-12	3.64e-09	-0.44	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159761813	chr6:159586955~159589169:-
LUAD	cis	rs2842992	0.83	rs2273819	ENSG00000237927.1	RP3-393E18.2	-7.08	5.3e-12	3.64e-09	-0.44	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159762293	chr6:159586955~159589169:-
LUAD	cis	rs80285556	1	rs17311679	ENSG00000161643.11	SIGLEC16	-7.08	5.3e-12	3.64e-09	-0.68	-0.31	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50018074	chr19:49969673~49975814:+
LUAD	cis	rs10853057	1	rs10853057	ENSG00000214174.7	AMZ2P1	7.07	5.32e-12	3.65e-09	0.53	0.31	White matter microstructure (global fractional anisotropy);	chr17:65001905	chr17:64966550~64975576:-
LUAD	cis	rs2243480	1	rs313809	ENSG00000273142.1	RP11-458F8.4	-7.07	5.32e-12	3.65e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66034996	chr7:66902857~66906297:+
LUAD	cis	rs11098499	0.908	rs28499576	ENSG00000248280.1	RP11-33B1.2	7.07	5.32e-12	3.65e-09	0.4	0.31	Corneal astigmatism;	chr4:119465522	chr4:119440561~119450157:-
LUAD	cis	rs67311347	1	rs73080137	ENSG00000223797.4	ENTPD3-AS1	7.07	5.32e-12	3.65e-09	0.33	0.31	Renal cell carcinoma;	chr3:40474921	chr3:40313802~40453329:-
LUAD	cis	rs1823913	0.895	rs10931491	ENSG00000227542.1	AC092614.2	-7.07	5.32e-12	3.66e-09	-0.4	-0.31	Obesity-related traits;	chr2:191256087	chr2:191229165~191246172:-
LUAD	cis	rs10463554	0.889	rs246899	ENSG00000175749.11	EIF3KP1	7.07	5.33e-12	3.66e-09	0.43	0.31	Parkinson's disease;	chr5:103241438	chr5:103032376~103033031:+
LUAD	cis	rs62229266	0.618	rs11088334	ENSG00000214914.3	RPL23AP3	7.07	5.34e-12	3.66e-09	0.37	0.31	Mitral valve prolapse;	chr21:36094531	chr21:36016079~36016546:-
LUAD	cis	rs8059260	0.736	rs77334546	ENSG00000274038.1	RP11-66H6.4	-7.07	5.34e-12	3.66e-09	-0.65	-0.31	Alcohol consumption over the past year;	chr16:10970061	chr16:11056556~11057034:+
LUAD	cis	rs321358	0.731	rs484021	ENSG00000271584.1	RP11-89C3.4	7.07	5.34e-12	3.66e-09	0.47	0.31	Body mass index;	chr11:111136353	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.731	rs7112075	ENSG00000271584.1	RP11-89C3.4	7.07	5.34e-12	3.66e-09	0.47	0.31	Body mass index;	chr11:111136407	chr11:111091932~111097357:-
LUAD	cis	rs2153535	0.584	rs9502721	ENSG00000230939.1	RP11-314C16.1	-7.07	5.34e-12	3.66e-09	-0.37	-0.31	Motion sickness;	chr6:8541146	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.607	rs9502722	ENSG00000230939.1	RP11-314C16.1	-7.07	5.34e-12	3.66e-09	-0.37	-0.31	Motion sickness;	chr6:8541250	chr6:8784178~8785445:+
LUAD	cis	rs748404	0.697	rs505249	ENSG00000205771.5	CATSPER2P1	-7.07	5.34e-12	3.66e-09	-0.39	-0.31	Lung cancer;	chr15:43267762	chr15:43726918~43747094:-
LUAD	cis	rs10200159	0.744	rs12616502	ENSG00000272606.1	RP11-554J4.1	7.07	5.34e-12	3.66e-09	0.54	0.31	Vitiligo;	chr2:55581879	chr2:55617909~55618373:+
LUAD	cis	rs2153535	0.601	rs2327054	ENSG00000230939.1	RP11-314C16.1	-7.07	5.35e-12	3.67e-09	-0.36	-0.31	Motion sickness;	chr6:8442897	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.623	rs2327055	ENSG00000230939.1	RP11-314C16.1	-7.07	5.35e-12	3.67e-09	-0.36	-0.31	Motion sickness;	chr6:8442912	chr6:8784178~8785445:+
LUAD	cis	rs2243480	1	rs781156	ENSG00000273142.1	RP11-458F8.4	-7.07	5.36e-12	3.68e-09	-0.31	-0.31	Diabetic kidney disease;	chr7:66014154	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs781149	ENSG00000273142.1	RP11-458F8.4	-7.07	5.36e-12	3.68e-09	-0.31	-0.31	Diabetic kidney disease;	chr7:66016297	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs451396	ENSG00000273142.1	RP11-458F8.4	-7.07	5.36e-12	3.68e-09	-0.31	-0.31	Diabetic kidney disease;	chr7:66019087	chr7:66902857~66906297:+
LUAD	cis	rs2243480	0.901	rs58207111	ENSG00000273142.1	RP11-458F8.4	-7.07	5.36e-12	3.68e-09	-0.31	-0.31	Diabetic kidney disease;	chr7:66021736	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs1167613	ENSG00000273142.1	RP11-458F8.4	-7.07	5.36e-12	3.68e-09	-0.31	-0.31	Diabetic kidney disease;	chr7:66022452	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs1715235	ENSG00000273142.1	RP11-458F8.4	-7.07	5.36e-12	3.68e-09	-0.31	-0.31	Diabetic kidney disease;	chr7:66023407	chr7:66902857~66906297:+
LUAD	cis	rs9549367	0.713	rs1323315	ENSG00000269125.1	RP11-98F14.11	7.07	5.37e-12	3.68e-09	0.38	0.31	Platelet distribution width;	chr13:113205344	chr13:113165002~113165183:-
LUAD	cis	rs2243480	0.901	rs778730	ENSG00000273142.1	RP11-458F8.4	-7.07	5.4e-12	3.71e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66358338	chr7:66902857~66906297:+
LUAD	cis	rs237743	1	rs35506374	ENSG00000222365.1	SNORD12B	-7.07	5.4e-12	3.71e-09	-0.36	-0.31	Height;	chr20:49311346	chr20:49280319~49280409:+
LUAD	cis	rs7017914	0.967	rs1838393	ENSG00000223220.1	Y_RNA	7.07	5.42e-12	3.71e-09	0.34	0.31	Bone mineral density;	chr8:70790356	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.935	rs7826483	ENSG00000223220.1	Y_RNA	7.07	5.42e-12	3.71e-09	0.34	0.31	Bone mineral density;	chr8:70790658	chr8:70780914~70781008:-
LUAD	cis	rs673078	0.66	rs12229607	ENSG00000275759.1	RP11-131L12.3	-7.07	5.42e-12	3.72e-09	-0.42	-0.31	Glucose homeostasis traits;	chr12:118338333	chr12:118428281~118428870:+
LUAD	cis	rs2153535	0.58	rs915350	ENSG00000230939.1	RP11-314C16.1	-7.07	5.42e-12	3.72e-09	-0.36	-0.31	Motion sickness;	chr6:8443253	chr6:8784178~8785445:+
LUAD	cis	rs6142102	0.961	rs6059596	ENSG00000276073.1	RP5-1125A11.7	-7.07	5.42e-12	3.72e-09	-0.33	-0.31	Skin pigmentation;	chr20:33969313	chr20:33985617~33988989:-
LUAD	cis	rs9903692	0.909	rs11079806	ENSG00000278765.1	RP5-890E16.5	7.07	5.44e-12	3.73e-09	0.41	0.31	Pulse pressure;	chr17:48065318	chr17:48066704~48067293:-
LUAD	cis	rs10899021	1	rs61900635	ENSG00000279353.1	RP11-864N7.4	7.07	5.45e-12	3.73e-09	0.56	0.31	Response to metformin (IC50);	chr11:74647965	chr11:74698231~74699658:-
LUAD	cis	rs9828933	0.832	rs2292662	ENSG00000280620.1	SCAANT1	7.07	5.46e-12	3.74e-09	0.44	0.31	Type 2 diabetes;	chr3:63911539	chr3:63911518~63911772:-
LUAD	cis	rs2739330	0.76	rs5751761	ENSG00000206090.4	AP000350.7	-7.07	5.47e-12	3.75e-09	-0.33	-0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23939998~23942798:+
LUAD	cis	rs2286503	0.78	rs929464	ENSG00000228649.7	AC005682.5	7.07	5.48e-12	3.75e-09	0.39	0.31	Fibrinogen;	chr7:22835151	chr7:22854178~22861579:+
LUAD	cis	rs11214589	0.651	rs17600713	ENSG00000270179.1	RP11-159N11.4	-7.07	5.48e-12	3.76e-09	-0.31	-0.31	Neuroticism;	chr11:113389225	chr11:113368478~113369117:+
LUAD	cis	rs2153535	0.542	rs915353	ENSG00000230939.1	RP11-314C16.1	-7.07	5.48e-12	3.76e-09	-0.36	-0.31	Motion sickness;	chr6:8440137	chr6:8784178~8785445:+
LUAD	cis	rs7429990	0.727	rs319695	ENSG00000229759.1	MRPS18AP1	-7.07	5.48e-12	3.76e-09	-0.32	-0.31	Educational attainment (years of education);	chr3:47842749	chr3:48256350~48256938:-
LUAD	cis	rs6504950	0.924	rs244353	ENSG00000275710.1	RP11-257O5.4	-7.07	5.49e-12	3.76e-09	-0.36	-0.31	Breast cancer;	chr17:55117408	chr17:54964474~54964679:+
LUAD	cis	rs75422866	0.867	rs7304743	ENSG00000280054.1	RP1-197B17.7	-7.07	5.52e-12	3.78e-09	-0.63	-0.31	Pneumonia;	chr12:47683658	chr12:47728151~47730598:-
LUAD	cis	rs2439831	0.571	rs689883	ENSG00000205771.5	CATSPER2P1	-7.07	5.52e-12	3.78e-09	-0.53	-0.31	Lung cancer in ever smokers;	chr15:43520398	chr15:43726918~43747094:-
LUAD	cis	rs2243480	1	rs778729	ENSG00000273142.1	RP11-458F8.4	-7.07	5.53e-12	3.79e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66359432	chr7:66902857~66906297:+
LUAD	cis	rs113835537	0.529	rs7950407	ENSG00000255517.5	CTD-3074O7.5	-7.07	5.54e-12	3.8e-09	-0.36	-0.31	Airway imaging phenotypes;	chr11:66490535	chr11:66473490~66480233:-
LUAD	cis	rs1799949	1	rs35330014	ENSG00000267681.1	CTD-3199J23.6	-7.07	5.56e-12	3.81e-09	-0.35	-0.31	Menopause (age at onset);	chr17:43060530	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs3092994	ENSG00000267681.1	CTD-3199J23.6	-7.07	5.56e-12	3.81e-09	-0.35	-0.31	Menopause (age at onset);	chr17:43063808	chr17:43144956~43145255:+
LUAD	cis	rs11098499	0.863	rs1480940	ENSG00000248280.1	RP11-33B1.2	7.07	5.57e-12	3.81e-09	0.4	0.31	Corneal astigmatism;	chr4:119536527	chr4:119440561~119450157:-
LUAD	cis	rs1823913	1	rs11681777	ENSG00000227542.1	AC092614.2	-7.07	5.57e-12	3.82e-09	-0.39	-0.31	Obesity-related traits;	chr2:191256741	chr2:191229165~191246172:-
LUAD	cis	rs673078	0.66	rs16948234	ENSG00000275759.1	RP11-131L12.3	7.07	5.58e-12	3.82e-09	0.43	0.31	Glucose homeostasis traits;	chr12:118282464	chr12:118428281~118428870:+
LUAD	cis	rs950169	0.887	rs220333	ENSG00000259728.4	LINC00933	7.07	5.58e-12	3.82e-09	0.46	0.31	Schizophrenia;	chr15:84547902	chr15:84570649~84580175:+
LUAD	cis	rs131777	0.532	rs131747	ENSG00000205559.3	CHKB-AS1	-7.07	5.59e-12	3.83e-09	-0.33	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586645	chr22:50583026~50583877:+
LUAD	cis	rs11098499	0.954	rs10008392	ENSG00000248280.1	RP11-33B1.2	7.07	5.6e-12	3.83e-09	0.39	0.31	Corneal astigmatism;	chr4:119397684	chr4:119440561~119450157:-
LUAD	cis	rs867371	0.892	rs4344697	ENSG00000255769.6	GOLGA2P10	-7.07	5.66e-12	3.87e-09	-0.33	-0.31	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82252873	chr15:82472993~82513950:-
LUAD	cis	rs4591358	0.689	rs59017643	ENSG00000223466.1	AC064834.2	-7.07	5.67e-12	3.88e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195546835	chr2:195533035~195538681:+
LUAD	cis	rs1185460	0.546	rs592190	ENSG00000271751.1	RP11-110I1.14	7.06	5.67e-12	3.88e-09	0.4	0.31	Coronary artery disease;	chr11:119084604	chr11:119065263~119065677:-
LUAD	cis	rs1185460	0.546	rs589925	ENSG00000271751.1	RP11-110I1.14	7.06	5.67e-12	3.88e-09	0.4	0.31	Coronary artery disease;	chr11:119084969	chr11:119065263~119065677:-
LUAD	cis	rs77204473	0.744	rs2301174	ENSG00000254851.1	RP11-109L13.1	7.06	5.67e-12	3.88e-09	0.69	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117192993	chr11:117135528~117138582:+
LUAD	cis	rs8177876	1	rs8177876	ENSG00000261838.4	RP11-303E16.6	7.06	5.68e-12	3.88e-09	0.78	0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81090670	chr16:81069854~81076598:+
LUAD	cis	rs2919917	0.628	rs894222	ENSG00000254352.1	RP11-578O24.2	-7.06	5.68e-12	3.88e-09	-0.41	-0.31	Lymphocyte counts;	chr8:78737034	chr8:78723796~78724136:-
LUAD	cis	rs7246657	1	rs12709812	ENSG00000276846.1	CTD-3220F14.3	-7.06	5.7e-12	3.9e-09	-0.43	-0.31	Coronary artery calcification;	chr19:37303948	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.653	rs28701616	ENSG00000276846.1	CTD-3220F14.3	7.06	5.72e-12	3.91e-09	0.48	0.31	Coronary artery calcification;	chr19:37190196	chr19:37314868~37315620:-
LUAD	cis	rs2243480	1	rs1546059	ENSG00000273142.1	RP11-458F8.4	7.06	5.73e-12	3.92e-09	0.31	0.31	Diabetic kidney disease;	chr7:66189722	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs6958289	ENSG00000273142.1	RP11-458F8.4	7.06	5.73e-12	3.92e-09	0.31	0.31	Diabetic kidney disease;	chr7:66192124	chr7:66902857~66906297:+
LUAD	cis	rs11098499	0.954	rs3733520	ENSG00000248280.1	RP11-33B1.2	7.06	5.75e-12	3.93e-09	0.39	0.31	Corneal astigmatism;	chr4:119502325	chr4:119440561~119450157:-
LUAD	cis	rs9322193	0.962	rs6899661	ENSG00000223701.3	RAET1E-AS1	7.06	5.75e-12	3.93e-09	0.36	0.31	Lung cancer;	chr6:149818093	chr6:149884431~149919508:+
LUAD	cis	rs2153535	0.542	rs6912740	ENSG00000230939.1	RP11-314C16.1	-7.06	5.75e-12	3.93e-09	-0.36	-0.31	Motion sickness;	chr6:8439726	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.542	rs6905925	ENSG00000230939.1	RP11-314C16.1	-7.06	5.75e-12	3.93e-09	-0.36	-0.31	Motion sickness;	chr6:8439797	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.541	rs6905934	ENSG00000230939.1	RP11-314C16.1	-7.06	5.75e-12	3.93e-09	-0.36	-0.31	Motion sickness;	chr6:8439810	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs2327050	ENSG00000230939.1	RP11-314C16.1	-7.06	5.75e-12	3.93e-09	-0.36	-0.31	Motion sickness;	chr6:8440397	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs4404802	ENSG00000230939.1	RP11-314C16.1	-7.06	5.75e-12	3.93e-09	-0.36	-0.31	Motion sickness;	chr6:8441819	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1932275	ENSG00000230939.1	RP11-314C16.1	-7.06	5.75e-12	3.93e-09	-0.36	-0.31	Motion sickness;	chr6:8442100	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1932276	ENSG00000230939.1	RP11-314C16.1	-7.06	5.75e-12	3.93e-09	-0.36	-0.31	Motion sickness;	chr6:8442360	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs915352	ENSG00000230939.1	RP11-314C16.1	-7.06	5.75e-12	3.93e-09	-0.36	-0.31	Motion sickness;	chr6:8442533	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs915351	ENSG00000230939.1	RP11-314C16.1	-7.06	5.75e-12	3.93e-09	-0.36	-0.31	Motion sickness;	chr6:8442560	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs2327056	ENSG00000230939.1	RP11-314C16.1	-7.06	5.75e-12	3.93e-09	-0.36	-0.31	Motion sickness;	chr6:8443072	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs3938660	ENSG00000230939.1	RP11-314C16.1	-7.06	5.75e-12	3.93e-09	-0.36	-0.31	Motion sickness;	chr6:8443102	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1577467	ENSG00000230939.1	RP11-314C16.1	-7.06	5.75e-12	3.93e-09	-0.36	-0.31	Motion sickness;	chr6:8444008	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.601	rs1855765	ENSG00000230939.1	RP11-314C16.1	-7.06	5.75e-12	3.93e-09	-0.36	-0.31	Motion sickness;	chr6:8444092	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9406143	ENSG00000230939.1	RP11-314C16.1	-7.06	5.75e-12	3.93e-09	-0.36	-0.31	Motion sickness;	chr6:8444350	chr6:8784178~8785445:+
LUAD	cis	rs11089937	0.616	rs12484496	ENSG00000211639.2	IGLV4-60	-7.06	5.76e-12	3.93e-09	-0.32	-0.31	Periodontitis (PAL4Q3);	chr22:22180296	chr22:22162199~22162681:+
LUAD	cis	rs11098499	0.863	rs12508173	ENSG00000248280.1	RP11-33B1.2	7.06	5.76e-12	3.93e-09	0.4	0.31	Corneal astigmatism;	chr4:119397371	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.908	rs12504149	ENSG00000248280.1	RP11-33B1.2	7.06	5.76e-12	3.93e-09	0.4	0.31	Corneal astigmatism;	chr4:119397422	chr4:119440561~119450157:-
LUAD	cis	rs9640161	0.789	rs10282458	ENSG00000261305.1	RP4-584D14.7	7.06	5.77e-12	3.94e-09	0.44	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150348213	chr7:150341771~150342607:+
LUAD	cis	rs2243480	0.711	rs2420172	ENSG00000273142.1	RP11-458F8.4	7.06	5.77e-12	3.94e-09	0.31	0.31	Diabetic kidney disease;	chr7:66170354	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs2420171	ENSG00000273142.1	RP11-458F8.4	7.06	5.77e-12	3.94e-09	0.31	0.31	Diabetic kidney disease;	chr7:66172773	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs6974723	ENSG00000273142.1	RP11-458F8.4	7.06	5.77e-12	3.94e-09	0.31	0.31	Diabetic kidney disease;	chr7:66172952	chr7:66902857~66906297:+
LUAD	cis	rs9660180	0.967	rs61422524	ENSG00000268575.1	RP1-283E3.8	-7.06	5.8e-12	3.96e-09	-0.28	-0.31	Body mass index;	chr1:1836126	chr1:1702736~1737688:-
LUAD	cis	rs9549367	0.756	rs9603814	ENSG00000269125.1	RP11-98F14.11	7.06	5.8e-12	3.96e-09	0.36	0.31	Platelet distribution width;	chr13:113246468	chr13:113165002~113165183:-
LUAD	cis	rs7246657	0.765	rs10402455	ENSG00000276846.1	CTD-3220F14.3	7.06	5.81e-12	3.97e-09	0.47	0.31	Coronary artery calcification;	chr19:37237805	chr19:37314868~37315620:-
LUAD	cis	rs8081395	0.805	rs1295927	ENSG00000266992.1	DHX40P1	7.06	5.82e-12	3.97e-09	0.35	0.31	White blood cell count;	chr17:59852174	chr17:59976009~60002384:-
LUAD	cis	rs2243480	0.708	rs35825036	ENSG00000273142.1	RP11-458F8.4	-7.06	5.82e-12	3.97e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66521515	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs13237037	ENSG00000273142.1	RP11-458F8.4	-7.06	5.82e-12	3.97e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66532895	chr7:66902857~66906297:+
LUAD	cis	rs2243480	0.901	rs13237344	ENSG00000273142.1	RP11-458F8.4	-7.06	5.82e-12	3.97e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66557269	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs1796228	ENSG00000273142.1	RP11-458F8.4	-7.06	5.82e-12	3.97e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66568097	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs1267820	ENSG00000273142.1	RP11-458F8.4	-7.06	5.82e-12	3.97e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66585308	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs2533288	ENSG00000273142.1	RP11-458F8.4	-7.06	5.82e-12	3.97e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66591724	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs2707844	ENSG00000273142.1	RP11-458F8.4	-7.06	5.82e-12	3.97e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66594522	chr7:66902857~66906297:+
LUAD	cis	rs944289	0.966	rs1169146	ENSG00000257826.1	RP11-116N8.4	-7.06	5.85e-12	3.99e-09	-0.32	-0.31	Thyroid cancer;	chr14:36163563	chr14:36061026~36067190:-
LUAD	cis	rs950169	0.959	rs12902070	ENSG00000225151.9	GOLGA2P7	-7.06	5.86e-12	4e-09	-0.44	-0.31	Schizophrenia;	chr15:84124806	chr15:84199311~84230136:-
LUAD	cis	rs10759883	0.563	rs694230	ENSG00000175611.10	LINC00476	7.06	5.86e-12	4e-09	0.36	0.31	Nicotine dependence;	chr9:95954227	chr9:95759231~95875977:-
LUAD	cis	rs9549367	0.713	rs3024745	ENSG00000269125.1	RP11-98F14.11	-7.06	5.87e-12	4e-09	-0.41	-0.31	Platelet distribution width;	chr13:113167284	chr13:113165002~113165183:-
LUAD	cis	rs62229266	0.804	rs62230821	ENSG00000214914.3	RPL23AP3	7.06	5.9e-12	4.02e-09	0.37	0.31	Mitral valve prolapse;	chr21:36052818	chr21:36016079~36016546:-
LUAD	cis	rs11098499	0.863	rs3733525	ENSG00000248280.1	RP11-33B1.2	7.06	5.9e-12	4.03e-09	0.39	0.31	Corneal astigmatism;	chr4:119525893	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.909	rs6842762	ENSG00000248280.1	RP11-33B1.2	7.06	5.91e-12	4.03e-09	0.39	0.31	Corneal astigmatism;	chr4:119477081	chr4:119440561~119450157:-
LUAD	cis	rs3762637	0.941	rs9863712	ENSG00000272758.4	RP11-299J3.8	-7.06	5.92e-12	4.03e-09	-0.48	-0.31	LDL cholesterol levels;	chr3:122381059	chr3:122416207~122443180:+
LUAD	cis	rs3762637	0.941	rs28679619	ENSG00000272758.4	RP11-299J3.8	-7.06	5.92e-12	4.03e-09	-0.48	-0.31	LDL cholesterol levels;	chr3:122381502	chr3:122416207~122443180:+
LUAD	cis	rs11098499	0.954	rs13107475	ENSG00000248280.1	RP11-33B1.2	7.06	5.93e-12	4.04e-09	0.39	0.31	Corneal astigmatism;	chr4:119471856	chr4:119440561~119450157:-
LUAD	cis	rs237743	1	rs56335217	ENSG00000222365.1	SNORD12B	-7.06	5.95e-12	4.06e-09	-0.36	-0.31	Height;	chr20:49254660	chr20:49280319~49280409:+
LUAD	cis	rs1345301	1	rs12470560	ENSG00000234389.1	AC007278.3	-7.06	5.96e-12	4.06e-09	-0.28	-0.31	Waist circumference;	chr2:102252380	chr2:102438713~102440475:+
LUAD	cis	rs6991838	0.671	rs13251307	ENSG00000272010.1	CTD-3025N20.3	7.06	5.96e-12	4.06e-09	0.32	0.31	Intelligence (multi-trait analysis);	chr8:65664911	chr8:65591850~65592472:-
LUAD	cis	rs11214589	0.905	rs12804573	ENSG00000270179.1	RP11-159N11.4	-7.06	5.97e-12	4.07e-09	-0.31	-0.31	Neuroticism;	chr11:113371004	chr11:113368478~113369117:+
LUAD	cis	rs11214589	0.905	rs12805699	ENSG00000270179.1	RP11-159N11.4	-7.06	5.97e-12	4.07e-09	-0.31	-0.31	Neuroticism;	chr11:113371088	chr11:113368478~113369117:+
LUAD	cis	rs4713118	0.662	rs9357060	ENSG00000219392.1	RP1-265C24.5	-7.06	5.98e-12	4.08e-09	-0.42	-0.31	Parkinson's disease;	chr6:28056708	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.662	rs9468271	ENSG00000219392.1	RP1-265C24.5	-7.06	5.98e-12	4.08e-09	-0.42	-0.31	Parkinson's disease;	chr6:28056792	chr6:28115628~28116551:+
LUAD	cis	rs6142102	0.812	rs761238	ENSG00000276073.1	RP5-1125A11.7	7.06	5.99e-12	4.08e-09	0.31	0.31	Skin pigmentation;	chr20:33932182	chr20:33985617~33988989:-
LUAD	cis	rs4713118	0.629	rs203889	ENSG00000219392.1	RP1-265C24.5	-7.06	6e-12	4.09e-09	-0.42	-0.31	Parkinson's disease;	chr6:28053997	chr6:28115628~28116551:+
LUAD	cis	rs2280018	0.526	rs2966128	ENSG00000188599.16	NPIPP1	-7.06	6e-12	4.09e-09	-0.27	-0.31	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059532	chr16:15104312~15123498:-
LUAD	cis	rs11098499	0.618	rs28491261	ENSG00000248280.1	RP11-33B1.2	7.06	6e-12	4.09e-09	0.4	0.31	Corneal astigmatism;	chr4:119373745	chr4:119440561~119450157:-
LUAD	cis	rs10899021	1	rs11236186	ENSG00000279353.1	RP11-864N7.4	7.05	6.07e-12	4.13e-09	0.56	0.31	Response to metformin (IC50);	chr11:74651820	chr11:74698231~74699658:-
LUAD	cis	rs10899021	1	rs7935426	ENSG00000279353.1	RP11-864N7.4	7.05	6.07e-12	4.13e-09	0.56	0.31	Response to metformin (IC50);	chr11:74652845	chr11:74698231~74699658:-
LUAD	cis	rs9322193	0.923	rs4869750	ENSG00000223701.3	RAET1E-AS1	7.05	6.09e-12	4.14e-09	0.36	0.31	Lung cancer;	chr6:149855996	chr6:149884431~149919508:+
LUAD	cis	rs4713118	0.513	rs149962	ENSG00000219392.1	RP1-265C24.5	-7.05	6.09e-12	4.14e-09	-0.39	-0.31	Parkinson's disease;	chr6:28048140	chr6:28115628~28116551:+
LUAD	cis	rs8059260	0.736	rs8044180	ENSG00000274038.1	RP11-66H6.4	-7.05	6.14e-12	4.17e-09	-0.57	-0.31	Alcohol consumption over the past year;	chr16:10952531	chr16:11056556~11057034:+
LUAD	cis	rs8059260	0.736	rs7192171	ENSG00000274038.1	RP11-66H6.4	-7.05	6.14e-12	4.17e-09	-0.57	-0.31	Alcohol consumption over the past year;	chr16:10955262	chr16:11056556~11057034:+
LUAD	cis	rs3779195	0.929	rs2906184	ENSG00000272950.1	RP11-307C18.1	-7.05	6.15e-12	4.18e-09	-0.52	-0.31	Sex hormone-binding globulin levels;	chr7:98310675	chr7:98322853~98323430:+
LUAD	cis	rs35955747	0.902	rs739427	ENSG00000236132.1	CTA-440B3.1	-7.05	6.15e-12	4.18e-09	-0.35	-0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31263115	chr22:31816379~31817491:-
LUAD	cis	rs11690935	0.595	rs788171	ENSG00000228389.1	AC068039.4	-7.05	6.15e-12	4.18e-09	-0.32	-0.31	Schizophrenia;	chr2:172057104	chr2:171773482~171775844:+
LUAD	cis	rs172166	0.769	rs149965	ENSG00000219392.1	RP1-265C24.5	-7.05	6.17e-12	4.19e-09	-0.39	-0.31	Cardiac Troponin-T levels;	chr6:28050911	chr6:28115628~28116551:+
LUAD	cis	rs11123170	0.543	rs2166421	ENSG00000274877.1	RP11-65I12.1	-7.05	6.17e-12	4.2e-09	-0.48	-0.31	Renal function-related traits (BUN);	chr2:113232665	chr2:113237595~113240825:+
LUAD	cis	rs2243480	0.803	rs13224048	ENSG00000273142.1	RP11-458F8.4	-7.05	6.19e-12	4.2e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66528779	chr7:66902857~66906297:+
LUAD	cis	rs6142102	0.923	rs4911383	ENSG00000276073.1	RP5-1125A11.7	-7.05	6.19e-12	4.21e-09	-0.32	-0.31	Skin pigmentation;	chr20:33967973	chr20:33985617~33988989:-
LUAD	cis	rs10129255	0.913	rs28861466	ENSG00000280411.1	IGHV1-69-2	-7.05	6.19e-12	4.21e-09	-0.24	-0.31	Kawasaki disease;	chr14:106718572	chr14:106762092~106762588:-
LUAD	cis	rs2243480	1	rs1723267	ENSG00000273142.1	RP11-458F8.4	-7.05	6.21e-12	4.22e-09	-0.31	-0.31	Diabetic kidney disease;	chr7:66008327	chr7:66902857~66906297:+
LUAD	cis	rs2153535	0.58	rs4140586	ENSG00000230939.1	RP11-314C16.1	-7.05	6.22e-12	4.23e-09	-0.36	-0.31	Motion sickness;	chr6:8502959	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.601	rs4140585	ENSG00000230939.1	RP11-314C16.1	-7.05	6.22e-12	4.23e-09	-0.36	-0.31	Motion sickness;	chr6:8503065	chr6:8784178~8785445:+
LUAD	cis	rs11098499	0.954	rs10518328	ENSG00000248280.1	RP11-33B1.2	7.05	6.22e-12	4.23e-09	0.39	0.31	Corneal astigmatism;	chr4:119480624	chr4:119440561~119450157:-
LUAD	cis	rs9326248	0.53	rs510988	ENSG00000280143.1	AP000892.6	7.05	6.23e-12	4.23e-09	0.48	0.31	Blood protein levels;	chr11:116943088	chr11:117204967~117210292:+
LUAD	cis	rs7115242	0.669	rs1241658	ENSG00000280143.1	AP000892.6	7.05	6.23e-12	4.23e-09	0.48	0.31	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116948901	chr11:117204967~117210292:+
LUAD	cis	rs9549367	0.789	rs2287250	ENSG00000269125.1	RP11-98F14.11	7.05	6.23e-12	4.23e-09	0.36	0.31	Platelet distribution width;	chr13:113235160	chr13:113165002~113165183:-
LUAD	cis	rs11098499	0.909	rs11723757	ENSG00000248280.1	RP11-33B1.2	7.05	6.23e-12	4.23e-09	0.39	0.31	Corneal astigmatism;	chr4:119378514	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs10014845	ENSG00000248280.1	RP11-33B1.2	7.05	6.23e-12	4.23e-09	0.39	0.31	Corneal astigmatism;	chr4:119379922	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.779	rs7674500	ENSG00000248280.1	RP11-33B1.2	7.05	6.23e-12	4.23e-09	0.39	0.31	Corneal astigmatism;	chr4:119382438	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.909	rs28884220	ENSG00000248280.1	RP11-33B1.2	7.05	6.23e-12	4.23e-09	0.39	0.31	Corneal astigmatism;	chr4:119386056	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.909	rs28793658	ENSG00000248280.1	RP11-33B1.2	7.05	6.23e-12	4.23e-09	0.39	0.31	Corneal astigmatism;	chr4:119386059	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.865	rs4507344	ENSG00000248280.1	RP11-33B1.2	7.05	6.23e-12	4.23e-09	0.39	0.31	Corneal astigmatism;	chr4:119386330	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.697	rs4373140	ENSG00000248280.1	RP11-33B1.2	7.05	6.23e-12	4.23e-09	0.39	0.31	Corneal astigmatism;	chr4:119386543	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs13113483	ENSG00000248280.1	RP11-33B1.2	7.05	6.23e-12	4.23e-09	0.39	0.31	Corneal astigmatism;	chr4:119387884	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.542	rs10440343	ENSG00000248280.1	RP11-33B1.2	7.05	6.23e-12	4.23e-09	0.39	0.31	Corneal astigmatism;	chr4:119388632	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.909	rs28668716	ENSG00000248280.1	RP11-33B1.2	7.05	6.23e-12	4.23e-09	0.39	0.31	Corneal astigmatism;	chr4:119388720	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.542	rs7677836	ENSG00000248280.1	RP11-33B1.2	7.05	6.23e-12	4.23e-09	0.39	0.31	Corneal astigmatism;	chr4:119389483	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.909	rs10002083	ENSG00000248280.1	RP11-33B1.2	7.05	6.23e-12	4.23e-09	0.39	0.31	Corneal astigmatism;	chr4:119389997	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs10024844	ENSG00000248280.1	RP11-33B1.2	7.05	6.23e-12	4.23e-09	0.39	0.31	Corneal astigmatism;	chr4:119390373	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.657	rs4463052	ENSG00000248280.1	RP11-33B1.2	7.05	6.23e-12	4.23e-09	0.39	0.31	Corneal astigmatism;	chr4:119392103	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs13151285	ENSG00000248280.1	RP11-33B1.2	7.05	6.23e-12	4.23e-09	0.39	0.31	Corneal astigmatism;	chr4:119393586	chr4:119440561~119450157:-
LUAD	cis	rs9640161	0.789	rs28439010	ENSG00000261305.1	RP4-584D14.7	7.05	6.24e-12	4.24e-09	0.45	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150349187	chr7:150341771~150342607:+
LUAD	cis	rs9326248	0.53	rs2513095	ENSG00000280143.1	AP000892.6	7.05	6.26e-12	4.24e-09	0.48	0.31	Blood protein levels;	chr11:116935553	chr11:117204967~117210292:+
LUAD	cis	rs2842992	0.714	rs2495278	ENSG00000237927.1	RP3-393E18.2	-7.05	6.27e-12	4.25e-09	-0.44	-0.31	Age-related macular degeneration (geographic atrophy);	chr6:159702642	chr6:159586955~159589169:-
LUAD	cis	rs733592	0.56	rs61918773	ENSG00000240399.1	RP1-228P16.1	-7.05	6.29e-12	4.26e-09	-0.3	-0.31	Plateletcrit;	chr12:48027991	chr12:48054813~48055591:-
LUAD	cis	rs35955747	0.934	rs131200	ENSG00000236132.1	CTA-440B3.1	-7.05	6.31e-12	4.28e-09	-0.34	-0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31307286	chr22:31816379~31817491:-
LUAD	cis	rs7017914	0.967	rs1348535	ENSG00000223220.1	Y_RNA	7.05	6.32e-12	4.29e-09	0.34	0.31	Bone mineral density;	chr8:70750506	chr8:70780914~70781008:-
LUAD	cis	rs11098499	0.954	rs12510138	ENSG00000248280.1	RP11-33B1.2	7.05	6.33e-12	4.29e-09	0.39	0.31	Corneal astigmatism;	chr4:119502780	chr4:119440561~119450157:-
LUAD	cis	rs72772090	0.539	rs10515250	ENSG00000248734.2	CTD-2260A17.1	-7.05	6.35e-12	4.3e-09	-0.48	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96814490	chr5:96784777~96785999:+
LUAD	cis	rs9640161	0.789	rs6964110	ENSG00000261305.1	RP4-584D14.7	7.05	6.35e-12	4.31e-09	0.43	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150344747	chr7:150341771~150342607:+
LUAD	cis	rs748404	0.69	rs2244981	ENSG00000249839.1	AC011330.5	-7.05	6.36e-12	4.31e-09	-0.4	-0.31	Lung cancer;	chr15:43460553	chr15:43663654~43684339:-
LUAD	cis	rs72772090	0.539	rs10515247	ENSG00000248734.2	CTD-2260A17.1	-7.05	6.36e-12	4.31e-09	-0.48	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776022	chr5:96784777~96785999:+
LUAD	cis	rs12134133	1	rs6540893	ENSG00000274245.1	RP11-357P18.2	7.05	6.37e-12	4.32e-09	0.4	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207262382	chr1:207372559~207373252:+
LUAD	cis	rs12134133	1	rs61822674	ENSG00000274245.1	RP11-357P18.2	7.05	6.37e-12	4.32e-09	0.4	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207263378	chr1:207372559~207373252:+
LUAD	cis	rs12134133	1	rs10442696	ENSG00000274245.1	RP11-357P18.2	7.05	6.37e-12	4.32e-09	0.4	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207264783	chr1:207372559~207373252:+
LUAD	cis	rs12134133	1	rs7535532	ENSG00000274245.1	RP11-357P18.2	7.05	6.37e-12	4.32e-09	0.4	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207264991	chr1:207372559~207373252:+
LUAD	cis	rs12134133	1	rs7543117	ENSG00000274245.1	RP11-357P18.2	7.05	6.37e-12	4.32e-09	0.4	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207265351	chr1:207372559~207373252:+
LUAD	cis	rs12134133	1	rs11582249	ENSG00000274245.1	RP11-357P18.2	7.05	6.37e-12	4.32e-09	0.4	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207268263	chr1:207372559~207373252:+
LUAD	cis	rs72772090	0.539	rs11747179	ENSG00000248734.2	CTD-2260A17.1	-7.05	6.39e-12	4.33e-09	-0.48	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777265	chr5:96784777~96785999:+
LUAD	cis	rs2243480	1	rs781157	ENSG00000273142.1	RP11-458F8.4	-7.05	6.4e-12	4.34e-09	-0.31	-0.31	Diabetic kidney disease;	chr7:66013324	chr7:66902857~66906297:+
LUAD	cis	rs17301013	0.507	rs6700482	ENSG00000227373.4	RP11-160H22.5	7.05	6.41e-12	4.34e-09	0.46	0.31	Systemic lupus erythematosus;	chr1:174306699	chr1:174115300~174160004:-
LUAD	cis	rs1823913	1	rs4853568	ENSG00000227542.1	AC092614.2	-7.05	6.41e-12	4.34e-09	-0.4	-0.31	Obesity-related traits;	chr2:191261464	chr2:191229165~191246172:-
LUAD	cis	rs7923609	0.578	rs3858121	ENSG00000232075.1	MRPL35P2	-7.05	6.42e-12	4.35e-09	-0.38	-0.31	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63640237	chr10:63634317~63634827:-
LUAD	cis	rs9487094	0.626	rs7773950	ENSG00000260273.1	RP11-425D10.10	7.05	6.42e-12	4.35e-09	0.41	0.31	Height;	chr6:109494237	chr6:109382795~109383666:+
LUAD	cis	rs4713118	0.513	rs149958	ENSG00000219392.1	RP1-265C24.5	-7.05	6.44e-12	4.36e-09	-0.39	-0.31	Parkinson's disease;	chr6:28045839	chr6:28115628~28116551:+
LUAD	cis	rs62229266	0.804	rs62230822	ENSG00000214914.3	RPL23AP3	7.05	6.44e-12	4.36e-09	0.37	0.31	Mitral valve prolapse;	chr21:36057647	chr21:36016079~36016546:-
LUAD	cis	rs6142102	0.923	rs6057961	ENSG00000276073.1	RP5-1125A11.7	-7.04	6.46e-12	4.38e-09	-0.32	-0.31	Skin pigmentation;	chr20:33986005	chr20:33985617~33988989:-
LUAD	cis	rs4938303	0.718	rs3212282	ENSG00000254851.1	RP11-109L13.1	-7.04	6.47e-12	4.38e-09	-0.47	-0.31	Triglycerides;	chr11:116731229	chr11:117135528~117138582:+
LUAD	cis	rs10129255	0.957	rs8009948	ENSG00000280411.1	IGHV1-69-2	-7.04	6.49e-12	4.39e-09	-0.24	-0.31	Kawasaki disease;	chr14:106805607	chr14:106762092~106762588:-
LUAD	cis	rs853679	0.567	rs6905380	ENSG00000204709.4	LINC01556	7.04	6.49e-12	4.4e-09	0.4	0.31	Depression;	chr6:28407125	chr6:28943877~28944537:+
LUAD	cis	rs77204473	0.744	rs6589606	ENSG00000254851.1	RP11-109L13.1	7.04	6.52e-12	4.41e-09	0.69	0.31	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117222170	chr11:117135528~117138582:+
LUAD	cis	rs1799949	0.965	rs8176322	ENSG00000267681.1	CTD-3199J23.6	-7.04	6.55e-12	4.43e-09	-0.35	-0.31	Menopause (age at onset);	chr17:43043756	chr17:43144956~43145255:+
LUAD	cis	rs35955747	0.902	rs713947	ENSG00000236132.1	CTA-440B3.1	7.04	6.55e-12	4.43e-09	0.34	0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31243523	chr22:31816379~31817491:-
LUAD	cis	rs35955747	0.902	rs11703927	ENSG00000236132.1	CTA-440B3.1	7.04	6.55e-12	4.43e-09	0.34	0.31	Neutrophil count;Sum basophil neutrophil counts;	chr22:31248978	chr22:31816379~31817491:-
LUAD	cis	rs17301013	0.507	rs10912759	ENSG00000227373.4	RP11-160H22.5	7.04	6.56e-12	4.43e-09	0.45	0.31	Systemic lupus erythematosus;	chr1:174312178	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs6425278	ENSG00000227373.4	RP11-160H22.5	7.04	6.56e-12	4.43e-09	0.45	0.31	Systemic lupus erythematosus;	chr1:174313148	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12083548	ENSG00000227373.4	RP11-160H22.5	7.04	6.56e-12	4.43e-09	0.45	0.31	Systemic lupus erythematosus;	chr1:174319134	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12083814	ENSG00000227373.4	RP11-160H22.5	7.04	6.56e-12	4.43e-09	0.45	0.31	Systemic lupus erythematosus;	chr1:174319917	chr1:174115300~174160004:-
LUAD	cis	rs6921919	0.638	rs1416920	ENSG00000216901.1	AL022393.7	7.04	6.57e-12	4.44e-09	0.37	0.31	Autism spectrum disorder or schizophrenia;	chr6:28335007	chr6:28176188~28176674:+
LUAD	cis	rs72772090	0.539	rs72773942	ENSG00000248734.2	CTD-2260A17.1	-7.04	6.57e-12	4.45e-09	-0.47	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96787663	chr5:96784777~96785999:+
LUAD	cis	rs2739330	0.76	rs5751761	ENSG00000099984.9	GSTT2	7.04	6.61e-12	4.47e-09	0.35	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23980123~23983911:+
LUAD	cis	rs4591358	0.689	rs2889034	ENSG00000223466.1	AC064834.2	-7.04	6.61e-12	4.47e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195548022	chr2:195533035~195538681:+
LUAD	cis	rs8100891	0.537	rs4805755	ENSG00000267213.4	AC007773.2	7.04	6.64e-12	4.49e-09	0.46	0.31	Neuroticism;	chr19:32363564	chr19:32390050~32405560:-
LUAD	cis	rs62229266	0.633	rs743420	ENSG00000214914.3	RPL23AP3	7.04	6.65e-12	4.5e-09	0.37	0.31	Mitral valve prolapse;	chr21:36015104	chr21:36016079~36016546:-
LUAD	cis	rs11098499	0.954	rs9998585	ENSG00000248280.1	RP11-33B1.2	7.04	6.66e-12	4.5e-09	0.39	0.31	Corneal astigmatism;	chr4:119475647	chr4:119440561~119450157:-
LUAD	cis	rs673078	0.607	rs2784	ENSG00000275759.1	RP11-131L12.3	-7.04	6.66e-12	4.5e-09	-0.48	-0.31	Glucose homeostasis traits;	chr12:118311745	chr12:118428281~118428870:+
LUAD	cis	rs10129255	0.5	rs2027903	ENSG00000211970.3	IGHV4-61	-7.04	6.67e-12	4.51e-09	-0.22	-0.31	Kawasaki disease;	chr14:106807047	chr14:106639119~106639657:-
LUAD	cis	rs10129255	0.518	rs28378320	ENSG00000211970.3	IGHV4-61	-7.04	6.67e-12	4.51e-09	-0.22	-0.31	Kawasaki disease;	chr14:106808609	chr14:106639119~106639657:-
LUAD	cis	rs10875746	0.669	rs11168516	ENSG00000240399.1	RP1-228P16.1	-7.04	6.67e-12	4.51e-09	-0.36	-0.31	Longevity (90 years and older);	chr12:48308282	chr12:48054813~48055591:-
LUAD	cis	rs11676348	0.935	rs6716276	ENSG00000261338.2	RP11-378A13.1	-7.04	6.67e-12	4.51e-09	-0.33	-0.31	Ulcerative colitis;	chr2:218097482	chr2:218255319~218257366:+
LUAD	cis	rs7044106	0.791	rs3904196	ENSG00000238181.2	AHCYP2	-7.04	6.68e-12	4.51e-09	-0.4	-0.31	Hip circumference adjusted for BMI;	chr9:120718091	chr9:120720673~120721972:+
LUAD	cis	rs2739330	0.685	rs4822453	ENSG00000206090.4	AP000350.7	7.04	6.7e-12	4.52e-09	0.34	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23939998~23942798:+
LUAD	cis	rs9487094	0.666	rs974034	ENSG00000260273.1	RP11-425D10.10	7.04	6.7e-12	4.53e-09	0.38	0.31	Height;	chr6:109368228	chr6:109382795~109383666:+
LUAD	cis	rs748404	0.578	rs2278856	ENSG00000249839.1	AC011330.5	-7.04	6.71e-12	4.53e-09	-0.4	-0.31	Lung cancer;	chr15:43339158	chr15:43663654~43684339:-
LUAD	cis	rs172166	0.611	rs203882	ENSG00000219392.1	RP1-265C24.5	-7.04	6.72e-12	4.54e-09	-0.4	-0.31	Cardiac Troponin-T levels;	chr6:28110724	chr6:28115628~28116551:+
LUAD	cis	rs2243480	1	rs9769882	ENSG00000273142.1	RP11-458F8.4	7.04	6.73e-12	4.54e-09	0.31	0.31	Diabetic kidney disease;	chr7:66177938	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs6966322	ENSG00000273142.1	RP11-458F8.4	7.04	6.73e-12	4.54e-09	0.31	0.31	Diabetic kidney disease;	chr7:66181767	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs4145008	ENSG00000273142.1	RP11-458F8.4	7.04	6.73e-12	4.54e-09	0.31	0.31	Diabetic kidney disease;	chr7:66182524	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs4718315	ENSG00000273142.1	RP11-458F8.4	7.04	6.73e-12	4.54e-09	0.31	0.31	Diabetic kidney disease;	chr7:66183554	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs4718316	ENSG00000273142.1	RP11-458F8.4	7.04	6.73e-12	4.54e-09	0.31	0.31	Diabetic kidney disease;	chr7:66183744	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs1873494	ENSG00000273142.1	RP11-458F8.4	7.04	6.73e-12	4.54e-09	0.31	0.31	Diabetic kidney disease;	chr7:66184912	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs6959002	ENSG00000273142.1	RP11-458F8.4	7.04	6.73e-12	4.54e-09	0.31	0.31	Diabetic kidney disease;	chr7:66185509	chr7:66902857~66906297:+
LUAD	cis	rs10129255	0.957	rs10150241	ENSG00000280411.1	IGHV1-69-2	7.04	6.73e-12	4.55e-09	0.22	0.31	Kawasaki disease;	chr14:106775945	chr14:106762092~106762588:-
LUAD	cis	rs3096299	0.967	rs28575874	ENSG00000274627.1	RP11-104N10.2	7.04	6.73e-12	4.55e-09	0.29	0.31	Multiple myeloma (IgH translocation);	chr16:89403482	chr16:89516797~89522217:+
LUAD	cis	rs150992	0.632	rs162341	ENSG00000248489.1	CTD-2007H13.3	7.04	6.74e-12	4.55e-09	0.33	0.31	Body mass index;	chr5:98967230	chr5:98929171~98995013:+
LUAD	cis	rs35160687	0.901	rs13020869	ENSG00000273080.1	RP11-301O19.1	7.04	6.74e-12	4.55e-09	0.34	0.31	Night sleep phenotypes;	chr2:86296237	chr2:86195590~86196049:+
LUAD	cis	rs1499614	1	rs2707840	ENSG00000273142.1	RP11-458F8.4	-7.04	6.76e-12	4.57e-09	-0.32	-0.31	Gout;	chr7:66693028	chr7:66902857~66906297:+
LUAD	cis	rs6142102	0.924	rs6059662	ENSG00000276073.1	RP5-1125A11.7	7.04	6.77e-12	4.57e-09	0.32	0.31	Skin pigmentation;	chr20:34087921	chr20:33985617~33988989:-
LUAD	cis	rs7017914	0.934	rs62508771	ENSG00000223220.1	Y_RNA	7.04	6.78e-12	4.57e-09	0.34	0.31	Bone mineral density;	chr8:70780453	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs6998786	ENSG00000223220.1	Y_RNA	7.04	6.78e-12	4.57e-09	0.34	0.31	Bone mineral density;	chr8:70782395	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs12680988	ENSG00000223220.1	Y_RNA	7.04	6.78e-12	4.57e-09	0.34	0.31	Bone mineral density;	chr8:70783655	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs1596566	ENSG00000223220.1	Y_RNA	7.04	6.78e-12	4.57e-09	0.34	0.31	Bone mineral density;	chr8:70786341	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs6993115	ENSG00000223220.1	Y_RNA	7.04	6.78e-12	4.57e-09	0.34	0.31	Bone mineral density;	chr8:70786948	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.934	rs6992879	ENSG00000223220.1	Y_RNA	7.04	6.78e-12	4.57e-09	0.34	0.31	Bone mineral density;	chr8:70787048	chr8:70780914~70781008:-
LUAD	cis	rs11098499	0.863	rs10013305	ENSG00000248280.1	RP11-33B1.2	7.04	6.8e-12	4.59e-09	0.39	0.31	Corneal astigmatism;	chr4:119529269	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs3775849	ENSG00000248280.1	RP11-33B1.2	7.04	6.8e-12	4.59e-09	0.39	0.31	Corneal astigmatism;	chr4:119529753	chr4:119440561~119450157:-
LUAD	cis	rs8031584	0.697	rs8036176	ENSG00000260382.1	RP11-540B6.2	7.04	6.8e-12	4.59e-09	0.39	0.31	Huntington's disease progression;	chr15:30883066	chr15:30882267~30883231:-
LUAD	cis	rs2243480	0.901	rs778732	ENSG00000273142.1	RP11-458F8.4	-7.04	6.8e-12	4.59e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66357373	chr7:66902857~66906297:+
LUAD	cis	rs72772090	0.539	rs10515248	ENSG00000248734.2	CTD-2260A17.1	-7.04	6.81e-12	4.59e-09	-0.47	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776301	chr5:96784777~96785999:+
LUAD	cis	rs72772090	0.539	rs56213813	ENSG00000248734.2	CTD-2260A17.1	-7.04	6.81e-12	4.59e-09	-0.47	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776580	chr5:96784777~96785999:+
LUAD	cis	rs72772090	0.52	rs56325109	ENSG00000248734.2	CTD-2260A17.1	-7.04	6.81e-12	4.59e-09	-0.47	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96776591	chr5:96784777~96785999:+
LUAD	cis	rs72772090	0.539	rs11747148	ENSG00000248734.2	CTD-2260A17.1	-7.04	6.81e-12	4.59e-09	-0.47	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777159	chr5:96784777~96785999:+
LUAD	cis	rs62229266	0.771	rs62230790	ENSG00000214914.3	RPL23AP3	7.04	6.81e-12	4.6e-09	0.38	0.31	Mitral valve prolapse;	chr21:36016613	chr21:36016079~36016546:-
LUAD	cis	rs11098499	0.863	rs12502389	ENSG00000248280.1	RP11-33B1.2	7.04	6.82e-12	4.6e-09	0.39	0.31	Corneal astigmatism;	chr4:119533036	chr4:119440561~119450157:-
LUAD	cis	rs2153535	0.58	rs9406165	ENSG00000230939.1	RP11-314C16.1	-7.04	6.83e-12	4.61e-09	-0.36	-0.31	Motion sickness;	chr6:8488604	chr6:8784178~8785445:+
LUAD	cis	rs673078	0.66	rs78690826	ENSG00000275759.1	RP11-131L12.3	-7.04	6.84e-12	4.62e-09	-0.47	-0.31	Glucose homeostasis traits;	chr12:118176693	chr12:118428281~118428870:+
LUAD	cis	rs4713118	0.513	rs149941	ENSG00000219392.1	RP1-265C24.5	-7.04	6.85e-12	4.62e-09	-0.39	-0.31	Parkinson's disease;	chr6:28033255	chr6:28115628~28116551:+
LUAD	cis	rs7017914	0.967	rs35207116	ENSG00000223220.1	Y_RNA	7.04	6.85e-12	4.62e-09	0.34	0.31	Bone mineral density;	chr8:70796736	chr8:70780914~70781008:-
LUAD	cis	rs9545047	0.625	rs9545109	ENSG00000227676.3	LINC01068	7.04	6.87e-12	4.63e-09	0.36	0.31	Schizophrenia;	chr13:79413480	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.518	rs7328494	ENSG00000227676.3	LINC01068	7.04	6.87e-12	4.63e-09	0.36	0.31	Schizophrenia;	chr13:79414673	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs2147568	ENSG00000227676.3	LINC01068	7.04	6.87e-12	4.63e-09	0.36	0.31	Schizophrenia;	chr13:79417091	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs9530917	ENSG00000227676.3	LINC01068	7.04	6.87e-12	4.63e-09	0.36	0.31	Schizophrenia;	chr13:79417719	chr13:79566727~79571436:+
LUAD	cis	rs9545047	0.604	rs7990321	ENSG00000227676.3	LINC01068	7.04	6.87e-12	4.63e-09	0.36	0.31	Schizophrenia;	chr13:79418066	chr13:79566727~79571436:+
LUAD	cis	rs7017914	0.967	rs62508819	ENSG00000223220.1	Y_RNA	7.04	6.89e-12	4.65e-09	0.34	0.31	Bone mineral density;	chr8:70805871	chr8:70780914~70781008:-
LUAD	cis	rs11214589	0.651	rs11214595	ENSG00000270179.1	RP11-159N11.4	-7.03	6.89e-12	4.65e-09	-0.31	-0.31	Neuroticism;	chr11:113388936	chr11:113368478~113369117:+
LUAD	cis	rs11098499	0.909	rs11723839	ENSG00000248280.1	RP11-33B1.2	7.03	6.91e-12	4.66e-09	0.39	0.31	Corneal astigmatism;	chr4:119378518	chr4:119440561~119450157:-
LUAD	cis	rs5769707	0.521	rs6009810	ENSG00000188511.11	C22orf34	7.03	6.91e-12	4.66e-09	0.38	0.31	Monocyte percentage of white cells;Monocyte count;	chr22:49665892	chr22:49414524~49657542:-
LUAD	cis	rs10759883	0.627	rs700962	ENSG00000175611.10	LINC00476	-7.03	6.91e-12	4.66e-09	-0.34	-0.31	Nicotine dependence;	chr9:95815766	chr9:95759231~95875977:-
LUAD	cis	rs9660180	0.935	rs2180311	ENSG00000268575.1	RP1-283E3.8	-7.03	6.91e-12	4.66e-09	-0.28	-0.31	Body mass index;	chr1:1817295	chr1:1702736~1737688:-
LUAD	cis	rs9660180	0.967	rs6664664	ENSG00000268575.1	RP1-283E3.8	-7.03	6.91e-12	4.66e-09	-0.28	-0.31	Body mass index;	chr1:1819825	chr1:1702736~1737688:-
LUAD	cis	rs72772090	0.539	rs111886458	ENSG00000248734.2	CTD-2260A17.1	-7.03	6.92e-12	4.67e-09	-0.47	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789344	chr5:96784777~96785999:+
LUAD	cis	rs10129255	0.719	rs7156660	ENSG00000211972.2	IGHV3-66	7.03	6.94e-12	4.68e-09	0.26	0.31	Kawasaki disease;	chr14:106673171	chr14:106675017~106675544:-
LUAD	cis	rs2153535	0.58	rs6941670	ENSG00000230939.1	RP11-314C16.1	-7.03	6.95e-12	4.68e-09	-0.36	-0.31	Motion sickness;	chr6:8446113	chr6:8784178~8785445:+
LUAD	cis	rs11098499	0.657	rs71614442	ENSG00000248280.1	RP11-33B1.2	7.03	6.96e-12	4.69e-09	0.39	0.31	Corneal astigmatism;	chr4:119458191	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs2892848	ENSG00000248280.1	RP11-33B1.2	7.03	6.96e-12	4.69e-09	0.39	0.31	Corneal astigmatism;	chr4:119460186	chr4:119440561~119450157:-
LUAD	cis	rs8059260	0.542	rs11860851	ENSG00000274038.1	RP11-66H6.4	-7.03	6.99e-12	4.71e-09	-0.54	-0.31	Alcohol consumption over the past year;	chr16:11033893	chr16:11056556~11057034:+
LUAD	cis	rs3096299	0.933	rs747485	ENSG00000274627.1	RP11-104N10.2	7.03	6.99e-12	4.71e-09	0.29	0.31	Multiple myeloma (IgH translocation);	chr16:89407686	chr16:89516797~89522217:+
LUAD	cis	rs2412819	0.571	rs2930531	ENSG00000205771.5	CATSPER2P1	7.03	7e-12	4.72e-09	0.46	0.31	Lung cancer;	chr15:43829372	chr15:43726918~43747094:-
LUAD	cis	rs9487094	0.626	rs2273752	ENSG00000260273.1	RP11-425D10.10	7.03	7e-12	4.72e-09	0.4	0.31	Height;	chr6:109738307	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.626	rs12201444	ENSG00000260273.1	RP11-425D10.10	7.03	7e-12	4.72e-09	0.4	0.31	Height;	chr6:109738751	chr6:109382795~109383666:+
LUAD	cis	rs2153535	0.58	rs2327062	ENSG00000230939.1	RP11-314C16.1	-7.03	7.01e-12	4.72e-09	-0.36	-0.31	Motion sickness;	chr6:8453625	chr6:8784178~8785445:+
LUAD	cis	rs17023223	0.581	rs2765529	ENSG00000231365.4	RP11-418J17.1	-7.03	7.02e-12	4.73e-09	-0.4	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119039277	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs1325938	ENSG00000231365.4	RP11-418J17.1	-7.03	7.02e-12	4.73e-09	-0.4	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119040019	chr1:119140396~119275973:+
LUAD	cis	rs11098499	0.954	rs59866101	ENSG00000248280.1	RP11-33B1.2	7.03	7.04e-12	4.74e-09	0.39	0.31	Corneal astigmatism;	chr4:119375436	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.618	rs6858383	ENSG00000248280.1	RP11-33B1.2	7.03	7.04e-12	4.74e-09	0.39	0.31	Corneal astigmatism;	chr4:119375617	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.697	rs6832410	ENSG00000248280.1	RP11-33B1.2	7.03	7.04e-12	4.74e-09	0.39	0.31	Corneal astigmatism;	chr4:119375645	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.865	rs1112817	ENSG00000248280.1	RP11-33B1.2	7.03	7.04e-12	4.74e-09	0.39	0.31	Corneal astigmatism;	chr4:119376645	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.779	rs10016060	ENSG00000248280.1	RP11-33B1.2	7.03	7.04e-12	4.74e-09	0.39	0.31	Corneal astigmatism;	chr4:119377257	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs10005644	ENSG00000248280.1	RP11-33B1.2	7.03	7.04e-12	4.74e-09	0.39	0.31	Corneal astigmatism;	chr4:119377322	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.697	rs10016448	ENSG00000248280.1	RP11-33B1.2	7.03	7.04e-12	4.74e-09	0.39	0.31	Corneal astigmatism;	chr4:119377690	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.657	rs9996569	ENSG00000248280.1	RP11-33B1.2	7.03	7.04e-12	4.74e-09	0.39	0.31	Corneal astigmatism;	chr4:119377849	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.908	rs11729050	ENSG00000248280.1	RP11-33B1.2	7.03	7.04e-12	4.74e-09	0.39	0.31	Corneal astigmatism;	chr4:119378911	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs28429722	ENSG00000248280.1	RP11-33B1.2	7.03	7.04e-12	4.74e-09	0.39	0.31	Corneal astigmatism;	chr4:119378938	chr4:119440561~119450157:-
LUAD	cis	rs172166	0.694	rs1770131	ENSG00000219392.1	RP1-265C24.5	-7.03	7.04e-12	4.74e-09	-0.4	-0.31	Cardiac Troponin-T levels;	chr6:28118635	chr6:28115628~28116551:+
LUAD	cis	rs72772090	0.539	rs11750464	ENSG00000248734.2	CTD-2260A17.1	7.03	7.04e-12	4.74e-09	0.47	0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777327	chr5:96784777~96785999:+
LUAD	cis	rs11123170	0.543	rs4849178	ENSG00000274877.1	RP11-65I12.1	-7.03	7.04e-12	4.74e-09	-0.45	-0.31	Renal function-related traits (BUN);	chr2:113225031	chr2:113237595~113240825:+
LUAD	cis	rs7429990	0.864	rs34616865	ENSG00000229759.1	MRPS18AP1	-7.03	7.04e-12	4.74e-09	-0.31	-0.31	Educational attainment (years of education);	chr3:47608508	chr3:48256350~48256938:-
LUAD	cis	rs4713118	0.629	rs203890	ENSG00000219392.1	RP1-265C24.5	-7.03	7.04e-12	4.74e-09	-0.42	-0.31	Parkinson's disease;	chr6:28054470	chr6:28115628~28116551:+
LUAD	cis	rs2439831	0.867	rs4075674	ENSG00000205771.5	CATSPER2P1	-7.03	7.05e-12	4.75e-09	-0.53	-0.31	Lung cancer in ever smokers;	chr15:43358032	chr15:43726918~43747094:-
LUAD	cis	rs4713118	0.513	rs149989	ENSG00000219392.1	RP1-265C24.5	-7.03	7.06e-12	4.75e-09	-0.39	-0.31	Parkinson's disease;	chr6:28030406	chr6:28115628~28116551:+
LUAD	cis	rs2243480	1	rs313813	ENSG00000273142.1	RP11-458F8.4	-7.03	7.06e-12	4.75e-09	-0.32	-0.31	Diabetic kidney disease;	chr7:66038513	chr7:66902857~66906297:+
LUAD	cis	rs6844153	1	rs74895929	ENSG00000240005.4	RP11-293A21.1	-7.03	7.07e-12	4.75e-09	-0.5	-0.31	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26846035	chr4:26859806~26860599:-
LUAD	cis	rs7567389	0.505	rs56273408	ENSG00000236682.1	AC068282.3	-7.03	7.07e-12	4.76e-09	-0.42	-0.31	Self-rated health;	chr2:127338012	chr2:127389130~127400580:+
LUAD	cis	rs62229266	0.804	rs56279140	ENSG00000214914.3	RPL23AP3	7.03	7.08e-12	4.76e-09	0.38	0.31	Mitral valve prolapse;	chr21:36052063	chr21:36016079~36016546:-
LUAD	cis	rs17023223	0.537	rs2645295	ENSG00000231365.4	RP11-418J17.1	-7.03	7.09e-12	4.77e-09	-0.39	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119039825	chr1:119140396~119275973:+
LUAD	cis	rs9549367	0.789	rs9549698	ENSG00000269125.1	RP11-98F14.11	-7.03	7.09e-12	4.77e-09	-0.38	-0.31	Platelet distribution width;	chr13:113223387	chr13:113165002~113165183:-
LUAD	cis	rs7115242	0.8	rs6589597	ENSG00000280143.1	AP000892.6	-7.03	7.09e-12	4.77e-09	-0.46	-0.31	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117127082	chr11:117204967~117210292:+
LUAD	cis	rs11098499	0.954	rs13133522	ENSG00000248280.1	RP11-33B1.2	7.03	7.09e-12	4.77e-09	0.39	0.31	Corneal astigmatism;	chr4:119403269	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs35091806	ENSG00000248280.1	RP11-33B1.2	7.03	7.09e-12	4.77e-09	0.39	0.31	Corneal astigmatism;	chr4:119404374	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.909	rs35165976	ENSG00000248280.1	RP11-33B1.2	7.03	7.09e-12	4.77e-09	0.39	0.31	Corneal astigmatism;	chr4:119404475	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs2389802	ENSG00000248280.1	RP11-33B1.2	7.03	7.09e-12	4.77e-09	0.39	0.31	Corneal astigmatism;	chr4:119404577	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs6846442	ENSG00000248280.1	RP11-33B1.2	7.03	7.09e-12	4.77e-09	0.39	0.31	Corneal astigmatism;	chr4:119405168	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.738	rs34566984	ENSG00000248280.1	RP11-33B1.2	7.03	7.09e-12	4.77e-09	0.39	0.31	Corneal astigmatism;	chr4:119440115	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs17009122	ENSG00000248280.1	RP11-33B1.2	7.03	7.09e-12	4.77e-09	0.39	0.31	Corneal astigmatism;	chr4:119441248	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs9685777	ENSG00000248280.1	RP11-33B1.2	7.03	7.09e-12	4.77e-09	0.39	0.31	Corneal astigmatism;	chr4:119444810	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs71614438	ENSG00000248280.1	RP11-33B1.2	7.03	7.09e-12	4.77e-09	0.39	0.31	Corneal astigmatism;	chr4:119450097	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.909	rs7659501	ENSG00000248280.1	RP11-33B1.2	7.03	7.09e-12	4.77e-09	0.39	0.31	Corneal astigmatism;	chr4:119450397	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.779	rs28495013	ENSG00000248280.1	RP11-33B1.2	7.03	7.09e-12	4.77e-09	0.39	0.31	Corneal astigmatism;	chr4:119454676	chr4:119440561~119450157:-
LUAD	cis	rs8059260	0.544	rs12925161	ENSG00000274038.1	RP11-66H6.4	-7.03	7.13e-12	4.79e-09	-0.6	-0.31	Alcohol consumption over the past year;	chr16:11112719	chr16:11056556~11057034:+
LUAD	cis	rs10129255	0.957	rs10141052	ENSG00000280411.1	IGHV1-69-2	-7.03	7.13e-12	4.79e-09	-0.22	-0.31	Kawasaki disease;	chr14:106776528	chr14:106762092~106762588:-
LUAD	cis	rs7615952	0.736	rs13063122	ENSG00000171084.14	FAM86JP	7.03	7.18e-12	4.83e-09	0.44	0.31	Blood pressure (smoking interaction);	chr3:125925017	chr3:125916620~125930024:+
LUAD	cis	rs8059260	1	rs8059260	ENSG00000274038.1	RP11-66H6.4	-7.03	7.19e-12	4.83e-09	-0.49	-0.31	Alcohol consumption over the past year;	chr16:10966294	chr16:11056556~11057034:+
LUAD	cis	rs11676348	0.805	rs13007219	ENSG00000261338.2	RP11-378A13.1	-7.03	7.19e-12	4.83e-09	-0.33	-0.31	Ulcerative colitis;	chr2:218099136	chr2:218255319~218257366:+
LUAD	cis	rs367615	0.642	rs439182	ENSG00000249476.1	CTD-2587M2.1	-7.03	7.21e-12	4.85e-09	-0.41	-0.31	Colorectal cancer (SNP x SNP interaction);	chr5:109616666	chr5:109237120~109326369:-
LUAD	cis	rs10899021	1	rs10899025	ENSG00000279353.1	RP11-864N7.4	7.03	7.22e-12	4.85e-09	0.56	0.31	Response to metformin (IC50);	chr11:74655995	chr11:74698231~74699658:-
LUAD	cis	rs2439831	0.85	rs544122	ENSG00000205771.5	CATSPER2P1	-7.03	7.23e-12	4.85e-09	-0.54	-0.31	Lung cancer in ever smokers;	chr15:43483534	chr15:43726918~43747094:-
LUAD	cis	rs1185460	1	rs1185460	ENSG00000271751.1	RP11-110I1.14	7.03	7.24e-12	4.86e-09	0.37	0.31	Coronary artery disease;	chr11:119072723	chr11:119065263~119065677:-
LUAD	cis	rs72772090	0.539	rs11743410	ENSG00000248734.2	CTD-2260A17.1	-7.03	7.24e-12	4.86e-09	-0.47	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96788750	chr5:96784777~96785999:+
LUAD	cis	rs72772090	0.539	rs11746534	ENSG00000248734.2	CTD-2260A17.1	-7.03	7.24e-12	4.86e-09	-0.47	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789104	chr5:96784777~96785999:+
LUAD	cis	rs72772090	0.539	rs55773007	ENSG00000248734.2	CTD-2260A17.1	-7.03	7.24e-12	4.86e-09	-0.47	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789215	chr5:96784777~96785999:+
LUAD	cis	rs72772090	0.539	rs10515249	ENSG00000248734.2	CTD-2260A17.1	-7.03	7.24e-12	4.86e-09	-0.47	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789556	chr5:96784777~96785999:+
LUAD	cis	rs72772090	0.539	rs72773947	ENSG00000248734.2	CTD-2260A17.1	-7.03	7.24e-12	4.86e-09	-0.47	-0.31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789830	chr5:96784777~96785999:+
LUAD	cis	rs2337406	0.539	rs2583292	ENSG00000211974.3	IGHV2-70	-7.03	7.25e-12	4.87e-09	-0.37	-0.31	Alzheimer's disease (late onset);	chr14:106649040	chr14:106723574~106724093:-
LUAD	cis	rs11098499	0.954	rs12506546	ENSG00000248280.1	RP11-33B1.2	7.03	7.26e-12	4.88e-09	0.39	0.31	Corneal astigmatism;	chr4:119380463	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs10518331	ENSG00000248280.1	RP11-33B1.2	7.03	7.27e-12	4.88e-09	0.39	0.31	Corneal astigmatism;	chr4:119402440	chr4:119440561~119450157:-
LUAD	cis	rs2919917	0.628	rs2583759	ENSG00000254352.1	RP11-578O24.2	-7.03	7.29e-12	4.89e-09	-0.41	-0.31	Lymphocyte counts;	chr8:78732729	chr8:78723796~78724136:-
LUAD	cis	rs2919917	0.628	rs2583778	ENSG00000254352.1	RP11-578O24.2	-7.03	7.29e-12	4.89e-09	-0.41	-0.31	Lymphocyte counts;	chr8:78738906	chr8:78723796~78724136:-
LUAD	cis	rs2439831	0.867	rs6493082	ENSG00000205771.5	CATSPER2P1	-7.03	7.3e-12	4.9e-09	-0.53	-0.31	Lung cancer in ever smokers;	chr15:43342610	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.867	rs8041132	ENSG00000205771.5	CATSPER2P1	-7.03	7.3e-12	4.9e-09	-0.53	-0.31	Lung cancer in ever smokers;	chr15:43342938	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.867	rs16957627	ENSG00000205771.5	CATSPER2P1	-7.03	7.3e-12	4.9e-09	-0.53	-0.31	Lung cancer in ever smokers;	chr15:43350459	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.717	rs7165471	ENSG00000205771.5	CATSPER2P1	-7.03	7.3e-12	4.9e-09	-0.53	-0.31	Lung cancer in ever smokers;	chr15:43352590	chr15:43726918~43747094:-
LUAD	cis	rs17684571	0.938	rs71564848	ENSG00000231441.1	RP11-472M19.2	7.03	7.32e-12	4.91e-09	0.43	0.31	Schizophrenia;	chr6:56684255	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.938	rs34576803	ENSG00000231441.1	RP11-472M19.2	7.03	7.32e-12	4.91e-09	0.43	0.31	Schizophrenia;	chr6:56684609	chr6:56844002~56864078:+
LUAD	cis	rs8059260	0.736	rs16957836	ENSG00000274038.1	RP11-66H6.4	-7.03	7.32e-12	4.91e-09	-0.57	-0.31	Alcohol consumption over the past year;	chr16:10959229	chr16:11056556~11057034:+
LUAD	cis	rs8059260	0.668	rs16957839	ENSG00000274038.1	RP11-66H6.4	-7.03	7.32e-12	4.91e-09	-0.57	-0.31	Alcohol consumption over the past year;	chr16:10962521	chr16:11056556~11057034:+
LUAD	cis	rs8059260	0.736	rs3871209	ENSG00000274038.1	RP11-66H6.4	-7.03	7.32e-12	4.91e-09	-0.57	-0.31	Alcohol consumption over the past year;	chr16:10962907	chr16:11056556~11057034:+
LUAD	cis	rs9640161	0.742	rs11983355	ENSG00000261305.1	RP4-584D14.7	7.03	7.32e-12	4.92e-09	0.45	0.31	Blood protein levels;Circulating chemerin levels;	chr7:150319608	chr7:150341771~150342607:+
LUAD	cis	rs11098499	0.863	rs10030660	ENSG00000248280.1	RP11-33B1.2	7.03	7.34e-12	4.92e-09	0.39	0.31	Corneal astigmatism;	chr4:119515549	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs13149407	ENSG00000248280.1	RP11-33B1.2	7.03	7.34e-12	4.92e-09	0.39	0.31	Corneal astigmatism;	chr4:119516670	chr4:119440561~119450157:-
LUAD	cis	rs66887589	0.748	rs28439855	ENSG00000248280.1	RP11-33B1.2	7.02	7.35e-12	4.94e-09	0.33	0.31	Diastolic blood pressure;	chr4:119341101	chr4:119440561~119450157:-
LUAD	cis	rs4591358	0.689	rs34373729	ENSG00000223466.1	AC064834.2	-7.02	7.4e-12	4.96e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195543775	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs59639651	ENSG00000223466.1	AC064834.2	-7.02	7.4e-12	4.96e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195544426	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs72927766	ENSG00000223466.1	AC064834.2	-7.02	7.4e-12	4.96e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195545003	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs7580459	ENSG00000223466.1	AC064834.2	-7.02	7.4e-12	4.96e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195545963	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs57555936	ENSG00000223466.1	AC064834.2	-7.02	7.4e-12	4.96e-09	-0.45	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195546440	chr2:195533035~195538681:+
LUAD	cis	rs7246657	0.943	rs10420722	ENSG00000276846.1	CTD-3220F14.3	7.02	7.41e-12	4.97e-09	0.43	0.31	Coronary artery calcification;	chr19:37482872	chr19:37314868~37315620:-
LUAD	cis	rs2286503	0.78	rs12113458	ENSG00000228649.7	AC005682.5	7.02	7.41e-12	4.97e-09	0.39	0.3	Fibrinogen;	chr7:22816009	chr7:22854178~22861579:+
LUAD	cis	rs2153535	0.546	rs9378559	ENSG00000230939.1	RP11-314C16.1	-7.02	7.41e-12	4.97e-09	-0.37	-0.3	Motion sickness;	chr6:8538825	chr6:8784178~8785445:+
LUAD	cis	rs150992	0.593	rs34496	ENSG00000248489.1	CTD-2007H13.3	7.02	7.42e-12	4.97e-09	0.33	0.3	Body mass index;	chr5:98963812	chr5:98929171~98995013:+
LUAD	cis	rs7646881	0.812	rs79303235	ENSG00000240207.5	RP11-379F4.4	-7.02	7.42e-12	4.98e-09	-0.4	-0.3	Tetralogy of Fallot;	chr3:158727004	chr3:158732263~158784070:+
LUAD	cis	rs673078	0.607	rs7302387	ENSG00000275759.1	RP11-131L12.3	-7.02	7.44e-12	4.99e-09	-0.48	-0.3	Glucose homeostasis traits;	chr12:118316546	chr12:118428281~118428870:+
LUAD	cis	rs673078	0.66	rs7961312	ENSG00000275759.1	RP11-131L12.3	-7.02	7.44e-12	4.99e-09	-0.48	-0.3	Glucose homeostasis traits;	chr12:118324431	chr12:118428281~118428870:+
LUAD	cis	rs17684571	0.938	rs13192037	ENSG00000231441.1	RP11-472M19.2	7.02	7.46e-12	5e-09	0.42	0.3	Schizophrenia;	chr6:56689474	chr6:56844002~56864078:+
LUAD	cis	rs2439831	1	rs527921	ENSG00000205771.5	CATSPER2P1	7.02	7.47e-12	5.01e-09	0.54	0.3	Lung cancer in ever smokers;	chr15:43478218	chr15:43726918~43747094:-
LUAD	cis	rs11098499	0.954	rs7436506	ENSG00000248280.1	RP11-33B1.2	7.02	7.49e-12	5.02e-09	0.39	0.3	Corneal astigmatism;	chr4:119472614	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.909	rs2127821	ENSG00000248280.1	RP11-33B1.2	7.02	7.49e-12	5.02e-09	0.39	0.3	Corneal astigmatism;	chr4:119473380	chr4:119440561~119450157:-
LUAD	cis	rs7646881	0.812	rs74618709	ENSG00000240207.5	RP11-379F4.4	-7.02	7.49e-12	5.02e-09	-0.39	-0.3	Tetralogy of Fallot;	chr3:158737492	chr3:158732263~158784070:+
LUAD	cis	rs881375	0.9	rs2241003	ENSG00000226752.6	PSMD5-AS1	-7.02	7.49e-12	5.02e-09	-0.32	-0.3	Rheumatoid arthritis;	chr9:120904499	chr9:120824828~120854385:+
LUAD	cis	rs10759883	0.627	rs596413	ENSG00000175611.10	LINC00476	7.02	7.5e-12	5.03e-09	0.36	0.3	Nicotine dependence;	chr9:95871561	chr9:95759231~95875977:-
LUAD	cis	rs1799949	1	rs8176103	ENSG00000267681.1	CTD-3199J23.6	-7.02	7.51e-12	5.03e-09	-0.36	-0.3	Menopause (age at onset);	chr17:43115033	chr17:43144956~43145255:+
LUAD	cis	rs6142102	0.961	rs973409	ENSG00000276073.1	RP5-1125A11.7	-7.02	7.51e-12	5.04e-09	-0.32	-0.3	Skin pigmentation;	chr20:33948558	chr20:33985617~33988989:-
LUAD	cis	rs9322193	0.884	rs7769115	ENSG00000223701.3	RAET1E-AS1	7.02	7.54e-12	5.05e-09	0.37	0.3	Lung cancer;	chr6:149848796	chr6:149884431~149919508:+
LUAD	cis	rs11098499	0.954	rs10006525	ENSG00000248280.1	RP11-33B1.2	7.02	7.54e-12	5.05e-09	0.39	0.3	Corneal astigmatism;	chr4:119487776	chr4:119440561~119450157:-
LUAD	cis	rs2153535	0.58	rs6905242	ENSG00000230939.1	RP11-314C16.1	-7.02	7.54e-12	5.05e-09	-0.36	-0.3	Motion sickness;	chr6:8471566	chr6:8784178~8785445:+
LUAD	cis	rs4713118	0.662	rs149900	ENSG00000219392.1	RP1-265C24.5	-7.02	7.55e-12	5.06e-09	-0.42	-0.3	Parkinson's disease;	chr6:28046819	chr6:28115628~28116551:+
LUAD	cis	rs321358	0.731	rs17459717	ENSG00000271584.1	RP11-89C3.4	7.02	7.56e-12	5.07e-09	0.47	0.3	Body mass index;	chr11:111139862	chr11:111091932~111097357:-
LUAD	cis	rs8091660	1	rs8091660	ENSG00000278983.1	RP11-426J5.3	7.02	7.57e-12	5.07e-09	0.35	0.3	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48561565	chr18:48564795~48568342:+
LUAD	cis	rs172166	0.611	rs203883	ENSG00000219392.1	RP1-265C24.5	-7.02	7.57e-12	5.07e-09	-0.4	-0.3	Cardiac Troponin-T levels;	chr6:28110578	chr6:28115628~28116551:+
LUAD	cis	rs10129255	0.5	rs1974468	ENSG00000224373.3	IGHV4-59	7.02	7.58e-12	5.08e-09	0.18	0.3	Kawasaki disease;	chr14:106686149	chr14:106627249~106627825:-
LUAD	cis	rs11098499	0.863	rs1383532	ENSG00000248280.1	RP11-33B1.2	-7.02	7.6e-12	5.09e-09	-0.39	-0.3	Corneal astigmatism;	chr4:119513249	chr4:119440561~119450157:-
LUAD	cis	rs150992	0.632	rs34491	ENSG00000248489.1	CTD-2007H13.3	7.02	7.6e-12	5.09e-09	0.33	0.3	Body mass index;	chr5:98974118	chr5:98929171~98995013:+
LUAD	cis	rs10759883	0.549	rs816680	ENSG00000175611.10	LINC00476	-7.02	7.62e-12	5.11e-09	-0.36	-0.3	Nicotine dependence;	chr9:95804111	chr9:95759231~95875977:-
LUAD	cis	rs10759883	0.612	rs816675	ENSG00000175611.10	LINC00476	-7.02	7.62e-12	5.11e-09	-0.36	-0.3	Nicotine dependence;	chr9:95806799	chr9:95759231~95875977:-
LUAD	cis	rs10759883	0.627	rs816674	ENSG00000175611.10	LINC00476	-7.02	7.62e-12	5.11e-09	-0.36	-0.3	Nicotine dependence;	chr9:95807835	chr9:95759231~95875977:-
LUAD	cis	rs11098499	0.954	rs878373	ENSG00000248280.1	RP11-33B1.2	7.02	7.63e-12	5.11e-09	0.39	0.3	Corneal astigmatism;	chr4:119316329	chr4:119440561~119450157:-
LUAD	cis	rs867371	0.519	rs1566560	ENSG00000255769.6	GOLGA2P10	-7.02	7.63e-12	5.11e-09	-0.32	-0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232116	chr15:82472993~82513950:-
LUAD	cis	rs867371	0.519	rs1566559	ENSG00000255769.6	GOLGA2P10	-7.02	7.63e-12	5.11e-09	-0.32	-0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232120	chr15:82472993~82513950:-
LUAD	cis	rs748404	0.578	rs478028	ENSG00000249839.1	AC011330.5	-7.02	7.63e-12	5.11e-09	-0.41	-0.3	Lung cancer;	chr15:43318574	chr15:43663654~43684339:-
LUAD	cis	rs950169	0.922	rs11630507	ENSG00000259728.4	LINC00933	7.02	7.64e-12	5.12e-09	0.45	0.3	Schizophrenia;	chr15:84552494	chr15:84570649~84580175:+
LUAD	cis	rs2243480	1	rs316330	ENSG00000273142.1	RP11-458F8.4	-7.02	7.65e-12	5.12e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:66140385	chr7:66902857~66906297:+
LUAD	cis	rs6921919	0.525	rs1361386	ENSG00000216901.1	AL022393.7	7.02	7.65e-12	5.12e-09	0.37	0.3	Autism spectrum disorder or schizophrenia;	chr6:28337827	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.638	rs6456815	ENSG00000216901.1	AL022393.7	7.02	7.65e-12	5.12e-09	0.37	0.3	Autism spectrum disorder or schizophrenia;	chr6:28338360	chr6:28176188~28176674:+
LUAD	cis	rs10129255	0.957	rs10141009	ENSG00000280411.1	IGHV1-69-2	-7.02	7.66e-12	5.13e-09	-0.22	-0.3	Kawasaki disease;	chr14:106776695	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.912	rs6576227	ENSG00000280411.1	IGHV1-69-2	-7.02	7.66e-12	5.13e-09	-0.22	-0.3	Kawasaki disease;	chr14:106778202	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.957	rs6576228	ENSG00000280411.1	IGHV1-69-2	-7.02	7.66e-12	5.13e-09	-0.22	-0.3	Kawasaki disease;	chr14:106778401	chr14:106762092~106762588:-
LUAD	cis	rs10759883	0.539	rs966217	ENSG00000175611.10	LINC00476	7.02	7.69e-12	5.14e-09	0.36	0.3	Nicotine dependence;	chr9:95943247	chr9:95759231~95875977:-
LUAD	cis	rs2243480	0.708	rs13242216	ENSG00000273142.1	RP11-458F8.4	-7.02	7.69e-12	5.15e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:66433290	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs67536397	ENSG00000273142.1	RP11-458F8.4	-7.02	7.69e-12	5.15e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:66482930	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs58669269	ENSG00000273142.1	RP11-458F8.4	-7.02	7.69e-12	5.15e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:66486966	chr7:66902857~66906297:+
LUAD	cis	rs2243480	0.901	rs34807232	ENSG00000273142.1	RP11-458F8.4	-7.02	7.69e-12	5.15e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:66500146	chr7:66902857~66906297:+
LUAD	cis	rs2153535	0.58	rs6913100	ENSG00000230939.1	RP11-314C16.1	-7.02	7.72e-12	5.17e-09	-0.36	-0.3	Motion sickness;	chr6:8456622	chr6:8784178~8785445:+
LUAD	cis	rs10129255	0.957	rs10136817	ENSG00000211972.2	IGHV3-66	7.02	7.73e-12	5.17e-09	0.27	0.3	Kawasaki disease;	chr14:106787730	chr14:106675017~106675544:-
LUAD	cis	rs2243480	0.711	rs2420172	ENSG00000226824.5	RP4-756H11.3	7.02	7.75e-12	5.18e-09	0.57	0.3	Diabetic kidney disease;	chr7:66170354	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs2420171	ENSG00000226824.5	RP4-756H11.3	7.02	7.75e-12	5.18e-09	0.57	0.3	Diabetic kidney disease;	chr7:66172773	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs6974723	ENSG00000226824.5	RP4-756H11.3	7.02	7.75e-12	5.18e-09	0.57	0.3	Diabetic kidney disease;	chr7:66172952	chr7:66654538~66669855:+
LUAD	cis	rs2153535	0.58	rs1932280	ENSG00000230939.1	RP11-314C16.1	-7.02	7.75e-12	5.18e-09	-0.36	-0.3	Motion sickness;	chr6:8473421	chr6:8784178~8785445:+
LUAD	cis	rs34779708	0.733	rs16935948	ENSG00000230534.5	RP11-297A16.2	7.02	7.76e-12	5.19e-09	0.37	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35260820	chr10:35098006~35127020:-
LUAD	cis	rs321358	0.731	rs1900556	ENSG00000271584.1	RP11-89C3.4	7.02	7.76e-12	5.19e-09	0.47	0.3	Body mass index;	chr11:111148276	chr11:111091932~111097357:-
LUAD	cis	rs9903692	0.954	rs8080662	ENSG00000278765.1	RP5-890E16.5	-7.02	7.77e-12	5.2e-09	-0.4	-0.3	Pulse pressure;	chr17:48113457	chr17:48066704~48067293:-
LUAD	cis	rs9326248	0.53	rs10750101	ENSG00000280143.1	AP000892.6	7.02	7.78e-12	5.2e-09	0.47	0.3	Blood protein levels;	chr11:117108973	chr11:117204967~117210292:+
LUAD	cis	rs8177876	0.658	rs16954505	ENSG00000261838.4	RP11-303E16.6	7.02	7.78e-12	5.2e-09	0.67	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81040555	chr16:81069854~81076598:+
LUAD	cis	rs9487094	0.689	rs8465	ENSG00000260273.1	RP11-425D10.10	7.02	7.79e-12	5.2e-09	0.38	0.3	Height;	chr6:109367335	chr6:109382795~109383666:+
LUAD	cis	rs904251	0.698	rs2646926	ENSG00000279942.1	RP1-153P14.7	-7.02	7.8e-12	5.21e-09	-0.3	-0.3	Cognitive performance;	chr6:37457212	chr6:37567716~37571460:+
LUAD	cis	rs3779195	0.929	rs1635612	ENSG00000272950.1	RP11-307C18.1	7.02	7.81e-12	5.22e-09	0.5	0.3	Sex hormone-binding globulin levels;	chr7:98385737	chr7:98322853~98323430:+
LUAD	cis	rs9326248	0.53	rs2000614	ENSG00000280143.1	AP000892.6	7.02	7.82e-12	5.23e-09	0.46	0.3	Blood protein levels;	chr11:117045026	chr11:117204967~117210292:+
LUAD	cis	rs9326248	0.53	rs2000616	ENSG00000280143.1	AP000892.6	7.02	7.82e-12	5.23e-09	0.46	0.3	Blood protein levels;	chr11:117045813	chr11:117204967~117210292:+
LUAD	cis	rs9326248	0.53	rs10750100	ENSG00000280143.1	AP000892.6	7.02	7.82e-12	5.23e-09	0.46	0.3	Blood protein levels;	chr11:117046528	chr11:117204967~117210292:+
LUAD	cis	rs1815787	1	rs1815787	ENSG00000280143.1	AP000892.6	7.02	7.82e-12	5.23e-09	0.46	0.3	Subjective well-being;	chr11:117050681	chr11:117204967~117210292:+
LUAD	cis	rs4141404	0.604	rs2103853	ENSG00000236132.1	CTA-440B3.1	-7.02	7.83e-12	5.23e-09	-0.35	-0.3	Paclitaxel-induced neuropathy;	chr22:31459489	chr22:31816379~31817491:-
LUAD	cis	rs10129255	0.518	rs12590732	ENSG00000211970.3	IGHV4-61	7.02	7.84e-12	5.24e-09	0.22	0.3	Kawasaki disease;	chr14:106779612	chr14:106639119~106639657:-
LUAD	cis	rs11098499	0.954	rs10017543	ENSG00000248280.1	RP11-33B1.2	7.01	7.85e-12	5.24e-09	0.39	0.3	Corneal astigmatism;	chr4:119400265	chr4:119440561~119450157:-
LUAD	cis	rs9549367	0.713	rs3024746	ENSG00000269125.1	RP11-98F14.11	-7.01	7.86e-12	5.25e-09	-0.4	-0.3	Platelet distribution width;	chr13:113167463	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.713	rs3024747	ENSG00000269125.1	RP11-98F14.11	-7.01	7.86e-12	5.25e-09	-0.4	-0.3	Platelet distribution width;	chr13:113167473	chr13:113165002~113165183:-
LUAD	cis	rs6504950	0.924	rs187242	ENSG00000275710.1	RP11-257O5.4	7.01	7.86e-12	5.25e-09	0.37	0.3	Breast cancer;	chr17:55115585	chr17:54964474~54964679:+
LUAD	cis	rs2243480	1	rs6964530	ENSG00000273142.1	RP11-458F8.4	7.01	7.87e-12	5.26e-09	0.32	0.3	Diabetic kidney disease;	chr7:66253864	chr7:66902857~66906297:+
LUAD	cis	rs7615952	0.932	rs13321217	ENSG00000171084.14	FAM86JP	7.01	7.9e-12	5.28e-09	0.43	0.3	Blood pressure (smoking interaction);	chr3:125912928	chr3:125916620~125930024:+
LUAD	cis	rs4713118	0.513	rs156738	ENSG00000219392.1	RP1-265C24.5	-7.01	7.92e-12	5.29e-09	-0.39	-0.3	Parkinson's disease;	chr6:28046247	chr6:28115628~28116551:+
LUAD	cis	rs2439831	0.867	rs6493085	ENSG00000205771.5	CATSPER2P1	-7.01	7.92e-12	5.29e-09	-0.53	-0.3	Lung cancer in ever smokers;	chr15:43361984	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.867	rs2412778	ENSG00000205771.5	CATSPER2P1	-7.01	7.92e-12	5.29e-09	-0.53	-0.3	Lung cancer in ever smokers;	chr15:43368784	chr15:43726918~43747094:-
LUAD	cis	rs638893	0.578	rs582200	ENSG00000278376.1	RP11-158I9.8	7.01	7.94e-12	5.3e-09	0.45	0.3	Vitiligo;	chr11:118798199	chr11:118791254~118793137:+
LUAD	cis	rs9487094	0.643	rs730089	ENSG00000260273.1	RP11-425D10.10	7.01	7.94e-12	5.3e-09	0.38	0.3	Height;	chr6:109393881	chr6:109382795~109383666:+
LUAD	cis	rs11098499	0.954	rs28572238	ENSG00000248280.1	RP11-33B1.2	7.01	7.94e-12	5.3e-09	0.39	0.3	Corneal astigmatism;	chr4:119395531	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.909	rs28714195	ENSG00000248280.1	RP11-33B1.2	7.01	7.94e-12	5.3e-09	0.39	0.3	Corneal astigmatism;	chr4:119395795	chr4:119440561~119450157:-
LUAD	cis	rs10759883	0.563	rs690063	ENSG00000175611.10	LINC00476	7.01	7.97e-12	5.32e-09	0.35	0.3	Nicotine dependence;	chr9:95931019	chr9:95759231~95875977:-
LUAD	cis	rs11676348	0.808	rs1008563	ENSG00000261338.2	RP11-378A13.1	-7.01	7.98e-12	5.33e-09	-0.32	-0.3	Ulcerative colitis;	chr2:218162165	chr2:218255319~218257366:+
LUAD	cis	rs11098499	0.865	rs2389809	ENSG00000248280.1	RP11-33B1.2	7.01	7.98e-12	5.33e-09	0.39	0.3	Corneal astigmatism;	chr4:119456244	chr4:119440561~119450157:-
LUAD	cis	rs1799949	0.965	rs8176130	ENSG00000267681.1	CTD-3199J23.6	-7.01	7.98e-12	5.33e-09	-0.35	-0.3	Menopause (age at onset);	chr17:43106026	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs8176120	ENSG00000267681.1	CTD-3199J23.6	-7.01	7.98e-12	5.33e-09	-0.35	-0.3	Menopause (age at onset);	chr17:43109216	chr17:43144956~43145255:+
LUAD	cis	rs9660180	0.934	rs12729990	ENSG00000268575.1	RP1-283E3.8	-7.01	8.01e-12	5.35e-09	-0.28	-0.3	Body mass index;	chr1:1880596	chr1:1702736~1737688:-
LUAD	cis	rs9487094	0.626	rs11153215	ENSG00000260273.1	RP11-425D10.10	7.01	8.01e-12	5.35e-09	0.4	0.3	Height;	chr6:109732518	chr6:109382795~109383666:+
LUAD	cis	rs11098499	0.954	rs7437420	ENSG00000248280.1	RP11-33B1.2	7.01	8.01e-12	5.35e-09	0.39	0.3	Corneal astigmatism;	chr4:119391748	chr4:119440561~119450157:-
LUAD	cis	rs321358	0.731	rs559757	ENSG00000271584.1	RP11-89C3.4	7.01	8.01e-12	5.35e-09	0.47	0.3	Body mass index;	chr11:111136885	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.731	rs560503	ENSG00000271584.1	RP11-89C3.4	7.01	8.01e-12	5.35e-09	0.47	0.3	Body mass index;	chr11:111136911	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.731	rs514347	ENSG00000271584.1	RP11-89C3.4	7.01	8.01e-12	5.35e-09	0.47	0.3	Body mass index;	chr11:111137333	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.731	rs565152	ENSG00000271584.1	RP11-89C3.4	7.01	8.01e-12	5.35e-09	0.47	0.3	Body mass index;	chr11:111137443	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.731	rs536679	ENSG00000271584.1	RP11-89C3.4	7.01	8.01e-12	5.35e-09	0.47	0.3	Body mass index;	chr11:111142497	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.731	rs502584	ENSG00000271584.1	RP11-89C3.4	7.01	8.01e-12	5.35e-09	0.47	0.3	Body mass index;	chr11:111142620	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.731	rs511835	ENSG00000271584.1	RP11-89C3.4	7.01	8.01e-12	5.35e-09	0.47	0.3	Body mass index;	chr11:111145338	chr11:111091932~111097357:-
LUAD	cis	rs2243480	0.901	rs35823062	ENSG00000273142.1	RP11-458F8.4	-7.01	8.03e-12	5.36e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:66500834	chr7:66902857~66906297:+
LUAD	cis	rs1823913	1	rs4853563	ENSG00000227542.1	AC092614.2	-7.01	8.03e-12	5.36e-09	-0.39	-0.3	Obesity-related traits;	chr2:191254808	chr2:191229165~191246172:-
LUAD	cis	rs10129255	0.53	rs11624912	ENSG00000224373.3	IGHV4-59	7.01	8.05e-12	5.37e-09	0.18	0.3	Kawasaki disease;	chr14:106673891	chr14:106627249~106627825:-
LUAD	cis	rs2243480	1	rs313814	ENSG00000273142.1	RP11-458F8.4	-7.01	8.06e-12	5.38e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:66038306	chr7:66902857~66906297:+
LUAD	cis	rs9487094	0.626	rs4947016	ENSG00000260273.1	RP11-425D10.10	7.01	8.06e-12	5.38e-09	0.4	0.3	Height;	chr6:109740895	chr6:109382795~109383666:+
LUAD	cis	rs11098499	0.954	rs10008459	ENSG00000248280.1	RP11-33B1.2	7.01	8.1e-12	5.4e-09	0.39	0.3	Corneal astigmatism;	chr4:119473076	chr4:119440561~119450157:-
LUAD	cis	rs72772090	0.539	rs72773981	ENSG00000248734.2	CTD-2260A17.1	-7.01	8.11e-12	5.41e-09	-0.46	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96820356	chr5:96784777~96785999:+
LUAD	cis	rs9322193	0.962	rs3763162	ENSG00000223701.3	RAET1E-AS1	-7.01	8.12e-12	5.42e-09	-0.36	-0.3	Lung cancer;	chr6:149819674	chr6:149884431~149919508:+
LUAD	cis	rs10129255	0.956	rs10137268	ENSG00000280411.1	IGHV1-69-2	-7.01	8.13e-12	5.42e-09	-0.24	-0.3	Kawasaki disease;	chr14:106697402	chr14:106762092~106762588:-
LUAD	cis	rs748404	0.588	rs506120	ENSG00000249839.1	AC011330.5	-7.01	8.13e-12	5.42e-09	-0.4	-0.3	Lung cancer;	chr15:43509826	chr15:43663654~43684339:-
LUAD	cis	rs465969	0.744	rs7758483	ENSG00000255389.1	C6orf3	-7.01	8.13e-12	5.42e-09	-0.67	-0.3	Psoriasis;	chr6:111467945	chr6:111599875~111602295:+
LUAD	cis	rs11098499	0.779	rs80242894	ENSG00000248280.1	RP11-33B1.2	7.01	8.13e-12	5.42e-09	0.39	0.3	Corneal astigmatism;	chr4:119454597	chr4:119440561~119450157:-
LUAD	cis	rs6142102	0.812	rs6059554	ENSG00000276073.1	RP5-1125A11.7	-7.01	8.13e-12	5.42e-09	-0.31	-0.3	Skin pigmentation;	chr20:33926286	chr20:33985617~33988989:-
LUAD	cis	rs9595908	0.9	rs1324415	ENSG00000212293.1	SNORA16	7.01	8.14e-12	5.43e-09	0.32	0.3	Body mass index;	chr13:32600186	chr13:32420390~32420516:-
LUAD	cis	rs8100891	0.537	rs113427979	ENSG00000267213.4	AC007773.2	-7.01	8.16e-12	5.44e-09	-0.48	-0.3	Neuroticism;	chr19:32364502	chr19:32390050~32405560:-
LUAD	cis	rs10129255	0.912	rs8009135	ENSG00000280411.1	IGHV1-69-2	-7.01	8.16e-12	5.44e-09	-0.23	-0.3	Kawasaki disease;	chr14:106777528	chr14:106762092~106762588:-
LUAD	cis	rs1075232	1	rs12438318	ENSG00000270055.1	CTD-3092A11.2	-7.01	8.2e-12	5.47e-09	-0.62	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31388242	chr15:30487963~30490313:+
LUAD	cis	rs8100891	0.506	rs4804992	ENSG00000267213.4	AC007773.2	-7.01	8.21e-12	5.48e-09	-0.46	-0.3	Neuroticism;	chr19:32367885	chr19:32390050~32405560:-
LUAD	cis	rs10759883	0.563	rs690056	ENSG00000175611.10	LINC00476	7.01	8.22e-12	5.48e-09	0.35	0.3	Nicotine dependence;	chr9:95938704	chr9:95759231~95875977:-
LUAD	cis	rs10759883	0.563	rs682682	ENSG00000175611.10	LINC00476	7.01	8.22e-12	5.48e-09	0.35	0.3	Nicotine dependence;	chr9:95939980	chr9:95759231~95875977:-
LUAD	cis	rs10129255	0.744	rs28517388	ENSG00000280411.1	IGHV1-69-2	-7.01	8.25e-12	5.5e-09	-0.24	-0.3	Kawasaki disease;	chr14:106704323	chr14:106762092~106762588:-
LUAD	cis	rs7115242	0.8	rs1320668	ENSG00000280143.1	AP000892.6	7.01	8.25e-12	5.5e-09	0.46	0.3	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117096950	chr11:117204967~117210292:+
LUAD	cis	rs10759883	0.563	rs10819668	ENSG00000175611.10	LINC00476	7.01	8.26e-12	5.5e-09	0.35	0.3	Nicotine dependence;	chr9:95959848	chr9:95759231~95875977:-
LUAD	cis	rs9660180	0.967	rs11260623	ENSG00000268575.1	RP1-283E3.8	-7.01	8.3e-12	5.53e-09	-0.28	-0.3	Body mass index;	chr1:1850017	chr1:1702736~1737688:-
LUAD	cis	rs6504950	0.85	rs11079143	ENSG00000275710.1	RP11-257O5.4	-7.01	8.31e-12	5.54e-09	-0.38	-0.3	Breast cancer;	chr17:55005761	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.888	rs244319	ENSG00000275710.1	RP11-257O5.4	7.01	8.31e-12	5.54e-09	0.37	0.3	Breast cancer;	chr17:55145513	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.888	rs244320	ENSG00000275710.1	RP11-257O5.4	7.01	8.31e-12	5.54e-09	0.37	0.3	Breast cancer;	chr17:55145559	chr17:54964474~54964679:+
LUAD	cis	rs34779708	0.733	rs4007271	ENSG00000230534.5	RP11-297A16.2	7.01	8.32e-12	5.54e-09	0.36	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35257683	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.702	rs4007272	ENSG00000230534.5	RP11-297A16.2	7.01	8.32e-12	5.54e-09	0.36	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35257931	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.733	rs4934740	ENSG00000230534.5	RP11-297A16.2	7.01	8.32e-12	5.54e-09	0.36	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35258213	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.702	rs4244995	ENSG00000230534.5	RP11-297A16.2	7.01	8.32e-12	5.54e-09	0.36	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35258247	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.733	rs4244997	ENSG00000230534.5	RP11-297A16.2	7.01	8.32e-12	5.54e-09	0.36	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35258326	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.733	rs4298846	ENSG00000230534.5	RP11-297A16.2	7.01	8.32e-12	5.54e-09	0.36	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35258452	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.733	rs4391768	ENSG00000230534.5	RP11-297A16.2	7.01	8.32e-12	5.54e-09	0.36	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35258667	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.733	rs7914468	ENSG00000230534.5	RP11-297A16.2	7.01	8.32e-12	5.54e-09	0.36	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35259143	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.733	rs7914560	ENSG00000230534.5	RP11-297A16.2	7.01	8.32e-12	5.54e-09	0.36	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35259171	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.733	rs4444023	ENSG00000230534.5	RP11-297A16.2	7.01	8.32e-12	5.54e-09	0.36	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35259426	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.733	rs12243593	ENSG00000230534.5	RP11-297A16.2	7.01	8.32e-12	5.54e-09	0.36	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35260117	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.733	rs3936502	ENSG00000230534.5	RP11-297A16.2	7.01	8.32e-12	5.54e-09	0.36	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35260290	chr10:35098006~35127020:-
LUAD	cis	rs8081395	0.801	rs2665404	ENSG00000266992.1	DHX40P1	7.01	8.32e-12	5.54e-09	0.34	0.3	White blood cell count;	chr17:59798035	chr17:59976009~60002384:-
LUAD	cis	rs11098499	0.863	rs10019674	ENSG00000248280.1	RP11-33B1.2	-7.01	8.34e-12	5.55e-09	-0.39	-0.3	Corneal astigmatism;	chr4:119522334	chr4:119440561~119450157:-
LUAD	cis	rs1799949	1	rs8176145	ENSG00000267681.1	CTD-3199J23.6	-7.01	8.35e-12	5.56e-09	-0.35	-0.3	Menopause (age at onset);	chr17:43097077	chr17:43144956~43145255:+
LUAD	cis	rs1799949	0.965	rs8176140	ENSG00000267681.1	CTD-3199J23.6	-7.01	8.35e-12	5.56e-09	-0.35	-0.3	Menopause (age at onset);	chr17:43099629	chr17:43144956~43145255:+
LUAD	cis	rs2439831	1	rs1814538	ENSG00000205771.5	CATSPER2P1	7.01	8.36e-12	5.56e-09	0.51	0.3	Lung cancer in ever smokers;	chr15:43467576	chr15:43726918~43747094:-
LUAD	cis	rs1062177	1	rs62394155	ENSG00000213433.5	RPLP1P6	-7.01	8.36e-12	5.57e-09	-0.41	-0.3	Preschool internalizing problems;	chr5:151868508	chr5:151765859~151766378:-
LUAD	cis	rs10759883	0.563	rs12348051	ENSG00000175611.10	LINC00476	7.01	8.37e-12	5.57e-09	0.36	0.3	Nicotine dependence;	chr9:95905928	chr9:95759231~95875977:-
LUAD	cis	rs10759883	0.563	rs689710	ENSG00000175611.10	LINC00476	7.01	8.37e-12	5.57e-09	0.36	0.3	Nicotine dependence;	chr9:95908339	chr9:95759231~95875977:-
LUAD	cis	rs8100891	0.537	rs10405382	ENSG00000267213.4	AC007773.2	-7	8.38e-12	5.58e-09	-0.47	-0.3	Neuroticism;	chr19:32405810	chr19:32390050~32405560:-
LUAD	cis	rs1799810	0.64	rs55998444	ENSG00000236682.1	AC068282.3	-7	8.38e-12	5.58e-09	-0.42	-0.3	Self-rated health;	chr2:127362270	chr2:127389130~127400580:+
LUAD	cis	rs2842992	0.915	rs1322427	ENSG00000237927.1	RP3-393E18.2	-7	8.41e-12	5.6e-09	-0.43	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159654422	chr6:159586955~159589169:-
LUAD	cis	rs2153535	0.58	rs1832100	ENSG00000230939.1	RP11-314C16.1	-7	8.42e-12	5.61e-09	-0.36	-0.3	Motion sickness;	chr6:8446723	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs2327058	ENSG00000230939.1	RP11-314C16.1	-7	8.42e-12	5.61e-09	-0.36	-0.3	Motion sickness;	chr6:8446785	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.601	rs2327059	ENSG00000230939.1	RP11-314C16.1	-7	8.42e-12	5.61e-09	-0.36	-0.3	Motion sickness;	chr6:8446838	chr6:8784178~8785445:+
LUAD	cis	rs10899021	0.92	rs12287097	ENSG00000279353.1	RP11-864N7.4	7	8.46e-12	5.63e-09	0.54	0.3	Response to metformin (IC50);	chr11:74621619	chr11:74698231~74699658:-
LUAD	cis	rs10899021	0.92	rs11236174	ENSG00000279353.1	RP11-864N7.4	7	8.46e-12	5.63e-09	0.54	0.3	Response to metformin (IC50);	chr11:74623156	chr11:74698231~74699658:-
LUAD	cis	rs9309473	1	rs7598396	ENSG00000163016.8	ALMS1P	7	8.48e-12	5.64e-09	0.37	0.3	Metabolite levels;	chr2:73425500	chr2:73644919~73685576:+
LUAD	cis	rs6991838	1	rs6991838	ENSG00000272010.1	CTD-3025N20.3	-7	8.48e-12	5.64e-09	-0.31	-0.3	Intelligence (multi-trait analysis);	chr8:65558727	chr8:65591850~65592472:-
LUAD	cis	rs1062177	1	rs12653926	ENSG00000213433.5	RPLP1P6	-7	8.51e-12	5.66e-09	-0.41	-0.3	Preschool internalizing problems;	chr5:151870687	chr5:151765859~151766378:-
LUAD	cis	rs11098499	0.954	rs10017371	ENSG00000248280.1	RP11-33B1.2	7	8.52e-12	5.67e-09	0.39	0.3	Corneal astigmatism;	chr4:119372621	chr4:119440561~119450157:-
LUAD	cis	rs2243480	1	rs781150	ENSG00000273142.1	RP11-458F8.4	-7	8.53e-12	5.67e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:66015986	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs313798	ENSG00000273142.1	RP11-458F8.4	-7	8.53e-12	5.67e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:66028044	chr7:66902857~66906297:+
LUAD	cis	rs10129255	0.5	rs1024350	ENSG00000224373.3	IGHV4-59	7	8.53e-12	5.67e-09	0.18	0.3	Kawasaki disease;	chr14:106685105	chr14:106627249~106627825:-
LUAD	cis	rs11098499	0.863	rs3775847	ENSG00000248280.1	RP11-33B1.2	7	8.55e-12	5.68e-09	0.39	0.3	Corneal astigmatism;	chr4:119526487	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs3775848	ENSG00000248280.1	RP11-33B1.2	7	8.55e-12	5.68e-09	0.39	0.3	Corneal astigmatism;	chr4:119526569	chr4:119440561~119450157:-
LUAD	cis	rs7674212	0.531	rs4699048	ENSG00000246560.2	RP11-10L12.4	7	8.55e-12	5.69e-09	0.39	0.3	Type 2 diabetes;	chr4:103005570	chr4:102828055~102844075:+
LUAD	cis	rs11123170	0.543	rs2863242	ENSG00000274877.1	RP11-65I12.1	-7	8.59e-12	5.71e-09	-0.47	-0.3	Renal function-related traits (BUN);	chr2:113231659	chr2:113237595~113240825:+
LUAD	cis	rs62229266	0.771	rs11701590	ENSG00000214914.3	RPL23AP3	7	8.59e-12	5.71e-09	0.38	0.3	Mitral valve prolapse;	chr21:36012432	chr21:36016079~36016546:-
LUAD	cis	rs7017914	0.967	rs12675271	ENSG00000223220.1	Y_RNA	7	8.6e-12	5.72e-09	0.34	0.3	Bone mineral density;	chr8:70689774	chr8:70780914~70781008:-
LUAD	cis	rs4713118	0.513	rs156739	ENSG00000219392.1	RP1-265C24.5	-7	8.63e-12	5.74e-09	-0.39	-0.3	Parkinson's disease;	chr6:28045632	chr6:28115628~28116551:+
LUAD	cis	rs7182621	0.774	rs12101368	ENSG00000182397.13	DNM1P46	7	8.64e-12	5.74e-09	0.37	0.3	Colonoscopy-negative controls vs population controls;	chr15:99872475	chr15:99790156~99806927:-
LUAD	cis	rs1799949	0.896	rs35908185	ENSG00000267681.1	CTD-3199J23.6	-7	8.65e-12	5.75e-09	-0.35	-0.3	Menopause (age at onset);	chr17:43103094	chr17:43144956~43145255:+
LUAD	cis	rs8177876	0.584	rs2549899	ENSG00000261838.4	RP11-303E16.6	-7	8.65e-12	5.75e-09	-0.54	-0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81055267	chr16:81069854~81076598:+
LUAD	cis	rs150992	0.587	rs4703052	ENSG00000248489.1	CTD-2007H13.3	-7	8.66e-12	5.75e-09	-0.33	-0.3	Body mass index;	chr5:99008818	chr5:98929171~98995013:+
LUAD	cis	rs10129255	0.5	rs4774008	ENSG00000224373.3	IGHV4-59	7	8.68e-12	5.77e-09	0.18	0.3	Kawasaki disease;	chr14:106681273	chr14:106627249~106627825:-
LUAD	cis	rs11098499	0.909	rs1809406	ENSG00000248280.1	RP11-33B1.2	7	8.7e-12	5.78e-09	0.39	0.3	Corneal astigmatism;	chr4:119455967	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.909	rs9994810	ENSG00000248280.1	RP11-33B1.2	7	8.7e-12	5.78e-09	0.39	0.3	Corneal astigmatism;	chr4:119460435	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.697	rs10020027	ENSG00000248280.1	RP11-33B1.2	7	8.7e-12	5.78e-09	0.39	0.3	Corneal astigmatism;	chr4:119460724	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.779	rs7356491	ENSG00000248280.1	RP11-33B1.2	7	8.7e-12	5.78e-09	0.39	0.3	Corneal astigmatism;	chr4:119460819	chr4:119440561~119450157:-
LUAD	cis	rs7208859	0.615	rs216462	ENSG00000263531.1	RP13-753N3.1	-7	8.71e-12	5.78e-09	-0.62	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30568879	chr17:30863921~30864940:-
LUAD	cis	rs3779195	1	rs3779195	ENSG00000272950.1	RP11-307C18.1	-7	8.71e-12	5.79e-09	-0.52	-0.3	Sex hormone-binding globulin levels;	chr7:98364050	chr7:98322853~98323430:+
LUAD	cis	rs2153535	0.58	rs4960411	ENSG00000230939.1	RP11-314C16.1	-7	8.73e-12	5.8e-09	-0.36	-0.3	Motion sickness;	chr6:8437998	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs4960412	ENSG00000230939.1	RP11-314C16.1	-7	8.73e-12	5.8e-09	-0.36	-0.3	Motion sickness;	chr6:8438028	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs4960413	ENSG00000230939.1	RP11-314C16.1	-7	8.73e-12	5.8e-09	-0.36	-0.3	Motion sickness;	chr6:8438233	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.601	rs4960414	ENSG00000230939.1	RP11-314C16.1	-7	8.73e-12	5.8e-09	-0.36	-0.3	Motion sickness;	chr6:8438308	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.542	rs9393012	ENSG00000230939.1	RP11-314C16.1	-7	8.73e-12	5.8e-09	-0.36	-0.3	Motion sickness;	chr6:8439576	chr6:8784178~8785445:+
LUAD	cis	rs4591358	0.689	rs72927760	ENSG00000223466.1	AC064834.2	-7	8.74e-12	5.8e-09	-0.45	-0.3	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195544584	chr2:195533035~195538681:+
LUAD	cis	rs8059260	0.542	rs7196077	ENSG00000274038.1	RP11-66H6.4	-7	8.74e-12	5.8e-09	-0.51	-0.3	Alcohol consumption over the past year;	chr16:11033198	chr16:11056556~11057034:+
LUAD	cis	rs10129255	0.957	rs10142859	ENSG00000211972.2	IGHV3-66	7	8.74e-12	5.81e-09	0.26	0.3	Kawasaki disease;	chr14:106782238	chr14:106675017~106675544:-
LUAD	cis	rs71403859	0.73	rs71386933	ENSG00000260886.1	TAT-AS1	7	8.77e-12	5.83e-09	0.54	0.3	Post bronchodilator FEV1;	chr16:71787897	chr16:71565789~71578187:+
LUAD	cis	rs2153535	0.58	rs1034272	ENSG00000230939.1	RP11-314C16.1	-7	8.77e-12	5.83e-09	-0.36	-0.3	Motion sickness;	chr6:8469102	chr6:8784178~8785445:+
LUAD	cis	rs2243480	1	rs9769882	ENSG00000226824.5	RP4-756H11.3	7	8.77e-12	5.83e-09	0.57	0.3	Diabetic kidney disease;	chr7:66177938	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs6966322	ENSG00000226824.5	RP4-756H11.3	7	8.77e-12	5.83e-09	0.57	0.3	Diabetic kidney disease;	chr7:66181767	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs4145008	ENSG00000226824.5	RP4-756H11.3	7	8.77e-12	5.83e-09	0.57	0.3	Diabetic kidney disease;	chr7:66182524	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs4718315	ENSG00000226824.5	RP4-756H11.3	7	8.77e-12	5.83e-09	0.57	0.3	Diabetic kidney disease;	chr7:66183554	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs4718316	ENSG00000226824.5	RP4-756H11.3	7	8.77e-12	5.83e-09	0.57	0.3	Diabetic kidney disease;	chr7:66183744	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs1873494	ENSG00000226824.5	RP4-756H11.3	7	8.77e-12	5.83e-09	0.57	0.3	Diabetic kidney disease;	chr7:66184912	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs6959002	ENSG00000226824.5	RP4-756H11.3	7	8.77e-12	5.83e-09	0.57	0.3	Diabetic kidney disease;	chr7:66185509	chr7:66654538~66669855:+
LUAD	cis	rs7945705	0.902	rs1560569	ENSG00000254860.4	TMEM9B-AS1	7	8.78e-12	5.83e-09	0.34	0.3	Hemoglobin concentration;	chr11:8918340	chr11:8964675~8977527:+
LUAD	cis	rs35955747	0.902	rs131202	ENSG00000236132.1	CTA-440B3.1	-7	8.78e-12	5.83e-09	-0.34	-0.3	Neutrophil count;Sum basophil neutrophil counts;	chr22:31313323	chr22:31816379~31817491:-
LUAD	cis	rs1075265	0.589	rs2253760	ENSG00000233266.1	HMGB1P31	7	8.78e-12	5.83e-09	0.39	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53806851	chr2:54051334~54051760:+
LUAD	cis	rs748404	0.587	rs9920879	ENSG00000249839.1	AC011330.5	-7	8.79e-12	5.84e-09	-0.4	-0.3	Lung cancer;	chr15:43347572	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.631	rs7166812	ENSG00000249839.1	AC011330.5	-7	8.79e-12	5.84e-09	-0.4	-0.3	Lung cancer;	chr15:43352562	chr15:43663654~43684339:-
LUAD	cis	rs321358	0.731	rs7940380	ENSG00000271584.1	RP11-89C3.4	7	8.81e-12	5.85e-09	0.47	0.3	Body mass index;	chr11:111149974	chr11:111091932~111097357:-
LUAD	cis	rs56205728	0.606	rs3784397	ENSG00000273855.1	RP11-133K1.12	7	8.82e-12	5.86e-09	0.36	0.3	Schizophrenia;	chr15:40304643	chr15:40285468~40285909:-
LUAD	cis	rs11098499	0.954	rs4345162	ENSG00000248280.1	RP11-33B1.2	7	8.83e-12	5.86e-09	0.39	0.3	Corneal astigmatism;	chr4:119391804	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.738	rs28408407	ENSG00000248280.1	RP11-33B1.2	7	8.86e-12	5.88e-09	0.39	0.3	Corneal astigmatism;	chr4:119454875	chr4:119440561~119450157:-
LUAD	cis	rs2842992	0.789	rs2842969	ENSG00000237927.1	RP3-393E18.2	-7	8.86e-12	5.88e-09	-0.44	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159724332	chr6:159586955~159589169:-
LUAD	cis	rs1075232	1	rs56396205	ENSG00000270055.1	CTD-3092A11.2	-7	8.87e-12	5.89e-09	-0.62	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31386182	chr15:30487963~30490313:+
LUAD	cis	rs1075232	1	rs4450360	ENSG00000270055.1	CTD-3092A11.2	-7	8.87e-12	5.89e-09	-0.62	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31389827	chr15:30487963~30490313:+
LUAD	cis	rs1075232	1	rs72722847	ENSG00000270055.1	CTD-3092A11.2	-7	8.87e-12	5.89e-09	-0.62	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31390143	chr15:30487963~30490313:+
LUAD	cis	rs75422866	0.867	rs73113143	ENSG00000274902.1	RP1-197B17.4	7	8.88e-12	5.89e-09	0.69	0.3	Pneumonia;	chr12:47623060	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs75568526	ENSG00000274902.1	RP1-197B17.4	7	8.88e-12	5.89e-09	0.69	0.3	Pneumonia;	chr12:47649718	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs116302411	ENSG00000274902.1	RP1-197B17.4	7	8.88e-12	5.89e-09	0.69	0.3	Pneumonia;	chr12:47649788	chr12:47731908~47732351:+
LUAD	cis	rs673078	0.66	rs17512142	ENSG00000275759.1	RP11-131L12.3	-7	8.9e-12	5.9e-09	-0.46	-0.3	Glucose homeostasis traits;	chr12:118186186	chr12:118428281~118428870:+
LUAD	cis	rs2153535	0.526	rs7748404	ENSG00000230939.1	RP11-314C16.1	-7	8.9e-12	5.91e-09	-0.36	-0.3	Motion sickness;	chr6:8472267	chr6:8784178~8785445:+
LUAD	cis	rs7615952	0.688	rs7624806	ENSG00000171084.14	FAM86JP	7	8.92e-12	5.91e-09	0.45	0.3	Blood pressure (smoking interaction);	chr3:125880231	chr3:125916620~125930024:+
LUAD	cis	rs10200159	0.744	rs7586124	ENSG00000272606.1	RP11-554J4.1	6.99	8.93e-12	5.93e-09	0.52	0.3	Vitiligo;	chr2:55558165	chr2:55617909~55618373:+
LUAD	cis	rs7688540	0.723	rs9684973	ENSG00000275426.1	CH17-262A2.1	6.99	8.95e-12	5.94e-09	0.38	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245032	chr4:149738~150317:+
LUAD	cis	rs1799949	1	rs4793190	ENSG00000267681.1	CTD-3199J23.6	-6.99	8.95e-12	5.94e-09	-0.35	-0.3	Menopause (age at onset);	chr17:43048092	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs8176297	ENSG00000267681.1	CTD-3199J23.6	-6.99	8.95e-12	5.94e-09	-0.35	-0.3	Menopause (age at onset);	chr17:43051308	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs8176296	ENSG00000267681.1	CTD-3199J23.6	-6.99	8.95e-12	5.94e-09	-0.35	-0.3	Menopause (age at onset);	chr17:43051574	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs4793191	ENSG00000267681.1	CTD-3199J23.6	-6.99	8.95e-12	5.94e-09	-0.35	-0.3	Menopause (age at onset);	chr17:43052360	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs4793192	ENSG00000267681.1	CTD-3199J23.6	-6.99	8.95e-12	5.94e-09	-0.35	-0.3	Menopause (age at onset);	chr17:43052373	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs8176289	ENSG00000267681.1	CTD-3199J23.6	-6.99	8.95e-12	5.94e-09	-0.35	-0.3	Menopause (age at onset);	chr17:43054039	chr17:43144956~43145255:+
LUAD	cis	rs1823913	1	rs4853562	ENSG00000227542.1	AC092614.2	-6.99	8.98e-12	5.95e-09	-0.39	-0.3	Obesity-related traits;	chr2:191253696	chr2:191229165~191246172:-
LUAD	cis	rs1823913	1	rs4853461	ENSG00000227542.1	AC092614.2	-6.99	8.98e-12	5.95e-09	-0.39	-0.3	Obesity-related traits;	chr2:191254572	chr2:191229165~191246172:-
LUAD	cis	rs9487094	0.666	rs3757235	ENSG00000260273.1	RP11-425D10.10	6.99	8.98e-12	5.95e-09	0.38	0.3	Height;	chr6:109390638	chr6:109382795~109383666:+
LUAD	cis	rs2243480	1	rs1546059	ENSG00000226824.5	RP4-756H11.3	6.99	9e-12	5.96e-09	0.57	0.3	Diabetic kidney disease;	chr7:66189722	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs6958289	ENSG00000226824.5	RP4-756H11.3	6.99	9e-12	5.96e-09	0.57	0.3	Diabetic kidney disease;	chr7:66192124	chr7:66654538~66669855:+
LUAD	cis	rs321358	0.731	rs73003515	ENSG00000271584.1	RP11-89C3.4	6.99	9.01e-12	5.97e-09	0.48	0.3	Body mass index;	chr11:111160734	chr11:111091932~111097357:-
LUAD	cis	rs2153535	0.58	rs7767756	ENSG00000230939.1	RP11-314C16.1	-6.99	9.03e-12	5.98e-09	-0.36	-0.3	Motion sickness;	chr6:8453195	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs7767926	ENSG00000230939.1	RP11-314C16.1	-6.99	9.03e-12	5.98e-09	-0.36	-0.3	Motion sickness;	chr6:8453324	chr6:8784178~8785445:+
LUAD	cis	rs10771431	1	rs11611670	ENSG00000111788.10	RP11-22B23.1	6.99	9.05e-12	6e-09	0.26	0.3	Breast size;	chr12:9232939	chr12:9277235~9313241:+
LUAD	cis	rs11098499	0.954	rs11722872	ENSG00000248280.1	RP11-33B1.2	6.99	9.05e-12	6e-09	0.39	0.3	Corneal astigmatism;	chr4:119311875	chr4:119440561~119450157:-
LUAD	cis	rs172166	0.694	rs203884	ENSG00000219392.1	RP1-265C24.5	-6.99	9.05e-12	6e-09	-0.39	-0.3	Cardiac Troponin-T levels;	chr6:28109596	chr6:28115628~28116551:+
LUAD	cis	rs9660180	0.935	rs9786942	ENSG00000268575.1	RP1-283E3.8	-6.99	9.06e-12	6e-09	-0.27	-0.3	Body mass index;	chr1:1827774	chr1:1702736~1737688:-
LUAD	cis	rs9660180	0.934	rs34849348	ENSG00000268575.1	RP1-283E3.8	-6.99	9.06e-12	6e-09	-0.27	-0.3	Body mass index;	chr1:1831318	chr1:1702736~1737688:-
LUAD	cis	rs748404	0.578	rs512628	ENSG00000249839.1	AC011330.5	-6.99	9.06e-12	6.01e-09	-0.41	-0.3	Lung cancer;	chr15:43326536	chr15:43663654~43684339:-
LUAD	cis	rs7115242	0.8	rs4245168	ENSG00000280143.1	AP000892.6	6.99	9.07e-12	6.01e-09	0.46	0.3	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117011922	chr11:117204967~117210292:+
LUAD	cis	rs2153535	0.58	rs962590	ENSG00000230939.1	RP11-314C16.1	-6.99	9.07e-12	6.01e-09	-0.36	-0.3	Motion sickness;	chr6:8450666	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs5001324	ENSG00000230939.1	RP11-314C16.1	-6.99	9.07e-12	6.01e-09	-0.36	-0.3	Motion sickness;	chr6:8451371	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs5001322	ENSG00000230939.1	RP11-314C16.1	-6.99	9.07e-12	6.01e-09	-0.36	-0.3	Motion sickness;	chr6:8451375	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs969422	ENSG00000230939.1	RP11-314C16.1	-6.99	9.07e-12	6.01e-09	-0.36	-0.3	Motion sickness;	chr6:8451547	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs969421	ENSG00000230939.1	RP11-314C16.1	-6.99	9.07e-12	6.01e-09	-0.36	-0.3	Motion sickness;	chr6:8451716	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.601	rs969420	ENSG00000230939.1	RP11-314C16.1	-6.99	9.07e-12	6.01e-09	-0.36	-0.3	Motion sickness;	chr6:8451733	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs7741456	ENSG00000230939.1	RP11-314C16.1	-6.99	9.07e-12	6.01e-09	-0.36	-0.3	Motion sickness;	chr6:8452191	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs7742689	ENSG00000230939.1	RP11-314C16.1	-6.99	9.07e-12	6.01e-09	-0.36	-0.3	Motion sickness;	chr6:8452200	chr6:8784178~8785445:+
LUAD	cis	rs150992	0.593	rs34497	ENSG00000248489.1	CTD-2007H13.3	6.99	9.1e-12	6.03e-09	0.33	0.3	Body mass index;	chr5:98962885	chr5:98929171~98995013:+
LUAD	cis	rs6142102	0.961	rs4911385	ENSG00000276073.1	RP5-1125A11.7	-6.99	9.1e-12	6.03e-09	-0.32	-0.3	Skin pigmentation;	chr20:33970787	chr20:33985617~33988989:-
LUAD	cis	rs11123170	0.543	rs4849180	ENSG00000274877.1	RP11-65I12.1	-6.99	9.17e-12	6.07e-09	-0.46	-0.3	Renal function-related traits (BUN);	chr2:113227609	chr2:113237595~113240825:+
LUAD	cis	rs7927592	0.789	rs2291467	ENSG00000212093.1	AP000807.1	6.99	9.18e-12	6.07e-09	0.35	0.3	Total body bone mineral density;	chr11:68449288	chr11:68506083~68506166:-
LUAD	cis	rs853679	0.567	rs3799499	ENSG00000204709.4	LINC01556	6.99	9.22e-12	6.1e-09	0.4	0.3	Depression;	chr6:28386473	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs17711344	ENSG00000219392.1	RP1-265C24.5	6.99	9.23e-12	6.11e-09	0.42	0.3	Depression;	chr6:28109824	chr6:28115628~28116551:+
LUAD	cis	rs17301013	0.507	rs2142864	ENSG00000227373.4	RP11-160H22.5	6.99	9.23e-12	6.11e-09	0.45	0.3	Systemic lupus erythematosus;	chr1:174304924	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs2860909	ENSG00000227373.4	RP11-160H22.5	6.99	9.23e-12	6.11e-09	0.45	0.3	Systemic lupus erythematosus;	chr1:174305211	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs7553317	ENSG00000227373.4	RP11-160H22.5	6.99	9.23e-12	6.11e-09	0.45	0.3	Systemic lupus erythematosus;	chr1:174307182	chr1:174115300~174160004:-
LUAD	cis	rs1499614	1	rs1267818	ENSG00000273142.1	RP11-458F8.4	-6.99	9.24e-12	6.12e-09	-0.32	-0.3	Gout;	chr7:66642037	chr7:66902857~66906297:+
LUAD	cis	rs765787	0.556	rs10851422	ENSG00000259520.4	CTD-2651B20.3	-6.99	9.26e-12	6.13e-09	-0.4	-0.3	Uric acid levels;	chr15:45221540	chr15:45251580~45279251:-
LUAD	cis	rs1075232	1	rs9672214	ENSG00000270055.1	CTD-3092A11.2	-6.99	9.28e-12	6.14e-09	-0.61	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31385572	chr15:30487963~30490313:+
LUAD	cis	rs7811142	0.83	rs118119933	ENSG00000242294.5	STAG3L5P	6.99	9.28e-12	6.14e-09	0.27	0.3	Platelet count;	chr7:100341427	chr7:100336079~100351900:+
LUAD	cis	rs12931792	0.846	rs9924308	ENSG00000183604.13	SMG1P5	-6.99	9.29e-12	6.14e-09	-0.31	-0.3	Tonsillectomy;	chr16:30143419	chr16:30267553~30335374:-
LUAD	cis	rs17301013	0.507	rs10912753	ENSG00000227373.4	RP11-160H22.5	6.99	9.32e-12	6.17e-09	0.45	0.3	Systemic lupus erythematosus;	chr1:174265226	chr1:174115300~174160004:-
LUAD	cis	rs7044106	0.791	rs735109	ENSG00000238181.2	AHCYP2	-6.99	9.33e-12	6.17e-09	-0.4	-0.3	Hip circumference adjusted for BMI;	chr9:120726601	chr9:120720673~120721972:+
LUAD	cis	rs673078	0.66	rs6490175	ENSG00000275759.1	RP11-131L12.3	-6.99	9.34e-12	6.18e-09	-0.39	-0.3	Glucose homeostasis traits;	chr12:118293559	chr12:118428281~118428870:+
LUAD	cis	rs6142102	0.886	rs6059583	ENSG00000276073.1	RP5-1125A11.7	-6.99	9.36e-12	6.19e-09	-0.32	-0.3	Skin pigmentation;	chr20:33944308	chr20:33985617~33988989:-
LUAD	cis	rs7688540	0.713	rs4624608	ENSG00000275426.1	CH17-262A2.1	6.99	9.37e-12	6.2e-09	0.39	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:213204	chr4:149738~150317:+
LUAD	cis	rs1318937	1	rs3821639	ENSG00000224660.1	SH3BP5-AS1	6.99	9.37e-12	6.2e-09	0.25	0.3	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15264159	chr3:15254184~15264493:+
LUAD	cis	rs2153535	0.562	rs9379211	ENSG00000230939.1	RP11-314C16.1	-6.99	9.37e-12	6.2e-09	-0.36	-0.3	Motion sickness;	chr6:8463694	chr6:8784178~8785445:+
LUAD	cis	rs748404	0.631	rs1133395	ENSG00000249839.1	AC011330.5	-6.99	9.38e-12	6.2e-09	-0.4	-0.3	Lung cancer;	chr15:43358186	chr15:43663654~43684339:-
LUAD	cis	rs17818399	0.708	rs13000706	ENSG00000279254.1	RP11-536C12.1	-6.99	9.4e-12	6.21e-09	-0.31	-0.3	Height;	chr2:46611108	chr2:46668870~46670778:+
LUAD	cis	rs748404	0.66	rs693510	ENSG00000249839.1	AC011330.5	-6.99	9.41e-12	6.21e-09	-0.39	-0.3	Lung cancer;	chr15:43422427	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.66	rs509306	ENSG00000249839.1	AC011330.5	-6.99	9.41e-12	6.21e-09	-0.39	-0.3	Lung cancer;	chr15:43422973	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.66	rs690512	ENSG00000249839.1	AC011330.5	-6.99	9.41e-12	6.21e-09	-0.39	-0.3	Lung cancer;	chr15:43425480	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.66	rs2249952	ENSG00000249839.1	AC011330.5	-6.99	9.41e-12	6.21e-09	-0.39	-0.3	Lung cancer;	chr15:43428335	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.631	rs2467745	ENSG00000249839.1	AC011330.5	-6.99	9.41e-12	6.21e-09	-0.39	-0.3	Lung cancer;	chr15:43430544	chr15:43663654~43684339:-
LUAD	cis	rs2153535	0.58	rs1319169	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8464223	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs965706	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8464475	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs6938071	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8464612	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.601	rs9406160	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8464674	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1335636	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8464814	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs986060	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8465195	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9393021	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8465890	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9406161	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8465911	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9405390	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8465976	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9405391	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8466315	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9406163	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8466409	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.504	rs9405393	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8467199	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs2184584	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8468174	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.541	rs7774752	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8468745	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9505450	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8469669	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9406164	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8469815	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs7341201	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8470037	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs7341206	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8470256	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs7341383	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8470401	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.504	rs9328472	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8470615	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1414345	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8471304	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1414348	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8471707	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1414349	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8472057	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1414350	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8472098	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9392224	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8472381	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.542	rs9378553	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8472399	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.601	rs1855768	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8472736	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1932281	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8473532	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs6900007	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8473802	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs2184585	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8473935	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs6902001	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8476822	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs4960423	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8476977	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1932282	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8477097	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9505455	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8478389	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9379216	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8481002	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs7450817	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8481188	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.56	rs2210798	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8481289	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs6597327	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8481924	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs7763190	ENSG00000230939.1	RP11-314C16.1	-6.99	9.41e-12	6.21e-09	-0.36	-0.3	Motion sickness;	chr6:8483964	chr6:8784178~8785445:+
LUAD	cis	rs11098499	0.954	rs6849171	ENSG00000248280.1	RP11-33B1.2	6.99	9.41e-12	6.21e-09	0.39	0.3	Corneal astigmatism;	chr4:119488394	chr4:119440561~119450157:-
LUAD	cis	rs1800795	0.652	rs7802307	ENSG00000179428.2	AC073072.5	-6.99	9.42e-12	6.22e-09	-0.36	-0.3	Cerebrospinal fluid clusterin levels in APOEe4- carriers;	chr7:22726814	chr7:22725395~22727620:-
LUAD	cis	rs748404	0.631	rs3809482	ENSG00000249839.1	AC011330.5	-6.99	9.45e-12	6.24e-09	-0.4	-0.3	Lung cancer;	chr15:43369604	chr15:43663654~43684339:-
LUAD	cis	rs1062177	1	rs17741826	ENSG00000213433.5	RPLP1P6	6.99	9.49e-12	6.26e-09	0.37	0.3	Preschool internalizing problems;	chr5:151769701	chr5:151765859~151766378:-
LUAD	cis	rs8059260	0.736	rs16957854	ENSG00000274038.1	RP11-66H6.4	-6.99	9.51e-12	6.27e-09	-0.62	-0.3	Alcohol consumption over the past year;	chr16:10976466	chr16:11056556~11057034:+
LUAD	cis	rs1499614	1	rs2707832	ENSG00000226824.5	RP4-756H11.3	-6.99	9.51e-12	6.27e-09	-0.56	-0.3	Gout;	chr7:66671562	chr7:66654538~66669855:+
LUAD	cis	rs7017914	0.934	rs7814274	ENSG00000223220.1	Y_RNA	-6.99	9.51e-12	6.28e-09	-0.34	-0.3	Bone mineral density;	chr8:70658176	chr8:70780914~70781008:-
LUAD	cis	rs9326248	0.53	rs7950364	ENSG00000280143.1	AP000892.6	6.99	9.52e-12	6.28e-09	0.47	0.3	Blood protein levels;	chr11:117028170	chr11:117204967~117210292:+
LUAD	cis	rs1185460	1	rs4614	ENSG00000271751.1	RP11-110I1.14	-6.98	9.58e-12	6.32e-09	-0.37	-0.3	Coronary artery disease;	chr11:119081661	chr11:119065263~119065677:-
LUAD	cis	rs6991838	0.765	rs10957358	ENSG00000272010.1	CTD-3025N20.3	6.98	9.59e-12	6.32e-09	0.32	0.3	Intelligence (multi-trait analysis);	chr8:65590067	chr8:65591850~65592472:-
LUAD	cis	rs2842992	0.747	rs733319	ENSG00000237927.1	RP3-393E18.2	-6.98	9.6e-12	6.33e-09	-0.44	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159800443	chr6:159586955~159589169:-
LUAD	cis	rs2842992	0.83	rs1853259	ENSG00000237927.1	RP3-393E18.2	6.98	9.6e-12	6.33e-09	0.44	0.3	Age-related macular degeneration (geographic atrophy);	chr6:159726409	chr6:159586955~159589169:-
LUAD	cis	rs10759883	0.539	rs10988817	ENSG00000175611.10	LINC00476	6.98	9.61e-12	6.34e-09	0.35	0.3	Nicotine dependence;	chr9:95960364	chr9:95759231~95875977:-
LUAD	cis	rs9549367	0.789	rs2287253	ENSG00000269125.1	RP11-98F14.11	6.98	9.62e-12	6.34e-09	0.36	0.3	Platelet distribution width;	chr13:113236761	chr13:113165002~113165183:-
LUAD	cis	rs2153535	0.58	rs2184586	ENSG00000230939.1	RP11-314C16.1	-6.98	9.62e-12	6.34e-09	-0.36	-0.3	Motion sickness;	chr6:8473949	chr6:8784178~8785445:+
LUAD	cis	rs6142102	0.961	rs761235	ENSG00000276073.1	RP5-1125A11.7	-6.98	9.64e-12	6.35e-09	-0.32	-0.3	Skin pigmentation;	chr20:33946602	chr20:33985617~33988989:-
LUAD	cis	rs2243480	1	rs11538349	ENSG00000273142.1	RP11-458F8.4	-6.98	9.65e-12	6.36e-09	-0.31	-0.3	Diabetic kidney disease;	chr7:65956884	chr7:66902857~66906297:+
LUAD	cis	rs11098499	0.82	rs13128602	ENSG00000248280.1	RP11-33B1.2	-6.98	9.66e-12	6.36e-09	-0.39	-0.3	Corneal astigmatism;	chr4:119538211	chr4:119440561~119450157:-
LUAD	cis	rs62355901	1	rs62355901	ENSG00000271828.1	CTD-2310F14.1	6.98	9.68e-12	6.38e-09	0.48	0.3	Breast cancer;	chr5:56757708	chr5:56927874~56929573:+
LUAD	cis	rs2243480	1	rs437889	ENSG00000226824.5	RP4-756H11.3	-6.98	9.68e-12	6.38e-09	-0.56	-0.3	Diabetic kidney disease;	chr7:66044247	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs402418	ENSG00000226824.5	RP4-756H11.3	-6.98	9.68e-12	6.38e-09	-0.56	-0.3	Diabetic kidney disease;	chr7:66044482	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.803	rs423187	ENSG00000226824.5	RP4-756H11.3	-6.98	9.68e-12	6.38e-09	-0.56	-0.3	Diabetic kidney disease;	chr7:66044512	chr7:66654538~66669855:+
LUAD	cis	rs4713118	0.629	rs203888	ENSG00000219392.1	RP1-265C24.5	-6.98	9.69e-12	6.38e-09	-0.4	-0.3	Parkinson's disease;	chr6:28053811	chr6:28115628~28116551:+
LUAD	cis	rs321358	0.731	rs539009	ENSG00000271584.1	RP11-89C3.4	6.98	9.69e-12	6.39e-09	0.47	0.3	Body mass index;	chr11:111137694	chr11:111091932~111097357:-
LUAD	cis	rs9326248	0.53	rs2513093	ENSG00000280143.1	AP000892.6	6.98	9.7e-12	6.39e-09	0.48	0.3	Blood protein levels;	chr11:116935971	chr11:117204967~117210292:+
LUAD	cis	rs853679	0.567	rs13196606	ENSG00000204709.4	LINC01556	6.98	9.7e-12	6.39e-09	0.39	0.3	Depression;	chr6:28402301	chr6:28943877~28944537:+
LUAD	cis	rs9640161	0.742	rs2108854	ENSG00000261305.1	RP4-584D14.7	-6.98	9.7e-12	6.39e-09	-0.44	-0.3	Blood protein levels;Circulating chemerin levels;	chr7:150320319	chr7:150341771~150342607:+
LUAD	cis	rs150992	0.632	rs326493	ENSG00000248489.1	CTD-2007H13.3	6.98	9.73e-12	6.41e-09	0.33	0.3	Body mass index;	chr5:98966251	chr5:98929171~98995013:+
LUAD	cis	rs2153535	0.563	rs1796687	ENSG00000230939.1	RP11-314C16.1	-6.98	9.73e-12	6.41e-09	-0.35	-0.3	Motion sickness;	chr6:8535885	chr6:8784178~8785445:+
LUAD	cis	rs11098499	0.954	rs1480931	ENSG00000248280.1	RP11-33B1.2	6.98	9.73e-12	6.41e-09	0.38	0.3	Corneal astigmatism;	chr4:119474654	chr4:119440561~119450157:-
LUAD	cis	rs11676348	0.71	rs11894169	ENSG00000261338.2	RP11-378A13.1	6.98	9.74e-12	6.42e-09	0.32	0.3	Ulcerative colitis;	chr2:218182123	chr2:218255319~218257366:+
LUAD	cis	rs2153535	0.58	rs1932284	ENSG00000230939.1	RP11-314C16.1	-6.98	9.75e-12	6.42e-09	-0.36	-0.3	Motion sickness;	chr6:8477461	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1932285	ENSG00000230939.1	RP11-314C16.1	-6.98	9.75e-12	6.42e-09	-0.36	-0.3	Motion sickness;	chr6:8477486	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs7775909	ENSG00000230939.1	RP11-314C16.1	-6.98	9.75e-12	6.42e-09	-0.36	-0.3	Motion sickness;	chr6:8477545	chr6:8784178~8785445:+
LUAD	cis	rs2439831	0.681	rs825739	ENSG00000205771.5	CATSPER2P1	-6.98	9.76e-12	6.43e-09	-0.52	-0.3	Lung cancer in ever smokers;	chr15:43300230	chr15:43726918~43747094:-
LUAD	cis	rs9640161	0.659	rs11974980	ENSG00000261305.1	RP4-584D14.7	6.98	9.76e-12	6.43e-09	0.43	0.3	Blood protein levels;Circulating chemerin levels;	chr7:150312749	chr7:150341771~150342607:+
LUAD	cis	rs9640161	0.659	rs11975886	ENSG00000261305.1	RP4-584D14.7	6.98	9.76e-12	6.43e-09	0.43	0.3	Blood protein levels;Circulating chemerin levels;	chr7:150313273	chr7:150341771~150342607:+
LUAD	cis	rs2015599	0.563	rs11050168	ENSG00000275476.1	RP11-996F15.4	6.98	9.79e-12	6.45e-09	0.34	0.3	Platelet count;Mean platelet volume;	chr12:29273760	chr12:29277397~29277882:-
LUAD	cis	rs944289	0.746	rs34407552	ENSG00000257826.1	RP11-116N8.4	-6.98	9.8e-12	6.45e-09	-0.32	-0.3	Thyroid cancer;	chr14:36132935	chr14:36061026~36067190:-
LUAD	cis	rs11098499	0.863	rs3822192	ENSG00000248280.1	RP11-33B1.2	6.98	9.81e-12	6.46e-09	0.39	0.3	Corneal astigmatism;	chr4:119524565	chr4:119440561~119450157:-
LUAD	cis	rs2243480	1	rs1723269	ENSG00000273142.1	RP11-458F8.4	-6.98	9.83e-12	6.47e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:66007799	chr7:66902857~66906297:+
LUAD	cis	rs67311347	1	rs7628796	ENSG00000223797.4	ENTPD3-AS1	-6.98	9.84e-12	6.48e-09	-0.33	-0.3	Renal cell carcinoma;	chr3:40465841	chr3:40313802~40453329:-
LUAD	cis	rs2243480	1	rs59794892	ENSG00000273142.1	RP11-458F8.4	-6.98	9.86e-12	6.49e-09	-0.31	-0.3	Diabetic kidney disease;	chr7:65950886	chr7:66902857~66906297:+
LUAD	cis	rs72772090	0.539	rs55996659	ENSG00000248734.2	CTD-2260A17.1	-6.98	9.89e-12	6.51e-09	-0.46	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96778446	chr5:96784777~96785999:+
LUAD	cis	rs11098499	0.78	rs7680914	ENSG00000248280.1	RP11-33B1.2	6.98	9.89e-12	6.51e-09	0.39	0.3	Corneal astigmatism;	chr4:119641898	chr4:119440561~119450157:-
LUAD	cis	rs2243480	1	rs2462569	ENSG00000273142.1	RP11-458F8.4	6.98	9.93e-12	6.53e-09	0.3	0.3	Diabetic kidney disease;	chr7:66009859	chr7:66902857~66906297:+
LUAD	cis	rs2153535	0.58	rs4639392	ENSG00000230939.1	RP11-314C16.1	-6.98	9.95e-12	6.54e-09	-0.36	-0.3	Motion sickness;	chr6:8446314	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs2184582	ENSG00000230939.1	RP11-314C16.1	-6.98	9.95e-12	6.54e-09	-0.36	-0.3	Motion sickness;	chr6:8447560	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs2184583	ENSG00000230939.1	RP11-314C16.1	-6.98	9.95e-12	6.54e-09	-0.36	-0.3	Motion sickness;	chr6:8447575	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9505446	ENSG00000230939.1	RP11-314C16.1	-6.98	9.95e-12	6.54e-09	-0.36	-0.3	Motion sickness;	chr6:8448458	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1335633	ENSG00000230939.1	RP11-314C16.1	-6.98	9.95e-12	6.54e-09	-0.36	-0.3	Motion sickness;	chr6:8448567	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1115079	ENSG00000230939.1	RP11-314C16.1	-6.98	9.95e-12	6.54e-09	-0.36	-0.3	Motion sickness;	chr6:8449382	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1115078	ENSG00000230939.1	RP11-314C16.1	-6.98	9.95e-12	6.54e-09	-0.36	-0.3	Motion sickness;	chr6:8449405	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs6597322	ENSG00000230939.1	RP11-314C16.1	-6.98	9.95e-12	6.54e-09	-0.36	-0.3	Motion sickness;	chr6:8449719	chr6:8784178~8785445:+
LUAD	cis	rs75422866	0.867	rs73102166	ENSG00000257433.4	RP1-197B17.3	6.98	9.95e-12	6.54e-09	0.66	0.3	Pneumonia;	chr12:47653769	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs73102168	ENSG00000257433.4	RP1-197B17.3	6.98	9.95e-12	6.54e-09	0.66	0.3	Pneumonia;	chr12:47654010	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs73102171	ENSG00000257433.4	RP1-197B17.3	6.98	9.95e-12	6.54e-09	0.66	0.3	Pneumonia;	chr12:47656077	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs76100981	ENSG00000257433.4	RP1-197B17.3	6.98	9.95e-12	6.54e-09	0.66	0.3	Pneumonia;	chr12:47660092	chr12:47706085~47742294:+
LUAD	cis	rs2739330	0.731	rs2000468	ENSG00000228039.3	KB-1125A3.10	6.98	9.97e-12	6.56e-09	0.35	0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23963780~23964374:+
LUAD	cis	rs7201929	0.959	rs35725751	ENSG00000259982.1	CDC37P1	-6.98	9.98e-12	6.56e-09	-0.46	-0.3	QT interval;	chr16:28834263	chr16:28700294~28701540:-
LUAD	cis	rs12458462	0.859	rs34242155	ENSG00000274828.1	RP11-567M16.6	6.98	9.98e-12	6.56e-09	0.31	0.3	Monocyte count;	chr18:79665192	chr18:79677287~79679358:-
LUAD	cis	rs10129255	0.518	rs7143784	ENSG00000224373.3	IGHV4-59	6.98	9.98e-12	6.56e-09	0.18	0.3	Kawasaki disease;	chr14:106687277	chr14:106627249~106627825:-
LUAD	cis	rs7567389	0.505	rs1518760	ENSG00000236682.1	AC068282.3	-6.98	1e-11	6.57e-09	-0.42	-0.3	Self-rated health;	chr2:127382924	chr2:127389130~127400580:+
LUAD	cis	rs783540	0.846	rs783534	ENSG00000278603.1	RP13-608F4.5	-6.98	1e-11	6.58e-09	-0.35	-0.3	Schizophrenia;	chr15:82581494	chr15:82472203~82472426:+
LUAD	cis	rs7849270	0.879	rs10819461	ENSG00000268707.1	RP11-247A12.7	-6.98	1e-11	6.58e-09	-0.36	-0.3	Blood metabolite ratios;	chr9:129079608	chr9:129170434~129170940:+
LUAD	cis	rs11098499	0.909	rs71614422	ENSG00000248280.1	RP11-33B1.2	6.98	1e-11	6.59e-09	0.39	0.3	Corneal astigmatism;	chr4:119438185	chr4:119440561~119450157:-
LUAD	cis	rs10759883	0.627	rs816683	ENSG00000175611.10	LINC00476	-6.98	1e-11	6.59e-09	-0.36	-0.3	Nicotine dependence;	chr9:95822819	chr9:95759231~95875977:-
LUAD	cis	rs11098499	0.909	rs79026312	ENSG00000248280.1	RP11-33B1.2	6.98	1e-11	6.59e-09	0.39	0.3	Corneal astigmatism;	chr4:119519522	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.909	rs35111518	ENSG00000248280.1	RP11-33B1.2	6.98	1e-11	6.59e-09	0.39	0.3	Corneal astigmatism;	chr4:119519527	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.954	rs66506550	ENSG00000248280.1	RP11-33B1.2	6.98	1e-11	6.6e-09	0.39	0.3	Corneal astigmatism;	chr4:119450290	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.865	rs4001305	ENSG00000248280.1	RP11-33B1.2	6.98	1e-11	6.6e-09	0.39	0.3	Corneal astigmatism;	chr4:119438081	chr4:119440561~119450157:-
LUAD	cis	rs2919917	0.59	rs2919919	ENSG00000254352.1	RP11-578O24.2	-6.98	1e-11	6.6e-09	-0.41	-0.3	Lymphocyte counts;	chr8:78745274	chr8:78723796~78724136:-
LUAD	cis	rs9595908	0.9	rs1324414	ENSG00000212293.1	SNORA16	6.98	1.01e-11	6.62e-09	0.32	0.3	Body mass index;	chr13:32600088	chr13:32420390~32420516:-
LUAD	cis	rs1823913	1	rs12623832	ENSG00000227542.1	AC092614.2	-6.98	1.01e-11	6.63e-09	-0.39	-0.3	Obesity-related traits;	chr2:191260918	chr2:191229165~191246172:-
LUAD	cis	rs2243480	0.901	rs57126451	ENSG00000273142.1	RP11-458F8.4	-6.98	1.01e-11	6.64e-09	-0.31	-0.3	Diabetic kidney disease;	chr7:65951319	chr7:66902857~66906297:+
LUAD	cis	rs11846409	0.932	rs28378201	ENSG00000211974.3	IGHV2-70	-6.98	1.01e-11	6.64e-09	-0.38	-0.3	Rheumatic heart disease;	chr14:106637262	chr14:106723574~106724093:-
LUAD	cis	rs11846409	0.86	rs74091720	ENSG00000211974.3	IGHV2-70	-6.98	1.01e-11	6.64e-09	-0.38	-0.3	Rheumatic heart disease;	chr14:106638192	chr14:106723574~106724093:-
LUAD	cis	rs9487094	0.689	rs9487070	ENSG00000260273.1	RP11-425D10.10	6.98	1.01e-11	6.65e-09	0.38	0.3	Height;	chr6:109361200	chr6:109382795~109383666:+
LUAD	cis	rs10129255	0.957	rs10142918	ENSG00000211972.2	IGHV3-66	6.98	1.01e-11	6.66e-09	0.26	0.3	Kawasaki disease;	chr14:106782206	chr14:106675017~106675544:-
LUAD	cis	rs11098499	0.78	rs12504773	ENSG00000248280.1	RP11-33B1.2	6.97	1.02e-11	6.68e-09	0.39	0.3	Corneal astigmatism;	chr4:119640994	chr4:119440561~119450157:-
LUAD	cis	rs9549367	0.713	rs3024764	ENSG00000269125.1	RP11-98F14.11	-6.97	1.02e-11	6.69e-09	-0.39	-0.3	Platelet distribution width;	chr13:113170000	chr13:113165002~113165183:-
LUAD	cis	rs1823913	0.599	rs1378156	ENSG00000227542.1	AC092614.2	-6.97	1.02e-11	6.69e-09	-0.37	-0.3	Obesity-related traits;	chr2:191272466	chr2:191229165~191246172:-
LUAD	cis	rs9487094	0.666	rs6920372	ENSG00000260273.1	RP11-425D10.10	6.97	1.02e-11	6.69e-09	0.38	0.3	Height;	chr6:109402736	chr6:109382795~109383666:+
LUAD	cis	rs6991838	0.771	rs13282323	ENSG00000272010.1	CTD-3025N20.3	6.97	1.02e-11	6.7e-09	0.32	0.3	Intelligence (multi-trait analysis);	chr8:65560557	chr8:65591850~65592472:-
LUAD	cis	rs12220777	1	rs12220777	ENSG00000230091.5	TMEM254-AS1	-6.97	1.02e-11	6.71e-09	-0.56	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80028348	chr10:80046860~80078912:-
LUAD	cis	rs950169	0.922	rs11631096	ENSG00000259728.4	LINC00933	6.97	1.02e-11	6.71e-09	0.45	0.3	Schizophrenia;	chr15:84557698	chr15:84570649~84580175:+
LUAD	cis	rs1062177	1	rs2964584	ENSG00000213433.5	RPLP1P6	-6.97	1.02e-11	6.72e-09	-0.4	-0.3	Preschool internalizing problems;	chr5:151763317	chr5:151765859~151766378:-
LUAD	cis	rs10200159	1	rs17047094	ENSG00000272606.1	RP11-554J4.1	6.97	1.02e-11	6.72e-09	0.51	0.3	Vitiligo;	chr2:55570701	chr2:55617909~55618373:+
LUAD	cis	rs11846409	0.587	rs1806881	ENSG00000211974.3	IGHV2-70	6.97	1.02e-11	6.72e-09	0.39	0.3	Rheumatic heart disease;	chr14:106650770	chr14:106723574~106724093:-
LUAD	cis	rs2842992	0.789	rs4709376	ENSG00000237927.1	RP3-393E18.2	-6.97	1.03e-11	6.75e-09	-0.44	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159805305	chr6:159586955~159589169:-
LUAD	cis	rs10759883	0.58	rs690495	ENSG00000175611.10	LINC00476	6.97	1.03e-11	6.75e-09	0.35	0.3	Nicotine dependence;	chr9:95893511	chr9:95759231~95875977:-
LUAD	cis	rs72772090	0.539	rs72773986	ENSG00000248734.2	CTD-2260A17.1	-6.97	1.03e-11	6.75e-09	-0.46	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96824014	chr5:96784777~96785999:+
LUAD	cis	rs11098499	0.82	rs11737395	ENSG00000248280.1	RP11-33B1.2	6.97	1.03e-11	6.77e-09	0.39	0.3	Corneal astigmatism;	chr4:119599549	chr4:119440561~119450157:-
LUAD	cis	rs2153535	0.58	rs1577468	ENSG00000230939.1	RP11-314C16.1	-6.97	1.03e-11	6.77e-09	-0.36	-0.3	Motion sickness;	chr6:8444033	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9378551	ENSG00000230939.1	RP11-314C16.1	-6.97	1.03e-11	6.79e-09	-0.36	-0.3	Motion sickness;	chr6:8463511	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9378552	ENSG00000230939.1	RP11-314C16.1	-6.97	1.03e-11	6.79e-09	-0.36	-0.3	Motion sickness;	chr6:8463515	chr6:8784178~8785445:+
LUAD	cis	rs9549367	0.712	rs2316443	ENSG00000269125.1	RP11-98F14.11	-6.97	1.04e-11	6.79e-09	-0.38	-0.3	Platelet distribution width;	chr13:113210523	chr13:113165002~113165183:-
LUAD	cis	rs2842992	0.789	rs2295901	ENSG00000237927.1	RP3-393E18.2	-6.97	1.04e-11	6.8e-09	-0.44	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159780263	chr6:159586955~159589169:-
LUAD	cis	rs2842992	0.789	rs3818300	ENSG00000237927.1	RP3-393E18.2	-6.97	1.04e-11	6.8e-09	-0.44	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159780645	chr6:159586955~159589169:-
LUAD	cis	rs237743	1	rs6012617	ENSG00000222365.1	SNORD12B	6.97	1.04e-11	6.8e-09	0.35	0.3	Height;	chr20:49220589	chr20:49280319~49280409:+
LUAD	cis	rs10129255	0.5	rs1024350	ENSG00000211970.3	IGHV4-61	-6.97	1.04e-11	6.8e-09	-0.21	-0.3	Kawasaki disease;	chr14:106685105	chr14:106639119~106639657:-
LUAD	cis	rs2439831	0.717	rs10518820	ENSG00000205771.5	CATSPER2P1	-6.97	1.04e-11	6.82e-09	-0.61	-0.3	Lung cancer in ever smokers;	chr15:43596778	chr15:43726918~43747094:-
LUAD	cis	rs2243480	0.803	rs36004293	ENSG00000273142.1	RP11-458F8.4	-6.97	1.04e-11	6.83e-09	-0.31	-0.3	Diabetic kidney disease;	chr7:65951525	chr7:66902857~66906297:+
LUAD	cis	rs2243480	0.803	rs35268390	ENSG00000273142.1	RP11-458F8.4	-6.97	1.04e-11	6.83e-09	-0.31	-0.3	Diabetic kidney disease;	chr7:65951549	chr7:66902857~66906297:+
LUAD	cis	rs853679	0.506	rs1150711	ENSG00000204709.4	LINC01556	6.97	1.04e-11	6.84e-09	0.39	0.3	Depression;	chr6:28240757	chr6:28943877~28944537:+
LUAD	cis	rs35160687	0.814	rs6547673	ENSG00000273080.1	RP11-301O19.1	6.97	1.04e-11	6.84e-09	0.33	0.3	Night sleep phenotypes;	chr2:86301815	chr2:86195590~86196049:+
LUAD	cis	rs673078	0.66	rs11068908	ENSG00000275759.1	RP11-131L12.3	-6.97	1.04e-11	6.84e-09	-0.42	-0.3	Glucose homeostasis traits;	chr12:118327265	chr12:118428281~118428870:+
LUAD	cis	rs10463554	0.853	rs246902	ENSG00000175749.11	EIF3KP1	6.97	1.05e-11	6.88e-09	0.4	0.3	Parkinson's disease;	chr5:103253553	chr5:103032376~103033031:+
LUAD	cis	rs7208859	0.573	rs73267829	ENSG00000263531.1	RP13-753N3.1	6.97	1.05e-11	6.89e-09	0.62	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30676921	chr17:30863921~30864940:-
LUAD	cis	rs11089937	0.616	rs4991802	ENSG00000211639.2	IGLV4-60	6.97	1.05e-11	6.9e-09	0.31	0.3	Periodontitis (PAL4Q3);	chr22:22179031	chr22:22162199~22162681:+
LUAD	cis	rs8059260	0.935	rs7203687	ENSG00000274038.1	RP11-66H6.4	-6.97	1.05e-11	6.91e-09	-0.42	-0.3	Alcohol consumption over the past year;	chr16:11013063	chr16:11056556~11057034:+
LUAD	cis	rs1499614	1	rs1267817	ENSG00000273142.1	RP11-458F8.4	-6.97	1.06e-11	6.94e-09	-0.32	-0.3	Gout;	chr7:66645053	chr7:66902857~66906297:+
LUAD	cis	rs9487094	0.666	rs2236084	ENSG00000260273.1	RP11-425D10.10	6.97	1.06e-11	6.94e-09	0.39	0.3	Height;	chr6:109476101	chr6:109382795~109383666:+
LUAD	cis	rs62229266	0.804	rs12483151	ENSG00000214914.3	RPL23AP3	6.97	1.06e-11	6.94e-09	0.37	0.3	Mitral valve prolapse;	chr21:36047280	chr21:36016079~36016546:-
LUAD	cis	rs62229266	0.804	rs880221	ENSG00000214914.3	RPL23AP3	6.97	1.06e-11	6.94e-09	0.37	0.3	Mitral valve prolapse;	chr21:36048487	chr21:36016079~36016546:-
LUAD	cis	rs2153535	0.58	rs6920779	ENSG00000230939.1	RP11-314C16.1	-6.97	1.06e-11	6.95e-09	-0.36	-0.3	Motion sickness;	chr6:8437391	chr6:8784178~8785445:+
LUAD	cis	rs11098499	0.779	rs7699346	ENSG00000248280.1	RP11-33B1.2	6.97	1.07e-11	6.98e-09	0.39	0.3	Corneal astigmatism;	chr4:119389387	chr4:119440561~119450157:-
LUAD	cis	rs9322193	0.962	rs17673294	ENSG00000223701.3	RAET1E-AS1	6.97	1.07e-11	7e-09	0.36	0.3	Lung cancer;	chr6:149813857	chr6:149884431~149919508:+
LUAD	cis	rs673078	0.66	rs17440336	ENSG00000275759.1	RP11-131L12.3	6.97	1.07e-11	7.02e-09	0.43	0.3	Glucose homeostasis traits;	chr12:118163305	chr12:118428281~118428870:+
LUAD	cis	rs950880	0.71	rs11693204	ENSG00000234389.1	AC007278.3	-6.97	1.07e-11	7.02e-09	-0.31	-0.3	Serum protein levels (sST2);	chr2:102319514	chr2:102438713~102440475:+
LUAD	cis	rs9549367	0.713	rs9577211	ENSG00000269125.1	RP11-98F14.11	-6.97	1.08e-11	7.04e-09	-0.39	-0.3	Platelet distribution width;	chr13:113176404	chr13:113165002~113165183:-
LUAD	cis	rs950169	0.92	rs12915390	ENSG00000225151.9	GOLGA2P7	-6.97	1.08e-11	7.05e-09	-0.43	-0.3	Schizophrenia;	chr15:84123317	chr15:84199311~84230136:-
LUAD	cis	rs1062177	1	rs2016409	ENSG00000213433.5	RPLP1P6	6.97	1.08e-11	7.06e-09	0.4	0.3	Preschool internalizing problems;	chr5:151746763	chr5:151765859~151766378:-
LUAD	cis	rs950169	1	rs79318564	ENSG00000225151.9	GOLGA2P7	-6.97	1.08e-11	7.08e-09	-0.44	-0.3	Schizophrenia;	chr15:84117398	chr15:84199311~84230136:-
LUAD	cis	rs66887589	0.777	rs2017058	ENSG00000248280.1	RP11-33B1.2	6.97	1.08e-11	7.09e-09	0.33	0.3	Diastolic blood pressure;	chr4:119336584	chr4:119440561~119450157:-
LUAD	cis	rs66887589	0.777	rs1814815	ENSG00000248280.1	RP11-33B1.2	6.97	1.08e-11	7.09e-09	0.33	0.3	Diastolic blood pressure;	chr4:119336936	chr4:119440561~119450157:-
LUAD	cis	rs10129255	0.5	rs2105991	ENSG00000224373.3	IGHV4-59	6.96	1.09e-11	7.11e-09	0.18	0.3	Kawasaki disease;	chr14:106682022	chr14:106627249~106627825:-
LUAD	cis	rs2153535	0.504	rs5001323	ENSG00000230939.1	RP11-314C16.1	-6.96	1.09e-11	7.11e-09	-0.36	-0.3	Motion sickness;	chr6:8451372	chr6:8784178~8785445:+
LUAD	cis	rs10759883	0.563	rs666093	ENSG00000175611.10	LINC00476	6.96	1.09e-11	7.12e-09	0.35	0.3	Nicotine dependence;	chr9:95983820	chr9:95759231~95875977:-
LUAD	cis	rs10759883	0.563	rs667705	ENSG00000175611.10	LINC00476	6.96	1.09e-11	7.12e-09	0.35	0.3	Nicotine dependence;	chr9:95984132	chr9:95759231~95875977:-
LUAD	cis	rs72772090	0.539	rs72773991	ENSG00000248734.2	CTD-2260A17.1	-6.96	1.09e-11	7.12e-09	-0.46	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96828072	chr5:96784777~96785999:+
LUAD	cis	rs4964805	0.505	rs15918	ENSG00000257681.1	RP11-341G23.4	6.96	1.09e-11	7.12e-09	0.36	0.3	Attention deficit hyperactivity disorder;	chr12:103773246	chr12:103746315~103768858:-
LUAD	cis	rs1062177	1	rs2915877	ENSG00000213433.5	RPLP1P6	-6.96	1.09e-11	7.12e-09	-0.39	-0.3	Preschool internalizing problems;	chr5:151771040	chr5:151765859~151766378:-
LUAD	cis	rs1062177	1	rs2964576	ENSG00000213433.5	RPLP1P6	-6.96	1.09e-11	7.12e-09	-0.39	-0.3	Preschool internalizing problems;	chr5:151771041	chr5:151765859~151766378:-
LUAD	cis	rs6920372	0.799	rs9480947	ENSG00000260273.1	RP11-425D10.10	6.96	1.09e-11	7.12e-09	0.38	0.3	Height;	chr6:109397362	chr6:109382795~109383666:+
LUAD	cis	rs2739330	0.76	rs1007888	ENSG00000206090.4	AP000350.7	6.96	1.09e-11	7.14e-09	0.34	0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23939998~23942798:+
LUAD	cis	rs673078	0.66	rs61943362	ENSG00000275759.1	RP11-131L12.3	-6.96	1.09e-11	7.15e-09	-0.47	-0.3	Glucose homeostasis traits;	chr12:118322042	chr12:118428281~118428870:+
LUAD	cis	rs17301013	0.507	rs6697959	ENSG00000227373.4	RP11-160H22.5	6.96	1.09e-11	7.16e-09	0.46	0.3	Systemic lupus erythematosus;	chr1:174285450	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12066504	ENSG00000227373.4	RP11-160H22.5	6.96	1.09e-11	7.16e-09	0.46	0.3	Systemic lupus erythematosus;	chr1:174288695	chr1:174115300~174160004:-
LUAD	cis	rs9326248	0.581	rs10892076	ENSG00000280143.1	AP000892.6	6.96	1.09e-11	7.16e-09	0.35	0.3	Blood protein levels;	chr11:117118220	chr11:117204967~117210292:+
LUAD	cis	rs11098499	0.954	rs6848389	ENSG00000248280.1	RP11-33B1.2	6.96	1.09e-11	7.17e-09	0.39	0.3	Corneal astigmatism;	chr4:119481467	chr4:119440561~119450157:-
LUAD	cis	rs2842992	0.747	rs9365095	ENSG00000237927.1	RP3-393E18.2	-6.96	1.1e-11	7.17e-09	-0.43	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159771896	chr6:159586955~159589169:-
LUAD	cis	rs2842992	0.789	rs7758895	ENSG00000237927.1	RP3-393E18.2	-6.96	1.1e-11	7.17e-09	-0.43	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159772433	chr6:159586955~159589169:-
LUAD	cis	rs2842992	0.789	rs4276525	ENSG00000237927.1	RP3-393E18.2	-6.96	1.1e-11	7.17e-09	-0.43	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159772580	chr6:159586955~159589169:-
LUAD	cis	rs2842992	0.789	rs9355748	ENSG00000237927.1	RP3-393E18.2	-6.96	1.1e-11	7.17e-09	-0.43	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159773850	chr6:159586955~159589169:-
LUAD	cis	rs11098499	0.863	rs3822194	ENSG00000248280.1	RP11-33B1.2	6.96	1.1e-11	7.18e-09	0.39	0.3	Corneal astigmatism;	chr4:119550493	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.866	rs72676074	ENSG00000248280.1	RP11-33B1.2	6.96	1.1e-11	7.19e-09	0.39	0.3	Corneal astigmatism;	chr4:119438686	chr4:119440561~119450157:-
LUAD	cis	rs7429990	0.864	rs13061412	ENSG00000229759.1	MRPS18AP1	-6.96	1.1e-11	7.2e-09	-0.3	-0.3	Educational attainment (years of education);	chr3:47660092	chr3:48256350~48256938:-
LUAD	cis	rs62229266	0.563	rs6517325	ENSG00000214914.3	RPL23AP3	6.96	1.1e-11	7.2e-09	0.37	0.3	Mitral valve prolapse;	chr21:36062680	chr21:36016079~36016546:-
LUAD	cis	rs2243480	1	rs2961102	ENSG00000273142.1	RP11-458F8.4	-6.96	1.1e-11	7.21e-09	-0.31	-0.3	Diabetic kidney disease;	chr7:65959671	chr7:66902857~66906297:+
LUAD	cis	rs67311347	0.956	rs4974029	ENSG00000223797.4	ENTPD3-AS1	6.96	1.11e-11	7.23e-09	0.32	0.3	Renal cell carcinoma;	chr3:40479827	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs7633809	ENSG00000223797.4	ENTPD3-AS1	-6.96	1.11e-11	7.23e-09	-0.32	-0.3	Renal cell carcinoma;	chr3:40476246	chr3:40313802~40453329:-
LUAD	cis	rs75422866	0.867	rs7304743	ENSG00000257433.4	RP1-197B17.3	-6.96	1.11e-11	7.24e-09	-0.58	-0.3	Pneumonia;	chr12:47683658	chr12:47706085~47742294:+
LUAD	cis	rs867371	1	rs7173339	ENSG00000255769.6	GOLGA2P10	-6.96	1.11e-11	7.24e-09	-0.32	-0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82175253	chr15:82472993~82513950:-
LUAD	cis	rs9660180	0.967	rs6687065	ENSG00000268575.1	RP1-283E3.8	-6.96	1.11e-11	7.25e-09	-0.27	-0.3	Body mass index;	chr1:1847030	chr1:1702736~1737688:-
LUAD	cis	rs11098499	0.909	rs1546502	ENSG00000248280.1	RP11-33B1.2	6.96	1.11e-11	7.27e-09	0.39	0.3	Corneal astigmatism;	chr4:119314743	chr4:119440561~119450157:-
LUAD	cis	rs4718428	0.705	rs13220977	ENSG00000226824.5	RP4-756H11.3	6.96	1.11e-11	7.28e-09	0.41	0.3	Corneal structure;	chr7:66872661	chr7:66654538~66669855:+
LUAD	cis	rs748404	0.631	rs2412781	ENSG00000249839.1	AC011330.5	6.96	1.12e-11	7.33e-09	0.39	0.3	Lung cancer;	chr15:43375702	chr15:43663654~43684339:-
LUAD	cis	rs2153535	0.546	rs1335640	ENSG00000230939.1	RP11-314C16.1	-6.96	1.12e-11	7.34e-09	-0.36	-0.3	Motion sickness;	chr6:8485092	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.541	rs1414352	ENSG00000230939.1	RP11-314C16.1	-6.96	1.12e-11	7.34e-09	-0.36	-0.3	Motion sickness;	chr6:8485314	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1577471	ENSG00000230939.1	RP11-314C16.1	-6.96	1.12e-11	7.34e-09	-0.36	-0.3	Motion sickness;	chr6:8485672	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1120392	ENSG00000230939.1	RP11-314C16.1	-6.96	1.12e-11	7.34e-09	-0.36	-0.3	Motion sickness;	chr6:8486820	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1335641	ENSG00000230939.1	RP11-314C16.1	-6.96	1.12e-11	7.34e-09	-0.36	-0.3	Motion sickness;	chr6:8487627	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs1335643	ENSG00000230939.1	RP11-314C16.1	-6.96	1.12e-11	7.34e-09	-0.36	-0.3	Motion sickness;	chr6:8487788	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9378554	ENSG00000230939.1	RP11-314C16.1	-6.96	1.12e-11	7.34e-09	-0.36	-0.3	Motion sickness;	chr6:8488235	chr6:8784178~8785445:+
LUAD	cis	rs556990	0.76	rs3024739	ENSG00000269125.1	RP11-98F14.11	-6.96	1.12e-11	7.34e-09	-0.41	-0.3	Blood protein levels;	chr13:113165634	chr13:113165002~113165183:-
LUAD	cis	rs2842992	0.724	rs15982	ENSG00000237927.1	RP3-393E18.2	-6.96	1.12e-11	7.35e-09	-0.42	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159778655	chr6:159586955~159589169:-
LUAD	cis	rs7044106	0.734	rs12553070	ENSG00000238181.2	AHCYP2	-6.96	1.13e-11	7.36e-09	-0.4	-0.3	Hip circumference adjusted for BMI;	chr9:120722988	chr9:120720673~120721972:+
LUAD	cis	rs2015599	0.623	rs7964831	ENSG00000275476.1	RP11-996F15.4	-6.96	1.13e-11	7.37e-09	-0.32	-0.3	Platelet count;Mean platelet volume;	chr12:29286655	chr12:29277397~29277882:-
LUAD	cis	rs9487094	0.644	rs3757230	ENSG00000260273.1	RP11-425D10.10	6.96	1.13e-11	7.37e-09	0.38	0.3	Height;	chr6:109383239	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.644	rs3757231	ENSG00000260273.1	RP11-425D10.10	6.96	1.13e-11	7.37e-09	0.38	0.3	Height;	chr6:109383248	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.666	rs4946970	ENSG00000260273.1	RP11-425D10.10	6.96	1.13e-11	7.37e-09	0.38	0.3	Height;	chr6:109384807	chr6:109382795~109383666:+
LUAD	cis	rs7674212	0.531	rs4698875	ENSG00000246560.2	RP11-10L12.4	6.96	1.13e-11	7.38e-09	0.4	0.3	Type 2 diabetes;	chr4:103012211	chr4:102828055~102844075:+
LUAD	cis	rs12022452	0.591	rs16827359	ENSG00000238287.1	RP11-656D10.3	6.96	1.13e-11	7.4e-09	0.46	0.3	Age-related hearing impairment (SNP x SNP interaction);	chr1:40535766	chr1:40493157~40508661:-
LUAD	cis	rs9487094	0.644	rs9791241	ENSG00000260273.1	RP11-425D10.10	6.96	1.15e-11	7.48e-09	0.38	0.3	Height;	chr6:109470900	chr6:109382795~109383666:+
LUAD	cis	rs867371	1	rs8042464	ENSG00000255769.6	GOLGA2P10	-6.96	1.15e-11	7.5e-09	-0.32	-0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173195	chr15:82472993~82513950:-
LUAD	cis	rs11098499	0.863	rs1383533	ENSG00000248280.1	RP11-33B1.2	6.96	1.15e-11	7.5e-09	0.39	0.3	Corneal astigmatism;	chr4:119513421	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs2291185	ENSG00000248280.1	RP11-33B1.2	6.96	1.15e-11	7.5e-09	0.39	0.3	Corneal astigmatism;	chr4:119513678	chr4:119440561~119450157:-
LUAD	cis	rs10759883	0.627	rs10125109	ENSG00000175611.10	LINC00476	-6.96	1.15e-11	7.52e-09	-0.36	-0.3	Nicotine dependence;	chr9:95799228	chr9:95759231~95875977:-
LUAD	cis	rs1823913	1	rs1840377	ENSG00000227542.1	AC092614.2	-6.96	1.15e-11	7.52e-09	-0.39	-0.3	Obesity-related traits;	chr2:191257992	chr2:191229165~191246172:-
LUAD	cis	rs1823913	1	rs4853564	ENSG00000227542.1	AC092614.2	-6.96	1.15e-11	7.52e-09	-0.39	-0.3	Obesity-related traits;	chr2:191258939	chr2:191229165~191246172:-
LUAD	cis	rs1823913	1	rs4853565	ENSG00000227542.1	AC092614.2	-6.96	1.15e-11	7.52e-09	-0.39	-0.3	Obesity-related traits;	chr2:191259020	chr2:191229165~191246172:-
LUAD	cis	rs1823913	1	rs4853462	ENSG00000227542.1	AC092614.2	-6.96	1.15e-11	7.52e-09	-0.39	-0.3	Obesity-related traits;	chr2:191259078	chr2:191229165~191246172:-
LUAD	cis	rs11098499	0.863	rs34868248	ENSG00000248280.1	RP11-33B1.2	6.96	1.16e-11	7.54e-09	0.39	0.3	Corneal astigmatism;	chr4:119521275	chr4:119440561~119450157:-
LUAD	cis	rs2919917	0.628	rs12544041	ENSG00000254352.1	RP11-578O24.2	-6.96	1.16e-11	7.54e-09	-0.4	-0.3	Lymphocyte counts;	chr8:78731404	chr8:78723796~78724136:-
LUAD	cis	rs8100891	0.537	rs10409835	ENSG00000267213.4	AC007773.2	-6.95	1.16e-11	7.54e-09	-0.46	-0.3	Neuroticism;	chr19:32397754	chr19:32390050~32405560:-
LUAD	cis	rs9487094	0.626	rs1322124	ENSG00000260273.1	RP11-425D10.10	6.95	1.16e-11	7.55e-09	0.39	0.3	Height;	chr6:109741670	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.62	rs6939953	ENSG00000260273.1	RP11-425D10.10	6.95	1.16e-11	7.56e-09	0.38	0.3	Height;	chr6:109390116	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.626	rs4141930	ENSG00000260273.1	RP11-425D10.10	6.95	1.16e-11	7.57e-09	0.4	0.3	Height;	chr6:109739615	chr6:109382795~109383666:+
LUAD	cis	rs9322193	0.772	rs7738696	ENSG00000223701.3	RAET1E-AS1	6.95	1.16e-11	7.57e-09	0.36	0.3	Lung cancer;	chr6:149848985	chr6:149884431~149919508:+
LUAD	cis	rs7674212	0.531	rs6816370	ENSG00000246560.2	RP11-10L12.4	6.95	1.16e-11	7.58e-09	0.4	0.3	Type 2 diabetes;	chr4:103018276	chr4:102828055~102844075:+
LUAD	cis	rs11098499	0.909	rs10020034	ENSG00000248280.1	RP11-33B1.2	6.95	1.16e-11	7.59e-09	0.39	0.3	Corneal astigmatism;	chr4:119373176	chr4:119440561~119450157:-
LUAD	cis	rs7615952	0.866	rs13063119	ENSG00000171084.14	FAM86JP	6.95	1.17e-11	7.62e-09	0.44	0.3	Blood pressure (smoking interaction);	chr3:125925004	chr3:125916620~125930024:+
LUAD	cis	rs1062177	1	rs2915880	ENSG00000213433.5	RPLP1P6	-6.95	1.17e-11	7.63e-09	-0.39	-0.3	Preschool internalizing problems;	chr5:151767773	chr5:151765859~151766378:-
LUAD	cis	rs150992	0.632	rs34489	ENSG00000248489.1	CTD-2007H13.3	-6.95	1.17e-11	7.64e-09	-0.33	-0.3	Body mass index;	chr5:98977180	chr5:98929171~98995013:+
LUAD	cis	rs4908760	0.64	rs3795310	ENSG00000232912.4	RP5-1115A15.1	-6.95	1.18e-11	7.66e-09	-0.28	-0.3	Vitiligo;	chr1:8371547	chr1:8424645~8434838:+
LUAD	cis	rs10899021	1	rs7102084	ENSG00000279353.1	RP11-864N7.4	6.95	1.18e-11	7.67e-09	0.55	0.3	Response to metformin (IC50);	chr11:74647087	chr11:74698231~74699658:-
LUAD	cis	rs6142102	0.961	rs8119937	ENSG00000276073.1	RP5-1125A11.7	-6.95	1.18e-11	7.67e-09	-0.31	-0.3	Skin pigmentation;	chr20:34057745	chr20:33985617~33988989:-
LUAD	cis	rs67311347	1	rs2276871	ENSG00000223797.4	ENTPD3-AS1	6.95	1.18e-11	7.67e-09	0.32	0.3	Renal cell carcinoma;	chr3:40457782	chr3:40313802~40453329:-
LUAD	cis	rs10200159	1	rs13428486	ENSG00000272606.1	RP11-554J4.1	6.95	1.18e-11	7.68e-09	0.51	0.3	Vitiligo;	chr2:55569451	chr2:55617909~55618373:+
LUAD	cis	rs9487094	0.666	rs3778478	ENSG00000260273.1	RP11-425D10.10	6.95	1.18e-11	7.69e-09	0.38	0.3	Height;	chr6:109470427	chr6:109382795~109383666:+
LUAD	cis	rs9640161	0.742	rs11767726	ENSG00000261305.1	RP4-584D14.7	-6.95	1.18e-11	7.7e-09	-0.43	-0.3	Blood protein levels;Circulating chemerin levels;	chr7:150321007	chr7:150341771~150342607:+
LUAD	cis	rs1799949	0.965	rs8176323	ENSG00000267681.1	CTD-3199J23.6	-6.95	1.18e-11	7.7e-09	-0.35	-0.3	Menopause (age at onset);	chr17:43043694	chr17:43144956~43145255:+
LUAD	cis	rs7115242	0.8	rs7931770	ENSG00000280143.1	AP000892.6	6.95	1.18e-11	7.71e-09	0.46	0.3	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116995574	chr11:117204967~117210292:+
LUAD	cis	rs2337406	0.866	rs4280141	ENSG00000211974.3	IGHV2-70	6.95	1.18e-11	7.71e-09	0.38	0.3	Alzheimer's disease (late onset);	chr14:106780476	chr14:106723574~106724093:-
LUAD	cis	rs6844153	0.938	rs16878655	ENSG00000240005.4	RP11-293A21.1	6.95	1.19e-11	7.75e-09	0.45	0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26964655	chr4:26859806~26860599:-
LUAD	cis	rs9487094	0.689	rs1046943	ENSG00000260273.1	RP11-425D10.10	6.95	1.19e-11	7.75e-09	0.38	0.3	Height;	chr6:109462738	chr6:109382795~109383666:+
LUAD	cis	rs2243480	1	rs34136756	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65916269	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs78803505	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65917585	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs34933526	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65918212	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs34577383	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65920739	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs6949812	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65922114	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs55895244	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65922691	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs6970243	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65923503	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs7794661	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65924743	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs7795242	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65925107	chr7:66902857~66906297:+
LUAD	cis	rs2243480	0.708	rs35310401	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65925372	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs35058610	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65925938	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs2177703	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65926730	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs35432774	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65928032	chr7:66902857~66906297:+
LUAD	cis	rs2243480	0.831	rs7806717	ENSG00000273142.1	RP11-458F8.4	6.95	1.19e-11	7.75e-09	0.32	0.3	Diabetic kidney disease;	chr7:65928187	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs56985706	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65929575	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs60683927	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65929781	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs58062456	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65929865	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs34529418	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65938222	chr7:66902857~66906297:+
LUAD	cis	rs2243480	0.901	rs35087093	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65940221	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs35046236	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65943626	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs36068983	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65944004	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs68189316	ENSG00000273142.1	RP11-458F8.4	-6.95	1.19e-11	7.75e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65944182	chr7:66902857~66906297:+
LUAD	cis	rs11098499	0.954	rs1022145	ENSG00000248280.1	RP11-33B1.2	6.95	1.19e-11	7.76e-09	0.39	0.3	Corneal astigmatism;	chr4:119309824	chr4:119440561~119450157:-
LUAD	cis	rs2439831	0.681	rs524527	ENSG00000205771.5	CATSPER2P1	6.95	1.19e-11	7.76e-09	0.52	0.3	Lung cancer in ever smokers;	chr15:43306918	chr15:43726918~43747094:-
LUAD	cis	rs11098499	0.863	rs3822195	ENSG00000248280.1	RP11-33B1.2	6.95	1.19e-11	7.77e-09	0.39	0.3	Corneal astigmatism;	chr4:119550505	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs3775854	ENSG00000248280.1	RP11-33B1.2	6.95	1.19e-11	7.77e-09	0.39	0.3	Corneal astigmatism;	chr4:119550816	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs2306457	ENSG00000248280.1	RP11-33B1.2	6.95	1.19e-11	7.77e-09	0.39	0.3	Corneal astigmatism;	chr4:119551684	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs6853998	ENSG00000248280.1	RP11-33B1.2	6.95	1.19e-11	7.77e-09	0.39	0.3	Corneal astigmatism;	chr4:119554705	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs6858777	ENSG00000248280.1	RP11-33B1.2	6.95	1.19e-11	7.77e-09	0.39	0.3	Corneal astigmatism;	chr4:119554811	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs11731756	ENSG00000248280.1	RP11-33B1.2	6.95	1.19e-11	7.77e-09	0.39	0.3	Corneal astigmatism;	chr4:119557541	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs34308924	ENSG00000248280.1	RP11-33B1.2	6.95	1.19e-11	7.77e-09	0.39	0.3	Corneal astigmatism;	chr4:119560276	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs2170276	ENSG00000248280.1	RP11-33B1.2	6.95	1.19e-11	7.77e-09	0.39	0.3	Corneal astigmatism;	chr4:119564669	chr4:119440561~119450157:-
LUAD	cis	rs237743	1	rs67652499	ENSG00000222365.1	SNORD12B	-6.95	1.19e-11	7.77e-09	-0.35	-0.3	Height;	chr20:49310154	chr20:49280319~49280409:+
LUAD	cis	rs8059260	0.736	rs8059156	ENSG00000274038.1	RP11-66H6.4	-6.95	1.2e-11	7.8e-09	-0.57	-0.3	Alcohol consumption over the past year;	chr16:10952135	chr16:11056556~11057034:+
LUAD	cis	rs9487094	0.666	rs1074765	ENSG00000260273.1	RP11-425D10.10	-6.95	1.2e-11	7.8e-09	-0.38	-0.3	Height;	chr6:109360458	chr6:109382795~109383666:+
LUAD	cis	rs11767557	1	rs11767557	ENSG00000229153.4	EPHA1-AS1	6.95	1.2e-11	7.8e-09	0.47	0.3	Alzheimer's disease (late onset);	chr7:143412046	chr7:143407813~143523449:+
LUAD	cis	rs17023223	0.537	rs2765534	ENSG00000231365.4	RP11-418J17.1	-6.95	1.2e-11	7.8e-09	-0.4	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119055169	chr1:119140396~119275973:+
LUAD	cis	rs321358	0.731	rs7939631	ENSG00000271584.1	RP11-89C3.4	6.95	1.2e-11	7.8e-09	0.47	0.3	Body mass index;	chr11:111153506	chr11:111091932~111097357:-
LUAD	cis	rs950880	0.553	rs3755272	ENSG00000234389.1	AC007278.3	-6.95	1.2e-11	7.82e-09	-0.34	-0.3	Serum protein levels (sST2);	chr2:102417365	chr2:102438713~102440475:+
LUAD	cis	rs9903692	0.954	rs875065	ENSG00000278765.1	RP5-890E16.5	6.95	1.2e-11	7.82e-09	0.39	0.3	Pulse pressure;	chr17:48062207	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.954	rs875066	ENSG00000278765.1	RP5-890E16.5	6.95	1.2e-11	7.82e-09	0.39	0.3	Pulse pressure;	chr17:48062370	chr17:48066704~48067293:-
LUAD	cis	rs755249	0.959	rs72663520	ENSG00000228060.1	RP11-69E11.8	-6.95	1.21e-11	7.86e-09	-0.3	-0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39537738	chr1:39565160~39573203:+
LUAD	cis	rs950169	0.922	rs67804993	ENSG00000259728.4	LINC00933	6.95	1.21e-11	7.87e-09	0.45	0.3	Schizophrenia;	chr15:84560799	chr15:84570649~84580175:+
LUAD	cis	rs237743	1	rs237743	ENSG00000222365.1	SNORD12B	6.95	1.21e-11	7.87e-09	0.34	0.3	Height;	chr20:49286482	chr20:49280319~49280409:+
LUAD	cis	rs801193	0.548	rs2659904	ENSG00000222364.1	RNU6-96P	-6.95	1.21e-11	7.89e-09	-0.34	-0.3	Aortic root size;	chr7:66713615	chr7:66395191~66395286:+
LUAD	cis	rs867371	0.762	rs12905578	ENSG00000255769.6	GOLGA2P10	6.95	1.21e-11	7.89e-09	0.34	0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82288923	chr15:82472993~82513950:-
LUAD	cis	rs9487094	0.689	rs6939548	ENSG00000260273.1	RP11-425D10.10	6.95	1.21e-11	7.89e-09	0.38	0.3	Height;	chr6:109464011	chr6:109382795~109383666:+
LUAD	cis	rs2439831	1	rs471229	ENSG00000205771.5	CATSPER2P1	-6.95	1.22e-11	7.9e-09	-0.52	-0.3	Lung cancer in ever smokers;	chr15:43441796	chr15:43726918~43747094:-
LUAD	cis	rs853679	0.527	rs853690	ENSG00000204709.4	LINC01556	6.95	1.22e-11	7.92e-09	0.38	0.3	Depression;	chr6:28317705	chr6:28943877~28944537:+
LUAD	cis	rs9326248	0.581	rs10892048	ENSG00000280143.1	AP000892.6	6.95	1.22e-11	7.93e-09	0.35	0.3	Blood protein levels;	chr11:116943880	chr11:117204967~117210292:+
LUAD	cis	rs34779708	0.649	rs34421369	ENSG00000230534.5	RP11-297A16.2	6.95	1.22e-11	7.94e-09	0.36	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35261347	chr10:35098006~35127020:-
LUAD	cis	rs10463554	0.746	rs6876072	ENSG00000175749.11	EIF3KP1	6.95	1.22e-11	7.95e-09	0.4	0.3	Parkinson's disease;	chr5:103251872	chr5:103032376~103033031:+
LUAD	cis	rs9326248	0.559	rs1269329	ENSG00000280143.1	AP000892.6	6.94	1.23e-11	8.01e-09	0.36	0.3	Blood protein levels;	chr11:116884325	chr11:117204967~117210292:+
LUAD	cis	rs4853012	1	rs2280643	ENSG00000257800.1	FNBP1P1	6.94	1.23e-11	8.02e-09	0.4	0.3	Gestational age at birth (maternal effect);	chr2:74131159	chr2:74120680~74123218:+
LUAD	cis	rs4853012	0.887	rs2280644	ENSG00000257800.1	FNBP1P1	6.94	1.23e-11	8.02e-09	0.4	0.3	Gestational age at birth (maternal effect);	chr2:74131284	chr2:74120680~74123218:+
LUAD	cis	rs6921919	0.848	rs56131013	ENSG00000204709.4	LINC01556	6.94	1.24e-11	8.03e-09	0.43	0.3	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:28943877~28944537:+
LUAD	cis	rs56205728	0.606	rs3784398	ENSG00000273855.1	RP11-133K1.12	6.94	1.24e-11	8.03e-09	0.35	0.3	Schizophrenia;	chr15:40304665	chr15:40285468~40285909:-
LUAD	cis	rs2243480	0.803	rs34804747	ENSG00000273142.1	RP11-458F8.4	-6.94	1.24e-11	8.04e-09	-0.31	-0.3	Diabetic kidney disease;	chr7:65947955	chr7:66902857~66906297:+
LUAD	cis	rs7626444	0.625	rs7648479	ENSG00000272359.1	U4	-6.94	1.24e-11	8.07e-09	-0.33	-0.3	Monocyte count;	chr3:196750342	chr3:196747192~196747324:-
LUAD	cis	rs904251	0.734	rs2797790	ENSG00000279942.1	RP1-153P14.7	6.94	1.25e-11	8.09e-09	0.3	0.3	Cognitive performance;	chr6:37479299	chr6:37567716~37571460:+
LUAD	cis	rs11098499	0.863	rs3775845	ENSG00000248280.1	RP11-33B1.2	6.94	1.25e-11	8.12e-09	0.39	0.3	Corneal astigmatism;	chr4:119511292	chr4:119440561~119450157:-
LUAD	cis	rs9487094	0.666	rs3734652	ENSG00000260273.1	RP11-425D10.10	6.94	1.25e-11	8.12e-09	0.38	0.3	Height;	chr6:109465777	chr6:109382795~109383666:+
LUAD	cis	rs465969	0.744	rs79052344	ENSG00000255389.1	C6orf3	-6.94	1.25e-11	8.13e-09	-0.65	-0.3	Psoriasis;	chr6:111550755	chr6:111599875~111602295:+
LUAD	cis	rs35955747	0.902	rs12166373	ENSG00000236132.1	CTA-440B3.1	6.94	1.25e-11	8.13e-09	0.34	0.3	Neutrophil count;Sum basophil neutrophil counts;	chr22:31304522	chr22:31816379~31817491:-
LUAD	cis	rs75422866	0.867	rs73102125	ENSG00000280054.1	RP1-197B17.7	6.94	1.25e-11	8.14e-09	0.67	0.3	Pneumonia;	chr12:47637869	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs12426849	ENSG00000280054.1	RP1-197B17.7	6.94	1.25e-11	8.14e-09	0.67	0.3	Pneumonia;	chr12:47638975	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs117950951	ENSG00000280054.1	RP1-197B17.7	6.94	1.25e-11	8.14e-09	0.67	0.3	Pneumonia;	chr12:47639794	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs7954764	ENSG00000280054.1	RP1-197B17.7	6.94	1.25e-11	8.14e-09	0.67	0.3	Pneumonia;	chr12:47641136	chr12:47728151~47730598:-
LUAD	cis	rs10129255	0.518	rs10150460	ENSG00000224373.3	IGHV4-59	-6.94	1.26e-11	8.15e-09	-0.18	-0.3	Kawasaki disease;	chr14:106677179	chr14:106627249~106627825:-
LUAD	cis	rs10759883	0.627	rs816684	ENSG00000175611.10	LINC00476	-6.94	1.26e-11	8.15e-09	-0.35	-0.3	Nicotine dependence;	chr9:95822707	chr9:95759231~95875977:-
LUAD	cis	rs11214589	0.807	rs2155463	ENSG00000270179.1	RP11-159N11.4	-6.94	1.26e-11	8.16e-09	-0.3	-0.3	Neuroticism;	chr11:113371579	chr11:113368478~113369117:+
LUAD	cis	rs67311347	0.91	rs7651204	ENSG00000223797.4	ENTPD3-AS1	-6.94	1.26e-11	8.17e-09	-0.32	-0.3	Renal cell carcinoma;	chr3:40471344	chr3:40313802~40453329:-
LUAD	cis	rs7615952	0.673	rs115942855	ENSG00000171084.14	FAM86JP	6.94	1.26e-11	8.17e-09	0.58	0.3	Blood pressure (smoking interaction);	chr3:125883117	chr3:125916620~125930024:+
LUAD	cis	rs34375054	0.672	rs58416336	ENSG00000279233.1	RP11-158L12.4	6.94	1.26e-11	8.19e-09	0.25	0.3	Post bronchodilator FEV1/FVC ratio;	chr12:125121882	chr12:125138245~125141711:+
LUAD	cis	rs9549367	0.789	rs9549361	ENSG00000269125.1	RP11-98F14.11	6.94	1.26e-11	8.19e-09	0.37	0.3	Platelet distribution width;	chr13:113244015	chr13:113165002~113165183:-
LUAD	cis	rs4964805	0.594	rs954920	ENSG00000257681.1	RP11-341G23.4	6.94	1.26e-11	8.19e-09	0.36	0.3	Attention deficit hyperactivity disorder;	chr12:103779532	chr12:103746315~103768858:-
LUAD	cis	rs11098499	0.954	rs59394118	ENSG00000248280.1	RP11-33B1.2	6.94	1.26e-11	8.19e-09	0.39	0.3	Corneal astigmatism;	chr4:119374396	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.865	rs9996417	ENSG00000248280.1	RP11-33B1.2	6.94	1.26e-11	8.19e-09	0.39	0.3	Corneal astigmatism;	chr4:119374707	chr4:119440561~119450157:-
LUAD	cis	rs950169	1	rs1911155	ENSG00000225151.9	GOLGA2P7	-6.94	1.27e-11	8.22e-09	-0.43	-0.3	Schizophrenia;	chr15:84118883	chr15:84199311~84230136:-
LUAD	cis	rs9487094	0.666	rs746794	ENSG00000260273.1	RP11-425D10.10	6.94	1.28e-11	8.27e-09	0.38	0.3	Height;	chr6:109391534	chr6:109382795~109383666:+
LUAD	cis	rs11098499	0.863	rs7669520	ENSG00000248280.1	RP11-33B1.2	6.94	1.28e-11	8.3e-09	0.39	0.3	Corneal astigmatism;	chr4:119594123	chr4:119440561~119450157:-
LUAD	cis	rs2153535	0.601	rs2015281	ENSG00000230939.1	RP11-314C16.1	-6.94	1.28e-11	8.31e-09	-0.36	-0.3	Motion sickness;	chr6:8539440	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.601	rs9505474	ENSG00000230939.1	RP11-314C16.1	-6.94	1.28e-11	8.31e-09	-0.36	-0.3	Motion sickness;	chr6:8539561	chr6:8784178~8785445:+
LUAD	cis	rs748404	0.578	rs552701	ENSG00000249839.1	AC011330.5	-6.94	1.28e-11	8.31e-09	-0.4	-0.3	Lung cancer;	chr15:43321612	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.578	rs573615	ENSG00000249839.1	AC011330.5	-6.94	1.28e-11	8.31e-09	-0.4	-0.3	Lung cancer;	chr15:43322083	chr15:43663654~43684339:-
LUAD	cis	rs62229266	0.804	rs11088331	ENSG00000214914.3	RPL23AP3	6.94	1.28e-11	8.31e-09	0.37	0.3	Mitral valve prolapse;	chr21:36049574	chr21:36016079~36016546:-
LUAD	cis	rs2286503	0.78	rs2286506	ENSG00000228649.7	AC005682.5	6.94	1.29e-11	8.35e-09	0.39	0.3	Fibrinogen;	chr7:22815196	chr7:22854178~22861579:+
LUAD	cis	rs2286503	0.752	rs2286504	ENSG00000228649.7	AC005682.5	6.94	1.29e-11	8.35e-09	0.39	0.3	Fibrinogen;	chr7:22815228	chr7:22854178~22861579:+
LUAD	cis	rs8177876	0.749	rs11537	ENSG00000261838.4	RP11-303E16.6	6.94	1.29e-11	8.36e-09	0.64	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046894	chr16:81069854~81076598:+
LUAD	cis	rs17023223	0.537	rs2765533	ENSG00000231365.4	RP11-418J17.1	-6.94	1.3e-11	8.4e-09	-0.4	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119054772	chr1:119140396~119275973:+
LUAD	cis	rs673078	0.66	rs61943365	ENSG00000275759.1	RP11-131L12.3	-6.94	1.3e-11	8.42e-09	-0.4	-0.3	Glucose homeostasis traits;	chr12:118339166	chr12:118428281~118428870:+
LUAD	cis	rs71403859	0.502	rs35394108	ENSG00000260886.1	TAT-AS1	6.94	1.3e-11	8.43e-09	0.49	0.3	Post bronchodilator FEV1;	chr16:71506736	chr16:71565789~71578187:+
LUAD	cis	rs9309473	1	rs6710438	ENSG00000163016.8	ALMS1P	-6.94	1.3e-11	8.43e-09	-0.37	-0.3	Metabolite levels;	chr2:73592981	chr2:73644919~73685576:+
LUAD	cis	rs8059260	0.604	rs34215426	ENSG00000274038.1	RP11-66H6.4	-6.94	1.3e-11	8.44e-09	-0.6	-0.3	Alcohol consumption over the past year;	chr16:11113614	chr16:11056556~11057034:+
LUAD	cis	rs11089937	0.616	rs5757247	ENSG00000211639.2	IGLV4-60	6.94	1.3e-11	8.44e-09	0.31	0.3	Periodontitis (PAL4Q3);	chr22:22177186	chr22:22162199~22162681:+
LUAD	cis	rs950169	0.922	rs6603022	ENSG00000259728.4	LINC00933	-6.94	1.3e-11	8.44e-09	-0.46	-0.3	Schizophrenia;	chr15:84161418	chr15:84570649~84580175:+
LUAD	cis	rs881375	0.678	rs10760125	ENSG00000226752.6	PSMD5-AS1	-6.94	1.3e-11	8.45e-09	-0.32	-0.3	Rheumatoid arthritis;	chr9:120900312	chr9:120824828~120854385:+
LUAD	cis	rs881375	0.678	rs9886724	ENSG00000226752.6	PSMD5-AS1	-6.94	1.3e-11	8.45e-09	-0.32	-0.3	Rheumatoid arthritis;	chr9:120902741	chr9:120824828~120854385:+
LUAD	cis	rs881375	0.631	rs10739577	ENSG00000226752.6	PSMD5-AS1	-6.94	1.3e-11	8.45e-09	-0.32	-0.3	Rheumatoid arthritis;	chr9:120906576	chr9:120824828~120854385:+
LUAD	cis	rs10740039	0.883	rs10994468	ENSG00000254271.1	RP11-131N11.4	6.94	1.31e-11	8.46e-09	0.35	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60666533	chr10:60734342~60741828:+
LUAD	cis	rs10899021	0.79	rs12296094	ENSG00000279353.1	RP11-864N7.4	6.94	1.31e-11	8.48e-09	0.54	0.3	Response to metformin (IC50);	chr11:74610655	chr11:74698231~74699658:-
LUAD	cis	rs4938303	0.671	rs2008915	ENSG00000254851.1	RP11-109L13.1	-6.94	1.31e-11	8.48e-09	-0.47	-0.3	Triglycerides;	chr11:116732418	chr11:117135528~117138582:+
LUAD	cis	rs11098499	0.865	rs11098513	ENSG00000248280.1	RP11-33B1.2	6.94	1.31e-11	8.51e-09	0.39	0.3	Corneal astigmatism;	chr4:119394920	chr4:119440561~119450157:-
LUAD	cis	rs55665837	1	rs12804549	ENSG00000251991.1	RNU7-49P	6.93	1.32e-11	8.52e-09	0.33	0.3	Vitamin D levels;	chr11:14416212	chr11:14478892~14478953:+
LUAD	cis	rs12022452	0.63	rs3795346	ENSG00000238287.1	RP11-656D10.3	-6.93	1.32e-11	8.52e-09	-0.49	-0.3	Age-related hearing impairment (SNP x SNP interaction);	chr1:40508753	chr1:40493157~40508661:-
LUAD	cis	rs9640161	0.659	rs17837498	ENSG00000261305.1	RP4-584D14.7	6.93	1.32e-11	8.52e-09	0.43	0.3	Blood protein levels;Circulating chemerin levels;	chr7:150312590	chr7:150341771~150342607:+
LUAD	cis	rs11098499	0.863	rs12498539	ENSG00000248280.1	RP11-33B1.2	6.93	1.32e-11	8.53e-09	0.39	0.3	Corneal astigmatism;	chr4:119547215	chr4:119440561~119450157:-
LUAD	cis	rs9549367	0.713	rs2146750	ENSG00000269125.1	RP11-98F14.11	6.93	1.32e-11	8.56e-09	0.39	0.3	Platelet distribution width;	chr13:113168216	chr13:113165002~113165183:-
LUAD	cis	rs12022452	0.591	rs11208356	ENSG00000238287.1	RP11-656D10.3	-6.93	1.32e-11	8.56e-09	-0.47	-0.3	Age-related hearing impairment (SNP x SNP interaction);	chr1:40541259	chr1:40493157~40508661:-
LUAD	cis	rs6142102	1	rs4911414	ENSG00000276073.1	RP5-1125A11.7	-6.93	1.32e-11	8.57e-09	-0.32	-0.3	Skin pigmentation;	chr20:34141638	chr20:33985617~33988989:-
LUAD	cis	rs10740039	0.804	rs4948424	ENSG00000254271.1	RP11-131N11.4	6.93	1.33e-11	8.6e-09	0.34	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60681812	chr10:60734342~60741828:+
LUAD	cis	rs4865169	0.791	rs11731868	ENSG00000269949.1	RP11-738E22.3	-6.93	1.34e-11	8.64e-09	-0.38	-0.3	Breast cancer;	chr4:57029048	chr4:56960927~56961373:-
LUAD	cis	rs9640161	0.659	rs59572505	ENSG00000261305.1	RP4-584D14.7	6.93	1.34e-11	8.65e-09	0.44	0.3	Blood protein levels;Circulating chemerin levels;	chr7:150317897	chr7:150341771~150342607:+
LUAD	cis	rs1799949	1	rs8176109	ENSG00000267681.1	CTD-3199J23.6	-6.93	1.34e-11	8.68e-09	-0.35	-0.3	Menopause (age at onset);	chr17:43113759	chr17:43144956~43145255:+
LUAD	cis	rs1075232	1	rs72722861	ENSG00000270055.1	CTD-3092A11.2	-6.93	1.34e-11	8.68e-09	-0.62	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31412085	chr15:30487963~30490313:+
LUAD	cis	rs9309711	0.961	rs35067331	ENSG00000225234.1	TRAPPC12-AS1	-6.93	1.34e-11	8.69e-09	-0.38	-0.3	Neurofibrillary tangles;	chr2:3470314	chr2:3481242~3482409:-
LUAD	cis	rs2337406	0.538	rs10141701	ENSG00000254174.1	IGHV1-12	6.93	1.34e-11	8.69e-09	0.26	0.3	Alzheimer's disease (late onset);	chr14:106633467	chr14:106122420~106122709:-
LUAD	cis	rs9326248	0.559	rs12808524	ENSG00000280143.1	AP000892.6	6.93	1.34e-11	8.69e-09	0.35	0.3	Blood protein levels;	chr11:117020277	chr11:117204967~117210292:+
LUAD	cis	rs6142102	0.923	rs6059586	ENSG00000276073.1	RP5-1125A11.7	-6.93	1.35e-11	8.74e-09	-0.31	-0.3	Skin pigmentation;	chr20:33952695	chr20:33985617~33988989:-
LUAD	cis	rs8177876	0.822	rs4306521	ENSG00000261838.4	RP11-303E16.6	6.93	1.35e-11	8.74e-09	0.66	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081288	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.822	rs4324142	ENSG00000261838.4	RP11-303E16.6	6.93	1.35e-11	8.74e-09	0.66	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081298	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.642	rs4324143	ENSG00000261838.4	RP11-303E16.6	6.93	1.35e-11	8.74e-09	0.66	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081383	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.818	rs59177227	ENSG00000261838.4	RP11-303E16.6	6.93	1.35e-11	8.74e-09	0.66	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081524	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.822	rs59685942	ENSG00000261838.4	RP11-303E16.6	6.93	1.35e-11	8.74e-09	0.66	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081534	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.822	rs10514515	ENSG00000261838.4	RP11-303E16.6	6.93	1.35e-11	8.74e-09	0.66	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081717	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.822	rs1410	ENSG00000261838.4	RP11-303E16.6	6.93	1.35e-11	8.74e-09	0.66	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082228	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.822	rs1412	ENSG00000261838.4	RP11-303E16.6	6.93	1.35e-11	8.74e-09	0.66	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082237	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.822	rs1414	ENSG00000261838.4	RP11-303E16.6	6.93	1.35e-11	8.74e-09	0.66	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082252	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.822	rs8177950	ENSG00000261838.4	RP11-303E16.6	6.93	1.35e-11	8.74e-09	0.66	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083290	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.731	rs8177948	ENSG00000261838.4	RP11-303E16.6	6.93	1.35e-11	8.74e-09	0.66	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083315	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.822	rs8177940	ENSG00000261838.4	RP11-303E16.6	6.93	1.35e-11	8.74e-09	0.66	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083789	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.73	rs76656387	ENSG00000261838.4	RP11-303E16.6	6.93	1.35e-11	8.74e-09	0.66	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083862	chr16:81069854~81076598:+
LUAD	cis	rs9595908	0.895	rs9591012	ENSG00000212293.1	SNORA16	6.93	1.35e-11	8.74e-09	0.35	0.3	Body mass index;	chr13:32484196	chr13:32420390~32420516:-
LUAD	cis	rs10463554	0.853	rs2432177	ENSG00000175749.11	EIF3KP1	6.93	1.36e-11	8.75e-09	0.43	0.3	Parkinson's disease;	chr5:103236172	chr5:103032376~103033031:+
LUAD	cis	rs6504950	0.886	rs4794551	ENSG00000275710.1	RP11-257O5.4	-6.93	1.36e-11	8.77e-09	-0.37	-0.3	Breast cancer;	chr17:54998066	chr17:54964474~54964679:+
LUAD	cis	rs6921919	0.638	rs2108926	ENSG00000216901.1	AL022393.7	6.93	1.36e-11	8.78e-09	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28340970	chr6:28176188~28176674:+
LUAD	cis	rs9660180	0.967	rs6603802	ENSG00000268575.1	RP1-283E3.8	-6.93	1.37e-11	8.82e-09	-0.27	-0.3	Body mass index;	chr1:1881082	chr1:1702736~1737688:-
LUAD	cis	rs7246657	0.943	rs10422074	ENSG00000276846.1	CTD-3220F14.3	6.93	1.37e-11	8.82e-09	0.42	0.3	Coronary artery calcification;	chr19:37403334	chr19:37314868~37315620:-
LUAD	cis	rs8059260	0.736	rs7192695	ENSG00000274038.1	RP11-66H6.4	-6.93	1.37e-11	8.82e-09	-0.52	-0.3	Alcohol consumption over the past year;	chr16:11005395	chr16:11056556~11057034:+
LUAD	cis	rs172166	0.694	rs203893	ENSG00000219392.1	RP1-265C24.5	-6.93	1.37e-11	8.85e-09	-0.39	-0.3	Cardiac Troponin-T levels;	chr6:28094288	chr6:28115628~28116551:+
LUAD	cis	rs10759883	0.563	rs10739705	ENSG00000175611.10	LINC00476	6.93	1.37e-11	8.86e-09	0.35	0.3	Nicotine dependence;	chr9:95900857	chr9:95759231~95875977:-
LUAD	cis	rs10759883	0.539	rs10987963	ENSG00000175611.10	LINC00476	6.93	1.37e-11	8.86e-09	0.35	0.3	Nicotine dependence;	chr9:95903798	chr9:95759231~95875977:-
LUAD	cis	rs62229266	0.773	rs878606	ENSG00000214914.3	RPL23AP3	6.93	1.37e-11	8.87e-09	0.37	0.3	Mitral valve prolapse;	chr21:36034394	chr21:36016079~36016546:-
LUAD	cis	rs72772090	0.539	rs11738115	ENSG00000248734.2	CTD-2260A17.1	6.93	1.38e-11	8.89e-09	0.46	0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777368	chr5:96784777~96785999:+
LUAD	cis	rs867371	0.502	rs8025964	ENSG00000255769.6	GOLGA2P10	-6.93	1.38e-11	8.9e-09	-0.31	-0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82229429	chr15:82472993~82513950:-
LUAD	cis	rs17684571	0.938	rs62412528	ENSG00000231441.1	RP11-472M19.2	6.93	1.38e-11	8.9e-09	0.42	0.3	Schizophrenia;	chr6:56693587	chr6:56844002~56864078:+
LUAD	cis	rs2243480	1	rs1796220	ENSG00000273142.1	RP11-458F8.4	-6.93	1.39e-11	8.95e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:66597113	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs2707831	ENSG00000273142.1	RP11-458F8.4	-6.93	1.39e-11	8.95e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:66597524	chr7:66902857~66906297:+
LUAD	cis	rs6504950	0.85	rs2628321	ENSG00000275710.1	RP11-257O5.4	6.93	1.39e-11	8.95e-09	0.37	0.3	Breast cancer;	chr17:55128556	chr17:54964474~54964679:+
LUAD	cis	rs2787486	1	rs2787486	ENSG00000275710.1	RP11-257O5.4	6.93	1.39e-11	8.95e-09	0.37	0.3	Breast cancer;	chr17:55132413	chr17:54964474~54964679:+
LUAD	cis	rs11214589	0.935	rs2186800	ENSG00000270179.1	RP11-159N11.4	-6.93	1.39e-11	8.96e-09	-0.3	-0.3	Neuroticism;	chr11:113372138	chr11:113368478~113369117:+
LUAD	cis	rs7246657	1	rs7247672	ENSG00000276846.1	CTD-3220F14.3	6.93	1.39e-11	8.97e-09	0.43	0.3	Coronary artery calcification;	chr19:37253026	chr19:37314868~37315620:-
LUAD	cis	rs7246657	1	rs8110011	ENSG00000276846.1	CTD-3220F14.3	6.93	1.39e-11	8.97e-09	0.43	0.3	Coronary artery calcification;	chr19:37254911	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.941	rs7259618	ENSG00000276846.1	CTD-3220F14.3	6.93	1.39e-11	8.97e-09	0.43	0.3	Coronary artery calcification;	chr19:37259817	chr19:37314868~37315620:-
LUAD	cis	rs9549367	0.789	rs2287244	ENSG00000269125.1	RP11-98F14.11	6.93	1.39e-11	8.97e-09	0.36	0.3	Platelet distribution width;	chr13:113232859	chr13:113165002~113165183:-
LUAD	cis	rs7160336	0.515	rs7152352	ENSG00000259065.1	RP5-1021I20.1	-6.93	1.4e-11	9e-09	-0.35	-0.3	Blood protein levels;	chr14:74144568	chr14:73787360~73803270:+
LUAD	cis	rs7646881	0.812	rs7624408	ENSG00000240207.5	RP11-379F4.4	-6.93	1.4e-11	9.01e-09	-0.39	-0.3	Tetralogy of Fallot;	chr3:158742269	chr3:158732263~158784070:+
LUAD	cis	rs7646881	0.812	rs7636023	ENSG00000240207.5	RP11-379F4.4	-6.93	1.4e-11	9.01e-09	-0.39	-0.3	Tetralogy of Fallot;	chr3:158742270	chr3:158732263~158784070:+
LUAD	cis	rs7646881	0.812	rs73017536	ENSG00000240207.5	RP11-379F4.4	-6.93	1.4e-11	9.01e-09	-0.39	-0.3	Tetralogy of Fallot;	chr3:158742813	chr3:158732263~158784070:+
LUAD	cis	rs7646881	0.812	rs73017540	ENSG00000240207.5	RP11-379F4.4	-6.93	1.4e-11	9.01e-09	-0.39	-0.3	Tetralogy of Fallot;	chr3:158742999	chr3:158732263~158784070:+
LUAD	cis	rs9287719	0.674	rs1387566	ENSG00000234818.1	AC092687.5	-6.93	1.4e-11	9.03e-09	-0.36	-0.3	Prostate cancer;	chr2:10688524	chr2:10589166~10604830:+
LUAD	cis	rs10759883	0.539	rs684455	ENSG00000175611.10	LINC00476	6.92	1.4e-11	9.05e-09	0.35	0.3	Nicotine dependence;	chr9:95964061	chr9:95759231~95875977:-
LUAD	cis	rs172166	0.694	rs188105	ENSG00000219392.1	RP1-265C24.5	-6.92	1.41e-11	9.06e-09	-0.39	-0.3	Cardiac Troponin-T levels;	chr6:28103615	chr6:28115628~28116551:+
LUAD	cis	rs2286503	0.839	rs1054471	ENSG00000228649.7	AC005682.5	6.92	1.41e-11	9.06e-09	0.38	0.3	Fibrinogen;	chr7:22813024	chr7:22854178~22861579:+
LUAD	cis	rs2286503	0.839	rs2240726	ENSG00000228649.7	AC005682.5	6.92	1.41e-11	9.06e-09	0.38	0.3	Fibrinogen;	chr7:22813516	chr7:22854178~22861579:+
LUAD	cis	rs9549367	0.789	rs9604040	ENSG00000269125.1	RP11-98F14.11	6.92	1.41e-11	9.07e-09	0.36	0.3	Platelet distribution width;	chr13:113256297	chr13:113165002~113165183:-
LUAD	cis	rs10759883	0.563	rs623438	ENSG00000175611.10	LINC00476	6.92	1.41e-11	9.08e-09	0.36	0.3	Nicotine dependence;	chr9:95938114	chr9:95759231~95875977:-
LUAD	cis	rs748404	0.516	rs523156	ENSG00000249839.1	AC011330.5	6.92	1.41e-11	9.1e-09	0.4	0.3	Lung cancer;	chr15:43519645	chr15:43663654~43684339:-
LUAD	cis	rs9595908	0.931	rs9315167	ENSG00000212293.1	SNORA16	6.92	1.41e-11	9.1e-09	0.35	0.3	Body mass index;	chr13:32495051	chr13:32420390~32420516:-
LUAD	cis	rs321358	0.731	rs73021576	ENSG00000271584.1	RP11-89C3.4	6.92	1.42e-11	9.12e-09	0.47	0.3	Body mass index;	chr11:111155690	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.707	rs73021578	ENSG00000271584.1	RP11-89C3.4	6.92	1.42e-11	9.12e-09	0.47	0.3	Body mass index;	chr11:111156211	chr11:111091932~111097357:-
LUAD	cis	rs2153535	0.584	rs9502723	ENSG00000230939.1	RP11-314C16.1	-6.92	1.42e-11	9.13e-09	-0.36	-0.3	Motion sickness;	chr6:8541271	chr6:8784178~8785445:+
LUAD	cis	rs1799949	1	rs4793194	ENSG00000267681.1	CTD-3199J23.6	-6.92	1.42e-11	9.14e-09	-0.35	-0.3	Menopause (age at onset);	chr17:43066316	chr17:43144956~43145255:+
LUAD	cis	rs75422866	0.717	rs73113159	ENSG00000257433.4	RP1-197B17.3	6.92	1.42e-11	9.14e-09	0.65	0.3	Pneumonia;	chr12:47631318	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.717	rs73113161	ENSG00000257433.4	RP1-197B17.3	6.92	1.42e-11	9.14e-09	0.65	0.3	Pneumonia;	chr12:47632361	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs117022227	ENSG00000257433.4	RP1-197B17.3	6.92	1.42e-11	9.14e-09	0.65	0.3	Pneumonia;	chr12:47633282	chr12:47706085~47742294:+
LUAD	cis	rs75422866	1	rs73102120	ENSG00000257433.4	RP1-197B17.3	6.92	1.42e-11	9.14e-09	0.65	0.3	Pneumonia;	chr12:47637280	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs12422974	ENSG00000257433.4	RP1-197B17.3	6.92	1.42e-11	9.14e-09	0.65	0.3	Pneumonia;	chr12:47644559	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs73102127	ENSG00000257433.4	RP1-197B17.3	6.92	1.42e-11	9.14e-09	0.65	0.3	Pneumonia;	chr12:47645341	chr12:47706085~47742294:+
LUAD	cis	rs9903692	0.909	rs8078125	ENSG00000278765.1	RP5-890E16.5	6.92	1.42e-11	9.15e-09	0.39	0.3	Pulse pressure;	chr17:48068347	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.954	rs11651097	ENSG00000278765.1	RP5-890E16.5	6.92	1.42e-11	9.15e-09	0.39	0.3	Pulse pressure;	chr17:48069677	chr17:48066704~48067293:-
LUAD	cis	rs7849270	0.959	rs1107329	ENSG00000268707.1	RP11-247A12.7	6.92	1.42e-11	9.15e-09	0.37	0.3	Blood metabolite ratios;	chr9:129155435	chr9:129170434~129170940:+
LUAD	cis	rs2243480	1	rs2420170	ENSG00000226824.5	RP4-756H11.3	6.92	1.42e-11	9.16e-09	0.56	0.3	Diabetic kidney disease;	chr7:66191066	chr7:66654538~66669855:+
LUAD	cis	rs9322193	0.884	rs7743823	ENSG00000223701.3	RAET1E-AS1	6.92	1.43e-11	9.19e-09	0.36	0.3	Lung cancer;	chr6:149849744	chr6:149884431~149919508:+
LUAD	cis	rs2243480	1	rs316307	ENSG00000273142.1	RP11-458F8.4	-6.92	1.43e-11	9.21e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:66105184	chr7:66902857~66906297:+
LUAD	cis	rs748404	0.587	rs690276	ENSG00000249839.1	AC011330.5	-6.92	1.43e-11	9.23e-09	-0.39	-0.3	Lung cancer;	chr15:43412360	chr15:43663654~43684339:-
LUAD	cis	rs75422866	0.867	rs73104115	ENSG00000257433.4	RP1-197B17.3	6.92	1.44e-11	9.25e-09	0.63	0.3	Pneumonia;	chr12:47684843	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs73104116	ENSG00000257433.4	RP1-197B17.3	6.92	1.44e-11	9.25e-09	0.63	0.3	Pneumonia;	chr12:47685023	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs73104138	ENSG00000257433.4	RP1-197B17.3	6.92	1.44e-11	9.25e-09	0.63	0.3	Pneumonia;	chr12:47692302	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.717	rs73104143	ENSG00000257433.4	RP1-197B17.3	6.92	1.44e-11	9.25e-09	0.63	0.3	Pneumonia;	chr12:47693449	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs73104144	ENSG00000257433.4	RP1-197B17.3	6.92	1.44e-11	9.25e-09	0.63	0.3	Pneumonia;	chr12:47694390	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs73104148	ENSG00000257433.4	RP1-197B17.3	6.92	1.44e-11	9.25e-09	0.63	0.3	Pneumonia;	chr12:47696732	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs73104152	ENSG00000257433.4	RP1-197B17.3	6.92	1.44e-11	9.25e-09	0.63	0.3	Pneumonia;	chr12:47699091	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs73104155	ENSG00000257433.4	RP1-197B17.3	6.92	1.44e-11	9.25e-09	0.63	0.3	Pneumonia;	chr12:47700790	chr12:47706085~47742294:+
LUAD	cis	rs2439831	0.681	rs540388	ENSG00000205771.5	CATSPER2P1	-6.92	1.45e-11	9.29e-09	-0.51	-0.3	Lung cancer in ever smokers;	chr15:43314296	chr15:43726918~43747094:-
LUAD	cis	rs1799949	1	rs35668327	ENSG00000267681.1	CTD-3199J23.6	-6.92	1.45e-11	9.29e-09	-0.35	-0.3	Menopause (age at onset);	chr17:43121078	chr17:43144956~43145255:+
LUAD	cis	rs748404	0.66	rs548704	ENSG00000249839.1	AC011330.5	-6.92	1.45e-11	9.31e-09	-0.39	-0.3	Lung cancer;	chr15:43499508	chr15:43663654~43684339:-
LUAD	cis	rs867371	0.717	rs3858954	ENSG00000255769.6	GOLGA2P10	-6.92	1.45e-11	9.31e-09	-0.34	-0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82265693	chr15:82472993~82513950:-
LUAD	cis	rs9326248	0.53	rs2000615	ENSG00000280143.1	AP000892.6	6.92	1.45e-11	9.33e-09	0.46	0.3	Blood protein levels;	chr11:117045103	chr11:117204967~117210292:+
LUAD	cis	rs11098499	0.863	rs6858592	ENSG00000248280.1	RP11-33B1.2	6.92	1.45e-11	9.34e-09	0.38	0.3	Corneal astigmatism;	chr4:119537537	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs1552095	ENSG00000248280.1	RP11-33B1.2	6.92	1.46e-11	9.36e-09	0.39	0.3	Corneal astigmatism;	chr4:119539151	chr4:119440561~119450157:-
LUAD	cis	rs1062177	1	rs2915882	ENSG00000213433.5	RPLP1P6	-6.92	1.46e-11	9.36e-09	-0.39	-0.3	Preschool internalizing problems;	chr5:151765875	chr5:151765859~151766378:-
LUAD	cis	rs9287719	0.674	rs10929690	ENSG00000234818.1	AC092687.5	-6.92	1.46e-11	9.36e-09	-0.36	-0.3	Prostate cancer;	chr2:10665848	chr2:10589166~10604830:+
LUAD	cis	rs10759883	0.563	rs686048	ENSG00000175611.10	LINC00476	6.92	1.46e-11	9.37e-09	0.35	0.3	Nicotine dependence;	chr9:95967100	chr9:95759231~95875977:-
LUAD	cis	rs9595908	0.931	rs35555940	ENSG00000212293.1	SNORA16	6.92	1.46e-11	9.39e-09	0.34	0.3	Body mass index;	chr13:32492975	chr13:32420390~32420516:-
LUAD	cis	rs6921919	0.848	rs6903652	ENSG00000204709.4	LINC01556	6.92	1.46e-11	9.39e-09	0.43	0.3	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:28943877~28944537:+
LUAD	cis	rs1061377	0.513	rs2711994	ENSG00000249207.1	RP11-360F5.1	6.92	1.46e-11	9.42e-09	0.37	0.3	Uric acid levels;	chr4:39148121	chr4:39112677~39126818:-
LUAD	cis	rs2153535	0.58	rs4587214	ENSG00000230939.1	RP11-314C16.1	-6.92	1.47e-11	9.43e-09	-0.36	-0.3	Motion sickness;	chr6:8453886	chr6:8784178~8785445:+
LUAD	cis	rs2243480	1	rs7804223	ENSG00000226824.5	RP4-756H11.3	6.92	1.47e-11	9.43e-09	0.56	0.3	Diabetic kidney disease;	chr7:66199572	chr7:66654538~66669855:+
LUAD	cis	rs7017914	0.902	rs10504481	ENSG00000223220.1	Y_RNA	6.92	1.47e-11	9.44e-09	0.34	0.3	Bone mineral density;	chr8:70787282	chr8:70780914~70781008:-
LUAD	cis	rs11690935	0.632	rs12991740	ENSG00000228389.1	AC068039.4	-6.92	1.47e-11	9.45e-09	-0.32	-0.3	Schizophrenia;	chr2:172021092	chr2:171773482~171775844:+
LUAD	cis	rs944289	0.509	rs934075	ENSG00000257826.1	RP11-116N8.4	-6.92	1.47e-11	9.46e-09	-0.33	-0.3	Thyroid cancer;	chr14:36169016	chr14:36061026~36067190:-
LUAD	cis	rs9326248	0.539	rs660443	ENSG00000280143.1	AP000892.6	6.92	1.47e-11	9.46e-09	0.35	0.3	Blood protein levels;	chr11:116889977	chr11:117204967~117210292:+
LUAD	cis	rs9487094	0.689	rs1476387	ENSG00000260273.1	RP11-425D10.10	6.92	1.47e-11	9.47e-09	0.38	0.3	Height;	chr6:109443332	chr6:109382795~109383666:+
LUAD	cis	rs2243480	1	rs56016656	ENSG00000273142.1	RP11-458F8.4	-6.92	1.47e-11	9.47e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65918494	chr7:66902857~66906297:+
LUAD	cis	rs2243480	0.803	rs55700941	ENSG00000273142.1	RP11-458F8.4	-6.92	1.47e-11	9.47e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65924813	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs56291018	ENSG00000273142.1	RP11-458F8.4	-6.92	1.47e-11	9.47e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65925352	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs36033484	ENSG00000273142.1	RP11-458F8.4	-6.92	1.47e-11	9.47e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65925571	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs34193460	ENSG00000273142.1	RP11-458F8.4	-6.92	1.47e-11	9.47e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65928123	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs34560516	ENSG00000273142.1	RP11-458F8.4	-6.92	1.47e-11	9.47e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65939105	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs57057549	ENSG00000273142.1	RP11-458F8.4	-6.92	1.47e-11	9.47e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65940751	chr7:66902857~66906297:+
LUAD	cis	rs11098499	0.82	rs28578366	ENSG00000248280.1	RP11-33B1.2	-6.92	1.48e-11	9.48e-09	-0.38	-0.3	Corneal astigmatism;	chr4:119615750	chr4:119440561~119450157:-
LUAD	cis	rs2842992	0.747	rs1547093	ENSG00000237927.1	RP3-393E18.2	-6.92	1.48e-11	9.49e-09	-0.43	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159784959	chr6:159586955~159589169:-
LUAD	cis	rs748404	0.65	rs518234	ENSG00000205771.5	CATSPER2P1	-6.92	1.48e-11	9.49e-09	-0.37	-0.3	Lung cancer;	chr15:43281223	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.65	rs518261	ENSG00000205771.5	CATSPER2P1	-6.92	1.48e-11	9.49e-09	-0.37	-0.3	Lung cancer;	chr15:43281231	chr15:43726918~43747094:-
LUAD	cis	rs11098499	0.644	rs3986377	ENSG00000248280.1	RP11-33B1.2	6.92	1.48e-11	9.49e-09	0.35	0.3	Corneal astigmatism;	chr4:119339115	chr4:119440561~119450157:-
LUAD	cis	rs10028773	0.556	rs4473640	ENSG00000248280.1	RP11-33B1.2	6.92	1.48e-11	9.49e-09	0.35	0.3	Educational attainment;	chr4:119339282	chr4:119440561~119450157:-
LUAD	cis	rs150992	0.72	rs469018	ENSG00000248489.1	CTD-2007H13.3	6.92	1.48e-11	9.5e-09	0.33	0.3	Body mass index;	chr5:98953530	chr5:98929171~98995013:+
LUAD	cis	rs7246657	0.882	rs8112610	ENSG00000276846.1	CTD-3220F14.3	6.92	1.48e-11	9.5e-09	0.4	0.3	Coronary artery calcification;	chr19:37437828	chr19:37314868~37315620:-
LUAD	cis	rs6860806	0.507	rs272878	ENSG00000233006.5	AC034220.3	-6.92	1.48e-11	9.5e-09	-0.29	-0.3	Breast cancer;	chr5:132336076	chr5:132311285~132369916:-
LUAD	cis	rs783540	1	rs783540	ENSG00000278603.1	RP13-608F4.5	6.92	1.48e-11	9.5e-09	0.34	0.3	Schizophrenia;	chr15:82585958	chr15:82472203~82472426:+
LUAD	cis	rs6991838	0.765	rs6472219	ENSG00000272010.1	CTD-3025N20.3	6.92	1.48e-11	9.5e-09	0.32	0.3	Intelligence (multi-trait analysis);	chr8:65644487	chr8:65591850~65592472:-
LUAD	cis	rs75422866	0.867	rs73104163	ENSG00000257433.4	RP1-197B17.3	6.92	1.48e-11	9.52e-09	0.67	0.3	Pneumonia;	chr12:47706187	chr12:47706085~47742294:+
LUAD	cis	rs75422866	1	rs12423045	ENSG00000257433.4	RP1-197B17.3	6.92	1.48e-11	9.52e-09	0.67	0.3	Pneumonia;	chr12:47706275	chr12:47706085~47742294:+
LUAD	cis	rs9660180	0.967	rs9660106	ENSG00000268575.1	RP1-283E3.8	-6.92	1.49e-11	9.56e-09	-0.27	-0.3	Body mass index;	chr1:1866508	chr1:1702736~1737688:-
LUAD	cis	rs6844153	0.938	rs12646473	ENSG00000240005.4	RP11-293A21.1	-6.92	1.49e-11	9.57e-09	-0.5	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26873833	chr4:26859806~26860599:-
LUAD	cis	rs748404	0.578	rs4547312	ENSG00000249839.1	AC011330.5	-6.92	1.49e-11	9.57e-09	-0.39	-0.3	Lung cancer;	chr15:43339940	chr15:43663654~43684339:-
LUAD	cis	rs62229266	0.835	rs998384	ENSG00000214914.3	RPL23AP3	6.92	1.49e-11	9.57e-09	0.37	0.3	Mitral valve prolapse;	chr21:36073228	chr21:36016079~36016546:-
LUAD	cis	rs2842992	0.83	rs2025189	ENSG00000237927.1	RP3-393E18.2	-6.92	1.49e-11	9.58e-09	-0.42	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159716486	chr6:159586955~159589169:-
LUAD	cis	rs2842992	0.83	rs2495279	ENSG00000237927.1	RP3-393E18.2	-6.92	1.49e-11	9.58e-09	-0.42	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159717764	chr6:159586955~159589169:-
LUAD	cis	rs1799949	0.965	rs8176161	ENSG00000267681.1	CTD-3199J23.6	-6.92	1.49e-11	9.59e-09	-0.35	-0.3	Menopause (age at onset);	chr17:43089373	chr17:43144956~43145255:+
LUAD	cis	rs1799949	0.894	rs8176160	ENSG00000267681.1	CTD-3199J23.6	-6.92	1.49e-11	9.59e-09	-0.35	-0.3	Menopause (age at onset);	chr17:43089486	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs2070834	ENSG00000267681.1	CTD-3199J23.6	-6.92	1.49e-11	9.59e-09	-0.35	-0.3	Menopause (age at onset);	chr17:43090268	chr17:43144956~43145255:+
LUAD	cis	rs6504950	0.924	rs244342	ENSG00000275710.1	RP11-257O5.4	6.92	1.49e-11	9.59e-09	0.36	0.3	Breast cancer;	chr17:55121046	chr17:54964474~54964679:+
LUAD	cis	rs7017914	0.967	rs17688313	ENSG00000223220.1	Y_RNA	-6.92	1.49e-11	9.59e-09	-0.34	-0.3	Bone mineral density;	chr8:70771629	chr8:70780914~70781008:-
LUAD	cis	rs9287719	0.674	rs11691060	ENSG00000234818.1	AC092687.5	-6.92	1.5e-11	9.6e-09	-0.36	-0.3	Prostate cancer;	chr2:10686935	chr2:10589166~10604830:+
LUAD	cis	rs9287719	0.674	rs11684157	ENSG00000234818.1	AC092687.5	-6.92	1.5e-11	9.6e-09	-0.36	-0.3	Prostate cancer;	chr2:10687031	chr2:10589166~10604830:+
LUAD	cis	rs7044106	0.791	rs4836830	ENSG00000238181.2	AHCYP2	-6.91	1.5e-11	9.6e-09	-0.4	-0.3	Hip circumference adjusted for BMI;	chr9:120721390	chr9:120720673~120721972:+
LUAD	cis	rs1155848	0.571	rs6563125	ENSG00000227354.5	RBM26-AS1	6.91	1.5e-11	9.6e-09	0.59	0.3	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79630618	chr13:79406309~79424328:+
LUAD	cis	rs1155848	0.571	rs58739959	ENSG00000227354.5	RBM26-AS1	6.91	1.5e-11	9.6e-09	0.59	0.3	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79633468	chr13:79406309~79424328:+
LUAD	cis	rs2153535	0.58	rs6921964	ENSG00000230939.1	RP11-314C16.1	-6.91	1.5e-11	9.6e-09	-0.35	-0.3	Motion sickness;	chr6:8446162	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.541	rs4637688	ENSG00000230939.1	RP11-314C16.1	-6.91	1.5e-11	9.6e-09	-0.35	-0.3	Motion sickness;	chr6:8446268	chr6:8784178~8785445:+
LUAD	cis	rs9595908	0.931	rs9595617	ENSG00000212293.1	SNORA16	6.91	1.5e-11	9.62e-09	0.34	0.3	Body mass index;	chr13:32483208	chr13:32420390~32420516:-
LUAD	cis	rs7646881	1	rs73015651	ENSG00000240207.5	RP11-379F4.4	-6.91	1.5e-11	9.62e-09	-0.37	-0.3	Tetralogy of Fallot;	chr3:158733133	chr3:158732263~158784070:+
LUAD	cis	rs10129255	0.957	rs2007467	ENSG00000280411.1	IGHV1-69-2	6.91	1.51e-11	9.69e-09	0.23	0.3	Kawasaki disease;	chr14:106771605	chr14:106762092~106762588:-
LUAD	cis	rs2842992	0.915	rs2758321	ENSG00000237927.1	RP3-393E18.2	-6.91	1.51e-11	9.71e-09	-0.4	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159650579	chr6:159586955~159589169:-
LUAD	cis	rs748404	0.66	rs690446	ENSG00000249839.1	AC011330.5	-6.91	1.52e-11	9.72e-09	-0.39	-0.3	Lung cancer;	chr15:43469066	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.631	rs560191	ENSG00000249839.1	AC011330.5	-6.91	1.52e-11	9.72e-09	-0.39	-0.3	Lung cancer;	chr15:43475576	chr15:43663654~43684339:-
LUAD	cis	rs673078	0.66	rs9943819	ENSG00000275759.1	RP11-131L12.3	-6.91	1.52e-11	9.73e-09	-0.39	-0.3	Glucose homeostasis traits;	chr12:118298917	chr12:118428281~118428870:+
LUAD	cis	rs1167827	0.68	rs1167796	ENSG00000278416.1	PMS2L2	-6.91	1.52e-11	9.73e-09	-0.38	-0.3	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75344015~75359550:-
LUAD	cis	rs588177	0.613	rs3782101	ENSG00000236935.1	AP003774.1	-6.91	1.52e-11	9.73e-09	-0.29	-0.3	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr11:64363808	chr11:64325050~64329504:-
LUAD	cis	rs7017914	1	rs13252719	ENSG00000223220.1	Y_RNA	6.91	1.52e-11	9.74e-09	0.34	0.3	Bone mineral density;	chr8:70822334	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.934	rs13274062	ENSG00000223220.1	Y_RNA	6.91	1.52e-11	9.74e-09	0.34	0.3	Bone mineral density;	chr8:70824852	chr8:70780914~70781008:-
LUAD	cis	rs2153535	0.601	rs1737581	ENSG00000230939.1	RP11-314C16.1	-6.91	1.52e-11	9.74e-09	-0.36	-0.3	Motion sickness;	chr6:8538905	chr6:8784178~8785445:+
LUAD	cis	rs11098499	0.954	rs10034623	ENSG00000248280.1	RP11-33B1.2	6.91	1.52e-11	9.74e-09	0.38	0.3	Corneal astigmatism;	chr4:119476674	chr4:119440561~119450157:-
LUAD	cis	rs9640161	0.658	rs60467296	ENSG00000261305.1	RP4-584D14.7	6.91	1.52e-11	9.76e-09	0.44	0.3	Blood protein levels;Circulating chemerin levels;	chr7:150318382	chr7:150341771~150342607:+
LUAD	cis	rs2842992	0.513	rs7759086	ENSG00000237927.1	RP3-393E18.2	-6.91	1.52e-11	9.77e-09	-0.41	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159772821	chr6:159586955~159589169:-
LUAD	cis	rs2243480	0.808	rs12698508	ENSG00000273142.1	RP11-458F8.4	-6.91	1.53e-11	9.78e-09	-0.32	-0.3	Diabetic kidney disease;	chr7:65946971	chr7:66902857~66906297:+
LUAD	cis	rs748404	0.604	rs2278857	ENSG00000249839.1	AC011330.5	-6.91	1.53e-11	9.79e-09	-0.39	-0.3	Lung cancer;	chr15:43340351	chr15:43663654~43684339:-
LUAD	cis	rs7208859	0.573	rs4055105	ENSG00000263531.1	RP13-753N3.1	6.91	1.53e-11	9.82e-09	0.6	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775532	chr17:30863921~30864940:-
LUAD	cis	rs9595908	0.931	rs9595595	ENSG00000212293.1	SNORA16	6.91	1.54e-11	9.84e-09	0.35	0.3	Body mass index;	chr13:32473678	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.931	rs11839309	ENSG00000212293.1	SNORA16	6.91	1.54e-11	9.84e-09	0.35	0.3	Body mass index;	chr13:32473853	chr13:32420390~32420516:-
LUAD	cis	rs2280018	0.526	rs1510148	ENSG00000188599.16	NPIPP1	-6.91	1.54e-11	9.84e-09	-0.26	-0.3	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15073522	chr16:15104312~15123498:-
LUAD	cis	rs75422866	0.867	rs73102195	ENSG00000257433.4	RP1-197B17.3	6.91	1.54e-11	9.85e-09	0.63	0.3	Pneumonia;	chr12:47666309	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs73102201	ENSG00000257433.4	RP1-197B17.3	6.91	1.54e-11	9.85e-09	0.63	0.3	Pneumonia;	chr12:47669269	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs73104104	ENSG00000257433.4	RP1-197B17.3	6.91	1.54e-11	9.85e-09	0.63	0.3	Pneumonia;	chr12:47671986	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs73104111	ENSG00000257433.4	RP1-197B17.3	6.91	1.54e-11	9.85e-09	0.63	0.3	Pneumonia;	chr12:47673994	chr12:47706085~47742294:+
LUAD	cis	rs853679	0.567	rs2232427	ENSG00000204709.4	LINC01556	6.91	1.54e-11	9.86e-09	0.4	0.3	Depression;	chr6:28391932	chr6:28943877~28944537:+
LUAD	cis	rs748404	0.56	rs529611	ENSG00000249839.1	AC011330.5	-6.91	1.54e-11	9.86e-09	-0.4	-0.3	Lung cancer;	chr15:43513790	chr15:43663654~43684339:-
LUAD	cis	rs5760092	0.572	rs738806	ENSG00000225282.1	AP000350.6	6.91	1.54e-11	9.86e-09	0.42	0.3	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23926900~23929574:+
LUAD	cis	rs35160687	0.871	rs11127028	ENSG00000273080.1	RP11-301O19.1	6.91	1.54e-11	9.88e-09	0.34	0.3	Night sleep phenotypes;	chr2:86310386	chr2:86195590~86196049:+
LUAD	cis	rs2015599	0.549	rs7134796	ENSG00000275476.1	RP11-996F15.4	6.91	1.54e-11	9.89e-09	0.33	0.3	Platelet count;Mean platelet volume;	chr12:29294361	chr12:29277397~29277882:-
LUAD	cis	rs2980439	0.846	rs2980437	ENSG00000253893.2	FAM85B	6.91	1.54e-11	9.89e-09	0.38	0.3	Neuroticism;	chr8:8237241	chr8:8167819~8226614:-
LUAD	cis	rs11089937	0.616	rs5757258	ENSG00000211639.2	IGLV4-60	6.91	1.55e-11	9.89e-09	0.31	0.3	Periodontitis (PAL4Q3);	chr22:22179648	chr22:22162199~22162681:+
LUAD	cis	rs10129255	0.536	rs17113249	ENSG00000224373.3	IGHV4-59	6.91	1.55e-11	9.91e-09	0.18	0.3	Kawasaki disease;	chr14:106678273	chr14:106627249~106627825:-
LUAD	cis	rs950169	0.922	rs11639244	ENSG00000259728.4	LINC00933	6.91	1.55e-11	9.92e-09	0.46	0.3	Schizophrenia;	chr15:84163898	chr15:84570649~84580175:+
LUAD	cis	rs35955747	0.902	rs131209	ENSG00000236132.1	CTA-440B3.1	-6.91	1.55e-11	9.94e-09	-0.33	-0.3	Neutrophil count;Sum basophil neutrophil counts;	chr22:31336475	chr22:31816379~31817491:-
LUAD	cis	rs56205728	0.606	rs2898991	ENSG00000273855.1	RP11-133K1.12	6.91	1.55e-11	9.95e-09	0.35	0.3	Schizophrenia;	chr15:40304367	chr15:40285468~40285909:-
LUAD	cis	rs1799949	1	rs8176220	ENSG00000267681.1	CTD-3199J23.6	-6.91	1.56e-11	9.96e-09	-0.34	-0.3	Menopause (age at onset);	chr17:43070445	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs1799966	ENSG00000267681.1	CTD-3199J23.6	-6.91	1.56e-11	9.96e-09	-0.34	-0.3	Menopause (age at onset);	chr17:43071077	chr17:43144956~43145255:+
LUAD	cis	rs2286503	1	rs2286499	ENSG00000228649.7	AC005682.5	6.91	1.56e-11	9.96e-09	0.37	0.3	Fibrinogen;	chr7:22817858	chr7:22854178~22861579:+
LUAD	cis	rs4964805	0.594	rs4981036	ENSG00000257681.1	RP11-341G23.4	6.91	1.56e-11	9.97e-09	0.35	0.3	Attention deficit hyperactivity disorder;	chr12:103770566	chr12:103746315~103768858:-
LUAD	cis	rs2243480	0.706	rs34466769	ENSG00000273142.1	RP11-458F8.4	-6.91	1.56e-11	9.99e-09	-0.27	-0.3	Diabetic kidney disease;	chr7:65988305	chr7:66902857~66906297:+
LUAD	cis	rs8177876	0.841	rs8177851	ENSG00000261838.4	RP11-303E16.6	6.91	1.56e-11	9.99e-09	0.73	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81092747	chr16:81069854~81076598:+
LUAD	cis	rs3096299	0.838	rs3096319	ENSG00000274627.1	RP11-104N10.2	6.91	1.56e-11	1e-08	0.29	0.3	Multiple myeloma (IgH translocation);	chr16:89336226	chr16:89516797~89522217:+
LUAD	cis	rs67311347	1	rs73080138	ENSG00000223797.4	ENTPD3-AS1	6.91	1.56e-11	1e-08	0.32	0.3	Renal cell carcinoma;	chr3:40474926	chr3:40313802~40453329:-
LUAD	cis	rs11098499	0.722	rs1814814	ENSG00000248280.1	RP11-33B1.2	6.91	1.57e-11	1e-08	0.35	0.3	Corneal astigmatism;	chr4:119336969	chr4:119440561~119450157:-
LUAD	cis	rs8059260	0.877	rs6498146	ENSG00000274038.1	RP11-66H6.4	6.91	1.57e-11	1e-08	0.41	0.3	Alcohol consumption over the past year;	chr16:11012850	chr16:11056556~11057034:+
LUAD	cis	rs9903692	0.954	rs7217496	ENSG00000278765.1	RP5-890E16.5	6.91	1.57e-11	1e-08	0.39	0.3	Pulse pressure;	chr17:48076840	chr17:48066704~48067293:-
LUAD	cis	rs10759883	0.539	rs649819	ENSG00000175611.10	LINC00476	6.91	1.57e-11	1.01e-08	0.35	0.3	Nicotine dependence;	chr9:95969323	chr9:95759231~95875977:-
LUAD	cis	rs867371	1	rs867370	ENSG00000255769.6	GOLGA2P10	6.91	1.57e-11	1.01e-08	0.33	0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82145921	chr15:82472993~82513950:-
LUAD	cis	rs867371	1	rs867371	ENSG00000255769.6	GOLGA2P10	6.91	1.57e-11	1.01e-08	0.33	0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82146005	chr15:82472993~82513950:-
LUAD	cis	rs10028773	0.546	rs13117947	ENSG00000248280.1	RP11-33B1.2	6.91	1.57e-11	1.01e-08	0.33	0.3	Educational attainment;	chr4:119335905	chr4:119440561~119450157:-
LUAD	cis	rs35160687	0.901	rs34048420	ENSG00000273080.1	RP11-301O19.1	6.91	1.57e-11	1.01e-08	0.34	0.3	Night sleep phenotypes;	chr2:86302625	chr2:86195590~86196049:+
LUAD	cis	rs35160687	0.901	rs34069316	ENSG00000273080.1	RP11-301O19.1	6.91	1.57e-11	1.01e-08	0.34	0.3	Night sleep phenotypes;	chr2:86302669	chr2:86195590~86196049:+
LUAD	cis	rs35160687	0.901	rs11127026	ENSG00000273080.1	RP11-301O19.1	6.91	1.57e-11	1.01e-08	0.34	0.3	Night sleep phenotypes;	chr2:86304625	chr2:86195590~86196049:+
LUAD	cis	rs35160687	0.901	rs12478575	ENSG00000273080.1	RP11-301O19.1	6.91	1.57e-11	1.01e-08	0.34	0.3	Night sleep phenotypes;	chr2:86308191	chr2:86195590~86196049:+
LUAD	cis	rs11098499	0.908	rs2017057	ENSG00000248280.1	RP11-33B1.2	6.91	1.58e-11	1.01e-08	0.39	0.3	Corneal astigmatism;	chr4:119336556	chr4:119440561~119450157:-
LUAD	cis	rs7246657	1	rs35398388	ENSG00000276846.1	CTD-3220F14.3	6.91	1.58e-11	1.01e-08	0.43	0.3	Coronary artery calcification;	chr19:37249456	chr19:37314868~37315620:-
LUAD	cis	rs3096299	0.935	rs3114890	ENSG00000274627.1	RP11-104N10.2	6.91	1.58e-11	1.01e-08	0.28	0.3	Multiple myeloma (IgH translocation);	chr16:89383138	chr16:89516797~89522217:+
LUAD	cis	rs1075265	0.589	rs2542571	ENSG00000233266.1	HMGB1P31	6.91	1.58e-11	1.01e-08	0.38	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53814846	chr2:54051334~54051760:+
LUAD	cis	rs2439831	1	rs2439841	ENSG00000205771.5	CATSPER2P1	-6.91	1.58e-11	1.01e-08	-0.51	-0.3	Lung cancer in ever smokers;	chr15:43442551	chr15:43726918~43747094:-
LUAD	cis	rs7017914	0.967	rs12680166	ENSG00000223220.1	Y_RNA	6.91	1.58e-11	1.01e-08	0.33	0.3	Bone mineral density;	chr8:70766403	chr8:70780914~70781008:-
LUAD	cis	rs172166	0.694	rs203876	ENSG00000219392.1	RP1-265C24.5	-6.91	1.58e-11	1.01e-08	-0.39	-0.3	Cardiac Troponin-T levels;	chr6:28078895	chr6:28115628~28116551:+
LUAD	cis	rs172166	0.694	rs203877	ENSG00000219392.1	RP1-265C24.5	-6.91	1.58e-11	1.01e-08	-0.39	-0.3	Cardiac Troponin-T levels;	chr6:28080846	chr6:28115628~28116551:+
LUAD	cis	rs172166	0.652	rs476167	ENSG00000219392.1	RP1-265C24.5	-6.91	1.59e-11	1.01e-08	-0.39	-0.3	Cardiac Troponin-T levels;	chr6:28098110	chr6:28115628~28116551:+
LUAD	cis	rs172166	0.694	rs203892	ENSG00000219392.1	RP1-265C24.5	-6.91	1.59e-11	1.01e-08	-0.39	-0.3	Cardiac Troponin-T levels;	chr6:28099418	chr6:28115628~28116551:+
LUAD	cis	rs9326248	0.53	rs7121347	ENSG00000280143.1	AP000892.6	6.91	1.59e-11	1.01e-08	0.46	0.3	Blood protein levels;	chr11:116996493	chr11:117204967~117210292:+
LUAD	cis	rs2439831	0.681	rs3742971	ENSG00000205771.5	CATSPER2P1	6.91	1.59e-11	1.01e-08	0.51	0.3	Lung cancer in ever smokers;	chr15:43330718	chr15:43726918~43747094:-
LUAD	cis	rs8059260	1	rs8057540	ENSG00000274038.1	RP11-66H6.4	-6.91	1.59e-11	1.02e-08	-0.49	-0.3	Alcohol consumption over the past year;	chr16:10951985	chr16:11056556~11057034:+
LUAD	cis	rs71403859	0.568	rs12149489	ENSG00000260886.1	TAT-AS1	6.91	1.59e-11	1.02e-08	0.51	0.3	Post bronchodilator FEV1;	chr16:71779877	chr16:71565789~71578187:+
LUAD	cis	rs4713118	0.513	rs149959	ENSG00000219392.1	RP1-265C24.5	-6.91	1.59e-11	1.02e-08	-0.38	-0.3	Parkinson's disease;	chr6:28046076	chr6:28115628~28116551:+
LUAD	cis	rs75422866	0.867	rs73113139	ENSG00000257433.4	RP1-197B17.3	6.9	1.59e-11	1.02e-08	0.65	0.3	Pneumonia;	chr12:47622826	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs73102140	ENSG00000257433.4	RP1-197B17.3	6.9	1.59e-11	1.02e-08	0.65	0.3	Pneumonia;	chr12:47647497	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs73102148	ENSG00000257433.4	RP1-197B17.3	6.9	1.59e-11	1.02e-08	0.65	0.3	Pneumonia;	chr12:47648013	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs73102151	ENSG00000257433.4	RP1-197B17.3	6.9	1.59e-11	1.02e-08	0.65	0.3	Pneumonia;	chr12:47648023	chr12:47706085~47742294:+
LUAD	cis	rs1799949	1	rs12516	ENSG00000267681.1	CTD-3199J23.6	-6.9	1.59e-11	1.02e-08	-0.34	-0.3	Menopause (age at onset);	chr17:43044391	chr17:43144956~43145255:+
LUAD	cis	rs34526934	0.566	rs35563571	ENSG00000226363.3	HAGLROS	6.9	1.6e-11	1.02e-08	0.42	0.3	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176179731	chr2:176177717~176179008:+
LUAD	cis	rs12908161	0.96	rs34452033	ENSG00000259728.4	LINC00933	6.9	1.6e-11	1.02e-08	0.44	0.3	Schizophrenia;	chr15:84678762	chr15:84570649~84580175:+
LUAD	cis	rs9487094	0.626	rs12215077	ENSG00000260273.1	RP11-425D10.10	-6.9	1.6e-11	1.02e-08	-0.39	-0.3	Height;	chr6:109731677	chr6:109382795~109383666:+
LUAD	cis	rs2842992	0.83	rs752779	ENSG00000237927.1	RP3-393E18.2	-6.9	1.6e-11	1.02e-08	-0.42	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159712925	chr6:159586955~159589169:-
LUAD	cis	rs1185460	1	rs1799993	ENSG00000271751.1	RP11-110I1.14	6.9	1.61e-11	1.03e-08	0.37	0.3	Coronary artery disease;	chr11:119087417	chr11:119065263~119065677:-
LUAD	cis	rs1198872	0.571	rs902130	ENSG00000272275.1	RP11-791G15.2	-6.9	1.61e-11	1.03e-08	-0.38	-0.3	Cardiac Troponin-T levels;	chr2:10770843	chr2:10767875~10770058:-
LUAD	cis	rs8177876	0.822	rs28672349	ENSG00000261838.4	RP11-303E16.6	6.9	1.61e-11	1.03e-08	0.66	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080768	chr16:81069854~81076598:+
LUAD	cis	rs748404	0.66	rs2439845	ENSG00000249839.1	AC011330.5	-6.9	1.61e-11	1.03e-08	-0.39	-0.3	Lung cancer;	chr15:43430412	chr15:43663654~43684339:-
LUAD	cis	rs1799949	0.965	rs12950779	ENSG00000267681.1	CTD-3199J23.6	-6.9	1.62e-11	1.03e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43154506	chr17:43144956~43145255:+
LUAD	cis	rs1062177	0.951	rs2915876	ENSG00000213433.5	RPLP1P6	-6.9	1.62e-11	1.04e-08	-0.39	-0.3	Preschool internalizing problems;	chr5:151771184	chr5:151765859~151766378:-
LUAD	cis	rs8177876	0.822	rs8177959	ENSG00000261838.4	RP11-303E16.6	6.9	1.62e-11	1.04e-08	0.66	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082082	chr16:81069854~81076598:+
LUAD	cis	rs17023223	0.537	rs2765530	ENSG00000231365.4	RP11-418J17.1	-6.9	1.63e-11	1.04e-08	-0.39	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119041773	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs2765531	ENSG00000231365.4	RP11-418J17.1	-6.9	1.63e-11	1.04e-08	-0.39	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119042874	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs2794313	ENSG00000231365.4	RP11-418J17.1	-6.9	1.63e-11	1.04e-08	-0.39	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119044817	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs2645301	ENSG00000231365.4	RP11-418J17.1	-6.9	1.63e-11	1.04e-08	-0.39	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119047797	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs2794312	ENSG00000231365.4	RP11-418J17.1	-6.9	1.63e-11	1.04e-08	-0.39	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119048423	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs2765532	ENSG00000231365.4	RP11-418J17.1	-6.9	1.63e-11	1.04e-08	-0.39	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119048923	chr1:119140396~119275973:+
LUAD	cis	rs11098499	0.691	rs9307471	ENSG00000248280.1	RP11-33B1.2	6.9	1.63e-11	1.04e-08	0.35	0.3	Corneal astigmatism;	chr4:119340107	chr4:119440561~119450157:-
LUAD	cis	rs6565180	1	rs11646130	ENSG00000183604.13	SMG1P5	-6.9	1.63e-11	1.04e-08	-0.33	-0.3	Tonsillectomy;	chr16:30365638	chr16:30267553~30335374:-
LUAD	cis	rs1061377	1	rs12499266	ENSG00000249685.1	RP11-360F5.3	-6.9	1.63e-11	1.04e-08	-0.36	-0.3	Uric acid levels;	chr4:39118133	chr4:39133913~39135608:+
LUAD	cis	rs6844153	0.887	rs62302535	ENSG00000240005.4	RP11-293A21.1	-6.9	1.64e-11	1.04e-08	-0.48	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26957254	chr4:26859806~26860599:-
LUAD	cis	rs9660180	0.837	rs915292	ENSG00000268575.1	RP1-283E3.8	-6.9	1.64e-11	1.04e-08	-0.27	-0.3	Body mass index;	chr1:1860718	chr1:1702736~1737688:-
LUAD	cis	rs77204473	0.744	rs2269399	ENSG00000254851.1	RP11-109L13.1	6.9	1.64e-11	1.04e-08	0.66	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117195637	chr11:117135528~117138582:+
LUAD	cis	rs35160687	0.901	rs12714180	ENSG00000273080.1	RP11-301O19.1	6.9	1.64e-11	1.05e-08	0.34	0.3	Night sleep phenotypes;	chr2:86298200	chr2:86195590~86196049:+
LUAD	cis	rs35160687	0.901	rs35281683	ENSG00000273080.1	RP11-301O19.1	6.9	1.64e-11	1.05e-08	0.34	0.3	Night sleep phenotypes;	chr2:86299249	chr2:86195590~86196049:+
LUAD	cis	rs35160687	0.901	rs10200186	ENSG00000273080.1	RP11-301O19.1	6.9	1.64e-11	1.05e-08	0.34	0.3	Night sleep phenotypes;	chr2:86300300	chr2:86195590~86196049:+
LUAD	cis	rs748404	0.588	rs2255410	ENSG00000249839.1	AC011330.5	-6.9	1.64e-11	1.05e-08	-0.39	-0.3	Lung cancer;	chr15:43538899	chr15:43663654~43684339:-
LUAD	cis	rs9326248	0.53	rs11216316	ENSG00000280143.1	AP000892.6	-6.9	1.64e-11	1.05e-08	-0.5	-0.3	Blood protein levels;	chr11:117210784	chr11:117204967~117210292:+
LUAD	cis	rs9903692	0.954	rs7224014	ENSG00000278765.1	RP5-890E16.5	6.9	1.64e-11	1.05e-08	0.39	0.3	Pulse pressure;	chr17:48073499	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.954	rs2240122	ENSG00000278765.1	RP5-890E16.5	6.9	1.64e-11	1.05e-08	0.39	0.3	Pulse pressure;	chr17:48075197	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.738	rs35202025	ENSG00000278765.1	RP5-890E16.5	6.9	1.64e-11	1.05e-08	0.39	0.3	Pulse pressure;	chr17:48075355	chr17:48066704~48067293:-
LUAD	cis	rs62229266	0.74	rs4817759	ENSG00000214914.3	RPL23AP3	6.9	1.64e-11	1.05e-08	0.37	0.3	Mitral valve prolapse;	chr21:36017261	chr21:36016079~36016546:-
LUAD	cis	rs62229266	0.771	rs2835232	ENSG00000214914.3	RPL23AP3	6.9	1.64e-11	1.05e-08	0.37	0.3	Mitral valve prolapse;	chr21:36021129	chr21:36016079~36016546:-
LUAD	cis	rs62229266	0.74	rs2835233	ENSG00000214914.3	RPL23AP3	6.9	1.64e-11	1.05e-08	0.37	0.3	Mitral valve prolapse;	chr21:36021284	chr21:36016079~36016546:-
LUAD	cis	rs1799949	1	rs16942	ENSG00000267681.1	CTD-3199J23.6	-6.9	1.64e-11	1.05e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43091983	chr17:43144956~43145255:+
LUAD	cis	rs6991838	0.798	rs62507575	ENSG00000272010.1	CTD-3025N20.3	6.9	1.64e-11	1.05e-08	0.31	0.3	Intelligence (multi-trait analysis);	chr8:65566486	chr8:65591850~65592472:-
LUAD	cis	rs11098499	0.691	rs10010355	ENSG00000248280.1	RP11-33B1.2	6.9	1.64e-11	1.05e-08	0.35	0.3	Corneal astigmatism;	chr4:119339888	chr4:119440561~119450157:-
LUAD	cis	rs1823913	1	rs1823913	ENSG00000227542.1	AC092614.2	6.9	1.65e-11	1.05e-08	0.38	0.3	Obesity-related traits;	chr2:191253321	chr2:191229165~191246172:-
LUAD	cis	rs321358	0.731	rs580656	ENSG00000271584.1	RP11-89C3.4	6.9	1.65e-11	1.05e-08	0.46	0.3	Body mass index;	chr11:111141436	chr11:111091932~111097357:-
LUAD	cis	rs748404	0.578	rs576557	ENSG00000249839.1	AC011330.5	-6.9	1.65e-11	1.05e-08	-0.4	-0.3	Lung cancer;	chr15:43305539	chr15:43663654~43684339:-
LUAD	cis	rs1799949	0.896	rs8176098	ENSG00000267681.1	CTD-3199J23.6	-6.9	1.65e-11	1.05e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43116189	chr17:43144956~43145255:+
LUAD	cis	rs7826238	0.566	rs2945886	ENSG00000253893.2	FAM85B	-6.9	1.65e-11	1.05e-08	-0.39	-0.3	Systolic blood pressure;	chr8:8290748	chr8:8167819~8226614:-
LUAD	cis	rs6565180	0.962	rs11642676	ENSG00000183604.13	SMG1P5	-6.9	1.65e-11	1.06e-08	-0.33	-0.3	Tonsillectomy;	chr16:30360334	chr16:30267553~30335374:-
LUAD	cis	rs321358	0.731	rs1517578	ENSG00000271584.1	RP11-89C3.4	6.9	1.66e-11	1.06e-08	0.47	0.3	Body mass index;	chr11:111150750	chr11:111091932~111097357:-
LUAD	cis	rs2739330	0.828	rs2186366	ENSG00000228039.3	KB-1125A3.10	-6.9	1.66e-11	1.06e-08	-0.37	-0.3	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23963780~23964374:+
LUAD	cis	rs2842992	0.872	rs9456440	ENSG00000237927.1	RP3-393E18.2	-6.9	1.66e-11	1.06e-08	-0.42	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159653431	chr6:159586955~159589169:-
LUAD	cis	rs321358	0.731	rs534858	ENSG00000271584.1	RP11-89C3.4	6.9	1.66e-11	1.06e-08	0.46	0.3	Body mass index;	chr11:111145583	chr11:111091932~111097357:-
LUAD	cis	rs11676348	0.873	rs10210012	ENSG00000261338.2	RP11-378A13.1	-6.9	1.67e-11	1.06e-08	-0.31	-0.3	Ulcerative colitis;	chr2:218148611	chr2:218255319~218257366:+
LUAD	cis	rs8031584	0.706	rs798084	ENSG00000260382.1	RP11-540B6.2	6.9	1.67e-11	1.06e-08	0.38	0.3	Huntington's disease progression;	chr15:30834732	chr15:30882267~30883231:-
LUAD	cis	rs944289	0.966	rs34992253	ENSG00000257826.1	RP11-116N8.4	-6.9	1.67e-11	1.06e-08	-0.32	-0.3	Thyroid cancer;	chr14:36177957	chr14:36061026~36067190:-
LUAD	cis	rs35160687	0.842	rs10200526	ENSG00000273080.1	RP11-301O19.1	6.9	1.67e-11	1.07e-08	0.34	0.3	Night sleep phenotypes;	chr2:86300476	chr2:86195590~86196049:+
LUAD	cis	rs1823913	0.927	rs13013390	ENSG00000227542.1	AC092614.2	6.9	1.68e-11	1.07e-08	0.37	0.3	Obesity-related traits;	chr2:191262001	chr2:191229165~191246172:-
LUAD	cis	rs9487094	0.626	rs12204548	ENSG00000260273.1	RP11-425D10.10	6.9	1.68e-11	1.07e-08	0.4	0.3	Height;	chr6:109715504	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.626	rs3799849	ENSG00000260273.1	RP11-425D10.10	6.9	1.68e-11	1.07e-08	0.4	0.3	Height;	chr6:109715560	chr6:109382795~109383666:+
LUAD	cis	rs75422866	0.867	rs73104103	ENSG00000257433.4	RP1-197B17.3	6.9	1.69e-11	1.08e-08	0.63	0.3	Pneumonia;	chr12:47669604	chr12:47706085~47742294:+
LUAD	cis	rs11214589	0.905	rs1078	ENSG00000270179.1	RP11-159N11.4	-6.9	1.69e-11	1.08e-08	-0.3	-0.3	Neuroticism;	chr11:113371155	chr11:113368478~113369117:+
LUAD	cis	rs748404	0.56	rs1869258	ENSG00000249839.1	AC011330.5	-6.9	1.69e-11	1.08e-08	-0.4	-0.3	Lung cancer;	chr15:43511423	chr15:43663654~43684339:-
LUAD	cis	rs881375	0.935	rs7034390	ENSG00000226752.6	PSMD5-AS1	-6.9	1.69e-11	1.08e-08	-0.33	-0.3	Rheumatoid arthritis;	chr9:120884210	chr9:120824828~120854385:+
LUAD	cis	rs748404	0.69	rs2924369	ENSG00000249839.1	AC011330.5	6.9	1.7e-11	1.08e-08	0.39	0.3	Lung cancer;	chr15:43485787	chr15:43663654~43684339:-
LUAD	cis	rs67311347	1	rs4571217	ENSG00000223797.4	ENTPD3-AS1	6.89	1.7e-11	1.08e-08	0.33	0.3	Renal cell carcinoma;	chr3:40480482	chr3:40313802~40453329:-
LUAD	cis	rs9660180	0.967	rs2272908	ENSG00000268575.1	RP1-283E3.8	6.89	1.7e-11	1.08e-08	0.27	0.3	Body mass index;	chr1:1790040	chr1:1702736~1737688:-
LUAD	cis	rs7182621	0.546	rs12906587	ENSG00000182397.13	DNM1P46	-6.89	1.7e-11	1.08e-08	-0.4	-0.3	Colonoscopy-negative controls vs population controls;	chr15:99837114	chr15:99790156~99806927:-
LUAD	cis	rs321358	0.731	rs536579	ENSG00000271584.1	RP11-89C3.4	6.89	1.71e-11	1.09e-08	0.46	0.3	Body mass index;	chr11:111145748	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.731	rs576877	ENSG00000271584.1	RP11-89C3.4	6.89	1.71e-11	1.09e-08	0.46	0.3	Body mass index;	chr11:111147472	chr11:111091932~111097357:-
LUAD	cis	rs17301013	0.507	rs10912762	ENSG00000227373.4	RP11-160H22.5	6.89	1.71e-11	1.09e-08	0.45	0.3	Systemic lupus erythematosus;	chr1:174312477	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12097252	ENSG00000227373.4	RP11-160H22.5	6.89	1.71e-11	1.09e-08	0.45	0.3	Systemic lupus erythematosus;	chr1:174318374	chr1:174115300~174160004:-
LUAD	cis	rs9326248	0.581	rs7120706	ENSG00000280143.1	AP000892.6	-6.89	1.71e-11	1.09e-08	-0.34	-0.3	Blood protein levels;	chr11:116959371	chr11:117204967~117210292:+
LUAD	cis	rs35955747	0.871	rs5994392	ENSG00000236132.1	CTA-440B3.1	6.89	1.71e-11	1.09e-08	0.33	0.3	Neutrophil count;Sum basophil neutrophil counts;	chr22:31387920	chr22:31816379~31817491:-
LUAD	cis	rs748404	0.66	rs2467742	ENSG00000249839.1	AC011330.5	-6.89	1.71e-11	1.09e-08	-0.39	-0.3	Lung cancer;	chr15:43458039	chr15:43663654~43684339:-
LUAD	cis	rs1799949	1	rs33926631	ENSG00000267681.1	CTD-3199J23.6	-6.89	1.71e-11	1.09e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43152446	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs1960605	ENSG00000267681.1	CTD-3199J23.6	-6.89	1.71e-11	1.09e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43153380	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs2037076	ENSG00000267681.1	CTD-3199J23.6	-6.89	1.71e-11	1.09e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43153866	chr17:43144956~43145255:+
LUAD	cis	rs17023223	0.537	rs1325940	ENSG00000231365.4	RP11-418J17.1	-6.89	1.72e-11	1.09e-08	-0.39	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119044064	chr1:119140396~119275973:+
LUAD	cis	rs2243480	0.615	rs34363376	ENSG00000273142.1	RP11-458F8.4	-6.89	1.73e-11	1.1e-08	-0.31	-0.3	Diabetic kidney disease;	chr7:66474549	chr7:66902857~66906297:+
LUAD	cis	rs34779708	0.733	rs12254018	ENSG00000230534.5	RP11-297A16.2	6.89	1.73e-11	1.1e-08	0.36	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35261713	chr10:35098006~35127020:-
LUAD	cis	rs7246657	0.943	rs10420430	ENSG00000276846.1	CTD-3220F14.3	6.89	1.74e-11	1.1e-08	0.42	0.3	Coronary artery calcification;	chr19:37403292	chr19:37314868~37315620:-
LUAD	cis	rs7044106	0.791	rs7043969	ENSG00000238181.2	AHCYP2	-6.89	1.74e-11	1.1e-08	-0.39	-0.3	Hip circumference adjusted for BMI;	chr9:120731711	chr9:120720673~120721972:+
LUAD	cis	rs9326248	0.53	rs7114963	ENSG00000280143.1	AP000892.6	6.89	1.74e-11	1.1e-08	0.46	0.3	Blood protein levels;	chr11:117005267	chr11:117204967~117210292:+
LUAD	cis	rs7115242	0.72	rs10790169	ENSG00000280143.1	AP000892.6	6.89	1.74e-11	1.1e-08	0.46	0.3	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117006443	chr11:117204967~117210292:+
LUAD	cis	rs7429990	0.833	rs3755637	ENSG00000229759.1	MRPS18AP1	-6.89	1.74e-11	1.11e-08	-0.3	-0.3	Educational attainment (years of education);	chr3:47580720	chr3:48256350~48256938:-
LUAD	cis	rs4713118	0.662	rs175954	ENSG00000219392.1	RP1-265C24.5	-6.89	1.74e-11	1.11e-08	-0.41	-0.3	Parkinson's disease;	chr6:28043807	chr6:28115628~28116551:+
LUAD	cis	rs6921919	0.697	rs6942030	ENSG00000216901.1	AL022393.7	6.89	1.74e-11	1.11e-08	0.36	0.3	Autism spectrum disorder or schizophrenia;	chr6:28348181	chr6:28176188~28176674:+
LUAD	cis	rs11214589	0.905	rs2186799	ENSG00000270179.1	RP11-159N11.4	-6.89	1.75e-11	1.11e-08	-0.3	-0.3	Neuroticism;	chr11:113371811	chr11:113368478~113369117:+
LUAD	cis	rs801193	0.66	rs1962050	ENSG00000222364.1	RNU6-96P	6.89	1.75e-11	1.11e-08	0.33	0.3	Aortic root size;	chr7:66775021	chr7:66395191~66395286:+
LUAD	cis	rs3931020	1	rs3931020	ENSG00000272864.1	RP11-17E13.2	-6.89	1.76e-11	1.12e-08	-0.37	-0.3	Resistin levels;	chr1:74769633	chr1:74698769~74699333:-
LUAD	cis	rs7017914	0.967	rs34042354	ENSG00000223220.1	Y_RNA	6.89	1.76e-11	1.12e-08	0.34	0.3	Bone mineral density;	chr8:70818726	chr8:70780914~70781008:-
LUAD	cis	rs944289	1	rs944289	ENSG00000257826.1	RP11-116N8.4	-6.89	1.76e-11	1.12e-08	-0.32	-0.3	Thyroid cancer;	chr14:36180040	chr14:36061026~36067190:-
LUAD	cis	rs237743	0.896	rs2063710	ENSG00000222365.1	SNORD12B	6.89	1.77e-11	1.12e-08	0.34	0.3	Height;	chr20:49215517	chr20:49280319~49280409:+
LUAD	cis	rs11098499	0.909	rs10026736	ENSG00000248280.1	RP11-33B1.2	6.89	1.77e-11	1.12e-08	0.39	0.3	Corneal astigmatism;	chr4:119463167	chr4:119440561~119450157:-
LUAD	cis	rs9903692	0.954	rs2051821	ENSG00000278765.1	RP5-890E16.5	6.89	1.77e-11	1.13e-08	0.39	0.3	Pulse pressure;	chr17:48066153	chr17:48066704~48067293:-
LUAD	cis	rs113835537	0.559	rs11227498	ENSG00000255517.5	CTD-3074O7.5	-6.89	1.77e-11	1.13e-08	-0.35	-0.3	Airway imaging phenotypes;	chr11:66502243	chr11:66473490~66480233:-
LUAD	cis	rs11123170	0.529	rs1015753	ENSG00000274877.1	RP11-65I12.1	-6.89	1.78e-11	1.13e-08	-0.46	-0.3	Renal function-related traits (BUN);	chr2:113211226	chr2:113237595~113240825:+
LUAD	cis	rs9326248	0.581	rs6589582	ENSG00000280143.1	AP000892.6	6.89	1.78e-11	1.13e-08	0.34	0.3	Blood protein levels;	chr11:116958484	chr11:117204967~117210292:+
LUAD	cis	rs9595908	0.9	rs9595883	ENSG00000212293.1	SNORA16	6.89	1.78e-11	1.13e-08	0.32	0.3	Body mass index;	chr13:32593563	chr13:32420390~32420516:-
LUAD	cis	rs7017914	0.967	rs13261712	ENSG00000223220.1	Y_RNA	6.89	1.78e-11	1.13e-08	0.34	0.3	Bone mineral density;	chr8:70820029	chr8:70780914~70781008:-
LUAD	cis	rs62355901	0.609	rs66893416	ENSG00000271828.1	CTD-2310F14.1	6.89	1.78e-11	1.13e-08	0.48	0.3	Breast cancer;	chr5:56755769	chr5:56927874~56929573:+
LUAD	cis	rs1062177	1	rs2964578	ENSG00000213433.5	RPLP1P6	-6.89	1.79e-11	1.13e-08	-0.39	-0.3	Preschool internalizing problems;	chr5:151767637	chr5:151765859~151766378:-
LUAD	cis	rs2412819	0.571	rs10163069	ENSG00000205771.5	CATSPER2P1	6.89	1.79e-11	1.13e-08	0.46	0.3	Lung cancer;	chr15:43755372	chr15:43726918~43747094:-
LUAD	cis	rs2929278	0.617	rs3986209	ENSG00000205771.5	CATSPER2P1	6.89	1.79e-11	1.13e-08	0.46	0.3	Schizophrenia;	chr15:43758675	chr15:43726918~43747094:-
LUAD	cis	rs7945705	0.783	rs11042125	ENSG00000254860.4	TMEM9B-AS1	6.89	1.79e-11	1.14e-08	0.33	0.3	Hemoglobin concentration;	chr11:8916502	chr11:8964675~8977527:+
LUAD	cis	rs75422866	0.867	rs7303895	ENSG00000257433.4	RP1-197B17.3	6.89	1.79e-11	1.14e-08	0.6	0.3	Pneumonia;	chr12:47683290	chr12:47706085~47742294:+
LUAD	cis	rs7017914	0.967	rs6987007	ENSG00000223220.1	Y_RNA	6.89	1.8e-11	1.14e-08	0.33	0.3	Bone mineral density;	chr8:70688707	chr8:70780914~70781008:-
LUAD	cis	rs867371	0.502	rs7176926	ENSG00000255769.6	GOLGA2P10	-6.89	1.8e-11	1.14e-08	-0.31	-0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82245753	chr15:82472993~82513950:-
LUAD	cis	rs67311347	1	rs1454497	ENSG00000223797.4	ENTPD3-AS1	-6.89	1.8e-11	1.14e-08	-0.32	-0.3	Renal cell carcinoma;	chr3:40454835	chr3:40313802~40453329:-
LUAD	cis	rs1062177	0.826	rs2915822	ENSG00000213433.5	RPLP1P6	6.89	1.8e-11	1.14e-08	0.39	0.3	Preschool internalizing problems;	chr5:151751340	chr5:151765859~151766378:-
LUAD	cis	rs8177876	0.841	rs117310590	ENSG00000261838.4	RP11-303E16.6	6.89	1.8e-11	1.14e-08	0.75	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81094790	chr16:81069854~81076598:+
LUAD	cis	rs2243480	0.908	rs55876148	ENSG00000273142.1	RP11-458F8.4	-6.89	1.81e-11	1.15e-08	-0.32	-0.3	Diabetic kidney disease;	chr7:65914813	chr7:66902857~66906297:+
LUAD	cis	rs9549367	0.713	rs3024756	ENSG00000269125.1	RP11-98F14.11	-6.89	1.81e-11	1.15e-08	-0.39	-0.3	Platelet distribution width;	chr13:113168636	chr13:113165002~113165183:-
LUAD	cis	rs9525916	1	rs9525916	ENSG00000227258.4	SMIM2-AS1	6.89	1.81e-11	1.15e-08	0.35	0.3	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);	chr13:44128733	chr13:44110451~44240517:+
LUAD	cis	rs2153535	0.58	rs7753192	ENSG00000230939.1	RP11-314C16.1	-6.88	1.81e-11	1.15e-08	-0.35	-0.3	Motion sickness;	chr6:8482404	chr6:8784178~8785445:+
LUAD	cis	rs7017914	0.967	rs59992214	ENSG00000223220.1	Y_RNA	6.88	1.81e-11	1.15e-08	0.33	0.3	Bone mineral density;	chr8:70687310	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.935	rs35564237	ENSG00000223220.1	Y_RNA	6.88	1.81e-11	1.15e-08	0.33	0.3	Bone mineral density;	chr8:70688239	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.934	rs62530772	ENSG00000223220.1	Y_RNA	6.88	1.81e-11	1.15e-08	0.33	0.3	Bone mineral density;	chr8:70689306	chr8:70780914~70781008:-
LUAD	cis	rs9487094	0.62	rs7768973	ENSG00000260273.1	RP11-425D10.10	6.88	1.82e-11	1.15e-08	0.37	0.3	Height;	chr6:109424122	chr6:109382795~109383666:+
LUAD	cis	rs7246657	0.943	rs7252325	ENSG00000276846.1	CTD-3220F14.3	6.88	1.82e-11	1.15e-08	0.41	0.3	Coronary artery calcification;	chr19:37439743	chr19:37314868~37315620:-
LUAD	cis	rs11098499	0.863	rs9884402	ENSG00000248280.1	RP11-33B1.2	6.88	1.82e-11	1.16e-08	0.38	0.3	Corneal astigmatism;	chr4:119568827	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.731	rs9995026	ENSG00000248280.1	RP11-33B1.2	6.88	1.82e-11	1.16e-08	0.38	0.3	Corneal astigmatism;	chr4:119569344	chr4:119440561~119450157:-
LUAD	cis	rs3096299	0.967	rs3102341	ENSG00000274627.1	RP11-104N10.2	6.88	1.83e-11	1.16e-08	0.29	0.3	Multiple myeloma (IgH translocation);	chr16:89384336	chr16:89516797~89522217:+
LUAD	cis	rs1062177	1	rs2915878	ENSG00000213433.5	RPLP1P6	-6.88	1.83e-11	1.16e-08	-0.39	-0.3	Preschool internalizing problems;	chr5:151770101	chr5:151765859~151766378:-
LUAD	cis	rs748404	0.631	rs7167882	ENSG00000249839.1	AC011330.5	-6.88	1.83e-11	1.16e-08	-0.38	-0.3	Lung cancer;	chr15:43386465	chr15:43663654~43684339:-
LUAD	cis	rs6565180	0.962	rs35480350	ENSG00000183604.13	SMG1P5	-6.88	1.83e-11	1.16e-08	-0.33	-0.3	Tonsillectomy;	chr16:30354718	chr16:30267553~30335374:-
LUAD	cis	rs6142102	0.961	rs1319363	ENSG00000276073.1	RP5-1125A11.7	-6.88	1.83e-11	1.16e-08	-0.31	-0.3	Skin pigmentation;	chr20:33954070	chr20:33985617~33988989:-
LUAD	cis	rs17301013	0.507	rs72713537	ENSG00000227373.4	RP11-160H22.5	6.88	1.83e-11	1.16e-08	0.45	0.3	Systemic lupus erythematosus;	chr1:174354189	chr1:174115300~174160004:-
LUAD	cis	rs113835537	0.529	rs11227495	ENSG00000255517.5	CTD-3074O7.5	-6.88	1.84e-11	1.16e-08	-0.35	-0.3	Airway imaging phenotypes;	chr11:66495772	chr11:66473490~66480233:-
LUAD	cis	rs1799949	1	rs8070085	ENSG00000267681.1	CTD-3199J23.6	6.88	1.84e-11	1.17e-08	0.35	0.3	Menopause (age at onset);	chr17:43189967	chr17:43144956~43145255:+
LUAD	cis	rs10129255	1	rs10129319	ENSG00000280411.1	IGHV1-69-2	-6.88	1.84e-11	1.17e-08	-0.22	-0.3	Kawasaki disease;	chr14:106767996	chr14:106762092~106762588:-
LUAD	cis	rs853679	0.567	rs9969098	ENSG00000204709.4	LINC01556	6.88	1.84e-11	1.17e-08	0.4	0.3	Depression;	chr6:28430971	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.567	rs16894106	ENSG00000204709.4	LINC01556	6.88	1.84e-11	1.17e-08	0.4	0.3	Depression;	chr6:28432562	chr6:28943877~28944537:+
LUAD	cis	rs1062177	0.906	rs2964573	ENSG00000213433.5	RPLP1P6	-6.88	1.85e-11	1.17e-08	-0.39	-0.3	Preschool internalizing problems;	chr5:151780561	chr5:151765859~151766378:-
LUAD	cis	rs783540	0.9	rs12916980	ENSG00000278603.1	RP13-608F4.5	-6.88	1.86e-11	1.18e-08	-0.34	-0.3	Schizophrenia;	chr15:82637696	chr15:82472203~82472426:+
LUAD	cis	rs6860806	0.531	rs274556	ENSG00000233006.5	AC034220.3	-6.88	1.86e-11	1.18e-08	-0.3	-0.3	Breast cancer;	chr5:132386383	chr5:132311285~132369916:-
LUAD	cis	rs11098499	0.82	rs6829903	ENSG00000248280.1	RP11-33B1.2	6.88	1.86e-11	1.18e-08	0.38	0.3	Corneal astigmatism;	chr4:119585729	chr4:119440561~119450157:-
LUAD	cis	rs1185460	0.565	rs2276060	ENSG00000271751.1	RP11-110I1.14	6.88	1.86e-11	1.18e-08	0.38	0.3	Coronary artery disease;	chr11:119048420	chr11:119065263~119065677:-
LUAD	cis	rs9549367	0.569	rs3024738	ENSG00000269125.1	RP11-98F14.11	6.88	1.87e-11	1.18e-08	0.39	0.3	Platelet distribution width;	chr13:113165607	chr13:113165002~113165183:-
LUAD	cis	rs17301013	0.507	rs10912757	ENSG00000227373.4	RP11-160H22.5	6.88	1.87e-11	1.18e-08	0.45	0.3	Systemic lupus erythematosus;	chr1:174299064	chr1:174115300~174160004:-
LUAD	cis	rs2337406	0.866	rs79901786	ENSG00000211974.3	IGHV2-70	-6.88	1.87e-11	1.19e-08	-0.38	-0.3	Alzheimer's disease (late onset);	chr14:106777623	chr14:106723574~106724093:-
LUAD	cis	rs6565180	0.962	rs6565182	ENSG00000183604.13	SMG1P5	-6.88	1.87e-11	1.19e-08	-0.33	-0.3	Tonsillectomy;	chr16:30363060	chr16:30267553~30335374:-
LUAD	cis	rs6991838	0.831	rs4394432	ENSG00000272010.1	CTD-3025N20.3	6.88	1.88e-11	1.19e-08	0.31	0.3	Intelligence (multi-trait analysis);	chr8:65560939	chr8:65591850~65592472:-
LUAD	cis	rs150992	0.609	rs447044	ENSG00000248489.1	CTD-2007H13.3	6.88	1.88e-11	1.19e-08	0.32	0.3	Body mass index;	chr5:98995572	chr5:98929171~98995013:+
LUAD	cis	rs4713118	0.662	rs9380045	ENSG00000219392.1	RP1-265C24.5	-6.88	1.88e-11	1.19e-08	-0.41	-0.3	Parkinson's disease;	chr6:28057501	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.616	rs9348789	ENSG00000219392.1	RP1-265C24.5	-6.88	1.88e-11	1.19e-08	-0.41	-0.3	Parkinson's disease;	chr6:28057708	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.662	rs9468274	ENSG00000219392.1	RP1-265C24.5	-6.88	1.88e-11	1.19e-08	-0.41	-0.3	Parkinson's disease;	chr6:28058299	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.662	rs9468275	ENSG00000219392.1	RP1-265C24.5	-6.88	1.88e-11	1.19e-08	-0.41	-0.3	Parkinson's disease;	chr6:28058358	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.662	rs9468276	ENSG00000219392.1	RP1-265C24.5	-6.88	1.88e-11	1.19e-08	-0.41	-0.3	Parkinson's disease;	chr6:28059910	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.662	rs9468277	ENSG00000219392.1	RP1-265C24.5	-6.88	1.88e-11	1.19e-08	-0.41	-0.3	Parkinson's disease;	chr6:28060612	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.662	rs9468278	ENSG00000219392.1	RP1-265C24.5	-6.88	1.88e-11	1.19e-08	-0.41	-0.3	Parkinson's disease;	chr6:28060704	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.662	rs13218430	ENSG00000219392.1	RP1-265C24.5	-6.88	1.88e-11	1.19e-08	-0.41	-0.3	Parkinson's disease;	chr6:28062059	chr6:28115628~28116551:+
LUAD	cis	rs783540	0.869	rs783521	ENSG00000278603.1	RP13-608F4.5	-6.88	1.89e-11	1.2e-08	-0.35	-0.3	Schizophrenia;	chr15:82611694	chr15:82472203~82472426:+
LUAD	cis	rs783540	0.835	rs783522	ENSG00000278603.1	RP13-608F4.5	-6.88	1.89e-11	1.2e-08	-0.35	-0.3	Schizophrenia;	chr15:82611862	chr15:82472203~82472426:+
LUAD	cis	rs3762637	0.941	rs9289192	ENSG00000272758.4	RP11-299J3.8	-6.88	1.89e-11	1.2e-08	-0.48	-0.3	LDL cholesterol levels;	chr3:122357268	chr3:122416207~122443180:+
LUAD	cis	rs7044106	0.791	rs10739572	ENSG00000238181.2	AHCYP2	-6.88	1.89e-11	1.2e-08	-0.39	-0.3	Hip circumference adjusted for BMI;	chr9:120727537	chr9:120720673~120721972:+
LUAD	cis	rs6921919	1	rs6921919	ENSG00000204709.4	LINC01556	6.88	1.9e-11	1.2e-08	0.42	0.3	Autism spectrum disorder or schizophrenia;	chr6:28357424	chr6:28943877~28944537:+
LUAD	cis	rs1075265	0.73	rs11893270	ENSG00000233266.1	HMGB1P31	6.88	1.9e-11	1.2e-08	0.37	0.3	Chronotype;Morning vs. evening chronotype;	chr2:54019828	chr2:54051334~54051760:+
LUAD	cis	rs7646881	0.812	rs61696028	ENSG00000240207.5	RP11-379F4.4	-6.88	1.9e-11	1.2e-08	-0.4	-0.3	Tetralogy of Fallot;	chr3:158737914	chr3:158732263~158784070:+
LUAD	cis	rs7646881	0.812	rs61387735	ENSG00000240207.5	RP11-379F4.4	-6.88	1.9e-11	1.2e-08	-0.4	-0.3	Tetralogy of Fallot;	chr3:158738372	chr3:158732263~158784070:+
LUAD	cis	rs7646881	0.767	rs73015669	ENSG00000240207.5	RP11-379F4.4	-6.88	1.9e-11	1.2e-08	-0.4	-0.3	Tetralogy of Fallot;	chr3:158738529	chr3:158732263~158784070:+
LUAD	cis	rs11676348	0.774	rs11683524	ENSG00000261338.2	RP11-378A13.1	-6.88	1.91e-11	1.21e-08	-0.32	-0.3	Ulcerative colitis;	chr2:218119881	chr2:218255319~218257366:+
LUAD	cis	rs4728142	0.738	rs3807306	ENSG00000275106.1	RP11-309L24.10	6.88	1.92e-11	1.21e-08	0.34	0.3	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128940626	chr7:128952527~128953316:-
LUAD	cis	rs150992	0.632	rs1472622	ENSG00000248489.1	CTD-2007H13.3	-6.88	1.92e-11	1.21e-08	-0.32	-0.3	Body mass index;	chr5:99000749	chr5:98929171~98995013:+
LUAD	cis	rs6683071	1	rs2378606	ENSG00000272750.1	RP11-378J18.8	6.88	1.92e-11	1.21e-08	0.34	0.3	Cognitive performance;	chr1:222746406	chr1:222658867~222661512:-
LUAD	cis	rs9326248	0.581	rs7120515	ENSG00000280143.1	AP000892.6	6.88	1.92e-11	1.21e-08	0.34	0.3	Blood protein levels;	chr11:117121210	chr11:117204967~117210292:+
LUAD	cis	rs75422866	0.867	rs7303895	ENSG00000274902.1	RP1-197B17.4	6.88	1.92e-11	1.22e-08	0.63	0.3	Pneumonia;	chr12:47683290	chr12:47731908~47732351:+
LUAD	cis	rs2153535	0.58	rs6905237	ENSG00000230939.1	RP11-314C16.1	-6.88	1.93e-11	1.22e-08	-0.36	-0.3	Motion sickness;	chr6:8471557	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.542	rs4440510	ENSG00000230939.1	RP11-314C16.1	-6.88	1.93e-11	1.22e-08	-0.36	-0.3	Motion sickness;	chr6:8471585	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.541	rs1414347	ENSG00000230939.1	RP11-314C16.1	-6.88	1.93e-11	1.22e-08	-0.36	-0.3	Motion sickness;	chr6:8471598	chr6:8784178~8785445:+
LUAD	cis	rs7688540	0.8	rs11731285	ENSG00000275426.1	CH17-262A2.1	6.88	1.93e-11	1.22e-08	0.37	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:271152	chr4:149738~150317:+
LUAD	cis	rs2243480	1	rs316329	ENSG00000273142.1	RP11-458F8.4	-6.87	1.93e-11	1.22e-08	-0.31	-0.3	Diabetic kidney disease;	chr7:66143429	chr7:66902857~66906297:+
LUAD	cis	rs35955747	0.87	rs5997986	ENSG00000236132.1	CTA-440B3.1	6.87	1.93e-11	1.22e-08	0.33	0.3	Neutrophil count;Sum basophil neutrophil counts;	chr22:31438953	chr22:31816379~31817491:-
LUAD	cis	rs17301013	0.507	rs1121537	ENSG00000227373.4	RP11-160H22.5	6.87	1.94e-11	1.22e-08	0.45	0.3	Systemic lupus erythematosus;	chr1:174307568	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs10912763	ENSG00000227373.4	RP11-160H22.5	6.87	1.94e-11	1.22e-08	0.45	0.3	Systemic lupus erythematosus;	chr1:174316083	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs10912764	ENSG00000227373.4	RP11-160H22.5	6.87	1.94e-11	1.22e-08	0.45	0.3	Systemic lupus erythematosus;	chr1:174316085	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs10912765	ENSG00000227373.4	RP11-160H22.5	6.87	1.94e-11	1.22e-08	0.45	0.3	Systemic lupus erythematosus;	chr1:174322812	chr1:174115300~174160004:-
LUAD	cis	rs7246657	0.598	rs10417545	ENSG00000276846.1	CTD-3220F14.3	6.87	1.94e-11	1.22e-08	0.47	0.3	Coronary artery calcification;	chr19:37163361	chr19:37314868~37315620:-
LUAD	cis	rs10129255	0.957	rs11846893	ENSG00000280411.1	IGHV1-69-2	-6.87	1.94e-11	1.23e-08	-0.22	-0.3	Kawasaki disease;	chr14:106779068	chr14:106762092~106762588:-
LUAD	cis	rs9309711	0.883	rs13429373	ENSG00000225234.1	TRAPPC12-AS1	-6.87	1.94e-11	1.23e-08	-0.38	-0.3	Neurofibrillary tangles;	chr2:3473243	chr2:3481242~3482409:-
LUAD	cis	rs71327718	1	rs71327718	ENSG00000171084.14	FAM86JP	6.87	1.94e-11	1.23e-08	0.55	0.3	Metabolite levels (HVA/5-HIAA ratio);	chr3:125874014	chr3:125916620~125930024:+
LUAD	cis	rs7246657	0.943	rs13343502	ENSG00000276846.1	CTD-3220F14.3	6.87	1.95e-11	1.23e-08	0.42	0.3	Coronary artery calcification;	chr19:37471390	chr19:37314868~37315620:-
LUAD	cis	rs783540	0.9	rs783525	ENSG00000278603.1	RP13-608F4.5	-6.87	1.95e-11	1.23e-08	-0.34	-0.3	Schizophrenia;	chr15:82615878	chr15:82472203~82472426:+
LUAD	cis	rs748404	0.66	rs694725	ENSG00000249839.1	AC011330.5	-6.87	1.95e-11	1.23e-08	-0.39	-0.3	Lung cancer;	chr15:43464012	chr15:43663654~43684339:-
LUAD	cis	rs881375	0.933	rs4837799	ENSG00000226752.6	PSMD5-AS1	-6.87	1.95e-11	1.23e-08	-0.33	-0.3	Rheumatoid arthritis;	chr9:120906048	chr9:120824828~120854385:+
LUAD	cis	rs8059260	0.673	rs7188928	ENSG00000274038.1	RP11-66H6.4	-6.87	1.96e-11	1.24e-08	-0.52	-0.3	Alcohol consumption over the past year;	chr16:10964896	chr16:11056556~11057034:+
LUAD	cis	rs10759883	0.563	rs7847983	ENSG00000175611.10	LINC00476	6.87	1.96e-11	1.24e-08	0.35	0.3	Nicotine dependence;	chr9:95948046	chr9:95759231~95875977:-
LUAD	cis	rs10759883	0.563	rs10819650	ENSG00000175611.10	LINC00476	6.87	1.96e-11	1.24e-08	0.35	0.3	Nicotine dependence;	chr9:95951161	chr9:95759231~95875977:-
LUAD	cis	rs10759883	0.563	rs10760679	ENSG00000175611.10	LINC00476	6.87	1.96e-11	1.24e-08	0.35	0.3	Nicotine dependence;	chr9:95951511	chr9:95759231~95875977:-
LUAD	cis	rs1167827	0.71	rs1167836	ENSG00000278416.1	PMS2L2	6.87	1.97e-11	1.24e-08	0.38	0.3	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75539580	chr7:75344015~75359550:-
LUAD	cis	rs8100891	0.537	rs3746016	ENSG00000267213.4	AC007773.2	-6.87	1.97e-11	1.25e-08	-0.45	-0.3	Neuroticism;	chr19:32386353	chr19:32390050~32405560:-
LUAD	cis	rs11846409	0.799	rs10467899	ENSG00000211974.3	IGHV2-70	-6.87	1.98e-11	1.25e-08	-0.38	-0.3	Rheumatic heart disease;	chr14:106644012	chr14:106723574~106724093:-
LUAD	cis	rs131777	0.526	rs86337	ENSG00000205559.3	CHKB-AS1	-6.87	1.98e-11	1.25e-08	-0.33	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50582239	chr22:50583026~50583877:+
LUAD	cis	rs2243480	1	rs1964692	ENSG00000273142.1	RP11-458F8.4	-6.87	1.98e-11	1.25e-08	-0.31	-0.3	Diabetic kidney disease;	chr7:65989196	chr7:66902857~66906297:+
LUAD	cis	rs950169	0.84	rs62019457	ENSG00000259728.4	LINC00933	6.87	1.98e-11	1.25e-08	0.44	0.3	Schizophrenia;	chr15:84558911	chr15:84570649~84580175:+
LUAD	cis	rs7927592	0.913	rs10047412	ENSG00000212093.1	AP000807.1	6.87	1.98e-11	1.25e-08	0.33	0.3	Total body bone mineral density;	chr11:68465444	chr11:68506083~68506166:-
LUAD	cis	rs3813579	0.568	rs4506909	ENSG00000261390.4	RP11-345M22.2	-6.87	1.98e-11	1.25e-08	-0.37	-0.3	Thyroid volume;	chr16:79719622	chr16:79715232~79770563:-
LUAD	cis	rs904251	0.507	rs11756941	ENSG00000279942.1	RP1-153P14.7	-6.87	1.98e-11	1.25e-08	-0.35	-0.3	Cognitive performance;	chr6:37448443	chr6:37567716~37571460:+
LUAD	cis	rs11846409	0.932	rs2015469	ENSG00000254174.1	IGHV1-12	6.87	1.99e-11	1.26e-08	0.26	0.3	Rheumatic heart disease;	chr14:106631857	chr14:106122420~106122709:-
LUAD	cis	rs11846409	0.932	rs56167903	ENSG00000254174.1	IGHV1-12	6.87	1.99e-11	1.26e-08	0.26	0.3	Rheumatic heart disease;	chr14:106632070	chr14:106122420~106122709:-
LUAD	cis	rs10740039	0.804	rs1837950	ENSG00000254271.1	RP11-131N11.4	-6.87	2e-11	1.26e-08	-0.34	-0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60685207	chr10:60734342~60741828:+
LUAD	cis	rs6504950	0.813	rs244321	ENSG00000275710.1	RP11-257O5.4	6.87	2e-11	1.26e-08	0.37	0.3	Breast cancer;	chr17:55146637	chr17:54964474~54964679:+
LUAD	cis	rs6504950	0.854	rs244322	ENSG00000275710.1	RP11-257O5.4	6.87	2e-11	1.26e-08	0.37	0.3	Breast cancer;	chr17:55147398	chr17:54964474~54964679:+
LUAD	cis	rs6142102	0.923	rs2268078	ENSG00000276073.1	RP5-1125A11.7	-6.87	2e-11	1.26e-08	-0.32	-0.3	Skin pigmentation;	chr20:34008898	chr20:33985617~33988989:-
LUAD	cis	rs9326248	0.53	rs10732856	ENSG00000280143.1	AP000892.6	6.87	2e-11	1.26e-08	0.45	0.3	Blood protein levels;	chr11:117036397	chr11:117204967~117210292:+
LUAD	cis	rs66887589	0.777	rs10015883	ENSG00000248280.1	RP11-33B1.2	6.87	2e-11	1.26e-08	0.33	0.3	Diastolic blood pressure;	chr4:119346991	chr4:119440561~119450157:-
LUAD	cis	rs4713118	0.955	rs9468203	ENSG00000219392.1	RP1-265C24.5	-6.87	2.01e-11	1.27e-08	-0.39	-0.3	Parkinson's disease;	chr6:27720888	chr6:28115628~28116551:+
LUAD	cis	rs2243480	1	rs2462569	ENSG00000226824.5	RP4-756H11.3	6.87	2.01e-11	1.27e-08	0.54	0.3	Diabetic kidney disease;	chr7:66009859	chr7:66654538~66669855:+
LUAD	cis	rs950169	0.922	rs8037078	ENSG00000259728.4	LINC00933	-6.87	2.01e-11	1.27e-08	-0.45	-0.3	Schizophrenia;	chr15:84150119	chr15:84570649~84580175:+
LUAD	cis	rs6504950	0.924	rs2628316	ENSG00000275710.1	RP11-257O5.4	-6.87	2.02e-11	1.27e-08	-0.36	-0.3	Breast cancer;	chr17:55142476	chr17:54964474~54964679:+
LUAD	cis	rs9318086	0.712	rs9318100	ENSG00000205861.10	C1QTNF9B-AS1	6.87	2.02e-11	1.27e-08	0.35	0.3	Myopia (pathological);	chr13:23868343	chr13:23888889~23897263:+
LUAD	cis	rs2286503	1	rs1029740	ENSG00000228649.7	AC005682.5	6.87	2.02e-11	1.27e-08	0.37	0.3	Fibrinogen;	chr7:22833967	chr7:22854178~22861579:+
LUAD	cis	rs2439831	0.867	rs11856184	ENSG00000205771.5	CATSPER2P1	-6.87	2.03e-11	1.28e-08	-0.53	-0.3	Lung cancer in ever smokers;	chr15:43626964	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.571	rs2470121	ENSG00000205771.5	CATSPER2P1	-6.87	2.03e-11	1.28e-08	-0.53	-0.3	Lung cancer in ever smokers;	chr15:43645420	chr15:43726918~43747094:-
LUAD	cis	rs1799949	1	rs8176318	ENSG00000267681.1	CTD-3199J23.6	-6.87	2.03e-11	1.28e-08	-0.34	-0.3	Menopause (age at onset);	chr17:43045257	chr17:43144956~43145255:+
LUAD	cis	rs7208859	0.623	rs609063	ENSG00000263531.1	RP13-753N3.1	6.87	2.03e-11	1.28e-08	0.6	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs383436	ENSG00000263531.1	RP13-753N3.1	6.87	2.03e-11	1.28e-08	0.6	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30632161	chr17:30863921~30864940:-
LUAD	cis	rs2243480	0.764	rs2460423	ENSG00000226824.5	RP4-756H11.3	-6.87	2.04e-11	1.28e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66136229	chr7:66654538~66669855:+
LUAD	cis	rs6142102	0.812	rs761236	ENSG00000276073.1	RP5-1125A11.7	-6.87	2.04e-11	1.29e-08	-0.31	-0.3	Skin pigmentation;	chr20:33932245	chr20:33985617~33988989:-
LUAD	cis	rs1113500	0.836	rs1539553	ENSG00000226822.1	RP11-356N1.2	-6.87	2.05e-11	1.29e-08	-0.35	-0.3	Growth-regulated protein alpha levels;	chr1:108047376	chr1:108071482~108074519:+
LUAD	cis	rs9584850	1	rs9584850	ENSG00000231194.1	FARP1-AS1	6.87	2.05e-11	1.29e-08	0.36	0.3	Neuroticism;	chr13:98449172	chr13:98435405~98435840:-
LUAD	cis	rs6921919	0.697	rs758398	ENSG00000204709.4	LINC01556	6.87	2.05e-11	1.29e-08	0.38	0.3	Autism spectrum disorder or schizophrenia;	chr6:28352897	chr6:28943877~28944537:+
LUAD	cis	rs11098499	0.954	rs12502423	ENSG00000248280.1	RP11-33B1.2	6.87	2.05e-11	1.29e-08	0.38	0.3	Corneal astigmatism;	chr4:119503017	chr4:119440561~119450157:-
LUAD	cis	rs755249	1	rs4660293	ENSG00000228060.1	RP11-69E11.8	6.86	2.06e-11	1.3e-08	0.29	0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39562508	chr1:39565160~39573203:+
LUAD	cis	rs9595066	0.627	rs9562536	ENSG00000227258.4	SMIM2-AS1	6.86	2.06e-11	1.3e-08	0.48	0.3	Schizophrenia;	chr13:44157452	chr13:44110451~44240517:+
LUAD	cis	rs321358	0.731	rs527397	ENSG00000271584.1	RP11-89C3.4	6.86	2.06e-11	1.3e-08	0.46	0.3	Body mass index;	chr11:111159907	chr11:111091932~111097357:-
LUAD	cis	rs7429990	0.76	rs319694	ENSG00000229759.1	MRPS18AP1	6.86	2.06e-11	1.3e-08	0.3	0.3	Educational attainment (years of education);	chr3:47843463	chr3:48256350~48256938:-
LUAD	cis	rs7646881	0.812	rs73017539	ENSG00000240207.5	RP11-379F4.4	-6.86	2.07e-11	1.3e-08	-0.39	-0.3	Tetralogy of Fallot;	chr3:158742954	chr3:158732263~158784070:+
LUAD	cis	rs6844153	0.941	rs75656258	ENSG00000240005.4	RP11-293A21.1	-6.86	2.07e-11	1.3e-08	-0.49	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26843577	chr4:26859806~26860599:-
LUAD	cis	rs673078	0.66	rs11068891	ENSG00000275759.1	RP11-131L12.3	6.86	2.07e-11	1.3e-08	0.39	0.3	Glucose homeostasis traits;	chr12:118259814	chr12:118428281~118428870:+
LUAD	cis	rs75422866	0.867	rs73111258	ENSG00000274902.1	RP1-197B17.4	6.86	2.07e-11	1.3e-08	0.67	0.3	Pneumonia;	chr12:47597313	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs7304743	ENSG00000274902.1	RP1-197B17.4	-6.86	2.08e-11	1.31e-08	-0.61	-0.3	Pneumonia;	chr12:47683658	chr12:47731908~47732351:+
LUAD	cis	rs10129255	0.536	rs17113249	ENSG00000211970.3	IGHV4-61	-6.86	2.08e-11	1.31e-08	-0.21	-0.3	Kawasaki disease;	chr14:106678273	chr14:106639119~106639657:-
LUAD	cis	rs9640161	0.659	rs7788316	ENSG00000261305.1	RP4-584D14.7	6.86	2.08e-11	1.31e-08	0.42	0.3	Blood protein levels;Circulating chemerin levels;	chr7:150316906	chr7:150341771~150342607:+
LUAD	cis	rs7927592	0.913	rs7106010	ENSG00000212093.1	AP000807.1	6.86	2.09e-11	1.31e-08	0.33	0.3	Total body bone mineral density;	chr11:68597744	chr11:68506083~68506166:-
LUAD	cis	rs881375	1	rs1609810	ENSG00000226752.6	PSMD5-AS1	-6.86	2.09e-11	1.31e-08	-0.33	-0.3	Rheumatoid arthritis;	chr9:120880073	chr9:120824828~120854385:+
LUAD	cis	rs881375	1	rs10818480	ENSG00000226752.6	PSMD5-AS1	-6.86	2.09e-11	1.31e-08	-0.33	-0.3	Rheumatoid arthritis;	chr9:120880892	chr9:120824828~120854385:+
LUAD	cis	rs2243480	1	rs431076	ENSG00000226824.5	RP4-756H11.3	-6.86	2.09e-11	1.32e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66135333	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs2257790	ENSG00000226824.5	RP4-756H11.3	-6.86	2.09e-11	1.32e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66135463	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs2460422	ENSG00000226824.5	RP4-756H11.3	-6.86	2.09e-11	1.32e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66136518	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs316334	ENSG00000226824.5	RP4-756H11.3	-6.86	2.09e-11	1.32e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66137139	chr7:66654538~66669855:+
LUAD	cis	rs9326248	0.581	rs7120963	ENSG00000280143.1	AP000892.6	-6.86	2.1e-11	1.32e-08	-0.34	-0.3	Blood protein levels;	chr11:116959545	chr11:117204967~117210292:+
LUAD	cis	rs9660180	0.967	rs12034740	ENSG00000268575.1	RP1-283E3.8	-6.86	2.1e-11	1.32e-08	-0.27	-0.3	Body mass index;	chr1:1797530	chr1:1702736~1737688:-
LUAD	cis	rs748404	0.66	rs2439846	ENSG00000249839.1	AC011330.5	-6.86	2.11e-11	1.32e-08	-0.39	-0.3	Lung cancer;	chr15:43448772	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.66	rs2467741	ENSG00000249839.1	AC011330.5	-6.86	2.11e-11	1.32e-08	-0.39	-0.3	Lung cancer;	chr15:43450428	chr15:43663654~43684339:-
LUAD	cis	rs62229266	0.804	rs2835231	ENSG00000214914.3	RPL23AP3	6.86	2.11e-11	1.33e-08	0.37	0.3	Mitral valve prolapse;	chr21:36018300	chr21:36016079~36016546:-
LUAD	cis	rs9326248	0.53	rs473188	ENSG00000280143.1	AP000892.6	6.86	2.12e-11	1.33e-08	0.46	0.3	Blood protein levels;	chr11:116941313	chr11:117204967~117210292:+
LUAD	cis	rs17301013	0.507	rs10912758	ENSG00000227373.4	RP11-160H22.5	6.86	2.12e-11	1.33e-08	0.45	0.3	Systemic lupus erythematosus;	chr1:174300822	chr1:174115300~174160004:-
LUAD	cis	rs3931020	0.671	rs1327088	ENSG00000272864.1	RP11-17E13.2	-6.86	2.12e-11	1.33e-08	-0.34	-0.3	Resistin levels;	chr1:74789807	chr1:74698769~74699333:-
LUAD	cis	rs7849270	0.959	rs4836641	ENSG00000268707.1	RP11-247A12.7	6.86	2.12e-11	1.33e-08	0.36	0.3	Blood metabolite ratios;	chr9:129149953	chr9:129170434~129170940:+
LUAD	cis	rs4713118	0.513	rs149942	ENSG00000219392.1	RP1-265C24.5	-6.86	2.13e-11	1.34e-08	-0.38	-0.3	Parkinson's disease;	chr6:28033832	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.513	rs149944	ENSG00000219392.1	RP1-265C24.5	-6.86	2.13e-11	1.34e-08	-0.38	-0.3	Parkinson's disease;	chr6:28035040	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.513	rs149945	ENSG00000219392.1	RP1-265C24.5	-6.86	2.13e-11	1.34e-08	-0.38	-0.3	Parkinson's disease;	chr6:28035075	chr6:28115628~28116551:+
LUAD	cis	rs1799949	1	rs8176273	ENSG00000267681.1	CTD-3199J23.6	-6.86	2.13e-11	1.34e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43059636	chr17:43144956~43145255:+
LUAD	cis	rs10740039	0.804	rs2028563	ENSG00000254271.1	RP11-131N11.4	-6.86	2.13e-11	1.34e-08	-0.34	-0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60677139	chr10:60734342~60741828:+
LUAD	cis	rs8031584	0.918	rs3817498	ENSG00000260382.1	RP11-540B6.2	6.86	2.13e-11	1.34e-08	0.35	0.3	Huntington's disease progression;	chr15:30976578	chr15:30882267~30883231:-
LUAD	cis	rs748404	0.631	rs6493086	ENSG00000249839.1	AC011330.5	-6.86	2.13e-11	1.34e-08	-0.39	-0.3	Lung cancer;	chr15:43363196	chr15:43663654~43684339:-
LUAD	cis	rs9660180	0.967	rs10907191	ENSG00000268575.1	RP1-283E3.8	-6.86	2.14e-11	1.34e-08	-0.27	-0.3	Body mass index;	chr1:1843381	chr1:1702736~1737688:-
LUAD	cis	rs783540	0.867	rs11855735	ENSG00000278603.1	RP13-608F4.5	6.86	2.14e-11	1.34e-08	0.34	0.3	Schizophrenia;	chr15:82627794	chr15:82472203~82472426:+
LUAD	cis	rs150992	0.587	rs11960896	ENSG00000248489.1	CTD-2007H13.3	-6.86	2.15e-11	1.35e-08	-0.33	-0.3	Body mass index;	chr5:99014294	chr5:98929171~98995013:+
LUAD	cis	rs1318937	1	rs11713836	ENSG00000224660.1	SH3BP5-AS1	6.86	2.15e-11	1.35e-08	0.25	0.3	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15253304	chr3:15254184~15264493:+
LUAD	cis	rs6142102	0.812	rs6059574	ENSG00000276073.1	RP5-1125A11.7	6.86	2.15e-11	1.35e-08	0.3	0.3	Skin pigmentation;	chr20:33935366	chr20:33985617~33988989:-
LUAD	cis	rs2153535	0.58	rs7341382	ENSG00000230939.1	RP11-314C16.1	-6.86	2.15e-11	1.35e-08	-0.35	-0.3	Motion sickness;	chr6:8470316	chr6:8784178~8785445:+
LUAD	cis	rs2980439	0.818	rs2948294	ENSG00000253893.2	FAM85B	-6.86	2.15e-11	1.35e-08	-0.38	-0.3	Neuroticism;	chr8:8237439	chr8:8167819~8226614:-
LUAD	cis	rs113835537	0.529	rs79798028	ENSG00000255517.5	CTD-3074O7.5	-6.86	2.16e-11	1.36e-08	-0.35	-0.3	Airway imaging phenotypes;	chr11:66431891	chr11:66473490~66480233:-
LUAD	cis	rs113835537	0.529	rs2279865	ENSG00000255517.5	CTD-3074O7.5	-6.86	2.16e-11	1.36e-08	-0.35	-0.3	Airway imaging phenotypes;	chr11:66435554	chr11:66473490~66480233:-
LUAD	cis	rs113835537	0.502	rs7104378	ENSG00000255517.5	CTD-3074O7.5	-6.86	2.16e-11	1.36e-08	-0.35	-0.3	Airway imaging phenotypes;	chr11:66449204	chr11:66473490~66480233:-
LUAD	cis	rs7829975	0.511	rs2948286	ENSG00000253893.2	FAM85B	-6.86	2.16e-11	1.36e-08	-0.39	-0.3	Mood instability;	chr8:8272638	chr8:8167819~8226614:-
LUAD	cis	rs80285556	1	rs55914901	ENSG00000161643.11	SIGLEC16	6.86	2.16e-11	1.36e-08	0.62	0.3	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50025089	chr19:49969673~49975814:+
LUAD	cis	rs11098499	0.644	rs17517414	ENSG00000248280.1	RP11-33B1.2	6.86	2.17e-11	1.36e-08	0.35	0.3	Corneal astigmatism;	chr4:119340946	chr4:119440561~119450157:-
LUAD	cis	rs10028773	0.666	rs12498657	ENSG00000248280.1	RP11-33B1.2	6.86	2.17e-11	1.36e-08	0.35	0.3	Educational attainment;	chr4:119341711	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.722	rs10006192	ENSG00000248280.1	RP11-33B1.2	6.86	2.17e-11	1.36e-08	0.35	0.3	Corneal astigmatism;	chr4:119341867	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.615	rs28551750	ENSG00000248280.1	RP11-33B1.2	6.86	2.17e-11	1.36e-08	0.35	0.3	Corneal astigmatism;	chr4:119343746	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.691	rs9995716	ENSG00000248280.1	RP11-33B1.2	6.86	2.17e-11	1.36e-08	0.35	0.3	Corneal astigmatism;	chr4:119343841	chr4:119440561~119450157:-
LUAD	cis	rs17023223	0.537	rs17023171	ENSG00000231365.4	RP11-418J17.1	-6.86	2.17e-11	1.36e-08	-0.39	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050645	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.581	rs12064109	ENSG00000231365.4	RP11-418J17.1	-6.86	2.17e-11	1.36e-08	-0.42	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119099673	chr1:119140396~119275973:+
LUAD	cis	rs9549367	0.713	rs3024757	ENSG00000269125.1	RP11-98F14.11	-6.86	2.17e-11	1.36e-08	-0.4	-0.3	Platelet distribution width;	chr13:113168872	chr13:113165002~113165183:-
LUAD	cis	rs8059260	0.935	rs9928255	ENSG00000274038.1	RP11-66H6.4	-6.86	2.19e-11	1.37e-08	-0.42	-0.3	Alcohol consumption over the past year;	chr16:11027408	chr16:11056556~11057034:+
LUAD	cis	rs748404	0.66	rs690472	ENSG00000249839.1	AC011330.5	-6.86	2.19e-11	1.37e-08	-0.39	-0.3	Lung cancer;	chr15:43472170	chr15:43663654~43684339:-
LUAD	cis	rs10899021	0.92	rs7112384	ENSG00000279353.1	RP11-864N7.4	6.86	2.19e-11	1.37e-08	0.54	0.3	Response to metformin (IC50);	chr11:74637160	chr11:74698231~74699658:-
LUAD	cis	rs10899021	0.92	rs7112664	ENSG00000279353.1	RP11-864N7.4	6.86	2.19e-11	1.37e-08	0.54	0.3	Response to metformin (IC50);	chr11:74637381	chr11:74698231~74699658:-
LUAD	cis	rs2243480	0.803	rs36127118	ENSG00000226824.5	RP4-756H11.3	-6.86	2.19e-11	1.37e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66100518	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs4149468	ENSG00000226824.5	RP4-756H11.3	-6.85	2.2e-11	1.38e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66360703	chr7:66654538~66669855:+
LUAD	cis	rs7849270	0.879	rs10760587	ENSG00000268707.1	RP11-247A12.7	6.85	2.2e-11	1.38e-08	0.34	0.3	Blood metabolite ratios;	chr9:129083737	chr9:129170434~129170940:+
LUAD	cis	rs11214589	0.774	rs7107223	ENSG00000270179.1	RP11-159N11.4	-6.85	2.2e-11	1.38e-08	-0.3	-0.3	Neuroticism;	chr11:113384852	chr11:113368478~113369117:+
LUAD	cis	rs62229266	0.693	rs2835264	ENSG00000214914.3	RPL23AP3	6.85	2.2e-11	1.38e-08	0.36	0.3	Mitral valve prolapse;	chr21:36063667	chr21:36016079~36016546:-
LUAD	cis	rs75920871	0.64	rs4938357	ENSG00000254851.1	RP11-109L13.1	-6.85	2.21e-11	1.38e-08	-0.51	-0.3	Subjective well-being;	chr11:117213324	chr11:117135528~117138582:+
LUAD	cis	rs10129255	0.518	rs7143784	ENSG00000211970.3	IGHV4-61	-6.85	2.21e-11	1.38e-08	-0.21	-0.3	Kawasaki disease;	chr14:106687277	chr14:106639119~106639657:-
LUAD	cis	rs9660180	0.967	rs6603803	ENSG00000268575.1	RP1-283E3.8	-6.85	2.21e-11	1.38e-08	-0.27	-0.3	Body mass index;	chr1:1881249	chr1:1702736~1737688:-
LUAD	cis	rs2019137	0.589	rs7560701	ENSG00000189223.12	PAX8-AS1	-6.85	2.21e-11	1.39e-08	-0.39	-0.3	Lymphocyte counts;	chr2:113269305	chr2:113211522~113276581:+
LUAD	cis	rs1061377	0.513	rs2566166	ENSG00000249207.1	RP11-360F5.1	6.85	2.21e-11	1.39e-08	0.36	0.3	Uric acid levels;	chr4:39148404	chr4:39112677~39126818:-
LUAD	cis	rs8059260	0.736	rs79361721	ENSG00000274038.1	RP11-66H6.4	-6.85	2.22e-11	1.39e-08	-0.61	-0.3	Alcohol consumption over the past year;	chr16:10968082	chr16:11056556~11057034:+
LUAD	cis	rs2153535	0.58	rs7747306	ENSG00000230939.1	RP11-314C16.1	6.85	2.22e-11	1.39e-08	0.35	0.3	Motion sickness;	chr6:8453430	chr6:8784178~8785445:+
LUAD	cis	rs9903692	0.954	rs8076380	ENSG00000278765.1	RP5-890E16.5	-6.85	2.22e-11	1.39e-08	-0.39	-0.3	Pulse pressure;	chr17:48113028	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.789	rs12601675	ENSG00000278765.1	RP5-890E16.5	-6.85	2.22e-11	1.39e-08	-0.39	-0.3	Pulse pressure;	chr17:48113566	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.754	rs12602948	ENSG00000278765.1	RP5-890E16.5	-6.85	2.22e-11	1.39e-08	-0.39	-0.3	Pulse pressure;	chr17:48113567	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.908	rs8066391	ENSG00000278765.1	RP5-890E16.5	-6.85	2.22e-11	1.39e-08	-0.39	-0.3	Pulse pressure;	chr17:48117934	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.908	rs11079809	ENSG00000278765.1	RP5-890E16.5	-6.85	2.22e-11	1.39e-08	-0.39	-0.3	Pulse pressure;	chr17:48120859	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.954	rs3744346	ENSG00000278765.1	RP5-890E16.5	-6.85	2.22e-11	1.39e-08	-0.39	-0.3	Pulse pressure;	chr17:48121514	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.908	rs7222136	ENSG00000278765.1	RP5-890E16.5	-6.85	2.22e-11	1.39e-08	-0.39	-0.3	Pulse pressure;	chr17:48122230	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.954	rs1010228	ENSG00000278765.1	RP5-890E16.5	-6.85	2.22e-11	1.39e-08	-0.39	-0.3	Pulse pressure;	chr17:48122986	chr17:48066704~48067293:-
LUAD	cis	rs6920372	0.708	rs13198852	ENSG00000260273.1	RP11-425D10.10	6.85	2.22e-11	1.39e-08	0.4	0.3	Height;	chr6:109747119	chr6:109382795~109383666:+
LUAD	cis	rs9903692	0.954	rs1860866	ENSG00000278765.1	RP5-890E16.5	-6.85	2.22e-11	1.39e-08	-0.39	-0.3	Pulse pressure;	chr17:48123669	chr17:48066704~48067293:-
LUAD	cis	rs867371	0.762	rs1846910	ENSG00000255769.6	GOLGA2P10	-6.85	2.23e-11	1.39e-08	-0.33	-0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82279439	chr15:82472993~82513950:-
LUAD	cis	rs783540	0.9	rs55924160	ENSG00000278603.1	RP13-608F4.5	-6.85	2.24e-11	1.4e-08	-0.34	-0.3	Schizophrenia;	chr15:82613445	chr15:82472203~82472426:+
LUAD	cis	rs748404	0.676	rs4401024	ENSG00000249839.1	AC011330.5	-6.85	2.24e-11	1.4e-08	-0.39	-0.3	Lung cancer;	chr15:43358137	chr15:43663654~43684339:-
LUAD	cis	rs9309473	1	rs7564890	ENSG00000163016.8	ALMS1P	6.85	2.25e-11	1.41e-08	0.37	0.3	Metabolite levels;	chr2:73414725	chr2:73644919~73685576:+
LUAD	cis	rs1062177	1	rs6890099	ENSG00000213433.5	RPLP1P6	-6.85	2.25e-11	1.41e-08	-0.39	-0.3	Preschool internalizing problems;	chr5:151772401	chr5:151765859~151766378:-
LUAD	cis	rs12439619	0.739	rs4778988	ENSG00000255769.6	GOLGA2P10	-6.85	2.25e-11	1.41e-08	-0.34	-0.3	Intelligence (multi-trait analysis);	chr15:82247996	chr15:82472993~82513950:-
LUAD	cis	rs2665103	0.632	rs3902959	ENSG00000255769.6	GOLGA2P10	-6.85	2.26e-11	1.41e-08	-0.31	-0.3	Intelligence (multi-trait analysis);	chr15:82252586	chr15:82472993~82513950:-
LUAD	cis	rs10899021	1	rs11236193	ENSG00000279353.1	RP11-864N7.4	6.85	2.26e-11	1.41e-08	0.56	0.3	Response to metformin (IC50);	chr11:74657262	chr11:74698231~74699658:-
LUAD	cis	rs9549367	0.789	rs3764125	ENSG00000269125.1	RP11-98F14.11	6.85	2.26e-11	1.41e-08	0.38	0.3	Platelet distribution width;	chr13:113243334	chr13:113165002~113165183:-
LUAD	cis	rs6844153	0.887	rs62302474	ENSG00000240005.4	RP11-293A21.1	-6.85	2.26e-11	1.42e-08	-0.5	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26909118	chr4:26859806~26860599:-
LUAD	cis	rs2337406	0.587	rs10129888	ENSG00000254174.1	IGHV1-12	6.85	2.27e-11	1.42e-08	0.26	0.3	Alzheimer's disease (late onset);	chr14:106647421	chr14:106122420~106122709:-
LUAD	cis	rs9595908	0.931	rs9595628	ENSG00000212293.1	SNORA16	6.85	2.27e-11	1.42e-08	0.34	0.3	Body mass index;	chr13:32491021	chr13:32420390~32420516:-
LUAD	cis	rs1062177	1	rs2964585	ENSG00000213433.5	RPLP1P6	-6.85	2.27e-11	1.42e-08	-0.39	-0.3	Preschool internalizing problems;	chr5:151762334	chr5:151765859~151766378:-
LUAD	cis	rs9903692	0.909	rs1468270	ENSG00000278765.1	RP5-890E16.5	6.85	2.27e-11	1.42e-08	0.4	0.3	Pulse pressure;	chr17:48047829	chr17:48066704~48067293:-
LUAD	cis	rs12458462	0.859	rs2242177	ENSG00000274828.1	RP11-567M16.6	6.85	2.27e-11	1.42e-08	0.31	0.3	Monocyte count;	chr18:79717379	chr18:79677287~79679358:-
LUAD	cis	rs8059260	0.736	rs74391397	ENSG00000274038.1	RP11-66H6.4	-6.85	2.27e-11	1.42e-08	-0.6	-0.3	Alcohol consumption over the past year;	chr16:10975570	chr16:11056556~11057034:+
LUAD	cis	rs71403859	0.502	rs17345863	ENSG00000260886.1	TAT-AS1	6.85	2.28e-11	1.43e-08	0.49	0.3	Post bronchodilator FEV1;	chr16:71489358	chr16:71565789~71578187:+
LUAD	cis	rs71403859	0.502	rs17280181	ENSG00000260886.1	TAT-AS1	6.85	2.28e-11	1.43e-08	0.49	0.3	Post bronchodilator FEV1;	chr16:71489611	chr16:71565789~71578187:+
LUAD	cis	rs9326248	0.53	rs2155583	ENSG00000280143.1	AP000892.6	6.85	2.29e-11	1.43e-08	0.45	0.3	Blood protein levels;	chr11:117044501	chr11:117204967~117210292:+
LUAD	cis	rs867371	0.502	rs2047679	ENSG00000255769.6	GOLGA2P10	-6.85	2.29e-11	1.43e-08	-0.31	-0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82239540	chr15:82472993~82513950:-
LUAD	cis	rs4141404	0.673	rs1968023	ENSG00000236132.1	CTA-440B3.1	6.85	2.3e-11	1.44e-08	0.41	0.3	Paclitaxel-induced neuropathy;	chr22:31546784	chr22:31816379~31817491:-
LUAD	cis	rs11214589	0.774	rs877137	ENSG00000270179.1	RP11-159N11.4	-6.85	2.31e-11	1.45e-08	-0.3	-0.3	Neuroticism;	chr11:113385608	chr11:113368478~113369117:+
LUAD	cis	rs7674212	0.556	rs34475639	ENSG00000246560.2	RP11-10L12.4	6.85	2.31e-11	1.45e-08	0.4	0.3	Type 2 diabetes;	chr4:103033694	chr4:102828055~102844075:+
LUAD	cis	rs10759883	0.539	rs10988755	ENSG00000175611.10	LINC00476	6.85	2.32e-11	1.45e-08	0.35	0.3	Nicotine dependence;	chr9:95944085	chr9:95759231~95875977:-
LUAD	cis	rs1609391	0.561	rs9817967	ENSG00000239213.4	NCK1-AS1	6.85	2.32e-11	1.45e-08	0.32	0.3	Neuroticism;	chr3:136910648	chr3:136841726~136862054:-
LUAD	cis	rs7567389	0.564	rs10209483	ENSG00000236682.1	AC068282.3	6.85	2.32e-11	1.45e-08	0.41	0.3	Self-rated health;	chr2:127401061	chr2:127389130~127400580:+
LUAD	cis	rs10759883	0.587	rs6478977	ENSG00000175611.10	LINC00476	-6.85	2.33e-11	1.45e-08	-0.35	-0.3	Nicotine dependence;	chr9:95797994	chr9:95759231~95875977:-
LUAD	cis	rs7626444	0.625	rs843529	ENSG00000272359.1	U4	6.85	2.33e-11	1.45e-08	0.33	0.3	Monocyte count;	chr3:196753724	chr3:196747192~196747324:-
LUAD	cis	rs3779195	0.929	rs4268041	ENSG00000272950.1	RP11-307C18.1	-6.85	2.33e-11	1.45e-08	-0.47	-0.3	Sex hormone-binding globulin levels;	chr7:98376226	chr7:98322853~98323430:+
LUAD	cis	rs7945705	0.869	rs11042154	ENSG00000254860.4	TMEM9B-AS1	6.85	2.33e-11	1.45e-08	0.34	0.3	Hemoglobin concentration;	chr11:9008153	chr11:8964675~8977527:+
LUAD	cis	rs748404	0.69	rs2467737	ENSG00000249839.1	AC011330.5	-6.85	2.33e-11	1.46e-08	-0.39	-0.3	Lung cancer;	chr15:43444990	chr15:43663654~43684339:-
LUAD	cis	rs853679	0.567	rs7740429	ENSG00000204709.4	LINC01556	6.85	2.33e-11	1.46e-08	0.4	0.3	Depression;	chr6:28431469	chr6:28943877~28944537:+
LUAD	cis	rs950169	0.922	rs4842941	ENSG00000259728.4	LINC00933	-6.85	2.33e-11	1.46e-08	-0.45	-0.3	Schizophrenia;	chr15:84162560	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.922	rs12911223	ENSG00000259728.4	LINC00933	-6.85	2.33e-11	1.46e-08	-0.45	-0.3	Schizophrenia;	chr15:84162919	chr15:84570649~84580175:+
LUAD	cis	rs2243480	1	rs431318	ENSG00000226824.5	RP4-756H11.3	-6.85	2.33e-11	1.46e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66046610	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs313803	ENSG00000226824.5	RP4-756H11.3	-6.85	2.33e-11	1.46e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66049744	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs313802	ENSG00000226824.5	RP4-756H11.3	-6.85	2.33e-11	1.46e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66051386	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.803	rs403089	ENSG00000226824.5	RP4-756H11.3	-6.85	2.33e-11	1.46e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66052736	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs458291	ENSG00000226824.5	RP4-756H11.3	-6.85	2.33e-11	1.46e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66055492	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs466983	ENSG00000226824.5	RP4-756H11.3	-6.85	2.33e-11	1.46e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66055509	chr7:66654538~66669855:+
LUAD	cis	rs2439831	0.681	rs1549525	ENSG00000205771.5	CATSPER2P1	-6.85	2.34e-11	1.46e-08	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43335657	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.681	rs7175434	ENSG00000205771.5	CATSPER2P1	-6.85	2.34e-11	1.46e-08	-0.5	-0.3	Lung cancer in ever smokers;	chr15:43336344	chr15:43726918~43747094:-
LUAD	cis	rs75422866	0.867	rs73113117	ENSG00000274902.1	RP1-197B17.4	6.84	2.34e-11	1.46e-08	0.67	0.3	Pneumonia;	chr12:47617299	chr12:47731908~47732351:+
LUAD	cis	rs11098499	0.863	rs7664986	ENSG00000248280.1	RP11-33B1.2	6.84	2.34e-11	1.46e-08	0.38	0.3	Corneal astigmatism;	chr4:119508797	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.818	rs10008791	ENSG00000248280.1	RP11-33B1.2	6.84	2.34e-11	1.46e-08	0.38	0.3	Corneal astigmatism;	chr4:119510314	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs11736416	ENSG00000248280.1	RP11-33B1.2	6.84	2.34e-11	1.46e-08	0.38	0.3	Corneal astigmatism;	chr4:119510506	chr4:119440561~119450157:-
LUAD	cis	rs3096299	0.967	rs2965932	ENSG00000274627.1	RP11-104N10.2	-6.84	2.34e-11	1.46e-08	-0.28	-0.3	Multiple myeloma (IgH translocation);	chr16:89410643	chr16:89516797~89522217:+
LUAD	cis	rs11846409	0.932	rs2583329	ENSG00000254174.1	IGHV1-12	-6.84	2.35e-11	1.47e-08	-0.26	-0.3	Rheumatic heart disease;	chr14:106632971	chr14:106122420~106122709:-
LUAD	cis	rs11846409	0.86	rs10150951	ENSG00000254174.1	IGHV1-12	6.84	2.35e-11	1.47e-08	0.26	0.3	Rheumatic heart disease;	chr14:106632988	chr14:106122420~106122709:-
LUAD	cis	rs6921919	0.848	rs6903823	ENSG00000204709.4	LINC01556	6.84	2.35e-11	1.47e-08	0.42	0.3	Autism spectrum disorder or schizophrenia;	chr6:28354519	chr6:28943877~28944537:+
LUAD	cis	rs1799949	1	rs3950989	ENSG00000267681.1	CTD-3199J23.6	-6.84	2.36e-11	1.47e-08	-0.34	-0.3	Menopause (age at onset);	chr17:43085936	chr17:43144956~43145255:+
LUAD	cis	rs7927592	0.913	rs4316515	ENSG00000212093.1	AP000807.1	-6.84	2.37e-11	1.48e-08	-0.33	-0.3	Total body bone mineral density;	chr11:68541372	chr11:68506083~68506166:-
LUAD	cis	rs950169	0.922	rs62029585	ENSG00000259728.4	LINC00933	6.84	2.37e-11	1.48e-08	0.45	0.3	Schizophrenia;	chr15:84397176	chr15:84570649~84580175:+
LUAD	cis	rs2153535	0.505	rs9405395	ENSG00000230939.1	RP11-314C16.1	-6.84	2.38e-11	1.48e-08	-0.36	-0.3	Motion sickness;	chr6:8468389	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.58	rs9392223	ENSG00000230939.1	RP11-314C16.1	-6.84	2.38e-11	1.48e-08	-0.36	-0.3	Motion sickness;	chr6:8468417	chr6:8784178~8785445:+
LUAD	cis	rs2919917	0.662	rs1483572	ENSG00000254352.1	RP11-578O24.2	6.84	2.38e-11	1.48e-08	0.35	0.3	Lymphocyte counts;	chr8:78723008	chr8:78723796~78724136:-
LUAD	cis	rs367615	0.842	rs2578484	ENSG00000249476.1	CTD-2587M2.1	-6.84	2.38e-11	1.48e-08	-0.37	-0.3	Colorectal cancer (SNP x SNP interaction);	chr5:109615107	chr5:109237120~109326369:-
LUAD	cis	rs11098499	0.73	rs12505735	ENSG00000248280.1	RP11-33B1.2	6.84	2.38e-11	1.49e-08	0.38	0.3	Corneal astigmatism;	chr4:119611801	chr4:119440561~119450157:-
LUAD	cis	rs881375	0.967	rs876445	ENSG00000226752.6	PSMD5-AS1	-6.84	2.39e-11	1.49e-08	-0.32	-0.3	Rheumatoid arthritis;	chr9:120914824	chr9:120824828~120854385:+
LUAD	cis	rs7626444	0.626	rs5021325	ENSG00000272359.1	U4	-6.84	2.4e-11	1.5e-08	-0.33	-0.3	Monocyte count;	chr3:196750758	chr3:196747192~196747324:-
LUAD	cis	rs150992	0.751	rs172874	ENSG00000248489.1	CTD-2007H13.3	6.84	2.4e-11	1.5e-08	0.33	0.3	Body mass index;	chr5:98969402	chr5:98929171~98995013:+
LUAD	cis	rs1062177	1	rs12518722	ENSG00000213433.5	RPLP1P6	-6.84	2.4e-11	1.5e-08	-0.4	-0.3	Preschool internalizing problems;	chr5:151851899	chr5:151765859~151766378:-
LUAD	cis	rs7646881	0.812	rs59192661	ENSG00000240207.5	RP11-379F4.4	-6.84	2.4e-11	1.5e-08	-0.39	-0.3	Tetralogy of Fallot;	chr3:158741238	chr3:158732263~158784070:+
LUAD	cis	rs1799949	0.965	rs8176193	ENSG00000267681.1	CTD-3199J23.6	-6.84	2.4e-11	1.5e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43079499	chr17:43144956~43145255:+
LUAD	cis	rs7811142	0.943	rs28578163	ENSG00000242294.5	STAG3L5P	6.84	2.42e-11	1.51e-08	0.25	0.3	Platelet count;	chr7:100447131	chr7:100336079~100351900:+
LUAD	cis	rs11123170	0.529	rs35606997	ENSG00000274877.1	RP11-65I12.1	-6.84	2.42e-11	1.51e-08	-0.44	-0.3	Renal function-related traits (BUN);	chr2:113215773	chr2:113237595~113240825:+
LUAD	cis	rs1609391	0.543	rs9828009	ENSG00000239213.4	NCK1-AS1	6.84	2.43e-11	1.51e-08	0.32	0.3	Neuroticism;	chr3:136912433	chr3:136841726~136862054:-
LUAD	cis	rs2439831	0.867	rs496584	ENSG00000205771.5	CATSPER2P1	-6.84	2.43e-11	1.52e-08	-0.52	-0.3	Lung cancer in ever smokers;	chr15:43539725	chr15:43726918~43747094:-
LUAD	cis	rs2243480	1	rs937108	ENSG00000273142.1	RP11-458F8.4	-6.84	2.43e-11	1.52e-08	-0.3	-0.3	Diabetic kidney disease;	chr7:65963465	chr7:66902857~66906297:+
LUAD	cis	rs17301013	0.507	rs6693198	ENSG00000227373.4	RP11-160H22.5	6.84	2.44e-11	1.52e-08	0.45	0.3	Systemic lupus erythematosus;	chr1:174304301	chr1:174115300~174160004:-
LUAD	cis	rs1799949	0.929	rs12937015	ENSG00000267681.1	CTD-3199J23.6	-6.84	2.44e-11	1.52e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43155456	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs4340367	ENSG00000267681.1	CTD-3199J23.6	-6.84	2.44e-11	1.52e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43155755	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs4792981	ENSG00000267681.1	CTD-3199J23.6	-6.84	2.44e-11	1.52e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43156257	chr17:43144956~43145255:+
LUAD	cis	rs1799949	0.965	rs35521261	ENSG00000267681.1	CTD-3199J23.6	-6.84	2.44e-11	1.52e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43161595	chr17:43144956~43145255:+
LUAD	cis	rs1799949	0.896	rs33933393	ENSG00000267681.1	CTD-3199J23.6	-6.84	2.44e-11	1.52e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43165415	chr17:43144956~43145255:+
LUAD	cis	rs2179367	0.959	rs4895789	ENSG00000231760.4	RP11-350J20.5	6.84	2.44e-11	1.52e-08	0.37	0.3	Dupuytren's disease;	chr6:149443518	chr6:149796151~149826294:-
LUAD	cis	rs12220777	0.585	rs11201146	ENSG00000230091.5	TMEM254-AS1	-6.84	2.45e-11	1.52e-08	-0.54	-0.3	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80007581	chr10:80046860~80078912:-
LUAD	cis	rs10129255	0.5	rs2105991	ENSG00000211970.3	IGHV4-61	-6.84	2.45e-11	1.53e-08	-0.21	-0.3	Kawasaki disease;	chr14:106682022	chr14:106639119~106639657:-
LUAD	cis	rs748404	0.69	rs1079309	ENSG00000249839.1	AC011330.5	-6.84	2.46e-11	1.53e-08	-0.39	-0.3	Lung cancer;	chr15:43490966	chr15:43663654~43684339:-
LUAD	cis	rs2015599	0.623	rs2288128	ENSG00000275476.1	RP11-996F15.4	6.84	2.46e-11	1.53e-08	0.32	0.3	Platelet count;Mean platelet volume;	chr12:29316054	chr12:29277397~29277882:-
LUAD	cis	rs2015599	0.584	rs2288129	ENSG00000275476.1	RP11-996F15.4	6.84	2.46e-11	1.53e-08	0.32	0.3	Platelet count;Mean platelet volume;	chr12:29316355	chr12:29277397~29277882:-
LUAD	cis	rs950169	0.881	rs34117475	ENSG00000259728.4	LINC00933	6.84	2.47e-11	1.54e-08	0.44	0.3	Schizophrenia;	chr15:84565212	chr15:84570649~84580175:+
LUAD	cis	rs75920871	0.589	rs56081989	ENSG00000254851.1	RP11-109L13.1	-6.84	2.47e-11	1.54e-08	-0.51	-0.3	Subjective well-being;	chr11:117214589	chr11:117135528~117138582:+
LUAD	cis	rs2439831	0.681	rs825740	ENSG00000205771.5	CATSPER2P1	-6.84	2.47e-11	1.54e-08	-0.52	-0.3	Lung cancer in ever smokers;	chr15:43300210	chr15:43726918~43747094:-
LUAD	cis	rs3762637	1	rs9836309	ENSG00000272758.4	RP11-299J3.8	-6.84	2.47e-11	1.54e-08	-0.47	-0.3	LDL cholesterol levels;	chr3:122416348	chr3:122416207~122443180:+
LUAD	cis	rs3762637	0.941	rs9873842	ENSG00000272758.4	RP11-299J3.8	-6.84	2.47e-11	1.54e-08	-0.47	-0.3	LDL cholesterol levels;	chr3:122416484	chr3:122416207~122443180:+
LUAD	cis	rs3762637	1	rs12633461	ENSG00000272758.4	RP11-299J3.8	-6.84	2.47e-11	1.54e-08	-0.47	-0.3	LDL cholesterol levels;	chr3:122417050	chr3:122416207~122443180:+
LUAD	cis	rs9309711	0.737	rs9284795	ENSG00000225234.1	TRAPPC12-AS1	-6.84	2.47e-11	1.54e-08	-0.37	-0.3	Neurofibrillary tangles;	chr2:3488294	chr2:3481242~3482409:-
LUAD	cis	rs10129255	0.518	rs2006284	ENSG00000224373.3	IGHV4-59	6.84	2.48e-11	1.55e-08	0.18	0.3	Kawasaki disease;	chr14:106676185	chr14:106627249~106627825:-
LUAD	cis	rs6860806	0.507	rs2631362	ENSG00000233006.5	AC034220.3	-6.84	2.48e-11	1.55e-08	-0.3	-0.3	Breast cancer;	chr5:132371601	chr5:132311285~132369916:-
LUAD	cis	rs720064	0.586	rs9958904	ENSG00000264745.1	TTC39C-AS1	-6.84	2.49e-11	1.55e-08	-0.32	-0.3	Strep throat;	chr18:23969940	chr18:23994213~24015339:-
LUAD	cis	rs75422866	0.51	rs73105829	ENSG00000280054.1	RP1-197B17.7	6.84	2.49e-11	1.55e-08	0.65	0.3	Pneumonia;	chr12:47734162	chr12:47728151~47730598:-
LUAD	cis	rs11089937	0.522	rs2005239	ENSG00000211639.2	IGLV4-60	6.84	2.49e-11	1.55e-08	0.31	0.3	Periodontitis (PAL4Q3);	chr22:22178083	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.616	rs743520	ENSG00000211639.2	IGLV4-60	6.84	2.49e-11	1.55e-08	0.31	0.3	Periodontitis (PAL4Q3);	chr22:22178249	chr22:22162199~22162681:+
LUAD	cis	rs67311347	1	rs11539046	ENSG00000223797.4	ENTPD3-AS1	-6.83	2.49e-11	1.55e-08	-0.32	-0.3	Renal cell carcinoma;	chr3:40462318	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs12633431	ENSG00000223797.4	ENTPD3-AS1	-6.83	2.49e-11	1.55e-08	-0.32	-0.3	Renal cell carcinoma;	chr3:40464249	chr3:40313802~40453329:-
LUAD	cis	rs67311347	0.956	rs6771527	ENSG00000223797.4	ENTPD3-AS1	-6.83	2.49e-11	1.55e-08	-0.32	-0.3	Renal cell carcinoma;	chr3:40465057	chr3:40313802~40453329:-
LUAD	cis	rs112721625	1	rs112721625	ENSG00000266992.1	DHX40P1	6.83	2.49e-11	1.55e-08	0.36	0.3	Monocyte count;	chr17:59850066	chr17:59976009~60002384:-
LUAD	cis	rs4964805	0.58	rs1866292	ENSG00000257681.1	RP11-341G23.4	6.83	2.5e-11	1.55e-08	0.36	0.3	Attention deficit hyperactivity disorder;	chr12:103780414	chr12:103746315~103768858:-
LUAD	cis	rs7626444	0.584	rs844542	ENSG00000272359.1	U4	-6.83	2.5e-11	1.55e-08	-0.33	-0.3	Monocyte count;	chr3:196752432	chr3:196747192~196747324:-
LUAD	cis	rs7626444	0.543	rs843528	ENSG00000272359.1	U4	-6.83	2.5e-11	1.55e-08	-0.33	-0.3	Monocyte count;	chr3:196753464	chr3:196747192~196747324:-
LUAD	cis	rs7246657	0.943	rs34603719	ENSG00000276846.1	CTD-3220F14.3	6.83	2.5e-11	1.55e-08	0.43	0.3	Coronary artery calcification;	chr19:37303626	chr19:37314868~37315620:-
LUAD	cis	rs748404	0.56	rs689797	ENSG00000249839.1	AC011330.5	-6.83	2.5e-11	1.55e-08	-0.39	-0.3	Lung cancer;	chr15:43534359	chr15:43663654~43684339:-
LUAD	cis	rs7208859	0.623	rs56018041	ENSG00000263531.1	RP13-753N3.1	6.83	2.5e-11	1.56e-08	0.59	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732967	chr17:30863921~30864940:-
LUAD	cis	rs17482078	0.918	rs13160231	ENSG00000248734.2	CTD-2260A17.1	6.83	2.5e-11	1.56e-08	0.38	0.3	Behcet's disease;Blood protein levels;	chr5:96818087	chr5:96784777~96785999:+
LUAD	cis	rs9487094	0.601	rs4945831	ENSG00000260273.1	RP11-425D10.10	6.83	2.5e-11	1.56e-08	0.37	0.3	Height;	chr6:109440234	chr6:109382795~109383666:+
LUAD	cis	rs11089937	0.522	rs5757259	ENSG00000211639.2	IGLV4-60	6.83	2.5e-11	1.56e-08	0.31	0.3	Periodontitis (PAL4Q3);	chr22:22179649	chr22:22162199~22162681:+
LUAD	cis	rs2280018	0.526	rs2941257	ENSG00000188599.16	NPIPP1	-6.83	2.51e-11	1.56e-08	-0.26	-0.3	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072588	chr16:15104312~15123498:-
LUAD	cis	rs113835537	0.529	rs11550299	ENSG00000255517.5	CTD-3074O7.5	-6.83	2.52e-11	1.56e-08	-0.35	-0.3	Airway imaging phenotypes;	chr11:66486614	chr11:66473490~66480233:-
LUAD	cis	rs113835537	0.529	rs4930379	ENSG00000255517.5	CTD-3074O7.5	-6.83	2.52e-11	1.56e-08	-0.35	-0.3	Airway imaging phenotypes;	chr11:66488203	chr11:66473490~66480233:-
LUAD	cis	rs113835537	0.529	rs4930183	ENSG00000255517.5	CTD-3074O7.5	-6.83	2.52e-11	1.56e-08	-0.35	-0.3	Airway imaging phenotypes;	chr11:66488261	chr11:66473490~66480233:-
LUAD	cis	rs17826219	0.706	rs57698184	ENSG00000263531.1	RP13-753N3.1	6.83	2.52e-11	1.56e-08	0.59	0.3	Body mass index;	chr17:30737900	chr17:30863921~30864940:-
LUAD	cis	rs17826219	0.706	rs9893922	ENSG00000263531.1	RP13-753N3.1	6.83	2.52e-11	1.56e-08	0.59	0.3	Body mass index;	chr17:30741407	chr17:30863921~30864940:-
LUAD	cis	rs17826219	0.5	rs9891256	ENSG00000263531.1	RP13-753N3.1	6.83	2.52e-11	1.56e-08	0.59	0.3	Body mass index;	chr17:30745674	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs7503335	ENSG00000263531.1	RP13-753N3.1	6.83	2.52e-11	1.56e-08	0.59	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30863921~30864940:-
LUAD	cis	rs1799949	0.931	rs34410138	ENSG00000267681.1	CTD-3199J23.6	-6.83	2.52e-11	1.56e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43127753	chr17:43144956~43145255:+
LUAD	cis	rs62229266	0.625	rs2051395	ENSG00000214914.3	RPL23AP3	-6.83	2.52e-11	1.56e-08	-0.35	-0.3	Mitral valve prolapse;	chr21:36058967	chr21:36016079~36016546:-
LUAD	cis	rs7811142	0.943	rs28660238	ENSG00000242294.5	STAG3L5P	6.83	2.52e-11	1.57e-08	0.25	0.3	Platelet count;	chr7:100425685	chr7:100336079~100351900:+
LUAD	cis	rs881375	0.967	rs2109895	ENSG00000226752.6	PSMD5-AS1	-6.83	2.52e-11	1.57e-08	-0.32	-0.3	Rheumatoid arthritis;	chr9:120915549	chr9:120824828~120854385:+
LUAD	cis	rs2243480	1	rs160633	ENSG00000226824.5	RP4-756H11.3	-6.83	2.53e-11	1.57e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66063241	chr7:66654538~66669855:+
LUAD	cis	rs10759883	0.587	rs603947	ENSG00000175611.10	LINC00476	6.83	2.53e-11	1.57e-08	0.34	0.3	Nicotine dependence;	chr9:95944647	chr9:95759231~95875977:-
LUAD	cis	rs9326248	0.539	rs10892058	ENSG00000280143.1	AP000892.6	6.83	2.53e-11	1.57e-08	0.34	0.3	Blood protein levels;	chr11:117005905	chr11:117204967~117210292:+
LUAD	cis	rs9326248	0.52	rs7127881	ENSG00000280143.1	AP000892.6	6.83	2.53e-11	1.57e-08	0.34	0.3	Blood protein levels;	chr11:117010082	chr11:117204967~117210292:+
LUAD	cis	rs10759883	0.58	rs10818738	ENSG00000175611.10	LINC00476	6.83	2.54e-11	1.58e-08	0.35	0.3	Nicotine dependence;	chr9:95846938	chr9:95759231~95875977:-
LUAD	cis	rs10759883	0.627	rs10818746	ENSG00000175611.10	LINC00476	6.83	2.54e-11	1.58e-08	0.35	0.3	Nicotine dependence;	chr9:95848031	chr9:95759231~95875977:-
LUAD	cis	rs10759883	0.627	rs10985769	ENSG00000175611.10	LINC00476	6.83	2.54e-11	1.58e-08	0.35	0.3	Nicotine dependence;	chr9:95848094	chr9:95759231~95875977:-
LUAD	cis	rs2439831	0.681	rs484029	ENSG00000205771.5	CATSPER2P1	-6.83	2.54e-11	1.58e-08	-0.51	-0.3	Lung cancer in ever smokers;	chr15:43327362	chr15:43726918~43747094:-
LUAD	cis	rs17023223	0.537	rs56708249	ENSG00000231365.4	RP11-418J17.1	-6.83	2.55e-11	1.58e-08	-0.38	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050582	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs17023174	ENSG00000231365.4	RP11-418J17.1	-6.83	2.55e-11	1.58e-08	-0.38	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050678	chr1:119140396~119275973:+
LUAD	cis	rs34779708	0.766	rs35308730	ENSG00000230534.5	RP11-297A16.2	6.83	2.55e-11	1.59e-08	0.36	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35260868	chr10:35098006~35127020:-
LUAD	cis	rs34779708	0.736	rs34195979	ENSG00000230534.5	RP11-297A16.2	6.83	2.55e-11	1.59e-08	0.36	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35260889	chr10:35098006~35127020:-
LUAD	cis	rs10463554	0.856	rs2432169	ENSG00000175749.11	EIF3KP1	6.83	2.56e-11	1.59e-08	0.4	0.3	Parkinson's disease;	chr5:103179056	chr5:103032376~103033031:+
LUAD	cis	rs2842992	0.692	rs9347342	ENSG00000237927.1	RP3-393E18.2	-6.83	2.56e-11	1.59e-08	-0.41	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159772097	chr6:159586955~159589169:-
LUAD	cis	rs6921919	0.697	rs12180820	ENSG00000216901.1	AL022393.7	-6.83	2.56e-11	1.59e-08	-0.35	-0.3	Autism spectrum disorder or schizophrenia;	chr6:28348701	chr6:28176188~28176674:+
LUAD	cis	rs9487094	0.666	rs2277113	ENSG00000260273.1	RP11-425D10.10	6.83	2.56e-11	1.59e-08	0.37	0.3	Height;	chr6:109454233	chr6:109382795~109383666:+
LUAD	cis	rs3931020	1	rs12410060	ENSG00000272864.1	RP11-17E13.2	-6.83	2.57e-11	1.59e-08	-0.38	-0.3	Resistin levels;	chr1:74780164	chr1:74698769~74699333:-
LUAD	cis	rs8177876	0.822	rs74437879	ENSG00000261838.4	RP11-303E16.6	6.83	2.57e-11	1.59e-08	0.65	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078987	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.822	rs76948085	ENSG00000261838.4	RP11-303E16.6	6.83	2.57e-11	1.59e-08	0.65	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079199	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.822	rs80315956	ENSG00000261838.4	RP11-303E16.6	6.83	2.57e-11	1.59e-08	0.65	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079254	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.642	rs16954572	ENSG00000261838.4	RP11-303E16.6	6.83	2.57e-11	1.59e-08	0.65	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079299	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.822	rs9929586	ENSG00000261838.4	RP11-303E16.6	6.83	2.57e-11	1.59e-08	0.65	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079416	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.822	rs9938965	ENSG00000261838.4	RP11-303E16.6	6.83	2.57e-11	1.59e-08	0.65	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079558	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.822	rs7204040	ENSG00000261838.4	RP11-303E16.6	6.83	2.57e-11	1.59e-08	0.65	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079888	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.731	rs7188508	ENSG00000261838.4	RP11-303E16.6	6.83	2.57e-11	1.59e-08	0.65	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080097	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.749	rs2549891	ENSG00000261838.4	RP11-303E16.6	-6.83	2.57e-11	1.59e-08	-0.56	-0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046761	chr16:81069854~81076598:+
LUAD	cis	rs17023223	0.537	rs2765542	ENSG00000231365.4	RP11-418J17.1	-6.83	2.57e-11	1.6e-08	-0.39	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119017703	chr1:119140396~119275973:+
LUAD	cis	rs2404602	0.598	rs71405204	ENSG00000259422.1	RP11-593F23.1	-6.83	2.58e-11	1.6e-08	-0.41	-0.3	Blood metabolite levels;	chr15:76342964	chr15:76174891~76181486:-
LUAD	cis	rs3762637	1	rs9858558	ENSG00000272758.4	RP11-299J3.8	-6.83	2.58e-11	1.6e-08	-0.47	-0.3	LDL cholesterol levels;	chr3:122420895	chr3:122416207~122443180:+
LUAD	cis	rs2283792	0.765	rs34550586	ENSG00000224086.5	LL22NC03-86G7.1	-6.83	2.58e-11	1.6e-08	-0.28	-0.3	Multiple sclerosis;	chr22:21791345	chr22:21938293~21977632:+
LUAD	cis	rs35955747	0.838	rs28716	ENSG00000236132.1	CTA-440B3.1	-6.83	2.59e-11	1.6e-08	-0.33	-0.3	Neutrophil count;Sum basophil neutrophil counts;	chr22:31334203	chr22:31816379~31817491:-
LUAD	cis	rs9903692	0.908	rs9807087	ENSG00000278765.1	RP5-890E16.5	-6.83	2.59e-11	1.61e-08	-0.39	-0.3	Pulse pressure;	chr17:48126776	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.954	rs7209730	ENSG00000278765.1	RP5-890E16.5	-6.83	2.59e-11	1.61e-08	-0.39	-0.3	Pulse pressure;	chr17:48130137	chr17:48066704~48067293:-
LUAD	cis	rs748404	0.631	rs28702649	ENSG00000249839.1	AC011330.5	-6.83	2.59e-11	1.61e-08	-0.39	-0.3	Lung cancer;	chr15:43356431	chr15:43663654~43684339:-
LUAD	cis	rs755249	0.958	rs17264866	ENSG00000228060.1	RP11-69E11.8	-6.83	2.59e-11	1.61e-08	-0.29	-0.3	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39557105	chr1:39565160~39573203:+
LUAD	cis	rs2243480	1	rs160646	ENSG00000226824.5	RP4-756H11.3	-6.83	2.6e-11	1.61e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66091293	chr7:66654538~66669855:+
LUAD	cis	rs6504950	0.888	rs244294	ENSG00000275710.1	RP11-257O5.4	6.83	2.6e-11	1.61e-08	0.37	0.3	Breast cancer;	chr17:55151182	chr17:54964474~54964679:+
LUAD	cis	rs6142102	0.961	rs4911390	ENSG00000276073.1	RP5-1125A11.7	-6.83	2.61e-11	1.62e-08	-0.31	-0.3	Skin pigmentation;	chr20:33977401	chr20:33985617~33988989:-
LUAD	cis	rs7829975	0.536	rs2980439	ENSG00000173295.6	FAM86B3P	6.83	2.61e-11	1.62e-08	0.32	0.3	Mood instability;	chr8:8237348	chr8:8228595~8244865:+
LUAD	cis	rs4591358	0.638	rs6732435	ENSG00000223466.1	AC064834.2	-6.83	2.62e-11	1.62e-08	-0.44	-0.3	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195541501	chr2:195533035~195538681:+
LUAD	cis	rs80285556	1	rs76812330	ENSG00000161643.11	SIGLEC16	6.83	2.63e-11	1.63e-08	0.62	0.3	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50028603	chr19:49969673~49975814:+
LUAD	cis	rs2842992	0.672	rs7738253	ENSG00000237927.1	RP3-393E18.2	-6.83	2.63e-11	1.63e-08	-0.42	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159772885	chr6:159586955~159589169:-
LUAD	cis	rs1799949	1	rs11655505	ENSG00000267681.1	CTD-3199J23.6	-6.83	2.63e-11	1.63e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43126360	chr17:43144956~43145255:+
LUAD	cis	rs1799949	0.965	rs4793204	ENSG00000267681.1	CTD-3199J23.6	-6.83	2.63e-11	1.63e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43127281	chr17:43144956~43145255:+
LUAD	cis	rs77204473	0.744	rs3781985	ENSG00000254851.1	RP11-109L13.1	6.83	2.63e-11	1.63e-08	0.66	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117194350	chr11:117135528~117138582:+
LUAD	cis	rs77204473	0.744	rs11606480	ENSG00000254851.1	RP11-109L13.1	6.83	2.63e-11	1.63e-08	0.66	0.3	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117194817	chr11:117135528~117138582:+
LUAD	cis	rs75422866	0.764	rs73104177	ENSG00000280054.1	RP1-197B17.7	6.83	2.63e-11	1.63e-08	0.75	0.3	Pneumonia;	chr12:47713550	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.764	rs73104184	ENSG00000280054.1	RP1-197B17.7	6.83	2.63e-11	1.63e-08	0.75	0.3	Pneumonia;	chr12:47715623	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.764	rs73104188	ENSG00000280054.1	RP1-197B17.7	6.83	2.63e-11	1.63e-08	0.75	0.3	Pneumonia;	chr12:47715885	chr12:47728151~47730598:-
LUAD	cis	rs9309711	0.922	rs7561600	ENSG00000225234.1	TRAPPC12-AS1	-6.83	2.64e-11	1.63e-08	-0.37	-0.3	Neurofibrillary tangles;	chr2:3482322	chr2:3481242~3482409:-
LUAD	cis	rs2243480	1	rs316304	ENSG00000226824.5	RP4-756H11.3	-6.83	2.64e-11	1.63e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66151907	chr7:66654538~66669855:+
LUAD	cis	rs853679	0.567	rs7774981	ENSG00000204709.4	LINC01556	6.83	2.64e-11	1.63e-08	0.39	0.3	Depression;	chr6:28379133	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.567	rs7754960	ENSG00000204709.4	LINC01556	6.83	2.64e-11	1.63e-08	0.39	0.3	Depression;	chr6:28379168	chr6:28943877~28944537:+
LUAD	cis	rs2243480	1	rs465359	ENSG00000226824.5	RP4-756H11.3	-6.83	2.64e-11	1.64e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66093177	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs462853	ENSG00000226824.5	RP4-756H11.3	-6.83	2.64e-11	1.64e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66093180	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs160644	ENSG00000226824.5	RP4-756H11.3	-6.83	2.64e-11	1.64e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66093199	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs160642	ENSG00000226824.5	RP4-756H11.3	-6.83	2.64e-11	1.64e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66093386	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.614	rs34032527	ENSG00000226824.5	RP4-756H11.3	-6.83	2.64e-11	1.64e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66100154	chr7:66654538~66669855:+
LUAD	cis	rs10129255	0.518	rs10150460	ENSG00000211970.3	IGHV4-61	6.83	2.64e-11	1.64e-08	0.21	0.3	Kawasaki disease;	chr14:106677179	chr14:106639119~106639657:-
LUAD	cis	rs2337406	0.587	rs10139664	ENSG00000254174.1	IGHV1-12	6.83	2.65e-11	1.64e-08	0.26	0.3	Alzheimer's disease (late onset);	chr14:106647254	chr14:106122420~106122709:-
LUAD	cis	rs7246657	0.943	rs8109038	ENSG00000276846.1	CTD-3220F14.3	-6.83	2.66e-11	1.64e-08	-0.4	-0.3	Coronary artery calcification;	chr19:37524807	chr19:37314868~37315620:-
LUAD	cis	rs1185460	0.967	rs1786690	ENSG00000271751.1	RP11-110I1.14	-6.83	2.66e-11	1.64e-08	-0.36	-0.3	Coronary artery disease;	chr11:119071357	chr11:119065263~119065677:-
LUAD	cis	rs881375	0.933	rs1548784	ENSG00000226752.6	PSMD5-AS1	-6.82	2.66e-11	1.64e-08	-0.32	-0.3	Rheumatoid arthritis;	chr9:120923002	chr9:120824828~120854385:+
LUAD	cis	rs72772090	0.539	rs11741100	ENSG00000248734.2	CTD-2260A17.1	-6.82	2.66e-11	1.64e-08	-0.46	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777541	chr5:96784777~96785999:+
LUAD	cis	rs2243480	1	rs316322	ENSG00000226824.5	RP4-756H11.3	-6.82	2.66e-11	1.65e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66146246	chr7:66654538~66669855:+
LUAD	cis	rs17826219	0.714	rs11650821	ENSG00000263531.1	RP13-753N3.1	6.82	2.67e-11	1.65e-08	0.6	0.3	Body mass index;	chr17:30641132	chr17:30863921~30864940:-
LUAD	cis	rs11089937	0.616	rs1076851	ENSG00000211639.2	IGLV4-60	6.82	2.68e-11	1.66e-08	0.31	0.3	Periodontitis (PAL4Q3);	chr22:22177442	chr22:22162199~22162681:+
LUAD	cis	rs6142102	1	rs6142102	ENSG00000276073.1	RP5-1125A11.7	-6.82	2.68e-11	1.66e-08	-0.31	-0.3	Skin pigmentation;	chr20:34116821	chr20:33985617~33988989:-
LUAD	cis	rs9549367	0.789	rs9549695	ENSG00000269125.1	RP11-98F14.11	6.82	2.68e-11	1.66e-08	0.37	0.3	Platelet distribution width;	chr13:113220500	chr13:113165002~113165183:-
LUAD	cis	rs1799949	1	rs2292595	ENSG00000267681.1	CTD-3199J23.6	-6.82	2.68e-11	1.66e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43138657	chr17:43144956~43145255:+
LUAD	cis	rs2243480	1	rs316332	ENSG00000226824.5	RP4-756H11.3	-6.82	2.69e-11	1.66e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66139312	chr7:66654538~66669855:+
LUAD	cis	rs6142102	0.962	rs2206448	ENSG00000276073.1	RP5-1125A11.7	-6.82	2.69e-11	1.67e-08	-0.3	-0.3	Skin pigmentation;	chr20:34121719	chr20:33985617~33988989:-
LUAD	cis	rs950880	0.553	rs2293225	ENSG00000234389.1	AC007278.3	-6.82	2.7e-11	1.67e-08	-0.33	-0.3	Serum protein levels (sST2);	chr2:102419429	chr2:102438713~102440475:+
LUAD	cis	rs7811142	0.943	rs67196635	ENSG00000242294.5	STAG3L5P	6.82	2.7e-11	1.67e-08	0.24	0.3	Platelet count;	chr7:100427941	chr7:100336079~100351900:+
LUAD	cis	rs7811142	1	rs6962151	ENSG00000242294.5	STAG3L5P	6.82	2.7e-11	1.67e-08	0.24	0.3	Platelet count;	chr7:100430861	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.943	rs67483801	ENSG00000242294.5	STAG3L5P	6.82	2.7e-11	1.67e-08	0.24	0.3	Platelet count;	chr7:100434135	chr7:100336079~100351900:+
LUAD	cis	rs7811142	1	rs11761784	ENSG00000242294.5	STAG3L5P	6.82	2.7e-11	1.67e-08	0.24	0.3	Platelet count;	chr7:100442347	chr7:100336079~100351900:+
LUAD	cis	rs7811142	1	rs112317829	ENSG00000242294.5	STAG3L5P	6.82	2.7e-11	1.67e-08	0.24	0.3	Platelet count;	chr7:100445550	chr7:100336079~100351900:+
LUAD	cis	rs7811142	1	rs67239991	ENSG00000242294.5	STAG3L5P	6.82	2.7e-11	1.67e-08	0.24	0.3	Platelet count;	chr7:100448881	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.943	rs111493473	ENSG00000242294.5	STAG3L5P	6.82	2.7e-11	1.67e-08	0.24	0.3	Platelet count;	chr7:100452119	chr7:100336079~100351900:+
LUAD	cis	rs2243480	1	rs778679	ENSG00000226824.5	RP4-756H11.3	-6.82	2.71e-11	1.68e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66375924	chr7:66654538~66669855:+
LUAD	cis	rs77683187	1	rs77683187	ENSG00000254851.1	RP11-109L13.1	6.82	2.71e-11	1.68e-08	0.71	0.3	Breast cancer;	chr11:117214494	chr11:117135528~117138582:+
LUAD	cis	rs11098499	0.863	rs3775841	ENSG00000248280.1	RP11-33B1.2	6.82	2.71e-11	1.68e-08	0.38	0.3	Corneal astigmatism;	chr4:119504622	chr4:119440561~119450157:-
LUAD	cis	rs7017914	0.935	rs6472551	ENSG00000223220.1	Y_RNA	6.82	2.71e-11	1.68e-08	0.33	0.3	Bone mineral density;	chr8:70869614	chr8:70780914~70781008:-
LUAD	cis	rs2243480	0.901	rs2456483	ENSG00000273142.1	RP11-458F8.4	-6.82	2.73e-11	1.69e-08	-0.31	-0.3	Diabetic kidney disease;	chr7:65996588	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs1701750	ENSG00000273142.1	RP11-458F8.4	-6.82	2.73e-11	1.69e-08	-0.31	-0.3	Diabetic kidney disease;	chr7:66002158	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs1701758	ENSG00000273142.1	RP11-458F8.4	-6.82	2.73e-11	1.69e-08	-0.31	-0.3	Diabetic kidney disease;	chr7:66005214	chr7:66902857~66906297:+
LUAD	cis	rs2243480	0.901	rs1701759	ENSG00000273142.1	RP11-458F8.4	-6.82	2.73e-11	1.69e-08	-0.31	-0.3	Diabetic kidney disease;	chr7:66005945	chr7:66902857~66906297:+
LUAD	cis	rs8005677	0.611	rs11624528	ENSG00000279656.1	RP11-298I3.6	6.82	2.73e-11	1.69e-08	0.37	0.3	Cognitive ability (multi-trait analysis);	chr14:22989947	chr14:23023083~23024217:-
LUAD	cis	rs35955747	0.934	rs4820045	ENSG00000236132.1	CTA-440B3.1	6.82	2.74e-11	1.69e-08	0.32	0.3	Neutrophil count;Sum basophil neutrophil counts;	chr22:31389983	chr22:31816379~31817491:-
LUAD	cis	rs9595908	0.827	rs9595885	ENSG00000212293.1	SNORA16	6.82	2.74e-11	1.69e-08	0.33	0.3	Body mass index;	chr13:32593913	chr13:32420390~32420516:-
LUAD	cis	rs8177876	0.642	rs56032321	ENSG00000261838.4	RP11-303E16.6	6.82	2.74e-11	1.69e-08	0.65	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81084301	chr16:81069854~81076598:+
LUAD	cis	rs2439831	0.867	rs2447211	ENSG00000205771.5	CATSPER2P1	-6.82	2.75e-11	1.69e-08	-0.53	-0.3	Lung cancer in ever smokers;	chr15:43644153	chr15:43726918~43747094:-
LUAD	cis	rs7208859	0.524	rs73988172	ENSG00000263531.1	RP13-753N3.1	6.82	2.76e-11	1.7e-08	0.58	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30863921~30864940:-
LUAD	cis	rs11098499	0.863	rs13134665	ENSG00000248280.1	RP11-33B1.2	6.82	2.76e-11	1.7e-08	0.38	0.3	Corneal astigmatism;	chr4:119505275	chr4:119440561~119450157:-
LUAD	cis	rs950169	0.845	rs4106951	ENSG00000259728.4	LINC00933	6.82	2.76e-11	1.7e-08	0.45	0.3	Schizophrenia;	chr15:84164642	chr15:84570649~84580175:+
LUAD	cis	rs57960857	1	rs57960857	ENSG00000251022.5	THAP9-AS1	6.82	2.76e-11	1.7e-08	0.31	0.3	Neutrophil percentage of white cells;	chr4:82886057	chr4:82893009~82900960:-
LUAD	cis	rs7044106	0.791	rs4617229	ENSG00000238181.2	AHCYP2	-6.82	2.76e-11	1.71e-08	-0.38	-0.3	Hip circumference adjusted for BMI;	chr9:120718418	chr9:120720673~120721972:+
LUAD	cis	rs11089937	0.616	rs12484472	ENSG00000211639.2	IGLV4-60	6.82	2.77e-11	1.71e-08	0.31	0.3	Periodontitis (PAL4Q3);	chr22:22180136	chr22:22162199~22162681:+
LUAD	cis	rs853679	0.567	rs16894091	ENSG00000204709.4	LINC01556	-6.82	2.78e-11	1.71e-08	-0.39	-0.3	Depression;	chr6:28422360	chr6:28943877~28944537:+
LUAD	cis	rs6142102	0.651	rs1015361	ENSG00000276073.1	RP5-1125A11.7	6.82	2.78e-11	1.71e-08	0.32	0.3	Skin pigmentation;	chr20:34150880	chr20:33985617~33988989:-
LUAD	cis	rs8091660	0.929	rs12606093	ENSG00000278983.1	RP11-426J5.3	6.82	2.78e-11	1.71e-08	0.34	0.3	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48550924	chr18:48564795~48568342:+
LUAD	cis	rs11098499	0.866	rs10518329	ENSG00000248280.1	RP11-33B1.2	6.82	2.78e-11	1.71e-08	0.35	0.3	Corneal astigmatism;	chr4:119480680	chr4:119440561~119450157:-
LUAD	cis	rs9309473	0.948	rs7607892	ENSG00000163016.8	ALMS1P	6.82	2.78e-11	1.72e-08	0.36	0.3	Metabolite levels;	chr2:73591580	chr2:73644919~73685576:+
LUAD	cis	rs2337406	0.866	rs988130	ENSG00000211974.3	IGHV2-70	-6.82	2.79e-11	1.72e-08	-0.38	-0.3	Alzheimer's disease (late onset);	chr14:106777154	chr14:106723574~106724093:-
LUAD	cis	rs3762637	0.941	rs75344200	ENSG00000272758.4	RP11-299J3.8	-6.82	2.79e-11	1.72e-08	-0.47	-0.3	LDL cholesterol levels;	chr3:122354574	chr3:122416207~122443180:+
LUAD	cis	rs2243480	1	rs313831	ENSG00000226824.5	RP4-756H11.3	-6.82	2.79e-11	1.72e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66086239	chr7:66654538~66669855:+
LUAD	cis	rs3096299	0.933	rs2965824	ENSG00000274627.1	RP11-104N10.2	6.82	2.8e-11	1.73e-08	0.28	0.3	Multiple myeloma (IgH translocation);	chr16:89388898	chr16:89516797~89522217:+
LUAD	cis	rs1799949	1	rs67060599	ENSG00000267681.1	CTD-3199J23.6	-6.82	2.8e-11	1.73e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43103085	chr17:43144956~43145255:+
LUAD	cis	rs8059260	0.604	rs9652600	ENSG00000274038.1	RP11-66H6.4	-6.82	2.81e-11	1.73e-08	-0.59	-0.3	Alcohol consumption over the past year;	chr16:11080157	chr16:11056556~11057034:+
LUAD	cis	rs7208859	0.623	rs28556733	ENSG00000263531.1	RP13-753N3.1	6.82	2.81e-11	1.73e-08	0.58	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30756927	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs28433704	ENSG00000263531.1	RP13-753N3.1	6.82	2.81e-11	1.73e-08	0.58	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757267	chr17:30863921~30864940:-
LUAD	cis	rs17826219	0.706	rs55764512	ENSG00000263531.1	RP13-753N3.1	6.82	2.81e-11	1.73e-08	0.58	0.3	Body mass index;	chr17:30758740	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs12103508	ENSG00000263531.1	RP13-753N3.1	6.82	2.81e-11	1.73e-08	0.58	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759763	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.524	rs11653605	ENSG00000263531.1	RP13-753N3.1	6.82	2.81e-11	1.73e-08	0.58	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30863921~30864940:-
LUAD	cis	rs17023223	0.537	rs12072768	ENSG00000231365.4	RP11-418J17.1	-6.82	2.82e-11	1.74e-08	-0.39	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119051295	chr1:119140396~119275973:+
LUAD	cis	rs1799949	1	rs8176269	ENSG00000267681.1	CTD-3199J23.6	-6.82	2.82e-11	1.74e-08	-0.34	-0.3	Menopause (age at onset);	chr17:43061609	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs8176265	ENSG00000267681.1	CTD-3199J23.6	-6.82	2.82e-11	1.74e-08	-0.34	-0.3	Menopause (age at onset);	chr17:43061979	chr17:43144956~43145255:+
LUAD	cis	rs62229266	0.659	rs2835258	ENSG00000214914.3	RPL23AP3	6.81	2.83e-11	1.74e-08	0.36	0.3	Mitral valve prolapse;	chr21:36052067	chr21:36016079~36016546:-
LUAD	cis	rs62229266	0.804	rs2255858	ENSG00000214914.3	RPL23AP3	6.81	2.83e-11	1.74e-08	0.36	0.3	Mitral valve prolapse;	chr21:36040454	chr21:36016079~36016546:-
LUAD	cis	rs7927592	0.913	rs7109294	ENSG00000212093.1	AP000807.1	6.81	2.83e-11	1.74e-08	0.33	0.3	Total body bone mineral density;	chr11:68564625	chr11:68506083~68506166:-
LUAD	cis	rs17826219	0.706	rs8075357	ENSG00000263531.1	RP13-753N3.1	6.81	2.83e-11	1.75e-08	0.59	0.3	Body mass index;	chr17:30730179	chr17:30863921~30864940:-
LUAD	cis	rs17826219	0.706	rs61643715	ENSG00000263531.1	RP13-753N3.1	6.81	2.83e-11	1.75e-08	0.59	0.3	Body mass index;	chr17:30730744	chr17:30863921~30864940:-
LUAD	cis	rs17826219	0.636	rs8080829	ENSG00000263531.1	RP13-753N3.1	6.81	2.83e-11	1.75e-08	0.59	0.3	Body mass index;	chr17:30731712	chr17:30863921~30864940:-
LUAD	cis	rs1185460	1	rs7127212	ENSG00000271751.1	RP11-110I1.14	6.81	2.83e-11	1.75e-08	0.37	0.3	Coronary artery disease;	chr11:119082492	chr11:119065263~119065677:-
LUAD	cis	rs11098499	0.863	rs10018280	ENSG00000248280.1	RP11-33B1.2	6.81	2.84e-11	1.75e-08	0.38	0.3	Corneal astigmatism;	chr4:119556984	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs6534141	ENSG00000248280.1	RP11-33B1.2	6.81	2.84e-11	1.75e-08	0.38	0.3	Corneal astigmatism;	chr4:119564068	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs3775858	ENSG00000248280.1	RP11-33B1.2	6.81	2.84e-11	1.75e-08	0.38	0.3	Corneal astigmatism;	chr4:119564873	chr4:119440561~119450157:-
LUAD	cis	rs9315786	0.924	rs7323436	ENSG00000176268.5	CYCSP34	-6.81	2.84e-11	1.75e-08	-0.3	-0.3	Neutrophil percentage of granulocytes;	chr13:40776843	chr13:40863599~40863902:-
LUAD	cis	rs2015599	0.623	rs3782510	ENSG00000257176.2	RP11-996F15.2	6.81	2.84e-11	1.75e-08	0.32	0.3	Platelet count;Mean platelet volume;	chr12:29301176	chr12:29280418~29317848:-
LUAD	cis	rs9525916	0.967	rs9533775	ENSG00000227258.4	SMIM2-AS1	-6.81	2.84e-11	1.75e-08	-0.35	-0.3	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);	chr13:44123820	chr13:44110451~44240517:+
LUAD	cis	rs10899021	0.915	rs11236198	ENSG00000279353.1	RP11-864N7.4	6.81	2.85e-11	1.75e-08	0.55	0.3	Response to metformin (IC50);	chr11:74661155	chr11:74698231~74699658:-
LUAD	cis	rs867371	0.722	rs8033050	ENSG00000255769.6	GOLGA2P10	-6.81	2.86e-11	1.76e-08	-0.33	-0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82269648	chr15:82472993~82513950:-
LUAD	cis	rs9487094	0.666	rs2211288	ENSG00000260273.1	RP11-425D10.10	6.81	2.86e-11	1.76e-08	0.37	0.3	Height;	chr6:109383848	chr6:109382795~109383666:+
LUAD	cis	rs875971	1	rs6961717	ENSG00000222364.1	RNU6-96P	6.81	2.87e-11	1.77e-08	0.33	0.3	Aortic root size;	chr7:66122550	chr7:66395191~66395286:+
LUAD	cis	rs2115630	0.691	rs61322921	ENSG00000225151.9	GOLGA2P7	6.81	2.87e-11	1.77e-08	0.34	0.3	P wave terminal force;	chr15:84620407	chr15:84199311~84230136:-
LUAD	cis	rs150992	0.655	rs327807	ENSG00000248489.1	CTD-2007H13.3	-6.81	2.87e-11	1.77e-08	-0.32	-0.3	Body mass index;	chr5:98942448	chr5:98929171~98995013:+
LUAD	cis	rs9309473	1	rs13398956	ENSG00000163016.8	ALMS1P	6.81	2.89e-11	1.78e-08	0.37	0.3	Metabolite levels;	chr2:73493131	chr2:73644919~73685576:+
LUAD	cis	rs9309473	1	rs56154726	ENSG00000163016.8	ALMS1P	6.81	2.89e-11	1.78e-08	0.37	0.3	Metabolite levels;	chr2:73494640	chr2:73644919~73685576:+
LUAD	cis	rs10759883	0.627	rs10985499	ENSG00000175611.10	LINC00476	6.81	2.89e-11	1.78e-08	0.35	0.3	Nicotine dependence;	chr9:95840724	chr9:95759231~95875977:-
LUAD	cis	rs1799949	1	rs12936816	ENSG00000267681.1	CTD-3199J23.6	-6.81	2.89e-11	1.78e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43149692	chr17:43144956~43145255:+
LUAD	cis	rs10759883	0.563	rs671058	ENSG00000175611.10	LINC00476	6.81	2.9e-11	1.78e-08	0.34	0.3	Nicotine dependence;	chr9:95931728	chr9:95759231~95875977:-
LUAD	cis	rs10200159	1	rs1045920	ENSG00000272606.1	RP11-554J4.1	6.81	2.9e-11	1.78e-08	0.52	0.3	Vitiligo;	chr2:55544033	chr2:55617909~55618373:+
LUAD	cis	rs6487679	1	rs6487679	ENSG00000111788.10	RP11-22B23.1	6.81	2.9e-11	1.79e-08	0.32	0.3	Non-alcoholic fatty liver disease histology (AST);	chr12:9218736	chr12:9277235~9313241:+
LUAD	cis	rs7208859	0.623	rs7219712	ENSG00000263531.1	RP13-753N3.1	6.81	2.9e-11	1.79e-08	0.59	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753552	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.573	rs8078656	ENSG00000263531.1	RP13-753N3.1	6.81	2.9e-11	1.79e-08	0.59	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753953	chr17:30863921~30864940:-
LUAD	cis	rs11098499	0.954	rs9993199	ENSG00000248280.1	RP11-33B1.2	-6.81	2.91e-11	1.79e-08	-0.38	-0.3	Corneal astigmatism;	chr4:119471718	chr4:119440561~119450157:-
LUAD	cis	rs875971	1	rs875971	ENSG00000222364.1	RNU6-96P	6.81	2.92e-11	1.79e-08	0.33	0.3	Aortic root size;	chr7:66152608	chr7:66395191~66395286:+
LUAD	cis	rs526231	0.578	rs6867392	ENSG00000175749.11	EIF3KP1	6.81	2.92e-11	1.8e-08	0.41	0.3	Primary biliary cholangitis;	chr5:102946183	chr5:103032376~103033031:+
LUAD	cis	rs7688540	0.8	rs28429717	ENSG00000275426.1	CH17-262A2.1	6.81	2.92e-11	1.8e-08	0.37	0.3	Facial morphology (factor 6, height of vermillion lower lip);	chr4:266384	chr4:149738~150317:+
LUAD	cis	rs7945705	0.818	rs2742537	ENSG00000254860.4	TMEM9B-AS1	6.81	2.92e-11	1.8e-08	0.33	0.3	Hemoglobin concentration;	chr11:8886842	chr11:8964675~8977527:+
LUAD	cis	rs2243480	1	rs1499614	ENSG00000226824.5	RP4-756H11.3	-6.81	2.92e-11	1.8e-08	-0.54	-0.3	Diabetic kidney disease;	chr7:66265811	chr7:66654538~66669855:+
LUAD	cis	rs1799949	0.896	rs8176086	ENSG00000267681.1	CTD-3199J23.6	-6.81	2.93e-11	1.8e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43122761	chr17:43144956~43145255:+
LUAD	cis	rs9368481	0.761	rs4358615	ENSG00000241549.7	GUSBP2	6.81	2.93e-11	1.8e-08	0.33	0.3	Autism spectrum disorder or schizophrenia;	chr6:27030788	chr6:26871484~26956554:-
LUAD	cis	rs2015599	0.623	rs12581107	ENSG00000257176.2	RP11-996F15.2	-6.81	2.93e-11	1.8e-08	-0.33	-0.3	Platelet count;Mean platelet volume;	chr12:29352358	chr12:29280418~29317848:-
LUAD	cis	rs2153535	0.58	rs2327064	ENSG00000230939.1	RP11-314C16.1	-6.81	2.93e-11	1.8e-08	-0.34	-0.3	Motion sickness;	chr6:8453819	chr6:8784178~8785445:+
LUAD	cis	rs10759883	0.627	rs12343734	ENSG00000175611.10	LINC00476	6.81	2.93e-11	1.8e-08	0.35	0.3	Nicotine dependence;	chr9:95847873	chr9:95759231~95875977:-
LUAD	cis	rs11098499	0.863	rs9997631	ENSG00000248280.1	RP11-33B1.2	6.81	2.94e-11	1.8e-08	0.38	0.3	Corneal astigmatism;	chr4:119548840	chr4:119440561~119450157:-
LUAD	cis	rs8059260	0.932	rs7186166	ENSG00000274038.1	RP11-66H6.4	-6.81	2.94e-11	1.81e-08	-0.42	-0.3	Alcohol consumption over the past year;	chr16:11011577	chr16:11056556~11057034:+
LUAD	cis	rs950169	1	rs11638297	ENSG00000225151.9	GOLGA2P7	-6.81	2.94e-11	1.81e-08	-0.42	-0.3	Schizophrenia;	chr15:84113665	chr15:84199311~84230136:-
LUAD	cis	rs2243480	1	rs316321	ENSG00000226824.5	RP4-756H11.3	-6.81	2.95e-11	1.81e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66146626	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs316318	ENSG00000226824.5	RP4-756H11.3	-6.81	2.95e-11	1.81e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66147917	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs316317	ENSG00000226824.5	RP4-756H11.3	-6.81	2.95e-11	1.81e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66148650	chr7:66654538~66669855:+
LUAD	cis	rs11690935	0.632	rs6433323	ENSG00000228389.1	AC068039.4	6.81	2.97e-11	1.82e-08	0.31	0.3	Schizophrenia;	chr2:172008155	chr2:171773482~171775844:+
LUAD	cis	rs9326248	0.515	rs2727793	ENSG00000280143.1	AP000892.6	6.81	2.97e-11	1.82e-08	0.35	0.3	Blood protein levels;	chr11:116812658	chr11:117204967~117210292:+
LUAD	cis	rs1799949	1	rs12952790	ENSG00000267681.1	CTD-3199J23.6	-6.81	2.98e-11	1.83e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43147590	chr17:43144956~43145255:+
LUAD	cis	rs75920871	0.589	rs67201490	ENSG00000254851.1	RP11-109L13.1	-6.81	2.98e-11	1.83e-08	-0.51	-0.3	Subjective well-being;	chr11:117212288	chr11:117135528~117138582:+
LUAD	cis	rs4722166	0.63	rs2091115	ENSG00000179428.2	AC073072.5	-6.81	2.99e-11	1.84e-08	-0.34	-0.3	Lung cancer;	chr7:22770547	chr7:22725395~22727620:-
LUAD	cis	rs67311347	0.956	rs7640228	ENSG00000223797.4	ENTPD3-AS1	-6.81	3.01e-11	1.85e-08	-0.32	-0.3	Renal cell carcinoma;	chr3:40474699	chr3:40313802~40453329:-
LUAD	cis	rs7246657	0.941	rs12982333	ENSG00000276846.1	CTD-3220F14.3	6.81	3.01e-11	1.85e-08	0.42	0.3	Coronary artery calcification;	chr19:37303822	chr19:37314868~37315620:-
LUAD	cis	rs2980439	0.818	rs2945249	ENSG00000253981.4	ALG1L13P	6.81	3.01e-11	1.85e-08	0.35	0.3	Neuroticism;	chr8:8237204	chr8:8236003~8244667:-
LUAD	cis	rs2455601	1	rs56336128	ENSG00000254860.4	TMEM9B-AS1	6.81	3.01e-11	1.85e-08	0.49	0.3	Schizophrenia;	chr11:8886752	chr11:8964675~8977527:+
LUAD	cis	rs9309473	0.898	rs10185080	ENSG00000163016.8	ALMS1P	6.81	3.01e-11	1.85e-08	0.37	0.3	Metabolite levels;	chr2:73570380	chr2:73644919~73685576:+
LUAD	cis	rs9309473	0.898	rs10197755	ENSG00000163016.8	ALMS1P	6.81	3.01e-11	1.85e-08	0.37	0.3	Metabolite levels;	chr2:73570496	chr2:73644919~73685576:+
LUAD	cis	rs150992	0.609	rs4703049	ENSG00000248489.1	CTD-2007H13.3	6.81	3.01e-11	1.85e-08	0.32	0.3	Body mass index;	chr5:99004679	chr5:98929171~98995013:+
LUAD	cis	rs34526934	0.566	rs9141	ENSG00000226363.3	HAGLROS	6.81	3.01e-11	1.85e-08	0.41	0.3	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176173242	chr2:176177717~176179008:+
LUAD	cis	rs1799949	1	rs2175957	ENSG00000267681.1	CTD-3199J23.6	-6.81	3.01e-11	1.85e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43134805	chr17:43144956~43145255:+
LUAD	cis	rs1799949	0.965	rs33988650	ENSG00000267681.1	CTD-3199J23.6	-6.81	3.01e-11	1.85e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43135863	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs11656097	ENSG00000267681.1	CTD-3199J23.6	-6.81	3.01e-11	1.85e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43138596	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs11658754	ENSG00000267681.1	CTD-3199J23.6	-6.81	3.01e-11	1.85e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43140722	chr17:43144956~43145255:+
LUAD	cis	rs2243480	1	rs464895	ENSG00000226824.5	RP4-756H11.3	-6.8	3.02e-11	1.85e-08	-0.56	-0.3	Diabetic kidney disease;	chr7:66062119	chr7:66654538~66669855:+
LUAD	cis	rs9326248	0.53	rs236918	ENSG00000280143.1	AP000892.6	-6.8	3.02e-11	1.85e-08	-0.49	-0.3	Blood protein levels;	chr11:117220893	chr11:117204967~117210292:+
LUAD	cis	rs875971	0.929	rs34406470	ENSG00000222364.1	RNU6-96P	-6.8	3.02e-11	1.86e-08	-0.33	-0.3	Aortic root size;	chr7:66464969	chr7:66395191~66395286:+
LUAD	cis	rs11098499	0.78	rs7692994	ENSG00000248280.1	RP11-33B1.2	6.8	3.03e-11	1.86e-08	0.36	0.3	Corneal astigmatism;	chr4:119506334	chr4:119440561~119450157:-
LUAD	cis	rs2439831	0.867	rs933941	ENSG00000205771.5	CATSPER2P1	-6.8	3.03e-11	1.86e-08	-0.52	-0.3	Lung cancer in ever smokers;	chr15:43340028	chr15:43726918~43747094:-
LUAD	cis	rs55665837	1	rs10047429	ENSG00000251991.1	RNU7-49P	6.8	3.03e-11	1.86e-08	0.33	0.3	Vitamin D levels;	chr11:14417486	chr11:14478892~14478953:+
LUAD	cis	rs17301013	0.507	rs10489255	ENSG00000227373.4	RP11-160H22.5	6.8	3.04e-11	1.86e-08	0.44	0.3	Systemic lupus erythematosus;	chr1:174341985	chr1:174115300~174160004:-
LUAD	cis	rs9487094	0.689	rs1074766	ENSG00000260273.1	RP11-425D10.10	6.8	3.04e-11	1.86e-08	0.36	0.3	Height;	chr6:109360263	chr6:109382795~109383666:+
LUAD	cis	rs1075265	0.548	rs2542575	ENSG00000233266.1	HMGB1P31	6.8	3.04e-11	1.87e-08	0.38	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53821221	chr2:54051334~54051760:+
LUAD	cis	rs1075265	0.568	rs2542577	ENSG00000233266.1	HMGB1P31	6.8	3.04e-11	1.87e-08	0.38	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53822111	chr2:54051334~54051760:+
LUAD	cis	rs2243480	1	rs313832	ENSG00000226824.5	RP4-756H11.3	-6.8	3.05e-11	1.87e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66085904	chr7:66654538~66669855:+
LUAD	cis	rs4938303	0.718	rs10892020	ENSG00000254851.1	RP11-109L13.1	-6.8	3.05e-11	1.87e-08	-0.41	-0.3	Triglycerides;	chr11:116718936	chr11:117135528~117138582:+
LUAD	cis	rs34779708	0.733	rs3936503	ENSG00000230534.5	RP11-297A16.2	-6.8	3.06e-11	1.87e-08	-0.35	-0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35260329	chr10:35098006~35127020:-
LUAD	cis	rs1609391	0.543	rs9859810	ENSG00000239213.4	NCK1-AS1	6.8	3.06e-11	1.87e-08	0.32	0.3	Neuroticism;	chr3:136911144	chr3:136841726~136862054:-
LUAD	cis	rs950880	0.71	rs12470867	ENSG00000234389.1	AC007278.3	-6.8	3.06e-11	1.88e-08	-0.31	-0.3	Serum protein levels (sST2);	chr2:102309906	chr2:102438713~102440475:+
LUAD	cis	rs7017914	0.967	rs2732091	ENSG00000223220.1	Y_RNA	-6.8	3.07e-11	1.88e-08	-0.32	-0.3	Bone mineral density;	chr8:71006188	chr8:70780914~70781008:-
LUAD	cis	rs853679	0.538	rs13199081	ENSG00000204709.4	LINC01556	6.8	3.07e-11	1.88e-08	0.39	0.3	Depression;	chr6:28364057	chr6:28943877~28944537:+
LUAD	cis	rs2179367	0.959	rs4897125	ENSG00000231760.4	RP11-350J20.5	6.8	3.07e-11	1.88e-08	0.37	0.3	Dupuytren's disease;	chr6:149445072	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.887	rs6570965	ENSG00000231760.4	RP11-350J20.5	6.8	3.07e-11	1.88e-08	0.37	0.3	Dupuytren's disease;	chr6:149396340	chr6:149796151~149826294:-
LUAD	cis	rs8059260	0.736	rs16957835	ENSG00000274038.1	RP11-66H6.4	-6.8	3.08e-11	1.89e-08	-0.52	-0.3	Alcohol consumption over the past year;	chr16:10958198	chr16:11056556~11057034:+
LUAD	cis	rs2015599	0.623	rs7358667	ENSG00000275476.1	RP11-996F15.4	6.8	3.08e-11	1.89e-08	0.32	0.3	Platelet count;Mean platelet volume;	chr12:29290236	chr12:29277397~29277882:-
LUAD	cis	rs9487094	0.644	rs910730	ENSG00000260273.1	RP11-425D10.10	6.8	3.09e-11	1.89e-08	0.37	0.3	Height;	chr6:109447092	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.67	rs1998811	ENSG00000260273.1	RP11-425D10.10	6.8	3.09e-11	1.89e-08	0.39	0.3	Height;	chr6:109490935	chr6:109382795~109383666:+
LUAD	cis	rs748404	0.66	rs2444251	ENSG00000249839.1	AC011330.5	-6.8	3.09e-11	1.89e-08	-0.39	-0.3	Lung cancer;	chr15:43496397	chr15:43663654~43684339:-
LUAD	cis	rs6822297	0.504	rs10010180	ENSG00000240005.4	RP11-293A21.1	6.8	3.1e-11	1.9e-08	0.37	0.3	Obesity-related traits;	chr4:26984359	chr4:26859806~26860599:-
LUAD	cis	rs2015599	0.623	rs1072724	ENSG00000275476.1	RP11-996F15.4	6.8	3.1e-11	1.9e-08	0.32	0.3	Platelet count;Mean platelet volume;	chr12:29289205	chr12:29277397~29277882:-
LUAD	cis	rs783540	0.935	rs2278355	ENSG00000278603.1	RP13-608F4.5	6.8	3.1e-11	1.9e-08	0.34	0.3	Schizophrenia;	chr15:82662403	chr15:82472203~82472426:+
LUAD	cis	rs67311347	1	rs11707278	ENSG00000223797.4	ENTPD3-AS1	6.8	3.11e-11	1.9e-08	0.31	0.3	Renal cell carcinoma;	chr3:40445584	chr3:40313802~40453329:-
LUAD	cis	rs1799949	0.93	rs3765640	ENSG00000267681.1	CTD-3199J23.6	-6.8	3.11e-11	1.9e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43124230	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs8176077	ENSG00000267681.1	CTD-3199J23.6	-6.8	3.11e-11	1.9e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43124331	chr17:43144956~43145255:+
LUAD	cis	rs1799949	0.965	rs12947782	ENSG00000267681.1	CTD-3199J23.6	-6.8	3.11e-11	1.9e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43127865	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs33945274	ENSG00000267681.1	CTD-3199J23.6	-6.8	3.11e-11	1.9e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43128056	chr17:43144956~43145255:+
LUAD	cis	rs1799949	0.965	rs33925201	ENSG00000267681.1	CTD-3199J23.6	-6.8	3.11e-11	1.9e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43128665	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs11653069	ENSG00000267681.1	CTD-3199J23.6	-6.8	3.11e-11	1.9e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43131360	chr17:43144956~43145255:+
LUAD	cis	rs7044106	0.791	rs735110	ENSG00000238181.2	AHCYP2	-6.8	3.11e-11	1.91e-08	-0.4	-0.3	Hip circumference adjusted for BMI;	chr9:120726662	chr9:120720673~120721972:+
LUAD	cis	rs7044106	0.791	rs10985001	ENSG00000238181.2	AHCYP2	-6.8	3.13e-11	1.91e-08	-0.39	-0.3	Hip circumference adjusted for BMI;	chr9:120721954	chr9:120720673~120721972:+
LUAD	cis	rs11676348	0.808	rs4674261	ENSG00000261338.2	RP11-378A13.1	-6.8	3.13e-11	1.92e-08	-0.31	-0.3	Ulcerative colitis;	chr2:218140286	chr2:218255319~218257366:+
LUAD	cis	rs321358	0.731	rs7927998	ENSG00000271584.1	RP11-89C3.4	6.8	3.13e-11	1.92e-08	0.46	0.3	Body mass index;	chr11:111153872	chr11:111091932~111097357:-
LUAD	cis	rs10028773	0.6	rs4001390	ENSG00000248280.1	RP11-33B1.2	6.8	3.13e-11	1.92e-08	0.34	0.3	Educational attainment;	chr4:119344628	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.691	rs2136911	ENSG00000248280.1	RP11-33B1.2	6.8	3.13e-11	1.92e-08	0.34	0.3	Corneal astigmatism;	chr4:119344704	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.554	rs2175381	ENSG00000248280.1	RP11-33B1.2	6.8	3.13e-11	1.92e-08	0.34	0.3	Corneal astigmatism;	chr4:119344812	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.599	rs3864142	ENSG00000248280.1	RP11-33B1.2	6.8	3.13e-11	1.92e-08	0.34	0.3	Corneal astigmatism;	chr4:119345036	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.605	rs6833140	ENSG00000248280.1	RP11-33B1.2	6.8	3.13e-11	1.92e-08	0.34	0.3	Corneal astigmatism;	chr4:119345667	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.779	rs6815934	ENSG00000248280.1	RP11-33B1.2	6.8	3.13e-11	1.92e-08	0.34	0.3	Corneal astigmatism;	chr4:119346155	chr4:119440561~119450157:-
LUAD	cis	rs881375	0.715	rs10985073	ENSG00000226752.6	PSMD5-AS1	-6.8	3.14e-11	1.92e-08	-0.31	-0.3	Rheumatoid arthritis;	chr9:120881577	chr9:120824828~120854385:+
LUAD	cis	rs2015599	0.54	rs12301475	ENSG00000275476.1	RP11-996F15.4	6.8	3.14e-11	1.92e-08	0.32	0.3	Platelet count;Mean platelet volume;	chr12:29253144	chr12:29277397~29277882:-
LUAD	cis	rs10759883	0.627	rs690633	ENSG00000175611.10	LINC00476	6.8	3.14e-11	1.92e-08	0.33	0.3	Nicotine dependence;	chr9:95867894	chr9:95759231~95875977:-
LUAD	cis	rs7674212	0.507	rs223317	ENSG00000246560.2	RP11-10L12.4	6.8	3.15e-11	1.93e-08	0.38	0.3	Type 2 diabetes;	chr4:102881667	chr4:102828055~102844075:+
LUAD	cis	rs172166	0.694	rs9295760	ENSG00000219392.1	RP1-265C24.5	-6.8	3.16e-11	1.93e-08	-0.39	-0.3	Cardiac Troponin-T levels;	chr6:28179607	chr6:28115628~28116551:+
LUAD	cis	rs7811142	1	rs28490152	ENSG00000242294.5	STAG3L5P	6.8	3.16e-11	1.93e-08	0.24	0.3	Platelet count;	chr7:100423359	chr7:100336079~100351900:+
LUAD	cis	rs2439831	0.681	rs478104	ENSG00000205771.5	CATSPER2P1	-6.8	3.16e-11	1.93e-08	-0.51	-0.3	Lung cancer in ever smokers;	chr15:43302702	chr15:43726918~43747094:-
LUAD	cis	rs765787	0.53	rs11070444	ENSG00000259520.4	CTD-2651B20.3	-6.8	3.17e-11	1.94e-08	-0.39	-0.3	Uric acid levels;	chr15:45220923	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs11070445	ENSG00000259520.4	CTD-2651B20.3	-6.8	3.17e-11	1.94e-08	-0.39	-0.3	Uric acid levels;	chr15:45220965	chr15:45251580~45279251:-
LUAD	cis	rs75422866	0.867	rs73113143	ENSG00000257433.4	RP1-197B17.3	6.8	3.17e-11	1.94e-08	0.64	0.3	Pneumonia;	chr12:47623060	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs75568526	ENSG00000257433.4	RP1-197B17.3	6.8	3.17e-11	1.94e-08	0.64	0.3	Pneumonia;	chr12:47649718	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs116302411	ENSG00000257433.4	RP1-197B17.3	6.8	3.17e-11	1.94e-08	0.64	0.3	Pneumonia;	chr12:47649788	chr12:47706085~47742294:+
LUAD	cis	rs67311347	0.955	rs6782746	ENSG00000223797.4	ENTPD3-AS1	-6.8	3.17e-11	1.94e-08	-0.32	-0.3	Renal cell carcinoma;	chr3:40469101	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs7628247	ENSG00000223797.4	ENTPD3-AS1	-6.8	3.17e-11	1.94e-08	-0.32	-0.3	Renal cell carcinoma;	chr3:40471191	chr3:40313802~40453329:-
LUAD	cis	rs6904897	0.563	rs6569976	ENSG00000232876.1	CTA-212D2.2	-6.8	3.19e-11	1.95e-08	-0.34	-0.3	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134903615	chr6:135055033~135060550:+
LUAD	cis	rs17301013	0.606	rs724889	ENSG00000227373.4	RP11-160H22.5	-6.8	3.2e-11	1.95e-08	-0.42	-0.3	Systemic lupus erythematosus;	chr1:174180326	chr1:174115300~174160004:-
LUAD	cis	rs1075232	0.826	rs12438813	ENSG00000270055.1	CTD-3092A11.2	-6.8	3.2e-11	1.95e-08	-0.6	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31413710	chr15:30487963~30490313:+
LUAD	cis	rs1075232	1	rs34959140	ENSG00000270055.1	CTD-3092A11.2	-6.8	3.2e-11	1.95e-08	-0.6	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31433020	chr15:30487963~30490313:+
LUAD	cis	rs7626444	0.563	rs2686598	ENSG00000272359.1	U4	-6.8	3.21e-11	1.96e-08	-0.33	-0.3	Monocyte count;	chr3:196760848	chr3:196747192~196747324:-
LUAD	cis	rs3779195	0.585	rs73709460	ENSG00000272950.1	RP11-307C18.1	-6.79	3.21e-11	1.96e-08	-0.53	-0.3	Sex hormone-binding globulin levels;	chr7:98265942	chr7:98322853~98323430:+
LUAD	cis	rs2015599	0.623	rs7313552	ENSG00000275476.1	RP11-996F15.4	6.79	3.22e-11	1.96e-08	0.32	0.3	Platelet count;Mean platelet volume;	chr12:29277302	chr12:29277397~29277882:-
LUAD	cis	rs2015599	0.584	rs7299283	ENSG00000275476.1	RP11-996F15.4	6.79	3.22e-11	1.96e-08	0.32	0.3	Platelet count;Mean platelet volume;	chr12:29277442	chr12:29277397~29277882:-
LUAD	cis	rs2243480	0.901	rs2949697	ENSG00000273142.1	RP11-458F8.4	-6.79	3.22e-11	1.97e-08	-0.31	-0.3	Diabetic kidney disease;	chr7:65999249	chr7:66902857~66906297:+
LUAD	cis	rs673078	0.66	rs61946063	ENSG00000275759.1	RP11-131L12.3	-6.79	3.23e-11	1.97e-08	-0.38	-0.3	Glucose homeostasis traits;	chr12:118294448	chr12:118428281~118428870:+
LUAD	cis	rs2243480	0.711	rs1626926	ENSG00000273142.1	RP11-458F8.4	-6.79	3.23e-11	1.97e-08	-0.3	-0.3	Diabetic kidney disease;	chr7:65970805	chr7:66902857~66906297:+
LUAD	cis	rs2283792	0.776	rs9610458	ENSG00000224086.5	LL22NC03-86G7.1	-6.79	3.23e-11	1.97e-08	-0.28	-0.3	Multiple sclerosis;	chr22:21851064	chr22:21938293~21977632:+
LUAD	cis	rs4964805	0.594	rs10861095	ENSG00000257681.1	RP11-341G23.4	6.79	3.24e-11	1.98e-08	0.34	0.3	Attention deficit hyperactivity disorder;	chr12:103771609	chr12:103746315~103768858:-
LUAD	cis	rs4964805	0.505	rs4981032	ENSG00000257681.1	RP11-341G23.4	6.79	3.24e-11	1.98e-08	0.34	0.3	Attention deficit hyperactivity disorder;	chr12:103772086	chr12:103746315~103768858:-
LUAD	cis	rs10754283	0.871	rs72712569	ENSG00000231613.1	RP5-943J3.1	-6.79	3.25e-11	1.98e-08	-0.31	-0.3	Amyotrophic lateral sclerosis (sporadic);	chr1:89660098	chr1:89788914~89790492:+
LUAD	cis	rs7849270	0.879	rs3124495	ENSG00000268707.1	RP11-247A12.7	6.79	3.26e-11	1.99e-08	0.36	0.3	Blood metabolite ratios;	chr9:129093731	chr9:129170434~129170940:+
LUAD	cis	rs2243480	1	rs10807702	ENSG00000232546.1	RP11-458F8.1	-6.79	3.26e-11	1.99e-08	-0.38	-0.3	Diabetic kidney disease;	chr7:66302856	chr7:66848496~66858136:+
LUAD	cis	rs62229266	0.804	rs998383	ENSG00000214914.3	RPL23AP3	6.79	3.27e-11	1.99e-08	0.36	0.3	Mitral valve prolapse;	chr21:36073441	chr21:36016079~36016546:-
LUAD	cis	rs17826219	0.636	rs7221463	ENSG00000263531.1	RP13-753N3.1	6.79	3.27e-11	1.99e-08	0.59	0.3	Body mass index;	chr17:30753533	chr17:30863921~30864940:-
LUAD	cis	rs1799949	0.93	rs33968979	ENSG00000267681.1	CTD-3199J23.6	-6.79	3.27e-11	2e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43145975	chr17:43144956~43145255:+
LUAD	cis	rs1799949	0.93	rs66499067	ENSG00000267681.1	CTD-3199J23.6	-6.79	3.28e-11	2e-08	-0.35	-0.3	Menopause (age at onset);	chr17:43096467	chr17:43144956~43145255:+
LUAD	cis	rs2243480	0.901	rs778687	ENSG00000226824.5	RP4-756H11.3	-6.79	3.28e-11	2e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66370832	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs778704	ENSG00000226824.5	RP4-756H11.3	-6.79	3.28e-11	2e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66398480	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.901	rs778693	ENSG00000226824.5	RP4-756H11.3	-6.79	3.28e-11	2e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66407358	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs778691	ENSG00000226824.5	RP4-756H11.3	-6.79	3.28e-11	2e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66408105	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs13235972	ENSG00000226824.5	RP4-756H11.3	-6.79	3.28e-11	2e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66418618	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs34192067	ENSG00000226824.5	RP4-756H11.3	-6.79	3.28e-11	2e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66422670	chr7:66654538~66669855:+
LUAD	cis	rs10200159	0.793	rs2867964	ENSG00000272606.1	RP11-554J4.1	6.79	3.28e-11	2e-08	0.48	0.3	Vitiligo;	chr2:55698289	chr2:55617909~55618373:+
LUAD	cis	rs10200159	0.793	rs11691977	ENSG00000272606.1	RP11-554J4.1	6.79	3.28e-11	2e-08	0.48	0.3	Vitiligo;	chr2:55698753	chr2:55617909~55618373:+
LUAD	cis	rs10200159	0.793	rs12623625	ENSG00000272606.1	RP11-554J4.1	6.79	3.28e-11	2e-08	0.48	0.3	Vitiligo;	chr2:55699981	chr2:55617909~55618373:+
LUAD	cis	rs72772090	0.539	rs17405676	ENSG00000248734.2	CTD-2260A17.1	-6.79	3.28e-11	2e-08	-0.45	-0.3	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96846912	chr5:96784777~96785999:+
LUAD	cis	rs7849270	0.798	rs7865337	ENSG00000268707.1	RP11-247A12.7	-6.79	3.28e-11	2e-08	-0.35	-0.3	Blood metabolite ratios;	chr9:129091799	chr9:129170434~129170940:+
LUAD	cis	rs6904897	0.538	rs4639353	ENSG00000232876.1	CTA-212D2.2	6.79	3.28e-11	2e-08	0.35	0.3	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134903190	chr6:135055033~135060550:+
LUAD	cis	rs9549367	0.789	rs6577031	ENSG00000269125.1	RP11-98F14.11	6.79	3.28e-11	2e-08	0.35	0.3	Platelet distribution width;	chr13:113223868	chr13:113165002~113165183:-
LUAD	cis	rs35955747	0.838	rs5997887	ENSG00000236132.1	CTA-440B3.1	6.79	3.29e-11	2e-08	0.33	0.3	Neutrophil count;Sum basophil neutrophil counts;	chr22:31147211	chr22:31816379~31817491:-
LUAD	cis	rs1823913	0.599	rs17346475	ENSG00000280083.1	RP11-317J9.1	6.79	3.29e-11	2.01e-08	0.35	0.3	Obesity-related traits;	chr2:191288488	chr2:191154118~191156070:-
LUAD	cis	rs11098499	0.863	rs3775843	ENSG00000248280.1	RP11-33B1.2	6.79	3.29e-11	2.01e-08	0.38	0.3	Corneal astigmatism;	chr4:119506689	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs3775844	ENSG00000248280.1	RP11-33B1.2	6.79	3.29e-11	2.01e-08	0.38	0.3	Corneal astigmatism;	chr4:119506878	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.661	rs10015965	ENSG00000248280.1	RP11-33B1.2	6.79	3.31e-11	2.01e-08	0.34	0.3	Corneal astigmatism;	chr4:119347082	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.535	rs10005542	ENSG00000248280.1	RP11-33B1.2	6.79	3.31e-11	2.01e-08	0.34	0.3	Corneal astigmatism;	chr4:119347147	chr4:119440561~119450157:-
LUAD	cis	rs6142102	0.607	rs6088408	ENSG00000276073.1	RP5-1125A11.7	6.79	3.31e-11	2.02e-08	0.34	0.3	Skin pigmentation;	chr20:34146800	chr20:33985617~33988989:-
LUAD	cis	rs3779195	0.524	rs76976120	ENSG00000272950.1	RP11-307C18.1	-6.79	3.31e-11	2.02e-08	-0.53	-0.3	Sex hormone-binding globulin levels;	chr7:98264860	chr7:98322853~98323430:+
LUAD	cis	rs3779195	0.585	rs56694862	ENSG00000272950.1	RP11-307C18.1	-6.79	3.31e-11	2.02e-08	-0.53	-0.3	Sex hormone-binding globulin levels;	chr7:98267808	chr7:98322853~98323430:+
LUAD	cis	rs9584850	0.874	rs9168	ENSG00000231194.1	FARP1-AS1	6.79	3.31e-11	2.02e-08	0.36	0.3	Neuroticism;	chr13:98449329	chr13:98435405~98435840:-
LUAD	cis	rs150992	0.587	rs4703340	ENSG00000248489.1	CTD-2007H13.3	-6.79	3.32e-11	2.02e-08	-0.32	-0.3	Body mass index;	chr5:99009083	chr5:98929171~98995013:+
LUAD	cis	rs67311347	1	rs9882171	ENSG00000223797.4	ENTPD3-AS1	6.79	3.32e-11	2.02e-08	0.32	0.3	Renal cell carcinoma;	chr3:40477330	chr3:40313802~40453329:-
LUAD	cis	rs6142102	0.812	rs725478	ENSG00000276073.1	RP5-1125A11.7	6.79	3.32e-11	2.02e-08	0.31	0.3	Skin pigmentation;	chr20:33930548	chr20:33985617~33988989:-
LUAD	cis	rs34779708	0.677	rs112355105	ENSG00000230534.5	RP11-297A16.2	6.79	3.32e-11	2.03e-08	0.35	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35261366	chr10:35098006~35127020:-
LUAD	cis	rs4713118	0.513	rs149950	ENSG00000219392.1	RP1-265C24.5	-6.79	3.33e-11	2.03e-08	-0.38	-0.3	Parkinson's disease;	chr6:28065261	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.513	rs149951	ENSG00000219392.1	RP1-265C24.5	-6.79	3.33e-11	2.03e-08	-0.38	-0.3	Parkinson's disease;	chr6:28065309	chr6:28115628~28116551:+
LUAD	cis	rs9318086	0.712	rs9318099	ENSG00000205861.10	C1QTNF9B-AS1	6.79	3.33e-11	2.03e-08	0.34	0.3	Myopia (pathological);	chr13:23868323	chr13:23888889~23897263:+
LUAD	cis	rs73219805	0.759	rs17055186	ENSG00000228451.3	SDAD1P1	-6.79	3.34e-11	2.03e-08	-0.53	-0.3	Schizophrenia;	chr8:26403394	chr8:26379259~26382953:-
LUAD	cis	rs67311347	1	rs7625736	ENSG00000223797.4	ENTPD3-AS1	-6.79	3.35e-11	2.04e-08	-0.31	-0.3	Renal cell carcinoma;	chr3:40399854	chr3:40313802~40453329:-
LUAD	cis	rs1609391	0.561	rs6439675	ENSG00000239213.4	NCK1-AS1	6.79	3.35e-11	2.04e-08	0.32	0.3	Neuroticism;	chr3:136906594	chr3:136841726~136862054:-
LUAD	cis	rs55665837	1	rs10047457	ENSG00000251991.1	RNU7-49P	6.79	3.36e-11	2.04e-08	0.33	0.3	Vitamin D levels;	chr11:14417913	chr11:14478892~14478953:+
LUAD	cis	rs12908161	1	rs12905057	ENSG00000259728.4	LINC00933	6.79	3.36e-11	2.04e-08	0.44	0.3	Schizophrenia;	chr15:84667534	chr15:84570649~84580175:+
LUAD	cis	rs7246657	0.943	rs12981532	ENSG00000276846.1	CTD-3220F14.3	6.79	3.36e-11	2.04e-08	0.41	0.3	Coronary artery calcification;	chr19:37398378	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs7246993	ENSG00000276846.1	CTD-3220F14.3	6.79	3.36e-11	2.04e-08	0.41	0.3	Coronary artery calcification;	chr19:37399252	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs10413602	ENSG00000276846.1	CTD-3220F14.3	6.79	3.36e-11	2.04e-08	0.41	0.3	Coronary artery calcification;	chr19:37400590	chr19:37314868~37315620:-
LUAD	cis	rs950880	0.677	rs56224165	ENSG00000234389.1	AC007278.3	-6.79	3.36e-11	2.04e-08	-0.31	-0.3	Serum protein levels (sST2);	chr2:102308763	chr2:102438713~102440475:+
LUAD	cis	rs9309473	0.948	rs13391552	ENSG00000163016.8	ALMS1P	6.79	3.37e-11	2.05e-08	0.36	0.3	Metabolite levels;	chr2:73591809	chr2:73644919~73685576:+
LUAD	cis	rs1799949	1	rs3092988	ENSG00000267681.1	CTD-3199J23.6	-6.79	3.37e-11	2.05e-08	-0.34	-0.3	Menopause (age at onset);	chr17:43049685	chr17:43144956~43145255:+
LUAD	cis	rs6921919	0.697	rs12180820	ENSG00000204709.4	LINC01556	-6.79	3.37e-11	2.05e-08	-0.37	-0.3	Autism spectrum disorder or schizophrenia;	chr6:28348701	chr6:28943877~28944537:+
LUAD	cis	rs237743	1	rs9753608	ENSG00000222365.1	SNORD12B	-6.79	3.38e-11	2.06e-08	-0.35	-0.3	Height;	chr20:49220669	chr20:49280319~49280409:+
LUAD	cis	rs9309473	1	rs7572722	ENSG00000163016.8	ALMS1P	6.79	3.38e-11	2.06e-08	0.37	0.3	Metabolite levels;	chr2:73497548	chr2:73644919~73685576:+
LUAD	cis	rs1185460	1	rs15818	ENSG00000271751.1	RP11-110I1.14	-6.79	3.39e-11	2.06e-08	-0.37	-0.3	Coronary artery disease;	chr11:119081463	chr11:119065263~119065677:-
LUAD	cis	rs7826238	0.72	rs12546760	ENSG00000253981.4	ALG1L13P	-6.79	3.39e-11	2.06e-08	-0.34	-0.3	Systolic blood pressure;	chr8:8517326	chr8:8236003~8244667:-
LUAD	cis	rs11846409	0.86	rs17112419	ENSG00000254174.1	IGHV1-12	6.79	3.39e-11	2.06e-08	0.25	0.3	Rheumatic heart disease;	chr14:106633260	chr14:106122420~106122709:-
LUAD	cis	rs7646881	0.812	rs6788069	ENSG00000240207.5	RP11-379F4.4	6.79	3.4e-11	2.07e-08	0.35	0.3	Tetralogy of Fallot;	chr3:158741670	chr3:158732263~158784070:+
LUAD	cis	rs1874124	0.577	rs2807853	ENSG00000238078.1	LINC01352	6.79	3.4e-11	2.07e-08	0.42	0.3	Cholesterol, total;	chr1:220851011	chr1:220829255~220832429:+
LUAD	cis	rs1874124	0.504	rs2491257	ENSG00000238078.1	LINC01352	6.79	3.4e-11	2.07e-08	0.42	0.3	Cholesterol, total;	chr1:220855900	chr1:220829255~220832429:+
LUAD	cis	rs944289	0.932	rs1169151	ENSG00000257826.1	RP11-116N8.4	6.79	3.4e-11	2.07e-08	0.31	0.3	Thyroid cancer;	chr14:36171395	chr14:36061026~36067190:-
LUAD	cis	rs7927592	0.913	rs67005337	ENSG00000212093.1	AP000807.1	6.79	3.4e-11	2.07e-08	0.33	0.3	Total body bone mineral density;	chr11:68540290	chr11:68506083~68506166:-
LUAD	cis	rs17301013	0.606	rs7547766	ENSG00000227373.4	RP11-160H22.5	6.79	3.4e-11	2.07e-08	0.42	0.3	Systemic lupus erythematosus;	chr1:174180977	chr1:174115300~174160004:-
LUAD	cis	rs7927592	0.913	rs11228276	ENSG00000212093.1	AP000807.1	6.79	3.4e-11	2.07e-08	0.33	0.3	Total body bone mineral density;	chr11:68540057	chr11:68506083~68506166:-
LUAD	cis	rs9903692	0.865	rs7220520	ENSG00000278765.1	RP5-890E16.5	6.79	3.41e-11	2.07e-08	0.38	0.3	Pulse pressure;	chr17:48090580	chr17:48066704~48067293:-
LUAD	cis	rs11123170	0.529	rs1015755	ENSG00000274877.1	RP11-65I12.1	-6.79	3.41e-11	2.07e-08	-0.46	-0.3	Renal function-related traits (BUN);	chr2:113210730	chr2:113237595~113240825:+
LUAD	cis	rs8177876	0.822	rs8056972	ENSG00000261838.4	RP11-303E16.6	6.79	3.41e-11	2.07e-08	0.64	0.3	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078817	chr16:81069854~81076598:+
LUAD	cis	rs950169	0.922	rs4842940	ENSG00000259728.4	LINC00933	-6.79	3.41e-11	2.08e-08	-0.44	-0.3	Schizophrenia;	chr15:84162473	chr15:84570649~84580175:+
LUAD	cis	rs7945705	0.87	rs4929922	ENSG00000254860.4	TMEM9B-AS1	6.79	3.41e-11	2.08e-08	0.35	0.3	Hemoglobin concentration;	chr11:8954229	chr11:8964675~8977527:+
LUAD	cis	rs1609391	0.543	rs1347209	ENSG00000239213.4	NCK1-AS1	6.78	3.44e-11	2.09e-08	0.32	0.3	Neuroticism;	chr3:136907855	chr3:136841726~136862054:-
LUAD	cis	rs4713118	0.662	rs9380046	ENSG00000219392.1	RP1-265C24.5	-6.78	3.45e-11	2.1e-08	-0.41	-0.3	Parkinson's disease;	chr6:28062721	chr6:28115628~28116551:+
LUAD	cis	rs2439831	1	rs2601014	ENSG00000205771.5	CATSPER2P1	-6.78	3.45e-11	2.1e-08	-0.53	-0.3	Lung cancer in ever smokers;	chr15:43463815	chr15:43726918~43747094:-
LUAD	cis	rs867371	0.502	rs1846908	ENSG00000255769.6	GOLGA2P10	-6.78	3.45e-11	2.1e-08	-0.31	-0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82230185	chr15:82472993~82513950:-
LUAD	cis	rs2665103	0.655	rs1501367	ENSG00000255769.6	GOLGA2P10	-6.78	3.45e-11	2.1e-08	-0.31	-0.3	Intelligence (multi-trait analysis);	chr15:82230475	chr15:82472993~82513950:-
LUAD	cis	rs1823913	0.599	rs12988037	ENSG00000227542.1	AC092614.2	6.78	3.46e-11	2.1e-08	0.36	0.3	Obesity-related traits;	chr2:191306419	chr2:191229165~191246172:-
LUAD	cis	rs5769707	0.521	rs74351010	ENSG00000188511.11	C22orf34	-6.78	3.47e-11	2.11e-08	-0.44	-0.3	Monocyte percentage of white cells;Monocyte count;	chr22:49643172	chr22:49414524~49657542:-
LUAD	cis	rs9903692	0.779	rs2285863	ENSG00000278765.1	RP5-890E16.5	6.78	3.48e-11	2.11e-08	0.39	0.3	Pulse pressure;	chr17:48048616	chr17:48066704~48067293:-
LUAD	cis	rs12594515	0.6	rs12903858	ENSG00000273972.1	CTD-2306A12.1	-6.78	3.48e-11	2.11e-08	-0.31	-0.3	Weight;Waist circumference;	chr15:45679968	chr15:45702640~45703183:+
LUAD	cis	rs2980439	0.818	rs2948294	ENSG00000173295.6	FAM86B3P	6.78	3.48e-11	2.11e-08	0.32	0.3	Neuroticism;	chr8:8237439	chr8:8228595~8244865:+
LUAD	cis	rs9903692	0.954	rs9747001	ENSG00000278765.1	RP5-890E16.5	6.78	3.48e-11	2.11e-08	0.38	0.3	Pulse pressure;	chr17:48077307	chr17:48066704~48067293:-
LUAD	cis	rs8081395	0.707	rs1024637	ENSG00000266992.1	DHX40P1	-6.78	3.49e-11	2.12e-08	-0.35	-0.3	White blood cell count;	chr17:59961532	chr17:59976009~60002384:-
LUAD	cis	rs11098499	0.954	rs12505469	ENSG00000248280.1	RP11-33B1.2	6.78	3.5e-11	2.12e-08	0.38	0.3	Corneal astigmatism;	chr4:119328430	chr4:119440561~119450157:-
LUAD	cis	rs113835537	0.559	rs74933537	ENSG00000255517.5	CTD-3074O7.5	-6.78	3.5e-11	2.13e-08	-0.35	-0.3	Airway imaging phenotypes;	chr11:66507487	chr11:66473490~66480233:-
LUAD	cis	rs35955747	0.869	rs7286648	ENSG00000236132.1	CTA-440B3.1	-6.78	3.51e-11	2.13e-08	-0.32	-0.3	Neutrophil count;Sum basophil neutrophil counts;	chr22:31143628	chr22:31816379~31817491:-
LUAD	cis	rs4722166	0.564	rs1800797	ENSG00000179428.2	AC073072.5	-6.78	3.51e-11	2.13e-08	-0.36	-0.3	Lung cancer;	chr7:22726602	chr7:22725395~22727620:-
LUAD	cis	rs8062405	0.573	rs7140	ENSG00000259982.1	CDC37P1	-6.78	3.51e-11	2.13e-08	-0.4	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28984436	chr16:28700294~28701540:-
LUAD	cis	rs1609391	0.543	rs6800690	ENSG00000239213.4	NCK1-AS1	6.78	3.52e-11	2.14e-08	0.32	0.3	Neuroticism;	chr3:136904184	chr3:136841726~136862054:-
LUAD	cis	rs1609391	0.543	rs7651085	ENSG00000239213.4	NCK1-AS1	6.78	3.52e-11	2.14e-08	0.32	0.3	Neuroticism;	chr3:136906497	chr3:136841726~136862054:-
LUAD	cis	rs1609391	0.543	rs6761993	ENSG00000239213.4	NCK1-AS1	6.78	3.52e-11	2.14e-08	0.32	0.3	Neuroticism;	chr3:136907060	chr3:136841726~136862054:-
LUAD	cis	rs9487094	0.689	rs9487103	ENSG00000260273.1	RP11-425D10.10	6.78	3.53e-11	2.14e-08	0.37	0.3	Height;	chr6:109430292	chr6:109382795~109383666:+
LUAD	cis	rs7626444	0.625	rs2931210	ENSG00000272359.1	U4	-6.78	3.55e-11	2.15e-08	-0.33	-0.3	Monocyte count;	chr3:196749805	chr3:196747192~196747324:-
LUAD	cis	rs881375	0.678	rs7021049	ENSG00000226752.6	PSMD5-AS1	-6.78	3.56e-11	2.16e-08	-0.31	-0.3	Rheumatoid arthritis;	chr9:120921704	chr9:120824828~120854385:+
LUAD	cis	rs11089937	0.616	rs11705598	ENSG00000211639.2	IGLV4-60	6.78	3.56e-11	2.16e-08	0.3	0.3	Periodontitis (PAL4Q3);	chr22:22178837	chr22:22162199~22162681:+
LUAD	cis	rs7615952	0.932	rs11922218	ENSG00000171084.14	FAM86JP	6.78	3.58e-11	2.17e-08	0.43	0.3	Blood pressure (smoking interaction);	chr3:125912446	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.866	rs11922276	ENSG00000171084.14	FAM86JP	6.78	3.58e-11	2.17e-08	0.43	0.3	Blood pressure (smoking interaction);	chr3:125912483	chr3:125916620~125930024:+
LUAD	cis	rs10740039	0.729	rs7091383	ENSG00000254271.1	RP11-131N11.4	6.78	3.58e-11	2.17e-08	0.34	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60676419	chr10:60734342~60741828:+
LUAD	cis	rs10759883	0.603	rs10760262	ENSG00000175611.10	LINC00476	6.78	3.58e-11	2.17e-08	0.35	0.3	Nicotine dependence;	chr9:95850234	chr9:95759231~95875977:-
LUAD	cis	rs11098499	0.954	rs6820115	ENSG00000248280.1	RP11-33B1.2	6.78	3.59e-11	2.17e-08	0.35	0.3	Corneal astigmatism;	chr4:119477027	chr4:119440561~119450157:-
LUAD	cis	rs2243480	1	rs2243480	ENSG00000273142.1	RP11-458F8.4	-6.78	3.59e-11	2.18e-08	-0.31	-0.3	Diabetic kidney disease;	chr7:66134209	chr7:66902857~66906297:+
LUAD	cis	rs2734839	0.537	rs10891549	ENSG00000270179.1	RP11-159N11.4	-6.78	3.6e-11	2.18e-08	-0.3	-0.3	Information processing speed;	chr11:113407725	chr11:113368478~113369117:+
LUAD	cis	rs113835537	0.529	rs17147644	ENSG00000255517.5	CTD-3074O7.5	-6.78	3.6e-11	2.18e-08	-0.35	-0.3	Airway imaging phenotypes;	chr11:66489189	chr11:66473490~66480233:-
LUAD	cis	rs12439619	1	rs12439619	ENSG00000255769.6	GOLGA2P10	-6.78	3.61e-11	2.19e-08	-0.33	-0.3	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82472993~82513950:-
LUAD	cis	rs9309473	1	rs6705489	ENSG00000163016.8	ALMS1P	6.78	3.61e-11	2.19e-08	0.37	0.3	Metabolite levels;	chr2:73421683	chr2:73644919~73685576:+
LUAD	cis	rs1345301	1	rs12475055	ENSG00000234389.1	AC007278.3	6.78	3.61e-11	2.19e-08	0.27	0.3	Waist circumference;	chr2:102262431	chr2:102438713~102440475:+
LUAD	cis	rs881375	1	rs1953126	ENSG00000226752.6	PSMD5-AS1	-6.78	3.61e-11	2.19e-08	-0.32	-0.3	Rheumatoid arthritis;	chr9:120878222	chr9:120824828~120854385:+
LUAD	cis	rs950169	0.922	rs4586394	ENSG00000259728.4	LINC00933	-6.78	3.61e-11	2.19e-08	-0.44	-0.3	Schizophrenia;	chr15:84153633	chr15:84570649~84580175:+
LUAD	cis	rs2243480	1	rs383402	ENSG00000273142.1	RP11-458F8.4	6.78	3.61e-11	2.19e-08	0.3	0.3	Diabetic kidney disease;	chr7:66121666	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs422164	ENSG00000226824.5	RP4-756H11.3	-6.78	3.61e-11	2.19e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66121618	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.908	rs1532573	ENSG00000226824.5	RP4-756H11.3	6.78	3.61e-11	2.19e-08	0.55	0.3	Diabetic kidney disease;	chr7:66333815	chr7:66654538~66669855:+
LUAD	cis	rs67180937	0.645	rs1909197	ENSG00000272750.1	RP11-378J18.8	-6.78	3.62e-11	2.19e-08	-0.34	-0.3	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222645879	chr1:222658867~222661512:-
LUAD	cis	rs11098499	0.908	rs1002152	ENSG00000248280.1	RP11-33B1.2	6.78	3.63e-11	2.2e-08	0.38	0.3	Corneal astigmatism;	chr4:119352232	chr4:119440561~119450157:-
LUAD	cis	rs1499614	0.803	rs1796229	ENSG00000226824.5	RP4-756H11.3	-6.78	3.63e-11	2.2e-08	-0.56	-0.3	Gout;	chr7:66654674	chr7:66654538~66669855:+
LUAD	cis	rs1499614	0.901	rs3936	ENSG00000226824.5	RP4-756H11.3	-6.78	3.63e-11	2.2e-08	-0.56	-0.3	Gout;	chr7:66661502	chr7:66654538~66669855:+
LUAD	cis	rs2286503	0.78	rs2240727	ENSG00000228649.7	AC005682.5	6.78	3.63e-11	2.2e-08	0.38	0.3	Fibrinogen;	chr7:22812893	chr7:22854178~22861579:+
LUAD	cis	rs9326248	0.53	rs6589575	ENSG00000280143.1	AP000892.6	6.78	3.63e-11	2.2e-08	0.47	0.3	Blood protein levels;	chr11:116862594	chr11:117204967~117210292:+
LUAD	cis	rs9326248	0.53	rs718847	ENSG00000280143.1	AP000892.6	6.78	3.63e-11	2.2e-08	0.47	0.3	Blood protein levels;	chr11:116863430	chr11:117204967~117210292:+
LUAD	cis	rs7208859	0.623	rs7217984	ENSG00000263531.1	RP13-753N3.1	6.78	3.64e-11	2.2e-08	0.58	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765748	chr17:30863921~30864940:-
LUAD	cis	rs6597981	0.604	rs7945912	ENSG00000255142.1	AP006621.6	6.78	3.64e-11	2.2e-08	0.24	0.3	Breast cancer;	chr11:750849	chr11:781645~782105:+
LUAD	cis	rs1062177	1	rs17804178	ENSG00000213433.5	RPLP1P6	-6.78	3.64e-11	2.2e-08	-0.39	-0.3	Preschool internalizing problems;	chr5:151818168	chr5:151765859~151766378:-
LUAD	cis	rs7829975	0.688	rs7827182	ENSG00000253893.2	FAM85B	-6.78	3.64e-11	2.21e-08	-0.37	-0.3	Mood instability;	chr8:8522961	chr8:8167819~8226614:-
LUAD	cis	rs3096299	0.967	rs2965827	ENSG00000274627.1	RP11-104N10.2	-6.78	3.64e-11	2.21e-08	-0.27	-0.3	Multiple myeloma (IgH translocation);	chr16:89390942	chr16:89516797~89522217:+
LUAD	cis	rs1799949	1	rs8176133	ENSG00000267681.1	CTD-3199J23.6	-6.77	3.65e-11	2.21e-08	-0.34	-0.3	Menopause (age at onset);	chr17:43105441	chr17:43144956~43145255:+
LUAD	cis	rs8100891	0.537	rs4805754	ENSG00000267213.4	AC007773.2	-6.77	3.66e-11	2.21e-08	-0.46	-0.3	Neuroticism;	chr19:32346260	chr19:32390050~32405560:-
LUAD	cis	rs2439831	0.867	rs2927072	ENSG00000205771.5	CATSPER2P1	-6.77	3.67e-11	2.22e-08	-0.53	-0.3	Lung cancer in ever smokers;	chr15:43630200	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.867	rs2920781	ENSG00000205771.5	CATSPER2P1	-6.77	3.67e-11	2.22e-08	-0.53	-0.3	Lung cancer in ever smokers;	chr15:43632484	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.764	rs2447193	ENSG00000205771.5	CATSPER2P1	-6.77	3.67e-11	2.22e-08	-0.53	-0.3	Lung cancer in ever smokers;	chr15:43637535	chr15:43726918~43747094:-
LUAD	cis	rs2842992	0.715	rs2277073	ENSG00000237927.1	RP3-393E18.2	-6.77	3.69e-11	2.23e-08	-0.42	-0.3	Age-related macular degeneration (geographic atrophy);	chr6:159761717	chr6:159586955~159589169:-
LUAD	cis	rs853679	0.567	rs13209596	ENSG00000204709.4	LINC01556	6.77	3.7e-11	2.24e-08	0.39	0.3	Depression;	chr6:28428413	chr6:28943877~28944537:+
LUAD	cis	rs1062177	0.901	rs1549622	ENSG00000213433.5	RPLP1P6	-6.77	3.7e-11	2.24e-08	-0.4	-0.3	Preschool internalizing problems;	chr5:151886488	chr5:151765859~151766378:-
LUAD	cis	rs150992	0.79	rs40075	ENSG00000248489.1	CTD-2007H13.3	6.77	3.7e-11	2.24e-08	0.32	0.3	Body mass index;	chr5:98976743	chr5:98929171~98995013:+
LUAD	cis	rs867371	0.502	rs28610286	ENSG00000255769.6	GOLGA2P10	-6.77	3.7e-11	2.24e-08	-0.31	-0.3	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82233314	chr15:82472993~82513950:-
LUAD	cis	rs2243480	1	rs10807702	ENSG00000226824.5	RP4-756H11.3	-6.77	3.7e-11	2.24e-08	-0.54	-0.3	Diabetic kidney disease;	chr7:66302856	chr7:66654538~66669855:+
LUAD	cis	rs9903692	0.954	rs12941295	ENSG00000278765.1	RP5-890E16.5	-6.77	3.7e-11	2.24e-08	-0.38	-0.3	Pulse pressure;	chr17:48110825	chr17:48066704~48067293:-
LUAD	cis	rs73219805	0.554	rs3808566	ENSG00000228451.3	SDAD1P1	6.77	3.7e-11	2.24e-08	0.49	0.3	Schizophrenia;	chr8:26365942	chr8:26379259~26382953:-
LUAD	cis	rs7674212	0.507	rs6843738	ENSG00000246560.2	RP11-10L12.4	6.77	3.7e-11	2.24e-08	0.4	0.3	Type 2 diabetes;	chr4:103014844	chr4:102828055~102844075:+
LUAD	cis	rs2243480	1	rs316313	ENSG00000226824.5	RP4-756H11.3	-6.77	3.71e-11	2.24e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66128561	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs316312	ENSG00000226824.5	RP4-756H11.3	-6.77	3.71e-11	2.24e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66131504	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs419603	ENSG00000226824.5	RP4-756H11.3	-6.77	3.71e-11	2.24e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66132354	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs387676	ENSG00000226824.5	RP4-756H11.3	-6.77	3.71e-11	2.24e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66133233	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs13310597	ENSG00000226824.5	RP4-756H11.3	-6.77	3.71e-11	2.24e-08	-0.55	-0.3	Diabetic kidney disease;	chr7:66133553	chr7:66654538~66669855:+
LUAD	cis	rs7208859	0.623	rs9898084	ENSG00000263531.1	RP13-753N3.1	6.77	3.71e-11	2.24e-08	0.58	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30863921~30864940:-
LUAD	cis	rs34779708	0.733	rs3853672	ENSG00000230534.5	RP11-297A16.2	6.77	3.71e-11	2.24e-08	0.36	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35260678	chr10:35098006~35127020:-
LUAD	cis	rs7044106	0.791	rs747819	ENSG00000238181.2	AHCYP2	-6.77	3.71e-11	2.24e-08	-0.39	-0.3	Hip circumference adjusted for BMI;	chr9:120726163	chr9:120720673~120721972:+
LUAD	cis	rs2015599	0.623	rs3782505	ENSG00000275476.1	RP11-996F15.4	6.77	3.72e-11	2.25e-08	0.32	0.3	Platelet count;Mean platelet volume;	chr12:29292236	chr12:29277397~29277882:-
LUAD	cis	rs11098499	0.738	rs72918577	ENSG00000248280.1	RP11-33B1.2	6.77	3.73e-11	2.25e-08	0.38	0.3	Corneal astigmatism;	chr4:119405546	chr4:119440561~119450157:-
LUAD	cis	rs7044106	0.791	rs10985000	ENSG00000238181.2	AHCYP2	-6.77	3.73e-11	2.25e-08	-0.39	-0.3	Hip circumference adjusted for BMI;	chr9:120721837	chr9:120720673~120721972:+
LUAD	cis	rs7923609	0.841	rs10761786	ENSG00000232075.1	MRPL35P2	-6.77	3.73e-11	2.25e-08	-0.35	-0.3	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63576447	chr10:63634317~63634827:-
LUAD	cis	rs2243480	1	rs35542501	ENSG00000273142.1	RP11-458F8.4	-6.77	3.73e-11	2.25e-08	-0.3	-0.3	Diabetic kidney disease;	chr7:65966228	chr7:66902857~66906297:+
LUAD	cis	rs2243480	0.708	rs781141	ENSG00000273142.1	RP11-458F8.4	-6.77	3.73e-11	2.25e-08	-0.3	-0.3	Diabetic kidney disease;	chr7:65973566	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs781142	ENSG00000273142.1	RP11-458F8.4	-6.77	3.73e-11	2.25e-08	-0.3	-0.3	Diabetic kidney disease;	chr7:65973791	chr7:66902857~66906297:+
LUAD	cis	rs8177876	0.822	rs1563077	ENSG00000261838.4	RP11-303E16.6	6.77	3.74e-11	2.26e-08	0.63	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81073951	chr16:81069854~81076598:+
LUAD	cis	rs673078	0.66	rs6490173	ENSG00000275759.1	RP11-131L12.3	-6.77	3.74e-11	2.26e-08	-0.38	-0.29	Glucose homeostasis traits;	chr12:118278637	chr12:118428281~118428870:+
LUAD	cis	rs10028773	0.568	rs6838457	ENSG00000248280.1	RP11-33B1.2	6.77	3.76e-11	2.27e-08	0.34	0.29	Educational attainment;	chr4:119346212	chr4:119440561~119450157:-
LUAD	cis	rs9903692	1	rs9903692	ENSG00000278765.1	RP5-890E16.5	6.77	3.76e-11	2.27e-08	0.39	0.29	Pulse pressure;	chr17:48196567	chr17:48066704~48067293:-
LUAD	cis	rs11098499	0.698	rs4422403	ENSG00000248280.1	RP11-33B1.2	6.77	3.76e-11	2.27e-08	0.35	0.29	Corneal astigmatism;	chr4:119337039	chr4:119440561~119450157:-
LUAD	cis	rs10759883	0.651	rs7852346	ENSG00000175611.10	LINC00476	-6.77	3.77e-11	2.28e-08	-0.34	-0.29	Nicotine dependence;	chr9:95786167	chr9:95759231~95875977:-
LUAD	cis	rs4964805	0.594	rs9132	ENSG00000257681.1	RP11-341G23.4	6.77	3.77e-11	2.28e-08	0.34	0.29	Attention deficit hyperactivity disorder;	chr12:103772465	chr12:103746315~103768858:-
LUAD	cis	rs2842992	0.789	rs7765490	ENSG00000237927.1	RP3-393E18.2	-6.77	3.78e-11	2.28e-08	-0.41	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159783294	chr6:159586955~159589169:-
LUAD	cis	rs875971	0.964	rs6945019	ENSG00000222364.1	RNU6-96P	-6.77	3.8e-11	2.29e-08	-0.33	-0.29	Aortic root size;	chr7:66457471	chr7:66395191~66395286:+
LUAD	cis	rs9903692	0.954	rs8065670	ENSG00000278765.1	RP5-890E16.5	-6.77	3.8e-11	2.29e-08	-0.38	-0.29	Pulse pressure;	chr17:48096478	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.908	rs12950402	ENSG00000278765.1	RP5-890E16.5	-6.77	3.8e-11	2.29e-08	-0.38	-0.29	Pulse pressure;	chr17:48102752	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.954	rs11079808	ENSG00000278765.1	RP5-890E16.5	-6.77	3.8e-11	2.29e-08	-0.38	-0.29	Pulse pressure;	chr17:48102870	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.954	rs4794448	ENSG00000278765.1	RP5-890E16.5	-6.77	3.8e-11	2.29e-08	-0.38	-0.29	Pulse pressure;	chr17:48103445	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.954	rs68175794	ENSG00000278765.1	RP5-890E16.5	-6.77	3.8e-11	2.29e-08	-0.38	-0.29	Pulse pressure;	chr17:48103742	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.862	rs12943543	ENSG00000278765.1	RP5-890E16.5	-6.77	3.8e-11	2.29e-08	-0.38	-0.29	Pulse pressure;	chr17:48104003	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.954	rs4794451	ENSG00000278765.1	RP5-890E16.5	-6.77	3.8e-11	2.29e-08	-0.38	-0.29	Pulse pressure;	chr17:48107419	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.862	rs4794453	ENSG00000278765.1	RP5-890E16.5	-6.77	3.8e-11	2.29e-08	-0.38	-0.29	Pulse pressure;	chr17:48107564	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.954	rs8077860	ENSG00000278765.1	RP5-890E16.5	-6.77	3.8e-11	2.29e-08	-0.38	-0.29	Pulse pressure;	chr17:48107973	chr17:48066704~48067293:-
LUAD	cis	rs9326248	0.559	rs482371	ENSG00000280143.1	AP000892.6	6.77	3.8e-11	2.29e-08	0.35	0.29	Blood protein levels;	chr11:116881447	chr11:117204967~117210292:+
LUAD	cis	rs66887589	0.774	rs9307477	ENSG00000248280.1	RP11-33B1.2	6.77	3.8e-11	2.29e-08	0.32	0.29	Diastolic blood pressure;	chr4:119500654	chr4:119440561~119450157:-
LUAD	cis	rs7674212	0.507	rs223331	ENSG00000246560.2	RP11-10L12.4	6.77	3.81e-11	2.3e-08	0.38	0.29	Type 2 diabetes;	chr4:102872408	chr4:102828055~102844075:+
LUAD	cis	rs11214589	0.875	rs10891540	ENSG00000270179.1	RP11-159N11.4	6.77	3.81e-11	2.3e-08	0.29	0.29	Neuroticism;	chr11:113368360	chr11:113368478~113369117:+
LUAD	cis	rs34779708	0.706	rs36027395	ENSG00000230534.5	RP11-297A16.2	6.77	3.82e-11	2.3e-08	0.36	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35261395	chr10:35098006~35127020:-
LUAD	cis	rs9309711	0.736	rs9678647	ENSG00000225234.1	TRAPPC12-AS1	6.77	3.82e-11	2.3e-08	0.36	0.29	Neurofibrillary tangles;	chr2:3493265	chr2:3481242~3482409:-
LUAD	cis	rs2015599	0.623	rs1006410	ENSG00000275476.1	RP11-996F15.4	6.77	3.83e-11	2.31e-08	0.32	0.29	Platelet count;Mean platelet volume;	chr12:29282682	chr12:29277397~29277882:-
LUAD	cis	rs9287719	0.674	rs6432130	ENSG00000234818.1	AC092687.5	-6.77	3.83e-11	2.31e-08	-0.36	-0.29	Prostate cancer;	chr2:10681431	chr2:10589166~10604830:+
LUAD	cis	rs7208859	0.573	rs56031503	ENSG00000263531.1	RP13-753N3.1	6.77	3.83e-11	2.31e-08	0.58	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30863921~30864940:-
LUAD	cis	rs3096299	0.935	rs3102387	ENSG00000274627.1	RP11-104N10.2	6.77	3.84e-11	2.31e-08	0.28	0.29	Multiple myeloma (IgH translocation);	chr16:89365868	chr16:89516797~89522217:+
LUAD	cis	rs11098499	0.569	rs10023641	ENSG00000248280.1	RP11-33B1.2	6.77	3.85e-11	2.32e-08	0.35	0.29	Corneal astigmatism;	chr4:119337255	chr4:119440561~119450157:-
LUAD	cis	rs9549367	0.662	rs3818334	ENSG00000269125.1	RP11-98F14.11	-6.77	3.85e-11	2.32e-08	-0.39	-0.29	Platelet distribution width;	chr13:113170860	chr13:113165002~113165183:-
LUAD	cis	rs8177876	0.822	rs56119129	ENSG00000261838.4	RP11-303E16.6	6.77	3.86e-11	2.33e-08	0.65	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81084661	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.731	rs77145371	ENSG00000261838.4	RP11-303E16.6	6.77	3.86e-11	2.33e-08	0.65	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085055	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.908	rs80187824	ENSG00000261838.4	RP11-303E16.6	6.77	3.86e-11	2.33e-08	0.65	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085075	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.731	rs74882687	ENSG00000261838.4	RP11-303E16.6	6.77	3.86e-11	2.33e-08	0.65	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085315	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.642	rs76909932	ENSG00000261838.4	RP11-303E16.6	6.77	3.86e-11	2.33e-08	0.65	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085449	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.822	rs8177939	ENSG00000261838.4	RP11-303E16.6	6.77	3.86e-11	2.33e-08	0.65	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085591	chr16:81069854~81076598:+
LUAD	cis	rs2337406	0.539	rs2583292	ENSG00000254174.1	IGHV1-12	6.77	3.88e-11	2.34e-08	0.25	0.29	Alzheimer's disease (late onset);	chr14:106649040	chr14:106122420~106122709:-
LUAD	cis	rs801193	0.591	rs2707839	ENSG00000222364.1	RNU6-96P	-6.76	3.89e-11	2.34e-08	-0.33	-0.29	Aortic root size;	chr7:66728097	chr7:66395191~66395286:+
LUAD	cis	rs6142102	0.812	rs6059578	ENSG00000276073.1	RP5-1125A11.7	-6.76	3.9e-11	2.35e-08	-0.31	-0.29	Skin pigmentation;	chr20:33939900	chr20:33985617~33988989:-
LUAD	cis	rs150992	0.609	rs161935	ENSG00000248489.1	CTD-2007H13.3	6.76	3.91e-11	2.35e-08	0.32	0.29	Body mass index;	chr5:98982733	chr5:98929171~98995013:+
LUAD	cis	rs2283792	0.905	rs5755694	ENSG00000224086.5	LL22NC03-86G7.1	-6.76	3.91e-11	2.36e-08	-0.28	-0.29	Multiple sclerosis;	chr22:21846241	chr22:21938293~21977632:+
LUAD	cis	rs881375	1	rs4323544	ENSG00000226752.6	PSMD5-AS1	-6.76	3.94e-11	2.37e-08	-0.32	-0.29	Rheumatoid arthritis;	chr9:120885099	chr9:120824828~120854385:+
LUAD	cis	rs7017914	0.967	rs1477944	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70703365	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs17760497	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70704810	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs34677078	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70705480	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs62530792	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70706532	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.902	rs35893260	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70707838	chr8:70780914~70781008:-
LUAD	cis	rs7017914	1	rs13253842	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70713268	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs13254908	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70713863	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs13264669	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70714537	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs34508469	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70716228	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs6472539	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70717575	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.934	rs56043721	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70718192	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs3954897	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70723720	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.811	rs4272413	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70723952	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.935	rs6981435	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70724913	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs6999739	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70724977	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs7013657	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70725324	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.934	rs7006615	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70727572	chr8:70780914~70781008:-
LUAD	cis	rs7017914	1	rs7007450	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70728034	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs11989553	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70728664	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs13272523	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70729237	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.934	rs62530826	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70729408	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs35295900	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70729826	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs35115527	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70730774	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.902	rs11991273	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70733625	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.869	rs11987511	ENSG00000223220.1	Y_RNA	6.76	3.94e-11	2.37e-08	0.33	0.29	Bone mineral density;	chr8:70733636	chr8:70780914~70781008:-
LUAD	cis	rs881375	0.867	rs6478487	ENSG00000226752.6	PSMD5-AS1	-6.76	3.94e-11	2.37e-08	-0.32	-0.29	Rheumatoid arthritis;	chr9:120910499	chr9:120824828~120854385:+
LUAD	cis	rs3096299	0.9	rs744327	ENSG00000274627.1	RP11-104N10.2	6.76	3.94e-11	2.37e-08	0.28	0.29	Multiple myeloma (IgH translocation);	chr16:89372862	chr16:89516797~89522217:+
LUAD	cis	rs17301013	0.507	rs6678209	ENSG00000227373.4	RP11-160H22.5	-6.76	3.95e-11	2.38e-08	-0.43	-0.29	Systemic lupus erythematosus;	chr1:174325607	chr1:174115300~174160004:-
LUAD	cis	rs6683071	0.894	rs12073392	ENSG00000272750.1	RP11-378J18.8	-6.76	3.95e-11	2.38e-08	-0.36	-0.29	Cognitive performance;	chr1:222753336	chr1:222658867~222661512:-
LUAD	cis	rs11846409	0.932	rs60659763	ENSG00000211974.3	IGHV2-70	-6.76	3.96e-11	2.38e-08	-0.37	-0.29	Rheumatic heart disease;	chr14:106634172	chr14:106723574~106724093:-
LUAD	cis	rs11846409	0.932	rs57080270	ENSG00000211974.3	IGHV2-70	-6.76	3.96e-11	2.38e-08	-0.37	-0.29	Rheumatic heart disease;	chr14:106634215	chr14:106723574~106724093:-
LUAD	cis	rs11846409	0.932	rs60917084	ENSG00000211974.3	IGHV2-70	-6.76	3.96e-11	2.38e-08	-0.37	-0.29	Rheumatic heart disease;	chr14:106634621	chr14:106723574~106724093:-
LUAD	cis	rs9326248	0.581	rs10892072	ENSG00000280143.1	AP000892.6	6.76	3.97e-11	2.39e-08	0.34	0.29	Blood protein levels;	chr11:117089597	chr11:117204967~117210292:+
LUAD	cis	rs2243480	1	rs1618893	ENSG00000273142.1	RP11-458F8.4	-6.76	3.98e-11	2.39e-08	-0.28	-0.29	Diabetic kidney disease;	chr7:66631132	chr7:66902857~66906297:+
LUAD	cis	rs9318086	0.663	rs2312295	ENSG00000205861.10	C1QTNF9B-AS1	-6.76	3.99e-11	2.4e-08	-0.35	-0.29	Myopia (pathological);	chr13:23883605	chr13:23888889~23897263:+
LUAD	cis	rs4713118	0.513	rs183244	ENSG00000219392.1	RP1-265C24.5	-6.76	4.01e-11	2.41e-08	-0.38	-0.29	Parkinson's disease;	chr6:28064060	chr6:28115628~28116551:+
LUAD	cis	rs7017914	0.967	rs7814648	ENSG00000223220.1	Y_RNA	6.76	4.03e-11	2.42e-08	0.33	0.29	Bone mineral density;	chr8:70691749	chr8:70780914~70781008:-
LUAD	cis	rs1799949	1	rs8176234	ENSG00000267681.1	CTD-3199J23.6	-6.76	4.03e-11	2.42e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43067763	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs8176233	ENSG00000267681.1	CTD-3199J23.6	-6.76	4.03e-11	2.42e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43067787	chr17:43144956~43145255:+
LUAD	cis	rs7567389	0.719	rs4662718	ENSG00000236682.1	AC068282.3	6.76	4.03e-11	2.42e-08	0.43	0.29	Self-rated health;	chr2:127257791	chr2:127389130~127400580:+
LUAD	cis	rs1799949	1	rs12950607	ENSG00000267681.1	CTD-3199J23.6	-6.76	4.04e-11	2.43e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43147911	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs11079056	ENSG00000267681.1	CTD-3199J23.6	-6.76	4.04e-11	2.43e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43148782	chr17:43144956~43145255:+
LUAD	cis	rs11098499	0.604	rs10022185	ENSG00000248280.1	RP11-33B1.2	6.76	4.04e-11	2.43e-08	0.38	0.29	Corneal astigmatism;	chr4:119650610	chr4:119440561~119450157:-
LUAD	cis	rs17684571	0.938	rs35408048	ENSG00000231441.1	RP11-472M19.2	6.76	4.06e-11	2.43e-08	0.42	0.29	Schizophrenia;	chr6:56694746	chr6:56844002~56864078:+
LUAD	cis	rs9309711	0.772	rs9309715	ENSG00000225234.1	TRAPPC12-AS1	6.76	4.06e-11	2.44e-08	0.37	0.29	Neurofibrillary tangles;	chr2:3488547	chr2:3481242~3482409:-
LUAD	cis	rs17023223	0.537	rs2645292	ENSG00000231365.4	RP11-418J17.1	-6.76	4.06e-11	2.44e-08	-0.39	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119030571	chr1:119140396~119275973:+
LUAD	cis	rs2337406	0.866	rs8003852	ENSG00000211974.3	IGHV2-70	-6.76	4.07e-11	2.44e-08	-0.37	-0.29	Alzheimer's disease (late onset);	chr14:106776648	chr14:106723574~106724093:-
LUAD	cis	rs2337406	0.866	rs988131	ENSG00000211974.3	IGHV2-70	-6.76	4.07e-11	2.44e-08	-0.37	-0.29	Alzheimer's disease (late onset);	chr14:106776833	chr14:106723574~106724093:-
LUAD	cis	rs2337406	0.866	rs8005518	ENSG00000211974.3	IGHV2-70	-6.76	4.07e-11	2.44e-08	-0.37	-0.29	Alzheimer's disease (late onset);	chr14:106777009	chr14:106723574~106724093:-
LUAD	cis	rs2337406	0.866	rs57684263	ENSG00000211974.3	IGHV2-70	-6.76	4.07e-11	2.44e-08	-0.37	-0.29	Alzheimer's disease (late onset);	chr14:106777263	chr14:106723574~106724093:-
LUAD	cis	rs2337406	0.866	rs7152809	ENSG00000211974.3	IGHV2-70	-6.76	4.07e-11	2.44e-08	-0.37	-0.29	Alzheimer's disease (late onset);	chr14:106778385	chr14:106723574~106724093:-
LUAD	cis	rs2337406	0.866	rs7152832	ENSG00000211974.3	IGHV2-70	-6.76	4.07e-11	2.44e-08	-0.37	-0.29	Alzheimer's disease (late onset);	chr14:106778427	chr14:106723574~106724093:-
LUAD	cis	rs2337406	0.5	rs7152934	ENSG00000211974.3	IGHV2-70	-6.76	4.07e-11	2.44e-08	-0.37	-0.29	Alzheimer's disease (late onset);	chr14:106778702	chr14:106723574~106724093:-
LUAD	cis	rs2337406	0.789	rs12050392	ENSG00000211974.3	IGHV2-70	-6.76	4.07e-11	2.44e-08	-0.37	-0.29	Alzheimer's disease (late onset);	chr14:106779073	chr14:106723574~106724093:-
LUAD	cis	rs2337406	0.866	rs74092505	ENSG00000211974.3	IGHV2-70	-6.76	4.07e-11	2.44e-08	-0.37	-0.29	Alzheimer's disease (late onset);	chr14:106779163	chr14:106723574~106724093:-
LUAD	cis	rs2337406	0.789	rs74092507	ENSG00000211974.3	IGHV2-70	-6.76	4.07e-11	2.44e-08	-0.37	-0.29	Alzheimer's disease (late onset);	chr14:106779174	chr14:106723574~106724093:-
LUAD	cis	rs2337406	0.866	rs74092511	ENSG00000211974.3	IGHV2-70	-6.76	4.07e-11	2.44e-08	-0.37	-0.29	Alzheimer's disease (late onset);	chr14:106779234	chr14:106723574~106724093:-
LUAD	cis	rs11098499	0.865	rs11722183	ENSG00000248280.1	RP11-33B1.2	6.76	4.07e-11	2.44e-08	0.38	0.29	Corneal astigmatism;	chr4:119359442	chr4:119440561~119450157:-
LUAD	cis	rs9326248	0.581	rs12225187	ENSG00000280143.1	AP000892.6	6.76	4.08e-11	2.45e-08	0.34	0.29	Blood protein levels;	chr11:116922515	chr11:117204967~117210292:+
LUAD	cis	rs6921919	0.789	rs11970439	ENSG00000204709.4	LINC01556	6.76	4.08e-11	2.45e-08	0.42	0.29	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:28943877~28944537:+
LUAD	cis	rs12429206	0.512	rs9535530	ENSG00000233672.5	RNASEH2B-AS1	-6.76	4.08e-11	2.45e-08	-0.38	-0.29	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50925136	chr13:50862172~50910764:-
LUAD	cis	rs10759883	0.627	rs11998982	ENSG00000175611.10	LINC00476	6.76	4.1e-11	2.46e-08	0.35	0.29	Nicotine dependence;	chr9:95851142	chr9:95759231~95875977:-
LUAD	cis	rs17023223	0.537	rs2645302	ENSG00000231365.4	RP11-418J17.1	-6.76	4.11e-11	2.47e-08	-0.38	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119047775	chr1:119140396~119275973:+
LUAD	cis	rs7811142	1	rs76913697	ENSG00000242294.5	STAG3L5P	6.76	4.12e-11	2.47e-08	0.25	0.29	Platelet count;	chr7:100405149	chr7:100336079~100351900:+
LUAD	cis	rs950169	0.922	rs11635505	ENSG00000259728.4	LINC00933	-6.76	4.12e-11	2.47e-08	-0.43	-0.29	Schizophrenia;	chr15:84553803	chr15:84570649~84580175:+
LUAD	cis	rs853679	0.55	rs1233704	ENSG00000219392.1	RP1-265C24.5	6.76	4.13e-11	2.47e-08	0.4	0.29	Depression;	chr6:28199145	chr6:28115628~28116551:+
LUAD	cis	rs10463554	0.853	rs246903	ENSG00000175749.11	EIF3KP1	6.76	4.13e-11	2.47e-08	0.39	0.29	Parkinson's disease;	chr5:103253753	chr5:103032376~103033031:+
LUAD	cis	rs4718428	0.705	rs12698547	ENSG00000273142.1	RP11-458F8.4	-6.76	4.13e-11	2.48e-08	-0.22	-0.29	Corneal structure;	chr7:66813271	chr7:66902857~66906297:+
LUAD	cis	rs881375	1	rs6478484	ENSG00000226752.6	PSMD5-AS1	-6.75	4.14e-11	2.48e-08	-0.32	-0.29	Rheumatoid arthritis;	chr9:120890102	chr9:120824828~120854385:+
LUAD	cis	rs881375	0.654	rs10760126	ENSG00000226752.6	PSMD5-AS1	-6.75	4.15e-11	2.49e-08	-0.31	-0.29	Rheumatoid arthritis;	chr9:120900340	chr9:120824828~120854385:+
LUAD	cis	rs881375	0.678	rs4836834	ENSG00000226752.6	PSMD5-AS1	-6.75	4.15e-11	2.49e-08	-0.31	-0.29	Rheumatoid arthritis;	chr9:120903623	chr9:120824828~120854385:+
LUAD	cis	rs748404	0.56	rs570933	ENSG00000249839.1	AC011330.5	-6.75	4.15e-11	2.49e-08	-0.39	-0.29	Lung cancer;	chr15:43531832	chr15:43663654~43684339:-
LUAD	cis	rs17023223	0.537	rs61808892	ENSG00000231365.4	RP11-418J17.1	-6.75	4.15e-11	2.49e-08	-0.39	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119056584	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.509	rs6668960	ENSG00000231365.4	RP11-418J17.1	-6.75	4.15e-11	2.49e-08	-0.39	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119058189	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs2361269	ENSG00000231365.4	RP11-418J17.1	-6.75	4.15e-11	2.49e-08	-0.39	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119059592	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs2645300	ENSG00000231365.4	RP11-418J17.1	-6.75	4.15e-11	2.49e-08	-0.39	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060444	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs2361270	ENSG00000231365.4	RP11-418J17.1	-6.75	4.15e-11	2.49e-08	-0.39	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060699	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs2361271	ENSG00000231365.4	RP11-418J17.1	-6.75	4.15e-11	2.49e-08	-0.39	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060782	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs2361273	ENSG00000231365.4	RP11-418J17.1	-6.75	4.15e-11	2.49e-08	-0.39	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119061077	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs10923741	ENSG00000231365.4	RP11-418J17.1	-6.75	4.15e-11	2.49e-08	-0.39	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119061850	chr1:119140396~119275973:+
LUAD	cis	rs17023223	0.537	rs10802073	ENSG00000231365.4	RP11-418J17.1	-6.75	4.15e-11	2.49e-08	-0.39	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119062032	chr1:119140396~119275973:+
LUAD	cis	rs2442825	0.693	rs2728928	ENSG00000206573.7	THUMPD3-AS1	-6.75	4.16e-11	2.49e-08	-0.22	-0.29	Cerebrospinal fluid clusterin levels;	chr3:9388275	chr3:9349689~9398579:-
LUAD	cis	rs8177876	0.731	rs4889227	ENSG00000261838.4	RP11-303E16.6	-6.75	4.16e-11	2.49e-08	-0.57	-0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81075576	chr16:81069854~81076598:+
LUAD	cis	rs2734839	0.964	rs12808482	ENSG00000270179.1	RP11-159N11.4	-6.75	4.17e-11	2.5e-08	-0.3	-0.29	Information processing speed;	chr11:113424276	chr11:113368478~113369117:+
LUAD	cis	rs75422866	0.867	rs78912815	ENSG00000257433.4	RP1-197B17.3	6.75	4.17e-11	2.5e-08	0.62	0.29	Pneumonia;	chr12:47612065	chr12:47706085~47742294:+
LUAD	cis	rs11098499	0.866	rs7665125	ENSG00000248280.1	RP11-33B1.2	6.75	4.17e-11	2.5e-08	0.35	0.29	Corneal astigmatism;	chr4:119480924	chr4:119440561~119450157:-
LUAD	cis	rs9309473	0.948	rs7603647	ENSG00000163016.8	ALMS1P	6.75	4.18e-11	2.5e-08	0.36	0.29	Metabolite levels;	chr2:73590111	chr2:73644919~73685576:+
LUAD	cis	rs7927592	0.871	rs11228284	ENSG00000212093.1	AP000807.1	6.75	4.2e-11	2.51e-08	0.33	0.29	Total body bone mineral density;	chr11:68555299	chr11:68506083~68506166:-
LUAD	cis	rs9309473	1	rs10207220	ENSG00000163016.8	ALMS1P	6.75	4.2e-11	2.52e-08	0.36	0.29	Metabolite levels;	chr2:73557919	chr2:73644919~73685576:+
LUAD	cis	rs11098499	0.691	rs17009144	ENSG00000248280.1	RP11-33B1.2	-6.75	4.2e-11	2.52e-08	-0.34	-0.29	Corneal astigmatism;	chr4:119349640	chr4:119440561~119450157:-
LUAD	cis	rs2404602	0.532	rs744336	ENSG00000259422.1	RP11-593F23.1	6.75	4.21e-11	2.52e-08	0.35	0.29	Blood metabolite levels;	chr15:76382283	chr15:76174891~76181486:-
LUAD	cis	rs1799949	1	rs16941	ENSG00000267681.1	CTD-3199J23.6	-6.75	4.21e-11	2.52e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43092418	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs16940	ENSG00000267681.1	CTD-3199J23.6	-6.75	4.21e-11	2.52e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43093220	chr17:43144956~43145255:+
LUAD	cis	rs6487679	1	rs1017302	ENSG00000111788.10	RP11-22B23.1	6.75	4.21e-11	2.52e-08	0.31	0.29	Non-alcoholic fatty liver disease histology (AST);	chr12:9214806	chr12:9277235~9313241:+
LUAD	cis	rs6487679	1	rs10734765	ENSG00000111788.10	RP11-22B23.1	6.75	4.21e-11	2.52e-08	0.31	0.29	Non-alcoholic fatty liver disease histology (AST);	chr12:9216789	chr12:9277235~9313241:+
LUAD	cis	rs321358	0.731	rs73003518	ENSG00000271584.1	RP11-89C3.4	6.75	4.21e-11	2.52e-08	0.45	0.29	Body mass index;	chr11:111163933	chr11:111091932~111097357:-
LUAD	cis	rs321358	0.731	rs73003519	ENSG00000271584.1	RP11-89C3.4	6.75	4.21e-11	2.52e-08	0.45	0.29	Body mass index;	chr11:111163943	chr11:111091932~111097357:-
LUAD	cis	rs2842992	0.83	rs2842966	ENSG00000237927.1	RP3-393E18.2	-6.75	4.22e-11	2.52e-08	-0.4	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159720560	chr6:159586955~159589169:-
LUAD	cis	rs75422866	0.51	rs73105819	ENSG00000280054.1	RP1-197B17.7	6.75	4.22e-11	2.52e-08	0.65	0.29	Pneumonia;	chr12:47727190	chr12:47728151~47730598:-
LUAD	cis	rs12908161	1	rs11638290	ENSG00000259728.4	LINC00933	6.75	4.22e-11	2.53e-08	0.43	0.29	Schizophrenia;	chr15:84684405	chr15:84570649~84580175:+
LUAD	cis	rs12908161	0.959	rs34028043	ENSG00000259728.4	LINC00933	6.75	4.22e-11	2.53e-08	0.43	0.29	Schizophrenia;	chr15:84688354	chr15:84570649~84580175:+
LUAD	cis	rs12908161	0.959	rs34784022	ENSG00000259728.4	LINC00933	6.75	4.22e-11	2.53e-08	0.43	0.29	Schizophrenia;	chr15:84688675	chr15:84570649~84580175:+
LUAD	cis	rs12908161	0.959	rs12908699	ENSG00000259728.4	LINC00933	6.75	4.22e-11	2.53e-08	0.43	0.29	Schizophrenia;	chr15:84697172	chr15:84570649~84580175:+
LUAD	cis	rs2243480	1	rs906134	ENSG00000273142.1	RP11-458F8.4	-6.75	4.22e-11	2.53e-08	-0.31	-0.29	Diabetic kidney disease;	chr7:65979301	chr7:66902857~66906297:+
LUAD	cis	rs3096299	0.933	rs28608022	ENSG00000274627.1	RP11-104N10.2	6.75	4.23e-11	2.53e-08	0.28	0.29	Multiple myeloma (IgH translocation);	chr16:89387884	chr16:89516797~89522217:+
LUAD	cis	rs10759883	0.627	rs816673	ENSG00000175611.10	LINC00476	-6.75	4.23e-11	2.53e-08	-0.34	-0.29	Nicotine dependence;	chr9:95811134	chr9:95759231~95875977:-
LUAD	cis	rs3762637	1	rs9879508	ENSG00000272758.4	RP11-299J3.8	-6.75	4.24e-11	2.53e-08	-0.47	-0.29	LDL cholesterol levels;	chr3:122417633	chr3:122416207~122443180:+
LUAD	cis	rs2115630	0.645	rs2292463	ENSG00000225151.9	GOLGA2P7	6.75	4.24e-11	2.54e-08	0.33	0.29	P wave terminal force;	chr15:84632519	chr15:84199311~84230136:-
LUAD	cis	rs9549367	0.724	rs7985335	ENSG00000269125.1	RP11-98F14.11	6.75	4.25e-11	2.54e-08	0.35	0.29	Platelet distribution width;	chr13:113214930	chr13:113165002~113165183:-
LUAD	cis	rs881375	0.933	rs7859805	ENSG00000226752.6	PSMD5-AS1	-6.75	4.26e-11	2.55e-08	-0.32	-0.29	Rheumatoid arthritis;	chr9:120901845	chr9:120824828~120854385:+
LUAD	cis	rs881375	0.933	rs10818485	ENSG00000226752.6	PSMD5-AS1	-6.75	4.26e-11	2.55e-08	-0.32	-0.29	Rheumatoid arthritis;	chr9:120905538	chr9:120824828~120854385:+
LUAD	cis	rs881375	0.967	rs10435843	ENSG00000226752.6	PSMD5-AS1	-6.75	4.26e-11	2.55e-08	-0.32	-0.29	Rheumatoid arthritis;	chr9:120905755	chr9:120824828~120854385:+
LUAD	cis	rs881375	0.967	rs10435844	ENSG00000226752.6	PSMD5-AS1	-6.75	4.26e-11	2.55e-08	-0.32	-0.29	Rheumatoid arthritis;	chr9:120905921	chr9:120824828~120854385:+
LUAD	cis	rs881375	0.967	rs7848332	ENSG00000226752.6	PSMD5-AS1	-6.75	4.26e-11	2.55e-08	-0.32	-0.29	Rheumatoid arthritis;	chr9:120907218	chr9:120824828~120854385:+
LUAD	cis	rs10129255	0.701	rs2005643	ENSG00000211972.2	IGHV3-66	6.75	4.26e-11	2.55e-08	0.25	0.29	Kawasaki disease;	chr14:106676288	chr14:106675017~106675544:-
LUAD	cis	rs2919917	0.666	rs10957898	ENSG00000254352.1	RP11-578O24.2	-6.75	4.26e-11	2.55e-08	-0.39	-0.29	Lymphocyte counts;	chr8:78705078	chr8:78723796~78724136:-
LUAD	cis	rs1150668	0.768	rs1150709	ENSG00000204709.4	LINC01556	-6.75	4.26e-11	2.55e-08	-0.35	-0.29	Pubertal anthropometrics;	chr6:28239585	chr6:28943877~28944537:+
LUAD	cis	rs7674212	0.507	rs223317	ENSG00000251288.2	RP11-10L12.2	-6.75	4.27e-11	2.55e-08	-0.37	-0.29	Type 2 diabetes;	chr4:102881667	chr4:102751401~102752641:+
LUAD	cis	rs2739330	0.587	rs4820571	ENSG00000206090.4	AP000350.7	6.75	4.27e-11	2.55e-08	0.33	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23939998~23942798:+
LUAD	cis	rs12594515	0.694	rs2068295	ENSG00000273972.1	CTD-2306A12.1	-6.75	4.27e-11	2.55e-08	-0.32	-0.29	Weight;Waist circumference;	chr15:45693348	chr15:45702640~45703183:+
LUAD	cis	rs12594515	0.694	rs2068294	ENSG00000273972.1	CTD-2306A12.1	-6.75	4.27e-11	2.55e-08	-0.32	-0.29	Weight;Waist circumference;	chr15:45693350	chr15:45702640~45703183:+
LUAD	cis	rs6496932	0.563	rs2344083	ENSG00000259295.5	CSPG4P12	6.75	4.27e-11	2.55e-08	0.36	0.29	Central corneal thickness;Corneal structure;	chr15:85354201	chr15:85191438~85213905:+
LUAD	cis	rs2439831	0.867	rs2447208	ENSG00000205771.5	CATSPER2P1	-6.75	4.28e-11	2.56e-08	-0.52	-0.29	Lung cancer in ever smokers;	chr15:43641697	chr15:43726918~43747094:-
LUAD	cis	rs465969	1	rs7750803	ENSG00000255389.1	C6orf3	6.75	4.28e-11	2.56e-08	0.65	0.29	Psoriasis;	chr6:111478910	chr6:111599875~111602295:+
LUAD	cis	rs9549367	0.713	rs3024776	ENSG00000269125.1	RP11-98F14.11	6.75	4.28e-11	2.56e-08	0.39	0.29	Platelet distribution width;	chr13:113172761	chr13:113165002~113165183:-
LUAD	cis	rs8100891	0.537	rs10415145	ENSG00000267213.4	AC007773.2	6.75	4.28e-11	2.56e-08	0.43	0.29	Neuroticism;	chr19:32350147	chr19:32390050~32405560:-
LUAD	cis	rs10129255	0.5	rs10142931	ENSG00000224373.3	IGHV4-59	6.75	4.28e-11	2.56e-08	0.17	0.29	Kawasaki disease;	chr14:106782288	chr14:106627249~106627825:-
LUAD	cis	rs6844153	1	rs57686546	ENSG00000240005.4	RP11-293A21.1	-6.75	4.29e-11	2.56e-08	-0.48	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26915162	chr4:26859806~26860599:-
LUAD	cis	rs55665837	0.922	rs12287212	ENSG00000251991.1	RNU7-49P	6.75	4.29e-11	2.57e-08	0.33	0.29	Vitamin D levels;	chr11:14428315	chr11:14478892~14478953:+
LUAD	cis	rs7688540	0.8	rs7694325	ENSG00000275426.1	CH17-262A2.1	6.75	4.3e-11	2.57e-08	0.36	0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:275253	chr4:149738~150317:+
LUAD	cis	rs59482735	1	rs59482735	ENSG00000226752.6	PSMD5-AS1	-6.75	4.31e-11	2.57e-08	-0.33	-0.29	Prostate-specific antigen levels;	chr9:120881148	chr9:120824828~120854385:+
LUAD	cis	rs4601821	0.522	rs754672	ENSG00000270179.1	RP11-159N11.4	-6.75	4.31e-11	2.57e-08	-0.29	-0.29	Alcoholic chronic pancreatitis;	chr11:113378414	chr11:113368478~113369117:+
LUAD	cis	rs755249	0.958	rs61781370	ENSG00000228060.1	RP11-69E11.8	-6.75	4.32e-11	2.58e-08	-0.3	-0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39579628	chr1:39565160~39573203:+
LUAD	cis	rs6920372	0.748	rs12528392	ENSG00000260273.1	RP11-425D10.10	6.75	4.32e-11	2.58e-08	0.39	0.29	Height;	chr6:109747411	chr6:109382795~109383666:+
LUAD	cis	rs6920372	0.692	rs11153216	ENSG00000260273.1	RP11-425D10.10	6.75	4.32e-11	2.58e-08	0.39	0.29	Height;	chr6:109748819	chr6:109382795~109383666:+
LUAD	cis	rs6920372	0.748	rs2025147	ENSG00000260273.1	RP11-425D10.10	6.75	4.32e-11	2.58e-08	0.39	0.29	Height;	chr6:109749564	chr6:109382795~109383666:+
LUAD	cis	rs10129255	0.5	rs8021941	ENSG00000224373.3	IGHV4-59	6.75	4.32e-11	2.58e-08	0.17	0.29	Kawasaki disease;	chr14:106781490	chr14:106627249~106627825:-
LUAD	cis	rs11098499	0.82	rs28535956	ENSG00000248280.1	RP11-33B1.2	-6.75	4.33e-11	2.59e-08	-0.38	-0.29	Corneal astigmatism;	chr4:119615703	chr4:119440561~119450157:-
LUAD	cis	rs881375	0.692	rs2072438	ENSG00000226752.6	PSMD5-AS1	-6.75	4.34e-11	2.59e-08	-0.31	-0.29	Rheumatoid arthritis;	chr9:120889023	chr9:120824828~120854385:+
LUAD	cis	rs4141404	0.737	rs5998067	ENSG00000236132.1	CTA-440B3.1	6.75	4.34e-11	2.59e-08	0.36	0.29	Paclitaxel-induced neuropathy;	chr22:31647644	chr22:31816379~31817491:-
LUAD	cis	rs7429990	0.774	rs3772402	ENSG00000229759.1	MRPS18AP1	-6.75	4.35e-11	2.59e-08	-0.3	-0.29	Educational attainment (years of education);	chr3:47574661	chr3:48256350~48256938:-
LUAD	cis	rs2734839	0.929	rs2734835	ENSG00000270179.1	RP11-159N11.4	-6.75	4.35e-11	2.6e-08	-0.3	-0.29	Information processing speed;	chr11:113420621	chr11:113368478~113369117:+
LUAD	cis	rs7646881	0.812	rs75107964	ENSG00000240207.5	RP11-379F4.4	-6.75	4.35e-11	2.6e-08	-0.42	-0.29	Tetralogy of Fallot;	chr3:158740962	chr3:158732263~158784070:+
LUAD	cis	rs3096299	0.967	rs11648663	ENSG00000274627.1	RP11-104N10.2	6.75	4.36e-11	2.6e-08	0.28	0.29	Multiple myeloma (IgH translocation);	chr16:89399899	chr16:89516797~89522217:+
LUAD	cis	rs7017914	0.967	rs7842851	ENSG00000223220.1	Y_RNA	6.75	4.36e-11	2.6e-08	0.32	0.29	Bone mineral density;	chr8:70751570	chr8:70780914~70781008:-
LUAD	cis	rs875971	1	rs2087647	ENSG00000222364.1	RNU6-96P	6.75	4.36e-11	2.6e-08	0.32	0.29	Aortic root size;	chr7:66128201	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs6958484	ENSG00000222364.1	RNU6-96P	6.75	4.36e-11	2.6e-08	0.32	0.29	Aortic root size;	chr7:66134459	chr7:66395191~66395286:+
LUAD	cis	rs7626444	0.584	rs7633044	ENSG00000272359.1	U4	-6.75	4.38e-11	2.61e-08	-0.33	-0.29	Monocyte count;	chr3:196763772	chr3:196747192~196747324:-
LUAD	cis	rs2734839	0.964	rs1800498	ENSG00000270179.1	RP11-159N11.4	-6.75	4.38e-11	2.61e-08	-0.3	-0.29	Information processing speed;	chr11:113420866	chr11:113368478~113369117:+
LUAD	cis	rs2734839	0.964	rs2234690	ENSG00000270179.1	RP11-159N11.4	-6.75	4.38e-11	2.61e-08	-0.3	-0.29	Information processing speed;	chr11:113421026	chr11:113368478~113369117:+
LUAD	cis	rs2734839	0.964	rs2587548	ENSG00000270179.1	RP11-159N11.4	-6.75	4.38e-11	2.61e-08	-0.3	-0.29	Information processing speed;	chr11:113421490	chr11:113368478~113369117:+
LUAD	cis	rs9549367	0.713	rs9549681	ENSG00000269125.1	RP11-98F14.11	-6.75	4.38e-11	2.61e-08	-0.39	-0.29	Platelet distribution width;	chr13:113175559	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.713	rs9549682	ENSG00000269125.1	RP11-98F14.11	-6.75	4.38e-11	2.61e-08	-0.39	-0.29	Platelet distribution width;	chr13:113175867	chr13:113165002~113165183:-
LUAD	cis	rs7044106	0.791	rs4837792	ENSG00000238181.2	AHCYP2	-6.75	4.39e-11	2.62e-08	-0.39	-0.29	Hip circumference adjusted for BMI;	chr9:120721281	chr9:120720673~120721972:+
LUAD	cis	rs748404	0.631	rs4296223	ENSG00000249839.1	AC011330.5	-6.75	4.4e-11	2.62e-08	-0.38	-0.29	Lung cancer;	chr15:43353048	chr15:43663654~43684339:-
LUAD	cis	rs7017914	0.967	rs1471114	ENSG00000223220.1	Y_RNA	6.74	4.41e-11	2.63e-08	0.33	0.29	Bone mineral density;	chr8:70763312	chr8:70780914~70781008:-
LUAD	cis	rs62229266	0.609	rs12482541	ENSG00000214914.3	RPL23AP3	6.74	4.41e-11	2.63e-08	0.35	0.29	Mitral valve prolapse;	chr21:36047445	chr21:36016079~36016546:-
LUAD	cis	rs62229266	0.609	rs2835253	ENSG00000214914.3	RPL23AP3	6.74	4.41e-11	2.63e-08	0.35	0.29	Mitral valve prolapse;	chr21:36047447	chr21:36016079~36016546:-
LUAD	cis	rs6920372	0.748	rs12190372	ENSG00000260273.1	RP11-425D10.10	6.74	4.41e-11	2.63e-08	0.39	0.29	Height;	chr6:109763331	chr6:109382795~109383666:+
LUAD	cis	rs4853012	0.539	rs9789534	ENSG00000257800.1	FNBP1P1	6.74	4.42e-11	2.63e-08	0.38	0.29	Gestational age at birth (maternal effect);	chr2:74135863	chr2:74120680~74123218:+
LUAD	cis	rs9487094	0.689	rs2884037	ENSG00000260273.1	RP11-425D10.10	6.74	4.42e-11	2.64e-08	0.36	0.29	Height;	chr6:109354092	chr6:109382795~109383666:+
LUAD	cis	rs7674212	0.507	rs223361	ENSG00000246560.2	RP11-10L12.4	6.74	4.42e-11	2.64e-08	0.38	0.29	Type 2 diabetes;	chr4:102848147	chr4:102828055~102844075:+
LUAD	cis	rs2243480	1	rs34970380	ENSG00000273142.1	RP11-458F8.4	-6.74	4.42e-11	2.64e-08	-0.31	-0.29	Diabetic kidney disease;	chr7:65966506	chr7:66902857~66906297:+
LUAD	cis	rs2243480	0.901	rs73148097	ENSG00000273142.1	RP11-458F8.4	-6.74	4.42e-11	2.64e-08	-0.31	-0.29	Diabetic kidney disease;	chr7:65966800	chr7:66902857~66906297:+
LUAD	cis	rs7626444	0.625	rs843531	ENSG00000272359.1	U4	-6.74	4.43e-11	2.64e-08	-0.33	-0.29	Monocyte count;	chr3:196754900	chr3:196747192~196747324:-
LUAD	cis	rs7626444	0.625	rs9877495	ENSG00000272359.1	U4	-6.74	4.43e-11	2.64e-08	-0.33	-0.29	Monocyte count;	chr3:196756409	chr3:196747192~196747324:-
LUAD	cis	rs7626444	0.625	rs2686599	ENSG00000272359.1	U4	-6.74	4.43e-11	2.64e-08	-0.33	-0.29	Monocyte count;	chr3:196756923	chr3:196747192~196747324:-
LUAD	cis	rs7626444	0.625	rs1403101	ENSG00000272359.1	U4	-6.74	4.43e-11	2.64e-08	-0.33	-0.29	Monocyte count;	chr3:196758203	chr3:196747192~196747324:-
LUAD	cis	rs7626444	0.628	rs1684464	ENSG00000272359.1	U4	-6.74	4.43e-11	2.64e-08	-0.33	-0.29	Monocyte count;	chr3:196758643	chr3:196747192~196747324:-
LUAD	cis	rs7626444	0.625	rs1486358	ENSG00000272359.1	U4	-6.74	4.43e-11	2.64e-08	-0.33	-0.29	Monocyte count;	chr3:196758719	chr3:196747192~196747324:-
LUAD	cis	rs2243480	1	rs1723270	ENSG00000273142.1	RP11-458F8.4	-6.74	4.44e-11	2.64e-08	-0.31	-0.29	Diabetic kidney disease;	chr7:66004843	chr7:66902857~66906297:+
LUAD	cis	rs9487094	0.666	rs7751582	ENSG00000260273.1	RP11-425D10.10	6.74	4.44e-11	2.65e-08	0.37	0.29	Height;	chr6:109427644	chr6:109382795~109383666:+
LUAD	cis	rs10759883	0.627	rs10818574	ENSG00000175611.10	LINC00476	6.74	4.44e-11	2.65e-08	0.34	0.29	Nicotine dependence;	chr9:95836685	chr9:95759231~95875977:-
LUAD	cis	rs3096299	0.781	rs3102381	ENSG00000274627.1	RP11-104N10.2	6.74	4.45e-11	2.65e-08	0.27	0.29	Multiple myeloma (IgH translocation);	chr16:89343312	chr16:89516797~89522217:+
LUAD	cis	rs6683071	1	rs6683071	ENSG00000272750.1	RP11-378J18.8	-6.74	4.45e-11	2.65e-08	-0.35	-0.29	Cognitive performance;	chr1:222750009	chr1:222658867~222661512:-
LUAD	cis	rs9309473	0.848	rs17009159	ENSG00000163016.8	ALMS1P	6.74	4.46e-11	2.66e-08	0.36	0.29	Metabolite levels;	chr2:73570635	chr2:73644919~73685576:+
LUAD	cis	rs9309473	1	rs7586463	ENSG00000163016.8	ALMS1P	6.74	4.46e-11	2.66e-08	0.36	0.29	Metabolite levels;	chr2:73571349	chr2:73644919~73685576:+
LUAD	cis	rs9309711	0.772	rs9309714	ENSG00000225234.1	TRAPPC12-AS1	-6.74	4.47e-11	2.66e-08	-0.37	-0.29	Neurofibrillary tangles;	chr2:3488059	chr2:3481242~3482409:-
LUAD	cis	rs4713118	0.513	rs202908	ENSG00000219392.1	RP1-265C24.5	-6.74	4.47e-11	2.66e-08	-0.38	-0.29	Parkinson's disease;	chr6:28043773	chr6:28115628~28116551:+
LUAD	cis	rs6504950	0.732	rs244373	ENSG00000275710.1	RP11-257O5.4	-6.74	4.48e-11	2.67e-08	-0.35	-0.29	Breast cancer;	chr17:55107588	chr17:54964474~54964679:+
LUAD	cis	rs7626444	0.565	rs7613010	ENSG00000272359.1	U4	-6.74	4.49e-11	2.67e-08	-0.33	-0.29	Monocyte count;	chr3:196763350	chr3:196747192~196747324:-
LUAD	cis	rs7626444	0.605	rs7642801	ENSG00000272359.1	U4	-6.74	4.49e-11	2.67e-08	-0.33	-0.29	Monocyte count;	chr3:196763435	chr3:196747192~196747324:-
LUAD	cis	rs853679	0.567	rs1005126	ENSG00000204709.4	LINC01556	6.74	4.49e-11	2.67e-08	0.39	0.29	Depression;	chr6:28399846	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.513	rs9368547	ENSG00000219392.1	RP1-265C24.5	-6.74	4.49e-11	2.68e-08	-0.38	-0.29	Parkinson's disease;	chr6:28060289	chr6:28115628~28116551:+
LUAD	cis	rs7567389	0.719	rs4150499	ENSG00000236682.1	AC068282.3	6.74	4.5e-11	2.68e-08	0.43	0.29	Self-rated health;	chr2:127271216	chr2:127389130~127400580:+
LUAD	cis	rs2842992	0.789	rs4709370	ENSG00000237927.1	RP3-393E18.2	-6.74	4.5e-11	2.68e-08	-0.42	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159789029	chr6:159586955~159589169:-
LUAD	cis	rs1823913	0.637	rs2067610	ENSG00000227542.1	AC092614.2	6.74	4.51e-11	2.68e-08	0.36	0.29	Obesity-related traits;	chr2:191299251	chr2:191229165~191246172:-
LUAD	cis	rs12130219	0.543	rs11204988	ENSG00000237975.5	FLG-AS1	6.74	4.51e-11	2.68e-08	0.48	0.29	Inflammatory skin disease;	chr1:152371417	chr1:152168125~152445456:+
LUAD	cis	rs1426063	0.541	rs58959724	ENSG00000249717.1	RP11-44F21.3	6.74	4.51e-11	2.69e-08	0.59	0.29	QT interval;	chr4:75073543	chr4:74955974~74970362:-
LUAD	cis	rs9287719	0.625	rs7567304	ENSG00000234818.1	AC092687.5	-6.74	4.52e-11	2.69e-08	-0.36	-0.29	Prostate cancer;	chr2:10649903	chr2:10589166~10604830:+
LUAD	cis	rs2726040	0.902	rs33957528	ENSG00000259982.1	CDC37P1	-6.74	4.53e-11	2.7e-08	-0.35	-0.29	Hip circumference;	chr16:28296619	chr16:28700294~28701540:-
LUAD	cis	rs6844153	1	rs7655686	ENSG00000240005.4	RP11-293A21.1	-6.74	4.53e-11	2.7e-08	-0.49	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26897955	chr4:26859806~26860599:-
LUAD	cis	rs8062405	0.573	rs8045689	ENSG00000259982.1	CDC37P1	-6.74	4.53e-11	2.7e-08	-0.4	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28976948	chr16:28700294~28701540:-
LUAD	cis	rs9584850	0.794	rs9630321	ENSG00000231194.1	FARP1-AS1	6.74	4.54e-11	2.7e-08	0.35	0.29	Neuroticism;	chr13:98454725	chr13:98435405~98435840:-
LUAD	cis	rs8059260	0.551	rs7187539	ENSG00000274038.1	RP11-66H6.4	-6.74	4.54e-11	2.7e-08	-0.52	-0.29	Alcohol consumption over the past year;	chr16:10964900	chr16:11056556~11057034:+
LUAD	cis	rs6921919	0.887	rs7766356	ENSG00000204709.4	LINC01556	6.74	4.55e-11	2.7e-08	0.47	0.29	Autism spectrum disorder or schizophrenia;	chr6:28432761	chr6:28943877~28944537:+
LUAD	cis	rs2243480	1	rs316315	ENSG00000226824.5	RP4-756H11.3	6.74	4.55e-11	2.71e-08	0.49	0.29	Diabetic kidney disease;	chr7:66126218	chr7:66654538~66669855:+
LUAD	cis	rs881375	0.967	rs1008381	ENSG00000226752.6	PSMD5-AS1	-6.74	4.55e-11	2.71e-08	-0.32	-0.29	Rheumatoid arthritis;	chr9:120918838	chr9:120824828~120854385:+
LUAD	cis	rs2734839	0.964	rs1076563	ENSG00000270179.1	RP11-159N11.4	-6.74	4.55e-11	2.71e-08	-0.3	-0.29	Information processing speed;	chr11:113425187	chr11:113368478~113369117:+
LUAD	cis	rs2734839	0.964	rs1116313	ENSG00000270179.1	RP11-159N11.4	-6.74	4.55e-11	2.71e-08	-0.3	-0.29	Information processing speed;	chr11:113425385	chr11:113368478~113369117:+
LUAD	cis	rs2243480	1	rs10247526	ENSG00000226824.5	RP4-756H11.3	6.74	4.56e-11	2.71e-08	0.55	0.29	Diabetic kidney disease;	chr7:66315709	chr7:66654538~66669855:+
LUAD	cis	rs7208859	0.623	rs73269916	ENSG00000263531.1	RP13-753N3.1	6.74	4.56e-11	2.71e-08	0.58	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30769308	chr17:30863921~30864940:-
LUAD	cis	rs8100891	0.537	rs73034216	ENSG00000267213.4	AC007773.2	-6.74	4.56e-11	2.71e-08	-0.46	-0.29	Neuroticism;	chr19:32392510	chr19:32390050~32405560:-
LUAD	cis	rs35955747	0.87	rs4820969	ENSG00000236132.1	CTA-440B3.1	6.74	4.59e-11	2.73e-08	0.32	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31377587	chr22:31816379~31817491:-
LUAD	cis	rs853679	0.769	rs7752448	ENSG00000204709.4	LINC01556	6.74	4.6e-11	2.74e-08	0.54	0.29	Depression;	chr6:28333322	chr6:28943877~28944537:+
LUAD	cis	rs150992	0.79	rs45931	ENSG00000248489.1	CTD-2007H13.3	6.74	4.6e-11	2.74e-08	0.32	0.29	Body mass index;	chr5:98978344	chr5:98929171~98995013:+
LUAD	cis	rs881375	0.967	rs7875829	ENSG00000226752.6	PSMD5-AS1	-6.74	4.6e-11	2.74e-08	-0.32	-0.29	Rheumatoid arthritis;	chr9:120898120	chr9:120824828~120854385:+
LUAD	cis	rs881375	0.867	rs10818484	ENSG00000226752.6	PSMD5-AS1	-6.74	4.6e-11	2.74e-08	-0.32	-0.29	Rheumatoid arthritis;	chr9:120898916	chr9:120824828~120854385:+
LUAD	cis	rs321358	0.731	rs494921	ENSG00000271584.1	RP11-89C3.4	-6.74	4.6e-11	2.74e-08	-0.46	-0.29	Body mass index;	chr11:111140385	chr11:111091932~111097357:-
LUAD	cis	rs3096299	0.9	rs4785663	ENSG00000274627.1	RP11-104N10.2	6.74	4.61e-11	2.74e-08	0.29	0.29	Multiple myeloma (IgH translocation);	chr16:89368480	chr16:89516797~89522217:+
LUAD	cis	rs465969	1	rs9400478	ENSG00000255389.1	C6orf3	6.74	4.61e-11	2.74e-08	0.65	0.29	Psoriasis;	chr6:111478441	chr6:111599875~111602295:+
LUAD	cis	rs17711722	0.565	rs4717276	ENSG00000236529.1	RP13-254B10.1	6.74	4.62e-11	2.75e-08	0.29	0.29	Calcium levels;	chr7:65829754	chr7:65840212~65840596:+
LUAD	cis	rs748404	0.631	rs6493084	ENSG00000249839.1	AC011330.5	-6.74	4.63e-11	2.75e-08	-0.38	-0.29	Lung cancer;	chr15:43355429	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.631	rs12905772	ENSG00000249839.1	AC011330.5	-6.74	4.63e-11	2.75e-08	-0.38	-0.29	Lung cancer;	chr15:43356246	chr15:43663654~43684339:-
LUAD	cis	rs11098499	0.863	rs2127823	ENSG00000248280.1	RP11-33B1.2	6.74	4.63e-11	2.75e-08	0.38	0.29	Corneal astigmatism;	chr4:119564515	chr4:119440561~119450157:-
LUAD	cis	rs2243480	1	rs410128	ENSG00000226824.5	RP4-756H11.3	-6.74	4.63e-11	2.75e-08	-0.56	-0.29	Diabetic kidney disease;	chr7:66138186	chr7:66654538~66669855:+
LUAD	cis	rs2412819	0.571	rs12443084	ENSG00000205771.5	CATSPER2P1	6.74	4.64e-11	2.76e-08	0.45	0.29	Lung cancer;	chr15:43748767	chr15:43726918~43747094:-
LUAD	cis	rs2946504	0.906	rs2946511	ENSG00000251468.2	RP11-369K16.1	6.74	4.64e-11	2.76e-08	0.36	0.29	Type 2 diabetes;	chr8:12949796	chr8:12958387~12962200:+
LUAD	cis	rs889312	0.504	rs62355900	ENSG00000271828.1	CTD-2310F14.1	6.74	4.64e-11	2.76e-08	0.47	0.29	Breast cancer (early onset);Breast cancer;	chr5:56756868	chr5:56927874~56929573:+
LUAD	cis	rs62355902	1	rs62355902	ENSG00000271828.1	CTD-2310F14.1	6.74	4.64e-11	2.76e-08	0.47	0.29	Breast cancer;Breast cancer (estrogen-receptor negative);	chr5:56757896	chr5:56927874~56929573:+
LUAD	cis	rs4964805	0.594	rs10861096	ENSG00000257681.1	RP11-341G23.4	6.74	4.65e-11	2.76e-08	0.34	0.29	Attention deficit hyperactivity disorder;	chr12:103775578	chr12:103746315~103768858:-
LUAD	cis	rs9309473	1	rs6755241	ENSG00000163016.8	ALMS1P	6.74	4.66e-11	2.77e-08	0.37	0.29	Metabolite levels;	chr2:73414236	chr2:73644919~73685576:+
LUAD	cis	rs34526934	0.566	rs62624470	ENSG00000226363.3	HAGLROS	6.74	4.67e-11	2.78e-08	0.41	0.29	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176176179	chr2:176177717~176179008:+
LUAD	cis	rs12458462	0.851	rs3859317	ENSG00000274828.1	RP11-567M16.6	6.74	4.68e-11	2.78e-08	0.3	0.29	Monocyte count;	chr18:79683093	chr18:79677287~79679358:-
LUAD	cis	rs9309711	0.698	rs9750503	ENSG00000225234.1	TRAPPC12-AS1	6.74	4.69e-11	2.78e-08	0.37	0.29	Neurofibrillary tangles;	chr2:3488001	chr2:3481242~3482409:-
LUAD	cis	rs9487094	0.666	rs9480956	ENSG00000260273.1	RP11-425D10.10	6.74	4.69e-11	2.78e-08	0.36	0.29	Height;	chr6:109424305	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.689	rs12214147	ENSG00000260273.1	RP11-425D10.10	6.74	4.69e-11	2.78e-08	0.36	0.29	Height;	chr6:109425054	chr6:109382795~109383666:+
LUAD	cis	rs75422866	0.867	rs35044089	ENSG00000257433.4	RP1-197B17.3	6.73	4.7e-11	2.79e-08	0.62	0.29	Pneumonia;	chr12:47610881	chr12:47706085~47742294:+
LUAD	cis	rs2243480	1	rs4718334	ENSG00000226824.5	RP4-756H11.3	6.73	4.7e-11	2.79e-08	0.55	0.29	Diabetic kidney disease;	chr7:66324467	chr7:66654538~66669855:+
LUAD	cis	rs748404	0.631	rs8042688	ENSG00000249839.1	AC011330.5	-6.73	4.71e-11	2.8e-08	-0.38	-0.29	Lung cancer;	chr15:43346327	chr15:43663654~43684339:-
LUAD	cis	rs7849270	0.959	rs9408986	ENSG00000268707.1	RP11-247A12.7	6.73	4.72e-11	2.8e-08	0.36	0.29	Blood metabolite ratios;	chr9:129126156	chr9:129170434~129170940:+
LUAD	cis	rs9368481	0.761	rs9348746	ENSG00000241549.7	GUSBP2	-6.73	4.72e-11	2.8e-08	-0.34	-0.29	Autism spectrum disorder or schizophrenia;	chr6:27002578	chr6:26871484~26956554:-
LUAD	cis	rs67311347	0.876	rs13068097	ENSG00000223797.4	ENTPD3-AS1	-6.73	4.73e-11	2.81e-08	-0.32	-0.29	Renal cell carcinoma;	chr3:40462933	chr3:40313802~40453329:-
LUAD	cis	rs17301013	0.507	rs6684688	ENSG00000227373.4	RP11-160H22.5	6.73	4.75e-11	2.82e-08	0.44	0.29	Systemic lupus erythematosus;	chr1:174357180	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs28628056	ENSG00000227373.4	RP11-160H22.5	6.73	4.75e-11	2.82e-08	0.44	0.29	Systemic lupus erythematosus;	chr1:174369545	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs10912772	ENSG00000227373.4	RP11-160H22.5	6.73	4.75e-11	2.82e-08	0.44	0.29	Systemic lupus erythematosus;	chr1:174370832	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12073751	ENSG00000227373.4	RP11-160H22.5	6.73	4.75e-11	2.82e-08	0.44	0.29	Systemic lupus erythematosus;	chr1:174373177	chr1:174115300~174160004:-
LUAD	cis	rs1823913	1	rs4853561	ENSG00000227542.1	AC092614.2	-6.73	4.75e-11	2.82e-08	-0.38	-0.29	Obesity-related traits;	chr2:191242980	chr2:191229165~191246172:-
LUAD	cis	rs1823913	1	rs6704784	ENSG00000227542.1	AC092614.2	-6.73	4.75e-11	2.82e-08	-0.38	-0.29	Obesity-related traits;	chr2:191244832	chr2:191229165~191246172:-
LUAD	cis	rs7626444	0.625	rs1798637	ENSG00000272359.1	U4	-6.73	4.79e-11	2.84e-08	-0.32	-0.29	Monocyte count;	chr3:196749768	chr3:196747192~196747324:-
LUAD	cis	rs7626444	0.625	rs7638090	ENSG00000272359.1	U4	-6.73	4.79e-11	2.84e-08	-0.32	-0.29	Monocyte count;	chr3:196749965	chr3:196747192~196747324:-
LUAD	cis	rs7626444	0.625	rs2669637	ENSG00000272359.1	U4	-6.73	4.79e-11	2.84e-08	-0.32	-0.29	Monocyte count;	chr3:196750498	chr3:196747192~196747324:-
LUAD	cis	rs7626444	0.625	rs1718410	ENSG00000272359.1	U4	-6.73	4.79e-11	2.84e-08	-0.32	-0.29	Monocyte count;	chr3:196750789	chr3:196747192~196747324:-
LUAD	cis	rs6142102	1	rs6059681	ENSG00000276073.1	RP5-1125A11.7	-6.73	4.79e-11	2.84e-08	-0.3	-0.29	Skin pigmentation;	chr20:34135535	chr20:33985617~33988989:-
LUAD	cis	rs9584850	0.874	rs3742137	ENSG00000231194.1	FARP1-AS1	6.73	4.79e-11	2.84e-08	0.36	0.29	Neuroticism;	chr13:98450195	chr13:98435405~98435840:-
LUAD	cis	rs6504622	0.902	rs7216991	ENSG00000262879.4	RP11-156P1.3	-6.73	4.8e-11	2.85e-08	-0.35	-0.29	Orofacial clefts;	chr17:46974887	chr17:46984045~47100323:-
LUAD	cis	rs6142102	1	rs4911412	ENSG00000276073.1	RP5-1125A11.7	-6.73	4.8e-11	2.85e-08	-0.3	-0.29	Skin pigmentation;	chr20:34128629	chr20:33985617~33988989:-
LUAD	cis	rs11098499	0.754	rs714899	ENSG00000248280.1	RP11-33B1.2	6.73	4.81e-11	2.85e-08	0.36	0.29	Corneal astigmatism;	chr4:119321880	chr4:119440561~119450157:-
LUAD	cis	rs6504950	0.888	rs2628315	ENSG00000275710.1	RP11-257O5.4	6.73	4.81e-11	2.85e-08	0.36	0.29	Breast cancer;	chr17:55149261	chr17:54964474~54964679:+
LUAD	cis	rs10759883	0.651	rs816670	ENSG00000175611.10	LINC00476	-6.73	4.81e-11	2.85e-08	-0.34	-0.29	Nicotine dependence;	chr9:95813152	chr9:95759231~95875977:-
LUAD	cis	rs2243480	1	rs160652	ENSG00000226824.5	RP4-756H11.3	-6.73	4.82e-11	2.85e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66073444	chr7:66654538~66669855:+
LUAD	cis	rs9368481	0.761	rs9379952	ENSG00000241549.7	GUSBP2	-6.73	4.82e-11	2.85e-08	-0.34	-0.29	Autism spectrum disorder or schizophrenia;	chr6:27020121	chr6:26871484~26956554:-
LUAD	cis	rs2337406	0.852	rs12050239	ENSG00000211974.3	IGHV2-70	-6.73	4.83e-11	2.86e-08	-0.37	-0.29	Alzheimer's disease (late onset);	chr14:106781132	chr14:106723574~106724093:-
LUAD	cis	rs2439831	0.681	rs3742969	ENSG00000205771.5	CATSPER2P1	-6.73	4.83e-11	2.86e-08	-0.49	-0.29	Lung cancer in ever smokers;	chr15:43329749	chr15:43726918~43747094:-
LUAD	cis	rs875971	1	rs7801282	ENSG00000222364.1	RNU6-96P	6.73	4.83e-11	2.86e-08	0.32	0.29	Aortic root size;	chr7:66148700	chr7:66395191~66395286:+
LUAD	cis	rs9326248	0.581	rs7106437	ENSG00000280143.1	AP000892.6	6.73	4.85e-11	2.87e-08	0.33	0.29	Blood protein levels;	chr11:117121360	chr11:117204967~117210292:+
LUAD	cis	rs67311347	1	rs13073003	ENSG00000223797.4	ENTPD3-AS1	-6.73	4.86e-11	2.88e-08	-0.31	-0.29	Renal cell carcinoma;	chr3:40462835	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs6801185	ENSG00000223797.4	ENTPD3-AS1	-6.73	4.86e-11	2.88e-08	-0.31	-0.29	Renal cell carcinoma;	chr3:40463569	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs13095055	ENSG00000223797.4	ENTPD3-AS1	-6.73	4.86e-11	2.88e-08	-0.31	-0.29	Renal cell carcinoma;	chr3:40464175	chr3:40313802~40453329:-
LUAD	cis	rs2117029	0.586	rs10875928	ENSG00000258017.1	RP11-386G11.10	-6.73	4.87e-11	2.88e-08	-0.36	-0.29	Intelligence (multi-trait analysis);	chr12:49162520	chr12:49127782~49147869:+
LUAD	cis	rs4964805	0.58	rs10861097	ENSG00000257681.1	RP11-341G23.4	6.73	4.87e-11	2.88e-08	0.34	0.29	Attention deficit hyperactivity disorder;	chr12:103776696	chr12:103746315~103768858:-
LUAD	cis	rs3762637	0.941	rs9810996	ENSG00000272758.4	RP11-299J3.8	-6.73	4.87e-11	2.89e-08	-0.46	-0.29	LDL cholesterol levels;	chr3:122355540	chr3:122416207~122443180:+
LUAD	cis	rs3762637	0.941	rs9810999	ENSG00000272758.4	RP11-299J3.8	-6.73	4.87e-11	2.89e-08	-0.46	-0.29	LDL cholesterol levels;	chr3:122355544	chr3:122416207~122443180:+
LUAD	cis	rs2243480	1	rs4718317	ENSG00000273142.1	RP11-458F8.4	6.73	4.88e-11	2.89e-08	0.3	0.29	Diabetic kidney disease;	chr7:66183914	chr7:66902857~66906297:+
LUAD	cis	rs760794	0.577	rs17483277	ENSG00000228412.5	RP4-625H18.2	6.73	4.9e-11	2.9e-08	0.35	0.29	Endometriosis;	chr6:19790340	chr6:19802164~19804752:-
LUAD	cis	rs1501911	0.713	rs10479344	ENSG00000248489.1	CTD-2007H13.3	-6.73	4.9e-11	2.9e-08	-0.32	-0.29	Lung function (FEV1/FVC);	chr5:99012676	chr5:98929171~98995013:+
LUAD	cis	rs9309473	0.861	rs6546857	ENSG00000163016.8	ALMS1P	6.73	4.91e-11	2.91e-08	0.37	0.29	Metabolite levels;	chr2:73610828	chr2:73644919~73685576:+
LUAD	cis	rs891378	0.651	rs7546693	ENSG00000274245.1	RP11-357P18.2	-6.73	4.92e-11	2.91e-08	-0.35	-0.29	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207192864	chr1:207372559~207373252:+
LUAD	cis	rs9326248	0.581	rs10892053	ENSG00000280143.1	AP000892.6	6.73	4.94e-11	2.92e-08	0.34	0.29	Blood protein levels;	chr11:116986287	chr11:117204967~117210292:+
LUAD	cis	rs6142102	0.923	rs4911379	ENSG00000276073.1	RP5-1125A11.7	-6.73	4.94e-11	2.92e-08	-0.3	-0.29	Skin pigmentation;	chr20:33947499	chr20:33985617~33988989:-
LUAD	cis	rs1799949	1	rs4793215	ENSG00000267681.1	CTD-3199J23.6	-6.73	4.94e-11	2.92e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43166915	chr17:43144956~43145255:+
LUAD	cis	rs10899021	0.79	rs59958321	ENSG00000279353.1	RP11-864N7.4	6.73	4.95e-11	2.93e-08	0.53	0.29	Response to metformin (IC50);	chr11:74643569	chr11:74698231~74699658:-
LUAD	cis	rs17684571	0.938	rs55742092	ENSG00000231441.1	RP11-472M19.2	6.73	4.95e-11	2.93e-08	0.4	0.29	Schizophrenia;	chr6:56708377	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.872	rs17684553	ENSG00000231441.1	RP11-472M19.2	6.73	4.95e-11	2.93e-08	0.4	0.29	Schizophrenia;	chr6:56708858	chr6:56844002~56864078:+
LUAD	cis	rs9903692	0.866	rs11079807	ENSG00000278765.1	RP5-890E16.5	-6.73	4.96e-11	2.93e-08	-0.38	-0.29	Pulse pressure;	chr17:48098685	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.954	rs10853094	ENSG00000278765.1	RP5-890E16.5	-6.73	4.96e-11	2.93e-08	-0.38	-0.29	Pulse pressure;	chr17:48098700	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.954	rs4794441	ENSG00000278765.1	RP5-890E16.5	-6.73	4.96e-11	2.93e-08	-0.38	-0.29	Pulse pressure;	chr17:48099094	chr17:48066704~48067293:-
LUAD	cis	rs12223324	0.654	rs10794338	ENSG00000279672.1	CMB9-55F22.1	-6.73	4.97e-11	2.94e-08	-0.36	-0.29	Fuchs's corneal dystrophy;	chr11:746992	chr11:779617~780755:+
LUAD	cis	rs950169	0.84	rs72748702	ENSG00000259728.4	LINC00933	6.73	4.98e-11	2.94e-08	0.44	0.29	Schizophrenia;	chr15:84246494	chr15:84570649~84580175:+
LUAD	cis	rs755249	1	rs755249	ENSG00000228060.1	RP11-69E11.8	-6.73	4.98e-11	2.94e-08	-0.29	-0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39529402	chr1:39565160~39573203:+
LUAD	cis	rs9326248	0.559	rs609177	ENSG00000280143.1	AP000892.6	6.73	4.99e-11	2.95e-08	0.34	0.29	Blood protein levels;	chr11:116899801	chr11:117204967~117210292:+
LUAD	cis	rs11096990	0.855	rs57488936	ENSG00000249207.1	RP11-360F5.1	6.72	5e-11	2.95e-08	0.33	0.29	Cognitive function;	chr4:39220626	chr4:39112677~39126818:-
LUAD	cis	rs7626444	0.627	rs5021326	ENSG00000272359.1	U4	-6.72	5.01e-11	2.96e-08	-0.33	-0.29	Monocyte count;	chr3:196750757	chr3:196747192~196747324:-
LUAD	cis	rs7626444	0.625	rs1357287	ENSG00000272359.1	U4	-6.72	5.01e-11	2.96e-08	-0.33	-0.29	Monocyte count;	chr3:196758096	chr3:196747192~196747324:-
LUAD	cis	rs6844153	1	rs6844153	ENSG00000240005.4	RP11-293A21.1	-6.72	5.01e-11	2.96e-08	-0.49	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26942692	chr4:26859806~26860599:-
LUAD	cis	rs9309473	1	rs10179134	ENSG00000163016.8	ALMS1P	6.72	5.02e-11	2.96e-08	0.37	0.29	Metabolite levels;	chr2:73410391	chr2:73644919~73685576:+
LUAD	cis	rs950169	0.922	rs62028133	ENSG00000259728.4	LINC00933	6.72	5.04e-11	2.98e-08	0.44	0.29	Schizophrenia;	chr15:84250623	chr15:84570649~84580175:+
LUAD	cis	rs881375	0.967	rs2416805	ENSG00000226752.6	PSMD5-AS1	-6.72	5.04e-11	2.98e-08	-0.32	-0.29	Rheumatoid arthritis;	chr9:120914204	chr9:120824828~120854385:+
LUAD	cis	rs12022452	0.591	rs61781641	ENSG00000238287.1	RP11-656D10.3	-6.72	5.04e-11	2.98e-08	-0.47	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40517412	chr1:40493157~40508661:-
LUAD	cis	rs12022452	0.591	rs11208315	ENSG00000238287.1	RP11-656D10.3	-6.72	5.04e-11	2.98e-08	-0.47	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40519730	chr1:40493157~40508661:-
LUAD	cis	rs12022452	0.591	rs12049435	ENSG00000238287.1	RP11-656D10.3	-6.72	5.04e-11	2.98e-08	-0.47	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40524888	chr1:40493157~40508661:-
LUAD	cis	rs9903692	0.648	rs35361214	ENSG00000278765.1	RP5-890E16.5	6.72	5.05e-11	2.98e-08	0.38	0.29	Pulse pressure;	chr17:48087729	chr17:48066704~48067293:-
LUAD	cis	rs1062177	0.826	rs2053063	ENSG00000213433.5	RPLP1P6	-6.72	5.05e-11	2.98e-08	-0.39	-0.29	Preschool internalizing problems;	chr5:151787203	chr5:151765859~151766378:-
LUAD	cis	rs35955747	0.934	rs5997966	ENSG00000236132.1	CTA-440B3.1	6.72	5.06e-11	2.98e-08	0.32	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31380260	chr22:31816379~31817491:-
LUAD	cis	rs11676348	0.808	rs12694430	ENSG00000261338.2	RP11-378A13.1	-6.72	5.06e-11	2.98e-08	-0.31	-0.29	Ulcerative colitis;	chr2:218151076	chr2:218255319~218257366:+
LUAD	cis	rs10740039	0.766	rs2119917	ENSG00000254271.1	RP11-131N11.4	6.72	5.06e-11	2.98e-08	0.34	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60677626	chr10:60734342~60741828:+
LUAD	cis	rs75422866	0.51	rs35784744	ENSG00000280054.1	RP1-197B17.7	6.72	5.06e-11	2.99e-08	0.64	0.29	Pneumonia;	chr12:47729646	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.541	rs12425816	ENSG00000280054.1	RP1-197B17.7	6.72	5.06e-11	2.99e-08	0.64	0.29	Pneumonia;	chr12:47731419	chr12:47728151~47730598:-
LUAD	cis	rs113835537	0.529	rs78999944	ENSG00000255517.5	CTD-3074O7.5	-6.72	5.08e-11	3e-08	-0.35	-0.29	Airway imaging phenotypes;	chr11:66483757	chr11:66473490~66480233:-
LUAD	cis	rs2842992	0.724	rs9365097	ENSG00000237927.1	RP3-393E18.2	-6.72	5.09e-11	3e-08	-0.41	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159790227	chr6:159586955~159589169:-
LUAD	cis	rs2842992	0.724	rs2273827	ENSG00000237927.1	RP3-393E18.2	-6.72	5.09e-11	3e-08	-0.41	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159790307	chr6:159586955~159589169:-
LUAD	cis	rs2842992	0.662	rs2273825	ENSG00000237927.1	RP3-393E18.2	-6.72	5.09e-11	3e-08	-0.41	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159790392	chr6:159586955~159589169:-
LUAD	cis	rs2842992	0.768	rs2273824	ENSG00000237927.1	RP3-393E18.2	-6.72	5.09e-11	3e-08	-0.41	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159790413	chr6:159586955~159589169:-
LUAD	cis	rs2842992	0.724	rs2273823	ENSG00000237927.1	RP3-393E18.2	-6.72	5.09e-11	3e-08	-0.41	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159790453	chr6:159586955~159589169:-
LUAD	cis	rs2842992	0.692	rs1128661	ENSG00000237927.1	RP3-393E18.2	-6.72	5.09e-11	3e-08	-0.41	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159790522	chr6:159586955~159589169:-
LUAD	cis	rs2842992	0.724	rs1128670	ENSG00000237927.1	RP3-393E18.2	-6.72	5.09e-11	3e-08	-0.41	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159790604	chr6:159586955~159589169:-
LUAD	cis	rs8059260	1	rs6498139	ENSG00000274038.1	RP11-66H6.4	-6.72	5.1e-11	3.01e-08	-0.48	-0.29	Alcohol consumption over the past year;	chr16:10954066	chr16:11056556~11057034:+
LUAD	cis	rs8059260	1	rs7185978	ENSG00000274038.1	RP11-66H6.4	-6.72	5.1e-11	3.01e-08	-0.48	-0.29	Alcohol consumption over the past year;	chr16:10954417	chr16:11056556~11057034:+
LUAD	cis	rs5753618	0.504	rs5753661	ENSG00000236132.1	CTA-440B3.1	-6.72	5.1e-11	3.01e-08	-0.36	-0.29	Colorectal cancer;	chr22:31503811	chr22:31816379~31817491:-
LUAD	cis	rs8177876	0.822	rs4324141	ENSG00000261838.4	RP11-303E16.6	-6.72	5.11e-11	3.01e-08	-0.63	-0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081220	chr16:81069854~81076598:+
LUAD	cis	rs55720021	1	rs55720021	ENSG00000232871.7	SEC1P	6.72	5.11e-11	3.01e-08	0.36	0.29	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr19:48640984	chr19:48638071~48682245:+
LUAD	cis	rs2243480	1	rs437889	ENSG00000273142.1	RP11-458F8.4	-6.72	5.11e-11	3.01e-08	-0.3	-0.29	Diabetic kidney disease;	chr7:66044247	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs402418	ENSG00000273142.1	RP11-458F8.4	-6.72	5.11e-11	3.01e-08	-0.3	-0.29	Diabetic kidney disease;	chr7:66044482	chr7:66902857~66906297:+
LUAD	cis	rs2243480	0.803	rs423187	ENSG00000273142.1	RP11-458F8.4	-6.72	5.11e-11	3.01e-08	-0.3	-0.29	Diabetic kidney disease;	chr7:66044512	chr7:66902857~66906297:+
LUAD	cis	rs7208859	0.623	rs426434	ENSG00000263531.1	RP13-753N3.1	6.72	5.11e-11	3.01e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30598335	chr17:30863921~30864940:-
LUAD	cis	rs10740039	0.842	rs10821819	ENSG00000254271.1	RP11-131N11.4	6.72	5.11e-11	3.01e-08	0.34	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60658857	chr10:60734342~60741828:+
LUAD	cis	rs7017914	0.905	rs2732102	ENSG00000223220.1	Y_RNA	-6.72	5.11e-11	3.01e-08	-0.32	-0.29	Bone mineral density;	chr8:71010637	chr8:70780914~70781008:-
LUAD	cis	rs2243480	1	rs67728539	ENSG00000273142.1	RP11-458F8.4	-6.72	5.12e-11	3.02e-08	-0.31	-0.29	Diabetic kidney disease;	chr7:65913137	chr7:66902857~66906297:+
LUAD	cis	rs2179367	0.887	rs2789492	ENSG00000231760.4	RP11-350J20.5	-6.72	5.13e-11	3.02e-08	-0.36	-0.29	Dupuytren's disease;	chr6:149426243	chr6:149796151~149826294:-
LUAD	cis	rs7927592	0.913	rs12285993	ENSG00000212093.1	AP000807.1	6.72	5.13e-11	3.02e-08	0.33	0.29	Total body bone mineral density;	chr11:68535070	chr11:68506083~68506166:-
LUAD	cis	rs10129255	0.957	rs10136560	ENSG00000211972.2	IGHV3-66	6.72	5.14e-11	3.03e-08	0.26	0.29	Kawasaki disease;	chr14:106787630	chr14:106675017~106675544:-
LUAD	cis	rs950169	0.686	rs12906474	ENSG00000259728.4	LINC00933	6.72	5.15e-11	3.03e-08	0.43	0.29	Schizophrenia;	chr15:84566006	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.81	rs2879976	ENSG00000259728.4	LINC00933	6.72	5.15e-11	3.03e-08	0.43	0.29	Schizophrenia;	chr15:84566347	chr15:84570649~84580175:+
LUAD	cis	rs9326248	0.581	rs10790167	ENSG00000280143.1	AP000892.6	6.72	5.15e-11	3.03e-08	0.34	0.29	Blood protein levels;	chr11:116930227	chr11:117204967~117210292:+
LUAD	cis	rs1799949	1	rs8176202	ENSG00000267681.1	CTD-3199J23.6	-6.72	5.16e-11	3.04e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43078211	chr17:43144956~43145255:+
LUAD	cis	rs55665837	1	rs12288873	ENSG00000251991.1	RNU7-49P	6.72	5.16e-11	3.04e-08	0.33	0.29	Vitamin D levels;	chr11:14428919	chr11:14478892~14478953:+
LUAD	cis	rs4141404	0.64	rs9606854	ENSG00000236132.1	CTA-440B3.1	-6.72	5.2e-11	3.06e-08	-0.41	-0.29	Paclitaxel-induced neuropathy;	chr22:31534581	chr22:31816379~31817491:-
LUAD	cis	rs17023223	0.537	rs2794310	ENSG00000231365.4	RP11-418J17.1	-6.72	5.2e-11	3.06e-08	-0.38	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119019307	chr1:119140396~119275973:+
LUAD	cis	rs1799949	1	rs1973646	ENSG00000267681.1	CTD-3199J23.6	-6.72	5.2e-11	3.06e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43158478	chr17:43144956~43145255:+
LUAD	cis	rs11096990	0.855	rs1597722	ENSG00000249207.1	RP11-360F5.1	-6.72	5.21e-11	3.07e-08	-0.33	-0.29	Cognitive function;	chr4:39173255	chr4:39112677~39126818:-
LUAD	cis	rs17301013	0.606	rs12087808	ENSG00000227373.4	RP11-160H22.5	6.72	5.22e-11	3.07e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174178848	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs10912740	ENSG00000227373.4	RP11-160H22.5	6.72	5.22e-11	3.07e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174180224	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs724888	ENSG00000227373.4	RP11-160H22.5	6.72	5.22e-11	3.07e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174180403	chr1:174115300~174160004:-
LUAD	cis	rs17711722	0.565	rs73372653	ENSG00000236529.1	RP13-254B10.1	6.72	5.23e-11	3.08e-08	0.3	0.29	Calcium levels;	chr7:65977808	chr7:65840212~65840596:+
LUAD	cis	rs9309473	1	rs7594511	ENSG00000163016.8	ALMS1P	6.72	5.24e-11	3.09e-08	0.36	0.29	Metabolite levels;	chr2:73454512	chr2:73644919~73685576:+
LUAD	cis	rs2243480	1	rs316315	ENSG00000273142.1	RP11-458F8.4	6.72	5.25e-11	3.09e-08	0.27	0.29	Diabetic kidney disease;	chr7:66126218	chr7:66902857~66906297:+
LUAD	cis	rs9309473	1	rs9653557	ENSG00000163016.8	ALMS1P	6.72	5.25e-11	3.09e-08	0.36	0.29	Metabolite levels;	chr2:73568835	chr2:73644919~73685576:+
LUAD	cis	rs17818399	0.574	rs6544907	ENSG00000279254.1	RP11-536C12.1	-6.72	5.27e-11	3.1e-08	-0.3	-0.29	Height;	chr2:46641180	chr2:46668870~46670778:+
LUAD	cis	rs6860806	0.507	rs635620	ENSG00000233006.5	AC034220.3	-6.72	5.27e-11	3.1e-08	-0.29	-0.29	Breast cancer;	chr5:132384571	chr5:132311285~132369916:-
LUAD	cis	rs6860806	0.507	rs635619	ENSG00000233006.5	AC034220.3	-6.72	5.27e-11	3.1e-08	-0.29	-0.29	Breast cancer;	chr5:132384573	chr5:132311285~132369916:-
LUAD	cis	rs7044106	0.791	rs10985004	ENSG00000238181.2	AHCYP2	-6.72	5.28e-11	3.1e-08	-0.39	-0.29	Hip circumference adjusted for BMI;	chr9:120722659	chr9:120720673~120721972:+
LUAD	cis	rs7017914	0.967	rs6982406	ENSG00000223220.1	Y_RNA	6.72	5.28e-11	3.11e-08	0.32	0.29	Bone mineral density;	chr8:70742373	chr8:70780914~70781008:-
LUAD	cis	rs2720460	0.502	rs223374	ENSG00000251288.2	RP11-10L12.2	-6.72	5.28e-11	3.11e-08	-0.36	-0.29	Testicular germ cell tumor;	chr4:102837144	chr4:102751401~102752641:+
LUAD	cis	rs17818399	0.597	rs12104572	ENSG00000279254.1	RP11-536C12.1	-6.72	5.28e-11	3.11e-08	-0.3	-0.29	Height;	chr2:46635327	chr2:46668870~46670778:+
LUAD	cis	rs1823913	0.599	rs13035132	ENSG00000227542.1	AC092614.2	6.72	5.29e-11	3.11e-08	0.35	0.29	Obesity-related traits;	chr2:191265275	chr2:191229165~191246172:-
LUAD	cis	rs2243480	1	rs160643	ENSG00000273142.1	RP11-458F8.4	-6.72	5.29e-11	3.11e-08	-0.28	-0.29	Diabetic kidney disease;	chr7:66093235	chr7:66902857~66906297:+
LUAD	cis	rs67311347	1	rs9827461	ENSG00000223797.4	ENTPD3-AS1	6.72	5.29e-11	3.11e-08	0.32	0.29	Renal cell carcinoma;	chr3:40447860	chr3:40313802~40453329:-
LUAD	cis	rs35934224	0.891	rs12158214	ENSG00000232926.1	AC000078.5	6.72	5.31e-11	3.12e-08	0.32	0.29	Glaucoma (primary open-angle);	chr22:19884168	chr22:19887289~19887970:+
LUAD	cis	rs2739330	0.828	rs4822454	ENSG00000228039.3	KB-1125A3.10	6.72	5.31e-11	3.12e-08	0.36	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23963780~23964374:+
LUAD	cis	rs748404	0.66	rs493377	ENSG00000249839.1	AC011330.5	-6.71	5.32e-11	3.13e-08	-0.38	-0.29	Lung cancer;	chr15:43481269	chr15:43663654~43684339:-
LUAD	cis	rs12908161	1	rs35316992	ENSG00000259728.4	LINC00933	6.71	5.32e-11	3.13e-08	0.43	0.29	Schizophrenia;	chr15:84704902	chr15:84570649~84580175:+
LUAD	cis	rs12908161	1	rs4643294	ENSG00000259728.4	LINC00933	6.71	5.32e-11	3.13e-08	0.43	0.29	Schizophrenia;	chr15:84707022	chr15:84570649~84580175:+
LUAD	cis	rs12908161	1	rs62021219	ENSG00000259728.4	LINC00933	6.71	5.32e-11	3.13e-08	0.43	0.29	Schizophrenia;	chr15:84712928	chr15:84570649~84580175:+
LUAD	cis	rs12908161	1	rs34900908	ENSG00000259728.4	LINC00933	6.71	5.32e-11	3.13e-08	0.43	0.29	Schizophrenia;	chr15:84714368	chr15:84570649~84580175:+
LUAD	cis	rs12908161	1	rs35524990	ENSG00000259728.4	LINC00933	6.71	5.32e-11	3.13e-08	0.43	0.29	Schizophrenia;	chr15:84714972	chr15:84570649~84580175:+
LUAD	cis	rs7017914	0.934	rs7015035	ENSG00000223220.1	Y_RNA	6.71	5.32e-11	3.13e-08	0.32	0.29	Bone mineral density;	chr8:70741366	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs34905858	ENSG00000223220.1	Y_RNA	6.71	5.32e-11	3.13e-08	0.32	0.29	Bone mineral density;	chr8:70747215	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.934	rs6998024	ENSG00000223220.1	Y_RNA	6.71	5.32e-11	3.13e-08	0.32	0.29	Bone mineral density;	chr8:70748605	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs35960437	ENSG00000223220.1	Y_RNA	6.71	5.32e-11	3.13e-08	0.32	0.29	Bone mineral density;	chr8:70749725	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs34409123	ENSG00000223220.1	Y_RNA	6.71	5.32e-11	3.13e-08	0.32	0.29	Bone mineral density;	chr8:70749881	chr8:70780914~70781008:-
LUAD	cis	rs2243480	1	rs160639	ENSG00000226824.5	RP4-756H11.3	-6.71	5.33e-11	3.13e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66115000	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs313824	ENSG00000226824.5	RP4-756H11.3	-6.71	5.33e-11	3.13e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66116220	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs186378	ENSG00000226824.5	RP4-756H11.3	-6.71	5.33e-11	3.13e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66117071	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs160637	ENSG00000226824.5	RP4-756H11.3	-6.71	5.33e-11	3.13e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66119331	chr7:66654538~66669855:+
LUAD	cis	rs5753618	0.539	rs695438	ENSG00000236132.1	CTA-440B3.1	-6.71	5.33e-11	3.13e-08	-0.34	-0.29	Colorectal cancer;	chr22:31415890	chr22:31816379~31817491:-
LUAD	cis	rs1799949	1	rs8176242	ENSG00000267681.1	CTD-3199J23.6	-6.71	5.34e-11	3.14e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43065857	chr17:43144956~43145255:+
LUAD	cis	rs1823913	1	rs1454749	ENSG00000227542.1	AC092614.2	6.71	5.34e-11	3.14e-08	0.38	0.29	Obesity-related traits;	chr2:191240909	chr2:191229165~191246172:-
LUAD	cis	rs7246657	1	rs10426297	ENSG00000276846.1	CTD-3220F14.3	6.71	5.36e-11	3.15e-08	0.41	0.29	Coronary artery calcification;	chr19:37307471	chr19:37314868~37315620:-
LUAD	cis	rs7246657	1	rs1823061	ENSG00000276846.1	CTD-3220F14.3	6.71	5.36e-11	3.15e-08	0.41	0.29	Coronary artery calcification;	chr19:37309724	chr19:37314868~37315620:-
LUAD	cis	rs2302464	1	rs4342183	ENSG00000214846.4	RP11-115L11.1	6.71	5.36e-11	3.15e-08	0.78	0.29	Cerebrospinal fluid biomarker levels;	chr4:15733817	chr4:15730962~15731627:-
LUAD	cis	rs2412819	0.545	rs3862143	ENSG00000205771.5	CATSPER2P1	6.71	5.37e-11	3.15e-08	0.45	0.29	Lung cancer;	chr15:43779282	chr15:43726918~43747094:-
LUAD	cis	rs7567389	0.51	rs1473623	ENSG00000236682.1	AC068282.3	6.71	5.38e-11	3.16e-08	0.36	0.29	Self-rated health;	chr2:127438644	chr2:127389130~127400580:+
LUAD	cis	rs673078	0.607	rs7294498	ENSG00000275759.1	RP11-131L12.3	-6.71	5.4e-11	3.17e-08	-0.38	-0.29	Glucose homeostasis traits;	chr12:118321680	chr12:118428281~118428870:+
LUAD	cis	rs12458462	0.892	rs12456692	ENSG00000274828.1	RP11-567M16.6	6.71	5.4e-11	3.17e-08	0.31	0.29	Monocyte count;	chr18:79722189	chr18:79677287~79679358:-
LUAD	cis	rs1113500	0.541	rs11185241	ENSG00000226822.1	RP11-356N1.2	6.71	5.41e-11	3.18e-08	0.4	0.29	Growth-regulated protein alpha levels;	chr1:108040403	chr1:108071482~108074519:+
LUAD	cis	rs9309473	1	rs10190219	ENSG00000163016.8	ALMS1P	6.71	5.42e-11	3.18e-08	0.36	0.29	Metabolite levels;	chr2:73431203	chr2:73644919~73685576:+
LUAD	cis	rs5753618	0.504	rs9606847	ENSG00000236132.1	CTA-440B3.1	-6.71	5.44e-11	3.19e-08	-0.36	-0.29	Colorectal cancer;	chr22:31505803	chr22:31816379~31817491:-
LUAD	cis	rs5753618	0.504	rs9606848	ENSG00000236132.1	CTA-440B3.1	-6.71	5.44e-11	3.19e-08	-0.36	-0.29	Colorectal cancer;	chr22:31505881	chr22:31816379~31817491:-
LUAD	cis	rs2286503	0.839	rs2240728	ENSG00000228649.7	AC005682.5	6.71	5.44e-11	3.19e-08	0.37	0.29	Fibrinogen;	chr7:22812880	chr7:22854178~22861579:+
LUAD	cis	rs9309473	1	rs62151652	ENSG00000163016.8	ALMS1P	6.71	5.45e-11	3.2e-08	0.36	0.29	Metabolite levels;	chr2:73473004	chr2:73644919~73685576:+
LUAD	cis	rs673078	0.66	rs73205551	ENSG00000275759.1	RP11-131L12.3	-6.71	5.46e-11	3.2e-08	-0.38	-0.29	Glucose homeostasis traits;	chr12:118330808	chr12:118428281~118428870:+
LUAD	cis	rs7246657	0.943	rs13343471	ENSG00000276846.1	CTD-3220F14.3	6.71	5.46e-11	3.2e-08	0.44	0.29	Coronary artery calcification;	chr19:37441228	chr19:37314868~37315620:-
LUAD	cis	rs4713118	0.662	rs149946	ENSG00000219392.1	RP1-265C24.5	6.71	5.47e-11	3.21e-08	0.39	0.29	Parkinson's disease;	chr6:28002253	chr6:28115628~28116551:+
LUAD	cis	rs2739330	0.892	rs4822455	ENSG00000206090.4	AP000350.7	6.71	5.47e-11	3.21e-08	0.33	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23939998~23942798:+
LUAD	cis	rs11098499	0.604	rs17051352	ENSG00000248280.1	RP11-33B1.2	6.71	5.47e-11	3.21e-08	0.38	0.29	Corneal astigmatism;	chr4:119660272	chr4:119440561~119450157:-
LUAD	cis	rs9326248	0.581	rs11216267	ENSG00000280143.1	AP000892.6	6.71	5.48e-11	3.21e-08	0.34	0.29	Blood protein levels;	chr11:117081676	chr11:117204967~117210292:+
LUAD	cis	rs1972460	0.506	rs62012050	ENSG00000255769.6	GOLGA2P10	-6.71	5.48e-11	3.21e-08	-0.34	-0.29	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82472993~82513950:-
LUAD	cis	rs9326248	0.52	rs10892060	ENSG00000280143.1	AP000892.6	6.71	5.48e-11	3.22e-08	0.34	0.29	Blood protein levels;	chr11:117010946	chr11:117204967~117210292:+
LUAD	cis	rs150992	0.593	rs326491	ENSG00000248489.1	CTD-2007H13.3	6.71	5.48e-11	3.22e-08	0.32	0.29	Body mass index;	chr5:98972225	chr5:98929171~98995013:+
LUAD	cis	rs950169	0.526	rs698620	ENSG00000225151.9	GOLGA2P7	6.71	5.49e-11	3.22e-08	0.34	0.29	Schizophrenia;	chr15:84633977	chr15:84199311~84230136:-
LUAD	cis	rs77204473	0.744	rs80143284	ENSG00000254851.1	RP11-109L13.1	6.71	5.5e-11	3.22e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117042854	chr11:117135528~117138582:+
LUAD	cis	rs7615952	0.8	rs12489350	ENSG00000171084.14	FAM86JP	6.71	5.51e-11	3.23e-08	0.42	0.29	Blood pressure (smoking interaction);	chr3:125925273	chr3:125916620~125930024:+
LUAD	cis	rs2283792	1	rs5999515	ENSG00000224086.5	LL22NC03-86G7.1	6.71	5.53e-11	3.24e-08	0.28	0.29	Multiple sclerosis;	chr22:21790812	chr22:21938293~21977632:+
LUAD	cis	rs9549367	0.707	rs9549353	ENSG00000269125.1	RP11-98F14.11	-6.71	5.54e-11	3.25e-08	-0.39	-0.29	Platelet distribution width;	chr13:113189113	chr13:113165002~113165183:-
LUAD	cis	rs7208859	0.673	rs1347360	ENSG00000263531.1	RP13-753N3.1	6.71	5.54e-11	3.25e-08	0.56	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587514	chr17:30863921~30864940:-
LUAD	cis	rs765787	0.53	rs12910270	ENSG00000259520.4	CTD-2651B20.3	-6.71	5.55e-11	3.25e-08	-0.39	-0.29	Uric acid levels;	chr15:45219888	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs12915804	ENSG00000259520.4	CTD-2651B20.3	-6.71	5.55e-11	3.25e-08	-0.39	-0.29	Uric acid levels;	chr15:45220364	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.556	rs12915965	ENSG00000259520.4	CTD-2651B20.3	-6.71	5.55e-11	3.25e-08	-0.39	-0.29	Uric acid levels;	chr15:45220449	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs12440238	ENSG00000259520.4	CTD-2651B20.3	-6.71	5.55e-11	3.25e-08	-0.39	-0.29	Uric acid levels;	chr15:45220707	chr15:45251580~45279251:-
LUAD	cis	rs2243480	1	rs316330	ENSG00000226824.5	RP4-756H11.3	-6.71	5.56e-11	3.26e-08	-0.56	-0.29	Diabetic kidney disease;	chr7:66140385	chr7:66654538~66669855:+
LUAD	cis	rs4718428	0.705	rs2901311	ENSG00000226824.5	RP4-756H11.3	-6.71	5.57e-11	3.26e-08	-0.4	-0.29	Corneal structure;	chr7:66950082	chr7:66654538~66669855:+
LUAD	cis	rs12429206	0.52	rs75594262	ENSG00000233672.5	RNASEH2B-AS1	-6.71	5.57e-11	3.26e-08	-0.43	-0.29	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50900249	chr13:50862172~50910764:-
LUAD	cis	rs6991838	0.765	rs4424306	ENSG00000200714.1	Y_RNA	6.71	5.57e-11	3.26e-08	0.34	0.29	Intelligence (multi-trait analysis);	chr8:65618674	chr8:65592731~65592820:+
LUAD	cis	rs9309473	0.898	rs28879089	ENSG00000163016.8	ALMS1P	6.71	5.57e-11	3.26e-08	0.36	0.29	Metabolite levels;	chr2:73585759	chr2:73644919~73685576:+
LUAD	cis	rs73219805	0.759	rs3808578	ENSG00000228451.3	SDAD1P1	-6.71	5.57e-11	3.26e-08	-0.52	-0.29	Schizophrenia;	chr8:26393906	chr8:26379259~26382953:-
LUAD	cis	rs2115630	0.691	rs8040066	ENSG00000225151.9	GOLGA2P7	6.71	5.58e-11	3.27e-08	0.34	0.29	P wave terminal force;	chr15:84633234	chr15:84199311~84230136:-
LUAD	cis	rs17301013	0.606	rs10912750	ENSG00000227373.4	RP11-160H22.5	6.71	5.6e-11	3.28e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174253637	chr1:174115300~174160004:-
LUAD	cis	rs2243480	1	rs313813	ENSG00000226824.5	RP4-756H11.3	-6.71	5.61e-11	3.28e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66038513	chr7:66654538~66669855:+
LUAD	cis	rs113835537	0.529	rs80100524	ENSG00000255517.5	CTD-3074O7.5	-6.71	5.61e-11	3.29e-08	-0.35	-0.29	Airway imaging phenotypes;	chr11:66478465	chr11:66473490~66480233:-
LUAD	cis	rs17301013	0.507	rs10489256	ENSG00000227373.4	RP11-160H22.5	6.71	5.62e-11	3.29e-08	0.45	0.29	Systemic lupus erythematosus;	chr1:174359663	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs4651016	ENSG00000227373.4	RP11-160H22.5	6.71	5.62e-11	3.29e-08	0.45	0.29	Systemic lupus erythematosus;	chr1:174375146	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs12082461	ENSG00000227373.4	RP11-160H22.5	6.71	5.63e-11	3.3e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174169876	chr1:174115300~174160004:-
LUAD	cis	rs2243480	1	rs35396113	ENSG00000226824.5	RP4-756H11.3	-6.71	5.63e-11	3.3e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66030474	chr7:66654538~66669855:+
LUAD	cis	rs11098499	0.691	rs12510133	ENSG00000248280.1	RP11-33B1.2	6.71	5.64e-11	3.3e-08	0.34	0.29	Corneal astigmatism;	chr4:119350189	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs12506487	ENSG00000248280.1	RP11-33B1.2	6.71	5.64e-11	3.3e-08	0.34	0.29	Corneal astigmatism;	chr4:119350206	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.691	rs12502524	ENSG00000248280.1	RP11-33B1.2	6.71	5.64e-11	3.3e-08	0.34	0.29	Corneal astigmatism;	chr4:119350259	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.691	rs28396837	ENSG00000248280.1	RP11-33B1.2	6.71	5.64e-11	3.3e-08	0.34	0.29	Corneal astigmatism;	chr4:119350386	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.629	rs28369518	ENSG00000248280.1	RP11-33B1.2	6.71	5.64e-11	3.3e-08	0.34	0.29	Corneal astigmatism;	chr4:119350475	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.722	rs10025925	ENSG00000248280.1	RP11-33B1.2	6.71	5.64e-11	3.3e-08	0.34	0.29	Corneal astigmatism;	chr4:119350589	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.731	rs10015579	ENSG00000248280.1	RP11-33B1.2	6.71	5.64e-11	3.3e-08	0.34	0.29	Corneal astigmatism;	chr4:119350647	chr4:119440561~119450157:-
LUAD	cis	rs55665837	1	rs34382046	ENSG00000251991.1	RNU7-49P	6.71	5.66e-11	3.31e-08	0.33	0.29	Vitamin D levels;	chr11:14429772	chr11:14478892~14478953:+
LUAD	cis	rs55665837	1	rs7945167	ENSG00000251991.1	RNU7-49P	6.71	5.66e-11	3.31e-08	0.33	0.29	Vitamin D levels;	chr11:14430274	chr11:14478892~14478953:+
LUAD	cis	rs55665837	0.961	rs60622588	ENSG00000251991.1	RNU7-49P	6.71	5.66e-11	3.31e-08	0.33	0.29	Vitamin D levels;	chr11:14435452	chr11:14478892~14478953:+
LUAD	cis	rs55665837	1	rs11023223	ENSG00000251991.1	RNU7-49P	6.71	5.66e-11	3.31e-08	0.33	0.29	Vitamin D levels;	chr11:14435566	chr11:14478892~14478953:+
LUAD	cis	rs7923609	0.902	rs10733793	ENSG00000232075.1	MRPL35P2	-6.71	5.66e-11	3.31e-08	-0.35	-0.29	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63564049	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.902	rs10822182	ENSG00000232075.1	MRPL35P2	-6.71	5.66e-11	3.31e-08	-0.35	-0.29	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63565718	chr10:63634317~63634827:-
LUAD	cis	rs1062177	1	rs892006	ENSG00000213433.5	RPLP1P6	-6.71	5.66e-11	3.31e-08	-0.38	-0.29	Preschool internalizing problems;	chr5:151801329	chr5:151765859~151766378:-
LUAD	cis	rs7626444	0.625	rs2669638	ENSG00000272359.1	U4	-6.71	5.66e-11	3.31e-08	-0.32	-0.29	Monocyte count;	chr3:196750527	chr3:196747192~196747324:-
LUAD	cis	rs7626444	0.625	rs2686593	ENSG00000272359.1	U4	-6.71	5.66e-11	3.31e-08	-0.32	-0.29	Monocyte count;	chr3:196750530	chr3:196747192~196747324:-
LUAD	cis	rs5753618	0.583	rs5753639	ENSG00000236132.1	CTA-440B3.1	6.7	5.66e-11	3.31e-08	0.35	0.29	Colorectal cancer;	chr22:31474414	chr22:31816379~31817491:-
LUAD	cis	rs2243480	0.901	rs778732	ENSG00000226824.5	RP4-756H11.3	-6.7	5.66e-11	3.31e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66357373	chr7:66654538~66669855:+
LUAD	cis	rs2734839	0.929	rs11608185	ENSG00000270179.1	RP11-159N11.4	-6.7	5.66e-11	3.31e-08	-0.29	-0.29	Information processing speed;	chr11:113424254	chr11:113368478~113369117:+
LUAD	cis	rs891378	0.785	rs10158940	ENSG00000274245.1	RP11-357P18.2	-6.7	5.66e-11	3.31e-08	-0.35	-0.29	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207191575	chr1:207372559~207373252:+
LUAD	cis	rs7811142	1	rs4472444	ENSG00000242294.5	STAG3L5P	6.7	5.67e-11	3.31e-08	0.24	0.29	Platelet count;	chr7:100473135	chr7:100336079~100351900:+
LUAD	cis	rs12594515	0.591	rs35554150	ENSG00000273972.1	CTD-2306A12.1	-6.7	5.67e-11	3.32e-08	-0.35	-0.29	Weight;Waist circumference;	chr15:45698100	chr15:45702640~45703183:+
LUAD	cis	rs150992	0.714	rs76798907	ENSG00000248489.1	CTD-2007H13.3	6.7	5.68e-11	3.32e-08	0.33	0.29	Body mass index;	chr5:98990780	chr5:98929171~98995013:+
LUAD	cis	rs17301013	0.606	rs10912737	ENSG00000227373.4	RP11-160H22.5	6.7	5.69e-11	3.33e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174172999	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.531	rs12079687	ENSG00000227373.4	RP11-160H22.5	6.7	5.69e-11	3.33e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174175545	chr1:174115300~174160004:-
LUAD	cis	rs950169	0.922	rs4338765	ENSG00000259728.4	LINC00933	6.7	5.7e-11	3.33e-08	0.44	0.29	Schizophrenia;	chr15:84248084	chr15:84570649~84580175:+
LUAD	cis	rs5753618	0.529	rs5749298	ENSG00000236132.1	CTA-440B3.1	-6.7	5.71e-11	3.34e-08	-0.36	-0.29	Colorectal cancer;	chr22:31545046	chr22:31816379~31817491:-
LUAD	cis	rs7829975	0.633	rs2979181	ENSG00000253893.2	FAM85B	-6.7	5.72e-11	3.34e-08	-0.36	-0.29	Mood instability;	chr8:8465578	chr8:8167819~8226614:-
LUAD	cis	rs875971	1	rs6979382	ENSG00000222364.1	RNU6-96P	-6.7	5.72e-11	3.35e-08	-0.33	-0.29	Aortic root size;	chr7:66421388	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs6961990	ENSG00000222364.1	RNU6-96P	-6.7	5.72e-11	3.35e-08	-0.33	-0.29	Aortic root size;	chr7:66423583	chr7:66395191~66395286:+
LUAD	cis	rs3813579	0.654	rs4480821	ENSG00000261390.4	RP11-345M22.2	-6.7	5.72e-11	3.35e-08	-0.36	-0.29	Thyroid volume;	chr16:79711416	chr16:79715232~79770563:-
LUAD	cis	rs5753618	0.555	rs5749291	ENSG00000236132.1	CTA-440B3.1	-6.7	5.73e-11	3.35e-08	-0.36	-0.29	Colorectal cancer;	chr22:31511537	chr22:31816379~31817491:-
LUAD	cis	rs5753618	0.504	rs7284622	ENSG00000236132.1	CTA-440B3.1	-6.7	5.73e-11	3.35e-08	-0.36	-0.29	Colorectal cancer;	chr22:31511999	chr22:31816379~31817491:-
LUAD	cis	rs12022452	0.591	rs4660415	ENSG00000238287.1	RP11-656D10.3	-6.7	5.74e-11	3.35e-08	-0.46	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40512819	chr1:40493157~40508661:-
LUAD	cis	rs12022452	0.556	rs11208298	ENSG00000238287.1	RP11-656D10.3	-6.7	5.74e-11	3.35e-08	-0.46	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40513206	chr1:40493157~40508661:-
LUAD	cis	rs2015599	0.514	rs10843376	ENSG00000275476.1	RP11-996F15.4	6.7	5.74e-11	3.36e-08	0.32	0.29	Platelet count;Mean platelet volume;	chr12:29283651	chr12:29277397~29277882:-
LUAD	cis	rs9318086	0.712	rs9510916	ENSG00000205861.10	C1QTNF9B-AS1	-6.7	5.75e-11	3.36e-08	-0.35	-0.29	Myopia (pathological);	chr13:23868650	chr13:23888889~23897263:+
LUAD	cis	rs113835537	0.529	rs3892818	ENSG00000255517.5	CTD-3074O7.5	-6.7	5.75e-11	3.36e-08	-0.34	-0.29	Airway imaging phenotypes;	chr11:66472720	chr11:66473490~66480233:-
LUAD	cis	rs2243480	1	rs1638734	ENSG00000273142.1	RP11-458F8.4	-6.7	5.76e-11	3.36e-08	-0.3	-0.29	Diabetic kidney disease;	chr7:66632552	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs313820	ENSG00000226824.5	RP4-756H11.3	-6.7	5.76e-11	3.36e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66109479	chr7:66654538~66669855:+
LUAD	cis	rs4713118	0.513	rs149954	ENSG00000219392.1	RP1-265C24.5	-6.7	5.77e-11	3.37e-08	-0.38	-0.29	Parkinson's disease;	chr6:28067468	chr6:28115628~28116551:+
LUAD	cis	rs9828933	0.752	rs73117082	ENSG00000280620.1	SCAANT1	6.7	5.77e-11	3.37e-08	0.47	0.29	Type 2 diabetes;	chr3:63961889	chr3:63911518~63911772:-
LUAD	cis	rs8177876	0.749	rs11865207	ENSG00000261838.4	RP11-303E16.6	6.7	5.77e-11	3.37e-08	0.54	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81056055	chr16:81069854~81076598:+
LUAD	cis	rs35955747	0.934	rs5997981	ENSG00000236132.1	CTA-440B3.1	6.7	5.79e-11	3.38e-08	0.32	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31412841	chr22:31816379~31817491:-
LUAD	cis	rs35955747	0.934	rs926928	ENSG00000236132.1	CTA-440B3.1	6.7	5.79e-11	3.38e-08	0.32	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31425733	chr22:31816379~31817491:-
LUAD	cis	rs748404	0.66	rs2467738	ENSG00000249839.1	AC011330.5	-6.7	5.8e-11	3.38e-08	-0.38	-0.29	Lung cancer;	chr15:43447738	chr15:43663654~43684339:-
LUAD	cis	rs8062405	0.573	rs11645306	ENSG00000259982.1	CDC37P1	-6.7	5.8e-11	3.39e-08	-0.4	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28972615	chr16:28700294~28701540:-
LUAD	cis	rs944289	0.531	rs1169149	ENSG00000257826.1	RP11-116N8.4	-6.7	5.81e-11	3.39e-08	-0.33	-0.29	Thyroid cancer;	chr14:36165019	chr14:36061026~36067190:-
LUAD	cis	rs2243480	1	rs4718333	ENSG00000226824.5	RP4-756H11.3	6.7	5.81e-11	3.39e-08	0.55	0.29	Diabetic kidney disease;	chr7:66307771	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs7792391	ENSG00000226824.5	RP4-756H11.3	6.7	5.81e-11	3.39e-08	0.55	0.29	Diabetic kidney disease;	chr7:66308442	chr7:66654538~66669855:+
LUAD	cis	rs465969	0.744	rs9400477	ENSG00000255389.1	C6orf3	6.7	5.82e-11	3.4e-08	0.65	0.29	Psoriasis;	chr6:111469440	chr6:111599875~111602295:+
LUAD	cis	rs465969	0.546	rs7772141	ENSG00000255389.1	C6orf3	6.7	5.82e-11	3.4e-08	0.65	0.29	Psoriasis;	chr6:111472358	chr6:111599875~111602295:+
LUAD	cis	rs465969	0.793	rs7776047	ENSG00000255389.1	C6orf3	6.7	5.82e-11	3.4e-08	0.65	0.29	Psoriasis;	chr6:111472391	chr6:111599875~111602295:+
LUAD	cis	rs7208859	0.573	rs7222803	ENSG00000263531.1	RP13-753N3.1	6.7	5.83e-11	3.4e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30863921~30864940:-
LUAD	cis	rs3762637	1	rs9842736	ENSG00000272758.4	RP11-299J3.8	-6.7	5.84e-11	3.41e-08	-0.46	-0.29	LDL cholesterol levels;	chr3:122442254	chr3:122416207~122443180:+
LUAD	cis	rs3762637	1	rs13321097	ENSG00000272758.4	RP11-299J3.8	-6.7	5.84e-11	3.41e-08	-0.46	-0.29	LDL cholesterol levels;	chr3:122443160	chr3:122416207~122443180:+
LUAD	cis	rs3762637	0.941	rs112768052	ENSG00000272758.4	RP11-299J3.8	-6.7	5.84e-11	3.41e-08	-0.46	-0.29	LDL cholesterol levels;	chr3:122450537	chr3:122416207~122443180:+
LUAD	cis	rs3762637	0.941	rs77599736	ENSG00000272758.4	RP11-299J3.8	-6.7	5.84e-11	3.41e-08	-0.46	-0.29	LDL cholesterol levels;	chr3:122460662	chr3:122416207~122443180:+
LUAD	cis	rs4718428	0.672	rs36038499	ENSG00000273142.1	RP11-458F8.4	-6.7	5.86e-11	3.42e-08	-0.22	-0.29	Corneal structure;	chr7:66824628	chr7:66902857~66906297:+
LUAD	cis	rs17826219	0.568	rs2626985	ENSG00000263531.1	RP13-753N3.1	6.7	5.87e-11	3.43e-08	0.57	0.29	Body mass index;	chr17:30750419	chr17:30863921~30864940:-
LUAD	cis	rs6142102	0.812	rs2377955	ENSG00000276073.1	RP5-1125A11.7	-6.7	5.88e-11	3.43e-08	-0.3	-0.29	Skin pigmentation;	chr20:33937564	chr20:33985617~33988989:-
LUAD	cis	rs2243480	1	rs778729	ENSG00000226824.5	RP4-756H11.3	-6.7	5.88e-11	3.43e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66359432	chr7:66654538~66669855:+
LUAD	cis	rs7208859	0.623	rs8067035	ENSG00000263531.1	RP13-753N3.1	6.7	5.88e-11	3.43e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775170	chr17:30863921~30864940:-
LUAD	cis	rs1799949	0.93	rs3092987	ENSG00000267681.1	CTD-3199J23.6	-6.7	5.88e-11	3.43e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43070706	chr17:43144956~43145255:+
LUAD	cis	rs950169	0.92	rs34672825	ENSG00000225151.9	GOLGA2P7	-6.7	5.89e-11	3.43e-08	-0.43	-0.29	Schizophrenia;	chr15:84034718	chr15:84199311~84230136:-
LUAD	cis	rs7246657	0.941	rs67293224	ENSG00000276846.1	CTD-3220F14.3	6.7	5.89e-11	3.44e-08	0.42	0.29	Coronary artery calcification;	chr19:37312346	chr19:37314868~37315620:-
LUAD	cis	rs1318937	0.915	rs78365740	ENSG00000224660.1	SH3BP5-AS1	6.7	5.89e-11	3.44e-08	0.24	0.29	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15258339	chr3:15254184~15264493:+
LUAD	cis	rs67311347	1	rs2371186	ENSG00000223797.4	ENTPD3-AS1	6.7	5.9e-11	3.44e-08	0.32	0.29	Renal cell carcinoma;	chr3:40447222	chr3:40313802~40453329:-
LUAD	cis	rs2243480	0.706	rs6460257	ENSG00000226824.5	RP4-756H11.3	-6.7	5.9e-11	3.44e-08	-0.48	-0.29	Diabetic kidney disease;	chr7:65731813	chr7:66654538~66669855:+
LUAD	cis	rs17301013	0.606	rs6670425	ENSG00000227373.4	RP11-160H22.5	6.7	5.92e-11	3.45e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174144204	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.581	rs6685499	ENSG00000227373.4	RP11-160H22.5	6.7	5.92e-11	3.45e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174144237	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs4652193	ENSG00000227373.4	RP11-160H22.5	6.7	5.92e-11	3.45e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174144554	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.632	rs12079214	ENSG00000227373.4	RP11-160H22.5	6.7	5.92e-11	3.45e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174149572	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs12065785	ENSG00000227373.4	RP11-160H22.5	6.7	5.92e-11	3.45e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174151296	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs16846717	ENSG00000227373.4	RP11-160H22.5	6.7	5.92e-11	3.45e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174152180	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs16846718	ENSG00000227373.4	RP11-160H22.5	6.7	5.92e-11	3.45e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174152782	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs10912735	ENSG00000227373.4	RP11-160H22.5	6.7	5.92e-11	3.45e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174159002	chr1:174115300~174160004:-
LUAD	cis	rs7017914	1	rs7017914	ENSG00000223220.1	Y_RNA	6.7	5.92e-11	3.45e-08	0.33	0.29	Bone mineral density;	chr8:70678968	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs13256250	ENSG00000223220.1	Y_RNA	6.7	5.92e-11	3.45e-08	0.33	0.29	Bone mineral density;	chr8:70683958	chr8:70780914~70781008:-
LUAD	cis	rs11089937	0.616	rs6001227	ENSG00000211639.2	IGLV4-60	6.7	5.95e-11	3.47e-08	0.31	0.29	Periodontitis (PAL4Q3);	chr22:22187099	chr22:22162199~22162681:+
LUAD	cis	rs7208859	0.524	rs60114476	ENSG00000263531.1	RP13-753N3.1	6.7	5.95e-11	3.47e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770649	chr17:30863921~30864940:-
LUAD	cis	rs17826219	0.636	rs2449770	ENSG00000263531.1	RP13-753N3.1	6.7	5.95e-11	3.47e-08	0.57	0.29	Body mass index;	chr17:30774046	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.524	rs59913838	ENSG00000263531.1	RP13-753N3.1	6.7	5.95e-11	3.47e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774545	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs8067338	ENSG00000263531.1	RP13-753N3.1	6.7	5.95e-11	3.47e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775327	chr17:30863921~30864940:-
LUAD	cis	rs1609391	0.561	rs9289523	ENSG00000239213.4	NCK1-AS1	6.7	5.96e-11	3.47e-08	0.31	0.29	Neuroticism;	chr3:136916747	chr3:136841726~136862054:-
LUAD	cis	rs1318937	1	rs2046725	ENSG00000224660.1	SH3BP5-AS1	6.7	5.96e-11	3.47e-08	0.24	0.29	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15253651	chr3:15254184~15264493:+
LUAD	cis	rs4865169	0.595	rs9998008	ENSG00000269949.1	RP11-738E22.3	6.7	5.97e-11	3.48e-08	0.36	0.29	Breast cancer;	chr4:56899886	chr4:56960927~56961373:-
LUAD	cis	rs9549367	0.713	rs56002882	ENSG00000269125.1	RP11-98F14.11	-6.7	5.98e-11	3.48e-08	-0.38	-0.29	Platelet distribution width;	chr13:113176380	chr13:113165002~113165183:-
LUAD	cis	rs950169	0.723	rs17589320	ENSG00000259728.4	LINC00933	6.7	6e-11	3.49e-08	0.44	0.29	Schizophrenia;	chr15:84251244	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.845	rs4502182	ENSG00000259728.4	LINC00933	6.7	6e-11	3.49e-08	0.44	0.29	Schizophrenia;	chr15:84254768	chr15:84570649~84580175:+
LUAD	cis	rs10899021	0.92	rs11236181	ENSG00000279353.1	RP11-864N7.4	6.7	6e-11	3.5e-08	0.52	0.29	Response to metformin (IC50);	chr11:74634778	chr11:74698231~74699658:-
LUAD	cis	rs150992	0.861	rs467728	ENSG00000248489.1	CTD-2007H13.3	6.7	6e-11	3.5e-08	0.32	0.29	Body mass index;	chr5:98953863	chr5:98929171~98995013:+
LUAD	cis	rs765787	0.53	rs12904331	ENSG00000259520.4	CTD-2651B20.3	-6.7	6.02e-11	3.5e-08	-0.39	-0.29	Uric acid levels;	chr15:45226095	chr15:45251580~45279251:-
LUAD	cis	rs10740039	0.671	rs7919726	ENSG00000254271.1	RP11-131N11.4	6.7	6.02e-11	3.5e-08	0.33	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60689748	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.804	rs10821824	ENSG00000254271.1	RP11-131N11.4	6.7	6.02e-11	3.5e-08	0.33	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60690449	chr10:60734342~60741828:+
LUAD	cis	rs9584850	0.915	rs7983438	ENSG00000231194.1	FARP1-AS1	6.7	6.02e-11	3.51e-08	0.35	0.29	Neuroticism;	chr13:98451063	chr13:98435405~98435840:-
LUAD	cis	rs1499614	1	rs1267818	ENSG00000226824.5	RP4-756H11.3	-6.69	6.03e-11	3.51e-08	-0.55	-0.29	Gout;	chr7:66642037	chr7:66654538~66669855:+
LUAD	cis	rs950169	0.881	rs34591918	ENSG00000259728.4	LINC00933	6.69	6.04e-11	3.52e-08	0.44	0.29	Schizophrenia;	chr15:84396135	chr15:84570649~84580175:+
LUAD	cis	rs1823913	0.599	rs13002286	ENSG00000227542.1	AC092614.2	-6.69	6.07e-11	3.53e-08	-0.36	-0.29	Obesity-related traits;	chr2:191285626	chr2:191229165~191246172:-
LUAD	cis	rs9595908	0.931	rs9591001	ENSG00000212293.1	SNORA16	-6.69	6.07e-11	3.53e-08	-0.33	-0.29	Body mass index;	chr13:32468733	chr13:32420390~32420516:-
LUAD	cis	rs9309473	1	rs13421462	ENSG00000163016.8	ALMS1P	6.69	6.07e-11	3.53e-08	0.36	0.29	Metabolite levels;	chr2:73492748	chr2:73644919~73685576:+
LUAD	cis	rs55665837	1	rs12295723	ENSG00000251991.1	RNU7-49P	6.69	6.07e-11	3.54e-08	0.32	0.29	Vitamin D levels;	chr11:14428655	chr11:14478892~14478953:+
LUAD	cis	rs150992	0.57	rs10050423	ENSG00000248489.1	CTD-2007H13.3	-6.69	6.08e-11	3.54e-08	-0.32	-0.29	Body mass index;	chr5:99006312	chr5:98929171~98995013:+
LUAD	cis	rs881375	0.967	rs758959	ENSG00000226752.6	PSMD5-AS1	-6.69	6.09e-11	3.54e-08	-0.32	-0.29	Rheumatoid arthritis;	chr9:120914421	chr9:120824828~120854385:+
LUAD	cis	rs765787	0.53	rs10851423	ENSG00000259520.4	CTD-2651B20.3	-6.69	6.09e-11	3.54e-08	-0.39	-0.29	Uric acid levels;	chr15:45223752	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs12913123	ENSG00000259520.4	CTD-2651B20.3	-6.69	6.09e-11	3.54e-08	-0.39	-0.29	Uric acid levels;	chr15:45224227	chr15:45251580~45279251:-
LUAD	cis	rs8059260	0.696	rs2110354	ENSG00000274038.1	RP11-66H6.4	-6.69	6.09e-11	3.54e-08	-0.4	-0.29	Alcohol consumption over the past year;	chr16:11013635	chr16:11056556~11057034:+
LUAD	cis	rs7246657	0.941	rs10418729	ENSG00000276846.1	CTD-3220F14.3	6.69	6.1e-11	3.55e-08	0.42	0.29	Coronary artery calcification;	chr19:37246163	chr19:37314868~37315620:-
LUAD	cis	rs2243480	1	rs4718317	ENSG00000232546.1	RP11-458F8.1	6.69	6.1e-11	3.55e-08	0.38	0.29	Diabetic kidney disease;	chr7:66183914	chr7:66848496~66858136:+
LUAD	cis	rs4722166	0.63	rs12700390	ENSG00000179428.2	AC073072.5	-6.69	6.14e-11	3.57e-08	-0.35	-0.29	Lung cancer;	chr7:22737510	chr7:22725395~22727620:-
LUAD	cis	rs4722166	0.63	rs12700391	ENSG00000179428.2	AC073072.5	-6.69	6.14e-11	3.57e-08	-0.35	-0.29	Lung cancer;	chr7:22737708	chr7:22725395~22727620:-
LUAD	cis	rs4722166	0.63	rs7781534	ENSG00000179428.2	AC073072.5	-6.69	6.14e-11	3.57e-08	-0.35	-0.29	Lung cancer;	chr7:22738973	chr7:22725395~22727620:-
LUAD	cis	rs4722166	0.63	rs1581497	ENSG00000179428.2	AC073072.5	-6.69	6.14e-11	3.57e-08	-0.35	-0.29	Lung cancer;	chr7:22739884	chr7:22725395~22727620:-
LUAD	cis	rs4722166	0.63	rs1829927	ENSG00000179428.2	AC073072.5	-6.69	6.14e-11	3.57e-08	-0.35	-0.29	Lung cancer;	chr7:22740299	chr7:22725395~22727620:-
LUAD	cis	rs9309473	0.95	rs6546854	ENSG00000163016.8	ALMS1P	6.69	6.15e-11	3.57e-08	0.36	0.29	Metabolite levels;	chr2:73606907	chr2:73644919~73685576:+
LUAD	cis	rs367615	0.68	rs77013	ENSG00000249476.1	CTD-2587M2.1	6.69	6.15e-11	3.58e-08	0.37	0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109627385	chr5:109237120~109326369:-
LUAD	cis	rs301901	0.683	rs34485458	ENSG00000250155.1	CTD-2353F22.1	-6.69	6.16e-11	3.58e-08	-0.31	-0.29	Height;	chr5:36861889	chr5:36666214~36725195:-
LUAD	cis	rs75422866	0.867	rs73113117	ENSG00000257433.4	RP1-197B17.3	6.69	6.16e-11	3.58e-08	0.62	0.29	Pneumonia;	chr12:47617299	chr12:47706085~47742294:+
LUAD	cis	rs150992	0.721	rs2937706	ENSG00000248489.1	CTD-2007H13.3	6.69	6.18e-11	3.59e-08	0.32	0.29	Body mass index;	chr5:98990434	chr5:98929171~98995013:+
LUAD	cis	rs7849270	1	rs7037163	ENSG00000268707.1	RP11-247A12.7	-6.69	6.18e-11	3.59e-08	-0.35	-0.29	Blood metabolite ratios;	chr9:129132061	chr9:129170434~129170940:+
LUAD	cis	rs6991838	0.673	rs7462352	ENSG00000272010.1	CTD-3025N20.3	6.69	6.18e-11	3.59e-08	0.3	0.29	Intelligence (multi-trait analysis);	chr8:65584378	chr8:65591850~65592472:-
LUAD	cis	rs2179367	0.919	rs4897124	ENSG00000231760.4	RP11-350J20.5	6.69	6.18e-11	3.59e-08	0.37	0.29	Dupuytren's disease;	chr6:149442073	chr6:149796151~149826294:-
LUAD	cis	rs948562	0.744	rs78111333	ENSG00000280010.1	AP001350.4	6.69	6.19e-11	3.6e-08	0.45	0.29	Lymphoma;	chr11:58482474	chr11:58627435~58628528:+
LUAD	cis	rs9903692	0.954	rs12936731	ENSG00000278765.1	RP5-890E16.5	6.69	6.19e-11	3.6e-08	0.38	0.29	Pulse pressure;	chr17:48050997	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.909	rs9899275	ENSG00000278765.1	RP5-890E16.5	6.69	6.19e-11	3.6e-08	0.38	0.29	Pulse pressure;	chr17:48051953	chr17:48066704~48067293:-
LUAD	cis	rs875971	0.545	rs17138156	ENSG00000237310.1	GS1-124K5.4	6.69	6.19e-11	3.6e-08	0.36	0.29	Aortic root size;	chr7:66249708	chr7:66493706~66495474:+
LUAD	cis	rs7945705	0.902	rs10743095	ENSG00000254860.4	TMEM9B-AS1	-6.69	6.2e-11	3.6e-08	-0.33	-0.29	Hemoglobin concentration;	chr11:8915437	chr11:8964675~8977527:+
LUAD	cis	rs9309473	1	rs7580825	ENSG00000163016.8	ALMS1P	6.69	6.2e-11	3.61e-08	0.37	0.29	Metabolite levels;	chr2:73408020	chr2:73644919~73685576:+
LUAD	cis	rs9549367	0.713	rs9549352	ENSG00000269125.1	RP11-98F14.11	-6.69	6.2e-11	3.61e-08	-0.39	-0.29	Platelet distribution width;	chr13:113178907	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.664	rs9549689	ENSG00000269125.1	RP11-98F14.11	-6.69	6.2e-11	3.61e-08	-0.39	-0.29	Platelet distribution width;	chr13:113194073	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.713	rs9549356	ENSG00000269125.1	RP11-98F14.11	-6.69	6.2e-11	3.61e-08	-0.39	-0.29	Platelet distribution width;	chr13:113197319	chr13:113165002~113165183:-
LUAD	cis	rs9318086	0.673	rs7981928	ENSG00000205861.10	C1QTNF9B-AS1	-6.69	6.22e-11	3.61e-08	-0.35	-0.29	Myopia (pathological);	chr13:23861041	chr13:23888889~23897263:+
LUAD	cis	rs67311347	0.956	rs9822870	ENSG00000223797.4	ENTPD3-AS1	-6.69	6.22e-11	3.62e-08	-0.31	-0.29	Renal cell carcinoma;	chr3:40473399	chr3:40313802~40453329:-
LUAD	cis	rs2439831	0.681	rs484846	ENSG00000205771.5	CATSPER2P1	-6.69	6.26e-11	3.63e-08	-0.5	-0.29	Lung cancer in ever smokers;	chr15:43308605	chr15:43726918~43747094:-
LUAD	cis	rs2134046	0.555	rs11854483	ENSG00000278603.1	RP13-608F4.5	6.69	6.26e-11	3.63e-08	0.34	0.29	Cognitive ability;	chr15:82267217	chr15:82472203~82472426:+
LUAD	cis	rs10129255	0.5	rs2027903	ENSG00000224373.3	IGHV4-59	6.69	6.26e-11	3.64e-08	0.17	0.29	Kawasaki disease;	chr14:106807047	chr14:106627249~106627825:-
LUAD	cis	rs10129255	0.518	rs28378320	ENSG00000224373.3	IGHV4-59	6.69	6.26e-11	3.64e-08	0.17	0.29	Kawasaki disease;	chr14:106808609	chr14:106627249~106627825:-
LUAD	cis	rs4713118	0.513	rs149897	ENSG00000219392.1	RP1-265C24.5	-6.69	6.27e-11	3.64e-08	-0.38	-0.29	Parkinson's disease;	chr6:28038872	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.513	rs156734	ENSG00000219392.1	RP1-265C24.5	-6.69	6.27e-11	3.64e-08	-0.38	-0.29	Parkinson's disease;	chr6:28039579	chr6:28115628~28116551:+
LUAD	cis	rs7208859	0.573	rs7214313	ENSG00000263531.1	RP13-753N3.1	6.69	6.27e-11	3.64e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811578	chr17:30863921~30864940:-
LUAD	cis	rs950169	0.724	rs11632668	ENSG00000259728.4	LINC00933	6.69	6.28e-11	3.65e-08	0.44	0.29	Schizophrenia;	chr15:84393989	chr15:84570649~84580175:+
LUAD	cis	rs10899021	0.79	rs7932194	ENSG00000279353.1	RP11-864N7.4	6.69	6.29e-11	3.65e-08	0.51	0.29	Response to metformin (IC50);	chr11:74616333	chr11:74698231~74699658:-
LUAD	cis	rs9318086	0.624	rs9510909	ENSG00000205861.10	C1QTNF9B-AS1	-6.69	6.29e-11	3.65e-08	-0.35	-0.29	Myopia (pathological);	chr13:23862621	chr13:23888889~23897263:+
LUAD	cis	rs11098499	0.754	rs10213554	ENSG00000248280.1	RP11-33B1.2	-6.69	6.31e-11	3.67e-08	-0.36	-0.29	Corneal astigmatism;	chr4:119339630	chr4:119440561~119450157:-
LUAD	cis	rs150992	0.609	rs363929	ENSG00000248489.1	CTD-2007H13.3	6.69	6.32e-11	3.67e-08	0.32	0.29	Body mass index;	chr5:98985933	chr5:98929171~98995013:+
LUAD	cis	rs2015599	0.623	rs3782510	ENSG00000275476.1	RP11-996F15.4	6.69	6.32e-11	3.67e-08	0.31	0.29	Platelet count;Mean platelet volume;	chr12:29301176	chr12:29277397~29277882:-
LUAD	cis	rs950169	0.922	rs17531523	ENSG00000259728.4	LINC00933	6.69	6.34e-11	3.68e-08	0.44	0.29	Schizophrenia;	chr15:84589218	chr15:84570649~84580175:+
LUAD	cis	rs7208859	0.562	rs8078897	ENSG00000263531.1	RP13-753N3.1	6.69	6.36e-11	3.69e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs9914499	ENSG00000263531.1	RP13-753N3.1	6.69	6.36e-11	3.69e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs12006	ENSG00000263531.1	RP13-753N3.1	6.69	6.36e-11	3.69e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs3752021	ENSG00000263531.1	RP13-753N3.1	6.69	6.36e-11	3.69e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs1061342	ENSG00000263531.1	RP13-753N3.1	6.69	6.36e-11	3.69e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs55938328	ENSG00000263531.1	RP13-753N3.1	6.69	6.36e-11	3.69e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs55961983	ENSG00000263531.1	RP13-753N3.1	6.69	6.36e-11	3.69e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30863921~30864940:-
LUAD	cis	rs17826219	0.568	rs7213925	ENSG00000263531.1	RP13-753N3.1	6.69	6.36e-11	3.69e-08	0.57	0.29	Body mass index;	chr17:30794616	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs11658945	ENSG00000263531.1	RP13-753N3.1	6.69	6.36e-11	3.69e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs11657990	ENSG00000263531.1	RP13-753N3.1	6.69	6.36e-11	3.69e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs11650982	ENSG00000263531.1	RP13-753N3.1	6.69	6.36e-11	3.69e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs9915546	ENSG00000263531.1	RP13-753N3.1	6.69	6.36e-11	3.69e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs9895815	ENSG00000263531.1	RP13-753N3.1	6.69	6.36e-11	3.69e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30863921~30864940:-
LUAD	cis	rs17826219	0.706	rs73271850	ENSG00000263531.1	RP13-753N3.1	6.69	6.36e-11	3.69e-08	0.57	0.29	Body mass index;	chr17:30815122	chr17:30863921~30864940:-
LUAD	cis	rs17826219	0.636	rs79565452	ENSG00000263531.1	RP13-753N3.1	6.69	6.36e-11	3.69e-08	0.57	0.29	Body mass index;	chr17:30815823	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs7208088	ENSG00000263531.1	RP13-753N3.1	6.69	6.36e-11	3.69e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs73269913	ENSG00000263531.1	RP13-753N3.1	6.69	6.36e-11	3.69e-08	0.58	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765165	chr17:30863921~30864940:-
LUAD	cis	rs7927592	0.913	rs3740631	ENSG00000212093.1	AP000807.1	6.69	6.37e-11	3.69e-08	0.33	0.29	Total body bone mineral density;	chr11:68574254	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs3824850	ENSG00000212093.1	AP000807.1	6.69	6.37e-11	3.69e-08	0.33	0.29	Total body bone mineral density;	chr11:68574405	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs3740629	ENSG00000212093.1	AP000807.1	6.69	6.37e-11	3.69e-08	0.33	0.29	Total body bone mineral density;	chr11:68576125	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs11228287	ENSG00000212093.1	AP000807.1	6.69	6.37e-11	3.69e-08	0.33	0.29	Total body bone mineral density;	chr11:68582286	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs10896346	ENSG00000212093.1	AP000807.1	6.69	6.37e-11	3.69e-08	0.33	0.29	Total body bone mineral density;	chr11:68585203	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs10896347	ENSG00000212093.1	AP000807.1	6.69	6.37e-11	3.69e-08	0.33	0.29	Total body bone mineral density;	chr11:68585659	chr11:68506083~68506166:-
LUAD	cis	rs67311347	1	rs7641495	ENSG00000223797.4	ENTPD3-AS1	-6.69	6.38e-11	3.7e-08	-0.31	-0.29	Renal cell carcinoma;	chr3:40453199	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs962847	ENSG00000223797.4	ENTPD3-AS1	-6.69	6.38e-11	3.7e-08	-0.31	-0.29	Renal cell carcinoma;	chr3:40453665	chr3:40313802~40453329:-
LUAD	cis	rs2243480	1	rs316326	ENSG00000226824.5	RP4-756H11.3	-6.69	6.4e-11	3.71e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66144466	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs316325	ENSG00000226824.5	RP4-756H11.3	-6.69	6.4e-11	3.71e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66144531	chr7:66654538~66669855:+
LUAD	cis	rs2439831	0.717	rs28495368	ENSG00000205771.5	CATSPER2P1	-6.68	6.42e-11	3.72e-08	-0.52	-0.29	Lung cancer in ever smokers;	chr15:43603444	chr15:43726918~43747094:-
LUAD	cis	rs891378	0.755	rs10157327	ENSG00000274245.1	RP11-357P18.2	-6.68	6.43e-11	3.72e-08	-0.35	-0.29	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207191756	chr1:207372559~207373252:+
LUAD	cis	rs7017914	0.967	rs13274381	ENSG00000223220.1	Y_RNA	6.68	6.44e-11	3.73e-08	0.33	0.29	Bone mineral density;	chr8:70852859	chr8:70780914~70781008:-
LUAD	cis	rs2243480	1	rs73142166	ENSG00000273142.1	RP11-458F8.4	-6.68	6.46e-11	3.74e-08	-0.31	-0.29	Diabetic kidney disease;	chr7:65910845	chr7:66902857~66906297:+
LUAD	cis	rs1823913	1	rs11691372	ENSG00000227542.1	AC092614.2	-6.68	6.48e-11	3.75e-08	-0.37	-0.29	Obesity-related traits;	chr2:191249952	chr2:191229165~191246172:-
LUAD	cis	rs9903692	0.909	rs12952163	ENSG00000278765.1	RP5-890E16.5	6.68	6.49e-11	3.76e-08	0.38	0.29	Pulse pressure;	chr17:48082029	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.697	rs6504024	ENSG00000278765.1	RP5-890E16.5	6.68	6.49e-11	3.76e-08	0.38	0.29	Pulse pressure;	chr17:48088224	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.779	rs6504025	ENSG00000278765.1	RP5-890E16.5	6.68	6.49e-11	3.76e-08	0.38	0.29	Pulse pressure;	chr17:48088711	chr17:48066704~48067293:-
LUAD	cis	rs875971	0.545	rs10261710	ENSG00000237310.1	GS1-124K5.4	6.68	6.49e-11	3.76e-08	0.37	0.29	Aortic root size;	chr7:66249202	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs67775320	ENSG00000237310.1	GS1-124K5.4	6.68	6.5e-11	3.76e-08	0.36	0.29	Aortic root size;	chr7:66193792	chr7:66493706~66495474:+
LUAD	cis	rs10129255	0.5	rs4774189	ENSG00000224373.3	IGHV4-59	6.68	6.5e-11	3.76e-08	0.17	0.29	Kawasaki disease;	chr14:106768275	chr14:106627249~106627825:-
LUAD	cis	rs35160687	0.842	rs1863051	ENSG00000273080.1	RP11-301O19.1	6.68	6.5e-11	3.77e-08	0.32	0.29	Night sleep phenotypes;	chr2:86332025	chr2:86195590~86196049:+
LUAD	cis	rs113835537	0.529	rs2305535	ENSG00000255517.5	CTD-3074O7.5	6.68	6.5e-11	3.77e-08	0.34	0.29	Airway imaging phenotypes;	chr11:66504766	chr11:66473490~66480233:-
LUAD	cis	rs2919917	0.628	rs12680932	ENSG00000254352.1	RP11-578O24.2	-6.68	6.51e-11	3.77e-08	-0.41	-0.29	Lymphocyte counts;	chr8:78685516	chr8:78723796~78724136:-
LUAD	cis	rs150992	0.609	rs78721487	ENSG00000248489.1	CTD-2007H13.3	6.68	6.51e-11	3.77e-08	0.32	0.29	Body mass index;	chr5:98992926	chr5:98929171~98995013:+
LUAD	cis	rs2455601	1	rs12418190	ENSG00000254860.4	TMEM9B-AS1	6.68	6.52e-11	3.78e-08	0.48	0.29	Schizophrenia;	chr11:8878271	chr11:8964675~8977527:+
LUAD	cis	rs7927592	0.871	rs55953412	ENSG00000212093.1	AP000807.1	6.68	6.53e-11	3.78e-08	0.33	0.29	Total body bone mineral density;	chr11:68560815	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs7102898	ENSG00000212093.1	AP000807.1	6.68	6.53e-11	3.78e-08	0.33	0.29	Total body bone mineral density;	chr11:68561402	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs948316	ENSG00000212093.1	AP000807.1	6.68	6.53e-11	3.78e-08	0.32	0.29	Total body bone mineral density;	chr11:68542202	chr11:68506083~68506166:-
LUAD	cis	rs4723738	1	rs6975531	ENSG00000227191.5	TRGC2	-6.68	6.55e-11	3.79e-08	-0.32	-0.29	Treatment response for severe sepsis;	chr7:38179748	chr7:38239580~38368091:-
LUAD	cis	rs9903692	0.954	rs9909933	ENSG00000278765.1	RP5-890E16.5	6.68	6.55e-11	3.79e-08	0.39	0.29	Pulse pressure;	chr17:48202870	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.909	rs2325885	ENSG00000278765.1	RP5-890E16.5	6.68	6.55e-11	3.79e-08	0.39	0.29	Pulse pressure;	chr17:48213013	chr17:48066704~48067293:-
LUAD	cis	rs1823913	0.599	rs55685315	ENSG00000227542.1	AC092614.2	6.68	6.55e-11	3.79e-08	0.35	0.29	Obesity-related traits;	chr2:191306451	chr2:191229165~191246172:-
LUAD	cis	rs7829975	0.511	rs1543238	ENSG00000253893.2	FAM85B	-6.68	6.55e-11	3.79e-08	-0.38	-0.29	Mood instability;	chr8:8277287	chr8:8167819~8226614:-
LUAD	cis	rs881375	0.678	rs7031752	ENSG00000226752.6	PSMD5-AS1	-6.68	6.55e-11	3.79e-08	-0.3	-0.29	Rheumatoid arthritis;	chr9:120901204	chr9:120824828~120854385:+
LUAD	cis	rs748404	0.56	rs2255663	ENSG00000249839.1	AC011330.5	6.68	6.56e-11	3.8e-08	0.38	0.29	Lung cancer;	chr15:43536810	chr15:43663654~43684339:-
LUAD	cis	rs1799949	1	rs33946455	ENSG00000267681.1	CTD-3199J23.6	-6.68	6.56e-11	3.8e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43169829	chr17:43144956~43145255:+
LUAD	cis	rs7811142	1	rs7809801	ENSG00000242294.5	STAG3L5P	6.68	6.57e-11	3.8e-08	0.24	0.29	Platelet count;	chr7:100474408	chr7:100336079~100351900:+
LUAD	cis	rs7811142	1	rs11766752	ENSG00000242294.5	STAG3L5P	6.68	6.57e-11	3.8e-08	0.24	0.29	Platelet count;	chr7:100475669	chr7:100336079~100351900:+
LUAD	cis	rs2243480	1	rs1638734	ENSG00000226824.5	RP4-756H11.3	-6.68	6.59e-11	3.81e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66632552	chr7:66654538~66669855:+
LUAD	cis	rs11098499	0.754	rs9999724	ENSG00000248280.1	RP11-33B1.2	6.68	6.59e-11	3.81e-08	0.36	0.29	Corneal astigmatism;	chr4:119318789	chr4:119440561~119450157:-
LUAD	cis	rs11089937	0.585	rs6001229	ENSG00000211639.2	IGLV4-60	-6.68	6.6e-11	3.82e-08	-0.31	-0.29	Periodontitis (PAL4Q3);	chr22:22187693	chr22:22162199~22162681:+
LUAD	cis	rs948562	1	rs79475579	ENSG00000280010.1	AP001350.4	6.68	6.6e-11	3.82e-08	0.46	0.29	Lymphoma;	chr11:58528427	chr11:58627435~58628528:+
LUAD	cis	rs948562	1	rs111901203	ENSG00000280010.1	AP001350.4	6.68	6.6e-11	3.82e-08	0.46	0.29	Lymphoma;	chr11:58530069	chr11:58627435~58628528:+
LUAD	cis	rs4964805	0.594	rs3751204	ENSG00000257681.1	RP11-341G23.4	6.68	6.6e-11	3.82e-08	0.34	0.29	Attention deficit hyperactivity disorder;	chr12:103777677	chr12:103746315~103768858:-
LUAD	cis	rs875971	0.545	rs1547529	ENSG00000237310.1	GS1-124K5.4	6.68	6.62e-11	3.83e-08	0.36	0.29	Aortic root size;	chr7:66258859	chr7:66493706~66495474:+
LUAD	cis	rs9309473	1	rs9309473	ENSG00000163016.8	ALMS1P	6.68	6.62e-11	3.83e-08	0.36	0.29	Metabolite levels;	chr2:73516855	chr2:73644919~73685576:+
LUAD	cis	rs67311347	1	rs9968170	ENSG00000223797.4	ENTPD3-AS1	-6.68	6.62e-11	3.83e-08	-0.31	-0.29	Renal cell carcinoma;	chr3:40452783	chr3:40313802~40453329:-
LUAD	cis	rs9487094	0.689	rs17070591	ENSG00000260273.1	RP11-425D10.10	6.68	6.63e-11	3.83e-08	0.36	0.29	Height;	chr6:109426518	chr6:109382795~109383666:+
LUAD	cis	rs2286503	0.752	rs59538378	ENSG00000228649.7	AC005682.5	6.68	6.64e-11	3.84e-08	0.38	0.29	Fibrinogen;	chr7:22837478	chr7:22854178~22861579:+
LUAD	cis	rs853679	0.527	rs853693	ENSG00000204709.4	LINC01556	6.68	6.64e-11	3.84e-08	0.37	0.29	Depression;	chr6:28314871	chr6:28943877~28944537:+
LUAD	cis	rs4718428	0.672	rs13241598	ENSG00000273142.1	RP11-458F8.4	-6.68	6.65e-11	3.84e-08	-0.22	-0.29	Corneal structure;	chr7:66835665	chr7:66902857~66906297:+
LUAD	cis	rs7246657	0.943	rs2081096	ENSG00000276846.1	CTD-3220F14.3	6.68	6.65e-11	3.84e-08	0.39	0.29	Coronary artery calcification;	chr19:37473798	chr19:37314868~37315620:-
LUAD	cis	rs2243480	0.706	rs34466769	ENSG00000226824.5	RP4-756H11.3	-6.68	6.65e-11	3.84e-08	-0.48	-0.29	Diabetic kidney disease;	chr7:65988305	chr7:66654538~66669855:+
LUAD	cis	rs67311347	1	rs12108041	ENSG00000223797.4	ENTPD3-AS1	6.68	6.65e-11	3.84e-08	0.31	0.29	Renal cell carcinoma;	chr3:40446044	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs1123019	ENSG00000223797.4	ENTPD3-AS1	6.68	6.65e-11	3.84e-08	0.31	0.29	Renal cell carcinoma;	chr3:40446789	chr3:40313802~40453329:-
LUAD	cis	rs66887589	0.807	rs13134517	ENSG00000248280.1	RP11-33B1.2	6.68	6.66e-11	3.85e-08	0.32	0.29	Diastolic blood pressure;	chr4:119484107	chr4:119440561~119450157:-
LUAD	cis	rs66887589	0.837	rs6534135	ENSG00000248280.1	RP11-33B1.2	6.68	6.66e-11	3.85e-08	0.32	0.29	Diastolic blood pressure;	chr4:119485147	chr4:119440561~119450157:-
LUAD	cis	rs66887589	0.837	rs7661498	ENSG00000248280.1	RP11-33B1.2	6.68	6.66e-11	3.85e-08	0.32	0.29	Diastolic blood pressure;	chr4:119486953	chr4:119440561~119450157:-
LUAD	cis	rs950169	0.922	rs12915832	ENSG00000259728.4	LINC00933	6.68	6.67e-11	3.85e-08	0.43	0.29	Schizophrenia;	chr15:84568226	chr15:84570649~84580175:+
LUAD	cis	rs8062405	0.573	rs7187575	ENSG00000259982.1	CDC37P1	-6.68	6.67e-11	3.85e-08	-0.4	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28978780	chr16:28700294~28701540:-
LUAD	cis	rs150992	0.587	rs13179812	ENSG00000248489.1	CTD-2007H13.3	-6.68	6.67e-11	3.86e-08	-0.32	-0.29	Body mass index;	chr5:99021029	chr5:98929171~98995013:+
LUAD	cis	rs8100891	0.537	rs10424665	ENSG00000267213.4	AC007773.2	-6.68	6.67e-11	3.86e-08	-0.43	-0.29	Neuroticism;	chr19:32404725	chr19:32390050~32405560:-
LUAD	cis	rs8059260	0.736	rs76818150	ENSG00000274038.1	RP11-66H6.4	-6.68	6.68e-11	3.86e-08	-0.6	-0.29	Alcohol consumption over the past year;	chr16:10955006	chr16:11056556~11057034:+
LUAD	cis	rs8059260	0.736	rs113433437	ENSG00000274038.1	RP11-66H6.4	-6.68	6.68e-11	3.86e-08	-0.6	-0.29	Alcohol consumption over the past year;	chr16:10959438	chr16:11056556~11057034:+
LUAD	cis	rs8059260	0.736	rs8046423	ENSG00000274038.1	RP11-66H6.4	-6.68	6.68e-11	3.86e-08	-0.6	-0.29	Alcohol consumption over the past year;	chr16:10964016	chr16:11056556~11057034:+
LUAD	cis	rs8059260	0.736	rs77599345	ENSG00000274038.1	RP11-66H6.4	-6.68	6.68e-11	3.86e-08	-0.6	-0.29	Alcohol consumption over the past year;	chr16:10964707	chr16:11056556~11057034:+
LUAD	cis	rs948562	0.744	rs12361887	ENSG00000280010.1	AP001350.4	6.68	6.68e-11	3.86e-08	0.46	0.29	Lymphoma;	chr11:58488205	chr11:58627435~58628528:+
LUAD	cis	rs55665837	1	rs12295888	ENSG00000251991.1	RNU7-49P	6.68	6.69e-11	3.86e-08	0.32	0.29	Vitamin D levels;	chr11:14428985	chr11:14478892~14478953:+
LUAD	cis	rs9309473	1	rs11674602	ENSG00000163016.8	ALMS1P	6.68	6.7e-11	3.87e-08	0.37	0.29	Metabolite levels;	chr2:73496058	chr2:73644919~73685576:+
LUAD	cis	rs9309711	0.961	rs11890651	ENSG00000225234.1	TRAPPC12-AS1	-6.68	6.71e-11	3.88e-08	-0.35	-0.29	Neurofibrillary tangles;	chr2:3479025	chr2:3481242~3482409:-
LUAD	cis	rs12458462	0.787	rs56006341	ENSG00000274828.1	RP11-567M16.6	6.68	6.72e-11	3.88e-08	0.3	0.29	Monocyte count;	chr18:79679844	chr18:79677287~79679358:-
LUAD	cis	rs2946504	0.628	rs2946510	ENSG00000251468.2	RP11-369K16.1	-6.68	6.73e-11	3.89e-08	-0.36	-0.29	Type 2 diabetes;	chr8:12950371	chr8:12958387~12962200:+
LUAD	cis	rs10129255	0.912	rs61997792	ENSG00000211972.2	IGHV3-66	6.68	6.73e-11	3.89e-08	0.26	0.29	Kawasaki disease;	chr14:106799304	chr14:106675017~106675544:-
LUAD	cis	rs950169	0.84	rs2896002	ENSG00000259728.4	LINC00933	6.68	6.74e-11	3.89e-08	0.44	0.29	Schizophrenia;	chr15:84390423	chr15:84570649~84580175:+
LUAD	cis	rs7811142	1	rs1000215	ENSG00000242294.5	STAG3L5P	6.68	6.74e-11	3.89e-08	0.24	0.29	Platelet count;	chr7:100406920	chr7:100336079~100351900:+
LUAD	cis	rs9326248	0.53	rs6589589	ENSG00000280143.1	AP000892.6	6.68	6.74e-11	3.89e-08	0.44	0.29	Blood protein levels;	chr11:117061712	chr11:117204967~117210292:+
LUAD	cis	rs875971	1	rs2077593	ENSG00000222364.1	RNU6-96P	-6.68	6.75e-11	3.9e-08	-0.33	-0.29	Aortic root size;	chr7:66427543	chr7:66395191~66395286:+
LUAD	cis	rs465969	0.744	rs76257900	ENSG00000255389.1	C6orf3	-6.68	6.78e-11	3.91e-08	-0.62	-0.29	Psoriasis;	chr6:111537286	chr6:111599875~111602295:+
LUAD	cis	rs10740039	0.768	rs7895268	ENSG00000254271.1	RP11-131N11.4	6.68	6.78e-11	3.92e-08	0.34	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60703479	chr10:60734342~60741828:+
LUAD	cis	rs881375	0.967	rs1008382	ENSG00000226752.6	PSMD5-AS1	-6.68	6.78e-11	3.92e-08	-0.31	-0.29	Rheumatoid arthritis;	chr9:120918977	chr9:120824828~120854385:+
LUAD	cis	rs891378	0.785	rs55957981	ENSG00000274245.1	RP11-357P18.2	-6.68	6.79e-11	3.92e-08	-0.35	-0.29	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207205594	chr1:207372559~207373252:+
LUAD	cis	rs55665837	1	rs3923294	ENSG00000251991.1	RNU7-49P	6.68	6.79e-11	3.92e-08	0.32	0.29	Vitamin D levels;	chr11:14419856	chr11:14478892~14478953:+
LUAD	cis	rs55665837	1	rs12287715	ENSG00000251991.1	RNU7-49P	6.68	6.79e-11	3.92e-08	0.32	0.29	Vitamin D levels;	chr11:14423029	chr11:14478892~14478953:+
LUAD	cis	rs11098499	0.722	rs7673476	ENSG00000248280.1	RP11-33B1.2	6.68	6.8e-11	3.92e-08	0.35	0.29	Corneal astigmatism;	chr4:119327528	chr4:119440561~119450157:-
LUAD	cis	rs11096990	0.892	rs11931354	ENSG00000249207.1	RP11-360F5.1	6.68	6.8e-11	3.93e-08	0.32	0.29	Cognitive function;	chr4:39229856	chr4:39112677~39126818:-
LUAD	cis	rs9928842	0.824	rs889515	ENSG00000280152.1	RP11-331F4.5	6.68	6.8e-11	3.93e-08	0.33	0.29	Alcoholic chronic pancreatitis;	chr16:75217401	chr16:75245994~75250077:-
LUAD	cis	rs720064	0.586	rs9950106	ENSG00000264745.1	TTC39C-AS1	6.68	6.81e-11	3.93e-08	0.31	0.29	Strep throat;	chr18:23967901	chr18:23994213~24015339:-
LUAD	cis	rs720064	0.586	rs9961089	ENSG00000264745.1	TTC39C-AS1	6.68	6.81e-11	3.93e-08	0.31	0.29	Strep throat;	chr18:23967999	chr18:23994213~24015339:-
LUAD	cis	rs801193	0.66	rs10950049	ENSG00000222364.1	RNU6-96P	-6.68	6.81e-11	3.93e-08	-0.32	-0.29	Aortic root size;	chr7:66765873	chr7:66395191~66395286:+
LUAD	cis	rs35160687	0.787	rs10186289	ENSG00000273080.1	RP11-301O19.1	6.68	6.81e-11	3.93e-08	0.32	0.29	Night sleep phenotypes;	chr2:86285865	chr2:86195590~86196049:+
LUAD	cis	rs875971	1	rs6460296	ENSG00000222364.1	RNU6-96P	-6.68	6.82e-11	3.93e-08	-0.32	-0.29	Aortic root size;	chr7:66430152	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs4717292	ENSG00000222364.1	RNU6-96P	-6.68	6.82e-11	3.93e-08	-0.32	-0.29	Aortic root size;	chr7:66430611	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.895	rs4718349	ENSG00000222364.1	RNU6-96P	-6.68	6.82e-11	3.93e-08	-0.32	-0.29	Aortic root size;	chr7:66444024	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs2420591	ENSG00000222364.1	RNU6-96P	-6.68	6.82e-11	3.93e-08	-0.32	-0.29	Aortic root size;	chr7:66447394	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.895	rs10755833	ENSG00000222364.1	RNU6-96P	-6.68	6.82e-11	3.93e-08	-0.32	-0.29	Aortic root size;	chr7:66448930	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.964	rs12668936	ENSG00000222364.1	RNU6-96P	-6.68	6.82e-11	3.93e-08	-0.32	-0.29	Aortic root size;	chr7:66449417	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.895	rs1833495	ENSG00000222364.1	RNU6-96P	-6.68	6.82e-11	3.93e-08	-0.32	-0.29	Aortic root size;	chr7:66456608	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.964	rs6945032	ENSG00000222364.1	RNU6-96P	-6.68	6.82e-11	3.93e-08	-0.32	-0.29	Aortic root size;	chr7:66457499	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.929	rs12673810	ENSG00000222364.1	RNU6-96P	-6.68	6.82e-11	3.93e-08	-0.32	-0.29	Aortic root size;	chr7:66458866	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs2042133	ENSG00000222364.1	RNU6-96P	-6.68	6.82e-11	3.93e-08	-0.32	-0.29	Aortic root size;	chr7:66466935	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.964	rs2161065	ENSG00000222364.1	RNU6-96P	-6.68	6.82e-11	3.93e-08	-0.32	-0.29	Aortic root size;	chr7:66467918	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs6961155	ENSG00000222364.1	RNU6-96P	-6.68	6.82e-11	3.93e-08	-0.32	-0.29	Aortic root size;	chr7:66468308	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.895	rs3857684	ENSG00000222364.1	RNU6-96P	-6.68	6.82e-11	3.93e-08	-0.32	-0.29	Aortic root size;	chr7:66473171	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs7789768	ENSG00000222364.1	RNU6-96P	-6.68	6.82e-11	3.93e-08	-0.32	-0.29	Aortic root size;	chr7:66473993	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs12698521	ENSG00000222364.1	RNU6-96P	-6.68	6.82e-11	3.93e-08	-0.32	-0.29	Aortic root size;	chr7:66474502	chr7:66395191~66395286:+
LUAD	cis	rs783540	0.867	rs7167880	ENSG00000278603.1	RP13-608F4.5	-6.68	6.82e-11	3.93e-08	-0.33	-0.29	Schizophrenia;	chr15:82625685	chr15:82472203~82472426:+
LUAD	cis	rs8081395	0.741	rs1292051	ENSG00000266992.1	DHX40P1	6.68	6.82e-11	3.94e-08	0.34	0.29	White blood cell count;	chr17:59886562	chr17:59976009~60002384:-
LUAD	cis	rs7626444	0.625	rs1104375	ENSG00000272359.1	U4	-6.68	6.82e-11	3.94e-08	-0.32	-0.29	Monocyte count;	chr3:196749172	chr3:196747192~196747324:-
LUAD	cis	rs2404602	0.684	rs2454451	ENSG00000259422.1	RP11-593F23.1	6.68	6.83e-11	3.94e-08	0.39	0.29	Blood metabolite levels;	chr15:76569120	chr15:76174891~76181486:-
LUAD	cis	rs9828933	0.516	rs704371	ENSG00000280620.1	SCAANT1	-6.68	6.83e-11	3.94e-08	-0.41	-0.29	Type 2 diabetes;	chr3:63881852	chr3:63911518~63911772:-
LUAD	cis	rs237743	1	rs13038202	ENSG00000222365.1	SNORD12B	-6.67	6.85e-11	3.95e-08	-0.34	-0.29	Height;	chr20:49219081	chr20:49280319~49280409:+
LUAD	cis	rs237743	1	rs2273145	ENSG00000222365.1	SNORD12B	-6.67	6.85e-11	3.95e-08	-0.34	-0.29	Height;	chr20:49223054	chr20:49280319~49280409:+
LUAD	cis	rs237743	1	rs11553387	ENSG00000222365.1	SNORD12B	-6.67	6.85e-11	3.95e-08	-0.34	-0.29	Height;	chr20:49225123	chr20:49280319~49280409:+
LUAD	cis	rs17711722	0.522	rs62469933	ENSG00000236529.1	RP13-254B10.1	6.67	6.85e-11	3.95e-08	0.29	0.29	Calcium levels;	chr7:65800652	chr7:65840212~65840596:+
LUAD	cis	rs783540	0.934	rs7182403	ENSG00000278603.1	RP13-608F4.5	-6.67	6.87e-11	3.96e-08	-0.33	-0.29	Schizophrenia;	chr15:82628862	chr15:82472203~82472426:+
LUAD	cis	rs1799949	0.93	rs8176194	ENSG00000267681.1	CTD-3199J23.6	-6.67	6.87e-11	3.96e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43079204	chr17:43144956~43145255:+
LUAD	cis	rs10129255	0.5	rs988132	ENSG00000224373.3	IGHV4-59	6.67	6.88e-11	3.97e-08	0.18	0.29	Kawasaki disease;	chr14:106776758	chr14:106627249~106627825:-
LUAD	cis	rs891378	0.755	rs6703809	ENSG00000274245.1	RP11-357P18.2	-6.67	6.89e-11	3.97e-08	-0.35	-0.29	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207228650	chr1:207372559~207373252:+
LUAD	cis	rs891378	0.727	rs11120492	ENSG00000274245.1	RP11-357P18.2	-6.67	6.89e-11	3.97e-08	-0.35	-0.29	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207234553	chr1:207372559~207373252:+
LUAD	cis	rs11098499	0.604	rs12642411	ENSG00000248280.1	RP11-33B1.2	6.67	6.89e-11	3.97e-08	0.37	0.29	Corneal astigmatism;	chr4:119659370	chr4:119440561~119450157:-
LUAD	cis	rs1062177	1	rs12515762	ENSG00000213433.5	RPLP1P6	-6.67	6.89e-11	3.97e-08	-0.39	-0.29	Preschool internalizing problems;	chr5:151830361	chr5:151765859~151766378:-
LUAD	cis	rs17301013	0.606	rs72711487	ENSG00000227373.4	RP11-160H22.5	6.67	6.9e-11	3.98e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174189002	chr1:174115300~174160004:-
LUAD	cis	rs7246657	1	rs34544865	ENSG00000276846.1	CTD-3220F14.3	6.67	6.9e-11	3.98e-08	0.45	0.29	Coronary artery calcification;	chr19:37310340	chr19:37314868~37315620:-
LUAD	cis	rs35955747	0.869	rs131219	ENSG00000236132.1	CTA-440B3.1	-6.67	6.91e-11	3.99e-08	-0.32	-0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31364264	chr22:31816379~31817491:-
LUAD	cis	rs34779708	0.741	rs34397613	ENSG00000230534.5	RP11-297A16.2	6.67	6.91e-11	3.99e-08	0.35	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35261385	chr10:35098006~35127020:-
LUAD	cis	rs13160562	0.623	rs26509	ENSG00000272109.1	CTD-2260A17.3	6.67	6.92e-11	3.99e-08	0.31	0.29	Alcohol dependence;	chr5:96746976	chr5:96804353~96806105:+
LUAD	cis	rs1823913	0.599	rs1378155	ENSG00000227542.1	AC092614.2	6.67	6.92e-11	3.99e-08	0.36	0.29	Obesity-related traits;	chr2:191266610	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.576	rs13011608	ENSG00000227542.1	AC092614.2	6.67	6.92e-11	3.99e-08	0.36	0.29	Obesity-related traits;	chr2:191267097	chr2:191229165~191246172:-
LUAD	cis	rs7927592	0.913	rs2282563	ENSG00000212093.1	AP000807.1	6.67	6.92e-11	3.99e-08	0.32	0.29	Total body bone mineral density;	chr11:68565732	chr11:68506083~68506166:-
LUAD	cis	rs950169	0.922	rs12912934	ENSG00000259728.4	LINC00933	6.67	6.92e-11	3.99e-08	0.44	0.29	Schizophrenia;	chr15:84571216	chr15:84570649~84580175:+
LUAD	cis	rs2243480	1	rs73150014	ENSG00000226824.5	RP4-756H11.3	-6.67	6.92e-11	3.99e-08	-0.54	-0.29	Diabetic kidney disease;	chr7:65985932	chr7:66654538~66669855:+
LUAD	cis	rs9903692	0.954	rs12450620	ENSG00000278765.1	RP5-890E16.5	6.67	6.93e-11	4e-08	0.38	0.29	Pulse pressure;	chr17:48052892	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.954	rs7212202	ENSG00000278765.1	RP5-890E16.5	6.67	6.93e-11	4e-08	0.38	0.29	Pulse pressure;	chr17:48055361	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.954	rs34750858	ENSG00000278765.1	RP5-890E16.5	6.67	6.93e-11	4e-08	0.38	0.29	Pulse pressure;	chr17:48055575	chr17:48066704~48067293:-
LUAD	cis	rs875971	0.545	rs17138149	ENSG00000237310.1	GS1-124K5.4	6.67	6.95e-11	4.01e-08	0.35	0.29	Aortic root size;	chr7:66228193	chr7:66493706~66495474:+
LUAD	cis	rs17023223	0.537	rs2645305	ENSG00000231365.4	RP11-418J17.1	-6.67	6.96e-11	4.01e-08	-0.38	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119018742	chr1:119140396~119275973:+
LUAD	cis	rs10129255	1	rs10129407	ENSG00000280411.1	IGHV1-69-2	-6.67	6.98e-11	4.02e-08	-0.22	-0.29	Kawasaki disease;	chr14:106767956	chr14:106762092~106762588:-
LUAD	cis	rs10740039	0.883	rs10761542	ENSG00000254271.1	RP11-131N11.4	6.67	6.98e-11	4.02e-08	0.33	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60655465	chr10:60734342~60741828:+
LUAD	cis	rs10740039	1	rs10761543	ENSG00000254271.1	RP11-131N11.4	6.67	6.98e-11	4.02e-08	0.33	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60655633	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs10761544	ENSG00000254271.1	RP11-131N11.4	6.67	6.98e-11	4.02e-08	0.33	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60655647	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.804	rs7900848	ENSG00000254271.1	RP11-131N11.4	6.67	6.98e-11	4.02e-08	0.33	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60655893	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs7898504	ENSG00000254271.1	RP11-131N11.4	6.67	6.98e-11	4.02e-08	0.33	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60658233	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.671	rs7913549	ENSG00000254271.1	RP11-131N11.4	6.67	6.98e-11	4.02e-08	0.33	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60658474	chr10:60734342~60741828:+
LUAD	cis	rs9322193	0.651	rs9322188	ENSG00000223701.3	RAET1E-AS1	-6.67	7e-11	4.03e-08	-0.33	-0.29	Lung cancer;	chr6:149588355	chr6:149884431~149919508:+
LUAD	cis	rs950169	0.922	rs11630760	ENSG00000259728.4	LINC00933	6.67	7e-11	4.03e-08	0.44	0.29	Schizophrenia;	chr15:84570106	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.887	rs71395453	ENSG00000259728.4	LINC00933	6.67	7e-11	4.03e-08	0.44	0.29	Schizophrenia;	chr15:84570259	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.922	rs11633075	ENSG00000259728.4	LINC00933	6.67	7e-11	4.03e-08	0.44	0.29	Schizophrenia;	chr15:84570741	chr15:84570649~84580175:+
LUAD	cis	rs748404	0.631	rs11070399	ENSG00000249839.1	AC011330.5	-6.67	7.03e-11	4.05e-08	-0.38	-0.29	Lung cancer;	chr15:43354149	chr15:43663654~43684339:-
LUAD	cis	rs12908161	1	rs12911736	ENSG00000259728.4	LINC00933	6.67	7.06e-11	4.06e-08	0.43	0.29	Schizophrenia;	chr15:84696777	chr15:84570649~84580175:+
LUAD	cis	rs7849270	1	rs1107328	ENSG00000268707.1	RP11-247A12.7	6.67	7.06e-11	4.06e-08	0.35	0.29	Blood metabolite ratios;	chr9:129155255	chr9:129170434~129170940:+
LUAD	cis	rs150992	0.609	rs7711061	ENSG00000248489.1	CTD-2007H13.3	-6.67	7.06e-11	4.06e-08	-0.32	-0.29	Body mass index;	chr5:99003535	chr5:98929171~98995013:+
LUAD	cis	rs1823913	0.599	rs13020656	ENSG00000227542.1	AC092614.2	6.67	7.06e-11	4.06e-08	0.36	0.29	Obesity-related traits;	chr2:191314197	chr2:191229165~191246172:-
LUAD	cis	rs7674212	0.581	rs11946020	ENSG00000251288.2	RP11-10L12.2	-6.67	7.08e-11	4.07e-08	-0.37	-0.29	Type 2 diabetes;	chr4:103023585	chr4:102751401~102752641:+
LUAD	cis	rs5753618	0.504	rs5753669	ENSG00000236132.1	CTA-440B3.1	-6.67	7.09e-11	4.08e-08	-0.36	-0.29	Colorectal cancer;	chr22:31509833	chr22:31816379~31817491:-
LUAD	cis	rs7429990	0.864	rs4274776	ENSG00000229759.1	MRPS18AP1	6.67	7.1e-11	4.08e-08	0.29	0.29	Educational attainment (years of education);	chr3:47605868	chr3:48256350~48256938:-
LUAD	cis	rs35955747	0.811	rs9606835	ENSG00000236132.1	CTA-440B3.1	-6.67	7.11e-11	4.09e-08	-0.32	-0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31370974	chr22:31816379~31817491:-
LUAD	cis	rs2665103	0.589	rs2134046	ENSG00000278603.1	RP13-608F4.5	6.67	7.11e-11	4.09e-08	0.34	0.29	Intelligence (multi-trait analysis);	chr15:82232203	chr15:82472203~82472426:+
LUAD	cis	rs1823913	0.599	rs55786000	ENSG00000227542.1	AC092614.2	6.67	7.12e-11	4.09e-08	0.35	0.29	Obesity-related traits;	chr2:191284500	chr2:191229165~191246172:-
LUAD	cis	rs881375	0.715	rs11794516	ENSG00000226752.6	PSMD5-AS1	-6.67	7.13e-11	4.1e-08	-0.31	-0.29	Rheumatoid arthritis;	chr9:120877952	chr9:120824828~120854385:+
LUAD	cis	rs12022452	0.556	rs12037288	ENSG00000238287.1	RP11-656D10.3	-6.67	7.14e-11	4.1e-08	-0.46	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40530625	chr1:40493157~40508661:-
LUAD	cis	rs12022452	0.591	rs1001400	ENSG00000238287.1	RP11-656D10.3	-6.67	7.14e-11	4.1e-08	-0.46	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40533230	chr1:40493157~40508661:-
LUAD	cis	rs150992	0.861	rs428836	ENSG00000248489.1	CTD-2007H13.3	6.67	7.15e-11	4.11e-08	0.32	0.29	Body mass index;	chr5:98951673	chr5:98929171~98995013:+
LUAD	cis	rs9368481	0.761	rs12661756	ENSG00000241549.7	GUSBP2	6.67	7.16e-11	4.11e-08	0.33	0.29	Autism spectrum disorder or schizophrenia;	chr6:27035704	chr6:26871484~26956554:-
LUAD	cis	rs72772090	0.539	rs72773917	ENSG00000248734.2	CTD-2260A17.1	-6.67	7.16e-11	4.11e-08	-0.46	-0.29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96775598	chr5:96784777~96785999:+
LUAD	cis	rs12130219	0.588	rs2282302	ENSG00000237975.5	FLG-AS1	6.67	7.16e-11	4.12e-08	0.46	0.29	Inflammatory skin disease;	chr1:152356893	chr1:152168125~152445456:+
LUAD	cis	rs6921919	0.945	rs61289879	ENSG00000204709.4	LINC01556	6.67	7.17e-11	4.12e-08	0.43	0.29	Autism spectrum disorder or schizophrenia;	chr6:28451385	chr6:28943877~28944537:+
LUAD	cis	rs3096299	0.781	rs2170839	ENSG00000274627.1	RP11-104N10.2	6.67	7.17e-11	4.12e-08	0.27	0.29	Multiple myeloma (IgH translocation);	chr16:89343044	chr16:89516797~89522217:+
LUAD	cis	rs7674212	0.507	rs223322	ENSG00000251288.2	RP11-10L12.2	-6.67	7.18e-11	4.13e-08	-0.37	-0.29	Type 2 diabetes;	chr4:102879037	chr4:102751401~102752641:+
LUAD	cis	rs12429206	0.547	rs75419800	ENSG00000233672.5	RNASEH2B-AS1	-6.67	7.19e-11	4.13e-08	-0.43	-0.29	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50898897	chr13:50862172~50910764:-
LUAD	cis	rs7044106	0.791	rs2416797	ENSG00000238181.2	AHCYP2	-6.67	7.21e-11	4.14e-08	-0.38	-0.29	Hip circumference adjusted for BMI;	chr9:120718322	chr9:120720673~120721972:+
LUAD	cis	rs7044106	0.791	rs2416798	ENSG00000238181.2	AHCYP2	-6.67	7.21e-11	4.14e-08	-0.38	-0.29	Hip circumference adjusted for BMI;	chr9:120718325	chr9:120720673~120721972:+
LUAD	cis	rs17826219	0.706	rs28469200	ENSG00000263531.1	RP13-753N3.1	6.67	7.21e-11	4.14e-08	0.57	0.29	Body mass index;	chr17:30806554	chr17:30863921~30864940:-
LUAD	cis	rs10129255	0.957	rs10136781	ENSG00000280411.1	IGHV1-69-2	-6.67	7.22e-11	4.15e-08	-0.21	-0.29	Kawasaki disease;	chr14:106780451	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.957	rs8022165	ENSG00000280411.1	IGHV1-69-2	-6.67	7.22e-11	4.15e-08	-0.21	-0.29	Kawasaki disease;	chr14:106781682	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.917	rs8022493	ENSG00000280411.1	IGHV1-69-2	-6.67	7.22e-11	4.15e-08	-0.21	-0.29	Kawasaki disease;	chr14:106781820	chr14:106762092~106762588:-
LUAD	cis	rs11096990	0.855	rs11730771	ENSG00000249207.1	RP11-360F5.1	6.67	7.23e-11	4.15e-08	0.33	0.29	Cognitive function;	chr4:39220787	chr4:39112677~39126818:-
LUAD	cis	rs2276314	0.6	rs28729782	ENSG00000278986.1	RP11-723J4.3	-6.67	7.23e-11	4.15e-08	-0.31	-0.29	Endometriosis;Drug-induced torsades de pointes;	chr18:36010566	chr18:35972151~35973916:+
LUAD	cis	rs7674212	0.507	rs223361	ENSG00000251288.2	RP11-10L12.2	-6.67	7.23e-11	4.15e-08	-0.36	-0.29	Type 2 diabetes;	chr4:102848147	chr4:102751401~102752641:+
LUAD	cis	rs7567389	0.785	rs4150474	ENSG00000236682.1	AC068282.3	6.67	7.23e-11	4.15e-08	0.42	0.29	Self-rated health;	chr2:127275751	chr2:127389130~127400580:+
LUAD	cis	rs150992	0.587	rs4448016	ENSG00000248489.1	CTD-2007H13.3	6.67	7.25e-11	4.16e-08	0.32	0.29	Body mass index;	chr5:99037904	chr5:98929171~98995013:+
LUAD	cis	rs8177376	1	rs7932766	ENSG00000254905.1	RP11-712L6.7	6.67	7.26e-11	4.16e-08	0.41	0.29	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126292967	chr11:126292922~126294254:-
LUAD	cis	rs3738443	0.645	rs11811599	ENSG00000259865.1	RP11-488L18.10	6.67	7.26e-11	4.17e-08	0.25	0.29	Alcohol dependence;	chr1:247203133	chr1:247187281~247188526:-
LUAD	cis	rs9326248	0.581	rs10892061	ENSG00000280143.1	AP000892.6	6.66	7.29e-11	4.18e-08	0.34	0.29	Blood protein levels;	chr11:117015398	chr11:117204967~117210292:+
LUAD	cis	rs75422866	0.51	rs73105818	ENSG00000280054.1	RP1-197B17.7	6.66	7.31e-11	4.19e-08	0.64	0.29	Pneumonia;	chr12:47726538	chr12:47728151~47730598:-
LUAD	cis	rs5753618	0.504	rs5753671	ENSG00000236132.1	CTA-440B3.1	-6.66	7.31e-11	4.19e-08	-0.36	-0.29	Colorectal cancer;	chr22:31514748	chr22:31816379~31817491:-
LUAD	cis	rs11098499	0.604	rs34278750	ENSG00000248280.1	RP11-33B1.2	6.66	7.32e-11	4.2e-08	0.37	0.29	Corneal astigmatism;	chr4:119649981	chr4:119440561~119450157:-
LUAD	cis	rs9549367	0.673	rs3024735	ENSG00000269125.1	RP11-98F14.11	-6.66	7.33e-11	4.2e-08	-0.38	-0.29	Platelet distribution width;	chr13:113165199	chr13:113165002~113165183:-
LUAD	cis	rs321358	0.731	rs1517581	ENSG00000271584.1	RP11-89C3.4	6.66	7.33e-11	4.2e-08	0.45	0.29	Body mass index;	chr11:111164533	chr11:111091932~111097357:-
LUAD	cis	rs6558530	0.965	rs730377	ENSG00000253982.1	CTD-2336O2.1	6.66	7.35e-11	4.22e-08	0.36	0.29	Systolic blood pressure;	chr8:1759785	chr8:1761990~1764502:-
LUAD	cis	rs2221433	1	rs2354423	ENSG00000260310.1	RP11-27M24.2	6.66	7.36e-11	4.22e-08	0.32	0.29	Eating disorders;	chr16:10578271	chr16:10576499~10578183:-
LUAD	cis	rs7674212	0.556	rs223401	ENSG00000251288.2	RP11-10L12.2	-6.66	7.37e-11	4.23e-08	-0.36	-0.29	Type 2 diabetes;	chr4:102817815	chr4:102751401~102752641:+
LUAD	cis	rs875971	1	rs35149210	ENSG00000222364.1	RNU6-96P	-6.66	7.38e-11	4.23e-08	-0.32	-0.29	Aortic root size;	chr7:66464938	chr7:66395191~66395286:+
LUAD	cis	rs8177876	0.822	rs1563075	ENSG00000261838.4	RP11-303E16.6	6.66	7.38e-11	4.23e-08	0.63	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074143	chr16:81069854~81076598:+
LUAD	cis	rs2412819	0.597	rs7181912	ENSG00000205771.5	CATSPER2P1	6.66	7.38e-11	4.23e-08	0.44	0.29	Lung cancer;	chr15:43770676	chr15:43726918~43747094:-
LUAD	cis	rs7927592	0.913	rs6591344	ENSG00000212093.1	AP000807.1	6.66	7.38e-11	4.23e-08	0.33	0.29	Total body bone mineral density;	chr11:68593405	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs7127948	ENSG00000212093.1	AP000807.1	6.66	7.38e-11	4.23e-08	0.33	0.29	Total body bone mineral density;	chr11:68595594	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs3758643	ENSG00000212093.1	AP000807.1	6.66	7.38e-11	4.23e-08	0.33	0.29	Total body bone mineral density;	chr11:68599725	chr11:68506083~68506166:-
LUAD	cis	rs4713118	0.699	rs573179	ENSG00000219392.1	RP1-265C24.5	-6.66	7.39e-11	4.24e-08	-0.41	-0.29	Parkinson's disease;	chr6:27881898	chr6:28115628~28116551:+
LUAD	cis	rs1609391	0.543	rs9881139	ENSG00000239213.4	NCK1-AS1	6.66	7.39e-11	4.24e-08	0.31	0.29	Neuroticism;	chr3:136915198	chr3:136841726~136862054:-
LUAD	cis	rs801193	0.66	rs1016265	ENSG00000222364.1	RNU6-96P	-6.66	7.4e-11	4.24e-08	-0.32	-0.29	Aortic root size;	chr7:66749580	chr7:66395191~66395286:+
LUAD	cis	rs801193	0.66	rs4610622	ENSG00000222364.1	RNU6-96P	-6.66	7.4e-11	4.24e-08	-0.32	-0.29	Aortic root size;	chr7:66759510	chr7:66395191~66395286:+
LUAD	cis	rs801193	0.613	rs2659900	ENSG00000222364.1	RNU6-96P	-6.66	7.41e-11	4.24e-08	-0.32	-0.29	Aortic root size;	chr7:66719456	chr7:66395191~66395286:+
LUAD	cis	rs9309473	1	rs13383871	ENSG00000163016.8	ALMS1P	6.66	7.41e-11	4.25e-08	0.36	0.29	Metabolite levels;	chr2:73404651	chr2:73644919~73685576:+
LUAD	cis	rs1823913	0.599	rs2168166	ENSG00000227542.1	AC092614.2	6.66	7.43e-11	4.25e-08	0.35	0.29	Obesity-related traits;	chr2:191288063	chr2:191229165~191246172:-
LUAD	cis	rs6142102	1	rs12480839	ENSG00000276073.1	RP5-1125A11.7	-6.66	7.44e-11	4.26e-08	-0.3	-0.29	Skin pigmentation;	chr20:34139624	chr20:33985617~33988989:-
LUAD	cis	rs950169	0.881	rs72750843	ENSG00000259728.4	LINC00933	6.66	7.45e-11	4.27e-08	0.44	0.29	Schizophrenia;	chr15:84592552	chr15:84570649~84580175:+
LUAD	cis	rs9309473	0.948	rs10199224	ENSG00000163016.8	ALMS1P	6.66	7.46e-11	4.27e-08	0.36	0.29	Metabolite levels;	chr2:73534319	chr2:73644919~73685576:+
LUAD	cis	rs4713118	0.699	rs200969	ENSG00000219392.1	RP1-265C24.5	-6.66	7.46e-11	4.27e-08	-0.41	-0.29	Parkinson's disease;	chr6:27891675	chr6:28115628~28116551:+
LUAD	cis	rs950169	0.922	rs12910334	ENSG00000259728.4	LINC00933	6.66	7.48e-11	4.28e-08	0.44	0.29	Schizophrenia;	chr15:84403620	chr15:84570649~84580175:+
LUAD	cis	rs2919917	0.688	rs3780003	ENSG00000254352.1	RP11-578O24.2	6.66	7.49e-11	4.29e-08	0.34	0.29	Lymphocyte counts;	chr8:78696019	chr8:78723796~78724136:-
LUAD	cis	rs17301013	0.507	rs12084291	ENSG00000227373.4	RP11-160H22.5	6.66	7.49e-11	4.29e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174395721	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs2901815	ENSG00000227373.4	RP11-160H22.5	6.66	7.49e-11	4.29e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174397404	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs1883262	ENSG00000227373.4	RP11-160H22.5	6.66	7.49e-11	4.29e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174401104	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs2860959	ENSG00000227373.4	RP11-160H22.5	6.66	7.49e-11	4.29e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174403704	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs10912779	ENSG00000227373.4	RP11-160H22.5	6.66	7.49e-11	4.29e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174404311	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12090860	ENSG00000227373.4	RP11-160H22.5	6.66	7.49e-11	4.29e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174405166	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12064126	ENSG00000227373.4	RP11-160H22.5	6.66	7.49e-11	4.29e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174405312	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs10798310	ENSG00000227373.4	RP11-160H22.5	6.66	7.49e-11	4.29e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174408581	chr1:174115300~174160004:-
LUAD	cis	rs17818399	0.62	rs3087822	ENSG00000279254.1	RP11-536C12.1	6.66	7.51e-11	4.3e-08	0.3	0.29	Height;	chr2:46624894	chr2:46668870~46670778:+
LUAD	cis	rs66887589	0.807	rs7694483	ENSG00000248280.1	RP11-33B1.2	6.66	7.53e-11	4.31e-08	0.32	0.29	Diastolic blood pressure;	chr4:119484774	chr4:119440561~119450157:-
LUAD	cis	rs17301013	0.507	rs10912777	ENSG00000227373.4	RP11-160H22.5	6.66	7.54e-11	4.31e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174393764	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs10912778	ENSG00000227373.4	RP11-160H22.5	6.66	7.54e-11	4.31e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174393827	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs2205937	ENSG00000227373.4	RP11-160H22.5	6.66	7.54e-11	4.31e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174394440	chr1:174115300~174160004:-
LUAD	cis	rs1185460	1	rs7938944	ENSG00000271751.1	RP11-110I1.14	-6.66	7.56e-11	4.32e-08	-0.36	-0.29	Coronary artery disease;	chr11:119083356	chr11:119065263~119065677:-
LUAD	cis	rs673078	0.66	rs11068910	ENSG00000275759.1	RP11-131L12.3	-6.66	7.56e-11	4.33e-08	-0.38	-0.29	Glucose homeostasis traits;	chr12:118336076	chr12:118428281~118428870:+
LUAD	cis	rs150992	0.79	rs161731	ENSG00000248489.1	CTD-2007H13.3	6.66	7.57e-11	4.33e-08	0.32	0.29	Body mass index;	chr5:98984339	chr5:98929171~98995013:+
LUAD	cis	rs9326248	0.581	rs4938331	ENSG00000280143.1	AP000892.6	6.66	7.57e-11	4.33e-08	0.34	0.29	Blood protein levels;	chr11:117059966	chr11:117204967~117210292:+
LUAD	cis	rs9326248	0.51	rs4938332	ENSG00000280143.1	AP000892.6	6.66	7.57e-11	4.33e-08	0.34	0.29	Blood protein levels;	chr11:117060082	chr11:117204967~117210292:+
LUAD	cis	rs9326248	0.559	rs4938334	ENSG00000280143.1	AP000892.6	6.66	7.57e-11	4.33e-08	0.34	0.29	Blood protein levels;	chr11:117060326	chr11:117204967~117210292:+
LUAD	cis	rs113835537	0.529	rs2277302	ENSG00000255517.5	CTD-3074O7.5	-6.66	7.58e-11	4.34e-08	-0.34	-0.29	Airway imaging phenotypes;	chr11:66473411	chr11:66473490~66480233:-
LUAD	cis	rs1823913	0.599	rs17346412	ENSG00000227542.1	AC092614.2	6.66	7.59e-11	4.34e-08	0.35	0.29	Obesity-related traits;	chr2:191285902	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.599	rs17412239	ENSG00000227542.1	AC092614.2	6.66	7.59e-11	4.34e-08	0.35	0.29	Obesity-related traits;	chr2:191285937	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.599	rs35098152	ENSG00000227542.1	AC092614.2	6.66	7.59e-11	4.34e-08	0.35	0.29	Obesity-related traits;	chr2:191286658	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.599	rs35150635	ENSG00000227542.1	AC092614.2	6.66	7.59e-11	4.34e-08	0.35	0.29	Obesity-related traits;	chr2:191287303	chr2:191229165~191246172:-
LUAD	cis	rs1799949	1	rs11651341	ENSG00000267681.1	CTD-3199J23.6	-6.66	7.59e-11	4.34e-08	-0.33	-0.29	Menopause (age at onset);	chr17:43350693	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs34572725	ENSG00000267681.1	CTD-3199J23.6	-6.66	7.59e-11	4.34e-08	-0.33	-0.29	Menopause (age at onset);	chr17:43351298	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs4534897	ENSG00000267681.1	CTD-3199J23.6	-6.66	7.59e-11	4.34e-08	-0.33	-0.29	Menopause (age at onset);	chr17:43354440	chr17:43144956~43145255:+
LUAD	cis	rs10759883	0.563	rs589362	ENSG00000175611.10	LINC00476	6.66	7.59e-11	4.34e-08	0.34	0.29	Nicotine dependence;	chr9:95966906	chr9:95759231~95875977:-
LUAD	cis	rs1113500	0.541	rs11185240	ENSG00000226822.1	RP11-356N1.2	6.66	7.6e-11	4.35e-08	0.39	0.29	Growth-regulated protein alpha levels;	chr1:108040188	chr1:108071482~108074519:+
LUAD	cis	rs7927592	0.913	rs12363722	ENSG00000212093.1	AP000807.1	6.66	7.62e-11	4.36e-08	0.33	0.29	Total body bone mineral density;	chr11:68468823	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.871	rs12360903	ENSG00000212093.1	AP000807.1	6.66	7.62e-11	4.36e-08	0.33	0.29	Total body bone mineral density;	chr11:68468846	chr11:68506083~68506166:-
LUAD	cis	rs1823913	0.622	rs55787447	ENSG00000227542.1	AC092614.2	6.66	7.62e-11	4.36e-08	0.35	0.29	Obesity-related traits;	chr2:191288596	chr2:191229165~191246172:-
LUAD	cis	rs801193	0.636	rs2659895	ENSG00000222364.1	RNU6-96P	-6.66	7.63e-11	4.36e-08	-0.32	-0.29	Aortic root size;	chr7:66731484	chr7:66395191~66395286:+
LUAD	cis	rs6921919	0.832	rs17312661	ENSG00000204709.4	LINC01556	6.66	7.64e-11	4.37e-08	0.48	0.29	Autism spectrum disorder or schizophrenia;	chr6:28332559	chr6:28943877~28944537:+
LUAD	cis	rs11089937	0.616	rs5757244	ENSG00000211639.2	IGLV4-60	6.66	7.64e-11	4.37e-08	0.3	0.29	Periodontitis (PAL4Q3);	chr22:22176637	chr22:22162199~22162681:+
LUAD	cis	rs6991838	0.67	rs869151	ENSG00000200714.1	Y_RNA	6.66	7.65e-11	4.37e-08	0.34	0.29	Intelligence (multi-trait analysis);	chr8:65726487	chr8:65592731~65592820:+
LUAD	cis	rs4964805	0.594	rs751448	ENSG00000257681.1	RP11-341G23.4	6.66	7.65e-11	4.37e-08	0.34	0.29	Attention deficit hyperactivity disorder;	chr12:103773407	chr12:103746315~103768858:-
LUAD	cis	rs7626444	0.625	rs1798634	ENSG00000272359.1	U4	-6.66	7.65e-11	4.38e-08	-0.32	-0.29	Monocyte count;	chr3:196747416	chr3:196747192~196747324:-
LUAD	cis	rs7626444	0.625	rs1798635	ENSG00000272359.1	U4	-6.66	7.65e-11	4.38e-08	-0.32	-0.29	Monocyte count;	chr3:196747418	chr3:196747192~196747324:-
LUAD	cis	rs783540	0.967	rs783523	ENSG00000278603.1	RP13-608F4.5	6.66	7.66e-11	4.38e-08	0.34	0.29	Schizophrenia;	chr15:82614804	chr15:82472203~82472426:+
LUAD	cis	rs7567389	0.719	rs1011019	ENSG00000236682.1	AC068282.3	6.66	7.67e-11	4.38e-08	0.42	0.29	Self-rated health;	chr2:127279984	chr2:127389130~127400580:+
LUAD	cis	rs7626444	0.625	rs2686590	ENSG00000272359.1	U4	-6.66	7.69e-11	4.4e-08	-0.32	-0.29	Monocyte count;	chr3:196765568	chr3:196747192~196747324:-
LUAD	cis	rs10740039	0.804	rs894384	ENSG00000254271.1	RP11-131N11.4	6.66	7.72e-11	4.41e-08	0.34	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60692535	chr10:60734342~60741828:+
LUAD	cis	rs77204473	1	rs2186844	ENSG00000254851.1	RP11-109L13.1	-6.66	7.73e-11	4.41e-08	-0.71	-0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117026197	chr11:117135528~117138582:+
LUAD	cis	rs950169	0.84	rs12905223	ENSG00000259728.4	LINC00933	6.66	7.73e-11	4.42e-08	0.43	0.29	Schizophrenia;	chr15:84571037	chr15:84570649~84580175:+
LUAD	cis	rs3762637	0.943	rs9841897	ENSG00000272758.4	RP11-299J3.8	-6.65	7.76e-11	4.43e-08	-0.45	-0.29	LDL cholesterol levels;	chr3:122563722	chr3:122416207~122443180:+
LUAD	cis	rs3762637	0.943	rs28372690	ENSG00000272758.4	RP11-299J3.8	-6.65	7.76e-11	4.43e-08	-0.45	-0.29	LDL cholesterol levels;	chr3:122564248	chr3:122416207~122443180:+
LUAD	cis	rs10129255	0.5	rs8011115	ENSG00000224373.3	IGHV4-59	6.65	7.76e-11	4.44e-08	0.17	0.29	Kawasaki disease;	chr14:106786292	chr14:106627249~106627825:-
LUAD	cis	rs875971	0.895	rs12698520	ENSG00000222364.1	RNU6-96P	-6.65	7.8e-11	4.45e-08	-0.32	-0.29	Aortic root size;	chr7:66453720	chr7:66395191~66395286:+
LUAD	cis	rs34526934	0.566	rs1374325	ENSG00000226363.3	HAGLROS	6.65	7.82e-11	4.46e-08	0.4	0.29	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176179243	chr2:176177717~176179008:+
LUAD	cis	rs760794	0.577	rs7752808	ENSG00000228412.5	RP4-625H18.2	6.65	7.84e-11	4.48e-08	0.35	0.29	Endometriosis;	chr6:19792665	chr6:19802164~19804752:-
LUAD	cis	rs17301013	0.507	rs12079011	ENSG00000227373.4	RP11-160H22.5	6.65	7.85e-11	4.48e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174441055	chr1:174115300~174160004:-
LUAD	cis	rs7923609	0.812	rs10822184	ENSG00000232075.1	MRPL35P2	6.65	7.86e-11	4.48e-08	0.35	0.29	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63577393	chr10:63634317~63634827:-
LUAD	cis	rs9309711	0.961	rs11686236	ENSG00000225234.1	TRAPPC12-AS1	-6.65	7.87e-11	4.49e-08	-0.37	-0.29	Neurofibrillary tangles;	chr2:3467778	chr2:3481242~3482409:-
LUAD	cis	rs10740039	0.883	rs1442540	ENSG00000254271.1	RP11-131N11.4	-6.65	7.87e-11	4.49e-08	-0.33	-0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60653548	chr10:60734342~60741828:+
LUAD	cis	rs7849270	1	rs2254230	ENSG00000268707.1	RP11-247A12.7	6.65	7.88e-11	4.5e-08	0.34	0.29	Blood metabolite ratios;	chr9:129142898	chr9:129170434~129170940:+
LUAD	cis	rs1799949	1	rs1060915	ENSG00000267681.1	CTD-3199J23.6	-6.65	7.89e-11	4.5e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43082453	chr17:43144956~43145255:+
LUAD	cis	rs321358	0.731	rs12421339	ENSG00000271584.1	RP11-89C3.4	6.65	7.89e-11	4.5e-08	0.44	0.29	Body mass index;	chr11:111168744	chr11:111091932~111097357:-
LUAD	cis	rs1499614	1	rs1267817	ENSG00000226824.5	RP4-756H11.3	-6.65	7.89e-11	4.5e-08	-0.55	-0.29	Gout;	chr7:66645053	chr7:66654538~66669855:+
LUAD	cis	rs7811142	1	rs11559117	ENSG00000242294.5	STAG3L5P	6.65	7.89e-11	4.5e-08	0.24	0.29	Platelet count;	chr7:100478991	chr7:100336079~100351900:+
LUAD	cis	rs7811142	1	rs2406253	ENSG00000242294.5	STAG3L5P	6.65	7.89e-11	4.5e-08	0.24	0.29	Platelet count;	chr7:100479650	chr7:100336079~100351900:+
LUAD	cis	rs7811142	1	rs4463351	ENSG00000242294.5	STAG3L5P	6.65	7.89e-11	4.5e-08	0.24	0.29	Platelet count;	chr7:100480603	chr7:100336079~100351900:+
LUAD	cis	rs7811142	1	rs60844404	ENSG00000242294.5	STAG3L5P	6.65	7.89e-11	4.5e-08	0.24	0.29	Platelet count;	chr7:100482851	chr7:100336079~100351900:+
LUAD	cis	rs7811142	1	rs113738841	ENSG00000242294.5	STAG3L5P	6.65	7.89e-11	4.5e-08	0.24	0.29	Platelet count;	chr7:100483683	chr7:100336079~100351900:+
LUAD	cis	rs7811142	1	rs11763511	ENSG00000242294.5	STAG3L5P	6.65	7.89e-11	4.5e-08	0.24	0.29	Platelet count;	chr7:100484321	chr7:100336079~100351900:+
LUAD	cis	rs56046484	0.956	rs34345801	ENSG00000259295.5	CSPG4P12	6.65	7.9e-11	4.51e-08	0.41	0.29	Testicular germ cell tumor;	chr15:85101842	chr15:85191438~85213905:+
LUAD	cis	rs11098499	0.588	rs2389874	ENSG00000248280.1	RP11-33B1.2	-6.65	7.9e-11	4.51e-08	-0.34	-0.29	Corneal astigmatism;	chr4:119633836	chr4:119440561~119450157:-
LUAD	cis	rs1823913	0.599	rs13015653	ENSG00000227542.1	AC092614.2	6.65	7.91e-11	4.51e-08	0.35	0.29	Obesity-related traits;	chr2:191306813	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.599	rs12994212	ENSG00000227542.1	AC092614.2	6.65	7.91e-11	4.51e-08	0.35	0.29	Obesity-related traits;	chr2:191306910	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.599	rs12994236	ENSG00000227542.1	AC092614.2	6.65	7.91e-11	4.51e-08	0.35	0.29	Obesity-related traits;	chr2:191306991	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.599	rs35495506	ENSG00000227542.1	AC092614.2	6.65	7.91e-11	4.51e-08	0.35	0.29	Obesity-related traits;	chr2:191307551	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.599	rs34691559	ENSG00000227542.1	AC092614.2	6.65	7.91e-11	4.51e-08	0.35	0.29	Obesity-related traits;	chr2:191307688	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.561	rs55790432	ENSG00000227542.1	AC092614.2	6.65	7.91e-11	4.51e-08	0.35	0.29	Obesity-related traits;	chr2:191307722	chr2:191229165~191246172:-
LUAD	cis	rs6921919	0.887	rs16894116	ENSG00000204709.4	LINC01556	6.65	7.91e-11	4.51e-08	0.42	0.29	Autism spectrum disorder or schizophrenia;	chr6:28447190	chr6:28943877~28944537:+
LUAD	cis	rs9487094	0.6	rs1885690	ENSG00000260273.1	RP11-425D10.10	6.65	7.91e-11	4.51e-08	0.36	0.29	Height;	chr6:109351795	chr6:109382795~109383666:+
LUAD	cis	rs62229266	0.625	rs62230813	ENSG00000214914.3	RPL23AP3	6.65	7.91e-11	4.51e-08	0.35	0.29	Mitral valve prolapse;	chr21:36031134	chr21:36016079~36016546:-
LUAD	cis	rs6991838	0.831	rs11992528	ENSG00000272010.1	CTD-3025N20.3	6.65	7.93e-11	4.52e-08	0.3	0.29	Intelligence (multi-trait analysis);	chr8:65561644	chr8:65591850~65592472:-
LUAD	cis	rs1185460	0.546	rs549893	ENSG00000271751.1	RP11-110I1.14	6.65	7.96e-11	4.54e-08	0.36	0.29	Coronary artery disease;	chr11:119089022	chr11:119065263~119065677:-
LUAD	cis	rs67311347	0.955	rs4974068	ENSG00000223797.4	ENTPD3-AS1	6.65	7.96e-11	4.54e-08	0.31	0.29	Renal cell carcinoma;	chr3:40335438	chr3:40313802~40453329:-
LUAD	cis	rs8177876	0.749	rs2911159	ENSG00000261838.4	RP11-303E16.6	-6.65	7.98e-11	4.55e-08	-0.52	-0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81057653	chr16:81069854~81076598:+
LUAD	cis	rs7017914	0.934	rs17689585	ENSG00000223220.1	Y_RNA	6.65	7.98e-11	4.55e-08	0.33	0.29	Bone mineral density;	chr8:70906566	chr8:70780914~70781008:-
LUAD	cis	rs10129255	0.957	rs12590799	ENSG00000280411.1	IGHV1-69-2	-6.65	7.98e-11	4.55e-08	-0.21	-0.29	Kawasaki disease;	chr14:106779713	chr14:106762092~106762588:-
LUAD	cis	rs2243480	1	rs1039664	ENSG00000232546.1	RP11-458F8.1	-6.65	7.98e-11	4.55e-08	-0.37	-0.29	Diabetic kidney disease;	chr7:65984729	chr7:66848496~66858136:+
LUAD	cis	rs17301013	0.507	rs116545832	ENSG00000227373.4	RP11-160H22.5	6.65	7.99e-11	4.55e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174438725	chr1:174115300~174160004:-
LUAD	cis	rs8031584	1	rs1474380	ENSG00000260382.1	RP11-540B6.2	6.65	8.01e-11	4.56e-08	0.34	0.29	Huntington's disease progression;	chr15:30977032	chr15:30882267~30883231:-
LUAD	cis	rs9326248	0.581	rs11216242	ENSG00000280143.1	AP000892.6	6.65	8.01e-11	4.57e-08	0.34	0.29	Blood protein levels;	chr11:117030833	chr11:117204967~117210292:+
LUAD	cis	rs9326248	0.581	rs12804122	ENSG00000280143.1	AP000892.6	6.65	8.01e-11	4.57e-08	0.34	0.29	Blood protein levels;	chr11:117031900	chr11:117204967~117210292:+
LUAD	cis	rs2179367	0.887	rs2143076	ENSG00000231760.4	RP11-350J20.5	6.65	8.05e-11	4.59e-08	0.35	0.29	Dupuytren's disease;	chr6:149425315	chr6:149796151~149826294:-
LUAD	cis	rs4722166	0.604	rs2390715	ENSG00000179428.2	AC073072.5	-6.65	8.05e-11	4.59e-08	-0.35	-0.29	Lung cancer;	chr7:22744259	chr7:22725395~22727620:-
LUAD	cis	rs10129255	0.785	rs10150044	ENSG00000280411.1	IGHV1-69-2	-6.65	8.05e-11	4.59e-08	-0.22	-0.29	Kawasaki disease;	chr14:106775695	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.957	rs10137980	ENSG00000280411.1	IGHV1-69-2	-6.65	8.05e-11	4.59e-08	-0.22	-0.29	Kawasaki disease;	chr14:106775735	chr14:106762092~106762588:-
LUAD	cis	rs77204473	1	rs12272973	ENSG00000254851.1	RP11-109L13.1	6.65	8.06e-11	4.59e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116992331	chr11:117135528~117138582:+
LUAD	cis	rs67311347	1	rs9833430	ENSG00000223797.4	ENTPD3-AS1	6.65	8.07e-11	4.59e-08	0.32	0.29	Renal cell carcinoma;	chr3:40417552	chr3:40313802~40453329:-
LUAD	cis	rs67311347	0.784	rs13326389	ENSG00000223797.4	ENTPD3-AS1	6.65	8.07e-11	4.59e-08	0.32	0.29	Renal cell carcinoma;	chr3:40418233	chr3:40313802~40453329:-
LUAD	cis	rs853679	0.607	rs33932084	ENSG00000204709.4	LINC01556	6.65	8.07e-11	4.6e-08	0.62	0.29	Depression;	chr6:28301047	chr6:28943877~28944537:+
LUAD	cis	rs75422866	0.764	rs73104177	ENSG00000274902.1	RP1-197B17.4	6.65	8.08e-11	4.6e-08	0.73	0.29	Pneumonia;	chr12:47713550	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.764	rs73104184	ENSG00000274902.1	RP1-197B17.4	6.65	8.08e-11	4.6e-08	0.73	0.29	Pneumonia;	chr12:47715623	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.764	rs73104188	ENSG00000274902.1	RP1-197B17.4	6.65	8.08e-11	4.6e-08	0.73	0.29	Pneumonia;	chr12:47715885	chr12:47731908~47732351:+
LUAD	cis	rs77204473	0.744	rs12970	ENSG00000254851.1	RP11-109L13.1	6.65	8.09e-11	4.6e-08	0.69	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117203393	chr11:117135528~117138582:+
LUAD	cis	rs2243480	1	rs958550	ENSG00000226824.5	RP4-756H11.3	6.65	8.09e-11	4.61e-08	0.5	0.29	Diabetic kidney disease;	chr7:66170692	chr7:66654538~66669855:+
LUAD	cis	rs10771431	0.935	rs1117735	ENSG00000111788.10	RP11-22B23.1	6.65	8.1e-11	4.61e-08	0.25	0.29	Breast size;	chr12:9220132	chr12:9277235~9313241:+
LUAD	cis	rs950169	0.92	rs11637666	ENSG00000225151.9	GOLGA2P7	-6.65	8.11e-11	4.61e-08	-0.43	-0.29	Schizophrenia;	chr15:84035122	chr15:84199311~84230136:-
LUAD	cis	rs7017914	0.967	rs6991329	ENSG00000223220.1	Y_RNA	6.65	8.11e-11	4.62e-08	0.33	0.29	Bone mineral density;	chr8:70681190	chr8:70780914~70781008:-
LUAD	cis	rs270601	0.837	rs367805	ENSG00000233006.5	AC034220.3	6.65	8.12e-11	4.62e-08	0.29	0.29	Acylcarnitine levels;	chr5:132365587	chr5:132311285~132369916:-
LUAD	cis	rs6844153	1	rs4557251	ENSG00000240005.4	RP11-293A21.1	-6.65	8.12e-11	4.62e-08	-0.49	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26848285	chr4:26859806~26860599:-
LUAD	cis	rs8062405	0.789	rs28676837	ENSG00000259982.1	CDC37P1	-6.65	8.12e-11	4.62e-08	-0.37	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28615742	chr16:28700294~28701540:-
LUAD	cis	rs10771431	0.967	rs7137443	ENSG00000111788.10	RP11-22B23.1	6.65	8.13e-11	4.63e-08	0.25	0.29	Breast size;	chr12:9219433	chr12:9277235~9313241:+
LUAD	cis	rs1062177	0.826	rs2915879	ENSG00000213433.5	RPLP1P6	-6.65	8.16e-11	4.64e-08	-0.38	-0.29	Preschool internalizing problems;	chr5:151767881	chr5:151765859~151766378:-
LUAD	cis	rs67311347	1	rs11715214	ENSG00000223797.4	ENTPD3-AS1	6.65	8.17e-11	4.65e-08	0.3	0.29	Renal cell carcinoma;	chr3:40361513	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs9860162	ENSG00000223797.4	ENTPD3-AS1	6.65	8.17e-11	4.65e-08	0.3	0.29	Renal cell carcinoma;	chr3:40362384	chr3:40313802~40453329:-
LUAD	cis	rs1823913	0.599	rs1454754	ENSG00000227542.1	AC092614.2	6.65	8.19e-11	4.66e-08	0.36	0.29	Obesity-related traits;	chr2:191303562	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.637	rs13010441	ENSG00000227542.1	AC092614.2	6.65	8.19e-11	4.66e-08	0.36	0.29	Obesity-related traits;	chr2:191303903	chr2:191229165~191246172:-
LUAD	cis	rs10899021	0.704	rs11236177	ENSG00000279353.1	RP11-864N7.4	6.65	8.22e-11	4.68e-08	0.52	0.29	Response to metformin (IC50);	chr11:74628022	chr11:74698231~74699658:-
LUAD	cis	rs10899021	0.79	rs10899022	ENSG00000279353.1	RP11-864N7.4	6.65	8.22e-11	4.68e-08	0.52	0.29	Response to metformin (IC50);	chr11:74628341	chr11:74698231~74699658:-
LUAD	cis	rs10899021	0.79	rs11236180	ENSG00000279353.1	RP11-864N7.4	6.65	8.22e-11	4.68e-08	0.52	0.29	Response to metformin (IC50);	chr11:74631883	chr11:74698231~74699658:-
LUAD	cis	rs77204473	0.744	rs2238005	ENSG00000254851.1	RP11-109L13.1	6.65	8.22e-11	4.68e-08	0.74	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117217366	chr11:117135528~117138582:+
LUAD	cis	rs77204473	0.744	rs2239009	ENSG00000254851.1	RP11-109L13.1	6.65	8.22e-11	4.68e-08	0.74	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117219006	chr11:117135528~117138582:+
LUAD	cis	rs77204473	0.744	rs78628783	ENSG00000254851.1	RP11-109L13.1	6.65	8.22e-11	4.68e-08	0.74	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117221335	chr11:117135528~117138582:+
LUAD	cis	rs77204473	0.744	rs80351364	ENSG00000254851.1	RP11-109L13.1	6.65	8.22e-11	4.68e-08	0.74	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117221678	chr11:117135528~117138582:+
LUAD	cis	rs9309473	1	rs7582606	ENSG00000163016.8	ALMS1P	6.65	8.23e-11	4.68e-08	0.36	0.29	Metabolite levels;	chr2:73586818	chr2:73644919~73685576:+
LUAD	cis	rs75422866	0.867	rs117388682	ENSG00000257433.4	RP1-197B17.3	6.64	8.25e-11	4.69e-08	0.62	0.29	Pneumonia;	chr12:47599713	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs79113930	ENSG00000257433.4	RP1-197B17.3	6.64	8.25e-11	4.69e-08	0.62	0.29	Pneumonia;	chr12:47600628	chr12:47706085~47742294:+
LUAD	cis	rs150992	0.861	rs151102	ENSG00000248489.1	CTD-2007H13.3	-6.64	8.25e-11	4.69e-08	-0.31	-0.29	Body mass index;	chr5:98947626	chr5:98929171~98995013:+
LUAD	cis	rs17818399	0.735	rs11894342	ENSG00000279254.1	RP11-536C12.1	-6.64	8.25e-11	4.69e-08	-0.3	-0.29	Height;	chr2:46609300	chr2:46668870~46670778:+
LUAD	cis	rs7567389	0.677	rs72848616	ENSG00000236682.1	AC068282.3	-6.64	8.26e-11	4.7e-08	-0.42	-0.29	Self-rated health;	chr2:127377521	chr2:127389130~127400580:+
LUAD	cis	rs7567389	0.71	rs72848618	ENSG00000236682.1	AC068282.3	-6.64	8.26e-11	4.7e-08	-0.42	-0.29	Self-rated health;	chr2:127377749	chr2:127389130~127400580:+
LUAD	cis	rs17301013	0.507	rs16846949	ENSG00000227373.4	RP11-160H22.5	6.64	8.27e-11	4.7e-08	0.45	0.29	Systemic lupus erythematosus;	chr1:174402071	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs7413513	ENSG00000227373.4	RP11-160H22.5	6.64	8.27e-11	4.7e-08	0.45	0.29	Systemic lupus erythematosus;	chr1:174403163	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs74128393	ENSG00000227373.4	RP11-160H22.5	6.64	8.27e-11	4.7e-08	0.45	0.29	Systemic lupus erythematosus;	chr1:174407961	chr1:174115300~174160004:-
LUAD	cis	rs67180937	0.542	rs61824282	ENSG00000272750.1	RP11-378J18.8	-6.64	8.29e-11	4.71e-08	-0.3	-0.29	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647869	chr1:222658867~222661512:-
LUAD	cis	rs748404	0.66	rs518288	ENSG00000249839.1	AC011330.5	-6.64	8.3e-11	4.72e-08	-0.38	-0.29	Lung cancer;	chr15:43471801	chr15:43663654~43684339:-
LUAD	cis	rs10129255	0.957	rs12589190	ENSG00000280411.1	IGHV1-69-2	-6.64	8.3e-11	4.72e-08	-0.22	-0.29	Kawasaki disease;	chr14:106783079	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.957	rs7493713	ENSG00000280411.1	IGHV1-69-2	-6.64	8.3e-11	4.72e-08	-0.22	-0.29	Kawasaki disease;	chr14:106783685	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.912	rs35468694	ENSG00000280411.1	IGHV1-69-2	-6.64	8.3e-11	4.72e-08	-0.22	-0.29	Kawasaki disease;	chr14:106784199	chr14:106762092~106762588:-
LUAD	cis	rs10129255	0.957	rs8019272	ENSG00000280411.1	IGHV1-69-2	-6.64	8.3e-11	4.72e-08	-0.22	-0.29	Kawasaki disease;	chr14:106784709	chr14:106762092~106762588:-
LUAD	cis	rs150992	0.587	rs10076291	ENSG00000248489.1	CTD-2007H13.3	-6.64	8.31e-11	4.72e-08	-0.32	-0.29	Body mass index;	chr5:99012954	chr5:98929171~98995013:+
LUAD	cis	rs2919917	0.628	rs13267679	ENSG00000254352.1	RP11-578O24.2	-6.64	8.31e-11	4.72e-08	-0.41	-0.29	Lymphocyte counts;	chr8:78711603	chr8:78723796~78724136:-
LUAD	cis	rs6558530	0.836	rs7461159	ENSG00000253982.1	CTD-2336O2.1	6.64	8.31e-11	4.72e-08	0.36	0.29	Systolic blood pressure;	chr8:1768450	chr8:1761990~1764502:-
LUAD	cis	rs9309473	0.95	rs6740766	ENSG00000163016.8	ALMS1P	6.64	8.34e-11	4.74e-08	0.36	0.29	Metabolite levels;	chr2:73553786	chr2:73644919~73685576:+
LUAD	cis	rs9309473	1	rs13431267	ENSG00000163016.8	ALMS1P	6.64	8.34e-11	4.74e-08	0.36	0.29	Metabolite levels;	chr2:73555073	chr2:73644919~73685576:+
LUAD	cis	rs9309473	0.95	rs6735946	ENSG00000163016.8	ALMS1P	6.64	8.34e-11	4.74e-08	0.36	0.29	Metabolite levels;	chr2:73562931	chr2:73644919~73685576:+
LUAD	cis	rs9309473	0.95	rs10198549	ENSG00000163016.8	ALMS1P	6.64	8.34e-11	4.74e-08	0.36	0.29	Metabolite levels;	chr2:73567277	chr2:73644919~73685576:+
LUAD	cis	rs9309473	1	rs7583255	ENSG00000163016.8	ALMS1P	6.64	8.34e-11	4.74e-08	0.36	0.29	Metabolite levels;	chr2:73570869	chr2:73644919~73685576:+
LUAD	cis	rs17301013	0.507	rs72715294	ENSG00000227373.4	RP11-160H22.5	6.64	8.35e-11	4.75e-08	0.45	0.29	Systemic lupus erythematosus;	chr1:174754922	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs1813136	ENSG00000227373.4	RP11-160H22.5	6.64	8.35e-11	4.75e-08	0.45	0.29	Systemic lupus erythematosus;	chr1:174756656	chr1:174115300~174160004:-
LUAD	cis	rs1823913	0.549	rs4516458	ENSG00000227542.1	AC092614.2	6.64	8.37e-11	4.75e-08	0.37	0.29	Obesity-related traits;	chr2:191325177	chr2:191229165~191246172:-
LUAD	cis	rs12439619	0.846	rs62013464	ENSG00000255769.6	GOLGA2P10	-6.64	8.37e-11	4.76e-08	-0.37	-0.29	Intelligence (multi-trait analysis);	chr15:82288250	chr15:82472993~82513950:-
LUAD	cis	rs10129255	1	rs10129255	ENSG00000280411.1	IGHV1-69-2	6.64	8.37e-11	4.76e-08	0.22	0.29	Kawasaki disease;	chr14:106767970	chr14:106762092~106762588:-
LUAD	cis	rs11846409	0.932	rs61233250	ENSG00000254174.1	IGHV1-12	6.64	8.38e-11	4.76e-08	0.25	0.29	Rheumatic heart disease;	chr14:106634072	chr14:106122420~106122709:-
LUAD	cis	rs2439831	0.867	rs2278860	ENSG00000205771.5	CATSPER2P1	6.64	8.38e-11	4.76e-08	0.49	0.29	Lung cancer in ever smokers;	chr15:43366848	chr15:43726918~43747094:-
LUAD	cis	rs12022452	0.506	rs61779163	ENSG00000238287.1	RP11-656D10.3	-6.64	8.39e-11	4.76e-08	-0.45	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40549751	chr1:40493157~40508661:-
LUAD	cis	rs6991838	0.806	rs11781358	ENSG00000272010.1	CTD-3025N20.3	6.64	8.4e-11	4.77e-08	0.3	0.29	Intelligence (multi-trait analysis);	chr8:65557691	chr8:65591850~65592472:-
LUAD	cis	rs7927592	0.913	rs7123564	ENSG00000212093.1	AP000807.1	6.64	8.41e-11	4.77e-08	0.33	0.29	Total body bone mineral density;	chr11:68594696	chr11:68506083~68506166:-
LUAD	cis	rs6142102	1	rs4911409	ENSG00000276073.1	RP5-1125A11.7	-6.64	8.41e-11	4.77e-08	-0.3	-0.29	Skin pigmentation;	chr20:34122904	chr20:33985617~33988989:-
LUAD	cis	rs11123170	0.529	rs112692022	ENSG00000274877.1	RP11-65I12.1	-6.64	8.41e-11	4.78e-08	-0.44	-0.29	Renal function-related traits (BUN);	chr2:113212605	chr2:113237595~113240825:+
LUAD	cis	rs2404602	0.647	rs11072616	ENSG00000259422.1	RP11-593F23.1	-6.64	8.41e-11	4.78e-08	-0.38	-0.29	Blood metabolite levels;	chr15:76692928	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.622	rs4886506	ENSG00000259422.1	RP11-593F23.1	6.64	8.42e-11	4.78e-08	0.38	0.29	Blood metabolite levels;	chr15:76914936	chr15:76174891~76181486:-
LUAD	cis	rs7246657	0.941	rs7256130	ENSG00000276846.1	CTD-3220F14.3	6.64	8.43e-11	4.79e-08	0.39	0.29	Coronary artery calcification;	chr19:37443079	chr19:37314868~37315620:-
LUAD	cis	rs6558530	0.965	rs730379	ENSG00000253982.1	CTD-2336O2.1	6.64	8.44e-11	4.79e-08	0.36	0.29	Systolic blood pressure;	chr8:1759927	chr8:1761990~1764502:-
LUAD	cis	rs9487094	0.689	rs9480936	ENSG00000260273.1	RP11-425D10.10	6.64	8.44e-11	4.79e-08	0.37	0.29	Height;	chr6:109358227	chr6:109382795~109383666:+
LUAD	cis	rs950169	0.544	rs12913702	ENSG00000259728.4	LINC00933	6.64	8.45e-11	4.79e-08	0.43	0.29	Schizophrenia;	chr15:84609953	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.509	rs71395455	ENSG00000259728.4	LINC00933	6.64	8.45e-11	4.79e-08	0.43	0.29	Schizophrenia;	chr15:84610573	chr15:84570649~84580175:+
LUAD	cis	rs6565180	0.963	rs4787642	ENSG00000183604.13	SMG1P5	-6.64	8.45e-11	4.8e-08	-0.31	-0.29	Tonsillectomy;	chr16:30348087	chr16:30267553~30335374:-
LUAD	cis	rs35955747	0.869	rs28715	ENSG00000236132.1	CTA-440B3.1	-6.64	8.45e-11	4.8e-08	-0.32	-0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31334183	chr22:31816379~31817491:-
LUAD	cis	rs2243480	1	rs313809	ENSG00000226824.5	RP4-756H11.3	-6.64	8.46e-11	4.8e-08	-0.54	-0.29	Diabetic kidney disease;	chr7:66034996	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.545	rs1267814	ENSG00000237310.1	GS1-124K5.4	-6.64	8.46e-11	4.8e-08	-0.35	-0.29	Aortic root size;	chr7:66579422	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.964	rs1643388	ENSG00000222364.1	RNU6-96P	-6.64	8.46e-11	4.8e-08	-0.32	-0.29	Aortic root size;	chr7:66379575	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs778722	ENSG00000222364.1	RNU6-96P	-6.64	8.46e-11	4.8e-08	-0.32	-0.29	Aortic root size;	chr7:66379841	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.964	rs778721	ENSG00000222364.1	RNU6-96P	-6.64	8.46e-11	4.8e-08	-0.32	-0.29	Aortic root size;	chr7:66380410	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.929	rs778712	ENSG00000222364.1	RNU6-96P	-6.64	8.46e-11	4.8e-08	-0.32	-0.29	Aortic root size;	chr7:66384991	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs778710	ENSG00000222364.1	RNU6-96P	-6.64	8.46e-11	4.8e-08	-0.32	-0.29	Aortic root size;	chr7:66389847	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.964	rs778708	ENSG00000222364.1	RNU6-96P	-6.64	8.46e-11	4.8e-08	-0.32	-0.29	Aortic root size;	chr7:66391332	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs778706	ENSG00000222364.1	RNU6-96P	-6.64	8.46e-11	4.8e-08	-0.32	-0.29	Aortic root size;	chr7:66395437	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.895	rs778700	ENSG00000222364.1	RNU6-96P	-6.64	8.46e-11	4.8e-08	-0.32	-0.29	Aortic root size;	chr7:66401463	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs778699	ENSG00000222364.1	RNU6-96P	-6.64	8.46e-11	4.8e-08	-0.32	-0.29	Aortic root size;	chr7:66403303	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs778696	ENSG00000222364.1	RNU6-96P	-6.64	8.46e-11	4.8e-08	-0.32	-0.29	Aortic root size;	chr7:66405826	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs778694	ENSG00000222364.1	RNU6-96P	-6.64	8.46e-11	4.8e-08	-0.32	-0.29	Aortic root size;	chr7:66406571	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.929	rs778692	ENSG00000222364.1	RNU6-96P	-6.64	8.46e-11	4.8e-08	-0.32	-0.29	Aortic root size;	chr7:66407462	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs4718343	ENSG00000222364.1	RNU6-96P	-6.64	8.46e-11	4.8e-08	-0.32	-0.29	Aortic root size;	chr7:66409301	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs4718344	ENSG00000222364.1	RNU6-96P	-6.64	8.46e-11	4.8e-08	-0.32	-0.29	Aortic root size;	chr7:66409394	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs1968225	ENSG00000222364.1	RNU6-96P	-6.64	8.46e-11	4.8e-08	-0.32	-0.29	Aortic root size;	chr7:66409786	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.737	rs7803424	ENSG00000222364.1	RNU6-96P	-6.64	8.46e-11	4.8e-08	-0.32	-0.29	Aortic root size;	chr7:66415618	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.83	rs7799834	ENSG00000222364.1	RNU6-96P	-6.64	8.46e-11	4.8e-08	-0.32	-0.29	Aortic root size;	chr7:66415707	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs6460295	ENSG00000222364.1	RNU6-96P	-6.64	8.46e-11	4.8e-08	-0.32	-0.29	Aortic root size;	chr7:66417741	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.964	rs6978721	ENSG00000222364.1	RNU6-96P	-6.64	8.46e-11	4.8e-08	-0.32	-0.29	Aortic root size;	chr7:66418217	chr7:66395191~66395286:+
LUAD	cis	rs8177876	0.822	rs10514514	ENSG00000261838.4	RP11-303E16.6	6.64	8.47e-11	4.8e-08	0.62	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081668	chr16:81069854~81076598:+
LUAD	cis	rs12458462	0.892	rs35928863	ENSG00000274828.1	RP11-567M16.6	6.64	8.47e-11	4.81e-08	0.3	0.29	Monocyte count;	chr18:79678956	chr18:79677287~79679358:-
LUAD	cis	rs875971	0.545	rs6460281	ENSG00000237310.1	GS1-124K5.4	6.64	8.48e-11	4.81e-08	0.36	0.29	Aortic root size;	chr7:66216128	chr7:66493706~66495474:+
LUAD	cis	rs55665837	1	rs12283797	ENSG00000251991.1	RNU7-49P	6.64	8.49e-11	4.81e-08	0.32	0.29	Vitamin D levels;	chr11:14420716	chr11:14478892~14478953:+
LUAD	cis	rs55665837	1	rs10832256	ENSG00000251991.1	RNU7-49P	6.64	8.49e-11	4.81e-08	0.32	0.29	Vitamin D levels;	chr11:14421329	chr11:14478892~14478953:+
LUAD	cis	rs55665837	1	rs10832257	ENSG00000251991.1	RNU7-49P	6.64	8.49e-11	4.81e-08	0.32	0.29	Vitamin D levels;	chr11:14421770	chr11:14478892~14478953:+
LUAD	cis	rs55665837	0.961	rs12795972	ENSG00000251991.1	RNU7-49P	6.64	8.49e-11	4.81e-08	0.32	0.29	Vitamin D levels;	chr11:14422229	chr11:14478892~14478953:+
LUAD	cis	rs1799949	1	rs33994002	ENSG00000267681.1	CTD-3199J23.6	-6.64	8.5e-11	4.82e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43176801	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs33920795	ENSG00000267681.1	CTD-3199J23.6	-6.64	8.5e-11	4.82e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43176993	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs33918839	ENSG00000267681.1	CTD-3199J23.6	-6.64	8.5e-11	4.82e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43177155	chr17:43144956~43145255:+
LUAD	cis	rs12468226	0.606	rs79092351	ENSG00000273456.1	RP11-686O6.2	6.64	8.5e-11	4.82e-08	0.41	0.29	Urate levels;	chr2:202204388	chr2:202374932~202375604:-
LUAD	cis	rs8031584	0.918	rs34095794	ENSG00000260382.1	RP11-540B6.2	6.64	8.5e-11	4.82e-08	0.34	0.29	Huntington's disease progression;	chr15:30977488	chr15:30882267~30883231:-
LUAD	cis	rs7598759	0.548	rs1584462	ENSG00000181798.2	LINC00471	-6.64	8.51e-11	4.83e-08	-0.32	-0.29	Noise-induced hearing loss;	chr2:231505087	chr2:231508426~231514339:-
LUAD	cis	rs11098499	0.863	rs1155576	ENSG00000248280.1	RP11-33B1.2	6.64	8.53e-11	4.83e-08	0.37	0.29	Corneal astigmatism;	chr4:119529004	chr4:119440561~119450157:-
LUAD	cis	rs2404602	0.532	rs206205	ENSG00000259422.1	RP11-593F23.1	6.64	8.53e-11	4.84e-08	0.34	0.29	Blood metabolite levels;	chr15:76443750	chr15:76174891~76181486:-
LUAD	cis	rs9928842	1	rs9928842	ENSG00000280152.1	RP11-331F4.5	6.64	8.55e-11	4.84e-08	0.33	0.29	Alcoholic chronic pancreatitis;	chr16:75208969	chr16:75245994~75250077:-
LUAD	cis	rs10771431	1	rs10771431	ENSG00000111788.10	RP11-22B23.1	6.64	8.55e-11	4.85e-08	0.25	0.29	Breast size;	chr12:9228263	chr12:9277235~9313241:+
LUAD	cis	rs77204473	1	rs11216186	ENSG00000254851.1	RP11-109L13.1	6.64	8.56e-11	4.85e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116913976	chr11:117135528~117138582:+
LUAD	cis	rs7567389	0.677	rs72845975	ENSG00000236682.1	AC068282.3	-6.64	8.56e-11	4.85e-08	-0.42	-0.29	Self-rated health;	chr2:127328698	chr2:127389130~127400580:+
LUAD	cis	rs7567389	0.677	rs72845976	ENSG00000236682.1	AC068282.3	-6.64	8.56e-11	4.85e-08	-0.42	-0.29	Self-rated health;	chr2:127328864	chr2:127389130~127400580:+
LUAD	cis	rs7567389	0.677	rs61422716	ENSG00000236682.1	AC068282.3	-6.64	8.56e-11	4.85e-08	-0.42	-0.29	Self-rated health;	chr2:127330075	chr2:127389130~127400580:+
LUAD	cis	rs7567389	0.677	rs10496661	ENSG00000236682.1	AC068282.3	-6.64	8.56e-11	4.85e-08	-0.42	-0.29	Self-rated health;	chr2:127332568	chr2:127389130~127400580:+
LUAD	cis	rs7567389	0.677	rs11680877	ENSG00000236682.1	AC068282.3	-6.64	8.56e-11	4.85e-08	-0.42	-0.29	Self-rated health;	chr2:127332874	chr2:127389130~127400580:+
LUAD	cis	rs7567389	0.677	rs72846002	ENSG00000236682.1	AC068282.3	-6.64	8.56e-11	4.85e-08	-0.42	-0.29	Self-rated health;	chr2:127360571	chr2:127389130~127400580:+
LUAD	cis	rs7567389	0.677	rs72848604	ENSG00000236682.1	AC068282.3	-6.64	8.56e-11	4.85e-08	-0.42	-0.29	Self-rated health;	chr2:127362542	chr2:127389130~127400580:+
LUAD	cis	rs7567389	0.677	rs11680949	ENSG00000236682.1	AC068282.3	-6.64	8.56e-11	4.85e-08	-0.42	-0.29	Self-rated health;	chr2:127365986	chr2:127389130~127400580:+
LUAD	cis	rs4141404	0.851	rs5749222	ENSG00000236132.1	CTA-440B3.1	6.64	8.57e-11	4.85e-08	0.34	0.29	Paclitaxel-induced neuropathy;	chr22:31160773	chr22:31816379~31817491:-
LUAD	cis	rs4141404	0.851	rs8135417	ENSG00000236132.1	CTA-440B3.1	6.64	8.57e-11	4.85e-08	0.34	0.29	Paclitaxel-induced neuropathy;	chr22:31163269	chr22:31816379~31817491:-
LUAD	cis	rs2734839	0.964	rs2734838	ENSG00000270179.1	RP11-159N11.4	-6.64	8.58e-11	4.86e-08	-0.3	-0.29	Information processing speed;	chr11:113415779	chr11:113368478~113369117:+
LUAD	cis	rs2946504	0.822	rs2977095	ENSG00000251468.2	RP11-369K16.1	6.64	8.58e-11	4.86e-08	0.35	0.29	Type 2 diabetes;	chr8:12947706	chr8:12958387~12962200:+
LUAD	cis	rs2243480	1	rs2465120	ENSG00000226824.5	RP4-756H11.3	-6.64	8.59e-11	4.86e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66155987	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.908	rs2460431	ENSG00000226824.5	RP4-756H11.3	6.64	8.59e-11	4.86e-08	0.55	0.29	Diabetic kidney disease;	chr7:66157859	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs4718309	ENSG00000226824.5	RP4-756H11.3	6.64	8.59e-11	4.86e-08	0.55	0.29	Diabetic kidney disease;	chr7:66162777	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs6460274	ENSG00000226824.5	RP4-756H11.3	6.64	8.59e-11	4.86e-08	0.55	0.29	Diabetic kidney disease;	chr7:66163497	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs7787230	ENSG00000226824.5	RP4-756H11.3	6.64	8.59e-11	4.86e-08	0.55	0.29	Diabetic kidney disease;	chr7:66164112	chr7:66654538~66669855:+
LUAD	cis	rs12594515	0.548	rs12912226	ENSG00000273972.1	CTD-2306A12.1	-6.64	8.59e-11	4.87e-08	-0.34	-0.29	Weight;Waist circumference;	chr15:45693510	chr15:45702640~45703183:+
LUAD	cis	rs950169	0.656	rs748455	ENSG00000259728.4	LINC00933	6.64	8.6e-11	4.87e-08	0.43	0.29	Schizophrenia;	chr15:84606344	chr15:84570649~84580175:+
LUAD	cis	rs8031584	0.918	rs61997139	ENSG00000260382.1	RP11-540B6.2	6.64	8.63e-11	4.89e-08	0.34	0.29	Huntington's disease progression;	chr15:30981399	chr15:30882267~30883231:-
LUAD	cis	rs77204473	0.744	rs12418705	ENSG00000254851.1	RP11-109L13.1	6.64	8.64e-11	4.89e-08	0.75	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117213680	chr11:117135528~117138582:+
LUAD	cis	rs516805	0.961	rs1267942	ENSG00000279453.1	RP3-425C14.4	-6.64	8.65e-11	4.9e-08	-0.33	-0.29	Lymphocyte counts;	chr6:122472375	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.961	rs471620	ENSG00000279453.1	RP3-425C14.4	-6.64	8.65e-11	4.9e-08	-0.33	-0.29	Lymphocyte counts;	chr6:122473532	chr6:122436789~122439223:-
LUAD	cis	rs2404602	0.503	rs284909	ENSG00000259422.1	RP11-593F23.1	6.64	8.66e-11	4.9e-08	0.34	0.29	Blood metabolite levels;	chr15:76444287	chr15:76174891~76181486:-
LUAD	cis	rs9322193	0.923	rs2342765	ENSG00000223701.3	RAET1E-AS1	6.64	8.67e-11	4.91e-08	0.35	0.29	Lung cancer;	chr6:149858873	chr6:149884431~149919508:+
LUAD	cis	rs7044106	0.791	rs10984994	ENSG00000238181.2	AHCYP2	6.64	8.69e-11	4.92e-08	0.38	0.29	Hip circumference adjusted for BMI;	chr9:120716491	chr9:120720673~120721972:+
LUAD	cis	rs9318086	0.712	rs12875437	ENSG00000205861.10	C1QTNF9B-AS1	-6.64	8.69e-11	4.92e-08	-0.34	-0.29	Myopia (pathological);	chr13:23879817	chr13:23888889~23897263:+
LUAD	cis	rs755249	0.958	rs2068663	ENSG00000228060.1	RP11-69E11.8	-6.64	8.7e-11	4.92e-08	-0.29	-0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572899	chr1:39565160~39573203:+
LUAD	cis	rs2243480	1	rs464895	ENSG00000273142.1	RP11-458F8.4	-6.64	8.7e-11	4.92e-08	-0.3	-0.29	Diabetic kidney disease;	chr7:66062119	chr7:66902857~66906297:+
LUAD	cis	rs7208859	0.623	rs79607958	ENSG00000263531.1	RP13-753N3.1	6.64	8.71e-11	4.93e-08	0.62	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607530	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs75136574	ENSG00000263531.1	RP13-753N3.1	6.64	8.71e-11	4.93e-08	0.62	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607531	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs77544470	ENSG00000263531.1	RP13-753N3.1	6.64	8.71e-11	4.93e-08	0.62	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607532	chr17:30863921~30864940:-
LUAD	cis	rs10129255	0.518	rs2006284	ENSG00000211970.3	IGHV4-61	-6.64	8.71e-11	4.93e-08	-0.21	-0.29	Kawasaki disease;	chr14:106676185	chr14:106639119~106639657:-
LUAD	cis	rs2115630	0.653	rs61394864	ENSG00000225151.9	GOLGA2P7	6.64	8.71e-11	4.93e-08	0.33	0.29	P wave terminal force;	chr15:84626943	chr15:84199311~84230136:-
LUAD	cis	rs4722166	0.63	rs4722168	ENSG00000179428.2	AC073072.5	-6.64	8.72e-11	4.93e-08	-0.35	-0.29	Lung cancer;	chr7:22739383	chr7:22725395~22727620:-
LUAD	cis	rs17301013	0.606	rs11802158	ENSG00000227373.4	RP11-160H22.5	6.64	8.72e-11	4.94e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174223973	chr1:174115300~174160004:-
LUAD	cis	rs881375	0.967	rs1860823	ENSG00000226752.6	PSMD5-AS1	-6.64	8.73e-11	4.94e-08	-0.32	-0.29	Rheumatoid arthritis;	chr9:120897026	chr9:120824828~120854385:+
LUAD	cis	rs881375	0.967	rs1860824	ENSG00000226752.6	PSMD5-AS1	-6.64	8.73e-11	4.94e-08	-0.32	-0.29	Rheumatoid arthritis;	chr9:120897061	chr9:120824828~120854385:+
LUAD	cis	rs77204473	0.744	rs3213459	ENSG00000254851.1	RP11-109L13.1	6.64	8.74e-11	4.95e-08	0.65	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117191773	chr11:117135528~117138582:+
LUAD	cis	rs2980439	0.557	rs2976876	ENSG00000253893.2	FAM85B	-6.64	8.75e-11	4.95e-08	-0.37	-0.29	Neuroticism;	chr8:8461340	chr8:8167819~8226614:-
LUAD	cis	rs9309473	0.95	rs10178678	ENSG00000163016.8	ALMS1P	6.64	8.75e-11	4.95e-08	0.36	0.29	Metabolite levels;	chr2:73535109	chr2:73644919~73685576:+
LUAD	cis	rs11846409	0.932	rs28378201	ENSG00000254174.1	IGHV1-12	6.63	8.78e-11	4.96e-08	0.25	0.29	Rheumatic heart disease;	chr14:106637262	chr14:106122420~106122709:-
LUAD	cis	rs11846409	0.86	rs74091720	ENSG00000254174.1	IGHV1-12	6.63	8.78e-11	4.96e-08	0.25	0.29	Rheumatic heart disease;	chr14:106638192	chr14:106122420~106122709:-
LUAD	cis	rs7115242	0.702	rs672058	ENSG00000280143.1	AP000892.6	6.63	8.78e-11	4.96e-08	0.44	0.29	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116893305	chr11:117204967~117210292:+
LUAD	cis	rs9326248	0.559	rs10892064	ENSG00000280143.1	AP000892.6	6.63	8.8e-11	4.97e-08	0.33	0.29	Blood protein levels;	chr11:117025837	chr11:117204967~117210292:+
LUAD	cis	rs9326248	0.539	rs10892065	ENSG00000280143.1	AP000892.6	6.63	8.8e-11	4.97e-08	0.33	0.29	Blood protein levels;	chr11:117026308	chr11:117204967~117210292:+
LUAD	cis	rs9595066	0.627	rs4942287	ENSG00000227258.4	SMIM2-AS1	-6.63	8.81e-11	4.98e-08	-0.45	-0.29	Schizophrenia;	chr13:44160560	chr13:44110451~44240517:+
LUAD	cis	rs7923609	0.902	rs4633333	ENSG00000232075.1	MRPL35P2	-6.63	8.83e-11	4.99e-08	-0.35	-0.29	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63568779	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.902	rs10740136	ENSG00000232075.1	MRPL35P2	-6.63	8.83e-11	4.99e-08	-0.35	-0.29	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63569862	chr10:63634317~63634827:-
LUAD	cis	rs1823913	0.599	rs13027086	ENSG00000227542.1	AC092614.2	6.63	8.86e-11	5.01e-08	0.36	0.29	Obesity-related traits;	chr2:191294058	chr2:191229165~191246172:-
LUAD	cis	rs2739330	0.828	rs5760107	ENSG00000206090.4	AP000350.7	6.63	8.87e-11	5.01e-08	0.33	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23939998~23942798:+
LUAD	cis	rs2739330	0.789	rs5760109	ENSG00000206090.4	AP000350.7	6.63	8.87e-11	5.01e-08	0.33	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23939998~23942798:+
LUAD	cis	rs6142102	0.602	rs1054534	ENSG00000275784.1	RP5-1125A11.6	-6.63	8.88e-11	5.02e-08	-0.31	-0.29	Skin pigmentation;	chr20:34017521	chr20:33989480~33991818:-
LUAD	cis	rs62229266	0.659	rs62230814	ENSG00000214914.3	RPL23AP3	6.63	8.89e-11	5.02e-08	0.35	0.29	Mitral valve prolapse;	chr21:36031248	chr21:36016079~36016546:-
LUAD	cis	rs7044106	0.791	rs10984997	ENSG00000238181.2	AHCYP2	-6.63	8.89e-11	5.02e-08	-0.38	-0.29	Hip circumference adjusted for BMI;	chr9:120718928	chr9:120720673~120721972:+
LUAD	cis	rs11214589	0.806	rs4551806	ENSG00000270179.1	RP11-159N11.4	-6.63	8.89e-11	5.02e-08	-0.29	-0.29	Neuroticism;	chr11:113379818	chr11:113368478~113369117:+
LUAD	cis	rs4722166	0.63	rs4722169	ENSG00000179428.2	AC073072.5	-6.63	8.89e-11	5.02e-08	-0.35	-0.29	Lung cancer;	chr7:22745800	chr7:22725395~22727620:-
LUAD	cis	rs881375	0.967	rs2270231	ENSG00000226752.6	PSMD5-AS1	-6.63	8.9e-11	5.03e-08	-0.31	-0.29	Rheumatoid arthritis;	chr9:120888704	chr9:120824828~120854385:+
LUAD	cis	rs881375	1	rs881375	ENSG00000226752.6	PSMD5-AS1	-6.63	8.9e-11	5.03e-08	-0.31	-0.29	Rheumatoid arthritis;	chr9:120890620	chr9:120824828~120854385:+
LUAD	cis	rs12429206	0.52	rs1870839	ENSG00000233672.5	RNASEH2B-AS1	-6.63	8.91e-11	5.03e-08	-0.42	-0.29	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50899732	chr13:50862172~50910764:-
LUAD	cis	rs7017914	0.967	rs1902614	ENSG00000223220.1	Y_RNA	6.63	8.92e-11	5.04e-08	0.32	0.29	Bone mineral density;	chr8:70743932	chr8:70780914~70781008:-
LUAD	cis	rs62229266	0.659	rs7275820	ENSG00000214914.3	RPL23AP3	6.63	8.92e-11	5.04e-08	0.35	0.29	Mitral valve prolapse;	chr21:36037116	chr21:36016079~36016546:-
LUAD	cis	rs1823913	0.526	rs36028476	ENSG00000227542.1	AC092614.2	6.63	8.92e-11	5.04e-08	0.36	0.29	Obesity-related traits;	chr2:191300595	chr2:191229165~191246172:-
LUAD	cis	rs9309473	0.948	rs10173534	ENSG00000163016.8	ALMS1P	6.63	8.94e-11	5.05e-08	0.36	0.29	Metabolite levels;	chr2:73586305	chr2:73644919~73685576:+
LUAD	cis	rs1823913	0.599	rs13035132	ENSG00000280083.1	RP11-317J9.1	-6.63	8.94e-11	5.05e-08	-0.34	-0.29	Obesity-related traits;	chr2:191265275	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.599	rs17412635	ENSG00000227542.1	AC092614.2	-6.63	8.94e-11	5.05e-08	-0.36	-0.29	Obesity-related traits;	chr2:191294834	chr2:191229165~191246172:-
LUAD	cis	rs10129255	1	rs4612959	ENSG00000280411.1	IGHV1-69-2	-6.63	8.97e-11	5.06e-08	-0.22	-0.29	Kawasaki disease;	chr14:106767055	chr14:106762092~106762588:-
LUAD	cis	rs6844153	0.887	rs3792685	ENSG00000240005.4	RP11-293A21.1	-6.63	8.97e-11	5.06e-08	-0.46	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26957585	chr4:26859806~26860599:-
LUAD	cis	rs3096299	0.933	rs889576	ENSG00000274627.1	RP11-104N10.2	-6.63	8.98e-11	5.07e-08	-0.28	-0.29	Multiple myeloma (IgH translocation);	chr16:89363245	chr16:89516797~89522217:+
LUAD	cis	rs11089937	0.584	rs5757245	ENSG00000211639.2	IGLV4-60	6.63	8.99e-11	5.07e-08	0.3	0.29	Periodontitis (PAL4Q3);	chr22:22176674	chr22:22162199~22162681:+
LUAD	cis	rs950169	0.8	rs34302901	ENSG00000259728.4	LINC00933	6.63	9e-11	5.08e-08	0.43	0.29	Schizophrenia;	chr15:84567712	chr15:84570649~84580175:+
LUAD	cis	rs1799949	1	rs2271574	ENSG00000267681.1	CTD-3199J23.6	-6.63	9e-11	5.08e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43175631	chr17:43144956~43145255:+
LUAD	cis	rs9326248	0.581	rs10892063	ENSG00000280143.1	AP000892.6	6.63	9.01e-11	5.08e-08	0.33	0.29	Blood protein levels;	chr11:117025439	chr11:117204967~117210292:+
LUAD	cis	rs55665837	1	rs11023216	ENSG00000251991.1	RNU7-49P	6.63	9.02e-11	5.09e-08	0.32	0.29	Vitamin D levels;	chr11:14415607	chr11:14478892~14478953:+
LUAD	cis	rs10129255	0.5	rs10143242	ENSG00000211970.3	IGHV4-61	-6.63	9.05e-11	5.1e-08	-0.21	-0.29	Kawasaki disease;	chr14:106681814	chr14:106639119~106639657:-
LUAD	cis	rs17301013	0.606	rs1853321	ENSG00000227373.4	RP11-160H22.5	6.63	9.06e-11	5.11e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174125295	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs6694208	ENSG00000227373.4	RP11-160H22.5	6.63	9.06e-11	5.11e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174127631	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs4650951	ENSG00000227373.4	RP11-160H22.5	6.63	9.06e-11	5.11e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174134368	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs4652191	ENSG00000227373.4	RP11-160H22.5	6.63	9.06e-11	5.11e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174135473	chr1:174115300~174160004:-
LUAD	cis	rs17711722	0.523	rs313812	ENSG00000236529.1	RP13-254B10.1	-6.63	9.06e-11	5.11e-08	-0.29	-0.29	Calcium levels;	chr7:66040056	chr7:65840212~65840596:+
LUAD	cis	rs1823913	0.599	rs17511445	ENSG00000227542.1	AC092614.2	-6.63	9.08e-11	5.12e-08	-0.35	-0.29	Obesity-related traits;	chr2:191279831	chr2:191229165~191246172:-
LUAD	cis	rs67311347	1	rs4973993	ENSG00000223797.4	ENTPD3-AS1	6.63	9.08e-11	5.12e-08	0.32	0.29	Renal cell carcinoma;	chr3:40411469	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs4973994	ENSG00000223797.4	ENTPD3-AS1	6.63	9.08e-11	5.12e-08	0.32	0.29	Renal cell carcinoma;	chr3:40411533	chr3:40313802~40453329:-
LUAD	cis	rs4713118	0.513	rs149955	ENSG00000219392.1	RP1-265C24.5	-6.63	9.08e-11	5.12e-08	-0.38	-0.29	Parkinson's disease;	chr6:28068447	chr6:28115628~28116551:+
LUAD	cis	rs17301013	0.606	rs12354141	ENSG00000227373.4	RP11-160H22.5	6.63	9.08e-11	5.12e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174166078	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs3086	ENSG00000227373.4	RP11-160H22.5	6.63	9.08e-11	5.12e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174167236	chr1:174115300~174160004:-
LUAD	cis	rs11098499	0.691	rs10028773	ENSG00000248280.1	RP11-33B1.2	-6.63	9.09e-11	5.12e-08	-0.33	-0.29	Corneal astigmatism;	chr4:119344104	chr4:119440561~119450157:-
LUAD	cis	rs17684571	0.938	rs4074102	ENSG00000231441.1	RP11-472M19.2	6.63	9.1e-11	5.13e-08	0.4	0.29	Schizophrenia;	chr6:56697497	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.938	rs4074101	ENSG00000231441.1	RP11-472M19.2	6.63	9.1e-11	5.13e-08	0.4	0.29	Schizophrenia;	chr6:56697654	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.938	rs35668437	ENSG00000231441.1	RP11-472M19.2	6.63	9.1e-11	5.13e-08	0.4	0.29	Schizophrenia;	chr6:56701058	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.938	rs17684511	ENSG00000231441.1	RP11-472M19.2	6.63	9.1e-11	5.13e-08	0.4	0.29	Schizophrenia;	chr6:56701217	chr6:56844002~56864078:+
LUAD	cis	rs2243480	1	rs160633	ENSG00000273142.1	RP11-458F8.4	-6.63	9.11e-11	5.14e-08	-0.3	-0.29	Diabetic kidney disease;	chr7:66063241	chr7:66902857~66906297:+
LUAD	cis	rs7773456	0.576	rs4140624	ENSG00000228412.5	RP4-625H18.2	-6.63	9.12e-11	5.14e-08	-0.39	-0.29	Lupus nephritis in systemic lupus erythematosus;	chr6:19818329	chr6:19802164~19804752:-
LUAD	cis	rs9326248	0.53	rs10790172	ENSG00000280143.1	AP000892.6	6.63	9.15e-11	5.16e-08	0.44	0.29	Blood protein levels;	chr11:117057024	chr11:117204967~117210292:+
LUAD	cis	rs17301013	0.507	rs12059307	ENSG00000227373.4	RP11-160H22.5	6.63	9.17e-11	5.17e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174342105	chr1:174115300~174160004:-
LUAD	cis	rs7829975	0.623	rs10092965	ENSG00000253981.4	ALG1L13P	6.63	9.18e-11	5.17e-08	0.34	0.29	Mood instability;	chr8:8515975	chr8:8236003~8244667:-
LUAD	cis	rs12712135	0.706	rs6543114	ENSG00000234389.1	AC007278.3	-6.63	9.18e-11	5.17e-08	-0.31	-0.29	Blood protein levels;	chr2:102309534	chr2:102438713~102440475:+
LUAD	cis	rs7567389	0.719	rs4150476	ENSG00000236682.1	AC068282.3	6.63	9.18e-11	5.17e-08	0.42	0.29	Self-rated health;	chr2:127275246	chr2:127389130~127400580:+
LUAD	cis	rs7567389	0.719	rs4150471	ENSG00000236682.1	AC068282.3	6.63	9.18e-11	5.17e-08	0.42	0.29	Self-rated health;	chr2:127276963	chr2:127389130~127400580:+
LUAD	cis	rs10759883	0.563	rs12345187	ENSG00000175611.10	LINC00476	6.63	9.19e-11	5.18e-08	0.32	0.29	Nicotine dependence;	chr9:95906088	chr9:95759231~95875977:-
LUAD	cis	rs9326248	0.53	rs1351452	ENSG00000280143.1	AP000892.6	-6.63	9.21e-11	5.19e-08	-0.43	-0.29	Blood protein levels;	chr11:117072638	chr11:117204967~117210292:+
LUAD	cis	rs1061377	1	rs35116118	ENSG00000249685.1	RP11-360F5.3	6.63	9.23e-11	5.2e-08	0.35	0.29	Uric acid levels;	chr4:39127293	chr4:39133913~39135608:+
LUAD	cis	rs1075265	0.568	rs3095756	ENSG00000233266.1	HMGB1P31	6.63	9.25e-11	5.21e-08	0.37	0.29	Chronotype;Morning vs. evening chronotype;	chr2:53822332	chr2:54051334~54051760:+
LUAD	cis	rs6991838	0.765	rs6472219	ENSG00000200714.1	Y_RNA	6.63	9.26e-11	5.21e-08	0.34	0.29	Intelligence (multi-trait analysis);	chr8:65644487	chr8:65592731~65592820:+
LUAD	cis	rs12022452	0.506	rs6673386	ENSG00000238287.1	RP11-656D10.3	-6.63	9.26e-11	5.21e-08	-0.45	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40546207	chr1:40493157~40508661:-
LUAD	cis	rs2243480	1	rs313814	ENSG00000226824.5	RP4-756H11.3	-6.63	9.27e-11	5.22e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66038306	chr7:66654538~66669855:+
LUAD	cis	rs11098499	0.722	rs17595727	ENSG00000248280.1	RP11-33B1.2	-6.63	9.27e-11	5.22e-08	-0.34	-0.29	Corneal astigmatism;	chr4:119340919	chr4:119440561~119450157:-
LUAD	cis	rs6565180	0.888	rs12447833	ENSG00000183604.13	SMG1P5	6.63	9.27e-11	5.22e-08	0.32	0.29	Tonsillectomy;	chr16:30378993	chr16:30267553~30335374:-
LUAD	cis	rs35955747	0.869	rs5997971	ENSG00000236132.1	CTA-440B3.1	6.63	9.28e-11	5.22e-08	0.32	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31396306	chr22:31816379~31817491:-
LUAD	cis	rs66887589	0.777	rs4643791	ENSG00000248280.1	RP11-33B1.2	-6.63	9.29e-11	5.23e-08	-0.32	-0.29	Diastolic blood pressure;	chr4:119344464	chr4:119440561~119450157:-
LUAD	cis	rs6142102	1	rs2143230	ENSG00000276073.1	RP5-1125A11.7	-6.63	9.31e-11	5.24e-08	-0.3	-0.29	Skin pigmentation;	chr20:34136539	chr20:33985617~33988989:-
LUAD	cis	rs17301013	0.606	rs10912746	ENSG00000227373.4	RP11-160H22.5	6.63	9.31e-11	5.24e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174210205	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs6692437	ENSG00000227373.4	RP11-160H22.5	6.63	9.31e-11	5.24e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174213771	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs2103640	ENSG00000227373.4	RP11-160H22.5	6.63	9.31e-11	5.24e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174219147	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs56338048	ENSG00000227373.4	RP11-160H22.5	6.63	9.31e-11	5.24e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174220266	chr1:174115300~174160004:-
LUAD	cis	rs10759883	0.627	rs10760261	ENSG00000175611.10	LINC00476	6.62	9.32e-11	5.25e-08	0.34	0.29	Nicotine dependence;	chr9:95850229	chr9:95759231~95875977:-
LUAD	cis	rs9318086	0.578	rs2077709	ENSG00000205861.10	C1QTNF9B-AS1	6.62	9.34e-11	5.25e-08	0.34	0.29	Myopia (pathological);	chr13:23901934	chr13:23888889~23897263:+
LUAD	cis	rs5753618	0.504	rs8138525	ENSG00000236132.1	CTA-440B3.1	6.62	9.35e-11	5.26e-08	0.36	0.29	Colorectal cancer;	chr22:31615943	chr22:31816379~31817491:-
LUAD	cis	rs2842992	0.662	rs2273826	ENSG00000237927.1	RP3-393E18.2	-6.62	9.36e-11	5.27e-08	-0.4	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159790389	chr6:159586955~159589169:-
LUAD	cis	rs9549367	0.713	rs11620600	ENSG00000269125.1	RP11-98F14.11	-6.62	9.38e-11	5.27e-08	-0.38	-0.29	Platelet distribution width;	chr13:113174776	chr13:113165002~113165183:-
LUAD	cis	rs7811142	1	rs7803454	ENSG00000242294.5	STAG3L5P	6.62	9.38e-11	5.28e-08	0.25	0.29	Platelet count;	chr7:100393925	chr7:100336079~100351900:+
LUAD	cis	rs1823913	0.599	rs58106487	ENSG00000227542.1	AC092614.2	6.62	9.4e-11	5.29e-08	0.36	0.29	Obesity-related traits;	chr2:191292404	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.599	rs2124093	ENSG00000227542.1	AC092614.2	6.62	9.4e-11	5.29e-08	0.35	0.29	Obesity-related traits;	chr2:191288280	chr2:191229165~191246172:-
LUAD	cis	rs67311347	1	rs12492035	ENSG00000223797.4	ENTPD3-AS1	6.62	9.4e-11	5.29e-08	0.32	0.29	Renal cell carcinoma;	chr3:40425619	chr3:40313802~40453329:-
LUAD	cis	rs17711722	0.522	rs6957759	ENSG00000236529.1	RP13-254B10.1	6.62	9.41e-11	5.29e-08	0.29	0.29	Calcium levels;	chr7:65806798	chr7:65840212~65840596:+
LUAD	cis	rs6142102	0.602	rs4911399	ENSG00000275784.1	RP5-1125A11.6	-6.62	9.42e-11	5.3e-08	-0.31	-0.29	Skin pigmentation;	chr20:34035612	chr20:33989480~33991818:-
LUAD	cis	rs1799949	1	rs4793212	ENSG00000267681.1	CTD-3199J23.6	-6.62	9.43e-11	5.3e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43150733	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs34534709	ENSG00000267681.1	CTD-3199J23.6	-6.62	9.43e-11	5.3e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43150923	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs34059614	ENSG00000267681.1	CTD-3199J23.6	-6.62	9.43e-11	5.3e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43151054	chr17:43144956~43145255:+
LUAD	cis	rs7674212	0.507	rs223471	ENSG00000246560.2	RP11-10L12.4	6.62	9.43e-11	5.3e-08	0.37	0.29	Type 2 diabetes;	chr4:102777629	chr4:102828055~102844075:+
LUAD	cis	rs4713118	0.699	rs200978	ENSG00000219392.1	RP1-265C24.5	-6.62	9.44e-11	5.31e-08	-0.41	-0.29	Parkinson's disease;	chr6:27885390	chr6:28115628~28116551:+
LUAD	cis	rs4722166	0.598	rs4722171	ENSG00000179428.2	AC073072.5	-6.62	9.44e-11	5.31e-08	-0.35	-0.29	Lung cancer;	chr7:22746098	chr7:22725395~22727620:-
LUAD	cis	rs7246657	0.943	rs35540940	ENSG00000276846.1	CTD-3220F14.3	6.62	9.46e-11	5.32e-08	0.4	0.29	Coronary artery calcification;	chr19:37517333	chr19:37314868~37315620:-
LUAD	cis	rs6142102	1	rs4911410	ENSG00000276073.1	RP5-1125A11.7	-6.62	9.49e-11	5.33e-08	-0.3	-0.29	Skin pigmentation;	chr20:34123168	chr20:33985617~33988989:-
LUAD	cis	rs875971	0.964	rs778735	ENSG00000222364.1	RNU6-96P	-6.62	9.51e-11	5.34e-08	-0.33	-0.29	Aortic root size;	chr7:66349822	chr7:66395191~66395286:+
LUAD	cis	rs67311347	1	rs977652	ENSG00000223797.4	ENTPD3-AS1	6.62	9.53e-11	5.35e-08	0.3	0.29	Renal cell carcinoma;	chr3:40437678	chr3:40313802~40453329:-
LUAD	cis	rs7826238	0.524	rs2921055	ENSG00000253893.2	FAM85B	-6.62	9.53e-11	5.36e-08	-0.36	-0.29	Systolic blood pressure;	chr8:8461832	chr8:8167819~8226614:-
LUAD	cis	rs1062177	0.774	rs2964574	ENSG00000213433.5	RPLP1P6	-6.62	9.53e-11	5.36e-08	-0.38	-0.29	Preschool internalizing problems;	chr5:151776150	chr5:151765859~151766378:-
LUAD	cis	rs11676348	0.838	rs17844697	ENSG00000261338.2	RP11-378A13.1	-6.62	9.54e-11	5.36e-08	-0.3	-0.29	Ulcerative colitis;	chr2:218134532	chr2:218255319~218257366:+
LUAD	cis	rs881375	1	rs10117059	ENSG00000226752.6	PSMD5-AS1	-6.62	9.55e-11	5.36e-08	-0.31	-0.29	Rheumatoid arthritis;	chr9:120891199	chr9:120824828~120854385:+
LUAD	cis	rs2015599	0.645	rs12578931	ENSG00000257176.2	RP11-996F15.2	-6.62	9.58e-11	5.38e-08	-0.32	-0.29	Platelet count;Mean platelet volume;	chr12:29358608	chr12:29280418~29317848:-
LUAD	cis	rs2015599	0.623	rs4931174	ENSG00000257176.2	RP11-996F15.2	-6.62	9.58e-11	5.38e-08	-0.32	-0.29	Platelet count;Mean platelet volume;	chr12:29360545	chr12:29280418~29317848:-
LUAD	cis	rs755249	0.567	rs1537817	ENSG00000228060.1	RP11-69E11.8	6.62	9.59e-11	5.39e-08	0.29	0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39173981	chr1:39565160~39573203:+
LUAD	cis	rs67311347	1	rs7631893	ENSG00000223797.4	ENTPD3-AS1	6.62	9.59e-11	5.39e-08	0.3	0.29	Renal cell carcinoma;	chr3:40399378	chr3:40313802~40453329:-
LUAD	cis	rs2117029	0.521	rs6580702	ENSG00000258017.1	RP11-386G11.10	-6.62	9.59e-11	5.39e-08	-0.36	-0.29	Intelligence (multi-trait analysis);	chr12:49169483	chr12:49127782~49147869:+
LUAD	cis	rs2243480	1	rs316331	ENSG00000226824.5	RP4-756H11.3	6.62	9.6e-11	5.39e-08	0.55	0.29	Diabetic kidney disease;	chr7:66139635	chr7:66654538~66669855:+
LUAD	cis	rs9903692	0.954	rs2109984	ENSG00000278765.1	RP5-890E16.5	6.62	9.63e-11	5.41e-08	0.38	0.29	Pulse pressure;	chr17:48093737	chr17:48066704~48067293:-
LUAD	cis	rs7017914	0.967	rs7819332	ENSG00000223220.1	Y_RNA	6.62	9.63e-11	5.41e-08	0.32	0.29	Bone mineral density;	chr8:70756030	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs7012404	ENSG00000223220.1	Y_RNA	6.62	9.63e-11	5.41e-08	0.32	0.29	Bone mineral density;	chr8:70756463	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs7018381	ENSG00000223220.1	Y_RNA	6.62	9.63e-11	5.41e-08	0.32	0.29	Bone mineral density;	chr8:70757882	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs13258584	ENSG00000223220.1	Y_RNA	6.62	9.63e-11	5.41e-08	0.32	0.29	Bone mineral density;	chr8:70759344	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.934	rs7009297	ENSG00000223220.1	Y_RNA	6.62	9.63e-11	5.41e-08	0.32	0.29	Bone mineral density;	chr8:70760131	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs7014012	ENSG00000223220.1	Y_RNA	6.62	9.63e-11	5.41e-08	0.32	0.29	Bone mineral density;	chr8:70760508	chr8:70780914~70781008:-
LUAD	cis	rs875971	0.545	rs6460276	ENSG00000237310.1	GS1-124K5.4	6.62	9.63e-11	5.41e-08	0.36	0.29	Aortic root size;	chr7:66182290	chr7:66493706~66495474:+
LUAD	cis	rs6142102	0.602	rs4911396	ENSG00000275784.1	RP5-1125A11.6	-6.62	9.64e-11	5.42e-08	-0.31	-0.29	Skin pigmentation;	chr20:33992139	chr20:33989480~33991818:-
LUAD	cis	rs67311347	1	rs17078813	ENSG00000223797.4	ENTPD3-AS1	6.62	9.65e-11	5.42e-08	0.32	0.29	Renal cell carcinoma;	chr3:40392671	chr3:40313802~40453329:-
LUAD	cis	rs1874124	0.577	rs2807872	ENSG00000238078.1	LINC01352	-6.62	9.65e-11	5.42e-08	-0.41	-0.29	Cholesterol, total;	chr1:220866908	chr1:220829255~220832429:+
LUAD	cis	rs6558530	0.965	rs6558529	ENSG00000253982.1	CTD-2336O2.1	6.62	9.66e-11	5.42e-08	0.35	0.29	Systolic blood pressure;	chr8:1758040	chr8:1761990~1764502:-
LUAD	cis	rs6142102	0.602	rs4911395	ENSG00000275784.1	RP5-1125A11.6	-6.62	9.66e-11	5.43e-08	-0.31	-0.29	Skin pigmentation;	chr20:33992095	chr20:33989480~33991818:-
LUAD	cis	rs6142102	0.602	rs2268079	ENSG00000275784.1	RP5-1125A11.6	-6.62	9.66e-11	5.43e-08	-0.31	-0.29	Skin pigmentation;	chr20:34008944	chr20:33989480~33991818:-
LUAD	cis	rs17711722	0.523	rs365896	ENSG00000236529.1	RP13-254B10.1	-6.62	9.67e-11	5.43e-08	-0.29	-0.29	Calcium levels;	chr7:66045710	chr7:65840212~65840596:+
LUAD	cis	rs7567389	0.51	rs6755028	ENSG00000236682.1	AC068282.3	6.62	9.68e-11	5.43e-08	0.37	0.29	Self-rated health;	chr2:127437866	chr2:127389130~127400580:+
LUAD	cis	rs1799949	1	rs11659028	ENSG00000267681.1	CTD-3199J23.6	-6.62	9.68e-11	5.43e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43043008	chr17:43144956~43145255:+
LUAD	cis	rs8100891	0.537	rs2302772	ENSG00000267213.4	AC007773.2	-6.62	9.71e-11	5.45e-08	-0.45	-0.29	Neuroticism;	chr19:32411144	chr19:32390050~32405560:-
LUAD	cis	rs6142102	0.847	rs4911413	ENSG00000276073.1	RP5-1125A11.7	-6.62	9.72e-11	5.45e-08	-0.3	-0.29	Skin pigmentation;	chr20:34133969	chr20:33985617~33988989:-
LUAD	cis	rs8177876	0.584	rs2602404	ENSG00000261838.4	RP11-303E16.6	-6.62	9.72e-11	5.46e-08	-0.51	-0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81056042	chr16:81069854~81076598:+
LUAD	cis	rs7927592	0.913	rs7115374	ENSG00000212093.1	AP000807.1	6.62	9.73e-11	5.46e-08	0.32	0.29	Total body bone mineral density;	chr11:68532608	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs67605986	ENSG00000212093.1	AP000807.1	6.62	9.73e-11	5.46e-08	0.32	0.29	Total body bone mineral density;	chr11:68533487	chr11:68506083~68506166:-
LUAD	cis	rs2734839	0.964	rs2734833	ENSG00000270179.1	RP11-159N11.4	-6.62	9.75e-11	5.47e-08	-0.29	-0.29	Information processing speed;	chr11:113422198	chr11:113368478~113369117:+
LUAD	cis	rs4141404	0.74	rs9609301	ENSG00000236132.1	CTA-440B3.1	-6.62	9.76e-11	5.47e-08	-0.36	-0.29	Paclitaxel-induced neuropathy;	chr22:31499954	chr22:31816379~31817491:-
LUAD	cis	rs5753618	0.504	rs9609303	ENSG00000236132.1	CTA-440B3.1	-6.62	9.76e-11	5.47e-08	-0.36	-0.29	Colorectal cancer;	chr22:31500323	chr22:31816379~31817491:-
LUAD	cis	rs5753618	0.504	rs9606846	ENSG00000236132.1	CTA-440B3.1	-6.62	9.76e-11	5.47e-08	-0.36	-0.29	Colorectal cancer;	chr22:31501585	chr22:31816379~31817491:-
LUAD	cis	rs5753618	0.555	rs9609304	ENSG00000236132.1	CTA-440B3.1	-6.62	9.76e-11	5.47e-08	-0.36	-0.29	Colorectal cancer;	chr22:31501809	chr22:31816379~31817491:-
LUAD	cis	rs9309473	0.848	rs9750915	ENSG00000163016.8	ALMS1P	6.62	9.76e-11	5.48e-08	0.36	0.29	Metabolite levels;	chr2:73584753	chr2:73644919~73685576:+
LUAD	cis	rs67311347	1	rs9857824	ENSG00000223797.4	ENTPD3-AS1	6.62	9.79e-11	5.49e-08	0.31	0.29	Renal cell carcinoma;	chr3:40417921	chr3:40313802~40453329:-
LUAD	cis	rs7017914	0.967	rs7825446	ENSG00000223220.1	Y_RNA	6.62	9.81e-11	5.5e-08	0.32	0.29	Bone mineral density;	chr8:70751939	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs6472543	ENSG00000223220.1	Y_RNA	6.62	9.81e-11	5.5e-08	0.32	0.29	Bone mineral density;	chr8:70752173	chr8:70780914~70781008:-
LUAD	cis	rs1799949	0.965	rs33961729	ENSG00000267681.1	CTD-3199J23.6	-6.62	9.82e-11	5.51e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43135907	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs11657835	ENSG00000267681.1	CTD-3199J23.6	-6.62	9.82e-11	5.51e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43139936	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs1135214	ENSG00000267681.1	CTD-3199J23.6	-6.62	9.82e-11	5.51e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43140306	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs11652332	ENSG00000267681.1	CTD-3199J23.6	-6.62	9.82e-11	5.51e-08	-0.34	-0.29	Menopause (age at onset);	chr17:43143472	chr17:43144956~43145255:+
LUAD	cis	rs2243480	1	rs431318	ENSG00000273142.1	RP11-458F8.4	-6.62	9.84e-11	5.51e-08	-0.3	-0.29	Diabetic kidney disease;	chr7:66046610	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs313803	ENSG00000273142.1	RP11-458F8.4	-6.62	9.84e-11	5.51e-08	-0.3	-0.29	Diabetic kidney disease;	chr7:66049744	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs313802	ENSG00000273142.1	RP11-458F8.4	-6.62	9.84e-11	5.51e-08	-0.3	-0.29	Diabetic kidney disease;	chr7:66051386	chr7:66902857~66906297:+
LUAD	cis	rs2243480	0.803	rs403089	ENSG00000273142.1	RP11-458F8.4	-6.62	9.84e-11	5.51e-08	-0.3	-0.29	Diabetic kidney disease;	chr7:66052736	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs458291	ENSG00000273142.1	RP11-458F8.4	-6.62	9.84e-11	5.51e-08	-0.3	-0.29	Diabetic kidney disease;	chr7:66055492	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs466983	ENSG00000273142.1	RP11-458F8.4	-6.62	9.84e-11	5.51e-08	-0.3	-0.29	Diabetic kidney disease;	chr7:66055509	chr7:66902857~66906297:+
LUAD	cis	rs9326248	0.53	rs1242229	ENSG00000280143.1	AP000892.6	6.62	9.84e-11	5.52e-08	0.47	0.29	Blood protein levels;	chr11:117191654	chr11:117204967~117210292:+
LUAD	cis	rs7829975	0.593	rs2921051	ENSG00000253893.2	FAM85B	-6.62	9.85e-11	5.52e-08	-0.35	-0.29	Mood instability;	chr8:8462594	chr8:8167819~8226614:-
LUAD	cis	rs9326248	0.539	rs518181	ENSG00000280143.1	AP000892.6	6.62	9.86e-11	5.53e-08	0.34	0.29	Blood protein levels;	chr11:116902071	chr11:117204967~117210292:+
LUAD	cis	rs67311347	1	rs73078158	ENSG00000223797.4	ENTPD3-AS1	6.62	9.86e-11	5.53e-08	0.31	0.29	Renal cell carcinoma;	chr3:40431076	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs73078164	ENSG00000223797.4	ENTPD3-AS1	6.62	9.86e-11	5.53e-08	0.31	0.29	Renal cell carcinoma;	chr3:40438798	chr3:40313802~40453329:-
LUAD	cis	rs948562	1	rs76435840	ENSG00000280010.1	AP001350.4	6.62	9.86e-11	5.53e-08	0.46	0.29	Lymphoma;	chr11:58518508	chr11:58627435~58628528:+
LUAD	cis	rs67311347	1	rs56992941	ENSG00000223797.4	ENTPD3-AS1	6.62	9.87e-11	5.53e-08	0.3	0.29	Renal cell carcinoma;	chr3:40430943	chr3:40313802~40453329:-
LUAD	cis	rs150992	0.632	rs161936	ENSG00000248489.1	CTD-2007H13.3	6.62	9.88e-11	5.54e-08	0.32	0.29	Body mass index;	chr5:98982953	chr5:98929171~98995013:+
LUAD	cis	rs9549367	0.713	rs3024761	ENSG00000269125.1	RP11-98F14.11	6.62	9.88e-11	5.54e-08	0.39	0.29	Platelet distribution width;	chr13:113169776	chr13:113165002~113165183:-
LUAD	cis	rs2739330	0.796	rs2154594	ENSG00000206090.4	AP000350.7	-6.62	9.9e-11	5.55e-08	-0.33	-0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23939998~23942798:+
LUAD	cis	rs6142102	0.961	rs4911411	ENSG00000276073.1	RP5-1125A11.7	-6.62	9.9e-11	5.55e-08	-0.3	-0.29	Skin pigmentation;	chr20:34128036	chr20:33985617~33988989:-
LUAD	cis	rs3762637	1	rs7626861	ENSG00000272758.4	RP11-299J3.8	-6.61	9.93e-11	5.57e-08	-0.45	-0.29	LDL cholesterol levels;	chr3:122436349	chr3:122416207~122443180:+
LUAD	cis	rs10759883	0.563	rs689761	ENSG00000175611.10	LINC00476	-6.61	9.94e-11	5.57e-08	-0.33	-0.29	Nicotine dependence;	chr9:95970902	chr9:95759231~95875977:-
LUAD	cis	rs75422866	0.51	rs75424057	ENSG00000280054.1	RP1-197B17.7	6.61	9.94e-11	5.57e-08	0.63	0.29	Pneumonia;	chr12:47737294	chr12:47728151~47730598:-
LUAD	cis	rs7567389	0.637	rs4150421	ENSG00000236682.1	AC068282.3	6.61	9.94e-11	5.57e-08	0.42	0.29	Self-rated health;	chr2:127287354	chr2:127389130~127400580:+
LUAD	cis	rs9584850	0.834	rs12463	ENSG00000231194.1	FARP1-AS1	6.61	9.96e-11	5.58e-08	0.35	0.29	Neuroticism;	chr13:98453048	chr13:98435405~98435840:-
LUAD	cis	rs9584850	0.834	rs8481	ENSG00000231194.1	FARP1-AS1	6.61	9.96e-11	5.58e-08	0.35	0.29	Neuroticism;	chr13:98453141	chr13:98435405~98435840:-
LUAD	cis	rs8177876	0.749	rs12927828	ENSG00000261838.4	RP11-303E16.6	6.61	9.96e-11	5.58e-08	0.53	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81057019	chr16:81069854~81076598:+
LUAD	cis	rs17301013	0.606	rs12079689	ENSG00000227373.4	RP11-160H22.5	6.61	9.98e-11	5.59e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174240514	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs7535987	ENSG00000227373.4	RP11-160H22.5	6.61	9.98e-11	5.59e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174240840	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.581	rs7551605	ENSG00000227373.4	RP11-160H22.5	6.61	9.98e-11	5.59e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174245718	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.581	rs12080977	ENSG00000227373.4	RP11-160H22.5	6.61	9.98e-11	5.59e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174247026	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs72713503	ENSG00000227373.4	RP11-160H22.5	6.61	9.98e-11	5.59e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174247553	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs16846816	ENSG00000227373.4	RP11-160H22.5	6.61	9.98e-11	5.59e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174251602	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.581	rs12083540	ENSG00000227373.4	RP11-160H22.5	6.61	9.98e-11	5.59e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174254096	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs12085311	ENSG00000227373.4	RP11-160H22.5	6.61	9.98e-11	5.59e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174256097	chr1:174115300~174160004:-
LUAD	cis	rs8177876	0.749	rs935942	ENSG00000261838.4	RP11-303E16.6	-6.61	9.98e-11	5.59e-08	-0.55	-0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078531	chr16:81069854~81076598:+
LUAD	cis	rs10740039	0.842	rs1442541	ENSG00000254271.1	RP11-131N11.4	6.61	1e-10	5.6e-08	0.33	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60626285	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs1867081	ENSG00000254271.1	RP11-131N11.4	6.61	1e-10	5.6e-08	0.33	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60626569	chr10:60734342~60741828:+
LUAD	cis	rs150992	0.57	rs7710032	ENSG00000248489.1	CTD-2007H13.3	-6.61	1e-10	5.6e-08	-0.32	-0.29	Body mass index;	chr5:99007501	chr5:98929171~98995013:+
LUAD	cis	rs7017914	0.967	rs2100908	ENSG00000223220.1	Y_RNA	6.61	1e-10	5.61e-08	0.32	0.29	Bone mineral density;	chr8:70671075	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs34558600	ENSG00000223220.1	Y_RNA	6.61	1e-10	5.61e-08	0.32	0.29	Bone mineral density;	chr8:70673917	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs6472538	ENSG00000223220.1	Y_RNA	6.61	1e-10	5.61e-08	0.32	0.29	Bone mineral density;	chr8:70674736	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs7001162	ENSG00000223220.1	Y_RNA	6.61	1e-10	5.61e-08	0.32	0.29	Bone mineral density;	chr8:70675235	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs56112621	ENSG00000223220.1	Y_RNA	6.61	1e-10	5.61e-08	0.32	0.29	Bone mineral density;	chr8:70676159	chr8:70780914~70781008:-
LUAD	cis	rs12554020	0.892	rs6479487	ENSG00000227603.1	RP11-165J3.6	6.61	1e-10	5.62e-08	0.43	0.29	Schizophrenia;	chr9:93475091	chr9:93435332~93437121:-
LUAD	cis	rs9287719	0.747	rs1534400	ENSG00000234818.1	AC092687.5	6.61	1.01e-10	5.63e-08	0.35	0.29	Prostate cancer;	chr2:10556707	chr2:10589166~10604830:+
LUAD	cis	rs7017914	0.967	rs13271442	ENSG00000223220.1	Y_RNA	6.61	1.01e-10	5.63e-08	0.32	0.29	Bone mineral density;	chr8:70672934	chr8:70780914~70781008:-
LUAD	cis	rs367615	0.918	rs10070104	ENSG00000249476.1	CTD-2587M2.1	-6.61	1.01e-10	5.65e-08	-0.37	-0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109530737	chr5:109237120~109326369:-
LUAD	cis	rs9309473	1	rs13432605	ENSG00000163016.8	ALMS1P	6.61	1.01e-10	5.66e-08	0.36	0.29	Metabolite levels;	chr2:73583854	chr2:73644919~73685576:+
LUAD	cis	rs720064	0.615	rs8095395	ENSG00000264745.1	TTC39C-AS1	6.61	1.01e-10	5.66e-08	0.31	0.29	Strep throat;	chr18:23962644	chr18:23994213~24015339:-
LUAD	cis	rs2243480	1	rs781150	ENSG00000226824.5	RP4-756H11.3	-6.61	1.01e-10	5.66e-08	-0.54	-0.29	Diabetic kidney disease;	chr7:66015986	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs313798	ENSG00000226824.5	RP4-756H11.3	-6.61	1.01e-10	5.66e-08	-0.54	-0.29	Diabetic kidney disease;	chr7:66028044	chr7:66654538~66669855:+
LUAD	cis	rs71335811	1	rs71335811	ENSG00000232871.7	SEC1P	-6.61	1.01e-10	5.66e-08	-0.35	-0.29	Myeloid white cell count;	chr19:48626814	chr19:48638071~48682245:+
LUAD	cis	rs62229266	0.652	rs7280551	ENSG00000214914.3	RPL23AP3	6.61	1.01e-10	5.67e-08	0.34	0.29	Mitral valve prolapse;	chr21:36037311	chr21:36016079~36016546:-
LUAD	cis	rs2243480	1	rs313799	ENSG00000232546.1	RP11-458F8.1	-6.61	1.01e-10	5.68e-08	-0.37	-0.29	Diabetic kidney disease;	chr7:66029343	chr7:66848496~66858136:+
LUAD	cis	rs3096299	0.967	rs2965830	ENSG00000274627.1	RP11-104N10.2	6.61	1.02e-10	5.68e-08	0.28	0.29	Multiple myeloma (IgH translocation);	chr16:89393882	chr16:89516797~89522217:+
LUAD	cis	rs17301013	0.507	rs2860954	ENSG00000227373.4	RP11-160H22.5	6.61	1.02e-10	5.71e-08	0.44	0.29	Systemic lupus erythematosus;	chr1:174344313	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs60864659	ENSG00000227373.4	RP11-160H22.5	6.61	1.02e-10	5.71e-08	0.44	0.29	Systemic lupus erythematosus;	chr1:174344641	chr1:174115300~174160004:-
LUAD	cis	rs7811142	0.943	rs10241492	ENSG00000242294.5	STAG3L5P	6.61	1.02e-10	5.71e-08	0.24	0.29	Platelet count;	chr7:100397190	chr7:100336079~100351900:+
LUAD	cis	rs7567389	0.719	rs4150402	ENSG00000236682.1	AC068282.3	-6.61	1.02e-10	5.71e-08	-0.42	-0.29	Self-rated health;	chr2:127292558	chr2:127389130~127400580:+
LUAD	cis	rs1075232	1	rs72722829	ENSG00000270055.1	CTD-3092A11.2	-6.61	1.02e-10	5.72e-08	-0.57	-0.29	Survival in colorectal cancer (non-distant metastatic);	chr15:31346911	chr15:30487963~30490313:+
LUAD	cis	rs1075232	1	rs16956707	ENSG00000270055.1	CTD-3092A11.2	-6.61	1.02e-10	5.72e-08	-0.57	-0.29	Survival in colorectal cancer (non-distant metastatic);	chr15:31349430	chr15:30487963~30490313:+
LUAD	cis	rs1823913	0.599	rs17511410	ENSG00000227542.1	AC092614.2	6.61	1.02e-10	5.72e-08	0.35	0.29	Obesity-related traits;	chr2:191278043	chr2:191229165~191246172:-
LUAD	cis	rs7927592	0.913	rs11228292	ENSG00000212093.1	AP000807.1	6.61	1.02e-10	5.72e-08	0.32	0.29	Total body bone mineral density;	chr11:68612304	chr11:68506083~68506166:-
LUAD	cis	rs2980436	1	rs2980436	ENSG00000253893.2	FAM85B	6.61	1.02e-10	5.73e-08	0.37	0.29	Schizophrenia;	chr8:8234503	chr8:8167819~8226614:-
LUAD	cis	rs3096299	0.933	rs2965823	ENSG00000274627.1	RP11-104N10.2	6.61	1.03e-10	5.73e-08	0.27	0.29	Multiple myeloma (IgH translocation);	chr16:89388516	chr16:89516797~89522217:+
LUAD	cis	rs7811142	0.943	rs111757992	ENSG00000242294.5	STAG3L5P	6.61	1.03e-10	5.75e-08	0.24	0.29	Platelet count;	chr7:100418731	chr7:100336079~100351900:+
LUAD	cis	rs4722166	0.541	rs1800795	ENSG00000179428.2	AC073072.5	-6.61	1.03e-10	5.77e-08	-0.34	-0.29	Lung cancer;	chr7:22727026	chr7:22725395~22727620:-
LUAD	cis	rs7927592	0.913	rs2236708	ENSG00000212093.1	AP000807.1	6.61	1.03e-10	5.77e-08	0.32	0.29	Total body bone mineral density;	chr11:68610577	chr11:68506083~68506166:-
LUAD	cis	rs875971	0.895	rs7788984	ENSG00000222364.1	RNU6-96P	-6.61	1.04e-10	5.78e-08	-0.32	-0.29	Aortic root size;	chr7:66450629	chr7:66395191~66395286:+
LUAD	cis	rs9309473	0.95	rs17009149	ENSG00000163016.8	ALMS1P	6.61	1.04e-10	5.79e-08	0.36	0.29	Metabolite levels;	chr2:73563241	chr2:73644919~73685576:+
LUAD	cis	rs17301013	0.507	rs10912766	ENSG00000227373.4	RP11-160H22.5	6.61	1.04e-10	5.79e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174341129	chr1:174115300~174160004:-
LUAD	cis	rs950169	0.922	rs11633534	ENSG00000259728.4	LINC00933	6.61	1.04e-10	5.79e-08	0.44	0.29	Schizophrenia;	chr15:84581411	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.922	rs11638445	ENSG00000259728.4	LINC00933	6.61	1.04e-10	5.8e-08	0.43	0.29	Schizophrenia;	chr15:84594463	chr15:84570649~84580175:+
LUAD	cis	rs17711722	0.528	rs73138179	ENSG00000226824.5	RP4-756H11.3	-6.61	1.04e-10	5.8e-08	-0.37	-0.29	Calcium levels;	chr7:65829495	chr7:66654538~66669855:+
LUAD	cis	rs2221433	1	rs2221433	ENSG00000260310.1	RP11-27M24.2	-6.61	1.04e-10	5.81e-08	-0.34	-0.29	Eating disorders;	chr16:10569770	chr16:10576499~10578183:-
LUAD	cis	rs7246657	0.943	rs10405325	ENSG00000276846.1	CTD-3220F14.3	6.61	1.04e-10	5.82e-08	0.42	0.29	Coronary artery calcification;	chr19:37392575	chr19:37314868~37315620:-
LUAD	cis	rs66887589	0.56	rs9684327	ENSG00000248280.1	RP11-33B1.2	6.61	1.04e-10	5.82e-08	0.32	0.29	Diastolic blood pressure;	chr4:119444286	chr4:119440561~119450157:-
LUAD	cis	rs67311347	1	rs12494022	ENSG00000223797.4	ENTPD3-AS1	6.61	1.05e-10	5.84e-08	0.32	0.29	Renal cell carcinoma;	chr3:40385161	chr3:40313802~40453329:-
LUAD	cis	rs8177876	0.822	rs4889225	ENSG00000261838.4	RP11-303E16.6	-6.61	1.05e-10	5.84e-08	-0.54	-0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074891	chr16:81069854~81076598:+
LUAD	cis	rs7829975	0.688	rs7817376	ENSG00000253893.2	FAM85B	6.61	1.05e-10	5.85e-08	0.37	0.29	Mood instability;	chr8:8523020	chr8:8167819~8226614:-
LUAD	cis	rs8062405	0.698	rs8046545	ENSG00000251417.2	RP11-1348G14.4	6.61	1.05e-10	5.85e-08	0.31	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28903896	chr16:28802743~28817828:+
LUAD	cis	rs8062405	0.698	rs10499	ENSG00000251417.2	RP11-1348G14.4	6.61	1.05e-10	5.85e-08	0.31	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28904206	chr16:28802743~28817828:+
LUAD	cis	rs11098499	0.954	rs6857105	ENSG00000248280.1	RP11-33B1.2	6.61	1.05e-10	5.86e-08	0.37	0.29	Corneal astigmatism;	chr4:119301143	chr4:119440561~119450157:-
LUAD	cis	rs7246657	0.943	rs7408563	ENSG00000276846.1	CTD-3220F14.3	6.61	1.05e-10	5.88e-08	0.41	0.29	Coronary artery calcification;	chr19:37317683	chr19:37314868~37315620:-
LUAD	cis	rs1499614	1	rs2707832	ENSG00000232546.1	RP11-458F8.1	-6.61	1.05e-10	5.88e-08	-0.37	-0.29	Gout;	chr7:66671562	chr7:66848496~66858136:+
LUAD	cis	rs4722166	0.508	rs1474348	ENSG00000179428.2	AC073072.5	-6.61	1.05e-10	5.88e-08	-0.34	-0.29	Lung cancer;	chr7:22728289	chr7:22725395~22727620:-
LUAD	cis	rs7826238	0.564	rs2921053	ENSG00000253893.2	FAM85B	-6.6	1.06e-10	5.88e-08	-0.36	-0.29	Systolic blood pressure;	chr8:8462453	chr8:8167819~8226614:-
LUAD	cis	rs9549367	0.789	rs12866090	ENSG00000269125.1	RP11-98F14.11	-6.6	1.06e-10	5.88e-08	-0.36	-0.29	Platelet distribution width;	chr13:113215096	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.762	rs9549694	ENSG00000269125.1	RP11-98F14.11	-6.6	1.06e-10	5.88e-08	-0.36	-0.29	Platelet distribution width;	chr13:113216196	chr13:113165002~113165183:-
LUAD	cis	rs150992	0.532	rs416750	ENSG00000248489.1	CTD-2007H13.3	6.6	1.06e-10	5.89e-08	0.32	0.29	Body mass index;	chr5:98999046	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.609	rs819232	ENSG00000248489.1	CTD-2007H13.3	6.6	1.06e-10	5.89e-08	0.32	0.29	Body mass index;	chr5:98999416	chr5:98929171~98995013:+
LUAD	cis	rs6772849	0.83	rs4857917	ENSG00000242551.2	POU5F1P6	-6.6	1.06e-10	5.89e-08	-0.34	-0.29	Monocyte percentage of white cells;Monocyte count;	chr3:128657335	chr3:128674735~128677005:-
LUAD	cis	rs10740039	0.804	rs894383	ENSG00000254271.1	RP11-131N11.4	6.6	1.06e-10	5.9e-08	0.33	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60683359	chr10:60734342~60741828:+
LUAD	cis	rs3002142	0.658	rs3008634	ENSG00000272750.1	RP11-378J18.8	6.6	1.06e-10	5.9e-08	0.38	0.29	LDL peak particle diameter (total fat intake interaction);	chr1:222672069	chr1:222658867~222661512:-
LUAD	cis	rs9326248	0.574	rs1263173	ENSG00000280143.1	AP000892.6	6.6	1.06e-10	5.9e-08	0.33	0.29	Blood protein levels;	chr11:116810292	chr11:117204967~117210292:+
LUAD	cis	rs2243480	1	rs73142162	ENSG00000273142.1	RP11-458F8.4	-6.6	1.06e-10	5.91e-08	-0.31	-0.29	Diabetic kidney disease;	chr7:65909309	chr7:66902857~66906297:+
LUAD	cis	rs7246657	0.943	rs10420754	ENSG00000276846.1	CTD-3220F14.3	6.6	1.06e-10	5.91e-08	0.39	0.29	Coronary artery calcification;	chr19:37468470	chr19:37314868~37315620:-
LUAD	cis	rs881375	0.902	rs2900180	ENSG00000226752.6	PSMD5-AS1	-6.6	1.06e-10	5.92e-08	-0.31	-0.29	Rheumatoid arthritis;	chr9:120944104	chr9:120824828~120854385:+
LUAD	cis	rs875971	0.964	rs60193905	ENSG00000222364.1	RNU6-96P	-6.6	1.06e-10	5.92e-08	-0.32	-0.29	Aortic root size;	chr7:66506273	chr7:66395191~66395286:+
LUAD	cis	rs7246657	0.943	rs4802766	ENSG00000276846.1	CTD-3220F14.3	6.6	1.06e-10	5.92e-08	0.41	0.29	Coronary artery calcification;	chr19:37491031	chr19:37314868~37315620:-
LUAD	cis	rs113835537	0.529	rs2305532	ENSG00000255517.5	CTD-3074O7.5	-6.6	1.06e-10	5.92e-08	-0.35	-0.29	Airway imaging phenotypes;	chr11:66531123	chr11:66473490~66480233:-
LUAD	cis	rs113835537	0.529	rs2305533	ENSG00000255517.5	CTD-3074O7.5	-6.6	1.06e-10	5.92e-08	-0.35	-0.29	Airway imaging phenotypes;	chr11:66531152	chr11:66473490~66480233:-
LUAD	cis	rs11098499	0.954	rs11098524	ENSG00000248280.1	RP11-33B1.2	6.6	1.06e-10	5.93e-08	0.37	0.29	Corneal astigmatism;	chr4:119468877	chr4:119440561~119450157:-
LUAD	cis	rs6142102	0.602	rs2268086	ENSG00000275784.1	RP5-1125A11.6	6.6	1.07e-10	5.93e-08	0.31	0.29	Skin pigmentation;	chr20:34060932	chr20:33989480~33991818:-
LUAD	cis	rs1062177	0.826	rs2915873	ENSG00000213433.5	RPLP1P6	-6.6	1.07e-10	5.94e-08	-0.38	-0.29	Preschool internalizing problems;	chr5:151777097	chr5:151765859~151766378:-
LUAD	cis	rs10760123	1	rs10760123	ENSG00000226752.6	PSMD5-AS1	-6.6	1.07e-10	5.95e-08	-0.31	-0.29	Allergic disease (asthma, hay fever or eczema);	chr9:120888256	chr9:120824828~120854385:+
LUAD	cis	rs62229266	0.804	rs2835241	ENSG00000214914.3	RPL23AP3	-6.6	1.07e-10	5.95e-08	-0.35	-0.29	Mitral valve prolapse;	chr21:36039082	chr21:36016079~36016546:-
LUAD	cis	rs9450351	0.744	rs7764843	ENSG00000203875.9	SNHG5	-6.6	1.07e-10	5.96e-08	-0.6	-0.29	Interferon gamma-induced protein 10 levels;	chr6:85903875	chr6:85660950~85678736:-
LUAD	cis	rs9450351	0.744	rs9351072	ENSG00000203875.9	SNHG5	-6.6	1.07e-10	5.96e-08	-0.6	-0.29	Interferon gamma-induced protein 10 levels;	chr6:85917611	chr6:85660950~85678736:-
LUAD	cis	rs17023223	0.537	rs2794311	ENSG00000231365.4	RP11-418J17.1	6.6	1.07e-10	5.97e-08	0.38	0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119053326	chr1:119140396~119275973:+
LUAD	cis	rs7811142	0.887	rs35111986	ENSG00000242294.5	STAG3L5P	6.6	1.07e-10	5.97e-08	0.25	0.29	Platelet count;	chr7:100402651	chr7:100336079~100351900:+
LUAD	cis	rs12458462	0.892	rs2242174	ENSG00000274828.1	RP11-567M16.6	6.6	1.07e-10	5.97e-08	0.3	0.29	Monocyte count;	chr18:79698037	chr18:79677287~79679358:-
LUAD	cis	rs12439619	0.508	rs8023960	ENSG00000276710.3	CSPG4P8	-6.6	1.08e-10	5.99e-08	-0.26	-0.29	Intelligence (multi-trait analysis);	chr15:82206704	chr15:82459472~82477258:+
LUAD	cis	rs4722166	0.603	rs7801406	ENSG00000179428.2	AC073072.5	-6.6	1.08e-10	5.99e-08	-0.35	-0.29	Lung cancer;	chr7:22748655	chr7:22725395~22727620:-
LUAD	cis	rs11428934	1	rs11428934	ENSG00000232871.7	SEC1P	6.6	1.08e-10	6e-08	0.35	0.29	Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;	chr19:48640988	chr19:48638071~48682245:+
LUAD	cis	rs77204473	1	rs79711490	ENSG00000254851.1	RP11-109L13.1	6.6	1.08e-10	6e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116914625	chr11:117135528~117138582:+
LUAD	cis	rs2117029	0.521	rs58336603	ENSG00000258017.1	RP11-386G11.10	-6.6	1.08e-10	6.01e-08	-0.36	-0.29	Intelligence (multi-trait analysis);	chr12:49163105	chr12:49127782~49147869:+
LUAD	cis	rs2117029	0.553	rs1991427	ENSG00000258017.1	RP11-386G11.10	-6.6	1.08e-10	6.01e-08	-0.36	-0.29	Intelligence (multi-trait analysis);	chr12:49164175	chr12:49127782~49147869:+
LUAD	cis	rs881375	0.967	rs7039505	ENSG00000226752.6	PSMD5-AS1	-6.6	1.08e-10	6.01e-08	-0.31	-0.29	Rheumatoid arthritis;	chr9:120943667	chr9:120824828~120854385:+
LUAD	cis	rs4718428	0.705	rs62465692	ENSG00000273142.1	RP11-458F8.4	-6.6	1.08e-10	6.02e-08	-0.22	-0.29	Corneal structure;	chr7:66830758	chr7:66902857~66906297:+
LUAD	cis	rs950169	0.84	rs4842854	ENSG00000259728.4	LINC00933	6.6	1.08e-10	6.02e-08	0.43	0.29	Schizophrenia;	chr15:84387641	chr15:84570649~84580175:+
LUAD	cis	rs17301013	0.606	rs4650950	ENSG00000227373.4	RP11-160H22.5	6.6	1.08e-10	6.02e-08	0.4	0.29	Systemic lupus erythematosus;	chr1:174134264	chr1:174115300~174160004:-
LUAD	cis	rs7598759	0.527	rs12987949	ENSG00000181798.2	LINC00471	-6.6	1.09e-10	6.04e-08	-0.31	-0.29	Noise-induced hearing loss;	chr2:231502800	chr2:231508426~231514339:-
LUAD	cis	rs875971	0.545	rs66594357	ENSG00000237310.1	GS1-124K5.4	6.6	1.09e-10	6.05e-08	0.35	0.29	Aortic root size;	chr7:66327797	chr7:66493706~66495474:+
LUAD	cis	rs9326248	0.581	rs6589590	ENSG00000280143.1	AP000892.6	6.6	1.09e-10	6.05e-08	0.33	0.29	Blood protein levels;	chr11:117065365	chr11:117204967~117210292:+
LUAD	cis	rs2243480	0.708	rs35825036	ENSG00000226824.5	RP4-756H11.3	-6.6	1.09e-10	6.05e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66521515	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs13237037	ENSG00000226824.5	RP4-756H11.3	-6.6	1.09e-10	6.05e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66532895	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.901	rs13237344	ENSG00000226824.5	RP4-756H11.3	-6.6	1.09e-10	6.05e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66557269	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs1796228	ENSG00000226824.5	RP4-756H11.3	-6.6	1.09e-10	6.05e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66568097	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs1267820	ENSG00000226824.5	RP4-756H11.3	-6.6	1.09e-10	6.05e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66585308	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs2533288	ENSG00000226824.5	RP4-756H11.3	-6.6	1.09e-10	6.05e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66591724	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs2707844	ENSG00000226824.5	RP4-756H11.3	-6.6	1.09e-10	6.05e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66594522	chr7:66654538~66669855:+
LUAD	cis	rs67311347	1	rs9849992	ENSG00000223797.4	ENTPD3-AS1	6.6	1.09e-10	6.06e-08	0.3	0.29	Renal cell carcinoma;	chr3:40360649	chr3:40313802~40453329:-
LUAD	cis	rs150992	0.587	rs10040066	ENSG00000248489.1	CTD-2007H13.3	-6.6	1.09e-10	6.07e-08	-0.32	-0.29	Body mass index;	chr5:99001333	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.609	rs4565239	ENSG00000248489.1	CTD-2007H13.3	-6.6	1.09e-10	6.07e-08	-0.32	-0.29	Body mass index;	chr5:99002144	chr5:98929171~98995013:+
LUAD	cis	rs9309473	0.95	rs10169213	ENSG00000163016.8	ALMS1P	6.6	1.09e-10	6.08e-08	0.36	0.29	Metabolite levels;	chr2:73560107	chr2:73644919~73685576:+
LUAD	cis	rs881375	0.967	rs2239658	ENSG00000226752.6	PSMD5-AS1	-6.6	1.09e-10	6.08e-08	-0.31	-0.29	Rheumatoid arthritis;	chr9:120909559	chr9:120824828~120854385:+
LUAD	cis	rs4718428	0.662	rs34577323	ENSG00000273142.1	RP11-458F8.4	-6.6	1.09e-10	6.08e-08	-0.22	-0.29	Corneal structure;	chr7:66845054	chr7:66902857~66906297:+
LUAD	cis	rs67311347	1	rs73078169	ENSG00000223797.4	ENTPD3-AS1	6.6	1.09e-10	6.09e-08	0.31	0.29	Renal cell carcinoma;	chr3:40442307	chr3:40313802~40453329:-
LUAD	cis	rs7598759	0.527	rs7571691	ENSG00000181798.2	LINC00471	-6.6	1.1e-10	6.09e-08	-0.31	-0.29	Noise-induced hearing loss;	chr2:231504690	chr2:231508426~231514339:-
LUAD	cis	rs7567389	0.71	rs72848615	ENSG00000236682.1	AC068282.3	-6.6	1.1e-10	6.1e-08	-0.42	-0.29	Self-rated health;	chr2:127376022	chr2:127389130~127400580:+
LUAD	cis	rs7567389	0.573	rs11541137	ENSG00000236682.1	AC068282.3	-6.6	1.1e-10	6.1e-08	-0.42	-0.29	Self-rated health;	chr2:127388195	chr2:127389130~127400580:+
LUAD	cis	rs516805	0.961	rs527978	ENSG00000279453.1	RP3-425C14.4	-6.6	1.1e-10	6.1e-08	-0.33	-0.29	Lymphocyte counts;	chr6:122475225	chr6:122436789~122439223:-
LUAD	cis	rs17301013	0.507	rs11799704	ENSG00000227373.4	RP11-160H22.5	6.6	1.1e-10	6.11e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174413640	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs2901817	ENSG00000227373.4	RP11-160H22.5	6.6	1.1e-10	6.11e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174414479	chr1:174115300~174160004:-
LUAD	cis	rs7927592	0.871	rs17603185	ENSG00000212093.1	AP000807.1	6.6	1.1e-10	6.12e-08	0.32	0.29	Total body bone mineral density;	chr11:68608773	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs4988291	ENSG00000212093.1	AP000807.1	6.6	1.1e-10	6.12e-08	0.32	0.29	Total body bone mineral density;	chr11:68614139	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.871	rs12941	ENSG00000212093.1	AP000807.1	6.6	1.1e-10	6.12e-08	0.32	0.29	Total body bone mineral density;	chr11:68614725	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs11228293	ENSG00000212093.1	AP000807.1	6.6	1.1e-10	6.12e-08	0.32	0.29	Total body bone mineral density;	chr11:68617178	chr11:68506083~68506166:-
LUAD	cis	rs77204473	0.744	rs2306472	ENSG00000254851.1	RP11-109L13.1	6.6	1.1e-10	6.12e-08	0.65	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117187346	chr11:117135528~117138582:+
LUAD	cis	rs9309473	1	rs6745368	ENSG00000163016.8	ALMS1P	6.6	1.1e-10	6.13e-08	0.36	0.29	Metabolite levels;	chr2:73582847	chr2:73644919~73685576:+
LUAD	cis	rs720064	0.525	rs7232062	ENSG00000264745.1	TTC39C-AS1	6.6	1.1e-10	6.14e-08	0.31	0.29	Strep throat;	chr18:23970609	chr18:23994213~24015339:-
LUAD	cis	rs875971	0.545	rs316328	ENSG00000237310.1	GS1-124K5.4	-6.6	1.11e-10	6.14e-08	-0.34	-0.29	Aortic root size;	chr7:66143851	chr7:66493706~66495474:+
LUAD	cis	rs1823913	0.599	rs17412094	ENSG00000227542.1	AC092614.2	6.6	1.11e-10	6.15e-08	0.35	0.29	Obesity-related traits;	chr2:191284202	chr2:191229165~191246172:-
LUAD	cis	rs11118620	0.853	rs11118622	ENSG00000257551.1	HLX-AS1	6.6	1.11e-10	6.17e-08	0.35	0.29	Heart failure;	chr1:220868833	chr1:220832763~220880140:-
LUAD	cis	rs2980439	0.783	rs2955587	ENSG00000253981.4	ALG1L13P	6.6	1.11e-10	6.18e-08	0.34	0.29	Neuroticism;	chr8:8240557	chr8:8236003~8244667:-
LUAD	cis	rs6558530	0.897	rs10481354	ENSG00000253982.1	CTD-2336O2.1	-6.6	1.11e-10	6.19e-08	-0.34	-0.29	Systolic blood pressure;	chr8:1755864	chr8:1761990~1764502:-
LUAD	cis	rs17301013	0.507	rs11799535	ENSG00000227373.4	RP11-160H22.5	6.6	1.12e-10	6.19e-08	0.45	0.29	Systemic lupus erythematosus;	chr1:174415790	chr1:174115300~174160004:-
LUAD	cis	rs2739330	0.731	rs2000468	ENSG00000206090.4	AP000350.7	6.6	1.12e-10	6.21e-08	0.32	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23939998~23942798:+
LUAD	cis	rs77204473	0.744	rs80273401	ENSG00000254851.1	RP11-109L13.1	6.6	1.12e-10	6.22e-08	0.73	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117037990	chr11:117135528~117138582:+
LUAD	cis	rs8177876	0.658	rs2911158	ENSG00000261838.4	RP11-303E16.6	-6.6	1.12e-10	6.23e-08	-0.51	-0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81057652	chr16:81069854~81076598:+
LUAD	cis	rs7188445	0.651	rs4889014	ENSG00000261390.4	RP11-345M22.2	6.59	1.12e-10	6.24e-08	0.35	0.29	Urate levels;	chr16:79684556	chr16:79715232~79770563:-
LUAD	cis	rs7188445	0.688	rs4889015	ENSG00000261390.4	RP11-345M22.2	6.59	1.12e-10	6.24e-08	0.35	0.29	Urate levels;	chr16:79684833	chr16:79715232~79770563:-
LUAD	cis	rs7044106	0.791	rs10760116	ENSG00000238181.2	AHCYP2	-6.59	1.12e-10	6.24e-08	-0.38	-0.29	Hip circumference adjusted for BMI;	chr9:120732403	chr9:120720673~120721972:+
LUAD	cis	rs2243480	0.708	rs13242216	ENSG00000226824.5	RP4-756H11.3	-6.59	1.12e-10	6.24e-08	-0.54	-0.29	Diabetic kidney disease;	chr7:66433290	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs67536397	ENSG00000226824.5	RP4-756H11.3	-6.59	1.12e-10	6.24e-08	-0.54	-0.29	Diabetic kidney disease;	chr7:66482930	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs58669269	ENSG00000226824.5	RP4-756H11.3	-6.59	1.12e-10	6.24e-08	-0.54	-0.29	Diabetic kidney disease;	chr7:66486966	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.901	rs34807232	ENSG00000226824.5	RP4-756H11.3	-6.59	1.12e-10	6.24e-08	-0.54	-0.29	Diabetic kidney disease;	chr7:66500146	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.545	rs2420456	ENSG00000237310.1	GS1-124K5.4	6.59	1.13e-10	6.24e-08	0.35	0.29	Aortic root size;	chr7:66280619	chr7:66493706~66495474:+
LUAD	cis	rs4722166	0.63	rs13311155	ENSG00000179428.2	AC073072.5	-6.59	1.13e-10	6.25e-08	-0.35	-0.29	Lung cancer;	chr7:22750170	chr7:22725395~22727620:-
LUAD	cis	rs4722166	0.63	rs13311199	ENSG00000179428.2	AC073072.5	-6.59	1.13e-10	6.25e-08	-0.35	-0.29	Lung cancer;	chr7:22750174	chr7:22725395~22727620:-
LUAD	cis	rs8177876	0.642	rs10514513	ENSG00000261838.4	RP11-303E16.6	6.59	1.13e-10	6.25e-08	0.61	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080578	chr16:81069854~81076598:+
LUAD	cis	rs7811142	0.943	rs11769886	ENSG00000242294.5	STAG3L5P	6.59	1.13e-10	6.25e-08	0.25	0.29	Platelet count;	chr7:100400984	chr7:100336079~100351900:+
LUAD	cis	rs765787	0.53	rs7167731	ENSG00000259520.4	CTD-2651B20.3	-6.59	1.13e-10	6.25e-08	-0.38	-0.29	Uric acid levels;	chr15:45218702	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs12915027	ENSG00000259520.4	CTD-2651B20.3	-6.59	1.13e-10	6.25e-08	-0.38	-0.29	Uric acid levels;	chr15:45220428	chr15:45251580~45279251:-
LUAD	cis	rs2404602	0.684	rs62026898	ENSG00000259422.1	RP11-593F23.1	-6.59	1.13e-10	6.26e-08	-0.38	-0.29	Blood metabolite levels;	chr15:76652030	chr15:76174891~76181486:-
LUAD	cis	rs2243480	0.808	rs12698508	ENSG00000226824.5	RP4-756H11.3	-6.59	1.13e-10	6.26e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:65946971	chr7:66654538~66669855:+
LUAD	cis	rs8100891	0.537	rs28562777	ENSG00000267213.4	AC007773.2	-6.59	1.13e-10	6.27e-08	-0.45	-0.29	Neuroticism;	chr19:32409913	chr19:32390050~32405560:-
LUAD	cis	rs1075232	1	rs12439239	ENSG00000270055.1	CTD-3092A11.2	-6.59	1.14e-10	6.3e-08	-0.58	-0.29	Survival in colorectal cancer (non-distant metastatic);	chr15:31359515	chr15:30487963~30490313:+
LUAD	cis	rs7829975	0.688	rs6601703	ENSG00000253893.2	FAM85B	-6.59	1.14e-10	6.31e-08	-0.36	-0.29	Mood instability;	chr8:8522714	chr8:8167819~8226614:-
LUAD	cis	rs7115242	0.8	rs10736487	ENSG00000280143.1	AP000892.6	6.59	1.14e-10	6.32e-08	0.44	0.29	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117079516	chr11:117204967~117210292:+
LUAD	cis	rs2117029	0.555	rs2047101	ENSG00000258017.1	RP11-386G11.10	-6.59	1.14e-10	6.32e-08	-0.37	-0.29	Intelligence (multi-trait analysis);	chr12:49103860	chr12:49127782~49147869:+
LUAD	cis	rs9595066	0.667	rs3809350	ENSG00000227258.4	SMIM2-AS1	6.59	1.14e-10	6.32e-08	0.48	0.29	Schizophrenia;	chr13:44162043	chr13:44110451~44240517:+
LUAD	cis	rs494459	0.536	rs34561290	ENSG00000255422.1	AP002954.4	-6.59	1.14e-10	6.32e-08	-0.35	-0.29	Height;	chr11:118860890	chr11:118704607~118750263:+
LUAD	cis	rs494459	0.536	rs11217072	ENSG00000255422.1	AP002954.4	-6.59	1.14e-10	6.32e-08	-0.35	-0.29	Height;	chr11:118861053	chr11:118704607~118750263:+
LUAD	cis	rs367615	0.918	rs17161895	ENSG00000249476.1	CTD-2587M2.1	6.59	1.14e-10	6.33e-08	0.37	0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109520130	chr5:109237120~109326369:-
LUAD	cis	rs6921919	1	rs35875412	ENSG00000204709.4	LINC01556	6.59	1.14e-10	6.34e-08	0.42	0.29	Autism spectrum disorder or schizophrenia;	chr6:28364041	chr6:28943877~28944537:+
LUAD	cis	rs12458462	0.892	rs2242175	ENSG00000274828.1	RP11-567M16.6	6.59	1.14e-10	6.35e-08	0.3	0.29	Monocyte count;	chr18:79704406	chr18:79677287~79679358:-
LUAD	cis	rs12220777	0.748	rs11201641	ENSG00000230091.5	TMEM254-AS1	6.59	1.14e-10	6.35e-08	0.5	0.29	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80091975	chr10:80046860~80078912:-
LUAD	cis	rs1823913	0.599	rs56328712	ENSG00000227542.1	AC092614.2	6.59	1.14e-10	6.35e-08	0.35	0.29	Obesity-related traits;	chr2:191273807	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.599	rs55862924	ENSG00000227542.1	AC092614.2	6.59	1.14e-10	6.35e-08	0.35	0.29	Obesity-related traits;	chr2:191273809	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.599	rs12989203	ENSG00000227542.1	AC092614.2	6.59	1.14e-10	6.35e-08	0.35	0.29	Obesity-related traits;	chr2:191276617	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.599	rs34262638	ENSG00000227542.1	AC092614.2	6.59	1.14e-10	6.35e-08	0.35	0.29	Obesity-related traits;	chr2:191279442	chr2:191229165~191246172:-
LUAD	cis	rs2524005	1	rs2524005	ENSG00000228078.1	HLA-U	-6.59	1.15e-10	6.35e-08	-0.44	-0.29	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29934101~29934286:+
LUAD	cis	rs2243480	0.711	rs2460426	ENSG00000226824.5	RP4-756H11.3	6.59	1.15e-10	6.36e-08	0.54	0.29	Diabetic kidney disease;	chr7:66158142	chr7:66654538~66669855:+
LUAD	cis	rs9549367	0.789	rs9549705	ENSG00000269125.1	RP11-98F14.11	-6.59	1.15e-10	6.36e-08	-0.36	-0.29	Platelet distribution width;	chr13:113234111	chr13:113165002~113165183:-
LUAD	cis	rs1426063	0.614	rs80030693	ENSG00000249717.1	RP11-44F21.3	6.59	1.15e-10	6.36e-08	0.58	0.29	QT interval;	chr4:75099929	chr4:74955974~74970362:-
LUAD	cis	rs1823913	0.599	rs10497713	ENSG00000227542.1	AC092614.2	6.59	1.15e-10	6.36e-08	0.35	0.29	Obesity-related traits;	chr2:191279312	chr2:191229165~191246172:-
LUAD	cis	rs17684571	0.938	rs17751682	ENSG00000231441.1	RP11-472M19.2	-6.59	1.15e-10	6.38e-08	-0.39	-0.29	Schizophrenia;	chr6:56695732	chr6:56844002~56864078:+
LUAD	cis	rs4964805	0.594	rs4964830	ENSG00000257681.1	RP11-341G23.4	-6.59	1.15e-10	6.38e-08	-0.34	-0.29	Attention deficit hyperactivity disorder;	chr12:103775130	chr12:103746315~103768858:-
LUAD	cis	rs2980439	0.846	rs2980437	ENSG00000253981.4	ALG1L13P	-6.59	1.15e-10	6.39e-08	-0.33	-0.29	Neuroticism;	chr8:8237241	chr8:8236003~8244667:-
LUAD	cis	rs710216	0.536	rs710222	ENSG00000227533.4	SLC2A1-AS1	6.59	1.16e-10	6.42e-08	0.32	0.29	Red cell distribution width;	chr1:42947982	chr1:42959049~42983358:+
LUAD	cis	rs2243480	0.803	rs13224048	ENSG00000226824.5	RP4-756H11.3	-6.59	1.16e-10	6.43e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:66528779	chr7:66654538~66669855:+
LUAD	cis	rs12458462	0.892	rs58675823	ENSG00000274828.1	RP11-567M16.6	6.59	1.16e-10	6.44e-08	0.3	0.29	Monocyte count;	chr18:79703672	chr18:79677287~79679358:-
LUAD	cis	rs150992	0.587	rs11949103	ENSG00000248489.1	CTD-2007H13.3	-6.59	1.16e-10	6.44e-08	-0.31	-0.29	Body mass index;	chr5:99011939	chr5:98929171~98995013:+
LUAD	cis	rs10875746	0.517	rs12721420	ENSG00000240399.1	RP1-228P16.1	-6.59	1.17e-10	6.46e-08	-0.38	-0.29	Longevity (90 years and older);	chr12:47965011	chr12:48054813~48055591:-
LUAD	cis	rs875971	0.545	rs11767262	ENSG00000237310.1	GS1-124K5.4	6.59	1.17e-10	6.47e-08	0.35	0.29	Aortic root size;	chr7:66302237	chr7:66493706~66495474:+
LUAD	cis	rs5753618	0.504	rs8142121	ENSG00000236132.1	CTA-440B3.1	-6.59	1.17e-10	6.47e-08	-0.37	-0.29	Colorectal cancer;	chr22:31486799	chr22:31816379~31817491:-
LUAD	cis	rs1823913	1	rs6749232	ENSG00000227542.1	AC092614.2	-6.59	1.17e-10	6.47e-08	-0.37	-0.29	Obesity-related traits;	chr2:191250326	chr2:191229165~191246172:-
LUAD	cis	rs765787	0.53	rs12592055	ENSG00000259520.4	CTD-2651B20.3	-6.59	1.17e-10	6.47e-08	-0.38	-0.29	Uric acid levels;	chr15:45222279	chr15:45251580~45279251:-
LUAD	cis	rs4722166	0.63	rs10950916	ENSG00000179428.2	AC073072.5	-6.59	1.17e-10	6.47e-08	-0.35	-0.29	Lung cancer;	chr7:22760048	chr7:22725395~22727620:-
LUAD	cis	rs2243480	1	rs35820085	ENSG00000273142.1	RP11-458F8.4	-6.59	1.17e-10	6.48e-08	-0.3	-0.29	Diabetic kidney disease;	chr7:65977771	chr7:66902857~66906297:+
LUAD	cis	rs113835537	0.529	rs57207756	ENSG00000255517.5	CTD-3074O7.5	-6.59	1.17e-10	6.48e-08	-0.35	-0.29	Airway imaging phenotypes;	chr11:66502889	chr11:66473490~66480233:-
LUAD	cis	rs113835537	0.529	rs17496250	ENSG00000255517.5	CTD-3074O7.5	-6.59	1.17e-10	6.48e-08	-0.35	-0.29	Airway imaging phenotypes;	chr11:66503303	chr11:66473490~66480233:-
LUAD	cis	rs2243480	0.901	rs35823062	ENSG00000226824.5	RP4-756H11.3	-6.59	1.17e-10	6.48e-08	-0.54	-0.29	Diabetic kidney disease;	chr7:66500834	chr7:66654538~66669855:+
LUAD	cis	rs9640161	0.711	rs10259796	ENSG00000261305.1	RP4-584D14.7	6.59	1.17e-10	6.48e-08	0.43	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150353338	chr7:150341771~150342607:+
LUAD	cis	rs853679	0.657	rs1778483	ENSG00000204709.4	LINC01556	6.59	1.17e-10	6.49e-08	0.37	0.29	Depression;	chr6:28273214	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.657	rs1778482	ENSG00000204709.4	LINC01556	6.59	1.17e-10	6.49e-08	0.37	0.29	Depression;	chr6:28273215	chr6:28943877~28944537:+
LUAD	cis	rs950169	1	rs1911155	ENSG00000259728.4	LINC00933	6.59	1.17e-10	6.49e-08	0.44	0.29	Schizophrenia;	chr15:84118883	chr15:84570649~84580175:+
LUAD	cis	rs35955747	0.934	rs13053245	ENSG00000236132.1	CTA-440B3.1	6.59	1.17e-10	6.49e-08	0.31	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31420756	chr22:31816379~31817491:-
LUAD	cis	rs17711722	0.51	rs11767457	ENSG00000236529.1	RP13-254B10.1	6.59	1.18e-10	6.51e-08	0.29	0.29	Calcium levels;	chr7:65825628	chr7:65840212~65840596:+
LUAD	cis	rs66887589	0.807	rs9799664	ENSG00000248280.1	RP11-33B1.2	6.59	1.18e-10	6.52e-08	0.32	0.29	Diastolic blood pressure;	chr4:119405523	chr4:119440561~119450157:-
LUAD	cis	rs17301013	0.606	rs6676161	ENSG00000227373.4	RP11-160H22.5	6.59	1.18e-10	6.52e-08	0.4	0.29	Systemic lupus erythematosus;	chr1:174138555	chr1:174115300~174160004:-
LUAD	cis	rs7208859	0.623	rs8068645	ENSG00000263531.1	RP13-753N3.1	6.59	1.18e-10	6.53e-08	0.57	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777324	chr17:30863921~30864940:-
LUAD	cis	rs10740039	0.883	rs1561850	ENSG00000254271.1	RP11-131N11.4	6.59	1.18e-10	6.54e-08	0.33	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60631583	chr10:60734342~60741828:+
LUAD	cis	rs950169	0.881	rs4842852	ENSG00000259728.4	LINC00933	6.59	1.18e-10	6.54e-08	0.43	0.29	Schizophrenia;	chr15:84387263	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.84	rs4842853	ENSG00000259728.4	LINC00933	6.59	1.18e-10	6.54e-08	0.43	0.29	Schizophrenia;	chr15:84387606	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.922	rs4842946	ENSG00000259728.4	LINC00933	6.59	1.18e-10	6.54e-08	0.43	0.29	Schizophrenia;	chr15:84387633	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.887	rs3860265	ENSG00000259728.4	LINC00933	6.59	1.18e-10	6.54e-08	0.43	0.29	Schizophrenia;	chr15:84390487	chr15:84570649~84580175:+
LUAD	cis	rs4927850	0.723	rs7630825	ENSG00000207650.1	MIR570	6.59	1.18e-10	6.55e-08	0.3	0.29	Pancreatic cancer;	chr3:196026869	chr3:195699401~195699497:+
LUAD	cis	rs7567389	0.535	rs4150416	ENSG00000236682.1	AC068282.3	6.59	1.18e-10	6.55e-08	0.39	0.29	Self-rated health;	chr2:127288972	chr2:127389130~127400580:+
LUAD	cis	rs4728142	0.779	rs3778753	ENSG00000275106.1	RP11-309L24.10	-6.59	1.19e-10	6.56e-08	-0.34	-0.29	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128939988	chr7:128952527~128953316:-
LUAD	cis	rs4728142	0.744	rs3778752	ENSG00000275106.1	RP11-309L24.10	-6.59	1.19e-10	6.56e-08	-0.34	-0.29	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128939993	chr7:128952527~128953316:-
LUAD	cis	rs1823913	0.561	rs60479498	ENSG00000227542.1	AC092614.2	6.59	1.19e-10	6.56e-08	0.35	0.29	Obesity-related traits;	chr2:191275197	chr2:191229165~191246172:-
LUAD	cis	rs2303759	0.918	rs1054770	ENSG00000268686.1	AC010524.2	-6.59	1.19e-10	6.57e-08	-0.41	-0.29	Multiple sclerosis;	chr19:49374858	chr19:49368705~49388081:-
LUAD	cis	rs6860806	0.507	rs273912	ENSG00000233006.5	AC034220.3	-6.59	1.19e-10	6.57e-08	-0.28	-0.29	Breast cancer;	chr5:132325656	chr5:132311285~132369916:-
LUAD	cis	rs11098499	0.575	rs9996586	ENSG00000248280.1	RP11-33B1.2	6.59	1.19e-10	6.57e-08	0.32	0.29	Corneal astigmatism;	chr4:119405787	chr4:119440561~119450157:-
LUAD	cis	rs853679	0.607	rs13211507	ENSG00000204709.4	LINC01556	6.59	1.19e-10	6.58e-08	0.61	0.29	Depression;	chr6:28289600	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs34691223	ENSG00000204709.4	LINC01556	6.59	1.19e-10	6.58e-08	0.61	0.29	Depression;	chr6:28290431	chr6:28943877~28944537:+
LUAD	cis	rs3096299	0.933	rs3114848	ENSG00000274627.1	RP11-104N10.2	6.59	1.19e-10	6.58e-08	0.27	0.29	Multiple myeloma (IgH translocation);	chr16:89386363	chr16:89516797~89522217:+
LUAD	cis	rs853679	0.506	rs1150693	ENSG00000219392.1	RP1-265C24.5	-6.59	1.19e-10	6.59e-08	-0.4	-0.29	Depression;	chr6:28206812	chr6:28115628~28116551:+
LUAD	cis	rs12022452	0.591	rs6672398	ENSG00000238287.1	RP11-656D10.3	-6.59	1.19e-10	6.6e-08	-0.45	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr1:40536505	chr1:40493157~40508661:-
LUAD	cis	rs67311347	1	rs11714032	ENSG00000223797.4	ENTPD3-AS1	6.59	1.19e-10	6.6e-08	0.32	0.29	Renal cell carcinoma;	chr3:40390114	chr3:40313802~40453329:-
LUAD	cis	rs1823913	0.599	rs35892286	ENSG00000227542.1	AC092614.2	6.58	1.2e-10	6.61e-08	0.35	0.29	Obesity-related traits;	chr2:191269010	chr2:191229165~191246172:-
LUAD	cis	rs113835537	0.529	rs11227509	ENSG00000255517.5	CTD-3074O7.5	-6.58	1.2e-10	6.63e-08	-0.34	-0.29	Airway imaging phenotypes;	chr11:66513723	chr11:66473490~66480233:-
LUAD	cis	rs113835537	0.529	rs11227510	ENSG00000255517.5	CTD-3074O7.5	-6.58	1.2e-10	6.63e-08	-0.34	-0.29	Airway imaging phenotypes;	chr11:66513749	chr11:66473490~66480233:-
LUAD	cis	rs113835537	0.529	rs2298806	ENSG00000255517.5	CTD-3074O7.5	-6.58	1.2e-10	6.63e-08	-0.34	-0.29	Airway imaging phenotypes;	chr11:66514624	chr11:66473490~66480233:-
LUAD	cis	rs113835537	0.529	rs2276406	ENSG00000255517.5	CTD-3074O7.5	-6.58	1.2e-10	6.63e-08	-0.34	-0.29	Airway imaging phenotypes;	chr11:66515786	chr11:66473490~66480233:-
LUAD	cis	rs67311347	1	rs17078941	ENSG00000223797.4	ENTPD3-AS1	-6.58	1.2e-10	6.63e-08	-0.32	-0.29	Renal cell carcinoma;	chr3:40409397	chr3:40313802~40453329:-
LUAD	cis	rs7567389	0.677	rs7556675	ENSG00000236682.1	AC068282.3	6.58	1.2e-10	6.63e-08	0.42	0.29	Self-rated health;	chr2:127296171	chr2:127389130~127400580:+
LUAD	cis	rs1823913	0.599	rs13001899	ENSG00000227542.1	AC092614.2	6.58	1.2e-10	6.64e-08	0.35	0.29	Obesity-related traits;	chr2:191285442	chr2:191229165~191246172:-
LUAD	cis	rs433852	0.718	rs386551	ENSG00000232871.7	SEC1P	-6.58	1.2e-10	6.65e-08	-0.35	-0.29	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48635029	chr19:48638071~48682245:+
LUAD	cis	rs2243480	1	rs160655	ENSG00000226824.5	RP4-756H11.3	-6.58	1.2e-10	6.65e-08	-0.52	-0.29	Diabetic kidney disease;	chr7:66068227	chr7:66654538~66669855:+
LUAD	cis	rs7927592	0.913	rs7106339	ENSG00000212093.1	AP000807.1	6.58	1.21e-10	6.66e-08	0.32	0.29	Total body bone mineral density;	chr11:68472773	chr11:68506083~68506166:-
LUAD	cis	rs6142102	0.58	rs6142101	ENSG00000275784.1	RP5-1125A11.6	-6.58	1.21e-10	6.67e-08	-0.3	-0.29	Skin pigmentation;	chr20:34110039	chr20:33989480~33991818:-
LUAD	cis	rs227932	0.764	rs76349338	ENSG00000234286.1	AC006026.13	-6.58	1.21e-10	6.67e-08	-0.49	-0.29	Schizophrenia;	chr7:23709138	chr7:23680195~23680786:-
LUAD	cis	rs9326248	0.52	rs236919	ENSG00000280143.1	AP000892.6	6.58	1.21e-10	6.69e-08	0.33	0.29	Blood protein levels;	chr11:117224645	chr11:117204967~117210292:+
LUAD	cis	rs2303759	0.918	rs10405465	ENSG00000268686.1	AC010524.2	-6.58	1.21e-10	6.69e-08	-0.4	-0.29	Multiple sclerosis;	chr19:49366041	chr19:49368705~49388081:-
LUAD	cis	rs7176527	1	rs3762169	ENSG00000188388.10	GOLGA6L3	6.58	1.21e-10	6.69e-08	0.39	0.29	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84598728	chr15:85240472~85247170:+
LUAD	cis	rs516805	0.961	rs483933	ENSG00000279453.1	RP3-425C14.4	-6.58	1.21e-10	6.71e-08	-0.33	-0.29	Lymphocyte counts;	chr6:122460377	chr6:122436789~122439223:-
LUAD	cis	rs113835537	0.529	rs2279864	ENSG00000255517.5	CTD-3074O7.5	-6.58	1.22e-10	6.72e-08	-0.34	-0.29	Airway imaging phenotypes;	chr11:66480373	chr11:66473490~66480233:-
LUAD	cis	rs10740039	0.81	rs4440977	ENSG00000254271.1	RP11-131N11.4	6.58	1.22e-10	6.73e-08	0.33	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60618163	chr10:60734342~60741828:+
LUAD	cis	rs2115536	0.692	rs6495450	ENSG00000278600.1	RP11-81A1.6	-6.58	1.22e-10	6.74e-08	-0.23	-0.29	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79870157	chr15:79920195~79922455:-
LUAD	cis	rs7923609	0.967	rs2393986	ENSG00000232075.1	MRPL35P2	-6.58	1.22e-10	6.75e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63560246	chr10:63634317~63634827:-
LUAD	cis	rs3096299	0.838	rs4785561	ENSG00000274627.1	RP11-104N10.2	6.58	1.22e-10	6.76e-08	0.26	0.29	Multiple myeloma (IgH translocation);	chr16:89362644	chr16:89516797~89522217:+
LUAD	cis	rs2283792	0.935	rs9610375	ENSG00000224086.5	LL22NC03-86G7.1	-6.58	1.22e-10	6.76e-08	-0.27	-0.29	Multiple sclerosis;	chr22:21832804	chr22:21938293~21977632:+
LUAD	cis	rs77204473	0.744	rs80054374	ENSG00000254851.1	RP11-109L13.1	6.58	1.23e-10	6.77e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117019951	chr11:117135528~117138582:+
LUAD	cis	rs77204473	0.744	rs2046149	ENSG00000254851.1	RP11-109L13.1	6.58	1.23e-10	6.78e-08	0.63	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117183993	chr11:117135528~117138582:+
LUAD	cis	rs1426063	0.614	rs78046076	ENSG00000249717.1	RP11-44F21.3	6.58	1.23e-10	6.79e-08	0.58	0.29	QT interval;	chr4:75091818	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.614	rs74670563	ENSG00000249717.1	RP11-44F21.3	6.58	1.23e-10	6.79e-08	0.58	0.29	QT interval;	chr4:75094656	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.614	rs115338890	ENSG00000249717.1	RP11-44F21.3	6.58	1.23e-10	6.79e-08	0.58	0.29	QT interval;	chr4:75094719	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.541	rs116304289	ENSG00000249717.1	RP11-44F21.3	6.58	1.23e-10	6.79e-08	0.58	0.29	QT interval;	chr4:75095072	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.614	rs76204704	ENSG00000249717.1	RP11-44F21.3	6.58	1.23e-10	6.79e-08	0.58	0.29	QT interval;	chr4:75097804	chr4:74955974~74970362:-
LUAD	cis	rs17301013	0.507	rs2760057	ENSG00000227373.4	RP11-160H22.5	6.58	1.23e-10	6.79e-08	0.42	0.29	Systemic lupus erythematosus;	chr1:174743384	chr1:174115300~174160004:-
LUAD	cis	rs4722166	0.63	rs6969258	ENSG00000179428.2	AC073072.5	-6.58	1.23e-10	6.8e-08	-0.35	-0.29	Lung cancer;	chr7:22742909	chr7:22725395~22727620:-
LUAD	cis	rs4925166	1	rs4925166	ENSG00000273018.4	CTD-2303H24.2	-6.58	1.23e-10	6.81e-08	-0.38	-0.29	Multiple sclerosis;	chr17:18307496	chr17:18511221~18551705:-
LUAD	cis	rs6142102	0.602	rs11696338	ENSG00000275784.1	RP5-1125A11.6	-6.58	1.24e-10	6.81e-08	-0.3	-0.29	Skin pigmentation;	chr20:34099805	chr20:33989480~33991818:-
LUAD	cis	rs2243480	0.901	rs778730	ENSG00000226824.5	RP4-756H11.3	-6.58	1.24e-10	6.82e-08	-0.54	-0.29	Diabetic kidney disease;	chr7:66358338	chr7:66654538~66669855:+
LUAD	cis	rs12439619	0.739	rs62012046	ENSG00000255769.6	GOLGA2P10	-6.58	1.24e-10	6.83e-08	-0.37	-0.29	Intelligence (multi-trait analysis);	chr15:82236824	chr15:82472993~82513950:-
LUAD	cis	rs12439619	0.774	rs62012047	ENSG00000255769.6	GOLGA2P10	-6.58	1.24e-10	6.83e-08	-0.37	-0.29	Intelligence (multi-trait analysis);	chr15:82236852	chr15:82472993~82513950:-
LUAD	cis	rs12439619	0.81	rs62012049	ENSG00000255769.6	GOLGA2P10	-6.58	1.24e-10	6.83e-08	-0.37	-0.29	Intelligence (multi-trait analysis);	chr15:82237722	chr15:82472993~82513950:-
LUAD	cis	rs2455601	1	rs11042108	ENSG00000254860.4	TMEM9B-AS1	6.58	1.24e-10	6.86e-08	0.48	0.29	Schizophrenia;	chr11:8884474	chr11:8964675~8977527:+
LUAD	cis	rs17507216	0.518	rs1877240	ENSG00000278603.1	RP13-608F4.5	6.58	1.24e-10	6.86e-08	0.43	0.29	Excessive daytime sleepiness;	chr15:82770126	chr15:82472203~82472426:+
LUAD	cis	rs9326248	0.53	rs2075292	ENSG00000280143.1	AP000892.6	6.58	1.25e-10	6.88e-08	0.45	0.29	Blood protein levels;	chr11:116861796	chr11:117204967~117210292:+
LUAD	cis	rs2243480	1	rs160652	ENSG00000273142.1	RP11-458F8.4	-6.58	1.25e-10	6.88e-08	-0.3	-0.29	Diabetic kidney disease;	chr7:66073444	chr7:66902857~66906297:+
LUAD	cis	rs11098499	0.604	rs2389887	ENSG00000248280.1	RP11-33B1.2	6.58	1.25e-10	6.88e-08	0.37	0.29	Corneal astigmatism;	chr4:119649489	chr4:119440561~119450157:-
LUAD	cis	rs694739	0.536	rs11231740	ENSG00000236935.1	AP003774.1	-6.58	1.25e-10	6.88e-08	-0.27	-0.29	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64279169	chr11:64325050~64329504:-
LUAD	cis	rs10740039	0.842	rs7069157	ENSG00000254271.1	RP11-131N11.4	6.58	1.25e-10	6.89e-08	0.33	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60629475	chr10:60734342~60741828:+
LUAD	cis	rs2243480	1	rs313799	ENSG00000226824.5	RP4-756H11.3	-6.58	1.25e-10	6.9e-08	-0.53	-0.29	Diabetic kidney disease;	chr7:66029343	chr7:66654538~66669855:+
LUAD	cis	rs7208859	0.623	rs122898	ENSG00000263531.1	RP13-753N3.1	-6.58	1.25e-10	6.91e-08	-0.57	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30863921~30864940:-
LUAD	cis	rs1426063	0.614	rs76093954	ENSG00000249717.1	RP11-44F21.3	6.58	1.25e-10	6.91e-08	0.58	0.29	QT interval;	chr4:75087994	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.614	rs114977200	ENSG00000249717.1	RP11-44F21.3	6.58	1.25e-10	6.91e-08	0.58	0.29	QT interval;	chr4:75088736	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.614	rs77625282	ENSG00000249717.1	RP11-44F21.3	6.58	1.25e-10	6.91e-08	0.58	0.29	QT interval;	chr4:75089646	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.614	rs75112697	ENSG00000249717.1	RP11-44F21.3	6.58	1.25e-10	6.91e-08	0.58	0.29	QT interval;	chr4:75089725	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.614	rs7684790	ENSG00000249717.1	RP11-44F21.3	6.58	1.25e-10	6.91e-08	0.58	0.29	QT interval;	chr4:75090873	chr4:74955974~74970362:-
LUAD	cis	rs7829975	0.501	rs2980769	ENSG00000253893.2	FAM85B	-6.58	1.26e-10	6.92e-08	-0.36	-0.29	Mood instability;	chr8:8462781	chr8:8167819~8226614:-
LUAD	cis	rs8177876	0.822	rs804902	ENSG00000261838.4	RP11-303E16.6	6.58	1.26e-10	6.94e-08	0.52	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81071360	chr16:81069854~81076598:+
LUAD	cis	rs7567389	0.719	rs4150404	ENSG00000236682.1	AC068282.3	6.58	1.26e-10	6.96e-08	0.42	0.29	Self-rated health;	chr2:127292424	chr2:127389130~127400580:+
LUAD	cis	rs6142102	0.651	rs6119463	ENSG00000276073.1	RP5-1125A11.7	6.58	1.26e-10	6.96e-08	0.32	0.29	Skin pigmentation;	chr20:34149412	chr20:33985617~33988989:-
LUAD	cis	rs131777	0.575	rs963980	ENSG00000205559.3	CHKB-AS1	-6.58	1.26e-10	6.96e-08	-0.34	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50583688	chr22:50583026~50583877:+
LUAD	cis	rs7626444	0.625	rs1798636	ENSG00000272359.1	U4	-6.58	1.27e-10	6.97e-08	-0.32	-0.29	Monocyte count;	chr3:196749733	chr3:196747192~196747324:-
LUAD	cis	rs2221433	0.961	rs6498087	ENSG00000260310.1	RP11-27M24.2	-6.58	1.27e-10	6.97e-08	-0.33	-0.29	Eating disorders;	chr16:10570402	chr16:10576499~10578183:-
LUAD	cis	rs1823913	0.599	rs17414109	ENSG00000227542.1	AC092614.2	6.58	1.27e-10	6.98e-08	0.35	0.29	Obesity-related traits;	chr2:191310675	chr2:191229165~191246172:-
LUAD	cis	rs8062405	0.757	rs2411453	ENSG00000259982.1	CDC37P1	-6.58	1.27e-10	6.98e-08	-0.36	-0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620700	chr16:28700294~28701540:-
LUAD	cis	rs720064	0.586	rs8083137	ENSG00000264745.1	TTC39C-AS1	6.57	1.27e-10	6.99e-08	0.31	0.29	Strep throat;	chr18:23962963	chr18:23994213~24015339:-
LUAD	cis	rs765787	0.505	rs4439707	ENSG00000259520.4	CTD-2651B20.3	-6.57	1.27e-10	7.01e-08	-0.39	-0.29	Uric acid levels;	chr15:45232018	chr15:45251580~45279251:-
LUAD	cis	rs30380	0.69	rs2911139	ENSG00000248734.2	CTD-2260A17.1	6.57	1.27e-10	7.01e-08	0.33	0.29	Cerebrospinal fluid biomarker levels;	chr5:96843890	chr5:96784777~96785999:+
LUAD	cis	rs2015599	0.601	rs17715086	ENSG00000275476.1	RP11-996F15.4	-6.57	1.28e-10	7.02e-08	-0.32	-0.29	Platelet count;Mean platelet volume;	chr12:29329073	chr12:29277397~29277882:-
LUAD	cis	rs77204473	1	rs78692246	ENSG00000254851.1	RP11-109L13.1	6.57	1.28e-10	7.03e-08	0.73	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116920591	chr11:117135528~117138582:+
LUAD	cis	rs853679	0.55	rs1233707	ENSG00000219392.1	RP1-265C24.5	-6.57	1.28e-10	7.04e-08	-0.39	-0.29	Depression;	chr6:28205175	chr6:28115628~28116551:+
LUAD	cis	rs4927850	0.918	rs4361313	ENSG00000207650.1	MIR570	6.57	1.28e-10	7.04e-08	0.3	0.29	Pancreatic cancer;	chr3:196025389	chr3:195699401~195699497:+
LUAD	cis	rs1799949	1	rs4793231	ENSG00000267681.1	CTD-3199J23.6	-6.57	1.28e-10	7.04e-08	-0.33	-0.29	Menopause (age at onset);	chr17:43350101	chr17:43144956~43145255:+
LUAD	cis	rs2243480	1	rs56016656	ENSG00000226824.5	RP4-756H11.3	-6.57	1.28e-10	7.04e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:65918494	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.803	rs55700941	ENSG00000226824.5	RP4-756H11.3	-6.57	1.28e-10	7.04e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:65924813	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs56291018	ENSG00000226824.5	RP4-756H11.3	-6.57	1.28e-10	7.04e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:65925352	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs36033484	ENSG00000226824.5	RP4-756H11.3	-6.57	1.28e-10	7.04e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:65925571	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs34193460	ENSG00000226824.5	RP4-756H11.3	-6.57	1.28e-10	7.04e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:65928123	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs34560516	ENSG00000226824.5	RP4-756H11.3	-6.57	1.28e-10	7.04e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:65939105	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs57057549	ENSG00000226824.5	RP4-756H11.3	-6.57	1.28e-10	7.04e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:65940751	chr7:66654538~66669855:+
LUAD	cis	rs17301013	0.606	rs727912	ENSG00000227373.4	RP11-160H22.5	6.57	1.28e-10	7.04e-08	0.4	0.29	Systemic lupus erythematosus;	chr1:174132729	chr1:174115300~174160004:-
LUAD	cis	rs2115630	0.645	rs3825877	ENSG00000225151.9	GOLGA2P7	6.57	1.28e-10	7.05e-08	0.33	0.29	P wave terminal force;	chr15:84631400	chr15:84199311~84230136:-
LUAD	cis	rs2115630	0.645	rs3825878	ENSG00000225151.9	GOLGA2P7	6.57	1.28e-10	7.05e-08	0.33	0.29	P wave terminal force;	chr15:84631524	chr15:84199311~84230136:-
LUAD	cis	rs62229266	0.633	rs34259635	ENSG00000214914.3	RPL23AP3	6.57	1.28e-10	7.05e-08	0.34	0.29	Mitral valve prolapse;	chr21:36031272	chr21:36016079~36016546:-
LUAD	cis	rs77204473	0.744	rs2046150	ENSG00000254851.1	RP11-109L13.1	6.57	1.28e-10	7.06e-08	0.67	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117182717	chr11:117135528~117138582:+
LUAD	cis	rs321358	0.731	rs17460781	ENSG00000271584.1	RP11-89C3.4	6.57	1.28e-10	7.07e-08	0.45	0.29	Body mass index;	chr11:111169966	chr11:111091932~111097357:-
LUAD	cis	rs7927592	0.913	rs10896338	ENSG00000212093.1	AP000807.1	6.57	1.29e-10	7.07e-08	0.32	0.29	Total body bone mineral density;	chr11:68531892	chr11:68506083~68506166:-
LUAD	cis	rs2720460	0.502	rs223374	ENSG00000246560.2	RP11-10L12.4	6.57	1.29e-10	7.08e-08	0.37	0.29	Testicular germ cell tumor;	chr4:102837144	chr4:102828055~102844075:+
LUAD	cis	rs10050311	0.79	rs17751427	ENSG00000251411.1	RP11-397E7.4	-6.57	1.29e-10	7.1e-08	-0.39	-0.29	Insulin-related traits;	chr4:86909939	chr4:86913266~86914817:-
LUAD	cis	rs2179367	0.887	rs506268	ENSG00000231760.4	RP11-350J20.5	6.57	1.29e-10	7.11e-08	0.35	0.29	Dupuytren's disease;	chr6:149364481	chr6:149796151~149826294:-
LUAD	cis	rs6921919	0.515	rs1339898	ENSG00000204709.4	LINC01556	6.57	1.29e-10	7.11e-08	0.37	0.29	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28943877~28944537:+
LUAD	cis	rs4927850	0.957	rs4927851	ENSG00000207650.1	MIR570	6.57	1.29e-10	7.12e-08	0.3	0.29	Pancreatic cancer;	chr3:196024982	chr3:195699401~195699497:+
LUAD	cis	rs858239	0.633	rs858300	ENSG00000226816.2	AC005082.12	6.57	1.3e-10	7.12e-08	0.37	0.29	Cerebrospinal fluid biomarker levels;	chr7:23205012	chr7:23206013~23208045:+
LUAD	cis	rs9309473	0.95	rs11126412	ENSG00000163016.8	ALMS1P	6.57	1.3e-10	7.12e-08	0.36	0.29	Metabolite levels;	chr2:73660507	chr2:73644919~73685576:+
LUAD	cis	rs875971	1	rs6460292	ENSG00000222364.1	RNU6-96P	6.57	1.3e-10	7.13e-08	0.32	0.29	Aortic root size;	chr7:66345088	chr7:66395191~66395286:+
LUAD	cis	rs7811142	1	rs60478351	ENSG00000242294.5	STAG3L5P	6.57	1.3e-10	7.14e-08	0.24	0.29	Platelet count;	chr7:100491394	chr7:100336079~100351900:+
LUAD	cis	rs10129255	0.518	rs12590732	ENSG00000224373.3	IGHV4-59	-6.57	1.3e-10	7.15e-08	-0.17	-0.29	Kawasaki disease;	chr14:106779612	chr14:106627249~106627825:-
LUAD	cis	rs6921919	0.697	rs6942030	ENSG00000204709.4	LINC01556	6.57	1.3e-10	7.15e-08	0.36	0.29	Autism spectrum disorder or schizophrenia;	chr6:28348181	chr6:28943877~28944537:+
LUAD	cis	rs10129255	0.957	rs61997760	ENSG00000280411.1	IGHV1-69-2	-6.57	1.3e-10	7.15e-08	-0.22	-0.29	Kawasaki disease;	chr14:106716993	chr14:106762092~106762588:-
LUAD	cis	rs10899021	0.79	rs12288525	ENSG00000279353.1	RP11-864N7.4	6.57	1.3e-10	7.16e-08	0.49	0.29	Response to metformin (IC50);	chr11:74621544	chr11:74698231~74699658:-
LUAD	cis	rs7674212	0.531	rs4698876	ENSG00000251288.2	RP11-10L12.2	-6.57	1.3e-10	7.17e-08	-0.36	-0.29	Type 2 diabetes;	chr4:103012410	chr4:102751401~102752641:+
LUAD	cis	rs7674212	0.531	rs7665026	ENSG00000251288.2	RP11-10L12.2	-6.57	1.3e-10	7.17e-08	-0.36	-0.29	Type 2 diabetes;	chr4:103015491	chr4:102751401~102752641:+
LUAD	cis	rs2034650	0.544	rs2289330	ENSG00000223313.1	RNU6-516P	6.57	1.3e-10	7.17e-08	0.38	0.29	Interstitial lung disease;	chr15:40412906	chr15:40529570~40529673:+
LUAD	cis	rs4722166	0.63	rs12537614	ENSG00000179428.2	AC073072.5	-6.57	1.31e-10	7.17e-08	-0.34	-0.29	Lung cancer;	chr7:22749932	chr7:22725395~22727620:-
LUAD	cis	rs2739330	0.828	rs4822454	ENSG00000206090.4	AP000350.7	6.57	1.31e-10	7.2e-08	0.33	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23939998~23942798:+
LUAD	cis	rs7567389	0.677	rs7607907	ENSG00000236682.1	AC068282.3	6.57	1.31e-10	7.2e-08	0.41	0.29	Self-rated health;	chr2:127386710	chr2:127389130~127400580:+
LUAD	cis	rs2739330	0.828	rs2330635	ENSG00000206090.4	AP000350.7	6.57	1.31e-10	7.2e-08	0.33	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23939998~23942798:+
LUAD	cis	rs10129255	0.5	rs6576230	ENSG00000224373.3	IGHV4-59	6.57	1.31e-10	7.22e-08	0.17	0.29	Kawasaki disease;	chr14:106778539	chr14:106627249~106627825:-
LUAD	cis	rs10129255	0.518	rs11847766	ENSG00000224373.3	IGHV4-59	6.57	1.31e-10	7.22e-08	0.17	0.29	Kawasaki disease;	chr14:106779186	chr14:106627249~106627825:-
LUAD	cis	rs4835473	0.932	rs10030428	ENSG00000251600.4	RP11-673E1.1	6.57	1.31e-10	7.22e-08	0.35	0.29	Immature fraction of reticulocytes;	chr4:143762699	chr4:143912331~143982454:+
LUAD	cis	rs10129255	0.5	rs988134	ENSG00000224373.3	IGHV4-59	6.57	1.31e-10	7.22e-08	0.17	0.29	Kawasaki disease;	chr14:106776698	chr14:106627249~106627825:-
LUAD	cis	rs10129255	0.5	rs988133	ENSG00000224373.3	IGHV4-59	6.57	1.31e-10	7.22e-08	0.17	0.29	Kawasaki disease;	chr14:106776724	chr14:106627249~106627825:-
LUAD	cis	rs748404	0.631	rs6493083	ENSG00000249839.1	AC011330.5	-6.57	1.32e-10	7.23e-08	-0.38	-0.29	Lung cancer;	chr15:43345787	chr15:43663654~43684339:-
LUAD	cis	rs875971	0.545	rs73142265	ENSG00000237310.1	GS1-124K5.4	6.57	1.32e-10	7.23e-08	0.36	0.29	Aortic root size;	chr7:66234510	chr7:66493706~66495474:+
LUAD	cis	rs367615	1	rs58931051	ENSG00000249476.1	CTD-2587M2.1	6.57	1.32e-10	7.23e-08	0.37	0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109572031	chr5:109237120~109326369:-
LUAD	cis	rs10740039	0.804	rs1372714	ENSG00000254271.1	RP11-131N11.4	6.57	1.32e-10	7.25e-08	0.33	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60686640	chr10:60734342~60741828:+
LUAD	cis	rs2243480	1	rs160643	ENSG00000226824.5	RP4-756H11.3	-6.57	1.32e-10	7.27e-08	-0.5	-0.29	Diabetic kidney disease;	chr7:66093235	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs4718307	ENSG00000222364.1	RNU6-96P	6.57	1.32e-10	7.27e-08	0.32	0.29	Aortic root size;	chr7:66146001	chr7:66395191~66395286:+
LUAD	cis	rs77204473	0.744	rs79870586	ENSG00000254851.1	RP11-109L13.1	6.57	1.32e-10	7.27e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117016005	chr11:117135528~117138582:+
LUAD	cis	rs67311347	0.956	rs13066971	ENSG00000223797.4	ENTPD3-AS1	-6.57	1.33e-10	7.29e-08	-0.3	-0.29	Renal cell carcinoma;	chr3:40421019	chr3:40313802~40453329:-
LUAD	cis	rs7811142	0.943	rs3900792	ENSG00000242294.5	STAG3L5P	6.57	1.33e-10	7.29e-08	0.24	0.29	Platelet count;	chr7:100406954	chr7:100336079~100351900:+
LUAD	cis	rs9309473	0.748	rs2421552	ENSG00000163016.8	ALMS1P	6.57	1.33e-10	7.3e-08	0.36	0.29	Metabolite levels;	chr2:73531676	chr2:73644919~73685576:+
LUAD	cis	rs12908161	1	rs12908161	ENSG00000259728.4	LINC00933	6.57	1.33e-10	7.3e-08	0.42	0.29	Schizophrenia;	chr15:84664594	chr15:84570649~84580175:+
LUAD	cis	rs67311347	0.955	rs4973999	ENSG00000223797.4	ENTPD3-AS1	6.57	1.33e-10	7.31e-08	0.3	0.29	Renal cell carcinoma;	chr3:40418892	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs1466236	ENSG00000223797.4	ENTPD3-AS1	6.57	1.33e-10	7.31e-08	0.3	0.29	Renal cell carcinoma;	chr3:40420671	chr3:40313802~40453329:-
LUAD	cis	rs62229266	0.659	rs2255734	ENSG00000214914.3	RPL23AP3	6.57	1.33e-10	7.31e-08	0.34	0.29	Mitral valve prolapse;	chr21:36039611	chr21:36016079~36016546:-
LUAD	cis	rs62229266	0.659	rs2835242	ENSG00000214914.3	RPL23AP3	6.57	1.33e-10	7.31e-08	0.34	0.29	Mitral valve prolapse;	chr21:36041234	chr21:36016079~36016546:-
LUAD	cis	rs62229266	0.659	rs2835243	ENSG00000214914.3	RPL23AP3	6.57	1.33e-10	7.31e-08	0.34	0.29	Mitral valve prolapse;	chr21:36041648	chr21:36016079~36016546:-
LUAD	cis	rs2243480	1	rs1723269	ENSG00000226824.5	RP4-756H11.3	-6.57	1.33e-10	7.31e-08	-0.54	-0.29	Diabetic kidney disease;	chr7:66007799	chr7:66654538~66669855:+
LUAD	cis	rs12439619	0.508	rs8042665	ENSG00000276710.3	CSPG4P8	-6.57	1.33e-10	7.31e-08	-0.26	-0.29	Intelligence (multi-trait analysis);	chr15:82189008	chr15:82459472~82477258:+
LUAD	cis	rs77204473	1	rs12418208	ENSG00000254851.1	RP11-109L13.1	6.57	1.34e-10	7.33e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116916917	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs1006176	ENSG00000254851.1	RP11-109L13.1	6.57	1.34e-10	7.33e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116917417	chr11:117135528~117138582:+
LUAD	cis	rs9309473	0.95	rs13408433	ENSG00000163016.8	ALMS1P	6.57	1.34e-10	7.34e-08	0.36	0.29	Metabolite levels;	chr2:73655945	chr2:73644919~73685576:+
LUAD	cis	rs66887589	0.775	rs6843229	ENSG00000248280.1	RP11-33B1.2	6.57	1.34e-10	7.34e-08	0.32	0.29	Diastolic blood pressure;	chr4:119502932	chr4:119440561~119450157:-
LUAD	cis	rs7674212	0.531	rs10006474	ENSG00000251288.2	RP11-10L12.2	-6.57	1.34e-10	7.36e-08	-0.36	-0.29	Type 2 diabetes;	chr4:103006890	chr4:102751401~102752641:+
LUAD	cis	rs7811142	1	rs67040465	ENSG00000242294.5	STAG3L5P	6.57	1.35e-10	7.38e-08	0.25	0.29	Platelet count;	chr7:100485455	chr7:100336079~100351900:+
LUAD	cis	rs77204473	0.744	rs12273545	ENSG00000254851.1	RP11-109L13.1	6.57	1.35e-10	7.38e-08	0.73	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117040296	chr11:117135528~117138582:+
LUAD	cis	rs77204473	0.744	rs77999164	ENSG00000254851.1	RP11-109L13.1	6.57	1.35e-10	7.38e-08	0.73	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117041401	chr11:117135528~117138582:+
LUAD	cis	rs7674212	0.531	rs10006474	ENSG00000246560.2	RP11-10L12.4	6.57	1.35e-10	7.38e-08	0.37	0.29	Type 2 diabetes;	chr4:103006890	chr4:102828055~102844075:+
LUAD	cis	rs7811142	1	rs11771419	ENSG00000242294.5	STAG3L5P	6.57	1.35e-10	7.4e-08	0.24	0.29	Platelet count;	chr7:100390780	chr7:100336079~100351900:+
LUAD	cis	rs7826238	0.535	rs2979179	ENSG00000253893.2	FAM85B	-6.57	1.35e-10	7.4e-08	-0.36	-0.29	Systolic blood pressure;	chr8:8462519	chr8:8167819~8226614:-
LUAD	cis	rs7615952	0.736	rs9862893	ENSG00000171084.14	FAM86JP	6.57	1.35e-10	7.4e-08	0.46	0.29	Blood pressure (smoking interaction);	chr3:125968131	chr3:125916620~125930024:+
LUAD	cis	rs2404602	0.647	rs11631394	ENSG00000259422.1	RP11-593F23.1	-6.56	1.35e-10	7.41e-08	-0.37	-0.29	Blood metabolite levels;	chr15:76680868	chr15:76174891~76181486:-
LUAD	cis	rs2243480	1	rs73150014	ENSG00000232546.1	RP11-458F8.1	-6.56	1.35e-10	7.42e-08	-0.38	-0.29	Diabetic kidney disease;	chr7:65985932	chr7:66848496~66858136:+
LUAD	cis	rs755249	0.567	rs67408364	ENSG00000228060.1	RP11-69E11.8	-6.56	1.35e-10	7.42e-08	-0.29	-0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39152884	chr1:39565160~39573203:+
LUAD	cis	rs950169	0.887	rs12903946	ENSG00000259728.4	LINC00933	6.56	1.35e-10	7.43e-08	0.43	0.29	Schizophrenia;	chr15:84399732	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.887	rs62029593	ENSG00000259728.4	LINC00933	6.56	1.35e-10	7.43e-08	0.43	0.29	Schizophrenia;	chr15:84400482	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.81	rs62029594	ENSG00000259728.4	LINC00933	6.56	1.35e-10	7.43e-08	0.43	0.29	Schizophrenia;	chr15:84400554	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.881	rs62029596	ENSG00000259728.4	LINC00933	6.56	1.35e-10	7.43e-08	0.43	0.29	Schizophrenia;	chr15:84400736	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.881	rs4081123	ENSG00000259728.4	LINC00933	6.56	1.35e-10	7.43e-08	0.43	0.29	Schizophrenia;	chr15:84401537	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.881	rs62029599	ENSG00000259728.4	LINC00933	6.56	1.35e-10	7.43e-08	0.43	0.29	Schizophrenia;	chr15:84401867	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.8	rs4099846	ENSG00000259728.4	LINC00933	6.56	1.35e-10	7.43e-08	0.43	0.29	Schizophrenia;	chr15:84402196	chr15:84570649~84580175:+
LUAD	cis	rs1499614	1	rs2707840	ENSG00000226824.5	RP4-756H11.3	-6.56	1.36e-10	7.43e-08	-0.54	-0.29	Gout;	chr7:66693028	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.929	rs4122249	ENSG00000222364.1	RNU6-96P	-6.56	1.36e-10	7.46e-08	-0.32	-0.29	Aortic root size;	chr7:66455949	chr7:66395191~66395286:+
LUAD	cis	rs1823913	0.538	rs35311234	ENSG00000227542.1	AC092614.2	6.56	1.36e-10	7.46e-08	0.35	0.29	Obesity-related traits;	chr2:191316952	chr2:191229165~191246172:-
LUAD	cis	rs55665837	1	rs7121171	ENSG00000251991.1	RNU7-49P	6.56	1.36e-10	7.46e-08	0.32	0.29	Vitamin D levels;	chr11:14424874	chr11:14478892~14478953:+
LUAD	cis	rs7849270	0.959	rs3118628	ENSG00000268707.1	RP11-247A12.7	6.56	1.36e-10	7.48e-08	0.35	0.29	Blood metabolite ratios;	chr9:129123000	chr9:129170434~129170940:+
LUAD	cis	rs2243480	0.908	rs55876148	ENSG00000226824.5	RP4-756H11.3	-6.56	1.37e-10	7.49e-08	-0.55	-0.29	Diabetic kidney disease;	chr7:65914813	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.545	rs73148639	ENSG00000237310.1	GS1-124K5.4	6.56	1.37e-10	7.5e-08	0.35	0.29	Aortic root size;	chr7:66390342	chr7:66493706~66495474:+
LUAD	cis	rs6142102	0.651	rs6059692	ENSG00000276073.1	RP5-1125A11.7	6.56	1.37e-10	7.5e-08	0.32	0.29	Skin pigmentation;	chr20:34158397	chr20:33985617~33988989:-
LUAD	cis	rs113835537	0.529	rs11227512	ENSG00000255517.5	CTD-3074O7.5	-6.56	1.37e-10	7.5e-08	-0.34	-0.29	Airway imaging phenotypes;	chr11:66513820	chr11:66473490~66480233:-
LUAD	cis	rs77204473	1	rs12294657	ENSG00000254851.1	RP11-109L13.1	6.56	1.37e-10	7.51e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116936652	chr11:117135528~117138582:+
LUAD	cis	rs2439831	0.85	rs694985	ENSG00000205771.5	CATSPER2P1	-6.56	1.37e-10	7.51e-08	-0.48	-0.29	Lung cancer in ever smokers;	chr15:43521189	chr15:43726918~43747094:-
LUAD	cis	rs6772849	0.805	rs61159406	ENSG00000242551.2	POU5F1P6	-6.56	1.37e-10	7.52e-08	-0.33	-0.29	Monocyte percentage of white cells;Monocyte count;	chr3:128617166	chr3:128674735~128677005:-
LUAD	cis	rs6772849	0.805	rs13325747	ENSG00000242551.2	POU5F1P6	-6.56	1.37e-10	7.52e-08	-0.33	-0.29	Monocyte percentage of white cells;Monocyte count;	chr3:128617180	chr3:128674735~128677005:-
LUAD	cis	rs67311347	1	rs9822644	ENSG00000223797.4	ENTPD3-AS1	6.56	1.37e-10	7.52e-08	0.31	0.29	Renal cell carcinoma;	chr3:40385118	chr3:40313802~40453329:-
LUAD	cis	rs75422866	0.764	rs67408202	ENSG00000280054.1	RP1-197B17.7	6.56	1.37e-10	7.53e-08	0.69	0.29	Pneumonia;	chr12:47713564	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.867	rs57848393	ENSG00000280054.1	RP1-197B17.7	6.56	1.37e-10	7.53e-08	0.69	0.29	Pneumonia;	chr12:47714734	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.764	rs67201012	ENSG00000280054.1	RP1-197B17.7	6.56	1.37e-10	7.53e-08	0.69	0.29	Pneumonia;	chr12:47715881	chr12:47728151~47730598:-
LUAD	cis	rs150992	0.821	rs326480	ENSG00000248489.1	CTD-2007H13.3	6.56	1.38e-10	7.53e-08	0.31	0.29	Body mass index;	chr5:98949263	chr5:98929171~98995013:+
LUAD	cis	rs1823913	0.637	rs1378162	ENSG00000227542.1	AC092614.2	6.56	1.38e-10	7.54e-08	0.35	0.29	Obesity-related traits;	chr2:191298523	chr2:191229165~191246172:-
LUAD	cis	rs8177876	0.658	rs16954513	ENSG00000261838.4	RP11-303E16.6	6.56	1.38e-10	7.56e-08	0.74	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81043599	chr16:81069854~81076598:+
LUAD	cis	rs17826219	0.706	rs2322197	ENSG00000263531.1	RP13-753N3.1	6.56	1.38e-10	7.57e-08	0.56	0.29	Body mass index;	chr17:30778787	chr17:30863921~30864940:-
LUAD	cis	rs62229266	0.659	rs2835245	ENSG00000214914.3	RPL23AP3	6.56	1.38e-10	7.58e-08	0.34	0.29	Mitral valve prolapse;	chr21:36044410	chr21:36016079~36016546:-
LUAD	cis	rs10740039	0.768	rs1372710	ENSG00000254271.1	RP11-131N11.4	6.56	1.39e-10	7.59e-08	0.33	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60603200	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.81	rs10821800	ENSG00000254271.1	RP11-131N11.4	6.56	1.39e-10	7.59e-08	0.33	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60607812	chr10:60734342~60741828:+
LUAD	cis	rs7811142	1	rs68116612	ENSG00000242294.5	STAG3L5P	6.56	1.39e-10	7.59e-08	0.24	0.29	Platelet count;	chr7:100408870	chr7:100336079~100351900:+
LUAD	cis	rs875971	0.545	rs3936065	ENSG00000237310.1	GS1-124K5.4	6.56	1.39e-10	7.61e-08	0.36	0.29	Aortic root size;	chr7:66325577	chr7:66493706~66495474:+
LUAD	cis	rs1823913	0.513	rs4334520	ENSG00000227542.1	AC092614.2	6.56	1.39e-10	7.61e-08	0.36	0.29	Obesity-related traits;	chr2:191329200	chr2:191229165~191246172:-
LUAD	cis	rs7923609	0.967	rs10740134	ENSG00000232075.1	MRPL35P2	-6.56	1.39e-10	7.62e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63555673	chr10:63634317~63634827:-
LUAD	cis	rs4722166	0.63	rs6461667	ENSG00000179428.2	AC073072.5	-6.56	1.4e-10	7.64e-08	-0.35	-0.29	Lung cancer;	chr7:22757124	chr7:22725395~22727620:-
LUAD	cis	rs7246657	0.943	rs10406177	ENSG00000276846.1	CTD-3220F14.3	6.56	1.4e-10	7.64e-08	0.39	0.29	Coronary artery calcification;	chr19:37417045	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.882	rs28623164	ENSG00000276846.1	CTD-3220F14.3	6.56	1.4e-10	7.64e-08	0.39	0.29	Coronary artery calcification;	chr19:37422551	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs7252346	ENSG00000276846.1	CTD-3220F14.3	6.56	1.4e-10	7.64e-08	0.39	0.29	Coronary artery calcification;	chr19:37423780	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs2891699	ENSG00000276846.1	CTD-3220F14.3	6.56	1.4e-10	7.64e-08	0.39	0.29	Coronary artery calcification;	chr19:37429335	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs9676967	ENSG00000276846.1	CTD-3220F14.3	6.56	1.4e-10	7.64e-08	0.39	0.29	Coronary artery calcification;	chr19:37437187	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs8109632	ENSG00000276846.1	CTD-3220F14.3	6.56	1.4e-10	7.64e-08	0.39	0.29	Coronary artery calcification;	chr19:37440223	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs7255407	ENSG00000276846.1	CTD-3220F14.3	6.56	1.4e-10	7.64e-08	0.39	0.29	Coronary artery calcification;	chr19:37443034	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs2112923	ENSG00000276846.1	CTD-3220F14.3	6.56	1.4e-10	7.64e-08	0.39	0.29	Coronary artery calcification;	chr19:37449425	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs3760825	ENSG00000276846.1	CTD-3220F14.3	6.56	1.4e-10	7.64e-08	0.39	0.29	Coronary artery calcification;	chr19:37454699	chr19:37314868~37315620:-
LUAD	cis	rs11098499	0.863	rs10004484	ENSG00000248280.1	RP11-33B1.2	6.56	1.4e-10	7.66e-08	0.36	0.29	Corneal astigmatism;	chr4:119521273	chr4:119440561~119450157:-
LUAD	cis	rs465969	0.744	rs13220692	ENSG00000255389.1	C6orf3	-6.56	1.4e-10	7.68e-08	-0.63	-0.29	Psoriasis;	chr6:111455836	chr6:111599875~111602295:+
LUAD	cis	rs7626444	0.625	rs843539	ENSG00000272359.1	U4	-6.56	1.41e-10	7.7e-08	-0.32	-0.29	Monocyte count;	chr3:196747985	chr3:196747192~196747324:-
LUAD	cis	rs3762637	1	rs76599189	ENSG00000272758.4	RP11-299J3.8	-6.56	1.41e-10	7.7e-08	-0.45	-0.29	LDL cholesterol levels;	chr3:122405229	chr3:122416207~122443180:+
LUAD	cis	rs77204473	1	rs12292371	ENSG00000254851.1	RP11-109L13.1	6.56	1.41e-10	7.71e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116925232	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs12292434	ENSG00000254851.1	RP11-109L13.1	6.56	1.41e-10	7.71e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116925349	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs79157715	ENSG00000254851.1	RP11-109L13.1	6.56	1.41e-10	7.71e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116929554	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs75776964	ENSG00000254851.1	RP11-109L13.1	6.56	1.41e-10	7.71e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116930345	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs74615346	ENSG00000254851.1	RP11-109L13.1	6.56	1.41e-10	7.71e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116932256	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs12272491	ENSG00000254851.1	RP11-109L13.1	6.56	1.41e-10	7.71e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116933654	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs12418735	ENSG00000254851.1	RP11-109L13.1	6.56	1.41e-10	7.71e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116934046	chr11:117135528~117138582:+
LUAD	cis	rs950169	1	rs79318564	ENSG00000259728.4	LINC00933	6.56	1.41e-10	7.72e-08	0.44	0.29	Schizophrenia;	chr15:84117398	chr15:84570649~84580175:+
LUAD	cis	rs17684571	0.938	rs71564849	ENSG00000231441.1	RP11-472M19.2	6.56	1.41e-10	7.72e-08	0.4	0.29	Schizophrenia;	chr6:56709421	chr6:56844002~56864078:+
LUAD	cis	rs465969	1	rs35856111	ENSG00000255389.1	C6orf3	-6.56	1.41e-10	7.72e-08	-0.63	-0.29	Psoriasis;	chr6:111452265	chr6:111599875~111602295:+
LUAD	cis	rs465969	0.793	rs7752225	ENSG00000255389.1	C6orf3	6.56	1.41e-10	7.72e-08	0.63	0.29	Psoriasis;	chr6:111459412	chr6:111599875~111602295:+
LUAD	cis	rs1499614	1	rs1638731	ENSG00000226824.5	RP4-756H11.3	-6.56	1.42e-10	7.74e-08	-0.54	-0.29	Gout;	chr7:66679692	chr7:66654538~66669855:+
LUAD	cis	rs1499614	1	rs1882655	ENSG00000226824.5	RP4-756H11.3	6.56	1.42e-10	7.74e-08	0.54	0.29	Gout;	chr7:66682070	chr7:66654538~66669855:+
LUAD	cis	rs1499614	0.831	rs3800822	ENSG00000226824.5	RP4-756H11.3	6.56	1.42e-10	7.74e-08	0.54	0.29	Gout;	chr7:66682162	chr7:66654538~66669855:+
LUAD	cis	rs11089937	0.616	rs713644	ENSG00000211639.2	IGLV4-60	6.56	1.42e-10	7.74e-08	0.3	0.29	Periodontitis (PAL4Q3);	chr22:22180747	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.616	rs713624	ENSG00000211639.2	IGLV4-60	6.56	1.42e-10	7.74e-08	0.3	0.29	Periodontitis (PAL4Q3);	chr22:22180754	chr22:22162199~22162681:+
LUAD	cis	rs67311347	0.956	rs9817233	ENSG00000223797.4	ENTPD3-AS1	6.56	1.42e-10	7.74e-08	0.31	0.29	Renal cell carcinoma;	chr3:40384127	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs9817142	ENSG00000223797.4	ENTPD3-AS1	6.56	1.42e-10	7.74e-08	0.31	0.29	Renal cell carcinoma;	chr3:40384283	chr3:40313802~40453329:-
LUAD	cis	rs2734839	0.964	rs12363125	ENSG00000270179.1	RP11-159N11.4	-6.56	1.42e-10	7.75e-08	-0.29	-0.29	Information processing speed;	chr11:113415194	chr11:113368478~113369117:+
LUAD	cis	rs17301013	0.507	rs10912786	ENSG00000227373.4	RP11-160H22.5	6.56	1.42e-10	7.75e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174427609	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12074416	ENSG00000227373.4	RP11-160H22.5	6.56	1.42e-10	7.75e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174430109	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12069134	ENSG00000227373.4	RP11-160H22.5	6.56	1.42e-10	7.75e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174434287	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs6677262	ENSG00000227373.4	RP11-160H22.5	6.56	1.42e-10	7.75e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174434539	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs60409344	ENSG00000227373.4	RP11-160H22.5	6.56	1.42e-10	7.75e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174438724	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs72713584	ENSG00000227373.4	RP11-160H22.5	6.56	1.42e-10	7.75e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174439129	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12077381	ENSG00000227373.4	RP11-160H22.5	6.56	1.42e-10	7.75e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174439566	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs74126805	ENSG00000227373.4	RP11-160H22.5	6.56	1.42e-10	7.75e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174440226	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12078960	ENSG00000227373.4	RP11-160H22.5	6.56	1.42e-10	7.75e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174440891	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12080407	ENSG00000227373.4	RP11-160H22.5	6.56	1.42e-10	7.75e-08	0.43	0.29	Systemic lupus erythematosus;	chr1:174441964	chr1:174115300~174160004:-
LUAD	cis	rs12458462	0.859	rs35493271	ENSG00000274828.1	RP11-567M16.6	6.56	1.42e-10	7.76e-08	0.3	0.29	Monocyte count;	chr18:79688793	chr18:79677287~79679358:-
LUAD	cis	rs9584850	0.874	rs3742136	ENSG00000231194.1	FARP1-AS1	6.56	1.42e-10	7.76e-08	0.35	0.29	Neuroticism;	chr13:98450353	chr13:98435405~98435840:-
LUAD	cis	rs7674212	0.531	rs4698876	ENSG00000246560.2	RP11-10L12.4	6.56	1.42e-10	7.78e-08	0.37	0.29	Type 2 diabetes;	chr4:103012410	chr4:102828055~102844075:+
LUAD	cis	rs7674212	0.531	rs7665026	ENSG00000246560.2	RP11-10L12.4	6.56	1.42e-10	7.78e-08	0.37	0.29	Type 2 diabetes;	chr4:103015491	chr4:102828055~102844075:+
LUAD	cis	rs67311347	1	rs7634375	ENSG00000223797.4	ENTPD3-AS1	6.56	1.43e-10	7.78e-08	0.31	0.29	Renal cell carcinoma;	chr3:40390455	chr3:40313802~40453329:-
LUAD	cis	rs853679	0.55	rs1225599	ENSG00000219392.1	RP1-265C24.5	-6.56	1.43e-10	7.79e-08	-0.39	-0.29	Depression;	chr6:28197412	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.574	rs1233705	ENSG00000219392.1	RP1-265C24.5	-6.56	1.43e-10	7.79e-08	-0.39	-0.29	Depression;	chr6:28198669	chr6:28115628~28116551:+
LUAD	cis	rs17711722	0.503	rs453835	ENSG00000226824.5	RP4-756H11.3	6.56	1.43e-10	7.79e-08	0.36	0.29	Calcium levels;	chr7:66046172	chr7:66654538~66669855:+
LUAD	cis	rs10129255	0.701	rs2005643	ENSG00000224373.3	IGHV4-59	6.56	1.43e-10	7.79e-08	0.18	0.29	Kawasaki disease;	chr14:106676288	chr14:106627249~106627825:-
LUAD	cis	rs2404602	0.647	rs11632765	ENSG00000259422.1	RP11-593F23.1	6.56	1.43e-10	7.81e-08	0.36	0.29	Blood metabolite levels;	chr15:76681920	chr15:76174891~76181486:-
LUAD	cis	rs77204473	1	rs77136879	ENSG00000254851.1	RP11-109L13.1	6.56	1.43e-10	7.81e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116937737	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs7480278	ENSG00000254851.1	RP11-109L13.1	6.56	1.43e-10	7.81e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116939073	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs80015203	ENSG00000254851.1	RP11-109L13.1	6.56	1.43e-10	7.81e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116940190	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs117877581	ENSG00000254851.1	RP11-109L13.1	6.56	1.43e-10	7.81e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116940238	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs116597701	ENSG00000254851.1	RP11-109L13.1	6.56	1.43e-10	7.81e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116940771	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs78066444	ENSG00000254851.1	RP11-109L13.1	6.56	1.43e-10	7.81e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116941342	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs75410648	ENSG00000254851.1	RP11-109L13.1	6.56	1.43e-10	7.81e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116942722	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs12421902	ENSG00000254851.1	RP11-109L13.1	6.56	1.43e-10	7.81e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116943930	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs11216193	ENSG00000254851.1	RP11-109L13.1	6.56	1.43e-10	7.81e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116944883	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs11216197	ENSG00000254851.1	RP11-109L13.1	6.56	1.43e-10	7.81e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116946062	chr11:117135528~117138582:+
LUAD	cis	rs2739330	0.753	rs4822452	ENSG00000228039.3	KB-1125A3.10	6.56	1.43e-10	7.81e-08	0.35	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23963780~23964374:+
LUAD	cis	rs7849270	0.959	rs2900271	ENSG00000268707.1	RP11-247A12.7	6.56	1.43e-10	7.81e-08	0.34	0.29	Blood metabolite ratios;	chr9:129132655	chr9:129170434~129170940:+
LUAD	cis	rs55665837	1	rs12276938	ENSG00000251991.1	RNU7-49P	6.56	1.43e-10	7.82e-08	0.32	0.29	Vitamin D levels;	chr11:14441942	chr11:14478892~14478953:+
LUAD	cis	rs77204473	1	rs12279433	ENSG00000254851.1	RP11-109L13.1	6.56	1.43e-10	7.82e-08	0.69	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116877505	chr11:117135528~117138582:+
LUAD	cis	rs1499614	1	rs2659913	ENSG00000226824.5	RP4-756H11.3	-6.56	1.44e-10	7.83e-08	-0.54	-0.29	Gout;	chr7:66692349	chr7:66654538~66669855:+
LUAD	cis	rs1499614	1	rs2659911	ENSG00000226824.5	RP4-756H11.3	-6.56	1.44e-10	7.83e-08	-0.54	-0.29	Gout;	chr7:66693433	chr7:66654538~66669855:+
LUAD	cis	rs1499614	1	rs2707838	ENSG00000226824.5	RP4-756H11.3	-6.56	1.44e-10	7.83e-08	-0.54	-0.29	Gout;	chr7:66694214	chr7:66654538~66669855:+
LUAD	cis	rs1499614	1	rs60326618	ENSG00000226824.5	RP4-756H11.3	-6.56	1.44e-10	7.83e-08	-0.54	-0.29	Gout;	chr7:66701371	chr7:66654538~66669855:+
LUAD	cis	rs1499614	1	rs2707830	ENSG00000226824.5	RP4-756H11.3	-6.56	1.44e-10	7.83e-08	-0.54	-0.29	Gout;	chr7:66702658	chr7:66654538~66669855:+
LUAD	cis	rs1499614	1	rs2707828	ENSG00000226824.5	RP4-756H11.3	-6.56	1.44e-10	7.83e-08	-0.54	-0.29	Gout;	chr7:66706390	chr7:66654538~66669855:+
LUAD	cis	rs1499614	0.803	rs1922723	ENSG00000226824.5	RP4-756H11.3	-6.56	1.44e-10	7.83e-08	-0.54	-0.29	Gout;	chr7:66710076	chr7:66654538~66669855:+
LUAD	cis	rs1499614	1	rs2659903	ENSG00000226824.5	RP4-756H11.3	-6.56	1.44e-10	7.83e-08	-0.54	-0.29	Gout;	chr7:66715944	chr7:66654538~66669855:+
LUAD	cis	rs1499614	1	rs2141924	ENSG00000226824.5	RP4-756H11.3	-6.56	1.44e-10	7.83e-08	-0.54	-0.29	Gout;	chr7:66721259	chr7:66654538~66669855:+
LUAD	cis	rs494459	0.536	rs57719838	ENSG00000255422.1	AP002954.4	-6.55	1.44e-10	7.84e-08	-0.35	-0.29	Height;	chr11:118854014	chr11:118704607~118750263:+
LUAD	cis	rs9368481	0.761	rs9357030	ENSG00000241549.7	GUSBP2	-6.55	1.44e-10	7.85e-08	-0.33	-0.29	Autism spectrum disorder or schizophrenia;	chr6:27017247	chr6:26871484~26956554:-
LUAD	cis	rs2243480	1	rs316329	ENSG00000226824.5	RP4-756H11.3	-6.55	1.44e-10	7.86e-08	-0.53	-0.29	Diabetic kidney disease;	chr7:66143429	chr7:66654538~66669855:+
LUAD	cis	rs11098499	0.604	rs2389886	ENSG00000248280.1	RP11-33B1.2	6.55	1.44e-10	7.86e-08	0.37	0.29	Corneal astigmatism;	chr4:119649267	chr4:119440561~119450157:-
LUAD	cis	rs7688540	0.8	rs12510827	ENSG00000275426.1	CH17-262A2.1	6.55	1.44e-10	7.87e-08	0.36	0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:259015	chr4:149738~150317:+
LUAD	cis	rs75920871	0.589	rs56061158	ENSG00000254851.1	RP11-109L13.1	-6.55	1.44e-10	7.87e-08	-0.51	-0.29	Subjective well-being;	chr11:117216402	chr11:117135528~117138582:+
LUAD	cis	rs6844153	0.887	rs6835631	ENSG00000240005.4	RP11-293A21.1	6.55	1.44e-10	7.87e-08	0.44	0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26946864	chr4:26859806~26860599:-
LUAD	cis	rs9326248	0.581	rs10502222	ENSG00000280143.1	AP000892.6	6.55	1.45e-10	7.88e-08	0.33	0.29	Blood protein levels;	chr11:116963014	chr11:117204967~117210292:+
LUAD	cis	rs9326248	0.559	rs10892052	ENSG00000280143.1	AP000892.6	6.55	1.45e-10	7.88e-08	0.33	0.29	Blood protein levels;	chr11:116963597	chr11:117204967~117210292:+
LUAD	cis	rs7246657	0.943	rs10404602	ENSG00000276846.1	CTD-3220F14.3	6.55	1.45e-10	7.88e-08	0.41	0.29	Coronary artery calcification;	chr19:37334731	chr19:37314868~37315620:-
LUAD	cis	rs1426063	0.614	rs115690958	ENSG00000249717.1	RP11-44F21.3	6.55	1.45e-10	7.89e-08	0.58	0.29	QT interval;	chr4:75078364	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.614	rs78681370	ENSG00000249717.1	RP11-44F21.3	6.55	1.45e-10	7.89e-08	0.58	0.29	QT interval;	chr4:75081556	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.614	rs17000212	ENSG00000249717.1	RP11-44F21.3	6.55	1.45e-10	7.89e-08	0.58	0.29	QT interval;	chr4:75081611	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.614	rs77018380	ENSG00000249717.1	RP11-44F21.3	6.55	1.45e-10	7.89e-08	0.58	0.29	QT interval;	chr4:75081621	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.614	rs76325897	ENSG00000249717.1	RP11-44F21.3	6.55	1.45e-10	7.89e-08	0.58	0.29	QT interval;	chr4:75084747	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.614	rs6534447	ENSG00000249717.1	RP11-44F21.3	-6.55	1.45e-10	7.89e-08	-0.58	-0.29	QT interval;	chr4:75080682	chr4:74955974~74970362:-
LUAD	cis	rs270601	0.909	rs2569265	ENSG00000233006.5	AC034220.3	-6.55	1.45e-10	7.89e-08	-0.29	-0.29	Acylcarnitine levels;	chr5:132368827	chr5:132311285~132369916:-
LUAD	cis	rs8062405	0.558	rs231976	ENSG00000259982.1	CDC37P1	6.55	1.45e-10	7.89e-08	0.34	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534266	chr16:28700294~28701540:-
LUAD	cis	rs853679	0.607	rs34878803	ENSG00000204709.4	LINC01556	6.55	1.45e-10	7.9e-08	0.61	0.29	Depression;	chr6:28282402	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs34396849	ENSG00000204709.4	LINC01556	6.55	1.45e-10	7.9e-08	0.61	0.29	Depression;	chr6:28283178	chr6:28943877~28944537:+
LUAD	cis	rs7927592	0.913	rs10896329	ENSG00000212093.1	AP000807.1	6.55	1.45e-10	7.91e-08	0.32	0.29	Total body bone mineral density;	chr11:68482561	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs12272917	ENSG00000212093.1	AP000807.1	6.55	1.45e-10	7.91e-08	0.32	0.29	Total body bone mineral density;	chr11:68495902	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs59056571	ENSG00000212093.1	AP000807.1	6.55	1.45e-10	7.91e-08	0.32	0.29	Total body bone mineral density;	chr11:68505505	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs66752716	ENSG00000212093.1	AP000807.1	6.55	1.45e-10	7.91e-08	0.32	0.29	Total body bone mineral density;	chr11:68506158	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs11228262	ENSG00000212093.1	AP000807.1	6.55	1.45e-10	7.91e-08	0.32	0.29	Total body bone mineral density;	chr11:68507439	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs55883802	ENSG00000212093.1	AP000807.1	6.55	1.45e-10	7.91e-08	0.32	0.29	Total body bone mineral density;	chr11:68511361	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs11228268	ENSG00000212093.1	AP000807.1	6.55	1.45e-10	7.91e-08	0.32	0.29	Total body bone mineral density;	chr11:68519979	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs4084149	ENSG00000212093.1	AP000807.1	6.55	1.45e-10	7.91e-08	0.32	0.29	Total body bone mineral density;	chr11:68521099	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs6591340	ENSG00000212093.1	AP000807.1	6.55	1.45e-10	7.91e-08	0.32	0.29	Total body bone mineral density;	chr11:68530168	chr11:68506083~68506166:-
LUAD	cis	rs7829975	0.688	rs13270194	ENSG00000253893.2	FAM85B	-6.55	1.45e-10	7.92e-08	-0.36	-0.29	Mood instability;	chr8:8520592	chr8:8167819~8226614:-
LUAD	cis	rs875971	1	rs1363055	ENSG00000222364.1	RNU6-96P	-6.55	1.46e-10	7.92e-08	-0.32	-0.29	Aortic root size;	chr7:66478288	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.964	rs9691480	ENSG00000222364.1	RNU6-96P	-6.55	1.46e-10	7.92e-08	-0.32	-0.29	Aortic root size;	chr7:66479319	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs7789554	ENSG00000222364.1	RNU6-96P	-6.55	1.46e-10	7.92e-08	-0.32	-0.29	Aortic root size;	chr7:66481051	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs4717300	ENSG00000222364.1	RNU6-96P	-6.55	1.46e-10	7.92e-08	-0.32	-0.29	Aortic root size;	chr7:66482393	chr7:66395191~66395286:+
LUAD	cis	rs71403859	0.502	rs12708914	ENSG00000260886.1	TAT-AS1	6.55	1.46e-10	7.93e-08	0.42	0.29	Post bronchodilator FEV1;	chr16:71436733	chr16:71565789~71578187:+
LUAD	cis	rs7626444	0.625	rs2686596	ENSG00000272359.1	U4	-6.55	1.46e-10	7.93e-08	-0.32	-0.29	Monocyte count;	chr3:196748248	chr3:196747192~196747324:-
LUAD	cis	rs35934224	0.891	rs33997573	ENSG00000232926.1	AC000078.5	6.55	1.46e-10	7.93e-08	0.34	0.29	Glaucoma (primary open-angle);	chr22:19881428	chr22:19887289~19887970:+
LUAD	cis	rs881375	0.933	rs4837804	ENSG00000226752.6	PSMD5-AS1	-6.55	1.46e-10	7.94e-08	-0.3	-0.29	Rheumatoid arthritis;	chr9:120943026	chr9:120824828~120854385:+
LUAD	cis	rs2842992	0.789	rs10945635	ENSG00000237927.1	RP3-393E18.2	-6.55	1.46e-10	7.95e-08	-0.41	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159793455	chr6:159586955~159589169:-
LUAD	cis	rs2842992	0.789	rs6908680	ENSG00000237927.1	RP3-393E18.2	-6.55	1.46e-10	7.95e-08	-0.41	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159797177	chr6:159586955~159589169:-
LUAD	cis	rs2842992	0.672	rs4708845	ENSG00000237927.1	RP3-393E18.2	-6.55	1.46e-10	7.95e-08	-0.41	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159798569	chr6:159586955~159589169:-
LUAD	cis	rs2842992	0.789	rs2342446	ENSG00000237927.1	RP3-393E18.2	-6.55	1.46e-10	7.95e-08	-0.41	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159799655	chr6:159586955~159589169:-
LUAD	cis	rs2842992	0.789	rs2146163	ENSG00000237927.1	RP3-393E18.2	-6.55	1.46e-10	7.95e-08	-0.41	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159803314	chr6:159586955~159589169:-
LUAD	cis	rs2842992	0.789	rs9364536	ENSG00000237927.1	RP3-393E18.2	-6.55	1.46e-10	7.95e-08	-0.41	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159804527	chr6:159586955~159589169:-
LUAD	cis	rs7017914	0.967	rs3098867	ENSG00000223220.1	Y_RNA	6.55	1.46e-10	7.95e-08	0.32	0.29	Bone mineral density;	chr8:71004636	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.934	rs2639904	ENSG00000223220.1	Y_RNA	6.55	1.46e-10	7.95e-08	0.32	0.29	Bone mineral density;	chr8:71004895	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs2639901	ENSG00000223220.1	Y_RNA	6.55	1.46e-10	7.95e-08	0.32	0.29	Bone mineral density;	chr8:71005516	chr8:70780914~70781008:-
LUAD	cis	rs7208859	0.573	rs8070182	ENSG00000263531.1	RP13-753N3.1	6.55	1.46e-10	7.95e-08	0.55	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30863921~30864940:-
LUAD	cis	rs950169	0.58	rs35516100	ENSG00000259728.4	LINC00933	6.55	1.46e-10	7.96e-08	0.42	0.29	Schizophrenia;	chr15:84652199	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.58	rs62021208	ENSG00000259728.4	LINC00933	6.55	1.46e-10	7.96e-08	0.42	0.29	Schizophrenia;	chr15:84653013	chr15:84570649~84580175:+
LUAD	cis	rs7674212	0.507	rs223471	ENSG00000251288.2	RP11-10L12.2	-6.55	1.46e-10	7.96e-08	-0.35	-0.29	Type 2 diabetes;	chr4:102777629	chr4:102751401~102752641:+
LUAD	cis	rs9309473	0.95	rs13431529	ENSG00000163016.8	ALMS1P	6.55	1.46e-10	7.96e-08	0.36	0.29	Metabolite levels;	chr2:73648914	chr2:73644919~73685576:+
LUAD	cis	rs7017914	0.934	rs17760050	ENSG00000223220.1	Y_RNA	6.55	1.46e-10	7.96e-08	0.32	0.29	Bone mineral density;	chr8:70662016	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.934	rs35214141	ENSG00000223220.1	Y_RNA	6.55	1.46e-10	7.96e-08	0.32	0.29	Bone mineral density;	chr8:70662329	chr8:70780914~70781008:-
LUAD	cis	rs1823913	0.549	rs4465792	ENSG00000227542.1	AC092614.2	6.55	1.46e-10	7.97e-08	0.36	0.29	Obesity-related traits;	chr2:191328884	chr2:191229165~191246172:-
LUAD	cis	rs11089937	0.616	rs66651705	ENSG00000211639.2	IGLV4-60	6.55	1.46e-10	7.97e-08	0.3	0.29	Periodontitis (PAL4Q3);	chr22:22179973	chr22:22162199~22162681:+
LUAD	cis	rs7017914	0.902	rs3098866	ENSG00000223220.1	Y_RNA	6.55	1.47e-10	7.98e-08	0.32	0.29	Bone mineral density;	chr8:71004339	chr8:70780914~70781008:-
LUAD	cis	rs748404	0.723	rs11853991	ENSG00000205771.5	CATSPER2P1	-6.55	1.47e-10	7.99e-08	-0.37	-0.29	Lung cancer;	chr15:43265351	chr15:43726918~43747094:-
LUAD	cis	rs1075265	0.73	rs7597189	ENSG00000233266.1	HMGB1P31	6.55	1.47e-10	8e-08	0.36	0.29	Chronotype;Morning vs. evening chronotype;	chr2:54014733	chr2:54051334~54051760:+
LUAD	cis	rs11089937	0.616	rs5750675	ENSG00000211639.2	IGLV4-60	6.55	1.47e-10	8e-08	0.3	0.29	Periodontitis (PAL4Q3);	chr22:22179233	chr22:22162199~22162681:+
LUAD	cis	rs1062177	1	rs2964571	ENSG00000213433.5	RPLP1P6	-6.55	1.47e-10	8e-08	-0.39	-0.29	Preschool internalizing problems;	chr5:151791695	chr5:151765859~151766378:-
LUAD	cis	rs1062177	1	rs2915869	ENSG00000213433.5	RPLP1P6	-6.55	1.47e-10	8e-08	-0.39	-0.29	Preschool internalizing problems;	chr5:151791948	chr5:151765859~151766378:-
LUAD	cis	rs10129255	0.518	rs8010020	ENSG00000224373.3	IGHV4-59	6.55	1.47e-10	8.01e-08	0.17	0.29	Kawasaki disease;	chr14:106778016	chr14:106627249~106627825:-
LUAD	cis	rs10129255	0.5	rs6576225	ENSG00000224373.3	IGHV4-59	6.55	1.47e-10	8.01e-08	0.17	0.29	Kawasaki disease;	chr14:106778120	chr14:106627249~106627825:-
LUAD	cis	rs10129255	0.5	rs6576226	ENSG00000224373.3	IGHV4-59	6.55	1.47e-10	8.01e-08	0.17	0.29	Kawasaki disease;	chr14:106778135	chr14:106627249~106627825:-
LUAD	cis	rs67311347	1	rs6762997	ENSG00000223797.4	ENTPD3-AS1	6.55	1.47e-10	8.01e-08	0.29	0.29	Renal cell carcinoma;	chr3:40436660	chr3:40313802~40453329:-
LUAD	cis	rs9318086	0.712	rs1886970	ENSG00000205861.10	C1QTNF9B-AS1	-6.55	1.48e-10	8.02e-08	-0.34	-0.29	Myopia (pathological);	chr13:23866359	chr13:23888889~23897263:+
LUAD	cis	rs2243480	1	rs2243480	ENSG00000226824.5	RP4-756H11.3	-6.55	1.48e-10	8.03e-08	-0.54	-0.29	Diabetic kidney disease;	chr7:66134209	chr7:66654538~66669855:+
LUAD	cis	rs7017914	0.934	rs3110239	ENSG00000223220.1	Y_RNA	6.55	1.48e-10	8.03e-08	0.32	0.29	Bone mineral density;	chr8:71004510	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.934	rs2732092	ENSG00000223220.1	Y_RNA	6.55	1.48e-10	8.03e-08	0.32	0.29	Bone mineral density;	chr8:71006364	chr8:70780914~70781008:-
LUAD	cis	rs17301013	0.507	rs72713591	ENSG00000227373.4	RP11-160H22.5	6.55	1.48e-10	8.04e-08	0.44	0.29	Systemic lupus erythematosus;	chr1:174442956	chr1:174115300~174160004:-
LUAD	cis	rs875971	0.545	rs13311962	ENSG00000237310.1	GS1-124K5.4	-6.55	1.48e-10	8.04e-08	-0.35	-0.29	Aortic root size;	chr7:66603142	chr7:66493706~66495474:+
LUAD	cis	rs7688540	0.8	rs61794998	ENSG00000275426.1	CH17-262A2.1	6.55	1.48e-10	8.06e-08	0.35	0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:233148	chr4:149738~150317:+
LUAD	cis	rs77204473	0.744	rs75890305	ENSG00000254851.1	RP11-109L13.1	6.55	1.49e-10	8.08e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117049253	chr11:117135528~117138582:+
LUAD	cis	rs113835537	0.529	rs11227499	ENSG00000255517.5	CTD-3074O7.5	-6.55	1.49e-10	8.08e-08	-0.33	-0.29	Airway imaging phenotypes;	chr11:66505353	chr11:66473490~66480233:-
LUAD	cis	rs1823913	0.599	rs34100174	ENSG00000227542.1	AC092614.2	6.55	1.49e-10	8.1e-08	0.35	0.29	Obesity-related traits;	chr2:191283579	chr2:191229165~191246172:-
LUAD	cis	rs783540	0.967	rs1864699	ENSG00000278603.1	RP13-608F4.5	6.55	1.49e-10	8.1e-08	0.33	0.29	Schizophrenia;	chr15:82654567	chr15:82472203~82472426:+
LUAD	cis	rs12439619	0.846	rs62010071	ENSG00000255769.6	GOLGA2P10	-6.55	1.49e-10	8.12e-08	-0.37	-0.29	Intelligence (multi-trait analysis);	chr15:82289442	chr15:82472993~82513950:-
LUAD	cis	rs7567389	0.677	rs4662720	ENSG00000236682.1	AC068282.3	6.55	1.49e-10	8.12e-08	0.42	0.29	Self-rated health;	chr2:127319031	chr2:127389130~127400580:+
LUAD	cis	rs2980439	0.556	rs2921059	ENSG00000253893.2	FAM85B	-6.55	1.5e-10	8.14e-08	-0.36	-0.29	Neuroticism;	chr8:8460377	chr8:8167819~8226614:-
LUAD	cis	rs2980439	0.557	rs2921056	ENSG00000253893.2	FAM85B	-6.55	1.5e-10	8.17e-08	-0.36	-0.29	Neuroticism;	chr8:8461672	chr8:8167819~8226614:-
LUAD	cis	rs2153535	0.601	rs7738877	ENSG00000230939.1	RP11-314C16.1	-6.55	1.51e-10	8.18e-08	-0.33	-0.29	Motion sickness;	chr6:8541997	chr6:8784178~8785445:+
LUAD	cis	rs17301013	0.581	rs12081445	ENSG00000227373.4	RP11-160H22.5	6.55	1.51e-10	8.19e-08	0.4	0.29	Systemic lupus erythematosus;	chr1:174226923	chr1:174115300~174160004:-
LUAD	cis	rs150992	0.507	rs377731	ENSG00000248489.1	CTD-2007H13.3	6.55	1.51e-10	8.21e-08	0.31	0.29	Body mass index;	chr5:98996535	chr5:98929171~98995013:+
LUAD	cis	rs2734839	0.964	rs4587762	ENSG00000270179.1	RP11-159N11.4	-6.55	1.51e-10	8.22e-08	-0.3	-0.29	Information processing speed;	chr11:113436171	chr11:113368478~113369117:+
LUAD	cis	rs9903692	0.657	rs1452665	ENSG00000278765.1	RP5-890E16.5	6.55	1.52e-10	8.23e-08	0.38	0.29	Pulse pressure;	chr17:48219789	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.954	rs9889470	ENSG00000278765.1	RP5-890E16.5	6.55	1.52e-10	8.23e-08	0.38	0.29	Pulse pressure;	chr17:48233713	chr17:48066704~48067293:-
LUAD	cis	rs4723738	1	rs1019180	ENSG00000227191.5	TRGC2	-6.55	1.52e-10	8.24e-08	-0.31	-0.29	Treatment response for severe sepsis;	chr7:38179410	chr7:38239580~38368091:-
LUAD	cis	rs7017914	0.934	rs1993862	ENSG00000223220.1	Y_RNA	6.55	1.52e-10	8.24e-08	0.32	0.29	Bone mineral density;	chr8:70667127	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.87	rs34282253	ENSG00000223220.1	Y_RNA	6.55	1.52e-10	8.24e-08	0.32	0.29	Bone mineral density;	chr8:70670131	chr8:70780914~70781008:-
LUAD	cis	rs7923609	0.74	rs10761784	ENSG00000232075.1	MRPL35P2	-6.55	1.52e-10	8.24e-08	-0.34	-0.29	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63548990	chr10:63634317~63634827:-
LUAD	cis	rs367615	0.918	rs17161889	ENSG00000249476.1	CTD-2587M2.1	-6.55	1.52e-10	8.25e-08	-0.37	-0.29	Colorectal cancer (SNP x SNP interaction);	chr5:109519550	chr5:109237120~109326369:-
LUAD	cis	rs8177376	1	rs17656	ENSG00000254905.1	RP11-712L6.7	6.55	1.53e-10	8.27e-08	0.39	0.29	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126263287	chr11:126292922~126294254:-
LUAD	cis	rs891378	0.785	rs7516640	ENSG00000274245.1	RP11-357P18.2	6.55	1.53e-10	8.27e-08	0.34	0.29	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207236069	chr1:207372559~207373252:+
LUAD	cis	rs3096299	0.967	rs28689480	ENSG00000274627.1	RP11-104N10.2	6.55	1.53e-10	8.27e-08	0.28	0.29	Multiple myeloma (IgH translocation);	chr16:89393685	chr16:89516797~89522217:+
LUAD	cis	rs496547	0.756	rs562059	ENSG00000255239.1	AP002954.6	6.55	1.53e-10	8.28e-08	0.35	0.29	Hip minimal joint space width;	chr11:118731349	chr11:118688039~118690600:-
LUAD	cis	rs2243480	1	rs427044	ENSG00000226824.5	RP4-756H11.3	-6.55	1.53e-10	8.28e-08	-0.54	-0.29	Diabetic kidney disease;	chr7:66043558	chr7:66654538~66669855:+
LUAD	cis	rs7567389	0.677	rs10850	ENSG00000236682.1	AC068282.3	6.54	1.53e-10	8.29e-08	0.42	0.29	Self-rated health;	chr2:127306369	chr2:127389130~127400580:+
LUAD	cis	rs4814920	0.756	rs1543472	ENSG00000275142.1	RP5-999L4.2	6.54	1.53e-10	8.29e-08	0.44	0.29	Bipolar disorder (body mass index interaction);	chr20:19867383	chr20:19871891~19872284:+
LUAD	cis	rs8100891	0.537	rs73036023	ENSG00000267213.4	AC007773.2	-6.54	1.53e-10	8.3e-08	-0.46	-0.29	Neuroticism;	chr19:32457414	chr19:32390050~32405560:-
LUAD	cis	rs6921919	0.945	rs16901847	ENSG00000204709.4	LINC01556	6.54	1.53e-10	8.3e-08	0.41	0.29	Autism spectrum disorder or schizophrenia;	chr6:28408074	chr6:28943877~28944537:+
LUAD	cis	rs891378	0.785	rs6540876	ENSG00000274245.1	RP11-357P18.2	-6.54	1.53e-10	8.31e-08	-0.34	-0.29	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207222873	chr1:207372559~207373252:+
LUAD	cis	rs2842992	0.709	rs1853257	ENSG00000237927.1	RP3-393E18.2	-6.54	1.53e-10	8.31e-08	-0.41	-0.29	Age-related macular degeneration (geographic atrophy);	chr6:159791678	chr6:159586955~159589169:-
LUAD	cis	rs11846409	0.932	rs2015469	ENSG00000211974.3	IGHV2-70	-6.54	1.53e-10	8.31e-08	-0.35	-0.29	Rheumatic heart disease;	chr14:106631857	chr14:106723574~106724093:-
LUAD	cis	rs11846409	0.932	rs56167903	ENSG00000211974.3	IGHV2-70	-6.54	1.53e-10	8.31e-08	-0.35	-0.29	Rheumatic heart disease;	chr14:106632070	chr14:106723574~106724093:-
LUAD	cis	rs950169	0.8	rs4842847	ENSG00000259728.4	LINC00933	6.54	1.53e-10	8.32e-08	0.44	0.29	Schizophrenia;	chr15:84262447	chr15:84570649~84580175:+
LUAD	cis	rs1800795	0.901	rs2069833	ENSG00000179428.2	AC073072.5	-6.54	1.54e-10	8.33e-08	-0.34	-0.29	Cerebrospinal fluid clusterin levels in APOEe4- carriers;	chr7:22728045	chr7:22725395~22727620:-
LUAD	cis	rs10129255	0.5	rs34326748	ENSG00000224373.3	IGHV4-59	6.54	1.54e-10	8.33e-08	0.17	0.29	Kawasaki disease;	chr14:106782523	chr14:106627249~106627825:-
LUAD	cis	rs10129255	0.5	rs10143385	ENSG00000224373.3	IGHV4-59	6.54	1.54e-10	8.33e-08	0.17	0.29	Kawasaki disease;	chr14:106782559	chr14:106627249~106627825:-
LUAD	cis	rs10740039	0.732	rs10159808	ENSG00000254271.1	RP11-131N11.4	6.54	1.54e-10	8.34e-08	0.33	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60602432	chr10:60734342~60741828:+
LUAD	cis	rs67311347	1	rs11707673	ENSG00000223797.4	ENTPD3-AS1	6.54	1.54e-10	8.37e-08	0.32	0.29	Renal cell carcinoma;	chr3:40409113	chr3:40313802~40453329:-
LUAD	cis	rs4591358	0.773	rs13002794	ENSG00000223466.1	AC064834.2	-6.54	1.54e-10	8.37e-08	-0.38	-0.29	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195517175	chr2:195533035~195538681:+
LUAD	cis	rs11118620	0.81	rs1603047	ENSG00000257551.1	HLX-AS1	6.54	1.55e-10	8.37e-08	0.35	0.29	Heart failure;	chr1:220849953	chr1:220832763~220880140:-
LUAD	cis	rs77204473	1	rs12293755	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116948548	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs12419047	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116949190	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs12421834	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116949307	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs12419437	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116949974	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs77467134	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116952391	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs76654964	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116952805	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs76146269	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116952901	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs12275355	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116953446	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs12289974	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116953570	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs2289890	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116953904	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs2289892	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116954524	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs12291040	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116955901	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs12270837	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116955927	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs878692	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116958223	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs12420857	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116958726	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs10892051	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116962002	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs12281729	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116967414	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs12417152	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116968577	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs11216204	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116968898	chr11:117135528~117138582:+
LUAD	cis	rs77204473	0.744	rs12279266	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116969317	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs74927399	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116975550	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs76949321	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116975627	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs11216209	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116977470	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs11216215	ENSG00000254851.1	RP11-109L13.1	6.54	1.55e-10	8.38e-08	0.71	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116981971	chr11:117135528~117138582:+
LUAD	cis	rs6844153	1	rs74642474	ENSG00000240005.4	RP11-293A21.1	-6.54	1.55e-10	8.38e-08	-0.48	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26854979	chr4:26859806~26860599:-
LUAD	cis	rs891378	0.785	rs1346720	ENSG00000274245.1	RP11-357P18.2	6.54	1.56e-10	8.42e-08	0.37	0.29	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207214421	chr1:207372559~207373252:+
LUAD	cis	rs11098499	0.863	rs1010739	ENSG00000248280.1	RP11-33B1.2	6.54	1.56e-10	8.44e-08	0.37	0.29	Corneal astigmatism;	chr4:119542316	chr4:119440561~119450157:-
LUAD	cis	rs875971	1	rs2036264	ENSG00000222364.1	RNU6-96P	6.54	1.56e-10	8.44e-08	0.32	0.29	Aortic root size;	chr7:66334917	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs7783613	ENSG00000222364.1	RNU6-96P	6.54	1.56e-10	8.44e-08	0.32	0.29	Aortic root size;	chr7:66340274	chr7:66395191~66395286:+
LUAD	cis	rs7646881	0.812	rs59957986	ENSG00000240207.5	RP11-379F4.4	-6.54	1.56e-10	8.45e-08	-0.38	-0.29	Tetralogy of Fallot;	chr3:158741124	chr3:158732263~158784070:+
LUAD	cis	rs7849270	1	rs7023900	ENSG00000268707.1	RP11-247A12.7	-6.54	1.56e-10	8.46e-08	-0.33	-0.29	Blood metabolite ratios;	chr9:129128873	chr9:129170434~129170940:+
LUAD	cis	rs494459	0.536	rs11217063	ENSG00000255422.1	AP002954.4	-6.54	1.56e-10	8.47e-08	-0.35	-0.29	Height;	chr11:118855233	chr11:118704607~118750263:+
LUAD	cis	rs494459	0.536	rs11217065	ENSG00000255422.1	AP002954.4	-6.54	1.56e-10	8.47e-08	-0.35	-0.29	Height;	chr11:118855938	chr11:118704607~118750263:+
LUAD	cis	rs875971	0.545	rs7783889	ENSG00000237310.1	GS1-124K5.4	6.54	1.57e-10	8.47e-08	0.35	0.29	Aortic root size;	chr7:66283366	chr7:66493706~66495474:+
LUAD	cis	rs783540	1	rs11637433	ENSG00000278603.1	RP13-608F4.5	6.54	1.57e-10	8.47e-08	0.33	0.29	Schizophrenia;	chr15:82652585	chr15:82472203~82472426:+
LUAD	cis	rs9584850	0.874	rs4584	ENSG00000231194.1	FARP1-AS1	6.54	1.57e-10	8.47e-08	0.35	0.29	Neuroticism;	chr13:98449615	chr13:98435405~98435840:-
LUAD	cis	rs131777	0.547	rs131753	ENSG00000205559.3	CHKB-AS1	-6.54	1.57e-10	8.49e-08	-0.33	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50584433	chr22:50583026~50583877:+
LUAD	cis	rs17711722	0.503	rs453835	ENSG00000224316.1	RP11-479O9.2	-6.54	1.57e-10	8.49e-08	-0.29	-0.29	Calcium levels;	chr7:66046172	chr7:65773620~65802067:+
LUAD	cis	rs9828933	0.752	rs28675788	ENSG00000280620.1	SCAANT1	6.54	1.57e-10	8.49e-08	0.45	0.29	Type 2 diabetes;	chr3:63956512	chr3:63911518~63911772:-
LUAD	cis	rs1823913	0.599	rs2124095	ENSG00000227542.1	AC092614.2	6.54	1.58e-10	8.52e-08	0.35	0.29	Obesity-related traits;	chr2:191301728	chr2:191229165~191246172:-
LUAD	cis	rs875971	0.545	rs73142245	ENSG00000237310.1	GS1-124K5.4	6.54	1.58e-10	8.54e-08	0.36	0.29	Aortic root size;	chr7:66226662	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs709595	ENSG00000222364.1	RNU6-96P	-6.54	1.58e-10	8.54e-08	-0.32	-0.29	Aortic root size;	chr7:66352346	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs811880	ENSG00000222364.1	RNU6-96P	-6.54	1.58e-10	8.54e-08	-0.32	-0.29	Aortic root size;	chr7:66353659	chr7:66395191~66395286:+
LUAD	cis	rs1823913	1	rs4853562	ENSG00000230611.1	HMGB1P27	6.54	1.58e-10	8.54e-08	0.34	0.29	Obesity-related traits;	chr2:191253696	chr2:191174233~191174835:+
LUAD	cis	rs1823913	1	rs4853461	ENSG00000230611.1	HMGB1P27	6.54	1.58e-10	8.54e-08	0.34	0.29	Obesity-related traits;	chr2:191254572	chr2:191174233~191174835:+
LUAD	cis	rs150992	0.609	rs539024	ENSG00000248489.1	CTD-2007H13.3	6.54	1.58e-10	8.55e-08	0.31	0.29	Body mass index;	chr5:98997103	chr5:98929171~98995013:+
LUAD	cis	rs9326248	0.581	rs7121898	ENSG00000280143.1	AP000892.6	6.54	1.58e-10	8.56e-08	0.33	0.29	Blood protein levels;	chr11:116926130	chr11:117204967~117210292:+
LUAD	cis	rs9326248	0.52	rs1446105	ENSG00000280143.1	AP000892.6	6.54	1.58e-10	8.56e-08	0.33	0.29	Blood protein levels;	chr11:116927828	chr11:117204967~117210292:+
LUAD	cis	rs321358	0.731	rs547367	ENSG00000271584.1	RP11-89C3.4	-6.54	1.58e-10	8.56e-08	-0.43	-0.29	Body mass index;	chr11:111165382	chr11:111091932~111097357:-
LUAD	cis	rs1075232	1	rs12437749	ENSG00000270055.1	CTD-3092A11.2	-6.54	1.58e-10	8.57e-08	-0.56	-0.29	Survival in colorectal cancer (non-distant metastatic);	chr15:31357685	chr15:30487963~30490313:+
LUAD	cis	rs77204473	1	rs12278943	ENSG00000254851.1	RP11-109L13.1	6.54	1.59e-10	8.57e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117003642	chr11:117135528~117138582:+
LUAD	cis	rs113835537	0.559	rs11227497	ENSG00000255517.5	CTD-3074O7.5	-6.54	1.59e-10	8.59e-08	-0.33	-0.29	Airway imaging phenotypes;	chr11:66501993	chr11:66473490~66480233:-
LUAD	cis	rs1823913	0.599	rs17346475	ENSG00000227542.1	AC092614.2	-6.54	1.59e-10	8.59e-08	-0.35	-0.29	Obesity-related traits;	chr2:191288488	chr2:191229165~191246172:-
LUAD	cis	rs150992	0.587	rs6885458	ENSG00000248489.1	CTD-2007H13.3	6.54	1.59e-10	8.6e-08	0.32	0.29	Body mass index;	chr5:99046048	chr5:98929171~98995013:+
LUAD	cis	rs2739330	0.929	rs5751775	ENSG00000228039.3	KB-1125A3.10	6.54	1.59e-10	8.61e-08	0.35	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23963780~23964374:+
LUAD	cis	rs11096990	0.929	rs56037933	ENSG00000249207.1	RP11-360F5.1	6.54	1.59e-10	8.61e-08	0.32	0.29	Cognitive function;	chr4:39225653	chr4:39112677~39126818:-
LUAD	cis	rs950169	0.959	rs12911210	ENSG00000259728.4	LINC00933	6.54	1.59e-10	8.62e-08	0.42	0.29	Schizophrenia;	chr15:84123331	chr15:84570649~84580175:+
LUAD	cis	rs75422866	0.51	rs73105803	ENSG00000280054.1	RP1-197B17.7	6.54	1.6e-10	8.64e-08	0.64	0.29	Pneumonia;	chr12:47722135	chr12:47728151~47730598:-
LUAD	cis	rs8177376	1	rs8177365	ENSG00000254905.1	RP11-712L6.7	6.54	1.6e-10	8.65e-08	0.4	0.29	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126289965	chr11:126292922~126294254:-
LUAD	cis	rs10899021	0.79	rs12280434	ENSG00000279353.1	RP11-864N7.4	6.54	1.6e-10	8.65e-08	0.5	0.29	Response to metformin (IC50);	chr11:74621782	chr11:74698231~74699658:-
LUAD	cis	rs10899021	0.79	rs10899019	ENSG00000279353.1	RP11-864N7.4	6.54	1.6e-10	8.65e-08	0.5	0.29	Response to metformin (IC50);	chr11:74624117	chr11:74698231~74699658:-
LUAD	cis	rs9640161	0.617	rs56019796	ENSG00000261305.1	RP4-584D14.7	6.54	1.6e-10	8.66e-08	0.4	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150312137	chr7:150341771~150342607:+
LUAD	cis	rs6844153	0.752	rs11737218	ENSG00000240005.4	RP11-293A21.1	6.54	1.6e-10	8.66e-08	0.39	0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26884151	chr4:26859806~26860599:-
LUAD	cis	rs2111504	0.583	rs2111503	ENSG00000267213.4	AC007773.2	6.54	1.6e-10	8.67e-08	0.37	0.29	Bipolar disorder;	chr19:32383819	chr19:32390050~32405560:-
LUAD	cis	rs2412819	0.571	rs28410121	ENSG00000205771.5	CATSPER2P1	6.54	1.61e-10	8.67e-08	0.43	0.29	Lung cancer;	chr15:43777831	chr15:43726918~43747094:-
LUAD	cis	rs9309473	0.898	rs10201159	ENSG00000163016.8	ALMS1P	6.54	1.61e-10	8.68e-08	0.36	0.29	Metabolite levels;	chr2:73631838	chr2:73644919~73685576:+
LUAD	cis	rs3762637	0.943	rs9289198	ENSG00000272758.4	RP11-299J3.8	-6.54	1.61e-10	8.69e-08	-0.45	-0.29	LDL cholesterol levels;	chr3:122558313	chr3:122416207~122443180:+
LUAD	cis	rs3762637	0.943	rs9289199	ENSG00000272758.4	RP11-299J3.8	-6.54	1.61e-10	8.69e-08	-0.45	-0.29	LDL cholesterol levels;	chr3:122558325	chr3:122416207~122443180:+
LUAD	cis	rs2117029	0.586	rs1874908	ENSG00000258017.1	RP11-386G11.10	-6.54	1.61e-10	8.69e-08	-0.35	-0.29	Intelligence (multi-trait analysis);	chr12:49190247	chr12:49127782~49147869:+
LUAD	cis	rs10771431	0.935	rs1988852	ENSG00000111788.10	RP11-22B23.1	6.54	1.61e-10	8.72e-08	0.24	0.29	Breast size;	chr12:9220266	chr12:9277235~9313241:+
LUAD	cis	rs6142102	0.602	rs4911402	ENSG00000275784.1	RP5-1125A11.6	-6.54	1.61e-10	8.72e-08	-0.3	-0.29	Skin pigmentation;	chr20:34079839	chr20:33989480~33991818:-
LUAD	cis	rs875971	0.545	rs1638724	ENSG00000237310.1	GS1-124K5.4	-6.54	1.61e-10	8.72e-08	-0.34	-0.29	Aortic root size;	chr7:66575494	chr7:66493706~66495474:+
LUAD	cis	rs1799949	1	rs4793197	ENSG00000267681.1	CTD-3199J23.6	-6.54	1.62e-10	8.73e-08	-0.33	-0.29	Menopause (age at onset);	chr17:43079885	chr17:43144956~43145255:+
LUAD	cis	rs9928842	0.882	rs8048956	ENSG00000280152.1	RP11-331F4.5	-6.54	1.62e-10	8.73e-08	-0.31	-0.29	Alcoholic chronic pancreatitis;	chr16:75221068	chr16:75245994~75250077:-
LUAD	cis	rs11098499	0.69	rs7674713	ENSG00000248280.1	RP11-33B1.2	6.54	1.62e-10	8.73e-08	0.36	0.29	Corneal astigmatism;	chr4:119401102	chr4:119440561~119450157:-
LUAD	cis	rs8177876	0.822	rs7203546	ENSG00000261838.4	RP11-303E16.6	-6.54	1.62e-10	8.74e-08	-0.55	-0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083317	chr16:81069854~81076598:+
LUAD	cis	rs1799949	0.965	rs11657883	ENSG00000267681.1	CTD-3199J23.6	-6.54	1.62e-10	8.74e-08	-0.33	-0.29	Menopause (age at onset);	chr17:43178007	chr17:43144956~43145255:+
LUAD	cis	rs881375	0.933	rs7031096	ENSG00000226752.6	PSMD5-AS1	-6.54	1.62e-10	8.74e-08	-0.31	-0.29	Rheumatoid arthritis;	chr9:120932664	chr9:120824828~120854385:+
LUAD	cis	rs881375	0.967	rs10739580	ENSG00000226752.6	PSMD5-AS1	-6.54	1.62e-10	8.74e-08	-0.31	-0.29	Rheumatoid arthritis;	chr9:120933004	chr9:120824828~120854385:+
LUAD	cis	rs12364620	1	rs12364620	ENSG00000212093.1	AP000807.1	6.54	1.62e-10	8.75e-08	0.32	0.29	Total body bone mineral density (age 0-15);	chr11:68484655	chr11:68506083~68506166:-
LUAD	cis	rs748404	0.66	rs690367	ENSG00000249839.1	AC011330.5	6.53	1.63e-10	8.77e-08	0.38	0.29	Lung cancer;	chr15:43456106	chr15:43663654~43684339:-
LUAD	cis	rs7246657	0.943	rs7255785	ENSG00000276846.1	CTD-3220F14.3	6.53	1.63e-10	8.79e-08	0.39	0.29	Coronary artery calcification;	chr19:37480781	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs7255996	ENSG00000276846.1	CTD-3220F14.3	6.53	1.63e-10	8.79e-08	0.39	0.29	Coronary artery calcification;	chr19:37480797	chr19:37314868~37315620:-
LUAD	cis	rs2243480	0.803	rs36127118	ENSG00000273142.1	RP11-458F8.4	-6.53	1.63e-10	8.8e-08	-0.29	-0.29	Diabetic kidney disease;	chr7:66100518	chr7:66902857~66906297:+
LUAD	cis	rs891378	0.755	rs7411168	ENSG00000274245.1	RP11-357P18.2	-6.53	1.63e-10	8.8e-08	-0.34	-0.29	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207201970	chr1:207372559~207373252:+
LUAD	cis	rs67311347	1	rs2305522	ENSG00000223797.4	ENTPD3-AS1	6.53	1.63e-10	8.8e-08	0.29	0.29	Renal cell carcinoma;	chr3:40387867	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs7636719	ENSG00000223797.4	ENTPD3-AS1	6.53	1.63e-10	8.8e-08	0.29	0.29	Renal cell carcinoma;	chr3:40390593	chr3:40313802~40453329:-
LUAD	cis	rs6860806	0.507	rs2631371	ENSG00000233006.5	AC034220.3	-6.53	1.63e-10	8.8e-08	-0.29	-0.29	Breast cancer;	chr5:132367999	chr5:132311285~132369916:-
LUAD	cis	rs1799949	0.965	rs35954893	ENSG00000267681.1	CTD-3199J23.6	-6.53	1.63e-10	8.81e-08	-0.33	-0.29	Menopause (age at onset);	chr17:43181769	chr17:43144956~43145255:+
LUAD	cis	rs1823913	1	rs4853563	ENSG00000230611.1	HMGB1P27	6.53	1.63e-10	8.81e-08	0.34	0.29	Obesity-related traits;	chr2:191254808	chr2:191174233~191174835:+
LUAD	cis	rs1075265	0.704	rs9631059	ENSG00000233266.1	HMGB1P31	6.53	1.63e-10	8.81e-08	0.36	0.29	Chronotype;Morning vs. evening chronotype;	chr2:54015160	chr2:54051334~54051760:+
LUAD	cis	rs67311347	1	rs897117	ENSG00000223797.4	ENTPD3-AS1	-6.53	1.64e-10	8.83e-08	-0.29	-0.29	Renal cell carcinoma;	chr3:40395803	chr3:40313802~40453329:-
LUAD	cis	rs172166	0.694	rs2791332	ENSG00000219392.1	RP1-265C24.5	-6.53	1.64e-10	8.85e-08	-0.38	-0.29	Cardiac Troponin-T levels;	chr6:28141010	chr6:28115628~28116551:+
LUAD	cis	rs11098499	0.874	rs13139045	ENSG00000248280.1	RP11-33B1.2	6.53	1.64e-10	8.86e-08	0.34	0.29	Corneal astigmatism;	chr4:119247433	chr4:119440561~119450157:-
LUAD	cis	rs35955747	0.869	rs8141987	ENSG00000236132.1	CTA-440B3.1	6.53	1.64e-10	8.86e-08	0.32	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31191169	chr22:31816379~31817491:-
LUAD	cis	rs35955747	0.869	rs8142988	ENSG00000236132.1	CTA-440B3.1	6.53	1.64e-10	8.86e-08	0.32	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31191172	chr22:31816379~31817491:-
LUAD	cis	rs7829975	0.623	rs10087493	ENSG00000253981.4	ALG1L13P	-6.53	1.64e-10	8.86e-08	-0.34	-0.29	Mood instability;	chr8:8516047	chr8:8236003~8244667:-
LUAD	cis	rs801193	0.66	rs974239	ENSG00000222364.1	RNU6-96P	-6.53	1.64e-10	8.86e-08	-0.32	-0.29	Aortic root size;	chr7:66748504	chr7:66395191~66395286:+
LUAD	cis	rs4713118	0.955	rs9468204	ENSG00000219392.1	RP1-265C24.5	-6.53	1.64e-10	8.86e-08	-0.39	-0.29	Parkinson's disease;	chr6:27721030	chr6:28115628~28116551:+
LUAD	cis	rs1061377	1	rs9990742	ENSG00000249685.1	RP11-360F5.3	6.53	1.65e-10	8.89e-08	0.34	0.29	Uric acid levels;	chr4:39119794	chr4:39133913~39135608:+
LUAD	cis	rs10129255	0.5	rs2027902	ENSG00000224373.3	IGHV4-59	6.53	1.65e-10	8.89e-08	0.17	0.29	Kawasaki disease;	chr14:106807157	chr14:106627249~106627825:-
LUAD	cis	rs6991838	0.778	rs11779601	ENSG00000272010.1	CTD-3025N20.3	6.53	1.65e-10	8.9e-08	0.3	0.29	Intelligence (multi-trait analysis);	chr8:65550241	chr8:65591850~65592472:-
LUAD	cis	rs7017914	0.934	rs13255886	ENSG00000223220.1	Y_RNA	6.53	1.65e-10	8.9e-08	0.32	0.29	Bone mineral density;	chr8:70653719	chr8:70780914~70781008:-
LUAD	cis	rs9309711	0.961	rs11678655	ENSG00000225234.1	TRAPPC12-AS1	-6.53	1.65e-10	8.91e-08	-0.36	-0.29	Neurofibrillary tangles;	chr2:3472463	chr2:3481242~3482409:-
LUAD	cis	rs9309711	0.961	rs11675119	ENSG00000225234.1	TRAPPC12-AS1	-6.53	1.65e-10	8.91e-08	-0.36	-0.29	Neurofibrillary tangles;	chr2:3472651	chr2:3481242~3482409:-
LUAD	cis	rs11118620	0.853	rs12037861	ENSG00000257551.1	HLX-AS1	6.53	1.65e-10	8.91e-08	0.35	0.29	Heart failure;	chr1:220864835	chr1:220832763~220880140:-
LUAD	cis	rs6142102	0.602	rs2300209	ENSG00000275784.1	RP5-1125A11.6	-6.53	1.65e-10	8.92e-08	-0.3	-0.29	Skin pigmentation;	chr20:34055294	chr20:33989480~33991818:-
LUAD	cis	rs6142102	0.602	rs932388	ENSG00000275784.1	RP5-1125A11.6	-6.53	1.65e-10	8.92e-08	-0.3	-0.29	Skin pigmentation;	chr20:34069572	chr20:33989480~33991818:-
LUAD	cis	rs7811142	1	rs11761725	ENSG00000242294.5	STAG3L5P	6.53	1.65e-10	8.92e-08	0.25	0.29	Platelet count;	chr7:100442192	chr7:100336079~100351900:+
LUAD	cis	rs6991838	0.778	rs11782837	ENSG00000272010.1	CTD-3025N20.3	6.53	1.66e-10	8.92e-08	0.3	0.29	Intelligence (multi-trait analysis);	chr8:65550328	chr8:65591850~65592472:-
LUAD	cis	rs875971	1	rs6958271	ENSG00000222364.1	RNU6-96P	-6.53	1.66e-10	8.95e-08	-0.32	-0.29	Aortic root size;	chr7:66514344	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs6958277	ENSG00000222364.1	RNU6-96P	-6.53	1.66e-10	8.95e-08	-0.32	-0.29	Aortic root size;	chr7:66514362	chr7:66395191~66395286:+
LUAD	cis	rs35934224	0.891	rs13054713	ENSG00000232926.1	AC000078.5	6.53	1.66e-10	8.96e-08	0.34	0.29	Glaucoma (primary open-angle);	chr22:19880391	chr22:19887289~19887970:+
LUAD	cis	rs17301013	0.507	rs72713532	ENSG00000227373.4	RP11-160H22.5	6.53	1.66e-10	8.97e-08	0.42	0.29	Systemic lupus erythematosus;	chr1:174337826	chr1:174115300~174160004:-
LUAD	cis	rs61776719	0.875	rs10890238	ENSG00000212541.1	RNU6-510P	-6.53	1.67e-10	8.99e-08	-0.34	-0.29	Coronary artery disease;	chr1:37979982	chr1:37991462~37991569:+
LUAD	cis	rs1075265	0.73	rs7597188	ENSG00000233266.1	HMGB1P31	6.53	1.67e-10	9e-08	0.36	0.29	Chronotype;Morning vs. evening chronotype;	chr2:54014732	chr2:54051334~54051760:+
LUAD	cis	rs17301013	0.581	rs1591944	ENSG00000227373.4	RP11-160H22.5	6.53	1.67e-10	9e-08	0.41	0.29	Systemic lupus erythematosus;	chr1:174204917	chr1:174115300~174160004:-
LUAD	cis	rs9640161	0.659	rs77354576	ENSG00000261305.1	RP4-584D14.7	6.53	1.67e-10	9.01e-08	0.4	0.29	Blood protein levels;Circulating chemerin levels;	chr7:150316211	chr7:150341771~150342607:+
LUAD	cis	rs783540	0.967	rs7494860	ENSG00000278603.1	RP13-608F4.5	6.53	1.67e-10	9.01e-08	0.33	0.29	Schizophrenia;	chr15:82665667	chr15:82472203~82472426:+
LUAD	cis	rs433852	0.718	rs550455	ENSG00000232871.7	SEC1P	-6.53	1.67e-10	9.01e-08	-0.34	-0.29	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48633258	chr19:48638071~48682245:+
LUAD	cis	rs11098499	0.754	rs66900435	ENSG00000248280.1	RP11-33B1.2	6.53	1.67e-10	9.01e-08	0.35	0.29	Corneal astigmatism;	chr4:119328270	chr4:119440561~119450157:-
LUAD	cis	rs131777	0.575	rs131760	ENSG00000205559.3	CHKB-AS1	-6.53	1.68e-10	9.05e-08	-0.34	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50573507	chr22:50583026~50583877:+
LUAD	cis	rs11846409	0.86	rs10150951	ENSG00000211974.3	IGHV2-70	-6.53	1.68e-10	9.06e-08	-0.35	-0.29	Rheumatic heart disease;	chr14:106632988	chr14:106723574~106724093:-
LUAD	cis	rs11846409	0.932	rs2583329	ENSG00000211974.3	IGHV2-70	6.53	1.68e-10	9.06e-08	0.35	0.29	Rheumatic heart disease;	chr14:106632971	chr14:106723574~106724093:-
LUAD	cis	rs227932	0.614	rs4722260	ENSG00000234286.1	AC006026.13	6.53	1.68e-10	9.06e-08	0.45	0.29	Schizophrenia;	chr7:23719851	chr7:23680195~23680786:-
LUAD	cis	rs7017914	0.934	rs10504479	ENSG00000223220.1	Y_RNA	6.53	1.68e-10	9.07e-08	0.32	0.29	Bone mineral density;	chr8:70665280	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.934	rs35109143	ENSG00000223220.1	Y_RNA	6.53	1.68e-10	9.07e-08	0.32	0.29	Bone mineral density;	chr8:70665665	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.902	rs13269513	ENSG00000223220.1	Y_RNA	6.53	1.68e-10	9.07e-08	0.32	0.29	Bone mineral density;	chr8:70665844	chr8:70780914~70781008:-
LUAD	cis	rs881375	0.967	rs7034492	ENSG00000226752.6	PSMD5-AS1	-6.53	1.69e-10	9.07e-08	-0.3	-0.29	Rheumatoid arthritis;	chr9:120924933	chr9:120824828~120854385:+
LUAD	cis	rs7688540	0.8	rs1578898	ENSG00000275426.1	CH17-262A2.1	6.53	1.69e-10	9.07e-08	0.35	0.29	Facial morphology (factor 6, height of vermillion lower lip);	chr4:235130	chr4:149738~150317:+
LUAD	cis	rs2455601	1	rs12223690	ENSG00000254860.4	TMEM9B-AS1	6.53	1.69e-10	9.08e-08	0.48	0.29	Schizophrenia;	chr11:8880277	chr11:8964675~8977527:+
LUAD	cis	rs2455601	1	rs7104661	ENSG00000254860.4	TMEM9B-AS1	6.53	1.69e-10	9.08e-08	0.48	0.29	Schizophrenia;	chr11:8880954	chr11:8964675~8977527:+
LUAD	cis	rs783540	1	rs11631963	ENSG00000278603.1	RP13-608F4.5	6.53	1.69e-10	9.08e-08	0.33	0.29	Schizophrenia;	chr15:82649451	chr15:82472203~82472426:+
LUAD	cis	rs35955747	0.934	rs5994397	ENSG00000236132.1	CTA-440B3.1	6.53	1.69e-10	9.09e-08	0.31	0.29	Neutrophil count;Sum basophil neutrophil counts;	chr22:31430164	chr22:31816379~31817491:-
LUAD	cis	rs11098499	0.566	rs7664440	ENSG00000248280.1	RP11-33B1.2	6.53	1.69e-10	9.11e-08	0.36	0.29	Corneal astigmatism;	chr4:119657385	chr4:119440561~119450157:-
LUAD	cis	rs881375	1	rs6478486	ENSG00000226752.6	PSMD5-AS1	-6.53	1.69e-10	9.11e-08	-0.31	-0.29	Rheumatoid arthritis;	chr9:120893051	chr9:120824828~120854385:+
LUAD	cis	rs881375	1	rs7037140	ENSG00000226752.6	PSMD5-AS1	-6.53	1.69e-10	9.11e-08	-0.31	-0.29	Rheumatoid arthritis;	chr9:120894049	chr9:120824828~120854385:+
LUAD	cis	rs8059260	0.866	rs12922318	ENSG00000274038.1	RP11-66H6.4	-6.53	1.7e-10	9.12e-08	-0.42	-0.29	Alcohol consumption over the past year;	chr16:10946769	chr16:11056556~11057034:+
LUAD	cis	rs7246657	0.943	rs10426666	ENSG00000276846.1	CTD-3220F14.3	6.53	1.7e-10	9.14e-08	0.41	0.29	Coronary artery calcification;	chr19:37337612	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs4969487	ENSG00000276846.1	CTD-3220F14.3	6.53	1.7e-10	9.14e-08	0.41	0.29	Coronary artery calcification;	chr19:37340137	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs28402338	ENSG00000276846.1	CTD-3220F14.3	6.53	1.7e-10	9.14e-08	0.41	0.29	Coronary artery calcification;	chr19:37343021	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs10424574	ENSG00000276846.1	CTD-3220F14.3	6.53	1.7e-10	9.14e-08	0.41	0.29	Coronary artery calcification;	chr19:37347491	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs10417503	ENSG00000276846.1	CTD-3220F14.3	6.53	1.7e-10	9.14e-08	0.41	0.29	Coronary artery calcification;	chr19:37351833	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs10403613	ENSG00000276846.1	CTD-3220F14.3	6.53	1.7e-10	9.14e-08	0.41	0.29	Coronary artery calcification;	chr19:37353404	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs9304566	ENSG00000276846.1	CTD-3220F14.3	6.53	1.7e-10	9.14e-08	0.41	0.29	Coronary artery calcification;	chr19:37354602	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs10422967	ENSG00000276846.1	CTD-3220F14.3	6.53	1.7e-10	9.14e-08	0.41	0.29	Coronary artery calcification;	chr19:37359235	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs4417644	ENSG00000276846.1	CTD-3220F14.3	6.53	1.7e-10	9.14e-08	0.41	0.29	Coronary artery calcification;	chr19:37361570	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs10405064	ENSG00000276846.1	CTD-3220F14.3	6.53	1.7e-10	9.14e-08	0.41	0.29	Coronary artery calcification;	chr19:37370959	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs8111782	ENSG00000276846.1	CTD-3220F14.3	6.53	1.7e-10	9.14e-08	0.41	0.29	Coronary artery calcification;	chr19:37377002	chr19:37314868~37315620:-
LUAD	cis	rs4713118	0.662	rs156744	ENSG00000219392.1	RP1-265C24.5	-6.53	1.7e-10	9.15e-08	-0.39	-0.29	Parkinson's disease;	chr6:27999496	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.662	rs149947	ENSG00000219392.1	RP1-265C24.5	-6.53	1.7e-10	9.15e-08	-0.39	-0.29	Parkinson's disease;	chr6:28004655	chr6:28115628~28116551:+
LUAD	cis	rs7674212	0.507	rs223413	ENSG00000251288.2	RP11-10L12.2	6.53	1.7e-10	9.15e-08	0.35	0.29	Type 2 diabetes;	chr4:102811709	chr4:102751401~102752641:+
LUAD	cis	rs75422866	0.51	rs73104197	ENSG00000280054.1	RP1-197B17.7	6.53	1.7e-10	9.16e-08	0.64	0.29	Pneumonia;	chr12:47717273	chr12:47728151~47730598:-
LUAD	cis	rs77204473	1	rs12287768	ENSG00000254851.1	RP11-109L13.1	6.53	1.71e-10	9.17e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116985606	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs12274771	ENSG00000254851.1	RP11-109L13.1	6.53	1.71e-10	9.17e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116985982	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs12274773	ENSG00000254851.1	RP11-109L13.1	6.53	1.71e-10	9.17e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116985993	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs75212922	ENSG00000254851.1	RP11-109L13.1	6.53	1.71e-10	9.17e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116986276	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs11216217	ENSG00000254851.1	RP11-109L13.1	6.53	1.71e-10	9.17e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116986936	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs11216218	ENSG00000254851.1	RP11-109L13.1	6.53	1.71e-10	9.17e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116991945	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs11216219	ENSG00000254851.1	RP11-109L13.1	6.53	1.71e-10	9.17e-08	0.72	0.29	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116992039	chr11:117135528~117138582:+
LUAD	cis	rs7849270	1	rs7036114	ENSG00000268707.1	RP11-247A12.7	-6.53	1.71e-10	9.18e-08	-0.33	-0.29	Blood metabolite ratios;	chr9:129131127	chr9:129170434~129170940:+
LUAD	cis	rs2337406	0.587	rs10129888	ENSG00000211974.3	IGHV2-70	-6.53	1.71e-10	9.18e-08	-0.36	-0.29	Alzheimer's disease (late onset);	chr14:106647421	chr14:106723574~106724093:-
LUAD	cis	rs4927850	0.958	rs1975582	ENSG00000207650.1	MIR570	6.53	1.71e-10	9.19e-08	0.3	0.29	Pancreatic cancer;	chr3:196024568	chr3:195699401~195699497:+
LUAD	cis	rs7017914	0.905	rs4434651	ENSG00000223220.1	Y_RNA	6.53	1.71e-10	9.21e-08	0.31	0.29	Bone mineral density;	chr8:71034952	chr8:70780914~70781008:-
LUAD	cis	rs4718428	0.705	rs4717331	ENSG00000273142.1	RP11-458F8.4	-6.53	1.72e-10	9.22e-08	-0.21	-0.29	Corneal structure;	chr7:66913899	chr7:66902857~66906297:+
LUAD	cis	rs7646881	0.812	rs73015665	ENSG00000240207.5	RP11-379F4.4	-6.53	1.72e-10	9.23e-08	-0.37	-0.29	Tetralogy of Fallot;	chr3:158736145	chr3:158732263~158784070:+
LUAD	cis	rs755249	0.567	rs66531516	ENSG00000228060.1	RP11-69E11.8	-6.53	1.72e-10	9.23e-08	-0.29	-0.29	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39163390	chr1:39565160~39573203:+
LUAD	cis	rs7811142	1	rs2897358	ENSG00000242294.5	STAG3L5P	6.53	1.72e-10	9.23e-08	0.24	0.29	Platelet count;	chr7:100491017	chr7:100336079~100351900:+
LUAD	cis	rs950169	0.58	rs11630887	ENSG00000259728.4	LINC00933	6.53	1.72e-10	9.23e-08	0.42	0.29	Schizophrenia;	chr15:84649784	chr15:84570649~84580175:+
LUAD	cis	rs2117029	0.586	rs6580701	ENSG00000258017.1	RP11-386G11.10	-6.53	1.72e-10	9.23e-08	-0.35	-0.29	Intelligence (multi-trait analysis);	chr12:49163482	chr12:49127782~49147869:+
LUAD	cis	rs30380	0.69	rs2216752	ENSG00000248734.2	CTD-2260A17.1	-6.53	1.72e-10	9.24e-08	-0.32	-0.29	Cerebrospinal fluid biomarker levels;	chr5:96849764	chr5:96784777~96785999:+
LUAD	cis	rs11907546	1	rs11907546	ENSG00000276073.1	RP5-1125A11.7	-6.53	1.72e-10	9.25e-08	-0.29	-0.29	Cancer (pleiotropy);Cancer;	chr20:34131991	chr20:33985617~33988989:-
LUAD	cis	rs1799949	1	rs11653231	ENSG00000267681.1	CTD-3199J23.6	-6.53	1.72e-10	9.25e-08	-0.33	-0.29	Menopause (age at onset);	chr17:43179443	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs1399323	ENSG00000267681.1	CTD-3199J23.6	-6.53	1.72e-10	9.25e-08	-0.33	-0.29	Menopause (age at onset);	chr17:43180313	chr17:43144956~43145255:+
LUAD	cis	rs1799949	0.93	rs4445938	ENSG00000267681.1	CTD-3199J23.6	-6.53	1.72e-10	9.25e-08	-0.33	-0.29	Menopause (age at onset);	chr17:43185883	chr17:43144956~43145255:+
LUAD	cis	rs2243480	0.803	rs160649	ENSG00000226824.5	RP4-756H11.3	-6.53	1.72e-10	9.25e-08	-0.52	-0.29	Diabetic kidney disease;	chr7:66078212	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs160648	ENSG00000226824.5	RP4-756H11.3	-6.53	1.72e-10	9.25e-08	-0.52	-0.29	Diabetic kidney disease;	chr7:66078397	chr7:66654538~66669855:+
LUAD	cis	rs2117029	0.521	rs2114845	ENSG00000258017.1	RP11-386G11.10	-6.53	1.72e-10	9.26e-08	-0.36	-0.29	Intelligence (multi-trait analysis);	chr12:49164750	chr12:49127782~49147869:+
LUAD	cis	rs11977715	0.538	rs10248407	ENSG00000233942.1	AC004012.1	-6.53	1.72e-10	9.26e-08	-0.35	-0.29	Middle childhood and early adolescence aggressive behavior;	chr7:95499441	chr7:95471835~95473998:+
LUAD	cis	rs12554020	0.892	rs6479483	ENSG00000227603.1	RP11-165J3.6	6.52	1.73e-10	9.31e-08	0.45	0.29	Schizophrenia;	chr9:93441746	chr9:93435332~93437121:-
LUAD	cis	rs9318086	0.935	rs9652080	ENSG00000205861.10	C1QTNF9B-AS1	6.52	1.74e-10	9.32e-08	0.34	0.29	Myopia (pathological);	chr13:23861287	chr13:23888889~23897263:+
LUAD	cis	rs150992	0.632	rs34490	ENSG00000248489.1	CTD-2007H13.3	6.52	1.74e-10	9.33e-08	0.31	0.29	Body mass index;	chr5:98974967	chr5:98929171~98995013:+
LUAD	cis	rs6504622	0.905	rs3851787	ENSG00000262879.4	RP11-156P1.3	6.52	1.74e-10	9.33e-08	0.34	0.29	Orofacial clefts;	chr17:46969616	chr17:46984045~47100323:-
LUAD	cis	rs6921919	1	rs6922111	ENSG00000204709.4	LINC01556	6.52	1.74e-10	9.34e-08	0.41	0.29	Autism spectrum disorder or schizophrenia;	chr6:28357531	chr6:28943877~28944537:+
LUAD	cis	rs9318086	0.935	rs9652081	ENSG00000205861.10	C1QTNF9B-AS1	6.52	1.74e-10	9.35e-08	0.34	0.29	Myopia (pathological);	chr13:23861371	chr13:23888889~23897263:+
LUAD	cis	rs9309473	0.847	rs13538	ENSG00000163016.8	ALMS1P	6.52	1.74e-10	9.35e-08	0.36	0.29	Metabolite levels;	chr2:73641201	chr2:73644919~73685576:+
LUAD	cis	rs17301013	0.507	rs6701534	ENSG00000227373.4	RP11-160H22.5	6.52	1.74e-10	9.35e-08	0.42	0.29	Systemic lupus erythematosus;	chr1:174418612	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs10798312	ENSG00000227373.4	RP11-160H22.5	6.52	1.74e-10	9.35e-08	0.42	0.29	Systemic lupus erythematosus;	chr1:174419089	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs4652422	ENSG00000227373.4	RP11-160H22.5	6.52	1.74e-10	9.35e-08	0.42	0.29	Systemic lupus erythematosus;	chr1:174419501	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs4233181	ENSG00000227373.4	RP11-160H22.5	6.52	1.74e-10	9.35e-08	0.42	0.29	Systemic lupus erythematosus;	chr1:174419697	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs10489258	ENSG00000227373.4	RP11-160H22.5	6.52	1.74e-10	9.35e-08	0.42	0.29	Systemic lupus erythematosus;	chr1:174420447	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs10798313	ENSG00000227373.4	RP11-160H22.5	6.52	1.74e-10	9.35e-08	0.42	0.29	Systemic lupus erythematosus;	chr1:174420995	chr1:174115300~174160004:-
LUAD	cis	rs2367970	0.57	rs7123583	ENSG00000254851.1	RP11-109L13.1	6.52	1.75e-10	9.37e-08	0.4	0.29	HDL cholesterol;	chr11:116729305	chr11:117135528~117138582:+
LUAD	cis	rs881375	1	rs10760121	ENSG00000226752.6	PSMD5-AS1	-6.52	1.75e-10	9.4e-08	-0.31	-0.29	Rheumatoid arthritis;	chr9:120885637	chr9:120824828~120854385:+
LUAD	cis	rs875971	0.545	rs75840613	ENSG00000237310.1	GS1-124K5.4	6.52	1.75e-10	9.4e-08	0.35	0.29	Aortic root size;	chr7:66376399	chr7:66493706~66495474:+
LUAD	cis	rs7626444	0.625	rs2686595	ENSG00000272359.1	U4	-6.52	1.75e-10	9.4e-08	-0.31	-0.29	Monocyte count;	chr3:196748271	chr3:196747192~196747324:-
LUAD	cis	rs113835537	0.529	rs11824771	ENSG00000255517.5	CTD-3074O7.5	-6.52	1.75e-10	9.4e-08	-0.33	-0.29	Airway imaging phenotypes;	chr11:66495079	chr11:66473490~66480233:-
LUAD	cis	rs9318086	0.904	rs9580769	ENSG00000205861.10	C1QTNF9B-AS1	6.52	1.75e-10	9.41e-08	0.33	0.29	Myopia (pathological);	chr13:23865585	chr13:23888889~23897263:+
LUAD	cis	rs75920871	1	rs11216221	ENSG00000254851.1	RP11-109L13.1	6.52	1.75e-10	9.41e-08	0.72	0.29	Subjective well-being;	chr11:116997421	chr11:117135528~117138582:+
LUAD	cis	rs2303759	0.918	rs2288480	ENSG00000268686.1	AC010524.2	-6.52	1.76e-10	9.42e-08	-0.4	-0.29	Multiple sclerosis;	chr19:49363759	chr19:49368705~49388081:-
LUAD	cis	rs2303759	1	rs2303759	ENSG00000268686.1	AC010524.2	-6.52	1.76e-10	9.42e-08	-0.4	-0.29	Multiple sclerosis;	chr19:49365794	chr19:49368705~49388081:-
LUAD	cis	rs2404602	0.735	rs437131	ENSG00000259422.1	RP11-593F23.1	6.52	1.76e-10	9.43e-08	0.36	0.29	Blood metabolite levels;	chr15:76488710	chr15:76174891~76181486:-
LUAD	cis	rs2739330	0.828	rs2330635	ENSG00000228039.3	KB-1125A3.10	6.52	1.76e-10	9.44e-08	0.35	0.29	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23963780~23964374:+
LUAD	cis	rs881375	0.933	rs7021206	ENSG00000226752.6	PSMD5-AS1	6.52	1.76e-10	9.45e-08	0.31	0.29	Rheumatoid arthritis;	chr9:120921879	chr9:120824828~120854385:+
LUAD	cis	rs944289	0.562	rs860200	ENSG00000257826.1	RP11-116N8.4	-6.52	1.77e-10	9.47e-08	-0.3	-0.29	Thyroid cancer;	chr14:36057079	chr14:36061026~36067190:-
LUAD	cis	rs7811142	1	rs74460138	ENSG00000242294.5	STAG3L5P	6.52	1.77e-10	9.47e-08	0.24	0.29	Platelet count;	chr7:100429716	chr7:100336079~100351900:+
LUAD	cis	rs7811142	1	rs4989959	ENSG00000242294.5	STAG3L5P	6.52	1.77e-10	9.47e-08	0.24	0.29	Platelet count;	chr7:100434665	chr7:100336079~100351900:+
LUAD	cis	rs465969	1	rs17090837	ENSG00000255389.1	C6orf3	-6.52	1.77e-10	9.5e-08	-0.62	-0.28	Psoriasis;	chr6:111430650	chr6:111599875~111602295:+
LUAD	cis	rs465969	1	rs35208445	ENSG00000255389.1	C6orf3	-6.52	1.77e-10	9.5e-08	-0.62	-0.28	Psoriasis;	chr6:111434944	chr6:111599875~111602295:+
LUAD	cis	rs465969	1	rs35248830	ENSG00000255389.1	C6orf3	-6.52	1.77e-10	9.5e-08	-0.62	-0.28	Psoriasis;	chr6:111435547	chr6:111599875~111602295:+
LUAD	cis	rs465969	1	rs35151650	ENSG00000255389.1	C6orf3	-6.52	1.77e-10	9.5e-08	-0.62	-0.28	Psoriasis;	chr6:111436524	chr6:111599875~111602295:+
LUAD	cis	rs465969	0.744	rs34089926	ENSG00000255389.1	C6orf3	-6.52	1.77e-10	9.5e-08	-0.62	-0.28	Psoriasis;	chr6:111439043	chr6:111599875~111602295:+
LUAD	cis	rs465969	1	rs4580915	ENSG00000255389.1	C6orf3	-6.52	1.77e-10	9.5e-08	-0.62	-0.28	Psoriasis;	chr6:111439561	chr6:111599875~111602295:+
LUAD	cis	rs2134046	0.587	rs11854289	ENSG00000278603.1	RP13-608F4.5	-6.52	1.77e-10	9.5e-08	-0.33	-0.28	Cognitive ability;	chr15:82266461	chr15:82472203~82472426:+
LUAD	cis	rs1799949	0.965	rs11651623	ENSG00000267681.1	CTD-3199J23.6	-6.52	1.77e-10	9.51e-08	-0.33	-0.28	Menopause (age at onset);	chr17:43177830	chr17:43144956~43145255:+
LUAD	cis	rs891378	0.675	rs7543002	ENSG00000274245.1	RP11-357P18.2	-6.52	1.77e-10	9.51e-08	-0.36	-0.28	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207205496	chr1:207372559~207373252:+
LUAD	cis	rs891378	0.785	rs7554219	ENSG00000274245.1	RP11-357P18.2	-6.52	1.77e-10	9.51e-08	-0.36	-0.28	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207205712	chr1:207372559~207373252:+
LUAD	cis	rs9309473	0.95	rs7596773	ENSG00000163016.8	ALMS1P	6.52	1.78e-10	9.53e-08	0.36	0.28	Metabolite levels;	chr2:73618873	chr2:73644919~73685576:+
LUAD	cis	rs9549367	0.826	rs35306827	ENSG00000269125.1	RP11-98F14.11	-6.52	1.78e-10	9.55e-08	-0.36	-0.28	Platelet distribution width;	chr13:113214731	chr13:113165002~113165183:-
LUAD	cis	rs8072100	0.84	rs9895746	ENSG00000228782.6	CTD-2026D20.3	6.52	1.79e-10	9.56e-08	0.31	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47401733	chr17:47450568~47492492:-
LUAD	cis	rs8062405	0.54	rs480400	ENSG00000259982.1	CDC37P1	6.52	1.79e-10	9.58e-08	0.34	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28563294	chr16:28700294~28701540:-
LUAD	cis	rs7246657	0.882	rs59224125	ENSG00000276846.1	CTD-3220F14.3	6.52	1.79e-10	9.61e-08	0.38	0.28	Coronary artery calcification;	chr19:37472303	chr19:37314868~37315620:-
LUAD	cis	rs2404602	0.598	rs11634019	ENSG00000259422.1	RP11-593F23.1	-6.52	1.8e-10	9.62e-08	-0.39	-0.28	Blood metabolite levels;	chr15:76342339	chr15:76174891~76181486:-
LUAD	cis	rs7246657	0.551	rs10419174	ENSG00000276846.1	CTD-3220F14.3	6.52	1.8e-10	9.62e-08	0.43	0.28	Coronary artery calcification;	chr19:37114439	chr19:37314868~37315620:-
LUAD	cis	rs1061377	1	rs9996285	ENSG00000249685.1	RP11-360F5.3	6.52	1.8e-10	9.62e-08	0.34	0.28	Uric acid levels;	chr4:39130556	chr4:39133913~39135608:+
LUAD	cis	rs1167827	0.68	rs1167800	ENSG00000278416.1	PMS2L2	6.52	1.8e-10	9.63e-08	0.37	0.28	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75546898	chr7:75344015~75359550:-
LUAD	cis	rs881375	0.934	rs1468671	ENSG00000226752.6	PSMD5-AS1	-6.52	1.8e-10	9.65e-08	-0.31	-0.28	Rheumatoid arthritis;	chr9:120895224	chr9:120824828~120854385:+
LUAD	cis	rs17684571	1	rs17684571	ENSG00000231441.1	RP11-472M19.2	6.52	1.8e-10	9.65e-08	0.39	0.28	Schizophrenia;	chr6:56710873	chr6:56844002~56864078:+
LUAD	cis	rs891378	0.675	rs6700746	ENSG00000274245.1	RP11-357P18.2	-6.52	1.8e-10	9.65e-08	-0.34	-0.28	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207228666	chr1:207372559~207373252:+
LUAD	cis	rs891378	0.785	rs10864144	ENSG00000274245.1	RP11-357P18.2	-6.52	1.8e-10	9.65e-08	-0.34	-0.28	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207229508	chr1:207372559~207373252:+
LUAD	cis	rs891378	0.785	rs60673767	ENSG00000274245.1	RP11-357P18.2	-6.52	1.8e-10	9.65e-08	-0.34	-0.28	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207230859	chr1:207372559~207373252:+
LUAD	cis	rs891378	0.655	rs1019829	ENSG00000274245.1	RP11-357P18.2	-6.52	1.8e-10	9.65e-08	-0.34	-0.28	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207231786	chr1:207372559~207373252:+
LUAD	cis	rs891378	0.785	rs11120485	ENSG00000274245.1	RP11-357P18.2	-6.52	1.8e-10	9.65e-08	-0.34	-0.28	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207232482	chr1:207372559~207373252:+
LUAD	cis	rs2117029	0.554	rs2334931	ENSG00000258017.1	RP11-386G11.10	-6.52	1.8e-10	9.66e-08	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49174130	chr12:49127782~49147869:+
LUAD	cis	rs2117029	0.586	rs10875929	ENSG00000258017.1	RP11-386G11.10	-6.52	1.8e-10	9.66e-08	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49174605	chr12:49127782~49147869:+
LUAD	cis	rs2117029	0.554	rs2334930	ENSG00000258017.1	RP11-386G11.10	-6.52	1.8e-10	9.66e-08	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49175528	chr12:49127782~49147869:+
LUAD	cis	rs2117029	0.586	rs11168904	ENSG00000258017.1	RP11-386G11.10	-6.52	1.8e-10	9.66e-08	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49177234	chr12:49127782~49147869:+
LUAD	cis	rs2117029	0.586	rs10875931	ENSG00000258017.1	RP11-386G11.10	-6.52	1.8e-10	9.66e-08	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49179513	chr12:49127782~49147869:+
LUAD	cis	rs2117029	0.554	rs7954530	ENSG00000258017.1	RP11-386G11.10	-6.52	1.8e-10	9.66e-08	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49179742	chr12:49127782~49147869:+
LUAD	cis	rs2117029	0.586	rs7957998	ENSG00000258017.1	RP11-386G11.10	-6.52	1.8e-10	9.66e-08	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49180240	chr12:49127782~49147869:+
LUAD	cis	rs2117029	0.553	rs11168909	ENSG00000258017.1	RP11-386G11.10	-6.52	1.8e-10	9.66e-08	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49183092	chr12:49127782~49147869:+
LUAD	cis	rs7115242	0.8	rs493134	ENSG00000280143.1	AP000892.6	6.52	1.81e-10	9.66e-08	0.44	0.28	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116962963	chr11:117204967~117210292:+
LUAD	cis	rs891378	0.727	rs7513914	ENSG00000274245.1	RP11-357P18.2	-6.52	1.81e-10	9.67e-08	-0.34	-0.28	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207236087	chr1:207372559~207373252:+
LUAD	cis	rs11096990	0.927	rs56009503	ENSG00000249207.1	RP11-360F5.1	6.52	1.81e-10	9.67e-08	0.32	0.28	Cognitive function;	chr4:39242642	chr4:39112677~39126818:-
LUAD	cis	rs4713118	0.955	rs9468206	ENSG00000219392.1	RP1-265C24.5	-6.52	1.81e-10	9.67e-08	-0.39	-0.28	Parkinson's disease;	chr6:27722674	chr6:28115628~28116551:+
LUAD	cis	rs17301013	0.507	rs4652460	ENSG00000227373.4	RP11-160H22.5	6.52	1.81e-10	9.69e-08	0.4	0.28	Systemic lupus erythematosus;	chr1:174459499	chr1:174115300~174160004:-
LUAD	cis	rs9549367	0.713	rs3024769	ENSG00000269125.1	RP11-98F14.11	6.52	1.81e-10	9.69e-08	0.37	0.28	Platelet distribution width;	chr13:113171287	chr13:113165002~113165183:-
LUAD	cis	rs1799949	0.93	rs35292991	ENSG00000267681.1	CTD-3199J23.6	-6.52	1.81e-10	9.69e-08	-0.33	-0.28	Menopause (age at onset);	chr17:43181999	chr17:43144956~43145255:+
LUAD	cis	rs494459	0.504	rs7929520	ENSG00000255422.1	AP002954.4	-6.52	1.81e-10	9.69e-08	-0.35	-0.28	Height;	chr11:118859432	chr11:118704607~118750263:+
LUAD	cis	rs11977715	0.521	rs6465466	ENSG00000233942.1	AC004012.1	-6.52	1.82e-10	9.71e-08	-0.35	-0.28	Middle childhood and early adolescence aggressive behavior;	chr7:95502275	chr7:95471835~95473998:+
LUAD	cis	rs8177876	0.915	rs1563072	ENSG00000261838.4	RP11-303E16.6	-6.52	1.82e-10	9.71e-08	-0.63	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81095811	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.841	rs874437	ENSG00000261838.4	RP11-303E16.6	-6.52	1.82e-10	9.71e-08	-0.63	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81095890	chr16:81069854~81076598:+
LUAD	cis	rs8177376	0.953	rs4935964	ENSG00000254905.1	RP11-712L6.7	6.52	1.82e-10	9.72e-08	0.4	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126285289	chr11:126292922~126294254:-
LUAD	cis	rs11096990	0.964	rs7687651	ENSG00000249207.1	RP11-360F5.1	6.52	1.82e-10	9.73e-08	0.32	0.28	Cognitive function;	chr4:39243072	chr4:39112677~39126818:-
LUAD	cis	rs875971	0.545	rs4718348	ENSG00000226824.5	RP4-756H11.3	-6.52	1.82e-10	9.73e-08	-0.43	-0.28	Aortic root size;	chr7:66441589	chr7:66654538~66669855:+
LUAD	cis	rs2439831	0.867	rs3101443	ENSG00000205771.5	CATSPER2P1	-6.52	1.82e-10	9.74e-08	-0.52	-0.28	Lung cancer in ever smokers;	chr15:43620174	chr15:43726918~43747094:-
LUAD	cis	rs17301013	0.507	rs34409674	ENSG00000227373.4	RP11-160H22.5	-6.52	1.83e-10	9.75e-08	-0.44	-0.28	Systemic lupus erythematosus;	chr1:174560246	chr1:174115300~174160004:-
LUAD	cis	rs2739330	0.828	rs5751770	ENSG00000206090.4	AP000350.7	6.52	1.83e-10	9.76e-08	0.32	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23939998~23942798:+
LUAD	cis	rs2439831	0.85	rs12442297	ENSG00000205771.5	CATSPER2P1	-6.52	1.83e-10	9.76e-08	-0.59	-0.28	Lung cancer in ever smokers;	chr15:43876272	chr15:43726918~43747094:-
LUAD	cis	rs6844153	0.887	rs60890366	ENSG00000240005.4	RP11-293A21.1	-6.52	1.83e-10	9.78e-08	-0.45	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26938615	chr4:26859806~26860599:-
LUAD	cis	rs1823913	0.637	rs4853569	ENSG00000280083.1	RP11-317J9.1	6.52	1.83e-10	9.79e-08	0.34	0.28	Obesity-related traits;	chr2:191266970	chr2:191154118~191156070:-
LUAD	cis	rs853679	0.55	rs1233701	ENSG00000219392.1	RP1-265C24.5	6.52	1.83e-10	9.8e-08	0.39	0.28	Depression;	chr6:28200948	chr6:28115628~28116551:+
LUAD	cis	rs11098499	0.566	rs17051356	ENSG00000248280.1	RP11-33B1.2	6.52	1.84e-10	9.81e-08	0.37	0.28	Corneal astigmatism;	chr4:119664153	chr4:119440561~119450157:-
LUAD	cis	rs7927592	0.956	rs10896341	ENSG00000212093.1	AP000807.1	6.51	1.84e-10	9.81e-08	0.32	0.28	Total body bone mineral density;	chr11:68545712	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs67947146	ENSG00000212093.1	AP000807.1	6.51	1.84e-10	9.81e-08	0.32	0.28	Total body bone mineral density;	chr11:68547512	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs7104345	ENSG00000212093.1	AP000807.1	6.51	1.84e-10	9.81e-08	0.32	0.28	Total body bone mineral density;	chr11:68549304	chr11:68506083~68506166:-
LUAD	cis	rs881375	0.967	rs7034653	ENSG00000226752.6	PSMD5-AS1	-6.51	1.84e-10	9.82e-08	-0.3	-0.28	Rheumatoid arthritis;	chr9:120925094	chr9:120824828~120854385:+
LUAD	cis	rs67311347	1	rs9854493	ENSG00000223797.4	ENTPD3-AS1	6.51	1.84e-10	9.82e-08	0.31	0.28	Renal cell carcinoma;	chr3:40382131	chr3:40313802~40453329:-
LUAD	cis	rs2243480	1	rs781156	ENSG00000232546.1	RP11-458F8.1	-6.51	1.84e-10	9.83e-08	-0.37	-0.28	Diabetic kidney disease;	chr7:66014154	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs781149	ENSG00000232546.1	RP11-458F8.1	-6.51	1.84e-10	9.83e-08	-0.37	-0.28	Diabetic kidney disease;	chr7:66016297	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs451396	ENSG00000232546.1	RP11-458F8.1	-6.51	1.84e-10	9.83e-08	-0.37	-0.28	Diabetic kidney disease;	chr7:66019087	chr7:66848496~66858136:+
LUAD	cis	rs2243480	0.901	rs58207111	ENSG00000232546.1	RP11-458F8.1	-6.51	1.84e-10	9.83e-08	-0.37	-0.28	Diabetic kidney disease;	chr7:66021736	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs1167613	ENSG00000232546.1	RP11-458F8.1	-6.51	1.84e-10	9.83e-08	-0.37	-0.28	Diabetic kidney disease;	chr7:66022452	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs1715235	ENSG00000232546.1	RP11-458F8.1	-6.51	1.84e-10	9.83e-08	-0.37	-0.28	Diabetic kidney disease;	chr7:66023407	chr7:66848496~66858136:+
LUAD	cis	rs7017914	0.935	rs56289931	ENSG00000223220.1	Y_RNA	6.51	1.84e-10	9.83e-08	0.32	0.28	Bone mineral density;	chr8:70925519	chr8:70780914~70781008:-
LUAD	cis	rs875971	0.545	rs4441996	ENSG00000237310.1	GS1-124K5.4	-6.51	1.84e-10	9.83e-08	-0.35	-0.28	Aortic root size;	chr7:66123233	chr7:66493706~66495474:+
LUAD	cis	rs7829975	0.688	rs7837587	ENSG00000253893.2	FAM85B	-6.51	1.84e-10	9.83e-08	-0.36	-0.28	Mood instability;	chr8:8521482	chr8:8167819~8226614:-
LUAD	cis	rs7246657	1	rs7246657	ENSG00000276846.1	CTD-3220F14.3	-6.51	1.84e-10	9.84e-08	-0.4	-0.28	Coronary artery calcification;	chr19:37256206	chr19:37314868~37315620:-
LUAD	cis	rs494459	0.536	rs10790267	ENSG00000255422.1	AP002954.4	-6.51	1.84e-10	9.85e-08	-0.35	-0.28	Height;	chr11:118856460	chr11:118704607~118750263:+
LUAD	cis	rs494459	0.536	rs11217067	ENSG00000255422.1	AP002954.4	-6.51	1.84e-10	9.85e-08	-0.35	-0.28	Height;	chr11:118856623	chr11:118704607~118750263:+
LUAD	cis	rs2510897	0.675	rs4936442	ENSG00000255422.1	AP002954.4	-6.51	1.84e-10	9.85e-08	-0.35	-0.28	Height;	chr11:118857611	chr11:118704607~118750263:+
LUAD	cis	rs801193	0.66	rs2659914	ENSG00000222364.1	RNU6-96P	-6.51	1.85e-10	9.85e-08	-0.32	-0.28	Aortic root size;	chr7:66691927	chr7:66395191~66395286:+
LUAD	cis	rs9595908	0.869	rs7337687	ENSG00000212293.1	SNORA16	-6.51	1.85e-10	9.86e-08	-0.3	-0.28	Body mass index;	chr13:32595560	chr13:32420390~32420516:-
LUAD	cis	rs2243480	1	rs781157	ENSG00000232546.1	RP11-458F8.1	-6.51	1.85e-10	9.86e-08	-0.37	-0.28	Diabetic kidney disease;	chr7:66013324	chr7:66848496~66858136:+
LUAD	cis	rs35955747	0.869	rs5753576	ENSG00000236132.1	CTA-440B3.1	-6.51	1.85e-10	9.87e-08	-0.31	-0.28	Neutrophil count;Sum basophil neutrophil counts;	chr22:31361749	chr22:31816379~31817491:-
LUAD	cis	rs77204473	0.744	rs12281009	ENSG00000254851.1	RP11-109L13.1	6.51	1.86e-10	9.9e-08	0.64	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117162243	chr11:117135528~117138582:+
LUAD	cis	rs13030978	0.505	rs72916554	ENSG00000227542.1	AC092614.2	6.51	1.86e-10	9.9e-08	0.36	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr2:191330532	chr2:191229165~191246172:-
LUAD	cis	rs2842992	0.673	rs6930904	ENSG00000237927.1	RP3-393E18.2	-6.51	1.86e-10	9.94e-08	-0.41	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159796401	chr6:159586955~159589169:-
LUAD	cis	rs12220777	0.748	rs7920814	ENSG00000230091.5	TMEM254-AS1	6.51	1.86e-10	9.95e-08	0.5	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80095713	chr10:80046860~80078912:-
LUAD	cis	rs6504622	0.818	rs28451958	ENSG00000262879.4	RP11-156P1.3	6.51	1.86e-10	9.95e-08	0.34	0.28	Orofacial clefts;	chr17:46968528	chr17:46984045~47100323:-
LUAD	cis	rs4141404	0.851	rs5997893	ENSG00000236132.1	CTA-440B3.1	6.51	1.87e-10	9.95e-08	0.34	0.28	Paclitaxel-induced neuropathy;	chr22:31160117	chr22:31816379~31817491:-
LUAD	cis	rs75422866	0.51	rs73105812	ENSG00000280054.1	RP1-197B17.7	6.51	1.87e-10	9.97e-08	0.64	0.28	Pneumonia;	chr12:47724404	chr12:47728151~47730598:-
LUAD	cis	rs2117029	0.521	rs7953169	ENSG00000258017.1	RP11-386G11.10	-6.51	1.87e-10	9.99e-08	-0.36	-0.28	Intelligence (multi-trait analysis);	chr12:49184389	chr12:49127782~49147869:+
LUAD	cis	rs34526934	0.566	rs34028621	ENSG00000226363.3	HAGLROS	6.51	1.88e-10	1e-07	0.39	0.28	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176178051	chr2:176177717~176179008:+
LUAD	cis	rs8091660	0.862	rs12607412	ENSG00000278983.1	RP11-426J5.3	6.51	1.88e-10	1e-07	0.34	0.28	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48545949	chr18:48564795~48568342:+
LUAD	cis	rs11603023	0.874	rs613243	ENSG00000255422.1	AP002954.4	-6.51	1.88e-10	1e-07	-0.34	-0.28	Cholesterol, total;	chr11:118643304	chr11:118704607~118750263:+
LUAD	cis	rs4718428	0.705	rs4717328	ENSG00000273142.1	RP11-458F8.4	-6.51	1.88e-10	1e-07	-0.21	-0.28	Corneal structure;	chr7:66887678	chr7:66902857~66906297:+
LUAD	cis	rs9309473	0.948	rs10183818	ENSG00000163016.8	ALMS1P	6.51	1.88e-10	1e-07	0.36	0.28	Metabolite levels;	chr2:73487429	chr2:73644919~73685576:+
LUAD	cis	rs1799949	0.965	rs11650132	ENSG00000267681.1	CTD-3199J23.6	-6.51	1.88e-10	1e-07	-0.33	-0.28	Menopause (age at onset);	chr17:43174070	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs11654731	ENSG00000267681.1	CTD-3199J23.6	-6.51	1.88e-10	1e-07	-0.33	-0.28	Menopause (age at onset);	chr17:43174923	chr17:43144956~43145255:+
LUAD	cis	rs1075265	0.68	rs6715488	ENSG00000233266.1	HMGB1P31	6.51	1.88e-10	1e-07	0.36	0.28	Chronotype;Morning vs. evening chronotype;	chr2:54004130	chr2:54051334~54051760:+
LUAD	cis	rs9309473	1	rs10169714	ENSG00000163016.8	ALMS1P	6.51	1.88e-10	1e-07	0.35	0.28	Metabolite levels;	chr2:73581646	chr2:73644919~73685576:+
LUAD	cis	rs9309473	1	rs7558944	ENSG00000163016.8	ALMS1P	6.51	1.88e-10	1e-07	0.35	0.28	Metabolite levels;	chr2:73583782	chr2:73644919~73685576:+
LUAD	cis	rs11118620	0.81	rs4587570	ENSG00000257551.1	HLX-AS1	6.51	1.9e-10	1.01e-07	0.35	0.28	Heart failure;	chr1:220860693	chr1:220832763~220880140:-
LUAD	cis	rs11214589	0.774	rs10891544	ENSG00000270179.1	RP11-159N11.4	6.51	1.9e-10	1.01e-07	0.28	0.28	Neuroticism;	chr11:113385430	chr11:113368478~113369117:+
LUAD	cis	rs2243480	0.908	rs313822	ENSG00000226824.5	RP4-756H11.3	-6.51	1.9e-10	1.01e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:66108952	chr7:66654538~66669855:+
LUAD	cis	rs11096990	0.964	rs6831700	ENSG00000249207.1	RP11-360F5.1	-6.51	1.9e-10	1.01e-07	-0.31	-0.28	Cognitive function;	chr4:39255344	chr4:39112677~39126818:-
LUAD	cis	rs1707322	0.685	rs11211177	ENSG00000234329.1	RP11-767N6.2	6.51	1.91e-10	1.02e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760677	chr1:45651039~45651826:-
LUAD	cis	rs7829975	0.623	rs7010753	ENSG00000253981.4	ALG1L13P	6.51	1.91e-10	1.02e-07	0.34	0.28	Mood instability;	chr8:8516446	chr8:8236003~8244667:-
LUAD	cis	rs11846409	0.932	rs61233250	ENSG00000211974.3	IGHV2-70	-6.51	1.91e-10	1.02e-07	-0.35	-0.28	Rheumatic heart disease;	chr14:106634072	chr14:106723574~106724093:-
LUAD	cis	rs62025270	0.522	rs338519	ENSG00000202081.1	RNU6-1280P	-6.51	1.91e-10	1.02e-07	-0.35	-0.28	Idiopathic pulmonary fibrosis;	chr15:85671648	chr15:85651522~85651628:-
LUAD	cis	rs875971	1	rs778726	ENSG00000222364.1	RNU6-96P	-6.51	1.91e-10	1.02e-07	-0.32	-0.28	Aortic root size;	chr7:66363744	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.964	rs778723	ENSG00000222364.1	RNU6-96P	-6.51	1.91e-10	1.02e-07	-0.32	-0.28	Aortic root size;	chr7:66364510	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.767	rs1695815	ENSG00000222364.1	RNU6-96P	-6.51	1.91e-10	1.02e-07	-0.32	-0.28	Aortic root size;	chr7:66366357	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs778685	ENSG00000222364.1	RNU6-96P	-6.51	1.91e-10	1.02e-07	-0.32	-0.28	Aortic root size;	chr7:66371189	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.929	rs778682	ENSG00000222364.1	RNU6-96P	-6.51	1.91e-10	1.02e-07	-0.32	-0.28	Aortic root size;	chr7:66372947	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.964	rs11765965	ENSG00000222364.1	RNU6-96P	-6.51	1.91e-10	1.02e-07	-0.32	-0.28	Aortic root size;	chr7:66377234	chr7:66395191~66395286:+
LUAD	cis	rs150992	0.609	rs709390	ENSG00000248489.1	CTD-2007H13.3	6.51	1.91e-10	1.02e-07	0.32	0.28	Body mass index;	chr5:98993771	chr5:98929171~98995013:+
LUAD	cis	rs67311347	1	rs4973898	ENSG00000223797.4	ENTPD3-AS1	-6.51	1.91e-10	1.02e-07	-0.29	-0.28	Renal cell carcinoma;	chr3:40418041	chr3:40313802~40453329:-
LUAD	cis	rs2243480	1	rs1723270	ENSG00000226824.5	RP4-756H11.3	-6.51	1.91e-10	1.02e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:66004843	chr7:66654538~66669855:+
LUAD	cis	rs891378	0.785	rs1896956	ENSG00000274245.1	RP11-357P18.2	-6.51	1.91e-10	1.02e-07	-0.34	-0.28	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207236302	chr1:207372559~207373252:+
LUAD	cis	rs516805	0.847	rs520867	ENSG00000279453.1	RP3-425C14.4	-6.51	1.91e-10	1.02e-07	-0.32	-0.28	Lymphocyte counts;	chr6:122465501	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.961	rs693669	ENSG00000279453.1	RP3-425C14.4	-6.51	1.91e-10	1.02e-07	-0.32	-0.28	Lymphocyte counts;	chr6:122465690	chr6:122436789~122439223:-
LUAD	cis	rs1823913	0.599	rs1378155	ENSG00000280083.1	RP11-317J9.1	-6.51	1.91e-10	1.02e-07	-0.34	-0.28	Obesity-related traits;	chr2:191266610	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.576	rs13011608	ENSG00000280083.1	RP11-317J9.1	-6.51	1.91e-10	1.02e-07	-0.34	-0.28	Obesity-related traits;	chr2:191267097	chr2:191154118~191156070:-
LUAD	cis	rs17301013	0.507	rs926349	ENSG00000227373.4	RP11-160H22.5	6.51	1.91e-10	1.02e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174368408	chr1:174115300~174160004:-
LUAD	cis	rs950169	0.58	rs11636189	ENSG00000259728.4	LINC00933	6.51	1.91e-10	1.02e-07	0.42	0.28	Schizophrenia;	chr15:84650323	chr15:84570649~84580175:+
LUAD	cis	rs2439831	0.85	rs8042868	ENSG00000205771.5	CATSPER2P1	-6.51	1.91e-10	1.02e-07	-0.57	-0.28	Lung cancer in ever smokers;	chr15:43647444	chr15:43726918~43747094:-
LUAD	cis	rs2455601	0.679	rs2653559	ENSG00000254860.4	TMEM9B-AS1	6.51	1.92e-10	1.02e-07	0.42	0.28	Schizophrenia;	chr11:8878847	chr11:8964675~8977527:+
LUAD	cis	rs10129255	0.5	rs2105989	ENSG00000224373.3	IGHV4-59	6.51	1.92e-10	1.02e-07	0.17	0.28	Kawasaki disease;	chr14:106682199	chr14:106627249~106627825:-
LUAD	cis	rs7927592	0.871	rs113020558	ENSG00000212093.1	AP000807.1	6.51	1.92e-10	1.02e-07	0.32	0.28	Total body bone mineral density;	chr11:68529364	chr11:68506083~68506166:-
LUAD	cis	rs2243480	0.901	rs12530490	ENSG00000226824.5	RP4-756H11.3	6.51	1.92e-10	1.02e-07	0.54	0.28	Diabetic kidney disease;	chr7:66226660	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs7778911	ENSG00000226824.5	RP4-756H11.3	6.51	1.92e-10	1.02e-07	0.54	0.28	Diabetic kidney disease;	chr7:66229519	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs1979823	ENSG00000226824.5	RP4-756H11.3	6.51	1.92e-10	1.02e-07	0.54	0.28	Diabetic kidney disease;	chr7:66239626	chr7:66654538~66669855:+
LUAD	cis	rs9640161	0.659	rs7806429	ENSG00000261305.1	RP4-584D14.7	6.51	1.92e-10	1.02e-07	0.4	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150316304	chr7:150341771~150342607:+
LUAD	cis	rs6860806	0.507	rs582490	ENSG00000233006.5	AC034220.3	-6.51	1.92e-10	1.02e-07	-0.29	-0.28	Breast cancer;	chr5:132374403	chr5:132311285~132369916:-
LUAD	cis	rs274567	0.501	rs581968	ENSG00000233006.5	AC034220.3	-6.51	1.92e-10	1.02e-07	-0.29	-0.28	Blood metabolite levels;	chr5:132374510	chr5:132311285~132369916:-
LUAD	cis	rs6860806	0.507	rs274572	ENSG00000233006.5	AC034220.3	-6.51	1.92e-10	1.02e-07	-0.29	-0.28	Breast cancer;	chr5:132375225	chr5:132311285~132369916:-
LUAD	cis	rs274567	0.501	rs274571	ENSG00000233006.5	AC034220.3	-6.51	1.92e-10	1.02e-07	-0.29	-0.28	Blood metabolite levels;	chr5:132376433	chr5:132311285~132369916:-
LUAD	cis	rs2439831	0.85	rs11856795	ENSG00000205771.5	CATSPER2P1	-6.51	1.93e-10	1.03e-07	-0.58	-0.28	Lung cancer in ever smokers;	chr15:43868384	chr15:43726918~43747094:-
LUAD	cis	rs10740039	0.846	rs10761529	ENSG00000254271.1	RP11-131N11.4	6.51	1.93e-10	1.03e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60627052	chr10:60734342~60741828:+
LUAD	cis	rs7246657	0.524	rs28542490	ENSG00000276846.1	CTD-3220F14.3	6.51	1.93e-10	1.03e-07	0.4	0.28	Coronary artery calcification;	chr19:36965682	chr19:37314868~37315620:-
LUAD	cis	rs17711722	0.51	rs11767457	ENSG00000226824.5	RP4-756H11.3	-6.51	1.93e-10	1.03e-07	-0.36	-0.28	Calcium levels;	chr7:65825628	chr7:66654538~66669855:+
LUAD	cis	rs7246657	0.509	rs10426093	ENSG00000276846.1	CTD-3220F14.3	6.51	1.93e-10	1.03e-07	0.43	0.28	Coronary artery calcification;	chr19:37124727	chr19:37314868~37315620:-
LUAD	cis	rs2243480	1	rs160646	ENSG00000273142.1	RP11-458F8.4	-6.51	1.93e-10	1.03e-07	-0.29	-0.28	Diabetic kidney disease;	chr7:66091293	chr7:66902857~66906297:+
LUAD	cis	rs73219805	0.597	rs3824232	ENSG00000228451.3	SDAD1P1	-6.51	1.93e-10	1.03e-07	-0.48	-0.28	Schizophrenia;	chr8:26370083	chr8:26379259~26382953:-
LUAD	cis	rs2243480	1	rs465359	ENSG00000273142.1	RP11-458F8.4	-6.51	1.93e-10	1.03e-07	-0.29	-0.28	Diabetic kidney disease;	chr7:66093177	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs462853	ENSG00000273142.1	RP11-458F8.4	-6.51	1.93e-10	1.03e-07	-0.29	-0.28	Diabetic kidney disease;	chr7:66093180	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs160644	ENSG00000273142.1	RP11-458F8.4	-6.51	1.93e-10	1.03e-07	-0.29	-0.28	Diabetic kidney disease;	chr7:66093199	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs160642	ENSG00000273142.1	RP11-458F8.4	-6.51	1.93e-10	1.03e-07	-0.29	-0.28	Diabetic kidney disease;	chr7:66093386	chr7:66902857~66906297:+
LUAD	cis	rs2243480	0.614	rs34032527	ENSG00000273142.1	RP11-458F8.4	-6.51	1.93e-10	1.03e-07	-0.29	-0.28	Diabetic kidney disease;	chr7:66100154	chr7:66902857~66906297:+
LUAD	cis	rs950169	0.763	rs35372971	ENSG00000259728.4	LINC00933	6.51	1.94e-10	1.03e-07	0.42	0.28	Schizophrenia;	chr15:84387097	chr15:84570649~84580175:+
LUAD	cis	rs2243480	1	rs160655	ENSG00000273142.1	RP11-458F8.4	-6.51	1.94e-10	1.03e-07	-0.28	-0.28	Diabetic kidney disease;	chr7:66068227	chr7:66902857~66906297:+
LUAD	cis	rs1823913	0.637	rs11688994	ENSG00000280083.1	RP11-317J9.1	-6.51	1.94e-10	1.03e-07	-0.33	-0.28	Obesity-related traits;	chr2:191266242	chr2:191154118~191156070:-
LUAD	cis	rs62025270	0.547	rs386346	ENSG00000202081.1	RNU6-1280P	-6.51	1.95e-10	1.04e-07	-0.34	-0.28	Idiopathic pulmonary fibrosis;	chr15:85651328	chr15:85651522~85651628:-
LUAD	cis	rs394563	0.901	rs448874	ENSG00000231760.4	RP11-350J20.5	6.5	1.95e-10	1.04e-07	0.36	0.28	Dupuytren's disease;	chr6:149475831	chr6:149796151~149826294:-
LUAD	cis	rs67311347	0.955	rs12487955	ENSG00000223797.4	ENTPD3-AS1	6.5	1.96e-10	1.04e-07	0.3	0.28	Renal cell carcinoma;	chr3:40371362	chr3:40313802~40453329:-
LUAD	cis	rs9318086	0.712	rs9510917	ENSG00000205861.10	C1QTNF9B-AS1	-6.5	1.96e-10	1.04e-07	-0.34	-0.28	Myopia (pathological);	chr13:23868707	chr13:23888889~23897263:+
LUAD	cis	rs2117029	0.555	rs3741621	ENSG00000258017.1	RP11-386G11.10	-6.5	1.96e-10	1.04e-07	-0.36	-0.28	Intelligence (multi-trait analysis);	chr12:49100242	chr12:49127782~49147869:+
LUAD	cis	rs465969	1	rs34382476	ENSG00000255389.1	C6orf3	-6.5	1.96e-10	1.04e-07	-0.62	-0.28	Psoriasis;	chr6:111423551	chr6:111599875~111602295:+
LUAD	cis	rs9834970	0.588	rs28522146	ENSG00000234073.1	AC011816.1	-6.5	1.96e-10	1.04e-07	-0.31	-0.28	Bipolar disorder with mood-incongruent psychosis;Bipolar disorder;Schizophrenia or bipolar disorder;Subjective response to lithium treatment;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr3:36865331	chr3:36880184~36880729:-
LUAD	cis	rs4713118	0.662	rs149969	ENSG00000219392.1	RP1-265C24.5	-6.5	1.96e-10	1.04e-07	-0.38	-0.28	Parkinson's disease;	chr6:28009959	chr6:28115628~28116551:+
LUAD	cis	rs1823913	1	rs12623832	ENSG00000230611.1	HMGB1P27	6.5	1.96e-10	1.04e-07	0.34	0.28	Obesity-related traits;	chr2:191260918	chr2:191174233~191174835:+
LUAD	cis	rs7246657	0.525	rs10401417	ENSG00000276846.1	CTD-3220F14.3	6.5	1.97e-10	1.05e-07	0.42	0.28	Coronary artery calcification;	chr19:36976638	chr19:37314868~37315620:-
LUAD	cis	rs10740039	0.732	rs10160182	ENSG00000254271.1	RP11-131N11.4	6.5	1.97e-10	1.05e-07	0.33	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60602693	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.768	rs10159993	ENSG00000254271.1	RP11-131N11.4	6.5	1.97e-10	1.05e-07	0.33	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60602788	chr10:60734342~60741828:+
LUAD	cis	rs7567389	0.504	rs2069898	ENSG00000236682.1	AC068282.3	-6.5	1.97e-10	1.05e-07	-0.37	-0.28	Self-rated health;	chr2:127416651	chr2:127389130~127400580:+
LUAD	cis	rs10129255	0.5	rs8006888	ENSG00000224373.3	IGHV4-59	6.5	1.97e-10	1.05e-07	0.17	0.28	Kawasaki disease;	chr14:106782219	chr14:106627249~106627825:-
LUAD	cis	rs10129255	0.536	rs10142951	ENSG00000224373.3	IGHV4-59	6.5	1.97e-10	1.05e-07	0.17	0.28	Kawasaki disease;	chr14:106782337	chr14:106627249~106627825:-
LUAD	cis	rs853679	0.666	rs200956	ENSG00000219392.1	RP1-265C24.5	-6.5	1.97e-10	1.05e-07	-0.42	-0.28	Depression;	chr6:27871968	chr6:28115628~28116551:+
LUAD	cis	rs950169	0.922	rs2033284	ENSG00000259728.4	LINC00933	6.5	1.97e-10	1.05e-07	0.43	0.28	Schizophrenia;	chr15:84391575	chr15:84570649~84580175:+
LUAD	cis	rs881375	0.967	rs7046108	ENSG00000226752.6	PSMD5-AS1	6.5	1.97e-10	1.05e-07	0.31	0.28	Rheumatoid arthritis;	chr9:120898061	chr9:120824828~120854385:+
LUAD	cis	rs12439619	0.846	rs7496227	ENSG00000255769.6	GOLGA2P10	-6.5	1.97e-10	1.05e-07	-0.36	-0.28	Intelligence (multi-trait analysis);	chr15:82275241	chr15:82472993~82513950:-
LUAD	cis	rs7567389	0.502	rs2069919	ENSG00000236682.1	AC068282.3	-6.5	1.97e-10	1.05e-07	-0.37	-0.28	Self-rated health;	chr2:127421977	chr2:127389130~127400580:+
LUAD	cis	rs3002142	0.57	rs3008633	ENSG00000272750.1	RP11-378J18.8	-6.5	1.97e-10	1.05e-07	-0.39	-0.28	LDL peak particle diameter (total fat intake interaction);	chr1:222671498	chr1:222658867~222661512:-
LUAD	cis	rs66887589	0.616	rs13113885	ENSG00000248280.1	RP11-33B1.2	6.5	1.98e-10	1.05e-07	0.32	0.28	Diastolic blood pressure;	chr4:119300021	chr4:119440561~119450157:-
LUAD	cis	rs67311347	1	rs4974017	ENSG00000223797.4	ENTPD3-AS1	6.5	1.98e-10	1.05e-07	0.29	0.28	Renal cell carcinoma;	chr3:40432028	chr3:40313802~40453329:-
LUAD	cis	rs77204473	0.744	rs10892067	ENSG00000254851.1	RP11-109L13.1	6.5	1.98e-10	1.05e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117057046	chr11:117135528~117138582:+
LUAD	cis	rs36229146	1	rs36229146	ENSG00000179428.2	AC073072.5	-6.5	1.99e-10	1.06e-07	-0.35	-0.28	Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr7:22744893	chr7:22725395~22727620:-
LUAD	cis	rs62229266	1	rs62229266	ENSG00000214914.3	RPL23AP3	6.5	1.99e-10	1.06e-07	0.35	0.28	Mitral valve prolapse;	chr21:36087973	chr21:36016079~36016546:-
LUAD	cis	rs6558530	0.965	rs7460287	ENSG00000253982.1	CTD-2336O2.1	6.5	1.99e-10	1.06e-07	0.35	0.28	Systolic blood pressure;	chr8:1760108	chr8:1761990~1764502:-
LUAD	cis	rs891378	0.755	rs1019830	ENSG00000274245.1	RP11-357P18.2	-6.5	1.99e-10	1.06e-07	-0.34	-0.28	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207236817	chr1:207372559~207373252:+
LUAD	cis	rs17301013	0.507	rs1754352	ENSG00000227373.4	RP11-160H22.5	6.5	1.99e-10	1.06e-07	0.42	0.28	Systemic lupus erythematosus;	chr1:174835984	chr1:174115300~174160004:-
LUAD	cis	rs10129255	0.5	rs8022547	ENSG00000224373.3	IGHV4-59	6.5	1.99e-10	1.06e-07	0.17	0.28	Kawasaki disease;	chr14:106781985	chr14:106627249~106627825:-
LUAD	cis	rs7927592	0.871	rs871212	ENSG00000212093.1	AP000807.1	6.5	2e-10	1.06e-07	0.31	0.28	Total body bone mineral density;	chr11:68581227	chr11:68506083~68506166:-
LUAD	cis	rs9309473	0.95	rs10189885	ENSG00000163016.8	ALMS1P	6.5	2e-10	1.06e-07	0.36	0.28	Metabolite levels;	chr2:73649928	chr2:73644919~73685576:+
LUAD	cis	rs7017914	0.967	rs2933853	ENSG00000223220.1	Y_RNA	6.5	2e-10	1.06e-07	0.32	0.28	Bone mineral density;	chr8:70996987	chr8:70780914~70781008:-
LUAD	cis	rs875971	0.545	rs2279757	ENSG00000237310.1	GS1-124K5.4	6.5	2.01e-10	1.07e-07	0.36	0.28	Aortic root size;	chr7:66363676	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs11766183	ENSG00000237310.1	GS1-124K5.4	6.5	2.01e-10	1.07e-07	0.36	0.28	Aortic root size;	chr7:66374173	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs1065265	ENSG00000237310.1	GS1-124K5.4	6.5	2.01e-10	1.07e-07	0.36	0.28	Aortic root size;	chr7:66376216	chr7:66493706~66495474:+
LUAD	cis	rs10129255	0.5	rs7161740	ENSG00000224373.3	IGHV4-59	6.5	2.02e-10	1.07e-07	0.17	0.28	Kawasaki disease;	chr14:106776119	chr14:106627249~106627825:-
LUAD	cis	rs10129255	0.556	rs6576222	ENSG00000224373.3	IGHV4-59	6.5	2.02e-10	1.07e-07	0.17	0.28	Kawasaki disease;	chr14:106776442	chr14:106627249~106627825:-
LUAD	cis	rs10129255	0.536	rs6576223	ENSG00000224373.3	IGHV4-59	6.5	2.02e-10	1.07e-07	0.17	0.28	Kawasaki disease;	chr14:106776448	chr14:106627249~106627825:-
LUAD	cis	rs77204473	1	rs11216199	ENSG00000254851.1	RP11-109L13.1	6.5	2.02e-10	1.07e-07	0.7	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116960300	chr11:117135528~117138582:+
LUAD	cis	rs11846409	0.86	rs17112419	ENSG00000211974.3	IGHV2-70	-6.5	2.02e-10	1.07e-07	-0.35	-0.28	Rheumatic heart disease;	chr14:106633260	chr14:106723574~106724093:-
LUAD	cis	rs6558530	0.965	rs4372027	ENSG00000253982.1	CTD-2336O2.1	6.5	2.03e-10	1.07e-07	0.35	0.28	Systolic blood pressure;	chr8:1759792	chr8:1761990~1764502:-
LUAD	cis	rs6558530	0.932	rs4370560	ENSG00000253982.1	CTD-2336O2.1	6.5	2.03e-10	1.08e-07	0.35	0.28	Systolic blood pressure;	chr8:1760028	chr8:1761990~1764502:-
LUAD	cis	rs7849270	1	rs34055941	ENSG00000268707.1	RP11-247A12.7	-6.5	2.03e-10	1.08e-07	-0.33	-0.28	Blood metabolite ratios;	chr9:129132797	chr9:129170434~129170940:+
LUAD	cis	rs2221433	1	rs4780948	ENSG00000260310.1	RP11-27M24.2	-6.5	2.03e-10	1.08e-07	-0.32	-0.28	Eating disorders;	chr16:10571652	chr16:10576499~10578183:-
LUAD	cis	rs75422866	0.51	rs74733564	ENSG00000280054.1	RP1-197B17.7	6.5	2.04e-10	1.08e-07	0.64	0.28	Pneumonia;	chr12:47724644	chr12:47728151~47730598:-
LUAD	cis	rs75422866	0.51	rs73105814	ENSG00000280054.1	RP1-197B17.7	6.5	2.04e-10	1.08e-07	0.64	0.28	Pneumonia;	chr12:47725817	chr12:47728151~47730598:-
LUAD	cis	rs7727544	0.735	rs273913	ENSG00000233006.5	AC034220.3	6.5	2.04e-10	1.08e-07	0.25	0.28	Blood metabolite levels;	chr5:132325463	chr5:132311285~132369916:-
LUAD	cis	rs7811142	1	rs66632384	ENSG00000242294.5	STAG3L5P	6.5	2.04e-10	1.08e-07	0.24	0.28	Platelet count;	chr7:100421281	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.943	rs73403312	ENSG00000242294.5	STAG3L5P	6.5	2.04e-10	1.08e-07	0.24	0.28	Platelet count;	chr7:100426530	chr7:100336079~100351900:+
LUAD	cis	rs367615	0.68	rs385728	ENSG00000249476.1	CTD-2587M2.1	-6.5	2.04e-10	1.08e-07	-0.36	-0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109630308	chr5:109237120~109326369:-
LUAD	cis	rs11846409	0.932	rs60659763	ENSG00000254174.1	IGHV1-12	6.5	2.05e-10	1.09e-07	0.25	0.28	Rheumatic heart disease;	chr14:106634172	chr14:106122420~106122709:-
LUAD	cis	rs11846409	0.932	rs57080270	ENSG00000254174.1	IGHV1-12	6.5	2.05e-10	1.09e-07	0.25	0.28	Rheumatic heart disease;	chr14:106634215	chr14:106122420~106122709:-
LUAD	cis	rs11846409	0.932	rs60917084	ENSG00000254174.1	IGHV1-12	6.5	2.05e-10	1.09e-07	0.25	0.28	Rheumatic heart disease;	chr14:106634621	chr14:106122420~106122709:-
LUAD	cis	rs11168854	0.595	rs11168857	ENSG00000258017.1	RP11-386G11.10	-6.5	2.06e-10	1.09e-07	-0.36	-0.28	Body mass index;	chr12:49096526	chr12:49127782~49147869:+
LUAD	cis	rs4834770	0.746	rs2389747	ENSG00000245958.5	RP11-33B1.1	-6.5	2.06e-10	1.09e-07	-0.25	-0.28	Blood protein levels;	chr4:119314947	chr4:119454791~119552025:+
LUAD	cis	rs4834770	0.717	rs1022146	ENSG00000245958.5	RP11-33B1.1	-6.5	2.06e-10	1.09e-07	-0.25	-0.28	Blood protein levels;	chr4:119314948	chr4:119454791~119552025:+
LUAD	cis	rs62025270	0.547	rs416916	ENSG00000202081.1	RNU6-1280P	-6.5	2.06e-10	1.09e-07	-0.35	-0.28	Idiopathic pulmonary fibrosis;	chr15:85649185	chr15:85651522~85651628:-
LUAD	cis	rs7615952	0.611	rs2971298	ENSG00000171084.14	FAM86JP	6.5	2.07e-10	1.09e-07	0.46	0.28	Blood pressure (smoking interaction);	chr3:125883870	chr3:125916620~125930024:+
LUAD	cis	rs950169	0.887	rs35986397	ENSG00000259728.4	LINC00933	6.5	2.07e-10	1.09e-07	0.43	0.28	Schizophrenia;	chr15:84400409	chr15:84570649~84580175:+
LUAD	cis	rs2117029	0.521	rs11168885	ENSG00000258017.1	RP11-386G11.10	-6.5	2.07e-10	1.1e-07	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49146204	chr12:49127782~49147869:+
LUAD	cis	rs853679	0.55	rs1150689	ENSG00000219392.1	RP1-265C24.5	-6.5	2.07e-10	1.1e-07	-0.39	-0.28	Depression;	chr6:28197321	chr6:28115628~28116551:+
LUAD	cis	rs9595908	0.931	rs9595630	ENSG00000212293.1	SNORA16	-6.5	2.07e-10	1.1e-07	-0.32	-0.28	Body mass index;	chr13:32491306	chr13:32420390~32420516:-
LUAD	cis	rs9309473	0.95	rs10206899	ENSG00000163016.8	ALMS1P	6.5	2.07e-10	1.1e-07	0.36	0.28	Metabolite levels;	chr2:73673773	chr2:73644919~73685576:+
LUAD	cis	rs9532669	0.926	rs4942007	ENSG00000168852.11	TPTE2P5	6.5	2.07e-10	1.1e-07	0.27	0.28	Cervical cancer;	chr13:40871887	chr13:40822296~40921749:-
LUAD	cis	rs7567389	0.534	rs2069904	ENSG00000236682.1	AC068282.3	-6.49	2.08e-10	1.1e-07	-0.37	-0.28	Self-rated health;	chr2:127418203	chr2:127389130~127400580:+
LUAD	cis	rs1061377	1	rs7685468	ENSG00000249685.1	RP11-360F5.3	6.49	2.08e-10	1.1e-07	0.34	0.28	Uric acid levels;	chr4:39116649	chr4:39133913~39135608:+
LUAD	cis	rs7246657	0.55	rs10411176	ENSG00000276846.1	CTD-3220F14.3	6.49	2.08e-10	1.1e-07	0.46	0.28	Coronary artery calcification;	chr19:37196051	chr19:37314868~37315620:-
LUAD	cis	rs12022452	0.506	rs11208363	ENSG00000238287.1	RP11-656D10.3	-6.49	2.08e-10	1.1e-07	-0.44	-0.28	Age-related hearing impairment (SNP x SNP interaction);	chr1:40544782	chr1:40493157~40508661:-
LUAD	cis	rs72772090	0.539	rs72775810	ENSG00000248734.2	CTD-2260A17.1	-6.49	2.08e-10	1.1e-07	-0.46	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96849604	chr5:96784777~96785999:+
LUAD	cis	rs875971	1	rs7781698	ENSG00000222364.1	RNU6-96P	-6.49	2.08e-10	1.1e-07	-0.32	-0.28	Aortic root size;	chr7:66431325	chr7:66395191~66395286:+
LUAD	cis	rs2739330	0.796	rs2154594	ENSG00000228039.3	KB-1125A3.10	-6.49	2.09e-10	1.11e-07	-0.35	-0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23963780~23964374:+
LUAD	cis	rs875971	1	rs11971949	ENSG00000222364.1	RNU6-96P	6.49	2.09e-10	1.11e-07	0.32	0.28	Aortic root size;	chr7:66161027	chr7:66395191~66395286:+
LUAD	cis	rs8177376	0.861	rs4937119	ENSG00000254905.1	RP11-712L6.7	6.49	2.1e-10	1.11e-07	0.4	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126297825	chr11:126292922~126294254:-
LUAD	cis	rs2243480	1	rs34815098	ENSG00000226824.5	RP4-756H11.3	-6.49	2.1e-10	1.11e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:65827267	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs4548056	ENSG00000226824.5	RP4-756H11.3	-6.49	2.1e-10	1.11e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:65833886	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs7456042	ENSG00000226824.5	RP4-756H11.3	-6.49	2.1e-10	1.11e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:65834791	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs35735127	ENSG00000226824.5	RP4-756H11.3	-6.49	2.1e-10	1.11e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:65835436	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.901	rs35256305	ENSG00000226824.5	RP4-756H11.3	-6.49	2.1e-10	1.11e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:65841418	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs73142121	ENSG00000226824.5	RP4-756H11.3	-6.49	2.1e-10	1.11e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:65846219	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.803	rs34004500	ENSG00000226824.5	RP4-756H11.3	-6.49	2.1e-10	1.11e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:65847191	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs35825738	ENSG00000226824.5	RP4-756H11.3	-6.49	2.1e-10	1.11e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:65853040	chr7:66654538~66669855:+
LUAD	cis	rs7246657	0.943	rs713256	ENSG00000276846.1	CTD-3220F14.3	6.49	2.1e-10	1.11e-07	0.4	0.28	Coronary artery calcification;	chr19:37374463	chr19:37314868~37315620:-
LUAD	cis	rs7674212	0.581	rs11946020	ENSG00000246560.2	RP11-10L12.4	6.49	2.1e-10	1.11e-07	0.37	0.28	Type 2 diabetes;	chr4:103023585	chr4:102828055~102844075:+
LUAD	cis	rs2179367	0.959	rs9373589	ENSG00000231760.4	RP11-350J20.5	6.49	2.1e-10	1.11e-07	0.35	0.28	Dupuytren's disease;	chr6:149386152	chr6:149796151~149826294:-
LUAD	cis	rs35955747	0.777	rs5997895	ENSG00000236132.1	CTA-440B3.1	6.49	2.11e-10	1.11e-07	0.31	0.28	Neutrophil count;Sum basophil neutrophil counts;	chr22:31170187	chr22:31816379~31817491:-
LUAD	cis	rs4723738	1	rs10240479	ENSG00000227191.5	TRGC2	-6.49	2.11e-10	1.11e-07	-0.31	-0.28	Treatment response for severe sepsis;	chr7:38181654	chr7:38239580~38368091:-
LUAD	cis	rs2117029	0.521	rs1056875	ENSG00000258017.1	RP11-386G11.10	-6.49	2.11e-10	1.12e-07	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49186397	chr12:49127782~49147869:+
LUAD	cis	rs67311347	1	rs28707772	ENSG00000223797.4	ENTPD3-AS1	6.49	2.11e-10	1.12e-07	0.31	0.28	Renal cell carcinoma;	chr3:40463175	chr3:40313802~40453329:-
LUAD	cis	rs11096990	0.892	rs6531696	ENSG00000249207.1	RP11-360F5.1	6.49	2.12e-10	1.12e-07	0.33	0.28	Cognitive function;	chr4:39190134	chr4:39112677~39126818:-
LUAD	cis	rs2842992	0.958	rs2758318	ENSG00000237927.1	RP3-393E18.2	-6.49	2.13e-10	1.13e-07	-0.39	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159648605	chr6:159586955~159589169:-
LUAD	cis	rs1799949	0.93	rs4584865	ENSG00000267681.1	CTD-3199J23.6	-6.49	2.13e-10	1.13e-07	-0.33	-0.28	Menopause (age at onset);	chr17:43347551	chr17:43144956~43145255:+
LUAD	cis	rs4722166	0.63	rs7808457	ENSG00000179428.2	AC073072.5	6.49	2.14e-10	1.13e-07	0.34	0.28	Lung cancer;	chr7:22758646	chr7:22725395~22727620:-
LUAD	cis	rs7246657	0.943	rs10415358	ENSG00000276846.1	CTD-3220F14.3	6.49	2.14e-10	1.13e-07	0.4	0.28	Coronary artery calcification;	chr19:37317961	chr19:37314868~37315620:-
LUAD	cis	rs17684571	0.938	rs17751695	ENSG00000231441.1	RP11-472M19.2	6.49	2.14e-10	1.13e-07	0.42	0.28	Schizophrenia;	chr6:56695966	chr6:56844002~56864078:+
LUAD	cis	rs7246657	0.714	rs12972195	ENSG00000276846.1	CTD-3220F14.3	6.49	2.14e-10	1.13e-07	0.39	0.28	Coronary artery calcification;	chr19:37261603	chr19:37314868~37315620:-
LUAD	cis	rs6565180	1	rs12930787	ENSG00000183604.13	SMG1P5	-6.49	2.14e-10	1.13e-07	-0.3	-0.28	Tonsillectomy;	chr16:30369982	chr16:30267553~30335374:-
LUAD	cis	rs875971	1	rs3735148	ENSG00000222364.1	RNU6-96P	-6.49	2.14e-10	1.13e-07	-0.32	-0.28	Aortic root size;	chr7:66506022	chr7:66395191~66395286:+
LUAD	cis	rs516805	0.923	rs487487	ENSG00000279453.1	RP3-425C14.4	-6.49	2.15e-10	1.13e-07	-0.32	-0.28	Lymphocyte counts;	chr6:122422357	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.961	rs556439	ENSG00000279453.1	RP3-425C14.4	-6.49	2.15e-10	1.13e-07	-0.32	-0.28	Lymphocyte counts;	chr6:122423864	chr6:122436789~122439223:-
LUAD	cis	rs7017914	0.967	rs12679261	ENSG00000223220.1	Y_RNA	6.49	2.15e-10	1.13e-07	0.32	0.28	Bone mineral density;	chr8:70932414	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs10089583	ENSG00000223220.1	Y_RNA	6.49	2.15e-10	1.13e-07	0.32	0.28	Bone mineral density;	chr8:70937249	chr8:70780914~70781008:-
LUAD	cis	rs2337406	0.587	rs10139664	ENSG00000211974.3	IGHV2-70	-6.49	2.15e-10	1.13e-07	-0.36	-0.28	Alzheimer's disease (late onset);	chr14:106647254	chr14:106723574~106724093:-
LUAD	cis	rs113835537	0.529	rs11227515	ENSG00000255517.5	CTD-3074O7.5	-6.49	2.15e-10	1.13e-07	-0.33	-0.28	Airway imaging phenotypes;	chr11:66519912	chr11:66473490~66480233:-
LUAD	cis	rs11098499	0.863	rs3822190	ENSG00000248280.1	RP11-33B1.2	6.49	2.15e-10	1.13e-07	0.37	0.28	Corneal astigmatism;	chr4:119506943	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.863	rs3822191	ENSG00000248280.1	RP11-33B1.2	6.49	2.15e-10	1.13e-07	0.37	0.28	Corneal astigmatism;	chr4:119506946	chr4:119440561~119450157:-
LUAD	cis	rs2243480	1	rs34703416	ENSG00000226824.5	RP4-756H11.3	-6.49	2.15e-10	1.13e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:65835655	chr7:66654538~66669855:+
LUAD	cis	rs465969	0.744	rs13212489	ENSG00000255389.1	C6orf3	-6.49	2.15e-10	1.13e-07	-0.6	-0.28	Psoriasis;	chr6:111536863	chr6:111599875~111602295:+
LUAD	cis	rs67311347	1	rs12488805	ENSG00000223797.4	ENTPD3-AS1	6.49	2.15e-10	1.13e-07	0.31	0.28	Renal cell carcinoma;	chr3:40381378	chr3:40313802~40453329:-
LUAD	cis	rs12439619	0.883	rs62012045	ENSG00000255769.6	GOLGA2P10	-6.49	2.15e-10	1.14e-07	-0.33	-0.28	Intelligence (multi-trait analysis);	chr15:82229366	chr15:82472993~82513950:-
LUAD	cis	rs10740039	0.768	rs10761549	ENSG00000254271.1	RP11-131N11.4	6.49	2.16e-10	1.14e-07	0.33	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60701902	chr10:60734342~60741828:+
LUAD	cis	rs17023223	0.509	rs10923740	ENSG00000231365.4	RP11-418J17.1	-6.49	2.17e-10	1.14e-07	-0.39	-0.28	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119057664	chr1:119140396~119275973:+
LUAD	cis	rs2765539	0.851	rs1409158	ENSG00000226172.2	RP4-712E4.1	6.49	2.17e-10	1.14e-07	0.36	0.28	Waist-hip ratio;	chr1:118996267	chr1:119000344~119001392:-
LUAD	cis	rs11089937	0.555	rs6001226	ENSG00000211639.2	IGLV4-60	6.49	2.17e-10	1.14e-07	0.3	0.28	Periodontitis (PAL4Q3);	chr22:22186888	chr22:22162199~22162681:+
LUAD	cis	rs17301013	0.606	rs72711443	ENSG00000227373.4	RP11-160H22.5	6.49	2.17e-10	1.15e-07	0.4	0.28	Systemic lupus erythematosus;	chr1:174090876	chr1:174115300~174160004:-
LUAD	cis	rs4722166	0.508	rs2069832	ENSG00000179428.2	AC073072.5	-6.49	2.17e-10	1.15e-07	-0.34	-0.28	Lung cancer;	chr7:22727814	chr7:22725395~22727620:-
LUAD	cis	rs7811142	1	rs7783159	ENSG00000242294.5	STAG3L5P	6.49	2.18e-10	1.15e-07	0.25	0.28	Platelet count;	chr7:100419831	chr7:100336079~100351900:+
LUAD	cis	rs1609391	0.543	rs2117009	ENSG00000239213.4	NCK1-AS1	-6.49	2.18e-10	1.15e-07	-0.3	-0.28	Neuroticism;	chr3:136914729	chr3:136841726~136862054:-
LUAD	cis	rs67311347	0.955	rs6599100	ENSG00000223797.4	ENTPD3-AS1	6.49	2.18e-10	1.15e-07	0.29	0.28	Renal cell carcinoma;	chr3:40405871	chr3:40313802~40453329:-
LUAD	cis	rs12439619	0.921	rs56042848	ENSG00000255769.6	GOLGA2P10	-6.49	2.18e-10	1.15e-07	-0.33	-0.28	Intelligence (multi-trait analysis);	chr15:82235244	chr15:82472993~82513950:-
LUAD	cis	rs62025270	0.547	rs338536	ENSG00000202081.1	RNU6-1280P	-6.49	2.18e-10	1.15e-07	-0.34	-0.28	Idiopathic pulmonary fibrosis;	chr15:85654009	chr15:85651522~85651628:-
LUAD	cis	rs3096299	0.967	rs7205785	ENSG00000274627.1	RP11-104N10.2	6.49	2.19e-10	1.15e-07	0.27	0.28	Multiple myeloma (IgH translocation);	chr16:89392576	chr16:89516797~89522217:+
LUAD	cis	rs1799949	1	rs2037075	ENSG00000267681.1	CTD-3199J23.6	-6.49	2.19e-10	1.15e-07	-0.33	-0.28	Menopause (age at onset);	chr17:43153809	chr17:43144956~43145255:+
LUAD	cis	rs1062177	0.756	rs2964588	ENSG00000213433.5	RPLP1P6	6.49	2.19e-10	1.15e-07	0.36	0.28	Preschool internalizing problems;	chr5:151738825	chr5:151765859~151766378:-
LUAD	cis	rs950169	0.922	rs62021167	ENSG00000259728.4	LINC00933	6.49	2.19e-10	1.15e-07	0.43	0.28	Schizophrenia;	chr15:84574820	chr15:84570649~84580175:+
LUAD	cis	rs7811142	1	rs6975729	ENSG00000242294.5	STAG3L5P	6.49	2.19e-10	1.15e-07	0.24	0.28	Platelet count;	chr7:100430564	chr7:100336079~100351900:+
LUAD	cis	rs7811142	1	rs1073	ENSG00000242294.5	STAG3L5P	6.49	2.19e-10	1.15e-07	0.24	0.28	Platelet count;	chr7:100433989	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.887	rs4074838	ENSG00000242294.5	STAG3L5P	6.49	2.19e-10	1.15e-07	0.24	0.28	Platelet count;	chr7:100435042	chr7:100336079~100351900:+
LUAD	cis	rs7811142	1	rs11764818	ENSG00000242294.5	STAG3L5P	6.49	2.19e-10	1.15e-07	0.24	0.28	Platelet count;	chr7:100445432	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.945	rs6955362	ENSG00000242294.5	STAG3L5P	6.49	2.19e-10	1.15e-07	0.24	0.28	Platelet count;	chr7:100458543	chr7:100336079~100351900:+
LUAD	cis	rs7811142	1	rs6975514	ENSG00000242294.5	STAG3L5P	6.49	2.19e-10	1.15e-07	0.24	0.28	Platelet count;	chr7:100458597	chr7:100336079~100351900:+
LUAD	cis	rs7811142	1	rs7811142	ENSG00000242294.5	STAG3L5P	6.49	2.19e-10	1.15e-07	0.24	0.28	Platelet count;	chr7:100467820	chr7:100336079~100351900:+
LUAD	cis	rs72772090	0.539	rs35898772	ENSG00000248734.2	CTD-2260A17.1	-6.49	2.19e-10	1.15e-07	-0.45	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96843982	chr5:96784777~96785999:+
LUAD	cis	rs35740288	0.77	rs12906580	ENSG00000202081.1	RNU6-1280P	-6.49	2.2e-10	1.16e-07	-0.34	-0.28	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85612056	chr15:85651522~85651628:-
LUAD	cis	rs75422866	0.867	rs73111258	ENSG00000257433.4	RP1-197B17.3	6.49	2.2e-10	1.16e-07	0.6	0.28	Pneumonia;	chr12:47597313	chr12:47706085~47742294:+
LUAD	cis	rs4927850	1	rs4927850	ENSG00000207650.1	MIR570	-6.49	2.2e-10	1.16e-07	-0.29	-0.28	Pancreatic cancer;	chr3:196024759	chr3:195699401~195699497:+
LUAD	cis	rs7017914	0.967	rs2732090	ENSG00000223220.1	Y_RNA	-6.49	2.2e-10	1.16e-07	-0.31	-0.28	Bone mineral density;	chr8:71006022	chr8:70780914~70781008:-
LUAD	cis	rs9309473	1	rs7598419	ENSG00000163016.8	ALMS1P	6.49	2.2e-10	1.16e-07	0.35	0.28	Metabolite levels;	chr2:73571096	chr2:73644919~73685576:+
LUAD	cis	rs1140227	0.502	rs10789304	ENSG00000235358.1	RP11-399E6.1	6.49	2.2e-10	1.16e-07	0.39	0.28	Intelligence (multi-trait analysis);	chr1:41121740	chr1:41242373~41284861:+
LUAD	cis	rs66887589	0.592	rs28580295	ENSG00000248280.1	RP11-33B1.2	6.49	2.2e-10	1.16e-07	0.32	0.28	Diastolic blood pressure;	chr4:119357718	chr4:119440561~119450157:-
LUAD	cis	rs6558530	0.931	rs4639549	ENSG00000253982.1	CTD-2336O2.1	6.49	2.2e-10	1.16e-07	0.35	0.28	Systolic blood pressure;	chr8:1759878	chr8:1761990~1764502:-
LUAD	cis	rs9318086	0.648	rs35449605	ENSG00000205861.10	C1QTNF9B-AS1	-6.48	2.21e-10	1.16e-07	-0.35	-0.28	Myopia (pathological);	chr13:23898443	chr13:23888889~23897263:+
LUAD	cis	rs12908161	1	rs11632465	ENSG00000259728.4	LINC00933	6.48	2.21e-10	1.16e-07	0.41	0.28	Schizophrenia;	chr15:84738814	chr15:84570649~84580175:+
LUAD	cis	rs17826219	0.636	rs12946563	ENSG00000263531.1	RP13-753N3.1	6.48	2.21e-10	1.16e-07	0.56	0.28	Body mass index;	chr17:30776148	chr17:30863921~30864940:-
LUAD	cis	rs4938330	0.681	rs12271169	ENSG00000254851.1	RP11-109L13.1	6.48	2.21e-10	1.16e-07	0.41	0.28	Blood protein levels;	chr11:117109305	chr11:117135528~117138582:+
LUAD	cis	rs9309473	0.904	rs79145598	ENSG00000163016.8	ALMS1P	6.48	2.21e-10	1.17e-07	0.35	0.28	Metabolite levels;	chr2:73594255	chr2:73644919~73685576:+
LUAD	cis	rs9309473	0.904	rs62149783	ENSG00000163016.8	ALMS1P	6.48	2.21e-10	1.17e-07	0.35	0.28	Metabolite levels;	chr2:73594257	chr2:73644919~73685576:+
LUAD	cis	rs875971	1	rs10244498	ENSG00000222364.1	RNU6-96P	-6.48	2.21e-10	1.17e-07	-0.31	-0.28	Aortic root size;	chr7:66651069	chr7:66395191~66395286:+
LUAD	cis	rs227932	0.764	rs6461725	ENSG00000234286.1	AC006026.13	-6.48	2.21e-10	1.17e-07	-0.48	-0.28	Schizophrenia;	chr7:23690555	chr7:23680195~23680786:-
LUAD	cis	rs7626444	0.647	rs844546	ENSG00000272359.1	U4	-6.48	2.22e-10	1.17e-07	-0.31	-0.28	Monocyte count;	chr3:196748403	chr3:196747192~196747324:-
LUAD	cis	rs7626444	0.625	rs843540	ENSG00000272359.1	U4	-6.48	2.22e-10	1.17e-07	-0.31	-0.28	Monocyte count;	chr3:196748442	chr3:196747192~196747324:-
LUAD	cis	rs8072100	0.84	rs12452796	ENSG00000228782.6	CTD-2026D20.3	-6.48	2.22e-10	1.17e-07	-0.3	-0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402367	chr17:47450568~47492492:-
LUAD	cis	rs17301013	0.507	rs2860955	ENSG00000227373.4	RP11-160H22.5	-6.48	2.22e-10	1.17e-07	-0.42	-0.28	Systemic lupus erythematosus;	chr1:174391380	chr1:174115300~174160004:-
LUAD	cis	rs2179367	0.887	rs2789488	ENSG00000231760.4	RP11-350J20.5	-6.48	2.22e-10	1.17e-07	-0.34	-0.28	Dupuytren's disease;	chr6:149404154	chr6:149796151~149826294:-
LUAD	cis	rs9309473	1	rs1114380	ENSG00000163016.8	ALMS1P	6.48	2.22e-10	1.17e-07	0.35	0.28	Metabolite levels;	chr2:73577581	chr2:73644919~73685576:+
LUAD	cis	rs2243480	1	rs1723267	ENSG00000232546.1	RP11-458F8.1	-6.48	2.22e-10	1.17e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66008327	chr7:66848496~66858136:+
LUAD	cis	rs4718428	0.705	rs4718422	ENSG00000273142.1	RP11-458F8.4	-6.48	2.22e-10	1.17e-07	-0.21	-0.28	Corneal structure;	chr7:66894282	chr7:66902857~66906297:+
LUAD	cis	rs4718428	0.705	rs13231140	ENSG00000273142.1	RP11-458F8.4	-6.48	2.22e-10	1.17e-07	-0.21	-0.28	Corneal structure;	chr7:66896631	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs781156	ENSG00000226824.5	RP4-756H11.3	-6.48	2.22e-10	1.17e-07	-0.52	-0.28	Diabetic kidney disease;	chr7:66014154	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs781149	ENSG00000226824.5	RP4-756H11.3	-6.48	2.22e-10	1.17e-07	-0.52	-0.28	Diabetic kidney disease;	chr7:66016297	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs451396	ENSG00000226824.5	RP4-756H11.3	-6.48	2.22e-10	1.17e-07	-0.52	-0.28	Diabetic kidney disease;	chr7:66019087	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.901	rs58207111	ENSG00000226824.5	RP4-756H11.3	-6.48	2.22e-10	1.17e-07	-0.52	-0.28	Diabetic kidney disease;	chr7:66021736	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs1167613	ENSG00000226824.5	RP4-756H11.3	-6.48	2.22e-10	1.17e-07	-0.52	-0.28	Diabetic kidney disease;	chr7:66022452	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs1715235	ENSG00000226824.5	RP4-756H11.3	-6.48	2.22e-10	1.17e-07	-0.52	-0.28	Diabetic kidney disease;	chr7:66023407	chr7:66654538~66669855:+
LUAD	cis	rs9828933	0.752	rs17069507	ENSG00000280620.1	SCAANT1	6.48	2.23e-10	1.17e-07	0.52	0.28	Type 2 diabetes;	chr3:63939280	chr3:63911518~63911772:-
LUAD	cis	rs1799949	0.965	rs11656945	ENSG00000267681.1	CTD-3199J23.6	-6.48	2.23e-10	1.17e-07	-0.33	-0.28	Menopause (age at onset);	chr17:43178248	chr17:43144956~43145255:+
LUAD	cis	rs6496932	0.563	rs2344083	ENSG00000259295.5	CSPG4P12	-6.48	2.23e-10	1.18e-07	-0.34	-0.28	Central corneal thickness;Corneal structure;	chr15:85354201	chr15:85191438~85213905:+
LUAD	cis	rs2842992	1	rs2842992	ENSG00000237927.1	RP3-393E18.2	-6.48	2.23e-10	1.18e-07	-0.39	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159650127	chr6:159586955~159589169:-
LUAD	cis	rs8059260	0.668	rs74423828	ENSG00000274038.1	RP11-66H6.4	-6.48	2.24e-10	1.18e-07	-0.54	-0.28	Alcohol consumption over the past year;	chr16:10975574	chr16:11056556~11057034:+
LUAD	cis	rs55726902	0.761	rs2544029	ENSG00000276691.1	RP5-1057I20.5	6.48	2.24e-10	1.18e-07	0.29	0.28	Allergic disease (asthma, hay fever or eczema);	chr12:47801174	chr12:47788426~47788971:+
LUAD	cis	rs17301013	0.507	rs10494492	ENSG00000227373.4	RP11-160H22.5	-6.48	2.24e-10	1.18e-07	-0.42	-0.28	Systemic lupus erythematosus;	chr1:174723499	chr1:174115300~174160004:-
LUAD	cis	rs853679	0.599	rs13193295	ENSG00000204709.4	LINC01556	6.48	2.24e-10	1.18e-07	0.62	0.28	Depression;	chr6:28035450	chr6:28943877~28944537:+
LUAD	cis	rs875971	0.545	rs7811204	ENSG00000237310.1	GS1-124K5.4	6.48	2.25e-10	1.18e-07	0.36	0.28	Aortic root size;	chr7:66387213	chr7:66493706~66495474:+
LUAD	cis	rs4722166	0.573	rs35436671	ENSG00000179428.2	AC073072.5	-6.48	2.26e-10	1.19e-07	-0.34	-0.28	Lung cancer;	chr7:22735889	chr7:22725395~22727620:-
LUAD	cis	rs3096299	0.874	rs3102342	ENSG00000274627.1	RP11-104N10.2	6.48	2.26e-10	1.19e-07	0.27	0.28	Multiple myeloma (IgH translocation);	chr16:89385167	chr16:89516797~89522217:+
LUAD	cis	rs12908161	0.96	rs17599989	ENSG00000259728.4	LINC00933	6.48	2.26e-10	1.19e-07	0.41	0.28	Schizophrenia;	chr15:84742305	chr15:84570649~84580175:+
LUAD	cis	rs881375	0.678	rs10760130	ENSG00000226752.6	PSMD5-AS1	-6.48	2.27e-10	1.19e-07	-0.29	-0.28	Rheumatoid arthritis;	chr9:120939712	chr9:120824828~120854385:+
LUAD	cis	rs6142102	1	rs6059673	ENSG00000276073.1	RP5-1125A11.7	-6.48	2.27e-10	1.19e-07	-0.3	-0.28	Skin pigmentation;	chr20:34117755	chr20:33985617~33988989:-
LUAD	cis	rs1799949	1	rs8077486	ENSG00000267681.1	CTD-3199J23.6	-6.48	2.27e-10	1.19e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43060788	chr17:43144956~43145255:+
LUAD	cis	rs2439831	0.85	rs61390361	ENSG00000205771.5	CATSPER2P1	-6.48	2.27e-10	1.2e-07	-0.58	-0.28	Lung cancer in ever smokers;	chr15:43867644	chr15:43726918~43747094:-
LUAD	cis	rs10129255	0.518	rs8009594	ENSG00000224373.3	IGHV4-59	6.48	2.28e-10	1.2e-07	0.17	0.28	Kawasaki disease;	chr14:106777494	chr14:106627249~106627825:-
LUAD	cis	rs6860806	0.507	rs200837	ENSG00000233006.5	AC034220.3	6.48	2.28e-10	1.2e-07	0.28	0.28	Breast cancer;	chr5:132364266	chr5:132311285~132369916:-
LUAD	cis	rs10129255	0.518	rs10136903	ENSG00000224373.3	IGHV4-59	6.48	2.28e-10	1.2e-07	0.17	0.28	Kawasaki disease;	chr14:106778866	chr14:106627249~106627825:-
LUAD	cis	rs2243480	0.615	rs34363376	ENSG00000226824.5	RP4-756H11.3	-6.48	2.28e-10	1.2e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:66474549	chr7:66654538~66669855:+
LUAD	cis	rs7017914	0.652	rs441890	ENSG00000223220.1	Y_RNA	6.48	2.28e-10	1.2e-07	0.31	0.28	Bone mineral density;	chr8:70652432	chr8:70780914~70781008:-
LUAD	cis	rs8062405	1	rs62036616	ENSG00000251417.2	RP11-1348G14.4	-6.48	2.29e-10	1.2e-07	-0.29	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28802743~28817828:+
LUAD	cis	rs12908161	0.92	rs12904605	ENSG00000259728.4	LINC00933	6.48	2.29e-10	1.2e-07	0.41	0.28	Schizophrenia;	chr15:84658188	chr15:84570649~84580175:+
LUAD	cis	rs881375	0.933	rs7028641	ENSG00000226752.6	PSMD5-AS1	-6.48	2.29e-10	1.2e-07	-0.3	-0.28	Rheumatoid arthritis;	chr9:120928863	chr9:120824828~120854385:+
LUAD	cis	rs7811142	1	rs60257855	ENSG00000242294.5	STAG3L5P	6.48	2.29e-10	1.2e-07	0.24	0.28	Platelet count;	chr7:100429157	chr7:100336079~100351900:+
LUAD	cis	rs875971	1	rs55962648	ENSG00000222364.1	RNU6-96P	6.48	2.29e-10	1.2e-07	0.32	0.28	Aortic root size;	chr7:66160764	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs2420168	ENSG00000222364.1	RNU6-96P	6.48	2.29e-10	1.2e-07	0.32	0.28	Aortic root size;	chr7:66165644	chr7:66395191~66395286:+
LUAD	cis	rs77204473	0.744	rs2170317	ENSG00000254851.1	RP11-109L13.1	6.48	2.29e-10	1.2e-07	0.62	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117200024	chr11:117135528~117138582:+
LUAD	cis	rs9549367	0.789	rs912012	ENSG00000269125.1	RP11-98F14.11	-6.48	2.29e-10	1.21e-07	-0.36	-0.28	Platelet distribution width;	chr13:113231838	chr13:113165002~113165183:-
LUAD	cis	rs66887589	0.592	rs62320740	ENSG00000248280.1	RP11-33B1.2	6.48	2.29e-10	1.21e-07	0.32	0.28	Diastolic blood pressure;	chr4:119358331	chr4:119440561~119450157:-
LUAD	cis	rs4803480	0.542	rs7255742	ENSG00000270164.1	LINC01480	-6.48	2.3e-10	1.21e-07	-0.25	-0.28	Schizophrenia;	chr19:41543459	chr19:41535183~41536904:+
LUAD	cis	rs2842992	0.915	rs2842980	ENSG00000237927.1	RP3-393E18.2	-6.48	2.3e-10	1.21e-07	-0.4	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159679084	chr6:159586955~159589169:-
LUAD	cis	rs10129255	0.957	rs6576233	ENSG00000280411.1	IGHV1-69-2	-6.48	2.3e-10	1.21e-07	-0.21	-0.28	Kawasaki disease;	chr14:106787239	chr14:106762092~106762588:-
LUAD	cis	rs7927592	0.956	rs948315	ENSG00000212093.1	AP000807.1	6.48	2.31e-10	1.21e-07	0.31	0.28	Total body bone mineral density;	chr11:68541672	chr11:68506083~68506166:-
LUAD	cis	rs8062405	1	rs62036622	ENSG00000251417.2	RP11-1348G14.4	-6.48	2.31e-10	1.21e-07	-0.3	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28802743~28817828:+
LUAD	cis	rs6142102	1	rs6059672	ENSG00000276073.1	RP5-1125A11.7	-6.48	2.31e-10	1.21e-07	-0.3	-0.28	Skin pigmentation;	chr20:34117662	chr20:33985617~33988989:-
LUAD	cis	rs7674212	0.531	rs4699048	ENSG00000251288.2	RP11-10L12.2	-6.48	2.31e-10	1.21e-07	-0.36	-0.28	Type 2 diabetes;	chr4:103005570	chr4:102751401~102752641:+
LUAD	cis	rs9309473	0.847	rs4547554	ENSG00000163016.8	ALMS1P	6.48	2.31e-10	1.21e-07	0.36	0.28	Metabolite levels;	chr2:73640735	chr2:73644919~73685576:+
LUAD	cis	rs1501911	0.611	rs56180458	ENSG00000248489.1	CTD-2007H13.3	6.48	2.31e-10	1.21e-07	0.32	0.28	Lung function (FEV1/FVC);	chr5:99043633	chr5:98929171~98995013:+
LUAD	cis	rs765787	0.53	rs12439643	ENSG00000259520.4	CTD-2651B20.3	-6.48	2.31e-10	1.21e-07	-0.38	-0.28	Uric acid levels;	chr15:45237569	chr15:45251580~45279251:-
LUAD	cis	rs7688540	0.76	rs12506250	ENSG00000275426.1	CH17-262A2.1	6.48	2.31e-10	1.21e-07	0.35	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:233593	chr4:149738~150317:+
LUAD	cis	rs765787	0.53	rs2899378	ENSG00000259520.4	CTD-2651B20.3	-6.48	2.31e-10	1.22e-07	-0.38	-0.28	Uric acid levels;	chr15:45245386	chr15:45251580~45279251:-
LUAD	cis	rs9928842	0.941	rs8057145	ENSG00000280152.1	RP11-331F4.5	6.48	2.32e-10	1.22e-07	0.32	0.28	Alcoholic chronic pancreatitis;	chr16:75222353	chr16:75245994~75250077:-
LUAD	cis	rs7246657	0.943	rs7255952	ENSG00000276846.1	CTD-3220F14.3	6.48	2.32e-10	1.22e-07	0.39	0.28	Coronary artery calcification;	chr19:37497895	chr19:37314868~37315620:-
LUAD	cis	rs7927592	0.83	rs11228240	ENSG00000212093.1	AP000807.1	6.48	2.32e-10	1.22e-07	0.32	0.28	Total body bone mineral density;	chr11:68450822	chr11:68506083~68506166:-
LUAD	cis	rs6142102	0.651	rs6088412	ENSG00000276073.1	RP5-1125A11.7	6.48	2.32e-10	1.22e-07	0.33	0.28	Skin pigmentation;	chr20:34154262	chr20:33985617~33988989:-
LUAD	cis	rs6558530	0.799	rs62477060	ENSG00000253982.1	CTD-2336O2.1	6.48	2.32e-10	1.22e-07	0.34	0.28	Systolic blood pressure;	chr8:1758332	chr8:1761990~1764502:-
LUAD	cis	rs2243480	1	rs313807	ENSG00000226824.5	RP4-756H11.3	-6.48	2.33e-10	1.22e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:66034494	chr7:66654538~66669855:+
LUAD	cis	rs12908161	0.959	rs1051168	ENSG00000259728.4	LINC00933	6.48	2.33e-10	1.22e-07	0.42	0.28	Schizophrenia;	chr15:84657289	chr15:84570649~84580175:+
LUAD	cis	rs8100891	0.537	rs738093	ENSG00000267213.4	AC007773.2	-6.48	2.33e-10	1.22e-07	-0.45	-0.28	Neuroticism;	chr19:32439601	chr19:32390050~32405560:-
LUAD	cis	rs875971	0.545	rs316324	ENSG00000237310.1	GS1-124K5.4	-6.48	2.33e-10	1.23e-07	-0.35	-0.28	Aortic root size;	chr7:66145627	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs316323	ENSG00000237310.1	GS1-124K5.4	-6.48	2.33e-10	1.23e-07	-0.35	-0.28	Aortic root size;	chr7:66146002	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs316316	ENSG00000237310.1	GS1-124K5.4	-6.48	2.33e-10	1.23e-07	-0.35	-0.28	Aortic root size;	chr7:66149270	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs316305	ENSG00000237310.1	GS1-124K5.4	-6.48	2.33e-10	1.23e-07	-0.35	-0.28	Aortic root size;	chr7:66152984	chr7:66493706~66495474:+
LUAD	cis	rs2439831	0.702	rs8033995	ENSG00000205771.5	CATSPER2P1	-6.48	2.34e-10	1.23e-07	-0.54	-0.28	Lung cancer in ever smokers;	chr15:43721311	chr15:43726918~43747094:-
LUAD	cis	rs7626444	0.625	rs2948170	ENSG00000272359.1	U4	-6.48	2.34e-10	1.23e-07	-0.32	-0.28	Monocyte count;	chr3:196765660	chr3:196747192~196747324:-
LUAD	cis	rs7246657	0.551	rs4806413	ENSG00000276846.1	CTD-3220F14.3	6.48	2.34e-10	1.23e-07	0.43	0.28	Coronary artery calcification;	chr19:37126814	chr19:37314868~37315620:-
LUAD	cis	rs12439619	0.846	rs62012056	ENSG00000255769.6	GOLGA2P10	-6.48	2.34e-10	1.23e-07	-0.36	-0.28	Intelligence (multi-trait analysis);	chr15:82247278	chr15:82472993~82513950:-
LUAD	cis	rs2911132	1	rs2911132	ENSG00000248734.2	CTD-2260A17.1	6.48	2.34e-10	1.23e-07	0.29	0.28	Urate levels (BMI interaction);	chr5:96851285	chr5:96784777~96785999:+
LUAD	cis	rs11098499	0.662	rs13108589	ENSG00000248280.1	RP11-33B1.2	6.47	2.34e-10	1.23e-07	0.35	0.28	Corneal astigmatism;	chr4:119346947	chr4:119440561~119450157:-
LUAD	cis	rs10129255	0.556	rs8010005	ENSG00000224373.3	IGHV4-59	6.47	2.35e-10	1.23e-07	0.17	0.28	Kawasaki disease;	chr14:106777987	chr14:106627249~106627825:-
LUAD	cis	rs10129255	0.556	rs6576224	ENSG00000224373.3	IGHV4-59	6.47	2.35e-10	1.23e-07	0.17	0.28	Kawasaki disease;	chr14:106777997	chr14:106627249~106627825:-
LUAD	cis	rs2153535	0.58	rs6597318	ENSG00000230939.1	RP11-314C16.1	-6.47	2.35e-10	1.23e-07	-0.34	-0.28	Motion sickness;	chr6:8437056	chr6:8784178~8785445:+
LUAD	cis	rs881375	0.967	rs2416806	ENSG00000226752.6	PSMD5-AS1	-6.47	2.36e-10	1.24e-07	-0.3	-0.28	Rheumatoid arthritis;	chr9:120928014	chr9:120824828~120854385:+
LUAD	cis	rs75422866	0.867	rs73102125	ENSG00000257433.4	RP1-197B17.3	6.47	2.36e-10	1.24e-07	0.58	0.28	Pneumonia;	chr12:47637869	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs12426849	ENSG00000257433.4	RP1-197B17.3	6.47	2.36e-10	1.24e-07	0.58	0.28	Pneumonia;	chr12:47638975	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs117950951	ENSG00000257433.4	RP1-197B17.3	6.47	2.36e-10	1.24e-07	0.58	0.28	Pneumonia;	chr12:47639794	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs7954764	ENSG00000257433.4	RP1-197B17.3	6.47	2.36e-10	1.24e-07	0.58	0.28	Pneumonia;	chr12:47641136	chr12:47706085~47742294:+
LUAD	cis	rs957448	1	rs72674866	ENSG00000253704.1	RP11-267M23.4	6.47	2.36e-10	1.24e-07	0.36	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94564619	chr8:94553722~94569745:+
LUAD	cis	rs957448	1	rs55897841	ENSG00000253704.1	RP11-267M23.4	6.47	2.36e-10	1.24e-07	0.36	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94565042	chr8:94553722~94569745:+
LUAD	cis	rs957448	0.948	rs72674867	ENSG00000253704.1	RP11-267M23.4	6.47	2.36e-10	1.24e-07	0.36	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94565973	chr8:94553722~94569745:+
LUAD	cis	rs7567389	0.719	rs6430936	ENSG00000236682.1	AC068282.3	6.47	2.36e-10	1.24e-07	0.41	0.28	Self-rated health;	chr2:127250110	chr2:127389130~127400580:+
LUAD	cis	rs7688540	0.8	rs11723492	ENSG00000275426.1	CH17-262A2.1	6.47	2.36e-10	1.24e-07	0.34	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:222634	chr4:149738~150317:+
LUAD	cis	rs9309473	1	rs56672945	ENSG00000163016.8	ALMS1P	6.47	2.37e-10	1.24e-07	0.35	0.28	Metabolite levels;	chr2:73395535	chr2:73644919~73685576:+
LUAD	cis	rs9309473	1	rs60844734	ENSG00000163016.8	ALMS1P	6.47	2.37e-10	1.24e-07	0.35	0.28	Metabolite levels;	chr2:73396077	chr2:73644919~73685576:+
LUAD	cis	rs113835537	0.597	rs2305534	ENSG00000255517.5	CTD-3074O7.5	-6.47	2.37e-10	1.24e-07	-0.34	-0.28	Airway imaging phenotypes;	chr11:66545732	chr11:66473490~66480233:-
LUAD	cis	rs7615952	0.799	rs13315434	ENSG00000171084.14	FAM86JP	6.47	2.37e-10	1.24e-07	0.4	0.28	Blood pressure (smoking interaction);	chr3:125922551	chr3:125916620~125930024:+
LUAD	cis	rs7246657	0.943	rs2291004	ENSG00000276846.1	CTD-3220F14.3	6.47	2.37e-10	1.24e-07	0.39	0.28	Coronary artery calcification;	chr19:37507050	chr19:37314868~37315620:-
LUAD	cis	rs853679	0.628	rs9368560	ENSG00000204709.4	LINC01556	6.47	2.37e-10	1.24e-07	0.41	0.28	Depression;	chr6:28192182	chr6:28943877~28944537:+
LUAD	cis	rs274567	0.602	rs272853	ENSG00000233006.5	AC034220.3	6.47	2.37e-10	1.24e-07	0.27	0.28	Blood metabolite levels;	chr5:132352868	chr5:132311285~132369916:-
LUAD	cis	rs1062177	0.724	rs2915828	ENSG00000213433.5	RPLP1P6	6.47	2.37e-10	1.24e-07	0.36	0.28	Preschool internalizing problems;	chr5:151738560	chr5:151765859~151766378:-
LUAD	cis	rs1062177	0.724	rs2964590	ENSG00000213433.5	RPLP1P6	6.47	2.37e-10	1.24e-07	0.36	0.28	Preschool internalizing problems;	chr5:151738585	chr5:151765859~151766378:-
LUAD	cis	rs4723738	0.935	rs10233340	ENSG00000227191.5	TRGC2	-6.47	2.37e-10	1.24e-07	-0.31	-0.28	Treatment response for severe sepsis;	chr7:38183679	chr7:38239580~38368091:-
LUAD	cis	rs4723738	1	rs35997004	ENSG00000227191.5	TRGC2	-6.47	2.37e-10	1.24e-07	-0.31	-0.28	Treatment response for severe sepsis;	chr7:38186081	chr7:38239580~38368091:-
LUAD	cis	rs4723738	1	rs11766312	ENSG00000227191.5	TRGC2	-6.47	2.37e-10	1.24e-07	-0.31	-0.28	Treatment response for severe sepsis;	chr7:38187990	chr7:38239580~38368091:-
LUAD	cis	rs4723738	1	rs10951552	ENSG00000227191.5	TRGC2	-6.47	2.37e-10	1.24e-07	-0.31	-0.28	Treatment response for severe sepsis;	chr7:38190180	chr7:38239580~38368091:-
LUAD	cis	rs1823913	1	rs1840377	ENSG00000230611.1	HMGB1P27	6.47	2.37e-10	1.24e-07	0.34	0.28	Obesity-related traits;	chr2:191257992	chr2:191174233~191174835:+
LUAD	cis	rs1823913	1	rs4853564	ENSG00000230611.1	HMGB1P27	6.47	2.37e-10	1.24e-07	0.34	0.28	Obesity-related traits;	chr2:191258939	chr2:191174233~191174835:+
LUAD	cis	rs1823913	1	rs4853565	ENSG00000230611.1	HMGB1P27	6.47	2.37e-10	1.24e-07	0.34	0.28	Obesity-related traits;	chr2:191259020	chr2:191174233~191174835:+
LUAD	cis	rs1823913	1	rs4853462	ENSG00000230611.1	HMGB1P27	6.47	2.37e-10	1.24e-07	0.34	0.28	Obesity-related traits;	chr2:191259078	chr2:191174233~191174835:+
LUAD	cis	rs55665837	1	rs11023215	ENSG00000251991.1	RNU7-49P	6.47	2.38e-10	1.25e-07	0.32	0.28	Vitamin D levels;	chr11:14415424	chr11:14478892~14478953:+
LUAD	cis	rs6991838	0.806	rs11777025	ENSG00000272010.1	CTD-3025N20.3	-6.47	2.38e-10	1.25e-07	-0.29	-0.28	Intelligence (multi-trait analysis);	chr8:65551438	chr8:65591850~65592472:-
LUAD	cis	rs9318086	0.648	rs9510927	ENSG00000205861.10	C1QTNF9B-AS1	-6.47	2.39e-10	1.25e-07	-0.34	-0.28	Myopia (pathological);	chr13:23893502	chr13:23888889~23897263:+
LUAD	cis	rs2734839	0.927	rs2734837	ENSG00000270179.1	RP11-159N11.4	-6.47	2.39e-10	1.25e-07	-0.29	-0.28	Information processing speed;	chr11:113416107	chr11:113368478~113369117:+
LUAD	cis	rs1799949	1	rs11649954	ENSG00000267681.1	CTD-3199J23.6	-6.47	2.39e-10	1.25e-07	-0.33	-0.28	Menopause (age at onset);	chr17:43342667	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs1824889	ENSG00000267681.1	CTD-3199J23.6	-6.47	2.39e-10	1.25e-07	-0.33	-0.28	Menopause (age at onset);	chr17:43344508	chr17:43144956~43145255:+
LUAD	cis	rs8177876	0.915	rs73597252	ENSG00000261838.4	RP11-303E16.6	6.47	2.39e-10	1.25e-07	0.68	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81097740	chr16:81069854~81076598:+
LUAD	cis	rs12908161	1	rs58416181	ENSG00000259728.4	LINC00933	6.47	2.39e-10	1.25e-07	0.42	0.28	Schizophrenia;	chr15:84721230	chr15:84570649~84580175:+
LUAD	cis	rs67311347	1	rs1004655	ENSG00000223797.4	ENTPD3-AS1	6.47	2.39e-10	1.25e-07	0.31	0.28	Renal cell carcinoma;	chr3:40448518	chr3:40313802~40453329:-
LUAD	cis	rs6504622	0.902	rs1052586	ENSG00000262879.4	RP11-156P1.3	-6.47	2.4e-10	1.26e-07	-0.33	-0.28	Orofacial clefts;	chr17:46941097	chr17:46984045~47100323:-
LUAD	cis	rs4713118	0.662	rs464312	ENSG00000219392.1	RP1-265C24.5	-6.47	2.4e-10	1.26e-07	-0.38	-0.28	Parkinson's disease;	chr6:27999813	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.662	rs469228	ENSG00000219392.1	RP1-265C24.5	-6.47	2.4e-10	1.26e-07	-0.38	-0.28	Parkinson's disease;	chr6:28002926	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.54	rs469227	ENSG00000219392.1	RP1-265C24.5	-6.47	2.4e-10	1.26e-07	-0.38	-0.28	Parkinson's disease;	chr6:28002927	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.662	rs149948	ENSG00000219392.1	RP1-265C24.5	-6.47	2.4e-10	1.26e-07	-0.38	-0.28	Parkinson's disease;	chr6:28007039	chr6:28115628~28116551:+
LUAD	cis	rs12022452	0.506	rs12569328	ENSG00000238287.1	RP11-656D10.3	-6.47	2.4e-10	1.26e-07	-0.44	-0.28	Age-related hearing impairment (SNP x SNP interaction);	chr1:40553549	chr1:40493157~40508661:-
LUAD	cis	rs875971	0.83	rs4718358	ENSG00000222364.1	RNU6-96P	-6.47	2.4e-10	1.26e-07	-0.32	-0.28	Aortic root size;	chr7:66508681	chr7:66395191~66395286:+
LUAD	cis	rs9309711	0.772	rs9752251	ENSG00000225234.1	TRAPPC12-AS1	-6.47	2.4e-10	1.26e-07	-0.35	-0.28	Neurofibrillary tangles;	chr2:3486098	chr2:3481242~3482409:-
LUAD	cis	rs72772090	0.539	rs11748328	ENSG00000248734.2	CTD-2260A17.1	-6.47	2.4e-10	1.26e-07	-0.46	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96834213	chr5:96784777~96785999:+
LUAD	cis	rs1799949	0.965	rs4793234	ENSG00000267681.1	CTD-3199J23.6	-6.47	2.41e-10	1.26e-07	-0.33	-0.28	Menopause (age at onset);	chr17:43358815	chr17:43144956~43145255:+
LUAD	cis	rs67311347	0.955	rs11719205	ENSG00000223797.4	ENTPD3-AS1	6.47	2.41e-10	1.26e-07	0.29	0.28	Renal cell carcinoma;	chr3:40375767	chr3:40313802~40453329:-
LUAD	cis	rs12022452	0.544	rs11208423	ENSG00000238287.1	RP11-656D10.3	-6.47	2.41e-10	1.26e-07	-0.43	-0.28	Age-related hearing impairment (SNP x SNP interaction);	chr1:40563942	chr1:40493157~40508661:-
LUAD	cis	rs7246657	0.943	rs10404920	ENSG00000276846.1	CTD-3220F14.3	6.47	2.41e-10	1.26e-07	0.41	0.28	Coronary artery calcification;	chr19:37390654	chr19:37314868~37315620:-
LUAD	cis	rs1707322	0.717	rs11211161	ENSG00000234329.1	RP11-767N6.2	6.47	2.41e-10	1.26e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45682466	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs61784793	ENSG00000234329.1	RP11-767N6.2	6.47	2.41e-10	1.26e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45683613	chr1:45651039~45651826:-
LUAD	cis	rs7044106	0.762	rs3904197	ENSG00000238181.2	AHCYP2	-6.47	2.41e-10	1.26e-07	-0.37	-0.28	Hip circumference adjusted for BMI;	chr9:120718100	chr9:120720673~120721972:+
LUAD	cis	rs875971	0.545	rs73142233	ENSG00000237310.1	GS1-124K5.4	6.47	2.42e-10	1.27e-07	0.36	0.28	Aortic root size;	chr7:66221293	chr7:66493706~66495474:+
LUAD	cis	rs2734839	0.964	rs12798900	ENSG00000270179.1	RP11-159N11.4	-6.47	2.42e-10	1.27e-07	-0.29	-0.28	Information processing speed;	chr11:113428274	chr11:113368478~113369117:+
LUAD	cis	rs2734839	1	rs2734839	ENSG00000270179.1	RP11-159N11.4	-6.47	2.42e-10	1.27e-07	-0.29	-0.28	Information processing speed;	chr11:113415768	chr11:113368478~113369117:+
LUAD	cis	rs17301013	0.507	rs72713586	ENSG00000227373.4	RP11-160H22.5	6.47	2.42e-10	1.27e-07	0.44	0.28	Systemic lupus erythematosus;	chr1:174441265	chr1:174115300~174160004:-
LUAD	cis	rs2283792	0.819	rs2266965	ENSG00000224086.5	LL22NC03-86G7.1	-6.47	2.42e-10	1.27e-07	-0.27	-0.28	Multiple sclerosis;	chr22:21766866	chr22:21938293~21977632:+
LUAD	cis	rs12468226	0.606	rs10445793	ENSG00000273456.1	RP11-686O6.2	6.47	2.42e-10	1.27e-07	0.41	0.28	Urate levels;	chr2:202190799	chr2:202374932~202375604:-
LUAD	cis	rs3762637	1	rs12630576	ENSG00000272758.4	RP11-299J3.8	-6.47	2.42e-10	1.27e-07	-0.44	-0.28	LDL cholesterol levels;	chr3:122420670	chr3:122416207~122443180:+
LUAD	cis	rs5753618	0.555	rs9609302	ENSG00000236132.1	CTA-440B3.1	-6.47	2.42e-10	1.27e-07	-0.36	-0.28	Colorectal cancer;	chr22:31500001	chr22:31816379~31817491:-
LUAD	cis	rs7017914	0.934	rs6987313	ENSG00000223220.1	Y_RNA	6.47	2.43e-10	1.27e-07	0.32	0.28	Bone mineral density;	chr8:70658754	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.902	rs35580034	ENSG00000223220.1	Y_RNA	6.47	2.43e-10	1.27e-07	0.32	0.28	Bone mineral density;	chr8:70659838	chr8:70780914~70781008:-
LUAD	cis	rs1075265	0.749	rs805436	ENSG00000233266.1	HMGB1P31	6.47	2.43e-10	1.27e-07	0.36	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53837843	chr2:54051334~54051760:+
LUAD	cis	rs950169	0.96	rs35159785	ENSG00000259728.4	LINC00933	6.47	2.43e-10	1.27e-07	0.44	0.28	Schizophrenia;	chr15:84135262	chr15:84570649~84580175:+
LUAD	cis	rs66486766	1	rs66486766	ENSG00000259728.4	LINC00933	6.47	2.43e-10	1.27e-07	0.44	0.28	Bipolar disorder lithium response (categorical) or schizophrenia;	chr15:84137308	chr15:84570649~84580175:+
LUAD	cis	rs875971	0.965	rs9969301	ENSG00000222364.1	RNU6-96P	6.47	2.43e-10	1.27e-07	0.32	0.28	Aortic root size;	chr7:66316668	chr7:66395191~66395286:+
LUAD	cis	rs10740039	0.81	rs10159646	ENSG00000254271.1	RP11-131N11.4	6.47	2.43e-10	1.27e-07	0.33	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60620366	chr10:60734342~60741828:+
LUAD	cis	rs1823913	0.599	rs67342262	ENSG00000227542.1	AC092614.2	6.47	2.43e-10	1.27e-07	0.35	0.28	Obesity-related traits;	chr2:191295612	chr2:191229165~191246172:-
LUAD	cis	rs8100891	0.537	rs2012353	ENSG00000267213.4	AC007773.2	-6.47	2.44e-10	1.27e-07	-0.45	-0.28	Neuroticism;	chr19:32408387	chr19:32390050~32405560:-
LUAD	cis	rs875971	0.964	rs55748098	ENSG00000222364.1	RNU6-96P	6.47	2.44e-10	1.27e-07	0.32	0.28	Aortic root size;	chr7:66298631	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.545	rs11770063	ENSG00000237310.1	GS1-124K5.4	6.47	2.44e-10	1.28e-07	0.36	0.28	Aortic root size;	chr7:66318029	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs4718335	ENSG00000237310.1	GS1-124K5.4	6.47	2.44e-10	1.28e-07	0.36	0.28	Aortic root size;	chr7:66339619	chr7:66493706~66495474:+
LUAD	cis	rs2739330	0.828	rs2877178	ENSG00000206090.4	AP000350.7	6.47	2.44e-10	1.28e-07	0.32	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23939998~23942798:+
LUAD	cis	rs2734839	0.964	rs11214605	ENSG00000270179.1	RP11-159N11.4	-6.47	2.44e-10	1.28e-07	-0.29	-0.28	Information processing speed;	chr11:113429879	chr11:113368478~113369117:+
LUAD	cis	rs516805	0.923	rs491171	ENSG00000279453.1	RP3-425C14.4	-6.47	2.45e-10	1.28e-07	-0.32	-0.28	Lymphocyte counts;	chr6:122408021	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.923	rs556675	ENSG00000279453.1	RP3-425C14.4	-6.47	2.45e-10	1.28e-07	-0.32	-0.28	Lymphocyte counts;	chr6:122408083	chr6:122436789~122439223:-
LUAD	cis	rs1062177	0.756	rs2915827	ENSG00000213433.5	RPLP1P6	6.47	2.45e-10	1.28e-07	0.36	0.28	Preschool internalizing problems;	chr5:151740144	chr5:151765859~151766378:-
LUAD	cis	rs7017914	0.902	rs7831792	ENSG00000223220.1	Y_RNA	6.47	2.45e-10	1.28e-07	0.32	0.28	Bone mineral density;	chr8:70653121	chr8:70780914~70781008:-
LUAD	cis	rs12468226	0.938	rs79117531	ENSG00000226261.1	AC064836.3	6.47	2.46e-10	1.28e-07	0.47	0.28	Urate levels;	chr2:202307690	chr2:202336024~202336727:-
LUAD	cis	rs7829975	0.688	rs6995407	ENSG00000253893.2	FAM85B	-6.47	2.46e-10	1.29e-07	-0.36	-0.28	Mood instability;	chr8:8527137	chr8:8167819~8226614:-
LUAD	cis	rs6921919	0.945	rs7765989	ENSG00000204709.4	LINC01556	6.47	2.46e-10	1.29e-07	0.41	0.28	Autism spectrum disorder or schizophrenia;	chr6:28432518	chr6:28943877~28944537:+
LUAD	cis	rs9318086	0.935	rs2025701	ENSG00000205861.10	C1QTNF9B-AS1	-6.47	2.47e-10	1.29e-07	-0.33	-0.28	Myopia (pathological);	chr13:23866442	chr13:23888889~23897263:+
LUAD	cis	rs227932	0.618	rs3807888	ENSG00000234286.1	AC006026.13	-6.47	2.47e-10	1.29e-07	-0.49	-0.28	Schizophrenia;	chr7:23710213	chr7:23680195~23680786:-
LUAD	cis	rs2243480	1	rs35396113	ENSG00000232546.1	RP11-458F8.1	-6.47	2.47e-10	1.29e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66030474	chr7:66848496~66858136:+
LUAD	cis	rs1823913	0.637	rs6741454	ENSG00000280083.1	RP11-317J9.1	6.47	2.47e-10	1.29e-07	0.34	0.28	Obesity-related traits;	chr2:191269520	chr2:191154118~191156070:-
LUAD	cis	rs6504950	0.579	rs17712917	ENSG00000275710.1	RP11-257O5.4	6.47	2.47e-10	1.29e-07	0.4	0.28	Breast cancer;	chr17:55194004	chr17:54964474~54964679:+
LUAD	cis	rs12439619	0.81	rs28876157	ENSG00000255769.6	GOLGA2P10	-6.47	2.48e-10	1.29e-07	-0.36	-0.28	Intelligence (multi-trait analysis);	chr15:82216708	chr15:82472993~82513950:-
LUAD	cis	rs1707322	0.752	rs6678444	ENSG00000234329.1	RP11-767N6.2	6.47	2.48e-10	1.29e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764175	chr1:45651039~45651826:-
LUAD	cis	rs2337406	0.587	rs916547	ENSG00000254174.1	IGHV1-12	6.47	2.48e-10	1.3e-07	0.25	0.28	Alzheimer's disease (late onset);	chr14:106646735	chr14:106122420~106122709:-
LUAD	cis	rs7017914	0.902	rs34882924	ENSG00000223220.1	Y_RNA	6.47	2.48e-10	1.3e-07	0.32	0.28	Bone mineral density;	chr8:70654073	chr8:70780914~70781008:-
LUAD	cis	rs10129255	0.518	rs8009612	ENSG00000224373.3	IGHV4-59	6.47	2.48e-10	1.3e-07	0.17	0.28	Kawasaki disease;	chr14:106777510	chr14:106627249~106627825:-
LUAD	cis	rs5753618	0.554	rs5753648	ENSG00000236132.1	CTA-440B3.1	-6.47	2.48e-10	1.3e-07	-0.37	-0.28	Colorectal cancer;	chr22:31483479	chr22:31816379~31817491:-
LUAD	cis	rs1707322	0.721	rs10890346	ENSG00000234329.1	RP11-767N6.2	-6.47	2.48e-10	1.3e-07	-0.3	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758220	chr1:45651039~45651826:-
LUAD	cis	rs10129255	0.5	rs10131875	ENSG00000224373.3	IGHV4-59	6.47	2.49e-10	1.3e-07	0.17	0.28	Kawasaki disease;	chr14:106792798	chr14:106627249~106627825:-
LUAD	cis	rs11977715	0.521	rs1476516	ENSG00000233942.1	AC004012.1	-6.47	2.49e-10	1.3e-07	-0.35	-0.28	Middle childhood and early adolescence aggressive behavior;	chr7:95489898	chr7:95471835~95473998:+
LUAD	cis	rs853679	0.607	rs13207345	ENSG00000204709.4	LINC01556	6.47	2.49e-10	1.3e-07	0.61	0.28	Depression;	chr6:28297795	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs72854513	ENSG00000204709.4	LINC01556	6.47	2.49e-10	1.3e-07	0.61	0.28	Depression;	chr6:28298177	chr6:28943877~28944537:+
LUAD	cis	rs55665837	1	rs10832254	ENSG00000251991.1	RNU7-49P	6.46	2.49e-10	1.3e-07	0.31	0.28	Vitamin D levels;	chr11:14413152	chr11:14478892~14478953:+
LUAD	cis	rs55665837	1	rs11023214	ENSG00000251991.1	RNU7-49P	6.46	2.49e-10	1.3e-07	0.31	0.28	Vitamin D levels;	chr11:14414713	chr11:14478892~14478953:+
LUAD	cis	rs1061377	0.965	rs7669376	ENSG00000249685.1	RP11-360F5.3	6.46	2.49e-10	1.3e-07	0.34	0.28	Uric acid levels;	chr4:39116717	chr4:39133913~39135608:+
LUAD	cis	rs10463554	0.716	rs152136	ENSG00000175749.11	EIF3KP1	6.46	2.49e-10	1.3e-07	0.38	0.28	Parkinson's disease;	chr5:103248167	chr5:103032376~103033031:+
LUAD	cis	rs67311347	1	rs4128740	ENSG00000223797.4	ENTPD3-AS1	6.46	2.49e-10	1.3e-07	0.31	0.28	Renal cell carcinoma;	chr3:40478041	chr3:40313802~40453329:-
LUAD	cis	rs875971	0.867	rs1002053	ENSG00000222364.1	RNU6-96P	6.46	2.5e-10	1.3e-07	0.32	0.28	Aortic root size;	chr7:66333558	chr7:66395191~66395286:+
LUAD	cis	rs1113500	0.565	rs1777455	ENSG00000226822.1	RP11-356N1.2	-6.46	2.5e-10	1.3e-07	-0.37	-0.28	Growth-regulated protein alpha levels;	chr1:108047666	chr1:108071482~108074519:+
LUAD	cis	rs2243480	1	rs2462569	ENSG00000232546.1	RP11-458F8.1	6.46	2.5e-10	1.3e-07	0.36	0.28	Diabetic kidney disease;	chr7:66009859	chr7:66848496~66858136:+
LUAD	cis	rs11977715	0.538	rs43067	ENSG00000233942.1	AC004012.1	-6.46	2.5e-10	1.3e-07	-0.35	-0.28	Middle childhood and early adolescence aggressive behavior;	chr7:95485392	chr7:95471835~95473998:+
LUAD	cis	rs113835537	0.529	rs11227525	ENSG00000255517.5	CTD-3074O7.5	-6.46	2.5e-10	1.31e-07	-0.34	-0.28	Airway imaging phenotypes;	chr11:66540594	chr11:66473490~66480233:-
LUAD	cis	rs2015599	0.623	rs10843385	ENSG00000275476.1	RP11-996F15.4	-6.46	2.5e-10	1.31e-07	-0.31	-0.28	Platelet count;Mean platelet volume;	chr12:29323100	chr12:29277397~29277882:-
LUAD	cis	rs2273788	0.837	rs13297520	ENSG00000204173.9	LRRC37A5P	6.46	2.5e-10	1.31e-07	0.36	0.28	Monocyte count;	chr9:111588861	chr9:111602831~111631289:-
LUAD	cis	rs2243480	1	rs781157	ENSG00000226824.5	RP4-756H11.3	-6.46	2.5e-10	1.31e-07	-0.52	-0.28	Diabetic kidney disease;	chr7:66013324	chr7:66654538~66669855:+
LUAD	cis	rs8072100	0.745	rs7214410	ENSG00000228782.6	CTD-2026D20.3	6.46	2.5e-10	1.31e-07	0.31	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47345262	chr17:47450568~47492492:-
LUAD	cis	rs11168854	0.719	rs11168902	ENSG00000258017.1	RP11-386G11.10	-6.46	2.51e-10	1.31e-07	-0.36	-0.28	Body mass index;	chr12:49174483	chr12:49127782~49147869:+
LUAD	cis	rs2117029	0.553	rs11168903	ENSG00000258017.1	RP11-386G11.10	-6.46	2.51e-10	1.31e-07	-0.36	-0.28	Intelligence (multi-trait analysis);	chr12:49174883	chr12:49127782~49147869:+
LUAD	cis	rs17301013	0.606	rs4650939	ENSG00000227373.4	RP11-160H22.5	6.46	2.51e-10	1.31e-07	0.4	0.28	Systemic lupus erythematosus;	chr1:174096823	chr1:174115300~174160004:-
LUAD	cis	rs1823913	0.637	rs2356354	ENSG00000280083.1	RP11-317J9.1	6.46	2.52e-10	1.31e-07	0.34	0.28	Obesity-related traits;	chr2:191270970	chr2:191154118~191156070:-
LUAD	cis	rs853679	0.55	rs1237875	ENSG00000219392.1	RP1-265C24.5	6.46	2.52e-10	1.31e-07	0.38	0.28	Depression;	chr6:28205232	chr6:28115628~28116551:+
LUAD	cis	rs7829975	0.688	rs13270194	ENSG00000253981.4	ALG1L13P	6.46	2.52e-10	1.31e-07	0.32	0.28	Mood instability;	chr8:8520592	chr8:8236003~8244667:-
LUAD	cis	rs12468226	1	rs7587234	ENSG00000226261.1	AC064836.3	6.46	2.53e-10	1.32e-07	0.47	0.28	Urate levels;	chr2:202351699	chr2:202336024~202336727:-
LUAD	cis	rs227932	0.764	rs4722246	ENSG00000234286.1	AC006026.13	6.46	2.53e-10	1.32e-07	0.49	0.28	Schizophrenia;	chr7:23682359	chr7:23680195~23680786:-
LUAD	cis	rs227932	0.614	rs12700458	ENSG00000234286.1	AC006026.13	6.46	2.53e-10	1.32e-07	0.49	0.28	Schizophrenia;	chr7:23682525	chr7:23680195~23680786:-
LUAD	cis	rs113835537	0.597	rs57288351	ENSG00000255517.5	CTD-3074O7.5	-6.46	2.53e-10	1.32e-07	-0.34	-0.28	Airway imaging phenotypes;	chr11:66540018	chr11:66473490~66480233:-
LUAD	cis	rs7811142	1	rs67163493	ENSG00000242294.5	STAG3L5P	6.46	2.53e-10	1.32e-07	0.24	0.28	Platelet count;	chr7:100426215	chr7:100336079~100351900:+
LUAD	cis	rs8059260	0.668	rs6498152	ENSG00000274038.1	RP11-66H6.4	-6.46	2.53e-10	1.32e-07	-0.39	-0.28	Alcohol consumption over the past year;	chr16:11030590	chr16:11056556~11057034:+
LUAD	cis	rs950169	0.544	rs12913702	ENSG00000225151.9	GOLGA2P7	-6.46	2.54e-10	1.32e-07	-0.39	-0.28	Schizophrenia;	chr15:84609953	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.509	rs71395455	ENSG00000225151.9	GOLGA2P7	-6.46	2.54e-10	1.32e-07	-0.39	-0.28	Schizophrenia;	chr15:84610573	chr15:84199311~84230136:-
LUAD	cis	rs6142102	0.778	rs6059581	ENSG00000276073.1	RP5-1125A11.7	-6.46	2.54e-10	1.32e-07	-0.29	-0.28	Skin pigmentation;	chr20:33940582	chr20:33985617~33988989:-
LUAD	cis	rs55665837	1	rs2305305	ENSG00000251991.1	RNU7-49P	6.46	2.54e-10	1.32e-07	0.32	0.28	Vitamin D levels;	chr11:14519396	chr11:14478892~14478953:+
LUAD	cis	rs10129255	0.5	rs7157975	ENSG00000224373.3	IGHV4-59	6.46	2.54e-10	1.32e-07	0.17	0.28	Kawasaki disease;	chr14:106804049	chr14:106627249~106627825:-
LUAD	cis	rs3762637	1	rs9843165	ENSG00000272758.4	RP11-299J3.8	-6.46	2.54e-10	1.32e-07	-0.44	-0.28	LDL cholesterol levels;	chr3:122412264	chr3:122416207~122443180:+
LUAD	cis	rs7849270	1	rs6478867	ENSG00000268707.1	RP11-247A12.7	6.46	2.54e-10	1.33e-07	0.32	0.28	Blood metabolite ratios;	chr9:129141644	chr9:129170434~129170940:+
LUAD	cis	rs8177876	0.749	rs2278025	ENSG00000261838.4	RP11-303E16.6	-6.46	2.55e-10	1.33e-07	-0.56	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81045636	chr16:81069854~81076598:+
LUAD	cis	rs1707322	0.662	rs11211160	ENSG00000234329.1	RP11-767N6.2	6.46	2.55e-10	1.33e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680557	chr1:45651039~45651826:-
LUAD	cis	rs783540	0.967	rs783527	ENSG00000278603.1	RP13-608F4.5	-6.46	2.55e-10	1.33e-07	-0.33	-0.28	Schizophrenia;	chr15:82617096	chr15:82472203~82472426:+
LUAD	cis	rs7927592	0.956	rs60212556	ENSG00000212093.1	AP000807.1	6.46	2.55e-10	1.33e-07	0.31	0.28	Total body bone mineral density;	chr11:68538026	chr11:68506083~68506166:-
LUAD	cis	rs11098499	0.562	rs13101722	ENSG00000248280.1	RP11-33B1.2	-6.46	2.55e-10	1.33e-07	-0.33	-0.28	Corneal astigmatism;	chr4:119634820	chr4:119440561~119450157:-
LUAD	cis	rs12699921	0.632	rs11768866	ENSG00000279048.1	RP11-511H23.2	-6.46	2.56e-10	1.33e-07	-0.23	-0.28	Fibrinogen levels;	chr7:17925956	chr7:17940503~17942922:+
LUAD	cis	rs673078	1	rs673078	ENSG00000275759.1	RP11-131L12.3	6.46	2.56e-10	1.33e-07	0.37	0.28	Glucose homeostasis traits;	chr12:118353636	chr12:118428281~118428870:+
LUAD	cis	rs9549367	0.789	rs9549708	ENSG00000269125.1	RP11-98F14.11	-6.46	2.56e-10	1.33e-07	-0.35	-0.28	Platelet distribution width;	chr13:113237573	chr13:113165002~113165183:-
LUAD	cis	rs11690935	0.731	rs10930491	ENSG00000228389.1	AC068039.4	-6.46	2.56e-10	1.33e-07	-0.3	-0.28	Schizophrenia;	chr2:171713314	chr2:171773482~171775844:+
LUAD	cis	rs7829975	1	rs7829975	ENSG00000253893.2	FAM85B	6.46	2.56e-10	1.33e-07	0.35	0.28	Mood instability;	chr8:8690607	chr8:8167819~8226614:-
LUAD	cis	rs2243480	1	rs6958420	ENSG00000226824.5	RP4-756H11.3	6.46	2.56e-10	1.34e-07	0.53	0.28	Diabetic kidney disease;	chr7:66286184	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs1392104	ENSG00000226824.5	RP4-756H11.3	6.46	2.56e-10	1.34e-07	0.53	0.28	Diabetic kidney disease;	chr7:66294120	chr7:66654538~66669855:+
LUAD	cis	rs950169	0.65	rs12902052	ENSG00000259728.4	LINC00933	6.46	2.57e-10	1.34e-07	0.43	0.28	Schizophrenia;	chr15:84582607	chr15:84570649~84580175:+
LUAD	cis	rs7811142	1	rs7787620	ENSG00000242294.5	STAG3L5P	6.46	2.57e-10	1.34e-07	0.24	0.28	Platelet count;	chr7:100491611	chr7:100336079~100351900:+
LUAD	cis	rs7811142	1	rs11769700	ENSG00000242294.5	STAG3L5P	6.46	2.57e-10	1.34e-07	0.24	0.28	Platelet count;	chr7:100492426	chr7:100336079~100351900:+
LUAD	cis	rs2117029	0.554	rs12579015	ENSG00000258017.1	RP11-386G11.10	-6.46	2.57e-10	1.34e-07	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49162648	chr12:49127782~49147869:+
LUAD	cis	rs9506514	0.722	rs4769124	ENSG00000222726.1	RNU2-7P	6.46	2.57e-10	1.34e-07	0.32	0.28	Coronary artery calcification;	chr13:20652706	chr13:20612161~20612338:+
LUAD	cis	rs394563	0.967	rs438852	ENSG00000231760.4	RP11-350J20.5	-6.46	2.57e-10	1.34e-07	-0.35	-0.28	Dupuytren's disease;	chr6:149473397	chr6:149796151~149826294:-
LUAD	cis	rs755249	0.833	rs61779313	ENSG00000228060.1	RP11-69E11.8	-6.46	2.57e-10	1.34e-07	-0.28	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39478577	chr1:39565160~39573203:+
LUAD	cis	rs155076	1	rs658244	ENSG00000233325.3	MIPEPP3	6.46	2.58e-10	1.34e-07	0.45	0.28	White matter hyperintensity burden;	chr13:21276837	chr13:21298139~21306373:+
LUAD	cis	rs11214589	1	rs11214589	ENSG00000270179.1	RP11-159N11.4	-6.46	2.58e-10	1.34e-07	-0.28	-0.28	Neuroticism;	chr11:113374326	chr11:113368478~113369117:+
LUAD	cis	rs1707322	0.752	rs4586014	ENSG00000234329.1	RP11-767N6.2	6.46	2.58e-10	1.35e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684771	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.648	rs4439382	ENSG00000234329.1	RP11-767N6.2	6.46	2.58e-10	1.35e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45685133	chr1:45651039~45651826:-
LUAD	cis	rs6504622	0.818	rs11079742	ENSG00000262879.4	RP11-156P1.3	-6.46	2.58e-10	1.35e-07	-0.33	-0.28	Orofacial clefts;	chr17:46942762	chr17:46984045~47100323:-
LUAD	cis	rs11214589	0.774	rs7116782	ENSG00000270179.1	RP11-159N11.4	-6.46	2.59e-10	1.35e-07	-0.28	-0.28	Neuroticism;	chr11:113380216	chr11:113368478~113369117:+
LUAD	cis	rs875971	0.862	rs28470208	ENSG00000222364.1	RNU6-96P	6.46	2.59e-10	1.35e-07	0.32	0.28	Aortic root size;	chr7:66119713	chr7:66395191~66395286:+
LUAD	cis	rs3096299	0.838	rs3102376	ENSG00000274627.1	RP11-104N10.2	6.46	2.59e-10	1.35e-07	0.27	0.28	Multiple myeloma (IgH translocation);	chr16:89336065	chr16:89516797~89522217:+
LUAD	cis	rs7927592	0.956	rs7104877	ENSG00000212093.1	AP000807.1	-6.46	2.59e-10	1.35e-07	-0.31	-0.28	Total body bone mineral density;	chr11:68610134	chr11:68506083~68506166:-
LUAD	cis	rs9450351	0.744	rs9359674	ENSG00000203875.9	SNHG5	6.46	2.6e-10	1.35e-07	0.59	0.28	Interferon gamma-induced protein 10 levels;	chr6:85996191	chr6:85660950~85678736:-
LUAD	cis	rs7849270	1	rs3124511	ENSG00000268707.1	RP11-247A12.7	6.46	2.6e-10	1.35e-07	0.33	0.28	Blood metabolite ratios;	chr9:129139179	chr9:129170434~129170940:+
LUAD	cis	rs950169	0.959	rs12902070	ENSG00000259728.4	LINC00933	6.46	2.6e-10	1.35e-07	0.43	0.28	Schizophrenia;	chr15:84124806	chr15:84570649~84580175:+
LUAD	cis	rs67311347	0.911	rs58282210	ENSG00000223797.4	ENTPD3-AS1	6.46	2.6e-10	1.35e-07	0.3	0.28	Renal cell carcinoma;	chr3:40376452	chr3:40313802~40453329:-
LUAD	cis	rs7829975	0.564	rs2976855	ENSG00000253893.2	FAM85B	-6.46	2.6e-10	1.35e-07	-0.35	-0.28	Mood instability;	chr8:8444284	chr8:8167819~8226614:-
LUAD	cis	rs7567389	0.504	rs41280570	ENSG00000236682.1	AC068282.3	-6.46	2.6e-10	1.35e-07	-0.37	-0.28	Self-rated health;	chr2:127418654	chr2:127389130~127400580:+
LUAD	cis	rs9318086	0.712	rs3794339	ENSG00000205861.10	C1QTNF9B-AS1	-6.46	2.6e-10	1.35e-07	-0.34	-0.28	Myopia (pathological);	chr13:23859926	chr13:23888889~23897263:+
LUAD	cis	rs17301013	0.507	rs7414200	ENSG00000227373.4	RP11-160H22.5	6.46	2.6e-10	1.35e-07	0.42	0.28	Systemic lupus erythematosus;	chr1:174569820	chr1:174115300~174160004:-
LUAD	cis	rs783540	0.934	rs1594511	ENSG00000278603.1	RP13-608F4.5	-6.46	2.6e-10	1.35e-07	-0.33	-0.28	Schizophrenia;	chr15:82638312	chr15:82472203~82472426:+
LUAD	cis	rs858239	0.73	rs858290	ENSG00000226816.2	AC005082.12	6.46	2.61e-10	1.36e-07	0.37	0.28	Cerebrospinal fluid biomarker levels;	chr7:23208417	chr7:23206013~23208045:+
LUAD	cis	rs858239	0.73	rs858289	ENSG00000226816.2	AC005082.12	6.46	2.61e-10	1.36e-07	0.37	0.28	Cerebrospinal fluid biomarker levels;	chr7:23208539	chr7:23206013~23208045:+
LUAD	cis	rs2745572	0.557	rs2745569	ENSG00000272279.1	RP11-157J24.2	-6.46	2.61e-10	1.36e-07	-0.34	-0.28	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1547396	chr6:1528364~1528911:-
LUAD	cis	rs2243480	1	rs316307	ENSG00000226824.5	RP4-756H11.3	-6.46	2.61e-10	1.36e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:66105184	chr7:66654538~66669855:+
LUAD	cis	rs67311347	1	rs73080126	ENSG00000223797.4	ENTPD3-AS1	6.46	2.61e-10	1.36e-07	0.31	0.28	Renal cell carcinoma;	chr3:40467662	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs28871903	ENSG00000223797.4	ENTPD3-AS1	6.46	2.61e-10	1.36e-07	0.31	0.28	Renal cell carcinoma;	chr3:40469603	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs56291770	ENSG00000223797.4	ENTPD3-AS1	6.46	2.61e-10	1.36e-07	0.31	0.28	Renal cell carcinoma;	chr3:40473879	chr3:40313802~40453329:-
LUAD	cis	rs5753618	0.504	rs9609329	ENSG00000236132.1	CTA-440B3.1	-6.46	2.61e-10	1.36e-07	-0.35	-0.28	Colorectal cancer;	chr22:31570327	chr22:31816379~31817491:-
LUAD	cis	rs6772849	0.896	rs4557179	ENSG00000242551.2	POU5F1P6	-6.46	2.61e-10	1.36e-07	-0.33	-0.28	Monocyte percentage of white cells;Monocyte count;	chr3:128647883	chr3:128674735~128677005:-
LUAD	cis	rs2276314	0.802	rs58906216	ENSG00000278986.1	RP11-723J4.3	-6.46	2.61e-10	1.36e-07	-0.34	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36050334	chr18:35972151~35973916:+
LUAD	cis	rs2276314	0.857	rs6507157	ENSG00000278986.1	RP11-723J4.3	-6.46	2.61e-10	1.36e-07	-0.34	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36051740	chr18:35972151~35973916:+
LUAD	cis	rs875971	0.545	rs73146609	ENSG00000237310.1	GS1-124K5.4	6.46	2.61e-10	1.36e-07	0.36	0.28	Aortic root size;	chr7:66302477	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs2173571	ENSG00000237310.1	GS1-124K5.4	6.46	2.61e-10	1.36e-07	0.36	0.28	Aortic root size;	chr7:66305392	chr7:66493706~66495474:+
LUAD	cis	rs2739330	0.828	rs5760107	ENSG00000228039.3	KB-1125A3.10	6.46	2.62e-10	1.36e-07	0.35	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23963780~23964374:+
LUAD	cis	rs2739330	0.789	rs5760109	ENSG00000228039.3	KB-1125A3.10	6.46	2.62e-10	1.36e-07	0.35	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23963780~23964374:+
LUAD	cis	rs1823913	1	rs6749232	ENSG00000230611.1	HMGB1P27	6.46	2.62e-10	1.36e-07	0.34	0.28	Obesity-related traits;	chr2:191250326	chr2:191174233~191174835:+
LUAD	cis	rs950169	1	rs35297609	ENSG00000259728.4	LINC00933	6.46	2.62e-10	1.36e-07	0.43	0.28	Schizophrenia;	chr15:84104144	chr15:84570649~84580175:+
LUAD	cis	rs950169	1	rs62026530	ENSG00000259728.4	LINC00933	6.46	2.62e-10	1.36e-07	0.43	0.28	Schizophrenia;	chr15:84107088	chr15:84570649~84580175:+
LUAD	cis	rs4141404	0.787	rs11913992	ENSG00000236132.1	CTA-440B3.1	6.46	2.62e-10	1.36e-07	0.32	0.28	Paclitaxel-induced neuropathy;	chr22:31189234	chr22:31816379~31817491:-
LUAD	cis	rs1799949	1	rs11653460	ENSG00000267681.1	CTD-3199J23.6	-6.46	2.62e-10	1.36e-07	-0.33	-0.28	Menopause (age at onset);	chr17:43179289	chr17:43144956~43145255:+
LUAD	cis	rs2408955	0.541	rs11168428	ENSG00000240399.1	RP1-228P16.1	-6.46	2.62e-10	1.36e-07	-0.27	-0.28	Glycated hemoglobin levels;	chr12:48153345	chr12:48054813~48055591:-
LUAD	cis	rs875971	0.545	rs73376401	ENSG00000237310.1	GS1-124K5.4	6.46	2.63e-10	1.36e-07	0.35	0.28	Aortic root size;	chr7:66174841	chr7:66493706~66495474:+
LUAD	cis	rs9549367	0.713	rs9549691	ENSG00000269125.1	RP11-98F14.11	-6.46	2.63e-10	1.37e-07	-0.37	-0.28	Platelet distribution width;	chr13:113207292	chr13:113165002~113165183:-
LUAD	cis	rs1707322	0.752	rs6662164	ENSG00000234329.1	RP11-767N6.2	6.46	2.63e-10	1.37e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680558	chr1:45651039~45651826:-
LUAD	cis	rs73219805	0.597	rs71517887	ENSG00000228451.3	SDAD1P1	-6.46	2.63e-10	1.37e-07	-0.49	-0.28	Schizophrenia;	chr8:26374081	chr8:26379259~26382953:-
LUAD	cis	rs17684571	0.938	rs35619924	ENSG00000231441.1	RP11-472M19.2	6.46	2.64e-10	1.37e-07	0.4	0.28	Schizophrenia;	chr6:56695868	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.938	rs10498811	ENSG00000231441.1	RP11-472M19.2	6.46	2.64e-10	1.37e-07	0.4	0.28	Schizophrenia;	chr6:56696475	chr6:56844002~56864078:+
LUAD	cis	rs891378	0.785	rs6700846	ENSG00000274245.1	RP11-357P18.2	-6.46	2.64e-10	1.37e-07	-0.36	-0.28	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207228799	chr1:207372559~207373252:+
LUAD	cis	rs2243480	1	rs313813	ENSG00000232546.1	RP11-458F8.1	-6.46	2.64e-10	1.37e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66038513	chr7:66848496~66858136:+
LUAD	cis	rs7246657	0.882	rs4803539	ENSG00000276846.1	CTD-3220F14.3	6.46	2.64e-10	1.37e-07	0.38	0.28	Coronary artery calcification;	chr19:37406620	chr19:37314868~37315620:-
LUAD	cis	rs2243480	0.901	rs313808	ENSG00000226824.5	RP4-756H11.3	-6.46	2.64e-10	1.37e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:66034886	chr7:66654538~66669855:+
LUAD	cis	rs9309473	1	rs11899902	ENSG00000163016.8	ALMS1P	6.46	2.65e-10	1.38e-07	0.35	0.28	Metabolite levels;	chr2:73404436	chr2:73644919~73685576:+
LUAD	cis	rs9309473	1	rs13428235	ENSG00000163016.8	ALMS1P	6.46	2.65e-10	1.38e-07	0.35	0.28	Metabolite levels;	chr2:73406302	chr2:73644919~73685576:+
LUAD	cis	rs6921919	0.638	rs2108926	ENSG00000204709.4	LINC01556	6.45	2.65e-10	1.38e-07	0.36	0.28	Autism spectrum disorder or schizophrenia;	chr6:28340970	chr6:28943877~28944537:+
LUAD	cis	rs950169	1	rs35658069	ENSG00000259728.4	LINC00933	6.45	2.65e-10	1.38e-07	0.43	0.28	Schizophrenia;	chr15:84111394	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.656	rs748455	ENSG00000225151.9	GOLGA2P7	-6.45	2.65e-10	1.38e-07	-0.39	-0.28	Schizophrenia;	chr15:84606344	chr15:84199311~84230136:-
LUAD	cis	rs2739330	0.828	rs4820572	ENSG00000206090.4	AP000350.7	6.45	2.65e-10	1.38e-07	0.33	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23939998~23942798:+
LUAD	cis	rs9549367	0.789	rs7338235	ENSG00000269125.1	RP11-98F14.11	-6.45	2.66e-10	1.38e-07	-0.34	-0.28	Platelet distribution width;	chr13:113234373	chr13:113165002~113165183:-
LUAD	cis	rs6860806	0.507	rs2631369	ENSG00000233006.5	AC034220.3	-6.45	2.67e-10	1.39e-07	-0.29	-0.28	Breast cancer;	chr5:132369574	chr5:132311285~132369916:-
LUAD	cis	rs274567	0.501	rs2631368	ENSG00000233006.5	AC034220.3	-6.45	2.67e-10	1.39e-07	-0.29	-0.28	Blood metabolite levels;	chr5:132369605	chr5:132311285~132369916:-
LUAD	cis	rs17684571	0.938	rs13196211	ENSG00000231441.1	RP11-472M19.2	6.45	2.68e-10	1.39e-07	0.4	0.28	Schizophrenia;	chr6:56697697	chr6:56844002~56864078:+
LUAD	cis	rs17684571	1	rs5024547	ENSG00000231441.1	RP11-472M19.2	6.45	2.68e-10	1.39e-07	0.4	0.28	Schizophrenia;	chr6:56698295	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.938	rs13206849	ENSG00000231441.1	RP11-472M19.2	6.45	2.68e-10	1.39e-07	0.4	0.28	Schizophrenia;	chr6:56701823	chr6:56844002~56864078:+
LUAD	cis	rs77204473	0.744	rs17120523	ENSG00000254851.1	RP11-109L13.1	6.45	2.68e-10	1.39e-07	0.73	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117223875	chr11:117135528~117138582:+
LUAD	cis	rs1799949	1	rs8074136	ENSG00000267681.1	CTD-3199J23.6	-6.45	2.68e-10	1.39e-07	-0.33	-0.28	Menopause (age at onset);	chr17:43190296	chr17:43144956~43145255:+
LUAD	cis	rs720475	1	rs720475	ENSG00000170356.8	OR2A20P	6.45	2.68e-10	1.39e-07	0.37	0.28	Breast cancer;	chr7:144377836	chr7:144250045~144252957:-
LUAD	cis	rs55665837	1	rs10832268	ENSG00000251991.1	RNU7-49P	6.45	2.68e-10	1.39e-07	0.32	0.28	Vitamin D levels;	chr11:14443522	chr11:14478892~14478953:+
LUAD	cis	rs55665837	1	rs10832269	ENSG00000251991.1	RNU7-49P	6.45	2.68e-10	1.39e-07	0.32	0.28	Vitamin D levels;	chr11:14443523	chr11:14478892~14478953:+
LUAD	cis	rs55665837	1	rs10832271	ENSG00000251991.1	RNU7-49P	6.45	2.68e-10	1.39e-07	0.32	0.28	Vitamin D levels;	chr11:14445373	chr11:14478892~14478953:+
LUAD	cis	rs9549367	0.789	rs6577034	ENSG00000269125.1	RP11-98F14.11	-6.45	2.68e-10	1.39e-07	-0.34	-0.28	Platelet distribution width;	chr13:113225586	chr13:113165002~113165183:-
LUAD	cis	rs17711722	0.528	rs73138179	ENSG00000236529.1	RP13-254B10.1	6.45	2.69e-10	1.39e-07	0.29	0.28	Calcium levels;	chr7:65829495	chr7:65840212~65840596:+
LUAD	cis	rs875971	0.545	rs10950036	ENSG00000237310.1	GS1-124K5.4	6.45	2.69e-10	1.39e-07	0.34	0.28	Aortic root size;	chr7:66353241	chr7:66493706~66495474:+
LUAD	cis	rs6860806	0.507	rs273901	ENSG00000233006.5	AC034220.3	6.45	2.69e-10	1.4e-07	0.28	0.28	Breast cancer;	chr5:132358667	chr5:132311285~132369916:-
LUAD	cis	rs270601	0.913	rs273899	ENSG00000233006.5	AC034220.3	6.45	2.69e-10	1.4e-07	0.28	0.28	Acylcarnitine levels;	chr5:132359485	chr5:132311285~132369916:-
LUAD	cis	rs875971	1	rs1981798	ENSG00000222364.1	RNU6-96P	-6.45	2.69e-10	1.4e-07	-0.32	-0.28	Aortic root size;	chr7:66489916	chr7:66395191~66395286:+
LUAD	cis	rs12908161	1	rs60957376	ENSG00000259728.4	LINC00933	6.45	2.69e-10	1.4e-07	0.41	0.28	Schizophrenia;	chr15:84737561	chr15:84570649~84580175:+
LUAD	cis	rs2337406	0.587	rs2516889	ENSG00000211974.3	IGHV2-70	6.45	2.69e-10	1.4e-07	0.35	0.28	Alzheimer's disease (late onset);	chr14:106648903	chr14:106723574~106724093:-
LUAD	cis	rs13160562	0.666	rs26481	ENSG00000272109.1	CTD-2260A17.3	-6.45	2.7e-10	1.4e-07	-0.3	-0.28	Alcohol dependence;	chr5:96767648	chr5:96804353~96806105:+
LUAD	cis	rs950169	1	rs12916348	ENSG00000259728.4	LINC00933	6.45	2.7e-10	1.4e-07	0.43	0.28	Schizophrenia;	chr15:84096775	chr15:84570649~84580175:+
LUAD	cis	rs1823913	1	rs4853568	ENSG00000230611.1	HMGB1P27	6.45	2.7e-10	1.4e-07	0.34	0.28	Obesity-related traits;	chr2:191261464	chr2:191174233~191174835:+
LUAD	cis	rs1823913	0.637	rs13382985	ENSG00000280083.1	RP11-317J9.1	6.45	2.71e-10	1.4e-07	0.33	0.28	Obesity-related traits;	chr2:191306335	chr2:191154118~191156070:-
LUAD	cis	rs10200159	0.793	rs12615063	ENSG00000272606.1	RP11-554J4.1	6.45	2.71e-10	1.4e-07	0.47	0.28	Vitiligo;	chr2:55680347	chr2:55617909~55618373:+
LUAD	cis	rs10200159	0.793	rs13420929	ENSG00000272606.1	RP11-554J4.1	6.45	2.71e-10	1.4e-07	0.47	0.28	Vitiligo;	chr2:55692185	chr2:55617909~55618373:+
LUAD	cis	rs10200159	0.793	rs7586115	ENSG00000272606.1	RP11-554J4.1	6.45	2.71e-10	1.4e-07	0.47	0.28	Vitiligo;	chr2:55692501	chr2:55617909~55618373:+
LUAD	cis	rs950169	0.92	rs12915390	ENSG00000259728.4	LINC00933	6.45	2.71e-10	1.41e-07	0.43	0.28	Schizophrenia;	chr15:84123317	chr15:84570649~84580175:+
LUAD	cis	rs9640161	0.658	rs74348353	ENSG00000261305.1	RP4-584D14.7	6.45	2.71e-10	1.41e-07	0.42	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150356566	chr7:150341771~150342607:+
LUAD	cis	rs4660456	0.504	rs2744805	ENSG00000237899.1	RP4-739H11.3	6.45	2.72e-10	1.41e-07	0.4	0.28	Platelet count;	chr1:40654827	chr1:40669089~40687588:-
LUAD	cis	rs8062405	0.69	rs6498089	ENSG00000259982.1	CDC37P1	-6.45	2.72e-10	1.41e-07	-0.35	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28617979	chr16:28700294~28701540:-
LUAD	cis	rs77204473	0.744	rs77955134	ENSG00000254851.1	RP11-109L13.1	6.45	2.73e-10	1.41e-07	0.72	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117021652	chr11:117135528~117138582:+
LUAD	cis	rs77204473	0.744	rs77594377	ENSG00000254851.1	RP11-109L13.1	6.45	2.73e-10	1.41e-07	0.72	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117021730	chr11:117135528~117138582:+
LUAD	cis	rs10740039	0.883	rs7068934	ENSG00000254271.1	RP11-131N11.4	6.45	2.74e-10	1.42e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60636490	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs10740038	ENSG00000254271.1	RP11-131N11.4	6.45	2.74e-10	1.42e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60643479	chr10:60734342~60741828:+
LUAD	cis	rs1318937	1	rs3773469	ENSG00000224660.1	SH3BP5-AS1	6.45	2.74e-10	1.42e-07	0.22	0.28	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15266733	chr3:15254184~15264493:+
LUAD	cis	rs11603023	0.874	rs577396	ENSG00000255422.1	AP002954.4	-6.45	2.75e-10	1.42e-07	-0.34	-0.28	Cholesterol, total;	chr11:118628753	chr11:118704607~118750263:+
LUAD	cis	rs11603023	0.874	rs11216934	ENSG00000255422.1	AP002954.4	-6.45	2.75e-10	1.42e-07	-0.34	-0.28	Cholesterol, total;	chr11:118630742	chr11:118704607~118750263:+
LUAD	cis	rs9309473	1	rs6755217	ENSG00000163016.8	ALMS1P	6.45	2.75e-10	1.42e-07	0.35	0.28	Metabolite levels;	chr2:73414157	chr2:73644919~73685576:+
LUAD	cis	rs11098499	0.754	rs1546503	ENSG00000248280.1	RP11-33B1.2	6.45	2.75e-10	1.42e-07	0.35	0.28	Corneal astigmatism;	chr4:119320012	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.708	rs1546506	ENSG00000248280.1	RP11-33B1.2	6.45	2.75e-10	1.42e-07	0.35	0.28	Corneal astigmatism;	chr4:119320085	chr4:119440561~119450157:-
LUAD	cis	rs34375054	0.525	rs7133614	ENSG00000279233.1	RP11-158L12.4	6.45	2.75e-10	1.43e-07	0.24	0.28	Post bronchodilator FEV1/FVC ratio;	chr12:125121411	chr12:125138245~125141711:+
LUAD	cis	rs9640161	0.789	rs34728606	ENSG00000261305.1	RP4-584D14.7	6.45	2.75e-10	1.43e-07	0.42	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150357605	chr7:150341771~150342607:+
LUAD	cis	rs17711722	0.503	rs453835	ENSG00000236529.1	RP13-254B10.1	-6.45	2.75e-10	1.43e-07	-0.29	-0.28	Calcium levels;	chr7:66046172	chr7:65840212~65840596:+
LUAD	cis	rs12554020	0.892	rs3815563	ENSG00000227603.1	RP11-165J3.6	6.45	2.76e-10	1.43e-07	0.41	0.28	Schizophrenia;	chr9:93450864	chr9:93435332~93437121:-
LUAD	cis	rs12554020	1	rs7853605	ENSG00000227603.1	RP11-165J3.6	6.45	2.76e-10	1.43e-07	0.41	0.28	Schizophrenia;	chr9:93451247	chr9:93435332~93437121:-
LUAD	cis	rs9847710	0.696	rs2564932	ENSG00000242142.1	SERBP1P3	-6.45	2.76e-10	1.43e-07	-0.33	-0.28	Ulcerative colitis;	chr3:52987994	chr3:53064283~53065091:-
LUAD	cis	rs9326248	0.559	rs476399	ENSG00000280143.1	AP000892.6	6.45	2.76e-10	1.43e-07	0.32	0.28	Blood protein levels;	chr11:116863012	chr11:117204967~117210292:+
LUAD	cis	rs783540	0.967	rs783526	ENSG00000278603.1	RP13-608F4.5	-6.45	2.76e-10	1.43e-07	-0.33	-0.28	Schizophrenia;	chr15:82617044	chr15:82472203~82472426:+
LUAD	cis	rs2243480	1	rs313807	ENSG00000232546.1	RP11-458F8.1	-6.45	2.76e-10	1.43e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66034494	chr7:66848496~66858136:+
LUAD	cis	rs875971	0.502	rs11769702	ENSG00000237310.1	GS1-124K5.4	6.45	2.77e-10	1.43e-07	0.36	0.28	Aortic root size;	chr7:66255529	chr7:66493706~66495474:+
LUAD	cis	rs367615	0.68	rs253247	ENSG00000249476.1	CTD-2587M2.1	6.45	2.77e-10	1.43e-07	0.37	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109648265	chr5:109237120~109326369:-
LUAD	cis	rs17711722	0.51	rs11767457	ENSG00000224316.1	RP11-479O9.2	6.45	2.77e-10	1.43e-07	0.28	0.28	Calcium levels;	chr7:65825628	chr7:65773620~65802067:+
LUAD	cis	rs2911132	1	rs2549803	ENSG00000248734.2	CTD-2260A17.1	6.45	2.78e-10	1.44e-07	0.3	0.28	Urate levels (BMI interaction);	chr5:96839226	chr5:96784777~96785999:+
LUAD	cis	rs7017914	0.934	rs2639921	ENSG00000223220.1	Y_RNA	6.45	2.78e-10	1.44e-07	0.31	0.28	Bone mineral density;	chr8:70962599	chr8:70780914~70781008:-
LUAD	cis	rs11096990	0.821	rs76235093	ENSG00000249207.1	RP11-360F5.1	6.45	2.78e-10	1.44e-07	0.32	0.28	Cognitive function;	chr4:39281157	chr4:39112677~39126818:-
LUAD	cis	rs1799949	0.501	rs2343819	ENSG00000267681.1	CTD-3199J23.6	-6.45	2.79e-10	1.44e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43332285	chr17:43144956~43145255:+
LUAD	cis	rs9834970	0.588	rs4642070	ENSG00000234073.1	AC011816.1	-6.45	2.79e-10	1.44e-07	-0.31	-0.28	Bipolar disorder with mood-incongruent psychosis;Bipolar disorder;Schizophrenia or bipolar disorder;Subjective response to lithium treatment;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr3:36859453	chr3:36880184~36880729:-
LUAD	cis	rs7811142	1	rs2406255	ENSG00000242294.5	STAG3L5P	6.45	2.79e-10	1.44e-07	0.25	0.28	Platelet count;	chr7:100456067	chr7:100336079~100351900:+
LUAD	cis	rs17301013	0.507	rs3920486	ENSG00000227373.4	RP11-160H22.5	6.45	2.8e-10	1.45e-07	0.42	0.28	Systemic lupus erythematosus;	chr1:174567714	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12079118	ENSG00000227373.4	RP11-160H22.5	6.45	2.8e-10	1.45e-07	0.42	0.28	Systemic lupus erythematosus;	chr1:174568885	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12079879	ENSG00000227373.4	RP11-160H22.5	6.45	2.8e-10	1.45e-07	0.42	0.28	Systemic lupus erythematosus;	chr1:174571877	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs2092084	ENSG00000227373.4	RP11-160H22.5	6.45	2.8e-10	1.45e-07	0.42	0.28	Systemic lupus erythematosus;	chr1:174581547	chr1:174115300~174160004:-
LUAD	cis	rs77204473	1	rs12289032	ENSG00000254851.1	RP11-109L13.1	6.45	2.8e-10	1.45e-07	0.72	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117028864	chr11:117135528~117138582:+
LUAD	cis	rs150992	0.548	rs12109067	ENSG00000248489.1	CTD-2007H13.3	6.45	2.8e-10	1.45e-07	0.32	0.28	Body mass index;	chr5:99038928	chr5:98929171~98995013:+
LUAD	cis	rs5753618	0.504	rs5753659	ENSG00000236132.1	CTA-440B3.1	-6.45	2.81e-10	1.45e-07	-0.34	-0.28	Colorectal cancer;	chr22:31497627	chr22:31816379~31817491:-
LUAD	cis	rs2303759	0.918	rs7251704	ENSG00000268686.1	AC010524.2	-6.45	2.81e-10	1.45e-07	-0.4	-0.28	Multiple sclerosis;	chr19:49387616	chr19:49368705~49388081:-
LUAD	cis	rs7246657	0.943	rs2126977	ENSG00000276846.1	CTD-3220F14.3	-6.45	2.81e-10	1.45e-07	-0.37	-0.28	Coronary artery calcification;	chr19:37504845	chr19:37314868~37315620:-
LUAD	cis	rs7688540	0.8	rs9328737	ENSG00000275426.1	CH17-262A2.1	6.44	2.82e-10	1.46e-07	0.35	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:252176	chr4:149738~150317:+
LUAD	cis	rs9640161	0.789	rs66688634	ENSG00000261305.1	RP4-584D14.7	6.44	2.82e-10	1.46e-07	0.42	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150356717	chr7:150341771~150342607:+
LUAD	cis	rs11096990	0.819	rs4974991	ENSG00000249207.1	RP11-360F5.1	6.44	2.82e-10	1.46e-07	0.32	0.28	Cognitive function;	chr4:39193147	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.892	rs6815686	ENSG00000249207.1	RP11-360F5.1	6.44	2.82e-10	1.46e-07	0.32	0.28	Cognitive function;	chr4:39198171	chr4:39112677~39126818:-
LUAD	cis	rs8031584	0.918	rs1425292	ENSG00000260382.1	RP11-540B6.2	6.44	2.82e-10	1.46e-07	0.34	0.28	Huntington's disease progression;	chr15:30993219	chr15:30882267~30883231:-
LUAD	cis	rs4713118	0.662	rs149901	ENSG00000219392.1	RP1-265C24.5	-6.44	2.82e-10	1.46e-07	-0.38	-0.28	Parkinson's disease;	chr6:27997725	chr6:28115628~28116551:+
LUAD	cis	rs7811142	1	rs11771241	ENSG00000242294.5	STAG3L5P	6.44	2.83e-10	1.47e-07	0.24	0.28	Platelet count;	chr7:100397162	chr7:100336079~100351900:+
LUAD	cis	rs2243480	1	rs6460260	ENSG00000226824.5	RP4-756H11.3	6.44	2.84e-10	1.47e-07	0.54	0.28	Diabetic kidney disease;	chr7:65750468	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs6460261	ENSG00000226824.5	RP4-756H11.3	6.44	2.84e-10	1.47e-07	0.54	0.28	Diabetic kidney disease;	chr7:65750593	chr7:66654538~66669855:+
LUAD	cis	rs7567389	0.719	rs6744237	ENSG00000236682.1	AC068282.3	6.44	2.84e-10	1.47e-07	0.42	0.28	Self-rated health;	chr2:127246469	chr2:127389130~127400580:+
LUAD	cis	rs4718428	0.607	rs66954441	ENSG00000273142.1	RP11-458F8.4	-6.44	2.84e-10	1.47e-07	-0.21	-0.28	Corneal structure;	chr7:66904222	chr7:66902857~66906297:+
LUAD	cis	rs853679	0.556	rs13200214	ENSG00000204709.4	LINC01556	6.44	2.84e-10	1.47e-07	0.62	0.28	Depression;	chr6:28049472	chr6:28943877~28944537:+
LUAD	cis	rs1075232	0.826	rs16956738	ENSG00000270055.1	CTD-3092A11.2	6.44	2.85e-10	1.47e-07	0.51	0.28	Survival in colorectal cancer (non-distant metastatic);	chr15:31444028	chr15:30487963~30490313:+
LUAD	cis	rs113835537	0.529	rs10896125	ENSG00000255517.5	CTD-3074O7.5	-6.44	2.85e-10	1.47e-07	-0.33	-0.28	Airway imaging phenotypes;	chr11:66521262	chr11:66473490~66480233:-
LUAD	cis	rs11098499	0.754	rs12506610	ENSG00000248280.1	RP11-33B1.2	6.44	2.85e-10	1.47e-07	0.35	0.28	Corneal astigmatism;	chr4:119320504	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.743	rs10003567	ENSG00000248280.1	RP11-33B1.2	6.44	2.85e-10	1.47e-07	0.35	0.28	Corneal astigmatism;	chr4:119320519	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs10006259	ENSG00000248280.1	RP11-33B1.2	6.44	2.85e-10	1.47e-07	0.35	0.28	Corneal astigmatism;	chr4:119320990	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs28652763	ENSG00000248280.1	RP11-33B1.2	6.44	2.85e-10	1.47e-07	0.35	0.28	Corneal astigmatism;	chr4:119321157	chr4:119440561~119450157:-
LUAD	cis	rs7017914	0.934	rs1389202	ENSG00000223220.1	Y_RNA	6.44	2.86e-10	1.48e-07	0.31	0.28	Bone mineral density;	chr8:70940050	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.967	rs13255735	ENSG00000223220.1	Y_RNA	6.44	2.86e-10	1.48e-07	0.31	0.28	Bone mineral density;	chr8:70947504	chr8:70780914~70781008:-
LUAD	cis	rs1061377	1	rs2381284	ENSG00000249685.1	RP11-360F5.3	6.44	2.86e-10	1.48e-07	0.34	0.28	Uric acid levels;	chr4:39117976	chr4:39133913~39135608:+
LUAD	cis	rs1061377	0.803	rs6857761	ENSG00000249685.1	RP11-360F5.3	6.44	2.86e-10	1.48e-07	0.34	0.28	Uric acid levels;	chr4:39118353	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs9997089	ENSG00000249685.1	RP11-360F5.3	6.44	2.86e-10	1.48e-07	0.34	0.28	Uric acid levels;	chr4:39119263	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs28465556	ENSG00000249685.1	RP11-360F5.3	6.44	2.86e-10	1.48e-07	0.34	0.28	Uric acid levels;	chr4:39119569	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs10027813	ENSG00000249685.1	RP11-360F5.3	6.44	2.86e-10	1.48e-07	0.34	0.28	Uric acid levels;	chr4:39119818	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs9990755	ENSG00000249685.1	RP11-360F5.3	6.44	2.86e-10	1.48e-07	0.34	0.28	Uric acid levels;	chr4:39119819	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs7676008	ENSG00000249685.1	RP11-360F5.3	6.44	2.86e-10	1.48e-07	0.34	0.28	Uric acid levels;	chr4:39120154	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs7655122	ENSG00000249685.1	RP11-360F5.3	6.44	2.86e-10	1.48e-07	0.34	0.28	Uric acid levels;	chr4:39120396	chr4:39133913~39135608:+
LUAD	cis	rs1061377	0.965	rs3733275	ENSG00000249685.1	RP11-360F5.3	6.44	2.86e-10	1.48e-07	0.34	0.28	Uric acid levels;	chr4:39121077	chr4:39133913~39135608:+
LUAD	cis	rs7927592	0.913	rs12284933	ENSG00000212093.1	AP000807.1	6.44	2.86e-10	1.48e-07	0.32	0.28	Total body bone mineral density;	chr11:68552021	chr11:68506083~68506166:-
LUAD	cis	rs11098499	0.615	rs59867181	ENSG00000248280.1	RP11-33B1.2	-6.44	2.86e-10	1.48e-07	-0.33	-0.28	Corneal astigmatism;	chr4:119635312	chr4:119440561~119450157:-
LUAD	cis	rs950169	0.544	rs2036949	ENSG00000259728.4	LINC00933	6.44	2.88e-10	1.48e-07	0.42	0.28	Schizophrenia;	chr15:84620374	chr15:84570649~84580175:+
LUAD	cis	rs11096990	0.964	rs6842390	ENSG00000249207.1	RP11-360F5.1	6.44	2.88e-10	1.49e-07	0.32	0.28	Cognitive function;	chr4:39261862	chr4:39112677~39126818:-
LUAD	cis	rs4722166	0.508	rs1474347	ENSG00000179428.2	AC073072.5	6.44	2.88e-10	1.49e-07	0.33	0.28	Lung cancer;	chr7:22728505	chr7:22725395~22727620:-
LUAD	cis	rs12908161	0.96	rs11633450	ENSG00000259728.4	LINC00933	6.44	2.88e-10	1.49e-07	0.41	0.28	Schizophrenia;	chr15:84764056	chr15:84570649~84580175:+
LUAD	cis	rs494459	0.838	rs2510897	ENSG00000278376.1	RP11-158I9.8	-6.44	2.88e-10	1.49e-07	-0.3	-0.28	Height;	chr11:118773873	chr11:118791254~118793137:+
LUAD	cis	rs9326248	0.53	rs588918	ENSG00000280143.1	AP000892.6	6.44	2.88e-10	1.49e-07	0.42	0.28	Blood protein levels;	chr11:116985926	chr11:117204967~117210292:+
LUAD	cis	rs55665837	1	rs11023227	ENSG00000251991.1	RNU7-49P	6.44	2.89e-10	1.49e-07	0.32	0.28	Vitamin D levels;	chr11:14437541	chr11:14478892~14478953:+
LUAD	cis	rs9549367	0.789	rs8001506	ENSG00000269125.1	RP11-98F14.11	-6.44	2.89e-10	1.49e-07	-0.34	-0.28	Platelet distribution width;	chr13:113212839	chr13:113165002~113165183:-
LUAD	cis	rs72772090	0.539	rs72775809	ENSG00000248734.2	CTD-2260A17.1	-6.44	2.89e-10	1.49e-07	-0.46	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96847853	chr5:96784777~96785999:+
LUAD	cis	rs853679	0.607	rs13190888	ENSG00000204709.4	LINC01556	6.44	2.9e-10	1.49e-07	0.61	0.28	Depression;	chr6:28318208	chr6:28943877~28944537:+
LUAD	cis	rs78773383	0.505	rs13123782	ENSG00000249207.1	RP11-360F5.1	6.44	2.9e-10	1.5e-07	0.3	0.28	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr4:39375785	chr4:39112677~39126818:-
LUAD	cis	rs7927592	0.956	rs7102273	ENSG00000212093.1	AP000807.1	6.44	2.9e-10	1.5e-07	0.31	0.28	Total body bone mineral density;	chr11:68618111	chr11:68506083~68506166:-
LUAD	cis	rs5753618	0.583	rs5753632	ENSG00000236132.1	CTA-440B3.1	-6.44	2.91e-10	1.5e-07	-0.34	-0.28	Colorectal cancer;	chr22:31467111	chr22:31816379~31817491:-
LUAD	cis	rs8177876	0.658	rs79603321	ENSG00000261838.4	RP11-303E16.6	6.44	2.91e-10	1.5e-07	0.59	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81039139	chr16:81069854~81076598:+
LUAD	cis	rs12908161	0.96	rs62019463	ENSG00000259728.4	LINC00933	6.44	2.91e-10	1.5e-07	0.41	0.28	Schizophrenia;	chr15:84744856	chr15:84570649~84580175:+
LUAD	cis	rs4141404	0.818	rs6518737	ENSG00000236132.1	CTA-440B3.1	6.44	2.91e-10	1.5e-07	0.32	0.28	Paclitaxel-induced neuropathy;	chr22:31186676	chr22:31816379~31817491:-
LUAD	cis	rs2302464	1	rs16892287	ENSG00000214846.4	RP11-115L11.1	6.44	2.91e-10	1.5e-07	0.75	0.28	Cerebrospinal fluid biomarker levels;	chr4:15730570	chr4:15730962~15731627:-
LUAD	cis	rs7657257	1	rs4321629	ENSG00000214846.4	RP11-115L11.1	6.44	2.91e-10	1.5e-07	0.75	0.28	Blood protein levels;	chr4:15730757	chr4:15730962~15731627:-
LUAD	cis	rs7657257	1	rs10516290	ENSG00000214846.4	RP11-115L11.1	6.44	2.91e-10	1.5e-07	0.75	0.28	Blood protein levels;	chr4:15730833	chr4:15730962~15731627:-
LUAD	cis	rs2302464	1	rs10516291	ENSG00000214846.4	RP11-115L11.1	6.44	2.91e-10	1.5e-07	0.75	0.28	Cerebrospinal fluid biomarker levels;	chr4:15731168	chr4:15730962~15731627:-
LUAD	cis	rs881375	0.933	rs2239657	ENSG00000226752.6	PSMD5-AS1	6.44	2.91e-10	1.5e-07	0.3	0.28	Rheumatoid arthritis;	chr9:120909242	chr9:120824828~120854385:+
LUAD	cis	rs875971	0.545	rs10950029	ENSG00000237310.1	GS1-124K5.4	6.44	2.91e-10	1.5e-07	0.34	0.28	Aortic root size;	chr7:66169334	chr7:66493706~66495474:+
LUAD	cis	rs6700559	0.654	rs2809345	ENSG00000260088.1	RP11-92G12.3	6.44	2.91e-10	1.5e-07	0.34	0.28	Coronary artery disease;	chr1:200627135	chr1:200669507~200694250:+
LUAD	cis	rs1061377	1	rs9998867	ENSG00000249685.1	RP11-360F5.3	6.44	2.91e-10	1.5e-07	0.34	0.28	Uric acid levels;	chr4:39117542	chr4:39133913~39135608:+
LUAD	cis	rs2243480	1	rs1723267	ENSG00000226824.5	RP4-756H11.3	-6.44	2.92e-10	1.5e-07	-0.52	-0.28	Diabetic kidney disease;	chr7:66008327	chr7:66654538~66669855:+
LUAD	cis	rs11168854	0.62	rs11168888	ENSG00000258017.1	RP11-386G11.10	-6.44	2.92e-10	1.51e-07	-0.36	-0.28	Body mass index;	chr12:49149614	chr12:49127782~49147869:+
LUAD	cis	rs12439619	0.846	rs62011975	ENSG00000255769.6	GOLGA2P10	-6.44	2.92e-10	1.51e-07	-0.36	-0.28	Intelligence (multi-trait analysis);	chr15:82159213	chr15:82472993~82513950:-
LUAD	cis	rs72634501	0.716	rs67062906	ENSG00000228060.1	RP11-69E11.8	-6.44	2.93e-10	1.51e-07	-0.28	-0.28	HDL cholesterol;	chr1:39151018	chr1:39565160~39573203:+
LUAD	cis	rs8177376	0.861	rs4340064	ENSG00000254905.1	RP11-712L6.7	6.44	2.93e-10	1.51e-07	0.39	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126242165	chr11:126292922~126294254:-
LUAD	cis	rs8177376	1	rs73017350	ENSG00000254905.1	RP11-712L6.7	6.44	2.93e-10	1.51e-07	0.39	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126246064	chr11:126292922~126294254:-
LUAD	cis	rs6991838	0.733	rs13281981	ENSG00000200714.1	Y_RNA	6.44	2.93e-10	1.51e-07	0.33	0.28	Intelligence (multi-trait analysis);	chr8:65611649	chr8:65592731~65592820:+
LUAD	cis	rs71403859	0.502	rs34380814	ENSG00000260886.1	TAT-AS1	6.44	2.94e-10	1.52e-07	0.43	0.28	Post bronchodilator FEV1;	chr16:71454272	chr16:71565789~71578187:+
LUAD	cis	rs9450351	0.744	rs6912150	ENSG00000203875.9	SNHG5	-6.44	2.95e-10	1.52e-07	-0.61	-0.28	Interferon gamma-induced protein 10 levels;	chr6:85925291	chr6:85660950~85678736:-
LUAD	cis	rs755249	0.53	rs4660475	ENSG00000228060.1	RP11-69E11.8	-6.44	2.95e-10	1.52e-07	-0.28	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39146568	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.53	rs66848709	ENSG00000228060.1	RP11-69E11.8	-6.44	2.95e-10	1.52e-07	-0.28	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39146885	chr1:39565160~39573203:+
LUAD	cis	rs875971	1	rs1167612	ENSG00000222364.1	RNU6-96P	6.44	2.95e-10	1.52e-07	0.32	0.28	Aortic root size;	chr7:66102989	chr7:66395191~66395286:+
LUAD	cis	rs6558530	0.836	rs7461600	ENSG00000253982.1	CTD-2336O2.1	6.44	2.95e-10	1.52e-07	0.36	0.28	Systolic blood pressure;	chr8:1766476	chr8:1761990~1764502:-
LUAD	cis	rs6504950	0.579	rs8075983	ENSG00000275710.1	RP11-257O5.4	6.44	2.96e-10	1.52e-07	0.39	0.28	Breast cancer;	chr17:55194557	chr17:54964474~54964679:+
LUAD	cis	rs2243480	1	rs316327	ENSG00000226824.5	RP4-756H11.3	6.44	2.97e-10	1.53e-07	0.52	0.28	Diabetic kidney disease;	chr7:66144214	chr7:66654538~66669855:+
LUAD	cis	rs8031584	0.872	rs11634761	ENSG00000260382.1	RP11-540B6.2	6.44	2.97e-10	1.53e-07	0.34	0.28	Huntington's disease progression;	chr15:30950970	chr15:30882267~30883231:-
LUAD	cis	rs8100891	0.537	rs16967141	ENSG00000267213.4	AC007773.2	-6.44	2.97e-10	1.53e-07	-0.45	-0.28	Neuroticism;	chr19:32480317	chr19:32390050~32405560:-
LUAD	cis	rs950169	0.58	rs11633762	ENSG00000259728.4	LINC00933	6.44	2.98e-10	1.53e-07	0.42	0.28	Schizophrenia;	chr15:84643921	chr15:84570649~84580175:+
LUAD	cis	rs9543976	1	rs9565177	ENSG00000261553.4	RP11-29G8.3	-6.44	2.98e-10	1.54e-07	-0.42	-0.28	Diabetic retinopathy;	chr13:75621267	chr13:75549773~75807120:+
LUAD	cis	rs7829975	0.688	rs7837587	ENSG00000253981.4	ALG1L13P	6.44	2.98e-10	1.54e-07	0.33	0.28	Mood instability;	chr8:8521482	chr8:8236003~8244667:-
LUAD	cis	rs7811142	1	rs11763414	ENSG00000242294.5	STAG3L5P	6.44	2.99e-10	1.54e-07	0.24	0.28	Platelet count;	chr7:100419221	chr7:100336079~100351900:+
LUAD	cis	rs71403859	0.554	rs12373065	ENSG00000260886.1	TAT-AS1	6.43	2.99e-10	1.54e-07	0.51	0.28	Post bronchodilator FEV1;	chr16:71836129	chr16:71565789~71578187:+
LUAD	cis	rs4141404	0.706	rs5753698	ENSG00000236132.1	CTA-440B3.1	-6.43	2.99e-10	1.54e-07	-0.35	-0.28	Paclitaxel-induced neuropathy;	chr22:31574068	chr22:31816379~31817491:-
LUAD	cis	rs8177376	1	rs8177376	ENSG00000254905.1	RP11-712L6.7	6.43	2.99e-10	1.54e-07	0.4	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126293717	chr11:126292922~126294254:-
LUAD	cis	rs11098499	0.754	rs938056	ENSG00000248280.1	RP11-33B1.2	6.43	2.99e-10	1.54e-07	0.35	0.28	Corneal astigmatism;	chr4:119316298	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs878376	ENSG00000248280.1	RP11-33B1.2	6.43	2.99e-10	1.54e-07	0.35	0.28	Corneal astigmatism;	chr4:119316547	chr4:119440561~119450157:-
LUAD	cis	rs12468226	0.938	rs115418918	ENSG00000226261.1	AC064836.3	6.43	3e-10	1.54e-07	0.47	0.28	Urate levels;	chr2:202315145	chr2:202336024~202336727:-
LUAD	cis	rs12468226	0.938	rs114922024	ENSG00000226261.1	AC064836.3	6.43	3e-10	1.54e-07	0.47	0.28	Urate levels;	chr2:202315958	chr2:202336024~202336727:-
LUAD	cis	rs12468226	0.938	rs77261109	ENSG00000226261.1	AC064836.3	6.43	3e-10	1.54e-07	0.47	0.28	Urate levels;	chr2:202316233	chr2:202336024~202336727:-
LUAD	cis	rs12468226	0.938	rs12466003	ENSG00000226261.1	AC064836.3	6.43	3e-10	1.54e-07	0.47	0.28	Urate levels;	chr2:202317317	chr2:202336024~202336727:-
LUAD	cis	rs12468226	0.938	rs76501067	ENSG00000226261.1	AC064836.3	6.43	3e-10	1.54e-07	0.47	0.28	Urate levels;	chr2:202318042	chr2:202336024~202336727:-
LUAD	cis	rs1062177	0.826	rs1549920	ENSG00000213433.5	RPLP1P6	-6.43	3e-10	1.54e-07	-0.36	-0.28	Preschool internalizing problems;	chr5:151761283	chr5:151765859~151766378:-
LUAD	cis	rs17301013	0.606	rs10912728	ENSG00000227373.4	RP11-160H22.5	6.43	3.01e-10	1.55e-07	0.4	0.28	Systemic lupus erythematosus;	chr1:174093234	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs4652168	ENSG00000227373.4	RP11-160H22.5	6.43	3.01e-10	1.55e-07	0.4	0.28	Systemic lupus erythematosus;	chr1:174095077	chr1:174115300~174160004:-
LUAD	cis	rs34375054	0.525	rs7133006	ENSG00000279233.1	RP11-158L12.4	6.43	3.01e-10	1.55e-07	0.24	0.28	Post bronchodilator FEV1/FVC ratio;	chr12:125121577	chr12:125138245~125141711:+
LUAD	cis	rs34375054	0.525	rs7133864	ENSG00000279233.1	RP11-158L12.4	6.43	3.01e-10	1.55e-07	0.24	0.28	Post bronchodilator FEV1/FVC ratio;	chr12:125121634	chr12:125138245~125141711:+
LUAD	cis	rs7246657	0.943	rs7259968	ENSG00000276846.1	CTD-3220F14.3	6.43	3.02e-10	1.55e-07	0.39	0.28	Coronary artery calcification;	chr19:37320952	chr19:37314868~37315620:-
LUAD	cis	rs7567389	0.504	rs2069895	ENSG00000236682.1	AC068282.3	-6.43	3.02e-10	1.55e-07	-0.37	-0.28	Self-rated health;	chr2:127416492	chr2:127389130~127400580:+
LUAD	cis	rs9309473	1	rs6736866	ENSG00000163016.8	ALMS1P	6.43	3.02e-10	1.55e-07	0.35	0.28	Metabolite levels;	chr2:73434858	chr2:73644919~73685576:+
LUAD	cis	rs2243480	0.908	rs313822	ENSG00000232546.1	RP11-458F8.1	-6.43	3.02e-10	1.55e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66108952	chr7:66848496~66858136:+
LUAD	cis	rs10129255	0.957	rs12590667	ENSG00000280411.1	IGHV1-69-2	6.43	3.02e-10	1.55e-07	0.2	0.28	Kawasaki disease;	chr14:106779223	chr14:106762092~106762588:-
LUAD	cis	rs55665837	1	rs11023224	ENSG00000251991.1	RNU7-49P	6.43	3.03e-10	1.56e-07	0.32	0.28	Vitamin D levels;	chr11:14436193	chr11:14478892~14478953:+
LUAD	cis	rs55665837	0.961	rs11023226	ENSG00000251991.1	RNU7-49P	6.43	3.03e-10	1.56e-07	0.32	0.28	Vitamin D levels;	chr11:14437271	chr11:14478892~14478953:+
LUAD	cis	rs55665837	1	rs10832264	ENSG00000251991.1	RNU7-49P	6.43	3.03e-10	1.56e-07	0.32	0.28	Vitamin D levels;	chr11:14438436	chr11:14478892~14478953:+
LUAD	cis	rs55665837	1	rs11023229	ENSG00000251991.1	RNU7-49P	6.43	3.03e-10	1.56e-07	0.32	0.28	Vitamin D levels;	chr11:14439455	chr11:14478892~14478953:+
LUAD	cis	rs875971	0.545	rs6970498	ENSG00000237310.1	GS1-124K5.4	6.43	3.03e-10	1.56e-07	0.35	0.28	Aortic root size;	chr7:66275908	chr7:66493706~66495474:+
LUAD	cis	rs2404602	0.684	rs11072602	ENSG00000259422.1	RP11-593F23.1	-6.43	3.03e-10	1.56e-07	-0.37	-0.28	Blood metabolite levels;	chr15:76581126	chr15:76174891~76181486:-
LUAD	cis	rs867371	0.896	rs8033831	ENSG00000255769.6	GOLGA2P10	-6.43	3.03e-10	1.56e-07	-0.3	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82220953	chr15:82472993~82513950:-
LUAD	cis	rs2243480	1	rs2961102	ENSG00000226824.5	RP4-756H11.3	-6.43	3.03e-10	1.56e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65959671	chr7:66654538~66669855:+
LUAD	cis	rs6860806	0.531	rs270607	ENSG00000233006.5	AC034220.3	6.43	3.03e-10	1.56e-07	0.28	0.28	Breast cancer;	chr5:132313493	chr5:132311285~132369916:-
LUAD	cis	rs56046484	0.956	rs16974820	ENSG00000259295.5	CSPG4P12	6.43	3.04e-10	1.56e-07	0.4	0.28	Testicular germ cell tumor;	chr15:85084075	chr15:85191438~85213905:+
LUAD	cis	rs17301013	0.507	rs16828481	ENSG00000227373.4	RP11-160H22.5	6.43	3.04e-10	1.56e-07	0.42	0.28	Systemic lupus erythematosus;	chr1:174415979	chr1:174115300~174160004:-
LUAD	cis	rs516805	0.961	rs572632	ENSG00000279453.1	RP3-425C14.4	-6.43	3.04e-10	1.57e-07	-0.32	-0.28	Lymphocyte counts;	chr6:122437753	chr6:122436789~122439223:-
LUAD	cis	rs55665837	0.778	rs11023212	ENSG00000251991.1	RNU7-49P	6.43	3.05e-10	1.57e-07	0.32	0.28	Vitamin D levels;	chr11:14410163	chr11:14478892~14478953:+
LUAD	cis	rs1061377	1	rs13182	ENSG00000249685.1	RP11-360F5.3	6.43	3.06e-10	1.57e-07	0.34	0.28	Uric acid levels;	chr4:39121293	chr4:39133913~39135608:+
LUAD	cis	rs7829975	0.688	rs7826654	ENSG00000253893.2	FAM85B	-6.43	3.06e-10	1.57e-07	-0.35	-0.28	Mood instability;	chr8:8521596	chr8:8167819~8226614:-
LUAD	cis	rs7829975	0.688	rs7826660	ENSG00000253893.2	FAM85B	-6.43	3.06e-10	1.57e-07	-0.35	-0.28	Mood instability;	chr8:8521597	chr8:8167819~8226614:-
LUAD	cis	rs10759883	0.627	rs10739622	ENSG00000175611.10	LINC00476	6.43	3.06e-10	1.58e-07	0.33	0.28	Nicotine dependence;	chr9:95852889	chr9:95759231~95875977:-
LUAD	cis	rs10759883	0.627	rs10760269	ENSG00000175611.10	LINC00476	6.43	3.06e-10	1.58e-07	0.33	0.28	Nicotine dependence;	chr9:95852897	chr9:95759231~95875977:-
LUAD	cis	rs8072100	0.84	rs9912311	ENSG00000228782.6	CTD-2026D20.3	6.43	3.07e-10	1.58e-07	0.3	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469766	chr17:47450568~47492492:-
LUAD	cis	rs150992	0.609	rs366000	ENSG00000248489.1	CTD-2007H13.3	-6.43	3.07e-10	1.58e-07	-0.31	-0.28	Body mass index;	chr5:98991705	chr5:98929171~98995013:+
LUAD	cis	rs2034650	0.544	rs8034217	ENSG00000223313.1	RNU6-516P	-6.43	3.07e-10	1.58e-07	-0.37	-0.28	Interstitial lung disease;	chr15:40429501	chr15:40529570~40529673:+
LUAD	cis	rs9595908	0.869	rs9595946	ENSG00000212293.1	SNORA16	6.43	3.08e-10	1.58e-07	0.3	0.28	Body mass index;	chr13:32628998	chr13:32420390~32420516:-
LUAD	cis	rs9549367	0.826	rs2302755	ENSG00000269125.1	RP11-98F14.11	-6.43	3.08e-10	1.58e-07	-0.35	-0.28	Platelet distribution width;	chr13:113244104	chr13:113165002~113165183:-
LUAD	cis	rs2243480	1	rs3885839	ENSG00000226824.5	RP4-756H11.3	-6.43	3.08e-10	1.58e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:65825416	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.901	rs3813708	ENSG00000226824.5	RP4-756H11.3	-6.43	3.08e-10	1.58e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:65840645	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs73142122	ENSG00000226824.5	RP4-756H11.3	-6.43	3.08e-10	1.58e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:65846311	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.901	rs73142137	ENSG00000226824.5	RP4-756H11.3	-6.43	3.08e-10	1.58e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:65878455	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.803	rs34804747	ENSG00000226824.5	RP4-756H11.3	-6.43	3.08e-10	1.58e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65947955	chr7:66654538~66669855:+
LUAD	cis	rs7811142	1	rs6979335	ENSG00000242294.5	STAG3L5P	6.43	3.09e-10	1.58e-07	0.24	0.28	Platelet count;	chr7:100492237	chr7:100336079~100351900:+
LUAD	cis	rs7811142	1	rs73405353	ENSG00000242294.5	STAG3L5P	6.43	3.09e-10	1.58e-07	0.24	0.28	Platelet count;	chr7:100493592	chr7:100336079~100351900:+
LUAD	cis	rs2243480	1	rs7804223	ENSG00000232546.1	RP11-458F8.1	6.43	3.09e-10	1.59e-07	0.37	0.28	Diabetic kidney disease;	chr7:66199572	chr7:66848496~66858136:+
LUAD	cis	rs875971	1	rs937495	ENSG00000222364.1	RNU6-96P	6.43	3.09e-10	1.59e-07	0.32	0.28	Aortic root size;	chr7:66314811	chr7:66395191~66395286:+
LUAD	cis	rs6558530	0.932	rs7842425	ENSG00000253982.1	CTD-2336O2.1	6.43	3.09e-10	1.59e-07	0.34	0.28	Systolic blood pressure;	chr8:1757875	chr8:1761990~1764502:-
LUAD	cis	rs17301013	0.606	rs28831202	ENSG00000227373.4	RP11-160H22.5	6.43	3.09e-10	1.59e-07	0.4	0.28	Systemic lupus erythematosus;	chr1:174099231	chr1:174115300~174160004:-
LUAD	cis	rs853679	0.55	rs6901017	ENSG00000219392.1	RP1-265C24.5	-6.43	3.09e-10	1.59e-07	-0.39	-0.28	Depression;	chr6:28184805	chr6:28115628~28116551:+
LUAD	cis	rs783540	0.967	rs17158390	ENSG00000278603.1	RP13-608F4.5	-6.43	3.09e-10	1.59e-07	-0.32	-0.28	Schizophrenia;	chr15:82624277	chr15:82472203~82472426:+
LUAD	cis	rs4718428	0.672	rs12530806	ENSG00000273142.1	RP11-458F8.4	-6.43	3.09e-10	1.59e-07	-0.21	-0.28	Corneal structure;	chr7:66925737	chr7:66902857~66906297:+
LUAD	cis	rs4718428	0.705	rs10267335	ENSG00000273142.1	RP11-458F8.4	-6.43	3.09e-10	1.59e-07	-0.21	-0.28	Corneal structure;	chr7:66938233	chr7:66902857~66906297:+
LUAD	cis	rs1062177	0.855	rs62395861	ENSG00000213433.5	RPLP1P6	-6.43	3.1e-10	1.59e-07	-0.38	-0.28	Preschool internalizing problems;	chr5:151889709	chr5:151765859~151766378:-
LUAD	cis	rs1062177	0.95	rs59580263	ENSG00000213433.5	RPLP1P6	-6.43	3.1e-10	1.59e-07	-0.38	-0.28	Preschool internalizing problems;	chr5:151890016	chr5:151765859~151766378:-
LUAD	cis	rs853679	0.607	rs34950484	ENSG00000204709.4	LINC01556	6.43	3.1e-10	1.59e-07	0.61	0.28	Depression;	chr6:28310911	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs34661125	ENSG00000204709.4	LINC01556	6.43	3.1e-10	1.59e-07	0.61	0.28	Depression;	chr6:28314117	chr6:28943877~28944537:+
LUAD	cis	rs2115630	0.846	rs8024538	ENSG00000225151.9	GOLGA2P7	6.43	3.11e-10	1.59e-07	0.32	0.28	P wave terminal force;	chr15:84825188	chr15:84199311~84230136:-
LUAD	cis	rs9640161	0.789	rs34311995	ENSG00000261305.1	RP4-584D14.7	6.43	3.11e-10	1.6e-07	0.41	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150362166	chr7:150341771~150342607:+
LUAD	cis	rs75422866	0.558	rs73104190	ENSG00000280054.1	RP1-197B17.7	6.43	3.11e-10	1.6e-07	0.63	0.28	Pneumonia;	chr12:47716040	chr12:47728151~47730598:-
LUAD	cis	rs9549367	0.774	rs2287246	ENSG00000269125.1	RP11-98F14.11	-6.43	3.11e-10	1.6e-07	-0.34	-0.28	Platelet distribution width;	chr13:113234813	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.789	rs2287247	ENSG00000269125.1	RP11-98F14.11	-6.43	3.11e-10	1.6e-07	-0.34	-0.28	Platelet distribution width;	chr13:113234898	chr13:113165002~113165183:-
LUAD	cis	rs10050311	0.858	rs1985944	ENSG00000251411.1	RP11-397E7.4	-6.43	3.12e-10	1.6e-07	-0.39	-0.28	Insulin-related traits;	chr4:86898130	chr4:86913266~86914817:-
LUAD	cis	rs10129255	0.5	rs11628999	ENSG00000224373.3	IGHV4-59	6.43	3.12e-10	1.6e-07	0.17	0.28	Kawasaki disease;	chr14:106800208	chr14:106627249~106627825:-
LUAD	cis	rs12468226	0.938	rs56684065	ENSG00000226261.1	AC064836.3	6.43	3.12e-10	1.6e-07	0.47	0.28	Urate levels;	chr2:202289528	chr2:202336024~202336727:-
LUAD	cis	rs12468226	0.938	rs1474001	ENSG00000226261.1	AC064836.3	6.43	3.12e-10	1.6e-07	0.47	0.28	Urate levels;	chr2:202290230	chr2:202336024~202336727:-
LUAD	cis	rs12468226	0.938	rs76664732	ENSG00000226261.1	AC064836.3	6.43	3.12e-10	1.6e-07	0.47	0.28	Urate levels;	chr2:202296298	chr2:202336024~202336727:-
LUAD	cis	rs12468226	0.938	rs16841867	ENSG00000226261.1	AC064836.3	6.43	3.12e-10	1.6e-07	0.47	0.28	Urate levels;	chr2:202303512	chr2:202336024~202336727:-
LUAD	cis	rs12468226	0.938	rs16839065	ENSG00000226261.1	AC064836.3	6.43	3.12e-10	1.6e-07	0.47	0.28	Urate levels;	chr2:202308774	chr2:202336024~202336727:-
LUAD	cis	rs881375	0.669	rs73541868	ENSG00000226752.6	PSMD5-AS1	-6.43	3.12e-10	1.6e-07	-0.29	-0.28	Rheumatoid arthritis;	chr9:120876986	chr9:120824828~120854385:+
LUAD	cis	rs853679	0.607	rs67998226	ENSG00000204709.4	LINC01556	6.43	3.12e-10	1.6e-07	0.6	0.28	Depression;	chr6:28270281	chr6:28943877~28944537:+
LUAD	cis	rs8072100	0.777	rs9914653	ENSG00000228782.6	CTD-2026D20.3	6.43	3.12e-10	1.6e-07	0.3	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47460029	chr17:47450568~47492492:-
LUAD	cis	rs11089937	0.616	rs12484482	ENSG00000211639.2	IGLV4-60	6.43	3.13e-10	1.61e-07	0.29	0.28	Periodontitis (PAL4Q3);	chr22:22180158	chr22:22162199~22162681:+
LUAD	cis	rs9309473	1	rs10187192	ENSG00000163016.8	ALMS1P	6.43	3.13e-10	1.61e-07	0.35	0.28	Metabolite levels;	chr2:73486373	chr2:73644919~73685576:+
LUAD	cis	rs7208859	0.623	rs8081299	ENSG00000263531.1	RP13-753N3.1	6.43	3.14e-10	1.61e-07	0.55	0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777278	chr17:30863921~30864940:-
LUAD	cis	rs321358	0.731	rs17460676	ENSG00000271584.1	RP11-89C3.4	6.43	3.14e-10	1.61e-07	0.44	0.28	Body mass index;	chr11:111166625	chr11:111091932~111097357:-
LUAD	cis	rs34375054	0.525	rs7136220	ENSG00000279233.1	RP11-158L12.4	6.43	3.15e-10	1.61e-07	0.24	0.28	Post bronchodilator FEV1/FVC ratio;	chr12:125118138	chr12:125138245~125141711:+
LUAD	cis	rs12220777	0.748	rs6584955	ENSG00000230091.5	TMEM254-AS1	6.43	3.15e-10	1.61e-07	0.49	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80100568	chr10:80046860~80078912:-
LUAD	cis	rs11098499	0.754	rs17595608	ENSG00000248280.1	RP11-33B1.2	6.43	3.15e-10	1.61e-07	0.35	0.28	Corneal astigmatism;	chr4:119329351	chr4:119440561~119450157:-
LUAD	cis	rs13160562	0.666	rs28096	ENSG00000272109.1	CTD-2260A17.3	-6.43	3.15e-10	1.62e-07	-0.3	-0.28	Alcohol dependence;	chr5:96773540	chr5:96804353~96806105:+
LUAD	cis	rs2739330	0.828	rs4820572	ENSG00000228039.3	KB-1125A3.10	6.43	3.15e-10	1.62e-07	0.35	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23963780~23964374:+
LUAD	cis	rs4660456	0.504	rs2253835	ENSG00000237899.1	RP4-739H11.3	6.43	3.15e-10	1.62e-07	0.4	0.28	Platelet count;	chr1:40635900	chr1:40669089~40687588:-
LUAD	cis	rs6844153	0.887	rs62302532	ENSG00000240005.4	RP11-293A21.1	-6.43	3.16e-10	1.62e-07	-0.44	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26947150	chr4:26859806~26860599:-
LUAD	cis	rs6844153	0.887	rs6448488	ENSG00000240005.4	RP11-293A21.1	-6.43	3.16e-10	1.62e-07	-0.44	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26949365	chr4:26859806~26860599:-
LUAD	cis	rs9549367	0.789	rs12584813	ENSG00000269125.1	RP11-98F14.11	-6.43	3.16e-10	1.62e-07	-0.34	-0.28	Platelet distribution width;	chr13:113241129	chr13:113165002~113165183:-
LUAD	cis	rs881375	0.967	rs7864019	ENSG00000226752.6	PSMD5-AS1	-6.43	3.16e-10	1.62e-07	-0.3	-0.28	Rheumatoid arthritis;	chr9:120930590	chr9:120824828~120854385:+
LUAD	cis	rs881375	0.967	rs10739579	ENSG00000226752.6	PSMD5-AS1	-6.43	3.16e-10	1.62e-07	-0.3	-0.28	Rheumatoid arthritis;	chr9:120932510	chr9:120824828~120854385:+
LUAD	cis	rs8005677	1	rs4982712	ENSG00000279656.1	RP11-298I3.6	6.43	3.16e-10	1.62e-07	0.34	0.28	Cognitive ability (multi-trait analysis);	chr14:22934519	chr14:23023083~23024217:-
LUAD	cis	rs17301013	0.507	rs12084948	ENSG00000227373.4	RP11-160H22.5	6.43	3.17e-10	1.62e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174525776	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs11809482	ENSG00000227373.4	RP11-160H22.5	6.43	3.17e-10	1.62e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174530269	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs909533	ENSG00000227373.4	RP11-160H22.5	6.43	3.17e-10	1.62e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174531428	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12093966	ENSG00000227373.4	RP11-160H22.5	6.43	3.17e-10	1.62e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174535120	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs7550472	ENSG00000227373.4	RP11-160H22.5	6.43	3.17e-10	1.62e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174536442	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs11484645	ENSG00000227373.4	RP11-160H22.5	6.43	3.17e-10	1.62e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174542993	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12063545	ENSG00000227373.4	RP11-160H22.5	6.43	3.17e-10	1.62e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174552863	chr1:174115300~174160004:-
LUAD	cis	rs75920871	0.562	rs68137714	ENSG00000254851.1	RP11-109L13.1	-6.43	3.17e-10	1.62e-07	-0.47	-0.28	Subjective well-being;	chr11:117154641	chr11:117135528~117138582:+
LUAD	cis	rs1823913	0.599	rs17412094	ENSG00000280083.1	RP11-317J9.1	-6.43	3.17e-10	1.62e-07	-0.33	-0.28	Obesity-related traits;	chr2:191284202	chr2:191154118~191156070:-
LUAD	cis	rs950169	0.541	rs10795	ENSG00000259728.4	LINC00933	6.43	3.17e-10	1.62e-07	0.41	0.28	Schizophrenia;	chr15:84634066	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.58	rs36126054	ENSG00000259728.4	LINC00933	6.43	3.17e-10	1.62e-07	0.41	0.28	Schizophrenia;	chr15:84634492	chr15:84570649~84580175:+
LUAD	cis	rs12554020	0.786	rs6479482	ENSG00000227603.1	RP11-165J3.6	6.42	3.18e-10	1.63e-07	0.43	0.28	Schizophrenia;	chr9:93435814	chr9:93435332~93437121:-
LUAD	cis	rs875971	0.545	rs6460298	ENSG00000237310.1	GS1-124K5.4	6.42	3.18e-10	1.63e-07	0.35	0.28	Aortic root size;	chr7:66442783	chr7:66493706~66495474:+
LUAD	cis	rs11690935	0.632	rs12998411	ENSG00000228389.1	AC068039.4	-6.42	3.18e-10	1.63e-07	-0.3	-0.28	Schizophrenia;	chr2:171674197	chr2:171773482~171775844:+
LUAD	cis	rs3762637	0.943	rs10439995	ENSG00000272758.4	RP11-299J3.8	-6.42	3.19e-10	1.63e-07	-0.44	-0.28	LDL cholesterol levels;	chr3:122470313	chr3:122416207~122443180:+
LUAD	cis	rs3762637	0.882	rs7630833	ENSG00000272758.4	RP11-299J3.8	-6.42	3.19e-10	1.63e-07	-0.44	-0.28	LDL cholesterol levels;	chr3:122471577	chr3:122416207~122443180:+
LUAD	cis	rs7927592	0.956	rs2155730	ENSG00000212093.1	AP000807.1	6.42	3.19e-10	1.63e-07	0.31	0.28	Total body bone mineral density;	chr11:68562006	chr11:68506083~68506166:-
LUAD	cis	rs67311347	1	rs12630072	ENSG00000223797.4	ENTPD3-AS1	6.42	3.19e-10	1.63e-07	0.31	0.28	Renal cell carcinoma;	chr3:40475699	chr3:40313802~40453329:-
LUAD	cis	rs2404602	0.552	rs4886823	ENSG00000259422.1	RP11-593F23.1	-6.42	3.19e-10	1.63e-07	-0.38	-0.28	Blood metabolite levels;	chr15:76673061	chr15:76174891~76181486:-
LUAD	cis	rs1799949	1	rs35956818	ENSG00000267681.1	CTD-3199J23.6	-6.42	3.2e-10	1.63e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43345617	chr17:43144956~43145255:+
LUAD	cis	rs12908161	0.92	rs35758837	ENSG00000259728.4	LINC00933	6.42	3.2e-10	1.63e-07	0.4	0.28	Schizophrenia;	chr15:84768151	chr15:84570649~84580175:+
LUAD	cis	rs5753618	0.555	rs5749286	ENSG00000236132.1	CTA-440B3.1	-6.42	3.2e-10	1.64e-07	-0.34	-0.28	Colorectal cancer;	chr22:31504373	chr22:31816379~31817491:-
LUAD	cis	rs77204473	0.744	rs117901629	ENSG00000254851.1	RP11-109L13.1	6.42	3.21e-10	1.64e-07	0.77	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117008963	chr11:117135528~117138582:+
LUAD	cis	rs11098499	0.754	rs1980027	ENSG00000248280.1	RP11-33B1.2	6.42	3.21e-10	1.64e-07	0.35	0.28	Corneal astigmatism;	chr4:119330422	chr4:119440561~119450157:-
LUAD	cis	rs2243480	1	rs59794892	ENSG00000226824.5	RP4-756H11.3	-6.42	3.21e-10	1.64e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65950886	chr7:66654538~66669855:+
LUAD	cis	rs765787	0.53	rs12905246	ENSG00000259520.4	CTD-2651B20.3	-6.42	3.22e-10	1.64e-07	-0.37	-0.28	Uric acid levels;	chr15:45208643	chr15:45251580~45279251:-
LUAD	cis	rs2179367	0.959	rs544947	ENSG00000231760.4	RP11-350J20.5	6.42	3.22e-10	1.64e-07	0.35	0.28	Dupuytren's disease;	chr6:149402412	chr6:149796151~149826294:-
LUAD	cis	rs77204473	0.744	rs77171490	ENSG00000254851.1	RP11-109L13.1	6.42	3.22e-10	1.64e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117168025	chr11:117135528~117138582:+
LUAD	cis	rs77204473	0.744	rs77678768	ENSG00000254851.1	RP11-109L13.1	6.42	3.22e-10	1.64e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117169789	chr11:117135528~117138582:+
LUAD	cis	rs77204473	0.744	rs80353869	ENSG00000254851.1	RP11-109L13.1	6.42	3.22e-10	1.64e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117177406	chr11:117135528~117138582:+
LUAD	cis	rs77204473	0.744	rs76883864	ENSG00000254851.1	RP11-109L13.1	6.42	3.22e-10	1.64e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117181009	chr11:117135528~117138582:+
LUAD	cis	rs783540	0.967	rs4779044	ENSG00000278603.1	RP13-608F4.5	6.42	3.22e-10	1.64e-07	0.32	0.28	Schizophrenia;	chr15:82670601	chr15:82472203~82472426:+
LUAD	cis	rs9640161	0.83	rs76741564	ENSG00000261305.1	RP4-584D14.7	6.42	3.22e-10	1.65e-07	0.41	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150362440	chr7:150341771~150342607:+
LUAD	cis	rs7945705	0.935	rs10769971	ENSG00000254860.4	TMEM9B-AS1	-6.42	3.22e-10	1.65e-07	-0.32	-0.28	Hemoglobin concentration;	chr11:8903729	chr11:8964675~8977527:+
LUAD	cis	rs7945705	0.967	rs10769973	ENSG00000254860.4	TMEM9B-AS1	-6.42	3.22e-10	1.65e-07	-0.32	-0.28	Hemoglobin concentration;	chr11:8907068	chr11:8964675~8977527:+
LUAD	cis	rs7626444	0.625	rs843541	ENSG00000272359.1	U4	-6.42	3.23e-10	1.65e-07	-0.31	-0.28	Monocyte count;	chr3:196748879	chr3:196747192~196747324:-
LUAD	cis	rs11089937	0.616	rs5995616	ENSG00000211639.2	IGLV4-60	-6.42	3.23e-10	1.65e-07	-0.3	-0.28	Periodontitis (PAL4Q3);	chr22:22186667	chr22:22162199~22162681:+
LUAD	cis	rs2439831	0.85	rs67541383	ENSG00000205771.5	CATSPER2P1	-6.42	3.23e-10	1.65e-07	-0.65	-0.28	Lung cancer in ever smokers;	chr15:43880350	chr15:43726918~43747094:-
LUAD	cis	rs5760092	0.572	rs738806	ENSG00000250470.1	AP000351.3	6.42	3.23e-10	1.65e-07	0.41	0.28	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23976904~23977585:-
LUAD	cis	rs11168854	0.656	rs7969963	ENSG00000258017.1	RP11-386G11.10	-6.42	3.23e-10	1.65e-07	-0.34	-0.28	Body mass index;	chr12:49118222	chr12:49127782~49147869:+
LUAD	cis	rs516805	0.961	rs510283	ENSG00000279453.1	RP3-425C14.4	-6.42	3.24e-10	1.65e-07	-0.32	-0.28	Lymphocyte counts;	chr6:122451547	chr6:122436789~122439223:-
LUAD	cis	rs4964805	0.626	rs869993	ENSG00000257681.1	RP11-341G23.4	6.42	3.24e-10	1.65e-07	0.33	0.28	Attention deficit hyperactivity disorder;	chr12:103781360	chr12:103746315~103768858:-
LUAD	cis	rs875971	0.528	rs801213	ENSG00000237310.1	GS1-124K5.4	-6.42	3.25e-10	1.66e-07	-0.34	-0.28	Aortic root size;	chr7:66549931	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs801212	ENSG00000237310.1	GS1-124K5.4	-6.42	3.25e-10	1.66e-07	-0.34	-0.28	Aortic root size;	chr7:66550643	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs801199	ENSG00000237310.1	GS1-124K5.4	-6.42	3.25e-10	1.66e-07	-0.34	-0.28	Aortic root size;	chr7:66560286	chr7:66493706~66495474:+
LUAD	cis	rs7829975	0.688	rs7826654	ENSG00000253981.4	ALG1L13P	6.42	3.25e-10	1.66e-07	0.33	0.28	Mood instability;	chr8:8521596	chr8:8236003~8244667:-
LUAD	cis	rs7829975	0.688	rs7826660	ENSG00000253981.4	ALG1L13P	6.42	3.25e-10	1.66e-07	0.33	0.28	Mood instability;	chr8:8521597	chr8:8236003~8244667:-
LUAD	cis	rs7849270	1	rs932835	ENSG00000268707.1	RP11-247A12.7	-6.42	3.25e-10	1.66e-07	-0.33	-0.28	Blood metabolite ratios;	chr9:129124792	chr9:129170434~129170940:+
LUAD	cis	rs1061377	0.513	rs2566162	ENSG00000249207.1	RP11-360F5.1	-6.42	3.25e-10	1.66e-07	-0.37	-0.28	Uric acid levels;	chr4:39126453	chr4:39112677~39126818:-
LUAD	cis	rs2739330	0.828	rs2154593	ENSG00000206090.4	AP000350.7	6.42	3.25e-10	1.66e-07	0.32	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23939998~23942798:+
LUAD	cis	rs1823913	0.562	rs17347499	ENSG00000227542.1	AC092614.2	6.42	3.25e-10	1.66e-07	0.35	0.28	Obesity-related traits;	chr2:191301116	chr2:191229165~191246172:-
LUAD	cis	rs494459	0.838	rs555639	ENSG00000278376.1	RP11-158I9.8	6.42	3.26e-10	1.66e-07	0.3	0.28	Height;	chr11:118758322	chr11:118791254~118793137:+
LUAD	cis	rs4834770	1	rs4336213	ENSG00000245958.5	RP11-33B1.1	-6.42	3.26e-10	1.66e-07	-0.25	-0.28	Blood protein levels;	chr4:119315314	chr4:119454791~119552025:+
LUAD	cis	rs10759883	0.563	rs625105	ENSG00000175611.10	LINC00476	6.42	3.26e-10	1.66e-07	0.32	0.28	Nicotine dependence;	chr9:96007466	chr9:95759231~95875977:-
LUAD	cis	rs6860806	0.507	rs183898	ENSG00000233006.5	AC034220.3	-6.42	3.26e-10	1.67e-07	-0.28	-0.28	Breast cancer;	chr5:132381210	chr5:132311285~132369916:-
LUAD	cis	rs1799949	1	rs9646412	ENSG00000267681.1	CTD-3199J23.6	-6.42	3.27e-10	1.67e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43348525	chr17:43144956~43145255:+
LUAD	cis	rs9318086	0.687	rs9507182	ENSG00000205861.10	C1QTNF9B-AS1	-6.42	3.27e-10	1.67e-07	-0.33	-0.28	Myopia (pathological);	chr13:23868226	chr13:23888889~23897263:+
LUAD	cis	rs765787	0.53	rs12442533	ENSG00000259520.4	CTD-2651B20.3	-6.42	3.27e-10	1.67e-07	-0.38	-0.28	Uric acid levels;	chr15:45237433	chr15:45251580~45279251:-
LUAD	cis	rs4964805	0.672	rs11111757	ENSG00000257681.1	RP11-341G23.4	6.42	3.27e-10	1.67e-07	0.33	0.28	Attention deficit hyperactivity disorder;	chr12:103766984	chr12:103746315~103768858:-
LUAD	cis	rs11098499	0.863	rs7699064	ENSG00000248280.1	RP11-33B1.2	-6.42	3.28e-10	1.67e-07	-0.36	-0.28	Corneal astigmatism;	chr4:119507154	chr4:119440561~119450157:-
LUAD	cis	rs1823913	0.895	rs10931491	ENSG00000230611.1	HMGB1P27	6.42	3.28e-10	1.67e-07	0.34	0.28	Obesity-related traits;	chr2:191256087	chr2:191174233~191174835:+
LUAD	cis	rs2243480	1	rs73142166	ENSG00000226824.5	RP4-756H11.3	-6.42	3.28e-10	1.68e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:65910845	chr7:66654538~66669855:+
LUAD	cis	rs7246657	0.943	rs9917081	ENSG00000276846.1	CTD-3220F14.3	6.42	3.28e-10	1.68e-07	0.4	0.28	Coronary artery calcification;	chr19:37385714	chr19:37314868~37315620:-
LUAD	cis	rs2404602	0.71	rs2469541	ENSG00000259422.1	RP11-593F23.1	-6.42	3.28e-10	1.68e-07	-0.33	-0.28	Blood metabolite levels;	chr15:76269777	chr15:76174891~76181486:-
LUAD	cis	rs6750795	0.765	rs6742387	ENSG00000181798.2	LINC00471	-6.42	3.28e-10	1.68e-07	-0.31	-0.28	Height;	chr2:231490121	chr2:231508426~231514339:-
LUAD	cis	rs12908161	1	rs36033486	ENSG00000259728.4	LINC00933	6.42	3.29e-10	1.68e-07	0.4	0.28	Schizophrenia;	chr15:84776461	chr15:84570649~84580175:+
LUAD	cis	rs12908161	1	rs12908549	ENSG00000259728.4	LINC00933	6.42	3.29e-10	1.68e-07	0.4	0.28	Schizophrenia;	chr15:84779120	chr15:84570649~84580175:+
LUAD	cis	rs875971	0.545	rs316306	ENSG00000226824.5	RP4-756H11.3	6.42	3.3e-10	1.68e-07	0.41	0.28	Aortic root size;	chr7:66153687	chr7:66654538~66669855:+
LUAD	cis	rs2117029	0.521	rs11168910	ENSG00000258017.1	RP11-386G11.10	-6.42	3.3e-10	1.68e-07	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49192707	chr12:49127782~49147869:+
LUAD	cis	rs35934224	0.783	rs7287073	ENSG00000232926.1	AC000078.5	6.42	3.32e-10	1.69e-07	0.35	0.28	Glaucoma (primary open-angle);	chr22:19876812	chr22:19887289~19887970:+
LUAD	cis	rs7246657	0.653	rs10402050	ENSG00000276846.1	CTD-3220F14.3	6.42	3.32e-10	1.69e-07	0.46	0.28	Coronary artery calcification;	chr19:37198056	chr19:37314868~37315620:-
LUAD	cis	rs17711722	0.565	rs4275112	ENSG00000236529.1	RP13-254B10.1	-6.42	3.32e-10	1.69e-07	-0.28	-0.28	Calcium levels;	chr7:65733651	chr7:65840212~65840596:+
LUAD	cis	rs2404602	0.647	rs7165053	ENSG00000259422.1	RP11-593F23.1	-6.42	3.33e-10	1.7e-07	-0.36	-0.28	Blood metabolite levels;	chr15:76686577	chr15:76174891~76181486:-
LUAD	cis	rs1061377	0.722	rs34803689	ENSG00000249685.1	RP11-360F5.3	6.42	3.34e-10	1.7e-07	0.34	0.28	Uric acid levels;	chr4:39116665	chr4:39133913~39135608:+
LUAD	cis	rs2276314	0.553	rs4799842	ENSG00000278986.1	RP11-723J4.3	-6.42	3.34e-10	1.7e-07	-0.29	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36048005	chr18:35972151~35973916:+
LUAD	cis	rs2243480	1	rs1499613	ENSG00000226824.5	RP4-756H11.3	6.42	3.34e-10	1.7e-07	0.52	0.28	Diabetic kidney disease;	chr7:66265873	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs1553174	ENSG00000226824.5	RP4-756H11.3	6.42	3.34e-10	1.7e-07	0.52	0.28	Diabetic kidney disease;	chr7:66266207	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs10950032	ENSG00000226824.5	RP4-756H11.3	6.42	3.34e-10	1.7e-07	0.52	0.28	Diabetic kidney disease;	chr7:66273604	chr7:66654538~66669855:+
LUAD	cis	rs2404602	0.647	rs12903586	ENSG00000259422.1	RP11-593F23.1	-6.42	3.34e-10	1.7e-07	-0.37	-0.28	Blood metabolite levels;	chr15:76875899	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.647	rs12903331	ENSG00000259422.1	RP11-593F23.1	-6.42	3.34e-10	1.7e-07	-0.37	-0.28	Blood metabolite levels;	chr15:76875927	chr15:76174891~76181486:-
LUAD	cis	rs7674212	0.556	rs6533039	ENSG00000251288.2	RP11-10L12.2	-6.42	3.34e-10	1.7e-07	-0.35	-0.28	Type 2 diabetes;	chr4:102938381	chr4:102751401~102752641:+
LUAD	cis	rs755249	0.917	rs61779331	ENSG00000228060.1	RP11-69E11.8	-6.42	3.34e-10	1.7e-07	-0.28	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39505256	chr1:39565160~39573203:+
LUAD	cis	rs853679	0.55	rs1150692	ENSG00000219392.1	RP1-265C24.5	-6.42	3.35e-10	1.71e-07	-0.39	-0.28	Depression;	chr6:28206179	chr6:28115628~28116551:+
LUAD	cis	rs17027258	0.697	rs1468789	ENSG00000234389.1	AC007278.3	-6.42	3.35e-10	1.71e-07	-0.32	-0.28	White blood cell types;	chr2:102476044	chr2:102438713~102440475:+
LUAD	cis	rs2243480	1	rs13247184	ENSG00000226824.5	RP4-756H11.3	-6.42	3.35e-10	1.71e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:65893941	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs35283677	ENSG00000226824.5	RP4-756H11.3	-6.42	3.35e-10	1.71e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:65894246	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs35421653	ENSG00000226824.5	RP4-756H11.3	-6.42	3.35e-10	1.71e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:65898442	chr7:66654538~66669855:+
LUAD	cis	rs7811142	1	rs7794485	ENSG00000242294.5	STAG3L5P	6.42	3.35e-10	1.71e-07	0.25	0.28	Platelet count;	chr7:100471313	chr7:100336079~100351900:+
LUAD	cis	rs2117029	0.523	rs12227296	ENSG00000258017.1	RP11-386G11.10	-6.42	3.35e-10	1.71e-07	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49136712	chr12:49127782~49147869:+
LUAD	cis	rs2117029	0.521	rs10875925	ENSG00000258017.1	RP11-386G11.10	-6.42	3.35e-10	1.71e-07	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49142575	chr12:49127782~49147869:+
LUAD	cis	rs2117029	0.586	rs11168882	ENSG00000258017.1	RP11-386G11.10	-6.42	3.35e-10	1.71e-07	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49143560	chr12:49127782~49147869:+
LUAD	cis	rs1707322	0.685	rs56177313	ENSG00000234329.1	RP11-767N6.2	6.42	3.36e-10	1.71e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760134	chr1:45651039~45651826:-
LUAD	cis	rs11098499	0.754	rs12510269	ENSG00000248280.1	RP11-33B1.2	6.42	3.36e-10	1.71e-07	0.35	0.28	Corneal astigmatism;	chr4:119320491	chr4:119440561~119450157:-
LUAD	cis	rs2911132	1	rs2617433	ENSG00000248734.2	CTD-2260A17.1	6.42	3.37e-10	1.71e-07	0.29	0.28	Urate levels (BMI interaction);	chr5:96840738	chr5:96784777~96785999:+
LUAD	cis	rs4718428	0.705	rs28648401	ENSG00000273142.1	RP11-458F8.4	-6.42	3.37e-10	1.72e-07	-0.21	-0.28	Corneal structure;	chr7:66902145	chr7:66902857~66906297:+
LUAD	cis	rs881375	0.967	rs10733648	ENSG00000226752.6	PSMD5-AS1	-6.41	3.38e-10	1.72e-07	-0.3	-0.28	Rheumatoid arthritis;	chr9:120938501	chr9:120824828~120854385:+
LUAD	cis	rs1061377	0.965	rs7677729	ENSG00000249685.1	RP11-360F5.3	6.41	3.38e-10	1.72e-07	0.34	0.28	Uric acid levels;	chr4:39120370	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs3796511	ENSG00000249685.1	RP11-360F5.3	6.41	3.38e-10	1.72e-07	0.34	0.28	Uric acid levels;	chr4:39120586	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs3733274	ENSG00000249685.1	RP11-360F5.3	6.41	3.38e-10	1.72e-07	0.34	0.28	Uric acid levels;	chr4:39120957	chr4:39133913~39135608:+
LUAD	cis	rs6558530	0.932	rs10102731	ENSG00000253982.1	CTD-2336O2.1	6.41	3.38e-10	1.72e-07	0.35	0.28	Systolic blood pressure;	chr8:1760854	chr8:1761990~1764502:-
LUAD	cis	rs2404602	0.647	rs10152247	ENSG00000259422.1	RP11-593F23.1	-6.41	3.38e-10	1.72e-07	-0.37	-0.28	Blood metabolite levels;	chr15:76649911	chr15:76174891~76181486:-
LUAD	cis	rs950169	1	rs11638394	ENSG00000259728.4	LINC00933	6.41	3.38e-10	1.72e-07	0.43	0.28	Schizophrenia;	chr15:84110176	chr15:84570649~84580175:+
LUAD	cis	rs7017914	0.967	rs1493198	ENSG00000223220.1	Y_RNA	6.41	3.39e-10	1.72e-07	0.31	0.28	Bone mineral density;	chr8:70939722	chr8:70780914~70781008:-
LUAD	cis	rs6860806	0.507	rs2631364	ENSG00000233006.5	AC034220.3	-6.41	3.39e-10	1.73e-07	-0.28	-0.28	Breast cancer;	chr5:132371222	chr5:132311285~132369916:-
LUAD	cis	rs6860806	0.531	rs2631359	ENSG00000233006.5	AC034220.3	-6.41	3.39e-10	1.73e-07	-0.28	-0.28	Breast cancer;	chr5:132372200	chr5:132311285~132369916:-
LUAD	cis	rs875971	0.545	rs12671152	ENSG00000226824.5	RP4-756H11.3	-6.41	3.39e-10	1.73e-07	-0.42	-0.28	Aortic root size;	chr7:66311140	chr7:66654538~66669855:+
LUAD	cis	rs67311347	0.955	rs4974067	ENSG00000223797.4	ENTPD3-AS1	6.41	3.4e-10	1.73e-07	0.29	0.28	Renal cell carcinoma;	chr3:40333060	chr3:40313802~40453329:-
LUAD	cis	rs8177376	0.813	rs667627	ENSG00000254905.1	RP11-712L6.7	6.41	3.4e-10	1.73e-07	0.38	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126277802	chr11:126292922~126294254:-
LUAD	cis	rs1062177	1	rs62377945	ENSG00000213433.5	RPLP1P6	-6.41	3.41e-10	1.73e-07	-0.38	-0.28	Preschool internalizing problems;	chr5:151828443	chr5:151765859~151766378:-
LUAD	cis	rs150992	0.609	rs393697	ENSG00000248489.1	CTD-2007H13.3	6.41	3.41e-10	1.73e-07	0.31	0.28	Body mass index;	chr5:98991357	chr5:98929171~98995013:+
LUAD	cis	rs2439831	0.85	rs3825783	ENSG00000205771.5	CATSPER2P1	-6.41	3.41e-10	1.73e-07	-0.55	-0.28	Lung cancer in ever smokers;	chr15:43810111	chr15:43726918~43747094:-
LUAD	cis	rs12908161	1	rs12910012	ENSG00000259728.4	LINC00933	6.41	3.42e-10	1.74e-07	0.41	0.28	Schizophrenia;	chr15:84755431	chr15:84570649~84580175:+
LUAD	cis	rs12908161	1	rs12899981	ENSG00000259728.4	LINC00933	6.41	3.42e-10	1.74e-07	0.41	0.28	Schizophrenia;	chr15:84759142	chr15:84570649~84580175:+
LUAD	cis	rs2303759	0.918	rs8107548	ENSG00000268686.1	AC010524.2	-6.41	3.42e-10	1.74e-07	-0.41	-0.28	Multiple sclerosis;	chr19:49367386	chr19:49368705~49388081:-
LUAD	cis	rs2404602	0.647	rs4886837	ENSG00000259422.1	RP11-593F23.1	-6.41	3.42e-10	1.74e-07	-0.37	-0.28	Blood metabolite levels;	chr15:76864076	chr15:76174891~76181486:-
LUAD	cis	rs7626444	0.625	rs843530	ENSG00000272359.1	U4	-6.41	3.42e-10	1.74e-07	-0.31	-0.28	Monocyte count;	chr3:196754153	chr3:196747192~196747324:-
LUAD	cis	rs9326248	0.53	rs579890	ENSG00000280143.1	AP000892.6	6.41	3.43e-10	1.74e-07	0.46	0.28	Blood protein levels;	chr11:116928247	chr11:117204967~117210292:+
LUAD	cis	rs3762637	1	rs7615673	ENSG00000272758.4	RP11-299J3.8	-6.41	3.43e-10	1.74e-07	-0.44	-0.28	LDL cholesterol levels;	chr3:122406697	chr3:122416207~122443180:+
LUAD	cis	rs55665837	1	rs10766182	ENSG00000251991.1	RNU7-49P	6.41	3.43e-10	1.74e-07	0.31	0.28	Vitamin D levels;	chr11:14477990	chr11:14478892~14478953:+
LUAD	cis	rs55665837	1	rs12364959	ENSG00000251991.1	RNU7-49P	6.41	3.43e-10	1.74e-07	0.31	0.28	Vitamin D levels;	chr11:14485889	chr11:14478892~14478953:+
LUAD	cis	rs55665837	1	rs34980103	ENSG00000251991.1	RNU7-49P	6.41	3.43e-10	1.74e-07	0.31	0.28	Vitamin D levels;	chr11:14491339	chr11:14478892~14478953:+
LUAD	cis	rs55665837	1	rs11023246	ENSG00000251991.1	RNU7-49P	6.41	3.43e-10	1.74e-07	0.31	0.28	Vitamin D levels;	chr11:14515410	chr11:14478892~14478953:+
LUAD	cis	rs1061377	1	rs7685082	ENSG00000249685.1	RP11-360F5.3	6.41	3.44e-10	1.75e-07	0.34	0.28	Uric acid levels;	chr4:39116472	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs7664078	ENSG00000249685.1	RP11-360F5.3	6.41	3.44e-10	1.75e-07	0.34	0.28	Uric acid levels;	chr4:39116583	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs9998481	ENSG00000249685.1	RP11-360F5.3	6.41	3.44e-10	1.75e-07	0.34	0.28	Uric acid levels;	chr4:39117215	chr4:39133913~39135608:+
LUAD	cis	rs113835537	0.529	rs11227502	ENSG00000255517.5	CTD-3074O7.5	-6.41	3.44e-10	1.75e-07	-0.33	-0.28	Airway imaging phenotypes;	chr11:66506677	chr11:66473490~66480233:-
LUAD	cis	rs4927850	0.881	rs7630489	ENSG00000207650.1	MIR570	6.41	3.44e-10	1.75e-07	0.29	0.28	Pancreatic cancer;	chr3:196026530	chr3:195699401~195699497:+
LUAD	cis	rs7246657	0.943	rs6508732	ENSG00000276846.1	CTD-3220F14.3	6.41	3.45e-10	1.75e-07	0.37	0.28	Coronary artery calcification;	chr19:37509566	chr19:37314868~37315620:-
LUAD	cis	rs8081395	0.805	rs2645485	ENSG00000266992.1	DHX40P1	6.41	3.45e-10	1.75e-07	0.33	0.28	White blood cell count;	chr17:59866920	chr17:59976009~60002384:-
LUAD	cis	rs9640161	0.83	rs35635199	ENSG00000261305.1	RP4-584D14.7	6.41	3.45e-10	1.75e-07	0.42	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150366253	chr7:150341771~150342607:+
LUAD	cis	rs12439619	0.768	rs28694364	ENSG00000255769.6	GOLGA2P10	-6.41	3.45e-10	1.75e-07	-0.36	-0.28	Intelligence (multi-trait analysis);	chr15:82208119	chr15:82472993~82513950:-
LUAD	cis	rs7674212	0.556	rs223401	ENSG00000246560.2	RP11-10L12.4	6.41	3.45e-10	1.75e-07	0.36	0.28	Type 2 diabetes;	chr4:102817815	chr4:102828055~102844075:+
LUAD	cis	rs2243480	1	rs313809	ENSG00000232546.1	RP11-458F8.1	-6.41	3.45e-10	1.75e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66034996	chr7:66848496~66858136:+
LUAD	cis	rs7615952	0.611	rs12488771	ENSG00000171084.14	FAM86JP	6.41	3.45e-10	1.75e-07	0.58	0.28	Blood pressure (smoking interaction);	chr3:125981683	chr3:125916620~125930024:+
LUAD	cis	rs9549367	0.789	rs2302757	ENSG00000269125.1	RP11-98F14.11	-6.41	3.46e-10	1.75e-07	-0.35	-0.28	Platelet distribution width;	chr13:113255025	chr13:113165002~113165183:-
LUAD	cis	rs367615	0.918	rs10051855	ENSG00000249476.1	CTD-2587M2.1	6.41	3.46e-10	1.76e-07	0.37	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109524257	chr5:109237120~109326369:-
LUAD	cis	rs367615	0.918	rs10055528	ENSG00000249476.1	CTD-2587M2.1	6.41	3.46e-10	1.76e-07	0.37	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109525428	chr5:109237120~109326369:-
LUAD	cis	rs4718428	0.705	rs3800817	ENSG00000232546.1	RP11-458F8.1	-6.41	3.46e-10	1.76e-07	-0.27	-0.28	Corneal structure;	chr7:66798563	chr7:66848496~66858136:+
LUAD	cis	rs17301013	0.507	rs6665535	ENSG00000227373.4	RP11-160H22.5	6.41	3.46e-10	1.76e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174522480	chr1:174115300~174160004:-
LUAD	cis	rs10129255	0.5	rs6576231	ENSG00000224373.3	IGHV4-59	6.41	3.47e-10	1.76e-07	0.17	0.28	Kawasaki disease;	chr14:106783693	chr14:106627249~106627825:-
LUAD	cis	rs7246657	0.551	rs12972146	ENSG00000276846.1	CTD-3220F14.3	6.41	3.47e-10	1.76e-07	0.43	0.28	Coronary artery calcification;	chr19:37135193	chr19:37314868~37315620:-
LUAD	cis	rs6558530	0.836	rs11136424	ENSG00000253982.1	CTD-2336O2.1	6.41	3.47e-10	1.76e-07	0.35	0.28	Systolic blood pressure;	chr8:1768870	chr8:1761990~1764502:-
LUAD	cis	rs5753618	0.539	rs5753596	ENSG00000236132.1	CTA-440B3.1	6.41	3.47e-10	1.76e-07	0.32	0.28	Colorectal cancer;	chr22:31391486	chr22:31816379~31817491:-
LUAD	cis	rs11098499	0.69	rs34818745	ENSG00000248280.1	RP11-33B1.2	6.41	3.47e-10	1.76e-07	0.36	0.28	Corneal astigmatism;	chr4:119335900	chr4:119440561~119450157:-
LUAD	cis	rs2243480	0.831	rs7806717	ENSG00000226824.5	RP4-756H11.3	6.41	3.47e-10	1.76e-07	0.53	0.28	Diabetic kidney disease;	chr7:65928187	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs34136756	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65916269	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs78803505	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65917585	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs34933526	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65918212	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs34577383	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65920739	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs6949812	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65922114	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs55895244	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65922691	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs6970243	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65923503	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs7794661	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65924743	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs7795242	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65925107	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.708	rs35310401	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65925372	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs35058610	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65925938	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs2177703	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65926730	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs35432774	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65928032	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs56985706	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65929575	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs60683927	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65929781	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs58062456	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65929865	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs34529418	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65938222	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.901	rs35087093	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65940221	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs35046236	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65943626	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs36068983	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65944004	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs68189316	ENSG00000226824.5	RP4-756H11.3	-6.41	3.47e-10	1.76e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65944182	chr7:66654538~66669855:+
LUAD	cis	rs9318086	0.753	rs9553094	ENSG00000205861.10	C1QTNF9B-AS1	6.41	3.47e-10	1.76e-07	0.34	0.28	Myopia (pathological);	chr13:23900474	chr13:23888889~23897263:+
LUAD	cis	rs12908161	1	rs17601029	ENSG00000259728.4	LINC00933	6.41	3.48e-10	1.76e-07	0.4	0.28	Schizophrenia;	chr15:84804478	chr15:84570649~84580175:+
LUAD	cis	rs10129255	0.5	rs11627315	ENSG00000224373.3	IGHV4-59	6.41	3.48e-10	1.76e-07	0.17	0.28	Kawasaki disease;	chr14:106802182	chr14:106627249~106627825:-
LUAD	cis	rs9309473	0.95	rs2947860	ENSG00000163016.8	ALMS1P	6.41	3.48e-10	1.76e-07	0.35	0.28	Metabolite levels;	chr2:73628259	chr2:73644919~73685576:+
LUAD	cis	rs496547	0.719	rs1790189	ENSG00000255422.1	AP002954.4	-6.41	3.48e-10	1.76e-07	-0.36	-0.28	Hip minimal joint space width;	chr11:118781617	chr11:118704607~118750263:+
LUAD	cis	rs2243480	1	rs1039664	ENSG00000226824.5	RP4-756H11.3	-6.41	3.48e-10	1.77e-07	-0.51	-0.28	Diabetic kidney disease;	chr7:65984729	chr7:66654538~66669855:+
LUAD	cis	rs2303759	0.874	rs10411630	ENSG00000268686.1	AC010524.2	-6.41	3.48e-10	1.77e-07	-0.4	-0.28	Multiple sclerosis;	chr19:49388057	chr19:49368705~49388081:-
LUAD	cis	rs9549367	0.789	rs35569628	ENSG00000269125.1	RP11-98F14.11	-6.41	3.49e-10	1.77e-07	-0.34	-0.28	Platelet distribution width;	chr13:113218398	chr13:113165002~113165183:-
LUAD	cis	rs10129255	0.53	rs11624912	ENSG00000211970.3	IGHV4-61	-6.41	3.49e-10	1.77e-07	-0.2	-0.28	Kawasaki disease;	chr14:106673891	chr14:106639119~106639657:-
LUAD	cis	rs2243480	0.666	rs1880311	ENSG00000226824.5	RP4-756H11.3	6.41	3.5e-10	1.77e-07	0.55	0.28	Diabetic kidney disease;	chr7:65811765	chr7:66654538~66669855:+
LUAD	cis	rs35740288	0.77	rs35348278	ENSG00000202081.1	RNU6-1280P	6.41	3.5e-10	1.77e-07	0.35	0.28	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85657109	chr15:85651522~85651628:-
LUAD	cis	rs875971	0.545	rs35459055	ENSG00000237310.1	GS1-124K5.4	6.41	3.5e-10	1.77e-07	0.34	0.28	Aortic root size;	chr7:66479399	chr7:66493706~66495474:+
LUAD	cis	rs9928842	0.882	rs6564241	ENSG00000280152.1	RP11-331F4.5	6.41	3.5e-10	1.77e-07	0.32	0.28	Alcoholic chronic pancreatitis;	chr16:75230076	chr16:75245994~75250077:-
LUAD	cis	rs10129255	0.5	rs8004923	ENSG00000224373.3	IGHV4-59	6.41	3.5e-10	1.77e-07	0.17	0.28	Kawasaki disease;	chr14:106785926	chr14:106627249~106627825:-
LUAD	cis	rs1062177	0.756	rs2964589	ENSG00000213433.5	RPLP1P6	6.41	3.5e-10	1.78e-07	0.37	0.28	Preschool internalizing problems;	chr5:151738628	chr5:151765859~151766378:-
LUAD	cis	rs2243480	1	rs2420170	ENSG00000232546.1	RP11-458F8.1	6.41	3.51e-10	1.78e-07	0.37	0.28	Diabetic kidney disease;	chr7:66191066	chr7:66848496~66858136:+
LUAD	cis	rs875971	1	rs6957199	ENSG00000222364.1	RNU6-96P	-6.41	3.51e-10	1.78e-07	-0.31	-0.28	Aortic root size;	chr7:66513532	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.545	rs6969224	ENSG00000237310.1	GS1-124K5.4	6.41	3.51e-10	1.78e-07	0.35	0.28	Aortic root size;	chr7:66370011	chr7:66493706~66495474:+
LUAD	cis	rs2117029	0.586	rs11168874	ENSG00000258017.1	RP11-386G11.10	-6.41	3.51e-10	1.78e-07	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49133753	chr12:49127782~49147869:+
LUAD	cis	rs7674212	0.507	rs223331	ENSG00000251288.2	RP11-10L12.2	-6.41	3.52e-10	1.79e-07	-0.35	-0.28	Type 2 diabetes;	chr4:102872408	chr4:102751401~102752641:+
LUAD	cis	rs6142102	0.602	rs6142069	ENSG00000275784.1	RP5-1125A11.6	-6.41	3.53e-10	1.79e-07	-0.3	-0.28	Skin pigmentation;	chr20:33972736	chr20:33989480~33991818:-
LUAD	cis	rs1799949	1	rs12944430	ENSG00000267681.1	CTD-3199J23.6	-6.41	3.53e-10	1.79e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43178803	chr17:43144956~43145255:+
LUAD	cis	rs1799949	0.965	rs11658499	ENSG00000267681.1	CTD-3199J23.6	-6.41	3.53e-10	1.79e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43182732	chr17:43144956~43145255:+
LUAD	cis	rs131777	0.577	rs5770928	ENSG00000205559.3	CHKB-AS1	-6.41	3.53e-10	1.79e-07	-0.33	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50590662	chr22:50583026~50583877:+
LUAD	cis	rs4718428	0.705	rs12698547	ENSG00000232546.1	RP11-458F8.1	-6.41	3.53e-10	1.79e-07	-0.27	-0.28	Corneal structure;	chr7:66813271	chr7:66848496~66858136:+
LUAD	cis	rs10129255	0.5	rs6576232	ENSG00000224373.3	IGHV4-59	6.41	3.54e-10	1.79e-07	0.17	0.28	Kawasaki disease;	chr14:106787090	chr14:106627249~106627825:-
LUAD	cis	rs7246657	0.943	rs7258692	ENSG00000276846.1	CTD-3220F14.3	6.41	3.54e-10	1.79e-07	0.4	0.28	Coronary artery calcification;	chr19:37327927	chr19:37314868~37315620:-
LUAD	cis	rs77204473	0.744	rs17120293	ENSG00000254851.1	RP11-109L13.1	6.41	3.54e-10	1.79e-07	0.66	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117074130	chr11:117135528~117138582:+
LUAD	cis	rs881375	0.967	rs1930781	ENSG00000226752.6	PSMD5-AS1	-6.41	3.54e-10	1.8e-07	-0.3	-0.28	Rheumatoid arthritis;	chr9:120925556	chr9:120824828~120854385:+
LUAD	cis	rs12908161	0.959	rs11637728	ENSG00000259728.4	LINC00933	6.41	3.55e-10	1.8e-07	0.41	0.28	Schizophrenia;	chr15:84660161	chr15:84570649~84580175:+
LUAD	cis	rs11089937	0.616	rs7286793	ENSG00000211639.2	IGLV4-60	6.41	3.55e-10	1.8e-07	0.3	0.28	Periodontitis (PAL4Q3);	chr22:22182951	chr22:22162199~22162681:+
LUAD	cis	rs875971	0.893	rs62465470	ENSG00000222364.1	RNU6-96P	6.41	3.56e-10	1.8e-07	0.31	0.28	Aortic root size;	chr7:66136231	chr7:66395191~66395286:+
LUAD	cis	rs4927850	1	rs10881564	ENSG00000207650.1	MIR570	6.41	3.56e-10	1.8e-07	0.29	0.28	Pancreatic cancer;	chr3:196023455	chr3:195699401~195699497:+
LUAD	cis	rs8062405	0.54	rs151226	ENSG00000259982.1	CDC37P1	6.41	3.56e-10	1.8e-07	0.33	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28538502	chr16:28700294~28701540:-
LUAD	cis	rs2243480	0.901	rs57126451	ENSG00000226824.5	RP4-756H11.3	-6.41	3.56e-10	1.8e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65951319	chr7:66654538~66669855:+
LUAD	cis	rs8177876	0.749	rs2970076	ENSG00000261838.4	RP11-303E16.6	6.41	3.57e-10	1.81e-07	0.49	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81056211	chr16:81069854~81076598:+
LUAD	cis	rs6700559	0.654	rs66717951	ENSG00000260088.1	RP11-92G12.3	6.41	3.57e-10	1.81e-07	0.35	0.28	Coronary artery disease;	chr1:200626437	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.654	rs2809346	ENSG00000260088.1	RP11-92G12.3	6.41	3.57e-10	1.81e-07	0.35	0.28	Coronary artery disease;	chr1:200627089	chr1:200669507~200694250:+
LUAD	cis	rs35160687	0.722	rs6728029	ENSG00000273080.1	RP11-301O19.1	-6.41	3.57e-10	1.81e-07	-0.31	-0.28	Night sleep phenotypes;	chr2:86328258	chr2:86195590~86196049:+
LUAD	cis	rs433852	0.904	rs8102492	ENSG00000232871.7	SEC1P	6.41	3.57e-10	1.81e-07	0.36	0.28	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48637552	chr19:48638071~48682245:+
LUAD	cis	rs9318086	0.648	rs7330140	ENSG00000205861.10	C1QTNF9B-AS1	-6.41	3.57e-10	1.81e-07	-0.34	-0.28	Myopia (pathological);	chr13:23898935	chr13:23888889~23897263:+
LUAD	cis	rs9318086	0.648	rs9507184	ENSG00000205861.10	C1QTNF9B-AS1	-6.41	3.57e-10	1.81e-07	-0.34	-0.28	Myopia (pathological);	chr13:23899503	chr13:23888889~23897263:+
LUAD	cis	rs9309711	0.961	rs11692184	ENSG00000225234.1	TRAPPC12-AS1	-6.41	3.58e-10	1.81e-07	-0.34	-0.28	Neurofibrillary tangles;	chr2:3476939	chr2:3481242~3482409:-
LUAD	cis	rs2243480	0.803	rs36004293	ENSG00000226824.5	RP4-756H11.3	-6.41	3.58e-10	1.81e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65951525	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.803	rs35268390	ENSG00000226824.5	RP4-756H11.3	-6.41	3.58e-10	1.81e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65951549	chr7:66654538~66669855:+
LUAD	cis	rs8177376	1	rs671492	ENSG00000254905.1	RP11-712L6.7	6.41	3.58e-10	1.81e-07	0.38	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126280025	chr11:126292922~126294254:-
LUAD	cis	rs4713118	0.513	rs1225591	ENSG00000219392.1	RP1-265C24.5	-6.41	3.58e-10	1.81e-07	-0.38	-0.28	Parkinson's disease;	chr6:28180974	chr6:28115628~28116551:+
LUAD	cis	rs4927850	1	rs7627706	ENSG00000207650.1	MIR570	6.4	3.58e-10	1.81e-07	0.29	0.28	Pancreatic cancer;	chr3:196026482	chr3:195699401~195699497:+
LUAD	cis	rs755249	0.567	rs16826000	ENSG00000228060.1	RP11-69E11.8	-6.4	3.59e-10	1.81e-07	-0.28	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39248188	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs16826009	ENSG00000228060.1	RP11-69E11.8	-6.4	3.59e-10	1.81e-07	-0.28	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39251230	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs4660208	ENSG00000228060.1	RP11-69E11.8	-6.4	3.59e-10	1.81e-07	-0.28	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39256542	chr1:39565160~39573203:+
LUAD	cis	rs1823913	1	rs11681777	ENSG00000230611.1	HMGB1P27	6.4	3.59e-10	1.81e-07	0.34	0.28	Obesity-related traits;	chr2:191256741	chr2:191174233~191174835:+
LUAD	cis	rs237743	1	rs1567865	ENSG00000222365.1	SNORD12B	-6.4	3.59e-10	1.82e-07	-0.33	-0.28	Height;	chr20:49265430	chr20:49280319~49280409:+
LUAD	cis	rs853679	0.546	rs71537572	ENSG00000204709.4	LINC01556	6.4	3.59e-10	1.82e-07	0.62	0.28	Depression;	chr6:28002937	chr6:28943877~28944537:+
LUAD	cis	rs1075265	0.87	rs1363062	ENSG00000233266.1	HMGB1P31	6.4	3.59e-10	1.82e-07	0.35	0.28	Chronotype;Morning vs. evening chronotype;	chr2:54054625	chr2:54051334~54051760:+
LUAD	cis	rs380904	0.552	rs10099003	ENSG00000254859.1	RP11-661A12.5	-6.4	3.59e-10	1.82e-07	-0.42	-0.28	Venous thromboembolism (SNP x SNP interaction);	chr8:143563290	chr8:143541973~143549729:-
LUAD	cis	rs67311347	0.91	rs7617361	ENSG00000223797.4	ENTPD3-AS1	6.4	3.6e-10	1.82e-07	0.29	0.28	Renal cell carcinoma;	chr3:40331768	chr3:40313802~40453329:-
LUAD	cis	rs950169	0.96	rs12905475	ENSG00000259728.4	LINC00933	6.4	3.6e-10	1.82e-07	0.43	0.28	Schizophrenia;	chr15:84131743	chr15:84570649~84580175:+
LUAD	cis	rs150992	0.587	rs1393210	ENSG00000248489.1	CTD-2007H13.3	-6.4	3.6e-10	1.82e-07	-0.31	-0.28	Body mass index;	chr5:99025892	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.587	rs11242567	ENSG00000248489.1	CTD-2007H13.3	-6.4	3.6e-10	1.82e-07	-0.31	-0.28	Body mass index;	chr5:99028686	chr5:98929171~98995013:+
LUAD	cis	rs12908161	1	rs62019464	ENSG00000259728.4	LINC00933	6.4	3.6e-10	1.82e-07	0.4	0.28	Schizophrenia;	chr15:84751238	chr15:84570649~84580175:+
LUAD	cis	rs2243480	0.901	rs313808	ENSG00000232546.1	RP11-458F8.1	-6.4	3.6e-10	1.82e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66034886	chr7:66848496~66858136:+
LUAD	cis	rs6921919	0.638	rs7772827	ENSG00000216901.1	AL022393.7	6.4	3.61e-10	1.82e-07	0.34	0.28	Autism spectrum disorder or schizophrenia;	chr6:28333366	chr6:28176188~28176674:+
LUAD	cis	rs10028773	0.515	rs9994651	ENSG00000248280.1	RP11-33B1.2	6.4	3.61e-10	1.83e-07	0.34	0.28	Educational attainment;	chr4:119666648	chr4:119440561~119450157:-
LUAD	cis	rs8177876	0.658	rs12456	ENSG00000261838.4	RP11-303E16.6	6.4	3.62e-10	1.83e-07	0.57	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81031454	chr16:81069854~81076598:+
LUAD	cis	rs113835537	0.627	rs11227534	ENSG00000255517.5	CTD-3074O7.5	-6.4	3.62e-10	1.83e-07	-0.34	-0.28	Airway imaging phenotypes;	chr11:66568700	chr11:66473490~66480233:-
LUAD	cis	rs10129255	0.5	rs59939897	ENSG00000224373.3	IGHV4-59	6.4	3.62e-10	1.83e-07	0.17	0.28	Kawasaki disease;	chr14:106783414	chr14:106627249~106627825:-
LUAD	cis	rs10129255	0.5	rs8014529	ENSG00000224373.3	IGHV4-59	6.4	3.62e-10	1.83e-07	0.17	0.28	Kawasaki disease;	chr14:106784065	chr14:106627249~106627825:-
LUAD	cis	rs10129255	0.5	rs12101190	ENSG00000224373.3	IGHV4-59	6.4	3.62e-10	1.83e-07	0.17	0.28	Kawasaki disease;	chr14:106784149	chr14:106627249~106627825:-
LUAD	cis	rs10129255	0.518	rs8004895	ENSG00000224373.3	IGHV4-59	6.4	3.62e-10	1.83e-07	0.17	0.28	Kawasaki disease;	chr14:106785139	chr14:106627249~106627825:-
LUAD	cis	rs35740288	0.77	rs11631018	ENSG00000202081.1	RNU6-1280P	6.4	3.62e-10	1.83e-07	0.35	0.28	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85597303	chr15:85651522~85651628:-
LUAD	cis	rs113835537	0.529	rs7950790	ENSG00000255517.5	CTD-3074O7.5	-6.4	3.62e-10	1.83e-07	-0.33	-0.28	Airway imaging phenotypes;	chr11:66490582	chr11:66473490~66480233:-
LUAD	cis	rs67311347	1	rs9865348	ENSG00000223797.4	ENTPD3-AS1	6.4	3.63e-10	1.83e-07	0.29	0.28	Renal cell carcinoma;	chr3:40356167	chr3:40313802~40453329:-
LUAD	cis	rs2404602	0.647	rs11633869	ENSG00000259422.1	RP11-593F23.1	6.4	3.63e-10	1.84e-07	0.37	0.28	Blood metabolite levels;	chr15:76840981	chr15:76174891~76181486:-
LUAD	cis	rs11098499	0.863	rs17050695	ENSG00000248280.1	RP11-33B1.2	6.4	3.63e-10	1.84e-07	0.35	0.28	Corneal astigmatism;	chr4:119568372	chr4:119440561~119450157:-
LUAD	cis	rs2442825	0.659	rs1129170	ENSG00000206573.7	THUMPD3-AS1	6.4	3.64e-10	1.84e-07	0.21	0.28	Cerebrospinal fluid clusterin levels;	chr3:9384227	chr3:9349689~9398579:-
LUAD	cis	rs891378	0.785	rs7516468	ENSG00000274245.1	RP11-357P18.2	-6.4	3.64e-10	1.84e-07	-0.33	-0.28	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207235943	chr1:207372559~207373252:+
LUAD	cis	rs2115630	0.645	rs4842978	ENSG00000225151.9	GOLGA2P7	6.4	3.64e-10	1.84e-07	0.33	0.28	P wave terminal force;	chr15:84654022	chr15:84199311~84230136:-
LUAD	cis	rs66887589	0.627	rs3872807	ENSG00000248280.1	RP11-33B1.2	6.4	3.65e-10	1.84e-07	0.31	0.28	Diastolic blood pressure;	chr4:119439096	chr4:119440561~119450157:-
LUAD	cis	rs2243480	1	rs1796220	ENSG00000226824.5	RP4-756H11.3	-6.4	3.65e-10	1.85e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:66597113	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs2707831	ENSG00000226824.5	RP4-756H11.3	-6.4	3.65e-10	1.85e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:66597524	chr7:66654538~66669855:+
LUAD	cis	rs9318086	0.935	rs9553083	ENSG00000205861.10	C1QTNF9B-AS1	6.4	3.66e-10	1.85e-07	0.33	0.28	Myopia (pathological);	chr13:23867386	chr13:23888889~23897263:+
LUAD	cis	rs8177876	0.749	rs2549896	ENSG00000261838.4	RP11-303E16.6	-6.4	3.66e-10	1.85e-07	-0.51	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81054334	chr16:81069854~81076598:+
LUAD	cis	rs6772849	0.93	rs4857916	ENSG00000242551.2	POU5F1P6	-6.4	3.67e-10	1.85e-07	-0.33	-0.28	Monocyte percentage of white cells;Monocyte count;	chr3:128657171	chr3:128674735~128677005:-
LUAD	cis	rs7829975	0.564	rs2921057	ENSG00000253893.2	FAM85B	-6.4	3.67e-10	1.85e-07	-0.35	-0.28	Mood instability;	chr8:8461157	chr8:8167819~8226614:-
LUAD	cis	rs150992	0.57	rs398436	ENSG00000248489.1	CTD-2007H13.3	6.4	3.67e-10	1.85e-07	0.31	0.28	Body mass index;	chr5:98991352	chr5:98929171~98995013:+
LUAD	cis	rs367615	0.918	rs10054960	ENSG00000249476.1	CTD-2587M2.1	6.4	3.68e-10	1.86e-07	0.37	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109530747	chr5:109237120~109326369:-
LUAD	cis	rs67311347	0.955	rs6773383	ENSG00000223797.4	ENTPD3-AS1	6.4	3.68e-10	1.86e-07	0.29	0.28	Renal cell carcinoma;	chr3:40335921	chr3:40313802~40453329:-
LUAD	cis	rs875971	0.862	rs1983372	ENSG00000222364.1	RNU6-96P	6.4	3.69e-10	1.86e-07	0.31	0.28	Aortic root size;	chr7:66146364	chr7:66395191~66395286:+
LUAD	cis	rs4787484	0.593	rs12917712	ENSG00000214725.6	CDIPT-AS1	6.4	3.69e-10	1.86e-07	0.34	0.28	Response to taxane treatment (placlitaxel);	chr16:29871169	chr16:29863593~29868053:+
LUAD	cis	rs7829975	0.688	rs7827182	ENSG00000253981.4	ALG1L13P	6.4	3.69e-10	1.87e-07	0.32	0.28	Mood instability;	chr8:8522961	chr8:8236003~8244667:-
LUAD	cis	rs6921919	0.789	rs6912584	ENSG00000204709.4	LINC01556	6.4	3.7e-10	1.87e-07	0.4	0.28	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr6:28943877~28944537:+
LUAD	cis	rs394563	0.602	rs409099	ENSG00000231760.4	RP11-350J20.5	6.4	3.7e-10	1.87e-07	0.34	0.28	Dupuytren's disease;	chr6:149445727	chr6:149796151~149826294:-
LUAD	cis	rs394563	0.602	rs409111	ENSG00000231760.4	RP11-350J20.5	6.4	3.7e-10	1.87e-07	0.34	0.28	Dupuytren's disease;	chr6:149445724	chr6:149796151~149826294:-
LUAD	cis	rs9595066	0.548	rs9562537	ENSG00000227258.4	SMIM2-AS1	6.4	3.7e-10	1.87e-07	0.49	0.28	Schizophrenia;	chr13:44181651	chr13:44110451~44240517:+
LUAD	cis	rs1707322	0.752	rs11211152	ENSG00000234329.1	RP11-767N6.2	6.4	3.7e-10	1.87e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648485	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs4607935	ENSG00000234329.1	RP11-767N6.2	6.4	3.7e-10	1.87e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651489	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.681	rs12048866	ENSG00000234329.1	RP11-767N6.2	6.4	3.7e-10	1.87e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651820	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs3811436	ENSG00000234329.1	RP11-767N6.2	6.4	3.7e-10	1.87e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660208	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs12024590	ENSG00000234329.1	RP11-767N6.2	6.4	3.7e-10	1.87e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45661824	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs12027622	ENSG00000234329.1	RP11-767N6.2	6.4	3.7e-10	1.87e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664580	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs4415615	ENSG00000234329.1	RP11-767N6.2	6.4	3.7e-10	1.87e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45666437	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs7529699	ENSG00000234329.1	RP11-767N6.2	6.4	3.7e-10	1.87e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668962	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.716	rs6699444	ENSG00000234329.1	RP11-767N6.2	6.4	3.7e-10	1.87e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669448	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs10430105	ENSG00000234329.1	RP11-767N6.2	6.4	3.7e-10	1.87e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45673204	chr1:45651039~45651826:-
LUAD	cis	rs4789693	0.518	rs6502117	ENSG00000265458.1	RP13-20L14.6	6.4	3.71e-10	1.87e-07	0.36	0.28	Glucocorticoid-induced osteonecrosis;	chr17:82494716	chr17:82454273~82458521:-
LUAD	cis	rs6991838	0.806	rs11781358	ENSG00000200714.1	Y_RNA	6.4	3.71e-10	1.87e-07	0.33	0.28	Intelligence (multi-trait analysis);	chr8:65557691	chr8:65592731~65592820:+
LUAD	cis	rs2243480	1	rs1039664	ENSG00000230295.1	RP11-458F8.2	-6.4	3.71e-10	1.87e-07	-0.33	-0.28	Diabetic kidney disease;	chr7:65984729	chr7:66880708~66882981:+
LUAD	cis	rs80285556	1	rs17661933	ENSG00000161643.11	SIGLEC16	-6.4	3.71e-10	1.87e-07	-0.56	-0.28	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50031263	chr19:49969673~49975814:+
LUAD	cis	rs950169	0.922	rs12906983	ENSG00000259728.4	LINC00933	6.4	3.72e-10	1.87e-07	0.43	0.28	Schizophrenia;	chr15:84262270	chr15:84570649~84580175:+
LUAD	cis	rs10050311	0.858	rs1010902	ENSG00000251411.1	RP11-397E7.4	-6.4	3.72e-10	1.88e-07	-0.38	-0.28	Insulin-related traits;	chr4:86898002	chr4:86913266~86914817:-
LUAD	cis	rs875971	0.571	rs78668714	ENSG00000237310.1	GS1-124K5.4	6.4	3.72e-10	1.88e-07	0.35	0.28	Aortic root size;	chr7:66474464	chr7:66493706~66495474:+
LUAD	cis	rs755249	0.917	rs61779330	ENSG00000228060.1	RP11-69E11.8	-6.4	3.72e-10	1.88e-07	-0.28	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39501551	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.876	rs72662001	ENSG00000228060.1	RP11-69E11.8	-6.4	3.72e-10	1.88e-07	-0.28	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39501608	chr1:39565160~39573203:+
LUAD	cis	rs2117029	0.521	rs12227610	ENSG00000258017.1	RP11-386G11.10	-6.4	3.73e-10	1.88e-07	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49146153	chr12:49127782~49147869:+
LUAD	cis	rs17301013	0.507	rs16847335	ENSG00000227373.4	RP11-160H22.5	6.4	3.73e-10	1.88e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174682746	chr1:174115300~174160004:-
LUAD	cis	rs55726902	0.761	rs2544030	ENSG00000276691.1	RP5-1057I20.5	6.4	3.73e-10	1.88e-07	0.28	0.28	Allergic disease (asthma, hay fever or eczema);	chr12:47801668	chr12:47788426~47788971:+
LUAD	cis	rs67311347	1	rs10510708	ENSG00000223797.4	ENTPD3-AS1	6.4	3.74e-10	1.88e-07	0.29	0.28	Renal cell carcinoma;	chr3:40363279	chr3:40313802~40453329:-
LUAD	cis	rs8081395	0.775	rs2645482	ENSG00000266992.1	DHX40P1	6.4	3.74e-10	1.88e-07	0.33	0.28	White blood cell count;	chr17:59865754	chr17:59976009~60002384:-
LUAD	cis	rs1075265	0.73	rs6711105	ENSG00000233266.1	HMGB1P31	6.4	3.74e-10	1.88e-07	0.35	0.28	Chronotype;Morning vs. evening chronotype;	chr2:54017775	chr2:54051334~54051760:+
LUAD	cis	rs1075265	0.704	rs6711217	ENSG00000233266.1	HMGB1P31	6.4	3.74e-10	1.88e-07	0.35	0.28	Chronotype;Morning vs. evening chronotype;	chr2:54017892	chr2:54051334~54051760:+
LUAD	cis	rs9640161	0.659	rs7781827	ENSG00000261305.1	RP4-584D14.7	6.4	3.74e-10	1.89e-07	0.4	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150311769	chr7:150341771~150342607:+
LUAD	cis	rs17023223	0.537	rs17023185	ENSG00000231365.4	RP11-418J17.1	-6.4	3.74e-10	1.89e-07	-0.38	-0.28	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119068164	chr1:119140396~119275973:+
LUAD	cis	rs3002142	0.658	rs1053316	ENSG00000272750.1	RP11-378J18.8	6.4	3.75e-10	1.89e-07	0.37	0.28	LDL peak particle diameter (total fat intake interaction);	chr1:222666496	chr1:222658867~222661512:-
LUAD	cis	rs2276314	0.857	rs28396546	ENSG00000278986.1	RP11-723J4.3	-6.4	3.75e-10	1.89e-07	-0.34	-0.28	Endometriosis;Drug-induced torsades de pointes;	chr18:36059061	chr18:35972151~35973916:+
LUAD	cis	rs11098499	0.562	rs58583086	ENSG00000248280.1	RP11-33B1.2	-6.4	3.75e-10	1.89e-07	-0.33	-0.28	Corneal astigmatism;	chr4:119635207	chr4:119440561~119450157:-
LUAD	cis	rs12439619	0.846	rs62012004	ENSG00000255769.6	GOLGA2P10	-6.4	3.75e-10	1.89e-07	-0.36	-0.28	Intelligence (multi-trait analysis);	chr15:82183924	chr15:82472993~82513950:-
LUAD	cis	rs6921919	0.638	rs1416920	ENSG00000204709.4	LINC01556	6.4	3.76e-10	1.89e-07	0.36	0.28	Autism spectrum disorder or schizophrenia;	chr6:28335007	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.546	rs35353359	ENSG00000204709.4	LINC01556	6.4	3.76e-10	1.89e-07	0.61	0.28	Depression;	chr6:28356601	chr6:28943877~28944537:+
LUAD	cis	rs8062405	0.964	rs62036614	ENSG00000251417.2	RP11-1348G14.4	-6.4	3.76e-10	1.89e-07	-0.29	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28802743~28817828:+
LUAD	cis	rs9309473	0.948	rs13392691	ENSG00000163016.8	ALMS1P	6.4	3.76e-10	1.89e-07	0.35	0.28	Metabolite levels;	chr2:73521853	chr2:73644919~73685576:+
LUAD	cis	rs1799949	0.965	rs7212284	ENSG00000267681.1	CTD-3199J23.6	-6.4	3.77e-10	1.9e-07	-0.31	-0.28	Menopause (age at onset);	chr17:43053924	chr17:43144956~43145255:+
LUAD	cis	rs2243480	1	rs1499614	ENSG00000232546.1	RP11-458F8.1	-6.4	3.77e-10	1.9e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:66265811	chr7:66848496~66858136:+
LUAD	cis	rs9318086	0.648	rs7331047	ENSG00000205861.10	C1QTNF9B-AS1	-6.4	3.77e-10	1.9e-07	-0.34	-0.28	Myopia (pathological);	chr13:23893203	chr13:23888889~23897263:+
LUAD	cis	rs2243480	1	rs316304	ENSG00000232546.1	RP11-458F8.1	-6.4	3.77e-10	1.9e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66151907	chr7:66848496~66858136:+
LUAD	cis	rs7849270	0.879	rs6478866	ENSG00000268707.1	RP11-247A12.7	-6.4	3.77e-10	1.9e-07	-0.32	-0.28	Blood metabolite ratios;	chr9:129133585	chr9:129170434~129170940:+
LUAD	cis	rs881375	0.631	rs2416808	ENSG00000226752.6	PSMD5-AS1	-6.4	3.77e-10	1.9e-07	-0.29	-0.28	Rheumatoid arthritis;	chr9:120944005	chr9:120824828~120854385:+
LUAD	cis	rs6903823	0.508	rs1150726	ENSG00000204709.4	LINC01556	6.4	3.78e-10	1.9e-07	0.34	0.28	Pulmonary function;	chr6:28275265	chr6:28943877~28944537:+
LUAD	cis	rs9549367	0.789	rs2287248	ENSG00000269125.1	RP11-98F14.11	-6.4	3.78e-10	1.9e-07	-0.34	-0.28	Platelet distribution width;	chr13:113234912	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.789	rs2287251	ENSG00000269125.1	RP11-98F14.11	-6.4	3.78e-10	1.9e-07	-0.34	-0.28	Platelet distribution width;	chr13:113235185	chr13:113165002~113165183:-
LUAD	cis	rs17301013	0.507	rs10489264	ENSG00000227373.4	RP11-160H22.5	6.4	3.78e-10	1.91e-07	0.42	0.28	Systemic lupus erythematosus;	chr1:174584310	chr1:174115300~174160004:-
LUAD	cis	rs67311347	1	rs11914297	ENSG00000223797.4	ENTPD3-AS1	6.4	3.79e-10	1.91e-07	0.29	0.28	Renal cell carcinoma;	chr3:40368579	chr3:40313802~40453329:-
LUAD	cis	rs7567389	0.576	rs2069902	ENSG00000236682.1	AC068282.3	-6.4	3.79e-10	1.91e-07	-0.36	-0.28	Self-rated health;	chr2:127417287	chr2:127389130~127400580:+
LUAD	cis	rs67311347	1	rs73078162	ENSG00000223797.4	ENTPD3-AS1	6.4	3.79e-10	1.91e-07	0.31	0.28	Renal cell carcinoma;	chr3:40435618	chr3:40313802~40453329:-
LUAD	cis	rs765787	0.53	rs2899379	ENSG00000259520.4	CTD-2651B20.3	-6.4	3.79e-10	1.91e-07	-0.38	-0.28	Uric acid levels;	chr15:45242601	chr15:45251580~45279251:-
LUAD	cis	rs875971	0.545	rs6979636	ENSG00000237310.1	GS1-124K5.4	6.4	3.8e-10	1.91e-07	0.34	0.28	Aortic root size;	chr7:66276638	chr7:66493706~66495474:+
LUAD	cis	rs783540	0.967	rs1269134	ENSG00000278603.1	RP13-608F4.5	-6.4	3.81e-10	1.92e-07	-0.32	-0.28	Schizophrenia;	chr15:82613877	chr15:82472203~82472426:+
LUAD	cis	rs2734839	0.964	rs2734831	ENSG00000270179.1	RP11-159N11.4	6.4	3.81e-10	1.92e-07	0.28	0.28	Information processing speed;	chr11:113422874	chr11:113368478~113369117:+
LUAD	cis	rs293748	0.771	rs292196	ENSG00000250155.1	CTD-2353F22.1	6.39	3.81e-10	1.92e-07	0.38	0.28	Obesity-related traits;	chr5:36914077	chr5:36666214~36725195:-
LUAD	cis	rs77204473	0.744	rs75216569	ENSG00000254851.1	RP11-109L13.1	6.39	3.81e-10	1.92e-07	0.72	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117036999	chr11:117135528~117138582:+
LUAD	cis	rs853679	0.517	rs9283884	ENSG00000219392.1	RP1-265C24.5	6.39	3.81e-10	1.92e-07	0.39	0.28	Depression;	chr6:28167882	chr6:28115628~28116551:+
LUAD	cis	rs6991838	0.798	rs6994889	ENSG00000272010.1	CTD-3025N20.3	6.39	3.82e-10	1.92e-07	0.29	0.28	Intelligence (multi-trait analysis);	chr8:65562547	chr8:65591850~65592472:-
LUAD	cis	rs9309473	1	rs6753344	ENSG00000163016.8	ALMS1P	-6.39	3.82e-10	1.92e-07	-0.35	-0.28	Metabolite levels;	chr2:73426010	chr2:73644919~73685576:+
LUAD	cis	rs1031391	0.716	rs10772416	ENSG00000256274.1	TAS2R64P	-6.39	3.82e-10	1.92e-07	-0.38	-0.28	Bitter taste perception;	chr12:11017488	chr12:11076769~11079171:-
LUAD	cis	rs1707322	0.752	rs12062535	ENSG00000234329.1	RP11-767N6.2	6.39	3.82e-10	1.92e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45757208	chr1:45651039~45651826:-
LUAD	cis	rs950169	0.58	rs1061737	ENSG00000259728.4	LINC00933	6.39	3.82e-10	1.92e-07	0.41	0.28	Schizophrenia;	chr15:84640559	chr15:84570649~84580175:+
LUAD	cis	rs11098499	0.789	rs9991166	ENSG00000248280.1	RP11-33B1.2	6.39	3.82e-10	1.92e-07	0.35	0.28	Corneal astigmatism;	chr4:119316696	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.708	rs10005237	ENSG00000248280.1	RP11-33B1.2	6.39	3.82e-10	1.92e-07	0.35	0.28	Corneal astigmatism;	chr4:119316742	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs878372	ENSG00000248280.1	RP11-33B1.2	6.39	3.82e-10	1.92e-07	0.35	0.28	Corneal astigmatism;	chr4:119317625	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs10213267	ENSG00000248280.1	RP11-33B1.2	6.39	3.82e-10	1.92e-07	0.35	0.28	Corneal astigmatism;	chr4:119317919	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs10212775	ENSG00000248280.1	RP11-33B1.2	6.39	3.82e-10	1.92e-07	0.35	0.28	Corneal astigmatism;	chr4:119318089	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs11732087	ENSG00000248280.1	RP11-33B1.2	6.39	3.82e-10	1.92e-07	0.35	0.28	Corneal astigmatism;	chr4:119318676	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs2964	ENSG00000248280.1	RP11-33B1.2	6.39	3.82e-10	1.92e-07	0.35	0.28	Corneal astigmatism;	chr4:119318976	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs1511025	ENSG00000248280.1	RP11-33B1.2	6.39	3.82e-10	1.92e-07	0.35	0.28	Corneal astigmatism;	chr4:119319083	chr4:119440561~119450157:-
LUAD	cis	rs8072100	0.846	rs4264433	ENSG00000228782.6	CTD-2026D20.3	-6.39	3.82e-10	1.92e-07	-0.3	-0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47659909	chr17:47450568~47492492:-
LUAD	cis	rs9326248	0.52	rs74830	ENSG00000280143.1	AP000892.6	-6.39	3.83e-10	1.92e-07	-0.32	-0.28	Blood protein levels;	chr11:117219842	chr11:117204967~117210292:+
LUAD	cis	rs155076	1	rs58519241	ENSG00000233325.3	MIPEPP3	6.39	3.83e-10	1.93e-07	0.44	0.28	White matter hyperintensity burden;	chr13:21270867	chr13:21298139~21306373:+
LUAD	cis	rs2243480	1	rs316322	ENSG00000232546.1	RP11-458F8.1	-6.39	3.84e-10	1.93e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66146246	chr7:66848496~66858136:+
LUAD	cis	rs3762637	1	rs11932	ENSG00000272758.4	RP11-299J3.8	6.39	3.84e-10	1.93e-07	0.4	0.28	LDL cholesterol levels;	chr3:122422288	chr3:122416207~122443180:+
LUAD	cis	rs7945705	0.967	rs10840148	ENSG00000254860.4	TMEM9B-AS1	-6.39	3.85e-10	1.93e-07	-0.32	-0.28	Hemoglobin concentration;	chr11:8901981	chr11:8964675~8977527:+
LUAD	cis	rs9309473	0.904	rs78450880	ENSG00000163016.8	ALMS1P	6.39	3.85e-10	1.94e-07	0.35	0.28	Metabolite levels;	chr2:73594254	chr2:73644919~73685576:+
LUAD	cis	rs6991838	0.778	rs11779601	ENSG00000200714.1	Y_RNA	6.39	3.87e-10	1.94e-07	0.33	0.28	Intelligence (multi-trait analysis);	chr8:65550241	chr8:65592731~65592820:+
LUAD	cis	rs7017914	0.902	rs6472542	ENSG00000223220.1	Y_RNA	-6.39	3.87e-10	1.94e-07	-0.3	-0.28	Bone mineral density;	chr8:70741852	chr8:70780914~70781008:-
LUAD	cis	rs10129255	0.719	rs7156660	ENSG00000224373.3	IGHV4-59	6.39	3.87e-10	1.94e-07	0.18	0.28	Kawasaki disease;	chr14:106673171	chr14:106627249~106627825:-
LUAD	cis	rs155076	1	rs261431	ENSG00000233325.3	MIPEPP3	-6.39	3.87e-10	1.95e-07	-0.42	-0.28	White matter hyperintensity burden;	chr13:21291599	chr13:21298139~21306373:+
LUAD	cis	rs111580313	0.792	rs79430710	ENSG00000270020.1	RP11-463O9.9	6.39	3.87e-10	1.95e-07	0.68	0.28	Systemic juvenile idiopathic arthritis;	chr16:86575505	chr16:86520383~86523897:-
LUAD	cis	rs7923609	0.902	rs7897379	ENSG00000232075.1	MRPL35P2	-6.39	3.88e-10	1.95e-07	-0.34	-0.28	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63541965	chr10:63634317~63634827:-
LUAD	cis	rs17301013	0.507	rs10912791	ENSG00000227373.4	RP11-160H22.5	6.39	3.89e-10	1.95e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174479298	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12079334	ENSG00000227373.4	RP11-160H22.5	6.39	3.89e-10	1.95e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174480815	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs4652494	ENSG00000227373.4	RP11-160H22.5	6.39	3.89e-10	1.95e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174495861	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs7537823	ENSG00000227373.4	RP11-160H22.5	6.39	3.89e-10	1.95e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174502222	chr1:174115300~174160004:-
LUAD	cis	rs8177376	1	rs674218	ENSG00000254905.1	RP11-712L6.7	6.39	3.89e-10	1.95e-07	0.39	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126239165	chr11:126292922~126294254:-
LUAD	cis	rs875971	0.929	rs10950041	ENSG00000222364.1	RNU6-96P	-6.39	3.89e-10	1.95e-07	-0.31	-0.28	Aortic root size;	chr7:66508888	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.929	rs6970860	ENSG00000222364.1	RNU6-96P	-6.39	3.89e-10	1.95e-07	-0.31	-0.28	Aortic root size;	chr7:66511647	chr7:66395191~66395286:+
LUAD	cis	rs9549367	0.826	rs2287249	ENSG00000269125.1	RP11-98F14.11	-6.39	3.9e-10	1.96e-07	-0.34	-0.28	Platelet distribution width;	chr13:113235041	chr13:113165002~113165183:-
LUAD	cis	rs7567389	0.719	rs1504135	ENSG00000236682.1	AC068282.3	6.39	3.9e-10	1.96e-07	0.41	0.28	Self-rated health;	chr2:127245675	chr2:127389130~127400580:+
LUAD	cis	rs7246657	0.943	rs10415937	ENSG00000276846.1	CTD-3220F14.3	6.39	3.91e-10	1.96e-07	0.39	0.28	Coronary artery calcification;	chr19:37339162	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs10414904	ENSG00000276846.1	CTD-3220F14.3	6.39	3.91e-10	1.96e-07	0.39	0.28	Coronary artery calcification;	chr19:37339186	chr19:37314868~37315620:-
LUAD	cis	rs9309473	0.948	rs11884776	ENSG00000163016.8	ALMS1P	6.39	3.91e-10	1.97e-07	0.34	0.28	Metabolite levels;	chr2:73519796	chr2:73644919~73685576:+
LUAD	cis	rs67311347	1	rs56303661	ENSG00000223797.4	ENTPD3-AS1	6.39	3.92e-10	1.97e-07	0.31	0.28	Renal cell carcinoma;	chr3:40479287	chr3:40313802~40453329:-
LUAD	cis	rs55665837	1	rs12792120	ENSG00000251991.1	RNU7-49P	6.39	3.92e-10	1.97e-07	0.31	0.28	Vitamin D levels;	chr11:14447897	chr11:14478892~14478953:+
LUAD	cis	rs2221433	1	rs1110269	ENSG00000260310.1	RP11-27M24.2	-6.39	3.92e-10	1.97e-07	-0.31	-0.28	Eating disorders;	chr16:10578731	chr16:10576499~10578183:-
LUAD	cis	rs9506514	0.509	rs9509294	ENSG00000222726.1	RNU2-7P	-6.39	3.93e-10	1.97e-07	-0.32	-0.28	Coronary artery calcification;	chr13:20600506	chr13:20612161~20612338:+
LUAD	cis	rs6844153	1	rs74601981	ENSG00000240005.4	RP11-293A21.1	-6.39	3.93e-10	1.97e-07	-0.48	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26915639	chr4:26859806~26860599:-
LUAD	cis	rs4927850	0.881	rs7624638	ENSG00000207650.1	MIR570	6.39	3.93e-10	1.98e-07	0.29	0.28	Pancreatic cancer;	chr3:196021858	chr3:195699401~195699497:+
LUAD	cis	rs17301013	0.531	rs6678286	ENSG00000227373.4	RP11-160H22.5	6.39	3.93e-10	1.98e-07	0.39	0.28	Systemic lupus erythematosus;	chr1:174200481	chr1:174115300~174160004:-
LUAD	cis	rs950169	0.919	rs17300292	ENSG00000259728.4	LINC00933	6.39	3.94e-10	1.98e-07	0.43	0.28	Schizophrenia;	chr15:84093816	chr15:84570649~84580175:+
LUAD	cis	rs394563	1	rs394563	ENSG00000231760.4	RP11-350J20.5	6.39	3.94e-10	1.98e-07	0.35	0.28	Dupuytren's disease;	chr6:149475878	chr6:149796151~149826294:-
LUAD	cis	rs783540	0.869	rs783533	ENSG00000278603.1	RP13-608F4.5	-6.39	3.95e-10	1.98e-07	-0.33	-0.28	Schizophrenia;	chr15:82581437	chr15:82472203~82472426:+
LUAD	cis	rs1707322	0.752	rs11488313	ENSG00000234329.1	RP11-767N6.2	6.39	3.96e-10	1.98e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45759108	chr1:45651039~45651826:-
LUAD	cis	rs881375	0.678	rs10985102	ENSG00000226752.6	PSMD5-AS1	-6.39	3.96e-10	1.98e-07	-0.29	-0.28	Rheumatoid arthritis;	chr9:120945219	chr9:120824828~120854385:+
LUAD	cis	rs1707322	0.752	rs11211145	ENSG00000234329.1	RP11-767N6.2	6.39	3.96e-10	1.99e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642819	chr1:45651039~45651826:-
LUAD	cis	rs11096990	0.892	rs11932351	ENSG00000249207.1	RP11-360F5.1	6.39	3.96e-10	1.99e-07	0.31	0.28	Cognitive function;	chr4:39229837	chr4:39112677~39126818:-
LUAD	cis	rs11690935	0.55	rs11676438	ENSG00000228389.1	AC068039.4	-6.39	3.97e-10	1.99e-07	-0.3	-0.28	Schizophrenia;	chr2:171970147	chr2:171773482~171775844:+
LUAD	cis	rs4972806	0.739	rs10834	ENSG00000226363.3	HAGLROS	-6.39	3.97e-10	1.99e-07	-0.36	-0.28	IgG glycosylation;	chr2:176177359	chr2:176177717~176179008:+
LUAD	cis	rs17301013	0.507	rs72713528	ENSG00000227373.4	RP11-160H22.5	6.39	3.97e-10	1.99e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174319862	chr1:174115300~174160004:-
LUAD	cis	rs6558530	1	rs6558530	ENSG00000253982.1	CTD-2336O2.1	6.39	3.97e-10	1.99e-07	0.34	0.28	Systolic blood pressure;	chr8:1758041	chr8:1761990~1764502:-
LUAD	cis	rs2117029	0.586	rs7954521	ENSG00000258017.1	RP11-386G11.10	-6.39	3.98e-10	2e-07	-0.34	-0.28	Intelligence (multi-trait analysis);	chr12:49151857	chr12:49127782~49147869:+
LUAD	cis	rs2117029	0.553	rs2162644	ENSG00000258017.1	RP11-386G11.10	-6.39	3.98e-10	2e-07	-0.34	-0.28	Intelligence (multi-trait analysis);	chr12:49154407	chr12:49127782~49147869:+
LUAD	cis	rs2117029	0.586	rs2114846	ENSG00000258017.1	RP11-386G11.10	-6.39	3.98e-10	2e-07	-0.34	-0.28	Intelligence (multi-trait analysis);	chr12:49154493	chr12:49127782~49147869:+
LUAD	cis	rs783540	1	rs6603033	ENSG00000278603.1	RP13-608F4.5	6.39	3.98e-10	2e-07	0.32	0.28	Schizophrenia;	chr15:82667123	chr15:82472203~82472426:+
LUAD	cis	rs801193	0.66	rs2659897	ENSG00000222364.1	RNU6-96P	6.39	3.99e-10	2e-07	0.31	0.28	Aortic root size;	chr7:66722728	chr7:66395191~66395286:+
LUAD	cis	rs17301013	0.507	rs11810824	ENSG00000227373.4	RP11-160H22.5	-6.39	4e-10	2.01e-07	-0.4	-0.28	Systemic lupus erythematosus;	chr1:174408223	chr1:174115300~174160004:-
LUAD	cis	rs1799949	0.965	rs34633610	ENSG00000267681.1	CTD-3199J23.6	-6.39	4.01e-10	2.01e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43342017	chr17:43144956~43145255:+
LUAD	cis	rs1799949	0.965	rs11654051	ENSG00000267681.1	CTD-3199J23.6	-6.39	4.01e-10	2.01e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43342288	chr17:43144956~43145255:+
LUAD	cis	rs1799949	0.93	rs56729776	ENSG00000267681.1	CTD-3199J23.6	-6.39	4.01e-10	2.01e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43344763	chr17:43144956~43145255:+
LUAD	cis	rs7849270	1	rs2541161	ENSG00000268707.1	RP11-247A12.7	6.39	4.01e-10	2.01e-07	0.32	0.28	Blood metabolite ratios;	chr9:129122523	chr9:129170434~129170940:+
LUAD	cis	rs1799949	0.965	rs11650913	ENSG00000267681.1	CTD-3199J23.6	-6.39	4.01e-10	2.01e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43179580	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs12936831	ENSG00000267681.1	CTD-3199J23.6	-6.39	4.01e-10	2.01e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43179799	chr17:43144956~43145255:+
LUAD	cis	rs6822297	0.504	rs7681802	ENSG00000240005.4	RP11-293A21.1	6.39	4.02e-10	2.01e-07	0.35	0.28	Obesity-related traits;	chr4:26989777	chr4:26859806~26860599:-
LUAD	cis	rs6822297	0.522	rs9998971	ENSG00000240005.4	RP11-293A21.1	6.39	4.02e-10	2.01e-07	0.35	0.28	Obesity-related traits;	chr4:27000082	chr4:26859806~26860599:-
LUAD	cis	rs6822297	0.504	rs12152700	ENSG00000240005.4	RP11-293A21.1	6.39	4.02e-10	2.01e-07	0.35	0.28	Obesity-related traits;	chr4:27005029	chr4:26859806~26860599:-
LUAD	cis	rs8031584	0.918	rs11639169	ENSG00000260382.1	RP11-540B6.2	6.39	4.03e-10	2.02e-07	0.34	0.28	Huntington's disease progression;	chr15:30963235	chr15:30882267~30883231:-
LUAD	cis	rs1113500	0.541	rs6692571	ENSG00000226822.1	RP11-356N1.2	6.39	4.03e-10	2.02e-07	0.37	0.28	Growth-regulated protein alpha levels;	chr1:108034062	chr1:108071482~108074519:+
LUAD	cis	rs950169	0.58	rs17598114	ENSG00000259728.4	LINC00933	6.39	4.03e-10	2.02e-07	0.41	0.28	Schizophrenia;	chr15:84628086	chr15:84570649~84580175:+
LUAD	cis	rs17301013	0.507	rs41472847	ENSG00000227373.4	RP11-160H22.5	-6.39	4.03e-10	2.02e-07	-0.42	-0.28	Systemic lupus erythematosus;	chr1:174475342	chr1:174115300~174160004:-
LUAD	cis	rs9595908	0.686	rs8001047	ENSG00000212293.1	SNORA16	-6.39	4.04e-10	2.02e-07	-0.29	-0.28	Body mass index;	chr13:32802746	chr13:32420390~32420516:-
LUAD	cis	rs7615952	0.932	rs6438948	ENSG00000171084.14	FAM86JP	-6.39	4.04e-10	2.02e-07	-0.39	-0.28	Blood pressure (smoking interaction);	chr3:125931202	chr3:125916620~125930024:+
LUAD	cis	rs367615	0.879	rs4351197	ENSG00000249476.1	CTD-2587M2.1	6.39	4.04e-10	2.02e-07	0.37	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109530966	chr5:109237120~109326369:-
LUAD	cis	rs7182621	0.512	rs34151878	ENSG00000259363.4	CTD-2054N24.2	-6.38	4.05e-10	2.03e-07	-0.38	-0.28	Colonoscopy-negative controls vs population controls;	chr15:99869179	chr15:99807023~99877148:+
LUAD	cis	rs2243480	1	rs73142162	ENSG00000226824.5	RP4-756H11.3	-6.38	4.05e-10	2.03e-07	-0.54	-0.28	Diabetic kidney disease;	chr7:65909309	chr7:66654538~66669855:+
LUAD	cis	rs6991838	0.778	rs11782837	ENSG00000200714.1	Y_RNA	6.38	4.05e-10	2.03e-07	0.33	0.28	Intelligence (multi-trait analysis);	chr8:65550328	chr8:65592731~65592820:+
LUAD	cis	rs367615	0.918	rs10067984	ENSG00000249476.1	CTD-2587M2.1	6.38	4.05e-10	2.03e-07	0.37	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109536983	chr5:109237120~109326369:-
LUAD	cis	rs367615	0.84	rs113540823	ENSG00000249476.1	CTD-2587M2.1	6.38	4.05e-10	2.03e-07	0.37	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109543383	chr5:109237120~109326369:-
LUAD	cis	rs367615	0.879	rs56689485	ENSG00000249476.1	CTD-2587M2.1	6.38	4.05e-10	2.03e-07	0.37	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109544127	chr5:109237120~109326369:-
LUAD	cis	rs12699921	0.632	rs12699918	ENSG00000279048.1	RP11-511H23.2	6.38	4.05e-10	2.03e-07	0.23	0.28	Fibrinogen levels;	chr7:17930277	chr7:17940503~17942922:+
LUAD	cis	rs2243480	0.711	rs2420172	ENSG00000232546.1	RP11-458F8.1	6.38	4.06e-10	2.03e-07	0.37	0.28	Diabetic kidney disease;	chr7:66170354	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs2420171	ENSG00000232546.1	RP11-458F8.1	6.38	4.06e-10	2.03e-07	0.37	0.28	Diabetic kidney disease;	chr7:66172773	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs6974723	ENSG00000232546.1	RP11-458F8.1	6.38	4.06e-10	2.03e-07	0.37	0.28	Diabetic kidney disease;	chr7:66172952	chr7:66848496~66858136:+
LUAD	cis	rs1075265	0.749	rs805434	ENSG00000233266.1	HMGB1P31	6.38	4.06e-10	2.03e-07	0.35	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53836196	chr2:54051334~54051760:+
LUAD	cis	rs526231	0.543	rs246905	ENSG00000175749.11	EIF3KP1	6.38	4.07e-10	2.04e-07	0.39	0.28	Primary biliary cholangitis;	chr5:103255242	chr5:103032376~103033031:+
LUAD	cis	rs12468226	1	rs13389798	ENSG00000226261.1	AC064836.3	6.38	4.07e-10	2.04e-07	0.46	0.28	Urate levels;	chr2:202348370	chr2:202336024~202336727:-
LUAD	cis	rs1799949	0.501	rs35399157	ENSG00000267681.1	CTD-3199J23.6	-6.38	4.09e-10	2.05e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43334234	chr17:43144956~43145255:+
LUAD	cis	rs1799949	0.602	rs4600503	ENSG00000267681.1	CTD-3199J23.6	-6.38	4.09e-10	2.05e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43336956	chr17:43144956~43145255:+
LUAD	cis	rs8059260	0.799	rs7194545	ENSG00000274038.1	RP11-66H6.4	-6.38	4.09e-10	2.05e-07	-0.39	-0.28	Alcohol consumption over the past year;	chr16:11030439	chr16:11056556~11057034:+
LUAD	cis	rs1062177	1	rs2347596	ENSG00000213433.5	RPLP1P6	-6.38	4.09e-10	2.05e-07	-0.37	-0.28	Preschool internalizing problems;	chr5:151799638	chr5:151765859~151766378:-
LUAD	cis	rs494459	0.838	rs488219	ENSG00000278376.1	RP11-158I9.8	-6.38	4.09e-10	2.05e-07	-0.3	-0.28	Height;	chr11:118749988	chr11:118791254~118793137:+
LUAD	cis	rs155076	1	rs261423	ENSG00000233325.3	MIPEPP3	6.38	4.09e-10	2.05e-07	0.44	0.28	White matter hyperintensity burden;	chr13:21278192	chr13:21298139~21306373:+
LUAD	cis	rs496547	0.686	rs540180	ENSG00000255422.1	AP002954.4	-6.38	4.09e-10	2.05e-07	-0.36	-0.28	Hip minimal joint space width;	chr11:118782920	chr11:118704607~118750263:+
LUAD	cis	rs496547	0.686	rs2508916	ENSG00000255422.1	AP002954.4	-6.38	4.09e-10	2.05e-07	-0.36	-0.28	Hip minimal joint space width;	chr11:118783942	chr11:118704607~118750263:+
LUAD	cis	rs7743045	0.652	rs72970476	ENSG00000253194.1	RP11-351A11.1	6.38	4.09e-10	2.05e-07	0.37	0.28	Mean platelet volume;	chr6:118997887	chr6:118934785~119031541:+
LUAD	cis	rs4718428	0.672	rs4718412	ENSG00000232546.1	RP11-458F8.1	6.38	4.1e-10	2.05e-07	0.26	0.28	Corneal structure;	chr7:66821880	chr7:66848496~66858136:+
LUAD	cis	rs1707322	0.682	rs10890334	ENSG00000234329.1	RP11-767N6.2	6.38	4.1e-10	2.05e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634706	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.682	rs10890335	ENSG00000234329.1	RP11-767N6.2	6.38	4.1e-10	2.05e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634722	chr1:45651039~45651826:-
LUAD	cis	rs56751865	1	rs56751865	ENSG00000254851.1	RP11-109L13.1	6.38	4.1e-10	2.05e-07	0.69	0.28	Lobe attachment (rater scored);	chr11:117066155	chr11:117135528~117138582:+
LUAD	cis	rs875971	0.545	rs10950025	ENSG00000237310.1	GS1-124K5.4	6.38	4.1e-10	2.05e-07	0.35	0.28	Aortic root size;	chr7:66158946	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.52	rs12666485	ENSG00000237310.1	GS1-124K5.4	6.38	4.1e-10	2.05e-07	0.35	0.28	Aortic root size;	chr7:66160135	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs67688847	ENSG00000237310.1	GS1-124K5.4	6.38	4.1e-10	2.05e-07	0.35	0.28	Aortic root size;	chr7:66161064	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs7787063	ENSG00000237310.1	GS1-124K5.4	6.38	4.1e-10	2.05e-07	0.35	0.28	Aortic root size;	chr7:66164012	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs12673308	ENSG00000237310.1	GS1-124K5.4	6.38	4.1e-10	2.05e-07	0.35	0.28	Aortic root size;	chr7:66166374	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs67397473	ENSG00000237310.1	GS1-124K5.4	6.38	4.1e-10	2.05e-07	0.35	0.28	Aortic root size;	chr7:66168318	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs10950027	ENSG00000237310.1	GS1-124K5.4	6.38	4.1e-10	2.05e-07	0.35	0.28	Aortic root size;	chr7:66169164	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs7792762	ENSG00000222364.1	RNU6-96P	-6.38	4.11e-10	2.05e-07	-0.31	-0.28	Aortic root size;	chr7:66539151	chr7:66395191~66395286:+
LUAD	cis	rs8100891	0.537	rs4805762	ENSG00000267213.4	AC007773.2	-6.38	4.11e-10	2.06e-07	-0.44	-0.28	Neuroticism;	chr19:32473048	chr19:32390050~32405560:-
LUAD	cis	rs9640161	0.83	rs17173682	ENSG00000261305.1	RP4-584D14.7	6.38	4.11e-10	2.06e-07	0.41	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150362513	chr7:150341771~150342607:+
LUAD	cis	rs12554020	0.786	rs7036984	ENSG00000227603.1	RP11-165J3.6	6.38	4.12e-10	2.06e-07	0.43	0.28	Schizophrenia;	chr9:93438258	chr9:93435332~93437121:-
LUAD	cis	rs2404602	0.684	rs965818	ENSG00000259422.1	RP11-593F23.1	-6.38	4.12e-10	2.06e-07	-0.37	-0.28	Blood metabolite levels;	chr15:76574444	chr15:76174891~76181486:-
LUAD	cis	rs2739330	0.929	rs5751777	ENSG00000228039.3	KB-1125A3.10	6.38	4.12e-10	2.06e-07	0.34	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23963780~23964374:+
LUAD	cis	rs1707322	0.752	rs4660313	ENSG00000234329.1	RP11-767N6.2	-6.38	4.12e-10	2.06e-07	-0.3	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645169	chr1:45651039~45651826:-
LUAD	cis	rs875971	1	rs709597	ENSG00000222364.1	RNU6-96P	6.38	4.13e-10	2.06e-07	0.31	0.28	Aortic root size;	chr7:66360996	chr7:66395191~66395286:+
LUAD	cis	rs17301013	0.507	rs4652797	ENSG00000227373.4	RP11-160H22.5	6.38	4.13e-10	2.06e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174791236	chr1:174115300~174160004:-
LUAD	cis	rs7688540	0.8	rs61792060	ENSG00000275426.1	CH17-262A2.1	6.38	4.13e-10	2.06e-07	0.34	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:262661	chr4:149738~150317:+
LUAD	cis	rs875971	0.862	rs1612452	ENSG00000222364.1	RNU6-96P	6.38	4.13e-10	2.06e-07	0.32	0.28	Aortic root size;	chr7:66108909	chr7:66395191~66395286:+
LUAD	cis	rs867371	0.502	rs3759800	ENSG00000255769.6	GOLGA2P10	6.38	4.13e-10	2.07e-07	0.29	0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82240622	chr15:82472993~82513950:-
LUAD	cis	rs35955747	0.902	rs140074	ENSG00000236132.1	CTA-440B3.1	-6.38	4.14e-10	2.07e-07	-0.31	-0.28	Neutrophil count;Sum basophil neutrophil counts;	chr22:31329648	chr22:31816379~31817491:-
LUAD	cis	rs2243480	0.901	rs2456483	ENSG00000226824.5	RP4-756H11.3	-6.38	4.15e-10	2.07e-07	-0.52	-0.28	Diabetic kidney disease;	chr7:65996588	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs1701750	ENSG00000226824.5	RP4-756H11.3	-6.38	4.15e-10	2.07e-07	-0.52	-0.28	Diabetic kidney disease;	chr7:66002158	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs1701758	ENSG00000226824.5	RP4-756H11.3	-6.38	4.15e-10	2.07e-07	-0.52	-0.28	Diabetic kidney disease;	chr7:66005214	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.901	rs1701759	ENSG00000226824.5	RP4-756H11.3	-6.38	4.15e-10	2.07e-07	-0.52	-0.28	Diabetic kidney disease;	chr7:66005945	chr7:66654538~66669855:+
LUAD	cis	rs1707322	0.721	rs10890341	ENSG00000234329.1	RP11-767N6.2	6.38	4.15e-10	2.08e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45681568	chr1:45651039~45651826:-
LUAD	cis	rs6921919	0.515	rs1339898	ENSG00000216901.1	AL022393.7	6.38	4.16e-10	2.08e-07	0.34	0.28	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28176188~28176674:+
LUAD	cis	rs2408955	0.522	rs2051851	ENSG00000240399.1	RP1-228P16.1	-6.38	4.16e-10	2.08e-07	-0.27	-0.28	Glycated hemoglobin levels;	chr12:48092157	chr12:48054813~48055591:-
LUAD	cis	rs9910055	0.664	rs433610	ENSG00000267080.4	ASB16-AS1	6.38	4.17e-10	2.08e-07	0.25	0.28	Total body bone mineral density;	chr17:44119913	chr17:44175973~44186717:-
LUAD	cis	rs11971779	0.68	rs10273527	ENSG00000273391.1	RP11-634H22.1	-6.38	4.19e-10	2.09e-07	-0.28	-0.28	Diisocyanate-induced asthma;	chr7:139351852	chr7:139359032~139359566:-
LUAD	cis	rs9595908	0.709	rs916289	ENSG00000212293.1	SNORA16	6.38	4.2e-10	2.1e-07	0.3	0.28	Body mass index;	chr13:32792110	chr13:32420390~32420516:-
LUAD	cis	rs6903823	0.508	rs1778484	ENSG00000204709.4	LINC01556	6.38	4.2e-10	2.1e-07	0.34	0.28	Pulmonary function;	chr6:28273021	chr6:28943877~28944537:+
LUAD	cis	rs2243480	1	rs160639	ENSG00000232546.1	RP11-458F8.1	-6.38	4.2e-10	2.1e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66115000	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs313824	ENSG00000232546.1	RP11-458F8.1	-6.38	4.2e-10	2.1e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66116220	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs186378	ENSG00000232546.1	RP11-458F8.1	-6.38	4.2e-10	2.1e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66117071	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs160637	ENSG00000232546.1	RP11-458F8.1	-6.38	4.2e-10	2.1e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66119331	chr7:66848496~66858136:+
LUAD	cis	rs7927592	0.956	rs11228269	ENSG00000212093.1	AP000807.1	6.38	4.21e-10	2.1e-07	0.31	0.28	Total body bone mineral density;	chr11:68522328	chr11:68506083~68506166:-
LUAD	cis	rs3762637	1	rs3762637	ENSG00000272758.4	RP11-299J3.8	-6.38	4.22e-10	2.1e-07	-0.43	-0.28	LDL cholesterol levels;	chr3:122426477	chr3:122416207~122443180:+
LUAD	cis	rs2404602	0.575	rs11072611	ENSG00000259422.1	RP11-593F23.1	6.38	4.22e-10	2.11e-07	0.38	0.28	Blood metabolite levels;	chr15:76655642	chr15:76174891~76181486:-
LUAD	cis	rs1823913	0.614	rs6755243	ENSG00000280083.1	RP11-317J9.1	6.38	4.23e-10	2.11e-07	0.33	0.28	Obesity-related traits;	chr2:191269810	chr2:191154118~191156070:-
LUAD	cis	rs155076	1	rs9509638	ENSG00000233325.3	MIPEPP3	6.38	4.23e-10	2.11e-07	0.45	0.28	White matter hyperintensity burden;	chr13:21286054	chr13:21298139~21306373:+
LUAD	cis	rs5753618	0.561	rs5753543	ENSG00000236132.1	CTA-440B3.1	6.38	4.23e-10	2.11e-07	0.35	0.28	Colorectal cancer;	chr22:31289472	chr22:31816379~31817491:-
LUAD	cis	rs5753618	0.561	rs2413049	ENSG00000236132.1	CTA-440B3.1	6.38	4.23e-10	2.11e-07	0.35	0.28	Colorectal cancer;	chr22:31290158	chr22:31816379~31817491:-
LUAD	cis	rs11098499	0.954	rs4309825	ENSG00000248280.1	RP11-33B1.2	-6.38	4.23e-10	2.11e-07	-0.35	-0.28	Corneal astigmatism;	chr4:119393726	chr4:119440561~119450157:-
LUAD	cis	rs881375	0.9	rs1930786	ENSG00000226752.6	PSMD5-AS1	-6.38	4.23e-10	2.11e-07	-0.3	-0.28	Rheumatoid arthritis;	chr9:120929191	chr9:120824828~120854385:+
LUAD	cis	rs1799949	0.965	rs8176087	ENSG00000267681.1	CTD-3199J23.6	-6.38	4.23e-10	2.11e-07	-0.33	-0.28	Menopause (age at onset);	chr17:43118649	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs34942571	ENSG00000267681.1	CTD-3199J23.6	-6.38	4.23e-10	2.11e-07	-0.33	-0.28	Menopause (age at onset);	chr17:43121362	chr17:43144956~43145255:+
LUAD	cis	rs2708377	0.789	rs3911150	ENSG00000247157.5	LINC01252	-6.38	4.24e-10	2.11e-07	-0.47	-0.28	Bitter taste perception;	chr12:11049649	chr12:11548030~11590369:+
LUAD	cis	rs7598759	0.548	rs11693738	ENSG00000181798.2	LINC00471	-6.38	4.24e-10	2.11e-07	-0.31	-0.28	Noise-induced hearing loss;	chr2:231495773	chr2:231508426~231514339:-
LUAD	cis	rs7598759	0.548	rs11686485	ENSG00000181798.2	LINC00471	-6.38	4.24e-10	2.11e-07	-0.31	-0.28	Noise-induced hearing loss;	chr2:231495986	chr2:231508426~231514339:-
LUAD	cis	rs950169	0.84	rs62029595	ENSG00000259728.4	LINC00933	6.38	4.25e-10	2.12e-07	0.42	0.28	Schizophrenia;	chr15:84400603	chr15:84570649~84580175:+
LUAD	cis	rs10740039	0.883	rs1442545	ENSG00000254271.1	RP11-131N11.4	6.38	4.25e-10	2.12e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60650268	chr10:60734342~60741828:+
LUAD	cis	rs2739330	0.828	rs5760108	ENSG00000206090.4	AP000350.7	6.38	4.26e-10	2.12e-07	0.32	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23939998~23942798:+
LUAD	cis	rs72772090	0.634	rs17401901	ENSG00000248734.2	CTD-2260A17.1	-6.38	4.27e-10	2.13e-07	-0.4	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96756221	chr5:96784777~96785999:+
LUAD	cis	rs72772090	0.634	rs72773906	ENSG00000248734.2	CTD-2260A17.1	-6.38	4.27e-10	2.13e-07	-0.4	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96756570	chr5:96784777~96785999:+
LUAD	cis	rs9309473	1	rs6711033	ENSG00000163016.8	ALMS1P	6.38	4.27e-10	2.13e-07	0.34	0.28	Metabolite levels;	chr2:73519516	chr2:73644919~73685576:+
LUAD	cis	rs293748	0.66	rs61748200	ENSG00000250155.1	CTD-2353F22.1	-6.38	4.27e-10	2.13e-07	-0.4	-0.28	Obesity-related traits;	chr5:37036390	chr5:36666214~36725195:-
LUAD	cis	rs783540	0.967	rs1145172	ENSG00000278603.1	RP13-608F4.5	-6.38	4.29e-10	2.14e-07	-0.33	-0.28	Schizophrenia;	chr15:82554866	chr15:82472203~82472426:+
LUAD	cis	rs7688540	0.8	rs28531997	ENSG00000275426.1	CH17-262A2.1	6.38	4.29e-10	2.14e-07	0.34	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:248998	chr4:149738~150317:+
LUAD	cis	rs17301013	0.507	rs72715218	ENSG00000227373.4	RP11-160H22.5	6.38	4.29e-10	2.14e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174529056	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs55748748	ENSG00000227373.4	RP11-160H22.5	6.38	4.29e-10	2.14e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174546252	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs41266050	ENSG00000227373.4	RP11-160H22.5	6.38	4.29e-10	2.14e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174547861	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs72715237	ENSG00000227373.4	RP11-160H22.5	6.38	4.29e-10	2.14e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174550527	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs72715240	ENSG00000227373.4	RP11-160H22.5	6.38	4.29e-10	2.14e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174560838	chr1:174115300~174160004:-
LUAD	cis	rs4927850	1	rs7625570	ENSG00000207650.1	MIR570	6.38	4.29e-10	2.14e-07	0.29	0.28	Pancreatic cancer;	chr3:196020527	chr3:195699401~195699497:+
LUAD	cis	rs765787	0.53	rs12903149	ENSG00000259520.4	CTD-2651B20.3	-6.38	4.29e-10	2.14e-07	-0.37	-0.28	Uric acid levels;	chr15:45246878	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs3759892	ENSG00000259520.4	CTD-2651B20.3	-6.38	4.29e-10	2.14e-07	-0.37	-0.28	Uric acid levels;	chr15:45250511	chr15:45251580~45279251:-
LUAD	cis	rs2243480	1	rs313820	ENSG00000232546.1	RP11-458F8.1	-6.37	4.29e-10	2.14e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66109479	chr7:66848496~66858136:+
LUAD	cis	rs2117029	0.586	rs10783307	ENSG00000258017.1	RP11-386G11.10	-6.37	4.29e-10	2.14e-07	-0.34	-0.28	Intelligence (multi-trait analysis);	chr12:49135822	chr12:49127782~49147869:+
LUAD	cis	rs2117029	0.554	rs12306494	ENSG00000258017.1	RP11-386G11.10	-6.37	4.29e-10	2.14e-07	-0.34	-0.28	Intelligence (multi-trait analysis);	chr12:49136998	chr12:49127782~49147869:+
LUAD	cis	rs2117029	0.586	rs11168884	ENSG00000258017.1	RP11-386G11.10	-6.37	4.29e-10	2.14e-07	-0.34	-0.28	Intelligence (multi-trait analysis);	chr12:49146109	chr12:49127782~49147869:+
LUAD	cis	rs12468226	1	rs16839090	ENSG00000226261.1	AC064836.3	6.37	4.3e-10	2.14e-07	0.46	0.28	Urate levels;	chr2:202348338	chr2:202336024~202336727:-
LUAD	cis	rs9640161	0.83	rs11768108	ENSG00000261305.1	RP4-584D14.7	6.37	4.3e-10	2.14e-07	0.41	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150367061	chr7:150341771~150342607:+
LUAD	cis	rs932287	0.54	rs4910442	ENSG00000254860.4	TMEM9B-AS1	-6.37	4.3e-10	2.14e-07	-0.32	-0.28	Colonoscopy-negative controls vs population controls;	chr11:9022790	chr11:8964675~8977527:+
LUAD	cis	rs4713118	0.955	rs9393848	ENSG00000219392.1	RP1-265C24.5	-6.37	4.31e-10	2.15e-07	-0.38	-0.28	Parkinson's disease;	chr6:27720590	chr6:28115628~28116551:+
LUAD	cis	rs783540	1	rs783531	ENSG00000278603.1	RP13-608F4.5	-6.37	4.31e-10	2.15e-07	-0.32	-0.28	Schizophrenia;	chr15:82580370	chr15:82472203~82472426:+
LUAD	cis	rs783540	0.934	rs783532	ENSG00000278603.1	RP13-608F4.5	-6.37	4.31e-10	2.15e-07	-0.32	-0.28	Schizophrenia;	chr15:82580618	chr15:82472203~82472426:+
LUAD	cis	rs10800713	0.607	rs6682828	ENSG00000260088.1	RP11-92G12.3	-6.37	4.31e-10	2.15e-07	-0.36	-0.28	Tandem gait;	chr1:200537968	chr1:200669507~200694250:+
LUAD	cis	rs9549367	0.826	rs9549710	ENSG00000269125.1	RP11-98F14.11	-6.37	4.32e-10	2.15e-07	-0.35	-0.28	Platelet distribution width;	chr13:113243750	chr13:113165002~113165183:-
LUAD	cis	rs2243480	1	rs6964245	ENSG00000226824.5	RP4-756H11.3	6.37	4.32e-10	2.15e-07	0.52	0.28	Diabetic kidney disease;	chr7:66253730	chr7:66654538~66669855:+
LUAD	cis	rs17301013	0.507	rs12065326	ENSG00000227373.4	RP11-160H22.5	6.37	4.32e-10	2.15e-07	0.42	0.28	Systemic lupus erythematosus;	chr1:174426892	chr1:174115300~174160004:-
LUAD	cis	rs2243480	1	rs34702770	ENSG00000232546.1	RP11-458F8.1	-6.37	4.32e-10	2.15e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:65879836	chr7:66848496~66858136:+
LUAD	cis	rs950169	0.58	rs11634322	ENSG00000259728.4	LINC00933	6.37	4.33e-10	2.15e-07	0.41	0.28	Schizophrenia;	chr15:84628978	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.58	rs4603535	ENSG00000259728.4	LINC00933	6.37	4.33e-10	2.15e-07	0.41	0.28	Schizophrenia;	chr15:84630641	chr15:84570649~84580175:+
LUAD	cis	rs2243480	1	rs1404147	ENSG00000226824.5	RP4-756H11.3	-6.37	4.33e-10	2.15e-07	-0.48	-0.28	Diabetic kidney disease;	chr7:65799537	chr7:66654538~66669855:+
LUAD	cis	rs35740288	0.77	rs55740125	ENSG00000202081.1	RNU6-1280P	6.37	4.33e-10	2.16e-07	0.34	0.28	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85612505	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.77	rs4843085	ENSG00000202081.1	RNU6-1280P	6.37	4.33e-10	2.16e-07	0.34	0.28	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85615268	chr15:85651522~85651628:-
LUAD	cis	rs7246657	0.943	rs3803895	ENSG00000276846.1	CTD-3220F14.3	6.37	4.33e-10	2.16e-07	0.38	0.28	Coronary artery calcification;	chr19:37407767	chr19:37314868~37315620:-
LUAD	cis	rs755249	0.917	rs72663503	ENSG00000228060.1	RP11-69E11.8	-6.37	4.34e-10	2.16e-07	-0.28	-0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39503387	chr1:39565160~39573203:+
LUAD	cis	rs2404602	0.684	rs4886816	ENSG00000259422.1	RP11-593F23.1	-6.37	4.34e-10	2.16e-07	-0.37	-0.28	Blood metabolite levels;	chr15:76582366	chr15:76174891~76181486:-
LUAD	cis	rs1061377	0.513	rs6840214	ENSG00000249207.1	RP11-360F5.1	6.37	4.34e-10	2.16e-07	0.36	0.28	Uric acid levels;	chr4:39118999	chr4:39112677~39126818:-
LUAD	cis	rs7246657	0.551	rs10404069	ENSG00000276846.1	CTD-3220F14.3	6.37	4.34e-10	2.16e-07	0.43	0.28	Coronary artery calcification;	chr19:37147502	chr19:37314868~37315620:-
LUAD	cis	rs732716	0.719	rs56088814	ENSG00000267980.1	AC007292.6	-6.37	4.34e-10	2.16e-07	-0.33	-0.28	Mean corpuscular volume;	chr19:4422181	chr19:4363789~4364640:+
LUAD	cis	rs7849270	1	rs3118625	ENSG00000268707.1	RP11-247A12.7	6.37	4.35e-10	2.16e-07	0.33	0.28	Blood metabolite ratios;	chr9:129110977	chr9:129170434~129170940:+
LUAD	cis	rs9309473	1	rs11899740	ENSG00000163016.8	ALMS1P	6.37	4.36e-10	2.17e-07	0.35	0.28	Metabolite levels;	chr2:73404084	chr2:73644919~73685576:+
LUAD	cis	rs6991838	0.702	rs13274205	ENSG00000200714.1	Y_RNA	6.37	4.36e-10	2.17e-07	0.33	0.28	Intelligence (multi-trait analysis);	chr8:65708124	chr8:65592731~65592820:+
LUAD	cis	rs7688540	0.76	rs28460123	ENSG00000275426.1	CH17-262A2.1	6.37	4.36e-10	2.17e-07	0.34	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:246419	chr4:149738~150317:+
LUAD	cis	rs4964805	0.626	rs4964827	ENSG00000257681.1	RP11-341G23.4	6.37	4.37e-10	2.18e-07	0.34	0.28	Attention deficit hyperactivity disorder;	chr12:103783303	chr12:103746315~103768858:-
LUAD	cis	rs875971	0.895	rs1974769	ENSG00000222364.1	RNU6-96P	-6.37	4.38e-10	2.18e-07	-0.31	-0.28	Aortic root size;	chr7:66485627	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.895	rs6460300	ENSG00000222364.1	RNU6-96P	-6.37	4.38e-10	2.18e-07	-0.31	-0.28	Aortic root size;	chr7:66487937	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs7803416	ENSG00000222364.1	RNU6-96P	-6.37	4.38e-10	2.18e-07	-0.31	-0.28	Aortic root size;	chr7:66489212	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs1981799	ENSG00000222364.1	RNU6-96P	-6.37	4.38e-10	2.18e-07	-0.31	-0.28	Aortic root size;	chr7:66490572	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.964	rs2277911	ENSG00000222364.1	RNU6-96P	-6.37	4.38e-10	2.18e-07	-0.31	-0.28	Aortic root size;	chr7:66493638	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.964	rs6978429	ENSG00000222364.1	RNU6-96P	-6.37	4.38e-10	2.18e-07	-0.31	-0.28	Aortic root size;	chr7:66494889	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs4718357	ENSG00000222364.1	RNU6-96P	-6.37	4.38e-10	2.18e-07	-0.31	-0.28	Aortic root size;	chr7:66495891	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.929	rs12535036	ENSG00000222364.1	RNU6-96P	-6.37	4.38e-10	2.18e-07	-0.31	-0.28	Aortic root size;	chr7:66499076	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs12533997	ENSG00000222364.1	RNU6-96P	-6.37	4.38e-10	2.18e-07	-0.31	-0.28	Aortic root size;	chr7:66500390	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs12698523	ENSG00000222364.1	RNU6-96P	-6.37	4.38e-10	2.18e-07	-0.31	-0.28	Aortic root size;	chr7:66503126	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs6970030	ENSG00000222364.1	RNU6-96P	-6.37	4.38e-10	2.18e-07	-0.31	-0.28	Aortic root size;	chr7:66503692	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.928	rs6970357	ENSG00000222364.1	RNU6-96P	-6.37	4.38e-10	2.18e-07	-0.31	-0.28	Aortic root size;	chr7:66503891	chr7:66395191~66395286:+
LUAD	cis	rs67311347	0.955	rs11711994	ENSG00000223797.4	ENTPD3-AS1	6.37	4.38e-10	2.18e-07	0.3	0.28	Renal cell carcinoma;	chr3:40349595	chr3:40313802~40453329:-
LUAD	cis	rs17301013	0.507	rs1474575	ENSG00000227373.4	RP11-160H22.5	-6.37	4.38e-10	2.18e-07	-0.41	-0.28	Systemic lupus erythematosus;	chr1:174569563	chr1:174115300~174160004:-
LUAD	cis	rs7598759	0.548	rs1823328	ENSG00000181798.2	LINC00471	-6.37	4.38e-10	2.18e-07	-0.31	-0.28	Noise-induced hearing loss;	chr2:231490473	chr2:231508426~231514339:-
LUAD	cis	rs765787	0.53	rs12904265	ENSG00000259520.4	CTD-2651B20.3	-6.37	4.39e-10	2.18e-07	-0.37	-0.28	Uric acid levels;	chr15:45234515	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs12440321	ENSG00000259520.4	CTD-2651B20.3	-6.37	4.39e-10	2.18e-07	-0.37	-0.28	Uric acid levels;	chr15:45237187	chr15:45251580~45279251:-
LUAD	cis	rs6991838	0.733	rs7822627	ENSG00000200714.1	Y_RNA	6.37	4.4e-10	2.19e-07	0.33	0.28	Intelligence (multi-trait analysis);	chr8:65714139	chr8:65592731~65592820:+
LUAD	cis	rs2665103	0.61	rs56398167	ENSG00000278603.1	RP13-608F4.5	6.37	4.4e-10	2.19e-07	0.32	0.28	Intelligence (multi-trait analysis);	chr15:82237482	chr15:82472203~82472426:+
LUAD	cis	rs875971	0.838	rs2173570	ENSG00000222364.1	RNU6-96P	6.37	4.4e-10	2.19e-07	0.32	0.28	Aortic root size;	chr7:66297976	chr7:66395191~66395286:+
LUAD	cis	rs7829975	0.624	rs7823056	ENSG00000253893.2	FAM85B	-6.37	4.4e-10	2.19e-07	-0.35	-0.28	Mood instability;	chr8:8525195	chr8:8167819~8226614:-
LUAD	cis	rs3762637	1	rs55853677	ENSG00000272758.4	RP11-299J3.8	-6.37	4.41e-10	2.19e-07	-0.43	-0.28	LDL cholesterol levels;	chr3:122421769	chr3:122416207~122443180:+
LUAD	cis	rs465969	1	rs17510733	ENSG00000255389.1	C6orf3	-6.37	4.41e-10	2.19e-07	-0.61	-0.28	Psoriasis;	chr6:111389715	chr6:111599875~111602295:+
LUAD	cis	rs465969	1	rs78945802	ENSG00000255389.1	C6orf3	-6.37	4.41e-10	2.19e-07	-0.61	-0.28	Psoriasis;	chr6:111407143	chr6:111599875~111602295:+
LUAD	cis	rs465969	1	rs17072683	ENSG00000255389.1	C6orf3	-6.37	4.41e-10	2.19e-07	-0.61	-0.28	Psoriasis;	chr6:111410007	chr6:111599875~111602295:+
LUAD	cis	rs77204473	1	rs79207844	ENSG00000254851.1	RP11-109L13.1	6.37	4.41e-10	2.19e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116934725	chr11:117135528~117138582:+
LUAD	cis	rs9549367	0.789	rs9549711	ENSG00000269125.1	RP11-98F14.11	-6.37	4.42e-10	2.2e-07	-0.35	-0.28	Platelet distribution width;	chr13:113246243	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.737	rs9549712	ENSG00000269125.1	RP11-98F14.11	-6.37	4.42e-10	2.2e-07	-0.35	-0.28	Platelet distribution width;	chr13:113248041	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.774	rs9549364	ENSG00000269125.1	RP11-98F14.11	-6.37	4.42e-10	2.2e-07	-0.35	-0.28	Platelet distribution width;	chr13:113249431	chr13:113165002~113165183:-
LUAD	cis	rs17301013	0.507	rs2281011	ENSG00000227373.4	RP11-160H22.5	6.37	4.43e-10	2.2e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174509890	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs2072759	ENSG00000227373.4	RP11-160H22.5	6.37	4.43e-10	2.2e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174510189	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs4652511	ENSG00000227373.4	RP11-160H22.5	6.37	4.43e-10	2.2e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174515500	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs4652513	ENSG00000227373.4	RP11-160H22.5	6.37	4.43e-10	2.2e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174515794	chr1:174115300~174160004:-
LUAD	cis	rs67311347	1	rs6793596	ENSG00000223797.4	ENTPD3-AS1	6.37	4.43e-10	2.2e-07	0.31	0.28	Renal cell carcinoma;	chr3:40416304	chr3:40313802~40453329:-
LUAD	cis	rs4927850	1	rs7627868	ENSG00000207650.1	MIR570	6.37	4.43e-10	2.2e-07	0.29	0.28	Pancreatic cancer;	chr3:196026602	chr3:195699401~195699497:+
LUAD	cis	rs12468226	0.752	rs34829484	ENSG00000273456.1	RP11-686O6.2	-6.37	4.43e-10	2.2e-07	-0.37	-0.28	Urate levels;	chr2:202137267	chr2:202374932~202375604:-
LUAD	cis	rs17301013	0.507	rs2142863	ENSG00000227373.4	RP11-160H22.5	6.37	4.43e-10	2.2e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174301582	chr1:174115300~174160004:-
LUAD	cis	rs2243480	0.831	rs57294491	ENSG00000226824.5	RP4-756H11.3	6.37	4.44e-10	2.2e-07	0.53	0.28	Diabetic kidney disease;	chr7:66219914	chr7:66654538~66669855:+
LUAD	cis	rs7927592	0.913	rs7107622	ENSG00000212093.1	AP000807.1	6.37	4.44e-10	2.21e-07	0.3	0.28	Total body bone mineral density;	chr11:68606715	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.956	rs7116899	ENSG00000212093.1	AP000807.1	6.37	4.45e-10	2.21e-07	0.31	0.28	Total body bone mineral density;	chr11:68618067	chr11:68506083~68506166:-
LUAD	cis	rs494459	0.657	rs614554	ENSG00000278376.1	RP11-158I9.8	-6.37	4.45e-10	2.21e-07	-0.29	-0.28	Height;	chr11:118764443	chr11:118791254~118793137:+
LUAD	cis	rs67311347	1	rs73078123	ENSG00000223797.4	ENTPD3-AS1	6.37	4.45e-10	2.21e-07	0.31	0.28	Renal cell carcinoma;	chr3:40417472	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs4973998	ENSG00000223797.4	ENTPD3-AS1	6.37	4.45e-10	2.21e-07	0.31	0.28	Renal cell carcinoma;	chr3:40418861	chr3:40313802~40453329:-
LUAD	cis	rs77204473	1	rs10128682	ENSG00000254851.1	RP11-109L13.1	6.37	4.45e-10	2.21e-07	0.68	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116992742	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs75826529	ENSG00000254851.1	RP11-109L13.1	6.37	4.45e-10	2.21e-07	0.68	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116994384	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs74460214	ENSG00000254851.1	RP11-109L13.1	6.37	4.45e-10	2.21e-07	0.68	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116994491	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs79349393	ENSG00000254851.1	RP11-109L13.1	6.37	4.45e-10	2.21e-07	0.68	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116994651	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs10892056	ENSG00000254851.1	RP11-109L13.1	6.37	4.45e-10	2.21e-07	0.68	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116999695	chr11:117135528~117138582:+
LUAD	cis	rs2243480	1	rs781150	ENSG00000232546.1	RP11-458F8.1	-6.37	4.46e-10	2.21e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66015986	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs313798	ENSG00000232546.1	RP11-458F8.1	-6.37	4.46e-10	2.21e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66028044	chr7:66848496~66858136:+
LUAD	cis	rs17301013	0.531	rs332806	ENSG00000227373.4	RP11-160H22.5	6.37	4.46e-10	2.21e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174653645	chr1:174115300~174160004:-
LUAD	cis	rs2243480	1	rs316321	ENSG00000232546.1	RP11-458F8.1	-6.37	4.46e-10	2.21e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66146626	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs316318	ENSG00000232546.1	RP11-458F8.1	-6.37	4.46e-10	2.21e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66147917	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs316317	ENSG00000232546.1	RP11-458F8.1	-6.37	4.46e-10	2.21e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66148650	chr7:66848496~66858136:+
LUAD	cis	rs17301013	0.507	rs464635	ENSG00000227373.4	RP11-160H22.5	6.37	4.46e-10	2.21e-07	0.4	0.28	Systemic lupus erythematosus;	chr1:174732730	chr1:174115300~174160004:-
LUAD	cis	rs2408955	0.522	rs973398	ENSG00000240399.1	RP1-228P16.1	-6.37	4.48e-10	2.22e-07	-0.27	-0.28	Glycated hemoglobin levels;	chr12:48097265	chr12:48054813~48055591:-
LUAD	cis	rs2243480	1	rs1546059	ENSG00000232546.1	RP11-458F8.1	6.37	4.48e-10	2.22e-07	0.36	0.28	Diabetic kidney disease;	chr7:66189722	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs6958289	ENSG00000232546.1	RP11-458F8.1	6.37	4.48e-10	2.22e-07	0.36	0.28	Diabetic kidney disease;	chr7:66192124	chr7:66848496~66858136:+
LUAD	cis	rs150992	0.609	rs2937709	ENSG00000248489.1	CTD-2007H13.3	6.37	4.48e-10	2.22e-07	0.31	0.28	Body mass index;	chr5:98993120	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.632	rs1104262	ENSG00000248489.1	CTD-2007H13.3	6.37	4.48e-10	2.22e-07	0.31	0.28	Body mass index;	chr5:98993145	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.609	rs2927654	ENSG00000248489.1	CTD-2007H13.3	6.37	4.48e-10	2.22e-07	0.31	0.28	Body mass index;	chr5:98993195	chr5:98929171~98995013:+
LUAD	cis	rs2378497	0.564	rs115883774	ENSG00000232679.1	RP11-400N13.3	6.37	4.48e-10	2.23e-07	0.33	0.28	Serum thyroid-stimulating hormone levels;	chr1:221986970	chr1:222041705~222064763:-
LUAD	cis	rs1707322	0.752	rs11211146	ENSG00000234329.1	RP11-767N6.2	6.37	4.5e-10	2.23e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644122	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs11211147	ENSG00000234329.1	RP11-767N6.2	6.37	4.5e-10	2.23e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644422	chr1:45651039~45651826:-
LUAD	cis	rs367615	0.918	rs72797472	ENSG00000249476.1	CTD-2587M2.1	6.37	4.52e-10	2.24e-07	0.37	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109545642	chr5:109237120~109326369:-
LUAD	cis	rs1062177	1	rs72802204	ENSG00000213433.5	RPLP1P6	-6.37	4.52e-10	2.24e-07	-0.38	-0.28	Preschool internalizing problems;	chr5:151803622	chr5:151765859~151766378:-
LUAD	cis	rs875971	0.545	rs4718325	ENSG00000237310.1	GS1-124K5.4	6.37	4.52e-10	2.24e-07	0.35	0.28	Aortic root size;	chr7:66215323	chr7:66493706~66495474:+
LUAD	cis	rs2739330	0.892	rs5751776	ENSG00000228039.3	KB-1125A3.10	6.37	4.53e-10	2.25e-07	0.34	0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23963780~23964374:+
LUAD	cis	rs10759883	0.627	rs12000073	ENSG00000175611.10	LINC00476	6.37	4.53e-10	2.25e-07	0.32	0.28	Nicotine dependence;	chr9:95853844	chr9:95759231~95875977:-
LUAD	cis	rs7927592	0.956	rs7106259	ENSG00000212093.1	AP000807.1	6.37	4.54e-10	2.25e-07	0.3	0.28	Total body bone mineral density;	chr11:68531044	chr11:68506083~68506166:-
LUAD	cis	rs113835537	0.529	rs75683511	ENSG00000255517.5	CTD-3074O7.5	-6.37	4.54e-10	2.25e-07	-0.34	-0.28	Airway imaging phenotypes;	chr11:66507555	chr11:66473490~66480233:-
LUAD	cis	rs7743045	0.652	rs3756940	ENSG00000253194.1	RP11-351A11.1	6.37	4.55e-10	2.25e-07	0.37	0.28	Mean platelet volume;	chr6:119002822	chr6:118934785~119031541:+
LUAD	cis	rs6921919	0.525	rs1361386	ENSG00000204709.4	LINC01556	6.37	4.55e-10	2.25e-07	0.35	0.28	Autism spectrum disorder or schizophrenia;	chr6:28337827	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.638	rs6456815	ENSG00000204709.4	LINC01556	6.37	4.55e-10	2.25e-07	0.35	0.28	Autism spectrum disorder or schizophrenia;	chr6:28338360	chr6:28943877~28944537:+
LUAD	cis	rs1062177	1	rs973529	ENSG00000213433.5	RPLP1P6	-6.37	4.55e-10	2.26e-07	-0.38	-0.28	Preschool internalizing problems;	chr5:151808597	chr5:151765859~151766378:-
LUAD	cis	rs1799949	0.683	rs55737636	ENSG00000267681.1	CTD-3199J23.6	-6.37	4.55e-10	2.26e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43112722	chr17:43144956~43145255:+
LUAD	cis	rs853679	0.517	rs16893666	ENSG00000204709.4	LINC01556	-6.37	4.55e-10	2.26e-07	-0.39	-0.28	Depression;	chr6:28086929	chr6:28943877~28944537:+
LUAD	cis	rs4660456	0.504	rs542214	ENSG00000237899.1	RP4-739H11.3	6.37	4.55e-10	2.26e-07	0.36	0.28	Platelet count;	chr1:40632806	chr1:40669089~40687588:-
LUAD	cis	rs7626444	0.625	rs843535	ENSG00000272359.1	U4	-6.37	4.56e-10	2.26e-07	-0.31	-0.28	Monocyte count;	chr3:196746193	chr3:196747192~196747324:-
LUAD	cis	rs56046484	0.957	rs35127646	ENSG00000259295.5	CSPG4P12	6.36	4.56e-10	2.26e-07	0.4	0.28	Testicular germ cell tumor;	chr15:85058640	chr15:85191438~85213905:+
LUAD	cis	rs56046484	1	rs56046484	ENSG00000259295.5	CSPG4P12	6.36	4.56e-10	2.26e-07	0.4	0.28	Testicular germ cell tumor;	chr15:85062196	chr15:85191438~85213905:+
LUAD	cis	rs12468226	0.938	rs114177656	ENSG00000226261.1	AC064836.3	6.36	4.56e-10	2.26e-07	0.47	0.28	Urate levels;	chr2:202291596	chr2:202336024~202336727:-
LUAD	cis	rs7176527	0.784	rs62021162	ENSG00000188388.10	GOLGA6L3	6.36	4.57e-10	2.26e-07	0.37	0.28	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84565602	chr15:85240472~85247170:+
LUAD	cis	rs783540	0.934	rs8043401	ENSG00000278603.1	RP13-608F4.5	6.36	4.57e-10	2.26e-07	0.32	0.28	Schizophrenia;	chr15:82687507	chr15:82472203~82472426:+
LUAD	cis	rs17301013	0.507	rs6687616	ENSG00000227373.4	RP11-160H22.5	6.36	4.57e-10	2.26e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174840322	chr1:174115300~174160004:-
LUAD	cis	rs67311347	0.826	rs9863679	ENSG00000223797.4	ENTPD3-AS1	6.36	4.57e-10	2.26e-07	0.31	0.28	Renal cell carcinoma;	chr3:40398123	chr3:40313802~40453329:-
LUAD	cis	rs155076	1	rs155076	ENSG00000233325.3	MIPEPP3	6.36	4.57e-10	2.26e-07	0.45	0.28	White matter hyperintensity burden;	chr13:21295975	chr13:21298139~21306373:+
LUAD	cis	rs6504622	0.875	rs3851786	ENSG00000262879.4	RP11-156P1.3	6.36	4.57e-10	2.27e-07	0.33	0.28	Orofacial clefts;	chr17:46969566	chr17:46984045~47100323:-
LUAD	cis	rs7849270	1	rs3124513	ENSG00000268707.1	RP11-247A12.7	6.36	4.58e-10	2.27e-07	0.32	0.28	Blood metabolite ratios;	chr9:129142314	chr9:129170434~129170940:+
LUAD	cis	rs7849270	1	rs3124514	ENSG00000268707.1	RP11-247A12.7	6.36	4.58e-10	2.27e-07	0.32	0.28	Blood metabolite ratios;	chr9:129142329	chr9:129170434~129170940:+
LUAD	cis	rs7927592	0.912	rs55767696	ENSG00000212093.1	AP000807.1	6.36	4.58e-10	2.27e-07	0.3	0.28	Total body bone mineral density;	chr11:68607652	chr11:68506083~68506166:-
LUAD	cis	rs7811142	0.887	rs111972532	ENSG00000242294.5	STAG3L5P	6.36	4.58e-10	2.27e-07	0.24	0.28	Platelet count;	chr7:100471465	chr7:100336079~100351900:+
LUAD	cis	rs1799949	0.55	rs2343818	ENSG00000267681.1	CTD-3199J23.6	-6.36	4.58e-10	2.27e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43332406	chr17:43144956~43145255:+
LUAD	cis	rs1499614	0.803	rs1796229	ENSG00000232546.1	RP11-458F8.1	-6.36	4.59e-10	2.27e-07	-0.37	-0.28	Gout;	chr7:66654674	chr7:66848496~66858136:+
LUAD	cis	rs1499614	0.901	rs3936	ENSG00000232546.1	RP11-458F8.1	-6.36	4.59e-10	2.27e-07	-0.37	-0.28	Gout;	chr7:66661502	chr7:66848496~66858136:+
LUAD	cis	rs494459	0.838	rs1784543	ENSG00000278376.1	RP11-158I9.8	-6.36	4.6e-10	2.28e-07	-0.29	-0.28	Height;	chr11:118760944	chr11:118791254~118793137:+
LUAD	cis	rs1012068	0.686	rs4820996	ENSG00000236132.1	CTA-440B3.1	-6.36	4.61e-10	2.28e-07	-0.33	-0.28	Chronic hepatitis C infection;	chr22:31928044	chr22:31816379~31817491:-
LUAD	cis	rs6822297	0.522	rs7700108	ENSG00000240005.4	RP11-293A21.1	6.36	4.61e-10	2.28e-07	0.34	0.28	Obesity-related traits;	chr4:26967785	chr4:26859806~26860599:-
LUAD	cis	rs7246657	0.551	rs10407224	ENSG00000276846.1	CTD-3220F14.3	6.36	4.61e-10	2.28e-07	0.43	0.28	Coronary artery calcification;	chr19:37160568	chr19:37314868~37315620:-
LUAD	cis	rs11098499	0.575	rs907204	ENSG00000248280.1	RP11-33B1.2	6.36	4.61e-10	2.28e-07	0.35	0.28	Corneal astigmatism;	chr4:119317499	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.575	rs907205	ENSG00000248280.1	RP11-33B1.2	6.36	4.61e-10	2.28e-07	0.35	0.28	Corneal astigmatism;	chr4:119317509	chr4:119440561~119450157:-
LUAD	cis	rs4141404	0.818	rs5997897	ENSG00000236132.1	CTA-440B3.1	6.36	4.61e-10	2.28e-07	0.32	0.28	Paclitaxel-induced neuropathy;	chr22:31174450	chr22:31816379~31817491:-
LUAD	cis	rs2115630	0.645	rs6496284	ENSG00000225151.9	GOLGA2P7	6.36	4.61e-10	2.28e-07	0.32	0.28	P wave terminal force;	chr15:84635039	chr15:84199311~84230136:-
LUAD	cis	rs67311347	1	rs9874499	ENSG00000223797.4	ENTPD3-AS1	6.36	4.62e-10	2.29e-07	0.29	0.28	Renal cell carcinoma;	chr3:40400417	chr3:40313802~40453329:-
LUAD	cis	rs2408955	0.522	rs7139330	ENSG00000240399.1	RP1-228P16.1	-6.36	4.62e-10	2.29e-07	-0.27	-0.28	Glycated hemoglobin levels;	chr12:48089701	chr12:48054813~48055591:-
LUAD	cis	rs2243480	0.803	rs35480979	ENSG00000232546.1	RP11-458F8.1	-6.36	4.63e-10	2.29e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:65892097	chr7:66848496~66858136:+
LUAD	cis	rs2179367	0.632	rs9285520	ENSG00000231760.4	RP11-350J20.5	-6.36	4.63e-10	2.29e-07	-0.41	-0.28	Dupuytren's disease;	chr6:149372001	chr6:149796151~149826294:-
LUAD	cis	rs367615	0.959	rs4957830	ENSG00000249476.1	CTD-2587M2.1	6.36	4.63e-10	2.29e-07	0.35	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109576057	chr5:109237120~109326369:-
LUAD	cis	rs7743045	0.652	rs12527291	ENSG00000253194.1	RP11-351A11.1	6.36	4.63e-10	2.29e-07	0.37	0.28	Mean platelet volume;	chr6:118977672	chr6:118934785~119031541:+
LUAD	cis	rs17301013	0.507	rs16847337	ENSG00000227373.4	RP11-160H22.5	-6.36	4.63e-10	2.29e-07	-0.42	-0.28	Systemic lupus erythematosus;	chr1:174683121	chr1:174115300~174160004:-
LUAD	cis	rs4713118	0.621	rs9368548	ENSG00000204709.4	LINC01556	6.36	4.63e-10	2.29e-07	0.39	0.28	Parkinson's disease;	chr6:28066959	chr6:28943877~28944537:+
LUAD	cis	rs17301013	0.507	rs411665	ENSG00000227373.4	RP11-160H22.5	6.36	4.63e-10	2.29e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174656563	chr1:174115300~174160004:-
LUAD	cis	rs12699921	0.566	rs2723515	ENSG00000279048.1	RP11-511H23.2	-6.36	4.63e-10	2.29e-07	-0.22	-0.28	Fibrinogen levels;	chr7:17815843	chr7:17940503~17942922:+
LUAD	cis	rs7017914	0.967	rs17689955	ENSG00000223220.1	Y_RNA	6.36	4.63e-10	2.29e-07	0.31	0.28	Bone mineral density;	chr8:70936629	chr8:70780914~70781008:-
LUAD	cis	rs7626444	0.585	rs860050	ENSG00000272359.1	U4	-6.36	4.64e-10	2.29e-07	-0.31	-0.28	Monocyte count;	chr3:196747576	chr3:196747192~196747324:-
LUAD	cis	rs6772849	0.93	rs9813197	ENSG00000242551.2	POU5F1P6	-6.36	4.64e-10	2.3e-07	-0.33	-0.28	Monocyte percentage of white cells;Monocyte count;	chr3:128650261	chr3:128674735~128677005:-
LUAD	cis	rs848490	0.894	rs17233275	ENSG00000214293.7	APTR	6.36	4.64e-10	2.3e-07	0.32	0.28	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77680725	chr7:77657660~77696265:-
LUAD	cis	rs7826238	0.539	rs2945891	ENSG00000253893.2	FAM85B	-6.36	4.64e-10	2.3e-07	-0.35	-0.28	Systolic blood pressure;	chr8:8297953	chr8:8167819~8226614:-
LUAD	cis	rs755249	0.567	rs1126313	ENSG00000228060.1	RP11-69E11.8	6.36	4.65e-10	2.3e-07	0.28	0.28	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39174072	chr1:39565160~39573203:+
LUAD	cis	rs17301013	0.507	rs2060158	ENSG00000227373.4	RP11-160H22.5	6.36	4.65e-10	2.3e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174667379	chr1:174115300~174160004:-
LUAD	cis	rs950169	0.734	rs67119537	ENSG00000225151.9	GOLGA2P7	-6.36	4.65e-10	2.3e-07	-0.36	-0.28	Schizophrenia;	chr15:84395671	chr15:84199311~84230136:-
LUAD	cis	rs7849270	1	rs10819469	ENSG00000268707.1	RP11-247A12.7	-6.36	4.66e-10	2.31e-07	-0.32	-0.28	Blood metabolite ratios;	chr9:129119788	chr9:129170434~129170940:+
LUAD	cis	rs35934224	0.783	rs7288061	ENSG00000232926.1	AC000078.5	6.36	4.68e-10	2.31e-07	0.35	0.28	Glaucoma (primary open-angle);	chr22:19876716	chr22:19887289~19887970:+
LUAD	cis	rs1799949	0.965	rs4793233	ENSG00000267681.1	CTD-3199J23.6	-6.36	4.68e-10	2.32e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43358069	chr17:43144956~43145255:+
LUAD	cis	rs2255336	0.938	rs59906810	ENSG00000245648.1	RP11-277P12.20	-6.36	4.69e-10	2.32e-07	-0.4	-0.28	Blood protein levels;	chr12:10446021	chr12:10363769~10398506:+
LUAD	cis	rs5760092	0.572	rs738806	ENSG00000231271.1	AP000350.8	6.36	4.69e-10	2.32e-07	0.39	0.28	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23949918~23954042:+
LUAD	cis	rs77204473	1	rs12276805	ENSG00000254851.1	RP11-109L13.1	6.36	4.69e-10	2.32e-07	0.68	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117008043	chr11:117135528~117138582:+
LUAD	cis	rs7017914	0.905	rs2639957	ENSG00000223220.1	Y_RNA	6.36	4.71e-10	2.33e-07	0.31	0.28	Bone mineral density;	chr8:71010967	chr8:70780914~70781008:-
LUAD	cis	rs2243480	1	rs9769882	ENSG00000232546.1	RP11-458F8.1	6.36	4.71e-10	2.33e-07	0.36	0.28	Diabetic kidney disease;	chr7:66177938	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs6966322	ENSG00000232546.1	RP11-458F8.1	6.36	4.71e-10	2.33e-07	0.36	0.28	Diabetic kidney disease;	chr7:66181767	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs4145008	ENSG00000232546.1	RP11-458F8.1	6.36	4.71e-10	2.33e-07	0.36	0.28	Diabetic kidney disease;	chr7:66182524	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs4718315	ENSG00000232546.1	RP11-458F8.1	6.36	4.71e-10	2.33e-07	0.36	0.28	Diabetic kidney disease;	chr7:66183554	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs4718316	ENSG00000232546.1	RP11-458F8.1	6.36	4.71e-10	2.33e-07	0.36	0.28	Diabetic kidney disease;	chr7:66183744	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs1873494	ENSG00000232546.1	RP11-458F8.1	6.36	4.71e-10	2.33e-07	0.36	0.28	Diabetic kidney disease;	chr7:66184912	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs6959002	ENSG00000232546.1	RP11-458F8.1	6.36	4.71e-10	2.33e-07	0.36	0.28	Diabetic kidney disease;	chr7:66185509	chr7:66848496~66858136:+
LUAD	cis	rs7829975	0.593	rs2921061	ENSG00000253893.2	FAM85B	-6.36	4.71e-10	2.33e-07	-0.35	-0.28	Mood instability;	chr8:8460105	chr8:8167819~8226614:-
LUAD	cis	rs3096299	1	rs3096299	ENSG00000274627.1	RP11-104N10.2	6.36	4.72e-10	2.33e-07	0.27	0.28	Multiple myeloma (IgH translocation);	chr16:89382255	chr16:89516797~89522217:+
LUAD	cis	rs2243480	1	rs34702770	ENSG00000226824.5	RP4-756H11.3	-6.36	4.73e-10	2.34e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65879836	chr7:66654538~66669855:+
LUAD	cis	rs8031584	0.918	rs61997138	ENSG00000260382.1	RP11-540B6.2	6.36	4.73e-10	2.34e-07	0.33	0.28	Huntington's disease progression;	chr15:30978573	chr15:30882267~30883231:-
LUAD	cis	rs8031584	0.918	rs61997140	ENSG00000260382.1	RP11-540B6.2	6.36	4.73e-10	2.34e-07	0.33	0.28	Huntington's disease progression;	chr15:30985109	chr15:30882267~30883231:-
LUAD	cis	rs950169	1	rs12915234	ENSG00000259728.4	LINC00933	6.36	4.74e-10	2.34e-07	0.43	0.28	Schizophrenia;	chr15:84089549	chr15:84570649~84580175:+
LUAD	cis	rs950169	1	rs34751999	ENSG00000259728.4	LINC00933	6.36	4.74e-10	2.34e-07	0.43	0.28	Schizophrenia;	chr15:84089667	chr15:84570649~84580175:+
LUAD	cis	rs875971	0.862	rs1167390	ENSG00000222364.1	RNU6-96P	6.36	4.75e-10	2.35e-07	0.32	0.28	Aortic root size;	chr7:66110906	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs35034167	ENSG00000222364.1	RNU6-96P	6.36	4.75e-10	2.35e-07	0.32	0.28	Aortic root size;	chr7:66115179	chr7:66395191~66395286:+
LUAD	cis	rs2911132	1	rs2911140	ENSG00000248734.2	CTD-2260A17.1	6.36	4.75e-10	2.35e-07	0.29	0.28	Urate levels (BMI interaction);	chr5:96844240	chr5:96784777~96785999:+
LUAD	cis	rs12439619	0.846	rs62012003	ENSG00000255769.6	GOLGA2P10	-6.36	4.76e-10	2.35e-07	-0.35	-0.28	Intelligence (multi-trait analysis);	chr15:82183236	chr15:82472993~82513950:-
LUAD	cis	rs9640161	0.789	rs11767409	ENSG00000261305.1	RP4-584D14.7	6.36	4.76e-10	2.35e-07	0.41	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150360954	chr7:150341771~150342607:+
LUAD	cis	rs1061377	1	rs34771104	ENSG00000249685.1	RP11-360F5.3	6.36	4.76e-10	2.35e-07	0.34	0.28	Uric acid levels;	chr4:39127432	chr4:39133913~39135608:+
LUAD	cis	rs10740039	0.883	rs7476720	ENSG00000254271.1	RP11-131N11.4	6.36	4.77e-10	2.35e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60650610	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs1975442	ENSG00000254271.1	RP11-131N11.4	6.36	4.77e-10	2.35e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60651161	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.804	rs7094818	ENSG00000254271.1	RP11-131N11.4	6.36	4.77e-10	2.35e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60652213	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs1470237	ENSG00000254271.1	RP11-131N11.4	6.36	4.77e-10	2.35e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60653381	chr10:60734342~60741828:+
LUAD	cis	rs7246657	0.943	rs10417844	ENSG00000276846.1	CTD-3220F14.3	6.36	4.77e-10	2.35e-07	0.38	0.28	Coronary artery calcification;	chr19:37346685	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs1373991	ENSG00000276846.1	CTD-3220F14.3	6.36	4.77e-10	2.35e-07	0.38	0.28	Coronary artery calcification;	chr19:37348009	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs10405407	ENSG00000276846.1	CTD-3220F14.3	6.36	4.77e-10	2.35e-07	0.38	0.28	Coronary artery calcification;	chr19:37348262	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs12709813	ENSG00000276846.1	CTD-3220F14.3	6.36	4.77e-10	2.35e-07	0.38	0.28	Coronary artery calcification;	chr19:37354081	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs13345116	ENSG00000276846.1	CTD-3220F14.3	6.36	4.77e-10	2.35e-07	0.38	0.28	Coronary artery calcification;	chr19:37356196	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.765	rs7247259	ENSG00000276846.1	CTD-3220F14.3	6.36	4.77e-10	2.35e-07	0.38	0.28	Coronary artery calcification;	chr19:37360188	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs3745765	ENSG00000276846.1	CTD-3220F14.3	6.36	4.77e-10	2.35e-07	0.38	0.28	Coronary artery calcification;	chr19:37363333	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs4803229	ENSG00000276846.1	CTD-3220F14.3	6.36	4.77e-10	2.35e-07	0.38	0.28	Coronary artery calcification;	chr19:37373780	chr19:37314868~37315620:-
LUAD	cis	rs9549367	0.756	rs9549702	ENSG00000269125.1	RP11-98F14.11	-6.36	4.77e-10	2.36e-07	-0.34	-0.28	Platelet distribution width;	chr13:113227630	chr13:113165002~113165183:-
LUAD	cis	rs853679	0.517	rs9393891	ENSG00000204709.4	LINC01556	6.36	4.77e-10	2.36e-07	0.39	0.28	Depression;	chr6:28111382	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9468286	ENSG00000204709.4	LINC01556	6.36	4.77e-10	2.36e-07	0.39	0.28	Depression;	chr6:28111650	chr6:28943877~28944537:+
LUAD	cis	rs9549367	0.789	rs2302754	ENSG00000269125.1	RP11-98F14.11	6.36	4.78e-10	2.36e-07	0.35	0.28	Platelet distribution width;	chr13:113244071	chr13:113165002~113165183:-
LUAD	cis	rs2911132	1	rs2911130	ENSG00000248734.2	CTD-2260A17.1	6.36	4.78e-10	2.36e-07	0.29	0.28	Urate levels (BMI interaction);	chr5:96847724	chr5:96784777~96785999:+
LUAD	cis	rs17301013	0.507	rs11806996	ENSG00000227373.4	RP11-160H22.5	6.36	4.78e-10	2.36e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174654784	chr1:174115300~174160004:-
LUAD	cis	rs7811142	1	rs11773661	ENSG00000242294.5	STAG3L5P	6.36	4.78e-10	2.36e-07	0.24	0.28	Platelet count;	chr7:100475446	chr7:100336079~100351900:+
LUAD	cis	rs7811142	0.943	rs66958101	ENSG00000242294.5	STAG3L5P	6.36	4.78e-10	2.36e-07	0.24	0.28	Platelet count;	chr7:100476397	chr7:100336079~100351900:+
LUAD	cis	rs55665837	0.961	rs11023237	ENSG00000251991.1	RNU7-49P	6.36	4.8e-10	2.37e-07	0.31	0.28	Vitamin D levels;	chr11:14478788	chr11:14478892~14478953:+
LUAD	cis	rs55665837	1	rs10466412	ENSG00000251991.1	RNU7-49P	6.36	4.8e-10	2.37e-07	0.31	0.28	Vitamin D levels;	chr11:14483643	chr11:14478892~14478953:+
LUAD	cis	rs17301013	0.507	rs3862941	ENSG00000227373.4	RP11-160H22.5	6.36	4.8e-10	2.37e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174689418	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.531	rs55688014	ENSG00000227373.4	RP11-160H22.5	6.36	4.8e-10	2.37e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174693321	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs55667039	ENSG00000227373.4	RP11-160H22.5	6.36	4.8e-10	2.37e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174698699	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs2861005	ENSG00000227373.4	RP11-160H22.5	6.36	4.8e-10	2.37e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174711832	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs17842156	ENSG00000227373.4	RP11-160H22.5	6.36	4.8e-10	2.37e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174715050	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs2146564	ENSG00000227373.4	RP11-160H22.5	6.36	4.8e-10	2.37e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174716214	chr1:174115300~174160004:-
LUAD	cis	rs2404602	0.647	rs11072636	ENSG00000259422.1	RP11-593F23.1	-6.36	4.8e-10	2.37e-07	-0.37	-0.28	Blood metabolite levels;	chr15:76893445	chr15:76174891~76181486:-
LUAD	cis	rs2665103	0.589	rs3858953	ENSG00000278603.1	RP13-608F4.5	6.36	4.81e-10	2.37e-07	0.32	0.28	Intelligence (multi-trait analysis);	chr15:82238049	chr15:82472203~82472426:+
LUAD	cis	rs1707322	0.716	rs6694889	ENSG00000234329.1	RP11-767N6.2	6.36	4.81e-10	2.37e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45636134	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.682	rs12041197	ENSG00000234329.1	RP11-767N6.2	6.36	4.81e-10	2.37e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638792	chr1:45651039~45651826:-
LUAD	cis	rs2243480	1	rs313831	ENSG00000273142.1	RP11-458F8.4	-6.36	4.81e-10	2.37e-07	-0.29	-0.28	Diabetic kidney disease;	chr7:66086239	chr7:66902857~66906297:+
LUAD	cis	rs72772090	0.539	rs11747896	ENSG00000248734.2	CTD-2260A17.1	6.36	4.81e-10	2.37e-07	0.42	0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777693	chr5:96784777~96785999:+
LUAD	cis	rs75422866	0.51	rs73105845	ENSG00000274902.1	RP1-197B17.4	6.36	4.82e-10	2.38e-07	0.64	0.28	Pneumonia;	chr12:47741824	chr12:47731908~47732351:+
LUAD	cis	rs7246657	0.882	rs10412043	ENSG00000276846.1	CTD-3220F14.3	6.36	4.82e-10	2.38e-07	0.39	0.28	Coronary artery calcification;	chr19:37335724	chr19:37314868~37315620:-
LUAD	cis	rs17301013	0.606	rs4233169	ENSG00000227373.4	RP11-160H22.5	6.36	4.82e-10	2.38e-07	0.39	0.28	Systemic lupus erythematosus;	chr1:174118986	chr1:174115300~174160004:-
LUAD	cis	rs1062177	0.855	rs6892117	ENSG00000213433.5	RPLP1P6	6.36	4.83e-10	2.38e-07	0.34	0.28	Preschool internalizing problems;	chr5:151885424	chr5:151765859~151766378:-
LUAD	cis	rs11676348	0.772	rs11676275	ENSG00000261338.2	RP11-378A13.1	-6.36	4.83e-10	2.38e-07	-0.29	-0.28	Ulcerative colitis;	chr2:218080085	chr2:218255319~218257366:+
LUAD	cis	rs2412819	0.571	rs4923965	ENSG00000205771.5	CATSPER2P1	6.36	4.83e-10	2.38e-07	0.43	0.28	Lung cancer;	chr15:43790232	chr15:43726918~43747094:-
LUAD	cis	rs2412819	0.571	rs4644832	ENSG00000205771.5	CATSPER2P1	6.36	4.83e-10	2.38e-07	0.43	0.28	Lung cancer;	chr15:43792507	chr15:43726918~43747094:-
LUAD	cis	rs2439831	1	rs7173487	ENSG00000205771.5	CATSPER2P1	-6.36	4.83e-10	2.38e-07	-0.53	-0.28	Lung cancer in ever smokers;	chr15:43458041	chr15:43726918~43747094:-
LUAD	cis	rs11168351	0.864	rs12228750	ENSG00000240399.1	RP1-228P16.1	-6.36	4.84e-10	2.39e-07	-0.27	-0.28	Bipolar disorder and schizophrenia;	chr12:48103214	chr12:48054813~48055591:-
LUAD	cis	rs11168351	0.864	rs10875743	ENSG00000240399.1	RP1-228P16.1	-6.36	4.84e-10	2.39e-07	-0.27	-0.28	Bipolar disorder and schizophrenia;	chr12:48104630	chr12:48054813~48055591:-
LUAD	cis	rs9318086	0.6	rs9507185	ENSG00000205861.10	C1QTNF9B-AS1	-6.36	4.84e-10	2.39e-07	-0.34	-0.28	Myopia (pathological);	chr13:23899595	chr13:23888889~23897263:+
LUAD	cis	rs765787	0.53	rs12906537	ENSG00000259520.4	CTD-2651B20.3	-6.36	4.84e-10	2.39e-07	-0.38	-0.28	Uric acid levels;	chr15:45227863	chr15:45251580~45279251:-
LUAD	cis	rs77204473	0.744	rs2239678	ENSG00000254851.1	RP11-109L13.1	6.36	4.84e-10	2.39e-07	0.68	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117199880	chr11:117135528~117138582:+
LUAD	cis	rs67311347	0.911	rs9863737	ENSG00000223797.4	ENTPD3-AS1	6.35	4.85e-10	2.39e-07	0.31	0.28	Renal cell carcinoma;	chr3:40398345	chr3:40313802~40453329:-
LUAD	cis	rs6142102	1	rs2378078	ENSG00000276073.1	RP5-1125A11.7	-6.35	4.85e-10	2.39e-07	-0.29	-0.28	Skin pigmentation;	chr20:34126922	chr20:33985617~33988989:-
LUAD	cis	rs35955747	1	rs35955747	ENSG00000236132.1	CTA-440B3.1	6.35	4.85e-10	2.39e-07	0.31	0.28	Neutrophil count;Sum basophil neutrophil counts;	chr22:31417072	chr22:31816379~31817491:-
LUAD	cis	rs875971	0.862	rs908915	ENSG00000222364.1	RNU6-96P	6.35	4.86e-10	2.39e-07	0.31	0.28	Aortic root size;	chr7:66149664	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs7809814	ENSG00000222364.1	RNU6-96P	6.35	4.86e-10	2.39e-07	0.31	0.28	Aortic root size;	chr7:66150410	chr7:66395191~66395286:+
LUAD	cis	rs150992	0.609	rs78254063	ENSG00000248489.1	CTD-2007H13.3	6.35	4.86e-10	2.4e-07	0.31	0.28	Body mass index;	chr5:98990803	chr5:98929171~98995013:+
LUAD	cis	rs1823913	1	rs11691372	ENSG00000230611.1	HMGB1P27	6.35	4.87e-10	2.4e-07	0.33	0.28	Obesity-related traits;	chr2:191249952	chr2:191174233~191174835:+
LUAD	cis	rs17301013	0.507	rs1793292	ENSG00000227373.4	RP11-160H22.5	-6.35	4.88e-10	2.4e-07	-0.4	-0.28	Systemic lupus erythematosus;	chr1:174778185	chr1:174115300~174160004:-
LUAD	cis	rs6991838	0.8	rs11786598	ENSG00000200714.1	Y_RNA	-6.35	4.88e-10	2.41e-07	-0.33	-0.28	Intelligence (multi-trait analysis);	chr8:65559944	chr8:65592731~65592820:+
LUAD	cis	rs950169	0.58	rs11635597	ENSG00000259728.4	LINC00933	6.35	4.88e-10	2.41e-07	0.41	0.28	Schizophrenia;	chr15:84622468	chr15:84570649~84580175:+
LUAD	cis	rs6904897	0.563	rs4896117	ENSG00000232876.1	CTA-212D2.2	6.35	4.89e-10	2.41e-07	0.33	0.28	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134908262	chr6:135055033~135060550:+
LUAD	cis	rs9549367	0.789	rs12584008	ENSG00000269125.1	RP11-98F14.11	-6.35	4.89e-10	2.41e-07	-0.35	-0.28	Platelet distribution width;	chr13:113226914	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.789	rs9549701	ENSG00000269125.1	RP11-98F14.11	-6.35	4.89e-10	2.41e-07	-0.35	-0.28	Platelet distribution width;	chr13:113227438	chr13:113165002~113165183:-
LUAD	cis	rs11096990	0.855	rs2711935	ENSG00000249207.1	RP11-360F5.1	6.35	4.9e-10	2.41e-07	0.32	0.28	Cognitive function;	chr4:39160837	chr4:39112677~39126818:-
LUAD	cis	rs66887589	0.72	rs11724758	ENSG00000248280.1	RP11-33B1.2	6.35	4.9e-10	2.42e-07	0.32	0.28	Diastolic blood pressure;	chr4:119318723	chr4:119440561~119450157:-
LUAD	cis	rs2243480	1	rs4718270	ENSG00000226824.5	RP4-756H11.3	-6.35	4.9e-10	2.42e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65737415	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.901	rs2900904	ENSG00000226824.5	RP4-756H11.3	-6.35	4.9e-10	2.42e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65739282	chr7:66654538~66669855:+
LUAD	cis	rs7688540	0.8	rs73793597	ENSG00000275426.1	CH17-262A2.1	6.35	4.91e-10	2.42e-07	0.34	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:262116	chr4:149738~150317:+
LUAD	cis	rs875971	0.545	rs75577046	ENSG00000237310.1	GS1-124K5.4	6.35	4.92e-10	2.42e-07	0.34	0.28	Aortic root size;	chr7:66493729	chr7:66493706~66495474:+
LUAD	cis	rs6142102	0.581	rs4911148	ENSG00000275784.1	RP5-1125A11.6	-6.35	4.93e-10	2.43e-07	-0.3	-0.28	Skin pigmentation;	chr20:34080438	chr20:33989480~33991818:-
LUAD	cis	rs5753618	0.561	rs1858821	ENSG00000236132.1	CTA-440B3.1	6.35	4.93e-10	2.43e-07	0.35	0.28	Colorectal cancer;	chr22:31280468	chr22:31816379~31817491:-
LUAD	cis	rs5753618	0.519	rs5997939	ENSG00000236132.1	CTA-440B3.1	6.35	4.93e-10	2.43e-07	0.35	0.28	Colorectal cancer;	chr22:31281144	chr22:31816379~31817491:-
LUAD	cis	rs5753618	0.561	rs2040533	ENSG00000236132.1	CTA-440B3.1	6.35	4.93e-10	2.43e-07	0.35	0.28	Colorectal cancer;	chr22:31283124	chr22:31816379~31817491:-
LUAD	cis	rs7688540	0.76	rs2883229	ENSG00000275426.1	CH17-262A2.1	6.35	4.93e-10	2.43e-07	0.34	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:237955	chr4:149738~150317:+
LUAD	cis	rs7246657	1	rs6508710	ENSG00000276846.1	CTD-3220F14.3	6.35	4.93e-10	2.43e-07	0.38	0.28	Coronary artery calcification;	chr19:37258984	chr19:37314868~37315620:-
LUAD	cis	rs17301013	0.507	rs1793298	ENSG00000227373.4	RP11-160H22.5	-6.35	4.93e-10	2.43e-07	-0.4	-0.28	Systemic lupus erythematosus;	chr1:174784601	chr1:174115300~174160004:-
LUAD	cis	rs1707322	0.721	rs4660314	ENSG00000234329.1	RP11-767N6.2	6.35	4.93e-10	2.43e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764213	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs12069121	ENSG00000234329.1	RP11-767N6.2	6.35	4.93e-10	2.43e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45766312	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.686	rs61784833	ENSG00000234329.1	RP11-767N6.2	6.35	4.93e-10	2.43e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45768100	chr1:45651039~45651826:-
LUAD	cis	rs2243480	1	rs35825738	ENSG00000232546.1	RP11-458F8.1	-6.35	4.94e-10	2.43e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:65853040	chr7:66848496~66858136:+
LUAD	cis	rs12439619	0.846	rs28697264	ENSG00000255769.6	GOLGA2P10	-6.35	4.94e-10	2.43e-07	-0.35	-0.28	Intelligence (multi-trait analysis);	chr15:82265559	chr15:82472993~82513950:-
LUAD	cis	rs8062405	0.558	rs151228	ENSG00000259982.1	CDC37P1	6.35	4.94e-10	2.43e-07	0.33	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28551705	chr16:28700294~28701540:-
LUAD	cis	rs62025270	0.547	rs338540	ENSG00000202081.1	RNU6-1280P	6.35	4.95e-10	2.44e-07	0.34	0.28	Idiopathic pulmonary fibrosis;	chr15:85652500	chr15:85651522~85651628:-
LUAD	cis	rs4141404	0.923	rs2413046	ENSG00000236132.1	CTA-440B3.1	6.35	4.95e-10	2.44e-07	0.35	0.28	Paclitaxel-induced neuropathy;	chr22:31269923	chr22:31816379~31817491:-
LUAD	cis	rs5753618	0.561	rs2413047	ENSG00000236132.1	CTA-440B3.1	6.35	4.95e-10	2.44e-07	0.35	0.28	Colorectal cancer;	chr22:31270040	chr22:31816379~31817491:-
LUAD	cis	rs34526934	0.608	rs7591820	ENSG00000226363.3	HAGLROS	6.35	4.95e-10	2.44e-07	0.38	0.28	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176163416	chr2:176177717~176179008:+
LUAD	cis	rs34526934	0.608	rs7606110	ENSG00000226363.3	HAGLROS	6.35	4.95e-10	2.44e-07	0.38	0.28	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176163823	chr2:176177717~176179008:+
LUAD	cis	rs17301013	0.507	rs6689327	ENSG00000227373.4	RP11-160H22.5	6.35	4.96e-10	2.44e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174464274	chr1:174115300~174160004:-
LUAD	cis	rs3096299	0.967	rs753852	ENSG00000274627.1	RP11-104N10.2	6.35	4.96e-10	2.44e-07	0.27	0.28	Multiple myeloma (IgH translocation);	chr16:89380011	chr16:89516797~89522217:+
LUAD	cis	rs3096299	0.967	rs753853	ENSG00000274627.1	RP11-104N10.2	6.35	4.96e-10	2.44e-07	0.27	0.28	Multiple myeloma (IgH translocation);	chr16:89380117	chr16:89516797~89522217:+
LUAD	cis	rs2117029	0.586	rs10783308	ENSG00000258017.1	RP11-386G11.10	-6.35	4.97e-10	2.45e-07	-0.34	-0.28	Intelligence (multi-trait analysis);	chr12:49137675	chr12:49127782~49147869:+
LUAD	cis	rs113835537	0.529	rs11227500	ENSG00000255517.5	CTD-3074O7.5	-6.35	4.98e-10	2.45e-07	-0.33	-0.28	Airway imaging phenotypes;	chr11:66505762	chr11:66473490~66480233:-
LUAD	cis	rs465969	1	rs17510761	ENSG00000255389.1	C6orf3	-6.35	4.98e-10	2.45e-07	-0.61	-0.28	Psoriasis;	chr6:111387380	chr6:111599875~111602295:+
LUAD	cis	rs465969	0.655	rs13203984	ENSG00000255389.1	C6orf3	-6.35	4.98e-10	2.45e-07	-0.61	-0.28	Psoriasis;	chr6:111388538	chr6:111599875~111602295:+
LUAD	cis	rs433852	0.898	rs376524	ENSG00000232871.7	SEC1P	-6.35	4.98e-10	2.45e-07	-0.36	-0.28	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48613181	chr19:48638071~48682245:+
LUAD	cis	rs875971	0.545	rs1909508	ENSG00000237310.1	GS1-124K5.4	6.35	4.98e-10	2.45e-07	0.34	0.28	Aortic root size;	chr7:66301366	chr7:66493706~66495474:+
LUAD	cis	rs11098499	0.754	rs1814813	ENSG00000248280.1	RP11-33B1.2	-6.35	5e-10	2.46e-07	-0.32	-0.28	Corneal astigmatism;	chr4:119337052	chr4:119440561~119450157:-
LUAD	cis	rs7615952	0.611	rs79405914	ENSG00000171084.14	FAM86JP	6.35	5e-10	2.46e-07	0.57	0.28	Blood pressure (smoking interaction);	chr3:126004780	chr3:125916620~125930024:+
LUAD	cis	rs7646881	0.767	rs73015629	ENSG00000240207.5	RP11-379F4.4	-6.35	5e-10	2.46e-07	-0.36	-0.28	Tetralogy of Fallot;	chr3:158716051	chr3:158732263~158784070:+
LUAD	cis	rs17301013	0.507	rs72715204	ENSG00000227373.4	RP11-160H22.5	6.35	5e-10	2.46e-07	0.42	0.28	Systemic lupus erythematosus;	chr1:174492787	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs2901820	ENSG00000227373.4	RP11-160H22.5	6.35	5e-10	2.46e-07	0.42	0.28	Systemic lupus erythematosus;	chr1:174505201	chr1:174115300~174160004:-
LUAD	cis	rs11096990	0.855	rs1820939	ENSG00000249207.1	RP11-360F5.1	6.35	5.01e-10	2.46e-07	0.33	0.28	Cognitive function;	chr4:39170115	chr4:39112677~39126818:-
LUAD	cis	rs950169	1	rs11638297	ENSG00000259728.4	LINC00933	6.35	5.01e-10	2.47e-07	0.42	0.28	Schizophrenia;	chr15:84113665	chr15:84570649~84580175:+
LUAD	cis	rs2243480	1	rs59794892	ENSG00000232546.1	RP11-458F8.1	-6.35	5.02e-10	2.47e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:65950886	chr7:66848496~66858136:+
LUAD	cis	rs2337406	0.587	rs10150642	ENSG00000254174.1	IGHV1-12	-6.35	5.02e-10	2.47e-07	-0.24	-0.28	Alzheimer's disease (late onset);	chr14:106647269	chr14:106122420~106122709:-
LUAD	cis	rs1823913	0.599	rs13001899	ENSG00000280083.1	RP11-317J9.1	-6.35	5.04e-10	2.48e-07	-0.33	-0.28	Obesity-related traits;	chr2:191285442	chr2:191154118~191156070:-
LUAD	cis	rs270601	0.955	rs273911	ENSG00000233006.5	AC034220.3	6.35	5.04e-10	2.48e-07	0.28	0.28	Acylcarnitine levels;	chr5:132325833	chr5:132311285~132369916:-
LUAD	cis	rs6860806	0.507	rs272891	ENSG00000233006.5	AC034220.3	6.35	5.04e-10	2.48e-07	0.28	0.28	Breast cancer;	chr5:132328701	chr5:132311285~132369916:-
LUAD	cis	rs8100891	0.537	rs28672356	ENSG00000267213.4	AC007773.2	-6.35	5.04e-10	2.48e-07	-0.44	-0.28	Neuroticism;	chr19:32416937	chr19:32390050~32405560:-
LUAD	cis	rs67311347	0.956	rs12633446	ENSG00000223797.4	ENTPD3-AS1	-6.35	5.04e-10	2.48e-07	-0.29	-0.28	Renal cell carcinoma;	chr3:40464170	chr3:40313802~40453329:-
LUAD	cis	rs494459	0.536	rs10790267	ENSG00000255239.1	AP002954.6	6.35	5.05e-10	2.48e-07	0.33	0.28	Height;	chr11:118856460	chr11:118688039~118690600:-
LUAD	cis	rs494459	0.536	rs11217067	ENSG00000255239.1	AP002954.6	6.35	5.05e-10	2.48e-07	0.33	0.28	Height;	chr11:118856623	chr11:118688039~118690600:-
LUAD	cis	rs2510897	0.675	rs4936442	ENSG00000255239.1	AP002954.6	6.35	5.05e-10	2.48e-07	0.33	0.28	Height;	chr11:118857611	chr11:118688039~118690600:-
LUAD	cis	rs2273788	0.837	rs1053968	ENSG00000204173.9	LRRC37A5P	6.35	5.05e-10	2.48e-07	0.35	0.28	Monocyte count;	chr9:111590312	chr9:111602831~111631289:-
LUAD	cis	rs11168854	0.719	rs11168890	ENSG00000258017.1	RP11-386G11.10	-6.35	5.06e-10	2.49e-07	-0.34	-0.28	Body mass index;	chr12:49150130	chr12:49127782~49147869:+
LUAD	cis	rs10129255	0.5	rs8011115	ENSG00000211970.3	IGHV4-61	-6.35	5.06e-10	2.49e-07	-0.2	-0.28	Kawasaki disease;	chr14:106786292	chr14:106639119~106639657:-
LUAD	cis	rs4591358	0.689	rs17178460	ENSG00000223466.1	AC064834.2	-6.35	5.06e-10	2.49e-07	-0.43	-0.28	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195555365	chr2:195533035~195538681:+
LUAD	cis	rs2243480	0.908	rs2460431	ENSG00000232546.1	RP11-458F8.1	6.35	5.06e-10	2.49e-07	0.37	0.28	Diabetic kidney disease;	chr7:66157859	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs4718309	ENSG00000232546.1	RP11-458F8.1	6.35	5.06e-10	2.49e-07	0.37	0.28	Diabetic kidney disease;	chr7:66162777	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs6460274	ENSG00000232546.1	RP11-458F8.1	6.35	5.06e-10	2.49e-07	0.37	0.28	Diabetic kidney disease;	chr7:66163497	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs7787230	ENSG00000232546.1	RP11-458F8.1	6.35	5.06e-10	2.49e-07	0.37	0.28	Diabetic kidney disease;	chr7:66164112	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs2465120	ENSG00000232546.1	RP11-458F8.1	-6.35	5.06e-10	2.49e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66155987	chr7:66848496~66858136:+
LUAD	cis	rs237743	0.786	rs34078534	ENSG00000222365.1	SNORD12B	-6.35	5.06e-10	2.49e-07	-0.33	-0.28	Height;	chr20:49208367	chr20:49280319~49280409:+
LUAD	cis	rs1823913	0.599	rs67781530	ENSG00000227542.1	AC092614.2	6.35	5.07e-10	2.49e-07	0.34	0.28	Obesity-related traits;	chr2:191295608	chr2:191229165~191246172:-
LUAD	cis	rs881375	0.715	rs7858209	ENSG00000226752.6	PSMD5-AS1	-6.35	5.07e-10	2.49e-07	-0.29	-0.28	Rheumatoid arthritis;	chr9:120883482	chr9:120824828~120854385:+
LUAD	cis	rs881375	0.715	rs10760119	ENSG00000226752.6	PSMD5-AS1	-6.35	5.07e-10	2.49e-07	-0.29	-0.28	Rheumatoid arthritis;	chr9:120883782	chr9:120824828~120854385:+
LUAD	cis	rs9640161	0.783	rs1132261	ENSG00000261305.1	RP4-584D14.7	6.35	5.08e-10	2.5e-07	0.41	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150362898	chr7:150341771~150342607:+
LUAD	cis	rs2243480	0.901	rs2949697	ENSG00000226824.5	RP4-756H11.3	-6.35	5.08e-10	2.5e-07	-0.52	-0.28	Diabetic kidney disease;	chr7:65999249	chr7:66654538~66669855:+
LUAD	cis	rs433852	1	rs433852	ENSG00000232871.7	SEC1P	-6.35	5.08e-10	2.5e-07	-0.36	-0.28	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48613847	chr19:48638071~48682245:+
LUAD	cis	rs875971	0.545	rs73152714	ENSG00000237310.1	GS1-124K5.4	6.35	5.08e-10	2.5e-07	0.34	0.28	Aortic root size;	chr7:66534641	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs4718364	ENSG00000237310.1	GS1-124K5.4	6.35	5.08e-10	2.5e-07	0.34	0.28	Aortic root size;	chr7:66536353	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs6961853	ENSG00000237310.1	GS1-124K5.4	6.35	5.08e-10	2.5e-07	0.34	0.28	Aortic root size;	chr7:66537035	chr7:66493706~66495474:+
LUAD	cis	rs7246657	0.653	rs10406612	ENSG00000276846.1	CTD-3220F14.3	6.35	5.09e-10	2.5e-07	0.45	0.28	Coronary artery calcification;	chr19:37225709	chr19:37314868~37315620:-
LUAD	cis	rs7044106	0.791	rs4836831	ENSG00000238181.2	AHCYP2	-6.35	5.09e-10	2.5e-07	-0.37	-0.28	Hip circumference adjusted for BMI;	chr9:120734292	chr9:120720673~120721972:+
LUAD	cis	rs1499614	1	rs1882655	ENSG00000232546.1	RP11-458F8.1	6.35	5.09e-10	2.5e-07	0.37	0.28	Gout;	chr7:66682070	chr7:66848496~66858136:+
LUAD	cis	rs1499614	0.831	rs3800822	ENSG00000232546.1	RP11-458F8.1	6.35	5.09e-10	2.5e-07	0.37	0.28	Gout;	chr7:66682162	chr7:66848496~66858136:+
LUAD	cis	rs1499614	1	rs1638731	ENSG00000232546.1	RP11-458F8.1	-6.35	5.09e-10	2.5e-07	-0.37	-0.28	Gout;	chr7:66679692	chr7:66848496~66858136:+
LUAD	cis	rs4713118	0.911	rs9461406	ENSG00000219392.1	RP1-265C24.5	6.35	5.1e-10	2.5e-07	0.37	0.28	Parkinson's disease;	chr6:27751985	chr6:28115628~28116551:+
LUAD	cis	rs2765539	0.851	rs1409159	ENSG00000226172.2	RP4-712E4.1	-6.35	5.1e-10	2.5e-07	-0.35	-0.28	Waist-hip ratio;	chr1:118995810	chr1:119000344~119001392:-
LUAD	cis	rs1707322	0.721	rs11211178	ENSG00000234329.1	RP11-767N6.2	6.35	5.1e-10	2.51e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45761894	chr1:45651039~45651826:-
LUAD	cis	rs75920871	0.588	rs7112111	ENSG00000254851.1	RP11-109L13.1	6.35	5.11e-10	2.51e-07	0.4	0.28	Subjective well-being;	chr11:117110142	chr11:117135528~117138582:+
LUAD	cis	rs155076	1	rs261430	ENSG00000233325.3	MIPEPP3	6.35	5.11e-10	2.51e-07	0.44	0.28	White matter hyperintensity burden;	chr13:21291103	chr13:21298139~21306373:+
LUAD	cis	rs2919917	0.688	rs6993386	ENSG00000254352.1	RP11-578O24.2	-6.35	5.11e-10	2.51e-07	-0.31	-0.28	Lymphocyte counts;	chr8:78741910	chr8:78723796~78724136:-
LUAD	cis	rs9640161	0.783	rs35435439	ENSG00000261305.1	RP4-584D14.7	6.35	5.12e-10	2.51e-07	0.41	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150366445	chr7:150341771~150342607:+
LUAD	cis	rs8072100	0.744	rs34537623	ENSG00000228782.6	CTD-2026D20.3	6.35	5.12e-10	2.51e-07	0.3	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47452837	chr17:47450568~47492492:-
LUAD	cis	rs2115536	0.692	rs6495451	ENSG00000278600.1	RP11-81A1.6	-6.35	5.13e-10	2.52e-07	-0.23	-0.28	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79871711	chr15:79920195~79922455:-
LUAD	cis	rs67311347	0.869	rs6790495	ENSG00000223797.4	ENTPD3-AS1	6.35	5.13e-10	2.52e-07	0.29	0.28	Renal cell carcinoma;	chr3:40325279	chr3:40313802~40453329:-
LUAD	cis	rs6504622	0.875	rs28553405	ENSG00000262879.4	RP11-156P1.3	6.35	5.14e-10	2.52e-07	0.33	0.28	Orofacial clefts;	chr17:46968529	chr17:46984045~47100323:-
LUAD	cis	rs2404602	0.684	rs3910756	ENSG00000259422.1	RP11-593F23.1	-6.35	5.14e-10	2.52e-07	-0.4	-0.28	Blood metabolite levels;	chr15:76653028	chr15:76174891~76181486:-
LUAD	cis	rs875971	0.545	rs2707851	ENSG00000237310.1	GS1-124K5.4	-6.35	5.14e-10	2.52e-07	-0.34	-0.28	Aortic root size;	chr7:66624178	chr7:66493706~66495474:+
LUAD	cis	rs11676348	0.772	rs12694427	ENSG00000261338.2	RP11-378A13.1	-6.34	5.16e-10	2.53e-07	-0.28	-0.28	Ulcerative colitis;	chr2:218080322	chr2:218255319~218257366:+
LUAD	cis	rs6991838	0.67	rs13275168	ENSG00000200714.1	Y_RNA	6.34	5.16e-10	2.53e-07	0.32	0.28	Intelligence (multi-trait analysis);	chr8:65685107	chr8:65592731~65592820:+
LUAD	cis	rs9549367	0.756	rs2316463	ENSG00000269125.1	RP11-98F14.11	-6.34	5.17e-10	2.54e-07	-0.35	-0.28	Platelet distribution width;	chr13:113247092	chr13:113165002~113165183:-
LUAD	cis	rs2243480	0.803	rs35480979	ENSG00000226824.5	RP4-756H11.3	-6.34	5.17e-10	2.54e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65892097	chr7:66654538~66669855:+
LUAD	cis	rs6504622	0.875	rs4968250	ENSG00000262879.4	RP11-156P1.3	6.34	5.17e-10	2.54e-07	0.33	0.28	Orofacial clefts;	chr17:46967985	chr17:46984045~47100323:-
LUAD	cis	rs6558530	0.932	rs6558531	ENSG00000253982.1	CTD-2336O2.1	6.34	5.18e-10	2.54e-07	0.34	0.28	Systolic blood pressure;	chr8:1759400	chr8:1761990~1764502:-
LUAD	cis	rs155076	1	rs2478824	ENSG00000233325.3	MIPEPP3	6.34	5.18e-10	2.54e-07	0.43	0.28	White matter hyperintensity burden;	chr13:21270005	chr13:21298139~21306373:+
LUAD	cis	rs155076	0.938	rs9509630	ENSG00000233325.3	MIPEPP3	6.34	5.18e-10	2.54e-07	0.43	0.28	White matter hyperintensity burden;	chr13:21270175	chr13:21298139~21306373:+
LUAD	cis	rs155076	0.938	rs9509633	ENSG00000233325.3	MIPEPP3	6.34	5.18e-10	2.54e-07	0.43	0.28	White matter hyperintensity burden;	chr13:21270343	chr13:21298139~21306373:+
LUAD	cis	rs155076	1	rs598754	ENSG00000233325.3	MIPEPP3	6.34	5.18e-10	2.54e-07	0.43	0.28	White matter hyperintensity burden;	chr13:21270871	chr13:21298139~21306373:+
LUAD	cis	rs155076	0.938	rs485361	ENSG00000233325.3	MIPEPP3	6.34	5.18e-10	2.54e-07	0.43	0.28	White matter hyperintensity burden;	chr13:21271687	chr13:21298139~21306373:+
LUAD	cis	rs155076	1	rs484365	ENSG00000233325.3	MIPEPP3	6.34	5.18e-10	2.54e-07	0.43	0.28	White matter hyperintensity burden;	chr13:21271805	chr13:21298139~21306373:+
LUAD	cis	rs155076	0.702	rs482731	ENSG00000233325.3	MIPEPP3	6.34	5.18e-10	2.54e-07	0.43	0.28	White matter hyperintensity burden;	chr13:21271936	chr13:21298139~21306373:+
LUAD	cis	rs155076	1	rs564685	ENSG00000233325.3	MIPEPP3	6.34	5.18e-10	2.54e-07	0.43	0.28	White matter hyperintensity burden;	chr13:21272740	chr13:21298139~21306373:+
LUAD	cis	rs155076	0.938	rs536209	ENSG00000233325.3	MIPEPP3	6.34	5.18e-10	2.54e-07	0.43	0.28	White matter hyperintensity burden;	chr13:21273575	chr13:21298139~21306373:+
LUAD	cis	rs10759883	0.627	rs7871709	ENSG00000175611.10	LINC00476	-6.34	5.19e-10	2.54e-07	-0.32	-0.28	Nicotine dependence;	chr9:95798328	chr9:95759231~95875977:-
LUAD	cis	rs5753618	0.561	rs2073857	ENSG00000236132.1	CTA-440B3.1	6.34	5.19e-10	2.55e-07	0.35	0.28	Colorectal cancer;	chr22:31262295	chr22:31816379~31817491:-
LUAD	cis	rs8062405	0.754	rs28410083	ENSG00000259982.1	CDC37P1	-6.34	5.2e-10	2.55e-07	-0.34	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620039	chr16:28700294~28701540:-
LUAD	cis	rs8062405	0.789	rs1968751	ENSG00000259982.1	CDC37P1	-6.34	5.2e-10	2.55e-07	-0.34	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620438	chr16:28700294~28701540:-
LUAD	cis	rs67311347	1	rs11129876	ENSG00000223797.4	ENTPD3-AS1	-6.34	5.2e-10	2.55e-07	-0.29	-0.28	Renal cell carcinoma;	chr3:40360145	chr3:40313802~40453329:-
LUAD	cis	rs7923609	0.756	rs6479908	ENSG00000232075.1	MRPL35P2	6.34	5.2e-10	2.55e-07	0.34	0.28	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63573888	chr10:63634317~63634827:-
LUAD	cis	rs3762637	1	rs9833415	ENSG00000272758.4	RP11-299J3.8	-6.34	5.21e-10	2.56e-07	-0.43	-0.28	LDL cholesterol levels;	chr3:122440993	chr3:122416207~122443180:+
LUAD	cis	rs3762637	1	rs9882100	ENSG00000272758.4	RP11-299J3.8	-6.34	5.21e-10	2.56e-07	-0.43	-0.28	LDL cholesterol levels;	chr3:122451061	chr3:122416207~122443180:+
LUAD	cis	rs3762637	1	rs9968189	ENSG00000272758.4	RP11-299J3.8	-6.34	5.21e-10	2.56e-07	-0.43	-0.28	LDL cholesterol levels;	chr3:122456289	chr3:122416207~122443180:+
LUAD	cis	rs3762637	0.941	rs60222267	ENSG00000272758.4	RP11-299J3.8	-6.34	5.21e-10	2.56e-07	-0.43	-0.28	LDL cholesterol levels;	chr3:122460785	chr3:122416207~122443180:+
LUAD	cis	rs3762637	0.882	rs56074178	ENSG00000272758.4	RP11-299J3.8	-6.34	5.21e-10	2.56e-07	-0.43	-0.28	LDL cholesterol levels;	chr3:122461164	chr3:122416207~122443180:+
LUAD	cis	rs2243480	1	rs1964692	ENSG00000226824.5	RP4-756H11.3	-6.34	5.22e-10	2.56e-07	-0.52	-0.28	Diabetic kidney disease;	chr7:65989196	chr7:66654538~66669855:+
LUAD	cis	rs950169	0.92	rs17300048	ENSG00000259728.4	LINC00933	6.34	5.22e-10	2.56e-07	0.42	0.28	Schizophrenia;	chr15:84080725	chr15:84570649~84580175:+
LUAD	cis	rs858239	0.896	rs1637192	ENSG00000226816.2	AC005082.12	6.34	5.23e-10	2.56e-07	0.36	0.28	Cerebrospinal fluid biomarker levels;	chr7:23220895	chr7:23206013~23208045:+
LUAD	cis	rs2734839	0.537	rs6277	ENSG00000270179.1	RP11-159N11.4	-6.34	5.23e-10	2.56e-07	-0.28	-0.28	Information processing speed;	chr11:113412737	chr11:113368478~113369117:+
LUAD	cis	rs12439619	0.846	rs62012059	ENSG00000255769.6	GOLGA2P10	-6.34	5.24e-10	2.57e-07	-0.36	-0.28	Intelligence (multi-trait analysis);	chr15:82251669	chr15:82472993~82513950:-
LUAD	cis	rs7684253	0.548	rs13108002	ENSG00000269949.1	RP11-738E22.3	-6.34	5.24e-10	2.57e-07	-0.36	-0.28	Migraine;	chr4:56852087	chr4:56960927~56961373:-
LUAD	cis	rs67311347	1	rs7617989	ENSG00000223797.4	ENTPD3-AS1	-6.34	5.24e-10	2.57e-07	-0.29	-0.28	Renal cell carcinoma;	chr3:40470972	chr3:40313802~40453329:-
LUAD	cis	rs11098499	0.754	rs7672372	ENSG00000248280.1	RP11-33B1.2	6.34	5.24e-10	2.57e-07	0.34	0.28	Corneal astigmatism;	chr4:119327251	chr4:119440561~119450157:-
LUAD	cis	rs8031584	0.918	rs34693097	ENSG00000260382.1	RP11-540B6.2	6.34	5.25e-10	2.57e-07	0.33	0.28	Huntington's disease progression;	chr15:30961781	chr15:30882267~30883231:-
LUAD	cis	rs8031584	0.918	rs35784593	ENSG00000260382.1	RP11-540B6.2	6.34	5.25e-10	2.57e-07	0.33	0.28	Huntington's disease progression;	chr15:30962385	chr15:30882267~30883231:-
LUAD	cis	rs1823913	0.637	rs13382985	ENSG00000227542.1	AC092614.2	-6.34	5.25e-10	2.57e-07	-0.34	-0.28	Obesity-related traits;	chr2:191306335	chr2:191229165~191246172:-
LUAD	cis	rs6142102	0.602	rs4911145	ENSG00000275784.1	RP5-1125A11.6	6.34	5.25e-10	2.57e-07	0.29	0.28	Skin pigmentation;	chr20:34027417	chr20:33989480~33991818:-
LUAD	cis	rs1499614	1	rs2659913	ENSG00000232546.1	RP11-458F8.1	-6.34	5.25e-10	2.57e-07	-0.37	-0.28	Gout;	chr7:66692349	chr7:66848496~66858136:+
LUAD	cis	rs1499614	1	rs2659911	ENSG00000232546.1	RP11-458F8.1	-6.34	5.25e-10	2.57e-07	-0.37	-0.28	Gout;	chr7:66693433	chr7:66848496~66858136:+
LUAD	cis	rs1499614	1	rs2707838	ENSG00000232546.1	RP11-458F8.1	-6.34	5.25e-10	2.57e-07	-0.37	-0.28	Gout;	chr7:66694214	chr7:66848496~66858136:+
LUAD	cis	rs1499614	1	rs60326618	ENSG00000232546.1	RP11-458F8.1	-6.34	5.25e-10	2.57e-07	-0.37	-0.28	Gout;	chr7:66701371	chr7:66848496~66858136:+
LUAD	cis	rs1499614	1	rs2707830	ENSG00000232546.1	RP11-458F8.1	-6.34	5.25e-10	2.57e-07	-0.37	-0.28	Gout;	chr7:66702658	chr7:66848496~66858136:+
LUAD	cis	rs1499614	1	rs2707828	ENSG00000232546.1	RP11-458F8.1	-6.34	5.25e-10	2.57e-07	-0.37	-0.28	Gout;	chr7:66706390	chr7:66848496~66858136:+
LUAD	cis	rs1499614	0.803	rs1922723	ENSG00000232546.1	RP11-458F8.1	-6.34	5.25e-10	2.57e-07	-0.37	-0.28	Gout;	chr7:66710076	chr7:66848496~66858136:+
LUAD	cis	rs1499614	1	rs2659903	ENSG00000232546.1	RP11-458F8.1	-6.34	5.25e-10	2.57e-07	-0.37	-0.28	Gout;	chr7:66715944	chr7:66848496~66858136:+
LUAD	cis	rs1499614	1	rs2141924	ENSG00000232546.1	RP11-458F8.1	-6.34	5.25e-10	2.57e-07	-0.37	-0.28	Gout;	chr7:66721259	chr7:66848496~66858136:+
LUAD	cis	rs1823913	0.637	rs4853578	ENSG00000280083.1	RP11-317J9.1	-6.34	5.26e-10	2.58e-07	-0.33	-0.28	Obesity-related traits;	chr2:191297215	chr2:191154118~191156070:-
LUAD	cis	rs2842992	1	rs2758322	ENSG00000237927.1	RP3-393E18.2	-6.34	5.26e-10	2.58e-07	-0.39	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159654156	chr6:159586955~159589169:-
LUAD	cis	rs2404602	0.647	rs907594	ENSG00000259422.1	RP11-593F23.1	-6.34	5.27e-10	2.58e-07	-0.37	-0.28	Blood metabolite levels;	chr15:76905404	chr15:76174891~76181486:-
LUAD	cis	rs67311347	1	rs7642906	ENSG00000223797.4	ENTPD3-AS1	-6.34	5.27e-10	2.58e-07	-0.29	-0.28	Renal cell carcinoma;	chr3:40451142	chr3:40313802~40453329:-
LUAD	cis	rs11098499	0.562	rs2389879	ENSG00000248280.1	RP11-33B1.2	-6.34	5.28e-10	2.58e-07	-0.32	-0.28	Corneal astigmatism;	chr4:119636529	chr4:119440561~119450157:-
LUAD	cis	rs2243480	1	rs10807701	ENSG00000226824.5	RP4-756H11.3	6.34	5.28e-10	2.58e-07	0.52	0.28	Diabetic kidney disease;	chr7:66259699	chr7:66654538~66669855:+
LUAD	cis	rs1799949	1	rs8176083	ENSG00000267681.1	CTD-3199J23.6	-6.34	5.29e-10	2.59e-07	-0.33	-0.28	Menopause (age at onset);	chr17:43123134	chr17:43144956~43145255:+
LUAD	cis	rs1707322	0.506	rs2991983	ENSG00000234329.1	RP11-767N6.2	-6.34	5.29e-10	2.59e-07	-0.3	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613719	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.717	rs3014249	ENSG00000234329.1	RP11-767N6.2	-6.34	5.29e-10	2.59e-07	-0.3	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613821	chr1:45651039~45651826:-
LUAD	cis	rs1914816	1	rs2255408	ENSG00000196274.5	Metazoa_SRP	-6.34	5.29e-10	2.59e-07	-0.31	-0.28	Response to tocilizumab in rheumatoid arthritis;	chr15:76210954	chr15:76230048~76230390:-
LUAD	cis	rs77204473	1	rs11216185	ENSG00000254851.1	RP11-109L13.1	6.34	5.29e-10	2.59e-07	0.68	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116912258	chr11:117135528~117138582:+
LUAD	cis	rs7017914	0.967	rs2639903	ENSG00000223220.1	Y_RNA	6.34	5.29e-10	2.59e-07	0.31	0.28	Bone mineral density;	chr8:71005209	chr8:70780914~70781008:-
LUAD	cis	rs10214930	1	rs2074580	ENSG00000235574.1	AC073150.6	6.34	5.3e-10	2.59e-07	0.39	0.28	Hypospadias;	chr7:27794234	chr7:27491682~27492765:-
LUAD	cis	rs10740039	0.883	rs1837946	ENSG00000254271.1	RP11-131N11.4	6.34	5.32e-10	2.6e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60633676	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs7089720	ENSG00000254271.1	RP11-131N11.4	6.34	5.32e-10	2.6e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60634063	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.804	rs7093882	ENSG00000254271.1	RP11-131N11.4	6.34	5.32e-10	2.6e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60634863	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs2119912	ENSG00000254271.1	RP11-131N11.4	6.34	5.32e-10	2.6e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60639754	chr10:60734342~60741828:+
LUAD	cis	rs4718428	0.705	rs68168107	ENSG00000273142.1	RP11-458F8.4	-6.34	5.33e-10	2.61e-07	-0.21	-0.28	Corneal structure;	chr7:66790251	chr7:66902857~66906297:+
LUAD	cis	rs12699921	0.607	rs35819944	ENSG00000279048.1	RP11-511H23.2	6.34	5.33e-10	2.61e-07	0.23	0.28	Fibrinogen levels;	chr7:17928168	chr7:17940503~17942922:+
LUAD	cis	rs12908161	1	rs17600551	ENSG00000259728.4	LINC00933	6.34	5.33e-10	2.61e-07	0.4	0.28	Schizophrenia;	chr15:84776027	chr15:84570649~84580175:+
LUAD	cis	rs12908161	1	rs62019469	ENSG00000259728.4	LINC00933	6.34	5.33e-10	2.61e-07	0.4	0.28	Schizophrenia;	chr15:84777989	chr15:84570649~84580175:+
LUAD	cis	rs6860806	0.507	rs273917	ENSG00000233006.5	AC034220.3	6.34	5.33e-10	2.61e-07	0.28	0.28	Breast cancer;	chr5:132323925	chr5:132311285~132369916:-
LUAD	cis	rs9549367	0.789	rs3794422	ENSG00000269125.1	RP11-98F14.11	-6.34	5.34e-10	2.61e-07	-0.35	-0.28	Platelet distribution width;	chr13:113239415	chr13:113165002~113165183:-
LUAD	cis	rs10740039	0.883	rs1442546	ENSG00000254271.1	RP11-131N11.4	6.34	5.34e-10	2.61e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60650240	chr10:60734342~60741828:+
LUAD	cis	rs2439831	0.85	rs3742982	ENSG00000205771.5	CATSPER2P1	-6.34	5.34e-10	2.61e-07	-0.56	-0.28	Lung cancer in ever smokers;	chr15:43884483	chr15:43726918~43747094:-
LUAD	cis	rs2243480	1	rs1723269	ENSG00000232546.1	RP11-458F8.1	-6.34	5.34e-10	2.61e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66007799	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs316327	ENSG00000232546.1	RP11-458F8.1	6.34	5.34e-10	2.61e-07	0.36	0.28	Diabetic kidney disease;	chr7:66144214	chr7:66848496~66858136:+
LUAD	cis	rs6860806	0.507	rs272868	ENSG00000233006.5	AC034220.3	6.34	5.34e-10	2.61e-07	0.28	0.28	Breast cancer;	chr5:132345058	chr5:132311285~132369916:-
LUAD	cis	rs7945705	0.967	rs7123429	ENSG00000254860.4	TMEM9B-AS1	6.34	5.35e-10	2.61e-07	0.32	0.28	Hemoglobin concentration;	chr11:8845261	chr11:8964675~8977527:+
LUAD	cis	rs8100891	0.537	rs2302773	ENSG00000267213.4	AC007773.2	-6.34	5.35e-10	2.62e-07	-0.44	-0.28	Neuroticism;	chr19:32436405	chr19:32390050~32405560:-
LUAD	cis	rs9326248	0.559	rs573549	ENSG00000280143.1	AP000892.6	6.34	5.35e-10	2.62e-07	0.32	0.28	Blood protein levels;	chr11:116865963	chr11:117204967~117210292:+
LUAD	cis	rs17711722	0.528	rs73138179	ENSG00000164669.11	INTS4P1	-6.34	5.36e-10	2.62e-07	-0.33	-0.28	Calcium levels;	chr7:65829495	chr7:65141225~65234216:+
LUAD	cis	rs2404602	0.647	rs3812908	ENSG00000259422.1	RP11-593F23.1	6.34	5.37e-10	2.63e-07	0.36	0.28	Blood metabolite levels;	chr15:76883817	chr15:76174891~76181486:-
LUAD	cis	rs2408955	0.504	rs11168441	ENSG00000240399.1	RP1-228P16.1	6.34	5.38e-10	2.63e-07	0.27	0.28	Glycated hemoglobin levels;	chr12:48182271	chr12:48054813~48055591:-
LUAD	cis	rs2243480	1	rs906134	ENSG00000226824.5	RP4-756H11.3	-6.34	5.39e-10	2.63e-07	-0.53	-0.28	Diabetic kidney disease;	chr7:65979301	chr7:66654538~66669855:+
LUAD	cis	rs1707322	0.686	rs1084086	ENSG00000234329.1	RP11-767N6.2	-6.34	5.39e-10	2.63e-07	-0.29	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45575428	chr1:45651039~45651826:-
LUAD	cis	rs8072100	0.807	rs2175290	ENSG00000228782.6	CTD-2026D20.3	6.34	5.4e-10	2.64e-07	0.29	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402551	chr17:47450568~47492492:-
LUAD	cis	rs67311347	0.869	rs9832311	ENSG00000223797.4	ENTPD3-AS1	6.34	5.4e-10	2.64e-07	0.29	0.28	Renal cell carcinoma;	chr3:40339831	chr3:40313802~40453329:-
LUAD	cis	rs17301013	0.507	rs60811893	ENSG00000227373.4	RP11-160H22.5	6.34	5.41e-10	2.65e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174765968	chr1:174115300~174160004:-
LUAD	cis	rs113835537	0.529	rs11227501	ENSG00000255517.5	CTD-3074O7.5	-6.34	5.42e-10	2.65e-07	-0.32	-0.28	Airway imaging phenotypes;	chr11:66506601	chr11:66473490~66480233:-
LUAD	cis	rs367615	0.659	rs13435970	ENSG00000249476.1	CTD-2587M2.1	6.34	5.42e-10	2.65e-07	0.37	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109548959	chr5:109237120~109326369:-
LUAD	cis	rs2302464	1	rs16892289	ENSG00000214846.4	RP11-115L11.1	-6.34	5.42e-10	2.65e-07	-0.71	-0.28	Cerebrospinal fluid biomarker levels;	chr4:15730680	chr4:15730962~15731627:-
LUAD	cis	rs72772090	0.634	rs12186366	ENSG00000248734.2	CTD-2260A17.1	-6.34	5.42e-10	2.65e-07	-0.4	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96753146	chr5:96784777~96785999:+
LUAD	cis	rs1799949	1	rs9646417	ENSG00000267681.1	CTD-3199J23.6	-6.34	5.42e-10	2.65e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43346885	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs1545764	ENSG00000267681.1	CTD-3199J23.6	-6.34	5.42e-10	2.65e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43347197	chr17:43144956~43145255:+
LUAD	cis	rs1914816	0.941	rs2456027	ENSG00000196274.5	Metazoa_SRP	6.34	5.42e-10	2.65e-07	0.31	0.28	Response to tocilizumab in rheumatoid arthritis;	chr15:76275868	chr15:76230048~76230390:-
LUAD	cis	rs783540	0.967	rs1259183	ENSG00000278603.1	RP13-608F4.5	-6.34	5.43e-10	2.65e-07	-0.32	-0.28	Schizophrenia;	chr15:82610683	chr15:82472203~82472426:+
LUAD	cis	rs465969	1	rs13213522	ENSG00000255389.1	C6orf3	-6.34	5.43e-10	2.65e-07	-0.61	-0.28	Psoriasis;	chr6:111384138	chr6:111599875~111602295:+
LUAD	cis	rs2015599	0.56	rs3948497	ENSG00000275476.1	RP11-996F15.4	-6.34	5.43e-10	2.65e-07	-0.31	-0.28	Platelet count;Mean platelet volume;	chr12:29247552	chr12:29277397~29277882:-
LUAD	cis	rs2283792	0.765	rs5999749	ENSG00000224086.5	LL22NC03-86G7.1	6.34	5.44e-10	2.66e-07	0.27	0.28	Multiple sclerosis;	chr22:21833371	chr22:21938293~21977632:+
LUAD	cis	rs8081395	0.711	rs11368	ENSG00000266992.1	DHX40P1	6.34	5.44e-10	2.66e-07	0.32	0.28	White blood cell count;	chr17:59954051	chr17:59976009~60002384:-
LUAD	cis	rs2739330	0.828	rs2186366	ENSG00000206090.4	AP000350.7	-6.34	5.45e-10	2.66e-07	-0.32	-0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23939998~23942798:+
LUAD	cis	rs9309711	0.77	rs13409323	ENSG00000225234.1	TRAPPC12-AS1	-6.34	5.45e-10	2.66e-07	-0.35	-0.28	Neurofibrillary tangles;	chr2:3484413	chr2:3481242~3482409:-
LUAD	cis	rs150992	0.609	rs113868271	ENSG00000248489.1	CTD-2007H13.3	6.33	5.46e-10	2.67e-07	0.31	0.28	Body mass index;	chr5:98992741	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.631	rs112393710	ENSG00000248489.1	CTD-2007H13.3	6.33	5.46e-10	2.67e-07	0.31	0.28	Body mass index;	chr5:98992761	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.631	rs111871078	ENSG00000248489.1	CTD-2007H13.3	6.33	5.46e-10	2.67e-07	0.31	0.28	Body mass index;	chr5:98992766	chr5:98929171~98995013:+
LUAD	cis	rs12439619	0.846	rs28470877	ENSG00000255769.6	GOLGA2P10	-6.33	5.47e-10	2.67e-07	-0.35	-0.28	Intelligence (multi-trait analysis);	chr15:82245797	chr15:82472993~82513950:-
LUAD	cis	rs9828933	0.752	rs13433909	ENSG00000280620.1	SCAANT1	6.33	5.47e-10	2.67e-07	0.42	0.28	Type 2 diabetes;	chr3:63962933	chr3:63911518~63911772:-
LUAD	cis	rs7182621	0.512	rs12903892	ENSG00000259363.4	CTD-2054N24.2	-6.33	5.47e-10	2.67e-07	-0.37	-0.28	Colonoscopy-negative controls vs population controls;	chr15:99869662	chr15:99807023~99877148:+
LUAD	cis	rs367615	0.918	rs4576198	ENSG00000249476.1	CTD-2587M2.1	6.33	5.48e-10	2.67e-07	0.37	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109531649	chr5:109237120~109326369:-
LUAD	cis	rs1061377	1	rs35437629	ENSG00000249685.1	RP11-360F5.3	6.33	5.48e-10	2.67e-07	0.33	0.28	Uric acid levels;	chr4:39131712	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs7657926	ENSG00000249685.1	RP11-360F5.3	6.33	5.48e-10	2.67e-07	0.33	0.28	Uric acid levels;	chr4:39132443	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs11096982	ENSG00000249685.1	RP11-360F5.3	6.33	5.48e-10	2.67e-07	0.33	0.28	Uric acid levels;	chr4:39133247	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs11727875	ENSG00000249685.1	RP11-360F5.3	6.33	5.48e-10	2.67e-07	0.33	0.28	Uric acid levels;	chr4:39133699	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs2890659	ENSG00000249685.1	RP11-360F5.3	6.33	5.48e-10	2.68e-07	0.33	0.28	Uric acid levels;	chr4:39125401	chr4:39133913~39135608:+
LUAD	cis	rs1061377	0.932	rs35464499	ENSG00000249685.1	RP11-360F5.3	6.33	5.48e-10	2.68e-07	0.33	0.28	Uric acid levels;	chr4:39127670	chr4:39133913~39135608:+
LUAD	cis	rs2243480	1	rs12698509	ENSG00000232546.1	RP11-458F8.1	-6.33	5.49e-10	2.68e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:65953889	chr7:66848496~66858136:+
LUAD	cis	rs62025270	0.547	rs338520	ENSG00000202081.1	RNU6-1280P	6.33	5.49e-10	2.68e-07	0.33	0.28	Idiopathic pulmonary fibrosis;	chr15:85671567	chr15:85651522~85651628:-
LUAD	cis	rs12554020	0.892	rs7025805	ENSG00000227603.1	RP11-165J3.6	-6.33	5.5e-10	2.68e-07	-0.43	-0.28	Schizophrenia;	chr9:93481463	chr9:93435332~93437121:-
LUAD	cis	rs17301013	0.507	rs72715281	ENSG00000227373.4	RP11-160H22.5	6.33	5.5e-10	2.68e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174711533	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs17842157	ENSG00000227373.4	RP11-160H22.5	6.33	5.5e-10	2.68e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174719442	chr1:174115300~174160004:-
LUAD	cis	rs7727544	0.735	rs273914	ENSG00000233006.5	AC034220.3	6.33	5.5e-10	2.69e-07	0.24	0.28	Blood metabolite levels;	chr5:132324738	chr5:132311285~132369916:-
LUAD	cis	rs9549367	0.789	rs2025247	ENSG00000269125.1	RP11-98F14.11	-6.33	5.51e-10	2.69e-07	-0.34	-0.28	Platelet distribution width;	chr13:113228250	chr13:113165002~113165183:-
LUAD	cis	rs4964805	0.612	rs11111758	ENSG00000257681.1	RP11-341G23.4	6.33	5.51e-10	2.69e-07	0.32	0.28	Attention deficit hyperactivity disorder;	chr12:103767306	chr12:103746315~103768858:-
LUAD	cis	rs897200	0.965	rs897199	ENSG00000280083.1	RP11-317J9.1	6.33	5.51e-10	2.69e-07	0.35	0.28	Behcet's disease;	chr2:191153263	chr2:191154118~191156070:-
LUAD	cis	rs897200	1	rs897198	ENSG00000280083.1	RP11-317J9.1	6.33	5.51e-10	2.69e-07	0.35	0.28	Behcet's disease;	chr2:191153281	chr2:191154118~191156070:-
LUAD	cis	rs35160687	0.842	rs10200619	ENSG00000273080.1	RP11-301O19.1	-6.33	5.52e-10	2.69e-07	-0.31	-0.28	Night sleep phenotypes;	chr2:86321725	chr2:86195590~86196049:+
LUAD	cis	rs8072100	0.84	rs9893901	ENSG00000228782.6	CTD-2026D20.3	6.33	5.53e-10	2.7e-07	0.3	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47429316	chr17:47450568~47492492:-
LUAD	cis	rs7849270	0.921	rs7868476	ENSG00000268707.1	RP11-247A12.7	-6.33	5.53e-10	2.7e-07	-0.32	-0.28	Blood metabolite ratios;	chr9:129155854	chr9:129170434~129170940:+
LUAD	cis	rs7849270	0.959	rs2094704	ENSG00000268707.1	RP11-247A12.7	-6.33	5.53e-10	2.7e-07	-0.32	-0.28	Blood metabolite ratios;	chr9:129156015	chr9:129170434~129170940:+
LUAD	cis	rs17684571	0.872	rs13219942	ENSG00000231441.1	RP11-472M19.2	6.33	5.53e-10	2.7e-07	0.41	0.28	Schizophrenia;	chr6:56713977	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.872	rs35326806	ENSG00000231441.1	RP11-472M19.2	6.33	5.53e-10	2.7e-07	0.41	0.28	Schizophrenia;	chr6:56714216	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.872	rs35494794	ENSG00000231441.1	RP11-472M19.2	6.33	5.53e-10	2.7e-07	0.41	0.28	Schizophrenia;	chr6:56716124	chr6:56844002~56864078:+
LUAD	cis	rs11096990	0.892	rs11937540	ENSG00000249207.1	RP11-360F5.1	6.33	5.54e-10	2.7e-07	0.32	0.28	Cognitive function;	chr4:39179897	chr4:39112677~39126818:-
LUAD	cis	rs2243480	1	rs313832	ENSG00000273142.1	RP11-458F8.4	-6.33	5.55e-10	2.71e-07	-0.29	-0.28	Diabetic kidney disease;	chr7:66085904	chr7:66902857~66906297:+
LUAD	cis	rs1914816	0.941	rs2460151	ENSG00000196274.5	Metazoa_SRP	6.33	5.58e-10	2.72e-07	0.32	0.28	Response to tocilizumab in rheumatoid arthritis;	chr15:76195166	chr15:76230048~76230390:-
LUAD	cis	rs12699921	0.632	rs2723501	ENSG00000279048.1	RP11-511H23.2	6.33	5.58e-10	2.72e-07	0.22	0.28	Fibrinogen levels;	chr7:17814909	chr7:17940503~17942922:+
LUAD	cis	rs2980439	0.846	rs2980437	ENSG00000173295.6	FAM86B3P	-6.33	5.59e-10	2.72e-07	-0.29	-0.28	Neuroticism;	chr8:8237241	chr8:8228595~8244865:+
LUAD	cis	rs7688540	0.76	rs7687833	ENSG00000275426.1	CH17-262A2.1	6.33	5.59e-10	2.72e-07	0.34	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:243531	chr4:149738~150317:+
LUAD	cis	rs8072100	0.84	rs9900360	ENSG00000228782.6	CTD-2026D20.3	6.33	5.59e-10	2.72e-07	0.3	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47414613	chr17:47450568~47492492:-
LUAD	cis	rs8072100	0.84	rs56952963	ENSG00000228782.6	CTD-2026D20.3	6.33	5.59e-10	2.72e-07	0.3	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47416460	chr17:47450568~47492492:-
LUAD	cis	rs6822297	0.504	rs9291487	ENSG00000240005.4	RP11-293A21.1	6.33	5.6e-10	2.73e-07	0.34	0.28	Obesity-related traits;	chr4:26965862	chr4:26859806~26860599:-
LUAD	cis	rs1707322	0.752	rs28545085	ENSG00000234329.1	RP11-767N6.2	6.33	5.62e-10	2.74e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736278	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs28812624	ENSG00000234329.1	RP11-767N6.2	6.33	5.62e-10	2.74e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45738064	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs28507722	ENSG00000234329.1	RP11-767N6.2	6.33	5.62e-10	2.74e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45740868	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs28568986	ENSG00000234329.1	RP11-767N6.2	6.33	5.62e-10	2.74e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45742071	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.717	rs28396194	ENSG00000234329.1	RP11-767N6.2	6.33	5.62e-10	2.74e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747555	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.717	rs28752166	ENSG00000234329.1	RP11-767N6.2	6.33	5.62e-10	2.74e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747637	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.717	rs10890345	ENSG00000234329.1	RP11-767N6.2	6.33	5.62e-10	2.74e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45748255	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs10789471	ENSG00000234329.1	RP11-767N6.2	6.33	5.62e-10	2.74e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45749947	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs11211173	ENSG00000234329.1	RP11-767N6.2	6.33	5.62e-10	2.74e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45753704	chr1:45651039~45651826:-
LUAD	cis	rs5753618	0.561	rs737684	ENSG00000236132.1	CTA-440B3.1	6.33	5.62e-10	2.74e-07	0.35	0.28	Colorectal cancer;	chr22:31263841	chr22:31816379~31817491:-
LUAD	cis	rs5753618	0.539	rs2228619	ENSG00000236132.1	CTA-440B3.1	6.33	5.62e-10	2.74e-07	0.35	0.28	Colorectal cancer;	chr22:31267856	chr22:31816379~31817491:-
LUAD	cis	rs35955747	0.749	rs2027982	ENSG00000236132.1	CTA-440B3.1	6.33	5.62e-10	2.74e-07	0.32	0.28	Neutrophil count;Sum basophil neutrophil counts;	chr22:31197449	chr22:31816379~31817491:-
LUAD	cis	rs2243480	1	rs313799	ENSG00000230295.1	RP11-458F8.2	-6.33	5.63e-10	2.74e-07	-0.33	-0.28	Diabetic kidney disease;	chr7:66029343	chr7:66880708~66882981:+
LUAD	cis	rs465969	1	rs459888	ENSG00000255389.1	C6orf3	6.33	5.63e-10	2.74e-07	0.58	0.28	Psoriasis;	chr6:111329953	chr6:111599875~111602295:+
LUAD	cis	rs6142102	0.59	rs6059691	ENSG00000276073.1	RP5-1125A11.7	6.33	5.63e-10	2.74e-07	0.31	0.28	Skin pigmentation;	chr20:34149161	chr20:33985617~33988989:-
LUAD	cis	rs7849270	1	rs9697030	ENSG00000268707.1	RP11-247A12.7	-6.33	5.63e-10	2.74e-07	-0.32	-0.28	Blood metabolite ratios;	chr9:129157902	chr9:129170434~129170940:+
LUAD	cis	rs2745572	0.515	rs2250686	ENSG00000272279.1	RP11-157J24.2	-6.33	5.64e-10	2.74e-07	-0.34	-0.28	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1548909	chr6:1528364~1528911:-
LUAD	cis	rs2745572	0.557	rs2745574	ENSG00000272279.1	RP11-157J24.2	-6.33	5.64e-10	2.74e-07	-0.34	-0.28	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1548990	chr6:1528364~1528911:-
LUAD	cis	rs2243480	1	rs316332	ENSG00000232546.1	RP11-458F8.1	-6.33	5.64e-10	2.74e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:66139312	chr7:66848496~66858136:+
LUAD	cis	rs6504622	0.935	rs740617	ENSG00000262879.4	RP11-156P1.3	6.33	5.64e-10	2.75e-07	0.33	0.28	Orofacial clefts;	chr17:46950635	chr17:46984045~47100323:-
LUAD	cis	rs1318937	1	rs1318937	ENSG00000224660.1	SH3BP5-AS1	-6.33	5.64e-10	2.75e-07	-0.2	-0.28	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15253857	chr3:15254184~15264493:+
LUAD	cis	rs11676348	0.772	rs6738953	ENSG00000261338.2	RP11-378A13.1	-6.33	5.64e-10	2.75e-07	-0.29	-0.28	Ulcerative colitis;	chr2:218085313	chr2:218255319~218257366:+
LUAD	cis	rs67311347	1	rs4973989	ENSG00000223797.4	ENTPD3-AS1	6.33	5.64e-10	2.75e-07	0.31	0.28	Renal cell carcinoma;	chr3:40410052	chr3:40313802~40453329:-
LUAD	cis	rs11690935	0.55	rs4280427	ENSG00000228389.1	AC068039.4	-6.33	5.65e-10	2.75e-07	-0.3	-0.28	Schizophrenia;	chr2:171956692	chr2:171773482~171775844:+
LUAD	cis	rs11690935	0.531	rs4280428	ENSG00000228389.1	AC068039.4	-6.33	5.65e-10	2.75e-07	-0.3	-0.28	Schizophrenia;	chr2:171956693	chr2:171773482~171775844:+
LUAD	cis	rs9640161	0.789	rs34495356	ENSG00000261305.1	RP4-584D14.7	6.33	5.66e-10	2.75e-07	0.41	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150360702	chr7:150341771~150342607:+
LUAD	cis	rs9640161	0.789	rs36035506	ENSG00000261305.1	RP4-584D14.7	6.33	5.66e-10	2.75e-07	0.41	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150360754	chr7:150341771~150342607:+
LUAD	cis	rs67311347	1	rs17078916	ENSG00000223797.4	ENTPD3-AS1	6.33	5.66e-10	2.76e-07	0.31	0.28	Renal cell carcinoma;	chr3:40403947	chr3:40313802~40453329:-
LUAD	cis	rs7688540	0.8	rs10028482	ENSG00000275426.1	CH17-262A2.1	6.33	5.67e-10	2.76e-07	0.34	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:254036	chr4:149738~150317:+
LUAD	cis	rs17301013	0.606	rs7536987	ENSG00000227373.4	RP11-160H22.5	6.33	5.68e-10	2.76e-07	0.38	0.28	Systemic lupus erythematosus;	chr1:174367978	chr1:174115300~174160004:-
LUAD	cis	rs8081395	0.737	rs4968401	ENSG00000266992.1	DHX40P1	-6.33	5.68e-10	2.76e-07	-0.32	-0.28	White blood cell count;	chr17:59963369	chr17:59976009~60002384:-
LUAD	cis	rs8177876	0.749	rs12927239	ENSG00000261838.4	RP11-303E16.6	6.33	5.69e-10	2.77e-07	0.54	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81053883	chr16:81069854~81076598:+
LUAD	cis	rs8177376	1	rs563011	ENSG00000254905.1	RP11-712L6.7	-6.33	5.69e-10	2.77e-07	-0.38	-0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126281527	chr11:126292922~126294254:-
LUAD	cis	rs77204473	1	rs12273762	ENSG00000254851.1	RP11-109L13.1	6.33	5.7e-10	2.77e-07	0.67	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116906347	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs9651681	ENSG00000254851.1	RP11-109L13.1	6.33	5.7e-10	2.77e-07	0.67	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116907349	chr11:117135528~117138582:+
LUAD	cis	rs875971	0.862	rs4368860	ENSG00000222364.1	RNU6-96P	6.33	5.7e-10	2.77e-07	0.31	0.28	Aortic root size;	chr7:66143495	chr7:66395191~66395286:+
LUAD	cis	rs2243480	0.908	rs4718273	ENSG00000226824.5	RP4-756H11.3	6.33	5.71e-10	2.78e-07	0.53	0.28	Diabetic kidney disease;	chr7:65751112	chr7:66654538~66669855:+
LUAD	cis	rs875971	1	rs12532998	ENSG00000222364.1	RNU6-96P	-6.33	5.71e-10	2.78e-07	-0.31	-0.28	Aortic root size;	chr7:66502472	chr7:66395191~66395286:+
LUAD	cis	rs55665837	1	rs10832276	ENSG00000251991.1	RNU7-49P	6.33	5.71e-10	2.78e-07	0.31	0.28	Vitamin D levels;	chr11:14461728	chr11:14478892~14478953:+
LUAD	cis	rs17301013	0.606	rs12076453	ENSG00000227373.4	RP11-160H22.5	6.33	5.72e-10	2.78e-07	0.38	0.28	Systemic lupus erythematosus;	chr1:174230438	chr1:174115300~174160004:-
LUAD	cis	rs1075265	0.704	rs10181999	ENSG00000233266.1	HMGB1P31	6.33	5.72e-10	2.78e-07	0.35	0.28	Chronotype;Morning vs. evening chronotype;	chr2:54025360	chr2:54051334~54051760:+
LUAD	cis	rs7044106	0.762	rs12003646	ENSG00000238181.2	AHCYP2	-6.33	5.72e-10	2.78e-07	-0.36	-0.28	Hip circumference adjusted for BMI;	chr9:120708343	chr9:120720673~120721972:+
LUAD	cis	rs2243480	1	rs431076	ENSG00000232546.1	RP11-458F8.1	-6.33	5.73e-10	2.79e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66135333	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs2257790	ENSG00000232546.1	RP11-458F8.1	-6.33	5.73e-10	2.79e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66135463	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs2460422	ENSG00000232546.1	RP11-458F8.1	-6.33	5.73e-10	2.79e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66136518	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs316334	ENSG00000232546.1	RP11-458F8.1	-6.33	5.73e-10	2.79e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66137139	chr7:66848496~66858136:+
LUAD	cis	rs9309473	1	rs11893881	ENSG00000163016.8	ALMS1P	6.33	5.74e-10	2.79e-07	0.34	0.28	Metabolite levels;	chr2:73597246	chr2:73644919~73685576:+
LUAD	cis	rs2243480	1	rs4149468	ENSG00000232546.1	RP11-458F8.1	-6.33	5.74e-10	2.79e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:66360703	chr7:66848496~66858136:+
LUAD	cis	rs3762637	1	rs28497203	ENSG00000272758.4	RP11-299J3.8	-6.33	5.74e-10	2.79e-07	-0.43	-0.28	LDL cholesterol levels;	chr3:122512972	chr3:122416207~122443180:+
LUAD	cis	rs950169	0.919	rs12915589	ENSG00000259728.4	LINC00933	6.33	5.75e-10	2.79e-07	0.42	0.28	Schizophrenia;	chr15:84065712	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.959	rs66801143	ENSG00000259728.4	LINC00933	6.33	5.75e-10	2.79e-07	0.42	0.28	Schizophrenia;	chr15:84067905	chr15:84570649~84580175:+
LUAD	cis	rs950169	1	rs35648189	ENSG00000259728.4	LINC00933	6.33	5.75e-10	2.79e-07	0.42	0.28	Schizophrenia;	chr15:84071996	chr15:84570649~84580175:+
LUAD	cis	rs7743045	0.652	rs9387621	ENSG00000253194.1	RP11-351A11.1	6.33	5.76e-10	2.8e-07	0.37	0.28	Mean platelet volume;	chr6:118973412	chr6:118934785~119031541:+
LUAD	cis	rs7017914	0.905	rs10091471	ENSG00000223220.1	Y_RNA	6.33	5.76e-10	2.8e-07	0.31	0.28	Bone mineral density;	chr8:71041520	chr8:70780914~70781008:-
LUAD	cis	rs8100891	0.537	rs11883143	ENSG00000267213.4	AC007773.2	-6.33	5.76e-10	2.8e-07	-0.42	-0.28	Neuroticism;	chr19:32478350	chr19:32390050~32405560:-
LUAD	cis	rs17301013	0.507	rs3117838	ENSG00000227373.4	RP11-160H22.5	6.33	5.76e-10	2.8e-07	0.4	0.28	Systemic lupus erythematosus;	chr1:174749205	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs332801	ENSG00000227373.4	RP11-160H22.5	6.33	5.76e-10	2.8e-07	0.4	0.28	Systemic lupus erythematosus;	chr1:174753192	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs332800	ENSG00000227373.4	RP11-160H22.5	6.33	5.76e-10	2.8e-07	0.4	0.28	Systemic lupus erythematosus;	chr1:174753467	chr1:174115300~174160004:-
LUAD	cis	rs897200	1	rs6736458	ENSG00000280083.1	RP11-317J9.1	6.33	5.76e-10	2.8e-07	0.35	0.28	Behcet's disease;	chr2:191158982	chr2:191154118~191156070:-
LUAD	cis	rs948562	0.69	rs75365860	ENSG00000280010.1	AP001350.4	6.33	5.77e-10	2.8e-07	0.43	0.28	Lymphoma;	chr11:58402023	chr11:58627435~58628528:+
LUAD	cis	rs8100891	0.537	rs10410770	ENSG00000267213.4	AC007773.2	-6.33	5.78e-10	2.81e-07	-0.45	-0.28	Neuroticism;	chr19:32411498	chr19:32390050~32405560:-
LUAD	cis	rs67311347	1	rs2085115	ENSG00000223797.4	ENTPD3-AS1	6.33	5.78e-10	2.81e-07	0.31	0.28	Renal cell carcinoma;	chr3:40456049	chr3:40313802~40453329:-
LUAD	cis	rs189798	0.807	rs330909	ENSG00000254340.1	RP11-10A14.3	6.33	5.78e-10	2.81e-07	0.36	0.28	Myopia (pathological);	chr8:9137877	chr8:9141424~9145435:+
LUAD	cis	rs1799949	1	rs4793229	ENSG00000267681.1	CTD-3199J23.6	6.33	5.79e-10	2.81e-07	0.32	0.28	Menopause (age at onset);	chr17:43340966	chr17:43144956~43145255:+
LUAD	cis	rs2243480	1	rs11538349	ENSG00000232546.1	RP11-458F8.1	-6.33	5.79e-10	2.81e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:65956884	chr7:66848496~66858136:+
LUAD	cis	rs4141404	0.737	rs5998058	ENSG00000236132.1	CTA-440B3.1	-6.33	5.79e-10	2.81e-07	-0.34	-0.28	Paclitaxel-induced neuropathy;	chr22:31610422	chr22:31816379~31817491:-
LUAD	cis	rs950169	0.58	rs2271431	ENSG00000225151.9	GOLGA2P7	-6.33	5.79e-10	2.81e-07	-0.37	-0.28	Schizophrenia;	chr15:84646233	chr15:84199311~84230136:-
LUAD	cis	rs56080343	0.515	rs73222056	ENSG00000275759.1	RP11-131L12.3	-6.32	5.8e-10	2.82e-07	-0.43	-0.28	Neuroticism;	chr12:118215875	chr12:118428281~118428870:+
LUAD	cis	rs113835537	0.529	rs11227503	ENSG00000255517.5	CTD-3074O7.5	-6.32	5.8e-10	2.82e-07	-0.33	-0.28	Airway imaging phenotypes;	chr11:66507771	chr11:66473490~66480233:-
LUAD	cis	rs1799949	0.864	rs60309406	ENSG00000267681.1	CTD-3199J23.6	-6.32	5.8e-10	2.82e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43358297	chr17:43144956~43145255:+
LUAD	cis	rs17023223	0.553	rs72691108	ENSG00000231365.4	RP11-418J17.1	-6.32	5.8e-10	2.82e-07	-0.39	-0.28	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119219552	chr1:119140396~119275973:+
LUAD	cis	rs875971	0.545	rs7810213	ENSG00000237310.1	GS1-124K5.4	6.32	5.81e-10	2.82e-07	0.35	0.28	Aortic root size;	chr7:66481592	chr7:66493706~66495474:+
LUAD	cis	rs150992	0.609	rs77892628	ENSG00000248489.1	CTD-2007H13.3	6.32	5.82e-10	2.83e-07	0.31	0.28	Body mass index;	chr5:98990624	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.609	rs77231989	ENSG00000248489.1	CTD-2007H13.3	6.32	5.82e-10	2.83e-07	0.31	0.28	Body mass index;	chr5:98990650	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.631	rs79191251	ENSG00000248489.1	CTD-2007H13.3	6.32	5.82e-10	2.83e-07	0.31	0.28	Body mass index;	chr5:98990680	chr5:98929171~98995013:+
LUAD	cis	rs7182621	0.793	rs12904168	ENSG00000182397.13	DNM1P46	6.32	5.82e-10	2.83e-07	0.34	0.28	Colonoscopy-negative controls vs population controls;	chr15:99869495	chr15:99790156~99806927:-
LUAD	cis	rs1707322	0.752	rs28719889	ENSG00000234329.1	RP11-767N6.2	6.32	5.83e-10	2.83e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736611	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.717	rs1972410	ENSG00000234329.1	RP11-767N6.2	6.32	5.84e-10	2.84e-07	0.29	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615275	chr1:45651039~45651826:-
LUAD	cis	rs1062177	0.95	rs892005	ENSG00000213433.5	RPLP1P6	-6.32	5.84e-10	2.84e-07	-0.37	-0.28	Preschool internalizing problems;	chr5:151801060	chr5:151765859~151766378:-
LUAD	cis	rs2404602	0.647	rs11072619	ENSG00000259422.1	RP11-593F23.1	-6.32	5.85e-10	2.84e-07	-0.36	-0.28	Blood metabolite levels;	chr15:76750901	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.647	rs11072620	ENSG00000259422.1	RP11-593F23.1	-6.32	5.85e-10	2.84e-07	-0.36	-0.28	Blood metabolite levels;	chr15:76756429	chr15:76174891~76181486:-
LUAD	cis	rs10899021	1	rs10899021	ENSG00000279353.1	RP11-864N7.4	-6.32	5.85e-10	2.84e-07	-0.48	-0.28	Response to metformin (IC50);	chr11:74627009	chr11:74698231~74699658:-
LUAD	cis	rs4713118	0.621	rs9295755	ENSG00000204709.4	LINC01556	-6.32	5.86e-10	2.84e-07	-0.38	-0.28	Parkinson's disease;	chr6:28065396	chr6:28943877~28944537:+
LUAD	cis	rs7017914	0.967	rs2639919	ENSG00000223220.1	Y_RNA	6.32	5.86e-10	2.85e-07	0.31	0.28	Bone mineral density;	chr8:70962893	chr8:70780914~70781008:-
LUAD	cis	rs17301013	0.507	rs6677243	ENSG00000227373.4	RP11-160H22.5	6.32	5.87e-10	2.85e-07	0.41	0.28	Systemic lupus erythematosus;	chr1:174339471	chr1:174115300~174160004:-
LUAD	cis	rs881375	0.678	rs10760129	ENSG00000226752.6	PSMD5-AS1	-6.32	5.87e-10	2.85e-07	-0.29	-0.28	Rheumatoid arthritis;	chr9:120937905	chr9:120824828~120854385:+
LUAD	cis	rs113835537	0.529	rs57634456	ENSG00000255517.5	CTD-3074O7.5	-6.32	5.88e-10	2.85e-07	-0.33	-0.28	Airway imaging phenotypes;	chr11:66483367	chr11:66473490~66480233:-
LUAD	cis	rs4713118	0.662	rs156744	ENSG00000204709.4	LINC01556	6.32	5.88e-10	2.85e-07	0.38	0.28	Parkinson's disease;	chr6:27999496	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.662	rs149947	ENSG00000204709.4	LINC01556	6.32	5.88e-10	2.85e-07	0.38	0.28	Parkinson's disease;	chr6:28004655	chr6:28943877~28944537:+
LUAD	cis	rs17301013	0.531	rs4650958	ENSG00000227373.4	RP11-160H22.5	6.32	5.9e-10	2.86e-07	0.39	0.28	Systemic lupus erythematosus;	chr1:174178378	chr1:174115300~174160004:-
LUAD	cis	rs55665837	1	rs55665837	ENSG00000251991.1	RNU7-49P	6.32	5.91e-10	2.87e-07	0.31	0.28	Vitamin D levels;	chr11:14473503	chr11:14478892~14478953:+
LUAD	cis	rs783540	1	rs7496954	ENSG00000278603.1	RP13-608F4.5	6.32	5.92e-10	2.87e-07	0.32	0.28	Schizophrenia;	chr15:82676784	chr15:82472203~82472426:+
LUAD	cis	rs875971	0.545	rs73150604	ENSG00000237310.1	GS1-124K5.4	6.32	5.92e-10	2.87e-07	0.35	0.28	Aortic root size;	chr7:66480545	chr7:66493706~66495474:+
LUAD	cis	rs17301013	0.507	rs4652512	ENSG00000227373.4	RP11-160H22.5	6.32	5.92e-10	2.87e-07	0.42	0.28	Systemic lupus erythematosus;	chr1:174515519	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs57512497	ENSG00000227373.4	RP11-160H22.5	6.32	5.92e-10	2.87e-07	0.42	0.28	Systemic lupus erythematosus;	chr1:174518346	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs11807229	ENSG00000227373.4	RP11-160H22.5	6.32	5.92e-10	2.87e-07	0.42	0.28	Systemic lupus erythematosus;	chr1:174519456	chr1:174115300~174160004:-
LUAD	cis	rs496547	0.686	rs487728	ENSG00000255422.1	AP002954.4	-6.32	5.93e-10	2.87e-07	-0.35	-0.28	Hip minimal joint space width;	chr11:118750785	chr11:118704607~118750263:+
LUAD	cis	rs10740039	0.768	rs10821801	ENSG00000254271.1	RP11-131N11.4	6.32	5.93e-10	2.88e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60612017	chr10:60734342~60741828:+
LUAD	cis	rs5753618	0.539	rs8135344	ENSG00000236132.1	CTA-440B3.1	6.32	5.93e-10	2.88e-07	0.35	0.28	Colorectal cancer;	chr22:31275946	chr22:31816379~31817491:-
LUAD	cis	rs5753618	0.561	rs4141404	ENSG00000236132.1	CTA-440B3.1	6.32	5.93e-10	2.88e-07	0.35	0.28	Colorectal cancer;	chr22:31279199	chr22:31816379~31817491:-
LUAD	cis	rs7246657	0.943	rs6508733	ENSG00000276846.1	CTD-3220F14.3	6.32	5.94e-10	2.88e-07	0.37	0.28	Coronary artery calcification;	chr19:37509646	chr19:37314868~37315620:-
LUAD	cis	rs12908161	1	rs11637142	ENSG00000259728.4	LINC00933	6.32	5.94e-10	2.88e-07	0.4	0.28	Schizophrenia;	chr15:84752696	chr15:84570649~84580175:+
LUAD	cis	rs783540	0.843	rs28374463	ENSG00000278603.1	RP13-608F4.5	-6.32	5.94e-10	2.88e-07	-0.32	-0.28	Schizophrenia;	chr15:82630613	chr15:82472203~82472426:+
LUAD	cis	rs4723738	1	rs10282407	ENSG00000227191.5	TRGC2	-6.32	5.94e-10	2.88e-07	-0.3	-0.28	Treatment response for severe sepsis;	chr7:38193791	chr7:38239580~38368091:-
LUAD	cis	rs7923609	0.871	rs10761787	ENSG00000232075.1	MRPL35P2	-6.32	5.94e-10	2.88e-07	-0.34	-0.28	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63593995	chr10:63634317~63634827:-
LUAD	cis	rs7246657	1	rs1529957	ENSG00000276846.1	CTD-3220F14.3	6.32	5.95e-10	2.89e-07	0.39	0.28	Coronary artery calcification;	chr19:37248899	chr19:37314868~37315620:-
LUAD	cis	rs10740039	0.729	rs6479721	ENSG00000254271.1	RP11-131N11.4	6.32	5.96e-10	2.89e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60613364	chr10:60734342~60741828:+
LUAD	cis	rs948562	1	rs948562	ENSG00000280010.1	AP001350.4	6.32	5.96e-10	2.89e-07	0.42	0.28	Lymphoma;	chr11:58580292	chr11:58627435~58628528:+
LUAD	cis	rs10740039	0.842	rs10761539	ENSG00000254271.1	RP11-131N11.4	6.32	5.96e-10	2.89e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60649733	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.842	rs7090892	ENSG00000254271.1	RP11-131N11.4	6.32	5.96e-10	2.89e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60652093	chr10:60734342~60741828:+
LUAD	cis	rs6142102	0.602	rs10485503	ENSG00000275784.1	RP5-1125A11.6	-6.32	5.96e-10	2.89e-07	-0.3	-0.28	Skin pigmentation;	chr20:33970036	chr20:33989480~33991818:-
LUAD	cis	rs2243480	0.803	rs36004293	ENSG00000232546.1	RP11-458F8.1	-6.32	5.96e-10	2.89e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:65951525	chr7:66848496~66858136:+
LUAD	cis	rs2243480	0.803	rs35268390	ENSG00000232546.1	RP11-458F8.1	-6.32	5.96e-10	2.89e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:65951549	chr7:66848496~66858136:+
LUAD	cis	rs2179367	0.959	rs628488	ENSG00000231760.4	RP11-350J20.5	6.32	5.98e-10	2.9e-07	0.35	0.28	Dupuytren's disease;	chr6:149398264	chr6:149796151~149826294:-
LUAD	cis	rs77204473	0.744	rs79955870	ENSG00000254851.1	RP11-109L13.1	6.32	5.99e-10	2.9e-07	0.7	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117066645	chr11:117135528~117138582:+
LUAD	cis	rs77204473	0.744	rs11216261	ENSG00000254851.1	RP11-109L13.1	6.32	5.99e-10	2.9e-07	0.7	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117069494	chr11:117135528~117138582:+
LUAD	cis	rs2034650	0.544	rs2289331	ENSG00000223313.1	RNU6-516P	6.32	6e-10	2.91e-07	0.36	0.28	Interstitial lung disease;	chr15:40407739	chr15:40529570~40529673:+
LUAD	cis	rs72772090	0.539	rs11750671	ENSG00000248734.2	CTD-2260A17.1	-6.32	6e-10	2.91e-07	-0.44	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96852779	chr5:96784777~96785999:+
LUAD	cis	rs7567389	0.719	rs6733478	ENSG00000236682.1	AC068282.3	6.32	6e-10	2.91e-07	0.4	0.28	Self-rated health;	chr2:127238413	chr2:127389130~127400580:+
LUAD	cis	rs783540	0.967	rs1145173	ENSG00000278603.1	RP13-608F4.5	-6.32	6e-10	2.91e-07	-0.32	-0.28	Schizophrenia;	chr15:82554675	chr15:82472203~82472426:+
LUAD	cis	rs6860806	0.507	rs272880	ENSG00000233006.5	AC034220.3	6.32	6e-10	2.91e-07	0.28	0.28	Breast cancer;	chr5:132334485	chr5:132311285~132369916:-
LUAD	cis	rs1823913	0.599	rs1823912	ENSG00000280083.1	RP11-317J9.1	-6.32	6.01e-10	2.91e-07	-0.33	-0.28	Obesity-related traits;	chr2:191266388	chr2:191154118~191156070:-
LUAD	cis	rs2412819	0.571	rs12900924	ENSG00000205771.5	CATSPER2P1	-6.32	6.01e-10	2.91e-07	-0.45	-0.28	Lung cancer;	chr15:43737329	chr15:43726918~43747094:-
LUAD	cis	rs7017914	0.934	rs13255152	ENSG00000223220.1	Y_RNA	6.32	6.01e-10	2.91e-07	0.31	0.28	Bone mineral density;	chr8:70947384	chr8:70780914~70781008:-
LUAD	cis	rs2412819	0.571	rs4923964	ENSG00000205771.5	CATSPER2P1	6.32	6.02e-10	2.92e-07	0.42	0.28	Lung cancer;	chr15:43722882	chr15:43726918~43747094:-
LUAD	cis	rs7246657	0.943	rs7253091	ENSG00000276846.1	CTD-3220F14.3	6.32	6.02e-10	2.92e-07	0.37	0.28	Coronary artery calcification;	chr19:37476312	chr19:37314868~37315620:-
LUAD	cis	rs9543976	0.92	rs9543992	ENSG00000261553.4	RP11-29G8.3	6.32	6.02e-10	2.92e-07	0.4	0.28	Diabetic retinopathy;	chr13:75600938	chr13:75549773~75807120:+
LUAD	cis	rs9543976	1	rs8192762	ENSG00000261553.4	RP11-29G8.3	6.32	6.02e-10	2.92e-07	0.4	0.28	Diabetic retinopathy;	chr13:75602544	chr13:75549773~75807120:+
LUAD	cis	rs6772849	0.93	rs13434160	ENSG00000242551.2	POU5F1P6	-6.32	6.02e-10	2.92e-07	-0.33	-0.28	Monocyte percentage of white cells;Monocyte count;	chr3:128655927	chr3:128674735~128677005:-
LUAD	cis	rs9584850	0.834	rs2031239	ENSG00000231194.1	FARP1-AS1	6.32	6.03e-10	2.92e-07	0.34	0.28	Neuroticism;	chr13:98459306	chr13:98435405~98435840:-
LUAD	cis	rs2117029	0.554	rs35884657	ENSG00000258017.1	RP11-386G11.10	-6.32	6.04e-10	2.92e-07	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49137317	chr12:49127782~49147869:+
LUAD	cis	rs875971	0.502	rs2465121	ENSG00000226824.5	RP4-756H11.3	6.32	6.04e-10	2.92e-07	0.41	0.28	Aortic root size;	chr7:66156017	chr7:66654538~66669855:+
LUAD	cis	rs2404602	0.647	rs3812909	ENSG00000259422.1	RP11-593F23.1	-6.32	6.04e-10	2.92e-07	-0.37	-0.28	Blood metabolite levels;	chr15:76883859	chr15:76174891~76181486:-
LUAD	cis	rs113835537	0.529	rs3816492	ENSG00000255517.5	CTD-3074O7.5	-6.32	6.04e-10	2.93e-07	-0.34	-0.28	Airway imaging phenotypes;	chr11:66529892	chr11:66473490~66480233:-
LUAD	cis	rs7567389	0.599	rs6430938	ENSG00000236682.1	AC068282.3	6.32	6.05e-10	2.93e-07	0.35	0.28	Self-rated health;	chr2:127405047	chr2:127389130~127400580:+
LUAD	cis	rs11690935	0.55	rs55653103	ENSG00000228389.1	AC068039.4	-6.32	6.05e-10	2.93e-07	-0.3	-0.28	Schizophrenia;	chr2:171996909	chr2:171773482~171775844:+
LUAD	cis	rs7115242	0.748	rs1035237	ENSG00000280143.1	AP000892.6	6.32	6.05e-10	2.93e-07	0.42	0.28	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116857134	chr11:117204967~117210292:+
LUAD	cis	rs9640161	0.789	rs13223702	ENSG00000261305.1	RP4-584D14.7	6.32	6.07e-10	2.94e-07	0.41	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150361879	chr7:150341771~150342607:+
LUAD	cis	rs1823913	1	rs4853561	ENSG00000230611.1	HMGB1P27	6.32	6.07e-10	2.94e-07	0.34	0.28	Obesity-related traits;	chr2:191242980	chr2:191174233~191174835:+
LUAD	cis	rs1823913	1	rs6704784	ENSG00000230611.1	HMGB1P27	6.32	6.07e-10	2.94e-07	0.34	0.28	Obesity-related traits;	chr2:191244832	chr2:191174233~191174835:+
LUAD	cis	rs67311347	1	rs73076046	ENSG00000223797.4	ENTPD3-AS1	6.32	6.08e-10	2.94e-07	0.31	0.28	Renal cell carcinoma;	chr3:40406233	chr3:40313802~40453329:-
LUAD	cis	rs6844153	1	rs57663175	ENSG00000240005.4	RP11-293A21.1	-6.32	6.09e-10	2.95e-07	-0.45	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26917770	chr4:26859806~26860599:-
LUAD	cis	rs1012068	0.662	rs11703779	ENSG00000236132.1	CTA-440B3.1	-6.32	6.09e-10	2.95e-07	-0.33	-0.28	Chronic hepatitis C infection;	chr22:31926398	chr22:31816379~31817491:-
LUAD	cis	rs7937890	0.9	rs7118682	ENSG00000254418.1	RP11-21L19.1	-6.32	6.09e-10	2.95e-07	-0.32	-0.28	Mitochondrial DNA levels;	chr11:14253004	chr11:14262846~14273691:-
LUAD	cis	rs2117029	0.619	rs9325145	ENSG00000258017.1	RP11-386G11.10	-6.32	6.1e-10	2.95e-07	-0.33	-0.28	Intelligence (multi-trait analysis);	chr12:49132101	chr12:49127782~49147869:+
LUAD	cis	rs2408955	0.568	rs12099462	ENSG00000240399.1	RP1-228P16.1	-6.32	6.1e-10	2.95e-07	-0.27	-0.28	Glycated hemoglobin levels;	chr12:48109321	chr12:48054813~48055591:-
LUAD	cis	rs8177376	0.953	rs3862627	ENSG00000254905.1	RP11-712L6.7	6.32	6.1e-10	2.95e-07	0.4	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126311697	chr11:126292922~126294254:-
LUAD	cis	rs5753618	0.561	rs2283879	ENSG00000236132.1	CTA-440B3.1	6.32	6.1e-10	2.95e-07	0.35	0.28	Colorectal cancer;	chr22:31242462	chr22:31816379~31817491:-
LUAD	cis	rs5753618	0.561	rs2283881	ENSG00000236132.1	CTA-440B3.1	6.32	6.1e-10	2.95e-07	0.35	0.28	Colorectal cancer;	chr22:31242946	chr22:31816379~31817491:-
LUAD	cis	rs12908161	0.92	rs35738019	ENSG00000259728.4	LINC00933	6.32	6.11e-10	2.96e-07	0.4	0.28	Schizophrenia;	chr15:84736979	chr15:84570649~84580175:+
LUAD	cis	rs12908161	1	rs34570071	ENSG00000259728.4	LINC00933	6.32	6.11e-10	2.96e-07	0.4	0.28	Schizophrenia;	chr15:84736981	chr15:84570649~84580175:+
LUAD	cis	rs67311347	1	rs12634013	ENSG00000223797.4	ENTPD3-AS1	6.32	6.11e-10	2.96e-07	0.31	0.28	Renal cell carcinoma;	chr3:40410897	chr3:40313802~40453329:-
LUAD	cis	rs11846409	0.587	rs1806881	ENSG00000254174.1	IGHV1-12	-6.32	6.11e-10	2.96e-07	-0.25	-0.28	Rheumatic heart disease;	chr14:106650770	chr14:106122420~106122709:-
LUAD	cis	rs4820294	0.926	rs62236671	ENSG00000233360.4	Z83844.1	6.32	6.12e-10	2.96e-07	0.29	0.28	Fat distribution (HIV);	chr22:37673298	chr22:37641832~37658377:-
LUAD	cis	rs1823913	0.599	rs17414109	ENSG00000280083.1	RP11-317J9.1	-6.32	6.12e-10	2.96e-07	-0.33	-0.28	Obesity-related traits;	chr2:191310675	chr2:191154118~191156070:-
LUAD	cis	rs12554020	0.892	rs7028729	ENSG00000227603.1	RP11-165J3.6	6.32	6.12e-10	2.96e-07	0.42	0.28	Schizophrenia;	chr9:93443206	chr9:93435332~93437121:-
LUAD	cis	rs4718428	0.672	rs13241598	ENSG00000232546.1	RP11-458F8.1	-6.32	6.12e-10	2.96e-07	-0.26	-0.28	Corneal structure;	chr7:66835665	chr7:66848496~66858136:+
LUAD	cis	rs67311347	1	rs73078163	ENSG00000223797.4	ENTPD3-AS1	6.32	6.13e-10	2.96e-07	0.3	0.28	Renal cell carcinoma;	chr3:40438467	chr3:40313802~40453329:-
LUAD	cis	rs11089937	0.616	rs7291684	ENSG00000211639.2	IGLV4-60	6.32	6.13e-10	2.96e-07	0.3	0.28	Periodontitis (PAL4Q3);	chr22:22183834	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.616	rs6001219	ENSG00000211639.2	IGLV4-60	6.32	6.13e-10	2.96e-07	0.3	0.28	Periodontitis (PAL4Q3);	chr22:22184348	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.616	rs5995615	ENSG00000211639.2	IGLV4-60	6.32	6.13e-10	2.96e-07	0.3	0.28	Periodontitis (PAL4Q3);	chr22:22185250	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.616	rs6001223	ENSG00000211639.2	IGLV4-60	6.32	6.13e-10	2.96e-07	0.3	0.28	Periodontitis (PAL4Q3);	chr22:22185359	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.616	rs928895	ENSG00000211639.2	IGLV4-60	6.32	6.13e-10	2.96e-07	0.3	0.28	Periodontitis (PAL4Q3);	chr22:22185915	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.616	rs928896	ENSG00000211639.2	IGLV4-60	6.32	6.13e-10	2.96e-07	0.3	0.28	Periodontitis (PAL4Q3);	chr22:22185929	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.616	rs6001224	ENSG00000211639.2	IGLV4-60	6.32	6.13e-10	2.96e-07	0.3	0.28	Periodontitis (PAL4Q3);	chr22:22186042	chr22:22162199~22162681:+
LUAD	cis	rs1823913	1	rs1454749	ENSG00000230611.1	HMGB1P27	-6.32	6.13e-10	2.96e-07	-0.34	-0.28	Obesity-related traits;	chr2:191240909	chr2:191174233~191174835:+
LUAD	cis	rs35160687	0.842	rs1863052	ENSG00000273080.1	RP11-301O19.1	6.32	6.13e-10	2.97e-07	0.31	0.28	Night sleep phenotypes;	chr2:86332235	chr2:86195590~86196049:+
LUAD	cis	rs293748	0.882	rs158794	ENSG00000250155.1	CTD-2353F22.1	-6.32	6.14e-10	2.97e-07	-0.39	-0.28	Obesity-related traits;	chr5:36882986	chr5:36666214~36725195:-
LUAD	cis	rs293748	0.882	rs151946	ENSG00000250155.1	CTD-2353F22.1	-6.32	6.14e-10	2.97e-07	-0.39	-0.28	Obesity-related traits;	chr5:36884064	chr5:36666214~36725195:-
LUAD	cis	rs293748	0.882	rs158793	ENSG00000250155.1	CTD-2353F22.1	-6.32	6.14e-10	2.97e-07	-0.39	-0.28	Obesity-related traits;	chr5:36884988	chr5:36666214~36725195:-
LUAD	cis	rs2243480	0.901	rs57126451	ENSG00000232546.1	RP11-458F8.1	-6.31	6.16e-10	2.98e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:65951319	chr7:66848496~66858136:+
LUAD	cis	rs11971779	0.648	rs6967836	ENSG00000273391.1	RP11-634H22.1	6.31	6.16e-10	2.98e-07	0.28	0.28	Diisocyanate-induced asthma;	chr7:139395198	chr7:139359032~139359566:-
LUAD	cis	rs1113500	0.524	rs12145813	ENSG00000226822.1	RP11-356N1.2	6.31	6.17e-10	2.98e-07	0.35	0.28	Growth-regulated protein alpha levels;	chr1:108027282	chr1:108071482~108074519:+
LUAD	cis	rs853679	0.607	rs56075693	ENSG00000204709.4	LINC01556	6.31	6.19e-10	2.99e-07	0.61	0.28	Depression;	chr6:28322551	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs34218844	ENSG00000204709.4	LINC01556	6.31	6.19e-10	2.99e-07	0.61	0.28	Depression;	chr6:28322870	chr6:28943877~28944537:+
LUAD	cis	rs77204473	0.744	rs11216252	ENSG00000254851.1	RP11-109L13.1	6.31	6.19e-10	2.99e-07	0.7	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117057507	chr11:117135528~117138582:+
LUAD	cis	rs77204473	0.744	rs11216253	ENSG00000254851.1	RP11-109L13.1	6.31	6.19e-10	2.99e-07	0.7	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117057509	chr11:117135528~117138582:+
LUAD	cis	rs77204473	0.744	rs11216265	ENSG00000254851.1	RP11-109L13.1	6.31	6.21e-10	3e-07	0.7	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117076464	chr11:117135528~117138582:+
LUAD	cis	rs7567389	0.504	rs5937	ENSG00000236682.1	AC068282.3	-6.31	6.22e-10	3.01e-07	-0.36	-0.28	Self-rated health;	chr2:127427194	chr2:127389130~127400580:+
LUAD	cis	rs4713118	0.911	rs2394000	ENSG00000219392.1	RP1-265C24.5	-6.31	6.22e-10	3.01e-07	-0.37	-0.28	Parkinson's disease;	chr6:27719212	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.955	rs9393847	ENSG00000219392.1	RP1-265C24.5	-6.31	6.22e-10	3.01e-07	-0.37	-0.28	Parkinson's disease;	chr6:27720194	chr6:28115628~28116551:+
LUAD	cis	rs6844153	0.752	rs12650172	ENSG00000240005.4	RP11-293A21.1	-6.31	6.23e-10	3.01e-07	-0.4	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26872784	chr4:26859806~26860599:-
LUAD	cis	rs367615	0.68	rs1103198	ENSG00000249476.1	CTD-2587M2.1	6.31	6.23e-10	3.01e-07	0.35	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109637882	chr5:109237120~109326369:-
LUAD	cis	rs494459	0.688	rs1048040	ENSG00000278376.1	RP11-158I9.8	-6.31	6.23e-10	3.01e-07	-0.29	-0.28	Height;	chr11:118747911	chr11:118791254~118793137:+
LUAD	cis	rs6964833	0.554	rs112506907	ENSG00000277053.3	GTF2IP1	-6.31	6.24e-10	3.01e-07	-0.35	-0.28	Menarche (age at onset);	chr7:74654407	chr7:75185385~75237696:-
LUAD	cis	rs4713118	0.955	rs9380010	ENSG00000219392.1	RP1-265C24.5	-6.31	6.24e-10	3.01e-07	-0.38	-0.28	Parkinson's disease;	chr6:27715793	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.955	rs9368528	ENSG00000219392.1	RP1-265C24.5	-6.31	6.24e-10	3.01e-07	-0.38	-0.28	Parkinson's disease;	chr6:27716019	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.955	rs9380011	ENSG00000219392.1	RP1-265C24.5	-6.31	6.24e-10	3.01e-07	-0.38	-0.28	Parkinson's disease;	chr6:27716145	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.955	rs9380012	ENSG00000219392.1	RP1-265C24.5	-6.31	6.24e-10	3.01e-07	-0.38	-0.28	Parkinson's disease;	chr6:27716875	chr6:28115628~28116551:+
LUAD	cis	rs6772849	0.93	rs6768344	ENSG00000242551.2	POU5F1P6	-6.31	6.25e-10	3.02e-07	-0.33	-0.28	Monocyte percentage of white cells;Monocyte count;	chr3:128654713	chr3:128674735~128677005:-
LUAD	cis	rs8081395	0.741	rs2645462	ENSG00000266992.1	DHX40P1	6.31	6.25e-10	3.02e-07	0.32	0.28	White blood cell count;	chr17:59906198	chr17:59976009~60002384:-
LUAD	cis	rs8081395	0.711	rs1292034	ENSG00000266992.1	DHX40P1	6.31	6.25e-10	3.02e-07	0.32	0.28	White blood cell count;	chr17:59912499	chr17:59976009~60002384:-
LUAD	cis	rs113835537	0.529	rs61561111	ENSG00000255517.5	CTD-3074O7.5	-6.31	6.25e-10	3.02e-07	-0.33	-0.28	Airway imaging phenotypes;	chr11:66508452	chr11:66473490~66480233:-
LUAD	cis	rs2243480	1	rs427044	ENSG00000232546.1	RP11-458F8.1	-6.31	6.26e-10	3.02e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:66043558	chr7:66848496~66858136:+
LUAD	cis	rs3762637	1	rs6777596	ENSG00000272758.4	RP11-299J3.8	-6.31	6.26e-10	3.02e-07	-0.44	-0.28	LDL cholesterol levels;	chr3:122414474	chr3:122416207~122443180:+
LUAD	cis	rs6844153	1	rs80197589	ENSG00000240005.4	RP11-293A21.1	-6.31	6.26e-10	3.02e-07	-0.45	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26887030	chr4:26859806~26860599:-
LUAD	cis	rs2243480	1	rs34970380	ENSG00000226824.5	RP4-756H11.3	-6.31	6.26e-10	3.03e-07	-0.52	-0.28	Diabetic kidney disease;	chr7:65966506	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.901	rs73148097	ENSG00000226824.5	RP4-756H11.3	-6.31	6.26e-10	3.03e-07	-0.52	-0.28	Diabetic kidney disease;	chr7:65966800	chr7:66654538~66669855:+
LUAD	cis	rs240993	0.909	rs240991	ENSG00000230177.1	RP5-1112D6.4	-6.31	6.27e-10	3.03e-07	-0.27	-0.28	Inflammatory skin disease;Psoriasis;	chr6:111346971	chr6:111277932~111278742:+
LUAD	cis	rs240993	1	rs240993	ENSG00000230177.1	RP5-1112D6.4	-6.31	6.27e-10	3.03e-07	-0.27	-0.28	Inflammatory skin disease;Psoriasis;	chr6:111352511	chr6:111277932~111278742:+
LUAD	cis	rs11098499	0.588	rs6534149	ENSG00000248280.1	RP11-33B1.2	-6.31	6.27e-10	3.03e-07	-0.32	-0.28	Corneal astigmatism;	chr4:119638137	chr4:119440561~119450157:-
LUAD	cis	rs2439831	0.681	rs2278858	ENSG00000205771.5	CATSPER2P1	-6.31	6.28e-10	3.03e-07	-0.52	-0.28	Lung cancer in ever smokers;	chr15:43340557	chr15:43726918~43747094:-
LUAD	cis	rs35160687	0.842	rs7593440	ENSG00000273080.1	RP11-301O19.1	-6.31	6.28e-10	3.03e-07	-0.31	-0.28	Night sleep phenotypes;	chr2:86323534	chr2:86195590~86196049:+
LUAD	cis	rs35160687	0.814	rs4392258	ENSG00000273080.1	RP11-301O19.1	-6.31	6.28e-10	3.03e-07	-0.31	-0.28	Night sleep phenotypes;	chr2:86325454	chr2:86195590~86196049:+
LUAD	cis	rs35160687	0.842	rs11685863	ENSG00000273080.1	RP11-301O19.1	-6.31	6.28e-10	3.03e-07	-0.31	-0.28	Night sleep phenotypes;	chr2:86327361	chr2:86195590~86196049:+
LUAD	cis	rs4718428	0.705	rs11028	ENSG00000232546.1	RP11-458F8.1	-6.31	6.28e-10	3.03e-07	-0.26	-0.28	Corneal structure;	chr7:66811230	chr7:66848496~66858136:+
LUAD	cis	rs7674212	0.507	rs223413	ENSG00000246560.2	RP11-10L12.4	-6.31	6.29e-10	3.03e-07	-0.35	-0.28	Type 2 diabetes;	chr4:102811709	chr4:102828055~102844075:+
LUAD	cis	rs853679	0.542	rs9393892	ENSG00000204709.4	LINC01556	6.31	6.29e-10	3.04e-07	0.39	0.28	Depression;	chr6:28113616	chr6:28943877~28944537:+
LUAD	cis	rs7567389	0.719	rs6738690	ENSG00000236682.1	AC068282.3	6.31	6.29e-10	3.04e-07	0.4	0.28	Self-rated health;	chr2:127235149	chr2:127389130~127400580:+
LUAD	cis	rs17301013	0.606	rs10912751	ENSG00000227373.4	RP11-160H22.5	6.31	6.3e-10	3.04e-07	0.39	0.28	Systemic lupus erythematosus;	chr1:174262992	chr1:174115300~174160004:-
LUAD	cis	rs1707322	0.716	rs10890342	ENSG00000234329.1	RP11-767N6.2	6.31	6.3e-10	3.04e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45691415	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs6658700	ENSG00000234329.1	RP11-767N6.2	6.31	6.3e-10	3.04e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45694588	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs12047629	ENSG00000234329.1	RP11-767N6.2	6.31	6.3e-10	3.04e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697130	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs11211169	ENSG00000234329.1	RP11-767N6.2	6.31	6.3e-10	3.04e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701037	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs11211171	ENSG00000234329.1	RP11-767N6.2	6.31	6.3e-10	3.04e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45702970	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs28623463	ENSG00000234329.1	RP11-767N6.2	6.31	6.3e-10	3.04e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45705086	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.716	rs28370457	ENSG00000234329.1	RP11-767N6.2	6.31	6.3e-10	3.04e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706390	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs28890893	ENSG00000234329.1	RP11-767N6.2	6.31	6.3e-10	3.04e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720904	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs28550303	ENSG00000234329.1	RP11-767N6.2	6.31	6.3e-10	3.04e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723242	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.716	rs28375469	ENSG00000234329.1	RP11-767N6.2	6.31	6.3e-10	3.04e-07	0.3	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45729703	chr1:45651039~45651826:-
LUAD	cis	rs17301013	0.507	rs392307	ENSG00000227373.4	RP11-160H22.5	6.31	6.3e-10	3.04e-07	0.4	0.28	Systemic lupus erythematosus;	chr1:174744243	chr1:174115300~174160004:-
LUAD	cis	rs875971	0.545	rs73378304	ENSG00000237310.1	GS1-124K5.4	6.31	6.3e-10	3.04e-07	0.34	0.28	Aortic root size;	chr7:66175760	chr7:66493706~66495474:+
LUAD	cis	rs75920871	0.623	rs7928320	ENSG00000254851.1	RP11-109L13.1	6.31	6.32e-10	3.05e-07	0.69	0.28	Subjective well-being;	chr11:117072037	chr11:117135528~117138582:+
LUAD	cis	rs516805	0.847	rs520046	ENSG00000279453.1	RP3-425C14.4	-6.31	6.33e-10	3.05e-07	-0.32	-0.28	Lymphocyte counts;	chr6:122446048	chr6:122436789~122439223:-
LUAD	cis	rs4723738	1	rs4723733	ENSG00000227191.5	TRGC2	6.31	6.35e-10	3.06e-07	0.3	0.28	Treatment response for severe sepsis;	chr7:38184011	chr7:38239580~38368091:-
LUAD	cis	rs2243480	0.908	rs55876148	ENSG00000232546.1	RP11-458F8.1	-6.31	6.37e-10	3.07e-07	-0.37	-0.28	Diabetic kidney disease;	chr7:65914813	chr7:66848496~66858136:+
LUAD	cis	rs9309473	1	rs7607014	ENSG00000163016.8	ALMS1P	-6.31	6.37e-10	3.07e-07	-0.33	-0.28	Metabolite levels;	chr2:73503047	chr2:73644919~73685576:+
LUAD	cis	rs11690935	0.55	rs7584187	ENSG00000228389.1	AC068039.4	6.31	6.38e-10	3.07e-07	0.29	0.28	Schizophrenia;	chr2:172001198	chr2:171773482~171775844:+
LUAD	cis	rs853679	0.55	rs1233699	ENSG00000219392.1	RP1-265C24.5	-6.31	6.38e-10	3.08e-07	-0.37	-0.28	Depression;	chr6:28201380	chr6:28115628~28116551:+
LUAD	cis	rs2243480	0.803	rs34804747	ENSG00000232546.1	RP11-458F8.1	-6.31	6.38e-10	3.08e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:65947955	chr7:66848496~66858136:+
LUAD	cis	rs75920871	0.513	rs76904522	ENSG00000254851.1	RP11-109L13.1	-6.31	6.4e-10	3.09e-07	-0.46	-0.28	Subjective well-being;	chr11:117144147	chr11:117135528~117138582:+
LUAD	cis	rs75920871	0.513	rs113560866	ENSG00000254851.1	RP11-109L13.1	-6.31	6.4e-10	3.09e-07	-0.46	-0.28	Subjective well-being;	chr11:117144473	chr11:117135528~117138582:+
LUAD	cis	rs11096990	0.855	rs56275407	ENSG00000249207.1	RP11-360F5.1	6.31	6.41e-10	3.09e-07	0.32	0.28	Cognitive function;	chr4:39177224	chr4:39112677~39126818:-
LUAD	cis	rs7615952	0.736	rs9866347	ENSG00000171084.14	FAM86JP	6.31	6.41e-10	3.09e-07	0.49	0.28	Blood pressure (smoking interaction);	chr3:125951082	chr3:125916620~125930024:+
LUAD	cis	rs7684253	0.548	rs13106200	ENSG00000269949.1	RP11-738E22.3	-6.31	6.42e-10	3.09e-07	-0.36	-0.28	Migraine;	chr4:56852029	chr4:56960927~56961373:-
LUAD	cis	rs7688540	0.8	rs9328738	ENSG00000275426.1	CH17-262A2.1	-6.31	6.42e-10	3.09e-07	-0.34	-0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:284407	chr4:149738~150317:+
LUAD	cis	rs7927592	0.913	rs10896330	ENSG00000212093.1	AP000807.1	6.31	6.42e-10	3.09e-07	0.3	0.28	Total body bone mineral density;	chr11:68487530	chr11:68506083~68506166:-
LUAD	cis	rs948562	0.69	rs11229391	ENSG00000280010.1	AP001350.4	6.31	6.42e-10	3.09e-07	0.43	0.28	Lymphoma;	chr11:58382503	chr11:58627435~58628528:+
LUAD	cis	rs2404602	0.61	rs28823285	ENSG00000259422.1	RP11-593F23.1	-6.31	6.43e-10	3.1e-07	-0.36	-0.28	Blood metabolite levels;	chr15:76758054	chr15:76174891~76181486:-
LUAD	cis	rs10740039	0.81	rs6479720	ENSG00000254271.1	RP11-131N11.4	6.31	6.43e-10	3.1e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60610935	chr10:60734342~60741828:+
LUAD	cis	rs7044106	0.791	rs10984995	ENSG00000238181.2	AHCYP2	-6.31	6.43e-10	3.1e-07	-0.36	-0.28	Hip circumference adjusted for BMI;	chr9:120716932	chr9:120720673~120721972:+
LUAD	cis	rs113835537	0.529	rs11227514	ENSG00000255517.5	CTD-3074O7.5	-6.31	6.44e-10	3.1e-07	-0.33	-0.28	Airway imaging phenotypes;	chr11:66519156	chr11:66473490~66480233:-
LUAD	cis	rs1061377	1	rs1897136	ENSG00000249685.1	RP11-360F5.3	6.31	6.44e-10	3.1e-07	0.33	0.28	Uric acid levels;	chr4:39131242	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs1897137	ENSG00000249685.1	RP11-360F5.3	6.31	6.44e-10	3.1e-07	0.33	0.28	Uric acid levels;	chr4:39131387	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs7681116	ENSG00000249685.1	RP11-360F5.3	6.31	6.44e-10	3.1e-07	0.33	0.28	Uric acid levels;	chr4:39133015	chr4:39133913~39135608:+
LUAD	cis	rs1061377	0.965	rs10018622	ENSG00000249685.1	RP11-360F5.3	6.31	6.44e-10	3.1e-07	0.33	0.28	Uric acid levels;	chr4:39133944	chr4:39133913~39135608:+
LUAD	cis	rs1061377	0.965	rs1046655	ENSG00000249685.1	RP11-360F5.3	6.31	6.44e-10	3.1e-07	0.33	0.28	Uric acid levels;	chr4:39126127	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs7694760	ENSG00000249685.1	RP11-360F5.3	6.31	6.44e-10	3.1e-07	0.33	0.28	Uric acid levels;	chr4:39126481	chr4:39133913~39135608:+
LUAD	cis	rs1061377	0.965	rs11728058	ENSG00000249685.1	RP11-360F5.3	6.31	6.44e-10	3.1e-07	0.33	0.28	Uric acid levels;	chr4:39128224	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs17508864	ENSG00000249685.1	RP11-360F5.3	6.31	6.44e-10	3.1e-07	0.33	0.28	Uric acid levels;	chr4:39129025	chr4:39133913~39135608:+
LUAD	cis	rs4927850	1	rs10881563	ENSG00000207650.1	MIR570	6.31	6.45e-10	3.11e-07	0.3	0.28	Pancreatic cancer;	chr3:196023354	chr3:195699401~195699497:+
LUAD	cis	rs155076	1	rs261432	ENSG00000233325.3	MIPEPP3	6.31	6.45e-10	3.11e-07	0.44	0.28	White matter hyperintensity burden;	chr13:21291776	chr13:21298139~21306373:+
LUAD	cis	rs17301013	0.507	rs12066700	ENSG00000227373.4	RP11-160H22.5	6.31	6.46e-10	3.11e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174282054	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12060460	ENSG00000227373.4	RP11-160H22.5	6.31	6.46e-10	3.11e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174284513	chr1:174115300~174160004:-
LUAD	cis	rs2243480	1	rs958550	ENSG00000273142.1	RP11-458F8.4	6.31	6.46e-10	3.11e-07	0.26	0.28	Diabetic kidney disease;	chr7:66170692	chr7:66902857~66906297:+
LUAD	cis	rs7688540	0.76	rs4510422	ENSG00000275426.1	CH17-262A2.1	6.31	6.48e-10	3.12e-07	0.34	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238151	chr4:149738~150317:+
LUAD	cis	rs875971	1	rs10257427	ENSG00000222364.1	RNU6-96P	6.31	6.49e-10	3.12e-07	0.31	0.28	Aortic root size;	chr7:66278221	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs10215948	ENSG00000222364.1	RNU6-96P	6.31	6.49e-10	3.12e-07	0.31	0.28	Aortic root size;	chr7:66282799	chr7:66395191~66395286:+
LUAD	cis	rs8177376	0.953	rs73017394	ENSG00000254905.1	RP11-712L6.7	6.31	6.49e-10	3.12e-07	0.4	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126311952	chr11:126292922~126294254:-
LUAD	cis	rs1823913	0.599	rs1823912	ENSG00000227542.1	AC092614.2	6.31	6.49e-10	3.12e-07	0.33	0.28	Obesity-related traits;	chr2:191266388	chr2:191229165~191246172:-
LUAD	cis	rs67311347	1	rs11714912	ENSG00000223797.4	ENTPD3-AS1	-6.31	6.5e-10	3.13e-07	-0.29	-0.28	Renal cell carcinoma;	chr3:40452574	chr3:40313802~40453329:-
LUAD	cis	rs6142102	0.625	rs6142068	ENSG00000275784.1	RP5-1125A11.6	6.31	6.5e-10	3.13e-07	0.29	0.28	Skin pigmentation;	chr20:33969366	chr20:33989480~33991818:-
LUAD	cis	rs2243480	1	rs4718269	ENSG00000226824.5	RP4-756H11.3	6.31	6.5e-10	3.13e-07	0.52	0.28	Diabetic kidney disease;	chr7:65735810	chr7:66654538~66669855:+
LUAD	cis	rs1155848	0.571	rs6563127	ENSG00000227354.5	RBM26-AS1	6.31	6.5e-10	3.13e-07	0.52	0.28	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79642012	chr13:79406309~79424328:+
LUAD	cis	rs2337406	0.587	rs2583291	ENSG00000211974.3	IGHV2-70	6.31	6.51e-10	3.14e-07	0.34	0.28	Alzheimer's disease (late onset);	chr14:106649293	chr14:106723574~106724093:-
LUAD	cis	rs6504622	0.905	rs3809854	ENSG00000262879.4	RP11-156P1.3	6.31	6.52e-10	3.14e-07	0.32	0.28	Orofacial clefts;	chr17:46951928	chr17:46984045~47100323:-
LUAD	cis	rs11603023	0.874	rs483598	ENSG00000255422.1	AP002954.4	-6.31	6.53e-10	3.14e-07	-0.33	-0.28	Cholesterol, total;	chr11:118638950	chr11:118704607~118750263:+
LUAD	cis	rs4713118	0.516	rs7739216	ENSG00000204709.4	LINC01556	6.3	6.53e-10	3.14e-07	0.38	0.28	Parkinson's disease;	chr6:28112168	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs35512245	ENSG00000204709.4	LINC01556	6.3	6.53e-10	3.14e-07	0.38	0.28	Depression;	chr6:28112175	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9380055	ENSG00000204709.4	LINC01556	6.3	6.53e-10	3.14e-07	0.38	0.28	Depression;	chr6:28113851	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9368553	ENSG00000204709.4	LINC01556	6.3	6.53e-10	3.14e-07	0.38	0.28	Depression;	chr6:28114487	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9368554	ENSG00000204709.4	LINC01556	6.3	6.53e-10	3.14e-07	0.38	0.28	Depression;	chr6:28114933	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs4713137	ENSG00000204709.4	LINC01556	6.3	6.53e-10	3.14e-07	0.38	0.28	Depression;	chr6:28115743	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9348793	ENSG00000204709.4	LINC01556	6.3	6.53e-10	3.14e-07	0.38	0.28	Depression;	chr6:28116411	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.586	rs6905516	ENSG00000204709.4	LINC01556	6.3	6.53e-10	3.14e-07	0.38	0.28	Parkinson's disease;	chr6:28118700	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.586	rs6905522	ENSG00000204709.4	LINC01556	6.3	6.53e-10	3.14e-07	0.38	0.28	Parkinson's disease;	chr6:28118701	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.586	rs9468290	ENSG00000204709.4	LINC01556	6.3	6.53e-10	3.14e-07	0.38	0.28	Parkinson's disease;	chr6:28119896	chr6:28943877~28944537:+
LUAD	cis	rs1823913	0.637	rs1470962	ENSG00000280083.1	RP11-317J9.1	6.3	6.54e-10	3.15e-07	0.32	0.28	Obesity-related traits;	chr2:191270271	chr2:191154118~191156070:-
LUAD	cis	rs7849270	1	rs10988223	ENSG00000268707.1	RP11-247A12.7	-6.3	6.55e-10	3.15e-07	-0.31	-0.28	Blood metabolite ratios;	chr9:129140742	chr9:129170434~129170940:+
LUAD	cis	rs4718428	0.662	rs34577323	ENSG00000232546.1	RP11-458F8.1	-6.3	6.55e-10	3.15e-07	-0.26	-0.28	Corneal structure;	chr7:66845054	chr7:66848496~66858136:+
LUAD	cis	rs8177876	0.822	rs7206814	ENSG00000261838.4	RP11-303E16.6	-6.3	6.56e-10	3.15e-07	-0.53	-0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074086	chr16:81069854~81076598:+
LUAD	cis	rs17301013	0.507	rs2064150	ENSG00000227373.4	RP11-160H22.5	-6.3	6.56e-10	3.16e-07	-0.42	-0.28	Systemic lupus erythematosus;	chr1:174339289	chr1:174115300~174160004:-
LUAD	cis	rs77204473	0.744	rs74955808	ENSG00000254851.1	RP11-109L13.1	6.3	6.57e-10	3.16e-07	0.71	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117121969	chr11:117135528~117138582:+
LUAD	cis	rs55665837	1	rs10832275	ENSG00000251991.1	RNU7-49P	6.3	6.57e-10	3.16e-07	0.31	0.28	Vitamin D levels;	chr11:14456678	chr11:14478892~14478953:+
LUAD	cis	rs4713118	0.955	rs9468201	ENSG00000219392.1	RP1-265C24.5	-6.3	6.58e-10	3.16e-07	-0.37	-0.28	Parkinson's disease;	chr6:27719256	chr6:28115628~28116551:+
LUAD	cis	rs3096299	0.754	rs3096320	ENSG00000274627.1	RP11-104N10.2	6.3	6.58e-10	3.16e-07	0.26	0.28	Multiple myeloma (IgH translocation);	chr16:89336649	chr16:89516797~89522217:+
LUAD	cis	rs3002142	0.658	rs2291833	ENSG00000272750.1	RP11-378J18.8	-6.3	6.58e-10	3.17e-07	-0.36	-0.28	LDL peak particle diameter (total fat intake interaction);	chr1:222653505	chr1:222658867~222661512:-
LUAD	cis	rs35740288	0.77	rs11630286	ENSG00000202081.1	RNU6-1280P	6.3	6.59e-10	3.17e-07	0.34	0.28	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85659298	chr15:85651522~85651628:-
LUAD	cis	rs10740039	0.883	rs1837945	ENSG00000254271.1	RP11-131N11.4	6.3	6.62e-10	3.18e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60633757	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs7089287	ENSG00000254271.1	RP11-131N11.4	6.3	6.62e-10	3.18e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60634006	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs7093573	ENSG00000254271.1	RP11-131N11.4	6.3	6.62e-10	3.18e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60634611	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs7097818	ENSG00000254271.1	RP11-131N11.4	6.3	6.62e-10	3.18e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60635106	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.842	rs2119913	ENSG00000254271.1	RP11-131N11.4	6.3	6.62e-10	3.18e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60635631	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.586	rs7068462	ENSG00000254271.1	RP11-131N11.4	6.3	6.62e-10	3.18e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60636240	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs7069814	ENSG00000254271.1	RP11-131N11.4	6.3	6.62e-10	3.18e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60637001	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs10821809	ENSG00000254271.1	RP11-131N11.4	6.3	6.62e-10	3.18e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60637612	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs10740037	ENSG00000254271.1	RP11-131N11.4	6.3	6.62e-10	3.18e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60637747	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.804	rs10761531	ENSG00000254271.1	RP11-131N11.4	6.3	6.62e-10	3.18e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60638177	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs10761533	ENSG00000254271.1	RP11-131N11.4	6.3	6.62e-10	3.18e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60638573	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.846	rs2165690	ENSG00000254271.1	RP11-131N11.4	6.3	6.62e-10	3.18e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60639609	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs2119911	ENSG00000254271.1	RP11-131N11.4	6.3	6.62e-10	3.18e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60639808	chr10:60734342~60741828:+
LUAD	cis	rs2439831	0.867	rs2470134	ENSG00000205771.5	CATSPER2P1	6.3	6.62e-10	3.18e-07	0.51	0.28	Lung cancer in ever smokers;	chr15:43557688	chr15:43726918~43747094:-
LUAD	cis	rs67311347	1	rs9875245	ENSG00000223797.4	ENTPD3-AS1	6.3	6.62e-10	3.18e-07	0.3	0.28	Renal cell carcinoma;	chr3:40400789	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs954589	ENSG00000223797.4	ENTPD3-AS1	6.3	6.62e-10	3.18e-07	0.3	0.28	Renal cell carcinoma;	chr3:40403054	chr3:40313802~40453329:-
LUAD	cis	rs7849270	1	rs3739847	ENSG00000268707.1	RP11-247A12.7	6.3	6.64e-10	3.19e-07	0.32	0.28	Blood metabolite ratios;	chr9:129149295	chr9:129170434~129170940:+
LUAD	cis	rs7688540	0.771	rs10005733	ENSG00000275426.1	CH17-262A2.1	6.3	6.64e-10	3.19e-07	0.37	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:298212	chr4:149738~150317:+
LUAD	cis	rs853679	0.607	rs56189111	ENSG00000204709.4	LINC01556	6.3	6.64e-10	3.19e-07	0.61	0.28	Depression;	chr6:28304196	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs35072899	ENSG00000204709.4	LINC01556	6.3	6.64e-10	3.19e-07	0.61	0.28	Depression;	chr6:28313764	chr6:28943877~28944537:+
LUAD	cis	rs150992	0.609	rs116183885	ENSG00000248489.1	CTD-2007H13.3	6.3	6.64e-10	3.19e-07	0.31	0.28	Body mass index;	chr5:98990735	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.534	rs115121903	ENSG00000248489.1	CTD-2007H13.3	6.3	6.64e-10	3.19e-07	0.31	0.28	Body mass index;	chr5:98990736	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.592	rs2455423	ENSG00000248489.1	CTD-2007H13.3	6.3	6.64e-10	3.19e-07	0.31	0.28	Body mass index;	chr5:98990844	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.609	rs559574	ENSG00000248489.1	CTD-2007H13.3	6.3	6.64e-10	3.19e-07	0.31	0.28	Body mass index;	chr5:98991122	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.609	rs443726	ENSG00000248489.1	CTD-2007H13.3	6.3	6.64e-10	3.19e-07	0.31	0.28	Body mass index;	chr5:98991163	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.592	rs407562	ENSG00000248489.1	CTD-2007H13.3	6.3	6.64e-10	3.19e-07	0.31	0.28	Body mass index;	chr5:98991512	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.632	rs395668	ENSG00000248489.1	CTD-2007H13.3	6.3	6.64e-10	3.19e-07	0.31	0.28	Body mass index;	chr5:98991611	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.609	rs449204	ENSG00000248489.1	CTD-2007H13.3	6.3	6.64e-10	3.19e-07	0.31	0.28	Body mass index;	chr5:98991775	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.609	rs378089	ENSG00000248489.1	CTD-2007H13.3	6.3	6.64e-10	3.19e-07	0.31	0.28	Body mass index;	chr5:98991818	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.587	rs422127	ENSG00000248489.1	CTD-2007H13.3	6.3	6.64e-10	3.19e-07	0.31	0.28	Body mass index;	chr5:98991984	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.609	rs113423144	ENSG00000248489.1	CTD-2007H13.3	6.3	6.64e-10	3.19e-07	0.31	0.28	Body mass index;	chr5:98992055	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.609	rs380156	ENSG00000248489.1	CTD-2007H13.3	6.3	6.64e-10	3.19e-07	0.31	0.28	Body mass index;	chr5:98992386	chr5:98929171~98995013:+
LUAD	cis	rs17301013	0.507	rs11805578	ENSG00000227373.4	RP11-160H22.5	6.3	6.64e-10	3.19e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174573174	chr1:174115300~174160004:-
LUAD	cis	rs8031584	0.958	rs35256769	ENSG00000260382.1	RP11-540B6.2	6.3	6.65e-10	3.2e-07	0.33	0.28	Huntington's disease progression;	chr15:30945573	chr15:30882267~30883231:-
LUAD	cis	rs8031584	0.958	rs11629793	ENSG00000260382.1	RP11-540B6.2	6.3	6.65e-10	3.2e-07	0.33	0.28	Huntington's disease progression;	chr15:30946220	chr15:30882267~30883231:-
LUAD	cis	rs2243480	1	rs709607	ENSG00000273142.1	RP11-458F8.4	6.3	6.65e-10	3.2e-07	0.28	0.28	Diabetic kidney disease;	chr7:65984554	chr7:66902857~66906297:+
LUAD	cis	rs1062177	0.855	rs919262	ENSG00000213433.5	RPLP1P6	6.3	6.67e-10	3.2e-07	0.35	0.28	Preschool internalizing problems;	chr5:151886523	chr5:151765859~151766378:-
LUAD	cis	rs4718428	0.672	rs36038499	ENSG00000232546.1	RP11-458F8.1	-6.3	6.67e-10	3.2e-07	-0.26	-0.28	Corneal structure;	chr7:66824628	chr7:66848496~66858136:+
LUAD	cis	rs2243480	0.711	rs2460426	ENSG00000232546.1	RP11-458F8.1	6.3	6.7e-10	3.22e-07	0.37	0.28	Diabetic kidney disease;	chr7:66158142	chr7:66848496~66858136:+
LUAD	cis	rs5753618	0.539	rs737888	ENSG00000236132.1	CTA-440B3.1	6.3	6.71e-10	3.22e-07	0.35	0.28	Colorectal cancer;	chr22:31215563	chr22:31816379~31817491:-
LUAD	cis	rs6860806	0.507	rs273915	ENSG00000233006.5	AC034220.3	6.3	6.71e-10	3.22e-07	0.28	0.28	Breast cancer;	chr5:132324426	chr5:132311285~132369916:-
LUAD	cis	rs1061377	1	rs1982009	ENSG00000249685.1	RP11-360F5.3	6.3	6.72e-10	3.23e-07	0.33	0.28	Uric acid levels;	chr4:39123253	chr4:39133913~39135608:+
LUAD	cis	rs1061377	0.965	rs1138494	ENSG00000249685.1	RP11-360F5.3	6.3	6.72e-10	3.23e-07	0.33	0.28	Uric acid levels;	chr4:39123315	chr4:39133913~39135608:+
LUAD	cis	rs1799949	0.965	rs2236762	ENSG00000267681.1	CTD-3199J23.6	-6.3	6.72e-10	3.23e-07	-0.31	-0.28	Menopause (age at onset);	chr17:43074658	chr17:43144956~43145255:+
LUAD	cis	rs12468226	0.938	rs80315897	ENSG00000226261.1	AC064836.3	6.3	6.72e-10	3.23e-07	0.47	0.28	Urate levels;	chr2:202318044	chr2:202336024~202336727:-
LUAD	cis	rs13217239	0.646	rs11756275	ENSG00000241549.7	GUSBP2	-6.3	6.73e-10	3.23e-07	-0.3	-0.28	Schizophrenia;	chr6:27039334	chr6:26871484~26956554:-
LUAD	cis	rs77204473	0.744	rs11216270	ENSG00000254851.1	RP11-109L13.1	6.3	6.73e-10	3.23e-07	0.7	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117082928	chr11:117135528~117138582:+
LUAD	cis	rs77204473	0.744	rs2368149	ENSG00000254851.1	RP11-109L13.1	6.3	6.73e-10	3.23e-07	0.7	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117085218	chr11:117135528~117138582:+
LUAD	cis	rs2243480	1	rs781157	ENSG00000230295.1	RP11-458F8.2	-6.3	6.74e-10	3.23e-07	-0.33	-0.28	Diabetic kidney disease;	chr7:66013324	chr7:66880708~66882981:+
LUAD	cis	rs881375	0.678	rs2269060	ENSG00000226752.6	PSMD5-AS1	-6.3	6.75e-10	3.24e-07	-0.29	-0.28	Rheumatoid arthritis;	chr9:120921291	chr9:120824828~120854385:+
LUAD	cis	rs1799949	0.526	rs4352088	ENSG00000267681.1	CTD-3199J23.6	-6.3	6.75e-10	3.24e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43337311	chr17:43144956~43145255:+
LUAD	cis	rs7176527	1	rs7176527	ENSG00000188388.10	GOLGA6L3	6.3	6.76e-10	3.24e-07	0.39	0.28	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84597563	chr15:85240472~85247170:+
LUAD	cis	rs67311347	1	rs73076035	ENSG00000223797.4	ENTPD3-AS1	6.3	6.77e-10	3.25e-07	0.31	0.28	Renal cell carcinoma;	chr3:40398390	chr3:40313802~40453329:-
LUAD	cis	rs7811142	1	rs67471932	ENSG00000242294.5	STAG3L5P	6.3	6.78e-10	3.25e-07	0.24	0.28	Platelet count;	chr7:100412362	chr7:100336079~100351900:+
LUAD	cis	rs1823913	0.637	rs12992372	ENSG00000280083.1	RP11-317J9.1	-6.3	6.78e-10	3.25e-07	-0.33	-0.28	Obesity-related traits;	chr2:191289251	chr2:191154118~191156070:-
LUAD	cis	rs34526934	0.608	rs34720456	ENSG00000226363.3	HAGLROS	6.3	6.79e-10	3.26e-07	0.38	0.28	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:176162564	chr2:176177717~176179008:+
LUAD	cis	rs7017914	0.967	rs2732087	ENSG00000223220.1	Y_RNA	6.3	6.79e-10	3.26e-07	0.31	0.28	Bone mineral density;	chr8:70948204	chr8:70780914~70781008:-
LUAD	cis	rs8100891	0.537	rs7258196	ENSG00000267213.4	AC007773.2	-6.3	6.8e-10	3.26e-07	-0.43	-0.28	Neuroticism;	chr19:32453659	chr19:32390050~32405560:-
LUAD	cis	rs10028773	0.515	rs9994488	ENSG00000248280.1	RP11-33B1.2	6.3	6.81e-10	3.26e-07	0.33	0.28	Educational attainment;	chr4:119666626	chr4:119440561~119450157:-
LUAD	cis	rs6772849	0.93	rs9873888	ENSG00000242551.2	POU5F1P6	-6.3	6.81e-10	3.26e-07	-0.32	-0.28	Monocyte percentage of white cells;Monocyte count;	chr3:128642144	chr3:128674735~128677005:-
LUAD	cis	rs1062177	1	rs2964612	ENSG00000213433.5	RPLP1P6	-6.3	6.82e-10	3.27e-07	-0.37	-0.28	Preschool internalizing problems;	chr5:151819189	chr5:151765859~151766378:-
LUAD	cis	rs2243480	1	rs709607	ENSG00000232546.1	RP11-458F8.1	6.3	6.82e-10	3.27e-07	0.35	0.28	Diabetic kidney disease;	chr7:65984554	chr7:66848496~66858136:+
LUAD	cis	rs2179367	0.959	rs2262617	ENSG00000231760.4	RP11-350J20.5	6.3	6.82e-10	3.27e-07	0.34	0.28	Dupuytren's disease;	chr6:149438590	chr6:149796151~149826294:-
LUAD	cis	rs8177876	0.686	rs2602402	ENSG00000261838.4	RP11-303E16.6	6.3	6.83e-10	3.27e-07	0.5	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81052725	chr16:81069854~81076598:+
LUAD	cis	rs67311347	0.869	rs7646899	ENSG00000223797.4	ENTPD3-AS1	6.3	6.83e-10	3.28e-07	0.29	0.28	Renal cell carcinoma;	chr3:40325491	chr3:40313802~40453329:-
LUAD	cis	rs8059260	0.541	rs6498167	ENSG00000274038.1	RP11-66H6.4	-6.3	6.84e-10	3.28e-07	-0.56	-0.28	Alcohol consumption over the past year;	chr16:11127727	chr16:11056556~11057034:+
LUAD	cis	rs75920871	0.588	rs7118591	ENSG00000254851.1	RP11-109L13.1	-6.3	6.84e-10	3.28e-07	-0.4	-0.28	Subjective well-being;	chr11:117037741	chr11:117135528~117138582:+
LUAD	cis	rs4723738	1	rs2159501	ENSG00000227191.5	TRGC2	-6.3	6.84e-10	3.28e-07	-0.3	-0.28	Treatment response for severe sepsis;	chr7:38199675	chr7:38239580~38368091:-
LUAD	cis	rs4723738	0.934	rs1860522	ENSG00000227191.5	TRGC2	-6.3	6.84e-10	3.28e-07	-0.3	-0.28	Treatment response for severe sepsis;	chr7:38200439	chr7:38239580~38368091:-
LUAD	cis	rs7849270	1	rs713219	ENSG00000268707.1	RP11-247A12.7	-6.3	6.85e-10	3.28e-07	-0.31	-0.28	Blood metabolite ratios;	chr9:129138641	chr9:129170434~129170940:+
LUAD	cis	rs17711722	0.51	rs11767457	ENSG00000164669.11	INTS4P1	-6.3	6.86e-10	3.29e-07	-0.33	-0.28	Calcium levels;	chr7:65825628	chr7:65141225~65234216:+
LUAD	cis	rs1799949	0.501	rs9675035	ENSG00000267681.1	CTD-3199J23.6	-6.3	6.86e-10	3.29e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43337648	chr17:43144956~43145255:+
LUAD	cis	rs2404602	0.53	rs11072614	ENSG00000259422.1	RP11-593F23.1	-6.3	6.86e-10	3.29e-07	-0.39	-0.28	Blood metabolite levels;	chr15:76674864	chr15:76174891~76181486:-
LUAD	cis	rs11690935	0.655	rs12052995	ENSG00000228389.1	AC068039.4	-6.3	6.86e-10	3.29e-07	-0.29	-0.28	Schizophrenia;	chr2:171680702	chr2:171773482~171775844:+
LUAD	cis	rs12220777	0.748	rs12259239	ENSG00000230091.5	TMEM254-AS1	6.3	6.87e-10	3.29e-07	0.49	0.28	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80103265	chr10:80046860~80078912:-
LUAD	cis	rs11098499	0.954	rs13145352	ENSG00000248280.1	RP11-33B1.2	-6.3	6.87e-10	3.29e-07	-0.36	-0.28	Corneal astigmatism;	chr4:119488808	chr4:119440561~119450157:-
LUAD	cis	rs4713118	0.662	rs149969	ENSG00000204709.4	LINC01556	6.3	6.88e-10	3.3e-07	0.36	0.28	Parkinson's disease;	chr6:28009959	chr6:28943877~28944537:+
LUAD	cis	rs30380	0.69	rs2042381	ENSG00000248734.2	CTD-2260A17.1	6.3	6.89e-10	3.3e-07	0.3	0.28	Cerebrospinal fluid biomarker levels;	chr5:96852963	chr5:96784777~96785999:+
LUAD	cis	rs2842992	0.83	rs1475123	ENSG00000237927.1	RP3-393E18.2	-6.3	6.89e-10	3.3e-07	-0.39	-0.28	Age-related macular degeneration (geographic atrophy);	chr6:159756975	chr6:159586955~159589169:-
LUAD	cis	rs853679	0.607	rs71559070	ENSG00000204709.4	LINC01556	6.3	6.89e-10	3.3e-07	0.61	0.28	Depression;	chr6:28071151	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs35902873	ENSG00000204709.4	LINC01556	6.3	6.89e-10	3.3e-07	0.61	0.28	Depression;	chr6:28091171	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs13197574	ENSG00000204709.4	LINC01556	6.3	6.89e-10	3.3e-07	0.61	0.28	Depression;	chr6:28092461	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs34166054	ENSG00000204709.4	LINC01556	6.3	6.89e-10	3.3e-07	0.61	0.28	Depression;	chr6:28098023	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs34662244	ENSG00000204709.4	LINC01556	6.3	6.89e-10	3.3e-07	0.61	0.28	Depression;	chr6:28106103	chr6:28943877~28944537:+
LUAD	cis	rs35952432	1	rs35952432	ENSG00000204709.4	LINC01556	6.3	6.89e-10	3.3e-07	0.61	0.28	Lung cancer;	chr6:28107123	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs13203816	ENSG00000204709.4	LINC01556	6.3	6.89e-10	3.3e-07	0.61	0.28	Depression;	chr6:28111820	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.556	rs34588114	ENSG00000204709.4	LINC01556	6.3	6.89e-10	3.3e-07	0.61	0.28	Depression;	chr6:28112850	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.546	rs34371502	ENSG00000204709.4	LINC01556	6.3	6.89e-10	3.3e-07	0.61	0.28	Depression;	chr6:28113980	chr6:28943877~28944537:+
LUAD	cis	rs67311347	1	rs1047855	ENSG00000223797.4	ENTPD3-AS1	-6.3	6.89e-10	3.3e-07	-0.3	-0.28	Renal cell carcinoma;	chr3:40427405	chr3:40313802~40453329:-
LUAD	cis	rs113835537	0.529	rs17065	ENSG00000255517.5	CTD-3074O7.5	-6.3	6.91e-10	3.31e-07	-0.34	-0.28	Airway imaging phenotypes;	chr11:66509564	chr11:66473490~66480233:-
LUAD	cis	rs67311347	1	rs11706148	ENSG00000223797.4	ENTPD3-AS1	6.3	6.91e-10	3.31e-07	0.3	0.28	Renal cell carcinoma;	chr3:40365752	chr3:40313802~40453329:-
LUAD	cis	rs6597981	0.592	rs10902218	ENSG00000255284.1	AP006621.5	-6.3	6.92e-10	3.31e-07	-0.25	-0.28	Breast cancer;	chr11:743813	chr11:777578~784297:+
LUAD	cis	rs7221109	0.601	rs7209404	ENSG00000278834.1	RP11-458J1.1	6.3	6.92e-10	3.31e-07	0.32	0.28	Type 1 diabetes;	chr17:40668150	chr17:40648300~40649718:+
LUAD	cis	rs7221109	0.645	rs7223332	ENSG00000278834.1	RP11-458J1.1	6.3	6.92e-10	3.31e-07	0.32	0.28	Type 1 diabetes;	chr17:40668384	chr17:40648300~40649718:+
LUAD	cis	rs783540	0.967	rs2870966	ENSG00000278603.1	RP13-608F4.5	-6.3	6.92e-10	3.32e-07	-0.32	-0.28	Schizophrenia;	chr15:82626493	chr15:82472203~82472426:+
LUAD	cis	rs150992	0.587	rs75001231	ENSG00000248489.1	CTD-2007H13.3	6.3	6.92e-10	3.32e-07	0.31	0.28	Body mass index;	chr5:98990085	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.609	rs2927647	ENSG00000248489.1	CTD-2007H13.3	6.3	6.92e-10	3.32e-07	0.31	0.28	Body mass index;	chr5:98990161	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.609	rs366353	ENSG00000248489.1	CTD-2007H13.3	-6.3	6.92e-10	3.32e-07	-0.3	-0.28	Body mass index;	chr5:98995663	chr5:98929171~98995013:+
LUAD	cis	rs7923609	0.846	rs7075901	ENSG00000232075.1	MRPL35P2	-6.3	6.92e-10	3.32e-07	-0.34	-0.28	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63521234	chr10:63634317~63634827:-
LUAD	cis	rs150992	0.609	rs1093794	ENSG00000248489.1	CTD-2007H13.3	-6.3	6.93e-10	3.32e-07	-0.31	-0.28	Body mass index;	chr5:98993334	chr5:98929171~98995013:+
LUAD	cis	rs875971	1	rs6945843	ENSG00000222364.1	RNU6-96P	6.29	6.93e-10	3.32e-07	0.31	0.28	Aortic root size;	chr7:66269796	chr7:66395191~66395286:+
LUAD	cis	rs10028773	0.7	rs7671797	ENSG00000248280.1	RP11-33B1.2	6.29	6.94e-10	3.32e-07	0.34	0.28	Educational attainment;	chr4:119327002	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs7672594	ENSG00000248280.1	RP11-33B1.2	6.29	6.94e-10	3.32e-07	0.34	0.28	Corneal astigmatism;	chr4:119327388	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs7672778	ENSG00000248280.1	RP11-33B1.2	6.29	6.94e-10	3.32e-07	0.34	0.28	Corneal astigmatism;	chr4:119327430	chr4:119440561~119450157:-
LUAD	cis	rs4964805	0.594	rs11111759	ENSG00000257681.1	RP11-341G23.4	6.29	6.94e-10	3.32e-07	0.32	0.28	Attention deficit hyperactivity disorder;	chr12:103769405	chr12:103746315~103768858:-
LUAD	cis	rs66887589	0.66	rs4833613	ENSG00000245958.5	RP11-33B1.1	6.29	6.95e-10	3.33e-07	0.24	0.28	Diastolic blood pressure;	chr4:119229001	chr4:119454791~119552025:+
LUAD	cis	rs5753618	0.539	rs2106294	ENSG00000236132.1	CTA-440B3.1	6.29	6.96e-10	3.33e-07	0.34	0.28	Colorectal cancer;	chr22:31249773	chr22:31816379~31817491:-
LUAD	cis	rs12468226	0.938	rs12464254	ENSG00000226261.1	AC064836.3	6.29	6.96e-10	3.33e-07	0.46	0.28	Urate levels;	chr2:202301641	chr2:202336024~202336727:-
LUAD	cis	rs11676348	0.774	rs4672870	ENSG00000261338.2	RP11-378A13.1	-6.29	6.97e-10	3.34e-07	-0.29	-0.28	Ulcerative colitis;	chr2:218077193	chr2:218255319~218257366:+
LUAD	cis	rs12468226	0.938	rs3731700	ENSG00000226261.1	AC064836.3	6.29	6.98e-10	3.34e-07	0.46	0.28	Urate levels;	chr2:202291213	chr2:202336024~202336727:-
LUAD	cis	rs12468226	0.938	rs12471060	ENSG00000226261.1	AC064836.3	6.29	6.98e-10	3.34e-07	0.46	0.28	Urate levels;	chr2:202309597	chr2:202336024~202336727:-
LUAD	cis	rs875971	0.964	rs697969	ENSG00000222364.1	RNU6-96P	6.29	6.99e-10	3.34e-07	0.31	0.28	Aortic root size;	chr7:66093491	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs1182882	ENSG00000222364.1	RNU6-96P	6.29	6.99e-10	3.34e-07	0.31	0.28	Aortic root size;	chr7:66097076	chr7:66395191~66395286:+
LUAD	cis	rs2117029	0.521	rs1039225	ENSG00000258017.1	RP11-386G11.10	-6.29	6.99e-10	3.34e-07	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49188909	chr12:49127782~49147869:+
LUAD	cis	rs172166	0.694	rs1225716	ENSG00000219392.1	RP1-265C24.5	-6.29	7e-10	3.35e-07	-0.37	-0.28	Cardiac Troponin-T levels;	chr6:28145968	chr6:28115628~28116551:+
LUAD	cis	rs11676348	0.772	rs10932745	ENSG00000261338.2	RP11-378A13.1	-6.29	7e-10	3.35e-07	-0.29	-0.28	Ulcerative colitis;	chr2:218078253	chr2:218255319~218257366:+
LUAD	cis	rs150992	0.79	rs325220	ENSG00000248489.1	CTD-2007H13.3	6.29	7.03e-10	3.36e-07	0.3	0.28	Body mass index;	chr5:98968860	chr5:98929171~98995013:+
LUAD	cis	rs35740288	0.77	rs11634707	ENSG00000202081.1	RNU6-1280P	6.29	7.05e-10	3.37e-07	0.34	0.28	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85608636	chr15:85651522~85651628:-
LUAD	cis	rs17301013	0.507	rs61528155	ENSG00000227373.4	RP11-160H22.5	6.29	7.05e-10	3.37e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174276140	chr1:174115300~174160004:-
LUAD	cis	rs227932	0.764	rs78660981	ENSG00000234286.1	AC006026.13	-6.29	7.05e-10	3.37e-07	-0.49	-0.28	Schizophrenia;	chr7:23719296	chr7:23680195~23680786:-
LUAD	cis	rs3762637	1	rs7644540	ENSG00000272758.4	RP11-299J3.8	-6.29	7.06e-10	3.37e-07	-0.43	-0.28	LDL cholesterol levels;	chr3:122491205	chr3:122416207~122443180:+
LUAD	cis	rs496547	0.686	rs524590	ENSG00000255422.1	AP002954.4	-6.29	7.06e-10	3.38e-07	-0.35	-0.28	Hip minimal joint space width;	chr11:118769354	chr11:118704607~118750263:+
LUAD	cis	rs1012068	0.686	rs5998176	ENSG00000236132.1	CTA-440B3.1	-6.29	7.08e-10	3.38e-07	-0.33	-0.28	Chronic hepatitis C infection;	chr22:31922107	chr22:31816379~31817491:-
LUAD	cis	rs7615952	0.8	rs2062773	ENSG00000171084.14	FAM86JP	6.29	7.08e-10	3.38e-07	0.39	0.28	Blood pressure (smoking interaction);	chr3:125920805	chr3:125916620~125930024:+
LUAD	cis	rs17301013	0.507	rs12065527	ENSG00000227373.4	RP11-160H22.5	6.29	7.08e-10	3.38e-07	0.4	0.28	Systemic lupus erythematosus;	chr1:174627066	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12064403	ENSG00000227373.4	RP11-160H22.5	6.29	7.08e-10	3.38e-07	0.4	0.28	Systemic lupus erythematosus;	chr1:174627067	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12065825	ENSG00000227373.4	RP11-160H22.5	6.29	7.08e-10	3.38e-07	0.4	0.28	Systemic lupus erythematosus;	chr1:174627902	chr1:174115300~174160004:-
LUAD	cis	rs804292	1	rs804292	ENSG00000255046.1	RP11-297N6.4	-6.29	7.09e-10	3.39e-07	-0.4	-0.28	Nicotine use;Alcohol dependence;	chr8:11786406	chr8:11797928~11802568:-
LUAD	cis	rs17301013	0.507	rs12076548	ENSG00000227373.4	RP11-160H22.5	-6.29	7.09e-10	3.39e-07	-0.41	-0.28	Systemic lupus erythematosus;	chr1:174479005	chr1:174115300~174160004:-
LUAD	cis	rs11096990	0.892	rs1473364	ENSG00000249207.1	RP11-360F5.1	-6.29	7.09e-10	3.39e-07	-0.31	-0.28	Cognitive function;	chr4:39211259	chr4:39112677~39126818:-
LUAD	cis	rs4591358	0.773	rs35070116	ENSG00000223466.1	AC064834.2	-6.29	7.09e-10	3.39e-07	-0.37	-0.28	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195515729	chr2:195533035~195538681:+
LUAD	cis	rs1707322	0.717	rs1547925	ENSG00000234329.1	RP11-767N6.2	-6.29	7.09e-10	3.39e-07	-0.29	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619684	chr1:45651039~45651826:-
LUAD	cis	rs7811142	1	rs73161759	ENSG00000242294.5	STAG3L5P	6.29	7.1e-10	3.39e-07	0.23	0.28	Platelet count;	chr7:100412371	chr7:100336079~100351900:+
LUAD	cis	rs897200	1	rs55925192	ENSG00000280083.1	RP11-317J9.1	6.29	7.1e-10	3.39e-07	0.35	0.28	Behcet's disease;	chr2:191154393	chr2:191154118~191156070:-
LUAD	cis	rs1154275	0.511	rs10934187	ENSG00000242770.2	RP11-180K7.1	-6.29	7.12e-10	3.4e-07	-0.28	-0.28	Takotsubo syndrome;	chr3:112794635	chr3:112802478~112812819:+
LUAD	cis	rs853679	0.517	rs6932109	ENSG00000204709.4	LINC01556	-6.29	7.13e-10	3.41e-07	-0.38	-0.28	Depression;	chr6:28110525	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs67340775	ENSG00000204709.4	LINC01556	6.29	7.14e-10	3.41e-07	0.6	0.28	Depression;	chr6:28336607	chr6:28943877~28944537:+
LUAD	cis	rs2243480	1	rs781156	ENSG00000230295.1	RP11-458F8.2	-6.29	7.16e-10	3.42e-07	-0.33	-0.28	Diabetic kidney disease;	chr7:66014154	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs781149	ENSG00000230295.1	RP11-458F8.2	-6.29	7.16e-10	3.42e-07	-0.33	-0.28	Diabetic kidney disease;	chr7:66016297	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs451396	ENSG00000230295.1	RP11-458F8.2	-6.29	7.16e-10	3.42e-07	-0.33	-0.28	Diabetic kidney disease;	chr7:66019087	chr7:66880708~66882981:+
LUAD	cis	rs2243480	0.901	rs58207111	ENSG00000230295.1	RP11-458F8.2	-6.29	7.16e-10	3.42e-07	-0.33	-0.28	Diabetic kidney disease;	chr7:66021736	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs1167613	ENSG00000230295.1	RP11-458F8.2	-6.29	7.16e-10	3.42e-07	-0.33	-0.28	Diabetic kidney disease;	chr7:66022452	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs1715235	ENSG00000230295.1	RP11-458F8.2	-6.29	7.16e-10	3.42e-07	-0.33	-0.28	Diabetic kidney disease;	chr7:66023407	chr7:66880708~66882981:+
LUAD	cis	rs2412819	0.571	rs7174260	ENSG00000205771.5	CATSPER2P1	-6.29	7.17e-10	3.42e-07	-0.44	-0.28	Lung cancer;	chr15:43751988	chr15:43726918~43747094:-
LUAD	cis	rs7017914	0.934	rs7830550	ENSG00000223220.1	Y_RNA	6.29	7.18e-10	3.43e-07	0.31	0.28	Bone mineral density;	chr8:70658196	chr8:70780914~70781008:-
LUAD	cis	rs950169	0.544	rs62021193	ENSG00000259728.4	LINC00933	6.29	7.19e-10	3.43e-07	0.4	0.28	Schizophrenia;	chr15:84627352	chr15:84570649~84580175:+
LUAD	cis	rs950169	1	rs1848093	ENSG00000259728.4	LINC00933	6.29	7.19e-10	3.43e-07	0.42	0.28	Schizophrenia;	chr15:84086775	chr15:84570649~84580175:+
LUAD	cis	rs11096990	0.964	rs3733280	ENSG00000249207.1	RP11-360F5.1	6.29	7.19e-10	3.43e-07	0.32	0.28	Cognitive function;	chr4:39269921	chr4:39112677~39126818:-
LUAD	cis	rs10740039	0.883	rs7088404	ENSG00000254271.1	RP11-131N11.4	6.29	7.19e-10	3.43e-07	0.32	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60633320	chr10:60734342~60741828:+
LUAD	cis	rs9326248	0.559	rs484646	ENSG00000280143.1	AP000892.6	6.29	7.2e-10	3.44e-07	0.32	0.28	Blood protein levels;	chr11:116862140	chr11:117204967~117210292:+
LUAD	cis	rs3738443	0.52	rs1771932	ENSG00000259865.1	RP11-488L18.10	6.29	7.2e-10	3.44e-07	0.23	0.28	Alcohol dependence;	chr1:247218747	chr1:247187281~247188526:-
LUAD	cis	rs72772090	0.539	rs72775817	ENSG00000248734.2	CTD-2260A17.1	-6.29	7.2e-10	3.44e-07	-0.44	-0.28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96855006	chr5:96784777~96785999:+
LUAD	cis	rs2524005	1	rs2524005	ENSG00000176998.4	HCG4	-6.29	7.2e-10	3.44e-07	-0.35	-0.28	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29791753~29792750:-
LUAD	cis	rs4927850	0.723	rs7630825	ENSG00000231464.1	AC024937.4	6.29	7.22e-10	3.45e-07	0.31	0.28	Pancreatic cancer;	chr3:196026869	chr3:195996738~195998233:+
LUAD	cis	rs7246657	0.943	rs4803460	ENSG00000276846.1	CTD-3220F14.3	6.29	7.22e-10	3.45e-07	0.38	0.28	Coronary artery calcification;	chr19:37394326	chr19:37314868~37315620:-
LUAD	cis	rs9640161	0.83	rs7800196	ENSG00000261305.1	RP4-584D14.7	6.29	7.22e-10	3.45e-07	0.39	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150364445	chr7:150341771~150342607:+
LUAD	cis	rs783540	0.934	rs10400906	ENSG00000278603.1	RP13-608F4.5	6.29	7.23e-10	3.45e-07	0.32	0.28	Schizophrenia;	chr15:82628387	chr15:82472203~82472426:+
LUAD	cis	rs11096990	0.927	rs6845858	ENSG00000249207.1	RP11-360F5.1	6.29	7.24e-10	3.45e-07	0.31	0.28	Cognitive function;	chr4:39237099	chr4:39112677~39126818:-
LUAD	cis	rs875971	1	rs697970	ENSG00000222364.1	RNU6-96P	6.29	7.24e-10	3.46e-07	0.31	0.28	Aortic root size;	chr7:66095065	chr7:66395191~66395286:+
LUAD	cis	rs950169	0.922	rs4842939	ENSG00000259728.4	LINC00933	-6.29	7.25e-10	3.46e-07	-0.38	-0.28	Schizophrenia;	chr15:84159214	chr15:84570649~84580175:+
LUAD	cis	rs11118620	1	rs11118620	ENSG00000257551.1	HLX-AS1	6.29	7.26e-10	3.47e-07	0.34	0.28	Heart failure;	chr1:220855166	chr1:220832763~220880140:-
LUAD	cis	rs1823913	0.562	rs17347499	ENSG00000280083.1	RP11-317J9.1	-6.29	7.26e-10	3.47e-07	-0.33	-0.28	Obesity-related traits;	chr2:191301116	chr2:191154118~191156070:-
LUAD	cis	rs12439619	0.774	rs2867649	ENSG00000255769.6	GOLGA2P10	-6.29	7.27e-10	3.47e-07	-0.35	-0.28	Intelligence (multi-trait analysis);	chr15:82262331	chr15:82472993~82513950:-
LUAD	cis	rs7246657	0.943	rs4803347	ENSG00000276846.1	CTD-3220F14.3	6.29	7.29e-10	3.48e-07	0.38	0.28	Coronary artery calcification;	chr19:37357115	chr19:37314868~37315620:-
LUAD	cis	rs2243480	1	rs35820085	ENSG00000226824.5	RP4-756H11.3	-6.29	7.3e-10	3.48e-07	-0.52	-0.28	Diabetic kidney disease;	chr7:65977771	chr7:66654538~66669855:+
LUAD	cis	rs8072100	1	rs4794016	ENSG00000228782.6	CTD-2026D20.3	-6.29	7.32e-10	3.49e-07	-0.29	-0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47648565	chr17:47450568~47492492:-
LUAD	cis	rs4718428	0.705	rs62465692	ENSG00000232546.1	RP11-458F8.1	-6.29	7.32e-10	3.49e-07	-0.26	-0.28	Corneal structure;	chr7:66830758	chr7:66848496~66858136:+
LUAD	cis	rs853679	0.542	rs6934769	ENSG00000204709.4	LINC01556	6.29	7.33e-10	3.49e-07	0.38	0.28	Depression;	chr6:28123153	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs17711801	ENSG00000204709.4	LINC01556	6.29	7.33e-10	3.49e-07	0.38	0.28	Depression;	chr6:28124529	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs6922063	ENSG00000204709.4	LINC01556	6.29	7.33e-10	3.49e-07	0.38	0.28	Depression;	chr6:28126588	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs2275508	ENSG00000204709.4	LINC01556	6.29	7.33e-10	3.49e-07	0.38	0.28	Depression;	chr6:28126953	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.527	rs9461433	ENSG00000204709.4	LINC01556	6.29	7.33e-10	3.49e-07	0.38	0.28	Parkinson's disease;	chr6:28127394	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9468292	ENSG00000204709.4	LINC01556	6.29	7.33e-10	3.49e-07	0.38	0.28	Depression;	chr6:28127577	chr6:28943877~28944537:+
LUAD	cis	rs1707322	0.721	rs10890336	ENSG00000234329.1	RP11-767N6.2	6.29	7.33e-10	3.49e-07	0.29	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645384	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs11211151	ENSG00000234329.1	RP11-767N6.2	6.29	7.33e-10	3.49e-07	0.29	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45647080	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs12045096	ENSG00000234329.1	RP11-767N6.2	6.29	7.33e-10	3.49e-07	0.29	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648756	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs4609469	ENSG00000234329.1	RP11-767N6.2	6.29	7.33e-10	3.49e-07	0.29	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651513	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs12049027	ENSG00000234329.1	RP11-767N6.2	6.29	7.33e-10	3.49e-07	0.29	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45652512	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs10789467	ENSG00000234329.1	RP11-767N6.2	6.29	7.33e-10	3.49e-07	0.29	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45653073	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs10890337	ENSG00000234329.1	RP11-767N6.2	6.29	7.33e-10	3.49e-07	0.29	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658855	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs3811435	ENSG00000234329.1	RP11-767N6.2	6.29	7.33e-10	3.49e-07	0.29	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660118	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs9793568	ENSG00000234329.1	RP11-767N6.2	6.29	7.33e-10	3.49e-07	0.29	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664701	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs11211157	ENSG00000234329.1	RP11-767N6.2	6.29	7.33e-10	3.49e-07	0.29	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667172	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs11211158	ENSG00000234329.1	RP11-767N6.2	6.29	7.33e-10	3.49e-07	0.29	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667178	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs6429575	ENSG00000234329.1	RP11-767N6.2	6.29	7.33e-10	3.49e-07	0.29	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668544	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.685	rs6690926	ENSG00000234329.1	RP11-767N6.2	6.29	7.33e-10	3.49e-07	0.29	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669306	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs8179402	ENSG00000234329.1	RP11-767N6.2	6.29	7.33e-10	3.49e-07	0.29	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45676794	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs8179296	ENSG00000234329.1	RP11-767N6.2	6.29	7.33e-10	3.49e-07	0.29	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45678119	chr1:45651039~45651826:-
LUAD	cis	rs4713118	0.955	rs9368529	ENSG00000219392.1	RP1-265C24.5	-6.29	7.33e-10	3.49e-07	-0.37	-0.28	Parkinson's disease;	chr6:27716852	chr6:28115628~28116551:+
LUAD	cis	rs5753618	0.509	rs4820951	ENSG00000236132.1	CTA-440B3.1	6.29	7.33e-10	3.5e-07	0.35	0.28	Colorectal cancer;	chr22:31190262	chr22:31816379~31817491:-
LUAD	cis	rs5753618	0.509	rs5749229	ENSG00000236132.1	CTA-440B3.1	6.29	7.33e-10	3.5e-07	0.35	0.28	Colorectal cancer;	chr22:31191232	chr22:31816379~31817491:-
LUAD	cis	rs4141404	0.787	rs4820042	ENSG00000236132.1	CTA-440B3.1	6.29	7.33e-10	3.5e-07	0.35	0.28	Paclitaxel-induced neuropathy;	chr22:31193070	chr22:31816379~31817491:-
LUAD	cis	rs5753618	0.509	rs5997912	ENSG00000236132.1	CTA-440B3.1	6.29	7.33e-10	3.5e-07	0.35	0.28	Colorectal cancer;	chr22:31197875	chr22:31816379~31817491:-
LUAD	cis	rs5753618	0.509	rs5997913	ENSG00000236132.1	CTA-440B3.1	6.29	7.33e-10	3.5e-07	0.35	0.28	Colorectal cancer;	chr22:31197973	chr22:31816379~31817491:-
LUAD	cis	rs293748	0.882	rs16903459	ENSG00000250155.1	CTD-2353F22.1	-6.29	7.34e-10	3.5e-07	-0.39	-0.28	Obesity-related traits;	chr5:37031314	chr5:36666214~36725195:-
LUAD	cis	rs1707322	0.721	rs11211149	ENSG00000234329.1	RP11-767N6.2	6.29	7.34e-10	3.5e-07	0.29	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45646546	chr1:45651039~45651826:-
LUAD	cis	rs1823913	0.538	rs35311234	ENSG00000280083.1	RP11-317J9.1	-6.29	7.34e-10	3.5e-07	-0.33	-0.28	Obesity-related traits;	chr2:191316952	chr2:191154118~191156070:-
LUAD	cis	rs3096299	0.9	rs4785666	ENSG00000274627.1	RP11-104N10.2	6.29	7.34e-10	3.5e-07	0.26	0.28	Multiple myeloma (IgH translocation);	chr16:89396363	chr16:89516797~89522217:+
LUAD	cis	rs2408955	0.521	rs7301003	ENSG00000240399.1	RP1-228P16.1	6.29	7.35e-10	3.5e-07	0.27	0.28	Glycated hemoglobin levels;	chr12:48156444	chr12:48054813~48055591:-
LUAD	cis	rs9543976	0.92	rs9543972	ENSG00000261553.4	RP11-29G8.3	6.28	7.37e-10	3.51e-07	0.4	0.28	Diabetic retinopathy;	chr13:75547539	chr13:75549773~75807120:+
LUAD	cis	rs2739330	0.796	rs5760106	ENSG00000228039.3	KB-1125A3.10	-6.28	7.38e-10	3.51e-07	-0.34	-0.28	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23963780~23964374:+
LUAD	cis	rs948562	1	rs3829218	ENSG00000280010.1	AP001350.4	6.28	7.38e-10	3.52e-07	0.43	0.28	Lymphoma;	chr11:58563836	chr11:58627435~58628528:+
LUAD	cis	rs2980439	0.818	rs2945249	ENSG00000173295.6	FAM86B3P	6.28	7.39e-10	3.52e-07	0.3	0.28	Neuroticism;	chr8:8237204	chr8:8228595~8244865:+
LUAD	cis	rs1823913	0.599	rs2124095	ENSG00000280083.1	RP11-317J9.1	-6.28	7.39e-10	3.52e-07	-0.33	-0.28	Obesity-related traits;	chr2:191301728	chr2:191154118~191156070:-
LUAD	cis	rs875971	0.545	rs73378304	ENSG00000226824.5	RP4-756H11.3	-6.28	7.4e-10	3.53e-07	-0.4	-0.28	Aortic root size;	chr7:66175760	chr7:66654538~66669855:+
LUAD	cis	rs1799949	0.965	rs1842147	ENSG00000267681.1	CTD-3199J23.6	-6.28	7.41e-10	3.53e-07	-0.32	-0.28	Menopause (age at onset);	chr17:43357824	chr17:43144956~43145255:+
LUAD	cis	rs2034650	0.544	rs661488	ENSG00000223313.1	RNU6-516P	6.28	7.41e-10	3.53e-07	0.36	0.28	Interstitial lung disease;	chr15:40429221	chr15:40529570~40529673:+
LUAD	cis	rs113835537	0.597	rs3737525	ENSG00000255517.5	CTD-3074O7.5	-6.28	7.41e-10	3.53e-07	-0.34	-0.28	Airway imaging phenotypes;	chr11:66538884	chr11:66473490~66480233:-
LUAD	cis	rs11098499	0.754	rs28643450	ENSG00000248280.1	RP11-33B1.2	6.28	7.42e-10	3.53e-07	0.34	0.28	Corneal astigmatism;	chr4:119324087	chr4:119440561~119450157:-
LUAD	cis	rs10129255	0.957	rs2007467	ENSG00000224373.3	IGHV4-59	-6.28	7.42e-10	3.53e-07	-0.18	-0.28	Kawasaki disease;	chr14:106771605	chr14:106627249~106627825:-
LUAD	cis	rs17301013	0.507	rs4652652	ENSG00000227373.4	RP11-160H22.5	6.28	7.42e-10	3.53e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174596582	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs4651103	ENSG00000227373.4	RP11-160H22.5	6.28	7.42e-10	3.53e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174596750	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs72715262	ENSG00000227373.4	RP11-160H22.5	6.28	7.42e-10	3.53e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174607088	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs4615901	ENSG00000227373.4	RP11-160H22.5	6.28	7.42e-10	3.53e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174609432	chr1:174115300~174160004:-
LUAD	cis	rs7727544	0.735	rs272894	ENSG00000233006.5	AC034220.3	6.28	7.42e-10	3.53e-07	0.24	0.28	Blood metabolite levels;	chr5:132326767	chr5:132311285~132369916:-
LUAD	cis	rs897200	1	rs16833453	ENSG00000280083.1	RP11-317J9.1	6.28	7.43e-10	3.54e-07	0.35	0.28	Behcet's disease;	chr2:191159824	chr2:191154118~191156070:-
LUAD	cis	rs897200	0.965	rs57081321	ENSG00000280083.1	RP11-317J9.1	6.28	7.43e-10	3.54e-07	0.35	0.28	Behcet's disease;	chr2:191160259	chr2:191154118~191156070:-
LUAD	cis	rs7927592	0.956	rs12277225	ENSG00000212093.1	AP000807.1	6.28	7.44e-10	3.54e-07	0.31	0.28	Total body bone mineral density;	chr11:68573499	chr11:68506083~68506166:-
LUAD	cis	rs55665837	1	rs10832278	ENSG00000251991.1	RNU7-49P	6.28	7.48e-10	3.56e-07	0.31	0.28	Vitamin D levels;	chr11:14475073	chr11:14478892~14478953:+
LUAD	cis	rs6558530	0.932	rs7846610	ENSG00000253982.1	CTD-2336O2.1	6.28	7.48e-10	3.56e-07	0.33	0.28	Systolic blood pressure;	chr8:1758509	chr8:1761990~1764502:-
LUAD	cis	rs6991838	0.778	rs11779602	ENSG00000272010.1	CTD-3025N20.3	6.28	7.49e-10	3.56e-07	0.28	0.28	Intelligence (multi-trait analysis);	chr8:65550247	chr8:65591850~65592472:-
LUAD	cis	rs367615	0.918	rs4270746	ENSG00000249476.1	CTD-2587M2.1	6.28	7.5e-10	3.57e-07	0.36	0.28	Colorectal cancer (SNP x SNP interaction);	chr5:109541138	chr5:109237120~109326369:-
LUAD	cis	rs9368481	0.761	rs7775041	ENSG00000241549.7	GUSBP2	-6.28	7.5e-10	3.57e-07	-0.31	-0.28	Autism spectrum disorder or schizophrenia;	chr6:27041733	chr6:26871484~26956554:-
LUAD	cis	rs12908161	0.959	rs17534709	ENSG00000259728.4	LINC00933	6.28	7.5e-10	3.57e-07	0.41	0.28	Schizophrenia;	chr15:84771166	chr15:84570649~84580175:+
LUAD	cis	rs11089937	0.554	rs5995628	ENSG00000211639.2	IGLV4-60	6.28	7.5e-10	3.57e-07	0.3	0.28	Periodontitis (PAL4Q3);	chr22:22194768	chr22:22162199~22162681:+
LUAD	cis	rs4591358	0.773	rs16836736	ENSG00000223466.1	AC064834.2	-6.28	7.51e-10	3.57e-07	-0.37	-0.28	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195511283	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.773	rs13035516	ENSG00000223466.1	AC064834.2	-6.28	7.51e-10	3.57e-07	-0.37	-0.28	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195513234	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.773	rs34475459	ENSG00000223466.1	AC064834.2	-6.28	7.51e-10	3.57e-07	-0.37	-0.28	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195515682	chr2:195533035~195538681:+
LUAD	cis	rs875971	0.862	rs1695820	ENSG00000222364.1	RNU6-96P	-6.28	7.51e-10	3.57e-07	-0.31	-0.28	Aortic root size;	chr7:66379576	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.83	rs778715	ENSG00000222364.1	RNU6-96P	-6.28	7.51e-10	3.57e-07	-0.31	-0.28	Aortic root size;	chr7:66384222	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.83	rs809025	ENSG00000222364.1	RNU6-96P	-6.28	7.51e-10	3.57e-07	-0.31	-0.28	Aortic root size;	chr7:66384832	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs778702	ENSG00000222364.1	RNU6-96P	-6.28	7.51e-10	3.57e-07	-0.31	-0.28	Aortic root size;	chr7:66399848	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs1643375	ENSG00000222364.1	RNU6-96P	-6.28	7.51e-10	3.57e-07	-0.31	-0.28	Aortic root size;	chr7:66407690	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs6962717	ENSG00000222364.1	RNU6-96P	-6.28	7.51e-10	3.57e-07	-0.31	-0.28	Aortic root size;	chr7:66418748	chr7:66395191~66395286:+
LUAD	cis	rs7598759	0.527	rs4973417	ENSG00000181798.2	LINC00471	-6.28	7.52e-10	3.58e-07	-0.3	-0.28	Noise-induced hearing loss;	chr2:231484925	chr2:231508426~231514339:-
LUAD	cis	rs2034650	0.544	rs11070272	ENSG00000223313.1	RNU6-516P	6.28	7.52e-10	3.58e-07	0.36	0.28	Interstitial lung disease;	chr15:40433064	chr15:40529570~40529673:+
LUAD	cis	rs3096299	0.934	rs9927904	ENSG00000274627.1	RP11-104N10.2	6.28	7.52e-10	3.58e-07	0.27	0.28	Multiple myeloma (IgH translocation);	chr16:89396439	chr16:89516797~89522217:+
LUAD	cis	rs4723738	0.967	rs10480164	ENSG00000227191.5	TRGC2	-6.28	7.52e-10	3.58e-07	-0.3	-0.28	Treatment response for severe sepsis;	chr7:38206281	chr7:38239580~38368091:-
LUAD	cis	rs4964805	0.549	rs2292682	ENSG00000257681.1	RP11-341G23.4	6.28	7.53e-10	3.58e-07	0.33	0.28	Attention deficit hyperactivity disorder;	chr12:103762742	chr12:103746315~103768858:-
LUAD	cis	rs11155671	0.53	rs6557133	ENSG00000268592.3	RAET1E-AS1	6.28	7.54e-10	3.59e-07	0.33	0.28	Testicular germ cell tumor;	chr6:149874248	chr6:149863494~149919507:+
LUAD	cis	rs801193	0.636	rs10233806	ENSG00000222364.1	RNU6-96P	6.28	7.55e-10	3.59e-07	0.31	0.28	Aortic root size;	chr7:66653261	chr7:66395191~66395286:+
LUAD	cis	rs6844153	0.752	rs12641261	ENSG00000240005.4	RP11-293A21.1	-6.28	7.55e-10	3.59e-07	-0.4	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26872814	chr4:26859806~26860599:-
LUAD	cis	rs6844153	0.752	rs6815719	ENSG00000240005.4	RP11-293A21.1	-6.28	7.55e-10	3.59e-07	-0.4	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26880232	chr4:26859806~26860599:-
LUAD	cis	rs875971	0.965	rs10267430	ENSG00000222364.1	RNU6-96P	6.28	7.56e-10	3.6e-07	0.31	0.28	Aortic root size;	chr7:66278036	chr7:66395191~66395286:+
LUAD	cis	rs11690935	0.632	rs34531723	ENSG00000228389.1	AC068039.4	-6.28	7.57e-10	3.6e-07	-0.29	-0.28	Schizophrenia;	chr2:171707584	chr2:171773482~171775844:+
LUAD	cis	rs293748	0.571	rs10042473	ENSG00000250155.1	CTD-2353F22.1	-6.28	7.59e-10	3.61e-07	-0.33	-0.28	Obesity-related traits;	chr5:37243651	chr5:36666214~36725195:-
LUAD	cis	rs9640161	0.83	rs35840727	ENSG00000261305.1	RP4-584D14.7	6.28	7.6e-10	3.61e-07	0.41	0.28	Blood protein levels;Circulating chemerin levels;	chr7:150366115	chr7:150341771~150342607:+
LUAD	cis	rs8062405	0.895	rs62036658	ENSG00000251417.2	RP11-1348G14.4	-6.28	7.6e-10	3.61e-07	-0.29	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28839050	chr16:28802743~28817828:+
LUAD	cis	rs948562	0.895	rs11229537	ENSG00000280010.1	AP001350.4	6.28	7.6e-10	3.61e-07	0.43	0.28	Lymphoma;	chr11:58585392	chr11:58627435~58628528:+
LUAD	cis	rs4718428	0.705	rs4718424	ENSG00000273142.1	RP11-458F8.4	-6.28	7.64e-10	3.63e-07	-0.21	-0.28	Corneal structure;	chr7:66911108	chr7:66902857~66906297:+
LUAD	cis	rs10759883	0.563	rs657451	ENSG00000175611.10	LINC00476	-6.28	7.65e-10	3.63e-07	-0.31	-0.28	Nicotine dependence;	chr9:96003496	chr9:95759231~95875977:-
LUAD	cis	rs17301013	0.507	rs16846861	ENSG00000227373.4	RP11-160H22.5	6.28	7.65e-10	3.63e-07	0.42	0.28	Systemic lupus erythematosus;	chr1:174338731	chr1:174115300~174160004:-
LUAD	cis	rs270601	0.913	rs273916	ENSG00000233006.5	AC034220.3	6.28	7.66e-10	3.64e-07	0.28	0.28	Acylcarnitine levels;	chr5:132324137	chr5:132311285~132369916:-
LUAD	cis	rs75920871	0.589	rs7941150	ENSG00000254851.1	RP11-109L13.1	-6.28	7.67e-10	3.64e-07	-0.47	-0.28	Subjective well-being;	chr11:117221105	chr11:117135528~117138582:+
LUAD	cis	rs11690935	0.632	rs2292816	ENSG00000228389.1	AC068039.4	-6.28	7.67e-10	3.64e-07	-0.29	-0.28	Schizophrenia;	chr2:171730204	chr2:171773482~171775844:+
LUAD	cis	rs12699921	0.632	rs2691594	ENSG00000279048.1	RP11-511H23.2	-6.28	7.67e-10	3.64e-07	-0.22	-0.28	Fibrinogen levels;	chr7:17825193	chr7:17940503~17942922:+
LUAD	cis	rs7567389	0.719	rs4662713	ENSG00000236682.1	AC068282.3	6.28	7.68e-10	3.65e-07	0.4	0.28	Self-rated health;	chr2:127236527	chr2:127389130~127400580:+
LUAD	cis	rs30380	0.632	rs27045	ENSG00000272109.1	CTD-2260A17.3	-6.28	7.68e-10	3.65e-07	-0.33	-0.28	Cerebrospinal fluid biomarker levels;	chr5:96803158	chr5:96804353~96806105:+
LUAD	cis	rs10129255	0.833	rs7156689	ENSG00000224373.3	IGHV4-59	6.28	7.68e-10	3.65e-07	0.18	0.28	Kawasaki disease;	chr14:106816039	chr14:106627249~106627825:-
LUAD	cis	rs77204473	1	rs17120132	ENSG00000254851.1	RP11-109L13.1	6.28	7.69e-10	3.65e-07	0.67	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116902602	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs17120136	ENSG00000254851.1	RP11-109L13.1	6.28	7.69e-10	3.65e-07	0.67	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903045	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs78694306	ENSG00000254851.1	RP11-109L13.1	6.28	7.69e-10	3.65e-07	0.67	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903528	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs115971514	ENSG00000254851.1	RP11-109L13.1	6.28	7.69e-10	3.65e-07	0.67	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903783	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs12280030	ENSG00000254851.1	RP11-109L13.1	6.28	7.69e-10	3.65e-07	0.67	0.28	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116904480	chr11:117135528~117138582:+
LUAD	cis	rs8072100	1	rs3809868	ENSG00000228782.6	CTD-2026D20.3	-6.28	7.69e-10	3.65e-07	-0.29	-0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47673230	chr17:47450568~47492492:-
LUAD	cis	rs2111504	0.583	rs2868082	ENSG00000267213.4	AC007773.2	6.28	7.69e-10	3.65e-07	0.36	0.28	Bipolar disorder;	chr19:32368475	chr19:32390050~32405560:-
LUAD	cis	rs3738443	0.599	rs6693807	ENSG00000259865.1	RP11-488L18.10	-6.28	7.69e-10	3.65e-07	-0.24	-0.28	Alcohol dependence;	chr1:247230353	chr1:247187281~247188526:-
LUAD	cis	rs987724	0.592	rs1430411	ENSG00000240875.4	LINC00886	-6.28	7.7e-10	3.66e-07	-0.3	-0.28	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156807607	chr3:156747346~156817062:-
LUAD	cis	rs11168854	0.651	rs12227770	ENSG00000258017.1	RP11-386G11.10	-6.28	7.7e-10	3.66e-07	-0.34	-0.28	Body mass index;	chr12:49183065	chr12:49127782~49147869:+
LUAD	cis	rs4835473	0.932	rs17018238	ENSG00000251600.4	RP11-673E1.1	-6.28	7.7e-10	3.66e-07	-0.34	-0.28	Immature fraction of reticulocytes;	chr4:143782737	chr4:143912331~143982454:+
LUAD	cis	rs7626444	0.647	rs843537	ENSG00000272359.1	U4	-6.28	7.71e-10	3.66e-07	-0.31	-0.28	Monocyte count;	chr3:196746532	chr3:196747192~196747324:-
LUAD	cis	rs5753618	0.561	rs2078803	ENSG00000236132.1	CTA-440B3.1	6.28	7.71e-10	3.66e-07	0.35	0.28	Colorectal cancer;	chr22:31256866	chr22:31816379~31817491:-
LUAD	cis	rs7923609	1	rs2393969	ENSG00000232075.1	MRPL35P2	-6.28	7.71e-10	3.66e-07	-0.33	-0.28	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63380680	chr10:63634317~63634827:-
LUAD	cis	rs155076	1	rs261407	ENSG00000233325.3	MIPEPP3	6.28	7.72e-10	3.66e-07	0.43	0.28	White matter hyperintensity burden;	chr13:21281074	chr13:21298139~21306373:+
LUAD	cis	rs155076	1	rs261406	ENSG00000233325.3	MIPEPP3	6.28	7.72e-10	3.66e-07	0.43	0.28	White matter hyperintensity burden;	chr13:21281715	chr13:21298139~21306373:+
LUAD	cis	rs8100891	0.537	rs11880569	ENSG00000267213.4	AC007773.2	-6.28	7.72e-10	3.66e-07	-0.44	-0.28	Neuroticism;	chr19:32478348	chr19:32390050~32405560:-
LUAD	cis	rs858239	0.698	rs858295	ENSG00000226816.2	AC005082.12	6.28	7.72e-10	3.67e-07	0.36	0.28	Cerebrospinal fluid biomarker levels;	chr7:23205950	chr7:23206013~23208045:+
LUAD	cis	rs67311347	0.955	rs11717036	ENSG00000223797.4	ENTPD3-AS1	-6.28	7.73e-10	3.67e-07	-0.28	-0.28	Renal cell carcinoma;	chr3:40338087	chr3:40313802~40453329:-
LUAD	cis	rs8100891	0.537	rs16967057	ENSG00000267213.4	AC007773.2	6.28	7.73e-10	3.67e-07	0.42	0.28	Neuroticism;	chr19:32423172	chr19:32390050~32405560:-
LUAD	cis	rs1823913	0.637	rs1378162	ENSG00000280083.1	RP11-317J9.1	-6.28	7.73e-10	3.67e-07	-0.33	-0.28	Obesity-related traits;	chr2:191298523	chr2:191154118~191156070:-
LUAD	cis	rs9549367	0.737	rs11619691	ENSG00000269125.1	RP11-98F14.11	-6.28	7.74e-10	3.67e-07	-0.35	-0.28	Platelet distribution width;	chr13:113250322	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.826	rs9549713	ENSG00000269125.1	RP11-98F14.11	-6.28	7.74e-10	3.67e-07	-0.35	-0.28	Platelet distribution width;	chr13:113250994	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.789	rs3850451	ENSG00000269125.1	RP11-98F14.11	-6.28	7.74e-10	3.67e-07	-0.35	-0.28	Platelet distribution width;	chr13:113251498	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.789	rs3861720	ENSG00000269125.1	RP11-98F14.11	-6.28	7.74e-10	3.67e-07	-0.35	-0.28	Platelet distribution width;	chr13:113251783	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.865	rs3861721	ENSG00000269125.1	RP11-98F14.11	-6.28	7.74e-10	3.67e-07	-0.35	-0.28	Platelet distribution width;	chr13:113251994	chr13:113165002~113165183:-
LUAD	cis	rs2117029	0.555	rs10783304	ENSG00000258017.1	RP11-386G11.10	-6.28	7.74e-10	3.68e-07	-0.35	-0.28	Intelligence (multi-trait analysis);	chr12:49106615	chr12:49127782~49147869:+
LUAD	cis	rs496547	0.719	rs472641	ENSG00000255422.1	AP002954.4	-6.28	7.75e-10	3.68e-07	-0.35	-0.28	Hip minimal joint space width;	chr11:118746835	chr11:118704607~118750263:+
LUAD	cis	rs7829975	0.688	rs6995407	ENSG00000253981.4	ALG1L13P	6.28	7.76e-10	3.68e-07	0.32	0.28	Mood instability;	chr8:8527137	chr8:8236003~8244667:-
LUAD	cis	rs2243480	0.764	rs2460423	ENSG00000232546.1	RP11-458F8.1	-6.28	7.76e-10	3.68e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:66136229	chr7:66848496~66858136:+
LUAD	cis	rs9549367	0.737	rs71446680	ENSG00000269125.1	RP11-98F14.11	-6.28	7.79e-10	3.7e-07	-0.34	-0.28	Platelet distribution width;	chr13:113240532	chr13:113165002~113165183:-
LUAD	cis	rs2243480	1	rs383402	ENSG00000232546.1	RP11-458F8.1	6.28	7.79e-10	3.7e-07	0.35	0.28	Diabetic kidney disease;	chr7:66121666	chr7:66848496~66858136:+
LUAD	cis	rs9309473	0.95	rs6756885	ENSG00000163016.8	ALMS1P	6.27	7.82e-10	3.71e-07	0.34	0.28	Metabolite levels;	chr2:73578045	chr2:73644919~73685576:+
LUAD	cis	rs5753618	0.504	rs9609297	ENSG00000236132.1	CTA-440B3.1	-6.27	7.82e-10	3.71e-07	-0.36	-0.28	Colorectal cancer;	chr22:31497745	chr22:31816379~31817491:-
LUAD	cis	rs11098499	0.754	rs12711071	ENSG00000248280.1	RP11-33B1.2	6.27	7.82e-10	3.71e-07	0.34	0.28	Corneal astigmatism;	chr4:119319779	chr4:119440561~119450157:-
LUAD	cis	rs783540	0.934	rs783530	ENSG00000278603.1	RP13-608F4.5	-6.27	7.83e-10	3.71e-07	-0.32	-0.28	Schizophrenia;	chr15:82597799	chr15:82472203~82472426:+
LUAD	cis	rs875971	1	rs11974219	ENSG00000222364.1	RNU6-96P	6.27	7.84e-10	3.72e-07	0.3	0.28	Aortic root size;	chr7:66182423	chr7:66395191~66395286:+
LUAD	cis	rs7246657	0.943	rs7248733	ENSG00000276846.1	CTD-3220F14.3	6.27	7.84e-10	3.72e-07	0.37	0.28	Coronary artery calcification;	chr19:37505459	chr19:37314868~37315620:-
LUAD	cis	rs67311347	1	rs7612015	ENSG00000223797.4	ENTPD3-AS1	6.27	7.85e-10	3.72e-07	0.28	0.28	Renal cell carcinoma;	chr3:40358483	chr3:40313802~40453329:-
LUAD	cis	rs8177376	0.953	rs73017399	ENSG00000254905.1	RP11-712L6.7	6.27	7.86e-10	3.72e-07	0.4	0.28	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126316417	chr11:126292922~126294254:-
LUAD	cis	rs17301013	0.507	rs12072050	ENSG00000227373.4	RP11-160H22.5	6.27	7.86e-10	3.73e-07	0.43	0.28	Systemic lupus erythematosus;	chr1:174269648	chr1:174115300~174160004:-
LUAD	cis	rs11096990	0.855	rs11737290	ENSG00000249207.1	RP11-360F5.1	6.27	7.86e-10	3.73e-07	0.32	0.28	Cognitive function;	chr4:39192318	chr4:39112677~39126818:-
LUAD	cis	rs507080	0.501	rs494459	ENSG00000278376.1	RP11-158I9.8	6.27	7.86e-10	3.73e-07	0.28	0.28	Serum metabolite levels;	chr11:118703966	chr11:118791254~118793137:+
LUAD	cis	rs7927592	0.956	rs2510384	ENSG00000212093.1	AP000807.1	6.27	7.87e-10	3.73e-07	0.32	0.28	Total body bone mineral density;	chr11:68624369	chr11:68506083~68506166:-
LUAD	cis	rs35160687	0.814	rs1863063	ENSG00000273080.1	RP11-301O19.1	6.27	7.88e-10	3.73e-07	0.3	0.28	Night sleep phenotypes;	chr2:86291126	chr2:86195590~86196049:+
LUAD	cis	rs6860806	0.507	rs156322	ENSG00000233006.5	AC034220.3	6.27	7.88e-10	3.73e-07	0.28	0.28	Breast cancer;	chr5:132318232	chr5:132311285~132369916:-
LUAD	cis	rs2243480	1	rs2243480	ENSG00000232546.1	RP11-458F8.1	-6.27	7.88e-10	3.73e-07	-0.36	-0.28	Diabetic kidney disease;	chr7:66134209	chr7:66848496~66858136:+
LUAD	cis	rs150992	0.609	rs2927648	ENSG00000248489.1	CTD-2007H13.3	6.27	7.89e-10	3.74e-07	0.3	0.28	Body mass index;	chr5:98990273	chr5:98929171~98995013:+
LUAD	cis	rs6860806	0.507	rs272892	ENSG00000233006.5	AC034220.3	6.27	7.9e-10	3.75e-07	0.28	0.27	Breast cancer;	chr5:132328656	chr5:132311285~132369916:-
LUAD	cis	rs6860806	0.531	rs272888	ENSG00000233006.5	AC034220.3	6.27	7.9e-10	3.75e-07	0.28	0.27	Breast cancer;	chr5:132329730	chr5:132311285~132369916:-
LUAD	cis	rs293748	0.882	rs13177875	ENSG00000250155.1	CTD-2353F22.1	-6.27	7.91e-10	3.75e-07	-0.38	-0.27	Obesity-related traits;	chr5:37078226	chr5:36666214~36725195:-
LUAD	cis	rs9549367	0.789	rs7994324	ENSG00000269125.1	RP11-98F14.11	-6.27	7.91e-10	3.75e-07	-0.35	-0.27	Platelet distribution width;	chr13:113252183	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.789	rs9549715	ENSG00000269125.1	RP11-98F14.11	-6.27	7.91e-10	3.75e-07	-0.35	-0.27	Platelet distribution width;	chr13:113253926	chr13:113165002~113165183:-
LUAD	cis	rs2179367	0.92	rs560051	ENSG00000231760.4	RP11-350J20.5	6.27	7.91e-10	3.75e-07	0.34	0.27	Dupuytren's disease;	chr6:149345841	chr6:149796151~149826294:-
LUAD	cis	rs2295359	0.637	rs12044149	ENSG00000275678.1	RP4-547N15.3	-6.27	7.91e-10	3.75e-07	-0.31	-0.27	Psoriasis;	chr1:67135003	chr1:67121605~67123956:-
LUAD	cis	rs55665837	0.961	rs12576926	ENSG00000251991.1	RNU7-49P	6.27	7.91e-10	3.75e-07	0.31	0.27	Vitamin D levels;	chr11:14458746	chr11:14478892~14478953:+
LUAD	cis	rs6860806	0.507	rs270606	ENSG00000233006.5	AC034220.3	6.27	7.91e-10	3.75e-07	0.27	0.27	Breast cancer;	chr5:132315174	chr5:132311285~132369916:-
LUAD	cis	rs3738443	0.594	rs6664697	ENSG00000259865.1	RP11-488L18.10	-6.27	7.92e-10	3.75e-07	-0.23	-0.27	Alcohol dependence;	chr1:247217308	chr1:247187281~247188526:-
LUAD	cis	rs8177876	0.822	rs4889231	ENSG00000261838.4	RP11-303E16.6	-6.27	7.93e-10	3.76e-07	-0.55	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080110	chr16:81069854~81076598:+
LUAD	cis	rs10740039	0.516	rs10740034	ENSG00000254271.1	RP11-131N11.4	6.27	7.93e-10	3.76e-07	0.31	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60592624	chr10:60734342~60741828:+
LUAD	cis	rs67311347	1	rs7648952	ENSG00000223797.4	ENTPD3-AS1	-6.27	7.95e-10	3.76e-07	-0.28	-0.27	Renal cell carcinoma;	chr3:40415547	chr3:40313802~40453329:-
LUAD	cis	rs2019137	0.589	rs7560701	ENSG00000274877.1	RP11-65I12.1	-6.27	7.97e-10	3.78e-07	-0.34	-0.27	Lymphocyte counts;	chr2:113269305	chr2:113237595~113240825:+
LUAD	cis	rs7188445	0.736	rs7500666	ENSG00000261390.4	RP11-345M22.2	6.27	7.98e-10	3.78e-07	0.34	0.27	Urate levels;	chr16:79672509	chr16:79715232~79770563:-
LUAD	cis	rs11096990	0.892	rs1901404	ENSG00000249207.1	RP11-360F5.1	6.27	7.98e-10	3.78e-07	0.31	0.27	Cognitive function;	chr4:39210990	chr4:39112677~39126818:-
LUAD	cis	rs2404602	0.647	rs4886840	ENSG00000259422.1	RP11-593F23.1	-6.27	8.01e-10	3.79e-07	-0.36	-0.27	Blood metabolite levels;	chr15:76886661	chr15:76174891~76181486:-
LUAD	cis	rs72772090	0.539	rs72775807	ENSG00000248734.2	CTD-2260A17.1	-6.27	8.02e-10	3.8e-07	-0.43	-0.27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96844058	chr5:96784777~96785999:+
LUAD	cis	rs17301013	0.507	rs6667107	ENSG00000227373.4	RP11-160H22.5	6.27	8.02e-10	3.8e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174628667	chr1:174115300~174160004:-
LUAD	cis	rs4591358	0.773	rs13008940	ENSG00000223466.1	AC064834.2	-6.27	8.02e-10	3.8e-07	-0.37	-0.27	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195509828	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.689	rs7578371	ENSG00000223466.1	AC064834.2	-6.27	8.02e-10	3.8e-07	-0.37	-0.27	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195510222	chr2:195533035~195538681:+
LUAD	cis	rs1799949	0.773	rs2137990	ENSG00000267681.1	CTD-3199J23.6	6.27	8.04e-10	3.8e-07	0.31	0.27	Menopause (age at onset);	chr17:43165879	chr17:43144956~43145255:+
LUAD	cis	rs875971	0.545	rs316328	ENSG00000226824.5	RP4-756H11.3	6.27	8.04e-10	3.81e-07	0.38	0.27	Aortic root size;	chr7:66143851	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs778679	ENSG00000232546.1	RP11-458F8.1	-6.27	8.04e-10	3.81e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66375924	chr7:66848496~66858136:+
LUAD	cis	rs853679	0.517	rs1947863	ENSG00000204709.4	LINC01556	6.27	8.05e-10	3.81e-07	0.38	0.27	Depression;	chr6:28131566	chr6:28943877~28944537:+
LUAD	cis	rs881375	0.678	rs10760128	ENSG00000226752.6	PSMD5-AS1	-6.27	8.07e-10	3.82e-07	-0.29	-0.27	Rheumatoid arthritis;	chr9:120934047	chr9:120824828~120854385:+
LUAD	cis	rs2739330	0.892	rs4822455	ENSG00000228039.3	KB-1125A3.10	6.27	8.08e-10	3.82e-07	0.34	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23963780~23964374:+
LUAD	cis	rs2404602	0.647	rs12905181	ENSG00000259422.1	RP11-593F23.1	-6.27	8.08e-10	3.82e-07	-0.36	-0.27	Blood metabolite levels;	chr15:76806090	chr15:76174891~76181486:-
LUAD	cis	rs2243480	1	rs1723267	ENSG00000230295.1	RP11-458F8.2	-6.27	8.08e-10	3.82e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:66008327	chr7:66880708~66882981:+
LUAD	cis	rs77204473	0.744	rs12419178	ENSG00000254851.1	RP11-109L13.1	6.27	8.09e-10	3.83e-07	0.63	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117180202	chr11:117135528~117138582:+
LUAD	cis	rs948562	0.627	rs11229387	ENSG00000280010.1	AP001350.4	6.27	8.1e-10	3.83e-07	0.38	0.27	Lymphoma;	chr11:58373645	chr11:58627435~58628528:+
LUAD	cis	rs17818399	1	rs62136864	ENSG00000279254.1	RP11-536C12.1	-6.27	8.1e-10	3.83e-07	-0.3	-0.27	Height;	chr2:46601985	chr2:46668870~46670778:+
LUAD	cis	rs113835537	0.597	rs11227527	ENSG00000255517.5	CTD-3074O7.5	-6.27	8.1e-10	3.83e-07	-0.33	-0.27	Airway imaging phenotypes;	chr11:66545555	chr11:66473490~66480233:-
LUAD	cis	rs6991838	0.733	rs10111844	ENSG00000200714.1	Y_RNA	6.27	8.11e-10	3.83e-07	0.32	0.27	Intelligence (multi-trait analysis);	chr8:65690374	chr8:65592731~65592820:+
LUAD	cis	rs72772090	0.634	rs17402639	ENSG00000248734.2	CTD-2260A17.1	-6.27	8.12e-10	3.84e-07	-0.41	-0.27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96771301	chr5:96784777~96785999:+
LUAD	cis	rs72772090	0.634	rs72773912	ENSG00000248734.2	CTD-2260A17.1	-6.27	8.12e-10	3.84e-07	-0.41	-0.27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96772097	chr5:96784777~96785999:+
LUAD	cis	rs9543976	0.858	rs9530447	ENSG00000261553.4	RP11-29G8.3	6.27	8.12e-10	3.84e-07	0.39	0.27	Diabetic retinopathy;	chr13:75592666	chr13:75549773~75807120:+
LUAD	cis	rs7927592	1	rs7927592	ENSG00000212093.1	AP000807.1	6.27	8.12e-10	3.84e-07	0.31	0.27	Total body bone mineral density;	chr11:68602492	chr11:68506083~68506166:-
LUAD	cis	rs2337406	0.587	rs2516886	ENSG00000211974.3	IGHV2-70	6.27	8.13e-10	3.84e-07	0.34	0.27	Alzheimer's disease (late onset);	chr14:106649674	chr14:106723574~106724093:-
LUAD	cis	rs67311347	1	rs17078511	ENSG00000223797.4	ENTPD3-AS1	6.27	8.14e-10	3.85e-07	0.28	0.27	Renal cell carcinoma;	chr3:40354763	chr3:40313802~40453329:-
LUAD	cis	rs9549367	0.789	rs34448227	ENSG00000269125.1	RP11-98F14.11	-6.27	8.15e-10	3.85e-07	-0.34	-0.27	Platelet distribution width;	chr13:113230440	chr13:113165002~113165183:-
LUAD	cis	rs10129255	0.536	rs10139058	ENSG00000224373.3	IGHV4-59	6.27	8.15e-10	3.85e-07	0.16	0.27	Kawasaki disease;	chr14:106685899	chr14:106627249~106627825:-
LUAD	cis	rs17301013	0.507	rs72715300	ENSG00000227373.4	RP11-160H22.5	6.27	8.16e-10	3.86e-07	0.42	0.27	Systemic lupus erythematosus;	chr1:174768405	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs55844798	ENSG00000227373.4	RP11-160H22.5	6.27	8.16e-10	3.86e-07	0.42	0.27	Systemic lupus erythematosus;	chr1:174768973	chr1:174115300~174160004:-
LUAD	cis	rs783540	1	rs1259180	ENSG00000278603.1	RP13-608F4.5	-6.27	8.16e-10	3.86e-07	-0.32	-0.27	Schizophrenia;	chr15:82575930	chr15:82472203~82472426:+
LUAD	cis	rs4273100	0.526	rs2074280	ENSG00000262319.1	CTC-457L16.2	-6.27	8.16e-10	3.86e-07	-0.36	-0.27	Schizophrenia;	chr17:19014602	chr17:19141017~19143689:-
LUAD	cis	rs3096299	0.679	rs3096322	ENSG00000274627.1	RP11-104N10.2	-6.27	8.19e-10	3.87e-07	-0.26	-0.27	Multiple myeloma (IgH translocation);	chr16:89374715	chr16:89516797~89522217:+
LUAD	cis	rs7727544	0.735	rs274559	ENSG00000233006.5	AC034220.3	-6.27	8.19e-10	3.87e-07	-0.24	-0.27	Blood metabolite levels;	chr5:132384378	chr5:132311285~132369916:-
LUAD	cis	rs875971	0.545	rs2460427	ENSG00000226824.5	RP4-756H11.3	6.27	8.2e-10	3.87e-07	0.4	0.27	Aortic root size;	chr7:66154218	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.545	rs2460427	ENSG00000237310.1	GS1-124K5.4	-6.27	8.2e-10	3.87e-07	-0.34	-0.27	Aortic root size;	chr7:66154218	chr7:66493706~66495474:+
LUAD	cis	rs853679	0.607	rs35030260	ENSG00000204709.4	LINC01556	6.27	8.2e-10	3.88e-07	0.61	0.27	Depression;	chr6:28337731	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs13217619	ENSG00000204709.4	LINC01556	6.27	8.2e-10	3.88e-07	0.61	0.27	Depression;	chr6:28338894	chr6:28943877~28944537:+
LUAD	cis	rs237743	1	rs381262	ENSG00000222365.1	SNORD12B	-6.27	8.21e-10	3.88e-07	-0.3	-0.27	Height;	chr20:49316942	chr20:49280319~49280409:+
LUAD	cis	rs7688540	0.74	rs28784663	ENSG00000275426.1	CH17-262A2.1	6.27	8.22e-10	3.88e-07	0.34	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:293257	chr4:149738~150317:+
LUAD	cis	rs12468226	0.938	rs6435139	ENSG00000226261.1	AC064836.3	-6.27	8.22e-10	3.88e-07	-0.45	-0.27	Urate levels;	chr2:202255145	chr2:202336024~202336727:-
LUAD	cis	rs2243480	1	rs1964692	ENSG00000232546.1	RP11-458F8.1	-6.27	8.23e-10	3.89e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65989196	chr7:66848496~66858136:+
LUAD	cis	rs7246657	0.524	rs10411251	ENSG00000276846.1	CTD-3220F14.3	6.27	8.24e-10	3.89e-07	0.38	0.27	Coronary artery calcification;	chr19:36937853	chr19:37314868~37315620:-
LUAD	cis	rs7044106	0.762	rs1530370	ENSG00000238181.2	AHCYP2	-6.27	8.25e-10	3.9e-07	-0.35	-0.27	Hip circumference adjusted for BMI;	chr9:120662274	chr9:120720673~120721972:+
LUAD	cis	rs496547	0.719	rs598373	ENSG00000255422.1	AP002954.4	-6.27	8.25e-10	3.9e-07	-0.35	-0.27	Hip minimal joint space width;	chr11:118793668	chr11:118704607~118750263:+
LUAD	cis	rs7811142	1	rs67315960	ENSG00000242294.5	STAG3L5P	6.27	8.26e-10	3.9e-07	0.23	0.27	Platelet count;	chr7:100417501	chr7:100336079~100351900:+
LUAD	cis	rs1106529	0.528	rs1779445	ENSG00000226172.2	RP4-712E4.1	-6.27	8.26e-10	3.9e-07	-0.39	-0.27	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);	chr1:118965789	chr1:119000344~119001392:-
LUAD	cis	rs9595908	0.9	rs61947058	ENSG00000212293.1	SNORA16	6.26	8.29e-10	3.91e-07	0.29	0.27	Body mass index;	chr13:32617419	chr13:32420390~32420516:-
LUAD	cis	rs875971	0.545	rs2420612	ENSG00000237310.1	GS1-124K5.4	6.26	8.29e-10	3.91e-07	0.35	0.27	Aortic root size;	chr7:66536825	chr7:66493706~66495474:+
LUAD	cis	rs1823913	0.503	rs35282329	ENSG00000227542.1	AC092614.2	6.26	8.3e-10	3.92e-07	0.35	0.27	Obesity-related traits;	chr2:191343925	chr2:191229165~191246172:-
LUAD	cis	rs8062405	1	rs7498555	ENSG00000251417.2	RP11-1348G14.4	-6.26	8.3e-10	3.92e-07	-0.29	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28882250	chr16:28802743~28817828:+
LUAD	cis	rs875971	1	rs1565531	ENSG00000222364.1	RNU6-96P	6.26	8.3e-10	3.92e-07	0.31	0.27	Aortic root size;	chr7:66198126	chr7:66395191~66395286:+
LUAD	cis	rs17826219	0.561	rs11655876	ENSG00000263531.1	RP13-753N3.1	6.26	8.32e-10	3.92e-07	0.49	0.27	Body mass index;	chr17:30690132	chr17:30863921~30864940:-
LUAD	cis	rs948562	0.69	rs7342155	ENSG00000280010.1	AP001350.4	6.26	8.32e-10	3.93e-07	0.43	0.27	Lymphoma;	chr11:58348171	chr11:58627435~58628528:+
LUAD	cis	rs8072100	0.84	rs11079774	ENSG00000228782.6	CTD-2026D20.3	6.26	8.33e-10	3.93e-07	0.29	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402340	chr17:47450568~47492492:-
LUAD	cis	rs2243480	0.901	rs2456483	ENSG00000232546.1	RP11-458F8.1	-6.26	8.34e-10	3.93e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65996588	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs1701750	ENSG00000232546.1	RP11-458F8.1	-6.26	8.34e-10	3.93e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66002158	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs1701758	ENSG00000232546.1	RP11-458F8.1	-6.26	8.34e-10	3.93e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66005214	chr7:66848496~66858136:+
LUAD	cis	rs2243480	0.901	rs1701759	ENSG00000232546.1	RP11-458F8.1	-6.26	8.34e-10	3.93e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66005945	chr7:66848496~66858136:+
LUAD	cis	rs9847710	0.708	rs2581811	ENSG00000242142.1	SERBP1P3	6.26	8.34e-10	3.94e-07	0.32	0.27	Ulcerative colitis;	chr3:53051785	chr3:53064283~53065091:-
LUAD	cis	rs3738443	0.594	rs60050650	ENSG00000259865.1	RP11-488L18.10	6.26	8.35e-10	3.94e-07	0.23	0.27	Alcohol dependence;	chr1:247213474	chr1:247187281~247188526:-
LUAD	cis	rs9549367	0.789	rs9549699	ENSG00000269125.1	RP11-98F14.11	-6.26	8.36e-10	3.94e-07	-0.34	-0.27	Platelet distribution width;	chr13:113223949	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.789	rs7999579	ENSG00000269125.1	RP11-98F14.11	-6.26	8.36e-10	3.94e-07	-0.34	-0.27	Platelet distribution width;	chr13:113225043	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.789	rs6577035	ENSG00000269125.1	RP11-98F14.11	-6.26	8.36e-10	3.94e-07	-0.34	-0.27	Platelet distribution width;	chr13:113225683	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.789	rs12584981	ENSG00000269125.1	RP11-98F14.11	-6.26	8.36e-10	3.94e-07	-0.34	-0.27	Platelet distribution width;	chr13:113226871	chr13:113165002~113165183:-
LUAD	cis	rs4718428	0.705	rs3800817	ENSG00000273142.1	RP11-458F8.4	-6.26	8.36e-10	3.94e-07	-0.21	-0.27	Corneal structure;	chr7:66798563	chr7:66902857~66906297:+
LUAD	cis	rs948562	1	rs12365551	ENSG00000280010.1	AP001350.4	6.26	8.36e-10	3.94e-07	0.43	0.27	Lymphoma;	chr11:58590895	chr11:58627435~58628528:+
LUAD	cis	rs7246657	0.551	rs62108899	ENSG00000276846.1	CTD-3220F14.3	6.26	8.36e-10	3.94e-07	0.45	0.27	Coronary artery calcification;	chr19:37104281	chr19:37314868~37315620:-
LUAD	cis	rs75920871	0.589	rs4938342	ENSG00000254851.1	RP11-109L13.1	-6.26	8.36e-10	3.95e-07	-0.47	-0.27	Subjective well-being;	chr11:117132704	chr11:117135528~117138582:+
LUAD	cis	rs17301013	0.507	rs6689153	ENSG00000227373.4	RP11-160H22.5	6.26	8.38e-10	3.95e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174639550	chr1:174115300~174160004:-
LUAD	cis	rs9601248	0.967	rs9545145	ENSG00000227676.3	LINC01068	-6.26	8.38e-10	3.95e-07	-0.34	-0.27	Major depressive disorder;	chr13:79599625	chr13:79566727~79571436:+
LUAD	cis	rs6840258	0.547	rs2053771	ENSG00000251411.1	RP11-397E7.4	-6.26	8.38e-10	3.95e-07	-0.38	-0.27	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86937396	chr4:86913266~86914817:-
LUAD	cis	rs67311347	1	rs9829800	ENSG00000223797.4	ENTPD3-AS1	6.26	8.38e-10	3.95e-07	0.29	0.27	Renal cell carcinoma;	chr3:40402436	chr3:40313802~40453329:-
LUAD	cis	rs1707322	0.721	rs56255771	ENSG00000234329.1	RP11-767N6.2	6.26	8.39e-10	3.96e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758647	chr1:45651039~45651826:-
LUAD	cis	rs2243480	1	rs34136756	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65916269	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs78803505	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65917585	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs34933526	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65918212	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs34577383	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65920739	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs6949812	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65922114	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs55895244	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65922691	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs6970243	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65923503	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs7794661	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65924743	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs7795242	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65925107	chr7:66848496~66858136:+
LUAD	cis	rs2243480	0.708	rs35310401	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65925372	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs35058610	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65925938	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs2177703	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65926730	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs35432774	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65928032	chr7:66848496~66858136:+
LUAD	cis	rs2243480	0.831	rs7806717	ENSG00000232546.1	RP11-458F8.1	6.26	8.39e-10	3.96e-07	0.36	0.27	Diabetic kidney disease;	chr7:65928187	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs56985706	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65929575	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs60683927	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65929781	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs58062456	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65929865	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs34529418	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65938222	chr7:66848496~66858136:+
LUAD	cis	rs2243480	0.901	rs35087093	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65940221	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs35046236	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65943626	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs36068983	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65944004	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs68189316	ENSG00000232546.1	RP11-458F8.1	-6.26	8.39e-10	3.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65944182	chr7:66848496~66858136:+
LUAD	cis	rs1799949	1	rs12944458	ENSG00000267681.1	CTD-3199J23.6	-6.26	8.39e-10	3.96e-07	-0.32	-0.27	Menopause (age at onset);	chr17:43028755	chr17:43144956~43145255:+
LUAD	cis	rs948562	1	rs11229535	ENSG00000280010.1	AP001350.4	6.26	8.4e-10	3.96e-07	0.43	0.27	Lymphoma;	chr11:58580913	chr11:58627435~58628528:+
LUAD	cis	rs2734839	0.537	rs11214603	ENSG00000270179.1	RP11-159N11.4	-6.26	8.43e-10	3.97e-07	-0.28	-0.27	Information processing speed;	chr11:113409200	chr11:113368478~113369117:+
LUAD	cis	rs1823913	0.599	rs7598639	ENSG00000227542.1	AC092614.2	6.26	8.43e-10	3.97e-07	0.33	0.27	Obesity-related traits;	chr2:191267958	chr2:191229165~191246172:-
LUAD	cis	rs17301013	0.507	rs10912829	ENSG00000227373.4	RP11-160H22.5	6.26	8.43e-10	3.97e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174635894	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs395109	ENSG00000227373.4	RP11-160H22.5	6.26	8.43e-10	3.97e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174641233	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs2760058	ENSG00000227373.4	RP11-160H22.5	6.26	8.43e-10	3.97e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174641320	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs333454	ENSG00000227373.4	RP11-160H22.5	6.26	8.43e-10	3.97e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174653939	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs333452	ENSG00000227373.4	RP11-160H22.5	6.26	8.43e-10	3.97e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174654718	chr1:174115300~174160004:-
LUAD	cis	rs2115630	0.645	rs1107179	ENSG00000225151.9	GOLGA2P7	-6.26	8.44e-10	3.97e-07	-0.32	-0.27	P wave terminal force;	chr15:84655131	chr15:84199311~84230136:-
LUAD	cis	rs11096990	0.892	rs28639548	ENSG00000249207.1	RP11-360F5.1	6.26	8.44e-10	3.97e-07	0.32	0.27	Cognitive function;	chr4:39185530	chr4:39112677~39126818:-
LUAD	cis	rs3738443	0.569	rs6704060	ENSG00000259865.1	RP11-488L18.10	6.26	8.45e-10	3.98e-07	0.23	0.27	Alcohol dependence;	chr1:247218222	chr1:247187281~247188526:-
LUAD	cis	rs71403859	0.502	rs36122765	ENSG00000260886.1	TAT-AS1	6.26	8.46e-10	3.99e-07	0.45	0.27	Post bronchodilator FEV1;	chr16:71470280	chr16:71565789~71578187:+
LUAD	cis	rs1799949	1	rs36036395	ENSG00000267681.1	CTD-3199J23.6	-6.26	8.48e-10	3.99e-07	-0.32	-0.27	Menopause (age at onset);	chr17:43029280	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs72829113	ENSG00000267681.1	CTD-3199J23.6	-6.26	8.48e-10	3.99e-07	-0.32	-0.27	Menopause (age at onset);	chr17:43029818	chr17:43144956~43145255:+
LUAD	cis	rs6991838	0.806	rs4285523	ENSG00000272010.1	CTD-3025N20.3	6.26	8.49e-10	4e-07	0.28	0.27	Intelligence (multi-trait analysis);	chr8:65552095	chr8:65591850~65592472:-
LUAD	cis	rs9880192	0.516	rs2713575	ENSG00000242551.2	POU5F1P6	-6.26	8.5e-10	4e-07	-0.31	-0.27	White blood cell count;Eosinophil percentage of white cells;Monocyte count;Neutrophil percentage of granulocytes;Monocyte-lymphocyte ratio;Eosinophil percentage of granulocytes;Eosinophil counts;	chr3:128575512	chr3:128674735~128677005:-
LUAD	cis	rs1075265	0.704	rs10084374	ENSG00000233266.1	HMGB1P31	6.26	8.5e-10	4.01e-07	0.34	0.27	Chronotype;Morning vs. evening chronotype;	chr2:54022175	chr2:54051334~54051760:+
LUAD	cis	rs274567	0.55	rs272885	ENSG00000233006.5	AC034220.3	6.26	8.52e-10	4.01e-07	0.27	0.27	Blood metabolite levels;	chr5:132332043	chr5:132311285~132369916:-
LUAD	cis	rs6840258	0.547	rs72667727	ENSG00000251411.1	RP11-397E7.4	-6.26	8.52e-10	4.01e-07	-0.39	-0.27	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86936370	chr4:86913266~86914817:-
LUAD	cis	rs2243480	1	rs464895	ENSG00000232546.1	RP11-458F8.1	-6.26	8.52e-10	4.01e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66062119	chr7:66848496~66858136:+
LUAD	cis	rs1707322	0.752	rs6703748	ENSG00000234329.1	RP11-767N6.2	6.26	8.53e-10	4.02e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45630304	chr1:45651039~45651826:-
LUAD	cis	rs8100891	0.537	rs1057397	ENSG00000267213.4	AC007773.2	-6.26	8.54e-10	4.02e-07	-0.43	-0.27	Neuroticism;	chr19:32484007	chr19:32390050~32405560:-
LUAD	cis	rs9543976	0.925	rs2876706	ENSG00000261553.4	RP11-29G8.3	6.26	8.57e-10	4.03e-07	0.41	0.27	Diabetic retinopathy;	chr13:75612169	chr13:75549773~75807120:+
LUAD	cis	rs12468226	1	rs58288071	ENSG00000226261.1	AC064836.3	6.26	8.57e-10	4.04e-07	0.46	0.27	Urate levels;	chr2:202350016	chr2:202336024~202336727:-
LUAD	cis	rs17301013	0.507	rs10912789	ENSG00000227373.4	RP11-160H22.5	6.26	8.59e-10	4.04e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174465616	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs6684141	ENSG00000227373.4	RP11-160H22.5	6.26	8.59e-10	4.04e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174467305	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12058377	ENSG00000227373.4	RP11-160H22.5	6.26	8.59e-10	4.04e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174470971	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs6656925	ENSG00000227373.4	RP11-160H22.5	6.26	8.59e-10	4.04e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174474161	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs2987872	ENSG00000227373.4	RP11-160H22.5	-6.26	8.6e-10	4.05e-07	-0.4	-0.27	Systemic lupus erythematosus;	chr1:174840935	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs1793305	ENSG00000227373.4	RP11-160H22.5	-6.26	8.6e-10	4.05e-07	-0.4	-0.27	Systemic lupus erythematosus;	chr1:174841124	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs1894201	ENSG00000227373.4	RP11-160H22.5	-6.26	8.6e-10	4.05e-07	-0.4	-0.27	Systemic lupus erythematosus;	chr1:174841452	chr1:174115300~174160004:-
LUAD	cis	rs2243480	1	rs2961102	ENSG00000232546.1	RP11-458F8.1	-6.26	8.62e-10	4.05e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65959671	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs67728539	ENSG00000226824.5	RP4-756H11.3	-6.26	8.62e-10	4.05e-07	-0.52	-0.27	Diabetic kidney disease;	chr7:65913137	chr7:66654538~66669855:+
LUAD	cis	rs6991838	0.806	rs17302392	ENSG00000272010.1	CTD-3025N20.3	6.26	8.62e-10	4.06e-07	0.28	0.27	Intelligence (multi-trait analysis);	chr8:65551073	chr8:65591850~65592472:-
LUAD	cis	rs17301013	0.507	rs2568096	ENSG00000227373.4	RP11-160H22.5	6.26	8.63e-10	4.06e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174735463	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs333436	ENSG00000227373.4	RP11-160H22.5	6.26	8.63e-10	4.06e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174739069	chr1:174115300~174160004:-
LUAD	cis	rs2243480	1	rs11538349	ENSG00000226824.5	RP4-756H11.3	-6.26	8.63e-10	4.06e-07	-0.5	-0.27	Diabetic kidney disease;	chr7:65956884	chr7:66654538~66669855:+
LUAD	cis	rs4713118	0.868	rs760587	ENSG00000219392.1	RP1-265C24.5	-6.26	8.65e-10	4.07e-07	-0.39	-0.27	Parkinson's disease;	chr6:27772521	chr6:28115628~28116551:+
LUAD	cis	rs10129255	0.833	rs61997797	ENSG00000224373.3	IGHV4-59	6.26	8.65e-10	4.07e-07	0.18	0.27	Kawasaki disease;	chr14:106815190	chr14:106627249~106627825:-
LUAD	cis	rs6991838	0.701	rs7829434	ENSG00000200714.1	Y_RNA	6.26	8.66e-10	4.07e-07	0.32	0.27	Intelligence (multi-trait analysis);	chr8:65716909	chr8:65592731~65592820:+
LUAD	cis	rs10129255	0.5	rs2027902	ENSG00000211970.3	IGHV4-61	-6.26	8.66e-10	4.07e-07	-0.19	-0.27	Kawasaki disease;	chr14:106807157	chr14:106639119~106639657:-
LUAD	cis	rs11690935	0.632	rs17581284	ENSG00000228389.1	AC068039.4	-6.26	8.69e-10	4.09e-07	-0.29	-0.27	Schizophrenia;	chr2:171802866	chr2:171773482~171775844:+
LUAD	cis	rs2243480	0.808	rs12698508	ENSG00000232546.1	RP11-458F8.1	-6.26	8.7e-10	4.09e-07	-0.37	-0.27	Diabetic kidney disease;	chr7:65946971	chr7:66848496~66858136:+
LUAD	cis	rs8081395	0.741	rs180519	ENSG00000266992.1	DHX40P1	6.26	8.71e-10	4.09e-07	0.32	0.27	White blood cell count;	chr17:59938910	chr17:59976009~60002384:-
LUAD	cis	rs755249	0.567	rs16825887	ENSG00000228060.1	RP11-69E11.8	6.26	8.71e-10	4.09e-07	0.28	0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39177710	chr1:39565160~39573203:+
LUAD	cis	rs67311347	1	rs6599094	ENSG00000223797.4	ENTPD3-AS1	6.26	8.71e-10	4.1e-07	0.28	0.27	Renal cell carcinoma;	chr3:40358102	chr3:40313802~40453329:-
LUAD	cis	rs720064	0.586	rs12957815	ENSG00000264745.1	TTC39C-AS1	6.26	8.72e-10	4.1e-07	0.29	0.27	Strep throat;	chr18:23976626	chr18:23994213~24015339:-
LUAD	cis	rs2243480	1	rs316326	ENSG00000232546.1	RP11-458F8.1	-6.26	8.73e-10	4.1e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66144466	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs316325	ENSG00000232546.1	RP11-458F8.1	-6.26	8.73e-10	4.1e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66144531	chr7:66848496~66858136:+
LUAD	cis	rs10759883	0.563	rs10819720	ENSG00000175611.10	LINC00476	6.26	8.73e-10	4.1e-07	0.32	0.27	Nicotine dependence;	chr9:96021506	chr9:95759231~95875977:-
LUAD	cis	rs7221109	0.56	rs2159430	ENSG00000278834.1	RP11-458J1.1	-6.26	8.73e-10	4.1e-07	-0.33	-0.27	Type 1 diabetes;	chr17:40704360	chr17:40648300~40649718:+
LUAD	cis	rs7221109	0.56	rs2462963	ENSG00000278834.1	RP11-458J1.1	-6.26	8.73e-10	4.1e-07	-0.33	-0.27	Type 1 diabetes;	chr17:40705505	chr17:40648300~40649718:+
LUAD	cis	rs113835537	0.529	rs4542420	ENSG00000255517.5	CTD-3074O7.5	-6.26	8.75e-10	4.11e-07	-0.32	-0.27	Airway imaging phenotypes;	chr11:66510139	chr11:66473490~66480233:-
LUAD	cis	rs7849270	1	rs3118632	ENSG00000268707.1	RP11-247A12.7	6.26	8.75e-10	4.11e-07	0.31	0.27	Blood metabolite ratios;	chr9:129139005	chr9:129170434~129170940:+
LUAD	cis	rs1012068	0.686	rs5994451	ENSG00000236132.1	CTA-440B3.1	-6.26	8.76e-10	4.11e-07	-0.33	-0.27	Chronic hepatitis C infection;	chr22:31927525	chr22:31816379~31817491:-
LUAD	cis	rs9543976	1	rs7989568	ENSG00000261553.4	RP11-29G8.3	6.26	8.77e-10	4.12e-07	0.38	0.27	Diabetic retinopathy;	chr13:75581428	chr13:75549773~75807120:+
LUAD	cis	rs2273788	0.793	rs34492085	ENSG00000204173.9	LRRC37A5P	6.26	8.78e-10	4.12e-07	0.34	0.27	Monocyte count;	chr9:111584381	chr9:111602831~111631289:-
LUAD	cis	rs9368481	0.645	rs10456350	ENSG00000241549.7	GUSBP2	6.26	8.78e-10	4.13e-07	0.31	0.27	Autism spectrum disorder or schizophrenia;	chr6:27007802	chr6:26871484~26956554:-
LUAD	cis	rs77204473	1	rs12292614	ENSG00000254851.1	RP11-109L13.1	6.25	8.8e-10	4.13e-07	0.66	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116877799	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs12286581	ENSG00000254851.1	RP11-109L13.1	6.25	8.8e-10	4.13e-07	0.66	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116878028	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs75294699	ENSG00000254851.1	RP11-109L13.1	6.25	8.8e-10	4.13e-07	0.66	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116878356	chr11:117135528~117138582:+
LUAD	cis	rs755249	0.567	rs112672438	ENSG00000228060.1	RP11-69E11.8	-6.25	8.81e-10	4.14e-07	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39181115	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs16825921	ENSG00000228060.1	RP11-69E11.8	-6.25	8.81e-10	4.14e-07	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39183526	chr1:39565160~39573203:+
LUAD	cis	rs2243480	1	rs34637256	ENSG00000226824.5	RP4-756H11.3	-6.25	8.82e-10	4.14e-07	-0.52	-0.27	Diabetic kidney disease;	chr7:65895144	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs35391607	ENSG00000226824.5	RP4-756H11.3	-6.25	8.82e-10	4.14e-07	-0.52	-0.27	Diabetic kidney disease;	chr7:65895842	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs13220979	ENSG00000226824.5	RP4-756H11.3	-6.25	8.82e-10	4.14e-07	-0.52	-0.27	Diabetic kidney disease;	chr7:65898217	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs34974928	ENSG00000226824.5	RP4-756H11.3	-6.25	8.82e-10	4.14e-07	-0.52	-0.27	Diabetic kidney disease;	chr7:65899019	chr7:66654538~66669855:+
LUAD	cis	rs881375	0.678	rs7037195	ENSG00000226752.6	PSMD5-AS1	-6.25	8.82e-10	4.14e-07	-0.29	-0.27	Rheumatoid arthritis;	chr9:120921722	chr9:120824828~120854385:+
LUAD	cis	rs2408955	0.5	rs12816820	ENSG00000240399.1	RP1-228P16.1	6.25	8.84e-10	4.15e-07	0.27	0.27	Glycated hemoglobin levels;	chr12:48164542	chr12:48054813~48055591:-
LUAD	cis	rs6844153	0.752	rs73811400	ENSG00000240005.4	RP11-293A21.1	-6.25	8.85e-10	4.15e-07	-0.39	-0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26887701	chr4:26859806~26860599:-
LUAD	cis	rs1061377	0.513	rs2712000	ENSG00000249207.1	RP11-360F5.1	-6.25	8.86e-10	4.16e-07	-0.35	-0.27	Uric acid levels;	chr4:39135462	chr4:39112677~39126818:-
LUAD	cis	rs7246657	0.943	rs6508711	ENSG00000276846.1	CTD-3220F14.3	6.25	8.86e-10	4.16e-07	0.38	0.27	Coronary artery calcification;	chr19:37324232	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.882	rs6508716	ENSG00000276846.1	CTD-3220F14.3	6.25	8.86e-10	4.16e-07	0.38	0.27	Coronary artery calcification;	chr19:37328108	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.882	rs13345148	ENSG00000276846.1	CTD-3220F14.3	6.25	8.86e-10	4.16e-07	0.38	0.27	Coronary artery calcification;	chr19:37328729	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs7257672	ENSG00000276846.1	CTD-3220F14.3	6.25	8.86e-10	4.16e-07	0.38	0.27	Coronary artery calcification;	chr19:37332957	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.891	rs7257495	ENSG00000276846.1	CTD-3220F14.3	6.25	8.86e-10	4.16e-07	0.38	0.27	Coronary artery calcification;	chr19:37332974	chr19:37314868~37315620:-
LUAD	cis	rs2243480	1	rs34637256	ENSG00000232546.1	RP11-458F8.1	-6.25	8.86e-10	4.16e-07	-0.37	-0.27	Diabetic kidney disease;	chr7:65895144	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs35391607	ENSG00000232546.1	RP11-458F8.1	-6.25	8.86e-10	4.16e-07	-0.37	-0.27	Diabetic kidney disease;	chr7:65895842	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs13220979	ENSG00000232546.1	RP11-458F8.1	-6.25	8.86e-10	4.16e-07	-0.37	-0.27	Diabetic kidney disease;	chr7:65898217	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs34974928	ENSG00000232546.1	RP11-458F8.1	-6.25	8.86e-10	4.16e-07	-0.37	-0.27	Diabetic kidney disease;	chr7:65899019	chr7:66848496~66858136:+
LUAD	cis	rs71403859	0.502	rs12927456	ENSG00000260886.1	TAT-AS1	6.25	8.87e-10	4.16e-07	0.46	0.27	Post bronchodilator FEV1;	chr16:71471803	chr16:71565789~71578187:+
LUAD	cis	rs67311347	0.911	rs6775936	ENSG00000223797.4	ENTPD3-AS1	6.25	8.87e-10	4.16e-07	0.29	0.27	Renal cell carcinoma;	chr3:40335908	chr3:40313802~40453329:-
LUAD	cis	rs17711722	0.503	rs453835	ENSG00000164669.11	INTS4P1	6.25	8.87e-10	4.17e-07	0.33	0.27	Calcium levels;	chr7:66046172	chr7:65141225~65234216:+
LUAD	cis	rs1113500	0.836	rs1122158	ENSG00000226822.1	RP11-356N1.2	6.25	8.89e-10	4.17e-07	0.32	0.27	Growth-regulated protein alpha levels;	chr1:108046046	chr1:108071482~108074519:+
LUAD	cis	rs2243480	0.831	rs57294491	ENSG00000232546.1	RP11-458F8.1	6.25	8.9e-10	4.18e-07	0.37	0.27	Diabetic kidney disease;	chr7:66219914	chr7:66848496~66858136:+
LUAD	cis	rs1062177	1	rs1062177	ENSG00000213433.5	RPLP1P6	-6.25	8.9e-10	4.18e-07	-0.37	-0.27	Preschool internalizing problems;	chr5:151805140	chr5:151765859~151766378:-
LUAD	cis	rs7246657	0.943	rs1035479	ENSG00000276846.1	CTD-3220F14.3	-6.25	8.9e-10	4.18e-07	-0.37	-0.27	Coronary artery calcification;	chr19:37402398	chr19:37314868~37315620:-
LUAD	cis	rs7923609	0.841	rs10822186	ENSG00000232075.1	MRPL35P2	-6.25	8.91e-10	4.18e-07	-0.33	-0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63590623	chr10:63634317~63634827:-
LUAD	cis	rs2243480	1	rs4718334	ENSG00000232546.1	RP11-458F8.1	6.25	8.91e-10	4.18e-07	0.36	0.27	Diabetic kidney disease;	chr7:66324467	chr7:66848496~66858136:+
LUAD	cis	rs4723738	1	rs7788819	ENSG00000227191.5	TRGC2	-6.25	8.92e-10	4.18e-07	-0.3	-0.27	Treatment response for severe sepsis;	chr7:38187056	chr7:38239580~38368091:-
LUAD	cis	rs4723738	1	rs17171307	ENSG00000227191.5	TRGC2	-6.25	8.92e-10	4.18e-07	-0.3	-0.27	Treatment response for severe sepsis;	chr7:38188976	chr7:38239580~38368091:-
LUAD	cis	rs2404602	0.622	rs11632670	ENSG00000259422.1	RP11-593F23.1	-6.25	8.92e-10	4.19e-07	-0.35	-0.27	Blood metabolite levels;	chr15:76681714	chr15:76174891~76181486:-
LUAD	cis	rs6860806	0.531	rs272887	ENSG00000233006.5	AC034220.3	6.25	8.93e-10	4.19e-07	0.28	0.27	Breast cancer;	chr5:132330020	chr5:132311285~132369916:-
LUAD	cis	rs6772849	0.93	rs9868579	ENSG00000242551.2	POU5F1P6	6.25	8.94e-10	4.19e-07	0.32	0.27	Monocyte percentage of white cells;Monocyte count;	chr3:128632211	chr3:128674735~128677005:-
LUAD	cis	rs8062405	1	rs12325113	ENSG00000251417.2	RP11-1348G14.4	-6.25	8.94e-10	4.19e-07	-0.29	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28802743~28817828:+
LUAD	cis	rs35934224	0.831	rs13057374	ENSG00000232926.1	AC000078.5	6.25	8.95e-10	4.2e-07	0.3	0.27	Glaucoma (primary open-angle);	chr22:19883574	chr22:19887289~19887970:+
LUAD	cis	rs9640161	0.83	rs13307276	ENSG00000261305.1	RP4-584D14.7	6.25	8.95e-10	4.2e-07	0.41	0.27	Blood protein levels;Circulating chemerin levels;	chr7:150364436	chr7:150341771~150342607:+
LUAD	cis	rs4718428	0.705	rs12536410	ENSG00000273142.1	RP11-458F8.4	-6.25	8.95e-10	4.2e-07	-0.2	-0.27	Corneal structure;	chr7:66789303	chr7:66902857~66906297:+
LUAD	cis	rs8177876	0.822	rs7185637	ENSG00000261838.4	RP11-303E16.6	-6.25	8.96e-10	4.2e-07	-0.52	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81089551	chr16:81069854~81076598:+
LUAD	cis	rs7849270	0.959	rs7032712	ENSG00000268707.1	RP11-247A12.7	-6.25	8.96e-10	4.2e-07	-0.31	-0.27	Blood metabolite ratios;	chr9:129130808	chr9:129170434~129170940:+
LUAD	cis	rs9549367	0.789	rs34989271	ENSG00000269125.1	RP11-98F14.11	-6.25	8.97e-10	4.21e-07	-0.34	-0.27	Platelet distribution width;	chr13:113240452	chr13:113165002~113165183:-
LUAD	cis	rs7044106	0.762	rs1158553	ENSG00000238181.2	AHCYP2	-6.25	8.97e-10	4.21e-07	-0.35	-0.27	Hip circumference adjusted for BMI;	chr9:120638696	chr9:120720673~120721972:+
LUAD	cis	rs4865169	0.595	rs4865165	ENSG00000269949.1	RP11-738E22.3	-6.25	8.98e-10	4.21e-07	-0.34	-0.27	Breast cancer;	chr4:56899380	chr4:56960927~56961373:-
LUAD	cis	rs7246657	0.943	rs10415024	ENSG00000276846.1	CTD-3220F14.3	6.25	8.98e-10	4.21e-07	0.39	0.27	Coronary artery calcification;	chr19:37323822	chr19:37314868~37315620:-
LUAD	cis	rs5753618	0.509	rs5753500	ENSG00000236132.1	CTA-440B3.1	6.25	8.99e-10	4.21e-07	0.35	0.27	Colorectal cancer;	chr22:31182893	chr22:31816379~31817491:-
LUAD	cis	rs728616	0.614	rs2181204	ENSG00000225484.5	NUTM2B-AS1	-6.25	8.99e-10	4.21e-07	-0.44	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79944756	chr10:79663088~79826594:-
LUAD	cis	rs3738443	0.678	rs61636449	ENSG00000259865.1	RP11-488L18.10	6.25	8.99e-10	4.22e-07	0.25	0.27	Alcohol dependence;	chr1:247213758	chr1:247187281~247188526:-
LUAD	cis	rs3738443	0.678	rs57861883	ENSG00000259865.1	RP11-488L18.10	6.25	8.99e-10	4.22e-07	0.25	0.27	Alcohol dependence;	chr1:247214089	chr1:247187281~247188526:-
LUAD	cis	rs7208859	0.673	rs9907197	ENSG00000263531.1	RP13-753N3.1	6.25	8.99e-10	4.22e-07	0.48	0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30691245	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs9915963	ENSG00000263531.1	RP13-753N3.1	6.25	8.99e-10	4.22e-07	0.48	0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30692625	chr17:30863921~30864940:-
LUAD	cis	rs12468226	1	rs112306637	ENSG00000226261.1	AC064836.3	6.25	9e-10	4.22e-07	0.46	0.27	Urate levels;	chr2:202334195	chr2:202336024~202336727:-
LUAD	cis	rs12468226	1	rs111252524	ENSG00000226261.1	AC064836.3	6.25	9e-10	4.22e-07	0.46	0.27	Urate levels;	chr2:202334465	chr2:202336024~202336727:-
LUAD	cis	rs12468226	1	rs112753638	ENSG00000226261.1	AC064836.3	6.25	9e-10	4.22e-07	0.46	0.27	Urate levels;	chr2:202334496	chr2:202336024~202336727:-
LUAD	cis	rs12468226	0.935	rs113188021	ENSG00000226261.1	AC064836.3	6.25	9e-10	4.22e-07	0.46	0.27	Urate levels;	chr2:202336237	chr2:202336024~202336727:-
LUAD	cis	rs12468226	1	rs6731027	ENSG00000226261.1	AC064836.3	6.25	9e-10	4.22e-07	0.46	0.27	Urate levels;	chr2:202337443	chr2:202336024~202336727:-
LUAD	cis	rs9595908	0.537	rs7993153	ENSG00000212293.1	SNORA16	6.25	9.02e-10	4.23e-07	0.29	0.27	Body mass index;	chr13:32804647	chr13:32420390~32420516:-
LUAD	cis	rs10740039	0.516	rs1348281	ENSG00000254271.1	RP11-131N11.4	-6.25	9.02e-10	4.23e-07	-0.3	-0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60596475	chr10:60734342~60741828:+
LUAD	cis	rs4713118	0.662	rs149946	ENSG00000204709.4	LINC01556	-6.25	9.02e-10	4.23e-07	-0.37	-0.27	Parkinson's disease;	chr6:28002253	chr6:28943877~28944537:+
LUAD	cis	rs66887589	0.967	rs59516282	ENSG00000248280.1	RP11-33B1.2	-6.25	9.04e-10	4.23e-07	-0.3	-0.27	Diastolic blood pressure;	chr4:119580861	chr4:119440561~119450157:-
LUAD	cis	rs1707322	0.721	rs10890333	ENSG00000234329.1	RP11-767N6.2	6.25	9.04e-10	4.24e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634650	chr1:45651039~45651826:-
LUAD	cis	rs3762637	1	rs7615930	ENSG00000272758.4	RP11-299J3.8	-6.25	9.05e-10	4.24e-07	-0.38	-0.27	LDL cholesterol levels;	chr3:122406903	chr3:122416207~122443180:+
LUAD	cis	rs2980439	0.87	rs2945230	ENSG00000253893.2	FAM85B	-6.25	9.06e-10	4.24e-07	-0.34	-0.27	Neuroticism;	chr8:8252414	chr8:8167819~8226614:-
LUAD	cis	rs1167827	0.68	rs1167796	ENSG00000127957.15	PMS2P3	6.25	9.06e-10	4.25e-07	0.26	0.27	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75502930~75528148:-
LUAD	cis	rs35160687	0.736	rs6746198	ENSG00000273080.1	RP11-301O19.1	-6.25	9.06e-10	4.25e-07	-0.31	-0.27	Night sleep phenotypes;	chr2:86314990	chr2:86195590~86196049:+
LUAD	cis	rs8062405	1	rs12446589	ENSG00000251417.2	RP11-1348G14.4	-6.25	9.06e-10	4.25e-07	-0.29	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28802743~28817828:+
LUAD	cis	rs13230714	1	rs13230714	ENSG00000204959.4	ARHGEF34P	-6.25	9.07e-10	4.25e-07	-0.37	-0.27	Breast cancer;	chr7:144477198	chr7:144272445~144286966:-
LUAD	cis	rs7727544	0.507	rs11741341	ENSG00000233006.5	AC034220.3	6.25	9.08e-10	4.25e-07	0.25	0.27	Blood metabolite levels;	chr5:132234525	chr5:132311285~132369916:-
LUAD	cis	rs113835537	0.597	rs2075792	ENSG00000255517.5	CTD-3074O7.5	-6.25	9.08e-10	4.25e-07	-0.33	-0.27	Airway imaging phenotypes;	chr11:66567085	chr11:66473490~66480233:-
LUAD	cis	rs113835537	0.529	rs74869459	ENSG00000255517.5	CTD-3074O7.5	-6.25	9.1e-10	4.26e-07	-0.33	-0.27	Airway imaging phenotypes;	chr11:66529098	chr11:66473490~66480233:-
LUAD	cis	rs948562	0.69	rs17473544	ENSG00000280010.1	AP001350.4	6.25	9.12e-10	4.27e-07	0.42	0.27	Lymphoma;	chr11:58388994	chr11:58627435~58628528:+
LUAD	cis	rs75422866	0.764	rs67408202	ENSG00000274902.1	RP1-197B17.4	6.25	9.13e-10	4.28e-07	0.65	0.27	Pneumonia;	chr12:47713564	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.867	rs57848393	ENSG00000274902.1	RP1-197B17.4	6.25	9.13e-10	4.28e-07	0.65	0.27	Pneumonia;	chr12:47714734	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.764	rs67201012	ENSG00000274902.1	RP1-197B17.4	6.25	9.13e-10	4.28e-07	0.65	0.27	Pneumonia;	chr12:47715881	chr12:47731908~47732351:+
LUAD	cis	rs113835537	0.529	rs117112180	ENSG00000255517.5	CTD-3074O7.5	-6.25	9.13e-10	4.28e-07	-0.34	-0.27	Airway imaging phenotypes;	chr11:66525802	chr11:66473490~66480233:-
LUAD	cis	rs150992	0.587	rs12189335	ENSG00000248489.1	CTD-2007H13.3	-6.25	9.13e-10	4.28e-07	-0.31	-0.27	Body mass index;	chr5:99009311	chr5:98929171~98995013:+
LUAD	cis	rs891378	0.876	rs1367067	ENSG00000274245.1	RP11-357P18.2	6.25	9.14e-10	4.28e-07	0.38	0.27	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207269019	chr1:207372559~207373252:+
LUAD	cis	rs8177376	0.861	rs604255	ENSG00000254905.1	RP11-712L6.7	6.25	9.15e-10	4.28e-07	0.39	0.27	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126327131	chr11:126292922~126294254:-
LUAD	cis	rs2404602	0.647	rs11634266	ENSG00000259422.1	RP11-593F23.1	-6.25	9.16e-10	4.29e-07	-0.36	-0.27	Blood metabolite levels;	chr15:76801120	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.647	rs7178250	ENSG00000259422.1	RP11-593F23.1	-6.25	9.16e-10	4.29e-07	-0.36	-0.27	Blood metabolite levels;	chr15:76806766	chr15:76174891~76181486:-
LUAD	cis	rs2243480	1	rs313814	ENSG00000232546.1	RP11-458F8.1	-6.25	9.17e-10	4.29e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66038306	chr7:66848496~66858136:+
LUAD	cis	rs227932	0.681	rs7776862	ENSG00000234286.1	AC006026.13	6.25	9.17e-10	4.29e-07	0.44	0.27	Schizophrenia;	chr7:23736607	chr7:23680195~23680786:-
LUAD	cis	rs1799949	1	rs11653253	ENSG00000267681.1	CTD-3199J23.6	-6.25	9.18e-10	4.29e-07	-0.32	-0.27	Menopause (age at onset);	chr17:43030645	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs12951869	ENSG00000267681.1	CTD-3199J23.6	-6.25	9.18e-10	4.29e-07	-0.32	-0.27	Menopause (age at onset);	chr17:43035550	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs11654452	ENSG00000267681.1	CTD-3199J23.6	-6.25	9.18e-10	4.29e-07	-0.32	-0.27	Menopause (age at onset);	chr17:43037366	chr17:43144956~43145255:+
LUAD	cis	rs4718428	0.705	rs11028	ENSG00000273142.1	RP11-458F8.4	-6.25	9.19e-10	4.3e-07	-0.2	-0.27	Corneal structure;	chr7:66811230	chr7:66902857~66906297:+
LUAD	cis	rs367615	0.959	rs2201016	ENSG00000249476.1	CTD-2587M2.1	6.25	9.2e-10	4.3e-07	0.35	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109611586	chr5:109237120~109326369:-
LUAD	cis	rs12908161	1	rs12903134	ENSG00000259728.4	LINC00933	6.25	9.2e-10	4.31e-07	0.39	0.27	Schizophrenia;	chr15:84794468	chr15:84570649~84580175:+
LUAD	cis	rs12908161	1	rs35726233	ENSG00000259728.4	LINC00933	6.25	9.2e-10	4.31e-07	0.39	0.27	Schizophrenia;	chr15:84794569	chr15:84570649~84580175:+
LUAD	cis	rs2179367	0.959	rs489551	ENSG00000231760.4	RP11-350J20.5	6.25	9.21e-10	4.31e-07	0.35	0.27	Dupuytren's disease;	chr6:149368321	chr6:149796151~149826294:-
LUAD	cis	rs17684571	0.872	rs34566275	ENSG00000231441.1	RP11-472M19.2	6.25	9.23e-10	4.31e-07	0.4	0.27	Schizophrenia;	chr6:56740130	chr6:56844002~56864078:+
LUAD	cis	rs875971	0.862	rs778734	ENSG00000222364.1	RNU6-96P	-6.25	9.23e-10	4.32e-07	-0.31	-0.27	Aortic root size;	chr7:66349862	chr7:66395191~66395286:+
LUAD	cis	rs6860806	0.507	rs272882	ENSG00000233006.5	AC034220.3	6.25	9.24e-10	4.32e-07	0.27	0.27	Breast cancer;	chr5:132333468	chr5:132311285~132369916:-
LUAD	cis	rs10214930	0.624	rs6949496	ENSG00000235574.1	AC073150.6	-6.25	9.25e-10	4.33e-07	-0.35	-0.27	Hypospadias;	chr7:27520075	chr7:27491682~27492765:-
LUAD	cis	rs12468226	0.938	rs116109808	ENSG00000226261.1	AC064836.3	6.25	9.25e-10	4.33e-07	0.46	0.27	Urate levels;	chr2:202287356	chr2:202336024~202336727:-
LUAD	cis	rs12468226	0.873	rs78175596	ENSG00000226261.1	AC064836.3	6.25	9.25e-10	4.33e-07	0.46	0.27	Urate levels;	chr2:202287993	chr2:202336024~202336727:-
LUAD	cis	rs12468226	0.938	rs74454549	ENSG00000226261.1	AC064836.3	6.25	9.25e-10	4.33e-07	0.46	0.27	Urate levels;	chr2:202288044	chr2:202336024~202336727:-
LUAD	cis	rs9928842	0.882	rs9927264	ENSG00000280152.1	RP11-331F4.5	6.25	9.26e-10	4.33e-07	0.3	0.27	Alcoholic chronic pancreatitis;	chr16:75226343	chr16:75245994~75250077:-
LUAD	cis	rs7927592	0.913	rs7925275	ENSG00000212093.1	AP000807.1	6.25	9.26e-10	4.33e-07	0.31	0.27	Total body bone mineral density;	chr11:68522965	chr11:68506083~68506166:-
LUAD	cis	rs10740039	0.883	rs7918897	ENSG00000254271.1	RP11-131N11.4	6.25	9.26e-10	4.33e-07	0.32	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60643754	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs7902632	ENSG00000254271.1	RP11-131N11.4	6.25	9.26e-10	4.33e-07	0.32	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60643811	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.96	rs10443928	ENSG00000254271.1	RP11-131N11.4	6.25	9.26e-10	4.33e-07	0.32	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60645718	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs10443929	ENSG00000254271.1	RP11-131N11.4	6.25	9.26e-10	4.33e-07	0.32	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60645852	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.842	rs7915540	ENSG00000254271.1	RP11-131N11.4	6.25	9.26e-10	4.33e-07	0.32	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60646538	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs7905018	ENSG00000254271.1	RP11-131N11.4	6.25	9.26e-10	4.33e-07	0.32	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60647585	chr10:60734342~60741828:+
LUAD	cis	rs8081395	0.741	rs180532	ENSG00000266992.1	DHX40P1	6.25	9.27e-10	4.33e-07	0.32	0.27	White blood cell count;	chr17:59925936	chr17:59976009~60002384:-
LUAD	cis	rs8081395	0.741	rs180530	ENSG00000266992.1	DHX40P1	6.25	9.27e-10	4.33e-07	0.32	0.27	White blood cell count;	chr17:59926233	chr17:59976009~60002384:-
LUAD	cis	rs948562	0.744	rs11229440	ENSG00000280010.1	AP001350.4	6.25	9.27e-10	4.33e-07	0.42	0.27	Lymphoma;	chr11:58426719	chr11:58627435~58628528:+
LUAD	cis	rs150992	0.631	rs112047336	ENSG00000248489.1	CTD-2007H13.3	6.25	9.29e-10	4.34e-07	0.3	0.27	Body mass index;	chr5:98990041	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.609	rs112042355	ENSG00000248489.1	CTD-2007H13.3	6.25	9.29e-10	4.34e-07	0.3	0.27	Body mass index;	chr5:98990046	chr5:98929171~98995013:+
LUAD	cis	rs7923609	0.967	rs7082470	ENSG00000232075.1	MRPL35P2	-6.25	9.29e-10	4.34e-07	-0.33	-0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63517266	chr10:63634317~63634827:-
LUAD	cis	rs2729354	0.514	rs1967179	ENSG00000265566.2	RN7SL605P	-6.25	9.3e-10	4.35e-07	-0.33	-0.27	Blood protein levels;	chr11:57581010	chr11:57528085~57528365:-
LUAD	cis	rs7923609	0.756	rs7090758	ENSG00000232075.1	MRPL35P2	6.25	9.31e-10	4.35e-07	0.33	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63575555	chr10:63634317~63634827:-
LUAD	cis	rs2404602	0.684	rs157759	ENSG00000259422.1	RP11-593F23.1	6.24	9.34e-10	4.36e-07	0.36	0.27	Blood metabolite levels;	chr15:76554649	chr15:76174891~76181486:-
LUAD	cis	rs67311347	1	rs11720360	ENSG00000223797.4	ENTPD3-AS1	6.24	9.34e-10	4.37e-07	0.3	0.27	Renal cell carcinoma;	chr3:40406906	chr3:40313802~40453329:-
LUAD	cis	rs12554020	1	rs59582399	ENSG00000227603.1	RP11-165J3.6	6.24	9.35e-10	4.37e-07	0.41	0.27	Schizophrenia;	chr9:93523881	chr9:93435332~93437121:-
LUAD	cis	rs4834770	0.718	rs4833618	ENSG00000245958.5	RP11-33B1.1	6.24	9.36e-10	4.37e-07	0.24	0.27	Blood protein levels;	chr4:119388345	chr4:119454791~119552025:+
LUAD	cis	rs4723738	1	rs2159499	ENSG00000227191.5	TRGC2	-6.24	9.37e-10	4.38e-07	-0.3	-0.27	Treatment response for severe sepsis;	chr7:38189300	chr7:38239580~38368091:-
LUAD	cis	rs9549367	0.789	rs7317558	ENSG00000269125.1	RP11-98F14.11	-6.24	9.37e-10	4.38e-07	-0.33	-0.27	Platelet distribution width;	chr13:113239311	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.826	rs1885688	ENSG00000269125.1	RP11-98F14.11	-6.24	9.37e-10	4.38e-07	-0.33	-0.27	Platelet distribution width;	chr13:113239922	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.789	rs9577218	ENSG00000269125.1	RP11-98F14.11	-6.24	9.37e-10	4.38e-07	-0.33	-0.27	Platelet distribution width;	chr13:113240597	chr13:113165002~113165183:-
LUAD	cis	rs2276314	0.512	rs1789506	ENSG00000278986.1	RP11-723J4.3	6.24	9.38e-10	4.38e-07	0.28	0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36045407	chr18:35972151~35973916:+
LUAD	cis	rs6597981	0.675	rs4963120	ENSG00000255284.1	AP006621.5	-6.24	9.38e-10	4.38e-07	-0.25	-0.27	Breast cancer;	chr11:825777	chr11:777578~784297:+
LUAD	cis	rs7246657	0.525	rs10405238	ENSG00000276846.1	CTD-3220F14.3	6.24	9.4e-10	4.39e-07	0.41	0.27	Coronary artery calcification;	chr19:36997153	chr19:37314868~37315620:-
LUAD	cis	rs6142102	0.602	rs68051854	ENSG00000275784.1	RP5-1125A11.6	-6.24	9.4e-10	4.39e-07	-0.29	-0.27	Skin pigmentation;	chr20:34114150	chr20:33989480~33991818:-
LUAD	cis	rs321358	0.731	rs555063	ENSG00000271584.1	RP11-89C3.4	6.24	9.4e-10	4.39e-07	0.4	0.27	Body mass index;	chr11:111168621	chr11:111091932~111097357:-
LUAD	cis	rs11098499	0.754	rs2036860	ENSG00000248280.1	RP11-33B1.2	6.24	9.4e-10	4.39e-07	0.34	0.27	Corneal astigmatism;	chr4:119327779	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs2036857	ENSG00000248280.1	RP11-33B1.2	6.24	9.4e-10	4.39e-07	0.34	0.27	Corneal astigmatism;	chr4:119328085	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs2036856	ENSG00000248280.1	RP11-33B1.2	6.24	9.4e-10	4.39e-07	0.34	0.27	Corneal astigmatism;	chr4:119328133	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs4443261	ENSG00000248280.1	RP11-33B1.2	6.24	9.4e-10	4.39e-07	0.34	0.27	Corneal astigmatism;	chr4:119328146	chr4:119440561~119450157:-
LUAD	cis	rs2933343	0.951	rs789220	ENSG00000261159.1	RP11-723O4.9	-6.24	9.42e-10	4.4e-07	-0.32	-0.27	IgG glycosylation;	chr3:128873292	chr3:128859716~128860526:-
LUAD	cis	rs7923609	0.729	rs7902616	ENSG00000232075.1	MRPL35P2	6.24	9.43e-10	4.4e-07	0.33	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63576613	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.756	rs10822183	ENSG00000232075.1	MRPL35P2	6.24	9.43e-10	4.4e-07	0.33	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63577381	chr10:63634317~63634827:-
LUAD	cis	rs4723738	1	rs11766341	ENSG00000227191.5	TRGC2	-6.24	9.43e-10	4.4e-07	-0.3	-0.27	Treatment response for severe sepsis;	chr7:38188147	chr7:38239580~38368091:-
LUAD	cis	rs783540	0.967	rs34186444	ENSG00000278603.1	RP13-608F4.5	-6.24	9.44e-10	4.41e-07	-0.32	-0.27	Schizophrenia;	chr15:82618749	chr15:82472203~82472426:+
LUAD	cis	rs8031584	0.918	rs34331396	ENSG00000260382.1	RP11-540B6.2	6.24	9.45e-10	4.41e-07	0.33	0.27	Huntington's disease progression;	chr15:30956533	chr15:30882267~30883231:-
LUAD	cis	rs17301013	0.507	rs72715224	ENSG00000227373.4	RP11-160H22.5	6.24	9.45e-10	4.41e-07	0.41	0.27	Systemic lupus erythematosus;	chr1:174534256	chr1:174115300~174160004:-
LUAD	cis	rs8177376	1	rs534804	ENSG00000254905.1	RP11-712L6.7	6.24	9.45e-10	4.41e-07	0.37	0.27	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126205873	chr11:126292922~126294254:-
LUAD	cis	rs1823913	0.503	rs35868016	ENSG00000227542.1	AC092614.2	6.24	9.46e-10	4.42e-07	0.34	0.27	Obesity-related traits;	chr2:191344082	chr2:191229165~191246172:-
LUAD	cis	rs1707322	0.721	rs12043945	ENSG00000234329.1	RP11-767N6.2	6.24	9.47e-10	4.42e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45641250	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs12091503	ENSG00000234329.1	RP11-767N6.2	6.24	9.47e-10	4.42e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642196	chr1:45651039~45651826:-
LUAD	cis	rs783540	0.934	rs803747	ENSG00000278603.1	RP13-608F4.5	-6.24	9.47e-10	4.42e-07	-0.32	-0.27	Schizophrenia;	chr15:82589345	chr15:82472203~82472426:+
LUAD	cis	rs783540	0.967	rs55972423	ENSG00000278603.1	RP13-608F4.5	-6.24	9.47e-10	4.42e-07	-0.32	-0.27	Schizophrenia;	chr15:82590203	chr15:82472203~82472426:+
LUAD	cis	rs9928842	0.941	rs1808427	ENSG00000280152.1	RP11-331F4.5	6.24	9.48e-10	4.42e-07	0.31	0.27	Alcoholic chronic pancreatitis;	chr16:75207496	chr16:75245994~75250077:-
LUAD	cis	rs801193	0.548	rs6975044	ENSG00000222364.1	RNU6-96P	-6.24	9.49e-10	4.43e-07	-0.31	-0.27	Aortic root size;	chr7:66762495	chr7:66395191~66395286:+
LUAD	cis	rs6991838	0.671	rs13251307	ENSG00000200714.1	Y_RNA	6.24	9.5e-10	4.43e-07	0.32	0.27	Intelligence (multi-trait analysis);	chr8:65664911	chr8:65592731~65592820:+
LUAD	cis	rs35740288	0.688	rs12904047	ENSG00000202081.1	RNU6-1280P	6.24	9.52e-10	4.44e-07	0.34	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85669635	chr15:85651522~85651628:-
LUAD	cis	rs2243480	0.901	rs2949697	ENSG00000232546.1	RP11-458F8.1	-6.24	9.52e-10	4.44e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65999249	chr7:66848496~66858136:+
LUAD	cis	rs7017914	0.905	rs2639898	ENSG00000223220.1	Y_RNA	6.24	9.55e-10	4.45e-07	0.3	0.27	Bone mineral density;	chr8:71008075	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.84	rs2732099	ENSG00000223220.1	Y_RNA	6.24	9.55e-10	4.45e-07	0.3	0.27	Bone mineral density;	chr8:71008815	chr8:70780914~70781008:-
LUAD	cis	rs10214930	1	rs10241783	ENSG00000235574.1	AC073150.6	6.24	9.55e-10	4.45e-07	0.39	0.27	Hypospadias;	chr7:27817901	chr7:27491682~27492765:-
LUAD	cis	rs2739330	0.828	rs5751770	ENSG00000228039.3	KB-1125A3.10	6.24	9.56e-10	4.46e-07	0.33	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23963780~23964374:+
LUAD	cis	rs728616	0.614	rs58606426	ENSG00000225484.5	NUTM2B-AS1	-6.24	9.56e-10	4.46e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79968556	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.614	rs57966752	ENSG00000225484.5	NUTM2B-AS1	-6.24	9.56e-10	4.46e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79968557	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.614	rs61860413	ENSG00000225484.5	NUTM2B-AS1	-6.24	9.56e-10	4.46e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79970363	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.614	rs61860414	ENSG00000225484.5	NUTM2B-AS1	-6.24	9.56e-10	4.46e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79970424	chr10:79663088~79826594:-
LUAD	cis	rs35740288	0.77	rs11638278	ENSG00000202081.1	RNU6-1280P	6.24	9.57e-10	4.46e-07	0.34	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85668173	chr15:85651522~85651628:-
LUAD	cis	rs7684253	0.548	rs62308071	ENSG00000269949.1	RP11-738E22.3	-6.24	9.57e-10	4.46e-07	-0.36	-0.27	Migraine;	chr4:56850720	chr4:56960927~56961373:-
LUAD	cis	rs67311347	0.955	rs2085114	ENSG00000223797.4	ENTPD3-AS1	6.24	9.59e-10	4.47e-07	0.3	0.27	Renal cell carcinoma;	chr3:40455946	chr3:40313802~40453329:-
LUAD	cis	rs9640161	0.83	rs17173681	ENSG00000261305.1	RP4-584D14.7	-6.24	9.62e-10	4.48e-07	-0.4	-0.27	Blood protein levels;Circulating chemerin levels;	chr7:150362325	chr7:150341771~150342607:+
LUAD	cis	rs6844153	0.752	rs28497454	ENSG00000240005.4	RP11-293A21.1	-6.24	9.62e-10	4.48e-07	-0.39	-0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26906230	chr4:26859806~26860599:-
LUAD	cis	rs7727544	0.684	rs272889	ENSG00000233006.5	AC034220.3	6.24	9.62e-10	4.48e-07	0.24	0.27	Blood metabolite levels;	chr5:132329685	chr5:132311285~132369916:-
LUAD	cis	rs7221109	0.56	rs2315020	ENSG00000278834.1	RP11-458J1.1	6.24	9.62e-10	4.48e-07	0.32	0.27	Type 1 diabetes;	chr17:40671414	chr17:40648300~40649718:+
LUAD	cis	rs9640161	0.789	rs10248490	ENSG00000261305.1	RP4-584D14.7	6.24	9.63e-10	4.49e-07	0.4	0.27	Blood protein levels;Circulating chemerin levels;	chr7:150354329	chr7:150341771~150342607:+
LUAD	cis	rs801193	0.569	rs2707824	ENSG00000222364.1	RNU6-96P	-6.24	9.64e-10	4.49e-07	-0.31	-0.27	Aortic root size;	chr7:66724256	chr7:66395191~66395286:+
LUAD	cis	rs2111504	0.583	rs1015839	ENSG00000267213.4	AC007773.2	6.24	9.64e-10	4.49e-07	0.35	0.27	Bipolar disorder;	chr19:32390365	chr19:32390050~32405560:-
LUAD	cis	rs7937890	0.904	rs67623158	ENSG00000254418.1	RP11-21L19.1	-6.24	9.65e-10	4.5e-07	-0.31	-0.27	Mitochondrial DNA levels;	chr11:14273650	chr11:14262846~14273691:-
LUAD	cis	rs75920871	0.589	rs115787357	ENSG00000254851.1	RP11-109L13.1	-6.24	9.65e-10	4.5e-07	-0.49	-0.27	Subjective well-being;	chr11:117193790	chr11:117135528~117138582:+
LUAD	cis	rs2179367	0.959	rs562428	ENSG00000231760.4	RP11-350J20.5	6.24	9.65e-10	4.5e-07	0.35	0.27	Dupuytren's disease;	chr6:149326389	chr6:149796151~149826294:-
LUAD	cis	rs948562	0.69	rs11229393	ENSG00000280010.1	AP001350.4	-6.24	9.66e-10	4.5e-07	-0.42	-0.27	Lymphoma;	chr11:58385132	chr11:58627435~58628528:+
LUAD	cis	rs7017914	0.905	rs1908033	ENSG00000223220.1	Y_RNA	6.24	9.66e-10	4.5e-07	0.3	0.27	Bone mineral density;	chr8:71010564	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs2732103	ENSG00000223220.1	Y_RNA	6.24	9.66e-10	4.5e-07	0.3	0.27	Bone mineral density;	chr8:71011261	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.837	rs2732105	ENSG00000223220.1	Y_RNA	6.24	9.67e-10	4.5e-07	0.3	0.27	Bone mineral density;	chr8:71011410	chr8:70780914~70781008:-
LUAD	cis	rs875971	0.528	rs801213	ENSG00000226824.5	RP4-756H11.3	6.24	9.67e-10	4.5e-07	0.39	0.27	Aortic root size;	chr7:66549931	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.545	rs801212	ENSG00000226824.5	RP4-756H11.3	6.24	9.67e-10	4.5e-07	0.39	0.27	Aortic root size;	chr7:66550643	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.545	rs801199	ENSG00000226824.5	RP4-756H11.3	6.24	9.67e-10	4.5e-07	0.39	0.27	Aortic root size;	chr7:66560286	chr7:66654538~66669855:+
LUAD	cis	rs4591358	0.773	rs34480328	ENSG00000223466.1	AC064834.2	-6.24	9.68e-10	4.51e-07	-0.37	-0.27	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195510684	chr2:195533035~195538681:+
LUAD	cis	rs5760092	0.755	rs4585126	ENSG00000228039.3	KB-1125A3.10	-6.24	9.69e-10	4.51e-07	-0.38	-0.27	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23963780~23964374:+
LUAD	cis	rs2243480	0.706	rs34466769	ENSG00000232546.1	RP11-458F8.1	-6.24	9.69e-10	4.51e-07	-0.32	-0.27	Diabetic kidney disease;	chr7:65988305	chr7:66848496~66858136:+
LUAD	cis	rs17684571	0.81	rs41267675	ENSG00000231441.1	RP11-472M19.2	6.24	9.72e-10	4.52e-07	0.4	0.27	Schizophrenia;	chr6:56735323	chr6:56844002~56864078:+
LUAD	cis	rs2243480	1	rs937108	ENSG00000232546.1	RP11-458F8.1	-6.24	9.73e-10	4.53e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:65963465	chr7:66848496~66858136:+
LUAD	cis	rs4674676	1	rs4674676	ENSG00000261428.2	RP11-16P6.1	6.24	9.74e-10	4.54e-07	0.41	0.27	Chin dimples;	chr2:222664393	chr2:222566899~222569719:-
LUAD	cis	rs12468226	1	rs16824599	ENSG00000226261.1	AC064836.3	6.24	9.74e-10	4.54e-07	0.46	0.27	Urate levels;	chr2:202358243	chr2:202336024~202336727:-
LUAD	cis	rs950169	0.92	rs2135551	ENSG00000259728.4	LINC00933	6.24	9.75e-10	4.54e-07	0.41	0.27	Schizophrenia;	chr15:84039099	chr15:84570649~84580175:+
LUAD	cis	rs728616	0.541	rs61860401	ENSG00000225484.5	NUTM2B-AS1	-6.24	9.75e-10	4.54e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79963766	chr10:79663088~79826594:-
LUAD	cis	rs755249	0.567	rs16825939	ENSG00000228060.1	RP11-69E11.8	-6.24	9.77e-10	4.55e-07	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39196836	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs67020650	ENSG00000228060.1	RP11-69E11.8	-6.24	9.77e-10	4.55e-07	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39202343	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs72661925	ENSG00000228060.1	RP11-69E11.8	-6.24	9.77e-10	4.55e-07	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39203865	chr1:39565160~39573203:+
LUAD	cis	rs11089937	0.616	rs4991801	ENSG00000211639.2	IGLV4-60	6.24	9.77e-10	4.55e-07	0.28	0.27	Periodontitis (PAL4Q3);	chr22:22178958	chr22:22162199~22162681:+
LUAD	cis	rs12458462	1	rs12458462	ENSG00000274828.1	RP11-567M16.6	6.24	9.77e-10	4.55e-07	0.29	0.27	Monocyte count;	chr18:79712436	chr18:79677287~79679358:-
LUAD	cis	rs10214930	1	rs7800116	ENSG00000235574.1	AC073150.6	6.24	9.77e-10	4.55e-07	0.38	0.27	Hypospadias;	chr7:27782565	chr7:27491682~27492765:-
LUAD	cis	rs17301013	0.507	rs1653630	ENSG00000227373.4	RP11-160H22.5	-6.24	9.79e-10	4.56e-07	-0.4	-0.27	Systemic lupus erythematosus;	chr1:174791810	chr1:174115300~174160004:-
LUAD	cis	rs2739330	0.828	rs4822451	ENSG00000206090.4	AP000350.7	6.24	9.8e-10	4.56e-07	0.32	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23939998~23942798:+
LUAD	cis	rs2739330	0.828	rs5760098	ENSG00000206090.4	AP000350.7	6.24	9.8e-10	4.56e-07	0.32	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23939998~23942798:+
LUAD	cis	rs7937890	0.904	rs11023169	ENSG00000254418.1	RP11-21L19.1	-6.24	9.81e-10	4.56e-07	-0.32	-0.27	Mitochondrial DNA levels;	chr11:14269439	chr11:14262846~14273691:-
LUAD	cis	rs7615952	0.688	rs9754526	ENSG00000171084.14	FAM86JP	6.24	9.82e-10	4.57e-07	0.39	0.27	Blood pressure (smoking interaction);	chr3:125824023	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.512	rs34085484	ENSG00000171084.14	FAM86JP	6.24	9.82e-10	4.57e-07	0.39	0.27	Blood pressure (smoking interaction);	chr3:125825343	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.575	rs35949599	ENSG00000171084.14	FAM86JP	6.24	9.82e-10	4.57e-07	0.39	0.27	Blood pressure (smoking interaction);	chr3:125825359	chr3:125916620~125930024:+
LUAD	cis	rs1799949	0.86	rs8176279	ENSG00000267681.1	CTD-3199J23.6	-6.24	9.83e-10	4.57e-07	-0.31	-0.27	Menopause (age at onset);	chr17:43058379	chr17:43144956~43145255:+
LUAD	cis	rs113835537	0.529	rs3741360	ENSG00000255517.5	CTD-3074O7.5	-6.24	9.83e-10	4.57e-07	-0.33	-0.27	Airway imaging phenotypes;	chr11:66532877	chr11:66473490~66480233:-
LUAD	cis	rs6844153	0.752	rs12644073	ENSG00000240005.4	RP11-293A21.1	-6.24	9.84e-10	4.57e-07	-0.39	-0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26895436	chr4:26859806~26860599:-
LUAD	cis	rs7727544	0.507	rs10051679	ENSG00000233006.5	AC034220.3	6.24	9.84e-10	4.58e-07	0.25	0.27	Blood metabolite levels;	chr5:132235238	chr5:132311285~132369916:-
LUAD	cis	rs367615	0.959	rs17161951	ENSG00000249476.1	CTD-2587M2.1	-6.24	9.86e-10	4.58e-07	-0.34	-0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109594889	chr5:109237120~109326369:-
LUAD	cis	rs2337406	0.538	rs10141701	ENSG00000211974.3	IGHV2-70	-6.24	9.86e-10	4.58e-07	-0.33	-0.27	Alzheimer's disease (late onset);	chr14:106633467	chr14:106723574~106724093:-
LUAD	cis	rs3813579	0.679	rs4329928	ENSG00000261390.4	RP11-345M22.2	6.24	9.87e-10	4.59e-07	0.33	0.27	Thyroid volume;	chr16:79713988	chr16:79715232~79770563:-
LUAD	cis	rs8072100	0.935	rs12150231	ENSG00000228782.6	CTD-2026D20.3	-6.24	9.87e-10	4.59e-07	-0.29	-0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47639725	chr17:47450568~47492492:-
LUAD	cis	rs8062405	1	rs72793811	ENSG00000251417.2	RP11-1348G14.4	-6.24	9.87e-10	4.59e-07	-0.29	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28802743~28817828:+
LUAD	cis	rs6772849	0.93	rs4467479	ENSG00000242551.2	POU5F1P6	-6.24	9.88e-10	4.59e-07	-0.32	-0.27	Monocyte percentage of white cells;Monocyte count;	chr3:128650212	chr3:128674735~128677005:-
LUAD	cis	rs6772849	0.93	rs12630379	ENSG00000242551.2	POU5F1P6	-6.24	9.88e-10	4.59e-07	-0.32	-0.27	Monocyte percentage of white cells;Monocyte count;	chr3:128651361	chr3:128674735~128677005:-
LUAD	cis	rs11096990	0.855	rs75746161	ENSG00000249207.1	RP11-360F5.1	6.24	9.89e-10	4.6e-07	0.32	0.27	Cognitive function;	chr4:39167481	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.855	rs6855008	ENSG00000249207.1	RP11-360F5.1	6.24	9.89e-10	4.6e-07	0.32	0.27	Cognitive function;	chr4:39172006	chr4:39112677~39126818:-
LUAD	cis	rs2034650	0.563	rs2412523	ENSG00000223313.1	RNU6-516P	6.23	9.9e-10	4.6e-07	0.35	0.27	Interstitial lung disease;	chr15:40417487	chr15:40529570~40529673:+
LUAD	cis	rs2243480	1	rs1618893	ENSG00000232546.1	RP11-458F8.1	-6.23	9.91e-10	4.61e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:66631132	chr7:66848496~66858136:+
LUAD	cis	rs67311347	1	rs28491638	ENSG00000223797.4	ENTPD3-AS1	6.23	9.91e-10	4.61e-07	0.3	0.27	Renal cell carcinoma;	chr3:40454772	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs28536038	ENSG00000223797.4	ENTPD3-AS1	6.23	9.91e-10	4.61e-07	0.3	0.27	Renal cell carcinoma;	chr3:40454891	chr3:40313802~40453329:-
LUAD	cis	rs72772090	0.539	rs11740375	ENSG00000248734.2	CTD-2260A17.1	-6.23	9.92e-10	4.61e-07	-0.42	-0.27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96777193	chr5:96784777~96785999:+
LUAD	cis	rs4964805	0.672	rs4964823	ENSG00000257681.1	RP11-341G23.4	6.23	9.92e-10	4.61e-07	0.33	0.27	Attention deficit hyperactivity disorder;	chr12:103787642	chr12:103746315~103768858:-
LUAD	cis	rs728616	0.614	rs10887218	ENSG00000225484.5	NUTM2B-AS1	-6.23	9.94e-10	4.62e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79951268	chr10:79663088~79826594:-
LUAD	cis	rs11168351	0.833	rs6580652	ENSG00000240399.1	RP1-228P16.1	-6.23	9.94e-10	4.62e-07	-0.27	-0.27	Bipolar disorder and schizophrenia;	chr12:48053322	chr12:48054813~48055591:-
LUAD	cis	rs1823913	0.503	rs34716486	ENSG00000227542.1	AC092614.2	6.23	9.95e-10	4.62e-07	0.34	0.27	Obesity-related traits;	chr2:191343335	chr2:191229165~191246172:-
LUAD	cis	rs8062405	1	rs4788095	ENSG00000251417.2	RP11-1348G14.4	-6.23	9.95e-10	4.62e-07	-0.28	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28802743~28817828:+
LUAD	cis	rs8062405	0.964	rs72793809	ENSG00000251417.2	RP11-1348G14.4	-6.23	9.95e-10	4.62e-07	-0.28	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs62036620	ENSG00000251417.2	RP11-1348G14.4	-6.23	9.95e-10	4.62e-07	-0.28	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs62036621	ENSG00000251417.2	RP11-1348G14.4	-6.23	9.95e-10	4.62e-07	-0.28	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28802743~28817828:+
LUAD	cis	rs66887589	0.592	rs62320740	ENSG00000245958.5	RP11-33B1.1	-6.23	9.95e-10	4.62e-07	-0.23	-0.27	Diastolic blood pressure;	chr4:119358331	chr4:119454791~119552025:+
LUAD	cis	rs5753618	0.561	rs5753609	ENSG00000236132.1	CTA-440B3.1	-6.23	9.96e-10	4.63e-07	-0.33	-0.27	Colorectal cancer;	chr22:31423226	chr22:31816379~31817491:-
LUAD	cis	rs8062405	1	rs12443881	ENSG00000251417.2	RP11-1348G14.4	-6.23	9.96e-10	4.63e-07	-0.29	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28802743~28817828:+
LUAD	cis	rs67311347	1	rs1466237	ENSG00000223797.4	ENTPD3-AS1	6.23	9.96e-10	4.63e-07	0.28	0.27	Renal cell carcinoma;	chr3:40420535	chr3:40313802~40453329:-
LUAD	cis	rs113835537	0.529	rs17495838	ENSG00000255517.5	CTD-3074O7.5	-6.23	9.98e-10	4.63e-07	-0.34	-0.27	Airway imaging phenotypes;	chr11:66428794	chr11:66473490~66480233:-
LUAD	cis	rs35740288	0.731	rs12898964	ENSG00000202081.1	RNU6-1280P	6.23	1e-09	4.65e-07	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85618046	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.731	rs2344440	ENSG00000202081.1	RNU6-1280P	6.23	1e-09	4.65e-07	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85618334	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.77	rs1157519	ENSG00000202081.1	RNU6-1280P	6.23	1e-09	4.65e-07	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85618427	chr15:85651522~85651628:-
LUAD	cis	rs17301013	0.606	rs2860907	ENSG00000227373.4	RP11-160H22.5	6.23	1e-09	4.66e-07	0.38	0.27	Systemic lupus erythematosus;	chr1:174203246	chr1:174115300~174160004:-
LUAD	cis	rs2179367	0.959	rs540538	ENSG00000231760.4	RP11-350J20.5	6.23	1e-09	4.66e-07	0.35	0.27	Dupuytren's disease;	chr6:149326808	chr6:149796151~149826294:-
LUAD	cis	rs10129255	0.536	rs3944157	ENSG00000224373.3	IGHV4-59	6.23	1.01e-09	4.67e-07	0.16	0.27	Kawasaki disease;	chr14:106682286	chr14:106627249~106627825:-
LUAD	cis	rs17301013	0.507	rs72715260	ENSG00000227373.4	RP11-160H22.5	6.23	1.01e-09	4.67e-07	0.43	0.27	Systemic lupus erythematosus;	chr1:174604995	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs4607949	ENSG00000227373.4	RP11-160H22.5	6.23	1.01e-09	4.68e-07	0.38	0.27	Systemic lupus erythematosus;	chr1:174212218	chr1:174115300~174160004:-
LUAD	cis	rs2179367	0.959	rs9373592	ENSG00000231760.4	RP11-350J20.5	6.23	1.01e-09	4.68e-07	0.35	0.27	Dupuytren's disease;	chr6:149412119	chr6:149796151~149826294:-
LUAD	cis	rs17301013	0.507	rs1923818	ENSG00000227373.4	RP11-160H22.5	6.23	1.01e-09	4.68e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174749737	chr1:174115300~174160004:-
LUAD	cis	rs7017914	0.905	rs2732104	ENSG00000223220.1	Y_RNA	6.23	1.01e-09	4.68e-07	0.3	0.27	Bone mineral density;	chr8:71011284	chr8:70780914~70781008:-
LUAD	cis	rs7221109	0.56	rs2429549	ENSG00000278834.1	RP11-458J1.1	-6.23	1.01e-09	4.68e-07	-0.32	-0.27	Type 1 diabetes;	chr17:40698154	chr17:40648300~40649718:+
LUAD	cis	rs155076	1	rs261427	ENSG00000233325.3	MIPEPP3	6.23	1.01e-09	4.69e-07	0.43	0.27	White matter hyperintensity burden;	chr13:21286859	chr13:21298139~21306373:+
LUAD	cis	rs4713118	0.512	rs2622319	ENSG00000219392.1	RP1-265C24.5	-6.23	1.01e-09	4.69e-07	-0.36	-0.27	Parkinson's disease;	chr6:28152623	chr6:28115628~28116551:+
LUAD	cis	rs172166	0.694	rs1150666	ENSG00000219392.1	RP1-265C24.5	-6.23	1.01e-09	4.69e-07	-0.36	-0.27	Cardiac Troponin-T levels;	chr6:28156150	chr6:28115628~28116551:+
LUAD	cis	rs801193	0.569	rs11772819	ENSG00000222364.1	RNU6-96P	-6.23	1.01e-09	4.69e-07	-0.31	-0.27	Aortic root size;	chr7:66752983	chr7:66395191~66395286:+
LUAD	cis	rs801193	0.569	rs7800620	ENSG00000222364.1	RNU6-96P	-6.23	1.01e-09	4.69e-07	-0.31	-0.27	Aortic root size;	chr7:66758701	chr7:66395191~66395286:+
LUAD	cis	rs293748	0.825	rs468022	ENSG00000250155.1	CTD-2353F22.1	-6.23	1.01e-09	4.7e-07	-0.39	-0.27	Obesity-related traits;	chr5:36988150	chr5:36666214~36725195:-
LUAD	cis	rs3762637	1	rs16845530	ENSG00000272758.4	RP11-299J3.8	-6.23	1.02e-09	4.71e-07	-0.41	-0.27	LDL cholesterol levels;	chr3:122423600	chr3:122416207~122443180:+
LUAD	cis	rs8072100	0.811	rs9889709	ENSG00000228782.6	CTD-2026D20.3	6.23	1.02e-09	4.71e-07	0.3	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47367863	chr17:47450568~47492492:-
LUAD	cis	rs2243480	1	rs437889	ENSG00000232546.1	RP11-458F8.1	-6.23	1.02e-09	4.71e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66044247	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs402418	ENSG00000232546.1	RP11-458F8.1	-6.23	1.02e-09	4.71e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66044482	chr7:66848496~66858136:+
LUAD	cis	rs2243480	0.803	rs423187	ENSG00000232546.1	RP11-458F8.1	-6.23	1.02e-09	4.71e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66044512	chr7:66848496~66858136:+
LUAD	cis	rs8059260	0.541	rs8046052	ENSG00000274038.1	RP11-66H6.4	-6.23	1.02e-09	4.71e-07	-0.54	-0.27	Alcohol consumption over the past year;	chr16:11129464	chr16:11056556~11057034:+
LUAD	cis	rs801193	0.569	rs13226966	ENSG00000222364.1	RNU6-96P	-6.23	1.02e-09	4.71e-07	-0.31	-0.27	Aortic root size;	chr7:66768636	chr7:66395191~66395286:+
LUAD	cis	rs1799949	1	rs4793189	ENSG00000267681.1	CTD-3199J23.6	-6.23	1.02e-09	4.72e-07	-0.32	-0.27	Menopause (age at onset);	chr17:43038698	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs11657053	ENSG00000267681.1	CTD-3199J23.6	-6.23	1.02e-09	4.72e-07	-0.32	-0.27	Menopause (age at onset);	chr17:43039112	chr17:43144956~43145255:+
LUAD	cis	rs2739330	0.796	rs5760106	ENSG00000206090.4	AP000350.7	-6.23	1.02e-09	4.72e-07	-0.31	-0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23939998~23942798:+
LUAD	cis	rs4820294	1	rs41280035	ENSG00000233360.4	Z83844.1	6.23	1.02e-09	4.72e-07	0.29	0.27	Fat distribution (HIV);	chr22:37658031	chr22:37641832~37658377:-
LUAD	cis	rs4713118	0.621	rs9295756	ENSG00000204709.4	LINC01556	6.23	1.02e-09	4.73e-07	0.38	0.27	Parkinson's disease;	chr6:28065618	chr6:28943877~28944537:+
LUAD	cis	rs11096990	0.964	rs4974999	ENSG00000249207.1	RP11-360F5.1	-6.23	1.02e-09	4.73e-07	-0.3	-0.27	Cognitive function;	chr4:39262294	chr4:39112677~39126818:-
LUAD	cis	rs2243480	1	rs778729	ENSG00000232546.1	RP11-458F8.1	-6.23	1.02e-09	4.73e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66359432	chr7:66848496~66858136:+
LUAD	cis	rs17666538	0.591	rs1669716	ENSG00000254207.1	RP11-43A14.1	6.23	1.02e-09	4.73e-07	0.51	0.27	IgG glycosylation;	chr8:643707	chr8:725188~725877:-
LUAD	cis	rs875971	0.651	rs313829	ENSG00000226824.5	RP4-756H11.3	6.23	1.02e-09	4.73e-07	0.39	0.27	Aortic root size;	chr7:66087510	chr7:66654538~66669855:+
LUAD	cis	rs8177876	0.642	rs12445303	ENSG00000261838.4	RP11-303E16.6	-6.23	1.02e-09	4.73e-07	-0.56	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081968	chr16:81069854~81076598:+
LUAD	cis	rs948562	0.69	rs12361133	ENSG00000280010.1	AP001350.4	6.23	1.02e-09	4.73e-07	0.43	0.27	Lymphoma;	chr11:58357532	chr11:58627435~58628528:+
LUAD	cis	rs5753618	0.561	rs715510	ENSG00000236132.1	CTA-440B3.1	6.23	1.02e-09	4.74e-07	0.34	0.27	Colorectal cancer;	chr22:31294542	chr22:31816379~31817491:-
LUAD	cis	rs5753618	0.561	rs737887	ENSG00000236132.1	CTA-440B3.1	6.23	1.02e-09	4.74e-07	0.34	0.27	Colorectal cancer;	chr22:31300629	chr22:31816379~31817491:-
LUAD	cis	rs4835473	0.932	rs13152209	ENSG00000251600.4	RP11-673E1.1	6.23	1.02e-09	4.74e-07	0.34	0.27	Immature fraction of reticulocytes;	chr4:143776088	chr4:143912331~143982454:+
LUAD	cis	rs6558530	0.897	rs7838456	ENSG00000253982.1	CTD-2336O2.1	6.23	1.02e-09	4.75e-07	0.33	0.27	Systolic blood pressure;	chr8:1759425	chr8:1761990~1764502:-
LUAD	cis	rs77204473	0.744	rs78832854	ENSG00000254851.1	RP11-109L13.1	6.23	1.02e-09	4.75e-07	0.66	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903759	chr11:117135528~117138582:+
LUAD	cis	rs4835473	0.571	rs1992656	ENSG00000251600.4	RP11-673E1.1	6.23	1.03e-09	4.76e-07	0.34	0.27	Immature fraction of reticulocytes;	chr4:143855286	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.571	rs1992655	ENSG00000251600.4	RP11-673E1.1	6.23	1.03e-09	4.76e-07	0.34	0.27	Immature fraction of reticulocytes;	chr4:143855290	chr4:143912331~143982454:+
LUAD	cis	rs2739330	0.796	rs5760097	ENSG00000206090.4	AP000350.7	6.23	1.03e-09	4.77e-07	0.32	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23939998~23942798:+
LUAD	cis	rs67311347	1	rs4246666	ENSG00000223797.4	ENTPD3-AS1	6.23	1.03e-09	4.77e-07	0.28	0.27	Renal cell carcinoma;	chr3:40366179	chr3:40313802~40453329:-
LUAD	cis	rs801193	0.569	rs2659908	ENSG00000222364.1	RNU6-96P	-6.23	1.03e-09	4.77e-07	-0.31	-0.27	Aortic root size;	chr7:66695835	chr7:66395191~66395286:+
LUAD	cis	rs11157436	1	rs11157440	ENSG00000211812.1	TRAV26-2	-6.23	1.03e-09	4.77e-07	-0.31	-0.27	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22181757	chr14:22202583~22203368:+
LUAD	cis	rs1318937	0.764	rs60977744	ENSG00000224660.1	SH3BP5-AS1	6.23	1.03e-09	4.77e-07	0.22	0.27	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15198464	chr3:15254184~15264493:+
LUAD	cis	rs1318937	0.764	rs58837640	ENSG00000224660.1	SH3BP5-AS1	6.23	1.03e-09	4.77e-07	0.22	0.27	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15199139	chr3:15254184~15264493:+
LUAD	cis	rs1318937	0.516	rs73023424	ENSG00000224660.1	SH3BP5-AS1	6.23	1.03e-09	4.77e-07	0.22	0.27	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15201995	chr3:15254184~15264493:+
LUAD	cis	rs1318937	0.764	rs66813829	ENSG00000224660.1	SH3BP5-AS1	6.23	1.03e-09	4.77e-07	0.22	0.27	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15202214	chr3:15254184~15264493:+
LUAD	cis	rs113835537	0.529	rs75003264	ENSG00000255517.5	CTD-3074O7.5	-6.23	1.03e-09	4.77e-07	-0.33	-0.27	Airway imaging phenotypes;	chr11:66488628	chr11:66473490~66480233:-
LUAD	cis	rs7044106	0.762	rs10760115	ENSG00000238181.2	AHCYP2	-6.23	1.03e-09	4.77e-07	-0.35	-0.27	Hip circumference adjusted for BMI;	chr9:120714674	chr9:120720673~120721972:+
LUAD	cis	rs4713118	0.955	rs34752872	ENSG00000219392.1	RP1-265C24.5	-6.23	1.03e-09	4.78e-07	-0.37	-0.27	Parkinson's disease;	chr6:27715465	chr6:28115628~28116551:+
LUAD	cis	rs6772849	0.83	rs7633674	ENSG00000242551.2	POU5F1P6	-6.23	1.03e-09	4.78e-07	-0.32	-0.27	Monocyte percentage of white cells;Monocyte count;	chr3:128636183	chr3:128674735~128677005:-
LUAD	cis	rs4713118	0.587	rs61471148	ENSG00000204709.4	LINC01556	6.23	1.03e-09	4.79e-07	0.38	0.27	Parkinson's disease;	chr6:28069254	chr6:28943877~28944537:+
LUAD	cis	rs9828933	0.752	rs13434089	ENSG00000280620.1	SCAANT1	-6.23	1.03e-09	4.79e-07	-0.43	-0.27	Type 2 diabetes;	chr3:63962890	chr3:63911518~63911772:-
LUAD	cis	rs9928842	0.722	rs1035540	ENSG00000280152.1	RP11-331F4.5	6.23	1.03e-09	4.79e-07	0.3	0.27	Alcoholic chronic pancreatitis;	chr16:75244897	chr16:75245994~75250077:-
LUAD	cis	rs17301013	0.556	rs10912774	ENSG00000227373.4	RP11-160H22.5	6.23	1.04e-09	4.79e-07	0.38	0.27	Systemic lupus erythematosus;	chr1:174387706	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs16846938	ENSG00000227373.4	RP11-160H22.5	6.23	1.04e-09	4.79e-07	0.38	0.27	Systemic lupus erythematosus;	chr1:174400537	chr1:174115300~174160004:-
LUAD	cis	rs11079757	0.681	rs34811916	ENSG00000262879.4	RP11-156P1.3	6.23	1.04e-09	4.79e-07	0.37	0.27	Erythema nodosum in inflammatory bowel disease;	chr17:47111431	chr17:46984045~47100323:-
LUAD	cis	rs150992	0.609	rs451141	ENSG00000248489.1	CTD-2007H13.3	-6.23	1.04e-09	4.8e-07	-0.31	-0.27	Body mass index;	chr5:98991691	chr5:98929171~98995013:+
LUAD	cis	rs9595908	0.544	rs7328213	ENSG00000212293.1	SNORA16	6.23	1.04e-09	4.8e-07	0.3	0.27	Body mass index;	chr13:32803692	chr13:32420390~32420516:-
LUAD	cis	rs17684571	0.872	rs34587484	ENSG00000231441.1	RP11-472M19.2	6.23	1.04e-09	4.8e-07	0.4	0.27	Schizophrenia;	chr6:56742926	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.872	rs34465210	ENSG00000231441.1	RP11-472M19.2	6.23	1.04e-09	4.8e-07	0.4	0.27	Schizophrenia;	chr6:56742930	chr6:56844002~56864078:+
LUAD	cis	rs1707322	0.686	rs2050376	ENSG00000234329.1	RP11-767N6.2	6.23	1.04e-09	4.81e-07	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45612958	chr1:45651039~45651826:-
LUAD	cis	rs7829975	0.564	rs2921060	ENSG00000253893.2	FAM85B	6.23	1.04e-09	4.81e-07	0.35	0.27	Mood instability;	chr8:8460307	chr8:8167819~8226614:-
LUAD	cis	rs7927592	0.956	rs10896343	ENSG00000212093.1	AP000807.1	6.23	1.04e-09	4.81e-07	0.3	0.27	Total body bone mineral density;	chr11:68550392	chr11:68506083~68506166:-
LUAD	cis	rs6991838	0.8	rs28547533	ENSG00000200714.1	Y_RNA	6.23	1.04e-09	4.82e-07	0.32	0.27	Intelligence (multi-trait analysis);	chr8:65559318	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.8	rs28626262	ENSG00000200714.1	Y_RNA	6.23	1.04e-09	4.82e-07	0.32	0.27	Intelligence (multi-trait analysis);	chr8:65559335	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.8	rs28709439	ENSG00000200714.1	Y_RNA	6.23	1.04e-09	4.82e-07	0.32	0.27	Intelligence (multi-trait analysis);	chr8:65559337	chr8:65592731~65592820:+
LUAD	cis	rs755249	0.567	rs72637906	ENSG00000228060.1	RP11-69E11.8	-6.23	1.04e-09	4.82e-07	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39242630	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs67886352	ENSG00000228060.1	RP11-69E11.8	-6.23	1.04e-09	4.82e-07	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39243031	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs60323161	ENSG00000228060.1	RP11-69E11.8	-6.23	1.04e-09	4.82e-07	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39244787	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs66727439	ENSG00000228060.1	RP11-69E11.8	-6.23	1.04e-09	4.82e-07	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39246258	chr1:39565160~39573203:+
LUAD	cis	rs2734839	0.929	rs7131627	ENSG00000270179.1	RP11-159N11.4	-6.23	1.04e-09	4.82e-07	-0.28	-0.27	Information processing speed;	chr11:113429107	chr11:113368478~113369117:+
LUAD	cis	rs10129255	0.957	rs12590799	ENSG00000211974.3	IGHV2-70	6.23	1.04e-09	4.82e-07	0.28	0.27	Kawasaki disease;	chr14:106779713	chr14:106723574~106724093:-
LUAD	cis	rs1075265	0.749	rs805430	ENSG00000233266.1	HMGB1P31	6.23	1.04e-09	4.82e-07	0.35	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53848279	chr2:54051334~54051760:+
LUAD	cis	rs2739330	0.828	rs5760099	ENSG00000206090.4	AP000350.7	6.23	1.04e-09	4.83e-07	0.32	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23939998~23942798:+
LUAD	cis	rs496547	0.557	rs516719	ENSG00000255422.1	AP002954.4	-6.23	1.04e-09	4.83e-07	-0.35	-0.27	Hip minimal joint space width;	chr11:118808736	chr11:118704607~118750263:+
LUAD	cis	rs56163509	1	rs56163509	ENSG00000251417.2	RP11-1348G14.4	-6.23	1.04e-09	4.83e-07	-0.29	-0.27	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28802743~28817828:+
LUAD	cis	rs8062405	0.964	rs7187333	ENSG00000251417.2	RP11-1348G14.4	-6.23	1.04e-09	4.83e-07	-0.29	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs62037369	ENSG00000251417.2	RP11-1348G14.4	-6.23	1.04e-09	4.83e-07	-0.29	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28802743~28817828:+
LUAD	cis	rs8062405	0.965	rs7359397	ENSG00000251417.2	RP11-1348G14.4	-6.23	1.04e-09	4.83e-07	-0.29	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28802743~28817828:+
LUAD	cis	rs7208859	0.623	rs8082537	ENSG00000263531.1	RP13-753N3.1	6.23	1.05e-09	4.83e-07	0.49	0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30688914	chr17:30863921~30864940:-
LUAD	cis	rs2243480	0.708	rs35825036	ENSG00000232546.1	RP11-458F8.1	-6.23	1.05e-09	4.83e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66521515	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs13237037	ENSG00000232546.1	RP11-458F8.1	-6.23	1.05e-09	4.83e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66532895	chr7:66848496~66858136:+
LUAD	cis	rs2243480	0.901	rs13237344	ENSG00000232546.1	RP11-458F8.1	-6.23	1.05e-09	4.83e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66557269	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs1796228	ENSG00000232546.1	RP11-458F8.1	-6.23	1.05e-09	4.83e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66568097	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs1267820	ENSG00000232546.1	RP11-458F8.1	-6.23	1.05e-09	4.83e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66585308	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs2533288	ENSG00000232546.1	RP11-458F8.1	-6.23	1.05e-09	4.83e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66591724	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs2707844	ENSG00000232546.1	RP11-458F8.1	-6.23	1.05e-09	4.83e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66594522	chr7:66848496~66858136:+
LUAD	cis	rs12554020	1	rs7048853	ENSG00000227603.1	RP11-165J3.6	6.23	1.05e-09	4.83e-07	0.41	0.27	Schizophrenia;	chr9:93490896	chr9:93435332~93437121:-
LUAD	cis	rs6844153	1	rs74356465	ENSG00000240005.4	RP11-293A21.1	-6.23	1.05e-09	4.84e-07	-0.44	-0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26902405	chr4:26859806~26860599:-
LUAD	cis	rs853679	1	rs853694	ENSG00000204709.4	LINC01556	6.23	1.05e-09	4.84e-07	0.43	0.27	Depression;	chr6:28311323	chr6:28943877~28944537:+
LUAD	cis	rs8072100	0.967	rs12452315	ENSG00000228782.6	CTD-2026D20.3	-6.23	1.05e-09	4.84e-07	-0.29	-0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402080	chr17:47450568~47492492:-
LUAD	cis	rs494459	0.838	rs581045	ENSG00000278376.1	RP11-158I9.8	-6.23	1.05e-09	4.84e-07	-0.29	-0.27	Height;	chr11:118761813	chr11:118791254~118793137:+
LUAD	cis	rs10214930	0.671	rs6957674	ENSG00000235574.1	AC073150.6	-6.23	1.05e-09	4.85e-07	-0.35	-0.27	Hypospadias;	chr7:27518691	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs2091171	ENSG00000235574.1	AC073150.6	-6.23	1.05e-09	4.85e-07	-0.35	-0.27	Hypospadias;	chr7:27519599	chr7:27491682~27492765:-
LUAD	cis	rs875971	0.862	rs778724	ENSG00000222364.1	RNU6-96P	-6.23	1.05e-09	4.85e-07	-0.31	-0.27	Aortic root size;	chr7:66364304	chr7:66395191~66395286:+
LUAD	cis	rs1799949	0.929	rs799906	ENSG00000267681.1	CTD-3199J23.6	-6.22	1.05e-09	4.86e-07	-0.31	-0.27	Menopause (age at onset);	chr17:43126099	chr17:43144956~43145255:+
LUAD	cis	rs1799949	0.965	rs799908	ENSG00000267681.1	CTD-3199J23.6	-6.22	1.05e-09	4.86e-07	-0.31	-0.27	Menopause (age at onset);	chr17:43126899	chr17:43144956~43145255:+
LUAD	cis	rs1707322	0.686	rs11211179	ENSG00000234329.1	RP11-767N6.2	6.22	1.05e-09	4.86e-07	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762410	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs10157795	ENSG00000234329.1	RP11-767N6.2	6.22	1.05e-09	4.86e-07	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762520	chr1:45651039~45651826:-
LUAD	cis	rs7176527	0.848	rs3748374	ENSG00000188388.10	GOLGA6L3	6.22	1.05e-09	4.86e-07	0.39	0.27	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84641012	chr15:85240472~85247170:+
LUAD	cis	rs1061377	0.862	rs12508577	ENSG00000249685.1	RP11-360F5.3	6.22	1.05e-09	4.87e-07	0.33	0.27	Uric acid levels;	chr4:39107779	chr4:39133913~39135608:+
LUAD	cis	rs2408955	0.561	rs9971924	ENSG00000240399.1	RP1-228P16.1	-6.22	1.05e-09	4.87e-07	-0.27	-0.27	Glycated hemoglobin levels;	chr12:48086049	chr12:48054813~48055591:-
LUAD	cis	rs66887589	0.592	rs28580295	ENSG00000245958.5	RP11-33B1.1	-6.22	1.06e-09	4.88e-07	-0.22	-0.27	Diastolic blood pressure;	chr4:119357718	chr4:119454791~119552025:+
LUAD	cis	rs12468226	1	rs16839077	ENSG00000226261.1	AC064836.3	6.22	1.06e-09	4.88e-07	0.46	0.27	Urate levels;	chr2:202343970	chr2:202336024~202336727:-
LUAD	cis	rs2243480	0.901	rs778687	ENSG00000232546.1	RP11-458F8.1	-6.22	1.06e-09	4.88e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66370832	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs778704	ENSG00000232546.1	RP11-458F8.1	-6.22	1.06e-09	4.88e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66398480	chr7:66848496~66858136:+
LUAD	cis	rs2243480	0.901	rs778693	ENSG00000232546.1	RP11-458F8.1	-6.22	1.06e-09	4.88e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66407358	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs778691	ENSG00000232546.1	RP11-458F8.1	-6.22	1.06e-09	4.88e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66408105	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs13235972	ENSG00000232546.1	RP11-458F8.1	-6.22	1.06e-09	4.88e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66418618	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs34192067	ENSG00000232546.1	RP11-458F8.1	-6.22	1.06e-09	4.88e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66422670	chr7:66848496~66858136:+
LUAD	cis	rs6860806	0.507	rs270601	ENSG00000233006.5	AC034220.3	6.22	1.06e-09	4.89e-07	0.27	0.27	Breast cancer;	chr5:132321304	chr5:132311285~132369916:-
LUAD	cis	rs17301013	0.507	rs7521109	ENSG00000227373.4	RP11-160H22.5	6.22	1.06e-09	4.89e-07	0.42	0.27	Systemic lupus erythematosus;	chr1:174802629	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12091076	ENSG00000227373.4	RP11-160H22.5	6.22	1.06e-09	4.89e-07	0.42	0.27	Systemic lupus erythematosus;	chr1:174321545	chr1:174115300~174160004:-
LUAD	cis	rs728616	0.614	rs11200859	ENSG00000225484.5	NUTM2B-AS1	-6.22	1.06e-09	4.89e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79953805	chr10:79663088~79826594:-
LUAD	cis	rs17301013	0.507	rs2183202	ENSG00000227373.4	RP11-160H22.5	6.22	1.06e-09	4.89e-07	0.42	0.27	Systemic lupus erythematosus;	chr1:174824553	chr1:174115300~174160004:-
LUAD	cis	rs10129255	1	rs10134517	ENSG00000280411.1	IGHV1-69-2	-6.22	1.06e-09	4.89e-07	-0.2	-0.27	Kawasaki disease;	chr14:106718498	chr14:106762092~106762588:-
LUAD	cis	rs4835473	0.932	rs10016223	ENSG00000251600.4	RP11-673E1.1	6.22	1.06e-09	4.9e-07	0.34	0.27	Immature fraction of reticulocytes;	chr4:143777429	chr4:143912331~143982454:+
LUAD	cis	rs4713118	0.621	rs4713132	ENSG00000204709.4	LINC01556	6.22	1.06e-09	4.9e-07	0.37	0.27	Parkinson's disease;	chr6:28066257	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.621	rs4713133	ENSG00000204709.4	LINC01556	6.22	1.06e-09	4.9e-07	0.37	0.27	Parkinson's disease;	chr6:28066263	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.621	rs4713134	ENSG00000204709.4	LINC01556	6.22	1.06e-09	4.9e-07	0.37	0.27	Parkinson's disease;	chr6:28066343	chr6:28943877~28944537:+
LUAD	cis	rs7937890	0.904	rs7484197	ENSG00000254418.1	RP11-21L19.1	6.22	1.06e-09	4.91e-07	0.32	0.27	Mitochondrial DNA levels;	chr11:14262108	chr11:14262846~14273691:-
LUAD	cis	rs77204473	1	rs12275565	ENSG00000254851.1	RP11-109L13.1	6.22	1.07e-09	4.92e-07	0.66	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116882836	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs12416987	ENSG00000254851.1	RP11-109L13.1	6.22	1.07e-09	4.92e-07	0.66	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116883549	chr11:117135528~117138582:+
LUAD	cis	rs5753618	0.539	rs4820962	ENSG00000236132.1	CTA-440B3.1	6.22	1.07e-09	4.92e-07	0.34	0.27	Colorectal cancer;	chr22:31293965	chr22:31816379~31817491:-
LUAD	cis	rs1318937	0.764	rs9853971	ENSG00000224660.1	SH3BP5-AS1	6.22	1.07e-09	4.92e-07	0.22	0.27	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15183840	chr3:15254184~15264493:+
LUAD	cis	rs12468226	1	rs113877751	ENSG00000226261.1	AC064836.3	6.22	1.07e-09	4.92e-07	0.46	0.27	Urate levels;	chr2:202329998	chr2:202336024~202336727:-
LUAD	cis	rs12468226	0.935	rs113021930	ENSG00000226261.1	AC064836.3	6.22	1.07e-09	4.92e-07	0.46	0.27	Urate levels;	chr2:202330448	chr2:202336024~202336727:-
LUAD	cis	rs12468226	1	rs113491584	ENSG00000226261.1	AC064836.3	6.22	1.07e-09	4.92e-07	0.46	0.27	Urate levels;	chr2:202331724	chr2:202336024~202336727:-
LUAD	cis	rs8062405	1	rs62036617	ENSG00000251417.2	RP11-1348G14.4	-6.22	1.07e-09	4.92e-07	-0.28	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28802743~28817828:+
LUAD	cis	rs2243480	1	rs73142162	ENSG00000232546.1	RP11-458F8.1	-6.22	1.07e-09	4.94e-07	-0.37	-0.27	Diabetic kidney disease;	chr7:65909309	chr7:66848496~66858136:+
LUAD	cis	rs4964805	0.802	rs11111778	ENSG00000257681.1	RP11-341G23.4	6.22	1.07e-09	4.94e-07	0.33	0.27	Attention deficit hyperactivity disorder;	chr12:103791653	chr12:103746315~103768858:-
LUAD	cis	rs1823913	0.637	rs4853465	ENSG00000280083.1	RP11-317J9.1	6.22	1.07e-09	4.95e-07	0.32	0.27	Obesity-related traits;	chr2:191294768	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.637	rs4853573	ENSG00000280083.1	RP11-317J9.1	6.22	1.07e-09	4.95e-07	0.32	0.27	Obesity-related traits;	chr2:191295866	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.614	rs4853466	ENSG00000280083.1	RP11-317J9.1	6.22	1.07e-09	4.95e-07	0.32	0.27	Obesity-related traits;	chr2:191295943	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.637	rs4853574	ENSG00000280083.1	RP11-317J9.1	6.22	1.07e-09	4.95e-07	0.32	0.27	Obesity-related traits;	chr2:191296113	chr2:191154118~191156070:-
LUAD	cis	rs67311347	0.955	rs73078170	ENSG00000223797.4	ENTPD3-AS1	6.22	1.07e-09	4.95e-07	0.31	0.27	Renal cell carcinoma;	chr3:40442456	chr3:40313802~40453329:-
LUAD	cis	rs2243480	1	rs316313	ENSG00000232546.1	RP11-458F8.1	-6.22	1.07e-09	4.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66128561	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs316312	ENSG00000232546.1	RP11-458F8.1	-6.22	1.07e-09	4.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66131504	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs419603	ENSG00000232546.1	RP11-458F8.1	-6.22	1.07e-09	4.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66132354	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs387676	ENSG00000232546.1	RP11-458F8.1	-6.22	1.07e-09	4.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66133233	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs13310597	ENSG00000232546.1	RP11-458F8.1	-6.22	1.07e-09	4.96e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66133553	chr7:66848496~66858136:+
LUAD	cis	rs783540	0.934	rs36109438	ENSG00000278603.1	RP13-608F4.5	-6.22	1.08e-09	4.96e-07	-0.32	-0.27	Schizophrenia;	chr15:82595709	chr15:82472203~82472426:+
LUAD	cis	rs2439831	0.867	rs2447196	ENSG00000205771.5	CATSPER2P1	6.22	1.08e-09	4.96e-07	0.47	0.27	Lung cancer in ever smokers;	chr15:43601620	chr15:43726918~43747094:-
LUAD	cis	rs728616	0.614	rs59169164	ENSG00000225484.5	NUTM2B-AS1	-6.22	1.08e-09	4.97e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79952159	chr10:79663088~79826594:-
LUAD	cis	rs875971	1	rs6956179	ENSG00000222364.1	RNU6-96P	6.22	1.08e-09	4.97e-07	0.31	0.27	Aortic root size;	chr7:66341672	chr7:66395191~66395286:+
LUAD	cis	rs8072100	0.967	rs4580230	ENSG00000228782.6	CTD-2026D20.3	6.22	1.08e-09	4.98e-07	0.29	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47661495	chr17:47450568~47492492:-
LUAD	cis	rs7221109	0.645	rs9896791	ENSG00000278834.1	RP11-458J1.1	6.22	1.08e-09	4.98e-07	0.32	0.27	Type 1 diabetes;	chr17:40669305	chr17:40648300~40649718:+
LUAD	cis	rs7221109	0.633	rs7217237	ENSG00000278834.1	RP11-458J1.1	6.22	1.08e-09	4.98e-07	0.32	0.27	Type 1 diabetes;	chr17:40670810	chr17:40648300~40649718:+
LUAD	cis	rs4947019	0.534	rs13437492	ENSG00000260273.1	RP11-425D10.10	-6.22	1.08e-09	4.99e-07	-0.57	-0.27	Hematological parameters;	chr6:109365424	chr6:109382795~109383666:+
LUAD	cis	rs496547	0.588	rs473298	ENSG00000255422.1	AP002954.4	-6.22	1.08e-09	4.99e-07	-0.35	-0.27	Hip minimal joint space width;	chr11:118808678	chr11:118704607~118750263:+
LUAD	cis	rs8100891	0.537	rs7253039	ENSG00000267213.4	AC007773.2	-6.22	1.08e-09	4.99e-07	-0.43	-0.27	Neuroticism;	chr19:32482171	chr19:32390050~32405560:-
LUAD	cis	rs6860806	0.507	rs270608	ENSG00000233006.5	AC034220.3	6.22	1.08e-09	4.99e-07	0.27	0.27	Breast cancer;	chr5:132312713	chr5:132311285~132369916:-
LUAD	cis	rs7221109	0.614	rs8076587	ENSG00000278834.1	RP11-458J1.1	6.22	1.08e-09	4.99e-07	0.32	0.27	Type 1 diabetes;	chr17:40667949	chr17:40648300~40649718:+
LUAD	cis	rs77204473	1	rs12278117	ENSG00000254851.1	RP11-109L13.1	6.22	1.08e-09	4.99e-07	0.66	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116877453	chr11:117135528~117138582:+
LUAD	cis	rs9928842	1	rs7202566	ENSG00000280152.1	RP11-331F4.5	6.22	1.08e-09	4.99e-07	0.31	0.27	Alcoholic chronic pancreatitis;	chr16:75213746	chr16:75245994~75250077:-
LUAD	cis	rs7657257	1	rs12643722	ENSG00000214846.4	RP11-115L11.1	6.22	1.08e-09	5e-07	0.72	0.27	Blood protein levels;	chr4:15728480	chr4:15730962~15731627:-
LUAD	cis	rs7657257	1	rs12640554	ENSG00000214846.4	RP11-115L11.1	6.22	1.08e-09	5e-07	0.72	0.27	Blood protein levels;	chr4:15728484	chr4:15730962~15731627:-
LUAD	cis	rs2302464	1	rs111541714	ENSG00000214846.4	RP11-115L11.1	6.22	1.08e-09	5e-07	0.72	0.27	Cerebrospinal fluid biomarker levels;	chr4:15728782	chr4:15730962~15731627:-
LUAD	cis	rs2302464	1	rs73125993	ENSG00000214846.4	RP11-115L11.1	6.22	1.08e-09	5e-07	0.72	0.27	Cerebrospinal fluid biomarker levels;	chr4:15728890	chr4:15730962~15731627:-
LUAD	cis	rs6860806	0.507	rs272883	ENSG00000233006.5	AC034220.3	6.22	1.08e-09	5e-07	0.27	0.27	Breast cancer;	chr5:132333005	chr5:132311285~132369916:-
LUAD	cis	rs1799949	0.794	rs116409325	ENSG00000267681.1	CTD-3199J23.6	-6.22	1.09e-09	5.01e-07	-0.32	-0.27	Menopause (age at onset);	chr17:43368092	chr17:43144956~43145255:+
LUAD	cis	rs1823913	0.637	rs979967	ENSG00000280083.1	RP11-317J9.1	-6.22	1.09e-09	5.01e-07	-0.32	-0.27	Obesity-related traits;	chr2:191304695	chr2:191154118~191156070:-
LUAD	cis	rs858239	0.6	rs2072369	ENSG00000230042.1	AK3P3	-6.22	1.09e-09	5.03e-07	-0.34	-0.27	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23129178~23129841:+
LUAD	cis	rs66887589	0.616	rs6822808	ENSG00000245958.5	RP11-33B1.1	-6.22	1.09e-09	5.03e-07	-0.22	-0.27	Diastolic blood pressure;	chr4:119296210	chr4:119454791~119552025:+
LUAD	cis	rs6687821	0.637	rs548440	ENSG00000267734.1	RP4-604K5.3	6.22	1.09e-09	5.03e-07	0.36	0.27	Yeast infection;	chr1:86846948	chr1:86932199~86934891:-
LUAD	cis	rs728616	0.614	rs1885552	ENSG00000225484.5	NUTM2B-AS1	-6.22	1.09e-09	5.03e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79952336	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.614	rs1885551	ENSG00000225484.5	NUTM2B-AS1	-6.22	1.09e-09	5.03e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79952597	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.614	rs12253608	ENSG00000225484.5	NUTM2B-AS1	-6.22	1.09e-09	5.03e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79952727	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.764	rs1885549	ENSG00000225484.5	NUTM2B-AS1	-6.22	1.09e-09	5.03e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79952794	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.614	rs12245076	ENSG00000225484.5	NUTM2B-AS1	-6.22	1.09e-09	5.03e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79953675	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.614	rs10887229	ENSG00000225484.5	NUTM2B-AS1	-6.22	1.09e-09	5.03e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79954018	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.614	rs10788321	ENSG00000225484.5	NUTM2B-AS1	-6.22	1.09e-09	5.03e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79954039	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.614	rs61858839	ENSG00000225484.5	NUTM2B-AS1	-6.22	1.09e-09	5.03e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79954162	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.614	rs61858841	ENSG00000225484.5	NUTM2B-AS1	-6.22	1.09e-09	5.03e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79954420	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.614	rs61858842	ENSG00000225484.5	NUTM2B-AS1	-6.22	1.09e-09	5.03e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955283	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.614	rs10887233	ENSG00000225484.5	NUTM2B-AS1	-6.22	1.09e-09	5.03e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955596	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.614	rs10887234	ENSG00000225484.5	NUTM2B-AS1	-6.22	1.09e-09	5.03e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955666	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.614	rs10887235	ENSG00000225484.5	NUTM2B-AS1	-6.22	1.09e-09	5.03e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955890	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.614	rs2146192	ENSG00000225484.5	NUTM2B-AS1	-6.22	1.09e-09	5.03e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955982	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.614	rs2146191	ENSG00000225484.5	NUTM2B-AS1	-6.22	1.09e-09	5.03e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955998	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.614	rs10887243	ENSG00000225484.5	NUTM2B-AS1	-6.22	1.09e-09	5.03e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79957339	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.614	rs10887244	ENSG00000225484.5	NUTM2B-AS1	-6.22	1.09e-09	5.03e-07	-0.47	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79957352	chr10:79663088~79826594:-
LUAD	cis	rs67311347	1	rs9834052	ENSG00000223797.4	ENTPD3-AS1	6.22	1.09e-09	5.03e-07	0.28	0.27	Renal cell carcinoma;	chr3:40357569	chr3:40313802~40453329:-
LUAD	cis	rs1707322	0.65	rs4553239	ENSG00000234329.1	RP11-767N6.2	6.22	1.09e-09	5.03e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684814	chr1:45651039~45651826:-
LUAD	cis	rs9309473	0.95	rs11689588	ENSG00000163016.8	ALMS1P	6.22	1.1e-09	5.05e-07	0.34	0.27	Metabolite levels;	chr2:73546564	chr2:73644919~73685576:+
LUAD	cis	rs1823913	1	rs1823913	ENSG00000230611.1	HMGB1P27	-6.22	1.1e-09	5.05e-07	-0.32	-0.27	Obesity-related traits;	chr2:191253321	chr2:191174233~191174835:+
LUAD	cis	rs5753618	0.509	rs1034589	ENSG00000236132.1	CTA-440B3.1	6.22	1.1e-09	5.05e-07	0.34	0.27	Colorectal cancer;	chr22:31183247	chr22:31816379~31817491:-
LUAD	cis	rs2408955	0.521	rs10875749	ENSG00000240399.1	RP1-228P16.1	-6.22	1.1e-09	5.05e-07	-0.27	-0.27	Glycated hemoglobin levels;	chr12:48138134	chr12:48054813~48055591:-
LUAD	cis	rs2739330	0.796	rs1006771	ENSG00000228039.3	KB-1125A3.10	6.22	1.1e-09	5.06e-07	0.34	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23963780~23964374:+
LUAD	cis	rs875971	0.862	rs6460290	ENSG00000222364.1	RNU6-96P	6.22	1.1e-09	5.07e-07	0.31	0.27	Aortic root size;	chr7:66344119	chr7:66395191~66395286:+
LUAD	cis	rs1823913	0.503	rs35672076	ENSG00000227542.1	AC092614.2	6.22	1.1e-09	5.07e-07	0.34	0.27	Obesity-related traits;	chr2:191343907	chr2:191229165~191246172:-
LUAD	cis	rs112990264	0.568	rs3006239	ENSG00000236317.1	RP11-348H3.5	6.22	1.1e-09	5.08e-07	0.44	0.27	Itch intensity from mosquito bite;	chr1:212812498	chr1:212855175~212855366:-
LUAD	cis	rs155076	1	rs195570	ENSG00000233325.3	MIPEPP3	6.22	1.1e-09	5.08e-07	0.44	0.27	White matter hyperintensity burden;	chr13:21293441	chr13:21298139~21306373:+
LUAD	cis	rs9543976	1	rs7339146	ENSG00000261553.4	RP11-29G8.3	-6.22	1.1e-09	5.08e-07	-0.4	-0.27	Diabetic retinopathy;	chr13:75599583	chr13:75549773~75807120:+
LUAD	cis	rs881375	0.678	rs2416804	ENSG00000226752.6	PSMD5-AS1	6.22	1.11e-09	5.08e-07	0.28	0.27	Rheumatoid arthritis;	chr9:120914118	chr9:120824828~120854385:+
LUAD	cis	rs67311347	0.956	rs11714871	ENSG00000223797.4	ENTPD3-AS1	6.22	1.11e-09	5.09e-07	0.28	0.27	Renal cell carcinoma;	chr3:40387447	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs2305521	ENSG00000223797.4	ENTPD3-AS1	6.22	1.11e-09	5.09e-07	0.28	0.27	Renal cell carcinoma;	chr3:40387692	chr3:40313802~40453329:-
LUAD	cis	rs1707322	0.682	rs28490344	ENSG00000234329.1	RP11-767N6.2	6.22	1.11e-09	5.09e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45732276	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs28501477	ENSG00000234329.1	RP11-767N6.2	6.22	1.11e-09	5.09e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45733412	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs28641748	ENSG00000234329.1	RP11-767N6.2	6.22	1.11e-09	5.09e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747164	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs6697821	ENSG00000234329.1	RP11-767N6.2	6.22	1.11e-09	5.09e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751050	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs4330955	ENSG00000234329.1	RP11-767N6.2	6.22	1.11e-09	5.09e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751813	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.691	rs12031182	ENSG00000234329.1	RP11-767N6.2	6.22	1.11e-09	5.09e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755327	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs10430123	ENSG00000234329.1	RP11-767N6.2	6.22	1.11e-09	5.09e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755768	chr1:45651039~45651826:-
LUAD	cis	rs11690935	0.655	rs1028127	ENSG00000228389.1	AC068039.4	-6.22	1.11e-09	5.09e-07	-0.29	-0.27	Schizophrenia;	chr2:171673526	chr2:171773482~171775844:+
LUAD	cis	rs2243480	1	rs12698509	ENSG00000230295.1	RP11-458F8.2	-6.22	1.11e-09	5.1e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65953889	chr7:66880708~66882981:+
LUAD	cis	rs853679	0.517	rs36078605	ENSG00000204709.4	LINC01556	6.22	1.11e-09	5.1e-07	0.38	0.27	Depression;	chr6:28110254	chr6:28943877~28944537:+
LUAD	cis	rs1318937	0.764	rs2129947	ENSG00000224660.1	SH3BP5-AS1	6.22	1.11e-09	5.1e-07	0.22	0.27	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15180755	chr3:15254184~15264493:+
LUAD	cis	rs11089937	0.616	rs4145537	ENSG00000211639.2	IGLV4-60	-6.22	1.11e-09	5.1e-07	-0.3	-0.27	Periodontitis (PAL4Q3);	chr22:22182550	chr22:22162199~22162681:+
LUAD	cis	rs755249	1	rs4660303	ENSG00000228060.1	RP11-69E11.8	-6.22	1.11e-09	5.11e-07	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39594801	chr1:39565160~39573203:+
LUAD	cis	rs875971	0.862	rs28491091	ENSG00000237310.1	GS1-124K5.4	-6.22	1.11e-09	5.12e-07	-0.3	-0.27	Aortic root size;	chr7:66204077	chr7:66493706~66495474:+
LUAD	cis	rs948562	0.69	rs79894420	ENSG00000280010.1	AP001350.4	6.21	1.11e-09	5.12e-07	0.43	0.27	Lymphoma;	chr11:58349359	chr11:58627435~58628528:+
LUAD	cis	rs6504622	0.905	rs2317997	ENSG00000262879.4	RP11-156P1.3	6.21	1.11e-09	5.12e-07	0.32	0.27	Orofacial clefts;	chr17:46950282	chr17:46984045~47100323:-
LUAD	cis	rs9640161	0.83	rs36069544	ENSG00000261305.1	RP4-584D14.7	6.21	1.11e-09	5.12e-07	0.4	0.27	Blood protein levels;Circulating chemerin levels;	chr7:150364449	chr7:150341771~150342607:+
LUAD	cis	rs17301013	0.507	rs12067852	ENSG00000227373.4	RP11-160H22.5	-6.21	1.12e-09	5.13e-07	-0.42	-0.27	Systemic lupus erythematosus;	chr1:174302481	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs72717616	ENSG00000227373.4	RP11-160H22.5	6.21	1.12e-09	5.13e-07	0.42	0.27	Systemic lupus erythematosus;	chr1:174812711	chr1:174115300~174160004:-
LUAD	cis	rs7044106	0.762	rs10760110	ENSG00000238181.2	AHCYP2	6.21	1.12e-09	5.13e-07	0.35	0.27	Hip circumference adjusted for BMI;	chr9:120650285	chr9:120720673~120721972:+
LUAD	cis	rs67311347	1	rs9822909	ENSG00000223797.4	ENTPD3-AS1	6.21	1.12e-09	5.13e-07	0.31	0.27	Renal cell carcinoma;	chr3:40415593	chr3:40313802~40453329:-
LUAD	cis	rs9640161	0.83	rs17173702	ENSG00000261305.1	RP4-584D14.7	6.21	1.12e-09	5.14e-07	0.41	0.27	Blood protein levels;Circulating chemerin levels;	chr7:150371516	chr7:150341771~150342607:+
LUAD	cis	rs9640161	0.83	rs17173703	ENSG00000261305.1	RP4-584D14.7	6.21	1.12e-09	5.14e-07	0.41	0.27	Blood protein levels;Circulating chemerin levels;	chr7:150371531	chr7:150341771~150342607:+
LUAD	cis	rs12468226	0.938	rs116601501	ENSG00000226261.1	AC064836.3	6.21	1.12e-09	5.14e-07	0.46	0.27	Urate levels;	chr2:202274567	chr2:202336024~202336727:-
LUAD	cis	rs12468226	0.938	rs76658848	ENSG00000226261.1	AC064836.3	6.21	1.12e-09	5.14e-07	0.46	0.27	Urate levels;	chr2:202275548	chr2:202336024~202336727:-
LUAD	cis	rs12468226	0.938	rs57571703	ENSG00000226261.1	AC064836.3	6.21	1.12e-09	5.14e-07	0.46	0.27	Urate levels;	chr2:202281997	chr2:202336024~202336727:-
LUAD	cis	rs12468226	0.938	rs78928733	ENSG00000226261.1	AC064836.3	6.21	1.12e-09	5.14e-07	0.46	0.27	Urate levels;	chr2:202283787	chr2:202336024~202336727:-
LUAD	cis	rs2243480	0.803	rs13224048	ENSG00000232546.1	RP11-458F8.1	-6.21	1.12e-09	5.15e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66528779	chr7:66848496~66858136:+
LUAD	cis	rs7246657	0.943	rs28373708	ENSG00000276846.1	CTD-3220F14.3	6.21	1.12e-09	5.15e-07	0.38	0.27	Coronary artery calcification;	chr19:37485757	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.943	rs1382357	ENSG00000276846.1	CTD-3220F14.3	6.21	1.12e-09	5.15e-07	0.38	0.27	Coronary artery calcification;	chr19:37486707	chr19:37314868~37315620:-
LUAD	cis	rs2179367	0.959	rs579789	ENSG00000231760.4	RP11-350J20.5	6.21	1.12e-09	5.15e-07	0.34	0.27	Dupuytren's disease;	chr6:149358235	chr6:149796151~149826294:-
LUAD	cis	rs7246657	0.943	rs1559229	ENSG00000276846.1	CTD-3220F14.3	6.21	1.12e-09	5.15e-07	0.38	0.27	Coronary artery calcification;	chr19:37385295	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.882	rs6508719	ENSG00000276846.1	CTD-3220F14.3	6.21	1.12e-09	5.15e-07	0.38	0.27	Coronary artery calcification;	chr19:37386517	chr19:37314868~37315620:-
LUAD	cis	rs4141404	0.828	rs2413043	ENSG00000236132.1	CTA-440B3.1	6.21	1.12e-09	5.15e-07	0.34	0.27	Paclitaxel-induced neuropathy;	chr22:31252590	chr22:31816379~31817491:-
LUAD	cis	rs4591358	0.689	rs72925794	ENSG00000223466.1	AC064834.2	-6.21	1.12e-09	5.15e-07	-0.36	-0.27	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195511813	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.773	rs72925795	ENSG00000223466.1	AC064834.2	-6.21	1.12e-09	5.15e-07	-0.36	-0.27	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195511814	chr2:195533035~195538681:+
LUAD	cis	rs2243480	1	rs316331	ENSG00000232546.1	RP11-458F8.1	6.21	1.12e-09	5.15e-07	0.36	0.27	Diabetic kidney disease;	chr7:66139635	chr7:66848496~66858136:+
LUAD	cis	rs2179367	0.959	rs237034	ENSG00000231760.4	RP11-350J20.5	6.21	1.12e-09	5.16e-07	0.35	0.27	Dupuytren's disease;	chr6:149390726	chr6:149796151~149826294:-
LUAD	cis	rs113835537	0.597	rs7939759	ENSG00000255517.5	CTD-3074O7.5	-6.21	1.12e-09	5.17e-07	-0.33	-0.27	Airway imaging phenotypes;	chr11:66570493	chr11:66473490~66480233:-
LUAD	cis	rs10740039	0.81	rs7098097	ENSG00000254271.1	RP11-131N11.4	6.21	1.13e-09	5.17e-07	0.31	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60605233	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.81	rs10740036	ENSG00000254271.1	RP11-131N11.4	6.21	1.13e-09	5.17e-07	0.31	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60606216	chr10:60734342~60741828:+
LUAD	cis	rs1015362	0.869	rs6088411	ENSG00000276073.1	RP5-1125A11.7	6.21	1.13e-09	5.17e-07	0.3	0.27	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:34152101	chr20:33985617~33988989:-
LUAD	cis	rs7017914	0.87	rs3098883	ENSG00000223220.1	Y_RNA	6.21	1.13e-09	5.17e-07	0.3	0.27	Bone mineral density;	chr8:71031332	chr8:70780914~70781008:-
LUAD	cis	rs67311347	0.955	rs9821036	ENSG00000223797.4	ENTPD3-AS1	6.21	1.13e-09	5.18e-07	0.29	0.27	Renal cell carcinoma;	chr3:40337516	chr3:40313802~40453329:-
LUAD	cis	rs67311347	0.911	rs6776044	ENSG00000223797.4	ENTPD3-AS1	6.21	1.13e-09	5.18e-07	0.29	0.27	Renal cell carcinoma;	chr3:40336012	chr3:40313802~40453329:-
LUAD	cis	rs7017914	0.905	rs3110255	ENSG00000223220.1	Y_RNA	6.21	1.13e-09	5.18e-07	0.3	0.27	Bone mineral density;	chr8:71025815	chr8:70780914~70781008:-
LUAD	cis	rs867371	0.929	rs1045508	ENSG00000255769.6	GOLGA2P10	6.21	1.13e-09	5.18e-07	0.29	0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82157565	chr15:82472993~82513950:-
LUAD	cis	rs17301013	0.507	rs10912822	ENSG00000227373.4	RP11-160H22.5	6.21	1.13e-09	5.18e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174624490	chr1:174115300~174160004:-
LUAD	cis	rs8062405	0.698	rs7188071	ENSG00000251417.2	RP11-1348G14.4	6.21	1.13e-09	5.19e-07	0.29	0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28906323	chr16:28802743~28817828:+
LUAD	cis	rs2243480	0.908	rs1532573	ENSG00000232546.1	RP11-458F8.1	6.21	1.13e-09	5.19e-07	0.36	0.27	Diabetic kidney disease;	chr7:66333815	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs422164	ENSG00000232546.1	RP11-458F8.1	-6.21	1.13e-09	5.19e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66121618	chr7:66848496~66858136:+
LUAD	cis	rs465969	1	rs463543	ENSG00000255389.1	C6orf3	-6.21	1.13e-09	5.19e-07	-0.6	-0.27	Psoriasis;	chr6:111346349	chr6:111599875~111602295:+
LUAD	cis	rs465969	1	rs459048	ENSG00000255389.1	C6orf3	-6.21	1.13e-09	5.19e-07	-0.6	-0.27	Psoriasis;	chr6:111368429	chr6:111599875~111602295:+
LUAD	cis	rs465969	1	rs479343	ENSG00000255389.1	C6orf3	-6.21	1.13e-09	5.19e-07	-0.6	-0.27	Psoriasis;	chr6:111369701	chr6:111599875~111602295:+
LUAD	cis	rs465969	0.744	rs458017	ENSG00000255389.1	C6orf3	-6.21	1.13e-09	5.19e-07	-0.6	-0.27	Psoriasis;	chr6:111374888	chr6:111599875~111602295:+
LUAD	cis	rs6772849	0.896	rs9816260	ENSG00000242551.2	POU5F1P6	-6.21	1.13e-09	5.19e-07	-0.32	-0.27	Monocyte percentage of white cells;Monocyte count;	chr3:128633240	chr3:128674735~128677005:-
LUAD	cis	rs3738443	0.678	rs6680707	ENSG00000259865.1	RP11-488L18.10	6.21	1.13e-09	5.2e-07	0.24	0.27	Alcohol dependence;	chr1:247213648	chr1:247187281~247188526:-
LUAD	cis	rs113835537	0.529	rs11227511	ENSG00000255517.5	CTD-3074O7.5	-6.21	1.14e-09	5.21e-07	-0.32	-0.27	Airway imaging phenotypes;	chr11:66513773	chr11:66473490~66480233:-
LUAD	cis	rs1707322	0.691	rs11211174	ENSG00000234329.1	RP11-767N6.2	6.21	1.14e-09	5.21e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755144	chr1:45651039~45651826:-
LUAD	cis	rs8062405	1	rs1987472	ENSG00000251417.2	RP11-1348G14.4	-6.21	1.14e-09	5.21e-07	-0.28	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28802743~28817828:+
LUAD	cis	rs8062405	0.895	rs56186137	ENSG00000251417.2	RP11-1348G14.4	-6.21	1.14e-09	5.21e-07	-0.28	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28802743~28817828:+
LUAD	cis	rs801193	0.569	rs7782587	ENSG00000222364.1	RNU6-96P	-6.21	1.14e-09	5.22e-07	-0.31	-0.27	Aortic root size;	chr7:66701485	chr7:66395191~66395286:+
LUAD	cis	rs801193	0.569	rs4717315	ENSG00000222364.1	RNU6-96P	-6.21	1.14e-09	5.22e-07	-0.31	-0.27	Aortic root size;	chr7:66713338	chr7:66395191~66395286:+
LUAD	cis	rs801193	0.527	rs2707837	ENSG00000222364.1	RNU6-96P	-6.21	1.14e-09	5.22e-07	-0.31	-0.27	Aortic root size;	chr7:66716086	chr7:66395191~66395286:+
LUAD	cis	rs2243480	1	rs67728539	ENSG00000232546.1	RP11-458F8.1	-6.21	1.14e-09	5.22e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:65913137	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs4718333	ENSG00000232546.1	RP11-458F8.1	6.21	1.14e-09	5.22e-07	0.36	0.27	Diabetic kidney disease;	chr7:66307771	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs7792391	ENSG00000232546.1	RP11-458F8.1	6.21	1.14e-09	5.22e-07	0.36	0.27	Diabetic kidney disease;	chr7:66308442	chr7:66848496~66858136:+
LUAD	cis	rs1061377	1	rs10026775	ENSG00000249685.1	RP11-360F5.3	6.21	1.14e-09	5.23e-07	0.33	0.27	Uric acid levels;	chr4:39115155	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs3733276	ENSG00000249685.1	RP11-360F5.3	6.21	1.14e-09	5.23e-07	0.33	0.27	Uric acid levels;	chr4:39115291	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs3733277	ENSG00000249685.1	RP11-360F5.3	6.21	1.14e-09	5.23e-07	0.33	0.27	Uric acid levels;	chr4:39115483	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs3733278	ENSG00000249685.1	RP11-360F5.3	6.21	1.14e-09	5.23e-07	0.33	0.27	Uric acid levels;	chr4:39115615	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs3733279	ENSG00000249685.1	RP11-360F5.3	6.21	1.14e-09	5.23e-07	0.33	0.27	Uric acid levels;	chr4:39115625	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs10018049	ENSG00000249685.1	RP11-360F5.3	6.21	1.14e-09	5.23e-07	0.33	0.27	Uric acid levels;	chr4:39115781	chr4:39133913~39135608:+
LUAD	cis	rs8072100	1	rs11870935	ENSG00000228782.6	CTD-2026D20.3	-6.21	1.14e-09	5.23e-07	-0.29	-0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47655239	chr17:47450568~47492492:-
LUAD	cis	rs8100891	0.537	rs28729153	ENSG00000267213.4	AC007773.2	-6.21	1.14e-09	5.24e-07	-0.44	-0.27	Neuroticism;	chr19:32416672	chr19:32390050~32405560:-
LUAD	cis	rs9918079	1	rs9918079	ENSG00000273133.1	RP11-799M12.2	6.21	1.14e-09	5.24e-07	0.47	0.27	Obesity-related traits;	chr4:15543787	chr4:15563698~15564253:-
LUAD	cis	rs2739330	0.753	rs4822452	ENSG00000206090.4	AP000350.7	6.21	1.14e-09	5.24e-07	0.31	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23939998~23942798:+
LUAD	cis	rs5753618	0.561	rs4820963	ENSG00000236132.1	CTA-440B3.1	6.21	1.14e-09	5.25e-07	0.34	0.27	Colorectal cancer;	chr22:31302180	chr22:31816379~31817491:-
LUAD	cis	rs2243480	0.901	rs778730	ENSG00000232546.1	RP11-458F8.1	-6.21	1.14e-09	5.25e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66358338	chr7:66848496~66858136:+
LUAD	cis	rs4835473	0.932	rs2323200	ENSG00000251600.4	RP11-673E1.1	6.21	1.15e-09	5.26e-07	0.33	0.27	Immature fraction of reticulocytes;	chr4:143765448	chr4:143912331~143982454:+
LUAD	cis	rs1799949	0.93	rs1554063	ENSG00000267681.1	CTD-3199J23.6	-6.21	1.15e-09	5.26e-07	-0.31	-0.27	Menopause (age at onset);	chr17:43135128	chr17:43144956~43145255:+
LUAD	cis	rs2337406	0.587	rs10150642	ENSG00000211974.3	IGHV2-70	6.21	1.15e-09	5.26e-07	0.33	0.27	Alzheimer's disease (late onset);	chr14:106647269	chr14:106723574~106724093:-
LUAD	cis	rs755249	0.567	rs16825942	ENSG00000228060.1	RP11-69E11.8	-6.21	1.15e-09	5.26e-07	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39196946	chr1:39565160~39573203:+
LUAD	cis	rs10740039	0.883	rs10994446	ENSG00000254271.1	RP11-131N11.4	6.21	1.15e-09	5.27e-07	0.31	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60639433	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.804	rs7902456	ENSG00000254271.1	RP11-131N11.4	6.21	1.15e-09	5.27e-07	0.31	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60643937	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.96	rs10761536	ENSG00000254271.1	RP11-131N11.4	6.21	1.15e-09	5.27e-07	0.31	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60644657	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs10994455	ENSG00000254271.1	RP11-131N11.4	6.21	1.15e-09	5.27e-07	0.31	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60645589	chr10:60734342~60741828:+
LUAD	cis	rs853679	0.55	rs1237875	ENSG00000204709.4	LINC01556	-6.21	1.15e-09	5.27e-07	-0.37	-0.27	Depression;	chr6:28205232	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs7764722	ENSG00000204709.4	LINC01556	6.21	1.15e-09	5.28e-07	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28943877~28944537:+
LUAD	cis	rs2243480	0.901	rs73142137	ENSG00000232546.1	RP11-458F8.1	-6.21	1.15e-09	5.28e-07	-0.37	-0.27	Diabetic kidney disease;	chr7:65878455	chr7:66848496~66858136:+
LUAD	cis	rs1075265	0.568	rs805416	ENSG00000233266.1	HMGB1P31	-6.21	1.15e-09	5.28e-07	-0.33	-0.27	Chronotype;Morning vs. evening chronotype;	chr2:53898121	chr2:54051334~54051760:+
LUAD	cis	rs2243480	1	rs56016656	ENSG00000232546.1	RP11-458F8.1	-6.21	1.15e-09	5.29e-07	-0.37	-0.27	Diabetic kidney disease;	chr7:65918494	chr7:66848496~66858136:+
LUAD	cis	rs2243480	0.803	rs55700941	ENSG00000232546.1	RP11-458F8.1	-6.21	1.15e-09	5.29e-07	-0.37	-0.27	Diabetic kidney disease;	chr7:65924813	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs56291018	ENSG00000232546.1	RP11-458F8.1	-6.21	1.15e-09	5.29e-07	-0.37	-0.27	Diabetic kidney disease;	chr7:65925352	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs36033484	ENSG00000232546.1	RP11-458F8.1	-6.21	1.15e-09	5.29e-07	-0.37	-0.27	Diabetic kidney disease;	chr7:65925571	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs34193460	ENSG00000232546.1	RP11-458F8.1	-6.21	1.15e-09	5.29e-07	-0.37	-0.27	Diabetic kidney disease;	chr7:65928123	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs34560516	ENSG00000232546.1	RP11-458F8.1	-6.21	1.15e-09	5.29e-07	-0.37	-0.27	Diabetic kidney disease;	chr7:65939105	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs57057549	ENSG00000232546.1	RP11-458F8.1	-6.21	1.15e-09	5.29e-07	-0.37	-0.27	Diabetic kidney disease;	chr7:65940751	chr7:66848496~66858136:+
LUAD	cis	rs7945705	0.967	rs10769970	ENSG00000254860.4	TMEM9B-AS1	-6.21	1.16e-09	5.31e-07	-0.31	-0.27	Hemoglobin concentration;	chr11:8896390	chr11:8964675~8977527:+
LUAD	cis	rs7727544	0.735	rs270605	ENSG00000233006.5	AC034220.3	6.21	1.16e-09	5.31e-07	0.24	0.27	Blood metabolite levels;	chr5:132316118	chr5:132311285~132369916:-
LUAD	cis	rs2243480	1	rs10247526	ENSG00000232546.1	RP11-458F8.1	6.21	1.16e-09	5.32e-07	0.36	0.27	Diabetic kidney disease;	chr7:66315709	chr7:66848496~66858136:+
LUAD	cis	rs67311347	0.955	rs6764102	ENSG00000223797.4	ENTPD3-AS1	6.21	1.16e-09	5.32e-07	0.29	0.27	Renal cell carcinoma;	chr3:40336662	chr3:40313802~40453329:-
LUAD	cis	rs9828933	1	rs1060897	ENSG00000280620.1	SCAANT1	-6.21	1.16e-09	5.33e-07	-0.37	-0.27	Type 2 diabetes;	chr3:64012196	chr3:63911518~63911772:-
LUAD	cis	rs56114371	0.53	rs9348774	ENSG00000219392.1	RP1-265C24.5	-6.21	1.16e-09	5.33e-07	-0.39	-0.27	Breast cancer;	chr6:27721151	chr6:28115628~28116551:+
LUAD	cis	rs1823913	0.599	rs6732976	ENSG00000280083.1	RP11-317J9.1	6.21	1.16e-09	5.33e-07	0.32	0.27	Obesity-related traits;	chr2:191281004	chr2:191154118~191156070:-
LUAD	cis	rs720064	0.555	rs7244601	ENSG00000264745.1	TTC39C-AS1	6.21	1.16e-09	5.33e-07	0.29	0.27	Strep throat;	chr18:23929704	chr18:23994213~24015339:-
LUAD	cis	rs507080	0.501	rs516503	ENSG00000278376.1	RP11-158I9.8	-6.21	1.17e-09	5.34e-07	-0.29	-0.27	Serum metabolite levels;	chr11:118709639	chr11:118791254~118793137:+
LUAD	cis	rs4718428	0.705	rs13220977	ENSG00000273142.1	RP11-458F8.4	6.21	1.17e-09	5.35e-07	0.2	0.27	Corneal structure;	chr7:66872661	chr7:66902857~66906297:+
LUAD	cis	rs10740039	0.883	rs34168977	ENSG00000254271.1	RP11-131N11.4	6.21	1.17e-09	5.35e-07	0.31	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60632916	chr10:60734342~60741828:+
LUAD	cis	rs17301013	0.507	rs333438	ENSG00000227373.4	RP11-160H22.5	6.21	1.17e-09	5.36e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174672782	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs2771401	ENSG00000227373.4	RP11-160H22.5	6.21	1.17e-09	5.36e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174678302	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs464540	ENSG00000227373.4	RP11-160H22.5	6.21	1.17e-09	5.36e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174679250	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs467437	ENSG00000227373.4	RP11-160H22.5	6.21	1.17e-09	5.36e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174679861	chr1:174115300~174160004:-
LUAD	cis	rs2404602	0.647	rs11072612	ENSG00000259422.1	RP11-593F23.1	-6.21	1.17e-09	5.36e-07	-0.35	-0.27	Blood metabolite levels;	chr15:76668643	chr15:76174891~76181486:-
LUAD	cis	rs7829975	0.511	rs2980426	ENSG00000253893.2	FAM85B	-6.21	1.17e-09	5.36e-07	-0.36	-0.27	Mood instability;	chr8:8288087	chr8:8167819~8226614:-
LUAD	cis	rs8062405	0.789	rs1968752	ENSG00000259982.1	CDC37P1	6.21	1.17e-09	5.37e-07	0.33	0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620264	chr16:28700294~28701540:-
LUAD	cis	rs1113500	0.565	rs11185226	ENSG00000226822.1	RP11-356N1.2	6.21	1.17e-09	5.37e-07	0.37	0.27	Growth-regulated protein alpha levels;	chr1:108005429	chr1:108071482~108074519:+
LUAD	cis	rs875971	0.502	rs2465121	ENSG00000237310.1	GS1-124K5.4	-6.21	1.17e-09	5.38e-07	-0.35	-0.27	Aortic root size;	chr7:66156017	chr7:66493706~66495474:+
LUAD	cis	rs75422866	0.51	rs73105829	ENSG00000274902.1	RP1-197B17.4	6.21	1.18e-09	5.38e-07	0.59	0.27	Pneumonia;	chr12:47734162	chr12:47731908~47732351:+
LUAD	cis	rs4718428	0.705	rs68168107	ENSG00000232546.1	RP11-458F8.1	-6.21	1.18e-09	5.38e-07	-0.26	-0.27	Corneal structure;	chr7:66790251	chr7:66848496~66858136:+
LUAD	cis	rs35934224	0.891	rs34249993	ENSG00000232926.1	AC000078.5	6.21	1.18e-09	5.39e-07	0.33	0.27	Glaucoma (primary open-angle);	chr22:19884647	chr22:19887289~19887970:+
LUAD	cis	rs7246657	0.551	rs12978093	ENSG00000276846.1	CTD-3220F14.3	6.21	1.18e-09	5.39e-07	0.4	0.27	Coronary artery calcification;	chr19:37093514	chr19:37314868~37315620:-
LUAD	cis	rs2243480	1	rs937108	ENSG00000230295.1	RP11-458F8.2	-6.21	1.18e-09	5.4e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65963465	chr7:66880708~66882981:+
LUAD	cis	rs7927592	0.956	rs11228258	ENSG00000212093.1	AP000807.1	-6.2	1.18e-09	5.41e-07	-0.29	-0.27	Total body bone mineral density;	chr11:68486860	chr11:68506083~68506166:-
LUAD	cis	rs948562	0.744	rs60998298	ENSG00000280010.1	AP001350.4	6.2	1.18e-09	5.42e-07	0.46	0.27	Lymphoma;	chr11:58534382	chr11:58627435~58628528:+
LUAD	cis	rs2243480	1	rs316307	ENSG00000232546.1	RP11-458F8.1	-6.2	1.18e-09	5.42e-07	-0.37	-0.27	Diabetic kidney disease;	chr7:66105184	chr7:66848496~66858136:+
LUAD	cis	rs75920871	0.588	rs3181	ENSG00000254851.1	RP11-109L13.1	6.2	1.18e-09	5.42e-07	0.4	0.27	Subjective well-being;	chr11:117036327	chr11:117135528~117138582:+
LUAD	cis	rs1113500	0.799	rs1777459	ENSG00000226822.1	RP11-356N1.2	-6.2	1.19e-09	5.43e-07	-0.32	-0.27	Growth-regulated protein alpha levels;	chr1:108042377	chr1:108071482~108074519:+
LUAD	cis	rs11096990	0.793	rs9997050	ENSG00000249207.1	RP11-360F5.1	6.2	1.19e-09	5.43e-07	0.33	0.27	Cognitive function;	chr4:39301045	chr4:39112677~39126818:-
LUAD	cis	rs2276314	0.857	rs3737474	ENSG00000278986.1	RP11-723J4.3	-6.2	1.19e-09	5.44e-07	-0.33	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36033632	chr18:35972151~35973916:+
LUAD	cis	rs1823913	0.599	rs17412635	ENSG00000280083.1	RP11-317J9.1	6.2	1.19e-09	5.44e-07	0.33	0.27	Obesity-related traits;	chr2:191294834	chr2:191154118~191156070:-
LUAD	cis	rs2734839	0.537	rs1554929	ENSG00000270179.1	RP11-159N11.4	-6.2	1.19e-09	5.45e-07	-0.27	-0.27	Information processing speed;	chr11:113408042	chr11:113368478~113369117:+
LUAD	cis	rs853679	0.517	rs2281588	ENSG00000204709.4	LINC01556	6.2	1.19e-09	5.46e-07	0.38	0.27	Depression;	chr6:28104824	chr6:28943877~28944537:+
LUAD	cis	rs875971	1	rs1544549	ENSG00000222364.1	RNU6-96P	6.2	1.19e-09	5.46e-07	0.3	0.27	Aortic root size;	chr7:66625676	chr7:66395191~66395286:+
LUAD	cis	rs35160687	0.712	rs11674249	ENSG00000273080.1	RP11-301O19.1	-6.2	1.2e-09	5.47e-07	-0.3	-0.27	Night sleep phenotypes;	chr2:86270283	chr2:86195590~86196049:+
LUAD	cis	rs17301013	0.507	rs72715259	ENSG00000227373.4	RP11-160H22.5	6.2	1.2e-09	5.47e-07	0.43	0.27	Systemic lupus erythematosus;	chr1:174604590	chr1:174115300~174160004:-
LUAD	cis	rs9353324	1	rs9444356	ENSG00000203875.9	SNHG5	-6.2	1.2e-09	5.48e-07	-0.59	-0.27	Interferon gamma-induced protein 10 levels;	chr6:85651200	chr6:85660950~85678736:-
LUAD	cis	rs12468226	0.938	rs12463937	ENSG00000226261.1	AC064836.3	6.2	1.2e-09	5.48e-07	0.46	0.27	Urate levels;	chr2:202246543	chr2:202336024~202336727:-
LUAD	cis	rs1707322	0.721	rs4559551	ENSG00000234329.1	RP11-767N6.2	6.2	1.2e-09	5.49e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701861	chr1:45651039~45651826:-
LUAD	cis	rs8100891	0.537	rs737093	ENSG00000267213.4	AC007773.2	-6.2	1.2e-09	5.49e-07	-0.43	-0.27	Neuroticism;	chr19:32486500	chr19:32390050~32405560:-
LUAD	cis	rs10740039	0.734	rs10821815	ENSG00000254271.1	RP11-131N11.4	6.2	1.2e-09	5.5e-07	0.31	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60644843	chr10:60734342~60741828:+
LUAD	cis	rs9368481	0.729	rs9379950	ENSG00000241549.7	GUSBP2	-6.2	1.2e-09	5.5e-07	-0.31	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26993769	chr6:26871484~26956554:-
LUAD	cis	rs9368481	1	rs9368481	ENSG00000241549.7	GUSBP2	-6.2	1.2e-09	5.5e-07	-0.31	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26993982	chr6:26871484~26956554:-
LUAD	cis	rs9368481	0.554	rs2754603	ENSG00000241549.7	GUSBP2	-6.2	1.2e-09	5.5e-07	-0.31	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26997360	chr6:26871484~26956554:-
LUAD	cis	rs9368481	0.761	rs9357028	ENSG00000241549.7	GUSBP2	-6.2	1.2e-09	5.5e-07	-0.31	-0.27	Autism spectrum disorder or schizophrenia;	chr6:26999445	chr6:26871484~26956554:-
LUAD	cis	rs11676348	0.712	rs12694426	ENSG00000261338.2	RP11-378A13.1	-6.2	1.21e-09	5.51e-07	-0.28	-0.27	Ulcerative colitis;	chr2:218077628	chr2:218255319~218257366:+
LUAD	cis	rs10129255	0.957	rs8009638	ENSG00000211974.3	IGHV2-70	6.2	1.21e-09	5.51e-07	0.28	0.27	Kawasaki disease;	chr14:106777570	chr14:106723574~106724093:-
LUAD	cis	rs7017914	0.935	rs2732093	ENSG00000223220.1	Y_RNA	6.2	1.21e-09	5.51e-07	0.3	0.27	Bone mineral density;	chr8:71006844	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs2639899	ENSG00000223220.1	Y_RNA	6.2	1.21e-09	5.51e-07	0.3	0.27	Bone mineral density;	chr8:71007227	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.875	rs2639897	ENSG00000223220.1	Y_RNA	6.2	1.21e-09	5.51e-07	0.3	0.27	Bone mineral density;	chr8:71008441	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs2639896	ENSG00000223220.1	Y_RNA	6.2	1.21e-09	5.51e-07	0.3	0.27	Bone mineral density;	chr8:71008548	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.87	rs1353057	ENSG00000223220.1	Y_RNA	6.2	1.21e-09	5.51e-07	0.3	0.27	Bone mineral density;	chr8:71009862	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs2639960	ENSG00000223220.1	Y_RNA	6.2	1.21e-09	5.51e-07	0.3	0.27	Bone mineral density;	chr8:71009904	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs2639958	ENSG00000223220.1	Y_RNA	6.2	1.21e-09	5.51e-07	0.3	0.27	Bone mineral density;	chr8:71009915	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs1908036	ENSG00000223220.1	Y_RNA	6.2	1.21e-09	5.51e-07	0.3	0.27	Bone mineral density;	chr8:71010089	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs1908035	ENSG00000223220.1	Y_RNA	6.2	1.21e-09	5.51e-07	0.3	0.27	Bone mineral density;	chr8:71010173	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs1908034	ENSG00000223220.1	Y_RNA	6.2	1.21e-09	5.51e-07	0.3	0.27	Bone mineral density;	chr8:71010319	chr8:70780914~70781008:-
LUAD	cis	rs10740039	0.842	rs7080024	ENSG00000254271.1	RP11-131N11.4	-6.2	1.21e-09	5.54e-07	-0.31	-0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60632033	chr10:60734342~60741828:+
LUAD	cis	rs7246657	0.525	rs10410594	ENSG00000276846.1	CTD-3220F14.3	6.2	1.21e-09	5.54e-07	0.41	0.27	Coronary artery calcification;	chr19:36986856	chr19:37314868~37315620:-
LUAD	cis	rs17818399	0.926	rs7590693	ENSG00000279254.1	RP11-536C12.1	-6.2	1.21e-09	5.54e-07	-0.31	-0.27	Height;	chr2:46596853	chr2:46668870~46670778:+
LUAD	cis	rs7927592	0.956	rs10896337	ENSG00000212093.1	AP000807.1	6.2	1.21e-09	5.54e-07	0.3	0.27	Total body bone mineral density;	chr11:68516768	chr11:68506083~68506166:-
LUAD	cis	rs2745572	0.538	rs4587210	ENSG00000272279.1	RP11-157J24.2	6.2	1.21e-09	5.54e-07	0.33	0.27	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1542956	chr6:1528364~1528911:-
LUAD	cis	rs13217239	0.646	rs7768407	ENSG00000241549.7	GUSBP2	6.2	1.21e-09	5.54e-07	0.3	0.27	Schizophrenia;	chr6:27049016	chr6:26871484~26956554:-
LUAD	cis	rs2408955	0.521	rs10875753	ENSG00000240399.1	RP1-228P16.1	6.2	1.21e-09	5.55e-07	0.26	0.27	Glycated hemoglobin levels;	chr12:48163358	chr12:48054813~48055591:-
LUAD	cis	rs1914816	1	rs2456072	ENSG00000196274.5	Metazoa_SRP	6.2	1.21e-09	5.55e-07	0.31	0.27	Response to tocilizumab in rheumatoid arthritis;	chr15:76253503	chr15:76230048~76230390:-
LUAD	cis	rs7727544	0.66	rs272886	ENSG00000233006.5	AC034220.3	6.2	1.21e-09	5.55e-07	0.24	0.27	Blood metabolite levels;	chr5:132330147	chr5:132311285~132369916:-
LUAD	cis	rs10178409	1	rs10178409	ENSG00000163016.8	ALMS1P	6.2	1.22e-09	5.55e-07	0.35	0.27	Urinary metabolites;	chr2:73628380	chr2:73644919~73685576:+
LUAD	cis	rs2412819	0.571	rs6493090	ENSG00000205771.5	CATSPER2P1	6.2	1.22e-09	5.55e-07	0.42	0.27	Lung cancer;	chr15:43792084	chr15:43726918~43747094:-
LUAD	cis	rs11690935	0.589	rs62183782	ENSG00000228389.1	AC068039.4	-6.2	1.22e-09	5.57e-07	-0.29	-0.27	Schizophrenia;	chr2:172000102	chr2:171773482~171775844:+
LUAD	cis	rs948562	0.744	rs12363774	ENSG00000280010.1	AP001350.4	6.2	1.22e-09	5.57e-07	0.42	0.27	Lymphoma;	chr11:58457562	chr11:58627435~58628528:+
LUAD	cis	rs6903823	0.508	rs1150721	ENSG00000204709.4	LINC01556	6.2	1.22e-09	5.57e-07	0.33	0.27	Pulmonary function;	chr6:28287263	chr6:28943877~28944537:+
LUAD	cis	rs11971779	0.68	rs7801613	ENSG00000273391.1	RP11-634H22.1	-6.2	1.22e-09	5.58e-07	-0.28	-0.27	Diisocyanate-induced asthma;	chr7:139355181	chr7:139359032~139359566:-
LUAD	cis	rs9543976	1	rs3818355	ENSG00000261553.4	RP11-29G8.3	6.2	1.22e-09	5.58e-07	0.41	0.27	Diabetic retinopathy;	chr13:75622731	chr13:75549773~75807120:+
LUAD	cis	rs11098499	1	rs3749591	ENSG00000248280.1	RP11-33B1.2	6.2	1.22e-09	5.58e-07	0.34	0.27	Corneal astigmatism;	chr4:119292875	chr4:119440561~119450157:-
LUAD	cis	rs2243480	1	rs13247184	ENSG00000232546.1	RP11-458F8.1	-6.2	1.22e-09	5.59e-07	-0.37	-0.27	Diabetic kidney disease;	chr7:65893941	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs35283677	ENSG00000232546.1	RP11-458F8.1	-6.2	1.22e-09	5.59e-07	-0.37	-0.27	Diabetic kidney disease;	chr7:65894246	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs35421653	ENSG00000232546.1	RP11-458F8.1	-6.2	1.22e-09	5.59e-07	-0.37	-0.27	Diabetic kidney disease;	chr7:65898442	chr7:66848496~66858136:+
LUAD	cis	rs394563	0.967	rs420099	ENSG00000231760.4	RP11-350J20.5	6.2	1.22e-09	5.59e-07	0.34	0.27	Dupuytren's disease;	chr6:149473154	chr6:149796151~149826294:-
LUAD	cis	rs113835537	0.529	rs12099041	ENSG00000255517.5	CTD-3074O7.5	-6.2	1.23e-09	5.59e-07	-0.32	-0.27	Airway imaging phenotypes;	chr11:66465302	chr11:66473490~66480233:-
LUAD	cis	rs113835537	0.529	rs7928882	ENSG00000255517.5	CTD-3074O7.5	-6.2	1.23e-09	5.59e-07	-0.32	-0.27	Airway imaging phenotypes;	chr11:66467294	chr11:66473490~66480233:-
LUAD	cis	rs113835537	0.529	rs57691879	ENSG00000255517.5	CTD-3074O7.5	-6.2	1.23e-09	5.59e-07	-0.32	-0.27	Airway imaging phenotypes;	chr11:66469133	chr11:66473490~66480233:-
LUAD	cis	rs6840258	0.547	rs17012170	ENSG00000251411.1	RP11-397E7.4	-6.2	1.23e-09	5.59e-07	-0.38	-0.27	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86939692	chr4:86913266~86914817:-
LUAD	cis	rs17301013	0.507	rs72717618	ENSG00000227373.4	RP11-160H22.5	6.2	1.23e-09	5.59e-07	0.42	0.27	Systemic lupus erythematosus;	chr1:174816839	chr1:174115300~174160004:-
LUAD	cis	rs2179367	0.959	rs564961	ENSG00000231760.4	RP11-350J20.5	6.2	1.23e-09	5.6e-07	0.34	0.27	Dupuytren's disease;	chr6:149336091	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.959	rs504985	ENSG00000231760.4	RP11-350J20.5	6.2	1.23e-09	5.6e-07	0.34	0.27	Dupuytren's disease;	chr6:149337842	chr6:149796151~149826294:-
LUAD	cis	rs11690935	0.632	rs62184165	ENSG00000228389.1	AC068039.4	-6.2	1.23e-09	5.6e-07	-0.29	-0.27	Schizophrenia;	chr2:171701818	chr2:171773482~171775844:+
LUAD	cis	rs957448	1	rs28817653	ENSG00000253704.1	RP11-267M23.4	6.2	1.23e-09	5.6e-07	0.34	0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94557822	chr8:94553722~94569745:+
LUAD	cis	rs9595908	0.568	rs4942926	ENSG00000212293.1	SNORA16	6.2	1.23e-09	5.61e-07	0.29	0.27	Body mass index;	chr13:32807204	chr13:32420390~32420516:-
LUAD	cis	rs4927850	1	rs7630875	ENSG00000207650.1	MIR570	6.2	1.23e-09	5.63e-07	0.28	0.27	Pancreatic cancer;	chr3:196026895	chr3:195699401~195699497:+
LUAD	cis	rs67311347	1	rs951560	ENSG00000223797.4	ENTPD3-AS1	6.2	1.24e-09	5.63e-07	0.28	0.27	Renal cell carcinoma;	chr3:40421980	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs2887995	ENSG00000223797.4	ENTPD3-AS1	6.2	1.24e-09	5.64e-07	0.28	0.27	Renal cell carcinoma;	chr3:40367538	chr3:40313802~40453329:-
LUAD	cis	rs1707322	0.721	rs11211163	ENSG00000234329.1	RP11-767N6.2	6.2	1.24e-09	5.64e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45687876	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs12037803	ENSG00000234329.1	RP11-767N6.2	6.2	1.24e-09	5.64e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690820	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs10789470	ENSG00000234329.1	RP11-767N6.2	6.2	1.24e-09	5.64e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692659	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs61784796	ENSG00000234329.1	RP11-767N6.2	6.2	1.24e-09	5.64e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697584	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs10749856	ENSG00000234329.1	RP11-767N6.2	6.2	1.24e-09	5.64e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45699174	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs10890344	ENSG00000234329.1	RP11-767N6.2	6.2	1.24e-09	5.64e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45700418	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs4564187	ENSG00000234329.1	RP11-767N6.2	6.2	1.24e-09	5.64e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701189	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.752	rs28438704	ENSG00000234329.1	RP11-767N6.2	6.2	1.24e-09	5.64e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45704872	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs28442079	ENSG00000234329.1	RP11-767N6.2	6.2	1.24e-09	5.64e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706329	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs28817701	ENSG00000234329.1	RP11-767N6.2	6.2	1.24e-09	5.64e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720378	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.691	rs28495425	ENSG00000234329.1	RP11-767N6.2	6.2	1.24e-09	5.64e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45721648	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.685	rs28617418	ENSG00000234329.1	RP11-767N6.2	6.2	1.24e-09	5.64e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723854	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.691	rs61784803	ENSG00000234329.1	RP11-767N6.2	-6.2	1.24e-09	5.64e-07	-0.29	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45713599	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.663	rs3935296	ENSG00000234329.1	RP11-767N6.2	-6.2	1.24e-09	5.64e-07	-0.29	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45714798	chr1:45651039~45651826:-
LUAD	cis	rs1799949	1	rs35070007	ENSG00000267681.1	CTD-3199J23.6	6.2	1.24e-09	5.64e-07	0.31	0.27	Menopause (age at onset);	chr17:43164730	chr17:43144956~43145255:+
LUAD	cis	rs10129255	0.957	rs61997760	ENSG00000211972.2	IGHV3-66	6.2	1.24e-09	5.64e-07	0.24	0.27	Kawasaki disease;	chr14:106716993	chr14:106675017~106675544:-
LUAD	cis	rs2179367	0.6	rs58747890	ENSG00000231760.4	RP11-350J20.5	6.2	1.24e-09	5.64e-07	0.42	0.27	Dupuytren's disease;	chr6:149459369	chr6:149796151~149826294:-
LUAD	cis	rs74233809	1	rs11191560	ENSG00000213277.3	MARCKSL1P1	6.2	1.24e-09	5.64e-07	0.45	0.27	Birth weight;	chr10:103109281	chr10:103175554~103176094:+
LUAD	cis	rs2006771	0.765	rs6518752	ENSG00000236132.1	CTA-440B3.1	-6.2	1.24e-09	5.65e-07	-0.3	-0.27	Nonsyndromic cleft lip with cleft palate;	chr22:31603141	chr22:31816379~31817491:-
LUAD	cis	rs3096299	0.802	rs3102336	ENSG00000274627.1	RP11-104N10.2	6.2	1.24e-09	5.65e-07	0.26	0.27	Multiple myeloma (IgH translocation);	chr16:89375598	chr16:89516797~89522217:+
LUAD	cis	rs853679	0.546	rs35016036	ENSG00000204709.4	LINC01556	6.2	1.24e-09	5.65e-07	0.61	0.27	Depression;	chr6:28347103	chr6:28943877~28944537:+
LUAD	cis	rs948562	0.744	rs11229444	ENSG00000280010.1	AP001350.4	6.2	1.24e-09	5.65e-07	0.42	0.27	Lymphoma;	chr11:58430400	chr11:58627435~58628528:+
LUAD	cis	rs853679	0.517	rs4713135	ENSG00000204709.4	LINC01556	6.2	1.24e-09	5.65e-07	0.38	0.27	Depression;	chr6:28071808	chr6:28943877~28944537:+
LUAD	cis	rs2734839	0.896	rs11608109	ENSG00000270179.1	RP11-159N11.4	-6.2	1.24e-09	5.66e-07	-0.28	-0.27	Information processing speed;	chr11:113432726	chr11:113368478~113369117:+
LUAD	cis	rs1707322	0.691	rs61784799	ENSG00000234329.1	RP11-767N6.2	-6.2	1.24e-09	5.66e-07	-0.29	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712076	chr1:45651039~45651826:-
LUAD	cis	rs4908768	0.501	rs6577492	ENSG00000232912.4	RP5-1115A15.1	6.2	1.24e-09	5.67e-07	0.25	0.27	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8515005	chr1:8424645~8434838:+
LUAD	cis	rs7923609	0.841	rs7920036	ENSG00000232075.1	MRPL35P2	-6.2	1.24e-09	5.67e-07	-0.33	-0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63534100	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.967	rs7920058	ENSG00000232075.1	MRPL35P2	-6.2	1.24e-09	5.67e-07	-0.33	-0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63534164	chr10:63634317~63634827:-
LUAD	cis	rs9847710	0.733	rs7613013	ENSG00000242142.1	SERBP1P3	6.2	1.25e-09	5.68e-07	0.31	0.27	Ulcerative colitis;	chr3:53043790	chr3:53064283~53065091:-
LUAD	cis	rs8072100	0.875	rs4794047	ENSG00000228782.6	CTD-2026D20.3	-6.2	1.25e-09	5.68e-07	-0.29	-0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47685639	chr17:47450568~47492492:-
LUAD	cis	rs2243480	1	rs160633	ENSG00000232546.1	RP11-458F8.1	-6.2	1.25e-09	5.69e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66063241	chr7:66848496~66858136:+
LUAD	cis	rs6687821	0.681	rs526985	ENSG00000267734.1	RP4-604K5.3	6.2	1.25e-09	5.69e-07	0.36	0.27	Yeast infection;	chr1:86850735	chr1:86932199~86934891:-
LUAD	cis	rs293748	0.882	rs293774	ENSG00000250155.1	CTD-2353F22.1	-6.19	1.25e-09	5.71e-07	-0.38	-0.27	Obesity-related traits;	chr5:36943166	chr5:36666214~36725195:-
LUAD	cis	rs7849270	1	rs7021449	ENSG00000268707.1	RP11-247A12.7	-6.19	1.25e-09	5.71e-07	-0.31	-0.27	Blood metabolite ratios;	chr9:129137033	chr9:129170434~129170940:+
LUAD	cis	rs11096990	0.929	rs55976583	ENSG00000249207.1	RP11-360F5.1	6.19	1.25e-09	5.72e-07	0.31	0.27	Cognitive function;	chr4:39222871	chr4:39112677~39126818:-
LUAD	cis	rs35740288	0.77	rs11632750	ENSG00000202081.1	RNU6-1280P	6.19	1.26e-09	5.72e-07	0.34	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85672383	chr15:85651522~85651628:-
LUAD	cis	rs7017914	0.967	rs4628281	ENSG00000223220.1	Y_RNA	6.19	1.26e-09	5.73e-07	0.31	0.27	Bone mineral density;	chr8:70926929	chr8:70780914~70781008:-
LUAD	cis	rs2276314	0.802	rs9963714	ENSG00000278986.1	RP11-723J4.3	-6.19	1.26e-09	5.73e-07	-0.33	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36012093	chr18:35972151~35973916:+
LUAD	cis	rs2276314	0.802	rs4799838	ENSG00000278986.1	RP11-723J4.3	-6.19	1.26e-09	5.73e-07	-0.33	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36017567	chr18:35972151~35973916:+
LUAD	cis	rs2276314	0.748	rs4799839	ENSG00000278986.1	RP11-723J4.3	-6.19	1.26e-09	5.73e-07	-0.33	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36017568	chr18:35972151~35973916:+
LUAD	cis	rs2276314	0.857	rs28375959	ENSG00000278986.1	RP11-723J4.3	-6.19	1.26e-09	5.73e-07	-0.33	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36021571	chr18:35972151~35973916:+
LUAD	cis	rs5753618	0.509	rs2079431	ENSG00000236132.1	CTA-440B3.1	6.19	1.26e-09	5.73e-07	0.34	0.27	Colorectal cancer;	chr22:31168348	chr22:31816379~31817491:-
LUAD	cis	rs2034650	0.525	rs11790	ENSG00000223313.1	RNU6-516P	6.19	1.26e-09	5.74e-07	0.35	0.27	Interstitial lung disease;	chr15:40420538	chr15:40529570~40529673:+
LUAD	cis	rs9595908	0.869	rs7998956	ENSG00000212293.1	SNORA16	6.19	1.26e-09	5.74e-07	0.29	0.27	Body mass index;	chr13:32622239	chr13:32420390~32420516:-
LUAD	cis	rs7923609	0.841	rs10740131	ENSG00000232075.1	MRPL35P2	-6.19	1.26e-09	5.74e-07	-0.33	-0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63511728	chr10:63634317~63634827:-
LUAD	cis	rs9928842	0.882	rs9319481	ENSG00000280152.1	RP11-331F4.5	6.19	1.26e-09	5.74e-07	0.3	0.27	Alcoholic chronic pancreatitis;	chr16:75225580	chr16:75245994~75250077:-
LUAD	cis	rs9928842	0.882	rs1107593	ENSG00000280152.1	RP11-331F4.5	6.19	1.26e-09	5.74e-07	0.3	0.27	Alcoholic chronic pancreatitis;	chr16:75227431	chr16:75245994~75250077:-
LUAD	cis	rs720064	0.586	rs12956330	ENSG00000264745.1	TTC39C-AS1	6.19	1.26e-09	5.74e-07	0.29	0.27	Strep throat;	chr18:23981536	chr18:23994213~24015339:-
LUAD	cis	rs2745572	0.557	rs2816299	ENSG00000272279.1	RP11-157J24.2	-6.19	1.26e-09	5.74e-07	-0.34	-0.27	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1548451	chr6:1528364~1528911:-
LUAD	cis	rs7927592	0.956	rs12271290	ENSG00000212093.1	AP000807.1	-6.19	1.26e-09	5.74e-07	-0.3	-0.27	Total body bone mineral density;	chr11:68558768	chr11:68506083~68506166:-
LUAD	cis	rs67311347	1	rs2168111	ENSG00000223797.4	ENTPD3-AS1	6.19	1.26e-09	5.75e-07	0.28	0.27	Renal cell carcinoma;	chr3:40353834	chr3:40313802~40453329:-
LUAD	cis	rs1707322	0.686	rs2230658	ENSG00000234329.1	RP11-767N6.2	-6.19	1.26e-09	5.75e-07	-0.29	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613182	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.686	rs2230659	ENSG00000234329.1	RP11-767N6.2	-6.19	1.26e-09	5.75e-07	-0.29	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613212	chr1:45651039~45651826:-
LUAD	cis	rs67311347	1	rs9848083	ENSG00000223797.4	ENTPD3-AS1	-6.19	1.26e-09	5.75e-07	-0.28	-0.27	Renal cell carcinoma;	chr3:40425488	chr3:40313802~40453329:-
LUAD	cis	rs1823913	0.637	rs2883912	ENSG00000280083.1	RP11-317J9.1	6.19	1.27e-09	5.77e-07	0.32	0.27	Obesity-related traits;	chr2:191284290	chr2:191154118~191156070:-
LUAD	cis	rs9928842	0.824	rs12924999	ENSG00000280152.1	RP11-331F4.5	6.19	1.27e-09	5.77e-07	0.3	0.27	Alcoholic chronic pancreatitis;	chr16:75228527	chr16:75245994~75250077:-
LUAD	cis	rs2179367	0.919	rs577001	ENSG00000231760.4	RP11-350J20.5	6.19	1.27e-09	5.77e-07	0.34	0.27	Dupuytren's disease;	chr6:149325172	chr6:149796151~149826294:-
LUAD	cis	rs948562	0.744	rs11229438	ENSG00000280010.1	AP001350.4	6.19	1.27e-09	5.77e-07	0.42	0.27	Lymphoma;	chr11:58423730	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.744	rs11229449	ENSG00000280010.1	AP001350.4	6.19	1.27e-09	5.77e-07	0.42	0.27	Lymphoma;	chr11:58434155	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.744	rs111377246	ENSG00000280010.1	AP001350.4	6.19	1.27e-09	5.77e-07	0.42	0.27	Lymphoma;	chr11:58436505	chr11:58627435~58628528:+
LUAD	cis	rs11676348	0.772	rs11687200	ENSG00000261338.2	RP11-378A13.1	-6.19	1.27e-09	5.78e-07	-0.28	-0.27	Ulcerative colitis;	chr2:218079892	chr2:218255319~218257366:+
LUAD	cis	rs1075265	0.749	rs6738369	ENSG00000233266.1	HMGB1P31	6.19	1.27e-09	5.78e-07	0.34	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53756547	chr2:54051334~54051760:+
LUAD	cis	rs12220777	0.748	rs11201633	ENSG00000230091.5	TMEM254-AS1	6.19	1.27e-09	5.78e-07	0.48	0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80090068	chr10:80046860~80078912:-
LUAD	cis	rs10129255	0.957	rs10136781	ENSG00000211974.3	IGHV2-70	6.19	1.27e-09	5.79e-07	0.28	0.27	Kawasaki disease;	chr14:106780451	chr14:106723574~106724093:-
LUAD	cis	rs10129255	0.957	rs8022165	ENSG00000211974.3	IGHV2-70	6.19	1.27e-09	5.79e-07	0.28	0.27	Kawasaki disease;	chr14:106781682	chr14:106723574~106724093:-
LUAD	cis	rs10129255	0.917	rs8022493	ENSG00000211974.3	IGHV2-70	6.19	1.27e-09	5.79e-07	0.28	0.27	Kawasaki disease;	chr14:106781820	chr14:106723574~106724093:-
LUAD	cis	rs34375054	0.525	rs10846829	ENSG00000279233.1	RP11-158L12.4	6.19	1.27e-09	5.79e-07	0.23	0.27	Post bronchodilator FEV1/FVC ratio;	chr12:125110512	chr12:125138245~125141711:+
LUAD	cis	rs3762637	0.882	rs72958418	ENSG00000272758.4	RP11-299J3.8	-6.19	1.27e-09	5.8e-07	-0.41	-0.27	LDL cholesterol levels;	chr3:122441526	chr3:122416207~122443180:+
LUAD	cis	rs755249	0.761	rs3768321	ENSG00000228060.1	RP11-69E11.8	-6.19	1.27e-09	5.8e-07	-0.29	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39570256	chr1:39565160~39573203:+
LUAD	cis	rs11098499	0.863	rs3736115	ENSG00000248280.1	RP11-33B1.2	-6.19	1.28e-09	5.8e-07	-0.35	-0.27	Corneal astigmatism;	chr4:119567548	chr4:119440561~119450157:-
LUAD	cis	rs75920871	0.588	rs721783	ENSG00000254851.1	RP11-109L13.1	6.19	1.28e-09	5.8e-07	0.4	0.27	Subjective well-being;	chr11:117036733	chr11:117135528~117138582:+
LUAD	cis	rs17826219	0.568	rs59858012	ENSG00000263531.1	RP13-753N3.1	6.19	1.28e-09	5.81e-07	0.61	0.27	Body mass index;	chr17:30751564	chr17:30863921~30864940:-
LUAD	cis	rs10129255	0.785	rs10150044	ENSG00000211974.3	IGHV2-70	6.19	1.28e-09	5.82e-07	0.29	0.27	Kawasaki disease;	chr14:106775695	chr14:106723574~106724093:-
LUAD	cis	rs10129255	0.957	rs10137980	ENSG00000211974.3	IGHV2-70	6.19	1.28e-09	5.82e-07	0.29	0.27	Kawasaki disease;	chr14:106775735	chr14:106723574~106724093:-
LUAD	cis	rs7017914	0.905	rs4571761	ENSG00000223220.1	Y_RNA	-6.19	1.28e-09	5.82e-07	-0.31	-0.27	Bone mineral density;	chr8:71044938	chr8:70780914~70781008:-
LUAD	cis	rs7246657	0.943	rs4452075	ENSG00000276846.1	CTD-3220F14.3	6.19	1.28e-09	5.82e-07	0.38	0.27	Coronary artery calcification;	chr19:37388687	chr19:37314868~37315620:-
LUAD	cis	rs950169	0.58	rs17532346	ENSG00000259728.4	LINC00933	6.19	1.28e-09	5.83e-07	0.4	0.27	Schizophrenia;	chr15:84628264	chr15:84570649~84580175:+
LUAD	cis	rs853679	0.607	rs13205911	ENSG00000204709.4	LINC01556	6.19	1.28e-09	5.83e-07	0.6	0.27	Depression;	chr6:28156336	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs13197176	ENSG00000204709.4	LINC01556	6.19	1.28e-09	5.83e-07	0.6	0.27	Depression;	chr6:28161454	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs13201308	ENSG00000204709.4	LINC01556	6.19	1.28e-09	5.83e-07	0.6	0.27	Depression;	chr6:28162311	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs34765154	ENSG00000204709.4	LINC01556	6.19	1.28e-09	5.83e-07	0.6	0.27	Depression;	chr6:28162672	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs34505829	ENSG00000204709.4	LINC01556	6.19	1.28e-09	5.83e-07	0.6	0.27	Depression;	chr6:28165461	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs35098436	ENSG00000204709.4	LINC01556	6.19	1.28e-09	5.83e-07	0.6	0.27	Depression;	chr6:28166443	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs72846794	ENSG00000204709.4	LINC01556	6.19	1.28e-09	5.83e-07	0.6	0.27	Depression;	chr6:28169721	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs13217984	ENSG00000204709.4	LINC01556	6.19	1.28e-09	5.83e-07	0.6	0.27	Depression;	chr6:28171932	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.556	rs67297533	ENSG00000204709.4	LINC01556	6.19	1.28e-09	5.83e-07	0.6	0.27	Depression;	chr6:28173475	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.505	rs35781323	ENSG00000204709.4	LINC01556	6.19	1.28e-09	5.83e-07	0.6	0.27	Depression;	chr6:28177054	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.55	rs9295762	ENSG00000219392.1	RP1-265C24.5	6.19	1.28e-09	5.84e-07	0.36	0.27	Depression;	chr6:28187640	chr6:28115628~28116551:+
LUAD	cis	rs9879311	0.866	rs775017	ENSG00000240288.6	GHRLOS	6.19	1.28e-09	5.84e-07	0.26	0.27	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10357280	chr3:10285754~10293449:+
LUAD	cis	rs944289	0.562	rs2780310	ENSG00000257826.1	RP11-116N8.4	6.19	1.28e-09	5.84e-07	0.29	0.27	Thyroid cancer;	chr14:36050852	chr14:36061026~36067190:-
LUAD	cis	rs12468226	0.938	rs77062060	ENSG00000226261.1	AC064836.3	6.19	1.29e-09	5.84e-07	0.46	0.27	Urate levels;	chr2:202285639	chr2:202336024~202336727:-
LUAD	cis	rs755249	0.567	rs4660543	ENSG00000228060.1	RP11-69E11.8	-6.19	1.29e-09	5.84e-07	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39213318	chr1:39565160~39573203:+
LUAD	cis	rs238295	0.628	rs6133219	ENSG00000230563.2	RP5-828H9.1	6.19	1.29e-09	5.85e-07	0.36	0.27	Occipital cortical area (total cortical area interaction);	chr20:5514423	chr20:5471207~5475182:+
LUAD	cis	rs2765539	1	rs7525637	ENSG00000226172.2	RP4-712E4.1	-6.19	1.29e-09	5.86e-07	-0.34	-0.27	Waist-hip ratio;	chr1:119000848	chr1:119000344~119001392:-
LUAD	cis	rs2006771	0.74	rs8140312	ENSG00000236132.1	CTA-440B3.1	-6.19	1.29e-09	5.86e-07	-0.31	-0.27	Nonsyndromic cleft lip with cleft palate;	chr22:31609608	chr22:31816379~31817491:-
LUAD	cis	rs6921919	0.583	rs4642462	ENSG00000204709.4	LINC01556	6.19	1.29e-09	5.87e-07	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28943877~28944537:+
LUAD	cis	rs948562	0.69	rs11229425	ENSG00000280010.1	AP001350.4	-6.19	1.29e-09	5.87e-07	-0.42	-0.27	Lymphoma;	chr11:58411114	chr11:58627435~58628528:+
LUAD	cis	rs11098499	0.691	rs9996644	ENSG00000248280.1	RP11-33B1.2	6.19	1.29e-09	5.87e-07	0.34	0.27	Corneal astigmatism;	chr4:119317722	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.691	rs9996494	ENSG00000248280.1	RP11-33B1.2	6.19	1.29e-09	5.87e-07	0.34	0.27	Corneal astigmatism;	chr4:119317725	chr4:119440561~119450157:-
LUAD	cis	rs2179367	0.959	rs480034	ENSG00000231760.4	RP11-350J20.5	-6.19	1.29e-09	5.88e-07	-0.35	-0.27	Dupuytren's disease;	chr6:149414294	chr6:149796151~149826294:-
LUAD	cis	rs7017914	0.846	rs6472561	ENSG00000223220.1	Y_RNA	-6.19	1.29e-09	5.88e-07	-0.31	-0.27	Bone mineral density;	chr8:71042948	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs4074909	ENSG00000223220.1	Y_RNA	-6.19	1.29e-09	5.88e-07	-0.31	-0.27	Bone mineral density;	chr8:71043592	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs4078067	ENSG00000223220.1	Y_RNA	-6.19	1.29e-09	5.88e-07	-0.31	-0.27	Bone mineral density;	chr8:71044236	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs4504667	ENSG00000223220.1	Y_RNA	-6.19	1.29e-09	5.88e-07	-0.31	-0.27	Bone mineral density;	chr8:71044557	chr8:70780914~70781008:-
LUAD	cis	rs2179367	0.959	rs536203	ENSG00000231760.4	RP11-350J20.5	6.19	1.29e-09	5.88e-07	0.34	0.27	Dupuytren's disease;	chr6:149330128	chr6:149796151~149826294:-
LUAD	cis	rs11096990	0.892	rs2381349	ENSG00000249207.1	RP11-360F5.1	6.19	1.3e-09	5.89e-07	0.3	0.27	Cognitive function;	chr4:39210390	chr4:39112677~39126818:-
LUAD	cis	rs1799949	1	rs2298862	ENSG00000267681.1	CTD-3199J23.6	-6.19	1.3e-09	5.89e-07	-0.32	-0.27	Menopause (age at onset);	chr17:43024671	chr17:43144956~43145255:+
LUAD	cis	rs1799949	0.93	rs2298861	ENSG00000267681.1	CTD-3199J23.6	-6.19	1.3e-09	5.89e-07	-0.32	-0.27	Menopause (age at onset);	chr17:43024814	chr17:43144956~43145255:+
LUAD	cis	rs10050311	0.79	rs72667716	ENSG00000251411.1	RP11-397E7.4	-6.19	1.3e-09	5.89e-07	-0.37	-0.27	Insulin-related traits;	chr4:86912775	chr4:86913266~86914817:-
LUAD	cis	rs2739330	0.828	rs2154593	ENSG00000228039.3	KB-1125A3.10	6.19	1.3e-09	5.9e-07	0.33	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23963780~23964374:+
LUAD	cis	rs8072100	1	rs8065437	ENSG00000228782.6	CTD-2026D20.3	6.19	1.3e-09	5.9e-07	0.29	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47644287	chr17:47450568~47492492:-
LUAD	cis	rs6687821	0.681	rs481583	ENSG00000267734.1	RP4-604K5.3	6.19	1.3e-09	5.9e-07	0.35	0.27	Yeast infection;	chr1:86849596	chr1:86932199~86934891:-
LUAD	cis	rs113835537	0.529	rs3819247	ENSG00000255517.5	CTD-3074O7.5	-6.19	1.3e-09	5.91e-07	-0.33	-0.27	Airway imaging phenotypes;	chr11:66526308	chr11:66473490~66480233:-
LUAD	cis	rs66887589	0.616	rs11098498	ENSG00000245958.5	RP11-33B1.1	-6.19	1.3e-09	5.91e-07	-0.22	-0.27	Diastolic blood pressure;	chr4:119265964	chr4:119454791~119552025:+
LUAD	cis	rs875971	0.545	rs6950988	ENSG00000237310.1	GS1-124K5.4	6.19	1.3e-09	5.92e-07	0.33	0.27	Aortic root size;	chr7:66511428	chr7:66493706~66495474:+
LUAD	cis	rs293748	0.882	rs158802	ENSG00000250155.1	CTD-2353F22.1	-6.19	1.31e-09	5.93e-07	-0.38	-0.27	Obesity-related traits;	chr5:36941446	chr5:36666214~36725195:-
LUAD	cis	rs17301013	0.606	rs10912747	ENSG00000227373.4	RP11-160H22.5	-6.19	1.31e-09	5.93e-07	-0.37	-0.27	Systemic lupus erythematosus;	chr1:174224564	chr1:174115300~174160004:-
LUAD	cis	rs875971	0.545	rs316324	ENSG00000226824.5	RP4-756H11.3	6.19	1.31e-09	5.93e-07	0.39	0.27	Aortic root size;	chr7:66145627	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.545	rs316323	ENSG00000226824.5	RP4-756H11.3	6.19	1.31e-09	5.93e-07	0.39	0.27	Aortic root size;	chr7:66146002	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.545	rs316316	ENSG00000226824.5	RP4-756H11.3	6.19	1.31e-09	5.93e-07	0.39	0.27	Aortic root size;	chr7:66149270	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.545	rs316305	ENSG00000226824.5	RP4-756H11.3	6.19	1.31e-09	5.93e-07	0.39	0.27	Aortic root size;	chr7:66152984	chr7:66654538~66669855:+
LUAD	cis	rs10129255	0.957	rs10150241	ENSG00000211974.3	IGHV2-70	-6.19	1.31e-09	5.93e-07	-0.28	-0.27	Kawasaki disease;	chr14:106775945	chr14:106723574~106724093:-
LUAD	cis	rs11168854	0.656	rs7969967	ENSG00000258017.1	RP11-386G11.10	6.19	1.31e-09	5.93e-07	0.33	0.27	Body mass index;	chr12:49118234	chr12:49127782~49147869:+
LUAD	cis	rs10214930	1	rs17155876	ENSG00000235574.1	AC073150.6	6.19	1.31e-09	5.94e-07	0.38	0.27	Hypospadias;	chr7:27811436	chr7:27491682~27492765:-
LUAD	cis	rs4723738	0.967	rs12531618	ENSG00000227191.5	TRGC2	-6.19	1.31e-09	5.94e-07	-0.29	-0.27	Treatment response for severe sepsis;	chr7:38213263	chr7:38239580~38368091:-
LUAD	cis	rs881375	0.678	rs10118357	ENSG00000226752.6	PSMD5-AS1	-6.19	1.31e-09	5.95e-07	-0.28	-0.27	Rheumatoid arthritis;	chr9:120917790	chr9:120824828~120854385:+
LUAD	cis	rs77204473	1	rs74881320	ENSG00000254851.1	RP11-109L13.1	6.19	1.31e-09	5.95e-07	0.67	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116895209	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs17120131	ENSG00000254851.1	RP11-109L13.1	6.19	1.31e-09	5.95e-07	0.67	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116901770	chr11:117135528~117138582:+
LUAD	cis	rs35740288	0.77	rs11635190	ENSG00000202081.1	RNU6-1280P	6.19	1.31e-09	5.97e-07	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85605300	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.77	rs11631449	ENSG00000202081.1	RNU6-1280P	6.19	1.31e-09	5.97e-07	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85605422	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.77	rs1871285	ENSG00000202081.1	RNU6-1280P	6.19	1.31e-09	5.97e-07	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85609256	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.77	rs4843081	ENSG00000202081.1	RNU6-1280P	6.19	1.31e-09	5.97e-07	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85609813	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.77	rs4843082	ENSG00000202081.1	RNU6-1280P	6.19	1.31e-09	5.97e-07	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85610159	chr15:85651522~85651628:-
LUAD	cis	rs6772849	0.896	rs35535737	ENSG00000242551.2	POU5F1P6	-6.19	1.32e-09	5.98e-07	-0.32	-0.27	Monocyte percentage of white cells;Monocyte count;	chr3:128664563	chr3:128674735~128677005:-
LUAD	cis	rs11846409	0.799	rs10467899	ENSG00000254174.1	IGHV1-12	6.19	1.32e-09	5.98e-07	0.24	0.27	Rheumatic heart disease;	chr14:106644012	chr14:106122420~106122709:-
LUAD	cis	rs5753618	0.561	rs5753521	ENSG00000236132.1	CTA-440B3.1	6.19	1.32e-09	5.98e-07	0.34	0.27	Colorectal cancer;	chr22:31242041	chr22:31816379~31817491:-
LUAD	cis	rs7923609	0.811	rs10822181	ENSG00000232075.1	MRPL35P2	6.19	1.32e-09	5.98e-07	0.33	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63565366	chr10:63634317~63634827:-
LUAD	cis	rs853679	0.517	rs4713145	ENSG00000204709.4	LINC01556	6.19	1.32e-09	5.99e-07	0.38	0.27	Depression;	chr6:28139049	chr6:28943877~28944537:+
LUAD	cis	rs394563	0.967	rs444784	ENSG00000231760.4	RP11-350J20.5	6.19	1.32e-09	5.99e-07	0.34	0.27	Dupuytren's disease;	chr6:149477230	chr6:149796151~149826294:-
LUAD	cis	rs1823913	0.599	rs13399251	ENSG00000227542.1	AC092614.2	6.19	1.32e-09	5.99e-07	0.33	0.27	Obesity-related traits;	chr2:191268758	chr2:191229165~191246172:-
LUAD	cis	rs7688540	0.8	rs6837796	ENSG00000275426.1	CH17-262A2.1	6.19	1.32e-09	5.99e-07	0.33	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:278733	chr4:149738~150317:+
LUAD	cis	rs2243480	0.711	rs1626926	ENSG00000226824.5	RP4-756H11.3	-6.19	1.32e-09	6e-07	-0.5	-0.27	Diabetic kidney disease;	chr7:65970805	chr7:66654538~66669855:+
LUAD	cis	rs8072100	1	rs4375701	ENSG00000228782.6	CTD-2026D20.3	6.19	1.32e-09	6e-07	0.29	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47634852	chr17:47450568~47492492:-
LUAD	cis	rs6921919	0.583	rs6907950	ENSG00000216901.1	AL022393.7	6.19	1.32e-09	6.01e-07	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28176188~28176674:+
LUAD	cis	rs4713118	0.869	rs10214440	ENSG00000219392.1	RP1-265C24.5	-6.19	1.33e-09	6.02e-07	-0.37	-0.27	Parkinson's disease;	chr6:27734661	chr6:28115628~28116551:+
LUAD	cis	rs867371	0.929	rs7173852	ENSG00000255769.6	GOLGA2P10	-6.18	1.33e-09	6.02e-07	-0.29	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82169512	chr15:82472993~82513950:-
LUAD	cis	rs494459	0.838	rs567680	ENSG00000278376.1	RP11-158I9.8	-6.18	1.33e-09	6.03e-07	-0.29	-0.27	Height;	chr11:118737823	chr11:118791254~118793137:+
LUAD	cis	rs17301013	0.581	rs4652204	ENSG00000227373.4	RP11-160H22.5	6.18	1.33e-09	6.03e-07	0.39	0.27	Systemic lupus erythematosus;	chr1:174150682	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs460878	ENSG00000227373.4	RP11-160H22.5	6.18	1.33e-09	6.03e-07	0.39	0.27	Systemic lupus erythematosus;	chr1:174732645	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs969472	ENSG00000227373.4	RP11-160H22.5	6.18	1.33e-09	6.04e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174458562	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs10798314	ENSG00000227373.4	RP11-160H22.5	6.18	1.33e-09	6.04e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174458958	chr1:174115300~174160004:-
LUAD	cis	rs10740039	0.842	rs10761537	ENSG00000254271.1	RP11-131N11.4	6.18	1.34e-09	6.05e-07	0.31	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60649263	chr10:60734342~60741828:+
LUAD	cis	rs30380	0.734	rs27044	ENSG00000248734.2	CTD-2260A17.1	6.18	1.34e-09	6.05e-07	0.3	0.27	Cerebrospinal fluid biomarker levels;	chr5:96783148	chr5:96784777~96785999:+
LUAD	cis	rs30380	0.69	rs27432	ENSG00000248734.2	CTD-2260A17.1	6.18	1.34e-09	6.05e-07	0.3	0.27	Cerebrospinal fluid biomarker levels;	chr5:96783569	chr5:96784777~96785999:+
LUAD	cis	rs783540	0.967	rs783529	ENSG00000278603.1	RP13-608F4.5	-6.18	1.34e-09	6.05e-07	-0.32	-0.27	Schizophrenia;	chr15:82599231	chr15:82472203~82472426:+
LUAD	cis	rs9584850	0.874	rs7988959	ENSG00000231194.1	FARP1-AS1	6.18	1.34e-09	6.06e-07	0.33	0.27	Neuroticism;	chr13:98451750	chr13:98435405~98435840:-
LUAD	cis	rs8031584	0.958	rs7168641	ENSG00000260382.1	RP11-540B6.2	6.18	1.34e-09	6.07e-07	0.32	0.27	Huntington's disease progression;	chr15:30943249	chr15:30882267~30883231:-
LUAD	cis	rs17301013	0.507	rs10912828	ENSG00000227373.4	RP11-160H22.5	6.18	1.34e-09	6.07e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174635701	chr1:174115300~174160004:-
LUAD	cis	rs155076	1	rs261404	ENSG00000233325.3	MIPEPP3	6.18	1.34e-09	6.07e-07	0.41	0.27	White matter hyperintensity burden;	chr13:21284023	chr13:21298139~21306373:+
LUAD	cis	rs2015599	0.645	rs12578931	ENSG00000275476.1	RP11-996F15.4	-6.18	1.34e-09	6.07e-07	-0.3	-0.27	Platelet count;Mean platelet volume;	chr12:29358608	chr12:29277397~29277882:-
LUAD	cis	rs2015599	0.623	rs4931174	ENSG00000275476.1	RP11-996F15.4	-6.18	1.34e-09	6.07e-07	-0.3	-0.27	Platelet count;Mean platelet volume;	chr12:29360545	chr12:29277397~29277882:-
LUAD	cis	rs7044106	0.762	rs1547268	ENSG00000238181.2	AHCYP2	-6.18	1.34e-09	6.07e-07	-0.35	-0.27	Hip circumference adjusted for BMI;	chr9:120646410	chr9:120720673~120721972:+
LUAD	cis	rs7044106	0.762	rs1547267	ENSG00000238181.2	AHCYP2	-6.18	1.34e-09	6.07e-07	-0.35	-0.27	Hip circumference adjusted for BMI;	chr9:120646458	chr9:120720673~120721972:+
LUAD	cis	rs7044106	0.762	rs4142158	ENSG00000238181.2	AHCYP2	-6.18	1.34e-09	6.07e-07	-0.35	-0.27	Hip circumference adjusted for BMI;	chr9:120648541	chr9:120720673~120721972:+
LUAD	cis	rs2276314	1	rs9304153	ENSG00000278986.1	RP11-723J4.3	-6.18	1.34e-09	6.08e-07	-0.34	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:35982187	chr18:35972151~35973916:+
LUAD	cis	rs9652601	0.622	rs3901386	ENSG00000274038.1	RP11-66H6.4	-6.18	1.34e-09	6.08e-07	-0.32	-0.27	Systemic lupus erythematosus;	chr16:11048863	chr16:11056556~11057034:+
LUAD	cis	rs4713118	0.869	rs6922574	ENSG00000219392.1	RP1-265C24.5	-6.18	1.34e-09	6.08e-07	-0.37	-0.27	Parkinson's disease;	chr6:27725224	chr6:28115628~28116551:+
LUAD	cis	rs748404	0.666	rs12906017	ENSG00000205771.5	CATSPER2P1	-6.18	1.34e-09	6.08e-07	-0.42	-0.27	Lung cancer;	chr15:43504710	chr15:43726918~43747094:-
LUAD	cis	rs3096299	0.566	rs4129126	ENSG00000274627.1	RP11-104N10.2	6.18	1.35e-09	6.09e-07	0.29	0.27	Multiple myeloma (IgH translocation);	chr16:89495067	chr16:89516797~89522217:+
LUAD	cis	rs10740039	0.516	rs7477771	ENSG00000254271.1	RP11-131N11.4	6.18	1.35e-09	6.09e-07	0.3	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60595970	chr10:60734342~60741828:+
LUAD	cis	rs1823913	0.526	rs36028476	ENSG00000280083.1	RP11-317J9.1	-6.18	1.35e-09	6.09e-07	-0.33	-0.27	Obesity-related traits;	chr2:191300595	chr2:191154118~191156070:-
LUAD	cis	rs8100891	0.537	rs1030094	ENSG00000267213.4	AC007773.2	-6.18	1.35e-09	6.09e-07	-0.41	-0.27	Neuroticism;	chr19:32419525	chr19:32390050~32405560:-
LUAD	cis	rs2117029	0.561	rs7957983	ENSG00000258017.1	RP11-386G11.10	-6.18	1.35e-09	6.1e-07	-0.33	-0.27	Intelligence (multi-trait analysis);	chr12:49115204	chr12:49127782~49147869:+
LUAD	cis	rs2117029	0.587	rs7958572	ENSG00000258017.1	RP11-386G11.10	-6.18	1.35e-09	6.1e-07	-0.33	-0.27	Intelligence (multi-trait analysis);	chr12:49115658	chr12:49127782~49147869:+
LUAD	cis	rs2739330	0.828	rs2877178	ENSG00000228039.3	KB-1125A3.10	6.18	1.35e-09	6.1e-07	0.33	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23963780~23964374:+
LUAD	cis	rs4718428	0.607	rs66954441	ENSG00000232546.1	RP11-458F8.1	-6.18	1.35e-09	6.11e-07	-0.26	-0.27	Corneal structure;	chr7:66904222	chr7:66848496~66858136:+
LUAD	cis	rs9549367	0.789	rs9549718	ENSG00000269125.1	RP11-98F14.11	-6.18	1.35e-09	6.12e-07	-0.34	-0.27	Platelet distribution width;	chr13:113255508	chr13:113165002~113165183:-
LUAD	cis	rs7927592	0.913	rs7116994	ENSG00000212093.1	AP000807.1	6.18	1.35e-09	6.12e-07	0.3	0.27	Total body bone mineral density;	chr11:68487159	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.956	rs12274114	ENSG00000212093.1	AP000807.1	6.18	1.35e-09	6.12e-07	0.3	0.27	Total body bone mineral density;	chr11:68488109	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs12294029	ENSG00000212093.1	AP000807.1	6.18	1.35e-09	6.12e-07	0.3	0.27	Total body bone mineral density;	chr11:68489591	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.956	rs7126340	ENSG00000212093.1	AP000807.1	6.18	1.35e-09	6.12e-07	0.3	0.27	Total body bone mineral density;	chr11:68489825	chr11:68506083~68506166:-
LUAD	cis	rs66887589	0.934	rs2389873	ENSG00000248280.1	RP11-33B1.2	-6.18	1.35e-09	6.12e-07	-0.3	-0.27	Diastolic blood pressure;	chr4:119633559	chr4:119440561~119450157:-
LUAD	cis	rs875971	0.862	rs6955837	ENSG00000237310.1	GS1-124K5.4	-6.18	1.35e-09	6.12e-07	-0.3	-0.27	Aortic root size;	chr7:66578155	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.825	rs10281499	ENSG00000237310.1	GS1-124K5.4	-6.18	1.35e-09	6.12e-07	-0.3	-0.27	Aortic root size;	chr7:66583979	chr7:66493706~66495474:+
LUAD	cis	rs6840258	0.547	rs4693795	ENSG00000251411.1	RP11-397E7.4	-6.18	1.35e-09	6.12e-07	-0.38	-0.27	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86946904	chr4:86913266~86914817:-
LUAD	cis	rs9543976	1	rs4885324	ENSG00000261553.4	RP11-29G8.3	6.18	1.35e-09	6.13e-07	0.4	0.27	Diabetic retinopathy;	chr13:75599611	chr13:75549773~75807120:+
LUAD	cis	rs7727544	0.735	rs272842	ENSG00000233006.5	AC034220.3	6.18	1.36e-09	6.14e-07	0.24	0.27	Blood metabolite levels;	chr5:132320824	chr5:132311285~132369916:-
LUAD	cis	rs35740288	0.77	rs11633893	ENSG00000202081.1	RNU6-1280P	-6.18	1.36e-09	6.14e-07	-0.33	-0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85605207	chr15:85651522~85651628:-
LUAD	cis	rs8177876	0.596	rs2317087	ENSG00000261838.4	RP11-303E16.6	-6.18	1.36e-09	6.14e-07	-0.66	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81104753	chr16:81069854~81076598:+
LUAD	cis	rs897200	1	rs897200	ENSG00000280083.1	RP11-317J9.1	6.18	1.36e-09	6.14e-07	0.34	0.27	Behcet's disease;	chr2:191153045	chr2:191154118~191156070:-
LUAD	cis	rs755249	1	rs76841360	ENSG00000228060.1	RP11-69E11.8	-6.18	1.36e-09	6.15e-07	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39594353	chr1:39565160~39573203:+
LUAD	cis	rs1167827	0.71	rs1167836	ENSG00000127957.15	PMS2P3	-6.18	1.36e-09	6.15e-07	-0.26	-0.27	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75539580	chr7:75502930~75528148:-
LUAD	cis	rs2412819	0.545	rs35822148	ENSG00000205771.5	CATSPER2P1	-6.18	1.36e-09	6.15e-07	-0.46	-0.27	Lung cancer;	chr15:43808084	chr15:43726918~43747094:-
LUAD	cis	rs17301013	0.606	rs77379897	ENSG00000227373.4	RP11-160H22.5	6.18	1.36e-09	6.15e-07	0.39	0.27	Systemic lupus erythematosus;	chr1:174169373	chr1:174115300~174160004:-
LUAD	cis	rs1707322	0.721	rs11211165	ENSG00000234329.1	RP11-767N6.2	6.18	1.36e-09	6.16e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692234	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs11211166	ENSG00000234329.1	RP11-767N6.2	6.18	1.36e-09	6.16e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692270	chr1:45651039~45651826:-
LUAD	cis	rs755249	0.756	rs72637908	ENSG00000228060.1	RP11-69E11.8	-6.18	1.36e-09	6.16e-07	-0.25	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39557375	chr1:39565160~39573203:+
LUAD	cis	rs2276314	0.532	rs11081927	ENSG00000278986.1	RP11-723J4.3	-6.18	1.36e-09	6.16e-07	-0.28	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36034319	chr18:35972151~35973916:+
LUAD	cis	rs7688540	0.8	rs10003142	ENSG00000275426.1	CH17-262A2.1	6.18	1.36e-09	6.16e-07	0.33	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:297970	chr4:149738~150317:+
LUAD	cis	rs7688540	0.771	rs11723803	ENSG00000275426.1	CH17-262A2.1	6.18	1.36e-09	6.16e-07	0.33	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:298580	chr4:149738~150317:+
LUAD	cis	rs113835537	0.597	rs10896129	ENSG00000255517.5	CTD-3074O7.5	-6.18	1.37e-09	6.19e-07	-0.33	-0.27	Airway imaging phenotypes;	chr11:66570829	chr11:66473490~66480233:-
LUAD	cis	rs113835537	0.559	rs57045447	ENSG00000255517.5	CTD-3074O7.5	-6.18	1.37e-09	6.19e-07	-0.33	-0.27	Airway imaging phenotypes;	chr11:66572212	chr11:66473490~66480233:-
LUAD	cis	rs17301013	0.606	rs56375942	ENSG00000227373.4	RP11-160H22.5	6.18	1.37e-09	6.19e-07	0.39	0.27	Systemic lupus erythematosus;	chr1:174176206	chr1:174115300~174160004:-
LUAD	cis	rs7923609	0.811	rs7899657	ENSG00000232075.1	MRPL35P2	6.18	1.37e-09	6.19e-07	0.33	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63563505	chr10:63634317~63634827:-
LUAD	cis	rs6504622	0.905	rs736603	ENSG00000262879.4	RP11-156P1.3	6.18	1.38e-09	6.22e-07	0.31	0.27	Orofacial clefts;	chr17:46947379	chr17:46984045~47100323:-
LUAD	cis	rs6504622	0.905	rs736604	ENSG00000262879.4	RP11-156P1.3	6.18	1.38e-09	6.22e-07	0.31	0.27	Orofacial clefts;	chr17:46947443	chr17:46984045~47100323:-
LUAD	cis	rs17301013	0.531	rs1793318	ENSG00000227373.4	RP11-160H22.5	-6.18	1.38e-09	6.22e-07	-0.39	-0.27	Systemic lupus erythematosus;	chr1:174824678	chr1:174115300~174160004:-
LUAD	cis	rs4972806	0.814	rs4246626	ENSG00000226363.3	HAGLROS	-6.18	1.38e-09	6.23e-07	-0.34	-0.27	IgG glycosylation;	chr2:176181702	chr2:176177717~176179008:+
LUAD	cis	rs8031584	0.958	rs8034856	ENSG00000260382.1	RP11-540B6.2	6.18	1.38e-09	6.23e-07	0.33	0.27	Huntington's disease progression;	chr15:30948754	chr15:30882267~30883231:-
LUAD	cis	rs1823913	0.637	rs4853575	ENSG00000280083.1	RP11-317J9.1	6.18	1.38e-09	6.24e-07	0.32	0.27	Obesity-related traits;	chr2:191296149	chr2:191154118~191156070:-
LUAD	cis	rs2015599	0.623	rs12581107	ENSG00000275476.1	RP11-996F15.4	-6.18	1.38e-09	6.24e-07	-0.3	-0.27	Platelet count;Mean platelet volume;	chr12:29352358	chr12:29277397~29277882:-
LUAD	cis	rs1823913	0.599	rs35892286	ENSG00000280083.1	RP11-317J9.1	-6.18	1.38e-09	6.25e-07	-0.32	-0.27	Obesity-related traits;	chr2:191269010	chr2:191154118~191156070:-
LUAD	cis	rs2283792	0.765	rs8139376	ENSG00000224086.5	LL22NC03-86G7.1	-6.18	1.38e-09	6.25e-07	-0.26	-0.27	Multiple sclerosis;	chr22:21755307	chr22:21938293~21977632:+
LUAD	cis	rs7615952	0.741	rs13314845	ENSG00000171084.14	FAM86JP	6.18	1.39e-09	6.26e-07	0.39	0.27	Blood pressure (smoking interaction);	chr3:125925939	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.733	rs13314847	ENSG00000171084.14	FAM86JP	6.18	1.39e-09	6.26e-07	0.39	0.27	Blood pressure (smoking interaction);	chr3:125925945	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.8	rs13086460	ENSG00000171084.14	FAM86JP	6.18	1.39e-09	6.26e-07	0.39	0.27	Blood pressure (smoking interaction);	chr3:125927574	chr3:125916620~125930024:+
LUAD	cis	rs2276314	1	rs9304154	ENSG00000278986.1	RP11-723J4.3	-6.18	1.39e-09	6.27e-07	-0.34	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:35982264	chr18:35972151~35973916:+
LUAD	cis	rs9450351	0.744	rs9444371	ENSG00000203875.9	SNHG5	-6.18	1.39e-09	6.28e-07	-0.56	-0.27	Interferon gamma-induced protein 10 levels;	chr6:85950676	chr6:85660950~85678736:-
LUAD	cis	rs853679	0.517	rs9380047	ENSG00000204709.4	LINC01556	6.18	1.39e-09	6.28e-07	0.38	0.27	Depression;	chr6:28070115	chr6:28943877~28944537:+
LUAD	cis	rs8177376	0.681	rs240548	ENSG00000254905.1	RP11-712L6.7	6.18	1.39e-09	6.28e-07	0.37	0.27	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126335072	chr11:126292922~126294254:-
LUAD	cis	rs77204473	1	rs10892040	ENSG00000254851.1	RP11-109L13.1	6.18	1.39e-09	6.29e-07	0.66	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116886270	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs11216174	ENSG00000254851.1	RP11-109L13.1	6.18	1.39e-09	6.29e-07	0.66	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116886532	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs11216175	ENSG00000254851.1	RP11-109L13.1	6.18	1.39e-09	6.29e-07	0.66	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116886682	chr11:117135528~117138582:+
LUAD	cis	rs77204473	1	rs12284346	ENSG00000254851.1	RP11-109L13.1	6.18	1.39e-09	6.29e-07	0.66	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116887077	chr11:117135528~117138582:+
LUAD	cis	rs948562	0.744	rs113707421	ENSG00000280010.1	AP001350.4	6.18	1.39e-09	6.29e-07	0.42	0.27	Lymphoma;	chr11:58449669	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.744	rs11229468	ENSG00000280010.1	AP001350.4	6.18	1.39e-09	6.29e-07	0.42	0.27	Lymphoma;	chr11:58451300	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.744	rs113392266	ENSG00000280010.1	AP001350.4	6.18	1.39e-09	6.29e-07	0.42	0.27	Lymphoma;	chr11:58452278	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.744	rs74406537	ENSG00000280010.1	AP001350.4	6.18	1.39e-09	6.29e-07	0.42	0.27	Lymphoma;	chr11:58452887	chr11:58627435~58628528:+
LUAD	cis	rs2243480	0.803	rs35480979	ENSG00000230295.1	RP11-458F8.2	-6.18	1.39e-09	6.29e-07	-0.34	-0.27	Diabetic kidney disease;	chr7:65892097	chr7:66880708~66882981:+
LUAD	cis	rs875971	1	rs11974264	ENSG00000222364.1	RNU6-96P	6.18	1.4e-09	6.31e-07	0.3	0.27	Aortic root size;	chr7:66182595	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs1540651	ENSG00000222364.1	RNU6-96P	6.18	1.4e-09	6.31e-07	0.3	0.27	Aortic root size;	chr7:66185134	chr7:66395191~66395286:+
LUAD	cis	rs2117029	0.555	rs9788140	ENSG00000258017.1	RP11-386G11.10	-6.18	1.4e-09	6.31e-07	-0.33	-0.27	Intelligence (multi-trait analysis);	chr12:49126738	chr12:49127782~49147869:+
LUAD	cis	rs2337406	0.866	rs4773949	ENSG00000211974.3	IGHV2-70	6.18	1.4e-09	6.33e-07	0.33	0.27	Alzheimer's disease (late onset);	chr14:106808070	chr14:106723574~106724093:-
LUAD	cis	rs17301013	0.507	rs2281010	ENSG00000227373.4	RP11-160H22.5	6.18	1.4e-09	6.33e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174509917	chr1:174115300~174160004:-
LUAD	cis	rs6903823	0.508	rs1150718	ENSG00000204709.4	LINC01556	6.18	1.4e-09	6.33e-07	0.34	0.27	Pulmonary function;	chr6:28289170	chr6:28943877~28944537:+
LUAD	cis	rs6903823	0.508	rs1233660	ENSG00000204709.4	LINC01556	6.18	1.4e-09	6.33e-07	0.34	0.27	Pulmonary function;	chr6:28292472	chr6:28943877~28944537:+
LUAD	cis	rs74233809	1	rs77420391	ENSG00000213277.3	MARCKSL1P1	6.18	1.4e-09	6.33e-07	0.46	0.27	Birth weight;	chr10:103186066	chr10:103175554~103176094:+
LUAD	cis	rs17301013	0.507	rs12065454	ENSG00000227373.4	RP11-160H22.5	6.18	1.41e-09	6.34e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174492226	chr1:174115300~174160004:-
LUAD	cis	rs875971	0.545	rs6950988	ENSG00000226824.5	RP4-756H11.3	-6.18	1.41e-09	6.35e-07	-0.39	-0.27	Aortic root size;	chr7:66511428	chr7:66654538~66669855:+
LUAD	cis	rs8100891	0.537	rs1057395	ENSG00000267213.4	AC007773.2	-6.18	1.41e-09	6.35e-07	-0.43	-0.27	Neuroticism;	chr19:32483832	chr19:32390050~32405560:-
LUAD	cis	rs1012068	0.662	rs5753816	ENSG00000236132.1	CTA-440B3.1	-6.18	1.41e-09	6.35e-07	-0.32	-0.27	Chronic hepatitis C infection;	chr22:31916856	chr22:31816379~31817491:-
LUAD	cis	rs8072100	1	rs8065669	ENSG00000228782.6	CTD-2026D20.3	6.18	1.41e-09	6.35e-07	0.29	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47647630	chr17:47450568~47492492:-
LUAD	cis	rs9595908	0.686	rs1015364	ENSG00000212293.1	SNORA16	6.18	1.41e-09	6.35e-07	0.29	0.27	Body mass index;	chr13:32784455	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.709	rs7983889	ENSG00000212293.1	SNORA16	6.18	1.41e-09	6.35e-07	0.29	0.27	Body mass index;	chr13:32785441	chr13:32420390~32420516:-
LUAD	cis	rs6565180	0.926	rs12446288	ENSG00000183604.13	SMG1P5	6.17	1.41e-09	6.36e-07	0.29	0.27	Tonsillectomy;	chr16:30377388	chr16:30267553~30335374:-
LUAD	cis	rs6921919	0.562	rs13198809	ENSG00000204709.4	LINC01556	6.17	1.41e-09	6.36e-07	0.6	0.27	Autism spectrum disorder or schizophrenia;	chr6:28355925	chr6:28943877~28944537:+
LUAD	cis	rs8072100	1	rs11650372	ENSG00000228782.6	CTD-2026D20.3	6.17	1.41e-09	6.36e-07	0.29	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47644429	chr17:47450568~47492492:-
LUAD	cis	rs7615952	0.932	rs13086087	ENSG00000171084.14	FAM86JP	6.17	1.41e-09	6.37e-07	0.39	0.27	Blood pressure (smoking interaction);	chr3:125927438	chr3:125916620~125930024:+
LUAD	cis	rs950169	1	rs12903820	ENSG00000259728.4	LINC00933	6.17	1.41e-09	6.37e-07	0.41	0.27	Schizophrenia;	chr15:84055068	chr15:84570649~84580175:+
LUAD	cis	rs12908161	1	rs35960805	ENSG00000259728.4	LINC00933	6.17	1.41e-09	6.38e-07	0.39	0.27	Schizophrenia;	chr15:84800749	chr15:84570649~84580175:+
LUAD	cis	rs12908161	1	rs12912388	ENSG00000259728.4	LINC00933	6.17	1.41e-09	6.38e-07	0.39	0.27	Schizophrenia;	chr15:84801319	chr15:84570649~84580175:+
LUAD	cis	rs853679	0.546	rs35744819	ENSG00000204709.4	LINC01556	6.17	1.41e-09	6.38e-07	0.6	0.27	Depression;	chr6:28350554	chr6:28943877~28944537:+
LUAD	cis	rs6504622	0.875	rs2316330	ENSG00000262879.4	RP11-156P1.3	6.17	1.42e-09	6.38e-07	0.32	0.27	Orofacial clefts;	chr17:46962666	chr17:46984045~47100323:-
LUAD	cis	rs6504622	0.905	rs3851785	ENSG00000262879.4	RP11-156P1.3	6.17	1.42e-09	6.38e-07	0.32	0.27	Orofacial clefts;	chr17:46962781	chr17:46984045~47100323:-
LUAD	cis	rs6504622	0.875	rs11652318	ENSG00000262879.4	RP11-156P1.3	6.17	1.42e-09	6.38e-07	0.32	0.27	Orofacial clefts;	chr17:46963728	chr17:46984045~47100323:-
LUAD	cis	rs72634501	0.642	rs67452844	ENSG00000228060.1	RP11-69E11.8	-6.17	1.42e-09	6.39e-07	-0.26	-0.27	HDL cholesterol;	chr1:39150610	chr1:39565160~39573203:+
LUAD	cis	rs35934224	0.891	rs5993850	ENSG00000232926.1	AC000078.5	6.17	1.42e-09	6.39e-07	0.29	0.27	Glaucoma (primary open-angle);	chr22:19882180	chr22:19887289~19887970:+
LUAD	cis	rs35934224	0.891	rs8141451	ENSG00000232926.1	AC000078.5	6.17	1.42e-09	6.39e-07	0.29	0.27	Glaucoma (primary open-angle);	chr22:19882513	chr22:19887289~19887970:+
LUAD	cis	rs13217239	0.646	rs35691005	ENSG00000241549.7	GUSBP2	6.17	1.42e-09	6.4e-07	0.29	0.27	Schizophrenia;	chr6:27004291	chr6:26871484~26956554:-
LUAD	cis	rs13217239	0.646	rs10946891	ENSG00000241549.7	GUSBP2	6.17	1.42e-09	6.4e-07	0.29	0.27	Schizophrenia;	chr6:27005436	chr6:26871484~26956554:-
LUAD	cis	rs13217239	0.646	rs12201393	ENSG00000241549.7	GUSBP2	6.17	1.42e-09	6.4e-07	0.29	0.27	Schizophrenia;	chr6:27007911	chr6:26871484~26956554:-
LUAD	cis	rs8177876	0.915	rs12444974	ENSG00000261838.4	RP11-303E16.6	6.17	1.42e-09	6.41e-07	0.62	0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81094625	chr16:81069854~81076598:+
LUAD	cis	rs7829975	0.688	rs7817376	ENSG00000253981.4	ALG1L13P	-6.17	1.42e-09	6.41e-07	-0.32	-0.27	Mood instability;	chr8:8523020	chr8:8236003~8244667:-
LUAD	cis	rs2179367	0.959	rs9285519	ENSG00000231760.4	RP11-350J20.5	6.17	1.43e-09	6.43e-07	0.34	0.27	Dupuytren's disease;	chr6:149371799	chr6:149796151~149826294:-
LUAD	cis	rs367615	0.918	rs115145487	ENSG00000249476.1	CTD-2587M2.1	6.17	1.43e-09	6.43e-07	0.36	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109552445	chr5:109237120~109326369:-
LUAD	cis	rs7674212	0.531	rs4698875	ENSG00000251288.2	RP11-10L12.2	-6.17	1.43e-09	6.43e-07	-0.35	-0.27	Type 2 diabetes;	chr4:103012211	chr4:102751401~102752641:+
LUAD	cis	rs10740039	0.81	rs1372709	ENSG00000254271.1	RP11-131N11.4	6.17	1.43e-09	6.44e-07	0.31	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60621666	chr10:60734342~60741828:+
LUAD	cis	rs2243480	1	rs11538349	ENSG00000230295.1	RP11-458F8.2	-6.17	1.43e-09	6.44e-07	-0.32	-0.27	Diabetic kidney disease;	chr7:65956884	chr7:66880708~66882981:+
LUAD	cis	rs17301013	0.507	rs1793316	ENSG00000227373.4	RP11-160H22.5	6.17	1.43e-09	6.45e-07	0.38	0.27	Systemic lupus erythematosus;	chr1:174825006	chr1:174115300~174160004:-
LUAD	cis	rs2739330	0.828	rs5760108	ENSG00000228039.3	KB-1125A3.10	6.17	1.44e-09	6.47e-07	0.33	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23963780~23964374:+
LUAD	cis	rs732716	0.785	rs62130979	ENSG00000267980.1	AC007292.6	-6.17	1.44e-09	6.47e-07	-0.33	-0.27	Mean corpuscular volume;	chr19:4432447	chr19:4363789~4364640:+
LUAD	cis	rs9992667	0.955	rs28418927	ENSG00000231160.8	KLF3-AS1	6.17	1.44e-09	6.49e-07	0.34	0.27	Eosinophil percentage of granulocytes;	chr4:38624509	chr4:38612701~38664883:-
LUAD	cis	rs71403859	0.504	rs12926413	ENSG00000260886.1	TAT-AS1	6.17	1.44e-09	6.49e-07	0.49	0.27	Post bronchodilator FEV1;	chr16:71938422	chr16:71565789~71578187:+
LUAD	cis	rs77204473	0.744	rs116861530	ENSG00000254851.1	RP11-109L13.1	6.17	1.44e-09	6.5e-07	0.69	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117091945	chr11:117135528~117138582:+
LUAD	cis	rs77204473	0.744	rs74420345	ENSG00000254851.1	RP11-109L13.1	6.17	1.44e-09	6.5e-07	0.69	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117092561	chr11:117135528~117138582:+
LUAD	cis	rs875971	0.545	rs12670811	ENSG00000237310.1	GS1-124K5.4	6.17	1.44e-09	6.5e-07	0.33	0.27	Aortic root size;	chr7:66358032	chr7:66493706~66495474:+
LUAD	cis	rs6504622	0.818	rs9910899	ENSG00000262879.4	RP11-156P1.3	6.17	1.44e-09	6.5e-07	0.32	0.27	Orofacial clefts;	chr17:46956976	chr17:46984045~47100323:-
LUAD	cis	rs6504622	0.818	rs9912794	ENSG00000262879.4	RP11-156P1.3	6.17	1.44e-09	6.5e-07	0.32	0.27	Orofacial clefts;	chr17:46957075	chr17:46984045~47100323:-
LUAD	cis	rs7615952	0.515	rs7630575	ENSG00000171084.14	FAM86JP	6.17	1.44e-09	6.5e-07	0.36	0.27	Blood pressure (smoking interaction);	chr3:125963487	chr3:125916620~125930024:+
LUAD	cis	rs2243480	0.901	rs12530490	ENSG00000232546.1	RP11-458F8.1	6.17	1.44e-09	6.5e-07	0.36	0.27	Diabetic kidney disease;	chr7:66226660	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs7778911	ENSG00000232546.1	RP11-458F8.1	6.17	1.44e-09	6.5e-07	0.36	0.27	Diabetic kidney disease;	chr7:66229519	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs1979823	ENSG00000232546.1	RP11-458F8.1	6.17	1.44e-09	6.5e-07	0.36	0.27	Diabetic kidney disease;	chr7:66239626	chr7:66848496~66858136:+
LUAD	cis	rs957448	1	rs56716157	ENSG00000253704.1	RP11-267M23.4	6.17	1.44e-09	6.5e-07	0.35	0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94530644	chr8:94553722~94569745:+
LUAD	cis	rs7176527	0.796	rs1057946	ENSG00000188388.10	GOLGA6L3	6.17	1.45e-09	6.52e-07	0.39	0.27	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84639555	chr15:85240472~85247170:+
LUAD	cis	rs9928842	0.823	rs6564243	ENSG00000280152.1	RP11-331F4.5	6.17	1.45e-09	6.52e-07	0.31	0.27	Alcoholic chronic pancreatitis;	chr16:75262103	chr16:75245994~75250077:-
LUAD	cis	rs755249	0.567	rs4660214	ENSG00000228060.1	RP11-69E11.8	-6.17	1.45e-09	6.52e-07	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39265878	chr1:39565160~39573203:+
LUAD	cis	rs66887589	0.616	rs11731675	ENSG00000245958.5	RP11-33B1.1	-6.17	1.45e-09	6.52e-07	-0.22	-0.27	Diastolic blood pressure;	chr4:119291359	chr4:119454791~119552025:+
LUAD	cis	rs6687821	0.637	rs493341	ENSG00000267734.1	RP4-604K5.3	6.17	1.45e-09	6.53e-07	0.35	0.27	Yeast infection;	chr1:86845499	chr1:86932199~86934891:-
LUAD	cis	rs4591358	0.648	rs56906982	ENSG00000223466.1	AC064834.2	-6.17	1.45e-09	6.53e-07	-0.36	-0.27	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195512939	chr2:195533035~195538681:+
LUAD	cis	rs4723738	1	rs4723734	ENSG00000227191.5	TRGC2	-6.17	1.45e-09	6.54e-07	-0.29	-0.27	Treatment response for severe sepsis;	chr7:38192459	chr7:38239580~38368091:-
LUAD	cis	rs7829975	0.633	rs2979181	ENSG00000253981.4	ALG1L13P	6.17	1.45e-09	6.54e-07	0.31	0.27	Mood instability;	chr8:8465578	chr8:8236003~8244667:-
LUAD	cis	rs113835537	0.66	rs7116940	ENSG00000255517.5	CTD-3074O7.5	-6.17	1.45e-09	6.54e-07	-0.34	-0.27	Airway imaging phenotypes;	chr11:66536424	chr11:66473490~66480233:-
LUAD	cis	rs9326248	0.603	rs7396061	ENSG00000280143.1	AP000892.6	6.17	1.46e-09	6.55e-07	0.31	0.27	Blood protein levels;	chr11:116880158	chr11:117204967~117210292:+
LUAD	cis	rs7923609	0.869	rs9971352	ENSG00000232075.1	MRPL35P2	-6.17	1.46e-09	6.55e-07	-0.33	-0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63505348	chr10:63634317~63634827:-
LUAD	cis	rs4713118	0.955	rs9468200	ENSG00000219392.1	RP1-265C24.5	-6.17	1.46e-09	6.55e-07	-0.37	-0.27	Parkinson's disease;	chr6:27715284	chr6:28115628~28116551:+
LUAD	cis	rs67311347	1	rs13324109	ENSG00000223797.4	ENTPD3-AS1	6.17	1.46e-09	6.56e-07	0.28	0.27	Renal cell carcinoma;	chr3:40419276	chr3:40313802~40453329:-
LUAD	cis	rs66887589	0.616	rs6843509	ENSG00000248280.1	RP11-33B1.2	6.17	1.46e-09	6.57e-07	0.3	0.27	Diastolic blood pressure;	chr4:119299041	chr4:119440561~119450157:-
LUAD	cis	rs494459	0.929	rs627391	ENSG00000278376.1	RP11-158I9.8	-6.17	1.46e-09	6.57e-07	-0.28	-0.27	Height;	chr11:118703207	chr11:118791254~118793137:+
LUAD	cis	rs13217239	0.646	rs10946897	ENSG00000241549.7	GUSBP2	6.17	1.46e-09	6.57e-07	0.29	0.27	Schizophrenia;	chr6:27027472	chr6:26871484~26956554:-
LUAD	cis	rs7221109	0.601	rs2109223	ENSG00000278834.1	RP11-458J1.1	6.17	1.46e-09	6.57e-07	0.32	0.27	Type 1 diabetes;	chr17:40690602	chr17:40648300~40649718:+
LUAD	cis	rs496547	0.686	rs477014	ENSG00000255422.1	AP002954.4	-6.17	1.46e-09	6.58e-07	-0.35	-0.27	Hip minimal joint space width;	chr11:118808277	chr11:118704607~118750263:+
LUAD	cis	rs74233809	1	rs11191587	ENSG00000213277.3	MARCKSL1P1	6.17	1.46e-09	6.58e-07	0.45	0.27	Birth weight;	chr10:103169959	chr10:103175554~103176094:+
LUAD	cis	rs11098499	1	rs11098500	ENSG00000248280.1	RP11-33B1.2	6.17	1.46e-09	6.58e-07	0.34	0.27	Corneal astigmatism;	chr4:119298084	chr4:119440561~119450157:-
LUAD	cis	rs8177376	1	rs657361	ENSG00000254905.1	RP11-712L6.7	6.17	1.46e-09	6.58e-07	0.38	0.27	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126241196	chr11:126292922~126294254:-
LUAD	cis	rs6844153	0.752	rs10029307	ENSG00000240005.4	RP11-293A21.1	-6.17	1.46e-09	6.59e-07	-0.39	-0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26902591	chr4:26859806~26860599:-
LUAD	cis	rs321358	0.697	rs522188	ENSG00000271584.1	RP11-89C3.4	-6.17	1.47e-09	6.59e-07	-0.41	-0.27	Body mass index;	chr11:111169869	chr11:111091932~111097357:-
LUAD	cis	rs2115536	0.64	rs934134	ENSG00000278600.1	RP11-81A1.6	-6.17	1.47e-09	6.59e-07	-0.22	-0.27	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79875876	chr15:79920195~79922455:-
LUAD	cis	rs2283792	0.715	rs55891647	ENSG00000224086.5	LL22NC03-86G7.1	-6.17	1.47e-09	6.6e-07	-0.26	-0.27	Multiple sclerosis;	chr22:21824198	chr22:21938293~21977632:+
LUAD	cis	rs8062405	1	rs72793812	ENSG00000251417.2	RP11-1348G14.4	-6.17	1.47e-09	6.6e-07	-0.28	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28802743~28817828:+
LUAD	cis	rs1823913	0.637	rs921737	ENSG00000280083.1	RP11-317J9.1	6.17	1.47e-09	6.6e-07	0.32	0.27	Obesity-related traits;	chr2:191286097	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.599	rs6736071	ENSG00000280083.1	RP11-317J9.1	6.17	1.47e-09	6.6e-07	0.32	0.27	Obesity-related traits;	chr2:191287265	chr2:191154118~191156070:-
LUAD	cis	rs17818399	0.712	rs13008088	ENSG00000279254.1	RP11-536C12.1	-6.17	1.47e-09	6.61e-07	-0.31	-0.27	Height;	chr2:46554441	chr2:46668870~46670778:+
LUAD	cis	rs2765539	0.515	rs2788183	ENSG00000226172.2	RP4-712E4.1	-6.17	1.47e-09	6.61e-07	-0.34	-0.27	Waist-hip ratio;	chr1:118929322	chr1:119000344~119001392:-
LUAD	cis	rs17023223	0.537	rs7525871	ENSG00000231365.4	RP11-418J17.1	-6.17	1.47e-09	6.62e-07	-0.37	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119079271	chr1:119140396~119275973:+
LUAD	cis	rs67311347	1	rs4973878	ENSG00000223797.4	ENTPD3-AS1	6.17	1.47e-09	6.62e-07	0.28	0.27	Renal cell carcinoma;	chr3:40366074	chr3:40313802~40453329:-
LUAD	cis	rs875971	0.862	rs778686	ENSG00000222364.1	RNU6-96P	-6.17	1.47e-09	6.62e-07	-0.31	-0.27	Aortic root size;	chr7:66370923	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs778684	ENSG00000222364.1	RNU6-96P	-6.17	1.47e-09	6.62e-07	-0.31	-0.27	Aortic root size;	chr7:66371416	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs778680	ENSG00000222364.1	RNU6-96P	-6.17	1.47e-09	6.62e-07	-0.31	-0.27	Aortic root size;	chr7:66375427	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs11769079	ENSG00000222364.1	RNU6-96P	-6.17	1.47e-09	6.62e-07	-0.31	-0.27	Aortic root size;	chr7:66377141	chr7:66395191~66395286:+
LUAD	cis	rs7849270	0.959	rs2297111	ENSG00000268707.1	RP11-247A12.7	-6.17	1.47e-09	6.63e-07	-0.31	-0.27	Blood metabolite ratios;	chr9:129142015	chr9:129170434~129170940:+
LUAD	cis	rs875971	1	rs2420820	ENSG00000222364.1	RNU6-96P	6.17	1.47e-09	6.63e-07	0.3	0.27	Aortic root size;	chr7:66626920	chr7:66395191~66395286:+
LUAD	cis	rs12468226	0.938	rs3843338	ENSG00000226261.1	AC064836.3	-6.17	1.47e-09	6.63e-07	-0.44	-0.27	Urate levels;	chr2:202246102	chr2:202336024~202336727:-
LUAD	cis	rs875971	1	rs2220626	ENSG00000222364.1	RNU6-96P	6.17	1.47e-09	6.63e-07	0.3	0.27	Aortic root size;	chr7:66081075	chr7:66395191~66395286:+
LUAD	cis	rs7727544	0.507	rs9791170	ENSG00000233006.5	AC034220.3	6.17	1.48e-09	6.63e-07	0.24	0.27	Blood metabolite levels;	chr5:132233934	chr5:132311285~132369916:-
LUAD	cis	rs7674212	0.507	rs6843738	ENSG00000251288.2	RP11-10L12.2	-6.17	1.48e-09	6.64e-07	-0.35	-0.27	Type 2 diabetes;	chr4:103014844	chr4:102751401~102752641:+
LUAD	cis	rs7923609	0.967	rs7085018	ENSG00000232075.1	MRPL35P2	-6.17	1.48e-09	6.65e-07	-0.33	-0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63526907	chr10:63634317~63634827:-
LUAD	cis	rs1914816	0.941	rs2469544	ENSG00000196274.5	Metazoa_SRP	6.17	1.48e-09	6.66e-07	0.3	0.27	Response to tocilizumab in rheumatoid arthritis;	chr15:76192606	chr15:76230048~76230390:-
LUAD	cis	rs6844153	0.68	rs61047003	ENSG00000240005.4	RP11-293A21.1	-6.17	1.48e-09	6.67e-07	-0.38	-0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26937139	chr4:26859806~26860599:-
LUAD	cis	rs67311347	0.91	rs13089215	ENSG00000223797.4	ENTPD3-AS1	-6.17	1.48e-09	6.67e-07	-0.28	-0.27	Renal cell carcinoma;	chr3:40454403	chr3:40313802~40453329:-
LUAD	cis	rs6903823	0.508	rs1150724	ENSG00000204709.4	LINC01556	6.17	1.48e-09	6.67e-07	0.33	0.27	Pulmonary function;	chr6:28282459	chr6:28943877~28944537:+
LUAD	cis	rs8031584	0.958	rs61997079	ENSG00000260382.1	RP11-540B6.2	6.17	1.49e-09	6.68e-07	0.32	0.27	Huntington's disease progression;	chr15:30946068	chr15:30882267~30883231:-
LUAD	cis	rs8031584	0.958	rs11637469	ENSG00000260382.1	RP11-540B6.2	6.17	1.49e-09	6.68e-07	0.32	0.27	Huntington's disease progression;	chr15:30946580	chr15:30882267~30883231:-
LUAD	cis	rs2404602	0.647	rs8025991	ENSG00000259422.1	RP11-593F23.1	-6.17	1.49e-09	6.68e-07	-0.35	-0.27	Blood metabolite levels;	chr15:76862927	chr15:76174891~76181486:-
LUAD	cis	rs7923609	0.756	rs7077256	ENSG00000232075.1	MRPL35P2	6.17	1.49e-09	6.69e-07	0.33	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63576425	chr10:63634317~63634827:-
LUAD	cis	rs1062177	0.756	rs2915826	ENSG00000213433.5	RPLP1P6	6.17	1.49e-09	6.7e-07	0.35	0.27	Preschool internalizing problems;	chr5:151740402	chr5:151765859~151766378:-
LUAD	cis	rs1062177	0.756	rs2964587	ENSG00000213433.5	RPLP1P6	6.17	1.49e-09	6.7e-07	0.35	0.27	Preschool internalizing problems;	chr5:151740411	chr5:151765859~151766378:-
LUAD	cis	rs858239	0.6	rs7341483	ENSG00000230042.1	AK3P3	6.16	1.49e-09	6.71e-07	0.34	0.27	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23129178~23129841:+
LUAD	cis	rs1799949	1	rs915945	ENSG00000267681.1	CTD-3199J23.6	-6.16	1.5e-09	6.72e-07	-0.32	-0.27	Menopause (age at onset);	chr17:43027847	chr17:43144956~43145255:+
LUAD	cis	rs1799949	1	rs12942277	ENSG00000267681.1	CTD-3199J23.6	-6.16	1.5e-09	6.72e-07	-0.32	-0.27	Menopause (age at onset);	chr17:43035957	chr17:43144956~43145255:+
LUAD	cis	rs1799949	0.965	rs34616041	ENSG00000267681.1	CTD-3199J23.6	-6.16	1.5e-09	6.72e-07	-0.32	-0.27	Menopause (age at onset);	chr17:43036769	chr17:43144956~43145255:+
LUAD	cis	rs11096990	0.964	rs11096987	ENSG00000249207.1	RP11-360F5.1	6.16	1.5e-09	6.72e-07	0.31	0.27	Cognitive function;	chr4:39257570	chr4:39112677~39126818:-
LUAD	cis	rs17684571	0.938	rs62412526	ENSG00000231441.1	RP11-472M19.2	6.16	1.5e-09	6.72e-07	0.37	0.27	Schizophrenia;	chr6:56689171	chr6:56844002~56864078:+
LUAD	cis	rs35740288	0.77	rs36044792	ENSG00000202081.1	RNU6-1280P	6.16	1.5e-09	6.73e-07	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85603320	chr15:85651522~85651628:-
LUAD	cis	rs1823913	0.614	rs4853463	ENSG00000280083.1	RP11-317J9.1	6.16	1.5e-09	6.73e-07	0.32	0.27	Obesity-related traits;	chr2:191278699	chr2:191154118~191156070:-
LUAD	cis	rs2946504	0.553	rs2946498	ENSG00000251468.2	RP11-369K16.1	-6.16	1.5e-09	6.73e-07	-0.34	-0.27	Type 2 diabetes;	chr8:12960578	chr8:12958387~12962200:+
LUAD	cis	rs6504622	0.818	rs9898527	ENSG00000262879.4	RP11-156P1.3	6.16	1.5e-09	6.74e-07	0.32	0.27	Orofacial clefts;	chr17:46958844	chr17:46984045~47100323:-
LUAD	cis	rs17301013	0.556	rs1754353	ENSG00000227373.4	RP11-160H22.5	-6.16	1.5e-09	6.74e-07	-0.4	-0.27	Systemic lupus erythematosus;	chr1:174822229	chr1:174115300~174160004:-
LUAD	cis	rs6142102	0.58	rs761233	ENSG00000275784.1	RP5-1125A11.6	-6.16	1.5e-09	6.76e-07	-0.29	-0.27	Skin pigmentation;	chr20:33981080	chr20:33989480~33991818:-
LUAD	cis	rs2980439	0.525	rs2945238	ENSG00000253893.2	FAM85B	-6.16	1.51e-09	6.77e-07	-0.34	-0.27	Neuroticism;	chr8:8312614	chr8:8167819~8226614:-
LUAD	cis	rs12699921	0.632	rs2723552	ENSG00000279048.1	RP11-511H23.2	-6.16	1.51e-09	6.77e-07	-0.22	-0.27	Fibrinogen levels;	chr7:17821038	chr7:17940503~17942922:+
LUAD	cis	rs7743045	0.711	rs4946371	ENSG00000253194.1	RP11-351A11.1	6.16	1.51e-09	6.78e-07	0.36	0.27	Mean platelet volume;	chr6:118935483	chr6:118934785~119031541:+
LUAD	cis	rs8081395	0.741	rs1292055	ENSG00000266992.1	DHX40P1	6.16	1.51e-09	6.79e-07	0.31	0.27	White blood cell count;	chr17:59881707	chr17:59976009~60002384:-
LUAD	cis	rs17301013	0.507	rs1793320	ENSG00000227373.4	RP11-160H22.5	6.16	1.51e-09	6.79e-07	0.39	0.27	Systemic lupus erythematosus;	chr1:174796308	chr1:174115300~174160004:-
LUAD	cis	rs67311347	0.911	rs9849224	ENSG00000223797.4	ENTPD3-AS1	6.16	1.52e-09	6.81e-07	0.28	0.27	Renal cell carcinoma;	chr3:40351071	chr3:40313802~40453329:-
LUAD	cis	rs17301013	0.606	rs10912754	ENSG00000227373.4	RP11-160H22.5	6.16	1.52e-09	6.81e-07	0.38	0.27	Systemic lupus erythematosus;	chr1:174273667	chr1:174115300~174160004:-
LUAD	cis	rs7829975	0.624	rs7823056	ENSG00000253981.4	ALG1L13P	6.16	1.52e-09	6.81e-07	0.31	0.27	Mood instability;	chr8:8525195	chr8:8236003~8244667:-
LUAD	cis	rs1823913	0.599	rs13399251	ENSG00000280083.1	RP11-317J9.1	-6.16	1.52e-09	6.81e-07	-0.32	-0.27	Obesity-related traits;	chr2:191268758	chr2:191154118~191156070:-
LUAD	cis	rs2980439	0.807	rs2980438	ENSG00000253981.4	ALG1L13P	6.16	1.52e-09	6.82e-07	0.31	0.27	Neuroticism;	chr8:8237303	chr8:8236003~8244667:-
LUAD	cis	rs12699921	0.572	rs2030725	ENSG00000279048.1	RP11-511H23.2	-6.16	1.52e-09	6.82e-07	-0.22	-0.27	Fibrinogen levels;	chr7:17828708	chr7:17940503~17942922:+
LUAD	cis	rs4964805	0.641	rs11111755	ENSG00000257681.1	RP11-341G23.4	6.16	1.52e-09	6.82e-07	0.31	0.27	Attention deficit hyperactivity disorder;	chr12:103765889	chr12:103746315~103768858:-
LUAD	cis	rs4964805	0.641	rs10861094	ENSG00000257681.1	RP11-341G23.4	6.16	1.52e-09	6.82e-07	0.31	0.27	Attention deficit hyperactivity disorder;	chr12:103765938	chr12:103746315~103768858:-
LUAD	cis	rs957448	1	rs60655325	ENSG00000253704.1	RP11-267M23.4	6.16	1.52e-09	6.83e-07	0.34	0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94552606	chr8:94553722~94569745:+
LUAD	cis	rs1823913	0.637	rs12624271	ENSG00000280083.1	RP11-317J9.1	6.16	1.52e-09	6.84e-07	0.32	0.27	Obesity-related traits;	chr2:191288586	chr2:191154118~191156070:-
LUAD	cis	rs875971	0.545	rs3735147	ENSG00000237310.1	GS1-124K5.4	6.16	1.52e-09	6.84e-07	0.33	0.27	Aortic root size;	chr7:66505541	chr7:66493706~66495474:+
LUAD	cis	rs1823913	0.637	rs11686185	ENSG00000280083.1	RP11-317J9.1	6.16	1.53e-09	6.84e-07	0.32	0.27	Obesity-related traits;	chr2:191289282	chr2:191154118~191156070:-
LUAD	cis	rs17711722	0.528	rs73138179	ENSG00000224316.1	RP11-479O9.2	6.16	1.53e-09	6.84e-07	0.27	0.27	Calcium levels;	chr7:65829495	chr7:65773620~65802067:+
LUAD	cis	rs2243480	1	rs427044	ENSG00000230295.1	RP11-458F8.2	-6.16	1.53e-09	6.85e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:66043558	chr7:66880708~66882981:+
LUAD	cis	rs875971	0.545	rs10950025	ENSG00000226824.5	RP4-756H11.3	-6.16	1.53e-09	6.85e-07	-0.39	-0.27	Aortic root size;	chr7:66158946	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.52	rs12666485	ENSG00000226824.5	RP4-756H11.3	-6.16	1.53e-09	6.85e-07	-0.39	-0.27	Aortic root size;	chr7:66160135	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.545	rs67688847	ENSG00000226824.5	RP4-756H11.3	-6.16	1.53e-09	6.85e-07	-0.39	-0.27	Aortic root size;	chr7:66161064	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.545	rs7787063	ENSG00000226824.5	RP4-756H11.3	-6.16	1.53e-09	6.85e-07	-0.39	-0.27	Aortic root size;	chr7:66164012	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.545	rs12673308	ENSG00000226824.5	RP4-756H11.3	-6.16	1.53e-09	6.85e-07	-0.39	-0.27	Aortic root size;	chr7:66166374	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.545	rs67397473	ENSG00000226824.5	RP4-756H11.3	-6.16	1.53e-09	6.85e-07	-0.39	-0.27	Aortic root size;	chr7:66168318	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.545	rs10950027	ENSG00000226824.5	RP4-756H11.3	-6.16	1.53e-09	6.85e-07	-0.39	-0.27	Aortic root size;	chr7:66169164	chr7:66654538~66669855:+
LUAD	cis	rs66887589	0.934	rs4834792	ENSG00000248280.1	RP11-33B1.2	-6.16	1.53e-09	6.87e-07	-0.3	-0.27	Diastolic blood pressure;	chr4:119634541	chr4:119440561~119450157:-
LUAD	cis	rs2276314	1	rs4799835	ENSG00000278986.1	RP11-723J4.3	-6.16	1.53e-09	6.88e-07	-0.34	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:35991305	chr18:35972151~35973916:+
LUAD	cis	rs2404602	0.647	rs12440511	ENSG00000259422.1	RP11-593F23.1	-6.16	1.53e-09	6.88e-07	-0.36	-0.27	Blood metabolite levels;	chr15:76700794	chr15:76174891~76181486:-
LUAD	cis	rs1318937	0.764	rs58768954	ENSG00000224660.1	SH3BP5-AS1	6.16	1.54e-09	6.88e-07	0.22	0.27	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15198798	chr3:15254184~15264493:+
LUAD	cis	rs1707322	0.752	rs11211168	ENSG00000234329.1	RP11-767N6.2	6.16	1.54e-09	6.89e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697975	chr1:45651039~45651826:-
LUAD	cis	rs1823913	0.599	rs67342262	ENSG00000280083.1	RP11-317J9.1	-6.16	1.54e-09	6.89e-07	-0.33	-0.27	Obesity-related traits;	chr2:191295612	chr2:191154118~191156070:-
LUAD	cis	rs2034650	0.563	rs12914315	ENSG00000223313.1	RNU6-516P	-6.16	1.54e-09	6.89e-07	-0.35	-0.27	Interstitial lung disease;	chr15:40421679	chr15:40529570~40529673:+
LUAD	cis	rs75920871	0.589	rs73008568	ENSG00000254851.1	RP11-109L13.1	-6.16	1.54e-09	6.89e-07	-0.48	-0.27	Subjective well-being;	chr11:117194291	chr11:117135528~117138582:+
LUAD	cis	rs1318937	1	rs3773471	ENSG00000224660.1	SH3BP5-AS1	-6.16	1.54e-09	6.9e-07	-0.2	-0.27	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15261540	chr3:15254184~15264493:+
LUAD	cis	rs875971	0.928	rs2036263	ENSG00000222364.1	RNU6-96P	6.16	1.54e-09	6.9e-07	0.31	0.27	Aortic root size;	chr7:66335210	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs10240949	ENSG00000222364.1	RNU6-96P	6.16	1.54e-09	6.9e-07	0.31	0.27	Aortic root size;	chr7:66339430	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs7782704	ENSG00000222364.1	RNU6-96P	6.16	1.54e-09	6.9e-07	0.31	0.27	Aortic root size;	chr7:66340379	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs6959268	ENSG00000222364.1	RNU6-96P	6.16	1.54e-09	6.9e-07	0.31	0.27	Aortic root size;	chr7:66347979	chr7:66395191~66395286:+
LUAD	cis	rs7396835	0.5	rs5092	ENSG00000280143.1	AP000892.6	6.16	1.54e-09	6.91e-07	0.38	0.27	Quantitative traits;	chr11:116822748	chr11:117204967~117210292:+
LUAD	cis	rs7017914	0.905	rs1353058	ENSG00000223220.1	Y_RNA	6.16	1.54e-09	6.92e-07	0.3	0.27	Bone mineral density;	chr8:71009783	chr8:70780914~70781008:-
LUAD	cis	rs9326248	0.52	rs2735183	ENSG00000280143.1	AP000892.6	6.16	1.54e-09	6.92e-07	0.31	0.27	Blood protein levels;	chr11:117144479	chr11:117204967~117210292:+
LUAD	cis	rs8072100	0.967	rs2317826	ENSG00000228782.6	CTD-2026D20.3	6.16	1.55e-09	6.94e-07	0.29	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47653533	chr17:47450568~47492492:-
LUAD	cis	rs875971	0.862	rs801194	ENSG00000237310.1	GS1-124K5.4	-6.16	1.55e-09	6.94e-07	-0.29	-0.27	Aortic root size;	chr7:66563508	chr7:66493706~66495474:+
LUAD	cis	rs4835473	0.932	rs10021860	ENSG00000251600.4	RP11-673E1.1	6.16	1.55e-09	6.94e-07	0.33	0.27	Immature fraction of reticulocytes;	chr4:143754593	chr4:143912331~143982454:+
LUAD	cis	rs1061377	1	rs9999327	ENSG00000249685.1	RP11-360F5.3	6.16	1.55e-09	6.95e-07	0.32	0.27	Uric acid levels;	chr4:39110111	chr4:39133913~39135608:+
LUAD	cis	rs1061377	0.965	rs6833654	ENSG00000249685.1	RP11-360F5.3	6.16	1.55e-09	6.95e-07	0.32	0.27	Uric acid levels;	chr4:39110701	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs1036038	ENSG00000249685.1	RP11-360F5.3	6.16	1.55e-09	6.95e-07	0.32	0.27	Uric acid levels;	chr4:39111383	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs1560396	ENSG00000249685.1	RP11-360F5.3	6.16	1.55e-09	6.95e-07	0.32	0.27	Uric acid levels;	chr4:39112092	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs1560397	ENSG00000249685.1	RP11-360F5.3	6.16	1.55e-09	6.95e-07	0.32	0.27	Uric acid levels;	chr4:39112265	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs2381285	ENSG00000249685.1	RP11-360F5.3	6.16	1.55e-09	6.95e-07	0.32	0.27	Uric acid levels;	chr4:39112775	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs2163272	ENSG00000249685.1	RP11-360F5.3	6.16	1.55e-09	6.95e-07	0.32	0.27	Uric acid levels;	chr4:39112790	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs2163273	ENSG00000249685.1	RP11-360F5.3	6.16	1.55e-09	6.95e-07	0.32	0.27	Uric acid levels;	chr4:39112835	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs62310332	ENSG00000249685.1	RP11-360F5.3	6.16	1.55e-09	6.95e-07	0.32	0.27	Uric acid levels;	chr4:39112939	chr4:39133913~39135608:+
LUAD	cis	rs1061377	0.965	rs3796510	ENSG00000249685.1	RP11-360F5.3	6.16	1.55e-09	6.95e-07	0.32	0.27	Uric acid levels;	chr4:39113309	chr4:39133913~39135608:+
LUAD	cis	rs1061377	0.932	rs6855118	ENSG00000249685.1	RP11-360F5.3	6.16	1.55e-09	6.95e-07	0.32	0.27	Uric acid levels;	chr4:39114322	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs6829234	ENSG00000249685.1	RP11-360F5.3	6.16	1.55e-09	6.95e-07	0.32	0.27	Uric acid levels;	chr4:39114586	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs6812540	ENSG00000249685.1	RP11-360F5.3	6.16	1.55e-09	6.95e-07	0.32	0.27	Uric acid levels;	chr4:39114803	chr4:39133913~39135608:+
LUAD	cis	rs75422866	0.51	rs73105845	ENSG00000280054.1	RP1-197B17.7	6.16	1.55e-09	6.95e-07	0.63	0.27	Pneumonia;	chr12:47741824	chr12:47728151~47730598:-
LUAD	cis	rs11098499	0.644	rs7693919	ENSG00000248280.1	RP11-33B1.2	6.16	1.55e-09	6.95e-07	0.34	0.27	Corneal astigmatism;	chr4:119619416	chr4:119440561~119450157:-
LUAD	cis	rs11690935	0.589	rs6729945	ENSG00000228389.1	AC068039.4	-6.16	1.55e-09	6.95e-07	-0.29	-0.27	Schizophrenia;	chr2:171999788	chr2:171773482~171775844:+
LUAD	cis	rs4835473	0.932	rs9997931	ENSG00000251600.4	RP11-673E1.1	6.16	1.55e-09	6.96e-07	0.33	0.27	Immature fraction of reticulocytes;	chr4:143904601	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.897	rs2036880	ENSG00000251600.4	RP11-673E1.1	6.16	1.55e-09	6.96e-07	0.33	0.27	Immature fraction of reticulocytes;	chr4:143907834	chr4:143912331~143982454:+
LUAD	cis	rs3762637	1	rs72958458	ENSG00000272758.4	RP11-299J3.8	-6.16	1.56e-09	6.97e-07	-0.42	-0.27	LDL cholesterol levels;	chr3:122466702	chr3:122416207~122443180:+
LUAD	cis	rs3762637	1	rs7642869	ENSG00000272758.4	RP11-299J3.8	-6.16	1.56e-09	6.97e-07	-0.42	-0.27	LDL cholesterol levels;	chr3:122471939	chr3:122416207~122443180:+
LUAD	cis	rs3762637	1	rs7617042	ENSG00000272758.4	RP11-299J3.8	-6.16	1.56e-09	6.97e-07	-0.42	-0.27	LDL cholesterol levels;	chr3:122472138	chr3:122416207~122443180:+
LUAD	cis	rs3762637	1	rs6790051	ENSG00000272758.4	RP11-299J3.8	-6.16	1.56e-09	6.97e-07	-0.42	-0.27	LDL cholesterol levels;	chr3:122473999	chr3:122416207~122443180:+
LUAD	cis	rs3762637	1	rs9878699	ENSG00000272758.4	RP11-299J3.8	-6.16	1.56e-09	6.97e-07	-0.42	-0.27	LDL cholesterol levels;	chr3:122475384	chr3:122416207~122443180:+
LUAD	cis	rs3762637	1	rs12638866	ENSG00000272758.4	RP11-299J3.8	-6.16	1.56e-09	6.97e-07	-0.42	-0.27	LDL cholesterol levels;	chr3:122475535	chr3:122416207~122443180:+
LUAD	cis	rs7811142	1	rs73161762	ENSG00000242294.5	STAG3L5P	6.16	1.56e-09	6.97e-07	0.24	0.27	Platelet count;	chr7:100417223	chr7:100336079~100351900:+
LUAD	cis	rs11157436	0.918	rs1983519	ENSG00000211812.1	TRAV26-2	-6.16	1.56e-09	6.98e-07	-0.32	-0.27	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22150310	chr14:22202583~22203368:+
LUAD	cis	rs111580313	0.685	rs79088793	ENSG00000270020.1	RP11-463O9.9	6.16	1.56e-09	6.98e-07	0.65	0.27	Systemic juvenile idiopathic arthritis;	chr16:86573421	chr16:86520383~86523897:-
LUAD	cis	rs950169	0.519	rs7237	ENSG00000259728.4	LINC00933	6.16	1.56e-09	6.98e-07	0.4	0.27	Schizophrenia;	chr15:84643346	chr15:84570649~84580175:+
LUAD	cis	rs4273100	0.834	rs59415593	ENSG00000279825.1	CTC-457L16.1	6.16	1.56e-09	6.99e-07	0.36	0.27	Schizophrenia;	chr17:19319911	chr17:19030857~19033529:+
LUAD	cis	rs12699921	0.632	rs1524777	ENSG00000279048.1	RP11-511H23.2	-6.16	1.56e-09	6.99e-07	-0.22	-0.27	Fibrinogen levels;	chr7:17799986	chr7:17940503~17942922:+
LUAD	cis	rs10214930	0.651	rs42085	ENSG00000235574.1	AC073150.6	6.16	1.56e-09	7e-07	0.34	0.27	Hypospadias;	chr7:27658320	chr7:27491682~27492765:-
LUAD	cis	rs1499614	0.901	rs2178742	ENSG00000226824.5	RP4-756H11.3	-6.16	1.56e-09	7e-07	-0.52	-0.27	Gout;	chr7:66732812	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs73142166	ENSG00000232546.1	RP11-458F8.1	-6.16	1.56e-09	7e-07	-0.37	-0.27	Diabetic kidney disease;	chr7:65910845	chr7:66848496~66858136:+
LUAD	cis	rs11098499	0.644	rs28787668	ENSG00000248280.1	RP11-33B1.2	6.16	1.57e-09	7.01e-07	0.34	0.27	Corneal astigmatism;	chr4:119633532	chr4:119440561~119450157:-
LUAD	cis	rs6921919	0.583	rs6928771	ENSG00000204709.4	LINC01556	6.16	1.57e-09	7.01e-07	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs6928773	ENSG00000204709.4	LINC01556	6.16	1.57e-09	7.01e-07	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28943877~28944537:+
LUAD	cis	rs875971	0.545	rs316306	ENSG00000237310.1	GS1-124K5.4	-6.16	1.57e-09	7.02e-07	-0.34	-0.27	Aortic root size;	chr7:66153687	chr7:66493706~66495474:+
LUAD	cis	rs6991838	0.702	rs34496943	ENSG00000200714.1	Y_RNA	6.16	1.57e-09	7.02e-07	0.32	0.27	Intelligence (multi-trait analysis);	chr8:65676978	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.733	rs13281090	ENSG00000200714.1	Y_RNA	6.16	1.57e-09	7.02e-07	0.32	0.27	Intelligence (multi-trait analysis);	chr8:65678244	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.701	rs17395275	ENSG00000200714.1	Y_RNA	6.16	1.57e-09	7.02e-07	0.32	0.27	Intelligence (multi-trait analysis);	chr8:65679003	chr8:65592731~65592820:+
LUAD	cis	rs783540	0.967	rs2567635	ENSG00000278603.1	RP13-608F4.5	-6.16	1.57e-09	7.03e-07	-0.32	-0.27	Schizophrenia;	chr15:82593431	chr15:82472203~82472426:+
LUAD	cis	rs783540	0.933	rs2567636	ENSG00000278603.1	RP13-608F4.5	-6.16	1.57e-09	7.03e-07	-0.32	-0.27	Schizophrenia;	chr15:82594678	chr15:82472203~82472426:+
LUAD	cis	rs1816752	1	rs1816752	ENSG00000273628.1	RP11-756A22.7	6.16	1.57e-09	7.04e-07	0.32	0.27	Obesity-related traits;	chr13:24406811	chr13:24933006~24936796:+
LUAD	cis	rs875971	0.862	rs709596	ENSG00000222364.1	RNU6-96P	-6.16	1.57e-09	7.04e-07	-0.3	-0.27	Aortic root size;	chr7:66360926	chr7:66395191~66395286:+
LUAD	cis	rs12468226	0.938	rs79117531	ENSG00000272966.1	RP11-686O6.1	6.16	1.57e-09	7.04e-07	0.47	0.27	Urate levels;	chr2:202307690	chr2:202336739~202337200:+
LUAD	cis	rs1499614	1	rs1267818	ENSG00000232546.1	RP11-458F8.1	-6.16	1.57e-09	7.04e-07	-0.36	-0.27	Gout;	chr7:66642037	chr7:66848496~66858136:+
LUAD	cis	rs150992	0.592	rs10038192	ENSG00000248489.1	CTD-2007H13.3	6.16	1.58e-09	7.05e-07	0.3	0.27	Body mass index;	chr5:98989755	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.571	rs10045959	ENSG00000248489.1	CTD-2007H13.3	6.16	1.58e-09	7.05e-07	0.3	0.27	Body mass index;	chr5:98989767	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.571	rs10037147	ENSG00000248489.1	CTD-2007H13.3	6.16	1.58e-09	7.05e-07	0.3	0.27	Body mass index;	chr5:98989768	chr5:98929171~98995013:+
LUAD	cis	rs9910055	0.762	rs1135215	ENSG00000267080.4	ASB16-AS1	-6.16	1.58e-09	7.06e-07	-0.25	-0.27	Total body bone mineral density;	chr17:44176151	chr17:44175973~44186717:-
LUAD	cis	rs1823913	0.599	rs7598639	ENSG00000280083.1	RP11-317J9.1	-6.16	1.58e-09	7.06e-07	-0.32	-0.27	Obesity-related traits;	chr2:191267958	chr2:191154118~191156070:-
LUAD	cis	rs853679	0.598	rs9380054	ENSG00000204709.4	LINC01556	6.16	1.58e-09	7.07e-07	0.38	0.27	Depression;	chr6:28099759	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.547	rs2116981	ENSG00000204709.4	LINC01556	6.16	1.58e-09	7.07e-07	0.38	0.27	Parkinson's disease;	chr6:28100173	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9368552	ENSG00000204709.4	LINC01556	6.16	1.58e-09	7.07e-07	0.38	0.27	Depression;	chr6:28100648	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.542	rs34131763	ENSG00000204709.4	LINC01556	6.16	1.58e-09	7.07e-07	0.38	0.27	Depression;	chr6:28107222	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs35193936	ENSG00000204709.4	LINC01556	6.16	1.58e-09	7.07e-07	0.38	0.27	Depression;	chr6:28108492	chr6:28943877~28944537:+
LUAD	cis	rs17301013	0.507	rs12085652	ENSG00000227373.4	RP11-160H22.5	6.16	1.58e-09	7.07e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174588864	chr1:174115300~174160004:-
LUAD	cis	rs12699921	0.632	rs2691621	ENSG00000279048.1	RP11-511H23.2	-6.16	1.58e-09	7.07e-07	-0.22	-0.27	Fibrinogen levels;	chr7:17782826	chr7:17940503~17942922:+
LUAD	cis	rs67311347	1	rs4973997	ENSG00000223797.4	ENTPD3-AS1	6.16	1.58e-09	7.08e-07	0.28	0.27	Renal cell carcinoma;	chr3:40418654	chr3:40313802~40453329:-
LUAD	cis	rs950169	0.58	rs11634320	ENSG00000259728.4	LINC00933	-6.16	1.58e-09	7.08e-07	-0.39	-0.27	Schizophrenia;	chr15:84628952	chr15:84570649~84580175:+
LUAD	cis	rs2243480	1	rs316330	ENSG00000232546.1	RP11-458F8.1	-6.15	1.59e-09	7.1e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66140385	chr7:66848496~66858136:+
LUAD	cis	rs9549367	0.789	rs34568744	ENSG00000269125.1	RP11-98F14.11	-6.15	1.59e-09	7.1e-07	-0.33	-0.27	Platelet distribution width;	chr13:113240250	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.789	rs57747440	ENSG00000269125.1	RP11-98F14.11	-6.15	1.59e-09	7.1e-07	-0.33	-0.27	Platelet distribution width;	chr13:113240436	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.789	rs71446679	ENSG00000269125.1	RP11-98F14.11	-6.15	1.59e-09	7.1e-07	-0.33	-0.27	Platelet distribution width;	chr13:113240507	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.789	rs71446682	ENSG00000269125.1	RP11-98F14.11	-6.15	1.59e-09	7.1e-07	-0.33	-0.27	Platelet distribution width;	chr13:113240594	chr13:113165002~113165183:-
LUAD	cis	rs9532669	0.89	rs9532627	ENSG00000168852.11	TPTE2P5	6.15	1.59e-09	7.11e-07	0.26	0.27	Cervical cancer;	chr13:40874811	chr13:40822296~40921749:-
LUAD	cis	rs9928842	0.77	rs4888364	ENSG00000280152.1	RP11-331F4.5	6.15	1.59e-09	7.11e-07	0.3	0.27	Alcoholic chronic pancreatitis;	chr16:75245612	chr16:75245994~75250077:-
LUAD	cis	rs7246657	0.525	rs1667357	ENSG00000276846.1	CTD-3220F14.3	6.15	1.59e-09	7.11e-07	0.4	0.27	Coronary artery calcification;	chr19:36993450	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.525	rs1667359	ENSG00000276846.1	CTD-3220F14.3	6.15	1.59e-09	7.11e-07	0.4	0.27	Coronary artery calcification;	chr19:36995270	chr19:37314868~37315620:-
LUAD	cis	rs12699921	0.599	rs2723554	ENSG00000279048.1	RP11-511H23.2	-6.15	1.59e-09	7.12e-07	-0.22	-0.27	Fibrinogen levels;	chr7:17802029	chr7:17940503~17942922:+
LUAD	cis	rs4713118	0.869	rs6456802	ENSG00000219392.1	RP1-265C24.5	-6.15	1.59e-09	7.12e-07	-0.36	-0.27	Parkinson's disease;	chr6:27730576	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.869	rs9393851	ENSG00000219392.1	RP1-265C24.5	-6.15	1.59e-09	7.12e-07	-0.36	-0.27	Parkinson's disease;	chr6:27731802	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.869	rs9461400	ENSG00000219392.1	RP1-265C24.5	-6.15	1.59e-09	7.12e-07	-0.36	-0.27	Parkinson's disease;	chr6:27732780	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.869	rs9295742	ENSG00000219392.1	RP1-265C24.5	-6.15	1.59e-09	7.12e-07	-0.36	-0.27	Parkinson's disease;	chr6:27735053	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.869	rs9461401	ENSG00000219392.1	RP1-265C24.5	-6.15	1.59e-09	7.12e-07	-0.36	-0.27	Parkinson's disease;	chr6:27735512	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.869	rs6914924	ENSG00000219392.1	RP1-265C24.5	-6.15	1.59e-09	7.12e-07	-0.36	-0.27	Parkinson's disease;	chr6:27743751	chr6:28115628~28116551:+
LUAD	cis	rs8177376	0.953	rs529328	ENSG00000254905.1	RP11-712L6.7	6.15	1.59e-09	7.12e-07	0.37	0.27	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126263746	chr11:126292922~126294254:-
LUAD	cis	rs7246657	0.891	rs7253114	ENSG00000276846.1	CTD-3220F14.3	6.15	1.59e-09	7.13e-07	0.37	0.27	Coronary artery calcification;	chr19:37497823	chr19:37314868~37315620:-
LUAD	cis	rs12458462	0.892	rs3786228	ENSG00000274828.1	RP11-567M16.6	-6.15	1.6e-09	7.13e-07	-0.28	-0.27	Monocyte count;	chr18:79704170	chr18:79677287~79679358:-
LUAD	cis	rs12468226	1	rs7597469	ENSG00000226261.1	AC064836.3	6.15	1.6e-09	7.13e-07	0.45	0.27	Urate levels;	chr2:202329547	chr2:202336024~202336727:-
LUAD	cis	rs7684253	0.526	rs34112167	ENSG00000269949.1	RP11-738E22.3	-6.15	1.6e-09	7.13e-07	-0.36	-0.27	Migraine;	chr4:56853383	chr4:56960927~56961373:-
LUAD	cis	rs9467773	0.511	rs11755443	ENSG00000241549.7	GUSBP2	6.15	1.6e-09	7.14e-07	0.29	0.27	Intelligence (multi-trait analysis);	chr6:26923824	chr6:26871484~26956554:-
LUAD	cis	rs11971779	0.68	rs2355786	ENSG00000273391.1	RP11-634H22.1	-6.15	1.6e-09	7.14e-07	-0.28	-0.27	Diisocyanate-induced asthma;	chr7:139380876	chr7:139359032~139359566:-
LUAD	cis	rs783540	0.809	rs3970696	ENSG00000278603.1	RP13-608F4.5	6.15	1.6e-09	7.14e-07	0.31	0.27	Schizophrenia;	chr15:82595006	chr15:82472203~82472426:+
LUAD	cis	rs17301013	0.606	rs57407575	ENSG00000227373.4	RP11-160H22.5	6.15	1.6e-09	7.14e-07	0.39	0.27	Systemic lupus erythematosus;	chr1:174115504	chr1:174115300~174160004:-
LUAD	cis	rs2665103	0.61	rs1972460	ENSG00000278603.1	RP13-608F4.5	6.15	1.6e-09	7.14e-07	0.31	0.27	Intelligence (multi-trait analysis);	chr15:82238289	chr15:82472203~82472426:+
LUAD	cis	rs516805	0.748	rs572261	ENSG00000279453.1	RP3-425C14.4	-6.15	1.6e-09	7.15e-07	-0.37	-0.27	Lymphocyte counts;	chr6:122408877	chr6:122436789~122439223:-
LUAD	cis	rs2179367	0.568	rs9498358	ENSG00000231760.4	RP11-350J20.5	6.15	1.6e-09	7.16e-07	0.42	0.27	Dupuytren's disease;	chr6:149458529	chr6:149796151~149826294:-
LUAD	cis	rs853679	0.517	rs1947862	ENSG00000204709.4	LINC01556	6.15	1.6e-09	7.16e-07	0.38	0.27	Depression;	chr6:28137418	chr6:28943877~28944537:+
LUAD	cis	rs11098499	0.532	rs12512646	ENSG00000248280.1	RP11-33B1.2	6.15	1.6e-09	7.16e-07	0.34	0.27	Corneal astigmatism;	chr4:119664578	chr4:119440561~119450157:-
LUAD	cis	rs2179367	0.959	rs537354	ENSG00000231760.4	RP11-350J20.5	6.15	1.6e-09	7.16e-07	0.34	0.27	Dupuytren's disease;	chr6:149344801	chr6:149796151~149826294:-
LUAD	cis	rs7674212	0.531	rs2866416	ENSG00000251288.2	RP11-10L12.2	-6.15	1.6e-09	7.16e-07	-0.35	-0.27	Type 2 diabetes;	chr4:102959554	chr4:102751401~102752641:+
LUAD	cis	rs6921919	0.583	rs6908137	ENSG00000204709.4	LINC01556	6.15	1.61e-09	7.18e-07	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28943877~28944537:+
LUAD	cis	rs55665837	0.524	rs61884009	ENSG00000251991.1	RNU7-49P	6.15	1.61e-09	7.19e-07	0.31	0.27	Vitamin D levels;	chr11:14404916	chr11:14478892~14478953:+
LUAD	cis	rs4964805	0.549	rs1976256	ENSG00000257681.1	RP11-341G23.4	6.15	1.61e-09	7.2e-07	0.32	0.27	Attention deficit hyperactivity disorder;	chr12:103763121	chr12:103746315~103768858:-
LUAD	cis	rs9879311	0.966	rs7619385	ENSG00000240288.6	GHRLOS	6.15	1.61e-09	7.21e-07	0.25	0.27	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10373225	chr3:10285754~10293449:+
LUAD	cis	rs7618501	0.633	rs9866695	ENSG00000234667.1	ACTBP13	6.15	1.61e-09	7.21e-07	0.3	0.27	Intelligence (multi-trait analysis);	chr3:50032019	chr3:49873347~49877980:-
LUAD	cis	rs74233809	1	rs11191593	ENSG00000213277.3	MARCKSL1P1	6.15	1.62e-09	7.21e-07	0.45	0.27	Birth weight;	chr10:103179458	chr10:103175554~103176094:+
LUAD	cis	rs2739330	0.828	rs5760102	ENSG00000206090.4	AP000350.7	6.15	1.62e-09	7.21e-07	0.31	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23939998~23942798:+
LUAD	cis	rs453301	0.522	rs2929455	ENSG00000253893.2	FAM85B	6.15	1.62e-09	7.22e-07	0.34	0.27	Joint mobility (Beighton score);	chr8:9225923	chr8:8167819~8226614:-
LUAD	cis	rs11098499	0.644	rs10050092	ENSG00000248280.1	RP11-33B1.2	6.15	1.62e-09	7.23e-07	0.34	0.27	Corneal astigmatism;	chr4:119610930	chr4:119440561~119450157:-
LUAD	cis	rs7017914	0.905	rs12542300	ENSG00000223220.1	Y_RNA	-6.15	1.62e-09	7.23e-07	-0.3	-0.27	Bone mineral density;	chr8:71039160	chr8:70780914~70781008:-
LUAD	cis	rs17301013	0.566	rs72711492	ENSG00000227373.4	RP11-160H22.5	6.15	1.62e-09	7.23e-07	0.39	0.27	Systemic lupus erythematosus;	chr1:174195464	chr1:174115300~174160004:-
LUAD	cis	rs1062177	0.855	rs1346489	ENSG00000213433.5	RPLP1P6	-6.15	1.62e-09	7.23e-07	-0.34	-0.27	Preschool internalizing problems;	chr5:151886973	chr5:151765859~151766378:-
LUAD	cis	rs9549367	0.756	rs2302756	ENSG00000269125.1	RP11-98F14.11	6.15	1.62e-09	7.23e-07	0.33	0.27	Platelet distribution width;	chr13:113245883	chr13:113165002~113165183:-
LUAD	cis	rs6921919	0.638	rs9468344	ENSG00000204709.4	LINC01556	6.15	1.62e-09	7.23e-07	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28341792	chr6:28943877~28944537:+
LUAD	cis	rs875971	0.83	rs6976714	ENSG00000222364.1	RNU6-96P	-6.15	1.62e-09	7.24e-07	-0.3	-0.27	Aortic root size;	chr7:66426474	chr7:66395191~66395286:+
LUAD	cis	rs2179367	0.959	rs9390677	ENSG00000231760.4	RP11-350J20.5	6.15	1.62e-09	7.24e-07	0.34	0.27	Dupuytren's disease;	chr6:149389361	chr6:149796151~149826294:-
LUAD	cis	rs4713118	0.869	rs6930992	ENSG00000219392.1	RP1-265C24.5	-6.15	1.62e-09	7.24e-07	-0.36	-0.27	Parkinson's disease;	chr6:27744341	chr6:28115628~28116551:+
LUAD	cis	rs7221109	0.56	rs2253717	ENSG00000278834.1	RP11-458J1.1	-6.15	1.62e-09	7.24e-07	-0.32	-0.27	Type 1 diabetes;	chr17:40711984	chr17:40648300~40649718:+
LUAD	cis	rs1707322	0.752	rs7541962	ENSG00000234329.1	RP11-767N6.2	6.15	1.63e-09	7.26e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769445	chr1:45651039~45651826:-
LUAD	cis	rs4835473	0.932	rs1839448	ENSG00000251600.4	RP11-673E1.1	6.15	1.63e-09	7.26e-07	0.33	0.27	Immature fraction of reticulocytes;	chr4:143752113	chr4:143912331~143982454:+
LUAD	cis	rs1499614	1	rs2659913	ENSG00000230295.1	RP11-458F8.2	-6.15	1.63e-09	7.26e-07	-0.33	-0.27	Gout;	chr7:66692349	chr7:66880708~66882981:+
LUAD	cis	rs1499614	1	rs2659911	ENSG00000230295.1	RP11-458F8.2	-6.15	1.63e-09	7.26e-07	-0.33	-0.27	Gout;	chr7:66693433	chr7:66880708~66882981:+
LUAD	cis	rs1499614	1	rs2707838	ENSG00000230295.1	RP11-458F8.2	-6.15	1.63e-09	7.26e-07	-0.33	-0.27	Gout;	chr7:66694214	chr7:66880708~66882981:+
LUAD	cis	rs1499614	1	rs60326618	ENSG00000230295.1	RP11-458F8.2	-6.15	1.63e-09	7.26e-07	-0.33	-0.27	Gout;	chr7:66701371	chr7:66880708~66882981:+
LUAD	cis	rs1499614	1	rs2707830	ENSG00000230295.1	RP11-458F8.2	-6.15	1.63e-09	7.26e-07	-0.33	-0.27	Gout;	chr7:66702658	chr7:66880708~66882981:+
LUAD	cis	rs1499614	1	rs2707828	ENSG00000230295.1	RP11-458F8.2	-6.15	1.63e-09	7.26e-07	-0.33	-0.27	Gout;	chr7:66706390	chr7:66880708~66882981:+
LUAD	cis	rs1499614	0.803	rs1922723	ENSG00000230295.1	RP11-458F8.2	-6.15	1.63e-09	7.26e-07	-0.33	-0.27	Gout;	chr7:66710076	chr7:66880708~66882981:+
LUAD	cis	rs1499614	1	rs2659903	ENSG00000230295.1	RP11-458F8.2	-6.15	1.63e-09	7.26e-07	-0.33	-0.27	Gout;	chr7:66715944	chr7:66880708~66882981:+
LUAD	cis	rs1499614	1	rs2141924	ENSG00000230295.1	RP11-458F8.2	-6.15	1.63e-09	7.26e-07	-0.33	-0.27	Gout;	chr7:66721259	chr7:66880708~66882981:+
LUAD	cis	rs853679	0.607	rs35001169	ENSG00000204709.4	LINC01556	6.15	1.63e-09	7.26e-07	0.6	0.27	Depression;	chr6:28219854	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.546	rs35656932	ENSG00000204709.4	LINC01556	6.15	1.63e-09	7.26e-07	0.6	0.27	Depression;	chr6:28223510	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs34243448	ENSG00000204709.4	LINC01556	6.15	1.63e-09	7.26e-07	0.6	0.27	Depression;	chr6:28225324	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs13204012	ENSG00000204709.4	LINC01556	6.15	1.63e-09	7.26e-07	0.6	0.27	Depression;	chr6:28233753	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs13205211	ENSG00000204709.4	LINC01556	6.15	1.63e-09	7.26e-07	0.6	0.27	Depression;	chr6:28235278	chr6:28943877~28944537:+
LUAD	cis	rs10214930	0.697	rs12665991	ENSG00000235574.1	AC073150.6	-6.15	1.63e-09	7.28e-07	-0.34	-0.27	Hypospadias;	chr7:27620152	chr7:27491682~27492765:-
LUAD	cis	rs950169	1	rs1818950	ENSG00000259728.4	LINC00933	6.15	1.63e-09	7.28e-07	0.41	0.27	Schizophrenia;	chr15:84053769	chr15:84570649~84580175:+
LUAD	cis	rs1113500	0.933	rs1419003	ENSG00000226822.1	RP11-356N1.2	6.15	1.63e-09	7.29e-07	0.32	0.27	Growth-regulated protein alpha levels;	chr1:108074333	chr1:108071482~108074519:+
LUAD	cis	rs8100891	0.537	rs2111504	ENSG00000267213.4	AC007773.2	-6.15	1.63e-09	7.29e-07	-0.41	-0.27	Neuroticism;	chr19:32426549	chr19:32390050~32405560:-
LUAD	cis	rs17684571	0.872	rs34803237	ENSG00000231441.1	RP11-472M19.2	6.15	1.63e-09	7.29e-07	0.4	0.27	Schizophrenia;	chr6:56759620	chr6:56844002~56864078:+
LUAD	cis	rs2439831	0.867	rs2614811	ENSG00000205771.5	CATSPER2P1	-6.15	1.64e-09	7.32e-07	-0.5	-0.27	Lung cancer in ever smokers;	chr15:43621289	chr15:43726918~43747094:-
LUAD	cis	rs35740288	0.77	rs745191	ENSG00000202081.1	RNU6-1280P	6.15	1.64e-09	7.32e-07	0.34	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85579939	chr15:85651522~85651628:-
LUAD	cis	rs71403859	0.504	rs35203704	ENSG00000260886.1	TAT-AS1	6.15	1.64e-09	7.32e-07	0.49	0.27	Post bronchodilator FEV1;	chr16:71925758	chr16:71565789~71578187:+
LUAD	cis	rs1823913	0.599	rs55685315	ENSG00000280083.1	RP11-317J9.1	-6.15	1.64e-09	7.33e-07	-0.32	-0.27	Obesity-related traits;	chr2:191306451	chr2:191154118~191156070:-
LUAD	cis	rs17684571	0.872	rs34455199	ENSG00000231441.1	RP11-472M19.2	6.15	1.64e-09	7.33e-07	0.4	0.27	Schizophrenia;	chr6:56759780	chr6:56844002~56864078:+
LUAD	cis	rs1499614	1	rs1638731	ENSG00000230295.1	RP11-458F8.2	-6.15	1.65e-09	7.34e-07	-0.33	-0.27	Gout;	chr7:66679692	chr7:66880708~66882981:+
LUAD	cis	rs1499614	1	rs1882655	ENSG00000230295.1	RP11-458F8.2	6.15	1.65e-09	7.34e-07	0.33	0.27	Gout;	chr7:66682070	chr7:66880708~66882981:+
LUAD	cis	rs1499614	0.831	rs3800822	ENSG00000230295.1	RP11-458F8.2	6.15	1.65e-09	7.34e-07	0.33	0.27	Gout;	chr7:66682162	chr7:66880708~66882981:+
LUAD	cis	rs1707322	0.686	rs2152078	ENSG00000234329.1	RP11-767N6.2	-6.15	1.65e-09	7.35e-07	-0.29	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45589928	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.686	rs2991979	ENSG00000234329.1	RP11-767N6.2	-6.15	1.65e-09	7.35e-07	-0.29	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45590186	chr1:45651039~45651826:-
LUAD	cis	rs2408955	0.542	rs7975632	ENSG00000240399.1	RP1-228P16.1	6.15	1.65e-09	7.35e-07	0.27	0.27	Glycated hemoglobin levels;	chr12:48049265	chr12:48054813~48055591:-
LUAD	cis	rs2115536	1	rs11072871	ENSG00000278600.1	RP11-81A1.6	-6.15	1.65e-09	7.36e-07	-0.22	-0.27	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79905589	chr15:79920195~79922455:-
LUAD	cis	rs10740039	0.883	rs7920170	ENSG00000254271.1	RP11-131N11.4	6.15	1.65e-09	7.37e-07	0.31	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60647766	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs10761538	ENSG00000254271.1	RP11-131N11.4	6.15	1.65e-09	7.37e-07	0.31	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60649463	chr10:60734342~60741828:+
LUAD	cis	rs17023223	0.537	rs7532510	ENSG00000231365.4	RP11-418J17.1	-6.15	1.66e-09	7.38e-07	-0.36	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119051613	chr1:119140396~119275973:+
LUAD	cis	rs2243480	1	rs937108	ENSG00000226824.5	RP4-756H11.3	-6.15	1.66e-09	7.38e-07	-0.5	-0.27	Diabetic kidney disease;	chr7:65963465	chr7:66654538~66669855:+
LUAD	cis	rs10740039	0.516	rs7072678	ENSG00000254271.1	RP11-131N11.4	-6.15	1.66e-09	7.38e-07	-0.3	-0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60585011	chr10:60734342~60741828:+
LUAD	cis	rs10214930	0.767	rs42087	ENSG00000235574.1	AC073150.6	6.15	1.66e-09	7.4e-07	0.36	0.27	Hypospadias;	chr7:27660863	chr7:27491682~27492765:-
LUAD	cis	rs11690935	0.549	rs796839	ENSG00000228389.1	AC068039.4	-6.15	1.66e-09	7.4e-07	-0.29	-0.27	Schizophrenia;	chr2:172051486	chr2:171773482~171775844:+
LUAD	cis	rs11690935	0.549	rs2129475	ENSG00000228389.1	AC068039.4	-6.15	1.66e-09	7.4e-07	-0.29	-0.27	Schizophrenia;	chr2:172052044	chr2:171773482~171775844:+
LUAD	cis	rs950169	1	rs12902672	ENSG00000259728.4	LINC00933	6.15	1.66e-09	7.4e-07	0.41	0.27	Schizophrenia;	chr15:84048234	chr15:84570649~84580175:+
LUAD	cis	rs8062405	1	rs4451951	ENSG00000251417.2	RP11-1348G14.4	-6.15	1.66e-09	7.4e-07	-0.28	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28802743~28817828:+
LUAD	cis	rs8062405	0.964	rs11860513	ENSG00000251417.2	RP11-1348G14.4	-6.15	1.66e-09	7.4e-07	-0.28	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28802743~28817828:+
LUAD	cis	rs8177376	1	rs655540	ENSG00000254905.1	RP11-712L6.7	6.15	1.66e-09	7.4e-07	0.37	0.27	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126281347	chr11:126292922~126294254:-
LUAD	cis	rs4713118	0.868	rs9468220	ENSG00000219392.1	RP1-265C24.5	6.15	1.66e-09	7.41e-07	0.37	0.27	Parkinson's disease;	chr6:27765197	chr6:28115628~28116551:+
LUAD	cis	rs11157436	0.958	rs3811277	ENSG00000211812.1	TRAV26-2	-6.15	1.66e-09	7.42e-07	-0.32	-0.27	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22190419	chr14:22202583~22203368:+
LUAD	cis	rs875971	0.825	rs1129531	ENSG00000222364.1	RNU6-96P	6.15	1.67e-09	7.42e-07	0.31	0.27	Aortic root size;	chr7:66154117	chr7:66395191~66395286:+
LUAD	cis	rs6991838	0.798	rs62507575	ENSG00000200714.1	Y_RNA	6.15	1.67e-09	7.42e-07	0.32	0.27	Intelligence (multi-trait analysis);	chr8:65566486	chr8:65592731~65592820:+
LUAD	cis	rs853679	0.607	rs35749575	ENSG00000204709.4	LINC01556	6.15	1.67e-09	7.42e-07	0.6	0.27	Depression;	chr6:28147040	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs72846780	ENSG00000204709.4	LINC01556	6.15	1.67e-09	7.42e-07	0.6	0.27	Depression;	chr6:28151277	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9380056	ENSG00000204709.4	LINC01556	6.15	1.67e-09	7.44e-07	0.38	0.27	Depression;	chr6:28136698	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9380057	ENSG00000204709.4	LINC01556	6.15	1.67e-09	7.44e-07	0.38	0.27	Depression;	chr6:28136856	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs6941992	ENSG00000204709.4	LINC01556	6.15	1.67e-09	7.44e-07	0.38	0.27	Depression;	chr6:28138363	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.516	rs4713142	ENSG00000204709.4	LINC01556	6.15	1.67e-09	7.44e-07	0.38	0.27	Parkinson's disease;	chr6:28138569	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs4713143	ENSG00000204709.4	LINC01556	6.15	1.67e-09	7.44e-07	0.38	0.27	Depression;	chr6:28138981	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs4713144	ENSG00000204709.4	LINC01556	6.15	1.67e-09	7.44e-07	0.38	0.27	Depression;	chr6:28139012	chr6:28943877~28944537:+
LUAD	cis	rs783540	1	rs1267657	ENSG00000278603.1	RP13-608F4.5	-6.15	1.67e-09	7.45e-07	-0.32	-0.27	Schizophrenia;	chr15:82546501	chr15:82472203~82472426:+
LUAD	cis	rs783540	1	rs803688	ENSG00000278603.1	RP13-608F4.5	-6.15	1.67e-09	7.45e-07	-0.32	-0.27	Schizophrenia;	chr15:82548043	chr15:82472203~82472426:+
LUAD	cis	rs35740288	0.77	rs17570529	ENSG00000202081.1	RNU6-1280P	6.15	1.68e-09	7.47e-07	0.34	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85582376	chr15:85651522~85651628:-
LUAD	cis	rs2765539	0.59	rs912960	ENSG00000226172.2	RP4-712E4.1	-6.15	1.68e-09	7.47e-07	-0.34	-0.27	Waist-hip ratio;	chr1:118935879	chr1:119000344~119001392:-
LUAD	cis	rs7017914	0.87	rs2639953	ENSG00000223220.1	Y_RNA	6.15	1.68e-09	7.48e-07	0.3	0.27	Bone mineral density;	chr8:71013425	chr8:70780914~70781008:-
LUAD	cis	rs72772090	0.539	rs72775818	ENSG00000248734.2	CTD-2260A17.1	-6.15	1.68e-09	7.48e-07	-0.43	-0.27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96857512	chr5:96784777~96785999:+
LUAD	cis	rs11096990	0.892	rs11729098	ENSG00000249207.1	RP11-360F5.1	6.14	1.68e-09	7.48e-07	0.31	0.27	Cognitive function;	chr4:39232357	chr4:39112677~39126818:-
LUAD	cis	rs1823913	0.599	rs67781530	ENSG00000280083.1	RP11-317J9.1	-6.14	1.68e-09	7.48e-07	-0.33	-0.27	Obesity-related traits;	chr2:191295608	chr2:191154118~191156070:-
LUAD	cis	rs875971	0.651	rs2420596	ENSG00000222364.1	RNU6-96P	-6.14	1.69e-09	7.52e-07	-0.31	-0.27	Aortic root size;	chr7:66450996	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.52	rs2420597	ENSG00000222364.1	RNU6-96P	-6.14	1.69e-09	7.52e-07	-0.31	-0.27	Aortic root size;	chr7:66450999	chr7:66395191~66395286:+
LUAD	cis	rs1387259	0.57	rs12368659	ENSG00000240399.1	RP1-228P16.1	6.14	1.69e-09	7.52e-07	0.26	0.27	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48168516	chr12:48054813~48055591:-
LUAD	cis	rs9595908	0.709	rs55797910	ENSG00000212293.1	SNORA16	6.14	1.69e-09	7.52e-07	0.29	0.27	Body mass index;	chr13:32787154	chr13:32420390~32420516:-
LUAD	cis	rs1823874	1	rs1823874	ENSG00000182397.13	DNM1P46	-6.14	1.69e-09	7.53e-07	-0.3	-0.27	IgG glycosylation;	chr15:99817230	chr15:99790156~99806927:-
LUAD	cis	rs17818399	0.89	rs34544165	ENSG00000279254.1	RP11-536C12.1	-6.14	1.69e-09	7.54e-07	-0.3	-0.27	Height;	chr2:46609767	chr2:46668870~46670778:+
LUAD	cis	rs4835473	0.932	rs2127788	ENSG00000251600.4	RP11-673E1.1	6.14	1.69e-09	7.54e-07	0.33	0.27	Immature fraction of reticulocytes;	chr4:143741996	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs6852195	ENSG00000251600.4	RP11-673E1.1	6.14	1.69e-09	7.54e-07	0.33	0.27	Immature fraction of reticulocytes;	chr4:143742584	chr4:143912331~143982454:+
LUAD	cis	rs516805	0.961	rs573709	ENSG00000279453.1	RP3-425C14.4	6.14	1.69e-09	7.54e-07	0.31	0.27	Lymphocyte counts;	chr6:122457673	chr6:122436789~122439223:-
LUAD	cis	rs12554020	0.892	rs12555047	ENSG00000227603.1	RP11-165J3.6	6.14	1.7e-09	7.54e-07	0.43	0.27	Schizophrenia;	chr9:93424208	chr9:93435332~93437121:-
LUAD	cis	rs2034650	0.563	rs12914710	ENSG00000223313.1	RNU6-516P	6.14	1.7e-09	7.54e-07	0.34	0.27	Interstitial lung disease;	chr15:40421650	chr15:40529570~40529673:+
LUAD	cis	rs2303759	0.918	rs9749416	ENSG00000268686.1	AC010524.2	-6.14	1.7e-09	7.56e-07	-0.38	-0.27	Multiple sclerosis;	chr19:49381748	chr19:49368705~49388081:-
LUAD	cis	rs35740288	0.77	rs62023931	ENSG00000202081.1	RNU6-1280P	6.14	1.7e-09	7.56e-07	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85589521	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.77	rs1382534	ENSG00000202081.1	RNU6-1280P	6.14	1.7e-09	7.56e-07	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85598939	chr15:85651522~85651628:-
LUAD	cis	rs2980439	0.607	rs2980419	ENSG00000253893.2	FAM85B	-6.14	1.7e-09	7.56e-07	-0.35	-0.27	Neuroticism;	chr8:8256619	chr8:8167819~8226614:-
LUAD	cis	rs2243480	1	rs6964530	ENSG00000226824.5	RP4-756H11.3	6.14	1.7e-09	7.56e-07	0.51	0.27	Diabetic kidney disease;	chr7:66253864	chr7:66654538~66669855:+
LUAD	cis	rs11098499	0.955	rs1511019	ENSG00000248280.1	RP11-33B1.2	6.14	1.7e-09	7.56e-07	0.34	0.27	Corneal astigmatism;	chr4:119244852	chr4:119440561~119450157:-
LUAD	cis	rs10129255	0.957	rs11846893	ENSG00000211974.3	IGHV2-70	6.14	1.7e-09	7.56e-07	0.28	0.27	Kawasaki disease;	chr14:106779068	chr14:106723574~106724093:-
LUAD	cis	rs875971	0.545	rs4441996	ENSG00000226824.5	RP4-756H11.3	6.14	1.7e-09	7.56e-07	0.39	0.27	Aortic root size;	chr7:66123233	chr7:66654538~66669855:+
LUAD	cis	rs10050311	0.79	rs61651372	ENSG00000251411.1	RP11-397E7.4	-6.14	1.7e-09	7.57e-07	-0.36	-0.27	Insulin-related traits;	chr4:86912903	chr4:86913266~86914817:-
LUAD	cis	rs1062177	1	rs12654573	ENSG00000213433.5	RPLP1P6	-6.14	1.7e-09	7.58e-07	-0.36	-0.27	Preschool internalizing problems;	chr5:151827912	chr5:151765859~151766378:-
LUAD	cis	rs948562	0.744	rs11229485	ENSG00000280010.1	AP001350.4	6.14	1.7e-09	7.58e-07	0.41	0.27	Lymphoma;	chr11:58465381	chr11:58627435~58628528:+
LUAD	cis	rs1799949	1	rs12944597	ENSG00000267681.1	CTD-3199J23.6	-6.14	1.71e-09	7.59e-07	-0.32	-0.27	Menopause (age at onset);	chr17:43035667	chr17:43144956~43145255:+
LUAD	cis	rs2243480	1	rs10807702	ENSG00000230295.1	RP11-458F8.2	-6.14	1.71e-09	7.6e-07	-0.32	-0.27	Diabetic kidney disease;	chr7:66302856	chr7:66880708~66882981:+
LUAD	cis	rs2412819	0.571	rs12900924	ENSG00000249839.1	AC011330.5	-6.14	1.71e-09	7.61e-07	-0.45	-0.27	Lung cancer;	chr15:43737329	chr15:43663654~43684339:-
LUAD	cis	rs7246657	0.943	rs2045908	ENSG00000276846.1	CTD-3220F14.3	6.14	1.71e-09	7.61e-07	0.37	0.27	Coronary artery calcification;	chr19:37488866	chr19:37314868~37315620:-
LUAD	cis	rs875971	0.545	rs3735147	ENSG00000226824.5	RP4-756H11.3	-6.14	1.71e-09	7.61e-07	-0.39	-0.27	Aortic root size;	chr7:66505541	chr7:66654538~66669855:+
LUAD	cis	rs7849270	0.959	rs713218	ENSG00000268707.1	RP11-247A12.7	-6.14	1.71e-09	7.62e-07	-0.3	-0.27	Blood metabolite ratios;	chr9:129138491	chr9:129170434~129170940:+
LUAD	cis	rs17301013	0.606	rs56239105	ENSG00000227373.4	RP11-160H22.5	6.14	1.72e-09	7.63e-07	0.38	0.27	Systemic lupus erythematosus;	chr1:174179346	chr1:174115300~174160004:-
LUAD	cis	rs227932	0.51	rs10950957	ENSG00000234286.1	AC006026.13	6.14	1.72e-09	7.63e-07	0.39	0.27	Schizophrenia;	chr7:23723661	chr7:23680195~23680786:-
LUAD	cis	rs17301013	0.507	rs1754354	ENSG00000227373.4	RP11-160H22.5	-6.14	1.72e-09	7.64e-07	-0.39	-0.27	Systemic lupus erythematosus;	chr1:174817196	chr1:174115300~174160004:-
LUAD	cis	rs367615	0.68	rs31595	ENSG00000249476.1	CTD-2587M2.1	6.14	1.72e-09	7.64e-07	0.34	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109643617	chr5:109237120~109326369:-
LUAD	cis	rs853679	0.607	rs68188794	ENSG00000204709.4	LINC01556	6.14	1.72e-09	7.65e-07	0.62	0.27	Depression;	chr6:28112999	chr6:28943877~28944537:+
LUAD	cis	rs67311347	1	rs6599102	ENSG00000223797.4	ENTPD3-AS1	6.14	1.72e-09	7.65e-07	0.28	0.27	Renal cell carcinoma;	chr3:40426915	chr3:40313802~40453329:-
LUAD	cis	rs1061377	1	rs6829450	ENSG00000249685.1	RP11-360F5.3	6.14	1.72e-09	7.65e-07	0.32	0.27	Uric acid levels;	chr4:39114721	chr4:39133913~39135608:+
LUAD	cis	rs2243480	1	rs35542501	ENSG00000226824.5	RP4-756H11.3	-6.14	1.72e-09	7.65e-07	-0.5	-0.27	Diabetic kidney disease;	chr7:65966228	chr7:66654538~66669855:+
LUAD	cis	rs2243480	0.708	rs781141	ENSG00000226824.5	RP4-756H11.3	-6.14	1.72e-09	7.65e-07	-0.5	-0.27	Diabetic kidney disease;	chr7:65973566	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs781142	ENSG00000226824.5	RP4-756H11.3	-6.14	1.72e-09	7.65e-07	-0.5	-0.27	Diabetic kidney disease;	chr7:65973791	chr7:66654538~66669855:+
LUAD	cis	rs11098499	0.754	rs4107728	ENSG00000248280.1	RP11-33B1.2	6.14	1.73e-09	7.67e-07	0.33	0.27	Corneal astigmatism;	chr4:119332755	chr4:119440561~119450157:-
LUAD	cis	rs4713118	0.869	rs6902689	ENSG00000219392.1	RP1-265C24.5	-6.14	1.73e-09	7.68e-07	-0.36	-0.27	Parkinson's disease;	chr6:27741662	chr6:28115628~28116551:+
LUAD	cis	rs7176527	0.8	rs56747535	ENSG00000188388.10	GOLGA6L3	6.14	1.73e-09	7.69e-07	0.39	0.27	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84632709	chr15:85240472~85247170:+
LUAD	cis	rs74233809	1	rs732998	ENSG00000213277.3	MARCKSL1P1	-6.14	1.73e-09	7.7e-07	-0.43	-0.27	Birth weight;	chr10:103138144	chr10:103175554~103176094:+
LUAD	cis	rs875971	0.862	rs2024192	ENSG00000237310.1	GS1-124K5.4	-6.14	1.73e-09	7.7e-07	-0.29	-0.27	Aortic root size;	chr7:66576460	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs4718377	ENSG00000237310.1	GS1-124K5.4	-6.14	1.73e-09	7.7e-07	-0.29	-0.27	Aortic root size;	chr7:66584691	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs10278014	ENSG00000237310.1	GS1-124K5.4	-6.14	1.73e-09	7.7e-07	-0.29	-0.27	Aortic root size;	chr7:66586277	chr7:66493706~66495474:+
LUAD	cis	rs2408955	0.501	rs8716	ENSG00000240399.1	RP1-228P16.1	6.14	1.73e-09	7.7e-07	0.26	0.27	Glycated hemoglobin levels;	chr12:48145699	chr12:48054813~48055591:-
LUAD	cis	rs6921919	0.609	rs1005127	ENSG00000216901.1	AL022393.7	6.14	1.73e-09	7.7e-07	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28399881	chr6:28176188~28176674:+
LUAD	cis	rs853679	0.515	rs4580862	ENSG00000216901.1	AL022393.7	6.14	1.73e-09	7.7e-07	0.33	0.27	Depression;	chr6:28399886	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs4357130	ENSG00000216901.1	AL022393.7	6.14	1.73e-09	7.7e-07	0.33	0.27	Autism spectrum disorder or schizophrenia;	chr6:28399906	chr6:28176188~28176674:+
LUAD	cis	rs7044106	0.762	rs7357638	ENSG00000238181.2	AHCYP2	-6.14	1.74e-09	7.71e-07	-0.35	-0.27	Hip circumference adjusted for BMI;	chr9:120626926	chr9:120720673~120721972:+
LUAD	cis	rs7044106	0.718	rs1960421	ENSG00000238181.2	AHCYP2	-6.14	1.74e-09	7.71e-07	-0.35	-0.27	Hip circumference adjusted for BMI;	chr9:120632616	chr9:120720673~120721972:+
LUAD	cis	rs11096990	0.855	rs3796524	ENSG00000249207.1	RP11-360F5.1	6.14	1.74e-09	7.72e-07	0.31	0.27	Cognitive function;	chr4:39194367	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.892	rs4974924	ENSG00000249207.1	RP11-360F5.1	6.14	1.74e-09	7.72e-07	0.31	0.27	Cognitive function;	chr4:39196091	chr4:39112677~39126818:-
LUAD	cis	rs7567389	0.504	rs13030463	ENSG00000236682.1	AC068282.3	-6.14	1.74e-09	7.72e-07	-0.35	-0.27	Self-rated health;	chr2:127431295	chr2:127389130~127400580:+
LUAD	cis	rs6860806	0.507	rs272854	ENSG00000233006.5	AC034220.3	6.14	1.74e-09	7.72e-07	0.27	0.27	Breast cancer;	chr5:132352324	chr5:132311285~132369916:-
LUAD	cis	rs12699921	0.632	rs2691581	ENSG00000279048.1	RP11-511H23.2	-6.14	1.74e-09	7.72e-07	-0.22	-0.27	Fibrinogen levels;	chr7:17789568	chr7:17940503~17942922:+
LUAD	cis	rs1062177	0.756	rs2915817	ENSG00000213433.5	RPLP1P6	6.14	1.74e-09	7.72e-07	0.35	0.27	Preschool internalizing problems;	chr5:151735956	chr5:151765859~151766378:-
LUAD	cis	rs948562	0.793	rs79869893	ENSG00000280010.1	AP001350.4	6.14	1.74e-09	7.73e-07	0.46	0.27	Lymphoma;	chr11:58514409	chr11:58627435~58628528:+
LUAD	cis	rs12908161	0.959	rs2175567	ENSG00000259728.4	LINC00933	6.14	1.74e-09	7.73e-07	0.39	0.27	Schizophrenia;	chr15:84657715	chr15:84570649~84580175:+
LUAD	cis	rs4141404	0.923	rs2413035	ENSG00000236132.1	CTA-440B3.1	6.14	1.74e-09	7.73e-07	0.34	0.27	Paclitaxel-induced neuropathy;	chr22:31204474	chr22:31816379~31817491:-
LUAD	cis	rs507080	0.501	rs637563	ENSG00000278376.1	RP11-158I9.8	-6.14	1.74e-09	7.74e-07	-0.28	-0.27	Serum metabolite levels;	chr11:118704770	chr11:118791254~118793137:+
LUAD	cis	rs8072100	0.811	rs1912483	ENSG00000228782.6	CTD-2026D20.3	6.14	1.74e-09	7.74e-07	0.29	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47366128	chr17:47450568~47492492:-
LUAD	cis	rs75422866	0.764	rs73104177	ENSG00000257433.4	RP1-197B17.3	6.14	1.74e-09	7.75e-07	0.64	0.27	Pneumonia;	chr12:47713550	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.764	rs73104184	ENSG00000257433.4	RP1-197B17.3	6.14	1.74e-09	7.75e-07	0.64	0.27	Pneumonia;	chr12:47715623	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.764	rs73104188	ENSG00000257433.4	RP1-197B17.3	6.14	1.74e-09	7.75e-07	0.64	0.27	Pneumonia;	chr12:47715885	chr12:47706085~47742294:+
LUAD	cis	rs2243480	1	rs34136756	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65916269	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs78803505	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65917585	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs34933526	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65918212	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs34577383	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65920739	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs6949812	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65922114	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs55895244	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65922691	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs6970243	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65923503	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs7794661	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65924743	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs7795242	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65925107	chr7:66880708~66882981:+
LUAD	cis	rs2243480	0.708	rs35310401	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65925372	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs35058610	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65925938	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs2177703	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65926730	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs35432774	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65928032	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs56985706	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65929575	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs60683927	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65929781	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs58062456	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65929865	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs34529418	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65938222	chr7:66880708~66882981:+
LUAD	cis	rs2243480	0.901	rs35087093	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65940221	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs35046236	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65943626	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs36068983	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65944004	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs68189316	ENSG00000230295.1	RP11-458F8.2	-6.14	1.75e-09	7.76e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65944182	chr7:66880708~66882981:+
LUAD	cis	rs2243480	0.831	rs7806717	ENSG00000230295.1	RP11-458F8.2	6.14	1.75e-09	7.76e-07	0.33	0.27	Diabetic kidney disease;	chr7:65928187	chr7:66880708~66882981:+
LUAD	cis	rs891378	0.793	rs12021745	ENSG00000274245.1	RP11-357P18.2	6.14	1.75e-09	7.76e-07	0.37	0.27	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207293254	chr1:207372559~207373252:+
LUAD	cis	rs7017914	0.905	rs3110244	ENSG00000223220.1	Y_RNA	-6.14	1.75e-09	7.76e-07	-0.3	-0.27	Bone mineral density;	chr8:71020962	chr8:70780914~70781008:-
LUAD	cis	rs4964805	0.549	rs11111752	ENSG00000257681.1	RP11-341G23.4	6.14	1.75e-09	7.76e-07	0.32	0.27	Attention deficit hyperactivity disorder;	chr12:103762774	chr12:103746315~103768858:-
LUAD	cis	rs9549367	0.789	rs2316442	ENSG00000269125.1	RP11-98F14.11	-6.14	1.75e-09	7.77e-07	-0.34	-0.27	Platelet distribution width;	chr13:113223173	chr13:113165002~113165183:-
LUAD	cis	rs55665837	1	rs4412729	ENSG00000251991.1	RNU7-49P	6.14	1.75e-09	7.77e-07	0.3	0.27	Vitamin D levels;	chr11:14417454	chr11:14478892~14478953:+
LUAD	cis	rs2404602	0.684	rs12437981	ENSG00000259422.1	RP11-593F23.1	-6.14	1.75e-09	7.77e-07	-0.36	-0.27	Blood metabolite levels;	chr15:76550060	chr15:76174891~76181486:-
LUAD	cis	rs1707322	0.627	rs3014213	ENSG00000234329.1	RP11-767N6.2	-6.14	1.75e-09	7.78e-07	-0.29	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45579850	chr1:45651039~45651826:-
LUAD	cis	rs2179367	0.959	rs4895788	ENSG00000231760.4	RP11-350J20.5	6.14	1.75e-09	7.78e-07	0.33	0.27	Dupuytren's disease;	chr6:149426955	chr6:149796151~149826294:-
LUAD	cis	rs12699921	0.568	rs2691605	ENSG00000279048.1	RP11-511H23.2	-6.14	1.76e-09	7.8e-07	-0.22	-0.27	Fibrinogen levels;	chr7:17837825	chr7:17940503~17942922:+
LUAD	cis	rs4835473	0.932	rs7356157	ENSG00000251600.4	RP11-673E1.1	6.14	1.76e-09	7.81e-07	0.33	0.27	Immature fraction of reticulocytes;	chr4:143739233	chr4:143912331~143982454:+
LUAD	cis	rs4713118	0.869	rs9468214	ENSG00000219392.1	RP1-265C24.5	-6.14	1.76e-09	7.81e-07	-0.36	-0.27	Parkinson's disease;	chr6:27745520	chr6:28115628~28116551:+
LUAD	cis	rs11098499	0.644	rs7676296	ENSG00000248280.1	RP11-33B1.2	6.14	1.76e-09	7.82e-07	0.34	0.27	Corneal astigmatism;	chr4:119634532	chr4:119440561~119450157:-
LUAD	cis	rs12439619	0.508	rs11856561	ENSG00000276710.3	CSPG4P8	-6.14	1.76e-09	7.82e-07	-0.25	-0.27	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82459472~82477258:+
LUAD	cis	rs9549367	0.773	rs9549717	ENSG00000269125.1	RP11-98F14.11	-6.14	1.77e-09	7.83e-07	-0.33	-0.27	Platelet distribution width;	chr13:113254512	chr13:113165002~113165183:-
LUAD	cis	rs67311347	1	rs12638199	ENSG00000223797.4	ENTPD3-AS1	6.14	1.77e-09	7.83e-07	0.28	0.27	Renal cell carcinoma;	chr3:40433794	chr3:40313802~40453329:-
LUAD	cis	rs9318086	0.648	rs4067969	ENSG00000205861.10	C1QTNF9B-AS1	-6.14	1.77e-09	7.84e-07	-0.33	-0.27	Myopia (pathological);	chr13:23894981	chr13:23888889~23897263:+
LUAD	cis	rs12699921	0.558	rs2691559	ENSG00000279048.1	RP11-511H23.2	-6.14	1.77e-09	7.84e-07	-0.22	-0.27	Fibrinogen levels;	chr7:17905636	chr7:17940503~17942922:+
LUAD	cis	rs7182621	0.846	rs12915935	ENSG00000182397.13	DNM1P46	6.14	1.77e-09	7.84e-07	0.32	0.27	Colonoscopy-negative controls vs population controls;	chr15:99871875	chr15:99790156~99806927:-
LUAD	cis	rs1823913	0.637	rs897197	ENSG00000280083.1	RP11-317J9.1	6.14	1.77e-09	7.86e-07	0.32	0.27	Obesity-related traits;	chr2:191281456	chr2:191154118~191156070:-
LUAD	cis	rs3738443	0.868	rs7546908	ENSG00000259865.1	RP11-488L18.10	-6.14	1.77e-09	7.87e-07	-0.27	-0.27	Alcohol dependence;	chr1:247200531	chr1:247187281~247188526:-
LUAD	cis	rs10214930	0.671	rs6959495	ENSG00000235574.1	AC073150.6	-6.14	1.78e-09	7.87e-07	-0.34	-0.27	Hypospadias;	chr7:27652673	chr7:27491682~27492765:-
LUAD	cis	rs11098499	0.754	rs12513083	ENSG00000248280.1	RP11-33B1.2	6.14	1.78e-09	7.88e-07	0.33	0.27	Corneal astigmatism;	chr4:119328457	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs12509621	ENSG00000248280.1	RP11-33B1.2	6.14	1.78e-09	7.88e-07	0.33	0.27	Corneal astigmatism;	chr4:119328505	chr4:119440561~119450157:-
LUAD	cis	rs7615952	0.866	rs1976459	ENSG00000171084.14	FAM86JP	6.14	1.78e-09	7.88e-07	0.39	0.27	Blood pressure (smoking interaction);	chr3:125928643	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.932	rs1976458	ENSG00000171084.14	FAM86JP	6.14	1.78e-09	7.88e-07	0.39	0.27	Blood pressure (smoking interaction);	chr3:125928669	chr3:125916620~125930024:+
LUAD	cis	rs7181230	0.813	rs4924417	ENSG00000275636.1	RP11-521C20.5	6.14	1.78e-09	7.88e-07	0.36	0.27	Dehydroepiandrosterone sulphate levels;	chr15:40074738	chr15:40078892~40079347:+
LUAD	cis	rs2179367	0.959	rs9377212	ENSG00000231760.4	RP11-350J20.5	6.14	1.78e-09	7.88e-07	0.33	0.27	Dupuytren's disease;	chr6:149383765	chr6:149796151~149826294:-
LUAD	cis	rs11603023	0.967	rs7936556	ENSG00000255422.1	AP002954.4	6.13	1.78e-09	7.89e-07	0.32	0.27	Cholesterol, total;	chr11:118630582	chr11:118704607~118750263:+
LUAD	cis	rs155076	1	rs261369	ENSG00000233325.3	MIPEPP3	6.13	1.79e-09	7.92e-07	0.43	0.27	White matter hyperintensity burden;	chr13:21294281	chr13:21298139~21306373:+
LUAD	cis	rs113835537	0.569	rs17496586	ENSG00000255517.5	CTD-3074O7.5	-6.13	1.79e-09	7.92e-07	-0.34	-0.27	Airway imaging phenotypes;	chr11:66548041	chr11:66473490~66480233:-
LUAD	cis	rs875971	0.545	rs1638735	ENSG00000237310.1	GS1-124K5.4	6.13	1.79e-09	7.93e-07	0.32	0.27	Aortic root size;	chr7:66630751	chr7:66493706~66495474:+
LUAD	cis	rs9847710	0.733	rs9818819	ENSG00000242142.1	SERBP1P3	6.13	1.79e-09	7.94e-07	0.31	0.27	Ulcerative colitis;	chr3:53042739	chr3:53064283~53065091:-
LUAD	cis	rs7743045	0.777	rs6916491	ENSG00000253194.1	RP11-351A11.1	6.13	1.79e-09	7.95e-07	0.36	0.27	Mean platelet volume;	chr6:118926569	chr6:118934785~119031541:+
LUAD	cis	rs10214930	0.957	rs7786569	ENSG00000235574.1	AC073150.6	6.13	1.8e-09	7.96e-07	0.39	0.27	Hypospadias;	chr7:27682832	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.957	rs42113	ENSG00000235574.1	AC073150.6	6.13	1.8e-09	7.96e-07	0.39	0.27	Hypospadias;	chr7:27682977	chr7:27491682~27492765:-
LUAD	cis	rs66887589	0.72	rs2036858	ENSG00000248280.1	RP11-33B1.2	6.13	1.8e-09	7.96e-07	0.31	0.27	Diastolic blood pressure;	chr4:119328082	chr4:119440561~119450157:-
LUAD	cis	rs11676348	0.772	rs12471105	ENSG00000261338.2	RP11-378A13.1	-6.13	1.8e-09	7.97e-07	-0.28	-0.27	Ulcerative colitis;	chr2:218085486	chr2:218255319~218257366:+
LUAD	cis	rs9595908	0.869	rs55880225	ENSG00000212293.1	SNORA16	6.13	1.8e-09	7.98e-07	0.29	0.27	Body mass index;	chr13:32616733	chr13:32420390~32420516:-
LUAD	cis	rs853679	0.55	rs1150689	ENSG00000204709.4	LINC01556	6.13	1.8e-09	7.98e-07	0.37	0.27	Depression;	chr6:28197321	chr6:28943877~28944537:+
LUAD	cis	rs6504622	0.791	rs61671555	ENSG00000262879.4	RP11-156P1.3	6.13	1.8e-09	7.99e-07	0.32	0.27	Orofacial clefts;	chr17:46960491	chr17:46984045~47100323:-
LUAD	cis	rs2115630	0.645	rs1107179	ENSG00000229212.6	RP11-561C5.4	-6.13	1.8e-09	7.99e-07	-0.32	-0.27	P wave terminal force;	chr15:84655131	chr15:85205440~85234795:-
LUAD	cis	rs10214930	0.697	rs12670771	ENSG00000235574.1	AC073150.6	-6.13	1.81e-09	8.01e-07	-0.34	-0.27	Hypospadias;	chr7:27616971	chr7:27491682~27492765:-
LUAD	cis	rs853679	0.546	rs13213986	ENSG00000204709.4	LINC01556	6.13	1.81e-09	8.01e-07	0.61	0.27	Depression;	chr6:28390232	chr6:28943877~28944537:+
LUAD	cis	rs1823913	0.637	rs979967	ENSG00000227542.1	AC092614.2	6.13	1.81e-09	8.02e-07	0.33	0.27	Obesity-related traits;	chr2:191304695	chr2:191229165~191246172:-
LUAD	cis	rs875971	0.83	rs12673450	ENSG00000237310.1	GS1-124K5.4	6.13	1.81e-09	8.02e-07	0.3	0.27	Aortic root size;	chr7:66544233	chr7:66493706~66495474:+
LUAD	cis	rs12468226	0.873	rs79071680	ENSG00000226261.1	AC064836.3	6.13	1.81e-09	8.02e-07	0.46	0.27	Urate levels;	chr2:202191520	chr2:202336024~202336727:-
LUAD	cis	rs12468226	0.873	rs79860867	ENSG00000226261.1	AC064836.3	6.13	1.81e-09	8.02e-07	0.46	0.27	Urate levels;	chr2:202192397	chr2:202336024~202336727:-
LUAD	cis	rs2404602	0.647	rs2404604	ENSG00000259422.1	RP11-593F23.1	-6.13	1.81e-09	8.02e-07	-0.36	-0.27	Blood metabolite levels;	chr15:76698764	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.591	rs11635162	ENSG00000259422.1	RP11-593F23.1	-6.13	1.81e-09	8.03e-07	-0.39	-0.27	Blood metabolite levels;	chr15:76658764	chr15:76174891~76181486:-
LUAD	cis	rs2243480	1	rs73150014	ENSG00000230295.1	RP11-458F8.2	-6.13	1.82e-09	8.04e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65985932	chr7:66880708~66882981:+
LUAD	cis	rs8072100	0.84	rs1912482	ENSG00000228782.6	CTD-2026D20.3	6.13	1.82e-09	8.05e-07	0.29	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47377517	chr17:47450568~47492492:-
LUAD	cis	rs8072100	0.84	rs2136751	ENSG00000228782.6	CTD-2026D20.3	6.13	1.82e-09	8.05e-07	0.29	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378727	chr17:47450568~47492492:-
LUAD	cis	rs17301013	0.606	rs1417186	ENSG00000227373.4	RP11-160H22.5	-6.13	1.82e-09	8.05e-07	-0.38	-0.27	Systemic lupus erythematosus;	chr1:174171090	chr1:174115300~174160004:-
LUAD	cis	rs3762637	0.769	rs13317855	ENSG00000272758.4	RP11-299J3.8	-6.13	1.82e-09	8.05e-07	-0.48	-0.27	LDL cholesterol levels;	chr3:122385387	chr3:122416207~122443180:+
LUAD	cis	rs494459	0.838	rs607125	ENSG00000278376.1	RP11-158I9.8	-6.13	1.82e-09	8.05e-07	-0.29	-0.27	Height;	chr11:118746590	chr11:118791254~118793137:+
LUAD	cis	rs2243480	0.711	rs1626926	ENSG00000232546.1	RP11-458F8.1	-6.13	1.82e-09	8.05e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:65970805	chr7:66848496~66858136:+
LUAD	cis	rs957448	1	rs12680965	ENSG00000253704.1	RP11-267M23.4	6.13	1.82e-09	8.06e-07	0.34	0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94554069	chr8:94553722~94569745:+
LUAD	cis	rs7646881	0.812	rs9864589	ENSG00000240207.5	RP11-379F4.4	-6.13	1.82e-09	8.06e-07	-0.33	-0.27	Tetralogy of Fallot;	chr3:158712917	chr3:158732263~158784070:+
LUAD	cis	rs4835473	0.932	rs12512649	ENSG00000251600.4	RP11-673E1.1	-6.13	1.82e-09	8.06e-07	-0.32	-0.27	Immature fraction of reticulocytes;	chr4:143736745	chr4:143912331~143982454:+
LUAD	cis	rs1113500	0.933	rs11185250	ENSG00000226822.1	RP11-356N1.2	6.13	1.82e-09	8.07e-07	0.32	0.27	Growth-regulated protein alpha levels;	chr1:108073795	chr1:108071482~108074519:+
LUAD	cis	rs9309711	0.736	rs9309717	ENSG00000225234.1	TRAPPC12-AS1	6.13	1.83e-09	8.08e-07	0.32	0.27	Neurofibrillary tangles;	chr2:3491307	chr2:3481242~3482409:-
LUAD	cis	rs17301013	0.606	rs56404641	ENSG00000227373.4	RP11-160H22.5	6.13	1.83e-09	8.08e-07	0.38	0.27	Systemic lupus erythematosus;	chr1:174176323	chr1:174115300~174160004:-
LUAD	cis	rs11157436	0.915	rs11622938	ENSG00000211812.1	TRAV26-2	-6.13	1.83e-09	8.08e-07	-0.31	-0.27	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22183456	chr14:22202583~22203368:+
LUAD	cis	rs1729407	0.774	rs2849167	ENSG00000280143.1	AP000892.6	-6.13	1.83e-09	8.08e-07	-0.3	-0.27	Apolipoprotein A-IV levels;	chr11:116814028	chr11:117204967~117210292:+
LUAD	cis	rs3762637	0.943	rs10222564	ENSG00000272758.4	RP11-299J3.8	-6.13	1.83e-09	8.1e-07	-0.4	-0.27	LDL cholesterol levels;	chr3:122547489	chr3:122416207~122443180:+
LUAD	cis	rs1707322	0.686	rs3014251	ENSG00000234329.1	RP11-767N6.2	-6.13	1.83e-09	8.11e-07	-0.29	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45611756	chr1:45651039~45651826:-
LUAD	cis	rs270601	0.633	rs733300	ENSG00000233006.5	AC034220.3	6.13	1.84e-09	8.12e-07	0.25	0.27	Acylcarnitine levels;	chr5:132236550	chr5:132311285~132369916:-
LUAD	cis	rs270601	0.633	rs4535443	ENSG00000233006.5	AC034220.3	6.13	1.84e-09	8.12e-07	0.25	0.27	Acylcarnitine levels;	chr5:132236868	chr5:132311285~132369916:-
LUAD	cis	rs2117029	0.587	rs57853986	ENSG00000258017.1	RP11-386G11.10	-6.13	1.84e-09	8.14e-07	-0.33	-0.27	Intelligence (multi-trait analysis);	chr12:49124612	chr12:49127782~49147869:+
LUAD	cis	rs11676348	0.712	rs11687434	ENSG00000261338.2	RP11-378A13.1	-6.13	1.84e-09	8.15e-07	-0.28	-0.27	Ulcerative colitis;	chr2:218080420	chr2:218255319~218257366:+
LUAD	cis	rs853679	0.55	rs1233707	ENSG00000204709.4	LINC01556	6.13	1.84e-09	8.15e-07	0.37	0.27	Depression;	chr6:28205175	chr6:28943877~28944537:+
LUAD	cis	rs6772849	0.93	rs4857914	ENSG00000242551.2	POU5F1P6	-6.13	1.85e-09	8.17e-07	-0.31	-0.27	Monocyte percentage of white cells;Monocyte count;	chr3:128631841	chr3:128674735~128677005:-
LUAD	cis	rs2276314	0.793	rs77590522	ENSG00000278986.1	RP11-723J4.3	-6.13	1.85e-09	8.18e-07	-0.33	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36049447	chr18:35972151~35973916:+
LUAD	cis	rs494459	0.964	rs576283	ENSG00000278376.1	RP11-158I9.8	-6.13	1.86e-09	8.2e-07	-0.28	-0.27	Height;	chr11:118703185	chr11:118791254~118793137:+
LUAD	cis	rs507080	0.524	rs524409	ENSG00000278376.1	RP11-158I9.8	-6.13	1.86e-09	8.2e-07	-0.28	-0.27	Serum metabolite levels;	chr11:118703602	chr11:118791254~118793137:+
LUAD	cis	rs9309473	1	rs1881245	ENSG00000163016.8	ALMS1P	6.13	1.86e-09	8.2e-07	0.33	0.27	Metabolite levels;	chr2:73422800	chr2:73644919~73685576:+
LUAD	cis	rs853679	0.546	rs36092177	ENSG00000204709.4	LINC01556	6.13	1.86e-09	8.21e-07	0.6	0.27	Depression;	chr6:28390030	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.546	rs2232429	ENSG00000204709.4	LINC01556	6.13	1.86e-09	8.21e-07	0.6	0.27	Depression;	chr6:28391855	chr6:28943877~28944537:+
LUAD	cis	rs11690935	0.55	rs6730085	ENSG00000228389.1	AC068039.4	-6.13	1.86e-09	8.21e-07	-0.29	-0.27	Schizophrenia;	chr2:171999938	chr2:171773482~171775844:+
LUAD	cis	rs4820294	1	rs62236665	ENSG00000233360.4	Z83844.1	6.13	1.86e-09	8.22e-07	0.28	0.27	Fat distribution (HIV);	chr22:37663840	chr22:37641832~37658377:-
LUAD	cis	rs4820294	1	rs78974622	ENSG00000233360.4	Z83844.1	6.13	1.86e-09	8.22e-07	0.28	0.27	Fat distribution (HIV);	chr22:37663918	chr22:37641832~37658377:-
LUAD	cis	rs1499614	1	rs1267817	ENSG00000232546.1	RP11-458F8.1	-6.13	1.86e-09	8.22e-07	-0.36	-0.27	Gout;	chr7:66645053	chr7:66848496~66858136:+
LUAD	cis	rs293748	0.882	rs245588	ENSG00000250155.1	CTD-2353F22.1	-6.13	1.86e-09	8.23e-07	-0.38	-0.27	Obesity-related traits;	chr5:36923108	chr5:36666214~36725195:-
LUAD	cis	rs1707322	0.717	rs12023439	ENSG00000234329.1	RP11-767N6.2	6.13	1.86e-09	8.23e-07	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638964	chr1:45651039~45651826:-
LUAD	cis	rs17711722	0.522	rs4642526	ENSG00000236529.1	RP13-254B10.1	6.13	1.86e-09	8.24e-07	0.27	0.27	Calcium levels;	chr7:65751755	chr7:65840212~65840596:+
LUAD	cis	rs10129255	0.509	rs756583	ENSG00000224373.3	IGHV4-59	6.13	1.86e-09	8.24e-07	0.16	0.27	Kawasaki disease;	chr14:106680002	chr14:106627249~106627825:-
LUAD	cis	rs2442825	0.693	rs2596913	ENSG00000206573.7	THUMPD3-AS1	6.13	1.86e-09	8.24e-07	0.2	0.27	Cerebrospinal fluid clusterin levels;	chr3:9394788	chr3:9349689~9398579:-
LUAD	cis	rs875971	0.965	rs7794930	ENSG00000222364.1	RNU6-96P	6.13	1.87e-09	8.24e-07	0.3	0.27	Aortic root size;	chr7:66313559	chr7:66395191~66395286:+
LUAD	cis	rs11157436	0.914	rs7142794	ENSG00000211812.1	TRAV26-2	-6.13	1.87e-09	8.25e-07	-0.31	-0.27	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22238175	chr14:22202583~22203368:+
LUAD	cis	rs10050311	0.858	rs72667703	ENSG00000251411.1	RP11-397E7.4	-6.13	1.87e-09	8.25e-07	-0.38	-0.27	Insulin-related traits;	chr4:86891825	chr4:86913266~86914817:-
LUAD	cis	rs4654783	1	rs4654783	ENSG00000228397.1	RP1-224A6.3	6.13	1.87e-09	8.26e-07	0.36	0.27	Endometriosis;	chr1:22113027	chr1:22023994~22024968:-
LUAD	cis	rs1930961	0.558	rs5996951	ENSG00000272977.1	CTA-390C10.10	-6.13	1.87e-09	8.26e-07	-0.39	-0.27	Bipolar disorder with mood-incongruent psychosis;	chr22:25529032	chr22:25476218~25479971:+
LUAD	cis	rs853679	0.55	rs1225599	ENSG00000204709.4	LINC01556	6.13	1.87e-09	8.26e-07	0.37	0.27	Depression;	chr6:28197412	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.574	rs1233705	ENSG00000204709.4	LINC01556	6.13	1.87e-09	8.26e-07	0.37	0.27	Depression;	chr6:28198669	chr6:28943877~28944537:+
LUAD	cis	rs7923609	0.756	rs7910951	ENSG00000232075.1	MRPL35P2	6.13	1.87e-09	8.27e-07	0.33	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63578544	chr10:63634317~63634827:-
LUAD	cis	rs12699921	0.599	rs9942602	ENSG00000279048.1	RP11-511H23.2	6.13	1.87e-09	8.27e-07	0.22	0.27	Fibrinogen levels;	chr7:17937431	chr7:17940503~17942922:+
LUAD	cis	rs11098499	0.532	rs4504231	ENSG00000248280.1	RP11-33B1.2	6.13	1.87e-09	8.27e-07	0.34	0.27	Corneal astigmatism;	chr4:119665736	chr4:119440561~119450157:-
LUAD	cis	rs875971	0.502	rs6460311	ENSG00000237310.1	GS1-124K5.4	-6.13	1.87e-09	8.28e-07	-0.34	-0.27	Aortic root size;	chr7:66646886	chr7:66493706~66495474:+
LUAD	cis	rs7945705	1	rs7937298	ENSG00000254860.4	TMEM9B-AS1	-6.13	1.88e-09	8.29e-07	-0.32	-0.27	Hemoglobin concentration;	chr11:8845962	chr11:8964675~8977527:+
LUAD	cis	rs8177876	0.749	rs79834398	ENSG00000261061.1	RP11-303E16.2	-6.13	1.88e-09	8.29e-07	-0.46	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81057033	chr16:81030770~81031485:+
LUAD	cis	rs71403859	0.502	rs34766979	ENSG00000260886.1	TAT-AS1	6.13	1.88e-09	8.29e-07	0.45	0.27	Post bronchodilator FEV1;	chr16:71441608	chr16:71565789~71578187:+
LUAD	cis	rs6921919	0.583	rs2041230	ENSG00000204709.4	LINC01556	6.13	1.88e-09	8.29e-07	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:28943877~28944537:+
LUAD	cis	rs7615952	0.558	rs17334039	ENSG00000171084.14	FAM86JP	6.13	1.88e-09	8.3e-07	0.38	0.27	Blood pressure (smoking interaction);	chr3:125821465	chr3:125916620~125930024:+
LUAD	cis	rs74233809	0.901	rs12416331	ENSG00000213277.3	MARCKSL1P1	6.13	1.88e-09	8.3e-07	0.46	0.27	Birth weight;	chr10:103169157	chr10:103175554~103176094:+
LUAD	cis	rs1823913	0.599	rs17346412	ENSG00000280083.1	RP11-317J9.1	-6.13	1.88e-09	8.3e-07	-0.32	-0.27	Obesity-related traits;	chr2:191285902	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.599	rs17412239	ENSG00000280083.1	RP11-317J9.1	-6.13	1.88e-09	8.3e-07	-0.32	-0.27	Obesity-related traits;	chr2:191285937	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.599	rs35098152	ENSG00000280083.1	RP11-317J9.1	-6.13	1.88e-09	8.3e-07	-0.32	-0.27	Obesity-related traits;	chr2:191286658	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.599	rs35150635	ENSG00000280083.1	RP11-317J9.1	-6.13	1.88e-09	8.3e-07	-0.32	-0.27	Obesity-related traits;	chr2:191287303	chr2:191154118~191156070:-
LUAD	cis	rs17301013	0.507	rs12097931	ENSG00000227373.4	RP11-160H22.5	6.13	1.88e-09	8.31e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174454841	chr1:174115300~174160004:-
LUAD	cis	rs7927592	0.956	rs7124078	ENSG00000212093.1	AP000807.1	6.13	1.88e-09	8.31e-07	0.3	0.27	Total body bone mineral density;	chr11:68531165	chr11:68506083~68506166:-
LUAD	cis	rs9595908	0.709	rs7318563	ENSG00000212293.1	SNORA16	6.13	1.88e-09	8.32e-07	0.29	0.27	Body mass index;	chr13:32749348	chr13:32420390~32420516:-
LUAD	cis	rs4713118	0.869	rs9366700	ENSG00000219392.1	RP1-265C24.5	-6.13	1.88e-09	8.32e-07	-0.36	-0.27	Parkinson's disease;	chr6:27729172	chr6:28115628~28116551:+
LUAD	cis	rs17301013	0.507	rs10912817	ENSG00000227373.4	RP11-160H22.5	6.13	1.89e-09	8.32e-07	0.4	0.27	Systemic lupus erythematosus;	chr1:174615581	chr1:174115300~174160004:-
LUAD	cis	rs12439619	0.53	rs7162177	ENSG00000276710.3	CSPG4P8	-6.13	1.89e-09	8.32e-07	-0.25	-0.27	Intelligence (multi-trait analysis);	chr15:82181728	chr15:82459472~82477258:+
LUAD	cis	rs10129255	0.957	rs8009464	ENSG00000211974.3	IGHV2-70	6.12	1.89e-09	8.33e-07	0.28	0.27	Kawasaki disease;	chr14:106777611	chr14:106723574~106724093:-
LUAD	cis	rs11098499	0.526	rs10026625	ENSG00000248280.1	RP11-33B1.2	6.12	1.89e-09	8.33e-07	0.31	0.27	Corneal astigmatism;	chr4:119358981	chr4:119440561~119450157:-
LUAD	cis	rs948562	0.69	rs60200286	ENSG00000280010.1	AP001350.4	6.12	1.89e-09	8.33e-07	0.42	0.27	Lymphoma;	chr11:58347242	chr11:58627435~58628528:+
LUAD	cis	rs494459	0.838	rs632124	ENSG00000278376.1	RP11-158I9.8	-6.12	1.89e-09	8.34e-07	-0.28	-0.27	Height;	chr11:118742526	chr11:118791254~118793137:+
LUAD	cis	rs875971	0.928	rs2036263	ENSG00000237310.1	GS1-124K5.4	-6.12	1.89e-09	8.34e-07	-0.29	-0.27	Aortic root size;	chr7:66335210	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs10240949	ENSG00000237310.1	GS1-124K5.4	-6.12	1.89e-09	8.34e-07	-0.29	-0.27	Aortic root size;	chr7:66339430	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs7782704	ENSG00000237310.1	GS1-124K5.4	-6.12	1.89e-09	8.34e-07	-0.29	-0.27	Aortic root size;	chr7:66340379	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs6959268	ENSG00000237310.1	GS1-124K5.4	-6.12	1.89e-09	8.34e-07	-0.29	-0.27	Aortic root size;	chr7:66347979	chr7:66493706~66495474:+
LUAD	cis	rs853679	0.546	rs13195291	ENSG00000204709.4	LINC01556	6.12	1.89e-09	8.34e-07	0.59	0.27	Depression;	chr6:28201463	chr6:28943877~28944537:+
LUAD	cis	rs7182621	0.546	rs11632596	ENSG00000259363.4	CTD-2054N24.2	-6.12	1.89e-09	8.35e-07	-0.36	-0.27	Colonoscopy-negative controls vs population controls;	chr15:99834385	chr15:99807023~99877148:+
LUAD	cis	rs875971	0.545	rs73152714	ENSG00000226824.5	RP4-756H11.3	-6.12	1.89e-09	8.36e-07	-0.39	-0.27	Aortic root size;	chr7:66534641	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.545	rs4718364	ENSG00000226824.5	RP4-756H11.3	-6.12	1.89e-09	8.36e-07	-0.39	-0.27	Aortic root size;	chr7:66536353	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.545	rs6961853	ENSG00000226824.5	RP4-756H11.3	-6.12	1.89e-09	8.36e-07	-0.39	-0.27	Aortic root size;	chr7:66537035	chr7:66654538~66669855:+
LUAD	cis	rs1823874	0.581	rs11855419	ENSG00000182397.13	DNM1P46	6.12	1.9e-09	8.36e-07	0.32	0.27	IgG glycosylation;	chr15:99787275	chr15:99790156~99806927:-
LUAD	cis	rs10214930	0.697	rs12537499	ENSG00000235574.1	AC073150.6	6.12	1.9e-09	8.37e-07	0.34	0.27	Hypospadias;	chr7:27551976	chr7:27491682~27492765:-
LUAD	cis	rs2303759	0.881	rs10412811	ENSG00000268686.1	AC010524.2	-6.12	1.9e-09	8.39e-07	-0.39	-0.27	Multiple sclerosis;	chr19:49381238	chr19:49368705~49388081:-
LUAD	cis	rs694739	0.536	rs671976	ENSG00000236935.1	AP003774.1	6.12	1.9e-09	8.39e-07	0.25	0.27	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64278557	chr11:64325050~64329504:-
LUAD	cis	rs62402013	1	rs62402013	ENSG00000241549.7	GUSBP2	6.12	1.9e-09	8.39e-07	0.3	0.27	Schizophrenia;	chr6:26947221	chr6:26871484~26956554:-
LUAD	cis	rs10129255	0.536	rs8004835	ENSG00000224373.3	IGHV4-59	6.12	1.9e-09	8.39e-07	0.16	0.27	Kawasaki disease;	chr14:106686361	chr14:106627249~106627825:-
LUAD	cis	rs1426063	0.614	rs76087197	ENSG00000249717.1	RP11-44F21.3	6.12	1.91e-09	8.4e-07	0.5	0.27	QT interval;	chr4:75134108	chr4:74955974~74970362:-
LUAD	cis	rs9847710	0.733	rs2581808	ENSG00000242142.1	SERBP1P3	6.12	1.91e-09	8.41e-07	0.31	0.27	Ulcerative colitis;	chr3:53055429	chr3:53064283~53065091:-
LUAD	cis	rs9847710	0.733	rs2581809	ENSG00000242142.1	SERBP1P3	6.12	1.91e-09	8.41e-07	0.31	0.27	Ulcerative colitis;	chr3:53055667	chr3:53064283~53065091:-
LUAD	cis	rs7829975	0.688	rs6601703	ENSG00000253981.4	ALG1L13P	6.12	1.91e-09	8.42e-07	0.31	0.27	Mood instability;	chr8:8522714	chr8:8236003~8244667:-
LUAD	cis	rs7923609	0.811	rs12245367	ENSG00000232075.1	MRPL35P2	6.12	1.91e-09	8.43e-07	0.32	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63561704	chr10:63634317~63634827:-
LUAD	cis	rs17301013	0.606	rs12077529	ENSG00000227373.4	RP11-160H22.5	6.12	1.91e-09	8.43e-07	0.37	0.27	Systemic lupus erythematosus;	chr1:174549874	chr1:174115300~174160004:-
LUAD	cis	rs9910055	0.718	rs7212854	ENSG00000267080.4	ASB16-AS1	-6.12	1.91e-09	8.44e-07	-0.25	-0.27	Total body bone mineral density;	chr17:44177049	chr17:44175973~44186717:-
LUAD	cis	rs875971	1	rs9986696	ENSG00000222364.1	RNU6-96P	6.12	1.92e-09	8.46e-07	0.3	0.27	Aortic root size;	chr7:66239589	chr7:66395191~66395286:+
LUAD	cis	rs11690935	0.632	rs34242651	ENSG00000228389.1	AC068039.4	-6.12	1.92e-09	8.48e-07	-0.29	-0.27	Schizophrenia;	chr2:171697489	chr2:171773482~171775844:+
LUAD	cis	rs4718428	0.705	rs28648401	ENSG00000232546.1	RP11-458F8.1	-6.12	1.93e-09	8.49e-07	-0.26	-0.27	Corneal structure;	chr7:66902145	chr7:66848496~66858136:+
LUAD	cis	rs7176527	1	rs3762168	ENSG00000188388.10	GOLGA6L3	6.12	1.93e-09	8.49e-07	0.37	0.27	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84599416	chr15:85240472~85247170:+
LUAD	cis	rs8072100	1	rs7210738	ENSG00000228782.6	CTD-2026D20.3	-6.12	1.93e-09	8.5e-07	-0.29	-0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47680232	chr17:47450568~47492492:-
LUAD	cis	rs2404602	0.684	rs8029283	ENSG00000259422.1	RP11-593F23.1	-6.12	1.93e-09	8.51e-07	-0.35	-0.27	Blood metabolite levels;	chr15:76544799	chr15:76174891~76181486:-
LUAD	cis	rs2946504	0.506	rs9644017	ENSG00000251468.2	RP11-369K16.1	-6.12	1.93e-09	8.51e-07	-0.34	-0.27	Type 2 diabetes;	chr8:12961375	chr8:12958387~12962200:+
LUAD	cis	rs2115630	0.645	rs2292463	ENSG00000229212.6	RP11-561C5.4	6.12	1.93e-09	8.52e-07	0.31	0.27	P wave terminal force;	chr15:84632519	chr15:85205440~85234795:-
LUAD	cis	rs944289	0.504	rs107196	ENSG00000257826.1	RP11-116N8.4	6.12	1.93e-09	8.52e-07	0.28	0.27	Thyroid cancer;	chr14:36054892	chr14:36061026~36067190:-
LUAD	cis	rs10759883	0.525	rs1556026	ENSG00000175611.10	LINC00476	6.12	1.93e-09	8.52e-07	0.32	0.27	Nicotine dependence;	chr9:96046454	chr9:95759231~95875977:-
LUAD	cis	rs8177376	0.953	rs73017385	ENSG00000254905.1	RP11-712L6.7	6.12	1.94e-09	8.52e-07	0.39	0.27	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126309680	chr11:126292922~126294254:-
LUAD	cis	rs1113500	0.836	rs1618973	ENSG00000226822.1	RP11-356N1.2	-6.12	1.94e-09	8.53e-07	-0.32	-0.27	Growth-regulated protein alpha levels;	chr1:108044145	chr1:108071482~108074519:+
LUAD	cis	rs7017914	0.905	rs1389206	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71012627	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs2639955	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71013107	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.869	rs2639954	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71013340	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.837	rs2639952	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71013495	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs2732108	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71013864	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs2732109	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71013988	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs1493203	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71014272	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs2732110	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71014576	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs2639951	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71014990	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs2732112	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71015606	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.811	rs1389204	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71016063	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs2732113	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71016314	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs2732114	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71016477	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs2732116	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71017092	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs2956610	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71017298	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs3098868	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71017457	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs3098870	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71017700	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs3110240	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71017869	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.875	rs3098871	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71018180	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs3098873	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71020351	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs3110241	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71020729	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs3110242	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71020732	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs3110243	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71020834	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.87	rs3098874	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71022103	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs3110247	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71022652	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs3110248	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71022700	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs3110249	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71023310	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs3098876	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71024009	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.87	rs3098877	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71024211	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.875	rs3110251	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71024739	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs3110252	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71024985	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs3110253	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71025318	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs3110254	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71025627	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.87	rs3110256	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71025901	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs3110257	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71025916	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs3098879	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71026225	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.935	rs3110258	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71026297	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.87	rs3098880	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71026686	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs3098881	ENSG00000223220.1	Y_RNA	6.12	1.94e-09	8.53e-07	0.3	0.27	Bone mineral density;	chr8:71027455	chr8:70780914~70781008:-
LUAD	cis	rs7615952	0.611	rs2947646	ENSG00000171084.14	FAM86JP	-6.12	1.94e-09	8.54e-07	-0.47	-0.27	Blood pressure (smoking interaction);	chr3:125874759	chr3:125916620~125930024:+
LUAD	cis	rs10129255	0.536	rs8004835	ENSG00000211970.3	IGHV4-61	-6.12	1.94e-09	8.55e-07	-0.19	-0.27	Kawasaki disease;	chr14:106686361	chr14:106639119~106639657:-
LUAD	cis	rs36093844	0.66	rs12274717	ENSG00000279742.1	RP11-700A24.1	-6.12	1.94e-09	8.55e-07	-0.36	-0.27	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85866671	chr11:85852557~85854943:-
LUAD	cis	rs853679	0.517	rs9380052	ENSG00000204709.4	LINC01556	6.12	1.94e-09	8.55e-07	0.37	0.27	Depression;	chr6:28096845	chr6:28943877~28944537:+
LUAD	cis	rs4820294	1	rs732856	ENSG00000233360.4	Z83844.1	-6.12	1.95e-09	8.57e-07	-0.28	-0.27	Fat distribution (HIV);	chr22:37664684	chr22:37641832~37658377:-
LUAD	cis	rs2117029	0.619	rs2241727	ENSG00000258017.1	RP11-386G11.10	-6.12	1.95e-09	8.58e-07	-0.33	-0.27	Intelligence (multi-trait analysis);	chr12:49131225	chr12:49127782~49147869:+
LUAD	cis	rs11098499	0.57	rs6832740	ENSG00000248280.1	RP11-33B1.2	6.12	1.95e-09	8.58e-07	0.34	0.27	Corneal astigmatism;	chr4:119624981	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.644	rs6855918	ENSG00000248280.1	RP11-33B1.2	6.12	1.95e-09	8.58e-07	0.34	0.27	Corneal astigmatism;	chr4:119625144	chr4:119440561~119450157:-
LUAD	cis	rs1823913	0.599	rs55786000	ENSG00000280083.1	RP11-317J9.1	-6.12	1.95e-09	8.59e-07	-0.32	-0.27	Obesity-related traits;	chr2:191284500	chr2:191154118~191156070:-
LUAD	cis	rs8072100	0.905	rs9895274	ENSG00000228782.6	CTD-2026D20.3	6.12	1.96e-09	8.6e-07	0.28	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47461751	chr17:47450568~47492492:-
LUAD	cis	rs10214930	0.752	rs2391448	ENSG00000235574.1	AC073150.6	-6.12	1.96e-09	8.61e-07	-0.36	-0.27	Hypospadias;	chr7:27638566	chr7:27491682~27492765:-
LUAD	cis	rs2439831	0.85	rs7179388	ENSG00000205771.5	CATSPER2P1	-6.12	1.96e-09	8.61e-07	-0.59	-0.27	Lung cancer in ever smokers;	chr15:43831747	chr15:43726918~43747094:-
LUAD	cis	rs7567389	0.504	rs1568278	ENSG00000236682.1	AC068282.3	-6.12	1.96e-09	8.61e-07	-0.35	-0.27	Self-rated health;	chr2:127432619	chr2:127389130~127400580:+
LUAD	cis	rs10214930	0.706	rs4722726	ENSG00000235574.1	AC073150.6	-6.12	1.96e-09	8.61e-07	-0.36	-0.27	Hypospadias;	chr7:27654589	chr7:27491682~27492765:-
LUAD	cis	rs7626444	0.584	rs11711813	ENSG00000272359.1	U4	-6.12	1.96e-09	8.61e-07	-0.3	-0.27	Monocyte count;	chr3:196740467	chr3:196747192~196747324:-
LUAD	cis	rs7927592	0.956	rs12365160	ENSG00000212093.1	AP000807.1	6.12	1.96e-09	8.62e-07	0.3	0.27	Total body bone mineral density;	chr11:68482951	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.956	rs11228256	ENSG00000212093.1	AP000807.1	6.12	1.96e-09	8.62e-07	0.3	0.27	Total body bone mineral density;	chr11:68483992	chr11:68506083~68506166:-
LUAD	cis	rs6844153	0.752	rs7681462	ENSG00000240005.4	RP11-293A21.1	-6.12	1.96e-09	8.63e-07	-0.39	-0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26894272	chr4:26859806~26860599:-
LUAD	cis	rs7246657	0.551	rs4806414	ENSG00000276846.1	CTD-3220F14.3	6.12	1.96e-09	8.63e-07	0.42	0.27	Coronary artery calcification;	chr19:37147886	chr19:37314868~37315620:-
LUAD	cis	rs4908768	0.539	rs7537982	ENSG00000232912.4	RP5-1115A15.1	6.12	1.96e-09	8.64e-07	0.25	0.27	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8583948	chr1:8424645~8434838:+
LUAD	cis	rs1799949	0.965	rs9897425	ENSG00000267681.1	CTD-3199J23.6	-6.12	1.96e-09	8.64e-07	-0.3	-0.27	Menopause (age at onset);	chr17:43352811	chr17:43144956~43145255:+
LUAD	cis	rs7923609	0.756	rs7911761	ENSG00000232075.1	MRPL35P2	6.12	1.97e-09	8.64e-07	0.33	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63578993	chr10:63634317~63634827:-
LUAD	cis	rs1113500	0.933	rs61797345	ENSG00000226822.1	RP11-356N1.2	6.12	1.97e-09	8.64e-07	0.31	0.27	Growth-regulated protein alpha levels;	chr1:108081106	chr1:108071482~108074519:+
LUAD	cis	rs7017914	0.905	rs2732094	ENSG00000223220.1	Y_RNA	6.12	1.97e-09	8.65e-07	0.3	0.27	Bone mineral density;	chr8:71007683	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs2732095	ENSG00000223220.1	Y_RNA	6.12	1.97e-09	8.65e-07	0.3	0.27	Bone mineral density;	chr8:71007711	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.87	rs2732096	ENSG00000223220.1	Y_RNA	6.12	1.97e-09	8.65e-07	0.3	0.27	Bone mineral density;	chr8:71007745	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.935	rs2732097	ENSG00000223220.1	Y_RNA	6.12	1.97e-09	8.65e-07	0.3	0.27	Bone mineral density;	chr8:71007778	chr8:70780914~70781008:-
LUAD	cis	rs10214930	0.697	rs1052741	ENSG00000235574.1	AC073150.6	-6.12	1.97e-09	8.65e-07	-0.34	-0.27	Hypospadias;	chr7:27525542	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs1052724	ENSG00000235574.1	AC073150.6	-6.12	1.97e-09	8.65e-07	-0.34	-0.27	Hypospadias;	chr7:27525587	chr7:27491682~27492765:-
LUAD	cis	rs2034650	0.544	rs600791	ENSG00000223313.1	RNU6-516P	6.12	1.97e-09	8.65e-07	0.35	0.27	Interstitial lung disease;	chr15:40428868	chr15:40529570~40529673:+
LUAD	cis	rs1113500	0.836	rs2801220	ENSG00000226822.1	RP11-356N1.2	-6.12	1.97e-09	8.65e-07	-0.32	-0.27	Growth-regulated protein alpha levels;	chr1:108042027	chr1:108071482~108074519:+
LUAD	cis	rs2243480	1	rs67728539	ENSG00000230295.1	RP11-458F8.2	-6.12	1.97e-09	8.66e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65913137	chr7:66880708~66882981:+
LUAD	cis	rs7221109	0.533	rs7210983	ENSG00000278834.1	RP11-458J1.1	6.12	1.97e-09	8.66e-07	0.31	0.27	Type 1 diabetes;	chr17:40660862	chr17:40648300~40649718:+
LUAD	cis	rs7674212	0.531	rs6816370	ENSG00000251288.2	RP11-10L12.2	-6.12	1.97e-09	8.67e-07	-0.35	-0.27	Type 2 diabetes;	chr4:103018276	chr4:102751401~102752641:+
LUAD	cis	rs853679	0.657	rs1778483	ENSG00000216901.1	AL022393.7	6.12	1.97e-09	8.67e-07	0.33	0.27	Depression;	chr6:28273214	chr6:28176188~28176674:+
LUAD	cis	rs853679	0.657	rs1778482	ENSG00000216901.1	AL022393.7	6.12	1.97e-09	8.67e-07	0.33	0.27	Depression;	chr6:28273215	chr6:28176188~28176674:+
LUAD	cis	rs17301013	0.507	rs72717608	ENSG00000227373.4	RP11-160H22.5	6.12	1.98e-09	8.68e-07	0.42	0.27	Systemic lupus erythematosus;	chr1:174788316	chr1:174115300~174160004:-
LUAD	cis	rs1061377	0.861	rs35739603	ENSG00000249685.1	RP11-360F5.3	6.12	1.98e-09	8.7e-07	0.32	0.27	Uric acid levels;	chr4:39107938	chr4:39133913~39135608:+
LUAD	cis	rs7849270	1	rs1009242	ENSG00000268707.1	RP11-247A12.7	-6.12	1.98e-09	8.7e-07	-0.31	-0.27	Blood metabolite ratios;	chr9:129154553	chr9:129170434~129170940:+
LUAD	cis	rs7849270	0.959	rs913276	ENSG00000268707.1	RP11-247A12.7	-6.12	1.98e-09	8.7e-07	-0.31	-0.27	Blood metabolite ratios;	chr9:129154885	chr9:129170434~129170940:+
LUAD	cis	rs7849270	1	rs7868408	ENSG00000268707.1	RP11-247A12.7	-6.12	1.98e-09	8.7e-07	-0.31	-0.27	Blood metabolite ratios;	chr9:129155585	chr9:129170434~129170940:+
LUAD	cis	rs7044106	0.762	rs10818471	ENSG00000238181.2	AHCYP2	-6.12	1.98e-09	8.71e-07	-0.34	-0.27	Hip circumference adjusted for BMI;	chr9:120631767	chr9:120720673~120721972:+
LUAD	cis	rs1823913	0.622	rs55787447	ENSG00000280083.1	RP11-317J9.1	-6.12	1.98e-09	8.72e-07	-0.32	-0.27	Obesity-related traits;	chr2:191288596	chr2:191154118~191156070:-
LUAD	cis	rs10214930	0.697	rs6963421	ENSG00000235574.1	AC073150.6	-6.12	1.98e-09	8.72e-07	-0.34	-0.27	Hypospadias;	chr7:27652809	chr7:27491682~27492765:-
LUAD	cis	rs11098499	0.604	rs2389882	ENSG00000248280.1	RP11-33B1.2	6.12	1.98e-09	8.72e-07	0.34	0.27	Corneal astigmatism;	chr4:119645578	chr4:119440561~119450157:-
LUAD	cis	rs12699921	0.598	rs2723504	ENSG00000279048.1	RP11-511H23.2	-6.12	1.99e-09	8.73e-07	-0.22	-0.27	Fibrinogen levels;	chr7:17815210	chr7:17940503~17942922:+
LUAD	cis	rs12699921	0.598	rs2723505	ENSG00000279048.1	RP11-511H23.2	-6.12	1.99e-09	8.73e-07	-0.22	-0.27	Fibrinogen levels;	chr7:17815226	chr7:17940503~17942922:+
LUAD	cis	rs1823913	0.599	rs2168166	ENSG00000280083.1	RP11-317J9.1	-6.12	1.99e-09	8.74e-07	-0.32	-0.27	Obesity-related traits;	chr2:191288063	chr2:191154118~191156070:-
LUAD	cis	rs11157436	0.958	rs1041859	ENSG00000211812.1	TRAV26-2	-6.12	1.99e-09	8.74e-07	-0.32	-0.27	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22204878	chr14:22202583~22203368:+
LUAD	cis	rs11157436	0.958	rs1041860	ENSG00000211812.1	TRAV26-2	-6.12	1.99e-09	8.74e-07	-0.32	-0.27	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22204897	chr14:22202583~22203368:+
LUAD	cis	rs74233809	1	rs74233809	ENSG00000213277.3	MARCKSL1P1	6.12	1.99e-09	8.75e-07	0.45	0.27	Birth weight;	chr10:103154183	chr10:103175554~103176094:+
LUAD	cis	rs4761702	1	rs4761701	ENSG00000257252.4	RP11-486A14.2	-6.12	1.99e-09	8.75e-07	-0.36	-0.27	Immature fraction of reticulocytes;	chr12:93315956	chr12:93317135~93377736:-
LUAD	cis	rs4761702	1	rs4761702	ENSG00000257252.4	RP11-486A14.2	-6.12	1.99e-09	8.75e-07	-0.36	-0.27	Immature fraction of reticulocytes;	chr12:93316116	chr12:93317135~93377736:-
LUAD	cis	rs6772849	0.93	rs68090762	ENSG00000242551.2	POU5F1P6	-6.12	1.99e-09	8.76e-07	-0.32	-0.27	Monocyte percentage of white cells;Monocyte count;	chr3:128625064	chr3:128674735~128677005:-
LUAD	cis	rs11157436	1	rs3811278	ENSG00000211812.1	TRAV26-2	-6.12	1.99e-09	8.76e-07	-0.32	-0.27	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22186227	chr14:22202583~22203368:+
LUAD	cis	rs30380	0.632	rs26498	ENSG00000272109.1	CTD-2260A17.3	6.12	1.99e-09	8.76e-07	0.33	0.27	Cerebrospinal fluid biomarker levels;	chr5:96803109	chr5:96804353~96806105:+
LUAD	cis	rs4713118	0.629	rs203888	ENSG00000204709.4	LINC01556	6.12	2e-09	8.76e-07	0.35	0.27	Parkinson's disease;	chr6:28053811	chr6:28943877~28944537:+
LUAD	cis	rs494459	0.838	rs566733	ENSG00000278376.1	RP11-158I9.8	-6.12	2e-09	8.76e-07	-0.28	-0.27	Height;	chr11:118737916	chr11:118791254~118793137:+
LUAD	cis	rs7688540	0.8	rs2353599	ENSG00000275426.1	CH17-262A2.1	6.12	2e-09	8.77e-07	0.33	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:286637	chr4:149738~150317:+
LUAD	cis	rs6921919	0.583	rs6922169	ENSG00000204709.4	LINC01556	6.12	2e-09	8.77e-07	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.559	rs13210866	ENSG00000204709.4	LINC01556	6.12	2e-09	8.77e-07	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs13201726	ENSG00000204709.4	LINC01556	6.12	2e-09	8.77e-07	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs2027361	ENSG00000204709.4	LINC01556	6.12	2e-09	8.77e-07	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28943877~28944537:+
LUAD	cis	rs6772849	0.896	rs61112519	ENSG00000242551.2	POU5F1P6	-6.11	2e-09	8.78e-07	-0.31	-0.27	Monocyte percentage of white cells;Monocyte count;	chr3:128619333	chr3:128674735~128677005:-
LUAD	cis	rs1799949	0.965	rs7223952	ENSG00000267681.1	CTD-3199J23.6	-6.11	2e-09	8.79e-07	-0.3	-0.27	Menopause (age at onset);	chr17:43042868	chr17:43144956~43145255:+
LUAD	cis	rs6921919	0.583	rs9468370	ENSG00000204709.4	LINC01556	6.11	2e-09	8.79e-07	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs9468368	ENSG00000216901.1	AL022393.7	6.11	2e-09	8.79e-07	0.32	0.27	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28176188~28176674:+
LUAD	cis	rs77204473	0.744	rs76567973	ENSG00000254851.1	RP11-109L13.1	6.11	2e-09	8.8e-07	0.67	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117100045	chr11:117135528~117138582:+
LUAD	cis	rs77204473	0.744	rs78135964	ENSG00000254851.1	RP11-109L13.1	6.11	2e-09	8.8e-07	0.67	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117100961	chr11:117135528~117138582:+
LUAD	cis	rs7615952	0.608	rs35668111	ENSG00000171084.14	FAM86JP	6.11	2.01e-09	8.81e-07	0.39	0.27	Blood pressure (smoking interaction);	chr3:125825792	chr3:125916620~125930024:+
LUAD	cis	rs4591358	0.648	rs17177798	ENSG00000223466.1	AC064834.2	-6.11	2.01e-09	8.81e-07	-0.39	-0.27	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195521352	chr2:195533035~195538681:+
LUAD	cis	rs2117029	0.556	rs1057725	ENSG00000258017.1	RP11-386G11.10	-6.11	2.01e-09	8.82e-07	-0.32	-0.27	Intelligence (multi-trait analysis);	chr12:49128795	chr12:49127782~49147869:+
LUAD	cis	rs4718428	0.705	rs4717328	ENSG00000232546.1	RP11-458F8.1	-6.11	2.01e-09	8.83e-07	-0.26	-0.27	Corneal structure;	chr7:66887678	chr7:66848496~66858136:+
LUAD	cis	rs2243480	0.901	rs2456483	ENSG00000230295.1	RP11-458F8.2	-6.11	2.01e-09	8.83e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65996588	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs1701750	ENSG00000230295.1	RP11-458F8.2	-6.11	2.01e-09	8.83e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:66002158	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs1701758	ENSG00000230295.1	RP11-458F8.2	-6.11	2.01e-09	8.83e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:66005214	chr7:66880708~66882981:+
LUAD	cis	rs2243480	0.901	rs1701759	ENSG00000230295.1	RP11-458F8.2	-6.11	2.01e-09	8.83e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:66005945	chr7:66880708~66882981:+
LUAD	cis	rs11971779	0.585	rs3922848	ENSG00000273391.1	RP11-634H22.1	6.11	2.01e-09	8.83e-07	0.27	0.27	Diisocyanate-induced asthma;	chr7:139361464	chr7:139359032~139359566:-
LUAD	cis	rs66887589	0.616	rs11732621	ENSG00000245958.5	RP11-33B1.1	-6.11	2.01e-09	8.84e-07	-0.22	-0.27	Diastolic blood pressure;	chr4:119291728	chr4:119454791~119552025:+
LUAD	cis	rs6504622	0.905	rs197926	ENSG00000262879.4	RP11-156P1.3	6.11	2.02e-09	8.85e-07	0.31	0.27	Orofacial clefts;	chr17:46934721	chr17:46984045~47100323:-
LUAD	cis	rs2404602	0.552	rs11630185	ENSG00000259422.1	RP11-593F23.1	-6.11	2.02e-09	8.85e-07	-0.39	-0.27	Blood metabolite levels;	chr15:76667442	chr15:76174891~76181486:-
LUAD	cis	rs2243480	1	rs2462569	ENSG00000230295.1	RP11-458F8.2	6.11	2.02e-09	8.85e-07	0.31	0.27	Diabetic kidney disease;	chr7:66009859	chr7:66880708~66882981:+
LUAD	cis	rs7923609	0.811	rs3847325	ENSG00000232075.1	MRPL35P2	6.11	2.02e-09	8.87e-07	0.32	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63571751	chr10:63634317~63634827:-
LUAD	cis	rs74233809	1	rs12219304	ENSG00000213277.3	MARCKSL1P1	6.11	2.02e-09	8.88e-07	0.45	0.27	Birth weight;	chr10:103171827	chr10:103175554~103176094:+
LUAD	cis	rs9595908	0.792	rs61947055	ENSG00000212293.1	SNORA16	6.11	2.02e-09	8.88e-07	0.29	0.27	Body mass index;	chr13:32614414	chr13:32420390~32420516:-
LUAD	cis	rs8177376	0.727	rs240555	ENSG00000254905.1	RP11-712L6.7	6.11	2.03e-09	8.88e-07	0.37	0.27	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126332190	chr11:126292922~126294254:-
LUAD	cis	rs2243480	1	rs1723270	ENSG00000232546.1	RP11-458F8.1	-6.11	2.03e-09	8.89e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66004843	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs958550	ENSG00000232546.1	RP11-458F8.1	6.11	2.03e-09	8.89e-07	0.32	0.27	Diabetic kidney disease;	chr7:66170692	chr7:66848496~66858136:+
LUAD	cis	rs875971	0.545	rs6460298	ENSG00000226824.5	RP4-756H11.3	-6.11	2.03e-09	8.91e-07	-0.39	-0.27	Aortic root size;	chr7:66442783	chr7:66654538~66669855:+
LUAD	cis	rs9834970	0.588	rs4441609	ENSG00000234073.1	AC011816.1	-6.11	2.04e-09	8.94e-07	-0.29	-0.27	Bipolar disorder with mood-incongruent psychosis;Bipolar disorder;Schizophrenia or bipolar disorder;Subjective response to lithium treatment;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr3:36851226	chr3:36880184~36880729:-
LUAD	cis	rs875971	0.895	rs6460278	ENSG00000237310.1	GS1-124K5.4	-6.11	2.04e-09	8.94e-07	-0.29	-0.27	Aortic root size;	chr7:66197749	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs6460279	ENSG00000237310.1	GS1-124K5.4	-6.11	2.04e-09	8.94e-07	-0.29	-0.27	Aortic root size;	chr7:66197774	chr7:66493706~66495474:+
LUAD	cis	rs5753618	0.509	rs2413033	ENSG00000236132.1	CTA-440B3.1	6.11	2.04e-09	8.94e-07	0.34	0.27	Colorectal cancer;	chr22:31178227	chr22:31816379~31817491:-
LUAD	cis	rs1426063	0.614	rs74949513	ENSG00000249717.1	RP11-44F21.3	6.11	2.04e-09	8.96e-07	0.5	0.27	QT interval;	chr4:75124631	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.614	rs77982391	ENSG00000249717.1	RP11-44F21.3	6.11	2.04e-09	8.96e-07	0.5	0.27	QT interval;	chr4:75125224	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.541	rs116664844	ENSG00000249717.1	RP11-44F21.3	6.11	2.04e-09	8.96e-07	0.5	0.27	QT interval;	chr4:75125677	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.541	rs114162294	ENSG00000249717.1	RP11-44F21.3	6.11	2.04e-09	8.96e-07	0.5	0.27	QT interval;	chr4:75125682	chr4:74955974~74970362:-
LUAD	cis	rs17301013	0.606	rs4650968	ENSG00000227373.4	RP11-160H22.5	6.11	2.04e-09	8.96e-07	0.38	0.27	Systemic lupus erythematosus;	chr1:174223322	chr1:174115300~174160004:-
LUAD	cis	rs2302464	1	rs12651052	ENSG00000214846.4	RP11-115L11.1	6.11	2.04e-09	8.96e-07	0.7	0.27	Cerebrospinal fluid biomarker levels;	chr4:15726813	chr4:15730962~15731627:-
LUAD	cis	rs2302464	1	rs56381553	ENSG00000214846.4	RP11-115L11.1	6.11	2.04e-09	8.96e-07	0.7	0.27	Cerebrospinal fluid biomarker levels;	chr4:15726824	chr4:15730962~15731627:-
LUAD	cis	rs2302464	1	rs12645513	ENSG00000214846.4	RP11-115L11.1	6.11	2.04e-09	8.96e-07	0.7	0.27	Cerebrospinal fluid biomarker levels;	chr4:15727155	chr4:15730962~15731627:-
LUAD	cis	rs2302464	1	rs58335439	ENSG00000214846.4	RP11-115L11.1	6.11	2.04e-09	8.96e-07	0.7	0.27	Cerebrospinal fluid biomarker levels;	chr4:15727183	chr4:15730962~15731627:-
LUAD	cis	rs2302464	1	rs73123625	ENSG00000214846.4	RP11-115L11.1	6.11	2.04e-09	8.96e-07	0.7	0.27	Cerebrospinal fluid biomarker levels;	chr4:15727550	chr4:15730962~15731627:-
LUAD	cis	rs10050311	0.858	rs1010903	ENSG00000251411.1	RP11-397E7.4	-6.11	2.05e-09	8.97e-07	-0.36	-0.27	Insulin-related traits;	chr4:86898040	chr4:86913266~86914817:-
LUAD	cis	rs948562	0.74	rs12361770	ENSG00000280010.1	AP001350.4	6.11	2.05e-09	8.99e-07	0.43	0.27	Lymphoma;	chr11:58666759	chr11:58627435~58628528:+
LUAD	cis	rs4273100	1	rs16960499	ENSG00000279825.1	CTC-457L16.1	6.11	2.05e-09	9e-07	0.36	0.27	Schizophrenia;	chr17:19299719	chr17:19030857~19033529:+
LUAD	cis	rs7567389	0.671	rs72845993	ENSG00000236682.1	AC068282.3	-6.11	2.06e-09	9.01e-07	-0.39	-0.27	Self-rated health;	chr2:127351025	chr2:127389130~127400580:+
LUAD	cis	rs7567389	0.677	rs72845997	ENSG00000236682.1	AC068282.3	-6.11	2.06e-09	9.01e-07	-0.39	-0.27	Self-rated health;	chr2:127352506	chr2:127389130~127400580:+
LUAD	cis	rs875971	0.965	rs6971509	ENSG00000222364.1	RNU6-96P	6.11	2.06e-09	9.03e-07	0.3	0.27	Aortic root size;	chr7:66249983	chr7:66395191~66395286:+
LUAD	cis	rs11676348	0.741	rs12694425	ENSG00000261338.2	RP11-378A13.1	6.11	2.06e-09	9.04e-07	0.28	0.27	Ulcerative colitis;	chr2:218077590	chr2:218255319~218257366:+
LUAD	cis	rs12699921	0.632	rs2723572	ENSG00000279048.1	RP11-511H23.2	-6.11	2.07e-09	9.05e-07	-0.21	-0.27	Fibrinogen levels;	chr7:17848964	chr7:17940503~17942922:+
LUAD	cis	rs8062405	0.965	rs8049439	ENSG00000251417.2	RP11-1348G14.4	-6.11	2.07e-09	9.05e-07	-0.27	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28802743~28817828:+
LUAD	cis	rs720064	0.586	rs9963697	ENSG00000264745.1	TTC39C-AS1	6.11	2.07e-09	9.05e-07	0.28	0.27	Strep throat;	chr18:23944796	chr18:23994213~24015339:-
LUAD	cis	rs17301013	0.606	rs6656491	ENSG00000227373.4	RP11-160H22.5	6.11	2.07e-09	9.05e-07	0.38	0.27	Systemic lupus erythematosus;	chr1:174127524	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.581	rs72711457	ENSG00000227373.4	RP11-160H22.5	6.11	2.07e-09	9.05e-07	0.38	0.27	Systemic lupus erythematosus;	chr1:174135385	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs6668008	ENSG00000227373.4	RP11-160H22.5	6.11	2.07e-09	9.05e-07	0.38	0.27	Systemic lupus erythematosus;	chr1:174138752	chr1:174115300~174160004:-
LUAD	cis	rs2948294	0.566	rs13274039	ENSG00000253893.2	FAM85B	-6.11	2.07e-09	9.06e-07	-0.36	-0.27	Red cell distribution width;	chr8:8254137	chr8:8167819~8226614:-
LUAD	cis	rs3779195	0.52	rs17169479	ENSG00000272950.1	RP11-307C18.1	6.11	2.07e-09	9.07e-07	0.46	0.27	Sex hormone-binding globulin levels;	chr7:98238721	chr7:98322853~98323430:+
LUAD	cis	rs11098499	0.955	rs35434465	ENSG00000248280.1	RP11-33B1.2	6.11	2.07e-09	9.07e-07	0.34	0.27	Corneal astigmatism;	chr4:119248223	chr4:119440561~119450157:-
LUAD	cis	rs765787	0.505	rs12593605	ENSG00000259520.4	CTD-2651B20.3	-6.11	2.08e-09	9.09e-07	-0.36	-0.27	Uric acid levels;	chr15:45205250	chr15:45251580~45279251:-
LUAD	cis	rs8031584	0.958	rs1043742	ENSG00000260382.1	RP11-540B6.2	6.11	2.08e-09	9.1e-07	0.32	0.27	Huntington's disease progression;	chr15:30940378	chr15:30882267~30883231:-
LUAD	cis	rs2243480	1	rs10807701	ENSG00000232546.1	RP11-458F8.1	6.11	2.08e-09	9.1e-07	0.35	0.27	Diabetic kidney disease;	chr7:66259699	chr7:66848496~66858136:+
LUAD	cis	rs4908768	0.501	rs7520617	ENSG00000232912.4	RP5-1115A15.1	6.11	2.08e-09	9.1e-07	0.25	0.27	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8513658	chr1:8424645~8434838:+
LUAD	cis	rs113835537	0.597	rs7116921	ENSG00000255517.5	CTD-3074O7.5	-6.11	2.08e-09	9.11e-07	-0.32	-0.27	Airway imaging phenotypes;	chr11:66536383	chr11:66473490~66480233:-
LUAD	cis	rs113835537	0.597	rs11227523	ENSG00000255517.5	CTD-3074O7.5	-6.11	2.08e-09	9.11e-07	-0.32	-0.27	Airway imaging phenotypes;	chr11:66538467	chr11:66473490~66480233:-
LUAD	cis	rs2243480	0.901	rs57126451	ENSG00000230295.1	RP11-458F8.2	-6.11	2.08e-09	9.11e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65951319	chr7:66880708~66882981:+
LUAD	cis	rs2412819	0.571	rs11070411	ENSG00000205771.5	CATSPER2P1	6.11	2.08e-09	9.12e-07	0.41	0.27	Lung cancer;	chr15:43766436	chr15:43726918~43747094:-
LUAD	cis	rs17301013	0.581	rs56158362	ENSG00000227373.4	RP11-160H22.5	6.11	2.09e-09	9.13e-07	0.38	0.27	Systemic lupus erythematosus;	chr1:174166437	chr1:174115300~174160004:-
LUAD	cis	rs4835473	0.932	rs6851999	ENSG00000251600.4	RP11-673E1.1	6.11	2.09e-09	9.13e-07	0.33	0.27	Immature fraction of reticulocytes;	chr4:143742567	chr4:143912331~143982454:+
LUAD	cis	rs11098499	1	rs6837898	ENSG00000248280.1	RP11-33B1.2	6.11	2.09e-09	9.13e-07	0.34	0.27	Corneal astigmatism;	chr4:119257999	chr4:119440561~119450157:-
LUAD	cis	rs2276314	0.512	rs1789515	ENSG00000278986.1	RP11-723J4.3	6.11	2.09e-09	9.14e-07	0.28	0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36055930	chr18:35972151~35973916:+
LUAD	cis	rs12439619	0.921	rs4778672	ENSG00000255769.6	GOLGA2P10	6.11	2.09e-09	9.14e-07	0.31	0.27	Intelligence (multi-trait analysis);	chr15:82245013	chr15:82472993~82513950:-
LUAD	cis	rs5753618	0.504	rs9609296	ENSG00000236132.1	CTA-440B3.1	-6.11	2.09e-09	9.15e-07	-0.33	-0.27	Colorectal cancer;	chr22:31495798	chr22:31816379~31817491:-
LUAD	cis	rs4591358	0.773	rs17781737	ENSG00000223466.1	AC064834.2	-6.11	2.09e-09	9.15e-07	-0.36	-0.27	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195508251	chr2:195533035~195538681:+
LUAD	cis	rs7923609	0.811	rs4746204	ENSG00000232075.1	MRPL35P2	6.11	2.1e-09	9.16e-07	0.32	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63568758	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.783	rs7907451	ENSG00000232075.1	MRPL35P2	6.11	2.1e-09	9.16e-07	0.32	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63568980	chr10:63634317~63634827:-
LUAD	cis	rs9595066	0.627	rs4941486	ENSG00000227258.4	SMIM2-AS1	6.11	2.1e-09	9.17e-07	0.43	0.27	Schizophrenia;	chr13:44175021	chr13:44110451~44240517:+
LUAD	cis	rs732716	0.785	rs56272533	ENSG00000267980.1	AC007292.6	-6.11	2.1e-09	9.17e-07	-0.31	-0.27	Mean corpuscular volume;	chr19:4420045	chr19:4363789~4364640:+
LUAD	cis	rs728616	0.614	rs10788319	ENSG00000225484.5	NUTM2B-AS1	-6.11	2.1e-09	9.18e-07	-0.46	-0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79953754	chr10:79663088~79826594:-
LUAD	cis	rs10214930	0.813	rs6462027	ENSG00000235574.1	AC073150.6	-6.11	2.1e-09	9.18e-07	-0.36	-0.27	Hypospadias;	chr7:27523619	chr7:27491682~27492765:-
LUAD	cis	rs891378	0.837	rs11120688	ENSG00000274245.1	RP11-357P18.2	6.11	2.1e-09	9.2e-07	0.37	0.27	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207312770	chr1:207372559~207373252:+
LUAD	cis	rs2111504	0.559	rs7250813	ENSG00000267213.4	AC007773.2	6.11	2.11e-09	9.22e-07	0.35	0.27	Bipolar disorder;	chr19:32358815	chr19:32390050~32405560:-
LUAD	cis	rs35740288	0.77	rs34048547	ENSG00000202081.1	RNU6-1280P	6.11	2.11e-09	9.23e-07	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85637836	chr15:85651522~85651628:-
LUAD	cis	rs1823913	0.599	rs4146103	ENSG00000227542.1	AC092614.2	6.11	2.11e-09	9.24e-07	0.32	0.27	Obesity-related traits;	chr2:191272000	chr2:191229165~191246172:-
LUAD	cis	rs10129255	0.556	rs9324093	ENSG00000211970.3	IGHV4-61	-6.11	2.11e-09	9.24e-07	-0.19	-0.27	Kawasaki disease;	chr14:106683893	chr14:106639119~106639657:-
LUAD	cis	rs6772849	0.93	rs55987729	ENSG00000242551.2	POU5F1P6	-6.11	2.11e-09	9.24e-07	-0.31	-0.27	Monocyte percentage of white cells;Monocyte count;	chr3:128621267	chr3:128674735~128677005:-
LUAD	cis	rs875971	0.862	rs6971059	ENSG00000222364.1	RNU6-96P	6.11	2.12e-09	9.24e-07	0.3	0.27	Aortic root size;	chr7:66602045	chr7:66395191~66395286:+
LUAD	cis	rs9549367	0.789	rs12869947	ENSG00000269125.1	RP11-98F14.11	-6.11	2.12e-09	9.26e-07	-0.33	-0.27	Platelet distribution width;	chr13:113241842	chr13:113165002~113165183:-
LUAD	cis	rs74233809	1	rs11191575	ENSG00000213277.3	MARCKSL1P1	6.1	2.13e-09	9.29e-07	0.45	0.27	Birth weight;	chr10:103138580	chr10:103175554~103176094:+
LUAD	cis	rs74233809	1	rs79993475	ENSG00000213277.3	MARCKSL1P1	6.1	2.13e-09	9.29e-07	0.45	0.27	Birth weight;	chr10:103141274	chr10:103175554~103176094:+
LUAD	cis	rs30380	0.587	rs151940	ENSG00000272109.1	CTD-2260A17.3	-6.1	2.13e-09	9.3e-07	-0.33	-0.27	Cerebrospinal fluid biomarker levels;	chr5:96812074	chr5:96804353~96806105:+
LUAD	cis	rs10214930	0.697	rs13242248	ENSG00000235574.1	AC073150.6	-6.1	2.13e-09	9.31e-07	-0.33	-0.27	Hypospadias;	chr7:27643252	chr7:27491682~27492765:-
LUAD	cis	rs10759883	0.539	rs689744	ENSG00000175611.10	LINC00476	6.1	2.13e-09	9.31e-07	0.32	0.27	Nicotine dependence;	chr9:96040417	chr9:95759231~95875977:-
LUAD	cis	rs10759883	0.539	rs2296858	ENSG00000175611.10	LINC00476	6.1	2.13e-09	9.31e-07	0.32	0.27	Nicotine dependence;	chr9:96041126	chr9:95759231~95875977:-
LUAD	cis	rs7923609	0.783	rs7100409	ENSG00000232075.1	MRPL35P2	6.1	2.14e-09	9.33e-07	0.32	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63570435	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.703	rs7100413	ENSG00000232075.1	MRPL35P2	6.1	2.14e-09	9.33e-07	0.32	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63570448	chr10:63634317~63634827:-
LUAD	cis	rs11971779	0.68	rs6978680	ENSG00000273391.1	RP11-634H22.1	-6.1	2.14e-09	9.35e-07	-0.27	-0.27	Diisocyanate-induced asthma;	chr7:139427302	chr7:139359032~139359566:-
LUAD	cis	rs2276314	0.857	rs28435069	ENSG00000278986.1	RP11-723J4.3	-6.1	2.14e-09	9.35e-07	-0.32	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36048512	chr18:35972151~35973916:+
LUAD	cis	rs2276314	0.857	rs8087539	ENSG00000278986.1	RP11-723J4.3	-6.1	2.14e-09	9.35e-07	-0.32	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36051574	chr18:35972151~35973916:+
LUAD	cis	rs7182621	0.622	rs12904160	ENSG00000182397.13	DNM1P46	6.1	2.14e-09	9.35e-07	0.32	0.27	Colonoscopy-negative controls vs population controls;	chr15:99869471	chr15:99790156~99806927:-
LUAD	cis	rs7017914	0.902	rs6472562	ENSG00000223220.1	Y_RNA	6.1	2.14e-09	9.36e-07	0.3	0.27	Bone mineral density;	chr8:71057643	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.902	rs6472563	ENSG00000223220.1	Y_RNA	6.1	2.14e-09	9.36e-07	0.3	0.27	Bone mineral density;	chr8:71057672	chr8:70780914~70781008:-
LUAD	cis	rs9318086	0.901	rs7336730	ENSG00000205861.10	C1QTNF9B-AS1	6.1	2.15e-09	9.37e-07	0.32	0.27	Myopia (pathological);	chr13:23877965	chr13:23888889~23897263:+
LUAD	cis	rs66887589	0.592	rs2175383	ENSG00000245958.5	RP11-33B1.1	-6.1	2.15e-09	9.39e-07	-0.22	-0.27	Diastolic blood pressure;	chr4:119294681	chr4:119454791~119552025:+
LUAD	cis	rs66887589	0.616	rs1052633	ENSG00000245958.5	RP11-33B1.1	-6.1	2.15e-09	9.39e-07	-0.22	-0.27	Diastolic blood pressure;	chr4:119294159	chr4:119454791~119552025:+
LUAD	cis	rs11971779	0.688	rs8137	ENSG00000273391.1	RP11-634H22.1	-6.1	2.15e-09	9.39e-07	-0.27	-0.27	Diisocyanate-induced asthma;	chr7:139419715	chr7:139359032~139359566:-
LUAD	cis	rs7923609	0.783	rs4746203	ENSG00000232075.1	MRPL35P2	6.1	2.15e-09	9.39e-07	0.32	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63564237	chr10:63634317~63634827:-
LUAD	cis	rs13217239	0.646	rs12209886	ENSG00000241549.7	GUSBP2	6.1	2.15e-09	9.4e-07	0.29	0.27	Schizophrenia;	chr6:27016978	chr6:26871484~26956554:-
LUAD	cis	rs6940638	0.531	rs12211984	ENSG00000241549.7	GUSBP2	6.1	2.15e-09	9.4e-07	0.29	0.27	Intelligence (multi-trait analysis);	chr6:27018275	chr6:26871484~26956554:-
LUAD	cis	rs13217239	0.646	rs10456351	ENSG00000241549.7	GUSBP2	6.1	2.15e-09	9.4e-07	0.29	0.27	Schizophrenia;	chr6:27019013	chr6:26871484~26956554:-
LUAD	cis	rs2439831	0.702	rs2467402	ENSG00000205771.5	CATSPER2P1	6.1	2.15e-09	9.4e-07	0.47	0.27	Lung cancer in ever smokers;	chr15:43732292	chr15:43726918~43747094:-
LUAD	cis	rs17301013	0.606	rs17300775	ENSG00000227373.4	RP11-160H22.5	6.1	2.15e-09	9.4e-07	0.38	0.27	Systemic lupus erythematosus;	chr1:174191901	chr1:174115300~174160004:-
LUAD	cis	rs10129255	0.536	rs6576201	ENSG00000224373.3	IGHV4-59	-6.1	2.16e-09	9.41e-07	-0.16	-0.27	Kawasaki disease;	chr14:106683696	chr14:106627249~106627825:-
LUAD	cis	rs2243480	1	rs59794892	ENSG00000230295.1	RP11-458F8.2	-6.1	2.16e-09	9.41e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65950886	chr7:66880708~66882981:+
LUAD	cis	rs11098499	0.955	rs13113112	ENSG00000248280.1	RP11-33B1.2	6.1	2.16e-09	9.41e-07	0.34	0.27	Corneal astigmatism;	chr4:119234885	chr4:119440561~119450157:-
LUAD	cis	rs11971779	0.68	rs10229358	ENSG00000273391.1	RP11-634H22.1	-6.1	2.16e-09	9.42e-07	-0.27	-0.27	Diisocyanate-induced asthma;	chr7:139367799	chr7:139359032~139359566:-
LUAD	cis	rs35740288	0.77	rs12898597	ENSG00000202081.1	RNU6-1280P	6.1	2.16e-09	9.43e-07	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85646688	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.77	rs11631386	ENSG00000202081.1	RNU6-1280P	6.1	2.16e-09	9.43e-07	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85648764	chr15:85651522~85651628:-
LUAD	cis	rs8177876	0.749	rs76892049	ENSG00000261061.1	RP11-303E16.2	-6.1	2.16e-09	9.44e-07	-0.46	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81055736	chr16:81030770~81031485:+
LUAD	cis	rs853679	0.607	rs67662114	ENSG00000204709.4	LINC01556	6.1	2.16e-09	9.44e-07	0.6	0.27	Depression;	chr6:27964523	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs13216117	ENSG00000204709.4	LINC01556	6.1	2.16e-09	9.44e-07	0.6	0.27	Depression;	chr6:27970706	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs36101351	ENSG00000204709.4	LINC01556	6.1	2.16e-09	9.44e-07	0.6	0.27	Depression;	chr6:27975591	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs28360499	ENSG00000204709.4	LINC01556	6.1	2.16e-09	9.44e-07	0.6	0.27	Depression;	chr6:27977618	chr6:28943877~28944537:+
LUAD	cis	rs987724	0.592	rs9858861	ENSG00000240875.4	LINC00886	-6.1	2.17e-09	9.46e-07	-0.29	-0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156824848	chr3:156747346~156817062:-
LUAD	cis	rs13217239	0.574	rs9366680	ENSG00000241549.7	GUSBP2	6.1	2.17e-09	9.46e-07	0.29	0.27	Schizophrenia;	chr6:27038344	chr6:26871484~26956554:-
LUAD	cis	rs2243480	1	rs431318	ENSG00000232546.1	RP11-458F8.1	-6.1	2.17e-09	9.47e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:66046610	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs313803	ENSG00000232546.1	RP11-458F8.1	-6.1	2.17e-09	9.47e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:66049744	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs313802	ENSG00000232546.1	RP11-458F8.1	-6.1	2.17e-09	9.47e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:66051386	chr7:66848496~66858136:+
LUAD	cis	rs2243480	0.803	rs403089	ENSG00000232546.1	RP11-458F8.1	-6.1	2.17e-09	9.47e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:66052736	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs458291	ENSG00000232546.1	RP11-458F8.1	-6.1	2.17e-09	9.47e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:66055492	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs466983	ENSG00000232546.1	RP11-458F8.1	-6.1	2.17e-09	9.47e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:66055509	chr7:66848496~66858136:+
LUAD	cis	rs9543976	0.858	rs8192763	ENSG00000261553.4	RP11-29G8.3	6.1	2.17e-09	9.47e-07	0.4	0.27	Diabetic retinopathy;	chr13:75605034	chr13:75549773~75807120:+
LUAD	cis	rs9543976	1	rs1535724	ENSG00000261553.4	RP11-29G8.3	6.1	2.17e-09	9.47e-07	0.4	0.27	Diabetic retinopathy;	chr13:75609137	chr13:75549773~75807120:+
LUAD	cis	rs4718428	0.705	rs4717331	ENSG00000232546.1	RP11-458F8.1	-6.1	2.17e-09	9.48e-07	-0.25	-0.27	Corneal structure;	chr7:66913899	chr7:66848496~66858136:+
LUAD	cis	rs1823913	0.637	rs2067610	ENSG00000280083.1	RP11-317J9.1	-6.1	2.17e-09	9.48e-07	-0.32	-0.27	Obesity-related traits;	chr2:191299251	chr2:191154118~191156070:-
LUAD	cis	rs2243480	0.901	rs2949697	ENSG00000230295.1	RP11-458F8.2	-6.1	2.17e-09	9.48e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65999249	chr7:66880708~66882981:+
LUAD	cis	rs1551277	0.538	rs55652830	ENSG00000146666.5	LINC00525	6.1	2.18e-09	9.49e-07	0.33	0.27	Anxiety disorder;	chr7:47805887	chr7:47761476~47766772:+
LUAD	cis	rs2243480	1	rs35542501	ENSG00000232546.1	RP11-458F8.1	-6.1	2.18e-09	9.49e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:65966228	chr7:66848496~66858136:+
LUAD	cis	rs2243480	0.708	rs781141	ENSG00000232546.1	RP11-458F8.1	-6.1	2.18e-09	9.49e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:65973566	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs781142	ENSG00000232546.1	RP11-458F8.1	-6.1	2.18e-09	9.49e-07	-0.35	-0.27	Diabetic kidney disease;	chr7:65973791	chr7:66848496~66858136:+
LUAD	cis	rs11690935	0.655	rs12997093	ENSG00000228389.1	AC068039.4	-6.1	2.18e-09	9.5e-07	-0.28	-0.27	Schizophrenia;	chr2:171707928	chr2:171773482~171775844:+
LUAD	cis	rs7849270	1	rs10988224	ENSG00000268707.1	RP11-247A12.7	-6.1	2.18e-09	9.5e-07	-0.3	-0.27	Blood metabolite ratios;	chr9:129141055	chr9:129170434~129170940:+
LUAD	cis	rs2911132	1	rs2911131	ENSG00000248734.2	CTD-2260A17.1	-6.1	2.18e-09	9.5e-07	-0.28	-0.27	Urate levels (BMI interaction);	chr5:96850246	chr5:96784777~96785999:+
LUAD	cis	rs1062177	0.855	rs919263	ENSG00000213433.5	RPLP1P6	-6.1	2.18e-09	9.51e-07	-0.34	-0.27	Preschool internalizing problems;	chr5:151886292	chr5:151765859~151766378:-
LUAD	cis	rs4803480	1	rs11882144	ENSG00000270164.1	LINC01480	-6.1	2.18e-09	9.51e-07	-0.26	-0.27	Schizophrenia;	chr19:41566244	chr19:41535183~41536904:+
LUAD	cis	rs2243480	0.803	rs36004293	ENSG00000230295.1	RP11-458F8.2	-6.1	2.18e-09	9.52e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65951525	chr7:66880708~66882981:+
LUAD	cis	rs2243480	0.803	rs35268390	ENSG00000230295.1	RP11-458F8.2	-6.1	2.18e-09	9.52e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65951549	chr7:66880708~66882981:+
LUAD	cis	rs853679	0.517	rs9366715	ENSG00000204709.4	LINC01556	6.1	2.18e-09	9.52e-07	0.37	0.27	Depression;	chr6:28096855	chr6:28943877~28944537:+
LUAD	cis	rs13217239	0.646	rs12527111	ENSG00000241549.7	GUSBP2	6.1	2.19e-09	9.52e-07	0.29	0.27	Schizophrenia;	chr6:27038696	chr6:26871484~26956554:-
LUAD	cis	rs853679	0.607	rs13208096	ENSG00000204709.4	LINC01556	6.1	2.19e-09	9.55e-07	0.6	0.27	Depression;	chr6:28257533	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.868	rs2893928	ENSG00000219392.1	RP1-265C24.5	-6.1	2.19e-09	9.55e-07	-0.39	-0.27	Parkinson's disease;	chr6:27770651	chr6:28115628~28116551:+
LUAD	cis	rs10214930	0.723	rs56139857	ENSG00000235574.1	AC073150.6	-6.1	2.19e-09	9.56e-07	-0.34	-0.27	Hypospadias;	chr7:27639352	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs11973492	ENSG00000235574.1	AC073150.6	-6.1	2.19e-09	9.56e-07	-0.34	-0.27	Hypospadias;	chr7:27640770	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.671	rs6945993	ENSG00000235574.1	AC073150.6	-6.1	2.19e-09	9.56e-07	-0.34	-0.27	Hypospadias;	chr7:27641391	chr7:27491682~27492765:-
LUAD	cis	rs2115536	0.692	rs8036559	ENSG00000278600.1	RP11-81A1.6	-6.1	2.2e-09	9.56e-07	-0.22	-0.27	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79878221	chr15:79920195~79922455:-
LUAD	cis	rs6921919	0.583	rs4254981	ENSG00000204709.4	LINC01556	6.1	2.2e-09	9.57e-07	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.525	rs6929825	ENSG00000204709.4	LINC01556	6.1	2.2e-09	9.57e-07	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs35599905	ENSG00000204709.4	LINC01556	6.1	2.2e-09	9.57e-07	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs1124131	ENSG00000204709.4	LINC01556	6.1	2.2e-09	9.57e-07	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs6899389	ENSG00000204709.4	LINC01556	6.1	2.2e-09	9.57e-07	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs6922374	ENSG00000204709.4	LINC01556	6.1	2.2e-09	9.57e-07	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs6899603	ENSG00000204709.4	LINC01556	6.1	2.2e-09	9.57e-07	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs6922429	ENSG00000204709.4	LINC01556	6.1	2.2e-09	9.57e-07	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28943877~28944537:+
LUAD	cis	rs11603023	0.967	rs654423	ENSG00000255422.1	AP002954.4	6.1	2.2e-09	9.57e-07	0.32	0.27	Cholesterol, total;	chr11:118641039	chr11:118704607~118750263:+
LUAD	cis	rs7849270	1	rs10988232	ENSG00000268707.1	RP11-247A12.7	-6.1	2.2e-09	9.58e-07	-0.31	-0.27	Blood metabolite ratios;	chr9:129153069	chr9:129170434~129170940:+
LUAD	cis	rs7044106	0.762	rs7044226	ENSG00000238181.2	AHCYP2	-6.1	2.21e-09	9.61e-07	-0.34	-0.27	Hip circumference adjusted for BMI;	chr9:120704050	chr9:120720673~120721972:+
LUAD	cis	rs12699921	0.632	rs2723494	ENSG00000279048.1	RP11-511H23.2	-6.1	2.21e-09	9.61e-07	-0.22	-0.27	Fibrinogen levels;	chr7:17814360	chr7:17940503~17942922:+
LUAD	cis	rs2117029	0.555	rs9788139	ENSG00000258017.1	RP11-386G11.10	-6.1	2.21e-09	9.61e-07	-0.33	-0.27	Intelligence (multi-trait analysis);	chr12:49126886	chr12:49127782~49147869:+
LUAD	cis	rs7246657	0.551	rs11084873	ENSG00000276846.1	CTD-3220F14.3	6.1	2.21e-09	9.62e-07	0.4	0.27	Coronary artery calcification;	chr19:37093008	chr19:37314868~37315620:-
LUAD	cis	rs875971	1	rs709597	ENSG00000237310.1	GS1-124K5.4	-6.1	2.21e-09	9.62e-07	-0.29	-0.27	Aortic root size;	chr7:66360996	chr7:66493706~66495474:+
LUAD	cis	rs9584850	0.834	rs3783005	ENSG00000231194.1	FARP1-AS1	-6.1	2.21e-09	9.62e-07	-0.32	-0.27	Neuroticism;	chr13:98459083	chr13:98435405~98435840:-
LUAD	cis	rs6921919	0.609	rs36018474	ENSG00000204709.4	LINC01556	6.1	2.21e-09	9.62e-07	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28943877~28944537:+
LUAD	cis	rs274567	0.501	rs272855	ENSG00000233006.5	AC034220.3	6.1	2.21e-09	9.62e-07	0.27	0.27	Blood metabolite levels;	chr5:132351482	chr5:132311285~132369916:-
LUAD	cis	rs720064	0.558	rs7245197	ENSG00000264745.1	TTC39C-AS1	6.1	2.21e-09	9.63e-07	0.29	0.27	Strep throat;	chr18:23926339	chr18:23994213~24015339:-
LUAD	cis	rs720064	0.586	rs12958287	ENSG00000264745.1	TTC39C-AS1	6.1	2.21e-09	9.63e-07	0.29	0.27	Strep throat;	chr18:23927465	chr18:23994213~24015339:-
LUAD	cis	rs1061377	1	rs4974997	ENSG00000249685.1	RP11-360F5.3	6.1	2.21e-09	9.64e-07	0.32	0.27	Uric acid levels;	chr4:39109151	chr4:39133913~39135608:+
LUAD	cis	rs172166	0.637	rs1071893	ENSG00000219392.1	RP1-265C24.5	-6.1	2.22e-09	9.65e-07	-0.34	-0.27	Cardiac Troponin-T levels;	chr6:28199857	chr6:28115628~28116551:+
LUAD	cis	rs11603023	0.805	rs687190	ENSG00000255239.1	AP002954.6	6.1	2.22e-09	9.67e-07	0.31	0.27	Cholesterol, total;	chr11:118671674	chr11:118688039~118690600:-
LUAD	cis	rs11157436	0.918	rs7159024	ENSG00000211812.1	TRAV26-2	-6.1	2.22e-09	9.67e-07	-0.31	-0.27	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22228760	chr14:22202583~22203368:+
LUAD	cis	rs172166	0.694	rs536704	ENSG00000204709.4	LINC01556	6.1	2.23e-09	9.69e-07	0.35	0.27	Cardiac Troponin-T levels;	chr6:28124825	chr6:28943877~28944537:+
LUAD	cis	rs10740039	0.81	rs9415605	ENSG00000254271.1	RP11-131N11.4	-6.1	2.23e-09	9.7e-07	-0.32	-0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60616809	chr10:60734342~60741828:+
LUAD	cis	rs11971779	0.68	rs6960876	ENSG00000273391.1	RP11-634H22.1	-6.1	2.24e-09	9.73e-07	-0.27	-0.27	Diisocyanate-induced asthma;	chr7:139427430	chr7:139359032~139359566:-
LUAD	cis	rs7615952	0.688	rs12638224	ENSG00000171084.14	FAM86JP	6.1	2.24e-09	9.73e-07	0.38	0.27	Blood pressure (smoking interaction);	chr3:125822477	chr3:125916620~125930024:+
LUAD	cis	rs10129255	0.957	rs8014696	ENSG00000211972.2	IGHV3-66	-6.1	2.24e-09	9.73e-07	-0.23	-0.27	Kawasaki disease;	chr14:106769752	chr14:106675017~106675544:-
LUAD	cis	rs9368481	0.678	rs62402024	ENSG00000241549.7	GUSBP2	6.1	2.24e-09	9.74e-07	0.3	0.27	Autism spectrum disorder or schizophrenia;	chr6:26956197	chr6:26871484~26956554:-
LUAD	cis	rs1075265	0.783	rs805438	ENSG00000233266.1	HMGB1P31	6.1	2.24e-09	9.74e-07	0.34	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53829051	chr2:54051334~54051760:+
LUAD	cis	rs7945705	0.87	rs10840142	ENSG00000254860.4	TMEM9B-AS1	-6.1	2.24e-09	9.75e-07	-0.3	-0.27	Hemoglobin concentration;	chr11:8884531	chr11:8964675~8977527:+
LUAD	cis	rs2243480	0.708	rs13242216	ENSG00000232546.1	RP11-458F8.1	-6.1	2.25e-09	9.77e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66433290	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs67536397	ENSG00000232546.1	RP11-458F8.1	-6.1	2.25e-09	9.77e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66482930	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs58669269	ENSG00000232546.1	RP11-458F8.1	-6.1	2.25e-09	9.77e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66486966	chr7:66848496~66858136:+
LUAD	cis	rs2243480	0.901	rs34807232	ENSG00000232546.1	RP11-458F8.1	-6.1	2.25e-09	9.77e-07	-0.36	-0.27	Diabetic kidney disease;	chr7:66500146	chr7:66848496~66858136:+
LUAD	cis	rs853679	0.882	rs4713140	ENSG00000219392.1	RP1-265C24.5	-6.1	2.25e-09	9.77e-07	-0.45	-0.27	Depression;	chr6:28129415	chr6:28115628~28116551:+
LUAD	cis	rs11098499	0.663	rs9996501	ENSG00000248280.1	RP11-33B1.2	6.09	2.25e-09	9.78e-07	0.33	0.27	Corneal astigmatism;	chr4:119317763	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.697	rs28458294	ENSG00000248280.1	RP11-33B1.2	6.09	2.25e-09	9.78e-07	0.33	0.27	Corneal astigmatism;	chr4:119317769	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.663	rs28369503	ENSG00000248280.1	RP11-33B1.2	6.09	2.25e-09	9.78e-07	0.33	0.27	Corneal astigmatism;	chr4:119317770	chr4:119440561~119450157:-
LUAD	cis	rs35740288	0.77	rs56092539	ENSG00000202081.1	RNU6-1280P	6.09	2.25e-09	9.79e-07	0.32	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85639281	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.77	rs11636185	ENSG00000202081.1	RNU6-1280P	6.09	2.25e-09	9.79e-07	0.32	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85639887	chr15:85651522~85651628:-
LUAD	cis	rs71403859	0.502	rs71403849	ENSG00000260886.1	TAT-AS1	6.09	2.25e-09	9.8e-07	0.42	0.27	Post bronchodilator FEV1;	chr16:71450462	chr16:71565789~71578187:+
LUAD	cis	rs10214930	0.697	rs6462024	ENSG00000235574.1	AC073150.6	-6.09	2.25e-09	9.8e-07	-0.34	-0.27	Hypospadias;	chr7:27522721	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs6462025	ENSG00000235574.1	AC073150.6	-6.09	2.25e-09	9.8e-07	-0.34	-0.27	Hypospadias;	chr7:27522722	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs6462026	ENSG00000235574.1	AC073150.6	-6.09	2.25e-09	9.8e-07	-0.34	-0.27	Hypospadias;	chr7:27522749	chr7:27491682~27492765:-
LUAD	cis	rs11977715	0.538	rs3801916	ENSG00000233942.1	AC004012.1	6.09	2.26e-09	9.8e-07	0.33	0.27	Middle childhood and early adolescence aggressive behavior;	chr7:95491707	chr7:95471835~95473998:+
LUAD	cis	rs2179367	0.959	rs9322178	ENSG00000231760.4	RP11-350J20.5	6.09	2.26e-09	9.81e-07	0.34	0.27	Dupuytren's disease;	chr6:149372131	chr6:149796151~149826294:-
LUAD	cis	rs875971	0.789	rs7808013	ENSG00000237310.1	GS1-124K5.4	-6.09	2.26e-09	9.81e-07	-0.29	-0.27	Aortic root size;	chr7:66606209	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.825	rs7384021	ENSG00000237310.1	GS1-124K5.4	-6.09	2.26e-09	9.81e-07	-0.29	-0.27	Aortic root size;	chr7:66612917	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.825	rs66981195	ENSG00000237310.1	GS1-124K5.4	-6.09	2.26e-09	9.81e-07	-0.29	-0.27	Aortic root size;	chr7:66614048	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs3926380	ENSG00000237310.1	GS1-124K5.4	-6.09	2.26e-09	9.81e-07	-0.29	-0.27	Aortic root size;	chr7:66615658	chr7:66493706~66495474:+
LUAD	cis	rs2243480	0.908	rs2460431	ENSG00000230295.1	RP11-458F8.2	6.09	2.26e-09	9.82e-07	0.33	0.27	Diabetic kidney disease;	chr7:66157859	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs4718309	ENSG00000230295.1	RP11-458F8.2	6.09	2.26e-09	9.82e-07	0.33	0.27	Diabetic kidney disease;	chr7:66162777	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs6460274	ENSG00000230295.1	RP11-458F8.2	6.09	2.26e-09	9.82e-07	0.33	0.27	Diabetic kidney disease;	chr7:66163497	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs7787230	ENSG00000230295.1	RP11-458F8.2	6.09	2.26e-09	9.82e-07	0.33	0.27	Diabetic kidney disease;	chr7:66164112	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs2465120	ENSG00000230295.1	RP11-458F8.2	-6.09	2.26e-09	9.82e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:66155987	chr7:66880708~66882981:+
LUAD	cis	rs2179367	0.959	rs585022	ENSG00000231760.4	RP11-350J20.5	6.09	2.26e-09	9.82e-07	0.34	0.27	Dupuytren's disease;	chr6:149432168	chr6:149796151~149826294:-
LUAD	cis	rs875971	0.862	rs6460290	ENSG00000237310.1	GS1-124K5.4	-6.09	2.26e-09	9.83e-07	-0.29	-0.27	Aortic root size;	chr7:66344119	chr7:66493706~66495474:+
LUAD	cis	rs1062177	0.756	rs2915815	ENSG00000213433.5	RPLP1P6	6.09	2.26e-09	9.83e-07	0.35	0.27	Preschool internalizing problems;	chr5:151736322	chr5:151765859~151766378:-
LUAD	cis	rs77204473	0.744	rs76942203	ENSG00000254851.1	RP11-109L13.1	6.09	2.26e-09	9.83e-07	0.67	0.27	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117102531	chr11:117135528~117138582:+
LUAD	cis	rs2880765	0.835	rs7180923	ENSG00000259295.5	CSPG4P12	6.09	2.26e-09	9.83e-07	0.31	0.27	Coronary artery disease;	chr15:85507659	chr15:85191438~85213905:+
LUAD	cis	rs17301013	0.659	rs59649440	ENSG00000227373.4	RP11-160H22.5	6.09	2.26e-09	9.83e-07	0.37	0.27	Systemic lupus erythematosus;	chr1:174332024	chr1:174115300~174160004:-
LUAD	cis	rs875971	0.862	rs1167408	ENSG00000222364.1	RNU6-96P	6.09	2.26e-09	9.84e-07	0.3	0.27	Aortic root size;	chr7:66091121	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.83	rs1167406	ENSG00000222364.1	RNU6-96P	6.09	2.26e-09	9.84e-07	0.3	0.27	Aortic root size;	chr7:66091949	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs709609	ENSG00000222364.1	RNU6-96P	6.09	2.26e-09	9.84e-07	0.3	0.27	Aortic root size;	chr7:66095574	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs1167399	ENSG00000222364.1	RNU6-96P	6.09	2.26e-09	9.84e-07	0.3	0.27	Aortic root size;	chr7:66096890	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs57866200	ENSG00000222364.1	RNU6-96P	6.09	2.26e-09	9.84e-07	0.3	0.27	Aortic root size;	chr7:66100405	chr7:66395191~66395286:+
LUAD	cis	rs10214930	0.697	rs6974052	ENSG00000235574.1	AC073150.6	-6.09	2.26e-09	9.84e-07	-0.34	-0.27	Hypospadias;	chr7:27515978	chr7:27491682~27492765:-
LUAD	cis	rs801193	0.569	rs2659907	ENSG00000222364.1	RNU6-96P	-6.09	2.26e-09	9.84e-07	-0.3	-0.27	Aortic root size;	chr7:66699045	chr7:66395191~66395286:+
LUAD	cis	rs9318086	0.648	rs78881146	ENSG00000205861.10	C1QTNF9B-AS1	-6.09	2.27e-09	9.84e-07	-0.33	-0.27	Myopia (pathological);	chr13:23894565	chr13:23888889~23897263:+
LUAD	cis	rs17301013	0.507	rs193082	ENSG00000227373.4	RP11-160H22.5	6.09	2.27e-09	9.84e-07	0.39	0.27	Systemic lupus erythematosus;	chr1:174725439	chr1:174115300~174160004:-
LUAD	cis	rs2243480	0.522	rs1638736	ENSG00000273142.1	RP11-458F8.4	-6.09	2.27e-09	9.84e-07	-0.31	-0.27	Diabetic kidney disease;	chr7:66627321	chr7:66902857~66906297:+
LUAD	cis	rs2404602	0.532	rs284892	ENSG00000259422.1	RP11-593F23.1	6.09	2.27e-09	9.84e-07	0.31	0.27	Blood metabolite levels;	chr15:76428696	chr15:76174891~76181486:-
LUAD	cis	rs6565180	0.926	rs4787643	ENSG00000183604.13	SMG1P5	6.09	2.27e-09	9.84e-07	0.28	0.27	Tonsillectomy;	chr16:30382339	chr16:30267553~30335374:-
LUAD	cis	rs6565180	0.926	rs4788409	ENSG00000183604.13	SMG1P5	6.09	2.27e-09	9.84e-07	0.28	0.27	Tonsillectomy;	chr16:30382450	chr16:30267553~30335374:-
LUAD	cis	rs2276314	0.857	rs62101379	ENSG00000278986.1	RP11-723J4.3	-6.09	2.27e-09	9.85e-07	-0.33	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36004939	chr18:35972151~35973916:+
LUAD	cis	rs7182621	0.512	rs71403471	ENSG00000259363.4	CTD-2054N24.2	-6.09	2.27e-09	9.85e-07	-0.37	-0.27	Colonoscopy-negative controls vs population controls;	chr15:99870656	chr15:99807023~99877148:+
LUAD	cis	rs10129255	0.957	rs10141009	ENSG00000211974.3	IGHV2-70	6.09	2.27e-09	9.86e-07	0.28	0.27	Kawasaki disease;	chr14:106776695	chr14:106723574~106724093:-
LUAD	cis	rs10129255	0.912	rs6576227	ENSG00000211974.3	IGHV2-70	6.09	2.27e-09	9.86e-07	0.28	0.27	Kawasaki disease;	chr14:106778202	chr14:106723574~106724093:-
LUAD	cis	rs10129255	0.957	rs6576228	ENSG00000211974.3	IGHV2-70	6.09	2.27e-09	9.86e-07	0.28	0.27	Kawasaki disease;	chr14:106778401	chr14:106723574~106724093:-
LUAD	cis	rs9450351	0.744	rs9353339	ENSG00000203875.9	SNHG5	6.09	2.27e-09	9.86e-07	0.55	0.27	Interferon gamma-induced protein 10 levels;	chr6:85794480	chr6:85660950~85678736:-
LUAD	cis	rs12022452	0.591	rs12042242	ENSG00000238287.1	RP11-656D10.3	6.09	2.27e-09	9.86e-07	0.43	0.27	Age-related hearing impairment (SNP x SNP interaction);	chr1:40528201	chr1:40493157~40508661:-
LUAD	cis	rs875971	0.545	rs1796222	ENSG00000237310.1	GS1-124K5.4	-6.09	2.27e-09	9.87e-07	-0.33	-0.27	Aortic root size;	chr7:66592167	chr7:66493706~66495474:+
LUAD	cis	rs9487094	0.6	rs3799842	ENSG00000260273.1	RP11-425D10.10	6.09	2.27e-09	9.87e-07	0.34	0.27	Height;	chr6:109471826	chr6:109382795~109383666:+
LUAD	cis	rs2665103	0.61	rs56398167	ENSG00000255769.6	GOLGA2P10	-6.09	2.28e-09	9.88e-07	-0.28	-0.27	Intelligence (multi-trait analysis);	chr15:82237482	chr15:82472993~82513950:-
LUAD	cis	rs2408955	0.522	rs4760679	ENSG00000240399.1	RP1-228P16.1	-6.09	2.28e-09	9.88e-07	-0.27	-0.27	Glycated hemoglobin levels;	chr12:48067852	chr12:48054813~48055591:-
LUAD	cis	rs10214930	0.781	rs6943883	ENSG00000235574.1	AC073150.6	-6.09	2.28e-09	9.88e-07	-0.36	-0.27	Hypospadias;	chr7:27653274	chr7:27491682~27492765:-
LUAD	cis	rs801193	0.569	rs11761542	ENSG00000222364.1	RNU6-96P	-6.09	2.28e-09	9.89e-07	-0.3	-0.27	Aortic root size;	chr7:66753209	chr7:66395191~66395286:+
LUAD	cis	rs2404602	0.692	rs4886503	ENSG00000259422.1	RP11-593F23.1	-6.09	2.28e-09	9.91e-07	-0.31	-0.27	Blood metabolite levels;	chr15:76816533	chr15:76174891~76181486:-
LUAD	cis	rs2243480	0.803	rs34804747	ENSG00000230295.1	RP11-458F8.2	-6.09	2.29e-09	9.92e-07	-0.33	-0.27	Diabetic kidney disease;	chr7:65947955	chr7:66880708~66882981:+
LUAD	cis	rs10740039	0.768	rs10994432	ENSG00000254271.1	RP11-131N11.4	6.09	2.29e-09	9.92e-07	0.31	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60623831	chr10:60734342~60741828:+
LUAD	cis	rs1499614	1	rs2707840	ENSG00000232546.1	RP11-458F8.1	-6.09	2.29e-09	9.92e-07	-0.35	-0.27	Gout;	chr7:66693028	chr7:66848496~66858136:+
LUAD	cis	rs7182621	0.639	rs1561048	ENSG00000259363.4	CTD-2054N24.2	-6.09	2.29e-09	9.92e-07	-0.35	-0.27	Colonoscopy-negative controls vs population controls;	chr15:99875369	chr15:99807023~99877148:+
LUAD	cis	rs6921919	0.583	rs1054372	ENSG00000204709.4	LINC01556	6.09	2.29e-09	9.93e-07	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs9468354	ENSG00000204709.4	LINC01556	6.09	2.29e-09	9.93e-07	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs7773051	ENSG00000204709.4	LINC01556	6.09	2.29e-09	9.93e-07	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs12697938	ENSG00000204709.4	LINC01556	6.09	2.29e-09	9.93e-07	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs13437294	ENSG00000204709.4	LINC01556	6.09	2.29e-09	9.93e-07	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.609	rs9468357	ENSG00000204709.4	LINC01556	6.09	2.29e-09	9.93e-07	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.556	rs13197633	ENSG00000204709.4	LINC01556	6.09	2.29e-09	9.93e-07	0.59	0.27	Depression;	chr6:28206979	chr6:28943877~28944537:+
LUAD	cis	rs7772486	0.641	rs2253757	ENSG00000235652.6	RP11-545I5.3	6.09	2.29e-09	9.94e-07	0.28	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145878550	chr6:145799409~145886585:+
LUAD	cis	rs875971	0.767	rs1643394	ENSG00000222364.1	RNU6-96P	-6.09	2.29e-09	9.94e-07	-0.3	-0.27	Aortic root size;	chr7:66371107	chr7:66395191~66395286:+
LUAD	cis	rs9601248	1	rs9601248	ENSG00000227676.3	LINC01068	-6.09	2.29e-09	9.95e-07	-0.32	-0.27	Major depressive disorder;	chr13:79594869	chr13:79566727~79571436:+
LUAD	cis	rs55665837	0.701	rs12286408	ENSG00000251991.1	RNU7-49P	6.09	2.29e-09	9.95e-07	0.31	0.27	Vitamin D levels;	chr11:14557830	chr11:14478892~14478953:+
LUAD	cis	rs7772486	0.597	rs2485631	ENSG00000235652.6	RP11-545I5.3	6.09	2.3e-09	9.96e-07	0.28	0.27	Lobe attachment (rater-scored or self-reported);	chr6:145868941	chr6:145799409~145886585:+
LUAD	cis	rs6921919	0.583	rs7764737	ENSG00000204709.4	LINC01556	6.09	2.3e-09	9.97e-07	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs9461458	ENSG00000204709.4	LINC01556	6.09	2.3e-09	9.97e-07	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.609	rs9468365	ENSG00000204709.4	LINC01556	6.09	2.3e-09	9.97e-07	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs1361385	ENSG00000204709.4	LINC01556	6.09	2.3e-09	9.97e-07	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs1416918	ENSG00000204709.4	LINC01556	6.09	2.3e-09	9.97e-07	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28943877~28944537:+
LUAD	cis	rs7017914	0.902	rs34856835	ENSG00000223220.1	Y_RNA	6.09	2.3e-09	9.98e-07	0.3	0.27	Bone mineral density;	chr8:71058376	chr8:70780914~70781008:-
LUAD	cis	rs4853012	0.775	rs12465641	ENSG00000257800.1	FNBP1P1	-6.09	2.3e-09	9.98e-07	-0.36	-0.27	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74120680~74123218:+
LUAD	cis	rs2115630	0.875	rs8039472	ENSG00000225151.9	GOLGA2P7	6.09	2.3e-09	9.98e-07	0.31	0.27	P wave terminal force;	chr15:84818413	chr15:84199311~84230136:-
LUAD	cis	rs6991838	0.765	rs10957358	ENSG00000200714.1	Y_RNA	6.09	2.3e-09	9.98e-07	0.32	0.27	Intelligence (multi-trait analysis);	chr8:65590067	chr8:65592731~65592820:+
LUAD	cis	rs4787484	0.964	rs7498372	ENSG00000214725.6	CDIPT-AS1	-6.09	2.3e-09	9.99e-07	-0.34	-0.27	Response to taxane treatment (placlitaxel);	chr16:29899404	chr16:29863593~29868053:+
LUAD	cis	rs7044106	0.762	rs4837789	ENSG00000238181.2	AHCYP2	-6.09	2.3e-09	9.99e-07	-0.34	-0.27	Hip circumference adjusted for BMI;	chr9:120663978	chr9:120720673~120721972:+
LUAD	cis	rs7615952	0.688	rs12638240	ENSG00000171084.14	FAM86JP	6.09	2.3e-09	9.99e-07	0.38	0.27	Blood pressure (smoking interaction);	chr3:125822395	chr3:125916620~125930024:+
LUAD	cis	rs875971	0.895	rs4145009	ENSG00000222364.1	RNU6-96P	6.09	2.31e-09	9.99e-07	0.31	0.27	Aortic root size;	chr7:66261628	chr7:66395191~66395286:+
LUAD	cis	rs755249	0.567	rs3818806	ENSG00000228060.1	RP11-69E11.8	-6.09	2.31e-09	1e-06	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39282599	chr1:39565160~39573203:+
LUAD	cis	rs10129255	0.556	rs9324093	ENSG00000224373.3	IGHV4-59	6.09	2.31e-09	1e-06	0.16	0.27	Kawasaki disease;	chr14:106683893	chr14:106627249~106627825:-
LUAD	cis	rs2439831	0.85	rs9944216	ENSG00000205771.5	CATSPER2P1	6.09	2.31e-09	1e-06	0.53	0.27	Lung cancer in ever smokers;	chr15:43868575	chr15:43726918~43747094:-
LUAD	cis	rs2243480	1	rs6964245	ENSG00000232546.1	RP11-458F8.1	6.09	2.31e-09	1e-06	0.35	0.27	Diabetic kidney disease;	chr7:66253730	chr7:66848496~66858136:+
LUAD	cis	rs4639966	0.569	rs603486	ENSG00000255422.1	AP002954.4	-6.09	2.32e-09	1e-06	-0.32	-0.27	Systemic lupus erythematosus;	chr11:118716638	chr11:118704607~118750263:+
LUAD	cis	rs875971	0.862	rs6460282	ENSG00000237310.1	GS1-124K5.4	-6.09	2.32e-09	1e-06	-0.29	-0.27	Aortic root size;	chr7:66226259	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs1167411	ENSG00000222364.1	RNU6-96P	6.09	2.32e-09	1.01e-06	0.3	0.27	Aortic root size;	chr7:66074277	chr7:66395191~66395286:+
LUAD	cis	rs853679	0.527	rs213228	ENSG00000204709.4	LINC01556	6.09	2.32e-09	1.01e-06	0.34	0.27	Depression;	chr6:28363475	chr6:28943877~28944537:+
LUAD	cis	rs8031584	0.958	rs3512	ENSG00000260382.1	RP11-540B6.2	6.09	2.33e-09	1.01e-06	0.32	0.27	Huntington's disease progression;	chr15:30942802	chr15:30882267~30883231:-
LUAD	cis	rs853679	0.546	rs13213152	ENSG00000204709.4	LINC01556	6.09	2.33e-09	1.01e-06	0.6	0.27	Depression;	chr6:28381921	chr6:28943877~28944537:+
LUAD	cis	rs1874124	0.836	rs17596947	ENSG00000238078.1	LINC01352	6.09	2.33e-09	1.01e-06	0.38	0.27	Cholesterol, total;	chr1:220820122	chr1:220829255~220832429:+
LUAD	cis	rs1061377	0.76	rs7678457	ENSG00000249685.1	RP11-360F5.3	6.09	2.33e-09	1.01e-06	0.32	0.27	Uric acid levels;	chr4:39136041	chr4:39133913~39135608:+
LUAD	cis	rs4713118	0.866	rs9468217	ENSG00000219392.1	RP1-265C24.5	-6.09	2.33e-09	1.01e-06	-0.37	-0.27	Parkinson's disease;	chr6:27758688	chr6:28115628~28116551:+
LUAD	cis	rs17301013	0.606	rs55698100	ENSG00000227373.4	RP11-160H22.5	6.09	2.33e-09	1.01e-06	0.39	0.27	Systemic lupus erythematosus;	chr1:174258295	chr1:174115300~174160004:-
LUAD	cis	rs6860806	0.507	rs274570	ENSG00000233006.5	AC034220.3	-6.09	2.34e-09	1.01e-06	-0.27	-0.27	Breast cancer;	chr5:132377534	chr5:132311285~132369916:-
LUAD	cis	rs11603023	0.967	rs644273	ENSG00000255422.1	AP002954.4	6.09	2.34e-09	1.01e-06	0.32	0.27	Cholesterol, total;	chr11:118640634	chr11:118704607~118750263:+
LUAD	cis	rs1061377	1	rs10030904	ENSG00000249685.1	RP11-360F5.3	6.09	2.34e-09	1.01e-06	0.32	0.27	Uric acid levels;	chr4:39113603	chr4:39133913~39135608:+
LUAD	cis	rs30380	0.734	rs30376	ENSG00000248734.2	CTD-2260A17.1	6.09	2.34e-09	1.01e-06	0.29	0.27	Cerebrospinal fluid biomarker levels;	chr5:96784555	chr5:96784777~96785999:+
LUAD	cis	rs801193	0.591	rs4506088	ENSG00000222364.1	RNU6-96P	6.09	2.34e-09	1.01e-06	0.3	0.27	Aortic root size;	chr7:66670470	chr7:66395191~66395286:+
LUAD	cis	rs17301013	0.632	rs10912782	ENSG00000227373.4	RP11-160H22.5	6.09	2.35e-09	1.02e-06	0.37	0.27	Systemic lupus erythematosus;	chr1:174418758	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12082012	ENSG00000227373.4	RP11-160H22.5	6.09	2.35e-09	1.02e-06	0.4	0.27	Systemic lupus erythematosus;	chr1:174588729	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs4451598	ENSG00000227373.4	RP11-160H22.5	6.09	2.35e-09	1.02e-06	0.4	0.27	Systemic lupus erythematosus;	chr1:174606576	chr1:174115300~174160004:-
LUAD	cis	rs3096299	0.933	rs3096297	ENSG00000274627.1	RP11-104N10.2	6.09	2.35e-09	1.02e-06	0.26	0.27	Multiple myeloma (IgH translocation);	chr16:89386747	chr16:89516797~89522217:+
LUAD	cis	rs9368481	0.729	rs9379948	ENSG00000241549.7	GUSBP2	6.09	2.35e-09	1.02e-06	0.3	0.27	Autism spectrum disorder or schizophrenia;	chr6:26977004	chr6:26871484~26956554:-
LUAD	cis	rs17818399	1	rs17818399	ENSG00000279254.1	RP11-536C12.1	-6.09	2.35e-09	1.02e-06	-0.3	-0.27	Height;	chr2:46598887	chr2:46668870~46670778:+
LUAD	cis	rs9368481	0.7	rs6911401	ENSG00000241549.7	GUSBP2	6.09	2.36e-09	1.02e-06	0.3	0.27	Autism spectrum disorder or schizophrenia;	chr6:26945435	chr6:26871484~26956554:-
LUAD	cis	rs9368481	0.729	rs10946881	ENSG00000241549.7	GUSBP2	6.09	2.36e-09	1.02e-06	0.3	0.27	Autism spectrum disorder or schizophrenia;	chr6:26946832	chr6:26871484~26956554:-
LUAD	cis	rs11098499	0.697	rs35280960	ENSG00000248280.1	RP11-33B1.2	6.09	2.36e-09	1.02e-06	0.33	0.27	Corneal astigmatism;	chr4:119335904	chr4:119440561~119450157:-
LUAD	cis	rs5753618	0.539	rs5997933	ENSG00000236132.1	CTA-440B3.1	6.09	2.36e-09	1.02e-06	0.33	0.27	Colorectal cancer;	chr22:31276766	chr22:31816379~31817491:-
LUAD	cis	rs56114371	0.53	rs9357045	ENSG00000219392.1	RP1-265C24.5	-6.09	2.36e-09	1.02e-06	-0.39	-0.27	Breast cancer;	chr6:27721148	chr6:28115628~28116551:+
LUAD	cis	rs10740039	0.516	rs10740035	ENSG00000254271.1	RP11-131N11.4	-6.09	2.36e-09	1.02e-06	-0.3	-0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60592848	chr10:60734342~60741828:+
LUAD	cis	rs172166	0.637	rs1225592	ENSG00000219392.1	RP1-265C24.5	-6.09	2.36e-09	1.02e-06	-0.35	-0.27	Cardiac Troponin-T levels;	chr6:28182464	chr6:28115628~28116551:+
LUAD	cis	rs172166	0.637	rs1225595	ENSG00000219392.1	RP1-265C24.5	-6.09	2.36e-09	1.02e-06	-0.35	-0.27	Cardiac Troponin-T levels;	chr6:28183562	chr6:28115628~28116551:+
LUAD	cis	rs4835473	0.808	rs1984810	ENSG00000251600.4	RP11-673E1.1	6.09	2.36e-09	1.02e-06	0.33	0.27	Immature fraction of reticulocytes;	chr4:143824970	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.831	rs1984809	ENSG00000251600.4	RP11-673E1.1	6.09	2.36e-09	1.02e-06	0.33	0.27	Immature fraction of reticulocytes;	chr4:143825018	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs10857413	ENSG00000251600.4	RP11-673E1.1	6.09	2.36e-09	1.02e-06	0.33	0.27	Immature fraction of reticulocytes;	chr4:143827752	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs6828935	ENSG00000251600.4	RP11-673E1.1	6.09	2.36e-09	1.02e-06	0.33	0.27	Immature fraction of reticulocytes;	chr4:143829113	chr4:143912331~143982454:+
LUAD	cis	rs4820294	0.961	rs62236664	ENSG00000233360.4	Z83844.1	6.09	2.37e-09	1.02e-06	0.28	0.27	Fat distribution (HIV);	chr22:37663420	chr22:37641832~37658377:-
LUAD	cis	rs2412819	0.571	rs56226333	ENSG00000205771.5	CATSPER2P1	-6.09	2.37e-09	1.02e-06	-0.43	-0.27	Lung cancer;	chr15:43632410	chr15:43726918~43747094:-
LUAD	cis	rs7017914	0.905	rs3110246	ENSG00000223220.1	Y_RNA	6.09	2.37e-09	1.03e-06	0.3	0.27	Bone mineral density;	chr8:71022378	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.905	rs3110250	ENSG00000223220.1	Y_RNA	6.09	2.37e-09	1.03e-06	0.3	0.27	Bone mineral density;	chr8:71024149	chr8:70780914~70781008:-
LUAD	cis	rs7044106	0.762	rs7024046	ENSG00000238181.2	AHCYP2	-6.09	2.37e-09	1.03e-06	-0.34	-0.27	Hip circumference adjusted for BMI;	chr9:120656900	chr9:120720673~120721972:+
LUAD	cis	rs1707322	0.721	rs10789468	ENSG00000234329.1	RP11-767N6.2	6.09	2.37e-09	1.03e-06	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658886	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs6429574	ENSG00000234329.1	RP11-767N6.2	6.09	2.37e-09	1.03e-06	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668382	chr1:45651039~45651826:-
LUAD	cis	rs113835537	0.597	rs4576	ENSG00000255517.5	CTD-3074O7.5	-6.09	2.37e-09	1.03e-06	-0.32	-0.27	Airway imaging phenotypes;	chr11:66563529	chr11:66473490~66480233:-
LUAD	cis	rs10214930	0.697	rs1880370	ENSG00000235574.1	AC073150.6	-6.09	2.38e-09	1.03e-06	-0.34	-0.27	Hypospadias;	chr7:27543693	chr7:27491682~27492765:-
LUAD	cis	rs1823913	0.637	rs4853575	ENSG00000227542.1	AC092614.2	-6.08	2.38e-09	1.03e-06	-0.32	-0.27	Obesity-related traits;	chr2:191296149	chr2:191229165~191246172:-
LUAD	cis	rs11098499	0.826	rs4472123	ENSG00000248280.1	RP11-33B1.2	6.08	2.38e-09	1.03e-06	0.33	0.27	Corneal astigmatism;	chr4:119315475	chr4:119440561~119450157:-
LUAD	cis	rs1874124	0.778	rs1335920	ENSG00000238078.1	LINC01352	-6.08	2.38e-09	1.03e-06	-0.4	-0.27	Cholesterol, total;	chr1:220844946	chr1:220829255~220832429:+
LUAD	cis	rs1823913	0.637	rs4853579	ENSG00000280083.1	RP11-317J9.1	6.08	2.38e-09	1.03e-06	0.32	0.27	Obesity-related traits;	chr2:191297413	chr2:191154118~191156070:-
LUAD	cis	rs2117029	0.619	rs2753	ENSG00000258017.1	RP11-386G11.10	-6.08	2.38e-09	1.03e-06	-0.33	-0.27	Intelligence (multi-trait analysis);	chr12:49127889	chr12:49127782~49147869:+
LUAD	cis	rs10129255	1	rs10134517	ENSG00000211972.2	IGHV3-66	6.08	2.38e-09	1.03e-06	0.23	0.27	Kawasaki disease;	chr14:106718498	chr14:106675017~106675544:-
LUAD	cis	rs9549367	0.865	rs9549366	ENSG00000269125.1	RP11-98F14.11	-6.08	2.38e-09	1.03e-06	-0.33	-0.27	Platelet distribution width;	chr13:113253330	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.789	rs9577220	ENSG00000269125.1	RP11-98F14.11	-6.08	2.38e-09	1.03e-06	-0.33	-0.27	Platelet distribution width;	chr13:113253980	chr13:113165002~113165183:-
LUAD	cis	rs9549367	0.789	rs9549716	ENSG00000269125.1	RP11-98F14.11	-6.08	2.38e-09	1.03e-06	-0.33	-0.27	Platelet distribution width;	chr13:113254164	chr13:113165002~113165183:-
LUAD	cis	rs12699921	0.632	rs1404424	ENSG00000279048.1	RP11-511H23.2	-6.08	2.38e-09	1.03e-06	-0.22	-0.27	Fibrinogen levels;	chr7:17906981	chr7:17940503~17942922:+
LUAD	cis	rs6921919	0.583	rs7740351	ENSG00000204709.4	LINC01556	6.08	2.39e-09	1.03e-06	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28943877~28944537:+
LUAD	cis	rs7743045	0.643	rs114000233	ENSG00000253194.1	RP11-351A11.1	6.08	2.39e-09	1.03e-06	0.36	0.27	Mean platelet volume;	chr6:118935167	chr6:118934785~119031541:+
LUAD	cis	rs9368481	0.672	rs3931463	ENSG00000241549.7	GUSBP2	6.08	2.39e-09	1.03e-06	0.3	0.27	Autism spectrum disorder or schizophrenia;	chr6:26972018	chr6:26871484~26956554:-
LUAD	cis	rs9487094	0.6	rs9372213	ENSG00000260273.1	RP11-425D10.10	6.08	2.39e-09	1.03e-06	0.33	0.27	Height;	chr6:109370985	chr6:109382795~109383666:+
LUAD	cis	rs4908768	0.501	rs11121186	ENSG00000232912.4	RP5-1115A15.1	6.08	2.39e-09	1.03e-06	0.25	0.27	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8480281	chr1:8424645~8434838:+
LUAD	cis	rs13217239	0.621	rs12527231	ENSG00000241549.7	GUSBP2	6.08	2.39e-09	1.03e-06	0.29	0.27	Schizophrenia;	chr6:27033509	chr6:26871484~26956554:-
LUAD	cis	rs13217239	0.646	rs12523820	ENSG00000241549.7	GUSBP2	6.08	2.39e-09	1.03e-06	0.29	0.27	Schizophrenia;	chr6:27033723	chr6:26871484~26956554:-
LUAD	cis	rs12908161	1	rs56864281	ENSG00000259728.4	LINC00933	6.08	2.39e-09	1.03e-06	0.39	0.27	Schizophrenia;	chr15:84814418	chr15:84570649~84580175:+
LUAD	cis	rs67311347	1	rs9874006	ENSG00000223797.4	ENTPD3-AS1	6.08	2.39e-09	1.03e-06	0.28	0.27	Renal cell carcinoma;	chr3:40430105	chr3:40313802~40453329:-
LUAD	cis	rs2243480	1	rs1796220	ENSG00000232546.1	RP11-458F8.1	-6.08	2.4e-09	1.04e-06	-0.36	-0.27	Diabetic kidney disease;	chr7:66597113	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs2707831	ENSG00000232546.1	RP11-458F8.1	-6.08	2.4e-09	1.04e-06	-0.36	-0.27	Diabetic kidney disease;	chr7:66597524	chr7:66848496~66858136:+
LUAD	cis	rs35828350	1	rs35828350	ENSG00000259728.4	LINC00933	6.08	2.4e-09	1.04e-06	0.39	0.27	Autism spectrum disorder or schizophrenia;	chr15:84812610	chr15:84570649~84580175:+
LUAD	cis	rs17301013	0.606	rs56152378	ENSG00000227373.4	RP11-160H22.5	6.08	2.4e-09	1.04e-06	0.38	0.27	Systemic lupus erythematosus;	chr1:174106480	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs4652179	ENSG00000227373.4	RP11-160H22.5	6.08	2.4e-09	1.04e-06	0.38	0.27	Systemic lupus erythematosus;	chr1:174107185	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.581	rs17353198	ENSG00000227373.4	RP11-160H22.5	6.08	2.4e-09	1.04e-06	0.38	0.27	Systemic lupus erythematosus;	chr1:174107439	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs17350991	ENSG00000227373.4	RP11-160H22.5	6.08	2.4e-09	1.04e-06	0.38	0.27	Systemic lupus erythematosus;	chr1:174114330	chr1:174115300~174160004:-
LUAD	cis	rs2404602	0.684	rs1011083	ENSG00000259422.1	RP11-593F23.1	-6.08	2.4e-09	1.04e-06	-0.36	-0.27	Blood metabolite levels;	chr15:76715186	chr15:76174891~76181486:-
LUAD	cis	rs35740288	0.77	rs11638379	ENSG00000202081.1	RNU6-1280P	6.08	2.4e-09	1.04e-06	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85568059	chr15:85651522~85651628:-
LUAD	cis	rs8072100	1	rs4794048	ENSG00000228782.6	CTD-2026D20.3	6.08	2.4e-09	1.04e-06	0.29	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47685707	chr17:47450568~47492492:-
LUAD	cis	rs853679	0.546	rs35017208	ENSG00000204709.4	LINC01556	6.08	2.41e-09	1.04e-06	0.6	0.27	Depression;	chr6:28377505	chr6:28943877~28944537:+
LUAD	cis	rs10759883	0.563	rs690286	ENSG00000175611.10	LINC00476	6.08	2.41e-09	1.04e-06	0.32	0.27	Nicotine dependence;	chr9:96034685	chr9:95759231~95875977:-
LUAD	cis	rs11098499	0.532	rs4833624	ENSG00000248280.1	RP11-33B1.2	6.08	2.41e-09	1.04e-06	0.34	0.27	Corneal astigmatism;	chr4:119664342	chr4:119440561~119450157:-
LUAD	cis	rs7945705	0.967	rs1569408	ENSG00000254860.4	TMEM9B-AS1	-6.08	2.41e-09	1.04e-06	-0.3	-0.27	Hemoglobin concentration;	chr11:8888185	chr11:8964675~8977527:+
LUAD	cis	rs2288884	0.559	rs8111873	ENSG00000275055.1	CTC-471J1.11	-6.08	2.41e-09	1.04e-06	-0.32	-0.27	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52014267	chr19:52049007~52049754:+
LUAD	cis	rs2243480	1	rs12698509	ENSG00000226824.5	RP4-756H11.3	-6.08	2.41e-09	1.04e-06	-0.49	-0.27	Diabetic kidney disease;	chr7:65953889	chr7:66654538~66669855:+
LUAD	cis	rs858239	0.6	rs10256359	ENSG00000230042.1	AK3P3	-6.08	2.41e-09	1.04e-06	-0.34	-0.27	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23129178~23129841:+
LUAD	cis	rs875971	0.862	rs6964437	ENSG00000237310.1	GS1-124K5.4	-6.08	2.42e-09	1.04e-06	-0.29	-0.27	Aortic root size;	chr7:66221457	chr7:66493706~66495474:+
LUAD	cis	rs10214930	0.671	rs6963585	ENSG00000235574.1	AC073150.6	-6.08	2.42e-09	1.04e-06	-0.34	-0.27	Hypospadias;	chr7:27544204	chr7:27491682~27492765:-
LUAD	cis	rs71403859	0.502	rs71403847	ENSG00000260886.1	TAT-AS1	6.08	2.42e-09	1.04e-06	0.43	0.27	Post bronchodilator FEV1;	chr16:71434323	chr16:71565789~71578187:+
LUAD	cis	rs853679	0.527	rs213228	ENSG00000216901.1	AL022393.7	6.08	2.42e-09	1.04e-06	0.32	0.27	Depression;	chr6:28363475	chr6:28176188~28176674:+
LUAD	cis	rs1823913	0.599	rs1454754	ENSG00000280083.1	RP11-317J9.1	-6.08	2.42e-09	1.05e-06	-0.32	-0.27	Obesity-related traits;	chr2:191303562	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.637	rs13010441	ENSG00000280083.1	RP11-317J9.1	-6.08	2.42e-09	1.05e-06	-0.32	-0.27	Obesity-related traits;	chr2:191303903	chr2:191154118~191156070:-
LUAD	cis	rs9595908	0.645	rs4942924	ENSG00000212293.1	SNORA16	6.08	2.42e-09	1.05e-06	0.28	0.27	Body mass index;	chr13:32806987	chr13:32420390~32420516:-
LUAD	cis	rs453301	0.522	rs2929309	ENSG00000253893.2	FAM85B	6.08	2.42e-09	1.05e-06	0.34	0.27	Joint mobility (Beighton score);	chr8:9226261	chr8:8167819~8226614:-
LUAD	cis	rs9368481	0.761	rs3931464	ENSG00000241549.7	GUSBP2	6.08	2.42e-09	1.05e-06	0.3	0.27	Autism spectrum disorder or schizophrenia;	chr6:26972077	chr6:26871484~26956554:-
LUAD	cis	rs3762637	0.943	rs7629285	ENSG00000272758.4	RP11-299J3.8	6.08	2.42e-09	1.05e-06	0.37	0.27	LDL cholesterol levels;	chr3:122546892	chr3:122416207~122443180:+
LUAD	cis	rs710216	0.536	rs710221	ENSG00000227533.4	SLC2A1-AS1	6.08	2.43e-09	1.05e-06	0.3	0.27	Red cell distribution width;	chr1:42948529	chr1:42959049~42983358:+
LUAD	cis	rs6921919	0.583	rs2071965	ENSG00000204709.4	LINC01556	6.08	2.43e-09	1.05e-06	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28943877~28944537:+
LUAD	cis	rs13217239	0.646	rs6937880	ENSG00000241549.7	GUSBP2	6.08	2.43e-09	1.05e-06	0.29	0.27	Schizophrenia;	chr6:27032457	chr6:26871484~26956554:-
LUAD	cis	rs11157436	1	rs12587157	ENSG00000211812.1	TRAV26-2	-6.08	2.43e-09	1.05e-06	-0.31	-0.27	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22181476	chr14:22202583~22203368:+
LUAD	cis	rs4660456	0.504	rs587963	ENSG00000237899.1	RP4-739H11.3	6.08	2.43e-09	1.05e-06	0.37	0.27	Platelet count;	chr1:40640045	chr1:40669089~40687588:-
LUAD	cis	rs12468226	0.938	rs80282360	ENSG00000226261.1	AC064836.3	6.08	2.43e-09	1.05e-06	0.45	0.27	Urate levels;	chr2:202275121	chr2:202336024~202336727:-
LUAD	cis	rs916888	0.773	rs9896243	ENSG00000261575.2	RP11-259G18.1	6.08	2.43e-09	1.05e-06	0.41	0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46267037~46268694:+
LUAD	cis	rs4718428	0.705	rs12536410	ENSG00000232546.1	RP11-458F8.1	-6.08	2.43e-09	1.05e-06	-0.25	-0.27	Corneal structure;	chr7:66789303	chr7:66848496~66858136:+
LUAD	cis	rs55665837	0.559	rs11023209	ENSG00000251991.1	RNU7-49P	6.08	2.43e-09	1.05e-06	0.3	0.27	Vitamin D levels;	chr11:14401054	chr11:14478892~14478953:+
LUAD	cis	rs11157436	1	rs61972228	ENSG00000211812.1	TRAV26-2	-6.08	2.43e-09	1.05e-06	-0.31	-0.27	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22179460	chr14:22202583~22203368:+
LUAD	cis	rs853679	0.517	rs3757187	ENSG00000204709.4	LINC01556	6.08	2.43e-09	1.05e-06	0.38	0.27	Depression;	chr6:28139876	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs3757185	ENSG00000204709.4	LINC01556	6.08	2.43e-09	1.05e-06	0.38	0.27	Depression;	chr6:28139998	chr6:28943877~28944537:+
LUAD	cis	rs6772849	0.896	rs4857859	ENSG00000242551.2	POU5F1P6	-6.08	2.43e-09	1.05e-06	-0.31	-0.27	Monocyte percentage of white cells;Monocyte count;	chr3:128629171	chr3:128674735~128677005:-
LUAD	cis	rs10740039	0.883	rs2393676	ENSG00000254271.1	RP11-131N11.4	6.08	2.44e-09	1.05e-06	0.3	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60630500	chr10:60734342~60741828:+
LUAD	cis	rs7684253	0.548	rs922570	ENSG00000269949.1	RP11-738E22.3	-6.08	2.44e-09	1.05e-06	-0.35	-0.27	Migraine;	chr4:56851192	chr4:56960927~56961373:-
LUAD	cis	rs4835473	0.932	rs1842484	ENSG00000251600.4	RP11-673E1.1	6.08	2.44e-09	1.05e-06	0.33	0.27	Immature fraction of reticulocytes;	chr4:143793829	chr4:143912331~143982454:+
LUAD	cis	rs2255336	1	rs2255336	ENSG00000245648.1	RP11-277P12.20	6.08	2.44e-09	1.05e-06	0.39	0.27	Blood protein levels;	chr12:10379727	chr12:10363769~10398506:+
LUAD	cis	rs2243480	0.908	rs313822	ENSG00000230295.1	RP11-458F8.2	-6.08	2.44e-09	1.05e-06	-0.33	-0.27	Diabetic kidney disease;	chr7:66108952	chr7:66880708~66882981:+
LUAD	cis	rs8072100	0.934	rs9905583	ENSG00000228782.6	CTD-2026D20.3	6.08	2.44e-09	1.05e-06	0.29	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47663650	chr17:47450568~47492492:-
LUAD	cis	rs7618501	0.633	rs6772095	ENSG00000234667.1	ACTBP13	-6.08	2.44e-09	1.05e-06	-0.3	-0.27	Intelligence (multi-trait analysis);	chr3:49940636	chr3:49873347~49877980:-
LUAD	cis	rs7618501	0.603	rs72942333	ENSG00000234667.1	ACTBP13	-6.08	2.44e-09	1.05e-06	-0.3	-0.27	Intelligence (multi-trait analysis);	chr3:49948685	chr3:49873347~49877980:-
LUAD	cis	rs7618501	0.633	rs6792892	ENSG00000234667.1	ACTBP13	-6.08	2.44e-09	1.05e-06	-0.3	-0.27	Intelligence (multi-trait analysis);	chr3:49958085	chr3:49873347~49877980:-
LUAD	cis	rs7849270	0.959	rs3124509	ENSG00000268707.1	RP11-247A12.7	6.08	2.44e-09	1.05e-06	0.31	0.27	Blood metabolite ratios;	chr9:129134720	chr9:129170434~129170940:+
LUAD	cis	rs2276314	0.857	rs28379448	ENSG00000278986.1	RP11-723J4.3	-6.08	2.45e-09	1.06e-06	-0.33	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36024401	chr18:35972151~35973916:+
LUAD	cis	rs2739330	0.828	rs4822451	ENSG00000228039.3	KB-1125A3.10	6.08	2.45e-09	1.06e-06	0.33	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23963780~23964374:+
LUAD	cis	rs2739330	0.828	rs5760098	ENSG00000228039.3	KB-1125A3.10	6.08	2.45e-09	1.06e-06	0.33	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23963780~23964374:+
LUAD	cis	rs1823913	0.599	rs34840299	ENSG00000227542.1	AC092614.2	6.08	2.45e-09	1.06e-06	0.32	0.27	Obesity-related traits;	chr2:191280379	chr2:191229165~191246172:-
LUAD	cis	rs7246657	0.891	rs2279149	ENSG00000276846.1	CTD-3220F14.3	6.08	2.45e-09	1.06e-06	0.37	0.27	Coronary artery calcification;	chr19:37533465	chr19:37314868~37315620:-
LUAD	cis	rs732716	0.785	rs62130978	ENSG00000267980.1	AC007292.6	-6.08	2.45e-09	1.06e-06	-0.31	-0.27	Mean corpuscular volume;	chr19:4429010	chr19:4363789~4364640:+
LUAD	cis	rs948562	0.744	rs11229484	ENSG00000280010.1	AP001350.4	6.08	2.45e-09	1.06e-06	0.4	0.27	Lymphoma;	chr11:58464724	chr11:58627435~58628528:+
LUAD	cis	rs55757919	1	rs55757919	ENSG00000237595.3	RP11-112L6.3	6.08	2.45e-09	1.06e-06	0.37	0.27	Monocyte percentage of white cells;	chr20:50132011	chr20:50162765~50166102:-
LUAD	cis	rs4835473	0.545	rs10022856	ENSG00000251600.4	RP11-673E1.1	6.08	2.45e-09	1.06e-06	0.33	0.27	Immature fraction of reticulocytes;	chr4:143793157	chr4:143912331~143982454:+
LUAD	cis	rs2243480	1	rs1964692	ENSG00000230295.1	RP11-458F8.2	-6.08	2.46e-09	1.06e-06	-0.32	-0.27	Diabetic kidney disease;	chr7:65989196	chr7:66880708~66882981:+
LUAD	cis	rs4591358	0.773	rs17781713	ENSG00000223466.1	AC064834.2	-6.08	2.46e-09	1.06e-06	-0.36	-0.27	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195506827	chr2:195533035~195538681:+
LUAD	cis	rs11971779	0.68	rs7799598	ENSG00000273391.1	RP11-634H22.1	6.08	2.46e-09	1.06e-06	0.27	0.27	Diisocyanate-induced asthma;	chr7:139367087	chr7:139359032~139359566:-
LUAD	cis	rs1061377	1	rs12646251	ENSG00000249685.1	RP11-360F5.3	6.08	2.46e-09	1.06e-06	0.32	0.27	Uric acid levels;	chr4:39132751	chr4:39133913~39135608:+
LUAD	cis	rs17684571	0.751	rs1610157	ENSG00000231441.1	RP11-472M19.2	6.08	2.46e-09	1.06e-06	0.41	0.27	Schizophrenia;	chr6:56844035	chr6:56844002~56864078:+
LUAD	cis	rs67311347	0.955	rs60554147	ENSG00000223797.4	ENTPD3-AS1	6.08	2.46e-09	1.06e-06	0.28	0.27	Renal cell carcinoma;	chr3:40431012	chr3:40313802~40453329:-
LUAD	cis	rs7688540	0.515	rs28415975	ENSG00000275426.1	CH17-262A2.1	6.08	2.46e-09	1.06e-06	0.34	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:266377	chr4:149738~150317:+
LUAD	cis	rs1823913	0.599	rs13427761	ENSG00000280083.1	RP11-317J9.1	6.08	2.46e-09	1.06e-06	0.32	0.27	Obesity-related traits;	chr2:191269256	chr2:191154118~191156070:-
LUAD	cis	rs4664293	0.769	rs2729726	ENSG00000226266.5	AC009961.3	-6.08	2.46e-09	1.06e-06	-0.37	-0.27	Monocyte percentage of white cells;	chr2:159811597	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.738	rs1549580	ENSG00000226266.5	AC009961.3	-6.08	2.46e-09	1.06e-06	-0.37	-0.27	Monocyte percentage of white cells;	chr2:159812177	chr2:159670708~159712435:-
LUAD	cis	rs7221109	0.677	rs7223354	ENSG00000278834.1	RP11-458J1.1	6.08	2.47e-09	1.06e-06	0.31	0.27	Type 1 diabetes;	chr17:40668420	chr17:40648300~40649718:+
LUAD	cis	rs7221109	0.677	rs6503549	ENSG00000278834.1	RP11-458J1.1	6.08	2.47e-09	1.06e-06	0.31	0.27	Type 1 diabetes;	chr17:40668492	chr17:40648300~40649718:+
LUAD	cis	rs9467773	0.511	rs17278688	ENSG00000241549.7	GUSBP2	6.08	2.47e-09	1.06e-06	0.29	0.27	Intelligence (multi-trait analysis);	chr6:26922357	chr6:26871484~26956554:-
LUAD	cis	rs3762637	1	rs78381804	ENSG00000272758.4	RP11-299J3.8	-6.08	2.47e-09	1.06e-06	-0.4	-0.27	LDL cholesterol levels;	chr3:122503415	chr3:122416207~122443180:+
LUAD	cis	rs801193	0.569	rs6978178	ENSG00000222364.1	RNU6-96P	6.08	2.47e-09	1.07e-06	0.3	0.27	Aortic root size;	chr7:66658097	chr7:66395191~66395286:+
LUAD	cis	rs853679	0.517	rs7755442	ENSG00000204709.4	LINC01556	6.08	2.47e-09	1.07e-06	0.37	0.27	Depression;	chr6:28071237	chr6:28943877~28944537:+
LUAD	cis	rs5760092	0.755	rs915589	ENSG00000099984.9	GSTT2	6.08	2.47e-09	1.07e-06	0.39	0.27	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23980123~23983911:+
LUAD	cis	rs4663866	0.505	rs3739064	ENSG00000186235.9	AC016757.3	6.08	2.48e-09	1.07e-06	0.39	0.27	Irritable bowel syndrome;	chr2:238267745	chr2:238224552~238231677:-
LUAD	cis	rs6921919	0.583	rs11755942	ENSG00000216901.1	AL022393.7	6.08	2.48e-09	1.07e-06	0.32	0.27	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28176188~28176674:+
LUAD	cis	rs2243480	1	rs6958420	ENSG00000232546.1	RP11-458F8.1	6.08	2.48e-09	1.07e-06	0.35	0.27	Diabetic kidney disease;	chr7:66286184	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs1392104	ENSG00000232546.1	RP11-458F8.1	6.08	2.48e-09	1.07e-06	0.35	0.27	Diabetic kidney disease;	chr7:66294120	chr7:66848496~66858136:+
LUAD	cis	rs1914816	0.941	rs2957037	ENSG00000196274.5	Metazoa_SRP	6.08	2.48e-09	1.07e-06	0.3	0.27	Response to tocilizumab in rheumatoid arthritis;	chr15:76193195	chr15:76230048~76230390:-
LUAD	cis	rs4723738	1	rs4723738	ENSG00000227191.5	TRGC2	-6.08	2.48e-09	1.07e-06	-0.29	-0.27	Treatment response for severe sepsis;	chr7:38201307	chr7:38239580~38368091:-
LUAD	cis	rs17301013	0.507	rs398350	ENSG00000227373.4	RP11-160H22.5	6.08	2.48e-09	1.07e-06	0.39	0.27	Systemic lupus erythematosus;	chr1:174706168	chr1:174115300~174160004:-
LUAD	cis	rs9910055	0.762	rs7213436	ENSG00000267080.4	ASB16-AS1	6.08	2.48e-09	1.07e-06	0.24	0.27	Total body bone mineral density;	chr17:44174795	chr17:44175973~44186717:-
LUAD	cis	rs66887589	0.616	rs6822808	ENSG00000248280.1	RP11-33B1.2	6.08	2.49e-09	1.07e-06	0.3	0.27	Diastolic blood pressure;	chr4:119296210	chr4:119440561~119450157:-
LUAD	cis	rs1275468	1	rs3858534	ENSG00000257497.2	RP11-585P4.5	-6.08	2.49e-09	1.07e-06	-0.37	-0.27	Polycystic ovary syndrome;	chr12:75553304	chr12:75483454~75489820:-
LUAD	cis	rs875971	0.502	rs1796227	ENSG00000237310.1	GS1-124K5.4	-6.08	2.49e-09	1.07e-06	-0.33	-0.27	Aortic root size;	chr7:66622032	chr7:66493706~66495474:+
LUAD	cis	rs2283792	0.715	rs56036797	ENSG00000224086.5	LL22NC03-86G7.1	-6.08	2.49e-09	1.07e-06	-0.26	-0.27	Multiple sclerosis;	chr22:21860875	chr22:21938293~21977632:+
LUAD	cis	rs9652601	0.691	rs9941107	ENSG00000274038.1	RP11-66H6.4	-6.08	2.49e-09	1.07e-06	-0.32	-0.27	Systemic lupus erythematosus;	chr16:11102184	chr16:11056556~11057034:+
LUAD	cis	rs30380	0.632	rs149189	ENSG00000272109.1	CTD-2260A17.3	-6.08	2.5e-09	1.08e-06	-0.33	-0.27	Cerebrospinal fluid biomarker levels;	chr5:96802101	chr5:96804353~96806105:+
LUAD	cis	rs30380	0.632	rs26495	ENSG00000272109.1	CTD-2260A17.3	-6.08	2.5e-09	1.08e-06	-0.33	-0.27	Cerebrospinal fluid biomarker levels;	chr5:96802137	chr5:96804353~96806105:+
LUAD	cis	rs10129255	1	rs10129255	ENSG00000211972.2	IGHV3-66	-6.08	2.5e-09	1.08e-06	-0.23	-0.27	Kawasaki disease;	chr14:106767970	chr14:106675017~106675544:-
LUAD	cis	rs6921919	0.583	rs6907950	ENSG00000204709.4	LINC01556	6.08	2.5e-09	1.08e-06	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28943877~28944537:+
LUAD	cis	rs732716	0.819	rs12459919	ENSG00000267980.1	AC007292.6	-6.08	2.5e-09	1.08e-06	-0.31	-0.27	Mean corpuscular volume;	chr19:4434506	chr19:4363789~4364640:+
LUAD	cis	rs4591358	0.773	rs13035226	ENSG00000223466.1	AC064834.2	-6.08	2.51e-09	1.08e-06	-0.36	-0.27	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195512957	chr2:195533035~195538681:+
LUAD	cis	rs9879311	1	rs9879311	ENSG00000240288.6	GHRLOS	6.08	2.51e-09	1.08e-06	0.25	0.27	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10373659	chr3:10285754~10293449:+
LUAD	cis	rs853679	0.55	rs1225598	ENSG00000219392.1	RP1-265C24.5	-6.08	2.51e-09	1.08e-06	-0.37	-0.27	Depression;	chr6:28193021	chr6:28115628~28116551:+
LUAD	cis	rs7849270	0.959	rs10988233	ENSG00000268707.1	RP11-247A12.7	-6.08	2.51e-09	1.08e-06	-0.3	-0.27	Blood metabolite ratios;	chr9:129153647	chr9:129170434~129170940:+
LUAD	cis	rs7246657	0.678	rs2927740	ENSG00000276846.1	CTD-3220F14.3	-6.08	2.52e-09	1.08e-06	-0.35	-0.27	Coronary artery calcification;	chr19:37650065	chr19:37314868~37315620:-
LUAD	cis	rs17301013	0.606	rs6666588	ENSG00000227373.4	RP11-160H22.5	6.08	2.52e-09	1.09e-06	0.38	0.27	Systemic lupus erythematosus;	chr1:174248972	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs72713504	ENSG00000227373.4	RP11-160H22.5	6.08	2.52e-09	1.09e-06	0.38	0.27	Systemic lupus erythematosus;	chr1:174251916	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs72713505	ENSG00000227373.4	RP11-160H22.5	6.08	2.52e-09	1.09e-06	0.38	0.27	Systemic lupus erythematosus;	chr1:174255911	chr1:174115300~174160004:-
LUAD	cis	rs1823913	0.599	rs13015653	ENSG00000280083.1	RP11-317J9.1	-6.07	2.52e-09	1.09e-06	-0.32	-0.27	Obesity-related traits;	chr2:191306813	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.599	rs12994212	ENSG00000280083.1	RP11-317J9.1	-6.07	2.52e-09	1.09e-06	-0.32	-0.27	Obesity-related traits;	chr2:191306910	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.599	rs12994236	ENSG00000280083.1	RP11-317J9.1	-6.07	2.52e-09	1.09e-06	-0.32	-0.27	Obesity-related traits;	chr2:191306991	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.599	rs35495506	ENSG00000280083.1	RP11-317J9.1	-6.07	2.52e-09	1.09e-06	-0.32	-0.27	Obesity-related traits;	chr2:191307551	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.599	rs34691559	ENSG00000280083.1	RP11-317J9.1	-6.07	2.52e-09	1.09e-06	-0.32	-0.27	Obesity-related traits;	chr2:191307688	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.561	rs55790432	ENSG00000280083.1	RP11-317J9.1	-6.07	2.52e-09	1.09e-06	-0.32	-0.27	Obesity-related traits;	chr2:191307722	chr2:191154118~191156070:-
LUAD	cis	rs2243480	1	rs35820085	ENSG00000232546.1	RP11-458F8.1	-6.07	2.52e-09	1.09e-06	-0.36	-0.27	Diabetic kidney disease;	chr7:65977771	chr7:66848496~66858136:+
LUAD	cis	rs1345301	0.514	rs57738191	ENSG00000234389.1	AC007278.3	-6.07	2.52e-09	1.09e-06	-0.24	-0.27	Waist circumference;	chr2:102251899	chr2:102438713~102440475:+
LUAD	cis	rs4660456	0.504	rs491619	ENSG00000237899.1	RP4-739H11.3	6.07	2.53e-09	1.09e-06	0.37	0.27	Platelet count;	chr1:40641688	chr1:40669089~40687588:-
LUAD	cis	rs4660456	0.542	rs850009	ENSG00000237899.1	RP4-739H11.3	6.07	2.53e-09	1.09e-06	0.37	0.27	Platelet count;	chr1:40643593	chr1:40669089~40687588:-
LUAD	cis	rs13217239	0.646	rs10456352	ENSG00000241549.7	GUSBP2	6.07	2.53e-09	1.09e-06	0.29	0.27	Schizophrenia;	chr6:27022579	chr6:26871484~26956554:-
LUAD	cis	rs13217239	0.646	rs4583981	ENSG00000241549.7	GUSBP2	6.07	2.53e-09	1.09e-06	0.29	0.27	Schizophrenia;	chr6:27024244	chr6:26871484~26956554:-
LUAD	cis	rs875971	0.862	rs6952182	ENSG00000237310.1	GS1-124K5.4	-6.07	2.53e-09	1.09e-06	-0.29	-0.27	Aortic root size;	chr7:66218330	chr7:66493706~66495474:+
LUAD	cis	rs1914816	0.941	rs2460146	ENSG00000196274.5	Metazoa_SRP	6.07	2.53e-09	1.09e-06	0.3	0.27	Response to tocilizumab in rheumatoid arthritis;	chr15:76262414	chr15:76230048~76230390:-
LUAD	cis	rs1914816	1	rs2456075	ENSG00000196274.5	Metazoa_SRP	6.07	2.53e-09	1.09e-06	0.3	0.27	Response to tocilizumab in rheumatoid arthritis;	chr15:76263645	chr15:76230048~76230390:-
LUAD	cis	rs2236295	0.814	rs1848797	ENSG00000238280.1	RP11-436D10.3	-6.07	2.53e-09	1.09e-06	-0.34	-0.27	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr10:62793174	chr10:62793562~62805887:-
LUAD	cis	rs2117029	0.555	rs7958241	ENSG00000258017.1	RP11-386G11.10	6.07	2.53e-09	1.09e-06	0.32	0.27	Intelligence (multi-trait analysis);	chr12:49115479	chr12:49127782~49147869:+
LUAD	cis	rs8031584	0.958	rs34294266	ENSG00000260382.1	RP11-540B6.2	6.07	2.53e-09	1.09e-06	0.32	0.27	Huntington's disease progression;	chr15:30954637	chr15:30882267~30883231:-
LUAD	cis	rs4718428	0.705	rs4718422	ENSG00000232546.1	RP11-458F8.1	-6.07	2.53e-09	1.09e-06	-0.25	-0.27	Corneal structure;	chr7:66894282	chr7:66848496~66858136:+
LUAD	cis	rs4718428	0.705	rs13231140	ENSG00000232546.1	RP11-458F8.1	-6.07	2.53e-09	1.09e-06	-0.25	-0.27	Corneal structure;	chr7:66896631	chr7:66848496~66858136:+
LUAD	cis	rs875971	1	rs1183245	ENSG00000222364.1	RNU6-96P	6.07	2.53e-09	1.09e-06	0.3	0.27	Aortic root size;	chr7:66076198	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs1144895	ENSG00000222364.1	RNU6-96P	6.07	2.53e-09	1.09e-06	0.3	0.27	Aortic root size;	chr7:66076320	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs1144894	ENSG00000222364.1	RNU6-96P	6.07	2.53e-09	1.09e-06	0.3	0.27	Aortic root size;	chr7:66077907	chr7:66395191~66395286:+
LUAD	cis	rs11690935	0.55	rs62183784	ENSG00000228389.1	AC068039.4	-6.07	2.54e-09	1.09e-06	-0.28	-0.27	Schizophrenia;	chr2:172001789	chr2:171773482~171775844:+
LUAD	cis	rs8062405	1	rs2008514	ENSG00000251417.2	RP11-1348G14.4	6.07	2.54e-09	1.09e-06	0.27	0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28802743~28817828:+
LUAD	cis	rs12699921	0.599	rs2462512	ENSG00000279048.1	RP11-511H23.2	-6.07	2.54e-09	1.09e-06	-0.21	-0.27	Fibrinogen levels;	chr7:17808215	chr7:17940503~17942922:+
LUAD	cis	rs3096299	0.679	rs3102338	ENSG00000274627.1	RP11-104N10.2	6.07	2.55e-09	1.1e-06	0.26	0.27	Multiple myeloma (IgH translocation);	chr16:89375842	chr16:89516797~89522217:+
LUAD	cis	rs4713118	0.662	rs149900	ENSG00000204709.4	LINC01556	6.07	2.55e-09	1.1e-06	0.36	0.27	Parkinson's disease;	chr6:28046819	chr6:28943877~28944537:+
LUAD	cis	rs848490	0.651	rs12113119	ENSG00000214293.7	APTR	6.07	2.55e-09	1.1e-06	0.3	0.27	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77685501	chr7:77657660~77696265:-
LUAD	cis	rs62229266	0.557	rs4817761	ENSG00000214914.3	RPL23AP3	6.07	2.55e-09	1.1e-06	0.33	0.27	Mitral valve prolapse;	chr21:36023258	chr21:36016079~36016546:-
LUAD	cis	rs17301013	0.507	rs332786	ENSG00000227373.4	RP11-160H22.5	6.07	2.56e-09	1.1e-06	0.39	0.27	Systemic lupus erythematosus;	chr1:174713584	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs332779	ENSG00000227373.4	RP11-160H22.5	6.07	2.56e-09	1.1e-06	0.39	0.27	Systemic lupus erythematosus;	chr1:174716623	chr1:174115300~174160004:-
LUAD	cis	rs11096990	0.964	rs7678689	ENSG00000249207.1	RP11-360F5.1	6.07	2.56e-09	1.1e-06	0.3	0.27	Cognitive function;	chr4:39261140	chr4:39112677~39126818:-
LUAD	cis	rs755249	0.874	rs61779310	ENSG00000228060.1	RP11-69E11.8	-6.07	2.56e-09	1.1e-06	-0.27	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39476625	chr1:39565160~39573203:+
LUAD	cis	rs10050311	0.858	rs76283582	ENSG00000251411.1	RP11-397E7.4	-6.07	2.57e-09	1.1e-06	-0.37	-0.27	Insulin-related traits;	chr4:86878202	chr4:86913266~86914817:-
LUAD	cis	rs1061377	1	rs4974998	ENSG00000249685.1	RP11-360F5.3	6.07	2.57e-09	1.1e-06	0.32	0.27	Uric acid levels;	chr4:39109129	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs7673299	ENSG00000249685.1	RP11-360F5.3	6.07	2.57e-09	1.1e-06	0.32	0.27	Uric acid levels;	chr4:39109138	chr4:39133913~39135608:+
LUAD	cis	rs6921919	0.583	rs11755942	ENSG00000204709.4	LINC01556	6.07	2.57e-09	1.1e-06	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28943877~28944537:+
LUAD	cis	rs1874124	0.577	rs2807880	ENSG00000238078.1	LINC01352	6.07	2.57e-09	1.1e-06	0.39	0.27	Cholesterol, total;	chr1:220869661	chr1:220829255~220832429:+
LUAD	cis	rs755249	0.567	rs4660546	ENSG00000228060.1	RP11-69E11.8	-6.07	2.57e-09	1.1e-06	-0.27	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39213730	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs2036463	ENSG00000228060.1	RP11-69E11.8	-6.07	2.57e-09	1.1e-06	-0.27	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222403	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs2036464	ENSG00000228060.1	RP11-69E11.8	-6.07	2.57e-09	1.1e-06	-0.27	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222570	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs905381	ENSG00000228060.1	RP11-69E11.8	-6.07	2.57e-09	1.1e-06	-0.27	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222880	chr1:39565160~39573203:+
LUAD	cis	rs4713118	0.911	rs9295746	ENSG00000219392.1	RP1-265C24.5	-6.07	2.57e-09	1.11e-06	-0.37	-0.27	Parkinson's disease;	chr6:27762285	chr6:28115628~28116551:+
LUAD	cis	rs10129255	0.957	rs10141052	ENSG00000211974.3	IGHV2-70	6.07	2.58e-09	1.11e-06	0.27	0.27	Kawasaki disease;	chr14:106776528	chr14:106723574~106724093:-
LUAD	cis	rs1075265	0.783	rs805439	ENSG00000233266.1	HMGB1P31	6.07	2.58e-09	1.11e-06	0.33	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53829437	chr2:54051334~54051760:+
LUAD	cis	rs1499614	0.901	rs2178742	ENSG00000232546.1	RP11-458F8.1	-6.07	2.58e-09	1.11e-06	-0.36	-0.27	Gout;	chr7:66732812	chr7:66848496~66858136:+
LUAD	cis	rs270601	0.661	rs10036208	ENSG00000233006.5	AC034220.3	6.07	2.58e-09	1.11e-06	0.25	0.27	Acylcarnitine levels;	chr5:132235630	chr5:132311285~132369916:-
LUAD	cis	rs858239	0.6	rs2003555	ENSG00000230042.1	AK3P3	-6.07	2.58e-09	1.11e-06	-0.34	-0.27	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.6	rs7784929	ENSG00000230042.1	AK3P3	-6.07	2.58e-09	1.11e-06	-0.34	-0.27	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23129178~23129841:+
LUAD	cis	rs2404602	0.647	rs35940181	ENSG00000259422.1	RP11-593F23.1	-6.07	2.58e-09	1.11e-06	-0.35	-0.27	Blood metabolite levels;	chr15:76887678	chr15:76174891~76181486:-
LUAD	cis	rs2665103	0.589	rs3858953	ENSG00000255769.6	GOLGA2P10	-6.07	2.58e-09	1.11e-06	-0.28	-0.27	Intelligence (multi-trait analysis);	chr15:82238049	chr15:82472993~82513950:-
LUAD	cis	rs496547	0.756	rs562059	ENSG00000255422.1	AP002954.4	-6.07	2.58e-09	1.11e-06	-0.34	-0.27	Hip minimal joint space width;	chr11:118731349	chr11:118704607~118750263:+
LUAD	cis	rs853679	1	rs1936365	ENSG00000204709.4	LINC01556	-6.07	2.58e-09	1.11e-06	-0.4	-0.27	Depression;	chr6:28300675	chr6:28943877~28944537:+
LUAD	cis	rs875971	0.862	rs10276077	ENSG00000237310.1	GS1-124K5.4	-6.07	2.58e-09	1.11e-06	-0.29	-0.27	Aortic root size;	chr7:66263424	chr7:66493706~66495474:+
LUAD	cis	rs6142102	0.646	rs2223553	ENSG00000275784.1	RP5-1125A11.6	-6.07	2.58e-09	1.11e-06	-0.28	-0.27	Skin pigmentation;	chr20:34121638	chr20:33989480~33991818:-
LUAD	cis	rs321358	0.731	rs516110	ENSG00000271584.1	RP11-89C3.4	6.07	2.59e-09	1.11e-06	0.4	0.27	Body mass index;	chr11:111166525	chr11:111091932~111097357:-
LUAD	cis	rs853679	0.517	rs9393890	ENSG00000204709.4	LINC01556	6.07	2.59e-09	1.11e-06	0.37	0.27	Depression;	chr6:28096077	chr6:28943877~28944537:+
LUAD	cis	rs496547	0.719	rs476246	ENSG00000255422.1	AP002954.4	6.07	2.59e-09	1.11e-06	0.34	0.27	Hip minimal joint space width;	chr11:118747211	chr11:118704607~118750263:+
LUAD	cis	rs5760092	0.755	rs4585126	ENSG00000206090.4	AP000350.7	-6.07	2.59e-09	1.11e-06	-0.35	-0.27	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23939998~23942798:+
LUAD	cis	rs1499614	1	rs2707832	ENSG00000230295.1	RP11-458F8.2	-6.07	2.59e-09	1.11e-06	-0.32	-0.27	Gout;	chr7:66671562	chr7:66880708~66882981:+
LUAD	cis	rs7615952	0.688	rs4422259	ENSG00000171084.14	FAM86JP	6.07	2.6e-09	1.12e-06	0.37	0.27	Blood pressure (smoking interaction);	chr3:125826988	chr3:125916620~125930024:+
LUAD	cis	rs7849270	1	rs7020708	ENSG00000268707.1	RP11-247A12.7	-6.07	2.6e-09	1.12e-06	-0.3	-0.27	Blood metabolite ratios;	chr9:129122852	chr9:129170434~129170940:+
LUAD	cis	rs1062177	0.855	rs6884630	ENSG00000213433.5	RPLP1P6	-6.07	2.6e-09	1.12e-06	-0.34	-0.27	Preschool internalizing problems;	chr5:151889436	chr5:151765859~151766378:-
LUAD	cis	rs35740288	0.703	rs10520598	ENSG00000202081.1	RNU6-1280P	6.07	2.6e-09	1.12e-06	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85630150	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.77	rs11635587	ENSG00000202081.1	RNU6-1280P	6.07	2.6e-09	1.12e-06	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85630402	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.77	rs35447727	ENSG00000202081.1	RNU6-1280P	6.07	2.6e-09	1.12e-06	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85631168	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.77	rs34058174	ENSG00000202081.1	RNU6-1280P	6.07	2.6e-09	1.12e-06	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85631231	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.587	rs4843089	ENSG00000202081.1	RNU6-1280P	6.07	2.6e-09	1.12e-06	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85632905	chr15:85651522~85651628:-
LUAD	cis	rs3096299	0.606	rs4785573	ENSG00000274627.1	RP11-104N10.2	6.07	2.6e-09	1.12e-06	0.29	0.27	Multiple myeloma (IgH translocation);	chr16:89498995	chr16:89516797~89522217:+
LUAD	cis	rs1061377	1	rs7675782	ENSG00000249685.1	RP11-360F5.3	6.07	2.6e-09	1.12e-06	0.32	0.27	Uric acid levels;	chr4:39120048	chr4:39133913~39135608:+
LUAD	cis	rs7567389	0.671	rs11692990	ENSG00000236682.1	AC068282.3	-6.07	2.61e-09	1.12e-06	-0.38	-0.27	Self-rated health;	chr2:127354614	chr2:127389130~127400580:+
LUAD	cis	rs755249	0.567	rs72661927	ENSG00000228060.1	RP11-69E11.8	-6.07	2.61e-09	1.12e-06	-0.27	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39209650	chr1:39565160~39573203:+
LUAD	cis	rs9506514	0.722	rs10400670	ENSG00000222726.1	RNU2-7P	6.07	2.61e-09	1.12e-06	0.3	0.27	Coronary artery calcification;	chr13:20679350	chr13:20612161~20612338:+
LUAD	cis	rs2404602	0.583	rs2139190	ENSG00000259422.1	RP11-593F23.1	6.07	2.62e-09	1.12e-06	0.3	0.27	Blood metabolite levels;	chr15:76263198	chr15:76174891~76181486:-
LUAD	cis	rs10129255	1	rs10129407	ENSG00000211972.2	IGHV3-66	6.07	2.62e-09	1.12e-06	0.23	0.27	Kawasaki disease;	chr14:106767956	chr14:106675017~106675544:-
LUAD	cis	rs2404602	0.583	rs12592501	ENSG00000259422.1	RP11-593F23.1	6.07	2.62e-09	1.12e-06	0.3	0.27	Blood metabolite levels;	chr15:76262449	chr15:76174891~76181486:-
LUAD	cis	rs9326248	0.501	rs4938351	ENSG00000280143.1	AP000892.6	6.07	2.62e-09	1.13e-06	0.31	0.27	Blood protein levels;	chr11:117151636	chr11:117204967~117210292:+
LUAD	cis	rs2243480	0.901	rs313808	ENSG00000230295.1	RP11-458F8.2	-6.07	2.62e-09	1.13e-06	-0.33	-0.27	Diabetic kidney disease;	chr7:66034886	chr7:66880708~66882981:+
LUAD	cis	rs4835473	0.897	rs11100812	ENSG00000251600.4	RP11-673E1.1	6.07	2.63e-09	1.13e-06	0.33	0.27	Immature fraction of reticulocytes;	chr4:143790400	chr4:143912331~143982454:+
LUAD	cis	rs7849270	1	rs10760589	ENSG00000268707.1	RP11-247A12.7	-6.07	2.63e-09	1.13e-06	-0.3	-0.27	Blood metabolite ratios;	chr9:129144014	chr9:129170434~129170940:+
LUAD	cis	rs4964805	0.626	rs11111767	ENSG00000257681.1	RP11-341G23.4	-6.07	2.63e-09	1.13e-06	-0.33	-0.27	Attention deficit hyperactivity disorder;	chr12:103782468	chr12:103746315~103768858:-
LUAD	cis	rs9309473	1	rs6546836	ENSG00000163016.8	ALMS1P	6.07	2.63e-09	1.13e-06	0.32	0.27	Metabolite levels;	chr2:73450706	chr2:73644919~73685576:+
LUAD	cis	rs12134133	0.752	rs6683677	ENSG00000274245.1	RP11-357P18.2	6.07	2.63e-09	1.13e-06	0.37	0.27	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207228335	chr1:207372559~207373252:+
LUAD	cis	rs7727544	0.709	rs272852	ENSG00000233006.5	AC034220.3	6.07	2.63e-09	1.13e-06	0.24	0.27	Blood metabolite levels;	chr5:132353074	chr5:132311285~132369916:-
LUAD	cis	rs987724	0.592	rs1430410	ENSG00000240875.4	LINC00886	-6.07	2.64e-09	1.13e-06	-0.28	-0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156807773	chr3:156747346~156817062:-
LUAD	cis	rs7923837	0.634	rs61862780	ENSG00000236493.2	EIF2S2P3	-6.07	2.64e-09	1.13e-06	-0.3	-0.27	Multiple sclerosis;Body mass index;	chr10:92708886	chr10:92668745~92669743:-
LUAD	cis	rs10129255	0.912	rs8009135	ENSG00000211974.3	IGHV2-70	6.07	2.64e-09	1.13e-06	0.28	0.27	Kawasaki disease;	chr14:106777528	chr14:106723574~106724093:-
LUAD	cis	rs1823913	0.599	rs12988037	ENSG00000280083.1	RP11-317J9.1	-6.07	2.64e-09	1.13e-06	-0.32	-0.27	Obesity-related traits;	chr2:191306419	chr2:191154118~191156070:-
LUAD	cis	rs5753618	0.509	rs5749224	ENSG00000236132.1	CTA-440B3.1	6.07	2.64e-09	1.13e-06	0.34	0.27	Colorectal cancer;	chr22:31162563	chr22:31816379~31817491:-
LUAD	cis	rs916888	0.773	rs199534	ENSG00000261575.2	RP11-259G18.1	6.07	2.64e-09	1.13e-06	0.43	0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46267037~46268694:+
LUAD	cis	rs11098499	0.754	rs1511017	ENSG00000248280.1	RP11-33B1.2	6.07	2.64e-09	1.13e-06	0.33	0.27	Corneal astigmatism;	chr4:119329650	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.789	rs12498994	ENSG00000248280.1	RP11-33B1.2	6.07	2.64e-09	1.13e-06	0.33	0.27	Corneal astigmatism;	chr4:119329663	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs12507565	ENSG00000248280.1	RP11-33B1.2	6.07	2.64e-09	1.13e-06	0.33	0.27	Corneal astigmatism;	chr4:119329966	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.826	rs12511640	ENSG00000248280.1	RP11-33B1.2	6.07	2.64e-09	1.13e-06	0.33	0.27	Corneal astigmatism;	chr4:119330093	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs1980026	ENSG00000248280.1	RP11-33B1.2	6.07	2.64e-09	1.13e-06	0.33	0.27	Corneal astigmatism;	chr4:119330488	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.743	rs11098501	ENSG00000248280.1	RP11-33B1.2	6.07	2.64e-09	1.13e-06	0.33	0.27	Corneal astigmatism;	chr4:119330862	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs11098502	ENSG00000248280.1	RP11-33B1.2	6.07	2.64e-09	1.13e-06	0.33	0.27	Corneal astigmatism;	chr4:119330908	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.708	rs11732686	ENSG00000248280.1	RP11-33B1.2	6.07	2.64e-09	1.13e-06	0.33	0.27	Corneal astigmatism;	chr4:119331175	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs11724409	ENSG00000248280.1	RP11-33B1.2	6.07	2.64e-09	1.13e-06	0.33	0.27	Corneal astigmatism;	chr4:119331206	chr4:119440561~119450157:-
LUAD	cis	rs12134133	0.752	rs6540874	ENSG00000274245.1	RP11-357P18.2	6.07	2.65e-09	1.14e-06	0.37	0.27	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207221638	chr1:207372559~207373252:+
LUAD	cis	rs7688540	0.8	rs12506277	ENSG00000275426.1	CH17-262A2.1	6.07	2.65e-09	1.14e-06	0.33	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:293860	chr4:149738~150317:+
LUAD	cis	rs7688540	0.8	rs12501727	ENSG00000275426.1	CH17-262A2.1	6.07	2.65e-09	1.14e-06	0.33	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:294285	chr4:149738~150317:+
LUAD	cis	rs9549367	0.789	rs9549365	ENSG00000269125.1	RP11-98F14.11	6.07	2.65e-09	1.14e-06	0.33	0.27	Platelet distribution width;	chr13:113253077	chr13:113165002~113165183:-
LUAD	cis	rs2243480	1	rs313807	ENSG00000230295.1	RP11-458F8.2	-6.07	2.65e-09	1.14e-06	-0.33	-0.27	Diabetic kidney disease;	chr7:66034494	chr7:66880708~66882981:+
LUAD	cis	rs1914816	1	rs1914816	ENSG00000196274.5	Metazoa_SRP	6.07	2.65e-09	1.14e-06	0.3	0.27	Response to tocilizumab in rheumatoid arthritis;	chr15:76254592	chr15:76230048~76230390:-
LUAD	cis	rs875971	0.545	rs1796217	ENSG00000237310.1	GS1-124K5.4	-6.07	2.66e-09	1.14e-06	-0.32	-0.27	Aortic root size;	chr7:66620931	chr7:66493706~66495474:+
LUAD	cis	rs1914816	0.887	rs2460155	ENSG00000196274.5	Metazoa_SRP	6.07	2.66e-09	1.14e-06	0.3	0.27	Response to tocilizumab in rheumatoid arthritis;	chr15:76186584	chr15:76230048~76230390:-
LUAD	cis	rs12908161	1	rs17600551	ENSG00000225151.9	GOLGA2P7	-6.07	2.66e-09	1.14e-06	-0.36	-0.27	Schizophrenia;	chr15:84776027	chr15:84199311~84230136:-
LUAD	cis	rs12908161	1	rs62019469	ENSG00000225151.9	GOLGA2P7	-6.07	2.66e-09	1.14e-06	-0.36	-0.27	Schizophrenia;	chr15:84777989	chr15:84199311~84230136:-
LUAD	cis	rs3813579	0.606	rs3813583	ENSG00000261390.4	RP11-345M22.2	-6.07	2.66e-09	1.14e-06	-0.33	-0.27	Thyroid volume;	chr16:79721183	chr16:79715232~79770563:-
LUAD	cis	rs7849270	1	rs10988214	ENSG00000268707.1	RP11-247A12.7	-6.07	2.66e-09	1.14e-06	-0.3	-0.27	Blood metabolite ratios;	chr9:129121473	chr9:129170434~129170940:+
LUAD	cis	rs7849270	1	rs932833	ENSG00000268707.1	RP11-247A12.7	-6.07	2.66e-09	1.14e-06	-0.3	-0.27	Blood metabolite ratios;	chr9:129121762	chr9:129170434~129170940:+
LUAD	cis	rs17301013	0.507	rs1622802	ENSG00000227373.4	RP11-160H22.5	-6.07	2.66e-09	1.14e-06	-0.39	-0.27	Systemic lupus erythematosus;	chr1:174766066	chr1:174115300~174160004:-
LUAD	cis	rs957448	1	rs16916881	ENSG00000253704.1	RP11-267M23.4	6.07	2.66e-09	1.14e-06	0.33	0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94554042	chr8:94553722~94569745:+
LUAD	cis	rs2404602	0.684	rs11072600	ENSG00000259422.1	RP11-593F23.1	-6.07	2.66e-09	1.14e-06	-0.35	-0.27	Blood metabolite levels;	chr15:76575574	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.575	rs11633309	ENSG00000259422.1	RP11-593F23.1	-6.07	2.67e-09	1.14e-06	-0.38	-0.27	Blood metabolite levels;	chr15:76670008	chr15:76174891~76181486:-
LUAD	cis	rs10214930	0.697	rs12672811	ENSG00000235574.1	AC073150.6	-6.07	2.67e-09	1.14e-06	-0.33	-0.27	Hypospadias;	chr7:27645264	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.671	rs2391449	ENSG00000235574.1	AC073150.6	-6.07	2.67e-09	1.14e-06	-0.33	-0.27	Hypospadias;	chr7:27645527	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.671	rs2391452	ENSG00000235574.1	AC073150.6	-6.07	2.67e-09	1.14e-06	-0.33	-0.27	Hypospadias;	chr7:27646533	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.624	rs13244903	ENSG00000235574.1	AC073150.6	-6.07	2.67e-09	1.14e-06	-0.33	-0.27	Hypospadias;	chr7:27649292	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.671	rs12530626	ENSG00000235574.1	AC073150.6	-6.07	2.67e-09	1.14e-06	-0.33	-0.27	Hypospadias;	chr7:27650189	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs12535844	ENSG00000235574.1	AC073150.6	-6.07	2.67e-09	1.14e-06	-0.33	-0.27	Hypospadias;	chr7:27650205	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.671	rs6948460	ENSG00000235574.1	AC073150.6	-6.07	2.67e-09	1.14e-06	-0.33	-0.27	Hypospadias;	chr7:27650619	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.647	rs6966587	ENSG00000235574.1	AC073150.6	-6.07	2.67e-09	1.14e-06	-0.33	-0.27	Hypospadias;	chr7:27650744	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.625	rs2391453	ENSG00000235574.1	AC073150.6	-6.07	2.67e-09	1.14e-06	-0.33	-0.27	Hypospadias;	chr7:27650968	chr7:27491682~27492765:-
LUAD	cis	rs9595908	0.869	rs2320301	ENSG00000212293.1	SNORA16	6.07	2.67e-09	1.14e-06	0.29	0.27	Body mass index;	chr13:32635067	chr13:32420390~32420516:-
LUAD	cis	rs7567389	0.677	rs72845991	ENSG00000236682.1	AC068282.3	-6.07	2.67e-09	1.14e-06	-0.38	-0.27	Self-rated health;	chr2:127350331	chr2:127389130~127400580:+
LUAD	cis	rs9879311	0.932	rs7427473	ENSG00000240288.6	GHRLOS	6.06	2.67e-09	1.15e-06	0.25	0.27	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10371513	chr3:10285754~10293449:+
LUAD	cis	rs4820294	1	rs739139	ENSG00000233360.4	Z83844.1	6.06	2.67e-09	1.15e-06	0.28	0.27	Fat distribution (HIV);	chr22:37671004	chr22:37641832~37658377:-
LUAD	cis	rs1075265	0.875	rs12616212	ENSG00000233266.1	HMGB1P31	6.06	2.68e-09	1.15e-06	0.34	0.27	Chronotype;Morning vs. evening chronotype;	chr2:54039109	chr2:54051334~54051760:+
LUAD	cis	rs10129255	0.957	rs11847726	ENSG00000224373.3	IGHV4-59	6.06	2.68e-09	1.15e-06	0.17	0.27	Kawasaki disease;	chr14:106779116	chr14:106627249~106627825:-
LUAD	cis	rs4820294	1	rs929039	ENSG00000233360.4	Z83844.1	6.06	2.68e-09	1.15e-06	0.28	0.27	Fat distribution (HIV);	chr22:37675504	chr22:37641832~37658377:-
LUAD	cis	rs2404602	0.647	rs11072610	ENSG00000259422.1	RP11-593F23.1	-6.06	2.68e-09	1.15e-06	-0.36	-0.27	Blood metabolite levels;	chr15:76638464	chr15:76174891~76181486:-
LUAD	cis	rs720064	0.555	rs11873358	ENSG00000264745.1	TTC39C-AS1	6.06	2.68e-09	1.15e-06	0.28	0.27	Strep throat;	chr18:23951942	chr18:23994213~24015339:-
LUAD	cis	rs7849270	0.959	rs10760591	ENSG00000268707.1	RP11-247A12.7	-6.06	2.68e-09	1.15e-06	-0.3	-0.27	Blood metabolite ratios;	chr9:129152749	chr9:129170434~129170940:+
LUAD	cis	rs11098499	0.955	rs1511018	ENSG00000248280.1	RP11-33B1.2	6.06	2.69e-09	1.15e-06	0.33	0.27	Corneal astigmatism;	chr4:119240425	chr4:119440561~119450157:-
LUAD	cis	rs9595908	0.606	rs4942922	ENSG00000212293.1	SNORA16	6.06	2.69e-09	1.15e-06	0.29	0.27	Body mass index;	chr13:32806832	chr13:32420390~32420516:-
LUAD	cis	rs12699921	0.599	rs6955984	ENSG00000279048.1	RP11-511H23.2	6.06	2.69e-09	1.15e-06	0.22	0.27	Fibrinogen levels;	chr7:17938589	chr7:17940503~17942922:+
LUAD	cis	rs7618501	0.633	rs2883057	ENSG00000234667.1	ACTBP13	-6.06	2.69e-09	1.15e-06	-0.3	-0.27	Intelligence (multi-trait analysis);	chr3:49960849	chr3:49873347~49877980:-
LUAD	cis	rs13217239	0.646	rs10946888	ENSG00000241549.7	GUSBP2	6.06	2.7e-09	1.15e-06	0.29	0.27	Schizophrenia;	chr6:26983899	chr6:26871484~26956554:-
LUAD	cis	rs9928842	0.77	rs8048371	ENSG00000280152.1	RP11-331F4.5	6.06	2.7e-09	1.16e-06	0.3	0.27	Alcoholic chronic pancreatitis;	chr16:75241649	chr16:75245994~75250077:-
LUAD	cis	rs66887589	0.616	rs7659403	ENSG00000245958.5	RP11-33B1.1	-6.06	2.7e-09	1.16e-06	-0.22	-0.27	Diastolic blood pressure;	chr4:119286099	chr4:119454791~119552025:+
LUAD	cis	rs9506514	0.712	rs11838795	ENSG00000222726.1	RNU2-7P	6.06	2.7e-09	1.16e-06	0.3	0.27	Coronary artery calcification;	chr13:20684189	chr13:20612161~20612338:+
LUAD	cis	rs11096990	0.964	rs6828598	ENSG00000249207.1	RP11-360F5.1	6.06	2.7e-09	1.16e-06	0.3	0.27	Cognitive function;	chr4:39259850	chr4:39112677~39126818:-
LUAD	cis	rs2739330	0.828	rs5760099	ENSG00000228039.3	KB-1125A3.10	6.06	2.7e-09	1.16e-06	0.33	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23963780~23964374:+
LUAD	cis	rs853679	0.517	rs4713141	ENSG00000204709.4	LINC01556	6.06	2.7e-09	1.16e-06	0.37	0.27	Depression;	chr6:28133900	chr6:28943877~28944537:+
LUAD	cis	rs8072100	0.84	rs12453233	ENSG00000228782.6	CTD-2026D20.3	6.06	2.71e-09	1.16e-06	0.29	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47377204	chr17:47450568~47492492:-
LUAD	cis	rs6504622	0.818	rs758391	ENSG00000262879.4	RP11-156P1.3	6.06	2.71e-09	1.16e-06	0.31	0.27	Orofacial clefts;	chr17:46939875	chr17:46984045~47100323:-
LUAD	cis	rs12468226	0.938	rs114177656	ENSG00000272966.1	RP11-686O6.1	6.06	2.71e-09	1.16e-06	0.46	0.27	Urate levels;	chr2:202291596	chr2:202336739~202337200:+
LUAD	cis	rs11971779	0.59	rs6944104	ENSG00000273391.1	RP11-634H22.1	6.06	2.71e-09	1.16e-06	0.27	0.27	Diisocyanate-induced asthma;	chr7:139366374	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.616	rs6944244	ENSG00000273391.1	RP11-634H22.1	6.06	2.71e-09	1.16e-06	0.27	0.27	Diisocyanate-induced asthma;	chr7:139366440	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs6962637	ENSG00000273391.1	RP11-634H22.1	6.06	2.71e-09	1.16e-06	0.27	0.27	Diisocyanate-induced asthma;	chr7:139366604	chr7:139359032~139359566:-
LUAD	cis	rs755249	0.567	rs41270799	ENSG00000228060.1	RP11-69E11.8	-6.06	2.71e-09	1.16e-06	-0.27	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39282990	chr1:39565160~39573203:+
LUAD	cis	rs2243480	0.711	rs2460426	ENSG00000230295.1	RP11-458F8.2	6.06	2.71e-09	1.16e-06	0.33	0.27	Diabetic kidney disease;	chr7:66158142	chr7:66880708~66882981:+
LUAD	cis	rs1075265	0.87	rs7569370	ENSG00000233266.1	HMGB1P31	6.06	2.71e-09	1.16e-06	0.34	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53989212	chr2:54051334~54051760:+
LUAD	cis	rs875971	0.862	rs9791712	ENSG00000237310.1	GS1-124K5.4	-6.06	2.72e-09	1.16e-06	-0.29	-0.27	Aortic root size;	chr7:66640176	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs9791713	ENSG00000237310.1	GS1-124K5.4	-6.06	2.72e-09	1.16e-06	-0.29	-0.27	Aortic root size;	chr7:66640211	chr7:66493706~66495474:+
LUAD	cis	rs7688540	0.8	rs10023604	ENSG00000275426.1	CH17-262A2.1	6.06	2.72e-09	1.16e-06	0.33	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:287249	chr4:149738~150317:+
LUAD	cis	rs2404602	0.647	rs12440965	ENSG00000259422.1	RP11-593F23.1	-6.06	2.72e-09	1.16e-06	-0.35	-0.27	Blood metabolite levels;	chr15:76666250	chr15:76174891~76181486:-
LUAD	cis	rs7044106	0.708	rs10760113	ENSG00000238181.2	AHCYP2	-6.06	2.72e-09	1.16e-06	-0.34	-0.27	Hip circumference adjusted for BMI;	chr9:120711772	chr9:120720673~120721972:+
LUAD	cis	rs2117029	0.653	rs1476137	ENSG00000258017.1	RP11-386G11.10	-6.06	2.72e-09	1.16e-06	-0.32	-0.27	Intelligence (multi-trait analysis);	chr12:49129930	chr12:49127782~49147869:+
LUAD	cis	rs2117029	0.553	rs731350	ENSG00000258017.1	RP11-386G11.10	-6.06	2.72e-09	1.16e-06	-0.32	-0.27	Intelligence (multi-trait analysis);	chr12:49130804	chr12:49127782~49147869:+
LUAD	cis	rs17684571	0.751	rs34896026	ENSG00000231441.1	RP11-472M19.2	6.06	2.72e-09	1.16e-06	0.41	0.27	Schizophrenia;	chr6:56829383	chr6:56844002~56864078:+
LUAD	cis	rs2739330	0.796	rs5760097	ENSG00000228039.3	KB-1125A3.10	6.06	2.72e-09	1.16e-06	0.33	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23963780~23964374:+
LUAD	cis	rs11295209	1	rs11295209	ENSG00000248280.1	RP11-33B1.2	-6.06	2.73e-09	1.17e-06	-0.3	-0.27	Plateletcrit;	chr4:119559079	chr4:119440561~119450157:-
LUAD	cis	rs755249	1	rs12037222	ENSG00000228060.1	RP11-69E11.8	-6.06	2.73e-09	1.17e-06	-0.28	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39599289	chr1:39565160~39573203:+
LUAD	cis	rs12699921	0.632	rs2691627	ENSG00000279048.1	RP11-511H23.2	-6.06	2.73e-09	1.17e-06	-0.21	-0.27	Fibrinogen levels;	chr7:17784627	chr7:17940503~17942922:+
LUAD	cis	rs1823913	0.526	rs35340557	ENSG00000227542.1	AC092614.2	6.06	2.73e-09	1.17e-06	0.33	0.27	Obesity-related traits;	chr2:191338688	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.503	rs35562914	ENSG00000227542.1	AC092614.2	6.06	2.73e-09	1.17e-06	0.33	0.27	Obesity-related traits;	chr2:191338969	chr2:191229165~191246172:-
LUAD	cis	rs853679	0.517	rs12174753	ENSG00000204709.4	LINC01556	6.06	2.73e-09	1.17e-06	0.37	0.27	Depression;	chr6:28074687	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs55747925	ENSG00000204709.4	LINC01556	6.06	2.73e-09	1.17e-06	0.37	0.27	Depression;	chr6:28076559	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs56310871	ENSG00000204709.4	LINC01556	6.06	2.73e-09	1.17e-06	0.37	0.27	Depression;	chr6:28076704	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs34716816	ENSG00000204709.4	LINC01556	6.06	2.73e-09	1.17e-06	0.37	0.27	Depression;	chr6:28078391	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9393884	ENSG00000204709.4	LINC01556	6.06	2.73e-09	1.17e-06	0.37	0.27	Depression;	chr6:28079011	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9380049	ENSG00000204709.4	LINC01556	6.06	2.73e-09	1.17e-06	0.37	0.27	Depression;	chr6:28080757	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9380050	ENSG00000204709.4	LINC01556	6.06	2.73e-09	1.17e-06	0.37	0.27	Depression;	chr6:28080760	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9393885	ENSG00000204709.4	LINC01556	6.06	2.73e-09	1.17e-06	0.37	0.27	Depression;	chr6:28082231	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9393886	ENSG00000204709.4	LINC01556	6.06	2.73e-09	1.17e-06	0.37	0.27	Depression;	chr6:28082261	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.515	rs9368549	ENSG00000204709.4	LINC01556	6.06	2.73e-09	1.17e-06	0.37	0.27	Parkinson's disease;	chr6:28082269	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs56364346	ENSG00000204709.4	LINC01556	6.06	2.73e-09	1.17e-06	0.37	0.27	Depression;	chr6:28082984	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9357061	ENSG00000204709.4	LINC01556	6.06	2.73e-09	1.17e-06	0.37	0.27	Depression;	chr6:28083994	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9368550	ENSG00000204709.4	LINC01556	6.06	2.73e-09	1.17e-06	0.37	0.27	Depression;	chr6:28084025	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.542	rs2295594	ENSG00000204709.4	LINC01556	6.06	2.73e-09	1.17e-06	0.37	0.27	Depression;	chr6:28085319	chr6:28943877~28944537:+
LUAD	cis	rs7927592	0.956	rs10896334	ENSG00000212093.1	AP000807.1	6.06	2.74e-09	1.17e-06	0.3	0.27	Total body bone mineral density;	chr11:68514026	chr11:68506083~68506166:-
LUAD	cis	rs9834970	0.566	rs4327336	ENSG00000234073.1	AC011816.1	-6.06	2.75e-09	1.17e-06	-0.29	-0.27	Bipolar disorder with mood-incongruent psychosis;Bipolar disorder;Schizophrenia or bipolar disorder;Subjective response to lithium treatment;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr3:36854779	chr3:36880184~36880729:-
LUAD	cis	rs17684571	0.751	rs71564863	ENSG00000231441.1	RP11-472M19.2	6.06	2.75e-09	1.17e-06	0.41	0.27	Schizophrenia;	chr6:56840372	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.751	rs13192540	ENSG00000231441.1	RP11-472M19.2	6.06	2.75e-09	1.17e-06	0.41	0.27	Schizophrenia;	chr6:56842637	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.751	rs13192931	ENSG00000231441.1	RP11-472M19.2	6.06	2.75e-09	1.17e-06	0.41	0.27	Schizophrenia;	chr6:56842921	chr6:56844002~56864078:+
LUAD	cis	rs11690935	0.632	rs6723259	ENSG00000228389.1	AC068039.4	-6.06	2.75e-09	1.17e-06	-0.29	-0.27	Schizophrenia;	chr2:171766017	chr2:171773482~171775844:+
LUAD	cis	rs1012068	0.686	rs5753818	ENSG00000236132.1	CTA-440B3.1	6.06	2.75e-09	1.18e-06	0.31	0.27	Chronic hepatitis C infection;	chr22:31917947	chr22:31816379~31817491:-
LUAD	cis	rs9595908	0.568	rs4942923	ENSG00000212293.1	SNORA16	6.06	2.75e-09	1.18e-06	0.28	0.27	Body mass index;	chr13:32806887	chr13:32420390~32420516:-
LUAD	cis	rs11690935	0.632	rs62183783	ENSG00000228389.1	AC068039.4	-6.06	2.76e-09	1.18e-06	-0.29	-0.27	Schizophrenia;	chr2:172000868	chr2:171773482~171775844:+
LUAD	cis	rs1707322	0.717	rs2253862	ENSG00000234329.1	RP11-767N6.2	-6.06	2.76e-09	1.18e-06	-0.28	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616288	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.717	rs2991988	ENSG00000234329.1	RP11-767N6.2	-6.06	2.76e-09	1.18e-06	-0.28	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616759	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.717	rs2991989	ENSG00000234329.1	RP11-767N6.2	-6.06	2.76e-09	1.18e-06	-0.28	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45617293	chr1:45651039~45651826:-
LUAD	cis	rs10050311	0.79	rs76583174	ENSG00000251411.1	RP11-397E7.4	-6.06	2.76e-09	1.18e-06	-0.37	-0.27	Insulin-related traits;	chr4:86917234	chr4:86913266~86914817:-
LUAD	cis	rs875971	0.545	rs73376401	ENSG00000226824.5	RP4-756H11.3	-6.06	2.77e-09	1.18e-06	-0.39	-0.27	Aortic root size;	chr7:66174841	chr7:66654538~66669855:+
LUAD	cis	rs748404	0.666	rs12906481	ENSG00000205771.5	CATSPER2P1	-6.06	2.77e-09	1.18e-06	-0.41	-0.27	Lung cancer;	chr15:43467356	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.666	rs35958032	ENSG00000205771.5	CATSPER2P1	-6.06	2.77e-09	1.18e-06	-0.41	-0.27	Lung cancer;	chr15:43494397	chr15:43726918~43747094:-
LUAD	cis	rs1914816	0.878	rs2456078	ENSG00000196274.5	Metazoa_SRP	6.06	2.77e-09	1.18e-06	0.3	0.27	Response to tocilizumab in rheumatoid arthritis;	chr15:76266529	chr15:76230048~76230390:-
LUAD	cis	rs2283792	0.691	rs11913721	ENSG00000224086.5	LL22NC03-86G7.1	-6.06	2.77e-09	1.18e-06	-0.26	-0.27	Multiple sclerosis;	chr22:21855846	chr22:21938293~21977632:+
LUAD	cis	rs11098499	1	rs11726229	ENSG00000248280.1	RP11-33B1.2	6.06	2.77e-09	1.18e-06	0.33	0.27	Corneal astigmatism;	chr4:119290425	chr4:119440561~119450157:-
LUAD	cis	rs72772090	0.539	rs56395748	ENSG00000248734.2	CTD-2260A17.1	-6.06	2.78e-09	1.19e-06	-0.42	-0.27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96841190	chr5:96784777~96785999:+
LUAD	cis	rs1154275	0.537	rs6800648	ENSG00000242770.2	RP11-180K7.1	6.06	2.78e-09	1.19e-06	0.28	0.27	Takotsubo syndrome;	chr3:112797586	chr3:112802478~112812819:+
LUAD	cis	rs7044106	0.708	rs10984992	ENSG00000238181.2	AHCYP2	-6.06	2.78e-09	1.19e-06	-0.34	-0.27	Hip circumference adjusted for BMI;	chr9:120711138	chr9:120720673~120721972:+
LUAD	cis	rs1823913	0.637	rs10931493	ENSG00000280083.1	RP11-317J9.1	-6.06	2.79e-09	1.19e-06	-0.31	-0.27	Obesity-related traits;	chr2:191288142	chr2:191154118~191156070:-
LUAD	cis	rs7615952	0.932	rs7629977	ENSG00000171084.14	FAM86JP	6.06	2.79e-09	1.19e-06	0.38	0.27	Blood pressure (smoking interaction);	chr3:125930730	chr3:125916620~125930024:+
LUAD	cis	rs2404602	0.647	rs11631959	ENSG00000259422.1	RP11-593F23.1	-6.06	2.79e-09	1.19e-06	-0.35	-0.27	Blood metabolite levels;	chr15:76747707	chr15:76174891~76181486:-
LUAD	cis	rs2946504	0.553	rs2977078	ENSG00000251468.2	RP11-369K16.1	-6.06	2.79e-09	1.19e-06	-0.33	-0.27	Type 2 diabetes;	chr8:12959997	chr8:12958387~12962200:+
LUAD	cis	rs507080	0.501	rs626645	ENSG00000278376.1	RP11-158I9.8	-6.06	2.79e-09	1.19e-06	-0.28	-0.27	Serum metabolite levels;	chr11:118704471	chr11:118791254~118793137:+
LUAD	cis	rs11971779	0.68	rs3924296	ENSG00000273391.1	RP11-634H22.1	6.06	2.79e-09	1.19e-06	0.27	0.27	Diisocyanate-induced asthma;	chr7:139357181	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.527	rs4379397	ENSG00000273391.1	RP11-634H22.1	6.06	2.79e-09	1.19e-06	0.27	0.27	Diisocyanate-induced asthma;	chr7:139358639	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.774	rs6467838	ENSG00000273391.1	RP11-634H22.1	6.06	2.79e-09	1.19e-06	0.27	0.27	Diisocyanate-induced asthma;	chr7:139358755	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs6961812	ENSG00000273391.1	RP11-634H22.1	6.06	2.79e-09	1.19e-06	0.27	0.27	Diisocyanate-induced asthma;	chr7:139359062	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs3924445	ENSG00000273391.1	RP11-634H22.1	6.06	2.79e-09	1.19e-06	0.27	0.27	Diisocyanate-induced asthma;	chr7:139359426	chr7:139359032~139359566:-
LUAD	cis	rs7615952	0.932	rs13314869	ENSG00000171084.14	FAM86JP	6.06	2.8e-09	1.19e-06	0.38	0.27	Blood pressure (smoking interaction);	chr3:125925826	chr3:125916620~125930024:+
LUAD	cis	rs2243480	0.901	rs35823062	ENSG00000232546.1	RP11-458F8.1	-6.06	2.8e-09	1.19e-06	-0.35	-0.27	Diabetic kidney disease;	chr7:66500834	chr7:66848496~66858136:+
LUAD	cis	rs12908161	0.959	rs3748376	ENSG00000259728.4	LINC00933	6.06	2.8e-09	1.19e-06	0.39	0.27	Schizophrenia;	chr15:84785121	chr15:84570649~84580175:+
LUAD	cis	rs6687821	0.515	rs523679	ENSG00000267734.1	RP4-604K5.3	6.06	2.8e-09	1.19e-06	0.33	0.27	Yeast infection;	chr1:86902412	chr1:86932199~86934891:-
LUAD	cis	rs6687821	0.515	rs525519	ENSG00000267734.1	RP4-604K5.3	6.06	2.8e-09	1.19e-06	0.33	0.27	Yeast infection;	chr1:86902611	chr1:86932199~86934891:-
LUAD	cis	rs9543976	1	rs2328964	ENSG00000261553.4	RP11-29G8.3	6.06	2.8e-09	1.2e-06	0.38	0.27	Diabetic retinopathy;	chr13:75564694	chr13:75549773~75807120:+
LUAD	cis	rs10200159	1	rs6705295	ENSG00000272606.1	RP11-554J4.1	6.06	2.81e-09	1.2e-06	0.43	0.27	Vitiligo;	chr2:55686874	chr2:55617909~55618373:+
LUAD	cis	rs17301013	0.507	rs913688	ENSG00000227373.4	RP11-160H22.5	-6.06	2.81e-09	1.2e-06	-0.39	-0.27	Systemic lupus erythematosus;	chr1:174805080	chr1:174115300~174160004:-
LUAD	cis	rs7246657	0.551	rs28462002	ENSG00000276846.1	CTD-3220F14.3	6.06	2.81e-09	1.2e-06	0.41	0.27	Coronary artery calcification;	chr19:37143560	chr19:37314868~37315620:-
LUAD	cis	rs6844153	0.752	rs28520489	ENSG00000240005.4	RP11-293A21.1	-6.06	2.81e-09	1.2e-06	-0.38	-0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26896082	chr4:26859806~26860599:-
LUAD	cis	rs2404602	0.684	rs11854850	ENSG00000259422.1	RP11-593F23.1	-6.06	2.81e-09	1.2e-06	-0.36	-0.27	Blood metabolite levels;	chr15:76552230	chr15:76174891~76181486:-
LUAD	cis	rs2243480	0.803	rs160649	ENSG00000273142.1	RP11-458F8.4	-6.06	2.82e-09	1.2e-06	-0.27	-0.27	Diabetic kidney disease;	chr7:66078212	chr7:66902857~66906297:+
LUAD	cis	rs2243480	1	rs160648	ENSG00000273142.1	RP11-458F8.4	-6.06	2.82e-09	1.2e-06	-0.27	-0.27	Diabetic kidney disease;	chr7:66078397	chr7:66902857~66906297:+
LUAD	cis	rs17301013	0.507	rs3117843	ENSG00000227373.4	RP11-160H22.5	6.06	2.82e-09	1.2e-06	0.39	0.27	Systemic lupus erythematosus;	chr1:174711581	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs332781	ENSG00000227373.4	RP11-160H22.5	6.06	2.82e-09	1.2e-06	0.39	0.27	Systemic lupus erythematosus;	chr1:174718483	chr1:174115300~174160004:-
LUAD	cis	rs1426063	0.614	rs7671634	ENSG00000249717.1	RP11-44F21.3	6.06	2.82e-09	1.2e-06	0.54	0.27	QT interval;	chr4:75090883	chr4:74955974~74970362:-
LUAD	cis	rs1823913	0.637	rs4853577	ENSG00000280083.1	RP11-317J9.1	6.06	2.82e-09	1.2e-06	0.32	0.27	Obesity-related traits;	chr2:191297118	chr2:191154118~191156070:-
LUAD	cis	rs875971	0.825	rs4587224	ENSG00000237310.1	GS1-124K5.4	-6.06	2.83e-09	1.21e-06	-0.29	-0.27	Aortic root size;	chr7:66271195	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.792	rs6971752	ENSG00000237310.1	GS1-124K5.4	-6.06	2.83e-09	1.21e-06	-0.29	-0.27	Aortic root size;	chr7:66272999	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs10950033	ENSG00000237310.1	GS1-124K5.4	-6.06	2.83e-09	1.21e-06	-0.29	-0.27	Aortic root size;	chr7:66274686	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs11760844	ENSG00000237310.1	GS1-124K5.4	-6.06	2.83e-09	1.21e-06	-0.29	-0.27	Aortic root size;	chr7:66274896	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs4149461	ENSG00000237310.1	GS1-124K5.4	-6.06	2.83e-09	1.21e-06	-0.29	-0.27	Aortic root size;	chr7:66279745	chr7:66493706~66495474:+
LUAD	cis	rs10214930	1	rs6462050	ENSG00000235574.1	AC073150.6	6.06	2.83e-09	1.21e-06	0.37	0.27	Hypospadias;	chr7:27804884	chr7:27491682~27492765:-
LUAD	cis	rs10214930	1	rs6462051	ENSG00000235574.1	AC073150.6	6.06	2.83e-09	1.21e-06	0.37	0.27	Hypospadias;	chr7:27805042	chr7:27491682~27492765:-
LUAD	cis	rs6504622	1	rs6504622	ENSG00000262879.4	RP11-156P1.3	6.06	2.83e-09	1.21e-06	0.31	0.27	Orofacial clefts;	chr17:46942365	chr17:46984045~47100323:-
LUAD	cis	rs7727544	0.735	rs274568	ENSG00000233006.5	AC034220.3	-6.05	2.83e-09	1.21e-06	-0.24	-0.27	Blood metabolite levels;	chr5:132377886	chr5:132311285~132369916:-
LUAD	cis	rs858239	0.6	rs13438179	ENSG00000230042.1	AK3P3	-6.05	2.83e-09	1.21e-06	-0.33	-0.27	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23129178~23129841:+
LUAD	cis	rs875971	0.862	rs13536	ENSG00000222364.1	RNU6-96P	6.05	2.84e-09	1.21e-06	0.3	0.27	Aortic root size;	chr7:66554203	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs801209	ENSG00000222364.1	RNU6-96P	6.05	2.84e-09	1.21e-06	0.3	0.27	Aortic root size;	chr7:66554403	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs801206	ENSG00000222364.1	RNU6-96P	6.05	2.84e-09	1.21e-06	0.3	0.27	Aortic root size;	chr7:66556979	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs801204	ENSG00000222364.1	RNU6-96P	6.05	2.84e-09	1.21e-06	0.3	0.27	Aortic root size;	chr7:66557934	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs801203	ENSG00000222364.1	RNU6-96P	6.05	2.84e-09	1.21e-06	0.3	0.27	Aortic root size;	chr7:66558025	chr7:66395191~66395286:+
LUAD	cis	rs67311347	0.868	rs10865895	ENSG00000223797.4	ENTPD3-AS1	6.05	2.84e-09	1.21e-06	0.28	0.27	Renal cell carcinoma;	chr3:40337186	chr3:40313802~40453329:-
LUAD	cis	rs453301	0.606	rs7462373	ENSG00000253981.4	ALG1L13P	-6.05	2.84e-09	1.21e-06	-0.3	-0.27	Joint mobility (Beighton score);	chr8:9041808	chr8:8236003~8244667:-
LUAD	cis	rs875971	0.83	rs6950137	ENSG00000222364.1	RNU6-96P	-6.05	2.84e-09	1.21e-06	-0.3	-0.27	Aortic root size;	chr7:66511623	chr7:66395191~66395286:+
LUAD	cis	rs4713118	0.868	rs742047	ENSG00000219392.1	RP1-265C24.5	-6.05	2.84e-09	1.21e-06	-0.37	-0.27	Parkinson's disease;	chr6:27771601	chr6:28115628~28116551:+
LUAD	cis	rs1823913	0.637	rs4853583	ENSG00000227542.1	AC092614.2	-6.05	2.85e-09	1.21e-06	-0.32	-0.27	Obesity-related traits;	chr2:191304648	chr2:191229165~191246172:-
LUAD	cis	rs1113500	0.548	rs7541433	ENSG00000226822.1	RP11-356N1.2	6.05	2.85e-09	1.21e-06	0.36	0.27	Growth-regulated protein alpha levels;	chr1:108103019	chr1:108071482~108074519:+
LUAD	cis	rs7182621	0.546	rs12906587	ENSG00000259363.4	CTD-2054N24.2	6.05	2.85e-09	1.21e-06	0.35	0.27	Colonoscopy-negative controls vs population controls;	chr15:99837114	chr15:99807023~99877148:+
LUAD	cis	rs2117029	0.555	rs2279596	ENSG00000258017.1	RP11-386G11.10	-6.05	2.85e-09	1.22e-06	-0.33	-0.27	Intelligence (multi-trait analysis);	chr12:49104968	chr12:49127782~49147869:+
LUAD	cis	rs2946504	0.822	rs2977097	ENSG00000251468.2	RP11-369K16.1	6.05	2.86e-09	1.22e-06	0.33	0.27	Type 2 diabetes;	chr8:12946592	chr8:12958387~12962200:+
LUAD	cis	rs8072100	0.905	rs8077106	ENSG00000228782.6	CTD-2026D20.3	-6.05	2.86e-09	1.22e-06	-0.28	-0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47575925	chr17:47450568~47492492:-
LUAD	cis	rs8072100	0.754	rs8081717	ENSG00000228782.6	CTD-2026D20.3	-6.05	2.86e-09	1.22e-06	-0.28	-0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47576555	chr17:47450568~47492492:-
LUAD	cis	rs6921919	0.583	rs2041230	ENSG00000216901.1	AL022393.7	6.05	2.86e-09	1.22e-06	0.32	0.27	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:28176188~28176674:+
LUAD	cis	rs62025270	0.547	rs8035496	ENSG00000202081.1	RNU6-1280P	-6.05	2.86e-09	1.22e-06	-0.34	-0.27	Idiopathic pulmonary fibrosis;	chr15:85591101	chr15:85651522~85651628:-
LUAD	cis	rs11096990	0.892	rs11930865	ENSG00000249207.1	RP11-360F5.1	6.05	2.86e-09	1.22e-06	0.3	0.27	Cognitive function;	chr4:39218711	chr4:39112677~39126818:-
LUAD	cis	rs1075265	0.818	rs12713253	ENSG00000233266.1	HMGB1P31	6.05	2.87e-09	1.22e-06	0.33	0.27	Chronotype;Morning vs. evening chronotype;	chr2:54037323	chr2:54051334~54051760:+
LUAD	cis	rs30380	0.632	rs26497	ENSG00000272109.1	CTD-2260A17.3	-6.05	2.87e-09	1.22e-06	-0.33	-0.27	Cerebrospinal fluid biomarker levels;	chr5:96803064	chr5:96804353~96806105:+
LUAD	cis	rs12908161	0.959	rs12906348	ENSG00000225151.9	GOLGA2P7	-6.05	2.87e-09	1.22e-06	-0.36	-0.27	Schizophrenia;	chr15:84786190	chr15:84199311~84230136:-
LUAD	cis	rs74233809	1	rs9633712	ENSG00000213277.3	MARCKSL1P1	6.05	2.87e-09	1.22e-06	0.44	0.27	Birth weight;	chr10:103114004	chr10:103175554~103176094:+
LUAD	cis	rs74233809	0.786	rs11191564	ENSG00000213277.3	MARCKSL1P1	6.05	2.87e-09	1.22e-06	0.44	0.27	Birth weight;	chr10:103118786	chr10:103175554~103176094:+
LUAD	cis	rs74233809	1	rs1060240	ENSG00000213277.3	MARCKSL1P1	6.05	2.87e-09	1.22e-06	0.44	0.27	Birth weight;	chr10:103123580	chr10:103175554~103176094:+
LUAD	cis	rs74233809	1	rs10883835	ENSG00000213277.3	MARCKSL1P1	6.05	2.87e-09	1.22e-06	0.44	0.27	Birth weight;	chr10:103124451	chr10:103175554~103176094:+
LUAD	cis	rs7044106	0.762	rs1867254	ENSG00000238181.2	AHCYP2	-6.05	2.88e-09	1.23e-06	-0.34	-0.27	Hip circumference adjusted for BMI;	chr9:120666800	chr9:120720673~120721972:+
LUAD	cis	rs9450351	0.744	rs6902904	ENSG00000203875.9	SNHG5	-6.05	2.88e-09	1.23e-06	-0.58	-0.27	Interferon gamma-induced protein 10 levels;	chr6:85492985	chr6:85660950~85678736:-
LUAD	cis	rs477895	1	rs34292685	ENSG00000236935.1	AP003774.1	-6.05	2.88e-09	1.23e-06	-0.34	-0.27	Mean platelet volume;	chr11:64281549	chr11:64325050~64329504:-
LUAD	cis	rs30380	0.587	rs469674	ENSG00000272109.1	CTD-2260A17.3	-6.05	2.88e-09	1.23e-06	-0.32	-0.27	Cerebrospinal fluid biomarker levels;	chr5:96794312	chr5:96804353~96806105:+
LUAD	cis	rs6921919	0.583	rs35560946	ENSG00000204709.4	LINC01556	6.05	2.89e-09	1.23e-06	0.35	0.27	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28943877~28944537:+
LUAD	cis	rs9543976	1	rs2031236	ENSG00000261553.4	RP11-29G8.3	-6.05	2.89e-09	1.23e-06	-0.38	-0.27	Diabetic retinopathy;	chr13:75595641	chr13:75549773~75807120:+
LUAD	cis	rs7849270	1	rs2297112	ENSG00000268707.1	RP11-247A12.7	-6.05	2.89e-09	1.23e-06	-0.3	-0.27	Blood metabolite ratios;	chr9:129137901	chr9:129170434~129170940:+
LUAD	cis	rs2765539	0.59	rs1325942	ENSG00000226172.2	RP4-712E4.1	-6.05	2.89e-09	1.23e-06	-0.34	-0.27	Waist-hip ratio;	chr1:118941210	chr1:119000344~119001392:-
LUAD	cis	rs875971	0.825	rs1860472	ENSG00000237310.1	GS1-124K5.4	-6.05	2.89e-09	1.23e-06	-0.29	-0.27	Aortic root size;	chr7:66617736	chr7:66493706~66495474:+
LUAD	cis	rs11096990	0.855	rs2566170	ENSG00000249207.1	RP11-360F5.1	6.05	2.9e-09	1.23e-06	0.31	0.27	Cognitive function;	chr4:39150757	chr4:39112677~39126818:-
LUAD	cis	rs4908768	0.501	rs6669503	ENSG00000232912.4	RP5-1115A15.1	6.05	2.9e-09	1.23e-06	0.25	0.27	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8504241	chr1:8424645~8434838:+
LUAD	cis	rs11096990	0.855	rs2566172	ENSG00000249207.1	RP11-360F5.1	6.05	2.9e-09	1.23e-06	0.31	0.27	Cognitive function;	chr4:39150943	chr4:39112677~39126818:-
LUAD	cis	rs394563	0.69	rs237009	ENSG00000231760.4	RP11-350J20.5	6.05	2.91e-09	1.24e-06	0.33	0.27	Dupuytren's disease;	chr6:149438416	chr6:149796151~149826294:-
LUAD	cis	rs113835537	0.597	rs3825065	ENSG00000255517.5	CTD-3074O7.5	-6.05	2.91e-09	1.24e-06	-0.32	-0.27	Airway imaging phenotypes;	chr11:66543540	chr11:66473490~66480233:-
LUAD	cis	rs875971	0.798	rs6460304	ENSG00000222364.1	RNU6-96P	-6.05	2.91e-09	1.24e-06	-0.3	-0.27	Aortic root size;	chr7:66499741	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs6945775	ENSG00000222364.1	RNU6-96P	-6.05	2.91e-09	1.24e-06	-0.3	-0.27	Aortic root size;	chr7:66503987	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.756	rs2901210	ENSG00000222364.1	RNU6-96P	6.05	2.91e-09	1.24e-06	0.3	0.27	Aortic root size;	chr7:66552518	chr7:66395191~66395286:+
LUAD	cis	rs7120173	1	rs7120173	ENSG00000254851.1	RP11-109L13.1	6.05	2.92e-09	1.24e-06	0.41	0.27	Visceral adipose tissue adjusted for BMI;	chr11:116958937	chr11:117135528~117138582:+
LUAD	cis	rs4834770	1	rs878374	ENSG00000245958.5	RP11-33B1.1	-6.05	2.92e-09	1.24e-06	-0.24	-0.27	Blood protein levels;	chr4:119316409	chr4:119454791~119552025:+
LUAD	cis	rs7182621	0.546	rs11635811	ENSG00000259363.4	CTD-2054N24.2	-6.05	2.92e-09	1.24e-06	-0.36	-0.27	Colonoscopy-negative controls vs population controls;	chr15:99839918	chr15:99807023~99877148:+
LUAD	cis	rs2439831	0.85	rs12441127	ENSG00000205771.5	CATSPER2P1	-6.05	2.92e-09	1.24e-06	-0.51	-0.27	Lung cancer in ever smokers;	chr15:43728977	chr15:43726918~43747094:-
LUAD	cis	rs17684571	0.872	rs34832779	ENSG00000231441.1	RP11-472M19.2	6.05	2.92e-09	1.24e-06	0.39	0.27	Schizophrenia;	chr6:56758350	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.872	rs13203000	ENSG00000231441.1	RP11-472M19.2	6.05	2.92e-09	1.24e-06	0.39	0.27	Schizophrenia;	chr6:56758921	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.872	rs13217390	ENSG00000231441.1	RP11-472M19.2	6.05	2.92e-09	1.24e-06	0.39	0.27	Schizophrenia;	chr6:56758953	chr6:56844002~56864078:+
LUAD	cis	rs2243480	1	rs410128	ENSG00000232546.1	RP11-458F8.1	-6.05	2.93e-09	1.24e-06	-0.36	-0.27	Diabetic kidney disease;	chr7:66138186	chr7:66848496~66858136:+
LUAD	cis	rs7945705	0.967	rs34842234	ENSG00000254860.4	TMEM9B-AS1	-6.05	2.93e-09	1.24e-06	-0.3	-0.27	Hemoglobin concentration;	chr11:8870347	chr11:8964675~8977527:+
LUAD	cis	rs7945705	0.967	rs7123861	ENSG00000254860.4	TMEM9B-AS1	-6.05	2.93e-09	1.24e-06	-0.3	-0.27	Hemoglobin concentration;	chr11:8870776	chr11:8964675~8977527:+
LUAD	cis	rs1113500	0.933	rs61797344	ENSG00000226822.1	RP11-356N1.2	6.05	2.93e-09	1.24e-06	0.31	0.27	Growth-regulated protein alpha levels;	chr1:108079958	chr1:108071482~108074519:+
LUAD	cis	rs9595908	0.686	rs7988353	ENSG00000212293.1	SNORA16	6.05	2.93e-09	1.24e-06	0.29	0.27	Body mass index;	chr13:32760250	chr13:32420390~32420516:-
LUAD	cis	rs17684571	0.751	rs35242294	ENSG00000231441.1	RP11-472M19.2	6.05	2.93e-09	1.25e-06	0.41	0.27	Schizophrenia;	chr6:56846131	chr6:56844002~56864078:+
LUAD	cis	rs17301013	0.606	rs6425277	ENSG00000227373.4	RP11-160H22.5	6.05	2.94e-09	1.25e-06	0.37	0.27	Systemic lupus erythematosus;	chr1:174296153	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs12074276	ENSG00000227373.4	RP11-160H22.5	6.05	2.94e-09	1.25e-06	0.37	0.27	Systemic lupus erythematosus;	chr1:174302167	chr1:174115300~174160004:-
LUAD	cis	rs7017914	0.905	rs2639956	ENSG00000223220.1	Y_RNA	6.05	2.94e-09	1.25e-06	0.3	0.27	Bone mineral density;	chr8:71011856	chr8:70780914~70781008:-
LUAD	cis	rs2404602	0.583	rs35707798	ENSG00000259422.1	RP11-593F23.1	6.05	2.94e-09	1.25e-06	0.3	0.27	Blood metabolite levels;	chr15:76272685	chr15:76174891~76181486:-
LUAD	cis	rs2243480	1	rs1499613	ENSG00000232546.1	RP11-458F8.1	6.05	2.94e-09	1.25e-06	0.35	0.27	Diabetic kidney disease;	chr7:66265873	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs1553174	ENSG00000232546.1	RP11-458F8.1	6.05	2.94e-09	1.25e-06	0.35	0.27	Diabetic kidney disease;	chr7:66266207	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs10950032	ENSG00000232546.1	RP11-458F8.1	6.05	2.94e-09	1.25e-06	0.35	0.27	Diabetic kidney disease;	chr7:66273604	chr7:66848496~66858136:+
LUAD	cis	rs2439831	1	rs9920763	ENSG00000205771.5	CATSPER2P1	-6.05	2.94e-09	1.25e-06	-0.56	-0.27	Lung cancer in ever smokers;	chr15:43468310	chr15:43726918~43747094:-
LUAD	cis	rs7727544	0.735	rs272884	ENSG00000233006.5	AC034220.3	6.05	2.94e-09	1.25e-06	0.24	0.27	Blood metabolite levels;	chr5:132332961	chr5:132311285~132369916:-
LUAD	cis	rs7727544	0.735	rs272881	ENSG00000233006.5	AC034220.3	6.05	2.94e-09	1.25e-06	0.24	0.27	Blood metabolite levels;	chr5:132333571	chr5:132311285~132369916:-
LUAD	cis	rs7727544	0.735	rs272879	ENSG00000233006.5	AC034220.3	6.05	2.94e-09	1.25e-06	0.24	0.27	Blood metabolite levels;	chr5:132334853	chr5:132311285~132369916:-
LUAD	cis	rs7727544	0.709	rs441969	ENSG00000233006.5	AC034220.3	6.05	2.95e-09	1.25e-06	0.24	0.27	Blood metabolite levels;	chr5:132366428	chr5:132311285~132369916:-
LUAD	cis	rs2117029	0.587	rs1865157	ENSG00000258017.1	RP11-386G11.10	-6.05	2.95e-09	1.25e-06	-0.32	-0.27	Intelligence (multi-trait analysis);	chr12:49129003	chr12:49127782~49147869:+
LUAD	cis	rs4964805	0.537	rs11111750	ENSG00000257681.1	RP11-341G23.4	6.05	2.95e-09	1.25e-06	0.31	0.27	Attention deficit hyperactivity disorder;	chr12:103761762	chr12:103746315~103768858:-
LUAD	cis	rs875971	0.545	rs12670811	ENSG00000226824.5	RP4-756H11.3	-6.05	2.95e-09	1.25e-06	-0.38	-0.27	Aortic root size;	chr7:66358032	chr7:66654538~66669855:+
LUAD	cis	rs2276314	0.553	rs12964535	ENSG00000278986.1	RP11-723J4.3	6.05	2.95e-09	1.25e-06	0.28	0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36031728	chr18:35972151~35973916:+
LUAD	cis	rs227932	0.681	rs79586340	ENSG00000234286.1	AC006026.13	-6.05	2.96e-09	1.26e-06	-0.46	-0.27	Schizophrenia;	chr7:23746122	chr7:23680195~23680786:-
LUAD	cis	rs227932	0.681	rs75405201	ENSG00000234286.1	AC006026.13	-6.05	2.96e-09	1.26e-06	-0.46	-0.27	Schizophrenia;	chr7:23746123	chr7:23680195~23680786:-
LUAD	cis	rs35740288	0.742	rs4843087	ENSG00000202081.1	RNU6-1280P	6.05	2.96e-09	1.26e-06	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85629624	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.77	rs62022867	ENSG00000202081.1	RNU6-1280P	6.05	2.96e-09	1.26e-06	0.33	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85630050	chr15:85651522~85651628:-
LUAD	cis	rs172166	0.611	rs203882	ENSG00000204709.4	LINC01556	6.05	2.97e-09	1.26e-06	0.35	0.27	Cardiac Troponin-T levels;	chr6:28110724	chr6:28943877~28944537:+
LUAD	cis	rs2276314	0.857	rs62101402	ENSG00000278986.1	RP11-723J4.3	-6.05	2.98e-09	1.26e-06	-0.32	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36049472	chr18:35972151~35973916:+
LUAD	cis	rs6142102	0.625	rs1883707	ENSG00000275784.1	RP5-1125A11.6	6.05	2.98e-09	1.26e-06	0.29	0.27	Skin pigmentation;	chr20:33964781	chr20:33989480~33991818:-
LUAD	cis	rs7849270	0.879	rs7859344	ENSG00000268707.1	RP11-247A12.7	-6.05	2.98e-09	1.26e-06	-0.3	-0.27	Blood metabolite ratios;	chr9:129086103	chr9:129170434~129170940:+
LUAD	cis	rs8062405	1	rs3088215	ENSG00000251417.2	RP11-1348G14.4	-6.05	2.98e-09	1.26e-06	-0.27	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs28403629	ENSG00000251417.2	RP11-1348G14.4	-6.05	2.98e-09	1.26e-06	-0.27	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs61737565	ENSG00000251417.2	RP11-1348G14.4	-6.05	2.98e-09	1.26e-06	-0.27	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs4788099	ENSG00000251417.2	RP11-1348G14.4	-6.05	2.98e-09	1.26e-06	-0.27	-0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28802743~28817828:+
LUAD	cis	rs8031584	0.958	rs11293	ENSG00000260382.1	RP11-540B6.2	6.05	2.98e-09	1.27e-06	0.32	0.27	Huntington's disease progression;	chr15:30942778	chr15:30882267~30883231:-
LUAD	cis	rs1707322	0.721	rs10890343	ENSG00000234329.1	RP11-767N6.2	6.05	2.99e-09	1.27e-06	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692250	chr1:45651039~45651826:-
LUAD	cis	rs11971779	0.523	rs10234578	ENSG00000273391.1	RP11-634H22.1	6.05	2.99e-09	1.27e-06	0.27	0.27	Diisocyanate-induced asthma;	chr7:139353242	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.616	rs7784192	ENSG00000273391.1	RP11-634H22.1	6.05	2.99e-09	1.27e-06	0.27	0.27	Diisocyanate-induced asthma;	chr7:139354903	chr7:139359032~139359566:-
LUAD	cis	rs875971	0.862	rs801195	ENSG00000237310.1	GS1-124K5.4	-6.05	2.99e-09	1.27e-06	-0.29	-0.27	Aortic root size;	chr7:66561128	chr7:66493706~66495474:+
LUAD	cis	rs9879311	0.966	rs6442165	ENSG00000240288.6	GHRLOS	6.05	3e-09	1.27e-06	0.25	0.27	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10373424	chr3:10285754~10293449:+
LUAD	cis	rs1707322	0.721	rs61784800	ENSG00000234329.1	RP11-767N6.2	-6.04	3e-09	1.27e-06	-0.28	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712440	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs6665808	ENSG00000234329.1	RP11-767N6.2	6.04	3e-09	1.27e-06	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45696611	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.682	rs28508523	ENSG00000234329.1	RP11-767N6.2	6.04	3e-09	1.27e-06	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723953	chr1:45651039~45651826:-
LUAD	cis	rs1061377	1	rs3796509	ENSG00000249685.1	RP11-360F5.3	6.04	3e-09	1.27e-06	0.32	0.27	Uric acid levels;	chr4:39108566	chr4:39133913~39135608:+
LUAD	cis	rs2276314	0.553	rs1789501	ENSG00000278986.1	RP11-723J4.3	6.04	3.01e-09	1.27e-06	0.28	0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36037097	chr18:35972151~35973916:+
LUAD	cis	rs453301	0.562	rs1038248	ENSG00000253893.2	FAM85B	6.04	3.01e-09	1.27e-06	0.33	0.27	Joint mobility (Beighton score);	chr8:9183348	chr8:8167819~8226614:-
LUAD	cis	rs39841	1	rs39841	ENSG00000248734.2	CTD-2260A17.1	6.04	3.01e-09	1.28e-06	0.29	0.27	Inflammatory skin disease;	chr5:96784466	chr5:96784777~96785999:+
LUAD	cis	rs858239	0.665	rs858306	ENSG00000226816.2	AC005082.12	6.04	3.01e-09	1.28e-06	0.34	0.27	Cerebrospinal fluid biomarker levels;	chr7:23203135	chr7:23206013~23208045:+
LUAD	cis	rs17301013	0.507	rs11802092	ENSG00000227373.4	RP11-160H22.5	6.04	3.02e-09	1.28e-06	0.39	0.27	Systemic lupus erythematosus;	chr1:174601773	chr1:174115300~174160004:-
LUAD	cis	rs11690935	0.632	rs6737308	ENSG00000228389.1	AC068039.4	-6.04	3.02e-09	1.28e-06	-0.29	-0.27	Schizophrenia;	chr2:172007137	chr2:171773482~171775844:+
LUAD	cis	rs7923609	0.934	rs10761756	ENSG00000232075.1	MRPL35P2	-6.04	3.02e-09	1.28e-06	-0.32	-0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63412568	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.967	rs10761758	ENSG00000232075.1	MRPL35P2	-6.04	3.02e-09	1.28e-06	-0.32	-0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63412987	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.967	rs7909269	ENSG00000232075.1	MRPL35P2	-6.04	3.02e-09	1.28e-06	-0.32	-0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63418006	chr10:63634317~63634827:-
LUAD	cis	rs66887589	0.592	rs2175383	ENSG00000248280.1	RP11-33B1.2	6.04	3.02e-09	1.28e-06	0.3	0.27	Diastolic blood pressure;	chr4:119294681	chr4:119440561~119450157:-
LUAD	cis	rs853679	0.55	rs1233699	ENSG00000204709.4	LINC01556	6.04	3.02e-09	1.28e-06	0.36	0.27	Depression;	chr6:28201380	chr6:28943877~28944537:+
LUAD	cis	rs10759883	0.627	rs816672	ENSG00000175611.10	LINC00476	6.04	3.02e-09	1.28e-06	0.31	0.27	Nicotine dependence;	chr9:95812171	chr9:95759231~95875977:-
LUAD	cis	rs1823913	0.614	rs4853576	ENSG00000280083.1	RP11-317J9.1	6.04	3.02e-09	1.28e-06	0.32	0.27	Obesity-related traits;	chr2:191296618	chr2:191154118~191156070:-
LUAD	cis	rs9595908	0.869	rs9595949	ENSG00000212293.1	SNORA16	6.04	3.03e-09	1.28e-06	0.28	0.27	Body mass index;	chr13:32629939	chr13:32420390~32420516:-
LUAD	cis	rs2739330	0.828	rs5760102	ENSG00000228039.3	KB-1125A3.10	6.04	3.03e-09	1.28e-06	0.33	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23963780~23964374:+
LUAD	cis	rs17684571	0.751	rs35225175	ENSG00000231441.1	RP11-472M19.2	6.04	3.03e-09	1.28e-06	0.41	0.27	Schizophrenia;	chr6:56822783	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.751	rs34866877	ENSG00000231441.1	RP11-472M19.2	6.04	3.03e-09	1.28e-06	0.41	0.27	Schizophrenia;	chr6:56829507	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.751	rs35407078	ENSG00000231441.1	RP11-472M19.2	6.04	3.03e-09	1.28e-06	0.41	0.27	Schizophrenia;	chr6:56830216	chr6:56844002~56864078:+
LUAD	cis	rs7923609	0.905	rs10740129	ENSG00000232075.1	MRPL35P2	-6.04	3.03e-09	1.28e-06	-0.32	-0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63491048	chr10:63634317~63634827:-
LUAD	cis	rs875971	0.862	rs7786892	ENSG00000222364.1	RNU6-96P	6.04	3.03e-09	1.28e-06	0.3	0.27	Aortic root size;	chr7:66163889	chr7:66395191~66395286:+
LUAD	cis	rs853679	0.517	rs2273564	ENSG00000204709.4	LINC01556	6.04	3.03e-09	1.28e-06	0.37	0.27	Depression;	chr6:28089816	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs1853097	ENSG00000204709.4	LINC01556	6.04	3.03e-09	1.28e-06	0.37	0.27	Depression;	chr6:28090857	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9393887	ENSG00000204709.4	LINC01556	6.04	3.03e-09	1.28e-06	0.37	0.27	Depression;	chr6:28091242	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9393888	ENSG00000204709.4	LINC01556	6.04	3.03e-09	1.28e-06	0.37	0.27	Depression;	chr6:28091439	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs3734573	ENSG00000204709.4	LINC01556	6.04	3.03e-09	1.28e-06	0.37	0.27	Depression;	chr6:28091659	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9357063	ENSG00000204709.4	LINC01556	6.04	3.03e-09	1.28e-06	0.37	0.27	Depression;	chr6:28092227	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs3823180	ENSG00000204709.4	LINC01556	6.04	3.03e-09	1.28e-06	0.37	0.27	Depression;	chr6:28093966	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9368551	ENSG00000204709.4	LINC01556	6.04	3.03e-09	1.28e-06	0.37	0.27	Depression;	chr6:28094014	chr6:28943877~28944537:+
LUAD	cis	rs4820294	1	rs4820294	ENSG00000233360.4	Z83844.1	6.04	3.03e-09	1.29e-06	0.28	0.27	Fat distribution (HIV);	chr22:37675036	chr22:37641832~37658377:-
LUAD	cis	rs1061377	1	rs4974931	ENSG00000249685.1	RP11-360F5.3	6.04	3.03e-09	1.29e-06	0.32	0.27	Uric acid levels;	chr4:39108896	chr4:39133913~39135608:+
LUAD	cis	rs6921919	0.609	rs9461455	ENSG00000204709.4	LINC01556	6.04	3.04e-09	1.29e-06	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28943877~28944537:+
LUAD	cis	rs1707322	0.721	rs6699418	ENSG00000234329.1	RP11-767N6.2	6.04	3.04e-09	1.29e-06	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634509	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs4431884	ENSG00000234329.1	RP11-767N6.2	6.04	3.04e-09	1.29e-06	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45635651	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.65	rs4660879	ENSG00000234329.1	RP11-767N6.2	6.04	3.04e-09	1.29e-06	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45639729	chr1:45651039~45651826:-
LUAD	cis	rs8177876	0.642	rs4454990	ENSG00000261061.1	RP11-303E16.2	6.04	3.04e-09	1.29e-06	0.39	0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81106550	chr16:81030770~81031485:+
LUAD	cis	rs17666538	0.585	rs336444	ENSG00000254207.1	RP11-43A14.1	-6.04	3.04e-09	1.29e-06	-0.48	-0.27	IgG glycosylation;	chr8:683123	chr8:725188~725877:-
LUAD	cis	rs6921919	0.583	rs9468368	ENSG00000204709.4	LINC01556	6.04	3.05e-09	1.29e-06	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28943877~28944537:+
LUAD	cis	rs2111504	0.583	rs8104714	ENSG00000267213.4	AC007773.2	6.04	3.05e-09	1.29e-06	0.34	0.27	Bipolar disorder;	chr19:32381203	chr19:32390050~32405560:-
LUAD	cis	rs7923609	0.967	rs10509189	ENSG00000232075.1	MRPL35P2	-6.04	3.06e-09	1.29e-06	-0.32	-0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63504366	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.967	rs4486511	ENSG00000232075.1	MRPL35P2	-6.04	3.06e-09	1.29e-06	-0.32	-0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63504506	chr10:63634317~63634827:-
LUAD	cis	rs11098499	0.754	rs7689729	ENSG00000248280.1	RP11-33B1.2	6.04	3.06e-09	1.3e-06	0.33	0.27	Corneal astigmatism;	chr4:119335037	chr4:119440561~119450157:-
LUAD	cis	rs10028773	0.7	rs7690338	ENSG00000248280.1	RP11-33B1.2	6.04	3.06e-09	1.3e-06	0.33	0.27	Educational attainment;	chr4:119335313	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.865	rs3956464	ENSG00000248280.1	RP11-33B1.2	6.04	3.06e-09	1.3e-06	0.33	0.27	Corneal astigmatism;	chr4:119335609	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.619	rs28502463	ENSG00000248280.1	RP11-33B1.2	6.04	3.06e-09	1.3e-06	0.33	0.27	Corneal astigmatism;	chr4:119335868	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.648	rs2002047	ENSG00000248280.1	RP11-33B1.2	6.04	3.06e-09	1.3e-06	0.33	0.27	Corneal astigmatism;	chr4:119336073	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.775	rs2002049	ENSG00000248280.1	RP11-33B1.2	6.04	3.06e-09	1.3e-06	0.33	0.27	Corneal astigmatism;	chr4:119336262	chr4:119440561~119450157:-
LUAD	cis	rs17666538	0.585	rs6559063	ENSG00000254207.1	RP11-43A14.1	6.04	3.06e-09	1.3e-06	0.54	0.27	IgG glycosylation;	chr8:673051	chr8:725188~725877:-
LUAD	cis	rs12699921	0.632	rs2723553	ENSG00000279048.1	RP11-511H23.2	-6.04	3.06e-09	1.3e-06	-0.22	-0.27	Fibrinogen levels;	chr7:17799715	chr7:17940503~17942922:+
LUAD	cis	rs6504622	0.905	rs9898981	ENSG00000262879.4	RP11-156P1.3	6.04	3.07e-09	1.3e-06	0.31	0.27	Orofacial clefts;	chr17:46949349	chr17:46984045~47100323:-
LUAD	cis	rs12554020	1	rs12554020	ENSG00000227603.1	RP11-165J3.6	6.04	3.07e-09	1.3e-06	0.39	0.27	Schizophrenia;	chr9:93507955	chr9:93435332~93437121:-
LUAD	cis	rs150992	0.631	rs79399563	ENSG00000248489.1	CTD-2007H13.3	6.04	3.07e-09	1.3e-06	0.31	0.27	Body mass index;	chr5:98993275	chr5:98929171~98995013:+
LUAD	cis	rs4713118	0.869	rs6901520	ENSG00000219392.1	RP1-265C24.5	-6.04	3.07e-09	1.3e-06	-0.36	-0.27	Parkinson's disease;	chr6:27746796	chr6:28115628~28116551:+
LUAD	cis	rs71636778	0.509	rs35583548	ENSG00000260063.1	RP5-968P14.2	-6.04	3.07e-09	1.3e-06	-0.46	-0.27	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26813658	chr1:26692132~26694131:-
LUAD	cis	rs7923609	0.841	rs2163188	ENSG00000232075.1	MRPL35P2	6.04	3.07e-09	1.3e-06	0.32	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63554951	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.811	rs7919685	ENSG00000232075.1	MRPL35P2	6.04	3.07e-09	1.3e-06	0.32	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63556040	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.749	rs12247907	ENSG00000232075.1	MRPL35P2	6.04	3.07e-09	1.3e-06	0.32	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63557285	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.871	rs7898861	ENSG00000232075.1	MRPL35P2	6.04	3.07e-09	1.3e-06	0.32	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63559918	chr10:63634317~63634827:-
LUAD	cis	rs10050311	0.858	rs55698195	ENSG00000251411.1	RP11-397E7.4	-6.04	3.07e-09	1.3e-06	-0.37	-0.27	Insulin-related traits;	chr4:86872297	chr4:86913266~86914817:-
LUAD	cis	rs8177376	0.727	rs4937121	ENSG00000254905.1	RP11-712L6.7	6.04	3.08e-09	1.3e-06	0.36	0.27	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126330659	chr11:126292922~126294254:-
LUAD	cis	rs55823223	0.646	rs55868394	ENSG00000267801.1	RP11-552F3.9	6.04	3.08e-09	1.3e-06	0.4	0.27	Psoriasis;	chr17:75855032	chr17:75876372~75879546:+
LUAD	cis	rs7923609	0.871	rs12245149	ENSG00000232075.1	MRPL35P2	6.04	3.08e-09	1.3e-06	0.32	0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63561387	chr10:63634317~63634827:-
LUAD	cis	rs35934224	0.771	rs34820460	ENSG00000232926.1	AC000078.5	6.04	3.08e-09	1.3e-06	0.29	0.27	Glaucoma (primary open-angle);	chr22:19881687	chr22:19887289~19887970:+
LUAD	cis	rs4713118	0.629	rs203887	ENSG00000219392.1	RP1-265C24.5	-6.04	3.08e-09	1.3e-06	-0.37	-0.27	Parkinson's disease;	chr6:28053491	chr6:28115628~28116551:+
LUAD	cis	rs7849270	1	rs10819464	ENSG00000268707.1	RP11-247A12.7	-6.04	3.09e-09	1.31e-06	-0.3	-0.27	Blood metabolite ratios;	chr9:129113998	chr9:129170434~129170940:+
LUAD	cis	rs66887589	0.616	rs10032299	ENSG00000248280.1	RP11-33B1.2	6.04	3.09e-09	1.31e-06	0.3	0.27	Diastolic blood pressure;	chr4:119285264	chr4:119440561~119450157:-
LUAD	cis	rs17301013	0.507	rs2860725	ENSG00000227373.4	RP11-160H22.5	-6.04	3.09e-09	1.31e-06	-0.39	-0.27	Systemic lupus erythematosus;	chr1:174815447	chr1:174115300~174160004:-
LUAD	cis	rs2243480	1	rs313813	ENSG00000230295.1	RP11-458F8.2	-6.04	3.1e-09	1.31e-06	-0.33	-0.27	Diabetic kidney disease;	chr7:66038513	chr7:66880708~66882981:+
LUAD	cis	rs1075265	0.87	rs17268179	ENSG00000233266.1	HMGB1P31	6.04	3.1e-09	1.31e-06	0.33	0.27	Chronotype;Morning vs. evening chronotype;	chr2:54036876	chr2:54051334~54051760:+
LUAD	cis	rs7246657	0.525	rs997516	ENSG00000276846.1	CTD-3220F14.3	6.04	3.1e-09	1.31e-06	0.4	0.27	Coronary artery calcification;	chr19:36983362	chr19:37314868~37315620:-
LUAD	cis	rs11098499	0.789	rs1980024	ENSG00000248280.1	RP11-33B1.2	6.04	3.1e-09	1.31e-06	0.33	0.27	Corneal astigmatism;	chr4:119331892	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.754	rs34425882	ENSG00000248280.1	RP11-33B1.2	6.04	3.1e-09	1.31e-06	0.33	0.27	Corneal astigmatism;	chr4:119332022	chr4:119440561~119450157:-
LUAD	cis	rs67311347	1	rs34762643	ENSG00000223797.4	ENTPD3-AS1	6.04	3.1e-09	1.31e-06	0.27	0.27	Renal cell carcinoma;	chr3:40433942	chr3:40313802~40453329:-
LUAD	cis	rs10050311	0.79	rs72667724	ENSG00000251411.1	RP11-397E7.4	-6.04	3.11e-09	1.31e-06	-0.37	-0.27	Insulin-related traits;	chr4:86929931	chr4:86913266~86914817:-
LUAD	cis	rs1707322	0.721	rs7519900	ENSG00000234329.1	RP11-767N6.2	6.04	3.11e-09	1.31e-06	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769275	chr1:45651039~45651826:-
LUAD	cis	rs11098499	0.754	rs17049949	ENSG00000248280.1	RP11-33B1.2	6.04	3.11e-09	1.31e-06	0.33	0.27	Corneal astigmatism;	chr4:119334135	chr4:119440561~119450157:-
LUAD	cis	rs1823913	0.549	rs4465792	ENSG00000280083.1	RP11-317J9.1	-6.04	3.12e-09	1.32e-06	-0.33	-0.27	Obesity-related traits;	chr2:191328884	chr2:191154118~191156070:-
LUAD	cis	rs3738443	0.672	rs6691539	ENSG00000259865.1	RP11-488L18.10	6.04	3.12e-09	1.32e-06	0.23	0.27	Alcohol dependence;	chr1:247209370	chr1:247187281~247188526:-
LUAD	cis	rs10214930	0.697	rs978447	ENSG00000235574.1	AC073150.6	-6.04	3.12e-09	1.32e-06	-0.34	-0.27	Hypospadias;	chr7:27543164	chr7:27491682~27492765:-
LUAD	cis	rs34524635	1	rs34524635	ENSG00000232075.1	MRPL35P2	-6.04	3.13e-09	1.32e-06	-0.32	-0.27	Vascular endothelial growth factor levels;	chr10:63501417	chr10:63634317~63634827:-
LUAD	cis	rs293748	0.571	rs13171061	ENSG00000250155.1	CTD-2353F22.1	-6.04	3.13e-09	1.32e-06	-0.34	-0.27	Obesity-related traits;	chr5:37154591	chr5:36666214~36725195:-
LUAD	cis	rs4834770	1	rs878375	ENSG00000245958.5	RP11-33B1.1	-6.04	3.13e-09	1.32e-06	-0.23	-0.27	Blood protein levels;	chr4:119316419	chr4:119454791~119552025:+
LUAD	cis	rs17301013	0.581	rs72711501	ENSG00000227373.4	RP11-160H22.5	6.04	3.13e-09	1.32e-06	0.38	0.27	Systemic lupus erythematosus;	chr1:174233081	chr1:174115300~174160004:-
LUAD	cis	rs6991838	0.806	rs4285523	ENSG00000200714.1	Y_RNA	6.04	3.13e-09	1.32e-06	0.31	0.27	Intelligence (multi-trait analysis);	chr8:65552095	chr8:65592731~65592820:+
LUAD	cis	rs1061377	1	rs36090629	ENSG00000249685.1	RP11-360F5.3	6.04	3.14e-09	1.32e-06	0.32	0.27	Uric acid levels;	chr4:39137195	chr4:39133913~39135608:+
LUAD	cis	rs1061377	0.87	rs73238544	ENSG00000249685.1	RP11-360F5.3	6.04	3.14e-09	1.32e-06	0.32	0.27	Uric acid levels;	chr4:39137343	chr4:39133913~39135608:+
LUAD	cis	rs2243480	1	rs34637256	ENSG00000230295.1	RP11-458F8.2	-6.04	3.14e-09	1.33e-06	-0.33	-0.27	Diabetic kidney disease;	chr7:65895144	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs35391607	ENSG00000230295.1	RP11-458F8.2	-6.04	3.14e-09	1.33e-06	-0.33	-0.27	Diabetic kidney disease;	chr7:65895842	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs13220979	ENSG00000230295.1	RP11-458F8.2	-6.04	3.14e-09	1.33e-06	-0.33	-0.27	Diabetic kidney disease;	chr7:65898217	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs34974928	ENSG00000230295.1	RP11-458F8.2	-6.04	3.14e-09	1.33e-06	-0.33	-0.27	Diabetic kidney disease;	chr7:65899019	chr7:66880708~66882981:+
LUAD	cis	rs11690935	0.632	rs11690807	ENSG00000228389.1	AC068039.4	-6.04	3.14e-09	1.33e-06	-0.28	-0.27	Schizophrenia;	chr2:171771610	chr2:171773482~171775844:+
LUAD	cis	rs2404602	0.735	rs4886495	ENSG00000259422.1	RP11-593F23.1	6.04	3.14e-09	1.33e-06	0.33	0.27	Blood metabolite levels;	chr15:76446618	chr15:76174891~76181486:-
LUAD	cis	rs11096990	0.964	rs56284364	ENSG00000249207.1	RP11-360F5.1	6.04	3.14e-09	1.33e-06	0.3	0.27	Cognitive function;	chr4:39255028	chr4:39112677~39126818:-
LUAD	cis	rs783540	1	rs698500	ENSG00000278603.1	RP13-608F4.5	-6.04	3.14e-09	1.33e-06	-0.31	-0.27	Schizophrenia;	chr15:82569019	chr15:82472203~82472426:+
LUAD	cis	rs4713118	0.621	rs10484403	ENSG00000204709.4	LINC01556	6.04	3.15e-09	1.33e-06	0.37	0.27	Parkinson's disease;	chr6:28065745	chr6:28943877~28944537:+
LUAD	cis	rs4820294	1	rs62236667	ENSG00000233360.4	Z83844.1	6.04	3.15e-09	1.33e-06	0.28	0.27	Fat distribution (HIV);	chr22:37665513	chr22:37641832~37658377:-
LUAD	cis	rs4820294	1	rs62236668	ENSG00000233360.4	Z83844.1	6.04	3.15e-09	1.33e-06	0.28	0.27	Fat distribution (HIV);	chr22:37667863	chr22:37641832~37658377:-
LUAD	cis	rs4820294	1	rs713835	ENSG00000233360.4	Z83844.1	6.04	3.15e-09	1.33e-06	0.28	0.27	Fat distribution (HIV);	chr22:37668643	chr22:37641832~37658377:-
LUAD	cis	rs881375	0.678	rs1014530	ENSG00000226752.6	PSMD5-AS1	-6.04	3.15e-09	1.33e-06	-0.28	-0.27	Rheumatoid arthritis;	chr9:120922814	chr9:120824828~120854385:+
LUAD	cis	rs78579487	1	rs78579487	ENSG00000240875.4	LINC00886	-6.04	3.15e-09	1.33e-06	-0.29	-0.27	Breast cancer;	chr3:156800879	chr3:156747346~156817062:-
LUAD	cis	rs987724	0.551	rs1835372	ENSG00000240875.4	LINC00886	-6.04	3.15e-09	1.33e-06	-0.29	-0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156801238	chr3:156747346~156817062:-
LUAD	cis	rs7923609	0.967	rs7095571	ENSG00000232075.1	MRPL35P2	-6.04	3.15e-09	1.33e-06	-0.33	-0.27	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63391199	chr10:63634317~63634827:-
LUAD	cis	rs66887589	0.934	rs12648182	ENSG00000248280.1	RP11-33B1.2	-6.04	3.16e-09	1.33e-06	-0.29	-0.27	Diastolic blood pressure;	chr4:119582736	chr4:119440561~119450157:-
LUAD	cis	rs1061377	1	rs13109200	ENSG00000249685.1	RP11-360F5.3	6.04	3.16e-09	1.33e-06	0.32	0.27	Uric acid levels;	chr4:39124396	chr4:39133913~39135608:+
LUAD	cis	rs1061377	1	rs13144374	ENSG00000249685.1	RP11-360F5.3	6.04	3.16e-09	1.33e-06	0.32	0.27	Uric acid levels;	chr4:39128859	chr4:39133913~39135608:+
LUAD	cis	rs367615	0.68	rs253246	ENSG00000249476.1	CTD-2587M2.1	6.04	3.16e-09	1.34e-06	0.35	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109648317	chr5:109237120~109326369:-
LUAD	cis	rs12699921	0.632	rs4316058	ENSG00000279048.1	RP11-511H23.2	-6.04	3.17e-09	1.34e-06	-0.21	-0.27	Fibrinogen levels;	chr7:17795103	chr7:17940503~17942922:+
LUAD	cis	rs875971	0.545	rs73142265	ENSG00000226824.5	RP4-756H11.3	-6.04	3.17e-09	1.34e-06	-0.39	-0.27	Aortic root size;	chr7:66234510	chr7:66654538~66669855:+
LUAD	cis	rs13030978	0.505	rs72916554	ENSG00000280083.1	RP11-317J9.1	-6.04	3.17e-09	1.34e-06	-0.33	-0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr2:191330532	chr2:191154118~191156070:-
LUAD	cis	rs11971779	0.68	rs6962366	ENSG00000273391.1	RP11-634H22.1	6.04	3.17e-09	1.34e-06	0.27	0.27	Diisocyanate-induced asthma;	chr7:139359121	chr7:139359032~139359566:-
LUAD	cis	rs2980439	0.783	rs2955587	ENSG00000173295.6	FAM86B3P	6.04	3.18e-09	1.34e-06	0.29	0.27	Neuroticism;	chr8:8240557	chr8:8228595~8244865:+
LUAD	cis	rs1823913	0.599	rs10497713	ENSG00000280083.1	RP11-317J9.1	-6.03	3.18e-09	1.34e-06	-0.32	-0.27	Obesity-related traits;	chr2:191279312	chr2:191154118~191156070:-
LUAD	cis	rs10214930	0.697	rs1851913	ENSG00000235574.1	AC073150.6	-6.03	3.18e-09	1.34e-06	-0.34	-0.27	Hypospadias;	chr7:27545457	chr7:27491682~27492765:-
LUAD	cis	rs494459	0.756	rs570806	ENSG00000278376.1	RP11-158I9.8	-6.03	3.18e-09	1.34e-06	-0.29	-0.27	Height;	chr11:118786602	chr11:118791254~118793137:+
LUAD	cis	rs11096990	0.964	rs11096986	ENSG00000249207.1	RP11-360F5.1	6.03	3.18e-09	1.34e-06	0.3	0.27	Cognitive function;	chr4:39257122	chr4:39112677~39126818:-
LUAD	cis	rs4972806	0.668	rs2072588	ENSG00000226363.3	HAGLROS	-6.03	3.18e-09	1.34e-06	-0.33	-0.27	IgG glycosylation;	chr2:176178202	chr2:176177717~176179008:+
LUAD	cis	rs4718428	0.672	rs12530806	ENSG00000232546.1	RP11-458F8.1	-6.03	3.19e-09	1.34e-06	-0.25	-0.27	Corneal structure;	chr7:66925737	chr7:66848496~66858136:+
LUAD	cis	rs4718428	0.705	rs10267335	ENSG00000232546.1	RP11-458F8.1	-6.03	3.19e-09	1.34e-06	-0.25	-0.27	Corneal structure;	chr7:66938233	chr7:66848496~66858136:+
LUAD	cis	rs748404	0.666	rs8027748	ENSG00000205771.5	CATSPER2P1	-6.03	3.19e-09	1.35e-06	-0.41	-0.27	Lung cancer;	chr15:43447622	chr15:43726918~43747094:-
LUAD	cis	rs17023223	0.537	rs12086549	ENSG00000231365.4	RP11-418J17.1	6.03	3.19e-09	1.35e-06	0.35	0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119071714	chr1:119140396~119275973:+
LUAD	cis	rs36093844	0.8	rs112468922	ENSG00000279742.1	RP11-700A24.1	-6.03	3.19e-09	1.35e-06	-0.35	-0.27	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85865651	chr11:85852557~85854943:-
LUAD	cis	rs4713118	0.826	rs2893929	ENSG00000219392.1	RP1-265C24.5	-6.03	3.2e-09	1.35e-06	-0.37	-0.27	Parkinson's disease;	chr6:27770953	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.666	rs4140646	ENSG00000219392.1	RP1-265C24.5	-6.03	3.2e-09	1.35e-06	-0.37	-0.27	Parkinson's disease;	chr6:27771022	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.666	rs2893930	ENSG00000219392.1	RP1-265C24.5	-6.03	3.2e-09	1.35e-06	-0.37	-0.27	Parkinson's disease;	chr6:27771027	chr6:28115628~28116551:+
LUAD	cis	rs7727544	0.735	rs4705933	ENSG00000233006.5	AC034220.3	6.03	3.2e-09	1.35e-06	0.24	0.27	Blood metabolite levels;	chr5:132342719	chr5:132311285~132369916:-
LUAD	cis	rs7727544	0.735	rs272867	ENSG00000233006.5	AC034220.3	6.03	3.2e-09	1.35e-06	0.24	0.27	Blood metabolite levels;	chr5:132345364	chr5:132311285~132369916:-
LUAD	cis	rs11098499	0.909	rs10017335	ENSG00000248280.1	RP11-33B1.2	-6.03	3.2e-09	1.35e-06	-0.34	-0.27	Corneal astigmatism;	chr4:119460368	chr4:119440561~119450157:-
LUAD	cis	rs2562456	0.876	rs7252585	ENSG00000268081.1	RP11-678G14.2	-6.03	3.2e-09	1.35e-06	-0.39	-0.27	Pain;	chr19:21475141	chr19:21554640~21569237:-
LUAD	cis	rs1426063	0.614	rs75846524	ENSG00000249717.1	RP11-44F21.3	6.03	3.21e-09	1.35e-06	0.54	0.27	QT interval;	chr4:75083172	chr4:74955974~74970362:-
LUAD	cis	rs8177876	0.658	rs75422577	ENSG00000261061.1	RP11-303E16.2	-6.03	3.21e-09	1.35e-06	-0.47	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81054561	chr16:81030770~81031485:+
LUAD	cis	rs897200	0.898	rs1031507	ENSG00000280083.1	RP11-317J9.1	6.03	3.21e-09	1.35e-06	0.34	0.27	Behcet's disease;	chr2:191155892	chr2:191154118~191156070:-
LUAD	cis	rs494459	0.536	rs57719838	ENSG00000255239.1	AP002954.6	6.03	3.21e-09	1.36e-06	0.31	0.27	Height;	chr11:118854014	chr11:118688039~118690600:-
LUAD	cis	rs189798	0.807	rs12785	ENSG00000254340.1	RP11-10A14.3	6.03	3.22e-09	1.36e-06	0.36	0.27	Myopia (pathological);	chr8:9137426	chr8:9141424~9145435:+
LUAD	cis	rs7618501	0.602	rs9311446	ENSG00000234667.1	ACTBP13	6.03	3.22e-09	1.36e-06	0.3	0.27	Intelligence (multi-trait analysis);	chr3:50054793	chr3:49873347~49877980:-
LUAD	cis	rs7618501	0.602	rs2245365	ENSG00000234667.1	ACTBP13	6.03	3.22e-09	1.36e-06	0.3	0.27	Intelligence (multi-trait analysis);	chr3:50059886	chr3:49873347~49877980:-
LUAD	cis	rs172166	0.637	rs1233691	ENSG00000219392.1	RP1-265C24.5	-6.03	3.22e-09	1.36e-06	-0.34	-0.27	Cardiac Troponin-T levels;	chr6:28186119	chr6:28115628~28116551:+
LUAD	cis	rs12699921	0.632	rs2691625	ENSG00000279048.1	RP11-511H23.2	-6.03	3.22e-09	1.36e-06	-0.21	-0.27	Fibrinogen levels;	chr7:17784000	chr7:17940503~17942922:+
LUAD	cis	rs6991838	0.725	rs6995134	ENSG00000272010.1	CTD-3025N20.3	6.03	3.22e-09	1.36e-06	0.27	0.27	Intelligence (multi-trait analysis);	chr8:65555472	chr8:65591850~65592472:-
LUAD	cis	rs9595908	0.709	rs9596222	ENSG00000212293.1	SNORA16	6.03	3.23e-09	1.36e-06	0.28	0.27	Body mass index;	chr13:32767679	chr13:32420390~32420516:-
LUAD	cis	rs2933343	0.953	rs2933344	ENSG00000261159.1	RP11-723O4.9	6.03	3.23e-09	1.36e-06	0.32	0.27	IgG glycosylation;	chr3:128939872	chr3:128859716~128860526:-
LUAD	cis	rs2255336	0.938	rs2255364	ENSG00000245648.1	RP11-277P12.20	6.03	3.23e-09	1.36e-06	0.39	0.27	Blood protein levels;	chr12:10379297	chr12:10363769~10398506:+
LUAD	cis	rs2255336	0.938	rs2255353	ENSG00000245648.1	RP11-277P12.20	6.03	3.23e-09	1.36e-06	0.39	0.27	Blood protein levels;	chr12:10379512	chr12:10363769~10398506:+
LUAD	cis	rs7714584	1	rs11741861	ENSG00000197083.10	ZNF300P1	-6.03	3.23e-09	1.36e-06	-0.54	-0.27	Crohn's disease;	chr5:150898347	chr5:150930645~150946289:-
LUAD	cis	rs853679	0.55	rs1233704	ENSG00000204709.4	LINC01556	-6.03	3.23e-09	1.36e-06	-0.36	-0.27	Depression;	chr6:28199145	chr6:28943877~28944537:+
LUAD	cis	rs7849270	1	rs3739843	ENSG00000268707.1	RP11-247A12.7	-6.03	3.23e-09	1.36e-06	-0.3	-0.27	Blood metabolite ratios;	chr9:129120682	chr9:129170434~129170940:+
LUAD	cis	rs948562	0.69	rs734777	ENSG00000280010.1	AP001350.4	6.03	3.23e-09	1.36e-06	0.42	0.27	Lymphoma;	chr11:58343636	chr11:58627435~58628528:+
LUAD	cis	rs11168854	0.93	rs10783302	ENSG00000258017.1	RP11-386G11.10	6.03	3.23e-09	1.36e-06	0.33	0.27	Body mass index;	chr12:49104347	chr12:49127782~49147869:+
LUAD	cis	rs131777	0.708	rs131749	ENSG00000205559.3	CHKB-AS1	6.03	3.23e-09	1.36e-06	0.31	0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586195	chr22:50583026~50583877:+
LUAD	cis	rs1062177	0.855	rs6896664	ENSG00000213433.5	RPLP1P6	-6.03	3.23e-09	1.36e-06	-0.33	-0.27	Preschool internalizing problems;	chr5:151885713	chr5:151765859~151766378:-
LUAD	cis	rs4713118	0.869	rs7776351	ENSG00000219392.1	RP1-265C24.5	6.03	3.23e-09	1.36e-06	0.36	0.27	Parkinson's disease;	chr6:27758952	chr6:28115628~28116551:+
LUAD	cis	rs9311474	1	rs6445358	ENSG00000243224.1	RP5-1157M23.2	-6.03	3.24e-09	1.37e-06	-0.27	-0.27	Electroencephalogram traits;	chr3:52274829	chr3:52239258~52241097:+
LUAD	cis	rs5753618	0.539	rs1034588	ENSG00000236132.1	CTA-440B3.1	6.03	3.24e-09	1.37e-06	0.33	0.27	Colorectal cancer;	chr22:31220315	chr22:31816379~31817491:-
LUAD	cis	rs4723738	1	rs6462817	ENSG00000227191.5	TRGC2	-6.03	3.24e-09	1.37e-06	-0.29	-0.27	Treatment response for severe sepsis;	chr7:38211264	chr7:38239580~38368091:-
LUAD	cis	rs11971779	0.68	rs7779900	ENSG00000273391.1	RP11-634H22.1	6.03	3.24e-09	1.37e-06	0.27	0.27	Diisocyanate-induced asthma;	chr7:139398241	chr7:139359032~139359566:-
LUAD	cis	rs66887589	0.616	rs11098497	ENSG00000245958.5	RP11-33B1.1	-6.03	3.25e-09	1.37e-06	-0.22	-0.27	Diastolic blood pressure;	chr4:119265913	chr4:119454791~119552025:+
LUAD	cis	rs8177876	0.749	rs754429	ENSG00000261061.1	RP11-303E16.2	-6.03	3.25e-09	1.37e-06	-0.45	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81062574	chr16:81030770~81031485:+
LUAD	cis	rs6921919	0.583	rs16894108	ENSG00000204709.4	LINC01556	6.03	3.25e-09	1.37e-06	0.34	0.27	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28943877~28944537:+
LUAD	cis	rs2276314	0.857	rs59649576	ENSG00000278986.1	RP11-723J4.3	-6.03	3.26e-09	1.37e-06	-0.32	-0.27	Endometriosis;Drug-induced torsades de pointes;	chr18:36036112	chr18:35972151~35973916:+
LUAD	cis	rs4908768	0.501	rs4908760	ENSG00000232912.4	RP5-1115A15.1	6.03	3.26e-09	1.37e-06	0.25	0.27	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8466082	chr1:8424645~8434838:+
LUAD	cis	rs8177376	1	rs598169	ENSG00000254905.1	RP11-712L6.7	6.03	3.26e-09	1.37e-06	0.37	0.27	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126219158	chr11:126292922~126294254:-
LUAD	cis	rs1799949	0.931	rs9912203	ENSG00000267681.1	CTD-3199J23.6	6.03	3.27e-09	1.37e-06	0.3	0.27	Menopause (age at onset);	chr17:43367777	chr17:43144956~43145255:+
LUAD	cis	rs7829975	0.509	rs2945269	ENSG00000253893.2	FAM85B	-6.03	3.27e-09	1.38e-06	-0.34	-0.27	Mood instability;	chr8:8258056	chr8:8167819~8226614:-
LUAD	cis	rs11098499	0.955	rs11944880	ENSG00000248280.1	RP11-33B1.2	-6.03	3.27e-09	1.38e-06	-0.33	-0.27	Corneal astigmatism;	chr4:119238179	chr4:119440561~119450157:-
LUAD	cis	rs9928842	0.823	rs2870472	ENSG00000280152.1	RP11-331F4.5	6.03	3.27e-09	1.38e-06	0.29	0.27	Alcoholic chronic pancreatitis;	chr16:75244943	chr16:75245994~75250077:-
LUAD	cis	rs9309473	0.95	rs73947808	ENSG00000163016.8	ALMS1P	6.03	3.27e-09	1.38e-06	0.34	0.27	Metabolite levels;	chr2:73494123	chr2:73644919~73685576:+
LUAD	cis	rs755249	0.53	rs112205225	ENSG00000228060.1	RP11-69E11.8	-6.03	3.27e-09	1.38e-06	-0.27	-0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39121716	chr1:39565160~39573203:+
LUAD	cis	rs875971	0.862	rs6460293	ENSG00000237310.1	GS1-124K5.4	-6.03	3.27e-09	1.38e-06	-0.29	-0.27	Aortic root size;	chr7:66345205	chr7:66493706~66495474:+
LUAD	cis	rs66887589	0.592	rs11731571	ENSG00000245958.5	RP11-33B1.1	-6.03	3.28e-09	1.38e-06	-0.22	-0.27	Diastolic blood pressure;	chr4:119300030	chr4:119454791~119552025:+
LUAD	cis	rs11096990	0.855	rs4974986	ENSG00000249207.1	RP11-360F5.1	6.03	3.28e-09	1.38e-06	0.31	0.27	Cognitive function;	chr4:39165308	chr4:39112677~39126818:-
LUAD	cis	rs7017914	0.905	rs2732106	ENSG00000223220.1	Y_RNA	6.03	3.28e-09	1.38e-06	0.3	0.27	Bone mineral density;	chr8:71011604	chr8:70780914~70781008:-
LUAD	cis	rs2562456	0.72	rs6511250	ENSG00000268081.1	RP11-678G14.2	-6.03	3.28e-09	1.38e-06	-0.4	-0.27	Pain;	chr19:21473244	chr19:21554640~21569237:-
LUAD	cis	rs11742741	0.579	rs4701424	ENSG00000248874.4	C5orf17	-6.03	3.28e-09	1.38e-06	-0.33	-0.27	Educational attainment;	chr5:24108437	chr5:23951348~24178263:+
LUAD	cis	rs1113500	0.541	rs9803640	ENSG00000226822.1	RP11-356N1.2	-6.03	3.28e-09	1.38e-06	-0.35	-0.27	Growth-regulated protein alpha levels;	chr1:108033645	chr1:108071482~108074519:+
LUAD	cis	rs858239	0.6	rs1468592	ENSG00000230042.1	AK3P3	6.03	3.28e-09	1.38e-06	0.33	0.27	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23129178~23129841:+
LUAD	cis	rs875971	0.83	rs427973	ENSG00000222364.1	RNU6-96P	-6.03	3.28e-09	1.38e-06	-0.3	-0.27	Aortic root size;	chr7:66061661	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.793	rs460678	ENSG00000222364.1	RNU6-96P	-6.03	3.29e-09	1.38e-06	-0.3	-0.27	Aortic root size;	chr7:66062213	chr7:66395191~66395286:+
LUAD	cis	rs6504622	0.791	rs758392	ENSG00000262879.4	RP11-156P1.3	-6.03	3.29e-09	1.39e-06	-0.31	-0.27	Orofacial clefts;	chr17:46940493	chr17:46984045~47100323:-
LUAD	cis	rs2243480	1	rs906134	ENSG00000232546.1	RP11-458F8.1	-6.03	3.3e-09	1.39e-06	-0.35	-0.27	Diabetic kidney disease;	chr7:65979301	chr7:66848496~66858136:+
LUAD	cis	rs2255336	0.938	rs2617152	ENSG00000245648.1	RP11-277P12.20	6.03	3.3e-09	1.39e-06	0.39	0.27	Blood protein levels;	chr12:10380507	chr12:10363769~10398506:+
LUAD	cis	rs75920871	0.528	rs4388921	ENSG00000254851.1	RP11-109L13.1	6.03	3.3e-09	1.39e-06	0.38	0.27	Subjective well-being;	chr11:117106062	chr11:117135528~117138582:+
LUAD	cis	rs1061377	1	rs1061377	ENSG00000249685.1	RP11-360F5.3	6.03	3.31e-09	1.39e-06	0.32	0.27	Uric acid levels;	chr4:39123130	chr4:39133913~39135608:+
LUAD	cis	rs55665837	0.559	rs9667144	ENSG00000251991.1	RNU7-49P	-6.03	3.31e-09	1.39e-06	-0.3	-0.27	Vitamin D levels;	chr11:14399555	chr11:14478892~14478953:+
LUAD	cis	rs4938330	0.512	rs4938327	ENSG00000254851.1	RP11-109L13.1	6.03	3.31e-09	1.39e-06	0.39	0.27	Blood protein levels;	chr11:117036012	chr11:117135528~117138582:+
LUAD	cis	rs2283792	0.765	rs7290469	ENSG00000224086.5	LL22NC03-86G7.1	-6.03	3.31e-09	1.39e-06	-0.26	-0.27	Multiple sclerosis;	chr22:21796693	chr22:21938293~21977632:+
LUAD	cis	rs801193	0.548	rs2109297	ENSG00000222364.1	RNU6-96P	6.03	3.31e-09	1.39e-06	0.3	0.27	Aortic root size;	chr7:66657397	chr7:66395191~66395286:+
LUAD	cis	rs801193	0.591	rs721717	ENSG00000222364.1	RNU6-96P	6.03	3.31e-09	1.39e-06	0.3	0.27	Aortic root size;	chr7:66665305	chr7:66395191~66395286:+
LUAD	cis	rs801193	0.569	rs6951302	ENSG00000222364.1	RNU6-96P	6.03	3.31e-09	1.39e-06	0.3	0.27	Aortic root size;	chr7:66667525	chr7:66395191~66395286:+
LUAD	cis	rs3779195	0.524	rs80195155	ENSG00000272950.1	RP11-307C18.1	-6.03	3.31e-09	1.39e-06	-0.46	-0.27	Sex hormone-binding globulin levels;	chr7:98248841	chr7:98322853~98323430:+
LUAD	cis	rs875971	0.862	rs709596	ENSG00000237310.1	GS1-124K5.4	6.03	3.31e-09	1.39e-06	0.29	0.27	Aortic root size;	chr7:66360926	chr7:66493706~66495474:+
LUAD	cis	rs7849270	1	rs10819466	ENSG00000268707.1	RP11-247A12.7	-6.03	3.32e-09	1.4e-06	-0.3	-0.27	Blood metabolite ratios;	chr9:129119213	chr9:129170434~129170940:+
LUAD	cis	rs1707322	0.717	rs3014237	ENSG00000234329.1	RP11-767N6.2	-6.03	3.32e-09	1.4e-06	-0.28	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624580	chr1:45651039~45651826:-
LUAD	cis	rs274567	0.501	rs272856	ENSG00000233006.5	AC034220.3	6.03	3.32e-09	1.4e-06	0.27	0.26	Blood metabolite levels;	chr5:132351388	chr5:132311285~132369916:-
LUAD	cis	rs875971	0.545	rs2420612	ENSG00000226824.5	RP4-756H11.3	-6.03	3.32e-09	1.4e-06	-0.39	-0.26	Aortic root size;	chr7:66536825	chr7:66654538~66669855:+
LUAD	cis	rs1823913	0.637	rs10931493	ENSG00000227542.1	AC092614.2	6.03	3.33e-09	1.4e-06	0.32	0.26	Obesity-related traits;	chr2:191288142	chr2:191229165~191246172:-
LUAD	cis	rs875971	1	rs6963646	ENSG00000222364.1	RNU6-96P	6.03	3.33e-09	1.4e-06	0.29	0.26	Aortic root size;	chr7:66220780	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.965	rs28682868	ENSG00000222364.1	RNU6-96P	6.03	3.33e-09	1.4e-06	0.29	0.26	Aortic root size;	chr7:66224822	chr7:66395191~66395286:+
LUAD	cis	rs9595908	0.622	rs7983267	ENSG00000212293.1	SNORA16	6.03	3.34e-09	1.4e-06	0.28	0.26	Body mass index;	chr13:32806767	chr13:32420390~32420516:-
LUAD	cis	rs6142102	0.625	rs2050208	ENSG00000275784.1	RP5-1125A11.6	-6.03	3.34e-09	1.4e-06	-0.29	-0.26	Skin pigmentation;	chr20:33955767	chr20:33989480~33991818:-
LUAD	cis	rs2243480	1	rs34970380	ENSG00000232546.1	RP11-458F8.1	-6.03	3.34e-09	1.4e-06	-0.35	-0.26	Diabetic kidney disease;	chr7:65966506	chr7:66848496~66858136:+
LUAD	cis	rs2243480	0.901	rs73148097	ENSG00000232546.1	RP11-458F8.1	-6.03	3.34e-09	1.4e-06	-0.35	-0.26	Diabetic kidney disease;	chr7:65966800	chr7:66848496~66858136:+
LUAD	cis	rs875971	0.862	rs2460432	ENSG00000222364.1	RNU6-96P	6.03	3.34e-09	1.4e-06	0.3	0.26	Aortic root size;	chr7:66089398	chr7:66395191~66395286:+
LUAD	cis	rs4835473	0.932	rs4383567	ENSG00000251600.4	RP11-673E1.1	6.03	3.34e-09	1.4e-06	0.32	0.26	Immature fraction of reticulocytes;	chr4:143788873	chr4:143912331~143982454:+
LUAD	cis	rs720064	0.586	rs2288592	ENSG00000264745.1	TTC39C-AS1	6.03	3.35e-09	1.41e-06	0.28	0.26	Strep throat;	chr18:23946123	chr18:23994213~24015339:-
LUAD	cis	rs957448	1	rs72674861	ENSG00000253704.1	RP11-267M23.4	6.03	3.35e-09	1.41e-06	0.34	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94550051	chr8:94553722~94569745:+
LUAD	cis	rs2880765	0.525	rs35899940	ENSG00000259295.5	CSPG4P12	6.03	3.36e-09	1.41e-06	0.33	0.26	Coronary artery disease;	chr15:85510466	chr15:85191438~85213905:+
LUAD	cis	rs8072100	0.967	rs4338849	ENSG00000228782.6	CTD-2026D20.3	6.03	3.36e-09	1.41e-06	0.28	0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47435117	chr17:47450568~47492492:-
LUAD	cis	rs13217239	0.646	rs10946898	ENSG00000241549.7	GUSBP2	6.03	3.36e-09	1.41e-06	0.28	0.26	Schizophrenia;	chr6:27036105	chr6:26871484~26956554:-
LUAD	cis	rs12699921	0.566	rs1997019	ENSG00000279048.1	RP11-511H23.2	-6.03	3.36e-09	1.41e-06	-0.22	-0.26	Fibrinogen levels;	chr7:17787856	chr7:17940503~17942922:+
LUAD	cis	rs6991838	0.778	rs11779602	ENSG00000200714.1	Y_RNA	6.03	3.36e-09	1.41e-06	0.31	0.26	Intelligence (multi-trait analysis);	chr8:65550247	chr8:65592731~65592820:+
LUAD	cis	rs3762637	1	rs10049131	ENSG00000272758.4	RP11-299J3.8	-6.03	3.37e-09	1.41e-06	-0.42	-0.26	LDL cholesterol levels;	chr3:122483255	chr3:122416207~122443180:+
LUAD	cis	rs4908768	0.501	rs4908761	ENSG00000232912.4	RP5-1115A15.1	6.02	3.37e-09	1.42e-06	0.25	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8492159	chr1:8424645~8434838:+
LUAD	cis	rs875971	0.862	rs778720	ENSG00000237310.1	GS1-124K5.4	-6.02	3.38e-09	1.42e-06	-0.29	-0.26	Aortic root size;	chr7:66381288	chr7:66493706~66495474:+
LUAD	cis	rs10740039	0.516	rs2393675	ENSG00000254271.1	RP11-131N11.4	6.02	3.38e-09	1.42e-06	0.3	0.26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60590990	chr10:60734342~60741828:+
LUAD	cis	rs12699921	0.632	rs2691601	ENSG00000279048.1	RP11-511H23.2	-6.02	3.38e-09	1.42e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17835808	chr7:17940503~17942922:+
LUAD	cis	rs6991838	0.806	rs13262793	ENSG00000272010.1	CTD-3025N20.3	6.02	3.38e-09	1.42e-06	0.27	0.26	Intelligence (multi-trait analysis);	chr8:65549662	chr8:65591850~65592472:-
LUAD	cis	rs74233809	1	rs79237883	ENSG00000213277.3	MARCKSL1P1	6.02	3.38e-09	1.42e-06	0.45	0.26	Birth weight;	chr10:103181189	chr10:103175554~103176094:+
LUAD	cis	rs74233809	1	rs34747231	ENSG00000213277.3	MARCKSL1P1	6.02	3.38e-09	1.42e-06	0.45	0.26	Birth weight;	chr10:103182487	chr10:103175554~103176094:+
LUAD	cis	rs5753618	0.509	rs5997902	ENSG00000236132.1	CTA-440B3.1	6.02	3.38e-09	1.42e-06	0.33	0.26	Colorectal cancer;	chr22:31187021	chr22:31816379~31817491:-
LUAD	cis	rs3096299	0.629	rs12929744	ENSG00000274627.1	RP11-104N10.2	6.02	3.39e-09	1.42e-06	0.25	0.26	Multiple myeloma (IgH translocation);	chr16:89427172	chr16:89516797~89522217:+
LUAD	cis	rs4591358	0.731	rs34634374	ENSG00000223466.1	AC064834.2	-6.02	3.39e-09	1.42e-06	-0.36	-0.26	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195509437	chr2:195533035~195538681:+
LUAD	cis	rs9595908	0.693	rs4942911	ENSG00000212293.1	SNORA16	6.02	3.39e-09	1.42e-06	0.29	0.26	Body mass index;	chr13:32793038	chr13:32420390~32420516:-
LUAD	cis	rs2243480	1	rs6964530	ENSG00000232546.1	RP11-458F8.1	6.02	3.39e-09	1.42e-06	0.35	0.26	Diabetic kidney disease;	chr7:66253864	chr7:66848496~66858136:+
LUAD	cis	rs8177376	0.727	rs586566	ENSG00000254905.1	RP11-712L6.7	6.02	3.39e-09	1.42e-06	0.36	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126329723	chr11:126292922~126294254:-
LUAD	cis	rs8177376	0.727	rs667469	ENSG00000254905.1	RP11-712L6.7	6.02	3.39e-09	1.42e-06	0.36	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126330171	chr11:126292922~126294254:-
LUAD	cis	rs10129255	0.509	rs756583	ENSG00000211970.3	IGHV4-61	-6.02	3.39e-09	1.42e-06	-0.19	-0.26	Kawasaki disease;	chr14:106680002	chr14:106639119~106639657:-
LUAD	cis	rs8177376	0.906	rs1613842	ENSG00000254905.1	RP11-712L6.7	6.02	3.4e-09	1.42e-06	0.38	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126326015	chr11:126292922~126294254:-
LUAD	cis	rs8177376	0.906	rs1695739	ENSG00000254905.1	RP11-712L6.7	6.02	3.4e-09	1.42e-06	0.38	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126326280	chr11:126292922~126294254:-
LUAD	cis	rs875971	0.862	rs6971059	ENSG00000237310.1	GS1-124K5.4	-6.02	3.4e-09	1.42e-06	-0.29	-0.26	Aortic root size;	chr7:66602045	chr7:66493706~66495474:+
LUAD	cis	rs2980439	0.807	rs2980438	ENSG00000253893.2	FAM85B	-6.02	3.4e-09	1.42e-06	-0.33	-0.26	Neuroticism;	chr8:8237303	chr8:8167819~8226614:-
LUAD	cis	rs1799949	0.931	rs34474989	ENSG00000267681.1	CTD-3199J23.6	-6.02	3.4e-09	1.43e-06	-0.3	-0.26	Menopause (age at onset);	chr17:43368042	chr17:43144956~43145255:+
LUAD	cis	rs7829975	0.514	rs2976926	ENSG00000253893.2	FAM85B	-6.02	3.4e-09	1.43e-06	-0.33	-0.26	Mood instability;	chr8:8404114	chr8:8167819~8226614:-
LUAD	cis	rs7826238	0.509	rs2948288	ENSG00000253893.2	FAM85B	-6.02	3.4e-09	1.43e-06	-0.34	-0.26	Systolic blood pressure;	chr8:8257782	chr8:8167819~8226614:-
LUAD	cis	rs11096990	0.892	rs7680520	ENSG00000249207.1	RP11-360F5.1	6.02	3.41e-09	1.43e-06	0.3	0.26	Cognitive function;	chr4:39219013	chr4:39112677~39126818:-
LUAD	cis	rs2442825	0.693	rs2728924	ENSG00000206573.7	THUMPD3-AS1	6.02	3.41e-09	1.43e-06	0.19	0.26	Cerebrospinal fluid clusterin levels;	chr3:9381294	chr3:9349689~9398579:-
LUAD	cis	rs7615952	0.515	rs4441610	ENSG00000171084.14	FAM86JP	6.02	3.41e-09	1.43e-06	0.34	0.26	Blood pressure (smoking interaction);	chr3:125962464	chr3:125916620~125930024:+
LUAD	cis	rs9543976	0.623	rs7982517	ENSG00000261553.4	RP11-29G8.3	6.02	3.41e-09	1.43e-06	0.34	0.26	Diabetic retinopathy;	chr13:75587903	chr13:75549773~75807120:+
LUAD	cis	rs7221109	0.601	rs2462964	ENSG00000278834.1	RP11-458J1.1	-6.02	3.42e-09	1.43e-06	-0.31	-0.26	Type 1 diabetes;	chr17:40706276	chr17:40648300~40649718:+
LUAD	cis	rs881375	0.967	rs1930780	ENSG00000226752.6	PSMD5-AS1	-6.02	3.42e-09	1.43e-06	-0.28	-0.26	Rheumatoid arthritis;	chr9:120923941	chr9:120824828~120854385:+
LUAD	cis	rs6142102	0.625	rs4911138	ENSG00000275784.1	RP5-1125A11.6	-6.02	3.42e-09	1.43e-06	-0.29	-0.26	Skin pigmentation;	chr20:33959893	chr20:33989480~33991818:-
LUAD	cis	rs6142102	0.625	rs4243974	ENSG00000275784.1	RP5-1125A11.6	-6.02	3.42e-09	1.43e-06	-0.29	-0.26	Skin pigmentation;	chr20:33960062	chr20:33989480~33991818:-
LUAD	cis	rs6142102	0.625	rs6142062	ENSG00000275784.1	RP5-1125A11.6	-6.02	3.42e-09	1.43e-06	-0.29	-0.26	Skin pigmentation;	chr20:33960706	chr20:33989480~33991818:-
LUAD	cis	rs6142102	0.625	rs6141432	ENSG00000275784.1	RP5-1125A11.6	-6.02	3.42e-09	1.43e-06	-0.29	-0.26	Skin pigmentation;	chr20:33960791	chr20:33989480~33991818:-
LUAD	cis	rs6142102	0.602	rs6141433	ENSG00000275784.1	RP5-1125A11.6	-6.02	3.42e-09	1.43e-06	-0.29	-0.26	Skin pigmentation;	chr20:33961056	chr20:33989480~33991818:-
LUAD	cis	rs853679	0.607	rs66886492	ENSG00000204709.4	LINC01556	6.02	3.42e-09	1.43e-06	0.59	0.26	Depression;	chr6:28121953	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.607	rs35345226	ENSG00000204709.4	LINC01556	6.02	3.42e-09	1.43e-06	0.59	0.26	Depression;	chr6:28123802	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.769	rs7752608	ENSG00000204709.4	LINC01556	6.02	3.42e-09	1.44e-06	0.53	0.26	Depression;	chr6:28333418	chr6:28943877~28944537:+
LUAD	cis	rs1823913	0.614	rs6755243	ENSG00000227542.1	AC092614.2	-6.02	3.42e-09	1.44e-06	-0.32	-0.26	Obesity-related traits;	chr2:191269810	chr2:191229165~191246172:-
LUAD	cis	rs7937890	0.874	rs2303972	ENSG00000254418.1	RP11-21L19.1	-6.02	3.42e-09	1.44e-06	-0.31	-0.26	Mitochondrial DNA levels;	chr11:14281736	chr11:14262846~14273691:-
LUAD	cis	rs394563	0.967	rs369643	ENSG00000231760.4	RP11-350J20.5	6.02	3.42e-09	1.44e-06	0.33	0.26	Dupuytren's disease;	chr6:149478662	chr6:149796151~149826294:-
LUAD	cis	rs848490	0.674	rs62460676	ENSG00000214293.7	APTR	6.02	3.43e-09	1.44e-06	0.3	0.26	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77680405	chr7:77657660~77696265:-
LUAD	cis	rs35160687	0.712	rs7560886	ENSG00000273080.1	RP11-301O19.1	-6.02	3.43e-09	1.44e-06	-0.29	-0.26	Night sleep phenotypes;	chr2:86265907	chr2:86195590~86196049:+
LUAD	cis	rs6504622	0.905	rs9889741	ENSG00000262879.4	RP11-156P1.3	6.02	3.44e-09	1.44e-06	0.31	0.26	Orofacial clefts;	chr17:46948967	chr17:46984045~47100323:-
LUAD	cis	rs2404602	0.655	rs10444809	ENSG00000259422.1	RP11-593F23.1	-6.02	3.44e-09	1.44e-06	-0.31	-0.26	Blood metabolite levels;	chr15:76832195	chr15:76174891~76181486:-
LUAD	cis	rs9506514	0.509	rs9509294	ENSG00000238286.1	SLC35E1P1	-6.02	3.44e-09	1.44e-06	-0.29	-0.26	Coronary artery calcification;	chr13:20600506	chr13:20607268~20608131:+
LUAD	cis	rs6142102	0.625	rs6142061	ENSG00000275784.1	RP5-1125A11.6	-6.02	3.44e-09	1.44e-06	-0.29	-0.26	Skin pigmentation;	chr20:33960529	chr20:33989480~33991818:-
LUAD	cis	rs783540	0.835	rs8030185	ENSG00000278603.1	RP13-608F4.5	6.02	3.44e-09	1.44e-06	0.31	0.26	Schizophrenia;	chr15:82722785	chr15:82472203~82472426:+
LUAD	cis	rs35740288	0.731	rs11634651	ENSG00000202081.1	RNU6-1280P	6.02	3.44e-09	1.44e-06	0.32	0.26	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85550695	chr15:85651522~85651628:-
LUAD	cis	rs875971	0.862	rs6958294	ENSG00000222364.1	RNU6-96P	6.02	3.44e-09	1.44e-06	0.3	0.26	Aortic root size;	chr7:66329809	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs2088655	ENSG00000222364.1	RNU6-96P	6.02	3.44e-09	1.44e-06	0.3	0.26	Aortic root size;	chr7:66330724	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.895	rs10447522	ENSG00000222364.1	RNU6-96P	6.02	3.44e-09	1.44e-06	0.3	0.26	Aortic root size;	chr7:66331087	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs2088653	ENSG00000222364.1	RNU6-96P	6.02	3.44e-09	1.44e-06	0.3	0.26	Aortic root size;	chr7:66343621	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs778736	ENSG00000222364.1	RNU6-96P	-6.02	3.44e-09	1.44e-06	-0.3	-0.26	Aortic root size;	chr7:66348861	chr7:66395191~66395286:+
LUAD	cis	rs11051970	0.513	rs2892655	ENSG00000274964.1	RP11-817I4.1	-6.02	3.44e-09	1.44e-06	-0.34	-0.26	Response to tocilizumab in rheumatoid arthritis;	chr12:32337295	chr12:32339368~32340724:+
LUAD	cis	rs3762637	1	rs9867429	ENSG00000272758.4	RP11-299J3.8	-6.02	3.45e-09	1.44e-06	-0.4	-0.26	LDL cholesterol levels;	chr3:122513821	chr3:122416207~122443180:+
LUAD	cis	rs496547	0.686	rs591756	ENSG00000255422.1	AP002954.4	-6.02	3.45e-09	1.44e-06	-0.34	-0.26	Hip minimal joint space width;	chr11:118808172	chr11:118704607~118750263:+
LUAD	cis	rs4834770	1	rs6857641	ENSG00000245958.5	RP11-33B1.1	-6.02	3.45e-09	1.44e-06	-0.23	-0.26	Blood protein levels;	chr4:119322356	chr4:119454791~119552025:+
LUAD	cis	rs11096990	0.928	rs2008681	ENSG00000249207.1	RP11-360F5.1	6.02	3.45e-09	1.45e-06	0.3	0.26	Cognitive function;	chr4:39266396	chr4:39112677~39126818:-
LUAD	cis	rs4713118	0.662	rs9380045	ENSG00000204709.4	LINC01556	6.02	3.45e-09	1.45e-06	0.36	0.26	Parkinson's disease;	chr6:28057501	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.616	rs9348789	ENSG00000204709.4	LINC01556	6.02	3.45e-09	1.45e-06	0.36	0.26	Parkinson's disease;	chr6:28057708	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.662	rs9468274	ENSG00000204709.4	LINC01556	6.02	3.45e-09	1.45e-06	0.36	0.26	Parkinson's disease;	chr6:28058299	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.662	rs9468275	ENSG00000204709.4	LINC01556	6.02	3.45e-09	1.45e-06	0.36	0.26	Parkinson's disease;	chr6:28058358	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.662	rs9468276	ENSG00000204709.4	LINC01556	6.02	3.45e-09	1.45e-06	0.36	0.26	Parkinson's disease;	chr6:28059910	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.662	rs9468277	ENSG00000204709.4	LINC01556	6.02	3.45e-09	1.45e-06	0.36	0.26	Parkinson's disease;	chr6:28060612	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.662	rs9468278	ENSG00000204709.4	LINC01556	6.02	3.45e-09	1.45e-06	0.36	0.26	Parkinson's disease;	chr6:28060704	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.662	rs13218430	ENSG00000204709.4	LINC01556	6.02	3.45e-09	1.45e-06	0.36	0.26	Parkinson's disease;	chr6:28062059	chr6:28943877~28944537:+
LUAD	cis	rs875971	0.597	rs11763224	ENSG00000237310.1	GS1-124K5.4	6.02	3.45e-09	1.45e-06	0.33	0.26	Aortic root size;	chr7:66518628	chr7:66493706~66495474:+
LUAD	cis	rs8072100	0.84	rs4968319	ENSG00000228782.6	CTD-2026D20.3	6.02	3.45e-09	1.45e-06	0.28	0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47387601	chr17:47450568~47492492:-
LUAD	cis	rs10214930	0.697	rs3847001	ENSG00000235574.1	AC073150.6	-6.02	3.46e-09	1.45e-06	-0.33	-0.26	Hypospadias;	chr7:27524686	chr7:27491682~27492765:-
LUAD	cis	rs6565180	0.791	rs4247355	ENSG00000183604.13	SMG1P5	6.02	3.46e-09	1.45e-06	0.28	0.26	Tonsillectomy;	chr16:30380778	chr16:30267553~30335374:-
LUAD	cis	rs1113500	0.897	rs11185263	ENSG00000226822.1	RP11-356N1.2	6.02	3.46e-09	1.45e-06	0.31	0.26	Growth-regulated protein alpha levels;	chr1:108097182	chr1:108071482~108074519:+
LUAD	cis	rs293748	0.771	rs158792	ENSG00000250155.1	CTD-2353F22.1	-6.02	3.46e-09	1.45e-06	-0.37	-0.26	Obesity-related traits;	chr5:36889068	chr5:36666214~36725195:-
LUAD	cis	rs853679	0.517	rs4713146	ENSG00000204709.4	LINC01556	6.02	3.46e-09	1.45e-06	0.38	0.26	Depression;	chr6:28143758	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9393894	ENSG00000204709.4	LINC01556	6.02	3.46e-09	1.45e-06	0.38	0.26	Depression;	chr6:28144784	chr6:28943877~28944537:+
LUAD	cis	rs916888	0.773	rs199533	ENSG00000261575.2	RP11-259G18.1	6.02	3.46e-09	1.45e-06	0.42	0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46267037~46268694:+
LUAD	cis	rs12908161	1	rs35630683	ENSG00000259728.4	LINC00933	6.02	3.47e-09	1.45e-06	0.38	0.26	Schizophrenia;	chr15:84806000	chr15:84570649~84580175:+
LUAD	cis	rs875971	1	rs6946143	ENSG00000222364.1	RNU6-96P	-6.02	3.47e-09	1.45e-06	-0.3	-0.26	Aortic root size;	chr7:66114735	chr7:66395191~66395286:+
LUAD	cis	rs11096990	0.855	rs2566184	ENSG00000249207.1	RP11-360F5.1	6.02	3.47e-09	1.45e-06	0.31	0.26	Cognitive function;	chr4:39162700	chr4:39112677~39126818:-
LUAD	cis	rs8177376	0.727	rs651983	ENSG00000254905.1	RP11-712L6.7	6.02	3.47e-09	1.45e-06	0.36	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126331343	chr11:126292922~126294254:-
LUAD	cis	rs8177376	0.727	rs651922	ENSG00000254905.1	RP11-712L6.7	6.02	3.47e-09	1.45e-06	0.36	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126331395	chr11:126292922~126294254:-
LUAD	cis	rs8177376	0.727	rs616360	ENSG00000254905.1	RP11-712L6.7	6.02	3.47e-09	1.45e-06	0.36	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126331508	chr11:126292922~126294254:-
LUAD	cis	rs8177376	0.727	rs651034	ENSG00000254905.1	RP11-712L6.7	6.02	3.47e-09	1.45e-06	0.36	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126331563	chr11:126292922~126294254:-
LUAD	cis	rs113835537	0.529	rs10501397	ENSG00000255517.5	CTD-3074O7.5	-6.02	3.47e-09	1.45e-06	-0.3	-0.26	Airway imaging phenotypes;	chr11:66505505	chr11:66473490~66480233:-
LUAD	cis	rs2288884	0.537	rs9636140	ENSG00000275055.1	CTC-471J1.11	-6.02	3.47e-09	1.45e-06	-0.32	-0.26	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52056610	chr19:52049007~52049754:+
LUAD	cis	rs4835473	0.932	rs13129702	ENSG00000251600.4	RP11-673E1.1	6.02	3.48e-09	1.46e-06	0.32	0.26	Immature fraction of reticulocytes;	chr4:143785132	chr4:143912331~143982454:+
LUAD	cis	rs2439831	0.85	rs7169322	ENSG00000205771.5	CATSPER2P1	-6.02	3.48e-09	1.46e-06	-0.55	-0.26	Lung cancer in ever smokers;	chr15:43838816	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.85	rs28707214	ENSG00000205771.5	CATSPER2P1	-6.02	3.48e-09	1.46e-06	-0.55	-0.26	Lung cancer in ever smokers;	chr15:43839425	chr15:43726918~43747094:-
LUAD	cis	rs2276314	0.857	rs6507158	ENSG00000278986.1	RP11-723J4.3	-6.02	3.48e-09	1.46e-06	-0.32	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:36056103	chr18:35972151~35973916:+
LUAD	cis	rs4834770	1	rs4834770	ENSG00000245958.5	RP11-33B1.1	-6.02	3.48e-09	1.46e-06	-0.23	-0.26	Blood protein levels;	chr4:119320694	chr4:119454791~119552025:+
LUAD	cis	rs6142102	0.625	rs6141436	ENSG00000275784.1	RP5-1125A11.6	-6.02	3.48e-09	1.46e-06	-0.29	-0.26	Skin pigmentation;	chr20:33966765	chr20:33989480~33991818:-
LUAD	cis	rs17711722	0.653	rs2460421	ENSG00000224316.1	RP11-479O9.2	-6.02	3.48e-09	1.46e-06	-0.26	-0.26	Calcium levels;	chr7:66026136	chr7:65773620~65802067:+
LUAD	cis	rs4908768	0.501	rs1024197	ENSG00000232912.4	RP5-1115A15.1	6.02	3.48e-09	1.46e-06	0.25	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8476998	chr1:8424645~8434838:+
LUAD	cis	rs4834770	1	rs6823963	ENSG00000245958.5	RP11-33B1.1	-6.02	3.48e-09	1.46e-06	-0.23	-0.26	Blood protein levels;	chr4:119321009	chr4:119454791~119552025:+
LUAD	cis	rs4834770	1	rs4834771	ENSG00000245958.5	RP11-33B1.1	-6.02	3.48e-09	1.46e-06	-0.23	-0.26	Blood protein levels;	chr4:119321617	chr4:119454791~119552025:+
LUAD	cis	rs4834770	1	rs1397613	ENSG00000245958.5	RP11-33B1.1	-6.02	3.48e-09	1.46e-06	-0.23	-0.26	Blood protein levels;	chr4:119321774	chr4:119454791~119552025:+
LUAD	cis	rs4834770	1	rs2282688	ENSG00000245958.5	RP11-33B1.1	-6.02	3.48e-09	1.46e-06	-0.23	-0.26	Blood protein levels;	chr4:119322567	chr4:119454791~119552025:+
LUAD	cis	rs516805	0.683	rs115988443	ENSG00000279453.1	RP3-425C14.4	6.02	3.48e-09	1.46e-06	0.37	0.26	Lymphocyte counts;	chr6:122383201	chr6:122436789~122439223:-
LUAD	cis	rs10129255	1	rs4612959	ENSG00000211972.2	IGHV3-66	6.02	3.49e-09	1.46e-06	0.23	0.26	Kawasaki disease;	chr14:106767055	chr14:106675017~106675544:-
LUAD	cis	rs875971	0.862	rs880166	ENSG00000237310.1	GS1-124K5.4	-6.02	3.49e-09	1.46e-06	-0.29	-0.26	Aortic root size;	chr7:66205775	chr7:66493706~66495474:+
LUAD	cis	rs6921919	0.583	rs740621	ENSG00000204709.4	LINC01556	6.02	3.49e-09	1.46e-06	0.34	0.26	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs740622	ENSG00000204709.4	LINC01556	6.02	3.49e-09	1.46e-06	0.34	0.26	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28943877~28944537:+
LUAD	cis	rs7615952	0.932	rs3811679	ENSG00000171084.14	FAM86JP	6.02	3.49e-09	1.46e-06	0.38	0.26	Blood pressure (smoking interaction);	chr3:125929440	chr3:125916620~125930024:+
LUAD	cis	rs2439831	0.681	rs28578454	ENSG00000205771.5	CATSPER2P1	-6.02	3.49e-09	1.46e-06	-0.5	-0.26	Lung cancer in ever smokers;	chr15:43310834	chr15:43726918~43747094:-
LUAD	cis	rs7849270	1	rs7849160	ENSG00000268707.1	RP11-247A12.7	-6.02	3.5e-09	1.46e-06	-0.3	-0.26	Blood metabolite ratios;	chr9:129112273	chr9:129170434~129170940:+
LUAD	cis	rs7727544	0.735	rs274557	ENSG00000233006.5	AC034220.3	-6.02	3.5e-09	1.47e-06	-0.24	-0.26	Blood metabolite levels;	chr5:132385512	chr5:132311285~132369916:-
LUAD	cis	rs6504950	0.566	rs7226272	ENSG00000275710.1	RP11-257O5.4	6.02	3.51e-09	1.47e-06	0.31	0.26	Breast cancer;	chr17:54969086	chr17:54964474~54964679:+
LUAD	cis	rs1061377	1	rs1036037	ENSG00000249685.1	RP11-360F5.3	6.02	3.51e-09	1.47e-06	0.32	0.26	Uric acid levels;	chr4:39111272	chr4:39133913~39135608:+
LUAD	cis	rs11603023	0.967	rs4245184	ENSG00000255422.1	AP002954.4	6.02	3.51e-09	1.47e-06	0.32	0.26	Cholesterol, total;	chr11:118639844	chr11:118704607~118750263:+
LUAD	cis	rs7849270	1	rs4713	ENSG00000268707.1	RP11-247A12.7	6.02	3.51e-09	1.47e-06	0.3	0.26	Blood metabolite ratios;	chr9:129148526	chr9:129170434~129170940:+
LUAD	cis	rs950169	0.519	rs7237	ENSG00000225151.9	GOLGA2P7	-6.02	3.51e-09	1.47e-06	-0.37	-0.26	Schizophrenia;	chr15:84643346	chr15:84199311~84230136:-
LUAD	cis	rs17301013	0.62	rs1793310	ENSG00000227373.4	RP11-160H22.5	-6.02	3.52e-09	1.47e-06	-0.36	-0.26	Systemic lupus erythematosus;	chr1:174770786	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.581	rs10912799	ENSG00000227373.4	RP11-160H22.5	6.02	3.52e-09	1.47e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174511422	chr1:174115300~174160004:-
LUAD	cis	rs2115630	0.691	rs61322921	ENSG00000229212.6	RP11-561C5.4	6.02	3.53e-09	1.47e-06	0.32	0.26	P wave terminal force;	chr15:84620407	chr15:85205440~85234795:-
LUAD	cis	rs853679	0.55	rs6901017	ENSG00000204709.4	LINC01556	6.02	3.53e-09	1.47e-06	0.36	0.26	Depression;	chr6:28184805	chr6:28943877~28944537:+
LUAD	cis	rs172166	0.611	rs203883	ENSG00000204709.4	LINC01556	6.02	3.53e-09	1.47e-06	0.34	0.26	Cardiac Troponin-T levels;	chr6:28110578	chr6:28943877~28944537:+
LUAD	cis	rs7246657	0.507	rs8107654	ENSG00000276846.1	CTD-3220F14.3	6.02	3.53e-09	1.47e-06	0.41	0.26	Coronary artery calcification;	chr19:36962632	chr19:37314868~37315620:-
LUAD	cis	rs2739330	0.734	rs2000467	ENSG00000228039.3	KB-1125A3.10	-6.02	3.53e-09	1.48e-06	-0.33	-0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23963780~23964374:+
LUAD	cis	rs62432291	0.681	rs378547	ENSG00000235086.1	FNDC1-IT1	6.02	3.53e-09	1.48e-06	0.44	0.26	Joint mobility (Beighton score);	chr6:159241493	chr6:159240786~159243329:+
LUAD	cis	rs12699921	0.632	rs10249221	ENSG00000279048.1	RP11-511H23.2	6.02	3.53e-09	1.48e-06	0.21	0.26	Fibrinogen levels;	chr7:17782436	chr7:17940503~17942922:+
LUAD	cis	rs801193	0.569	rs6978178	ENSG00000237310.1	GS1-124K5.4	-6.02	3.54e-09	1.48e-06	-0.29	-0.26	Aortic root size;	chr7:66658097	chr7:66493706~66495474:+
LUAD	cis	rs6142102	0.625	rs1883706	ENSG00000275784.1	RP5-1125A11.6	-6.02	3.54e-09	1.48e-06	-0.29	-0.26	Skin pigmentation;	chr20:33965071	chr20:33989480~33991818:-
LUAD	cis	rs6142102	0.625	rs1883705	ENSG00000275784.1	RP5-1125A11.6	-6.02	3.54e-09	1.48e-06	-0.29	-0.26	Skin pigmentation;	chr20:33965072	chr20:33989480~33991818:-
LUAD	cis	rs7727544	0.684	rs272893	ENSG00000233006.5	AC034220.3	6.02	3.54e-09	1.48e-06	0.24	0.26	Blood metabolite levels;	chr5:132327369	chr5:132311285~132369916:-
LUAD	cis	rs875971	0.964	rs160635	ENSG00000222364.1	RNU6-96P	-6.02	3.54e-09	1.48e-06	-0.3	-0.26	Aortic root size;	chr7:66063931	chr7:66395191~66395286:+
LUAD	cis	rs7923609	0.756	rs12768534	ENSG00000232075.1	MRPL35P2	-6.02	3.55e-09	1.48e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63581137	chr10:63634317~63634827:-
LUAD	cis	rs7945705	0.818	rs1988708	ENSG00000254860.4	TMEM9B-AS1	6.02	3.55e-09	1.48e-06	0.29	0.26	Hemoglobin concentration;	chr11:8861346	chr11:8964675~8977527:+
LUAD	cis	rs1823913	0.637	rs1947456	ENSG00000227542.1	AC092614.2	-6.02	3.55e-09	1.48e-06	-0.32	-0.26	Obesity-related traits;	chr2:191298759	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.614	rs11693878	ENSG00000227542.1	AC092614.2	-6.02	3.55e-09	1.48e-06	-0.32	-0.26	Obesity-related traits;	chr2:191299399	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.637	rs10931494	ENSG00000227542.1	AC092614.2	-6.02	3.55e-09	1.48e-06	-0.32	-0.26	Obesity-related traits;	chr2:191299442	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.637	rs10931495	ENSG00000227542.1	AC092614.2	-6.02	3.55e-09	1.48e-06	-0.32	-0.26	Obesity-related traits;	chr2:191299447	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.637	rs12623156	ENSG00000227542.1	AC092614.2	-6.02	3.55e-09	1.48e-06	-0.32	-0.26	Obesity-related traits;	chr2:191299661	chr2:191229165~191246172:-
LUAD	cis	rs7615952	0.673	rs3811677	ENSG00000171084.14	FAM86JP	6.02	3.56e-09	1.49e-06	0.38	0.26	Blood pressure (smoking interaction);	chr3:125929237	chr3:125916620~125930024:+
LUAD	cis	rs10050311	0.79	rs4693154	ENSG00000251411.1	RP11-397E7.4	-6.02	3.56e-09	1.49e-06	-0.37	-0.26	Insulin-related traits;	chr4:86922109	chr4:86913266~86914817:-
LUAD	cis	rs2283792	0.765	rs9610374	ENSG00000224086.5	LL22NC03-86G7.1	-6.02	3.56e-09	1.49e-06	-0.26	-0.26	Multiple sclerosis;	chr22:21832514	chr22:21938293~21977632:+
LUAD	cis	rs3096299	0.589	rs3114898	ENSG00000274627.1	RP11-104N10.2	6.01	3.57e-09	1.49e-06	0.25	0.26	Multiple myeloma (IgH translocation);	chr16:89325907	chr16:89516797~89522217:+
LUAD	cis	rs9309473	1	rs6715819	ENSG00000163016.8	ALMS1P	6.01	3.57e-09	1.49e-06	0.33	0.26	Metabolite levels;	chr2:73545182	chr2:73644919~73685576:+
LUAD	cis	rs9595908	0.869	rs9591185	ENSG00000212293.1	SNORA16	6.01	3.57e-09	1.49e-06	0.28	0.26	Body mass index;	chr13:32627829	chr13:32420390~32420516:-
LUAD	cis	rs1134634	0.52	rs4393989	ENSG00000273133.1	RP11-799M12.2	-6.01	3.57e-09	1.49e-06	-0.39	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15614276	chr4:15563698~15564253:-
LUAD	cis	rs66887589	0.616	rs10032299	ENSG00000245958.5	RP11-33B1.1	-6.01	3.57e-09	1.49e-06	-0.22	-0.26	Diastolic blood pressure;	chr4:119285264	chr4:119454791~119552025:+
LUAD	cis	rs17301013	0.507	rs333422	ENSG00000227373.4	RP11-160H22.5	-6.01	3.57e-09	1.49e-06	-0.38	-0.26	Systemic lupus erythematosus;	chr1:174664167	chr1:174115300~174160004:-
LUAD	cis	rs858239	0.6	rs7785842	ENSG00000230042.1	AK3P3	-6.01	3.57e-09	1.49e-06	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23129178~23129841:+
LUAD	cis	rs2946504	0.607	rs2977080	ENSG00000251468.2	RP11-369K16.1	-6.01	3.57e-09	1.49e-06	-0.33	-0.26	Type 2 diabetes;	chr8:12959492	chr8:12958387~12962200:+
LUAD	cis	rs2946504	0.553	rs2977079	ENSG00000251468.2	RP11-369K16.1	-6.01	3.57e-09	1.49e-06	-0.33	-0.26	Type 2 diabetes;	chr8:12959500	chr8:12958387~12962200:+
LUAD	cis	rs35160687	0.712	rs11691726	ENSG00000273080.1	RP11-301O19.1	-6.01	3.58e-09	1.49e-06	-0.3	-0.26	Night sleep phenotypes;	chr2:86267147	chr2:86195590~86196049:+
LUAD	cis	rs12701220	0.655	rs7778968	ENSG00000229043.2	AC091729.9	-6.01	3.58e-09	1.49e-06	-0.32	-0.26	Bronchopulmonary dysplasia;	chr7:1104986	chr7:1160374~1165267:+
LUAD	cis	rs858239	0.6	rs7456915	ENSG00000230042.1	AK3P3	-6.01	3.58e-09	1.5e-06	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23129178~23129841:+
LUAD	cis	rs875971	0.862	rs10274883	ENSG00000237310.1	GS1-124K5.4	-6.01	3.59e-09	1.5e-06	-0.29	-0.26	Aortic root size;	chr7:66651104	chr7:66493706~66495474:+
LUAD	cis	rs801193	0.569	rs881285	ENSG00000237310.1	GS1-124K5.4	-6.01	3.59e-09	1.5e-06	-0.29	-0.26	Aortic root size;	chr7:66654433	chr7:66493706~66495474:+
LUAD	cis	rs801193	0.569	rs3846973	ENSG00000237310.1	GS1-124K5.4	-6.01	3.59e-09	1.5e-06	-0.29	-0.26	Aortic root size;	chr7:66655048	chr7:66493706~66495474:+
LUAD	cis	rs801193	0.569	rs2013908	ENSG00000237310.1	GS1-124K5.4	-6.01	3.59e-09	1.5e-06	-0.29	-0.26	Aortic root size;	chr7:66656082	chr7:66493706~66495474:+
LUAD	cis	rs1823913	0.525	rs7424440	ENSG00000227542.1	AC092614.2	6.01	3.59e-09	1.5e-06	0.33	0.26	Obesity-related traits;	chr2:191337919	chr2:191229165~191246172:-
LUAD	cis	rs1707322	0.717	rs1135812	ENSG00000234329.1	RP11-767N6.2	6.01	3.59e-09	1.5e-06	0.28	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629600	chr1:45651039~45651826:-
LUAD	cis	rs7044106	0.762	rs13291660	ENSG00000238181.2	AHCYP2	-6.01	3.59e-09	1.5e-06	-0.34	-0.26	Hip circumference adjusted for BMI;	chr9:120630470	chr9:120720673~120721972:+
LUAD	cis	rs11096990	0.891	rs61691409	ENSG00000249207.1	RP11-360F5.1	6.01	3.59e-09	1.5e-06	0.3	0.26	Cognitive function;	chr4:39243801	chr4:39112677~39126818:-
LUAD	cis	rs9309711	0.813	rs11690865	ENSG00000225234.1	TRAPPC12-AS1	-6.01	3.59e-09	1.5e-06	-0.34	-0.26	Neurofibrillary tangles;	chr2:3468179	chr2:3481242~3482409:-
LUAD	cis	rs2404602	0.53	rs12915184	ENSG00000259422.1	RP11-593F23.1	-6.01	3.59e-09	1.5e-06	-0.38	-0.26	Blood metabolite levels;	chr15:76673581	chr15:76174891~76181486:-
LUAD	cis	rs11157436	1	rs2293731	ENSG00000211812.1	TRAV26-2	-6.01	3.59e-09	1.5e-06	-0.31	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22148880	chr14:22202583~22203368:+
LUAD	cis	rs8177376	0.727	rs240552	ENSG00000254905.1	RP11-712L6.7	6.01	3.6e-09	1.5e-06	0.36	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126333818	chr11:126292922~126294254:-
LUAD	cis	rs2439831	0.85	rs28564774	ENSG00000205771.5	CATSPER2P1	-6.01	3.6e-09	1.5e-06	-0.55	-0.26	Lung cancer in ever smokers;	chr15:43833277	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.85	rs12441984	ENSG00000205771.5	CATSPER2P1	-6.01	3.6e-09	1.5e-06	-0.55	-0.26	Lung cancer in ever smokers;	chr15:43834087	chr15:43726918~43747094:-
LUAD	cis	rs728616	0.614	rs3934643	ENSG00000225484.5	NUTM2B-AS1	-6.01	3.6e-09	1.5e-06	-0.48	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79977061	chr10:79663088~79826594:-
LUAD	cis	rs1707322	0.691	rs11211175	ENSG00000234329.1	RP11-767N6.2	6.01	3.61e-09	1.5e-06	0.28	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755212	chr1:45651039~45651826:-
LUAD	cis	rs6991838	0.778	rs13261559	ENSG00000272010.1	CTD-3025N20.3	6.01	3.61e-09	1.51e-06	0.27	0.26	Intelligence (multi-trait analysis);	chr8:65549808	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.778	rs7843697	ENSG00000272010.1	CTD-3025N20.3	6.01	3.61e-09	1.51e-06	0.27	0.26	Intelligence (multi-trait analysis);	chr8:65550533	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.778	rs7843724	ENSG00000272010.1	CTD-3025N20.3	6.01	3.61e-09	1.51e-06	0.27	0.26	Intelligence (multi-trait analysis);	chr8:65550581	chr8:65591850~65592472:-
LUAD	cis	rs2243480	1	rs160652	ENSG00000232546.1	RP11-458F8.1	-6.01	3.61e-09	1.51e-06	-0.35	-0.26	Diabetic kidney disease;	chr7:66073444	chr7:66848496~66858136:+
LUAD	cis	rs17301013	0.606	rs4650969	ENSG00000227373.4	RP11-160H22.5	6.01	3.61e-09	1.51e-06	0.38	0.26	Systemic lupus erythematosus;	chr1:174229622	chr1:174115300~174160004:-
LUAD	cis	rs9595908	0.709	rs4942897	ENSG00000212293.1	SNORA16	6.01	3.61e-09	1.51e-06	0.28	0.26	Body mass index;	chr13:32757615	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.694	rs3752474	ENSG00000212293.1	SNORA16	6.01	3.61e-09	1.51e-06	0.28	0.26	Body mass index;	chr13:32758510	chr13:32420390~32420516:-
LUAD	cis	rs801193	0.569	rs2659893	ENSG00000222364.1	RNU6-96P	-6.01	3.62e-09	1.51e-06	-0.3	-0.26	Aortic root size;	chr7:66735006	chr7:66395191~66395286:+
LUAD	cis	rs801193	0.569	rs2659892	ENSG00000222364.1	RNU6-96P	-6.01	3.62e-09	1.51e-06	-0.3	-0.26	Aortic root size;	chr7:66735318	chr7:66395191~66395286:+
LUAD	cis	rs801193	0.548	rs2659891	ENSG00000222364.1	RNU6-96P	-6.01	3.62e-09	1.51e-06	-0.3	-0.26	Aortic root size;	chr7:66736127	chr7:66395191~66395286:+
LUAD	cis	rs801193	0.569	rs2707847	ENSG00000222364.1	RNU6-96P	-6.01	3.62e-09	1.51e-06	-0.3	-0.26	Aortic root size;	chr7:66737884	chr7:66395191~66395286:+
LUAD	cis	rs801193	0.548	rs7805152	ENSG00000222364.1	RNU6-96P	-6.01	3.62e-09	1.51e-06	-0.3	-0.26	Aortic root size;	chr7:66744266	chr7:66395191~66395286:+
LUAD	cis	rs293748	0.571	rs13171414	ENSG00000250155.1	CTD-2353F22.1	-6.01	3.62e-09	1.51e-06	-0.33	-0.26	Obesity-related traits;	chr5:37231977	chr5:36666214~36725195:-
LUAD	cis	rs11096990	0.964	rs35494908	ENSG00000249207.1	RP11-360F5.1	6.01	3.62e-09	1.51e-06	0.3	0.26	Cognitive function;	chr4:39252574	chr4:39112677~39126818:-
LUAD	cis	rs2243480	0.831	rs57294491	ENSG00000230295.1	RP11-458F8.2	6.01	3.62e-09	1.51e-06	0.33	0.26	Diabetic kidney disease;	chr7:66219914	chr7:66880708~66882981:+
LUAD	cis	rs8072100	1	rs8072100	ENSG00000228782.6	CTD-2026D20.3	-6.01	3.62e-09	1.51e-06	-0.28	-0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47597321	chr17:47450568~47492492:-
LUAD	cis	rs7615952	0.641	rs12488180	ENSG00000171084.14	FAM86JP	6.01	3.62e-09	1.51e-06	0.38	0.26	Blood pressure (smoking interaction);	chr3:126063393	chr3:125916620~125930024:+
LUAD	cis	rs11096990	0.964	rs9998591	ENSG00000249207.1	RP11-360F5.1	-6.01	3.62e-09	1.51e-06	-0.3	-0.26	Cognitive function;	chr4:39240491	chr4:39112677~39126818:-
LUAD	cis	rs755249	0.567	rs4660603	ENSG00000228060.1	RP11-69E11.8	6.01	3.62e-09	1.51e-06	0.27	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39270662	chr1:39565160~39573203:+
LUAD	cis	rs1729407	0.647	rs2727791	ENSG00000280143.1	AP000892.6	6.01	3.62e-09	1.51e-06	0.3	0.26	Apolipoprotein A-IV levels;	chr11:116813846	chr11:117204967~117210292:+
LUAD	cis	rs56145559	1	rs56145559	ENSG00000163016.8	ALMS1P	6.01	3.63e-09	1.51e-06	0.33	0.26	Schizophrenia;	chr2:73396311	chr2:73644919~73685576:+
LUAD	cis	rs875971	0.862	rs2024192	ENSG00000222364.1	RNU6-96P	6.01	3.63e-09	1.52e-06	0.3	0.26	Aortic root size;	chr7:66576460	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs4718377	ENSG00000222364.1	RNU6-96P	6.01	3.63e-09	1.52e-06	0.3	0.26	Aortic root size;	chr7:66584691	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs10278014	ENSG00000222364.1	RNU6-96P	6.01	3.63e-09	1.52e-06	0.3	0.26	Aortic root size;	chr7:66586277	chr7:66395191~66395286:+
LUAD	cis	rs8062405	1	rs8062405	ENSG00000251417.2	RP11-1348G14.4	6.01	3.64e-09	1.52e-06	0.27	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28802743~28817828:+
LUAD	cis	rs11157436	1	rs75648426	ENSG00000211812.1	TRAV26-2	-6.01	3.64e-09	1.52e-06	-0.3	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22184044	chr14:22202583~22203368:+
LUAD	cis	rs8177876	0.822	rs16954582	ENSG00000261838.4	RP11-303E16.6	6.01	3.64e-09	1.52e-06	0.58	0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080552	chr16:81069854~81076598:+
LUAD	cis	rs6142102	0.527	rs1015362	ENSG00000276073.1	RP5-1125A11.7	6.01	3.64e-09	1.52e-06	0.29	0.26	Skin pigmentation;	chr20:34150806	chr20:33985617~33988989:-
LUAD	cis	rs12699921	0.589	rs2723556	ENSG00000279048.1	RP11-511H23.2	-6.01	3.64e-09	1.52e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17827972	chr7:17940503~17942922:+
LUAD	cis	rs4591358	0.689	rs1913894	ENSG00000223466.1	AC064834.2	-6.01	3.64e-09	1.52e-06	-0.41	-0.26	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195534032	chr2:195533035~195538681:+
LUAD	cis	rs17684571	0.751	rs13207768	ENSG00000231441.1	RP11-472M19.2	6.01	3.64e-09	1.52e-06	0.4	0.26	Schizophrenia;	chr6:56851277	chr6:56844002~56864078:+
LUAD	cis	rs35160687	0.712	rs6738585	ENSG00000273080.1	RP11-301O19.1	-6.01	3.65e-09	1.52e-06	-0.3	-0.26	Night sleep phenotypes;	chr2:86283161	chr2:86195590~86196049:+
LUAD	cis	rs35160687	0.712	rs6725234	ENSG00000273080.1	RP11-301O19.1	-6.01	3.65e-09	1.52e-06	-0.3	-0.26	Night sleep phenotypes;	chr2:86283165	chr2:86195590~86196049:+
LUAD	cis	rs1113500	0.933	rs1414674	ENSG00000226822.1	RP11-356N1.2	6.01	3.65e-09	1.52e-06	0.31	0.26	Growth-regulated protein alpha levels;	chr1:108083325	chr1:108071482~108074519:+
LUAD	cis	rs1823913	0.513	rs4334520	ENSG00000280083.1	RP11-317J9.1	-6.01	3.65e-09	1.52e-06	-0.33	-0.26	Obesity-related traits;	chr2:191329200	chr2:191154118~191156070:-
LUAD	cis	rs7246657	0.722	rs2972438	ENSG00000276846.1	CTD-3220F14.3	6.01	3.65e-09	1.52e-06	0.35	0.26	Coronary artery calcification;	chr19:37719946	chr19:37314868~37315620:-
LUAD	cis	rs2599510	0.783	rs2568464	ENSG00000276334.1	AL133243.1	-6.01	3.65e-09	1.52e-06	-0.3	-0.26	Interleukin-18 levels;	chr2:32623591	chr2:32521927~32523547:+
LUAD	cis	rs9828933	0.882	rs3733127	ENSG00000280620.1	SCAANT1	6.01	3.65e-09	1.52e-06	0.38	0.26	Type 2 diabetes;	chr3:64002498	chr3:63911518~63911772:-
LUAD	cis	rs72634501	0.54	rs16826036	ENSG00000228060.1	RP11-69E11.8	-6.01	3.65e-09	1.52e-06	-0.27	-0.26	HDL cholesterol;	chr1:39292127	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs16826038	ENSG00000228060.1	RP11-69E11.8	-6.01	3.65e-09	1.52e-06	-0.27	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39292962	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs61782157	ENSG00000228060.1	RP11-69E11.8	-6.01	3.65e-09	1.52e-06	-0.27	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39297217	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs41270803	ENSG00000228060.1	RP11-69E11.8	-6.01	3.65e-09	1.52e-06	-0.27	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39300369	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs61783376	ENSG00000228060.1	RP11-69E11.8	-6.01	3.65e-09	1.52e-06	-0.27	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39303328	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs4660636	ENSG00000228060.1	RP11-69E11.8	-6.01	3.65e-09	1.52e-06	-0.27	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39304555	chr1:39565160~39573203:+
LUAD	cis	rs7945705	0.934	rs1988709	ENSG00000254860.4	TMEM9B-AS1	-6.01	3.66e-09	1.52e-06	-0.3	-0.26	Hemoglobin concentration;	chr11:8861343	chr11:8964675~8977527:+
LUAD	cis	rs55665837	1	rs2305306	ENSG00000251991.1	RNU7-49P	6.01	3.66e-09	1.53e-06	0.3	0.26	Vitamin D levels;	chr11:14513453	chr11:14478892~14478953:+
LUAD	cis	rs875971	0.571	rs78668714	ENSG00000226824.5	RP4-756H11.3	-6.01	3.66e-09	1.53e-06	-0.39	-0.26	Aortic root size;	chr7:66474464	chr7:66654538~66669855:+
LUAD	cis	rs2286503	0.533	rs1880239	ENSG00000228649.7	AC005682.5	6.01	3.66e-09	1.53e-06	0.37	0.26	Fibrinogen;	chr7:22832065	chr7:22854178~22861579:+
LUAD	cis	rs11098499	0.722	rs28713555	ENSG00000248280.1	RP11-33B1.2	6.01	3.67e-09	1.53e-06	0.33	0.26	Corneal astigmatism;	chr4:119330840	chr4:119440561~119450157:-
LUAD	cis	rs3096299	0.748	rs3102339	ENSG00000274627.1	RP11-104N10.2	6.01	3.67e-09	1.53e-06	0.26	0.26	Multiple myeloma (IgH translocation);	chr16:89376303	chr16:89516797~89522217:+
LUAD	cis	rs2243480	0.706	rs34466769	ENSG00000230295.1	RP11-458F8.2	-6.01	3.67e-09	1.53e-06	-0.28	-0.26	Diabetic kidney disease;	chr7:65988305	chr7:66880708~66882981:+
LUAD	cis	rs30380	0.632	rs26496	ENSG00000272109.1	CTD-2260A17.3	-6.01	3.67e-09	1.53e-06	-0.32	-0.26	Cerebrospinal fluid biomarker levels;	chr5:96802179	chr5:96804353~96806105:+
LUAD	cis	rs172166	0.694	rs1770131	ENSG00000204709.4	LINC01556	6.01	3.68e-09	1.53e-06	0.34	0.26	Cardiac Troponin-T levels;	chr6:28118635	chr6:28943877~28944537:+
LUAD	cis	rs11690935	0.655	rs17614941	ENSG00000228389.1	AC068039.4	-6.01	3.68e-09	1.53e-06	-0.27	-0.26	Schizophrenia;	chr2:171684868	chr2:171773482~171775844:+
LUAD	cis	rs367615	0.879	rs2201015	ENSG00000249476.1	CTD-2587M2.1	6.01	3.68e-09	1.53e-06	0.32	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109611749	chr5:109237120~109326369:-
LUAD	cis	rs10129255	0.872	rs8015406	ENSG00000224373.3	IGHV4-59	6.01	3.69e-09	1.54e-06	0.17	0.26	Kawasaki disease;	chr14:106670611	chr14:106627249~106627825:-
LUAD	cis	rs17301013	0.606	rs12086693	ENSG00000227373.4	RP11-160H22.5	6.01	3.69e-09	1.54e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174527651	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs12062170	ENSG00000227373.4	RP11-160H22.5	6.01	3.69e-09	1.54e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174528420	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs12062483	ENSG00000227373.4	RP11-160H22.5	6.01	3.69e-09	1.54e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174529089	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs6681970	ENSG00000227373.4	RP11-160H22.5	6.01	3.69e-09	1.54e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174532698	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs6668096	ENSG00000227373.4	RP11-160H22.5	6.01	3.69e-09	1.54e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174537343	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs6692173	ENSG00000227373.4	RP11-160H22.5	6.01	3.69e-09	1.54e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174544474	chr1:174115300~174160004:-
LUAD	cis	rs9543976	0.623	rs7317250	ENSG00000261553.4	RP11-29G8.3	6.01	3.69e-09	1.54e-06	0.33	0.26	Diabetic retinopathy;	chr13:75593005	chr13:75549773~75807120:+
LUAD	cis	rs4713118	0.869	rs7773070	ENSG00000219392.1	RP1-265C24.5	-6.01	3.69e-09	1.54e-06	-0.36	-0.26	Parkinson's disease;	chr6:27761048	chr6:28115628~28116551:+
LUAD	cis	rs858239	0.6	rs28483572	ENSG00000230042.1	AK3P3	-6.01	3.7e-09	1.54e-06	-0.34	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23129178~23129841:+
LUAD	cis	rs9595908	0.669	rs17594908	ENSG00000212293.1	SNORA16	6.01	3.7e-09	1.54e-06	0.29	0.26	Body mass index;	chr13:32789427	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.669	rs2025474	ENSG00000212293.1	SNORA16	6.01	3.7e-09	1.54e-06	0.29	0.26	Body mass index;	chr13:32792319	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.669	rs4941669	ENSG00000212293.1	SNORA16	6.01	3.7e-09	1.54e-06	0.29	0.26	Body mass index;	chr13:32793045	chr13:32420390~32420516:-
LUAD	cis	rs875971	0.862	rs1860469	ENSG00000222364.1	RNU6-96P	6.01	3.7e-09	1.54e-06	0.31	0.26	Aortic root size;	chr7:66641888	chr7:66395191~66395286:+
LUAD	cis	rs9326248	0.59	rs2542063	ENSG00000280143.1	AP000892.6	6.01	3.7e-09	1.54e-06	0.3	0.26	Blood protein levels;	chr11:116814051	chr11:117204967~117210292:+
LUAD	cis	rs1061377	1	rs28607301	ENSG00000249685.1	RP11-360F5.3	6.01	3.71e-09	1.54e-06	0.32	0.26	Uric acid levels;	chr4:39136460	chr4:39133913~39135608:+
LUAD	cis	rs2255336	0.882	rs2733847	ENSG00000245648.1	RP11-277P12.20	6.01	3.71e-09	1.54e-06	0.39	0.26	Blood protein levels;	chr12:10380608	chr12:10363769~10398506:+
LUAD	cis	rs853679	0.513	rs13437444	ENSG00000204709.4	LINC01556	6.01	3.71e-09	1.54e-06	0.4	0.26	Depression;	chr6:28103220	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs34513104	ENSG00000204709.4	LINC01556	6.01	3.71e-09	1.54e-06	0.34	0.26	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs9461456	ENSG00000204709.4	LINC01556	6.01	3.71e-09	1.54e-06	0.34	0.26	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.525	rs9468360	ENSG00000204709.4	LINC01556	6.01	3.71e-09	1.54e-06	0.34	0.26	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs16894021	ENSG00000204709.4	LINC01556	6.01	3.71e-09	1.54e-06	0.34	0.26	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs11751693	ENSG00000204709.4	LINC01556	6.01	3.71e-09	1.54e-06	0.34	0.26	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs7749736	ENSG00000204709.4	LINC01556	6.01	3.71e-09	1.54e-06	0.34	0.26	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.525	rs9468361	ENSG00000204709.4	LINC01556	6.01	3.71e-09	1.54e-06	0.34	0.26	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs7775132	ENSG00000204709.4	LINC01556	6.01	3.71e-09	1.54e-06	0.34	0.26	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28943877~28944537:+
LUAD	cis	rs227932	0.571	rs3801898	ENSG00000234286.1	AC006026.13	-6.01	3.72e-09	1.55e-06	-0.46	-0.26	Schizophrenia;	chr7:23762526	chr7:23680195~23680786:-
LUAD	cis	rs7674212	0.507	rs10516495	ENSG00000251288.2	RP11-10L12.2	-6.01	3.72e-09	1.55e-06	-0.35	-0.26	Type 2 diabetes;	chr4:102978933	chr4:102751401~102752641:+
LUAD	cis	rs848490	0.651	rs7810273	ENSG00000214293.7	APTR	6.01	3.72e-09	1.55e-06	0.3	0.26	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77685327	chr7:77657660~77696265:-
LUAD	cis	rs36093844	1	rs36093844	ENSG00000279742.1	RP11-700A24.1	6.01	3.72e-09	1.55e-06	0.3	0.26	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85865084	chr11:85852557~85854943:-
LUAD	cis	rs875971	0.862	rs2901152	ENSG00000222364.1	RNU6-96P	6.01	3.72e-09	1.55e-06	0.3	0.26	Aortic root size;	chr7:66300017	chr7:66395191~66395286:+
LUAD	cis	rs10214930	0.697	rs12700822	ENSG00000235574.1	AC073150.6	-6.01	3.73e-09	1.55e-06	-0.33	-0.26	Hypospadias;	chr7:27605807	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs13308974	ENSG00000235574.1	AC073150.6	-6.01	3.73e-09	1.55e-06	-0.33	-0.26	Hypospadias;	chr7:27612719	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.671	rs12534603	ENSG00000235574.1	AC073150.6	-6.01	3.73e-09	1.55e-06	-0.33	-0.26	Hypospadias;	chr7:27613034	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.647	rs7790498	ENSG00000235574.1	AC073150.6	-6.01	3.73e-09	1.55e-06	-0.33	-0.26	Hypospadias;	chr7:27613588	chr7:27491682~27492765:-
LUAD	cis	rs875971	0.502	rs6460311	ENSG00000226824.5	RP4-756H11.3	6.01	3.73e-09	1.55e-06	0.39	0.26	Aortic root size;	chr7:66646886	chr7:66654538~66669855:+
LUAD	cis	rs2442825	0.693	rs2600194	ENSG00000206573.7	THUMPD3-AS1	6.01	3.74e-09	1.55e-06	0.19	0.26	Cerebrospinal fluid clusterin levels;	chr3:9382941	chr3:9349689~9398579:-
LUAD	cis	rs9595908	0.869	rs9595962	ENSG00000212293.1	SNORA16	6.01	3.74e-09	1.55e-06	0.28	0.26	Body mass index;	chr13:32634429	chr13:32420390~32420516:-
LUAD	cis	rs113835537	0.529	rs116867234	ENSG00000255517.5	CTD-3074O7.5	-6.01	3.74e-09	1.56e-06	-0.32	-0.26	Airway imaging phenotypes;	chr11:66441553	chr11:66473490~66480233:-
LUAD	cis	rs113835537	0.529	rs17580784	ENSG00000255517.5	CTD-3074O7.5	-6.01	3.74e-09	1.56e-06	-0.32	-0.26	Airway imaging phenotypes;	chr11:66447388	chr11:66473490~66480233:-
LUAD	cis	rs875971	0.502	rs11769702	ENSG00000226824.5	RP4-756H11.3	-6.01	3.75e-09	1.56e-06	-0.39	-0.26	Aortic root size;	chr7:66255529	chr7:66654538~66669855:+
LUAD	cis	rs7923609	0.812	rs10761753	ENSG00000232075.1	MRPL35P2	-6.01	3.75e-09	1.56e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63402143	chr10:63634317~63634827:-
LUAD	cis	rs7945705	0.935	rs1883098	ENSG00000254860.4	TMEM9B-AS1	6.01	3.75e-09	1.56e-06	0.29	0.26	Hemoglobin concentration;	chr11:8869047	chr11:8964675~8977527:+
LUAD	cis	rs875971	0.545	rs6970498	ENSG00000226824.5	RP4-756H11.3	-6.01	3.75e-09	1.56e-06	-0.39	-0.26	Aortic root size;	chr7:66275908	chr7:66654538~66669855:+
LUAD	cis	rs2734839	0.964	rs12800853	ENSG00000270179.1	RP11-159N11.4	-6.01	3.75e-09	1.56e-06	-0.27	-0.26	Information processing speed;	chr11:113431792	chr11:113368478~113369117:+
LUAD	cis	rs12699921	0.632	rs2691555	ENSG00000279048.1	RP11-511H23.2	-6.01	3.76e-09	1.56e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17898660	chr7:17940503~17942922:+
LUAD	cis	rs2276314	0.857	rs56230698	ENSG00000278986.1	RP11-723J4.3	-6.01	3.76e-09	1.56e-06	-0.32	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:36048922	chr18:35972151~35973916:+
LUAD	cis	rs10214930	0.671	rs10951172	ENSG00000235574.1	AC073150.6	-6.01	3.76e-09	1.56e-06	-0.33	-0.26	Hypospadias;	chr7:27574492	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs4719898	ENSG00000235574.1	AC073150.6	-6.01	3.77e-09	1.57e-06	-0.33	-0.26	Hypospadias;	chr7:27524042	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs6462029	ENSG00000235574.1	AC073150.6	-6.01	3.77e-09	1.57e-06	-0.33	-0.26	Hypospadias;	chr7:27541876	chr7:27491682~27492765:-
LUAD	cis	rs7945705	0.935	rs2653593	ENSG00000254860.4	TMEM9B-AS1	6	3.78e-09	1.57e-06	0.3	0.26	Hemoglobin concentration;	chr11:8855770	chr11:8964675~8977527:+
LUAD	cis	rs3762637	0.943	rs9822345	ENSG00000272758.4	RP11-299J3.8	-6	3.78e-09	1.57e-06	-0.4	-0.26	LDL cholesterol levels;	chr3:122526751	chr3:122416207~122443180:+
LUAD	cis	rs875971	1	rs6956179	ENSG00000237310.1	GS1-124K5.4	-6	3.78e-09	1.57e-06	-0.29	-0.26	Aortic root size;	chr7:66341672	chr7:66493706~66495474:+
LUAD	cis	rs2243480	0.803	rs36127118	ENSG00000232546.1	RP11-458F8.1	-6	3.78e-09	1.57e-06	-0.34	-0.26	Diabetic kidney disease;	chr7:66100518	chr7:66848496~66858136:+
LUAD	cis	rs7923609	0.934	rs10761771	ENSG00000232075.1	MRPL35P2	-6	3.78e-09	1.57e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63470404	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.869	rs10733792	ENSG00000232075.1	MRPL35P2	-6	3.78e-09	1.57e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63472779	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.838	rs7909960	ENSG00000232075.1	MRPL35P2	-6	3.78e-09	1.57e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63479417	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.967	rs7915779	ENSG00000232075.1	MRPL35P2	-6	3.78e-09	1.57e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63484484	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.967	rs2393977	ENSG00000232075.1	MRPL35P2	-6	3.78e-09	1.57e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63487849	chr10:63634317~63634827:-
LUAD	cis	rs1707322	0.686	rs1547924	ENSG00000234329.1	RP11-767N6.2	6	3.79e-09	1.57e-06	0.28	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619440	chr1:45651039~45651826:-
LUAD	cis	rs172166	0.543	rs1150691	ENSG00000216901.1	AL022393.7	6	3.79e-09	1.58e-06	0.31	0.26	Cardiac Troponin-T levels;	chr6:28200255	chr6:28176188~28176674:+
LUAD	cis	rs2276314	0.512	rs4393644	ENSG00000278986.1	RP11-723J4.3	-6	3.79e-09	1.58e-06	-0.29	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:35878684	chr18:35972151~35973916:+
LUAD	cis	rs875971	0.755	rs76288834	ENSG00000237310.1	GS1-124K5.4	-6	3.79e-09	1.58e-06	-0.29	-0.26	Aortic root size;	chr7:66604815	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs73136346	ENSG00000237310.1	GS1-124K5.4	-6	3.79e-09	1.58e-06	-0.34	-0.26	Aortic root size;	chr7:66101095	chr7:66493706~66495474:+
LUAD	cis	rs72615157	0.664	rs6953580	ENSG00000242294.5	STAG3L5P	6	3.8e-09	1.58e-06	0.22	0.26	Lung function (FEV1/FVC);	chr7:100227652	chr7:100336079~100351900:+
LUAD	cis	rs1113500	0.524	rs11185270	ENSG00000226822.1	RP11-356N1.2	6	3.8e-09	1.58e-06	0.35	0.26	Growth-regulated protein alpha levels;	chr1:108111740	chr1:108071482~108074519:+
LUAD	cis	rs1113500	0.548	rs17020971	ENSG00000226822.1	RP11-356N1.2	6	3.8e-09	1.58e-06	0.35	0.26	Growth-regulated protein alpha levels;	chr1:108112666	chr1:108071482~108074519:+
LUAD	cis	rs11096990	0.855	rs2711989	ENSG00000249207.1	RP11-360F5.1	6	3.8e-09	1.58e-06	0.31	0.26	Cognitive function;	chr4:39150416	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.855	rs2566169	ENSG00000249207.1	RP11-360F5.1	6	3.8e-09	1.58e-06	0.31	0.26	Cognitive function;	chr4:39150420	chr4:39112677~39126818:-
LUAD	cis	rs875971	0.798	rs57739047	ENSG00000222364.1	RNU6-96P	-6	3.81e-09	1.58e-06	-0.3	-0.26	Aortic root size;	chr7:66507579	chr7:66395191~66395286:+
LUAD	cis	rs1823874	0.962	rs12906206	ENSG00000182397.13	DNM1P46	-6	3.81e-09	1.58e-06	-0.29	-0.26	IgG glycosylation;	chr15:99818921	chr15:99790156~99806927:-
LUAD	cis	rs11096990	0.855	rs2566177	ENSG00000249207.1	RP11-360F5.1	6	3.81e-09	1.58e-06	0.31	0.26	Cognitive function;	chr4:39154558	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.855	rs2711934	ENSG00000249207.1	RP11-360F5.1	6	3.81e-09	1.58e-06	0.31	0.26	Cognitive function;	chr4:39156254	chr4:39112677~39126818:-
LUAD	cis	rs916888	0.773	rs199447	ENSG00000261575.2	RP11-259G18.1	6	3.82e-09	1.59e-06	0.43	0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46267037~46268694:+
LUAD	cis	rs6142102	0.625	rs4012234	ENSG00000275784.1	RP5-1125A11.6	-6	3.82e-09	1.59e-06	-0.29	-0.26	Skin pigmentation;	chr20:33965241	chr20:33989480~33991818:-
LUAD	cis	rs6142102	0.649	rs4911382	ENSG00000275784.1	RP5-1125A11.6	-6	3.82e-09	1.59e-06	-0.29	-0.26	Skin pigmentation;	chr20:33965289	chr20:33989480~33991818:-
LUAD	cis	rs67311347	1	rs9835219	ENSG00000223797.4	ENTPD3-AS1	6	3.82e-09	1.59e-06	0.28	0.26	Renal cell carcinoma;	chr3:40382602	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs7642552	ENSG00000223797.4	ENTPD3-AS1	6	3.82e-09	1.59e-06	0.28	0.26	Renal cell carcinoma;	chr3:40383325	chr3:40313802~40453329:-
LUAD	cis	rs7727544	0.735	rs2569266	ENSG00000233006.5	AC034220.3	-6	3.82e-09	1.59e-06	-0.24	-0.26	Blood metabolite levels;	chr5:132371099	chr5:132311285~132369916:-
LUAD	cis	rs10129255	0.536	rs3944157	ENSG00000211970.3	IGHV4-61	-6	3.82e-09	1.59e-06	-0.19	-0.26	Kawasaki disease;	chr14:106682286	chr14:106639119~106639657:-
LUAD	cis	rs12699921	0.632	rs2691615	ENSG00000279048.1	RP11-511H23.2	-6	3.83e-09	1.59e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17847557	chr7:17940503~17942922:+
LUAD	cis	rs875971	0.545	rs35459055	ENSG00000226824.5	RP4-756H11.3	-6	3.83e-09	1.59e-06	-0.38	-0.26	Aortic root size;	chr7:66479399	chr7:66654538~66669855:+
LUAD	cis	rs4713118	0.869	rs2056925	ENSG00000219392.1	RP1-265C24.5	-6	3.84e-09	1.59e-06	-0.36	-0.26	Parkinson's disease;	chr6:27723126	chr6:28115628~28116551:+
LUAD	cis	rs2243480	0.711	rs1626926	ENSG00000230295.1	RP11-458F8.2	-6	3.84e-09	1.59e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:65970805	chr7:66880708~66882981:+
LUAD	cis	rs2034650	0.544	rs8034416	ENSG00000223313.1	RNU6-516P	6	3.84e-09	1.59e-06	0.35	0.26	Interstitial lung disease;	chr15:40411140	chr15:40529570~40529673:+
LUAD	cis	rs875971	0.767	rs12668005	ENSG00000237310.1	GS1-124K5.4	6	3.84e-09	1.59e-06	0.29	0.26	Aortic root size;	chr7:66444034	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs11765791	ENSG00000237310.1	GS1-124K5.4	6	3.84e-09	1.59e-06	0.29	0.26	Aortic root size;	chr7:66471587	chr7:66493706~66495474:+
LUAD	cis	rs858239	0.6	rs10256524	ENSG00000230042.1	AK3P3	-6	3.84e-09	1.6e-06	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23129178~23129841:+
LUAD	cis	rs875971	0.862	rs2909688	ENSG00000237310.1	GS1-124K5.4	6	3.84e-09	1.6e-06	0.29	0.26	Aortic root size;	chr7:66376625	chr7:66493706~66495474:+
LUAD	cis	rs66887589	0.967	rs1480933	ENSG00000245958.5	RP11-33B1.1	-6	3.85e-09	1.6e-06	-0.21	-0.26	Diastolic blood pressure;	chr4:119512093	chr4:119454791~119552025:+
LUAD	cis	rs1816752	1	rs7999554	ENSG00000273628.1	RP11-756A22.7	6	3.85e-09	1.6e-06	0.31	0.26	Obesity-related traits;	chr13:24435631	chr13:24933006~24936796:+
LUAD	cis	rs3762637	1	rs7645862	ENSG00000272758.4	RP11-299J3.8	-6	3.85e-09	1.6e-06	-0.4	-0.26	LDL cholesterol levels;	chr3:122502292	chr3:122416207~122443180:+
LUAD	cis	rs7044106	0.762	rs10760107	ENSG00000238181.2	AHCYP2	-6	3.85e-09	1.6e-06	-0.34	-0.26	Hip circumference adjusted for BMI;	chr9:120621352	chr9:120720673~120721972:+
LUAD	cis	rs62158211	0.955	rs7556815	ENSG00000234997.1	AC016745.3	-6	3.85e-09	1.6e-06	-0.33	-0.26	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113328208	chr2:113424495~113425324:+
LUAD	cis	rs875971	0.825	rs801202	ENSG00000237310.1	GS1-124K5.4	-6	3.85e-09	1.6e-06	-0.29	-0.26	Aortic root size;	chr7:66558942	chr7:66493706~66495474:+
LUAD	cis	rs8031584	0.541	rs1983459	ENSG00000270015.1	RP11-540B6.6	-6	3.86e-09	1.6e-06	-0.18	-0.26	Huntington's disease progression;	chr15:30916546	chr15:30926514~30928407:+
LUAD	cis	rs875971	0.545	rs73148639	ENSG00000226824.5	RP4-756H11.3	-6	3.86e-09	1.6e-06	-0.38	-0.26	Aortic root size;	chr7:66390342	chr7:66654538~66669855:+
LUAD	cis	rs7727544	0.735	rs2631370	ENSG00000233006.5	AC034220.3	-6	3.86e-09	1.6e-06	-0.24	-0.26	Blood metabolite levels;	chr5:132368084	chr5:132311285~132369916:-
LUAD	cis	rs12699921	0.537	rs2691582	ENSG00000279048.1	RP11-511H23.2	-6	3.86e-09	1.6e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17789623	chr7:17940503~17942922:+
LUAD	cis	rs11971779	0.68	rs12154842	ENSG00000273391.1	RP11-634H22.1	6	3.86e-09	1.6e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139393738	chr7:139359032~139359566:-
LUAD	cis	rs875971	0.862	rs778736	ENSG00000237310.1	GS1-124K5.4	6	3.86e-09	1.6e-06	0.29	0.26	Aortic root size;	chr7:66348861	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs6958294	ENSG00000237310.1	GS1-124K5.4	-6	3.86e-09	1.6e-06	-0.29	-0.26	Aortic root size;	chr7:66329809	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs2088655	ENSG00000237310.1	GS1-124K5.4	-6	3.86e-09	1.6e-06	-0.29	-0.26	Aortic root size;	chr7:66330724	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.895	rs10447522	ENSG00000237310.1	GS1-124K5.4	-6	3.86e-09	1.6e-06	-0.29	-0.26	Aortic root size;	chr7:66331087	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs2088653	ENSG00000237310.1	GS1-124K5.4	-6	3.86e-09	1.6e-06	-0.29	-0.26	Aortic root size;	chr7:66343621	chr7:66493706~66495474:+
LUAD	cis	rs4713118	0.824	rs9468223	ENSG00000219392.1	RP1-265C24.5	-6	3.86e-09	1.6e-06	-0.36	-0.26	Parkinson's disease;	chr6:27772887	chr6:28115628~28116551:+
LUAD	cis	rs875971	0.545	rs75577046	ENSG00000226824.5	RP4-756H11.3	-6	3.86e-09	1.6e-06	-0.38	-0.26	Aortic root size;	chr7:66493729	chr7:66654538~66669855:+
LUAD	cis	rs17684571	0.751	rs35080938	ENSG00000231441.1	RP11-472M19.2	6	3.86e-09	1.6e-06	0.4	0.26	Schizophrenia;	chr6:56847992	chr6:56844002~56864078:+
LUAD	cis	rs7772486	0.558	rs62435775	ENSG00000235652.6	RP11-545I5.3	6	3.87e-09	1.6e-06	0.28	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145815279	chr6:145799409~145886585:+
LUAD	cis	rs6840258	0.547	rs72667721	ENSG00000251411.1	RP11-397E7.4	-6	3.87e-09	1.6e-06	-0.37	-0.26	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86919644	chr4:86913266~86914817:-
LUAD	cis	rs6921919	0.583	rs9468367	ENSG00000216901.1	AL022393.7	6	3.87e-09	1.61e-06	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28176188~28176674:+
LUAD	cis	rs6840258	0.66	rs72667741	ENSG00000251411.1	RP11-397E7.4	-6	3.88e-09	1.61e-06	-0.36	-0.26	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86970923	chr4:86913266~86914817:-
LUAD	cis	rs17301013	0.606	rs10798307	ENSG00000227373.4	RP11-160H22.5	6	3.88e-09	1.61e-06	0.37	0.26	Systemic lupus erythematosus;	chr1:174264172	chr1:174115300~174160004:-
LUAD	cis	rs67311347	1	rs28434528	ENSG00000223797.4	ENTPD3-AS1	6	3.89e-09	1.61e-06	0.27	0.26	Renal cell carcinoma;	chr3:40443402	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs11716675	ENSG00000223797.4	ENTPD3-AS1	6	3.89e-09	1.61e-06	0.27	0.26	Renal cell carcinoma;	chr3:40443789	chr3:40313802~40453329:-
LUAD	cis	rs9438901	0.592	rs1293259	ENSG00000261349.1	RP3-465N24.5	6	3.89e-09	1.61e-06	0.47	0.26	Red cell distribution width;	chr1:25369344	chr1:25266102~25267136:-
LUAD	cis	rs36093844	0.948	rs11234451	ENSG00000279742.1	RP11-700A24.1	-6	3.9e-09	1.62e-06	-0.3	-0.26	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85862659	chr11:85852557~85854943:-
LUAD	cis	rs9487094	0.621	rs9398202	ENSG00000260273.1	RP11-425D10.10	6	3.9e-09	1.62e-06	0.33	0.26	Height;	chr6:109458989	chr6:109382795~109383666:+
LUAD	cis	rs7017914	0.905	rs2732115	ENSG00000223220.1	Y_RNA	6	3.9e-09	1.62e-06	0.3	0.26	Bone mineral density;	chr8:71016619	chr8:70780914~70781008:-
LUAD	cis	rs5753618	0.583	rs738657	ENSG00000236132.1	CTA-440B3.1	-6	3.9e-09	1.62e-06	-0.31	-0.26	Colorectal cancer;	chr22:31445763	chr22:31816379~31817491:-
LUAD	cis	rs35740288	0.77	rs11631660	ENSG00000202081.1	RNU6-1280P	-6	3.9e-09	1.62e-06	-0.32	-0.26	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85672181	chr15:85651522~85651628:-
LUAD	cis	rs875971	0.862	rs6460302	ENSG00000237310.1	GS1-124K5.4	6	3.9e-09	1.62e-06	0.29	0.26	Aortic root size;	chr7:66495270	chr7:66493706~66495474:+
LUAD	cis	rs897200	1	rs7561569	ENSG00000280083.1	RP11-317J9.1	6	3.91e-09	1.62e-06	0.33	0.26	Behcet's disease;	chr2:191154820	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.637	rs10931497	ENSG00000280083.1	RP11-317J9.1	6	3.92e-09	1.62e-06	0.31	0.26	Obesity-related traits;	chr2:191306254	chr2:191154118~191156070:-
LUAD	cis	rs4908768	0.501	rs910581	ENSG00000232912.4	RP5-1115A15.1	6	3.92e-09	1.62e-06	0.25	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8469464	chr1:8424645~8434838:+
LUAD	cis	rs77204473	1	rs77349713	ENSG00000254851.1	RP11-109L13.1	6	3.92e-09	1.63e-06	0.64	0.26	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116894760	chr11:117135528~117138582:+
LUAD	cis	rs2439831	0.85	rs28513374	ENSG00000205771.5	CATSPER2P1	-6	3.92e-09	1.63e-06	-0.55	-0.26	Lung cancer in ever smokers;	chr15:43833297	chr15:43726918~43747094:-
LUAD	cis	rs2243480	1	rs35396113	ENSG00000230295.1	RP11-458F8.2	-6	3.93e-09	1.63e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66030474	chr7:66880708~66882981:+
LUAD	cis	rs2404602	0.647	rs12904417	ENSG00000259422.1	RP11-593F23.1	6	3.93e-09	1.63e-06	0.34	0.26	Blood metabolite levels;	chr15:76671811	chr15:76174891~76181486:-
LUAD	cis	rs4835473	0.932	rs7356305	ENSG00000251600.4	RP11-673E1.1	6	3.94e-09	1.63e-06	0.32	0.26	Immature fraction of reticulocytes;	chr4:143737850	chr4:143912331~143982454:+
LUAD	cis	rs11690935	0.632	rs1607254	ENSG00000228389.1	AC068039.4	-6	3.94e-09	1.63e-06	-0.28	-0.26	Schizophrenia;	chr2:171770042	chr2:171773482~171775844:+
LUAD	cis	rs12468226	0.873	rs76552560	ENSG00000226261.1	AC064836.3	6	3.94e-09	1.63e-06	0.44	0.26	Urate levels;	chr2:202173123	chr2:202336024~202336727:-
LUAD	cis	rs7923609	0.967	rs7085621	ENSG00000232075.1	MRPL35P2	-6	3.94e-09	1.63e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63449166	chr10:63634317~63634827:-
LUAD	cis	rs1707322	0.821	rs11211182	ENSG00000234329.1	RP11-767N6.2	6	3.94e-09	1.63e-06	0.28	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45774498	chr1:45651039~45651826:-
LUAD	cis	rs17666538	0.539	rs1703925	ENSG00000254207.1	RP11-43A14.1	6	3.95e-09	1.64e-06	0.53	0.26	IgG glycosylation;	chr8:658279	chr8:725188~725877:-
LUAD	cis	rs77204473	0.744	rs10892068	ENSG00000254851.1	RP11-109L13.1	-6	3.95e-09	1.64e-06	-0.63	-0.26	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117057830	chr11:117135528~117138582:+
LUAD	cis	rs10214930	0.957	rs2057998	ENSG00000235574.1	AC073150.6	6	3.95e-09	1.64e-06	0.37	0.26	Hypospadias;	chr7:27756902	chr7:27491682~27492765:-
LUAD	cis	rs2404602	0.583	rs3759853	ENSG00000259422.1	RP11-593F23.1	6	3.95e-09	1.64e-06	0.3	0.26	Blood metabolite levels;	chr15:76295436	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.583	rs4381566	ENSG00000259422.1	RP11-593F23.1	6	3.95e-09	1.64e-06	0.3	0.26	Blood metabolite levels;	chr15:76296921	chr15:76174891~76181486:-
LUAD	cis	rs11690935	0.61	rs3770458	ENSG00000228389.1	AC068039.4	-6	3.95e-09	1.64e-06	-0.28	-0.26	Schizophrenia;	chr2:171794777	chr2:171773482~171775844:+
LUAD	cis	rs1816752	1	rs7326932	ENSG00000273628.1	RP11-756A22.7	6	3.95e-09	1.64e-06	0.31	0.26	Obesity-related traits;	chr13:24430355	chr13:24933006~24936796:+
LUAD	cis	rs113835537	0.529	rs75685325	ENSG00000255517.5	CTD-3074O7.5	-6	3.95e-09	1.64e-06	-0.32	-0.26	Airway imaging phenotypes;	chr11:66467771	chr11:66473490~66480233:-
LUAD	cis	rs113835537	0.529	rs57724777	ENSG00000255517.5	CTD-3074O7.5	-6	3.95e-09	1.64e-06	-0.32	-0.26	Airway imaging phenotypes;	chr11:66468960	chr11:66473490~66480233:-
LUAD	cis	rs12699921	0.632	rs2691628	ENSG00000279048.1	RP11-511H23.2	-6	3.95e-09	1.64e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17784732	chr7:17940503~17942922:+
LUAD	cis	rs7927592	0.956	rs7944870	ENSG00000212093.1	AP000807.1	6	3.96e-09	1.64e-06	0.29	0.26	Total body bone mineral density;	chr11:68541640	chr11:68506083~68506166:-
LUAD	cis	rs453301	0.653	rs7016139	ENSG00000173295.6	FAM86B3P	-6	3.96e-09	1.64e-06	-0.29	-0.26	Joint mobility (Beighton score);	chr8:9037960	chr8:8228595~8244865:+
LUAD	cis	rs765787	0.53	rs12323957	ENSG00000259520.4	CTD-2651B20.3	-6	3.96e-09	1.64e-06	-0.35	-0.26	Uric acid levels;	chr15:45198575	chr15:45251580~45279251:-
LUAD	cis	rs6142102	0.58	rs4911139	ENSG00000275784.1	RP5-1125A11.6	-6	3.96e-09	1.64e-06	-0.28	-0.26	Skin pigmentation;	chr20:33963729	chr20:33989480~33991818:-
LUAD	cis	rs1061377	0.513	rs2566163	ENSG00000249207.1	RP11-360F5.1	-6	3.96e-09	1.64e-06	-0.36	-0.26	Uric acid levels;	chr4:39128345	chr4:39112677~39126818:-
LUAD	cis	rs9928842	0.823	rs4888365	ENSG00000280152.1	RP11-331F4.5	6	3.96e-09	1.64e-06	0.3	0.26	Alcoholic chronic pancreatitis;	chr16:75248349	chr16:75245994~75250077:-
LUAD	cis	rs4835473	0.932	rs35164917	ENSG00000251600.4	RP11-673E1.1	6	3.97e-09	1.64e-06	0.32	0.26	Immature fraction of reticulocytes;	chr4:143748891	chr4:143912331~143982454:+
LUAD	cis	rs10170846	0.626	rs9288575	ENSG00000261428.2	RP11-16P6.1	6	3.98e-09	1.65e-06	0.4	0.26	Schizophrenia (inflammation and infection response interaction);	chr2:222630414	chr2:222566899~222569719:-
LUAD	cis	rs17301013	0.502	rs6703836	ENSG00000227373.4	RP11-160H22.5	6	3.98e-09	1.65e-06	0.38	0.26	Systemic lupus erythematosus;	chr1:174099675	chr1:174115300~174160004:-
LUAD	cis	rs2404602	0.647	rs11637096	ENSG00000259422.1	RP11-593F23.1	-6	3.98e-09	1.65e-06	-0.35	-0.26	Blood metabolite levels;	chr15:76638761	chr15:76174891~76181486:-
LUAD	cis	rs4713118	0.662	rs149961	ENSG00000204709.4	LINC01556	6	3.99e-09	1.65e-06	0.35	0.26	Parkinson's disease;	chr6:28047791	chr6:28943877~28944537:+
LUAD	cis	rs8031584	0.781	rs4779498	ENSG00000270015.1	RP11-540B6.6	-6	3.99e-09	1.65e-06	-0.19	-0.26	Huntington's disease progression;	chr15:30885273	chr15:30926514~30928407:+
LUAD	cis	rs3096299	0.869	rs748941	ENSG00000274627.1	RP11-104N10.2	6	3.99e-09	1.65e-06	0.26	0.26	Multiple myeloma (IgH translocation);	chr16:89374346	chr16:89516797~89522217:+
LUAD	cis	rs2283792	0.74	rs11912377	ENSG00000224086.5	LL22NC03-86G7.1	-6	3.99e-09	1.65e-06	-0.26	-0.26	Multiple sclerosis;	chr22:21864332	chr22:21938293~21977632:+
LUAD	cis	rs8062405	1	rs7187776	ENSG00000251417.2	RP11-1348G14.4	-6	4e-09	1.65e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28802743~28817828:+
LUAD	cis	rs10129255	0.536	rs10139058	ENSG00000211970.3	IGHV4-61	-5.99	4e-09	1.66e-06	-0.19	-0.26	Kawasaki disease;	chr14:106685899	chr14:106639119~106639657:-
LUAD	cis	rs11157436	0.958	rs17255537	ENSG00000211812.1	TRAV26-2	-5.99	4e-09	1.66e-06	-0.3	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22208225	chr14:22202583~22203368:+
LUAD	cis	rs293748	0.771	rs158797	ENSG00000250155.1	CTD-2353F22.1	-5.99	4e-09	1.66e-06	-0.37	-0.26	Obesity-related traits;	chr5:36870318	chr5:36666214~36725195:-
LUAD	cis	rs11157436	0.846	rs12435431	ENSG00000211812.1	TRAV26-2	-5.99	4e-09	1.66e-06	-0.29	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22230301	chr14:22202583~22203368:+
LUAD	cis	rs755249	0.53	rs4660443	ENSG00000228060.1	RP11-69E11.8	-5.99	4e-09	1.66e-06	-0.27	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39126107	chr1:39565160~39573203:+
LUAD	cis	rs11971779	0.68	rs6467848	ENSG00000273391.1	RP11-634H22.1	5.99	4.01e-09	1.66e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139395459	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.648	rs6467849	ENSG00000273391.1	RP11-634H22.1	5.99	4.01e-09	1.66e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139395766	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs1986447	ENSG00000273391.1	RP11-634H22.1	5.99	4.01e-09	1.66e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139397334	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.59	rs9642120	ENSG00000273391.1	RP11-634H22.1	5.99	4.01e-09	1.66e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139399225	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.618	rs9640925	ENSG00000273391.1	RP11-634H22.1	5.99	4.01e-09	1.66e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139400542	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs7804388	ENSG00000273391.1	RP11-634H22.1	5.99	4.01e-09	1.66e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139401667	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs4732373	ENSG00000273391.1	RP11-634H22.1	5.99	4.01e-09	1.66e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139401789	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.618	rs6943788	ENSG00000273391.1	RP11-634H22.1	5.99	4.01e-09	1.66e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139402951	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.523	rs10279160	ENSG00000273391.1	RP11-634H22.1	5.99	4.01e-09	1.66e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139406015	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.59	rs4732374	ENSG00000273391.1	RP11-634H22.1	5.99	4.01e-09	1.66e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139406707	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.648	rs9642121	ENSG00000273391.1	RP11-634H22.1	5.99	4.01e-09	1.66e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139407875	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.715	rs7781459	ENSG00000273391.1	RP11-634H22.1	5.99	4.01e-09	1.66e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139409136	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.584	rs7786469	ENSG00000273391.1	RP11-634H22.1	5.99	4.01e-09	1.66e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139409875	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.584	rs17613864	ENSG00000273391.1	RP11-634H22.1	5.99	4.01e-09	1.66e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139410841	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.555	rs4728466	ENSG00000273391.1	RP11-634H22.1	5.99	4.01e-09	1.66e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139411619	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs4732376	ENSG00000273391.1	RP11-634H22.1	5.99	4.01e-09	1.66e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139413278	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.648	rs6974099	ENSG00000273391.1	RP11-634H22.1	5.99	4.01e-09	1.66e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139413820	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs10261557	ENSG00000273391.1	RP11-634H22.1	5.99	4.01e-09	1.66e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139414291	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.553	rs11973507	ENSG00000273391.1	RP11-634H22.1	5.99	4.01e-09	1.66e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139414715	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs10265718	ENSG00000273391.1	RP11-634H22.1	5.99	4.01e-09	1.66e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139415322	chr7:139359032~139359566:-
LUAD	cis	rs12908161	0.683	rs12903256	ENSG00000259728.4	LINC00933	5.99	4.01e-09	1.66e-06	0.34	0.26	Schizophrenia;	chr15:84764910	chr15:84570649~84580175:+
LUAD	cis	rs77204473	0.744	rs17120344	ENSG00000254851.1	RP11-109L13.1	-5.99	4.02e-09	1.66e-06	-0.67	-0.26	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117125629	chr11:117135528~117138582:+
LUAD	cis	rs516805	0.748	rs12211888	ENSG00000279453.1	RP3-425C14.4	5.99	4.02e-09	1.66e-06	0.36	0.26	Lymphocyte counts;	chr6:122384621	chr6:122436789~122439223:-
LUAD	cis	rs55665837	0.559	rs11023210	ENSG00000251991.1	RNU7-49P	-5.99	4.02e-09	1.66e-06	-0.29	-0.26	Vitamin D levels;	chr11:14401216	chr11:14478892~14478953:+
LUAD	cis	rs224090	0.54	rs11592442	ENSG00000238280.1	RP11-436D10.3	-5.99	4.02e-09	1.66e-06	-0.33	-0.26	Crohn's disease;	chr10:62774144	chr10:62793562~62805887:-
LUAD	cis	rs875971	0.862	rs6460306	ENSG00000237310.1	GS1-124K5.4	-5.99	4.03e-09	1.66e-06	-0.29	-0.26	Aortic root size;	chr7:66595806	chr7:66493706~66495474:+
LUAD	cis	rs6772849	0.796	rs9841521	ENSG00000242551.2	POU5F1P6	-5.99	4.03e-09	1.67e-06	-0.31	-0.26	Monocyte percentage of white cells;Monocyte count;	chr3:128673431	chr3:128674735~128677005:-
LUAD	cis	rs11096990	0.821	rs2711991	ENSG00000249207.1	RP11-360F5.1	5.99	4.03e-09	1.67e-06	0.3	0.26	Cognitive function;	chr4:39149733	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.855	rs2566168	ENSG00000249207.1	RP11-360F5.1	5.99	4.03e-09	1.67e-06	0.3	0.26	Cognitive function;	chr4:39150053	chr4:39112677~39126818:-
LUAD	cis	rs189798	0.738	rs330908	ENSG00000254340.1	RP11-10A14.3	5.99	4.04e-09	1.67e-06	0.33	0.26	Myopia (pathological);	chr8:9137656	chr8:9141424~9145435:+
LUAD	cis	rs12908161	1	rs35808647	ENSG00000259728.4	LINC00933	5.99	4.04e-09	1.67e-06	0.39	0.26	Schizophrenia;	chr15:84834210	chr15:84570649~84580175:+
LUAD	cis	rs875971	0.862	rs11763189	ENSG00000222364.1	RNU6-96P	-5.99	4.04e-09	1.67e-06	-0.3	-0.26	Aortic root size;	chr7:66518542	chr7:66395191~66395286:+
LUAD	cis	rs7849270	0.921	rs6478864	ENSG00000268707.1	RP11-247A12.7	-5.99	4.05e-09	1.67e-06	-0.3	-0.26	Blood metabolite ratios;	chr9:129118351	chr9:129170434~129170940:+
LUAD	cis	rs7849270	0.851	rs7861663	ENSG00000268707.1	RP11-247A12.7	-5.99	4.05e-09	1.67e-06	-0.3	-0.26	Blood metabolite ratios;	chr9:129118667	chr9:129170434~129170940:+
LUAD	cis	rs875971	0.545	rs17138156	ENSG00000226824.5	RP4-756H11.3	-5.99	4.05e-09	1.67e-06	-0.38	-0.26	Aortic root size;	chr7:66249708	chr7:66654538~66669855:+
LUAD	cis	rs3738443	0.523	rs56338561	ENSG00000259865.1	RP11-488L18.10	5.99	4.05e-09	1.68e-06	0.23	0.26	Alcohol dependence;	chr1:247210592	chr1:247187281~247188526:-
LUAD	cis	rs9494145	0.68	rs4895441	ENSG00000232876.1	CTA-212D2.2	5.99	4.06e-09	1.68e-06	0.35	0.26	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135105435	chr6:135055033~135060550:+
LUAD	cis	rs2283792	0.765	rs2266966	ENSG00000224086.5	LL22NC03-86G7.1	-5.99	4.06e-09	1.68e-06	-0.26	-0.26	Multiple sclerosis;	chr22:21767265	chr22:21938293~21977632:+
LUAD	cis	rs35160687	0.644	rs56394965	ENSG00000273080.1	RP11-301O19.1	-5.99	4.07e-09	1.68e-06	-0.29	-0.26	Night sleep phenotypes;	chr2:86271226	chr2:86195590~86196049:+
LUAD	cis	rs1823913	0.599	rs6732976	ENSG00000227542.1	AC092614.2	-5.99	4.07e-09	1.68e-06	-0.32	-0.26	Obesity-related traits;	chr2:191281004	chr2:191229165~191246172:-
LUAD	cis	rs66887589	0.616	rs13113885	ENSG00000245958.5	RP11-33B1.1	-5.99	4.07e-09	1.68e-06	-0.22	-0.26	Diastolic blood pressure;	chr4:119300021	chr4:119454791~119552025:+
LUAD	cis	rs1134634	0.52	rs10003739	ENSG00000273133.1	RP11-799M12.2	-5.99	4.08e-09	1.68e-06	-0.38	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15617063	chr4:15563698~15564253:-
LUAD	cis	rs853679	0.55	rs9295762	ENSG00000204709.4	LINC01556	-5.99	4.08e-09	1.68e-06	-0.35	-0.26	Depression;	chr6:28187640	chr6:28943877~28944537:+
LUAD	cis	rs67311347	1	rs112619360	ENSG00000223797.4	ENTPD3-AS1	5.99	4.08e-09	1.68e-06	0.28	0.26	Renal cell carcinoma;	chr3:40391154	chr3:40313802~40453329:-
LUAD	cis	rs9601248	0.51	rs9601250	ENSG00000227676.3	LINC01068	5.99	4.08e-09	1.69e-06	0.35	0.26	Major depressive disorder;	chr13:79614567	chr13:79566727~79571436:+
LUAD	cis	rs12712135	0.706	rs6543114	ENSG00000234389.1	AC007278.3	5.99	4.09e-09	1.69e-06	0.27	0.26	Blood protein levels;	chr2:102309534	chr2:102438713~102440475:+
LUAD	cis	rs875971	0.545	rs10950036	ENSG00000226824.5	RP4-756H11.3	-5.99	4.09e-09	1.69e-06	-0.38	-0.26	Aortic root size;	chr7:66353241	chr7:66654538~66669855:+
LUAD	cis	rs948562	0.947	rs1938601	ENSG00000280010.1	AP001350.4	5.99	4.1e-09	1.69e-06	0.42	0.26	Lymphoma;	chr11:58646988	chr11:58627435~58628528:+
LUAD	cis	rs11098499	0.909	rs28555550	ENSG00000248280.1	RP11-33B1.2	5.99	4.1e-09	1.69e-06	0.33	0.26	Corneal astigmatism;	chr4:119289885	chr4:119440561~119450157:-
LUAD	cis	rs11098499	1	rs28419773	ENSG00000248280.1	RP11-33B1.2	5.99	4.1e-09	1.69e-06	0.33	0.26	Corneal astigmatism;	chr4:119289906	chr4:119440561~119450157:-
LUAD	cis	rs2243480	1	rs316307	ENSG00000230295.1	RP11-458F8.2	-5.99	4.1e-09	1.69e-06	-0.33	-0.26	Diabetic kidney disease;	chr7:66105184	chr7:66880708~66882981:+
LUAD	cis	rs1062177	1	rs2915887	ENSG00000213433.5	RPLP1P6	-5.99	4.1e-09	1.69e-06	-0.35	-0.26	Preschool internalizing problems;	chr5:151825943	chr5:151765859~151766378:-
LUAD	cis	rs9813712	0.571	rs9836814	ENSG00000249846.5	RP11-77P16.4	5.99	4.1e-09	1.7e-06	0.31	0.26	Response to amphetamines;	chr3:130216054	chr3:130112550~130120579:+
LUAD	cis	rs494459	0.536	rs34561290	ENSG00000255239.1	AP002954.6	5.99	4.1e-09	1.7e-06	0.31	0.26	Height;	chr11:118860890	chr11:118688039~118690600:-
LUAD	cis	rs494459	0.536	rs11217072	ENSG00000255239.1	AP002954.6	5.99	4.1e-09	1.7e-06	0.31	0.26	Height;	chr11:118861053	chr11:118688039~118690600:-
LUAD	cis	rs6921919	0.609	rs1005127	ENSG00000204709.4	LINC01556	5.99	4.11e-09	1.7e-06	0.34	0.26	Autism spectrum disorder or schizophrenia;	chr6:28399881	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.515	rs4580862	ENSG00000204709.4	LINC01556	5.99	4.11e-09	1.7e-06	0.34	0.26	Depression;	chr6:28399886	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs4357130	ENSG00000204709.4	LINC01556	5.99	4.11e-09	1.7e-06	0.34	0.26	Autism spectrum disorder or schizophrenia;	chr6:28399906	chr6:28943877~28944537:+
LUAD	cis	rs1823913	0.599	rs34100174	ENSG00000280083.1	RP11-317J9.1	-5.99	4.11e-09	1.7e-06	-0.31	-0.26	Obesity-related traits;	chr2:191283579	chr2:191154118~191156070:-
LUAD	cis	rs10214930	0.697	rs986706	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27573133	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs7806605	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27573966	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs4722719	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27575303	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs5009225	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27577166	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs10807841	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27580132	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.671	rs1009252	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27582054	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs7789788	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27582992	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs1608664	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27584309	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs4140899	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27585408	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs1524532	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27586067	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs2391443	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27586310	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs12539707	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27586546	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs7783447	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27587236	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.65	rs4348389	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27589331	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs1980329	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27590681	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs12667235	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27592012	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.723	rs6948814	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27593782	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs12668430	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27593899	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.671	rs28416309	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27594123	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs28429439	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27594180	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs1404278	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27595107	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.723	rs6960834	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27596367	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs6980382	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27598043	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs6947731	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27599076	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs1030003	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27600240	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs6462036	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27601444	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.625	rs6462037	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27601481	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs7811436	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27601667	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs2110528	ENSG00000235574.1	AC073150.6	-5.99	4.11e-09	1.7e-06	-0.33	-0.26	Hypospadias;	chr7:27603400	chr7:27491682~27492765:-
LUAD	cis	rs7181230	0.885	rs35781999	ENSG00000275636.1	RP11-521C20.5	5.99	4.11e-09	1.7e-06	0.36	0.26	Dehydroepiandrosterone sulphate levels;	chr15:40063205	chr15:40078892~40079347:+
LUAD	cis	rs10759883	0.539	rs7847393	ENSG00000175611.10	LINC00476	5.99	4.12e-09	1.7e-06	0.31	0.26	Nicotine dependence;	chr9:96033431	chr9:95759231~95875977:-
LUAD	cis	rs1823913	0.599	rs13427761	ENSG00000227542.1	AC092614.2	-5.99	4.12e-09	1.7e-06	-0.32	-0.26	Obesity-related traits;	chr2:191269256	chr2:191229165~191246172:-
LUAD	cis	rs897200	1	rs11684030	ENSG00000280083.1	RP11-317J9.1	5.99	4.12e-09	1.7e-06	0.33	0.26	Behcet's disease;	chr2:191152153	chr2:191154118~191156070:-
LUAD	cis	rs11157436	0.958	rs764161	ENSG00000211812.1	TRAV26-2	-5.99	4.13e-09	1.7e-06	-0.3	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22231182	chr14:22202583~22203368:+
LUAD	cis	rs2111504	0.583	rs1008425	ENSG00000267213.4	AC007773.2	5.99	4.13e-09	1.7e-06	0.34	0.26	Bipolar disorder;	chr19:32361239	chr19:32390050~32405560:-
LUAD	cis	rs2111504	0.559	rs12460112	ENSG00000267213.4	AC007773.2	5.99	4.13e-09	1.7e-06	0.34	0.26	Bipolar disorder;	chr19:32363928	chr19:32390050~32405560:-
LUAD	cis	rs10740039	0.81	rs1006956	ENSG00000254271.1	RP11-131N11.4	-5.99	4.13e-09	1.7e-06	-0.3	-0.26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60608218	chr10:60734342~60741828:+
LUAD	cis	rs2034650	0.506	rs1984793	ENSG00000223313.1	RNU6-516P	5.99	4.13e-09	1.71e-06	0.34	0.26	Interstitial lung disease;	chr15:40407172	chr15:40529570~40529673:+
LUAD	cis	rs7849270	0.851	rs1819381	ENSG00000268707.1	RP11-247A12.7	-5.99	4.13e-09	1.71e-06	-0.3	-0.26	Blood metabolite ratios;	chr9:129145728	chr9:129170434~129170940:+
LUAD	cis	rs11977715	0.538	rs43063	ENSG00000233942.1	AC004012.1	-5.99	4.13e-09	1.71e-06	-0.31	-0.26	Middle childhood and early adolescence aggressive behavior;	chr7:95480475	chr7:95471835~95473998:+
LUAD	cis	rs875971	0.898	rs6977501	ENSG00000222364.1	RNU6-96P	5.99	4.15e-09	1.71e-06	0.29	0.26	Aortic root size;	chr7:66228355	chr7:66395191~66395286:+
LUAD	cis	rs2243480	1	rs160646	ENSG00000232546.1	RP11-458F8.1	-5.99	4.15e-09	1.71e-06	-0.34	-0.26	Diabetic kidney disease;	chr7:66091293	chr7:66848496~66858136:+
LUAD	cis	rs6991838	0.806	rs35284121	ENSG00000272010.1	CTD-3025N20.3	5.99	4.15e-09	1.71e-06	0.27	0.26	Intelligence (multi-trait analysis);	chr8:65551230	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.751	rs35553155	ENSG00000272010.1	CTD-3025N20.3	5.99	4.15e-09	1.71e-06	0.27	0.26	Intelligence (multi-trait analysis);	chr8:65551232	chr8:65591850~65592472:-
LUAD	cis	rs6991838	0.806	rs35024820	ENSG00000272010.1	CTD-3025N20.3	5.99	4.15e-09	1.71e-06	0.27	0.26	Intelligence (multi-trait analysis);	chr8:65551296	chr8:65591850~65592472:-
LUAD	cis	rs875971	0.862	rs4718383	ENSG00000222364.1	RNU6-96P	5.99	4.16e-09	1.71e-06	0.3	0.26	Aortic root size;	chr7:66643422	chr7:66395191~66395286:+
LUAD	cis	rs2404602	0.647	rs920712	ENSG00000259422.1	RP11-593F23.1	-5.99	4.16e-09	1.71e-06	-0.35	-0.26	Blood metabolite levels;	chr15:76741593	chr15:76174891~76181486:-
LUAD	cis	rs7829975	0.593	rs2921077	ENSG00000253893.2	FAM85B	-5.99	4.16e-09	1.72e-06	-0.33	-0.26	Mood instability;	chr8:8446992	chr8:8167819~8226614:-
LUAD	cis	rs35160687	0.712	rs4832031	ENSG00000273080.1	RP11-301O19.1	5.99	4.16e-09	1.72e-06	0.29	0.26	Night sleep phenotypes;	chr2:86251857	chr2:86195590~86196049:+
LUAD	cis	rs11157436	0.958	rs61972229	ENSG00000211812.1	TRAV26-2	-5.99	4.16e-09	1.72e-06	-0.3	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22189754	chr14:22202583~22203368:+
LUAD	cis	rs11157436	0.958	rs17183301	ENSG00000211812.1	TRAV26-2	-5.99	4.16e-09	1.72e-06	-0.3	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22190003	chr14:22202583~22203368:+
LUAD	cis	rs67311347	1	rs67311347	ENSG00000223797.4	ENTPD3-AS1	5.99	4.16e-09	1.72e-06	0.29	0.26	Renal cell carcinoma;	chr3:40491752	chr3:40313802~40453329:-
LUAD	cis	rs17301013	0.507	rs2568098	ENSG00000227373.4	RP11-160H22.5	5.99	4.16e-09	1.72e-06	0.38	0.26	Systemic lupus erythematosus;	chr1:174732183	chr1:174115300~174160004:-
LUAD	cis	rs748404	0.666	rs7177146	ENSG00000205771.5	CATSPER2P1	-5.99	4.17e-09	1.72e-06	-0.4	-0.26	Lung cancer;	chr15:43506110	chr15:43726918~43747094:-
LUAD	cis	rs875971	0.545	rs73142245	ENSG00000226824.5	RP4-756H11.3	-5.99	4.17e-09	1.72e-06	-0.39	-0.26	Aortic root size;	chr7:66226662	chr7:66654538~66669855:+
LUAD	cis	rs897200	1	rs16833437	ENSG00000280083.1	RP11-317J9.1	5.99	4.18e-09	1.72e-06	0.33	0.26	Behcet's disease;	chr2:191154646	chr2:191154118~191156070:-
LUAD	cis	rs7727544	0.684	rs270602	ENSG00000233006.5	AC034220.3	5.99	4.18e-09	1.72e-06	0.23	0.26	Blood metabolite levels;	chr5:132321007	chr5:132311285~132369916:-
LUAD	cis	rs2404602	0.716	rs12907805	ENSG00000259422.1	RP11-593F23.1	5.99	4.18e-09	1.72e-06	0.3	0.26	Blood metabolite levels;	chr15:76398265	chr15:76174891~76181486:-
LUAD	cis	rs4713118	0.662	rs464312	ENSG00000204709.4	LINC01556	5.99	4.18e-09	1.72e-06	0.36	0.26	Parkinson's disease;	chr6:27999813	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.662	rs469228	ENSG00000204709.4	LINC01556	5.99	4.18e-09	1.72e-06	0.36	0.26	Parkinson's disease;	chr6:28002926	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.54	rs469227	ENSG00000204709.4	LINC01556	5.99	4.18e-09	1.72e-06	0.36	0.26	Parkinson's disease;	chr6:28002927	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.662	rs149948	ENSG00000204709.4	LINC01556	5.99	4.18e-09	1.72e-06	0.36	0.26	Parkinson's disease;	chr6:28007039	chr6:28943877~28944537:+
LUAD	cis	rs7246657	0.943	rs2279148	ENSG00000276846.1	CTD-3220F14.3	5.99	4.19e-09	1.73e-06	0.36	0.26	Coronary artery calcification;	chr19:37533781	chr19:37314868~37315620:-
LUAD	cis	rs293748	0.54	rs12652735	ENSG00000250155.1	CTD-2353F22.1	-5.99	4.19e-09	1.73e-06	-0.33	-0.26	Obesity-related traits;	chr5:37230629	chr5:36666214~36725195:-
LUAD	cis	rs2243480	1	rs316322	ENSG00000230295.1	RP11-458F8.2	-5.99	4.19e-09	1.73e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66146246	chr7:66880708~66882981:+
LUAD	cis	rs6772849	0.931	rs60825080	ENSG00000242551.2	POU5F1P6	-5.99	4.2e-09	1.73e-06	-0.31	-0.26	Monocyte percentage of white cells;Monocyte count;	chr3:128665991	chr3:128674735~128677005:-
LUAD	cis	rs8031584	0.958	rs34909055	ENSG00000260382.1	RP11-540B6.2	5.99	4.2e-09	1.73e-06	0.31	0.26	Huntington's disease progression;	chr15:30991967	chr15:30882267~30883231:-
LUAD	cis	rs1823913	0.599	rs4146103	ENSG00000280083.1	RP11-317J9.1	-5.99	4.2e-09	1.73e-06	-0.31	-0.26	Obesity-related traits;	chr2:191272000	chr2:191154118~191156070:-
LUAD	cis	rs11651753	0.613	rs4793732	ENSG00000264920.1	RP11-6N17.4	-5.99	4.2e-09	1.73e-06	-0.34	-0.26	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47956488	chr17:47891255~47895812:-
LUAD	cis	rs1823913	0.614	rs4853463	ENSG00000227542.1	AC092614.2	-5.99	4.2e-09	1.73e-06	-0.32	-0.26	Obesity-related traits;	chr2:191278699	chr2:191229165~191246172:-
LUAD	cis	rs2098713	0.512	rs13166974	ENSG00000250155.1	CTD-2353F22.1	-5.99	4.2e-09	1.73e-06	-0.33	-0.26	Telomere length;	chr5:37171263	chr5:36666214~36725195:-
LUAD	cis	rs7849270	1	rs1571229	ENSG00000268707.1	RP11-247A12.7	-5.99	4.21e-09	1.73e-06	-0.3	-0.26	Blood metabolite ratios;	chr9:129151432	chr9:129170434~129170940:+
LUAD	cis	rs875971	0.545	rs313830	ENSG00000237310.1	GS1-124K5.4	-5.99	4.21e-09	1.74e-06	-0.34	-0.26	Aortic root size;	chr7:66086944	chr7:66493706~66495474:+
LUAD	cis	rs2179367	0.92	rs638407	ENSG00000231760.4	RP11-350J20.5	5.99	4.21e-09	1.74e-06	0.33	0.26	Dupuytren's disease;	chr6:149417214	chr6:149796151~149826294:-
LUAD	cis	rs7727544	0.735	rs274558	ENSG00000233006.5	AC034220.3	-5.99	4.21e-09	1.74e-06	-0.23	-0.26	Blood metabolite levels;	chr5:132385482	chr5:132311285~132369916:-
LUAD	cis	rs10740039	0.81	rs2165691	ENSG00000254271.1	RP11-131N11.4	5.99	4.22e-09	1.74e-06	0.3	0.26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60611891	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.81	rs1442543	ENSG00000254271.1	RP11-131N11.4	5.99	4.22e-09	1.74e-06	0.3	0.26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60613704	chr10:60734342~60741828:+
LUAD	cis	rs4713118	0.866	rs2179094	ENSG00000219392.1	RP1-265C24.5	-5.99	4.22e-09	1.74e-06	-0.35	-0.26	Parkinson's disease;	chr6:27774046	chr6:28115628~28116551:+
LUAD	cis	rs35934224	0.783	rs16984299	ENSG00000232926.1	AC000078.5	-5.99	4.22e-09	1.74e-06	-0.28	-0.26	Glaucoma (primary open-angle);	chr22:19876070	chr22:19887289~19887970:+
LUAD	cis	rs10129255	0.5	rs1024350	ENSG00000211967.3	IGHV3-53	-5.99	4.22e-09	1.74e-06	-0.19	-0.26	Kawasaki disease;	chr14:106685105	chr14:106592676~106593347:-
LUAD	cis	rs12554020	0.786	rs12554164	ENSG00000227603.1	RP11-165J3.6	5.99	4.22e-09	1.74e-06	0.49	0.26	Schizophrenia;	chr9:93456677	chr9:93435332~93437121:-
LUAD	cis	rs12468226	0.938	rs4675274	ENSG00000226261.1	AC064836.3	-5.99	4.22e-09	1.74e-06	-0.43	-0.26	Urate levels;	chr2:202243145	chr2:202336024~202336727:-
LUAD	cis	rs1275468	1	rs3847669	ENSG00000257497.2	RP11-585P4.5	-5.99	4.22e-09	1.74e-06	-0.36	-0.26	Polycystic ovary syndrome;	chr12:75555378	chr12:75483454~75489820:-
LUAD	cis	rs10170846	0.53	rs56353541	ENSG00000261428.2	RP11-16P6.1	5.99	4.23e-09	1.74e-06	0.32	0.26	Schizophrenia (inflammation and infection response interaction);	chr2:222556468	chr2:222566899~222569719:-
LUAD	cis	rs2243480	1	rs465359	ENSG00000232546.1	RP11-458F8.1	-5.99	4.23e-09	1.74e-06	-0.34	-0.26	Diabetic kidney disease;	chr7:66093177	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs462853	ENSG00000232546.1	RP11-458F8.1	-5.99	4.23e-09	1.74e-06	-0.34	-0.26	Diabetic kidney disease;	chr7:66093180	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs160644	ENSG00000232546.1	RP11-458F8.1	-5.99	4.23e-09	1.74e-06	-0.34	-0.26	Diabetic kidney disease;	chr7:66093199	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs160642	ENSG00000232546.1	RP11-458F8.1	-5.99	4.23e-09	1.74e-06	-0.34	-0.26	Diabetic kidney disease;	chr7:66093386	chr7:66848496~66858136:+
LUAD	cis	rs2243480	0.614	rs34032527	ENSG00000232546.1	RP11-458F8.1	-5.99	4.23e-09	1.74e-06	-0.34	-0.26	Diabetic kidney disease;	chr7:66100154	chr7:66848496~66858136:+
LUAD	cis	rs6565180	0.926	rs8046445	ENSG00000183604.13	SMG1P5	-5.99	4.23e-09	1.74e-06	-0.28	-0.26	Tonsillectomy;	chr16:30374941	chr16:30267553~30335374:-
LUAD	cis	rs293748	0.771	rs35011787	ENSG00000250155.1	CTD-2353F22.1	-5.99	4.23e-09	1.74e-06	-0.37	-0.26	Obesity-related traits;	chr5:37010302	chr5:36666214~36725195:-
LUAD	cis	rs293748	0.771	rs35701604	ENSG00000250155.1	CTD-2353F22.1	-5.99	4.23e-09	1.74e-06	-0.37	-0.26	Obesity-related traits;	chr5:37021831	chr5:36666214~36725195:-
LUAD	cis	rs875971	0.83	rs778711	ENSG00000237310.1	GS1-124K5.4	5.98	4.23e-09	1.74e-06	0.29	0.26	Aortic root size;	chr7:66386670	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs1083554	ENSG00000237310.1	GS1-124K5.4	5.98	4.23e-09	1.74e-06	0.29	0.26	Aortic root size;	chr7:66387354	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs778707	ENSG00000237310.1	GS1-124K5.4	5.98	4.23e-09	1.74e-06	0.29	0.26	Aortic root size;	chr7:66392040	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs778705	ENSG00000237310.1	GS1-124K5.4	5.98	4.23e-09	1.74e-06	0.29	0.26	Aortic root size;	chr7:66396128	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs778697	ENSG00000237310.1	GS1-124K5.4	5.98	4.23e-09	1.74e-06	0.29	0.26	Aortic root size;	chr7:66405439	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.798	rs7789615	ENSG00000237310.1	GS1-124K5.4	5.98	4.23e-09	1.74e-06	0.29	0.26	Aortic root size;	chr7:66413674	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs6978028	ENSG00000237310.1	GS1-124K5.4	5.98	4.23e-09	1.74e-06	0.29	0.26	Aortic root size;	chr7:66421313	chr7:66493706~66495474:+
LUAD	cis	rs2288884	1	rs2043298	ENSG00000275055.1	CTC-471J1.11	5.98	4.24e-09	1.74e-06	0.39	0.26	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52069814	chr19:52049007~52049754:+
LUAD	cis	rs1799949	0.859	rs11657004	ENSG00000267681.1	CTD-3199J23.6	-5.98	4.24e-09	1.75e-06	-0.3	-0.26	Menopause (age at onset);	chr17:43365383	chr17:43144956~43145255:+
LUAD	cis	rs12699921	0.658	rs1404422	ENSG00000279048.1	RP11-511H23.2	-5.98	4.24e-09	1.75e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17795362	chr7:17940503~17942922:+
LUAD	cis	rs732716	0.785	rs55660045	ENSG00000267980.1	AC007292.6	-5.98	4.25e-09	1.75e-06	-0.31	-0.26	Mean corpuscular volume;	chr19:4425308	chr19:4363789~4364640:+
LUAD	cis	rs11742741	0.539	rs13164843	ENSG00000248874.4	C5orf17	-5.98	4.26e-09	1.75e-06	-0.33	-0.26	Educational attainment;	chr5:24102085	chr5:23951348~24178263:+
LUAD	cis	rs932287	0.666	rs10840161	ENSG00000254860.4	TMEM9B-AS1	-5.98	4.26e-09	1.75e-06	-0.3	-0.26	Colonoscopy-negative controls vs population controls;	chr11:9032277	chr11:8964675~8977527:+
LUAD	cis	rs11690935	0.632	rs35854151	ENSG00000228389.1	AC068039.4	-5.98	4.26e-09	1.75e-06	-0.28	-0.26	Schizophrenia;	chr2:171800929	chr2:171773482~171775844:+
LUAD	cis	rs1707322	0.682	rs12037459	ENSG00000234329.1	RP11-767N6.2	5.98	4.26e-09	1.75e-06	0.28	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629287	chr1:45651039~45651826:-
LUAD	cis	rs10740039	0.516	rs7072017	ENSG00000254271.1	RP11-131N11.4	5.98	4.26e-09	1.75e-06	0.29	0.26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60584568	chr10:60734342~60741828:+
LUAD	cis	rs875971	0.965	rs697968	ENSG00000222364.1	RNU6-96P	5.98	4.27e-09	1.76e-06	0.3	0.26	Aortic root size;	chr7:66070046	chr7:66395191~66395286:+
LUAD	cis	rs17301013	0.507	rs1329281	ENSG00000227373.4	RP11-160H22.5	-5.98	4.27e-09	1.76e-06	-0.38	-0.26	Systemic lupus erythematosus;	chr1:174766432	chr1:174115300~174160004:-
LUAD	cis	rs11098499	0.913	rs56122576	ENSG00000248280.1	RP11-33B1.2	5.98	4.27e-09	1.76e-06	0.34	0.26	Corneal astigmatism;	chr4:119208181	chr4:119440561~119450157:-
LUAD	cis	rs875971	0.825	rs28480509	ENSG00000222364.1	RNU6-96P	5.98	4.28e-09	1.76e-06	0.3	0.26	Aortic root size;	chr7:66634237	chr7:66395191~66395286:+
LUAD	cis	rs1062177	0.756	rs2964592	ENSG00000213433.5	RPLP1P6	5.98	4.28e-09	1.76e-06	0.34	0.26	Preschool internalizing problems;	chr5:151736127	chr5:151765859~151766378:-
LUAD	cis	rs1707322	0.686	rs2991987	ENSG00000234329.1	RP11-767N6.2	-5.98	4.29e-09	1.76e-06	-0.28	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615750	chr1:45651039~45651826:-
LUAD	cis	rs2153535	0.584	rs55945625	ENSG00000230939.1	RP11-314C16.1	5.98	4.3e-09	1.77e-06	0.31	0.26	Motion sickness;	chr6:8371134	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.584	rs62395677	ENSG00000230939.1	RP11-314C16.1	5.98	4.3e-09	1.77e-06	0.31	0.26	Motion sickness;	chr6:8371356	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.584	rs62395678	ENSG00000230939.1	RP11-314C16.1	5.98	4.3e-09	1.77e-06	0.31	0.26	Motion sickness;	chr6:8371456	chr6:8784178~8785445:+
LUAD	cis	rs875971	0.545	rs73142233	ENSG00000226824.5	RP4-756H11.3	-5.98	4.3e-09	1.77e-06	-0.39	-0.26	Aortic root size;	chr7:66221293	chr7:66654538~66669855:+
LUAD	cis	rs2412819	0.571	rs11070411	ENSG00000249839.1	AC011330.5	5.98	4.3e-09	1.77e-06	0.41	0.26	Lung cancer;	chr15:43766436	chr15:43663654~43684339:-
LUAD	cis	rs4889009	0.533	rs12596569	ENSG00000261390.4	RP11-345M22.2	5.98	4.31e-09	1.77e-06	0.32	0.26	Thyroid peroxidase antibody positivity;	chr16:79701354	chr16:79715232~79770563:-
LUAD	cis	rs6921919	0.551	rs13201753	ENSG00000204709.4	LINC01556	5.98	4.31e-09	1.77e-06	0.34	0.26	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28943877~28944537:+
LUAD	cis	rs1823913	0.637	rs4853465	ENSG00000227542.1	AC092614.2	-5.98	4.31e-09	1.77e-06	-0.32	-0.26	Obesity-related traits;	chr2:191294768	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.637	rs4853573	ENSG00000227542.1	AC092614.2	-5.98	4.31e-09	1.77e-06	-0.32	-0.26	Obesity-related traits;	chr2:191295866	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.614	rs4853466	ENSG00000227542.1	AC092614.2	-5.98	4.31e-09	1.77e-06	-0.32	-0.26	Obesity-related traits;	chr2:191295943	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.637	rs4853574	ENSG00000227542.1	AC092614.2	-5.98	4.31e-09	1.77e-06	-0.32	-0.26	Obesity-related traits;	chr2:191296113	chr2:191229165~191246172:-
LUAD	cis	rs4713118	0.869	rs9461405	ENSG00000219392.1	RP1-265C24.5	-5.98	4.31e-09	1.77e-06	-0.35	-0.26	Parkinson's disease;	chr6:27751596	chr6:28115628~28116551:+
LUAD	cis	rs1823913	0.599	rs58106487	ENSG00000280083.1	RP11-317J9.1	-5.98	4.32e-09	1.78e-06	-0.32	-0.26	Obesity-related traits;	chr2:191292404	chr2:191154118~191156070:-
LUAD	cis	rs2243480	1	rs35542501	ENSG00000230295.1	RP11-458F8.2	-5.98	4.32e-09	1.78e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:65966228	chr7:66880708~66882981:+
LUAD	cis	rs2243480	0.708	rs781141	ENSG00000230295.1	RP11-458F8.2	-5.98	4.32e-09	1.78e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:65973566	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs781142	ENSG00000230295.1	RP11-458F8.2	-5.98	4.32e-09	1.78e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:65973791	chr7:66880708~66882981:+
LUAD	cis	rs496547	0.721	rs2508570	ENSG00000255422.1	AP002954.4	-5.98	4.32e-09	1.78e-06	-0.33	-0.26	Hip minimal joint space width;	chr11:118807900	chr11:118704607~118750263:+
LUAD	cis	rs2404602	0.684	rs57682236	ENSG00000259422.1	RP11-593F23.1	-5.98	4.32e-09	1.78e-06	-0.36	-0.26	Blood metabolite levels;	chr15:76576137	chr15:76174891~76181486:-
LUAD	cis	rs9368481	0.761	rs4713062	ENSG00000241549.7	GUSBP2	-5.98	4.33e-09	1.78e-06	-0.29	-0.26	Autism spectrum disorder or schizophrenia;	chr6:26980416	chr6:26871484~26956554:-
LUAD	cis	rs6921919	0.583	rs16894108	ENSG00000216901.1	AL022393.7	5.98	4.33e-09	1.78e-06	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28176188~28176674:+
LUAD	cis	rs12699921	0.632	rs2140710	ENSG00000279048.1	RP11-511H23.2	-5.98	4.33e-09	1.78e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17855952	chr7:17940503~17942922:+
LUAD	cis	rs7923609	0.967	rs7912893	ENSG00000232075.1	MRPL35P2	-5.98	4.33e-09	1.78e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63402240	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.967	rs10761762	ENSG00000232075.1	MRPL35P2	-5.98	4.33e-09	1.78e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63424957	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.934	rs10761763	ENSG00000232075.1	MRPL35P2	-5.98	4.33e-09	1.78e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63428558	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.967	rs10761766	ENSG00000232075.1	MRPL35P2	-5.98	4.33e-09	1.78e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63430567	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.967	rs3740331	ENSG00000232075.1	MRPL35P2	-5.98	4.33e-09	1.78e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63432528	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.967	rs3956912	ENSG00000232075.1	MRPL35P2	-5.98	4.33e-09	1.78e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63446121	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.967	rs10509186	ENSG00000232075.1	MRPL35P2	-5.98	4.33e-09	1.78e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63447258	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.936	rs10740125	ENSG00000232075.1	MRPL35P2	-5.98	4.33e-09	1.78e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63449849	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.967	rs10740126	ENSG00000232075.1	MRPL35P2	-5.98	4.33e-09	1.78e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63451175	chr10:63634317~63634827:-
LUAD	cis	rs17666538	0.585	rs1669733	ENSG00000254207.1	RP11-43A14.1	-5.98	4.34e-09	1.78e-06	-0.5	-0.26	IgG glycosylation;	chr8:656696	chr8:725188~725877:-
LUAD	cis	rs75422866	0.51	rs35784744	ENSG00000274902.1	RP1-197B17.4	5.98	4.35e-09	1.79e-06	0.57	0.26	Pneumonia;	chr12:47729646	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.541	rs12425816	ENSG00000274902.1	RP1-197B17.4	5.98	4.35e-09	1.79e-06	0.57	0.26	Pneumonia;	chr12:47731419	chr12:47731908~47732351:+
LUAD	cis	rs897984	0.647	rs7203999	ENSG00000260911.2	RP11-196G11.2	-5.98	4.35e-09	1.79e-06	-0.24	-0.26	Dementia with Lewy bodies;	chr16:31006233	chr16:31043150~31049868:+
LUAD	cis	rs1167827	0.68	rs1167800	ENSG00000127957.15	PMS2P3	-5.98	4.35e-09	1.79e-06	-0.26	-0.26	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75546898	chr7:75502930~75528148:-
LUAD	cis	rs875971	0.83	rs6976714	ENSG00000237310.1	GS1-124K5.4	5.98	4.36e-09	1.79e-06	0.29	0.26	Aortic root size;	chr7:66426474	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs12537823	ENSG00000237310.1	GS1-124K5.4	5.98	4.36e-09	1.79e-06	0.29	0.26	Aortic root size;	chr7:66255897	chr7:66493706~66495474:+
LUAD	cis	rs8031584	0.781	rs4779498	ENSG00000260382.1	RP11-540B6.2	5.98	4.36e-09	1.79e-06	0.32	0.26	Huntington's disease progression;	chr15:30885273	chr15:30882267~30883231:-
LUAD	cis	rs10740039	0.516	rs9731224	ENSG00000254271.1	RP11-131N11.4	5.98	4.37e-09	1.79e-06	0.29	0.26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60583390	chr10:60734342~60741828:+
LUAD	cis	rs10129255	0.536	rs17113249	ENSG00000211967.3	IGHV3-53	-5.98	4.37e-09	1.79e-06	-0.19	-0.26	Kawasaki disease;	chr14:106678273	chr14:106592676~106593347:-
LUAD	cis	rs11971779	0.648	rs7799165	ENSG00000273391.1	RP11-634H22.1	5.98	4.37e-09	1.8e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139400211	chr7:139359032~139359566:-
LUAD	cis	rs858239	0.6	rs7799422	ENSG00000230042.1	AK3P3	-5.98	4.37e-09	1.8e-06	-0.34	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23129178~23129841:+
LUAD	cis	rs11096990	0.964	rs16995206	ENSG00000249207.1	RP11-360F5.1	5.98	4.37e-09	1.8e-06	0.3	0.26	Cognitive function;	chr4:39262887	chr4:39112677~39126818:-
LUAD	cis	rs7430456	1	rs7430456	ENSG00000228221.4	LINC00578	-5.98	4.38e-09	1.8e-06	-0.31	-0.26	Breast cancer;	chr3:177768082	chr3:177441921~177752305:+
LUAD	cis	rs1075265	0.749	rs805380	ENSG00000233266.1	HMGB1P31	5.98	4.38e-09	1.8e-06	0.33	0.26	Chronotype;Morning vs. evening chronotype;	chr2:53867284	chr2:54051334~54051760:+
LUAD	cis	rs10214930	0.767	rs56282178	ENSG00000235574.1	AC073150.6	5.98	4.39e-09	1.8e-06	0.35	0.26	Hypospadias;	chr7:27658973	chr7:27491682~27492765:-
LUAD	cis	rs189798	0.592	rs10111263	ENSG00000253893.2	FAM85B	5.98	4.39e-09	1.8e-06	0.33	0.26	Myopia (pathological);	chr8:9111923	chr8:8167819~8226614:-
LUAD	cis	rs12699921	0.632	rs2691600	ENSG00000279048.1	RP11-511H23.2	-5.98	4.4e-09	1.81e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17833542	chr7:17940503~17942922:+
LUAD	cis	rs17301013	0.581	rs11801385	ENSG00000227373.4	RP11-160H22.5	5.98	4.4e-09	1.81e-06	0.38	0.26	Systemic lupus erythematosus;	chr1:174089454	chr1:174115300~174160004:-
LUAD	cis	rs875971	0.545	rs1796219	ENSG00000237310.1	GS1-124K5.4	-5.98	4.4e-09	1.81e-06	-0.34	-0.26	Aortic root size;	chr7:66645977	chr7:66493706~66495474:+
LUAD	cis	rs66887589	0.616	rs11732621	ENSG00000248280.1	RP11-33B1.2	5.98	4.4e-09	1.81e-06	0.29	0.26	Diastolic blood pressure;	chr4:119291728	chr4:119440561~119450157:-
LUAD	cis	rs9595066	0.712	rs4391951	ENSG00000227258.4	SMIM2-AS1	-5.98	4.41e-09	1.81e-06	-0.42	-0.26	Schizophrenia;	chr13:44180935	chr13:44110451~44240517:+
LUAD	cis	rs12468226	0.938	rs56684065	ENSG00000272966.1	RP11-686O6.1	5.98	4.41e-09	1.81e-06	0.46	0.26	Urate levels;	chr2:202289528	chr2:202336739~202337200:+
LUAD	cis	rs12468226	0.938	rs1474001	ENSG00000272966.1	RP11-686O6.1	5.98	4.41e-09	1.81e-06	0.46	0.26	Urate levels;	chr2:202290230	chr2:202336739~202337200:+
LUAD	cis	rs12468226	0.938	rs76664732	ENSG00000272966.1	RP11-686O6.1	5.98	4.41e-09	1.81e-06	0.46	0.26	Urate levels;	chr2:202296298	chr2:202336739~202337200:+
LUAD	cis	rs12468226	0.938	rs16841867	ENSG00000272966.1	RP11-686O6.1	5.98	4.41e-09	1.81e-06	0.46	0.26	Urate levels;	chr2:202303512	chr2:202336739~202337200:+
LUAD	cis	rs12468226	0.938	rs16839065	ENSG00000272966.1	RP11-686O6.1	5.98	4.41e-09	1.81e-06	0.46	0.26	Urate levels;	chr2:202308774	chr2:202336739~202337200:+
LUAD	cis	rs853679	1	rs853676	ENSG00000204709.4	LINC01556	5.98	4.42e-09	1.81e-06	0.42	0.26	Depression;	chr6:28331910	chr6:28943877~28944537:+
LUAD	cis	rs11157436	0.958	rs12433649	ENSG00000211812.1	TRAV26-2	-5.98	4.42e-09	1.81e-06	-0.3	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22231828	chr14:22202583~22203368:+
LUAD	cis	rs6558530	0.73	rs10100341	ENSG00000253982.1	CTD-2336O2.1	5.98	4.42e-09	1.82e-06	0.32	0.26	Systolic blood pressure;	chr8:1775583	chr8:1761990~1764502:-
LUAD	cis	rs12291225	0.535	rs16930126	ENSG00000251991.1	RNU7-49P	-5.98	4.43e-09	1.82e-06	-0.29	-0.26	Sense of smell;	chr11:14383437	chr11:14478892~14478953:+
LUAD	cis	rs875971	0.862	rs4236208	ENSG00000222364.1	RNU6-96P	5.98	4.43e-09	1.82e-06	0.3	0.26	Aortic root size;	chr7:66284091	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs10261398	ENSG00000222364.1	RNU6-96P	5.98	4.43e-09	1.82e-06	0.3	0.26	Aortic root size;	chr7:66285177	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs10224872	ENSG00000222364.1	RNU6-96P	5.98	4.43e-09	1.82e-06	0.3	0.26	Aortic root size;	chr7:66294786	chr7:66395191~66395286:+
LUAD	cis	rs1823913	0.637	rs4613316	ENSG00000227542.1	AC092614.2	5.98	4.43e-09	1.82e-06	0.32	0.26	Obesity-related traits;	chr2:191326074	chr2:191229165~191246172:-
LUAD	cis	rs7773456	0.576	rs12206194	ENSG00000228412.5	RP4-625H18.2	5.98	4.43e-09	1.82e-06	0.35	0.26	Lupus nephritis in systemic lupus erythematosus;	chr6:19819677	chr6:19802164~19804752:-
LUAD	cis	rs11051970	0.527	rs2388989	ENSG00000274964.1	RP11-817I4.1	-5.98	4.43e-09	1.82e-06	-0.34	-0.26	Response to tocilizumab in rheumatoid arthritis;	chr12:32337341	chr12:32339368~32340724:+
LUAD	cis	rs11051970	0.559	rs2388988	ENSG00000274964.1	RP11-817I4.1	-5.98	4.43e-09	1.82e-06	-0.34	-0.26	Response to tocilizumab in rheumatoid arthritis;	chr12:32337414	chr12:32339368~32340724:+
LUAD	cis	rs11051970	0.559	rs4604975	ENSG00000274964.1	RP11-817I4.1	-5.98	4.43e-09	1.82e-06	-0.34	-0.26	Response to tocilizumab in rheumatoid arthritis;	chr12:32337441	chr12:32339368~32340724:+
LUAD	cis	rs6921919	0.583	rs7759191	ENSG00000204709.4	LINC01556	5.98	4.43e-09	1.82e-06	0.34	0.26	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28943877~28944537:+
LUAD	cis	rs516805	0.748	rs11154077	ENSG00000279453.1	RP3-425C14.4	5.98	4.44e-09	1.82e-06	0.36	0.26	Lymphocyte counts;	chr6:122386994	chr6:122436789~122439223:-
LUAD	cis	rs2439831	0.867	rs935901	ENSG00000205771.5	CATSPER2P1	-5.98	4.44e-09	1.82e-06	-0.55	-0.26	Lung cancer in ever smokers;	chr15:43359058	chr15:43726918~43747094:-
LUAD	cis	rs755249	0.567	rs72661940	ENSG00000228060.1	RP11-69E11.8	-5.98	4.44e-09	1.82e-06	-0.28	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39262975	chr1:39565160~39573203:+
LUAD	cis	rs2288884	0.515	rs73053909	ENSG00000275055.1	CTC-471J1.11	-5.98	4.44e-09	1.82e-06	-0.31	-0.26	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52032864	chr19:52049007~52049754:+
LUAD	cis	rs875971	0.862	rs2420174	ENSG00000237310.1	GS1-124K5.4	-5.98	4.44e-09	1.82e-06	-0.28	-0.26	Aortic root size;	chr7:66180374	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs2420173	ENSG00000237310.1	GS1-124K5.4	-5.98	4.44e-09	1.82e-06	-0.28	-0.26	Aortic root size;	chr7:66180412	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs4718319	ENSG00000237310.1	GS1-124K5.4	-5.98	4.44e-09	1.82e-06	-0.28	-0.26	Aortic root size;	chr7:66187797	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.723	rs28391294	ENSG00000237310.1	GS1-124K5.4	-5.98	4.44e-09	1.82e-06	-0.28	-0.26	Aortic root size;	chr7:66189328	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.83	rs6967708	ENSG00000237310.1	GS1-124K5.4	-5.98	4.44e-09	1.82e-06	-0.28	-0.26	Aortic root size;	chr7:66192326	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.895	rs7782806	ENSG00000237310.1	GS1-124K5.4	-5.98	4.44e-09	1.82e-06	-0.28	-0.26	Aortic root size;	chr7:66192910	chr7:66493706~66495474:+
LUAD	cis	rs453301	0.682	rs2929308	ENSG00000253893.2	FAM85B	5.98	4.44e-09	1.82e-06	0.33	0.26	Joint mobility (Beighton score);	chr8:9226611	chr8:8167819~8226614:-
LUAD	cis	rs6921919	0.583	rs35560946	ENSG00000216901.1	AL022393.7	5.98	4.44e-09	1.82e-06	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28176188~28176674:+
LUAD	cis	rs12468226	0.938	rs115418918	ENSG00000272966.1	RP11-686O6.1	5.98	4.44e-09	1.82e-06	0.46	0.26	Urate levels;	chr2:202315145	chr2:202336739~202337200:+
LUAD	cis	rs12468226	0.938	rs114922024	ENSG00000272966.1	RP11-686O6.1	5.98	4.44e-09	1.82e-06	0.46	0.26	Urate levels;	chr2:202315958	chr2:202336739~202337200:+
LUAD	cis	rs12468226	0.938	rs77261109	ENSG00000272966.1	RP11-686O6.1	5.98	4.44e-09	1.82e-06	0.46	0.26	Urate levels;	chr2:202316233	chr2:202336739~202337200:+
LUAD	cis	rs12468226	0.938	rs12466003	ENSG00000272966.1	RP11-686O6.1	5.98	4.44e-09	1.82e-06	0.46	0.26	Urate levels;	chr2:202317317	chr2:202336739~202337200:+
LUAD	cis	rs12468226	0.938	rs76501067	ENSG00000272966.1	RP11-686O6.1	5.98	4.44e-09	1.82e-06	0.46	0.26	Urate levels;	chr2:202318042	chr2:202336739~202337200:+
LUAD	cis	rs3762637	1	rs7609972	ENSG00000272758.4	RP11-299J3.8	-5.98	4.44e-09	1.82e-06	-0.4	-0.26	LDL cholesterol levels;	chr3:122480579	chr3:122416207~122443180:+
LUAD	cis	rs5753618	0.561	rs13054220	ENSG00000236132.1	CTA-440B3.1	-5.98	4.44e-09	1.82e-06	-0.33	-0.26	Colorectal cancer;	chr22:31308506	chr22:31816379~31817491:-
LUAD	cis	rs5753618	0.561	rs9609254	ENSG00000236132.1	CTA-440B3.1	-5.98	4.44e-09	1.82e-06	-0.33	-0.26	Colorectal cancer;	chr22:31309956	chr22:31816379~31817491:-
LUAD	cis	rs8177876	0.749	rs58144189	ENSG00000261061.1	RP11-303E16.2	-5.98	4.44e-09	1.82e-06	-0.45	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81064478	chr16:81030770~81031485:+
LUAD	cis	rs7712401	0.642	rs17388251	ENSG00000263432.2	RN7SL689P	5.98	4.45e-09	1.82e-06	0.31	0.26	Mean platelet volume;	chr5:123024708	chr5:123022487~123022783:-
LUAD	cis	rs17301013	0.507	rs6696465	ENSG00000227373.4	RP11-160H22.5	-5.98	4.45e-09	1.82e-06	-0.38	-0.26	Systemic lupus erythematosus;	chr1:174769700	chr1:174115300~174160004:-
LUAD	cis	rs4834770	1	rs10034579	ENSG00000245958.5	RP11-33B1.1	-5.98	4.45e-09	1.82e-06	-0.23	-0.26	Blood protein levels;	chr4:119322874	chr4:119454791~119552025:+
LUAD	cis	rs1823913	0.614	rs6434459	ENSG00000227542.1	AC092614.2	-5.98	4.45e-09	1.83e-06	-0.32	-0.26	Obesity-related traits;	chr2:191300886	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.592	rs7588555	ENSG00000227542.1	AC092614.2	-5.98	4.45e-09	1.83e-06	-0.32	-0.26	Obesity-related traits;	chr2:191300912	chr2:191229165~191246172:-
LUAD	cis	rs8062405	1	rs9972693	ENSG00000251417.2	RP11-1348G14.4	-5.98	4.45e-09	1.83e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28802743~28817828:+
LUAD	cis	rs8062405	0.964	rs9972768	ENSG00000251417.2	RP11-1348G14.4	-5.98	4.45e-09	1.83e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28802743~28817828:+
LUAD	cis	rs8062405	0.965	rs56040780	ENSG00000251417.2	RP11-1348G14.4	-5.98	4.45e-09	1.83e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28802743~28817828:+
LUAD	cis	rs8062405	0.965	rs62037363	ENSG00000251417.2	RP11-1348G14.4	-5.98	4.45e-09	1.83e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs7205323	ENSG00000251417.2	RP11-1348G14.4	-5.98	4.45e-09	1.83e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs4788101	ENSG00000251417.2	RP11-1348G14.4	-5.98	4.45e-09	1.83e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs62037365	ENSG00000251417.2	RP11-1348G14.4	-5.98	4.45e-09	1.83e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28802743~28817828:+
LUAD	cis	rs8062405	0.929	rs11150609	ENSG00000251417.2	RP11-1348G14.4	-5.98	4.45e-09	1.83e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28802743~28817828:+
LUAD	cis	rs2980439	0.525	rs1850511	ENSG00000253893.2	FAM85B	-5.98	4.46e-09	1.83e-06	-0.33	-0.26	Neuroticism;	chr8:8312807	chr8:8167819~8226614:-
LUAD	cis	rs6921919	0.583	rs9461459	ENSG00000216901.1	AL022393.7	5.98	4.46e-09	1.83e-06	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs28360638	ENSG00000216901.1	AL022393.7	5.98	4.46e-09	1.83e-06	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28176188~28176674:+
LUAD	cis	rs77204473	1	rs12294191	ENSG00000254851.1	RP11-109L13.1	5.98	4.46e-09	1.83e-06	0.62	0.26	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116889108	chr11:117135528~117138582:+
LUAD	cis	rs270601	0.69	rs162907	ENSG00000233006.5	AC034220.3	-5.98	4.46e-09	1.83e-06	-0.24	-0.26	Acylcarnitine levels;	chr5:132244459	chr5:132311285~132369916:-
LUAD	cis	rs6921919	0.583	rs7764737	ENSG00000216901.1	AL022393.7	5.98	4.46e-09	1.83e-06	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs9461458	ENSG00000216901.1	AL022393.7	5.98	4.46e-09	1.83e-06	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.609	rs9468365	ENSG00000216901.1	AL022393.7	5.98	4.46e-09	1.83e-06	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs1361385	ENSG00000216901.1	AL022393.7	5.98	4.46e-09	1.83e-06	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs1416918	ENSG00000216901.1	AL022393.7	5.98	4.46e-09	1.83e-06	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28176188~28176674:+
LUAD	cis	rs858239	0.601	rs15775	ENSG00000230042.1	AK3P3	-5.98	4.47e-09	1.83e-06	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23129178~23129841:+
LUAD	cis	rs853679	0.517	rs4713150	ENSG00000204709.4	LINC01556	5.98	4.47e-09	1.83e-06	0.37	0.26	Depression;	chr6:28168434	chr6:28943877~28944537:+
LUAD	cis	rs5753618	0.561	rs4820043	ENSG00000236132.1	CTA-440B3.1	5.98	4.47e-09	1.83e-06	0.33	0.26	Colorectal cancer;	chr22:31251108	chr22:31816379~31817491:-
LUAD	cis	rs17301013	0.531	rs1653634	ENSG00000227373.4	RP11-160H22.5	-5.98	4.47e-09	1.83e-06	-0.38	-0.26	Systemic lupus erythematosus;	chr1:174783348	chr1:174115300~174160004:-
LUAD	cis	rs1823913	0.599	rs13020656	ENSG00000280083.1	RP11-317J9.1	-5.98	4.47e-09	1.83e-06	-0.31	-0.26	Obesity-related traits;	chr2:191314197	chr2:191154118~191156070:-
LUAD	cis	rs875971	0.545	rs4718325	ENSG00000226824.5	RP4-756H11.3	-5.98	4.47e-09	1.83e-06	-0.39	-0.26	Aortic root size;	chr7:66215323	chr7:66654538~66669855:+
LUAD	cis	rs72615157	0.612	rs7786505	ENSG00000242294.5	STAG3L5P	5.98	4.47e-09	1.83e-06	0.22	0.26	Lung function (FEV1/FVC);	chr7:100219962	chr7:100336079~100351900:+
LUAD	cis	rs853679	0.882	rs4713139	ENSG00000219392.1	RP1-265C24.5	-5.98	4.48e-09	1.83e-06	-0.45	-0.26	Depression;	chr6:28124907	chr6:28115628~28116551:+
LUAD	cis	rs8177376	0.681	rs678422	ENSG00000254905.1	RP11-712L6.7	5.98	4.48e-09	1.84e-06	0.36	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126330009	chr11:126292922~126294254:-
LUAD	cis	rs77204473	0.744	rs114221654	ENSG00000254851.1	RP11-109L13.1	5.98	4.48e-09	1.84e-06	0.68	0.26	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117109963	chr11:117135528~117138582:+
LUAD	cis	rs2243480	1	rs313809	ENSG00000230295.1	RP11-458F8.2	-5.97	4.48e-09	1.84e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66034996	chr7:66880708~66882981:+
LUAD	cis	rs6921919	0.583	rs3800328	ENSG00000204709.4	LINC01556	5.97	4.49e-09	1.84e-06	0.34	0.26	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.609	rs67211468	ENSG00000204709.4	LINC01556	5.97	4.49e-09	1.84e-06	0.34	0.26	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28943877~28944537:+
LUAD	cis	rs1707322	0.821	rs10749857	ENSG00000234329.1	RP11-767N6.2	5.97	4.49e-09	1.84e-06	0.28	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782471	chr1:45651039~45651826:-
LUAD	cis	rs10050311	0.79	rs55831707	ENSG00000251411.1	RP11-397E7.4	-5.97	4.49e-09	1.84e-06	-0.36	-0.26	Insulin-related traits;	chr4:86918376	chr4:86913266~86914817:-
LUAD	cis	rs7221109	0.677	rs917593	ENSG00000278834.1	RP11-458J1.1	5.97	4.49e-09	1.84e-06	0.3	0.26	Type 1 diabetes;	chr17:40660274	chr17:40648300~40649718:+
LUAD	cis	rs8062405	1	rs62037364	ENSG00000251417.2	RP11-1348G14.4	-5.97	4.49e-09	1.84e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28802743~28817828:+
LUAD	cis	rs6921919	0.583	rs9461459	ENSG00000204709.4	LINC01556	5.97	4.49e-09	1.84e-06	0.33	0.26	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs28360638	ENSG00000204709.4	LINC01556	5.97	4.49e-09	1.84e-06	0.33	0.26	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28943877~28944537:+
LUAD	cis	rs74233809	1	rs12220375	ENSG00000213277.3	MARCKSL1P1	5.97	4.5e-09	1.84e-06	0.44	0.26	Birth weight;	chr10:103141734	chr10:103175554~103176094:+
LUAD	cis	rs6687821	0.681	rs517395	ENSG00000267734.1	RP4-604K5.3	5.97	4.5e-09	1.84e-06	0.35	0.26	Yeast infection;	chr1:86854562	chr1:86932199~86934891:-
LUAD	cis	rs496547	0.719	rs472641	ENSG00000255239.1	AP002954.6	5.97	4.5e-09	1.84e-06	0.32	0.26	Hip minimal joint space width;	chr11:118746835	chr11:118688039~118690600:-
LUAD	cis	rs7017914	0.905	rs4738105	ENSG00000223220.1	Y_RNA	-5.97	4.51e-09	1.85e-06	-0.3	-0.26	Bone mineral density;	chr8:71046683	chr8:70780914~70781008:-
LUAD	cis	rs9549367	0.789	rs3764124	ENSG00000269125.1	RP11-98F14.11	-5.97	4.51e-09	1.85e-06	-0.33	-0.26	Platelet distribution width;	chr13:113243006	chr13:113165002~113165183:-
LUAD	cis	rs17301013	0.606	rs12064743	ENSG00000227373.4	RP11-160H22.5	5.97	4.51e-09	1.85e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174496646	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs7536102	ENSG00000227373.4	RP11-160H22.5	5.97	4.51e-09	1.85e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174496801	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs7522253	ENSG00000227373.4	RP11-160H22.5	5.97	4.51e-09	1.85e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174496980	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs4652500	ENSG00000227373.4	RP11-160H22.5	5.97	4.51e-09	1.85e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174500656	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.507	rs12071794	ENSG00000227373.4	RP11-160H22.5	5.97	4.51e-09	1.85e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174500767	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.556	rs7535845	ENSG00000227373.4	RP11-160H22.5	5.97	4.51e-09	1.85e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174502672	chr1:174115300~174160004:-
LUAD	cis	rs3779195	0.585	rs58699591	ENSG00000272950.1	RP11-307C18.1	-5.97	4.51e-09	1.85e-06	-0.45	-0.26	Sex hormone-binding globulin levels;	chr7:98247392	chr7:98322853~98323430:+
LUAD	cis	rs1387259	0.839	rs7487682	ENSG00000240399.1	RP1-228P16.1	-5.97	4.51e-09	1.85e-06	-0.25	-0.26	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48185882	chr12:48054813~48055591:-
LUAD	cis	rs17301013	0.606	rs1793307	ENSG00000227373.4	RP11-160H22.5	-5.97	4.51e-09	1.85e-06	-0.36	-0.26	Systemic lupus erythematosus;	chr1:174758716	chr1:174115300~174160004:-
LUAD	cis	rs7923609	0.936	rs10761778	ENSG00000232075.1	MRPL35P2	-5.97	4.51e-09	1.85e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63514022	chr10:63634317~63634827:-
LUAD	cis	rs5753618	0.561	rs9606830	ENSG00000236132.1	CTA-440B3.1	-5.97	4.51e-09	1.85e-06	-0.33	-0.26	Colorectal cancer;	chr22:31321813	chr22:31816379~31817491:-
LUAD	cis	rs17301013	0.606	rs1618408	ENSG00000227373.4	RP11-160H22.5	-5.97	4.52e-09	1.85e-06	-0.36	-0.26	Systemic lupus erythematosus;	chr1:174777402	chr1:174115300~174160004:-
LUAD	cis	rs2243480	0.908	rs55876148	ENSG00000230295.1	RP11-458F8.2	-5.97	4.52e-09	1.85e-06	-0.33	-0.26	Diabetic kidney disease;	chr7:65914813	chr7:66880708~66882981:+
LUAD	cis	rs507080	0.501	rs625735	ENSG00000278376.1	RP11-158I9.8	-5.97	4.53e-09	1.85e-06	-0.27	-0.26	Serum metabolite levels;	chr11:118704710	chr11:118791254~118793137:+
LUAD	cis	rs4972806	0.849	rs2113561	ENSG00000226363.3	HAGLROS	-5.97	4.53e-09	1.85e-06	-0.33	-0.26	IgG glycosylation;	chr2:176166197	chr2:176177717~176179008:+
LUAD	cis	rs77204473	1	rs17120157	ENSG00000254851.1	RP11-109L13.1	-5.97	4.53e-09	1.85e-06	-0.64	-0.26	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116941912	chr11:117135528~117138582:+
LUAD	cis	rs1823913	0.599	rs2124093	ENSG00000280083.1	RP11-317J9.1	-5.97	4.53e-09	1.85e-06	-0.31	-0.26	Obesity-related traits;	chr2:191288280	chr2:191154118~191156070:-
LUAD	cis	rs10129255	0.518	rs10150460	ENSG00000211967.3	IGHV3-53	5.97	4.53e-09	1.86e-06	0.19	0.26	Kawasaki disease;	chr14:106677179	chr14:106592676~106593347:-
LUAD	cis	rs227932	0.541	rs78177212	ENSG00000234286.1	AC006026.13	-5.97	4.55e-09	1.86e-06	-0.44	-0.26	Schizophrenia;	chr7:23770500	chr7:23680195~23680786:-
LUAD	cis	rs4713118	0.629	rs203890	ENSG00000204709.4	LINC01556	5.97	4.55e-09	1.86e-06	0.36	0.26	Parkinson's disease;	chr6:28054470	chr6:28943877~28944537:+
LUAD	cis	rs62432291	0.681	rs2932987	ENSG00000235086.1	FNDC1-IT1	5.97	4.55e-09	1.86e-06	0.45	0.26	Joint mobility (Beighton score);	chr6:159234641	chr6:159240786~159243329:+
LUAD	cis	rs67311347	1	rs9841335	ENSG00000223797.4	ENTPD3-AS1	5.97	4.55e-09	1.86e-06	0.27	0.26	Renal cell carcinoma;	chr3:40434367	chr3:40313802~40453329:-
LUAD	cis	rs11157436	0.958	rs764160	ENSG00000211812.1	TRAV26-2	-5.97	4.55e-09	1.86e-06	-0.3	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22231098	chr14:22202583~22203368:+
LUAD	cis	rs2765539	0.561	rs2645290	ENSG00000226172.2	RP4-712E4.1	5.97	4.55e-09	1.86e-06	0.33	0.26	Waist-hip ratio;	chr1:118929285	chr1:119000344~119001392:-
LUAD	cis	rs1426063	0.614	rs79750906	ENSG00000249717.1	RP11-44F21.3	5.97	4.56e-09	1.86e-06	0.48	0.26	QT interval;	chr4:75139193	chr4:74955974~74970362:-
LUAD	cis	rs7221109	0.56	rs2469818	ENSG00000278834.1	RP11-458J1.1	-5.97	4.56e-09	1.86e-06	-0.31	-0.26	Type 1 diabetes;	chr17:40708479	chr17:40648300~40649718:+
LUAD	cis	rs11157436	1	rs12587166	ENSG00000211812.1	TRAV26-2	-5.97	4.56e-09	1.86e-06	-0.3	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22165492	chr14:22202583~22203368:+
LUAD	cis	rs7923609	0.934	rs7923544	ENSG00000232075.1	MRPL35P2	-5.97	4.56e-09	1.87e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63422496	chr10:63634317~63634827:-
LUAD	cis	rs875971	0.545	rs7783889	ENSG00000226824.5	RP4-756H11.3	-5.97	4.56e-09	1.87e-06	-0.38	-0.26	Aortic root size;	chr7:66283366	chr7:66654538~66669855:+
LUAD	cis	rs3738443	0.868	rs60698393	ENSG00000259865.1	RP11-488L18.10	5.97	4.56e-09	1.87e-06	0.27	0.26	Alcohol dependence;	chr1:247198135	chr1:247187281~247188526:-
LUAD	cis	rs1426063	0.668	rs6534595	ENSG00000249717.1	RP11-44F21.3	5.97	4.57e-09	1.87e-06	0.36	0.26	QT interval;	chr4:75104432	chr4:74955974~74970362:-
LUAD	cis	rs2404602	0.66	rs11852777	ENSG00000259422.1	RP11-593F23.1	-5.97	4.58e-09	1.87e-06	-0.35	-0.26	Blood metabolite levels;	chr15:76637451	chr15:76174891~76181486:-
LUAD	cis	rs7849270	1	rs746489	ENSG00000268707.1	RP11-247A12.7	-5.97	4.58e-09	1.87e-06	-0.3	-0.26	Blood metabolite ratios;	chr9:129147814	chr9:129170434~129170940:+
LUAD	cis	rs7849270	0.959	rs913275	ENSG00000268707.1	RP11-247A12.7	-5.97	4.58e-09	1.87e-06	-0.3	-0.26	Blood metabolite ratios;	chr9:129148365	chr9:129170434~129170940:+
LUAD	cis	rs7849270	1	rs7869804	ENSG00000268707.1	RP11-247A12.7	-5.97	4.58e-09	1.87e-06	-0.3	-0.26	Blood metabolite ratios;	chr9:129150865	chr9:129170434~129170940:+
LUAD	cis	rs17301013	0.507	rs3118990	ENSG00000227373.4	RP11-160H22.5	-5.97	4.58e-09	1.87e-06	-0.38	-0.26	Systemic lupus erythematosus;	chr1:174818586	chr1:174115300~174160004:-
LUAD	cis	rs875971	0.545	rs1796219	ENSG00000226824.5	RP4-756H11.3	5.97	4.58e-09	1.87e-06	0.39	0.26	Aortic root size;	chr7:66645977	chr7:66654538~66669855:+
LUAD	cis	rs2117029	0.619	rs11168862	ENSG00000258017.1	RP11-386G11.10	-5.97	4.59e-09	1.88e-06	-0.33	-0.26	Intelligence (multi-trait analysis);	chr12:49112175	chr12:49127782~49147869:+
LUAD	cis	rs875971	0.862	rs10263690	ENSG00000222364.1	RNU6-96P	5.97	4.59e-09	1.88e-06	0.3	0.26	Aortic root size;	chr7:66301466	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs10250544	ENSG00000222364.1	RNU6-96P	5.97	4.59e-09	1.88e-06	0.3	0.26	Aortic root size;	chr7:66301574	chr7:66395191~66395286:+
LUAD	cis	rs1816752	0.935	rs4770676	ENSG00000273628.1	RP11-756A22.7	5.97	4.59e-09	1.88e-06	0.31	0.26	Obesity-related traits;	chr13:24429745	chr13:24933006~24936796:+
LUAD	cis	rs9847710	0.683	rs2581818	ENSG00000242142.1	SERBP1P3	5.97	4.59e-09	1.88e-06	0.3	0.26	Ulcerative colitis;	chr3:53037636	chr3:53064283~53065091:-
LUAD	cis	rs2117029	0.619	rs10747562	ENSG00000258017.1	RP11-386G11.10	-5.97	4.59e-09	1.88e-06	-0.33	-0.26	Intelligence (multi-trait analysis);	chr12:49111401	chr12:49127782~49147869:+
LUAD	cis	rs801193	0.548	rs2109297	ENSG00000237310.1	GS1-124K5.4	-5.97	4.6e-09	1.88e-06	-0.29	-0.26	Aortic root size;	chr7:66657397	chr7:66493706~66495474:+
LUAD	cis	rs801193	0.591	rs721717	ENSG00000237310.1	GS1-124K5.4	-5.97	4.6e-09	1.88e-06	-0.29	-0.26	Aortic root size;	chr7:66665305	chr7:66493706~66495474:+
LUAD	cis	rs801193	0.569	rs6951302	ENSG00000237310.1	GS1-124K5.4	-5.97	4.6e-09	1.88e-06	-0.29	-0.26	Aortic root size;	chr7:66667525	chr7:66493706~66495474:+
LUAD	cis	rs10214930	1	rs1859328	ENSG00000235574.1	AC073150.6	-5.97	4.6e-09	1.88e-06	-0.38	-0.26	Hypospadias;	chr7:27838458	chr7:27491682~27492765:-
LUAD	cis	rs71403859	0.502	rs8051974	ENSG00000260886.1	TAT-AS1	5.97	4.6e-09	1.88e-06	0.4	0.26	Post bronchodilator FEV1;	chr16:71454868	chr16:71565789~71578187:+
LUAD	cis	rs8062405	1	rs55991577	ENSG00000251417.2	RP11-1348G14.4	-5.97	4.61e-09	1.88e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs56358680	ENSG00000251417.2	RP11-1348G14.4	-5.97	4.61e-09	1.88e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs62036626	ENSG00000251417.2	RP11-1348G14.4	-5.97	4.61e-09	1.88e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs62036657	ENSG00000251417.2	RP11-1348G14.4	-5.97	4.61e-09	1.88e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs12444171	ENSG00000251417.2	RP11-1348G14.4	-5.97	4.61e-09	1.88e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs56404918	ENSG00000251417.2	RP11-1348G14.4	-5.97	4.61e-09	1.88e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs55719896	ENSG00000251417.2	RP11-1348G14.4	-5.97	4.61e-09	1.88e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs55830740	ENSG00000251417.2	RP11-1348G14.4	-5.97	4.61e-09	1.88e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28802743~28817828:+
LUAD	cis	rs172166	0.637	rs1233708	ENSG00000219392.1	RP1-265C24.5	-5.97	4.61e-09	1.89e-06	-0.33	-0.26	Cardiac Troponin-T levels;	chr6:28205441	chr6:28115628~28116551:+
LUAD	cis	rs11690935	0.55	rs62183785	ENSG00000228389.1	AC068039.4	-5.97	4.61e-09	1.89e-06	-0.28	-0.26	Schizophrenia;	chr2:172002068	chr2:171773482~171775844:+
LUAD	cis	rs1823913	0.637	rs1947456	ENSG00000280083.1	RP11-317J9.1	5.97	4.62e-09	1.89e-06	0.31	0.26	Obesity-related traits;	chr2:191298759	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.614	rs11693878	ENSG00000280083.1	RP11-317J9.1	5.97	4.62e-09	1.89e-06	0.31	0.26	Obesity-related traits;	chr2:191299399	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.637	rs10931494	ENSG00000280083.1	RP11-317J9.1	5.97	4.62e-09	1.89e-06	0.31	0.26	Obesity-related traits;	chr2:191299442	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.637	rs10931495	ENSG00000280083.1	RP11-317J9.1	5.97	4.62e-09	1.89e-06	0.31	0.26	Obesity-related traits;	chr2:191299447	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.637	rs12623156	ENSG00000280083.1	RP11-317J9.1	5.97	4.62e-09	1.89e-06	0.31	0.26	Obesity-related traits;	chr2:191299661	chr2:191154118~191156070:-
LUAD	cis	rs6921919	0.583	rs9468355	ENSG00000216901.1	AL022393.7	5.97	4.62e-09	1.89e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28374100	chr6:28176188~28176674:+
LUAD	cis	rs875971	0.862	rs949930	ENSG00000222364.1	RNU6-96P	5.97	4.62e-09	1.89e-06	0.3	0.26	Aortic root size;	chr7:66301835	chr7:66395191~66395286:+
LUAD	cis	rs7945705	0.967	rs56316046	ENSG00000254860.4	TMEM9B-AS1	-5.97	4.62e-09	1.89e-06	-0.3	-0.26	Hemoglobin concentration;	chr11:8855051	chr11:8964675~8977527:+
LUAD	cis	rs3738443	0.52	rs6699577	ENSG00000259865.1	RP11-488L18.10	5.97	4.62e-09	1.89e-06	0.23	0.26	Alcohol dependence;	chr1:247224152	chr1:247187281~247188526:-
LUAD	cis	rs10129255	0.518	rs7143784	ENSG00000211967.3	IGHV3-53	-5.97	4.62e-09	1.89e-06	-0.19	-0.26	Kawasaki disease;	chr14:106687277	chr14:106592676~106593347:-
LUAD	cis	rs367615	0.68	rs816542	ENSG00000249476.1	CTD-2587M2.1	5.97	4.62e-09	1.89e-06	0.34	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109646923	chr5:109237120~109326369:-
LUAD	cis	rs9543976	0.623	rs8192756	ENSG00000261553.4	RP11-29G8.3	5.97	4.63e-09	1.89e-06	0.34	0.26	Diabetic retinopathy;	chr13:75590802	chr13:75549773~75807120:+
LUAD	cis	rs9543976	0.623	rs3783028	ENSG00000261553.4	RP11-29G8.3	5.97	4.63e-09	1.89e-06	0.34	0.26	Diabetic retinopathy;	chr13:75591146	chr13:75549773~75807120:+
LUAD	cis	rs9543976	0.623	rs7139740	ENSG00000261553.4	RP11-29G8.3	5.97	4.63e-09	1.89e-06	0.34	0.26	Diabetic retinopathy;	chr13:75592806	chr13:75549773~75807120:+
LUAD	cis	rs7927592	0.913	rs7118897	ENSG00000212093.1	AP000807.1	5.97	4.63e-09	1.89e-06	0.29	0.26	Total body bone mineral density;	chr11:68593212	chr11:68506083~68506166:-
LUAD	cis	rs1823913	0.599	rs13027086	ENSG00000280083.1	RP11-317J9.1	-5.97	4.63e-09	1.89e-06	-0.32	-0.26	Obesity-related traits;	chr2:191294058	chr2:191154118~191156070:-
LUAD	cis	rs12908161	0.959	rs12906348	ENSG00000259728.4	LINC00933	5.97	4.63e-09	1.89e-06	0.38	0.26	Schizophrenia;	chr15:84786190	chr15:84570649~84580175:+
LUAD	cis	rs11690935	0.531	rs62183800	ENSG00000228389.1	AC068039.4	-5.97	4.63e-09	1.89e-06	-0.28	-0.26	Schizophrenia;	chr2:172002365	chr2:171773482~171775844:+
LUAD	cis	rs11690935	0.55	rs62183801	ENSG00000228389.1	AC068039.4	-5.97	4.63e-09	1.89e-06	-0.28	-0.26	Schizophrenia;	chr2:172002567	chr2:171773482~171775844:+
LUAD	cis	rs11690935	0.55	rs6718013	ENSG00000228389.1	AC068039.4	-5.97	4.63e-09	1.89e-06	-0.28	-0.26	Schizophrenia;	chr2:172004277	chr2:171773482~171775844:+
LUAD	cis	rs7849270	1	rs7849270	ENSG00000268707.1	RP11-247A12.7	-5.97	4.63e-09	1.89e-06	-0.3	-0.26	Blood metabolite ratios;	chr9:129112362	chr9:129170434~129170940:+
LUAD	cis	rs1707322	0.721	rs10430124	ENSG00000234329.1	RP11-767N6.2	5.97	4.64e-09	1.89e-06	0.28	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755945	chr1:45651039~45651826:-
LUAD	cis	rs875971	0.545	rs221986	ENSG00000237310.1	GS1-124K5.4	-5.97	4.64e-09	1.9e-06	-0.33	-0.26	Aortic root size;	chr7:66105323	chr7:66493706~66495474:+
LUAD	cis	rs2404602	0.552	rs11636612	ENSG00000259422.1	RP11-593F23.1	-5.97	4.64e-09	1.9e-06	-0.38	-0.26	Blood metabolite levels;	chr15:76667189	chr15:76174891~76181486:-
LUAD	cis	rs66887589	0.616	rs1052633	ENSG00000248280.1	RP11-33B1.2	5.97	4.65e-09	1.9e-06	0.29	0.26	Diastolic blood pressure;	chr4:119294159	chr4:119440561~119450157:-
LUAD	cis	rs2255336	0.938	rs2617172	ENSG00000245648.1	RP11-277P12.20	5.97	4.67e-09	1.91e-06	0.4	0.26	Blood protein levels;	chr12:10409887	chr12:10363769~10398506:+
LUAD	cis	rs853679	0.55	rs1150692	ENSG00000204709.4	LINC01556	5.97	4.67e-09	1.91e-06	0.36	0.26	Depression;	chr6:28206179	chr6:28943877~28944537:+
LUAD	cis	rs950169	1	rs950169	ENSG00000259728.4	LINC00933	5.97	4.67e-09	1.91e-06	0.4	0.26	Schizophrenia;	chr15:84037709	chr15:84570649~84580175:+
LUAD	cis	rs728616	0.764	rs11201025	ENSG00000225484.5	NUTM2B-AS1	-5.97	4.67e-09	1.91e-06	-0.47	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79982402	chr10:79663088~79826594:-
LUAD	cis	rs67311347	0.866	rs2371183	ENSG00000223797.4	ENTPD3-AS1	-5.97	4.67e-09	1.91e-06	-0.27	-0.26	Renal cell carcinoma;	chr3:40292756	chr3:40313802~40453329:-
LUAD	cis	rs2439831	0.85	rs2228368	ENSG00000205771.5	CATSPER2P1	-5.97	4.68e-09	1.91e-06	-0.51	-0.26	Lung cancer in ever smokers;	chr15:43809812	chr15:43726918~43747094:-
LUAD	cis	rs2243480	1	rs160634	ENSG00000273142.1	RP11-458F8.4	5.97	4.68e-09	1.91e-06	0.26	0.26	Diabetic kidney disease;	chr7:66063677	chr7:66902857~66906297:+
LUAD	cis	rs7849270	0.959	rs7039031	ENSG00000268707.1	RP11-247A12.7	-5.97	4.68e-09	1.91e-06	-0.29	-0.26	Blood metabolite ratios;	chr9:129137116	chr9:129170434~129170940:+
LUAD	cis	rs17023223	0.537	rs3936018	ENSG00000231365.4	RP11-418J17.1	-5.97	4.68e-09	1.91e-06	-0.37	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119139747	chr1:119140396~119275973:+
LUAD	cis	rs17482078	0.885	rs10045403	ENSG00000248734.2	CTD-2260A17.1	5.97	4.69e-09	1.91e-06	0.31	0.26	Behcet's disease;Blood protein levels;	chr5:96812030	chr5:96784777~96785999:+
LUAD	cis	rs66887589	0.934	rs7672519	ENSG00000248280.1	RP11-33B1.2	-5.97	4.69e-09	1.92e-06	-0.29	-0.26	Diastolic blood pressure;	chr4:119622957	chr4:119440561~119450157:-
LUAD	cis	rs875971	0.862	rs10274883	ENSG00000222364.1	RNU6-96P	5.97	4.7e-09	1.92e-06	0.3	0.26	Aortic root size;	chr7:66651104	chr7:66395191~66395286:+
LUAD	cis	rs801193	0.569	rs881285	ENSG00000222364.1	RNU6-96P	5.97	4.7e-09	1.92e-06	0.3	0.26	Aortic root size;	chr7:66654433	chr7:66395191~66395286:+
LUAD	cis	rs801193	0.569	rs3846973	ENSG00000222364.1	RNU6-96P	5.97	4.7e-09	1.92e-06	0.3	0.26	Aortic root size;	chr7:66655048	chr7:66395191~66395286:+
LUAD	cis	rs801193	0.569	rs2013908	ENSG00000222364.1	RNU6-96P	5.97	4.7e-09	1.92e-06	0.3	0.26	Aortic root size;	chr7:66656082	chr7:66395191~66395286:+
LUAD	cis	rs2212361	0.558	rs11020815	ENSG00000255893.1	RP11-685N10.1	-5.97	4.7e-09	1.92e-06	-0.34	-0.26	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94535890	chr11:94472908~94473570:-
LUAD	cis	rs62025270	0.547	rs1026722	ENSG00000202081.1	RNU6-1280P	5.97	4.71e-09	1.92e-06	0.33	0.26	Idiopathic pulmonary fibrosis;	chr15:85576168	chr15:85651522~85651628:-
LUAD	cis	rs11098499	0.754	rs9991959	ENSG00000248280.1	RP11-33B1.2	-5.97	4.71e-09	1.92e-06	-0.32	-0.26	Corneal astigmatism;	chr4:119332618	chr4:119440561~119450157:-
LUAD	cis	rs7182621	0.639	rs34701806	ENSG00000259363.4	CTD-2054N24.2	-5.97	4.71e-09	1.92e-06	-0.35	-0.26	Colonoscopy-negative controls vs population controls;	chr15:99872953	chr15:99807023~99877148:+
LUAD	cis	rs1075265	0.87	rs6749817	ENSG00000233266.1	HMGB1P31	5.97	4.71e-09	1.92e-06	0.33	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54032396	chr2:54051334~54051760:+
LUAD	cis	rs6687821	0.515	rs61800752	ENSG00000267734.1	RP4-604K5.3	5.97	4.71e-09	1.92e-06	0.33	0.26	Yeast infection;	chr1:86932001	chr1:86932199~86934891:-
LUAD	cis	rs6687821	0.515	rs56291917	ENSG00000267734.1	RP4-604K5.3	5.97	4.71e-09	1.92e-06	0.33	0.26	Yeast infection;	chr1:86934926	chr1:86932199~86934891:-
LUAD	cis	rs10754283	0.901	rs10922683	ENSG00000231613.1	RP5-943J3.1	5.97	4.72e-09	1.92e-06	0.27	0.26	Amyotrophic lateral sclerosis (sporadic);	chr1:89650509	chr1:89788914~89790492:+
LUAD	cis	rs853679	0.517	rs1340004	ENSG00000204709.4	LINC01556	5.97	4.72e-09	1.93e-06	0.37	0.26	Depression;	chr6:28135913	chr6:28943877~28944537:+
LUAD	cis	rs1816752	1	rs9511265	ENSG00000273628.1	RP11-756A22.7	5.97	4.73e-09	1.93e-06	0.31	0.26	Obesity-related traits;	chr13:24438221	chr13:24933006~24936796:+
LUAD	cis	rs77204473	1	rs35184536	ENSG00000254851.1	RP11-109L13.1	5.97	4.73e-09	1.93e-06	0.7	0.26	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116908097	chr11:117135528~117138582:+
LUAD	cis	rs4660456	0.504	rs587064	ENSG00000237899.1	RP4-739H11.3	5.97	4.73e-09	1.93e-06	0.37	0.26	Platelet count;	chr1:40640238	chr1:40669089~40687588:-
LUAD	cis	rs293748	0.571	rs13181187	ENSG00000250155.1	CTD-2353F22.1	-5.97	4.73e-09	1.93e-06	-0.33	-0.26	Obesity-related traits;	chr5:37239275	chr5:36666214~36725195:-
LUAD	cis	rs9640161	0.83	rs12703061	ENSG00000261305.1	RP4-584D14.7	5.97	4.73e-09	1.93e-06	0.39	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150365456	chr7:150341771~150342607:+
LUAD	cis	rs7923609	0.871	rs6479905	ENSG00000232075.1	MRPL35P2	5.97	4.73e-09	1.93e-06	0.31	0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63555471	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.746	rs7070761	ENSG00000232075.1	MRPL35P2	5.97	4.73e-09	1.93e-06	0.31	0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63557296	chr10:63634317~63634827:-
LUAD	cis	rs11971779	0.68	rs11760420	ENSG00000273391.1	RP11-634H22.1	5.97	4.74e-09	1.93e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139430022	chr7:139359032~139359566:-
LUAD	cis	rs9595908	0.869	rs7983457	ENSG00000212293.1	SNORA16	-5.97	4.74e-09	1.93e-06	-0.28	-0.26	Body mass index;	chr13:32631797	chr13:32420390~32420516:-
LUAD	cis	rs9309473	1	rs1403284	ENSG00000163016.8	ALMS1P	-5.96	4.75e-09	1.94e-06	-0.33	-0.26	Metabolite levels;	chr2:73499535	chr2:73644919~73685576:+
LUAD	cis	rs8062405	0.931	rs12928404	ENSG00000251417.2	RP11-1348G14.4	-5.96	4.76e-09	1.94e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835925	chr16:28802743~28817828:+
LUAD	cis	rs875971	0.545	rs75840613	ENSG00000226824.5	RP4-756H11.3	-5.96	4.76e-09	1.94e-06	-0.38	-0.26	Aortic root size;	chr7:66376399	chr7:66654538~66669855:+
LUAD	cis	rs2288884	0.636	rs73066154	ENSG00000275055.1	CTC-471J1.11	-5.96	4.76e-09	1.94e-06	-0.33	-0.26	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52060240	chr19:52049007~52049754:+
LUAD	cis	rs2404602	0.735	rs4886798	ENSG00000259422.1	RP11-593F23.1	5.96	4.76e-09	1.94e-06	0.34	0.26	Blood metabolite levels;	chr15:76380885	chr15:76174891~76181486:-
LUAD	cis	rs7615952	0.688	rs17334074	ENSG00000171084.14	FAM86JP	-5.96	4.76e-09	1.94e-06	-0.37	-0.26	Blood pressure (smoking interaction);	chr3:125821617	chr3:125916620~125930024:+
LUAD	cis	rs66887589	0.934	rs6817317	ENSG00000248280.1	RP11-33B1.2	-5.96	4.76e-09	1.94e-06	-0.29	-0.26	Diastolic blood pressure;	chr4:119621672	chr4:119440561~119450157:-
LUAD	cis	rs147858478	1	rs147858478	ENSG00000233006.5	AC034220.3	5.96	4.77e-09	1.94e-06	0.23	0.26	High light scatter reticulocyte percentage of red cells;	chr5:132347099	chr5:132311285~132369916:-
LUAD	cis	rs11157436	1	rs72638482	ENSG00000211812.1	TRAV26-2	-5.96	4.77e-09	1.94e-06	-0.3	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22153322	chr14:22202583~22203368:+
LUAD	cis	rs1823913	0.637	rs1349938	ENSG00000280083.1	RP11-317J9.1	5.96	4.77e-09	1.94e-06	0.31	0.26	Obesity-related traits;	chr2:191299970	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.592	rs1349939	ENSG00000280083.1	RP11-317J9.1	5.96	4.77e-09	1.94e-06	0.31	0.26	Obesity-related traits;	chr2:191300079	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.637	rs4853581	ENSG00000280083.1	RP11-317J9.1	5.96	4.77e-09	1.94e-06	0.31	0.26	Obesity-related traits;	chr2:191301533	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.614	rs7565987	ENSG00000280083.1	RP11-317J9.1	5.96	4.77e-09	1.94e-06	0.31	0.26	Obesity-related traits;	chr2:191301815	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.614	rs1973067	ENSG00000280083.1	RP11-317J9.1	5.96	4.77e-09	1.94e-06	0.31	0.26	Obesity-related traits;	chr2:191302021	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.637	rs1973068	ENSG00000280083.1	RP11-317J9.1	5.96	4.77e-09	1.94e-06	0.31	0.26	Obesity-related traits;	chr2:191302227	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.637	rs7569231	ENSG00000280083.1	RP11-317J9.1	5.96	4.77e-09	1.94e-06	0.31	0.26	Obesity-related traits;	chr2:191302373	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.637	rs6434461	ENSG00000280083.1	RP11-317J9.1	5.96	4.77e-09	1.94e-06	0.31	0.26	Obesity-related traits;	chr2:191302661	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.614	rs6434462	ENSG00000280083.1	RP11-317J9.1	5.96	4.77e-09	1.94e-06	0.31	0.26	Obesity-related traits;	chr2:191302705	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.637	rs6750360	ENSG00000280083.1	RP11-317J9.1	5.96	4.77e-09	1.94e-06	0.31	0.26	Obesity-related traits;	chr2:191303089	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.637	rs11677694	ENSG00000280083.1	RP11-317J9.1	5.96	4.77e-09	1.94e-06	0.31	0.26	Obesity-related traits;	chr2:191303203	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.571	rs6737307	ENSG00000280083.1	RP11-317J9.1	5.96	4.77e-09	1.94e-06	0.31	0.26	Obesity-related traits;	chr2:191303247	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.637	rs4853582	ENSG00000280083.1	RP11-317J9.1	5.96	4.77e-09	1.94e-06	0.31	0.26	Obesity-related traits;	chr2:191303483	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.637	rs35200176	ENSG00000280083.1	RP11-317J9.1	5.96	4.77e-09	1.94e-06	0.31	0.26	Obesity-related traits;	chr2:191303534	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.637	rs17348013	ENSG00000280083.1	RP11-317J9.1	5.96	4.77e-09	1.94e-06	0.31	0.26	Obesity-related traits;	chr2:191303726	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.614	rs12616167	ENSG00000227542.1	AC092614.2	-5.96	4.77e-09	1.94e-06	-0.32	-0.26	Obesity-related traits;	chr2:191311274	chr2:191229165~191246172:-
LUAD	cis	rs293748	0.771	rs293746	ENSG00000250155.1	CTD-2353F22.1	-5.96	4.77e-09	1.95e-06	-0.37	-0.26	Obesity-related traits;	chr5:36895168	chr5:36666214~36725195:-
LUAD	cis	rs293748	0.771	rs292160	ENSG00000250155.1	CTD-2353F22.1	-5.96	4.77e-09	1.95e-06	-0.37	-0.26	Obesity-related traits;	chr5:36895971	chr5:36666214~36725195:-
LUAD	cis	rs11096990	0.855	rs2566183	ENSG00000249207.1	RP11-360F5.1	5.96	4.78e-09	1.95e-06	0.31	0.26	Cognitive function;	chr4:39162288	chr4:39112677~39126818:-
LUAD	cis	rs4718428	0.672	rs4718412	ENSG00000273142.1	RP11-458F8.4	5.96	4.78e-09	1.95e-06	0.2	0.26	Corneal structure;	chr7:66821880	chr7:66902857~66906297:+
LUAD	cis	rs4713118	0.662	rs9380046	ENSG00000204709.4	LINC01556	5.96	4.78e-09	1.95e-06	0.36	0.26	Parkinson's disease;	chr6:28062721	chr6:28943877~28944537:+
LUAD	cis	rs293748	0.515	rs12658479	ENSG00000250155.1	CTD-2353F22.1	5.96	4.78e-09	1.95e-06	0.32	0.26	Obesity-related traits;	chr5:37206519	chr5:36666214~36725195:-
LUAD	cis	rs2255336	0.938	rs61917750	ENSG00000245648.1	RP11-277P12.20	-5.96	4.8e-09	1.95e-06	-0.41	-0.26	Blood protein levels;	chr12:10480824	chr12:10363769~10398506:+
LUAD	cis	rs4142995	0.586	rs2389858	ENSG00000279048.1	RP11-511H23.2	-5.96	4.8e-09	1.95e-06	-0.21	-0.26	HDL cholesterol;HDL cholesterol levels;	chr7:17868507	chr7:17940503~17942922:+
LUAD	cis	rs2439831	0.85	rs10438303	ENSG00000205771.5	CATSPER2P1	-5.96	4.8e-09	1.95e-06	-0.51	-0.26	Lung cancer in ever smokers;	chr15:43724219	chr15:43726918~43747094:-
LUAD	cis	rs875971	0.571	rs160641	ENSG00000237310.1	GS1-124K5.4	-5.96	4.8e-09	1.95e-06	-0.33	-0.26	Aortic root size;	chr7:66112359	chr7:66493706~66495474:+
LUAD	cis	rs11157436	0.958	rs61972231	ENSG00000211812.1	TRAV26-2	-5.96	4.81e-09	1.96e-06	-0.3	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22206508	chr14:22202583~22203368:+
LUAD	cis	rs6142102	0.602	rs6141435	ENSG00000275784.1	RP5-1125A11.6	-5.96	4.81e-09	1.96e-06	-0.28	-0.26	Skin pigmentation;	chr20:33963473	chr20:33989480~33991818:-
LUAD	cis	rs4728142	1	rs4728142	ENSG00000275106.1	RP11-309L24.10	-5.96	4.82e-09	1.96e-06	-0.31	-0.26	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128933913	chr7:128952527~128953316:-
LUAD	cis	rs172166	0.694	rs1631552	ENSG00000204709.4	LINC01556	5.96	4.82e-09	1.96e-06	0.34	0.26	Cardiac Troponin-T levels;	chr6:28121921	chr6:28943877~28944537:+
LUAD	cis	rs2404602	0.684	rs4886819	ENSG00000259422.1	RP11-593F23.1	-5.96	4.82e-09	1.96e-06	-0.35	-0.26	Blood metabolite levels;	chr15:76609357	chr15:76174891~76181486:-
LUAD	cis	rs10214930	0.767	rs6957378	ENSG00000235574.1	AC073150.6	5.96	4.82e-09	1.96e-06	0.35	0.26	Hypospadias;	chr7:27657330	chr7:27491682~27492765:-
LUAD	cis	rs6687821	0.515	rs512912	ENSG00000267734.1	RP4-604K5.3	5.96	4.83e-09	1.96e-06	0.32	0.26	Yeast infection;	chr1:86898359	chr1:86932199~86934891:-
LUAD	cis	rs4664293	0.51	rs2042776	ENSG00000226266.5	AC009961.3	5.96	4.83e-09	1.96e-06	0.43	0.26	Monocyte percentage of white cells;	chr2:159653793	chr2:159670708~159712435:-
LUAD	cis	rs227932	0.571	rs12536173	ENSG00000234286.1	AC006026.13	-5.96	4.83e-09	1.97e-06	-0.45	-0.26	Schizophrenia;	chr7:23834413	chr7:23680195~23680786:-
LUAD	cis	rs4713118	0.869	rs9283880	ENSG00000219392.1	RP1-265C24.5	-5.96	4.84e-09	1.97e-06	-0.35	-0.26	Parkinson's disease;	chr6:27747464	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.869	rs9283881	ENSG00000219392.1	RP1-265C24.5	-5.96	4.84e-09	1.97e-06	-0.35	-0.26	Parkinson's disease;	chr6:27747476	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.869	rs9283882	ENSG00000219392.1	RP1-265C24.5	-5.96	4.84e-09	1.97e-06	-0.35	-0.26	Parkinson's disease;	chr6:27747479	chr6:28115628~28116551:+
LUAD	cis	rs8062405	0.737	rs11861132	ENSG00000251417.2	RP11-1348G14.4	-5.96	4.85e-09	1.97e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28802743~28817828:+
LUAD	cis	rs881375	0.715	rs10818482	ENSG00000226752.6	PSMD5-AS1	5.96	4.85e-09	1.97e-06	0.27	0.26	Rheumatoid arthritis;	chr9:120885807	chr9:120824828~120854385:+
LUAD	cis	rs6504950	0.566	rs7208403	ENSG00000275710.1	RP11-257O5.4	5.96	4.85e-09	1.97e-06	0.31	0.26	Breast cancer;	chr17:54969306	chr17:54964474~54964679:+
LUAD	cis	rs453301	0.571	rs2929454	ENSG00000253893.2	FAM85B	5.96	4.85e-09	1.97e-06	0.33	0.26	Joint mobility (Beighton score);	chr8:9226344	chr8:8167819~8226614:-
LUAD	cis	rs1122900	1	rs1122900	ENSG00000250155.1	CTD-2353F22.1	5.96	4.85e-09	1.97e-06	0.27	0.26	Aggressive periodontitis;	chr5:36689079	chr5:36666214~36725195:-
LUAD	cis	rs2337406	1	rs17112416	ENSG00000211974.3	IGHV2-70	5.96	4.85e-09	1.97e-06	0.35	0.26	Alzheimer's disease (late onset);	chr14:106686773	chr14:106723574~106724093:-
LUAD	cis	rs4803480	0.935	rs1476769	ENSG00000270164.1	LINC01480	-5.96	4.85e-09	1.97e-06	-0.26	-0.26	Schizophrenia;	chr19:41577925	chr19:41535183~41536904:+
LUAD	cis	rs4803480	0.873	rs1476770	ENSG00000270164.1	LINC01480	-5.96	4.85e-09	1.97e-06	-0.26	-0.26	Schizophrenia;	chr19:41578033	chr19:41535183~41536904:+
LUAD	cis	rs7712401	0.601	rs154502	ENSG00000263432.2	RN7SL689P	5.96	4.86e-09	1.98e-06	0.33	0.26	Mean platelet volume;	chr5:122871351	chr5:123022487~123022783:-
LUAD	cis	rs12699921	0.598	rs2723567	ENSG00000279048.1	RP11-511H23.2	-5.96	4.86e-09	1.98e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17858856	chr7:17940503~17942922:+
LUAD	cis	rs1134634	0.52	rs7682586	ENSG00000273133.1	RP11-799M12.2	-5.96	4.87e-09	1.98e-06	-0.38	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15624620	chr4:15563698~15564253:-
LUAD	cis	rs1134634	0.52	rs75099653	ENSG00000273133.1	RP11-799M12.2	-5.96	4.87e-09	1.98e-06	-0.38	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15626397	chr4:15563698~15564253:-
LUAD	cis	rs1134634	0.52	rs12645849	ENSG00000273133.1	RP11-799M12.2	-5.96	4.87e-09	1.98e-06	-0.38	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15627457	chr4:15563698~15564253:-
LUAD	cis	rs7221109	0.585	rs6503547	ENSG00000278834.1	RP11-458J1.1	5.96	4.87e-09	1.98e-06	0.3	0.26	Type 1 diabetes;	chr17:40662956	chr17:40648300~40649718:+
LUAD	cis	rs6687821	0.515	rs507966	ENSG00000267734.1	RP4-604K5.3	5.96	4.87e-09	1.98e-06	0.32	0.26	Yeast infection;	chr1:86904391	chr1:86932199~86934891:-
LUAD	cis	rs2243480	0.901	rs778732	ENSG00000232546.1	RP11-458F8.1	-5.96	4.87e-09	1.98e-06	-0.35	-0.26	Diabetic kidney disease;	chr7:66357373	chr7:66848496~66858136:+
LUAD	cis	rs875971	0.862	rs13536	ENSG00000237310.1	GS1-124K5.4	-5.96	4.88e-09	1.99e-06	-0.29	-0.26	Aortic root size;	chr7:66554203	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs801209	ENSG00000237310.1	GS1-124K5.4	-5.96	4.88e-09	1.99e-06	-0.29	-0.26	Aortic root size;	chr7:66554403	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs801206	ENSG00000237310.1	GS1-124K5.4	-5.96	4.88e-09	1.99e-06	-0.29	-0.26	Aortic root size;	chr7:66556979	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs801204	ENSG00000237310.1	GS1-124K5.4	-5.96	4.88e-09	1.99e-06	-0.29	-0.26	Aortic root size;	chr7:66557934	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs801203	ENSG00000237310.1	GS1-124K5.4	-5.96	4.88e-09	1.99e-06	-0.29	-0.26	Aortic root size;	chr7:66558025	chr7:66493706~66495474:+
LUAD	cis	rs6840258	0.66	rs72667737	ENSG00000251411.1	RP11-397E7.4	-5.96	4.89e-09	1.99e-06	-0.36	-0.26	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86955264	chr4:86913266~86914817:-
LUAD	cis	rs6840258	0.66	rs72667739	ENSG00000251411.1	RP11-397E7.4	-5.96	4.89e-09	1.99e-06	-0.36	-0.26	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86956347	chr4:86913266~86914817:-
LUAD	cis	rs12554020	0.786	rs16909158	ENSG00000227603.1	RP11-165J3.6	5.96	4.89e-09	1.99e-06	0.49	0.26	Schizophrenia;	chr9:93457882	chr9:93435332~93437121:-
LUAD	cis	rs10754283	0.934	rs6661282	ENSG00000231613.1	RP5-943J3.1	5.96	4.89e-09	1.99e-06	0.27	0.26	Amyotrophic lateral sclerosis (sporadic);	chr1:89654433	chr1:89788914~89790492:+
LUAD	cis	rs11051970	0.559	rs11051945	ENSG00000274964.1	RP11-817I4.1	-5.96	4.89e-09	1.99e-06	-0.34	-0.26	Response to tocilizumab in rheumatoid arthritis;	chr12:32336191	chr12:32339368~32340724:+
LUAD	cis	rs11051970	0.559	rs11051946	ENSG00000274964.1	RP11-817I4.1	-5.96	4.89e-09	1.99e-06	-0.34	-0.26	Response to tocilizumab in rheumatoid arthritis;	chr12:32336335	chr12:32339368~32340724:+
LUAD	cis	rs1499614	0.803	rs1796229	ENSG00000230295.1	RP11-458F8.2	-5.96	4.89e-09	1.99e-06	-0.32	-0.26	Gout;	chr7:66654674	chr7:66880708~66882981:+
LUAD	cis	rs1499614	0.901	rs3936	ENSG00000230295.1	RP11-458F8.2	-5.96	4.89e-09	1.99e-06	-0.32	-0.26	Gout;	chr7:66661502	chr7:66880708~66882981:+
LUAD	cis	rs17301013	0.606	rs10912798	ENSG00000227373.4	RP11-160H22.5	5.96	4.89e-09	1.99e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174511420	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.556	rs10912800	ENSG00000227373.4	RP11-160H22.5	5.96	4.89e-09	1.99e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174513939	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs56213002	ENSG00000227373.4	RP11-160H22.5	5.96	4.89e-09	1.99e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174516512	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.541	rs10798319	ENSG00000227373.4	RP11-160H22.5	5.96	4.89e-09	1.99e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174516983	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs9730220	ENSG00000227373.4	RP11-160H22.5	5.96	4.89e-09	1.99e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174519092	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs1407127	ENSG00000227373.4	RP11-160H22.5	-5.96	4.89e-09	1.99e-06	-0.37	-0.26	Systemic lupus erythematosus;	chr1:174119548	chr1:174115300~174160004:-
LUAD	cis	rs875971	0.862	rs9791712	ENSG00000222364.1	RNU6-96P	5.96	4.89e-09	1.99e-06	0.3	0.26	Aortic root size;	chr7:66640176	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs9791713	ENSG00000222364.1	RNU6-96P	5.96	4.89e-09	1.99e-06	0.3	0.26	Aortic root size;	chr7:66640211	chr7:66395191~66395286:+
LUAD	cis	rs948562	0.523	rs12362065	ENSG00000280010.1	AP001350.4	5.96	4.9e-09	1.99e-06	0.41	0.26	Lymphoma;	chr11:58287727	chr11:58627435~58628528:+
LUAD	cis	rs1823913	0.637	rs12622194	ENSG00000280083.1	RP11-317J9.1	5.96	4.9e-09	1.99e-06	0.31	0.26	Obesity-related traits;	chr2:191298680	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.637	rs13019567	ENSG00000280083.1	RP11-317J9.1	5.96	4.9e-09	1.99e-06	0.31	0.26	Obesity-related traits;	chr2:191298736	chr2:191154118~191156070:-
LUAD	cis	rs2243480	1	rs316304	ENSG00000230295.1	RP11-458F8.2	-5.96	4.9e-09	1.99e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66151907	chr7:66880708~66882981:+
LUAD	cis	rs6687821	0.548	rs539915	ENSG00000267734.1	RP4-604K5.3	5.96	4.9e-09	1.99e-06	0.35	0.26	Yeast infection;	chr1:86856101	chr1:86932199~86934891:-
LUAD	cis	rs8040855	0.599	rs2342123	ENSG00000259774.1	RP11-182J1.13	5.96	4.91e-09	2e-06	0.3	0.26	Bulimia nervosa;	chr15:85181918	chr15:84422618~84425882:+
LUAD	cis	rs875971	0.825	rs1129531	ENSG00000237310.1	GS1-124K5.4	-5.96	4.91e-09	2e-06	-0.29	-0.26	Aortic root size;	chr7:66154117	chr7:66493706~66495474:+
LUAD	cis	rs9595908	0.709	rs7988089	ENSG00000212293.1	SNORA16	5.96	4.92e-09	2e-06	0.28	0.26	Body mass index;	chr13:32759738	chr13:32420390~32420516:-
LUAD	cis	rs6921919	0.525	rs11760133	ENSG00000204709.4	LINC01556	5.96	4.92e-09	2e-06	0.34	0.26	Autism spectrum disorder or schizophrenia;	chr6:28418962	chr6:28943877~28944537:+
LUAD	cis	rs11157436	0.958	rs2075494	ENSG00000211812.1	TRAV26-2	-5.96	4.93e-09	2e-06	-0.3	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22202564	chr14:22202583~22203368:+
LUAD	cis	rs11157436	0.958	rs2242542	ENSG00000211812.1	TRAV26-2	-5.96	4.93e-09	2e-06	-0.3	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22203081	chr14:22202583~22203368:+
LUAD	cis	rs1113500	0.933	rs11185255	ENSG00000226822.1	RP11-356N1.2	5.96	4.93e-09	2e-06	0.31	0.26	Growth-regulated protein alpha levels;	chr1:108090569	chr1:108071482~108074519:+
LUAD	cis	rs1113500	0.933	rs11185256	ENSG00000226822.1	RP11-356N1.2	5.96	4.93e-09	2e-06	0.31	0.26	Growth-regulated protein alpha levels;	chr1:108091335	chr1:108071482~108074519:+
LUAD	cis	rs853679	0.517	rs12332979	ENSG00000204709.4	LINC01556	5.96	4.93e-09	2e-06	0.37	0.26	Depression;	chr6:28173770	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs67878650	ENSG00000204709.4	LINC01556	5.96	4.93e-09	2e-06	0.37	0.26	Depression;	chr6:28174809	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.569	rs9348798	ENSG00000204709.4	LINC01556	5.96	4.93e-09	2e-06	0.37	0.26	Depression;	chr6:28175233	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9380065	ENSG00000204709.4	LINC01556	5.96	4.93e-09	2e-06	0.37	0.26	Depression;	chr6:28176973	chr6:28943877~28944537:+
LUAD	cis	rs2283792	0.765	rs5999752	ENSG00000224086.5	LL22NC03-86G7.1	-5.96	4.93e-09	2e-06	-0.25	-0.26	Multiple sclerosis;	chr22:21833894	chr22:21938293~21977632:+
LUAD	cis	rs7181230	0.885	rs28444847	ENSG00000275636.1	RP11-521C20.5	5.96	4.95e-09	2.01e-06	0.35	0.26	Dehydroepiandrosterone sulphate levels;	chr15:40064403	chr15:40078892~40079347:+
LUAD	cis	rs2280018	0.609	rs2941253	ENSG00000188599.16	NPIPP1	-5.96	4.95e-09	2.01e-06	-0.23	-0.26	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15079889	chr16:15104312~15123498:-
LUAD	cis	rs11676348	0.772	rs7422358	ENSG00000261338.2	RP11-378A13.1	-5.96	4.95e-09	2.01e-06	-0.27	-0.26	Ulcerative colitis;	chr2:218088055	chr2:218255319~218257366:+
LUAD	cis	rs7829975	0.514	rs2945873	ENSG00000253893.2	FAM85B	-5.96	4.95e-09	2.01e-06	-0.33	-0.26	Mood instability;	chr8:8402935	chr8:8167819~8226614:-
LUAD	cis	rs35160687	0.712	rs11675942	ENSG00000273080.1	RP11-301O19.1	-5.96	4.95e-09	2.01e-06	-0.29	-0.26	Night sleep phenotypes;	chr2:86280565	chr2:86195590~86196049:+
LUAD	cis	rs35160687	0.688	rs4832033	ENSG00000273080.1	RP11-301O19.1	-5.96	4.95e-09	2.01e-06	-0.29	-0.26	Night sleep phenotypes;	chr2:86281640	chr2:86195590~86196049:+
LUAD	cis	rs1823913	0.637	rs10931497	ENSG00000227542.1	AC092614.2	-5.96	4.95e-09	2.01e-06	-0.32	-0.26	Obesity-related traits;	chr2:191306254	chr2:191229165~191246172:-
LUAD	cis	rs1707322	0.647	rs6686944	ENSG00000234329.1	RP11-767N6.2	5.96	4.95e-09	2.01e-06	0.28	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690636	chr1:45651039~45651826:-
LUAD	cis	rs1823913	0.637	rs12622194	ENSG00000227542.1	AC092614.2	-5.96	4.95e-09	2.01e-06	-0.32	-0.26	Obesity-related traits;	chr2:191298680	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.637	rs13019567	ENSG00000227542.1	AC092614.2	-5.96	4.95e-09	2.01e-06	-0.32	-0.26	Obesity-related traits;	chr2:191298736	chr2:191229165~191246172:-
LUAD	cis	rs66887589	0.616	rs6843509	ENSG00000245958.5	RP11-33B1.1	-5.96	4.95e-09	2.01e-06	-0.21	-0.26	Diastolic blood pressure;	chr4:119299041	chr4:119454791~119552025:+
LUAD	cis	rs2243480	1	rs316321	ENSG00000230295.1	RP11-458F8.2	-5.96	4.95e-09	2.01e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66146626	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs316318	ENSG00000230295.1	RP11-458F8.2	-5.96	4.95e-09	2.01e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66147917	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs316317	ENSG00000230295.1	RP11-458F8.2	-5.96	4.95e-09	2.01e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66148650	chr7:66880708~66882981:+
LUAD	cis	rs17684571	0.751	rs35828379	ENSG00000231441.1	RP11-472M19.2	5.96	4.95e-09	2.01e-06	0.4	0.26	Schizophrenia;	chr6:56839003	chr6:56844002~56864078:+
LUAD	cis	rs897200	0.898	rs7572482	ENSG00000280083.1	RP11-317J9.1	-5.96	4.96e-09	2.02e-06	-0.33	-0.26	Behcet's disease;	chr2:191150346	chr2:191154118~191156070:-
LUAD	cis	rs72615157	0.716	rs75779608	ENSG00000242294.5	STAG3L5P	5.96	4.97e-09	2.02e-06	0.23	0.26	Lung function (FEV1/FVC);	chr7:100171334	chr7:100336079~100351900:+
LUAD	cis	rs853679	0.713	rs200991	ENSG00000219392.1	RP1-265C24.5	5.96	4.97e-09	2.02e-06	0.4	0.26	Depression;	chr6:27847716	chr6:28115628~28116551:+
LUAD	cis	rs2243480	1	rs781150	ENSG00000230295.1	RP11-458F8.2	-5.96	4.97e-09	2.02e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66015986	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs313798	ENSG00000230295.1	RP11-458F8.2	-5.96	4.97e-09	2.02e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66028044	chr7:66880708~66882981:+
LUAD	cis	rs1707322	0.752	rs4660880	ENSG00000234329.1	RP11-767N6.2	5.96	4.97e-09	2.02e-06	0.28	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645368	chr1:45651039~45651826:-
LUAD	cis	rs9532669	0.926	rs4254182	ENSG00000168852.11	TPTE2P5	5.96	4.98e-09	2.02e-06	0.25	0.26	Cervical cancer;	chr13:40879120	chr13:40822296~40921749:-
LUAD	cis	rs1823913	0.599	rs17511445	ENSG00000280083.1	RP11-317J9.1	5.96	4.99e-09	2.03e-06	0.31	0.26	Obesity-related traits;	chr2:191279831	chr2:191154118~191156070:-
LUAD	cis	rs875971	0.862	rs13232191	ENSG00000222364.1	RNU6-96P	-5.96	4.99e-09	2.03e-06	-0.3	-0.26	Aortic root size;	chr7:66521661	chr7:66395191~66395286:+
LUAD	cis	rs6921919	0.583	rs6908137	ENSG00000216901.1	AL022393.7	5.96	4.99e-09	2.03e-06	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28176188~28176674:+
LUAD	cis	rs7181230	0.885	rs17723133	ENSG00000275636.1	RP11-521C20.5	-5.96	5e-09	2.03e-06	-0.35	-0.26	Dehydroepiandrosterone sulphate levels;	chr15:40073217	chr15:40078892~40079347:+
LUAD	cis	rs8177376	0.906	rs8177380	ENSG00000254905.1	RP11-712L6.7	-5.96	5e-09	2.03e-06	-0.36	-0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126295671	chr11:126292922~126294254:-
LUAD	cis	rs4591358	0.773	rs35785148	ENSG00000223466.1	AC064834.2	-5.96	5.01e-09	2.03e-06	-0.36	-0.26	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195516751	chr2:195533035~195538681:+
LUAD	cis	rs7811142	1	rs7783550	ENSG00000242294.5	STAG3L5P	-5.96	5.01e-09	2.04e-06	-0.22	-0.26	Platelet count;	chr7:100390182	chr7:100336079~100351900:+
LUAD	cis	rs7727544	0.636	rs2631365	ENSG00000233006.5	AC034220.3	-5.96	5.01e-09	2.04e-06	-0.24	-0.26	Blood metabolite levels;	chr5:132370257	chr5:132311285~132369916:-
LUAD	cis	rs7923609	0.871	rs2393984	ENSG00000232075.1	MRPL35P2	5.96	5.02e-09	2.04e-06	0.31	0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63555211	chr10:63634317~63634827:-
LUAD	cis	rs875971	0.825	rs1000464	ENSG00000237310.1	GS1-124K5.4	-5.96	5.02e-09	2.04e-06	-0.29	-0.26	Aortic root size;	chr7:66312922	chr7:66493706~66495474:+
LUAD	cis	rs2288884	0.537	rs7254131	ENSG00000275055.1	CTC-471J1.11	-5.96	5.02e-09	2.04e-06	-0.31	-0.26	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52035774	chr19:52049007~52049754:+
LUAD	cis	rs1823913	0.599	rs17511410	ENSG00000280083.1	RP11-317J9.1	-5.96	5.02e-09	2.04e-06	-0.31	-0.26	Obesity-related traits;	chr2:191278043	chr2:191154118~191156070:-
LUAD	cis	rs71636778	0.509	rs35021342	ENSG00000260063.1	RP5-968P14.2	-5.95	5.03e-09	2.04e-06	-0.46	-0.26	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26759736	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs34201939	ENSG00000260063.1	RP5-968P14.2	-5.95	5.03e-09	2.04e-06	-0.46	-0.26	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26767220	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs35615194	ENSG00000260063.1	RP5-968P14.2	-5.95	5.03e-09	2.04e-06	-0.46	-0.26	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26791680	chr1:26692132~26694131:-
LUAD	cis	rs7849270	1	rs7036236	ENSG00000268707.1	RP11-247A12.7	-5.95	5.03e-09	2.04e-06	-0.3	-0.26	Blood metabolite ratios;	chr9:129137020	chr9:129170434~129170940:+
LUAD	cis	rs2239547	0.603	rs12489490	ENSG00000242142.1	SERBP1P3	5.95	5.03e-09	2.04e-06	0.33	0.26	Schizophrenia;	chr3:53030006	chr3:53064283~53065091:-
LUAD	cis	rs10214930	0.697	rs10447552	ENSG00000235574.1	AC073150.6	5.95	5.03e-09	2.04e-06	0.33	0.26	Hypospadias;	chr7:27643679	chr7:27491682~27492765:-
LUAD	cis	rs1823874	0.924	rs4965542	ENSG00000182397.13	DNM1P46	-5.95	5.04e-09	2.04e-06	-0.29	-0.26	IgG glycosylation;	chr15:99816414	chr15:99790156~99806927:-
LUAD	cis	rs172166	0.637	rs1071893	ENSG00000204709.4	LINC01556	5.95	5.04e-09	2.04e-06	0.33	0.26	Cardiac Troponin-T levels;	chr6:28199857	chr6:28943877~28944537:+
LUAD	cis	rs987724	0.571	rs7641929	ENSG00000240875.4	LINC00886	-5.95	5.04e-09	2.05e-06	-0.28	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156811605	chr3:156747346~156817062:-
LUAD	cis	rs7208859	0.673	rs1347360	ENSG00000263603.1	CTD-2349P21.5	-5.95	5.04e-09	2.05e-06	-0.44	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587514	chr17:30729469~30731202:+
LUAD	cis	rs7804306	0.826	rs73053556	ENSG00000233264.2	AC006042.8	5.95	5.05e-09	2.05e-06	0.54	0.26	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8066180	chr7:7980312~7982228:+
LUAD	cis	rs7804306	0.826	rs73053562	ENSG00000233264.2	AC006042.8	5.95	5.05e-09	2.05e-06	0.54	0.26	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8068527	chr7:7980312~7982228:+
LUAD	cis	rs7804306	0.826	rs55746128	ENSG00000233264.2	AC006042.8	5.95	5.05e-09	2.05e-06	0.54	0.26	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8070757	chr7:7980312~7982228:+
LUAD	cis	rs7923609	0.811	rs3847326	ENSG00000232075.1	MRPL35P2	5.95	5.05e-09	2.05e-06	0.32	0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63572099	chr10:63634317~63634827:-
LUAD	cis	rs875971	0.862	rs778686	ENSG00000237310.1	GS1-124K5.4	5.95	5.06e-09	2.05e-06	0.29	0.26	Aortic root size;	chr7:66370923	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs778684	ENSG00000237310.1	GS1-124K5.4	5.95	5.06e-09	2.05e-06	0.29	0.26	Aortic root size;	chr7:66371416	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs778680	ENSG00000237310.1	GS1-124K5.4	5.95	5.06e-09	2.05e-06	0.29	0.26	Aortic root size;	chr7:66375427	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs11769079	ENSG00000237310.1	GS1-124K5.4	5.95	5.06e-09	2.05e-06	0.29	0.26	Aortic root size;	chr7:66377141	chr7:66493706~66495474:+
LUAD	cis	rs2243480	1	rs316327	ENSG00000230295.1	RP11-458F8.2	5.95	5.06e-09	2.05e-06	0.31	0.26	Diabetic kidney disease;	chr7:66144214	chr7:66880708~66882981:+
LUAD	cis	rs875971	0.502	rs1796227	ENSG00000226824.5	RP4-756H11.3	5.95	5.07e-09	2.06e-06	0.38	0.26	Aortic root size;	chr7:66622032	chr7:66654538~66669855:+
LUAD	cis	rs240993	0.715	rs7742724	ENSG00000230177.1	RP5-1112D6.4	5.95	5.07e-09	2.06e-06	0.26	0.26	Inflammatory skin disease;Psoriasis;	chr6:111517816	chr6:111277932~111278742:+
LUAD	cis	rs987724	0.531	rs12492804	ENSG00000240875.4	LINC00886	-5.95	5.07e-09	2.06e-06	-0.28	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156814356	chr3:156747346~156817062:-
LUAD	cis	rs987724	0.592	rs12497539	ENSG00000240875.4	LINC00886	-5.95	5.07e-09	2.06e-06	-0.28	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156816148	chr3:156747346~156817062:-
LUAD	cis	rs987724	0.571	rs59717073	ENSG00000240875.4	LINC00886	-5.95	5.07e-09	2.06e-06	-0.28	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156816456	chr3:156747346~156817062:-
LUAD	cis	rs7637701	0.818	rs11717133	ENSG00000240875.4	LINC00886	-5.95	5.07e-09	2.06e-06	-0.28	-0.26	Breast cancer;	chr3:156816792	chr3:156747346~156817062:-
LUAD	cis	rs2283792	0.765	rs9610338	ENSG00000224086.5	LL22NC03-86G7.1	5.95	5.07e-09	2.06e-06	0.25	0.26	Multiple sclerosis;	chr22:21797532	chr22:21938293~21977632:+
LUAD	cis	rs10214930	0.697	rs6462034	ENSG00000235574.1	AC073150.6	-5.95	5.08e-09	2.06e-06	-0.33	-0.26	Hypospadias;	chr7:27588965	chr7:27491682~27492765:-
LUAD	cis	rs720064	0.586	rs2241643	ENSG00000264745.1	TTC39C-AS1	5.95	5.08e-09	2.06e-06	0.28	0.26	Strep throat;	chr18:23949758	chr18:23994213~24015339:-
LUAD	cis	rs17301013	0.54	rs72713601	ENSG00000227373.4	RP11-160H22.5	5.95	5.08e-09	2.06e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174482987	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs9729907	ENSG00000227373.4	RP11-160H22.5	5.95	5.08e-09	2.06e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174483607	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.581	rs2901818	ENSG00000227373.4	RP11-160H22.5	5.95	5.08e-09	2.06e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174486239	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs6658315	ENSG00000227373.4	RP11-160H22.5	5.95	5.08e-09	2.06e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174489961	chr1:174115300~174160004:-
LUAD	cis	rs9309473	0.948	rs10170849	ENSG00000163016.8	ALMS1P	5.95	5.08e-09	2.06e-06	0.32	0.26	Metabolite levels;	chr2:73520805	chr2:73644919~73685576:+
LUAD	cis	rs4273100	1	rs4924986	ENSG00000279825.1	CTC-457L16.1	-5.95	5.08e-09	2.06e-06	-0.33	-0.26	Schizophrenia;	chr17:19339154	chr17:19030857~19033529:+
LUAD	cis	rs875971	1	rs6946143	ENSG00000237310.1	GS1-124K5.4	5.95	5.08e-09	2.06e-06	0.28	0.26	Aortic root size;	chr7:66114735	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs1968126	ENSG00000237310.1	GS1-124K5.4	-5.95	5.09e-09	2.06e-06	-0.28	-0.26	Aortic root size;	chr7:66592017	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.825	rs6951503	ENSG00000237310.1	GS1-124K5.4	-5.95	5.09e-09	2.06e-06	-0.29	-0.26	Aortic root size;	chr7:66253949	chr7:66493706~66495474:+
LUAD	cis	rs9309473	1	rs10187416	ENSG00000163016.8	ALMS1P	5.95	5.1e-09	2.07e-06	0.32	0.26	Metabolite levels;	chr2:73486614	chr2:73644919~73685576:+
LUAD	cis	rs9309473	0.95	rs10207264	ENSG00000163016.8	ALMS1P	5.95	5.1e-09	2.07e-06	0.32	0.26	Metabolite levels;	chr2:73486970	chr2:73644919~73685576:+
LUAD	cis	rs897200	0.898	rs7574070	ENSG00000280083.1	RP11-317J9.1	-5.95	5.1e-09	2.07e-06	-0.33	-0.26	Behcet's disease;	chr2:191145762	chr2:191154118~191156070:-
LUAD	cis	rs7727544	0.661	rs273900	ENSG00000233006.5	AC034220.3	5.95	5.1e-09	2.07e-06	0.23	0.26	Blood metabolite levels;	chr5:132358913	chr5:132311285~132369916:-
LUAD	cis	rs4948102	0.595	rs7793921	ENSG00000273720.1	RP11-613E4.4	-5.95	5.11e-09	2.07e-06	-0.32	-0.26	Plasma homocysteine levels (post-methionine load test);	chr7:56053188	chr7:55743073~55743457:+
LUAD	cis	rs4948102	0.595	rs10255049	ENSG00000273720.1	RP11-613E4.4	-5.95	5.11e-09	2.07e-06	-0.32	-0.26	Plasma homocysteine levels (post-methionine load test);	chr7:56053611	chr7:55743073~55743457:+
LUAD	cis	rs7804306	0.826	rs74761423	ENSG00000233264.2	AC006042.8	5.95	5.11e-09	2.07e-06	0.54	0.26	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8059693	chr7:7980312~7982228:+
LUAD	cis	rs7804306	0.655	rs73053544	ENSG00000233264.2	AC006042.8	5.95	5.11e-09	2.07e-06	0.54	0.26	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8059883	chr7:7980312~7982228:+
LUAD	cis	rs10740039	0.516	rs10761526	ENSG00000254271.1	RP11-131N11.4	5.95	5.11e-09	2.07e-06	0.29	0.26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60594661	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.516	rs1009410	ENSG00000254271.1	RP11-131N11.4	5.95	5.11e-09	2.07e-06	0.29	0.26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60595039	chr10:60734342~60741828:+
LUAD	cis	rs2243480	1	rs1638734	ENSG00000232546.1	RP11-458F8.1	-5.95	5.12e-09	2.07e-06	-0.35	-0.26	Diabetic kidney disease;	chr7:66632552	chr7:66848496~66858136:+
LUAD	cis	rs875971	0.862	rs6460293	ENSG00000222364.1	RNU6-96P	5.95	5.12e-09	2.07e-06	0.3	0.26	Aortic root size;	chr7:66345205	chr7:66395191~66395286:+
LUAD	cis	rs2243480	1	rs313831	ENSG00000232546.1	RP11-458F8.1	-5.95	5.12e-09	2.08e-06	-0.34	-0.26	Diabetic kidney disease;	chr7:66086239	chr7:66848496~66858136:+
LUAD	cis	rs9309473	0.95	rs1052162	ENSG00000163016.8	ALMS1P	-5.95	5.13e-09	2.08e-06	-0.31	-0.26	Metabolite levels;	chr2:73602245	chr2:73644919~73685576:+
LUAD	cis	rs1874124	0.577	rs2807872	ENSG00000272823.1	RP11-295M18.6	-5.95	5.13e-09	2.08e-06	-0.38	-0.26	Cholesterol, total;	chr1:220866908	chr1:220828676~220829211:-
LUAD	cis	rs1823913	0.637	rs4853579	ENSG00000227542.1	AC092614.2	-5.95	5.13e-09	2.08e-06	-0.32	-0.26	Obesity-related traits;	chr2:191297413	chr2:191229165~191246172:-
LUAD	cis	rs11971779	0.68	rs2355783	ENSG00000273391.1	RP11-634H22.1	5.95	5.13e-09	2.08e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139391133	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs111461944	ENSG00000273391.1	RP11-634H22.1	5.95	5.13e-09	2.08e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139393157	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs7795520	ENSG00000273391.1	RP11-634H22.1	5.95	5.13e-09	2.08e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139394461	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs6467846	ENSG00000273391.1	RP11-634H22.1	5.95	5.13e-09	2.08e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139394639	chr7:139359032~139359566:-
LUAD	cis	rs6921919	0.583	rs740621	ENSG00000216901.1	AL022393.7	5.95	5.14e-09	2.08e-06	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs740622	ENSG00000216901.1	AL022393.7	5.95	5.14e-09	2.08e-06	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28176188~28176674:+
LUAD	cis	rs10129255	0.789	rs61997796	ENSG00000224373.3	IGHV4-59	5.95	5.15e-09	2.08e-06	0.18	0.26	Kawasaki disease;	chr14:106813798	chr14:106627249~106627825:-
LUAD	cis	rs7923609	0.934	rs2893919	ENSG00000232075.1	MRPL35P2	-5.95	5.15e-09	2.08e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63375018	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.967	rs2393966	ENSG00000232075.1	MRPL35P2	-5.95	5.15e-09	2.08e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63375054	chr10:63634317~63634827:-
LUAD	cis	rs7923609	1	rs4310508	ENSG00000232075.1	MRPL35P2	-5.95	5.15e-09	2.08e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63378813	chr10:63634317~63634827:-
LUAD	cis	rs7923609	1	rs7910927	ENSG00000232075.1	MRPL35P2	-5.95	5.15e-09	2.08e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63379150	chr10:63634317~63634827:-
LUAD	cis	rs1707322	0.717	rs1135850	ENSG00000234329.1	RP11-767N6.2	5.95	5.15e-09	2.09e-06	0.28	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628020	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.717	rs3014246	ENSG00000234329.1	RP11-767N6.2	-5.95	5.15e-09	2.09e-06	-0.28	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620405	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.655	rs3014240	ENSG00000234329.1	RP11-767N6.2	-5.95	5.15e-09	2.09e-06	-0.28	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45623553	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.686	rs3014235	ENSG00000234329.1	RP11-767N6.2	-5.95	5.15e-09	2.09e-06	-0.28	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625840	chr1:45651039~45651826:-
LUAD	cis	rs66887589	0.87	rs59590064	ENSG00000248280.1	RP11-33B1.2	-5.95	5.15e-09	2.09e-06	-0.29	-0.26	Diastolic blood pressure;	chr4:119618598	chr4:119440561~119450157:-
LUAD	cis	rs2243480	1	rs431076	ENSG00000230295.1	RP11-458F8.2	-5.95	5.15e-09	2.09e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66135333	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs2257790	ENSG00000230295.1	RP11-458F8.2	-5.95	5.15e-09	2.09e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66135463	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs2460422	ENSG00000230295.1	RP11-458F8.2	-5.95	5.15e-09	2.09e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66136518	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs316334	ENSG00000230295.1	RP11-458F8.2	-5.95	5.15e-09	2.09e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66137139	chr7:66880708~66882981:+
LUAD	cis	rs12699921	0.632	rs2723570	ENSG00000279048.1	RP11-511H23.2	-5.95	5.16e-09	2.09e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17853533	chr7:17940503~17942922:+
LUAD	cis	rs801193	0.591	rs4506088	ENSG00000237310.1	GS1-124K5.4	-5.95	5.16e-09	2.09e-06	-0.28	-0.26	Aortic root size;	chr7:66670470	chr7:66493706~66495474:+
LUAD	cis	rs30380	0.666	rs26512	ENSG00000272109.1	CTD-2260A17.3	-5.95	5.16e-09	2.09e-06	-0.31	-0.26	Cerebrospinal fluid biomarker levels;	chr5:96792697	chr5:96804353~96806105:+
LUAD	cis	rs1499614	1	rs2707840	ENSG00000230295.1	RP11-458F8.2	-5.95	5.16e-09	2.09e-06	-0.32	-0.26	Gout;	chr7:66693028	chr7:66880708~66882981:+
LUAD	cis	rs66887589	0.934	rs7681980	ENSG00000248280.1	RP11-33B1.2	-5.95	5.17e-09	2.09e-06	-0.29	-0.26	Diastolic blood pressure;	chr4:119612068	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.955	rs35197422	ENSG00000248280.1	RP11-33B1.2	5.95	5.17e-09	2.09e-06	0.32	0.26	Corneal astigmatism;	chr4:119248159	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.955	rs1511015	ENSG00000248280.1	RP11-33B1.2	5.95	5.17e-09	2.09e-06	0.32	0.26	Corneal astigmatism;	chr4:119249318	chr4:119440561~119450157:-
LUAD	cis	rs11098499	1	rs10029750	ENSG00000248280.1	RP11-33B1.2	5.95	5.17e-09	2.09e-06	0.32	0.26	Corneal astigmatism;	chr4:119251388	chr4:119440561~119450157:-
LUAD	cis	rs7849270	1	rs1360172	ENSG00000268707.1	RP11-247A12.7	-5.95	5.18e-09	2.1e-06	-0.3	-0.26	Blood metabolite ratios;	chr9:129145701	chr9:129170434~129170940:+
LUAD	cis	rs853679	1	rs853679	ENSG00000204709.4	LINC01556	5.95	5.19e-09	2.1e-06	0.41	0.26	Depression;	chr6:28329086	chr6:28943877~28944537:+
LUAD	cis	rs853679	1	rs853678	ENSG00000204709.4	LINC01556	5.95	5.19e-09	2.1e-06	0.41	0.26	Depression;	chr6:28329536	chr6:28943877~28944537:+
LUAD	cis	rs1914816	0.941	rs2938691	ENSG00000196274.5	Metazoa_SRP	5.95	5.19e-09	2.1e-06	0.3	0.26	Response to tocilizumab in rheumatoid arthritis;	chr15:76214865	chr15:76230048~76230390:-
LUAD	cis	rs2283792	0.765	rs9340	ENSG00000224086.5	LL22NC03-86G7.1	-5.95	5.19e-09	2.1e-06	-0.25	-0.26	Multiple sclerosis;	chr22:21761064	chr22:21938293~21977632:+
LUAD	cis	rs1075265	0.749	rs805375	ENSG00000233266.1	HMGB1P31	5.95	5.2e-09	2.1e-06	0.33	0.26	Chronotype;Morning vs. evening chronotype;	chr2:53863268	chr2:54051334~54051760:+
LUAD	cis	rs6772849	0.93	rs1962040	ENSG00000242551.2	POU5F1P6	-5.95	5.2e-09	2.1e-06	-0.31	-0.26	Monocyte percentage of white cells;Monocyte count;	chr3:128605318	chr3:128674735~128677005:-
LUAD	cis	rs9910055	0.762	rs227579	ENSG00000267080.4	ASB16-AS1	5.95	5.2e-09	2.1e-06	0.24	0.26	Total body bone mineral density;	chr17:44145766	chr17:44175973~44186717:-
LUAD	cis	rs858239	0.6	rs6961406	ENSG00000230042.1	AK3P3	-5.95	5.2e-09	2.1e-06	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.6	rs6461690	ENSG00000230042.1	AK3P3	-5.95	5.2e-09	2.1e-06	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.6	rs6967419	ENSG00000230042.1	AK3P3	-5.95	5.2e-09	2.1e-06	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23129178~23129841:+
LUAD	cis	rs3738443	0.545	rs12566906	ENSG00000259865.1	RP11-488L18.10	5.95	5.2e-09	2.1e-06	0.23	0.26	Alcohol dependence;	chr1:247224904	chr1:247187281~247188526:-
LUAD	cis	rs11098499	0.913	rs10010696	ENSG00000248280.1	RP11-33B1.2	5.95	5.21e-09	2.11e-06	0.32	0.26	Corneal astigmatism;	chr4:119243148	chr4:119440561~119450157:-
LUAD	cis	rs10740039	0.516	rs1442549	ENSG00000254271.1	RP11-131N11.4	5.95	5.21e-09	2.11e-06	0.29	0.26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60574542	chr10:60734342~60741828:+
LUAD	cis	rs11098499	1	rs28374891	ENSG00000248280.1	RP11-33B1.2	5.95	5.21e-09	2.11e-06	0.32	0.26	Corneal astigmatism;	chr4:119262395	chr4:119440561~119450157:-
LUAD	cis	rs957448	0.948	rs1470153	ENSG00000253704.1	RP11-267M23.4	5.95	5.21e-09	2.11e-06	0.33	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94514587	chr8:94553722~94569745:+
LUAD	cis	rs12699921	0.632	rs2691585	ENSG00000279048.1	RP11-511H23.2	-5.95	5.21e-09	2.11e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17798064	chr7:17940503~17942922:+
LUAD	cis	rs4713118	0.869	rs9283883	ENSG00000219392.1	RP1-265C24.5	-5.95	5.22e-09	2.11e-06	-0.35	-0.26	Parkinson's disease;	chr6:27747691	chr6:28115628~28116551:+
LUAD	cis	rs875971	1	rs2036264	ENSG00000237310.1	GS1-124K5.4	-5.95	5.22e-09	2.11e-06	-0.28	-0.26	Aortic root size;	chr7:66334917	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs7783613	ENSG00000237310.1	GS1-124K5.4	-5.95	5.22e-09	2.11e-06	-0.28	-0.26	Aortic root size;	chr7:66340274	chr7:66493706~66495474:+
LUAD	cis	rs7727544	0.735	rs272860	ENSG00000233006.5	AC034220.3	5.95	5.22e-09	2.11e-06	0.23	0.26	Blood metabolite levels;	chr5:132348482	chr5:132311285~132369916:-
LUAD	cis	rs12908161	0.959	rs34342559	ENSG00000259728.4	LINC00933	5.95	5.24e-09	2.12e-06	0.38	0.26	Schizophrenia;	chr15:84788040	chr15:84570649~84580175:+
LUAD	cis	rs12908161	0.959	rs35557864	ENSG00000259728.4	LINC00933	5.95	5.24e-09	2.12e-06	0.38	0.26	Schizophrenia;	chr15:84788398	chr15:84570649~84580175:+
LUAD	cis	rs2404602	0.574	rs4886795	ENSG00000259422.1	RP11-593F23.1	-5.95	5.24e-09	2.12e-06	-0.37	-0.26	Blood metabolite levels;	chr15:76349877	chr15:76174891~76181486:-
LUAD	cis	rs4713118	0.513	rs149972	ENSG00000204709.4	LINC01556	5.95	5.24e-09	2.12e-06	0.33	0.26	Parkinson's disease;	chr6:28015449	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.513	rs149975	ENSG00000204709.4	LINC01556	5.95	5.24e-09	2.12e-06	0.33	0.26	Parkinson's disease;	chr6:28018562	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.55	rs34477097	ENSG00000219392.1	RP1-265C24.5	-5.95	5.24e-09	2.12e-06	-0.35	-0.26	Depression;	chr6:28229408	chr6:28115628~28116551:+
LUAD	cis	rs2288884	0.515	rs17779341	ENSG00000275055.1	CTC-471J1.11	-5.95	5.25e-09	2.12e-06	-0.32	-0.26	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52047148	chr19:52049007~52049754:+
LUAD	cis	rs9910055	0.762	rs2240226	ENSG00000267080.4	ASB16-AS1	-5.95	5.25e-09	2.12e-06	-0.24	-0.26	Total body bone mineral density;	chr17:44188850	chr17:44175973~44186717:-
LUAD	cis	rs9595908	0.581	rs2032507	ENSG00000212293.1	SNORA16	5.95	5.25e-09	2.12e-06	0.27	0.26	Body mass index;	chr13:32779298	chr13:32420390~32420516:-
LUAD	cis	rs516805	0.748	rs6912610	ENSG00000279453.1	RP3-425C14.4	5.95	5.26e-09	2.12e-06	0.35	0.26	Lymphocyte counts;	chr6:122379961	chr6:122436789~122439223:-
LUAD	cis	rs10129255	1	rs8010605	ENSG00000224373.3	IGHV4-59	5.95	5.27e-09	2.13e-06	0.17	0.26	Kawasaki disease;	chr14:106678742	chr14:106627249~106627825:-
LUAD	cis	rs9595908	0.645	rs7983065	ENSG00000212293.1	SNORA16	5.95	5.28e-09	2.13e-06	0.28	0.26	Body mass index;	chr13:32806648	chr13:32420390~32420516:-
LUAD	cis	rs6504622	0.818	rs9303532	ENSG00000262879.4	RP11-156P1.3	-5.95	5.29e-09	2.14e-06	-0.31	-0.26	Orofacial clefts;	chr17:46956636	chr17:46984045~47100323:-
LUAD	cis	rs35740288	0.694	rs17618909	ENSG00000202081.1	RNU6-1280P	5.95	5.29e-09	2.14e-06	0.32	0.26	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85552231	chr15:85651522~85651628:-
LUAD	cis	rs10129255	0.536	rs6576201	ENSG00000211970.3	IGHV4-61	5.95	5.29e-09	2.14e-06	0.18	0.26	Kawasaki disease;	chr14:106683696	chr14:106639119~106639657:-
LUAD	cis	rs11971779	0.715	rs10085527	ENSG00000273391.1	RP11-634H22.1	5.95	5.29e-09	2.14e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139379614	chr7:139359032~139359566:-
LUAD	cis	rs755249	0.883	rs12035330	ENSG00000228060.1	RP11-69E11.8	-5.95	5.3e-09	2.14e-06	-0.25	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39535388	chr1:39565160~39573203:+
LUAD	cis	rs6687821	0.515	rs502404	ENSG00000267734.1	RP4-604K5.3	5.95	5.31e-09	2.14e-06	0.32	0.26	Yeast infection;	chr1:86878204	chr1:86932199~86934891:-
LUAD	cis	rs858239	0.601	rs1034963	ENSG00000230042.1	AK3P3	-5.95	5.31e-09	2.15e-06	-0.32	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23129178~23129841:+
LUAD	cis	rs1113500	0.933	rs10494089	ENSG00000226822.1	RP11-356N1.2	5.94	5.32e-09	2.15e-06	0.31	0.26	Growth-regulated protein alpha levels;	chr1:108084073	chr1:108071482~108074519:+
LUAD	cis	rs1113500	0.933	rs745795	ENSG00000226822.1	RP11-356N1.2	5.94	5.32e-09	2.15e-06	0.31	0.26	Growth-regulated protein alpha levels;	chr1:108086723	chr1:108071482~108074519:+
LUAD	cis	rs1113500	0.933	rs2077259	ENSG00000226822.1	RP11-356N1.2	5.94	5.32e-09	2.15e-06	0.31	0.26	Growth-regulated protein alpha levels;	chr1:108086929	chr1:108071482~108074519:+
LUAD	cis	rs270601	0.77	rs10463891	ENSG00000233006.5	AC034220.3	-5.94	5.33e-09	2.15e-06	-0.24	-0.26	Acylcarnitine levels;	chr5:132261699	chr5:132311285~132369916:-
LUAD	cis	rs11098499	1	rs7659194	ENSG00000248280.1	RP11-33B1.2	5.94	5.33e-09	2.15e-06	0.33	0.26	Corneal astigmatism;	chr4:119285992	chr4:119440561~119450157:-
LUAD	cis	rs4908768	0.539	rs1061039	ENSG00000232912.4	RP5-1115A15.1	5.94	5.34e-09	2.15e-06	0.24	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8582529	chr1:8424645~8434838:+
LUAD	cis	rs948562	0.744	rs4313600	ENSG00000280010.1	AP001350.4	5.94	5.34e-09	2.16e-06	0.39	0.26	Lymphoma;	chr11:58463748	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.69	rs11229480	ENSG00000280010.1	AP001350.4	5.94	5.34e-09	2.16e-06	0.39	0.26	Lymphoma;	chr11:58464209	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.744	rs11229481	ENSG00000280010.1	AP001350.4	5.94	5.34e-09	2.16e-06	0.39	0.26	Lymphoma;	chr11:58464426	chr11:58627435~58628528:+
LUAD	cis	rs2283792	0.765	rs6518968	ENSG00000224086.5	LL22NC03-86G7.1	-5.94	5.34e-09	2.16e-06	-0.25	-0.26	Multiple sclerosis;	chr22:21793327	chr22:21938293~21977632:+
LUAD	cis	rs9595908	0.709	rs2025473	ENSG00000212293.1	SNORA16	5.94	5.34e-09	2.16e-06	0.28	0.26	Body mass index;	chr13:32791632	chr13:32420390~32420516:-
LUAD	cis	rs875971	0.597	rs11763224	ENSG00000226824.5	RP4-756H11.3	-5.94	5.34e-09	2.16e-06	-0.39	-0.26	Aortic root size;	chr7:66518628	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.767	rs61348003	ENSG00000237310.1	GS1-124K5.4	5.94	5.34e-09	2.16e-06	0.29	0.26	Aortic root size;	chr7:66540947	chr7:66493706~66495474:+
LUAD	cis	rs67311347	0.544	rs2123998	ENSG00000223797.4	ENTPD3-AS1	-5.94	5.35e-09	2.16e-06	-0.27	-0.26	Renal cell carcinoma;	chr3:40317514	chr3:40313802~40453329:-
LUAD	cis	rs2404602	0.583	rs12438741	ENSG00000259422.1	RP11-593F23.1	5.94	5.35e-09	2.16e-06	0.29	0.26	Blood metabolite levels;	chr15:76249773	chr15:76174891~76181486:-
LUAD	cis	rs10214930	0.697	rs10951171	ENSG00000235574.1	AC073150.6	-5.94	5.35e-09	2.16e-06	-0.33	-0.26	Hypospadias;	chr7:27571988	chr7:27491682~27492765:-
LUAD	cis	rs2115630	0.645	rs3825877	ENSG00000229212.6	RP11-561C5.4	5.94	5.35e-09	2.16e-06	0.31	0.26	P wave terminal force;	chr15:84631400	chr15:85205440~85234795:-
LUAD	cis	rs2115630	0.645	rs3825878	ENSG00000229212.6	RP11-561C5.4	5.94	5.35e-09	2.16e-06	0.31	0.26	P wave terminal force;	chr15:84631524	chr15:85205440~85234795:-
LUAD	cis	rs9595908	0.669	rs2032508	ENSG00000212293.1	SNORA16	5.94	5.35e-09	2.16e-06	0.29	0.26	Body mass index;	chr13:32779332	chr13:32420390~32420516:-
LUAD	cis	rs1134634	0.52	rs7661102	ENSG00000273133.1	RP11-799M12.2	-5.94	5.35e-09	2.16e-06	-0.38	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15596914	chr4:15563698~15564253:-
LUAD	cis	rs9595908	0.709	rs17516498	ENSG00000212293.1	SNORA16	5.94	5.36e-09	2.16e-06	0.27	0.26	Body mass index;	chr13:32750477	chr13:32420390~32420516:-
LUAD	cis	rs7618501	0.665	rs7621352	ENSG00000234667.1	ACTBP13	5.94	5.36e-09	2.16e-06	0.29	0.26	Intelligence (multi-trait analysis);	chr3:50033330	chr3:49873347~49877980:-
LUAD	cis	rs10214930	0.706	rs10081338	ENSG00000235574.1	AC073150.6	5.94	5.36e-09	2.16e-06	0.35	0.26	Hypospadias;	chr7:27658969	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.767	rs10081339	ENSG00000235574.1	AC073150.6	5.94	5.36e-09	2.16e-06	0.35	0.26	Hypospadias;	chr7:27658975	chr7:27491682~27492765:-
LUAD	cis	rs7208859	0.673	rs216409	ENSG00000263603.1	CTD-2349P21.5	5.94	5.36e-09	2.17e-06	0.4	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30579251	chr17:30729469~30731202:+
LUAD	cis	rs875971	0.862	rs949930	ENSG00000237310.1	GS1-124K5.4	-5.94	5.36e-09	2.17e-06	-0.29	-0.26	Aortic root size;	chr7:66301835	chr7:66493706~66495474:+
LUAD	cis	rs1823913	0.637	rs1349938	ENSG00000227542.1	AC092614.2	-5.94	5.37e-09	2.17e-06	-0.32	-0.26	Obesity-related traits;	chr2:191299970	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.592	rs1349939	ENSG00000227542.1	AC092614.2	-5.94	5.37e-09	2.17e-06	-0.32	-0.26	Obesity-related traits;	chr2:191300079	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.637	rs4853581	ENSG00000227542.1	AC092614.2	-5.94	5.37e-09	2.17e-06	-0.32	-0.26	Obesity-related traits;	chr2:191301533	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.614	rs7565987	ENSG00000227542.1	AC092614.2	-5.94	5.37e-09	2.17e-06	-0.32	-0.26	Obesity-related traits;	chr2:191301815	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.614	rs1973067	ENSG00000227542.1	AC092614.2	-5.94	5.37e-09	2.17e-06	-0.32	-0.26	Obesity-related traits;	chr2:191302021	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.637	rs1973068	ENSG00000227542.1	AC092614.2	-5.94	5.37e-09	2.17e-06	-0.32	-0.26	Obesity-related traits;	chr2:191302227	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.637	rs7569231	ENSG00000227542.1	AC092614.2	-5.94	5.37e-09	2.17e-06	-0.32	-0.26	Obesity-related traits;	chr2:191302373	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.637	rs6434461	ENSG00000227542.1	AC092614.2	-5.94	5.37e-09	2.17e-06	-0.32	-0.26	Obesity-related traits;	chr2:191302661	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.614	rs6434462	ENSG00000227542.1	AC092614.2	-5.94	5.37e-09	2.17e-06	-0.32	-0.26	Obesity-related traits;	chr2:191302705	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.637	rs6750360	ENSG00000227542.1	AC092614.2	-5.94	5.37e-09	2.17e-06	-0.32	-0.26	Obesity-related traits;	chr2:191303089	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.637	rs11677694	ENSG00000227542.1	AC092614.2	-5.94	5.37e-09	2.17e-06	-0.32	-0.26	Obesity-related traits;	chr2:191303203	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.571	rs6737307	ENSG00000227542.1	AC092614.2	-5.94	5.37e-09	2.17e-06	-0.32	-0.26	Obesity-related traits;	chr2:191303247	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.637	rs4853582	ENSG00000227542.1	AC092614.2	-5.94	5.37e-09	2.17e-06	-0.32	-0.26	Obesity-related traits;	chr2:191303483	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.637	rs35200176	ENSG00000227542.1	AC092614.2	-5.94	5.37e-09	2.17e-06	-0.32	-0.26	Obesity-related traits;	chr2:191303534	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.637	rs17348013	ENSG00000227542.1	AC092614.2	-5.94	5.37e-09	2.17e-06	-0.32	-0.26	Obesity-related traits;	chr2:191303726	chr2:191229165~191246172:-
LUAD	cis	rs720064	0.586	rs8099403	ENSG00000264745.1	TTC39C-AS1	-5.94	5.37e-09	2.17e-06	-0.27	-0.26	Strep throat;	chr18:23933031	chr18:23994213~24015339:-
LUAD	cis	rs2948294	0.566	rs13261997	ENSG00000253893.2	FAM85B	-5.94	5.37e-09	2.17e-06	-0.34	-0.26	Red cell distribution width;	chr8:8254773	chr8:8167819~8226614:-
LUAD	cis	rs7923609	0.905	rs7092784	ENSG00000232075.1	MRPL35P2	-5.94	5.38e-09	2.17e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63454989	chr10:63634317~63634827:-
LUAD	cis	rs77204473	0.744	rs2306471	ENSG00000254851.1	RP11-109L13.1	5.94	5.39e-09	2.18e-06	0.64	0.26	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117145734	chr11:117135528~117138582:+
LUAD	cis	rs7727544	0.684	rs274561	ENSG00000233006.5	AC034220.3	5.94	5.41e-09	2.18e-06	0.23	0.26	Blood metabolite levels;	chr5:132383536	chr5:132311285~132369916:-
LUAD	cis	rs875971	0.83	rs12673450	ENSG00000222364.1	RNU6-96P	-5.94	5.41e-09	2.18e-06	-0.3	-0.26	Aortic root size;	chr7:66544233	chr7:66395191~66395286:+
LUAD	cis	rs8062405	0.964	rs78613234	ENSG00000251417.2	RP11-1348G14.4	-5.94	5.42e-09	2.18e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs62036624	ENSG00000251417.2	RP11-1348G14.4	-5.94	5.42e-09	2.18e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28802743~28817828:+
LUAD	cis	rs853679	0.517	rs9468298	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Depression;	chr6:28154567	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9295759	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Depression;	chr6:28156691	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9348796	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Depression;	chr6:28158424	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs11552219	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Depression;	chr6:28159056	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9380058	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Depression;	chr6:28159666	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9393895	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Depression;	chr6:28159843	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9357066	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Depression;	chr6:28162053	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9393898	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Depression;	chr6:28162598	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9368556	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Depression;	chr6:28163375	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9368557	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Depression;	chr6:28163759	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9380059	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Depression;	chr6:28164580	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9380060	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Depression;	chr6:28164825	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs35227624	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Depression;	chr6:28164948	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9380061	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Depression;	chr6:28165025	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9368558	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Depression;	chr6:28165528	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.587	rs9393899	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Parkinson's disease;	chr6:28165750	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.527	rs4713151	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Parkinson's disease;	chr6:28168578	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9393901	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Depression;	chr6:28169019	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs3173443	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Depression;	chr6:28169249	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9348797	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Depression;	chr6:28169755	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9380062	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Depression;	chr6:28169791	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.542	rs9380063	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.18e-06	0.37	0.26	Depression;	chr6:28170075	chr6:28943877~28944537:+
LUAD	cis	rs2239557	0.529	rs2041185	ENSG00000259065.1	RP5-1021I20.1	5.94	5.42e-09	2.18e-06	0.32	0.26	Common traits (Other);	chr14:73815387	chr14:73787360~73803270:+
LUAD	cis	rs875971	0.862	rs6947339	ENSG00000237310.1	GS1-124K5.4	5.94	5.42e-09	2.18e-06	0.29	0.26	Aortic root size;	chr7:66423483	chr7:66493706~66495474:+
LUAD	cis	rs12468226	0.873	rs60722019	ENSG00000226261.1	AC064836.3	5.94	5.42e-09	2.18e-06	0.44	0.26	Urate levels;	chr2:202282060	chr2:202336024~202336727:-
LUAD	cis	rs7829975	0.511	rs2976906	ENSG00000253893.2	FAM85B	-5.94	5.42e-09	2.19e-06	-0.32	-0.26	Mood instability;	chr8:8484905	chr8:8167819~8226614:-
LUAD	cis	rs875971	0.825	rs28480509	ENSG00000237310.1	GS1-124K5.4	-5.94	5.42e-09	2.19e-06	-0.29	-0.26	Aortic root size;	chr7:66634237	chr7:66493706~66495474:+
LUAD	cis	rs4713118	0.662	rs175954	ENSG00000204709.4	LINC01556	5.94	5.42e-09	2.19e-06	0.35	0.26	Parkinson's disease;	chr6:28043807	chr6:28943877~28944537:+
LUAD	cis	rs6504622	0.935	rs62075889	ENSG00000262879.4	RP11-156P1.3	-5.94	5.43e-09	2.19e-06	-0.31	-0.26	Orofacial clefts;	chr17:46950671	chr17:46984045~47100323:-
LUAD	cis	rs6504622	1	rs12940071	ENSG00000262879.4	RP11-156P1.3	-5.94	5.43e-09	2.19e-06	-0.31	-0.26	Orofacial clefts;	chr17:46950686	chr17:46984045~47100323:-
LUAD	cis	rs7923609	0.934	rs10822153	ENSG00000232075.1	MRPL35P2	-5.94	5.44e-09	2.19e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63297053	chr10:63634317~63634827:-
LUAD	cis	rs7772486	0.597	rs1970306	ENSG00000235652.6	RP11-545I5.3	5.94	5.44e-09	2.19e-06	0.27	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145833407	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.597	rs9386136	ENSG00000235652.6	RP11-545I5.3	5.94	5.44e-09	2.19e-06	0.27	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145837164	chr6:145799409~145886585:+
LUAD	cis	rs494459	0.536	rs11217063	ENSG00000255239.1	AP002954.6	5.94	5.44e-09	2.19e-06	0.31	0.26	Height;	chr11:118855233	chr11:118688039~118690600:-
LUAD	cis	rs494459	0.536	rs11217065	ENSG00000255239.1	AP002954.6	5.94	5.44e-09	2.19e-06	0.31	0.26	Height;	chr11:118855938	chr11:118688039~118690600:-
LUAD	cis	rs10214930	1	rs4719906	ENSG00000235574.1	AC073150.6	5.94	5.44e-09	2.19e-06	0.37	0.26	Hypospadias;	chr7:27733233	chr7:27491682~27492765:-
LUAD	cis	rs4713118	0.662	rs9357060	ENSG00000204709.4	LINC01556	5.94	5.45e-09	2.2e-06	0.36	0.26	Parkinson's disease;	chr6:28056708	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.662	rs9468271	ENSG00000204709.4	LINC01556	5.94	5.45e-09	2.2e-06	0.36	0.26	Parkinson's disease;	chr6:28056792	chr6:28943877~28944537:+
LUAD	cis	rs2404602	0.647	rs34103231	ENSG00000259422.1	RP11-593F23.1	-5.94	5.46e-09	2.2e-06	-0.36	-0.26	Blood metabolite levels;	chr15:76620349	chr15:76174891~76181486:-
LUAD	cis	rs2276314	1	rs1540042	ENSG00000278986.1	RP11-723J4.3	-5.94	5.46e-09	2.2e-06	-0.32	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:35975273	chr18:35972151~35973916:+
LUAD	cis	rs9309473	1	rs11903916	ENSG00000163016.8	ALMS1P	5.94	5.46e-09	2.2e-06	0.31	0.26	Metabolite levels;	chr2:73588201	chr2:73644919~73685576:+
LUAD	cis	rs1134634	0.52	rs4698403	ENSG00000273133.1	RP11-799M12.2	-5.94	5.46e-09	2.2e-06	-0.38	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15628204	chr4:15563698~15564253:-
LUAD	cis	rs11742741	0.539	rs6880304	ENSG00000248874.4	C5orf17	-5.94	5.46e-09	2.2e-06	-0.33	-0.26	Educational attainment;	chr5:24113952	chr5:23951348~24178263:+
LUAD	cis	rs1823913	0.561	rs60479498	ENSG00000280083.1	RP11-317J9.1	-5.94	5.47e-09	2.2e-06	-0.31	-0.26	Obesity-related traits;	chr2:191275197	chr2:191154118~191156070:-
LUAD	cis	rs17826219	0.568	rs11658027	ENSG00000263603.1	CTD-2349P21.5	5.94	5.48e-09	2.21e-06	0.45	0.26	Body mass index;	chr17:30767864	chr17:30729469~30731202:+
LUAD	cis	rs11098499	0.955	rs56386062	ENSG00000248280.1	RP11-33B1.2	5.94	5.48e-09	2.21e-06	0.33	0.26	Corneal astigmatism;	chr4:119233980	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.955	rs4145951	ENSG00000248280.1	RP11-33B1.2	5.94	5.48e-09	2.21e-06	0.33	0.26	Corneal astigmatism;	chr4:119234662	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.955	rs35916640	ENSG00000248280.1	RP11-33B1.2	5.94	5.48e-09	2.21e-06	0.33	0.26	Corneal astigmatism;	chr4:119234697	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.955	rs13114751	ENSG00000248280.1	RP11-33B1.2	5.94	5.48e-09	2.21e-06	0.33	0.26	Corneal astigmatism;	chr4:119235462	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.913	rs35271032	ENSG00000248280.1	RP11-33B1.2	5.94	5.48e-09	2.21e-06	0.33	0.26	Corneal astigmatism;	chr4:119235504	chr4:119440561~119450157:-
LUAD	cis	rs2404602	0.735	rs2436994	ENSG00000259422.1	RP11-593F23.1	-5.94	5.48e-09	2.21e-06	-0.33	-0.26	Blood metabolite levels;	chr15:76508722	chr15:76174891~76181486:-
LUAD	cis	rs2255336	0.938	rs61917723	ENSG00000245648.1	RP11-277P12.20	-5.94	5.49e-09	2.21e-06	-0.41	-0.26	Blood protein levels;	chr12:10472728	chr12:10363769~10398506:+
LUAD	cis	rs7246657	0.722	rs8103647	ENSG00000276846.1	CTD-3220F14.3	5.94	5.49e-09	2.21e-06	0.35	0.26	Coronary artery calcification;	chr19:37609551	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.722	rs8100646	ENSG00000276846.1	CTD-3220F14.3	5.94	5.49e-09	2.21e-06	0.35	0.26	Coronary artery calcification;	chr19:37617042	chr19:37314868~37315620:-
LUAD	cis	rs293748	0.54	rs10461978	ENSG00000250155.1	CTD-2353F22.1	-5.94	5.49e-09	2.21e-06	-0.33	-0.26	Obesity-related traits;	chr5:37274810	chr5:36666214~36725195:-
LUAD	cis	rs11971779	0.666	rs6467847	ENSG00000273391.1	RP11-634H22.1	5.94	5.5e-09	2.21e-06	0.28	0.26	Diisocyanate-induced asthma;	chr7:139394690	chr7:139359032~139359566:-
LUAD	cis	rs7208859	0.562	rs216408	ENSG00000263603.1	CTD-2349P21.5	5.94	5.5e-09	2.22e-06	0.39	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30580739	chr17:30729469~30731202:+
LUAD	cis	rs7182621	0.639	rs35049216	ENSG00000259363.4	CTD-2054N24.2	-5.94	5.5e-09	2.22e-06	-0.36	-0.26	Colonoscopy-negative controls vs population controls;	chr15:99872562	chr15:99807023~99877148:+
LUAD	cis	rs7674212	0.556	rs34475639	ENSG00000251288.2	RP11-10L12.2	-5.94	5.51e-09	2.22e-06	-0.34	-0.26	Type 2 diabetes;	chr4:103033694	chr4:102751401~102752641:+
LUAD	cis	rs875971	0.862	rs778734	ENSG00000237310.1	GS1-124K5.4	5.94	5.51e-09	2.22e-06	0.29	0.26	Aortic root size;	chr7:66349862	chr7:66493706~66495474:+
LUAD	cis	rs17666538	0.585	rs4735812	ENSG00000254207.1	RP11-43A14.1	5.94	5.52e-09	2.22e-06	0.53	0.26	IgG glycosylation;	chr8:657766	chr8:725188~725877:-
LUAD	cis	rs2255336	0.938	rs7298494	ENSG00000245648.1	RP11-277P12.20	-5.94	5.52e-09	2.22e-06	-0.41	-0.26	Blood protein levels;	chr12:10460666	chr12:10363769~10398506:+
LUAD	cis	rs35934224	0.831	rs8141610	ENSG00000232926.1	AC000078.5	-5.94	5.52e-09	2.22e-06	-0.31	-0.26	Glaucoma (primary open-angle);	chr22:19882624	chr22:19887289~19887970:+
LUAD	cis	rs9308062	1	rs9308062	ENSG00000273449.1	RP11-218F10.3	-5.94	5.52e-09	2.22e-06	-0.2	-0.26	Small cell lung carcinoma;	chr4:163517048	chr4:163529771~163530697:+
LUAD	cis	rs875971	0.862	rs7783779	ENSG00000237310.1	GS1-124K5.4	-5.94	5.52e-09	2.22e-06	-0.29	-0.26	Aortic root size;	chr7:66331639	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs1968126	ENSG00000222364.1	RNU6-96P	5.94	5.52e-09	2.22e-06	0.29	0.26	Aortic root size;	chr7:66592017	chr7:66395191~66395286:+
LUAD	cis	rs4713118	0.629	rs203889	ENSG00000204709.4	LINC01556	5.94	5.53e-09	2.23e-06	0.35	0.26	Parkinson's disease;	chr6:28053997	chr6:28943877~28944537:+
LUAD	cis	rs7714584	1	rs17727568	ENSG00000197083.10	ZNF300P1	5.94	5.53e-09	2.23e-06	0.56	0.26	Crohn's disease;	chr5:150865126	chr5:150930645~150946289:-
LUAD	cis	rs1134634	0.52	rs10008889	ENSG00000273133.1	RP11-799M12.2	-5.94	5.53e-09	2.23e-06	-0.38	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15622896	chr4:15563698~15564253:-
LUAD	cis	rs1707322	0.717	rs3014245	ENSG00000234329.1	RP11-767N6.2	-5.94	5.54e-09	2.23e-06	-0.28	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621241	chr1:45651039~45651826:-
LUAD	cis	rs2665103	0.589	rs2134046	ENSG00000255769.6	GOLGA2P10	-5.94	5.54e-09	2.23e-06	-0.28	-0.26	Intelligence (multi-trait analysis);	chr15:82232203	chr15:82472993~82513950:-
LUAD	cis	rs10214930	0.697	rs6958467	ENSG00000235574.1	AC073150.6	-5.94	5.55e-09	2.23e-06	-0.32	-0.26	Hypospadias;	chr7:27564193	chr7:27491682~27492765:-
LUAD	cis	rs1823913	0.549	rs4516458	ENSG00000280083.1	RP11-317J9.1	-5.94	5.56e-09	2.24e-06	-0.32	-0.26	Obesity-related traits;	chr2:191325177	chr2:191154118~191156070:-
LUAD	cis	rs2243480	1	rs1723269	ENSG00000230295.1	RP11-458F8.2	-5.94	5.57e-09	2.24e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66007799	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs160655	ENSG00000232546.1	RP11-458F8.1	-5.94	5.57e-09	2.24e-06	-0.33	-0.26	Diabetic kidney disease;	chr7:66068227	chr7:66848496~66858136:+
LUAD	cis	rs2404602	0.583	rs12908334	ENSG00000259422.1	RP11-593F23.1	5.94	5.58e-09	2.24e-06	0.29	0.26	Blood metabolite levels;	chr15:76289251	chr15:76174891~76181486:-
LUAD	cis	rs1426063	0.748	rs7654088	ENSG00000249717.1	RP11-44F21.3	-5.94	5.59e-09	2.25e-06	-0.34	-0.26	QT interval;	chr4:75107103	chr4:74955974~74970362:-
LUAD	cis	rs11971779	0.648	rs6467852	ENSG00000273391.1	RP11-634H22.1	5.94	5.59e-09	2.25e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139427845	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.616	rs7779314	ENSG00000273391.1	RP11-634H22.1	5.94	5.59e-09	2.25e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139427950	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.715	rs7779390	ENSG00000273391.1	RP11-634H22.1	5.94	5.59e-09	2.25e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139428207	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.584	rs34762928	ENSG00000273391.1	RP11-634H22.1	5.94	5.59e-09	2.25e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139428422	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.553	rs10228643	ENSG00000273391.1	RP11-634H22.1	5.94	5.59e-09	2.25e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139430674	chr7:139359032~139359566:-
LUAD	cis	rs9309711	0.736	rs13409102	ENSG00000225234.1	TRAPPC12-AS1	-5.94	5.6e-09	2.25e-06	-0.34	-0.26	Neurofibrillary tangles;	chr2:3492550	chr2:3481242~3482409:-
LUAD	cis	rs2404602	0.622	rs11632365	ENSG00000259422.1	RP11-593F23.1	-5.94	5.6e-09	2.25e-06	-0.38	-0.26	Blood metabolite levels;	chr15:76846739	chr15:76174891~76181486:-
LUAD	cis	rs8062405	1	rs8061590	ENSG00000251417.2	RP11-1348G14.4	-5.94	5.6e-09	2.25e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28883809	chr16:28802743~28817828:+
LUAD	cis	rs10050311	0.585	rs113536481	ENSG00000251411.1	RP11-397E7.4	-5.94	5.61e-09	2.26e-06	-0.37	-0.26	Insulin-related traits;	chr4:86943979	chr4:86913266~86914817:-
LUAD	cis	rs6558530	0.73	rs10097891	ENSG00000253982.1	CTD-2336O2.1	5.94	5.61e-09	2.26e-06	0.32	0.26	Systolic blood pressure;	chr8:1778643	chr8:1761990~1764502:-
LUAD	cis	rs6921919	0.583	rs16894060	ENSG00000216901.1	AL022393.7	5.94	5.62e-09	2.26e-06	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28176188~28176674:+
LUAD	cis	rs4972806	0.814	rs6710370	ENSG00000226363.3	HAGLROS	-5.94	5.63e-09	2.26e-06	-0.32	-0.26	IgG glycosylation;	chr2:176181241	chr2:176177717~176179008:+
LUAD	cis	rs10214930	0.697	rs12700817	ENSG00000235574.1	AC073150.6	-5.94	5.63e-09	2.26e-06	-0.33	-0.26	Hypospadias;	chr7:27551474	chr7:27491682~27492765:-
LUAD	cis	rs10754283	0.967	rs4658307	ENSG00000231613.1	RP5-943J3.1	5.93	5.63e-09	2.26e-06	0.27	0.26	Amyotrophic lateral sclerosis (sporadic);	chr1:89652027	chr1:89788914~89790492:+
LUAD	cis	rs12699921	0.632	rs2691597	ENSG00000279048.1	RP11-511H23.2	-5.93	5.64e-09	2.27e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17830717	chr7:17940503~17942922:+
LUAD	cis	rs13230714	0.858	rs714429	ENSG00000204959.4	ARHGEF34P	-5.93	5.64e-09	2.27e-06	-0.34	-0.26	Breast cancer;	chr7:144456641	chr7:144272445~144286966:-
LUAD	cis	rs9318086	1	rs9318086	ENSG00000205861.10	C1QTNF9B-AS1	5.93	5.64e-09	2.27e-06	0.31	0.26	Myopia (pathological);	chr13:23858328	chr13:23888889~23897263:+
LUAD	cis	rs516805	0.596	rs1531186	ENSG00000279453.1	RP3-425C14.4	-5.93	5.64e-09	2.27e-06	-0.35	-0.26	Lymphocyte counts;	chr6:122208219	chr6:122436789~122439223:-
LUAD	cis	rs875971	0.545	rs1638735	ENSG00000226824.5	RP4-756H11.3	-5.93	5.64e-09	2.27e-06	-0.37	-0.26	Aortic root size;	chr7:66630751	chr7:66654538~66669855:+
LUAD	cis	rs7221109	0.592	rs917595	ENSG00000278834.1	RP11-458J1.1	5.93	5.65e-09	2.27e-06	0.3	0.26	Type 1 diabetes;	chr17:40663246	chr17:40648300~40649718:+
LUAD	cis	rs1707322	0.682	rs3014241	ENSG00000234329.1	RP11-767N6.2	-5.93	5.65e-09	2.27e-06	-0.28	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45622207	chr1:45651039~45651826:-
LUAD	cis	rs293748	0.54	rs13163937	ENSG00000250155.1	CTD-2353F22.1	-5.93	5.65e-09	2.27e-06	-0.33	-0.26	Obesity-related traits;	chr5:37253547	chr5:36666214~36725195:-
LUAD	cis	rs7945705	0.846	rs2742540	ENSG00000254860.4	TMEM9B-AS1	-5.93	5.66e-09	2.27e-06	-0.29	-0.26	Hemoglobin concentration;	chr11:8877981	chr11:8964675~8977527:+
LUAD	cis	rs6558530	0.73	rs7014327	ENSG00000253982.1	CTD-2336O2.1	5.93	5.66e-09	2.28e-06	0.31	0.26	Systolic blood pressure;	chr8:1775886	chr8:1761990~1764502:-
LUAD	cis	rs7811142	1	rs1000215	ENSG00000078319.8	PMS2P1	-5.93	5.67e-09	2.28e-06	-0.3	-0.26	Platelet count;	chr7:100406920	chr7:100320992~100341908:-
LUAD	cis	rs7044106	0.762	rs966396	ENSG00000238181.2	AHCYP2	-5.93	5.67e-09	2.28e-06	-0.34	-0.26	Hip circumference adjusted for BMI;	chr9:120691003	chr9:120720673~120721972:+
LUAD	cis	rs11089937	0.568	rs5756988	ENSG00000211638.2	IGLV8-61	5.93	5.67e-09	2.28e-06	0.3	0.26	Periodontitis (PAL4Q3);	chr22:22132397	chr22:22098700~22099212:+
LUAD	cis	rs6504622	0.967	rs11869840	ENSG00000262879.4	RP11-156P1.3	-5.93	5.67e-09	2.28e-06	-0.3	-0.26	Orofacial clefts;	chr17:46918734	chr17:46984045~47100323:-
LUAD	cis	rs11098499	0.913	rs11098496	ENSG00000248280.1	RP11-33B1.2	5.93	5.68e-09	2.28e-06	0.32	0.26	Corneal astigmatism;	chr4:119246311	chr4:119440561~119450157:-
LUAD	cis	rs1499614	0.901	rs2178742	ENSG00000230295.1	RP11-458F8.2	-5.93	5.69e-09	2.29e-06	-0.33	-0.26	Gout;	chr7:66732812	chr7:66880708~66882981:+
LUAD	cis	rs7221109	0.71	rs1048572	ENSG00000278834.1	RP11-458J1.1	-5.93	5.69e-09	2.29e-06	-0.3	-0.26	Type 1 diabetes;	chr17:40640990	chr17:40648300~40649718:+
LUAD	cis	rs9326248	0.539	rs7120565	ENSG00000280143.1	AP000892.6	5.93	5.69e-09	2.29e-06	0.3	0.26	Blood protein levels;	chr11:117172233	chr11:117204967~117210292:+
LUAD	cis	rs2404602	0.583	rs12907668	ENSG00000259422.1	RP11-593F23.1	5.93	5.7e-09	2.29e-06	0.29	0.26	Blood metabolite levels;	chr15:76297426	chr15:76174891~76181486:-
LUAD	cis	rs12699921	0.632	rs1404414	ENSG00000279048.1	RP11-511H23.2	5.93	5.7e-09	2.29e-06	0.21	0.26	Fibrinogen levels;	chr7:17826764	chr7:17940503~17942922:+
LUAD	cis	rs858239	0.57	rs10271613	ENSG00000230042.1	AK3P3	-5.93	5.72e-09	2.3e-06	-0.32	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.57	rs10242166	ENSG00000230042.1	AK3P3	-5.93	5.72e-09	2.3e-06	-0.32	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23129178~23129841:+
LUAD	cis	rs8177376	1	rs692955	ENSG00000254905.1	RP11-712L6.7	5.93	5.72e-09	2.3e-06	0.37	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126214601	chr11:126292922~126294254:-
LUAD	cis	rs2562456	0.917	rs2681392	ENSG00000268081.1	RP11-678G14.2	-5.93	5.72e-09	2.3e-06	-0.4	-0.26	Pain;	chr19:21513185	chr19:21554640~21569237:-
LUAD	cis	rs1075265	0.722	rs2111623	ENSG00000233266.1	HMGB1P31	-5.93	5.73e-09	2.3e-06	-0.32	-0.26	Chronotype;Morning vs. evening chronotype;	chr2:53757820	chr2:54051334~54051760:+
LUAD	cis	rs2404602	0.684	rs1603860	ENSG00000259422.1	RP11-593F23.1	-5.93	5.73e-09	2.3e-06	-0.34	-0.26	Blood metabolite levels;	chr15:76557250	chr15:76174891~76181486:-
LUAD	cis	rs4718428	0.705	rs4718424	ENSG00000232546.1	RP11-458F8.1	-5.93	5.73e-09	2.3e-06	-0.25	-0.26	Corneal structure;	chr7:66911108	chr7:66848496~66858136:+
LUAD	cis	rs1499614	0.522	rs13247442	ENSG00000273142.1	RP11-458F8.4	-5.93	5.73e-09	2.3e-06	-0.32	-0.26	Gout;	chr7:66723871	chr7:66902857~66906297:+
LUAD	cis	rs853679	0.517	rs9357065	ENSG00000204709.4	LINC01556	5.93	5.74e-09	2.3e-06	0.37	0.26	Depression;	chr6:28161802	chr6:28943877~28944537:+
LUAD	cis	rs7945705	0.935	rs11042103	ENSG00000254860.4	TMEM9B-AS1	-5.93	5.74e-09	2.3e-06	-0.3	-0.26	Hemoglobin concentration;	chr11:8867153	chr11:8964675~8977527:+
LUAD	cis	rs7911264	0.967	rs2497318	ENSG00000236493.2	EIF2S2P3	-5.93	5.74e-09	2.3e-06	-0.3	-0.26	Inflammatory bowel disease;	chr10:92672243	chr10:92668745~92669743:-
LUAD	cis	rs12699921	0.632	rs2691609	ENSG00000279048.1	RP11-511H23.2	-5.93	5.74e-09	2.31e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17841539	chr7:17940503~17942922:+
LUAD	cis	rs7221109	0.677	rs8068721	ENSG00000278834.1	RP11-458J1.1	5.93	5.74e-09	2.31e-06	0.3	0.26	Type 1 diabetes;	chr17:40657572	chr17:40648300~40649718:+
LUAD	cis	rs7221109	0.625	rs2008469	ENSG00000278834.1	RP11-458J1.1	5.93	5.74e-09	2.31e-06	0.3	0.26	Type 1 diabetes;	chr17:40660343	chr17:40648300~40649718:+
LUAD	cis	rs7221109	0.677	rs12943859	ENSG00000278834.1	RP11-458J1.1	5.93	5.74e-09	2.31e-06	0.3	0.26	Type 1 diabetes;	chr17:40661128	chr17:40648300~40649718:+
LUAD	cis	rs2303759	0.83	rs7257053	ENSG00000268686.1	AC010524.2	-5.93	5.75e-09	2.31e-06	-0.37	-0.26	Multiple sclerosis;	chr19:49391199	chr19:49368705~49388081:-
LUAD	cis	rs75422866	0.51	rs75424057	ENSG00000274902.1	RP1-197B17.4	5.93	5.75e-09	2.31e-06	0.57	0.26	Pneumonia;	chr12:47737294	chr12:47731908~47732351:+
LUAD	cis	rs1113500	0.933	rs3909076	ENSG00000226822.1	RP11-356N1.2	5.93	5.75e-09	2.31e-06	0.31	0.26	Growth-regulated protein alpha levels;	chr1:108089138	chr1:108071482~108074519:+
LUAD	cis	rs11098499	0.955	rs13129661	ENSG00000248280.1	RP11-33B1.2	5.93	5.75e-09	2.31e-06	0.33	0.26	Corneal astigmatism;	chr4:119231754	chr4:119440561~119450157:-
LUAD	cis	rs12699921	0.632	rs2691613	ENSG00000279048.1	RP11-511H23.2	-5.93	5.76e-09	2.31e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17844358	chr7:17940503~17942922:+
LUAD	cis	rs1707322	0.686	rs2991977	ENSG00000280836.1	AL355480.1	5.93	5.76e-09	2.31e-06	0.34	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45588011	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.656	rs2991981	ENSG00000280836.1	AL355480.1	5.93	5.76e-09	2.31e-06	0.34	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45591472	chr1:45581219~45581321:-
LUAD	cis	rs67311347	0.822	rs11709089	ENSG00000223797.4	ENTPD3-AS1	5.93	5.76e-09	2.31e-06	0.28	0.26	Renal cell carcinoma;	chr3:40309993	chr3:40313802~40453329:-
LUAD	cis	rs67311347	0.866	rs9826419	ENSG00000223797.4	ENTPD3-AS1	5.93	5.76e-09	2.31e-06	0.28	0.26	Renal cell carcinoma;	chr3:40310560	chr3:40313802~40453329:-
LUAD	cis	rs67311347	0.866	rs3214006	ENSG00000223797.4	ENTPD3-AS1	5.93	5.76e-09	2.31e-06	0.28	0.26	Renal cell carcinoma;	chr3:40310643	chr3:40313802~40453329:-
LUAD	cis	rs67311347	0.824	rs73073561	ENSG00000223797.4	ENTPD3-AS1	5.93	5.76e-09	2.31e-06	0.28	0.26	Renal cell carcinoma;	chr3:40315807	chr3:40313802~40453329:-
LUAD	cis	rs11690935	0.589	rs2271758	ENSG00000228389.1	AC068039.4	-5.93	5.76e-09	2.31e-06	-0.28	-0.26	Schizophrenia;	chr2:171844647	chr2:171773482~171775844:+
LUAD	cis	rs1075265	0.84	rs10084355	ENSG00000233266.1	HMGB1P31	5.93	5.77e-09	2.31e-06	0.33	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54021711	chr2:54051334~54051760:+
LUAD	cis	rs66887589	0.592	rs11731571	ENSG00000248280.1	RP11-33B1.2	5.93	5.77e-09	2.32e-06	0.29	0.26	Diastolic blood pressure;	chr4:119300030	chr4:119440561~119450157:-
LUAD	cis	rs10754283	0.967	rs10737707	ENSG00000231613.1	RP5-943J3.1	5.93	5.77e-09	2.32e-06	0.27	0.26	Amyotrophic lateral sclerosis (sporadic);	chr1:89653745	chr1:89788914~89790492:+
LUAD	cis	rs10754283	0.967	rs10737708	ENSG00000231613.1	RP5-943J3.1	5.93	5.77e-09	2.32e-06	0.27	0.26	Amyotrophic lateral sclerosis (sporadic);	chr1:89654245	chr1:89788914~89790492:+
LUAD	cis	rs10754283	0.967	rs10801763	ENSG00000231613.1	RP5-943J3.1	5.93	5.77e-09	2.32e-06	0.27	0.26	Amyotrophic lateral sclerosis (sporadic);	chr1:89655263	chr1:89788914~89790492:+
LUAD	cis	rs1823913	0.637	rs4853577	ENSG00000227542.1	AC092614.2	-5.93	5.78e-09	2.32e-06	-0.32	-0.26	Obesity-related traits;	chr2:191297118	chr2:191229165~191246172:-
LUAD	cis	rs2243480	1	rs316329	ENSG00000232546.1	RP11-458F8.1	-5.93	5.78e-09	2.32e-06	-0.34	-0.26	Diabetic kidney disease;	chr7:66143429	chr7:66848496~66858136:+
LUAD	cis	rs2255336	0.938	rs2417734	ENSG00000245648.1	RP11-277P12.20	5.93	5.79e-09	2.32e-06	0.38	0.26	Blood protein levels;	chr12:10380807	chr12:10363769~10398506:+
LUAD	cis	rs2255336	0.938	rs1382265	ENSG00000245648.1	RP11-277P12.20	5.93	5.79e-09	2.32e-06	0.38	0.26	Blood protein levels;	chr12:10381206	chr12:10363769~10398506:+
LUAD	cis	rs2255336	0.938	rs1478310	ENSG00000245648.1	RP11-277P12.20	5.93	5.79e-09	2.32e-06	0.38	0.26	Blood protein levels;	chr12:10382279	chr12:10363769~10398506:+
LUAD	cis	rs2255336	0.938	rs1600127	ENSG00000245648.1	RP11-277P12.20	5.93	5.79e-09	2.32e-06	0.38	0.26	Blood protein levels;	chr12:10383648	chr12:10363769~10398506:+
LUAD	cis	rs2255336	0.882	rs2617156	ENSG00000245648.1	RP11-277P12.20	5.93	5.79e-09	2.32e-06	0.38	0.26	Blood protein levels;	chr12:10384280	chr12:10363769~10398506:+
LUAD	cis	rs2255336	0.938	rs2617157	ENSG00000245648.1	RP11-277P12.20	5.93	5.79e-09	2.32e-06	0.38	0.26	Blood protein levels;	chr12:10384299	chr12:10363769~10398506:+
LUAD	cis	rs2255336	0.938	rs2927561	ENSG00000245648.1	RP11-277P12.20	5.93	5.79e-09	2.32e-06	0.38	0.26	Blood protein levels;	chr12:10384974	chr12:10363769~10398506:+
LUAD	cis	rs2255336	0.882	rs2126889	ENSG00000245648.1	RP11-277P12.20	5.93	5.79e-09	2.32e-06	0.38	0.26	Blood protein levels;	chr12:10385280	chr12:10363769~10398506:+
LUAD	cis	rs9494145	0.68	rs9389269	ENSG00000232876.1	CTA-212D2.2	-5.93	5.79e-09	2.32e-06	-0.36	-0.26	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135106021	chr6:135055033~135060550:+
LUAD	cis	rs293748	0.771	rs292181	ENSG00000250155.1	CTD-2353F22.1	-5.93	5.8e-09	2.33e-06	-0.37	-0.26	Obesity-related traits;	chr5:36952474	chr5:36666214~36725195:-
LUAD	cis	rs293748	0.771	rs292186	ENSG00000250155.1	CTD-2353F22.1	-5.93	5.8e-09	2.33e-06	-0.37	-0.26	Obesity-related traits;	chr5:36967320	chr5:36666214~36725195:-
LUAD	cis	rs293748	0.771	rs294695	ENSG00000250155.1	CTD-2353F22.1	-5.93	5.8e-09	2.33e-06	-0.37	-0.26	Obesity-related traits;	chr5:36986586	chr5:36666214~36725195:-
LUAD	cis	rs3779195	0.585	rs7777991	ENSG00000272950.1	RP11-307C18.1	-5.93	5.8e-09	2.33e-06	-0.45	-0.26	Sex hormone-binding globulin levels;	chr7:98236445	chr7:98322853~98323430:+
LUAD	cis	rs2276314	1	rs9956938	ENSG00000278986.1	RP11-723J4.3	-5.93	5.8e-09	2.33e-06	-0.33	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:35987098	chr18:35972151~35973916:+
LUAD	cis	rs2404602	0.618	rs12442266	ENSG00000259422.1	RP11-593F23.1	5.93	5.8e-09	2.33e-06	0.29	0.26	Blood metabolite levels;	chr15:76274801	chr15:76174891~76181486:-
LUAD	cis	rs2276314	0.512	rs7234973	ENSG00000278986.1	RP11-723J4.3	-5.93	5.81e-09	2.33e-06	-0.28	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:35870373	chr18:35972151~35973916:+
LUAD	cis	rs1823913	0.637	rs12992372	ENSG00000227542.1	AC092614.2	5.93	5.81e-09	2.33e-06	0.32	0.26	Obesity-related traits;	chr2:191289251	chr2:191229165~191246172:-
LUAD	cis	rs9494145	0.68	rs9402686	ENSG00000232876.1	CTA-212D2.2	-5.93	5.81e-09	2.33e-06	-0.36	-0.26	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135106679	chr6:135055033~135060550:+
LUAD	cis	rs17301013	0.606	rs17350956	ENSG00000227373.4	RP11-160H22.5	5.93	5.82e-09	2.33e-06	0.38	0.26	Systemic lupus erythematosus;	chr1:174093863	chr1:174115300~174160004:-
LUAD	cis	rs3738443	0.817	rs6698690	ENSG00000259865.1	RP11-488L18.10	5.93	5.83e-09	2.34e-06	0.27	0.26	Alcohol dependence;	chr1:247199176	chr1:247187281~247188526:-
LUAD	cis	rs848490	0.651	rs11489586	ENSG00000214293.7	APTR	5.93	5.83e-09	2.34e-06	0.29	0.26	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77685900	chr7:77657660~77696265:-
LUAD	cis	rs875971	0.825	rs1860472	ENSG00000222364.1	RNU6-96P	5.93	5.83e-09	2.34e-06	0.29	0.26	Aortic root size;	chr7:66617736	chr7:66395191~66395286:+
LUAD	cis	rs67311347	1	rs72861689	ENSG00000223797.4	ENTPD3-AS1	5.93	5.83e-09	2.34e-06	0.27	0.26	Renal cell carcinoma;	chr3:40394399	chr3:40313802~40453329:-
LUAD	cis	rs9450351	0.744	rs9353348	ENSG00000203875.9	SNHG5	-5.93	5.84e-09	2.34e-06	-0.53	-0.26	Interferon gamma-induced protein 10 levels;	chr6:85981635	chr6:85660950~85678736:-
LUAD	cis	rs7618501	0.635	rs7635002	ENSG00000234667.1	ACTBP13	-5.93	5.84e-09	2.34e-06	-0.29	-0.26	Intelligence (multi-trait analysis);	chr3:49951722	chr3:49873347~49877980:-
LUAD	cis	rs957448	0.948	rs11992893	ENSG00000253704.1	RP11-267M23.4	5.93	5.85e-09	2.34e-06	0.33	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94508473	chr8:94553722~94569745:+
LUAD	cis	rs957448	1	rs12678305	ENSG00000253704.1	RP11-267M23.4	5.93	5.85e-09	2.34e-06	0.33	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94508911	chr8:94553722~94569745:+
LUAD	cis	rs957448	1	rs1048029	ENSG00000253704.1	RP11-267M23.4	5.93	5.85e-09	2.34e-06	0.33	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94510149	chr8:94553722~94569745:+
LUAD	cis	rs12701220	0.553	rs7782024	ENSG00000229043.2	AC091729.9	-5.93	5.85e-09	2.34e-06	-0.32	-0.26	Bronchopulmonary dysplasia;	chr7:1117866	chr7:1160374~1165267:+
LUAD	cis	rs2115630	0.691	rs2292462	ENSG00000225151.9	GOLGA2P7	5.93	5.85e-09	2.35e-06	0.3	0.26	P wave terminal force;	chr15:84657523	chr15:84199311~84230136:-
LUAD	cis	rs2276314	1	rs1789513	ENSG00000278986.1	RP11-723J4.3	5.93	5.85e-09	2.35e-06	0.32	0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:35965667	chr18:35972151~35973916:+
LUAD	cis	rs783540	0.681	rs1259178	ENSG00000278603.1	RP13-608F4.5	-5.93	5.86e-09	2.35e-06	-0.32	-0.26	Schizophrenia;	chr15:82603127	chr15:82472203~82472426:+
LUAD	cis	rs853679	0.517	rs4713152	ENSG00000204709.4	LINC01556	5.93	5.86e-09	2.35e-06	0.37	0.26	Depression;	chr6:28169676	chr6:28943877~28944537:+
LUAD	cis	rs2404602	0.583	rs12898415	ENSG00000259422.1	RP11-593F23.1	5.93	5.86e-09	2.35e-06	0.29	0.26	Blood metabolite levels;	chr15:76281891	chr15:76174891~76181486:-
LUAD	cis	rs494459	0.838	rs12796102	ENSG00000278376.1	RP11-158I9.8	-5.93	5.86e-09	2.35e-06	-0.28	-0.26	Height;	chr11:118791319	chr11:118791254~118793137:+
LUAD	cis	rs11971779	0.553	rs10085770	ENSG00000273391.1	RP11-634H22.1	5.93	5.87e-09	2.35e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139415603	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs2355788	ENSG00000273391.1	RP11-634H22.1	5.93	5.87e-09	2.35e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139417151	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.618	rs3778931	ENSG00000273391.1	RP11-634H22.1	5.93	5.87e-09	2.35e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139417744	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.616	rs10278377	ENSG00000273391.1	RP11-634H22.1	5.93	5.87e-09	2.35e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139418325	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.618	rs13068	ENSG00000273391.1	RP11-634H22.1	5.93	5.87e-09	2.35e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139419395	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.648	rs6946113	ENSG00000273391.1	RP11-634H22.1	5.93	5.87e-09	2.35e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139421380	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs6946393	ENSG00000273391.1	RP11-634H22.1	5.93	5.87e-09	2.35e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139421423	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.553	rs10269108	ENSG00000273391.1	RP11-634H22.1	5.93	5.87e-09	2.35e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139421586	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs9683	ENSG00000273391.1	RP11-634H22.1	5.93	5.87e-09	2.35e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139422993	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs10085901	ENSG00000273391.1	RP11-634H22.1	5.93	5.87e-09	2.35e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139424243	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs10085902	ENSG00000273391.1	RP11-634H22.1	5.93	5.87e-09	2.35e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139424359	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.617	rs66652773	ENSG00000273391.1	RP11-634H22.1	5.93	5.87e-09	2.35e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139424827	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.648	rs10085708	ENSG00000273391.1	RP11-634H22.1	5.93	5.87e-09	2.35e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139426208	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs7805767	ENSG00000273391.1	RP11-634H22.1	5.93	5.87e-09	2.35e-06	0.27	0.26	Diisocyanate-induced asthma;	chr7:139426669	chr7:139359032~139359566:-
LUAD	cis	rs957448	0.904	rs56302978	ENSG00000253704.1	RP11-267M23.4	5.93	5.87e-09	2.35e-06	0.33	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94505883	chr8:94553722~94569745:+
LUAD	cis	rs6142102	0.538	rs6142058	ENSG00000275784.1	RP5-1125A11.6	-5.93	5.87e-09	2.35e-06	-0.28	-0.26	Skin pigmentation;	chr20:33954995	chr20:33989480~33991818:-
LUAD	cis	rs2734839	0.964	rs7131440	ENSG00000270179.1	RP11-159N11.4	5.93	5.87e-09	2.35e-06	0.27	0.26	Information processing speed;	chr11:113429188	chr11:113368478~113369117:+
LUAD	cis	rs7945705	0.935	rs11042102	ENSG00000254860.4	TMEM9B-AS1	-5.93	5.88e-09	2.35e-06	-0.3	-0.26	Hemoglobin concentration;	chr11:8860617	chr11:8964675~8977527:+
LUAD	cis	rs6840258	0.66	rs17012200	ENSG00000251411.1	RP11-397E7.4	5.93	5.89e-09	2.36e-06	0.35	0.26	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86963494	chr4:86913266~86914817:-
LUAD	cis	rs7182621	0.639	rs12906050	ENSG00000259363.4	CTD-2054N24.2	-5.93	5.89e-09	2.36e-06	-0.35	-0.26	Colonoscopy-negative controls vs population controls;	chr15:99873384	chr15:99807023~99877148:+
LUAD	cis	rs7182621	0.639	rs35248328	ENSG00000259363.4	CTD-2054N24.2	-5.93	5.89e-09	2.36e-06	-0.35	-0.26	Colonoscopy-negative controls vs population controls;	chr15:99873399	chr15:99807023~99877148:+
LUAD	cis	rs17684571	0.751	rs13195601	ENSG00000231441.1	RP11-472M19.2	5.93	5.89e-09	2.36e-06	0.4	0.26	Schizophrenia;	chr6:56836186	chr6:56844002~56864078:+
LUAD	cis	rs4713118	0.869	rs9295743	ENSG00000219392.1	RP1-265C24.5	-5.93	5.89e-09	2.36e-06	-0.35	-0.26	Parkinson's disease;	chr6:27747323	chr6:28115628~28116551:+
LUAD	cis	rs875971	0.756	rs2901210	ENSG00000237310.1	GS1-124K5.4	-5.93	5.9e-09	2.36e-06	-0.29	-0.26	Aortic root size;	chr7:66552518	chr7:66493706~66495474:+
LUAD	cis	rs7618501	0.633	rs6446189	ENSG00000234667.1	ACTBP13	-5.93	5.9e-09	2.36e-06	-0.29	-0.26	Intelligence (multi-trait analysis);	chr3:49971133	chr3:49873347~49877980:-
LUAD	cis	rs12908161	0.959	rs62019472	ENSG00000259728.4	LINC00933	5.93	5.9e-09	2.36e-06	0.38	0.26	Schizophrenia;	chr15:84788262	chr15:84570649~84580175:+
LUAD	cis	rs858239	0.601	rs73272048	ENSG00000230042.1	AK3P3	-5.93	5.9e-09	2.36e-06	-0.32	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23129178~23129841:+
LUAD	cis	rs10129255	1	rs10129319	ENSG00000211972.2	IGHV3-66	5.93	5.91e-09	2.37e-06	0.22	0.26	Kawasaki disease;	chr14:106767996	chr14:106675017~106675544:-
LUAD	cis	rs875971	0.862	rs1695820	ENSG00000237310.1	GS1-124K5.4	5.93	5.92e-09	2.37e-06	0.28	0.26	Aortic root size;	chr7:66379576	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.83	rs778715	ENSG00000237310.1	GS1-124K5.4	5.93	5.92e-09	2.37e-06	0.28	0.26	Aortic root size;	chr7:66384222	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.83	rs809025	ENSG00000237310.1	GS1-124K5.4	5.93	5.92e-09	2.37e-06	0.28	0.26	Aortic root size;	chr7:66384832	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs778702	ENSG00000237310.1	GS1-124K5.4	5.93	5.92e-09	2.37e-06	0.28	0.26	Aortic root size;	chr7:66399848	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs1643375	ENSG00000237310.1	GS1-124K5.4	5.93	5.92e-09	2.37e-06	0.28	0.26	Aortic root size;	chr7:66407690	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs6962717	ENSG00000237310.1	GS1-124K5.4	5.93	5.92e-09	2.37e-06	0.28	0.26	Aortic root size;	chr7:66418748	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs35378740	ENSG00000222364.1	RNU6-96P	-5.93	5.92e-09	2.37e-06	-0.3	-0.26	Aortic root size;	chr7:66522725	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs10950043	ENSG00000222364.1	RNU6-96P	-5.93	5.92e-09	2.37e-06	-0.3	-0.26	Aortic root size;	chr7:66523623	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs17747530	ENSG00000222364.1	RNU6-96P	-5.93	5.92e-09	2.37e-06	-0.3	-0.26	Aortic root size;	chr7:66529742	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs13226170	ENSG00000222364.1	RNU6-96P	-5.93	5.92e-09	2.37e-06	-0.3	-0.26	Aortic root size;	chr7:66534311	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs2420611	ENSG00000222364.1	RNU6-96P	-5.93	5.92e-09	2.37e-06	-0.3	-0.26	Aortic root size;	chr7:66534333	chr7:66395191~66395286:+
LUAD	cis	rs55823223	0.702	rs3785437	ENSG00000267801.1	RP11-552F3.9	5.93	5.92e-09	2.37e-06	0.4	0.26	Psoriasis;	chr17:75910141	chr17:75876372~75879546:+
LUAD	cis	rs875971	0.862	rs4236208	ENSG00000237310.1	GS1-124K5.4	-5.93	5.92e-09	2.37e-06	-0.29	-0.26	Aortic root size;	chr7:66284091	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs10261398	ENSG00000237310.1	GS1-124K5.4	-5.93	5.92e-09	2.37e-06	-0.29	-0.26	Aortic root size;	chr7:66285177	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs10224872	ENSG00000237310.1	GS1-124K5.4	-5.93	5.92e-09	2.37e-06	-0.29	-0.26	Aortic root size;	chr7:66294786	chr7:66493706~66495474:+
LUAD	cis	rs3738443	0.817	rs61839996	ENSG00000259865.1	RP11-488L18.10	5.93	5.92e-09	2.37e-06	0.27	0.26	Alcohol dependence;	chr1:247197571	chr1:247187281~247188526:-
LUAD	cis	rs3738443	0.83	rs58405512	ENSG00000259865.1	RP11-488L18.10	5.93	5.92e-09	2.37e-06	0.27	0.26	Alcohol dependence;	chr1:247198454	chr1:247187281~247188526:-
LUAD	cis	rs6921919	0.583	rs3734563	ENSG00000204709.4	LINC01556	5.93	5.92e-09	2.37e-06	0.33	0.26	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs1591913	ENSG00000204709.4	LINC01556	5.93	5.92e-09	2.37e-06	0.33	0.26	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28943877~28944537:+
LUAD	cis	rs957448	0.554	rs72674877	ENSG00000253704.1	RP11-267M23.4	5.93	5.92e-09	2.37e-06	0.3	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94580479	chr8:94553722~94569745:+
LUAD	cis	rs293748	0.771	rs16903490	ENSG00000250155.1	CTD-2353F22.1	-5.93	5.93e-09	2.37e-06	-0.37	-0.26	Obesity-related traits;	chr5:37067944	chr5:36666214~36725195:-
LUAD	cis	rs2288884	1	rs72483951	ENSG00000275055.1	CTC-471J1.11	-5.93	5.93e-09	2.37e-06	-0.41	-0.26	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52070429	chr19:52049007~52049754:+
LUAD	cis	rs957448	1	rs72674843	ENSG00000253704.1	RP11-267M23.4	5.93	5.94e-09	2.38e-06	0.33	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94520772	chr8:94553722~94569745:+
LUAD	cis	rs2404602	0.684	rs12591622	ENSG00000259422.1	RP11-593F23.1	-5.93	5.94e-09	2.38e-06	-0.35	-0.26	Blood metabolite levels;	chr15:76638314	chr15:76174891~76181486:-
LUAD	cis	rs6921919	0.515	rs1558205	ENSG00000204709.4	LINC01556	-5.93	5.94e-09	2.38e-06	-0.33	-0.26	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28943877~28944537:+
LUAD	cis	rs74233809	1	rs11191580	ENSG00000213277.3	MARCKSL1P1	-5.93	5.94e-09	2.38e-06	-0.44	-0.26	Birth weight;	chr10:103146454	chr10:103175554~103176094:+
LUAD	cis	rs7849270	0.921	rs7019373	ENSG00000268707.1	RP11-247A12.7	-5.93	5.95e-09	2.38e-06	-0.29	-0.26	Blood metabolite ratios;	chr9:129134942	chr9:129170434~129170940:+
LUAD	cis	rs12908161	0.959	rs62019472	ENSG00000225151.9	GOLGA2P7	-5.93	5.95e-09	2.38e-06	-0.35	-0.26	Schizophrenia;	chr15:84788262	chr15:84199311~84230136:-
LUAD	cis	rs66887589	0.616	rs7659403	ENSG00000248280.1	RP11-33B1.2	5.93	5.95e-09	2.38e-06	0.29	0.26	Diastolic blood pressure;	chr4:119286099	chr4:119440561~119450157:-
LUAD	cis	rs2243480	1	rs313832	ENSG00000232546.1	RP11-458F8.1	-5.93	5.95e-09	2.38e-06	-0.34	-0.26	Diabetic kidney disease;	chr7:66085904	chr7:66848496~66858136:+
LUAD	cis	rs875971	0.862	rs778724	ENSG00000237310.1	GS1-124K5.4	5.93	5.95e-09	2.38e-06	0.28	0.26	Aortic root size;	chr7:66364304	chr7:66493706~66495474:+
LUAD	cis	rs293748	0.571	rs16903531	ENSG00000250155.1	CTD-2353F22.1	-5.92	5.96e-09	2.39e-06	-0.33	-0.26	Obesity-related traits;	chr5:37197058	chr5:36666214~36725195:-
LUAD	cis	rs4835473	0.932	rs28796049	ENSG00000251600.4	RP11-673E1.1	5.92	5.97e-09	2.39e-06	0.32	0.26	Immature fraction of reticulocytes;	chr4:143733990	chr4:143912331~143982454:+
LUAD	cis	rs6921919	0.583	rs7764722	ENSG00000216901.1	AL022393.7	5.92	5.97e-09	2.39e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28176188~28176674:+
LUAD	cis	rs7923609	0.967	rs7896783	ENSG00000232075.1	MRPL35P2	-5.92	5.98e-09	2.39e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63402393	chr10:63634317~63634827:-
LUAD	cis	rs9326248	0.52	rs6589602	ENSG00000280143.1	AP000892.6	5.92	5.98e-09	2.39e-06	0.3	0.26	Blood protein levels;	chr11:117166349	chr11:117204967~117210292:+
LUAD	cis	rs7397814	0.558	rs4764447	ENSG00000214776.8	RP11-726G1.1	-5.92	5.99e-09	2.4e-06	-0.31	-0.26	IgG glycosylation;	chr12:9426513	chr12:9467552~9576275:+
LUAD	cis	rs6840258	0.66	rs74784659	ENSG00000251411.1	RP11-397E7.4	-5.92	6e-09	2.4e-06	-0.36	-0.26	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86967777	chr4:86913266~86914817:-
LUAD	cis	rs6840258	0.66	rs17012213	ENSG00000251411.1	RP11-397E7.4	-5.92	6e-09	2.4e-06	-0.36	-0.26	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86968015	chr4:86913266~86914817:-
LUAD	cis	rs6840258	0.66	rs17012216	ENSG00000251411.1	RP11-397E7.4	-5.92	6e-09	2.4e-06	-0.36	-0.26	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86968285	chr4:86913266~86914817:-
LUAD	cis	rs801193	0.569	rs35070132	ENSG00000222364.1	RNU6-96P	-5.92	6e-09	2.4e-06	-0.3	-0.26	Aortic root size;	chr7:66773096	chr7:66395191~66395286:+
LUAD	cis	rs8072100	0.688	rs12602134	ENSG00000228782.6	CTD-2026D20.3	-5.92	6e-09	2.4e-06	-0.27	-0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47504770	chr17:47450568~47492492:-
LUAD	cis	rs2439831	0.85	rs7181039	ENSG00000205771.5	CATSPER2P1	-5.92	6e-09	2.4e-06	-0.55	-0.26	Lung cancer in ever smokers;	chr15:43886914	chr15:43726918~43747094:-
LUAD	cis	rs453301	0.686	rs11787026	ENSG00000253981.4	ALG1L13P	5.92	6.01e-09	2.4e-06	0.3	0.26	Joint mobility (Beighton score);	chr8:9044861	chr8:8236003~8244667:-
LUAD	cis	rs1823913	0.599	rs56328712	ENSG00000280083.1	RP11-317J9.1	-5.92	6.02e-09	2.41e-06	-0.31	-0.26	Obesity-related traits;	chr2:191273807	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.599	rs55862924	ENSG00000280083.1	RP11-317J9.1	-5.92	6.02e-09	2.41e-06	-0.31	-0.26	Obesity-related traits;	chr2:191273809	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.599	rs12989203	ENSG00000280083.1	RP11-317J9.1	-5.92	6.02e-09	2.41e-06	-0.31	-0.26	Obesity-related traits;	chr2:191276617	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.599	rs34262638	ENSG00000280083.1	RP11-317J9.1	-5.92	6.02e-09	2.41e-06	-0.31	-0.26	Obesity-related traits;	chr2:191279442	chr2:191154118~191156070:-
LUAD	cis	rs9543976	0.623	rs974373	ENSG00000261553.4	RP11-29G8.3	5.92	6.02e-09	2.41e-06	0.34	0.26	Diabetic retinopathy;	chr13:75589660	chr13:75549773~75807120:+
LUAD	cis	rs9595908	0.669	rs9285094	ENSG00000212293.1	SNORA16	5.92	6.02e-09	2.41e-06	0.28	0.26	Body mass index;	chr13:32761453	chr13:32420390~32420516:-
LUAD	cis	rs7246657	0.722	rs16958863	ENSG00000276846.1	CTD-3220F14.3	5.92	6.03e-09	2.41e-06	0.34	0.26	Coronary artery calcification;	chr19:37633334	chr19:37314868~37315620:-
LUAD	cis	rs2283792	0.765	rs9610328	ENSG00000224086.5	LL22NC03-86G7.1	-5.92	6.03e-09	2.41e-06	-0.25	-0.26	Multiple sclerosis;	chr22:21793085	chr22:21938293~21977632:+
LUAD	cis	rs17818399	0.962	rs2122715	ENSG00000279254.1	RP11-536C12.1	-5.92	6.04e-09	2.41e-06	-0.29	-0.26	Height;	chr2:46618710	chr2:46668870~46670778:+
LUAD	cis	rs11098499	0.913	rs68128210	ENSG00000248280.1	RP11-33B1.2	5.92	6.04e-09	2.42e-06	0.34	0.26	Corneal astigmatism;	chr4:119216664	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.913	rs13126596	ENSG00000248280.1	RP11-33B1.2	5.92	6.04e-09	2.42e-06	0.34	0.26	Corneal astigmatism;	chr4:119219574	chr4:119440561~119450157:-
LUAD	cis	rs30380	0.688	rs27524	ENSG00000272109.1	CTD-2260A17.3	-5.92	6.05e-09	2.42e-06	-0.27	-0.26	Cerebrospinal fluid biomarker levels;	chr5:96766240	chr5:96804353~96806105:+
LUAD	cis	rs9595908	0.568	rs61945198	ENSG00000212293.1	SNORA16	5.92	6.05e-09	2.42e-06	0.28	0.26	Body mass index;	chr13:32797780	chr13:32420390~32420516:-
LUAD	cis	rs2790457	0.874	rs2790446	ENSG00000254635.4	WAC-AS1	-5.92	6.05e-09	2.42e-06	-0.29	-0.26	Multiple myeloma;	chr10:28512101	chr10:28522652~28532743:-
LUAD	cis	rs957448	1	rs1055797	ENSG00000253704.1	RP11-267M23.4	5.92	6.06e-09	2.42e-06	0.33	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94511005	chr8:94553722~94569745:+
LUAD	cis	rs3931020	0.616	rs277380	ENSG00000272864.1	RP11-17E13.2	5.92	6.06e-09	2.42e-06	0.37	0.26	Resistin levels;	chr1:74797404	chr1:74698769~74699333:-
LUAD	cis	rs875971	0.545	rs1796226	ENSG00000237310.1	GS1-124K5.4	5.92	6.06e-09	2.42e-06	0.31	0.26	Aortic root size;	chr7:66622723	chr7:66493706~66495474:+
LUAD	cis	rs6921919	0.583	rs9468367	ENSG00000204709.4	LINC01556	5.92	6.06e-09	2.42e-06	0.33	0.26	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28943877~28944537:+
LUAD	cis	rs62445005	1	rs62445005	ENSG00000211698.2	TRGV4	5.92	6.07e-09	2.42e-06	0.31	0.26	Shingles;	chr7:38346957	chr7:38353715~38354517:-
LUAD	cis	rs66887589	0.934	rs2715016	ENSG00000248280.1	RP11-33B1.2	-5.92	6.07e-09	2.43e-06	-0.29	-0.26	Diastolic blood pressure;	chr4:119531201	chr4:119440561~119450157:-
LUAD	cis	rs2243480	0.764	rs2460423	ENSG00000230295.1	RP11-458F8.2	-5.92	6.07e-09	2.43e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66136229	chr7:66880708~66882981:+
LUAD	cis	rs11603023	0.772	rs540800	ENSG00000255239.1	AP002954.6	5.92	6.08e-09	2.43e-06	0.3	0.26	Cholesterol, total;	chr11:118694942	chr11:118688039~118690600:-
LUAD	cis	rs9368481	0.761	rs6918835	ENSG00000241549.7	GUSBP2	-5.92	6.08e-09	2.43e-06	-0.3	-0.26	Autism spectrum disorder or schizophrenia;	chr6:27050048	chr6:26871484~26956554:-
LUAD	cis	rs9543976	1	rs9573592	ENSG00000261553.4	RP11-29G8.3	-5.92	6.08e-09	2.43e-06	-0.41	-0.26	Diabetic retinopathy;	chr13:75623707	chr13:75549773~75807120:+
LUAD	cis	rs1707322	0.686	rs1250	ENSG00000234329.1	RP11-767N6.2	5.92	6.09e-09	2.43e-06	0.28	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628355	chr1:45651039~45651826:-
LUAD	cis	rs858239	0.632	rs1985769	ENSG00000230042.1	AK3P3	-5.92	6.1e-09	2.44e-06	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.6	rs28499396	ENSG00000230042.1	AK3P3	-5.92	6.1e-09	2.44e-06	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.6	rs7789237	ENSG00000230042.1	AK3P3	-5.92	6.1e-09	2.44e-06	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23129178~23129841:+
LUAD	cis	rs35934224	0.831	rs1044732	ENSG00000232926.1	AC000078.5	5.92	6.1e-09	2.44e-06	0.31	0.26	Glaucoma (primary open-angle);	chr22:19875619	chr22:19887289~19887970:+
LUAD	cis	rs1113500	0.933	rs10881498	ENSG00000226822.1	RP11-356N1.2	5.92	6.11e-09	2.44e-06	0.31	0.26	Growth-regulated protein alpha levels;	chr1:108092362	chr1:108071482~108074519:+
LUAD	cis	rs2243480	0.615	rs34363376	ENSG00000232546.1	RP11-458F8.1	-5.92	6.11e-09	2.44e-06	-0.35	-0.26	Diabetic kidney disease;	chr7:66474549	chr7:66848496~66858136:+
LUAD	cis	rs1134634	0.52	rs56041141	ENSG00000273133.1	RP11-799M12.2	-5.92	6.12e-09	2.44e-06	-0.38	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15598222	chr4:15563698~15564253:-
LUAD	cis	rs1134634	0.52	rs28522268	ENSG00000273133.1	RP11-799M12.2	-5.92	6.12e-09	2.44e-06	-0.38	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15601844	chr4:15563698~15564253:-
LUAD	cis	rs1823913	0.637	rs6722183	ENSG00000227542.1	AC092614.2	-5.92	6.12e-09	2.44e-06	-0.32	-0.26	Obesity-related traits;	chr2:191333203	chr2:191229165~191246172:-
LUAD	cis	rs74233809	1	rs79082900	ENSG00000213277.3	MARCKSL1P1	5.92	6.12e-09	2.44e-06	0.44	0.26	Birth weight;	chr10:103117545	chr10:103175554~103176094:+
LUAD	cis	rs1823913	0.614	rs4853576	ENSG00000227542.1	AC092614.2	-5.92	6.13e-09	2.45e-06	-0.32	-0.26	Obesity-related traits;	chr2:191296618	chr2:191229165~191246172:-
LUAD	cis	rs17684571	1	rs16888128	ENSG00000231441.1	RP11-472M19.2	5.92	6.13e-09	2.45e-06	0.35	0.26	Schizophrenia;	chr6:56704306	chr6:56844002~56864078:+
LUAD	cis	rs12908161	1	rs35960805	ENSG00000225151.9	GOLGA2P7	-5.92	6.13e-09	2.45e-06	-0.35	-0.26	Schizophrenia;	chr15:84800749	chr15:84199311~84230136:-
LUAD	cis	rs12908161	1	rs12912388	ENSG00000225151.9	GOLGA2P7	-5.92	6.13e-09	2.45e-06	-0.35	-0.26	Schizophrenia;	chr15:84801319	chr15:84199311~84230136:-
LUAD	cis	rs10214930	0.624	rs4719902	ENSG00000235574.1	AC073150.6	-5.92	6.13e-09	2.45e-06	-0.33	-0.26	Hypospadias;	chr7:27548723	chr7:27491682~27492765:-
LUAD	cis	rs7221109	0.633	rs7209735	ENSG00000278834.1	RP11-458J1.1	5.92	6.14e-09	2.45e-06	0.3	0.26	Type 1 diabetes;	chr17:40662346	chr17:40648300~40649718:+
LUAD	cis	rs66887589	0.807	rs7694483	ENSG00000245958.5	RP11-33B1.1	-5.92	6.15e-09	2.45e-06	-0.21	-0.26	Diastolic blood pressure;	chr4:119484774	chr4:119454791~119552025:+
LUAD	cis	rs17301013	0.507	rs10798324	ENSG00000227373.4	RP11-160H22.5	-5.92	6.16e-09	2.46e-06	-0.38	-0.26	Systemic lupus erythematosus;	chr1:174787485	chr1:174115300~174160004:-
LUAD	cis	rs12935418	1	rs62054589	ENSG00000261838.4	RP11-303E16.6	5.92	6.16e-09	2.46e-06	0.47	0.26	Mean corpuscular volume;	chr16:81035143	chr16:81069854~81076598:+
LUAD	cis	rs2404602	0.716	rs12917430	ENSG00000259422.1	RP11-593F23.1	5.92	6.16e-09	2.46e-06	0.3	0.26	Blood metabolite levels;	chr15:76382019	chr15:76174891~76181486:-
LUAD	cis	rs1113500	0.933	rs3893034	ENSG00000226822.1	RP11-356N1.2	5.92	6.17e-09	2.46e-06	0.31	0.26	Growth-regulated protein alpha levels;	chr1:108089556	chr1:108071482~108074519:+
LUAD	cis	rs1113500	0.933	rs12132785	ENSG00000226822.1	RP11-356N1.2	5.92	6.17e-09	2.46e-06	0.31	0.26	Growth-regulated protein alpha levels;	chr1:108090461	chr1:108071482~108074519:+
LUAD	cis	rs72772090	0.634	rs10515246	ENSG00000248734.2	CTD-2260A17.1	-5.92	6.18e-09	2.47e-06	-0.38	-0.26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96763561	chr5:96784777~96785999:+
LUAD	cis	rs1874124	0.577	rs2807853	ENSG00000272823.1	RP11-295M18.6	5.92	6.18e-09	2.47e-06	0.38	0.26	Cholesterol, total;	chr1:220851011	chr1:220828676~220829211:-
LUAD	cis	rs1874124	0.504	rs2491257	ENSG00000272823.1	RP11-295M18.6	5.92	6.18e-09	2.47e-06	0.38	0.26	Cholesterol, total;	chr1:220855900	chr1:220828676~220829211:-
LUAD	cis	rs2288884	0.581	rs9636144	ENSG00000275055.1	CTC-471J1.11	-5.92	6.19e-09	2.47e-06	-0.32	-0.26	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52057881	chr19:52049007~52049754:+
LUAD	cis	rs6687821	0.515	rs496675	ENSG00000267734.1	RP4-604K5.3	5.92	6.19e-09	2.47e-06	0.32	0.26	Yeast infection;	chr1:86858756	chr1:86932199~86934891:-
LUAD	cis	rs6687821	0.515	rs552483	ENSG00000267734.1	RP4-604K5.3	5.92	6.19e-09	2.47e-06	0.32	0.26	Yeast infection;	chr1:86860335	chr1:86932199~86934891:-
LUAD	cis	rs9652601	0.691	rs12924985	ENSG00000274038.1	RP11-66H6.4	-5.92	6.19e-09	2.47e-06	-0.32	-0.26	Systemic lupus erythematosus;	chr16:11114465	chr16:11056556~11057034:+
LUAD	cis	rs7618501	0.633	rs12485600	ENSG00000234667.1	ACTBP13	-5.92	6.2e-09	2.47e-06	-0.29	-0.26	Intelligence (multi-trait analysis);	chr3:49988097	chr3:49873347~49877980:-
LUAD	cis	rs875971	0.545	rs11767262	ENSG00000226824.5	RP4-756H11.3	-5.92	6.2e-09	2.47e-06	-0.37	-0.26	Aortic root size;	chr7:66302237	chr7:66654538~66669855:+
LUAD	cis	rs2412819	0.571	rs8038068	ENSG00000205771.5	CATSPER2P1	-5.92	6.2e-09	2.47e-06	-0.42	-0.26	Lung cancer;	chr15:43622175	chr15:43726918~43747094:-
LUAD	cis	rs2412819	0.571	rs56246169	ENSG00000205771.5	CATSPER2P1	-5.92	6.2e-09	2.47e-06	-0.42	-0.26	Lung cancer;	chr15:43628358	chr15:43726918~43747094:-
LUAD	cis	rs2412819	0.571	rs17727853	ENSG00000205771.5	CATSPER2P1	-5.92	6.2e-09	2.47e-06	-0.42	-0.26	Lung cancer;	chr15:43630299	chr15:43726918~43747094:-
LUAD	cis	rs2412819	0.571	rs62018900	ENSG00000205771.5	CATSPER2P1	-5.92	6.2e-09	2.47e-06	-0.42	-0.26	Lung cancer;	chr15:43633252	chr15:43726918~43747094:-
LUAD	cis	rs2412819	0.545	rs35333173	ENSG00000205771.5	CATSPER2P1	-5.92	6.2e-09	2.47e-06	-0.42	-0.26	Lung cancer;	chr15:43640818	chr15:43726918~43747094:-
LUAD	cis	rs2412819	0.571	rs112667279	ENSG00000205771.5	CATSPER2P1	-5.92	6.2e-09	2.47e-06	-0.42	-0.26	Lung cancer;	chr15:43649258	chr15:43726918~43747094:-
LUAD	cis	rs496547	0.686	rs524590	ENSG00000255239.1	AP002954.6	5.92	6.2e-09	2.47e-06	0.32	0.26	Hip minimal joint space width;	chr11:118769354	chr11:118688039~118690600:-
LUAD	cis	rs7849270	1	rs10819471	ENSG00000268707.1	RP11-247A12.7	-5.92	6.2e-09	2.47e-06	-0.3	-0.26	Blood metabolite ratios;	chr9:129134046	chr9:129170434~129170940:+
LUAD	cis	rs875971	0.767	rs1643394	ENSG00000237310.1	GS1-124K5.4	5.92	6.22e-09	2.48e-06	0.28	0.26	Aortic root size;	chr7:66371107	chr7:66493706~66495474:+
LUAD	cis	rs1823913	0.637	rs12624271	ENSG00000227542.1	AC092614.2	-5.92	6.22e-09	2.48e-06	-0.32	-0.26	Obesity-related traits;	chr2:191288586	chr2:191229165~191246172:-
LUAD	cis	rs2243480	1	rs316332	ENSG00000230295.1	RP11-458F8.2	-5.92	6.23e-09	2.48e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66139312	chr7:66880708~66882981:+
LUAD	cis	rs9847710	0.733	rs2581790	ENSG00000242142.1	SERBP1P3	5.92	6.24e-09	2.49e-06	0.29	0.26	Ulcerative colitis;	chr3:53067764	chr3:53064283~53065091:-
LUAD	cis	rs875971	0.862	rs1875057	ENSG00000237310.1	GS1-124K5.4	-5.92	6.25e-09	2.49e-06	-0.28	-0.26	Aortic root size;	chr7:66266868	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs6960446	ENSG00000237310.1	GS1-124K5.4	-5.92	6.25e-09	2.49e-06	-0.28	-0.26	Aortic root size;	chr7:66268272	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.789	rs10260426	ENSG00000237310.1	GS1-124K5.4	-5.92	6.25e-09	2.49e-06	-0.28	-0.26	Aortic root size;	chr7:66271055	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs7796162	ENSG00000237310.1	GS1-124K5.4	-5.92	6.25e-09	2.49e-06	-0.28	-0.26	Aortic root size;	chr7:66280771	chr7:66493706~66495474:+
LUAD	cis	rs9450351	0.744	rs9450313	ENSG00000203875.9	SNHG5	-5.92	6.25e-09	2.49e-06	-0.56	-0.26	Interferon gamma-induced protein 10 levels;	chr6:85684419	chr6:85660950~85678736:-
LUAD	cis	rs7618501	0.633	rs9853222	ENSG00000234667.1	ACTBP13	-5.92	6.25e-09	2.49e-06	-0.29	-0.26	Intelligence (multi-trait analysis);	chr3:49985493	chr3:49873347~49877980:-
LUAD	cis	rs7618501	0.635	rs34080578	ENSG00000234667.1	ACTBP13	-5.92	6.25e-09	2.49e-06	-0.29	-0.26	Intelligence (multi-trait analysis);	chr3:49988596	chr3:49873347~49877980:-
LUAD	cis	rs9928842	0.823	rs11149811	ENSG00000280152.1	RP11-331F4.5	5.92	6.25e-09	2.49e-06	0.3	0.26	Alcoholic chronic pancreatitis;	chr16:75266810	chr16:75245994~75250077:-
LUAD	cis	rs889312	0.532	rs16886181	ENSG00000271828.1	CTD-2310F14.1	5.92	6.25e-09	2.49e-06	0.41	0.26	Breast cancer (early onset);Breast cancer;	chr5:56733416	chr5:56927874~56929573:+
LUAD	cis	rs875971	0.545	rs73146609	ENSG00000226824.5	RP4-756H11.3	-5.92	6.25e-09	2.49e-06	-0.39	-0.26	Aortic root size;	chr7:66302477	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.545	rs2173571	ENSG00000226824.5	RP4-756H11.3	-5.92	6.25e-09	2.49e-06	-0.39	-0.26	Aortic root size;	chr7:66305392	chr7:66654538~66669855:+
LUAD	cis	rs9928842	0.882	rs11641896	ENSG00000280152.1	RP11-331F4.5	5.92	6.26e-09	2.5e-06	0.3	0.26	Alcoholic chronic pancreatitis;	chr16:75266281	chr16:75245994~75250077:-
LUAD	cis	rs17301013	0.606	rs162815	ENSG00000227373.4	RP11-160H22.5	5.92	6.27e-09	2.5e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174738792	chr1:174115300~174160004:-
LUAD	cis	rs2439831	0.702	rs16977724	ENSG00000205771.5	CATSPER2P1	-5.92	6.27e-09	2.5e-06	-0.57	-0.26	Lung cancer in ever smokers;	chr15:43859101	chr15:43726918~43747094:-
LUAD	cis	rs783540	0.843	rs9652567	ENSG00000278603.1	RP13-608F4.5	5.92	6.27e-09	2.5e-06	0.3	0.26	Schizophrenia;	chr15:82699762	chr15:82472203~82472426:+
LUAD	cis	rs5753618	0.583	rs5753628	ENSG00000236132.1	CTA-440B3.1	-5.92	6.27e-09	2.5e-06	-0.32	-0.26	Colorectal cancer;	chr22:31464336	chr22:31816379~31817491:-
LUAD	cis	rs7246657	0.722	rs3101746	ENSG00000276846.1	CTD-3220F14.3	-5.92	6.28e-09	2.5e-06	-0.36	-0.26	Coronary artery calcification;	chr19:37655499	chr19:37314868~37315620:-
LUAD	cis	rs7044106	0.762	rs10984972	ENSG00000238181.2	AHCYP2	-5.92	6.28e-09	2.5e-06	-0.33	-0.26	Hip circumference adjusted for BMI;	chr9:120647586	chr9:120720673~120721972:+
LUAD	cis	rs2283792	0.765	rs2266969	ENSG00000224086.5	LL22NC03-86G7.1	-5.92	6.28e-09	2.5e-06	-0.25	-0.26	Multiple sclerosis;	chr22:21819618	chr22:21938293~21977632:+
LUAD	cis	rs10129255	0.957	rs6576233	ENSG00000211974.3	IGHV2-70	5.92	6.28e-09	2.5e-06	0.27	0.26	Kawasaki disease;	chr14:106787239	chr14:106723574~106724093:-
LUAD	cis	rs10246939	0.579	rs12703413	ENSG00000228775.6	WEE2-AS1	-5.92	6.28e-09	2.5e-06	-0.31	-0.26	Bitter taste perception;	chr7:141847047	chr7:141704338~141738346:-
LUAD	cis	rs4908760	0.965	rs10864354	ENSG00000232912.4	RP5-1115A15.1	5.92	6.29e-09	2.5e-06	0.25	0.26	Vitiligo;	chr1:8489681	chr1:8424645~8434838:+
LUAD	cis	rs7618501	0.633	rs4688755	ENSG00000234667.1	ACTBP13	5.92	6.29e-09	2.51e-06	0.29	0.26	Intelligence (multi-trait analysis);	chr3:50026991	chr3:49873347~49877980:-
LUAD	cis	rs1501911	0.509	rs34487	ENSG00000248489.1	CTD-2007H13.3	5.91	6.31e-09	2.51e-06	0.28	0.26	Lung function (FEV1/FVC);	chr5:98872725	chr5:98929171~98995013:+
LUAD	cis	rs1501911	0.509	rs327786	ENSG00000248489.1	CTD-2007H13.3	5.91	6.31e-09	2.51e-06	0.28	0.26	Lung function (FEV1/FVC);	chr5:98878301	chr5:98929171~98995013:+
LUAD	cis	rs2034650	0.563	rs11070270	ENSG00000223313.1	RNU6-516P	-5.91	6.31e-09	2.51e-06	-0.33	-0.26	Interstitial lung disease;	chr15:40416223	chr15:40529570~40529673:+
LUAD	cis	rs875971	0.861	rs801215	ENSG00000222364.1	RNU6-96P	5.91	6.31e-09	2.51e-06	0.3	0.26	Aortic root size;	chr7:66546951	chr7:66395191~66395286:+
LUAD	cis	rs1426063	0.748	rs10005117	ENSG00000249717.1	RP11-44F21.3	5.91	6.31e-09	2.51e-06	0.35	0.26	QT interval;	chr4:75108281	chr4:74955974~74970362:-
LUAD	cis	rs2115536	0.73	rs12898642	ENSG00000278600.1	RP11-81A1.6	-5.91	6.31e-09	2.52e-06	-0.21	-0.26	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79889708	chr15:79920195~79922455:-
LUAD	cis	rs7618501	0.633	rs6771546	ENSG00000234667.1	ACTBP13	-5.91	6.32e-09	2.52e-06	-0.29	-0.26	Intelligence (multi-trait analysis);	chr3:49931139	chr3:49873347~49877980:-
LUAD	cis	rs7618501	0.633	rs55751738	ENSG00000234667.1	ACTBP13	-5.91	6.32e-09	2.52e-06	-0.29	-0.26	Intelligence (multi-trait analysis);	chr3:49934668	chr3:49873347~49877980:-
LUAD	cis	rs1823913	0.637	rs4853583	ENSG00000280083.1	RP11-317J9.1	5.91	6.32e-09	2.52e-06	0.31	0.26	Obesity-related traits;	chr2:191304648	chr2:191154118~191156070:-
LUAD	cis	rs3762637	0.943	rs78429050	ENSG00000272758.4	RP11-299J3.8	-5.91	6.33e-09	2.52e-06	-0.4	-0.26	LDL cholesterol levels;	chr3:122533581	chr3:122416207~122443180:+
LUAD	cis	rs9879311	0.966	rs4684684	ENSG00000240288.6	GHRLOS	5.91	6.34e-09	2.52e-06	0.24	0.26	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10369660	chr3:10285754~10293449:+
LUAD	cis	rs12908161	1	rs17601029	ENSG00000225151.9	GOLGA2P7	-5.91	6.35e-09	2.53e-06	-0.35	-0.26	Schizophrenia;	chr15:84804478	chr15:84199311~84230136:-
LUAD	cis	rs853679	0.546	rs34546986	ENSG00000204709.4	LINC01556	5.91	6.35e-09	2.53e-06	0.59	0.26	Depression;	chr6:28394532	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.546	rs34871267	ENSG00000204709.4	LINC01556	5.91	6.35e-09	2.53e-06	0.59	0.26	Depression;	chr6:28396455	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.546	rs35883476	ENSG00000204709.4	LINC01556	5.91	6.35e-09	2.53e-06	0.59	0.26	Depression;	chr6:28400731	chr6:28943877~28944537:+
LUAD	cis	rs948562	0.793	rs11229552	ENSG00000280010.1	AP001350.4	5.91	6.35e-09	2.53e-06	0.43	0.26	Lymphoma;	chr11:58633441	chr11:58627435~58628528:+
LUAD	cis	rs7044106	0.762	rs1158554	ENSG00000238181.2	AHCYP2	-5.91	6.35e-09	2.53e-06	-0.33	-0.26	Hip circumference adjusted for BMI;	chr9:120638620	chr9:120720673~120721972:+
LUAD	cis	rs8177376	0.727	rs658614	ENSG00000254905.1	RP11-712L6.7	5.91	6.36e-09	2.53e-06	0.36	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126328096	chr11:126292922~126294254:-
LUAD	cis	rs293748	0.571	rs13169211	ENSG00000250155.1	CTD-2353F22.1	-5.91	6.37e-09	2.53e-06	-0.33	-0.26	Obesity-related traits;	chr5:37131567	chr5:36666214~36725195:-
LUAD	cis	rs293748	0.571	rs9632396	ENSG00000250155.1	CTD-2353F22.1	-5.91	6.37e-09	2.53e-06	-0.33	-0.26	Obesity-related traits;	chr5:37140229	chr5:36666214~36725195:-
LUAD	cis	rs293748	0.571	rs10512664	ENSG00000250155.1	CTD-2353F22.1	-5.91	6.37e-09	2.53e-06	-0.33	-0.26	Obesity-related traits;	chr5:37158021	chr5:36666214~36725195:-
LUAD	cis	rs2179367	0.613	rs62426122	ENSG00000231760.4	RP11-350J20.5	5.91	6.37e-09	2.54e-06	0.36	0.26	Dupuytren's disease;	chr6:149427449	chr6:149796151~149826294:-
LUAD	cis	rs875971	0.862	rs10282433	ENSG00000237310.1	GS1-124K5.4	-5.91	6.38e-09	2.54e-06	-0.29	-0.26	Aortic root size;	chr7:66256452	chr7:66493706~66495474:+
LUAD	cis	rs17138358	0.515	rs1357796	ENSG00000279048.1	RP11-511H23.2	-5.91	6.38e-09	2.54e-06	-0.21	-0.26	HDL cholesterol levels;	chr7:17833852	chr7:17940503~17942922:+
LUAD	cis	rs765787	0.505	rs11630884	ENSG00000259520.4	CTD-2651B20.3	5.91	6.4e-09	2.55e-06	0.34	0.26	Uric acid levels;	chr15:45240048	chr15:45251580~45279251:-
LUAD	cis	rs7945705	0.902	rs2568059	ENSG00000254860.4	TMEM9B-AS1	5.91	6.4e-09	2.55e-06	0.29	0.26	Hemoglobin concentration;	chr11:8862614	chr11:8964675~8977527:+
LUAD	cis	rs12699921	0.632	rs4543433	ENSG00000279048.1	RP11-511H23.2	-5.91	6.41e-09	2.55e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17926529	chr7:17940503~17942922:+
LUAD	cis	rs853679	0.546	rs2232426	ENSG00000204709.4	LINC01556	5.91	6.41e-09	2.55e-06	0.58	0.26	Depression;	chr6:28392882	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.546	rs2232423	ENSG00000204709.4	LINC01556	5.91	6.41e-09	2.55e-06	0.58	0.26	Depression;	chr6:28398374	chr6:28943877~28944537:+
LUAD	cis	rs12908161	0.92	rs35758837	ENSG00000225151.9	GOLGA2P7	-5.91	6.41e-09	2.55e-06	-0.35	-0.26	Schizophrenia;	chr15:84768151	chr15:84199311~84230136:-
LUAD	cis	rs875971	0.862	rs4718330	ENSG00000237310.1	GS1-124K5.4	-5.91	6.42e-09	2.55e-06	-0.28	-0.26	Aortic root size;	chr7:66250256	chr7:66493706~66495474:+
LUAD	cis	rs17301013	0.606	rs7530265	ENSG00000227373.4	RP11-160H22.5	5.91	6.42e-09	2.55e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174564603	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs12080535	ENSG00000227373.4	RP11-160H22.5	5.91	6.42e-09	2.55e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174569832	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs12083628	ENSG00000227373.4	RP11-160H22.5	5.91	6.42e-09	2.55e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174572097	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs6691118	ENSG00000227373.4	RP11-160H22.5	5.91	6.42e-09	2.55e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174577798	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.54	rs61624206	ENSG00000227373.4	RP11-160H22.5	5.91	6.42e-09	2.55e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174578374	chr1:174115300~174160004:-
LUAD	cis	rs9595908	0.606	rs4942925	ENSG00000212293.1	SNORA16	5.91	6.43e-09	2.56e-06	0.28	0.26	Body mass index;	chr13:32807106	chr13:32420390~32420516:-
LUAD	cis	rs1075265	0.935	rs6545384	ENSG00000233266.1	HMGB1P31	5.91	6.43e-09	2.56e-06	0.33	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54073927	chr2:54051334~54051760:+
LUAD	cis	rs11122895	0.61	rs13397902	ENSG00000236307.2	EEF1E1P1	5.91	6.43e-09	2.56e-06	0.28	0.26	Allergic sensitization;	chr2:111849928	chr2:111887914~111888741:+
LUAD	cis	rs293748	0.771	rs159140	ENSG00000250155.1	CTD-2353F22.1	-5.91	6.44e-09	2.56e-06	-0.37	-0.26	Obesity-related traits;	chr5:36925903	chr5:36666214~36725195:-
LUAD	cis	rs4835473	0.932	rs5015760	ENSG00000251600.4	RP11-673E1.1	-5.91	6.44e-09	2.56e-06	-0.32	-0.26	Immature fraction of reticulocytes;	chr4:143737955	chr4:143912331~143982454:+
LUAD	cis	rs7246657	0.722	rs2927742	ENSG00000276846.1	CTD-3220F14.3	-5.91	6.45e-09	2.56e-06	-0.35	-0.26	Coronary artery calcification;	chr19:37642717	chr19:37314868~37315620:-
LUAD	cis	rs7772486	0.597	rs2246132	ENSG00000235652.6	RP11-545I5.3	5.91	6.45e-09	2.56e-06	0.27	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145861379	chr6:145799409~145886585:+
LUAD	cis	rs875971	0.825	rs801202	ENSG00000222364.1	RNU6-96P	5.91	6.45e-09	2.56e-06	0.3	0.26	Aortic root size;	chr7:66558942	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.895	rs4145009	ENSG00000237310.1	GS1-124K5.4	-5.91	6.45e-09	2.56e-06	-0.29	-0.26	Aortic root size;	chr7:66261628	chr7:66493706~66495474:+
LUAD	cis	rs2404602	0.684	rs8037847	ENSG00000259422.1	RP11-593F23.1	-5.91	6.45e-09	2.56e-06	-0.34	-0.26	Blood metabolite levels;	chr15:76564210	chr15:76174891~76181486:-
LUAD	cis	rs10214930	0.697	rs12155430	ENSG00000235574.1	AC073150.6	-5.91	6.47e-09	2.57e-06	-0.32	-0.26	Hypospadias;	chr7:27631677	chr7:27491682~27492765:-
LUAD	cis	rs2562456	0.874	rs9304986	ENSG00000268081.1	RP11-678G14.2	-5.91	6.48e-09	2.57e-06	-0.4	-0.26	Pain;	chr19:21499260	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.917	rs2650805	ENSG00000268081.1	RP11-678G14.2	-5.91	6.48e-09	2.57e-06	-0.4	-0.26	Pain;	chr19:21505137	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.917	rs6511256	ENSG00000268081.1	RP11-678G14.2	-5.91	6.48e-09	2.57e-06	-0.4	-0.26	Pain;	chr19:21510513	chr19:21554640~21569237:-
LUAD	cis	rs180730	0.561	rs3106314	ENSG00000251609.2	SETP12	-5.91	6.48e-09	2.57e-06	-0.33	-0.26	Fasting plasma glucose;	chr4:120895637	chr4:120895494~120897083:-
LUAD	cis	rs1134634	0.52	rs10022610	ENSG00000273133.1	RP11-799M12.2	-5.91	6.48e-09	2.58e-06	-0.38	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15635864	chr4:15563698~15564253:-
LUAD	cis	rs755249	0.53	rs1472662	ENSG00000228060.1	RP11-69E11.8	-5.91	6.49e-09	2.58e-06	-0.27	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39124737	chr1:39565160~39573203:+
LUAD	cis	rs11051970	0.527	rs7309590	ENSG00000274964.1	RP11-817I4.1	-5.91	6.5e-09	2.58e-06	-0.34	-0.26	Response to tocilizumab in rheumatoid arthritis;	chr12:32337915	chr12:32339368~32340724:+
LUAD	cis	rs7923609	0.967	rs10761752	ENSG00000232075.1	MRPL35P2	-5.91	6.5e-09	2.58e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63400561	chr10:63634317~63634827:-
LUAD	cis	rs2412819	0.571	rs7174260	ENSG00000249839.1	AC011330.5	-5.91	6.5e-09	2.58e-06	-0.43	-0.26	Lung cancer;	chr15:43751988	chr15:43663654~43684339:-
LUAD	cis	rs12699921	0.632	rs2723502	ENSG00000279048.1	RP11-511H23.2	-5.91	6.51e-09	2.59e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17814993	chr7:17940503~17942922:+
LUAD	cis	rs948562	0.947	rs11541682	ENSG00000280010.1	AP001350.4	5.91	6.53e-09	2.59e-06	0.42	0.26	Lymphoma;	chr11:58618279	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.947	rs17489568	ENSG00000280010.1	AP001350.4	5.91	6.53e-09	2.59e-06	0.42	0.26	Lymphoma;	chr11:58622534	chr11:58627435~58628528:+
LUAD	cis	rs180730	0.519	rs1470696	ENSG00000251609.2	SETP12	5.91	6.53e-09	2.59e-06	0.34	0.26	Fasting plasma glucose;	chr4:120921412	chr4:120895494~120897083:-
LUAD	cis	rs1113500	0.862	rs2336128	ENSG00000226822.1	RP11-356N1.2	5.91	6.54e-09	2.6e-06	0.31	0.26	Growth-regulated protein alpha levels;	chr1:108098117	chr1:108071482~108074519:+
LUAD	cis	rs9595908	0.709	rs7322668	ENSG00000212293.1	SNORA16	5.91	6.55e-09	2.6e-06	0.28	0.26	Body mass index;	chr13:32780298	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.709	rs7318610	ENSG00000212293.1	SNORA16	5.91	6.55e-09	2.6e-06	0.28	0.26	Body mass index;	chr13:32781912	chr13:32420390~32420516:-
LUAD	cis	rs853679	0.517	rs9393896	ENSG00000204709.4	LINC01556	5.91	6.55e-09	2.6e-06	0.37	0.26	Depression;	chr6:28159925	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9393897	ENSG00000204709.4	LINC01556	5.91	6.55e-09	2.6e-06	0.37	0.26	Depression;	chr6:28159932	chr6:28943877~28944537:+
LUAD	cis	rs7772486	0.558	rs9376965	ENSG00000235652.6	RP11-545I5.3	5.91	6.55e-09	2.6e-06	0.27	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145808919	chr6:145799409~145886585:+
LUAD	cis	rs9309473	0.95	rs1918863	ENSG00000163016.8	ALMS1P	5.91	6.56e-09	2.61e-06	0.31	0.26	Metabolite levels;	chr2:73417353	chr2:73644919~73685576:+
LUAD	cis	rs17301013	0.606	rs5015737	ENSG00000227373.4	RP11-160H22.5	5.91	6.57e-09	2.61e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174452857	chr1:174115300~174160004:-
LUAD	cis	rs12699921	0.598	rs1524774	ENSG00000279048.1	RP11-511H23.2	-5.91	6.58e-09	2.61e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17827352	chr7:17940503~17942922:+
LUAD	cis	rs7804306	0.826	rs55832940	ENSG00000233264.2	AC006042.8	5.91	6.58e-09	2.61e-06	0.53	0.26	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8054449	chr7:7980312~7982228:+
LUAD	cis	rs2115630	0.691	rs8040066	ENSG00000229212.6	RP11-561C5.4	5.91	6.59e-09	2.62e-06	0.31	0.26	P wave terminal force;	chr15:84633234	chr15:85205440~85234795:-
LUAD	cis	rs12699921	0.598	rs2691607	ENSG00000279048.1	RP11-511H23.2	-5.91	6.59e-09	2.62e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17839480	chr7:17940503~17942922:+
LUAD	cis	rs2179367	0.959	rs652807	ENSG00000231760.4	RP11-350J20.5	-5.91	6.59e-09	2.62e-06	-0.32	-0.26	Dupuytren's disease;	chr6:149416359	chr6:149796151~149826294:-
LUAD	cis	rs957448	0.554	rs12680855	ENSG00000253704.1	RP11-267M23.4	5.91	6.59e-09	2.62e-06	0.3	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94570427	chr8:94553722~94569745:+
LUAD	cis	rs875971	0.862	rs801195	ENSG00000222364.1	RNU6-96P	5.91	6.6e-09	2.62e-06	0.29	0.26	Aortic root size;	chr7:66561128	chr7:66395191~66395286:+
LUAD	cis	rs11096990	0.819	rs2711992	ENSG00000249207.1	RP11-360F5.1	5.91	6.6e-09	2.62e-06	0.3	0.26	Cognitive function;	chr4:39148651	chr4:39112677~39126818:-
LUAD	cis	rs875971	1	rs6961717	ENSG00000237310.1	GS1-124K5.4	-5.91	6.61e-09	2.62e-06	-0.28	-0.26	Aortic root size;	chr7:66122550	chr7:66493706~66495474:+
LUAD	cis	rs9910055	0.762	rs6503489	ENSG00000267080.4	ASB16-AS1	-5.91	6.61e-09	2.62e-06	-0.24	-0.26	Total body bone mineral density;	chr17:44168921	chr17:44175973~44186717:-
LUAD	cis	rs875971	0.756	rs4718328	ENSG00000237310.1	GS1-124K5.4	-5.91	6.62e-09	2.63e-06	-0.28	-0.26	Aortic root size;	chr7:66228350	chr7:66493706~66495474:+
LUAD	cis	rs74233809	1	rs12219901	ENSG00000213277.3	MARCKSL1P1	5.91	6.62e-09	2.63e-06	0.45	0.26	Birth weight;	chr10:103081210	chr10:103175554~103176094:+
LUAD	cis	rs74233809	1	rs10458729	ENSG00000213277.3	MARCKSL1P1	5.91	6.62e-09	2.63e-06	0.45	0.26	Birth weight;	chr10:103081722	chr10:103175554~103176094:+
LUAD	cis	rs11098499	0.955	rs1397608	ENSG00000248280.1	RP11-33B1.2	5.91	6.63e-09	2.63e-06	0.32	0.26	Corneal astigmatism;	chr4:119240589	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.955	rs7685268	ENSG00000248280.1	RP11-33B1.2	5.91	6.63e-09	2.63e-06	0.32	0.26	Corneal astigmatism;	chr4:119241033	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.955	rs7684942	ENSG00000248280.1	RP11-33B1.2	5.91	6.63e-09	2.63e-06	0.32	0.26	Corneal astigmatism;	chr4:119241046	chr4:119440561~119450157:-
LUAD	cis	rs6921919	0.525	rs16894095	ENSG00000216901.1	AL022393.7	5.91	6.63e-09	2.63e-06	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28422453	chr6:28176188~28176674:+
LUAD	cis	rs9353324	1	rs9353324	ENSG00000203875.9	SNHG5	-5.91	6.64e-09	2.63e-06	-0.56	-0.26	Interferon gamma-induced protein 10 levels;	chr6:85653156	chr6:85660950~85678736:-
LUAD	cis	rs875971	0.52	rs160645	ENSG00000237310.1	GS1-124K5.4	-5.91	6.64e-09	2.63e-06	-0.33	-0.26	Aortic root size;	chr7:66091320	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs1547529	ENSG00000226824.5	RP4-756H11.3	-5.91	6.64e-09	2.63e-06	-0.38	-0.26	Aortic root size;	chr7:66258859	chr7:66654538~66669855:+
LUAD	cis	rs858239	0.601	rs929507	ENSG00000230042.1	AK3P3	-5.91	6.64e-09	2.64e-06	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.601	rs929508	ENSG00000230042.1	AK3P3	-5.91	6.64e-09	2.64e-06	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23129178~23129841:+
LUAD	cis	rs4713118	0.513	rs149942	ENSG00000204709.4	LINC01556	5.91	6.65e-09	2.64e-06	0.33	0.26	Parkinson's disease;	chr6:28033832	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.513	rs149944	ENSG00000204709.4	LINC01556	5.91	6.65e-09	2.64e-06	0.33	0.26	Parkinson's disease;	chr6:28035040	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.513	rs149945	ENSG00000204709.4	LINC01556	5.91	6.65e-09	2.64e-06	0.33	0.26	Parkinson's disease;	chr6:28035075	chr6:28943877~28944537:+
LUAD	cis	rs12554020	1	rs4552973	ENSG00000227603.1	RP11-165J3.6	5.91	6.65e-09	2.64e-06	0.38	0.26	Schizophrenia;	chr9:93539437	chr9:93435332~93437121:-
LUAD	cis	rs1799949	0.894	rs36062488	ENSG00000267681.1	CTD-3199J23.6	5.91	6.66e-09	2.64e-06	0.29	0.26	Menopause (age at onset);	chr17:43185455	chr17:43144956~43145255:+
LUAD	cis	rs2283792	0.765	rs1063311	ENSG00000224086.5	LL22NC03-86G7.1	-5.91	6.67e-09	2.64e-06	-0.25	-0.26	Multiple sclerosis;	chr22:21762178	chr22:21938293~21977632:+
LUAD	cis	rs12908161	0.959	rs34342559	ENSG00000225151.9	GOLGA2P7	-5.9	6.67e-09	2.65e-06	-0.35	-0.26	Schizophrenia;	chr15:84788040	chr15:84199311~84230136:-
LUAD	cis	rs12908161	0.959	rs35557864	ENSG00000225151.9	GOLGA2P7	-5.9	6.67e-09	2.65e-06	-0.35	-0.26	Schizophrenia;	chr15:84788398	chr15:84199311~84230136:-
LUAD	cis	rs11098499	1	rs12506395	ENSG00000248280.1	RP11-33B1.2	5.9	6.67e-09	2.65e-06	0.32	0.26	Corneal astigmatism;	chr4:119263939	chr4:119440561~119450157:-
LUAD	cis	rs2404602	0.735	rs283789	ENSG00000259422.1	RP11-593F23.1	5.9	6.68e-09	2.65e-06	0.33	0.26	Blood metabolite levels;	chr15:76485236	chr15:76174891~76181486:-
LUAD	cis	rs74233809	1	rs11191555	ENSG00000213277.3	MARCKSL1P1	5.9	6.68e-09	2.65e-06	0.44	0.26	Birth weight;	chr10:103097766	chr10:103175554~103176094:+
LUAD	cis	rs74233809	1	rs11191557	ENSG00000213277.3	MARCKSL1P1	5.9	6.68e-09	2.65e-06	0.44	0.26	Birth weight;	chr10:103104857	chr10:103175554~103176094:+
LUAD	cis	rs74233809	1	rs11191558	ENSG00000213277.3	MARCKSL1P1	5.9	6.68e-09	2.65e-06	0.44	0.26	Birth weight;	chr10:103104921	chr10:103175554~103176094:+
LUAD	cis	rs74233809	1	rs12413046	ENSG00000213277.3	MARCKSL1P1	5.9	6.68e-09	2.65e-06	0.44	0.26	Birth weight;	chr10:103111447	chr10:103175554~103176094:+
LUAD	cis	rs74233809	1	rs10883832	ENSG00000213277.3	MARCKSL1P1	5.9	6.68e-09	2.65e-06	0.44	0.26	Birth weight;	chr10:103111522	chr10:103175554~103176094:+
LUAD	cis	rs9309473	0.606	rs1589576	ENSG00000163016.8	ALMS1P	5.9	6.69e-09	2.65e-06	0.37	0.26	Metabolite levels;	chr2:73511677	chr2:73644919~73685576:+
LUAD	cis	rs8072100	0.967	rs9894905	ENSG00000228782.6	CTD-2026D20.3	5.9	6.69e-09	2.65e-06	0.27	0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47408616	chr17:47450568~47492492:-
LUAD	cis	rs1134634	0.52	rs11932730	ENSG00000273133.1	RP11-799M12.2	5.9	6.7e-09	2.66e-06	0.38	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15564135	chr4:15563698~15564253:-
LUAD	cis	rs875971	0.79	rs10257911	ENSG00000237310.1	GS1-124K5.4	-5.9	6.7e-09	2.66e-06	-0.28	-0.26	Aortic root size;	chr7:66278783	chr7:66493706~66495474:+
LUAD	cis	rs853679	0.517	rs868987	ENSG00000204709.4	LINC01556	-5.9	6.7e-09	2.66e-06	-0.37	-0.26	Depression;	chr6:28142370	chr6:28943877~28944537:+
LUAD	cis	rs7221109	0.677	rs7219483	ENSG00000278834.1	RP11-458J1.1	5.9	6.71e-09	2.66e-06	0.3	0.26	Type 1 diabetes;	chr17:40651705	chr17:40648300~40649718:+
LUAD	cis	rs7221109	0.645	rs2014704	ENSG00000278834.1	RP11-458J1.1	5.9	6.71e-09	2.66e-06	0.3	0.26	Type 1 diabetes;	chr17:40651997	chr17:40648300~40649718:+
LUAD	cis	rs7923609	0.967	rs10761751	ENSG00000232075.1	MRPL35P2	-5.9	6.71e-09	2.66e-06	-0.32	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63395125	chr10:63634317~63634827:-
LUAD	cis	rs875971	0.651	rs2420596	ENSG00000237310.1	GS1-124K5.4	5.9	6.71e-09	2.66e-06	0.28	0.26	Aortic root size;	chr7:66450996	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.52	rs2420597	ENSG00000237310.1	GS1-124K5.4	5.9	6.71e-09	2.66e-06	0.28	0.26	Aortic root size;	chr7:66450999	chr7:66493706~66495474:+
LUAD	cis	rs2276314	1	rs4573997	ENSG00000278986.1	RP11-723J4.3	-5.9	6.72e-09	2.66e-06	-0.32	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:35972605	chr18:35972151~35973916:+
LUAD	cis	rs957448	0.554	rs10956919	ENSG00000253704.1	RP11-267M23.4	5.9	6.72e-09	2.66e-06	0.3	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94572945	chr8:94553722~94569745:+
LUAD	cis	rs12468226	0.873	rs59293950	ENSG00000226261.1	AC064836.3	5.9	6.72e-09	2.66e-06	0.44	0.26	Urate levels;	chr2:202214069	chr2:202336024~202336727:-
LUAD	cis	rs17301013	0.507	rs332767	ENSG00000227373.4	RP11-160H22.5	5.9	6.73e-09	2.67e-06	0.37	0.26	Systemic lupus erythematosus;	chr1:174686386	chr1:174115300~174160004:-
LUAD	cis	rs17023223	0.553	rs55696509	ENSG00000231365.4	RP11-418J17.1	-5.9	6.74e-09	2.67e-06	-0.38	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119144033	chr1:119140396~119275973:+
LUAD	cis	rs2115630	0.653	rs61394864	ENSG00000229212.6	RP11-561C5.4	5.9	6.74e-09	2.67e-06	0.31	0.26	P wave terminal force;	chr15:84626943	chr15:85205440~85234795:-
LUAD	cis	rs293748	0.571	rs13177573	ENSG00000250155.1	CTD-2353F22.1	5.9	6.74e-09	2.67e-06	0.32	0.26	Obesity-related traits;	chr5:37233335	chr5:36666214~36725195:-
LUAD	cis	rs10214930	1	rs6970578	ENSG00000235574.1	AC073150.6	5.9	6.74e-09	2.67e-06	0.35	0.26	Hypospadias;	chr7:27804419	chr7:27491682~27492765:-
LUAD	cis	rs6921919	0.551	rs13201753	ENSG00000216901.1	AL022393.7	5.9	6.74e-09	2.67e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28176188~28176674:+
LUAD	cis	rs67311347	1	rs6795475	ENSG00000223797.4	ENTPD3-AS1	5.9	6.75e-09	2.67e-06	0.27	0.26	Renal cell carcinoma;	chr3:40447790	chr3:40313802~40453329:-
LUAD	cis	rs2276314	0.857	rs28431958	ENSG00000278986.1	RP11-723J4.3	-5.9	6.75e-09	2.67e-06	-0.32	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:35998438	chr18:35972151~35973916:+
LUAD	cis	rs957448	0.607	rs12680842	ENSG00000253704.1	RP11-267M23.4	5.9	6.75e-09	2.68e-06	0.3	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94570378	chr8:94553722~94569745:+
LUAD	cis	rs867371	1	rs13380317	ENSG00000259429.4	UBE2Q2P2	5.9	6.76e-09	2.68e-06	0.22	0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214449	chr15:82355142~82420075:+
LUAD	cis	rs875971	0.862	rs35378740	ENSG00000237310.1	GS1-124K5.4	5.9	6.76e-09	2.68e-06	0.28	0.26	Aortic root size;	chr7:66522725	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs10950043	ENSG00000237310.1	GS1-124K5.4	5.9	6.76e-09	2.68e-06	0.28	0.26	Aortic root size;	chr7:66523623	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs17747530	ENSG00000237310.1	GS1-124K5.4	5.9	6.76e-09	2.68e-06	0.28	0.26	Aortic root size;	chr7:66529742	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs13226170	ENSG00000237310.1	GS1-124K5.4	5.9	6.76e-09	2.68e-06	0.28	0.26	Aortic root size;	chr7:66534311	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs2420611	ENSG00000237310.1	GS1-124K5.4	5.9	6.76e-09	2.68e-06	0.28	0.26	Aortic root size;	chr7:66534333	chr7:66493706~66495474:+
LUAD	cis	rs4713118	0.868	rs7756968	ENSG00000219392.1	RP1-265C24.5	-5.9	6.77e-09	2.68e-06	-0.37	-0.26	Parkinson's disease;	chr6:27767175	chr6:28115628~28116551:+
LUAD	cis	rs8177876	0.822	rs56166222	ENSG00000261061.1	RP11-303E16.2	-5.9	6.78e-09	2.68e-06	-0.45	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81067920	chr16:81030770~81031485:+
LUAD	cis	rs1387259	0.839	rs7486941	ENSG00000240399.1	RP1-228P16.1	-5.9	6.78e-09	2.68e-06	-0.24	-0.26	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48184848	chr12:48054813~48055591:-
LUAD	cis	rs72634501	0.531	rs67758468	ENSG00000228060.1	RP11-69E11.8	-5.9	6.78e-09	2.68e-06	-0.25	-0.26	HDL cholesterol;	chr1:39156916	chr1:39565160~39573203:+
LUAD	cis	rs10214930	0.671	rs1005128	ENSG00000235574.1	AC073150.6	-5.9	6.79e-09	2.69e-06	-0.33	-0.26	Hypospadias;	chr7:27569057	chr7:27491682~27492765:-
LUAD	cis	rs1799949	0.965	rs799916	ENSG00000267681.1	CTD-3199J23.6	5.9	6.79e-09	2.69e-06	0.28	0.26	Menopause (age at onset);	chr17:43091173	chr17:43144956~43145255:+
LUAD	cis	rs875971	0.83	rs427575	ENSG00000222364.1	RNU6-96P	-5.9	6.8e-09	2.69e-06	-0.29	-0.26	Aortic root size;	chr7:66054232	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.8	rs427557	ENSG00000222364.1	RNU6-96P	-5.9	6.8e-09	2.69e-06	-0.29	-0.26	Aortic root size;	chr7:66054263	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.83	rs587360	ENSG00000222364.1	RNU6-96P	-5.9	6.8e-09	2.69e-06	-0.29	-0.26	Aortic root size;	chr7:66057711	chr7:66395191~66395286:+
LUAD	cis	rs4803480	0.935	rs758349	ENSG00000270164.1	LINC01480	-5.9	6.8e-09	2.69e-06	-0.26	-0.26	Schizophrenia;	chr19:41578753	chr19:41535183~41536904:+
LUAD	cis	rs2243480	1	rs778679	ENSG00000230295.1	RP11-458F8.2	-5.9	6.81e-09	2.7e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66375924	chr7:66880708~66882981:+
LUAD	cis	rs7246657	0.722	rs1531549	ENSG00000276846.1	CTD-3220F14.3	5.9	6.83e-09	2.7e-06	0.34	0.26	Coronary artery calcification;	chr19:37597108	chr19:37314868~37315620:-
LUAD	cis	rs12699921	0.632	rs2723571	ENSG00000279048.1	RP11-511H23.2	-5.9	6.83e-09	2.7e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17851591	chr7:17940503~17942922:+
LUAD	cis	rs9595908	0.709	rs4942880	ENSG00000212293.1	SNORA16	5.9	6.83e-09	2.7e-06	0.28	0.26	Body mass index;	chr13:32751641	chr13:32420390~32420516:-
LUAD	cis	rs3002131	0.688	rs2936040	ENSG00000225265.1	TAF1A-AS1	-5.9	6.84e-09	2.71e-06	-0.4	-0.26	Interleukin-10 levels;	chr1:222590319	chr1:222589825~222593032:+
LUAD	cis	rs11089937	0.616	rs4991798	ENSG00000211639.2	IGLV4-60	5.9	6.85e-09	2.71e-06	0.27	0.26	Periodontitis (PAL4Q3);	chr22:22178915	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.616	rs4991799	ENSG00000211639.2	IGLV4-60	5.9	6.85e-09	2.71e-06	0.27	0.26	Periodontitis (PAL4Q3);	chr22:22178938	chr22:22162199~22162681:+
LUAD	cis	rs11089937	0.616	rs4991800	ENSG00000211639.2	IGLV4-60	5.9	6.85e-09	2.71e-06	0.27	0.26	Periodontitis (PAL4Q3);	chr22:22178942	chr22:22162199~22162681:+
LUAD	cis	rs881375	0.967	rs1548783	ENSG00000226752.6	PSMD5-AS1	-5.9	6.85e-09	2.71e-06	-0.29	-0.26	Rheumatoid arthritis;	chr9:120896361	chr9:120824828~120854385:+
LUAD	cis	rs9341808	0.53	rs3805876	ENSG00000272129.1	RP11-250B2.6	5.9	6.86e-09	2.71e-06	0.32	0.26	Sitting height ratio;	chr6:80321822	chr6:80355424~80356859:+
LUAD	cis	rs13217239	0.646	rs4403259	ENSG00000241549.7	GUSBP2	5.9	6.86e-09	2.71e-06	0.28	0.26	Schizophrenia;	chr6:27029838	chr6:26871484~26956554:-
LUAD	cis	rs2243480	1	rs56016656	ENSG00000230295.1	RP11-458F8.2	-5.9	6.87e-09	2.72e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:65918494	chr7:66880708~66882981:+
LUAD	cis	rs2243480	0.803	rs55700941	ENSG00000230295.1	RP11-458F8.2	-5.9	6.87e-09	2.72e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:65924813	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs56291018	ENSG00000230295.1	RP11-458F8.2	-5.9	6.87e-09	2.72e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:65925352	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs36033484	ENSG00000230295.1	RP11-458F8.2	-5.9	6.87e-09	2.72e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:65925571	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs34193460	ENSG00000230295.1	RP11-458F8.2	-5.9	6.87e-09	2.72e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:65928123	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs34560516	ENSG00000230295.1	RP11-458F8.2	-5.9	6.87e-09	2.72e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:65939105	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs57057549	ENSG00000230295.1	RP11-458F8.2	-5.9	6.87e-09	2.72e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:65940751	chr7:66880708~66882981:+
LUAD	cis	rs7618501	0.633	rs4688690	ENSG00000234667.1	ACTBP13	-5.9	6.87e-09	2.72e-06	-0.29	-0.26	Intelligence (multi-trait analysis);	chr3:49984859	chr3:49873347~49877980:-
LUAD	cis	rs7618501	0.633	rs11130234	ENSG00000234667.1	ACTBP13	-5.9	6.87e-09	2.72e-06	-0.29	-0.26	Intelligence (multi-trait analysis);	chr3:49987325	chr3:49873347~49877980:-
LUAD	cis	rs7618501	0.633	rs4688758	ENSG00000234667.1	ACTBP13	-5.9	6.87e-09	2.72e-06	-0.29	-0.26	Intelligence (multi-trait analysis);	chr3:49990952	chr3:49873347~49877980:-
LUAD	cis	rs9341808	0.53	rs3805877	ENSG00000272129.1	RP11-250B2.6	5.9	6.87e-09	2.72e-06	0.32	0.26	Sitting height ratio;	chr6:80321812	chr6:80355424~80356859:+
LUAD	cis	rs7246657	0.722	rs1975937	ENSG00000276846.1	CTD-3220F14.3	5.9	6.88e-09	2.72e-06	0.34	0.26	Coronary artery calcification;	chr19:37601031	chr19:37314868~37315620:-
LUAD	cis	rs875971	0.862	rs7798630	ENSG00000222364.1	RNU6-96P	5.9	6.88e-09	2.72e-06	0.29	0.26	Aortic root size;	chr7:66306492	chr7:66395191~66395286:+
LUAD	cis	rs8031584	1	rs35607976	ENSG00000260382.1	RP11-540B6.2	5.9	6.88e-09	2.72e-06	0.34	0.26	Huntington's disease progression;	chr15:30985585	chr15:30882267~30883231:-
LUAD	cis	rs755249	0.567	rs41270821	ENSG00000228060.1	RP11-69E11.8	-5.9	6.88e-09	2.72e-06	-0.27	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39458060	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs2296175	ENSG00000228060.1	RP11-69E11.8	-5.9	6.88e-09	2.72e-06	-0.27	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39458726	chr1:39565160~39573203:+
LUAD	cis	rs11971779	0.68	rs17613690	ENSG00000273391.1	RP11-634H22.1	-5.9	6.88e-09	2.72e-06	-0.27	-0.26	Diisocyanate-induced asthma;	chr7:139403655	chr7:139359032~139359566:-
LUAD	cis	rs11098499	0.644	rs34835603	ENSG00000248280.1	RP11-33B1.2	5.9	6.89e-09	2.72e-06	0.33	0.26	Corneal astigmatism;	chr4:119632273	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.615	rs28850368	ENSG00000248280.1	RP11-33B1.2	5.9	6.89e-09	2.72e-06	0.33	0.26	Corneal astigmatism;	chr4:119633158	chr4:119440561~119450157:-
LUAD	cis	rs7772486	0.534	rs34541797	ENSG00000235652.6	RP11-545I5.3	5.9	6.9e-09	2.73e-06	0.28	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145884168	chr6:145799409~145886585:+
LUAD	cis	rs1823913	0.927	rs13013390	ENSG00000230611.1	HMGB1P27	-5.9	6.9e-09	2.73e-06	-0.3	-0.26	Obesity-related traits;	chr2:191262001	chr2:191174233~191174835:+
LUAD	cis	rs35955747	0.778	rs9609263	ENSG00000236132.1	CTA-440B3.1	5.9	6.91e-09	2.73e-06	0.29	0.26	Neutrophil count;Sum basophil neutrophil counts;	chr22:31349288	chr22:31816379~31817491:-
LUAD	cis	rs875971	0.545	rs6460276	ENSG00000226824.5	RP4-756H11.3	-5.9	6.91e-09	2.73e-06	-0.38	-0.26	Aortic root size;	chr7:66182290	chr7:66654538~66669855:+
LUAD	cis	rs10129255	0.957	rs12589190	ENSG00000211974.3	IGHV2-70	5.9	6.92e-09	2.73e-06	0.27	0.26	Kawasaki disease;	chr14:106783079	chr14:106723574~106724093:-
LUAD	cis	rs10129255	0.957	rs7493713	ENSG00000211974.3	IGHV2-70	5.9	6.92e-09	2.73e-06	0.27	0.26	Kawasaki disease;	chr14:106783685	chr14:106723574~106724093:-
LUAD	cis	rs10129255	0.912	rs35468694	ENSG00000211974.3	IGHV2-70	5.9	6.92e-09	2.73e-06	0.27	0.26	Kawasaki disease;	chr14:106784199	chr14:106723574~106724093:-
LUAD	cis	rs10129255	0.957	rs8019272	ENSG00000211974.3	IGHV2-70	5.9	6.92e-09	2.73e-06	0.27	0.26	Kawasaki disease;	chr14:106784709	chr14:106723574~106724093:-
LUAD	cis	rs8062405	0.679	rs72793818	ENSG00000251417.2	RP11-1348G14.4	-5.9	6.92e-09	2.73e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28802743~28817828:+
LUAD	cis	rs897984	0.609	rs57576577	ENSG00000260911.2	RP11-196G11.2	5.9	6.93e-09	2.74e-06	0.24	0.26	Dementia with Lewy bodies;	chr16:31025046	chr16:31043150~31049868:+
LUAD	cis	rs875971	1	rs3981131	ENSG00000222364.1	RNU6-96P	-5.9	6.93e-09	2.74e-06	-0.29	-0.26	Aortic root size;	chr7:66486690	chr7:66395191~66395286:+
LUAD	cis	rs11838725	1	rs11838725	ENSG00000176268.5	CYCSP34	5.9	6.94e-09	2.74e-06	0.25	0.26	CSF tryptophan concentration in tuberculous meningitis;	chr13:41096949	chr13:40863599~40863902:-
LUAD	cis	rs3779195	0.591	rs77968419	ENSG00000272950.1	RP11-307C18.1	-5.9	6.94e-09	2.74e-06	-0.46	-0.26	Sex hormone-binding globulin levels;	chr7:98237168	chr7:98322853~98323430:+
LUAD	cis	rs875971	0.825	rs59466412	ENSG00000222364.1	RNU6-96P	5.9	6.94e-09	2.74e-06	0.3	0.26	Aortic root size;	chr7:66100371	chr7:66395191~66395286:+
LUAD	cis	rs9595908	0.709	rs7318510	ENSG00000212293.1	SNORA16	5.9	6.96e-09	2.75e-06	0.28	0.26	Body mass index;	chr13:32752122	chr13:32420390~32420516:-
LUAD	cis	rs7044106	0.664	rs7861679	ENSG00000238181.2	AHCYP2	5.9	6.97e-09	2.75e-06	0.33	0.26	Hip circumference adjusted for BMI;	chr9:120613311	chr9:120720673~120721972:+
LUAD	cis	rs7182621	0.639	rs12906068	ENSG00000259363.4	CTD-2054N24.2	-5.9	6.98e-09	2.76e-06	-0.36	-0.26	Colonoscopy-negative controls vs population controls;	chr15:99873422	chr15:99807023~99877148:+
LUAD	cis	rs113835537	0.529	rs60358007	ENSG00000255517.5	CTD-3074O7.5	-5.9	6.98e-09	2.76e-06	-0.32	-0.26	Airway imaging phenotypes;	chr11:66454882	chr11:66473490~66480233:-
LUAD	cis	rs7743045	0.614	rs4946386	ENSG00000253194.1	RP11-351A11.1	5.9	6.98e-09	2.76e-06	0.36	0.26	Mean platelet volume;	chr6:119001827	chr6:118934785~119031541:+
LUAD	cis	rs875971	0.545	rs7810213	ENSG00000226824.5	RP4-756H11.3	-5.9	6.99e-09	2.76e-06	-0.38	-0.26	Aortic root size;	chr7:66481592	chr7:66654538~66669855:+
LUAD	cis	rs2276314	1	rs2298716	ENSG00000278986.1	RP11-723J4.3	-5.9	6.99e-09	2.76e-06	-0.32	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:35972635	chr18:35972151~35973916:+
LUAD	cis	rs10129255	0.828	rs10140989	ENSG00000224373.3	IGHV4-59	5.9	7e-09	2.76e-06	0.17	0.26	Kawasaki disease;	chr14:106668657	chr14:106627249~106627825:-
LUAD	cis	rs875971	0.862	rs1983372	ENSG00000237310.1	GS1-124K5.4	-5.9	7e-09	2.77e-06	-0.28	-0.26	Aortic root size;	chr7:66146364	chr7:66493706~66495474:+
LUAD	cis	rs12908161	1	rs36033486	ENSG00000225151.9	GOLGA2P7	-5.9	7.01e-09	2.77e-06	-0.35	-0.26	Schizophrenia;	chr15:84776461	chr15:84199311~84230136:-
LUAD	cis	rs12908161	1	rs12908549	ENSG00000225151.9	GOLGA2P7	-5.9	7.01e-09	2.77e-06	-0.35	-0.26	Schizophrenia;	chr15:84779120	chr15:84199311~84230136:-
LUAD	cis	rs4972806	0.814	rs966801	ENSG00000226363.3	HAGLROS	-5.9	7.01e-09	2.77e-06	-0.33	-0.26	IgG glycosylation;	chr2:176173099	chr2:176177717~176179008:+
LUAD	cis	rs6504950	0.566	rs12937360	ENSG00000275710.1	RP11-257O5.4	5.9	7.01e-09	2.77e-06	0.31	0.26	Breast cancer;	chr17:54968937	chr17:54964474~54964679:+
LUAD	cis	rs11976180	0.569	rs12703565	ENSG00000170356.8	OR2A20P	-5.9	7.02e-09	2.77e-06	-0.41	-0.26	Obesity-related traits;	chr7:144057308	chr7:144250045~144252957:-
LUAD	cis	rs516805	0.886	rs557528	ENSG00000279453.1	RP3-425C14.4	-5.9	7.02e-09	2.77e-06	-0.3	-0.26	Lymphocyte counts;	chr6:122482793	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.961	rs559721	ENSG00000279453.1	RP3-425C14.4	-5.9	7.02e-09	2.77e-06	-0.3	-0.26	Lymphocyte counts;	chr6:122482796	chr6:122436789~122439223:-
LUAD	cis	rs9910055	0.762	rs2526020	ENSG00000267080.4	ASB16-AS1	-5.9	7.02e-09	2.77e-06	-0.24	-0.26	Total body bone mineral density;	chr17:44139220	chr17:44175973~44186717:-
LUAD	cis	rs1075265	0.901	rs2048749	ENSG00000233266.1	HMGB1P31	5.9	7.02e-09	2.77e-06	0.33	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54130483	chr2:54051334~54051760:+
LUAD	cis	rs3931020	0.616	rs277381	ENSG00000272864.1	RP11-17E13.2	5.9	7.02e-09	2.77e-06	0.37	0.26	Resistin levels;	chr1:74801131	chr1:74698769~74699333:-
LUAD	cis	rs4713118	0.868	rs10484401	ENSG00000219392.1	RP1-265C24.5	5.9	7.02e-09	2.77e-06	0.36	0.26	Parkinson's disease;	chr6:27778811	chr6:28115628~28116551:+
LUAD	cis	rs11971779	0.65	rs10085842	ENSG00000273391.1	RP11-634H22.1	5.9	7.02e-09	2.77e-06	0.26	0.26	Diisocyanate-induced asthma;	chr7:139379836	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.648	rs28754644	ENSG00000273391.1	RP11-634H22.1	5.9	7.02e-09	2.77e-06	0.26	0.26	Diisocyanate-induced asthma;	chr7:139380311	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.715	rs6954219	ENSG00000273391.1	RP11-634H22.1	5.9	7.02e-09	2.77e-06	0.26	0.26	Diisocyanate-induced asthma;	chr7:139380364	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs6467840	ENSG00000273391.1	RP11-634H22.1	5.9	7.02e-09	2.77e-06	0.26	0.26	Diisocyanate-induced asthma;	chr7:139380655	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.564	rs6467841	ENSG00000273391.1	RP11-634H22.1	5.9	7.02e-09	2.77e-06	0.26	0.26	Diisocyanate-induced asthma;	chr7:139381346	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs7792752	ENSG00000273391.1	RP11-634H22.1	5.9	7.02e-09	2.77e-06	0.26	0.26	Diisocyanate-induced asthma;	chr7:139381450	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.616	rs6974907	ENSG00000273391.1	RP11-634H22.1	5.9	7.02e-09	2.77e-06	0.26	0.26	Diisocyanate-induced asthma;	chr7:139383983	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs4732369	ENSG00000273391.1	RP11-634H22.1	5.9	7.02e-09	2.77e-06	0.26	0.26	Diisocyanate-induced asthma;	chr7:139384427	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.584	rs10236055	ENSG00000273391.1	RP11-634H22.1	5.9	7.02e-09	2.77e-06	0.26	0.26	Diisocyanate-induced asthma;	chr7:139385245	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.584	rs6942519	ENSG00000273391.1	RP11-634H22.1	5.9	7.02e-09	2.77e-06	0.26	0.26	Diisocyanate-induced asthma;	chr7:139385344	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs6467843	ENSG00000273391.1	RP11-634H22.1	5.9	7.02e-09	2.77e-06	0.26	0.26	Diisocyanate-induced asthma;	chr7:139385777	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs2355785	ENSG00000273391.1	RP11-634H22.1	5.9	7.02e-09	2.77e-06	0.26	0.26	Diisocyanate-induced asthma;	chr7:139386237	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.588	rs6972408	ENSG00000273391.1	RP11-634H22.1	5.9	7.02e-09	2.77e-06	0.26	0.26	Diisocyanate-induced asthma;	chr7:139386728	chr7:139359032~139359566:-
LUAD	cis	rs875971	0.83	rs778711	ENSG00000222364.1	RNU6-96P	-5.9	7.03e-09	2.77e-06	-0.29	-0.26	Aortic root size;	chr7:66386670	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs1083554	ENSG00000222364.1	RNU6-96P	-5.9	7.03e-09	2.77e-06	-0.29	-0.26	Aortic root size;	chr7:66387354	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs778707	ENSG00000222364.1	RNU6-96P	-5.9	7.03e-09	2.77e-06	-0.29	-0.26	Aortic root size;	chr7:66392040	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs778705	ENSG00000222364.1	RNU6-96P	-5.9	7.03e-09	2.77e-06	-0.29	-0.26	Aortic root size;	chr7:66396128	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs778697	ENSG00000222364.1	RNU6-96P	-5.9	7.03e-09	2.77e-06	-0.29	-0.26	Aortic root size;	chr7:66405439	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.798	rs7789615	ENSG00000222364.1	RNU6-96P	-5.9	7.03e-09	2.77e-06	-0.29	-0.26	Aortic root size;	chr7:66413674	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs6978028	ENSG00000222364.1	RNU6-96P	-5.9	7.03e-09	2.77e-06	-0.29	-0.26	Aortic root size;	chr7:66421313	chr7:66395191~66395286:+
LUAD	cis	rs8031584	0.958	rs7176569	ENSG00000260382.1	RP11-540B6.2	-5.9	7.05e-09	2.78e-06	-0.31	-0.26	Huntington's disease progression;	chr15:30952292	chr15:30882267~30883231:-
LUAD	cis	rs12458462	0.509	rs3786241	ENSG00000274828.1	RP11-567M16.6	5.9	7.06e-09	2.78e-06	0.26	0.26	Monocyte count;	chr18:79734328	chr18:79677287~79679358:-
LUAD	cis	rs6504622	0.935	rs17608961	ENSG00000262879.4	RP11-156P1.3	-5.89	7.06e-09	2.79e-06	-0.3	-0.26	Orofacial clefts;	chr17:46952302	chr17:46984045~47100323:-
LUAD	cis	rs8072100	0.676	rs7221345	ENSG00000228782.6	CTD-2026D20.3	5.89	7.07e-09	2.79e-06	0.29	0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47327778	chr17:47450568~47492492:-
LUAD	cis	rs8072100	0.676	rs9905308	ENSG00000228782.6	CTD-2026D20.3	5.89	7.07e-09	2.79e-06	0.29	0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47332020	chr17:47450568~47492492:-
LUAD	cis	rs2404602	0.716	rs4079681	ENSG00000259422.1	RP11-593F23.1	5.89	7.07e-09	2.79e-06	0.29	0.26	Blood metabolite levels;	chr15:76402889	chr15:76174891~76181486:-
LUAD	cis	rs2439831	0.85	rs12440573	ENSG00000205771.5	CATSPER2P1	-5.89	7.07e-09	2.79e-06	-0.53	-0.26	Lung cancer in ever smokers;	chr15:43816799	chr15:43726918~43747094:-
LUAD	cis	rs17711722	0.583	rs10085415	ENSG00000164669.11	INTS4P1	5.89	7.08e-09	2.79e-06	0.32	0.26	Calcium levels;	chr7:65628655	chr7:65141225~65234216:+
LUAD	cis	rs853679	0.517	rs9295761	ENSG00000204709.4	LINC01556	5.89	7.09e-09	2.8e-06	0.37	0.26	Depression;	chr6:28180209	chr6:28943877~28944537:+
LUAD	cis	rs2412819	0.571	rs678084	ENSG00000249839.1	AC011330.5	5.89	7.09e-09	2.8e-06	0.4	0.26	Lung cancer;	chr15:43828361	chr15:43663654~43684339:-
LUAD	cis	rs848490	0.674	rs4727461	ENSG00000214293.7	APTR	5.89	7.09e-09	2.8e-06	0.3	0.26	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77691071	chr7:77657660~77696265:-
LUAD	cis	rs875971	0.545	rs7811204	ENSG00000226824.5	RP4-756H11.3	-5.89	7.09e-09	2.8e-06	-0.39	-0.26	Aortic root size;	chr7:66387213	chr7:66654538~66669855:+
LUAD	cis	rs2243480	1	rs316326	ENSG00000230295.1	RP11-458F8.2	-5.89	7.1e-09	2.8e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66144466	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs316325	ENSG00000230295.1	RP11-458F8.2	-5.89	7.1e-09	2.8e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66144531	chr7:66880708~66882981:+
LUAD	cis	rs11690935	0.589	rs62182403	ENSG00000228389.1	AC068039.4	-5.89	7.1e-09	2.8e-06	-0.28	-0.26	Schizophrenia;	chr2:171890672	chr2:171773482~171775844:+
LUAD	cis	rs7712401	0.715	rs436160	ENSG00000263432.2	RN7SL689P	-5.89	7.1e-09	2.8e-06	-0.33	-0.26	Mean platelet volume;	chr5:123020258	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.715	rs434789	ENSG00000263432.2	RN7SL689P	-5.89	7.1e-09	2.8e-06	-0.33	-0.26	Mean platelet volume;	chr5:123021615	chr5:123022487~123022783:-
LUAD	cis	rs1707322	0.686	rs2991986	ENSG00000234329.1	RP11-767N6.2	-5.89	7.12e-09	2.81e-06	-0.27	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615610	chr1:45651039~45651826:-
LUAD	cis	rs875971	0.545	rs73150604	ENSG00000226824.5	RP4-756H11.3	-5.89	7.13e-09	2.81e-06	-0.38	-0.26	Aortic root size;	chr7:66480545	chr7:66654538~66669855:+
LUAD	cis	rs765787	0.53	rs28524974	ENSG00000259520.4	CTD-2651B20.3	5.89	7.14e-09	2.81e-06	0.34	0.26	Uric acid levels;	chr15:45251330	chr15:45251580~45279251:-
LUAD	cis	rs950169	0.526	rs698620	ENSG00000229212.6	RP11-561C5.4	5.89	7.14e-09	2.82e-06	0.31	0.26	Schizophrenia;	chr15:84633977	chr15:85205440~85234795:-
LUAD	cis	rs2562456	0.833	rs2562487	ENSG00000268081.1	RP11-678G14.2	5.89	7.15e-09	2.82e-06	0.4	0.26	Pain;	chr19:21468580	chr19:21554640~21569237:-
LUAD	cis	rs957448	0.554	rs4735297	ENSG00000253704.1	RP11-267M23.4	5.89	7.15e-09	2.82e-06	0.3	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94577112	chr8:94553722~94569745:+
LUAD	cis	rs67311347	1	rs1119179	ENSG00000223797.4	ENTPD3-AS1	-5.89	7.15e-09	2.82e-06	-0.28	-0.26	Renal cell carcinoma;	chr3:40383438	chr3:40313802~40453329:-
LUAD	cis	rs2243480	0.522	rs778717	ENSG00000273142.1	RP11-458F8.4	-5.89	7.15e-09	2.82e-06	-0.31	-0.26	Diabetic kidney disease;	chr7:66383164	chr7:66902857~66906297:+
LUAD	cis	rs2599510	0.744	rs4952212	ENSG00000276334.1	AL133243.1	-5.89	7.15e-09	2.82e-06	-0.3	-0.26	Interleukin-18 levels;	chr2:32393425	chr2:32521927~32523547:+
LUAD	cis	rs2404602	0.647	rs11072607	ENSG00000259422.1	RP11-593F23.1	-5.89	7.15e-09	2.82e-06	-0.35	-0.26	Blood metabolite levels;	chr15:76616188	chr15:76174891~76181486:-
LUAD	cis	rs9309473	0.898	rs9807961	ENSG00000163016.8	ALMS1P	5.89	7.15e-09	2.82e-06	0.32	0.26	Metabolite levels;	chr2:73466916	chr2:73644919~73685576:+
LUAD	cis	rs8177876	0.658	rs2970077	ENSG00000261838.4	RP11-303E16.6	5.89	7.16e-09	2.82e-06	0.47	0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81041195	chr16:81069854~81076598:+
LUAD	cis	rs7618501	0.602	rs6780731	ENSG00000234667.1	ACTBP13	-5.89	7.16e-09	2.82e-06	-0.29	-0.26	Intelligence (multi-trait analysis);	chr3:49980045	chr3:49873347~49877980:-
LUAD	cis	rs10214930	0.697	rs1404276	ENSG00000235574.1	AC073150.6	-5.89	7.17e-09	2.82e-06	-0.33	-0.26	Hypospadias;	chr7:27551228	chr7:27491682~27492765:-
LUAD	cis	rs7849270	0.725	rs59012667	ENSG00000268707.1	RP11-247A12.7	-5.89	7.17e-09	2.83e-06	-0.3	-0.26	Blood metabolite ratios;	chr9:129088202	chr9:129170434~129170940:+
LUAD	cis	rs11098499	0.865	rs10213221	ENSG00000248280.1	RP11-33B1.2	5.89	7.17e-09	2.83e-06	0.32	0.26	Corneal astigmatism;	chr4:119334771	chr4:119440561~119450157:-
LUAD	cis	rs853679	0.599	rs202906	ENSG00000204709.4	LINC01556	-5.89	7.18e-09	2.83e-06	-0.42	-0.26	Depression;	chr6:28043874	chr6:28943877~28944537:+
LUAD	cis	rs1134634	0.52	rs10034328	ENSG00000273133.1	RP11-799M12.2	-5.89	7.18e-09	2.83e-06	-0.38	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15616764	chr4:15563698~15564253:-
LUAD	cis	rs2404602	0.716	rs56216512	ENSG00000259422.1	RP11-593F23.1	5.89	7.19e-09	2.83e-06	0.3	0.26	Blood metabolite levels;	chr15:76394595	chr15:76174891~76181486:-
LUAD	cis	rs12468226	1	rs7597469	ENSG00000272966.1	RP11-686O6.1	5.89	7.19e-09	2.83e-06	0.45	0.26	Urate levels;	chr2:202329547	chr2:202336739~202337200:+
LUAD	cis	rs9595908	0.629	rs962454	ENSG00000212293.1	SNORA16	5.89	7.19e-09	2.83e-06	0.28	0.26	Body mass index;	chr13:32719131	chr13:32420390~32420516:-
LUAD	cis	rs4908768	0.501	rs1922983	ENSG00000232912.4	RP5-1115A15.1	5.89	7.21e-09	2.84e-06	0.24	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8471266	chr1:8424645~8434838:+
LUAD	cis	rs9595066	0.627	rs4432167	ENSG00000227258.4	SMIM2-AS1	-5.89	7.21e-09	2.84e-06	-0.39	-0.26	Schizophrenia;	chr13:44178225	chr13:44110451~44240517:+
LUAD	cis	rs11098499	0.789	rs10212719	ENSG00000248280.1	RP11-33B1.2	5.89	7.21e-09	2.84e-06	0.32	0.26	Corneal astigmatism;	chr4:119333282	chr4:119440561~119450157:-
LUAD	cis	rs853679	0.506	rs1150693	ENSG00000204709.4	LINC01556	5.89	7.21e-09	2.84e-06	0.36	0.26	Depression;	chr6:28206812	chr6:28943877~28944537:+
LUAD	cis	rs35740288	0.77	rs1382538	ENSG00000202081.1	RNU6-1280P	5.89	7.22e-09	2.84e-06	0.33	0.26	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85622665	chr15:85651522~85651628:-
LUAD	cis	rs875971	0.789	rs7808013	ENSG00000222364.1	RNU6-96P	5.89	7.22e-09	2.84e-06	0.29	0.26	Aortic root size;	chr7:66606209	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.825	rs7384021	ENSG00000222364.1	RNU6-96P	5.89	7.22e-09	2.84e-06	0.29	0.26	Aortic root size;	chr7:66612917	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.825	rs66981195	ENSG00000222364.1	RNU6-96P	5.89	7.22e-09	2.84e-06	0.29	0.26	Aortic root size;	chr7:66614048	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs3926380	ENSG00000222364.1	RNU6-96P	5.89	7.22e-09	2.84e-06	0.29	0.26	Aortic root size;	chr7:66615658	chr7:66395191~66395286:+
LUAD	cis	rs11976180	1	rs6464574	ENSG00000170356.8	OR2A20P	-5.89	7.23e-09	2.85e-06	-0.33	-0.26	Obesity-related traits;	chr7:144051164	chr7:144250045~144252957:-
LUAD	cis	rs897984	0.542	rs11864839	ENSG00000260911.2	RP11-196G11.2	5.89	7.23e-09	2.85e-06	0.24	0.26	Dementia with Lewy bodies;	chr16:31083930	chr16:31043150~31049868:+
LUAD	cis	rs7299940	0.694	rs12296337	ENSG00000256299.1	RP11-989F5.3	5.89	7.24e-09	2.85e-06	0.29	0.26	Panic disorder;	chr12:130891406	chr12:130810821~130812622:-
LUAD	cis	rs8040855	0.579	rs28521166	ENSG00000259774.1	RP11-182J1.13	-5.89	7.24e-09	2.85e-06	-0.3	-0.26	Bulimia nervosa;	chr15:85184801	chr15:84422618~84425882:+
LUAD	cis	rs1134634	0.52	rs872678	ENSG00000273133.1	RP11-799M12.2	-5.89	7.24e-09	2.85e-06	-0.38	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15654075	chr4:15563698~15564253:-
LUAD	cis	rs783540	0.632	rs17356528	ENSG00000278603.1	RP13-608F4.5	-5.89	7.24e-09	2.85e-06	-0.33	-0.26	Schizophrenia;	chr15:82636799	chr15:82472203~82472426:+
LUAD	cis	rs948562	0.947	rs7482383	ENSG00000280010.1	AP001350.4	5.89	7.25e-09	2.86e-06	0.42	0.26	Lymphoma;	chr11:58602225	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.947	rs76985515	ENSG00000280010.1	AP001350.4	5.89	7.25e-09	2.86e-06	0.42	0.26	Lymphoma;	chr11:58604321	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.947	rs78176302	ENSG00000280010.1	AP001350.4	5.89	7.25e-09	2.86e-06	0.42	0.26	Lymphoma;	chr11:58615176	chr11:58627435~58628528:+
LUAD	cis	rs916888	0.773	rs199451	ENSG00000261575.2	RP11-259G18.1	5.89	7.26e-09	2.86e-06	0.41	0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46267037~46268694:+
LUAD	cis	rs1075265	0.655	rs13432632	ENSG00000233266.1	HMGB1P31	5.89	7.26e-09	2.86e-06	0.33	0.26	Chronotype;Morning vs. evening chronotype;	chr2:53713586	chr2:54051334~54051760:+
LUAD	cis	rs7712401	0.715	rs6859163	ENSG00000263432.2	RN7SL689P	-5.89	7.27e-09	2.86e-06	-0.33	-0.26	Mean platelet volume;	chr5:123019225	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.715	rs385996	ENSG00000263432.2	RN7SL689P	-5.89	7.27e-09	2.86e-06	-0.33	-0.26	Mean platelet volume;	chr5:123019533	chr5:123022487~123022783:-
LUAD	cis	rs7618501	0.633	rs2856234	ENSG00000234667.1	ACTBP13	5.89	7.29e-09	2.87e-06	0.29	0.26	Intelligence (multi-trait analysis);	chr3:50101709	chr3:49873347~49877980:-
LUAD	cis	rs2439831	0.85	rs28595038	ENSG00000205771.5	CATSPER2P1	-5.89	7.29e-09	2.87e-06	-0.49	-0.26	Lung cancer in ever smokers;	chr15:43752661	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.85	rs10163054	ENSG00000205771.5	CATSPER2P1	-5.89	7.29e-09	2.87e-06	-0.49	-0.26	Lung cancer in ever smokers;	chr15:43755440	chr15:43726918~43747094:-
LUAD	cis	rs7849270	0.959	rs1410017	ENSG00000268707.1	RP11-247A12.7	-5.89	7.31e-09	2.88e-06	-0.29	-0.26	Blood metabolite ratios;	chr9:129151151	chr9:129170434~129170940:+
LUAD	cis	rs17666538	0.585	rs10090260	ENSG00000254207.1	RP11-43A14.1	5.89	7.32e-09	2.88e-06	0.51	0.26	IgG glycosylation;	chr8:658034	chr8:725188~725877:-
LUAD	cis	rs66887589	0.934	rs41464847	ENSG00000248280.1	RP11-33B1.2	-5.89	7.32e-09	2.88e-06	-0.28	-0.26	Diastolic blood pressure;	chr4:119611246	chr4:119440561~119450157:-
LUAD	cis	rs10129255	0.913	rs10140943	ENSG00000224373.3	IGHV4-59	5.89	7.33e-09	2.88e-06	0.17	0.26	Kawasaki disease;	chr14:106767441	chr14:106627249~106627825:-
LUAD	cis	rs2115536	0.967	rs4778734	ENSG00000278600.1	RP11-81A1.6	-5.89	7.33e-09	2.88e-06	-0.21	-0.26	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79918509	chr15:79920195~79922455:-
LUAD	cis	rs2288884	1	rs17779301	ENSG00000275055.1	CTC-471J1.11	5.89	7.33e-09	2.88e-06	0.4	0.26	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52035990	chr19:52049007~52049754:+
LUAD	cis	rs10129255	1	rs10134517	ENSG00000211974.3	IGHV2-70	5.89	7.34e-09	2.89e-06	0.27	0.26	Kawasaki disease;	chr14:106718498	chr14:106723574~106724093:-
LUAD	cis	rs12554020	0.786	rs16909150	ENSG00000227603.1	RP11-165J3.6	-5.89	7.36e-09	2.89e-06	-0.48	-0.26	Schizophrenia;	chr9:93454464	chr9:93435332~93437121:-
LUAD	cis	rs2243480	1	rs4149468	ENSG00000230295.1	RP11-458F8.2	-5.89	7.36e-09	2.89e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66360703	chr7:66880708~66882981:+
LUAD	cis	rs9309473	1	rs1534471	ENSG00000163016.8	ALMS1P	5.89	7.37e-09	2.9e-06	0.31	0.26	Metabolite levels;	chr2:73420380	chr2:73644919~73685576:+
LUAD	cis	rs755249	0.567	rs2018212	ENSG00000228060.1	RP11-69E11.8	-5.89	7.37e-09	2.9e-06	-0.27	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39439916	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs4660751	ENSG00000228060.1	RP11-69E11.8	-5.89	7.37e-09	2.9e-06	-0.27	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39440201	chr1:39565160~39573203:+
LUAD	cis	rs7945705	0.782	rs2742545	ENSG00000254860.4	TMEM9B-AS1	5.89	7.38e-09	2.9e-06	0.29	0.26	Hemoglobin concentration;	chr11:8862761	chr11:8964675~8977527:+
LUAD	cis	rs7945705	0.84	rs10840136	ENSG00000254860.4	TMEM9B-AS1	5.89	7.38e-09	2.9e-06	0.29	0.26	Hemoglobin concentration;	chr11:8863477	chr11:8964675~8977527:+
LUAD	cis	rs4908768	0.539	rs11121204	ENSG00000232912.4	RP5-1115A15.1	-5.89	7.38e-09	2.9e-06	-0.24	-0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8594246	chr1:8424645~8434838:+
LUAD	cis	rs6921919	0.583	rs3734563	ENSG00000216901.1	AL022393.7	5.89	7.39e-09	2.9e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs1591913	ENSG00000216901.1	AL022393.7	5.89	7.39e-09	2.9e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28176188~28176674:+
LUAD	cis	rs10214930	0.697	rs759269	ENSG00000235574.1	AC073150.6	-5.89	7.39e-09	2.9e-06	-0.33	-0.26	Hypospadias;	chr7:27552728	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.56	rs1015750	ENSG00000235574.1	AC073150.6	-5.89	7.39e-09	2.9e-06	-0.33	-0.26	Hypospadias;	chr7:27553600	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs7780431	ENSG00000235574.1	AC073150.6	-5.89	7.39e-09	2.9e-06	-0.33	-0.26	Hypospadias;	chr7:27553749	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs1554641	ENSG00000235574.1	AC073150.6	-5.89	7.39e-09	2.9e-06	-0.33	-0.26	Hypospadias;	chr7:27555068	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.813	rs2391451	ENSG00000235574.1	AC073150.6	-5.89	7.39e-09	2.91e-06	-0.34	-0.26	Hypospadias;	chr7:27646203	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.813	rs12700829	ENSG00000235574.1	AC073150.6	-5.89	7.39e-09	2.91e-06	-0.34	-0.26	Hypospadias;	chr7:27647483	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.813	rs2160125	ENSG00000235574.1	AC073150.6	-5.89	7.39e-09	2.91e-06	-0.34	-0.26	Hypospadias;	chr7:27648667	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.813	rs12700830	ENSG00000235574.1	AC073150.6	-5.89	7.39e-09	2.91e-06	-0.34	-0.26	Hypospadias;	chr7:27649240	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.752	rs2391454	ENSG00000235574.1	AC073150.6	-5.89	7.39e-09	2.91e-06	-0.34	-0.26	Hypospadias;	chr7:27651005	chr7:27491682~27492765:-
LUAD	cis	rs12699921	0.599	rs2691583	ENSG00000279048.1	RP11-511H23.2	-5.89	7.39e-09	2.91e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17792182	chr7:17940503~17942922:+
LUAD	cis	rs2276314	1	rs2298715	ENSG00000278986.1	RP11-723J4.3	-5.89	7.42e-09	2.91e-06	-0.32	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:35972462	chr18:35972151~35973916:+
LUAD	cis	rs6687821	0.593	rs797947	ENSG00000267734.1	RP4-604K5.3	5.89	7.42e-09	2.91e-06	0.34	0.26	Yeast infection;	chr1:86844606	chr1:86932199~86934891:-
LUAD	cis	rs62432291	0.681	rs404461	ENSG00000235086.1	FNDC1-IT1	5.89	7.43e-09	2.92e-06	0.44	0.26	Joint mobility (Beighton score);	chr6:159219677	chr6:159240786~159243329:+
LUAD	cis	rs394563	0.622	rs237024	ENSG00000231760.4	RP11-350J20.5	5.89	7.43e-09	2.92e-06	0.31	0.26	Dupuytren's disease;	chr6:149400829	chr6:149796151~149826294:-
LUAD	cis	rs7618501	0.633	rs9814664	ENSG00000234667.1	ACTBP13	5.89	7.43e-09	2.92e-06	0.29	0.26	Intelligence (multi-trait analysis);	chr3:50041108	chr3:49873347~49877980:-
LUAD	cis	rs2442825	0.72	rs2648561	ENSG00000206573.7	THUMPD3-AS1	5.89	7.44e-09	2.92e-06	0.19	0.26	Cerebrospinal fluid clusterin levels;	chr3:9376399	chr3:9349689~9398579:-
LUAD	cis	rs180730	0.519	rs1901135	ENSG00000251609.2	SETP12	5.89	7.44e-09	2.92e-06	0.34	0.26	Fasting plasma glucose;	chr4:120907364	chr4:120895494~120897083:-
LUAD	cis	rs180730	0.539	rs3804178	ENSG00000251609.2	SETP12	5.89	7.44e-09	2.92e-06	0.34	0.26	Fasting plasma glucose;	chr4:120907911	chr4:120895494~120897083:-
LUAD	cis	rs9595908	0.869	rs9591191	ENSG00000212293.1	SNORA16	5.89	7.44e-09	2.92e-06	0.28	0.26	Body mass index;	chr13:32633397	chr13:32420390~32420516:-
LUAD	cis	rs1113500	1	rs1777483	ENSG00000226822.1	RP11-356N1.2	-5.89	7.44e-09	2.92e-06	-0.3	-0.26	Growth-regulated protein alpha levels;	chr1:108066786	chr1:108071482~108074519:+
LUAD	cis	rs5753618	0.583	rs9606843	ENSG00000236132.1	CTA-440B3.1	-5.89	7.44e-09	2.92e-06	-0.32	-0.26	Colorectal cancer;	chr22:31457385	chr22:31816379~31817491:-
LUAD	cis	rs10214930	0.697	rs2110526	ENSG00000235574.1	AC073150.6	-5.89	7.46e-09	2.93e-06	-0.33	-0.26	Hypospadias;	chr7:27596061	chr7:27491682~27492765:-
LUAD	cis	rs71403859	0.502	rs7195767	ENSG00000260886.1	TAT-AS1	5.89	7.47e-09	2.93e-06	0.42	0.26	Post bronchodilator FEV1;	chr16:71431040	chr16:71565789~71578187:+
LUAD	cis	rs12908161	0.959	rs11637728	ENSG00000225151.9	GOLGA2P7	-5.88	7.49e-09	2.94e-06	-0.35	-0.26	Schizophrenia;	chr15:84660161	chr15:84199311~84230136:-
LUAD	cis	rs1707322	0.721	rs7520123	ENSG00000234329.1	RP11-767N6.2	5.88	7.49e-09	2.94e-06	0.27	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769547	chr1:45651039~45651826:-
LUAD	cis	rs2117029	0.555	rs10747561	ENSG00000258017.1	RP11-386G11.10	-5.88	7.5e-09	2.94e-06	-0.32	-0.26	Intelligence (multi-trait analysis);	chr12:49106726	chr12:49127782~49147869:+
LUAD	cis	rs853679	0.513	rs9468296	ENSG00000204709.4	LINC01556	5.88	7.5e-09	2.94e-06	0.37	0.26	Depression;	chr6:28145952	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.824	rs742046	ENSG00000219392.1	RP1-265C24.5	-5.88	7.5e-09	2.95e-06	-0.35	-0.26	Parkinson's disease;	chr6:27771475	chr6:28115628~28116551:+
LUAD	cis	rs6142102	0.625	rs4911384	ENSG00000275784.1	RP5-1125A11.6	-5.88	7.51e-09	2.95e-06	-0.28	-0.26	Skin pigmentation;	chr20:33968001	chr20:33989480~33991818:-
LUAD	cis	rs10129255	0.872	rs1858683	ENSG00000224373.3	IGHV4-59	5.88	7.51e-09	2.95e-06	0.17	0.26	Kawasaki disease;	chr14:106670217	chr14:106627249~106627825:-
LUAD	cis	rs858239	0.632	rs6952947	ENSG00000230042.1	AK3P3	5.88	7.51e-09	2.95e-06	0.33	0.26	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23129178~23129841:+
LUAD	cis	rs7618501	0.571	rs2240329	ENSG00000234667.1	ACTBP13	5.88	7.52e-09	2.95e-06	0.29	0.26	Intelligence (multi-trait analysis);	chr3:50070079	chr3:49873347~49877980:-
LUAD	cis	rs496547	0.719	rs476246	ENSG00000255239.1	AP002954.6	-5.88	7.52e-09	2.95e-06	-0.31	-0.26	Hip minimal joint space width;	chr11:118747211	chr11:118688039~118690600:-
LUAD	cis	rs4908768	0.539	rs6670508	ENSG00000232912.4	RP5-1115A15.1	5.88	7.53e-09	2.95e-06	0.24	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8587858	chr1:8424645~8434838:+
LUAD	cis	rs7727544	0.735	rs272875	ENSG00000233006.5	AC034220.3	5.88	7.53e-09	2.95e-06	0.23	0.26	Blood metabolite levels;	chr5:132339195	chr5:132311285~132369916:-
LUAD	cis	rs957448	0.554	rs12540967	ENSG00000253704.1	RP11-267M23.4	5.88	7.53e-09	2.96e-06	0.3	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94576862	chr8:94553722~94569745:+
LUAD	cis	rs1134634	0.52	rs28528670	ENSG00000273133.1	RP11-799M12.2	-5.88	7.53e-09	2.96e-06	-0.38	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15591295	chr4:15563698~15564253:-
LUAD	cis	rs12699921	0.594	rs2691620	ENSG00000279048.1	RP11-511H23.2	-5.88	7.54e-09	2.96e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17851213	chr7:17940503~17942922:+
LUAD	cis	rs36093844	1	rs11234452	ENSG00000279742.1	RP11-700A24.1	-5.88	7.54e-09	2.96e-06	-0.29	-0.26	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85865758	chr11:85852557~85854943:-
LUAD	cis	rs2404602	0.716	rs117129193	ENSG00000259422.1	RP11-593F23.1	5.88	7.54e-09	2.96e-06	0.3	0.26	Blood metabolite levels;	chr15:76364462	chr15:76174891~76181486:-
LUAD	cis	rs11971779	0.648	rs10230407	ENSG00000273391.1	RP11-634H22.1	5.88	7.55e-09	2.96e-06	0.26	0.26	Diisocyanate-induced asthma;	chr7:139419147	chr7:139359032~139359566:-
LUAD	cis	rs9813712	0.596	rs2587988	ENSG00000228252.7	COL6A4P2	-5.88	7.56e-09	2.97e-06	-0.24	-0.26	Response to amphetamines;	chr3:130201415	chr3:130212823~130273806:+
LUAD	cis	rs2243480	1	rs160639	ENSG00000230295.1	RP11-458F8.2	-5.88	7.56e-09	2.97e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66115000	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs313824	ENSG00000230295.1	RP11-458F8.2	-5.88	7.56e-09	2.97e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66116220	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs186378	ENSG00000230295.1	RP11-458F8.2	-5.88	7.56e-09	2.97e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66117071	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs160637	ENSG00000230295.1	RP11-458F8.2	-5.88	7.56e-09	2.97e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66119331	chr7:66880708~66882981:+
LUAD	cis	rs35740288	0.752	rs11636138	ENSG00000202081.1	RNU6-1280P	5.88	7.56e-09	2.97e-06	0.33	0.26	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85744316	chr15:85651522~85651628:-
LUAD	cis	rs12699921	0.607	rs1404425	ENSG00000279048.1	RP11-511H23.2	-5.88	7.57e-09	2.97e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17788034	chr7:17940503~17942922:+
LUAD	cis	rs1823913	0.637	rs921737	ENSG00000227542.1	AC092614.2	-5.88	7.57e-09	2.97e-06	-0.31	-0.26	Obesity-related traits;	chr2:191286097	chr2:191229165~191246172:-
LUAD	cis	rs1823913	0.599	rs6736071	ENSG00000227542.1	AC092614.2	-5.88	7.57e-09	2.97e-06	-0.31	-0.26	Obesity-related traits;	chr2:191287265	chr2:191229165~191246172:-
LUAD	cis	rs4947019	0.609	rs9487109	ENSG00000260273.1	RP11-425D10.10	5.88	7.58e-09	2.97e-06	0.59	0.26	Hematological parameters;	chr6:109436323	chr6:109382795~109383666:+
LUAD	cis	rs6142102	0.625	rs4911381	ENSG00000275784.1	RP5-1125A11.6	5.88	7.58e-09	2.97e-06	0.28	0.26	Skin pigmentation;	chr20:33962539	chr20:33989480~33991818:-
LUAD	cis	rs3762637	1	rs28434553	ENSG00000272758.4	RP11-299J3.8	-5.88	7.59e-09	2.98e-06	-0.39	-0.26	LDL cholesterol levels;	chr3:122510668	chr3:122416207~122443180:+
LUAD	cis	rs3762637	0.941	rs9837149	ENSG00000272758.4	RP11-299J3.8	-5.88	7.59e-09	2.98e-06	-0.39	-0.26	LDL cholesterol levels;	chr3:122511998	chr3:122416207~122443180:+
LUAD	cis	rs9860428	0.711	rs9810246	ENSG00000242770.2	RP11-180K7.1	5.88	7.59e-09	2.98e-06	0.28	0.26	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112807706	chr3:112802478~112812819:+
LUAD	cis	rs12699921	0.632	rs2691618	ENSG00000279048.1	RP11-511H23.2	-5.88	7.59e-09	2.98e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17850572	chr7:17940503~17942922:+
LUAD	cis	rs394563	0.591	rs237026	ENSG00000231760.4	RP11-350J20.5	5.88	7.59e-09	2.98e-06	0.31	0.26	Dupuytren's disease;	chr6:149399545	chr6:149796151~149826294:-
LUAD	cis	rs4835473	0.838	rs34819068	ENSG00000251600.4	RP11-673E1.1	-5.88	7.59e-09	2.98e-06	-0.32	-0.26	Immature fraction of reticulocytes;	chr4:143787330	chr4:143912331~143982454:+
LUAD	cis	rs1823913	0.637	rs11686185	ENSG00000227542.1	AC092614.2	-5.88	7.6e-09	2.98e-06	-0.31	-0.26	Obesity-related traits;	chr2:191289282	chr2:191229165~191246172:-
LUAD	cis	rs7927592	0.956	rs12281742	ENSG00000212093.1	AP000807.1	-5.88	7.61e-09	2.99e-06	-0.28	-0.26	Total body bone mineral density;	chr11:68536161	chr11:68506083~68506166:-
LUAD	cis	rs4972806	0.776	rs2072589	ENSG00000226363.3	HAGLROS	-5.88	7.62e-09	2.99e-06	-0.32	-0.26	IgG glycosylation;	chr2:176178143	chr2:176177717~176179008:+
LUAD	cis	rs1075265	0.87	rs6724389	ENSG00000233266.1	HMGB1P31	5.88	7.62e-09	2.99e-06	0.33	0.26	Chronotype;Morning vs. evening chronotype;	chr2:53985698	chr2:54051334~54051760:+
LUAD	cis	rs10129255	0.518	rs2006284	ENSG00000211967.3	IGHV3-53	-5.88	7.63e-09	2.99e-06	-0.19	-0.26	Kawasaki disease;	chr14:106676185	chr14:106592676~106593347:-
LUAD	cis	rs875971	1	rs10257427	ENSG00000237310.1	GS1-124K5.4	-5.88	7.64e-09	3e-06	-0.28	-0.26	Aortic root size;	chr7:66278221	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs10215948	ENSG00000237310.1	GS1-124K5.4	-5.88	7.64e-09	3e-06	-0.28	-0.26	Aortic root size;	chr7:66282799	chr7:66493706~66495474:+
LUAD	cis	rs2283792	0.715	rs56227348	ENSG00000224086.5	LL22NC03-86G7.1	-5.88	7.65e-09	3e-06	-0.25	-0.26	Multiple sclerosis;	chr22:21791443	chr22:21938293~21977632:+
LUAD	cis	rs293748	0.771	rs159141	ENSG00000250155.1	CTD-2353F22.1	-5.88	7.65e-09	3e-06	-0.36	-0.26	Obesity-related traits;	chr5:36925544	chr5:36666214~36725195:-
LUAD	cis	rs12188164	0.502	rs55929184	ENSG00000225138.6	CTD-2228K2.7	5.88	7.65e-09	3e-06	0.25	0.26	Cystic fibrosis severity;	chr5:405461	chr5:473236~480884:+
LUAD	cis	rs10214930	1	rs10214930	ENSG00000235574.1	AC073150.6	5.88	7.65e-09	3e-06	0.36	0.26	Hypospadias;	chr7:27745330	chr7:27491682~27492765:-
LUAD	cis	rs10214930	1	rs4722740	ENSG00000235574.1	AC073150.6	5.88	7.65e-09	3e-06	0.36	0.26	Hypospadias;	chr7:27747390	chr7:27491682~27492765:-
LUAD	cis	rs2790457	0.518	rs2993984	ENSG00000254635.4	WAC-AS1	-5.88	7.65e-09	3e-06	-0.28	-0.26	Multiple myeloma;	chr10:28509727	chr10:28522652~28532743:-
LUAD	cis	rs12655019	0.92	rs7725377	ENSG00000271828.1	CTD-2310F14.1	-5.88	7.67e-09	3.01e-06	-0.45	-0.26	Breast cancer (early onset);	chr5:56960769	chr5:56927874~56929573:+
LUAD	cis	rs8177376	0.727	rs589442	ENSG00000254905.1	RP11-712L6.7	5.88	7.68e-09	3.01e-06	0.36	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126328101	chr11:126292922~126294254:-
LUAD	cis	rs30380	0.632	rs27640	ENSG00000272109.1	CTD-2260A17.3	-5.88	7.68e-09	3.01e-06	-0.31	-0.26	Cerebrospinal fluid biomarker levels;	chr5:96792202	chr5:96804353~96806105:+
LUAD	cis	rs30380	0.632	rs27434	ENSG00000272109.1	CTD-2260A17.3	-5.88	7.68e-09	3.01e-06	-0.31	-0.26	Cerebrospinal fluid biomarker levels;	chr5:96793809	chr5:96804353~96806105:+
LUAD	cis	rs2255336	0.938	rs73070926	ENSG00000245648.1	RP11-277P12.20	-5.88	7.68e-09	3.01e-06	-0.41	-0.26	Blood protein levels;	chr12:10459717	chr12:10363769~10398506:+
LUAD	cis	rs9595908	0.709	rs9315179	ENSG00000212293.1	SNORA16	5.88	7.68e-09	3.01e-06	0.28	0.26	Body mass index;	chr13:32773889	chr13:32420390~32420516:-
LUAD	cis	rs2404602	0.716	rs7179142	ENSG00000259422.1	RP11-593F23.1	5.88	7.69e-09	3.01e-06	0.29	0.26	Blood metabolite levels;	chr15:76405927	chr15:76174891~76181486:-
LUAD	cis	rs11051970	0.559	rs7300646	ENSG00000274964.1	RP11-817I4.1	-5.88	7.7e-09	3.01e-06	-0.33	-0.26	Response to tocilizumab in rheumatoid arthritis;	chr12:32335695	chr12:32339368~32340724:+
LUAD	cis	rs13217239	0.646	rs6456767	ENSG00000241549.7	GUSBP2	-5.88	7.71e-09	3.02e-06	-0.29	-0.26	Schizophrenia;	chr6:27102764	chr6:26871484~26956554:-
LUAD	cis	rs9595908	0.694	rs9596233	ENSG00000212293.1	SNORA16	5.88	7.71e-09	3.02e-06	0.27	0.26	Body mass index;	chr13:32776878	chr13:32420390~32420516:-
LUAD	cis	rs11971779	0.68	rs6947215	ENSG00000273391.1	RP11-634H22.1	5.88	7.72e-09	3.02e-06	0.26	0.26	Diisocyanate-induced asthma;	chr7:139341892	chr7:139359032~139359566:-
LUAD	cis	rs2179367	0.537	rs12192159	ENSG00000231760.4	RP11-350J20.5	5.88	7.72e-09	3.02e-06	0.39	0.26	Dupuytren's disease;	chr6:149445969	chr6:149796151~149826294:-
LUAD	cis	rs1015362	0.54	rs2378026	ENSG00000276073.1	RP5-1125A11.7	-5.88	7.73e-09	3.03e-06	-0.33	-0.26	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33921845	chr20:33985617~33988989:-
LUAD	cis	rs1707322	0.721	rs11211181	ENSG00000234329.1	RP11-767N6.2	5.88	7.73e-09	3.03e-06	0.27	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45771128	chr1:45651039~45651826:-
LUAD	cis	rs12554020	0.786	rs79469056	ENSG00000227603.1	RP11-165J3.6	5.88	7.73e-09	3.03e-06	0.48	0.26	Schizophrenia;	chr9:93453807	chr9:93435332~93437121:-
LUAD	cis	rs4538475	0.556	rs4613561	ENSG00000214846.4	RP11-115L11.1	5.88	7.73e-09	3.03e-06	0.37	0.26	Parkinson's disease;	chr4:15736267	chr4:15730962~15731627:-
LUAD	cis	rs1134634	0.52	rs741180	ENSG00000273133.1	RP11-799M12.2	-5.88	7.73e-09	3.03e-06	-0.38	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15561787	chr4:15563698~15564253:-
LUAD	cis	rs11157436	0.958	rs2204963	ENSG00000211812.1	TRAV26-2	-5.88	7.74e-09	3.03e-06	-0.3	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22187871	chr14:22202583~22203368:+
LUAD	cis	rs7044106	0.762	rs3903886	ENSG00000238181.2	AHCYP2	5.88	7.74e-09	3.03e-06	0.32	0.26	Hip circumference adjusted for BMI;	chr9:120621368	chr9:120720673~120721972:+
LUAD	cis	rs9287719	0.601	rs12996735	ENSG00000243819.4	RN7SL832P	5.88	7.74e-09	3.03e-06	0.28	0.26	Prostate cancer;	chr2:10576590	chr2:10690344~10692099:+
LUAD	cis	rs10246939	0.579	rs58093678	ENSG00000228775.6	WEE2-AS1	5.88	7.74e-09	3.03e-06	0.31	0.26	Bitter taste perception;	chr7:141856719	chr7:141704338~141738346:-
LUAD	cis	rs7727544	0.684	rs274560	ENSG00000233006.5	AC034220.3	-5.88	7.74e-09	3.03e-06	-0.23	-0.26	Blood metabolite levels;	chr5:132383758	chr5:132311285~132369916:-
LUAD	cis	rs2243480	1	rs73142166	ENSG00000230295.1	RP11-458F8.2	-5.88	7.75e-09	3.03e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:65910845	chr7:66880708~66882981:+
LUAD	cis	rs2880765	0.506	rs719138	ENSG00000259295.5	CSPG4P12	5.88	7.75e-09	3.03e-06	0.32	0.26	Coronary artery disease;	chr15:85511831	chr15:85191438~85213905:+
LUAD	cis	rs66887589	0.627	rs3872807	ENSG00000245958.5	RP11-33B1.1	-5.88	7.77e-09	3.04e-06	-0.21	-0.26	Diastolic blood pressure;	chr4:119439096	chr4:119454791~119552025:+
LUAD	cis	rs2243480	1	rs313814	ENSG00000230295.1	RP11-458F8.2	-5.88	7.79e-09	3.05e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66038306	chr7:66880708~66882981:+
LUAD	cis	rs12468226	1	rs113877751	ENSG00000272966.1	RP11-686O6.1	5.88	7.79e-09	3.05e-06	0.45	0.26	Urate levels;	chr2:202329998	chr2:202336739~202337200:+
LUAD	cis	rs12468226	0.935	rs113021930	ENSG00000272966.1	RP11-686O6.1	5.88	7.79e-09	3.05e-06	0.45	0.26	Urate levels;	chr2:202330448	chr2:202336739~202337200:+
LUAD	cis	rs12468226	1	rs113491584	ENSG00000272966.1	RP11-686O6.1	5.88	7.79e-09	3.05e-06	0.45	0.26	Urate levels;	chr2:202331724	chr2:202336739~202337200:+
LUAD	cis	rs2255336	0.938	rs2617169	ENSG00000245648.1	RP11-277P12.20	5.88	7.79e-09	3.05e-06	0.4	0.26	Blood protein levels;	chr12:10408225	chr12:10363769~10398506:+
LUAD	cis	rs875971	0.545	rs6460281	ENSG00000226824.5	RP4-756H11.3	-5.88	7.79e-09	3.05e-06	-0.37	-0.26	Aortic root size;	chr7:66216128	chr7:66654538~66669855:+
LUAD	cis	rs394563	0.591	rs237018	ENSG00000231760.4	RP11-350J20.5	5.88	7.79e-09	3.05e-06	0.32	0.26	Dupuytren's disease;	chr6:149422794	chr6:149796151~149826294:-
LUAD	cis	rs7246657	0.524	rs35080624	ENSG00000276846.1	CTD-3220F14.3	5.88	7.8e-09	3.05e-06	0.41	0.26	Coronary artery calcification;	chr19:36965680	chr19:37314868~37315620:-
LUAD	cis	rs5753618	0.607	rs5753621	ENSG00000236132.1	CTA-440B3.1	-5.88	7.8e-09	3.05e-06	-0.32	-0.26	Colorectal cancer;	chr22:31451661	chr22:31816379~31817491:-
LUAD	cis	rs1113500	0.933	rs4517375	ENSG00000226822.1	RP11-356N1.2	-5.88	7.8e-09	3.05e-06	-0.3	-0.26	Growth-regulated protein alpha levels;	chr1:108095708	chr1:108071482~108074519:+
LUAD	cis	rs875971	0.755	rs10228885	ENSG00000222364.1	RNU6-96P	5.88	7.81e-09	3.06e-06	0.29	0.26	Aortic root size;	chr7:66315542	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs3893216	ENSG00000222364.1	RNU6-96P	5.88	7.81e-09	3.06e-06	0.29	0.26	Aortic root size;	chr7:66325720	chr7:66395191~66395286:+
LUAD	cis	rs4908768	0.501	rs12756257	ENSG00000232912.4	RP5-1115A15.1	5.88	7.82e-09	3.06e-06	0.24	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8556874	chr1:8424645~8434838:+
LUAD	cis	rs2243480	1	rs313820	ENSG00000230295.1	RP11-458F8.2	-5.88	7.83e-09	3.06e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66109479	chr7:66880708~66882981:+
LUAD	cis	rs10200159	1	rs6545509	ENSG00000272606.1	RP11-554J4.1	5.88	7.83e-09	3.06e-06	0.53	0.26	Vitiligo;	chr2:55607461	chr2:55617909~55618373:+
LUAD	cis	rs7712401	0.715	rs1139334	ENSG00000263432.2	RN7SL689P	-5.88	7.83e-09	3.07e-06	-0.33	-0.26	Mean platelet volume;	chr5:123022724	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.715	rs1062350	ENSG00000263432.2	RN7SL689P	-5.88	7.83e-09	3.07e-06	-0.33	-0.26	Mean platelet volume;	chr5:123022811	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.678	rs401535	ENSG00000263432.2	RN7SL689P	-5.88	7.83e-09	3.07e-06	-0.33	-0.26	Mean platelet volume;	chr5:123022990	chr5:123022487~123022783:-
LUAD	cis	rs2276314	1	rs2276314	ENSG00000278986.1	RP11-723J4.3	5.88	7.84e-09	3.07e-06	0.31	0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:35977503	chr18:35972151~35973916:+
LUAD	cis	rs7618501	0.633	rs4688757	ENSG00000234667.1	ACTBP13	-5.88	7.84e-09	3.07e-06	-0.29	-0.26	Intelligence (multi-trait analysis);	chr3:49997890	chr3:49873347~49877980:-
LUAD	cis	rs7945705	0.967	rs10840141	ENSG00000254860.4	TMEM9B-AS1	-5.88	7.84e-09	3.07e-06	-0.29	-0.26	Hemoglobin concentration;	chr11:8880671	chr11:8964675~8977527:+
LUAD	cis	rs673078	0.607	rs17440956	ENSG00000275409.1	RP11-131L12.4	5.88	7.84e-09	3.07e-06	0.35	0.26	Glucose homeostasis traits;	chr12:118394639	chr12:118430147~118430699:+
LUAD	cis	rs8031584	0.918	rs35396566	ENSG00000260382.1	RP11-540B6.2	5.88	7.85e-09	3.07e-06	0.34	0.26	Huntington's disease progression;	chr15:30970854	chr15:30882267~30883231:-
LUAD	cis	rs9910055	0.676	rs11079983	ENSG00000267080.4	ASB16-AS1	-5.88	7.85e-09	3.07e-06	-0.24	-0.26	Total body bone mineral density;	chr17:44120802	chr17:44175973~44186717:-
LUAD	cis	rs1061377	1	rs56119980	ENSG00000249685.1	RP11-360F5.3	5.88	7.86e-09	3.07e-06	0.31	0.26	Uric acid levels;	chr4:39139390	chr4:39133913~39135608:+
LUAD	cis	rs2404602	0.716	rs17460201	ENSG00000259422.1	RP11-593F23.1	-5.88	7.86e-09	3.08e-06	-0.3	-0.26	Blood metabolite levels;	chr15:76381286	chr15:76174891~76181486:-
LUAD	cis	rs3738443	0.678	rs4314914	ENSG00000259865.1	RP11-488L18.10	5.88	7.86e-09	3.08e-06	0.24	0.26	Alcohol dependence;	chr1:247210326	chr1:247187281~247188526:-
LUAD	cis	rs2442825	0.693	rs2255558	ENSG00000206573.7	THUMPD3-AS1	5.88	7.86e-09	3.08e-06	0.19	0.26	Cerebrospinal fluid clusterin levels;	chr3:9375148	chr3:9349689~9398579:-
LUAD	cis	rs238295	0.696	rs6038189	ENSG00000230563.2	RP5-828H9.1	5.88	7.88e-09	3.08e-06	0.36	0.26	Occipital cortical area (total cortical area interaction);	chr20:5513196	chr20:5471207~5475182:+
LUAD	cis	rs6142102	0.602	rs4911380	ENSG00000275784.1	RP5-1125A11.6	-5.88	7.89e-09	3.09e-06	-0.28	-0.26	Skin pigmentation;	chr20:33958418	chr20:33989480~33991818:-
LUAD	cis	rs2412819	0.571	rs66903736	ENSG00000205771.5	CATSPER2P1	-5.88	7.9e-09	3.09e-06	-0.42	-0.26	Lung cancer;	chr15:43619435	chr15:43726918~43747094:-
LUAD	cis	rs2412819	0.571	rs66749753	ENSG00000205771.5	CATSPER2P1	-5.88	7.9e-09	3.09e-06	-0.42	-0.26	Lung cancer;	chr15:43619601	chr15:43726918~43747094:-
LUAD	cis	rs875971	0.545	rs2420456	ENSG00000226824.5	RP4-756H11.3	-5.87	7.91e-09	3.09e-06	-0.37	-0.26	Aortic root size;	chr7:66280619	chr7:66654538~66669855:+
LUAD	cis	rs26528	0.584	rs153103	ENSG00000259982.1	CDC37P1	-5.87	7.92e-09	3.09e-06	-0.32	-0.26	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr16:28517302	chr16:28700294~28701540:-
LUAD	cis	rs11096990	0.855	rs2566173	ENSG00000249207.1	RP11-360F5.1	5.87	7.92e-09	3.1e-06	0.3	0.26	Cognitive function;	chr4:39151111	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.855	rs2043102	ENSG00000249207.1	RP11-360F5.1	5.87	7.92e-09	3.1e-06	0.3	0.26	Cognitive function;	chr4:39151292	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.855	rs2711986	ENSG00000249207.1	RP11-360F5.1	5.87	7.92e-09	3.1e-06	0.3	0.26	Cognitive function;	chr4:39152258	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.75	rs2465242	ENSG00000249207.1	RP11-360F5.1	5.87	7.92e-09	3.1e-06	0.3	0.26	Cognitive function;	chr4:39153796	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.855	rs2465243	ENSG00000249207.1	RP11-360F5.1	5.87	7.92e-09	3.1e-06	0.3	0.26	Cognitive function;	chr4:39154036	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.855	rs2566176	ENSG00000249207.1	RP11-360F5.1	5.87	7.92e-09	3.1e-06	0.3	0.26	Cognitive function;	chr4:39154373	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.855	rs2566178	ENSG00000249207.1	RP11-360F5.1	5.87	7.92e-09	3.1e-06	0.3	0.26	Cognitive function;	chr4:39155194	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.819	rs2435528	ENSG00000249207.1	RP11-360F5.1	5.87	7.92e-09	3.1e-06	0.3	0.26	Cognitive function;	chr4:39155916	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.855	rs2711933	ENSG00000249207.1	RP11-360F5.1	5.87	7.92e-09	3.1e-06	0.3	0.26	Cognitive function;	chr4:39156090	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.855	rs2566179	ENSG00000249207.1	RP11-360F5.1	5.87	7.92e-09	3.1e-06	0.3	0.26	Cognitive function;	chr4:39156413	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.855	rs2566180	ENSG00000249207.1	RP11-360F5.1	5.87	7.92e-09	3.1e-06	0.3	0.26	Cognitive function;	chr4:39157381	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.855	rs2566181	ENSG00000249207.1	RP11-360F5.1	5.87	7.92e-09	3.1e-06	0.3	0.26	Cognitive function;	chr4:39157987	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.819	rs2381225	ENSG00000249207.1	RP11-360F5.1	5.87	7.92e-09	3.1e-06	0.3	0.26	Cognitive function;	chr4:39158915	chr4:39112677~39126818:-
LUAD	cis	rs11096990	0.819	rs1367297	ENSG00000249207.1	RP11-360F5.1	5.87	7.92e-09	3.1e-06	0.3	0.26	Cognitive function;	chr4:39159614	chr4:39112677~39126818:-
LUAD	cis	rs10214930	0.813	rs6946305	ENSG00000235574.1	AC073150.6	-5.87	7.93e-09	3.1e-06	-0.35	-0.26	Hypospadias;	chr7:27641576	chr7:27491682~27492765:-
LUAD	cis	rs875971	0.545	rs6969224	ENSG00000226824.5	RP4-756H11.3	-5.87	7.93e-09	3.1e-06	-0.38	-0.26	Aortic root size;	chr7:66370011	chr7:66654538~66669855:+
LUAD	cis	rs2276314	1	rs4799832	ENSG00000278986.1	RP11-723J4.3	-5.87	7.93e-09	3.1e-06	-0.32	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:35979683	chr18:35972151~35973916:+
LUAD	cis	rs67311347	1	rs67680017	ENSG00000223797.4	ENTPD3-AS1	5.87	7.93e-09	3.1e-06	0.28	0.26	Renal cell carcinoma;	chr3:40491673	chr3:40313802~40453329:-
LUAD	cis	rs10214930	0.697	rs6462031	ENSG00000235574.1	AC073150.6	-5.87	7.94e-09	3.1e-06	-0.33	-0.26	Hypospadias;	chr7:27549871	chr7:27491682~27492765:-
LUAD	cis	rs997295	0.535	rs11630854	ENSG00000270964.1	RP11-502I4.3	-5.87	7.95e-09	3.11e-06	-0.27	-0.26	Motion sickness;	chr15:67565778	chr15:67541072~67542604:-
LUAD	cis	rs494459	0.838	rs555649	ENSG00000278376.1	RP11-158I9.8	-5.87	7.96e-09	3.11e-06	-0.27	-0.26	Height;	chr11:118781100	chr11:118791254~118793137:+
LUAD	cis	rs30380	0.506	rs469735	ENSG00000272109.1	CTD-2260A17.3	-5.87	7.96e-09	3.11e-06	-0.31	-0.26	Cerebrospinal fluid biomarker levels;	chr5:96794311	chr5:96804353~96806105:+
LUAD	cis	rs875971	0.755	rs10228885	ENSG00000237310.1	GS1-124K5.4	-5.87	7.96e-09	3.11e-06	-0.28	-0.26	Aortic root size;	chr7:66315542	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs3893216	ENSG00000237310.1	GS1-124K5.4	-5.87	7.96e-09	3.11e-06	-0.28	-0.26	Aortic root size;	chr7:66325720	chr7:66493706~66495474:+
LUAD	cis	rs149313	1	rs149313	ENSG00000248734.2	CTD-2260A17.1	-5.87	7.97e-09	3.11e-06	-0.24	-0.26	Blood protein levels;	chr5:96734501	chr5:96784777~96785999:+
LUAD	cis	rs17684571	0.938	rs34724718	ENSG00000231441.1	RP11-472M19.2	5.87	7.97e-09	3.11e-06	0.35	0.26	Schizophrenia;	chr6:56693024	chr6:56844002~56864078:+
LUAD	cis	rs9860428	0.682	rs9809444	ENSG00000242770.2	RP11-180K7.1	5.87	7.99e-09	3.12e-06	0.28	0.26	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112807206	chr3:112802478~112812819:+
LUAD	cis	rs797680	0.576	rs55838267	ENSG00000223745.6	RP4-717I23.3	5.87	7.99e-09	3.12e-06	0.25	0.26	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93338159	chr1:93262186~93346025:-
LUAD	cis	rs293748	0.515	rs13179402	ENSG00000250155.1	CTD-2353F22.1	-5.87	7.99e-09	3.12e-06	-0.33	-0.26	Obesity-related traits;	chr5:37256242	chr5:36666214~36725195:-
LUAD	cis	rs7188445	0.736	rs8048539	ENSG00000261390.4	RP11-345M22.2	5.87	8e-09	3.12e-06	0.32	0.26	Urate levels;	chr16:79670255	chr16:79715232~79770563:-
LUAD	cis	rs17301013	0.606	rs11487399	ENSG00000227373.4	RP11-160H22.5	5.87	8.01e-09	3.13e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174527129	chr1:174115300~174160004:-
LUAD	cis	rs8177876	0.658	rs77874075	ENSG00000261061.1	RP11-303E16.2	-5.87	8.01e-09	3.13e-06	-0.46	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81032734	chr16:81030770~81031485:+
LUAD	cis	rs9595908	0.694	rs2224883	ENSG00000212293.1	SNORA16	5.87	8.01e-09	3.13e-06	0.28	0.26	Body mass index;	chr13:32763753	chr13:32420390~32420516:-
LUAD	cis	rs11157436	0.958	rs17183308	ENSG00000211812.1	TRAV26-2	-5.87	8.01e-09	3.13e-06	-0.3	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22195090	chr14:22202583~22203368:+
LUAD	cis	rs875971	0.861	rs801215	ENSG00000237310.1	GS1-124K5.4	-5.87	8.01e-09	3.13e-06	-0.28	-0.26	Aortic root size;	chr7:66546951	chr7:66493706~66495474:+
LUAD	cis	rs2115630	0.645	rs6496284	ENSG00000229212.6	RP11-561C5.4	5.87	8.02e-09	3.13e-06	0.31	0.26	P wave terminal force;	chr15:84635039	chr15:85205440~85234795:-
LUAD	cis	rs853679	0.55	rs1225598	ENSG00000204709.4	LINC01556	5.87	8.03e-09	3.13e-06	0.36	0.26	Depression;	chr6:28193021	chr6:28943877~28944537:+
LUAD	cis	rs9543976	0.623	rs4611344	ENSG00000261553.4	RP11-29G8.3	5.87	8.03e-09	3.14e-06	0.33	0.26	Diabetic retinopathy;	chr13:75601192	chr13:75549773~75807120:+
LUAD	cis	rs9543976	0.545	rs2328963	ENSG00000261553.4	RP11-29G8.3	5.87	8.03e-09	3.14e-06	0.33	0.26	Diabetic retinopathy;	chr13:75601390	chr13:75549773~75807120:+
LUAD	cis	rs1823913	0.637	rs6741454	ENSG00000227542.1	AC092614.2	-5.87	8.03e-09	3.14e-06	-0.32	-0.26	Obesity-related traits;	chr2:191269520	chr2:191229165~191246172:-
LUAD	cis	rs1134634	0.52	rs16892140	ENSG00000273133.1	RP11-799M12.2	-5.87	8.04e-09	3.14e-06	-0.38	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15546927	chr4:15563698~15564253:-
LUAD	cis	rs1134634	0.52	rs10025837	ENSG00000273133.1	RP11-799M12.2	-5.87	8.04e-09	3.14e-06	-0.38	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15548362	chr4:15563698~15564253:-
LUAD	cis	rs7945705	0.875	rs2653616	ENSG00000254860.4	TMEM9B-AS1	5.87	8.04e-09	3.14e-06	0.29	0.26	Hemoglobin concentration;	chr11:8864345	chr11:8964675~8977527:+
LUAD	cis	rs2404602	0.647	rs12914196	ENSG00000259422.1	RP11-593F23.1	-5.87	8.04e-09	3.14e-06	-0.35	-0.26	Blood metabolite levels;	chr15:76649020	chr15:76174891~76181486:-
LUAD	cis	rs2212361	0.527	rs7931179	ENSG00000255893.1	RP11-685N10.1	-5.87	8.04e-09	3.14e-06	-0.34	-0.26	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94531037	chr11:94472908~94473570:-
LUAD	cis	rs2212361	0.558	rs7934286	ENSG00000255893.1	RP11-685N10.1	-5.87	8.04e-09	3.14e-06	-0.34	-0.26	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94531347	chr11:94472908~94473570:-
LUAD	cis	rs875971	0.789	rs28815324	ENSG00000237310.1	GS1-124K5.4	-5.87	8.04e-09	3.14e-06	-0.33	-0.26	Aortic root size;	chr7:66100789	chr7:66493706~66495474:+
LUAD	cis	rs13217239	0.572	rs9379958	ENSG00000241549.7	GUSBP2	-5.87	8.04e-09	3.14e-06	-0.29	-0.26	Schizophrenia;	chr6:27098384	chr6:26871484~26956554:-
LUAD	cis	rs13217239	0.646	rs9393789	ENSG00000241549.7	GUSBP2	-5.87	8.04e-09	3.14e-06	-0.29	-0.26	Schizophrenia;	chr6:27099249	chr6:26871484~26956554:-
LUAD	cis	rs10129255	1	rs10129319	ENSG00000211974.3	IGHV2-70	5.87	8.05e-09	3.14e-06	0.27	0.26	Kawasaki disease;	chr14:106767996	chr14:106723574~106724093:-
LUAD	cis	rs7246657	0.508	rs1628959	ENSG00000276846.1	CTD-3220F14.3	5.87	8.05e-09	3.14e-06	0.4	0.26	Coronary artery calcification;	chr19:36999474	chr19:37314868~37315620:-
LUAD	cis	rs9368481	0.594	rs2636425	ENSG00000241549.7	GUSBP2	5.87	8.05e-09	3.14e-06	0.29	0.26	Autism spectrum disorder or schizophrenia;	chr6:26831681	chr6:26871484~26956554:-
LUAD	cis	rs9928842	0.882	rs3169330	ENSG00000280152.1	RP11-331F4.5	5.87	8.05e-09	3.14e-06	0.29	0.26	Alcoholic chronic pancreatitis;	chr16:75235369	chr16:75245994~75250077:-
LUAD	cis	rs875971	0.545	rs66594357	ENSG00000226824.5	RP4-756H11.3	-5.87	8.06e-09	3.15e-06	-0.37	-0.26	Aortic root size;	chr7:66327797	chr7:66654538~66669855:+
LUAD	cis	rs4713118	0.628	rs9295740	ENSG00000219392.1	RP1-265C24.5	-5.87	8.06e-09	3.15e-06	-0.37	-0.26	Parkinson's disease;	chr6:27721723	chr6:28115628~28116551:+
LUAD	cis	rs368187	0.721	rs1759760	ENSG00000257826.1	RP11-116N8.4	5.87	8.06e-09	3.15e-06	0.27	0.26	Thyroid cancer;	chr14:36052560	chr14:36061026~36067190:-
LUAD	cis	rs9494145	0.68	rs9376092	ENSG00000232876.1	CTA-212D2.2	5.87	8.07e-09	3.15e-06	0.35	0.26	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135106006	chr6:135055033~135060550:+
LUAD	cis	rs2153535	1	rs2153535	ENSG00000230939.1	RP11-314C16.1	5.87	8.07e-09	3.15e-06	0.29	0.26	Motion sickness;	chr6:8369446	chr6:8784178~8785445:+
LUAD	cis	rs10050311	0.79	rs17751557	ENSG00000251411.1	RP11-397E7.4	-5.87	8.07e-09	3.15e-06	-0.34	-0.26	Insulin-related traits;	chr4:86913454	chr4:86913266~86914817:-
LUAD	cis	rs494459	0.504	rs7929520	ENSG00000255239.1	AP002954.6	5.87	8.08e-09	3.15e-06	0.3	0.26	Height;	chr11:118859432	chr11:118688039~118690600:-
LUAD	cis	rs6558530	0.73	rs4875958	ENSG00000253982.1	CTD-2336O2.1	-5.87	8.08e-09	3.15e-06	-0.3	-0.26	Systolic blood pressure;	chr8:1772924	chr8:1761990~1764502:-
LUAD	cis	rs9595908	0.832	rs13378546	ENSG00000212293.1	SNORA16	5.87	8.08e-09	3.15e-06	0.28	0.26	Body mass index;	chr13:32631522	chr13:32420390~32420516:-
LUAD	cis	rs11971779	0.68	rs7805824	ENSG00000273391.1	RP11-634H22.1	-5.87	8.09e-09	3.15e-06	-0.26	-0.26	Diisocyanate-induced asthma;	chr7:139426423	chr7:139359032~139359566:-
LUAD	cis	rs516805	0.667	rs2816139	ENSG00000279453.1	RP3-425C14.4	-5.87	8.09e-09	3.16e-06	-0.36	-0.26	Lymphocyte counts;	chr6:122182267	chr6:122436789~122439223:-
LUAD	cis	rs7727544	0.684	rs272869	ENSG00000233006.5	AC034220.3	5.87	8.09e-09	3.16e-06	0.23	0.26	Blood metabolite levels;	chr5:132342304	chr5:132311285~132369916:-
LUAD	cis	rs7429990	0.864	rs1403579	ENSG00000229759.1	MRPS18AP1	5.87	8.09e-09	3.16e-06	0.27	0.26	Educational attainment (years of education);	chr3:47617889	chr3:48256350~48256938:-
LUAD	cis	rs4713118	0.629	rs149899	ENSG00000204709.4	LINC01556	5.87	8.1e-09	3.16e-06	0.35	0.26	Parkinson's disease;	chr6:28052201	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.629	rs172165	ENSG00000204709.4	LINC01556	5.87	8.1e-09	3.16e-06	0.35	0.26	Parkinson's disease;	chr6:28053036	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.597	rs172166	ENSG00000204709.4	LINC01556	5.87	8.1e-09	3.16e-06	0.35	0.26	Parkinson's disease;	chr6:28053042	chr6:28943877~28944537:+
LUAD	cis	rs1062177	0.756	rs2964591	ENSG00000213433.5	RPLP1P6	5.87	8.1e-09	3.16e-06	0.32	0.26	Preschool internalizing problems;	chr5:151737836	chr5:151765859~151766378:-
LUAD	cis	rs35740288	0.77	rs10520592	ENSG00000202081.1	RNU6-1280P	5.87	8.11e-09	3.16e-06	0.32	0.26	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85570911	chr15:85651522~85651628:-
LUAD	cis	rs896854	0.654	rs28716845	ENSG00000253528.2	RP11-347C18.4	5.87	8.11e-09	3.16e-06	0.25	0.26	Type 2 diabetes;	chr8:94962257	chr8:94974573~94974853:-
LUAD	cis	rs896854	0.596	rs7823059	ENSG00000253528.2	RP11-347C18.4	5.87	8.11e-09	3.16e-06	0.25	0.26	Type 2 diabetes;	chr8:94962733	chr8:94974573~94974853:-
LUAD	cis	rs896854	0.653	rs13266313	ENSG00000253528.2	RP11-347C18.4	5.87	8.11e-09	3.16e-06	0.25	0.26	Type 2 diabetes;	chr8:94963074	chr8:94974573~94974853:-
LUAD	cis	rs896854	0.654	rs4735340	ENSG00000253528.2	RP11-347C18.4	5.87	8.11e-09	3.16e-06	0.25	0.26	Type 2 diabetes;	chr8:94964023	chr8:94974573~94974853:-
LUAD	cis	rs1134634	0.52	rs73127647	ENSG00000273133.1	RP11-799M12.2	-5.87	8.12e-09	3.17e-06	-0.38	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15639969	chr4:15563698~15564253:-
LUAD	cis	rs4835473	0.808	rs4054643	ENSG00000251600.4	RP11-673E1.1	-5.87	8.12e-09	3.17e-06	-0.32	-0.26	Immature fraction of reticulocytes;	chr4:143787329	chr4:143912331~143982454:+
LUAD	cis	rs9309473	1	rs2140195	ENSG00000163016.8	ALMS1P	5.87	8.13e-09	3.17e-06	0.31	0.26	Metabolite levels;	chr2:73475217	chr2:73644919~73685576:+
LUAD	cis	rs755249	0.53	rs16826087	ENSG00000228060.1	RP11-69E11.8	-5.87	8.13e-09	3.17e-06	-0.26	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39346846	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs3754346	ENSG00000228060.1	RP11-69E11.8	-5.87	8.13e-09	3.17e-06	-0.26	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349288	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs16826093	ENSG00000228060.1	RP11-69E11.8	-5.87	8.13e-09	3.17e-06	-0.26	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349471	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs41270811	ENSG00000228060.1	RP11-69E11.8	-5.87	8.13e-09	3.17e-06	-0.26	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349672	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs61779274	ENSG00000228060.1	RP11-69E11.8	-5.87	8.13e-09	3.17e-06	-0.26	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39351269	chr1:39565160~39573203:+
LUAD	cis	rs957448	1	rs2381885	ENSG00000253704.1	RP11-267M23.4	5.87	8.14e-09	3.17e-06	0.33	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94499974	chr8:94553722~94569745:+
LUAD	cis	rs2288884	1	rs11673286	ENSG00000275055.1	CTC-471J1.11	-5.87	8.14e-09	3.17e-06	-0.4	-0.26	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52037065	chr19:52049007~52049754:+
LUAD	cis	rs875971	0.862	rs6955837	ENSG00000222364.1	RNU6-96P	5.87	8.15e-09	3.17e-06	0.29	0.26	Aortic root size;	chr7:66578155	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.825	rs10281499	ENSG00000222364.1	RNU6-96P	5.87	8.15e-09	3.17e-06	0.29	0.26	Aortic root size;	chr7:66583979	chr7:66395191~66395286:+
LUAD	cis	rs9890032	0.509	rs11656986	ENSG00000266490.1	CTD-2349P21.9	5.87	8.15e-09	3.18e-06	0.25	0.26	Hip circumference adjusted for BMI;	chr17:30694324	chr17:30792372~30792833:+
LUAD	cis	rs1823913	0.599	rs13002286	ENSG00000280083.1	RP11-317J9.1	5.87	8.15e-09	3.18e-06	0.31	0.26	Obesity-related traits;	chr2:191285626	chr2:191154118~191156070:-
LUAD	cis	rs755249	0.567	rs61779275	ENSG00000228060.1	RP11-69E11.8	-5.87	8.15e-09	3.18e-06	-0.26	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39354638	chr1:39565160~39573203:+
LUAD	cis	rs897200	1	rs1598253	ENSG00000280083.1	RP11-317J9.1	5.87	8.15e-09	3.18e-06	0.32	0.26	Behcet's disease;	chr2:191153691	chr2:191154118~191156070:-
LUAD	cis	rs2303759	0.515	rs2334867	ENSG00000268686.1	AC010524.2	5.87	8.16e-09	3.18e-06	0.39	0.26	Multiple sclerosis;	chr19:49284948	chr19:49368705~49388081:-
LUAD	cis	rs858239	0.6	rs10256361	ENSG00000230042.1	AK3P3	-5.87	8.17e-09	3.18e-06	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23129178~23129841:+
LUAD	cis	rs8072100	0.935	rs78551919	ENSG00000228782.6	CTD-2026D20.3	-5.87	8.17e-09	3.18e-06	-0.27	-0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47548636	chr17:47450568~47492492:-
LUAD	cis	rs7945705	0.818	rs2742552	ENSG00000254860.4	TMEM9B-AS1	5.87	8.17e-09	3.18e-06	0.29	0.26	Hemoglobin concentration;	chr11:8855305	chr11:8964675~8977527:+
LUAD	cis	rs7945705	0.818	rs2653613	ENSG00000254860.4	TMEM9B-AS1	5.87	8.17e-09	3.18e-06	0.29	0.26	Hemoglobin concentration;	chr11:8857558	chr11:8964675~8977527:+
LUAD	cis	rs516805	0.748	rs55863504	ENSG00000279453.1	RP3-425C14.4	5.87	8.18e-09	3.19e-06	0.35	0.26	Lymphocyte counts;	chr6:122376339	chr6:122436789~122439223:-
LUAD	cis	rs7017914	0.84	rs1481804	ENSG00000223220.1	Y_RNA	5.87	8.2e-09	3.19e-06	0.29	0.26	Bone mineral density;	chr8:71057195	chr8:70780914~70781008:-
LUAD	cis	rs2243480	0.901	rs778730	ENSG00000230295.1	RP11-458F8.2	-5.87	8.2e-09	3.19e-06	-0.31	-0.26	Diabetic kidney disease;	chr7:66358338	chr7:66880708~66882981:+
LUAD	cis	rs2179367	0.586	rs62426088	ENSG00000231760.4	RP11-350J20.5	5.87	8.2e-09	3.19e-06	0.37	0.26	Dupuytren's disease;	chr6:149339301	chr6:149796151~149826294:-
LUAD	cis	rs2276314	1	rs8086395	ENSG00000278986.1	RP11-723J4.3	-5.87	8.21e-09	3.2e-06	-0.32	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:35984629	chr18:35972151~35973916:+
LUAD	cis	rs2276314	0.947	rs3898595	ENSG00000278986.1	RP11-723J4.3	-5.87	8.21e-09	3.2e-06	-0.32	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:35985922	chr18:35972151~35973916:+
LUAD	cis	rs2243480	1	rs1499614	ENSG00000230295.1	RP11-458F8.2	-5.87	8.21e-09	3.2e-06	-0.31	-0.26	Diabetic kidney disease;	chr7:66265811	chr7:66880708~66882981:+
LUAD	cis	rs10129255	0.957	rs12590667	ENSG00000211972.2	IGHV3-66	-5.87	8.21e-09	3.2e-06	-0.22	-0.26	Kawasaki disease;	chr14:106779223	chr14:106675017~106675544:-
LUAD	cis	rs9595908	0.709	rs7319275	ENSG00000212293.1	SNORA16	5.87	8.22e-09	3.2e-06	0.27	0.26	Body mass index;	chr13:32733280	chr13:32420390~32420516:-
LUAD	cis	rs9309473	1	rs7584575	ENSG00000163016.8	ALMS1P	5.87	8.22e-09	3.2e-06	0.31	0.26	Metabolite levels;	chr2:73439274	chr2:73644919~73685576:+
LUAD	cis	rs2933343	0.951	rs1055128	ENSG00000261159.1	RP11-723O4.9	5.87	8.22e-09	3.2e-06	0.31	0.26	IgG glycosylation;	chr3:128872205	chr3:128859716~128860526:-
LUAD	cis	rs1823913	0.637	rs4853584	ENSG00000227542.1	AC092614.2	-5.87	8.22e-09	3.2e-06	-0.31	-0.26	Obesity-related traits;	chr2:191310596	chr2:191229165~191246172:-
LUAD	cis	rs2562456	0.917	rs2650825	ENSG00000268081.1	RP11-678G14.2	5.87	8.22e-09	3.2e-06	0.41	0.26	Pain;	chr19:21516423	chr19:21554640~21569237:-
LUAD	cis	rs10129255	1	rs11627342	ENSG00000224373.3	IGHV4-59	5.87	8.22e-09	3.2e-06	0.17	0.26	Kawasaki disease;	chr14:106675823	chr14:106627249~106627825:-
LUAD	cis	rs848490	0.674	rs7803449	ENSG00000214293.7	APTR	5.87	8.22e-09	3.2e-06	0.29	0.26	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77679660	chr7:77657660~77696265:-
LUAD	cis	rs875971	0.862	rs801194	ENSG00000222364.1	RNU6-96P	5.87	8.23e-09	3.2e-06	0.29	0.26	Aortic root size;	chr7:66563508	chr7:66395191~66395286:+
LUAD	cis	rs35740288	0.77	rs11630112	ENSG00000202081.1	RNU6-1280P	5.87	8.23e-09	3.21e-06	0.32	0.26	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85577015	chr15:85651522~85651628:-
LUAD	cis	rs8062405	1	rs11861174	ENSG00000251417.2	RP11-1348G14.4	-5.87	8.23e-09	3.21e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs4788102	ENSG00000251417.2	RP11-1348G14.4	-5.87	8.23e-09	3.21e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs62037367	ENSG00000251417.2	RP11-1348G14.4	-5.87	8.23e-09	3.21e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs7198606	ENSG00000251417.2	RP11-1348G14.4	-5.87	8.23e-09	3.21e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28802743~28817828:+
LUAD	cis	rs8062405	0.929	rs11864750	ENSG00000251417.2	RP11-1348G14.4	-5.87	8.23e-09	3.21e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28802743~28817828:+
LUAD	cis	rs8062405	0.964	rs7193733	ENSG00000251417.2	RP11-1348G14.4	-5.87	8.23e-09	3.21e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs8055982	ENSG00000251417.2	RP11-1348G14.4	-5.87	8.23e-09	3.21e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs7498665	ENSG00000251417.2	RP11-1348G14.4	-5.87	8.23e-09	3.21e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28802743~28817828:+
LUAD	cis	rs8062405	0.964	rs11864107	ENSG00000251417.2	RP11-1348G14.4	-5.87	8.23e-09	3.21e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28802743~28817828:+
LUAD	cis	rs8062405	1	rs62037371	ENSG00000251417.2	RP11-1348G14.4	-5.87	8.23e-09	3.21e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28802743~28817828:+
LUAD	cis	rs496547	0.654	rs688161	ENSG00000255422.1	AP002954.4	-5.87	8.24e-09	3.21e-06	-0.33	-0.26	Hip minimal joint space width;	chr11:118807001	chr11:118704607~118750263:+
LUAD	cis	rs6921919	0.583	rs34513104	ENSG00000216901.1	AL022393.7	5.87	8.24e-09	3.21e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs9461456	ENSG00000216901.1	AL022393.7	5.87	8.24e-09	3.21e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.525	rs9468360	ENSG00000216901.1	AL022393.7	5.87	8.24e-09	3.21e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs16894021	ENSG00000216901.1	AL022393.7	5.87	8.24e-09	3.21e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs11751693	ENSG00000216901.1	AL022393.7	5.87	8.24e-09	3.21e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs7749736	ENSG00000216901.1	AL022393.7	5.87	8.24e-09	3.21e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.525	rs9468361	ENSG00000216901.1	AL022393.7	5.87	8.24e-09	3.21e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs7775132	ENSG00000216901.1	AL022393.7	5.87	8.24e-09	3.21e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28176188~28176674:+
LUAD	cis	rs2412819	0.571	rs28410121	ENSG00000249839.1	AC011330.5	5.87	8.25e-09	3.21e-06	0.4	0.26	Lung cancer;	chr15:43777831	chr15:43663654~43684339:-
LUAD	cis	rs9543976	0.557	rs6562916	ENSG00000261553.4	RP11-29G8.3	5.87	8.26e-09	3.21e-06	0.34	0.26	Diabetic retinopathy;	chr13:75597086	chr13:75549773~75807120:+
LUAD	cis	rs9543976	0.623	rs4885322	ENSG00000261553.4	RP11-29G8.3	5.87	8.26e-09	3.21e-06	0.34	0.26	Diabetic retinopathy;	chr13:75597195	chr13:75549773~75807120:+
LUAD	cis	rs9543976	0.623	rs4885323	ENSG00000261553.4	RP11-29G8.3	5.87	8.26e-09	3.21e-06	0.34	0.26	Diabetic retinopathy;	chr13:75598278	chr13:75549773~75807120:+
LUAD	cis	rs2243480	0.522	rs73150635	ENSG00000273142.1	RP11-458F8.4	-5.87	8.27e-09	3.22e-06	-0.31	-0.26	Diabetic kidney disease;	chr7:66507503	chr7:66902857~66906297:+
LUAD	cis	rs2115630	0.645	rs4842978	ENSG00000229212.6	RP11-561C5.4	5.87	8.27e-09	3.22e-06	0.31	0.26	P wave terminal force;	chr15:84654022	chr15:85205440~85234795:-
LUAD	cis	rs4908760	0.931	rs1463049	ENSG00000232912.4	RP5-1115A15.1	5.87	8.28e-09	3.22e-06	0.24	0.26	Vitiligo;	chr1:8537049	chr1:8424645~8434838:+
LUAD	cis	rs7945705	0.875	rs2568065	ENSG00000254860.4	TMEM9B-AS1	5.87	8.29e-09	3.23e-06	0.28	0.26	Hemoglobin concentration;	chr11:8868101	chr11:8964675~8977527:+
LUAD	cis	rs1876905	0.569	rs354523	ENSG00000272356.1	RP5-1112D6.8	-5.87	8.3e-09	3.23e-06	-0.28	-0.26	Mean corpuscular hemoglobin;	chr6:111188122	chr6:111309203~111313517:+
LUAD	cis	rs2404602	0.684	rs2047504	ENSG00000259422.1	RP11-593F23.1	-5.87	8.32e-09	3.24e-06	-0.34	-0.26	Blood metabolite levels;	chr15:76591175	chr15:76174891~76181486:-
LUAD	cis	rs7829975	0.902	rs777707	ENSG00000253893.2	FAM85B	-5.87	8.32e-09	3.24e-06	-0.32	-0.26	Mood instability;	chr8:8726834	chr8:8167819~8226614:-
LUAD	cis	rs2998286	0.541	rs332180	ENSG00000254635.4	WAC-AS1	-5.87	8.32e-09	3.24e-06	-0.38	-0.26	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28621166	chr10:28522652~28532743:-
LUAD	cis	rs875971	0.545	rs11770063	ENSG00000226824.5	RP4-756H11.3	-5.87	8.32e-09	3.24e-06	-0.38	-0.26	Aortic root size;	chr7:66318029	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.545	rs4718335	ENSG00000226824.5	RP4-756H11.3	-5.87	8.32e-09	3.24e-06	-0.38	-0.26	Aortic root size;	chr7:66339619	chr7:66654538~66669855:+
LUAD	cis	rs1707322	0.789	rs10789473	ENSG00000234329.1	RP11-767N6.2	5.87	8.33e-09	3.24e-06	0.27	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782459	chr1:45651039~45651826:-
LUAD	cis	rs875971	0.755	rs76288834	ENSG00000222364.1	RNU6-96P	5.87	8.34e-09	3.24e-06	0.29	0.26	Aortic root size;	chr7:66604815	chr7:66395191~66395286:+
LUAD	cis	rs10129255	0.957	rs12590667	ENSG00000211974.3	IGHV2-70	-5.87	8.35e-09	3.25e-06	-0.26	-0.26	Kawasaki disease;	chr14:106779223	chr14:106723574~106724093:-
LUAD	cis	rs853679	1	rs853685	ENSG00000204709.4	LINC01556	5.87	8.35e-09	3.25e-06	0.4	0.26	Depression;	chr6:28321008	chr6:28943877~28944537:+
LUAD	cis	rs5753618	0.561	rs4603880	ENSG00000236132.1	CTA-440B3.1	-5.87	8.35e-09	3.25e-06	-0.32	-0.26	Colorectal cancer;	chr22:31348735	chr22:31816379~31817491:-
LUAD	cis	rs875971	0.545	rs67775320	ENSG00000226824.5	RP4-756H11.3	-5.87	8.35e-09	3.25e-06	-0.37	-0.26	Aortic root size;	chr7:66193792	chr7:66654538~66669855:+
LUAD	cis	rs3095008	0.603	rs2190434	ENSG00000243004.4	AC005062.2	5.87	8.36e-09	3.25e-06	0.29	0.26	Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide);	chr7:20212410	chr7:19918981~20140453:-
LUAD	cis	rs2946504	0.861	rs2946494	ENSG00000251468.2	RP11-369K16.1	-5.87	8.36e-09	3.25e-06	-0.34	-0.26	Type 2 diabetes;	chr8:12962601	chr8:12958387~12962200:+
LUAD	cis	rs62229266	0.771	rs7280136	ENSG00000214914.3	RPL23AP3	-5.86	8.36e-09	3.25e-06	-0.32	-0.26	Mitral valve prolapse;	chr21:36060612	chr21:36016079~36016546:-
LUAD	cis	rs11098499	0.955	rs6815725	ENSG00000248280.1	RP11-33B1.2	5.86	8.36e-09	3.25e-06	0.32	0.26	Corneal astigmatism;	chr4:119237255	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.675	rs11098534	ENSG00000248280.1	RP11-33B1.2	5.86	8.36e-09	3.25e-06	0.32	0.26	Corneal astigmatism;	chr4:119635617	chr4:119440561~119450157:-
LUAD	cis	rs7712401	0.715	rs13164161	ENSG00000263432.2	RN7SL689P	-5.86	8.37e-09	3.26e-06	-0.32	-0.26	Mean platelet volume;	chr5:123011202	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.715	rs401226	ENSG00000263432.2	RN7SL689P	-5.86	8.37e-09	3.26e-06	-0.32	-0.26	Mean platelet volume;	chr5:123012031	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.715	rs395981	ENSG00000263432.2	RN7SL689P	-5.86	8.37e-09	3.26e-06	-0.32	-0.26	Mean platelet volume;	chr5:123012216	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.715	rs424247	ENSG00000263432.2	RN7SL689P	-5.86	8.37e-09	3.26e-06	-0.32	-0.26	Mean platelet volume;	chr5:123012298	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.715	rs424262	ENSG00000263432.2	RN7SL689P	-5.86	8.37e-09	3.26e-06	-0.32	-0.26	Mean platelet volume;	chr5:123012317	chr5:123022487~123022783:-
LUAD	cis	rs2283792	0.765	rs9607285	ENSG00000224086.5	LL22NC03-86G7.1	-5.86	8.38e-09	3.26e-06	-0.25	-0.26	Multiple sclerosis;	chr22:21808704	chr22:21938293~21977632:+
LUAD	cis	rs2243480	1	rs2961102	ENSG00000230295.1	RP11-458F8.2	-5.86	8.38e-09	3.26e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:65959671	chr7:66880708~66882981:+
LUAD	cis	rs2404602	0.669	rs1875885	ENSG00000259422.1	RP11-593F23.1	5.86	8.39e-09	3.26e-06	0.3	0.26	Blood metabolite levels;	chr15:76345740	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.669	rs1875884	ENSG00000259422.1	RP11-593F23.1	5.86	8.39e-09	3.26e-06	0.3	0.26	Blood metabolite levels;	chr15:76345820	chr15:76174891~76181486:-
LUAD	cis	rs875971	0.571	rs160647	ENSG00000237310.1	GS1-124K5.4	-5.86	8.4e-09	3.27e-06	-0.33	-0.26	Aortic root size;	chr7:66089365	chr7:66493706~66495474:+
LUAD	cis	rs848490	0.656	rs55714086	ENSG00000214293.7	APTR	5.86	8.41e-09	3.27e-06	0.29	0.26	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77807168	chr7:77657660~77696265:-
LUAD	cis	rs2243480	0.901	rs778732	ENSG00000230295.1	RP11-458F8.2	-5.86	8.41e-09	3.27e-06	-0.31	-0.26	Diabetic kidney disease;	chr7:66357373	chr7:66880708~66882981:+
LUAD	cis	rs11098499	0.955	rs11931312	ENSG00000248280.1	RP11-33B1.2	5.86	8.42e-09	3.27e-06	0.32	0.26	Corneal astigmatism;	chr4:119237868	chr4:119440561~119450157:-
LUAD	cis	rs2599510	0.811	rs176410	ENSG00000276334.1	AL133243.1	-5.86	8.42e-09	3.27e-06	-0.3	-0.26	Interleukin-18 levels;	chr2:32418369	chr2:32521927~32523547:+
LUAD	cis	rs7618501	0.573	rs7634917	ENSG00000234667.1	ACTBP13	5.86	8.42e-09	3.27e-06	0.29	0.26	Intelligence (multi-trait analysis);	chr3:50011866	chr3:49873347~49877980:-
LUAD	cis	rs12291225	0.535	rs11023203	ENSG00000251991.1	RNU7-49P	5.86	8.42e-09	3.27e-06	0.29	0.26	Sense of smell;	chr11:14388269	chr11:14478892~14478953:+
LUAD	cis	rs293748	0.571	rs13184464	ENSG00000250155.1	CTD-2353F22.1	-5.86	8.42e-09	3.27e-06	-0.33	-0.26	Obesity-related traits;	chr5:37191983	chr5:36666214~36725195:-
LUAD	cis	rs9326248	0.569	rs4938315	ENSG00000280143.1	AP000892.6	5.86	8.43e-09	3.28e-06	0.39	0.26	Blood protein levels;	chr11:116860489	chr11:117204967~117210292:+
LUAD	cis	rs66887589	0.967	rs3775842	ENSG00000245958.5	RP11-33B1.1	-5.86	8.43e-09	3.28e-06	-0.21	-0.26	Diastolic blood pressure;	chr4:119506577	chr4:119454791~119552025:+
LUAD	cis	rs6142102	0.502	rs58393429	ENSG00000275784.1	RP5-1125A11.6	-5.86	8.46e-09	3.29e-06	-0.28	-0.26	Skin pigmentation;	chr20:33957996	chr20:33989480~33991818:-
LUAD	cis	rs10129255	0.957	rs8014696	ENSG00000211974.3	IGHV2-70	-5.86	8.48e-09	3.29e-06	-0.27	-0.26	Kawasaki disease;	chr14:106769752	chr14:106723574~106724093:-
LUAD	cis	rs1930961	0.558	rs12160908	ENSG00000272977.1	CTA-390C10.10	-5.86	8.48e-09	3.3e-06	-0.38	-0.26	Bipolar disorder with mood-incongruent psychosis;	chr22:25532653	chr22:25476218~25479971:+
LUAD	cis	rs2439831	0.85	rs16950562	ENSG00000205771.5	CATSPER2P1	-5.86	8.49e-09	3.3e-06	-0.48	-0.26	Lung cancer in ever smokers;	chr15:43744166	chr15:43726918~43747094:-
LUAD	cis	rs1823913	0.927	rs13025919	ENSG00000230611.1	HMGB1P27	-5.86	8.49e-09	3.3e-06	-0.32	-0.26	Obesity-related traits;	chr2:191260175	chr2:191174233~191174835:+
LUAD	cis	rs875971	0.545	rs2279757	ENSG00000226824.5	RP4-756H11.3	-5.86	8.5e-09	3.3e-06	-0.38	-0.26	Aortic root size;	chr7:66363676	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.545	rs11766183	ENSG00000226824.5	RP4-756H11.3	-5.86	8.5e-09	3.3e-06	-0.38	-0.26	Aortic root size;	chr7:66374173	chr7:66654538~66669855:+
LUAD	cis	rs875971	0.545	rs1065265	ENSG00000226824.5	RP4-756H11.3	-5.86	8.5e-09	3.3e-06	-0.38	-0.26	Aortic root size;	chr7:66376216	chr7:66654538~66669855:+
LUAD	cis	rs7727544	0.66	rs2631361	ENSG00000233006.5	AC034220.3	-5.86	8.5e-09	3.3e-06	-0.23	-0.26	Blood metabolite levels;	chr5:132371688	chr5:132311285~132369916:-
LUAD	cis	rs10214930	0.697	rs6974932	ENSG00000235574.1	AC073150.6	5.86	8.5e-09	3.3e-06	0.33	0.26	Hypospadias;	chr7:27657211	chr7:27491682~27492765:-
LUAD	cis	rs17301013	0.606	rs12067463	ENSG00000227373.4	RP11-160H22.5	5.86	8.51e-09	3.3e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174625437	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs10912823	ENSG00000227373.4	RP11-160H22.5	5.86	8.51e-09	3.3e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174625602	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs6677874	ENSG00000227373.4	RP11-160H22.5	5.86	8.51e-09	3.3e-06	0.36	0.26	Systemic lupus erythematosus;	chr1:174628410	chr1:174115300~174160004:-
LUAD	cis	rs9595908	0.669	rs9596218	ENSG00000212293.1	SNORA16	5.86	8.52e-09	3.31e-06	0.28	0.26	Body mass index;	chr13:32764222	chr13:32420390~32420516:-
LUAD	cis	rs189798	0.807	rs9949	ENSG00000254340.1	RP11-10A14.3	5.86	8.53e-09	3.31e-06	0.36	0.26	Myopia (pathological);	chr8:9137002	chr8:9141424~9145435:+
LUAD	cis	rs4767841	0.552	rs12827937	ENSG00000248636.5	RP11-768F21.1	-5.86	8.54e-09	3.31e-06	-0.3	-0.26	Urgency urinary incontinence;	chr12:119612444	chr12:119387987~119668079:-
LUAD	cis	rs4972806	0.849	rs2071581	ENSG00000226363.3	HAGLROS	-5.86	8.55e-09	3.32e-06	-0.32	-0.26	IgG glycosylation;	chr2:176161420	chr2:176177717~176179008:+
LUAD	cis	rs4713118	0.824	rs9468225	ENSG00000219392.1	RP1-265C24.5	-5.86	8.55e-09	3.32e-06	-0.34	-0.26	Parkinson's disease;	chr6:27777940	chr6:28115628~28116551:+
LUAD	cis	rs4908768	0.501	rs11121199	ENSG00000232912.4	RP5-1115A15.1	5.86	8.56e-09	3.32e-06	0.24	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8540133	chr1:8424645~8434838:+
LUAD	cis	rs853679	0.527	rs9461443	ENSG00000219392.1	RP1-265C24.5	-5.86	8.56e-09	3.32e-06	-0.35	-0.26	Depression;	chr6:28226851	chr6:28115628~28116551:+
LUAD	cis	rs9595908	0.832	rs9315172	ENSG00000212293.1	SNORA16	5.86	8.56e-09	3.32e-06	0.28	0.26	Body mass index;	chr13:32634035	chr13:32420390~32420516:-
LUAD	cis	rs2404602	0.647	rs11072631	ENSG00000259422.1	RP11-593F23.1	-5.86	8.56e-09	3.32e-06	-0.35	-0.26	Blood metabolite levels;	chr15:76840568	chr15:76174891~76181486:-
LUAD	cis	rs3931020	0.657	rs277376	ENSG00000272864.1	RP11-17E13.2	5.86	8.57e-09	3.33e-06	0.36	0.26	Resistin levels;	chr1:74776562	chr1:74698769~74699333:-
LUAD	cis	rs55665837	0.701	rs2007361	ENSG00000251991.1	RNU7-49P	5.86	8.59e-09	3.33e-06	0.31	0.26	Vitamin D levels;	chr11:14641176	chr11:14478892~14478953:+
LUAD	cis	rs1134634	0.52	rs28661857	ENSG00000273133.1	RP11-799M12.2	-5.86	8.6e-09	3.34e-06	-0.38	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15589842	chr4:15563698~15564253:-
LUAD	cis	rs2115536	1	rs7163338	ENSG00000278600.1	RP11-81A1.6	-5.86	8.6e-09	3.34e-06	-0.21	-0.26	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79906066	chr15:79920195~79922455:-
LUAD	cis	rs12291225	0.535	rs10832248	ENSG00000251991.1	RNU7-49P	5.86	8.6e-09	3.34e-06	0.29	0.26	Sense of smell;	chr11:14391541	chr11:14478892~14478953:+
LUAD	cis	rs1707322	0.827	rs6683274	ENSG00000234329.1	RP11-767N6.2	5.86	8.61e-09	3.34e-06	0.28	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45775966	chr1:45651039~45651826:-
LUAD	cis	rs11742741	0.539	rs12153459	ENSG00000248874.4	C5orf17	-5.86	8.62e-09	3.35e-06	-0.32	-0.26	Educational attainment;	chr5:24105812	chr5:23951348~24178263:+
LUAD	cis	rs9309473	1	rs7604682	ENSG00000163016.8	ALMS1P	5.86	8.62e-09	3.35e-06	0.31	0.26	Metabolite levels;	chr2:73560899	chr2:73644919~73685576:+
LUAD	cis	rs172166	0.694	rs188105	ENSG00000204709.4	LINC01556	5.86	8.62e-09	3.35e-06	0.34	0.26	Cardiac Troponin-T levels;	chr6:28103615	chr6:28943877~28944537:+
LUAD	cis	rs2179367	0.959	rs514839	ENSG00000231760.4	RP11-350J20.5	5.86	8.63e-09	3.35e-06	0.32	0.26	Dupuytren's disease;	chr6:149327304	chr6:149796151~149826294:-
LUAD	cis	rs875971	0.895	rs12531677	ENSG00000222364.1	RNU6-96P	5.86	8.63e-09	3.35e-06	0.29	0.26	Aortic root size;	chr7:66304099	chr7:66395191~66395286:+
LUAD	cis	rs7618501	0.633	rs7621026	ENSG00000234667.1	ACTBP13	-5.86	8.64e-09	3.35e-06	-0.29	-0.26	Intelligence (multi-trait analysis);	chr3:49937901	chr3:49873347~49877980:-
LUAD	cis	rs7618501	0.633	rs3774733	ENSG00000234667.1	ACTBP13	-5.86	8.65e-09	3.35e-06	-0.29	-0.26	Intelligence (multi-trait analysis);	chr3:49999690	chr3:49873347~49877980:-
LUAD	cis	rs9928842	0.823	rs8061356	ENSG00000280152.1	RP11-331F4.5	5.86	8.65e-09	3.36e-06	0.28	0.26	Alcoholic chronic pancreatitis;	chr16:75260334	chr16:75245994~75250077:-
LUAD	cis	rs4908768	0.501	rs2016084	ENSG00000232912.4	RP5-1115A15.1	5.86	8.66e-09	3.36e-06	0.24	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8553359	chr1:8424645~8434838:+
LUAD	cis	rs7246657	0.722	rs2909105	ENSG00000276846.1	CTD-3220F14.3	-5.86	8.68e-09	3.37e-06	-0.35	-0.26	Coronary artery calcification;	chr19:37677005	chr19:37314868~37315620:-
LUAD	cis	rs2153535	1	rs11243251	ENSG00000230939.1	RP11-314C16.1	5.86	8.69e-09	3.37e-06	0.29	0.26	Motion sickness;	chr6:8367974	chr6:8784178~8785445:+
LUAD	cis	rs7208859	0.573	rs8078182	ENSG00000263531.1	RP13-753N3.1	5.86	8.7e-09	3.37e-06	0.45	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822646	chr17:30863921~30864940:-
LUAD	cis	rs17818399	0.781	rs12105006	ENSG00000279254.1	RP11-536C12.1	5.86	8.7e-09	3.38e-06	0.29	0.26	Height;	chr2:46635447	chr2:46668870~46670778:+
LUAD	cis	rs957448	0.554	rs12541408	ENSG00000253704.1	RP11-267M23.4	5.86	8.71e-09	3.38e-06	0.29	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94573579	chr8:94553722~94569745:+
LUAD	cis	rs8062405	1	rs8055138	ENSG00000251417.2	RP11-1348G14.4	-5.86	8.72e-09	3.38e-06	-0.27	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28802743~28817828:+
LUAD	cis	rs56046484	1	rs28718705	ENSG00000259295.5	CSPG4P12	5.86	8.72e-09	3.38e-06	0.36	0.26	Testicular germ cell tumor;	chr15:85074579	chr15:85191438~85213905:+
LUAD	cis	rs7712401	0.715	rs13163098	ENSG00000263432.2	RN7SL689P	-5.86	8.72e-09	3.38e-06	-0.32	-0.26	Mean platelet volume;	chr5:123010841	chr5:123022487~123022783:-
LUAD	cis	rs858239	0.6	rs2014768	ENSG00000230042.1	AK3P3	-5.86	8.73e-09	3.39e-06	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.6	rs6978827	ENSG00000230042.1	AK3P3	-5.86	8.73e-09	3.39e-06	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.6	rs7790157	ENSG00000230042.1	AK3P3	-5.86	8.73e-09	3.39e-06	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23129178~23129841:+
LUAD	cis	rs66887589	0.616	rs11098497	ENSG00000248280.1	RP11-33B1.2	5.86	8.75e-09	3.39e-06	0.29	0.26	Diastolic blood pressure;	chr4:119265913	chr4:119440561~119450157:-
LUAD	cis	rs12554020	0.892	rs78816659	ENSG00000227603.1	RP11-165J3.6	5.86	8.75e-09	3.39e-06	0.49	0.26	Schizophrenia;	chr9:93575141	chr9:93435332~93437121:-
LUAD	cis	rs10214930	0.813	rs2391447	ENSG00000235574.1	AC073150.6	-5.86	8.75e-09	3.39e-06	-0.34	-0.26	Hypospadias;	chr7:27634945	chr7:27491682~27492765:-
LUAD	cis	rs36093844	0.898	rs12361800	ENSG00000279742.1	RP11-700A24.1	-5.86	8.76e-09	3.39e-06	-0.3	-0.26	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85854821	chr11:85852557~85854943:-
LUAD	cis	rs2288884	1	rs58817690	ENSG00000275055.1	CTC-471J1.11	-5.86	8.76e-09	3.4e-06	-0.4	-0.26	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52033439	chr19:52049007~52049754:+
LUAD	cis	rs1075265	0.68	rs805396	ENSG00000233266.1	HMGB1P31	5.86	8.76e-09	3.4e-06	0.32	0.26	Chronotype;Morning vs. evening chronotype;	chr2:53882314	chr2:54051334~54051760:+
LUAD	cis	rs10246939	0.544	rs6955562	ENSG00000228775.6	WEE2-AS1	5.86	8.79e-09	3.41e-06	0.32	0.26	Bitter taste perception;	chr7:141886641	chr7:141704338~141738346:-
LUAD	cis	rs2243480	1	rs410128	ENSG00000230295.1	RP11-458F8.2	-5.86	8.79e-09	3.41e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66138186	chr7:66880708~66882981:+
LUAD	cis	rs6772849	0.93	rs7639400	ENSG00000242551.2	POU5F1P6	-5.86	8.8e-09	3.41e-06	-0.31	-0.26	Monocyte percentage of white cells;Monocyte count;	chr3:128604513	chr3:128674735~128677005:-
LUAD	cis	rs875971	0.545	rs17138149	ENSG00000226824.5	RP4-756H11.3	-5.86	8.8e-09	3.41e-06	-0.37	-0.26	Aortic root size;	chr7:66228193	chr7:66654538~66669855:+
LUAD	cis	rs6991838	0.806	rs17302392	ENSG00000200714.1	Y_RNA	5.86	8.8e-09	3.41e-06	0.3	0.26	Intelligence (multi-trait analysis);	chr8:65551073	chr8:65592731~65592820:+
LUAD	cis	rs7849270	0.885	rs10760588	ENSG00000268707.1	RP11-247A12.7	-5.86	8.81e-09	3.41e-06	-0.29	-0.26	Blood metabolite ratios;	chr9:129115195	chr9:129170434~129170940:+
LUAD	cis	rs2933343	1	rs789213	ENSG00000261159.1	RP11-723O4.9	-5.86	8.82e-09	3.42e-06	-0.31	-0.26	IgG glycosylation;	chr3:128897516	chr3:128859716~128860526:-
LUAD	cis	rs7176527	0.519	rs12148368	ENSG00000230373.7	GOLGA6L5P	5.86	8.82e-09	3.42e-06	0.27	0.26	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84563274	chr15:84507885~84516814:-
LUAD	cis	rs1876905	0.597	rs354551	ENSG00000272356.1	RP5-1112D6.8	-5.86	8.83e-09	3.42e-06	-0.29	-0.26	Mean corpuscular hemoglobin;	chr6:111224337	chr6:111309203~111313517:+
LUAD	cis	rs4972806	0.849	rs2857541	ENSG00000226363.3	HAGLROS	-5.85	8.85e-09	3.43e-06	-0.32	-0.26	IgG glycosylation;	chr2:176164358	chr2:176177717~176179008:+
LUAD	cis	rs12468226	0.938	rs77062060	ENSG00000272966.1	RP11-686O6.1	5.85	8.86e-09	3.43e-06	0.45	0.26	Urate levels;	chr2:202285639	chr2:202336739~202337200:+
LUAD	cis	rs10740039	0.516	rs7088259	ENSG00000254271.1	RP11-131N11.4	5.85	8.86e-09	3.43e-06	0.29	0.26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60559094	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.516	rs2393646	ENSG00000254271.1	RP11-131N11.4	5.85	8.86e-09	3.43e-06	0.29	0.26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60559676	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.516	rs2068042	ENSG00000254271.1	RP11-131N11.4	5.85	8.86e-09	3.43e-06	0.29	0.26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60560535	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.516	rs10740032	ENSG00000254271.1	RP11-131N11.4	5.85	8.86e-09	3.43e-06	0.29	0.26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60562627	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.516	rs958852	ENSG00000254271.1	RP11-131N11.4	5.85	8.86e-09	3.43e-06	0.29	0.26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60562860	chr10:60734342~60741828:+
LUAD	cis	rs755249	0.567	rs41270807	ENSG00000228060.1	RP11-69E11.8	-5.85	8.86e-09	3.43e-06	-0.26	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39336143	chr1:39565160~39573203:+
LUAD	cis	rs9543976	0.623	rs9543990	ENSG00000261553.4	RP11-29G8.3	5.85	8.87e-09	3.43e-06	0.33	0.26	Diabetic retinopathy;	chr13:75598298	chr13:75549773~75807120:+
LUAD	cis	rs7615952	1	rs7615952	ENSG00000171084.14	FAM86JP	-5.85	8.87e-09	3.43e-06	-0.36	-0.26	Blood pressure (smoking interaction);	chr3:125930560	chr3:125916620~125930024:+
LUAD	cis	rs2243480	0.808	rs12698508	ENSG00000230295.1	RP11-458F8.2	-5.85	8.87e-09	3.43e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:65946971	chr7:66880708~66882981:+
LUAD	cis	rs9847710	0.696	rs2581822	ENSG00000242142.1	SERBP1P3	5.85	8.87e-09	3.43e-06	0.3	0.26	Ulcerative colitis;	chr3:52987733	chr3:53064283~53065091:-
LUAD	cis	rs62229266	0.557	rs4817760	ENSG00000214914.3	RPL23AP3	5.85	8.88e-09	3.44e-06	0.32	0.26	Mitral valve prolapse;	chr21:36023003	chr21:36016079~36016546:-
LUAD	cis	rs12468226	0.873	rs60722019	ENSG00000272966.1	RP11-686O6.1	5.85	8.89e-09	3.44e-06	0.45	0.26	Urate levels;	chr2:202282060	chr2:202336739~202337200:+
LUAD	cis	rs11098499	0.913	rs10006304	ENSG00000248280.1	RP11-33B1.2	5.85	8.89e-09	3.44e-06	0.33	0.26	Corneal astigmatism;	chr4:119203150	chr4:119440561~119450157:-
LUAD	cis	rs10129255	0.5	rs2105991	ENSG00000211967.3	IGHV3-53	-5.85	8.89e-09	3.44e-06	-0.18	-0.26	Kawasaki disease;	chr14:106682022	chr14:106592676~106593347:-
LUAD	cis	rs2404602	0.583	rs12913096	ENSG00000259422.1	RP11-593F23.1	5.85	8.9e-09	3.44e-06	0.29	0.26	Blood metabolite levels;	chr15:76259511	chr15:76174891~76181486:-
LUAD	cis	rs12699921	0.632	rs949451	ENSG00000279048.1	RP11-511H23.2	-5.85	8.9e-09	3.45e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17818931	chr7:17940503~17942922:+
LUAD	cis	rs7615952	1	rs9289275	ENSG00000171084.14	FAM86JP	5.85	8.92e-09	3.45e-06	0.38	0.26	Blood pressure (smoking interaction);	chr3:125929816	chr3:125916620~125930024:+
LUAD	cis	rs4927850	1	rs7614767	ENSG00000207650.1	MIR570	5.85	8.92e-09	3.45e-06	0.27	0.26	Pancreatic cancer;	chr3:196026580	chr3:195699401~195699497:+
LUAD	cis	rs4803480	0.935	rs9304595	ENSG00000270164.1	LINC01480	5.85	8.93e-09	3.46e-06	0.25	0.26	Schizophrenia;	chr19:41571639	chr19:41535183~41536904:+
LUAD	cis	rs1707322	0.717	rs3014245	ENSG00000280836.1	AL355480.1	5.85	8.93e-09	3.46e-06	0.34	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621241	chr1:45581219~45581321:-
LUAD	cis	rs9543976	0.623	rs6562913	ENSG00000261553.4	RP11-29G8.3	5.85	8.93e-09	3.46e-06	0.33	0.26	Diabetic retinopathy;	chr13:75593297	chr13:75549773~75807120:+
LUAD	cis	rs9506514	0.722	rs11147813	ENSG00000222726.1	RNU2-7P	5.85	8.94e-09	3.46e-06	0.3	0.26	Coronary artery calcification;	chr13:20684419	chr13:20612161~20612338:+
LUAD	cis	rs526231	0.697	rs253759	ENSG00000175749.11	EIF3KP1	5.85	8.94e-09	3.46e-06	0.4	0.26	Primary biliary cholangitis;	chr5:103279974	chr5:103032376~103033031:+
LUAD	cis	rs2276314	0.857	rs28651028	ENSG00000278986.1	RP11-723J4.3	-5.85	8.97e-09	3.47e-06	-0.31	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:36058947	chr18:35972151~35973916:+
LUAD	cis	rs11157436	0.871	rs8003190	ENSG00000211812.1	TRAV26-2	-5.85	8.97e-09	3.47e-06	-0.3	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22212096	chr14:22202583~22203368:+
LUAD	cis	rs7246657	0.722	rs2909098	ENSG00000276846.1	CTD-3220F14.3	-5.85	8.98e-09	3.47e-06	-0.35	-0.26	Coronary artery calcification;	chr19:37713347	chr19:37314868~37315620:-
LUAD	cis	rs9311474	1	rs7614727	ENSG00000243224.1	RP5-1157M23.2	-5.85	8.98e-09	3.47e-06	-0.26	-0.26	Electroencephalogram traits;	chr3:52261879	chr3:52239258~52241097:+
LUAD	cis	rs748404	0.55	rs12912505	ENSG00000205771.5	CATSPER2P1	-5.85	8.99e-09	3.48e-06	-0.4	-0.26	Lung cancer;	chr15:43525206	chr15:43726918~43747094:-
LUAD	cis	rs6921919	0.583	rs1054372	ENSG00000216901.1	AL022393.7	5.85	8.99e-09	3.48e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs9468354	ENSG00000216901.1	AL022393.7	5.85	8.99e-09	3.48e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs7773051	ENSG00000216901.1	AL022393.7	5.85	8.99e-09	3.48e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs12697938	ENSG00000216901.1	AL022393.7	5.85	8.99e-09	3.48e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs13437294	ENSG00000216901.1	AL022393.7	5.85	8.99e-09	3.48e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.609	rs9468357	ENSG00000216901.1	AL022393.7	5.85	8.99e-09	3.48e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28176188~28176674:+
LUAD	cis	rs10214930	0.697	rs12670415	ENSG00000235574.1	AC073150.6	-5.85	9.01e-09	3.48e-06	-0.32	-0.26	Hypospadias;	chr7:27562604	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.624	rs6959126	ENSG00000235574.1	AC073150.6	-5.85	9.01e-09	3.48e-06	-0.32	-0.26	Hypospadias;	chr7:27564631	chr7:27491682~27492765:-
LUAD	cis	rs4908760	0.965	rs12080583	ENSG00000232912.4	RP5-1115A15.1	5.85	9.02e-09	3.49e-06	0.24	0.26	Vitiligo;	chr1:8464817	chr1:8424645~8434838:+
LUAD	cis	rs11098499	1	rs11098499	ENSG00000248280.1	RP11-33B1.2	5.85	9.03e-09	3.49e-06	0.32	0.26	Corneal astigmatism;	chr4:119266456	chr4:119440561~119450157:-
LUAD	cis	rs957448	1	rs12679345	ENSG00000253704.1	RP11-267M23.4	5.85	9.04e-09	3.49e-06	0.32	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94552305	chr8:94553722~94569745:+
LUAD	cis	rs875971	0.545	rs313828	ENSG00000237310.1	GS1-124K5.4	-5.85	9.06e-09	3.5e-06	-0.33	-0.26	Aortic root size;	chr7:66087627	chr7:66493706~66495474:+
LUAD	cis	rs7727544	0.684	rs2631363	ENSG00000233006.5	AC034220.3	-5.85	9.06e-09	3.5e-06	-0.23	-0.26	Blood metabolite levels;	chr5:132371403	chr5:132311285~132369916:-
LUAD	cis	rs2243480	1	rs2243480	ENSG00000230295.1	RP11-458F8.2	-5.85	9.07e-09	3.5e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66134209	chr7:66880708~66882981:+
LUAD	cis	rs7945705	0.967	rs10769968	ENSG00000254860.4	TMEM9B-AS1	-5.85	9.07e-09	3.5e-06	-0.29	-0.26	Hemoglobin concentration;	chr11:8886036	chr11:8964675~8977527:+
LUAD	cis	rs35740288	0.77	rs11630968	ENSG00000202081.1	RNU6-1280P	5.85	9.07e-09	3.5e-06	0.32	0.26	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85574770	chr15:85651522~85651628:-
LUAD	cis	rs11098499	0.955	rs1551	ENSG00000248280.1	RP11-33B1.2	5.85	9.07e-09	3.5e-06	0.32	0.26	Corneal astigmatism;	chr4:119237345	chr4:119440561~119450157:-
LUAD	cis	rs293748	0.771	rs292179	ENSG00000250155.1	CTD-2353F22.1	-5.85	9.07e-09	3.51e-06	-0.36	-0.26	Obesity-related traits;	chr5:36947511	chr5:36666214~36725195:-
LUAD	cis	rs10754283	0.934	rs10493829	ENSG00000231613.1	RP5-943J3.1	5.85	9.08e-09	3.51e-06	0.27	0.26	Amyotrophic lateral sclerosis (sporadic);	chr1:89652274	chr1:89788914~89790492:+
LUAD	cis	rs10129255	0.957	rs10138532	ENSG00000224373.3	IGHV4-59	5.85	9.08e-09	3.51e-06	0.17	0.26	Kawasaki disease;	chr14:106803901	chr14:106627249~106627825:-
LUAD	cis	rs944990	0.576	rs4744243	ENSG00000227603.1	RP11-165J3.6	-5.85	9.09e-09	3.51e-06	-0.28	-0.26	Body mass index;	chr9:93477942	chr9:93435332~93437121:-
LUAD	cis	rs853679	0.517	rs1904841	ENSG00000204709.4	LINC01556	5.85	9.09e-09	3.51e-06	0.37	0.26	Depression;	chr6:28140307	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs1904840	ENSG00000204709.4	LINC01556	5.85	9.09e-09	3.51e-06	0.37	0.26	Depression;	chr6:28140454	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9368555	ENSG00000204709.4	LINC01556	5.85	9.09e-09	3.51e-06	0.37	0.26	Depression;	chr6:28141189	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.715	rs200480	ENSG00000216901.1	AL022393.7	5.85	9.09e-09	3.51e-06	0.29	0.26	Parkinson's disease;	chr6:27805886	chr6:28176188~28176674:+
LUAD	cis	rs9595908	0.709	rs7327412	ENSG00000212293.1	SNORA16	-5.85	9.09e-09	3.51e-06	-0.27	-0.26	Body mass index;	chr13:32774430	chr13:32420390~32420516:-
LUAD	cis	rs1823913	0.66	rs1454752	ENSG00000280083.1	RP11-317J9.1	5.85	9.11e-09	3.52e-06	0.31	0.26	Obesity-related traits;	chr2:191298668	chr2:191154118~191156070:-
LUAD	cis	rs3762637	0.941	rs7653592	ENSG00000272758.4	RP11-299J3.8	-5.85	9.11e-09	3.52e-06	-0.39	-0.26	LDL cholesterol levels;	chr3:122499524	chr3:122416207~122443180:+
LUAD	cis	rs73219805	1	rs1042992	ENSG00000228451.3	SDAD1P1	5.85	9.12e-09	3.52e-06	0.38	0.26	Schizophrenia;	chr8:26411675	chr8:26379259~26382953:-
LUAD	cis	rs720064	0.555	rs9956312	ENSG00000264745.1	TTC39C-AS1	5.85	9.12e-09	3.52e-06	0.27	0.26	Strep throat;	chr18:23969713	chr18:23994213~24015339:-
LUAD	cis	rs875971	0.862	rs11984115	ENSG00000222364.1	RNU6-96P	5.85	9.13e-09	3.52e-06	0.29	0.26	Aortic root size;	chr7:66308872	chr7:66395191~66395286:+
LUAD	cis	rs916888	0.687	rs199456	ENSG00000261575.2	RP11-259G18.1	5.85	9.13e-09	3.53e-06	0.41	0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46267037~46268694:+
LUAD	cis	rs1799949	0.965	rs9911630	ENSG00000267681.1	CTD-3199J23.6	-5.85	9.13e-09	3.53e-06	-0.29	-0.26	Menopause (age at onset);	chr17:43036325	chr17:43144956~43145255:+
LUAD	cis	rs17301013	0.507	rs72717617	ENSG00000227373.4	RP11-160H22.5	5.85	9.14e-09	3.53e-06	0.4	0.26	Systemic lupus erythematosus;	chr1:174815514	chr1:174115300~174160004:-
LUAD	cis	rs10129255	0.957	rs8009073	ENSG00000224373.3	IGHV4-59	5.85	9.15e-09	3.53e-06	0.17	0.26	Kawasaki disease;	chr14:106777278	chr14:106627249~106627825:-
LUAD	cis	rs732716	0.785	rs34080966	ENSG00000267980.1	AC007292.6	5.85	9.15e-09	3.53e-06	0.29	0.26	Mean corpuscular volume;	chr19:4417848	chr19:4363789~4364640:+
LUAD	cis	rs1061377	1	rs1036036	ENSG00000249685.1	RP11-360F5.3	5.85	9.16e-09	3.54e-06	0.31	0.26	Uric acid levels;	chr4:39111104	chr4:39133913~39135608:+
LUAD	cis	rs1075265	0.744	rs10203576	ENSG00000233266.1	HMGB1P31	5.85	9.16e-09	3.54e-06	0.32	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54060939	chr2:54051334~54051760:+
LUAD	cis	rs765787	0.53	rs1706834	ENSG00000259520.4	CTD-2651B20.3	5.85	9.17e-09	3.54e-06	0.34	0.26	Uric acid levels;	chr15:45225656	chr15:45251580~45279251:-
LUAD	cis	rs4908760	0.899	rs61783642	ENSG00000232912.4	RP5-1115A15.1	5.85	9.17e-09	3.54e-06	0.24	0.26	Vitiligo;	chr1:8531338	chr1:8424645~8434838:+
LUAD	cis	rs2404602	0.735	rs2454454	ENSG00000259422.1	RP11-593F23.1	-5.85	9.18e-09	3.55e-06	-0.32	-0.26	Blood metabolite levels;	chr15:76531306	chr15:76174891~76181486:-
LUAD	cis	rs75920871	0.588	rs1871756	ENSG00000254851.1	RP11-109L13.1	5.85	9.19e-09	3.55e-06	0.38	0.26	Subjective well-being;	chr11:117082929	chr11:117135528~117138582:+
LUAD	cis	rs2243480	1	rs316330	ENSG00000230295.1	RP11-458F8.2	-5.85	9.19e-09	3.55e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66140385	chr7:66880708~66882981:+
LUAD	cis	rs858239	0.601	rs4140959	ENSG00000230042.1	AK3P3	-5.85	9.2e-09	3.55e-06	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23129178~23129841:+
LUAD	cis	rs875971	1	rs6460292	ENSG00000237310.1	GS1-124K5.4	-5.85	9.2e-09	3.55e-06	-0.28	-0.26	Aortic root size;	chr7:66345088	chr7:66493706~66495474:+
LUAD	cis	rs801193	0.569	rs13242290	ENSG00000222364.1	RNU6-96P	5.85	9.21e-09	3.55e-06	0.29	0.26	Aortic root size;	chr7:66656898	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.767	rs12668005	ENSG00000222364.1	RNU6-96P	-5.85	9.21e-09	3.55e-06	-0.29	-0.26	Aortic root size;	chr7:66444034	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs11765791	ENSG00000222364.1	RNU6-96P	-5.85	9.21e-09	3.55e-06	-0.29	-0.26	Aortic root size;	chr7:66471587	chr7:66395191~66395286:+
LUAD	cis	rs67311347	1	rs66841330	ENSG00000223797.4	ENTPD3-AS1	5.85	9.21e-09	3.56e-06	0.29	0.26	Renal cell carcinoma;	chr3:40489632	chr3:40313802~40453329:-
LUAD	cis	rs6504622	1	rs4968285	ENSG00000262879.4	RP11-156P1.3	-5.85	9.24e-09	3.56e-06	-0.29	-0.26	Orofacial clefts;	chr17:46938266	chr17:46984045~47100323:-
LUAD	cis	rs853679	0.882	rs9393908	ENSG00000219392.1	RP1-265C24.5	-5.85	9.24e-09	3.57e-06	-0.44	-0.26	Depression;	chr6:28223052	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.882	rs9366717	ENSG00000219392.1	RP1-265C24.5	-5.85	9.24e-09	3.57e-06	-0.44	-0.26	Depression;	chr6:28223279	chr6:28115628~28116551:+
LUAD	cis	rs9353324	1	rs7745560	ENSG00000203875.9	SNHG5	5.85	9.27e-09	3.58e-06	0.52	0.26	Interferon gamma-induced protein 10 levels;	chr6:85579203	chr6:85660950~85678736:-
LUAD	cis	rs1707322	0.682	rs12037459	ENSG00000280836.1	AL355480.1	-5.85	9.27e-09	3.58e-06	-0.34	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629287	chr1:45581219~45581321:-
LUAD	cis	rs8177876	0.749	rs1035541	ENSG00000261061.1	RP11-303E16.2	-5.85	9.27e-09	3.58e-06	-0.45	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81065249	chr16:81030770~81031485:+
LUAD	cis	rs948562	0.569	rs74810062	ENSG00000280010.1	AP001350.4	5.85	9.27e-09	3.58e-06	0.42	0.26	Lymphoma;	chr11:58446218	chr11:58627435~58628528:+
LUAD	cis	rs7849270	0.959	rs10739742	ENSG00000268707.1	RP11-247A12.7	-5.85	9.28e-09	3.58e-06	-0.29	-0.26	Blood metabolite ratios;	chr9:129159389	chr9:129170434~129170940:+
LUAD	cis	rs7208859	0.573	rs73267873	ENSG00000263531.1	RP13-753N3.1	5.85	9.28e-09	3.58e-06	0.47	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741439	chr17:30863921~30864940:-
LUAD	cis	rs17826219	0.561	rs4085382	ENSG00000263531.1	RP13-753N3.1	5.85	9.28e-09	3.58e-06	0.47	0.26	Body mass index;	chr17:30744184	chr17:30863921~30864940:-
LUAD	cis	rs950169	0.58	rs11634320	ENSG00000225151.9	GOLGA2P7	5.85	9.28e-09	3.58e-06	0.35	0.26	Schizophrenia;	chr15:84628952	chr15:84199311~84230136:-
LUAD	cis	rs4664293	0.801	rs7589771	ENSG00000226266.5	AC009961.3	-5.85	9.29e-09	3.58e-06	-0.35	-0.26	Monocyte percentage of white cells;	chr2:159727621	chr2:159670708~159712435:-
LUAD	cis	rs4908760	0.965	rs7542312	ENSG00000232912.4	RP5-1115A15.1	5.85	9.3e-09	3.59e-06	0.24	0.26	Vitiligo;	chr1:8513412	chr1:8424645~8434838:+
LUAD	cis	rs62246343	0.786	rs11547584	ENSG00000254485.4	RP11-380O24.1	5.85	9.3e-09	3.59e-06	0.37	0.26	Fibrinogen levels;	chr3:9365020	chr3:9292588~9363303:-
LUAD	cis	rs35160687	0.712	rs11127020	ENSG00000273080.1	RP11-301O19.1	-5.85	9.31e-09	3.59e-06	-0.29	-0.26	Night sleep phenotypes;	chr2:86247421	chr2:86195590~86196049:+
LUAD	cis	rs3096299	0.748	rs2965822	ENSG00000274627.1	RP11-104N10.2	5.85	9.31e-09	3.59e-06	0.25	0.26	Multiple myeloma (IgH translocation);	chr16:89378269	chr16:89516797~89522217:+
LUAD	cis	rs1823913	0.927	rs35339956	ENSG00000230611.1	HMGB1P27	-5.85	9.32e-09	3.59e-06	-0.32	-0.26	Obesity-related traits;	chr2:191261668	chr2:191174233~191174835:+
LUAD	cis	rs755249	0.567	rs16826069	ENSG00000228060.1	RP11-69E11.8	-5.85	9.33e-09	3.6e-06	-0.26	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39331383	chr1:39565160~39573203:+
LUAD	cis	rs6921919	0.583	rs4642462	ENSG00000216901.1	AL022393.7	5.85	9.33e-09	3.6e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28176188~28176674:+
LUAD	cis	rs9640161	0.83	rs6722	ENSG00000261305.1	RP4-584D14.7	5.85	9.34e-09	3.6e-06	0.35	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150371844	chr7:150341771~150342607:+
LUAD	cis	rs11673344	0.642	rs12462708	ENSG00000226686.6	LINC01535	-5.85	9.34e-09	3.6e-06	-0.32	-0.26	Obesity-related traits;	chr19:37306676	chr19:37251912~37265535:+
LUAD	cis	rs8072100	0.934	rs6504872	ENSG00000228782.6	CTD-2026D20.3	5.84	9.36e-09	3.61e-06	0.28	0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47361586	chr17:47450568~47492492:-
LUAD	cis	rs1823913	0.614	rs6434459	ENSG00000280083.1	RP11-317J9.1	5.84	9.36e-09	3.61e-06	0.31	0.26	Obesity-related traits;	chr2:191300886	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.592	rs7588555	ENSG00000280083.1	RP11-317J9.1	5.84	9.36e-09	3.61e-06	0.31	0.26	Obesity-related traits;	chr2:191300912	chr2:191154118~191156070:-
LUAD	cis	rs853679	0.517	rs9393893	ENSG00000204709.4	LINC01556	5.84	9.36e-09	3.61e-06	0.37	0.26	Depression;	chr6:28141484	chr6:28943877~28944537:+
LUAD	cis	rs4908768	0.501	rs12061328	ENSG00000232912.4	RP5-1115A15.1	5.84	9.36e-09	3.61e-06	0.24	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8471903	chr1:8424645~8434838:+
LUAD	cis	rs4604732	0.631	rs4436425	ENSG00000227135.1	GCSAML-AS1	-5.84	9.37e-09	3.61e-06	-0.39	-0.26	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247469021	chr1:247524679~247526752:-
LUAD	cis	rs7714584	1	rs11739677	ENSG00000197083.10	ZNF300P1	5.84	9.37e-09	3.61e-06	0.52	0.26	Crohn's disease;	chr5:150915321	chr5:150930645~150946289:-
LUAD	cis	rs12699921	0.599	rs4721665	ENSG00000279048.1	RP11-511H23.2	-5.84	9.38e-09	3.61e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17876696	chr7:17940503~17942922:+
LUAD	cis	rs11098499	0.535	rs7671759	ENSG00000248280.1	RP11-33B1.2	5.84	9.38e-09	3.61e-06	0.32	0.26	Corneal astigmatism;	chr4:119326939	chr4:119440561~119450157:-
LUAD	cis	rs987724	0.512	rs9842198	ENSG00000240875.4	LINC00886	-5.84	9.38e-09	3.61e-06	-0.28	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156821415	chr3:156747346~156817062:-
LUAD	cis	rs7615952	0.599	rs2270986	ENSG00000171084.14	FAM86JP	5.84	9.38e-09	3.61e-06	0.37	0.26	Blood pressure (smoking interaction);	chr3:125982256	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.599	rs12496921	ENSG00000171084.14	FAM86JP	5.84	9.38e-09	3.61e-06	0.37	0.26	Blood pressure (smoking interaction);	chr3:125983105	chr3:125916620~125930024:+
LUAD	cis	rs1823913	0.637	rs897197	ENSG00000227542.1	AC092614.2	-5.84	9.38e-09	3.62e-06	-0.31	-0.26	Obesity-related traits;	chr2:191281456	chr2:191229165~191246172:-
LUAD	cis	rs516805	0.748	rs510471	ENSG00000279453.1	RP3-425C14.4	-5.84	9.38e-09	3.62e-06	-0.34	-0.26	Lymphocyte counts;	chr6:122391714	chr6:122436789~122439223:-
LUAD	cis	rs4820294	1	rs7291867	ENSG00000233360.4	Z83844.1	5.84	9.39e-09	3.62e-06	0.27	0.26	Fat distribution (HIV);	chr22:37666105	chr22:37641832~37658377:-
LUAD	cis	rs17301013	0.606	rs459078	ENSG00000227373.4	RP11-160H22.5	5.84	9.39e-09	3.62e-06	0.35	0.26	Systemic lupus erythematosus;	chr1:174733772	chr1:174115300~174160004:-
LUAD	cis	rs6921919	0.609	rs36018474	ENSG00000216901.1	AL022393.7	5.84	9.4e-09	3.62e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28176188~28176674:+
LUAD	cis	rs17301013	0.507	rs3118988	ENSG00000227373.4	RP11-160H22.5	-5.84	9.41e-09	3.63e-06	-0.38	-0.26	Systemic lupus erythematosus;	chr1:174819245	chr1:174115300~174160004:-
LUAD	cis	rs7208859	0.573	rs79505916	ENSG00000263603.1	CTD-2349P21.5	-5.84	9.43e-09	3.63e-06	-0.46	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30735308	chr17:30729469~30731202:+
LUAD	cis	rs7181230	0.885	rs4497657	ENSG00000275636.1	RP11-521C20.5	5.84	9.43e-09	3.63e-06	0.34	0.26	Dehydroepiandrosterone sulphate levels;	chr15:40067232	chr15:40078892~40079347:+
LUAD	cis	rs7615952	1	rs7616044	ENSG00000171084.14	FAM86JP	5.84	9.44e-09	3.64e-06	0.37	0.26	Blood pressure (smoking interaction);	chr3:125930511	chr3:125916620~125930024:+
LUAD	cis	rs2288884	0.559	rs73052102	ENSG00000275055.1	CTC-471J1.11	-5.84	9.44e-09	3.64e-06	-0.31	-0.26	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52021748	chr19:52049007~52049754:+
LUAD	cis	rs12908161	0.959	rs3748376	ENSG00000225151.9	GOLGA2P7	-5.84	9.44e-09	3.64e-06	-0.35	-0.26	Schizophrenia;	chr15:84785121	chr15:84199311~84230136:-
LUAD	cis	rs4713118	0.662	rs149901	ENSG00000204709.4	LINC01556	5.84	9.44e-09	3.64e-06	0.35	0.26	Parkinson's disease;	chr6:27997725	chr6:28943877~28944537:+
LUAD	cis	rs6921919	0.583	rs7759191	ENSG00000216901.1	AL022393.7	5.84	9.44e-09	3.64e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28176188~28176674:+
LUAD	cis	rs12468226	0.938	rs3731700	ENSG00000272966.1	RP11-686O6.1	5.84	9.45e-09	3.64e-06	0.45	0.26	Urate levels;	chr2:202291213	chr2:202336739~202337200:+
LUAD	cis	rs12468226	0.938	rs12471060	ENSG00000272966.1	RP11-686O6.1	5.84	9.45e-09	3.64e-06	0.45	0.26	Urate levels;	chr2:202309597	chr2:202336739~202337200:+
LUAD	cis	rs8177876	0.658	rs2278022	ENSG00000261061.1	RP11-303E16.2	-5.84	9.45e-09	3.64e-06	-0.45	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81043216	chr16:81030770~81031485:+
LUAD	cis	rs2911132	0.967	rs2042380	ENSG00000248734.2	CTD-2260A17.1	5.84	9.45e-09	3.64e-06	0.26	0.26	Urate levels (BMI interaction);	chr5:96851563	chr5:96784777~96785999:+
LUAD	cis	rs2276314	1	rs62101367	ENSG00000278986.1	RP11-723J4.3	-5.84	9.46e-09	3.64e-06	-0.32	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:35970921	chr18:35972151~35973916:+
LUAD	cis	rs2898681	0.618	rs116241740	ENSG00000248375.1	RP11-177B4.1	-5.84	9.46e-09	3.64e-06	-0.47	-0.26	Optic nerve measurement (cup area);	chr4:52867356	chr4:52720081~52720831:-
LUAD	cis	rs748404	0.666	rs12905220	ENSG00000205771.5	CATSPER2P1	-5.84	9.48e-09	3.65e-06	-0.39	-0.26	Lung cancer;	chr15:43465641	chr15:43726918~43747094:-
LUAD	cis	rs853679	0.55	rs1233701	ENSG00000204709.4	LINC01556	-5.84	9.48e-09	3.65e-06	-0.35	-0.26	Depression;	chr6:28200948	chr6:28943877~28944537:+
LUAD	cis	rs4908768	0.539	rs1809332	ENSG00000232912.4	RP5-1115A15.1	5.84	9.49e-09	3.65e-06	0.24	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8596375	chr1:8424645~8434838:+
LUAD	cis	rs7246657	0.722	rs2972458	ENSG00000276846.1	CTD-3220F14.3	-5.84	9.5e-09	3.66e-06	-0.34	-0.26	Coronary artery calcification;	chr19:37644502	chr19:37314868~37315620:-
LUAD	cis	rs2179367	0.632	rs9498324	ENSG00000231760.4	RP11-350J20.5	5.84	9.5e-09	3.66e-06	0.37	0.26	Dupuytren's disease;	chr6:149338973	chr6:149796151~149826294:-
LUAD	cis	rs11098499	0.575	rs9996586	ENSG00000245958.5	RP11-33B1.1	-5.84	9.51e-09	3.66e-06	-0.21	-0.26	Corneal astigmatism;	chr4:119405787	chr4:119454791~119552025:+
LUAD	cis	rs765787	0.53	rs13329228	ENSG00000259520.4	CTD-2651B20.3	5.84	9.51e-09	3.66e-06	0.33	0.26	Uric acid levels;	chr15:45240819	chr15:45251580~45279251:-
LUAD	cis	rs12468226	0.938	rs80315897	ENSG00000272966.1	RP11-686O6.1	5.84	9.51e-09	3.66e-06	0.45	0.26	Urate levels;	chr2:202318044	chr2:202336739~202337200:+
LUAD	cis	rs9595908	0.709	rs9591311	ENSG00000212293.1	SNORA16	5.84	9.52e-09	3.66e-06	0.27	0.26	Body mass index;	chr13:32757339	chr13:32420390~32420516:-
LUAD	cis	rs10214930	0.697	rs2041714	ENSG00000235574.1	AC073150.6	-5.84	9.53e-09	3.67e-06	-0.32	-0.26	Hypospadias;	chr7:27559228	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs12700819	ENSG00000235574.1	AC073150.6	-5.84	9.53e-09	3.67e-06	-0.32	-0.26	Hypospadias;	chr7:27560271	chr7:27491682~27492765:-
LUAD	cis	rs67311347	0.822	rs9826847	ENSG00000223797.4	ENTPD3-AS1	5.84	9.54e-09	3.67e-06	0.28	0.26	Renal cell carcinoma;	chr3:40303821	chr3:40313802~40453329:-
LUAD	cis	rs12699921	0.565	rs2714876	ENSG00000279048.1	RP11-511H23.2	-5.84	9.54e-09	3.67e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17887983	chr7:17940503~17942922:+
LUAD	cis	rs12699921	0.632	rs2714877	ENSG00000279048.1	RP11-511H23.2	-5.84	9.54e-09	3.67e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17888027	chr7:17940503~17942922:+
LUAD	cis	rs2255336	0.938	rs9651850	ENSG00000245648.1	RP11-277P12.20	-5.84	9.55e-09	3.67e-06	-0.41	-0.26	Blood protein levels;	chr12:10490533	chr12:10363769~10398506:+
LUAD	cis	rs3931020	0.688	rs405445	ENSG00000272864.1	RP11-17E13.2	5.84	9.55e-09	3.68e-06	0.36	0.26	Resistin levels;	chr1:74755466	chr1:74698769~74699333:-
LUAD	cis	rs2243480	1	rs778729	ENSG00000230295.1	RP11-458F8.2	-5.84	9.55e-09	3.68e-06	-0.31	-0.26	Diabetic kidney disease;	chr7:66359432	chr7:66880708~66882981:+
LUAD	cis	rs7714584	1	rs76433514	ENSG00000197083.10	ZNF300P1	5.84	9.56e-09	3.68e-06	0.52	0.26	Crohn's disease;	chr5:150926970	chr5:150930645~150946289:-
LUAD	cis	rs9309473	0.898	rs6546851	ENSG00000163016.8	ALMS1P	5.84	9.57e-09	3.68e-06	0.31	0.26	Metabolite levels;	chr2:73606156	chr2:73644919~73685576:+
LUAD	cis	rs7044106	0.718	rs1981021	ENSG00000238181.2	AHCYP2	-5.84	9.57e-09	3.68e-06	-0.33	-0.26	Hip circumference adjusted for BMI;	chr9:120626115	chr9:120720673~120721972:+
LUAD	cis	rs7044106	0.734	rs1981020	ENSG00000238181.2	AHCYP2	-5.84	9.57e-09	3.68e-06	-0.33	-0.26	Hip circumference adjusted for BMI;	chr9:120626186	chr9:120720673~120721972:+
LUAD	cis	rs7115242	0.92	rs6589574	ENSG00000280143.1	AP000892.6	5.84	9.57e-09	3.68e-06	0.46	0.26	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116859922	chr11:117204967~117210292:+
LUAD	cis	rs516805	0.667	rs2606608	ENSG00000279453.1	RP3-425C14.4	-5.84	9.57e-09	3.68e-06	-0.35	-0.26	Lymphocyte counts;	chr6:122195051	chr6:122436789~122439223:-
LUAD	cis	rs2404602	0.611	rs2404734	ENSG00000259422.1	RP11-593F23.1	-5.84	9.58e-09	3.68e-06	-0.34	-0.26	Blood metabolite levels;	chr15:76643824	chr15:76174891~76181486:-
LUAD	cis	rs858239	0.6	rs1115941	ENSG00000230042.1	AK3P3	-5.84	9.59e-09	3.69e-06	-0.32	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.6	rs6960001	ENSG00000230042.1	AK3P3	-5.84	9.6e-09	3.69e-06	-0.32	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.6	rs10237755	ENSG00000230042.1	AK3P3	-5.84	9.6e-09	3.69e-06	-0.32	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.6	rs6961131	ENSG00000230042.1	AK3P3	-5.84	9.6e-09	3.69e-06	-0.32	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23129178~23129841:+
LUAD	cis	rs2412819	0.571	rs2930531	ENSG00000249839.1	AC011330.5	5.84	9.61e-09	3.7e-06	0.4	0.26	Lung cancer;	chr15:43829372	chr15:43663654~43684339:-
LUAD	cis	rs1823913	0.637	rs4853569	ENSG00000227542.1	AC092614.2	-5.84	9.61e-09	3.7e-06	-0.31	-0.26	Obesity-related traits;	chr2:191266970	chr2:191229165~191246172:-
LUAD	cis	rs6921919	0.583	rs4254981	ENSG00000216901.1	AL022393.7	5.84	9.62e-09	3.7e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.525	rs6929825	ENSG00000216901.1	AL022393.7	5.84	9.62e-09	3.7e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs35599905	ENSG00000216901.1	AL022393.7	5.84	9.62e-09	3.7e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs1124131	ENSG00000216901.1	AL022393.7	5.84	9.62e-09	3.7e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs6899389	ENSG00000216901.1	AL022393.7	5.84	9.62e-09	3.7e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs6922374	ENSG00000216901.1	AL022393.7	5.84	9.62e-09	3.7e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs6899603	ENSG00000216901.1	AL022393.7	5.84	9.62e-09	3.7e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs6922429	ENSG00000216901.1	AL022393.7	5.84	9.62e-09	3.7e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28176188~28176674:+
LUAD	cis	rs66887589	0.807	rs13134517	ENSG00000245958.5	RP11-33B1.1	-5.84	9.63e-09	3.7e-06	-0.21	-0.26	Diastolic blood pressure;	chr4:119484107	chr4:119454791~119552025:+
LUAD	cis	rs66887589	0.837	rs6534135	ENSG00000245958.5	RP11-33B1.1	-5.84	9.63e-09	3.7e-06	-0.21	-0.26	Diastolic blood pressure;	chr4:119485147	chr4:119454791~119552025:+
LUAD	cis	rs66887589	0.837	rs7661498	ENSG00000245958.5	RP11-33B1.1	-5.84	9.63e-09	3.7e-06	-0.21	-0.26	Diastolic blood pressure;	chr4:119486953	chr4:119454791~119552025:+
LUAD	cis	rs4947019	0.534	rs75527655	ENSG00000260273.1	RP11-425D10.10	5.84	9.63e-09	3.7e-06	0.57	0.26	Hematological parameters;	chr6:109392693	chr6:109382795~109383666:+
LUAD	cis	rs10129255	0.5	rs4774008	ENSG00000211967.3	IGHV3-53	-5.84	9.64e-09	3.7e-06	-0.18	-0.26	Kawasaki disease;	chr14:106681273	chr14:106592676~106593347:-
LUAD	cis	rs7923609	0.936	rs10761779	ENSG00000232075.1	MRPL35P2	-5.84	9.64e-09	3.71e-06	-0.31	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63515167	chr10:63634317~63634827:-
LUAD	cis	rs2734839	0.964	rs4938017	ENSG00000270179.1	RP11-159N11.4	5.84	9.65e-09	3.71e-06	0.27	0.26	Information processing speed;	chr11:113433207	chr11:113368478~113369117:+
LUAD	cis	rs7712401	0.601	rs30028	ENSG00000263432.2	RN7SL689P	5.84	9.65e-09	3.71e-06	0.32	0.26	Mean platelet volume;	chr5:122947574	chr5:123022487~123022783:-
LUAD	cis	rs1707322	0.686	rs3014242	ENSG00000234329.1	RP11-767N6.2	-5.84	9.66e-09	3.71e-06	-0.27	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621905	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.686	rs3014239	ENSG00000234329.1	RP11-767N6.2	-5.84	9.66e-09	3.71e-06	-0.27	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624129	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.686	rs3014236	ENSG00000234329.1	RP11-767N6.2	-5.84	9.66e-09	3.71e-06	-0.27	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625633	chr1:45651039~45651826:-
LUAD	cis	rs2276314	0.947	rs16967319	ENSG00000278986.1	RP11-723J4.3	-5.84	9.67e-09	3.72e-06	-0.32	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:35993562	chr18:35972151~35973916:+
LUAD	cis	rs10214930	0.697	rs9639552	ENSG00000235574.1	AC073150.6	-5.84	9.68e-09	3.72e-06	-0.32	-0.26	Hypospadias;	chr7:27535904	chr7:27491682~27492765:-
LUAD	cis	rs944289	0.53	rs2755193	ENSG00000257826.1	RP11-116N8.4	5.84	9.68e-09	3.72e-06	0.27	0.26	Thyroid cancer;	chr14:36049416	chr14:36061026~36067190:-
LUAD	cis	rs1134634	0.52	rs4698408	ENSG00000273133.1	RP11-799M12.2	-5.84	9.68e-09	3.72e-06	-0.38	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15657425	chr4:15563698~15564253:-
LUAD	cis	rs755249	0.567	rs61783378	ENSG00000228060.1	RP11-69E11.8	-5.84	9.7e-09	3.73e-06	-0.27	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39311487	chr1:39565160~39573203:+
LUAD	cis	rs6921919	0.673	rs13201681	ENSG00000204709.4	LINC01556	5.84	9.71e-09	3.73e-06	0.58	0.26	Autism spectrum disorder or schizophrenia;	chr6:28426903	chr6:28943877~28944537:+
LUAD	cis	rs7618501	0.633	rs2526751	ENSG00000234667.1	ACTBP13	5.84	9.72e-09	3.73e-06	0.29	0.26	Intelligence (multi-trait analysis);	chr3:50027434	chr3:49873347~49877980:-
LUAD	cis	rs12468226	0.938	rs116601501	ENSG00000272966.1	RP11-686O6.1	5.84	9.72e-09	3.73e-06	0.45	0.26	Urate levels;	chr2:202274567	chr2:202336739~202337200:+
LUAD	cis	rs12468226	0.938	rs76658848	ENSG00000272966.1	RP11-686O6.1	5.84	9.72e-09	3.73e-06	0.45	0.26	Urate levels;	chr2:202275548	chr2:202336739~202337200:+
LUAD	cis	rs12468226	0.938	rs57571703	ENSG00000272966.1	RP11-686O6.1	5.84	9.72e-09	3.73e-06	0.45	0.26	Urate levels;	chr2:202281997	chr2:202336739~202337200:+
LUAD	cis	rs12468226	0.938	rs78928733	ENSG00000272966.1	RP11-686O6.1	5.84	9.72e-09	3.73e-06	0.45	0.26	Urate levels;	chr2:202283787	chr2:202336739~202337200:+
LUAD	cis	rs11742741	0.539	rs12152823	ENSG00000248874.4	C5orf17	-5.84	9.73e-09	3.74e-06	-0.32	-0.26	Educational attainment;	chr5:24105632	chr5:23951348~24178263:+
LUAD	cis	rs2255336	0.873	rs12301897	ENSG00000245648.1	RP11-277P12.20	-5.84	9.76e-09	3.75e-06	-0.41	-0.26	Blood protein levels;	chr12:10491974	chr12:10363769~10398506:+
LUAD	cis	rs858239	0.57	rs6968242	ENSG00000230042.1	AK3P3	-5.84	9.78e-09	3.75e-06	-0.32	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23129178~23129841:+
LUAD	cis	rs2243480	0.901	rs778687	ENSG00000230295.1	RP11-458F8.2	-5.84	9.78e-09	3.75e-06	-0.31	-0.26	Diabetic kidney disease;	chr7:66370832	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs778704	ENSG00000230295.1	RP11-458F8.2	-5.84	9.78e-09	3.75e-06	-0.31	-0.26	Diabetic kidney disease;	chr7:66398480	chr7:66880708~66882981:+
LUAD	cis	rs2243480	0.901	rs778693	ENSG00000230295.1	RP11-458F8.2	-5.84	9.78e-09	3.75e-06	-0.31	-0.26	Diabetic kidney disease;	chr7:66407358	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs778691	ENSG00000230295.1	RP11-458F8.2	-5.84	9.78e-09	3.75e-06	-0.31	-0.26	Diabetic kidney disease;	chr7:66408105	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs13235972	ENSG00000230295.1	RP11-458F8.2	-5.84	9.78e-09	3.75e-06	-0.31	-0.26	Diabetic kidney disease;	chr7:66418618	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs34192067	ENSG00000230295.1	RP11-458F8.2	-5.84	9.78e-09	3.75e-06	-0.31	-0.26	Diabetic kidney disease;	chr7:66422670	chr7:66880708~66882981:+
LUAD	cis	rs853679	0.517	rs4711164	ENSG00000204709.4	LINC01556	5.84	9.78e-09	3.75e-06	0.37	0.26	Depression;	chr6:28147378	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs4711165	ENSG00000204709.4	LINC01556	5.84	9.78e-09	3.75e-06	0.37	0.26	Depression;	chr6:28147406	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs4713148	ENSG00000204709.4	LINC01556	5.84	9.78e-09	3.75e-06	0.37	0.26	Depression;	chr6:28148143	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9348794	ENSG00000204709.4	LINC01556	5.84	9.78e-09	3.75e-06	0.37	0.26	Depression;	chr6:28149979	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9468297	ENSG00000204709.4	LINC01556	5.84	9.78e-09	3.75e-06	0.37	0.26	Depression;	chr6:28151096	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs9295758	ENSG00000204709.4	LINC01556	5.84	9.78e-09	3.75e-06	0.37	0.26	Depression;	chr6:28152885	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.517	rs17774663	ENSG00000204709.4	LINC01556	5.84	9.78e-09	3.75e-06	0.37	0.26	Depression;	chr6:28153120	chr6:28943877~28944537:+
LUAD	cis	rs944289	0.53	rs2780308	ENSG00000257826.1	RP11-116N8.4	5.84	9.79e-09	3.76e-06	0.27	0.26	Thyroid cancer;	chr14:36050062	chr14:36061026~36067190:-
LUAD	cis	rs944289	0.53	rs2780309	ENSG00000257826.1	RP11-116N8.4	5.84	9.79e-09	3.76e-06	0.27	0.26	Thyroid cancer;	chr14:36050646	chr14:36061026~36067190:-
LUAD	cis	rs66887589	0.774	rs9307477	ENSG00000245958.5	RP11-33B1.1	-5.84	9.8e-09	3.76e-06	-0.21	-0.26	Diastolic blood pressure;	chr4:119500654	chr4:119454791~119552025:+
LUAD	cis	rs8177876	0.749	rs10459872	ENSG00000261061.1	RP11-303E16.2	5.84	9.8e-09	3.76e-06	0.41	0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81061346	chr16:81030770~81031485:+
LUAD	cis	rs9595908	0.63	rs4057297	ENSG00000212293.1	SNORA16	5.84	9.8e-09	3.76e-06	0.27	0.26	Body mass index;	chr13:32731612	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.63	rs1929939	ENSG00000212293.1	SNORA16	5.84	9.8e-09	3.76e-06	0.27	0.26	Body mass index;	chr13:32733547	chr13:32420390~32420516:-
LUAD	cis	rs67311347	0.955	rs1129200	ENSG00000223797.4	ENTPD3-AS1	5.84	9.81e-09	3.77e-06	0.28	0.26	Renal cell carcinoma;	chr3:40490766	chr3:40313802~40453329:-
LUAD	cis	rs1707322	0.656	rs9429172	ENSG00000234329.1	RP11-767N6.2	-5.84	9.82e-09	3.77e-06	-0.28	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45626804	chr1:45651039~45651826:-
LUAD	cis	rs896854	0.624	rs9297949	ENSG00000253528.2	RP11-347C18.4	5.84	9.83e-09	3.77e-06	0.25	0.26	Type 2 diabetes;	chr8:94957217	chr8:94974573~94974853:-
LUAD	cis	rs896854	0.654	rs10429443	ENSG00000253528.2	RP11-347C18.4	5.84	9.83e-09	3.77e-06	0.25	0.26	Type 2 diabetes;	chr8:94958936	chr8:94974573~94974853:-
LUAD	cis	rs896854	0.654	rs896846	ENSG00000253528.2	RP11-347C18.4	5.84	9.83e-09	3.77e-06	0.25	0.26	Type 2 diabetes;	chr8:94960225	chr8:94974573~94974853:-
LUAD	cis	rs896854	0.654	rs896847	ENSG00000253528.2	RP11-347C18.4	5.84	9.83e-09	3.77e-06	0.25	0.26	Type 2 diabetes;	chr8:94960323	chr8:94974573~94974853:-
LUAD	cis	rs896854	0.654	rs13281625	ENSG00000253528.2	RP11-347C18.4	5.84	9.83e-09	3.77e-06	0.25	0.26	Type 2 diabetes;	chr8:94960510	chr8:94974573~94974853:-
LUAD	cis	rs896854	0.625	rs13281709	ENSG00000253528.2	RP11-347C18.4	5.84	9.83e-09	3.77e-06	0.25	0.26	Type 2 diabetes;	chr8:94960591	chr8:94974573~94974853:-
LUAD	cis	rs896854	0.625	rs4735335	ENSG00000253528.2	RP11-347C18.4	5.84	9.83e-09	3.77e-06	0.25	0.26	Type 2 diabetes;	chr8:94961099	chr8:94974573~94974853:-
LUAD	cis	rs896854	0.654	rs4735337	ENSG00000253528.2	RP11-347C18.4	5.84	9.83e-09	3.77e-06	0.25	0.26	Type 2 diabetes;	chr8:94961237	chr8:94974573~94974853:-
LUAD	cis	rs896854	0.654	rs28591375	ENSG00000253528.2	RP11-347C18.4	5.84	9.83e-09	3.77e-06	0.25	0.26	Type 2 diabetes;	chr8:94961409	chr8:94974573~94974853:-
LUAD	cis	rs896854	0.654	rs4735339	ENSG00000253528.2	RP11-347C18.4	5.84	9.83e-09	3.77e-06	0.25	0.26	Type 2 diabetes;	chr8:94962145	chr8:94974573~94974853:-
LUAD	cis	rs6921919	0.583	rs9468370	ENSG00000216901.1	AL022393.7	5.84	9.83e-09	3.77e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28176188~28176674:+
LUAD	cis	rs61776719	0.738	rs7555461	ENSG00000212541.1	RNU6-510P	5.84	9.84e-09	3.77e-06	0.31	0.26	Coronary artery disease;	chr1:37979077	chr1:37991462~37991569:+
LUAD	cis	rs12468226	0.938	rs116109808	ENSG00000272966.1	RP11-686O6.1	5.84	9.85e-09	3.78e-06	0.45	0.26	Urate levels;	chr2:202287356	chr2:202336739~202337200:+
LUAD	cis	rs12468226	0.873	rs78175596	ENSG00000272966.1	RP11-686O6.1	5.84	9.85e-09	3.78e-06	0.45	0.26	Urate levels;	chr2:202287993	chr2:202336739~202337200:+
LUAD	cis	rs12468226	0.938	rs74454549	ENSG00000272966.1	RP11-686O6.1	5.84	9.85e-09	3.78e-06	0.45	0.26	Urate levels;	chr2:202288044	chr2:202336739~202337200:+
LUAD	cis	rs36093844	0.752	rs57534090	ENSG00000279742.1	RP11-700A24.1	-5.84	9.85e-09	3.78e-06	-0.34	-0.26	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85861977	chr11:85852557~85854943:-
LUAD	cis	rs27434	0.821	rs28337	ENSG00000272109.1	CTD-2260A17.3	-5.84	9.85e-09	3.78e-06	-0.31	-0.26	Ankylosing spondylitis;	chr5:96789611	chr5:96804353~96806105:+
LUAD	cis	rs30380	0.587	rs30185	ENSG00000272109.1	CTD-2260A17.3	-5.84	9.85e-09	3.78e-06	-0.31	-0.26	Cerebrospinal fluid biomarker levels;	chr5:96789762	chr5:96804353~96806105:+
LUAD	cis	rs12468226	0.873	rs78798541	ENSG00000226261.1	AC064836.3	5.84	9.86e-09	3.78e-06	0.44	0.26	Urate levels;	chr2:202194708	chr2:202336024~202336727:-
LUAD	cis	rs1816752	0.935	rs3816219	ENSG00000273628.1	RP11-756A22.7	5.84	9.86e-09	3.78e-06	0.3	0.26	Obesity-related traits;	chr13:24442995	chr13:24933006~24936796:+
LUAD	cis	rs875971	0.545	rs3936065	ENSG00000226824.5	RP4-756H11.3	-5.84	9.86e-09	3.78e-06	-0.38	-0.26	Aortic root size;	chr7:66325577	chr7:66654538~66669855:+
LUAD	cis	rs9859260	0.744	rs557527	ENSG00000231464.1	AC024937.4	-5.84	9.87e-09	3.78e-06	-0.3	-0.26	Mean corpuscular volume;	chr3:196053838	chr3:195996738~195998233:+
LUAD	cis	rs7712401	0.715	rs407392	ENSG00000263432.2	RN7SL689P	-5.84	9.87e-09	3.78e-06	-0.32	-0.26	Mean platelet volume;	chr5:123025299	chr5:123022487~123022783:-
LUAD	cis	rs75920871	0.588	rs7101763	ENSG00000254851.1	RP11-109L13.1	5.84	9.88e-09	3.79e-06	0.38	0.26	Subjective well-being;	chr11:117071269	chr11:117135528~117138582:+
LUAD	cis	rs62432291	0.681	rs431205	ENSG00000235086.1	FNDC1-IT1	-5.84	9.88e-09	3.79e-06	-0.44	-0.26	Joint mobility (Beighton score);	chr6:159241467	chr6:159240786~159243329:+
LUAD	cis	rs4713118	0.513	rs1225591	ENSG00000204709.4	LINC01556	5.83	9.9e-09	3.8e-06	0.35	0.26	Parkinson's disease;	chr6:28180974	chr6:28943877~28944537:+
LUAD	cis	rs4908768	0.501	rs1463051	ENSG00000232912.4	RP5-1115A15.1	-5.83	9.93e-09	3.81e-06	-0.24	-0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8536834	chr1:8424645~8434838:+
LUAD	cis	rs944289	0.561	rs1169122	ENSG00000257826.1	RP11-116N8.4	-5.83	9.93e-09	3.81e-06	-0.28	-0.26	Thyroid cancer;	chr14:36148896	chr14:36061026~36067190:-
LUAD	cis	rs9652601	0.622	rs1003603	ENSG00000274038.1	RP11-66H6.4	-5.83	9.94e-09	3.81e-06	-0.3	-0.26	Systemic lupus erythematosus;	chr16:11020766	chr16:11056556~11057034:+
LUAD	cis	rs12699921	0.598	rs1965534	ENSG00000279048.1	RP11-511H23.2	-5.83	9.95e-09	3.81e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17790488	chr7:17940503~17942922:+
LUAD	cis	rs1799949	1	rs2271573	ENSG00000267681.1	CTD-3199J23.6	-5.83	9.96e-09	3.82e-06	-0.31	-0.26	Menopause (age at onset);	chr17:43175604	chr17:43144956~43145255:+
LUAD	cis	rs948562	0.793	rs79170562	ENSG00000280010.1	AP001350.4	5.83	9.96e-09	3.82e-06	0.43	0.26	Lymphoma;	chr11:58604081	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.793	rs1944051	ENSG00000280010.1	AP001350.4	5.83	9.96e-09	3.82e-06	0.43	0.26	Lymphoma;	chr11:58607820	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.696	rs17568220	ENSG00000280010.1	AP001350.4	5.83	9.96e-09	3.82e-06	0.43	0.26	Lymphoma;	chr11:58627550	chr11:58627435~58628528:+
LUAD	cis	rs7945705	0.935	rs2568061	ENSG00000254860.4	TMEM9B-AS1	5.83	9.96e-09	3.82e-06	0.29	0.26	Hemoglobin concentration;	chr11:8864713	chr11:8964675~8977527:+
LUAD	cis	rs2455601	0.744	rs11042107	ENSG00000254860.4	TMEM9B-AS1	5.83	9.96e-09	3.82e-06	0.4	0.26	Schizophrenia;	chr11:8884324	chr11:8964675~8977527:+
LUAD	cis	rs12908161	1	rs35630683	ENSG00000225151.9	GOLGA2P7	-5.83	9.98e-09	3.82e-06	-0.34	-0.26	Schizophrenia;	chr15:84806000	chr15:84199311~84230136:-
LUAD	cis	rs10050311	0.858	rs72667705	ENSG00000251411.1	RP11-397E7.4	-5.83	9.99e-09	3.83e-06	-0.36	-0.26	Insulin-related traits;	chr4:86892986	chr4:86913266~86914817:-
LUAD	cis	rs7246657	0.722	rs2075284	ENSG00000276846.1	CTD-3220F14.3	-5.83	9.99e-09	3.83e-06	-0.35	-0.26	Coronary artery calcification;	chr19:37698715	chr19:37314868~37315620:-
LUAD	cis	rs765787	0.53	rs11634794	ENSG00000259520.4	CTD-2651B20.3	5.83	9.99e-09	3.83e-06	0.33	0.26	Uric acid levels;	chr15:45242294	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs11636404	ENSG00000259520.4	CTD-2651B20.3	5.83	9.99e-09	3.83e-06	0.33	0.26	Uric acid levels;	chr15:45243663	chr15:45251580~45279251:-
LUAD	cis	rs62246343	0.786	rs73126664	ENSG00000254485.4	RP11-380O24.1	5.83	1e-08	3.83e-06	0.37	0.26	Fibrinogen levels;	chr3:9362966	chr3:9292588~9363303:-
LUAD	cis	rs7618501	0.601	rs2624825	ENSG00000234667.1	ACTBP13	5.83	1e-08	3.84e-06	0.29	0.26	Intelligence (multi-trait analysis);	chr3:50117556	chr3:49873347~49877980:-
LUAD	cis	rs7618501	0.602	rs2071206	ENSG00000234667.1	ACTBP13	5.83	1e-08	3.84e-06	0.29	0.26	Intelligence (multi-trait analysis);	chr3:50122676	chr3:49873347~49877980:-
LUAD	cis	rs875971	0.862	rs11984115	ENSG00000237310.1	GS1-124K5.4	-5.83	1.01e-08	3.85e-06	-0.28	-0.26	Aortic root size;	chr7:66308872	chr7:66493706~66495474:+
LUAD	cis	rs4713118	0.868	rs35069907	ENSG00000219392.1	RP1-265C24.5	-5.83	1.01e-08	3.85e-06	-0.36	-0.26	Parkinson's disease;	chr6:27778913	chr6:28115628~28116551:+
LUAD	cis	rs66887589	0.807	rs9799664	ENSG00000245958.5	RP11-33B1.1	-5.83	1.01e-08	3.85e-06	-0.21	-0.26	Diastolic blood pressure;	chr4:119405523	chr4:119454791~119552025:+
LUAD	cis	rs6921919	0.583	rs3800328	ENSG00000216901.1	AL022393.7	5.83	1.01e-08	3.86e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.609	rs67211468	ENSG00000216901.1	AL022393.7	5.83	1.01e-08	3.86e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28176188~28176674:+
LUAD	cis	rs2412819	0.545	rs17795279	ENSG00000249839.1	AC011330.5	5.83	1.01e-08	3.86e-06	0.42	0.26	Lung cancer;	chr15:43637180	chr15:43663654~43684339:-
LUAD	cis	rs1075265	0.783	rs6545376	ENSG00000233266.1	HMGB1P31	5.83	1.01e-08	3.86e-06	0.33	0.26	Chronotype;Morning vs. evening chronotype;	chr2:53987685	chr2:54051334~54051760:+
LUAD	cis	rs2243480	1	rs160634	ENSG00000226824.5	RP4-756H11.3	5.83	1.01e-08	3.86e-06	0.45	0.26	Diabetic kidney disease;	chr7:66063677	chr7:66654538~66669855:+
LUAD	cis	rs1823913	0.599	rs1378156	ENSG00000280083.1	RP11-317J9.1	5.83	1.01e-08	3.87e-06	0.31	0.26	Obesity-related traits;	chr2:191272466	chr2:191154118~191156070:-
LUAD	cis	rs7804306	0.826	rs77672302	ENSG00000233264.2	AC006042.8	5.83	1.01e-08	3.87e-06	0.51	0.26	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8048681	chr7:7980312~7982228:+
LUAD	cis	rs8072100	0.875	rs62073966	ENSG00000228782.6	CTD-2026D20.3	-5.83	1.01e-08	3.87e-06	-0.27	-0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47522647	chr17:47450568~47492492:-
LUAD	cis	rs9640161	0.83	rs3735165	ENSG00000261305.1	RP4-584D14.7	5.83	1.01e-08	3.87e-06	0.35	0.26	Blood protein levels;Circulating chemerin levels;	chr7:150371282	chr7:150341771~150342607:+
LUAD	cis	rs10214930	0.647	rs11767188	ENSG00000235574.1	AC073150.6	-5.83	1.01e-08	3.87e-06	-0.32	-0.26	Hypospadias;	chr7:27532326	chr7:27491682~27492765:-
LUAD	cis	rs4972806	0.814	rs1446575	ENSG00000226363.3	HAGLROS	-5.83	1.01e-08	3.87e-06	-0.32	-0.26	IgG glycosylation;	chr2:176183073	chr2:176177717~176179008:+
LUAD	cis	rs8177876	0.915	rs8059692	ENSG00000261838.4	RP11-303E16.6	5.83	1.01e-08	3.87e-06	0.54	0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81096889	chr16:81069854~81076598:+
LUAD	cis	rs9309473	0.948	rs6719753	ENSG00000163016.8	ALMS1P	5.83	1.01e-08	3.87e-06	0.31	0.26	Metabolite levels;	chr2:73521927	chr2:73644919~73685576:+
LUAD	cis	rs2243480	1	rs160643	ENSG00000232546.1	RP11-458F8.1	-5.83	1.01e-08	3.88e-06	-0.31	-0.26	Diabetic kidney disease;	chr7:66093235	chr7:66848496~66858136:+
LUAD	cis	rs8081395	0.58	rs180515	ENSG00000266992.1	DHX40P1	5.83	1.01e-08	3.88e-06	0.32	0.26	White blood cell count;	chr17:59946914	chr17:59976009~60002384:-
LUAD	cis	rs2404602	0.552	rs11634428	ENSG00000259422.1	RP11-593F23.1	-5.83	1.01e-08	3.88e-06	-0.37	-0.26	Blood metabolite levels;	chr15:76792241	chr15:76174891~76181486:-
LUAD	cis	rs1113500	0.862	rs2336129	ENSG00000226822.1	RP11-356N1.2	-5.83	1.01e-08	3.88e-06	-0.3	-0.26	Growth-regulated protein alpha levels;	chr1:108098047	chr1:108071482~108074519:+
LUAD	cis	rs7246657	0.722	rs10410588	ENSG00000276846.1	CTD-3220F14.3	5.83	1.01e-08	3.88e-06	0.34	0.26	Coronary artery calcification;	chr19:37551508	chr19:37314868~37315620:-
LUAD	cis	rs2283792	0.765	rs2283793	ENSG00000224086.5	LL22NC03-86G7.1	-5.83	1.01e-08	3.88e-06	-0.25	-0.26	Multiple sclerosis;	chr22:21827189	chr22:21938293~21977632:+
LUAD	cis	rs72615157	0.613	rs56089143	ENSG00000242294.5	STAG3L5P	5.83	1.01e-08	3.88e-06	0.22	0.26	Lung function (FEV1/FVC);	chr7:100222221	chr7:100336079~100351900:+
LUAD	cis	rs9341808	0.556	rs1474791	ENSG00000272129.1	RP11-250B2.6	5.83	1.01e-08	3.88e-06	0.32	0.26	Sitting height ratio;	chr6:80323380	chr6:80355424~80356859:+
LUAD	cis	rs9652601	0.691	rs9921287	ENSG00000274038.1	RP11-66H6.4	-5.83	1.02e-08	3.89e-06	-0.31	-0.26	Systemic lupus erythematosus;	chr16:11115882	chr16:11056556~11057034:+
LUAD	cis	rs55665837	0.701	rs10160597	ENSG00000251991.1	RNU7-49P	5.83	1.02e-08	3.89e-06	0.3	0.26	Vitamin D levels;	chr11:14582446	chr11:14478892~14478953:+
LUAD	cis	rs293748	0.54	rs6879284	ENSG00000250155.1	CTD-2353F22.1	-5.83	1.02e-08	3.89e-06	-0.31	-0.26	Obesity-related traits;	chr5:37230185	chr5:36666214~36725195:-
LUAD	cis	rs7246657	0.722	rs16958861	ENSG00000276846.1	CTD-3220F14.3	5.83	1.02e-08	3.89e-06	0.34	0.26	Coronary artery calcification;	chr19:37633278	chr19:37314868~37315620:-
LUAD	cis	rs36423	0.528	rs1205066	ENSG00000266869.1	RP6-114E22.1	5.83	1.02e-08	3.89e-06	0.38	0.26	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71880340	chr14:71848606~71908430:+
LUAD	cis	rs2243480	1	rs4718334	ENSG00000230295.1	RP11-458F8.2	5.83	1.02e-08	3.89e-06	0.31	0.26	Diabetic kidney disease;	chr7:66324467	chr7:66880708~66882981:+
LUAD	cis	rs172166	0.652	rs476167	ENSG00000204709.4	LINC01556	5.83	1.02e-08	3.9e-06	0.33	0.26	Cardiac Troponin-T levels;	chr6:28098110	chr6:28943877~28944537:+
LUAD	cis	rs172166	0.694	rs203892	ENSG00000204709.4	LINC01556	5.83	1.02e-08	3.9e-06	0.33	0.26	Cardiac Troponin-T levels;	chr6:28099418	chr6:28943877~28944537:+
LUAD	cis	rs858239	0.601	rs4599714	ENSG00000230042.1	AK3P3	-5.83	1.02e-08	3.9e-06	-0.32	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.601	rs10278776	ENSG00000230042.1	AK3P3	-5.83	1.02e-08	3.9e-06	-0.32	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23129178~23129841:+
LUAD	cis	rs12699921	0.632	rs2723496	ENSG00000279048.1	RP11-511H23.2	-5.83	1.02e-08	3.9e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17786367	chr7:17940503~17942922:+
LUAD	cis	rs12699921	0.632	rs2691553	ENSG00000279048.1	RP11-511H23.2	-5.83	1.02e-08	3.9e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17786658	chr7:17940503~17942922:+
LUAD	cis	rs12699921	0.598	rs1852010	ENSG00000279048.1	RP11-511H23.2	-5.83	1.02e-08	3.9e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17786744	chr7:17940503~17942922:+
LUAD	cis	rs2212361	0.558	rs12294732	ENSG00000255893.1	RP11-685N10.1	-5.83	1.02e-08	3.9e-06	-0.33	-0.26	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94531716	chr11:94472908~94473570:-
LUAD	cis	rs2212361	0.527	rs12282965	ENSG00000255893.1	RP11-685N10.1	-5.83	1.02e-08	3.9e-06	-0.34	-0.26	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94528348	chr11:94472908~94473570:-
LUAD	cis	rs367615	0.68	rs166181	ENSG00000249476.1	CTD-2587M2.1	5.83	1.02e-08	3.91e-06	0.33	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109648392	chr5:109237120~109326369:-
LUAD	cis	rs944289	0.6	rs2415320	ENSG00000257826.1	RP11-116N8.4	-5.83	1.02e-08	3.91e-06	-0.29	-0.26	Thyroid cancer;	chr14:36148733	chr14:36061026~36067190:-
LUAD	cis	rs11020821	0.884	rs12286498	ENSG00000255893.1	RP11-685N10.1	-5.83	1.02e-08	3.91e-06	-0.34	-0.26	Response to angiotensin II receptor blocker therapy;Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94529857	chr11:94472908~94473570:-
LUAD	cis	rs1075265	0.836	rs1363063	ENSG00000233266.1	HMGB1P31	5.83	1.02e-08	3.91e-06	0.33	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54047433	chr2:54051334~54051760:+
LUAD	cis	rs875971	0.862	rs6460302	ENSG00000222364.1	RNU6-96P	-5.83	1.02e-08	3.91e-06	-0.29	-0.26	Aortic root size;	chr7:66495270	chr7:66395191~66395286:+
LUAD	cis	rs75920871	0.588	rs4548653	ENSG00000254851.1	RP11-109L13.1	5.83	1.02e-08	3.92e-06	0.38	0.26	Subjective well-being;	chr11:117032600	chr11:117135528~117138582:+
LUAD	cis	rs1799949	0.965	rs9646413	ENSG00000267681.1	CTD-3199J23.6	-5.83	1.02e-08	3.92e-06	-0.29	-0.26	Menopause (age at onset);	chr17:43348789	chr17:43144956~43145255:+
LUAD	cis	rs67311347	0.824	rs59922539	ENSG00000223797.4	ENTPD3-AS1	5.83	1.03e-08	3.92e-06	0.28	0.26	Renal cell carcinoma;	chr3:40295619	chr3:40313802~40453329:-
LUAD	cis	rs12699921	0.568	rs67452591	ENSG00000279048.1	RP11-511H23.2	-5.83	1.03e-08	3.92e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17876573	chr7:17940503~17942922:+
LUAD	cis	rs17214007	0.735	rs2075513	ENSG00000263335.1	AF001548.5	-5.83	1.03e-08	3.93e-06	-0.37	-0.26	Cognitive function;	chr16:15782614	chr16:15726674~15732993:+
LUAD	cis	rs4972806	0.849	rs1542180	ENSG00000226363.3	HAGLROS	-5.83	1.03e-08	3.93e-06	-0.32	-0.26	IgG glycosylation;	chr2:176164039	chr2:176177717~176179008:+
LUAD	cis	rs2439831	0.85	rs28413704	ENSG00000205771.5	CATSPER2P1	-5.83	1.03e-08	3.93e-06	-0.53	-0.26	Lung cancer in ever smokers;	chr15:43856229	chr15:43726918~43747094:-
LUAD	cis	rs10214930	0.647	rs2098316	ENSG00000235574.1	AC073150.6	-5.83	1.03e-08	3.93e-06	-0.32	-0.26	Hypospadias;	chr7:27529018	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs2080246	ENSG00000235574.1	AC073150.6	-5.83	1.03e-08	3.93e-06	-0.32	-0.26	Hypospadias;	chr7:27530085	chr7:27491682~27492765:-
LUAD	cis	rs12908161	1	rs11632465	ENSG00000225151.9	GOLGA2P7	-5.83	1.03e-08	3.93e-06	-0.35	-0.26	Schizophrenia;	chr15:84738814	chr15:84199311~84230136:-
LUAD	cis	rs66887589	0.967	rs2892869	ENSG00000248280.1	RP11-33B1.2	-5.83	1.03e-08	3.93e-06	-0.28	-0.26	Diastolic blood pressure;	chr4:119600142	chr4:119440561~119450157:-
LUAD	cis	rs11651753	0.636	rs4794332	ENSG00000264920.1	RP11-6N17.4	-5.83	1.03e-08	3.94e-06	-0.32	-0.26	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47963201	chr17:47891255~47895812:-
LUAD	cis	rs1134634	0.52	rs4280723	ENSG00000273133.1	RP11-799M12.2	5.83	1.03e-08	3.94e-06	0.37	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15574095	chr4:15563698~15564253:-
LUAD	cis	rs12188164	0.515	rs11742006	ENSG00000225138.6	CTD-2228K2.7	5.83	1.03e-08	3.94e-06	0.25	0.26	Cystic fibrosis severity;	chr5:408414	chr5:473236~480884:+
LUAD	cis	rs4713118	0.513	rs149954	ENSG00000204709.4	LINC01556	5.83	1.03e-08	3.94e-06	0.33	0.26	Parkinson's disease;	chr6:28067468	chr6:28943877~28944537:+
LUAD	cis	rs9860428	0.774	rs9814008	ENSG00000242770.2	RP11-180K7.1	5.83	1.03e-08	3.95e-06	0.27	0.26	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112845336	chr3:112802478~112812819:+
LUAD	cis	rs11651753	0.689	rs2525107	ENSG00000264920.1	RP11-6N17.4	5.83	1.03e-08	3.95e-06	0.32	0.26	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47964038	chr17:47891255~47895812:-
LUAD	cis	rs875971	0.862	rs13232191	ENSG00000237310.1	GS1-124K5.4	5.83	1.03e-08	3.95e-06	0.28	0.26	Aortic root size;	chr7:66521661	chr7:66493706~66495474:+
LUAD	cis	rs12554020	0.786	rs78271342	ENSG00000227603.1	RP11-165J3.6	5.83	1.03e-08	3.95e-06	0.48	0.26	Schizophrenia;	chr9:93468959	chr9:93435332~93437121:-
LUAD	cis	rs1707322	0.827	rs6694302	ENSG00000234329.1	RP11-767N6.2	5.83	1.03e-08	3.95e-06	0.27	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45779973	chr1:45651039~45651826:-
LUAD	cis	rs858239	0.632	rs13438452	ENSG00000230042.1	AK3P3	-5.83	1.03e-08	3.95e-06	-0.32	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23129178~23129841:+
LUAD	cis	rs12468226	0.938	rs6435139	ENSG00000272966.1	RP11-686O6.1	-5.83	1.04e-08	3.96e-06	-0.43	-0.26	Urate levels;	chr2:202255145	chr2:202336739~202337200:+
LUAD	cis	rs3096299	0.754	rs3102382	ENSG00000274627.1	RP11-104N10.2	5.83	1.04e-08	3.96e-06	0.24	0.26	Multiple myeloma (IgH translocation);	chr16:89343334	chr16:89516797~89522217:+
LUAD	cis	rs7712401	0.715	rs6862366	ENSG00000263432.2	RN7SL689P	-5.83	1.04e-08	3.96e-06	-0.32	-0.26	Mean platelet volume;	chr5:123024463	chr5:123022487~123022783:-
LUAD	cis	rs2255336	0.938	rs12298043	ENSG00000245648.1	RP11-277P12.20	-5.83	1.04e-08	3.96e-06	-0.41	-0.26	Blood protein levels;	chr12:10456883	chr12:10363769~10398506:+
LUAD	cis	rs4835473	0.9	rs10032963	ENSG00000251600.4	RP11-673E1.1	5.83	1.04e-08	3.96e-06	0.31	0.26	Immature fraction of reticulocytes;	chr4:143733068	chr4:143912331~143982454:+
LUAD	cis	rs2117029	0.521	rs12229524	ENSG00000258017.1	RP11-386G11.10	-5.83	1.04e-08	3.97e-06	-0.32	-0.26	Intelligence (multi-trait analysis);	chr12:49191570	chr12:49127782~49147869:+
LUAD	cis	rs2179367	0.632	rs10155766	ENSG00000231760.4	RP11-350J20.5	5.83	1.04e-08	3.97e-06	0.37	0.26	Dupuytren's disease;	chr6:149364577	chr6:149796151~149826294:-
LUAD	cis	rs5753618	0.561	rs9609264	ENSG00000236132.1	CTA-440B3.1	-5.83	1.04e-08	3.97e-06	-0.32	-0.26	Colorectal cancer;	chr22:31350733	chr22:31816379~31817491:-
LUAD	cis	rs7829975	0.774	rs1703982	ENSG00000253893.2	FAM85B	5.83	1.04e-08	3.98e-06	0.33	0.26	Mood instability;	chr8:8740878	chr8:8167819~8226614:-
LUAD	cis	rs12468226	0.938	rs12464254	ENSG00000272966.1	RP11-686O6.1	5.83	1.04e-08	3.98e-06	0.45	0.26	Urate levels;	chr2:202301641	chr2:202336739~202337200:+
LUAD	cis	rs12439619	0.705	rs4778665	ENSG00000255769.6	GOLGA2P10	-5.83	1.04e-08	3.98e-06	-0.34	-0.26	Intelligence (multi-trait analysis);	chr15:82144163	chr15:82472993~82513950:-
LUAD	cis	rs875971	0.862	rs7798630	ENSG00000237310.1	GS1-124K5.4	-5.83	1.04e-08	3.98e-06	-0.28	-0.26	Aortic root size;	chr7:66306492	chr7:66493706~66495474:+
LUAD	cis	rs9813712	0.548	rs9880123	ENSG00000249846.5	RP11-77P16.4	-5.83	1.05e-08	3.99e-06	-0.3	-0.26	Response to amphetamines;	chr3:130215275	chr3:130112550~130120579:+
LUAD	cis	rs35955747	0.722	rs5997898	ENSG00000236132.1	CTA-440B3.1	5.83	1.05e-08	3.99e-06	0.29	0.26	Neutrophil count;Sum basophil neutrophil counts;	chr22:31176977	chr22:31816379~31817491:-
LUAD	cis	rs7044106	0.762	rs7849566	ENSG00000238181.2	AHCYP2	-5.82	1.05e-08	3.99e-06	-0.33	-0.26	Hip circumference adjusted for BMI;	chr9:120698491	chr9:120720673~120721972:+
LUAD	cis	rs8177876	0.749	rs75923695	ENSG00000261061.1	RP11-303E16.2	-5.82	1.05e-08	4e-06	-0.44	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81060289	chr16:81030770~81031485:+
LUAD	cis	rs1134634	0.52	rs73125606	ENSG00000273133.1	RP11-799M12.2	-5.82	1.05e-08	4e-06	-0.37	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15545691	chr4:15563698~15564253:-
LUAD	cis	rs11096990	0.855	rs2711988	ENSG00000249207.1	RP11-360F5.1	5.82	1.05e-08	4e-06	0.3	0.26	Cognitive function;	chr4:39151128	chr4:39112677~39126818:-
LUAD	cis	rs2243480	0.522	rs1638736	ENSG00000226824.5	RP4-756H11.3	-5.82	1.05e-08	4.01e-06	-0.54	-0.26	Diabetic kidney disease;	chr7:66627321	chr7:66654538~66669855:+
LUAD	cis	rs7246657	0.722	rs35863684	ENSG00000276846.1	CTD-3220F14.3	5.82	1.05e-08	4.01e-06	0.34	0.26	Coronary artery calcification;	chr19:37618876	chr19:37314868~37315620:-
LUAD	cis	rs7221109	0.522	rs2462970	ENSG00000278834.1	RP11-458J1.1	-5.82	1.05e-08	4.01e-06	-0.29	-0.26	Type 1 diabetes;	chr17:40714797	chr17:40648300~40649718:+
LUAD	cis	rs66887589	0.967	rs1155577	ENSG00000245958.5	RP11-33B1.1	5.82	1.05e-08	4.01e-06	0.21	0.26	Diastolic blood pressure;	chr4:119528655	chr4:119454791~119552025:+
LUAD	cis	rs12908161	1	rs60957376	ENSG00000225151.9	GOLGA2P7	-5.82	1.05e-08	4.02e-06	-0.35	-0.26	Schizophrenia;	chr15:84737561	chr15:84199311~84230136:-
LUAD	cis	rs4664293	0.801	rs6432552	ENSG00000226266.5	AC009961.3	-5.82	1.05e-08	4.02e-06	-0.35	-0.26	Monocyte percentage of white cells;	chr2:159717613	chr2:159670708~159712435:-
LUAD	cis	rs2439831	0.702	rs9989313	ENSG00000205771.5	CATSPER2P1	-5.82	1.05e-08	4.02e-06	-0.53	-0.26	Lung cancer in ever smokers;	chr15:43860619	chr15:43726918~43747094:-
LUAD	cis	rs3096299	0.702	rs2086825	ENSG00000274627.1	RP11-104N10.2	5.82	1.05e-08	4.02e-06	0.24	0.26	Multiple myeloma (IgH translocation);	chr16:89405134	chr16:89516797~89522217:+
LUAD	cis	rs875971	0.862	rs4718330	ENSG00000222364.1	RNU6-96P	5.82	1.05e-08	4.02e-06	0.29	0.26	Aortic root size;	chr7:66250256	chr7:66395191~66395286:+
LUAD	cis	rs6687821	0.515	rs10489917	ENSG00000267734.1	RP4-604K5.3	5.82	1.05e-08	4.02e-06	0.31	0.26	Yeast infection;	chr1:86932105	chr1:86932199~86934891:-
LUAD	cis	rs6687821	0.515	rs12072434	ENSG00000267734.1	RP4-604K5.3	5.82	1.05e-08	4.02e-06	0.31	0.26	Yeast infection;	chr1:86935026	chr1:86932199~86934891:-
LUAD	cis	rs6687821	0.515	rs1923144	ENSG00000267734.1	RP4-604K5.3	5.82	1.05e-08	4.02e-06	0.31	0.26	Yeast infection;	chr1:86938548	chr1:86932199~86934891:-
LUAD	cis	rs5753618	0.583	rs5753631	ENSG00000236132.1	CTA-440B3.1	-5.82	1.06e-08	4.03e-06	-0.32	-0.26	Colorectal cancer;	chr22:31467036	chr22:31816379~31817491:-
LUAD	cis	rs2562456	0.917	rs10420016	ENSG00000268081.1	RP11-678G14.2	-5.82	1.06e-08	4.04e-06	-0.39	-0.26	Pain;	chr19:21505800	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.917	rs2681389	ENSG00000268081.1	RP11-678G14.2	-5.82	1.06e-08	4.04e-06	-0.39	-0.26	Pain;	chr19:21509773	chr19:21554640~21569237:-
LUAD	cis	rs7829975	0.623	rs10087493	ENSG00000173295.6	FAM86B3P	-5.82	1.06e-08	4.04e-06	-0.28	-0.26	Mood instability;	chr8:8516047	chr8:8228595~8244865:+
LUAD	cis	rs62432291	0.681	rs294912	ENSG00000235086.1	FNDC1-IT1	-5.82	1.06e-08	4.04e-06	-0.45	-0.26	Joint mobility (Beighton score);	chr6:159246305	chr6:159240786~159243329:+
LUAD	cis	rs17023223	0.537	rs6662165	ENSG00000231365.4	RP11-418J17.1	-5.82	1.06e-08	4.04e-06	-0.35	-0.26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119071448	chr1:119140396~119275973:+
LUAD	cis	rs2276314	0.762	rs3826600	ENSG00000278986.1	RP11-723J4.3	-5.82	1.06e-08	4.04e-06	-0.31	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:36029090	chr18:35972151~35973916:+
LUAD	cis	rs12468226	0.574	rs4675271	ENSG00000273456.1	RP11-686O6.2	-5.82	1.06e-08	4.04e-06	-0.35	-0.26	Urate levels;	chr2:202170967	chr2:202374932~202375604:-
LUAD	cis	rs1707322	0.785	rs10890348	ENSG00000234329.1	RP11-767N6.2	5.82	1.06e-08	4.04e-06	0.27	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776751	chr1:45651039~45651826:-
LUAD	cis	rs897984	0.542	rs4468641	ENSG00000260911.2	RP11-196G11.2	5.82	1.06e-08	4.04e-06	0.23	0.26	Dementia with Lewy bodies;	chr16:31085555	chr16:31043150~31049868:+
LUAD	cis	rs56046484	1	rs2304415	ENSG00000259295.5	CSPG4P12	5.82	1.06e-08	4.05e-06	0.36	0.26	Testicular germ cell tumor;	chr15:85075610	chr15:85191438~85213905:+
LUAD	cis	rs66887589	0.72	rs2036858	ENSG00000245958.5	RP11-33B1.1	-5.82	1.06e-08	4.05e-06	-0.21	-0.26	Diastolic blood pressure;	chr4:119328082	chr4:119454791~119552025:+
LUAD	cis	rs12908161	0.92	rs35738019	ENSG00000225151.9	GOLGA2P7	-5.82	1.06e-08	4.05e-06	-0.35	-0.26	Schizophrenia;	chr15:84736979	chr15:84199311~84230136:-
LUAD	cis	rs12908161	1	rs34570071	ENSG00000225151.9	GOLGA2P7	-5.82	1.06e-08	4.05e-06	-0.35	-0.26	Schizophrenia;	chr15:84736981	chr15:84199311~84230136:-
LUAD	cis	rs17684571	0.751	rs17684941	ENSG00000231441.1	RP11-472M19.2	-5.82	1.06e-08	4.05e-06	-0.39	-0.26	Schizophrenia;	chr6:56862636	chr6:56844002~56864078:+
LUAD	cis	rs9595908	0.655	rs56080053	ENSG00000212293.1	SNORA16	5.82	1.06e-08	4.05e-06	0.28	0.26	Body mass index;	chr13:32720045	chr13:32420390~32420516:-
LUAD	cis	rs673078	0.66	rs61945176	ENSG00000275409.1	RP11-131L12.4	-5.82	1.06e-08	4.06e-06	-0.34	-0.26	Glucose homeostasis traits;	chr12:118204735	chr12:118430147~118430699:+
LUAD	cis	rs10129255	0.589	rs78599641	ENSG00000211967.3	IGHV3-53	-5.82	1.06e-08	4.06e-06	-0.2	-0.26	Kawasaki disease;	chr14:106637576	chr14:106592676~106593347:-
LUAD	cis	rs12699921	0.599	rs998342	ENSG00000279048.1	RP11-511H23.2	-5.82	1.07e-08	4.06e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17785965	chr7:17940503~17942922:+
LUAD	cis	rs755249	0.532	rs2296173	ENSG00000228060.1	RP11-69E11.8	-5.82	1.07e-08	4.07e-06	-0.26	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39447679	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs3118014	ENSG00000228060.1	RP11-69E11.8	-5.82	1.07e-08	4.07e-06	-0.26	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39448418	chr1:39565160~39573203:+
LUAD	cis	rs875971	0.658	rs432667	ENSG00000222364.1	RNU6-96P	-5.82	1.07e-08	4.07e-06	-0.29	-0.26	Aortic root size;	chr7:66049646	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs908915	ENSG00000237310.1	GS1-124K5.4	-5.82	1.07e-08	4.07e-06	-0.28	-0.26	Aortic root size;	chr7:66149664	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs7809814	ENSG00000237310.1	GS1-124K5.4	-5.82	1.07e-08	4.07e-06	-0.28	-0.26	Aortic root size;	chr7:66150410	chr7:66493706~66495474:+
LUAD	cis	rs8177876	0.658	rs2316730	ENSG00000261838.4	RP11-303E16.6	5.82	1.07e-08	4.08e-06	0.57	0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81106035	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.915	rs6420421	ENSG00000261838.4	RP11-303E16.6	-5.82	1.07e-08	4.08e-06	-0.54	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81094601	chr16:81069854~81076598:+
LUAD	cis	rs8177876	0.749	rs5023849	ENSG00000261838.4	RP11-303E16.6	-5.82	1.07e-08	4.08e-06	-0.54	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81094694	chr16:81069854~81076598:+
LUAD	cis	rs858239	0.601	rs1981665	ENSG00000230042.1	AK3P3	-5.82	1.07e-08	4.08e-06	-0.32	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23129178~23129841:+
LUAD	cis	rs2412819	0.571	rs4923964	ENSG00000249839.1	AC011330.5	5.82	1.07e-08	4.09e-06	0.41	0.26	Lung cancer;	chr15:43722882	chr15:43663654~43684339:-
LUAD	cis	rs755249	0.567	rs17264671	ENSG00000228060.1	RP11-69E11.8	-5.82	1.07e-08	4.09e-06	-0.26	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39352380	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs4660690	ENSG00000228060.1	RP11-69E11.8	-5.82	1.07e-08	4.09e-06	-0.26	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39353831	chr1:39565160~39573203:+
LUAD	cis	rs6687821	0.515	rs496588	ENSG00000267734.1	RP4-604K5.3	5.82	1.07e-08	4.09e-06	0.32	0.26	Yeast infection;	chr1:86858728	chr1:86932199~86934891:-
LUAD	cis	rs6921919	0.583	rs6922169	ENSG00000216901.1	AL022393.7	5.82	1.07e-08	4.09e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.559	rs13210866	ENSG00000216901.1	AL022393.7	5.82	1.07e-08	4.09e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs13201726	ENSG00000216901.1	AL022393.7	5.82	1.07e-08	4.09e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs2027361	ENSG00000216901.1	AL022393.7	5.82	1.07e-08	4.09e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28176188~28176674:+
LUAD	cis	rs897984	0.609	rs17839567	ENSG00000260911.2	RP11-196G11.2	5.82	1.08e-08	4.1e-06	0.23	0.26	Dementia with Lewy bodies;	chr16:31046624	chr16:31043150~31049868:+
LUAD	cis	rs673078	0.607	rs7305647	ENSG00000275409.1	RP11-131L12.4	-5.82	1.08e-08	4.1e-06	-0.36	-0.26	Glucose homeostasis traits;	chr12:118417761	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs61943444	ENSG00000275409.1	RP11-131L12.4	-5.82	1.08e-08	4.1e-06	-0.36	-0.26	Glucose homeostasis traits;	chr12:118421641	chr12:118430147~118430699:+
LUAD	cis	rs2111504	0.806	rs7252443	ENSG00000267213.4	AC007773.2	-5.82	1.08e-08	4.1e-06	-0.36	-0.26	Bipolar disorder;	chr19:32449827	chr19:32390050~32405560:-
LUAD	cis	rs1075265	0.729	rs7571086	ENSG00000233266.1	HMGB1P31	5.82	1.08e-08	4.1e-06	0.32	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54007899	chr2:54051334~54051760:+
LUAD	cis	rs516805	0.748	rs11154078	ENSG00000279453.1	RP3-425C14.4	5.82	1.08e-08	4.11e-06	0.35	0.26	Lymphocyte counts;	chr6:122387058	chr6:122436789~122439223:-
LUAD	cis	rs73219805	1	rs17310286	ENSG00000228451.3	SDAD1P1	5.82	1.08e-08	4.11e-06	0.38	0.26	Schizophrenia;	chr8:26411516	chr8:26379259~26382953:-
LUAD	cis	rs1707322	0.827	rs12125508	ENSG00000234329.1	RP11-767N6.2	5.82	1.08e-08	4.11e-06	0.27	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45780338	chr1:45651039~45651826:-
LUAD	cis	rs2243480	1	rs422164	ENSG00000230295.1	RP11-458F8.2	-5.82	1.08e-08	4.11e-06	-0.31	-0.26	Diabetic kidney disease;	chr7:66121618	chr7:66880708~66882981:+
LUAD	cis	rs2243480	0.908	rs1532573	ENSG00000230295.1	RP11-458F8.2	5.82	1.08e-08	4.11e-06	0.31	0.26	Diabetic kidney disease;	chr7:66333815	chr7:66880708~66882981:+
LUAD	cis	rs2283792	0.74	rs2283791	ENSG00000224086.5	LL22NC03-86G7.1	-5.82	1.08e-08	4.12e-06	-0.25	-0.26	Multiple sclerosis;	chr22:21776656	chr22:21938293~21977632:+
LUAD	cis	rs2404602	0.684	rs10851888	ENSG00000259422.1	RP11-593F23.1	-5.82	1.08e-08	4.12e-06	-0.35	-0.26	Blood metabolite levels;	chr15:76610165	chr15:76174891~76181486:-
LUAD	cis	rs9859260	0.71	rs41298097	ENSG00000231464.1	AC024937.4	-5.82	1.09e-08	4.13e-06	-0.3	-0.26	Mean corpuscular volume;	chr3:196052284	chr3:195996738~195998233:+
LUAD	cis	rs9859260	0.71	rs34906439	ENSG00000231464.1	AC024937.4	-5.82	1.09e-08	4.13e-06	-0.3	-0.26	Mean corpuscular volume;	chr3:196052835	chr3:195996738~195998233:+
LUAD	cis	rs9309473	1	rs3813227	ENSG00000163016.8	ALMS1P	-5.82	1.09e-08	4.13e-06	-0.31	-0.26	Metabolite levels;	chr2:73424839	chr2:73644919~73685576:+
LUAD	cis	rs875971	0.862	rs12537823	ENSG00000222364.1	RNU6-96P	-5.82	1.09e-08	4.13e-06	-0.29	-0.26	Aortic root size;	chr7:66255897	chr7:66395191~66395286:+
LUAD	cis	rs7772486	0.597	rs6912351	ENSG00000235652.6	RP11-545I5.3	-5.82	1.09e-08	4.14e-06	-0.27	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145942935	chr6:145799409~145886585:+
LUAD	cis	rs6921919	0.583	rs6928771	ENSG00000216901.1	AL022393.7	5.82	1.09e-08	4.14e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28176188~28176674:+
LUAD	cis	rs6921919	0.583	rs6928773	ENSG00000216901.1	AL022393.7	5.82	1.09e-08	4.14e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28176188~28176674:+
LUAD	cis	rs875971	1	rs11974219	ENSG00000237310.1	GS1-124K5.4	-5.82	1.09e-08	4.14e-06	-0.27	-0.26	Aortic root size;	chr7:66182423	chr7:66493706~66495474:+
LUAD	cis	rs6921919	0.609	rs9461455	ENSG00000216901.1	AL022393.7	5.82	1.09e-08	4.14e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28176188~28176674:+
LUAD	cis	rs9309473	0.948	rs2421577	ENSG00000163016.8	ALMS1P	5.82	1.09e-08	4.15e-06	0.31	0.26	Metabolite levels;	chr2:73613871	chr2:73644919~73685576:+
LUAD	cis	rs12699921	0.632	rs2723503	ENSG00000279048.1	RP11-511H23.2	-5.82	1.09e-08	4.15e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17782012	chr7:17940503~17942922:+
LUAD	cis	rs12699921	0.632	rs10264355	ENSG00000279048.1	RP11-511H23.2	5.82	1.09e-08	4.15e-06	0.21	0.26	Fibrinogen levels;	chr7:17782391	chr7:17940503~17942922:+
LUAD	cis	rs12699921	0.632	rs10264445	ENSG00000279048.1	RP11-511H23.2	5.82	1.09e-08	4.15e-06	0.21	0.26	Fibrinogen levels;	chr7:17782425	chr7:17940503~17942922:+
LUAD	cis	rs12699921	0.607	rs10264447	ENSG00000279048.1	RP11-511H23.2	5.82	1.09e-08	4.15e-06	0.21	0.26	Fibrinogen levels;	chr7:17782430	chr7:17940503~17942922:+
LUAD	cis	rs4908768	0.501	rs6577491	ENSG00000232912.4	RP5-1115A15.1	5.82	1.09e-08	4.15e-06	0.24	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8514913	chr1:8424645~8434838:+
LUAD	cis	rs4713118	0.513	rs149897	ENSG00000204709.4	LINC01556	5.82	1.09e-08	4.15e-06	0.33	0.26	Parkinson's disease;	chr6:28038872	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.513	rs156734	ENSG00000204709.4	LINC01556	5.82	1.09e-08	4.15e-06	0.33	0.26	Parkinson's disease;	chr6:28039579	chr6:28943877~28944537:+
LUAD	cis	rs4908768	0.501	rs11121201	ENSG00000232912.4	RP5-1115A15.1	5.82	1.09e-08	4.16e-06	0.24	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8572732	chr1:8424645~8434838:+
LUAD	cis	rs916888	0.773	rs1378358	ENSG00000261575.2	RP11-259G18.1	5.82	1.09e-08	4.16e-06	0.41	0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46267037~46268694:+
LUAD	cis	rs9595908	0.686	rs9591314	ENSG00000212293.1	SNORA16	5.82	1.09e-08	4.16e-06	0.28	0.26	Body mass index;	chr13:32760248	chr13:32420390~32420516:-
LUAD	cis	rs56080343	0.808	rs1045552	ENSG00000275409.1	RP11-131L12.4	-5.82	1.09e-08	4.16e-06	-0.36	-0.26	Neuroticism;	chr12:118417678	chr12:118430147~118430699:+
LUAD	cis	rs10129255	0.53	rs11624912	ENSG00000211967.3	IGHV3-53	-5.82	1.1e-08	4.17e-06	-0.18	-0.26	Kawasaki disease;	chr14:106673891	chr14:106592676~106593347:-
LUAD	cis	rs293748	0.771	rs167146	ENSG00000250155.1	CTD-2353F22.1	-5.82	1.1e-08	4.17e-06	-0.36	-0.26	Obesity-related traits;	chr5:36922204	chr5:36666214~36725195:-
LUAD	cis	rs12699921	0.598	rs2691602	ENSG00000279048.1	RP11-511H23.2	-5.82	1.1e-08	4.17e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17836153	chr7:17940503~17942922:+
LUAD	cis	rs72615157	0.634	rs79986079	ENSG00000242294.5	STAG3L5P	5.82	1.1e-08	4.18e-06	0.22	0.26	Lung function (FEV1/FVC);	chr7:100204421	chr7:100336079~100351900:+
LUAD	cis	rs875971	0.564	rs313804	ENSG00000222364.1	RNU6-96P	-5.82	1.1e-08	4.18e-06	-0.29	-0.26	Aortic root size;	chr7:66049635	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.662	rs448725	ENSG00000222364.1	RNU6-96P	-5.82	1.1e-08	4.18e-06	-0.29	-0.26	Aortic root size;	chr7:66049641	chr7:66395191~66395286:+
LUAD	cis	rs2243480	1	rs316313	ENSG00000230295.1	RP11-458F8.2	-5.82	1.1e-08	4.18e-06	-0.31	-0.26	Diabetic kidney disease;	chr7:66128561	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs316312	ENSG00000230295.1	RP11-458F8.2	-5.82	1.1e-08	4.18e-06	-0.31	-0.26	Diabetic kidney disease;	chr7:66131504	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs419603	ENSG00000230295.1	RP11-458F8.2	-5.82	1.1e-08	4.18e-06	-0.31	-0.26	Diabetic kidney disease;	chr7:66132354	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs387676	ENSG00000230295.1	RP11-458F8.2	-5.82	1.1e-08	4.18e-06	-0.31	-0.26	Diabetic kidney disease;	chr7:66133233	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs13310597	ENSG00000230295.1	RP11-458F8.2	-5.82	1.1e-08	4.18e-06	-0.31	-0.26	Diabetic kidney disease;	chr7:66133553	chr7:66880708~66882981:+
LUAD	cis	rs12699921	0.632	rs1524776	ENSG00000279048.1	RP11-511H23.2	-5.82	1.1e-08	4.18e-06	-0.2	-0.26	Fibrinogen levels;	chr7:17832470	chr7:17940503~17942922:+
LUAD	cis	rs4835473	0.932	rs13119602	ENSG00000251600.4	RP11-673E1.1	-5.82	1.1e-08	4.19e-06	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143736621	chr4:143912331~143982454:+
LUAD	cis	rs7674212	0.581	rs13150953	ENSG00000251288.2	RP11-10L12.2	-5.82	1.1e-08	4.19e-06	-0.32	-0.26	Type 2 diabetes;	chr4:103021341	chr4:102751401~102752641:+
LUAD	cis	rs7674212	0.556	rs13151569	ENSG00000251288.2	RP11-10L12.2	-5.82	1.1e-08	4.19e-06	-0.32	-0.26	Type 2 diabetes;	chr4:103021633	chr4:102751401~102752641:+
LUAD	cis	rs150992	0.688	rs161947	ENSG00000248489.1	CTD-2007H13.3	5.82	1.1e-08	4.19e-06	0.34	0.26	Body mass index;	chr5:98932868	chr5:98929171~98995013:+
LUAD	cis	rs2919009	0.537	rs11199650	ENSG00000271670.1	RP11-95I16.4	5.82	1.1e-08	4.19e-06	0.31	0.26	Obesity-related traits;	chr10:120923297	chr10:120879256~120880667:-
LUAD	cis	rs66887589	0.87	rs10518336	ENSG00000245958.5	RP11-33B1.1	-5.82	1.1e-08	4.19e-06	-0.21	-0.26	Diastolic blood pressure;	chr4:119601779	chr4:119454791~119552025:+
LUAD	cis	rs75920871	0.588	rs4620758	ENSG00000254851.1	RP11-109L13.1	5.82	1.1e-08	4.2e-06	0.38	0.26	Subjective well-being;	chr11:117075002	chr11:117135528~117138582:+
LUAD	cis	rs35160687	0.712	rs4832261	ENSG00000273080.1	RP11-301O19.1	5.82	1.11e-08	4.2e-06	0.28	0.26	Night sleep phenotypes;	chr2:86257375	chr2:86195590~86196049:+
LUAD	cis	rs7044106	0.762	rs1324473	ENSG00000238181.2	AHCYP2	5.81	1.11e-08	4.2e-06	0.32	0.26	Hip circumference adjusted for BMI;	chr9:120642332	chr9:120720673~120721972:+
LUAD	cis	rs12699921	0.632	rs2723545	ENSG00000279048.1	RP11-511H23.2	-5.81	1.11e-08	4.2e-06	-0.2	-0.26	Fibrinogen levels;	chr7:17820068	chr7:17940503~17942922:+
LUAD	cis	rs875971	1	rs10244498	ENSG00000237310.1	GS1-124K5.4	5.81	1.11e-08	4.21e-06	0.27	0.26	Aortic root size;	chr7:66651069	chr7:66493706~66495474:+
LUAD	cis	rs7044106	0.762	rs10739570	ENSG00000238181.2	AHCYP2	-5.81	1.11e-08	4.21e-06	-0.33	-0.26	Hip circumference adjusted for BMI;	chr9:120618944	chr9:120720673~120721972:+
LUAD	cis	rs496547	0.686	rs487728	ENSG00000255239.1	AP002954.6	5.81	1.11e-08	4.21e-06	0.31	0.26	Hip minimal joint space width;	chr11:118750785	chr11:118688039~118690600:-
LUAD	cis	rs7923609	1	rs7923609	ENSG00000232075.1	MRPL35P2	-5.81	1.11e-08	4.22e-06	-0.31	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63374062	chr10:63634317~63634827:-
LUAD	cis	rs1874124	0.836	rs7549963	ENSG00000238078.1	LINC01352	-5.81	1.11e-08	4.22e-06	-0.37	-0.26	Cholesterol, total;	chr1:220814918	chr1:220829255~220832429:+
LUAD	cis	rs35740288	0.857	rs11632034	ENSG00000202081.1	RNU6-1280P	5.81	1.11e-08	4.23e-06	0.32	0.26	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85740841	chr15:85651522~85651628:-
LUAD	cis	rs7618501	0.633	rs4688689	ENSG00000234667.1	ACTBP13	-5.81	1.11e-08	4.23e-06	-0.28	-0.26	Intelligence (multi-trait analysis);	chr3:49998109	chr3:49873347~49877980:-
LUAD	cis	rs185968827	1	rs185968827	ENSG00000231441.1	RP11-472M19.2	5.81	1.12e-08	4.24e-06	0.39	0.26	Alzheimer disease and age of onset;	chr6:56843712	chr6:56844002~56864078:+
LUAD	cis	rs10214930	0.781	rs12700823	ENSG00000235574.1	AC073150.6	-5.81	1.12e-08	4.24e-06	-0.34	-0.26	Hypospadias;	chr7:27619602	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.752	rs6966091	ENSG00000235574.1	AC073150.6	-5.81	1.12e-08	4.24e-06	-0.34	-0.26	Hypospadias;	chr7:27620394	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.752	rs12531518	ENSG00000235574.1	AC073150.6	-5.81	1.12e-08	4.24e-06	-0.34	-0.26	Hypospadias;	chr7:27621520	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.752	rs7808275	ENSG00000235574.1	AC073150.6	-5.81	1.12e-08	4.24e-06	-0.34	-0.26	Hypospadias;	chr7:27621885	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.752	rs12540063	ENSG00000235574.1	AC073150.6	-5.81	1.12e-08	4.24e-06	-0.34	-0.26	Hypospadias;	chr7:27621926	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.705	rs12700824	ENSG00000235574.1	AC073150.6	-5.81	1.12e-08	4.24e-06	-0.34	-0.26	Hypospadias;	chr7:27622135	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.752	rs7782422	ENSG00000235574.1	AC073150.6	-5.81	1.12e-08	4.24e-06	-0.34	-0.26	Hypospadias;	chr7:27623884	chr7:27491682~27492765:-
LUAD	cis	rs858239	0.6	rs28646184	ENSG00000230042.1	AK3P3	-5.81	1.12e-08	4.25e-06	-0.32	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23129178~23129841:+
LUAD	cis	rs4664293	0.801	rs7590595	ENSG00000226266.5	AC009961.3	-5.81	1.12e-08	4.25e-06	-0.35	-0.26	Monocyte percentage of white cells;	chr2:159715198	chr2:159670708~159712435:-
LUAD	cis	rs2404602	0.716	rs17461634	ENSG00000259422.1	RP11-593F23.1	5.81	1.12e-08	4.26e-06	0.29	0.26	Blood metabolite levels;	chr15:76471766	chr15:76174891~76181486:-
LUAD	cis	rs17301013	0.606	rs12089182	ENSG00000227373.4	RP11-160H22.5	5.81	1.12e-08	4.26e-06	0.35	0.26	Systemic lupus erythematosus;	chr1:174463816	chr1:174115300~174160004:-
LUAD	cis	rs10246939	0.529	rs60165685	ENSG00000228775.6	WEE2-AS1	5.81	1.12e-08	4.26e-06	0.31	0.26	Bitter taste perception;	chr7:141861190	chr7:141704338~141738346:-
LUAD	cis	rs8072100	0.934	rs8067286	ENSG00000228782.6	CTD-2026D20.3	-5.81	1.12e-08	4.26e-06	-0.27	-0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47517224	chr17:47450568~47492492:-
LUAD	cis	rs875971	0.862	rs4368860	ENSG00000237310.1	GS1-124K5.4	-5.81	1.12e-08	4.27e-06	-0.28	-0.26	Aortic root size;	chr7:66143495	chr7:66493706~66495474:+
LUAD	cis	rs11651753	0.636	rs4793731	ENSG00000264920.1	RP11-6N17.4	-5.81	1.12e-08	4.27e-06	-0.32	-0.26	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47956327	chr17:47891255~47895812:-
LUAD	cis	rs11651753	0.636	rs4793733	ENSG00000264920.1	RP11-6N17.4	-5.81	1.12e-08	4.27e-06	-0.32	-0.26	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47956616	chr17:47891255~47895812:-
LUAD	cis	rs11651753	0.636	rs35280206	ENSG00000264920.1	RP11-6N17.4	-5.81	1.12e-08	4.27e-06	-0.32	-0.26	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47957645	chr17:47891255~47895812:-
LUAD	cis	rs2898681	0.58	rs41279517	ENSG00000248375.1	RP11-177B4.1	-5.81	1.12e-08	4.27e-06	-0.47	-0.26	Optic nerve measurement (cup area);	chr4:52863604	chr4:52720081~52720831:-
LUAD	cis	rs2898681	0.567	rs77657787	ENSG00000248375.1	RP11-177B4.1	-5.81	1.12e-08	4.27e-06	-0.47	-0.26	Optic nerve measurement (cup area);	chr4:52863814	chr4:52720081~52720831:-
LUAD	cis	rs4664293	0.801	rs7607143	ENSG00000226266.5	AC009961.3	-5.81	1.13e-08	4.27e-06	-0.35	-0.26	Monocyte percentage of white cells;	chr2:159728250	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.833	rs10170336	ENSG00000226266.5	AC009961.3	-5.81	1.13e-08	4.27e-06	-0.35	-0.26	Monocyte percentage of white cells;	chr2:159732832	chr2:159670708~159712435:-
LUAD	cis	rs896854	0.54	rs2011567	ENSG00000253528.2	RP11-347C18.4	5.81	1.13e-08	4.27e-06	0.25	0.26	Type 2 diabetes;	chr8:94959692	chr8:94974573~94974853:-
LUAD	cis	rs7849270	0.879	rs10988197	ENSG00000268707.1	RP11-247A12.7	-5.81	1.13e-08	4.28e-06	-0.29	-0.26	Blood metabolite ratios;	chr9:129078980	chr9:129170434~129170940:+
LUAD	cis	rs875971	0.862	rs10276077	ENSG00000222364.1	RNU6-96P	5.81	1.13e-08	4.28e-06	0.29	0.26	Aortic root size;	chr7:66263424	chr7:66395191~66395286:+
LUAD	cis	rs10754283	0.901	rs10922684	ENSG00000231613.1	RP5-943J3.1	5.81	1.13e-08	4.28e-06	0.26	0.26	Amyotrophic lateral sclerosis (sporadic);	chr1:89652375	chr1:89788914~89790492:+
LUAD	cis	rs2243480	1	rs73142162	ENSG00000230295.1	RP11-458F8.2	-5.81	1.13e-08	4.28e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:65909309	chr7:66880708~66882981:+
LUAD	cis	rs801193	0.636	rs10233806	ENSG00000237310.1	GS1-124K5.4	-5.81	1.13e-08	4.28e-06	-0.27	-0.26	Aortic root size;	chr7:66653261	chr7:66493706~66495474:+
LUAD	cis	rs11098499	1	rs58601355	ENSG00000248280.1	RP11-33B1.2	5.81	1.13e-08	4.29e-06	0.33	0.26	Corneal astigmatism;	chr4:119265212	chr4:119440561~119450157:-
LUAD	cis	rs755249	0.567	rs61779306	ENSG00000228060.1	RP11-69E11.8	-5.81	1.13e-08	4.29e-06	-0.26	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39456754	chr1:39565160~39573203:+
LUAD	cis	rs17711722	0.565	rs73372653	ENSG00000224316.1	RP11-479O9.2	5.81	1.13e-08	4.29e-06	0.26	0.26	Calcium levels;	chr7:65977808	chr7:65773620~65802067:+
LUAD	cis	rs9595908	0.709	rs1929937	ENSG00000212293.1	SNORA16	5.81	1.13e-08	4.29e-06	0.27	0.26	Body mass index;	chr13:32722907	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.709	rs7325016	ENSG00000212293.1	SNORA16	5.81	1.13e-08	4.29e-06	0.27	0.26	Body mass index;	chr13:32728681	chr13:32420390~32420516:-
LUAD	cis	rs17684571	0.872	rs35206656	ENSG00000231441.1	RP11-472M19.2	5.81	1.13e-08	4.3e-06	0.34	0.26	Schizophrenia;	chr6:56706662	chr6:56844002~56864078:+
LUAD	cis	rs755249	0.917	rs61781392	ENSG00000228060.1	RP11-69E11.8	-5.81	1.13e-08	4.3e-06	-0.27	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39617969	chr1:39565160~39573203:+
LUAD	cis	rs7923609	0.936	rs4405189	ENSG00000232075.1	MRPL35P2	-5.81	1.13e-08	4.3e-06	-0.31	-0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63254175	chr10:63634317~63634827:-
LUAD	cis	rs4908768	0.501	rs6702060	ENSG00000232912.4	RP5-1115A15.1	5.81	1.13e-08	4.3e-06	0.24	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8546965	chr1:8424645~8434838:+
LUAD	cis	rs4908768	0.501	rs6577502	ENSG00000232912.4	RP5-1115A15.1	5.81	1.13e-08	4.3e-06	0.24	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8555518	chr1:8424645~8434838:+
LUAD	cis	rs4908768	0.501	rs1473420	ENSG00000232912.4	RP5-1115A15.1	5.81	1.13e-08	4.3e-06	0.24	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8556779	chr1:8424645~8434838:+
LUAD	cis	rs10740039	0.516	rs1442551	ENSG00000254271.1	RP11-131N11.4	5.81	1.13e-08	4.3e-06	0.29	0.26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60564733	chr10:60734342~60741828:+
LUAD	cis	rs4723738	1	rs7795499	ENSG00000227191.5	TRGC2	-5.81	1.13e-08	4.3e-06	-0.27	-0.26	Treatment response for severe sepsis;	chr7:38228794	chr7:38239580~38368091:-
LUAD	cis	rs7246657	0.722	rs2287229	ENSG00000276846.1	CTD-3220F14.3	-5.81	1.13e-08	4.3e-06	-0.35	-0.26	Coronary artery calcification;	chr19:37697751	chr19:37314868~37315620:-
LUAD	cis	rs2832077	1	rs2832077	ENSG00000232855.5	AF131217.1	5.81	1.14e-08	4.31e-06	0.29	0.26	Cognitive test performance;	chr21:28768699	chr21:28439346~28674848:-
LUAD	cis	rs950169	0.58	rs11636189	ENSG00000225151.9	GOLGA2P7	-5.81	1.14e-08	4.31e-06	-0.35	-0.26	Schizophrenia;	chr15:84650323	chr15:84199311~84230136:-
LUAD	cis	rs4835473	0.9	rs58106929	ENSG00000251600.4	RP11-673E1.1	5.81	1.14e-08	4.31e-06	0.31	0.26	Immature fraction of reticulocytes;	chr4:143733166	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs7698963	ENSG00000251600.4	RP11-673E1.1	5.81	1.14e-08	4.31e-06	0.31	0.26	Immature fraction of reticulocytes;	chr4:143733190	chr4:143912331~143982454:+
LUAD	cis	rs755249	0.917	rs61232586	ENSG00000228060.1	RP11-69E11.8	-5.81	1.14e-08	4.32e-06	-0.27	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39620685	chr1:39565160~39573203:+
LUAD	cis	rs9859260	0.744	rs539816	ENSG00000231464.1	AC024937.4	-5.81	1.14e-08	4.32e-06	-0.3	-0.26	Mean corpuscular volume;	chr3:196057205	chr3:195996738~195998233:+
LUAD	cis	rs9859260	0.744	rs492349	ENSG00000231464.1	AC024937.4	-5.81	1.14e-08	4.32e-06	-0.3	-0.26	Mean corpuscular volume;	chr3:196057321	chr3:195996738~195998233:+
LUAD	cis	rs9859260	0.744	rs492288	ENSG00000231464.1	AC024937.4	-5.81	1.14e-08	4.32e-06	-0.3	-0.26	Mean corpuscular volume;	chr3:196057339	chr3:195996738~195998233:+
LUAD	cis	rs1823913	0.637	rs2883912	ENSG00000227542.1	AC092614.2	-5.81	1.14e-08	4.33e-06	-0.31	-0.26	Obesity-related traits;	chr2:191284290	chr2:191229165~191246172:-
LUAD	cis	rs950169	0.58	rs17532346	ENSG00000225151.9	GOLGA2P7	-5.81	1.15e-08	4.34e-06	-0.35	-0.26	Schizophrenia;	chr15:84628264	chr15:84199311~84230136:-
LUAD	cis	rs394563	0.69	rs237010	ENSG00000231760.4	RP11-350J20.5	5.81	1.15e-08	4.34e-06	0.31	0.26	Dupuytren's disease;	chr6:149437614	chr6:149796151~149826294:-
LUAD	cis	rs10129255	0.957	rs10140904	ENSG00000224373.3	IGHV4-59	5.81	1.15e-08	4.34e-06	0.17	0.26	Kawasaki disease;	chr14:106776558	chr14:106627249~106627825:-
LUAD	cis	rs7044106	0.762	rs10984974	ENSG00000238181.2	AHCYP2	-5.81	1.15e-08	4.34e-06	-0.32	-0.26	Hip circumference adjusted for BMI;	chr9:120659278	chr9:120720673~120721972:+
LUAD	cis	rs10214930	0.781	rs961723	ENSG00000235574.1	AC073150.6	-5.81	1.15e-08	4.34e-06	-0.34	-0.26	Hypospadias;	chr7:27618354	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.813	rs961724	ENSG00000235574.1	AC073150.6	-5.81	1.15e-08	4.34e-06	-0.34	-0.26	Hypospadias;	chr7:27618416	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.813	rs961725	ENSG00000235574.1	AC073150.6	-5.81	1.15e-08	4.34e-06	-0.34	-0.26	Hypospadias;	chr7:27618451	chr7:27491682~27492765:-
LUAD	cis	rs2288884	0.559	rs61287503	ENSG00000275055.1	CTC-471J1.11	-5.81	1.15e-08	4.34e-06	-0.31	-0.26	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52017939	chr19:52049007~52049754:+
LUAD	cis	rs10754283	0.967	rs10922685	ENSG00000231613.1	RP5-943J3.1	5.81	1.15e-08	4.35e-06	0.26	0.26	Amyotrophic lateral sclerosis (sporadic);	chr1:89652761	chr1:89788914~89790492:+
LUAD	cis	rs17301013	0.606	rs1894198	ENSG00000227373.4	RP11-160H22.5	-5.81	1.15e-08	4.35e-06	-0.35	-0.26	Systemic lupus erythematosus;	chr1:174835393	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.659	rs1894199	ENSG00000227373.4	RP11-160H22.5	-5.81	1.15e-08	4.35e-06	-0.35	-0.26	Systemic lupus erythematosus;	chr1:174835545	chr1:174115300~174160004:-
LUAD	cis	rs7615952	0.599	rs16834938	ENSG00000171084.14	FAM86JP	5.81	1.15e-08	4.35e-06	0.35	0.26	Blood pressure (smoking interaction);	chr3:125987203	chr3:125916620~125930024:+
LUAD	cis	rs36423	0.528	rs1205063	ENSG00000266869.1	RP6-114E22.1	5.81	1.15e-08	4.36e-06	0.37	0.26	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71881828	chr14:71848606~71908430:+
LUAD	cis	rs4591358	0.773	rs35261538	ENSG00000223466.1	AC064834.2	-5.81	1.15e-08	4.37e-06	-0.35	-0.26	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195509681	chr2:195533035~195538681:+
LUAD	cis	rs7246657	0.722	rs12979640	ENSG00000276846.1	CTD-3220F14.3	-5.81	1.15e-08	4.37e-06	-0.34	-0.26	Coronary artery calcification;	chr19:37688255	chr19:37314868~37315620:-
LUAD	cis	rs36093844	0.8	rs59179556	ENSG00000279742.1	RP11-700A24.1	-5.81	1.15e-08	4.37e-06	-0.33	-0.26	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85862854	chr11:85852557~85854943:-
LUAD	cis	rs237743	0.963	rs73611371	ENSG00000222365.1	SNORD12B	-5.81	1.16e-08	4.37e-06	-0.3	-0.26	Height;	chr20:49218618	chr20:49280319~49280409:+
LUAD	cis	rs9309711	0.922	rs13399524	ENSG00000225234.1	TRAPPC12-AS1	-5.81	1.16e-08	4.37e-06	-0.31	-0.26	Neurofibrillary tangles;	chr2:3476435	chr2:3481242~3482409:-
LUAD	cis	rs9923856	0.519	rs7197754	ENSG00000274038.1	RP11-66H6.4	-5.81	1.16e-08	4.38e-06	-0.31	-0.26	Atopic dermatitis;Adult asthma;	chr16:11036522	chr16:11056556~11057034:+
LUAD	cis	rs875971	1	rs4718307	ENSG00000237310.1	GS1-124K5.4	-5.81	1.16e-08	4.39e-06	-0.27	-0.26	Aortic root size;	chr7:66146001	chr7:66493706~66495474:+
LUAD	cis	rs7221109	0.56	rs758630	ENSG00000278834.1	RP11-458J1.1	-5.81	1.16e-08	4.39e-06	-0.29	-0.26	Type 1 diabetes;	chr17:40713053	chr17:40648300~40649718:+
LUAD	cis	rs4713118	0.513	rs149941	ENSG00000204709.4	LINC01556	5.81	1.16e-08	4.39e-06	0.32	0.26	Parkinson's disease;	chr6:28033255	chr6:28943877~28944537:+
LUAD	cis	rs2412819	0.571	rs12443084	ENSG00000249839.1	AC011330.5	5.81	1.16e-08	4.39e-06	0.4	0.26	Lung cancer;	chr15:43748767	chr15:43663654~43684339:-
LUAD	cis	rs875971	0.895	rs12531677	ENSG00000237310.1	GS1-124K5.4	-5.81	1.16e-08	4.4e-06	-0.28	-0.26	Aortic root size;	chr7:66304099	chr7:66493706~66495474:+
LUAD	cis	rs2439831	0.85	rs8032649	ENSG00000205771.5	CATSPER2P1	5.81	1.16e-08	4.41e-06	0.49	0.26	Lung cancer in ever smokers;	chr15:43842724	chr15:43726918~43747094:-
LUAD	cis	rs453301	0.571	rs2929456	ENSG00000253893.2	FAM85B	5.81	1.17e-08	4.41e-06	0.32	0.26	Joint mobility (Beighton score);	chr8:9225906	chr8:8167819~8226614:-
LUAD	cis	rs8177376	0.834	rs12287976	ENSG00000254905.1	RP11-712L6.7	5.81	1.17e-08	4.41e-06	0.34	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126302693	chr11:126292922~126294254:-
LUAD	cis	rs801193	0.66	rs2659914	ENSG00000237310.1	GS1-124K5.4	5.81	1.17e-08	4.41e-06	0.27	0.26	Aortic root size;	chr7:66691927	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs937495	ENSG00000237310.1	GS1-124K5.4	-5.81	1.17e-08	4.42e-06	-0.28	-0.26	Aortic root size;	chr7:66314811	chr7:66493706~66495474:+
LUAD	cis	rs17301013	0.606	rs913687	ENSG00000227373.4	RP11-160H22.5	5.81	1.17e-08	4.42e-06	0.35	0.26	Systemic lupus erythematosus;	chr1:174805993	chr1:174115300~174160004:-
LUAD	cis	rs7246657	0.722	rs968073	ENSG00000276846.1	CTD-3220F14.3	-5.81	1.17e-08	4.42e-06	-0.35	-0.26	Coronary artery calcification;	chr19:37701120	chr19:37314868~37315620:-
LUAD	cis	rs916888	0.773	rs199535	ENSG00000261575.2	RP11-259G18.1	5.81	1.17e-08	4.42e-06	0.4	0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46267037~46268694:+
LUAD	cis	rs9910055	0.762	rs4239142	ENSG00000267080.4	ASB16-AS1	5.8	1.17e-08	4.42e-06	0.23	0.26	Total body bone mineral density;	chr17:44128508	chr17:44175973~44186717:-
LUAD	cis	rs950169	0.58	rs11630887	ENSG00000225151.9	GOLGA2P7	-5.8	1.17e-08	4.42e-06	-0.35	-0.26	Schizophrenia;	chr15:84649784	chr15:84199311~84230136:-
LUAD	cis	rs75920871	0.528	rs983567	ENSG00000254851.1	RP11-109L13.1	5.8	1.17e-08	4.43e-06	0.38	0.26	Subjective well-being;	chr11:116912884	chr11:117135528~117138582:+
LUAD	cis	rs4908768	0.501	rs35865480	ENSG00000232912.4	RP5-1115A15.1	5.8	1.17e-08	4.43e-06	0.24	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8543718	chr1:8424645~8434838:+
LUAD	cis	rs30380	0.632	rs30186	ENSG00000272109.1	CTD-2260A17.3	-5.8	1.17e-08	4.43e-06	-0.3	-0.26	Cerebrospinal fluid biomarker levels;	chr5:96788744	chr5:96804353~96806105:+
LUAD	cis	rs8062405	1	rs80275162	ENSG00000251417.2	RP11-1348G14.4	-5.8	1.17e-08	4.44e-06	-0.26	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28802743~28817828:+
LUAD	cis	rs875971	1	rs2087647	ENSG00000237310.1	GS1-124K5.4	-5.8	1.18e-08	4.44e-06	-0.27	-0.26	Aortic root size;	chr7:66128201	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs6958484	ENSG00000237310.1	GS1-124K5.4	-5.8	1.18e-08	4.44e-06	-0.27	-0.26	Aortic root size;	chr7:66134459	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs7783779	ENSG00000222364.1	RNU6-96P	5.8	1.18e-08	4.45e-06	0.29	0.26	Aortic root size;	chr7:66331639	chr7:66395191~66395286:+
LUAD	cis	rs9860428	0.774	rs10934188	ENSG00000242770.2	RP11-180K7.1	5.8	1.18e-08	4.45e-06	0.27	0.26	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112821421	chr3:112802478~112812819:+
LUAD	cis	rs7246657	0.722	rs2927746	ENSG00000276846.1	CTD-3220F14.3	-5.8	1.18e-08	4.45e-06	-0.35	-0.26	Coronary artery calcification;	chr19:37665669	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.722	rs2927747	ENSG00000276846.1	CTD-3220F14.3	-5.8	1.18e-08	4.45e-06	-0.35	-0.26	Coronary artery calcification;	chr19:37668629	chr19:37314868~37315620:-
LUAD	cis	rs1426063	0.748	rs6534607	ENSG00000249717.1	RP11-44F21.3	5.8	1.18e-08	4.45e-06	0.34	0.26	QT interval;	chr4:75106366	chr4:74955974~74970362:-
LUAD	cis	rs6570726	0.599	rs426371	ENSG00000235652.6	RP11-545I5.3	-5.8	1.18e-08	4.45e-06	-0.27	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145565333	chr6:145799409~145886585:+
LUAD	cis	rs4908768	0.501	rs6577488	ENSG00000232912.4	RP5-1115A15.1	5.8	1.18e-08	4.45e-06	0.24	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8474469	chr1:8424645~8434838:+
LUAD	cis	rs4908768	0.501	rs4351668	ENSG00000232912.4	RP5-1115A15.1	5.8	1.18e-08	4.45e-06	0.24	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8475758	chr1:8424645~8434838:+
LUAD	cis	rs4908768	0.501	rs7551849	ENSG00000232912.4	RP5-1115A15.1	5.8	1.18e-08	4.45e-06	0.24	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8479403	chr1:8424645~8434838:+
LUAD	cis	rs17138358	0.506	rs2691623	ENSG00000279048.1	RP11-511H23.2	-5.8	1.18e-08	4.45e-06	-0.21	-0.26	HDL cholesterol levels;	chr7:17853953	chr7:17940503~17942922:+
LUAD	cis	rs2243480	1	rs10247526	ENSG00000230295.1	RP11-458F8.2	5.8	1.18e-08	4.45e-06	0.31	0.26	Diabetic kidney disease;	chr7:66315709	chr7:66880708~66882981:+
LUAD	cis	rs2276314	0.512	rs9949178	ENSG00000278986.1	RP11-723J4.3	5.8	1.18e-08	4.46e-06	0.27	0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:35870612	chr18:35972151~35973916:+
LUAD	cis	rs875971	1	rs1565531	ENSG00000237310.1	GS1-124K5.4	-5.8	1.18e-08	4.46e-06	-0.27	-0.26	Aortic root size;	chr7:66198126	chr7:66493706~66495474:+
LUAD	cis	rs367615	0.55	rs10060801	ENSG00000249476.1	CTD-2587M2.1	5.8	1.18e-08	4.46e-06	0.27	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109546081	chr5:109237120~109326369:-
LUAD	cis	rs4908760	0.731	rs12075458	ENSG00000232912.4	RP5-1115A15.1	5.8	1.18e-08	4.46e-06	0.24	0.26	Vitiligo;	chr1:8698735	chr1:8424645~8434838:+
LUAD	cis	rs74233809	1	rs11191548	ENSG00000213277.3	MARCKSL1P1	-5.8	1.18e-08	4.47e-06	-0.44	-0.26	Birth weight;	chr10:103086421	chr10:103175554~103176094:+
LUAD	cis	rs67311347	0.866	rs11712426	ENSG00000223797.4	ENTPD3-AS1	5.8	1.18e-08	4.47e-06	0.28	0.26	Renal cell carcinoma;	chr3:40288831	chr3:40313802~40453329:-
LUAD	cis	rs12908161	1	rs11637142	ENSG00000225151.9	GOLGA2P7	-5.8	1.18e-08	4.47e-06	-0.34	-0.26	Schizophrenia;	chr15:84752696	chr15:84199311~84230136:-
LUAD	cis	rs2179367	0.632	rs10872636	ENSG00000231760.4	RP11-350J20.5	5.8	1.18e-08	4.48e-06	0.36	0.26	Dupuytren's disease;	chr6:149353678	chr6:149796151~149826294:-
LUAD	cis	rs1823913	0.927	rs56209234	ENSG00000230611.1	HMGB1P27	-5.8	1.19e-08	4.48e-06	-0.32	-0.26	Obesity-related traits;	chr2:191261748	chr2:191174233~191174835:+
LUAD	cis	rs2243480	1	rs316331	ENSG00000230295.1	RP11-458F8.2	5.8	1.19e-08	4.48e-06	0.32	0.26	Diabetic kidney disease;	chr7:66139635	chr7:66880708~66882981:+
LUAD	cis	rs77204473	0.744	rs12277910	ENSG00000254851.1	RP11-109L13.1	-5.8	1.19e-08	4.48e-06	-0.6	-0.26	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117087817	chr11:117135528~117138582:+
LUAD	cis	rs875971	0.825	rs4587224	ENSG00000222364.1	RNU6-96P	5.8	1.19e-08	4.49e-06	0.29	0.26	Aortic root size;	chr7:66271195	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.792	rs6971752	ENSG00000222364.1	RNU6-96P	5.8	1.19e-08	4.49e-06	0.29	0.26	Aortic root size;	chr7:66272999	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs10950033	ENSG00000222364.1	RNU6-96P	5.8	1.19e-08	4.49e-06	0.29	0.26	Aortic root size;	chr7:66274686	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs11760844	ENSG00000222364.1	RNU6-96P	5.8	1.19e-08	4.49e-06	0.29	0.26	Aortic root size;	chr7:66274896	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs4149461	ENSG00000222364.1	RNU6-96P	5.8	1.19e-08	4.49e-06	0.29	0.26	Aortic root size;	chr7:66279745	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.965	rs9969301	ENSG00000237310.1	GS1-124K5.4	-5.8	1.19e-08	4.49e-06	-0.28	-0.26	Aortic root size;	chr7:66316668	chr7:66493706~66495474:+
LUAD	cis	rs75920871	0.588	rs1940626	ENSG00000254851.1	RP11-109L13.1	5.8	1.19e-08	4.49e-06	0.38	0.26	Subjective well-being;	chr11:116957405	chr11:117135528~117138582:+
LUAD	cis	rs7688540	0.771	rs7669892	ENSG00000275426.1	CH17-262A2.1	-5.8	1.19e-08	4.49e-06	-0.3	-0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:315464	chr4:149738~150317:+
LUAD	cis	rs12468226	1	rs112306637	ENSG00000272966.1	RP11-686O6.1	5.8	1.19e-08	4.49e-06	0.44	0.26	Urate levels;	chr2:202334195	chr2:202336739~202337200:+
LUAD	cis	rs12468226	1	rs111252524	ENSG00000272966.1	RP11-686O6.1	5.8	1.19e-08	4.49e-06	0.44	0.26	Urate levels;	chr2:202334465	chr2:202336739~202337200:+
LUAD	cis	rs12468226	1	rs112753638	ENSG00000272966.1	RP11-686O6.1	5.8	1.19e-08	4.49e-06	0.44	0.26	Urate levels;	chr2:202334496	chr2:202336739~202337200:+
LUAD	cis	rs12468226	0.935	rs113188021	ENSG00000272966.1	RP11-686O6.1	5.8	1.19e-08	4.49e-06	0.44	0.26	Urate levels;	chr2:202336237	chr2:202336739~202337200:+
LUAD	cis	rs12468226	1	rs6731027	ENSG00000272966.1	RP11-686O6.1	5.8	1.19e-08	4.49e-06	0.44	0.26	Urate levels;	chr2:202337443	chr2:202336739~202337200:+
LUAD	cis	rs2243480	0.708	rs35825036	ENSG00000230295.1	RP11-458F8.2	-5.8	1.19e-08	4.49e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66521515	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs13237037	ENSG00000230295.1	RP11-458F8.2	-5.8	1.19e-08	4.49e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66532895	chr7:66880708~66882981:+
LUAD	cis	rs2243480	0.901	rs13237344	ENSG00000230295.1	RP11-458F8.2	-5.8	1.19e-08	4.49e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66557269	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs1796228	ENSG00000230295.1	RP11-458F8.2	-5.8	1.19e-08	4.49e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66568097	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs1267820	ENSG00000230295.1	RP11-458F8.2	-5.8	1.19e-08	4.49e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66585308	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs2533288	ENSG00000230295.1	RP11-458F8.2	-5.8	1.19e-08	4.49e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66591724	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs2707844	ENSG00000230295.1	RP11-458F8.2	-5.8	1.19e-08	4.49e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:66594522	chr7:66880708~66882981:+
LUAD	cis	rs1823874	0.581	rs12910401	ENSG00000182397.13	DNM1P46	-5.8	1.19e-08	4.5e-06	-0.31	-0.26	IgG glycosylation;	chr15:99799692	chr15:99790156~99806927:-
LUAD	cis	rs600231	0.665	rs1616810	ENSG00000245532.5	NEAT1	5.8	1.19e-08	4.51e-06	0.2	0.26	Bone mineral density;	chr11:65452634	chr11:65422774~65445540:+
LUAD	cis	rs875971	1	rs11974264	ENSG00000237310.1	GS1-124K5.4	-5.8	1.19e-08	4.51e-06	-0.27	-0.26	Aortic root size;	chr7:66182595	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs1540651	ENSG00000237310.1	GS1-124K5.4	-5.8	1.19e-08	4.51e-06	-0.27	-0.26	Aortic root size;	chr7:66185134	chr7:66493706~66495474:+
LUAD	cis	rs36093844	0.8	rs2044390	ENSG00000279742.1	RP11-700A24.1	-5.8	1.19e-08	4.51e-06	-0.33	-0.26	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85858791	chr11:85852557~85854943:-
LUAD	cis	rs4835473	0.669	rs75704080	ENSG00000251600.4	RP11-673E1.1	-5.8	1.2e-08	4.52e-06	-0.32	-0.26	Immature fraction of reticulocytes;	chr4:143779066	chr4:143912331~143982454:+
LUAD	cis	rs9652601	0.691	rs9939397	ENSG00000274038.1	RP11-66H6.4	-5.8	1.2e-08	4.52e-06	-0.31	-0.26	Systemic lupus erythematosus;	chr16:11115907	chr16:11056556~11057034:+
LUAD	cis	rs875971	0.545	rs1796226	ENSG00000226824.5	RP4-756H11.3	-5.8	1.2e-08	4.52e-06	-0.36	-0.26	Aortic root size;	chr7:66622723	chr7:66654538~66669855:+
LUAD	cis	rs9847710	0.696	rs2581821	ENSG00000242142.1	SERBP1P3	5.8	1.2e-08	4.53e-06	0.3	0.26	Ulcerative colitis;	chr3:52987572	chr3:53064283~53065091:-
LUAD	cis	rs2243480	0.522	rs12698511	ENSG00000273142.1	RP11-458F8.4	-5.8	1.2e-08	4.53e-06	-0.3	-0.26	Diabetic kidney disease;	chr7:66009932	chr7:66902857~66906297:+
LUAD	cis	rs875971	0.965	rs10267430	ENSG00000237310.1	GS1-124K5.4	-5.8	1.2e-08	4.54e-06	-0.28	-0.26	Aortic root size;	chr7:66278036	chr7:66493706~66495474:+
LUAD	cis	rs9595066	0.627	rs4394973	ENSG00000227258.4	SMIM2-AS1	-5.8	1.2e-08	4.54e-06	-0.39	-0.26	Schizophrenia;	chr13:44179173	chr13:44110451~44240517:+
LUAD	cis	rs7829975	0.84	rs555617	ENSG00000253893.2	FAM85B	5.8	1.2e-08	4.54e-06	0.32	0.26	Mood instability;	chr8:8735335	chr8:8167819~8226614:-
LUAD	cis	rs10214930	0.813	rs2391444	ENSG00000235574.1	AC073150.6	-5.8	1.2e-08	4.54e-06	-0.34	-0.26	Hypospadias;	chr7:27602801	chr7:27491682~27492765:-
LUAD	cis	rs4908768	0.501	rs1463050	ENSG00000232912.4	RP5-1115A15.1	5.8	1.2e-08	4.55e-06	0.24	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8536983	chr1:8424645~8434838:+
LUAD	cis	rs7674212	1	rs7691873	ENSG00000246560.2	RP11-10L12.4	-5.8	1.21e-08	4.55e-06	-0.33	-0.26	Type 2 diabetes;	chr4:103066742	chr4:102828055~102844075:+
LUAD	cis	rs12554020	0.786	rs7035657	ENSG00000227603.1	RP11-165J3.6	-5.8	1.21e-08	4.55e-06	-0.37	-0.26	Schizophrenia;	chr9:93434769	chr9:93435332~93437121:-
LUAD	cis	rs293748	0.54	rs13166829	ENSG00000250155.1	CTD-2353F22.1	-5.8	1.21e-08	4.55e-06	-0.32	-0.26	Obesity-related traits;	chr5:37222124	chr5:36666214~36725195:-
LUAD	cis	rs7849270	1	rs2541164	ENSG00000268707.1	RP11-247A12.7	-5.8	1.21e-08	4.56e-06	-0.3	-0.26	Blood metabolite ratios;	chr9:129114629	chr9:129170434~129170940:+
LUAD	cis	rs75422866	0.764	rs67408202	ENSG00000257433.4	RP1-197B17.3	5.8	1.21e-08	4.56e-06	0.57	0.26	Pneumonia;	chr12:47713564	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.867	rs57848393	ENSG00000257433.4	RP1-197B17.3	5.8	1.21e-08	4.56e-06	0.57	0.26	Pneumonia;	chr12:47714734	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.764	rs67201012	ENSG00000257433.4	RP1-197B17.3	5.8	1.21e-08	4.56e-06	0.57	0.26	Pneumonia;	chr12:47715881	chr12:47706085~47742294:+
LUAD	cis	rs875971	1	rs1544549	ENSG00000237310.1	GS1-124K5.4	-5.8	1.21e-08	4.56e-06	-0.28	-0.26	Aortic root size;	chr7:66625676	chr7:66493706~66495474:+
LUAD	cis	rs4820294	0.669	rs1894532	ENSG00000233360.4	Z83844.1	5.8	1.21e-08	4.56e-06	0.26	0.26	Fat distribution (HIV);	chr22:37663743	chr22:37641832~37658377:-
LUAD	cis	rs6921919	0.583	rs9468355	ENSG00000204709.4	LINC01556	5.8	1.21e-08	4.56e-06	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28374100	chr6:28943877~28944537:+
LUAD	cis	rs66887589	0.56	rs9684327	ENSG00000245958.5	RP11-33B1.1	-5.8	1.21e-08	4.57e-06	-0.21	-0.26	Diastolic blood pressure;	chr4:119444286	chr4:119454791~119552025:+
LUAD	cis	rs2288884	0.537	rs12151130	ENSG00000275055.1	CTC-471J1.11	-5.8	1.21e-08	4.57e-06	-0.3	-0.26	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52060531	chr19:52049007~52049754:+
LUAD	cis	rs950169	0.58	rs35516100	ENSG00000225151.9	GOLGA2P7	-5.8	1.21e-08	4.57e-06	-0.35	-0.26	Schizophrenia;	chr15:84652199	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.58	rs62021208	ENSG00000225151.9	GOLGA2P7	-5.8	1.21e-08	4.57e-06	-0.35	-0.26	Schizophrenia;	chr15:84653013	chr15:84199311~84230136:-
LUAD	cis	rs17684571	0.872	rs13198938	ENSG00000231441.1	RP11-472M19.2	5.8	1.21e-08	4.57e-06	0.37	0.26	Schizophrenia;	chr6:56733628	chr6:56844002~56864078:+
LUAD	cis	rs7712401	0.715	rs15577	ENSG00000263432.2	RN7SL689P	-5.8	1.21e-08	4.58e-06	-0.32	-0.26	Mean platelet volume;	chr5:123023495	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.715	rs451195	ENSG00000263432.2	RN7SL689P	-5.8	1.21e-08	4.58e-06	-0.32	-0.26	Mean platelet volume;	chr5:123023945	chr5:123022487~123022783:-
LUAD	cis	rs4713118	0.513	rs183244	ENSG00000204709.4	LINC01556	5.8	1.21e-08	4.58e-06	0.33	0.26	Parkinson's disease;	chr6:28064060	chr6:28943877~28944537:+
LUAD	cis	rs13230714	0.858	rs2888075	ENSG00000204959.4	ARHGEF34P	5.8	1.22e-08	4.58e-06	0.33	0.26	Breast cancer;	chr7:144456786	chr7:144272445~144286966:-
LUAD	cis	rs7772486	0.558	rs702322	ENSG00000235652.6	RP11-545I5.3	-5.8	1.22e-08	4.59e-06	-0.27	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145686030	chr6:145799409~145886585:+
LUAD	cis	rs2276314	1	rs4799834	ENSG00000278986.1	RP11-723J4.3	-5.8	1.22e-08	4.59e-06	-0.32	-0.26	Endometriosis;Drug-induced torsades de pointes;	chr18:35986280	chr18:35972151~35973916:+
LUAD	cis	rs2153535	0.967	rs10484750	ENSG00000230939.1	RP11-314C16.1	5.8	1.22e-08	4.59e-06	0.29	0.26	Motion sickness;	chr6:8378376	chr6:8784178~8785445:+
LUAD	cis	rs17301013	0.606	rs333423	ENSG00000227373.4	RP11-160H22.5	5.8	1.22e-08	4.59e-06	0.35	0.26	Systemic lupus erythematosus;	chr1:174666557	chr1:174115300~174160004:-
LUAD	cis	rs2212361	0.6	rs34185869	ENSG00000255893.1	RP11-685N10.1	-5.8	1.22e-08	4.59e-06	-0.33	-0.26	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94535430	chr11:94472908~94473570:-
LUAD	cis	rs2212361	0.593	rs34288874	ENSG00000255893.1	RP11-685N10.1	-5.8	1.22e-08	4.59e-06	-0.33	-0.26	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94535484	chr11:94472908~94473570:-
LUAD	cis	rs2404602	0.647	rs35710279	ENSG00000259422.1	RP11-593F23.1	-5.8	1.22e-08	4.59e-06	-0.34	-0.26	Blood metabolite levels;	chr15:76789893	chr15:76174891~76181486:-
LUAD	cis	rs2933343	0.951	rs796862	ENSG00000261159.1	RP11-723O4.9	5.8	1.22e-08	4.6e-06	0.31	0.26	IgG glycosylation;	chr3:128874197	chr3:128859716~128860526:-
LUAD	cis	rs9595908	0.832	rs2032495	ENSG00000212293.1	SNORA16	5.8	1.22e-08	4.6e-06	0.27	0.26	Body mass index;	chr13:32630605	chr13:32420390~32420516:-
LUAD	cis	rs7017914	0.875	rs2732107	ENSG00000223220.1	Y_RNA	5.8	1.22e-08	4.61e-06	0.29	0.26	Bone mineral density;	chr8:71013073	chr8:70780914~70781008:-
LUAD	cis	rs10129255	0.957	rs10150241	ENSG00000224373.3	IGHV4-59	-5.8	1.22e-08	4.61e-06	-0.16	-0.26	Kawasaki disease;	chr14:106775945	chr14:106627249~106627825:-
LUAD	cis	rs950169	0.544	rs2036949	ENSG00000225151.9	GOLGA2P7	-5.8	1.22e-08	4.61e-06	-0.35	-0.26	Schizophrenia;	chr15:84620374	chr15:84199311~84230136:-
LUAD	cis	rs2439831	0.85	rs28718261	ENSG00000205771.5	CATSPER2P1	-5.8	1.22e-08	4.61e-06	-0.5	-0.26	Lung cancer in ever smokers;	chr15:43751595	chr15:43726918~43747094:-
LUAD	cis	rs17666538	0.535	rs896522	ENSG00000254207.1	RP11-43A14.1	5.8	1.23e-08	4.62e-06	0.51	0.26	IgG glycosylation;	chr8:666991	chr8:725188~725877:-
LUAD	cis	rs17666538	0.535	rs1669613	ENSG00000254207.1	RP11-43A14.1	5.8	1.23e-08	4.62e-06	0.51	0.26	IgG glycosylation;	chr8:667565	chr8:725188~725877:-
LUAD	cis	rs7714584	1	rs75294883	ENSG00000197083.10	ZNF300P1	5.8	1.23e-08	4.62e-06	0.58	0.26	Crohn's disease;	chr5:150816941	chr5:150930645~150946289:-
LUAD	cis	rs4947019	0.534	rs9487087	ENSG00000260273.1	RP11-425D10.10	5.8	1.23e-08	4.62e-06	0.56	0.26	Hematological parameters;	chr6:109401184	chr6:109382795~109383666:+
LUAD	cis	rs394563	0.591	rs237035	ENSG00000231760.4	RP11-350J20.5	5.8	1.23e-08	4.62e-06	0.31	0.26	Dupuytren's disease;	chr6:149389712	chr6:149796151~149826294:-
LUAD	cis	rs875971	0.862	rs6460306	ENSG00000222364.1	RNU6-96P	5.8	1.23e-08	4.62e-06	0.29	0.26	Aortic root size;	chr7:66595806	chr7:66395191~66395286:+
LUAD	cis	rs763567	0.9	rs525489	ENSG00000271811.1	RP1-79C4.4	5.8	1.23e-08	4.62e-06	0.31	0.26	Tonsillectomy;	chr1:170665861	chr1:170667381~170669425:+
LUAD	cis	rs763567	0.835	rs503706	ENSG00000271811.1	RP1-79C4.4	5.8	1.23e-08	4.62e-06	0.31	0.26	Tonsillectomy;	chr1:170665943	chr1:170667381~170669425:+
LUAD	cis	rs948562	0.793	rs1800169	ENSG00000280010.1	AP001350.4	5.8	1.23e-08	4.62e-06	0.43	0.26	Lymphoma;	chr11:58624028	chr11:58627435~58628528:+
LUAD	cis	rs10129255	0.5	rs988132	ENSG00000211967.3	IGHV3-53	-5.8	1.23e-08	4.62e-06	-0.19	-0.26	Kawasaki disease;	chr14:106776758	chr14:106592676~106593347:-
LUAD	cis	rs12908161	1	rs12911736	ENSG00000225151.9	GOLGA2P7	-5.8	1.23e-08	4.62e-06	-0.35	-0.26	Schizophrenia;	chr15:84696777	chr15:84199311~84230136:-
LUAD	cis	rs875971	0.862	rs1860469	ENSG00000237310.1	GS1-124K5.4	-5.8	1.23e-08	4.62e-06	-0.28	-0.26	Aortic root size;	chr7:66641888	chr7:66493706~66495474:+
LUAD	cis	rs2765539	0.851	rs1325939	ENSG00000226172.2	RP4-712E4.1	5.8	1.23e-08	4.62e-06	0.31	0.26	Waist-hip ratio;	chr1:119041345	chr1:119000344~119001392:-
LUAD	cis	rs8177376	0.727	rs601985	ENSG00000254905.1	RP11-712L6.7	5.8	1.23e-08	4.63e-06	0.34	0.26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126327662	chr11:126292922~126294254:-
LUAD	cis	rs2243480	1	rs13247184	ENSG00000230295.1	RP11-458F8.2	-5.8	1.23e-08	4.63e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:65893941	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs35283677	ENSG00000230295.1	RP11-458F8.2	-5.8	1.23e-08	4.63e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:65894246	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs35421653	ENSG00000230295.1	RP11-458F8.2	-5.8	1.23e-08	4.63e-06	-0.32	-0.26	Diabetic kidney disease;	chr7:65898442	chr7:66880708~66882981:+
LUAD	cis	rs11098499	1	rs13116504	ENSG00000248280.1	RP11-33B1.2	5.8	1.23e-08	4.63e-06	0.32	0.26	Corneal astigmatism;	chr4:119288257	chr4:119440561~119450157:-
LUAD	cis	rs2404602	0.583	rs11072580	ENSG00000259422.1	RP11-593F23.1	5.8	1.23e-08	4.63e-06	0.29	0.26	Blood metabolite levels;	chr15:76247890	chr15:76174891~76181486:-
LUAD	cis	rs7246657	0.722	rs2972430	ENSG00000276846.1	CTD-3220F14.3	-5.8	1.23e-08	4.63e-06	-0.35	-0.26	Coronary artery calcification;	chr19:37691210	chr19:37314868~37315620:-
LUAD	cis	rs4835473	0.932	rs9308176	ENSG00000251600.4	RP11-673E1.1	-5.8	1.23e-08	4.63e-06	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:144072718	chr4:143912331~143982454:+
LUAD	cis	rs853679	0.527	rs853693	ENSG00000216901.1	AL022393.7	5.8	1.23e-08	4.64e-06	0.31	0.26	Depression;	chr6:28314871	chr6:28176188~28176674:+
LUAD	cis	rs763567	0.605	rs619456	ENSG00000271811.1	RP1-79C4.4	-5.8	1.23e-08	4.64e-06	-0.3	-0.26	Tonsillectomy;	chr1:170616691	chr1:170667381~170669425:+
LUAD	cis	rs7246657	0.722	rs2909093	ENSG00000276846.1	CTD-3220F14.3	-5.8	1.23e-08	4.64e-06	-0.35	-0.26	Coronary artery calcification;	chr19:37708561	chr19:37314868~37315620:-
LUAD	cis	rs2288884	1	rs2288884	ENSG00000275055.1	CTC-471J1.11	-5.8	1.23e-08	4.65e-06	-0.39	-0.26	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52029018	chr19:52049007~52049754:+
LUAD	cis	rs9595908	0.709	rs56347753	ENSG00000212293.1	SNORA16	5.8	1.23e-08	4.65e-06	0.27	0.26	Body mass index;	chr13:32721685	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.669	rs9596149	ENSG00000212293.1	SNORA16	5.8	1.23e-08	4.65e-06	0.27	0.26	Body mass index;	chr13:32722533	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.709	rs4281583	ENSG00000212293.1	SNORA16	5.8	1.23e-08	4.65e-06	0.27	0.26	Body mass index;	chr13:32722781	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.709	rs7322827	ENSG00000212293.1	SNORA16	5.8	1.23e-08	4.65e-06	0.27	0.26	Body mass index;	chr13:32724396	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.629	rs9596156	ENSG00000212293.1	SNORA16	5.8	1.23e-08	4.65e-06	0.27	0.26	Body mass index;	chr13:32724977	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.733	rs9591282	ENSG00000212293.1	SNORA16	5.8	1.23e-08	4.65e-06	0.27	0.26	Body mass index;	chr13:32725844	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.669	rs7319787	ENSG00000212293.1	SNORA16	5.8	1.23e-08	4.65e-06	0.27	0.26	Body mass index;	chr13:32728320	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.669	rs7331529	ENSG00000212293.1	SNORA16	5.8	1.23e-08	4.65e-06	0.27	0.26	Body mass index;	chr13:32728409	chr13:32420390~32420516:-
LUAD	cis	rs673078	0.607	rs6490177	ENSG00000275409.1	RP11-131L12.4	-5.8	1.24e-08	4.65e-06	-0.33	-0.26	Glucose homeostasis traits;	chr12:118358280	chr12:118430147~118430699:+
LUAD	cis	rs7772486	0.558	rs2142978	ENSG00000235652.6	RP11-545I5.3	-5.79	1.24e-08	4.66e-06	-0.27	-0.26	Lobe attachment (rater-scored or self-reported);	chr6:145690925	chr6:145799409~145886585:+
LUAD	cis	rs2179367	0.553	rs7762222	ENSG00000231760.4	RP11-350J20.5	5.79	1.24e-08	4.66e-06	0.38	0.26	Dupuytren's disease;	chr6:149444846	chr6:149796151~149826294:-
LUAD	cis	rs12291225	0.535	rs12806025	ENSG00000251991.1	RNU7-49P	5.79	1.24e-08	4.66e-06	0.28	0.26	Sense of smell;	chr11:14392271	chr11:14478892~14478953:+
LUAD	cis	rs3738443	0.868	rs61840048	ENSG00000259865.1	RP11-488L18.10	5.79	1.24e-08	4.67e-06	0.26	0.26	Alcohol dependence;	chr1:247199829	chr1:247187281~247188526:-
LUAD	cis	rs1134634	0.52	rs16892152	ENSG00000273133.1	RP11-799M12.2	-5.79	1.24e-08	4.67e-06	-0.38	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15559630	chr4:15563698~15564253:-
LUAD	cis	rs6772849	0.775	rs67105978	ENSG00000242551.2	POU5F1P6	-5.79	1.24e-08	4.67e-06	-0.3	-0.26	Monocyte percentage of white cells;Monocyte count;	chr3:128696337	chr3:128674735~128677005:-
LUAD	cis	rs7927592	0.956	rs10896348	ENSG00000212093.1	AP000807.1	5.79	1.24e-08	4.67e-06	0.28	0.26	Total body bone mineral density;	chr11:68589900	chr11:68506083~68506166:-
LUAD	cis	rs35740288	0.77	rs12907126	ENSG00000202081.1	RNU6-1280P	5.79	1.24e-08	4.67e-06	0.32	0.26	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85628126	chr15:85651522~85651628:-
LUAD	cis	rs10740039	0.81	rs10761528	ENSG00000254271.1	RP11-131N11.4	5.79	1.24e-08	4.68e-06	0.29	0.26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60607902	chr10:60734342~60741828:+
LUAD	cis	rs2404602	0.647	rs11072628	ENSG00000259422.1	RP11-593F23.1	-5.79	1.24e-08	4.68e-06	-0.34	-0.26	Blood metabolite levels;	chr15:76815420	chr15:76174891~76181486:-
LUAD	cis	rs950169	0.544	rs62021193	ENSG00000225151.9	GOLGA2P7	-5.79	1.24e-08	4.68e-06	-0.35	-0.26	Schizophrenia;	chr15:84627352	chr15:84199311~84230136:-
LUAD	cis	rs7945705	0.935	rs2568062	ENSG00000254860.4	TMEM9B-AS1	5.79	1.25e-08	4.69e-06	0.28	0.26	Hemoglobin concentration;	chr11:8866398	chr11:8964675~8977527:+
LUAD	cis	rs2412819	0.559	rs8040336	ENSG00000205771.5	CATSPER2P1	-5.79	1.25e-08	4.69e-06	-0.3	-0.26	Lung cancer;	chr15:43761419	chr15:43726918~43747094:-
LUAD	cis	rs66887589	0.775	rs6843229	ENSG00000245958.5	RP11-33B1.1	-5.79	1.25e-08	4.69e-06	-0.21	-0.26	Diastolic blood pressure;	chr4:119502932	chr4:119454791~119552025:+
LUAD	cis	rs10214930	0.606	rs4719900	ENSG00000235574.1	AC073150.6	-5.79	1.25e-08	4.69e-06	-0.32	-0.26	Hypospadias;	chr7:27528502	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs2080245	ENSG00000235574.1	AC073150.6	-5.79	1.25e-08	4.69e-06	-0.32	-0.26	Hypospadias;	chr7:27529911	chr7:27491682~27492765:-
LUAD	cis	rs293748	0.771	rs158410	ENSG00000250155.1	CTD-2353F22.1	-5.79	1.25e-08	4.7e-06	-0.36	-0.26	Obesity-related traits;	chr5:36858559	chr5:36666214~36725195:-
LUAD	cis	rs17666538	0.585	rs4448252	ENSG00000254207.1	RP11-43A14.1	5.79	1.25e-08	4.7e-06	0.51	0.26	IgG glycosylation;	chr8:665597	chr8:725188~725877:-
LUAD	cis	rs17666538	0.535	rs4338080	ENSG00000254207.1	RP11-43A14.1	5.79	1.25e-08	4.7e-06	0.51	0.26	IgG glycosylation;	chr8:665598	chr8:725188~725877:-
LUAD	cis	rs875971	0.502	rs2946580	ENSG00000237310.1	GS1-124K5.4	-5.79	1.25e-08	4.71e-06	-0.33	-0.26	Aortic root size;	chr7:66066855	chr7:66493706~66495474:+
LUAD	cis	rs9309473	1	rs6546835	ENSG00000163016.8	ALMS1P	5.79	1.25e-08	4.71e-06	0.31	0.26	Metabolite levels;	chr2:73437587	chr2:73644919~73685576:+
LUAD	cis	rs9309473	1	rs2901438	ENSG00000163016.8	ALMS1P	5.79	1.25e-08	4.71e-06	0.31	0.26	Metabolite levels;	chr2:73438528	chr2:73644919~73685576:+
LUAD	cis	rs2404602	0.735	rs11857015	ENSG00000259422.1	RP11-593F23.1	-5.79	1.25e-08	4.71e-06	-0.33	-0.26	Blood metabolite levels;	chr15:76357049	chr15:76174891~76181486:-
LUAD	cis	rs12699921	0.632	rs4532510	ENSG00000279048.1	RP11-511H23.2	5.79	1.25e-08	4.71e-06	0.21	0.26	Fibrinogen levels;	chr7:17931601	chr7:17940503~17942922:+
LUAD	cis	rs6570726	0.599	rs4398765	ENSG00000235652.6	RP11-545I5.3	5.79	1.26e-08	4.72e-06	0.27	0.26	Lobe attachment (rater-scored or self-reported);	chr6:145613870	chr6:145799409~145886585:+
LUAD	cis	rs755249	0.876	rs61781391	ENSG00000228060.1	RP11-69E11.8	-5.79	1.26e-08	4.73e-06	-0.27	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39611865	chr1:39565160~39573203:+
LUAD	cis	rs496547	0.588	rs473298	ENSG00000255239.1	AP002954.6	5.79	1.26e-08	4.74e-06	0.31	0.26	Hip minimal joint space width;	chr11:118808678	chr11:118688039~118690600:-
LUAD	cis	rs10214930	0.697	rs1524533	ENSG00000235574.1	AC073150.6	-5.79	1.26e-08	4.74e-06	-0.32	-0.26	Hypospadias;	chr7:27586177	chr7:27491682~27492765:-
LUAD	cis	rs875971	0.798	rs12698522	ENSG00000222364.1	RNU6-96P	-5.79	1.26e-08	4.74e-06	-0.29	-0.26	Aortic root size;	chr7:66502354	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.83	rs28714531	ENSG00000222364.1	RNU6-96P	-5.79	1.26e-08	4.74e-06	-0.29	-0.26	Aortic root size;	chr7:66503250	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs12698526	ENSG00000222364.1	RNU6-96P	-5.79	1.26e-08	4.74e-06	-0.29	-0.26	Aortic root size;	chr7:66504118	chr7:66395191~66395286:+
LUAD	cis	rs2933343	1	rs2929859	ENSG00000261159.1	RP11-723O4.9	5.79	1.26e-08	4.75e-06	0.31	0.26	IgG glycosylation;	chr3:128889498	chr3:128859716~128860526:-
LUAD	cis	rs2599510	0.811	rs176413	ENSG00000276334.1	AL133243.1	-5.79	1.26e-08	4.75e-06	-0.3	-0.26	Interleukin-18 levels;	chr2:32421779	chr2:32521927~32523547:+
LUAD	cis	rs755249	0.567	rs61779308	ENSG00000228060.1	RP11-69E11.8	-5.79	1.26e-08	4.75e-06	-0.26	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39472585	chr1:39565160~39573203:+
LUAD	cis	rs17214007	0.877	rs7201553	ENSG00000263335.1	AF001548.5	-5.79	1.26e-08	4.75e-06	-0.36	-0.26	Cognitive function;	chr16:15781186	chr16:15726674~15732993:+
LUAD	cis	rs9595908	0.709	rs1924606	ENSG00000212293.1	SNORA16	5.79	1.27e-08	4.75e-06	0.27	0.26	Body mass index;	chr13:32759230	chr13:32420390~32420516:-
LUAD	cis	rs916888	0.779	rs199528	ENSG00000261575.2	RP11-259G18.1	5.79	1.27e-08	4.75e-06	0.41	0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46267037~46268694:+
LUAD	cis	rs916888	0.821	rs199525	ENSG00000261575.2	RP11-259G18.1	5.79	1.27e-08	4.75e-06	0.41	0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46267037~46268694:+
LUAD	cis	rs55665837	0.701	rs11023265	ENSG00000251991.1	RNU7-49P	5.79	1.27e-08	4.75e-06	0.3	0.26	Vitamin D levels;	chr11:14594492	chr11:14478892~14478953:+
LUAD	cis	rs997295	0.57	rs28730805	ENSG00000270964.1	RP11-502I4.3	-5.79	1.27e-08	4.75e-06	-0.27	-0.26	Motion sickness;	chr15:67587080	chr15:67541072~67542604:-
LUAD	cis	rs875971	0.862	rs4718383	ENSG00000237310.1	GS1-124K5.4	-5.79	1.27e-08	4.76e-06	-0.28	-0.26	Aortic root size;	chr7:66643422	chr7:66493706~66495474:+
LUAD	cis	rs8062405	1	rs3888190	ENSG00000251417.2	RP11-1348G14.4	-5.79	1.27e-08	4.76e-06	-0.26	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28802743~28817828:+
LUAD	cis	rs4803480	0.543	rs7257282	ENSG00000270164.1	LINC01480	-5.79	1.27e-08	4.76e-06	-0.23	-0.26	Schizophrenia;	chr19:41536585	chr19:41535183~41536904:+
LUAD	cis	rs2998286	0.678	rs332184	ENSG00000254635.4	WAC-AS1	-5.79	1.27e-08	4.76e-06	-0.37	-0.26	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28624042	chr10:28522652~28532743:-
LUAD	cis	rs875971	0.825	rs1000464	ENSG00000222364.1	RNU6-96P	5.79	1.27e-08	4.76e-06	0.29	0.26	Aortic root size;	chr7:66312922	chr7:66395191~66395286:+
LUAD	cis	rs7181230	0.885	rs3923235	ENSG00000275636.1	RP11-521C20.5	5.79	1.27e-08	4.76e-06	0.35	0.26	Dehydroepiandrosterone sulphate levels;	chr15:40078920	chr15:40078892~40079347:+
LUAD	cis	rs875971	0.862	rs6460282	ENSG00000222364.1	RNU6-96P	5.79	1.27e-08	4.76e-06	0.29	0.26	Aortic root size;	chr7:66226259	chr7:66395191~66395286:+
LUAD	cis	rs1134634	0.52	rs2041671	ENSG00000273133.1	RP11-799M12.2	-5.79	1.27e-08	4.77e-06	-0.37	-0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15550575	chr4:15563698~15564253:-
LUAD	cis	rs875971	0.798	rs12698522	ENSG00000237310.1	GS1-124K5.4	5.79	1.27e-08	4.77e-06	0.28	0.26	Aortic root size;	chr7:66502354	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.83	rs28714531	ENSG00000237310.1	GS1-124K5.4	5.79	1.27e-08	4.77e-06	0.28	0.26	Aortic root size;	chr7:66503250	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs12698526	ENSG00000237310.1	GS1-124K5.4	5.79	1.27e-08	4.77e-06	0.28	0.26	Aortic root size;	chr7:66504118	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs1638724	ENSG00000226824.5	RP4-756H11.3	5.79	1.27e-08	4.77e-06	0.36	0.26	Aortic root size;	chr7:66575494	chr7:66654538~66669855:+
LUAD	cis	rs2404602	0.647	rs11072626	ENSG00000259422.1	RP11-593F23.1	-5.79	1.27e-08	4.77e-06	-0.33	-0.26	Blood metabolite levels;	chr15:76798485	chr15:76174891~76181486:-
LUAD	cis	rs12699921	0.632	rs2723569	ENSG00000279048.1	RP11-511H23.2	-5.79	1.27e-08	4.78e-06	-0.21	-0.26	Fibrinogen levels;	chr7:17854048	chr7:17940503~17942922:+
LUAD	cis	rs4835473	0.778	rs75562808	ENSG00000251600.4	RP11-673E1.1	-5.79	1.27e-08	4.78e-06	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143779065	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs6858195	ENSG00000251600.4	RP11-673E1.1	-5.79	1.27e-08	4.78e-06	-0.31	-0.26	Immature fraction of reticulocytes;	chr4:143768444	chr4:143912331~143982454:+
LUAD	cis	rs6921919	0.583	rs7740351	ENSG00000216901.1	AL022393.7	5.79	1.27e-08	4.78e-06	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28176188~28176674:+
LUAD	cis	rs2404602	0.684	rs28895952	ENSG00000259422.1	RP11-593F23.1	-5.79	1.27e-08	4.78e-06	-0.34	-0.26	Blood metabolite levels;	chr15:76564435	chr15:76174891~76181486:-
LUAD	cis	rs66887589	0.616	rs11731675	ENSG00000248280.1	RP11-33B1.2	5.79	1.28e-08	4.79e-06	0.29	0.26	Diastolic blood pressure;	chr4:119291359	chr4:119440561~119450157:-
LUAD	cis	rs4713118	0.513	rs149950	ENSG00000204709.4	LINC01556	5.79	1.28e-08	4.79e-06	0.32	0.26	Parkinson's disease;	chr6:28065261	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.513	rs149951	ENSG00000204709.4	LINC01556	5.79	1.28e-08	4.79e-06	0.32	0.26	Parkinson's disease;	chr6:28065309	chr6:28943877~28944537:+
LUAD	cis	rs9601248	0.627	rs9545151	ENSG00000227354.5	RBM26-AS1	-5.79	1.28e-08	4.79e-06	-0.29	-0.26	Major depressive disorder;	chr13:79608400	chr13:79406309~79424328:+
LUAD	cis	rs7246657	0.638	rs7246461	ENSG00000276846.1	CTD-3220F14.3	-5.79	1.28e-08	4.8e-06	-0.34	-0.26	Coronary artery calcification;	chr19:37705680	chr19:37314868~37315620:-
LUAD	cis	rs950169	0.58	rs11635597	ENSG00000225151.9	GOLGA2P7	-5.79	1.28e-08	4.8e-06	-0.35	-0.26	Schizophrenia;	chr15:84622468	chr15:84199311~84230136:-
LUAD	cis	rs2212361	0.558	rs7934178	ENSG00000255893.1	RP11-685N10.1	-5.79	1.28e-08	4.8e-06	-0.33	-0.26	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94531307	chr11:94472908~94473570:-
LUAD	cis	rs2212361	0.558	rs7934183	ENSG00000255893.1	RP11-685N10.1	-5.79	1.28e-08	4.8e-06	-0.33	-0.26	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94531321	chr11:94472908~94473570:-
LUAD	cis	rs6772849	0.768	rs9820741	ENSG00000242551.2	POU5F1P6	-5.79	1.28e-08	4.82e-06	-0.3	-0.26	Monocyte percentage of white cells;Monocyte count;	chr3:128697237	chr3:128674735~128677005:-
LUAD	cis	rs1707322	0.826	rs10890349	ENSG00000234329.1	RP11-767N6.2	5.79	1.28e-08	4.82e-06	0.27	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784283	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.758	rs10789474	ENSG00000234329.1	RP11-767N6.2	5.79	1.28e-08	4.82e-06	0.27	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784368	chr1:45651039~45651826:-
LUAD	cis	rs1322639	0.614	rs9364361	ENSG00000261039.2	RP11-417E7.2	-5.79	1.28e-08	4.82e-06	-0.41	-0.26	Pulse pressure;	chr6:169180404	chr6:169175304~169182740:-
LUAD	cis	rs2404602	0.716	rs4886813	ENSG00000259422.1	RP11-593F23.1	-5.79	1.28e-08	4.82e-06	-0.29	-0.26	Blood metabolite levels;	chr15:76545880	chr15:76174891~76181486:-
LUAD	cis	rs155076	1	rs12870992	ENSG00000233325.3	MIPEPP3	-5.79	1.29e-08	4.83e-06	-0.41	-0.26	White matter hyperintensity burden;	chr13:21271880	chr13:21298139~21306373:+
LUAD	cis	rs950169	0.58	rs11634322	ENSG00000225151.9	GOLGA2P7	-5.79	1.29e-08	4.83e-06	-0.35	-0.26	Schizophrenia;	chr15:84628978	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.58	rs4603535	ENSG00000225151.9	GOLGA2P7	-5.79	1.29e-08	4.83e-06	-0.35	-0.26	Schizophrenia;	chr15:84630641	chr15:84199311~84230136:-
LUAD	cis	rs67311347	1	rs2276868	ENSG00000223797.4	ENTPD3-AS1	-5.79	1.29e-08	4.83e-06	-0.26	-0.26	Renal cell carcinoma;	chr3:40457354	chr3:40313802~40453329:-
LUAD	cis	rs2255336	0.938	rs7953692	ENSG00000245648.1	RP11-277P12.20	-5.79	1.29e-08	4.83e-06	-0.41	-0.26	Blood protein levels;	chr12:10482432	chr12:10363769~10398506:+
LUAD	cis	rs9847710	0.67	rs2564933	ENSG00000242142.1	SERBP1P3	5.79	1.29e-08	4.83e-06	0.3	0.26	Ulcerative colitis;	chr3:52989357	chr3:53064283~53065091:-
LUAD	cis	rs875971	0.862	rs11763189	ENSG00000237310.1	GS1-124K5.4	5.79	1.29e-08	4.84e-06	0.28	0.26	Aortic root size;	chr7:66518542	chr7:66493706~66495474:+
LUAD	cis	rs2404602	0.672	rs35374222	ENSG00000259422.1	RP11-593F23.1	-5.79	1.29e-08	4.84e-06	-0.34	-0.26	Blood metabolite levels;	chr15:76779053	chr15:76174891~76181486:-
LUAD	cis	rs11105298	0.891	rs11105312	ENSG00000258302.2	RP11-981P6.1	5.79	1.29e-08	4.84e-06	0.32	0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89526956	chr12:89561129~89594878:+
LUAD	cis	rs11105298	0.891	rs10777185	ENSG00000258302.2	RP11-981P6.1	5.79	1.29e-08	4.84e-06	0.32	0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89527498	chr12:89561129~89594878:+
LUAD	cis	rs7923609	0.967	rs3999089	ENSG00000232075.1	MRPL35P2	5.79	1.29e-08	4.85e-06	0.31	0.26	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63444048	chr10:63634317~63634827:-
LUAD	cis	rs950169	0.541	rs10795	ENSG00000225151.9	GOLGA2P7	-5.79	1.3e-08	4.86e-06	-0.35	-0.26	Schizophrenia;	chr15:84634066	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.58	rs36126054	ENSG00000225151.9	GOLGA2P7	-5.79	1.3e-08	4.86e-06	-0.35	-0.26	Schizophrenia;	chr15:84634492	chr15:84199311~84230136:-
LUAD	cis	rs4964805	0.802	rs934847	ENSG00000257681.1	RP11-341G23.4	5.79	1.3e-08	4.86e-06	0.31	0.26	Attention deficit hyperactivity disorder;	chr12:103791915	chr12:103746315~103768858:-
LUAD	cis	rs2179367	0.959	rs521845	ENSG00000231760.4	RP11-350J20.5	-5.79	1.3e-08	4.87e-06	-0.31	-0.26	Dupuytren's disease;	chr6:149350562	chr6:149796151~149826294:-
LUAD	cis	rs2243480	1	rs160643	ENSG00000230295.1	RP11-458F8.2	-5.79	1.3e-08	4.87e-06	-0.29	-0.26	Diabetic kidney disease;	chr7:66093235	chr7:66880708~66882981:+
LUAD	cis	rs9309473	0.948	rs2421550	ENSG00000163016.8	ALMS1P	5.79	1.3e-08	4.87e-06	0.31	0.26	Metabolite levels;	chr2:73431558	chr2:73644919~73685576:+
LUAD	cis	rs7688540	0.8	rs6857106	ENSG00000275426.1	CH17-262A2.1	-5.79	1.3e-08	4.88e-06	-0.3	-0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:255641	chr4:149738~150317:+
LUAD	cis	rs9326246	0.556	rs662799	ENSG00000254851.1	RP11-109L13.1	-5.79	1.3e-08	4.88e-06	-0.53	-0.26	Coronary artery disease;	chr11:116792991	chr11:117135528~117138582:+
LUAD	cis	rs897984	0.645	rs58726213	ENSG00000260911.2	RP11-196G11.2	5.79	1.3e-08	4.88e-06	0.23	0.26	Dementia with Lewy bodies;	chr16:31033362	chr16:31043150~31049868:+
LUAD	cis	rs916888	0.773	rs199445	ENSG00000261575.2	RP11-259G18.1	5.79	1.3e-08	4.88e-06	0.4	0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46267037~46268694:+
LUAD	cis	rs916888	0.773	rs199443	ENSG00000261575.2	RP11-259G18.1	5.79	1.3e-08	4.88e-06	0.4	0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46267037~46268694:+
LUAD	cis	rs10214930	0.813	rs6954905	ENSG00000235574.1	AC073150.6	-5.79	1.3e-08	4.88e-06	-0.34	-0.26	Hypospadias;	chr7:27625206	chr7:27491682~27492765:-
LUAD	cis	rs516805	0.961	rs9385248	ENSG00000279453.1	RP3-425C14.4	-5.79	1.3e-08	4.88e-06	-0.29	-0.26	Lymphocyte counts;	chr6:122490982	chr6:122436789~122439223:-
LUAD	cis	rs10214930	0.647	rs2391438	ENSG00000235574.1	AC073150.6	-5.79	1.3e-08	4.89e-06	-0.32	-0.26	Hypospadias;	chr7:27530554	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs1014373	ENSG00000235574.1	AC073150.6	-5.79	1.3e-08	4.89e-06	-0.32	-0.26	Hypospadias;	chr7:27531474	chr7:27491682~27492765:-
LUAD	cis	rs914615	0.508	rs4971079	ENSG00000160766.13	GBAP1	-5.79	1.3e-08	4.89e-06	-0.26	-0.26	Urinary albumin-to-creatinine ratio;	chr1:155157915	chr1:155213821~155227422:-
LUAD	cis	rs867371	1	rs13380319	ENSG00000259429.4	UBE2Q2P2	-5.79	1.31e-08	4.89e-06	-0.22	-0.26	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214526	chr15:82355142~82420075:+
LUAD	cis	rs858239	0.539	rs6965833	ENSG00000230042.1	AK3P3	-5.79	1.31e-08	4.9e-06	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.539	rs6949363	ENSG00000230042.1	AK3P3	-5.79	1.31e-08	4.9e-06	-0.33	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23129178~23129841:+
LUAD	cis	rs6687821	0.515	rs1199726	ENSG00000267734.1	RP4-604K5.3	5.78	1.31e-08	4.91e-06	0.32	0.26	Yeast infection;	chr1:86951691	chr1:86932199~86934891:-
LUAD	cis	rs673078	0.607	rs73207504	ENSG00000275409.1	RP11-131L12.4	-5.78	1.31e-08	4.91e-06	-0.36	-0.26	Glucose homeostasis traits;	chr12:118427914	chr12:118430147~118430699:+
LUAD	cis	rs9326246	0.643	rs2072560	ENSG00000254851.1	RP11-109L13.1	-5.78	1.31e-08	4.91e-06	-0.56	-0.26	Coronary artery disease;	chr11:116791110	chr11:117135528~117138582:+
LUAD	cis	rs2442825	0.693	rs2596916	ENSG00000206573.7	THUMPD3-AS1	5.78	1.31e-08	4.92e-06	0.18	0.26	Cerebrospinal fluid clusterin levels;	chr3:9380526	chr3:9349689~9398579:-
LUAD	cis	rs2408955	0.522	rs3997	ENSG00000240399.1	RP1-228P16.1	-5.78	1.31e-08	4.92e-06	-0.26	-0.26	Glycated hemoglobin levels;	chr12:48087804	chr12:48054813~48055591:-
LUAD	cis	rs2408955	0.522	rs10875721	ENSG00000240399.1	RP1-228P16.1	-5.78	1.32e-08	4.94e-06	-0.26	-0.25	Glycated hemoglobin levels;	chr12:48019810	chr12:48054813~48055591:-
LUAD	cis	rs7246657	0.722	rs2291002	ENSG00000276846.1	CTD-3220F14.3	5.78	1.32e-08	4.94e-06	0.33	0.25	Coronary artery calcification;	chr19:37543024	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.722	rs10404031	ENSG00000276846.1	CTD-3220F14.3	5.78	1.32e-08	4.94e-06	0.33	0.25	Coronary artery calcification;	chr19:37545052	chr19:37314868~37315620:-
LUAD	cis	rs4787484	1	rs7189750	ENSG00000214725.6	CDIPT-AS1	-5.78	1.32e-08	4.94e-06	-0.32	-0.25	Response to taxane treatment (placlitaxel);	chr16:29900095	chr16:29863593~29868053:+
LUAD	cis	rs2243480	0.522	rs431168	ENSG00000273142.1	RP11-458F8.4	-5.78	1.32e-08	4.95e-06	-0.3	-0.25	Diabetic kidney disease;	chr7:66046617	chr7:66902857~66906297:+
LUAD	cis	rs875971	0.767	rs61348003	ENSG00000222364.1	RNU6-96P	-5.78	1.32e-08	4.95e-06	-0.29	-0.25	Aortic root size;	chr7:66540947	chr7:66395191~66395286:+
LUAD	cis	rs2765539	1	rs2765539	ENSG00000226172.2	RP4-712E4.1	-5.78	1.32e-08	4.95e-06	-0.32	-0.25	Waist-hip ratio;	chr1:119006795	chr1:119000344~119001392:-
LUAD	cis	rs2179367	0.632	rs997682	ENSG00000231760.4	RP11-350J20.5	-5.78	1.32e-08	4.96e-06	-0.36	-0.25	Dupuytren's disease;	chr6:149345484	chr6:149796151~149826294:-
LUAD	cis	rs7618501	0.602	rs2240327	ENSG00000234667.1	ACTBP13	-5.78	1.32e-08	4.96e-06	-0.28	-0.25	Intelligence (multi-trait analysis);	chr3:50075601	chr3:49873347~49877980:-
LUAD	cis	rs72615157	0.634	rs7789890	ENSG00000242294.5	STAG3L5P	5.78	1.32e-08	4.96e-06	0.22	0.25	Lung function (FEV1/FVC);	chr7:100202936	chr7:100336079~100351900:+
LUAD	cis	rs9309473	1	rs7576245	ENSG00000163016.8	ALMS1P	5.78	1.32e-08	4.96e-06	0.31	0.25	Metabolite levels;	chr2:73602551	chr2:73644919~73685576:+
LUAD	cis	rs9595908	0.63	rs79837633	ENSG00000212293.1	SNORA16	5.78	1.33e-08	4.96e-06	0.27	0.25	Body mass index;	chr13:32754590	chr13:32420390~32420516:-
LUAD	cis	rs1426063	0.614	rs17000261	ENSG00000249717.1	RP11-44F21.3	5.78	1.33e-08	4.96e-06	0.47	0.25	QT interval;	chr4:75108766	chr4:74955974~74970362:-
LUAD	cis	rs55665837	0.583	rs78843135	ENSG00000251991.1	RNU7-49P	5.78	1.33e-08	4.97e-06	0.28	0.25	Vitamin D levels;	chr11:14389708	chr11:14478892~14478953:+
LUAD	cis	rs875971	0.545	rs10261710	ENSG00000226824.5	RP4-756H11.3	-5.78	1.33e-08	4.97e-06	-0.38	-0.25	Aortic root size;	chr7:66249202	chr7:66654538~66669855:+
LUAD	cis	rs1134634	0.52	rs13121363	ENSG00000273133.1	RP11-799M12.2	5.78	1.33e-08	4.97e-06	0.37	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15567369	chr4:15563698~15564253:-
LUAD	cis	rs1134634	0.52	rs13116304	ENSG00000273133.1	RP11-799M12.2	5.78	1.33e-08	4.97e-06	0.37	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15567523	chr4:15563698~15564253:-
LUAD	cis	rs12188164	0.686	rs72711365	ENSG00000225138.6	CTD-2228K2.7	5.78	1.33e-08	4.97e-06	0.25	0.25	Cystic fibrosis severity;	chr5:416557	chr5:473236~480884:+
LUAD	cis	rs7714584	1	rs17800987	ENSG00000197083.10	ZNF300P1	5.78	1.33e-08	4.97e-06	0.5	0.25	Crohn's disease;	chr5:150943866	chr5:150930645~150946289:-
LUAD	cis	rs10129255	0.5	rs1974468	ENSG00000211967.3	IGHV3-53	-5.78	1.33e-08	4.98e-06	-0.18	-0.25	Kawasaki disease;	chr14:106686149	chr14:106592676~106593347:-
LUAD	cis	rs7246657	0.722	rs2927739	ENSG00000276846.1	CTD-3220F14.3	-5.78	1.33e-08	4.99e-06	-0.35	-0.25	Coronary artery calcification;	chr19:37658429	chr19:37314868~37315620:-
LUAD	cis	rs10759883	0.539	rs10115110	ENSG00000175611.10	LINC00476	5.78	1.33e-08	4.99e-06	0.3	0.25	Nicotine dependence;	chr9:96033023	chr9:95759231~95875977:-
LUAD	cis	rs9595908	0.709	rs7331632	ENSG00000212293.1	SNORA16	5.78	1.33e-08	4.99e-06	0.27	0.25	Body mass index;	chr13:32753864	chr13:32420390~32420516:-
LUAD	cis	rs3738443	0.868	rs4351686	ENSG00000259865.1	RP11-488L18.10	5.78	1.34e-08	4.99e-06	0.27	0.25	Alcohol dependence;	chr1:247190028	chr1:247187281~247188526:-
LUAD	cis	rs1075265	0.729	rs10201364	ENSG00000233266.1	HMGB1P31	5.78	1.34e-08	5e-06	0.32	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53990220	chr2:54051334~54051760:+
LUAD	cis	rs301901	0.729	rs125682	ENSG00000250155.1	CTD-2353F22.1	-5.78	1.34e-08	5e-06	-0.27	-0.25	Height;	chr5:37337045	chr5:36666214~36725195:-
LUAD	cis	rs304029	0.716	rs2307068	ENSG00000231249.1	ITPR1-AS1	5.78	1.34e-08	5e-06	0.27	0.25	Diabetic kidney disease;	chr3:4491276	chr3:4490891~4493163:-
LUAD	cis	rs6991838	0.673	rs7462352	ENSG00000200714.1	Y_RNA	5.78	1.34e-08	5e-06	0.3	0.25	Intelligence (multi-trait analysis);	chr8:65584378	chr8:65592731~65592820:+
LUAD	cis	rs2404602	0.647	rs12898416	ENSG00000259422.1	RP11-593F23.1	-5.78	1.34e-08	5e-06	-0.34	-0.25	Blood metabolite levels;	chr15:76749951	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.647	rs12904149	ENSG00000259422.1	RP11-593F23.1	-5.78	1.34e-08	5e-06	-0.34	-0.25	Blood metabolite levels;	chr15:76751311	chr15:76174891~76181486:-
LUAD	cis	rs673078	0.607	rs61943367	ENSG00000275409.1	RP11-131L12.4	-5.78	1.34e-08	5e-06	-0.36	-0.25	Glucose homeostasis traits;	chr12:118366316	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs61943368	ENSG00000275409.1	RP11-131L12.4	-5.78	1.34e-08	5e-06	-0.36	-0.25	Glucose homeostasis traits;	chr12:118366568	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs61943385	ENSG00000275409.1	RP11-131L12.4	-5.78	1.34e-08	5e-06	-0.36	-0.25	Glucose homeostasis traits;	chr12:118370339	chr12:118430147~118430699:+
LUAD	cis	rs9311474	0.967	rs11717383	ENSG00000243224.1	RP5-1157M23.2	-5.78	1.34e-08	5e-06	-0.25	-0.25	Electroencephalogram traits;	chr3:52253452	chr3:52239258~52241097:+
LUAD	cis	rs9311474	1	rs1060330	ENSG00000243224.1	RP5-1157M23.2	-5.78	1.34e-08	5e-06	-0.25	-0.25	Electroencephalogram traits;	chr3:52254929	chr3:52239258~52241097:+
LUAD	cis	rs4820294	0.669	rs9622678	ENSG00000233360.4	Z83844.1	5.78	1.34e-08	5e-06	0.26	0.25	Fat distribution (HIV);	chr22:37661331	chr22:37641832~37658377:-
LUAD	cis	rs9500256	0.683	rs10458024	ENSG00000215190.7	LINC00680	-5.78	1.34e-08	5.01e-06	-0.33	-0.25	Eosinophilic esophagitis (pediatric);	chr6:57997811	chr6:57946074~57961501:-
LUAD	cis	rs783540	0.934	rs4779050	ENSG00000278603.1	RP13-608F4.5	5.78	1.34e-08	5.01e-06	0.29	0.25	Schizophrenia;	chr15:82699986	chr15:82472203~82472426:+
LUAD	cis	rs7246657	0.722	rs10406379	ENSG00000276846.1	CTD-3220F14.3	5.78	1.34e-08	5.01e-06	0.33	0.25	Coronary artery calcification;	chr19:37545823	chr19:37314868~37315620:-
LUAD	cis	rs7615952	0.641	rs6438951	ENSG00000171084.14	FAM86JP	5.78	1.34e-08	5.01e-06	0.36	0.25	Blood pressure (smoking interaction);	chr3:125978156	chr3:125916620~125930024:+
LUAD	cis	rs4713118	0.786	rs200502	ENSG00000219392.1	RP1-265C24.5	-5.78	1.34e-08	5.01e-06	-0.34	-0.25	Parkinson's disease;	chr6:27820284	chr6:28115628~28116551:+
LUAD	cis	rs875971	0.862	rs10263690	ENSG00000237310.1	GS1-124K5.4	-5.78	1.34e-08	5.02e-06	-0.28	-0.25	Aortic root size;	chr7:66301466	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs10250544	ENSG00000237310.1	GS1-124K5.4	-5.78	1.34e-08	5.02e-06	-0.28	-0.25	Aortic root size;	chr7:66301574	chr7:66493706~66495474:+
LUAD	cis	rs17301013	0.606	rs333437	ENSG00000227373.4	RP11-160H22.5	5.78	1.34e-08	5.02e-06	0.35	0.25	Systemic lupus erythematosus;	chr1:174672224	chr1:174115300~174160004:-
LUAD	cis	rs7246657	0.722	rs2909102	ENSG00000276846.1	CTD-3220F14.3	-5.78	1.34e-08	5.02e-06	-0.34	-0.25	Coronary artery calcification;	chr19:37676463	chr19:37314868~37315620:-
LUAD	cis	rs394563	0.934	rs384334	ENSG00000231760.4	RP11-350J20.5	5.78	1.34e-08	5.02e-06	0.32	0.25	Dupuytren's disease;	chr6:149475036	chr6:149796151~149826294:-
LUAD	cis	rs2288884	0.636	rs1560690	ENSG00000275055.1	CTC-471J1.11	-5.78	1.34e-08	5.02e-06	-0.31	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52075094	chr19:52049007~52049754:+
LUAD	cis	rs1707322	0.717	rs3014237	ENSG00000280836.1	AL355480.1	5.78	1.34e-08	5.02e-06	0.34	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624580	chr1:45581219~45581321:-
LUAD	cis	rs17684571	0.7	rs13208409	ENSG00000231441.1	RP11-472M19.2	5.78	1.34e-08	5.03e-06	0.37	0.25	Schizophrenia;	chr6:56763747	chr6:56844002~56864078:+
LUAD	cis	rs916888	0.773	rs199457	ENSG00000261575.2	RP11-259G18.1	5.78	1.35e-08	5.03e-06	0.4	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46267037~46268694:+
LUAD	cis	rs858239	0.601	rs6461693	ENSG00000230042.1	AK3P3	5.78	1.35e-08	5.04e-06	0.32	0.25	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23129178~23129841:+
LUAD	cis	rs17684571	0.751	rs13194625	ENSG00000231441.1	RP11-472M19.2	5.78	1.35e-08	5.04e-06	0.38	0.25	Schizophrenia;	chr6:56820446	chr6:56844002~56864078:+
LUAD	cis	rs7727544	0.684	rs274567	ENSG00000233006.5	AC034220.3	-5.78	1.35e-08	5.04e-06	-0.23	-0.25	Blood metabolite levels;	chr5:132378717	chr5:132311285~132369916:-
LUAD	cis	rs10129255	0.957	rs10141009	ENSG00000224373.3	IGHV4-59	5.78	1.35e-08	5.05e-06	0.16	0.25	Kawasaki disease;	chr14:106776695	chr14:106627249~106627825:-
LUAD	cis	rs10129255	0.912	rs6576227	ENSG00000224373.3	IGHV4-59	5.78	1.35e-08	5.05e-06	0.16	0.25	Kawasaki disease;	chr14:106778202	chr14:106627249~106627825:-
LUAD	cis	rs10129255	0.957	rs6576228	ENSG00000224373.3	IGHV4-59	5.78	1.35e-08	5.05e-06	0.16	0.25	Kawasaki disease;	chr14:106778401	chr14:106627249~106627825:-
LUAD	cis	rs2439831	0.85	rs12441861	ENSG00000205771.5	CATSPER2P1	-5.78	1.35e-08	5.06e-06	-0.47	-0.25	Lung cancer in ever smokers;	chr15:43768685	chr15:43726918~43747094:-
LUAD	cis	rs765787	0.53	rs1648289	ENSG00000259520.4	CTD-2651B20.3	5.78	1.35e-08	5.06e-06	0.33	0.25	Uric acid levels;	chr15:45224296	chr15:45251580~45279251:-
LUAD	cis	rs765787	0.53	rs1648287	ENSG00000259520.4	CTD-2651B20.3	5.78	1.35e-08	5.06e-06	0.33	0.25	Uric acid levels;	chr15:45224758	chr15:45251580~45279251:-
LUAD	cis	rs9860428	0.774	rs7651207	ENSG00000242770.2	RP11-180K7.1	5.78	1.36e-08	5.07e-06	0.27	0.25	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112822625	chr3:112802478~112812819:+
LUAD	cis	rs3931020	0.688	rs452242	ENSG00000272864.1	RP11-17E13.2	5.78	1.36e-08	5.07e-06	0.36	0.25	Resistin levels;	chr1:74759941	chr1:74698769~74699333:-
LUAD	cis	rs11098499	1	rs35643470	ENSG00000248280.1	RP11-33B1.2	5.78	1.36e-08	5.07e-06	0.32	0.25	Corneal astigmatism;	chr4:119263793	chr4:119440561~119450157:-
LUAD	cis	rs1499614	1	rs1267818	ENSG00000230295.1	RP11-458F8.2	-5.78	1.36e-08	5.07e-06	-0.31	-0.25	Gout;	chr7:66642037	chr7:66880708~66882981:+
LUAD	cis	rs4835473	0.932	rs17694797	ENSG00000251600.4	RP11-673E1.1	-5.78	1.36e-08	5.07e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143778812	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs35947975	ENSG00000251600.4	RP11-673E1.1	-5.78	1.36e-08	5.07e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143778969	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1375987	ENSG00000251600.4	RP11-673E1.1	-5.78	1.36e-08	5.07e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143779622	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs7687151	ENSG00000251600.4	RP11-673E1.1	-5.78	1.36e-08	5.07e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143781681	chr4:143912331~143982454:+
LUAD	cis	rs12188164	0.686	rs56279338	ENSG00000225138.6	CTD-2228K2.7	5.78	1.36e-08	5.08e-06	0.25	0.25	Cystic fibrosis severity;	chr5:416003	chr5:473236~480884:+
LUAD	cis	rs1113500	0.897	rs2336127	ENSG00000226822.1	RP11-356N1.2	5.78	1.36e-08	5.09e-06	0.3	0.25	Growth-regulated protein alpha levels;	chr1:108098248	chr1:108071482~108074519:+
LUAD	cis	rs7829975	0.511	rs2980426	ENSG00000253981.4	ALG1L13P	5.78	1.36e-08	5.09e-06	0.31	0.25	Mood instability;	chr8:8288087	chr8:8236003~8244667:-
LUAD	cis	rs2412819	0.571	rs8030536	ENSG00000205771.5	CATSPER2P1	-5.78	1.36e-08	5.09e-06	-0.41	-0.25	Lung cancer;	chr15:43627365	chr15:43726918~43747094:-
LUAD	cis	rs8177876	0.915	rs4889233	ENSG00000261838.4	RP11-303E16.6	-5.78	1.36e-08	5.09e-06	-0.54	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81093378	chr16:81069854~81076598:+
LUAD	cis	rs2303759	0.543	rs7255778	ENSG00000268686.1	AC010524.2	-5.78	1.36e-08	5.09e-06	-0.35	-0.25	Multiple sclerosis;	chr19:49403351	chr19:49368705~49388081:-
LUAD	cis	rs7772486	0.558	rs9497403	ENSG00000235652.6	RP11-545I5.3	-5.78	1.36e-08	5.09e-06	-0.27	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145733559	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.727	rs2235481	ENSG00000235652.6	RP11-545I5.3	-5.78	1.36e-08	5.09e-06	-0.27	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145735712	chr6:145799409~145886585:+
LUAD	cis	rs2276314	1	rs56050783	ENSG00000278986.1	RP11-723J4.3	-5.78	1.37e-08	5.1e-06	-0.31	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:35973828	chr18:35972151~35973916:+
LUAD	cis	rs2276314	1	rs58054756	ENSG00000278986.1	RP11-723J4.3	-5.78	1.37e-08	5.1e-06	-0.31	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:35974090	chr18:35972151~35973916:+
LUAD	cis	rs367615	1	rs367615	ENSG00000249476.1	CTD-2587M2.1	-5.78	1.37e-08	5.1e-06	-0.32	-0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109613236	chr5:109237120~109326369:-
LUAD	cis	rs11157436	0.958	rs17255510	ENSG00000211812.1	TRAV26-2	5.78	1.37e-08	5.1e-06	0.29	0.25	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22194962	chr14:22202583~22203368:+
LUAD	cis	rs131777	0.545	rs140514	ENSG00000205559.3	CHKB-AS1	-5.78	1.37e-08	5.11e-06	-0.29	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50580150	chr22:50583026~50583877:+
LUAD	cis	rs3762637	1	rs72960431	ENSG00000272758.4	RP11-299J3.8	-5.78	1.37e-08	5.11e-06	-0.38	-0.25	LDL cholesterol levels;	chr3:122509814	chr3:122416207~122443180:+
LUAD	cis	rs4713118	0.588	rs200994	ENSG00000219392.1	RP1-265C24.5	5.78	1.37e-08	5.12e-06	0.36	0.25	Parkinson's disease;	chr6:27846035	chr6:28115628~28116551:+
LUAD	cis	rs4908768	0.539	rs4480384	ENSG00000232912.4	RP5-1115A15.1	5.78	1.37e-08	5.12e-06	0.23	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8599655	chr1:8424645~8434838:+
LUAD	cis	rs1113500	0.933	rs4590700	ENSG00000226822.1	RP11-356N1.2	5.78	1.37e-08	5.12e-06	0.3	0.25	Growth-regulated protein alpha levels;	chr1:108095722	chr1:108071482~108074519:+
LUAD	cis	rs10129255	0.957	rs8009464	ENSG00000211972.2	IGHV3-66	5.78	1.37e-08	5.13e-06	0.22	0.25	Kawasaki disease;	chr14:106777611	chr14:106675017~106675544:-
LUAD	cis	rs2243480	1	rs1723270	ENSG00000230295.1	RP11-458F8.2	-5.78	1.38e-08	5.13e-06	-0.31	-0.25	Diabetic kidney disease;	chr7:66004843	chr7:66880708~66882981:+
LUAD	cis	rs1113500	0.933	rs12035689	ENSG00000226822.1	RP11-356N1.2	5.78	1.38e-08	5.13e-06	0.3	0.25	Growth-regulated protein alpha levels;	chr1:108094134	chr1:108071482~108074519:+
LUAD	cis	rs1113500	0.862	rs3853494	ENSG00000226822.1	RP11-356N1.2	5.78	1.38e-08	5.13e-06	0.3	0.25	Growth-regulated protein alpha levels;	chr1:108094712	chr1:108071482~108074519:+
LUAD	cis	rs10129255	0.957	rs11846893	ENSG00000224373.3	IGHV4-59	5.78	1.38e-08	5.14e-06	0.16	0.25	Kawasaki disease;	chr14:106779068	chr14:106627249~106627825:-
LUAD	cis	rs36093844	0.898	rs11234446	ENSG00000279742.1	RP11-700A24.1	-5.78	1.38e-08	5.14e-06	-0.29	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85855126	chr11:85852557~85854943:-
LUAD	cis	rs4835473	0.9	rs4285038	ENSG00000251600.4	RP11-673E1.1	-5.78	1.38e-08	5.14e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143763637	chr4:143912331~143982454:+
LUAD	cis	rs12468226	0.606	rs10445793	ENSG00000226261.1	AC064836.3	5.78	1.38e-08	5.15e-06	0.39	0.25	Urate levels;	chr2:202190799	chr2:202336024~202336727:-
LUAD	cis	rs1134634	0.52	rs28419165	ENSG00000273133.1	RP11-799M12.2	-5.78	1.38e-08	5.15e-06	-0.38	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15587722	chr4:15563698~15564253:-
LUAD	cis	rs1075265	0.87	rs10207537	ENSG00000233266.1	HMGB1P31	5.78	1.38e-08	5.15e-06	0.32	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54101700	chr2:54051334~54051760:+
LUAD	cis	rs997295	0.57	rs7172298	ENSG00000270964.1	RP11-502I4.3	-5.78	1.38e-08	5.15e-06	-0.27	-0.25	Motion sickness;	chr15:67580645	chr15:67541072~67542604:-
LUAD	cis	rs4835473	0.932	rs6827971	ENSG00000251600.4	RP11-673E1.1	-5.78	1.38e-08	5.15e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143822126	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs4835305	ENSG00000251600.4	RP11-673E1.1	-5.78	1.38e-08	5.15e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143823646	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs11721700	ENSG00000251600.4	RP11-673E1.1	-5.78	1.38e-08	5.15e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143824264	chr4:143912331~143982454:+
LUAD	cis	rs8062405	0.688	rs3924376	ENSG00000251417.2	RP11-1348G14.4	5.77	1.38e-08	5.16e-06	0.27	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28802743~28817828:+
LUAD	cis	rs17666538	0.535	rs1669658	ENSG00000254207.1	RP11-43A14.1	5.77	1.38e-08	5.16e-06	0.5	0.25	IgG glycosylation;	chr8:657380	chr8:725188~725877:-
LUAD	cis	rs17301013	0.507	rs1613634	ENSG00000227373.4	RP11-160H22.5	-5.77	1.38e-08	5.16e-06	-0.37	-0.25	Systemic lupus erythematosus;	chr1:174803184	chr1:174115300~174160004:-
LUAD	cis	rs7927592	0.956	rs6591341	ENSG00000212093.1	AP000807.1	5.77	1.38e-08	5.16e-06	0.28	0.25	Total body bone mineral density;	chr11:68568010	chr11:68506083~68506166:-
LUAD	cis	rs1113500	0.933	rs10785834	ENSG00000226822.1	RP11-356N1.2	5.77	1.38e-08	5.16e-06	0.3	0.25	Growth-regulated protein alpha levels;	chr1:108096479	chr1:108071482~108074519:+
LUAD	cis	rs2998286	0.723	rs332190	ENSG00000254635.4	WAC-AS1	-5.77	1.38e-08	5.17e-06	-0.37	-0.25	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28630899	chr10:28522652~28532743:-
LUAD	cis	rs853679	0.882	rs3757188	ENSG00000219392.1	RP1-265C24.5	-5.77	1.39e-08	5.17e-06	-0.44	-0.25	Depression;	chr6:28139579	chr6:28115628~28116551:+
LUAD	cis	rs881375	0.678	rs10818488	ENSG00000226752.6	PSMD5-AS1	-5.77	1.39e-08	5.17e-06	-0.26	-0.25	Rheumatoid arthritis;	chr9:120942809	chr9:120824828~120854385:+
LUAD	cis	rs55665837	0.524	rs2882128	ENSG00000251991.1	RNU7-49P	5.77	1.39e-08	5.17e-06	0.28	0.25	Vitamin D levels;	chr11:14393088	chr11:14478892~14478953:+
LUAD	cis	rs2765539	0.545	rs1623409	ENSG00000226172.2	RP4-712E4.1	-5.77	1.39e-08	5.18e-06	-0.33	-0.25	Waist-hip ratio;	chr1:118962218	chr1:119000344~119001392:-
LUAD	cis	rs7246657	0.722	rs10409605	ENSG00000276846.1	CTD-3220F14.3	5.77	1.39e-08	5.18e-06	0.33	0.25	Coronary artery calcification;	chr19:37632236	chr19:37314868~37315620:-
LUAD	cis	rs17684571	0.687	rs17752213	ENSG00000231441.1	RP11-472M19.2	5.77	1.39e-08	5.18e-06	0.38	0.25	Schizophrenia;	chr6:56864627	chr6:56844002~56864078:+
LUAD	cis	rs10129255	0.957	rs6576233	ENSG00000224373.3	IGHV4-59	5.77	1.39e-08	5.18e-06	0.16	0.25	Kawasaki disease;	chr14:106787239	chr14:106627249~106627825:-
LUAD	cis	rs270601	0.721	rs162894	ENSG00000233006.5	AC034220.3	5.77	1.39e-08	5.18e-06	0.24	0.25	Acylcarnitine levels;	chr5:132276179	chr5:132311285~132369916:-
LUAD	cis	rs10129255	1	rs4612959	ENSG00000211974.3	IGHV2-70	5.77	1.39e-08	5.18e-06	0.27	0.25	Kawasaki disease;	chr14:106767055	chr14:106723574~106724093:-
LUAD	cis	rs875971	0.862	rs11773628	ENSG00000222364.1	RNU6-96P	5.77	1.39e-08	5.19e-06	0.29	0.25	Aortic root size;	chr7:66517644	chr7:66395191~66395286:+
LUAD	cis	rs3931020	0.688	rs277374	ENSG00000272864.1	RP11-17E13.2	5.77	1.39e-08	5.19e-06	0.36	0.25	Resistin levels;	chr1:74734802	chr1:74698769~74699333:-
LUAD	cis	rs5753618	0.561	rs714909	ENSG00000236132.1	CTA-440B3.1	-5.77	1.39e-08	5.19e-06	-0.32	-0.25	Colorectal cancer;	chr22:31345081	chr22:31816379~31817491:-
LUAD	cis	rs7188445	0.736	rs4888043	ENSG00000261390.4	RP11-345M22.2	5.77	1.39e-08	5.2e-06	0.31	0.25	Urate levels;	chr16:79668744	chr16:79715232~79770563:-
LUAD	cis	rs950169	0.58	rs11633762	ENSG00000225151.9	GOLGA2P7	-5.77	1.4e-08	5.2e-06	-0.35	-0.25	Schizophrenia;	chr15:84643921	chr15:84199311~84230136:-
LUAD	cis	rs11098499	0.913	rs12186259	ENSG00000248280.1	RP11-33B1.2	5.77	1.4e-08	5.2e-06	0.33	0.25	Corneal astigmatism;	chr4:119230884	chr4:119440561~119450157:-
LUAD	cis	rs516805	0.923	rs538457	ENSG00000279453.1	RP3-425C14.4	-5.77	1.4e-08	5.21e-06	-0.29	-0.25	Lymphocyte counts;	chr6:122485610	chr6:122436789~122439223:-
LUAD	cis	rs10740039	0.516	rs2154392	ENSG00000254271.1	RP11-131N11.4	5.77	1.4e-08	5.21e-06	0.29	0.25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60557728	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.516	rs6479717	ENSG00000254271.1	RP11-131N11.4	5.77	1.4e-08	5.21e-06	0.29	0.25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60559530	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.516	rs2068044	ENSG00000254271.1	RP11-131N11.4	5.77	1.4e-08	5.21e-06	0.29	0.25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60560679	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.516	rs1975443	ENSG00000254271.1	RP11-131N11.4	5.77	1.4e-08	5.21e-06	0.29	0.25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60561584	chr10:60734342~60741828:+
LUAD	cis	rs4604732	0.631	rs4411161	ENSG00000227135.1	GCSAML-AS1	-5.77	1.4e-08	5.21e-06	-0.39	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247469072	chr1:247524679~247526752:-
LUAD	cis	rs75920871	0.589	rs2075547	ENSG00000254851.1	RP11-109L13.1	-5.77	1.4e-08	5.22e-06	-0.43	-0.25	Subjective well-being;	chr11:117197818	chr11:117135528~117138582:+
LUAD	cis	rs783540	0.656	rs783524	ENSG00000278603.1	RP13-608F4.5	-5.77	1.4e-08	5.22e-06	-0.32	-0.25	Schizophrenia;	chr15:82615393	chr15:82472203~82472426:+
LUAD	cis	rs4639966	0.589	rs480958	ENSG00000255422.1	AP002954.4	-5.77	1.4e-08	5.23e-06	-0.32	-0.25	Systemic lupus erythematosus;	chr11:118707281	chr11:118704607~118750263:+
LUAD	cis	rs2404602	0.647	rs12898810	ENSG00000259422.1	RP11-593F23.1	-5.77	1.4e-08	5.23e-06	-0.35	-0.25	Blood metabolite levels;	chr15:76612397	chr15:76174891~76181486:-
LUAD	cis	rs7615952	0.641	rs7632497	ENSG00000171084.14	FAM86JP	5.77	1.41e-08	5.25e-06	0.37	0.25	Blood pressure (smoking interaction);	chr3:126064243	chr3:125916620~125930024:+
LUAD	cis	rs2111504	0.806	rs10403559	ENSG00000267213.4	AC007773.2	-5.77	1.41e-08	5.25e-06	-0.36	-0.25	Bipolar disorder;	chr19:32462195	chr19:32390050~32405560:-
LUAD	cis	rs1426063	0.61	rs72862239	ENSG00000249717.1	RP11-44F21.3	5.77	1.41e-08	5.25e-06	0.49	0.25	QT interval;	chr4:75071967	chr4:74955974~74970362:-
LUAD	cis	rs2243480	0.901	rs35823062	ENSG00000230295.1	RP11-458F8.2	-5.77	1.41e-08	5.25e-06	-0.31	-0.25	Diabetic kidney disease;	chr7:66500834	chr7:66880708~66882981:+
LUAD	cis	rs875971	1	rs778726	ENSG00000237310.1	GS1-124K5.4	5.77	1.41e-08	5.26e-06	0.27	0.25	Aortic root size;	chr7:66363744	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.964	rs778723	ENSG00000237310.1	GS1-124K5.4	5.77	1.41e-08	5.26e-06	0.27	0.25	Aortic root size;	chr7:66364510	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.767	rs1695815	ENSG00000237310.1	GS1-124K5.4	5.77	1.41e-08	5.26e-06	0.27	0.25	Aortic root size;	chr7:66366357	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs778685	ENSG00000237310.1	GS1-124K5.4	5.77	1.41e-08	5.26e-06	0.27	0.25	Aortic root size;	chr7:66371189	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.929	rs778682	ENSG00000237310.1	GS1-124K5.4	5.77	1.41e-08	5.26e-06	0.27	0.25	Aortic root size;	chr7:66372947	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.964	rs11765965	ENSG00000237310.1	GS1-124K5.4	5.77	1.41e-08	5.26e-06	0.27	0.25	Aortic root size;	chr7:66377234	chr7:66493706~66495474:+
LUAD	cis	rs2243480	1	rs4718333	ENSG00000230295.1	RP11-458F8.2	5.77	1.41e-08	5.26e-06	0.31	0.25	Diabetic kidney disease;	chr7:66307771	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs7792391	ENSG00000230295.1	RP11-458F8.2	5.77	1.41e-08	5.26e-06	0.31	0.25	Diabetic kidney disease;	chr7:66308442	chr7:66880708~66882981:+
LUAD	cis	rs948562	0.573	rs7480262	ENSG00000280010.1	AP001350.4	5.77	1.41e-08	5.26e-06	0.39	0.25	Lymphoma;	chr11:58296313	chr11:58627435~58628528:+
LUAD	cis	rs875971	0.862	rs6460307	ENSG00000237310.1	GS1-124K5.4	5.77	1.41e-08	5.26e-06	0.28	0.25	Aortic root size;	chr7:66595884	chr7:66493706~66495474:+
LUAD	cis	rs66887589	0.616	rs11098498	ENSG00000248280.1	RP11-33B1.2	5.77	1.41e-08	5.26e-06	0.28	0.25	Diastolic blood pressure;	chr4:119265964	chr4:119440561~119450157:-
LUAD	cis	rs2404602	0.647	rs11855296	ENSG00000259422.1	RP11-593F23.1	-5.77	1.42e-08	5.27e-06	-0.34	-0.25	Blood metabolite levels;	chr15:76800621	chr15:76174891~76181486:-
LUAD	cis	rs875971	0.862	rs6947339	ENSG00000222364.1	RNU6-96P	-5.77	1.42e-08	5.27e-06	-0.29	-0.25	Aortic root size;	chr7:66423483	chr7:66395191~66395286:+
LUAD	cis	rs17684571	0.7	rs4299824	ENSG00000231441.1	RP11-472M19.2	5.77	1.42e-08	5.27e-06	0.37	0.25	Schizophrenia;	chr6:56815697	chr6:56844002~56864078:+
LUAD	cis	rs9549367	1	rs9549367	ENSG00000269125.1	RP11-98F14.11	-5.77	1.42e-08	5.27e-06	-0.32	-0.25	Platelet distribution width;	chr13:113257218	chr13:113165002~113165183:-
LUAD	cis	rs2179367	0.6	rs9498356	ENSG00000231760.4	RP11-350J20.5	5.77	1.42e-08	5.28e-06	0.37	0.25	Dupuytren's disease;	chr6:149443337	chr6:149796151~149826294:-
LUAD	cis	rs7712401	0.562	rs401729	ENSG00000263432.2	RN7SL689P	5.77	1.42e-08	5.28e-06	0.32	0.25	Mean platelet volume;	chr5:122928590	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs2910140	ENSG00000263432.2	RN7SL689P	5.77	1.42e-08	5.28e-06	0.32	0.25	Mean platelet volume;	chr5:122928700	chr5:123022487~123022783:-
LUAD	cis	rs1015362	0.581	rs4911373	ENSG00000276073.1	RP5-1125A11.7	-5.77	1.42e-08	5.28e-06	-0.32	-0.25	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33920952	chr20:33985617~33988989:-
LUAD	cis	rs1501911	0.509	rs692759	ENSG00000248489.1	CTD-2007H13.3	-5.77	1.42e-08	5.29e-06	-0.27	-0.25	Lung function (FEV1/FVC);	chr5:98856841	chr5:98929171~98995013:+
LUAD	cis	rs35740288	0.857	rs3803506	ENSG00000202081.1	RNU6-1280P	5.77	1.42e-08	5.29e-06	0.32	0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85747709	chr15:85651522~85651628:-
LUAD	cis	rs10214930	0.671	rs11762342	ENSG00000235574.1	AC073150.6	-5.77	1.42e-08	5.29e-06	-0.31	-0.25	Hypospadias;	chr7:27622314	chr7:27491682~27492765:-
LUAD	cis	rs732716	0.785	rs62129354	ENSG00000267980.1	AC007292.6	-5.77	1.42e-08	5.29e-06	-0.3	-0.25	Mean corpuscular volume;	chr19:4396508	chr19:4363789~4364640:+
LUAD	cis	rs2243480	0.803	rs13224048	ENSG00000230295.1	RP11-458F8.2	-5.77	1.42e-08	5.3e-06	-0.31	-0.25	Diabetic kidney disease;	chr7:66528779	chr7:66880708~66882981:+
LUAD	cis	rs2288884	0.537	rs7254254	ENSG00000275055.1	CTC-471J1.11	-5.77	1.42e-08	5.3e-06	-0.3	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52035824	chr19:52049007~52049754:+
LUAD	cis	rs9309473	1	rs6740223	ENSG00000163016.8	ALMS1P	5.77	1.42e-08	5.3e-06	0.31	0.25	Metabolite levels;	chr2:73426204	chr2:73644919~73685576:+
LUAD	cis	rs9309473	1	rs6707722	ENSG00000163016.8	ALMS1P	5.77	1.42e-08	5.3e-06	0.31	0.25	Metabolite levels;	chr2:73427235	chr2:73644919~73685576:+
LUAD	cis	rs172166	0.694	rs203876	ENSG00000204709.4	LINC01556	5.77	1.42e-08	5.3e-06	0.33	0.25	Cardiac Troponin-T levels;	chr6:28078895	chr6:28943877~28944537:+
LUAD	cis	rs172166	0.694	rs203877	ENSG00000204709.4	LINC01556	5.77	1.42e-08	5.3e-06	0.33	0.25	Cardiac Troponin-T levels;	chr6:28080846	chr6:28943877~28944537:+
LUAD	cis	rs8040855	0.599	rs8037195	ENSG00000259774.1	RP11-182J1.13	-5.77	1.42e-08	5.3e-06	-0.29	-0.25	Bulimia nervosa;	chr15:85181455	chr15:84422618~84425882:+
LUAD	cis	rs7181230	0.885	rs2412478	ENSG00000275636.1	RP11-521C20.5	5.77	1.42e-08	5.3e-06	0.34	0.25	Dehydroepiandrosterone sulphate levels;	chr15:40068971	chr15:40078892~40079347:+
LUAD	cis	rs7615952	0.576	rs6780025	ENSG00000171084.14	FAM86JP	5.77	1.43e-08	5.31e-06	0.38	0.25	Blood pressure (smoking interaction);	chr3:126096781	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.576	rs6804482	ENSG00000171084.14	FAM86JP	5.77	1.43e-08	5.31e-06	0.38	0.25	Blood pressure (smoking interaction);	chr3:126096919	chr3:125916620~125930024:+
LUAD	cis	rs916888	0.773	rs169201	ENSG00000261575.2	RP11-259G18.1	5.77	1.43e-08	5.31e-06	0.41	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46267037~46268694:+
LUAD	cis	rs2302464	1	rs6835705	ENSG00000214846.4	RP11-115L11.1	-5.77	1.43e-08	5.31e-06	-0.67	-0.25	Cerebrospinal fluid biomarker levels;	chr4:15736747	chr4:15730962~15731627:-
LUAD	cis	rs1075265	0.87	rs1421617	ENSG00000233266.1	HMGB1P31	5.77	1.43e-08	5.31e-06	0.32	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54032995	chr2:54051334~54051760:+
LUAD	cis	rs12188164	0.515	rs11745246	ENSG00000225138.6	CTD-2228K2.7	5.77	1.43e-08	5.31e-06	0.25	0.25	Cystic fibrosis severity;	chr5:410828	chr5:473236~480884:+
LUAD	cis	rs4713118	0.513	rs149989	ENSG00000204709.4	LINC01556	5.77	1.43e-08	5.32e-06	0.32	0.25	Parkinson's disease;	chr6:28030406	chr6:28943877~28944537:+
LUAD	cis	rs8040855	0.579	rs4843029	ENSG00000259774.1	RP11-182J1.13	-5.77	1.43e-08	5.32e-06	-0.29	-0.25	Bulimia nervosa;	chr15:85182164	chr15:84422618~84425882:+
LUAD	cis	rs11098499	0.913	rs67073020	ENSG00000248280.1	RP11-33B1.2	5.77	1.43e-08	5.32e-06	0.33	0.25	Corneal astigmatism;	chr4:119231402	chr4:119440561~119450157:-
LUAD	cis	rs11096990	0.964	rs6835064	ENSG00000249207.1	RP11-360F5.1	5.77	1.43e-08	5.33e-06	0.28	0.25	Cognitive function;	chr4:39264346	chr4:39112677~39126818:-
LUAD	cis	rs2562456	0.834	rs2173727	ENSG00000268081.1	RP11-678G14.2	-5.77	1.43e-08	5.33e-06	-0.38	-0.25	Pain;	chr19:21491155	chr19:21554640~21569237:-
LUAD	cis	rs2404602	0.647	rs12439141	ENSG00000259422.1	RP11-593F23.1	-5.77	1.43e-08	5.33e-06	-0.34	-0.25	Blood metabolite levels;	chr15:76803082	chr15:76174891~76181486:-
LUAD	cis	rs7615952	0.641	rs61048217	ENSG00000171084.14	FAM86JP	5.77	1.43e-08	5.34e-06	0.38	0.25	Blood pressure (smoking interaction);	chr3:126089062	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.641	rs60839048	ENSG00000171084.14	FAM86JP	5.77	1.43e-08	5.34e-06	0.38	0.25	Blood pressure (smoking interaction);	chr3:126089095	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.641	rs7640158	ENSG00000171084.14	FAM86JP	5.77	1.43e-08	5.34e-06	0.38	0.25	Blood pressure (smoking interaction);	chr3:126089168	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.641	rs2365019	ENSG00000171084.14	FAM86JP	5.77	1.43e-08	5.34e-06	0.38	0.25	Blood pressure (smoking interaction);	chr3:126089292	chr3:125916620~125930024:+
LUAD	cis	rs950169	0.58	rs17598114	ENSG00000225151.9	GOLGA2P7	-5.77	1.43e-08	5.34e-06	-0.35	-0.25	Schizophrenia;	chr15:84628086	chr15:84199311~84230136:-
LUAD	cis	rs673078	0.607	rs4767671	ENSG00000275409.1	RP11-131L12.4	-5.77	1.44e-08	5.34e-06	-0.37	-0.25	Glucose homeostasis traits;	chr12:118396038	chr12:118430147~118430699:+
LUAD	cis	rs36093844	0.752	rs75639684	ENSG00000279742.1	RP11-700A24.1	-5.77	1.44e-08	5.34e-06	-0.33	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85860533	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.752	rs79734467	ENSG00000279742.1	RP11-700A24.1	-5.77	1.44e-08	5.34e-06	-0.33	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85860910	chr11:85852557~85854943:-
LUAD	cis	rs10214930	0.651	rs4722728	ENSG00000235574.1	AC073150.6	5.77	1.44e-08	5.34e-06	0.32	0.25	Hypospadias;	chr7:27654669	chr7:27491682~27492765:-
LUAD	cis	rs10129255	0.912	rs8009135	ENSG00000211972.2	IGHV3-66	5.77	1.44e-08	5.34e-06	0.22	0.25	Kawasaki disease;	chr14:106777528	chr14:106675017~106675544:-
LUAD	cis	rs75422866	0.51	rs73105819	ENSG00000274902.1	RP1-197B17.4	5.77	1.44e-08	5.34e-06	0.56	0.25	Pneumonia;	chr12:47727190	chr12:47731908~47732351:+
LUAD	cis	rs17666538	0.585	rs1669615	ENSG00000254207.1	RP11-43A14.1	5.77	1.44e-08	5.35e-06	0.51	0.25	IgG glycosylation;	chr8:666665	chr8:725188~725877:-
LUAD	cis	rs1031391	0.716	rs10772416	ENSG00000270863.1	DDX55P1	-5.77	1.44e-08	5.35e-06	-0.36	-0.25	Bitter taste perception;	chr12:11017488	chr12:11512723~11514136:+
LUAD	cis	rs12223324	0.654	rs10794338	ENSG00000255142.1	AP006621.6	-5.77	1.44e-08	5.36e-06	-0.24	-0.25	Fuchs's corneal dystrophy;	chr11:746992	chr11:781645~782105:+
LUAD	cis	rs755249	0.761	rs61781390	ENSG00000228060.1	RP11-69E11.8	-5.77	1.44e-08	5.36e-06	-0.27	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39610222	chr1:39565160~39573203:+
LUAD	cis	rs9640161	0.83	rs3757423	ENSG00000261305.1	RP4-584D14.7	-5.77	1.44e-08	5.36e-06	-0.35	-0.25	Blood protein levels;Circulating chemerin levels;	chr7:150370625	chr7:150341771~150342607:+
LUAD	cis	rs2412819	0.571	rs10163069	ENSG00000249839.1	AC011330.5	5.77	1.45e-08	5.38e-06	0.4	0.25	Lung cancer;	chr15:43755372	chr15:43663654~43684339:-
LUAD	cis	rs2929278	0.617	rs3986209	ENSG00000249839.1	AC011330.5	5.77	1.45e-08	5.38e-06	0.4	0.25	Schizophrenia;	chr15:43758675	chr15:43663654~43684339:-
LUAD	cis	rs17666538	0.585	rs6559065	ENSG00000254207.1	RP11-43A14.1	5.77	1.45e-08	5.38e-06	0.51	0.25	IgG glycosylation;	chr8:673156	chr8:725188~725877:-
LUAD	cis	rs17684571	0.683	rs13215883	ENSG00000231441.1	RP11-472M19.2	5.77	1.45e-08	5.38e-06	0.39	0.25	Schizophrenia;	chr6:56858927	chr6:56844002~56864078:+
LUAD	cis	rs11096990	1	rs11096990	ENSG00000249207.1	RP11-360F5.1	-5.77	1.45e-08	5.38e-06	-0.29	-0.25	Cognitive function;	chr4:39285329	chr4:39112677~39126818:-
LUAD	cis	rs1426063	0.614	rs114761716	ENSG00000249717.1	RP11-44F21.3	5.77	1.45e-08	5.39e-06	0.47	0.25	QT interval;	chr4:75107209	chr4:74955974~74970362:-
LUAD	cis	rs3738443	0.768	rs6668154	ENSG00000259865.1	RP11-488L18.10	5.77	1.45e-08	5.39e-06	0.27	0.25	Alcohol dependence;	chr1:247187981	chr1:247187281~247188526:-
LUAD	cis	rs3738443	0.768	rs6665647	ENSG00000259865.1	RP11-488L18.10	5.77	1.45e-08	5.39e-06	0.27	0.25	Alcohol dependence;	chr1:247188127	chr1:247187281~247188526:-
LUAD	cis	rs3738443	0.817	rs1115202	ENSG00000259865.1	RP11-488L18.10	5.77	1.45e-08	5.39e-06	0.27	0.25	Alcohol dependence;	chr1:247189878	chr1:247187281~247188526:-
LUAD	cis	rs3738443	0.868	rs61839994	ENSG00000259865.1	RP11-488L18.10	5.77	1.45e-08	5.39e-06	0.27	0.25	Alcohol dependence;	chr1:247195479	chr1:247187281~247188526:-
LUAD	cis	rs3738443	0.868	rs7536883	ENSG00000259865.1	RP11-488L18.10	5.77	1.45e-08	5.39e-06	0.27	0.25	Alcohol dependence;	chr1:247196266	chr1:247187281~247188526:-
LUAD	cis	rs7804306	1	rs35641104	ENSG00000233264.2	AC006042.8	5.77	1.45e-08	5.39e-06	0.44	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8046289	chr7:7980312~7982228:+
LUAD	cis	rs7804306	1	rs12702689	ENSG00000233264.2	AC006042.8	5.77	1.45e-08	5.39e-06	0.44	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8046767	chr7:7980312~7982228:+
LUAD	cis	rs6772849	0.804	rs4857920	ENSG00000242551.2	POU5F1P6	-5.77	1.45e-08	5.39e-06	-0.3	-0.25	Monocyte percentage of white cells;Monocyte count;	chr3:128688780	chr3:128674735~128677005:-
LUAD	cis	rs75920871	0.588	rs7119185	ENSG00000254851.1	RP11-109L13.1	5.77	1.45e-08	5.4e-06	0.37	0.25	Subjective well-being;	chr11:117015380	chr11:117135528~117138582:+
LUAD	cis	rs7714584	1	rs12659118	ENSG00000197083.10	ZNF300P1	5.77	1.45e-08	5.4e-06	0.53	0.25	Crohn's disease;	chr5:150945060	chr5:150930645~150946289:-
LUAD	cis	rs2921073	0.509	rs2976931	ENSG00000253893.2	FAM85B	-5.77	1.46e-08	5.42e-06	-0.32	-0.25	Parkinson's disease;	chr8:8399807	chr8:8167819~8226614:-
LUAD	cis	rs801193	0.569	rs2659908	ENSG00000237310.1	GS1-124K5.4	5.77	1.46e-08	5.42e-06	0.28	0.25	Aortic root size;	chr7:66695835	chr7:66493706~66495474:+
LUAD	cis	rs301901	0.569	rs217846	ENSG00000250155.1	CTD-2353F22.1	5.77	1.46e-08	5.42e-06	0.27	0.25	Height;	chr5:37367180	chr5:36666214~36725195:-
LUAD	cis	rs9652601	0.691	rs9926078	ENSG00000274038.1	RP11-66H6.4	-5.77	1.46e-08	5.42e-06	-0.31	-0.25	Systemic lupus erythematosus;	chr16:11109708	chr16:11056556~11057034:+
LUAD	cis	rs7829975	0.511	rs2976902	ENSG00000253893.2	FAM85B	-5.77	1.46e-08	5.42e-06	-0.31	-0.25	Mood instability;	chr8:8483595	chr8:8167819~8226614:-
LUAD	cis	rs2404602	0.716	rs17362383	ENSG00000259422.1	RP11-593F23.1	5.77	1.46e-08	5.42e-06	0.29	0.25	Blood metabolite levels;	chr15:76358361	chr15:76174891~76181486:-
LUAD	cis	rs7727544	0.735	rs274566	ENSG00000233006.5	AC034220.3	-5.77	1.46e-08	5.42e-06	-0.23	-0.25	Blood metabolite levels;	chr5:132379319	chr5:132311285~132369916:-
LUAD	cis	rs7772486	0.603	rs2223411	ENSG00000235652.6	RP11-545I5.3	-5.76	1.46e-08	5.43e-06	-0.27	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145707631	chr6:145799409~145886585:+
LUAD	cis	rs12439619	0.705	rs17354185	ENSG00000255769.6	GOLGA2P10	5.76	1.46e-08	5.44e-06	0.33	0.25	Intelligence (multi-trait analysis);	chr15:82133829	chr15:82472993~82513950:-
LUAD	cis	rs35740288	0.731	rs11638407	ENSG00000202081.1	RNU6-1280P	5.76	1.46e-08	5.44e-06	0.31	0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85551424	chr15:85651522~85651628:-
LUAD	cis	rs12908161	0.96	rs17599989	ENSG00000225151.9	GOLGA2P7	-5.76	1.46e-08	5.44e-06	-0.34	-0.25	Schizophrenia;	chr15:84742305	chr15:84199311~84230136:-
LUAD	cis	rs1823913	0.614	rs12616167	ENSG00000280083.1	RP11-317J9.1	5.76	1.47e-08	5.44e-06	0.3	0.25	Obesity-related traits;	chr2:191311274	chr2:191154118~191156070:-
LUAD	cis	rs7945705	0.905	rs2568054	ENSG00000254860.4	TMEM9B-AS1	5.76	1.47e-08	5.46e-06	0.29	0.25	Hemoglobin concentration;	chr11:8854482	chr11:8964675~8977527:+
LUAD	cis	rs896854	0.654	rs1453377	ENSG00000253528.2	RP11-347C18.4	5.76	1.47e-08	5.47e-06	0.25	0.25	Type 2 diabetes;	chr8:94957719	chr8:94974573~94974853:-
LUAD	cis	rs6504622	0.934	rs3760377	ENSG00000262879.4	RP11-156P1.3	-5.76	1.47e-08	5.47e-06	-0.3	-0.25	Orofacial clefts;	chr17:46964713	chr17:46984045~47100323:-
LUAD	cis	rs6504622	1	rs11079745	ENSG00000262879.4	RP11-156P1.3	-5.76	1.47e-08	5.47e-06	-0.3	-0.25	Orofacial clefts;	chr17:46966781	chr17:46984045~47100323:-
LUAD	cis	rs875971	0.862	rs2909688	ENSG00000222364.1	RNU6-96P	-5.76	1.48e-08	5.47e-06	-0.29	-0.25	Aortic root size;	chr7:66376625	chr7:66395191~66395286:+
LUAD	cis	rs72634501	0.622	rs4660416	ENSG00000228060.1	RP11-69E11.8	-5.76	1.48e-08	5.48e-06	-0.26	-0.25	HDL cholesterol;	chr1:39113314	chr1:39565160~39573203:+
LUAD	cis	rs1426063	0.614	rs17000260	ENSG00000249717.1	RP11-44F21.3	5.76	1.48e-08	5.48e-06	0.46	0.25	QT interval;	chr4:75108576	chr4:74955974~74970362:-
LUAD	cis	rs10214930	0.602	rs2098315	ENSG00000235574.1	AC073150.6	-5.76	1.48e-08	5.48e-06	-0.32	-0.25	Hypospadias;	chr7:27541026	chr7:27491682~27492765:-
LUAD	cis	rs875971	1	rs2420820	ENSG00000237310.1	GS1-124K5.4	-5.76	1.48e-08	5.48e-06	-0.28	-0.25	Aortic root size;	chr7:66626920	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs2420174	ENSG00000222364.1	RNU6-96P	5.76	1.48e-08	5.49e-06	0.29	0.25	Aortic root size;	chr7:66180374	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs2420173	ENSG00000222364.1	RNU6-96P	5.76	1.48e-08	5.49e-06	0.29	0.25	Aortic root size;	chr7:66180412	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs4718319	ENSG00000222364.1	RNU6-96P	5.76	1.48e-08	5.49e-06	0.29	0.25	Aortic root size;	chr7:66187797	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.723	rs28391294	ENSG00000222364.1	RNU6-96P	5.76	1.48e-08	5.49e-06	0.29	0.25	Aortic root size;	chr7:66189328	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.83	rs6967708	ENSG00000222364.1	RNU6-96P	5.76	1.48e-08	5.49e-06	0.29	0.25	Aortic root size;	chr7:66192326	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.895	rs7782806	ENSG00000222364.1	RNU6-96P	5.76	1.48e-08	5.49e-06	0.29	0.25	Aortic root size;	chr7:66192910	chr7:66395191~66395286:+
LUAD	cis	rs10214930	1	rs10250333	ENSG00000235574.1	AC073150.6	5.76	1.48e-08	5.49e-06	0.36	0.25	Hypospadias;	chr7:27723003	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.958	rs28521509	ENSG00000235574.1	AC073150.6	5.76	1.48e-08	5.49e-06	0.36	0.25	Hypospadias;	chr7:27723008	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.958	rs10268051	ENSG00000235574.1	AC073150.6	5.76	1.48e-08	5.49e-06	0.36	0.25	Hypospadias;	chr7:27723971	chr7:27491682~27492765:-
LUAD	cis	rs7712401	0.525	rs246312	ENSG00000263432.2	RN7SL689P	5.76	1.48e-08	5.49e-06	0.32	0.25	Mean platelet volume;	chr5:122933760	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs246308	ENSG00000263432.2	RN7SL689P	5.76	1.48e-08	5.49e-06	0.32	0.25	Mean platelet volume;	chr5:122934395	chr5:123022487~123022783:-
LUAD	cis	rs4787484	1	rs11344	ENSG00000214725.6	CDIPT-AS1	-5.76	1.48e-08	5.49e-06	-0.32	-0.25	Response to taxane treatment (placlitaxel);	chr16:29899197	chr16:29863593~29868053:+
LUAD	cis	rs2933343	1	rs789232	ENSG00000261159.1	RP11-723O4.9	5.76	1.48e-08	5.5e-06	0.31	0.25	IgG glycosylation;	chr3:128884237	chr3:128859716~128860526:-
LUAD	cis	rs2933343	1	rs1683811	ENSG00000261159.1	RP11-723O4.9	5.76	1.48e-08	5.5e-06	0.31	0.25	IgG glycosylation;	chr3:128893270	chr3:128859716~128860526:-
LUAD	cis	rs875971	1	rs3981131	ENSG00000237310.1	GS1-124K5.4	5.76	1.48e-08	5.51e-06	0.27	0.25	Aortic root size;	chr7:66486690	chr7:66493706~66495474:+
LUAD	cis	rs1823913	0.637	rs11688994	ENSG00000227542.1	AC092614.2	5.76	1.48e-08	5.51e-06	0.31	0.25	Obesity-related traits;	chr2:191266242	chr2:191229165~191246172:-
LUAD	cis	rs1426063	0.614	rs76931926	ENSG00000249717.1	RP11-44F21.3	5.76	1.48e-08	5.51e-06	0.47	0.25	QT interval;	chr4:75106902	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.614	rs115279737	ENSG00000249717.1	RP11-44F21.3	5.76	1.48e-08	5.51e-06	0.47	0.25	QT interval;	chr4:75107557	chr4:74955974~74970362:-
LUAD	cis	rs1707322	0.686	rs2991977	ENSG00000234329.1	RP11-767N6.2	-5.76	1.48e-08	5.51e-06	-0.27	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45588011	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.656	rs2991981	ENSG00000234329.1	RP11-767N6.2	-5.76	1.48e-08	5.51e-06	-0.27	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45591472	chr1:45651039~45651826:-
LUAD	cis	rs4835473	0.932	rs17018500	ENSG00000251600.4	RP11-673E1.1	-5.76	1.49e-08	5.51e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143824849	chr4:143912331~143982454:+
LUAD	cis	rs755249	0.567	rs3768301	ENSG00000228060.1	RP11-69E11.8	-5.76	1.49e-08	5.52e-06	-0.26	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39405121	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs113214136	ENSG00000228060.1	RP11-69E11.8	-5.76	1.49e-08	5.52e-06	-0.26	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39408867	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs3768302	ENSG00000228060.1	RP11-69E11.8	-5.76	1.49e-08	5.52e-06	-0.26	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39414647	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.532	rs17343193	ENSG00000228060.1	RP11-69E11.8	-5.76	1.49e-08	5.52e-06	-0.26	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39415796	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs61779300	ENSG00000228060.1	RP11-69E11.8	-5.76	1.49e-08	5.52e-06	-0.26	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39420091	chr1:39565160~39573203:+
LUAD	cis	rs7246657	0.678	rs4802024	ENSG00000276846.1	CTD-3220F14.3	5.76	1.49e-08	5.52e-06	0.33	0.25	Coronary artery calcification;	chr19:37561291	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.722	rs6508736	ENSG00000276846.1	CTD-3220F14.3	5.76	1.49e-08	5.52e-06	0.33	0.25	Coronary artery calcification;	chr19:37570855	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.55	rs9941475	ENSG00000276846.1	CTD-3220F14.3	5.76	1.49e-08	5.52e-06	0.33	0.25	Coronary artery calcification;	chr19:37573615	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.765	rs4803262	ENSG00000276846.1	CTD-3220F14.3	5.76	1.49e-08	5.52e-06	0.33	0.25	Coronary artery calcification;	chr19:37575858	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.712	rs4803263	ENSG00000276846.1	CTD-3220F14.3	5.76	1.49e-08	5.52e-06	0.33	0.25	Coronary artery calcification;	chr19:37575880	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.722	rs10412510	ENSG00000276846.1	CTD-3220F14.3	5.76	1.49e-08	5.52e-06	0.33	0.25	Coronary artery calcification;	chr19:37585043	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.722	rs3829688	ENSG00000276846.1	CTD-3220F14.3	5.76	1.49e-08	5.52e-06	0.33	0.25	Coronary artery calcification;	chr19:37586199	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.722	rs13744	ENSG00000276846.1	CTD-3220F14.3	5.76	1.49e-08	5.52e-06	0.33	0.25	Coronary artery calcification;	chr19:37587011	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.722	rs10403173	ENSG00000276846.1	CTD-3220F14.3	5.76	1.49e-08	5.52e-06	0.33	0.25	Coronary artery calcification;	chr19:37587779	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.679	rs12461113	ENSG00000276846.1	CTD-3220F14.3	5.76	1.49e-08	5.52e-06	0.33	0.25	Coronary artery calcification;	chr19:37592287	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.639	rs12459015	ENSG00000276846.1	CTD-3220F14.3	5.76	1.49e-08	5.52e-06	0.33	0.25	Coronary artery calcification;	chr19:37592288	chr19:37314868~37315620:-
LUAD	cis	rs17214007	0.877	rs11075281	ENSG00000263335.1	AF001548.5	-5.76	1.49e-08	5.52e-06	-0.36	-0.25	Cognitive function;	chr16:15780585	chr16:15726674~15732993:+
LUAD	cis	rs11105298	0.786	rs10858897	ENSG00000258302.2	RP11-981P6.1	5.76	1.49e-08	5.52e-06	0.32	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89528255	chr12:89561129~89594878:+
LUAD	cis	rs10129255	0.957	rs17113284	ENSG00000224373.3	IGHV4-59	-5.76	1.49e-08	5.52e-06	-0.17	-0.25	Kawasaki disease;	chr14:106684476	chr14:106627249~106627825:-
LUAD	cis	rs2898681	0.528	rs73814883	ENSG00000248375.1	RP11-177B4.1	-5.76	1.49e-08	5.53e-06	-0.47	-0.25	Optic nerve measurement (cup area);	chr4:52861887	chr4:52720081~52720831:-
LUAD	cis	rs6565180	1	rs8049108	ENSG00000183604.13	SMG1P5	-5.76	1.49e-08	5.53e-06	-0.27	-0.25	Tonsillectomy;	chr16:30365165	chr16:30267553~30335374:-
LUAD	cis	rs4803480	0.872	rs2058149	ENSG00000270164.1	LINC01480	-5.76	1.49e-08	5.53e-06	-0.25	-0.25	Schizophrenia;	chr19:41580312	chr19:41535183~41536904:+
LUAD	cis	rs7923609	1	rs10822163	ENSG00000232075.1	MRPL35P2	-5.76	1.49e-08	5.53e-06	-0.31	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63364338	chr10:63634317~63634827:-
LUAD	cis	rs12908161	1	rs12903134	ENSG00000225151.9	GOLGA2P7	-5.76	1.49e-08	5.53e-06	-0.34	-0.25	Schizophrenia;	chr15:84794468	chr15:84199311~84230136:-
LUAD	cis	rs12908161	1	rs35726233	ENSG00000225151.9	GOLGA2P7	-5.76	1.49e-08	5.53e-06	-0.34	-0.25	Schizophrenia;	chr15:84794569	chr15:84199311~84230136:-
LUAD	cis	rs875971	0.893	rs62465470	ENSG00000237310.1	GS1-124K5.4	-5.76	1.49e-08	5.54e-06	-0.27	-0.25	Aortic root size;	chr7:66136231	chr7:66493706~66495474:+
LUAD	cis	rs10761482	0.5	rs1890926	ENSG00000254271.1	RP11-131N11.4	5.76	1.49e-08	5.54e-06	0.28	0.25	Schizophrenia;	chr10:60530347	chr10:60734342~60741828:+
LUAD	cis	rs17684571	0.751	rs10498812	ENSG00000231441.1	RP11-472M19.2	5.76	1.49e-08	5.54e-06	0.38	0.25	Schizophrenia;	chr6:56819412	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.751	rs13220628	ENSG00000231441.1	RP11-472M19.2	5.76	1.49e-08	5.54e-06	0.38	0.25	Schizophrenia;	chr6:56819445	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.751	rs13203148	ENSG00000231441.1	RP11-472M19.2	5.76	1.49e-08	5.54e-06	0.38	0.25	Schizophrenia;	chr6:56822235	chr6:56844002~56864078:+
LUAD	cis	rs858239	0.601	rs10255228	ENSG00000230042.1	AK3P3	-5.76	1.49e-08	5.54e-06	-0.32	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23129178~23129841:+
LUAD	cis	rs67311347	0.866	rs56331709	ENSG00000223797.4	ENTPD3-AS1	5.76	1.49e-08	5.54e-06	0.28	0.25	Renal cell carcinoma;	chr3:40315067	chr3:40313802~40453329:-
LUAD	cis	rs7923609	1	rs7070296	ENSG00000232075.1	MRPL35P2	-5.76	1.49e-08	5.54e-06	-0.31	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63310678	chr10:63634317~63634827:-
LUAD	cis	rs6565180	0.962	rs6565183	ENSG00000183604.13	SMG1P5	-5.76	1.5e-08	5.54e-06	-0.27	-0.25	Tonsillectomy;	chr16:30371434	chr16:30267553~30335374:-
LUAD	cis	rs301901	0.698	rs217845	ENSG00000250155.1	CTD-2353F22.1	5.76	1.5e-08	5.55e-06	0.27	0.25	Height;	chr5:37367360	chr5:36666214~36725195:-
LUAD	cis	rs600231	0.708	rs1784100	ENSG00000245532.5	NEAT1	5.76	1.5e-08	5.55e-06	0.2	0.25	Bone mineral density;	chr11:65481756	chr11:65422774~65445540:+
LUAD	cis	rs11690935	0.632	rs9789538	ENSG00000228389.1	AC068039.4	-5.76	1.5e-08	5.55e-06	-0.27	-0.25	Schizophrenia;	chr2:171761964	chr2:171773482~171775844:+
LUAD	cis	rs6840258	0.607	rs56023922	ENSG00000251411.1	RP11-397E7.4	-5.76	1.5e-08	5.56e-06	-0.36	-0.25	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86994934	chr4:86913266~86914817:-
LUAD	cis	rs2919009	0.602	rs7906342	ENSG00000271670.1	RP11-95I16.4	5.76	1.5e-08	5.57e-06	0.31	0.25	Obesity-related traits;	chr10:120923654	chr10:120879256~120880667:-
LUAD	cis	rs2288884	0.515	rs3752118	ENSG00000275055.1	CTC-471J1.11	-5.76	1.5e-08	5.57e-06	-0.3	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52048233	chr19:52049007~52049754:+
LUAD	cis	rs875971	0.964	rs55748098	ENSG00000237310.1	GS1-124K5.4	-5.76	1.5e-08	5.57e-06	-0.28	-0.25	Aortic root size;	chr7:66298631	chr7:66493706~66495474:+
LUAD	cis	rs2404602	0.716	rs56351018	ENSG00000259422.1	RP11-593F23.1	5.76	1.5e-08	5.57e-06	0.29	0.25	Blood metabolite levels;	chr15:76532250	chr15:76174891~76181486:-
LUAD	cis	rs7804306	1	rs35425218	ENSG00000233264.2	AC006042.8	5.76	1.51e-08	5.58e-06	0.44	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7977124	chr7:7980312~7982228:+
LUAD	cis	rs17684571	0.687	rs13214893	ENSG00000231441.1	RP11-472M19.2	5.76	1.51e-08	5.58e-06	0.39	0.25	Schizophrenia;	chr6:56865425	chr6:56844002~56864078:+
LUAD	cis	rs1499614	1	rs1267817	ENSG00000230295.1	RP11-458F8.2	-5.76	1.51e-08	5.58e-06	-0.31	-0.25	Gout;	chr7:66645053	chr7:66880708~66882981:+
LUAD	cis	rs875971	1	rs709595	ENSG00000237310.1	GS1-124K5.4	5.76	1.51e-08	5.59e-06	0.28	0.25	Aortic root size;	chr7:66352346	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs811880	ENSG00000237310.1	GS1-124K5.4	5.76	1.51e-08	5.59e-06	0.28	0.25	Aortic root size;	chr7:66353659	chr7:66493706~66495474:+
LUAD	cis	rs172166	0.694	rs2791332	ENSG00000204709.4	LINC01556	5.76	1.51e-08	5.59e-06	0.33	0.25	Cardiac Troponin-T levels;	chr6:28141010	chr6:28943877~28944537:+
LUAD	cis	rs2404602	0.583	rs2176623	ENSG00000259422.1	RP11-593F23.1	5.76	1.51e-08	5.59e-06	0.29	0.25	Blood metabolite levels;	chr15:76276238	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.647	rs55778276	ENSG00000259422.1	RP11-593F23.1	-5.76	1.51e-08	5.59e-06	-0.34	-0.25	Blood metabolite levels;	chr15:76844249	chr15:76174891~76181486:-
LUAD	cis	rs6840258	0.66	rs55816619	ENSG00000251411.1	RP11-397E7.4	-5.76	1.51e-08	5.59e-06	-0.36	-0.25	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87038653	chr4:86913266~86914817:-
LUAD	cis	rs7712401	0.601	rs27976	ENSG00000263432.2	RN7SL689P	-5.76	1.51e-08	5.6e-06	-0.32	-0.25	Mean platelet volume;	chr5:122870765	chr5:123022487~123022783:-
LUAD	cis	rs7208859	0.673	rs216411	ENSG00000263603.1	CTD-2349P21.5	5.76	1.51e-08	5.6e-06	0.38	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576475	chr17:30729469~30731202:+
LUAD	cis	rs36093844	0.8	rs78356210	ENSG00000279742.1	RP11-700A24.1	-5.76	1.51e-08	5.6e-06	-0.34	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85870224	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.752	rs113529766	ENSG00000279742.1	RP11-700A24.1	-5.76	1.51e-08	5.6e-06	-0.34	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85872358	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.8	rs76464398	ENSG00000279742.1	RP11-700A24.1	-5.76	1.51e-08	5.6e-06	-0.34	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85872855	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.706	rs116940726	ENSG00000279742.1	RP11-700A24.1	-5.76	1.51e-08	5.6e-06	-0.34	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85873009	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.752	rs1445505	ENSG00000279742.1	RP11-700A24.1	-5.76	1.51e-08	5.6e-06	-0.34	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85873679	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.8	rs1445504	ENSG00000279742.1	RP11-700A24.1	-5.76	1.51e-08	5.6e-06	-0.34	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85873836	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.706	rs1445503	ENSG00000279742.1	RP11-700A24.1	-5.76	1.51e-08	5.6e-06	-0.34	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85873968	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.698	rs79435802	ENSG00000279742.1	RP11-700A24.1	-5.76	1.51e-08	5.6e-06	-0.34	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85874163	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.706	rs79814326	ENSG00000279742.1	RP11-700A24.1	-5.76	1.51e-08	5.6e-06	-0.34	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85874530	chr11:85852557~85854943:-
LUAD	cis	rs7246657	0.722	rs954504	ENSG00000276846.1	CTD-3220F14.3	5.76	1.51e-08	5.6e-06	0.33	0.25	Coronary artery calcification;	chr19:37554492	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.722	rs8110865	ENSG00000276846.1	CTD-3220F14.3	5.76	1.51e-08	5.6e-06	0.33	0.25	Coronary artery calcification;	chr19:37556485	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.722	rs4802029	ENSG00000276846.1	CTD-3220F14.3	5.76	1.51e-08	5.6e-06	0.33	0.25	Coronary artery calcification;	chr19:37564710	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.722	rs28512414	ENSG00000276846.1	CTD-3220F14.3	5.76	1.51e-08	5.6e-06	0.33	0.25	Coronary artery calcification;	chr19:37565672	chr19:37314868~37315620:-
LUAD	cis	rs875971	0.83	rs6950137	ENSG00000237310.1	GS1-124K5.4	5.76	1.51e-08	5.61e-06	0.28	0.25	Aortic root size;	chr7:66511623	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.545	rs6979636	ENSG00000226824.5	RP4-756H11.3	-5.76	1.52e-08	5.61e-06	-0.37	-0.25	Aortic root size;	chr7:66276638	chr7:66654538~66669855:+
LUAD	cis	rs6921919	0.525	rs16894095	ENSG00000204709.4	LINC01556	5.76	1.52e-08	5.62e-06	0.33	0.25	Autism spectrum disorder or schizophrenia;	chr6:28422453	chr6:28943877~28944537:+
LUAD	cis	rs950169	0.58	rs2271431	ENSG00000259728.4	LINC00933	5.76	1.52e-08	5.62e-06	0.37	0.25	Schizophrenia;	chr15:84646233	chr15:84570649~84580175:+
LUAD	cis	rs6543140	0.964	rs2080288	ENSG00000234389.1	AC007278.3	5.76	1.52e-08	5.62e-06	0.25	0.25	Blood protein levels;	chr2:102405706	chr2:102438713~102440475:+
LUAD	cis	rs3096299	0.583	rs2965949	ENSG00000274627.1	RP11-104N10.2	5.76	1.52e-08	5.62e-06	0.27	0.25	Multiple myeloma (IgH translocation);	chr16:89454044	chr16:89516797~89522217:+
LUAD	cis	rs4908760	0.795	rs6693009	ENSG00000232912.4	RP5-1115A15.1	5.76	1.52e-08	5.63e-06	0.23	0.25	Vitiligo;	chr1:8683651	chr1:8424645~8434838:+
LUAD	cis	rs1113500	0.527	rs1777482	ENSG00000226822.1	RP11-356N1.2	-5.76	1.52e-08	5.63e-06	-0.29	-0.25	Growth-regulated protein alpha levels;	chr1:108068752	chr1:108071482~108074519:+
LUAD	cis	rs10214930	0.671	rs6462038	ENSG00000235574.1	AC073150.6	-5.76	1.52e-08	5.63e-06	-0.31	-0.25	Hypospadias;	chr7:27620831	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.752	rs1115347	ENSG00000235574.1	AC073150.6	-5.76	1.52e-08	5.63e-06	-0.31	-0.25	Hypospadias;	chr7:27622979	chr7:27491682~27492765:-
LUAD	cis	rs2836950	0.545	rs1888489	ENSG00000255568.3	BRWD1-AS2	-5.76	1.52e-08	5.63e-06	-0.25	-0.25	Menarche (age at onset);	chr21:39161238	chr21:39313935~39314962:+
LUAD	cis	rs12468226	0.873	rs3181153	ENSG00000226261.1	AC064836.3	-5.76	1.52e-08	5.64e-06	-0.41	-0.25	Urate levels;	chr2:202205155	chr2:202336024~202336727:-
LUAD	cis	rs1816752	0.905	rs1348110	ENSG00000273628.1	RP11-756A22.7	5.76	1.52e-08	5.64e-06	0.29	0.25	Obesity-related traits;	chr13:24406537	chr13:24933006~24936796:+
LUAD	cis	rs858239	0.539	rs10279194	ENSG00000230042.1	AK3P3	-5.76	1.52e-08	5.64e-06	-0.32	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23151464	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.539	rs3950345	ENSG00000230042.1	AK3P3	-5.76	1.52e-08	5.64e-06	-0.32	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23151495	chr7:23129178~23129841:+
LUAD	cis	rs7727544	0.684	rs272849	ENSG00000233006.5	AC034220.3	5.76	1.52e-08	5.64e-06	0.23	0.25	Blood metabolite levels;	chr5:132354548	chr5:132311285~132369916:-
LUAD	cis	rs1113500	0.862	rs11185264	ENSG00000226822.1	RP11-356N1.2	5.76	1.52e-08	5.64e-06	0.3	0.25	Growth-regulated protein alpha levels;	chr1:108097884	chr1:108071482~108074519:+
LUAD	cis	rs807029	0.758	rs807025	ENSG00000272572.1	RP11-179B2.2	-5.76	1.53e-08	5.64e-06	-0.35	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101005064	chr10:100911103~100912739:-
LUAD	cis	rs10129255	0.957	rs10141052	ENSG00000224373.3	IGHV4-59	5.76	1.53e-08	5.65e-06	0.16	0.25	Kawasaki disease;	chr14:106776528	chr14:106627249~106627825:-
LUAD	cis	rs875971	0.838	rs2173570	ENSG00000237310.1	GS1-124K5.4	-5.76	1.53e-08	5.66e-06	-0.28	-0.25	Aortic root size;	chr7:66297976	chr7:66493706~66495474:+
LUAD	cis	rs17711722	0.523	rs313812	ENSG00000224316.1	RP11-479O9.2	-5.76	1.53e-08	5.66e-06	-0.25	-0.25	Calcium levels;	chr7:66040056	chr7:65773620~65802067:+
LUAD	cis	rs4604732	0.536	rs12037221	ENSG00000227135.1	GCSAML-AS1	-5.76	1.53e-08	5.66e-06	-0.39	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247467910	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.588	rs4925551	ENSG00000227135.1	GCSAML-AS1	-5.76	1.53e-08	5.66e-06	-0.39	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247468422	chr1:247524679~247526752:-
LUAD	cis	rs2288884	1	rs76368799	ENSG00000275055.1	CTC-471J1.11	-5.76	1.53e-08	5.66e-06	-0.4	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52058254	chr19:52049007~52049754:+
LUAD	cis	rs948562	0.535	rs11229439	ENSG00000280010.1	AP001350.4	5.76	1.53e-08	5.67e-06	0.41	0.25	Lymphoma;	chr11:58425138	chr11:58627435~58628528:+
LUAD	cis	rs8177876	0.915	rs11866124	ENSG00000261838.4	RP11-303E16.6	-5.76	1.53e-08	5.67e-06	-0.54	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81093866	chr16:81069854~81076598:+
LUAD	cis	rs6687821	0.515	rs10782587	ENSG00000267734.1	RP4-604K5.3	-5.76	1.53e-08	5.67e-06	-0.31	-0.25	Yeast infection;	chr1:86962204	chr1:86932199~86934891:-
LUAD	cis	rs4789693	0.518	rs6502108	ENSG00000265458.1	RP13-20L14.6	-5.76	1.53e-08	5.67e-06	-0.33	-0.25	Glucocorticoid-induced osteonecrosis;	chr17:82417023	chr17:82454273~82458521:-
LUAD	cis	rs2276314	0.857	rs7237599	ENSG00000278986.1	RP11-723J4.3	-5.76	1.53e-08	5.68e-06	-0.3	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:36059433	chr18:35972151~35973916:+
LUAD	cis	rs12699921	0.632	rs2691604	ENSG00000279048.1	RP11-511H23.2	-5.76	1.54e-08	5.68e-06	-0.2	-0.25	Fibrinogen levels;	chr7:17781389	chr7:17940503~17942922:+
LUAD	cis	rs1075265	0.749	rs805379	ENSG00000233266.1	HMGB1P31	5.76	1.54e-08	5.68e-06	0.32	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53865847	chr2:54051334~54051760:+
LUAD	cis	rs35160687	0.712	rs17438687	ENSG00000273080.1	RP11-301O19.1	-5.76	1.54e-08	5.69e-06	-0.28	-0.25	Night sleep phenotypes;	chr2:86252164	chr2:86195590~86196049:+
LUAD	cis	rs4908768	0.501	rs6668508	ENSG00000232912.4	RP5-1115A15.1	5.76	1.54e-08	5.69e-06	0.23	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8514059	chr1:8424645~8434838:+
LUAD	cis	rs4908768	0.501	rs6577494	ENSG00000232912.4	RP5-1115A15.1	5.76	1.54e-08	5.69e-06	0.23	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8516866	chr1:8424645~8434838:+
LUAD	cis	rs35740288	0.857	rs11630274	ENSG00000202081.1	RNU6-1280P	5.76	1.54e-08	5.69e-06	0.32	0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85745156	chr15:85651522~85651628:-
LUAD	cis	rs748404	0.666	rs12899865	ENSG00000205771.5	CATSPER2P1	-5.76	1.54e-08	5.69e-06	-0.37	-0.25	Lung cancer;	chr15:43448819	chr15:43726918~43747094:-
LUAD	cis	rs765787	0.53	rs28526629	ENSG00000259520.4	CTD-2651B20.3	5.76	1.54e-08	5.69e-06	0.33	0.25	Uric acid levels;	chr15:45248264	chr15:45251580~45279251:-
LUAD	cis	rs858239	0.539	rs2178139	ENSG00000230042.1	AK3P3	-5.76	1.54e-08	5.69e-06	-0.32	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23152017	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.539	rs2141306	ENSG00000230042.1	AK3P3	-5.76	1.54e-08	5.69e-06	-0.32	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23152045	chr7:23129178~23129841:+
LUAD	cis	rs875971	0.895	rs6460278	ENSG00000222364.1	RNU6-96P	5.76	1.54e-08	5.7e-06	0.29	0.25	Aortic root size;	chr7:66197749	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs6460279	ENSG00000222364.1	RNU6-96P	5.76	1.54e-08	5.7e-06	0.29	0.25	Aortic root size;	chr7:66197774	chr7:66395191~66395286:+
LUAD	cis	rs7712401	0.601	rs438196	ENSG00000263432.2	RN7SL689P	5.76	1.54e-08	5.7e-06	0.32	0.25	Mean platelet volume;	chr5:122927368	chr5:123022487~123022783:-
LUAD	cis	rs301901	0.634	rs4869429	ENSG00000250155.1	CTD-2353F22.1	5.76	1.54e-08	5.7e-06	0.27	0.25	Height;	chr5:37407777	chr5:36666214~36725195:-
LUAD	cis	rs875971	0.964	rs6945019	ENSG00000237310.1	GS1-124K5.4	5.76	1.54e-08	5.7e-06	0.27	0.25	Aortic root size;	chr7:66457471	chr7:66493706~66495474:+
LUAD	cis	rs9652601	0.622	rs8049882	ENSG00000274038.1	RP11-66H6.4	-5.76	1.54e-08	5.7e-06	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11025629	chr16:11056556~11057034:+
LUAD	cis	rs720064	0.557	rs12969459	ENSG00000264745.1	TTC39C-AS1	5.76	1.54e-08	5.7e-06	0.27	0.25	Strep throat;	chr18:23922095	chr18:23994213~24015339:-
LUAD	cis	rs875971	0.867	rs1002053	ENSG00000237310.1	GS1-124K5.4	-5.76	1.54e-08	5.7e-06	-0.28	-0.25	Aortic root size;	chr7:66333558	chr7:66493706~66495474:+
LUAD	cis	rs4538475	0.556	rs4403048	ENSG00000214846.4	RP11-115L11.1	5.76	1.54e-08	5.71e-06	0.37	0.25	Parkinson's disease;	chr4:15735497	chr4:15730962~15731627:-
LUAD	cis	rs7727544	0.684	rs611084	ENSG00000233006.5	AC034220.3	-5.75	1.55e-08	5.71e-06	-0.23	-0.25	Blood metabolite levels;	chr5:132374047	chr5:132311285~132369916:-
LUAD	cis	rs13631	0.697	rs1018330	ENSG00000268996.3	MAN1B1-AS1	5.75	1.55e-08	5.71e-06	0.3	0.25	Cerebrospinal fluid biomarker levels;	chr9:137085933	chr9:137084946~137086817:-
LUAD	cis	rs8072100	0.539	rs36043200	ENSG00000228782.6	CTD-2026D20.3	-5.75	1.55e-08	5.71e-06	-0.27	-0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47552040	chr17:47450568~47492492:-
LUAD	cis	rs1075265	0.87	rs7569214	ENSG00000233266.1	HMGB1P31	5.75	1.55e-08	5.72e-06	0.32	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53989049	chr2:54051334~54051760:+
LUAD	cis	rs1426063	0.614	rs78784058	ENSG00000249717.1	RP11-44F21.3	5.75	1.55e-08	5.72e-06	0.47	0.25	QT interval;	chr4:75108738	chr4:74955974~74970362:-
LUAD	cis	rs7246657	0.722	rs1564206	ENSG00000276846.1	CTD-3220F14.3	5.75	1.55e-08	5.72e-06	0.33	0.25	Coronary artery calcification;	chr19:37549174	chr19:37314868~37315620:-
LUAD	cis	rs875971	0.545	rs1909508	ENSG00000226824.5	RP4-756H11.3	-5.75	1.55e-08	5.73e-06	-0.36	-0.25	Aortic root size;	chr7:66301366	chr7:66654538~66669855:+
LUAD	cis	rs7945705	0.935	rs2653567	ENSG00000254860.4	TMEM9B-AS1	5.75	1.55e-08	5.74e-06	0.28	0.25	Hemoglobin concentration;	chr11:8868083	chr11:8964675~8977527:+
LUAD	cis	rs12468226	0.679	rs6435133	ENSG00000226261.1	AC064836.3	-5.75	1.55e-08	5.74e-06	-0.41	-0.25	Urate levels;	chr2:202209237	chr2:202336024~202336727:-
LUAD	cis	rs948562	0.744	rs12362087	ENSG00000280010.1	AP001350.4	5.75	1.55e-08	5.74e-06	0.37	0.25	Lymphoma;	chr11:58456447	chr11:58627435~58628528:+
LUAD	cis	rs7618501	0.633	rs2526748	ENSG00000234667.1	ACTBP13	5.75	1.55e-08	5.74e-06	0.28	0.25	Intelligence (multi-trait analysis);	chr3:50043006	chr3:49873347~49877980:-
LUAD	cis	rs35740288	0.787	rs2291048	ENSG00000202081.1	RNU6-1280P	-5.75	1.55e-08	5.74e-06	-0.32	-0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85682427	chr15:85651522~85651628:-
LUAD	cis	rs2179367	0.632	rs6920383	ENSG00000231760.4	RP11-350J20.5	5.75	1.56e-08	5.75e-06	0.36	0.25	Dupuytren's disease;	chr6:149356361	chr6:149796151~149826294:-
LUAD	cis	rs2288884	1	rs80278704	ENSG00000275055.1	CTC-471J1.11	-5.75	1.56e-08	5.75e-06	-0.4	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52045930	chr19:52049007~52049754:+
LUAD	cis	rs2288884	1	rs11669540	ENSG00000275055.1	CTC-471J1.11	-5.75	1.56e-08	5.75e-06	-0.4	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52046486	chr19:52049007~52049754:+
LUAD	cis	rs2288884	1	rs78543982	ENSG00000275055.1	CTC-471J1.11	-5.75	1.56e-08	5.75e-06	-0.4	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52047614	chr19:52049007~52049754:+
LUAD	cis	rs2288884	0.943	rs3752120	ENSG00000275055.1	CTC-471J1.11	-5.75	1.56e-08	5.75e-06	-0.4	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52048768	chr19:52049007~52049754:+
LUAD	cis	rs7712401	0.601	rs30027	ENSG00000263432.2	RN7SL689P	5.75	1.56e-08	5.75e-06	0.32	0.25	Mean platelet volume;	chr5:122947695	chr5:123022487~123022783:-
LUAD	cis	rs7615952	0.599	rs67566088	ENSG00000171084.14	FAM86JP	5.75	1.56e-08	5.75e-06	0.37	0.25	Blood pressure (smoking interaction);	chr3:126050130	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.641	rs12495947	ENSG00000171084.14	FAM86JP	5.75	1.56e-08	5.75e-06	0.37	0.25	Blood pressure (smoking interaction);	chr3:126052855	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.641	rs6805074	ENSG00000171084.14	FAM86JP	5.75	1.56e-08	5.75e-06	0.37	0.25	Blood pressure (smoking interaction);	chr3:126053431	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.641	rs4422257	ENSG00000171084.14	FAM86JP	5.75	1.56e-08	5.75e-06	0.37	0.25	Blood pressure (smoking interaction);	chr3:126055520	chr3:125916620~125930024:+
LUAD	cis	rs4713118	0.513	rs149878	ENSG00000219392.1	RP1-265C24.5	-5.75	1.56e-08	5.76e-06	-0.33	-0.25	Parkinson's disease;	chr6:27910960	chr6:28115628~28116551:+
LUAD	cis	rs12680842	0.883	rs13265241	ENSG00000253704.1	RP11-267M23.4	5.75	1.56e-08	5.76e-06	0.29	0.25	Body mass index;	chr8:94575129	chr8:94553722~94569745:+
LUAD	cis	rs7246657	0.722	rs10402671	ENSG00000276846.1	CTD-3220F14.3	5.75	1.56e-08	5.76e-06	0.34	0.25	Coronary artery calcification;	chr19:37626185	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.722	rs10417576	ENSG00000276846.1	CTD-3220F14.3	5.75	1.56e-08	5.76e-06	0.34	0.25	Coronary artery calcification;	chr19:37628311	chr19:37314868~37315620:-
LUAD	cis	rs3096299	0.606	rs2965946	ENSG00000274627.1	RP11-104N10.2	5.75	1.56e-08	5.76e-06	0.27	0.25	Multiple myeloma (IgH translocation);	chr16:89450204	chr16:89516797~89522217:+
LUAD	cis	rs2115536	0.73	rs4238512	ENSG00000278600.1	RP11-81A1.6	5.75	1.56e-08	5.76e-06	0.21	0.25	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79891556	chr15:79920195~79922455:-
LUAD	cis	rs17301013	0.606	rs332764	ENSG00000227373.4	RP11-160H22.5	5.75	1.56e-08	5.77e-06	0.35	0.25	Systemic lupus erythematosus;	chr1:174693056	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs332763	ENSG00000227373.4	RP11-160H22.5	5.75	1.56e-08	5.77e-06	0.35	0.25	Systemic lupus erythematosus;	chr1:174693482	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.581	rs332772	ENSG00000227373.4	RP11-160H22.5	5.75	1.56e-08	5.77e-06	0.35	0.25	Systemic lupus erythematosus;	chr1:174695740	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs333471	ENSG00000227373.4	RP11-160H22.5	5.75	1.56e-08	5.77e-06	0.35	0.25	Systemic lupus erythematosus;	chr1:174705062	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.606	rs332798	ENSG00000227373.4	RP11-160H22.5	5.75	1.56e-08	5.77e-06	0.35	0.25	Systemic lupus erythematosus;	chr1:174729096	chr1:174115300~174160004:-
LUAD	cis	rs9847710	0.733	rs11923593	ENSG00000242142.1	SERBP1P3	5.75	1.56e-08	5.77e-06	0.29	0.25	Ulcerative colitis;	chr3:53054774	chr3:53064283~53065091:-
LUAD	cis	rs9595908	0.709	rs9285093	ENSG00000212293.1	SNORA16	5.75	1.56e-08	5.78e-06	0.27	0.25	Body mass index;	chr13:32745500	chr13:32420390~32420516:-
LUAD	cis	rs673078	0.607	rs61943443	ENSG00000275409.1	RP11-131L12.4	-5.75	1.56e-08	5.78e-06	-0.35	-0.25	Glucose homeostasis traits;	chr12:118416602	chr12:118430147~118430699:+
LUAD	cis	rs2276314	0.857	rs9304155	ENSG00000278986.1	RP11-723J4.3	-5.75	1.57e-08	5.78e-06	-0.31	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:36005747	chr18:35972151~35973916:+
LUAD	cis	rs875971	0.964	rs778735	ENSG00000237310.1	GS1-124K5.4	5.75	1.57e-08	5.78e-06	0.28	0.25	Aortic root size;	chr7:66349822	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.965	rs7794930	ENSG00000237310.1	GS1-124K5.4	-5.75	1.57e-08	5.79e-06	-0.27	-0.25	Aortic root size;	chr7:66313559	chr7:66493706~66495474:+
LUAD	cis	rs3738443	0.904	rs61840000	ENSG00000259865.1	RP11-488L18.10	5.75	1.57e-08	5.79e-06	0.28	0.25	Alcohol dependence;	chr1:247199027	chr1:247187281~247188526:-
LUAD	cis	rs10740039	0.516	rs1938546	ENSG00000254271.1	RP11-131N11.4	5.75	1.57e-08	5.79e-06	0.29	0.25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60556228	chr10:60734342~60741828:+
LUAD	cis	rs9652601	0.719	rs12103174	ENSG00000274038.1	RP11-66H6.4	-5.75	1.57e-08	5.8e-06	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11109873	chr16:11056556~11057034:+
LUAD	cis	rs9652601	0.649	rs767448	ENSG00000274038.1	RP11-66H6.4	-5.75	1.57e-08	5.8e-06	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11110364	chr16:11056556~11057034:+
LUAD	cis	rs6504622	1	rs1047779	ENSG00000262879.4	RP11-156P1.3	-5.75	1.57e-08	5.8e-06	-0.29	-0.25	Orofacial clefts;	chr17:46941877	chr17:46984045~47100323:-
LUAD	cis	rs9910055	0.718	rs2526022	ENSG00000267080.4	ASB16-AS1	-5.75	1.58e-08	5.82e-06	-0.23	-0.25	Total body bone mineral density;	chr17:44135848	chr17:44175973~44186717:-
LUAD	cis	rs9910055	0.762	rs2526021	ENSG00000267080.4	ASB16-AS1	-5.75	1.58e-08	5.82e-06	-0.23	-0.25	Total body bone mineral density;	chr17:44135979	chr17:44175973~44186717:-
LUAD	cis	rs801193	0.569	rs13242290	ENSG00000237310.1	GS1-124K5.4	-5.75	1.58e-08	5.82e-06	-0.28	-0.25	Aortic root size;	chr7:66656898	chr7:66493706~66495474:+
LUAD	cis	rs9595908	0.869	rs9591189	ENSG00000212293.1	SNORA16	5.75	1.58e-08	5.82e-06	0.27	0.25	Body mass index;	chr13:32632514	chr13:32420390~32420516:-
LUAD	cis	rs875971	0.545	rs73376394	ENSG00000237310.1	GS1-124K5.4	5.75	1.58e-08	5.83e-06	0.31	0.25	Aortic root size;	chr7:66172694	chr7:66493706~66495474:+
LUAD	cis	rs9813712	0.548	rs9880123	ENSG00000228252.7	COL6A4P2	-5.75	1.58e-08	5.83e-06	-0.24	-0.25	Response to amphetamines;	chr3:130215275	chr3:130212823~130273806:+
LUAD	cis	rs6543140	0.964	rs1035126	ENSG00000234389.1	AC007278.3	5.75	1.58e-08	5.84e-06	0.25	0.25	Blood protein levels;	chr2:102403521	chr2:102438713~102440475:+
LUAD	cis	rs9309473	0.95	rs6745480	ENSG00000163016.8	ALMS1P	5.75	1.58e-08	5.84e-06	0.3	0.25	Metabolite levels;	chr2:73612928	chr2:73644919~73685576:+
LUAD	cis	rs2688482	0.512	rs3103954	ENSG00000224769.1	AC069213.1	5.75	1.58e-08	5.84e-06	0.44	0.25	Lung disease severity in cystic fibrosis;	chr3:195789759	chr3:195614947~195620233:+
LUAD	cis	rs4713118	0.513	rs9368547	ENSG00000204709.4	LINC01556	5.75	1.59e-08	5.85e-06	0.32	0.25	Parkinson's disease;	chr6:28060289	chr6:28943877~28944537:+
LUAD	cis	rs950169	0.58	rs1061737	ENSG00000225151.9	GOLGA2P7	-5.75	1.59e-08	5.87e-06	-0.35	-0.25	Schizophrenia;	chr15:84640559	chr15:84199311~84230136:-
LUAD	cis	rs66887589	0.72	rs11724758	ENSG00000245958.5	RP11-33B1.1	-5.75	1.59e-08	5.87e-06	-0.21	-0.25	Diastolic blood pressure;	chr4:119318723	chr4:119454791~119552025:+
LUAD	cis	rs2439831	0.85	rs7168158	ENSG00000205771.5	CATSPER2P1	-5.75	1.59e-08	5.88e-06	-0.49	-0.25	Lung cancer in ever smokers;	chr15:43758178	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.85	rs7174208	ENSG00000205771.5	CATSPER2P1	-5.75	1.59e-08	5.88e-06	-0.49	-0.25	Lung cancer in ever smokers;	chr15:43760484	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.85	rs12101756	ENSG00000205771.5	CATSPER2P1	-5.75	1.59e-08	5.88e-06	-0.49	-0.25	Lung cancer in ever smokers;	chr15:43761689	chr15:43726918~43747094:-
LUAD	cis	rs8031584	0.56	rs7171208	ENSG00000270015.1	RP11-540B6.6	5.75	1.59e-08	5.88e-06	0.17	0.25	Huntington's disease progression;	chr15:30906726	chr15:30926514~30928407:+
LUAD	cis	rs1816752	1	rs7988810	ENSG00000273628.1	RP11-756A22.7	5.75	1.59e-08	5.88e-06	0.3	0.25	Obesity-related traits;	chr13:24444958	chr13:24933006~24936796:+
LUAD	cis	rs9543976	1	rs73223984	ENSG00000261553.4	RP11-29G8.3	-5.75	1.59e-08	5.88e-06	-0.41	-0.25	Diabetic retinopathy;	chr13:75607005	chr13:75549773~75807120:+
LUAD	cis	rs1707322	0.686	rs2152078	ENSG00000280836.1	AL355480.1	5.75	1.6e-08	5.89e-06	0.34	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45589928	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.686	rs2991979	ENSG00000280836.1	AL355480.1	5.75	1.6e-08	5.89e-06	0.34	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45590186	chr1:45581219~45581321:-
LUAD	cis	rs2179367	0.6	rs11155654	ENSG00000231760.4	RP11-350J20.5	5.75	1.6e-08	5.89e-06	0.38	0.25	Dupuytren's disease;	chr6:149442001	chr6:149796151~149826294:-
LUAD	cis	rs2280018	0.963	rs4985147	ENSG00000188599.16	NPIPP1	-5.75	1.6e-08	5.9e-06	-0.21	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15074903	chr16:15104312~15123498:-
LUAD	cis	rs2946504	0.861	rs2946497	ENSG00000251468.2	RP11-369K16.1	-5.75	1.6e-08	5.9e-06	-0.33	-0.25	Type 2 diabetes;	chr8:12960804	chr8:12958387~12962200:+
LUAD	cis	rs10129255	0.957	rs10150241	ENSG00000211972.2	IGHV3-66	-5.75	1.6e-08	5.9e-06	-0.22	-0.25	Kawasaki disease;	chr14:106775945	chr14:106675017~106675544:-
LUAD	cis	rs2404602	0.631	rs9646213	ENSG00000259422.1	RP11-593F23.1	5.75	1.6e-08	5.9e-06	0.29	0.25	Blood metabolite levels;	chr15:76515331	chr15:76174891~76181486:-
LUAD	cis	rs9543976	0.623	rs7996884	ENSG00000261553.4	RP11-29G8.3	5.75	1.6e-08	5.9e-06	0.33	0.25	Diabetic retinopathy;	chr13:75598608	chr13:75549773~75807120:+
LUAD	cis	rs9543976	0.623	rs6562918	ENSG00000261553.4	RP11-29G8.3	5.75	1.6e-08	5.9e-06	0.33	0.25	Diabetic retinopathy;	chr13:75600441	chr13:75549773~75807120:+
LUAD	cis	rs881375	0.702	rs3761847	ENSG00000226752.6	PSMD5-AS1	-5.75	1.6e-08	5.91e-06	-0.26	-0.25	Rheumatoid arthritis;	chr9:120927961	chr9:120824828~120854385:+
LUAD	cis	rs875971	0.545	rs13311962	ENSG00000226824.5	RP4-756H11.3	5.75	1.6e-08	5.91e-06	0.36	0.25	Aortic root size;	chr7:66603142	chr7:66654538~66669855:+
LUAD	cis	rs36093844	0.8	rs76663264	ENSG00000279742.1	RP11-700A24.1	-5.75	1.6e-08	5.91e-06	-0.34	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85867412	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.8	rs75605851	ENSG00000279742.1	RP11-700A24.1	-5.75	1.6e-08	5.91e-06	-0.34	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85868988	chr11:85852557~85854943:-
LUAD	cis	rs867371	1	rs8041868	ENSG00000259429.4	UBE2Q2P2	-5.75	1.61e-08	5.92e-06	-0.22	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82179985	chr15:82355142~82420075:+
LUAD	cis	rs875971	0.756	rs4718328	ENSG00000222364.1	RNU6-96P	5.75	1.61e-08	5.92e-06	0.29	0.25	Aortic root size;	chr7:66228350	chr7:66395191~66395286:+
LUAD	cis	rs10761482	0.544	rs1938544	ENSG00000254271.1	RP11-131N11.4	5.75	1.61e-08	5.92e-06	0.28	0.25	Schizophrenia;	chr10:60524901	chr10:60734342~60741828:+
LUAD	cis	rs10761482	0.5	rs1938543	ENSG00000254271.1	RP11-131N11.4	5.75	1.61e-08	5.92e-06	0.28	0.25	Schizophrenia;	chr10:60524902	chr10:60734342~60741828:+
LUAD	cis	rs293748	0.571	rs12652882	ENSG00000250155.1	CTD-2353F22.1	-5.75	1.61e-08	5.92e-06	-0.32	-0.25	Obesity-related traits;	chr5:37188340	chr5:36666214~36725195:-
LUAD	cis	rs17214007	0.877	rs2075514	ENSG00000263335.1	AF001548.5	-5.75	1.61e-08	5.93e-06	-0.36	-0.25	Cognitive function;	chr16:15778752	chr16:15726674~15732993:+
LUAD	cis	rs17214007	0.877	rs11644832	ENSG00000263335.1	AF001548.5	-5.75	1.61e-08	5.93e-06	-0.36	-0.25	Cognitive function;	chr16:15778891	chr16:15726674~15732993:+
LUAD	cis	rs17214007	0.877	rs11645883	ENSG00000263335.1	AF001548.5	-5.75	1.61e-08	5.93e-06	-0.36	-0.25	Cognitive function;	chr16:15778950	chr16:15726674~15732993:+
LUAD	cis	rs1113500	0.933	rs10785833	ENSG00000226822.1	RP11-356N1.2	5.75	1.61e-08	5.93e-06	0.3	0.25	Growth-regulated protein alpha levels;	chr1:108096460	chr1:108071482~108074519:+
LUAD	cis	rs1113500	0.897	rs55980437	ENSG00000226822.1	RP11-356N1.2	5.75	1.61e-08	5.93e-06	0.3	0.25	Growth-regulated protein alpha levels;	chr1:108096876	chr1:108071482~108074519:+
LUAD	cis	rs1113500	0.702	rs11185262	ENSG00000226822.1	RP11-356N1.2	5.75	1.61e-08	5.93e-06	0.3	0.25	Growth-regulated protein alpha levels;	chr1:108097120	chr1:108071482~108074519:+
LUAD	cis	rs2948294	0.588	rs12544596	ENSG00000253893.2	FAM85B	-5.75	1.61e-08	5.94e-06	-0.34	-0.25	Red cell distribution width;	chr8:8258824	chr8:8167819~8226614:-
LUAD	cis	rs12468226	0.873	rs12472035	ENSG00000226261.1	AC064836.3	5.75	1.61e-08	5.94e-06	0.43	0.25	Urate levels;	chr2:202221970	chr2:202336024~202336727:-
LUAD	cis	rs858239	0.932	rs1624451	ENSG00000226816.2	AC005082.12	-5.75	1.61e-08	5.95e-06	-0.32	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23222816	chr7:23206013~23208045:+
LUAD	cis	rs875971	0.862	rs2901152	ENSG00000237310.1	GS1-124K5.4	-5.75	1.62e-08	5.95e-06	-0.28	-0.25	Aortic root size;	chr7:66300017	chr7:66493706~66495474:+
LUAD	cis	rs2439831	0.85	rs28504496	ENSG00000205771.5	CATSPER2P1	-5.75	1.62e-08	5.95e-06	-0.49	-0.25	Lung cancer in ever smokers;	chr15:43724685	chr15:43726918~43747094:-
LUAD	cis	rs875971	0.508	rs6947808	ENSG00000224316.1	RP11-479O9.2	-5.75	1.62e-08	5.95e-06	-0.25	-0.25	Aortic root size;	chr7:66580095	chr7:65773620~65802067:+
LUAD	cis	rs35934224	0.783	rs13056219	ENSG00000232926.1	AC000078.5	5.75	1.62e-08	5.96e-06	0.31	0.25	Glaucoma (primary open-angle);	chr22:19873323	chr22:19887289~19887970:+
LUAD	cis	rs4718428	0.705	rs13220977	ENSG00000232546.1	RP11-458F8.1	5.75	1.62e-08	5.96e-06	0.24	0.25	Corneal structure;	chr7:66872661	chr7:66848496~66858136:+
LUAD	cis	rs7618501	0.633	rs13060128	ENSG00000234667.1	ACTBP13	-5.75	1.62e-08	5.96e-06	-0.29	-0.25	Intelligence (multi-trait analysis);	chr3:49987595	chr3:49873347~49877980:-
LUAD	cis	rs7618501	0.633	rs2353579	ENSG00000234667.1	ACTBP13	-5.75	1.62e-08	5.96e-06	-0.29	-0.25	Intelligence (multi-trait analysis);	chr3:49990341	chr3:49873347~49877980:-
LUAD	cis	rs2404602	0.716	rs17364076	ENSG00000259422.1	RP11-593F23.1	5.75	1.62e-08	5.98e-06	0.29	0.25	Blood metabolite levels;	chr15:76468550	chr15:76174891~76181486:-
LUAD	cis	rs12908161	1	rs58416181	ENSG00000225151.9	GOLGA2P7	-5.75	1.62e-08	5.98e-06	-0.35	-0.25	Schizophrenia;	chr15:84721230	chr15:84199311~84230136:-
LUAD	cis	rs4835473	0.778	rs6856553	ENSG00000251600.4	RP11-673E1.1	-5.75	1.63e-08	5.99e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143825973	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.868	rs11737787	ENSG00000251600.4	RP11-673E1.1	-5.75	1.63e-08	5.99e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143826498	chr4:143912331~143982454:+
LUAD	cis	rs2404602	0.569	rs283793	ENSG00000259422.1	RP11-593F23.1	5.75	1.63e-08	5.99e-06	0.33	0.25	Blood metabolite levels;	chr15:76482411	chr15:76174891~76181486:-
LUAD	cis	rs7727544	0.684	rs274546	ENSG00000233006.5	AC034220.3	5.75	1.63e-08	6e-06	0.23	0.25	Blood metabolite levels;	chr5:132364175	chr5:132311285~132369916:-
LUAD	cis	rs2302464	1	rs73123607	ENSG00000214846.4	RP11-115L11.1	5.75	1.63e-08	6e-06	0.61	0.25	Cerebrospinal fluid biomarker levels;	chr4:15725058	chr4:15730962~15731627:-
LUAD	cis	rs2302464	1	rs6844968	ENSG00000214846.4	RP11-115L11.1	5.75	1.63e-08	6e-06	0.61	0.25	Cerebrospinal fluid biomarker levels;	chr4:15725641	chr4:15730962~15731627:-
LUAD	cis	rs2302464	1	rs58978163	ENSG00000214846.4	RP11-115L11.1	5.75	1.63e-08	6e-06	0.61	0.25	Cerebrospinal fluid biomarker levels;	chr4:15726385	chr4:15730962~15731627:-
LUAD	cis	rs172166	0.694	rs203893	ENSG00000204709.4	LINC01556	5.75	1.63e-08	6e-06	0.33	0.25	Cardiac Troponin-T levels;	chr6:28094288	chr6:28943877~28944537:+
LUAD	cis	rs10214930	0.697	rs6958747	ENSG00000235574.1	AC073150.6	5.75	1.63e-08	6e-06	0.31	0.25	Hypospadias;	chr7:27652244	chr7:27491682~27492765:-
LUAD	cis	rs4654783	0.627	rs66766977	ENSG00000228397.1	RP1-224A6.3	5.75	1.63e-08	6e-06	0.31	0.25	Endometriosis;	chr1:22104599	chr1:22023994~22024968:-
LUAD	cis	rs1707322	1	rs785467	ENSG00000234329.1	RP11-767N6.2	-5.75	1.63e-08	6e-06	-0.27	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055887	chr1:45651039~45651826:-
LUAD	cis	rs4820294	0.646	rs9622675	ENSG00000233360.4	Z83844.1	5.75	1.63e-08	6.01e-06	0.26	0.25	Fat distribution (HIV);	chr22:37657658	chr22:37641832~37658377:-
LUAD	cis	rs30380	0.632	rs26500	ENSG00000272109.1	CTD-2260A17.3	-5.74	1.63e-08	6.01e-06	-0.31	-0.25	Cerebrospinal fluid biomarker levels;	chr5:96798009	chr5:96804353~96806105:+
LUAD	cis	rs9879311	0.966	rs28113	ENSG00000240288.6	GHRLOS	5.74	1.63e-08	6.01e-06	0.24	0.25	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10358959	chr3:10285754~10293449:+
LUAD	cis	rs2179367	0.632	rs66672129	ENSG00000231760.4	RP11-350J20.5	5.74	1.64e-08	6.02e-06	0.37	0.25	Dupuytren's disease;	chr6:149334387	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs9498322	ENSG00000231760.4	RP11-350J20.5	5.74	1.64e-08	6.02e-06	0.37	0.25	Dupuytren's disease;	chr6:149335950	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs9498323	ENSG00000231760.4	RP11-350J20.5	5.74	1.64e-08	6.02e-06	0.37	0.25	Dupuytren's disease;	chr6:149336077	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs12204793	ENSG00000231760.4	RP11-350J20.5	5.74	1.64e-08	6.02e-06	0.37	0.25	Dupuytren's disease;	chr6:149340102	chr6:149796151~149826294:-
LUAD	cis	rs4948102	0.595	rs7793921	ENSG00000226278.1	PSPHP1	-5.74	1.64e-08	6.02e-06	-0.29	-0.25	Plasma homocysteine levels (post-methionine load test);	chr7:56053188	chr7:55764797~55773288:+
LUAD	cis	rs4948102	0.595	rs10255049	ENSG00000226278.1	PSPHP1	-5.74	1.64e-08	6.02e-06	-0.29	-0.25	Plasma homocysteine levels (post-methionine load test);	chr7:56053611	chr7:55764797~55773288:+
LUAD	cis	rs4604732	0.631	rs12038793	ENSG00000227135.1	GCSAML-AS1	5.74	1.64e-08	6.02e-06	0.39	0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247460960	chr1:247524679~247526752:-
LUAD	cis	rs2243480	0.711	rs2420172	ENSG00000230295.1	RP11-458F8.2	5.74	1.64e-08	6.02e-06	0.31	0.25	Diabetic kidney disease;	chr7:66170354	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs2420171	ENSG00000230295.1	RP11-458F8.2	5.74	1.64e-08	6.02e-06	0.31	0.25	Diabetic kidney disease;	chr7:66172773	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs6974723	ENSG00000230295.1	RP11-458F8.2	5.74	1.64e-08	6.02e-06	0.31	0.25	Diabetic kidney disease;	chr7:66172952	chr7:66880708~66882981:+
LUAD	cis	rs453301	0.686	rs10217044	ENSG00000253981.4	ALG1L13P	-5.74	1.64e-08	6.03e-06	-0.3	-0.25	Joint mobility (Beighton score);	chr8:9037242	chr8:8236003~8244667:-
LUAD	cis	rs10129255	0.518	rs8009612	ENSG00000211967.3	IGHV3-53	-5.74	1.64e-08	6.03e-06	-0.18	-0.25	Kawasaki disease;	chr14:106777510	chr14:106592676~106593347:-
LUAD	cis	rs7615952	0.641	rs66520539	ENSG00000171084.14	FAM86JP	5.74	1.64e-08	6.04e-06	0.37	0.25	Blood pressure (smoking interaction);	chr3:126061531	chr3:125916620~125930024:+
LUAD	cis	rs10129255	0.518	rs8009594	ENSG00000211967.3	IGHV3-53	-5.74	1.64e-08	6.04e-06	-0.18	-0.25	Kawasaki disease;	chr14:106777494	chr14:106592676~106593347:-
LUAD	cis	rs10214930	0.602	rs1115346	ENSG00000235574.1	AC073150.6	-5.74	1.64e-08	6.04e-06	-0.3	-0.25	Hypospadias;	chr7:27622485	chr7:27491682~27492765:-
LUAD	cis	rs35160687	0.712	rs4832030	ENSG00000273080.1	RP11-301O19.1	-5.74	1.64e-08	6.05e-06	-0.28	-0.25	Night sleep phenotypes;	chr2:86251746	chr2:86195590~86196049:+
LUAD	cis	rs35160687	0.712	rs12988844	ENSG00000273080.1	RP11-301O19.1	-5.74	1.64e-08	6.05e-06	-0.28	-0.25	Night sleep phenotypes;	chr2:86251912	chr2:86195590~86196049:+
LUAD	cis	rs12554020	0.579	rs74740549	ENSG00000227603.1	RP11-165J3.6	5.74	1.64e-08	6.05e-06	0.48	0.25	Schizophrenia;	chr9:93480399	chr9:93435332~93437121:-
LUAD	cis	rs4713118	0.662	rs9393881	ENSG00000204709.4	LINC01556	5.74	1.65e-08	6.05e-06	0.34	0.25	Parkinson's disease;	chr6:28055973	chr6:28943877~28944537:+
LUAD	cis	rs2933343	1	rs1680784	ENSG00000261159.1	RP11-723O4.9	5.74	1.65e-08	6.06e-06	0.31	0.25	IgG glycosylation;	chr3:128925615	chr3:128859716~128860526:-
LUAD	cis	rs10214930	0.813	rs7786973	ENSG00000235574.1	AC073150.6	-5.74	1.65e-08	6.06e-06	-0.34	-0.25	Hypospadias;	chr7:27542629	chr7:27491682~27492765:-
LUAD	cis	rs10246939	0.544	rs12668089	ENSG00000228775.6	WEE2-AS1	5.74	1.65e-08	6.06e-06	0.31	0.25	Bitter taste perception;	chr7:141875111	chr7:141704338~141738346:-
LUAD	cis	rs875971	0.964	rs1643388	ENSG00000237310.1	GS1-124K5.4	5.74	1.65e-08	6.06e-06	0.27	0.25	Aortic root size;	chr7:66379575	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs778722	ENSG00000237310.1	GS1-124K5.4	5.74	1.65e-08	6.06e-06	0.27	0.25	Aortic root size;	chr7:66379841	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.964	rs778721	ENSG00000237310.1	GS1-124K5.4	5.74	1.65e-08	6.06e-06	0.27	0.25	Aortic root size;	chr7:66380410	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.929	rs778712	ENSG00000237310.1	GS1-124K5.4	5.74	1.65e-08	6.06e-06	0.27	0.25	Aortic root size;	chr7:66384991	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs778710	ENSG00000237310.1	GS1-124K5.4	5.74	1.65e-08	6.06e-06	0.27	0.25	Aortic root size;	chr7:66389847	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.964	rs778708	ENSG00000237310.1	GS1-124K5.4	5.74	1.65e-08	6.06e-06	0.27	0.25	Aortic root size;	chr7:66391332	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs778706	ENSG00000237310.1	GS1-124K5.4	5.74	1.65e-08	6.06e-06	0.27	0.25	Aortic root size;	chr7:66395437	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.895	rs778700	ENSG00000237310.1	GS1-124K5.4	5.74	1.65e-08	6.06e-06	0.27	0.25	Aortic root size;	chr7:66401463	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs778699	ENSG00000237310.1	GS1-124K5.4	5.74	1.65e-08	6.06e-06	0.27	0.25	Aortic root size;	chr7:66403303	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs778696	ENSG00000237310.1	GS1-124K5.4	5.74	1.65e-08	6.06e-06	0.27	0.25	Aortic root size;	chr7:66405826	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs778694	ENSG00000237310.1	GS1-124K5.4	5.74	1.65e-08	6.06e-06	0.27	0.25	Aortic root size;	chr7:66406571	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.929	rs778692	ENSG00000237310.1	GS1-124K5.4	5.74	1.65e-08	6.06e-06	0.27	0.25	Aortic root size;	chr7:66407462	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs4718343	ENSG00000237310.1	GS1-124K5.4	5.74	1.65e-08	6.06e-06	0.27	0.25	Aortic root size;	chr7:66409301	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs4718344	ENSG00000237310.1	GS1-124K5.4	5.74	1.65e-08	6.06e-06	0.27	0.25	Aortic root size;	chr7:66409394	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs1968225	ENSG00000237310.1	GS1-124K5.4	5.74	1.65e-08	6.06e-06	0.27	0.25	Aortic root size;	chr7:66409786	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.737	rs7803424	ENSG00000237310.1	GS1-124K5.4	5.74	1.65e-08	6.06e-06	0.27	0.25	Aortic root size;	chr7:66415618	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.83	rs7799834	ENSG00000237310.1	GS1-124K5.4	5.74	1.65e-08	6.06e-06	0.27	0.25	Aortic root size;	chr7:66415707	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs6460295	ENSG00000237310.1	GS1-124K5.4	5.74	1.65e-08	6.06e-06	0.27	0.25	Aortic root size;	chr7:66417741	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.964	rs6978721	ENSG00000237310.1	GS1-124K5.4	5.74	1.65e-08	6.06e-06	0.27	0.25	Aortic root size;	chr7:66418217	chr7:66493706~66495474:+
LUAD	cis	rs9847710	0.696	rs2244461	ENSG00000242142.1	SERBP1P3	5.74	1.65e-08	6.06e-06	0.3	0.25	Ulcerative colitis;	chr3:53021826	chr3:53064283~53065091:-
LUAD	cis	rs17684571	0.7	rs13200768	ENSG00000231441.1	RP11-472M19.2	5.74	1.65e-08	6.06e-06	0.38	0.25	Schizophrenia;	chr6:56786828	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.7	rs13204466	ENSG00000231441.1	RP11-472M19.2	5.74	1.65e-08	6.06e-06	0.38	0.25	Schizophrenia;	chr6:56787376	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.7	rs34612783	ENSG00000231441.1	RP11-472M19.2	5.74	1.65e-08	6.06e-06	0.38	0.25	Schizophrenia;	chr6:56787851	chr6:56844002~56864078:+
LUAD	cis	rs875971	0.862	rs6952182	ENSG00000222364.1	RNU6-96P	5.74	1.65e-08	6.07e-06	0.29	0.25	Aortic root size;	chr7:66218330	chr7:66395191~66395286:+
LUAD	cis	rs8177876	0.749	rs2287995	ENSG00000261061.1	RP11-303E16.2	-5.74	1.65e-08	6.07e-06	-0.43	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81061494	chr16:81030770~81031485:+
LUAD	cis	rs2439831	0.702	rs7171750	ENSG00000205771.5	CATSPER2P1	-5.74	1.65e-08	6.08e-06	-0.49	-0.25	Lung cancer in ever smokers;	chr15:43733660	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.85	rs11070408	ENSG00000205771.5	CATSPER2P1	-5.74	1.65e-08	6.08e-06	-0.49	-0.25	Lung cancer in ever smokers;	chr15:43742590	chr15:43726918~43747094:-
LUAD	cis	rs9543976	0.623	rs7986566	ENSG00000261553.4	RP11-29G8.3	5.74	1.65e-08	6.08e-06	0.34	0.25	Diabetic retinopathy;	chr13:75623795	chr13:75549773~75807120:+
LUAD	cis	rs11098499	0.754	rs1980025	ENSG00000248280.1	RP11-33B1.2	-5.74	1.65e-08	6.08e-06	-0.31	-0.25	Corneal astigmatism;	chr4:119331651	chr4:119440561~119450157:-
LUAD	cis	rs36093844	0.752	rs17817308	ENSG00000279742.1	RP11-700A24.1	-5.74	1.66e-08	6.08e-06	-0.34	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85882486	chr11:85852557~85854943:-
LUAD	cis	rs7772486	0.597	rs6570732	ENSG00000235652.6	RP11-545I5.3	-5.74	1.66e-08	6.09e-06	-0.27	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145924015	chr6:145799409~145886585:+
LUAD	cis	rs12468226	0.938	rs10166594	ENSG00000226261.1	AC064836.3	5.74	1.66e-08	6.09e-06	0.39	0.25	Urate levels;	chr2:202250262	chr2:202336024~202336727:-
LUAD	cis	rs4713118	0.513	rs149955	ENSG00000204709.4	LINC01556	5.74	1.66e-08	6.09e-06	0.33	0.25	Parkinson's disease;	chr6:28068447	chr6:28943877~28944537:+
LUAD	cis	rs4835473	0.932	rs34683160	ENSG00000251600.4	RP11-673E1.1	-5.74	1.66e-08	6.1e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143765227	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs72946226	ENSG00000251600.4	RP11-673E1.1	-5.74	1.66e-08	6.1e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143765238	chr4:143912331~143982454:+
LUAD	cis	rs1823913	0.637	rs2356354	ENSG00000227542.1	AC092614.2	-5.74	1.66e-08	6.1e-06	-0.31	-0.25	Obesity-related traits;	chr2:191270970	chr2:191229165~191246172:-
LUAD	cis	rs2288884	0.515	rs8112458	ENSG00000275055.1	CTC-471J1.11	-5.74	1.66e-08	6.1e-06	-0.29	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52030052	chr19:52049007~52049754:+
LUAD	cis	rs7712401	0.601	rs431878	ENSG00000263432.2	RN7SL689P	-5.74	1.66e-08	6.1e-06	-0.32	-0.25	Mean platelet volume;	chr5:122926096	chr5:123022487~123022783:-
LUAD	cis	rs17666538	0.585	rs1037393	ENSG00000254207.1	RP11-43A14.1	5.74	1.66e-08	6.11e-06	0.51	0.25	IgG glycosylation;	chr8:672634	chr8:725188~725877:-
LUAD	cis	rs17666538	0.585	rs6559064	ENSG00000254207.1	RP11-43A14.1	5.74	1.66e-08	6.11e-06	0.51	0.25	IgG glycosylation;	chr8:673061	chr8:725188~725877:-
LUAD	cis	rs9595908	0.669	rs9596205	ENSG00000212293.1	SNORA16	-5.74	1.66e-08	6.11e-06	-0.28	-0.25	Body mass index;	chr13:32754487	chr13:32420390~32420516:-
LUAD	cis	rs9652601	0.622	rs9935174	ENSG00000274038.1	RP11-66H6.4	-5.74	1.66e-08	6.11e-06	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11017490	chr16:11056556~11057034:+
LUAD	cis	rs7615952	0.576	rs12497295	ENSG00000171084.14	FAM86JP	5.74	1.67e-08	6.13e-06	0.38	0.25	Blood pressure (smoking interaction);	chr3:126099807	chr3:125916620~125930024:+
LUAD	cis	rs2404602	0.647	rs12913024	ENSG00000259422.1	RP11-593F23.1	-5.74	1.68e-08	6.16e-06	-0.34	-0.25	Blood metabolite levels;	chr15:76852875	chr15:76174891~76181486:-
LUAD	cis	rs4835473	0.932	rs10857415	ENSG00000251600.4	RP11-673E1.1	5.74	1.68e-08	6.16e-06	0.32	0.25	Immature fraction of reticulocytes;	chr4:143908753	chr4:143912331~143982454:+
LUAD	cis	rs17684571	0.872	rs13198399	ENSG00000231441.1	RP11-472M19.2	5.74	1.68e-08	6.17e-06	0.37	0.25	Schizophrenia;	chr6:56733196	chr6:56844002~56864078:+
LUAD	cis	rs673078	0.607	rs17440893	ENSG00000275409.1	RP11-131L12.4	-5.74	1.68e-08	6.17e-06	-0.35	-0.25	Glucose homeostasis traits;	chr12:118362532	chr12:118430147~118430699:+
LUAD	cis	rs1707322	0.752	rs7541962	ENSG00000280836.1	AL355480.1	-5.74	1.68e-08	6.17e-06	-0.34	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769445	chr1:45581219~45581321:-
LUAD	cis	rs7208859	0.623	rs59447372	ENSG00000263603.1	CTD-2349P21.5	-5.74	1.68e-08	6.17e-06	-0.45	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30730567	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs8079891	ENSG00000263603.1	CTD-2349P21.5	-5.74	1.68e-08	6.17e-06	-0.45	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30731845	chr17:30729469~30731202:+
LUAD	cis	rs1062177	0.694	rs2915816	ENSG00000213433.5	RPLP1P6	5.74	1.68e-08	6.18e-06	0.32	0.25	Preschool internalizing problems;	chr5:151736296	chr5:151765859~151766378:-
LUAD	cis	rs66887589	0.967	rs6844263	ENSG00000245958.5	RP11-33B1.1	-5.74	1.68e-08	6.18e-06	-0.2	-0.25	Diastolic blood pressure;	chr4:119512652	chr4:119454791~119552025:+
LUAD	cis	rs1823913	0.637	rs4853584	ENSG00000280083.1	RP11-317J9.1	5.74	1.68e-08	6.18e-06	0.3	0.25	Obesity-related traits;	chr2:191310596	chr2:191154118~191156070:-
LUAD	cis	rs728616	0.614	rs55768100	ENSG00000225484.5	NUTM2B-AS1	-5.74	1.69e-08	6.19e-06	-0.43	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79964721	chr10:79663088~79826594:-
LUAD	cis	rs858239	0.539	rs2141305	ENSG00000230042.1	AK3P3	-5.74	1.69e-08	6.19e-06	-0.32	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23152280	chr7:23129178~23129841:+
LUAD	cis	rs7829975	0.54	rs2976909	ENSG00000253981.4	ALG1L13P	-5.74	1.69e-08	6.2e-06	-0.29	-0.25	Mood instability;	chr8:8489180	chr8:8236003~8244667:-
LUAD	cis	rs10129255	1	rs10141557	ENSG00000224373.3	IGHV4-59	5.74	1.69e-08	6.2e-06	0.17	0.25	Kawasaki disease;	chr14:106767990	chr14:106627249~106627825:-
LUAD	cis	rs2348418	0.579	rs2126896	ENSG00000247934.4	RP11-967K21.1	-5.74	1.69e-08	6.2e-06	-0.27	-0.25	Lung function (FEV1);Lung function (FVC);	chr12:28239701	chr12:28163298~28190738:-
LUAD	cis	rs875971	0.545	rs1267814	ENSG00000226824.5	RP4-756H11.3	5.74	1.69e-08	6.2e-06	0.36	0.25	Aortic root size;	chr7:66579422	chr7:66654538~66669855:+
LUAD	cis	rs6687821	0.515	rs5859	ENSG00000267734.1	RP4-604K5.3	5.74	1.69e-08	6.21e-06	0.31	0.25	Yeast infection;	chr1:86862842	chr1:86932199~86934891:-
LUAD	cis	rs6687821	0.515	rs554213	ENSG00000267734.1	RP4-604K5.3	5.74	1.69e-08	6.21e-06	0.31	0.25	Yeast infection;	chr1:86876474	chr1:86932199~86934891:-
LUAD	cis	rs6687821	0.515	rs576955	ENSG00000267734.1	RP4-604K5.3	5.74	1.69e-08	6.21e-06	0.31	0.25	Yeast infection;	chr1:86876627	chr1:86932199~86934891:-
LUAD	cis	rs293748	0.882	rs34525350	ENSG00000250155.1	CTD-2353F22.1	-5.74	1.69e-08	6.21e-06	-0.36	-0.25	Obesity-related traits;	chr5:37089535	chr5:36666214~36725195:-
LUAD	cis	rs2439831	0.85	rs12442129	ENSG00000205771.5	CATSPER2P1	-5.74	1.7e-08	6.22e-06	-0.49	-0.25	Lung cancer in ever smokers;	chr15:43763658	chr15:43726918~43747094:-
LUAD	cis	rs853679	0.517	rs17711344	ENSG00000204709.4	LINC01556	-5.74	1.7e-08	6.22e-06	-0.35	-0.25	Depression;	chr6:28109824	chr6:28943877~28944537:+
LUAD	cis	rs8177376	0.727	rs645852	ENSG00000254905.1	RP11-712L6.7	5.74	1.7e-08	6.22e-06	0.34	0.25	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126327509	chr11:126292922~126294254:-
LUAD	cis	rs8177376	0.727	rs646775	ENSG00000254905.1	RP11-712L6.7	5.74	1.7e-08	6.22e-06	0.34	0.25	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126327704	chr11:126292922~126294254:-
LUAD	cis	rs11651753	0.636	rs12602494	ENSG00000264920.1	RP11-6N17.4	-5.74	1.7e-08	6.23e-06	-0.32	-0.25	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47960241	chr17:47891255~47895812:-
LUAD	cis	rs453301	0.606	rs6601279	ENSG00000253981.4	ALG1L13P	-5.74	1.7e-08	6.24e-06	-0.3	-0.25	Joint mobility (Beighton score);	chr8:9050721	chr8:8236003~8244667:-
LUAD	cis	rs453301	0.606	rs6981060	ENSG00000253981.4	ALG1L13P	-5.74	1.7e-08	6.24e-06	-0.3	-0.25	Joint mobility (Beighton score);	chr8:9050725	chr8:8236003~8244667:-
LUAD	cis	rs12468226	0.938	rs12463937	ENSG00000272966.1	RP11-686O6.1	5.74	1.7e-08	6.24e-06	0.44	0.25	Urate levels;	chr2:202246543	chr2:202336739~202337200:+
LUAD	cis	rs7712401	0.601	rs34233716	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122980670	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.54	rs416763	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122981546	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs35339188	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122981990	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs36099390	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122982024	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs35157167	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122982506	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs396941	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122982570	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.58	rs439739	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122982726	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs371604	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122982737	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs34707663	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122984768	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs385547	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122986138	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs454617	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122986232	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs442427	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122986570	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs436546	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122987095	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs397731	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122987264	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.58	rs35902490	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122987703	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.562	rs383638	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122988983	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.562	rs62377399	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122988984	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs442911	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122989856	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs425573	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122990313	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.562	rs364723	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122990769	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs35847506	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122991413	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs390234	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122995828	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs4555798	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122996419	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs62377424	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122996627	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs35699701	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122998061	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs35256179	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122998560	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs35858098	ENSG00000263432.2	RN7SL689P	-5.74	1.71e-08	6.25e-06	-0.32	-0.25	Mean platelet volume;	chr5:122998670	chr5:123022487~123022783:-
LUAD	cis	rs301901	0.548	rs2366176	ENSG00000250155.1	CTD-2353F22.1	5.74	1.71e-08	6.25e-06	0.28	0.25	Height;	chr5:37439326	chr5:36666214~36725195:-
LUAD	cis	rs10761482	0.5	rs2211220	ENSG00000254271.1	RP11-131N11.4	5.74	1.71e-08	6.25e-06	0.28	0.25	Schizophrenia;	chr10:60511733	chr10:60734342~60741828:+
LUAD	cis	rs7948661	1	rs9332781	ENSG00000278376.1	RP11-158I9.8	5.74	1.71e-08	6.25e-06	0.54	0.25	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118475884	chr11:118791254~118793137:+
LUAD	cis	rs10214930	0.697	rs10951169	ENSG00000235574.1	AC073150.6	5.74	1.71e-08	6.26e-06	0.31	0.25	Hypospadias;	chr7:27516295	chr7:27491682~27492765:-
LUAD	cis	rs997295	0.57	rs737226	ENSG00000270964.1	RP11-502I4.3	-5.74	1.71e-08	6.26e-06	-0.26	-0.25	Motion sickness;	chr15:67548435	chr15:67541072~67542604:-
LUAD	cis	rs997295	0.57	rs11632574	ENSG00000270964.1	RP11-502I4.3	-5.74	1.71e-08	6.26e-06	-0.26	-0.25	Motion sickness;	chr15:67560067	chr15:67541072~67542604:-
LUAD	cis	rs3738443	0.868	rs6660351	ENSG00000259865.1	RP11-488L18.10	5.74	1.71e-08	6.26e-06	0.27	0.25	Alcohol dependence;	chr1:247184526	chr1:247187281~247188526:-
LUAD	cis	rs997295	0.57	rs72747464	ENSG00000270964.1	RP11-502I4.3	-5.74	1.71e-08	6.26e-06	-0.27	-0.25	Motion sickness;	chr15:67526202	chr15:67541072~67542604:-
LUAD	cis	rs7044106	0.537	rs10739573	ENSG00000238181.2	AHCYP2	-5.74	1.71e-08	6.27e-06	-0.36	-0.25	Hip circumference adjusted for BMI;	chr9:120727540	chr9:120720673~120721972:+
LUAD	cis	rs7615952	0.515	rs7637246	ENSG00000171084.14	FAM86JP	5.74	1.71e-08	6.27e-06	0.36	0.25	Blood pressure (smoking interaction);	chr3:125959863	chr3:125916620~125930024:+
LUAD	cis	rs1113500	0.933	rs10881500	ENSG00000226822.1	RP11-356N1.2	5.74	1.72e-08	6.29e-06	0.3	0.25	Growth-regulated protein alpha levels;	chr1:108096273	chr1:108071482~108074519:+
LUAD	cis	rs1113500	0.897	rs10785832	ENSG00000226822.1	RP11-356N1.2	5.74	1.72e-08	6.29e-06	0.3	0.25	Growth-regulated protein alpha levels;	chr1:108096277	chr1:108071482~108074519:+
LUAD	cis	rs10091374	1	rs2380651	ENSG00000253967.1	RP11-333A23.4	-5.74	1.72e-08	6.29e-06	-0.28	-0.25	Cardiac Troponin-T levels;	chr8:70473322	chr8:70471134~70485687:+
LUAD	cis	rs7617773	0.851	rs13068288	ENSG00000228638.1	FCF1P2	-5.74	1.72e-08	6.29e-06	-0.32	-0.25	Coronary artery disease;	chr3:48290261	chr3:48290793~48291375:-
LUAD	cis	rs17301013	0.606	rs332784	ENSG00000227373.4	RP11-160H22.5	5.74	1.72e-08	6.29e-06	0.35	0.25	Systemic lupus erythematosus;	chr1:174719927	chr1:174115300~174160004:-
LUAD	cis	rs1707322	0.686	rs2991986	ENSG00000280836.1	AL355480.1	5.74	1.72e-08	6.29e-06	0.33	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615610	chr1:45581219~45581321:-
LUAD	cis	rs2276314	0.857	rs4799408	ENSG00000278986.1	RP11-723J4.3	5.74	1.72e-08	6.3e-06	0.31	0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:36009019	chr18:35972151~35973916:+
LUAD	cis	rs7945705	0.902	rs10743093	ENSG00000254860.4	TMEM9B-AS1	-5.74	1.72e-08	6.3e-06	-0.29	-0.25	Hemoglobin concentration;	chr11:8847582	chr11:8964675~8977527:+
LUAD	cis	rs11096990	0.892	rs11730558	ENSG00000249207.1	RP11-360F5.1	-5.74	1.72e-08	6.3e-06	-0.29	-0.25	Cognitive function;	chr4:39228151	chr4:39112677~39126818:-
LUAD	cis	rs875971	0.862	rs778720	ENSG00000222364.1	RNU6-96P	5.74	1.72e-08	6.3e-06	0.29	0.25	Aortic root size;	chr7:66381288	chr7:66395191~66395286:+
LUAD	cis	rs896854	0.654	rs13278601	ENSG00000253528.2	RP11-347C18.4	5.74	1.72e-08	6.31e-06	0.24	0.25	Type 2 diabetes;	chr8:94960746	chr8:94974573~94974853:-
LUAD	cis	rs7923609	1	rs10761742	ENSG00000232075.1	MRPL35P2	-5.74	1.72e-08	6.31e-06	-0.31	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63325288	chr10:63634317~63634827:-
LUAD	cis	rs6940638	0.513	rs4424065	ENSG00000241549.7	GUSBP2	-5.74	1.72e-08	6.32e-06	-0.27	-0.25	Intelligence (multi-trait analysis);	chr6:27068677	chr6:26871484~26956554:-
LUAD	cis	rs2243480	0.708	rs13242216	ENSG00000230295.1	RP11-458F8.2	-5.74	1.72e-08	6.32e-06	-0.31	-0.25	Diabetic kidney disease;	chr7:66433290	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs67536397	ENSG00000230295.1	RP11-458F8.2	-5.74	1.72e-08	6.32e-06	-0.31	-0.25	Diabetic kidney disease;	chr7:66482930	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs58669269	ENSG00000230295.1	RP11-458F8.2	-5.74	1.72e-08	6.32e-06	-0.31	-0.25	Diabetic kidney disease;	chr7:66486966	chr7:66880708~66882981:+
LUAD	cis	rs2243480	0.901	rs34807232	ENSG00000230295.1	RP11-458F8.2	-5.74	1.72e-08	6.32e-06	-0.31	-0.25	Diabetic kidney disease;	chr7:66500146	chr7:66880708~66882981:+
LUAD	cis	rs9532669	0.926	rs9594450	ENSG00000168852.11	TPTE2P5	5.73	1.73e-08	6.32e-06	0.27	0.25	Cervical cancer;	chr13:40880067	chr13:40822296~40921749:-
LUAD	cis	rs783540	0.592	rs2567632	ENSG00000278603.1	RP13-608F4.5	-5.73	1.73e-08	6.32e-06	-0.32	-0.25	Schizophrenia;	chr15:82616053	chr15:82472203~82472426:+
LUAD	cis	rs2404602	0.647	rs11852395	ENSG00000259422.1	RP11-593F23.1	-5.73	1.73e-08	6.32e-06	-0.34	-0.25	Blood metabolite levels;	chr15:76795444	chr15:76174891~76181486:-
LUAD	cis	rs66887589	0.967	rs2892869	ENSG00000245958.5	RP11-33B1.1	5.73	1.73e-08	6.33e-06	0.2	0.25	Diastolic blood pressure;	chr4:119600142	chr4:119454791~119552025:+
LUAD	cis	rs2255336	0.938	rs12315123	ENSG00000245648.1	RP11-277P12.20	-5.73	1.73e-08	6.33e-06	-0.4	-0.25	Blood protein levels;	chr12:10481540	chr12:10363769~10398506:+
LUAD	cis	rs11105298	0.891	rs10858894	ENSG00000258302.2	RP11-981P6.1	5.73	1.73e-08	6.33e-06	0.33	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89520484	chr12:89561129~89594878:+
LUAD	cis	rs11105298	0.891	rs11105310	ENSG00000258302.2	RP11-981P6.1	5.73	1.73e-08	6.33e-06	0.33	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89524900	chr12:89561129~89594878:+
LUAD	cis	rs11105298	0.891	rs10777184	ENSG00000258302.2	RP11-981P6.1	5.73	1.73e-08	6.33e-06	0.33	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89525791	chr12:89561129~89594878:+
LUAD	cis	rs9992667	0.955	rs73232881	ENSG00000231160.8	KLF3-AS1	5.73	1.73e-08	6.34e-06	0.33	0.25	Eosinophil percentage of granulocytes;	chr4:38662510	chr4:38612701~38664883:-
LUAD	cis	rs1075265	0.756	rs2542576	ENSG00000233266.1	HMGB1P31	5.73	1.73e-08	6.34e-06	0.32	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53821659	chr2:54051334~54051760:+
LUAD	cis	rs13217239	0.646	rs7451149	ENSG00000241549.7	GUSBP2	-5.73	1.73e-08	6.34e-06	-0.28	-0.25	Schizophrenia;	chr6:27089739	chr6:26871484~26956554:-
LUAD	cis	rs7246657	0.722	rs12974225	ENSG00000276846.1	CTD-3220F14.3	-5.73	1.73e-08	6.35e-06	-0.34	-0.25	Coronary artery calcification;	chr19:37749458	chr19:37314868~37315620:-
LUAD	cis	rs9652601	0.691	rs6498160	ENSG00000274038.1	RP11-66H6.4	-5.73	1.74e-08	6.36e-06	-0.31	-0.25	Systemic lupus erythematosus;	chr16:11105590	chr16:11056556~11057034:+
LUAD	cis	rs1113500	0.548	rs3853495	ENSG00000226822.1	RP11-356N1.2	5.73	1.74e-08	6.36e-06	0.34	0.25	Growth-regulated protein alpha levels;	chr1:108100623	chr1:108071482~108074519:+
LUAD	cis	rs881375	0.678	rs3761846	ENSG00000226752.6	PSMD5-AS1	-5.73	1.74e-08	6.36e-06	-0.26	-0.25	Rheumatoid arthritis;	chr9:120927319	chr9:120824828~120854385:+
LUAD	cis	rs367615	0.918	rs13173339	ENSG00000249476.1	CTD-2587M2.1	5.73	1.74e-08	6.38e-06	0.33	0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109535617	chr5:109237120~109326369:-
LUAD	cis	rs4308124	0.708	rs6747657	ENSG00000227992.1	AC108463.2	-5.73	1.75e-08	6.39e-06	-0.33	-0.25	Vitiligo;	chr2:111245586	chr2:111203964~111206215:-
LUAD	cis	rs2302464	1	rs11944132	ENSG00000214846.4	RP11-115L11.1	5.73	1.75e-08	6.4e-06	0.61	0.25	Cerebrospinal fluid biomarker levels;	chr4:15724291	chr4:15730962~15731627:-
LUAD	cis	rs2599510	0.783	rs62136349	ENSG00000276334.1	AL133243.1	5.73	1.75e-08	6.4e-06	0.3	0.25	Interleukin-18 levels;	chr2:32602437	chr2:32521927~32523547:+
LUAD	cis	rs516805	0.634	rs2816142	ENSG00000279453.1	RP3-425C14.4	5.73	1.75e-08	6.4e-06	0.34	0.25	Lymphocyte counts;	chr6:122177653	chr6:122436789~122439223:-
LUAD	cis	rs7923609	1	rs12355784	ENSG00000232075.1	MRPL35P2	-5.73	1.75e-08	6.41e-06	-0.31	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63361805	chr10:63634317~63634827:-
LUAD	cis	rs17684571	0.938	rs4073960	ENSG00000231441.1	RP11-472M19.2	5.73	1.75e-08	6.42e-06	0.34	0.25	Schizophrenia;	chr6:56683561	chr6:56844002~56864078:+
LUAD	cis	rs10129255	0.5	rs2027903	ENSG00000211967.3	IGHV3-53	-5.73	1.76e-08	6.42e-06	-0.18	-0.25	Kawasaki disease;	chr14:106807047	chr14:106592676~106593347:-
LUAD	cis	rs10129255	0.518	rs28378320	ENSG00000211967.3	IGHV3-53	-5.73	1.76e-08	6.42e-06	-0.18	-0.25	Kawasaki disease;	chr14:106808609	chr14:106592676~106593347:-
LUAD	cis	rs1707322	0.717	rs2275086	ENSG00000234329.1	RP11-767N6.2	-5.73	1.76e-08	6.43e-06	-0.27	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620207	chr1:45651039~45651826:-
LUAD	cis	rs62432291	0.681	rs433786	ENSG00000235086.1	FNDC1-IT1	-5.73	1.76e-08	6.44e-06	-0.45	-0.25	Joint mobility (Beighton score);	chr6:159244914	chr6:159240786~159243329:+
LUAD	cis	rs897984	0.542	rs3751855	ENSG00000260911.2	RP11-196G11.2	5.73	1.76e-08	6.44e-06	0.23	0.25	Dementia with Lewy bodies;	chr16:31079888	chr16:31043150~31049868:+
LUAD	cis	rs7044106	0.762	rs4837790	ENSG00000238181.2	AHCYP2	-5.73	1.76e-08	6.44e-06	-0.32	-0.25	Hip circumference adjusted for BMI;	chr9:120684047	chr9:120720673~120721972:+
LUAD	cis	rs2562456	0.917	rs9304987	ENSG00000268081.1	RP11-678G14.2	-5.73	1.76e-08	6.44e-06	-0.39	-0.25	Pain;	chr19:21499472	chr19:21554640~21569237:-
LUAD	cis	rs7580658	0.864	rs3088374	ENSG00000236682.1	AC068282.3	-5.73	1.76e-08	6.44e-06	-0.32	-0.25	Protein C levels;	chr2:127304472	chr2:127389130~127400580:+
LUAD	cis	rs61776719	0.81	rs34655914	ENSG00000212541.1	RNU6-510P	-5.73	1.76e-08	6.45e-06	-0.3	-0.25	Coronary artery disease;	chr1:37931669	chr1:37991462~37991569:+
LUAD	cis	rs61776719	0.84	rs35267671	ENSG00000212541.1	RNU6-510P	-5.73	1.76e-08	6.45e-06	-0.3	-0.25	Coronary artery disease;	chr1:37931697	chr1:37991462~37991569:+
LUAD	cis	rs1707322	0.821	rs11211182	ENSG00000280836.1	AL355480.1	-5.73	1.76e-08	6.45e-06	-0.33	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45774498	chr1:45581219~45581321:-
LUAD	cis	rs17684571	0.7	rs13205667	ENSG00000231441.1	RP11-472M19.2	5.73	1.76e-08	6.45e-06	0.38	0.25	Schizophrenia;	chr6:56775176	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.7	rs13200559	ENSG00000231441.1	RP11-472M19.2	5.73	1.76e-08	6.45e-06	0.38	0.25	Schizophrenia;	chr6:56777522	chr6:56844002~56864078:+
LUAD	cis	rs9595908	0.832	rs9595976	ENSG00000212293.1	SNORA16	5.73	1.77e-08	6.45e-06	0.28	0.25	Body mass index;	chr13:32637910	chr13:32420390~32420516:-
LUAD	cis	rs2179367	0.632	rs11155645	ENSG00000231760.4	RP11-350J20.5	5.73	1.77e-08	6.47e-06	0.36	0.25	Dupuytren's disease;	chr6:149360056	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs9498332	ENSG00000231760.4	RP11-350J20.5	5.73	1.77e-08	6.47e-06	0.36	0.25	Dupuytren's disease;	chr6:149367490	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs9498333	ENSG00000231760.4	RP11-350J20.5	5.73	1.77e-08	6.47e-06	0.36	0.25	Dupuytren's disease;	chr6:149368196	chr6:149796151~149826294:-
LUAD	cis	rs7927592	0.731	rs11228288	ENSG00000212093.1	AP000807.1	5.73	1.77e-08	6.47e-06	0.26	0.25	Total body bone mineral density;	chr11:68586082	chr11:68506083~68506166:-
LUAD	cis	rs5753618	0.583	rs71324184	ENSG00000236132.1	CTA-440B3.1	-5.73	1.77e-08	6.47e-06	-0.3	-0.25	Colorectal cancer;	chr22:31356075	chr22:31816379~31817491:-
LUAD	cis	rs997295	0.57	rs7170299	ENSG00000270964.1	RP11-502I4.3	-5.73	1.77e-08	6.48e-06	-0.26	-0.25	Motion sickness;	chr15:67580380	chr15:67541072~67542604:-
LUAD	cis	rs7712401	0.601	rs13155907	ENSG00000263432.2	RN7SL689P	-5.73	1.77e-08	6.48e-06	-0.31	-0.25	Mean platelet volume;	chr5:122998938	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs62377430	ENSG00000263432.2	RN7SL689P	-5.73	1.77e-08	6.48e-06	-0.31	-0.25	Mean platelet volume;	chr5:122998993	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs34348084	ENSG00000263432.2	RN7SL689P	-5.73	1.77e-08	6.48e-06	-0.31	-0.25	Mean platelet volume;	chr5:122999419	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs35334805	ENSG00000263432.2	RN7SL689P	-5.73	1.77e-08	6.48e-06	-0.31	-0.25	Mean platelet volume;	chr5:122999566	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs13164134	ENSG00000263432.2	RN7SL689P	-5.73	1.77e-08	6.48e-06	-0.31	-0.25	Mean platelet volume;	chr5:123002246	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs13185741	ENSG00000263432.2	RN7SL689P	-5.73	1.77e-08	6.48e-06	-0.31	-0.25	Mean platelet volume;	chr5:123002315	chr5:123022487~123022783:-
LUAD	cis	rs4141404	0.816	rs5749227	ENSG00000236132.1	CTA-440B3.1	5.73	1.78e-08	6.49e-06	0.36	0.25	Paclitaxel-induced neuropathy;	chr22:31185180	chr22:31816379~31817491:-
LUAD	cis	rs10129255	0.5	rs8021941	ENSG00000211967.3	IGHV3-53	-5.73	1.78e-08	6.5e-06	-0.18	-0.25	Kawasaki disease;	chr14:106781490	chr14:106592676~106593347:-
LUAD	cis	rs11603023	0.967	rs494560	ENSG00000255422.1	AP002954.4	5.73	1.78e-08	6.5e-06	0.3	0.25	Cholesterol, total;	chr11:118650844	chr11:118704607~118750263:+
LUAD	cis	rs9595908	0.669	rs7983309	ENSG00000212293.1	SNORA16	5.73	1.78e-08	6.5e-06	0.27	0.25	Body mass index;	chr13:32740254	chr13:32420390~32420516:-
LUAD	cis	rs858239	0.6	rs9691762	ENSG00000230042.1	AK3P3	-5.73	1.78e-08	6.51e-06	-0.32	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23129178~23129841:+
LUAD	cis	rs10761482	0.5	rs7072229	ENSG00000254271.1	RP11-131N11.4	5.73	1.78e-08	6.51e-06	0.28	0.25	Schizophrenia;	chr10:60524462	chr10:60734342~60741828:+
LUAD	cis	rs7618501	0.633	rs2624843	ENSG00000234667.1	ACTBP13	-5.73	1.78e-08	6.51e-06	-0.28	-0.25	Intelligence (multi-trait analysis);	chr3:49960530	chr3:49873347~49877980:-
LUAD	cis	rs516805	0.961	rs544099	ENSG00000279453.1	RP3-425C14.4	5.73	1.78e-08	6.52e-06	0.29	0.25	Lymphocyte counts;	chr6:122479837	chr6:122436789~122439223:-
LUAD	cis	rs380904	0.519	rs12541790	ENSG00000254859.1	RP11-661A12.5	-5.73	1.79e-08	6.52e-06	-0.4	-0.25	Venous thromboembolism (SNP x SNP interaction);	chr8:143561151	chr8:143541973~143549729:-
LUAD	cis	rs897984	0.609	rs732173	ENSG00000260911.2	RP11-196G11.2	5.73	1.79e-08	6.53e-06	0.23	0.25	Dementia with Lewy bodies;	chr16:31038702	chr16:31043150~31049868:+
LUAD	cis	rs897984	0.609	rs1108431	ENSG00000260911.2	RP11-196G11.2	5.73	1.79e-08	6.53e-06	0.23	0.25	Dementia with Lewy bodies;	chr16:31043286	chr16:31043150~31049868:+
LUAD	cis	rs9309473	1	rs3738848	ENSG00000163016.8	ALMS1P	5.73	1.79e-08	6.53e-06	0.31	0.25	Metabolite levels;	chr2:73534754	chr2:73644919~73685576:+
LUAD	cis	rs301901	0.698	rs217840	ENSG00000250155.1	CTD-2353F22.1	5.73	1.79e-08	6.53e-06	0.27	0.25	Height;	chr5:37373000	chr5:36666214~36725195:-
LUAD	cis	rs9309473	1	rs10496193	ENSG00000163016.8	ALMS1P	5.73	1.79e-08	6.53e-06	0.31	0.25	Metabolite levels;	chr2:73546376	chr2:73644919~73685576:+
LUAD	cis	rs3762637	1	rs10934602	ENSG00000272758.4	RP11-299J3.8	5.73	1.79e-08	6.53e-06	0.38	0.25	LDL cholesterol levels;	chr3:122504335	chr3:122416207~122443180:+
LUAD	cis	rs1799949	0.965	rs6503727	ENSG00000267681.1	CTD-3199J23.6	-5.73	1.79e-08	6.54e-06	-0.28	-0.25	Menopause (age at onset);	chr17:43160842	chr17:43144956~43145255:+
LUAD	cis	rs853679	0.513	rs13437444	ENSG00000219392.1	RP1-265C24.5	-5.73	1.79e-08	6.54e-06	-0.39	-0.25	Depression;	chr6:28103220	chr6:28115628~28116551:+
LUAD	cis	rs2404602	0.716	rs12441247	ENSG00000259422.1	RP11-593F23.1	5.73	1.79e-08	6.55e-06	0.29	0.25	Blood metabolite levels;	chr15:76519975	chr15:76174891~76181486:-
LUAD	cis	rs9595908	0.709	rs7322505	ENSG00000212293.1	SNORA16	5.73	1.79e-08	6.55e-06	0.27	0.25	Body mass index;	chr13:32756282	chr13:32420390~32420516:-
LUAD	cis	rs875971	1	rs6979382	ENSG00000237310.1	GS1-124K5.4	5.73	1.8e-08	6.56e-06	0.27	0.25	Aortic root size;	chr7:66421388	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs6961990	ENSG00000237310.1	GS1-124K5.4	5.73	1.8e-08	6.56e-06	0.27	0.25	Aortic root size;	chr7:66423583	chr7:66493706~66495474:+
LUAD	cis	rs7923609	1	rs4400684	ENSG00000232075.1	MRPL35P2	-5.73	1.8e-08	6.56e-06	-0.31	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63252927	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.967	rs4454603	ENSG00000232075.1	MRPL35P2	-5.73	1.8e-08	6.56e-06	-0.31	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63252990	chr10:63634317~63634827:-
LUAD	cis	rs7923609	1	rs4595427	ENSG00000232075.1	MRPL35P2	-5.73	1.8e-08	6.56e-06	-0.31	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63253184	chr10:63634317~63634827:-
LUAD	cis	rs957448	1	rs1992370	ENSG00000253704.1	RP11-267M23.4	5.73	1.8e-08	6.56e-06	0.32	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94546466	chr8:94553722~94569745:+
LUAD	cis	rs4713118	0.786	rs200503	ENSG00000219392.1	RP1-265C24.5	-5.73	1.8e-08	6.57e-06	-0.33	-0.25	Parkinson's disease;	chr6:27818104	chr6:28115628~28116551:+
LUAD	cis	rs875971	0.862	rs6964437	ENSG00000222364.1	RNU6-96P	5.73	1.8e-08	6.57e-06	0.29	0.25	Aortic root size;	chr7:66221457	chr7:66395191~66395286:+
LUAD	cis	rs9309711	0.736	rs28619526	ENSG00000225234.1	TRAPPC12-AS1	-5.73	1.8e-08	6.57e-06	-0.32	-0.25	Neurofibrillary tangles;	chr2:3493033	chr2:3481242~3482409:-
LUAD	cis	rs7712401	0.601	rs386602	ENSG00000263432.2	RN7SL689P	-5.73	1.8e-08	6.57e-06	-0.31	-0.25	Mean platelet volume;	chr5:122986262	chr5:123022487~123022783:-
LUAD	cis	rs66887589	0.967	rs1155577	ENSG00000248280.1	RP11-33B1.2	-5.73	1.8e-08	6.57e-06	-0.28	-0.25	Diastolic blood pressure;	chr4:119528655	chr4:119440561~119450157:-
LUAD	cis	rs6504622	1	rs2003539	ENSG00000262879.4	RP11-156P1.3	-5.73	1.8e-08	6.58e-06	-0.29	-0.25	Orofacial clefts;	chr17:46947953	chr17:46984045~47100323:-
LUAD	cis	rs3931020	0.688	rs525487	ENSG00000272864.1	RP11-17E13.2	5.73	1.8e-08	6.59e-06	0.36	0.25	Resistin levels;	chr1:74751736	chr1:74698769~74699333:-
LUAD	cis	rs7829975	0.511	rs2921028	ENSG00000253893.2	FAM85B	-5.73	1.8e-08	6.59e-06	-0.31	-0.25	Mood instability;	chr8:8482967	chr8:8167819~8226614:-
LUAD	cis	rs1707322	1	rs12403666	ENSG00000234329.1	RP11-767N6.2	5.73	1.81e-08	6.59e-06	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45965949	chr1:45651039~45651826:-
LUAD	cis	rs35828350	1	rs35828350	ENSG00000225151.9	GOLGA2P7	-5.73	1.81e-08	6.6e-06	-0.34	-0.25	Autism spectrum disorder or schizophrenia;	chr15:84812610	chr15:84199311~84230136:-
LUAD	cis	rs10129255	0.5	rs10142931	ENSG00000211967.3	IGHV3-53	-5.73	1.81e-08	6.6e-06	-0.18	-0.25	Kawasaki disease;	chr14:106782288	chr14:106592676~106593347:-
LUAD	cis	rs62432291	0.681	rs423533	ENSG00000235086.1	FNDC1-IT1	-5.73	1.81e-08	6.61e-06	-0.44	-0.25	Joint mobility (Beighton score);	chr6:159243484	chr6:159240786~159243329:+
LUAD	cis	rs910316	0.575	rs12889133	ENSG00000279594.1	RP11-950C14.10	5.73	1.81e-08	6.61e-06	0.3	0.25	Height;	chr14:74998386	chr14:75011269~75012851:-
LUAD	cis	rs35740288	0.77	rs11634177	ENSG00000202081.1	RNU6-1280P	-5.73	1.81e-08	6.61e-06	-0.31	-0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85605159	chr15:85651522~85651628:-
LUAD	cis	rs2255336	0.938	rs2734414	ENSG00000245648.1	RP11-277P12.20	5.73	1.81e-08	6.61e-06	0.35	0.25	Blood protein levels;	chr12:10446203	chr12:10363769~10398506:+
LUAD	cis	rs4908760	0.868	rs12131864	ENSG00000232912.4	RP5-1115A15.1	5.73	1.81e-08	6.61e-06	0.23	0.25	Vitiligo;	chr1:8531103	chr1:8424645~8434838:+
LUAD	cis	rs1707322	1	rs1707303	ENSG00000234329.1	RP11-767N6.2	-5.73	1.81e-08	6.61e-06	-0.27	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46132601	chr1:45651039~45651826:-
LUAD	cis	rs7618501	0.633	rs12496973	ENSG00000234667.1	ACTBP13	-5.73	1.82e-08	6.62e-06	-0.28	-0.25	Intelligence (multi-trait analysis);	chr3:49964812	chr3:49873347~49877980:-
LUAD	cis	rs7618501	0.633	rs11130228	ENSG00000234667.1	ACTBP13	-5.73	1.82e-08	6.62e-06	-0.28	-0.25	Intelligence (multi-trait analysis);	chr3:49965813	chr3:49873347~49877980:-
LUAD	cis	rs27524	0.537	rs57889668	ENSG00000272109.1	CTD-2260A17.3	5.73	1.82e-08	6.62e-06	0.31	0.25	Hodgkin's lymphoma;Psoriasis;	chr5:96745230	chr5:96804353~96806105:+
LUAD	cis	rs6142102	0.625	rs6142067	ENSG00000275784.1	RP5-1125A11.6	-5.73	1.82e-08	6.63e-06	-0.27	-0.25	Skin pigmentation;	chr20:33968766	chr20:33989480~33991818:-
LUAD	cis	rs1799949	0.536	rs4793227	ENSG00000267681.1	CTD-3199J23.6	-5.73	1.82e-08	6.63e-06	-0.28	-0.25	Menopause (age at onset);	chr17:43334882	chr17:43144956~43145255:+
LUAD	cis	rs12188164	0.515	rs11744936	ENSG00000225138.6	CTD-2228K2.7	5.73	1.82e-08	6.64e-06	0.24	0.25	Cystic fibrosis severity;	chr5:411997	chr5:473236~480884:+
LUAD	cis	rs3771180	0.505	rs2160203	ENSG00000234389.1	AC007278.3	5.73	1.82e-08	6.64e-06	0.27	0.25	Asthma;	chr2:102344364	chr2:102438713~102440475:+
LUAD	cis	rs891378	1	rs925131	ENSG00000274245.1	RP11-357P18.2	-5.73	1.82e-08	6.64e-06	-0.34	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207330376	chr1:207372559~207373252:+
LUAD	cis	rs1707322	0.686	rs2275085	ENSG00000234329.1	RP11-767N6.2	-5.73	1.82e-08	6.64e-06	-0.27	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620180	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.717	rs3014246	ENSG00000280836.1	AL355480.1	5.72	1.82e-08	6.65e-06	0.34	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620405	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.655	rs3014240	ENSG00000280836.1	AL355480.1	5.72	1.82e-08	6.65e-06	0.34	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45623553	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.686	rs3014235	ENSG00000280836.1	AL355480.1	5.72	1.82e-08	6.65e-06	0.34	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625840	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.717	rs1135850	ENSG00000280836.1	AL355480.1	-5.72	1.82e-08	6.65e-06	-0.34	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628020	chr1:45581219~45581321:-
LUAD	cis	rs1075265	0.791	rs1833498	ENSG00000233266.1	HMGB1P31	5.72	1.82e-08	6.65e-06	0.32	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54080801	chr2:54051334~54051760:+
LUAD	cis	rs801193	0.569	rs2659893	ENSG00000237310.1	GS1-124K5.4	5.72	1.83e-08	6.65e-06	0.28	0.25	Aortic root size;	chr7:66735006	chr7:66493706~66495474:+
LUAD	cis	rs801193	0.569	rs2659892	ENSG00000237310.1	GS1-124K5.4	5.72	1.83e-08	6.65e-06	0.28	0.25	Aortic root size;	chr7:66735318	chr7:66493706~66495474:+
LUAD	cis	rs801193	0.548	rs2659891	ENSG00000237310.1	GS1-124K5.4	5.72	1.83e-08	6.65e-06	0.28	0.25	Aortic root size;	chr7:66736127	chr7:66493706~66495474:+
LUAD	cis	rs801193	0.569	rs2707847	ENSG00000237310.1	GS1-124K5.4	5.72	1.83e-08	6.65e-06	0.28	0.25	Aortic root size;	chr7:66737884	chr7:66493706~66495474:+
LUAD	cis	rs801193	0.548	rs7805152	ENSG00000237310.1	GS1-124K5.4	5.72	1.83e-08	6.65e-06	0.28	0.25	Aortic root size;	chr7:66744266	chr7:66493706~66495474:+
LUAD	cis	rs7430456	0.874	rs7428501	ENSG00000228221.4	LINC00578	5.72	1.83e-08	6.67e-06	0.3	0.25	Breast cancer;	chr3:177751974	chr3:177441921~177752305:+
LUAD	cis	rs2412819	0.571	rs4923965	ENSG00000249839.1	AC011330.5	5.72	1.83e-08	6.68e-06	0.4	0.25	Lung cancer;	chr15:43790232	chr15:43663654~43684339:-
LUAD	cis	rs2412819	0.571	rs4644832	ENSG00000249839.1	AC011330.5	5.72	1.83e-08	6.68e-06	0.4	0.25	Lung cancer;	chr15:43792507	chr15:43663654~43684339:-
LUAD	cis	rs7246657	0.722	rs2972437	ENSG00000276846.1	CTD-3220F14.3	5.72	1.83e-08	6.68e-06	0.34	0.25	Coronary artery calcification;	chr19:37719610	chr19:37314868~37315620:-
LUAD	cis	rs6772849	0.775	rs9828414	ENSG00000242551.2	POU5F1P6	-5.72	1.83e-08	6.69e-06	-0.3	-0.25	Monocyte percentage of white cells;Monocyte count;	chr3:128693874	chr3:128674735~128677005:-
LUAD	cis	rs6772849	0.804	rs9832430	ENSG00000242551.2	POU5F1P6	-5.72	1.83e-08	6.69e-06	-0.3	-0.25	Monocyte percentage of white cells;Monocyte count;	chr3:128694054	chr3:128674735~128677005:-
LUAD	cis	rs6772849	0.775	rs66822528	ENSG00000242551.2	POU5F1P6	-5.72	1.83e-08	6.69e-06	-0.3	-0.25	Monocyte percentage of white cells;Monocyte count;	chr3:128696254	chr3:128674735~128677005:-
LUAD	cis	rs1816752	1	rs9507341	ENSG00000273628.1	RP11-756A22.7	-5.72	1.84e-08	6.69e-06	-0.3	-0.25	Obesity-related traits;	chr13:24432440	chr13:24933006~24936796:+
LUAD	cis	rs516805	0.667	rs2606610	ENSG00000279453.1	RP3-425C14.4	-5.72	1.84e-08	6.69e-06	-0.34	-0.25	Lymphocyte counts;	chr6:122189959	chr6:122436789~122439223:-
LUAD	cis	rs10129255	0.518	rs8010020	ENSG00000211967.3	IGHV3-53	-5.72	1.84e-08	6.7e-06	-0.18	-0.25	Kawasaki disease;	chr14:106778016	chr14:106592676~106593347:-
LUAD	cis	rs10129255	0.5	rs6576225	ENSG00000211967.3	IGHV3-53	-5.72	1.84e-08	6.7e-06	-0.18	-0.25	Kawasaki disease;	chr14:106778120	chr14:106592676~106593347:-
LUAD	cis	rs10129255	0.5	rs6576226	ENSG00000211967.3	IGHV3-53	-5.72	1.84e-08	6.7e-06	-0.18	-0.25	Kawasaki disease;	chr14:106778135	chr14:106592676~106593347:-
LUAD	cis	rs6570726	0.62	rs12201226	ENSG00000235652.6	RP11-545I5.3	5.72	1.84e-08	6.7e-06	0.27	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145592283	chr6:145799409~145886585:+
LUAD	cis	rs2243480	0.901	rs12530490	ENSG00000230295.1	RP11-458F8.2	5.72	1.84e-08	6.7e-06	0.31	0.25	Diabetic kidney disease;	chr7:66226660	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs7778911	ENSG00000230295.1	RP11-458F8.2	5.72	1.84e-08	6.7e-06	0.31	0.25	Diabetic kidney disease;	chr7:66229519	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs1979823	ENSG00000230295.1	RP11-458F8.2	5.72	1.84e-08	6.7e-06	0.31	0.25	Diabetic kidney disease;	chr7:66239626	chr7:66880708~66882981:+
LUAD	cis	rs2337406	0.714	rs115401799	ENSG00000211974.3	IGHV2-70	-5.72	1.84e-08	6.72e-06	-0.35	-0.25	Alzheimer's disease (late onset);	chr14:106813739	chr14:106723574~106724093:-
LUAD	cis	rs13217239	0.608	rs6930508	ENSG00000241549.7	GUSBP2	-5.72	1.84e-08	6.72e-06	-0.28	-0.25	Schizophrenia;	chr6:27085363	chr6:26871484~26956554:-
LUAD	cis	rs13217239	0.646	rs2142685	ENSG00000241549.7	GUSBP2	-5.72	1.84e-08	6.72e-06	-0.28	-0.25	Schizophrenia;	chr6:27086718	chr6:26871484~26956554:-
LUAD	cis	rs9652601	0.691	rs9933507	ENSG00000274038.1	RP11-66H6.4	-5.72	1.84e-08	6.72e-06	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11107571	chr16:11056556~11057034:+
LUAD	cis	rs7430456	0.839	rs9824506	ENSG00000228221.4	LINC00578	-5.72	1.85e-08	6.72e-06	-0.3	-0.25	Breast cancer;	chr3:177751431	chr3:177441921~177752305:+
LUAD	cis	rs35740288	0.731	rs35085180	ENSG00000202081.1	RNU6-1280P	5.72	1.85e-08	6.73e-06	0.31	0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85559381	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.77	rs75039806	ENSG00000202081.1	RNU6-1280P	5.72	1.85e-08	6.73e-06	0.31	0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85561813	chr15:85651522~85651628:-
LUAD	cis	rs4664293	0.737	rs1549579	ENSG00000226266.5	AC009961.3	-5.72	1.85e-08	6.73e-06	-0.34	-0.25	Monocyte percentage of white cells;	chr2:159812150	chr2:159670708~159712435:-
LUAD	cis	rs2790457	0.958	rs2532744	ENSG00000254635.4	WAC-AS1	-5.72	1.85e-08	6.73e-06	-0.28	-0.25	Multiple myeloma;	chr10:28613689	chr10:28522652~28532743:-
LUAD	cis	rs2404602	0.735	rs2957614	ENSG00000259422.1	RP11-593F23.1	5.72	1.85e-08	6.74e-06	0.32	0.25	Blood metabolite levels;	chr15:76404294	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.735	rs2461870	ENSG00000259422.1	RP11-593F23.1	-5.72	1.85e-08	6.74e-06	-0.31	-0.25	Blood metabolite levels;	chr15:76521579	chr15:76174891~76181486:-
LUAD	cis	rs8072100	0.846	rs6503796	ENSG00000228782.6	CTD-2026D20.3	5.72	1.85e-08	6.74e-06	0.27	0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47687883	chr17:47450568~47492492:-
LUAD	cis	rs807029	0.533	rs67813203	ENSG00000272572.1	RP11-179B2.2	-5.72	1.85e-08	6.74e-06	-0.36	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100978794	chr10:100911103~100912739:-
LUAD	cis	rs807029	0.533	rs2295716	ENSG00000272572.1	RP11-179B2.2	-5.72	1.85e-08	6.74e-06	-0.36	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100984457	chr10:100911103~100912739:-
LUAD	cis	rs66887589	1	rs66887589	ENSG00000248280.1	RP11-33B1.2	-5.72	1.85e-08	6.74e-06	-0.28	-0.25	Diastolic blood pressure;	chr4:119588124	chr4:119440561~119450157:-
LUAD	cis	rs9309473	1	rs7585004	ENSG00000163016.8	ALMS1P	5.72	1.86e-08	6.75e-06	0.31	0.25	Metabolite levels;	chr2:73439517	chr2:73644919~73685576:+
LUAD	cis	rs1134634	0.52	rs3822298	ENSG00000273133.1	RP11-799M12.2	-5.72	1.86e-08	6.76e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15554780	chr4:15563698~15564253:-
LUAD	cis	rs1134634	0.52	rs1473166	ENSG00000273133.1	RP11-799M12.2	-5.72	1.86e-08	6.76e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15555868	chr4:15563698~15564253:-
LUAD	cis	rs1134634	0.52	rs2160044	ENSG00000273133.1	RP11-799M12.2	-5.72	1.86e-08	6.76e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15556720	chr4:15563698~15564253:-
LUAD	cis	rs12134133	0.752	rs6673080	ENSG00000274245.1	RP11-357P18.2	5.72	1.86e-08	6.76e-06	0.35	0.25	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207216859	chr1:207372559~207373252:+
LUAD	cis	rs72634501	0.716	rs4660165	ENSG00000228060.1	RP11-69E11.8	5.72	1.86e-08	6.77e-06	0.26	0.25	HDL cholesterol;	chr1:39112860	chr1:39565160~39573203:+
LUAD	cis	rs9309473	0.95	rs7567585	ENSG00000163016.8	ALMS1P	5.72	1.86e-08	6.77e-06	0.31	0.25	Metabolite levels;	chr2:73524839	chr2:73644919~73685576:+
LUAD	cis	rs1707322	1	rs10890380	ENSG00000234329.1	RP11-767N6.2	5.72	1.86e-08	6.77e-06	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983797	chr1:45651039~45651826:-
LUAD	cis	rs7829975	0.511	rs1543238	ENSG00000253981.4	ALG1L13P	5.72	1.86e-08	6.77e-06	0.3	0.25	Mood instability;	chr8:8277287	chr8:8236003~8244667:-
LUAD	cis	rs2404602	0.647	rs12910081	ENSG00000259422.1	RP11-593F23.1	-5.72	1.86e-08	6.77e-06	-0.33	-0.25	Blood metabolite levels;	chr15:76730618	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.647	rs10851889	ENSG00000259422.1	RP11-593F23.1	-5.72	1.86e-08	6.77e-06	-0.33	-0.25	Blood metabolite levels;	chr15:76730995	chr15:76174891~76181486:-
LUAD	cis	rs8031584	1	rs35811129	ENSG00000260382.1	RP11-540B6.2	5.72	1.86e-08	6.78e-06	0.33	0.25	Huntington's disease progression;	chr15:30949143	chr15:30882267~30883231:-
LUAD	cis	rs2288884	1	rs79817140	ENSG00000275055.1	CTC-471J1.11	-5.72	1.86e-08	6.78e-06	-0.4	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52068404	chr19:52049007~52049754:+
LUAD	cis	rs2288884	1	rs11669385	ENSG00000275055.1	CTC-471J1.11	-5.72	1.86e-08	6.78e-06	-0.4	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52068699	chr19:52049007~52049754:+
LUAD	cis	rs7246657	0.654	rs10407568	ENSG00000276846.1	CTD-3220F14.3	5.72	1.86e-08	6.78e-06	0.33	0.25	Coronary artery calcification;	chr19:37632108	chr19:37314868~37315620:-
LUAD	cis	rs1823913	0.599	rs34840299	ENSG00000280083.1	RP11-317J9.1	-5.72	1.86e-08	6.79e-06	-0.3	-0.25	Obesity-related traits;	chr2:191280379	chr2:191154118~191156070:-
LUAD	cis	rs2404602	0.647	rs10851892	ENSG00000259422.1	RP11-593F23.1	-5.72	1.86e-08	6.79e-06	-0.34	-0.25	Blood metabolite levels;	chr15:76884150	chr15:76174891~76181486:-
LUAD	cis	rs2179367	0.537	rs6911411	ENSG00000231760.4	RP11-350J20.5	5.72	1.87e-08	6.79e-06	0.39	0.25	Dupuytren's disease;	chr6:149366954	chr6:149796151~149826294:-
LUAD	cis	rs858239	0.6	rs7776649	ENSG00000230042.1	AK3P3	-5.72	1.87e-08	6.79e-06	-0.32	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23129178~23129841:+
LUAD	cis	rs6921919	0.583	rs16894060	ENSG00000204709.4	LINC01556	5.72	1.87e-08	6.79e-06	0.32	0.25	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28943877~28944537:+
LUAD	cis	rs1707322	1	rs6429588	ENSG00000234329.1	RP11-767N6.2	5.72	1.87e-08	6.8e-06	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45988386	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs4660331	ENSG00000234329.1	RP11-767N6.2	5.72	1.87e-08	6.8e-06	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45993111	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs12097799	ENSG00000234329.1	RP11-767N6.2	5.72	1.87e-08	6.8e-06	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45994214	chr1:45651039~45651826:-
LUAD	cis	rs6840258	0.66	rs55851914	ENSG00000251411.1	RP11-397E7.4	-5.72	1.87e-08	6.81e-06	-0.35	-0.25	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86955903	chr4:86913266~86914817:-
LUAD	cis	rs9992667	0.911	rs28656945	ENSG00000231160.8	KLF3-AS1	5.72	1.87e-08	6.81e-06	0.32	0.25	Eosinophil percentage of granulocytes;	chr4:38665125	chr4:38612701~38664883:-
LUAD	cis	rs74233809	1	rs11191519	ENSG00000213277.3	MARCKSL1P1	5.72	1.87e-08	6.81e-06	0.44	0.25	Birth weight;	chr10:103025161	chr10:103175554~103176094:+
LUAD	cis	rs2288884	0.559	rs7257830	ENSG00000275055.1	CTC-471J1.11	-5.72	1.87e-08	6.82e-06	-0.3	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52005392	chr19:52049007~52049754:+
LUAD	cis	rs1874124	0.577	rs2807880	ENSG00000272823.1	RP11-295M18.6	5.72	1.87e-08	6.82e-06	0.37	0.25	Cholesterol, total;	chr1:220869661	chr1:220828676~220829211:-
LUAD	cis	rs172166	0.637	rs1225597	ENSG00000204709.4	LINC01556	5.72	1.88e-08	6.83e-06	0.32	0.25	Cardiac Troponin-T levels;	chr6:28194309	chr6:28943877~28944537:+
LUAD	cis	rs12289961	0.634	rs11229378	ENSG00000280010.1	AP001350.4	5.72	1.88e-08	6.84e-06	0.41	0.25	Lymphoma;	chr11:58364344	chr11:58627435~58628528:+
LUAD	cis	rs12289961	0.634	rs77183714	ENSG00000280010.1	AP001350.4	5.72	1.88e-08	6.84e-06	0.41	0.25	Lymphoma;	chr11:58364460	chr11:58627435~58628528:+
LUAD	cis	rs2255336	0.938	rs12578507	ENSG00000245648.1	RP11-277P12.20	-5.72	1.88e-08	6.84e-06	-0.4	-0.25	Blood protein levels;	chr12:10470396	chr12:10363769~10398506:+
LUAD	cis	rs62432291	0.681	rs438853	ENSG00000235086.1	FNDC1-IT1	-5.72	1.88e-08	6.84e-06	-0.41	-0.25	Joint mobility (Beighton score);	chr6:159209320	chr6:159240786~159243329:+
LUAD	cis	rs2562456	0.917	rs2650793	ENSG00000268081.1	RP11-678G14.2	-5.72	1.88e-08	6.85e-06	-0.38	-0.25	Pain;	chr19:21493313	chr19:21554640~21569237:-
LUAD	cis	rs7208859	0.673	rs8077116	ENSG00000263603.1	CTD-2349P21.5	-5.72	1.88e-08	6.85e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30729469~30731202:+
LUAD	cis	rs1113500	0.509	rs1619485	ENSG00000226822.1	RP11-356N1.2	-5.72	1.88e-08	6.85e-06	-0.29	-0.25	Growth-regulated protein alpha levels;	chr1:108065725	chr1:108071482~108074519:+
LUAD	cis	rs9992667	0.955	rs28491682	ENSG00000231160.8	KLF3-AS1	5.72	1.89e-08	6.86e-06	0.32	0.25	Eosinophil percentage of granulocytes;	chr4:38639268	chr4:38612701~38664883:-
LUAD	cis	rs7044106	0.762	rs1470307	ENSG00000238181.2	AHCYP2	-5.72	1.89e-08	6.86e-06	-0.32	-0.25	Hip circumference adjusted for BMI;	chr9:120670761	chr9:120720673~120721972:+
LUAD	cis	rs17301013	0.581	rs12082139	ENSG00000227373.4	RP11-160H22.5	5.72	1.89e-08	6.87e-06	0.35	0.25	Systemic lupus erythematosus;	chr1:174589043	chr1:174115300~174160004:-
LUAD	cis	rs673078	0.607	rs17512644	ENSG00000275409.1	RP11-131L12.4	-5.72	1.89e-08	6.87e-06	-0.35	-0.25	Glucose homeostasis traits;	chr12:118359963	chr12:118430147~118430699:+
LUAD	cis	rs8180040	0.654	rs4682831	ENSG00000271161.1	BOLA2P2	-5.72	1.89e-08	6.87e-06	-0.24	-0.25	Colorectal cancer;	chr3:46985648	chr3:47499841~47500407:+
LUAD	cis	rs7246657	0.663	rs9304568	ENSG00000276846.1	CTD-3220F14.3	5.72	1.89e-08	6.87e-06	0.33	0.25	Coronary artery calcification;	chr19:37563606	chr19:37314868~37315620:-
LUAD	cis	rs11105298	0.891	rs10858899	ENSG00000258302.2	RP11-981P6.1	5.72	1.89e-08	6.87e-06	0.32	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89530034	chr12:89561129~89594878:+
LUAD	cis	rs1707322	0.827	rs10890347	ENSG00000234329.1	RP11-767N6.2	-5.72	1.89e-08	6.87e-06	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776660	chr1:45651039~45651826:-
LUAD	cis	rs2412819	0.571	rs8030536	ENSG00000249839.1	AC011330.5	-5.72	1.89e-08	6.89e-06	-0.42	-0.25	Lung cancer;	chr15:43627365	chr15:43663654~43684339:-
LUAD	cis	rs881375	0.678	rs1930782	ENSG00000226752.6	PSMD5-AS1	-5.72	1.89e-08	6.89e-06	-0.26	-0.25	Rheumatoid arthritis;	chr9:120925627	chr9:120824828~120854385:+
LUAD	cis	rs7044106	0.708	rs920745	ENSG00000238181.2	AHCYP2	-5.72	1.9e-08	6.89e-06	-0.32	-0.25	Hip circumference adjusted for BMI;	chr9:120667665	chr9:120720673~120721972:+
LUAD	cis	rs7044106	0.734	rs10491784	ENSG00000238181.2	AHCYP2	-5.72	1.9e-08	6.89e-06	-0.32	-0.25	Hip circumference adjusted for BMI;	chr9:120670011	chr9:120720673~120721972:+
LUAD	cis	rs7712401	0.607	rs246270	ENSG00000263432.2	RN7SL689P	5.72	1.9e-08	6.9e-06	0.31	0.25	Mean platelet volume;	chr5:122922954	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.562	rs377316	ENSG00000263432.2	RN7SL689P	5.72	1.9e-08	6.9e-06	0.31	0.25	Mean platelet volume;	chr5:122924180	chr5:123022487~123022783:-
LUAD	cis	rs12908161	0.853	rs12912342	ENSG00000259728.4	LINC00933	5.72	1.9e-08	6.9e-06	0.34	0.25	Schizophrenia;	chr15:84704985	chr15:84570649~84580175:+
LUAD	cis	rs7714584	1	rs11747065	ENSG00000197083.10	ZNF300P1	5.72	1.9e-08	6.9e-06	0.5	0.25	Crohn's disease;	chr5:150915924	chr5:150930645~150946289:-
LUAD	cis	rs12908161	1	rs12905057	ENSG00000225151.9	GOLGA2P7	-5.72	1.9e-08	6.91e-06	-0.35	-0.25	Schizophrenia;	chr15:84667534	chr15:84199311~84230136:-
LUAD	cis	rs9860428	0.933	rs6808135	ENSG00000242770.2	RP11-180K7.1	5.72	1.9e-08	6.91e-06	0.26	0.25	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112847301	chr3:112802478~112812819:+
LUAD	cis	rs12699921	0.632	rs2691616	ENSG00000279048.1	RP11-511H23.2	-5.72	1.91e-08	6.92e-06	-0.2	-0.25	Fibrinogen levels;	chr7:17782557	chr7:17940503~17942922:+
LUAD	cis	rs4835473	0.932	rs34618381	ENSG00000251600.4	RP11-673E1.1	-5.72	1.91e-08	6.92e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143762612	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs11100808	ENSG00000251600.4	RP11-673E1.1	-5.72	1.91e-08	6.92e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143762728	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs7661407	ENSG00000251600.4	RP11-673E1.1	-5.72	1.91e-08	6.92e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143762982	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1562777	ENSG00000251600.4	RP11-673E1.1	-5.72	1.91e-08	6.92e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143763676	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1562778	ENSG00000251600.4	RP11-673E1.1	-5.72	1.91e-08	6.92e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143763816	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1562779	ENSG00000251600.4	RP11-673E1.1	-5.72	1.91e-08	6.92e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143763999	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1597441	ENSG00000251600.4	RP11-673E1.1	-5.72	1.91e-08	6.92e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143764158	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1597442	ENSG00000251600.4	RP11-673E1.1	-5.72	1.91e-08	6.92e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143764359	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1597443	ENSG00000251600.4	RP11-673E1.1	-5.72	1.91e-08	6.92e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143764406	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1597444	ENSG00000251600.4	RP11-673E1.1	-5.72	1.91e-08	6.92e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143764547	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs60038202	ENSG00000251600.4	RP11-673E1.1	-5.72	1.91e-08	6.92e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143764662	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs34886773	ENSG00000251600.4	RP11-673E1.1	-5.72	1.91e-08	6.92e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143764678	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1450230	ENSG00000251600.4	RP11-673E1.1	-5.72	1.91e-08	6.92e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143765118	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs34230433	ENSG00000251600.4	RP11-673E1.1	-5.72	1.91e-08	6.92e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143765253	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs7696869	ENSG00000251600.4	RP11-673E1.1	-5.72	1.91e-08	6.92e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143765855	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs7698287	ENSG00000251600.4	RP11-673E1.1	-5.72	1.91e-08	6.92e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143765859	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs11721495	ENSG00000251600.4	RP11-673E1.1	-5.72	1.91e-08	6.92e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143767216	chr4:143912331~143982454:+
LUAD	cis	rs2288884	0.636	rs11669439	ENSG00000275055.1	CTC-471J1.11	-5.72	1.91e-08	6.92e-06	-0.31	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52069047	chr19:52049007~52049754:+
LUAD	cis	rs10129255	0.5	rs988134	ENSG00000211967.3	IGHV3-53	-5.72	1.91e-08	6.93e-06	-0.18	-0.25	Kawasaki disease;	chr14:106776698	chr14:106592676~106593347:-
LUAD	cis	rs10129255	0.5	rs988133	ENSG00000211967.3	IGHV3-53	-5.72	1.91e-08	6.93e-06	-0.18	-0.25	Kawasaki disease;	chr14:106776724	chr14:106592676~106593347:-
LUAD	cis	rs728616	0.558	rs723192	ENSG00000225484.5	NUTM2B-AS1	-5.72	1.91e-08	6.93e-06	-0.42	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948257	chr10:79663088~79826594:-
LUAD	cis	rs11098499	0.754	rs10212714	ENSG00000248280.1	RP11-33B1.2	5.72	1.91e-08	6.94e-06	0.32	0.25	Corneal astigmatism;	chr4:119333147	chr4:119440561~119450157:-
LUAD	cis	rs10129255	0.957	rs10136560	ENSG00000224373.3	IGHV4-59	5.72	1.91e-08	6.94e-06	0.17	0.25	Kawasaki disease;	chr14:106787630	chr14:106627249~106627825:-
LUAD	cis	rs673078	0.607	rs7137055	ENSG00000275409.1	RP11-131L12.4	-5.72	1.91e-08	6.94e-06	-0.35	-0.25	Glucose homeostasis traits;	chr12:118395030	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs7137184	ENSG00000275409.1	RP11-131L12.4	-5.72	1.91e-08	6.94e-06	-0.35	-0.25	Glucose homeostasis traits;	chr12:118395163	chr12:118430147~118430699:+
LUAD	cis	rs67311347	0.911	rs6773917	ENSG00000223797.4	ENTPD3-AS1	5.72	1.91e-08	6.94e-06	0.27	0.25	Renal cell carcinoma;	chr3:40427763	chr3:40313802~40453329:-
LUAD	cis	rs948562	0.947	rs75708979	ENSG00000280010.1	AP001350.4	5.72	1.92e-08	6.96e-06	0.42	0.25	Lymphoma;	chr11:58662312	chr11:58627435~58628528:+
LUAD	cis	rs9549367	0.569	rs3024719	ENSG00000269125.1	RP11-98F14.11	-5.72	1.92e-08	6.96e-06	-0.37	-0.25	Platelet distribution width;	chr13:113159911	chr13:113165002~113165183:-
LUAD	cis	rs2880765	0.835	rs4526974	ENSG00000259295.5	CSPG4P12	5.72	1.93e-08	6.99e-06	0.29	0.25	Coronary artery disease;	chr15:85481053	chr15:85191438~85213905:+
LUAD	cis	rs2280018	1	rs2280017	ENSG00000188599.16	NPIPP1	5.72	1.93e-08	6.99e-06	0.21	0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15057504	chr16:15104312~15123498:-
LUAD	cis	rs765787	0.53	rs11636395	ENSG00000259520.4	CTD-2651B20.3	5.72	1.93e-08	6.99e-06	0.33	0.25	Uric acid levels;	chr15:45243486	chr15:45251580~45279251:-
LUAD	cis	rs2179367	0.632	rs62426068	ENSG00000231760.4	RP11-350J20.5	5.71	1.93e-08	7e-06	0.37	0.25	Dupuytren's disease;	chr6:149325795	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs62426069	ENSG00000231760.4	RP11-350J20.5	5.71	1.93e-08	7e-06	0.37	0.25	Dupuytren's disease;	chr6:149325804	chr6:149796151~149826294:-
LUAD	cis	rs2288884	1	rs76768215	ENSG00000275055.1	CTC-471J1.11	-5.71	1.93e-08	7e-06	-0.4	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52069370	chr19:52049007~52049754:+
LUAD	cis	rs7208859	0.623	rs73267858	ENSG00000263603.1	CTD-2349P21.5	-5.71	1.93e-08	7.01e-06	-0.45	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732719	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs56095789	ENSG00000263603.1	CTD-2349P21.5	-5.71	1.93e-08	7.01e-06	-0.45	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733152	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs11656844	ENSG00000263603.1	CTD-2349P21.5	-5.71	1.93e-08	7.01e-06	-0.45	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733579	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs11652533	ENSG00000263603.1	CTD-2349P21.5	-5.71	1.93e-08	7.01e-06	-0.45	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733583	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs11652631	ENSG00000263603.1	CTD-2349P21.5	-5.71	1.93e-08	7.01e-06	-0.45	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733748	chr17:30729469~30731202:+
LUAD	cis	rs2749097	1	rs12024831	ENSG00000244256.3	RN7SL130P	-5.71	1.93e-08	7.01e-06	-0.37	-0.25	Alcohol consumption (transferrin glycosylation);	chr1:63671796	chr1:63655743~63656047:+
LUAD	cis	rs2665103	0.61	rs1972460	ENSG00000255769.6	GOLGA2P10	-5.71	1.93e-08	7.01e-06	-0.26	-0.25	Intelligence (multi-trait analysis);	chr15:82238289	chr15:82472993~82513950:-
LUAD	cis	rs2408955	0.522	rs6580650	ENSG00000240399.1	RP1-228P16.1	-5.71	1.94e-08	7.02e-06	-0.26	-0.25	Glycated hemoglobin levels;	chr12:48024773	chr12:48054813~48055591:-
LUAD	cis	rs5753618	0.561	rs9606831	ENSG00000236132.1	CTA-440B3.1	-5.71	1.94e-08	7.02e-06	-0.32	-0.25	Colorectal cancer;	chr22:31336526	chr22:31816379~31817491:-
LUAD	cis	rs11971779	0.68	rs17691238	ENSG00000273391.1	RP11-634H22.1	-5.71	1.94e-08	7.02e-06	-0.26	-0.25	Diisocyanate-induced asthma;	chr7:139367538	chr7:139359032~139359566:-
LUAD	cis	rs12468226	1	rs16839090	ENSG00000272966.1	RP11-686O6.1	5.71	1.94e-08	7.02e-06	0.43	0.25	Urate levels;	chr2:202348338	chr2:202336739~202337200:+
LUAD	cis	rs7712401	0.601	rs30045	ENSG00000263432.2	RN7SL689P	5.71	1.94e-08	7.03e-06	0.3	0.25	Mean platelet volume;	chr5:122935924	chr5:123022487~123022783:-
LUAD	cis	rs1113500	0.509	rs17020915	ENSG00000226822.1	RP11-356N1.2	5.71	1.94e-08	7.04e-06	0.34	0.25	Growth-regulated protein alpha levels;	chr1:108104384	chr1:108071482~108074519:+
LUAD	cis	rs1113500	0.548	rs11185269	ENSG00000226822.1	RP11-356N1.2	5.71	1.94e-08	7.04e-06	0.34	0.25	Growth-regulated protein alpha levels;	chr1:108105014	chr1:108071482~108074519:+
LUAD	cis	rs7804306	1	rs34156160	ENSG00000233264.2	AC006042.8	5.71	1.94e-08	7.04e-06	0.44	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8043155	chr7:7980312~7982228:+
LUAD	cis	rs2276314	0.857	rs72883058	ENSG00000278986.1	RP11-723J4.3	-5.71	1.94e-08	7.04e-06	-0.3	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:36032954	chr18:35972151~35973916:+
LUAD	cis	rs7712401	0.601	rs40818	ENSG00000263432.2	RN7SL689P	5.71	1.94e-08	7.04e-06	0.31	0.25	Mean platelet volume;	chr5:122959378	chr5:123022487~123022783:-
LUAD	cis	rs9918079	0.884	rs11728037	ENSG00000273133.1	RP11-799M12.2	-5.71	1.95e-08	7.06e-06	-0.43	-0.25	Obesity-related traits;	chr4:15593275	chr4:15563698~15564253:-
LUAD	cis	rs860295	0.541	rs11264359	ENSG00000225855.5	RUSC1-AS1	5.71	1.95e-08	7.08e-06	0.17	0.25	Body mass index;	chr1:155313038	chr1:155316863~155324176:-
LUAD	cis	rs75422866	0.51	rs73105818	ENSG00000274902.1	RP1-197B17.4	5.71	1.95e-08	7.08e-06	0.55	0.25	Pneumonia;	chr12:47726538	chr12:47731908~47732351:+
LUAD	cis	rs66887589	0.967	rs13104219	ENSG00000245958.5	RP11-33B1.1	-5.71	1.96e-08	7.09e-06	-0.2	-0.25	Diastolic blood pressure;	chr4:119517019	chr4:119454791~119552025:+
LUAD	cis	rs957448	1	rs10956915	ENSG00000253704.1	RP11-267M23.4	5.71	1.96e-08	7.09e-06	0.32	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94502362	chr8:94553722~94569745:+
LUAD	cis	rs9309473	0.95	rs6546858	ENSG00000163016.8	ALMS1P	5.71	1.96e-08	7.1e-06	0.3	0.25	Metabolite levels;	chr2:73611486	chr2:73644919~73685576:+
LUAD	cis	rs7712401	0.601	rs30026	ENSG00000263432.2	RN7SL689P	5.71	1.96e-08	7.1e-06	0.31	0.25	Mean platelet volume;	chr5:122948873	chr5:123022487~123022783:-
LUAD	cis	rs875971	0.79	rs10257911	ENSG00000222364.1	RNU6-96P	5.71	1.96e-08	7.1e-06	0.29	0.25	Aortic root size;	chr7:66278783	chr7:66395191~66395286:+
LUAD	cis	rs801193	0.569	rs7782587	ENSG00000237310.1	GS1-124K5.4	5.71	1.96e-08	7.11e-06	0.27	0.25	Aortic root size;	chr7:66701485	chr7:66493706~66495474:+
LUAD	cis	rs801193	0.569	rs4717315	ENSG00000237310.1	GS1-124K5.4	5.71	1.96e-08	7.11e-06	0.27	0.25	Aortic root size;	chr7:66713338	chr7:66493706~66495474:+
LUAD	cis	rs801193	0.527	rs2707837	ENSG00000237310.1	GS1-124K5.4	5.71	1.96e-08	7.11e-06	0.27	0.25	Aortic root size;	chr7:66716086	chr7:66493706~66495474:+
LUAD	cis	rs12554020	0.892	rs76977206	ENSG00000227603.1	RP11-165J3.6	5.71	1.96e-08	7.11e-06	0.48	0.25	Schizophrenia;	chr9:93518181	chr9:93435332~93437121:-
LUAD	cis	rs2404602	0.716	rs8039545	ENSG00000259422.1	RP11-593F23.1	5.71	1.96e-08	7.11e-06	0.29	0.25	Blood metabolite levels;	chr15:76414906	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.716	rs7164060	ENSG00000259422.1	RP11-593F23.1	5.71	1.96e-08	7.11e-06	0.29	0.25	Blood metabolite levels;	chr15:76415353	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.716	rs7164813	ENSG00000259422.1	RP11-593F23.1	5.71	1.96e-08	7.11e-06	0.29	0.25	Blood metabolite levels;	chr15:76415725	chr15:76174891~76181486:-
LUAD	cis	rs61776719	0.905	rs17465420	ENSG00000212541.1	RNU6-510P	-5.71	1.96e-08	7.11e-06	-0.3	-0.25	Coronary artery disease;	chr1:37932916	chr1:37991462~37991569:+
LUAD	cis	rs2581794	1	rs2581794	ENSG00000242142.1	SERBP1P3	5.71	1.96e-08	7.11e-06	0.28	0.25	Schizophrenia;	chr3:53002190	chr3:53064283~53065091:-
LUAD	cis	rs30380	0.586	rs28119	ENSG00000272109.1	CTD-2260A17.3	-5.71	1.96e-08	7.11e-06	-0.3	-0.25	Cerebrospinal fluid biomarker levels;	chr5:96796030	chr5:96804353~96806105:+
LUAD	cis	rs7246657	0.722	rs4802051	ENSG00000276846.1	CTD-3220F14.3	5.71	1.97e-08	7.12e-06	0.33	0.25	Coronary artery calcification;	chr19:37581427	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.663	rs4803276	ENSG00000276846.1	CTD-3220F14.3	5.71	1.97e-08	7.12e-06	0.33	0.25	Coronary artery calcification;	chr19:37581429	chr19:37314868~37315620:-
LUAD	cis	rs6558530	0.73	rs6991773	ENSG00000253982.1	CTD-2336O2.1	5.71	1.97e-08	7.12e-06	0.32	0.25	Systolic blood pressure;	chr8:1775011	chr8:1761990~1764502:-
LUAD	cis	rs1707322	0.717	rs2253862	ENSG00000280836.1	AL355480.1	5.71	1.97e-08	7.12e-06	0.34	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616288	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.717	rs2991988	ENSG00000280836.1	AL355480.1	5.71	1.97e-08	7.12e-06	0.34	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616759	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.717	rs2991989	ENSG00000280836.1	AL355480.1	5.71	1.97e-08	7.12e-06	0.34	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45617293	chr1:45581219~45581321:-
LUAD	cis	rs7849270	1	rs3124512	ENSG00000268707.1	RP11-247A12.7	5.71	1.97e-08	7.12e-06	0.3	0.25	Blood metabolite ratios;	chr9:129141602	chr9:129170434~129170940:+
LUAD	cis	rs7712401	0.601	rs246268	ENSG00000263432.2	RN7SL689P	5.71	1.97e-08	7.13e-06	0.31	0.25	Mean platelet volume;	chr5:122920647	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.623	rs426877	ENSG00000263432.2	RN7SL689P	-5.71	1.97e-08	7.14e-06	-0.31	-0.25	Mean platelet volume;	chr5:122978940	chr5:123022487~123022783:-
LUAD	cis	rs7615952	0.599	rs1875683	ENSG00000171084.14	FAM86JP	5.71	1.97e-08	7.15e-06	0.36	0.25	Blood pressure (smoking interaction);	chr3:126013638	chr3:125916620~125930024:+
LUAD	cis	rs12908161	1	rs56864281	ENSG00000225151.9	GOLGA2P7	-5.71	1.97e-08	7.15e-06	-0.34	-0.25	Schizophrenia;	chr15:84814418	chr15:84199311~84230136:-
LUAD	cis	rs2243480	1	rs9769882	ENSG00000230295.1	RP11-458F8.2	5.71	1.97e-08	7.15e-06	0.3	0.25	Diabetic kidney disease;	chr7:66177938	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs6966322	ENSG00000230295.1	RP11-458F8.2	5.71	1.97e-08	7.15e-06	0.3	0.25	Diabetic kidney disease;	chr7:66181767	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs4145008	ENSG00000230295.1	RP11-458F8.2	5.71	1.97e-08	7.15e-06	0.3	0.25	Diabetic kidney disease;	chr7:66182524	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs4718315	ENSG00000230295.1	RP11-458F8.2	5.71	1.97e-08	7.15e-06	0.3	0.25	Diabetic kidney disease;	chr7:66183554	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs4718316	ENSG00000230295.1	RP11-458F8.2	5.71	1.97e-08	7.15e-06	0.3	0.25	Diabetic kidney disease;	chr7:66183744	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs1873494	ENSG00000230295.1	RP11-458F8.2	5.71	1.97e-08	7.15e-06	0.3	0.25	Diabetic kidney disease;	chr7:66184912	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs6959002	ENSG00000230295.1	RP11-458F8.2	5.71	1.97e-08	7.15e-06	0.3	0.25	Diabetic kidney disease;	chr7:66185509	chr7:66880708~66882981:+
LUAD	cis	rs801193	0.569	rs2707824	ENSG00000237310.1	GS1-124K5.4	5.71	1.98e-08	7.16e-06	0.27	0.25	Aortic root size;	chr7:66724256	chr7:66493706~66495474:+
LUAD	cis	rs1707322	0.686	rs1541131	ENSG00000234329.1	RP11-767N6.2	-5.71	1.98e-08	7.16e-06	-0.27	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619262	chr1:45651039~45651826:-
LUAD	cis	rs2243480	1	rs316315	ENSG00000232546.1	RP11-458F8.1	5.71	1.98e-08	7.16e-06	0.29	0.25	Diabetic kidney disease;	chr7:66126218	chr7:66848496~66858136:+
LUAD	cis	rs9652601	0.691	rs7198004	ENSG00000274038.1	RP11-66H6.4	-5.71	1.98e-08	7.16e-06	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11113760	chr16:11056556~11057034:+
LUAD	cis	rs9847710	0.696	rs2581777	ENSG00000242142.1	SERBP1P3	5.71	1.98e-08	7.16e-06	0.3	0.25	Ulcerative colitis;	chr3:53020711	chr3:53064283~53065091:-
LUAD	cis	rs2948294	0.588	rs7011221	ENSG00000253893.2	FAM85B	-5.71	1.98e-08	7.16e-06	-0.33	-0.25	Red cell distribution width;	chr8:8256724	chr8:8167819~8226614:-
LUAD	cis	rs881375	0.678	rs10739581	ENSG00000226752.6	PSMD5-AS1	-5.71	1.98e-08	7.16e-06	-0.26	-0.25	Rheumatoid arthritis;	chr9:120934593	chr9:120824828~120854385:+
LUAD	cis	rs2276314	0.857	rs62101393	ENSG00000278986.1	RP11-723J4.3	-5.71	1.98e-08	7.16e-06	-0.31	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:36012205	chr18:35972151~35973916:+
LUAD	cis	rs2276314	0.857	rs62101394	ENSG00000278986.1	RP11-723J4.3	-5.71	1.98e-08	7.16e-06	-0.31	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:36012336	chr18:35972151~35973916:+
LUAD	cis	rs2276314	0.857	rs4799409	ENSG00000278986.1	RP11-723J4.3	-5.71	1.98e-08	7.16e-06	-0.31	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:36012639	chr18:35972151~35973916:+
LUAD	cis	rs2404602	0.647	rs2404600	ENSG00000259422.1	RP11-593F23.1	-5.71	1.98e-08	7.16e-06	-0.34	-0.25	Blood metabolite levels;	chr15:76881216	chr15:76174891~76181486:-
LUAD	cis	rs7712401	0.601	rs448505	ENSG00000263432.2	RN7SL689P	-5.71	1.98e-08	7.17e-06	-0.31	-0.25	Mean platelet volume;	chr5:123000995	chr5:123022487~123022783:-
LUAD	cis	rs10129255	1	rs10129255	ENSG00000211974.3	IGHV2-70	-5.71	1.98e-08	7.17e-06	-0.26	-0.25	Kawasaki disease;	chr14:106767970	chr14:106723574~106724093:-
LUAD	cis	rs11098499	0.754	rs10518300	ENSG00000248280.1	RP11-33B1.2	-5.71	1.98e-08	7.18e-06	-0.32	-0.25	Corneal astigmatism;	chr4:119328344	chr4:119440561~119450157:-
LUAD	cis	rs17818399	0.962	rs7565274	ENSG00000279254.1	RP11-536C12.1	-5.71	1.98e-08	7.18e-06	-0.28	-0.25	Height;	chr2:46614722	chr2:46668870~46670778:+
LUAD	cis	rs7714584	1	rs58717741	ENSG00000197083.10	ZNF300P1	5.71	1.98e-08	7.18e-06	0.51	0.25	Crohn's disease;	chr5:150905374	chr5:150930645~150946289:-
LUAD	cis	rs1075265	0.84	rs805309	ENSG00000233266.1	HMGB1P31	5.71	1.98e-08	7.18e-06	0.32	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53968877	chr2:54051334~54051760:+
LUAD	cis	rs12468226	0.873	rs12470401	ENSG00000226261.1	AC064836.3	5.71	1.98e-08	7.18e-06	0.43	0.25	Urate levels;	chr2:202236436	chr2:202336024~202336727:-
LUAD	cis	rs948562	0.585	rs11229477	ENSG00000280010.1	AP001350.4	5.71	1.99e-08	7.19e-06	0.41	0.25	Lymphoma;	chr11:58461125	chr11:58627435~58628528:+
LUAD	cis	rs2412819	0.545	rs3862143	ENSG00000249839.1	AC011330.5	5.71	1.99e-08	7.19e-06	0.4	0.25	Lung cancer;	chr15:43779282	chr15:43663654~43684339:-
LUAD	cis	rs2243480	1	rs4718317	ENSG00000230295.1	RP11-458F8.2	5.71	1.99e-08	7.19e-06	0.3	0.25	Diabetic kidney disease;	chr7:66183914	chr7:66880708~66882981:+
LUAD	cis	rs9992667	0.955	rs73232876	ENSG00000231160.8	KLF3-AS1	5.71	1.99e-08	7.19e-06	0.32	0.25	Eosinophil percentage of granulocytes;	chr4:38645888	chr4:38612701~38664883:-
LUAD	cis	rs2117029	0.555	rs7978448	ENSG00000258017.1	RP11-386G11.10	-5.71	1.99e-08	7.19e-06	-0.32	-0.25	Intelligence (multi-trait analysis);	chr12:49113157	chr12:49127782~49147869:+
LUAD	cis	rs2404602	0.716	rs1588961	ENSG00000259422.1	RP11-593F23.1	5.71	1.99e-08	7.2e-06	0.29	0.25	Blood metabolite levels;	chr15:76460357	chr15:76174891~76181486:-
LUAD	cis	rs925255	0.747	rs6547851	ENSG00000270210.1	RP11-373D23.3	-5.71	1.99e-08	7.2e-06	-0.29	-0.25	Inflammatory bowel disease;Crohn's disease;	chr2:28406500	chr2:28425945~28426719:+
LUAD	cis	rs2404602	0.655	rs4886507	ENSG00000259422.1	RP11-593F23.1	5.71	1.99e-08	7.2e-06	0.29	0.25	Blood metabolite levels;	chr15:76917353	chr15:76174891~76181486:-
LUAD	cis	rs7246657	0.663	rs10408619	ENSG00000276846.1	CTD-3220F14.3	5.71	1.99e-08	7.2e-06	0.33	0.25	Coronary artery calcification;	chr19:37579573	chr19:37314868~37315620:-
LUAD	cis	rs7923837	0.634	rs1544210	ENSG00000236493.2	EIF2S2P3	-5.71	1.99e-08	7.2e-06	-0.29	-0.25	Multiple sclerosis;Body mass index;	chr10:92728044	chr10:92668745~92669743:-
LUAD	cis	rs673078	0.607	rs17440942	ENSG00000275409.1	RP11-131L12.4	5.71	1.99e-08	7.21e-06	0.35	0.25	Glucose homeostasis traits;	chr12:118394030	chr12:118430147~118430699:+
LUAD	cis	rs17684571	0.7	rs62411366	ENSG00000231441.1	RP11-472M19.2	5.71	1.99e-08	7.21e-06	0.37	0.25	Schizophrenia;	chr6:56773015	chr6:56844002~56864078:+
LUAD	cis	rs1707322	1	rs946527	ENSG00000234329.1	RP11-767N6.2	5.71	2e-08	7.22e-06	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46020298	chr1:45651039~45651826:-
LUAD	cis	rs7615952	0.599	rs6766327	ENSG00000171084.14	FAM86JP	5.71	2e-08	7.23e-06	0.36	0.25	Blood pressure (smoking interaction);	chr3:126004834	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.641	rs12491577	ENSG00000171084.14	FAM86JP	5.71	2e-08	7.23e-06	0.36	0.25	Blood pressure (smoking interaction);	chr3:126012288	chr3:125916620~125930024:+
LUAD	cis	rs6543140	0.89	rs61122764	ENSG00000234389.1	AC007278.3	5.71	2e-08	7.23e-06	0.25	0.25	Blood protein levels;	chr2:102383060	chr2:102438713~102440475:+
LUAD	cis	rs75422866	0.51	rs73105803	ENSG00000274902.1	RP1-197B17.4	5.71	2e-08	7.23e-06	0.56	0.25	Pneumonia;	chr12:47722135	chr12:47731908~47732351:+
LUAD	cis	rs2179367	0.632	rs9498325	ENSG00000231760.4	RP11-350J20.5	5.71	2e-08	7.23e-06	0.35	0.25	Dupuytren's disease;	chr6:149345993	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs9498326	ENSG00000231760.4	RP11-350J20.5	5.71	2e-08	7.23e-06	0.35	0.25	Dupuytren's disease;	chr6:149346112	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.6	rs9498352	ENSG00000231760.4	RP11-350J20.5	5.71	2e-08	7.24e-06	0.38	0.25	Dupuytren's disease;	chr6:149439108	chr6:149796151~149826294:-
LUAD	cis	rs7804306	0.826	rs35567393	ENSG00000233264.2	AC006042.8	5.71	2e-08	7.24e-06	0.44	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8033938	chr7:7980312~7982228:+
LUAD	cis	rs2179367	0.568	rs62426092	ENSG00000231760.4	RP11-350J20.5	5.71	2e-08	7.24e-06	0.36	0.25	Dupuytren's disease;	chr6:149352720	chr6:149796151~149826294:-
LUAD	cis	rs4908768	0.501	rs12046643	ENSG00000232912.4	RP5-1115A15.1	5.71	2e-08	7.24e-06	0.23	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8487806	chr1:8424645~8434838:+
LUAD	cis	rs4908760	0.965	rs10864353	ENSG00000232912.4	RP5-1115A15.1	5.71	2e-08	7.24e-06	0.23	0.25	Vitiligo;	chr1:8489656	chr1:8424645~8434838:+
LUAD	cis	rs4908768	0.501	rs6677736	ENSG00000232912.4	RP5-1115A15.1	5.71	2e-08	7.24e-06	0.23	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8492744	chr1:8424645~8434838:+
LUAD	cis	rs4908768	0.501	rs7527389	ENSG00000232912.4	RP5-1115A15.1	5.71	2e-08	7.24e-06	0.23	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8496485	chr1:8424645~8434838:+
LUAD	cis	rs4908768	0.501	rs7518608	ENSG00000232912.4	RP5-1115A15.1	5.71	2e-08	7.24e-06	0.23	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8497260	chr1:8424645~8434838:+
LUAD	cis	rs4908760	0.965	rs10864356	ENSG00000232912.4	RP5-1115A15.1	5.71	2e-08	7.24e-06	0.23	0.25	Vitiligo;	chr1:8509812	chr1:8424645~8434838:+
LUAD	cis	rs10129255	1	rs61997605	ENSG00000224373.3	IGHV4-59	5.71	2e-08	7.25e-06	0.16	0.25	Kawasaki disease;	chr14:106678368	chr14:106627249~106627825:-
LUAD	cis	rs10129255	1	rs8012033	ENSG00000224373.3	IGHV4-59	5.71	2e-08	7.25e-06	0.16	0.25	Kawasaki disease;	chr14:106678854	chr14:106627249~106627825:-
LUAD	cis	rs732716	0.785	rs11667543	ENSG00000267980.1	AC007292.6	-5.71	2.01e-08	7.26e-06	-0.3	-0.25	Mean corpuscular volume;	chr19:4374853	chr19:4363789~4364640:+
LUAD	cis	rs2412819	0.597	rs7181912	ENSG00000249839.1	AC011330.5	5.71	2.01e-08	7.26e-06	0.4	0.25	Lung cancer;	chr15:43770676	chr15:43663654~43684339:-
LUAD	cis	rs944289	0.6	rs2899846	ENSG00000257826.1	RP11-116N8.4	-5.71	2.01e-08	7.27e-06	-0.28	-0.25	Thyroid cancer;	chr14:36140737	chr14:36061026~36067190:-
LUAD	cis	rs2243480	1	rs1546059	ENSG00000230295.1	RP11-458F8.2	5.71	2.01e-08	7.27e-06	0.3	0.25	Diabetic kidney disease;	chr7:66189722	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs6958289	ENSG00000230295.1	RP11-458F8.2	5.71	2.01e-08	7.27e-06	0.3	0.25	Diabetic kidney disease;	chr7:66192124	chr7:66880708~66882981:+
LUAD	cis	rs4835473	0.838	rs6832094	ENSG00000251600.4	RP11-673E1.1	-5.71	2.01e-08	7.27e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143795388	chr4:143912331~143982454:+
LUAD	cis	rs11098499	0.644	rs3806808	ENSG00000248280.1	RP11-33B1.2	5.71	2.01e-08	7.28e-06	0.32	0.25	Corneal astigmatism;	chr4:119629930	chr4:119440561~119450157:-
LUAD	cis	rs17666538	0.535	rs168062	ENSG00000254207.1	RP11-43A14.1	5.71	2.01e-08	7.28e-06	0.49	0.25	IgG glycosylation;	chr8:682444	chr8:725188~725877:-
LUAD	cis	rs875971	0.545	rs1796222	ENSG00000226824.5	RP4-756H11.3	5.71	2.02e-08	7.28e-06	0.37	0.25	Aortic root size;	chr7:66592167	chr7:66654538~66669855:+
LUAD	cis	rs2179367	0.632	rs9485384	ENSG00000231760.4	RP11-350J20.5	5.71	2.02e-08	7.29e-06	0.37	0.25	Dupuytren's disease;	chr6:149328808	chr6:149796151~149826294:-
LUAD	cis	rs4835473	0.742	rs7695853	ENSG00000251600.4	RP11-673E1.1	5.71	2.02e-08	7.29e-06	0.31	0.25	Immature fraction of reticulocytes;	chr4:143883243	chr4:143912331~143982454:+
LUAD	cis	rs2404602	0.647	rs4312276	ENSG00000259422.1	RP11-593F23.1	-5.71	2.02e-08	7.29e-06	-0.34	-0.25	Blood metabolite levels;	chr15:76872020	chr15:76174891~76181486:-
LUAD	cis	rs55665837	0.665	rs11023273	ENSG00000251991.1	RNU7-49P	5.71	2.02e-08	7.3e-06	0.29	0.25	Vitamin D levels;	chr11:14609273	chr11:14478892~14478953:+
LUAD	cis	rs948562	0.947	rs78629620	ENSG00000280010.1	AP001350.4	5.71	2.02e-08	7.31e-06	0.41	0.25	Lymphoma;	chr11:58662329	chr11:58627435~58628528:+
LUAD	cis	rs2933343	1	rs789227	ENSG00000261159.1	RP11-723O4.9	5.71	2.02e-08	7.31e-06	0.31	0.25	IgG glycosylation;	chr3:128881742	chr3:128859716~128860526:-
LUAD	cis	rs149313	0.901	rs697976	ENSG00000248734.2	CTD-2260A17.1	5.71	2.02e-08	7.31e-06	0.24	0.25	Blood protein levels;	chr5:96733063	chr5:96784777~96785999:+
LUAD	cis	rs172166	0.637	rs1233691	ENSG00000204709.4	LINC01556	5.71	2.03e-08	7.33e-06	0.33	0.25	Cardiac Troponin-T levels;	chr6:28186119	chr6:28943877~28944537:+
LUAD	cis	rs4908760	0.899	rs6577496	ENSG00000232912.4	RP5-1115A15.1	5.71	2.03e-08	7.33e-06	0.23	0.25	Vitiligo;	chr1:8521168	chr1:8424645~8434838:+
LUAD	cis	rs75920871	0.588	rs4938321	ENSG00000254851.1	RP11-109L13.1	5.71	2.03e-08	7.33e-06	0.37	0.25	Subjective well-being;	chr11:116981791	chr11:117135528~117138582:+
LUAD	cis	rs6558530	0.73	rs7341635	ENSG00000253982.1	CTD-2336O2.1	5.71	2.03e-08	7.34e-06	0.32	0.25	Systolic blood pressure;	chr8:1773477	chr8:1761990~1764502:-
LUAD	cis	rs7618501	0.633	rs35065728	ENSG00000234667.1	ACTBP13	-5.71	2.03e-08	7.34e-06	-0.28	-0.25	Intelligence (multi-trait analysis);	chr3:49971743	chr3:49873347~49877980:-
LUAD	cis	rs4835473	0.9	rs1375983	ENSG00000251600.4	RP11-673E1.1	-5.71	2.03e-08	7.34e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143760423	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1375984	ENSG00000251600.4	RP11-673E1.1	-5.71	2.03e-08	7.34e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143760510	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1375985	ENSG00000251600.4	RP11-673E1.1	-5.71	2.03e-08	7.34e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143760556	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs17018200	ENSG00000251600.4	RP11-673E1.1	-5.71	2.03e-08	7.34e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143760866	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs11100805	ENSG00000251600.4	RP11-673E1.1	-5.71	2.03e-08	7.34e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143760979	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.868	rs56115009	ENSG00000251600.4	RP11-673E1.1	-5.71	2.03e-08	7.34e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143761073	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs10857406	ENSG00000251600.4	RP11-673E1.1	-5.71	2.03e-08	7.34e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143761216	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs10857407	ENSG00000251600.4	RP11-673E1.1	-5.71	2.03e-08	7.34e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143761226	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs10857408	ENSG00000251600.4	RP11-673E1.1	-5.71	2.03e-08	7.34e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143761333	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs10857409	ENSG00000251600.4	RP11-673E1.1	-5.71	2.03e-08	7.34e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143761461	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs10857410	ENSG00000251600.4	RP11-673E1.1	-5.71	2.03e-08	7.34e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143761566	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs10857411	ENSG00000251600.4	RP11-673E1.1	-5.71	2.03e-08	7.34e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143761599	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1006406	ENSG00000251600.4	RP11-673E1.1	-5.71	2.03e-08	7.34e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143761710	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1562776	ENSG00000251600.4	RP11-673E1.1	-5.71	2.03e-08	7.34e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143761999	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs34697602	ENSG00000251600.4	RP11-673E1.1	-5.71	2.03e-08	7.34e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143762499	chr4:143912331~143982454:+
LUAD	cis	rs2599510	0.783	rs13399071	ENSG00000276334.1	AL133243.1	5.71	2.03e-08	7.34e-06	0.29	0.25	Interleukin-18 levels;	chr2:32568716	chr2:32521927~32523547:+
LUAD	cis	rs2179367	0.632	rs9485389	ENSG00000231760.4	RP11-350J20.5	-5.7	2.04e-08	7.35e-06	-0.36	-0.25	Dupuytren's disease;	chr6:149420078	chr6:149796151~149826294:-
LUAD	cis	rs748404	0.666	rs72709879	ENSG00000205771.5	CATSPER2P1	-5.7	2.04e-08	7.36e-06	-0.38	-0.25	Lung cancer;	chr15:43507777	chr15:43726918~43747094:-
LUAD	cis	rs12699921	0.599	rs4721661	ENSG00000279048.1	RP11-511H23.2	-5.7	2.04e-08	7.36e-06	-0.2	-0.25	Fibrinogen levels;	chr7:17834677	chr7:17940503~17942922:+
LUAD	cis	rs9876781	0.56	rs2362451	ENSG00000229759.1	MRPS18AP1	-5.7	2.04e-08	7.36e-06	-0.25	-0.25	Longevity;	chr3:48358338	chr3:48256350~48256938:-
LUAD	cis	rs2765539	0.59	rs4659137	ENSG00000226172.2	RP4-712E4.1	-5.7	2.04e-08	7.36e-06	-0.33	-0.25	Waist-hip ratio;	chr1:118978171	chr1:119000344~119001392:-
LUAD	cis	rs858239	0.601	rs3735228	ENSG00000230042.1	AK3P3	-5.7	2.04e-08	7.36e-06	-0.31	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23129178~23129841:+
LUAD	cis	rs12468226	0.938	rs80282360	ENSG00000272966.1	RP11-686O6.1	5.7	2.04e-08	7.37e-06	0.44	0.25	Urate levels;	chr2:202275121	chr2:202336739~202337200:+
LUAD	cis	rs12699921	0.632	rs2691629	ENSG00000279048.1	RP11-511H23.2	-5.7	2.04e-08	7.37e-06	-0.2	-0.25	Fibrinogen levels;	chr7:17785007	chr7:17940503~17942922:+
LUAD	cis	rs12699921	0.632	rs2723500	ENSG00000279048.1	RP11-511H23.2	-5.7	2.04e-08	7.37e-06	-0.2	-0.25	Fibrinogen levels;	chr7:17785111	chr7:17940503~17942922:+
LUAD	cis	rs12699921	0.632	rs2691630	ENSG00000279048.1	RP11-511H23.2	-5.7	2.04e-08	7.37e-06	-0.2	-0.25	Fibrinogen levels;	chr7:17785163	chr7:17940503~17942922:+
LUAD	cis	rs12699921	0.632	rs2723499	ENSG00000279048.1	RP11-511H23.2	-5.7	2.04e-08	7.37e-06	-0.2	-0.25	Fibrinogen levels;	chr7:17785261	chr7:17940503~17942922:+
LUAD	cis	rs12699921	0.632	rs2723498	ENSG00000279048.1	RP11-511H23.2	-5.7	2.04e-08	7.37e-06	-0.2	-0.25	Fibrinogen levels;	chr7:17785362	chr7:17940503~17942922:+
LUAD	cis	rs7712401	0.645	rs154497	ENSG00000263432.2	RN7SL689P	5.7	2.04e-08	7.37e-06	0.32	0.25	Mean platelet volume;	chr5:122885725	chr5:123022487~123022783:-
LUAD	cis	rs7182621	0.639	rs1561047	ENSG00000259363.4	CTD-2054N24.2	-5.7	2.04e-08	7.38e-06	-0.34	-0.25	Colonoscopy-negative controls vs population controls;	chr15:99874606	chr15:99807023~99877148:+
LUAD	cis	rs7615952	0.599	rs7652883	ENSG00000171084.14	FAM86JP	5.7	2.05e-08	7.38e-06	0.35	0.25	Blood pressure (smoking interaction);	chr3:125989134	chr3:125916620~125930024:+
LUAD	cis	rs7208859	0.673	rs1347359	ENSG00000263603.1	CTD-2349P21.5	-5.7	2.05e-08	7.39e-06	-0.38	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587511	chr17:30729469~30731202:+
LUAD	cis	rs673078	0.607	rs7968011	ENSG00000275409.1	RP11-131L12.4	-5.7	2.05e-08	7.39e-06	-0.35	-0.25	Glucose homeostasis traits;	chr12:118382001	chr12:118430147~118430699:+
LUAD	cis	rs944289	0.536	rs1951375	ENSG00000257826.1	RP11-116N8.4	-5.7	2.05e-08	7.4e-06	-0.26	-0.25	Thyroid cancer;	chr14:36051569	chr14:36061026~36067190:-
LUAD	cis	rs2408955	0.522	rs4760612	ENSG00000240399.1	RP1-228P16.1	-5.7	2.05e-08	7.4e-06	-0.25	-0.25	Glycated hemoglobin levels;	chr12:48028073	chr12:48054813~48055591:-
LUAD	cis	rs2288884	0.515	rs11084133	ENSG00000275055.1	CTC-471J1.11	-5.7	2.05e-08	7.4e-06	-0.3	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52041125	chr19:52049007~52049754:+
LUAD	cis	rs7727544	0.66	rs274563	ENSG00000233006.5	AC034220.3	-5.7	2.05e-08	7.4e-06	-0.23	-0.25	Blood metabolite levels;	chr5:132382167	chr5:132311285~132369916:-
LUAD	cis	rs9992667	0.955	rs12499028	ENSG00000231160.8	KLF3-AS1	5.7	2.05e-08	7.41e-06	0.32	0.25	Eosinophil percentage of granulocytes;	chr4:38638087	chr4:38612701~38664883:-
LUAD	cis	rs9992667	0.826	rs7656708	ENSG00000231160.8	KLF3-AS1	5.7	2.05e-08	7.41e-06	0.32	0.25	Eosinophil percentage of granulocytes;	chr4:38640041	chr4:38612701~38664883:-
LUAD	cis	rs9992667	0.744	rs7657152	ENSG00000231160.8	KLF3-AS1	5.7	2.05e-08	7.41e-06	0.32	0.25	Eosinophil percentage of granulocytes;	chr4:38640315	chr4:38612701~38664883:-
LUAD	cis	rs2288884	0.943	rs11671792	ENSG00000275055.1	CTC-471J1.11	-5.7	2.06e-08	7.42e-06	-0.4	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52078430	chr19:52049007~52049754:+
LUAD	cis	rs1707322	0.963	rs10890373	ENSG00000234329.1	RP11-767N6.2	5.7	2.06e-08	7.42e-06	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45928083	chr1:45651039~45651826:-
LUAD	cis	rs35740288	0.822	rs17574774	ENSG00000202081.1	RNU6-1280P	-5.7	2.06e-08	7.43e-06	-0.31	-0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85690139	chr15:85651522~85651628:-
LUAD	cis	rs916888	0.821	rs70600	ENSG00000261575.2	RP11-259G18.1	5.7	2.06e-08	7.43e-06	0.4	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46267037~46268694:+
LUAD	cis	rs4908760	0.965	rs1884352	ENSG00000232912.4	RP5-1115A15.1	5.7	2.06e-08	7.43e-06	0.23	0.25	Vitiligo;	chr1:8477229	chr1:8424645~8434838:+
LUAD	cis	rs11105298	0.891	rs10858896	ENSG00000258302.2	RP11-981P6.1	5.7	2.06e-08	7.44e-06	0.32	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89526407	chr12:89561129~89594878:+
LUAD	cis	rs11105298	0.786	rs10777186	ENSG00000258302.2	RP11-981P6.1	5.7	2.06e-08	7.44e-06	0.32	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89527500	chr12:89561129~89594878:+
LUAD	cis	rs453301	0.658	rs3855900	ENSG00000253981.4	ALG1L13P	-5.7	2.07e-08	7.45e-06	-0.29	-0.25	Joint mobility (Beighton score);	chr8:9044411	chr8:8236003~8244667:-
LUAD	cis	rs2179367	0.632	rs55826712	ENSG00000231760.4	RP11-350J20.5	5.7	2.07e-08	7.45e-06	0.35	0.25	Dupuytren's disease;	chr6:149344716	chr6:149796151~149826294:-
LUAD	cis	rs7246657	0.722	rs1564208	ENSG00000276846.1	CTD-3220F14.3	5.7	2.07e-08	7.45e-06	0.33	0.25	Coronary artery calcification;	chr19:37550319	chr19:37314868~37315620:-
LUAD	cis	rs1707322	1	rs1707322	ENSG00000234329.1	RP11-767N6.2	5.7	2.07e-08	7.45e-06	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039475	chr1:45651039~45651826:-
LUAD	cis	rs6687821	0.515	rs12734749	ENSG00000267734.1	RP4-604K5.3	-5.7	2.07e-08	7.46e-06	-0.31	-0.25	Yeast infection;	chr1:86971063	chr1:86932199~86934891:-
LUAD	cis	rs1799949	0.602	rs8176257	ENSG00000267681.1	CTD-3199J23.6	-5.7	2.07e-08	7.46e-06	-0.32	-0.25	Menopause (age at onset);	chr17:43064188	chr17:43144956~43145255:+
LUAD	cis	rs74233809	1	rs77787671	ENSG00000213277.3	MARCKSL1P1	5.7	2.07e-08	7.47e-06	0.44	0.25	Birth weight;	chr10:103016448	chr10:103175554~103176094:+
LUAD	cis	rs11690935	0.55	rs6746701	ENSG00000228389.1	AC068039.4	-5.7	2.07e-08	7.48e-06	-0.27	-0.25	Schizophrenia;	chr2:172004347	chr2:171773482~171775844:+
LUAD	cis	rs7044106	0.537	rs4434680	ENSG00000238181.2	AHCYP2	-5.7	2.08e-08	7.48e-06	-0.36	-0.25	Hip circumference adjusted for BMI;	chr9:120727410	chr9:120720673~120721972:+
LUAD	cis	rs17138358	0.515	rs2691610	ENSG00000279048.1	RP11-511H23.2	-5.7	2.08e-08	7.49e-06	-0.2	-0.25	HDL cholesterol levels;	chr7:17781815	chr7:17940503~17942922:+
LUAD	cis	rs9807989	0.839	rs6749114	ENSG00000234389.1	AC007278.3	5.7	2.08e-08	7.49e-06	0.24	0.25	Asthma;	chr2:102351127	chr2:102438713~102440475:+
LUAD	cis	rs17301013	0.606	rs1754360	ENSG00000227373.4	RP11-160H22.5	-5.7	2.08e-08	7.49e-06	-0.34	-0.25	Systemic lupus erythematosus;	chr1:174775825	chr1:174115300~174160004:-
LUAD	cis	rs1823913	0.637	rs4853578	ENSG00000227542.1	AC092614.2	5.7	2.09e-08	7.51e-06	0.31	0.25	Obesity-related traits;	chr2:191297215	chr2:191229165~191246172:-
LUAD	cis	rs6687821	0.515	rs10747338	ENSG00000267734.1	RP4-604K5.3	-5.7	2.09e-08	7.52e-06	-0.31	-0.25	Yeast infection;	chr1:87043716	chr1:86932199~86934891:-
LUAD	cis	rs2933343	0.951	rs7648327	ENSG00000261159.1	RP11-723O4.9	5.7	2.09e-08	7.52e-06	0.31	0.25	IgG glycosylation;	chr3:128851865	chr3:128859716~128860526:-
LUAD	cis	rs62432291	0.681	rs445957	ENSG00000235086.1	FNDC1-IT1	-5.7	2.09e-08	7.52e-06	-0.42	-0.25	Joint mobility (Beighton score);	chr6:159241032	chr6:159240786~159243329:+
LUAD	cis	rs875971	0.895	rs12698520	ENSG00000237310.1	GS1-124K5.4	5.7	2.09e-08	7.52e-06	0.27	0.25	Aortic root size;	chr7:66453720	chr7:66493706~66495474:+
LUAD	cis	rs75920871	0.588	rs6589587	ENSG00000254851.1	RP11-109L13.1	5.7	2.09e-08	7.53e-06	0.37	0.25	Subjective well-being;	chr11:117004622	chr11:117135528~117138582:+
LUAD	cis	rs2408955	0.521	rs11168437	ENSG00000240399.1	RP1-228P16.1	5.7	2.09e-08	7.53e-06	0.25	0.25	Glycated hemoglobin levels;	chr12:48172373	chr12:48054813~48055591:-
LUAD	cis	rs10129255	0.912	rs8011090	ENSG00000224373.3	IGHV4-59	5.7	2.09e-08	7.54e-06	0.16	0.25	Kawasaki disease;	chr14:106678896	chr14:106627249~106627825:-
LUAD	cis	rs66887589	0.967	rs56173225	ENSG00000248280.1	RP11-33B1.2	-5.7	2.09e-08	7.54e-06	-0.28	-0.25	Diastolic blood pressure;	chr4:119588817	chr4:119440561~119450157:-
LUAD	cis	rs66887589	0.967	rs7678973	ENSG00000248280.1	RP11-33B1.2	-5.7	2.09e-08	7.54e-06	-0.28	-0.25	Diastolic blood pressure;	chr4:119590662	chr4:119440561~119450157:-
LUAD	cis	rs66887589	0.934	rs56843000	ENSG00000248280.1	RP11-33B1.2	-5.7	2.09e-08	7.54e-06	-0.28	-0.25	Diastolic blood pressure;	chr4:119595442	chr4:119440561~119450157:-
LUAD	cis	rs2948294	0.588	rs4840913	ENSG00000253893.2	FAM85B	-5.7	2.09e-08	7.54e-06	-0.33	-0.25	Red cell distribution width;	chr8:8259384	chr8:8167819~8226614:-
LUAD	cis	rs2404602	0.669	rs12441484	ENSG00000259422.1	RP11-593F23.1	5.7	2.1e-08	7.55e-06	0.29	0.25	Blood metabolite levels;	chr15:76817534	chr15:76174891~76181486:-
LUAD	cis	rs4273100	1	rs12602286	ENSG00000279825.1	CTC-457L16.1	-5.7	2.1e-08	7.55e-06	-0.32	-0.25	Schizophrenia;	chr17:19333641	chr17:19030857~19033529:+
LUAD	cis	rs7176527	0.784	rs62021162	ENSG00000229212.6	RP11-561C5.4	5.7	2.1e-08	7.55e-06	0.36	0.25	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84565602	chr15:85205440~85234795:-
LUAD	cis	rs3762637	0.823	rs59569049	ENSG00000272758.4	RP11-299J3.8	-5.7	2.1e-08	7.58e-06	-0.38	-0.25	LDL cholesterol levels;	chr3:122519941	chr3:122416207~122443180:+
LUAD	cis	rs1707322	0.627	rs3014213	ENSG00000280836.1	AL355480.1	5.7	2.11e-08	7.58e-06	0.33	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45579850	chr1:45581219~45581321:-
LUAD	cis	rs10129255	0.785	rs10150044	ENSG00000224373.3	IGHV4-59	5.7	2.11e-08	7.59e-06	0.16	0.25	Kawasaki disease;	chr14:106775695	chr14:106627249~106627825:-
LUAD	cis	rs10129255	0.957	rs10137980	ENSG00000224373.3	IGHV4-59	5.7	2.11e-08	7.59e-06	0.16	0.25	Kawasaki disease;	chr14:106775735	chr14:106627249~106627825:-
LUAD	cis	rs12699921	0.632	rs2254176	ENSG00000279048.1	RP11-511H23.2	-5.7	2.11e-08	7.6e-06	-0.2	-0.25	Fibrinogen levels;	chr7:17785981	chr7:17940503~17942922:+
LUAD	cis	rs75920871	0.557	rs7123336	ENSG00000254851.1	RP11-109L13.1	5.7	2.11e-08	7.6e-06	0.37	0.25	Subjective well-being;	chr11:116912103	chr11:117135528~117138582:+
LUAD	cis	rs9595908	0.785	rs4942804	ENSG00000212293.1	SNORA16	5.7	2.11e-08	7.6e-06	0.26	0.25	Body mass index;	chr13:32684365	chr13:32420390~32420516:-
LUAD	cis	rs673078	0.607	rs11068919	ENSG00000275409.1	RP11-131L12.4	-5.7	2.11e-08	7.6e-06	-0.33	-0.25	Glucose homeostasis traits;	chr12:118354925	chr12:118430147~118430699:+
LUAD	cis	rs10129255	1	rs9324091	ENSG00000224373.3	IGHV4-59	5.7	2.11e-08	7.61e-06	0.16	0.25	Kawasaki disease;	chr14:106676625	chr14:106627249~106627825:-
LUAD	cis	rs75422866	0.51	rs73104197	ENSG00000274902.1	RP1-197B17.4	5.7	2.12e-08	7.62e-06	0.56	0.25	Pneumonia;	chr12:47717273	chr12:47731908~47732351:+
LUAD	cis	rs9652601	0.622	rs8056098	ENSG00000274038.1	RP11-66H6.4	-5.7	2.12e-08	7.62e-06	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11044955	chr16:11056556~11057034:+
LUAD	cis	rs172166	0.637	rs1225592	ENSG00000204709.4	LINC01556	5.7	2.12e-08	7.62e-06	0.32	0.25	Cardiac Troponin-T levels;	chr6:28182464	chr6:28943877~28944537:+
LUAD	cis	rs172166	0.637	rs1225595	ENSG00000204709.4	LINC01556	5.7	2.12e-08	7.62e-06	0.32	0.25	Cardiac Troponin-T levels;	chr6:28183562	chr6:28943877~28944537:+
LUAD	cis	rs16863064	1	rs16863064	ENSG00000279891.1	FLJ42393	5.7	2.12e-08	7.63e-06	0.36	0.25	Schizophrenia;	chr3:188169789	chr3:188178543~188180812:+
LUAD	cis	rs875971	1	rs2077593	ENSG00000237310.1	GS1-124K5.4	5.7	2.12e-08	7.63e-06	0.27	0.25	Aortic root size;	chr7:66427543	chr7:66493706~66495474:+
LUAD	cis	rs755249	0.567	rs61779309	ENSG00000228060.1	RP11-69E11.8	-5.7	2.12e-08	7.63e-06	-0.26	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39474827	chr1:39565160~39573203:+
LUAD	cis	rs948562	0.585	rs17472536	ENSG00000280010.1	AP001350.4	5.7	2.12e-08	7.63e-06	0.42	0.25	Lymphoma;	chr11:58346066	chr11:58627435~58628528:+
LUAD	cis	rs6921919	0.806	rs213230	ENSG00000216901.1	AL022393.7	5.7	2.12e-08	7.64e-06	0.32	0.25	Autism spectrum disorder or schizophrenia;	chr6:28362487	chr6:28176188~28176674:+
LUAD	cis	rs9860428	0.868	rs9871605	ENSG00000242770.2	RP11-180K7.1	5.7	2.13e-08	7.65e-06	0.26	0.25	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112845234	chr3:112802478~112812819:+
LUAD	cis	rs7246657	0.606	rs2972439	ENSG00000276846.1	CTD-3220F14.3	-5.7	2.13e-08	7.65e-06	-0.34	-0.25	Coronary artery calcification;	chr19:37721680	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.722	rs2909100	ENSG00000276846.1	CTD-3220F14.3	-5.7	2.13e-08	7.65e-06	-0.34	-0.25	Coronary artery calcification;	chr19:37721779	chr19:37314868~37315620:-
LUAD	cis	rs12554020	0.786	rs883785	ENSG00000227603.1	RP11-165J3.6	5.7	2.13e-08	7.66e-06	0.47	0.25	Schizophrenia;	chr9:93519841	chr9:93435332~93437121:-
LUAD	cis	rs12554020	0.681	rs883783	ENSG00000227603.1	RP11-165J3.6	5.7	2.13e-08	7.66e-06	0.47	0.25	Schizophrenia;	chr9:93519987	chr9:93435332~93437121:-
LUAD	cis	rs881375	0.526	rs1930785	ENSG00000226752.6	PSMD5-AS1	-5.7	2.13e-08	7.66e-06	-0.26	-0.25	Rheumatoid arthritis;	chr9:120928959	chr9:120824828~120854385:+
LUAD	cis	rs66887589	0.967	rs13104219	ENSG00000248280.1	RP11-33B1.2	5.7	2.13e-08	7.66e-06	0.28	0.25	Diastolic blood pressure;	chr4:119517019	chr4:119440561~119450157:-
LUAD	cis	rs7712401	0.601	rs30069	ENSG00000263432.2	RN7SL689P	5.7	2.13e-08	7.67e-06	0.31	0.25	Mean platelet volume;	chr5:122957331	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs30067	ENSG00000263432.2	RN7SL689P	5.7	2.13e-08	7.67e-06	0.31	0.25	Mean platelet volume;	chr5:122957973	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs187405	ENSG00000263432.2	RN7SL689P	5.7	2.13e-08	7.67e-06	0.31	0.25	Mean platelet volume;	chr5:122959300	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.562	rs30062	ENSG00000263432.2	RN7SL689P	5.7	2.13e-08	7.67e-06	0.31	0.25	Mean platelet volume;	chr5:122960681	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs30060	ENSG00000263432.2	RN7SL689P	5.7	2.13e-08	7.67e-06	0.31	0.25	Mean platelet volume;	chr5:122961005	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.525	rs2910150	ENSG00000263432.2	RN7SL689P	5.7	2.13e-08	7.67e-06	0.31	0.25	Mean platelet volume;	chr5:122961050	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs30059	ENSG00000263432.2	RN7SL689P	5.7	2.13e-08	7.67e-06	0.31	0.25	Mean platelet volume;	chr5:122961814	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs30058	ENSG00000263432.2	RN7SL689P	5.7	2.13e-08	7.67e-06	0.31	0.25	Mean platelet volume;	chr5:122962008	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.623	rs30057	ENSG00000263432.2	RN7SL689P	5.7	2.13e-08	7.67e-06	0.31	0.25	Mean platelet volume;	chr5:122962423	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.584	rs39820	ENSG00000263432.2	RN7SL689P	5.7	2.13e-08	7.67e-06	0.31	0.25	Mean platelet volume;	chr5:122964226	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs30055	ENSG00000263432.2	RN7SL689P	5.7	2.13e-08	7.67e-06	0.31	0.25	Mean platelet volume;	chr5:122965384	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs39819	ENSG00000263432.2	RN7SL689P	5.7	2.13e-08	7.67e-06	0.31	0.25	Mean platelet volume;	chr5:122965981	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs30054	ENSG00000263432.2	RN7SL689P	5.7	2.13e-08	7.67e-06	0.31	0.25	Mean platelet volume;	chr5:122966304	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.562	rs30053	ENSG00000263432.2	RN7SL689P	5.7	2.13e-08	7.67e-06	0.31	0.25	Mean platelet volume;	chr5:122967948	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.562	rs30052	ENSG00000263432.2	RN7SL689P	5.7	2.13e-08	7.67e-06	0.31	0.25	Mean platelet volume;	chr5:122969314	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs30049	ENSG00000263432.2	RN7SL689P	5.7	2.13e-08	7.67e-06	0.31	0.25	Mean platelet volume;	chr5:122970402	chr5:123022487~123022783:-
LUAD	cis	rs755249	0.917	rs61781393	ENSG00000228060.1	RP11-69E11.8	-5.7	2.14e-08	7.69e-06	-0.26	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39622092	chr1:39565160~39573203:+
LUAD	cis	rs7714584	1	rs4958426	ENSG00000197083.10	ZNF300P1	5.7	2.14e-08	7.69e-06	0.54	0.25	Crohn's disease;	chr5:150898784	chr5:150930645~150946289:-
LUAD	cis	rs9652601	0.691	rs7203150	ENSG00000274038.1	RP11-66H6.4	-5.7	2.14e-08	7.7e-06	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11113865	chr16:11056556~11057034:+
LUAD	cis	rs1134634	0.52	rs11943107	ENSG00000273133.1	RP11-799M12.2	-5.7	2.14e-08	7.7e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15573042	chr4:15563698~15564253:-
LUAD	cis	rs1134634	0.52	rs4280724	ENSG00000273133.1	RP11-799M12.2	-5.7	2.14e-08	7.7e-06	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15574128	chr4:15563698~15564253:-
LUAD	cis	rs7829975	0.514	rs2920991	ENSG00000253893.2	FAM85B	-5.7	2.14e-08	7.7e-06	-0.31	-0.25	Mood instability;	chr8:8401607	chr8:8167819~8226614:-
LUAD	cis	rs6570726	0.935	rs406343	ENSG00000235652.6	RP11-545I5.3	5.7	2.14e-08	7.7e-06	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145553252	chr6:145799409~145886585:+
LUAD	cis	rs12908161	0.959	rs61074241	ENSG00000225151.9	GOLGA2P7	-5.7	2.14e-08	7.7e-06	-0.36	-0.25	Schizophrenia;	chr15:84790165	chr15:84199311~84230136:-
LUAD	cis	rs673078	0.66	rs17586342	ENSG00000275409.1	RP11-131L12.4	-5.7	2.14e-08	7.7e-06	-0.34	-0.25	Glucose homeostasis traits;	chr12:118162399	chr12:118430147~118430699:+
LUAD	cis	rs62246343	0.786	rs62246267	ENSG00000254485.4	RP11-380O24.1	5.7	2.14e-08	7.71e-06	0.37	0.25	Fibrinogen levels;	chr3:9361477	chr3:9292588~9363303:-
LUAD	cis	rs35740288	0.721	rs17637276	ENSG00000202081.1	RNU6-1280P	5.7	2.14e-08	7.71e-06	0.32	0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85700289	chr15:85651522~85651628:-
LUAD	cis	rs9309473	0.95	rs6546847	ENSG00000163016.8	ALMS1P	5.7	2.14e-08	7.71e-06	0.3	0.25	Metabolite levels;	chr2:73558231	chr2:73644919~73685576:+
LUAD	cis	rs9309473	0.898	rs7580750	ENSG00000163016.8	ALMS1P	5.7	2.14e-08	7.71e-06	0.3	0.25	Metabolite levels;	chr2:73560999	chr2:73644919~73685576:+
LUAD	cis	rs2288884	1	rs12609219	ENSG00000275055.1	CTC-471J1.11	-5.7	2.15e-08	7.72e-06	-0.4	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52077743	chr19:52049007~52049754:+
LUAD	cis	rs1707322	0.656	rs3014210	ENSG00000280836.1	AL355480.1	5.7	2.15e-08	7.72e-06	0.33	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45600936	chr1:45581219~45581321:-
LUAD	cis	rs55665837	0.701	rs10766188	ENSG00000251991.1	RNU7-49P	5.7	2.15e-08	7.72e-06	0.3	0.25	Vitamin D levels;	chr11:14639280	chr11:14478892~14478953:+
LUAD	cis	rs9595908	0.686	rs9596155	ENSG00000212293.1	SNORA16	5.7	2.15e-08	7.72e-06	0.27	0.25	Body mass index;	chr13:32724002	chr13:32420390~32420516:-
LUAD	cis	rs7615952	0.641	rs12487875	ENSG00000171084.14	FAM86JP	5.69	2.15e-08	7.73e-06	0.37	0.25	Blood pressure (smoking interaction);	chr3:126068381	chr3:125916620~125930024:+
LUAD	cis	rs4964805	0.77	rs11111779	ENSG00000257681.1	RP11-341G23.4	5.69	2.15e-08	7.74e-06	0.3	0.25	Attention deficit hyperactivity disorder;	chr12:103791718	chr12:103746315~103768858:-
LUAD	cis	rs9435732	1	rs9435732	ENSG00000235241.1	RP11-108M9.5	5.69	2.15e-08	7.74e-06	0.29	0.25	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16981663	chr1:16889095~16889602:+
LUAD	cis	rs10214930	0.781	rs974883	ENSG00000235574.1	AC073150.6	-5.69	2.16e-08	7.75e-06	-0.33	-0.25	Hypospadias;	chr7:27549115	chr7:27491682~27492765:-
LUAD	cis	rs380904	0.519	rs1377663	ENSG00000254859.1	RP11-661A12.5	-5.69	2.16e-08	7.78e-06	-0.39	-0.25	Venous thromboembolism (SNP x SNP interaction);	chr8:143562617	chr8:143541973~143549729:-
LUAD	cis	rs673078	0.562	rs4767672	ENSG00000275409.1	RP11-131L12.4	-5.69	2.17e-08	7.78e-06	-0.35	-0.25	Glucose homeostasis traits;	chr12:118397048	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs73205594	ENSG00000275409.1	RP11-131L12.4	-5.69	2.17e-08	7.78e-06	-0.35	-0.25	Glucose homeostasis traits;	chr12:118397168	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs61943400	ENSG00000275409.1	RP11-131L12.4	-5.69	2.17e-08	7.78e-06	-0.35	-0.25	Glucose homeostasis traits;	chr12:118398236	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs61943401	ENSG00000275409.1	RP11-131L12.4	-5.69	2.17e-08	7.78e-06	-0.35	-0.25	Glucose homeostasis traits;	chr12:118398527	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs61943402	ENSG00000275409.1	RP11-131L12.4	-5.69	2.17e-08	7.78e-06	-0.35	-0.25	Glucose homeostasis traits;	chr12:118398808	chr12:118430147~118430699:+
LUAD	cis	rs2276314	0.857	rs28791905	ENSG00000278986.1	RP11-723J4.3	-5.69	2.17e-08	7.78e-06	-0.31	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:36022250	chr18:35972151~35973916:+
LUAD	cis	rs2933343	1	rs1683782	ENSG00000261159.1	RP11-723O4.9	5.69	2.17e-08	7.78e-06	0.31	0.25	IgG glycosylation;	chr3:128921434	chr3:128859716~128860526:-
LUAD	cis	rs2933343	1	rs6785869	ENSG00000261159.1	RP11-723O4.9	5.69	2.17e-08	7.78e-06	0.31	0.25	IgG glycosylation;	chr3:128924301	chr3:128859716~128860526:-
LUAD	cis	rs2933343	1	rs1683778	ENSG00000261159.1	RP11-723O4.9	5.69	2.17e-08	7.78e-06	0.31	0.25	IgG glycosylation;	chr3:128925752	chr3:128859716~128860526:-
LUAD	cis	rs9813712	0.571	rs11715351	ENSG00000249846.5	RP11-77P16.4	-5.69	2.17e-08	7.78e-06	-0.29	-0.25	Response to amphetamines;	chr3:130214704	chr3:130112550~130120579:+
LUAD	cis	rs7772486	0.597	rs7746618	ENSG00000235652.6	RP11-545I5.3	-5.69	2.17e-08	7.78e-06	-0.27	-0.25	Lobe attachment (rater-scored or self-reported);	chr6:145960231	chr6:145799409~145886585:+
LUAD	cis	rs10129255	1	rs10129407	ENSG00000211974.3	IGHV2-70	5.69	2.17e-08	7.79e-06	0.26	0.25	Kawasaki disease;	chr14:106767956	chr14:106723574~106724093:-
LUAD	cis	rs7804306	0.826	rs73050951	ENSG00000233264.2	AC006042.8	5.69	2.17e-08	7.8e-06	0.51	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8032762	chr7:7980312~7982228:+
LUAD	cis	rs7804306	0.826	rs73050956	ENSG00000233264.2	AC006042.8	5.69	2.17e-08	7.8e-06	0.51	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8036076	chr7:7980312~7982228:+
LUAD	cis	rs7804306	0.826	rs73050958	ENSG00000233264.2	AC006042.8	5.69	2.17e-08	7.8e-06	0.51	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8036162	chr7:7980312~7982228:+
LUAD	cis	rs7804306	0.826	rs73050959	ENSG00000233264.2	AC006042.8	5.69	2.17e-08	7.8e-06	0.51	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8037069	chr7:7980312~7982228:+
LUAD	cis	rs7804306	0.826	rs73049270	ENSG00000233264.2	AC006042.8	5.69	2.17e-08	7.81e-06	0.5	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7982015	chr7:7980312~7982228:+
LUAD	cis	rs7804306	0.826	rs73049276	ENSG00000233264.2	AC006042.8	5.69	2.17e-08	7.81e-06	0.5	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7982385	chr7:7980312~7982228:+
LUAD	cis	rs875971	0.929	rs34406470	ENSG00000237310.1	GS1-124K5.4	5.69	2.18e-08	7.81e-06	0.27	0.25	Aortic root size;	chr7:66464969	chr7:66493706~66495474:+
LUAD	cis	rs17684571	0.7	rs35873865	ENSG00000231441.1	RP11-472M19.2	5.69	2.18e-08	7.81e-06	0.38	0.25	Schizophrenia;	chr6:56790203	chr6:56844002~56864078:+
LUAD	cis	rs10754283	0.967	rs10737706	ENSG00000231613.1	RP5-943J3.1	5.69	2.18e-08	7.82e-06	0.25	0.25	Amyotrophic lateral sclerosis (sporadic);	chr1:89647020	chr1:89788914~89790492:+
LUAD	cis	rs867371	0.964	rs7169961	ENSG00000259429.4	UBE2Q2P2	-5.69	2.18e-08	7.83e-06	-0.22	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186588	chr15:82355142~82420075:+
LUAD	cis	rs867371	1	rs6495643	ENSG00000259429.4	UBE2Q2P2	-5.69	2.18e-08	7.83e-06	-0.22	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186913	chr15:82355142~82420075:+
LUAD	cis	rs12554020	0.786	rs3893381	ENSG00000227603.1	RP11-165J3.6	-5.69	2.18e-08	7.83e-06	-0.46	-0.25	Schizophrenia;	chr9:93519576	chr9:93435332~93437121:-
LUAD	cis	rs1823913	0.503	rs34716486	ENSG00000280083.1	RP11-317J9.1	-5.69	2.18e-08	7.84e-06	-0.31	-0.25	Obesity-related traits;	chr2:191343335	chr2:191154118~191156070:-
LUAD	cis	rs1113500	0.933	rs10881497	ENSG00000226822.1	RP11-356N1.2	-5.69	2.18e-08	7.84e-06	-0.29	-0.25	Growth-regulated protein alpha levels;	chr1:108091893	chr1:108071482~108074519:+
LUAD	cis	rs673078	0.571	rs17440823	ENSG00000275409.1	RP11-131L12.4	-5.69	2.18e-08	7.84e-06	-0.35	-0.25	Glucose homeostasis traits;	chr12:118353023	chr12:118430147~118430699:+
LUAD	cis	rs1075265	0.933	rs7560947	ENSG00000233266.1	HMGB1P31	5.69	2.19e-08	7.84e-06	0.32	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54087473	chr2:54051334~54051760:+
LUAD	cis	rs5760092	0.755	rs4585126	ENSG00000099984.9	GSTT2	5.69	2.19e-08	7.86e-06	0.34	0.25	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23980123~23983911:+
LUAD	cis	rs10129255	0.5	rs4774189	ENSG00000211967.3	IGHV3-53	-5.69	2.19e-08	7.86e-06	-0.18	-0.25	Kawasaki disease;	chr14:106768275	chr14:106592676~106593347:-
LUAD	cis	rs2243480	1	rs906134	ENSG00000230295.1	RP11-458F8.2	-5.69	2.19e-08	7.86e-06	-0.31	-0.25	Diabetic kidney disease;	chr7:65979301	chr7:66880708~66882981:+
LUAD	cis	rs1799949	0.602	rs8176199	ENSG00000267681.1	CTD-3199J23.6	-5.69	2.19e-08	7.86e-06	-0.33	-0.25	Menopause (age at onset);	chr17:43078507	chr17:43144956~43145255:+
LUAD	cis	rs6772849	0.775	rs12486377	ENSG00000242551.2	POU5F1P6	-5.69	2.19e-08	7.86e-06	-0.3	-0.25	Monocyte percentage of white cells;Monocyte count;	chr3:128696010	chr3:128674735~128677005:-
LUAD	cis	rs2179367	0.632	rs11155642	ENSG00000231760.4	RP11-350J20.5	5.69	2.19e-08	7.87e-06	0.36	0.25	Dupuytren's disease;	chr6:149332984	chr6:149796151~149826294:-
LUAD	cis	rs7712401	0.601	rs30072	ENSG00000263432.2	RN7SL689P	5.69	2.19e-08	7.88e-06	0.31	0.25	Mean platelet volume;	chr5:122956525	chr5:123022487~123022783:-
LUAD	cis	rs2115630	0.691	rs2292462	ENSG00000229212.6	RP11-561C5.4	5.69	2.2e-08	7.88e-06	0.3	0.25	P wave terminal force;	chr15:84657523	chr15:85205440~85234795:-
LUAD	cis	rs8031584	0.541	rs2959037	ENSG00000270015.1	RP11-540B6.6	5.69	2.2e-08	7.88e-06	0.17	0.25	Huntington's disease progression;	chr15:30925961	chr15:30926514~30928407:+
LUAD	cis	rs2832077	1	rs12329875	ENSG00000232855.5	AF131217.1	5.69	2.2e-08	7.88e-06	0.28	0.25	Cognitive test performance;	chr21:28765474	chr21:28439346~28674848:-
LUAD	cis	rs113835537	0.529	rs3179961	ENSG00000255517.5	CTD-3074O7.5	-5.69	2.2e-08	7.89e-06	-0.3	-0.25	Airway imaging phenotypes;	chr11:66476983	chr11:66473490~66480233:-
LUAD	cis	rs1707322	0.927	rs6690386	ENSG00000234329.1	RP11-767N6.2	5.69	2.2e-08	7.89e-06	0.27	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45787339	chr1:45651039~45651826:-
LUAD	cis	rs2404602	0.716	rs1946650	ENSG00000259422.1	RP11-593F23.1	5.69	2.2e-08	7.89e-06	0.29	0.25	Blood metabolite levels;	chr15:76556122	chr15:76174891~76181486:-
LUAD	cis	rs7923609	0.87	rs10822156	ENSG00000232075.1	MRPL35P2	-5.69	2.2e-08	7.89e-06	-0.31	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63320967	chr10:63634317~63634827:-
LUAD	cis	rs925255	0.817	rs7606480	ENSG00000270210.1	RP11-373D23.3	-5.69	2.2e-08	7.89e-06	-0.3	-0.25	Inflammatory bowel disease;Crohn's disease;	chr2:28409510	chr2:28425945~28426719:+
LUAD	cis	rs10214930	0.813	rs9639559	ENSG00000235574.1	AC073150.6	-5.69	2.2e-08	7.9e-06	-0.33	-0.25	Hypospadias;	chr7:27565876	chr7:27491682~27492765:-
LUAD	cis	rs7617773	0.78	rs13084616	ENSG00000228638.1	FCF1P2	5.69	2.2e-08	7.9e-06	0.3	0.25	Coronary artery disease;	chr3:48298209	chr3:48290793~48291375:-
LUAD	cis	rs875971	1	rs7792762	ENSG00000237310.1	GS1-124K5.4	5.69	2.2e-08	7.9e-06	0.27	0.25	Aortic root size;	chr7:66539151	chr7:66493706~66495474:+
LUAD	cis	rs9652601	0.622	rs2286974	ENSG00000274038.1	RP11-66H6.4	-5.69	2.2e-08	7.9e-06	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11020655	chr16:11056556~11057034:+
LUAD	cis	rs12468226	0.817	rs6722588	ENSG00000226261.1	AC064836.3	-5.69	2.21e-08	7.91e-06	-0.41	-0.25	Urate levels;	chr2:202187163	chr2:202336024~202336727:-
LUAD	cis	rs17684571	0.7	rs17684802	ENSG00000231441.1	RP11-472M19.2	-5.69	2.21e-08	7.91e-06	-0.36	-0.25	Schizophrenia;	chr6:56813854	chr6:56844002~56864078:+
LUAD	cis	rs1113500	0.548	rs9970655	ENSG00000226822.1	RP11-356N1.2	5.69	2.21e-08	7.92e-06	0.34	0.25	Growth-regulated protein alpha levels;	chr1:108100915	chr1:108071482~108074519:+
LUAD	cis	rs867371	0.502	rs3759800	ENSG00000278603.1	RP13-608F4.5	-5.69	2.21e-08	7.92e-06	-0.28	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82240622	chr15:82472203~82472426:+
LUAD	cis	rs748404	0.666	rs66629206	ENSG00000205771.5	CATSPER2P1	-5.69	2.21e-08	7.92e-06	-0.38	-0.25	Lung cancer;	chr15:43458804	chr15:43726918~43747094:-
LUAD	cis	rs944289	0.576	rs1169140	ENSG00000257826.1	RP11-116N8.4	-5.69	2.21e-08	7.93e-06	-0.28	-0.25	Thyroid cancer;	chr14:36159160	chr14:36061026~36067190:-
LUAD	cis	rs9992667	0.868	rs113071828	ENSG00000231160.8	KLF3-AS1	5.69	2.21e-08	7.94e-06	0.32	0.25	Eosinophil percentage of granulocytes;	chr4:38664197	chr4:38612701~38664883:-
LUAD	cis	rs4908768	0.539	rs2100888	ENSG00000232912.4	RP5-1115A15.1	5.69	2.22e-08	7.95e-06	0.23	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8599223	chr1:8424645~8434838:+
LUAD	cis	rs9992667	0.955	rs7654470	ENSG00000231160.8	KLF3-AS1	5.69	2.22e-08	7.95e-06	0.32	0.25	Eosinophil percentage of granulocytes;	chr4:38634608	chr4:38612701~38664883:-
LUAD	cis	rs897984	0.572	rs4889526	ENSG00000260911.2	RP11-196G11.2	5.69	2.22e-08	7.96e-06	0.23	0.25	Dementia with Lewy bodies;	chr16:31019023	chr16:31043150~31049868:+
LUAD	cis	rs1426063	0.614	rs17000262	ENSG00000249717.1	RP11-44F21.3	5.69	2.22e-08	7.96e-06	0.45	0.25	QT interval;	chr4:75108836	chr4:74955974~74970362:-
LUAD	cis	rs957448	1	rs957447	ENSG00000253704.1	RP11-267M23.4	5.69	2.22e-08	7.97e-06	0.32	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94528995	chr8:94553722~94569745:+
LUAD	cis	rs957448	1	rs72674852	ENSG00000253704.1	RP11-267M23.4	5.69	2.22e-08	7.97e-06	0.32	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94536523	chr8:94553722~94569745:+
LUAD	cis	rs867371	1	rs8041924	ENSG00000259429.4	UBE2Q2P2	-5.69	2.22e-08	7.97e-06	-0.22	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82181320	chr15:82355142~82420075:+
LUAD	cis	rs17301853	1	rs17301853	ENSG00000227373.4	RP11-160H22.5	5.69	2.22e-08	7.97e-06	0.5	0.25	Migraine without aura;Migraine - clinic-based;	chr1:174583673	chr1:174115300~174160004:-
LUAD	cis	rs2243480	1	rs316329	ENSG00000230295.1	RP11-458F8.2	-5.69	2.23e-08	7.98e-06	-0.3	-0.25	Diabetic kidney disease;	chr7:66143429	chr7:66880708~66882981:+
LUAD	cis	rs10515750	0.643	rs10054755	ENSG00000251405.2	CTB-109A12.1	5.69	2.23e-08	7.98e-06	0.45	0.25	Lung function (FEV1/FVC);	chr5:157384037	chr5:157362615~157460078:-
LUAD	cis	rs875971	0.862	rs1875057	ENSG00000222364.1	RNU6-96P	5.69	2.23e-08	7.99e-06	0.28	0.25	Aortic root size;	chr7:66266868	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs6960446	ENSG00000222364.1	RNU6-96P	5.69	2.23e-08	7.99e-06	0.28	0.25	Aortic root size;	chr7:66268272	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.789	rs10260426	ENSG00000222364.1	RNU6-96P	5.69	2.23e-08	7.99e-06	0.28	0.25	Aortic root size;	chr7:66271055	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.862	rs7796162	ENSG00000222364.1	RNU6-96P	5.69	2.23e-08	7.99e-06	0.28	0.25	Aortic root size;	chr7:66280771	chr7:66395191~66395286:+
LUAD	cis	rs4964805	0.626	rs11111771	ENSG00000257681.1	RP11-341G23.4	-5.69	2.23e-08	7.99e-06	-0.3	-0.25	Attention deficit hyperactivity disorder;	chr12:103785493	chr12:103746315~103768858:-
LUAD	cis	rs7208859	0.623	rs8075163	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30729469~30731202:+
LUAD	cis	rs17826219	0.706	rs8075107	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Body mass index;	chr17:30779631	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs7223209	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs7223404	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs9916725	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs9916727	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs73269945	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs9897728	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs1054400	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs1054397	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs9890558	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs3752020	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs9890855	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs9893422	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs9891166	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs73269974	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs34756112	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.573	rs60724269	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs76633166	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs1061346	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs1061343	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs73269988	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs9899525	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs9911784	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs9911997	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs9890862	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs78071511	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs2035494	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs9915566	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.573	rs8064686	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs11657369	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs8075341	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs73271842	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.524	rs28760584	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs7212991	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs28627615	ENSG00000263603.1	CTD-2349P21.5	-5.69	2.23e-08	8e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30729469~30731202:+
LUAD	cis	rs4908768	0.501	rs11121194	ENSG00000232912.4	RP5-1115A15.1	5.69	2.23e-08	8e-06	0.23	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8509847	chr1:8424645~8434838:+
LUAD	cis	rs2337406	0.925	rs2011167	ENSG00000211974.3	IGHV2-70	-5.69	2.23e-08	8e-06	-0.34	-0.25	Alzheimer's disease (late onset);	chr14:106680831	chr14:106723574~106724093:-
LUAD	cis	rs9859260	0.744	rs3933	ENSG00000231464.1	AC024937.4	-5.69	2.23e-08	8e-06	-0.29	-0.25	Mean corpuscular volume;	chr3:196058126	chr3:195996738~195998233:+
LUAD	cis	rs10740039	0.516	rs2893840	ENSG00000254271.1	RP11-131N11.4	5.69	2.24e-08	8e-06	0.28	0.25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60554257	chr10:60734342~60741828:+
LUAD	cis	rs875971	1	rs7801282	ENSG00000237310.1	GS1-124K5.4	-5.69	2.24e-08	8.02e-06	-0.27	-0.25	Aortic root size;	chr7:66148700	chr7:66493706~66495474:+
LUAD	cis	rs9487094	0.961	rs1358998	ENSG00000260273.1	RP11-425D10.10	-5.69	2.24e-08	8.02e-06	-0.33	-0.25	Height;	chr6:109380015	chr6:109382795~109383666:+
LUAD	cis	rs16863064	0.932	rs9817667	ENSG00000279891.1	FLJ42393	5.69	2.24e-08	8.03e-06	0.36	0.25	Schizophrenia;	chr3:188169906	chr3:188178543~188180812:+
LUAD	cis	rs9928842	0.54	rs8051363	ENSG00000280152.1	RP11-331F4.5	5.69	2.24e-08	8.03e-06	0.24	0.25	Alcoholic chronic pancreatitis;	chr16:75221319	chr16:75245994~75250077:-
LUAD	cis	rs957448	1	rs16916874	ENSG00000253704.1	RP11-267M23.4	5.69	2.24e-08	8.03e-06	0.32	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94537749	chr8:94553722~94569745:+
LUAD	cis	rs17301853	0.818	rs78923809	ENSG00000227373.4	RP11-160H22.5	5.69	2.24e-08	8.03e-06	0.5	0.25	Migraine without aura;Migraine - clinic-based;	chr1:174616446	chr1:174115300~174160004:-
LUAD	cis	rs1075265	0.756	rs698854	ENSG00000233266.1	HMGB1P31	5.69	2.25e-08	8.05e-06	0.32	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53826784	chr2:54051334~54051760:+
LUAD	cis	rs1113500	1	rs1113500	ENSG00000226822.1	RP11-356N1.2	-5.69	2.25e-08	8.05e-06	-0.29	-0.25	Growth-regulated protein alpha levels;	chr1:108052820	chr1:108071482~108074519:+
LUAD	cis	rs35740288	0.731	rs12913556	ENSG00000202081.1	RNU6-1280P	5.69	2.25e-08	8.06e-06	0.31	0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85558965	chr15:85651522~85651628:-
LUAD	cis	rs35934224	0.783	rs7290770	ENSG00000232926.1	AC000078.5	5.69	2.25e-08	8.06e-06	0.3	0.25	Glaucoma (primary open-angle);	chr22:19873638	chr22:19887289~19887970:+
LUAD	cis	rs6570726	0.599	rs9376951	ENSG00000235652.6	RP11-545I5.3	5.69	2.25e-08	8.07e-06	0.26	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145577775	chr6:145799409~145886585:+
LUAD	cis	rs2749097	1	rs2749096	ENSG00000244256.3	RN7SL130P	-5.69	2.25e-08	8.07e-06	-0.36	-0.25	Alcohol consumption (transferrin glycosylation);	chr1:63661991	chr1:63655743~63656047:+
LUAD	cis	rs2412819	0.545	rs35822148	ENSG00000249839.1	AC011330.5	-5.69	2.26e-08	8.09e-06	-0.44	-0.25	Lung cancer;	chr15:43808084	chr15:43663654~43684339:-
LUAD	cis	rs12554020	0.892	rs16909273	ENSG00000227603.1	RP11-165J3.6	5.69	2.26e-08	8.09e-06	0.47	0.25	Schizophrenia;	chr9:93532820	chr9:93435332~93437121:-
LUAD	cis	rs10214930	1	rs4481475	ENSG00000235574.1	AC073150.6	-5.69	2.26e-08	8.09e-06	-0.35	-0.25	Hypospadias;	chr7:27731902	chr7:27491682~27492765:-
LUAD	cis	rs7923609	0.936	rs10822160	ENSG00000232075.1	MRPL35P2	-5.69	2.26e-08	8.1e-06	-0.3	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63353036	chr10:63634317~63634827:-
LUAD	cis	rs2933343	0.951	rs789217	ENSG00000261159.1	RP11-723O4.9	5.69	2.27e-08	8.12e-06	0.3	0.25	IgG glycosylation;	chr3:128874358	chr3:128859716~128860526:-
LUAD	cis	rs10129255	0.957	rs10141009	ENSG00000211972.2	IGHV3-66	5.69	2.27e-08	8.12e-06	0.21	0.25	Kawasaki disease;	chr14:106776695	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.912	rs6576227	ENSG00000211972.2	IGHV3-66	5.69	2.27e-08	8.12e-06	0.21	0.25	Kawasaki disease;	chr14:106778202	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.957	rs6576228	ENSG00000211972.2	IGHV3-66	5.69	2.27e-08	8.12e-06	0.21	0.25	Kawasaki disease;	chr14:106778401	chr14:106675017~106675544:-
LUAD	cis	rs4908768	0.501	rs6577499	ENSG00000232912.4	RP5-1115A15.1	-5.69	2.27e-08	8.12e-06	-0.23	-0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8552045	chr1:8424645~8434838:+
LUAD	cis	rs1113500	0.933	rs11185261	ENSG00000226822.1	RP11-356N1.2	5.68	2.27e-08	8.13e-06	0.29	0.25	Growth-regulated protein alpha levels;	chr1:108096081	chr1:108071482~108074519:+
LUAD	cis	rs1113500	0.897	rs4628530	ENSG00000226822.1	RP11-356N1.2	5.68	2.27e-08	8.13e-06	0.29	0.25	Growth-regulated protein alpha levels;	chr1:108096086	chr1:108071482~108074519:+
LUAD	cis	rs6687821	0.515	rs4484904	ENSG00000267734.1	RP4-604K5.3	-5.68	2.27e-08	8.14e-06	-0.31	-0.25	Yeast infection;	chr1:87048234	chr1:86932199~86934891:-
LUAD	cis	rs875971	1	rs6460296	ENSG00000237310.1	GS1-124K5.4	5.68	2.28e-08	8.15e-06	0.27	0.25	Aortic root size;	chr7:66430152	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs4717292	ENSG00000237310.1	GS1-124K5.4	5.68	2.28e-08	8.15e-06	0.27	0.25	Aortic root size;	chr7:66430611	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.895	rs4718349	ENSG00000237310.1	GS1-124K5.4	5.68	2.28e-08	8.15e-06	0.27	0.25	Aortic root size;	chr7:66444024	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs2420591	ENSG00000237310.1	GS1-124K5.4	5.68	2.28e-08	8.15e-06	0.27	0.25	Aortic root size;	chr7:66447394	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.895	rs10755833	ENSG00000237310.1	GS1-124K5.4	5.68	2.28e-08	8.15e-06	0.27	0.25	Aortic root size;	chr7:66448930	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.964	rs12668936	ENSG00000237310.1	GS1-124K5.4	5.68	2.28e-08	8.15e-06	0.27	0.25	Aortic root size;	chr7:66449417	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.895	rs1833495	ENSG00000237310.1	GS1-124K5.4	5.68	2.28e-08	8.15e-06	0.27	0.25	Aortic root size;	chr7:66456608	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.964	rs6945032	ENSG00000237310.1	GS1-124K5.4	5.68	2.28e-08	8.15e-06	0.27	0.25	Aortic root size;	chr7:66457499	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.929	rs12673810	ENSG00000237310.1	GS1-124K5.4	5.68	2.28e-08	8.15e-06	0.27	0.25	Aortic root size;	chr7:66458866	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs2042133	ENSG00000237310.1	GS1-124K5.4	5.68	2.28e-08	8.15e-06	0.27	0.25	Aortic root size;	chr7:66466935	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.964	rs2161065	ENSG00000237310.1	GS1-124K5.4	5.68	2.28e-08	8.15e-06	0.27	0.25	Aortic root size;	chr7:66467918	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs6961155	ENSG00000237310.1	GS1-124K5.4	5.68	2.28e-08	8.15e-06	0.27	0.25	Aortic root size;	chr7:66468308	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.895	rs3857684	ENSG00000237310.1	GS1-124K5.4	5.68	2.28e-08	8.15e-06	0.27	0.25	Aortic root size;	chr7:66473171	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs7789768	ENSG00000237310.1	GS1-124K5.4	5.68	2.28e-08	8.15e-06	0.27	0.25	Aortic root size;	chr7:66473993	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs12698521	ENSG00000237310.1	GS1-124K5.4	5.68	2.28e-08	8.15e-06	0.27	0.25	Aortic root size;	chr7:66474502	chr7:66493706~66495474:+
LUAD	cis	rs2243480	1	rs7804223	ENSG00000230295.1	RP11-458F8.2	5.68	2.28e-08	8.15e-06	0.3	0.25	Diabetic kidney disease;	chr7:66199572	chr7:66880708~66882981:+
LUAD	cis	rs2562456	0.92	rs2650784	ENSG00000268081.1	RP11-678G14.2	-5.68	2.28e-08	8.16e-06	-0.37	-0.25	Pain;	chr19:21483795	chr19:21554640~21569237:-
LUAD	cis	rs7712401	0.601	rs418562	ENSG00000263432.2	RN7SL689P	-5.68	2.28e-08	8.16e-06	-0.31	-0.25	Mean platelet volume;	chr5:123004567	chr5:123022487~123022783:-
LUAD	cis	rs4908768	0.539	rs6663123	ENSG00000232912.4	RP5-1115A15.1	5.68	2.28e-08	8.17e-06	0.23	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8582872	chr1:8424645~8434838:+
LUAD	cis	rs9807989	0.708	rs6543124	ENSG00000234389.1	AC007278.3	5.68	2.28e-08	8.17e-06	0.24	0.25	Asthma;	chr2:102370999	chr2:102438713~102440475:+
LUAD	cis	rs3002131	0.736	rs2936027	ENSG00000225265.1	TAF1A-AS1	-5.68	2.28e-08	8.17e-06	-0.39	-0.25	Interleukin-10 levels;	chr1:222588974	chr1:222589825~222593032:+
LUAD	cis	rs2243480	1	rs1796220	ENSG00000230295.1	RP11-458F8.2	-5.68	2.29e-08	8.18e-06	-0.31	-0.25	Diabetic kidney disease;	chr7:66597113	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs2707831	ENSG00000230295.1	RP11-458F8.2	-5.68	2.29e-08	8.18e-06	-0.31	-0.25	Diabetic kidney disease;	chr7:66597524	chr7:66880708~66882981:+
LUAD	cis	rs7208859	0.524	rs11653098	ENSG00000263603.1	CTD-2349P21.5	-5.68	2.29e-08	8.18e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30729469~30731202:+
LUAD	cis	rs55665837	0.701	rs11023272	ENSG00000251991.1	RNU7-49P	5.68	2.29e-08	8.18e-06	0.29	0.25	Vitamin D levels;	chr11:14608824	chr11:14478892~14478953:+
LUAD	cis	rs66887589	0.66	rs4833613	ENSG00000248280.1	RP11-33B1.2	-5.68	2.29e-08	8.18e-06	-0.29	-0.25	Diastolic blood pressure;	chr4:119229001	chr4:119440561~119450157:-
LUAD	cis	rs30380	0.632	rs26489	ENSG00000272109.1	CTD-2260A17.3	-5.68	2.29e-08	8.19e-06	-0.3	-0.25	Cerebrospinal fluid biomarker levels;	chr5:96797724	chr5:96804353~96806105:+
LUAD	cis	rs673078	0.607	rs55929628	ENSG00000275409.1	RP11-131L12.4	-5.68	2.29e-08	8.19e-06	-0.37	-0.25	Glucose homeostasis traits;	chr12:118371332	chr12:118430147~118430699:+
LUAD	cis	rs1707322	1	rs3922887	ENSG00000234329.1	RP11-767N6.2	5.68	2.29e-08	8.19e-06	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008130	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs3922886	ENSG00000234329.1	RP11-767N6.2	5.68	2.29e-08	8.19e-06	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008230	chr1:45651039~45651826:-
LUAD	cis	rs801193	0.591	rs9986881	ENSG00000224316.1	RP11-479O9.2	5.68	2.29e-08	8.2e-06	0.25	0.25	Aortic root size;	chr7:66708053	chr7:65773620~65802067:+
LUAD	cis	rs875971	0.798	rs57739047	ENSG00000237310.1	GS1-124K5.4	5.68	2.3e-08	8.21e-06	0.28	0.25	Aortic root size;	chr7:66507579	chr7:66493706~66495474:+
LUAD	cis	rs7829975	0.514	rs2976929	ENSG00000253893.2	FAM85B	-5.68	2.3e-08	8.22e-06	-0.32	-0.25	Mood instability;	chr8:8401202	chr8:8167819~8226614:-
LUAD	cis	rs1318937	0.764	rs9864422	ENSG00000224660.1	SH3BP5-AS1	5.68	2.3e-08	8.23e-06	0.2	0.25	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15185745	chr3:15254184~15264493:+
LUAD	cis	rs55665837	0.701	rs11023278	ENSG00000251991.1	RNU7-49P	5.68	2.31e-08	8.24e-06	0.29	0.25	Vitamin D levels;	chr11:14619638	chr11:14478892~14478953:+
LUAD	cis	rs7712401	0.601	rs246321	ENSG00000263432.2	RN7SL689P	5.68	2.31e-08	8.25e-06	0.31	0.25	Mean platelet volume;	chr5:122972604	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs246320	ENSG00000263432.2	RN7SL689P	5.68	2.31e-08	8.25e-06	0.31	0.25	Mean platelet volume;	chr5:122972886	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.645	rs246316	ENSG00000263432.2	RN7SL689P	5.68	2.31e-08	8.25e-06	0.31	0.25	Mean platelet volume;	chr5:122930502	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs246315	ENSG00000263432.2	RN7SL689P	5.68	2.31e-08	8.25e-06	0.31	0.25	Mean platelet volume;	chr5:122930743	chr5:123022487~123022783:-
LUAD	cis	rs7927592	0.956	rs11228278	ENSG00000212093.1	AP000807.1	5.68	2.31e-08	8.26e-06	0.27	0.25	Total body bone mineral density;	chr11:68541062	chr11:68506083~68506166:-
LUAD	cis	rs3931020	0.657	rs7522428	ENSG00000272864.1	RP11-17E13.2	-5.68	2.32e-08	8.28e-06	-0.36	-0.25	Resistin levels;	chr1:74712676	chr1:74698769~74699333:-
LUAD	cis	rs875971	1	rs35149210	ENSG00000237310.1	GS1-124K5.4	5.68	2.32e-08	8.3e-06	0.27	0.25	Aortic root size;	chr7:66464938	chr7:66493706~66495474:+
LUAD	cis	rs7712401	0.601	rs193539	ENSG00000263432.2	RN7SL689P	5.68	2.32e-08	8.3e-06	0.31	0.25	Mean platelet volume;	chr5:122921922	chr5:123022487~123022783:-
LUAD	cis	rs957448	1	rs12543207	ENSG00000253704.1	RP11-267M23.4	5.68	2.32e-08	8.3e-06	0.32	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94485202	chr8:94553722~94569745:+
LUAD	cis	rs11105298	0.891	rs8181784	ENSG00000258302.2	RP11-981P6.1	5.68	2.33e-08	8.31e-06	0.3	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89434814	chr12:89561129~89594878:+
LUAD	cis	rs2212361	0.529	rs11020821	ENSG00000255893.1	RP11-685N10.1	-5.68	2.33e-08	8.32e-06	-0.33	-0.25	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94538497	chr11:94472908~94473570:-
LUAD	cis	rs9595908	0.709	rs3492	ENSG00000212293.1	SNORA16	5.68	2.33e-08	8.32e-06	0.27	0.25	Body mass index;	chr13:32775203	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.709	rs7326102	ENSG00000212293.1	SNORA16	5.68	2.33e-08	8.32e-06	0.27	0.25	Body mass index;	chr13:32777857	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.669	rs17516561	ENSG00000212293.1	SNORA16	5.68	2.33e-08	8.32e-06	0.27	0.25	Body mass index;	chr13:32782063	chr13:32420390~32420516:-
LUAD	cis	rs673078	0.607	rs61943392	ENSG00000275409.1	RP11-131L12.4	-5.68	2.33e-08	8.32e-06	-0.35	-0.25	Glucose homeostasis traits;	chr12:118382618	chr12:118430147~118430699:+
LUAD	cis	rs807029	0.533	rs722435	ENSG00000272572.1	RP11-179B2.2	-5.68	2.33e-08	8.34e-06	-0.36	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100985305	chr10:100911103~100912739:-
LUAD	cis	rs748404	0.666	rs60018990	ENSG00000205771.5	CATSPER2P1	-5.68	2.34e-08	8.35e-06	-0.38	-0.25	Lung cancer;	chr15:43504606	chr15:43726918~43747094:-
LUAD	cis	rs2998286	0.774	rs2790442	ENSG00000254635.4	WAC-AS1	-5.68	2.34e-08	8.35e-06	-0.36	-0.25	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28539597	chr10:28522652~28532743:-
LUAD	cis	rs2998286	0.678	rs2807758	ENSG00000254635.4	WAC-AS1	-5.68	2.34e-08	8.35e-06	-0.36	-0.25	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28549643	chr10:28522652~28532743:-
LUAD	cis	rs2404602	0.532	rs12591100	ENSG00000259422.1	RP11-593F23.1	-5.68	2.34e-08	8.36e-06	-0.29	-0.25	Blood metabolite levels;	chr15:76408460	chr15:76174891~76181486:-
LUAD	cis	rs9807989	0.801	rs6752482	ENSG00000234389.1	AC007278.3	5.68	2.34e-08	8.37e-06	0.24	0.25	Asthma;	chr2:102351398	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.839	rs4988956	ENSG00000234389.1	AC007278.3	5.68	2.34e-08	8.37e-06	0.24	0.25	Asthma;	chr2:102351547	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.839	rs10192036	ENSG00000234389.1	AC007278.3	5.68	2.34e-08	8.37e-06	0.24	0.25	Asthma;	chr2:102351751	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.839	rs10204137	ENSG00000234389.1	AC007278.3	5.68	2.34e-08	8.37e-06	0.24	0.25	Asthma;	chr2:102351752	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.839	rs4988958	ENSG00000234389.1	AC007278.3	5.68	2.34e-08	8.37e-06	0.24	0.25	Asthma;	chr2:102351825	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.839	rs10192157	ENSG00000234389.1	AC007278.3	5.68	2.34e-08	8.37e-06	0.24	0.25	Asthma;	chr2:102351896	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.839	rs10206753	ENSG00000234389.1	AC007278.3	5.68	2.34e-08	8.37e-06	0.24	0.25	Asthma;	chr2:102351902	chr2:102438713~102440475:+
LUAD	cis	rs9992667	0.955	rs1000571	ENSG00000231160.8	KLF3-AS1	5.68	2.35e-08	8.37e-06	0.32	0.25	Eosinophil percentage of granulocytes;	chr4:38661274	chr4:38612701~38664883:-
LUAD	cis	rs9992667	0.955	rs12507197	ENSG00000231160.8	KLF3-AS1	5.68	2.35e-08	8.37e-06	0.32	0.25	Eosinophil percentage of granulocytes;	chr4:38662039	chr4:38612701~38664883:-
LUAD	cis	rs9992667	0.955	rs60029573	ENSG00000231160.8	KLF3-AS1	5.68	2.35e-08	8.37e-06	0.32	0.25	Eosinophil percentage of granulocytes;	chr4:38662242	chr4:38612701~38664883:-
LUAD	cis	rs801193	1	rs2659915	ENSG00000237310.1	GS1-124K5.4	5.68	2.35e-08	8.37e-06	0.27	0.25	Aortic root size;	chr7:66688114	chr7:66493706~66495474:+
LUAD	cis	rs73219805	1	rs73217798	ENSG00000228451.3	SDAD1P1	-5.68	2.35e-08	8.38e-06	-0.38	-0.25	Schizophrenia;	chr8:26406847	chr8:26379259~26382953:-
LUAD	cis	rs11105298	0.891	rs1054807	ENSG00000258302.2	RP11-981P6.1	5.68	2.35e-08	8.38e-06	0.32	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89519642	chr12:89561129~89594878:+
LUAD	cis	rs2919009	0.607	rs2919007	ENSG00000271670.1	RP11-95I16.4	5.68	2.35e-08	8.39e-06	0.33	0.25	Obesity-related traits;	chr10:120842499	chr10:120879256~120880667:-
LUAD	cis	rs11105298	0.891	rs10858898	ENSG00000258302.2	RP11-981P6.1	5.68	2.35e-08	8.4e-06	0.32	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89528334	chr12:89561129~89594878:+
LUAD	cis	rs12699921	0.632	rs2723497	ENSG00000279048.1	RP11-511H23.2	-5.68	2.35e-08	8.4e-06	-0.2	-0.25	Fibrinogen levels;	chr7:17786204	chr7:17940503~17942922:+
LUAD	cis	rs35160687	0.712	rs2303358	ENSG00000273080.1	RP11-301O19.1	-5.68	2.36e-08	8.4e-06	-0.28	-0.25	Night sleep phenotypes;	chr2:86251541	chr2:86195590~86196049:+
LUAD	cis	rs667920	0.573	rs9682783	ENSG00000239213.4	NCK1-AS1	5.68	2.36e-08	8.41e-06	0.31	0.25	Coronary artery disease;	chr3:136820847	chr3:136841726~136862054:-
LUAD	cis	rs1113500	0.933	rs4593854	ENSG00000226822.1	RP11-356N1.2	5.68	2.36e-08	8.41e-06	0.29	0.25	Growth-regulated protein alpha levels;	chr1:108095897	chr1:108071482~108074519:+
LUAD	cis	rs7621025	0.5	rs9845460	ENSG00000239213.4	NCK1-AS1	5.68	2.36e-08	8.41e-06	0.31	0.25	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136868275	chr3:136841726~136862054:-
LUAD	cis	rs7208859	0.623	rs9912283	ENSG00000263603.1	CTD-2349P21.5	-5.68	2.36e-08	8.42e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30729469~30731202:+
LUAD	cis	rs4835473	0.9	rs13119630	ENSG00000251600.4	RP11-673E1.1	-5.68	2.36e-08	8.42e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143773901	chr4:143912331~143982454:+
LUAD	cis	rs1707322	1	rs6661500	ENSG00000234329.1	RP11-767N6.2	5.68	2.36e-08	8.42e-06	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45999990	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs4660883	ENSG00000234329.1	RP11-767N6.2	5.68	2.36e-08	8.42e-06	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45770426	chr1:45651039~45651826:-
LUAD	cis	rs1113500	0.565	rs1781071	ENSG00000226822.1	RP11-356N1.2	5.68	2.36e-08	8.42e-06	0.32	0.25	Growth-regulated protein alpha levels;	chr1:108028412	chr1:108071482~108074519:+
LUAD	cis	rs3931020	0.657	rs10890142	ENSG00000272864.1	RP11-17E13.2	-5.68	2.36e-08	8.42e-06	-0.36	-0.25	Resistin levels;	chr1:74713445	chr1:74698769~74699333:-
LUAD	cis	rs17214007	0.597	rs11649126	ENSG00000263335.1	AF001548.5	-5.68	2.36e-08	8.43e-06	-0.37	-0.25	Cognitive function;	chr16:15626390	chr16:15726674~15732993:+
LUAD	cis	rs9309473	0.606	rs6759452	ENSG00000163016.8	ALMS1P	5.68	2.36e-08	8.43e-06	0.38	0.25	Metabolite levels;	chr2:73651225	chr2:73644919~73685576:+
LUAD	cis	rs2832077	1	rs2832065	ENSG00000232855.5	AF131217.1	5.68	2.36e-08	8.43e-06	0.28	0.25	Cognitive test performance;	chr21:28763040	chr21:28439346~28674848:-
LUAD	cis	rs2749097	1	rs11208268	ENSG00000244256.3	RN7SL130P	-5.68	2.36e-08	8.43e-06	-0.36	-0.25	Alcohol consumption (transferrin glycosylation);	chr1:63672553	chr1:63655743~63656047:+
LUAD	cis	rs875971	0.798	rs6460304	ENSG00000237310.1	GS1-124K5.4	5.68	2.37e-08	8.44e-06	0.28	0.25	Aortic root size;	chr7:66499741	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs6945775	ENSG00000237310.1	GS1-124K5.4	5.68	2.37e-08	8.44e-06	0.28	0.25	Aortic root size;	chr7:66503987	chr7:66493706~66495474:+
LUAD	cis	rs7250849	1	rs7250849	ENSG00000273837.1	LLNLR-470E3.1	5.68	2.37e-08	8.44e-06	0.41	0.25	Blood protein levels;	chr19:51655063	chr19:51639478~51639931:-
LUAD	cis	rs1426063	0.614	rs75345649	ENSG00000249717.1	RP11-44F21.3	5.68	2.37e-08	8.44e-06	0.47	0.25	QT interval;	chr4:75100963	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.614	rs77333523	ENSG00000249717.1	RP11-44F21.3	5.68	2.37e-08	8.44e-06	0.47	0.25	QT interval;	chr4:75101024	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.614	rs17199632	ENSG00000249717.1	RP11-44F21.3	5.68	2.37e-08	8.44e-06	0.47	0.25	QT interval;	chr4:75103663	chr4:74955974~74970362:-
LUAD	cis	rs2179367	0.543	rs9498328	ENSG00000231760.4	RP11-350J20.5	5.68	2.37e-08	8.45e-06	0.35	0.25	Dupuytren's disease;	chr6:149348715	chr6:149796151~149826294:-
LUAD	cis	rs4947019	0.609	rs79097132	ENSG00000260273.1	RP11-425D10.10	5.68	2.37e-08	8.46e-06	0.55	0.25	Hematological parameters;	chr6:109404619	chr6:109382795~109383666:+
LUAD	cis	rs7083	0.935	rs523366	ENSG00000254851.1	RP11-109L13.1	5.68	2.37e-08	8.46e-06	0.32	0.25	Blood protein levels;	chr11:117248836	chr11:117135528~117138582:+
LUAD	cis	rs944289	0.576	rs10150608	ENSG00000257826.1	RP11-116N8.4	-5.68	2.38e-08	8.47e-06	-0.28	-0.25	Thyroid cancer;	chr14:36142221	chr14:36061026~36067190:-
LUAD	cis	rs4835473	0.801	rs35839125	ENSG00000251600.4	RP11-673E1.1	-5.68	2.38e-08	8.48e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143792351	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.75	rs12498381	ENSG00000251600.4	RP11-673E1.1	-5.68	2.38e-08	8.48e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143793928	chr4:143912331~143982454:+
LUAD	cis	rs7712401	0.601	rs30022	ENSG00000263432.2	RN7SL689P	5.68	2.38e-08	8.48e-06	0.31	0.25	Mean platelet volume;	chr5:122950021	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.546	rs30021	ENSG00000263432.2	RN7SL689P	5.68	2.38e-08	8.48e-06	0.31	0.25	Mean platelet volume;	chr5:122950199	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs246328	ENSG00000263432.2	RN7SL689P	5.68	2.38e-08	8.48e-06	0.31	0.25	Mean platelet volume;	chr5:122951933	chr5:123022487~123022783:-
LUAD	cis	rs9828933	0.938	rs2578011	ENSG00000280620.1	SCAANT1	5.68	2.38e-08	8.49e-06	0.36	0.25	Type 2 diabetes;	chr3:64019143	chr3:63911518~63911772:-
LUAD	cis	rs6840258	0.66	rs6531941	ENSG00000251411.1	RP11-397E7.4	5.68	2.38e-08	8.5e-06	0.32	0.25	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86974808	chr4:86913266~86914817:-
LUAD	cis	rs368187	0.71	rs2780303	ENSG00000257826.1	RP11-116N8.4	5.68	2.38e-08	8.5e-06	0.27	0.25	Thyroid cancer;	chr14:36045580	chr14:36061026~36067190:-
LUAD	cis	rs1075265	0.704	rs805402	ENSG00000233266.1	HMGB1P31	5.68	2.39e-08	8.5e-06	0.31	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53889212	chr2:54051334~54051760:+
LUAD	cis	rs7743045	0.573	rs6929403	ENSG00000253194.1	RP11-351A11.1	5.68	2.39e-08	8.51e-06	0.32	0.25	Mean platelet volume;	chr6:119025747	chr6:118934785~119031541:+
LUAD	cis	rs2404602	0.692	rs35498563	ENSG00000259422.1	RP11-593F23.1	5.68	2.39e-08	8.51e-06	0.29	0.25	Blood metabolite levels;	chr15:76666527	chr15:76174891~76181486:-
LUAD	cis	rs4835473	0.932	rs7696106	ENSG00000251600.4	RP11-673E1.1	-5.68	2.39e-08	8.52e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143765454	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs7680045	ENSG00000251600.4	RP11-673E1.1	-5.68	2.39e-08	8.52e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143765470	chr4:143912331~143982454:+
LUAD	cis	rs875971	0.965	rs6971509	ENSG00000237310.1	GS1-124K5.4	-5.68	2.39e-08	8.52e-06	-0.27	-0.25	Aortic root size;	chr7:66249983	chr7:66493706~66495474:+
LUAD	cis	rs1075265	0.836	rs11687324	ENSG00000233266.1	HMGB1P31	5.68	2.39e-08	8.53e-06	0.32	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54046589	chr2:54051334~54051760:+
LUAD	cis	rs7208859	0.673	rs9907197	ENSG00000263603.1	CTD-2349P21.5	-5.68	2.4e-08	8.54e-06	-0.39	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30691245	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs9915963	ENSG00000263603.1	CTD-2349P21.5	-5.68	2.4e-08	8.54e-06	-0.39	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30692625	chr17:30729469~30731202:+
LUAD	cis	rs10214930	0.813	rs759270	ENSG00000235574.1	AC073150.6	-5.68	2.4e-08	8.54e-06	-0.33	-0.25	Hypospadias;	chr7:27606842	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.781	rs759271	ENSG00000235574.1	AC073150.6	-5.68	2.4e-08	8.54e-06	-0.33	-0.25	Hypospadias;	chr7:27607494	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.813	rs2391445	ENSG00000235574.1	AC073150.6	-5.68	2.4e-08	8.54e-06	-0.33	-0.25	Hypospadias;	chr7:27609252	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.813	rs2391446	ENSG00000235574.1	AC073150.6	-5.68	2.4e-08	8.54e-06	-0.33	-0.25	Hypospadias;	chr7:27609301	chr7:27491682~27492765:-
LUAD	cis	rs2749097	1	rs61765315	ENSG00000244256.3	RN7SL130P	-5.67	2.4e-08	8.55e-06	-0.36	-0.25	Alcohol consumption (transferrin glycosylation);	chr1:63662638	chr1:63655743~63656047:+
LUAD	cis	rs7712401	0.601	rs185009	ENSG00000263432.2	RN7SL689P	5.67	2.4e-08	8.55e-06	0.31	0.25	Mean platelet volume;	chr5:122938072	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.541	rs42537	ENSG00000263432.2	RN7SL689P	5.67	2.4e-08	8.55e-06	0.31	0.25	Mean platelet volume;	chr5:122938993	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.58	rs185008	ENSG00000263432.2	RN7SL689P	5.67	2.4e-08	8.55e-06	0.31	0.25	Mean platelet volume;	chr5:122939039	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.58	rs30041	ENSG00000263432.2	RN7SL689P	5.67	2.4e-08	8.55e-06	0.31	0.25	Mean platelet volume;	chr5:122939658	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.58	rs42536	ENSG00000263432.2	RN7SL689P	5.67	2.4e-08	8.55e-06	0.31	0.25	Mean platelet volume;	chr5:122940728	chr5:123022487~123022783:-
LUAD	cis	rs2179367	0.6	rs9498353	ENSG00000231760.4	RP11-350J20.5	5.67	2.4e-08	8.56e-06	0.37	0.25	Dupuytren's disease;	chr6:149439860	chr6:149796151~149826294:-
LUAD	cis	rs848490	0.615	rs2428939	ENSG00000214293.7	APTR	-5.67	2.4e-08	8.56e-06	-0.29	-0.25	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77932977	chr7:77657660~77696265:-
LUAD	cis	rs12908161	1	rs12908161	ENSG00000225151.9	GOLGA2P7	-5.67	2.41e-08	8.57e-06	-0.34	-0.25	Schizophrenia;	chr15:84664594	chr15:84199311~84230136:-
LUAD	cis	rs948562	0.535	rs11229369	ENSG00000280010.1	AP001350.4	5.67	2.41e-08	8.57e-06	0.42	0.25	Lymphoma;	chr11:58341039	chr11:58627435~58628528:+
LUAD	cis	rs7208859	0.623	rs7208441	ENSG00000263603.1	CTD-2349P21.5	-5.67	2.41e-08	8.57e-06	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30729469~30731202:+
LUAD	cis	rs7923609	1	rs1935	ENSG00000232075.1	MRPL35P2	-5.67	2.41e-08	8.57e-06	-0.3	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63168063	chr10:63634317~63634827:-
LUAD	cis	rs4835473	0.9	rs7689374	ENSG00000251600.4	RP11-673E1.1	-5.67	2.41e-08	8.58e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143769567	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs6537183	ENSG00000251600.4	RP11-673E1.1	-5.67	2.41e-08	8.58e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143770441	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs12512202	ENSG00000251600.4	RP11-673E1.1	-5.67	2.41e-08	8.58e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143771248	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs6843671	ENSG00000251600.4	RP11-673E1.1	-5.67	2.41e-08	8.58e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143772041	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs35395070	ENSG00000251600.4	RP11-673E1.1	-5.67	2.41e-08	8.58e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143772283	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs34614750	ENSG00000251600.4	RP11-673E1.1	-5.67	2.41e-08	8.58e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143772369	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs35002497	ENSG00000251600.4	RP11-673E1.1	-5.67	2.41e-08	8.58e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143772952	chr4:143912331~143982454:+
LUAD	cis	rs10214930	0.697	rs3925338	ENSG00000235574.1	AC073150.6	-5.67	2.41e-08	8.58e-06	-0.31	-0.25	Hypospadias;	chr7:27553820	chr7:27491682~27492765:-
LUAD	cis	rs7246657	0.722	rs11083432	ENSG00000276846.1	CTD-3220F14.3	-5.67	2.41e-08	8.58e-06	-0.33	-0.25	Coronary artery calcification;	chr19:37691732	chr19:37314868~37315620:-
LUAD	cis	rs36093844	0.605	rs79719453	ENSG00000279742.1	RP11-700A24.1	-5.67	2.41e-08	8.58e-06	-0.34	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85871174	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.706	rs75334800	ENSG00000279742.1	RP11-700A24.1	-5.67	2.41e-08	8.58e-06	-0.34	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85875538	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.752	rs77497327	ENSG00000279742.1	RP11-700A24.1	-5.67	2.41e-08	8.58e-06	-0.34	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85875898	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.8	rs79276445	ENSG00000279742.1	RP11-700A24.1	-5.67	2.41e-08	8.58e-06	-0.34	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85876784	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.8	rs78681528	ENSG00000279742.1	RP11-700A24.1	-5.67	2.41e-08	8.58e-06	-0.34	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85877113	chr11:85852557~85854943:-
LUAD	cis	rs1707322	1	rs1707317	ENSG00000234329.1	RP11-767N6.2	-5.67	2.41e-08	8.59e-06	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044970	chr1:45651039~45651826:-
LUAD	cis	rs75920871	0.588	rs10892054	ENSG00000254851.1	RP11-109L13.1	5.67	2.41e-08	8.59e-06	0.37	0.25	Subjective well-being;	chr11:116997505	chr11:117135528~117138582:+
LUAD	cis	rs75920871	0.588	rs10892055	ENSG00000254851.1	RP11-109L13.1	5.67	2.41e-08	8.59e-06	0.37	0.25	Subjective well-being;	chr11:116997655	chr11:117135528~117138582:+
LUAD	cis	rs17666538	0.71	rs11987001	ENSG00000254207.1	RP11-43A14.1	5.67	2.41e-08	8.59e-06	0.54	0.25	IgG glycosylation;	chr8:680755	chr8:725188~725877:-
LUAD	cis	rs2243480	0.803	rs160649	ENSG00000232546.1	RP11-458F8.1	-5.67	2.42e-08	8.61e-06	-0.32	-0.25	Diabetic kidney disease;	chr7:66078212	chr7:66848496~66858136:+
LUAD	cis	rs2243480	1	rs160648	ENSG00000232546.1	RP11-458F8.1	-5.67	2.42e-08	8.61e-06	-0.32	-0.25	Diabetic kidney disease;	chr7:66078397	chr7:66848496~66858136:+
LUAD	cis	rs516805	0.528	rs2606631	ENSG00000279453.1	RP3-425C14.4	-5.67	2.42e-08	8.61e-06	-0.34	-0.25	Lymphocyte counts;	chr6:122099510	chr6:122436789~122439223:-
LUAD	cis	rs2404602	0.655	rs3829489	ENSG00000259422.1	RP11-593F23.1	5.67	2.42e-08	8.62e-06	0.29	0.25	Blood metabolite levels;	chr15:76930915	chr15:76174891~76181486:-
LUAD	cis	rs5753618	0.583	rs2899164	ENSG00000236132.1	CTA-440B3.1	-5.67	2.42e-08	8.62e-06	-0.31	-0.25	Colorectal cancer;	chr22:31394303	chr22:31816379~31817491:-
LUAD	cis	rs17507216	1	rs17356118	ENSG00000255769.6	GOLGA2P10	-5.67	2.42e-08	8.62e-06	-0.31	-0.25	Excessive daytime sleepiness;	chr15:82569149	chr15:82472993~82513950:-
LUAD	cis	rs763567	0.539	rs593479	ENSG00000271811.1	RP1-79C4.4	5.67	2.43e-08	8.63e-06	0.29	0.25	Tonsillectomy;	chr1:170673758	chr1:170667381~170669425:+
LUAD	cis	rs9500256	0.655	rs12208465	ENSG00000215190.7	LINC00680	-5.67	2.43e-08	8.63e-06	-0.32	-0.25	Eosinophilic esophagitis (pediatric);	chr6:58004603	chr6:57946074~57961501:-
LUAD	cis	rs1075265	0.783	rs805450	ENSG00000233266.1	HMGB1P31	5.67	2.43e-08	8.63e-06	0.32	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53951772	chr2:54051334~54051760:+
LUAD	cis	rs2404602	0.716	rs12594577	ENSG00000259422.1	RP11-593F23.1	5.67	2.43e-08	8.64e-06	0.29	0.25	Blood metabolite levels;	chr15:76536452	chr15:76174891~76181486:-
LUAD	cis	rs7911264	0.905	rs7918084	ENSG00000236493.2	EIF2S2P3	5.67	2.43e-08	8.64e-06	0.28	0.25	Inflammatory bowel disease;	chr10:92669710	chr10:92668745~92669743:-
LUAD	cis	rs1075265	0.783	rs805453	ENSG00000233266.1	HMGB1P31	5.67	2.43e-08	8.64e-06	0.32	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53955761	chr2:54051334~54051760:+
LUAD	cis	rs66887589	0.777	rs4643791	ENSG00000245958.5	RP11-33B1.1	5.67	2.43e-08	8.64e-06	0.2	0.25	Diastolic blood pressure;	chr4:119344464	chr4:119454791~119552025:+
LUAD	cis	rs2283792	0.765	rs9607298	ENSG00000224086.5	LL22NC03-86G7.1	-5.67	2.43e-08	8.65e-06	-0.24	-0.25	Multiple sclerosis;	chr22:21829844	chr22:21938293~21977632:+
LUAD	cis	rs1134634	0.52	rs7665390	ENSG00000273133.1	RP11-799M12.2	-5.67	2.43e-08	8.66e-06	-0.36	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15576115	chr4:15563698~15564253:-
LUAD	cis	rs875971	0.545	rs73376394	ENSG00000226824.5	RP4-756H11.3	-5.67	2.43e-08	8.66e-06	-0.36	-0.25	Aortic root size;	chr7:66172694	chr7:66654538~66669855:+
LUAD	cis	rs7727544	0.684	rs2516788	ENSG00000233006.5	AC034220.3	-5.67	2.44e-08	8.66e-06	-0.22	-0.25	Blood metabolite levels;	chr5:132379873	chr5:132311285~132369916:-
LUAD	cis	rs755249	0.529	rs4660732	ENSG00000228060.1	RP11-69E11.8	-5.67	2.44e-08	8.67e-06	-0.26	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39397543	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs61779285	ENSG00000228060.1	RP11-69E11.8	-5.67	2.44e-08	8.67e-06	-0.26	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39401383	chr1:39565160~39573203:+
LUAD	cis	rs2243480	1	rs6958420	ENSG00000230295.1	RP11-458F8.2	5.67	2.44e-08	8.67e-06	0.3	0.25	Diabetic kidney disease;	chr7:66286184	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs1392104	ENSG00000230295.1	RP11-458F8.2	5.67	2.44e-08	8.67e-06	0.3	0.25	Diabetic kidney disease;	chr7:66294120	chr7:66880708~66882981:+
LUAD	cis	rs600231	0.651	rs2846862	ENSG00000245532.5	NEAT1	5.67	2.44e-08	8.67e-06	0.2	0.25	Bone mineral density;	chr11:65452319	chr11:65422774~65445540:+
LUAD	cis	rs7712401	0.623	rs30043	ENSG00000263432.2	RN7SL689P	5.67	2.44e-08	8.68e-06	0.31	0.25	Mean platelet volume;	chr5:122936598	chr5:123022487~123022783:-
LUAD	cis	rs7923609	0.935	rs10995477	ENSG00000232075.1	MRPL35P2	-5.67	2.44e-08	8.68e-06	-0.3	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63250912	chr10:63634317~63634827:-
LUAD	cis	rs9500256	0.655	rs12210275	ENSG00000215190.7	LINC00680	-5.67	2.44e-08	8.68e-06	-0.32	-0.25	Eosinophilic esophagitis (pediatric);	chr6:58005481	chr6:57946074~57961501:-
LUAD	cis	rs2998286	0.813	rs2790431	ENSG00000254635.4	WAC-AS1	-5.67	2.44e-08	8.69e-06	-0.36	-0.25	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28500266	chr10:28522652~28532743:-
LUAD	cis	rs755249	0.567	rs61779284	ENSG00000228060.1	RP11-69E11.8	-5.67	2.45e-08	8.69e-06	-0.25	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39389505	chr1:39565160~39573203:+
LUAD	cis	rs7044106	0.762	rs10491783	ENSG00000238181.2	AHCYP2	-5.67	2.45e-08	8.69e-06	-0.32	-0.25	Hip circumference adjusted for BMI;	chr9:120687877	chr9:120720673~120721972:+
LUAD	cis	rs7044106	0.762	rs966397	ENSG00000238181.2	AHCYP2	-5.67	2.45e-08	8.69e-06	-0.32	-0.25	Hip circumference adjusted for BMI;	chr9:120691034	chr9:120720673~120721972:+
LUAD	cis	rs897984	0.542	rs11865038	ENSG00000260911.2	RP11-196G11.2	5.67	2.45e-08	8.7e-06	0.23	0.25	Dementia with Lewy bodies;	chr16:31083850	chr16:31043150~31049868:+
LUAD	cis	rs897984	0.542	rs11864806	ENSG00000260911.2	RP11-196G11.2	5.67	2.45e-08	8.7e-06	0.23	0.25	Dementia with Lewy bodies;	chr16:31083883	chr16:31043150~31049868:+
LUAD	cis	rs897984	0.542	rs7199949	ENSG00000260911.2	RP11-196G11.2	5.67	2.45e-08	8.7e-06	0.23	0.25	Dementia with Lewy bodies;	chr16:31084843	chr16:31043150~31049868:+
LUAD	cis	rs4308124	0.708	rs10179596	ENSG00000227992.1	AC108463.2	-5.67	2.45e-08	8.7e-06	-0.34	-0.25	Vitiligo;	chr2:111212803	chr2:111203964~111206215:-
LUAD	cis	rs4308124	0.708	rs6727313	ENSG00000227992.1	AC108463.2	-5.67	2.45e-08	8.7e-06	-0.34	-0.25	Vitiligo;	chr2:111213963	chr2:111203964~111206215:-
LUAD	cis	rs4308124	0.708	rs10178095	ENSG00000227992.1	AC108463.2	-5.67	2.45e-08	8.7e-06	-0.34	-0.25	Vitiligo;	chr2:111214939	chr2:111203964~111206215:-
LUAD	cis	rs944289	0.562	rs12431566	ENSG00000257826.1	RP11-116N8.4	5.67	2.45e-08	8.7e-06	0.26	0.25	Thyroid cancer;	chr14:36051211	chr14:36061026~36067190:-
LUAD	cis	rs2933343	0.951	rs789251	ENSG00000261159.1	RP11-723O4.9	5.67	2.45e-08	8.71e-06	0.31	0.25	IgG glycosylation;	chr3:128857927	chr3:128859716~128860526:-
LUAD	cis	rs12908161	1	rs35316992	ENSG00000225151.9	GOLGA2P7	-5.67	2.45e-08	8.72e-06	-0.34	-0.25	Schizophrenia;	chr15:84704902	chr15:84199311~84230136:-
LUAD	cis	rs12908161	1	rs4643294	ENSG00000225151.9	GOLGA2P7	-5.67	2.45e-08	8.72e-06	-0.34	-0.25	Schizophrenia;	chr15:84707022	chr15:84199311~84230136:-
LUAD	cis	rs12908161	1	rs62021219	ENSG00000225151.9	GOLGA2P7	-5.67	2.45e-08	8.72e-06	-0.34	-0.25	Schizophrenia;	chr15:84712928	chr15:84199311~84230136:-
LUAD	cis	rs12908161	1	rs34900908	ENSG00000225151.9	GOLGA2P7	-5.67	2.45e-08	8.72e-06	-0.34	-0.25	Schizophrenia;	chr15:84714368	chr15:84199311~84230136:-
LUAD	cis	rs12908161	1	rs35524990	ENSG00000225151.9	GOLGA2P7	-5.67	2.45e-08	8.72e-06	-0.34	-0.25	Schizophrenia;	chr15:84714972	chr15:84199311~84230136:-
LUAD	cis	rs1799949	0.965	rs4793230	ENSG00000267681.1	CTD-3199J23.6	-5.67	2.45e-08	8.72e-06	-0.28	-0.25	Menopause (age at onset);	chr17:43350035	chr17:43144956~43145255:+
LUAD	cis	rs4835473	0.9	rs4835303	ENSG00000251600.4	RP11-673E1.1	-5.67	2.45e-08	8.72e-06	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143821533	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs4835034	ENSG00000251600.4	RP11-673E1.1	-5.67	2.45e-08	8.72e-06	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143821538	chr4:143912331~143982454:+
LUAD	cis	rs30380	1	rs151964	ENSG00000272109.1	CTD-2260A17.3	-5.67	2.46e-08	8.73e-06	-0.27	-0.25	Cerebrospinal fluid biomarker levels;	chr5:96787963	chr5:96804353~96806105:+
LUAD	cis	rs7804306	0.826	rs73049252	ENSG00000233264.2	AC006042.8	5.67	2.46e-08	8.73e-06	0.5	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7976971	chr7:7980312~7982228:+
LUAD	cis	rs7804306	0.826	rs73049256	ENSG00000233264.2	AC006042.8	5.67	2.46e-08	8.73e-06	0.5	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7978858	chr7:7980312~7982228:+
LUAD	cis	rs1198872	0.563	rs1686497	ENSG00000272275.1	RP11-791G15.2	-5.67	2.46e-08	8.73e-06	-0.32	-0.25	Cardiac Troponin-T levels;	chr2:10821058	chr2:10767875~10770058:-
LUAD	cis	rs1799949	0.894	rs71367985	ENSG00000267681.1	CTD-3199J23.6	-5.67	2.46e-08	8.73e-06	-0.28	-0.25	Menopause (age at onset);	chr17:43222443	chr17:43144956~43145255:+
LUAD	cis	rs7181230	0.885	rs28826672	ENSG00000275636.1	RP11-521C20.5	5.67	2.46e-08	8.73e-06	0.34	0.25	Dehydroepiandrosterone sulphate levels;	chr15:40068165	chr15:40078892~40079347:+
LUAD	cis	rs897984	0.513	rs17839568	ENSG00000260911.2	RP11-196G11.2	5.67	2.46e-08	8.75e-06	0.23	0.25	Dementia with Lewy bodies;	chr16:31088462	chr16:31043150~31049868:+
LUAD	cis	rs172166	0.637	rs1225597	ENSG00000219392.1	RP1-265C24.5	-5.67	2.46e-08	8.75e-06	-0.32	-0.25	Cardiac Troponin-T levels;	chr6:28194309	chr6:28115628~28116551:+
LUAD	cis	rs4604732	0.536	rs7528219	ENSG00000227135.1	GCSAML-AS1	-5.67	2.46e-08	8.75e-06	-0.38	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247465005	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.588	rs7549955	ENSG00000227135.1	GCSAML-AS1	-5.67	2.46e-08	8.75e-06	-0.38	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247465019	chr1:247524679~247526752:-
LUAD	cis	rs858239	0.896	rs1637193	ENSG00000226816.2	AC005082.12	5.67	2.46e-08	8.75e-06	0.32	0.25	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23206013~23208045:+
LUAD	cis	rs10050311	1	rs10050311	ENSG00000251411.1	RP11-397E7.4	-5.67	2.46e-08	8.75e-06	-0.36	-0.25	Insulin-related traits;	chr4:86833266	chr4:86913266~86914817:-
LUAD	cis	rs9652601	0.622	rs8045749	ENSG00000274038.1	RP11-66H6.4	-5.67	2.47e-08	8.76e-06	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11025796	chr16:11056556~11057034:+
LUAD	cis	rs875971	0.862	rs7786892	ENSG00000237310.1	GS1-124K5.4	-5.67	2.47e-08	8.76e-06	-0.27	-0.25	Aortic root size;	chr7:66163889	chr7:66493706~66495474:+
LUAD	cis	rs507080	0.771	rs687664	ENSG00000278376.1	RP11-158I9.8	-5.67	2.47e-08	8.76e-06	-0.27	-0.25	Serum metabolite levels;	chr11:118703476	chr11:118791254~118793137:+
LUAD	cis	rs507080	0.771	rs523715	ENSG00000278376.1	RP11-158I9.8	-5.67	2.47e-08	8.76e-06	-0.27	-0.25	Serum metabolite levels;	chr11:118703479	chr11:118791254~118793137:+
LUAD	cis	rs453301	0.606	rs6601279	ENSG00000233609.3	RP11-62H7.2	-5.67	2.47e-08	8.76e-06	-0.21	-0.25	Joint mobility (Beighton score);	chr8:9050721	chr8:8961200~8979025:+
LUAD	cis	rs453301	0.606	rs6981060	ENSG00000233609.3	RP11-62H7.2	-5.67	2.47e-08	8.76e-06	-0.21	-0.25	Joint mobility (Beighton score);	chr8:9050725	chr8:8961200~8979025:+
LUAD	cis	rs858239	1	rs166663	ENSG00000226816.2	AC005082.12	5.67	2.47e-08	8.77e-06	0.33	0.25	Cerebrospinal fluid biomarker levels;	chr7:23277123	chr7:23206013~23208045:+
LUAD	cis	rs7115242	0.925	rs7925256	ENSG00000280143.1	AP000892.6	5.67	2.47e-08	8.78e-06	0.45	0.25	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117174619	chr11:117204967~117210292:+
LUAD	cis	rs516805	0.667	rs9490411	ENSG00000279453.1	RP3-425C14.4	5.67	2.47e-08	8.79e-06	0.35	0.25	Lymphocyte counts;	chr6:122217270	chr6:122436789~122439223:-
LUAD	cis	rs4841134	0.625	rs12235038	ENSG00000233609.3	RP11-62H7.2	-5.67	2.48e-08	8.8e-06	-0.2	-0.25	Age-related disease endophenotypes;	chr8:9379893	chr8:8961200~8979025:+
LUAD	cis	rs4908768	0.539	rs11121205	ENSG00000232912.4	RP5-1115A15.1	5.67	2.48e-08	8.8e-06	0.23	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8598026	chr1:8424645~8434838:+
LUAD	cis	rs2179367	0.632	rs9498329	ENSG00000231760.4	RP11-350J20.5	5.67	2.48e-08	8.81e-06	0.35	0.25	Dupuytren's disease;	chr6:149349941	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs59820585	ENSG00000231760.4	RP11-350J20.5	5.67	2.48e-08	8.81e-06	0.35	0.25	Dupuytren's disease;	chr6:149350249	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs56924465	ENSG00000231760.4	RP11-350J20.5	5.67	2.48e-08	8.81e-06	0.35	0.25	Dupuytren's disease;	chr6:149350270	chr6:149796151~149826294:-
LUAD	cis	rs875971	0.83	rs4718358	ENSG00000237310.1	GS1-124K5.4	5.67	2.48e-08	8.81e-06	0.27	0.25	Aortic root size;	chr7:66508681	chr7:66493706~66495474:+
LUAD	cis	rs2404602	0.735	rs2280306	ENSG00000259422.1	RP11-593F23.1	-5.67	2.48e-08	8.81e-06	-0.32	-0.25	Blood metabolite levels;	chr15:76359917	chr15:76174891~76181486:-
LUAD	cis	rs2288884	0.943	rs12611112	ENSG00000275055.1	CTC-471J1.11	-5.67	2.48e-08	8.81e-06	-0.4	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52071686	chr19:52049007~52049754:+
LUAD	cis	rs75422866	0.51	rs74733564	ENSG00000274902.1	RP1-197B17.4	5.67	2.48e-08	8.81e-06	0.56	0.25	Pneumonia;	chr12:47724644	chr12:47731908~47732351:+
LUAD	cis	rs75422866	0.51	rs73105814	ENSG00000274902.1	RP1-197B17.4	5.67	2.48e-08	8.81e-06	0.56	0.25	Pneumonia;	chr12:47725817	chr12:47731908~47732351:+
LUAD	cis	rs4591358	0.773	rs17177580	ENSG00000223466.1	AC064834.2	5.67	2.48e-08	8.81e-06	0.33	0.25	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195508426	chr2:195533035~195538681:+
LUAD	cis	rs4835473	0.897	rs35140014	ENSG00000251600.4	RP11-673E1.1	5.67	2.48e-08	8.82e-06	0.31	0.25	Immature fraction of reticulocytes;	chr4:143964292	chr4:143912331~143982454:+
LUAD	cis	rs9879311	0.966	rs4684685	ENSG00000240288.6	GHRLOS	5.67	2.48e-08	8.82e-06	0.23	0.25	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10369869	chr3:10285754~10293449:+
LUAD	cis	rs2404602	0.692	rs35138393	ENSG00000259422.1	RP11-593F23.1	5.67	2.49e-08	8.82e-06	0.29	0.25	Blood metabolite levels;	chr15:76685276	chr15:76174891~76181486:-
LUAD	cis	rs10740039	0.516	rs2393645	ENSG00000254271.1	RP11-131N11.4	5.67	2.49e-08	8.82e-06	0.28	0.25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60555269	chr10:60734342~60741828:+
LUAD	cis	rs1075265	0.704	rs805410	ENSG00000233266.1	HMGB1P31	5.67	2.49e-08	8.83e-06	0.31	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53893360	chr2:54051334~54051760:+
LUAD	cis	rs9311474	1	rs7629072	ENSG00000243224.1	RP5-1157M23.2	-5.67	2.49e-08	8.83e-06	-0.25	-0.25	Electroencephalogram traits;	chr3:52271617	chr3:52239258~52241097:+
LUAD	cis	rs9807989	0.765	rs13424006	ENSG00000234389.1	AC007278.3	5.67	2.49e-08	8.83e-06	0.24	0.25	Asthma;	chr2:102350776	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.765	rs6751967	ENSG00000234389.1	AC007278.3	5.67	2.49e-08	8.83e-06	0.24	0.25	Asthma;	chr2:102350953	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.765	rs6751977	ENSG00000234389.1	AC007278.3	5.67	2.49e-08	8.83e-06	0.24	0.25	Asthma;	chr2:102350970	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.765	rs6704565	ENSG00000234389.1	AC007278.3	5.67	2.49e-08	8.83e-06	0.24	0.25	Asthma;	chr2:102350971	chr2:102438713~102440475:+
LUAD	cis	rs6840258	0.66	rs72667736	ENSG00000251411.1	RP11-397E7.4	-5.67	2.49e-08	8.84e-06	-0.35	-0.25	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86954803	chr4:86913266~86914817:-
LUAD	cis	rs7811142	0.775	rs1059129	ENSG00000078319.8	PMS2P1	-5.67	2.49e-08	8.84e-06	-0.29	-0.25	Platelet count;	chr7:100328899	chr7:100320992~100341908:-
LUAD	cis	rs7811142	0.562	rs7786844	ENSG00000078319.8	PMS2P1	-5.67	2.49e-08	8.84e-06	-0.29	-0.25	Platelet count;	chr7:100336385	chr7:100320992~100341908:-
LUAD	cis	rs7811142	0.83	rs6979910	ENSG00000078319.8	PMS2P1	-5.67	2.49e-08	8.84e-06	-0.29	-0.25	Platelet count;	chr7:100343007	chr7:100320992~100341908:-
LUAD	cis	rs875971	0.862	rs10282433	ENSG00000222364.1	RNU6-96P	5.67	2.49e-08	8.84e-06	0.28	0.25	Aortic root size;	chr7:66256452	chr7:66395191~66395286:+
LUAD	cis	rs858239	0.6	rs7776644	ENSG00000230042.1	AK3P3	-5.67	2.49e-08	8.84e-06	-0.32	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23129178~23129841:+
LUAD	cis	rs2243480	1	rs34970380	ENSG00000230295.1	RP11-458F8.2	-5.67	2.5e-08	8.86e-06	-0.31	-0.25	Diabetic kidney disease;	chr7:65966506	chr7:66880708~66882981:+
LUAD	cis	rs2243480	0.901	rs73148097	ENSG00000230295.1	RP11-458F8.2	-5.67	2.5e-08	8.86e-06	-0.31	-0.25	Diabetic kidney disease;	chr7:65966800	chr7:66880708~66882981:+
LUAD	cis	rs2404602	0.735	rs11638767	ENSG00000259422.1	RP11-593F23.1	-5.67	2.5e-08	8.86e-06	-0.32	-0.25	Blood metabolite levels;	chr15:76363597	chr15:76174891~76181486:-
LUAD	cis	rs453301	0.538	rs7830804	ENSG00000173295.6	FAM86B3P	-5.67	2.5e-08	8.86e-06	-0.27	-0.25	Joint mobility (Beighton score);	chr8:9113252	chr8:8228595~8244865:+
LUAD	cis	rs4713118	0.739	rs2893931	ENSG00000219392.1	RP1-265C24.5	-5.67	2.5e-08	8.87e-06	-0.34	-0.25	Parkinson's disease;	chr6:27780231	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.824	rs2092075	ENSG00000219392.1	RP1-265C24.5	-5.67	2.5e-08	8.87e-06	-0.34	-0.25	Parkinson's disease;	chr6:27781551	chr6:28115628~28116551:+
LUAD	cis	rs172166	0.694	rs1225716	ENSG00000204709.4	LINC01556	5.67	2.5e-08	8.88e-06	0.33	0.25	Cardiac Troponin-T levels;	chr6:28145968	chr6:28943877~28944537:+
LUAD	cis	rs9813712	0.571	rs11715351	ENSG00000228252.7	COL6A4P2	-5.67	2.51e-08	8.89e-06	-0.24	-0.25	Response to amphetamines;	chr3:130214704	chr3:130212823~130273806:+
LUAD	cis	rs1823913	0.503	rs35868016	ENSG00000280083.1	RP11-317J9.1	-5.67	2.51e-08	8.89e-06	-0.31	-0.25	Obesity-related traits;	chr2:191344082	chr2:191154118~191156070:-
LUAD	cis	rs9595908	0.709	rs4942892	ENSG00000212293.1	SNORA16	-5.67	2.51e-08	8.89e-06	-0.26	-0.25	Body mass index;	chr13:32754269	chr13:32420390~32420516:-
LUAD	cis	rs36093844	0.898	rs12361645	ENSG00000279742.1	RP11-700A24.1	-5.67	2.51e-08	8.9e-06	-0.29	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85884063	chr11:85852557~85854943:-
LUAD	cis	rs7430456	0.87	rs9864169	ENSG00000228221.4	LINC00578	5.67	2.51e-08	8.9e-06	0.29	0.25	Breast cancer;	chr3:177746841	chr3:177441921~177752305:+
LUAD	cis	rs7430456	0.901	rs12696448	ENSG00000228221.4	LINC00578	5.67	2.51e-08	8.9e-06	0.29	0.25	Breast cancer;	chr3:177746860	chr3:177441921~177752305:+
LUAD	cis	rs3096299	0.617	rs2353030	ENSG00000274627.1	RP11-104N10.2	-5.67	2.51e-08	8.91e-06	-0.23	-0.25	Multiple myeloma (IgH translocation);	chr16:89339419	chr16:89516797~89522217:+
LUAD	cis	rs1322639	0.614	rs7751131	ENSG00000261039.2	RP11-417E7.2	-5.67	2.51e-08	8.91e-06	-0.4	-0.25	Pulse pressure;	chr6:169178615	chr6:169175304~169182740:-
LUAD	cis	rs1322639	0.574	rs9364360	ENSG00000261039.2	RP11-417E7.2	-5.67	2.51e-08	8.91e-06	-0.4	-0.25	Pulse pressure;	chr6:169180079	chr6:169175304~169182740:-
LUAD	cis	rs801193	0.569	rs10950050	ENSG00000237310.1	GS1-124K5.4	5.67	2.51e-08	8.91e-06	0.26	0.25	Aortic root size;	chr7:66774601	chr7:66493706~66495474:+
LUAD	cis	rs11822910	0.654	rs2439450	ENSG00000265566.2	RN7SL605P	5.67	2.52e-08	8.93e-06	0.32	0.25	Platelet distribution width;	chr11:57445588	chr11:57528085~57528365:-
LUAD	cis	rs7927592	0.626	rs11228279	ENSG00000212093.1	AP000807.1	-5.67	2.52e-08	8.93e-06	-0.25	-0.25	Total body bone mineral density;	chr11:68542212	chr11:68506083~68506166:-
LUAD	cis	rs12554020	0.786	rs76640831	ENSG00000227603.1	RP11-165J3.6	5.67	2.52e-08	8.93e-06	0.48	0.25	Schizophrenia;	chr9:93474133	chr9:93435332~93437121:-
LUAD	cis	rs3020264	0.669	rs7005662	ENSG00000271743.1	CTD-2541M15.3	5.67	2.52e-08	8.93e-06	0.34	0.25	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6619105	chr8:6615604~6617198:-
LUAD	cis	rs2911132	0.628	rs2032890	ENSG00000248734.2	CTD-2260A17.1	5.67	2.52e-08	8.93e-06	0.28	0.25	Urate levels (BMI interaction);	chr5:96785448	chr5:96784777~96785999:+
LUAD	cis	rs875971	0.545	rs1796217	ENSG00000226824.5	RP4-756H11.3	5.67	2.52e-08	8.93e-06	0.36	0.25	Aortic root size;	chr7:66620931	chr7:66654538~66669855:+
LUAD	cis	rs9595908	0.709	rs3213532	ENSG00000212293.1	SNORA16	5.67	2.52e-08	8.94e-06	0.27	0.25	Body mass index;	chr13:32773550	chr13:32420390~32420516:-
LUAD	cis	rs673078	0.607	rs17441061	ENSG00000275409.1	RP11-131L12.4	-5.67	2.52e-08	8.94e-06	-0.35	-0.25	Glucose homeostasis traits;	chr12:118409847	chr12:118430147~118430699:+
LUAD	cis	rs4835473	0.932	rs1450233	ENSG00000251600.4	RP11-673E1.1	-5.67	2.52e-08	8.94e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143774710	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs4308330	ENSG00000251600.4	RP11-673E1.1	-5.67	2.52e-08	8.94e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143774761	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs11725708	ENSG00000251600.4	RP11-673E1.1	-5.67	2.52e-08	8.94e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143775683	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs17762299	ENSG00000251600.4	RP11-673E1.1	-5.67	2.52e-08	8.94e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143777196	chr4:143912331~143982454:+
LUAD	cis	rs11651753	0.561	rs35336840	ENSG00000264920.1	RP11-6N17.4	-5.67	2.52e-08	8.94e-06	-0.31	-0.25	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47888742	chr17:47891255~47895812:-
LUAD	cis	rs897984	0.609	rs72800847	ENSG00000260911.2	RP11-196G11.2	5.67	2.52e-08	8.95e-06	0.23	0.25	Dementia with Lewy bodies;	chr16:31011318	chr16:31043150~31049868:+
LUAD	cis	rs4767841	0.552	rs11064861	ENSG00000248636.5	RP11-768F21.1	-5.67	2.53e-08	8.96e-06	-0.29	-0.25	Urgency urinary incontinence;	chr12:119633855	chr12:119387987~119668079:-
LUAD	cis	rs6844153	0.713	rs11734308	ENSG00000240005.4	RP11-293A21.1	-5.67	2.53e-08	8.96e-06	-0.36	-0.25	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26934877	chr4:26859806~26860599:-
LUAD	cis	rs4820294	0.669	rs7287340	ENSG00000233360.4	Z83844.1	5.67	2.53e-08	8.97e-06	0.25	0.25	Fat distribution (HIV);	chr22:37658318	chr22:37641832~37658377:-
LUAD	cis	rs4820294	0.669	rs7287358	ENSG00000233360.4	Z83844.1	5.67	2.53e-08	8.97e-06	0.25	0.25	Fat distribution (HIV);	chr22:37658396	chr22:37641832~37658377:-
LUAD	cis	rs2439831	0.85	rs3736180	ENSG00000205771.5	CATSPER2P1	-5.67	2.53e-08	8.97e-06	-0.52	-0.25	Lung cancer in ever smokers;	chr15:43814426	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.85	rs28684672	ENSG00000205771.5	CATSPER2P1	-5.67	2.53e-08	8.97e-06	-0.52	-0.25	Lung cancer in ever smokers;	chr15:43815464	chr15:43726918~43747094:-
LUAD	cis	rs7615952	0.641	rs7618515	ENSG00000171084.14	FAM86JP	5.66	2.53e-08	8.98e-06	0.37	0.25	Blood pressure (smoking interaction);	chr3:126071735	chr3:125916620~125930024:+
LUAD	cis	rs9311474	1	rs2276834	ENSG00000243224.1	RP5-1157M23.2	-5.66	2.54e-08	8.99e-06	-0.26	-0.25	Electroencephalogram traits;	chr3:52291743	chr3:52239258~52241097:+
LUAD	cis	rs12468226	0.817	rs12693965	ENSG00000226261.1	AC064836.3	-5.66	2.54e-08	8.99e-06	-0.41	-0.25	Urate levels;	chr2:202210188	chr2:202336024~202336727:-
LUAD	cis	rs875971	0.545	rs4718348	ENSG00000237310.1	GS1-124K5.4	5.66	2.54e-08	8.99e-06	0.32	0.25	Aortic root size;	chr7:66441589	chr7:66493706~66495474:+
LUAD	cis	rs7811142	0.83	rs11768967	ENSG00000078319.8	PMS2P1	-5.66	2.54e-08	9e-06	-0.29	-0.25	Platelet count;	chr7:100370021	chr7:100320992~100341908:-
LUAD	cis	rs7811142	0.83	rs6975660	ENSG00000078319.8	PMS2P1	-5.66	2.54e-08	9e-06	-0.29	-0.25	Platelet count;	chr7:100377643	chr7:100320992~100341908:-
LUAD	cis	rs7811142	0.83	rs73401443	ENSG00000078319.8	PMS2P1	-5.66	2.54e-08	9e-06	-0.29	-0.25	Platelet count;	chr7:100379959	chr7:100320992~100341908:-
LUAD	cis	rs7811142	0.83	rs10085549	ENSG00000078319.8	PMS2P1	-5.66	2.54e-08	9e-06	-0.29	-0.25	Platelet count;	chr7:100385512	chr7:100320992~100341908:-
LUAD	cis	rs984222	0.838	rs10923724	ENSG00000226172.2	RP4-712E4.1	-5.66	2.54e-08	9.02e-06	-0.27	-0.25	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119004219	chr1:119000344~119001392:-
LUAD	cis	rs7221109	0.633	rs9915135	ENSG00000278834.1	RP11-458J1.1	5.66	2.55e-08	9.02e-06	0.29	0.25	Type 1 diabetes;	chr17:40634823	chr17:40648300~40649718:+
LUAD	cis	rs10129255	0.957	rs10141052	ENSG00000211972.2	IGHV3-66	5.66	2.55e-08	9.03e-06	0.21	0.25	Kawasaki disease;	chr14:106776528	chr14:106675017~106675544:-
LUAD	cis	rs36093844	0.615	rs77258124	ENSG00000279742.1	RP11-700A24.1	-5.66	2.55e-08	9.05e-06	-0.33	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85867038	chr11:85852557~85854943:-
LUAD	cis	rs2404602	0.692	rs1116535	ENSG00000259422.1	RP11-593F23.1	-5.66	2.56e-08	9.05e-06	-0.29	-0.25	Blood metabolite levels;	chr15:76717173	chr15:76174891~76181486:-
LUAD	cis	rs12468226	0.938	rs3843338	ENSG00000272966.1	RP11-686O6.1	-5.66	2.56e-08	9.06e-06	-0.42	-0.25	Urate levels;	chr2:202246102	chr2:202336739~202337200:+
LUAD	cis	rs8031584	0.56	rs1056118	ENSG00000270015.1	RP11-540B6.6	5.66	2.56e-08	9.06e-06	0.17	0.25	Huntington's disease progression;	chr15:30911583	chr15:30926514~30928407:+
LUAD	cis	rs858239	0.539	rs6945510	ENSG00000230042.1	AK3P3	-5.66	2.56e-08	9.07e-06	-0.32	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23152621	chr7:23129178~23129841:+
LUAD	cis	rs2404602	0.692	rs35395069	ENSG00000259422.1	RP11-593F23.1	5.66	2.57e-08	9.08e-06	0.29	0.25	Blood metabolite levels;	chr15:76693993	chr15:76174891~76181486:-
LUAD	cis	rs4820294	0.669	rs9622677	ENSG00000233360.4	Z83844.1	5.66	2.57e-08	9.09e-06	0.25	0.25	Fat distribution (HIV);	chr22:37658255	chr22:37641832~37658377:-
LUAD	cis	rs2880765	0.525	rs2062234	ENSG00000259295.5	CSPG4P12	5.66	2.57e-08	9.11e-06	0.31	0.25	Coronary artery disease;	chr15:85511259	chr15:85191438~85213905:+
LUAD	cis	rs875971	0.862	rs28491091	ENSG00000222364.1	RNU6-96P	5.66	2.57e-08	9.11e-06	0.28	0.25	Aortic root size;	chr7:66204077	chr7:66395191~66395286:+
LUAD	cis	rs30380	1	rs26510	ENSG00000272109.1	CTD-2260A17.3	-5.66	2.57e-08	9.11e-06	-0.27	-0.25	Cerebrospinal fluid biomarker levels;	chr5:96790207	chr5:96804353~96806105:+
LUAD	cis	rs12699921	0.598	rs2691611	ENSG00000279048.1	RP11-511H23.2	-5.66	2.58e-08	9.12e-06	-0.2	-0.25	Fibrinogen levels;	chr7:17843804	chr7:17940503~17942922:+
LUAD	cis	rs2255336	0.882	rs2733853	ENSG00000245648.1	RP11-277P12.20	5.66	2.58e-08	9.13e-06	0.37	0.25	Blood protein levels;	chr12:10381483	chr12:10363769~10398506:+
LUAD	cis	rs7829975	0.514	rs2920983	ENSG00000253893.2	FAM85B	-5.66	2.58e-08	9.14e-06	-0.31	-0.25	Mood instability;	chr8:8410553	chr8:8167819~8226614:-
LUAD	cis	rs867371	1	rs2088858	ENSG00000259429.4	UBE2Q2P2	-5.66	2.59e-08	9.15e-06	-0.22	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182408	chr15:82355142~82420075:+
LUAD	cis	rs867371	1	rs4778982	ENSG00000259429.4	UBE2Q2P2	-5.66	2.59e-08	9.15e-06	-0.22	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182931	chr15:82355142~82420075:+
LUAD	cis	rs867371	1	rs2867579	ENSG00000259429.4	UBE2Q2P2	-5.66	2.59e-08	9.15e-06	-0.22	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183043	chr15:82355142~82420075:+
LUAD	cis	rs867371	1	rs881308	ENSG00000259429.4	UBE2Q2P2	-5.66	2.59e-08	9.15e-06	-0.22	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183456	chr15:82355142~82420075:+
LUAD	cis	rs3931020	0.688	rs277396	ENSG00000272864.1	RP11-17E13.2	5.66	2.59e-08	9.15e-06	0.35	0.25	Resistin levels;	chr1:74747964	chr1:74698769~74699333:-
LUAD	cis	rs7829975	0.514	rs2979151	ENSG00000253893.2	FAM85B	5.66	2.59e-08	9.16e-06	0.31	0.25	Mood instability;	chr8:8400509	chr8:8167819~8226614:-
LUAD	cis	rs673078	0.607	rs7136676	ENSG00000275409.1	RP11-131L12.4	-5.66	2.59e-08	9.16e-06	-0.34	-0.25	Glucose homeostasis traits;	chr12:118403605	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs17441033	ENSG00000275409.1	RP11-131L12.4	-5.66	2.59e-08	9.16e-06	-0.34	-0.25	Glucose homeostasis traits;	chr12:118404101	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.562	rs61943405	ENSG00000275409.1	RP11-131L12.4	-5.66	2.59e-08	9.16e-06	-0.34	-0.25	Glucose homeostasis traits;	chr12:118405030	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs61943406	ENSG00000275409.1	RP11-131L12.4	-5.66	2.59e-08	9.16e-06	-0.34	-0.25	Glucose homeostasis traits;	chr12:118405767	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs17441075	ENSG00000275409.1	RP11-131L12.4	-5.66	2.59e-08	9.16e-06	-0.34	-0.25	Glucose homeostasis traits;	chr12:118410542	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs965524	ENSG00000275409.1	RP11-131L12.4	-5.66	2.59e-08	9.16e-06	-0.34	-0.25	Glucose homeostasis traits;	chr12:118412361	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs74685643	ENSG00000275409.1	RP11-131L12.4	-5.66	2.59e-08	9.16e-06	-0.34	-0.25	Glucose homeostasis traits;	chr12:118412761	chr12:118430147~118430699:+
LUAD	cis	rs8059260	0.544	rs16958051	ENSG00000274038.1	RP11-66H6.4	5.66	2.6e-08	9.19e-06	0.48	0.25	Alcohol consumption over the past year;	chr16:11097362	chr16:11056556~11057034:+
LUAD	cis	rs7712401	0.562	rs30073	ENSG00000263432.2	RN7SL689P	5.66	2.6e-08	9.21e-06	0.31	0.25	Mean platelet volume;	chr5:122954814	chr5:123022487~123022783:-
LUAD	cis	rs4604732	0.536	rs12074913	ENSG00000227135.1	GCSAML-AS1	-5.66	2.6e-08	9.21e-06	-0.38	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247468305	chr1:247524679~247526752:-
LUAD	cis	rs7662987	0.793	rs28730602	ENSG00000272777.1	RP11-571L19.8	5.66	2.61e-08	9.22e-06	0.4	0.25	Smoking initiation;	chr4:99080531	chr4:99067256~99068125:-
LUAD	cis	rs9859260	0.71	rs419068	ENSG00000231464.1	AC024937.4	-5.66	2.61e-08	9.22e-06	-0.29	-0.25	Mean corpuscular volume;	chr3:196055305	chr3:195996738~195998233:+
LUAD	cis	rs9859260	0.71	rs366268	ENSG00000231464.1	AC024937.4	-5.66	2.61e-08	9.22e-06	-0.29	-0.25	Mean corpuscular volume;	chr3:196055306	chr3:195996738~195998233:+
LUAD	cis	rs9859260	0.744	rs419059	ENSG00000231464.1	AC024937.4	-5.66	2.61e-08	9.22e-06	-0.29	-0.25	Mean corpuscular volume;	chr3:196055313	chr3:195996738~195998233:+
LUAD	cis	rs10214930	0.813	rs6462033	ENSG00000235574.1	AC073150.6	-5.66	2.61e-08	9.23e-06	-0.33	-0.25	Hypospadias;	chr7:27579066	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.723	rs1524529	ENSG00000235574.1	AC073150.6	-5.66	2.61e-08	9.23e-06	-0.33	-0.25	Hypospadias;	chr7:27580796	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.813	rs1608663	ENSG00000235574.1	AC073150.6	-5.66	2.61e-08	9.23e-06	-0.33	-0.25	Hypospadias;	chr7:27584157	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.767	rs1980330	ENSG00000235574.1	AC073150.6	-5.66	2.61e-08	9.23e-06	-0.33	-0.25	Hypospadias;	chr7:27590704	chr7:27491682~27492765:-
LUAD	cis	rs2255336	0.938	rs2733845	ENSG00000245648.1	RP11-277P12.20	-5.66	2.61e-08	9.23e-06	-0.37	-0.25	Blood protein levels;	chr12:10387216	chr12:10363769~10398506:+
LUAD	cis	rs10129255	0.5	rs9324092	ENSG00000211967.3	IGHV3-53	5.66	2.61e-08	9.23e-06	0.18	0.25	Kawasaki disease;	chr14:106683806	chr14:106592676~106593347:-
LUAD	cis	rs12908161	1	rs35808647	ENSG00000225151.9	GOLGA2P7	-5.66	2.61e-08	9.24e-06	-0.35	-0.25	Schizophrenia;	chr15:84834210	chr15:84199311~84230136:-
LUAD	cis	rs2790457	0.874	rs1265840	ENSG00000254635.4	WAC-AS1	-5.66	2.61e-08	9.24e-06	-0.27	-0.25	Multiple myeloma;	chr10:28630712	chr10:28522652~28532743:-
LUAD	cis	rs11603023	0.625	rs633683	ENSG00000255422.1	AP002954.4	-5.66	2.62e-08	9.25e-06	-0.31	-0.25	Cholesterol, total;	chr11:118634025	chr11:118704607~118750263:+
LUAD	cis	rs7712401	0.601	rs30047	ENSG00000263432.2	RN7SL689P	5.66	2.62e-08	9.25e-06	0.31	0.25	Mean platelet volume;	chr5:122934829	chr5:123022487~123022783:-
LUAD	cis	rs17301013	0.632	rs1653636	ENSG00000227373.4	RP11-160H22.5	-5.66	2.62e-08	9.25e-06	-0.34	-0.25	Systemic lupus erythematosus;	chr1:174767739	chr1:174115300~174160004:-
LUAD	cis	rs2404602	0.692	rs7350777	ENSG00000259422.1	RP11-593F23.1	5.66	2.62e-08	9.26e-06	0.29	0.25	Blood metabolite levels;	chr15:76693100	chr15:76174891~76181486:-
LUAD	cis	rs17818399	0.781	rs4952837	ENSG00000279254.1	RP11-536C12.1	-5.66	2.62e-08	9.26e-06	-0.29	-0.25	Height;	chr2:46638595	chr2:46668870~46670778:+
LUAD	cis	rs17818399	0.781	rs6746598	ENSG00000279254.1	RP11-536C12.1	-5.66	2.62e-08	9.26e-06	-0.29	-0.25	Height;	chr2:46638634	chr2:46668870~46670778:+
LUAD	cis	rs11971779	0.715	rs6943973	ENSG00000273391.1	RP11-634H22.1	5.66	2.62e-08	9.26e-06	0.26	0.25	Diisocyanate-induced asthma;	chr7:139345147	chr7:139359032~139359566:-
LUAD	cis	rs4835473	0.932	rs1597445	ENSG00000251600.4	RP11-673E1.1	-5.66	2.62e-08	9.26e-06	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143768543	chr4:143912331~143982454:+
LUAD	cis	rs11098499	1	rs6849889	ENSG00000248280.1	RP11-33B1.2	5.66	2.62e-08	9.26e-06	0.32	0.25	Corneal astigmatism;	chr4:119265193	chr4:119440561~119450157:-
LUAD	cis	rs7923609	0.902	rs10822158	ENSG00000232075.1	MRPL35P2	-5.66	2.62e-08	9.27e-06	-0.31	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63334623	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.846	rs10740115	ENSG00000232075.1	MRPL35P2	-5.66	2.62e-08	9.27e-06	-0.31	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63335230	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.846	rs10740116	ENSG00000232075.1	MRPL35P2	-5.66	2.62e-08	9.27e-06	-0.31	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63335232	chr10:63634317~63634827:-
LUAD	cis	rs8031584	0.541	rs1983459	ENSG00000260382.1	RP11-540B6.2	5.66	2.62e-08	9.27e-06	0.28	0.25	Huntington's disease progression;	chr15:30916546	chr15:30882267~30883231:-
LUAD	cis	rs748404	0.666	rs12907870	ENSG00000205771.5	CATSPER2P1	-5.66	2.62e-08	9.27e-06	-0.37	-0.25	Lung cancer;	chr15:43453971	chr15:43726918~43747094:-
LUAD	cis	rs997295	0.713	rs10518739	ENSG00000270964.1	RP11-502I4.3	5.66	2.62e-08	9.27e-06	0.26	0.25	Motion sickness;	chr15:67722633	chr15:67541072~67542604:-
LUAD	cis	rs62432291	0.681	rs3003173	ENSG00000235086.1	FNDC1-IT1	-5.66	2.63e-08	9.29e-06	-0.44	-0.25	Joint mobility (Beighton score);	chr6:159244660	chr6:159240786~159243329:+
LUAD	cis	rs7674212	1	rs7674212	ENSG00000246560.2	RP11-10L12.4	5.66	2.63e-08	9.3e-06	0.32	0.25	Type 2 diabetes;	chr4:103067742	chr4:102828055~102844075:+
LUAD	cis	rs6687821	0.515	rs10873806	ENSG00000267734.1	RP4-604K5.3	-5.66	2.64e-08	9.31e-06	-0.31	-0.25	Yeast infection;	chr1:86974915	chr1:86932199~86934891:-
LUAD	cis	rs10214930	0.813	rs6462039	ENSG00000235574.1	AC073150.6	5.66	2.64e-08	9.31e-06	0.33	0.25	Hypospadias;	chr7:27626763	chr7:27491682~27492765:-
LUAD	cis	rs848490	0.674	rs17807185	ENSG00000214293.7	APTR	5.66	2.64e-08	9.31e-06	0.28	0.25	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77678978	chr7:77657660~77696265:-
LUAD	cis	rs7772486	0.536	rs9373467	ENSG00000235652.6	RP11-545I5.3	5.66	2.64e-08	9.33e-06	0.26	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145634469	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs411641	ENSG00000235652.6	RP11-545I5.3	5.66	2.64e-08	9.33e-06	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145506396	chr6:145799409~145886585:+
LUAD	cis	rs997295	0.713	rs3784695	ENSG00000270964.1	RP11-502I4.3	-5.66	2.64e-08	9.33e-06	-0.26	-0.25	Motion sickness;	chr15:67710264	chr15:67541072~67542604:-
LUAD	cis	rs9914544	0.628	rs4924924	ENSG00000273018.4	CTD-2303H24.2	-5.66	2.64e-08	9.34e-06	-0.3	-0.25	Educational attainment (years of education);	chr17:18774461	chr17:18511221~18551705:-
LUAD	cis	rs858239	1	rs156407	ENSG00000226816.2	AC005082.12	5.66	2.64e-08	9.34e-06	0.33	0.25	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23206013~23208045:+
LUAD	cis	rs2243480	1	rs709607	ENSG00000230295.1	RP11-458F8.2	5.66	2.64e-08	9.34e-06	0.3	0.25	Diabetic kidney disease;	chr7:65984554	chr7:66880708~66882981:+
LUAD	cis	rs7849270	0.76	rs1075650	ENSG00000268707.1	RP11-247A12.7	5.66	2.65e-08	9.34e-06	0.3	0.25	Blood metabolite ratios;	chr9:129176634	chr9:129170434~129170940:+
LUAD	cis	rs4835473	0.932	rs62339580	ENSG00000251600.4	RP11-673E1.1	-5.66	2.65e-08	9.35e-06	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143785090	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs62339581	ENSG00000251600.4	RP11-673E1.1	-5.66	2.65e-08	9.35e-06	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143785172	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs7666368	ENSG00000251600.4	RP11-673E1.1	-5.66	2.65e-08	9.35e-06	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143785372	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs7690428	ENSG00000251600.4	RP11-673E1.1	-5.66	2.65e-08	9.35e-06	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143785400	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs34781605	ENSG00000251600.4	RP11-673E1.1	-5.66	2.65e-08	9.35e-06	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143785486	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs11100810	ENSG00000251600.4	RP11-673E1.1	-5.66	2.65e-08	9.35e-06	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143787518	chr4:143912331~143982454:+
LUAD	cis	rs7615952	0.512	rs1077621	ENSG00000171084.14	FAM86JP	5.66	2.65e-08	9.36e-06	0.37	0.25	Blood pressure (smoking interaction);	chr3:126100956	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.512	rs4646765	ENSG00000171084.14	FAM86JP	5.66	2.65e-08	9.36e-06	0.37	0.25	Blood pressure (smoking interaction);	chr3:126101864	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.576	rs4646763	ENSG00000171084.14	FAM86JP	5.66	2.65e-08	9.36e-06	0.37	0.25	Blood pressure (smoking interaction);	chr3:126103286	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.576	rs4646759	ENSG00000171084.14	FAM86JP	5.66	2.65e-08	9.36e-06	0.37	0.25	Blood pressure (smoking interaction);	chr3:126104103	chr3:125916620~125930024:+
LUAD	cis	rs2412819	0.571	rs6493090	ENSG00000249839.1	AC011330.5	5.66	2.65e-08	9.36e-06	0.4	0.25	Lung cancer;	chr15:43792084	chr15:43663654~43684339:-
LUAD	cis	rs6570726	0.935	rs419847	ENSG00000235652.6	RP11-545I5.3	5.66	2.65e-08	9.36e-06	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145506142	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs419850	ENSG00000235652.6	RP11-545I5.3	5.66	2.65e-08	9.36e-06	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145506145	chr6:145799409~145886585:+
LUAD	cis	rs7923609	1	rs10822161	ENSG00000232075.1	MRPL35P2	-5.66	2.65e-08	9.37e-06	-0.3	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63358443	chr10:63634317~63634827:-
LUAD	cis	rs10246939	0.543	rs9640357	ENSG00000270923.1	TAS2R6P	-5.66	2.65e-08	9.37e-06	-0.27	-0.25	Bitter taste perception;	chr7:141843298	chr7:141787815~141788640:+
LUAD	cis	rs1799949	0.965	rs799912	ENSG00000267681.1	CTD-3199J23.6	-5.66	2.65e-08	9.37e-06	-0.28	-0.25	Menopause (age at onset);	chr17:43105117	chr17:43144956~43145255:+
LUAD	cis	rs477895	1	rs7939107	ENSG00000236935.1	AP003774.1	-5.66	2.66e-08	9.38e-06	-0.31	-0.25	Mean platelet volume;	chr11:64267301	chr11:64325050~64329504:-
LUAD	cis	rs477895	1	rs7938380	ENSG00000236935.1	AP003774.1	-5.66	2.66e-08	9.38e-06	-0.31	-0.25	Mean platelet volume;	chr11:64267394	chr11:64325050~64329504:-
LUAD	cis	rs71386933	0.543	rs36114735	ENSG00000260886.1	TAT-AS1	5.66	2.66e-08	9.38e-06	0.5	0.25	Post bronchodilator FEV1;	chr16:71983784	chr16:71565789~71578187:+
LUAD	cis	rs75920871	0.588	rs1815789	ENSG00000254851.1	RP11-109L13.1	5.66	2.66e-08	9.38e-06	0.37	0.25	Subjective well-being;	chr11:116964237	chr11:117135528~117138582:+
LUAD	cis	rs75920871	0.588	rs1815788	ENSG00000254851.1	RP11-109L13.1	5.66	2.66e-08	9.38e-06	0.37	0.25	Subjective well-being;	chr11:116964255	chr11:117135528~117138582:+
LUAD	cis	rs7968440	0.902	rs2684901	ENSG00000200428.1	Y_RNA	-5.66	2.66e-08	9.38e-06	-0.31	-0.25	Fibrinogen;	chr12:50657985	chr12:50743568~50743684:+
LUAD	cis	rs9860428	0.935	rs1114404	ENSG00000242770.2	RP11-180K7.1	5.66	2.66e-08	9.39e-06	0.25	0.25	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112844072	chr3:112802478~112812819:+
LUAD	cis	rs12468226	0.873	rs6435138	ENSG00000226261.1	AC064836.3	-5.66	2.66e-08	9.39e-06	-0.41	-0.25	Urate levels;	chr2:202234310	chr2:202336024~202336727:-
LUAD	cis	rs10214930	0.957	rs10230973	ENSG00000235574.1	AC073150.6	5.66	2.66e-08	9.4e-06	0.36	0.25	Hypospadias;	chr7:27743305	chr7:27491682~27492765:-
LUAD	cis	rs2404602	0.692	rs12437733	ENSG00000259422.1	RP11-593F23.1	5.66	2.66e-08	9.4e-06	0.29	0.25	Blood metabolite levels;	chr15:76863221	chr15:76174891~76181486:-
LUAD	cis	rs7829975	0.564	rs2976855	ENSG00000253981.4	ALG1L13P	5.66	2.66e-08	9.4e-06	0.29	0.25	Mood instability;	chr8:8444284	chr8:8236003~8244667:-
LUAD	cis	rs7712401	0.601	rs398142	ENSG00000263432.2	RN7SL689P	-5.66	2.67e-08	9.43e-06	-0.31	-0.25	Mean platelet volume;	chr5:123009881	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.58	rs383262	ENSG00000263432.2	RN7SL689P	-5.66	2.67e-08	9.43e-06	-0.31	-0.25	Mean platelet volume;	chr5:123009989	chr5:123022487~123022783:-
LUAD	cis	rs9595908	0.758	rs2031354	ENSG00000212293.1	SNORA16	5.66	2.68e-08	9.44e-06	0.27	0.25	Body mass index;	chr13:32641454	chr13:32420390~32420516:-
LUAD	cis	rs11742741	0.539	rs13168500	ENSG00000248874.4	C5orf17	-5.66	2.68e-08	9.44e-06	-0.31	-0.25	Educational attainment;	chr5:24094615	chr5:23951348~24178263:+
LUAD	cis	rs7246657	0.508	rs1644702	ENSG00000276846.1	CTD-3220F14.3	5.65	2.68e-08	9.46e-06	0.38	0.25	Coronary artery calcification;	chr19:37001005	chr19:37314868~37315620:-
LUAD	cis	rs2408955	0.522	rs11168408	ENSG00000240399.1	RP1-228P16.1	-5.65	2.68e-08	9.46e-06	-0.25	-0.25	Glycated hemoglobin levels;	chr12:48104544	chr12:48054813~48055591:-
LUAD	cis	rs7743045	0.625	rs12664251	ENSG00000253194.1	RP11-351A11.1	5.65	2.68e-08	9.46e-06	0.34	0.25	Mean platelet volume;	chr6:119023381	chr6:118934785~119031541:+
LUAD	cis	rs944289	0.6	rs1169123	ENSG00000257826.1	RP11-116N8.4	-5.65	2.68e-08	9.47e-06	-0.27	-0.25	Thyroid cancer;	chr14:36149287	chr14:36061026~36067190:-
LUAD	cis	rs875971	0.571	rs160641	ENSG00000226824.5	RP4-756H11.3	5.65	2.68e-08	9.47e-06	0.37	0.25	Aortic root size;	chr7:66112359	chr7:66654538~66669855:+
LUAD	cis	rs8031584	0.723	rs11632229	ENSG00000270015.1	RP11-540B6.6	5.65	2.68e-08	9.47e-06	0.18	0.25	Huntington's disease progression;	chr15:30887331	chr15:30926514~30928407:+
LUAD	cis	rs66887589	0.967	rs56173225	ENSG00000245958.5	RP11-33B1.1	5.65	2.69e-08	9.47e-06	0.2	0.25	Diastolic blood pressure;	chr4:119588817	chr4:119454791~119552025:+
LUAD	cis	rs66887589	0.967	rs7678973	ENSG00000245958.5	RP11-33B1.1	5.65	2.69e-08	9.47e-06	0.2	0.25	Diastolic blood pressure;	chr4:119590662	chr4:119454791~119552025:+
LUAD	cis	rs66887589	0.934	rs56843000	ENSG00000245958.5	RP11-33B1.1	5.65	2.69e-08	9.47e-06	0.2	0.25	Diastolic blood pressure;	chr4:119595442	chr4:119454791~119552025:+
LUAD	cis	rs2337406	0.925	rs76288499	ENSG00000211974.3	IGHV2-70	-5.65	2.69e-08	9.49e-06	-0.34	-0.25	Alzheimer's disease (late onset);	chr14:106686309	chr14:106723574~106724093:-
LUAD	cis	rs9652601	0.696	rs12917656	ENSG00000274038.1	RP11-66H6.4	-5.65	2.69e-08	9.49e-06	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11094005	chr16:11056556~11057034:+
LUAD	cis	rs4141404	0.851	rs5749248	ENSG00000236132.1	CTA-440B3.1	5.65	2.69e-08	9.49e-06	0.35	0.25	Paclitaxel-induced neuropathy;	chr22:31287725	chr22:31816379~31817491:-
LUAD	cis	rs673078	0.66	rs7974718	ENSG00000275409.1	RP11-131L12.4	-5.65	2.69e-08	9.5e-06	-0.33	-0.25	Glucose homeostasis traits;	chr12:118243258	chr12:118430147~118430699:+
LUAD	cis	rs7208859	0.673	rs56846352	ENSG00000263531.1	RP13-753N3.1	5.65	2.69e-08	9.5e-06	0.43	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792170	chr17:30863921~30864940:-
LUAD	cis	rs10129255	0.957	rs8005468	ENSG00000224373.3	IGHV4-59	5.65	2.7e-08	9.51e-06	0.16	0.25	Kawasaki disease;	chr14:106686431	chr14:106627249~106627825:-
LUAD	cis	rs9640161	0.83	rs3757425	ENSG00000261305.1	RP4-584D14.7	5.65	2.7e-08	9.52e-06	0.34	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150370551	chr7:150341771~150342607:+
LUAD	cis	rs9640161	0.83	rs3757424	ENSG00000261305.1	RP4-584D14.7	5.65	2.7e-08	9.52e-06	0.34	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150370590	chr7:150341771~150342607:+
LUAD	cis	rs1150668	0.768	rs1233713	ENSG00000219392.1	RP1-265C24.5	-5.65	2.7e-08	9.52e-06	-0.31	-0.25	Pubertal anthropometrics;	chr6:28230503	chr6:28115628~28116551:+
LUAD	cis	rs11096990	0.892	rs3733288	ENSG00000249207.1	RP11-360F5.1	5.65	2.7e-08	9.52e-06	0.29	0.25	Cognitive function;	chr4:39216949	chr4:39112677~39126818:-
LUAD	cis	rs7826238	0.601	rs2979206	ENSG00000253893.2	FAM85B	-5.65	2.7e-08	9.53e-06	-0.31	-0.25	Systolic blood pressure;	chr8:8488071	chr8:8167819~8226614:-
LUAD	cis	rs867371	0.896	rs6495647	ENSG00000259429.4	UBE2Q2P2	-5.65	2.7e-08	9.53e-06	-0.22	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82244708	chr15:82355142~82420075:+
LUAD	cis	rs17684571	1	rs16888133	ENSG00000231441.1	RP11-472M19.2	5.65	2.7e-08	9.54e-06	0.33	0.25	Schizophrenia;	chr6:56709593	chr6:56844002~56864078:+
LUAD	cis	rs9652601	0.622	rs1861548	ENSG00000274038.1	RP11-66H6.4	-5.65	2.7e-08	9.54e-06	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11024643	chr16:11056556~11057034:+
LUAD	cis	rs9543976	0.623	rs8192764	ENSG00000261553.4	RP11-29G8.3	5.65	2.71e-08	9.54e-06	0.33	0.25	Diabetic retinopathy;	chr13:75605079	chr13:75549773~75807120:+
LUAD	cis	rs896854	0.625	rs7823886	ENSG00000253528.2	RP11-347C18.4	5.65	2.71e-08	9.54e-06	0.24	0.25	Type 2 diabetes;	chr8:94974231	chr8:94974573~94974853:-
LUAD	cis	rs35160687	0.644	rs4832271	ENSG00000273080.1	RP11-301O19.1	-5.65	2.71e-08	9.54e-06	-0.28	-0.25	Night sleep phenotypes;	chr2:86278204	chr2:86195590~86196049:+
LUAD	cis	rs2243480	1	rs1499613	ENSG00000230295.1	RP11-458F8.2	5.65	2.71e-08	9.55e-06	0.3	0.25	Diabetic kidney disease;	chr7:66265873	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs1553174	ENSG00000230295.1	RP11-458F8.2	5.65	2.71e-08	9.55e-06	0.3	0.25	Diabetic kidney disease;	chr7:66266207	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs10950032	ENSG00000230295.1	RP11-458F8.2	5.65	2.71e-08	9.55e-06	0.3	0.25	Diabetic kidney disease;	chr7:66273604	chr7:66880708~66882981:+
LUAD	cis	rs1075265	0.73	rs2111868	ENSG00000233266.1	HMGB1P31	5.65	2.71e-08	9.55e-06	0.32	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53958916	chr2:54051334~54051760:+
LUAD	cis	rs875971	1	rs6957199	ENSG00000237310.1	GS1-124K5.4	5.65	2.71e-08	9.57e-06	0.27	0.25	Aortic root size;	chr7:66513532	chr7:66493706~66495474:+
LUAD	cis	rs944289	0.576	rs1169131	ENSG00000257826.1	RP11-116N8.4	-5.65	2.71e-08	9.57e-06	-0.28	-0.25	Thyroid cancer;	chr14:36153349	chr14:36061026~36067190:-
LUAD	cis	rs17684571	0.938	rs16888130	ENSG00000231441.1	RP11-472M19.2	5.65	2.72e-08	9.59e-06	0.33	0.25	Schizophrenia;	chr6:56709382	chr6:56844002~56864078:+
LUAD	cis	rs7968440	1	rs2684898	ENSG00000200428.1	Y_RNA	-5.65	2.72e-08	9.59e-06	-0.31	-0.25	Fibrinogen;	chr12:50653042	chr12:50743568~50743684:+
LUAD	cis	rs2243480	1	rs464895	ENSG00000230295.1	RP11-458F8.2	-5.65	2.72e-08	9.59e-06	-0.31	-0.25	Diabetic kidney disease;	chr7:66062119	chr7:66880708~66882981:+
LUAD	cis	rs7397814	0.558	rs4764447	ENSG00000256673.1	RP11-599J14.2	5.65	2.72e-08	9.6e-06	0.29	0.25	IgG glycosylation;	chr12:9426513	chr12:9398355~9414851:-
LUAD	cis	rs891378	0.874	rs59036171	ENSG00000274245.1	RP11-357P18.2	-5.65	2.73e-08	9.61e-06	-0.3	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207271583	chr1:207372559~207373252:+
LUAD	cis	rs10800713	0.954	rs10800710	ENSG00000260088.1	RP11-92G12.3	-5.65	2.73e-08	9.61e-06	-0.35	-0.25	Tandem gait;	chr1:200569240	chr1:200669507~200694250:+
LUAD	cis	rs10800713	0.954	rs10800711	ENSG00000260088.1	RP11-92G12.3	-5.65	2.73e-08	9.61e-06	-0.35	-0.25	Tandem gait;	chr1:200569757	chr1:200669507~200694250:+
LUAD	cis	rs10800713	0.954	rs12092148	ENSG00000260088.1	RP11-92G12.3	-5.65	2.73e-08	9.61e-06	-0.35	-0.25	Tandem gait;	chr1:200570655	chr1:200669507~200694250:+
LUAD	cis	rs10800713	0.826	rs11586257	ENSG00000260088.1	RP11-92G12.3	-5.65	2.73e-08	9.61e-06	-0.35	-0.25	Tandem gait;	chr1:200572236	chr1:200669507~200694250:+
LUAD	cis	rs10800713	0.954	rs10800712	ENSG00000260088.1	RP11-92G12.3	-5.65	2.73e-08	9.61e-06	-0.35	-0.25	Tandem gait;	chr1:200576059	chr1:200669507~200694250:+
LUAD	cis	rs10800713	0.908	rs10919978	ENSG00000260088.1	RP11-92G12.3	-5.65	2.73e-08	9.61e-06	-0.35	-0.25	Tandem gait;	chr1:200576923	chr1:200669507~200694250:+
LUAD	cis	rs10800713	0.954	rs4353125	ENSG00000260088.1	RP11-92G12.3	-5.65	2.73e-08	9.61e-06	-0.35	-0.25	Tandem gait;	chr1:200582178	chr1:200669507~200694250:+
LUAD	cis	rs10129255	0.957	rs8009464	ENSG00000224373.3	IGHV4-59	5.65	2.73e-08	9.61e-06	0.16	0.25	Kawasaki disease;	chr14:106777611	chr14:106627249~106627825:-
LUAD	cis	rs4835473	0.932	rs13134327	ENSG00000251600.4	RP11-673E1.1	5.65	2.73e-08	9.62e-06	0.3	0.25	Immature fraction of reticulocytes;	chr4:143738642	chr4:143912331~143982454:+
LUAD	cis	rs2599510	0.783	rs2710630	ENSG00000276334.1	AL133243.1	-5.65	2.73e-08	9.62e-06	-0.29	-0.25	Interleukin-18 levels;	chr2:32540930	chr2:32521927~32523547:+
LUAD	cis	rs9595908	0.669	rs4057298	ENSG00000212293.1	SNORA16	5.65	2.73e-08	9.62e-06	0.27	0.25	Body mass index;	chr13:32734227	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.669	rs17516382	ENSG00000212293.1	SNORA16	5.65	2.73e-08	9.62e-06	0.27	0.25	Body mass index;	chr13:32735426	chr13:32420390~32420516:-
LUAD	cis	rs801193	0.569	rs11761542	ENSG00000237310.1	GS1-124K5.4	5.65	2.74e-08	9.64e-06	0.27	0.25	Aortic root size;	chr7:66753209	chr7:66493706~66495474:+
LUAD	cis	rs7684253	0.587	rs9685436	ENSG00000269949.1	RP11-738E22.3	-5.65	2.74e-08	9.65e-06	-0.33	-0.25	Migraine;	chr4:56881195	chr4:56960927~56961373:-
LUAD	cis	rs948562	0.519	rs4127347	ENSG00000280010.1	AP001350.4	5.65	2.74e-08	9.65e-06	0.37	0.25	Lymphoma;	chr11:58282283	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.573	rs77894570	ENSG00000280010.1	AP001350.4	5.65	2.74e-08	9.65e-06	0.37	0.25	Lymphoma;	chr11:58283639	chr11:58627435~58628528:+
LUAD	cis	rs4604732	0.578	rs12040725	ENSG00000227135.1	GCSAML-AS1	-5.65	2.74e-08	9.65e-06	-0.39	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247481395	chr1:247524679~247526752:-
LUAD	cis	rs1035539	1	rs1035539	ENSG00000280152.1	RP11-331F4.5	5.65	2.74e-08	9.66e-06	0.22	0.25	Alcoholic chronic pancreatitis;	chr16:75242877	chr16:75245994~75250077:-
LUAD	cis	rs6504622	0.818	rs3851784	ENSG00000262879.4	RP11-156P1.3	5.65	2.74e-08	9.66e-06	0.29	0.25	Orofacial clefts;	chr17:46962751	chr17:46984045~47100323:-
LUAD	cis	rs2243480	1	rs2420170	ENSG00000230295.1	RP11-458F8.2	5.65	2.74e-08	9.66e-06	0.3	0.25	Diabetic kidney disease;	chr7:66191066	chr7:66880708~66882981:+
LUAD	cis	rs3738443	0.868	rs56029850	ENSG00000259865.1	RP11-488L18.10	5.65	2.74e-08	9.67e-06	0.25	0.25	Alcohol dependence;	chr1:247201027	chr1:247187281~247188526:-
LUAD	cis	rs3738443	0.868	rs55643126	ENSG00000259865.1	RP11-488L18.10	5.65	2.74e-08	9.67e-06	0.25	0.25	Alcohol dependence;	chr1:247201042	chr1:247187281~247188526:-
LUAD	cis	rs7826238	0.509	rs2948288	ENSG00000253981.4	ALG1L13P	5.65	2.75e-08	9.67e-06	0.29	0.25	Systolic blood pressure;	chr8:8257782	chr8:8236003~8244667:-
LUAD	cis	rs36093844	0.752	rs7121363	ENSG00000279742.1	RP11-700A24.1	-5.65	2.75e-08	9.68e-06	-0.32	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85864067	chr11:85852557~85854943:-
LUAD	cis	rs16863064	0.932	rs9816875	ENSG00000279891.1	FLJ42393	5.65	2.75e-08	9.68e-06	0.36	0.25	Schizophrenia;	chr3:188169404	chr3:188178543~188180812:+
LUAD	cis	rs12468226	0.873	rs6761131	ENSG00000226261.1	AC064836.3	-5.65	2.75e-08	9.69e-06	-0.41	-0.25	Urate levels;	chr2:202237675	chr2:202336024~202336727:-
LUAD	cis	rs1015362	0.54	rs2050209	ENSG00000276073.1	RP5-1125A11.7	5.65	2.75e-08	9.7e-06	0.31	0.25	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33897730	chr20:33985617~33988989:-
LUAD	cis	rs7923609	1	rs10822149	ENSG00000232075.1	MRPL35P2	-5.65	2.76e-08	9.71e-06	-0.3	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63227652	chr10:63634317~63634827:-
LUAD	cis	rs7923609	1	rs10761727	ENSG00000232075.1	MRPL35P2	-5.65	2.76e-08	9.71e-06	-0.3	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63235733	chr10:63634317~63634827:-
LUAD	cis	rs7923609	0.967	rs10761729	ENSG00000232075.1	MRPL35P2	-5.65	2.76e-08	9.71e-06	-0.3	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63235844	chr10:63634317~63634827:-
LUAD	cis	rs7923609	1	rs4399232	ENSG00000232075.1	MRPL35P2	-5.65	2.76e-08	9.71e-06	-0.3	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63239730	chr10:63634317~63634827:-
LUAD	cis	rs75422866	0.51	rs73105812	ENSG00000274902.1	RP1-197B17.4	5.65	2.76e-08	9.72e-06	0.56	0.25	Pneumonia;	chr12:47724404	chr12:47731908~47732351:+
LUAD	cis	rs2404602	0.692	rs55729975	ENSG00000259422.1	RP11-593F23.1	5.65	2.76e-08	9.73e-06	0.29	0.25	Blood metabolite levels;	chr15:76510885	chr15:76174891~76181486:-
LUAD	cis	rs72615157	0.634	rs74742883	ENSG00000242294.5	STAG3L5P	5.65	2.76e-08	9.73e-06	0.21	0.25	Lung function (FEV1/FVC);	chr7:100188142	chr7:100336079~100351900:+
LUAD	cis	rs2404602	0.692	rs2117369	ENSG00000259422.1	RP11-593F23.1	5.65	2.77e-08	9.73e-06	0.28	0.25	Blood metabolite levels;	chr15:76456520	chr15:76174891~76181486:-
LUAD	cis	rs72615157	0.628	rs7801070	ENSG00000242294.5	STAG3L5P	5.65	2.77e-08	9.75e-06	0.21	0.25	Lung function (FEV1/FVC);	chr7:100249524	chr7:100336079~100351900:+
LUAD	cis	rs910316	1	rs12879542	ENSG00000259138.1	RP11-950C14.7	5.65	2.77e-08	9.75e-06	0.26	0.25	Height;	chr14:75040822	chr14:75127153~75136930:+
LUAD	cis	rs2404602	0.716	rs2164101	ENSG00000259422.1	RP11-593F23.1	5.65	2.77e-08	9.76e-06	0.28	0.25	Blood metabolite levels;	chr15:76456776	chr15:76174891~76181486:-
LUAD	cis	rs5753618	0.561	rs5749265	ENSG00000236132.1	CTA-440B3.1	-5.65	2.78e-08	9.77e-06	-0.31	-0.25	Colorectal cancer;	chr22:31400911	chr22:31816379~31817491:-
LUAD	cis	rs7923609	1	rs7073746	ENSG00000232075.1	MRPL35P2	-5.65	2.78e-08	9.77e-06	-0.3	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63144311	chr10:63634317~63634827:-
LUAD	cis	rs7927592	0.731	rs7108376	ENSG00000212093.1	AP000807.1	-5.65	2.78e-08	9.78e-06	-0.25	-0.25	Total body bone mineral density;	chr11:68580402	chr11:68506083~68506166:-
LUAD	cis	rs72615157	0.645	rs11771660	ENSG00000242294.5	STAG3L5P	5.65	2.79e-08	9.8e-06	0.21	0.25	Lung function (FEV1/FVC);	chr7:100253646	chr7:100336079~100351900:+
LUAD	cis	rs494459	0.726	rs1784300	ENSG00000278376.1	RP11-158I9.8	-5.65	2.79e-08	9.8e-06	-0.27	-0.25	Height;	chr11:118808920	chr11:118791254~118793137:+
LUAD	cis	rs9992667	0.955	rs2078179	ENSG00000231160.8	KLF3-AS1	5.65	2.79e-08	9.8e-06	0.32	0.25	Eosinophil percentage of granulocytes;	chr4:38662878	chr4:38612701~38664883:-
LUAD	cis	rs9992667	0.664	rs112691446	ENSG00000231160.8	KLF3-AS1	5.65	2.79e-08	9.8e-06	0.32	0.25	Eosinophil percentage of granulocytes;	chr4:38663521	chr4:38612701~38664883:-
LUAD	cis	rs12935418	1	rs12935418	ENSG00000261838.4	RP11-303E16.6	5.65	2.79e-08	9.81e-06	0.46	0.25	Mean corpuscular volume;	chr16:81036403	chr16:81069854~81076598:+
LUAD	cis	rs7657257	1	rs11931532	ENSG00000214846.4	RP11-115L11.1	5.65	2.79e-08	9.81e-06	0.6	0.25	Blood protein levels;	chr4:15724143	chr4:15730962~15731627:-
LUAD	cis	rs4835473	0.771	rs34069296	ENSG00000251600.4	RP11-673E1.1	-5.65	2.79e-08	9.81e-06	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143759656	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.897	rs7687915	ENSG00000251600.4	RP11-673E1.1	-5.65	2.79e-08	9.81e-06	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143759801	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1993015	ENSG00000251600.4	RP11-673E1.1	-5.65	2.79e-08	9.81e-06	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143760202	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs1993016	ENSG00000251600.4	RP11-673E1.1	-5.65	2.79e-08	9.81e-06	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143760217	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1993017	ENSG00000251600.4	RP11-673E1.1	-5.65	2.79e-08	9.81e-06	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143760285	chr4:143912331~143982454:+
LUAD	cis	rs1198872	0.563	rs1106185	ENSG00000272275.1	RP11-791G15.2	5.65	2.79e-08	9.82e-06	0.32	0.25	Cardiac Troponin-T levels;	chr2:10823444	chr2:10767875~10770058:-
LUAD	cis	rs7829975	0.902	rs485107	ENSG00000253893.2	FAM85B	5.65	2.79e-08	9.82e-06	0.32	0.25	Mood instability;	chr8:8723898	chr8:8167819~8226614:-
LUAD	cis	rs36093844	0.898	rs11234462	ENSG00000279742.1	RP11-700A24.1	-5.65	2.79e-08	9.83e-06	-0.29	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85885881	chr11:85852557~85854943:-
LUAD	cis	rs896854	0.654	rs16893776	ENSG00000253528.2	RP11-347C18.4	5.65	2.79e-08	9.83e-06	0.24	0.25	Type 2 diabetes;	chr8:94961376	chr8:94974573~94974853:-
LUAD	cis	rs4835473	0.932	rs1450236	ENSG00000251600.4	RP11-673E1.1	-5.65	2.8e-08	9.84e-06	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143783069	chr4:143912331~143982454:+
LUAD	cis	rs2599510	0.783	rs2038534	ENSG00000276334.1	AL133243.1	5.65	2.8e-08	9.84e-06	0.29	0.25	Interleukin-18 levels;	chr2:32434421	chr2:32521927~32523547:+
LUAD	cis	rs11105298	0.891	rs11105314	ENSG00000258302.2	RP11-981P6.1	5.65	2.8e-08	9.85e-06	0.31	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89530782	chr12:89561129~89594878:+
LUAD	cis	rs11673344	0.642	rs55926714	ENSG00000226686.6	LINC01535	5.65	2.8e-08	9.85e-06	0.32	0.25	Obesity-related traits;	chr19:37307974	chr19:37251912~37265535:+
LUAD	cis	rs5753618	0.583	rs5753601	ENSG00000236132.1	CTA-440B3.1	-5.65	2.8e-08	9.85e-06	-0.31	-0.25	Colorectal cancer;	chr22:31402273	chr22:31816379~31817491:-
LUAD	cis	rs5753618	0.583	rs8141150	ENSG00000236132.1	CTA-440B3.1	-5.65	2.8e-08	9.85e-06	-0.31	-0.25	Colorectal cancer;	chr22:31404350	chr22:31816379~31817491:-
LUAD	cis	rs5753618	0.583	rs9606839	ENSG00000236132.1	CTA-440B3.1	-5.65	2.8e-08	9.85e-06	-0.31	-0.25	Colorectal cancer;	chr22:31406724	chr22:31816379~31817491:-
LUAD	cis	rs7923837	0.574	rs2488075	ENSG00000236493.2	EIF2S2P3	-5.65	2.8e-08	9.86e-06	-0.28	-0.25	Multiple sclerosis;Body mass index;	chr10:92730417	chr10:92668745~92669743:-
LUAD	cis	rs62432291	0.681	rs7757530	ENSG00000235086.1	FNDC1-IT1	5.65	2.8e-08	9.86e-06	0.42	0.25	Joint mobility (Beighton score);	chr6:159226897	chr6:159240786~159243329:+
LUAD	cis	rs807029	0.577	rs3740488	ENSG00000272572.1	RP11-179B2.2	-5.65	2.8e-08	9.86e-06	-0.35	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100994276	chr10:100911103~100912739:-
LUAD	cis	rs897984	0.542	rs750952	ENSG00000260911.2	RP11-196G11.2	5.65	2.81e-08	9.87e-06	0.22	0.25	Dementia with Lewy bodies;	chr16:31082633	chr16:31043150~31049868:+
LUAD	cis	rs36093844	0.752	rs80193798	ENSG00000279742.1	RP11-700A24.1	-5.65	2.81e-08	9.88e-06	-0.33	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85866486	chr11:85852557~85854943:-
LUAD	cis	rs1707322	1	rs4660332	ENSG00000234329.1	RP11-767N6.2	5.65	2.81e-08	9.89e-06	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995746	chr1:45651039~45651826:-
LUAD	cis	rs6687821	0.515	rs1970607	ENSG00000267734.1	RP4-604K5.3	5.65	2.82e-08	9.9e-06	0.3	0.25	Yeast infection;	chr1:86962619	chr1:86932199~86934891:-
LUAD	cis	rs1707322	1	rs10890375	ENSG00000234329.1	RP11-767N6.2	5.65	2.82e-08	9.9e-06	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940909	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs10890377	ENSG00000234329.1	RP11-767N6.2	5.65	2.82e-08	9.9e-06	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940922	chr1:45651039~45651826:-
LUAD	cis	rs12701220	0.503	rs13222294	ENSG00000229043.2	AC091729.9	-5.65	2.82e-08	9.91e-06	-0.33	-0.25	Bronchopulmonary dysplasia;	chr7:1133333	chr7:1160374~1165267:+
LUAD	cis	rs2179367	0.632	rs9498321	ENSG00000231760.4	RP11-350J20.5	5.65	2.82e-08	9.91e-06	0.37	0.25	Dupuytren's disease;	chr6:149322573	chr6:149796151~149826294:-
LUAD	cis	rs7044106	0.762	rs1886337	ENSG00000238181.2	AHCYP2	-5.65	2.82e-08	9.91e-06	-0.32	-0.25	Hip circumference adjusted for BMI;	chr9:120681498	chr9:120720673~120721972:+
LUAD	cis	rs4835473	0.932	rs2218791	ENSG00000251600.4	RP11-673E1.1	-5.65	2.82e-08	9.91e-06	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143749300	chr4:143912331~143982454:+
LUAD	cis	rs2948294	0.524	rs13270062	ENSG00000253893.2	FAM85B	-5.65	2.82e-08	9.91e-06	-0.33	-0.25	Red cell distribution width;	chr8:8255128	chr8:8167819~8226614:-
LUAD	cis	rs910316	0.783	rs11850751	ENSG00000259138.1	RP11-950C14.7	5.65	2.82e-08	9.93e-06	0.27	0.25	Height;	chr14:75123410	chr14:75127153~75136930:+
LUAD	cis	rs12699921	0.658	rs2691592	ENSG00000279048.1	RP11-511H23.2	-5.65	2.82e-08	9.93e-06	-0.2	-0.25	Fibrinogen levels;	chr7:17779817	chr7:17940503~17942922:+
LUAD	cis	rs12699921	0.598	rs2691593	ENSG00000279048.1	RP11-511H23.2	-5.65	2.82e-08	9.93e-06	-0.2	-0.25	Fibrinogen levels;	chr7:17780032	chr7:17940503~17942922:+
LUAD	cis	rs12699921	0.632	rs2723507	ENSG00000279048.1	RP11-511H23.2	-5.65	2.82e-08	9.93e-06	-0.2	-0.25	Fibrinogen levels;	chr7:17780305	chr7:17940503~17942922:+
LUAD	cis	rs12699921	0.632	rs2691596	ENSG00000279048.1	RP11-511H23.2	-5.65	2.82e-08	9.93e-06	-0.2	-0.25	Fibrinogen levels;	chr7:17780460	chr7:17940503~17942922:+
LUAD	cis	rs12699921	0.632	rs2723506	ENSG00000279048.1	RP11-511H23.2	-5.65	2.82e-08	9.93e-06	-0.2	-0.25	Fibrinogen levels;	chr7:17780675	chr7:17940503~17942922:+
LUAD	cis	rs1707322	1	rs785490	ENSG00000234329.1	RP11-767N6.2	-5.65	2.83e-08	9.93e-06	-0.27	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46111452	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs785493	ENSG00000234329.1	RP11-767N6.2	-5.65	2.83e-08	9.93e-06	-0.27	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46119187	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.964	rs785496	ENSG00000234329.1	RP11-767N6.2	-5.65	2.83e-08	9.93e-06	-0.27	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46122334	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs785497	ENSG00000234329.1	RP11-767N6.2	-5.65	2.83e-08	9.93e-06	-0.27	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126231	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.964	rs785499	ENSG00000234329.1	RP11-767N6.2	-5.65	2.83e-08	9.93e-06	-0.27	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126748	chr1:45651039~45651826:-
LUAD	cis	rs11673344	0.642	rs12462487	ENSG00000226686.6	LINC01535	5.64	2.83e-08	9.93e-06	0.32	0.25	Obesity-related traits;	chr19:37311211	chr19:37251912~37265535:+
LUAD	cis	rs7727544	0.645	rs272857	ENSG00000233006.5	AC034220.3	5.64	2.83e-08	9.94e-06	0.23	0.25	Blood metabolite levels;	chr5:132349604	chr5:132311285~132369916:-
LUAD	cis	rs4538475	0.556	rs4266290	ENSG00000214846.4	RP11-115L11.1	5.64	2.83e-08	9.95e-06	0.36	0.25	Parkinson's disease;	chr4:15735495	chr4:15730962~15731627:-
LUAD	cis	rs1707322	0.89	rs2297883	ENSG00000234329.1	RP11-767N6.2	-5.64	2.83e-08	9.95e-06	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46045815	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs1707338	ENSG00000234329.1	RP11-767N6.2	-5.64	2.83e-08	9.95e-06	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46046309	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.964	rs1707339	ENSG00000234329.1	RP11-767N6.2	-5.64	2.83e-08	9.95e-06	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46047507	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs1768818	ENSG00000234329.1	RP11-767N6.2	-5.64	2.83e-08	9.95e-06	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048614	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs1768817	ENSG00000234329.1	RP11-767N6.2	-5.64	2.83e-08	9.95e-06	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048862	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs785470	ENSG00000234329.1	RP11-767N6.2	-5.64	2.83e-08	9.95e-06	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46053950	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs785469	ENSG00000234329.1	RP11-767N6.2	-5.64	2.83e-08	9.95e-06	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055419	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs785468	ENSG00000234329.1	RP11-767N6.2	-5.64	2.83e-08	9.95e-06	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055845	chr1:45651039~45651826:-
LUAD	cis	rs17711722	0.523	rs365896	ENSG00000224316.1	RP11-479O9.2	-5.64	2.83e-08	9.96e-06	-0.25	-0.25	Calcium levels;	chr7:66045710	chr7:65773620~65802067:+
LUAD	cis	rs11105298	0.891	rs11105299	ENSG00000258302.2	RP11-981P6.1	5.64	2.83e-08	9.96e-06	0.32	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89484166	chr12:89561129~89594878:+
LUAD	cis	rs6921919	0.583	rs2071965	ENSG00000216901.1	AL022393.7	5.64	2.84e-08	9.96e-06	0.3	0.25	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28176188~28176674:+
LUAD	cis	rs997295	0.57	rs17241808	ENSG00000270964.1	RP11-502I4.3	-5.64	2.84e-08	9.96e-06	-0.26	-0.25	Motion sickness;	chr15:67600454	chr15:67541072~67542604:-
LUAD	cis	rs7712401	0.562	rs30046	ENSG00000263432.2	RN7SL689P	5.64	2.84e-08	9.96e-06	0.31	0.25	Mean platelet volume;	chr5:122935538	chr5:123022487~123022783:-
LUAD	cis	rs1707322	0.721	rs7519900	ENSG00000280836.1	AL355480.1	-5.64	2.84e-08	9.97e-06	-0.33	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769275	chr1:45581219~45581321:-
LUAD	cis	rs7927592	0.763	rs2513277	ENSG00000212093.1	AP000807.1	5.64	2.84e-08	9.97e-06	0.26	0.25	Total body bone mineral density;	chr11:68593419	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.763	rs4340059	ENSG00000212093.1	AP000807.1	5.64	2.84e-08	9.97e-06	0.26	0.25	Total body bone mineral density;	chr11:68594965	chr11:68506083~68506166:-
LUAD	cis	rs12699921	0.632	rs2691595	ENSG00000279048.1	RP11-511H23.2	-5.64	2.84e-08	9.98e-06	-0.2	-0.25	Fibrinogen levels;	chr7:17780421	chr7:17940503~17942922:+
LUAD	cis	rs7811142	0.83	rs6955367	ENSG00000078319.8	PMS2P1	-5.64	2.84e-08	9.99e-06	-0.29	-0.25	Platelet count;	chr7:100363571	chr7:100320992~100341908:-
LUAD	cis	rs7044106	0.615	rs10818470	ENSG00000238181.2	AHCYP2	-5.64	2.84e-08	9.99e-06	-0.32	-0.25	Hip circumference adjusted for BMI;	chr9:120596926	chr9:120720673~120721972:+
LUAD	cis	rs10759883	0.539	rs10117340	ENSG00000175611.10	LINC00476	-5.64	2.84e-08	9.99e-06	-0.29	-0.25	Nicotine dependence;	chr9:96032530	chr9:95759231~95875977:-
LUAD	cis	rs8177876	0.915	rs73597252	ENSG00000261061.1	RP11-303E16.2	-5.64	2.84e-08	9.99e-06	-0.46	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81097740	chr16:81030770~81031485:+
LUAD	cis	rs603446	0.583	rs180377	ENSG00000254851.1	RP11-109L13.1	-5.64	2.85e-08	9.99e-06	-0.32	-0.25	Triglycerides;	chr11:116718411	chr11:117135528~117138582:+
LUAD	cis	rs6907340	0.517	rs6939160	ENSG00000228412.5	RP4-625H18.2	5.64	2.85e-08	1e-05	0.31	0.25	Endometriosis;	chr6:19802086	chr6:19802164~19804752:-
LUAD	cis	rs11098499	0.644	rs10012252	ENSG00000248280.1	RP11-33B1.2	5.64	2.85e-08	1e-05	0.31	0.25	Corneal astigmatism;	chr4:119637984	chr4:119440561~119450157:-
LUAD	cis	rs7712401	0.601	rs173480	ENSG00000263432.2	RN7SL689P	5.64	2.85e-08	1e-05	0.31	0.25	Mean platelet volume;	chr5:122918436	chr5:123022487~123022783:-
LUAD	cis	rs4713118	0.869	rs9348775	ENSG00000219392.1	RP1-265C24.5	-5.64	2.85e-08	1e-05	-0.33	-0.25	Parkinson's disease;	chr6:27727550	chr6:28115628~28116551:+
LUAD	cis	rs673078	0.607	rs61943389	ENSG00000275409.1	RP11-131L12.4	-5.64	2.85e-08	1e-05	-0.35	-0.25	Glucose homeostasis traits;	chr12:118377467	chr12:118430147~118430699:+
LUAD	cis	rs9309473	0.95	rs6546853	ENSG00000163016.8	ALMS1P	5.64	2.85e-08	1e-05	0.3	0.25	Metabolite levels;	chr2:73606612	chr2:73644919~73685576:+
LUAD	cis	rs8081395	0.627	rs12952730	ENSG00000266992.1	DHX40P1	5.64	2.85e-08	1e-05	0.31	0.25	White blood cell count;	chr17:59901475	chr17:59976009~60002384:-
LUAD	cis	rs8081395	0.627	rs180536	ENSG00000266992.1	DHX40P1	5.64	2.85e-08	1e-05	0.31	0.25	White blood cell count;	chr17:59919445	chr17:59976009~60002384:-
LUAD	cis	rs10129255	0.557	rs4043727	ENSG00000211972.2	IGHV3-66	5.64	2.85e-08	1e-05	0.22	0.25	Kawasaki disease;	chr14:106649820	chr14:106675017~106675544:-
LUAD	cis	rs4947019	0.609	rs4946968	ENSG00000260273.1	RP11-425D10.10	5.64	2.85e-08	1e-05	0.55	0.25	Hematological parameters;	chr6:109357907	chr6:109382795~109383666:+
LUAD	cis	rs9859260	0.744	rs406271	ENSG00000231464.1	AC024937.4	-5.64	2.86e-08	1e-05	-0.29	-0.25	Mean corpuscular volume;	chr3:196050105	chr3:195996738~195998233:+
LUAD	cis	rs673078	0.607	rs61943388	ENSG00000275409.1	RP11-131L12.4	-5.64	2.86e-08	1e-05	-0.35	-0.25	Glucose homeostasis traits;	chr12:118374590	chr12:118430147~118430699:+
LUAD	cis	rs875971	0.543	rs801191	ENSG00000224316.1	RP11-479O9.2	-5.64	2.86e-08	1e-05	-0.25	-0.25	Aortic root size;	chr7:66567968	chr7:65773620~65802067:+
LUAD	cis	rs10129255	0.912	rs67410411	ENSG00000224373.3	IGHV4-59	5.64	2.86e-08	1e-05	0.16	0.25	Kawasaki disease;	chr14:106680324	chr14:106627249~106627825:-
LUAD	cis	rs4835473	0.932	rs13133444	ENSG00000251600.4	RP11-673E1.1	5.64	2.86e-08	1.01e-05	0.3	0.25	Immature fraction of reticulocytes;	chr4:143738191	chr4:143912331~143982454:+
LUAD	cis	rs9309473	0.95	rs6546859	ENSG00000163016.8	ALMS1P	5.64	2.86e-08	1.01e-05	0.3	0.25	Metabolite levels;	chr2:73614928	chr2:73644919~73685576:+
LUAD	cis	rs10754283	0.967	rs6428559	ENSG00000231613.1	RP5-943J3.1	5.64	2.87e-08	1.01e-05	0.25	0.25	Amyotrophic lateral sclerosis (sporadic);	chr1:89633477	chr1:89788914~89790492:+
LUAD	cis	rs116139393	0.54	rs12539942	ENSG00000187953.9	PMS2CL	-5.64	2.87e-08	1.01e-05	-0.32	-0.25	Alzheimer's disease (APOE e4 interaction);	chr7:6736954	chr7:6710128~6753862:+
LUAD	cis	rs7221109	0.71	rs4890093	ENSG00000278834.1	RP11-458J1.1	5.64	2.87e-08	1.01e-05	0.29	0.25	Type 1 diabetes;	chr17:40639691	chr17:40648300~40649718:+
LUAD	cis	rs74233809	1	rs76752100	ENSG00000213277.3	MARCKSL1P1	5.64	2.87e-08	1.01e-05	0.43	0.25	Birth weight;	chr10:103034329	chr10:103175554~103176094:+
LUAD	cis	rs9287719	0.649	rs6721857	ENSG00000243819.4	RN7SL832P	-5.64	2.87e-08	1.01e-05	-0.26	-0.25	Prostate cancer;	chr2:10581084	chr2:10690344~10692099:+
LUAD	cis	rs11146838	1	rs11146838	ENSG00000263064.2	RP11-291L22.7	5.64	2.87e-08	1.01e-05	0.27	0.25	Breast cancer;	chr10:38856846	chr10:38448689~38448949:+
LUAD	cis	rs4908760	0.965	rs301814	ENSG00000232912.4	RP5-1115A15.1	5.64	2.87e-08	1.01e-05	0.23	0.25	Vitiligo;	chr1:8450517	chr1:8424645~8434838:+
LUAD	cis	rs2880765	0.835	rs4843062	ENSG00000259295.5	CSPG4P12	5.64	2.87e-08	1.01e-05	0.29	0.25	Coronary artery disease;	chr15:85496906	chr15:85191438~85213905:+
LUAD	cis	rs10129255	0.957	rs8009638	ENSG00000211972.2	IGHV3-66	5.64	2.88e-08	1.01e-05	0.21	0.25	Kawasaki disease;	chr14:106777570	chr14:106675017~106675544:-
LUAD	cis	rs7712401	0.601	rs154496	ENSG00000263432.2	RN7SL689P	5.64	2.88e-08	1.01e-05	0.32	0.25	Mean platelet volume;	chr5:122886036	chr5:123022487~123022783:-
LUAD	cis	rs10129255	0.957	rs8009638	ENSG00000224373.3	IGHV4-59	5.64	2.88e-08	1.01e-05	0.16	0.25	Kawasaki disease;	chr14:106777570	chr14:106627249~106627825:-
LUAD	cis	rs3931020	0.688	rs455032	ENSG00000272864.1	RP11-17E13.2	5.64	2.88e-08	1.01e-05	0.35	0.25	Resistin levels;	chr1:74730804	chr1:74698769~74699333:-
LUAD	cis	rs3931020	0.688	rs968358	ENSG00000272864.1	RP11-17E13.2	-5.64	2.88e-08	1.01e-05	-0.35	-0.25	Resistin levels;	chr1:74728305	chr1:74698769~74699333:-
LUAD	cis	rs673078	0.66	rs17512609	ENSG00000275409.1	RP11-131L12.4	-5.64	2.88e-08	1.01e-05	-0.35	-0.25	Glucose homeostasis traits;	chr12:118354072	chr12:118430147~118430699:+
LUAD	cis	rs4908768	0.52	rs6695867	ENSG00000232912.4	RP5-1115A15.1	5.64	2.89e-08	1.01e-05	0.23	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8670720	chr1:8424645~8434838:+
LUAD	cis	rs9595908	0.785	rs9315173	ENSG00000212293.1	SNORA16	5.64	2.89e-08	1.01e-05	0.26	0.25	Body mass index;	chr13:32645674	chr13:32420390~32420516:-
LUAD	cis	rs6687821	0.515	rs12025384	ENSG00000267734.1	RP4-604K5.3	-5.64	2.89e-08	1.02e-05	-0.3	-0.25	Yeast infection;	chr1:86972227	chr1:86932199~86934891:-
LUAD	cis	rs801193	0.569	rs13226966	ENSG00000237310.1	GS1-124K5.4	5.64	2.89e-08	1.02e-05	0.27	0.25	Aortic root size;	chr7:66768636	chr7:66493706~66495474:+
LUAD	cis	rs2404602	0.622	rs9635380	ENSG00000259422.1	RP11-593F23.1	-5.64	2.89e-08	1.02e-05	-0.34	-0.25	Blood metabolite levels;	chr15:76811138	chr15:76174891~76181486:-
LUAD	cis	rs10129255	0.957	rs61997760	ENSG00000211974.3	IGHV2-70	5.64	2.9e-08	1.02e-05	0.27	0.25	Kawasaki disease;	chr14:106716993	chr14:106723574~106724093:-
LUAD	cis	rs2439831	0.85	rs16950562	ENSG00000249839.1	AC011330.5	-5.64	2.9e-08	1.02e-05	-0.48	-0.25	Lung cancer in ever smokers;	chr15:43744166	chr15:43663654~43684339:-
LUAD	cis	rs4908768	0.539	rs6666191	ENSG00000232912.4	RP5-1115A15.1	5.64	2.9e-08	1.02e-05	0.23	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8598383	chr1:8424645~8434838:+
LUAD	cis	rs73186030	0.546	rs67818421	ENSG00000272758.4	RP11-299J3.8	5.64	2.9e-08	1.02e-05	0.31	0.25	Serum parathyroid hormone levels;	chr3:122389871	chr3:122416207~122443180:+
LUAD	cis	rs12699921	0.599	rs2723540	ENSG00000279048.1	RP11-511H23.2	-5.64	2.9e-08	1.02e-05	-0.2	-0.25	Fibrinogen levels;	chr7:17866067	chr7:17940503~17942922:+
LUAD	cis	rs13217239	0.646	rs4269366	ENSG00000241549.7	GUSBP2	5.64	2.91e-08	1.02e-05	0.27	0.25	Schizophrenia;	chr6:27048634	chr6:26871484~26956554:-
LUAD	cis	rs12699921	0.632	rs2691612	ENSG00000279048.1	RP11-511H23.2	-5.64	2.91e-08	1.02e-05	-0.2	-0.25	Fibrinogen levels;	chr7:17844293	chr7:17940503~17942922:+
LUAD	cis	rs17826219	0.5	rs28452421	ENSG00000263603.1	CTD-2349P21.5	-5.64	2.91e-08	1.02e-05	-0.44	-0.25	Body mass index;	chr17:30756962	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.573	rs28779471	ENSG00000263603.1	CTD-2349P21.5	-5.64	2.91e-08	1.02e-05	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30729469~30731202:+
LUAD	cis	rs17826219	0.5	rs61685770	ENSG00000263603.1	CTD-2349P21.5	-5.64	2.91e-08	1.02e-05	-0.44	-0.25	Body mass index;	chr17:30758695	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs57486336	ENSG00000263603.1	CTD-2349P21.5	-5.64	2.91e-08	1.02e-05	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs12103440	ENSG00000263603.1	CTD-2349P21.5	-5.64	2.91e-08	1.02e-05	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs11657777	ENSG00000263603.1	CTD-2349P21.5	-5.64	2.91e-08	1.02e-05	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30729469~30731202:+
LUAD	cis	rs9652601	0.691	rs12917716	ENSG00000274038.1	RP11-66H6.4	-5.64	2.92e-08	1.02e-05	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11095291	chr16:11056556~11057034:+
LUAD	cis	rs10129255	0.912	rs61997792	ENSG00000224373.3	IGHV4-59	5.64	2.92e-08	1.02e-05	0.16	0.25	Kawasaki disease;	chr14:106799304	chr14:106627249~106627825:-
LUAD	cis	rs6687821	0.5	rs2753270	ENSG00000267734.1	RP4-604K5.3	5.64	2.92e-08	1.02e-05	0.31	0.25	Yeast infection;	chr1:86947874	chr1:86932199~86934891:-
LUAD	cis	rs7712401	0.601	rs418229	ENSG00000263432.2	RN7SL689P	-5.64	2.93e-08	1.03e-05	-0.31	-0.25	Mean platelet volume;	chr5:123005969	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs374403	ENSG00000263432.2	RN7SL689P	-5.64	2.93e-08	1.03e-05	-0.31	-0.25	Mean platelet volume;	chr5:123006018	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs446782	ENSG00000263432.2	RN7SL689P	-5.64	2.93e-08	1.03e-05	-0.31	-0.25	Mean platelet volume;	chr5:123006173	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs404442	ENSG00000263432.2	RN7SL689P	-5.64	2.93e-08	1.03e-05	-0.31	-0.25	Mean platelet volume;	chr5:123009236	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs417268	ENSG00000263432.2	RN7SL689P	-5.64	2.93e-08	1.03e-05	-0.31	-0.25	Mean platelet volume;	chr5:123009317	chr5:123022487~123022783:-
LUAD	cis	rs7221109	0.677	rs7209467	ENSG00000278834.1	RP11-458J1.1	5.64	2.93e-08	1.03e-05	0.29	0.25	Type 1 diabetes;	chr17:40653033	chr17:40648300~40649718:+
LUAD	cis	rs9910055	0.747	rs2905981	ENSG00000267080.4	ASB16-AS1	-5.64	2.93e-08	1.03e-05	-0.23	-0.25	Total body bone mineral density;	chr17:44161257	chr17:44175973~44186717:-
LUAD	cis	rs30380	0.632	rs26491	ENSG00000272109.1	CTD-2260A17.3	-5.64	2.93e-08	1.03e-05	-0.3	-0.25	Cerebrospinal fluid biomarker levels;	chr5:96798410	chr5:96804353~96806105:+
LUAD	cis	rs6840360	0.904	rs73862064	ENSG00000270265.1	RP11-731D1.4	-5.64	2.93e-08	1.03e-05	-0.25	-0.25	Intelligence (multi-trait analysis);	chr4:151581948	chr4:151333775~151353224:-
LUAD	cis	rs9910055	0.762	rs11080007	ENSG00000267080.4	ASB16-AS1	5.64	2.94e-08	1.03e-05	0.22	0.25	Total body bone mineral density;	chr17:44188074	chr17:44175973~44186717:-
LUAD	cis	rs2836950	0.565	rs8131132	ENSG00000255568.3	BRWD1-AS2	-5.64	2.94e-08	1.03e-05	-0.24	-0.25	Menarche (age at onset);	chr21:39166330	chr21:39313935~39314962:+
LUAD	cis	rs2562456	0.516	rs56072098	ENSG00000268081.1	RP11-678G14.2	-5.64	2.94e-08	1.03e-05	-0.38	-0.25	Pain;	chr19:21469158	chr19:21554640~21569237:-
LUAD	cis	rs516805	0.748	rs12189881	ENSG00000279453.1	RP3-425C14.4	5.64	2.94e-08	1.03e-05	0.34	0.25	Lymphocyte counts;	chr6:122375109	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.748	rs72974455	ENSG00000279453.1	RP3-425C14.4	5.64	2.94e-08	1.03e-05	0.34	0.25	Lymphocyte counts;	chr6:122377134	chr6:122436789~122439223:-
LUAD	cis	rs10483853	0.525	rs2302041	ENSG00000258695.2	RP3-414A15.2	-5.64	2.94e-08	1.03e-05	-0.37	-0.25	Coronary artery calcification;	chr14:73494166	chr14:73522878~73530610:+
LUAD	cis	rs910316	1	rs4903275	ENSG00000259138.1	RP11-950C14.7	5.64	2.95e-08	1.03e-05	0.26	0.25	Height;	chr14:75045806	chr14:75127153~75136930:+
LUAD	cis	rs180730	0.561	rs3115313	ENSG00000251609.2	SETP12	-5.64	2.95e-08	1.03e-05	-0.32	-0.25	Fasting plasma glucose;	chr4:120887708	chr4:120895494~120897083:-
LUAD	cis	rs9903692	0.954	rs9899461	ENSG00000278765.1	RP5-890E16.5	-5.64	2.95e-08	1.03e-05	-0.33	-0.25	Pulse pressure;	chr17:48051991	chr17:48066704~48067293:-
LUAD	cis	rs3738443	0.868	rs12569042	ENSG00000259865.1	RP11-488L18.10	5.64	2.96e-08	1.03e-05	0.26	0.25	Alcohol dependence;	chr1:247203078	chr1:247187281~247188526:-
LUAD	cis	rs8031584	0.541	rs2955797	ENSG00000270015.1	RP11-540B6.6	5.64	2.96e-08	1.04e-05	0.17	0.25	Huntington's disease progression;	chr15:30918778	chr15:30926514~30928407:+
LUAD	cis	rs5753618	0.583	rs7285619	ENSG00000236132.1	CTA-440B3.1	-5.64	2.96e-08	1.04e-05	-0.31	-0.25	Colorectal cancer;	chr22:31446568	chr22:31816379~31817491:-
LUAD	cis	rs301807	0.533	rs1466654	ENSG00000232912.4	RP5-1115A15.1	5.64	2.96e-08	1.04e-05	0.23	0.25	Vitiligo;Sum eosinophil basophil counts;	chr1:8315853	chr1:8424645~8434838:+
LUAD	cis	rs1707322	1	rs7527079	ENSG00000234329.1	RP11-767N6.2	5.64	2.96e-08	1.04e-05	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45947778	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs34446427	ENSG00000234329.1	RP11-767N6.2	5.64	2.96e-08	1.04e-05	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45951983	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.963	rs4660900	ENSG00000234329.1	RP11-767N6.2	5.64	2.96e-08	1.04e-05	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45953933	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs4454479	ENSG00000234329.1	RP11-767N6.2	5.64	2.96e-08	1.04e-05	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45957883	chr1:45651039~45651826:-
LUAD	cis	rs4698412	0.531	rs6852450	ENSG00000214846.4	RP11-115L11.1	-5.64	2.96e-08	1.04e-05	-0.33	-0.25	Parkinson's disease;	chr4:15741363	chr4:15730962~15731627:-
LUAD	cis	rs10761482	0.5	rs10821790	ENSG00000254271.1	RP11-131N11.4	5.64	2.97e-08	1.04e-05	0.28	0.25	Schizophrenia;	chr10:60529009	chr10:60734342~60741828:+
LUAD	cis	rs1707322	0.721	rs7520123	ENSG00000280836.1	AL355480.1	-5.64	2.97e-08	1.04e-05	-0.32	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769547	chr1:45581219~45581321:-
LUAD	cis	rs17214007	0.877	rs4482303	ENSG00000263335.1	AF001548.5	-5.64	2.97e-08	1.04e-05	-0.35	-0.25	Cognitive function;	chr16:15777020	chr16:15726674~15732993:+
LUAD	cis	rs4713118	0.513	rs149962	ENSG00000204709.4	LINC01556	5.64	2.97e-08	1.04e-05	0.31	0.25	Parkinson's disease;	chr6:28048140	chr6:28943877~28944537:+
LUAD	cis	rs1707322	1	rs4074225	ENSG00000234329.1	RP11-767N6.2	5.64	2.98e-08	1.04e-05	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45926692	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs4134387	ENSG00000234329.1	RP11-767N6.2	5.64	2.98e-08	1.04e-05	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45929486	chr1:45651039~45651826:-
LUAD	cis	rs516805	0.667	rs9320856	ENSG00000279453.1	RP3-425C14.4	-5.64	2.98e-08	1.04e-05	-0.34	-0.25	Lymphocyte counts;	chr6:122219888	chr6:122436789~122439223:-
LUAD	cis	rs7811142	0.667	rs3873746	ENSG00000078319.8	PMS2P1	-5.64	2.98e-08	1.04e-05	-0.29	-0.25	Platelet count;	chr7:100337474	chr7:100320992~100341908:-
LUAD	cis	rs9543976	1	rs2296146	ENSG00000261553.4	RP11-29G8.3	-5.63	2.99e-08	1.04e-05	-0.38	-0.25	Diabetic retinopathy;	chr13:75569436	chr13:75549773~75807120:+
LUAD	cis	rs6687821	0.515	rs10493794	ENSG00000267734.1	RP4-604K5.3	-5.63	2.99e-08	1.05e-05	-0.31	-0.25	Yeast infection;	chr1:87004946	chr1:86932199~86934891:-
LUAD	cis	rs6687821	0.515	rs10747335	ENSG00000267734.1	RP4-604K5.3	-5.63	2.99e-08	1.05e-05	-0.31	-0.25	Yeast infection;	chr1:87006739	chr1:86932199~86934891:-
LUAD	cis	rs7208859	0.673	rs73263981	ENSG00000263603.1	CTD-2349P21.5	-5.63	3e-08	1.05e-05	-0.37	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593484	chr17:30729469~30731202:+
LUAD	cis	rs4604732	0.588	rs7549495	ENSG00000227135.1	GCSAML-AS1	-5.63	3e-08	1.05e-05	-0.37	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247464504	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.536	rs76191272	ENSG00000227135.1	GCSAML-AS1	-5.63	3e-08	1.05e-05	-0.37	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247464753	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.588	rs7552443	ENSG00000227135.1	GCSAML-AS1	-5.63	3e-08	1.05e-05	-0.37	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247465281	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.588	rs7552461	ENSG00000227135.1	GCSAML-AS1	-5.63	3e-08	1.05e-05	-0.37	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247465342	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.588	rs9943231	ENSG00000227135.1	GCSAML-AS1	-5.63	3e-08	1.05e-05	-0.37	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247466527	chr1:247524679~247526752:-
LUAD	cis	rs11105298	0.891	rs11105287	ENSG00000258302.2	RP11-981P6.1	5.63	3e-08	1.05e-05	0.31	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89435693	chr12:89561129~89594878:+
LUAD	cis	rs853679	0.766	rs9368561	ENSG00000219392.1	RP1-265C24.5	-5.63	3e-08	1.05e-05	-0.43	-0.25	Depression;	chr6:28200565	chr6:28115628~28116551:+
LUAD	cis	rs2153535	0.869	rs11962457	ENSG00000230939.1	RP11-314C16.1	5.63	3.01e-08	1.05e-05	0.28	0.25	Motion sickness;	chr6:8375622	chr6:8784178~8785445:+
LUAD	cis	rs875971	1	rs6945843	ENSG00000237310.1	GS1-124K5.4	-5.63	3.01e-08	1.05e-05	-0.27	-0.25	Aortic root size;	chr7:66269796	chr7:66493706~66495474:+
LUAD	cis	rs2749097	1	rs8294	ENSG00000244256.3	RN7SL130P	-5.63	3.01e-08	1.05e-05	-0.36	-0.25	Alcohol consumption (transferrin glycosylation);	chr1:63659697	chr1:63655743~63656047:+
LUAD	cis	rs7712401	0.601	rs246269	ENSG00000263432.2	RN7SL689P	5.63	3.01e-08	1.05e-05	0.31	0.25	Mean platelet volume;	chr5:122921046	chr5:123022487~123022783:-
LUAD	cis	rs1075265	0.749	rs10203095	ENSG00000233266.1	HMGB1P31	5.63	3.01e-08	1.05e-05	0.31	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53737150	chr2:54051334~54051760:+
LUAD	cis	rs732716	0.74	rs62129356	ENSG00000267980.1	AC007292.6	-5.63	3.01e-08	1.05e-05	-0.29	-0.25	Mean corpuscular volume;	chr19:4400317	chr19:4363789~4364640:+
LUAD	cis	rs7927592	0.956	rs11228277	ENSG00000212093.1	AP000807.1	5.63	3.01e-08	1.05e-05	0.27	0.25	Total body bone mineral density;	chr11:68540856	chr11:68506083~68506166:-
LUAD	cis	rs17301013	0.606	rs1793315	ENSG00000227373.4	RP11-160H22.5	-5.63	3.01e-08	1.05e-05	-0.34	-0.25	Systemic lupus erythematosus;	chr1:174808923	chr1:174115300~174160004:-
LUAD	cis	rs875971	1	rs1363055	ENSG00000237310.1	GS1-124K5.4	5.63	3.01e-08	1.05e-05	0.27	0.25	Aortic root size;	chr7:66478288	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.964	rs9691480	ENSG00000237310.1	GS1-124K5.4	5.63	3.01e-08	1.05e-05	0.27	0.25	Aortic root size;	chr7:66479319	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs7789554	ENSG00000237310.1	GS1-124K5.4	5.63	3.01e-08	1.05e-05	0.27	0.25	Aortic root size;	chr7:66481051	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs4717300	ENSG00000237310.1	GS1-124K5.4	5.63	3.01e-08	1.05e-05	0.27	0.25	Aortic root size;	chr7:66482393	chr7:66493706~66495474:+
LUAD	cis	rs9287719	0.649	rs9973374	ENSG00000243819.4	RN7SL832P	5.63	3.01e-08	1.05e-05	0.26	0.25	Prostate cancer;	chr2:10576258	chr2:10690344~10692099:+
LUAD	cis	rs7615952	0.576	rs2276727	ENSG00000171084.14	FAM86JP	5.63	3.02e-08	1.05e-05	0.36	0.25	Blood pressure (smoking interaction);	chr3:126107400	chr3:125916620~125930024:+
LUAD	cis	rs8040855	0.791	rs8042888	ENSG00000259774.1	RP11-182J1.13	-5.63	3.02e-08	1.05e-05	-0.31	-0.25	Bulimia nervosa;	chr15:85152360	chr15:84422618~84425882:+
LUAD	cis	rs4947019	0.609	rs9487099	ENSG00000260273.1	RP11-425D10.10	5.63	3.02e-08	1.05e-05	0.57	0.25	Hematological parameters;	chr6:109423803	chr6:109382795~109383666:+
LUAD	cis	rs9807989	0.801	rs6734742	ENSG00000234389.1	AC007278.3	5.63	3.02e-08	1.05e-05	0.24	0.25	Asthma;	chr2:102351397	chr2:102438713~102440475:+
LUAD	cis	rs6546847	0.531	rs2567601	ENSG00000163016.8	ALMS1P	5.63	3.02e-08	1.06e-05	0.37	0.25	Urinary metabolites (H-NMR features);	chr2:73758040	chr2:73644919~73685576:+
LUAD	cis	rs516805	0.667	rs2045354	ENSG00000279453.1	RP3-425C14.4	-5.63	3.02e-08	1.06e-05	-0.34	-0.25	Lymphocyte counts;	chr6:122209244	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.63	rs2606596	ENSG00000279453.1	RP3-425C14.4	-5.63	3.02e-08	1.06e-05	-0.34	-0.25	Lymphocyte counts;	chr6:122211597	chr6:122436789~122439223:-
LUAD	cis	rs7615952	0.599	rs6779141	ENSG00000171084.14	FAM86JP	5.63	3.03e-08	1.06e-05	0.36	0.25	Blood pressure (smoking interaction);	chr3:125991152	chr3:125916620~125930024:+
LUAD	cis	rs66887589	1	rs66887589	ENSG00000245958.5	RP11-33B1.1	5.63	3.03e-08	1.06e-05	0.2	0.25	Diastolic blood pressure;	chr4:119588124	chr4:119454791~119552025:+
LUAD	cis	rs4713118	0.513	rs156739	ENSG00000204709.4	LINC01556	5.63	3.03e-08	1.06e-05	0.31	0.25	Parkinson's disease;	chr6:28045632	chr6:28943877~28944537:+
LUAD	cis	rs62432291	0.681	rs447637	ENSG00000235086.1	FNDC1-IT1	-5.63	3.04e-08	1.06e-05	-0.43	-0.25	Joint mobility (Beighton score);	chr6:159237694	chr6:159240786~159243329:+
LUAD	cis	rs5753618	0.583	rs5749268	ENSG00000236132.1	CTA-440B3.1	-5.63	3.04e-08	1.06e-05	-0.31	-0.25	Colorectal cancer;	chr22:31413166	chr22:31816379~31817491:-
LUAD	cis	rs7968440	1	rs2252589	ENSG00000200428.1	Y_RNA	-5.63	3.04e-08	1.06e-05	-0.31	-0.25	Fibrinogen;	chr12:50648174	chr12:50743568~50743684:+
LUAD	cis	rs1707322	0.896	rs946528	ENSG00000234329.1	RP11-767N6.2	-5.63	3.04e-08	1.06e-05	-0.25	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019890	chr1:45651039~45651826:-
LUAD	cis	rs944289	0.553	rs1169134	ENSG00000257826.1	RP11-116N8.4	-5.63	3.04e-08	1.06e-05	-0.28	-0.25	Thyroid cancer;	chr14:36155514	chr14:36061026~36067190:-
LUAD	cis	rs944289	0.537	rs1169137	ENSG00000257826.1	RP11-116N8.4	-5.63	3.04e-08	1.06e-05	-0.28	-0.25	Thyroid cancer;	chr14:36156548	chr14:36061026~36067190:-
LUAD	cis	rs2790457	0.958	rs1265829	ENSG00000254635.4	WAC-AS1	-5.63	3.04e-08	1.06e-05	-0.27	-0.25	Multiple myeloma;	chr10:28622374	chr10:28522652~28532743:-
LUAD	cis	rs2286503	0.646	rs17147344	ENSG00000228649.7	AC005682.5	5.63	3.04e-08	1.06e-05	0.36	0.25	Fibrinogen;	chr7:22841237	chr7:22854178~22861579:+
LUAD	cis	rs62355901	0.83	rs12653202	ENSG00000271828.1	CTD-2310F14.1	5.63	3.05e-08	1.06e-05	0.37	0.25	Breast cancer;	chr5:56721091	chr5:56927874~56929573:+
LUAD	cis	rs7804306	1	rs35009545	ENSG00000233264.2	AC006042.8	5.63	3.05e-08	1.06e-05	0.44	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8037223	chr7:7980312~7982228:+
LUAD	cis	rs12468226	0.873	rs3769817	ENSG00000226261.1	AC064836.3	-5.63	3.05e-08	1.06e-05	-0.4	-0.25	Urate levels;	chr2:202214584	chr2:202336024~202336727:-
LUAD	cis	rs12468226	0.873	rs6435134	ENSG00000226261.1	AC064836.3	-5.63	3.05e-08	1.06e-05	-0.4	-0.25	Urate levels;	chr2:202214857	chr2:202336024~202336727:-
LUAD	cis	rs4713118	0.512	rs2622319	ENSG00000204709.4	LINC01556	5.63	3.05e-08	1.06e-05	0.33	0.25	Parkinson's disease;	chr6:28152623	chr6:28943877~28944537:+
LUAD	cis	rs172166	0.694	rs1150666	ENSG00000204709.4	LINC01556	5.63	3.05e-08	1.06e-05	0.33	0.25	Cardiac Troponin-T levels;	chr6:28156150	chr6:28943877~28944537:+
LUAD	cis	rs10129255	0.912	rs8009135	ENSG00000224373.3	IGHV4-59	5.63	3.05e-08	1.06e-05	0.16	0.25	Kawasaki disease;	chr14:106777528	chr14:106627249~106627825:-
LUAD	cis	rs1707322	0.963	rs10789484	ENSG00000234329.1	RP11-767N6.2	5.63	3.05e-08	1.07e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941306	chr1:45651039~45651826:-
LUAD	cis	rs7712401	0.623	rs30044	ENSG00000263432.2	RN7SL689P	5.63	3.05e-08	1.07e-05	0.31	0.25	Mean platelet volume;	chr5:122936385	chr5:123022487~123022783:-
LUAD	cis	rs4713118	0.513	rs202908	ENSG00000204709.4	LINC01556	5.63	3.05e-08	1.07e-05	0.32	0.25	Parkinson's disease;	chr6:28043773	chr6:28943877~28944537:+
LUAD	cis	rs8081395	0.741	rs180520	ENSG00000266992.1	DHX40P1	5.63	3.06e-08	1.07e-05	0.29	0.25	White blood cell count;	chr17:59937788	chr17:59976009~60002384:-
LUAD	cis	rs673078	0.607	rs7312555	ENSG00000275409.1	RP11-131L12.4	-5.63	3.06e-08	1.07e-05	-0.36	-0.25	Glucose homeostasis traits;	chr12:118414120	chr12:118430147~118430699:+
LUAD	cis	rs897984	0.511	rs7196726	ENSG00000260911.2	RP11-196G11.2	5.63	3.06e-08	1.07e-05	0.22	0.25	Dementia with Lewy bodies;	chr16:31080754	chr16:31043150~31049868:+
LUAD	cis	rs1707322	1	rs10890376	ENSG00000234329.1	RP11-767N6.2	5.63	3.06e-08	1.07e-05	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940910	chr1:45651039~45651826:-
LUAD	cis	rs2179367	0.632	rs9498334	ENSG00000231760.4	RP11-350J20.5	5.63	3.06e-08	1.07e-05	0.36	0.25	Dupuytren's disease;	chr6:149370902	chr6:149796151~149826294:-
LUAD	cis	rs6991838	0.798	rs6994889	ENSG00000200714.1	Y_RNA	5.63	3.06e-08	1.07e-05	0.29	0.25	Intelligence (multi-trait analysis);	chr8:65562547	chr8:65592731~65592820:+
LUAD	cis	rs7712401	0.584	rs30037	ENSG00000263432.2	RN7SL689P	5.63	3.06e-08	1.07e-05	0.31	0.25	Mean platelet volume;	chr5:122942295	chr5:123022487~123022783:-
LUAD	cis	rs4654783	0.627	rs1046310	ENSG00000228397.1	RP1-224A6.3	5.63	3.06e-08	1.07e-05	0.31	0.25	Endometriosis;	chr1:22117394	chr1:22023994~22024968:-
LUAD	cis	rs2404602	0.647	rs907593	ENSG00000259422.1	RP11-593F23.1	-5.63	3.06e-08	1.07e-05	-0.34	-0.25	Blood metabolite levels;	chr15:76904612	chr15:76174891~76181486:-
LUAD	cis	rs1075265	0.749	rs2357693	ENSG00000233266.1	HMGB1P31	5.63	3.07e-08	1.07e-05	0.31	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53735699	chr2:54051334~54051760:+
LUAD	cis	rs9595908	0.669	rs28637641	ENSG00000212293.1	SNORA16	5.63	3.07e-08	1.07e-05	0.27	0.25	Body mass index;	chr13:32726997	chr13:32420390~32420516:-
LUAD	cis	rs1707322	1	rs4073847	ENSG00000234329.1	RP11-767N6.2	-5.63	3.07e-08	1.07e-05	-0.25	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45997340	chr1:45651039~45651826:-
LUAD	cis	rs1799949	0.965	rs799917	ENSG00000267681.1	CTD-3199J23.6	-5.63	3.07e-08	1.07e-05	-0.28	-0.25	Menopause (age at onset);	chr17:43092919	chr17:43144956~43145255:+
LUAD	cis	rs7221109	0.677	rs3752026	ENSG00000278834.1	RP11-458J1.1	5.63	3.07e-08	1.07e-05	0.29	0.25	Type 1 diabetes;	chr17:40648309	chr17:40648300~40649718:+
LUAD	cis	rs2276314	0.857	rs9960670	ENSG00000278986.1	RP11-723J4.3	-5.63	3.07e-08	1.07e-05	-0.31	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:35997749	chr18:35972151~35973916:+
LUAD	cis	rs10129255	0.957	rs12590735	ENSG00000224373.3	IGHV4-59	5.63	3.07e-08	1.07e-05	0.16	0.25	Kawasaki disease;	chr14:106779660	chr14:106627249~106627825:-
LUAD	cis	rs2243480	1	rs10807701	ENSG00000230295.1	RP11-458F8.2	5.63	3.07e-08	1.07e-05	0.3	0.25	Diabetic kidney disease;	chr7:66259699	chr7:66880708~66882981:+
LUAD	cis	rs1707322	0.963	rs4630155	ENSG00000234329.1	RP11-767N6.2	5.63	3.08e-08	1.07e-05	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45791438	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.963	rs4508055	ENSG00000234329.1	RP11-767N6.2	5.63	3.08e-08	1.07e-05	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792059	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.963	rs12076580	ENSG00000234329.1	RP11-767N6.2	5.63	3.08e-08	1.07e-05	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792487	chr1:45651039~45651826:-
LUAD	cis	rs12908161	1	rs12910012	ENSG00000225151.9	GOLGA2P7	-5.63	3.08e-08	1.07e-05	-0.34	-0.25	Schizophrenia;	chr15:84755431	chr15:84199311~84230136:-
LUAD	cis	rs12908161	1	rs12899981	ENSG00000225151.9	GOLGA2P7	-5.63	3.08e-08	1.07e-05	-0.34	-0.25	Schizophrenia;	chr15:84759142	chr15:84199311~84230136:-
LUAD	cis	rs35160687	0.644	rs10204589	ENSG00000273080.1	RP11-301O19.1	5.63	3.08e-08	1.07e-05	0.28	0.25	Night sleep phenotypes;	chr2:86266100	chr2:86195590~86196049:+
LUAD	cis	rs1823913	0.503	rs35282329	ENSG00000280083.1	RP11-317J9.1	-5.63	3.08e-08	1.07e-05	-0.31	-0.25	Obesity-related traits;	chr2:191343925	chr2:191154118~191156070:-
LUAD	cis	rs2243480	1	rs6964245	ENSG00000230295.1	RP11-458F8.2	5.63	3.08e-08	1.07e-05	0.3	0.25	Diabetic kidney disease;	chr7:66253730	chr7:66880708~66882981:+
LUAD	cis	rs10761482	0.5	rs1574466	ENSG00000254271.1	RP11-131N11.4	5.63	3.08e-08	1.07e-05	0.27	0.25	Schizophrenia;	chr10:60534634	chr10:60734342~60741828:+
LUAD	cis	rs17301853	0.908	rs3862942	ENSG00000227373.4	RP11-160H22.5	5.63	3.08e-08	1.07e-05	0.49	0.25	Migraine without aura;Migraine - clinic-based;	chr1:174724440	chr1:174115300~174160004:-
LUAD	cis	rs2404602	0.716	rs12592171	ENSG00000259422.1	RP11-593F23.1	5.63	3.09e-08	1.08e-05	0.28	0.25	Blood metabolite levels;	chr15:76462792	chr15:76174891~76181486:-
LUAD	cis	rs1113500	0.933	rs11185260	ENSG00000226822.1	RP11-356N1.2	-5.63	3.09e-08	1.08e-05	-0.29	-0.25	Growth-regulated protein alpha levels;	chr1:108092457	chr1:108071482~108074519:+
LUAD	cis	rs4835473	0.932	rs1973608	ENSG00000251600.4	RP11-673E1.1	5.63	3.09e-08	1.08e-05	0.31	0.25	Immature fraction of reticulocytes;	chr4:143913057	chr4:143912331~143982454:+
LUAD	cis	rs10129255	0.5	rs7161740	ENSG00000211967.3	IGHV3-53	-5.63	3.09e-08	1.08e-05	-0.18	-0.25	Kawasaki disease;	chr14:106776119	chr14:106592676~106593347:-
LUAD	cis	rs10129255	0.556	rs6576222	ENSG00000211967.3	IGHV3-53	-5.63	3.09e-08	1.08e-05	-0.18	-0.25	Kawasaki disease;	chr14:106776442	chr14:106592676~106593347:-
LUAD	cis	rs10129255	0.536	rs6576223	ENSG00000211967.3	IGHV3-53	-5.63	3.09e-08	1.08e-05	-0.18	-0.25	Kawasaki disease;	chr14:106776448	chr14:106592676~106593347:-
LUAD	cis	rs2179367	0.6	rs1001305	ENSG00000231760.4	RP11-350J20.5	5.63	3.09e-08	1.08e-05	0.38	0.25	Dupuytren's disease;	chr6:149436808	chr6:149796151~149826294:-
LUAD	cis	rs9543976	1	rs73223968	ENSG00000261553.4	RP11-29G8.3	-5.63	3.09e-08	1.08e-05	-0.37	-0.25	Diabetic retinopathy;	chr13:75567585	chr13:75549773~75807120:+
LUAD	cis	rs4835473	0.808	rs62339607	ENSG00000251600.4	RP11-673E1.1	-5.63	3.09e-08	1.08e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143791474	chr4:143912331~143982454:+
LUAD	cis	rs516805	0.528	rs2679703	ENSG00000279453.1	RP3-425C14.4	-5.63	3.1e-08	1.08e-05	-0.33	-0.25	Lymphocyte counts;	chr6:122099490	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.528	rs2606632	ENSG00000279453.1	RP3-425C14.4	-5.63	3.1e-08	1.08e-05	-0.33	-0.25	Lymphocyte counts;	chr6:122099728	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.528	rs2606634	ENSG00000279453.1	RP3-425C14.4	-5.63	3.1e-08	1.08e-05	-0.33	-0.25	Lymphocyte counts;	chr6:122100337	chr6:122436789~122439223:-
LUAD	cis	rs1707322	0.686	rs3014242	ENSG00000280836.1	AL355480.1	5.63	3.1e-08	1.08e-05	0.33	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621905	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.686	rs3014239	ENSG00000280836.1	AL355480.1	5.63	3.1e-08	1.08e-05	0.33	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624129	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.686	rs3014236	ENSG00000280836.1	AL355480.1	5.63	3.1e-08	1.08e-05	0.33	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625633	chr1:45581219~45581321:-
LUAD	cis	rs496547	0.654	rs688161	ENSG00000255239.1	AP002954.6	5.63	3.1e-08	1.08e-05	0.3	0.25	Hip minimal joint space width;	chr11:118807001	chr11:118688039~118690600:-
LUAD	cis	rs2404602	0.679	rs12899871	ENSG00000259422.1	RP11-593F23.1	5.63	3.1e-08	1.08e-05	0.28	0.25	Blood metabolite levels;	chr15:76465006	chr15:76174891~76181486:-
LUAD	cis	rs2836950	0.565	rs2836934	ENSG00000255568.3	BRWD1-AS2	-5.63	3.1e-08	1.08e-05	-0.24	-0.25	Menarche (age at onset);	chr21:39192959	chr21:39313935~39314962:+
LUAD	cis	rs9309473	0.95	rs6726694	ENSG00000163016.8	ALMS1P	5.63	3.11e-08	1.08e-05	0.29	0.25	Metabolite levels;	chr2:73620103	chr2:73644919~73685576:+
LUAD	cis	rs875971	0.929	rs10950041	ENSG00000237310.1	GS1-124K5.4	5.63	3.11e-08	1.08e-05	0.27	0.25	Aortic root size;	chr7:66508888	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.929	rs6970860	ENSG00000237310.1	GS1-124K5.4	5.63	3.11e-08	1.08e-05	0.27	0.25	Aortic root size;	chr7:66511647	chr7:66493706~66495474:+
LUAD	cis	rs4713118	0.869	rs4713121	ENSG00000219392.1	RP1-265C24.5	-5.63	3.11e-08	1.08e-05	-0.34	-0.25	Parkinson's disease;	chr6:27754285	chr6:28115628~28116551:+
LUAD	cis	rs6772849	0.93	rs4857912	ENSG00000242551.2	POU5F1P6	-5.63	3.11e-08	1.08e-05	-0.29	-0.25	Monocyte percentage of white cells;Monocyte count;	chr3:128610381	chr3:128674735~128677005:-
LUAD	cis	rs7826238	0.653	rs2979202	ENSG00000253893.2	FAM85B	-5.63	3.11e-08	1.08e-05	-0.31	-0.25	Systolic blood pressure;	chr8:8486617	chr8:8167819~8226614:-
LUAD	cis	rs7208859	0.623	rs9895785	ENSG00000263603.1	CTD-2349P21.5	5.63	3.11e-08	1.08e-05	0.44	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30729469~30731202:+
LUAD	cis	rs4820294	0.669	rs35662099	ENSG00000233360.4	Z83844.1	5.63	3.11e-08	1.08e-05	0.25	0.25	Fat distribution (HIV);	chr22:37657902	chr22:37641832~37658377:-
LUAD	cis	rs1707322	1	rs1622208	ENSG00000234329.1	RP11-767N6.2	-5.63	3.12e-08	1.09e-05	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46032703	chr1:45651039~45651826:-
LUAD	cis	rs11098499	0.874	rs10022508	ENSG00000248280.1	RP11-33B1.2	5.63	3.12e-08	1.09e-05	0.32	0.25	Corneal astigmatism;	chr4:119194073	chr4:119440561~119450157:-
LUAD	cis	rs1707322	0.721	rs4660883	ENSG00000280836.1	AL355480.1	-5.63	3.12e-08	1.09e-05	-0.33	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45770426	chr1:45581219~45581321:-
LUAD	cis	rs997295	0.513	rs11635495	ENSG00000270964.1	RP11-502I4.3	-5.63	3.12e-08	1.09e-05	-0.26	-0.25	Motion sickness;	chr15:67512344	chr15:67541072~67542604:-
LUAD	cis	rs7712401	0.601	rs246265	ENSG00000263432.2	RN7SL689P	5.63	3.12e-08	1.09e-05	0.31	0.25	Mean platelet volume;	chr5:122919255	chr5:123022487~123022783:-
LUAD	cis	rs10246939	0.505	rs10952508	ENSG00000228775.6	WEE2-AS1	5.63	3.12e-08	1.09e-05	0.33	0.25	Bitter taste perception;	chr7:141879415	chr7:141704338~141738346:-
LUAD	cis	rs1707322	1	rs10789486	ENSG00000234329.1	RP11-767N6.2	5.63	3.12e-08	1.09e-05	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45942995	chr1:45651039~45651826:-
LUAD	cis	rs4835473	0.838	rs4271960	ENSG00000251600.4	RP11-673E1.1	-5.63	3.13e-08	1.09e-05	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143763591	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.808	rs2323198	ENSG00000251600.4	RP11-673E1.1	-5.63	3.13e-08	1.09e-05	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143763595	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs2323199	ENSG00000251600.4	RP11-673E1.1	-5.63	3.13e-08	1.09e-05	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143763606	chr4:143912331~143982454:+
LUAD	cis	rs2404602	0.669	rs17464903	ENSG00000259422.1	RP11-593F23.1	5.63	3.13e-08	1.09e-05	0.29	0.25	Blood metabolite levels;	chr15:76903145	chr15:76174891~76181486:-
LUAD	cis	rs2212361	0.615	rs6483345	ENSG00000255893.1	RP11-685N10.1	-5.63	3.13e-08	1.09e-05	-0.3	-0.25	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94530983	chr11:94472908~94473570:-
LUAD	cis	rs2179367	0.632	rs2143075	ENSG00000231760.4	RP11-350J20.5	5.63	3.13e-08	1.09e-05	0.35	0.25	Dupuytren's disease;	chr6:149425507	chr6:149796151~149826294:-
LUAD	cis	rs7615952	0.576	rs66671308	ENSG00000171084.14	FAM86JP	5.63	3.14e-08	1.09e-05	0.36	0.25	Blood pressure (smoking interaction);	chr3:126074683	chr3:125916620~125930024:+
LUAD	cis	rs9543976	0.623	rs9318361	ENSG00000261553.4	RP11-29G8.3	5.63	3.14e-08	1.09e-05	0.33	0.25	Diabetic retinopathy;	chr13:75602944	chr13:75549773~75807120:+
LUAD	cis	rs3762637	0.823	rs9849013	ENSG00000272758.4	RP11-299J3.8	-5.63	3.14e-08	1.09e-05	-0.38	-0.25	LDL cholesterol levels;	chr3:122531758	chr3:122416207~122443180:+
LUAD	cis	rs8072100	0.871	rs7206971	ENSG00000228782.6	CTD-2026D20.3	-5.63	3.14e-08	1.09e-05	-0.27	-0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47347749	chr17:47450568~47492492:-
LUAD	cis	rs4787484	1	rs7189550	ENSG00000214725.6	CDIPT-AS1	5.63	3.14e-08	1.09e-05	0.31	0.25	Response to taxane treatment (placlitaxel);	chr16:29899939	chr16:29863593~29868053:+
LUAD	cis	rs11603023	0.804	rs527619	ENSG00000255239.1	AP002954.6	-5.63	3.14e-08	1.09e-05	-0.29	-0.25	Cholesterol, total;	chr11:118692577	chr11:118688039~118690600:-
LUAD	cis	rs4947019	0.688	rs9480937	ENSG00000260273.1	RP11-425D10.10	-5.63	3.14e-08	1.09e-05	-0.57	-0.25	Hematological parameters;	chr6:109358629	chr6:109382795~109383666:+
LUAD	cis	rs3738443	0.868	rs7551871	ENSG00000259865.1	RP11-488L18.10	5.63	3.14e-08	1.09e-05	0.25	0.25	Alcohol dependence;	chr1:247199888	chr1:247187281~247188526:-
LUAD	cis	rs516805	0.748	rs11154072	ENSG00000279453.1	RP3-425C14.4	5.63	3.15e-08	1.1e-05	0.34	0.25	Lymphocyte counts;	chr6:122374632	chr6:122436789~122439223:-
LUAD	cis	rs5753618	0.583	rs5753615	ENSG00000236132.1	CTA-440B3.1	-5.63	3.15e-08	1.1e-05	-0.31	-0.25	Colorectal cancer;	chr22:31432041	chr22:31816379~31817491:-
LUAD	cis	rs2243480	1	rs160652	ENSG00000230295.1	RP11-458F8.2	-5.63	3.15e-08	1.1e-05	-0.3	-0.25	Diabetic kidney disease;	chr7:66073444	chr7:66880708~66882981:+
LUAD	cis	rs875971	0.508	rs10242423	ENSG00000224316.1	RP11-479O9.2	-5.62	3.15e-08	1.1e-05	-0.25	-0.25	Aortic root size;	chr7:66594188	chr7:65773620~65802067:+
LUAD	cis	rs11098499	0.874	rs6851169	ENSG00000248280.1	RP11-33B1.2	5.62	3.15e-08	1.1e-05	0.32	0.25	Corneal astigmatism;	chr4:119196355	chr4:119440561~119450157:-
LUAD	cis	rs1154275	0.563	rs9859168	ENSG00000242770.2	RP11-180K7.1	5.62	3.15e-08	1.1e-05	0.26	0.25	Takotsubo syndrome;	chr3:112797059	chr3:112802478~112812819:+
LUAD	cis	rs2404602	0.716	rs67888330	ENSG00000259422.1	RP11-593F23.1	5.62	3.16e-08	1.1e-05	0.28	0.25	Blood metabolite levels;	chr15:76460142	chr15:76174891~76181486:-
LUAD	cis	rs673078	0.607	rs11068926	ENSG00000275409.1	RP11-131L12.4	-5.62	3.16e-08	1.1e-05	-0.33	-0.25	Glucose homeostasis traits;	chr12:118367320	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs4442583	ENSG00000275409.1	RP11-131L12.4	-5.62	3.16e-08	1.1e-05	-0.33	-0.25	Glucose homeostasis traits;	chr12:118367914	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs61943370	ENSG00000275409.1	RP11-131L12.4	-5.62	3.16e-08	1.1e-05	-0.33	-0.25	Glucose homeostasis traits;	chr12:118369469	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs61943371	ENSG00000275409.1	RP11-131L12.4	-5.62	3.16e-08	1.1e-05	-0.33	-0.25	Glucose homeostasis traits;	chr12:118369600	chr12:118430147~118430699:+
LUAD	cis	rs7927592	0.956	rs7113287	ENSG00000212093.1	AP000807.1	5.62	3.16e-08	1.1e-05	0.27	0.25	Total body bone mineral density;	chr11:68604718	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.913	rs6591346	ENSG00000212093.1	AP000807.1	5.62	3.16e-08	1.1e-05	0.27	0.25	Total body bone mineral density;	chr11:68617150	chr11:68506083~68506166:-
LUAD	cis	rs8062405	0.655	rs7184597	ENSG00000251417.2	RP11-1348G14.4	5.62	3.16e-08	1.1e-05	0.26	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28802743~28817828:+
LUAD	cis	rs867371	0.502	rs1846908	ENSG00000278603.1	RP13-608F4.5	5.62	3.16e-08	1.1e-05	0.28	0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82230185	chr15:82472203~82472426:+
LUAD	cis	rs2665103	0.655	rs1501367	ENSG00000278603.1	RP13-608F4.5	5.62	3.16e-08	1.1e-05	0.28	0.25	Intelligence (multi-trait analysis);	chr15:82230475	chr15:82472203~82472426:+
LUAD	cis	rs10129255	0.957	rs10142859	ENSG00000224373.3	IGHV4-59	5.62	3.16e-08	1.1e-05	0.16	0.25	Kawasaki disease;	chr14:106782238	chr14:106627249~106627825:-
LUAD	cis	rs600231	0.665	rs1621277	ENSG00000245532.5	NEAT1	-5.62	3.17e-08	1.1e-05	-0.19	-0.25	Bone mineral density;	chr11:65454483	chr11:65422774~65445540:+
LUAD	cis	rs2948294	0.545	rs11776397	ENSG00000253893.2	FAM85B	-5.62	3.17e-08	1.1e-05	-0.33	-0.25	Red cell distribution width;	chr8:8257639	chr8:8167819~8226614:-
LUAD	cis	rs6687821	0.515	rs4311860	ENSG00000267734.1	RP4-604K5.3	-5.62	3.17e-08	1.1e-05	-0.3	-0.25	Yeast infection;	chr1:87031539	chr1:86932199~86934891:-
LUAD	cis	rs7017914	0.69	rs3098872	ENSG00000223220.1	Y_RNA	-5.62	3.18e-08	1.1e-05	-0.29	-0.25	Bone mineral density;	chr8:71019969	chr8:70780914~70781008:-
LUAD	cis	rs1876905	0.68	rs187130	ENSG00000272356.1	RP5-1112D6.8	-5.62	3.18e-08	1.1e-05	-0.27	-0.25	Mean corpuscular hemoglobin;	chr6:111188360	chr6:111309203~111313517:+
LUAD	cis	rs36423	0.528	rs1205061	ENSG00000266869.1	RP6-114E22.1	5.62	3.18e-08	1.1e-05	0.37	0.25	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71882819	chr14:71848606~71908430:+
LUAD	cis	rs2790457	0.958	rs2772433	ENSG00000254635.4	WAC-AS1	5.62	3.18e-08	1.11e-05	0.27	0.25	Multiple myeloma;	chr10:28607017	chr10:28522652~28532743:-
LUAD	cis	rs11096990	0.964	rs16988409	ENSG00000249207.1	RP11-360F5.1	-5.62	3.18e-08	1.11e-05	-0.28	-0.25	Cognitive function;	chr4:39267730	chr4:39112677~39126818:-
LUAD	cis	rs1707322	1	rs4660335	ENSG00000234329.1	RP11-767N6.2	5.62	3.18e-08	1.11e-05	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46009046	chr1:45651039~45651826:-
LUAD	cis	rs7927592	0.731	rs2156463	ENSG00000212093.1	AP000807.1	5.62	3.18e-08	1.11e-05	0.26	0.25	Total body bone mineral density;	chr11:68618843	chr11:68506083~68506166:-
LUAD	cis	rs783540	0.5	rs783541	ENSG00000276710.3	CSPG4P8	5.62	3.18e-08	1.11e-05	0.26	0.25	Schizophrenia;	chr15:82586310	chr15:82459472~82477258:+
LUAD	cis	rs2276314	0.512	rs9951125	ENSG00000278986.1	RP11-723J4.3	-5.62	3.18e-08	1.11e-05	-0.26	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:35872841	chr18:35972151~35973916:+
LUAD	cis	rs7923609	0.875	rs10822143	ENSG00000232075.1	MRPL35P2	-5.62	3.19e-08	1.11e-05	-0.3	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63128096	chr10:63634317~63634827:-
LUAD	cis	rs1426063	0.614	rs76512224	ENSG00000249717.1	RP11-44F21.3	5.62	3.19e-08	1.11e-05	0.46	0.25	QT interval;	chr4:75144808	chr4:74955974~74970362:-
LUAD	cis	rs875971	0.895	rs7788984	ENSG00000237310.1	GS1-124K5.4	5.62	3.19e-08	1.11e-05	0.27	0.25	Aortic root size;	chr7:66450629	chr7:66493706~66495474:+
LUAD	cis	rs9652601	0.665	rs17805769	ENSG00000274038.1	RP11-66H6.4	-5.62	3.19e-08	1.11e-05	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11092016	chr16:11056556~11057034:+
LUAD	cis	rs2255336	0.938	rs2734561	ENSG00000245648.1	RP11-277P12.20	5.62	3.19e-08	1.11e-05	0.36	0.25	Blood protein levels;	chr12:10402386	chr12:10363769~10398506:+
LUAD	cis	rs2255336	0.882	rs2246809	ENSG00000245648.1	RP11-277P12.20	5.62	3.19e-08	1.11e-05	0.36	0.25	Blood protein levels;	chr12:10404445	chr12:10363769~10398506:+
LUAD	cis	rs10515750	0.643	rs10063539	ENSG00000251405.2	CTB-109A12.1	5.62	3.2e-08	1.11e-05	0.44	0.25	Lung function (FEV1/FVC);	chr5:157384666	chr5:157362615~157460078:-
LUAD	cis	rs875971	0.545	rs2707851	ENSG00000226824.5	RP4-756H11.3	5.62	3.2e-08	1.11e-05	0.35	0.25	Aortic root size;	chr7:66624178	chr7:66654538~66669855:+
LUAD	cis	rs7208859	0.524	rs8065744	ENSG00000263603.1	CTD-2349P21.5	-5.62	3.2e-08	1.11e-05	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30772431	chr17:30729469~30731202:+
LUAD	cis	rs17826219	0.706	rs8071236	ENSG00000263603.1	CTD-2349P21.5	-5.62	3.2e-08	1.11e-05	-0.44	-0.25	Body mass index;	chr17:30772984	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs56163556	ENSG00000263603.1	CTD-2349P21.5	-5.62	3.2e-08	1.11e-05	-0.44	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774850	chr17:30729469~30731202:+
LUAD	cis	rs516805	0.748	rs155466	ENSG00000279453.1	RP3-425C14.4	-5.62	3.2e-08	1.11e-05	-0.37	-0.25	Lymphocyte counts;	chr6:122512286	chr6:122436789~122439223:-
LUAD	cis	rs9807989	0.801	rs4851566	ENSG00000234389.1	AC007278.3	5.62	3.21e-08	1.11e-05	0.24	0.25	Asthma;	chr2:102356339	chr2:102438713~102440475:+
LUAD	cis	rs189798	0.807	rs330912	ENSG00000254340.1	RP11-10A14.3	5.62	3.21e-08	1.11e-05	0.34	0.25	Myopia (pathological);	chr8:9138784	chr8:9141424~9145435:+
LUAD	cis	rs673078	0.607	rs4767669	ENSG00000275409.1	RP11-131L12.4	-5.62	3.21e-08	1.11e-05	-0.35	-0.25	Glucose homeostasis traits;	chr12:118390651	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs4767670	ENSG00000275409.1	RP11-131L12.4	-5.62	3.21e-08	1.11e-05	-0.35	-0.25	Glucose homeostasis traits;	chr12:118390737	chr12:118430147~118430699:+
LUAD	cis	rs17711722	0.565	rs4717276	ENSG00000224316.1	RP11-479O9.2	5.62	3.21e-08	1.11e-05	0.25	0.25	Calcium levels;	chr7:65829754	chr7:65773620~65802067:+
LUAD	cis	rs17684571	0.7	rs34966024	ENSG00000231441.1	RP11-472M19.2	5.62	3.21e-08	1.11e-05	0.36	0.25	Schizophrenia;	chr6:56766213	chr6:56844002~56864078:+
LUAD	cis	rs75422866	0.558	rs73104190	ENSG00000274902.1	RP1-197B17.4	5.62	3.21e-08	1.11e-05	0.55	0.25	Pneumonia;	chr12:47716040	chr12:47731908~47732351:+
LUAD	cis	rs1816752	0.905	rs2000153	ENSG00000273628.1	RP11-756A22.7	5.62	3.21e-08	1.11e-05	0.29	0.25	Obesity-related traits;	chr13:24405752	chr13:24933006~24936796:+
LUAD	cis	rs1113500	0.965	rs10881495	ENSG00000226822.1	RP11-356N1.2	5.62	3.21e-08	1.11e-05	0.29	0.25	Growth-regulated protein alpha levels;	chr1:108068364	chr1:108071482~108074519:+
LUAD	cis	rs6687821	0.506	rs559491	ENSG00000267734.1	RP4-604K5.3	5.62	3.21e-08	1.11e-05	0.34	0.25	Yeast infection;	chr1:86853136	chr1:86932199~86934891:-
LUAD	cis	rs6687821	0.548	rs492624	ENSG00000267734.1	RP4-604K5.3	5.62	3.21e-08	1.11e-05	0.34	0.25	Yeast infection;	chr1:86854981	chr1:86932199~86934891:-
LUAD	cis	rs35160687	0.644	rs28488524	ENSG00000273080.1	RP11-301O19.1	-5.62	3.21e-08	1.12e-05	-0.28	-0.25	Night sleep phenotypes;	chr2:86284021	chr2:86195590~86196049:+
LUAD	cis	rs2998286	0.813	rs2790430	ENSG00000254635.4	WAC-AS1	-5.62	3.22e-08	1.12e-05	-0.36	-0.25	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28498865	chr10:28522652~28532743:-
LUAD	cis	rs5753618	0.583	rs2273251	ENSG00000236132.1	CTA-440B3.1	-5.62	3.22e-08	1.12e-05	-0.3	-0.25	Colorectal cancer;	chr22:31447581	chr22:31816379~31817491:-
LUAD	cis	rs2288884	0.559	rs8104890	ENSG00000275055.1	CTC-471J1.11	-5.62	3.22e-08	1.12e-05	-0.3	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52016355	chr19:52049007~52049754:+
LUAD	cis	rs1876905	0.68	rs1215848	ENSG00000272356.1	RP5-1112D6.8	-5.62	3.22e-08	1.12e-05	-0.27	-0.25	Mean corpuscular hemoglobin;	chr6:111204333	chr6:111309203~111313517:+
LUAD	cis	rs1876905	0.68	rs402940	ENSG00000272356.1	RP5-1112D6.8	-5.62	3.22e-08	1.12e-05	-0.27	-0.25	Mean corpuscular hemoglobin;	chr6:111206785	chr6:111309203~111313517:+
LUAD	cis	rs1234598	1	rs1234598	ENSG00000272356.1	RP5-1112D6.8	-5.62	3.22e-08	1.12e-05	-0.27	-0.25	Mean corpuscular volume;	chr6:111208250	chr6:111309203~111313517:+
LUAD	cis	rs1876905	0.68	rs354543	ENSG00000272356.1	RP5-1112D6.8	-5.62	3.22e-08	1.12e-05	-0.27	-0.25	Mean corpuscular hemoglobin;	chr6:111209050	chr6:111309203~111313517:+
LUAD	cis	rs62432291	0.681	rs418859	ENSG00000235086.1	FNDC1-IT1	5.62	3.22e-08	1.12e-05	0.42	0.25	Joint mobility (Beighton score);	chr6:159228663	chr6:159240786~159243329:+
LUAD	cis	rs155076	0.666	rs4638420	ENSG00000233325.3	MIPEPP3	-5.62	3.22e-08	1.12e-05	-0.38	-0.25	White matter hyperintensity burden;	chr13:21298209	chr13:21298139~21306373:+
LUAD	cis	rs8098244	0.557	rs2226835	ENSG00000264745.1	TTC39C-AS1	5.62	3.23e-08	1.12e-05	0.26	0.25	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23715912	chr18:23994213~24015339:-
LUAD	cis	rs7927592	0.763	rs3740628	ENSG00000212093.1	AP000807.1	5.62	3.23e-08	1.12e-05	0.26	0.25	Total body bone mineral density;	chr11:68613947	chr11:68506083~68506166:-
LUAD	cis	rs6991838	0.806	rs11777025	ENSG00000200714.1	Y_RNA	-5.62	3.23e-08	1.12e-05	-0.28	-0.25	Intelligence (multi-trait analysis);	chr8:65551438	chr8:65592731~65592820:+
LUAD	cis	rs6546847	0.531	rs2567602	ENSG00000163016.8	ALMS1P	5.62	3.23e-08	1.12e-05	0.37	0.25	Urinary metabolites (H-NMR features);	chr2:73758409	chr2:73644919~73685576:+
LUAD	cis	rs5753618	0.583	rs7293171	ENSG00000236132.1	CTA-440B3.1	-5.62	3.23e-08	1.12e-05	-0.31	-0.25	Colorectal cancer;	chr22:31406338	chr22:31816379~31817491:-
LUAD	cis	rs4713118	0.513	rs156738	ENSG00000204709.4	LINC01556	5.62	3.24e-08	1.12e-05	0.31	0.25	Parkinson's disease;	chr6:28046247	chr6:28943877~28944537:+
LUAD	cis	rs9595908	0.785	rs9652200	ENSG00000212293.1	SNORA16	5.62	3.24e-08	1.12e-05	0.26	0.25	Body mass index;	chr13:32715613	chr13:32420390~32420516:-
LUAD	cis	rs9860428	0.774	rs13094280	ENSG00000242770.2	RP11-180K7.1	5.62	3.24e-08	1.12e-05	0.26	0.25	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112825903	chr3:112802478~112812819:+
LUAD	cis	rs9928842	0.771	rs8059190	ENSG00000280152.1	RP11-331F4.5	5.62	3.25e-08	1.13e-05	0.27	0.25	Alcoholic chronic pancreatitis;	chr16:75226899	chr16:75245994~75250077:-
LUAD	cis	rs2243480	0.803	rs36127118	ENSG00000230295.1	RP11-458F8.2	-5.62	3.25e-08	1.13e-05	-0.3	-0.25	Diabetic kidney disease;	chr7:66100518	chr7:66880708~66882981:+
LUAD	cis	rs7208859	0.614	rs216412	ENSG00000263603.1	CTD-2349P21.5	5.62	3.25e-08	1.13e-05	0.37	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576376	chr17:30729469~30731202:+
LUAD	cis	rs10214930	0.915	rs6462042	ENSG00000235574.1	AC073150.6	5.62	3.25e-08	1.13e-05	0.34	0.25	Hypospadias;	chr7:27682833	chr7:27491682~27492765:-
LUAD	cis	rs12699921	0.632	rs1852011	ENSG00000279048.1	RP11-511H23.2	-5.62	3.25e-08	1.13e-05	-0.2	-0.25	Fibrinogen levels;	chr7:17787004	chr7:17940503~17942922:+
LUAD	cis	rs10761482	0.5	rs1892547	ENSG00000254271.1	RP11-131N11.4	5.62	3.25e-08	1.13e-05	0.27	0.25	Schizophrenia;	chr10:60533200	chr10:60734342~60741828:+
LUAD	cis	rs7712401	0.601	rs246322	ENSG00000263432.2	RN7SL689P	-5.62	3.26e-08	1.13e-05	-0.31	-0.25	Mean platelet volume;	chr5:122971574	chr5:123022487~123022783:-
LUAD	cis	rs2404602	0.632	rs34338978	ENSG00000259422.1	RP11-593F23.1	5.62	3.26e-08	1.13e-05	0.29	0.25	Blood metabolite levels;	chr15:76934464	chr15:76174891~76181486:-
LUAD	cis	rs1707322	0.964	rs785516	ENSG00000234329.1	RP11-767N6.2	-5.62	3.26e-08	1.13e-05	-0.27	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46099086	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs785517	ENSG00000234329.1	RP11-767N6.2	-5.62	3.26e-08	1.13e-05	-0.27	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46101863	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs785484	ENSG00000234329.1	RP11-767N6.2	-5.62	3.26e-08	1.13e-05	-0.27	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46108343	chr1:45651039~45651826:-
LUAD	cis	rs10129255	0.536	rs10139058	ENSG00000211967.3	IGHV3-53	-5.62	3.26e-08	1.13e-05	-0.18	-0.25	Kawasaki disease;	chr14:106685899	chr14:106592676~106593347:-
LUAD	cis	rs1823913	0.503	rs35672076	ENSG00000280083.1	RP11-317J9.1	-5.62	3.26e-08	1.13e-05	-0.31	-0.25	Obesity-related traits;	chr2:191343907	chr2:191154118~191156070:-
LUAD	cis	rs801193	0.636	rs2659895	ENSG00000237310.1	GS1-124K5.4	5.62	3.26e-08	1.13e-05	0.27	0.25	Aortic root size;	chr7:66731484	chr7:66493706~66495474:+
LUAD	cis	rs7712401	0.601	rs34126945	ENSG00000263432.2	RN7SL689P	-5.62	3.26e-08	1.13e-05	-0.3	-0.25	Mean platelet volume;	chr5:122994034	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs2164773	ENSG00000263432.2	RN7SL689P	-5.62	3.26e-08	1.13e-05	-0.31	-0.25	Mean platelet volume;	chr5:123003222	chr5:123022487~123022783:-
LUAD	cis	rs9652601	0.691	rs11861236	ENSG00000274038.1	RP11-66H6.4	-5.62	3.27e-08	1.13e-05	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11089769	chr16:11056556~11057034:+
LUAD	cis	rs2404602	0.655	rs34748201	ENSG00000259422.1	RP11-593F23.1	5.62	3.27e-08	1.13e-05	0.29	0.25	Blood metabolite levels;	chr15:76929189	chr15:76174891~76181486:-
LUAD	cis	rs9287719	0.649	rs2884232	ENSG00000243819.4	RN7SL832P	5.62	3.27e-08	1.13e-05	0.26	0.25	Prostate cancer;	chr2:10579553	chr2:10690344~10692099:+
LUAD	cis	rs7044106	0.762	rs10760112	ENSG00000238181.2	AHCYP2	-5.62	3.27e-08	1.13e-05	-0.32	-0.25	Hip circumference adjusted for BMI;	chr9:120705292	chr9:120720673~120721972:+
LUAD	cis	rs2243480	1	rs313831	ENSG00000230295.1	RP11-458F8.2	-5.62	3.27e-08	1.14e-05	-0.3	-0.25	Diabetic kidney disease;	chr7:66086239	chr7:66880708~66882981:+
LUAD	cis	rs75920871	0.545	rs7939934	ENSG00000254851.1	RP11-109L13.1	5.62	3.27e-08	1.14e-05	0.36	0.25	Subjective well-being;	chr11:116990552	chr11:117135528~117138582:+
LUAD	cis	rs9807989	0.773	rs72823661	ENSG00000234389.1	AC007278.3	5.62	3.28e-08	1.14e-05	0.24	0.25	Asthma;	chr2:102352256	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.801	rs72823663	ENSG00000234389.1	AC007278.3	5.62	3.28e-08	1.14e-05	0.24	0.25	Asthma;	chr2:102352278	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.811	rs67088699	ENSG00000234389.1	AC007278.3	5.62	3.28e-08	1.14e-05	0.24	0.25	Asthma;	chr2:102352291	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.773	rs5010059	ENSG00000234389.1	AC007278.3	5.62	3.28e-08	1.14e-05	0.24	0.25	Asthma;	chr2:102352366	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.839	rs11695627	ENSG00000234389.1	AC007278.3	5.62	3.28e-08	1.14e-05	0.24	0.25	Asthma;	chr2:102353645	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.801	rs7558339	ENSG00000234389.1	AC007278.3	5.62	3.28e-08	1.14e-05	0.24	0.25	Asthma;	chr2:102353783	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.811	rs7608638	ENSG00000234389.1	AC007278.3	5.62	3.28e-08	1.14e-05	0.24	0.25	Asthma;	chr2:102353829	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.811	rs4485584	ENSG00000234389.1	AC007278.3	5.62	3.28e-08	1.14e-05	0.24	0.25	Asthma;	chr2:102354290	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.811	rs4485585	ENSG00000234389.1	AC007278.3	5.62	3.28e-08	1.14e-05	0.24	0.25	Asthma;	chr2:102354299	chr2:102438713~102440475:+
LUAD	cis	rs9807989	1	rs9807989	ENSG00000234389.1	AC007278.3	5.62	3.28e-08	1.14e-05	0.24	0.25	Asthma;	chr2:102354740	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.839	rs9808453	ENSG00000234389.1	AC007278.3	5.62	3.28e-08	1.14e-05	0.24	0.25	Asthma;	chr2:102354846	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.839	rs4851565	ENSG00000234389.1	AC007278.3	5.62	3.28e-08	1.14e-05	0.24	0.25	Asthma;	chr2:102355021	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.765	rs9807962	ENSG00000234389.1	AC007278.3	5.62	3.28e-08	1.14e-05	0.24	0.25	Asthma;	chr2:102355204	chr2:102438713~102440475:+
LUAD	cis	rs12908161	1	rs11638290	ENSG00000225151.9	GOLGA2P7	-5.62	3.28e-08	1.14e-05	-0.34	-0.25	Schizophrenia;	chr15:84684405	chr15:84199311~84230136:-
LUAD	cis	rs12908161	0.959	rs34028043	ENSG00000225151.9	GOLGA2P7	-5.62	3.28e-08	1.14e-05	-0.34	-0.25	Schizophrenia;	chr15:84688354	chr15:84199311~84230136:-
LUAD	cis	rs12908161	0.959	rs34784022	ENSG00000225151.9	GOLGA2P7	-5.62	3.28e-08	1.14e-05	-0.34	-0.25	Schizophrenia;	chr15:84688675	chr15:84199311~84230136:-
LUAD	cis	rs12908161	0.959	rs12908699	ENSG00000225151.9	GOLGA2P7	-5.62	3.28e-08	1.14e-05	-0.34	-0.25	Schizophrenia;	chr15:84697172	chr15:84199311~84230136:-
LUAD	cis	rs1075265	0.901	rs1058320	ENSG00000233266.1	HMGB1P31	5.62	3.28e-08	1.14e-05	0.31	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54085016	chr2:54051334~54051760:+
LUAD	cis	rs35740288	0.721	rs11636347	ENSG00000202081.1	RNU6-1280P	5.62	3.28e-08	1.14e-05	0.32	0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85698002	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.77	rs11635711	ENSG00000202081.1	RNU6-1280P	5.62	3.28e-08	1.14e-05	0.3	0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85583255	chr15:85651522~85651628:-
LUAD	cis	rs4604732	0.536	rs10925056	ENSG00000227135.1	GCSAML-AS1	-5.62	3.28e-08	1.14e-05	-0.39	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247487170	chr1:247524679~247526752:-
LUAD	cis	rs12908161	1	rs62019464	ENSG00000225151.9	GOLGA2P7	-5.62	3.28e-08	1.14e-05	-0.33	-0.25	Schizophrenia;	chr15:84751238	chr15:84199311~84230136:-
LUAD	cis	rs2337406	1	rs17095456	ENSG00000211974.3	IGHV2-70	-5.62	3.28e-08	1.14e-05	-0.34	-0.25	Alzheimer's disease (late onset);	chr14:106676559	chr14:106723574~106724093:-
LUAD	cis	rs7712401	0.601	rs415534	ENSG00000263432.2	RN7SL689P	-5.62	3.29e-08	1.14e-05	-0.31	-0.25	Mean platelet volume;	chr5:122989606	chr5:123022487~123022783:-
LUAD	cis	rs2836950	0.565	rs8134214	ENSG00000255568.3	BRWD1-AS2	-5.62	3.29e-08	1.14e-05	-0.24	-0.25	Menarche (age at onset);	chr21:39170441	chr21:39313935~39314962:+
LUAD	cis	rs2243480	1	rs160646	ENSG00000230295.1	RP11-458F8.2	-5.62	3.29e-08	1.14e-05	-0.3	-0.25	Diabetic kidney disease;	chr7:66091293	chr7:66880708~66882981:+
LUAD	cis	rs12468226	0.817	rs6435135	ENSG00000226261.1	AC064836.3	-5.62	3.29e-08	1.14e-05	-0.4	-0.25	Urate levels;	chr2:202217469	chr2:202336024~202336727:-
LUAD	cis	rs4852324	0.536	rs71418714	ENSG00000217702.2	RP11-287D1.4	5.62	3.3e-08	1.14e-05	0.6	0.25	Systemic lupus erythematosus;	chr2:73992759	chr2:74130583~74135395:+
LUAD	cis	rs11976180	0.517	rs6949375	ENSG00000170356.8	OR2A20P	-5.62	3.3e-08	1.14e-05	-0.4	-0.25	Obesity-related traits;	chr7:144076758	chr7:144250045~144252957:-
LUAD	cis	rs4500972	1	rs4500972	ENSG00000163016.8	ALMS1P	5.62	3.3e-08	1.14e-05	0.3	0.25	Glomerular filtration rate (creatinine);	chr2:73540770	chr2:73644919~73685576:+
LUAD	cis	rs801193	0.613	rs2659900	ENSG00000237310.1	GS1-124K5.4	5.62	3.3e-08	1.14e-05	0.26	0.25	Aortic root size;	chr7:66719456	chr7:66493706~66495474:+
LUAD	cis	rs72615157	0.697	rs2056726	ENSG00000242294.5	STAG3L5P	5.62	3.3e-08	1.14e-05	0.21	0.25	Lung function (FEV1/FVC);	chr7:100182660	chr7:100336079~100351900:+
LUAD	cis	rs2749592	0.513	rs1208708	ENSG00000263064.2	RP11-291L22.7	5.62	3.3e-08	1.14e-05	0.26	0.25	Age-related hearing impairment (SNP x SNP interaction);	chr10:37796648	chr10:38448689~38448949:+
LUAD	cis	rs453301	0.686	rs2409120	ENSG00000253981.4	ALG1L13P	-5.62	3.31e-08	1.15e-05	-0.29	-0.25	Joint mobility (Beighton score);	chr8:9025061	chr8:8236003~8244667:-
LUAD	cis	rs1707322	0.964	rs785508	ENSG00000234329.1	RP11-767N6.2	-5.62	3.31e-08	1.15e-05	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061487	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.964	rs785509	ENSG00000234329.1	RP11-767N6.2	-5.62	3.31e-08	1.15e-05	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061628	chr1:45651039~45651826:-
LUAD	cis	rs2276314	0.857	rs16967327	ENSG00000278986.1	RP11-723J4.3	-5.62	3.31e-08	1.15e-05	-0.3	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:36007073	chr18:35972151~35973916:+
LUAD	cis	rs11105298	0.838	rs4842488	ENSG00000258302.2	RP11-981P6.1	5.62	3.31e-08	1.15e-05	0.31	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89487787	chr12:89561129~89594878:+
LUAD	cis	rs11105298	0.891	rs6538189	ENSG00000258302.2	RP11-981P6.1	5.62	3.31e-08	1.15e-05	0.31	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89492146	chr12:89561129~89594878:+
LUAD	cis	rs11105298	0.891	rs6538190	ENSG00000258302.2	RP11-981P6.1	5.62	3.31e-08	1.15e-05	0.31	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89492165	chr12:89561129~89594878:+
LUAD	cis	rs11105298	0.891	rs1008764	ENSG00000258302.2	RP11-981P6.1	5.62	3.31e-08	1.15e-05	0.31	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89493872	chr12:89561129~89594878:+
LUAD	cis	rs11673344	0.58	rs320881	ENSG00000226686.6	LINC01535	5.62	3.31e-08	1.15e-05	0.32	0.25	Obesity-related traits;	chr19:37246948	chr19:37251912~37265535:+
LUAD	cis	rs897984	0.609	rs4889609	ENSG00000260911.2	RP11-196G11.2	5.62	3.31e-08	1.15e-05	0.22	0.25	Dementia with Lewy bodies;	chr16:31015106	chr16:31043150~31049868:+
LUAD	cis	rs72615157	0.634	rs2272343	ENSG00000242294.5	STAG3L5P	5.62	3.32e-08	1.15e-05	0.21	0.25	Lung function (FEV1/FVC);	chr7:100180662	chr7:100336079~100351900:+
LUAD	cis	rs1707322	1	rs10789485	ENSG00000234329.1	RP11-767N6.2	5.62	3.32e-08	1.15e-05	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941636	chr1:45651039~45651826:-
LUAD	cis	rs673078	0.607	rs17512652	ENSG00000275409.1	RP11-131L12.4	-5.62	3.32e-08	1.15e-05	-0.35	-0.25	Glucose homeostasis traits;	chr12:118361278	chr12:118430147~118430699:+
LUAD	cis	rs1707322	0.656	rs3014210	ENSG00000234329.1	RP11-767N6.2	-5.62	3.32e-08	1.15e-05	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45600936	chr1:45651039~45651826:-
LUAD	cis	rs600231	0.665	rs2846861	ENSG00000245532.5	NEAT1	5.62	3.32e-08	1.15e-05	0.19	0.25	Bone mineral density;	chr11:65454834	chr11:65422774~65445540:+
LUAD	cis	rs600231	0.665	rs1784858	ENSG00000245532.5	NEAT1	5.62	3.32e-08	1.15e-05	0.19	0.25	Bone mineral density;	chr11:65455481	chr11:65422774~65445540:+
LUAD	cis	rs9652601	0.649	rs12599402	ENSG00000274038.1	RP11-66H6.4	-5.62	3.32e-08	1.15e-05	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11096031	chr16:11056556~11057034:+
LUAD	cis	rs10822145	1	rs10822145	ENSG00000232075.1	MRPL35P2	-5.61	3.33e-08	1.15e-05	-0.3	-0.25	Triglycerides;	chr10:63174788	chr10:63634317~63634827:-
LUAD	cis	rs1707322	1	rs10890365	ENSG00000234329.1	RP11-767N6.2	5.61	3.33e-08	1.15e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893676	chr1:45651039~45651826:-
LUAD	cis	rs11098499	0.526	rs10026625	ENSG00000245958.5	RP11-33B1.1	-5.61	3.33e-08	1.15e-05	-0.21	-0.25	Corneal astigmatism;	chr4:119358981	chr4:119454791~119552025:+
LUAD	cis	rs496547	0.719	rs598373	ENSG00000255239.1	AP002954.6	5.61	3.33e-08	1.15e-05	0.31	0.25	Hip minimal joint space width;	chr11:118793668	chr11:118688039~118690600:-
LUAD	cis	rs11651753	0.636	rs4793737	ENSG00000264920.1	RP11-6N17.4	-5.61	3.34e-08	1.15e-05	-0.31	-0.25	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47964891	chr17:47891255~47895812:-
LUAD	cis	rs854462	0.925	rs712040	ENSG00000274767.1	AC131056.3	-5.61	3.34e-08	1.16e-05	-0.39	-0.25	Blood protein levels;	chr17:36058228	chr17:36183235~36196471:+
LUAD	cis	rs516805	0.667	rs2816078	ENSG00000279453.1	RP3-425C14.4	-5.61	3.34e-08	1.16e-05	-0.34	-0.25	Lymphocyte counts;	chr6:122201755	chr6:122436789~122439223:-
LUAD	cis	rs6543140	0.964	rs4851010	ENSG00000234389.1	AC007278.3	-5.61	3.34e-08	1.16e-05	-0.25	-0.25	Blood protein levels;	chr2:102439667	chr2:102438713~102440475:+
LUAD	cis	rs193541	0.545	rs112390044	ENSG00000263432.2	RN7SL689P	-5.61	3.35e-08	1.16e-05	-0.32	-0.25	Glucose homeostasis traits;	chr5:122976307	chr5:123022487~123022783:-
LUAD	cis	rs1799949	0.965	rs799910	ENSG00000267681.1	CTD-3199J23.6	-5.61	3.35e-08	1.16e-05	-0.28	-0.25	Menopause (age at onset);	chr17:43127544	chr17:43144956~43145255:+
LUAD	cis	rs4927850	1	rs4927850	ENSG00000242086.7	LINC00969	-5.61	3.35e-08	1.16e-05	-0.22	-0.25	Pancreatic cancer;	chr3:196024759	chr3:195658062~195739964:+
LUAD	cis	rs66887589	0.87	rs10518336	ENSG00000248280.1	RP11-33B1.2	5.61	3.35e-08	1.16e-05	0.28	0.25	Diastolic blood pressure;	chr4:119601779	chr4:119440561~119450157:-
LUAD	cis	rs10754283	0.967	rs10801761	ENSG00000231613.1	RP5-943J3.1	5.61	3.36e-08	1.16e-05	0.25	0.25	Amyotrophic lateral sclerosis (sporadic);	chr1:89649710	chr1:89788914~89790492:+
LUAD	cis	rs7615952	0.599	rs60847438	ENSG00000171084.14	FAM86JP	5.61	3.36e-08	1.16e-05	0.36	0.25	Blood pressure (smoking interaction);	chr3:126027162	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.534	rs1503072	ENSG00000171084.14	FAM86JP	5.61	3.36e-08	1.16e-05	0.36	0.25	Blood pressure (smoking interaction);	chr3:126035848	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.599	rs7631268	ENSG00000171084.14	FAM86JP	5.61	3.36e-08	1.16e-05	0.36	0.25	Blood pressure (smoking interaction);	chr3:126036821	chr3:125916620~125930024:+
LUAD	cis	rs897984	0.542	rs6565217	ENSG00000260911.2	RP11-196G11.2	5.61	3.37e-08	1.16e-05	0.22	0.25	Dementia with Lewy bodies;	chr16:31072003	chr16:31043150~31049868:+
LUAD	cis	rs7182621	1	rs7182621	ENSG00000182397.13	DNM1P46	-5.61	3.37e-08	1.16e-05	-0.29	-0.25	Colonoscopy-negative controls vs population controls;	chr15:99884400	chr15:99790156~99806927:-
LUAD	cis	rs7829975	0.807	rs519019	ENSG00000253893.2	FAM85B	5.61	3.37e-08	1.17e-05	0.31	0.25	Mood instability;	chr8:8737594	chr8:8167819~8226614:-
LUAD	cis	rs2599510	0.811	rs2583713	ENSG00000276334.1	AL133243.1	5.61	3.38e-08	1.17e-05	0.29	0.25	Interleukin-18 levels;	chr2:32597662	chr2:32521927~32523547:+
LUAD	cis	rs7849270	1	rs3124510	ENSG00000268707.1	RP11-247A12.7	5.61	3.38e-08	1.17e-05	0.27	0.25	Blood metabolite ratios;	chr9:129137411	chr9:129170434~129170940:+
LUAD	cis	rs12468226	1	rs58288071	ENSG00000272966.1	RP11-686O6.1	5.61	3.38e-08	1.17e-05	0.43	0.25	Urate levels;	chr2:202350016	chr2:202336739~202337200:+
LUAD	cis	rs155076	0.666	rs9509640	ENSG00000233325.3	MIPEPP3	-5.61	3.38e-08	1.17e-05	-0.38	-0.25	White matter hyperintensity burden;	chr13:21298741	chr13:21298139~21306373:+
LUAD	cis	rs11742741	0.539	rs11743753	ENSG00000248874.4	C5orf17	5.61	3.38e-08	1.17e-05	0.31	0.25	Educational attainment;	chr5:24093021	chr5:23951348~24178263:+
LUAD	cis	rs2179367	0.632	rs12211357	ENSG00000231760.4	RP11-350J20.5	5.61	3.38e-08	1.17e-05	0.36	0.25	Dupuytren's disease;	chr6:149331148	chr6:149796151~149826294:-
LUAD	cis	rs858239	0.863	rs274054	ENSG00000226816.2	AC005082.12	5.61	3.38e-08	1.17e-05	0.33	0.25	Cerebrospinal fluid biomarker levels;	chr7:23350848	chr7:23206013~23208045:+
LUAD	cis	rs891378	1	rs7543250	ENSG00000274245.1	RP11-357P18.2	5.61	3.39e-08	1.17e-05	0.3	0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207251698	chr1:207372559~207373252:+
LUAD	cis	rs4308124	0.708	rs7585313	ENSG00000227992.1	AC108463.2	-5.61	3.39e-08	1.17e-05	-0.33	-0.25	Vitiligo;	chr2:111217626	chr2:111203964~111206215:-
LUAD	cis	rs2836950	0.52	rs1980407	ENSG00000255568.3	BRWD1-AS2	-5.61	3.39e-08	1.17e-05	-0.24	-0.25	Menarche (age at onset);	chr21:39172035	chr21:39313935~39314962:+
LUAD	cis	rs2836950	0.565	rs2836931	ENSG00000255568.3	BRWD1-AS2	-5.61	3.39e-08	1.17e-05	-0.24	-0.25	Menarche (age at onset);	chr21:39174643	chr21:39313935~39314962:+
LUAD	cis	rs4908760	0.827	rs2401138	ENSG00000232912.4	RP5-1115A15.1	-5.61	3.39e-08	1.17e-05	-0.23	-0.25	Vitiligo;	chr1:8644000	chr1:8424645~8434838:+
LUAD	cis	rs2404602	1	rs12148786	ENSG00000259422.1	RP11-593F23.1	5.61	3.39e-08	1.17e-05	0.29	0.25	Blood metabolite levels;	chr15:76508021	chr15:76174891~76181486:-
LUAD	cis	rs6921919	0.525	rs11760133	ENSG00000216901.1	AL022393.7	5.61	3.4e-08	1.17e-05	0.3	0.25	Autism spectrum disorder or schizophrenia;	chr6:28418962	chr6:28176188~28176674:+
LUAD	cis	rs6558530	0.698	rs7015858	ENSG00000253982.1	CTD-2336O2.1	5.61	3.4e-08	1.17e-05	0.31	0.25	Systolic blood pressure;	chr8:1776141	chr8:1761990~1764502:-
LUAD	cis	rs10129255	0.957	rs8014696	ENSG00000224373.3	IGHV4-59	-5.61	3.4e-08	1.17e-05	-0.16	-0.25	Kawasaki disease;	chr14:106769752	chr14:106627249~106627825:-
LUAD	cis	rs7615952	0.599	rs66532274	ENSG00000171084.14	FAM86JP	5.61	3.4e-08	1.18e-05	0.33	0.25	Blood pressure (smoking interaction);	chr3:126013002	chr3:125916620~125930024:+
LUAD	cis	rs1799949	0.929	rs799905	ENSG00000267681.1	CTD-3199J23.6	-5.61	3.41e-08	1.18e-05	-0.28	-0.25	Menopause (age at onset);	chr17:43125170	chr17:43144956~43145255:+
LUAD	cis	rs2412819	0.571	rs2930529	ENSG00000249839.1	AC011330.5	5.61	3.41e-08	1.18e-05	0.38	0.25	Lung cancer;	chr15:43819467	chr15:43663654~43684339:-
LUAD	cis	rs2412819	0.571	rs2930530	ENSG00000249839.1	AC011330.5	5.61	3.41e-08	1.18e-05	0.38	0.25	Lung cancer;	chr15:43823268	chr15:43663654~43684339:-
LUAD	cis	rs12908161	0.959	rs2175567	ENSG00000225151.9	GOLGA2P7	-5.61	3.41e-08	1.18e-05	-0.34	-0.25	Schizophrenia;	chr15:84657715	chr15:84199311~84230136:-
LUAD	cis	rs9311474	0.935	rs7622851	ENSG00000243224.1	RP5-1157M23.2	-5.61	3.41e-08	1.18e-05	-0.26	-0.25	Electroencephalogram traits;	chr3:52299655	chr3:52239258~52241097:+
LUAD	cis	rs673078	0.66	rs17440433	ENSG00000275409.1	RP11-131L12.4	-5.61	3.41e-08	1.18e-05	-0.36	-0.25	Glucose homeostasis traits;	chr12:118201507	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.66	rs17512219	ENSG00000275409.1	RP11-131L12.4	-5.61	3.41e-08	1.18e-05	-0.36	-0.25	Glucose homeostasis traits;	chr12:118211468	chr12:118430147~118430699:+
LUAD	cis	rs1707322	0.928	rs6681068	ENSG00000234329.1	RP11-767N6.2	5.61	3.41e-08	1.18e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45932710	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs11211228	ENSG00000234329.1	RP11-767N6.2	5.61	3.41e-08	1.18e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934168	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.963	rs11211229	ENSG00000234329.1	RP11-767N6.2	5.61	3.41e-08	1.18e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934845	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs9803784	ENSG00000234329.1	RP11-767N6.2	5.61	3.41e-08	1.18e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45936235	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.963	rs12022335	ENSG00000234329.1	RP11-767N6.2	5.61	3.41e-08	1.18e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45937060	chr1:45651039~45651826:-
LUAD	cis	rs1823913	0.503	rs34689696	ENSG00000227542.1	AC092614.2	5.61	3.41e-08	1.18e-05	0.32	0.25	Obesity-related traits;	chr2:191355247	chr2:191229165~191246172:-
LUAD	cis	rs4908768	0.539	rs1934138	ENSG00000232912.4	RP5-1115A15.1	5.61	3.41e-08	1.18e-05	0.23	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8585757	chr1:8424645~8434838:+
LUAD	cis	rs2919009	0.664	rs10510083	ENSG00000271670.1	RP11-95I16.4	5.61	3.41e-08	1.18e-05	0.32	0.25	Obesity-related traits;	chr10:120925013	chr10:120879256~120880667:-
LUAD	cis	rs801193	0.569	rs11772819	ENSG00000237310.1	GS1-124K5.4	5.61	3.43e-08	1.18e-05	0.27	0.25	Aortic root size;	chr7:66752983	chr7:66493706~66495474:+
LUAD	cis	rs801193	0.569	rs7800620	ENSG00000237310.1	GS1-124K5.4	5.61	3.43e-08	1.18e-05	0.27	0.25	Aortic root size;	chr7:66758701	chr7:66493706~66495474:+
LUAD	cis	rs1667284	0.935	rs1791161	ENSG00000266521.1	RP11-650P15.1	5.61	3.43e-08	1.18e-05	0.29	0.25	Problematic alcohol use in trauma-exposed individuals;	chr18:31624247	chr18:31496645~31497195:-
LUAD	cis	rs4767841	0.552	rs11064855	ENSG00000248636.5	RP11-768F21.1	-5.61	3.44e-08	1.19e-05	-0.29	-0.25	Urgency urinary incontinence;	chr12:119626986	chr12:119387987~119668079:-
LUAD	cis	rs763567	0.9	rs473133	ENSG00000271811.1	RP1-79C4.4	5.61	3.44e-08	1.19e-05	0.3	0.25	Tonsillectomy;	chr1:170666938	chr1:170667381~170669425:+
LUAD	cis	rs9287719	0.649	rs10929677	ENSG00000243819.4	RN7SL832P	5.61	3.44e-08	1.19e-05	0.26	0.25	Prostate cancer;	chr2:10577422	chr2:10690344~10692099:+
LUAD	cis	rs11051970	0.559	rs11051944	ENSG00000274964.1	RP11-817I4.1	-5.61	3.44e-08	1.19e-05	-0.31	-0.25	Response to tocilizumab in rheumatoid arthritis;	chr12:32332984	chr12:32339368~32340724:+
LUAD	cis	rs1876905	0.569	rs354542	ENSG00000272356.1	RP5-1112D6.8	-5.61	3.44e-08	1.19e-05	-0.27	-0.25	Mean corpuscular hemoglobin;	chr6:111193483	chr6:111309203~111313517:+
LUAD	cis	rs1876905	0.68	rs1216020	ENSG00000272356.1	RP5-1112D6.8	-5.61	3.44e-08	1.19e-05	-0.27	-0.25	Mean corpuscular hemoglobin;	chr6:111194004	chr6:111309203~111313517:+
LUAD	cis	rs1876905	0.569	rs354541	ENSG00000272356.1	RP5-1112D6.8	-5.61	3.44e-08	1.19e-05	-0.27	-0.25	Mean corpuscular hemoglobin;	chr6:111195262	chr6:111309203~111313517:+
LUAD	cis	rs1876905	0.68	rs354537	ENSG00000272356.1	RP5-1112D6.8	-5.61	3.44e-08	1.19e-05	-0.27	-0.25	Mean corpuscular hemoglobin;	chr6:111197097	chr6:111309203~111313517:+
LUAD	cis	rs1876905	0.68	rs354536	ENSG00000272356.1	RP5-1112D6.8	-5.61	3.44e-08	1.19e-05	-0.27	-0.25	Mean corpuscular hemoglobin;	chr6:111197808	chr6:111309203~111313517:+
LUAD	cis	rs1876905	0.68	rs557028	ENSG00000272356.1	RP5-1112D6.8	-5.61	3.44e-08	1.19e-05	-0.27	-0.25	Mean corpuscular hemoglobin;	chr6:111201606	chr6:111309203~111313517:+
LUAD	cis	rs6570726	0.905	rs430248	ENSG00000235652.6	RP11-545I5.3	5.61	3.45e-08	1.19e-05	0.25	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145552968	chr6:145799409~145886585:+
LUAD	cis	rs7044106	0.762	rs1411158	ENSG00000238181.2	AHCYP2	-5.61	3.45e-08	1.19e-05	-0.32	-0.25	Hip circumference adjusted for BMI;	chr9:120702526	chr9:120720673~120721972:+
LUAD	cis	rs853679	0.882	rs9461432	ENSG00000219392.1	RP1-265C24.5	-5.61	3.46e-08	1.19e-05	-0.42	-0.25	Depression;	chr6:28119105	chr6:28115628~28116551:+
LUAD	cis	rs2404602	0.692	rs34181263	ENSG00000259422.1	RP11-593F23.1	5.61	3.46e-08	1.2e-05	0.29	0.25	Blood metabolite levels;	chr15:76773047	chr15:76174891~76181486:-
LUAD	cis	rs7617773	0.784	rs9850672	ENSG00000228638.1	FCF1P2	-5.61	3.47e-08	1.2e-05	-0.29	-0.25	Coronary artery disease;	chr3:48259682	chr3:48290793~48291375:-
LUAD	cis	rs7712401	0.601	rs246275	ENSG00000263432.2	RN7SL689P	5.61	3.47e-08	1.2e-05	0.31	0.25	Mean platelet volume;	chr5:122895718	chr5:123022487~123022783:-
LUAD	cis	rs10214930	0.697	rs1111647	ENSG00000235574.1	AC073150.6	-5.61	3.47e-08	1.2e-05	-0.3	-0.25	Hypospadias;	chr7:27521114	chr7:27491682~27492765:-
LUAD	cis	rs9914544	0.591	rs9900052	ENSG00000273018.4	CTD-2303H24.2	-5.61	3.47e-08	1.2e-05	-0.29	-0.25	Educational attainment (years of education);	chr17:18796085	chr17:18511221~18551705:-
LUAD	cis	rs11157436	1	rs11157436	ENSG00000211812.1	TRAV26-2	5.61	3.47e-08	1.2e-05	0.28	0.25	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22168978	chr14:22202583~22203368:+
LUAD	cis	rs9595908	0.669	rs56291634	ENSG00000212293.1	SNORA16	5.61	3.48e-08	1.2e-05	0.27	0.25	Body mass index;	chr13:32720404	chr13:32420390~32420516:-
LUAD	cis	rs7811142	0.666	rs28401739	ENSG00000078319.8	PMS2P1	-5.61	3.48e-08	1.2e-05	-0.29	-0.25	Platelet count;	chr7:100308061	chr7:100320992~100341908:-
LUAD	cis	rs7181230	0.885	rs749748	ENSG00000275636.1	RP11-521C20.5	5.61	3.49e-08	1.2e-05	0.33	0.25	Dehydroepiandrosterone sulphate levels;	chr15:40057708	chr15:40078892~40079347:+
LUAD	cis	rs2404602	0.716	rs12437627	ENSG00000259422.1	RP11-593F23.1	5.61	3.5e-08	1.21e-05	0.28	0.25	Blood metabolite levels;	chr15:76552709	chr15:76174891~76181486:-
LUAD	cis	rs7618501	0.633	rs7628058	ENSG00000234667.1	ACTBP13	-5.61	3.5e-08	1.21e-05	-0.28	-0.25	Intelligence (multi-trait analysis);	chr3:50002041	chr3:49873347~49877980:-
LUAD	cis	rs2243480	1	rs1618893	ENSG00000230295.1	RP11-458F8.2	-5.61	3.5e-08	1.21e-05	-0.28	-0.25	Diabetic kidney disease;	chr7:66631132	chr7:66880708~66882981:+
LUAD	cis	rs1707322	0.656	rs9429172	ENSG00000280836.1	AL355480.1	5.61	3.5e-08	1.21e-05	0.33	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45626804	chr1:45581219~45581321:-
LUAD	cis	rs7948661	0.661	rs113028342	ENSG00000278376.1	RP11-158I9.8	5.61	3.5e-08	1.21e-05	0.53	0.25	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118462822	chr11:118791254~118793137:+
LUAD	cis	rs62432291	0.681	rs404435	ENSG00000235086.1	FNDC1-IT1	-5.61	3.5e-08	1.21e-05	-0.42	-0.25	Joint mobility (Beighton score);	chr6:159233455	chr6:159240786~159243329:+
LUAD	cis	rs62432291	0.614	rs370434	ENSG00000235086.1	FNDC1-IT1	-5.61	3.5e-08	1.21e-05	-0.42	-0.25	Joint mobility (Beighton score);	chr6:159233519	chr6:159240786~159243329:+
LUAD	cis	rs62432291	0.681	rs402388	ENSG00000235086.1	FNDC1-IT1	-5.61	3.5e-08	1.21e-05	-0.42	-0.25	Joint mobility (Beighton score);	chr6:159233962	chr6:159240786~159243329:+
LUAD	cis	rs62432291	0.764	rs436743	ENSG00000235086.1	FNDC1-IT1	-5.61	3.5e-08	1.21e-05	-0.42	-0.25	Joint mobility (Beighton score);	chr6:159234070	chr6:159240786~159243329:+
LUAD	cis	rs62432291	0.681	rs3003174	ENSG00000235086.1	FNDC1-IT1	-5.61	3.5e-08	1.21e-05	-0.42	-0.25	Joint mobility (Beighton score);	chr6:159234294	chr6:159240786~159243329:+
LUAD	cis	rs62432291	0.681	rs2501176	ENSG00000235086.1	FNDC1-IT1	-5.61	3.5e-08	1.21e-05	-0.42	-0.25	Joint mobility (Beighton score);	chr6:159234351	chr6:159240786~159243329:+
LUAD	cis	rs62432291	0.681	rs2501177	ENSG00000235086.1	FNDC1-IT1	-5.61	3.5e-08	1.21e-05	-0.42	-0.25	Joint mobility (Beighton score);	chr6:159234561	chr6:159240786~159243329:+
LUAD	cis	rs293748	0.605	rs13188136	ENSG00000250155.1	CTD-2353F22.1	-5.61	3.5e-08	1.21e-05	-0.32	-0.25	Obesity-related traits;	chr5:37117132	chr5:36666214~36725195:-
LUAD	cis	rs2179367	0.632	rs11155640	ENSG00000231760.4	RP11-350J20.5	5.61	3.5e-08	1.21e-05	0.36	0.25	Dupuytren's disease;	chr6:149323648	chr6:149796151~149826294:-
LUAD	cis	rs2404602	0.692	rs12910734	ENSG00000259422.1	RP11-593F23.1	5.61	3.5e-08	1.21e-05	0.29	0.25	Blood metabolite levels;	chr15:76857590	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.692	rs12594556	ENSG00000259422.1	RP11-593F23.1	5.61	3.5e-08	1.21e-05	0.29	0.25	Blood metabolite levels;	chr15:76873022	chr15:76174891~76181486:-
LUAD	cis	rs4604732	0.588	rs6677477	ENSG00000227135.1	GCSAML-AS1	-5.61	3.5e-08	1.21e-05	-0.37	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247466109	chr1:247524679~247526752:-
LUAD	cis	rs7804306	0.826	rs73049300	ENSG00000233264.2	AC006042.8	5.61	3.51e-08	1.21e-05	0.49	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8002315	chr7:7980312~7982228:+
LUAD	cis	rs7804306	0.826	rs58348680	ENSG00000233264.2	AC006042.8	5.61	3.51e-08	1.21e-05	0.49	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8005655	chr7:7980312~7982228:+
LUAD	cis	rs10129255	0.556	rs8010005	ENSG00000211967.3	IGHV3-53	-5.61	3.51e-08	1.21e-05	-0.18	-0.25	Kawasaki disease;	chr14:106777987	chr14:106592676~106593347:-
LUAD	cis	rs10129255	0.556	rs6576224	ENSG00000211967.3	IGHV3-53	-5.61	3.51e-08	1.21e-05	-0.18	-0.25	Kawasaki disease;	chr14:106777997	chr14:106592676~106593347:-
LUAD	cis	rs867371	0.502	rs28610286	ENSG00000278603.1	RP13-608F4.5	5.61	3.51e-08	1.21e-05	0.28	0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82233314	chr15:82472203~82472426:+
LUAD	cis	rs848490	0.722	rs4729772	ENSG00000214293.7	APTR	5.61	3.51e-08	1.21e-05	0.28	0.25	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77826582	chr7:77657660~77696265:-
LUAD	cis	rs10800713	0.908	rs6670625	ENSG00000260088.1	RP11-92G12.3	-5.61	3.51e-08	1.21e-05	-0.35	-0.25	Tandem gait;	chr1:200587514	chr1:200669507~200694250:+
LUAD	cis	rs2404602	0.74	rs34924128	ENSG00000259422.1	RP11-593F23.1	5.6	3.52e-08	1.21e-05	0.29	0.25	Blood metabolite levels;	chr15:76672828	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.692	rs67010831	ENSG00000259422.1	RP11-593F23.1	5.6	3.52e-08	1.21e-05	0.29	0.25	Blood metabolite levels;	chr15:76672967	chr15:76174891~76181486:-
LUAD	cis	rs11157436	0.958	rs17183356	ENSG00000211812.1	TRAV26-2	-5.6	3.52e-08	1.21e-05	-0.29	-0.25	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22219101	chr14:22202583~22203368:+
LUAD	cis	rs2404602	0.692	rs2137307	ENSG00000259422.1	RP11-593F23.1	5.6	3.52e-08	1.21e-05	0.29	0.25	Blood metabolite levels;	chr15:76856679	chr15:76174891~76181486:-
LUAD	cis	rs2303759	0.676	rs10426452	ENSG00000268686.1	AC010524.2	-5.6	3.52e-08	1.21e-05	-0.33	-0.25	Multiple sclerosis;	chr19:49404433	chr19:49368705~49388081:-
LUAD	cis	rs858239	0.539	rs2178140	ENSG00000230042.1	AK3P3	-5.6	3.52e-08	1.21e-05	-0.32	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23152006	chr7:23129178~23129841:+
LUAD	cis	rs11105298	0.891	rs10777162	ENSG00000258302.2	RP11-981P6.1	5.6	3.52e-08	1.21e-05	0.31	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89436746	chr12:89561129~89594878:+
LUAD	cis	rs875971	1	rs7781698	ENSG00000237310.1	GS1-124K5.4	5.6	3.53e-08	1.22e-05	0.27	0.25	Aortic root size;	chr7:66431325	chr7:66493706~66495474:+
LUAD	cis	rs801193	0.591	rs2707839	ENSG00000237310.1	GS1-124K5.4	5.6	3.53e-08	1.22e-05	0.26	0.25	Aortic root size;	chr7:66728097	chr7:66493706~66495474:+
LUAD	cis	rs131777	0.545	rs131759	ENSG00000205559.3	CHKB-AS1	-5.6	3.53e-08	1.22e-05	-0.28	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50577052	chr22:50583026~50583877:+
LUAD	cis	rs11098499	0.874	rs9995277	ENSG00000248280.1	RP11-33B1.2	5.6	3.53e-08	1.22e-05	0.32	0.25	Corneal astigmatism;	chr4:119187448	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.874	rs6826823	ENSG00000248280.1	RP11-33B1.2	5.6	3.53e-08	1.22e-05	0.32	0.25	Corneal astigmatism;	chr4:119190943	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.874	rs12509054	ENSG00000248280.1	RP11-33B1.2	5.6	3.53e-08	1.22e-05	0.32	0.25	Corneal astigmatism;	chr4:119193920	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.874	rs12502503	ENSG00000248280.1	RP11-33B1.2	5.6	3.53e-08	1.22e-05	0.32	0.25	Corneal astigmatism;	chr4:119195100	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.874	rs6832670	ENSG00000248280.1	RP11-33B1.2	5.6	3.53e-08	1.22e-05	0.32	0.25	Corneal astigmatism;	chr4:119197637	chr4:119440561~119450157:-
LUAD	cis	rs9652601	0.691	rs9888868	ENSG00000274038.1	RP11-66H6.4	-5.6	3.54e-08	1.22e-05	-0.3	-0.25	Systemic lupus erythematosus;	chr16:11089706	chr16:11056556~11057034:+
LUAD	cis	rs74233809	1	rs12219027	ENSG00000213277.3	MARCKSL1P1	5.6	3.54e-08	1.22e-05	0.42	0.25	Birth weight;	chr10:103051446	chr10:103175554~103176094:+
LUAD	cis	rs12699921	0.607	rs1051603	ENSG00000279048.1	RP11-511H23.2	-5.6	3.54e-08	1.22e-05	-0.2	-0.25	Fibrinogen levels;	chr7:17822402	chr7:17940503~17942922:+
LUAD	cis	rs2408955	0.521	rs1476607	ENSG00000240399.1	RP1-228P16.1	-5.6	3.54e-08	1.22e-05	-0.25	-0.25	Glycated hemoglobin levels;	chr12:48131021	chr12:48054813~48055591:-
LUAD	cis	rs62432291	0.614	rs420339	ENSG00000235086.1	FNDC1-IT1	-5.6	3.54e-08	1.22e-05	-0.42	-0.25	Joint mobility (Beighton score);	chr6:159236163	chr6:159240786~159243329:+
LUAD	cis	rs62432291	0.681	rs425906	ENSG00000235086.1	FNDC1-IT1	-5.6	3.54e-08	1.22e-05	-0.42	-0.25	Joint mobility (Beighton score);	chr6:159236543	chr6:159240786~159243329:+
LUAD	cis	rs62432291	0.681	rs388001	ENSG00000235086.1	FNDC1-IT1	-5.6	3.54e-08	1.22e-05	-0.42	-0.25	Joint mobility (Beighton score);	chr6:159237427	chr6:159240786~159243329:+
LUAD	cis	rs62432291	0.681	rs378339	ENSG00000235086.1	FNDC1-IT1	-5.6	3.54e-08	1.22e-05	-0.42	-0.25	Joint mobility (Beighton score);	chr6:159237820	chr6:159240786~159243329:+
LUAD	cis	rs62432291	0.681	rs419836	ENSG00000235086.1	FNDC1-IT1	-5.6	3.54e-08	1.22e-05	-0.42	-0.25	Joint mobility (Beighton score);	chr6:159238449	chr6:159240786~159243329:+
LUAD	cis	rs62432291	0.681	rs450538	ENSG00000235086.1	FNDC1-IT1	-5.6	3.54e-08	1.22e-05	-0.42	-0.25	Joint mobility (Beighton score);	chr6:159238491	chr6:159240786~159243329:+
LUAD	cis	rs62432291	0.764	rs433256	ENSG00000235086.1	FNDC1-IT1	-5.6	3.54e-08	1.22e-05	-0.42	-0.25	Joint mobility (Beighton score);	chr6:159239073	chr6:159240786~159243329:+
LUAD	cis	rs62432291	0.681	rs429339	ENSG00000235086.1	FNDC1-IT1	-5.6	3.54e-08	1.22e-05	-0.42	-0.25	Joint mobility (Beighton score);	chr6:159239116	chr6:159240786~159243329:+
LUAD	cis	rs748404	0.666	rs72709850	ENSG00000205771.5	CATSPER2P1	-5.6	3.54e-08	1.22e-05	-0.37	-0.25	Lung cancer;	chr15:43462486	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.666	rs34633582	ENSG00000205771.5	CATSPER2P1	-5.6	3.54e-08	1.22e-05	-0.37	-0.25	Lung cancer;	chr15:43462683	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.666	rs36078097	ENSG00000205771.5	CATSPER2P1	-5.6	3.54e-08	1.22e-05	-0.37	-0.25	Lung cancer;	chr15:43466209	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.666	rs7181783	ENSG00000205771.5	CATSPER2P1	-5.6	3.54e-08	1.22e-05	-0.37	-0.25	Lung cancer;	chr15:43469723	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.666	rs35903301	ENSG00000205771.5	CATSPER2P1	-5.6	3.54e-08	1.22e-05	-0.37	-0.25	Lung cancer;	chr15:43472332	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.666	rs34002293	ENSG00000205771.5	CATSPER2P1	-5.6	3.54e-08	1.22e-05	-0.37	-0.25	Lung cancer;	chr15:43472401	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.666	rs34181131	ENSG00000205771.5	CATSPER2P1	-5.6	3.54e-08	1.22e-05	-0.37	-0.25	Lung cancer;	chr15:43478527	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.666	rs7173383	ENSG00000205771.5	CATSPER2P1	-5.6	3.54e-08	1.22e-05	-0.37	-0.25	Lung cancer;	chr15:43480838	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.666	rs55801120	ENSG00000205771.5	CATSPER2P1	-5.6	3.54e-08	1.22e-05	-0.37	-0.25	Lung cancer;	chr15:43495042	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.666	rs12911740	ENSG00000205771.5	CATSPER2P1	-5.6	3.54e-08	1.22e-05	-0.37	-0.25	Lung cancer;	chr15:43498254	chr15:43726918~43747094:-
LUAD	cis	rs7911264	0.967	rs9419741	ENSG00000236493.2	EIF2S2P3	-5.6	3.54e-08	1.22e-05	-0.28	-0.25	Inflammatory bowel disease;	chr10:92670768	chr10:92668745~92669743:-
LUAD	cis	rs1113500	0.548	rs6583062	ENSG00000226822.1	RP11-356N1.2	5.6	3.54e-08	1.22e-05	0.34	0.25	Growth-regulated protein alpha levels;	chr1:108113841	chr1:108071482~108074519:+
LUAD	cis	rs1113500	0.548	rs3853497	ENSG00000226822.1	RP11-356N1.2	5.6	3.54e-08	1.22e-05	0.34	0.25	Growth-regulated protein alpha levels;	chr1:108114562	chr1:108071482~108074519:+
LUAD	cis	rs1707322	1	rs10890381	ENSG00000234329.1	RP11-767N6.2	5.6	3.54e-08	1.22e-05	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986099	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs10890378	ENSG00000234329.1	RP11-767N6.2	-5.6	3.55e-08	1.22e-05	-0.25	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45944985	chr1:45651039~45651826:-
LUAD	cis	rs1154275	0.537	rs6772960	ENSG00000242770.2	RP11-180K7.1	5.6	3.56e-08	1.22e-05	0.26	0.25	Takotsubo syndrome;	chr3:112796693	chr3:112802478~112812819:+
LUAD	cis	rs4820294	0.669	rs12628135	ENSG00000233360.4	Z83844.1	5.6	3.56e-08	1.22e-05	0.25	0.25	Fat distribution (HIV);	chr22:37669648	chr22:37641832~37658377:-
LUAD	cis	rs2276314	0.947	rs4799831	ENSG00000278986.1	RP11-723J4.3	-5.6	3.56e-08	1.22e-05	-0.31	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:35974812	chr18:35972151~35973916:+
LUAD	cis	rs30380	1	rs30187	ENSG00000272109.1	CTD-2260A17.3	-5.6	3.56e-08	1.23e-05	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr5:96788627	chr5:96804353~96806105:+
LUAD	cis	rs4947019	0.686	rs9487083	ENSG00000260273.1	RP11-425D10.10	5.6	3.56e-08	1.23e-05	0.54	0.25	Hematological parameters;	chr6:109394399	chr6:109382795~109383666:+
LUAD	cis	rs5753618	0.583	rs8138596	ENSG00000236132.1	CTA-440B3.1	-5.6	3.57e-08	1.23e-05	-0.31	-0.25	Colorectal cancer;	chr22:31390975	chr22:31816379~31817491:-
LUAD	cis	rs11105298	0.891	rs11105313	ENSG00000258302.2	RP11-981P6.1	-5.6	3.57e-08	1.23e-05	-0.31	-0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89529599	chr12:89561129~89594878:+
LUAD	cis	rs4948102	0.595	rs7793921	ENSG00000275875.1	RP11-613E4.5	-5.6	3.57e-08	1.23e-05	-0.27	-0.25	Plasma homocysteine levels (post-methionine load test);	chr7:56053188	chr7:55741525~55741869:+
LUAD	cis	rs4948102	0.595	rs10255049	ENSG00000275875.1	RP11-613E4.5	-5.6	3.57e-08	1.23e-05	-0.27	-0.25	Plasma homocysteine levels (post-methionine load test);	chr7:56053611	chr7:55741525~55741869:+
LUAD	cis	rs2404602	0.692	rs72738889	ENSG00000259422.1	RP11-593F23.1	5.6	3.57e-08	1.23e-05	0.29	0.25	Blood metabolite levels;	chr15:76699722	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.692	rs3816266	ENSG00000259422.1	RP11-593F23.1	5.6	3.57e-08	1.23e-05	0.29	0.25	Blood metabolite levels;	chr15:76701494	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.692	rs2304920	ENSG00000259422.1	RP11-593F23.1	5.6	3.57e-08	1.23e-05	0.29	0.25	Blood metabolite levels;	chr15:76701526	chr15:76174891~76181486:-
LUAD	cis	rs12699921	0.566	rs2691586	ENSG00000279048.1	RP11-511H23.2	-5.6	3.57e-08	1.23e-05	-0.2	-0.25	Fibrinogen levels;	chr7:17798236	chr7:17940503~17942922:+
LUAD	cis	rs17711722	0.51	rs11767457	ENSG00000226002.1	RP11-460N20.5	5.6	3.57e-08	1.23e-05	0.28	0.25	Calcium levels;	chr7:65825628	chr7:65084103~65100232:+
LUAD	cis	rs1154275	0.537	rs6763014	ENSG00000242770.2	RP11-180K7.1	5.6	3.57e-08	1.23e-05	0.26	0.25	Takotsubo syndrome;	chr3:112793800	chr3:112802478~112812819:+
LUAD	cis	rs1707322	1	rs11211223	ENSG00000234329.1	RP11-767N6.2	5.6	3.57e-08	1.23e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914933	chr1:45651039~45651826:-
LUAD	cis	rs7246657	0.508	rs10419845	ENSG00000276846.1	CTD-3220F14.3	5.6	3.58e-08	1.23e-05	0.39	0.25	Coronary artery calcification;	chr19:37000290	chr19:37314868~37315620:-
LUAD	cis	rs875971	1	rs875971	ENSG00000237310.1	GS1-124K5.4	-5.6	3.58e-08	1.23e-05	-0.27	-0.25	Aortic root size;	chr7:66152608	chr7:66493706~66495474:+
LUAD	cis	rs1075265	0.62	rs10192626	ENSG00000233266.1	HMGB1P31	5.6	3.58e-08	1.23e-05	0.31	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53760885	chr2:54051334~54051760:+
LUAD	cis	rs4834770	0.792	rs7676969	ENSG00000245958.5	RP11-33B1.1	-5.6	3.58e-08	1.23e-05	-0.23	-0.25	Blood protein levels;	chr4:119252569	chr4:119454791~119552025:+
LUAD	cis	rs4834770	0.685	rs4496567	ENSG00000245958.5	RP11-33B1.1	-5.6	3.58e-08	1.23e-05	-0.23	-0.25	Blood protein levels;	chr4:119254470	chr4:119454791~119552025:+
LUAD	cis	rs7712401	0.715	rs6880480	ENSG00000263432.2	RN7SL689P	-5.6	3.58e-08	1.23e-05	-0.31	-0.25	Mean platelet volume;	chr5:123019031	chr5:123022487~123022783:-
LUAD	cis	rs2404602	0.692	rs58361452	ENSG00000259422.1	RP11-593F23.1	5.6	3.58e-08	1.23e-05	0.29	0.25	Blood metabolite levels;	chr15:76681031	chr15:76174891~76181486:-
LUAD	cis	rs180730	0.561	rs343194	ENSG00000251609.2	SETP12	-5.6	3.58e-08	1.23e-05	-0.32	-0.25	Fasting plasma glucose;	chr4:120880199	chr4:120895494~120897083:-
LUAD	cis	rs1113500	0.932	rs1343205	ENSG00000226822.1	RP11-356N1.2	5.6	3.59e-08	1.23e-05	0.29	0.25	Growth-regulated protein alpha levels;	chr1:108055251	chr1:108071482~108074519:+
LUAD	cis	rs172166	0.769	rs149965	ENSG00000204709.4	LINC01556	5.6	3.59e-08	1.23e-05	0.31	0.25	Cardiac Troponin-T levels;	chr6:28050911	chr6:28943877~28944537:+
LUAD	cis	rs7617773	0.817	rs11709691	ENSG00000228638.1	FCF1P2	-5.6	3.59e-08	1.23e-05	-0.3	-0.25	Coronary artery disease;	chr3:48262179	chr3:48290793~48291375:-
LUAD	cis	rs9834970	0.588	rs9985296	ENSG00000234073.1	AC011816.1	5.6	3.59e-08	1.23e-05	0.27	0.25	Bipolar disorder with mood-incongruent psychosis;Bipolar disorder;Schizophrenia or bipolar disorder;Subjective response to lithium treatment;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr3:36848130	chr3:36880184~36880729:-
LUAD	cis	rs1707322	1	rs12077546	ENSG00000234329.1	RP11-767N6.2	5.6	3.59e-08	1.23e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966134	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs12124291	ENSG00000234329.1	RP11-767N6.2	5.6	3.59e-08	1.23e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966460	chr1:45651039~45651826:-
LUAD	cis	rs10246939	0.543	rs10952509	ENSG00000228775.6	WEE2-AS1	5.6	3.59e-08	1.23e-05	0.33	0.25	Bitter taste perception;	chr7:141890884	chr7:141704338~141738346:-
LUAD	cis	rs10246939	0.543	rs12538701	ENSG00000228775.6	WEE2-AS1	5.6	3.59e-08	1.23e-05	0.33	0.25	Bitter taste perception;	chr7:141893634	chr7:141704338~141738346:-
LUAD	cis	rs17684571	0.751	rs6918949	ENSG00000231441.1	RP11-472M19.2	-5.6	3.6e-08	1.24e-05	-0.37	-0.25	Schizophrenia;	chr6:56845183	chr6:56844002~56864078:+
LUAD	cis	rs66887589	0.967	rs6844263	ENSG00000248280.1	RP11-33B1.2	5.6	3.6e-08	1.24e-05	0.27	0.25	Diastolic blood pressure;	chr4:119512652	chr4:119440561~119450157:-
LUAD	cis	rs3931020	0.657	rs277368	ENSG00000272864.1	RP11-17E13.2	5.6	3.6e-08	1.24e-05	0.35	0.25	Resistin levels;	chr1:74764922	chr1:74698769~74699333:-
LUAD	cis	rs10129255	0.957	rs10142918	ENSG00000224373.3	IGHV4-59	5.6	3.6e-08	1.24e-05	0.16	0.25	Kawasaki disease;	chr14:106782206	chr14:106627249~106627825:-
LUAD	cis	rs1075265	0.744	rs2909460	ENSG00000233266.1	HMGB1P31	5.6	3.6e-08	1.24e-05	0.32	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53967611	chr2:54051334~54051760:+
LUAD	cis	rs1075265	0.811	rs805308	ENSG00000233266.1	HMGB1P31	5.6	3.6e-08	1.24e-05	0.32	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53967797	chr2:54051334~54051760:+
LUAD	cis	rs11098499	0.874	rs6822498	ENSG00000248280.1	RP11-33B1.2	5.6	3.6e-08	1.24e-05	0.32	0.25	Corneal astigmatism;	chr4:119199028	chr4:119440561~119450157:-
LUAD	cis	rs2288884	0.943	rs11084131	ENSG00000275055.1	CTC-471J1.11	-5.6	3.61e-08	1.24e-05	-0.38	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52011193	chr19:52049007~52049754:+
LUAD	cis	rs2288884	0.943	rs11084132	ENSG00000275055.1	CTC-471J1.11	-5.6	3.61e-08	1.24e-05	-0.38	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52011327	chr19:52049007~52049754:+
LUAD	cis	rs2404602	0.655	rs4886824	ENSG00000259422.1	RP11-593F23.1	5.6	3.61e-08	1.24e-05	0.29	0.25	Blood metabolite levels;	chr15:76676915	chr15:76174891~76181486:-
LUAD	cis	rs7208859	0.623	rs426434	ENSG00000263603.1	CTD-2349P21.5	-5.6	3.61e-08	1.24e-05	-0.42	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30598335	chr17:30729469~30731202:+
LUAD	cis	rs36093844	0.8	rs17817331	ENSG00000279742.1	RP11-700A24.1	5.6	3.61e-08	1.24e-05	0.33	0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85884295	chr11:85852557~85854943:-
LUAD	cis	rs1862618	0.525	rs2662021	ENSG00000271828.1	CTD-2310F14.1	-5.6	3.61e-08	1.24e-05	-0.37	-0.25	Initial pursuit acceleration;	chr5:56965864	chr5:56927874~56929573:+
LUAD	cis	rs910316	1	rs7156328	ENSG00000259138.1	RP11-950C14.7	5.6	3.62e-08	1.24e-05	0.26	0.25	Height;	chr14:75066238	chr14:75127153~75136930:+
LUAD	cis	rs12554020	0.686	rs77734990	ENSG00000227603.1	RP11-165J3.6	5.6	3.62e-08	1.24e-05	0.47	0.25	Schizophrenia;	chr9:93561870	chr9:93435332~93437121:-
LUAD	cis	rs7618501	0.602	rs10049087	ENSG00000234667.1	ACTBP13	5.6	3.62e-08	1.24e-05	0.28	0.25	Intelligence (multi-trait analysis);	chr3:50085984	chr3:49873347~49877980:-
LUAD	cis	rs465969	1	rs9387010	ENSG00000255389.1	C6orf3	5.6	3.62e-08	1.24e-05	0.49	0.25	Psoriasis;	chr6:111384741	chr6:111599875~111602295:+
LUAD	cis	rs7208859	0.623	rs7214570	ENSG00000263603.1	CTD-2349P21.5	-5.6	3.62e-08	1.24e-05	-0.43	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30820146	chr17:30729469~30731202:+
LUAD	cis	rs12554020	0.892	rs12551084	ENSG00000227603.1	RP11-165J3.6	5.6	3.63e-08	1.25e-05	0.47	0.25	Schizophrenia;	chr9:93538013	chr9:93435332~93437121:-
LUAD	cis	rs12554020	1	rs35540150	ENSG00000227603.1	RP11-165J3.6	5.6	3.63e-08	1.25e-05	0.47	0.25	Schizophrenia;	chr9:93538572	chr9:93435332~93437121:-
LUAD	cis	rs9309473	0.95	rs6546860	ENSG00000163016.8	ALMS1P	5.6	3.63e-08	1.25e-05	0.29	0.25	Metabolite levels;	chr2:73617122	chr2:73644919~73685576:+
LUAD	cis	rs62432291	0.681	rs420137	ENSG00000235086.1	FNDC1-IT1	-5.6	3.63e-08	1.25e-05	-0.42	-0.25	Joint mobility (Beighton score);	chr6:159231899	chr6:159240786~159243329:+
LUAD	cis	rs897984	0.571	rs7184567	ENSG00000260911.2	RP11-196G11.2	5.6	3.63e-08	1.25e-05	0.22	0.25	Dementia with Lewy bodies;	chr16:31009757	chr16:31043150~31049868:+
LUAD	cis	rs1707322	1	rs11211248	ENSG00000234329.1	RP11-767N6.2	5.6	3.64e-08	1.25e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46011172	chr1:45651039~45651826:-
LUAD	cis	rs2302464	1	rs57326588	ENSG00000214846.4	RP11-115L11.1	5.6	3.64e-08	1.25e-05	0.59	0.25	Cerebrospinal fluid biomarker levels;	chr4:15723813	chr4:15730962~15731627:-
LUAD	cis	rs712039	0.652	rs829161	ENSG00000276054.1	RP11-378E13.3	-5.6	3.64e-08	1.25e-05	-0.36	-0.25	Tuberculosis;	chr17:37403775	chr17:37386886~37387926:+
LUAD	cis	rs6991838	0.806	rs13262793	ENSG00000200714.1	Y_RNA	5.6	3.64e-08	1.25e-05	0.28	0.25	Intelligence (multi-trait analysis);	chr8:65549662	chr8:65592731~65592820:+
LUAD	cis	rs2765539	0.887	rs2765541	ENSG00000226172.2	RP4-712E4.1	-5.6	3.65e-08	1.25e-05	-0.3	-0.25	Waist-hip ratio;	chr1:119016034	chr1:119000344~119001392:-
LUAD	cis	rs2404602	0.692	rs8043474	ENSG00000259422.1	RP11-593F23.1	5.6	3.65e-08	1.25e-05	0.29	0.25	Blood metabolite levels;	chr15:76682382	chr15:76174891~76181486:-
LUAD	cis	rs11098499	1	rs13435802	ENSG00000248280.1	RP11-33B1.2	-5.6	3.65e-08	1.25e-05	-0.3	-0.25	Corneal astigmatism;	chr4:119256805	chr4:119440561~119450157:-
LUAD	cis	rs2243480	1	rs160633	ENSG00000230295.1	RP11-458F8.2	-5.6	3.65e-08	1.25e-05	-0.3	-0.25	Diabetic kidney disease;	chr7:66063241	chr7:66880708~66882981:+
LUAD	cis	rs4835473	0.932	rs1375986	ENSG00000251600.4	RP11-673E1.1	-5.6	3.65e-08	1.25e-05	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143746048	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.868	rs35420625	ENSG00000251600.4	RP11-673E1.1	-5.6	3.65e-08	1.25e-05	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143746089	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs4835009	ENSG00000251600.4	RP11-673E1.1	-5.6	3.65e-08	1.25e-05	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143746130	chr4:143912331~143982454:+
LUAD	cis	rs17684571	0.7	rs13203327	ENSG00000231441.1	RP11-472M19.2	5.6	3.66e-08	1.26e-05	0.37	0.25	Schizophrenia;	chr6:56792498	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.7	rs71564854	ENSG00000231441.1	RP11-472M19.2	5.6	3.66e-08	1.26e-05	0.37	0.25	Schizophrenia;	chr6:56794662	chr6:56844002~56864078:+
LUAD	cis	rs1707322	0.964	rs12067716	ENSG00000234329.1	RP11-767N6.2	5.6	3.66e-08	1.26e-05	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968756	chr1:45651039~45651826:-
LUAD	cis	rs2276314	0.512	rs12458709	ENSG00000278986.1	RP11-723J4.3	5.6	3.67e-08	1.26e-05	0.26	0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:35861928	chr18:35972151~35973916:+
LUAD	cis	rs7923609	0.776	rs10761785	ENSG00000232075.1	MRPL35P2	-5.6	3.67e-08	1.26e-05	-0.3	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63559006	chr10:63634317~63634827:-
LUAD	cis	rs12699921	0.632	rs2723508	ENSG00000279048.1	RP11-511H23.2	-5.6	3.67e-08	1.26e-05	-0.2	-0.25	Fibrinogen levels;	chr7:17778440	chr7:17940503~17942922:+
LUAD	cis	rs1707322	1	rs785507	ENSG00000234329.1	RP11-767N6.2	-5.6	3.67e-08	1.26e-05	-0.27	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46075886	chr1:45651039~45651826:-
LUAD	cis	rs2276314	0.857	rs62101376	ENSG00000278986.1	RP11-723J4.3	-5.6	3.68e-08	1.26e-05	-0.31	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:36002992	chr18:35972151~35973916:+
LUAD	cis	rs9813712	0.571	rs9836814	ENSG00000228252.7	COL6A4P2	5.6	3.68e-08	1.26e-05	0.23	0.25	Response to amphetamines;	chr3:130216054	chr3:130212823~130273806:+
LUAD	cis	rs11098499	0.874	rs13123591	ENSG00000248280.1	RP11-33B1.2	5.6	3.68e-08	1.26e-05	0.32	0.25	Corneal astigmatism;	chr4:119184835	chr4:119440561~119450157:-
LUAD	cis	rs1075265	0.716	rs7573991	ENSG00000233266.1	HMGB1P31	5.6	3.69e-08	1.27e-05	0.31	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53726830	chr2:54051334~54051760:+
LUAD	cis	rs673078	0.607	rs4766899	ENSG00000275409.1	RP11-131L12.4	-5.6	3.69e-08	1.27e-05	-0.31	-0.25	Glucose homeostasis traits;	chr12:118374888	chr12:118430147~118430699:+
LUAD	cis	rs1707322	1	rs6671754	ENSG00000234329.1	RP11-767N6.2	5.6	3.69e-08	1.27e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968318	chr1:45651039~45651826:-
LUAD	cis	rs7923837	0.656	rs2497306	ENSG00000236493.2	EIF2S2P3	-5.6	3.69e-08	1.27e-05	-0.28	-0.25	Multiple sclerosis;Body mass index;	chr10:92725454	chr10:92668745~92669743:-
LUAD	cis	rs2832077	0.943	rs2832091	ENSG00000232855.5	AF131217.1	5.6	3.69e-08	1.27e-05	0.28	0.25	Cognitive test performance;	chr21:28790533	chr21:28439346~28674848:-
LUAD	cis	rs4713118	0.824	rs7759217	ENSG00000219392.1	RP1-265C24.5	-5.6	3.7e-08	1.27e-05	-0.33	-0.25	Parkinson's disease;	chr6:27762684	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.784	rs9468219	ENSG00000219392.1	RP1-265C24.5	-5.6	3.7e-08	1.27e-05	-0.33	-0.25	Parkinson's disease;	chr6:27763976	chr6:28115628~28116551:+
LUAD	cis	rs12554020	0.686	rs56275034	ENSG00000227603.1	RP11-165J3.6	5.6	3.7e-08	1.27e-05	0.47	0.25	Schizophrenia;	chr9:93563474	chr9:93435332~93437121:-
LUAD	cis	rs12554020	0.892	rs75775593	ENSG00000227603.1	RP11-165J3.6	5.6	3.7e-08	1.27e-05	0.47	0.25	Schizophrenia;	chr9:93568611	chr9:93435332~93437121:-
LUAD	cis	rs2288884	1	rs17835749	ENSG00000275055.1	CTC-471J1.11	-5.6	3.7e-08	1.27e-05	-0.4	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52075442	chr19:52049007~52049754:+
LUAD	cis	rs4835473	0.966	rs11722639	ENSG00000251600.4	RP11-673E1.1	-5.6	3.7e-08	1.27e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143746884	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.966	rs11722673	ENSG00000251600.4	RP11-673E1.1	-5.6	3.7e-08	1.27e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143746946	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs6821979	ENSG00000251600.4	RP11-673E1.1	-5.6	3.7e-08	1.27e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143748091	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1982392	ENSG00000251600.4	RP11-673E1.1	-5.6	3.7e-08	1.27e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143748604	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1982393	ENSG00000251600.4	RP11-673E1.1	-5.6	3.7e-08	1.27e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143748736	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs9683880	ENSG00000251600.4	RP11-673E1.1	-5.6	3.7e-08	1.27e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143748787	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs7687976	ENSG00000251600.4	RP11-673E1.1	-5.6	3.7e-08	1.27e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143749171	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs7683287	ENSG00000251600.4	RP11-673E1.1	-5.6	3.7e-08	1.27e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143749270	chr4:143912331~143982454:+
LUAD	cis	rs7712401	0.601	rs154500	ENSG00000263432.2	RN7SL689P	5.59	3.71e-08	1.27e-05	0.31	0.25	Mean platelet volume;	chr5:122876296	chr5:123022487~123022783:-
LUAD	cis	rs9543976	0.623	rs9544004	ENSG00000261553.4	RP11-29G8.3	5.59	3.71e-08	1.27e-05	0.33	0.25	Diabetic retinopathy;	chr13:75617748	chr13:75549773~75807120:+
LUAD	cis	rs9543976	0.588	rs7324195	ENSG00000261553.4	RP11-29G8.3	5.59	3.71e-08	1.27e-05	0.33	0.25	Diabetic retinopathy;	chr13:75618386	chr13:75549773~75807120:+
LUAD	cis	rs7714584	1	rs59715748	ENSG00000197083.10	ZNF300P1	5.59	3.71e-08	1.27e-05	0.55	0.25	Crohn's disease;	chr5:150809725	chr5:150930645~150946289:-
LUAD	cis	rs7923609	1	rs10761723	ENSG00000232075.1	MRPL35P2	-5.59	3.72e-08	1.27e-05	-0.3	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63195821	chr10:63634317~63634827:-
LUAD	cis	rs74233809	1	rs11191543	ENSG00000213277.3	MARCKSL1P1	5.59	3.72e-08	1.28e-05	0.42	0.25	Birth weight;	chr10:103064630	chr10:103175554~103176094:+
LUAD	cis	rs12699921	0.598	rs1404421	ENSG00000279048.1	RP11-511H23.2	-5.59	3.72e-08	1.28e-05	-0.2	-0.25	Fibrinogen levels;	chr7:17777807	chr7:17940503~17942922:+
LUAD	cis	rs4835473	0.9	rs935732	ENSG00000251600.4	RP11-673E1.1	-5.59	3.72e-08	1.28e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143759164	chr4:143912331~143982454:+
LUAD	cis	rs1823913	0.637	rs6722183	ENSG00000280083.1	RP11-317J9.1	5.59	3.73e-08	1.28e-05	0.29	0.25	Obesity-related traits;	chr2:191333203	chr2:191154118~191156070:-
LUAD	cis	rs8098244	0.557	rs10853571	ENSG00000264745.1	TTC39C-AS1	5.59	3.73e-08	1.28e-05	0.26	0.25	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23710723	chr18:23994213~24015339:-
LUAD	cis	rs1823913	0.637	rs1470962	ENSG00000227542.1	AC092614.2	-5.59	3.73e-08	1.28e-05	-0.3	-0.25	Obesity-related traits;	chr2:191270271	chr2:191229165~191246172:-
LUAD	cis	rs6687821	0.515	rs6697798	ENSG00000267734.1	RP4-604K5.3	-5.59	3.73e-08	1.28e-05	-0.3	-0.25	Yeast infection;	chr1:87020598	chr1:86932199~86934891:-
LUAD	cis	rs12908161	0.96	rs62019463	ENSG00000225151.9	GOLGA2P7	-5.59	3.74e-08	1.28e-05	-0.33	-0.25	Schizophrenia;	chr15:84744856	chr15:84199311~84230136:-
LUAD	cis	rs2337406	1	rs11845269	ENSG00000211974.3	IGHV2-70	-5.59	3.74e-08	1.28e-05	-0.32	-0.25	Alzheimer's disease (late onset);	chr14:106683851	chr14:106723574~106724093:-
LUAD	cis	rs807029	0.533	rs67692077	ENSG00000272572.1	RP11-179B2.2	-5.59	3.74e-08	1.28e-05	-0.36	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100980514	chr10:100911103~100912739:-
LUAD	cis	rs807029	0.533	rs12571302	ENSG00000272572.1	RP11-179B2.2	-5.59	3.74e-08	1.28e-05	-0.36	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100983006	chr10:100911103~100912739:-
LUAD	cis	rs2599510	0.811	rs2754523	ENSG00000276334.1	AL133243.1	5.59	3.74e-08	1.28e-05	0.29	0.25	Interleukin-18 levels;	chr2:32612043	chr2:32521927~32523547:+
LUAD	cis	rs3931020	0.657	rs277369	ENSG00000272864.1	RP11-17E13.2	5.59	3.75e-08	1.28e-05	0.35	0.25	Resistin levels;	chr1:74768977	chr1:74698769~74699333:-
LUAD	cis	rs7811142	0.83	rs7792959	ENSG00000078319.8	PMS2P1	-5.59	3.75e-08	1.28e-05	-0.29	-0.25	Platelet count;	chr7:100374780	chr7:100320992~100341908:-
LUAD	cis	rs36093844	0.8	rs11826218	ENSG00000279742.1	RP11-700A24.1	-5.59	3.75e-08	1.28e-05	-0.33	-0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85857479	chr11:85852557~85854943:-
LUAD	cis	rs11976180	0.517	rs6949375	ENSG00000228960.5	OR2A9P	-5.59	3.75e-08	1.29e-05	-0.41	-0.25	Obesity-related traits;	chr7:144076758	chr7:144294480~144300934:+
LUAD	cis	rs10214930	0.697	rs6970104	ENSG00000235574.1	AC073150.6	5.59	3.75e-08	1.29e-05	0.29	0.25	Hypospadias;	chr7:27624575	chr7:27491682~27492765:-
LUAD	cis	rs12908161	0.853	rs11633788	ENSG00000259728.4	LINC00933	5.59	3.76e-08	1.29e-05	0.32	0.25	Schizophrenia;	chr15:84761911	chr15:84570649~84580175:+
LUAD	cis	rs2243480	1	rs313832	ENSG00000230295.1	RP11-458F8.2	-5.59	3.76e-08	1.29e-05	-0.3	-0.25	Diabetic kidney disease;	chr7:66085904	chr7:66880708~66882981:+
LUAD	cis	rs9309473	0.95	rs6546849	ENSG00000163016.8	ALMS1P	5.59	3.76e-08	1.29e-05	0.3	0.25	Metabolite levels;	chr2:73603910	chr2:73644919~73685576:+
LUAD	cis	rs7804306	1	rs35143180	ENSG00000233264.2	AC006042.8	5.59	3.76e-08	1.29e-05	0.44	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8017141	chr7:7980312~7982228:+
LUAD	cis	rs2455601	0.608	rs1368017	ENSG00000254860.4	TMEM9B-AS1	5.59	3.76e-08	1.29e-05	0.31	0.25	Schizophrenia;	chr11:8845523	chr11:8964675~8977527:+
LUAD	cis	rs155076	0.711	rs4770131	ENSG00000233325.3	MIPEPP3	-5.59	3.76e-08	1.29e-05	-0.36	-0.25	White matter hyperintensity burden;	chr13:21323329	chr13:21298139~21306373:+
LUAD	cis	rs11051970	0.559	rs10844188	ENSG00000274964.1	RP11-817I4.1	-5.59	3.77e-08	1.29e-05	-0.31	-0.25	Response to tocilizumab in rheumatoid arthritis;	chr12:32334710	chr12:32339368~32340724:+
LUAD	cis	rs9928842	0.771	rs4888363	ENSG00000280152.1	RP11-331F4.5	5.59	3.77e-08	1.29e-05	0.26	0.25	Alcoholic chronic pancreatitis;	chr16:75243446	chr16:75245994~75250077:-
LUAD	cis	rs7618501	0.669	rs7634084	ENSG00000234667.1	ACTBP13	-5.59	3.77e-08	1.29e-05	-0.28	-0.25	Intelligence (multi-trait analysis);	chr3:49912401	chr3:49873347~49877980:-
LUAD	cis	rs17684571	0.751	rs13190854	ENSG00000231441.1	RP11-472M19.2	5.59	3.77e-08	1.29e-05	0.37	0.25	Schizophrenia;	chr6:56827020	chr6:56844002~56864078:+
LUAD	cis	rs1707322	0.929	rs785500	ENSG00000234329.1	RP11-767N6.2	-5.59	3.77e-08	1.29e-05	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46127372	chr1:45651039~45651826:-
LUAD	cis	rs4713118	0.824	rs9366702	ENSG00000219392.1	RP1-265C24.5	-5.59	3.77e-08	1.29e-05	-0.33	-0.25	Parkinson's disease;	chr6:27766691	chr6:28115628~28116551:+
LUAD	cis	rs9543976	1	rs55927305	ENSG00000261553.4	RP11-29G8.3	-5.59	3.78e-08	1.29e-05	-0.38	-0.25	Diabetic retinopathy;	chr13:75561213	chr13:75549773~75807120:+
LUAD	cis	rs9876781	0.507	rs1824362	ENSG00000229759.1	MRPS18AP1	-5.59	3.78e-08	1.29e-05	-0.24	-0.25	Longevity;	chr3:48360459	chr3:48256350~48256938:-
LUAD	cis	rs7829975	0.777	rs560544	ENSG00000253893.2	FAM85B	5.59	3.78e-08	1.29e-05	0.31	0.25	Mood instability;	chr8:8779919	chr8:8167819~8226614:-
LUAD	cis	rs4835473	0.932	rs2060656	ENSG00000251600.4	RP11-673E1.1	-5.59	3.78e-08	1.3e-05	-0.31	-0.25	Immature fraction of reticulocytes;	chr4:143739330	chr4:143912331~143982454:+
LUAD	cis	rs948562	0.744	rs11229479	ENSG00000280010.1	AP001350.4	5.59	3.79e-08	1.3e-05	0.37	0.25	Lymphoma;	chr11:58463158	chr11:58627435~58628528:+
LUAD	cis	rs219780	0.687	rs219790	ENSG00000233818.1	AP000695.4	5.59	3.79e-08	1.3e-05	0.27	0.25	Kidney stones;	chr21:36456564	chr21:36445731~36532408:+
LUAD	cis	rs1150668	0.799	rs853684	ENSG00000219392.1	RP1-265C24.5	-5.59	3.79e-08	1.3e-05	-0.31	-0.25	Pubertal anthropometrics;	chr6:28326773	chr6:28115628~28116551:+
LUAD	cis	rs3762637	0.943	rs72960447	ENSG00000272758.4	RP11-299J3.8	-5.59	3.79e-08	1.3e-05	-0.37	-0.25	LDL cholesterol levels;	chr3:122516258	chr3:122416207~122443180:+
LUAD	cis	rs3762637	0.943	rs6762156	ENSG00000272758.4	RP11-299J3.8	-5.59	3.79e-08	1.3e-05	-0.37	-0.25	LDL cholesterol levels;	chr3:122517178	chr3:122416207~122443180:+
LUAD	cis	rs7804306	0.826	rs73049290	ENSG00000233264.2	AC006042.8	5.59	3.79e-08	1.3e-05	0.49	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7992584	chr7:7980312~7982228:+
LUAD	cis	rs4835473	0.932	rs35300159	ENSG00000251600.4	RP11-673E1.1	-5.59	3.79e-08	1.3e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143751768	chr4:143912331~143982454:+
LUAD	cis	rs1198872	0.563	rs2005011	ENSG00000272275.1	RP11-791G15.2	-5.59	3.8e-08	1.3e-05	-0.31	-0.25	Cardiac Troponin-T levels;	chr2:10823799	chr2:10767875~10770058:-
LUAD	cis	rs1198872	0.563	rs2008967	ENSG00000272275.1	RP11-791G15.2	-5.59	3.8e-08	1.3e-05	-0.31	-0.25	Cardiac Troponin-T levels;	chr2:10824167	chr2:10767875~10770058:-
LUAD	cis	rs2832077	0.943	rs2832094	ENSG00000232855.5	AF131217.1	5.59	3.8e-08	1.3e-05	0.28	0.25	Cognitive test performance;	chr21:28793588	chr21:28439346~28674848:-
LUAD	cis	rs6991838	0.778	rs13261559	ENSG00000200714.1	Y_RNA	5.59	3.8e-08	1.3e-05	0.28	0.25	Intelligence (multi-trait analysis);	chr8:65549808	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.778	rs7843697	ENSG00000200714.1	Y_RNA	5.59	3.8e-08	1.3e-05	0.28	0.25	Intelligence (multi-trait analysis);	chr8:65550533	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.778	rs7843724	ENSG00000200714.1	Y_RNA	5.59	3.8e-08	1.3e-05	0.28	0.25	Intelligence (multi-trait analysis);	chr8:65550581	chr8:65592731~65592820:+
LUAD	cis	rs10761482	0.515	rs2393642	ENSG00000254271.1	RP11-131N11.4	5.59	3.8e-08	1.3e-05	0.27	0.25	Schizophrenia;	chr10:60522732	chr10:60734342~60741828:+
LUAD	cis	rs4835473	0.897	rs2060654	ENSG00000251600.4	RP11-673E1.1	-5.59	3.8e-08	1.3e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143739155	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs2060655	ENSG00000251600.4	RP11-673E1.1	-5.59	3.8e-08	1.3e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143739159	chr4:143912331~143982454:+
LUAD	cis	rs948562	0.519	rs12365107	ENSG00000280010.1	AP001350.4	5.59	3.8e-08	1.3e-05	0.35	0.25	Lymphoma;	chr11:58288226	chr11:58627435~58628528:+
LUAD	cis	rs516805	0.748	rs6908508	ENSG00000279453.1	RP3-425C14.4	5.59	3.81e-08	1.3e-05	0.33	0.25	Lymphocyte counts;	chr6:122387857	chr6:122436789~122439223:-
LUAD	cis	rs875971	0.628	rs6974355	ENSG00000237310.1	GS1-124K5.4	5.59	3.81e-08	1.31e-05	0.27	0.25	Aortic root size;	chr7:66376994	chr7:66493706~66495474:+
LUAD	cis	rs1707322	0.686	rs1084086	ENSG00000280836.1	AL355480.1	5.59	3.82e-08	1.31e-05	0.32	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45575428	chr1:45581219~45581321:-
LUAD	cis	rs9494145	0.648	rs7758845	ENSG00000232876.1	CTA-212D2.2	-5.59	3.82e-08	1.31e-05	-0.33	-0.25	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135107399	chr6:135055033~135060550:+
LUAD	cis	rs8040855	0.557	rs9744503	ENSG00000259774.1	RP11-182J1.13	-5.59	3.82e-08	1.31e-05	-0.28	-0.25	Bulimia nervosa;	chr15:85180986	chr15:84422618~84425882:+
LUAD	cis	rs172166	0.694	rs9295760	ENSG00000204709.4	LINC01556	5.59	3.82e-08	1.31e-05	0.33	0.25	Cardiac Troponin-T levels;	chr6:28179607	chr6:28943877~28944537:+
LUAD	cis	rs2404602	0.669	rs17367297	ENSG00000259422.1	RP11-593F23.1	5.59	3.82e-08	1.31e-05	0.28	0.25	Blood metabolite levels;	chr15:76865685	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.692	rs12913810	ENSG00000259422.1	RP11-593F23.1	5.59	3.82e-08	1.31e-05	0.28	0.25	Blood metabolite levels;	chr15:76874334	chr15:76174891~76181486:-
LUAD	cis	rs2688482	0.557	rs2550236	ENSG00000224769.1	AC069213.1	5.59	3.83e-08	1.31e-05	0.41	0.25	Lung disease severity in cystic fibrosis;	chr3:195795450	chr3:195614947~195620233:+
LUAD	cis	rs948562	0.573	rs73479901	ENSG00000280010.1	AP001350.4	5.59	3.83e-08	1.31e-05	0.37	0.25	Lymphoma;	chr11:58276171	chr11:58627435~58628528:+
LUAD	cis	rs7181230	0.885	rs28736699	ENSG00000275636.1	RP11-521C20.5	5.59	3.83e-08	1.31e-05	0.33	0.25	Dehydroepiandrosterone sulphate levels;	chr15:40055234	chr15:40078892~40079347:+
LUAD	cis	rs4604732	0.574	rs111928142	ENSG00000227135.1	GCSAML-AS1	-5.59	3.83e-08	1.31e-05	-0.38	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247461927	chr1:247524679~247526752:-
LUAD	cis	rs948562	0.642	rs60483579	ENSG00000280010.1	AP001350.4	5.59	3.83e-08	1.31e-05	0.42	0.25	Lymphoma;	chr11:58660991	chr11:58627435~58628528:+
LUAD	cis	rs62432291	0.681	rs2932988	ENSG00000235086.1	FNDC1-IT1	-5.59	3.83e-08	1.31e-05	-0.42	-0.25	Joint mobility (Beighton score);	chr6:159234370	chr6:159240786~159243329:+
LUAD	cis	rs9287719	0.593	rs13009015	ENSG00000243819.4	RN7SL832P	5.59	3.83e-08	1.31e-05	0.27	0.25	Prostate cancer;	chr2:10622992	chr2:10690344~10692099:+
LUAD	cis	rs7804306	1	rs73050929	ENSG00000233264.2	AC006042.8	5.59	3.84e-08	1.31e-05	0.49	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8019638	chr7:7980312~7982228:+
LUAD	cis	rs7712401	0.601	rs2126935	ENSG00000263432.2	RN7SL689P	-5.59	3.84e-08	1.31e-05	-0.3	-0.25	Mean platelet volume;	chr5:122977876	chr5:123022487~123022783:-
LUAD	cis	rs897984	0.572	rs112906665	ENSG00000260911.2	RP11-196G11.2	5.59	3.84e-08	1.31e-05	0.22	0.25	Dementia with Lewy bodies;	chr16:31028818	chr16:31043150~31049868:+
LUAD	cis	rs897984	0.609	rs12445650	ENSG00000260911.2	RP11-196G11.2	5.59	3.84e-08	1.31e-05	0.22	0.25	Dementia with Lewy bodies;	chr16:31033576	chr16:31043150~31049868:+
LUAD	cis	rs875971	0.825	rs6951503	ENSG00000222364.1	RNU6-96P	5.59	3.84e-08	1.31e-05	0.28	0.25	Aortic root size;	chr7:66253949	chr7:66395191~66395286:+
LUAD	cis	rs875971	1	rs12532998	ENSG00000237310.1	GS1-124K5.4	5.59	3.84e-08	1.32e-05	0.27	0.25	Aortic root size;	chr7:66502472	chr7:66493706~66495474:+
LUAD	cis	rs2404602	0.692	rs12904198	ENSG00000259422.1	RP11-593F23.1	5.59	3.84e-08	1.32e-05	0.28	0.25	Blood metabolite levels;	chr15:76854637	chr15:76174891~76181486:-
LUAD	cis	rs7923609	0.967	rs6479896	ENSG00000232075.1	MRPL35P2	-5.59	3.84e-08	1.32e-05	-0.3	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63367072	chr10:63634317~63634827:-
LUAD	cis	rs10761750	1	rs10761750	ENSG00000232075.1	MRPL35P2	-5.59	3.84e-08	1.32e-05	-0.3	-0.25	Vascular endothelial growth factor levels;	chr10:63368859	chr10:63634317~63634827:-
LUAD	cis	rs4947019	0.609	rs2177092	ENSG00000260273.1	RP11-425D10.10	5.59	3.85e-08	1.32e-05	0.55	0.25	Hematological parameters;	chr6:109365466	chr6:109382795~109383666:+
LUAD	cis	rs2302464	1	rs73123615	ENSG00000214846.4	RP11-115L11.1	5.59	3.85e-08	1.32e-05	0.6	0.25	Cerebrospinal fluid biomarker levels;	chr4:15726553	chr4:15730962~15731627:-
LUAD	cis	rs2302464	1	rs16892276	ENSG00000214846.4	RP11-115L11.1	5.59	3.85e-08	1.32e-05	0.6	0.25	Cerebrospinal fluid biomarker levels;	chr4:15726614	chr4:15730962~15731627:-
LUAD	cis	rs2302464	1	rs60913985	ENSG00000214846.4	RP11-115L11.1	5.59	3.85e-08	1.32e-05	0.6	0.25	Cerebrospinal fluid biomarker levels;	chr4:15726671	chr4:15730962~15731627:-
LUAD	cis	rs6570726	0.935	rs407721	ENSG00000235652.6	RP11-545I5.3	5.59	3.85e-08	1.32e-05	0.24	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145550218	chr6:145799409~145886585:+
LUAD	cis	rs9309473	0.615	rs11680965	ENSG00000163016.8	ALMS1P	5.59	3.85e-08	1.32e-05	0.37	0.25	Metabolite levels;	chr2:73498789	chr2:73644919~73685576:+
LUAD	cis	rs56046484	1	rs2304416	ENSG00000259295.5	CSPG4P12	-5.59	3.85e-08	1.32e-05	-0.34	-0.25	Testicular germ cell tumor;	chr15:85075651	chr15:85191438~85213905:+
LUAD	cis	rs673078	0.66	rs7136216	ENSG00000275409.1	RP11-131L12.4	-5.59	3.86e-08	1.32e-05	-0.32	-0.25	Glucose homeostasis traits;	chr12:118170475	chr12:118430147~118430699:+
LUAD	cis	rs2404602	0.692	rs66866130	ENSG00000259422.1	RP11-593F23.1	5.59	3.86e-08	1.32e-05	0.28	0.25	Blood metabolite levels;	chr15:76836233	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.692	rs35170561	ENSG00000259422.1	RP11-593F23.1	5.59	3.86e-08	1.32e-05	0.28	0.25	Blood metabolite levels;	chr15:76838354	chr15:76174891~76181486:-
LUAD	cis	rs12468226	1	rs16824599	ENSG00000272966.1	RP11-686O6.1	5.59	3.86e-08	1.32e-05	0.43	0.25	Urate levels;	chr2:202358243	chr2:202336739~202337200:+
LUAD	cis	rs948562	0.519	rs2096558	ENSG00000280010.1	AP001350.4	5.59	3.86e-08	1.32e-05	0.35	0.25	Lymphoma;	chr11:58286715	chr11:58627435~58628528:+
LUAD	cis	rs7826238	0.566	rs2945886	ENSG00000253981.4	ALG1L13P	5.59	3.86e-08	1.32e-05	0.29	0.25	Systolic blood pressure;	chr8:8290748	chr8:8236003~8244667:-
LUAD	cis	rs516805	0.63	rs2606606	ENSG00000279453.1	RP3-425C14.4	-5.59	3.88e-08	1.32e-05	-0.34	-0.25	Lymphocyte counts;	chr6:122201126	chr6:122436789~122439223:-
LUAD	cis	rs2880765	0.835	rs11856869	ENSG00000259295.5	CSPG4P12	5.59	3.88e-08	1.32e-05	0.28	0.25	Coronary artery disease;	chr15:85485866	chr15:85191438~85213905:+
LUAD	cis	rs2919009	0.581	rs61872768	ENSG00000271670.1	RP11-95I16.4	5.59	3.88e-08	1.33e-05	0.32	0.25	Obesity-related traits;	chr10:120934409	chr10:120879256~120880667:-
LUAD	cis	rs896854	0.812	rs4582532	ENSG00000253528.2	RP11-347C18.4	5.59	3.88e-08	1.33e-05	0.24	0.25	Type 2 diabetes;	chr8:94957029	chr8:94974573~94974853:-
LUAD	cis	rs896854	0.812	rs2340586	ENSG00000253528.2	RP11-347C18.4	5.59	3.88e-08	1.33e-05	0.24	0.25	Type 2 diabetes;	chr8:94957033	chr8:94974573~94974853:-
LUAD	cis	rs2412819	0.52	rs17727763	ENSG00000205771.5	CATSPER2P1	-5.59	3.89e-08	1.33e-05	-0.42	-0.25	Lung cancer;	chr15:43623873	chr15:43726918~43747094:-
LUAD	cis	rs11096990	0.855	rs2711990	ENSG00000249207.1	RP11-360F5.1	5.59	3.89e-08	1.33e-05	0.28	0.25	Cognitive function;	chr4:39150116	chr4:39112677~39126818:-
LUAD	cis	rs858239	0.632	rs7811903	ENSG00000230042.1	AK3P3	-5.59	3.89e-08	1.33e-05	-0.31	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23129178~23129841:+
LUAD	cis	rs4835473	0.932	rs2323191	ENSG00000251600.4	RP11-673E1.1	-5.59	3.89e-08	1.33e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143744472	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs1375982	ENSG00000251600.4	RP11-673E1.1	-5.59	3.89e-08	1.33e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143745764	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs4835237	ENSG00000251600.4	RP11-673E1.1	-5.59	3.89e-08	1.33e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143746349	chr4:143912331~143982454:+
LUAD	cis	rs9914544	0.628	rs67053020	ENSG00000273018.4	CTD-2303H24.2	-5.59	3.89e-08	1.33e-05	-0.3	-0.25	Educational attainment (years of education);	chr17:18776748	chr17:18511221~18551705:-
LUAD	cis	rs801193	0.591	rs9986881	ENSG00000236529.1	RP13-254B10.1	5.59	3.89e-08	1.33e-05	0.25	0.25	Aortic root size;	chr7:66708053	chr7:65840212~65840596:+
LUAD	cis	rs4908768	0.539	rs922366	ENSG00000232912.4	RP5-1115A15.1	5.59	3.89e-08	1.33e-05	0.23	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8593674	chr1:8424645~8434838:+
LUAD	cis	rs2302464	1	rs16892272	ENSG00000214846.4	RP11-115L11.1	5.59	3.89e-08	1.33e-05	0.6	0.25	Cerebrospinal fluid biomarker levels;	chr4:15726456	chr4:15730962~15731627:-
LUAD	cis	rs9595908	0.785	rs3848085	ENSG00000212293.1	SNORA16	5.59	3.89e-08	1.33e-05	0.26	0.25	Body mass index;	chr13:32687527	chr13:32420390~32420516:-
LUAD	cis	rs807029	0.577	rs701835	ENSG00000272572.1	RP11-179B2.2	-5.59	3.9e-08	1.33e-05	-0.36	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101002370	chr10:100911103~100912739:-
LUAD	cis	rs2404602	0.647	rs11072625	ENSG00000259422.1	RP11-593F23.1	5.59	3.9e-08	1.33e-05	0.33	0.25	Blood metabolite levels;	chr15:76792643	chr15:76174891~76181486:-
LUAD	cis	rs9595908	0.785	rs7332884	ENSG00000212293.1	SNORA16	5.59	3.9e-08	1.33e-05	0.26	0.25	Body mass index;	chr13:32642412	chr13:32420390~32420516:-
LUAD	cis	rs867371	0.502	rs8025964	ENSG00000278603.1	RP13-608F4.5	5.59	3.9e-08	1.33e-05	0.28	0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82229429	chr15:82472203~82472426:+
LUAD	cis	rs4835473	0.868	rs62337291	ENSG00000251600.4	RP11-673E1.1	-5.59	3.9e-08	1.33e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143807903	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs13121861	ENSG00000251600.4	RP11-673E1.1	-5.59	3.9e-08	1.33e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143814007	chr4:143912331~143982454:+
LUAD	cis	rs7712401	0.623	rs26372	ENSG00000263432.2	RN7SL689P	-5.59	3.9e-08	1.33e-05	-0.31	-0.25	Mean platelet volume;	chr5:122870752	chr5:123022487~123022783:-
LUAD	cis	rs807029	0.533	rs3740485	ENSG00000272572.1	RP11-179B2.2	-5.59	3.9e-08	1.33e-05	-0.35	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100990864	chr10:100911103~100912739:-
LUAD	cis	rs807029	0.533	rs3740486	ENSG00000272572.1	RP11-179B2.2	-5.59	3.9e-08	1.33e-05	-0.35	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100990866	chr10:100911103~100912739:-
LUAD	cis	rs807029	0.533	rs3740487	ENSG00000272572.1	RP11-179B2.2	-5.59	3.9e-08	1.33e-05	-0.35	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100991026	chr10:100911103~100912739:-
LUAD	cis	rs6687821	0.515	rs7534355	ENSG00000267734.1	RP4-604K5.3	-5.59	3.9e-08	1.33e-05	-0.3	-0.25	Yeast infection;	chr1:87015237	chr1:86932199~86934891:-
LUAD	cis	rs8177876	0.749	rs12444969	ENSG00000261061.1	RP11-303E16.2	-5.59	3.91e-08	1.33e-05	-0.45	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81050211	chr16:81030770~81031485:+
LUAD	cis	rs11098499	0.874	rs7661020	ENSG00000248280.1	RP11-33B1.2	5.59	3.91e-08	1.33e-05	0.32	0.25	Corneal astigmatism;	chr4:119185827	chr4:119440561~119450157:-
LUAD	cis	rs944289	0.553	rs1169128	ENSG00000257826.1	RP11-116N8.4	-5.59	3.91e-08	1.34e-05	-0.28	-0.25	Thyroid cancer;	chr14:36151659	chr14:36061026~36067190:-
LUAD	cis	rs6687821	0.515	rs1112998	ENSG00000267734.1	RP4-604K5.3	-5.59	3.91e-08	1.34e-05	-0.3	-0.25	Yeast infection;	chr1:86983198	chr1:86932199~86934891:-
LUAD	cis	rs13217239	0.646	rs9379956	ENSG00000241549.7	GUSBP2	-5.59	3.91e-08	1.34e-05	-0.27	-0.25	Schizophrenia;	chr6:27065956	chr6:26871484~26956554:-
LUAD	cis	rs13217239	0.646	rs7747454	ENSG00000241549.7	GUSBP2	-5.59	3.91e-08	1.34e-05	-0.27	-0.25	Schizophrenia;	chr6:27066474	chr6:26871484~26956554:-
LUAD	cis	rs800160	0.777	rs2651783	ENSG00000236264.4	RPL26P30	-5.58	3.92e-08	1.34e-05	-0.33	-0.25	Bacteremia;	chr11:2324660	chr11:2335132~2335776:-
LUAD	cis	rs7208859	0.623	rs9912440	ENSG00000263603.1	CTD-2349P21.5	-5.58	3.92e-08	1.34e-05	-0.43	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30821754	chr17:30729469~30731202:+
LUAD	cis	rs2404602	0.716	rs17363713	ENSG00000259422.1	RP11-593F23.1	5.58	3.92e-08	1.34e-05	0.28	0.25	Blood metabolite levels;	chr15:76453787	chr15:76174891~76181486:-
LUAD	cis	rs293748	0.771	rs151945	ENSG00000250155.1	CTD-2353F22.1	-5.58	3.93e-08	1.34e-05	-0.34	-0.25	Obesity-related traits;	chr5:36838494	chr5:36666214~36725195:-
LUAD	cis	rs2404602	0.692	rs55676827	ENSG00000259422.1	RP11-593F23.1	5.58	3.93e-08	1.34e-05	0.28	0.25	Blood metabolite levels;	chr15:76669375	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.692	rs10444858	ENSG00000259422.1	RP11-593F23.1	5.58	3.93e-08	1.34e-05	0.28	0.25	Blood metabolite levels;	chr15:76670163	chr15:76174891~76181486:-
LUAD	cis	rs7176527	0.579	rs366717	ENSG00000188388.10	GOLGA6L3	5.58	3.93e-08	1.34e-05	0.31	0.25	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84544848	chr15:85240472~85247170:+
LUAD	cis	rs4835473	0.932	rs971390	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143751264	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.868	rs971391	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143751324	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs971392	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143751384	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.838	rs35978782	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143751713	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs34060266	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143751766	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs13139419	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143751862	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.868	rs13106052	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143751995	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs13134401	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143752008	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs13106287	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143752091	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs13134679	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143752187	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs13108134	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143752213	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs34406317	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143752237	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs35863996	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143752260	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs6836896	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143752404	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs2874983	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143752589	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs2874984	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143752622	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs2323192	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143752646	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs2323193	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143752812	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs34152627	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143753205	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs35670108	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143753280	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs6832005	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143754284	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.838	rs55963933	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143755048	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.868	rs35243309	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143755116	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs34790336	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143755284	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs35740243	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143755395	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs4395452	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143755678	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.741	rs6537180	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143755984	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.741	rs6537181	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143755995	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs6814065	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143756233	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs6816347	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143756674	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.808	rs6847256	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143757032	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.868	rs57413073	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143757852	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs34732468	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143758009	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs12510395	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143758107	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs12513087	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143758551	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs12513119	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143758619	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs12513130	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143758666	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.868	rs7681891	ENSG00000251600.4	RP11-673E1.1	-5.58	3.93e-08	1.34e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143759289	chr4:143912331~143982454:+
LUAD	cis	rs957448	0.554	rs12682601	ENSG00000253704.1	RP11-267M23.4	5.58	3.93e-08	1.34e-05	0.29	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94582492	chr8:94553722~94569745:+
LUAD	cis	rs11742741	0.579	rs4701422	ENSG00000248874.4	C5orf17	-5.58	3.93e-08	1.34e-05	-0.31	-0.25	Educational attainment;	chr5:24108058	chr5:23951348~24178263:+
LUAD	cis	rs2404602	0.716	rs8025134	ENSG00000259422.1	RP11-593F23.1	5.58	3.93e-08	1.34e-05	0.28	0.25	Blood metabolite levels;	chr15:76489388	chr15:76174891~76181486:-
LUAD	cis	rs6570726	0.935	rs413916	ENSG00000235652.6	RP11-545I5.3	5.58	3.93e-08	1.34e-05	0.24	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145510264	chr6:145799409~145886585:+
LUAD	cis	rs2790457	0.958	rs2772431	ENSG00000254635.4	WAC-AS1	-5.58	3.94e-08	1.34e-05	-0.27	-0.25	Multiple myeloma;	chr10:28601231	chr10:28522652~28532743:-
LUAD	cis	rs2404602	0.669	rs12595313	ENSG00000259422.1	RP11-593F23.1	5.58	3.94e-08	1.34e-05	0.28	0.25	Blood metabolite levels;	chr15:76686029	chr15:76174891~76181486:-
LUAD	cis	rs11651753	0.613	rs3096	ENSG00000264920.1	RP11-6N17.4	-5.58	3.94e-08	1.34e-05	-0.31	-0.25	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47952066	chr17:47891255~47895812:-
LUAD	cis	rs2404602	0.608	rs17361504	ENSG00000259422.1	RP11-593F23.1	5.58	3.95e-08	1.35e-05	0.28	0.25	Blood metabolite levels;	chr15:76309530	chr15:76174891~76181486:-
LUAD	cis	rs1075265	0.811	rs805322	ENSG00000233266.1	HMGB1P31	-5.58	3.95e-08	1.35e-05	-0.31	-0.25	Chronotype;Morning vs. evening chronotype;	chr2:53912758	chr2:54051334~54051760:+
LUAD	cis	rs891378	1	rs10864180	ENSG00000274245.1	RP11-357P18.2	-5.58	3.95e-08	1.35e-05	-0.3	-0.25	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207272416	chr1:207372559~207373252:+
LUAD	cis	rs944289	0.553	rs1169127	ENSG00000257826.1	RP11-116N8.4	-5.58	3.95e-08	1.35e-05	-0.28	-0.25	Thyroid cancer;	chr14:36151474	chr14:36061026~36067190:-
LUAD	cis	rs944289	0.515	rs1169130	ENSG00000257826.1	RP11-116N8.4	-5.58	3.95e-08	1.35e-05	-0.28	-0.25	Thyroid cancer;	chr14:36152701	chr14:36061026~36067190:-
LUAD	cis	rs11971779	0.68	rs4077889	ENSG00000273391.1	RP11-634H22.1	5.58	3.95e-08	1.35e-05	0.25	0.25	Diisocyanate-induced asthma;	chr7:139349168	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.68	rs11980313	ENSG00000273391.1	RP11-634H22.1	5.58	3.95e-08	1.35e-05	0.25	0.25	Diisocyanate-induced asthma;	chr7:139349897	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.584	rs6962029	ENSG00000273391.1	RP11-634H22.1	5.58	3.95e-08	1.35e-05	0.25	0.25	Diisocyanate-induced asthma;	chr7:139349973	chr7:139359032~139359566:-
LUAD	cis	rs496547	0.557	rs516719	ENSG00000255239.1	AP002954.6	5.58	3.95e-08	1.35e-05	0.3	0.25	Hip minimal joint space width;	chr11:118808736	chr11:118688039~118690600:-
LUAD	cis	rs4835473	0.932	rs4835013	ENSG00000251600.4	RP11-673E1.1	5.58	3.96e-08	1.35e-05	0.3	0.25	Immature fraction of reticulocytes;	chr4:143748485	chr4:143912331~143982454:+
LUAD	cis	rs765787	0.505	rs1648302	ENSG00000259520.4	CTD-2651B20.3	5.58	3.96e-08	1.35e-05	0.32	0.25	Uric acid levels;	chr15:45202040	chr15:45251580~45279251:-
LUAD	cis	rs71403859	0.502	rs34015581	ENSG00000260886.1	TAT-AS1	5.58	3.96e-08	1.35e-05	0.41	0.25	Post bronchodilator FEV1;	chr16:71474326	chr16:71565789~71578187:+
LUAD	cis	rs2179367	0.632	rs9498336	ENSG00000231760.4	RP11-350J20.5	5.58	3.96e-08	1.35e-05	0.35	0.25	Dupuytren's disease;	chr6:149374208	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs1980774	ENSG00000231760.4	RP11-350J20.5	5.58	3.96e-08	1.35e-05	0.35	0.25	Dupuytren's disease;	chr6:149375030	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs9498337	ENSG00000231760.4	RP11-350J20.5	5.58	3.96e-08	1.35e-05	0.35	0.25	Dupuytren's disease;	chr6:149375970	chr6:149796151~149826294:-
LUAD	cis	rs2276314	0.857	rs8097597	ENSG00000278986.1	RP11-723J4.3	-5.58	3.96e-08	1.35e-05	-0.3	-0.25	Endometriosis;Drug-induced torsades de pointes;	chr18:36039485	chr18:35972151~35973916:+
LUAD	cis	rs7804306	0.826	rs56017154	ENSG00000233264.2	AC006042.8	5.58	3.97e-08	1.35e-05	0.49	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7995282	chr7:7980312~7982228:+
LUAD	cis	rs7804306	0.826	rs73049293	ENSG00000233264.2	AC006042.8	5.58	3.97e-08	1.35e-05	0.49	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7999017	chr7:7980312~7982228:+
LUAD	cis	rs7804306	0.826	rs73049297	ENSG00000233264.2	AC006042.8	5.58	3.97e-08	1.35e-05	0.49	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7999429	chr7:7980312~7982228:+
LUAD	cis	rs71403859	0.502	rs35981926	ENSG00000260886.1	TAT-AS1	5.58	3.97e-08	1.35e-05	0.46	0.25	Post bronchodilator FEV1;	chr16:71466852	chr16:71565789~71578187:+
LUAD	cis	rs3762637	0.943	rs3817040	ENSG00000272758.4	RP11-299J3.8	-5.58	3.97e-08	1.35e-05	-0.37	-0.25	LDL cholesterol levels;	chr3:122535922	chr3:122416207~122443180:+
LUAD	cis	rs9601248	0.841	rs9545146	ENSG00000227676.3	LINC01068	-5.58	3.97e-08	1.35e-05	-0.31	-0.25	Major depressive disorder;	chr13:79601471	chr13:79566727~79571436:+
LUAD	cis	rs2836950	0.565	rs2836926	ENSG00000255568.3	BRWD1-AS2	-5.58	3.97e-08	1.35e-05	-0.24	-0.25	Menarche (age at onset);	chr21:39164864	chr21:39313935~39314962:+
LUAD	cis	rs8040855	0.599	rs6496792	ENSG00000259774.1	RP11-182J1.13	-5.58	3.97e-08	1.35e-05	-0.28	-0.25	Bulimia nervosa;	chr15:85182514	chr15:84422618~84425882:+
LUAD	cis	rs8040855	0.599	rs6496793	ENSG00000259774.1	RP11-182J1.13	-5.58	3.97e-08	1.35e-05	-0.28	-0.25	Bulimia nervosa;	chr15:85182515	chr15:84422618~84425882:+
LUAD	cis	rs8040855	0.599	rs6496795	ENSG00000259774.1	RP11-182J1.13	-5.58	3.97e-08	1.35e-05	-0.28	-0.25	Bulimia nervosa;	chr15:85182622	chr15:84422618~84425882:+
LUAD	cis	rs8040855	0.599	rs4577058	ENSG00000259774.1	RP11-182J1.13	-5.58	3.97e-08	1.35e-05	-0.28	-0.25	Bulimia nervosa;	chr15:85183227	chr15:84422618~84425882:+
LUAD	cis	rs2412819	0.597	rs541871	ENSG00000249839.1	AC011330.5	-5.58	3.97e-08	1.35e-05	-0.38	-0.25	Lung cancer;	chr15:43868656	chr15:43663654~43684339:-
LUAD	cis	rs673078	0.66	rs76842574	ENSG00000275409.1	RP11-131L12.4	-5.58	3.97e-08	1.35e-05	-0.31	-0.25	Glucose homeostasis traits;	chr12:118371789	chr12:118430147~118430699:+
LUAD	cis	rs2243480	1	rs465359	ENSG00000230295.1	RP11-458F8.2	-5.58	3.97e-08	1.35e-05	-0.3	-0.25	Diabetic kidney disease;	chr7:66093177	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs462853	ENSG00000230295.1	RP11-458F8.2	-5.58	3.97e-08	1.35e-05	-0.3	-0.25	Diabetic kidney disease;	chr7:66093180	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs160644	ENSG00000230295.1	RP11-458F8.2	-5.58	3.97e-08	1.35e-05	-0.3	-0.25	Diabetic kidney disease;	chr7:66093199	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs160642	ENSG00000230295.1	RP11-458F8.2	-5.58	3.97e-08	1.35e-05	-0.3	-0.25	Diabetic kidney disease;	chr7:66093386	chr7:66880708~66882981:+
LUAD	cis	rs2243480	0.614	rs34032527	ENSG00000230295.1	RP11-458F8.2	-5.58	3.97e-08	1.35e-05	-0.3	-0.25	Diabetic kidney disease;	chr7:66100154	chr7:66880708~66882981:+
LUAD	cis	rs8040855	0.599	rs1964724	ENSG00000259774.1	RP11-182J1.13	-5.58	3.98e-08	1.35e-05	-0.28	-0.25	Bulimia nervosa;	chr15:85183269	chr15:84422618~84425882:+
LUAD	cis	rs7712401	0.601	rs154501	ENSG00000263432.2	RN7SL689P	5.58	3.98e-08	1.36e-05	0.31	0.25	Mean platelet volume;	chr5:122875899	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs246271	ENSG00000263432.2	RN7SL689P	5.58	3.98e-08	1.36e-05	0.31	0.25	Mean platelet volume;	chr5:122877127	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs257813	ENSG00000263432.2	RN7SL689P	5.58	3.98e-08	1.36e-05	0.31	0.25	Mean platelet volume;	chr5:122881473	chr5:123022487~123022783:-
LUAD	cis	rs2288884	1	rs56808319	ENSG00000275055.1	CTC-471J1.11	-5.58	3.99e-08	1.36e-05	-0.4	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52074621	chr19:52049007~52049754:+
LUAD	cis	rs2404602	0.716	rs67920045	ENSG00000259422.1	RP11-593F23.1	5.58	3.99e-08	1.36e-05	0.28	0.25	Blood metabolite levels;	chr15:76507743	chr15:76174891~76181486:-
LUAD	cis	rs673078	0.607	rs7299040	ENSG00000275409.1	RP11-131L12.4	-5.58	3.99e-08	1.36e-05	-0.35	-0.25	Glucose homeostasis traits;	chr12:118380660	chr12:118430147~118430699:+
LUAD	cis	rs2288884	0.945	rs78336183	ENSG00000275055.1	CTC-471J1.11	-5.58	3.99e-08	1.36e-05	-0.36	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52058230	chr19:52049007~52049754:+
LUAD	cis	rs10129255	0.957	rs10136817	ENSG00000224373.3	IGHV4-59	5.58	3.99e-08	1.36e-05	0.16	0.25	Kawasaki disease;	chr14:106787730	chr14:106627249~106627825:-
LUAD	cis	rs896854	0.654	rs2011566	ENSG00000253528.2	RP11-347C18.4	5.58	4e-08	1.36e-05	0.24	0.25	Type 2 diabetes;	chr8:94959693	chr8:94974573~94974853:-
LUAD	cis	rs516805	0.667	rs2606598	ENSG00000279453.1	RP3-425C14.4	5.58	4e-08	1.36e-05	0.33	0.25	Lymphocyte counts;	chr6:122206501	chr6:122436789~122439223:-
LUAD	cis	rs4767841	0.552	rs10849682	ENSG00000248636.5	RP11-768F21.1	-5.58	4e-08	1.36e-05	-0.29	-0.25	Urgency urinary incontinence;	chr12:119622325	chr12:119387987~119668079:-
LUAD	cis	rs2404602	0.692	rs7169663	ENSG00000259422.1	RP11-593F23.1	5.58	4e-08	1.36e-05	0.28	0.25	Blood metabolite levels;	chr15:76900502	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.692	rs35999717	ENSG00000259422.1	RP11-593F23.1	5.58	4e-08	1.36e-05	0.28	0.25	Blood metabolite levels;	chr15:76901026	chr15:76174891~76181486:-
LUAD	cis	rs11105298	1	rs11105298	ENSG00000258302.2	RP11-981P6.1	-5.58	4.01e-08	1.36e-05	-0.3	-0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89482366	chr12:89561129~89594878:+
LUAD	cis	rs7712401	0.601	rs152039	ENSG00000263432.2	RN7SL689P	5.58	4.01e-08	1.36e-05	0.3	0.25	Mean platelet volume;	chr5:122884970	chr5:123022487~123022783:-
LUAD	cis	rs2179367	0.586	rs9498341	ENSG00000231760.4	RP11-350J20.5	5.58	4.01e-08	1.36e-05	0.35	0.25	Dupuytren's disease;	chr6:149379737	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs9498342	ENSG00000231760.4	RP11-350J20.5	5.58	4.01e-08	1.36e-05	0.35	0.25	Dupuytren's disease;	chr6:149379806	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs12191079	ENSG00000231760.4	RP11-350J20.5	5.58	4.01e-08	1.36e-05	0.35	0.25	Dupuytren's disease;	chr6:149380333	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs12204461	ENSG00000231760.4	RP11-350J20.5	5.58	4.01e-08	1.36e-05	0.35	0.25	Dupuytren's disease;	chr6:149380399	chr6:149796151~149826294:-
LUAD	cis	rs3096299	0.702	rs2086824	ENSG00000274627.1	RP11-104N10.2	-5.58	4.01e-08	1.37e-05	-0.23	-0.25	Multiple myeloma (IgH translocation);	chr16:89404838	chr16:89516797~89522217:+
LUAD	cis	rs155076	0.711	rs9550724	ENSG00000233325.3	MIPEPP3	-5.58	4.01e-08	1.37e-05	-0.36	-0.25	White matter hyperintensity burden;	chr13:21310891	chr13:21298139~21306373:+
LUAD	cis	rs9652601	0.691	rs998592	ENSG00000274038.1	RP11-66H6.4	5.58	4.02e-08	1.37e-05	0.3	0.25	Systemic lupus erythematosus;	chr16:11105821	chr16:11056556~11057034:+
LUAD	cis	rs875971	1	rs55962648	ENSG00000237310.1	GS1-124K5.4	-5.58	4.02e-08	1.37e-05	-0.26	-0.25	Aortic root size;	chr7:66160764	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs2420168	ENSG00000237310.1	GS1-124K5.4	-5.58	4.02e-08	1.37e-05	-0.26	-0.25	Aortic root size;	chr7:66165644	chr7:66493706~66495474:+
LUAD	cis	rs7221109	0.71	rs9906785	ENSG00000278834.1	RP11-458J1.1	5.58	4.02e-08	1.37e-05	0.29	0.25	Type 1 diabetes;	chr17:40641157	chr17:40648300~40649718:+
LUAD	cis	rs113835537	0.627	rs4630309	ENSG00000255517.5	CTD-3074O7.5	5.58	4.02e-08	1.37e-05	0.31	0.25	Airway imaging phenotypes;	chr11:66565601	chr11:66473490~66480233:-
LUAD	cis	rs11089937	0.524	rs2877021	ENSG00000211638.2	IGLV8-61	-5.58	4.02e-08	1.37e-05	-0.27	-0.25	Periodontitis (PAL4Q3);	chr22:22165909	chr22:22098700~22099212:+
LUAD	cis	rs2749097	1	rs11208259	ENSG00000244256.3	RN7SL130P	-5.58	4.03e-08	1.37e-05	-0.36	-0.25	Alcohol consumption (transferrin glycosylation);	chr1:63657549	chr1:63655743~63656047:+
LUAD	cis	rs910316	1	rs10140851	ENSG00000259138.1	RP11-950C14.7	5.58	4.03e-08	1.37e-05	0.26	0.25	Height;	chr14:75045909	chr14:75127153~75136930:+
LUAD	cis	rs36093844	0.752	rs17744675	ENSG00000279742.1	RP11-700A24.1	5.58	4.03e-08	1.37e-05	0.31	0.25	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85882863	chr11:85852557~85854943:-
LUAD	cis	rs155076	0.938	rs261375	ENSG00000233325.3	MIPEPP3	-5.58	4.03e-08	1.37e-05	-0.4	-0.25	White matter hyperintensity burden;	chr13:21297743	chr13:21298139~21306373:+
LUAD	cis	rs4835473	0.932	rs4325971	ENSG00000251600.4	RP11-673E1.1	-5.58	4.03e-08	1.37e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143740167	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs4443230	ENSG00000251600.4	RP11-673E1.1	-5.58	4.03e-08	1.37e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143740372	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs4637344	ENSG00000251600.4	RP11-673E1.1	-5.58	4.03e-08	1.37e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143740434	chr4:143912331~143982454:+
LUAD	cis	rs6687821	0.515	rs7552285	ENSG00000267734.1	RP4-604K5.3	-5.58	4.03e-08	1.37e-05	-0.3	-0.25	Yeast infection;	chr1:87017482	chr1:86932199~86934891:-
LUAD	cis	rs763567	0.565	rs546258	ENSG00000271811.1	RP1-79C4.4	-5.58	4.04e-08	1.37e-05	-0.29	-0.25	Tonsillectomy;	chr1:170610453	chr1:170667381~170669425:+
LUAD	cis	rs673078	0.607	rs61943404	ENSG00000275409.1	RP11-131L12.4	-5.58	4.04e-08	1.37e-05	-0.34	-0.25	Glucose homeostasis traits;	chr12:118402062	chr12:118430147~118430699:+
LUAD	cis	rs2933343	0.951	rs789220	ENSG00000231305.3	RP11-723O4.2	-5.58	4.04e-08	1.37e-05	-0.29	-0.25	IgG glycosylation;	chr3:128873292	chr3:128861313~128871540:-
LUAD	cis	rs9807989	0.811	rs11688559	ENSG00000234389.1	AC007278.3	5.58	4.04e-08	1.37e-05	0.24	0.25	Asthma;	chr2:102353453	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.811	rs11688568	ENSG00000234389.1	AC007278.3	5.58	4.04e-08	1.37e-05	0.24	0.25	Asthma;	chr2:102353489	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.811	rs11688573	ENSG00000234389.1	AC007278.3	5.58	4.04e-08	1.37e-05	0.24	0.25	Asthma;	chr2:102353511	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.811	rs11689730	ENSG00000234389.1	AC007278.3	5.58	4.04e-08	1.37e-05	0.24	0.25	Asthma;	chr2:102353524	chr2:102438713~102440475:+
LUAD	cis	rs2933343	0.859	rs789247	ENSG00000261159.1	RP11-723O4.9	5.58	4.04e-08	1.37e-05	0.3	0.25	IgG glycosylation;	chr3:128861742	chr3:128859716~128860526:-
LUAD	cis	rs2933343	0.903	rs2638846	ENSG00000261159.1	RP11-723O4.9	5.58	4.04e-08	1.37e-05	0.3	0.25	IgG glycosylation;	chr3:128868320	chr3:128859716~128860526:-
LUAD	cis	rs66887589	0.967	rs3775842	ENSG00000248280.1	RP11-33B1.2	5.58	4.04e-08	1.37e-05	0.27	0.25	Diastolic blood pressure;	chr4:119506577	chr4:119440561~119450157:-
LUAD	cis	rs1707322	1	rs10890382	ENSG00000234329.1	RP11-767N6.2	5.58	4.04e-08	1.38e-05	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46004002	chr1:45651039~45651826:-
LUAD	cis	rs6687821	0.515	rs2764427	ENSG00000267734.1	RP4-604K5.3	-5.58	4.06e-08	1.38e-05	-0.3	-0.25	Yeast infection;	chr1:87076636	chr1:86932199~86934891:-
LUAD	cis	rs8031584	1	rs35239376	ENSG00000260382.1	RP11-540B6.2	5.58	4.06e-08	1.38e-05	0.32	0.25	Huntington's disease progression;	chr15:30998335	chr15:30882267~30883231:-
LUAD	cis	rs7662987	0.793	rs7669660	ENSG00000272777.1	RP11-571L19.8	5.58	4.06e-08	1.38e-05	0.39	0.25	Smoking initiation;	chr4:99071451	chr4:99067256~99068125:-
LUAD	cis	rs7662987	0.793	rs12106	ENSG00000272777.1	RP11-571L19.8	5.58	4.06e-08	1.38e-05	0.39	0.25	Smoking initiation;	chr4:99072199	chr4:99067256~99068125:-
LUAD	cis	rs2243480	1	rs35820085	ENSG00000230295.1	RP11-458F8.2	-5.58	4.06e-08	1.38e-05	-0.3	-0.25	Diabetic kidney disease;	chr7:65977771	chr7:66880708~66882981:+
LUAD	cis	rs62355901	0.739	rs61055995	ENSG00000271828.1	CTD-2310F14.1	5.58	4.06e-08	1.38e-05	0.37	0.25	Breast cancer;	chr5:56723237	chr5:56927874~56929573:+
LUAD	cis	rs6991838	0.771	rs13282323	ENSG00000200714.1	Y_RNA	5.58	4.06e-08	1.38e-05	0.29	0.25	Intelligence (multi-trait analysis);	chr8:65560557	chr8:65592731~65592820:+
LUAD	cis	rs2404602	0.647	rs36114653	ENSG00000259422.1	RP11-593F23.1	-5.58	4.06e-08	1.38e-05	-0.33	-0.25	Blood metabolite levels;	chr15:76733052	chr15:76174891~76181486:-
LUAD	cis	rs7617773	0.817	rs13068265	ENSG00000228638.1	FCF1P2	-5.58	4.07e-08	1.38e-05	-0.29	-0.25	Coronary artery disease;	chr3:48260124	chr3:48290793~48291375:-
LUAD	cis	rs9910055	0.762	rs184478	ENSG00000267080.4	ASB16-AS1	5.58	4.07e-08	1.38e-05	0.22	0.25	Total body bone mineral density;	chr17:44132383	chr17:44175973~44186717:-
LUAD	cis	rs2288884	0.943	rs75722407	ENSG00000275055.1	CTC-471J1.11	-5.58	4.07e-08	1.38e-05	-0.39	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52021989	chr19:52049007~52049754:+
LUAD	cis	rs2404602	0.622	rs11637296	ENSG00000259422.1	RP11-593F23.1	-5.58	4.08e-08	1.39e-05	-0.34	-0.25	Blood metabolite levels;	chr15:76915544	chr15:76174891~76181486:-
LUAD	cis	rs1707322	1	rs1707337	ENSG00000234329.1	RP11-767N6.2	-5.58	4.08e-08	1.39e-05	-0.25	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46043097	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs1768807	ENSG00000234329.1	RP11-767N6.2	-5.58	4.08e-08	1.39e-05	-0.25	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044898	chr1:45651039~45651826:-
LUAD	cis	rs9500256	0.655	rs12191043	ENSG00000215190.7	LINC00680	-5.58	4.08e-08	1.39e-05	-0.32	-0.25	Eosinophilic esophagitis (pediatric);	chr6:58020205	chr6:57946074~57961501:-
LUAD	cis	rs1799949	0.602	rs8176235	ENSG00000267681.1	CTD-3199J23.6	-5.58	4.08e-08	1.39e-05	-0.31	-0.25	Menopause (age at onset);	chr17:43067543	chr17:43144956~43145255:+
LUAD	cis	rs2404602	0.692	rs12911174	ENSG00000259422.1	RP11-593F23.1	5.58	4.08e-08	1.39e-05	0.28	0.25	Blood metabolite levels;	chr15:76857602	chr15:76174891~76181486:-
LUAD	cis	rs62158211	0.955	rs1823125	ENSG00000234997.1	AC016745.3	5.58	4.08e-08	1.39e-05	0.3	0.25	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113332835	chr2:113424495~113425324:+
LUAD	cis	rs8031584	0.541	rs2955797	ENSG00000260382.1	RP11-540B6.2	-5.58	4.08e-08	1.39e-05	-0.28	-0.25	Huntington's disease progression;	chr15:30918778	chr15:30882267~30883231:-
LUAD	cis	rs2404602	0.622	rs1567671	ENSG00000259422.1	RP11-593F23.1	-5.58	4.08e-08	1.39e-05	-0.34	-0.25	Blood metabolite levels;	chr15:76916859	chr15:76174891~76181486:-
LUAD	cis	rs1707322	0.686	rs2991987	ENSG00000280836.1	AL355480.1	5.58	4.09e-08	1.39e-05	0.33	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615750	chr1:45581219~45581321:-
LUAD	cis	rs17684571	0.7	rs13194904	ENSG00000231441.1	RP11-472M19.2	5.58	4.09e-08	1.39e-05	0.37	0.25	Schizophrenia;	chr6:56811443	chr6:56844002~56864078:+
LUAD	cis	rs10754283	0.84	rs6428560	ENSG00000231613.1	RP5-943J3.1	5.58	4.09e-08	1.39e-05	0.25	0.25	Amyotrophic lateral sclerosis (sporadic);	chr1:89636903	chr1:89788914~89790492:+
LUAD	cis	rs1874124	0.778	rs1335920	ENSG00000272823.1	RP11-295M18.6	-5.58	4.1e-08	1.39e-05	-0.37	-0.25	Cholesterol, total;	chr1:220844946	chr1:220828676~220829211:-
LUAD	cis	rs8062405	0.691	rs11646653	ENSG00000251417.2	RP11-1348G14.4	5.58	4.1e-08	1.39e-05	0.26	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28802743~28817828:+
LUAD	cis	rs732716	0.74	rs78869060	ENSG00000267980.1	AC007292.6	-5.58	4.1e-08	1.39e-05	-0.29	-0.25	Mean corpuscular volume;	chr19:4444745	chr19:4363789~4364640:+
LUAD	cis	rs909685	1	rs2069235	ENSG00000280216.1	RP3-333H23.9	5.58	4.1e-08	1.39e-05	0.27	0.25	Rheumatoid arthritis;	chr22:39351775	chr22:39379610~39380015:+
LUAD	cis	rs2288884	0.636	rs8101936	ENSG00000275055.1	CTC-471J1.11	-5.58	4.11e-08	1.4e-05	-0.31	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52073226	chr19:52049007~52049754:+
LUAD	cis	rs2288884	0.636	rs8105801	ENSG00000275055.1	CTC-471J1.11	-5.58	4.11e-08	1.4e-05	-0.31	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52074095	chr19:52049007~52049754:+
LUAD	cis	rs9549367	0.774	rs9549696	ENSG00000269125.1	RP11-98F14.11	-5.58	4.11e-08	1.4e-05	-0.31	-0.25	Platelet distribution width;	chr13:113220748	chr13:113165002~113165183:-
LUAD	cis	rs4947019	0.609	rs116647873	ENSG00000260273.1	RP11-425D10.10	5.58	4.11e-08	1.4e-05	0.54	0.25	Hematological parameters;	chr6:109398216	chr6:109382795~109383666:+
LUAD	cis	rs7712401	0.623	rs30032	ENSG00000263432.2	RN7SL689P	5.58	4.11e-08	1.4e-05	0.31	0.25	Mean platelet volume;	chr5:122902692	chr5:123022487~123022783:-
LUAD	cis	rs2263638	0.565	rs2488794	ENSG00000228701.1	TNKS2-AS1	-5.58	4.11e-08	1.4e-05	-0.39	-0.25	Airflow obstruction;	chr10:92408060	chr10:91782839~91798291:-
LUAD	cis	rs9287719	0.625	rs12473787	ENSG00000243819.4	RN7SL832P	5.58	4.11e-08	1.4e-05	0.26	0.25	Prostate cancer;	chr2:10577068	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.649	rs2160258	ENSG00000243819.4	RN7SL832P	5.58	4.11e-08	1.4e-05	0.26	0.25	Prostate cancer;	chr2:10577095	chr2:10690344~10692099:+
LUAD	cis	rs11105298	0.891	rs11105309	ENSG00000258302.2	RP11-981P6.1	5.58	4.12e-08	1.4e-05	0.31	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89516073	chr12:89561129~89594878:+
LUAD	cis	rs1154275	0.537	rs6789210	ENSG00000242770.2	RP11-180K7.1	5.58	4.12e-08	1.4e-05	0.25	0.25	Takotsubo syndrome;	chr3:112797481	chr3:112802478~112812819:+
LUAD	cis	rs9287719	0.649	rs9973456	ENSG00000243819.4	RN7SL832P	5.58	4.12e-08	1.4e-05	0.26	0.25	Prostate cancer;	chr2:10578004	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.649	rs10175884	ENSG00000243819.4	RN7SL832P	5.58	4.12e-08	1.4e-05	0.26	0.25	Prostate cancer;	chr2:10578408	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.649	rs10190673	ENSG00000243819.4	RN7SL832P	5.58	4.12e-08	1.4e-05	0.26	0.25	Prostate cancer;	chr2:10578492	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.649	rs10198971	ENSG00000243819.4	RN7SL832P	5.58	4.12e-08	1.4e-05	0.26	0.25	Prostate cancer;	chr2:10578573	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.649	rs10190774	ENSG00000243819.4	RN7SL832P	5.58	4.12e-08	1.4e-05	0.26	0.25	Prostate cancer;	chr2:10578620	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.649	rs10188373	ENSG00000243819.4	RN7SL832P	5.58	4.12e-08	1.4e-05	0.26	0.25	Prostate cancer;	chr2:10578676	chr2:10690344~10692099:+
LUAD	cis	rs10246939	0.505	rs13236432	ENSG00000228775.6	WEE2-AS1	5.58	4.13e-08	1.4e-05	0.31	0.25	Bitter taste perception;	chr7:141850980	chr7:141704338~141738346:-
LUAD	cis	rs67311347	0.866	rs1454491	ENSG00000223797.4	ENTPD3-AS1	5.58	4.13e-08	1.4e-05	0.26	0.25	Renal cell carcinoma;	chr3:40311156	chr3:40313802~40453329:-
LUAD	cis	rs1707322	1	rs1612419	ENSG00000234329.1	RP11-767N6.2	-5.57	4.14e-08	1.4e-05	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081273	chr1:45651039~45651826:-
LUAD	cis	rs2404602	0.619	rs7342603	ENSG00000259422.1	RP11-593F23.1	5.57	4.14e-08	1.41e-05	0.28	0.25	Blood metabolite levels;	chr15:76690284	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.692	rs8024476	ENSG00000259422.1	RP11-593F23.1	5.57	4.14e-08	1.41e-05	0.28	0.25	Blood metabolite levels;	chr15:76691613	chr15:76174891~76181486:-
LUAD	cis	rs2243480	0.522	rs431168	ENSG00000226824.5	RP4-756H11.3	-5.57	4.14e-08	1.41e-05	-0.53	-0.25	Diabetic kidney disease;	chr7:66046617	chr7:66654538~66669855:+
LUAD	cis	rs4834770	0.792	rs6823331	ENSG00000245958.5	RP11-33B1.1	-5.57	4.14e-08	1.41e-05	-0.23	-0.25	Blood protein levels;	chr4:119259635	chr4:119454791~119552025:+
LUAD	cis	rs10761482	0.5	rs6479716	ENSG00000254271.1	RP11-131N11.4	5.57	4.14e-08	1.41e-05	0.27	0.25	Schizophrenia;	chr10:60542800	chr10:60734342~60741828:+
LUAD	cis	rs367615	0.68	rs2256556	ENSG00000249476.1	CTD-2587M2.1	-5.57	4.15e-08	1.41e-05	-0.31	-0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109629206	chr5:109237120~109326369:-
LUAD	cis	rs35740288	0.862	rs11637444	ENSG00000202081.1	RNU6-1280P	5.57	4.15e-08	1.41e-05	0.31	0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85767957	chr15:85651522~85651628:-
LUAD	cis	rs8098244	0.638	rs12965685	ENSG00000264745.1	TTC39C-AS1	5.57	4.15e-08	1.41e-05	0.25	0.25	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23861753	chr18:23994213~24015339:-
LUAD	cis	rs2288884	0.559	rs2903710	ENSG00000275055.1	CTC-471J1.11	-5.57	4.15e-08	1.41e-05	-0.29	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52004285	chr19:52049007~52049754:+
LUAD	cis	rs12468226	0.873	rs79071680	ENSG00000272966.1	RP11-686O6.1	5.57	4.15e-08	1.41e-05	0.44	0.25	Urate levels;	chr2:202191520	chr2:202336739~202337200:+
LUAD	cis	rs12468226	0.873	rs79860867	ENSG00000272966.1	RP11-686O6.1	5.57	4.15e-08	1.41e-05	0.44	0.25	Urate levels;	chr2:202192397	chr2:202336739~202337200:+
LUAD	cis	rs948562	0.711	rs12361623	ENSG00000280010.1	AP001350.4	5.57	4.15e-08	1.41e-05	0.36	0.25	Lymphoma;	chr11:58454953	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.744	rs12362108	ENSG00000280010.1	AP001350.4	5.57	4.15e-08	1.41e-05	0.36	0.25	Lymphoma;	chr11:58456879	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.744	rs11229472	ENSG00000280010.1	AP001350.4	5.57	4.15e-08	1.41e-05	0.36	0.25	Lymphoma;	chr11:58458778	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.744	rs12362953	ENSG00000280010.1	AP001350.4	5.57	4.15e-08	1.41e-05	0.36	0.25	Lymphoma;	chr11:58459432	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.744	rs11229475	ENSG00000280010.1	AP001350.4	5.57	4.15e-08	1.41e-05	0.36	0.25	Lymphoma;	chr11:58459910	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.725	rs11229476	ENSG00000280010.1	AP001350.4	5.57	4.15e-08	1.41e-05	0.36	0.25	Lymphoma;	chr11:58461120	chr11:58627435~58628528:+
LUAD	cis	rs8103033	0.786	rs6508899	ENSG00000226025.8	LGALS17A	5.57	4.15e-08	1.41e-05	0.27	0.25	Obesity-related traits;	chr19:39661982	chr19:39679374~39686373:+
LUAD	cis	rs7044106	0.708	rs959558	ENSG00000238181.2	AHCYP2	-5.57	4.16e-08	1.41e-05	-0.31	-0.25	Hip circumference adjusted for BMI;	chr9:120606633	chr9:120720673~120721972:+
LUAD	cis	rs6772849	0.93	rs12487604	ENSG00000242551.2	POU5F1P6	-5.57	4.16e-08	1.41e-05	-0.3	-0.25	Monocyte percentage of white cells;Monocyte count;	chr3:128618232	chr3:128674735~128677005:-
LUAD	cis	rs1075265	0.518	rs13414393	ENSG00000272156.1	RP11-477N3.1	-5.57	4.17e-08	1.41e-05	-0.31	-0.25	Chronotype;Morning vs. evening chronotype;	chr2:54048025	chr2:54082554~54085066:+
LUAD	cis	rs11700536	1	rs11700536	ENSG00000236663.1	AP001631.9	-5.57	4.17e-08	1.41e-05	-0.28	-0.25	Interleukin-18 levels;	chr21:43138577	chr21:43140523~43141092:-
LUAD	cis	rs73186030	0.546	rs9857972	ENSG00000272758.4	RP11-299J3.8	5.57	4.17e-08	1.42e-05	0.31	0.25	Serum parathyroid hormone levels;	chr3:122390602	chr3:122416207~122443180:+
LUAD	cis	rs4308124	0.708	rs6716091	ENSG00000227992.1	AC108463.2	-5.57	4.17e-08	1.42e-05	-0.33	-0.25	Vitiligo;	chr2:111233556	chr2:111203964~111206215:-
LUAD	cis	rs7246657	0.722	rs2972447	ENSG00000276846.1	CTD-3220F14.3	-5.57	4.17e-08	1.42e-05	-0.33	-0.25	Coronary artery calcification;	chr19:37638835	chr19:37314868~37315620:-
LUAD	cis	rs7246657	0.678	rs2972446	ENSG00000276846.1	CTD-3220F14.3	-5.57	4.17e-08	1.42e-05	-0.33	-0.25	Coronary artery calcification;	chr19:37638992	chr19:37314868~37315620:-
LUAD	cis	rs66887589	0.748	rs28439855	ENSG00000245958.5	RP11-33B1.1	-5.57	4.17e-08	1.42e-05	-0.2	-0.25	Diastolic blood pressure;	chr4:119341101	chr4:119454791~119552025:+
LUAD	cis	rs6907340	0.517	rs9465533	ENSG00000228412.5	RP4-625H18.2	5.57	4.17e-08	1.42e-05	0.31	0.25	Endometriosis;	chr6:19801477	chr6:19802164~19804752:-
LUAD	cis	rs1510272	0.515	rs6762762	ENSG00000243926.1	TIPARP-AS1	-5.57	4.18e-08	1.42e-05	-0.31	-0.25	Testicular germ cell tumor;	chr3:156625194	chr3:156671862~156674378:-
LUAD	cis	rs1707322	1	rs785510	ENSG00000234329.1	RP11-767N6.2	-5.57	4.19e-08	1.42e-05	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062946	chr1:45651039~45651826:-
LUAD	cis	rs12188164	0.686	rs72711367	ENSG00000225138.6	CTD-2228K2.7	5.57	4.19e-08	1.42e-05	0.25	0.25	Cystic fibrosis severity;	chr5:418379	chr5:473236~480884:+
LUAD	cis	rs7937890	0.732	rs7946902	ENSG00000254418.1	RP11-21L19.1	-5.57	4.21e-08	1.43e-05	-0.29	-0.25	Mitochondrial DNA levels;	chr11:14251762	chr11:14262846~14273691:-
LUAD	cis	rs7712401	0.623	rs538424	ENSG00000263432.2	RN7SL689P	5.57	4.21e-08	1.43e-05	0.31	0.25	Mean platelet volume;	chr5:122893068	chr5:123022487~123022783:-
LUAD	cis	rs1707322	0.717	rs2275086	ENSG00000280836.1	AL355480.1	5.57	4.22e-08	1.43e-05	0.33	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620207	chr1:45581219~45581321:-
LUAD	cis	rs2921036	0.545	rs4840975	ENSG00000253893.2	FAM85B	5.57	4.23e-08	1.43e-05	0.31	0.25	Neuroticism;	chr8:8505748	chr8:8167819~8226614:-
LUAD	cis	rs17684571	0.751	rs35073881	ENSG00000231441.1	RP11-472M19.2	5.57	4.23e-08	1.43e-05	0.37	0.25	Schizophrenia;	chr6:56842410	chr6:56844002~56864078:+
LUAD	cis	rs7674212	0.581	rs10516496	ENSG00000251288.2	RP11-10L12.2	-5.57	4.24e-08	1.44e-05	-0.31	-0.25	Type 2 diabetes;	chr4:103021008	chr4:102751401~102752641:+
LUAD	cis	rs2179367	0.6	rs9498354	ENSG00000231760.4	RP11-350J20.5	-5.57	4.24e-08	1.44e-05	-0.35	-0.25	Dupuytren's disease;	chr6:149441715	chr6:149796151~149826294:-
LUAD	cis	rs875971	0.862	rs10256544	ENSG00000222364.1	RNU6-96P	-5.57	4.24e-08	1.44e-05	-0.28	-0.25	Aortic root size;	chr7:66210141	chr7:66395191~66395286:+
LUAD	cis	rs2412819	0.545	rs17795279	ENSG00000205771.5	CATSPER2P1	5.57	4.24e-08	1.44e-05	0.39	0.25	Lung cancer;	chr15:43637180	chr15:43726918~43747094:-
LUAD	cis	rs2832077	0.943	rs2832084	ENSG00000232855.5	AF131217.1	5.57	4.24e-08	1.44e-05	0.28	0.25	Cognitive test performance;	chr21:28782476	chr21:28439346~28674848:-
LUAD	cis	rs1667284	1	rs1667283	ENSG00000266521.1	RP11-650P15.1	5.57	4.24e-08	1.44e-05	0.29	0.25	Problematic alcohol use in trauma-exposed individuals;	chr18:31643658	chr18:31496645~31497195:-
LUAD	cis	rs2739330	0.796	rs1006771	ENSG00000206090.4	AP000350.7	5.57	4.25e-08	1.44e-05	0.29	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23939998~23942798:+
LUAD	cis	rs7968440	1	rs2731442	ENSG00000200428.1	Y_RNA	-5.57	4.25e-08	1.44e-05	-0.31	-0.25	Fibrinogen;	chr12:50660872	chr12:50743568~50743684:+
LUAD	cis	rs516805	0.673	rs561953	ENSG00000279453.1	RP3-425C14.4	-5.57	4.26e-08	1.44e-05	-0.32	-0.25	Lymphocyte counts;	chr6:122440341	chr6:122436789~122439223:-
LUAD	cis	rs17684571	0.7	rs4457154	ENSG00000231441.1	RP11-472M19.2	5.57	4.26e-08	1.44e-05	0.37	0.25	Schizophrenia;	chr6:56805653	chr6:56844002~56864078:+
LUAD	cis	rs30380	1	rs246454	ENSG00000272109.1	CTD-2260A17.3	-5.57	4.26e-08	1.44e-05	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr5:96787561	chr5:96804353~96806105:+
LUAD	cis	rs30380	0.922	rs246453	ENSG00000272109.1	CTD-2260A17.3	-5.57	4.26e-08	1.44e-05	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr5:96787633	chr5:96804353~96806105:+
LUAD	cis	rs897984	0.609	rs35468353	ENSG00000260911.2	RP11-196G11.2	5.57	4.27e-08	1.44e-05	0.22	0.25	Dementia with Lewy bodies;	chr16:31045112	chr16:31043150~31049868:+
LUAD	cis	rs897984	0.609	rs11862744	ENSG00000260911.2	RP11-196G11.2	5.57	4.27e-08	1.44e-05	0.22	0.25	Dementia with Lewy bodies;	chr16:31046479	chr16:31043150~31049868:+
LUAD	cis	rs2749097	1	rs4643	ENSG00000244256.3	RN7SL130P	-5.57	4.27e-08	1.45e-05	-0.36	-0.25	Alcohol consumption (transferrin glycosylation);	chr1:63659768	chr1:63655743~63656047:+
LUAD	cis	rs9847710	0.901	rs2564964	ENSG00000242142.1	SERBP1P3	5.57	4.27e-08	1.45e-05	0.27	0.25	Ulcerative colitis;	chr3:53004102	chr3:53064283~53065091:-
LUAD	cis	rs11105298	0.891	rs10858854	ENSG00000258302.2	RP11-981P6.1	5.57	4.28e-08	1.45e-05	0.32	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89441951	chr12:89561129~89594878:+
LUAD	cis	rs1707322	1	rs7517560	ENSG00000234329.1	RP11-767N6.2	5.57	4.28e-08	1.45e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45960271	chr1:45651039~45651826:-
LUAD	cis	rs1876905	0.68	rs1150082	ENSG00000272356.1	RP5-1112D6.8	-5.57	4.28e-08	1.45e-05	-0.27	-0.25	Mean corpuscular hemoglobin;	chr6:111189519	chr6:111309203~111313517:+
LUAD	cis	rs807029	0.577	rs11190787	ENSG00000272572.1	RP11-179B2.2	-5.57	4.28e-08	1.45e-05	-0.35	-0.25	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100998868	chr10:100911103~100912739:-
LUAD	cis	rs867371	0.896	rs8033831	ENSG00000259429.4	UBE2Q2P2	-5.57	4.28e-08	1.45e-05	-0.21	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82220953	chr15:82355142~82420075:+
LUAD	cis	rs1707322	1	rs785498	ENSG00000234329.1	RP11-767N6.2	-5.57	4.28e-08	1.45e-05	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126742	chr1:45651039~45651826:-
LUAD	cis	rs9595908	0.709	rs3752476	ENSG00000212293.1	SNORA16	-5.57	4.29e-08	1.45e-05	-0.25	-0.25	Body mass index;	chr13:32770965	chr13:32420390~32420516:-
LUAD	cis	rs2179367	0.632	rs9498344	ENSG00000231760.4	RP11-350J20.5	5.57	4.3e-08	1.45e-05	0.35	0.25	Dupuytren's disease;	chr6:149401053	chr6:149796151~149826294:-
LUAD	cis	rs875971	0.545	rs12671152	ENSG00000237310.1	GS1-124K5.4	5.57	4.3e-08	1.46e-05	0.31	0.25	Aortic root size;	chr7:66311140	chr7:66493706~66495474:+
LUAD	cis	rs12554020	1	rs55766809	ENSG00000227603.1	RP11-165J3.6	5.57	4.3e-08	1.46e-05	0.36	0.25	Schizophrenia;	chr9:93428436	chr9:93435332~93437121:-
LUAD	cis	rs10800713	0.954	rs6427835	ENSG00000260088.1	RP11-92G12.3	-5.57	4.3e-08	1.46e-05	-0.35	-0.25	Tandem gait;	chr1:200591725	chr1:200669507~200694250:+
LUAD	cis	rs7430456	0.81	rs6443489	ENSG00000228221.4	LINC00578	5.57	4.31e-08	1.46e-05	0.29	0.25	Breast cancer;	chr3:177737489	chr3:177441921~177752305:+
LUAD	cis	rs12908161	0.959	rs1051168	ENSG00000225151.9	GOLGA2P7	-5.57	4.31e-08	1.46e-05	-0.34	-0.25	Schizophrenia;	chr15:84657289	chr15:84199311~84230136:-
LUAD	cis	rs3762637	0.943	rs9289196	ENSG00000272758.4	RP11-299J3.8	-5.57	4.32e-08	1.46e-05	-0.34	-0.25	LDL cholesterol levels;	chr3:122549659	chr3:122416207~122443180:+
LUAD	cis	rs601999	1	rs601999	ENSG00000108785.7	HSD17B1P1	5.57	4.32e-08	1.46e-05	0.28	0.25	Parkinson's disease;	chr17:42546140	chr17:42546764~42548706:+
LUAD	cis	rs4835473	0.932	rs56277406	ENSG00000251600.4	RP11-673E1.1	-5.57	4.32e-08	1.46e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143740620	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs13143879	ENSG00000251600.4	RP11-673E1.1	-5.57	4.32e-08	1.46e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143740901	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs36086465	ENSG00000251600.4	RP11-673E1.1	-5.57	4.32e-08	1.46e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143742738	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs873430	ENSG00000251600.4	RP11-673E1.1	-5.57	4.32e-08	1.46e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143742953	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs873431	ENSG00000251600.4	RP11-673E1.1	-5.57	4.32e-08	1.46e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143743035	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs899903	ENSG00000251600.4	RP11-673E1.1	-5.57	4.32e-08	1.46e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143743551	chr4:143912331~143982454:+
LUAD	cis	rs4664293	0.605	rs890095	ENSG00000226266.5	AC009961.3	5.57	4.33e-08	1.46e-05	0.33	0.25	Monocyte percentage of white cells;	chr2:159604708	chr2:159670708~159712435:-
LUAD	cis	rs1075265	0.622	rs4671529	ENSG00000233266.1	HMGB1P31	5.57	4.33e-08	1.46e-05	0.32	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53697167	chr2:54051334~54051760:+
LUAD	cis	rs17684571	0.938	rs16888124	ENSG00000231441.1	RP11-472M19.2	5.57	4.33e-08	1.46e-05	0.33	0.25	Schizophrenia;	chr6:56700826	chr6:56844002~56864078:+
LUAD	cis	rs6687821	0.515	rs4656139	ENSG00000267734.1	RP4-604K5.3	-5.57	4.33e-08	1.46e-05	-0.3	-0.25	Yeast infection;	chr1:87059180	chr1:86932199~86934891:-
LUAD	cis	rs6504622	0.967	rs9889762	ENSG00000262879.4	RP11-156P1.3	5.57	4.33e-08	1.46e-05	0.28	0.25	Orofacial clefts;	chr17:46949000	chr17:46984045~47100323:-
LUAD	cis	rs2179367	0.881	rs2744432	ENSG00000231760.4	RP11-350J20.5	-5.57	4.33e-08	1.47e-05	-0.32	-0.25	Dupuytren's disease;	chr6:149422735	chr6:149796151~149826294:-
LUAD	cis	rs10129255	0.913	rs28861466	ENSG00000211974.3	IGHV2-70	5.57	4.33e-08	1.47e-05	0.27	0.25	Kawasaki disease;	chr14:106718572	chr14:106723574~106724093:-
LUAD	cis	rs6772849	0.662	rs12494372	ENSG00000242551.2	POU5F1P6	-5.57	4.34e-08	1.47e-05	-0.29	-0.25	Monocyte percentage of white cells;Monocyte count;	chr3:128682850	chr3:128674735~128677005:-
LUAD	cis	rs1075265	0.722	rs7596349	ENSG00000233266.1	HMGB1P31	5.57	4.34e-08	1.47e-05	0.31	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53709123	chr2:54051334~54051760:+
LUAD	cis	rs494459	0.691	rs607472	ENSG00000278376.1	RP11-158I9.8	-5.57	4.35e-08	1.47e-05	-0.26	-0.25	Height;	chr11:118809363	chr11:118791254~118793137:+
LUAD	cis	rs6095360	0.727	rs13036715	ENSG00000222365.1	SNORD12B	-5.57	4.35e-08	1.47e-05	-0.28	-0.25	Intelligence (multi-trait analysis);	chr20:49201278	chr20:49280319~49280409:+
LUAD	cis	rs6687821	0.515	rs7524526	ENSG00000267734.1	RP4-604K5.3	-5.57	4.35e-08	1.47e-05	-0.3	-0.25	Yeast infection;	chr1:87027154	chr1:86932199~86934891:-
LUAD	cis	rs12908161	0.92	rs12904605	ENSG00000225151.9	GOLGA2P7	-5.57	4.35e-08	1.47e-05	-0.34	-0.25	Schizophrenia;	chr15:84658188	chr15:84199311~84230136:-
LUAD	cis	rs867371	0.519	rs1566560	ENSG00000278603.1	RP13-608F4.5	5.57	4.36e-08	1.47e-05	0.28	0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232116	chr15:82472203~82472426:+
LUAD	cis	rs867371	0.519	rs1566559	ENSG00000278603.1	RP13-608F4.5	5.57	4.36e-08	1.47e-05	0.28	0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232120	chr15:82472203~82472426:+
LUAD	cis	rs12188164	0.686	rs72711369	ENSG00000225138.6	CTD-2228K2.7	5.57	4.36e-08	1.47e-05	0.25	0.25	Cystic fibrosis severity;	chr5:420402	chr5:473236~480884:+
LUAD	cis	rs12188164	0.686	rs72711370	ENSG00000225138.6	CTD-2228K2.7	5.57	4.36e-08	1.47e-05	0.25	0.25	Cystic fibrosis severity;	chr5:420942	chr5:473236~480884:+
LUAD	cis	rs12188164	0.714	rs11741954	ENSG00000225138.6	CTD-2228K2.7	5.57	4.36e-08	1.47e-05	0.25	0.25	Cystic fibrosis severity;	chr5:421340	chr5:473236~480884:+
LUAD	cis	rs17818399	0.533	rs13420857	ENSG00000279254.1	RP11-536C12.1	5.57	4.36e-08	1.47e-05	0.26	0.25	Height;	chr2:46570866	chr2:46668870~46670778:+
LUAD	cis	rs4908760	0.792	rs11121215	ENSG00000232912.4	RP5-1115A15.1	5.56	4.36e-08	1.47e-05	0.23	0.25	Vitiligo;	chr1:8673069	chr1:8424645~8434838:+
LUAD	cis	rs2836950	0.565	rs7279497	ENSG00000255568.3	BRWD1-AS2	5.56	4.36e-08	1.47e-05	0.24	0.25	Menarche (age at onset);	chr21:39159380	chr21:39313935~39314962:+
LUAD	cis	rs12699921	0.632	rs2691557	ENSG00000279048.1	RP11-511H23.2	-5.56	4.37e-08	1.48e-05	-0.2	-0.25	Fibrinogen levels;	chr7:17902974	chr7:17940503~17942922:+
LUAD	cis	rs2919009	0.544	rs28829929	ENSG00000271670.1	RP11-95I16.4	5.56	4.37e-08	1.48e-05	0.3	0.25	Obesity-related traits;	chr10:120881969	chr10:120879256~120880667:-
LUAD	cis	rs9309473	0.851	rs6546850	ENSG00000163016.8	ALMS1P	5.56	4.37e-08	1.48e-05	0.29	0.25	Metabolite levels;	chr2:73604020	chr2:73644919~73685576:+
LUAD	cis	rs9309473	0.898	rs6546852	ENSG00000163016.8	ALMS1P	5.56	4.37e-08	1.48e-05	0.29	0.25	Metabolite levels;	chr2:73606304	chr2:73644919~73685576:+
LUAD	cis	rs10246939	0.544	rs6957037	ENSG00000228775.6	WEE2-AS1	5.56	4.37e-08	1.48e-05	0.3	0.25	Bitter taste perception;	chr7:141865557	chr7:141704338~141738346:-
LUAD	cis	rs673078	0.607	rs2036489	ENSG00000275409.1	RP11-131L12.4	-5.56	4.38e-08	1.48e-05	-0.3	-0.25	Glucose homeostasis traits;	chr12:118364643	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs10082823	ENSG00000275409.1	RP11-131L12.4	-5.56	4.38e-08	1.48e-05	-0.3	-0.25	Glucose homeostasis traits;	chr12:118365386	chr12:118430147~118430699:+
LUAD	cis	rs875971	1	rs6963646	ENSG00000237310.1	GS1-124K5.4	-5.56	4.39e-08	1.49e-05	-0.26	-0.25	Aortic root size;	chr7:66220780	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.965	rs28682868	ENSG00000237310.1	GS1-124K5.4	-5.56	4.39e-08	1.49e-05	-0.26	-0.25	Aortic root size;	chr7:66224822	chr7:66493706~66495474:+
LUAD	cis	rs4908760	0.827	rs10864360	ENSG00000232912.4	RP5-1115A15.1	5.56	4.4e-08	1.49e-05	0.22	0.25	Vitiligo;	chr1:8664463	chr1:8424645~8434838:+
LUAD	cis	rs8103033	0.676	rs1988274	ENSG00000226025.8	LGALS17A	-5.56	4.4e-08	1.49e-05	-0.28	-0.25	Obesity-related traits;	chr19:39664258	chr19:39679374~39686373:+
LUAD	cis	rs180730	0.561	rs3099888	ENSG00000251609.2	SETP12	-5.56	4.4e-08	1.49e-05	-0.32	-0.25	Fasting plasma glucose;	chr4:120882580	chr4:120895494~120897083:-
LUAD	cis	rs7727544	0.548	rs4705938	ENSG00000233006.5	AC034220.3	5.56	4.4e-08	1.49e-05	0.22	0.25	Blood metabolite levels;	chr5:132358384	chr5:132311285~132369916:-
LUAD	cis	rs1707322	0.896	rs785512	ENSG00000234329.1	RP11-767N6.2	-5.56	4.41e-08	1.49e-05	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46068871	chr1:45651039~45651826:-
LUAD	cis	rs7208859	0.528	rs3764416	ENSG00000263531.1	RP13-753N3.1	-5.56	4.41e-08	1.49e-05	-0.45	-0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30573690	chr17:30863921~30864940:-
LUAD	cis	rs10050311	0.79	rs17012132	ENSG00000251411.1	RP11-397E7.4	-5.56	4.42e-08	1.49e-05	-0.38	-0.25	Insulin-related traits;	chr4:86860135	chr4:86913266~86914817:-
LUAD	cis	rs7712401	0.601	rs246303	ENSG00000263432.2	RN7SL689P	5.56	4.42e-08	1.49e-05	0.31	0.25	Mean platelet volume;	chr5:122916022	chr5:123022487~123022783:-
LUAD	cis	rs67180937	0.553	rs2133188	ENSG00000272750.1	RP11-378J18.8	5.56	4.42e-08	1.49e-05	0.3	0.25	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222640411	chr1:222658867~222661512:-
LUAD	cis	rs6991838	0.831	rs4394432	ENSG00000200714.1	Y_RNA	5.56	4.42e-08	1.49e-05	0.29	0.25	Intelligence (multi-trait analysis);	chr8:65560939	chr8:65592731~65592820:+
LUAD	cis	rs11603023	0.874	rs613243	ENSG00000255239.1	AP002954.6	5.56	4.42e-08	1.49e-05	0.28	0.25	Cholesterol, total;	chr11:118643304	chr11:118688039~118690600:-
LUAD	cis	rs7618501	0.633	rs6446193	ENSG00000234667.1	ACTBP13	5.56	4.42e-08	1.49e-05	0.27	0.25	Intelligence (multi-trait analysis);	chr3:50022325	chr3:49873347~49877980:-
LUAD	cis	rs66887589	0.776	rs10518337	ENSG00000248280.1	RP11-33B1.2	-5.56	4.42e-08	1.49e-05	-0.27	-0.25	Diastolic blood pressure;	chr4:119653719	chr4:119440561~119450157:-
LUAD	cis	rs12701220	0.522	rs1881116	ENSG00000229043.2	AC091729.9	-5.56	4.43e-08	1.5e-05	-0.29	-0.25	Bronchopulmonary dysplasia;	chr7:1014322	chr7:1160374~1165267:+
LUAD	cis	rs8098244	0.557	rs8089282	ENSG00000264745.1	TTC39C-AS1	5.56	4.44e-08	1.5e-05	0.26	0.25	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23708402	chr18:23994213~24015339:-
LUAD	cis	rs643506	0.845	rs762550	ENSG00000230911.1	PPIHP1	-5.56	4.44e-08	1.5e-05	-0.31	-0.25	Breast cancer;	chr11:111912376	chr11:112029858~112030367:-
LUAD	cis	rs2179367	0.613	rs12207047	ENSG00000231760.4	RP11-350J20.5	5.56	4.44e-08	1.5e-05	0.34	0.25	Dupuytren's disease;	chr6:149423496	chr6:149796151~149826294:-
LUAD	cis	rs7712401	0.601	rs30048	ENSG00000263432.2	RN7SL689P	5.56	4.44e-08	1.5e-05	0.3	0.25	Mean platelet volume;	chr5:122934698	chr5:123022487~123022783:-
LUAD	cis	rs13217239	0.646	rs62401067	ENSG00000241549.7	GUSBP2	5.56	4.44e-08	1.5e-05	0.27	0.25	Schizophrenia;	chr6:27050322	chr6:26871484~26956554:-
LUAD	cis	rs7615952	0.688	rs12485622	ENSG00000171084.14	FAM86JP	5.56	4.44e-08	1.5e-05	0.35	0.25	Blood pressure (smoking interaction);	chr3:125991896	chr3:125916620~125930024:+
LUAD	cis	rs6907340	0.517	rs9465531	ENSG00000228412.5	RP4-625H18.2	5.56	4.44e-08	1.5e-05	0.31	0.25	Endometriosis;	chr6:19798418	chr6:19802164~19804752:-
LUAD	cis	rs12468226	0.606	rs79092351	ENSG00000226261.1	AC064836.3	5.56	4.45e-08	1.5e-05	0.37	0.25	Urate levels;	chr2:202204388	chr2:202336024~202336727:-
LUAD	cis	rs11105298	0.891	rs10858890	ENSG00000258302.2	RP11-981P6.1	5.56	4.45e-08	1.5e-05	0.31	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89513389	chr12:89561129~89594878:+
LUAD	cis	rs1707322	1	rs4660906	ENSG00000234329.1	RP11-767N6.2	5.56	4.45e-08	1.5e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46005188	chr1:45651039~45651826:-
LUAD	cis	rs7826238	0.517	rs35144760	ENSG00000253893.2	FAM85B	5.56	4.45e-08	1.5e-05	0.32	0.25	Systolic blood pressure;	chr8:8504213	chr8:8167819~8226614:-
LUAD	cis	rs35740288	0.787	rs2008916	ENSG00000202081.1	RNU6-1280P	5.56	4.46e-08	1.5e-05	0.31	0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85677959	chr15:85651522~85651628:-
LUAD	cis	rs72634501	0.716	rs67637163	ENSG00000228060.1	RP11-69E11.8	-5.56	4.46e-08	1.5e-05	-0.26	-0.25	HDL cholesterol;	chr1:39110949	chr1:39565160~39573203:+
LUAD	cis	rs507080	0.733	rs517445	ENSG00000278376.1	RP11-158I9.8	-5.56	4.46e-08	1.51e-05	-0.27	-0.25	Serum metabolite levels;	chr11:118702826	chr11:118791254~118793137:+
LUAD	cis	rs9952991	0.941	rs45450798	ENSG00000260302.1	RP11-973H7.1	5.56	4.46e-08	1.51e-05	0.45	0.25	Inflammatory skin disease;	chr18:12792941	chr18:12774651~12775923:-
LUAD	cis	rs9952991	0.941	rs60735058	ENSG00000260302.1	RP11-973H7.1	5.56	4.46e-08	1.51e-05	0.45	0.25	Inflammatory skin disease;	chr18:12795471	chr18:12774651~12775923:-
LUAD	cis	rs193541	0.632	rs4835896	ENSG00000263432.2	RN7SL689P	-5.56	4.46e-08	1.51e-05	-0.33	-0.25	Glucose homeostasis traits;	chr5:122785545	chr5:123022487~123022783:-
LUAD	cis	rs67311347	0.955	rs73080163	ENSG00000223797.4	ENTPD3-AS1	5.56	4.47e-08	1.51e-05	0.27	0.25	Renal cell carcinoma;	chr3:40491570	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs73080165	ENSG00000223797.4	ENTPD3-AS1	5.56	4.47e-08	1.51e-05	0.27	0.25	Renal cell carcinoma;	chr3:40491571	chr3:40313802~40453329:-
LUAD	cis	rs1707322	1	rs12124847	ENSG00000234329.1	RP11-767N6.2	5.56	4.48e-08	1.51e-05	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45915178	chr1:45651039~45651826:-
LUAD	cis	rs2836950	0.545	rs2297256	ENSG00000255568.3	BRWD1-AS2	-5.56	4.48e-08	1.51e-05	-0.23	-0.25	Menarche (age at onset);	chr21:39186495	chr21:39313935~39314962:+
LUAD	cis	rs10129255	0.957	rs11846893	ENSG00000211972.2	IGHV3-66	5.56	4.49e-08	1.51e-05	0.21	0.25	Kawasaki disease;	chr14:106779068	chr14:106675017~106675544:-
LUAD	cis	rs2404602	0.692	rs2120108	ENSG00000259422.1	RP11-593F23.1	-5.56	4.49e-08	1.51e-05	-0.28	-0.25	Blood metabolite levels;	chr15:76577588	chr15:76174891~76181486:-
LUAD	cis	rs673078	0.66	rs17619932	ENSG00000275409.1	RP11-131L12.4	-5.56	4.49e-08	1.51e-05	-0.32	-0.25	Glucose homeostasis traits;	chr12:118352228	chr12:118430147~118430699:+
LUAD	cis	rs4664293	0.585	rs35081473	ENSG00000226266.5	AC009961.3	5.56	4.49e-08	1.51e-05	0.33	0.25	Monocyte percentage of white cells;	chr2:159679970	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.605	rs7556888	ENSG00000226266.5	AC009961.3	5.56	4.49e-08	1.51e-05	0.33	0.25	Monocyte percentage of white cells;	chr2:159683750	chr2:159670708~159712435:-
LUAD	cis	rs9847710	0.869	rs2564920	ENSG00000242142.1	SERBP1P3	5.56	4.49e-08	1.52e-05	0.27	0.25	Ulcerative colitis;	chr3:52999041	chr3:53064283~53065091:-
LUAD	cis	rs9847710	0.838	rs12635298	ENSG00000242142.1	SERBP1P3	5.56	4.49e-08	1.52e-05	0.27	0.25	Ulcerative colitis;	chr3:52999780	chr3:53064283~53065091:-
LUAD	cis	rs7618915	1	rs7618915	ENSG00000243224.1	RP5-1157M23.2	-5.56	4.5e-08	1.52e-05	-0.26	-0.25	Bipolar disorder;	chr3:52245578	chr3:52239258~52241097:+
LUAD	cis	rs12701220	0.655	rs7784403	ENSG00000229043.2	AC091729.9	-5.56	4.5e-08	1.52e-05	-0.3	-0.25	Bronchopulmonary dysplasia;	chr7:1113441	chr7:1160374~1165267:+
LUAD	cis	rs17684571	0.7	rs34805046	ENSG00000231441.1	RP11-472M19.2	5.56	4.5e-08	1.52e-05	0.37	0.25	Schizophrenia;	chr6:56815813	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.765	rs34425815	ENSG00000231441.1	RP11-472M19.2	5.56	4.5e-08	1.52e-05	0.37	0.25	Schizophrenia;	chr6:56816040	chr6:56844002~56864078:+
LUAD	cis	rs4835473	0.932	rs6813011	ENSG00000251600.4	RP11-673E1.1	5.56	4.5e-08	1.52e-05	0.3	0.25	Immature fraction of reticulocytes;	chr4:143914496	chr4:143912331~143982454:+
LUAD	cis	rs11105298	0.891	rs10858889	ENSG00000258302.2	RP11-981P6.1	5.56	4.51e-08	1.52e-05	0.31	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89508827	chr12:89561129~89594878:+
LUAD	cis	rs2880765	0.835	rs12324277	ENSG00000259295.5	CSPG4P12	5.56	4.51e-08	1.52e-05	0.28	0.25	Coronary artery disease;	chr15:85498504	chr15:85191438~85213905:+
LUAD	cis	rs600231	0.665	rs2105608	ENSG00000245532.5	NEAT1	5.56	4.51e-08	1.52e-05	0.19	0.25	Bone mineral density;	chr11:65461147	chr11:65422774~65445540:+
LUAD	cis	rs2070074	0.591	rs41274863	ENSG00000230074.1	RP11-195F19.9	-5.56	4.51e-08	1.52e-05	-0.65	-0.25	CTACK levels;	chr9:34638348	chr9:34665665~34681298:+
LUAD	cis	rs853679	0.599	rs149990	ENSG00000204709.4	LINC01556	5.56	4.52e-08	1.52e-05	0.43	0.25	Depression;	chr6:28030480	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.599	rs149943	ENSG00000204709.4	LINC01556	5.56	4.52e-08	1.52e-05	0.43	0.25	Depression;	chr6:28034610	chr6:28943877~28944537:+
LUAD	cis	rs2919009	0.598	rs2420896	ENSG00000271670.1	RP11-95I16.4	5.56	4.52e-08	1.53e-05	0.31	0.25	Obesity-related traits;	chr10:120936893	chr10:120879256~120880667:-
LUAD	cis	rs2919009	0.581	rs2420897	ENSG00000271670.1	RP11-95I16.4	5.56	4.52e-08	1.53e-05	0.31	0.25	Obesity-related traits;	chr10:120936918	chr10:120879256~120880667:-
LUAD	cis	rs2919009	0.62	rs4437952	ENSG00000271670.1	RP11-95I16.4	5.56	4.52e-08	1.53e-05	0.31	0.25	Obesity-related traits;	chr10:120937138	chr10:120879256~120880667:-
LUAD	cis	rs2919009	0.581	rs2118962	ENSG00000271670.1	RP11-95I16.4	5.56	4.52e-08	1.53e-05	0.31	0.25	Obesity-related traits;	chr10:120937721	chr10:120879256~120880667:-
LUAD	cis	rs997295	0.57	rs60066681	ENSG00000270964.1	RP11-502I4.3	-5.56	4.53e-08	1.53e-05	-0.26	-0.25	Motion sickness;	chr15:67515738	chr15:67541072~67542604:-
LUAD	cis	rs7615952	0.599	rs2333408	ENSG00000171084.14	FAM86JP	5.56	4.53e-08	1.53e-05	0.34	0.25	Blood pressure (smoking interaction);	chr3:126013255	chr3:125916620~125930024:+
LUAD	cis	rs35538253	0.522	rs10492823	ENSG00000260886.1	TAT-AS1	5.56	4.53e-08	1.53e-05	0.42	0.25	Post bronchodilator FEV1;	chr16:71984961	chr16:71565789~71578187:+
LUAD	cis	rs9595908	0.709	rs17594677	ENSG00000212293.1	SNORA16	5.56	4.54e-08	1.53e-05	0.26	0.25	Body mass index;	chr13:32734875	chr13:32420390~32420516:-
LUAD	cis	rs2439831	0.85	rs16965120	ENSG00000205771.5	CATSPER2P1	-5.56	4.54e-08	1.53e-05	-0.46	-0.25	Lung cancer in ever smokers;	chr15:43808144	chr15:43726918~43747094:-
LUAD	cis	rs948562	0.744	rs11229474	ENSG00000280010.1	AP001350.4	5.56	4.54e-08	1.53e-05	0.37	0.25	Lymphoma;	chr11:58459729	chr11:58627435~58628528:+
LUAD	cis	rs4908768	0.52	rs11121224	ENSG00000232912.4	RP5-1115A15.1	5.56	4.54e-08	1.53e-05	0.23	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8713456	chr1:8424645~8434838:+
LUAD	cis	rs496547	0.686	rs477014	ENSG00000255239.1	AP002954.6	5.56	4.54e-08	1.53e-05	0.3	0.25	Hip minimal joint space width;	chr11:118808277	chr11:118688039~118690600:-
LUAD	cis	rs4722166	0.695	rs7787893	ENSG00000179428.2	AC073072.5	-5.56	4.55e-08	1.53e-05	-0.29	-0.25	Lung cancer;	chr7:22734818	chr7:22725395~22727620:-
LUAD	cis	rs172166	0.516	rs1225710	ENSG00000219392.1	RP1-265C24.5	5.56	4.55e-08	1.54e-05	0.3	0.25	Cardiac Troponin-T levels;	chr6:28132862	chr6:28115628~28116551:+
LUAD	cis	rs293748	0.771	rs181755	ENSG00000250155.1	CTD-2353F22.1	-5.56	4.56e-08	1.54e-05	-0.34	-0.25	Obesity-related traits;	chr5:36839162	chr5:36666214~36725195:-
LUAD	cis	rs17214007	0.877	rs4541094	ENSG00000263335.1	AF001548.5	-5.56	4.56e-08	1.54e-05	-0.35	-0.25	Cognitive function;	chr16:15776878	chr16:15726674~15732993:+
LUAD	cis	rs13631	0.728	rs7466635	ENSG00000268996.3	MAN1B1-AS1	-5.56	4.56e-08	1.54e-05	-0.29	-0.25	Cerebrospinal fluid biomarker levels;	chr9:137085965	chr9:137084946~137086817:-
LUAD	cis	rs11051970	0.559	rs4931621	ENSG00000274964.1	RP11-817I4.1	-5.56	4.56e-08	1.54e-05	-0.31	-0.25	Response to tocilizumab in rheumatoid arthritis;	chr12:32333569	chr12:32339368~32340724:+
LUAD	cis	rs11051970	0.559	rs3816819	ENSG00000274964.1	RP11-817I4.1	-5.56	4.56e-08	1.54e-05	-0.31	-0.25	Response to tocilizumab in rheumatoid arthritis;	chr12:32334123	chr12:32339368~32340724:+
LUAD	cis	rs11051970	0.559	rs2291421	ENSG00000274964.1	RP11-817I4.1	-5.56	4.56e-08	1.54e-05	-0.31	-0.25	Response to tocilizumab in rheumatoid arthritis;	chr12:32334173	chr12:32339368~32340724:+
LUAD	cis	rs4908768	0.539	rs7547411	ENSG00000232912.4	RP5-1115A15.1	5.56	4.56e-08	1.54e-05	0.23	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8578086	chr1:8424645~8434838:+
LUAD	cis	rs987724	0.519	rs9818684	ENSG00000240875.4	LINC00886	5.56	4.57e-08	1.54e-05	0.27	0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156806431	chr3:156747346~156817062:-
LUAD	cis	rs4835473	0.932	rs4835278	ENSG00000251600.4	RP11-673E1.1	-5.56	4.57e-08	1.54e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143788433	chr4:143912331~143982454:+
LUAD	cis	rs673078	0.66	rs61946063	ENSG00000275409.1	RP11-131L12.4	-5.56	4.58e-08	1.54e-05	-0.31	-0.25	Glucose homeostasis traits;	chr12:118294448	chr12:118430147~118430699:+
LUAD	cis	rs4308124	0.679	rs7600458	ENSG00000227992.1	AC108463.2	-5.56	4.58e-08	1.54e-05	-0.33	-0.25	Vitiligo;	chr2:111206013	chr2:111203964~111206215:-
LUAD	cis	rs4308124	0.708	rs56693625	ENSG00000227992.1	AC108463.2	-5.56	4.58e-08	1.54e-05	-0.33	-0.25	Vitiligo;	chr2:111207578	chr2:111203964~111206215:-
LUAD	cis	rs4308124	0.708	rs61358692	ENSG00000227992.1	AC108463.2	-5.56	4.58e-08	1.54e-05	-0.33	-0.25	Vitiligo;	chr2:111207582	chr2:111203964~111206215:-
LUAD	cis	rs2404602	0.716	rs2404737	ENSG00000259422.1	RP11-593F23.1	5.56	4.58e-08	1.54e-05	0.28	0.25	Blood metabolite levels;	chr15:76579876	chr15:76174891~76181486:-
LUAD	cis	rs4604732	0.578	rs112449432	ENSG00000227135.1	GCSAML-AS1	-5.56	4.58e-08	1.54e-05	-0.39	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247460878	chr1:247524679~247526752:-
LUAD	cis	rs1061377	0.965	rs12511857	ENSG00000249685.1	RP11-360F5.3	5.56	4.58e-08	1.54e-05	0.31	0.25	Uric acid levels;	chr4:39143252	chr4:39133913~39135608:+
LUAD	cis	rs4908760	0.759	rs6577514	ENSG00000232912.4	RP5-1115A15.1	5.56	4.59e-08	1.54e-05	0.22	0.25	Vitiligo;	chr1:8652684	chr1:8424645~8434838:+
LUAD	cis	rs12931792	0.712	rs56399904	ENSG00000183604.13	SMG1P5	5.56	4.59e-08	1.55e-05	0.25	0.25	Tonsillectomy;	chr16:30154862	chr16:30267553~30335374:-
LUAD	cis	rs17684571	0.7	rs1610156	ENSG00000231441.1	RP11-472M19.2	5.56	4.59e-08	1.55e-05	0.37	0.25	Schizophrenia;	chr6:56844274	chr6:56844002~56864078:+
LUAD	cis	rs755249	0.501	rs661316	ENSG00000228060.1	RP11-69E11.8	-5.56	4.59e-08	1.55e-05	-0.23	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39165625	chr1:39565160~39573203:+
LUAD	cis	rs74233809	1	rs11191515	ENSG00000213277.3	MARCKSL1P1	5.56	4.59e-08	1.55e-05	0.44	0.25	Birth weight;	chr10:103016770	chr10:103175554~103176094:+
LUAD	cis	rs6687821	0.515	rs4656138	ENSG00000267734.1	RP4-604K5.3	-5.56	4.59e-08	1.55e-05	-0.3	-0.25	Yeast infection;	chr1:87045494	chr1:86932199~86934891:-
LUAD	cis	rs897984	0.762	rs2054213	ENSG00000260911.2	RP11-196G11.2	-5.56	4.6e-08	1.55e-05	-0.22	-0.25	Dementia with Lewy bodies;	chr16:30960489	chr16:31043150~31049868:+
LUAD	cis	rs896854	0.625	rs4735336	ENSG00000253528.2	RP11-347C18.4	-5.56	4.6e-08	1.55e-05	-0.23	-0.25	Type 2 diabetes;	chr8:94961182	chr8:94974573~94974853:-
LUAD	cis	rs17772222	0.917	rs10143767	ENSG00000258983.2	RP11-507K2.2	5.55	4.61e-08	1.55e-05	0.29	0.25	Coronary artery calcification;	chr14:88514867	chr14:88499334~88515502:+
LUAD	cis	rs1075265	0.783	rs6708095	ENSG00000233266.1	HMGB1P31	5.55	4.61e-08	1.55e-05	0.31	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53710365	chr2:54051334~54051760:+
LUAD	cis	rs71403859	0.57	rs77809998	ENSG00000260886.1	TAT-AS1	5.55	4.61e-08	1.55e-05	0.44	0.25	Post bronchodilator FEV1;	chr16:71396784	chr16:71565789~71578187:+
LUAD	cis	rs1707322	0.928	rs7527244	ENSG00000234329.1	RP11-767N6.2	5.55	4.61e-08	1.55e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45903100	chr1:45651039~45651826:-
LUAD	cis	rs1075265	0.901	rs1118618	ENSG00000233266.1	HMGB1P31	5.55	4.61e-08	1.55e-05	0.32	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54099333	chr2:54051334~54051760:+
LUAD	cis	rs7170668	0.597	rs17493093	ENSG00000259134.4	LINC00924	5.55	4.61e-08	1.55e-05	0.3	0.25	Motion sickness;	chr15:95506447	chr15:95433095~95507847:+
LUAD	cis	rs9309473	0.615	rs62149774	ENSG00000163016.8	ALMS1P	5.55	4.61e-08	1.55e-05	0.37	0.25	Metabolite levels;	chr2:73560525	chr2:73644919~73685576:+
LUAD	cis	rs80028505	1	rs2237096	ENSG00000271304.1	DPRXP2	5.55	4.61e-08	1.55e-05	0.49	0.25	Foot ulcer in diabetes and neuropathy;	chr6:36040225	chr6:35989515~35990436:-
LUAD	cis	rs12699921	0.632	rs2103144	ENSG00000279048.1	RP11-511H23.2	-5.55	4.62e-08	1.55e-05	-0.2	-0.25	Fibrinogen levels;	chr7:17900529	chr7:17940503~17942922:+
LUAD	cis	rs2790457	0.958	rs2772432	ENSG00000254635.4	WAC-AS1	-5.55	4.62e-08	1.56e-05	-0.27	-0.25	Multiple myeloma;	chr10:28605366	chr10:28522652~28532743:-
LUAD	cis	rs8031584	0.679	rs34017474	ENSG00000260382.1	RP11-540B6.2	5.55	4.62e-08	1.56e-05	0.28	0.25	Huntington's disease progression;	chr15:30938408	chr15:30882267~30883231:-
LUAD	cis	rs600231	0.598	rs2508712	ENSG00000245532.5	NEAT1	5.55	4.62e-08	1.56e-05	0.19	0.25	Bone mineral density;	chr11:65464790	chr11:65422774~65445540:+
LUAD	cis	rs720064	0.655	rs12964862	ENSG00000264745.1	TTC39C-AS1	5.55	4.62e-08	1.56e-05	0.26	0.25	Strep throat;	chr18:23700711	chr18:23994213~24015339:-
LUAD	cis	rs8098244	0.536	rs12955616	ENSG00000264745.1	TTC39C-AS1	5.55	4.62e-08	1.56e-05	0.26	0.25	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23701097	chr18:23994213~24015339:-
LUAD	cis	rs1823913	0.614	rs1947457	ENSG00000227542.1	AC092614.2	5.55	4.64e-08	1.56e-05	0.53	0.25	Obesity-related traits;	chr2:191298970	chr2:191229165~191246172:-
LUAD	cis	rs11971779	0.648	rs6947309	ENSG00000273391.1	RP11-634H22.1	5.55	4.64e-08	1.56e-05	0.25	0.25	Diisocyanate-induced asthma;	chr7:139351084	chr7:139359032~139359566:-
LUAD	cis	rs74233809	1	rs11191531	ENSG00000213277.3	MARCKSL1P1	5.55	4.64e-08	1.56e-05	0.42	0.25	Birth weight;	chr10:103047141	chr10:103175554~103176094:+
LUAD	cis	rs7182621	0.509	rs12917012	ENSG00000182397.13	DNM1P46	5.55	4.65e-08	1.56e-05	0.28	0.25	Colonoscopy-negative controls vs population controls;	chr15:99868778	chr15:99790156~99806927:-
LUAD	cis	rs516805	0.706	rs1267943	ENSG00000279453.1	RP3-425C14.4	-5.55	4.65e-08	1.56e-05	-0.32	-0.25	Lymphocyte counts;	chr6:122462498	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.706	rs541551	ENSG00000279453.1	RP3-425C14.4	-5.55	4.65e-08	1.56e-05	-0.32	-0.25	Lymphocyte counts;	chr6:122462736	chr6:122436789~122439223:-
LUAD	cis	rs74233809	1	rs943037	ENSG00000213277.3	MARCKSL1P1	5.55	4.65e-08	1.56e-05	0.43	0.25	Birth weight;	chr10:103076162	chr10:103175554~103176094:+
LUAD	cis	rs1707322	1	rs2458400	ENSG00000234329.1	RP11-767N6.2	-5.55	4.65e-08	1.56e-05	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46065126	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs9429186	ENSG00000234329.1	RP11-767N6.2	-5.55	4.65e-08	1.56e-05	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074015	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs785506	ENSG00000234329.1	RP11-767N6.2	-5.55	4.65e-08	1.56e-05	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074980	chr1:45651039~45651826:-
LUAD	cis	rs2439831	0.85	rs28858500	ENSG00000205771.5	CATSPER2P1	-5.55	4.66e-08	1.57e-05	-0.51	-0.25	Lung cancer in ever smokers;	chr15:43864744	chr15:43726918~43747094:-
LUAD	cis	rs10214930	0.752	rs1015265	ENSG00000235574.1	AC073150.6	-5.55	4.66e-08	1.57e-05	-0.33	-0.25	Hypospadias;	chr7:27599990	chr7:27491682~27492765:-
LUAD	cis	rs2921073	0.51	rs2976945	ENSG00000253893.2	FAM85B	-5.55	4.66e-08	1.57e-05	-0.31	-0.25	Parkinson's disease;	chr8:8413361	chr8:8167819~8226614:-
LUAD	cis	rs4835473	0.864	rs67749935	ENSG00000251600.4	RP11-673E1.1	-5.55	4.66e-08	1.57e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143739852	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs66934100	ENSG00000251600.4	RP11-673E1.1	-5.55	4.66e-08	1.57e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143739872	chr4:143912331~143982454:+
LUAD	cis	rs1154275	0.537	rs6793183	ENSG00000242770.2	RP11-180K7.1	5.55	4.66e-08	1.57e-05	0.25	0.25	Takotsubo syndrome;	chr3:112798908	chr3:112802478~112812819:+
LUAD	cis	rs17507216	0.958	rs72751643	ENSG00000255769.6	GOLGA2P10	-5.55	4.67e-08	1.57e-05	-0.31	-0.25	Excessive daytime sleepiness;	chr15:82559444	chr15:82472993~82513950:-
LUAD	cis	rs11105306	1	rs11105306	ENSG00000258302.2	RP11-981P6.1	5.55	4.67e-08	1.57e-05	0.31	0.25	NT-proBNP levels in acute coronary syndrome;	chr12:89503611	chr12:89561129~89594878:+
LUAD	cis	rs507080	0.733	rs611733	ENSG00000278376.1	RP11-158I9.8	-5.55	4.67e-08	1.57e-05	-0.27	-0.25	Serum metabolite levels;	chr11:118702051	chr11:118791254~118793137:+
LUAD	cis	rs507080	0.733	rs552079	ENSG00000278376.1	RP11-158I9.8	-5.55	4.67e-08	1.57e-05	-0.27	-0.25	Serum metabolite levels;	chr11:118702313	chr11:118791254~118793137:+
LUAD	cis	rs507080	0.733	rs673547	ENSG00000278376.1	RP11-158I9.8	-5.55	4.67e-08	1.57e-05	-0.27	-0.25	Serum metabolite levels;	chr11:118702630	chr11:118791254~118793137:+
LUAD	cis	rs2179367	0.613	rs12207261	ENSG00000231760.4	RP11-350J20.5	5.55	4.68e-08	1.57e-05	0.34	0.25	Dupuytren's disease;	chr6:149423722	chr6:149796151~149826294:-
LUAD	cis	rs867371	0.929	rs7176075	ENSG00000259429.4	UBE2Q2P2	-5.55	4.68e-08	1.57e-05	-0.21	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82178998	chr15:82355142~82420075:+
LUAD	cis	rs8180040	0.701	rs7617689	ENSG00000271161.1	BOLA2P2	-5.55	4.68e-08	1.58e-05	-0.23	-0.25	Colorectal cancer;	chr3:46954952	chr3:47499841~47500407:+
LUAD	cis	rs7927592	0.83	rs10896339	ENSG00000212093.1	AP000807.1	5.55	4.68e-08	1.58e-05	0.27	0.25	Total body bone mineral density;	chr11:68535378	chr11:68506083~68506166:-
LUAD	cis	rs7804306	0.655	rs34746652	ENSG00000233264.2	AC006042.8	5.55	4.69e-08	1.58e-05	0.43	0.25	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8012957	chr7:7980312~7982228:+
LUAD	cis	rs1707322	1	rs785465	ENSG00000234329.1	RP11-767N6.2	5.55	4.69e-08	1.58e-05	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46056905	chr1:45651039~45651826:-
LUAD	cis	rs10214930	0.697	rs6974387	ENSG00000235574.1	AC073150.6	-5.55	4.69e-08	1.58e-05	-0.3	-0.25	Hypospadias;	chr7:27626788	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs7806812	ENSG00000235574.1	AC073150.6	-5.55	4.69e-08	1.58e-05	-0.3	-0.25	Hypospadias;	chr7:27626960	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.697	rs12667610	ENSG00000235574.1	AC073150.6	-5.55	4.69e-08	1.58e-05	-0.3	-0.25	Hypospadias;	chr7:27627866	chr7:27491682~27492765:-
LUAD	cis	rs6546847	0.531	rs2567603	ENSG00000163016.8	ALMS1P	5.55	4.7e-08	1.58e-05	0.37	0.25	Urinary metabolites (H-NMR features);	chr2:73758998	chr2:73644919~73685576:+
LUAD	cis	rs74233809	1	rs75970938	ENSG00000213277.3	MARCKSL1P1	5.55	4.7e-08	1.58e-05	0.44	0.25	Birth weight;	chr10:103033891	chr10:103175554~103176094:+
LUAD	cis	rs74233809	1	rs79668541	ENSG00000213277.3	MARCKSL1P1	5.55	4.7e-08	1.58e-05	0.44	0.25	Birth weight;	chr10:103034147	chr10:103175554~103176094:+
LUAD	cis	rs7017914	0.652	rs2035929	ENSG00000223220.1	Y_RNA	-5.55	4.7e-08	1.58e-05	-0.28	-0.25	Bone mineral density;	chr8:71001137	chr8:70780914~70781008:-
LUAD	cis	rs755249	0.762	rs1775654	ENSG00000228060.1	RP11-69E11.8	-5.55	4.7e-08	1.58e-05	-0.22	-0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39484408	chr1:39565160~39573203:+
LUAD	cis	rs516805	0.597	rs666046	ENSG00000279453.1	RP3-425C14.4	-5.55	4.71e-08	1.58e-05	-0.33	-0.25	Lymphocyte counts;	chr6:122290427	chr6:122436789~122439223:-
LUAD	cis	rs7617773	0.817	rs34225441	ENSG00000228638.1	FCF1P2	-5.55	4.71e-08	1.58e-05	-0.3	-0.25	Coronary artery disease;	chr3:48267401	chr3:48290793~48291375:-
LUAD	cis	rs4835473	0.9	rs56084616	ENSG00000251600.4	RP11-673E1.1	-5.55	4.72e-08	1.58e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143746697	chr4:143912331~143982454:+
LUAD	cis	rs35740288	0.822	rs2306225	ENSG00000202081.1	RNU6-1280P	5.55	4.72e-08	1.59e-05	0.31	0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85684721	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.822	rs11638720	ENSG00000202081.1	RNU6-1280P	5.55	4.72e-08	1.59e-05	0.31	0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85686042	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.822	rs1961601	ENSG00000202081.1	RNU6-1280P	5.55	4.72e-08	1.59e-05	0.31	0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85686375	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.822	rs2016517	ENSG00000202081.1	RNU6-1280P	5.55	4.72e-08	1.59e-05	0.31	0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85686387	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.787	rs727379	ENSG00000202081.1	RNU6-1280P	5.55	4.72e-08	1.59e-05	0.31	0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85686659	chr15:85651522~85651628:-
LUAD	cis	rs4713118	0.513	rs149959	ENSG00000204709.4	LINC01556	5.55	4.72e-08	1.59e-05	0.31	0.25	Parkinson's disease;	chr6:28046076	chr6:28943877~28944537:+
LUAD	cis	rs2070074	0.591	rs41274865	ENSG00000230074.1	RP11-195F19.9	-5.55	4.72e-08	1.59e-05	-0.65	-0.25	CTACK levels;	chr9:34647805	chr9:34665665~34681298:+
LUAD	cis	rs2070074	0.591	rs2277202	ENSG00000230074.1	RP11-195F19.9	-5.55	4.72e-08	1.59e-05	-0.65	-0.25	CTACK levels;	chr9:34648023	chr9:34665665~34681298:+
LUAD	cis	rs2070074	0.591	rs41274867	ENSG00000230074.1	RP11-195F19.9	-5.55	4.72e-08	1.59e-05	-0.65	-0.25	CTACK levels;	chr9:34648091	chr9:34665665~34681298:+
LUAD	cis	rs896854	0.654	rs6982393	ENSG00000253528.2	RP11-347C18.4	5.55	4.72e-08	1.59e-05	0.24	0.25	Type 2 diabetes;	chr8:94968480	chr8:94974573~94974853:-
LUAD	cis	rs3747113	0.954	rs2298378	ENSG00000128262.7	POM121L9P	-5.55	4.72e-08	1.59e-05	-0.26	-0.25	Gut microbiome composition (summer);	chr22:24323637	chr22:24251828~24265525:+
LUAD	cis	rs1345301	0.587	rs10186746	ENSG00000234389.1	AC007278.3	-5.55	4.73e-08	1.59e-05	-0.23	-0.25	Waist circumference;	chr2:102249917	chr2:102438713~102440475:+
LUAD	cis	rs17507216	0.591	rs7163848	ENSG00000255769.6	GOLGA2P10	-5.55	4.73e-08	1.59e-05	-0.32	-0.25	Excessive daytime sleepiness;	chr15:82729563	chr15:82472993~82513950:-
LUAD	cis	rs7044106	0.708	rs2416760	ENSG00000238181.2	AHCYP2	-5.55	4.73e-08	1.59e-05	-0.31	-0.25	Hip circumference adjusted for BMI;	chr9:120612361	chr9:120720673~120721972:+
LUAD	cis	rs9595908	0.785	rs9596109	ENSG00000212293.1	SNORA16	5.55	4.74e-08	1.59e-05	0.26	0.25	Body mass index;	chr13:32712611	chr13:32420390~32420516:-
LUAD	cis	rs4835473	0.808	rs2060652	ENSG00000251600.4	RP11-673E1.1	-5.55	4.74e-08	1.59e-05	-0.3	-0.25	Immature fraction of reticulocytes;	chr4:143739129	chr4:143912331~143982454:+
LUAD	cis	rs1075265	0.749	rs2692518	ENSG00000233266.1	HMGB1P31	5.55	4.74e-08	1.59e-05	0.31	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53804746	chr2:54051334~54051760:+
LUAD	cis	rs9287719	0.601	rs62128635	ENSG00000243819.4	RN7SL832P	5.55	4.75e-08	1.59e-05	0.27	0.25	Prostate cancer;	chr2:10585208	chr2:10690344~10692099:+
LUAD	cis	rs10129255	0.5	rs10143242	ENSG00000211967.3	IGHV3-53	-5.55	4.75e-08	1.6e-05	-0.17	-0.25	Kawasaki disease;	chr14:106681814	chr14:106592676~106593347:-
LUAD	cis	rs9926296	0.715	rs467035	ENSG00000260259.1	RP11-368I7.4	-5.55	4.75e-08	1.6e-05	-0.24	-0.25	Vitiligo;	chr16:89673877	chr16:89682620~89686569:-
LUAD	cis	rs763567	0.626	rs1234230	ENSG00000271811.1	RP1-79C4.4	-5.55	4.75e-08	1.6e-05	-0.29	-0.25	Tonsillectomy;	chr1:170602702	chr1:170667381~170669425:+
LUAD	cis	rs3096299	0.606	rs4785674	ENSG00000274627.1	RP11-104N10.2	5.55	4.75e-08	1.6e-05	0.26	0.25	Multiple myeloma (IgH translocation);	chr16:89470205	chr16:89516797~89522217:+
LUAD	cis	rs2919009	0.581	rs56118695	ENSG00000271670.1	RP11-95I16.4	5.55	4.76e-08	1.6e-05	0.31	0.25	Obesity-related traits;	chr10:120938383	chr10:120879256~120880667:-
LUAD	cis	rs1876905	0.68	rs373526	ENSG00000272356.1	RP5-1112D6.8	5.55	4.76e-08	1.6e-05	0.26	0.25	Mean corpuscular hemoglobin;	chr6:111190261	chr6:111309203~111313517:+
LUAD	cis	rs1707322	1	rs785486	ENSG00000234329.1	RP11-767N6.2	-5.55	4.76e-08	1.6e-05	-0.25	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46109476	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.865	rs785501	ENSG00000234329.1	RP11-767N6.2	-5.55	4.76e-08	1.6e-05	-0.25	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46113939	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs785504	ENSG00000234329.1	RP11-767N6.2	-5.55	4.76e-08	1.6e-05	-0.25	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46130024	chr1:45651039~45651826:-
LUAD	cis	rs2404602	0.716	rs1125932	ENSG00000259422.1	RP11-593F23.1	5.55	4.76e-08	1.6e-05	0.28	0.25	Blood metabolite levels;	chr15:76528199	chr15:76174891~76181486:-
LUAD	cis	rs10027350	0.757	rs4459977	ENSG00000281501.1	SEPSECS-AS1	5.55	4.77e-08	1.6e-05	0.31	0.25	Childhood ear infection;	chr4:25183937	chr4:25160641~25201440:+
LUAD	cis	rs2404602	0.735	rs4886805	ENSG00000259422.1	RP11-593F23.1	5.55	4.77e-08	1.6e-05	0.32	0.25	Blood metabolite levels;	chr15:76447043	chr15:76174891~76181486:-
LUAD	cis	rs9652601	0.691	rs12928726	ENSG00000274038.1	RP11-66H6.4	-5.55	4.77e-08	1.6e-05	-0.29	-0.25	Systemic lupus erythematosus;	chr16:11097715	chr16:11056556~11057034:+
LUAD	cis	rs10800713	0.954	rs6667081	ENSG00000260088.1	RP11-92G12.3	-5.55	4.77e-08	1.6e-05	-0.35	-0.25	Tandem gait;	chr1:200593366	chr1:200669507~200694250:+
LUAD	cis	rs11976180	1	rs2961117	ENSG00000170356.8	OR2A20P	-5.55	4.77e-08	1.6e-05	-0.31	-0.25	Obesity-related traits;	chr7:144058160	chr7:144250045~144252957:-
LUAD	cis	rs7712401	0.601	rs144597	ENSG00000263432.2	RN7SL689P	5.55	4.77e-08	1.6e-05	0.31	0.25	Mean platelet volume;	chr5:122887537	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs246282	ENSG00000263432.2	RN7SL689P	5.55	4.77e-08	1.6e-05	0.31	0.25	Mean platelet volume;	chr5:122889910	chr5:123022487~123022783:-
LUAD	cis	rs2243480	1	rs437889	ENSG00000230295.1	RP11-458F8.2	-5.55	4.78e-08	1.61e-05	-0.3	-0.25	Diabetic kidney disease;	chr7:66044247	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs402418	ENSG00000230295.1	RP11-458F8.2	-5.55	4.78e-08	1.61e-05	-0.3	-0.25	Diabetic kidney disease;	chr7:66044482	chr7:66880708~66882981:+
LUAD	cis	rs2243480	0.803	rs423187	ENSG00000230295.1	RP11-458F8.2	-5.55	4.78e-08	1.61e-05	-0.3	-0.25	Diabetic kidney disease;	chr7:66044512	chr7:66880708~66882981:+
LUAD	cis	rs4568518	0.502	rs4543441	ENSG00000279048.1	RP11-511H23.2	5.55	4.78e-08	1.61e-05	0.2	0.25	Measles;	chr7:17943674	chr7:17940503~17942922:+
LUAD	cis	rs1106529	0.51	rs7526102	ENSG00000226172.2	RP4-712E4.1	-5.55	4.79e-08	1.61e-05	-0.32	-0.25	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);	chr1:118984604	chr1:119000344~119001392:-
LUAD	cis	rs72615157	0.634	rs74774557	ENSG00000242294.5	STAG3L5P	5.55	4.79e-08	1.61e-05	0.21	0.25	Lung function (FEV1/FVC);	chr7:100212802	chr7:100336079~100351900:+
LUAD	cis	rs6570726	0.935	rs110289	ENSG00000235652.6	RP11-545I5.3	5.55	4.79e-08	1.61e-05	0.24	0.25	Lobe attachment (rater-scored or self-reported);	chr6:145544040	chr6:145799409~145886585:+
LUAD	cis	rs1876905	0.62	rs354530	ENSG00000272356.1	RP5-1112D6.8	-5.55	4.79e-08	1.61e-05	-0.27	-0.25	Mean corpuscular hemoglobin;	chr6:111183286	chr6:111309203~111313517:+
LUAD	cis	rs853679	0.585	rs201001	ENSG00000219392.1	RP1-265C24.5	-5.55	4.8e-08	1.61e-05	-0.34	-0.25	Depression;	chr6:27841121	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.585	rs201000	ENSG00000219392.1	RP1-265C24.5	-5.55	4.8e-08	1.61e-05	-0.34	-0.25	Depression;	chr6:27841381	chr6:28115628~28116551:+
LUAD	cis	rs2440129	0.611	rs11571335	ENSG00000215067.8	ALOX12-AS1	5.55	4.8e-08	1.61e-05	0.25	0.25	Tonsillectomy;	chr17:7000944	chr17:6876635~7012349:-
LUAD	cis	rs6687821	0.515	rs2390224	ENSG00000267734.1	RP4-604K5.3	-5.55	4.81e-08	1.62e-05	-0.3	-0.25	Yeast infection;	chr1:86991201	chr1:86932199~86934891:-
LUAD	cis	rs9549367	0.804	rs9549704	ENSG00000269125.1	RP11-98F14.11	-5.55	4.81e-08	1.62e-05	-0.32	-0.25	Platelet distribution width;	chr13:113230873	chr13:113165002~113165183:-
LUAD	cis	rs4835473	0.932	rs5016160	ENSG00000251600.4	RP11-673E1.1	5.55	4.82e-08	1.62e-05	0.3	0.25	Immature fraction of reticulocytes;	chr4:143738305	chr4:143912331~143982454:+
LUAD	cis	rs453301	0.686	rs6601281	ENSG00000253981.4	ALG1L13P	-5.55	4.82e-08	1.62e-05	-0.29	-0.25	Joint mobility (Beighton score);	chr8:9053494	chr8:8236003~8244667:-
LUAD	cis	rs1707322	1	rs6657720	ENSG00000234329.1	RP11-767N6.2	5.55	4.82e-08	1.62e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45920597	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs7519181	ENSG00000234329.1	RP11-767N6.2	5.55	4.82e-08	1.62e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45922157	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs7526369	ENSG00000234329.1	RP11-767N6.2	5.55	4.82e-08	1.62e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45924888	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.963	rs10890371	ENSG00000234329.1	RP11-767N6.2	5.55	4.82e-08	1.62e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925225	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs10890372	ENSG00000234329.1	RP11-767N6.2	5.55	4.82e-08	1.62e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925348	chr1:45651039~45651826:-
LUAD	cis	rs9287719	0.649	rs12473957	ENSG00000243819.4	RN7SL832P	-5.55	4.82e-08	1.62e-05	-0.26	-0.25	Prostate cancer;	chr2:10577588	chr2:10690344~10692099:+
LUAD	cis	rs997295	0.57	rs72747462	ENSG00000270964.1	RP11-502I4.3	-5.55	4.82e-08	1.62e-05	-0.26	-0.25	Motion sickness;	chr15:67526200	chr15:67541072~67542604:-
LUAD	cis	rs10754283	0.935	rs1934046	ENSG00000231613.1	RP5-943J3.1	-5.55	4.83e-08	1.62e-05	-0.25	-0.25	Amyotrophic lateral sclerosis (sporadic);	chr1:89653731	chr1:89788914~89790492:+
LUAD	cis	rs4927850	0.958	rs1975582	ENSG00000242086.7	LINC00969	5.55	4.84e-08	1.62e-05	0.22	0.25	Pancreatic cancer;	chr3:196024568	chr3:195658062~195739964:+
LUAD	cis	rs12468226	0.873	rs78798541	ENSG00000272966.1	RP11-686O6.1	5.55	4.84e-08	1.62e-05	0.43	0.25	Urate levels;	chr2:202194708	chr2:202336739~202337200:+
LUAD	cis	rs4908768	0.501	rs12030885	ENSG00000232912.4	RP5-1115A15.1	5.55	4.84e-08	1.62e-05	0.23	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8721337	chr1:8424645~8434838:+
LUAD	cis	rs11105298	0.786	rs10858867	ENSG00000258302.2	RP11-981P6.1	5.55	4.84e-08	1.62e-05	0.31	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89457389	chr12:89561129~89594878:+
LUAD	cis	rs11105298	0.891	rs10858869	ENSG00000258302.2	RP11-981P6.1	5.55	4.84e-08	1.62e-05	0.31	0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89463834	chr12:89561129~89594878:+
LUAD	cis	rs1707322	0.896	rs809774	ENSG00000234329.1	RP11-767N6.2	-5.55	4.85e-08	1.63e-05	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46094572	chr1:45651039~45651826:-
LUAD	cis	rs17684571	0.751	rs7761729	ENSG00000231441.1	RP11-472M19.2	5.55	4.85e-08	1.63e-05	0.34	0.25	Schizophrenia;	chr6:56846478	chr6:56844002~56864078:+
LUAD	cis	rs172166	0.543	rs1150691	ENSG00000219392.1	RP1-265C24.5	-5.55	4.85e-08	1.63e-05	-0.31	-0.25	Cardiac Troponin-T levels;	chr6:28200255	chr6:28115628~28116551:+
LUAD	cis	rs4908760	0.566	rs7532459	ENSG00000232912.4	RP5-1115A15.1	5.55	4.85e-08	1.63e-05	0.23	0.25	Vitiligo;	chr1:8617714	chr1:8424645~8434838:+
LUAD	cis	rs453301	0.686	rs6601281	ENSG00000173295.6	FAM86B3P	-5.55	4.85e-08	1.63e-05	-0.26	-0.25	Joint mobility (Beighton score);	chr8:9053494	chr8:8228595~8244865:+
LUAD	cis	rs1426063	0.614	rs17199779	ENSG00000249717.1	RP11-44F21.3	-5.55	4.85e-08	1.63e-05	-0.46	-0.25	QT interval;	chr4:75105647	chr4:74955974~74970362:-
LUAD	cis	rs9847710	0.869	rs11708675	ENSG00000242142.1	SERBP1P3	5.55	4.86e-08	1.63e-05	0.27	0.25	Ulcerative colitis;	chr3:52997896	chr3:53064283~53065091:-
LUAD	cis	rs2749097	1	rs11208263	ENSG00000244256.3	RN7SL130P	-5.54	4.86e-08	1.63e-05	-0.36	-0.25	Alcohol consumption (transferrin glycosylation);	chr1:63659259	chr1:63655743~63656047:+
LUAD	cis	rs4664293	0.585	rs10460301	ENSG00000226266.5	AC009961.3	5.54	4.86e-08	1.63e-05	0.33	0.25	Monocyte percentage of white cells;	chr2:159778566	chr2:159670708~159712435:-
LUAD	cis	rs1075265	0.933	rs7562055	ENSG00000233266.1	HMGB1P31	5.54	4.87e-08	1.63e-05	0.31	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54112694	chr2:54051334~54051760:+
LUAD	cis	rs875971	1	rs1981798	ENSG00000237310.1	GS1-124K5.4	5.54	4.87e-08	1.63e-05	0.26	0.25	Aortic root size;	chr7:66489916	chr7:66493706~66495474:+
LUAD	cis	rs12554020	0.786	rs56073019	ENSG00000227603.1	RP11-165J3.6	5.54	4.87e-08	1.63e-05	0.47	0.25	Schizophrenia;	chr9:93491169	chr9:93435332~93437121:-
LUAD	cis	rs12554020	0.786	rs75576302	ENSG00000227603.1	RP11-165J3.6	5.54	4.87e-08	1.63e-05	0.47	0.25	Schizophrenia;	chr9:93492940	chr9:93435332~93437121:-
LUAD	cis	rs12554020	0.786	rs76703294	ENSG00000227603.1	RP11-165J3.6	5.54	4.87e-08	1.63e-05	0.47	0.25	Schizophrenia;	chr9:93493884	chr9:93435332~93437121:-
LUAD	cis	rs4660456	0.504	rs570671	ENSG00000237899.1	RP4-739H11.3	5.54	4.87e-08	1.63e-05	0.35	0.25	Platelet count;	chr1:40625455	chr1:40669089~40687588:-
LUAD	cis	rs944289	0.553	rs1169147	ENSG00000257826.1	RP11-116N8.4	-5.54	4.88e-08	1.63e-05	-0.28	-0.25	Thyroid cancer;	chr14:36163697	chr14:36061026~36067190:-
LUAD	cis	rs2303759	0.676	rs7248378	ENSG00000268686.1	AC010524.2	-5.54	4.88e-08	1.64e-05	-0.33	-0.25	Multiple sclerosis;	chr19:49404887	chr19:49368705~49388081:-
LUAD	cis	rs1113500	0.573	rs10748507	ENSG00000226822.1	RP11-356N1.2	5.54	4.88e-08	1.64e-05	0.33	0.25	Growth-regulated protein alpha levels;	chr1:108088899	chr1:108071482~108074519:+
LUAD	cis	rs4713118	0.513	rs149958	ENSG00000204709.4	LINC01556	5.54	4.88e-08	1.64e-05	0.31	0.25	Parkinson's disease;	chr6:28045839	chr6:28943877~28944537:+
LUAD	cis	rs1707322	1	rs11211243	ENSG00000234329.1	RP11-767N6.2	5.54	4.88e-08	1.64e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45989761	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs11211244	ENSG00000234329.1	RP11-767N6.2	5.54	4.88e-08	1.64e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991001	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs4660903	ENSG00000234329.1	RP11-767N6.2	5.54	4.88e-08	1.64e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991929	chr1:45651039~45651826:-
LUAD	cis	rs35160687	0.712	rs9677502	ENSG00000273080.1	RP11-301O19.1	-5.54	4.88e-08	1.64e-05	-0.27	-0.25	Night sleep phenotypes;	chr2:86253815	chr2:86195590~86196049:+
LUAD	cis	rs897984	0.609	rs55979739	ENSG00000260911.2	RP11-196G11.2	5.54	4.89e-08	1.64e-05	0.22	0.25	Dementia with Lewy bodies;	chr16:31037834	chr16:31043150~31049868:+
LUAD	cis	rs897984	0.609	rs732172	ENSG00000260911.2	RP11-196G11.2	5.54	4.89e-08	1.64e-05	0.22	0.25	Dementia with Lewy bodies;	chr16:31038712	chr16:31043150~31049868:+
LUAD	cis	rs2412819	0.571	rs2729494	ENSG00000249839.1	AC011330.5	5.54	4.89e-08	1.64e-05	0.38	0.25	Lung cancer;	chr15:43837395	chr15:43663654~43684339:-
LUAD	cis	rs2412819	0.571	rs528764	ENSG00000249839.1	AC011330.5	5.54	4.89e-08	1.64e-05	0.38	0.25	Lung cancer;	chr15:43838650	chr15:43663654~43684339:-
LUAD	cis	rs7221109	0.677	rs1029792	ENSG00000278834.1	RP11-458J1.1	5.54	4.89e-08	1.64e-05	0.29	0.25	Type 1 diabetes;	chr17:40652689	chr17:40648300~40649718:+
LUAD	cis	rs7116495	1	rs3814721	ENSG00000254682.1	RP11-660L16.2	5.54	4.89e-08	1.64e-05	0.49	0.25	Severe influenza A (H1N1) infection;	chr11:71998226	chr11:71448674~71452157:+
LUAD	cis	rs801193	0.66	rs974239	ENSG00000237310.1	GS1-124K5.4	5.54	4.89e-08	1.64e-05	0.26	0.25	Aortic root size;	chr7:66748504	chr7:66493706~66495474:+
LUAD	cis	rs1707322	0.963	rs6666763	ENSG00000234329.1	RP11-767N6.2	5.54	4.9e-08	1.64e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45970779	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs4489497	ENSG00000234329.1	RP11-767N6.2	5.54	4.9e-08	1.64e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45973026	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs11211235	ENSG00000234329.1	RP11-767N6.2	5.54	4.9e-08	1.64e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45974703	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.893	rs9919275	ENSG00000234329.1	RP11-767N6.2	5.54	4.9e-08	1.64e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45975688	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs11211236	ENSG00000234329.1	RP11-767N6.2	5.54	4.9e-08	1.64e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45978095	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs4660328	ENSG00000234329.1	RP11-767N6.2	5.54	4.9e-08	1.64e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45979159	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.928	rs61785614	ENSG00000234329.1	RP11-767N6.2	5.54	4.9e-08	1.64e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45980375	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs9793167	ENSG00000234329.1	RP11-767N6.2	5.54	4.9e-08	1.64e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981128	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs11211237	ENSG00000234329.1	RP11-767N6.2	5.54	4.9e-08	1.64e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981657	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.963	rs11211238	ENSG00000234329.1	RP11-767N6.2	5.54	4.9e-08	1.64e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983743	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs4460583	ENSG00000234329.1	RP11-767N6.2	5.54	4.9e-08	1.64e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45984246	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.963	rs4459051	ENSG00000234329.1	RP11-767N6.2	5.54	4.9e-08	1.64e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45985531	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs11211239	ENSG00000234329.1	RP11-767N6.2	5.54	4.9e-08	1.64e-05	0.25	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986275	chr1:45651039~45651826:-
LUAD	cis	rs9287719	0.649	rs7589694	ENSG00000243819.4	RN7SL832P	5.54	4.9e-08	1.64e-05	0.26	0.25	Prostate cancer;	chr2:10560748	chr2:10690344~10692099:+
LUAD	cis	rs180730	0.509	rs1588521	ENSG00000251609.2	SETP12	-5.54	4.91e-08	1.64e-05	-0.32	-0.25	Fasting plasma glucose;	chr4:120881202	chr4:120895494~120897083:-
LUAD	cis	rs948562	0.947	rs73470773	ENSG00000280010.1	AP001350.4	5.54	4.91e-08	1.64e-05	0.38	0.25	Lymphoma;	chr11:58648100	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.947	rs73470778	ENSG00000280010.1	AP001350.4	5.54	4.91e-08	1.64e-05	0.38	0.25	Lymphoma;	chr11:58650594	chr11:58627435~58628528:+
LUAD	cis	rs1154275	0.537	rs6797028	ENSG00000242770.2	RP11-180K7.1	5.54	4.91e-08	1.65e-05	0.26	0.25	Takotsubo syndrome;	chr3:112796340	chr3:112802478~112812819:+
LUAD	cis	rs4698412	0.646	rs4698120	ENSG00000214846.4	RP11-115L11.1	-5.54	4.91e-08	1.65e-05	-0.33	-0.25	Parkinson's disease;	chr4:15741709	chr4:15730962~15731627:-
LUAD	cis	rs7181230	0.885	rs4924413	ENSG00000275636.1	RP11-521C20.5	5.54	4.92e-08	1.65e-05	0.33	0.25	Dehydroepiandrosterone sulphate levels;	chr15:40056496	chr15:40078892~40079347:+
LUAD	cis	rs12931792	0.712	rs4787495	ENSG00000183604.13	SMG1P5	-5.54	4.92e-08	1.65e-05	-0.24	-0.25	Tonsillectomy;	chr16:30154404	chr16:30267553~30335374:-
LUAD	cis	rs6558530	0.73	rs13256424	ENSG00000253982.1	CTD-2336O2.1	5.54	4.92e-08	1.65e-05	0.31	0.25	Systolic blood pressure;	chr8:1776838	chr8:1761990~1764502:-
LUAD	cis	rs17818399	0.612	rs4952834	ENSG00000279254.1	RP11-536C12.1	-5.54	4.92e-08	1.65e-05	-0.28	-0.25	Height;	chr2:46550323	chr2:46668870~46670778:+
LUAD	cis	rs477895	0.938	rs28395875	ENSG00000236935.1	AP003774.1	-5.54	4.93e-08	1.65e-05	-0.3	-0.25	Mean platelet volume;	chr11:64256576	chr11:64325050~64329504:-
LUAD	cis	rs17214007	0.877	rs11075280	ENSG00000263335.1	AF001548.5	-5.54	4.93e-08	1.65e-05	-0.35	-0.25	Cognitive function;	chr16:15776630	chr16:15726674~15732993:+
LUAD	cis	rs7927592	0.763	rs10896340	ENSG00000212093.1	AP000807.1	-5.54	4.93e-08	1.65e-05	-0.25	-0.24	Total body bone mineral density;	chr11:68545177	chr11:68506083~68506166:-
LUAD	cis	rs12468226	0.817	rs2350360	ENSG00000272966.1	RP11-686O6.1	-5.54	4.94e-08	1.65e-05	-0.41	-0.24	Urate levels;	chr2:202222980	chr2:202336739~202337200:+
LUAD	cis	rs875971	0.862	rs880166	ENSG00000222364.1	RNU6-96P	5.54	4.94e-08	1.65e-05	0.28	0.24	Aortic root size;	chr7:66205775	chr7:66395191~66395286:+
LUAD	cis	rs2439831	0.702	rs28699233	ENSG00000205771.5	CATSPER2P1	-5.54	4.94e-08	1.65e-05	-0.56	-0.24	Lung cancer in ever smokers;	chr15:43830668	chr15:43726918~43747094:-
LUAD	cis	rs8127691	0.904	rs3804031	ENSG00000237604.1	AP001056.1	5.54	4.94e-08	1.66e-05	0.29	0.24	Inflammatory bowel disease;	chr21:44209721	chr21:44175489~44176453:+
LUAD	cis	rs9652601	0.691	rs3893660	ENSG00000274038.1	RP11-66H6.4	-5.54	4.95e-08	1.66e-05	-0.3	-0.24	Systemic lupus erythematosus;	chr16:11100073	chr16:11056556~11057034:+
LUAD	cis	rs4713118	0.824	rs13211701	ENSG00000219392.1	RP1-265C24.5	-5.54	4.95e-08	1.66e-05	-0.33	-0.24	Parkinson's disease;	chr6:27782300	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.824	rs9468229	ENSG00000219392.1	RP1-265C24.5	-5.54	4.95e-08	1.66e-05	-0.33	-0.24	Parkinson's disease;	chr6:27782307	chr6:28115628~28116551:+
LUAD	cis	rs875971	0.895	rs1974769	ENSG00000237310.1	GS1-124K5.4	5.54	4.95e-08	1.66e-05	0.26	0.24	Aortic root size;	chr7:66485627	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.895	rs6460300	ENSG00000237310.1	GS1-124K5.4	5.54	4.95e-08	1.66e-05	0.26	0.24	Aortic root size;	chr7:66487937	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs7803416	ENSG00000237310.1	GS1-124K5.4	5.54	4.95e-08	1.66e-05	0.26	0.24	Aortic root size;	chr7:66489212	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs1981799	ENSG00000237310.1	GS1-124K5.4	5.54	4.95e-08	1.66e-05	0.26	0.24	Aortic root size;	chr7:66490572	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.964	rs2277911	ENSG00000237310.1	GS1-124K5.4	5.54	4.95e-08	1.66e-05	0.26	0.24	Aortic root size;	chr7:66493638	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.964	rs6978429	ENSG00000237310.1	GS1-124K5.4	5.54	4.95e-08	1.66e-05	0.26	0.24	Aortic root size;	chr7:66494889	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs4718357	ENSG00000237310.1	GS1-124K5.4	5.54	4.95e-08	1.66e-05	0.26	0.24	Aortic root size;	chr7:66495891	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.929	rs12535036	ENSG00000237310.1	GS1-124K5.4	5.54	4.95e-08	1.66e-05	0.26	0.24	Aortic root size;	chr7:66499076	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs12533997	ENSG00000237310.1	GS1-124K5.4	5.54	4.95e-08	1.66e-05	0.26	0.24	Aortic root size;	chr7:66500390	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs12698523	ENSG00000237310.1	GS1-124K5.4	5.54	4.95e-08	1.66e-05	0.26	0.24	Aortic root size;	chr7:66503126	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs6970030	ENSG00000237310.1	GS1-124K5.4	5.54	4.95e-08	1.66e-05	0.26	0.24	Aortic root size;	chr7:66503692	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.928	rs6970357	ENSG00000237310.1	GS1-124K5.4	5.54	4.95e-08	1.66e-05	0.26	0.24	Aortic root size;	chr7:66503891	chr7:66493706~66495474:+
LUAD	cis	rs2288884	0.559	rs11084130	ENSG00000275055.1	CTC-471J1.11	-5.54	4.96e-08	1.66e-05	-0.29	-0.24	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52009443	chr19:52049007~52049754:+
LUAD	cis	rs5753618	0.583	rs7287267	ENSG00000236132.1	CTA-440B3.1	-5.54	4.96e-08	1.66e-05	-0.3	-0.24	Colorectal cancer;	chr22:31352429	chr22:31816379~31817491:-
LUAD	cis	rs17684571	0.751	rs74777312	ENSG00000231441.1	RP11-472M19.2	5.54	4.96e-08	1.66e-05	0.37	0.24	Schizophrenia;	chr6:56845568	chr6:56844002~56864078:+
LUAD	cis	rs17711722	0.528	rs73138179	ENSG00000226002.1	RP11-460N20.5	5.54	4.97e-08	1.66e-05	0.28	0.24	Calcium levels;	chr7:65829495	chr7:65084103~65100232:+
LUAD	cis	rs453301	0.606	rs6601279	ENSG00000173295.6	FAM86B3P	-5.54	4.98e-08	1.66e-05	-0.26	-0.24	Joint mobility (Beighton score);	chr8:9050721	chr8:8228595~8244865:+
LUAD	cis	rs453301	0.606	rs6981060	ENSG00000173295.6	FAM86B3P	-5.54	4.98e-08	1.66e-05	-0.26	-0.24	Joint mobility (Beighton score);	chr8:9050725	chr8:8228595~8244865:+
LUAD	cis	rs7618501	0.602	rs2240326	ENSG00000234667.1	ACTBP13	5.54	4.98e-08	1.66e-05	0.27	0.24	Intelligence (multi-trait analysis);	chr3:50090953	chr3:49873347~49877980:-
LUAD	cis	rs7618501	0.54	rs11130241	ENSG00000234667.1	ACTBP13	5.54	4.98e-08	1.66e-05	0.27	0.24	Intelligence (multi-trait analysis);	chr3:50094026	chr3:49873347~49877980:-
LUAD	cis	rs7937890	0.681	rs4756784	ENSG00000254418.1	RP11-21L19.1	-5.54	4.98e-08	1.67e-05	-0.29	-0.24	Mitochondrial DNA levels;	chr11:14249358	chr11:14262846~14273691:-
LUAD	cis	rs1510272	0.515	rs2089735	ENSG00000243926.1	TIPARP-AS1	-5.54	4.98e-08	1.67e-05	-0.3	-0.24	Testicular germ cell tumor;	chr3:156624763	chr3:156671862~156674378:-
LUAD	cis	rs1707322	1	rs6687301	ENSG00000234329.1	RP11-767N6.2	5.54	4.99e-08	1.67e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45917180	chr1:45651039~45651826:-
LUAD	cis	rs10214930	0.671	rs6415251	ENSG00000235574.1	AC073150.6	-5.54	4.99e-08	1.67e-05	-0.3	-0.24	Hypospadias;	chr7:27629079	chr7:27491682~27492765:-
LUAD	cis	rs2070074	0.591	rs41306057	ENSG00000230074.1	RP11-195F19.9	-5.54	4.99e-08	1.67e-05	-0.65	-0.24	CTACK levels;	chr9:34636826	chr9:34665665~34681298:+
LUAD	cis	rs8040855	0.825	rs4843021	ENSG00000259774.1	RP11-182J1.13	-5.54	4.99e-08	1.67e-05	-0.31	-0.24	Bulimia nervosa;	chr15:85151317	chr15:84422618~84425882:+
LUAD	cis	rs10761482	0.5	rs1938524	ENSG00000254271.1	RP11-131N11.4	5.54	5e-08	1.67e-05	0.27	0.24	Schizophrenia;	chr10:60543815	chr10:60734342~60741828:+
LUAD	cis	rs932287	0.505	rs2742536	ENSG00000254860.4	TMEM9B-AS1	5.54	5e-08	1.67e-05	0.28	0.24	Colonoscopy-negative controls vs population controls;	chr11:8888269	chr11:8964675~8977527:+
LUAD	cis	rs673078	0.615	rs56324376	ENSG00000275409.1	RP11-131L12.4	-5.54	5e-08	1.67e-05	-0.3	-0.24	Glucose homeostasis traits;	chr12:118372134	chr12:118430147~118430699:+
LUAD	cis	rs6687821	0.515	rs524515	ENSG00000267734.1	RP4-604K5.3	5.54	5.01e-08	1.68e-05	0.3	0.24	Yeast infection;	chr1:86907736	chr1:86932199~86934891:-
LUAD	cis	rs7829975	0.623	rs10092965	ENSG00000173295.6	FAM86B3P	5.54	5.02e-08	1.68e-05	0.26	0.24	Mood instability;	chr8:8515975	chr8:8228595~8244865:+
LUAD	cis	rs4820294	0.77	rs7285699	ENSG00000233360.4	Z83844.1	5.54	5.02e-08	1.68e-05	0.25	0.24	Fat distribution (HIV);	chr22:37670549	chr22:37641832~37658377:-
LUAD	cis	rs7131987	0.65	rs10843377	ENSG00000257176.2	RP11-996F15.2	5.54	5.02e-08	1.68e-05	0.28	0.24	QT interval;	chr12:29284120	chr12:29280418~29317848:-
LUAD	cis	rs875971	0.522	rs1917563	ENSG00000236529.1	RP13-254B10.1	-5.54	5.02e-08	1.68e-05	-0.25	-0.24	Aortic root size;	chr7:65950660	chr7:65840212~65840596:+
LUAD	cis	rs4835473	0.838	rs56033497	ENSG00000251600.4	RP11-673E1.1	-5.54	5.02e-08	1.68e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143792341	chr4:143912331~143982454:+
LUAD	cis	rs225245	0.531	rs321609	ENSG00000267592.1	CTC-507E2.2	5.54	5.03e-08	1.68e-05	0.29	0.24	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr17:35553657	chr17:35596904~35597128:-
LUAD	cis	rs116095464	1	rs62331562	ENSG00000277812.1	AC021087.1	5.54	5.03e-08	1.68e-05	0.68	0.24	Breast cancer;	chr5:349183	chr5:262769~262881:+
LUAD	cis	rs6687821	0.515	rs1573202	ENSG00000267734.1	RP4-604K5.3	-5.54	5.03e-08	1.68e-05	-0.3	-0.24	Yeast infection;	chr1:87046037	chr1:86932199~86934891:-
LUAD	cis	rs9595908	0.655	rs2213377	ENSG00000212293.1	SNORA16	5.54	5.03e-08	1.68e-05	0.27	0.24	Body mass index;	chr13:32743076	chr13:32420390~32420516:-
LUAD	cis	rs910316	0.967	rs175505	ENSG00000259138.1	RP11-950C14.7	-5.54	5.03e-08	1.68e-05	-0.26	-0.24	Height;	chr14:75062916	chr14:75127153~75136930:+
LUAD	cis	rs4835473	0.932	rs6853460	ENSG00000251600.4	RP11-673E1.1	-5.54	5.04e-08	1.68e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143750392	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs6853676	ENSG00000251600.4	RP11-673E1.1	-5.54	5.04e-08	1.68e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143750495	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs6848393	ENSG00000251600.4	RP11-673E1.1	-5.54	5.04e-08	1.68e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143750537	chr4:143912331~143982454:+
LUAD	cis	rs4308124	0.708	rs28766030	ENSG00000227992.1	AC108463.2	-5.54	5.04e-08	1.68e-05	-0.33	-0.24	Vitiligo;	chr2:111204852	chr2:111203964~111206215:-
LUAD	cis	rs4308124	0.708	rs28871990	ENSG00000227992.1	AC108463.2	-5.54	5.04e-08	1.68e-05	-0.33	-0.24	Vitiligo;	chr2:111204864	chr2:111203964~111206215:-
LUAD	cis	rs4308124	0.708	rs67816163	ENSG00000227992.1	AC108463.2	-5.54	5.04e-08	1.68e-05	-0.33	-0.24	Vitiligo;	chr2:111205733	chr2:111203964~111206215:-
LUAD	cis	rs1318937	0.764	rs11128738	ENSG00000224660.1	SH3BP5-AS1	5.54	5.04e-08	1.68e-05	0.18	0.24	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15200989	chr3:15254184~15264493:+
LUAD	cis	rs9828933	0.832	rs3774723	ENSG00000280620.1	SCAANT1	5.54	5.04e-08	1.69e-05	0.36	0.24	Type 2 diabetes;	chr3:63976663	chr3:63911518~63911772:-
LUAD	cis	rs3931020	0.688	rs1051122	ENSG00000272864.1	RP11-17E13.2	-5.54	5.05e-08	1.69e-05	-0.35	-0.24	Resistin levels;	chr1:74724768	chr1:74698769~74699333:-
LUAD	cis	rs9309473	0.66	rs11686541	ENSG00000163016.8	ALMS1P	5.54	5.05e-08	1.69e-05	0.37	0.24	Metabolite levels;	chr2:73477348	chr2:73644919~73685576:+
LUAD	cis	rs41307935	0.908	rs34618114	ENSG00000260063.1	RP5-968P14.2	-5.54	5.06e-08	1.69e-05	-0.44	-0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26771828	chr1:26692132~26694131:-
LUAD	cis	rs7923609	1	rs4379723	ENSG00000232075.1	MRPL35P2	-5.54	5.06e-08	1.69e-05	-0.3	-0.24	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63203689	chr10:63634317~63634827:-
LUAD	cis	rs4767841	0.562	rs10849683	ENSG00000248636.5	RP11-768F21.1	-5.54	5.06e-08	1.69e-05	-0.29	-0.24	Urgency urinary incontinence;	chr12:119624203	chr12:119387987~119668079:-
LUAD	cis	rs394563	0.591	rs237029	ENSG00000231760.4	RP11-350J20.5	5.54	5.07e-08	1.69e-05	0.3	0.24	Dupuytren's disease;	chr6:149396289	chr6:149796151~149826294:-
LUAD	cis	rs8098244	0.557	rs11082724	ENSG00000264745.1	TTC39C-AS1	5.54	5.07e-08	1.69e-05	0.26	0.24	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23732544	chr18:23994213~24015339:-
LUAD	cis	rs7826238	0.601	rs2976907	ENSG00000253893.2	FAM85B	-5.54	5.07e-08	1.69e-05	-0.31	-0.24	Systolic blood pressure;	chr8:8487658	chr8:8167819~8226614:-
LUAD	cis	rs10214930	0.697	rs10951175	ENSG00000235574.1	AC073150.6	-5.54	5.07e-08	1.69e-05	-0.29	-0.24	Hypospadias;	chr7:27631439	chr7:27491682~27492765:-
LUAD	cis	rs7618501	0.633	rs2252833	ENSG00000234667.1	ACTBP13	-5.54	5.07e-08	1.69e-05	-0.28	-0.24	Intelligence (multi-trait analysis);	chr3:49966776	chr3:49873347~49877980:-
LUAD	cis	rs496547	0.721	rs2508570	ENSG00000255239.1	AP002954.6	5.54	5.07e-08	1.69e-05	0.3	0.24	Hip minimal joint space width;	chr11:118807900	chr11:118688039~118690600:-
LUAD	cis	rs8081395	0.741	rs1292056	ENSG00000266992.1	DHX40P1	5.54	5.07e-08	1.69e-05	0.28	0.24	White blood cell count;	chr17:59881686	chr17:59976009~60002384:-
LUAD	cis	rs10214930	0.813	rs6415252	ENSG00000235574.1	AC073150.6	-5.54	5.08e-08	1.7e-05	-0.32	-0.24	Hypospadias;	chr7:27629241	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.813	rs7779990	ENSG00000235574.1	AC073150.6	-5.54	5.08e-08	1.7e-05	-0.32	-0.24	Hypospadias;	chr7:27632280	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.813	rs12700825	ENSG00000235574.1	AC073150.6	-5.54	5.08e-08	1.7e-05	-0.32	-0.24	Hypospadias;	chr7:27632952	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.813	rs11764753	ENSG00000235574.1	AC073150.6	-5.54	5.08e-08	1.7e-05	-0.32	-0.24	Hypospadias;	chr7:27633340	chr7:27491682~27492765:-
LUAD	cis	rs10214930	0.813	rs7806415	ENSG00000235574.1	AC073150.6	-5.54	5.08e-08	1.7e-05	-0.32	-0.24	Hypospadias;	chr7:27633918	chr7:27491682~27492765:-
LUAD	cis	rs35740288	0.721	rs4843093	ENSG00000202081.1	RNU6-1280P	5.54	5.08e-08	1.7e-05	0.31	0.24	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85694202	chr15:85651522~85651628:-
LUAD	cis	rs2288884	0.943	rs1433089	ENSG00000275055.1	CTC-471J1.11	-5.54	5.08e-08	1.7e-05	-0.37	-0.24	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52003732	chr19:52049007~52049754:+
LUAD	cis	rs1823874	0.613	rs4608318	ENSG00000182397.13	DNM1P46	-5.54	5.09e-08	1.7e-05	-0.3	-0.24	IgG glycosylation;	chr15:99823621	chr15:99790156~99806927:-
LUAD	cis	rs1823874	0.677	rs2168069	ENSG00000182397.13	DNM1P46	-5.54	5.09e-08	1.7e-05	-0.3	-0.24	IgG glycosylation;	chr15:99823798	chr15:99790156~99806927:-
LUAD	cis	rs2404602	0.735	rs3765115	ENSG00000259422.1	RP11-593F23.1	-5.54	5.09e-08	1.7e-05	-0.31	-0.24	Blood metabolite levels;	chr15:76381375	chr15:76174891~76181486:-
LUAD	cis	rs2919009	0.544	rs7917351	ENSG00000271670.1	RP11-95I16.4	5.54	5.09e-08	1.7e-05	0.3	0.24	Obesity-related traits;	chr10:120852260	chr10:120879256~120880667:-
LUAD	cis	rs948562	0.573	rs17471365	ENSG00000280010.1	AP001350.4	-5.54	5.09e-08	1.7e-05	-0.36	-0.24	Lymphoma;	chr11:58275959	chr11:58627435~58628528:+
LUAD	cis	rs4908768	0.501	rs7530745	ENSG00000232912.4	RP5-1115A15.1	5.54	5.1e-08	1.7e-05	0.23	0.24	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8497631	chr1:8424645~8434838:+
LUAD	cis	rs9595908	0.785	rs4120131	ENSG00000212293.1	SNORA16	-5.54	5.1e-08	1.7e-05	-0.26	-0.24	Body mass index;	chr13:32702949	chr13:32420390~32420516:-
LUAD	cis	rs17023223	0.537	rs12081585	ENSG00000231365.4	RP11-418J17.1	-5.54	5.1e-08	1.7e-05	-0.33	-0.24	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119073333	chr1:119140396~119275973:+
LUAD	cis	rs7615952	0.599	rs12486459	ENSG00000171084.14	FAM86JP	5.54	5.1e-08	1.7e-05	0.36	0.24	Blood pressure (smoking interaction);	chr3:126022622	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.599	rs67575510	ENSG00000171084.14	FAM86JP	5.54	5.1e-08	1.7e-05	0.36	0.24	Blood pressure (smoking interaction);	chr3:126023512	chr3:125916620~125930024:+
LUAD	cis	rs9847710	0.869	rs2581793	ENSG00000242142.1	SERBP1P3	5.54	5.1e-08	1.7e-05	0.26	0.24	Ulcerative colitis;	chr3:53001639	chr3:53064283~53065091:-
LUAD	cis	rs6991838	0.806	rs35284121	ENSG00000200714.1	Y_RNA	5.54	5.1e-08	1.7e-05	0.28	0.24	Intelligence (multi-trait analysis);	chr8:65551230	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.751	rs35553155	ENSG00000200714.1	Y_RNA	5.54	5.1e-08	1.7e-05	0.28	0.24	Intelligence (multi-trait analysis);	chr8:65551232	chr8:65592731~65592820:+
LUAD	cis	rs6991838	0.806	rs35024820	ENSG00000200714.1	Y_RNA	5.54	5.1e-08	1.7e-05	0.28	0.24	Intelligence (multi-trait analysis);	chr8:65551296	chr8:65592731~65592820:+
LUAD	cis	rs4835473	0.932	rs13135034	ENSG00000251600.4	RP11-673E1.1	5.54	5.11e-08	1.71e-05	0.3	0.24	Immature fraction of reticulocytes;	chr4:143738247	chr4:143912331~143982454:+
LUAD	cis	rs948562	0.744	rs73485969	ENSG00000280010.1	AP001350.4	5.54	5.11e-08	1.71e-05	0.37	0.24	Lymphoma;	chr11:58452253	chr11:58627435~58628528:+
LUAD	cis	rs7712401	0.562	rs246267	ENSG00000263432.2	RN7SL689P	5.54	5.11e-08	1.71e-05	0.3	0.24	Mean platelet volume;	chr5:122920409	chr5:123022487~123022783:-
LUAD	cis	rs7131987	0.65	rs4331146	ENSG00000257176.2	RP11-996F15.2	-5.54	5.12e-08	1.71e-05	-0.28	-0.24	QT interval;	chr12:29287150	chr12:29280418~29317848:-
LUAD	cis	rs10129255	0.518	rs10136903	ENSG00000211967.3	IGHV3-53	-5.54	5.12e-08	1.71e-05	-0.17	-0.24	Kawasaki disease;	chr14:106778866	chr14:106592676~106593347:-
LUAD	cis	rs858239	0.712	rs200717	ENSG00000226816.2	AC005082.12	5.53	5.13e-08	1.71e-05	0.32	0.24	Cerebrospinal fluid biomarker levels;	chr7:23352652	chr7:23206013~23208045:+
LUAD	cis	rs9900062	0.844	rs9908143	ENSG00000270714.1	MINOS1P2	-5.53	5.13e-08	1.71e-05	-0.37	-0.24	QT interval;	chr17:64758468	chr17:64747264~64747492:-
LUAD	cis	rs4835473	0.932	rs11100806	ENSG00000251600.4	RP11-673E1.1	5.53	5.13e-08	1.71e-05	0.3	0.24	Immature fraction of reticulocytes;	chr4:143761006	chr4:143912331~143982454:+
LUAD	cis	rs765787	0.53	rs4514617	ENSG00000259520.4	CTD-2651B20.3	5.53	5.14e-08	1.72e-05	0.32	0.24	Uric acid levels;	chr15:45243241	chr15:45251580~45279251:-
LUAD	cis	rs10129255	0.913	rs28861466	ENSG00000224373.3	IGHV4-59	5.53	5.15e-08	1.72e-05	0.16	0.24	Kawasaki disease;	chr14:106718572	chr14:106627249~106627825:-
LUAD	cis	rs4835473	0.932	rs11721523	ENSG00000251600.4	RP11-673E1.1	-5.53	5.15e-08	1.72e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143767301	chr4:143912331~143982454:+
LUAD	cis	rs9595908	0.785	rs9591236	ENSG00000212293.1	SNORA16	5.53	5.16e-08	1.72e-05	0.26	0.24	Body mass index;	chr13:32671667	chr13:32420390~32420516:-
LUAD	cis	rs4767841	0.552	rs4767833	ENSG00000248636.5	RP11-768F21.1	-5.53	5.16e-08	1.72e-05	-0.28	-0.24	Urgency urinary incontinence;	chr12:119613165	chr12:119387987~119668079:-
LUAD	cis	rs2404602	0.692	rs55864032	ENSG00000259422.1	RP11-593F23.1	5.53	5.16e-08	1.72e-05	0.28	0.24	Blood metabolite levels;	chr15:76830207	chr15:76174891~76181486:-
LUAD	cis	rs763567	0.585	rs553905	ENSG00000271811.1	RP1-79C4.4	-5.53	5.16e-08	1.72e-05	-0.29	-0.24	Tonsillectomy;	chr1:170611336	chr1:170667381~170669425:+
LUAD	cis	rs8180040	0.726	rs61729713	ENSG00000271161.1	BOLA2P2	-5.53	5.17e-08	1.72e-05	-0.23	-0.24	Colorectal cancer;	chr3:46985702	chr3:47499841~47500407:+
LUAD	cis	rs801193	0.844	rs732465	ENSG00000224316.1	RP11-479O9.2	5.53	5.18e-08	1.73e-05	0.24	0.24	Aortic root size;	chr7:66533463	chr7:65773620~65802067:+
LUAD	cis	rs58873874	0.522	rs6875379	ENSG00000251405.2	CTB-109A12.1	5.53	5.18e-08	1.73e-05	0.45	0.24	Bipolar disorder (body mass index interaction);	chr5:157391295	chr5:157362615~157460078:-
LUAD	cis	rs1707322	1	rs4539075	ENSG00000234329.1	RP11-767N6.2	5.53	5.18e-08	1.73e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45892338	chr1:45651039~45651826:-
LUAD	cis	rs7712401	0.601	rs30035	ENSG00000263432.2	RN7SL689P	5.53	5.18e-08	1.73e-05	0.31	0.24	Mean platelet volume;	chr5:122942850	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs246306	ENSG00000263432.2	RN7SL689P	5.53	5.18e-08	1.73e-05	0.31	0.24	Mean platelet volume;	chr5:122943523	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.562	rs2927639	ENSG00000263432.2	RN7SL689P	5.53	5.18e-08	1.73e-05	0.31	0.24	Mean platelet volume;	chr5:122943971	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs246273	ENSG00000263432.2	RN7SL689P	5.53	5.18e-08	1.73e-05	0.31	0.24	Mean platelet volume;	chr5:122945280	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.691	rs62377436	ENSG00000263432.2	RN7SL689P	-5.53	5.19e-08	1.73e-05	-0.31	-0.24	Mean platelet volume;	chr5:123018007	chr5:123022487~123022783:-
LUAD	cis	rs801193	0.66	rs10950049	ENSG00000237310.1	GS1-124K5.4	5.53	5.19e-08	1.73e-05	0.26	0.24	Aortic root size;	chr7:66765873	chr7:66493706~66495474:+
LUAD	cis	rs2288884	0.636	rs6509620	ENSG00000275055.1	CTC-471J1.11	-5.53	5.2e-08	1.73e-05	-0.3	-0.24	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52077543	chr19:52049007~52049754:+
LUAD	cis	rs9879311	0.966	rs775018	ENSG00000240288.6	GHRLOS	5.53	5.2e-08	1.73e-05	0.23	0.24	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10358461	chr3:10285754~10293449:+
LUAD	cis	rs35740288	0.929	rs1978391	ENSG00000202081.1	RNU6-1280P	-5.53	5.2e-08	1.73e-05	-0.31	-0.24	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85768464	chr15:85651522~85651628:-
LUAD	cis	rs6543140	0.929	rs11465700	ENSG00000234389.1	AC007278.3	5.53	5.2e-08	1.73e-05	0.24	0.24	Blood protein levels;	chr2:102441208	chr2:102438713~102440475:+
LUAD	cis	rs1667284	0.967	rs1791221	ENSG00000266521.1	RP11-650P15.1	5.53	5.2e-08	1.73e-05	0.28	0.24	Problematic alcohol use in trauma-exposed individuals;	chr18:31639928	chr18:31496645~31497195:-
LUAD	cis	rs1320333	0.772	rs2867116	ENSG00000233296.1	AC092159.2	5.53	5.21e-08	1.74e-05	0.44	0.24	Obesity-related traits;	chr2:682363	chr2:677186~697371:+
LUAD	cis	rs5753618	0.583	rs5753612	ENSG00000236132.1	CTA-440B3.1	-5.53	5.21e-08	1.74e-05	-0.3	-0.24	Colorectal cancer;	chr22:31425493	chr22:31816379~31817491:-
LUAD	cis	rs35160687	0.712	rs11681689	ENSG00000273080.1	RP11-301O19.1	-5.53	5.21e-08	1.74e-05	-0.27	-0.24	Night sleep phenotypes;	chr2:86256039	chr2:86195590~86196049:+
LUAD	cis	rs7617773	0.78	rs11706277	ENSG00000228638.1	FCF1P2	-5.53	5.21e-08	1.74e-05	-0.3	-0.24	Coronary artery disease;	chr3:48318943	chr3:48290793~48291375:-
LUAD	cis	rs9595908	0.785	rs6561500	ENSG00000212293.1	SNORA16	5.53	5.21e-08	1.74e-05	0.25	0.24	Body mass index;	chr13:32681234	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.785	rs3912038	ENSG00000212293.1	SNORA16	5.53	5.21e-08	1.74e-05	0.25	0.24	Body mass index;	chr13:32682061	chr13:32420390~32420516:-
LUAD	cis	rs7772486	0.59	rs1890170	ENSG00000235652.6	RP11-545I5.3	-5.53	5.22e-08	1.74e-05	-0.26	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145750703	chr6:145799409~145886585:+
LUAD	cis	rs17826219	0.561	rs11655876	ENSG00000263603.1	CTD-2349P21.5	-5.53	5.22e-08	1.74e-05	-0.38	-0.24	Body mass index;	chr17:30690132	chr17:30729469~30731202:+
LUAD	cis	rs2288884	0.515	rs2869602	ENSG00000275055.1	CTC-471J1.11	-5.53	5.22e-08	1.74e-05	-0.29	-0.24	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52072324	chr19:52049007~52049754:+
LUAD	cis	rs30380	1	rs27710	ENSG00000272109.1	CTD-2260A17.3	5.53	5.22e-08	1.74e-05	0.26	0.24	Cerebrospinal fluid biomarker levels;	chr5:96790494	chr5:96804353~96806105:+
LUAD	cis	rs6565180	1	rs68051857	ENSG00000183604.13	SMG1P5	-5.53	5.22e-08	1.74e-05	-0.26	-0.24	Tonsillectomy;	chr16:30348690	chr16:30267553~30335374:-
LUAD	cis	rs11105298	0.786	rs3803128	ENSG00000258302.2	RP11-981P6.1	5.53	5.23e-08	1.74e-05	0.31	0.24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89466542	chr12:89561129~89594878:+
LUAD	cis	rs11105298	0.891	rs10506972	ENSG00000258302.2	RP11-981P6.1	5.53	5.23e-08	1.74e-05	0.31	0.24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89467752	chr12:89561129~89594878:+
LUAD	cis	rs11105298	0.891	rs12228177	ENSG00000258302.2	RP11-981P6.1	5.53	5.23e-08	1.74e-05	0.31	0.24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89468253	chr12:89561129~89594878:+
LUAD	cis	rs11105298	0.891	rs10858871	ENSG00000258302.2	RP11-981P6.1	5.53	5.23e-08	1.74e-05	0.31	0.24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89477836	chr12:89561129~89594878:+
LUAD	cis	rs11105298	0.891	rs10858872	ENSG00000258302.2	RP11-981P6.1	5.53	5.23e-08	1.74e-05	0.31	0.24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89479155	chr12:89561129~89594878:+
LUAD	cis	rs4654783	0.627	rs2092322	ENSG00000228397.1	RP1-224A6.3	-5.53	5.23e-08	1.74e-05	-0.29	-0.24	Endometriosis;	chr1:22109230	chr1:22023994~22024968:-
LUAD	cis	rs673078	0.66	rs17512574	ENSG00000275409.1	RP11-131L12.4	-5.53	5.23e-08	1.74e-05	-0.34	-0.24	Glucose homeostasis traits;	chr12:118350198	chr12:118430147~118430699:+
LUAD	cis	rs9952991	0.527	rs2847259	ENSG00000260302.1	RP11-973H7.1	-5.53	5.23e-08	1.74e-05	-0.36	-0.24	Inflammatory skin disease;	chr18:12775822	chr18:12774651~12775923:-
LUAD	cis	rs2440129	0.632	rs2292353	ENSG00000215067.8	ALOX12-AS1	5.53	5.24e-08	1.75e-05	0.25	0.24	Tonsillectomy;	chr17:7000218	chr17:6876635~7012349:-
LUAD	cis	rs36093844	0.948	rs56271770	ENSG00000279742.1	RP11-700A24.1	-5.53	5.25e-08	1.75e-05	-0.28	-0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85837357	chr11:85852557~85854943:-
LUAD	cis	rs853679	0.882	rs9468287	ENSG00000219392.1	RP1-265C24.5	-5.53	5.25e-08	1.75e-05	-0.42	-0.24	Depression;	chr6:28111963	chr6:28115628~28116551:+
LUAD	cis	rs7829975	0.509	rs2945269	ENSG00000253981.4	ALG1L13P	5.53	5.25e-08	1.75e-05	0.29	0.24	Mood instability;	chr8:8258056	chr8:8236003~8244667:-
LUAD	cis	rs6543140	0.964	rs6748390	ENSG00000234389.1	AC007278.3	5.53	5.25e-08	1.75e-05	0.24	0.24	Blood protein levels;	chr2:102445715	chr2:102438713~102440475:+
LUAD	cis	rs8098244	0.597	rs12964391	ENSG00000264745.1	TTC39C-AS1	5.53	5.25e-08	1.75e-05	0.26	0.24	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23734541	chr18:23994213~24015339:-
LUAD	cis	rs11105298	0.891	rs10858900	ENSG00000258302.2	RP11-981P6.1	5.53	5.26e-08	1.75e-05	0.31	0.24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89531304	chr12:89561129~89594878:+
LUAD	cis	rs11105298	0.891	rs11105316	ENSG00000258302.2	RP11-981P6.1	5.53	5.26e-08	1.75e-05	0.31	0.24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89531423	chr12:89561129~89594878:+
LUAD	cis	rs1707322	1	rs11211232	ENSG00000234329.1	RP11-767N6.2	5.53	5.27e-08	1.75e-05	0.26	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45945474	chr1:45651039~45651826:-
LUAD	cis	rs17684571	0.751	rs6905603	ENSG00000231441.1	RP11-472M19.2	5.53	5.27e-08	1.75e-05	0.37	0.24	Schizophrenia;	chr6:56848145	chr6:56844002~56864078:+
LUAD	cis	rs6142102	0.517	rs6142046	ENSG00000275784.1	RP5-1125A11.6	-5.53	5.27e-08	1.75e-05	-0.26	-0.24	Skin pigmentation;	chr20:33926255	chr20:33989480~33991818:-
LUAD	cis	rs2836950	0.509	rs11088466	ENSG00000255568.3	BRWD1-AS2	-5.53	5.27e-08	1.75e-05	-0.24	-0.24	Menarche (age at onset);	chr21:39208091	chr21:39313935~39314962:+
LUAD	cis	rs496547	0.686	rs591756	ENSG00000255239.1	AP002954.6	5.53	5.27e-08	1.75e-05	0.3	0.24	Hip minimal joint space width;	chr11:118808172	chr11:118688039~118690600:-
LUAD	cis	rs36423	0.702	rs1205076	ENSG00000266869.1	RP6-114E22.1	5.53	5.27e-08	1.75e-05	0.38	0.24	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71871335	chr14:71848606~71908430:+
LUAD	cis	rs2404602	0.735	rs2436996	ENSG00000259422.1	RP11-593F23.1	-5.53	5.27e-08	1.75e-05	-0.31	-0.24	Blood metabolite levels;	chr15:76525079	chr15:76174891~76181486:-
LUAD	cis	rs9287719	0.566	rs34595606	ENSG00000243819.4	RN7SL832P	5.53	5.28e-08	1.76e-05	0.27	0.24	Prostate cancer;	chr2:10582392	chr2:10690344~10692099:+
LUAD	cis	rs1707322	1	rs7553924	ENSG00000234329.1	RP11-767N6.2	5.53	5.28e-08	1.76e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886952	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs4641257	ENSG00000234329.1	RP11-767N6.2	5.53	5.28e-08	1.76e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45887917	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs6693336	ENSG00000234329.1	RP11-767N6.2	5.53	5.28e-08	1.76e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45888923	chr1:45651039~45651826:-
LUAD	cis	rs9914544	0.628	rs4630608	ENSG00000273018.4	CTD-2303H24.2	-5.53	5.29e-08	1.76e-05	-0.29	-0.24	Educational attainment (years of education);	chr17:18775235	chr17:18511221~18551705:-
LUAD	cis	rs1275468	0.731	rs1627431	ENSG00000257497.2	RP11-585P4.5	-5.53	5.29e-08	1.76e-05	-0.37	-0.24	Polycystic ovary syndrome;	chr12:75569132	chr12:75483454~75489820:-
LUAD	cis	rs116095464	1	rs56700778	ENSG00000277812.1	AC021087.1	5.53	5.3e-08	1.76e-05	0.69	0.24	Breast cancer;	chr5:313071	chr5:262769~262881:+
LUAD	cis	rs801193	0.773	rs801207	ENSG00000224316.1	RP11-479O9.2	-5.53	5.3e-08	1.76e-05	-0.24	-0.24	Aortic root size;	chr7:66555603	chr7:65773620~65802067:+
LUAD	cis	rs2273788	1	rs12555931	ENSG00000204173.9	LRRC37A5P	5.53	5.3e-08	1.76e-05	0.27	0.24	Monocyte count;	chr9:111581096	chr9:111602831~111631289:-
LUAD	cis	rs17684571	0.7	rs16888171	ENSG00000231441.1	RP11-472M19.2	5.53	5.3e-08	1.77e-05	0.34	0.24	Schizophrenia;	chr6:56810369	chr6:56844002~56864078:+
LUAD	cis	rs1113500	0.966	rs11185249	ENSG00000226822.1	RP11-356N1.2	5.53	5.31e-08	1.77e-05	0.28	0.24	Growth-regulated protein alpha levels;	chr1:108069024	chr1:108071482~108074519:+
LUAD	cis	rs8177376	0.906	rs240559	ENSG00000254905.1	RP11-712L6.7	5.53	5.31e-08	1.77e-05	0.35	0.24	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126321217	chr11:126292922~126294254:-
LUAD	cis	rs10246939	0.579	rs9640205	ENSG00000228775.6	WEE2-AS1	5.53	5.31e-08	1.77e-05	0.3	0.24	Bitter taste perception;	chr7:141844400	chr7:141704338~141738346:-
LUAD	cis	rs7712401	0.601	rs28892	ENSG00000263432.2	RN7SL689P	-5.53	5.31e-08	1.77e-05	-0.31	-0.24	Mean platelet volume;	chr5:122948131	chr5:123022487~123022783:-
LUAD	cis	rs9595908	0.536	rs73452706	ENSG00000212293.1	SNORA16	5.53	5.31e-08	1.77e-05	0.26	0.24	Body mass index;	chr13:32718155	chr13:32420390~32420516:-
LUAD	cis	rs673078	0.607	rs61943391	ENSG00000275409.1	RP11-131L12.4	-5.53	5.33e-08	1.77e-05	-0.34	-0.24	Glucose homeostasis traits;	chr12:118382603	chr12:118430147~118430699:+
LUAD	cis	rs6964587	0.743	rs33993294	ENSG00000188693.7	CYP51A1-AS1	-5.53	5.33e-08	1.77e-05	-0.29	-0.24	Breast cancer;	chr7:92369341	chr7:92134604~92180725:+
LUAD	cis	rs6964587	0.773	rs38793	ENSG00000188693.7	CYP51A1-AS1	5.53	5.33e-08	1.77e-05	0.29	0.24	Breast cancer;	chr7:92397873	chr7:92134604~92180725:+
LUAD	cis	rs673078	0.66	rs61943535	ENSG00000275409.1	RP11-131L12.4	-5.53	5.33e-08	1.77e-05	-0.35	-0.24	Glucose homeostasis traits;	chr12:118168307	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.66	rs76621503	ENSG00000275409.1	RP11-131L12.4	-5.53	5.33e-08	1.77e-05	-0.35	-0.24	Glucose homeostasis traits;	chr12:118179370	chr12:118430147~118430699:+
LUAD	cis	rs7665090	0.728	rs228617	ENSG00000246560.2	RP11-10L12.4	-5.53	5.33e-08	1.77e-05	-0.3	-0.24	Primary biliary cholangitis;	chr4:102659631	chr4:102828055~102844075:+
LUAD	cis	rs9847710	0.808	rs2564919	ENSG00000242142.1	SERBP1P3	5.53	5.33e-08	1.77e-05	0.27	0.24	Ulcerative colitis;	chr3:52999279	chr3:53064283~53065091:-
LUAD	cis	rs7208859	0.623	rs122898	ENSG00000263603.1	CTD-2349P21.5	5.53	5.35e-08	1.78e-05	0.42	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30729469~30731202:+
LUAD	cis	rs2919009	0.544	rs2901280	ENSG00000271670.1	RP11-95I16.4	-5.53	5.35e-08	1.78e-05	-0.3	-0.24	Obesity-related traits;	chr10:120895865	chr10:120879256~120880667:-
LUAD	cis	rs62432291	0.681	rs294913	ENSG00000235086.1	FNDC1-IT1	-5.53	5.35e-08	1.78e-05	-0.42	-0.24	Joint mobility (Beighton score);	chr6:159246195	chr6:159240786~159243329:+
LUAD	cis	rs2946504	0.861	rs6986271	ENSG00000251468.2	RP11-369K16.1	-5.53	5.36e-08	1.78e-05	-0.32	-0.24	Type 2 diabetes;	chr8:12959345	chr8:12958387~12962200:+
LUAD	cis	rs11098499	0.644	rs2389880	ENSG00000248280.1	RP11-33B1.2	5.53	5.36e-08	1.78e-05	0.31	0.24	Corneal astigmatism;	chr4:119638715	chr4:119440561~119450157:-
LUAD	cis	rs957448	1	rs7829886	ENSG00000253704.1	RP11-267M23.4	5.53	5.37e-08	1.78e-05	0.3	0.24	Nonsyndromic cleft lip with cleft palate;	chr8:94485160	chr8:94553722~94569745:+
LUAD	cis	rs74233809	1	rs3781285	ENSG00000213277.3	MARCKSL1P1	5.53	5.37e-08	1.79e-05	0.43	0.24	Birth weight;	chr10:103065908	chr10:103175554~103176094:+
LUAD	cis	rs35740288	0.689	rs11630688	ENSG00000202081.1	RNU6-1280P	5.53	5.38e-08	1.79e-05	0.31	0.24	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85710048	chr15:85651522~85651628:-
LUAD	cis	rs910316	0.523	rs4026175	ENSG00000279594.1	RP11-950C14.10	5.53	5.38e-08	1.79e-05	0.29	0.24	Height;	chr14:75035537	chr14:75011269~75012851:-
LUAD	cis	rs9309473	0.615	rs74523560	ENSG00000163016.8	ALMS1P	5.53	5.38e-08	1.79e-05	0.38	0.24	Metabolite levels;	chr2:73537058	chr2:73644919~73685576:+
LUAD	cis	rs7615952	0.599	rs6803160	ENSG00000171084.14	FAM86JP	5.53	5.38e-08	1.79e-05	0.35	0.24	Blood pressure (smoking interaction);	chr3:125990711	chr3:125916620~125930024:+
LUAD	cis	rs1707322	0.964	rs785483	ENSG00000234329.1	RP11-767N6.2	-5.53	5.38e-08	1.79e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46093499	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.964	rs796773	ENSG00000234329.1	RP11-767N6.2	-5.53	5.38e-08	1.79e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46098803	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.896	rs785518	ENSG00000234329.1	RP11-767N6.2	-5.53	5.38e-08	1.79e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102750	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs785519	ENSG00000234329.1	RP11-767N6.2	-5.53	5.38e-08	1.79e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102890	chr1:45651039~45651826:-
LUAD	cis	rs6687821	0.515	rs1407132	ENSG00000267734.1	RP4-604K5.3	5.53	5.38e-08	1.79e-05	0.3	0.24	Yeast infection;	chr1:86928231	chr1:86932199~86934891:-
LUAD	cis	rs748404	0.589	rs3862138	ENSG00000205771.5	CATSPER2P1	-5.53	5.38e-08	1.79e-05	-0.37	-0.24	Lung cancer;	chr15:43523801	chr15:43726918~43747094:-
LUAD	cis	rs673078	0.607	rs7132753	ENSG00000275409.1	RP11-131L12.4	-5.53	5.39e-08	1.79e-05	-0.34	-0.24	Glucose homeostasis traits;	chr12:118420383	chr12:118430147~118430699:+
LUAD	cis	rs8072100	0.967	rs7219303	ENSG00000228782.6	CTD-2026D20.3	-5.53	5.39e-08	1.79e-05	-0.25	-0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47660335	chr17:47450568~47492492:-
LUAD	cis	rs8098244	0.515	rs4387667	ENSG00000264745.1	TTC39C-AS1	5.53	5.39e-08	1.79e-05	0.26	0.24	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23716161	chr18:23994213~24015339:-
LUAD	cis	rs394563	0.591	rs237028	ENSG00000231760.4	RP11-350J20.5	5.53	5.39e-08	1.79e-05	0.3	0.24	Dupuytren's disease;	chr6:149397514	chr6:149796151~149826294:-
LUAD	cis	rs2790457	0.958	rs2532742	ENSG00000254635.4	WAC-AS1	-5.53	5.4e-08	1.79e-05	-0.27	-0.24	Multiple myeloma;	chr10:28578291	chr10:28522652~28532743:-
LUAD	cis	rs62432291	0.681	rs386818	ENSG00000235086.1	FNDC1-IT1	-5.53	5.4e-08	1.79e-05	-0.42	-0.24	Joint mobility (Beighton score);	chr6:159239223	chr6:159240786~159243329:+
LUAD	cis	rs9500256	0.655	rs12209098	ENSG00000215190.7	LINC00680	5.53	5.41e-08	1.8e-05	0.31	0.24	Eosinophilic esophagitis (pediatric);	chr6:58014194	chr6:57946074~57961501:-
LUAD	cis	rs7182621	0.639	rs36069387	ENSG00000182397.13	DNM1P46	5.52	5.41e-08	1.8e-05	0.29	0.24	Colonoscopy-negative controls vs population controls;	chr15:99884540	chr15:99790156~99806927:-
LUAD	cis	rs8040855	0.86	rs6496775	ENSG00000259774.1	RP11-182J1.13	-5.52	5.41e-08	1.8e-05	-0.31	-0.24	Bulimia nervosa;	chr15:85164910	chr15:84422618~84425882:+
LUAD	cis	rs9322193	0.923	rs9371207	ENSG00000268592.3	RAET1E-AS1	5.52	5.41e-08	1.8e-05	0.32	0.24	Lung cancer;	chr6:149858087	chr6:149863494~149919507:+
LUAD	cis	rs948562	0.947	rs7481388	ENSG00000280010.1	AP001350.4	5.52	5.41e-08	1.8e-05	0.36	0.24	Lymphoma;	chr11:58592143	chr11:58627435~58628528:+
LUAD	cis	rs2439831	0.85	rs28413881	ENSG00000205771.5	CATSPER2P1	-5.52	5.41e-08	1.8e-05	-0.5	-0.24	Lung cancer in ever smokers;	chr15:43881901	chr15:43726918~43747094:-
LUAD	cis	rs75422866	0.51	rs73105829	ENSG00000257433.4	RP1-197B17.3	5.52	5.41e-08	1.8e-05	0.5	0.24	Pneumonia;	chr12:47734162	chr12:47706085~47742294:+
LUAD	cis	rs2404602	0.735	rs11072598	ENSG00000259422.1	RP11-593F23.1	-5.52	5.42e-08	1.8e-05	-0.32	-0.24	Blood metabolite levels;	chr15:76472447	chr15:76174891~76181486:-
LUAD	cis	rs4835473	0.712	rs2198000	ENSG00000251600.4	RP11-673E1.1	-5.52	5.42e-08	1.8e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143750005	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs2198002	ENSG00000251600.4	RP11-673E1.1	-5.52	5.42e-08	1.8e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143750028	chr4:143912331~143982454:+
LUAD	cis	rs9309473	0.528	rs79799178	ENSG00000163016.8	ALMS1P	5.52	5.42e-08	1.8e-05	0.36	0.24	Metabolite levels;	chr2:73564108	chr2:73644919~73685576:+
LUAD	cis	rs453301	0.686	rs1045527	ENSG00000253981.4	ALG1L13P	-5.52	5.42e-08	1.8e-05	-0.29	-0.24	Joint mobility (Beighton score);	chr8:9032531	chr8:8236003~8244667:-
LUAD	cis	rs4835473	0.932	rs6838887	ENSG00000251600.4	RP11-673E1.1	-5.52	5.43e-08	1.8e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143748130	chr4:143912331~143982454:+
LUAD	cis	rs6687821	0.515	rs11161914	ENSG00000267734.1	RP4-604K5.3	-5.52	5.44e-08	1.81e-05	-0.3	-0.24	Yeast infection;	chr1:86977846	chr1:86932199~86934891:-
LUAD	cis	rs7617773	0.817	rs9837228	ENSG00000228638.1	FCF1P2	5.52	5.44e-08	1.81e-05	0.28	0.24	Coronary artery disease;	chr3:48282976	chr3:48290793~48291375:-
LUAD	cis	rs1707322	0.827	rs6683274	ENSG00000280836.1	AL355480.1	-5.52	5.44e-08	1.81e-05	-0.33	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45775966	chr1:45581219~45581321:-
LUAD	cis	rs4664293	0.605	rs12991516	ENSG00000226266.5	AC009961.3	-5.52	5.44e-08	1.81e-05	-0.32	-0.24	Monocyte percentage of white cells;	chr2:159585554	chr2:159670708~159712435:-
LUAD	cis	rs2790457	0.793	rs2153302	ENSG00000254635.4	WAC-AS1	-5.52	5.44e-08	1.81e-05	-0.27	-0.24	Multiple myeloma;	chr10:28529607	chr10:28522652~28532743:-
LUAD	cis	rs7712401	0.765	rs4349713	ENSG00000263432.2	RN7SL689P	5.52	5.45e-08	1.81e-05	0.31	0.24	Mean platelet volume;	chr5:123055931	chr5:123022487~123022783:-
LUAD	cis	rs3096299	0.591	rs748940	ENSG00000274627.1	RP11-104N10.2	5.52	5.45e-08	1.81e-05	0.24	0.24	Multiple myeloma (IgH translocation);	chr16:89374349	chr16:89516797~89522217:+
LUAD	cis	rs4713118	0.824	rs2179095	ENSG00000219392.1	RP1-265C24.5	5.52	5.45e-08	1.81e-05	0.32	0.24	Parkinson's disease;	chr6:27783079	chr6:28115628~28116551:+
LUAD	cis	rs6496044	0.507	rs7175731	ENSG00000259407.1	RP11-158M2.3	5.52	5.45e-08	1.81e-05	0.22	0.24	Interstitial lung disease;	chr15:85611115	chr15:85744109~85750281:-
LUAD	cis	rs6496044	0.507	rs1471455	ENSG00000259407.1	RP11-158M2.3	5.52	5.45e-08	1.81e-05	0.22	0.24	Interstitial lung disease;	chr15:85611496	chr15:85744109~85750281:-
LUAD	cis	rs35740288	0.787	rs35250181	ENSG00000202081.1	RNU6-1280P	5.52	5.46e-08	1.81e-05	0.31	0.24	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85699431	chr15:85651522~85651628:-
LUAD	cis	rs10091374	0.839	rs6472533	ENSG00000253967.1	RP11-333A23.4	-5.52	5.47e-08	1.81e-05	-0.28	-0.24	Cardiac Troponin-T levels;	chr8:70482378	chr8:70471134~70485687:+
LUAD	cis	rs36093844	0.8	rs75203358	ENSG00000279742.1	RP11-700A24.1	-5.52	5.47e-08	1.82e-05	-0.33	-0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85856347	chr11:85852557~85854943:-
LUAD	cis	rs2880765	0.835	rs56406982	ENSG00000259295.5	CSPG4P12	5.52	5.47e-08	1.82e-05	0.28	0.24	Coronary artery disease;	chr15:85493148	chr15:85191438~85213905:+
LUAD	cis	rs9928842	0.679	rs4888361	ENSG00000280152.1	RP11-331F4.5	5.52	5.47e-08	1.82e-05	0.26	0.24	Alcoholic chronic pancreatitis;	chr16:75233778	chr16:75245994~75250077:-
LUAD	cis	rs6991838	1	rs6991838	ENSG00000200714.1	Y_RNA	-5.52	5.47e-08	1.82e-05	-0.28	-0.24	Intelligence (multi-trait analysis);	chr8:65558727	chr8:65592731~65592820:+
LUAD	cis	rs7580658	0.724	rs71414745	ENSG00000236682.1	AC068282.3	-5.52	5.47e-08	1.82e-05	-0.31	-0.24	Protein C levels;	chr2:127235012	chr2:127389130~127400580:+
LUAD	cis	rs12468226	1	rs16839077	ENSG00000272966.1	RP11-686O6.1	5.52	5.48e-08	1.82e-05	0.42	0.24	Urate levels;	chr2:202343970	chr2:202336739~202337200:+
LUAD	cis	rs7712401	0.601	rs154506	ENSG00000263432.2	RN7SL689P	5.52	5.49e-08	1.82e-05	0.31	0.24	Mean platelet volume;	chr5:122867086	chr5:123022487~123022783:-
LUAD	cis	rs763567	0.585	rs577827	ENSG00000271811.1	RP1-79C4.4	5.52	5.49e-08	1.82e-05	0.29	0.24	Tonsillectomy;	chr1:170593942	chr1:170667381~170669425:+
LUAD	cis	rs71636778	0.509	rs35917448	ENSG00000260063.1	RP5-968P14.2	-5.52	5.49e-08	1.82e-05	-0.45	-0.24	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26690834	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs71514277	ENSG00000260063.1	RP5-968P14.2	-5.52	5.49e-08	1.82e-05	-0.45	-0.24	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26707937	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.57	rs12737407	ENSG00000260063.1	RP5-968P14.2	-5.52	5.49e-08	1.82e-05	-0.45	-0.24	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26709671	chr1:26692132~26694131:-
LUAD	cis	rs17264034	0.861	rs1508798	ENSG00000250786.1	SNHG18	-5.52	5.49e-08	1.82e-05	-0.34	-0.24	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9556582	chr5:9546200~9550609:+
LUAD	cis	rs2404602	0.647	rs11072618	ENSG00000259422.1	RP11-593F23.1	-5.52	5.5e-08	1.82e-05	-0.33	-0.24	Blood metabolite levels;	chr15:76727001	chr15:76174891~76181486:-
LUAD	cis	rs4568518	0.53	rs4493811	ENSG00000279048.1	RP11-511H23.2	5.52	5.5e-08	1.83e-05	0.2	0.24	Measles;	chr7:17943746	chr7:17940503~17942922:+
LUAD	cis	rs2948294	0.566	rs13274039	ENSG00000173295.6	FAM86B3P	5.52	5.51e-08	1.83e-05	0.27	0.24	Red cell distribution width;	chr8:8254137	chr8:8228595~8244865:+
LUAD	cis	rs2404602	0.662	rs908817	ENSG00000259422.1	RP11-593F23.1	-5.52	5.51e-08	1.83e-05	-0.32	-0.24	Blood metabolite levels;	chr15:76346850	chr15:76174891~76181486:-
LUAD	cis	rs7044106	0.708	rs991121	ENSG00000238181.2	AHCYP2	-5.52	5.52e-08	1.83e-05	-0.31	-0.24	Hip circumference adjusted for BMI;	chr9:120608067	chr9:120720673~120721972:+
LUAD	cis	rs11098499	0.754	rs1849457	ENSG00000248280.1	RP11-33B1.2	5.52	5.53e-08	1.83e-05	0.31	0.24	Corneal astigmatism;	chr4:119333200	chr4:119440561~119450157:-
LUAD	cis	rs673078	0.66	rs6490175	ENSG00000275409.1	RP11-131L12.4	-5.52	5.53e-08	1.83e-05	-0.31	-0.24	Glucose homeostasis traits;	chr12:118293559	chr12:118430147~118430699:+
LUAD	cis	rs11105298	0.891	rs10858851	ENSG00000258302.2	RP11-981P6.1	5.52	5.53e-08	1.83e-05	0.31	0.24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89437093	chr12:89561129~89594878:+
LUAD	cis	rs2111504	0.583	rs10853921	ENSG00000267213.4	AC007773.2	-5.52	5.53e-08	1.84e-05	-0.32	-0.24	Bipolar disorder;	chr19:32370899	chr19:32390050~32405560:-
LUAD	cis	rs1075265	0.84	rs2884254	ENSG00000233266.1	HMGB1P31	5.52	5.54e-08	1.84e-05	0.31	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53979326	chr2:54051334~54051760:+
LUAD	cis	rs74233809	1	rs12220743	ENSG00000213277.3	MARCKSL1P1	5.52	5.54e-08	1.84e-05	0.43	0.24	Birth weight;	chr10:103092155	chr10:103175554~103176094:+
LUAD	cis	rs12289961	0.634	rs11229433	ENSG00000280010.1	AP001350.4	5.52	5.54e-08	1.84e-05	0.4	0.24	Lymphoma;	chr11:58417863	chr11:58627435~58628528:+
LUAD	cis	rs853679	0.546	rs175597	ENSG00000219392.1	RP1-265C24.5	-5.52	5.54e-08	1.84e-05	-0.47	-0.24	Depression;	chr6:27842848	chr6:28115628~28116551:+
LUAD	cis	rs2404602	0.735	rs1607015	ENSG00000259422.1	RP11-593F23.1	-5.52	5.55e-08	1.84e-05	-0.31	-0.24	Blood metabolite levels;	chr15:76410088	chr15:76174891~76181486:-
LUAD	cis	rs673078	0.607	rs61943399	ENSG00000275409.1	RP11-131L12.4	-5.52	5.55e-08	1.84e-05	-0.34	-0.24	Glucose homeostasis traits;	chr12:118393628	chr12:118430147~118430699:+
LUAD	cis	rs6687758	0.687	rs12137323	ENSG00000228437.4	RP11-400N13.2	5.52	5.56e-08	1.84e-05	0.37	0.24	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221952186	chr1:221966341~221984964:+
LUAD	cis	rs2599510	0.748	rs6718214	ENSG00000276334.1	AL133243.1	-5.52	5.56e-08	1.84e-05	-0.28	-0.24	Interleukin-18 levels;	chr2:32325416	chr2:32521927~32523547:+
LUAD	cis	rs9847710	0.566	rs2564951	ENSG00000242142.1	SERBP1P3	5.52	5.56e-08	1.84e-05	0.29	0.24	Ulcerative colitis;	chr3:53026433	chr3:53064283~53065091:-
LUAD	cis	rs10129255	0.957	rs10136781	ENSG00000224373.3	IGHV4-59	5.52	5.56e-08	1.84e-05	0.15	0.24	Kawasaki disease;	chr14:106780451	chr14:106627249~106627825:-
LUAD	cis	rs10129255	0.957	rs8022165	ENSG00000224373.3	IGHV4-59	5.52	5.56e-08	1.84e-05	0.15	0.24	Kawasaki disease;	chr14:106781682	chr14:106627249~106627825:-
LUAD	cis	rs10129255	0.917	rs8022493	ENSG00000224373.3	IGHV4-59	5.52	5.56e-08	1.84e-05	0.15	0.24	Kawasaki disease;	chr14:106781820	chr14:106627249~106627825:-
LUAD	cis	rs1015362	0.504	rs6059552	ENSG00000276073.1	RP5-1125A11.7	-5.52	5.57e-08	1.84e-05	-0.3	-0.24	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33923820	chr20:33985617~33988989:-
LUAD	cis	rs925255	0.713	rs9309662	ENSG00000270210.1	RP11-373D23.3	-5.52	5.57e-08	1.85e-05	-0.28	-0.24	Inflammatory bowel disease;Crohn's disease;	chr2:28407025	chr2:28425945~28426719:+
LUAD	cis	rs8072100	0.537	rs9912450	ENSG00000228782.6	CTD-2026D20.3	5.52	5.57e-08	1.85e-05	0.28	0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47324842	chr17:47450568~47492492:-
LUAD	cis	rs6964587	0.773	rs12536421	ENSG00000188693.7	CYP51A1-AS1	-5.52	5.57e-08	1.85e-05	-0.29	-0.24	Breast cancer;	chr7:92378906	chr7:92134604~92180725:+
LUAD	cis	rs875971	0.545	rs221986	ENSG00000226824.5	RP4-756H11.3	5.52	5.57e-08	1.85e-05	0.37	0.24	Aortic root size;	chr7:66105323	chr7:66654538~66669855:+
LUAD	cis	rs4664293	0.546	rs12469866	ENSG00000226266.5	AC009961.3	5.52	5.57e-08	1.85e-05	0.33	0.24	Monocyte percentage of white cells;	chr2:159766119	chr2:159670708~159712435:-
LUAD	cis	rs4722166	0.597	rs1554606	ENSG00000179428.2	AC073072.5	-5.52	5.58e-08	1.85e-05	-0.28	-0.24	Lung cancer;	chr7:22729088	chr7:22725395~22727620:-
LUAD	cis	rs36093844	0.752	rs56396016	ENSG00000279742.1	RP11-700A24.1	-5.52	5.58e-08	1.85e-05	-0.33	-0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85885347	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.747	rs17817314	ENSG00000279742.1	RP11-700A24.1	-5.52	5.58e-08	1.85e-05	-0.33	-0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85883929	chr11:85852557~85854943:-
LUAD	cis	rs2404602	0.655	rs8028294	ENSG00000259422.1	RP11-593F23.1	5.52	5.58e-08	1.85e-05	0.28	0.24	Blood metabolite levels;	chr15:76792536	chr15:76174891~76181486:-
LUAD	cis	rs673078	0.607	rs2062519	ENSG00000275409.1	RP11-131L12.4	-5.52	5.58e-08	1.85e-05	-0.3	-0.24	Glucose homeostasis traits;	chr12:118367577	chr12:118430147~118430699:+
LUAD	cis	rs66887589	0.777	rs2017058	ENSG00000245958.5	RP11-33B1.1	-5.52	5.59e-08	1.85e-05	-0.19	-0.24	Diastolic blood pressure;	chr4:119336584	chr4:119454791~119552025:+
LUAD	cis	rs66887589	0.777	rs1814815	ENSG00000245958.5	RP11-33B1.1	-5.52	5.59e-08	1.85e-05	-0.19	-0.24	Diastolic blood pressure;	chr4:119336936	chr4:119454791~119552025:+
LUAD	cis	rs875971	0.929	rs4122249	ENSG00000237310.1	GS1-124K5.4	5.52	5.59e-08	1.85e-05	0.27	0.24	Aortic root size;	chr7:66455949	chr7:66493706~66495474:+
LUAD	cis	rs673078	0.607	rs17441172	ENSG00000275409.1	RP11-131L12.4	5.52	5.59e-08	1.85e-05	0.34	0.24	Glucose homeostasis traits;	chr12:118430456	chr12:118430147~118430699:+
LUAD	cis	rs2243480	0.522	rs778717	ENSG00000226824.5	RP4-756H11.3	-5.52	5.6e-08	1.86e-05	-0.53	-0.24	Diabetic kidney disease;	chr7:66383164	chr7:66654538~66669855:+
LUAD	cis	rs673078	0.607	rs950288	ENSG00000275409.1	RP11-131L12.4	-5.52	5.6e-08	1.86e-05	-0.34	-0.24	Glucose homeostasis traits;	chr12:118392201	chr12:118430147~118430699:+
LUAD	cis	rs2404602	0.692	rs58973160	ENSG00000259422.1	RP11-593F23.1	5.52	5.61e-08	1.86e-05	0.28	0.24	Blood metabolite levels;	chr15:76708001	chr15:76174891~76181486:-
LUAD	cis	rs2179367	0.632	rs55836833	ENSG00000231760.4	RP11-350J20.5	5.52	5.61e-08	1.86e-05	0.35	0.24	Dupuytren's disease;	chr6:149403736	chr6:149796151~149826294:-
LUAD	cis	rs10214930	0.697	rs4722724	ENSG00000235574.1	AC073150.6	5.52	5.61e-08	1.86e-05	0.29	0.24	Hypospadias;	chr7:27615314	chr7:27491682~27492765:-
LUAD	cis	rs30380	1	rs469758	ENSG00000272109.1	CTD-2260A17.3	-5.52	5.62e-08	1.86e-05	-0.26	-0.24	Cerebrospinal fluid biomarker levels;	chr5:96786011	chr5:96804353~96806105:+
LUAD	cis	rs6921919	0.848	rs9468350	ENSG00000216901.1	AL022393.7	5.52	5.62e-08	1.86e-05	0.32	0.24	Autism spectrum disorder or schizophrenia;	chr6:28351330	chr6:28176188~28176674:+
LUAD	cis	rs2404602	0.647	rs12910820	ENSG00000259422.1	RP11-593F23.1	-5.52	5.62e-08	1.86e-05	-0.32	-0.24	Blood metabolite levels;	chr15:76730484	chr15:76174891~76181486:-
LUAD	cis	rs2280018	0.963	rs12928424	ENSG00000188599.16	NPIPP1	-5.52	5.62e-08	1.86e-05	-0.2	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056916	chr16:15104312~15123498:-
LUAD	cis	rs30380	0.553	rs27527	ENSG00000272109.1	CTD-2260A17.3	-5.52	5.62e-08	1.86e-05	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr5:96816265	chr5:96804353~96806105:+
LUAD	cis	rs5753618	0.583	rs34545960	ENSG00000236132.1	CTA-440B3.1	-5.52	5.63e-08	1.86e-05	-0.3	-0.24	Colorectal cancer;	chr22:31416476	chr22:31816379~31817491:-
LUAD	cis	rs5753618	0.583	rs5749270	ENSG00000236132.1	CTA-440B3.1	-5.52	5.63e-08	1.86e-05	-0.3	-0.24	Colorectal cancer;	chr22:31416867	chr22:31816379~31817491:-
LUAD	cis	rs1823874	0.71	rs4246297	ENSG00000182397.13	DNM1P46	-5.52	5.63e-08	1.86e-05	-0.3	-0.24	IgG glycosylation;	chr15:99826723	chr15:99790156~99806927:-
LUAD	cis	rs7618915	0.851	rs34228726	ENSG00000243224.1	RP5-1157M23.2	-5.52	5.63e-08	1.86e-05	-0.26	-0.24	Bipolar disorder;	chr3:52288781	chr3:52239258~52241097:+
LUAD	cis	rs6142102	0.812	rs6120440	ENSG00000275784.1	RP5-1125A11.6	5.52	5.64e-08	1.87e-05	0.29	0.24	Skin pigmentation;	chr20:33929779	chr20:33989480~33991818:-
LUAD	cis	rs875971	1	rs9986696	ENSG00000237310.1	GS1-124K5.4	-5.52	5.65e-08	1.87e-05	-0.26	-0.24	Aortic root size;	chr7:66239589	chr7:66493706~66495474:+
LUAD	cis	rs75920871	0.528	rs10892071	ENSG00000254851.1	RP11-109L13.1	5.52	5.65e-08	1.87e-05	0.35	0.24	Subjective well-being;	chr11:117083849	chr11:117135528~117138582:+
LUAD	cis	rs2404602	0.716	rs66754747	ENSG00000259422.1	RP11-593F23.1	5.52	5.65e-08	1.87e-05	0.28	0.24	Blood metabolite levels;	chr15:76536227	chr15:76174891~76181486:-
LUAD	cis	rs12908161	0.959	rs17598603	ENSG00000225151.9	GOLGA2P7	5.52	5.65e-08	1.87e-05	0.32	0.24	Schizophrenia;	chr15:84656980	chr15:84199311~84230136:-
LUAD	cis	rs36093844	0.8	rs79349553	ENSG00000279742.1	RP11-700A24.1	-5.52	5.66e-08	1.87e-05	-0.32	-0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85856793	chr11:85852557~85854943:-
LUAD	cis	rs10129255	0.957	rs56134540	ENSG00000224373.3	IGHV4-59	5.52	5.66e-08	1.87e-05	0.16	0.24	Kawasaki disease;	chr14:106691290	chr14:106627249~106627825:-
LUAD	cis	rs1823874	0.581	rs12905599	ENSG00000182397.13	DNM1P46	-5.52	5.66e-08	1.87e-05	-0.29	-0.24	IgG glycosylation;	chr15:99799733	chr15:99790156~99806927:-
LUAD	cis	rs891378	0.959	rs1864370	ENSG00000274245.1	RP11-357P18.2	-5.52	5.66e-08	1.87e-05	-0.3	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207245687	chr1:207372559~207373252:+
LUAD	cis	rs891378	1	rs1429906	ENSG00000274245.1	RP11-357P18.2	-5.52	5.66e-08	1.87e-05	-0.3	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207246982	chr1:207372559~207373252:+
LUAD	cis	rs10214930	0.651	rs42111	ENSG00000235574.1	AC073150.6	5.52	5.67e-08	1.88e-05	0.3	0.24	Hypospadias;	chr7:27682962	chr7:27491682~27492765:-
LUAD	cis	rs7829975	0.593	rs2921077	ENSG00000253981.4	ALG1L13P	5.52	5.67e-08	1.88e-05	0.28	0.24	Mood instability;	chr8:8446992	chr8:8236003~8244667:-
LUAD	cis	rs10129255	1	rs10129319	ENSG00000224373.3	IGHV4-59	5.52	5.67e-08	1.88e-05	0.16	0.24	Kawasaki disease;	chr14:106767996	chr14:106627249~106627825:-
LUAD	cis	rs2276314	0.512	rs7227264	ENSG00000278986.1	RP11-723J4.3	-5.52	5.67e-08	1.88e-05	-0.26	-0.24	Endometriosis;Drug-induced torsades de pointes;	chr18:35874668	chr18:35972151~35973916:+
LUAD	cis	rs944289	0.553	rs1305576	ENSG00000257826.1	RP11-116N8.4	-5.52	5.68e-08	1.88e-05	-0.27	-0.24	Thyroid cancer;	chr14:36161528	chr14:36061026~36067190:-
LUAD	cis	rs875971	0.898	rs6977501	ENSG00000237310.1	GS1-124K5.4	-5.52	5.68e-08	1.88e-05	-0.26	-0.24	Aortic root size;	chr7:66228355	chr7:66493706~66495474:+
LUAD	cis	rs1707322	0.964	rs12067716	ENSG00000280836.1	AL355480.1	-5.52	5.68e-08	1.88e-05	-0.32	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968756	chr1:45581219~45581321:-
LUAD	cis	rs6687821	0.515	rs4656133	ENSG00000267734.1	RP4-604K5.3	-5.52	5.69e-08	1.88e-05	-0.3	-0.24	Yeast infection;	chr1:87000140	chr1:86932199~86934891:-
LUAD	cis	rs11105298	0.891	rs10777163	ENSG00000258302.2	RP11-981P6.1	5.52	5.69e-08	1.88e-05	0.31	0.24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89436943	chr12:89561129~89594878:+
LUAD	cis	rs9450351	0.744	rs9450317	ENSG00000203875.9	SNHG5	-5.52	5.7e-08	1.88e-05	-0.55	-0.24	Interferon gamma-induced protein 10 levels;	chr6:85715052	chr6:85660950~85678736:-
LUAD	cis	rs858239	0.601	rs764533	ENSG00000230042.1	AK3P3	-5.51	5.7e-08	1.89e-05	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23129178~23129841:+
LUAD	cis	rs875971	0.508	rs10253883	ENSG00000224316.1	RP11-479O9.2	-5.51	5.71e-08	1.89e-05	-0.24	-0.24	Aortic root size;	chr7:66596151	chr7:65773620~65802067:+
LUAD	cis	rs6565180	1	rs6565180	ENSG00000183604.13	SMG1P5	-5.51	5.72e-08	1.89e-05	-0.26	-0.24	Tonsillectomy;	chr16:30350020	chr16:30267553~30335374:-
LUAD	cis	rs7246657	0.639	rs3112434	ENSG00000276846.1	CTD-3220F14.3	-5.51	5.72e-08	1.89e-05	-0.33	-0.24	Coronary artery calcification;	chr19:37707247	chr19:37314868~37315620:-
LUAD	cis	rs858239	0.699	rs1881201	ENSG00000226816.2	AC005082.12	-5.51	5.72e-08	1.89e-05	-0.31	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23206013~23208045:+
LUAD	cis	rs516805	0.596	rs2606625	ENSG00000279453.1	RP3-425C14.4	-5.51	5.73e-08	1.9e-05	-0.33	-0.24	Lymphocyte counts;	chr6:122165363	chr6:122436789~122439223:-
LUAD	cis	rs9318086	0.776	rs1326130	ENSG00000205861.10	C1QTNF9B-AS1	-5.51	5.74e-08	1.9e-05	-0.28	-0.24	Myopia (pathological);	chr13:23873525	chr13:23888889~23897263:+
LUAD	cis	rs910316	1	rs3742780	ENSG00000259138.1	RP11-950C14.7	5.51	5.74e-08	1.9e-05	0.26	0.24	Height;	chr14:75038305	chr14:75127153~75136930:+
LUAD	cis	rs1707322	0.789	rs7540578	ENSG00000234329.1	RP11-767N6.2	5.51	5.75e-08	1.9e-05	0.26	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45786472	chr1:45651039~45651826:-
LUAD	cis	rs7804306	1	rs13225545	ENSG00000233264.2	AC006042.8	5.51	5.75e-08	1.9e-05	0.46	0.24	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8027509	chr7:7980312~7982228:+
LUAD	cis	rs2946504	0.861	rs2977081	ENSG00000251468.2	RP11-369K16.1	-5.51	5.76e-08	1.9e-05	-0.32	-0.24	Type 2 diabetes;	chr8:12958272	chr8:12958387~12962200:+
LUAD	cis	rs7617773	0.817	rs3937	ENSG00000228638.1	FCF1P2	-5.51	5.76e-08	1.9e-05	-0.29	-0.24	Coronary artery disease;	chr3:48270912	chr3:48290793~48291375:-
LUAD	cis	rs2404602	0.735	rs62028423	ENSG00000259422.1	RP11-593F23.1	-5.51	5.76e-08	1.9e-05	-0.32	-0.24	Blood metabolite levels;	chr15:76462173	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.647	rs62026889	ENSG00000259422.1	RP11-593F23.1	-5.51	5.76e-08	1.9e-05	-0.33	-0.24	Blood metabolite levels;	chr15:76625544	chr15:76174891~76181486:-
LUAD	cis	rs4722166	0.597	rs2069845	ENSG00000179428.2	AC073072.5	-5.51	5.76e-08	1.9e-05	-0.28	-0.24	Lung cancer;	chr7:22730530	chr7:22725395~22727620:-
LUAD	cis	rs10129255	0.957	rs12589190	ENSG00000211972.2	IGHV3-66	5.51	5.76e-08	1.9e-05	0.21	0.24	Kawasaki disease;	chr14:106783079	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.957	rs7493713	ENSG00000211972.2	IGHV3-66	5.51	5.76e-08	1.9e-05	0.21	0.24	Kawasaki disease;	chr14:106783685	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.912	rs35468694	ENSG00000211972.2	IGHV3-66	5.51	5.76e-08	1.9e-05	0.21	0.24	Kawasaki disease;	chr14:106784199	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.957	rs8019272	ENSG00000211972.2	IGHV3-66	5.51	5.76e-08	1.9e-05	0.21	0.24	Kawasaki disease;	chr14:106784709	chr14:106675017~106675544:-
LUAD	cis	rs1722141	0.634	rs2453850	ENSG00000229628.1	AC073115.7	5.51	5.77e-08	1.91e-05	0.39	0.24	Sitting height ratio;	chr7:45941135	chr7:45990905~46000898:+
LUAD	cis	rs2749097	1	rs2749097	ENSG00000244256.3	RN7SL130P	-5.51	5.77e-08	1.91e-05	-0.35	-0.24	Alcohol consumption (transferrin glycosylation);	chr1:63661797	chr1:63655743~63656047:+
LUAD	cis	rs858239	0.571	rs2390755	ENSG00000230042.1	AK3P3	-5.51	5.77e-08	1.91e-05	-0.31	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23151097	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.539	rs4365988	ENSG00000230042.1	AK3P3	-5.51	5.77e-08	1.91e-05	-0.31	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23151252	chr7:23129178~23129841:+
LUAD	cis	rs12468226	0.938	rs4675274	ENSG00000272966.1	RP11-686O6.1	-5.51	5.77e-08	1.91e-05	-0.41	-0.24	Urate levels;	chr2:202243145	chr2:202336739~202337200:+
LUAD	cis	rs11051970	0.559	rs12578899	ENSG00000274964.1	RP11-817I4.1	-5.51	5.78e-08	1.91e-05	-0.31	-0.24	Response to tocilizumab in rheumatoid arthritis;	chr12:32332017	chr12:32339368~32340724:+
LUAD	cis	rs1823874	0.581	rs9920347	ENSG00000182397.13	DNM1P46	5.51	5.78e-08	1.91e-05	0.29	0.24	IgG glycosylation;	chr15:99799126	chr15:99790156~99806927:-
LUAD	cis	rs8098244	0.597	rs883083	ENSG00000264745.1	TTC39C-AS1	5.51	5.78e-08	1.91e-05	0.25	0.24	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23856448	chr18:23994213~24015339:-
LUAD	cis	rs67311347	0.544	rs60329764	ENSG00000223797.4	ENTPD3-AS1	-5.51	5.78e-08	1.91e-05	-0.25	-0.24	Renal cell carcinoma;	chr3:40293130	chr3:40313802~40453329:-
LUAD	cis	rs801193	0.569	rs10950050	ENSG00000222364.1	RNU6-96P	-5.51	5.78e-08	1.91e-05	-0.27	-0.24	Aortic root size;	chr7:66774601	chr7:66395191~66395286:+
LUAD	cis	rs10129255	0.957	rs10132367	ENSG00000224373.3	IGHV4-59	5.51	5.8e-08	1.91e-05	0.16	0.24	Kawasaki disease;	chr14:106690981	chr14:106627249~106627825:-
LUAD	cis	rs9287719	0.674	rs12620209	ENSG00000243819.4	RN7SL832P	5.51	5.8e-08	1.92e-05	0.26	0.24	Prostate cancer;	chr2:10580315	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.674	rs12622551	ENSG00000243819.4	RN7SL832P	5.51	5.8e-08	1.92e-05	0.26	0.24	Prostate cancer;	chr2:10580317	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.649	rs10182589	ENSG00000243819.4	RN7SL832P	5.51	5.8e-08	1.92e-05	0.26	0.24	Prostate cancer;	chr2:10580538	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.649	rs10208103	ENSG00000243819.4	RN7SL832P	5.51	5.8e-08	1.92e-05	0.26	0.24	Prostate cancer;	chr2:10580741	chr2:10690344~10692099:+
LUAD	cis	rs2412819	0.597	rs2412821	ENSG00000249839.1	AC011330.5	-5.51	5.8e-08	1.92e-05	-0.38	-0.24	Lung cancer;	chr15:43864966	chr15:43663654~43684339:-
LUAD	cis	rs7714584	1	rs12656600	ENSG00000197083.10	ZNF300P1	5.51	5.81e-08	1.92e-05	0.48	0.24	Crohn's disease;	chr5:150932310	chr5:150930645~150946289:-
LUAD	cis	rs910316	1	rs7303	ENSG00000259138.1	RP11-950C14.7	5.51	5.81e-08	1.92e-05	0.26	0.24	Height;	chr14:75053362	chr14:75127153~75136930:+
LUAD	cis	rs910316	1	rs10143132	ENSG00000259138.1	RP11-950C14.7	5.51	5.81e-08	1.92e-05	0.26	0.24	Height;	chr14:75059147	chr14:75127153~75136930:+
LUAD	cis	rs10129255	0.957	rs2007467	ENSG00000211974.3	IGHV2-70	-5.51	5.82e-08	1.92e-05	-0.26	-0.24	Kawasaki disease;	chr14:106771605	chr14:106723574~106724093:-
LUAD	cis	rs10028773	0.546	rs13117947	ENSG00000245958.5	RP11-33B1.1	-5.51	5.82e-08	1.92e-05	-0.2	-0.24	Educational attainment;	chr4:119335905	chr4:119454791~119552025:+
LUAD	cis	rs9287719	0.601	rs12995465	ENSG00000243819.4	RN7SL832P	5.51	5.83e-08	1.92e-05	0.26	0.24	Prostate cancer;	chr2:10576702	chr2:10690344~10692099:+
LUAD	cis	rs2348418	0.733	rs9651832	ENSG00000247934.4	RP11-967K21.1	-5.51	5.83e-08	1.92e-05	-0.28	-0.24	Lung function (FEV1);Lung function (FVC);	chr12:28242489	chr12:28163298~28190738:-
LUAD	cis	rs10129255	0.957	rs10142859	ENSG00000211974.3	IGHV2-70	5.51	5.83e-08	1.93e-05	0.26	0.24	Kawasaki disease;	chr14:106782238	chr14:106723574~106724093:-
LUAD	cis	rs7712401	0.601	rs1990890	ENSG00000263432.2	RN7SL689P	5.51	5.85e-08	1.93e-05	0.3	0.24	Mean platelet volume;	chr5:122847275	chr5:123022487~123022783:-
LUAD	cis	rs867371	1	rs8037224	ENSG00000259429.4	UBE2Q2P2	-5.51	5.85e-08	1.93e-05	-0.21	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82172189	chr15:82355142~82420075:+
LUAD	cis	rs11690935	0.61	rs59844139	ENSG00000228389.1	AC068039.4	-5.51	5.86e-08	1.93e-05	-0.26	-0.24	Schizophrenia;	chr2:171875473	chr2:171773482~171775844:+
LUAD	cis	rs4927850	0.918	rs4361313	ENSG00000242086.7	LINC00969	5.51	5.86e-08	1.94e-05	0.22	0.24	Pancreatic cancer;	chr3:196025389	chr3:195658062~195739964:+
LUAD	cis	rs732716	0.785	rs56033249	ENSG00000267980.1	AC007292.6	-5.51	5.87e-08	1.94e-05	-0.29	-0.24	Mean corpuscular volume;	chr19:4369450	chr19:4363789~4364640:+
LUAD	cis	rs6496044	0.526	rs4291869	ENSG00000259295.5	CSPG4P12	5.51	5.87e-08	1.94e-05	0.28	0.24	Interstitial lung disease;	chr15:85511292	chr15:85191438~85213905:+
LUAD	cis	rs9860428	0.564	rs10804503	ENSG00000242770.2	RP11-180K7.1	5.51	5.87e-08	1.94e-05	0.26	0.24	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112794511	chr3:112802478~112812819:+
LUAD	cis	rs7617773	0.746	rs11713476	ENSG00000228638.1	FCF1P2	-5.51	5.87e-08	1.94e-05	-0.29	-0.24	Coronary artery disease;	chr3:48333944	chr3:48290793~48291375:-
LUAD	cis	rs62432291	0.681	rs439126	ENSG00000235086.1	FNDC1-IT1	-5.51	5.87e-08	1.94e-05	-0.42	-0.24	Joint mobility (Beighton score);	chr6:159235600	chr6:159240786~159243329:+
LUAD	cis	rs7772486	0.558	rs7753273	ENSG00000235652.6	RP11-545I5.3	-5.51	5.88e-08	1.94e-05	-0.25	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145744903	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.62	rs367693	ENSG00000235652.6	RP11-545I5.3	5.51	5.88e-08	1.94e-05	0.26	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145494813	chr6:145799409~145886585:+
LUAD	cis	rs875971	1	rs6958271	ENSG00000237310.1	GS1-124K5.4	5.51	5.88e-08	1.94e-05	0.26	0.24	Aortic root size;	chr7:66514344	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs6958277	ENSG00000237310.1	GS1-124K5.4	5.51	5.88e-08	1.94e-05	0.26	0.24	Aortic root size;	chr7:66514362	chr7:66493706~66495474:+
LUAD	cis	rs1707322	1	rs7532204	ENSG00000234329.1	RP11-767N6.2	-5.51	5.89e-08	1.95e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019403	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.835	rs946525	ENSG00000234329.1	RP11-767N6.2	-5.51	5.89e-08	1.95e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021605	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs946524	ENSG00000234329.1	RP11-767N6.2	-5.51	5.89e-08	1.95e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021888	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs4660336	ENSG00000234329.1	RP11-767N6.2	-5.51	5.89e-08	1.95e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46022304	chr1:45651039~45651826:-
LUAD	cis	rs858239	0.699	rs955187	ENSG00000226816.2	AC005082.12	-5.51	5.9e-08	1.95e-05	-0.32	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23206013~23208045:+
LUAD	cis	rs2404602	0.692	rs35557205	ENSG00000259422.1	RP11-593F23.1	5.51	5.9e-08	1.95e-05	0.28	0.24	Blood metabolite levels;	chr15:76838370	chr15:76174891~76181486:-
LUAD	cis	rs6687821	0.515	rs4431894	ENSG00000267734.1	RP4-604K5.3	-5.51	5.9e-08	1.95e-05	-0.3	-0.24	Yeast infection;	chr1:87063801	chr1:86932199~86934891:-
LUAD	cis	rs6687821	0.515	rs7543542	ENSG00000267734.1	RP4-604K5.3	-5.51	5.9e-08	1.95e-05	-0.3	-0.24	Yeast infection;	chr1:87069356	chr1:86932199~86934891:-
LUAD	cis	rs6687821	0.515	rs2390264	ENSG00000267734.1	RP4-604K5.3	-5.51	5.9e-08	1.95e-05	-0.3	-0.24	Yeast infection;	chr1:87072743	chr1:86932199~86934891:-
LUAD	cis	rs6687821	0.515	rs2798674	ENSG00000267734.1	RP4-604K5.3	-5.51	5.9e-08	1.95e-05	-0.3	-0.24	Yeast infection;	chr1:87074834	chr1:86932199~86934891:-
LUAD	cis	rs1707322	0.964	rs6675259	ENSG00000234329.1	RP11-767N6.2	-5.51	5.91e-08	1.95e-05	-0.26	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46036623	chr1:45651039~45651826:-
LUAD	cis	rs12468226	1	rs7587234	ENSG00000272966.1	RP11-686O6.1	5.51	5.91e-08	1.95e-05	0.41	0.24	Urate levels;	chr2:202351699	chr2:202336739~202337200:+
LUAD	cis	rs7208859	0.573	rs11654035	ENSG00000263603.1	CTD-2349P21.5	-5.51	5.92e-08	1.95e-05	-0.43	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30729469~30731202:+
LUAD	cis	rs6570726	0.875	rs12524077	ENSG00000235652.6	RP11-545I5.3	5.51	5.92e-08	1.95e-05	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145545197	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.875	rs416243	ENSG00000235652.6	RP11-545I5.3	5.51	5.92e-08	1.95e-05	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145546945	chr6:145799409~145886585:+
LUAD	cis	rs6496932	0.563	rs2344083	ENSG00000259630.2	CTD-2262B20.1	-5.51	5.92e-08	1.95e-05	-0.29	-0.24	Central corneal thickness;Corneal structure;	chr15:85354201	chr15:85415228~85415633:+
LUAD	cis	rs67180937	0.553	rs2936023	ENSG00000272750.1	RP11-378J18.8	5.51	5.92e-08	1.95e-05	0.3	0.24	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222656989	chr1:222658867~222661512:-
LUAD	cis	rs2255336	0.938	rs4548707	ENSG00000245648.1	RP11-277P12.20	-5.51	5.92e-08	1.95e-05	-0.37	-0.24	Blood protein levels;	chr12:10467634	chr12:10363769~10398506:+
LUAD	cis	rs62246343	0.719	rs62246301	ENSG00000254485.4	RP11-380O24.1	5.51	5.93e-08	1.95e-05	0.36	0.24	Fibrinogen levels;	chr3:9409599	chr3:9292588~9363303:-
LUAD	cis	rs62246343	0.719	rs62246302	ENSG00000254485.4	RP11-380O24.1	5.51	5.93e-08	1.95e-05	0.36	0.24	Fibrinogen levels;	chr3:9411761	chr3:9292588~9363303:-
LUAD	cis	rs2832077	0.943	rs11701445	ENSG00000232855.5	AF131217.1	5.51	5.93e-08	1.96e-05	0.27	0.24	Cognitive test performance;	chr21:28788485	chr21:28439346~28674848:-
LUAD	cis	rs1707322	1	rs11211200	ENSG00000234329.1	RP11-767N6.2	5.51	5.93e-08	1.96e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45822680	chr1:45651039~45651826:-
LUAD	cis	rs853679	0.546	rs200996	ENSG00000219392.1	RP1-265C24.5	-5.51	5.93e-08	1.96e-05	-0.46	-0.24	Depression;	chr6:27844050	chr6:28115628~28116551:+
LUAD	cis	rs36093844	0.8	rs17817326	ENSG00000279742.1	RP11-700A24.1	-5.51	5.95e-08	1.96e-05	-0.33	-0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85884170	chr11:85852557~85854943:-
LUAD	cis	rs2439831	0.85	rs60883262	ENSG00000205771.5	CATSPER2P1	-5.51	5.95e-08	1.96e-05	-0.47	-0.24	Lung cancer in ever smokers;	chr15:43784305	chr15:43726918~43747094:-
LUAD	cis	rs10129255	0.957	rs28887506	ENSG00000224373.3	IGHV4-59	5.51	5.95e-08	1.96e-05	0.16	0.24	Kawasaki disease;	chr14:106785589	chr14:106627249~106627825:-
LUAD	cis	rs9309473	0.606	rs62149804	ENSG00000163016.8	ALMS1P	5.51	5.96e-08	1.96e-05	0.36	0.24	Metabolite levels;	chr2:73609879	chr2:73644919~73685576:+
LUAD	cis	rs2790457	0.792	rs1265841	ENSG00000254635.4	WAC-AS1	-5.51	5.96e-08	1.96e-05	-0.26	-0.24	Multiple myeloma;	chr10:28631772	chr10:28522652~28532743:-
LUAD	cis	rs516805	0.563	rs2606635	ENSG00000279453.1	RP3-425C14.4	-5.51	5.96e-08	1.96e-05	-0.33	-0.24	Lymphocyte counts;	chr6:122101222	chr6:122436789~122439223:-
LUAD	cis	rs2562456	0.837	rs11085462	ENSG00000268081.1	RP11-678G14.2	5.51	5.96e-08	1.96e-05	0.37	0.24	Pain;	chr19:21567449	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.793	rs7259708	ENSG00000268081.1	RP11-678G14.2	5.51	5.96e-08	1.96e-05	0.37	0.24	Pain;	chr19:21567846	chr19:21554640~21569237:-
LUAD	cis	rs2799081	1	rs2799081	ENSG00000216901.1	AL022393.7	5.51	5.96e-08	1.96e-05	0.3	0.24	Myopia;	chr6:28302807	chr6:28176188~28176674:+
LUAD	cis	rs2935183	1	rs2935183	ENSG00000228782.6	CTD-2026D20.3	-5.51	5.96e-08	1.96e-05	-0.26	-0.24	Multiple sclerosis or amyotrophic lateral sclerosis;	chr17:47530206	chr17:47450568~47492492:-
LUAD	cis	rs8177876	0.749	rs78707250	ENSG00000261061.1	RP11-303E16.2	-5.51	5.96e-08	1.97e-05	-0.43	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046757	chr16:81030770~81031485:+
LUAD	cis	rs858239	0.539	rs4295546	ENSG00000230042.1	AK3P3	-5.51	5.97e-08	1.97e-05	-0.31	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23151402	chr7:23129178~23129841:+
LUAD	cis	rs801193	0.66	rs1016265	ENSG00000237310.1	GS1-124K5.4	5.51	5.97e-08	1.97e-05	0.26	0.24	Aortic root size;	chr7:66749580	chr7:66493706~66495474:+
LUAD	cis	rs801193	0.66	rs4610622	ENSG00000237310.1	GS1-124K5.4	5.51	5.97e-08	1.97e-05	0.26	0.24	Aortic root size;	chr7:66759510	chr7:66493706~66495474:+
LUAD	cis	rs9309473	0.66	rs11679594	ENSG00000163016.8	ALMS1P	5.51	5.97e-08	1.97e-05	0.36	0.24	Metabolite levels;	chr2:73552380	chr2:73644919~73685576:+
LUAD	cis	rs7804306	0.826	rs73050940	ENSG00000233264.2	AC006042.8	5.51	5.97e-08	1.97e-05	0.5	0.24	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8027882	chr7:7980312~7982228:+
LUAD	cis	rs7804306	0.826	rs56142807	ENSG00000233264.2	AC006042.8	5.51	5.97e-08	1.97e-05	0.5	0.24	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8028562	chr7:7980312~7982228:+
LUAD	cis	rs8072100	0.817	rs9892497	ENSG00000228782.6	CTD-2026D20.3	5.51	5.98e-08	1.97e-05	0.26	0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47468553	chr17:47450568~47492492:-
LUAD	cis	rs7927592	0.672	rs10501398	ENSG00000212093.1	AP000807.1	-5.51	5.98e-08	1.97e-05	-0.24	-0.24	Total body bone mineral density;	chr11:68564247	chr11:68506083~68506166:-
LUAD	cis	rs7221109	0.744	rs1048573	ENSG00000278834.1	RP11-458J1.1	5.51	5.99e-08	1.97e-05	0.28	0.24	Type 1 diabetes;	chr17:40640950	chr17:40648300~40649718:+
LUAD	cis	rs2179367	0.632	rs9498335	ENSG00000231760.4	RP11-350J20.5	5.51	5.99e-08	1.97e-05	0.35	0.24	Dupuytren's disease;	chr6:149372648	chr6:149796151~149826294:-
LUAD	cis	rs875971	0.862	rs6460307	ENSG00000222364.1	RNU6-96P	-5.51	5.99e-08	1.97e-05	-0.27	-0.24	Aortic root size;	chr7:66595884	chr7:66395191~66395286:+
LUAD	cis	rs1015362	0.503	rs4911371	ENSG00000276073.1	RP5-1125A11.7	-5.51	6e-08	1.98e-05	-0.31	-0.24	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33904096	chr20:33985617~33988989:-
LUAD	cis	rs293748	0.713	rs158789	ENSG00000250155.1	CTD-2353F22.1	-5.51	6e-08	1.98e-05	-0.34	-0.24	Obesity-related traits;	chr5:36834955	chr5:36666214~36725195:-
LUAD	cis	rs2276314	1	rs16967317	ENSG00000278986.1	RP11-723J4.3	-5.51	6e-08	1.98e-05	-0.3	-0.24	Endometriosis;Drug-induced torsades de pointes;	chr18:35993437	chr18:35972151~35973916:+
LUAD	cis	rs7714584	1	rs11740172	ENSG00000197083.10	ZNF300P1	5.51	6e-08	1.98e-05	0.48	0.24	Crohn's disease;	chr5:150920716	chr5:150930645~150946289:-
LUAD	cis	rs4713118	0.516	rs6931858	ENSG00000204709.4	LINC01556	5.51	6.01e-08	1.98e-05	0.33	0.24	Parkinson's disease;	chr6:28110633	chr6:28943877~28944537:+
LUAD	cis	rs301901	0.698	rs2886593	ENSG00000250155.1	CTD-2353F22.1	5.51	6.01e-08	1.98e-05	0.26	0.24	Height;	chr5:37427041	chr5:36666214~36725195:-
LUAD	cis	rs11098499	0.874	rs17839089	ENSG00000248280.1	RP11-33B1.2	5.51	6.01e-08	1.98e-05	0.31	0.24	Corneal astigmatism;	chr4:119189914	chr4:119440561~119450157:-
LUAD	cis	rs240993	0.812	rs9400476	ENSG00000230177.1	RP5-1112D6.4	5.5	6.02e-08	1.98e-05	0.24	0.24	Inflammatory skin disease;Psoriasis;	chr6:111463172	chr6:111277932~111278742:+
LUAD	cis	rs673078	0.607	rs59594854	ENSG00000275409.1	RP11-131L12.4	-5.5	6.02e-08	1.98e-05	-0.31	-0.24	Glucose homeostasis traits;	chr12:118374000	chr12:118430147~118430699:+
LUAD	cis	rs12468226	0.817	rs6722588	ENSG00000272966.1	RP11-686O6.1	-5.5	6.02e-08	1.98e-05	-0.41	-0.24	Urate levels;	chr2:202187163	chr2:202336739~202337200:+
LUAD	cis	rs3931020	0.688	rs277375	ENSG00000272864.1	RP11-17E13.2	-5.5	6.02e-08	1.98e-05	-0.34	-0.24	Resistin levels;	chr1:74738459	chr1:74698769~74699333:-
LUAD	cis	rs2439831	0.702	rs7175032	ENSG00000205771.5	CATSPER2P1	-5.5	6.02e-08	1.98e-05	-0.46	-0.24	Lung cancer in ever smokers;	chr15:43768038	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.85	rs3862142	ENSG00000205771.5	CATSPER2P1	-5.5	6.02e-08	1.98e-05	-0.46	-0.24	Lung cancer in ever smokers;	chr15:43772608	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.702	rs2788	ENSG00000205771.5	CATSPER2P1	-5.5	6.02e-08	1.98e-05	-0.46	-0.24	Lung cancer in ever smokers;	chr15:43772688	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.85	rs28891769	ENSG00000205771.5	CATSPER2P1	-5.5	6.02e-08	1.98e-05	-0.46	-0.24	Lung cancer in ever smokers;	chr15:43780662	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.85	rs28578398	ENSG00000205771.5	CATSPER2P1	-5.5	6.02e-08	1.98e-05	-0.46	-0.24	Lung cancer in ever smokers;	chr15:43782848	chr15:43726918~43747094:-
LUAD	cis	rs7712401	0.601	rs246274	ENSG00000263432.2	RN7SL689P	5.5	6.03e-08	1.99e-05	0.3	0.24	Mean platelet volume;	chr5:122945108	chr5:123022487~123022783:-
LUAD	cis	rs516805	0.748	rs562616	ENSG00000279453.1	RP3-425C14.4	-5.5	6.04e-08	1.99e-05	-0.32	-0.24	Lymphocyte counts;	chr6:122467041	chr6:122436789~122439223:-
LUAD	cis	rs2179367	0.632	rs12196656	ENSG00000231760.4	RP11-350J20.5	5.5	6.04e-08	1.99e-05	0.35	0.24	Dupuytren's disease;	chr6:149383104	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs12211570	ENSG00000231760.4	RP11-350J20.5	5.5	6.04e-08	1.99e-05	0.35	0.24	Dupuytren's disease;	chr6:149383616	chr6:149796151~149826294:-
LUAD	cis	rs9435732	0.524	rs9435660	ENSG00000235241.1	RP11-108M9.5	5.5	6.05e-08	1.99e-05	0.31	0.24	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16987578	chr1:16889095~16889602:+
LUAD	cis	rs2548724	0.588	rs17333350	ENSG00000250682.4	LINC00491	-5.5	6.05e-08	1.99e-05	-0.29	-0.24	Type 2 diabetes;	chr5:102478905	chr5:102609156~102671559:-
LUAD	cis	rs62432291	0.681	rs420054	ENSG00000235086.1	FNDC1-IT1	-5.5	6.05e-08	1.99e-05	-0.41	-0.24	Joint mobility (Beighton score);	chr6:159234052	chr6:159240786~159243329:+
LUAD	cis	rs4273100	1	rs4924986	ENSG00000228157.4	AC007952.5	-5.5	6.05e-08	1.99e-05	-0.38	-0.24	Schizophrenia;	chr17:19339154	chr17:19092974~19096837:+
LUAD	cis	rs66887589	0.777	rs10015883	ENSG00000245958.5	RP11-33B1.1	-5.5	6.06e-08	1.99e-05	-0.19	-0.24	Diastolic blood pressure;	chr4:119346991	chr4:119454791~119552025:+
LUAD	cis	rs7618501	0.574	rs6765484	ENSG00000234667.1	ACTBP13	5.5	6.06e-08	1.99e-05	0.27	0.24	Intelligence (multi-trait analysis);	chr3:50003880	chr3:49873347~49877980:-
LUAD	cis	rs6921919	0.806	rs213230	ENSG00000204709.4	LINC01556	5.5	6.06e-08	1.99e-05	0.33	0.24	Autism spectrum disorder or schizophrenia;	chr6:28362487	chr6:28943877~28944537:+
LUAD	cis	rs2404602	0.684	rs1011084	ENSG00000259422.1	RP11-593F23.1	-5.5	6.06e-08	1.99e-05	-0.33	-0.24	Blood metabolite levels;	chr15:76715139	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.647	rs11629727	ENSG00000259422.1	RP11-593F23.1	-5.5	6.06e-08	1.99e-05	-0.33	-0.24	Blood metabolite levels;	chr15:76716697	chr15:76174891~76181486:-
LUAD	cis	rs8031584	0.651	rs28664821	ENSG00000259845.1	HERC2P10	-5.5	6.06e-08	1.99e-05	-0.28	-0.24	Huntington's disease progression;	chr15:30880120	chr15:30815271~30844153:+
LUAD	cis	rs1707322	1	rs10890370	ENSG00000234329.1	RP11-767N6.2	5.5	6.06e-08	1.99e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45923545	chr1:45651039~45651826:-
LUAD	cis	rs783540	0.5	rs7163840	ENSG00000278603.1	RP13-608F4.5	-5.5	6.07e-08	2e-05	-0.32	-0.24	Schizophrenia;	chr15:82729551	chr15:82472203~82472426:+
LUAD	cis	rs2404602	0.735	rs11637490	ENSG00000259422.1	RP11-593F23.1	-5.5	6.08e-08	2e-05	-0.31	-0.24	Blood metabolite levels;	chr15:76467224	chr15:76174891~76181486:-
LUAD	cis	rs1154275	0.537	rs9832885	ENSG00000242770.2	RP11-180K7.1	5.5	6.08e-08	2e-05	0.26	0.24	Takotsubo syndrome;	chr3:112799612	chr3:112802478~112812819:+
LUAD	cis	rs9595908	0.785	rs9315174	ENSG00000212293.1	SNORA16	5.5	6.08e-08	2e-05	0.26	0.24	Body mass index;	chr13:32645750	chr13:32420390~32420516:-
LUAD	cis	rs7617773	0.78	rs6442111	ENSG00000228638.1	FCF1P2	-5.5	6.08e-08	2e-05	-0.29	-0.24	Coronary artery disease;	chr3:48270570	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.851	rs6775179	ENSG00000228638.1	FCF1P2	-5.5	6.08e-08	2e-05	-0.29	-0.24	Coronary artery disease;	chr3:48271928	chr3:48290793~48291375:-
LUAD	cis	rs7712401	0.601	rs2910136	ENSG00000263432.2	RN7SL689P	-5.5	6.08e-08	2e-05	-0.3	-0.24	Mean platelet volume;	chr5:122918322	chr5:123022487~123022783:-
LUAD	cis	rs10129255	0.53	rs11624912	ENSG00000254174.1	IGHV1-12	5.5	6.1e-08	2.01e-05	0.16	0.24	Kawasaki disease;	chr14:106673891	chr14:106122420~106122709:-
LUAD	cis	rs7176527	0.848	rs72630462	ENSG00000188388.10	GOLGA6L3	5.5	6.1e-08	2.01e-05	0.35	0.24	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84706886	chr15:85240472~85247170:+
LUAD	cis	rs1707322	0.717	rs1547925	ENSG00000280836.1	AL355480.1	5.5	6.1e-08	2.01e-05	0.32	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619684	chr1:45581219~45581321:-
LUAD	cis	rs71636778	0.509	rs12738345	ENSG00000260063.1	RP5-968P14.2	-5.5	6.11e-08	2.01e-05	-0.45	-0.24	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26693253	chr1:26692132~26694131:-
LUAD	cis	rs1707322	1	rs1613296	ENSG00000234329.1	RP11-767N6.2	-5.5	6.11e-08	2.01e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081180	chr1:45651039~45651826:-
LUAD	cis	rs673078	0.607	rs73207578	ENSG00000275409.1	RP11-131L12.4	-5.5	6.12e-08	2.01e-05	-0.34	-0.24	Glucose homeostasis traits;	chr12:118447080	chr12:118430147~118430699:+
LUAD	cis	rs875971	0.862	rs11773628	ENSG00000237310.1	GS1-124K5.4	-5.5	6.12e-08	2.01e-05	-0.27	-0.24	Aortic root size;	chr7:66517644	chr7:66493706~66495474:+
LUAD	cis	rs2562456	0.755	rs1879234	ENSG00000268081.1	RP11-678G14.2	-5.5	6.12e-08	2.01e-05	-0.37	-0.24	Pain;	chr19:21521677	chr19:21554640~21569237:-
LUAD	cis	rs9595908	0.758	rs7329120	ENSG00000212293.1	SNORA16	5.5	6.12e-08	2.01e-05	0.26	0.24	Body mass index;	chr13:32646605	chr13:32420390~32420516:-
LUAD	cis	rs516805	0.63	rs2606638	ENSG00000279453.1	RP3-425C14.4	-5.5	6.13e-08	2.01e-05	-0.33	-0.24	Lymphocyte counts;	chr6:122102107	chr6:122436789~122439223:-
LUAD	cis	rs8098244	0.557	rs11660632	ENSG00000264745.1	TTC39C-AS1	5.5	6.13e-08	2.01e-05	0.25	0.24	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23696084	chr18:23994213~24015339:-
LUAD	cis	rs7618501	0.602	rs2624816	ENSG00000234667.1	ACTBP13	5.5	6.13e-08	2.01e-05	0.27	0.24	Intelligence (multi-trait analysis);	chr3:50079879	chr3:49873347~49877980:-
LUAD	cis	rs4938303	0.718	rs10892023	ENSG00000280143.1	AP000892.6	5.5	6.14e-08	2.02e-05	0.34	0.24	Triglycerides;	chr11:116727532	chr11:117204967~117210292:+
LUAD	cis	rs4835473	0.838	rs13134571	ENSG00000251600.4	RP11-673E1.1	-5.5	6.14e-08	2.02e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143738771	chr4:143912331~143982454:+
LUAD	cis	rs1876905	0.62	rs377716	ENSG00000272356.1	RP5-1112D6.8	-5.5	6.14e-08	2.02e-05	-0.28	-0.24	Mean corpuscular hemoglobin;	chr6:111181705	chr6:111309203~111313517:+
LUAD	cis	rs4835473	0.808	rs2060653	ENSG00000251600.4	RP11-673E1.1	-5.5	6.14e-08	2.02e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143739132	chr4:143912331~143982454:+
LUAD	cis	rs897984	0.762	rs1870293	ENSG00000260911.2	RP11-196G11.2	-5.5	6.14e-08	2.02e-05	-0.22	-0.24	Dementia with Lewy bodies;	chr16:30959620	chr16:31043150~31049868:+
LUAD	cis	rs2404602	1	rs2120107	ENSG00000259422.1	RP11-593F23.1	5.5	6.15e-08	2.02e-05	0.29	0.24	Blood metabolite levels;	chr15:76577448	chr15:76174891~76181486:-
LUAD	cis	rs875971	0.545	rs73136346	ENSG00000226824.5	RP4-756H11.3	5.5	6.15e-08	2.02e-05	0.36	0.24	Aortic root size;	chr7:66101095	chr7:66654538~66669855:+
LUAD	cis	rs1707322	0.721	rs11211181	ENSG00000280836.1	AL355480.1	-5.5	6.16e-08	2.02e-05	-0.31	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45771128	chr1:45581219~45581321:-
LUAD	cis	rs9309473	0.606	rs79234109	ENSG00000163016.8	ALMS1P	5.5	6.17e-08	2.03e-05	0.37	0.24	Metabolite levels;	chr2:73621227	chr2:73644919~73685576:+
LUAD	cis	rs7618501	0.602	rs2526743	ENSG00000234667.1	ACTBP13	5.5	6.17e-08	2.03e-05	0.27	0.24	Intelligence (multi-trait analysis);	chr3:50077812	chr3:49873347~49877980:-
LUAD	cis	rs1707322	0.928	rs10732844	ENSG00000234329.1	RP11-767N6.2	5.5	6.17e-08	2.03e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907016	chr1:45651039~45651826:-
LUAD	cis	rs4908760	0.827	rs11121210	ENSG00000232912.4	RP5-1115A15.1	5.5	6.17e-08	2.03e-05	0.22	0.24	Vitiligo;	chr1:8648470	chr1:8424645~8434838:+
LUAD	cis	rs2562456	0.876	rs11085465	ENSG00000268081.1	RP11-678G14.2	-5.5	6.18e-08	2.03e-05	-0.36	-0.24	Pain;	chr19:21568988	chr19:21554640~21569237:-
LUAD	cis	rs1150668	0.799	rs7206	ENSG00000219392.1	RP1-265C24.5	-5.5	6.18e-08	2.03e-05	-0.31	-0.24	Pubertal anthropometrics;	chr6:28233360	chr6:28115628~28116551:+
LUAD	cis	rs338389	0.591	rs8037902	ENSG00000260657.2	RP11-315D16.4	5.5	6.18e-08	2.03e-05	0.28	0.24	Survival in rectal cancer;	chr15:67988365	chr15:68267792~68277994:-
LUAD	cis	rs6543140	0.964	rs2141781	ENSG00000234389.1	AC007278.3	5.5	6.18e-08	2.03e-05	0.25	0.24	Blood protein levels;	chr2:102466446	chr2:102438713~102440475:+
LUAD	cis	rs6543140	0.964	rs11903551	ENSG00000234389.1	AC007278.3	5.5	6.18e-08	2.03e-05	0.25	0.24	Blood protein levels;	chr2:102467721	chr2:102438713~102440475:+
LUAD	cis	rs6543140	0.964	rs6543143	ENSG00000234389.1	AC007278.3	5.5	6.18e-08	2.03e-05	0.25	0.24	Blood protein levels;	chr2:102468960	chr2:102438713~102440475:+
LUAD	cis	rs6543140	0.964	rs13383602	ENSG00000234389.1	AC007278.3	5.5	6.18e-08	2.03e-05	0.25	0.24	Blood protein levels;	chr2:102469502	chr2:102438713~102440475:+
LUAD	cis	rs7712401	0.601	rs246287	ENSG00000263432.2	RN7SL689P	5.5	6.19e-08	2.03e-05	0.3	0.24	Mean platelet volume;	chr5:122909731	chr5:123022487~123022783:-
LUAD	cis	rs9368481	0.547	rs2093303	ENSG00000241549.7	GUSBP2	5.5	6.19e-08	2.03e-05	0.27	0.24	Autism spectrum disorder or schizophrenia;	chr6:26896627	chr6:26871484~26956554:-
LUAD	cis	rs807029	0.533	rs2863095	ENSG00000272572.1	RP11-179B2.2	-5.5	6.2e-08	2.04e-05	-0.35	-0.24	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100986746	chr10:100911103~100912739:-
LUAD	cis	rs7927592	0.763	rs11822059	ENSG00000212093.1	AP000807.1	5.5	6.2e-08	2.04e-05	0.25	0.24	Total body bone mineral density;	chr11:68533354	chr11:68506083~68506166:-
LUAD	cis	rs948562	0.69	rs73484144	ENSG00000280010.1	AP001350.4	5.5	6.2e-08	2.04e-05	0.37	0.24	Lymphoma;	chr11:58337718	chr11:58627435~58628528:+
LUAD	cis	rs9847710	0.838	rs2564962	ENSG00000242142.1	SERBP1P3	5.5	6.21e-08	2.04e-05	0.27	0.24	Ulcerative colitis;	chr3:52997622	chr3:53064283~53065091:-
LUAD	cis	rs910316	1	rs12889472	ENSG00000259138.1	RP11-950C14.7	5.5	6.21e-08	2.04e-05	0.26	0.24	Height;	chr14:75077276	chr14:75127153~75136930:+
LUAD	cis	rs62432291	0.681	rs435521	ENSG00000235086.1	FNDC1-IT1	5.5	6.21e-08	2.04e-05	0.41	0.24	Joint mobility (Beighton score);	chr6:159241606	chr6:159240786~159243329:+
LUAD	cis	rs6964587	0.773	rs2097810	ENSG00000188693.7	CYP51A1-AS1	-5.5	6.22e-08	2.04e-05	-0.29	-0.24	Breast cancer;	chr7:92347912	chr7:92134604~92180725:+
LUAD	cis	rs12468226	1	rs13389798	ENSG00000272966.1	RP11-686O6.1	5.5	6.22e-08	2.04e-05	0.41	0.24	Urate levels;	chr2:202348370	chr2:202336739~202337200:+
LUAD	cis	rs6565180	1	rs11863150	ENSG00000183604.13	SMG1P5	5.5	6.23e-08	2.04e-05	0.26	0.24	Tonsillectomy;	chr16:30374182	chr16:30267553~30335374:-
LUAD	cis	rs35740288	0.787	rs2291047	ENSG00000202081.1	RNU6-1280P	5.5	6.23e-08	2.05e-05	0.31	0.24	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85682574	chr15:85651522~85651628:-
LUAD	cis	rs755249	0.501	rs1889830	ENSG00000228060.1	RP11-69E11.8	5.5	6.24e-08	2.05e-05	0.22	0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39264500	chr1:39565160~39573203:+
LUAD	cis	rs10200159	1	rs11676573	ENSG00000272606.1	RP11-554J4.1	5.5	6.24e-08	2.05e-05	0.51	0.24	Vitiligo;	chr2:55572780	chr2:55617909~55618373:+
LUAD	cis	rs62246343	0.719	rs62246303	ENSG00000254485.4	RP11-380O24.1	5.5	6.24e-08	2.05e-05	0.36	0.24	Fibrinogen levels;	chr3:9413078	chr3:9292588~9363303:-
LUAD	cis	rs74233809	1	rs12413409	ENSG00000213277.3	MARCKSL1P1	5.5	6.25e-08	2.05e-05	0.41	0.24	Birth weight;	chr10:102959339	chr10:103175554~103176094:+
LUAD	cis	rs6687821	0.515	rs6663434	ENSG00000267734.1	RP4-604K5.3	-5.5	6.25e-08	2.05e-05	-0.3	-0.24	Yeast infection;	chr1:87042570	chr1:86932199~86934891:-
LUAD	cis	rs4938303	0.718	rs10892020	ENSG00000280143.1	AP000892.6	5.5	6.25e-08	2.05e-05	0.3	0.24	Triglycerides;	chr11:116718936	chr11:117204967~117210292:+
LUAD	cis	rs7804306	0.826	rs112270482	ENSG00000233264.2	AC006042.8	5.5	6.25e-08	2.05e-05	0.44	0.24	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7981281	chr7:7980312~7982228:+
LUAD	cis	rs375092	0.611	rs75733834	ENSG00000230658.1	KLHL7-AS1	5.5	6.26e-08	2.05e-05	0.49	0.24	Personality dimensions;	chr7:23375762	chr7:23101228~23105703:-
LUAD	cis	rs875971	0.52	rs160645	ENSG00000226824.5	RP4-756H11.3	5.5	6.26e-08	2.06e-05	0.36	0.24	Aortic root size;	chr7:66091320	chr7:66654538~66669855:+
LUAD	cis	rs2404602	0.647	rs1443115	ENSG00000259422.1	RP11-593F23.1	-5.5	6.26e-08	2.06e-05	-0.33	-0.24	Blood metabolite levels;	chr15:76749488	chr15:76174891~76181486:-
LUAD	cis	rs2286492	0.655	rs117841439	ENSG00000228649.7	AC005682.5	-5.5	6.27e-08	2.06e-05	-0.45	-0.24	Bipolar disorder;	chr7:22870922	chr7:22854178~22861579:+
LUAD	cis	rs1823874	0.71	rs58572174	ENSG00000182397.13	DNM1P46	-5.5	6.27e-08	2.06e-05	-0.3	-0.24	IgG glycosylation;	chr15:99822635	chr15:99790156~99806927:-
LUAD	cis	rs1823874	0.677	rs1993295	ENSG00000182397.13	DNM1P46	-5.5	6.27e-08	2.06e-05	-0.3	-0.24	IgG glycosylation;	chr15:99823332	chr15:99790156~99806927:-
LUAD	cis	rs1823874	0.71	rs1993297	ENSG00000182397.13	DNM1P46	-5.5	6.27e-08	2.06e-05	-0.3	-0.24	IgG glycosylation;	chr15:99823423	chr15:99790156~99806927:-
LUAD	cis	rs6687821	0.515	rs2390219	ENSG00000267734.1	RP4-604K5.3	-5.5	6.27e-08	2.06e-05	-0.3	-0.24	Yeast infection;	chr1:86988738	chr1:86932199~86934891:-
LUAD	cis	rs2404602	0.735	rs11635463	ENSG00000259422.1	RP11-593F23.1	-5.5	6.27e-08	2.06e-05	-0.32	-0.24	Blood metabolite levels;	chr15:76470645	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.709	rs11072597	ENSG00000259422.1	RP11-593F23.1	-5.5	6.27e-08	2.06e-05	-0.32	-0.24	Blood metabolite levels;	chr15:76471173	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.735	rs11857327	ENSG00000259422.1	RP11-593F23.1	-5.5	6.27e-08	2.06e-05	-0.32	-0.24	Blood metabolite levels;	chr15:76471922	chr15:76174891~76181486:-
LUAD	cis	rs12554020	1	rs3933797	ENSG00000227603.1	RP11-165J3.6	5.5	6.27e-08	2.06e-05	0.35	0.24	Schizophrenia;	chr9:93423049	chr9:93435332~93437121:-
LUAD	cis	rs12554020	1	rs3933796	ENSG00000227603.1	RP11-165J3.6	5.5	6.27e-08	2.06e-05	0.35	0.24	Schizophrenia;	chr9:93423123	chr9:93435332~93437121:-
LUAD	cis	rs12554020	1	rs7859267	ENSG00000227603.1	RP11-165J3.6	5.5	6.27e-08	2.06e-05	0.35	0.24	Schizophrenia;	chr9:93426827	chr9:93435332~93437121:-
LUAD	cis	rs858239	0.6	rs7787110	ENSG00000230042.1	AK3P3	-5.5	6.27e-08	2.06e-05	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23129178~23129841:+
LUAD	cis	rs2179367	0.632	rs763590	ENSG00000231760.4	RP11-350J20.5	5.5	6.28e-08	2.06e-05	0.35	0.24	Dupuytren's disease;	chr6:149398831	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs17506789	ENSG00000231760.4	RP11-350J20.5	5.5	6.28e-08	2.06e-05	0.35	0.24	Dupuytren's disease;	chr6:149399710	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.586	rs34097428	ENSG00000231760.4	RP11-350J20.5	5.5	6.28e-08	2.06e-05	0.35	0.24	Dupuytren's disease;	chr6:149399822	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs12154153	ENSG00000231760.4	RP11-350J20.5	5.5	6.28e-08	2.06e-05	0.35	0.24	Dupuytren's disease;	chr6:149401686	chr6:149796151~149826294:-
LUAD	cis	rs2412819	0.571	rs8038068	ENSG00000249839.1	AC011330.5	-5.5	6.3e-08	2.07e-05	-0.41	-0.24	Lung cancer;	chr15:43622175	chr15:43663654~43684339:-
LUAD	cis	rs2412819	0.571	rs56246169	ENSG00000249839.1	AC011330.5	-5.5	6.3e-08	2.07e-05	-0.41	-0.24	Lung cancer;	chr15:43628358	chr15:43663654~43684339:-
LUAD	cis	rs2412819	0.571	rs17727853	ENSG00000249839.1	AC011330.5	-5.5	6.3e-08	2.07e-05	-0.41	-0.24	Lung cancer;	chr15:43630299	chr15:43663654~43684339:-
LUAD	cis	rs2412819	0.571	rs62018900	ENSG00000249839.1	AC011330.5	-5.5	6.3e-08	2.07e-05	-0.41	-0.24	Lung cancer;	chr15:43633252	chr15:43663654~43684339:-
LUAD	cis	rs2412819	0.545	rs35333173	ENSG00000249839.1	AC011330.5	-5.5	6.3e-08	2.07e-05	-0.41	-0.24	Lung cancer;	chr15:43640818	chr15:43663654~43684339:-
LUAD	cis	rs2412819	0.571	rs112667279	ENSG00000249839.1	AC011330.5	-5.5	6.3e-08	2.07e-05	-0.41	-0.24	Lung cancer;	chr15:43649258	chr15:43663654~43684339:-
LUAD	cis	rs10214930	0.723	rs12700826	ENSG00000235574.1	AC073150.6	-5.5	6.3e-08	2.07e-05	-0.29	-0.24	Hypospadias;	chr7:27633107	chr7:27491682~27492765:-
LUAD	cis	rs763567	0.585	rs476810	ENSG00000271811.1	RP1-79C4.4	-5.5	6.3e-08	2.07e-05	-0.28	-0.24	Tonsillectomy;	chr1:170604673	chr1:170667381~170669425:+
LUAD	cis	rs763567	0.585	rs1234233	ENSG00000271811.1	RP1-79C4.4	-5.5	6.3e-08	2.07e-05	-0.28	-0.24	Tonsillectomy;	chr1:170605787	chr1:170667381~170669425:+
LUAD	cis	rs763567	0.546	rs566850	ENSG00000271811.1	RP1-79C4.4	-5.5	6.3e-08	2.07e-05	-0.28	-0.24	Tonsillectomy;	chr1:170607597	chr1:170667381~170669425:+
LUAD	cis	rs4273100	0.646	rs6587216	ENSG00000279825.1	CTC-457L16.1	-5.5	6.31e-08	2.07e-05	-0.28	-0.24	Schizophrenia;	chr17:19321084	chr17:19030857~19033529:+
LUAD	cis	rs7615952	0.599	rs6438953	ENSG00000171084.14	FAM86JP	5.5	6.31e-08	2.07e-05	0.32	0.24	Blood pressure (smoking interaction);	chr3:126006108	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.599	rs1044215	ENSG00000171084.14	FAM86JP	5.5	6.31e-08	2.07e-05	0.32	0.24	Blood pressure (smoking interaction);	chr3:126006716	chr3:125916620~125930024:+
LUAD	cis	rs2439831	0.85	rs28524541	ENSG00000205771.5	CATSPER2P1	-5.5	6.32e-08	2.07e-05	-0.5	-0.24	Lung cancer in ever smokers;	chr15:43832633	chr15:43726918~43747094:-
LUAD	cis	rs14027	0.921	rs16893077	ENSG00000279347.1	RP11-85I17.2	-5.5	6.32e-08	2.07e-05	-0.21	-0.24	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119740332	chr8:119838736~119840385:-
LUAD	cis	rs3762637	0.943	rs9872708	ENSG00000272758.4	RP11-299J3.8	-5.5	6.32e-08	2.07e-05	-0.36	-0.24	LDL cholesterol levels;	chr3:122523960	chr3:122416207~122443180:+
LUAD	cis	rs3762637	0.943	rs28403550	ENSG00000272758.4	RP11-299J3.8	-5.5	6.32e-08	2.07e-05	-0.36	-0.24	LDL cholesterol levels;	chr3:122532991	chr3:122416207~122443180:+
LUAD	cis	rs77204473	1	rs17120119	ENSG00000254851.1	RP11-109L13.1	5.5	6.32e-08	2.07e-05	0.57	0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116876566	chr11:117135528~117138582:+
LUAD	cis	rs2179367	0.632	rs7349921	ENSG00000231760.4	RP11-350J20.5	5.5	6.33e-08	2.08e-05	0.35	0.24	Dupuytren's disease;	chr6:149392727	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs60153446	ENSG00000231760.4	RP11-350J20.5	5.5	6.33e-08	2.08e-05	0.35	0.24	Dupuytren's disease;	chr6:149393186	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs61259243	ENSG00000231760.4	RP11-350J20.5	5.5	6.33e-08	2.08e-05	0.35	0.24	Dupuytren's disease;	chr6:149393457	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs62426115	ENSG00000231760.4	RP11-350J20.5	5.5	6.33e-08	2.08e-05	0.35	0.24	Dupuytren's disease;	chr6:149393718	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs68080376	ENSG00000231760.4	RP11-350J20.5	5.5	6.33e-08	2.08e-05	0.35	0.24	Dupuytren's disease;	chr6:149393873	chr6:149796151~149826294:-
LUAD	cis	rs11976180	1	rs2961120	ENSG00000170356.8	OR2A20P	-5.5	6.34e-08	2.08e-05	-0.31	-0.24	Obesity-related traits;	chr7:144059492	chr7:144250045~144252957:-
LUAD	cis	rs11976180	1	rs2951360	ENSG00000170356.8	OR2A20P	-5.5	6.34e-08	2.08e-05	-0.31	-0.24	Obesity-related traits;	chr7:144060256	chr7:144250045~144252957:-
LUAD	cis	rs1876905	0.597	rs354538	ENSG00000272356.1	RP5-1112D6.8	-5.5	6.34e-08	2.08e-05	-0.27	-0.24	Mean corpuscular hemoglobin;	chr6:111196863	chr6:111309203~111313517:+
LUAD	cis	rs507080	0.733	rs489126	ENSG00000278376.1	RP11-158I9.8	-5.5	6.34e-08	2.08e-05	-0.26	-0.24	Serum metabolite levels;	chr11:118702038	chr11:118791254~118793137:+
LUAD	cis	rs916888	0.773	rs199439	ENSG00000261575.2	RP11-259G18.1	5.49	6.35e-08	2.08e-05	0.38	0.24	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46267037~46268694:+
LUAD	cis	rs56046484	0.75	rs7173332	ENSG00000259295.5	CSPG4P12	5.49	6.35e-08	2.08e-05	0.38	0.24	Testicular germ cell tumor;	chr15:84978503	chr15:85191438~85213905:+
LUAD	cis	rs1707322	1	rs11211219	ENSG00000234329.1	RP11-767N6.2	5.49	6.35e-08	2.08e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893806	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs11211222	ENSG00000234329.1	RP11-767N6.2	5.49	6.35e-08	2.08e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45902085	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.963	rs9787412	ENSG00000234329.1	RP11-767N6.2	5.49	6.35e-08	2.08e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45905924	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs4660896	ENSG00000234329.1	RP11-767N6.2	5.49	6.35e-08	2.08e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45906744	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs12133129	ENSG00000234329.1	RP11-767N6.2	5.49	6.35e-08	2.08e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907676	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.963	rs4553121	ENSG00000234329.1	RP11-767N6.2	5.49	6.35e-08	2.08e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45909581	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.963	rs6690652	ENSG00000234329.1	RP11-767N6.2	5.49	6.35e-08	2.08e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45911020	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs6695421	ENSG00000234329.1	RP11-767N6.2	5.49	6.35e-08	2.08e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914535	chr1:45651039~45651826:-
LUAD	cis	rs496547	0.686	rs540180	ENSG00000255239.1	AP002954.6	5.49	6.35e-08	2.08e-05	0.3	0.24	Hip minimal joint space width;	chr11:118782920	chr11:118688039~118690600:-
LUAD	cis	rs496547	0.686	rs2508916	ENSG00000255239.1	AP002954.6	5.49	6.35e-08	2.08e-05	0.3	0.24	Hip minimal joint space width;	chr11:118783942	chr11:118688039~118690600:-
LUAD	cis	rs4835473	0.897	rs7681903	ENSG00000251600.4	RP11-673E1.1	-5.49	6.35e-08	2.08e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143759326	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.897	rs7656753	ENSG00000251600.4	RP11-673E1.1	-5.49	6.35e-08	2.08e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143759414	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.897	rs7656786	ENSG00000251600.4	RP11-673E1.1	-5.49	6.35e-08	2.08e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143759455	chr4:143912331~143982454:+
LUAD	cis	rs9287719	0.649	rs12621977	ENSG00000243819.4	RN7SL832P	5.49	6.35e-08	2.08e-05	0.26	0.24	Prostate cancer;	chr2:10581805	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.649	rs12617968	ENSG00000243819.4	RN7SL832P	5.49	6.35e-08	2.08e-05	0.26	0.24	Prostate cancer;	chr2:10581819	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.614	rs12622053	ENSG00000243819.4	RN7SL832P	5.49	6.35e-08	2.08e-05	0.26	0.24	Prostate cancer;	chr2:10582014	chr2:10690344~10692099:+
LUAD	cis	rs10754283	0.967	rs6663363	ENSG00000231613.1	RP5-943J3.1	5.49	6.35e-08	2.08e-05	0.25	0.24	Amyotrophic lateral sclerosis (sporadic);	chr1:89651295	chr1:89788914~89790492:+
LUAD	cis	rs897984	0.542	rs35713203	ENSG00000260911.2	RP11-196G11.2	5.49	6.36e-08	2.08e-05	0.22	0.24	Dementia with Lewy bodies;	chr16:31079086	chr16:31043150~31049868:+
LUAD	cis	rs8072100	0.748	rs9912592	ENSG00000228782.6	CTD-2026D20.3	5.49	6.36e-08	2.08e-05	0.26	0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47479579	chr17:47450568~47492492:-
LUAD	cis	rs75920871	0.528	rs12274465	ENSG00000254851.1	RP11-109L13.1	5.49	6.36e-08	2.08e-05	0.35	0.24	Subjective well-being;	chr11:117086473	chr11:117135528~117138582:+
LUAD	cis	rs673078	0.66	rs6490173	ENSG00000275409.1	RP11-131L12.4	-5.49	6.36e-08	2.09e-05	-0.31	-0.24	Glucose homeostasis traits;	chr12:118278637	chr12:118430147~118430699:+
LUAD	cis	rs6751744	0.855	rs7585513	ENSG00000230783.1	AC009961.2	-5.49	6.37e-08	2.09e-05	-0.3	-0.24	Dysphagia;	chr2:159550379	chr2:159689217~159690291:-
LUAD	cis	rs67180937	0.553	rs1498382	ENSG00000272750.1	RP11-378J18.8	5.49	6.37e-08	2.09e-05	0.3	0.24	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222641495	chr1:222658867~222661512:-
LUAD	cis	rs1032726	0.663	rs61629858	ENSG00000242770.2	RP11-180K7.1	-5.49	6.37e-08	2.09e-05	-0.28	-0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr3:112935600	chr3:112802478~112812819:+
LUAD	cis	rs2919009	0.58	rs4281410	ENSG00000271670.1	RP11-95I16.4	5.49	6.37e-08	2.09e-05	0.3	0.24	Obesity-related traits;	chr10:120871075	chr10:120879256~120880667:-
LUAD	cis	rs4706831	0.647	rs627240	ENSG00000272129.1	RP11-250B2.6	-5.49	6.38e-08	2.09e-05	-0.3	-0.24	Joint mobility (Beighton score);	chr6:80276168	chr6:80355424~80356859:+
LUAD	cis	rs35740288	0.822	rs34734963	ENSG00000202081.1	RNU6-1280P	5.49	6.38e-08	2.09e-05	0.31	0.24	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85674413	chr15:85651522~85651628:-
LUAD	cis	rs41307935	0.908	rs34014719	ENSG00000260063.1	RP5-968P14.2	-5.49	6.39e-08	2.09e-05	-0.44	-0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26746275	chr1:26692132~26694131:-
LUAD	cis	rs11089937	0.597	rs9619794	ENSG00000211638.2	IGLV8-61	-5.49	6.39e-08	2.09e-05	-0.28	-0.24	Periodontitis (PAL4Q3);	chr22:22132999	chr22:22098700~22099212:+
LUAD	cis	rs7662987	0.793	rs7684735	ENSG00000272777.1	RP11-571L19.8	5.49	6.39e-08	2.09e-05	0.38	0.24	Smoking initiation;	chr4:99070355	chr4:99067256~99068125:-
LUAD	cis	rs12468226	0.817	rs2350360	ENSG00000226261.1	AC064836.3	-5.49	6.39e-08	2.09e-05	-0.39	-0.24	Urate levels;	chr2:202222980	chr2:202336024~202336727:-
LUAD	cis	rs9309473	0.606	rs78941213	ENSG00000163016.8	ALMS1P	5.49	6.4e-08	2.09e-05	0.37	0.24	Metabolite levels;	chr2:73658010	chr2:73644919~73685576:+
LUAD	cis	rs1707322	0.686	rs1541131	ENSG00000280836.1	AL355480.1	5.49	6.4e-08	2.1e-05	0.32	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619262	chr1:45581219~45581321:-
LUAD	cis	rs673078	0.607	rs61943447	ENSG00000275409.1	RP11-131L12.4	-5.49	6.4e-08	2.1e-05	-0.34	-0.24	Glucose homeostasis traits;	chr12:118430598	chr12:118430147~118430699:+
LUAD	cis	rs2919009	0.882	rs3011384	ENSG00000271670.1	RP11-95I16.4	5.49	6.41e-08	2.1e-05	0.31	0.24	Obesity-related traits;	chr10:120833599	chr10:120879256~120880667:-
LUAD	cis	rs853679	0.599	rs156743	ENSG00000204709.4	LINC01556	5.49	6.41e-08	2.1e-05	0.43	0.24	Depression;	chr6:27999311	chr6:28943877~28944537:+
LUAD	cis	rs4660214	0.756	rs11205823	ENSG00000228060.1	RP11-69E11.8	5.49	6.41e-08	2.1e-05	0.22	0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39248566	chr1:39565160~39573203:+
LUAD	cis	rs12699921	0.598	rs1524775	ENSG00000279048.1	RP11-511H23.2	-5.49	6.42e-08	2.1e-05	-0.2	-0.24	Fibrinogen levels;	chr7:17896742	chr7:17940503~17942922:+
LUAD	cis	rs4654783	0.521	rs59709264	ENSG00000228397.1	RP1-224A6.3	5.49	6.42e-08	2.1e-05	0.3	0.24	Endometriosis;	chr1:22122832	chr1:22023994~22024968:-
LUAD	cis	rs896854	0.654	rs10104909	ENSG00000253528.2	RP11-347C18.4	5.49	6.42e-08	2.1e-05	0.23	0.24	Type 2 diabetes;	chr8:94965745	chr8:94974573~94974853:-
LUAD	cis	rs4835473	0.932	rs4615131	ENSG00000251600.4	RP11-673E1.1	-5.49	6.42e-08	2.1e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143740295	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs4499657	ENSG00000251600.4	RP11-673E1.1	-5.49	6.42e-08	2.1e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143740316	chr4:143912331~143982454:+
LUAD	cis	rs35740288	0.787	rs11635418	ENSG00000202081.1	RNU6-1280P	5.49	6.42e-08	2.1e-05	0.31	0.24	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85700947	chr15:85651522~85651628:-
LUAD	cis	rs453301	0.686	rs11785634	ENSG00000253981.4	ALG1L13P	-5.49	6.43e-08	2.1e-05	-0.28	-0.24	Joint mobility (Beighton score);	chr8:9035087	chr8:8236003~8244667:-
LUAD	cis	rs17023223	0.537	rs10802075	ENSG00000231365.4	RP11-418J17.1	-5.49	6.43e-08	2.1e-05	-0.33	-0.24	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119084604	chr1:119140396~119275973:+
LUAD	cis	rs1426063	0.614	rs17266308	ENSG00000249717.1	RP11-44F21.3	-5.49	6.43e-08	2.1e-05	-0.43	-0.24	QT interval;	chr4:75137695	chr4:74955974~74970362:-
LUAD	cis	rs2404602	1	rs2404741	ENSG00000259422.1	RP11-593F23.1	5.49	6.43e-08	2.11e-05	0.29	0.24	Blood metabolite levels;	chr15:76559394	chr15:76174891~76181486:-
LUAD	cis	rs2404602	1	rs2404740	ENSG00000259422.1	RP11-593F23.1	5.49	6.43e-08	2.11e-05	0.29	0.24	Blood metabolite levels;	chr15:76559802	chr15:76174891~76181486:-
LUAD	cis	rs875971	0.545	rs10950029	ENSG00000226824.5	RP4-756H11.3	-5.49	6.43e-08	2.11e-05	-0.34	-0.24	Aortic root size;	chr7:66169334	chr7:66654538~66669855:+
LUAD	cis	rs2404602	0.716	rs67204011	ENSG00000259422.1	RP11-593F23.1	5.49	6.43e-08	2.11e-05	0.28	0.24	Blood metabolite levels;	chr15:76554214	chr15:76174891~76181486:-
LUAD	cis	rs7580658	0.637	rs4560059	ENSG00000236682.1	AC068282.3	-5.49	6.45e-08	2.11e-05	-0.31	-0.24	Protein C levels;	chr2:127214652	chr2:127389130~127400580:+
LUAD	cis	rs1707322	1	rs10789479	ENSG00000234329.1	RP11-767N6.2	5.49	6.45e-08	2.11e-05	0.26	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886828	chr1:45651039~45651826:-
LUAD	cis	rs948562	0.744	rs73485972	ENSG00000280010.1	AP001350.4	5.49	6.45e-08	2.11e-05	0.36	0.24	Lymphoma;	chr11:58452991	chr11:58627435~58628528:+
LUAD	cis	rs9992667	1	rs10032639	ENSG00000231160.8	KLF3-AS1	5.49	6.46e-08	2.11e-05	0.31	0.24	Eosinophil percentage of granulocytes;	chr4:38673107	chr4:38612701~38664883:-
LUAD	cis	rs1707322	0.963	rs1768815	ENSG00000234329.1	RP11-767N6.2	-5.49	6.46e-08	2.11e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062931	chr1:45651039~45651826:-
LUAD	cis	rs11089937	0.559	rs2330014	ENSG00000211638.2	IGLV8-61	-5.49	6.46e-08	2.11e-05	-0.27	-0.24	Periodontitis (PAL4Q3);	chr22:22166155	chr22:22098700~22099212:+
LUAD	cis	rs7829975	0.564	rs2921057	ENSG00000253981.4	ALG1L13P	5.49	6.46e-08	2.11e-05	0.28	0.24	Mood instability;	chr8:8461157	chr8:8236003~8244667:-
LUAD	cis	rs7208859	0.524	rs73263982	ENSG00000263603.1	CTD-2349P21.5	-5.49	6.46e-08	2.11e-05	-0.36	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593606	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs216433	ENSG00000263603.1	CTD-2349P21.5	-5.49	6.46e-08	2.11e-05	-0.36	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30594842	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs216435	ENSG00000263603.1	CTD-2349P21.5	-5.49	6.46e-08	2.11e-05	-0.36	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595719	chr17:30729469~30731202:+
LUAD	cis	rs748404	0.666	rs62021180	ENSG00000205771.5	CATSPER2P1	-5.49	6.46e-08	2.12e-05	-0.37	-0.24	Lung cancer;	chr15:43420139	chr15:43726918~43747094:-
LUAD	cis	rs66887589	0.967	rs1480933	ENSG00000248280.1	RP11-33B1.2	5.49	6.48e-08	2.12e-05	0.27	0.24	Diastolic blood pressure;	chr4:119512093	chr4:119440561~119450157:-
LUAD	cis	rs858239	0.6	rs10235786	ENSG00000230042.1	AK3P3	-5.49	6.48e-08	2.12e-05	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23129178~23129841:+
LUAD	cis	rs7829975	0.871	rs777709	ENSG00000253893.2	FAM85B	5.49	6.48e-08	2.12e-05	0.3	0.24	Mood instability;	chr8:8726362	chr8:8167819~8226614:-
LUAD	cis	rs7911264	0.967	rs2488087	ENSG00000236493.2	EIF2S2P3	-5.49	6.48e-08	2.12e-05	-0.27	-0.24	Inflammatory bowel disease;	chr10:92686284	chr10:92668745~92669743:-
LUAD	cis	rs7208859	0.623	rs8082537	ENSG00000263603.1	CTD-2349P21.5	-5.49	6.49e-08	2.12e-05	-0.38	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30688914	chr17:30729469~30731202:+
LUAD	cis	rs944990	0.597	rs4744245	ENSG00000227603.1	RP11-165J3.6	5.49	6.49e-08	2.12e-05	0.27	0.24	Body mass index;	chr9:93480372	chr9:93435332~93437121:-
LUAD	cis	rs4654783	0.627	rs4655024	ENSG00000228397.1	RP1-224A6.3	5.49	6.49e-08	2.12e-05	0.3	0.24	Endometriosis;	chr1:22126221	chr1:22023994~22024968:-
LUAD	cis	rs4664293	1	rs6745766	ENSG00000226266.5	AC009961.3	-5.49	6.5e-08	2.13e-05	-0.33	-0.24	Monocyte percentage of white cells;	chr2:159598284	chr2:159670708~159712435:-
LUAD	cis	rs2348418	0.733	rs10771414	ENSG00000247934.4	RP11-967K21.1	5.49	6.51e-08	2.13e-05	0.28	0.24	Lung function (FEV1);Lung function (FVC);	chr12:28241369	chr12:28163298~28190738:-
LUAD	cis	rs17684571	0.751	rs28360570	ENSG00000231441.1	RP11-472M19.2	5.49	6.51e-08	2.13e-05	0.37	0.24	Schizophrenia;	chr6:56852832	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.872	rs13198597	ENSG00000231441.1	RP11-472M19.2	5.49	6.51e-08	2.13e-05	0.37	0.24	Schizophrenia;	chr6:56852929	chr6:56844002~56864078:+
LUAD	cis	rs293748	0.771	rs245587	ENSG00000250155.1	CTD-2353F22.1	-5.49	6.51e-08	2.13e-05	-0.34	-0.24	Obesity-related traits;	chr5:36839445	chr5:36666214~36725195:-
LUAD	cis	rs1015362	0.503	rs1883708	ENSG00000276073.1	RP5-1125A11.7	-5.49	6.52e-08	2.13e-05	-0.3	-0.24	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33924107	chr20:33985617~33988989:-
LUAD	cis	rs2243480	1	rs709607	ENSG00000226824.5	RP4-756H11.3	5.49	6.52e-08	2.13e-05	0.44	0.24	Diabetic kidney disease;	chr7:65984554	chr7:66654538~66669855:+
LUAD	cis	rs1667284	1	rs1667286	ENSG00000266521.1	RP11-650P15.1	5.49	6.53e-08	2.14e-05	0.28	0.24	Problematic alcohol use in trauma-exposed individuals;	chr18:31649190	chr18:31496645~31497195:-
LUAD	cis	rs6687821	0.515	rs10127488	ENSG00000267734.1	RP4-604K5.3	-5.49	6.53e-08	2.14e-05	-0.3	-0.24	Yeast infection;	chr1:87039907	chr1:86932199~86934891:-
LUAD	cis	rs748404	0.697	rs513970	ENSG00000249839.1	AC011330.5	-5.49	6.55e-08	2.14e-05	-0.31	-0.24	Lung cancer;	chr15:43287368	chr15:43663654~43684339:-
LUAD	cis	rs950169	0.922	rs12910334	ENSG00000259295.5	CSPG4P12	5.49	6.55e-08	2.14e-05	0.35	0.24	Schizophrenia;	chr15:84403620	chr15:85191438~85213905:+
LUAD	cis	rs155076	0.666	rs4770128	ENSG00000233325.3	MIPEPP3	-5.49	6.55e-08	2.14e-05	-0.35	-0.24	White matter hyperintensity burden;	chr13:21307783	chr13:21298139~21306373:+
LUAD	cis	rs4835473	0.932	rs1813908	ENSG00000251600.4	RP11-673E1.1	5.49	6.56e-08	2.14e-05	0.31	0.24	Immature fraction of reticulocytes;	chr4:143728174	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.897	rs4835454	ENSG00000251600.4	RP11-673E1.1	5.49	6.56e-08	2.14e-05	0.31	0.24	Immature fraction of reticulocytes;	chr4:143730081	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1839449	ENSG00000251600.4	RP11-673E1.1	5.49	6.56e-08	2.14e-05	0.31	0.24	Immature fraction of reticulocytes;	chr4:143730222	chr4:143912331~143982454:+
LUAD	cis	rs4761702	0.524	rs12581099	ENSG00000257252.4	RP11-486A14.2	-5.49	6.56e-08	2.14e-05	-0.38	-0.24	Immature fraction of reticulocytes;	chr12:93333720	chr12:93317135~93377736:-
LUAD	cis	rs1816752	0.875	rs8001187	ENSG00000273628.1	RP11-756A22.7	5.49	6.56e-08	2.14e-05	0.28	0.24	Obesity-related traits;	chr13:24402276	chr13:24933006~24936796:+
LUAD	cis	rs1816752	0.783	rs9507333	ENSG00000273628.1	RP11-756A22.7	5.49	6.56e-08	2.14e-05	0.28	0.24	Obesity-related traits;	chr13:24404172	chr13:24933006~24936796:+
LUAD	cis	rs7829975	0.535	rs4841005	ENSG00000253893.2	FAM85B	5.49	6.57e-08	2.15e-05	0.31	0.24	Mood instability;	chr8:8643720	chr8:8167819~8226614:-
LUAD	cis	rs4604732	0.536	rs4433437	ENSG00000227135.1	GCSAML-AS1	-5.49	6.57e-08	2.15e-05	-0.38	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247473278	chr1:247524679~247526752:-
LUAD	cis	rs7615952	0.599	rs2279821	ENSG00000171084.14	FAM86JP	5.49	6.57e-08	2.15e-05	0.36	0.24	Blood pressure (smoking interaction);	chr3:126015465	chr3:125916620~125930024:+
LUAD	cis	rs950169	0.92	rs11637666	ENSG00000259728.4	LINC00933	5.49	6.57e-08	2.15e-05	0.39	0.24	Schizophrenia;	chr15:84035122	chr15:84570649~84580175:+
LUAD	cis	rs11089937	0.597	rs5756991	ENSG00000211638.2	IGLV8-61	-5.49	6.58e-08	2.15e-05	-0.28	-0.24	Periodontitis (PAL4Q3);	chr22:22132541	chr22:22098700~22099212:+
LUAD	cis	rs11089937	0.54	rs5756992	ENSG00000211638.2	IGLV8-61	-5.49	6.58e-08	2.15e-05	-0.28	-0.24	Periodontitis (PAL4Q3);	chr22:22132636	chr22:22098700~22099212:+
LUAD	cis	rs11089937	0.597	rs9622919	ENSG00000211638.2	IGLV8-61	-5.49	6.58e-08	2.15e-05	-0.28	-0.24	Periodontitis (PAL4Q3);	chr22:22132863	chr22:22098700~22099212:+
LUAD	cis	rs11089937	0.597	rs9619793	ENSG00000211638.2	IGLV8-61	-5.49	6.58e-08	2.15e-05	-0.28	-0.24	Periodontitis (PAL4Q3);	chr22:22132952	chr22:22098700~22099212:+
LUAD	cis	rs11603023	0.874	rs483598	ENSG00000255239.1	AP002954.6	5.49	6.58e-08	2.15e-05	0.28	0.24	Cholesterol, total;	chr11:118638950	chr11:118688039~118690600:-
LUAD	cis	rs7618501	0.538	rs9856572	ENSG00000234667.1	ACTBP13	5.49	6.58e-08	2.15e-05	0.27	0.24	Intelligence (multi-trait analysis);	chr3:50071640	chr3:49873347~49877980:-
LUAD	cis	rs4835473	0.808	rs13134564	ENSG00000251600.4	RP11-673E1.1	-5.49	6.58e-08	2.15e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143738763	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs13139738	ENSG00000251600.4	RP11-673E1.1	-5.49	6.58e-08	2.15e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143738828	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs17018165	ENSG00000251600.4	RP11-673E1.1	-5.49	6.58e-08	2.15e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143738849	chr4:143912331~143982454:+
LUAD	cis	rs2836950	0.545	rs2836940	ENSG00000255568.3	BRWD1-AS2	-5.49	6.6e-08	2.16e-05	-0.24	-0.24	Menarche (age at onset);	chr21:39216770	chr21:39313935~39314962:+
LUAD	cis	rs858239	0.6	rs10233039	ENSG00000230042.1	AK3P3	-5.49	6.6e-08	2.16e-05	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23129178~23129841:+
LUAD	cis	rs11105298	0.891	rs10858852	ENSG00000258302.2	RP11-981P6.1	5.49	6.61e-08	2.16e-05	0.31	0.24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89439561	chr12:89561129~89594878:+
LUAD	cis	rs11105298	0.891	rs4842653	ENSG00000258302.2	RP11-981P6.1	5.49	6.61e-08	2.16e-05	0.31	0.24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89440336	chr12:89561129~89594878:+
LUAD	cis	rs11105298	0.891	rs4842654	ENSG00000258302.2	RP11-981P6.1	5.49	6.61e-08	2.16e-05	0.31	0.24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89440651	chr12:89561129~89594878:+
LUAD	cis	rs11105298	0.838	rs10858862	ENSG00000258302.2	RP11-981P6.1	5.49	6.61e-08	2.16e-05	0.31	0.24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89448276	chr12:89561129~89594878:+
LUAD	cis	rs11105298	0.891	rs10858864	ENSG00000258302.2	RP11-981P6.1	5.49	6.61e-08	2.16e-05	0.31	0.24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89452453	chr12:89561129~89594878:+
LUAD	cis	rs11105298	0.891	rs10858865	ENSG00000258302.2	RP11-981P6.1	5.49	6.61e-08	2.16e-05	0.31	0.24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89452699	chr12:89561129~89594878:+
LUAD	cis	rs10129255	0.957	rs10142918	ENSG00000211974.3	IGHV2-70	5.49	6.61e-08	2.16e-05	0.26	0.24	Kawasaki disease;	chr14:106782206	chr14:106723574~106724093:-
LUAD	cis	rs732716	0.785	rs11085073	ENSG00000267980.1	AC007292.6	5.49	6.62e-08	2.16e-05	0.28	0.24	Mean corpuscular volume;	chr19:4375165	chr19:4363789~4364640:+
LUAD	cis	rs6570726	0.577	rs441982	ENSG00000235652.6	RP11-545I5.3	5.49	6.62e-08	2.16e-05	0.26	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145521712	chr6:145799409~145886585:+
LUAD	cis	rs7829975	0.626	rs907183	ENSG00000253893.2	FAM85B	5.49	6.63e-08	2.16e-05	0.31	0.24	Mood instability;	chr8:8872251	chr8:8167819~8226614:-
LUAD	cis	rs11742741	0.579	rs13184473	ENSG00000248874.4	C5orf17	-5.49	6.63e-08	2.17e-05	-0.3	-0.24	Educational attainment;	chr5:24110968	chr5:23951348~24178263:+
LUAD	cis	rs9595908	0.785	rs4942791	ENSG00000212293.1	SNORA16	5.49	6.63e-08	2.17e-05	0.26	0.24	Body mass index;	chr13:32663085	chr13:32420390~32420516:-
LUAD	cis	rs2439831	0.681	rs956391	ENSG00000205771.5	CATSPER2P1	5.49	6.63e-08	2.17e-05	0.4	0.24	Lung cancer in ever smokers;	chr15:43325295	chr15:43726918~43747094:-
LUAD	cis	rs673078	0.607	rs61944669	ENSG00000275409.1	RP11-131L12.4	-5.49	6.63e-08	2.17e-05	-0.34	-0.24	Glucose homeostasis traits;	chr12:118448530	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs61944670	ENSG00000275409.1	RP11-131L12.4	-5.49	6.63e-08	2.17e-05	-0.34	-0.24	Glucose homeostasis traits;	chr12:118448697	chr12:118430147~118430699:+
LUAD	cis	rs1707322	0.717	rs1135812	ENSG00000280836.1	AL355480.1	-5.49	6.63e-08	2.17e-05	-0.32	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629600	chr1:45581219~45581321:-
LUAD	cis	rs2179367	0.632	rs9498338	ENSG00000231760.4	RP11-350J20.5	5.49	6.64e-08	2.17e-05	0.35	0.24	Dupuytren's disease;	chr6:149376428	chr6:149796151~149826294:-
LUAD	cis	rs944289	0.553	rs1169132	ENSG00000257826.1	RP11-116N8.4	-5.49	6.64e-08	2.17e-05	-0.28	-0.24	Thyroid cancer;	chr14:36153446	chr14:36061026~36067190:-
LUAD	cis	rs1275468	0.798	rs2366987	ENSG00000257497.2	RP11-585P4.5	-5.49	6.64e-08	2.17e-05	-0.33	-0.24	Polycystic ovary syndrome;	chr12:75536346	chr12:75483454~75489820:-
LUAD	cis	rs1150668	0.799	rs9301	ENSG00000219392.1	RP1-265C24.5	-5.49	6.65e-08	2.17e-05	-0.3	-0.24	Pubertal anthropometrics;	chr6:28324929	chr6:28115628~28116551:+
LUAD	cis	rs6570726	0.557	rs403956	ENSG00000235652.6	RP11-545I5.3	5.49	6.65e-08	2.17e-05	0.26	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145508820	chr6:145799409~145886585:+
LUAD	cis	rs4143844	0.867	rs11629900	ENSG00000259251.2	RP11-643M14.1	5.49	6.65e-08	2.17e-05	0.44	0.24	Bipolar disorder and schizophrenia;	chr15:61954938	chr15:62060503~62062434:+
LUAD	cis	rs10129255	0.5	rs8021941	ENSG00000254174.1	IGHV1-12	5.49	6.65e-08	2.17e-05	0.16	0.24	Kawasaki disease;	chr14:106781490	chr14:106122420~106122709:-
LUAD	cis	rs6921919	0.638	rs7772827	ENSG00000204709.4	LINC01556	5.49	6.65e-08	2.17e-05	0.31	0.24	Autism spectrum disorder or schizophrenia;	chr6:28333366	chr6:28943877~28944537:+
LUAD	cis	rs270601	0.71	rs371709	ENSG00000233006.5	AC034220.3	5.49	6.66e-08	2.17e-05	0.23	0.24	Acylcarnitine levels;	chr5:132247547	chr5:132311285~132369916:-
LUAD	cis	rs9847710	0.869	rs2564917	ENSG00000242142.1	SERBP1P3	5.49	6.66e-08	2.17e-05	0.26	0.24	Ulcerative colitis;	chr3:53003679	chr3:53064283~53065091:-
LUAD	cis	rs2404602	0.669	rs12148877	ENSG00000259422.1	RP11-593F23.1	5.49	6.67e-08	2.18e-05	0.28	0.24	Blood metabolite levels;	chr15:76627618	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.692	rs12902452	ENSG00000259422.1	RP11-593F23.1	5.49	6.67e-08	2.18e-05	0.28	0.24	Blood metabolite levels;	chr15:76629124	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.608	rs12439484	ENSG00000259422.1	RP11-593F23.1	5.49	6.68e-08	2.18e-05	0.28	0.24	Blood metabolite levels;	chr15:76310596	chr15:76174891~76181486:-
LUAD	cis	rs4591358	0.678	rs13015934	ENSG00000223466.1	AC064834.2	-5.49	6.68e-08	2.18e-05	-0.33	-0.24	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195504897	chr2:195533035~195538681:+
LUAD	cis	rs1499614	0.522	rs13247442	ENSG00000232546.1	RP11-458F8.1	-5.49	6.69e-08	2.18e-05	-0.37	-0.24	Gout;	chr7:66723871	chr7:66848496~66858136:+
LUAD	cis	rs11079757	0.604	rs72823425	ENSG00000262879.4	RP11-156P1.3	5.49	6.69e-08	2.18e-05	0.35	0.24	Erythema nodosum in inflammatory bowel disease;	chr17:47111303	chr17:46984045~47100323:-
LUAD	cis	rs875971	0.964	rs60193905	ENSG00000237310.1	GS1-124K5.4	5.48	6.7e-08	2.18e-05	0.26	0.24	Aortic root size;	chr7:66506273	chr7:66493706~66495474:+
LUAD	cis	rs7176527	1	rs7176527	ENSG00000229212.6	RP11-561C5.4	5.48	6.71e-08	2.19e-05	0.36	0.24	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84597563	chr15:85205440~85234795:-
LUAD	cis	rs7617773	0.817	rs17786132	ENSG00000228638.1	FCF1P2	-5.48	6.71e-08	2.19e-05	-0.29	-0.24	Coronary artery disease;	chr3:48207930	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.817	rs35456569	ENSG00000228638.1	FCF1P2	-5.48	6.71e-08	2.19e-05	-0.29	-0.24	Coronary artery disease;	chr3:48209409	chr3:48290793~48291375:-
LUAD	cis	rs2404602	0.692	rs34478400	ENSG00000259422.1	RP11-593F23.1	5.48	6.71e-08	2.19e-05	0.28	0.24	Blood metabolite levels;	chr15:76631169	chr15:76174891~76181486:-
LUAD	cis	rs875971	0.706	rs1643374	ENSG00000237310.1	GS1-124K5.4	5.48	6.72e-08	2.19e-05	0.26	0.24	Aortic root size;	chr7:66407695	chr7:66493706~66495474:+
LUAD	cis	rs950169	0.887	rs12903946	ENSG00000259295.5	CSPG4P12	5.48	6.72e-08	2.19e-05	0.35	0.24	Schizophrenia;	chr15:84399732	chr15:85191438~85213905:+
LUAD	cis	rs950169	0.887	rs62029593	ENSG00000259295.5	CSPG4P12	5.48	6.72e-08	2.19e-05	0.35	0.24	Schizophrenia;	chr15:84400482	chr15:85191438~85213905:+
LUAD	cis	rs950169	0.81	rs62029594	ENSG00000259295.5	CSPG4P12	5.48	6.72e-08	2.19e-05	0.35	0.24	Schizophrenia;	chr15:84400554	chr15:85191438~85213905:+
LUAD	cis	rs950169	0.881	rs62029596	ENSG00000259295.5	CSPG4P12	5.48	6.72e-08	2.19e-05	0.35	0.24	Schizophrenia;	chr15:84400736	chr15:85191438~85213905:+
LUAD	cis	rs950169	0.881	rs4081123	ENSG00000259295.5	CSPG4P12	5.48	6.72e-08	2.19e-05	0.35	0.24	Schizophrenia;	chr15:84401537	chr15:85191438~85213905:+
LUAD	cis	rs950169	0.881	rs62029599	ENSG00000259295.5	CSPG4P12	5.48	6.72e-08	2.19e-05	0.35	0.24	Schizophrenia;	chr15:84401867	chr15:85191438~85213905:+
LUAD	cis	rs950169	0.8	rs4099846	ENSG00000259295.5	CSPG4P12	5.48	6.72e-08	2.19e-05	0.35	0.24	Schizophrenia;	chr15:84402196	chr15:85191438~85213905:+
LUAD	cis	rs2998286	0.723	rs2807729	ENSG00000254635.4	WAC-AS1	5.48	6.72e-08	2.19e-05	0.35	0.24	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28526427	chr10:28522652~28532743:-
LUAD	cis	rs10129255	0.5	rs10142931	ENSG00000254174.1	IGHV1-12	5.48	6.73e-08	2.2e-05	0.16	0.24	Kawasaki disease;	chr14:106782288	chr14:106122420~106122709:-
LUAD	cis	rs17684571	0.938	rs16888118	ENSG00000231441.1	RP11-472M19.2	5.48	6.73e-08	2.2e-05	0.32	0.24	Schizophrenia;	chr6:56687838	chr6:56844002~56864078:+
LUAD	cis	rs1075265	0.598	rs59294779	ENSG00000233266.1	HMGB1P31	5.48	6.74e-08	2.2e-05	0.32	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53716002	chr2:54051334~54051760:+
LUAD	cis	rs4835473	0.9	rs35670120	ENSG00000251600.4	RP11-673E1.1	-5.48	6.74e-08	2.2e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143787041	chr4:143912331~143982454:+
LUAD	cis	rs6687821	0.515	rs4508067	ENSG00000267734.1	RP4-604K5.3	-5.48	6.75e-08	2.2e-05	-0.3	-0.24	Yeast infection;	chr1:87048787	chr1:86932199~86934891:-
LUAD	cis	rs801193	0.773	rs801207	ENSG00000237310.1	GS1-124K5.4	-5.48	6.75e-08	2.2e-05	-0.26	-0.24	Aortic root size;	chr7:66555603	chr7:66493706~66495474:+
LUAD	cis	rs507080	0.697	rs656287	ENSG00000278376.1	RP11-158I9.8	-5.48	6.75e-08	2.2e-05	-0.26	-0.24	Serum metabolite levels;	chr11:118701081	chr11:118791254~118793137:+
LUAD	cis	rs507080	0.733	rs570949	ENSG00000278376.1	RP11-158I9.8	-5.48	6.75e-08	2.2e-05	-0.26	-0.24	Serum metabolite levels;	chr11:118701202	chr11:118791254~118793137:+
LUAD	cis	rs10129255	0.957	rs2013423	ENSG00000224373.3	IGHV4-59	5.48	6.76e-08	2.2e-05	0.16	0.24	Kawasaki disease;	chr14:106690675	chr14:106627249~106627825:-
LUAD	cis	rs17684571	0.687	rs35461301	ENSG00000231441.1	RP11-472M19.2	5.48	6.76e-08	2.2e-05	0.36	0.24	Schizophrenia;	chr6:56832577	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.687	rs35851452	ENSG00000231441.1	RP11-472M19.2	5.48	6.76e-08	2.2e-05	0.36	0.24	Schizophrenia;	chr6:56832602	chr6:56844002~56864078:+
LUAD	cis	rs80028505	0.908	rs58390233	ENSG00000271304.1	DPRXP2	5.48	6.76e-08	2.21e-05	0.49	0.24	Foot ulcer in diabetes and neuropathy;	chr6:36037323	chr6:35989515~35990436:-
LUAD	cis	rs1707322	0.964	rs1768802	ENSG00000234329.1	RP11-767N6.2	-5.48	6.77e-08	2.21e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46082196	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs1588663	ENSG00000234329.1	RP11-767N6.2	-5.48	6.77e-08	2.21e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083153	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs1768801	ENSG00000234329.1	RP11-767N6.2	-5.48	6.77e-08	2.21e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083465	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs1768800	ENSG00000234329.1	RP11-767N6.2	-5.48	6.77e-08	2.21e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083516	chr1:45651039~45651826:-
LUAD	cis	rs4835473	0.643	rs34680080	ENSG00000251600.4	RP11-673E1.1	-5.48	6.78e-08	2.21e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143797290	chr4:143912331~143982454:+
LUAD	cis	rs2562456	0.561	rs12610883	ENSG00000268081.1	RP11-678G14.2	5.48	6.78e-08	2.21e-05	0.37	0.24	Pain;	chr19:21567257	chr19:21554640~21569237:-
LUAD	cis	rs4908768	0.501	rs6577513	ENSG00000232912.4	RP5-1115A15.1	5.48	6.78e-08	2.21e-05	0.22	0.24	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8642694	chr1:8424645~8434838:+
LUAD	cis	rs6496044	0.547	rs1564719	ENSG00000259295.5	CSPG4P12	5.48	6.79e-08	2.21e-05	0.28	0.24	Interstitial lung disease;	chr15:85511035	chr15:85191438~85213905:+
LUAD	cis	rs516805	0.568	rs56290570	ENSG00000279453.1	RP3-425C14.4	5.48	6.79e-08	2.21e-05	0.33	0.24	Lymphocyte counts;	chr6:122240177	chr6:122436789~122439223:-
LUAD	cis	rs7617773	0.815	rs6793150	ENSG00000228638.1	FCF1P2	-5.48	6.79e-08	2.21e-05	-0.29	-0.24	Coronary artery disease;	chr3:48310070	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.78	rs6793239	ENSG00000228638.1	FCF1P2	-5.48	6.79e-08	2.21e-05	-0.29	-0.24	Coronary artery disease;	chr3:48310128	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.78	rs6782166	ENSG00000228638.1	FCF1P2	-5.48	6.79e-08	2.21e-05	-0.29	-0.24	Coronary artery disease;	chr3:48310193	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.78	rs4130522	ENSG00000228638.1	FCF1P2	-5.48	6.79e-08	2.21e-05	-0.29	-0.24	Coronary artery disease;	chr3:48310823	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.78	rs13081169	ENSG00000228638.1	FCF1P2	-5.48	6.79e-08	2.21e-05	-0.29	-0.24	Coronary artery disease;	chr3:48315307	chr3:48290793~48291375:-
LUAD	cis	rs10129255	0.5	rs8011115	ENSG00000211967.3	IGHV3-53	-5.48	6.79e-08	2.21e-05	-0.17	-0.24	Kawasaki disease;	chr14:106786292	chr14:106592676~106593347:-
LUAD	cis	rs4927850	0.957	rs4927851	ENSG00000242086.7	LINC00969	5.48	6.8e-08	2.22e-05	0.22	0.24	Pancreatic cancer;	chr3:196024982	chr3:195658062~195739964:+
LUAD	cis	rs11051970	0.559	rs7963887	ENSG00000274964.1	RP11-817I4.1	-5.48	6.81e-08	2.22e-05	-0.31	-0.24	Response to tocilizumab in rheumatoid arthritis;	chr12:32323073	chr12:32339368~32340724:+
LUAD	cis	rs11051970	0.559	rs10844184	ENSG00000274964.1	RP11-817I4.1	-5.48	6.81e-08	2.22e-05	-0.31	-0.24	Response to tocilizumab in rheumatoid arthritis;	chr12:32323918	chr12:32339368~32340724:+
LUAD	cis	rs4835473	0.864	rs13145791	ENSG00000251600.4	RP11-673E1.1	-5.48	6.81e-08	2.22e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143735688	chr4:143912331~143982454:+
LUAD	cis	rs2404602	0.692	rs35195096	ENSG00000259422.1	RP11-593F23.1	5.48	6.81e-08	2.22e-05	0.28	0.24	Blood metabolite levels;	chr15:76646106	chr15:76174891~76181486:-
LUAD	cis	rs1707322	1	rs6672115	ENSG00000234329.1	RP11-767N6.2	5.48	6.81e-08	2.22e-05	0.26	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807207	chr1:45651039~45651826:-
LUAD	cis	rs910316	1	rs4903284	ENSG00000259138.1	RP11-950C14.7	5.48	6.82e-08	2.22e-05	0.26	0.24	Height;	chr14:75125780	chr14:75127153~75136930:+
LUAD	cis	rs2404602	0.716	rs2404736	ENSG00000259422.1	RP11-593F23.1	5.48	6.82e-08	2.22e-05	0.28	0.24	Blood metabolite levels;	chr15:76583602	chr15:76174891~76181486:-
LUAD	cis	rs1707322	0.963	rs10789478	ENSG00000234329.1	RP11-767N6.2	5.48	6.82e-08	2.22e-05	0.26	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45884834	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.682	rs3014241	ENSG00000280836.1	AL355480.1	5.48	6.83e-08	2.23e-05	0.32	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45622207	chr1:45581219~45581321:-
LUAD	cis	rs6991838	0.831	rs11992528	ENSG00000200714.1	Y_RNA	5.48	6.83e-08	2.23e-05	0.28	0.24	Intelligence (multi-trait analysis);	chr8:65561644	chr8:65592731~65592820:+
LUAD	cis	rs9506514	0.722	rs4769124	ENSG00000238286.1	SLC35E1P1	5.48	6.84e-08	2.23e-05	0.26	0.24	Coronary artery calcification;	chr13:20652706	chr13:20607268~20608131:+
LUAD	cis	rs801193	0.66	rs2659897	ENSG00000237310.1	GS1-124K5.4	-5.48	6.86e-08	2.23e-05	-0.26	-0.24	Aortic root size;	chr7:66722728	chr7:66493706~66495474:+
LUAD	cis	rs7804306	1	rs34059590	ENSG00000233264.2	AC006042.8	5.48	6.86e-08	2.23e-05	0.44	0.24	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8026584	chr7:7980312~7982228:+
LUAD	cis	rs2288884	0.559	rs12611043	ENSG00000275055.1	CTC-471J1.11	-5.48	6.86e-08	2.23e-05	-0.3	-0.24	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52084372	chr19:52049007~52049754:+
LUAD	cis	rs10129255	0.5	rs6576230	ENSG00000211967.3	IGHV3-53	-5.48	6.87e-08	2.24e-05	-0.17	-0.24	Kawasaki disease;	chr14:106778539	chr14:106592676~106593347:-
LUAD	cis	rs10129255	0.518	rs11847766	ENSG00000211967.3	IGHV3-53	-5.48	6.87e-08	2.24e-05	-0.17	-0.24	Kawasaki disease;	chr14:106779186	chr14:106592676~106593347:-
LUAD	cis	rs2243480	1	rs1638734	ENSG00000230295.1	RP11-458F8.2	-5.48	6.87e-08	2.24e-05	-0.3	-0.24	Diabetic kidney disease;	chr7:66632552	chr7:66880708~66882981:+
LUAD	cis	rs11089937	0.589	rs4239891	ENSG00000211638.2	IGLV8-61	-5.48	6.87e-08	2.24e-05	-0.27	-0.24	Periodontitis (PAL4Q3);	chr22:22165674	chr22:22098700~22099212:+
LUAD	cis	rs2179367	0.632	rs11155649	ENSG00000231760.4	RP11-350J20.5	5.48	6.88e-08	2.24e-05	0.34	0.24	Dupuytren's disease;	chr6:149405830	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs11155650	ENSG00000231760.4	RP11-350J20.5	5.48	6.88e-08	2.24e-05	0.34	0.24	Dupuytren's disease;	chr6:149407613	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs11155651	ENSG00000231760.4	RP11-350J20.5	5.48	6.88e-08	2.24e-05	0.34	0.24	Dupuytren's disease;	chr6:149408146	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs7896	ENSG00000231760.4	RP11-350J20.5	5.48	6.88e-08	2.24e-05	0.34	0.24	Dupuytren's disease;	chr6:149410340	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs12196750	ENSG00000231760.4	RP11-350J20.5	5.48	6.88e-08	2.24e-05	0.34	0.24	Dupuytren's disease;	chr6:149413335	chr6:149796151~149826294:-
LUAD	cis	rs853679	0.76	rs11967137	ENSG00000219392.1	RP1-265C24.5	-5.48	6.88e-08	2.24e-05	-0.35	-0.24	Depression;	chr6:28231986	chr6:28115628~28116551:+
LUAD	cis	rs1322639	0.574	rs9689193	ENSG00000261039.2	RP11-417E7.2	-5.48	6.88e-08	2.24e-05	-0.4	-0.24	Pulse pressure;	chr6:169187979	chr6:169175304~169182740:-
LUAD	cis	rs17214007	0.877	rs10852376	ENSG00000263335.1	AF001548.5	5.48	6.9e-08	2.25e-05	0.34	0.24	Cognitive function;	chr16:15778216	chr16:15726674~15732993:+
LUAD	cis	rs4604732	0.631	rs1106721	ENSG00000227135.1	GCSAML-AS1	-5.48	6.9e-08	2.25e-05	-0.37	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247461374	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.631	rs1106720	ENSG00000227135.1	GCSAML-AS1	-5.48	6.9e-08	2.25e-05	-0.37	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247461379	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.631	rs12039596	ENSG00000227135.1	GCSAML-AS1	-5.48	6.9e-08	2.25e-05	-0.37	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247461464	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.578	rs12036417	ENSG00000227135.1	GCSAML-AS1	-5.48	6.9e-08	2.25e-05	-0.37	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247461503	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.631	rs12039642	ENSG00000227135.1	GCSAML-AS1	-5.48	6.9e-08	2.25e-05	-0.37	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247461596	chr1:247524679~247526752:-
LUAD	cis	rs9992667	0.955	rs11937257	ENSG00000231160.8	KLF3-AS1	5.48	6.91e-08	2.25e-05	0.29	0.24	Eosinophil percentage of granulocytes;	chr4:38643839	chr4:38612701~38664883:-
LUAD	cis	rs7617773	0.817	rs6801801	ENSG00000228638.1	FCF1P2	-5.48	6.91e-08	2.25e-05	-0.28	-0.24	Coronary artery disease;	chr3:48284943	chr3:48290793~48291375:-
LUAD	cis	rs2412819	0.597	rs514311	ENSG00000249839.1	AC011330.5	-5.48	6.91e-08	2.25e-05	-0.37	-0.24	Lung cancer;	chr15:43869376	chr15:43663654~43684339:-
LUAD	cis	rs7618501	0.602	rs2301166	ENSG00000234667.1	ACTBP13	5.48	6.92e-08	2.25e-05	0.27	0.24	Intelligence (multi-trait analysis);	chr3:50110872	chr3:49873347~49877980:-
LUAD	cis	rs2880765	0.835	rs7178991	ENSG00000259295.5	CSPG4P12	5.48	6.92e-08	2.25e-05	0.28	0.24	Coronary artery disease;	chr15:85507713	chr15:85191438~85213905:+
LUAD	cis	rs2404602	0.679	rs12900494	ENSG00000259422.1	RP11-593F23.1	5.48	6.93e-08	2.26e-05	0.28	0.24	Blood metabolite levels;	chr15:76620163	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.716	rs7169394	ENSG00000259422.1	RP11-593F23.1	5.48	6.93e-08	2.26e-05	0.28	0.24	Blood metabolite levels;	chr15:76620933	chr15:76174891~76181486:-
LUAD	cis	rs116095464	1	rs56095714	ENSG00000277812.1	AC021087.1	5.48	6.93e-08	2.26e-05	0.69	0.24	Breast cancer;	chr5:311141	chr5:262769~262881:+
LUAD	cis	rs4908768	0.501	rs11121212	ENSG00000232912.4	RP5-1115A15.1	5.48	6.94e-08	2.26e-05	0.22	0.24	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8665934	chr1:8424645~8434838:+
LUAD	cis	rs10129255	0.957	rs10136781	ENSG00000211972.2	IGHV3-66	5.48	6.96e-08	2.26e-05	0.21	0.24	Kawasaki disease;	chr14:106780451	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.957	rs8022165	ENSG00000211972.2	IGHV3-66	5.48	6.96e-08	2.26e-05	0.21	0.24	Kawasaki disease;	chr14:106781682	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.917	rs8022493	ENSG00000211972.2	IGHV3-66	5.48	6.96e-08	2.26e-05	0.21	0.24	Kawasaki disease;	chr14:106781820	chr14:106675017~106675544:-
LUAD	cis	rs1707322	1	rs4524994	ENSG00000234329.1	RP11-767N6.2	5.48	6.96e-08	2.26e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45904591	chr1:45651039~45651826:-
LUAD	cis	rs7017914	0.652	rs12674966	ENSG00000223220.1	Y_RNA	5.48	6.96e-08	2.26e-05	0.28	0.24	Bone mineral density;	chr8:70772175	chr8:70780914~70781008:-
LUAD	cis	rs853679	0.546	rs200995	ENSG00000219392.1	RP1-265C24.5	5.48	6.96e-08	2.27e-05	0.44	0.24	Depression;	chr6:27845916	chr6:28115628~28116551:+
LUAD	cis	rs867371	1	rs1501372	ENSG00000259429.4	UBE2Q2P2	-5.48	6.96e-08	2.27e-05	-0.21	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176114	chr15:82355142~82420075:+
LUAD	cis	rs867371	1	rs1846911	ENSG00000259429.4	UBE2Q2P2	-5.48	6.96e-08	2.27e-05	-0.21	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176309	chr15:82355142~82420075:+
LUAD	cis	rs516805	0.748	rs1267941	ENSG00000279453.1	RP3-425C14.4	-5.48	6.97e-08	2.27e-05	-0.32	-0.24	Lymphocyte counts;	chr6:122471888	chr6:122436789~122439223:-
LUAD	cis	rs1876905	0.68	rs783085	ENSG00000272356.1	RP5-1112D6.8	-5.48	6.97e-08	2.27e-05	-0.27	-0.24	Mean corpuscular hemoglobin;	chr6:111155482	chr6:111309203~111313517:+
LUAD	cis	rs984222	0.838	rs7553422	ENSG00000226172.2	RP4-712E4.1	-5.48	6.97e-08	2.27e-05	-0.26	-0.24	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118998096	chr1:119000344~119001392:-
LUAD	cis	rs8103033	0.786	rs6508898	ENSG00000226025.8	LGALS17A	-5.48	6.97e-08	2.27e-05	-0.27	-0.24	Obesity-related traits;	chr19:39661841	chr19:39679374~39686373:+
LUAD	cis	rs12554020	0.685	rs55893789	ENSG00000227603.1	RP11-165J3.6	5.48	6.97e-08	2.27e-05	0.47	0.24	Schizophrenia;	chr9:93408608	chr9:93435332~93437121:-
LUAD	cis	rs12554020	0.681	rs78759589	ENSG00000227603.1	RP11-165J3.6	5.48	6.97e-08	2.27e-05	0.47	0.24	Schizophrenia;	chr9:93409518	chr9:93435332~93437121:-
LUAD	cis	rs516805	0.706	rs9490431	ENSG00000279453.1	RP3-425C14.4	5.48	6.97e-08	2.27e-05	0.33	0.24	Lymphocyte counts;	chr6:122361132	chr6:122436789~122439223:-
LUAD	cis	rs6568401	0.6	rs7746872	ENSG00000219088.1	RP3-359N14.1	-5.48	6.99e-08	2.27e-05	-0.34	-0.24	Primary tooth development (time to first tooth eruption);	chr6:105732246	chr6:105666326~105667998:+
LUAD	cis	rs3758785	0.621	rs7128673	ENSG00000255893.1	RP11-685N10.1	-5.48	6.99e-08	2.27e-05	-0.3	-0.24	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94453072	chr11:94472908~94473570:-
LUAD	cis	rs11651753	0.561	rs11654010	ENSG00000264920.1	RP11-6N17.4	5.48	6.99e-08	2.28e-05	0.3	0.24	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47883499	chr17:47891255~47895812:-
LUAD	cis	rs559928	0.606	rs61083753	ENSG00000236935.1	AP003774.1	5.48	7e-08	2.28e-05	0.33	0.24	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64125193	chr11:64325050~64329504:-
LUAD	cis	rs72615157	0.561	rs113844570	ENSG00000242294.5	STAG3L5P	5.48	7e-08	2.28e-05	0.21	0.24	Lung function (FEV1/FVC);	chr7:100276155	chr7:100336079~100351900:+
LUAD	cis	rs7617773	0.779	rs77957078	ENSG00000228638.1	FCF1P2	-5.48	7e-08	2.28e-05	-0.29	-0.24	Coronary artery disease;	chr3:48289796	chr3:48290793~48291375:-
LUAD	cis	rs556990	0.57	rs5960	ENSG00000269125.1	RP11-98F14.11	5.48	7.01e-08	2.28e-05	0.34	0.24	Blood protein levels;	chr13:113147423	chr13:113165002~113165183:-
LUAD	cis	rs1707322	1	rs7539800	ENSG00000234329.1	RP11-767N6.2	-5.48	7.02e-08	2.28e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796457	chr1:45651039~45651826:-
LUAD	cis	rs7131987	0.65	rs6487808	ENSG00000257176.2	RP11-996F15.2	5.48	7.02e-08	2.28e-05	0.27	0.24	QT interval;	chr12:29310426	chr12:29280418~29317848:-
LUAD	cis	rs2790457	0.917	rs2790462	ENSG00000254635.4	WAC-AS1	-5.48	7.02e-08	2.28e-05	-0.27	-0.24	Multiple myeloma;	chr10:28584273	chr10:28522652~28532743:-
LUAD	cis	rs2412819	0.571	rs495880	ENSG00000249839.1	AC011330.5	5.48	7.02e-08	2.28e-05	0.37	0.24	Lung cancer;	chr15:43855067	chr15:43663654~43684339:-
LUAD	cis	rs2688608	0.62	rs7080350	ENSG00000271816.1	BMS1P4	-5.48	7.03e-08	2.28e-05	-0.2	-0.24	Inflammatory bowel disease;	chr10:73818085	chr10:73699151~73730487:-
LUAD	cis	rs7849270	0.842	rs184457	ENSG00000268707.1	RP11-247A12.7	5.48	7.03e-08	2.29e-05	0.29	0.24	Blood metabolite ratios;	chr9:129177740	chr9:129170434~129170940:+
LUAD	cis	rs6964587	0.773	rs17757926	ENSG00000188693.7	CYP51A1-AS1	-5.48	7.04e-08	2.29e-05	-0.29	-0.24	Breast cancer;	chr7:92358388	chr7:92134604~92180725:+
LUAD	cis	rs1707322	0.752	rs6678444	ENSG00000280836.1	AL355480.1	-5.48	7.04e-08	2.29e-05	-0.32	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764175	chr1:45581219~45581321:-
LUAD	cis	rs897984	0.542	rs59061704	ENSG00000260911.2	RP11-196G11.2	5.48	7.05e-08	2.29e-05	0.22	0.24	Dementia with Lewy bodies;	chr16:31051383	chr16:31043150~31049868:+
LUAD	cis	rs6700559	0.692	rs2809342	ENSG00000260088.1	RP11-92G12.3	-5.48	7.05e-08	2.29e-05	-0.31	-0.24	Coronary artery disease;	chr1:200628522	chr1:200669507~200694250:+
LUAD	cis	rs2380205	0.546	rs626344	ENSG00000232807.2	RP11-536K7.3	-5.48	7.05e-08	2.29e-05	-0.25	-0.24	Breast cancer;	chr10:5908272	chr10:5934270~5945900:-
LUAD	cis	rs496547	0.719	rs1790189	ENSG00000255239.1	AP002954.6	5.48	7.06e-08	2.29e-05	0.3	0.24	Hip minimal joint space width;	chr11:118781617	chr11:118688039~118690600:-
LUAD	cis	rs1075265	0.704	rs13417926	ENSG00000233266.1	HMGB1P31	5.48	7.06e-08	2.29e-05	0.31	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53825520	chr2:54051334~54051760:+
LUAD	cis	rs8100891	0.922	rs7255223	ENSG00000267213.4	AC007773.2	5.47	7.06e-08	2.29e-05	0.32	0.24	Neuroticism;	chr19:32333404	chr19:32390050~32405560:-
LUAD	cis	rs9494145	0.531	rs9399136	ENSG00000232876.1	CTA-212D2.2	-5.47	7.07e-08	2.3e-05	-0.34	-0.24	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135081201	chr6:135055033~135060550:+
LUAD	cis	rs8040855	0.599	rs4643289	ENSG00000259774.1	RP11-182J1.13	-5.47	7.07e-08	2.3e-05	-0.28	-0.24	Bulimia nervosa;	chr15:85183483	chr15:84422618~84425882:+
LUAD	cis	rs66887589	0.87	rs2389875	ENSG00000248280.1	RP11-33B1.2	-5.47	7.08e-08	2.3e-05	-0.27	-0.24	Diastolic blood pressure;	chr4:119635859	chr4:119440561~119450157:-
LUAD	cis	rs9595908	0.709	rs9285092	ENSG00000212293.1	SNORA16	5.47	7.08e-08	2.3e-05	0.26	0.24	Body mass index;	chr13:32745496	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.709	rs4942867	ENSG00000212293.1	SNORA16	5.47	7.08e-08	2.3e-05	0.26	0.24	Body mass index;	chr13:32745916	chr13:32420390~32420516:-
LUAD	cis	rs10246939	0.579	rs35647444	ENSG00000270923.1	TAS2R6P	-5.47	7.08e-08	2.3e-05	-0.26	-0.24	Bitter taste perception;	chr7:141833957	chr7:141787815~141788640:+
LUAD	cis	rs7208859	0.573	rs4055105	ENSG00000263603.1	CTD-2349P21.5	-5.47	7.09e-08	2.3e-05	-0.43	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775532	chr17:30729469~30731202:+
LUAD	cis	rs7246657	0.663	rs4803287	ENSG00000276846.1	CTD-3220F14.3	5.47	7.09e-08	2.3e-05	0.31	0.24	Coronary artery calcification;	chr19:37588534	chr19:37314868~37315620:-
LUAD	cis	rs2880765	0.835	rs6496027	ENSG00000259295.5	CSPG4P12	5.47	7.09e-08	2.3e-05	0.28	0.24	Coronary artery disease;	chr15:85506757	chr15:85191438~85213905:+
LUAD	cis	rs7617773	0.78	rs35297395	ENSG00000228638.1	FCF1P2	-5.47	7.09e-08	2.3e-05	-0.29	-0.24	Coronary artery disease;	chr3:48301392	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.78	rs36075665	ENSG00000228638.1	FCF1P2	-5.47	7.09e-08	2.3e-05	-0.29	-0.24	Coronary artery disease;	chr3:48301597	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.78	rs34630841	ENSG00000228638.1	FCF1P2	-5.47	7.09e-08	2.3e-05	-0.29	-0.24	Coronary artery disease;	chr3:48301771	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.78	rs35190747	ENSG00000228638.1	FCF1P2	-5.47	7.09e-08	2.3e-05	-0.29	-0.24	Coronary artery disease;	chr3:48301800	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.743	rs7621785	ENSG00000228638.1	FCF1P2	-5.47	7.09e-08	2.3e-05	-0.29	-0.24	Coronary artery disease;	chr3:48302218	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.78	rs4511915	ENSG00000228638.1	FCF1P2	-5.47	7.09e-08	2.3e-05	-0.29	-0.24	Coronary artery disease;	chr3:48302368	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.78	rs13066758	ENSG00000228638.1	FCF1P2	-5.47	7.09e-08	2.3e-05	-0.29	-0.24	Coronary artery disease;	chr3:48302387	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.78	rs4392440	ENSG00000228638.1	FCF1P2	-5.47	7.09e-08	2.3e-05	-0.29	-0.24	Coronary artery disease;	chr3:48302430	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.78	rs13082859	ENSG00000228638.1	FCF1P2	-5.47	7.09e-08	2.3e-05	-0.29	-0.24	Coronary artery disease;	chr3:48303185	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.78	rs36121690	ENSG00000228638.1	FCF1P2	-5.47	7.09e-08	2.3e-05	-0.29	-0.24	Coronary artery disease;	chr3:48304021	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.78	rs35778847	ENSG00000228638.1	FCF1P2	-5.47	7.09e-08	2.3e-05	-0.29	-0.24	Coronary artery disease;	chr3:48305495	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.78	rs34749846	ENSG00000228638.1	FCF1P2	-5.47	7.09e-08	2.3e-05	-0.29	-0.24	Coronary artery disease;	chr3:48305678	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.78	rs7632297	ENSG00000228638.1	FCF1P2	-5.47	7.09e-08	2.3e-05	-0.29	-0.24	Coronary artery disease;	chr3:48306673	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.78	rs79089926	ENSG00000228638.1	FCF1P2	-5.47	7.09e-08	2.3e-05	-0.29	-0.24	Coronary artery disease;	chr3:48307074	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.78	rs4511916	ENSG00000228638.1	FCF1P2	-5.47	7.09e-08	2.3e-05	-0.29	-0.24	Coronary artery disease;	chr3:48308876	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.815	rs7624450	ENSG00000228638.1	FCF1P2	-5.47	7.09e-08	2.3e-05	-0.29	-0.24	Coronary artery disease;	chr3:48308885	chr3:48290793~48291375:-
LUAD	cis	rs7829975	0.511	rs2948286	ENSG00000253981.4	ALG1L13P	5.47	7.1e-08	2.31e-05	0.29	0.24	Mood instability;	chr8:8272638	chr8:8236003~8244667:-
LUAD	cis	rs2836950	0.52	rs8130240	ENSG00000255568.3	BRWD1-AS2	-5.47	7.11e-08	2.31e-05	-0.24	-0.24	Menarche (age at onset);	chr21:39166182	chr21:39313935~39314962:+
LUAD	cis	rs867371	1	rs9944197	ENSG00000259429.4	UBE2Q2P2	-5.47	7.11e-08	2.31e-05	-0.21	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82158261	chr15:82355142~82420075:+
LUAD	cis	rs867371	1	rs1392976	ENSG00000259429.4	UBE2Q2P2	5.47	7.11e-08	2.31e-05	0.21	0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82153834	chr15:82355142~82420075:+
LUAD	cis	rs11976180	1	rs1320893	ENSG00000204959.4	ARHGEF34P	5.47	7.11e-08	2.31e-05	0.3	0.24	Obesity-related traits;	chr7:144055019	chr7:144272445~144286966:-
LUAD	cis	rs910316	1	rs10873275	ENSG00000259138.1	RP11-950C14.7	5.47	7.11e-08	2.31e-05	0.26	0.24	Height;	chr14:75064757	chr14:75127153~75136930:+
LUAD	cis	rs193541	0.545	rs12518979	ENSG00000263432.2	RN7SL689P	-5.47	7.11e-08	2.31e-05	-0.31	-0.24	Glucose homeostasis traits;	chr5:122846092	chr5:123022487~123022783:-
LUAD	cis	rs10761482	0.5	rs7906760	ENSG00000254271.1	RP11-131N11.4	5.47	7.13e-08	2.32e-05	0.26	0.24	Schizophrenia;	chr10:60526895	chr10:60734342~60741828:+
LUAD	cis	rs10515750	0.643	rs10063413	ENSG00000251405.2	CTB-109A12.1	-5.47	7.13e-08	2.32e-05	-0.43	-0.24	Lung function (FEV1/FVC);	chr5:157384435	chr5:157362615~157460078:-
LUAD	cis	rs673078	0.607	rs76809232	ENSG00000275409.1	RP11-131L12.4	-5.47	7.13e-08	2.32e-05	-0.33	-0.24	Glucose homeostasis traits;	chr12:118444979	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs61944660	ENSG00000275409.1	RP11-131L12.4	-5.47	7.13e-08	2.32e-05	-0.33	-0.24	Glucose homeostasis traits;	chr12:118445326	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs61944662	ENSG00000275409.1	RP11-131L12.4	-5.47	7.13e-08	2.32e-05	-0.33	-0.24	Glucose homeostasis traits;	chr12:118445520	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs4254101	ENSG00000275409.1	RP11-131L12.4	-5.47	7.13e-08	2.32e-05	-0.33	-0.24	Glucose homeostasis traits;	chr12:118445877	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs4622305	ENSG00000275409.1	RP11-131L12.4	-5.47	7.13e-08	2.32e-05	-0.33	-0.24	Glucose homeostasis traits;	chr12:118445912	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs73207575	ENSG00000275409.1	RP11-131L12.4	-5.47	7.13e-08	2.32e-05	-0.33	-0.24	Glucose homeostasis traits;	chr12:118446711	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs61944663	ENSG00000275409.1	RP11-131L12.4	-5.47	7.13e-08	2.32e-05	-0.33	-0.24	Glucose homeostasis traits;	chr12:118446886	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs73207577	ENSG00000275409.1	RP11-131L12.4	-5.47	7.13e-08	2.32e-05	-0.33	-0.24	Glucose homeostasis traits;	chr12:118447012	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs73207579	ENSG00000275409.1	RP11-131L12.4	-5.47	7.13e-08	2.32e-05	-0.33	-0.24	Glucose homeostasis traits;	chr12:118447123	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs61944664	ENSG00000275409.1	RP11-131L12.4	-5.47	7.13e-08	2.32e-05	-0.33	-0.24	Glucose homeostasis traits;	chr12:118447145	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs7969871	ENSG00000275409.1	RP11-131L12.4	-5.47	7.13e-08	2.32e-05	-0.33	-0.24	Glucose homeostasis traits;	chr12:118447331	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.56	rs7970361	ENSG00000275409.1	RP11-131L12.4	-5.47	7.13e-08	2.32e-05	-0.33	-0.24	Glucose homeostasis traits;	chr12:118447723	chr12:118430147~118430699:+
LUAD	cis	rs712039	0.652	rs712038	ENSG00000276054.1	RP11-378E13.3	5.47	7.14e-08	2.32e-05	0.36	0.24	Tuberculosis;	chr17:37402468	chr17:37386886~37387926:+
LUAD	cis	rs712039	0.652	rs829160	ENSG00000276054.1	RP11-378E13.3	5.47	7.14e-08	2.32e-05	0.36	0.24	Tuberculosis;	chr17:37403002	chr17:37386886~37387926:+
LUAD	cis	rs75920871	0.528	rs7950093	ENSG00000254851.1	RP11-109L13.1	5.47	7.14e-08	2.32e-05	0.35	0.24	Subjective well-being;	chr11:117092803	chr11:117135528~117138582:+
LUAD	cis	rs8098244	0.638	rs9962076	ENSG00000264745.1	TTC39C-AS1	5.47	7.14e-08	2.32e-05	0.25	0.24	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23850198	chr18:23994213~24015339:-
LUAD	cis	rs8098244	0.638	rs2001437	ENSG00000264745.1	TTC39C-AS1	5.47	7.14e-08	2.32e-05	0.25	0.24	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23854811	chr18:23994213~24015339:-
LUAD	cis	rs2455601	0.608	rs16906256	ENSG00000254860.4	TMEM9B-AS1	5.47	7.15e-08	2.32e-05	0.31	0.24	Schizophrenia;	chr11:8865550	chr11:8964675~8977527:+
LUAD	cis	rs2455601	0.608	rs10840137	ENSG00000254860.4	TMEM9B-AS1	5.47	7.15e-08	2.32e-05	0.31	0.24	Schizophrenia;	chr11:8868532	chr11:8964675~8977527:+
LUAD	cis	rs8072100	0.817	rs9905581	ENSG00000228782.6	CTD-2026D20.3	5.47	7.15e-08	2.32e-05	0.26	0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469819	chr17:47450568~47492492:-
LUAD	cis	rs6860806	0.507	rs169256	ENSG00000233006.5	AC034220.3	5.47	7.15e-08	2.32e-05	0.26	0.24	Breast cancer;	chr5:132352840	chr5:132311285~132369916:-
LUAD	cis	rs4664293	0.51	rs1968343	ENSG00000226266.5	AC009961.3	5.47	7.15e-08	2.32e-05	0.33	0.24	Monocyte percentage of white cells;	chr2:159712247	chr2:159670708~159712435:-
LUAD	cis	rs2790457	0.792	rs1265830	ENSG00000254635.4	WAC-AS1	5.47	7.15e-08	2.32e-05	0.27	0.24	Multiple myeloma;	chr10:28623294	chr10:28522652~28532743:-
LUAD	cis	rs2404602	0.716	rs8030411	ENSG00000259422.1	RP11-593F23.1	5.47	7.18e-08	2.33e-05	0.27	0.24	Blood metabolite levels;	chr15:76407514	chr15:76174891~76181486:-
LUAD	cis	rs516805	0.667	rs2816165	ENSG00000279453.1	RP3-425C14.4	-5.47	7.19e-08	2.33e-05	-0.34	-0.24	Lymphocyte counts;	chr6:122114717	chr6:122436789~122439223:-
LUAD	cis	rs1707322	0.929	rs785513	ENSG00000234329.1	RP11-767N6.2	-5.47	7.2e-08	2.33e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46072648	chr1:45651039~45651826:-
LUAD	cis	rs755249	0.567	rs72661961	ENSG00000228060.1	RP11-69E11.8	-5.47	7.2e-08	2.33e-05	-0.25	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39366096	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.532	rs61779277	ENSG00000228060.1	RP11-69E11.8	-5.47	7.2e-08	2.33e-05	-0.25	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39367863	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.532	rs61779278	ENSG00000228060.1	RP11-69E11.8	-5.47	7.2e-08	2.33e-05	-0.25	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39368945	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs2296172	ENSG00000228060.1	RP11-69E11.8	-5.47	7.2e-08	2.33e-05	-0.25	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39370145	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs61779279	ENSG00000228060.1	RP11-69E11.8	-5.47	7.2e-08	2.33e-05	-0.25	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39371430	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs76111861	ENSG00000228060.1	RP11-69E11.8	-5.47	7.2e-08	2.33e-05	-0.25	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39377018	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.567	rs72661965	ENSG00000228060.1	RP11-69E11.8	-5.47	7.2e-08	2.33e-05	-0.25	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39380918	chr1:39565160~39573203:+
LUAD	cis	rs67311347	0.605	rs1880762	ENSG00000223797.4	ENTPD3-AS1	5.47	7.2e-08	2.33e-05	0.26	0.24	Renal cell carcinoma;	chr3:40241724	chr3:40313802~40453329:-
LUAD	cis	rs12908161	0.96	rs34452033	ENSG00000225151.9	GOLGA2P7	-5.47	7.23e-08	2.34e-05	-0.33	-0.24	Schizophrenia;	chr15:84678762	chr15:84199311~84230136:-
LUAD	cis	rs948562	0.69	rs57922517	ENSG00000280010.1	AP001350.4	5.47	7.23e-08	2.34e-05	0.37	0.24	Lymphoma;	chr11:58334054	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.69	rs78776290	ENSG00000280010.1	AP001350.4	5.47	7.23e-08	2.34e-05	0.37	0.24	Lymphoma;	chr11:58334410	chr11:58627435~58628528:+
LUAD	cis	rs7804306	1	rs73050915	ENSG00000233264.2	AC006042.8	5.47	7.23e-08	2.34e-05	0.48	0.24	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8010614	chr7:7980312~7982228:+
LUAD	cis	rs1075265	0.933	rs7573491	ENSG00000233266.1	HMGB1P31	5.47	7.23e-08	2.34e-05	0.31	0.24	Chronotype;Morning vs. evening chronotype;	chr2:54115875	chr2:54051334~54051760:+
LUAD	cis	rs1075265	0.933	rs2042143	ENSG00000233266.1	HMGB1P31	5.47	7.23e-08	2.34e-05	0.31	0.24	Chronotype;Morning vs. evening chronotype;	chr2:54116377	chr2:54051334~54051760:+
LUAD	cis	rs783540	0.609	rs803686	ENSG00000278603.1	RP13-608F4.5	-5.47	7.24e-08	2.35e-05	-0.31	-0.24	Schizophrenia;	chr15:82550590	chr15:82472203~82472426:+
LUAD	cis	rs4835473	0.9	rs4054634	ENSG00000251600.4	RP11-673E1.1	-5.47	7.24e-08	2.35e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143787045	chr4:143912331~143982454:+
LUAD	cis	rs7804306	0.826	rs113537684	ENSG00000233264.2	AC006042.8	5.47	7.24e-08	2.35e-05	0.46	0.24	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7985192	chr7:7980312~7982228:+
LUAD	cis	rs8072100	0.748	rs9908016	ENSG00000228782.6	CTD-2026D20.3	5.47	7.25e-08	2.35e-05	0.26	0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47473995	chr17:47450568~47492492:-
LUAD	cis	rs8072100	0.782	rs28507314	ENSG00000228782.6	CTD-2026D20.3	5.47	7.25e-08	2.35e-05	0.26	0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47474036	chr17:47450568~47492492:-
LUAD	cis	rs6570726	0.791	rs11155433	ENSG00000235652.6	RP11-545I5.3	-5.47	7.26e-08	2.35e-05	-0.24	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145586695	chr6:145799409~145886585:+
LUAD	cis	rs1876905	0.68	rs354547	ENSG00000272356.1	RP5-1112D6.8	5.47	7.26e-08	2.35e-05	0.25	0.24	Mean corpuscular hemoglobin;	chr6:111213919	chr6:111309203~111313517:+
LUAD	cis	rs11096990	0.855	rs2167494	ENSG00000249207.1	RP11-360F5.1	5.47	7.27e-08	2.36e-05	0.29	0.24	Cognitive function;	chr4:39214601	chr4:39112677~39126818:-
LUAD	cis	rs2404602	0.692	rs8037005	ENSG00000259422.1	RP11-593F23.1	5.47	7.27e-08	2.36e-05	0.28	0.24	Blood metabolite levels;	chr15:76658768	chr15:76174891~76181486:-
LUAD	cis	rs17684571	0.751	rs17752106	ENSG00000231441.1	RP11-472M19.2	5.47	7.28e-08	2.36e-05	0.36	0.24	Schizophrenia;	chr6:56837455	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.751	rs17684878	ENSG00000231441.1	RP11-472M19.2	5.47	7.28e-08	2.36e-05	0.36	0.24	Schizophrenia;	chr6:56838178	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.751	rs17684884	ENSG00000231441.1	RP11-472M19.2	5.47	7.28e-08	2.36e-05	0.36	0.24	Schizophrenia;	chr6:56838852	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.751	rs7761501	ENSG00000231441.1	RP11-472M19.2	5.47	7.28e-08	2.36e-05	0.36	0.24	Schizophrenia;	chr6:56839187	chr6:56844002~56864078:+
LUAD	cis	rs2836950	0.565	rs4816617	ENSG00000255568.3	BRWD1-AS2	-5.47	7.28e-08	2.36e-05	-0.24	-0.24	Menarche (age at onset);	chr21:39168764	chr21:39313935~39314962:+
LUAD	cis	rs17666538	0.792	rs1669715	ENSG00000254207.1	RP11-43A14.1	5.47	7.28e-08	2.36e-05	0.5	0.24	IgG glycosylation;	chr8:643641	chr8:725188~725877:-
LUAD	cis	rs10246939	0.543	rs11767119	ENSG00000228775.6	WEE2-AS1	5.47	7.29e-08	2.36e-05	0.32	0.24	Bitter taste perception;	chr7:141912316	chr7:141704338~141738346:-
LUAD	cis	rs30380	1	rs30379	ENSG00000272109.1	CTD-2260A17.3	-5.47	7.3e-08	2.36e-05	-0.26	-0.24	Cerebrospinal fluid biomarker levels;	chr5:96786556	chr5:96804353~96806105:+
LUAD	cis	rs30380	1	rs30380	ENSG00000272109.1	CTD-2260A17.3	-5.47	7.3e-08	2.36e-05	-0.26	-0.24	Cerebrospinal fluid biomarker levels;	chr5:96786577	chr5:96804353~96806105:+
LUAD	cis	rs12468226	1	rs11899836	ENSG00000226261.1	AC064836.3	5.47	7.3e-08	2.36e-05	0.38	0.24	Urate levels;	chr2:202371316	chr2:202336024~202336727:-
LUAD	cis	rs848490	0.762	rs7796089	ENSG00000214293.7	APTR	5.47	7.3e-08	2.36e-05	0.29	0.24	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77882781	chr7:77657660~77696265:-
LUAD	cis	rs1318937	0.915	rs3773472	ENSG00000224660.1	SH3BP5-AS1	5.47	7.31e-08	2.37e-05	0.18	0.24	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15261246	chr3:15254184~15264493:+
LUAD	cis	rs673078	0.607	rs73207564	ENSG00000275409.1	RP11-131L12.4	-5.47	7.32e-08	2.37e-05	-0.34	-0.24	Glucose homeostasis traits;	chr12:118429566	chr12:118430147~118430699:+
LUAD	cis	rs1823913	0.637	rs4613316	ENSG00000280083.1	RP11-317J9.1	-5.47	7.32e-08	2.37e-05	-0.29	-0.24	Obesity-related traits;	chr2:191326074	chr2:191154118~191156070:-
LUAD	cis	rs8072100	0.817	rs12449647	ENSG00000228782.6	CTD-2026D20.3	5.47	7.32e-08	2.37e-05	0.26	0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47471592	chr17:47450568~47492492:-
LUAD	cis	rs9438901	0.655	rs609320	ENSG00000261349.1	RP3-465N24.5	5.47	7.32e-08	2.37e-05	0.4	0.24	Red cell distribution width;	chr1:25390874	chr1:25266102~25267136:-
LUAD	cis	rs673078	0.607	rs8467	ENSG00000275409.1	RP11-131L12.4	-5.47	7.33e-08	2.37e-05	-0.33	-0.24	Glucose homeostasis traits;	chr12:118417479	chr12:118430147~118430699:+
LUAD	cis	rs7208859	0.673	rs423151	ENSG00000263603.1	CTD-2349P21.5	-5.47	7.33e-08	2.37e-05	-0.36	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30625268	chr17:30729469~30731202:+
LUAD	cis	rs9309473	0.606	rs62149777	ENSG00000163016.8	ALMS1P	5.47	7.33e-08	2.37e-05	0.37	0.24	Metabolite levels;	chr2:73568237	chr2:73644919~73685576:+
LUAD	cis	rs10214930	0.56	rs42088	ENSG00000235574.1	AC073150.6	5.47	7.33e-08	2.37e-05	0.29	0.24	Hypospadias;	chr7:27662242	chr7:27491682~27492765:-
LUAD	cis	rs6570726	0.935	rs387965	ENSG00000235652.6	RP11-545I5.3	5.47	7.34e-08	2.38e-05	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145548230	chr6:145799409~145886585:+
LUAD	cis	rs1075265	0.73	rs7601692	ENSG00000233266.1	HMGB1P31	5.47	7.34e-08	2.38e-05	0.31	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53705532	chr2:54051334~54051760:+
LUAD	cis	rs7617773	0.643	rs78159520	ENSG00000228638.1	FCF1P2	-5.47	7.34e-08	2.38e-05	-0.29	-0.24	Coronary artery disease;	chr3:48307533	chr3:48290793~48291375:-
LUAD	cis	rs1318937	0.764	rs60896928	ENSG00000224660.1	SH3BP5-AS1	5.47	7.34e-08	2.38e-05	0.18	0.24	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15201343	chr3:15254184~15264493:+
LUAD	cis	rs875971	0.522	rs9530	ENSG00000236529.1	RP13-254B10.1	5.47	7.34e-08	2.38e-05	0.25	0.24	Aortic root size;	chr7:65960907	chr7:65840212~65840596:+
LUAD	cis	rs4664293	0.585	rs13019325	ENSG00000226266.5	AC009961.3	5.47	7.35e-08	2.38e-05	0.33	0.24	Monocyte percentage of white cells;	chr2:159772479	chr2:159670708~159712435:-
LUAD	cis	rs453301	0.686	rs6987107	ENSG00000253981.4	ALG1L13P	-5.47	7.35e-08	2.38e-05	-0.29	-0.24	Joint mobility (Beighton score);	chr8:9036071	chr8:8236003~8244667:-
LUAD	cis	rs673078	0.607	rs10850967	ENSG00000275409.1	RP11-131L12.4	-5.47	7.35e-08	2.38e-05	-0.3	-0.24	Glucose homeostasis traits;	chr12:118380072	chr12:118430147~118430699:+
LUAD	cis	rs10129255	0.589	rs78599641	ENSG00000211972.2	IGHV3-66	5.47	7.35e-08	2.38e-05	0.21	0.24	Kawasaki disease;	chr14:106637576	chr14:106675017~106675544:-
LUAD	cis	rs6565180	1	rs11862806	ENSG00000183604.13	SMG1P5	-5.47	7.35e-08	2.38e-05	-0.26	-0.24	Tonsillectomy;	chr16:30352750	chr16:30267553~30335374:-
LUAD	cis	rs9910055	0.762	rs2631299	ENSG00000267080.4	ASB16-AS1	-5.47	7.36e-08	2.38e-05	-0.22	-0.24	Total body bone mineral density;	chr17:44142405	chr17:44175973~44186717:-
LUAD	cis	rs9595908	0.84	rs2301388	ENSG00000212293.1	SNORA16	5.47	7.36e-08	2.38e-05	0.26	0.24	Body mass index;	chr13:32648478	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.758	rs2301389	ENSG00000212293.1	SNORA16	5.47	7.36e-08	2.38e-05	0.26	0.24	Body mass index;	chr13:32648694	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.785	rs2301390	ENSG00000212293.1	SNORA16	5.47	7.36e-08	2.38e-05	0.26	0.24	Body mass index;	chr13:32649307	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.746	rs2031355	ENSG00000212293.1	SNORA16	5.47	7.37e-08	2.38e-05	0.26	0.24	Body mass index;	chr13:32641495	chr13:32420390~32420516:-
LUAD	cis	rs6921919	0.515	rs1558205	ENSG00000216901.1	AL022393.7	-5.47	7.38e-08	2.39e-05	-0.29	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28176188~28176674:+
LUAD	cis	rs957448	0.507	rs1984711	ENSG00000253704.1	RP11-267M23.4	5.47	7.39e-08	2.39e-05	0.28	0.24	Nonsyndromic cleft lip with cleft palate;	chr8:94600276	chr8:94553722~94569745:+
LUAD	cis	rs17301853	0.915	rs78167602	ENSG00000227373.4	RP11-160H22.5	5.47	7.39e-08	2.39e-05	0.48	0.24	Migraine without aura;Migraine - clinic-based;	chr1:174926185	chr1:174115300~174160004:-
LUAD	cis	rs9532669	0.889	rs7333447	ENSG00000168852.11	TPTE2P5	5.47	7.39e-08	2.39e-05	0.23	0.24	Cervical cancer;	chr13:40917586	chr13:40822296~40921749:-
LUAD	cis	rs896854	0.714	rs6471503	ENSG00000253528.2	RP11-347C18.4	5.47	7.4e-08	2.39e-05	0.23	0.24	Type 2 diabetes;	chr8:94978055	chr8:94974573~94974853:-
LUAD	cis	rs1823913	0.526	rs35340557	ENSG00000280083.1	RP11-317J9.1	-5.47	7.4e-08	2.39e-05	-0.29	-0.24	Obesity-related traits;	chr2:191338688	chr2:191154118~191156070:-
LUAD	cis	rs1823913	0.503	rs35562914	ENSG00000280083.1	RP11-317J9.1	-5.47	7.4e-08	2.39e-05	-0.29	-0.24	Obesity-related traits;	chr2:191338969	chr2:191154118~191156070:-
LUAD	cis	rs36093844	0.848	rs55836023	ENSG00000279742.1	RP11-700A24.1	-5.47	7.41e-08	2.4e-05	-0.31	-0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85855114	chr11:85852557~85854943:-
LUAD	cis	rs17711722	0.503	rs453835	ENSG00000226002.1	RP11-460N20.5	-5.47	7.41e-08	2.4e-05	-0.27	-0.24	Calcium levels;	chr7:66046172	chr7:65084103~65100232:+
LUAD	cis	rs7208859	0.673	rs216424	ENSG00000263531.1	RP13-753N3.1	5.47	7.41e-08	2.4e-05	0.42	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30616046	chr17:30863921~30864940:-
LUAD	cis	rs7804306	0.655	rs117620902	ENSG00000233264.2	AC006042.8	5.47	7.41e-08	2.4e-05	0.53	0.24	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8061518	chr7:7980312~7982228:+
LUAD	cis	rs6142102	0.625	rs6142056	ENSG00000275784.1	RP5-1125A11.6	-5.47	7.42e-08	2.4e-05	-0.26	-0.24	Skin pigmentation;	chr20:33953349	chr20:33989480~33991818:-
LUAD	cis	rs301901	0.675	rs2366274	ENSG00000250155.1	CTD-2353F22.1	-5.47	7.42e-08	2.4e-05	-0.26	-0.24	Height;	chr5:37266341	chr5:36666214~36725195:-
LUAD	cis	rs301901	0.734	rs216385	ENSG00000250155.1	CTD-2353F22.1	-5.47	7.42e-08	2.4e-05	-0.26	-0.24	Height;	chr5:37275173	chr5:36666214~36725195:-
LUAD	cis	rs1707322	1	rs12097761	ENSG00000234329.1	RP11-767N6.2	5.47	7.42e-08	2.4e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825490	chr1:45651039~45651826:-
LUAD	cis	rs858239	0.539	rs870476	ENSG00000230042.1	AK3P3	-5.47	7.43e-08	2.4e-05	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23153652	chr7:23129178~23129841:+
LUAD	cis	rs1075265	0.656	rs2542574	ENSG00000233266.1	HMGB1P31	5.47	7.43e-08	2.4e-05	0.3	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53820295	chr2:54051334~54051760:+
LUAD	cis	rs2412819	0.571	rs56226333	ENSG00000249839.1	AC011330.5	-5.47	7.43e-08	2.4e-05	-0.4	-0.24	Lung cancer;	chr15:43632410	chr15:43663654~43684339:-
LUAD	cis	rs6570726	0.577	rs399502	ENSG00000235652.6	RP11-545I5.3	5.47	7.44e-08	2.4e-05	0.25	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145484738	chr6:145799409~145886585:+
LUAD	cis	rs17684571	0.751	rs4415160	ENSG00000231441.1	RP11-472M19.2	-5.47	7.44e-08	2.4e-05	-0.35	-0.24	Schizophrenia;	chr6:56821424	chr6:56844002~56864078:+
LUAD	cis	rs7617773	0.674	rs13069029	ENSG00000228638.1	FCF1P2	-5.47	7.44e-08	2.41e-05	-0.29	-0.24	Coronary artery disease;	chr3:48313534	chr3:48290793~48291375:-
LUAD	cis	rs293748	0.771	rs158799	ENSG00000250155.1	CTD-2353F22.1	-5.46	7.45e-08	2.41e-05	-0.33	-0.24	Obesity-related traits;	chr5:36869149	chr5:36666214~36725195:-
LUAD	cis	rs9322193	0.923	rs2880436	ENSG00000268592.3	RAET1E-AS1	5.46	7.45e-08	2.41e-05	0.31	0.24	Lung cancer;	chr6:149859123	chr6:149863494~149919507:+
LUAD	cis	rs9992667	0.955	rs1491199	ENSG00000231160.8	KLF3-AS1	5.46	7.45e-08	2.41e-05	0.3	0.24	Eosinophil percentage of granulocytes;	chr4:38641393	chr4:38612701~38664883:-
LUAD	cis	rs17711722	0.727	rs1880555	ENSG00000236529.1	RP13-254B10.1	5.46	7.46e-08	2.41e-05	0.25	0.24	Calcium levels;	chr7:65967580	chr7:65840212~65840596:+
LUAD	cis	rs7927592	0.956	rs55816191	ENSG00000212093.1	AP000807.1	5.46	7.46e-08	2.41e-05	0.27	0.24	Total body bone mineral density;	chr11:68495511	chr11:68506083~68506166:-
LUAD	cis	rs17684571	0.7	rs35886823	ENSG00000231441.1	RP11-472M19.2	5.46	7.46e-08	2.41e-05	0.34	0.24	Schizophrenia;	chr6:56816682	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.751	rs7771085	ENSG00000231441.1	RP11-472M19.2	5.46	7.47e-08	2.41e-05	0.36	0.24	Schizophrenia;	chr6:56818631	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.7	rs36037734	ENSG00000231441.1	RP11-472M19.2	5.46	7.48e-08	2.42e-05	0.36	0.24	Schizophrenia;	chr6:56801202	chr6:56844002~56864078:+
LUAD	cis	rs755249	0.567	rs6668369	ENSG00000228060.1	RP11-69E11.8	-5.46	7.49e-08	2.42e-05	-0.25	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39382675	chr1:39565160~39573203:+
LUAD	cis	rs6840258	0.6	rs1447994	ENSG00000251411.1	RP11-397E7.4	5.46	7.49e-08	2.42e-05	0.31	0.24	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86966902	chr4:86913266~86914817:-
LUAD	cis	rs6840258	0.66	rs10015639	ENSG00000251411.1	RP11-397E7.4	5.46	7.49e-08	2.42e-05	0.31	0.24	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86970413	chr4:86913266~86914817:-
LUAD	cis	rs301901	0.734	rs216387	ENSG00000250155.1	CTD-2353F22.1	-5.46	7.52e-08	2.43e-05	-0.26	-0.24	Height;	chr5:37276657	chr5:36666214~36725195:-
LUAD	cis	rs9952991	0.941	rs2014857	ENSG00000260302.1	RP11-973H7.1	-5.46	7.52e-08	2.43e-05	-0.42	-0.24	Inflammatory skin disease;	chr18:12774327	chr18:12774651~12775923:-
LUAD	cis	rs9952991	0.883	rs2847260	ENSG00000260302.1	RP11-973H7.1	-5.46	7.52e-08	2.43e-05	-0.42	-0.24	Inflammatory skin disease;	chr18:12775592	chr18:12774651~12775923:-
LUAD	cis	rs9952991	0.883	rs2542147	ENSG00000260302.1	RP11-973H7.1	-5.46	7.52e-08	2.43e-05	-0.42	-0.24	Inflammatory skin disease;	chr18:12775852	chr18:12774651~12775923:-
LUAD	cis	rs72634501	0.716	rs72660086	ENSG00000228060.1	RP11-69E11.8	-5.46	7.52e-08	2.43e-05	-0.26	-0.24	HDL cholesterol;	chr1:39106320	chr1:39565160~39573203:+
LUAD	cis	rs7617773	0.817	rs3731555	ENSG00000228638.1	FCF1P2	-5.46	7.52e-08	2.43e-05	-0.29	-0.24	Coronary artery disease;	chr3:48164612	chr3:48290793~48291375:-
LUAD	cis	rs1075265	0.756	rs805423	ENSG00000233266.1	HMGB1P31	5.46	7.52e-08	2.43e-05	0.31	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53899904	chr2:54051334~54051760:+
LUAD	cis	rs35740288	0.929	rs11073537	ENSG00000202081.1	RNU6-1280P	5.46	7.53e-08	2.43e-05	0.31	0.24	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85769450	chr15:85651522~85651628:-
LUAD	cis	rs2439831	0.85	rs7169988	ENSG00000205771.5	CATSPER2P1	-5.46	7.54e-08	2.43e-05	-0.46	-0.24	Lung cancer in ever smokers;	chr15:43768237	chr15:43726918~43747094:-
LUAD	cis	rs7714584	1	rs11746807	ENSG00000197083.10	ZNF300P1	5.46	7.55e-08	2.44e-05	0.48	0.24	Crohn's disease;	chr5:150920857	chr5:150930645~150946289:-
LUAD	cis	rs17684571	0.751	rs7775182	ENSG00000231441.1	RP11-472M19.2	5.46	7.55e-08	2.44e-05	0.36	0.24	Schizophrenia;	chr6:56831848	chr6:56844002~56864078:+
LUAD	cis	rs6142102	0.625	rs9753690	ENSG00000275784.1	RP5-1125A11.6	-5.46	7.56e-08	2.44e-05	-0.26	-0.24	Skin pigmentation;	chr20:33952995	chr20:33989480~33991818:-
LUAD	cis	rs6142102	0.625	rs7263727	ENSG00000275784.1	RP5-1125A11.6	-5.46	7.56e-08	2.44e-05	-0.26	-0.24	Skin pigmentation;	chr20:33953133	chr20:33989480~33991818:-
LUAD	cis	rs10129255	0.556	rs9324093	ENSG00000211967.3	IGHV3-53	-5.46	7.56e-08	2.44e-05	-0.17	-0.24	Kawasaki disease;	chr14:106683893	chr14:106592676~106593347:-
LUAD	cis	rs673078	0.607	rs73207573	ENSG00000275409.1	RP11-131L12.4	-5.46	7.56e-08	2.44e-05	-0.33	-0.24	Glucose homeostasis traits;	chr12:118444664	chr12:118430147~118430699:+
LUAD	cis	rs17684571	0.751	rs13203681	ENSG00000231441.1	RP11-472M19.2	5.46	7.57e-08	2.45e-05	0.34	0.24	Schizophrenia;	chr6:56841361	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.751	rs36094082	ENSG00000231441.1	RP11-472M19.2	5.46	7.57e-08	2.45e-05	0.34	0.24	Schizophrenia;	chr6:56842153	chr6:56844002~56864078:+
LUAD	cis	rs853679	0.824	rs34712084	ENSG00000219392.1	RP1-265C24.5	-5.46	7.58e-08	2.45e-05	-0.42	-0.24	Depression;	chr6:28076050	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.824	rs1321505	ENSG00000219392.1	RP1-265C24.5	-5.46	7.58e-08	2.45e-05	-0.42	-0.24	Depression;	chr6:28085045	chr6:28115628~28116551:+
LUAD	cis	rs712039	0.652	rs853200	ENSG00000276054.1	RP11-378E13.3	5.46	7.58e-08	2.45e-05	0.37	0.24	Tuberculosis;	chr17:37444013	chr17:37386886~37387926:+
LUAD	cis	rs875971	0.862	rs28470208	ENSG00000237310.1	GS1-124K5.4	-5.46	7.59e-08	2.45e-05	-0.26	-0.24	Aortic root size;	chr7:66119713	chr7:66493706~66495474:+
LUAD	cis	rs2243480	1	rs431318	ENSG00000230295.1	RP11-458F8.2	-5.46	7.59e-08	2.45e-05	-0.29	-0.24	Diabetic kidney disease;	chr7:66046610	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs313803	ENSG00000230295.1	RP11-458F8.2	-5.46	7.59e-08	2.45e-05	-0.29	-0.24	Diabetic kidney disease;	chr7:66049744	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs313802	ENSG00000230295.1	RP11-458F8.2	-5.46	7.59e-08	2.45e-05	-0.29	-0.24	Diabetic kidney disease;	chr7:66051386	chr7:66880708~66882981:+
LUAD	cis	rs2243480	0.803	rs403089	ENSG00000230295.1	RP11-458F8.2	-5.46	7.59e-08	2.45e-05	-0.29	-0.24	Diabetic kidney disease;	chr7:66052736	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs458291	ENSG00000230295.1	RP11-458F8.2	-5.46	7.59e-08	2.45e-05	-0.29	-0.24	Diabetic kidney disease;	chr7:66055492	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs466983	ENSG00000230295.1	RP11-458F8.2	-5.46	7.59e-08	2.45e-05	-0.29	-0.24	Diabetic kidney disease;	chr7:66055509	chr7:66880708~66882981:+
LUAD	cis	rs2018683	0.624	rs1006521	ENSG00000228421.2	AC005013.5	5.46	7.6e-08	2.45e-05	0.28	0.24	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28956604	chr7:28957667~28959345:+
LUAD	cis	rs9287719	0.686	rs10174605	ENSG00000243819.4	RN7SL832P	5.46	7.6e-08	2.45e-05	0.26	0.24	Prostate cancer;	chr2:10585106	chr2:10690344~10692099:+
LUAD	cis	rs7044106	0.718	rs10616	ENSG00000238181.2	AHCYP2	-5.46	7.61e-08	2.46e-05	-0.31	-0.24	Hip circumference adjusted for BMI;	chr9:120601255	chr9:120720673~120721972:+
LUAD	cis	rs11089937	0.568	rs5756989	ENSG00000211638.2	IGLV8-61	-5.46	7.62e-08	2.46e-05	-0.28	-0.24	Periodontitis (PAL4Q3);	chr22:22132415	chr22:22098700~22099212:+
LUAD	cis	rs1707322	0.964	rs785516	ENSG00000280836.1	AL355480.1	5.46	7.64e-08	2.47e-05	0.32	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46099086	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs785517	ENSG00000280836.1	AL355480.1	5.46	7.64e-08	2.47e-05	0.32	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46101863	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs785484	ENSG00000280836.1	AL355480.1	5.46	7.64e-08	2.47e-05	0.32	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46108343	chr1:45581219~45581321:-
LUAD	cis	rs9506514	0.722	rs11147813	ENSG00000238286.1	SLC35E1P1	5.46	7.64e-08	2.47e-05	0.27	0.24	Coronary artery calcification;	chr13:20684419	chr13:20607268~20608131:+
LUAD	cis	rs4835473	0.9	rs13137885	ENSG00000251600.4	RP11-673E1.1	-5.46	7.64e-08	2.47e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143734212	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs13105550	ENSG00000251600.4	RP11-673E1.1	-5.46	7.64e-08	2.47e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143734220	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs13105571	ENSG00000251600.4	RP11-673E1.1	-5.46	7.64e-08	2.47e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143734241	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs36083417	ENSG00000251600.4	RP11-673E1.1	-5.46	7.64e-08	2.47e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143734253	chr4:143912331~143982454:+
LUAD	cis	rs12554020	1	rs55846141	ENSG00000227603.1	RP11-165J3.6	5.46	7.66e-08	2.47e-05	0.46	0.24	Schizophrenia;	chr9:93427679	chr9:93435332~93437121:-
LUAD	cis	rs1075265	0.836	rs10208233	ENSG00000233266.1	HMGB1P31	5.46	7.66e-08	2.47e-05	0.31	0.24	Chronotype;Morning vs. evening chronotype;	chr2:54066433	chr2:54051334~54051760:+
LUAD	cis	rs7208859	0.623	rs11658022	ENSG00000263603.1	CTD-2349P21.5	-5.46	7.66e-08	2.47e-05	-0.43	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30729469~30731202:+
LUAD	cis	rs9287719	0.601	rs10177062	ENSG00000243819.4	RN7SL832P	5.46	7.67e-08	2.47e-05	0.26	0.24	Prostate cancer;	chr2:10573572	chr2:10690344~10692099:+
LUAD	cis	rs1707322	0.685	rs11211177	ENSG00000280836.1	AL355480.1	-5.46	7.67e-08	2.48e-05	-0.32	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760677	chr1:45581219~45581321:-
LUAD	cis	rs4803480	1	rs3745937	ENSG00000270164.1	LINC01480	-5.46	7.67e-08	2.48e-05	-0.24	-0.24	Schizophrenia;	chr19:41564935	chr19:41535183~41536904:+
LUAD	cis	rs1150668	0.799	rs1150707	ENSG00000219392.1	RP1-265C24.5	-5.46	7.7e-08	2.48e-05	-0.3	-0.24	Pubertal anthropometrics;	chr6:28229827	chr6:28115628~28116551:+
LUAD	cis	rs4835473	0.932	rs2323190	ENSG00000251600.4	RP11-673E1.1	-5.46	7.7e-08	2.48e-05	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143744282	chr4:143912331~143982454:+
LUAD	cis	rs6543140	0.964	rs6736135	ENSG00000234389.1	AC007278.3	5.46	7.7e-08	2.48e-05	0.24	0.24	Blood protein levels;	chr2:102448464	chr2:102438713~102440475:+
LUAD	cis	rs2919009	0.664	rs2289337	ENSG00000271670.1	RP11-95I16.4	5.46	7.7e-08	2.48e-05	0.31	0.24	Obesity-related traits;	chr10:120889970	chr10:120879256~120880667:-
LUAD	cis	rs783540	0.934	rs4779053	ENSG00000278603.1	RP13-608F4.5	5.46	7.7e-08	2.48e-05	0.28	0.24	Schizophrenia;	chr15:82702846	chr15:82472203~82472426:+
LUAD	cis	rs75920871	0.528	rs7935913	ENSG00000254851.1	RP11-109L13.1	-5.46	7.71e-08	2.49e-05	-0.34	-0.24	Subjective well-being;	chr11:117073632	chr11:117135528~117138582:+
LUAD	cis	rs638893	0.617	rs7933007	ENSG00000278376.1	RP11-158I9.8	5.46	7.71e-08	2.49e-05	0.28	0.24	Vitiligo;	chr11:118859960	chr11:118791254~118793137:+
LUAD	cis	rs875971	0.789	rs28815324	ENSG00000226824.5	RP4-756H11.3	5.46	7.71e-08	2.49e-05	0.36	0.24	Aortic root size;	chr7:66100789	chr7:66654538~66669855:+
LUAD	cis	rs7617773	0.78	rs3197223	ENSG00000228638.1	FCF1P2	-5.46	7.71e-08	2.49e-05	-0.29	-0.24	Coronary artery disease;	chr3:48294367	chr3:48290793~48291375:-
LUAD	cis	rs9399135	0.507	rs7766963	ENSG00000232876.1	CTA-212D2.2	5.46	7.71e-08	2.49e-05	0.28	0.24	Red blood cell count;	chr6:135111745	chr6:135055033~135060550:+
LUAD	cis	rs7826238	0.623	rs2976893	ENSG00000253981.4	ALG1L13P	-5.46	7.71e-08	2.49e-05	-0.27	-0.24	Systolic blood pressure;	chr8:8480709	chr8:8236003~8244667:-
LUAD	cis	rs55665837	0.539	rs10766196	ENSG00000251991.1	RNU7-49P	5.46	7.71e-08	2.49e-05	0.27	0.24	Vitamin D levels;	chr11:14891585	chr11:14478892~14478953:+
LUAD	cis	rs12468226	1	rs76284304	ENSG00000226261.1	AC064836.3	5.46	7.72e-08	2.49e-05	0.39	0.24	Urate levels;	chr2:202427116	chr2:202336024~202336727:-
LUAD	cis	rs997295	0.535	rs11632776	ENSG00000270964.1	RP11-502I4.3	-5.46	7.73e-08	2.49e-05	-0.26	-0.24	Motion sickness;	chr15:67560307	chr15:67541072~67542604:-
LUAD	cis	rs7714584	1	rs61530785	ENSG00000197083.10	ZNF300P1	5.46	7.74e-08	2.49e-05	0.47	0.24	Crohn's disease;	chr5:150881802	chr5:150930645~150946289:-
LUAD	cis	rs12554020	0.786	rs6479495	ENSG00000227603.1	RP11-165J3.6	5.46	7.74e-08	2.49e-05	0.38	0.24	Schizophrenia;	chr9:93572320	chr9:93435332~93437121:-
LUAD	cis	rs950169	0.881	rs34591918	ENSG00000259295.5	CSPG4P12	5.46	7.74e-08	2.5e-05	0.35	0.24	Schizophrenia;	chr15:84396135	chr15:85191438~85213905:+
LUAD	cis	rs7829975	0.54	rs2976909	ENSG00000173295.6	FAM86B3P	-5.46	7.76e-08	2.5e-05	-0.25	-0.24	Mood instability;	chr8:8489180	chr8:8228595~8244865:+
LUAD	cis	rs1707322	1	rs4660905	ENSG00000234329.1	RP11-767N6.2	-5.46	7.76e-08	2.5e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995915	chr1:45651039~45651826:-
LUAD	cis	rs2880765	0.835	rs2170736	ENSG00000259295.5	CSPG4P12	5.46	7.76e-08	2.5e-05	0.28	0.24	Coronary artery disease;	chr15:85500167	chr15:85191438~85213905:+
LUAD	cis	rs2880765	0.835	rs2170735	ENSG00000259295.5	CSPG4P12	5.46	7.76e-08	2.5e-05	0.28	0.24	Coronary artery disease;	chr15:85500254	chr15:85191438~85213905:+
LUAD	cis	rs2880765	0.835	rs4340287	ENSG00000259295.5	CSPG4P12	5.46	7.76e-08	2.5e-05	0.28	0.24	Coronary artery disease;	chr15:85500506	chr15:85191438~85213905:+
LUAD	cis	rs7849270	0.801	rs10819475	ENSG00000268707.1	RP11-247A12.7	5.46	7.77e-08	2.5e-05	0.29	0.24	Blood metabolite ratios;	chr9:129168561	chr9:129170434~129170940:+
LUAD	cis	rs7849270	0.76	rs419636	ENSG00000268707.1	RP11-247A12.7	5.46	7.77e-08	2.5e-05	0.29	0.24	Blood metabolite ratios;	chr9:129168998	chr9:129170434~129170940:+
LUAD	cis	rs875971	0.862	rs6944374	ENSG00000237310.1	GS1-124K5.4	-5.46	7.77e-08	2.5e-05	-0.26	-0.24	Aortic root size;	chr7:66221942	chr7:66493706~66495474:+
LUAD	cis	rs673078	0.607	rs17441214	ENSG00000275409.1	RP11-131L12.4	-5.46	7.77e-08	2.5e-05	-0.35	-0.24	Glucose homeostasis traits;	chr12:118436721	chr12:118430147~118430699:+
LUAD	cis	rs875971	1	rs11971949	ENSG00000237310.1	GS1-124K5.4	-5.46	7.77e-08	2.5e-05	-0.26	-0.24	Aortic root size;	chr7:66161027	chr7:66493706~66495474:+
LUAD	cis	rs4718428	0.705	rs2901311	ENSG00000232546.1	RP11-458F8.1	-5.46	7.77e-08	2.51e-05	-0.23	-0.24	Corneal structure;	chr7:66950082	chr7:66848496~66858136:+
LUAD	cis	rs600231	0.708	rs602838	ENSG00000245532.5	NEAT1	5.46	7.78e-08	2.51e-05	0.19	0.24	Bone mineral density;	chr11:65485776	chr11:65422774~65445540:+
LUAD	cis	rs4938303	0.756	rs12802944	ENSG00000254851.1	RP11-109L13.1	5.46	7.78e-08	2.51e-05	0.37	0.24	Triglycerides;	chr11:116705684	chr11:117135528~117138582:+
LUAD	cis	rs9322193	0.923	rs9766037	ENSG00000268592.3	RAET1E-AS1	5.46	7.79e-08	2.51e-05	0.29	0.24	Lung cancer;	chr6:149616921	chr6:149863494~149919507:+
LUAD	cis	rs6504622	1	rs4968286	ENSG00000262879.4	RP11-156P1.3	-5.46	7.79e-08	2.51e-05	-0.28	-0.24	Orofacial clefts;	chr17:46940279	chr17:46984045~47100323:-
LUAD	cis	rs516805	0.706	rs9490430	ENSG00000279453.1	RP3-425C14.4	5.46	7.79e-08	2.51e-05	0.33	0.24	Lymphocyte counts;	chr6:122360951	chr6:122436789~122439223:-
LUAD	cis	rs7617773	0.817	rs3731534	ENSG00000228638.1	FCF1P2	-5.46	7.79e-08	2.51e-05	-0.29	-0.24	Coronary artery disease;	chr3:48170287	chr3:48290793~48291375:-
LUAD	cis	rs4835473	0.9	rs4257605	ENSG00000251600.4	RP11-673E1.1	-5.46	7.8e-08	2.51e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143740081	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs4498094	ENSG00000251600.4	RP11-673E1.1	-5.46	7.8e-08	2.51e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143740097	chr4:143912331~143982454:+
LUAD	cis	rs932287	0.536	rs10840160	ENSG00000254860.4	TMEM9B-AS1	5.46	7.8e-08	2.51e-05	0.28	0.24	Colonoscopy-negative controls vs population controls;	chr11:9031989	chr11:8964675~8977527:+
LUAD	cis	rs4835473	0.932	rs10025527	ENSG00000251600.4	RP11-673E1.1	5.46	7.8e-08	2.51e-05	0.3	0.24	Immature fraction of reticulocytes;	chr4:143968391	chr4:143912331~143982454:+
LUAD	cis	rs4947019	0.609	rs9487074	ENSG00000260273.1	RP11-425D10.10	5.46	7.8e-08	2.51e-05	0.54	0.24	Hematological parameters;	chr6:109368478	chr6:109382795~109383666:+
LUAD	cis	rs9516	0.564	rs10898993	ENSG00000254974.1	RP11-702H23.2	5.46	7.8e-08	2.51e-05	0.28	0.24	Facial morphology (factor 15, philtrum width);	chr11:74463919	chr11:74485580~74486051:-
LUAD	cis	rs9309473	0.797	rs6723247	ENSG00000163016.8	ALMS1P	5.46	7.8e-08	2.51e-05	0.29	0.24	Metabolite levels;	chr2:73619622	chr2:73644919~73685576:+
LUAD	cis	rs17818399	0.675	rs35949012	ENSG00000279254.1	RP11-536C12.1	-5.46	7.82e-08	2.52e-05	-0.28	-0.24	Height;	chr2:46633262	chr2:46668870~46670778:+
LUAD	cis	rs17818399	0.815	rs17768018	ENSG00000279254.1	RP11-536C12.1	-5.46	7.82e-08	2.52e-05	-0.28	-0.24	Height;	chr2:46634872	chr2:46668870~46670778:+
LUAD	cis	rs12935418	1	rs2602431	ENSG00000261838.4	RP11-303E16.6	-5.46	7.82e-08	2.52e-05	-0.39	-0.24	Mean corpuscular volume;	chr16:81037092	chr16:81069854~81076598:+
LUAD	cis	rs36093844	0.752	rs17744699	ENSG00000279742.1	RP11-700A24.1	-5.46	7.82e-08	2.52e-05	-0.33	-0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85886120	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.752	rs17817343	ENSG00000279742.1	RP11-700A24.1	-5.46	7.82e-08	2.52e-05	-0.33	-0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85887269	chr11:85852557~85854943:-
LUAD	cis	rs8031584	0.56	rs7171208	ENSG00000260382.1	RP11-540B6.2	-5.46	7.82e-08	2.52e-05	-0.27	-0.24	Huntington's disease progression;	chr15:30906726	chr15:30882267~30883231:-
LUAD	cis	rs7968440	1	rs2731440	ENSG00000200428.1	Y_RNA	-5.46	7.83e-08	2.52e-05	-0.3	-0.24	Fibrinogen;	chr12:50663844	chr12:50743568~50743684:+
LUAD	cis	rs7968440	1	rs2731439	ENSG00000200428.1	Y_RNA	-5.46	7.83e-08	2.52e-05	-0.3	-0.24	Fibrinogen;	chr12:50666567	chr12:50743568~50743684:+
LUAD	cis	rs1823913	0.525	rs7424440	ENSG00000280083.1	RP11-317J9.1	-5.46	7.84e-08	2.53e-05	-0.29	-0.24	Obesity-related traits;	chr2:191337919	chr2:191154118~191156070:-
LUAD	cis	rs5758511	0.689	rs56906457	ENSG00000205702.9	CYP2D7	5.46	7.85e-08	2.53e-05	0.26	0.24	Birth weight;	chr22:42232329	chr22:42140203~42144577:-
LUAD	cis	rs1876905	0.68	rs354528	ENSG00000272356.1	RP5-1112D6.8	-5.45	7.87e-08	2.53e-05	-0.26	-0.24	Mean corpuscular hemoglobin;	chr6:111184068	chr6:111309203~111313517:+
LUAD	cis	rs1876905	0.62	rs354525	ENSG00000272356.1	RP5-1112D6.8	-5.45	7.87e-08	2.53e-05	-0.26	-0.24	Mean corpuscular hemoglobin;	chr6:111186193	chr6:111309203~111313517:+
LUAD	cis	rs858239	0.601	rs4440529	ENSG00000230042.1	AK3P3	-5.45	7.87e-08	2.53e-05	-0.31	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23129132	chr7:23129178~23129841:+
LUAD	cis	rs67311347	1	rs6762251	ENSG00000223797.4	ENTPD3-AS1	-5.45	7.87e-08	2.53e-05	-0.26	-0.24	Renal cell carcinoma;	chr3:40489645	chr3:40313802~40453329:-
LUAD	cis	rs889312	0.532	rs16886165	ENSG00000271828.1	CTD-2310F14.1	5.45	7.88e-08	2.54e-05	0.36	0.24	Breast cancer (early onset);Breast cancer;	chr5:56727256	chr5:56927874~56929573:+
LUAD	cis	rs11105298	0.891	rs10858902	ENSG00000258302.2	RP11-981P6.1	5.45	7.88e-08	2.54e-05	0.31	0.24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89534012	chr12:89561129~89594878:+
LUAD	cis	rs11105298	0.891	rs10858903	ENSG00000258302.2	RP11-981P6.1	5.45	7.88e-08	2.54e-05	0.31	0.24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89534195	chr12:89561129~89594878:+
LUAD	cis	rs17264034	0.821	rs60322708	ENSG00000250786.1	SNHG18	5.45	7.89e-08	2.54e-05	0.34	0.24	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9555837	chr5:9546200~9550609:+
LUAD	cis	rs4964805	1	rs34307072	ENSG00000257681.1	RP11-341G23.4	5.45	7.9e-08	2.54e-05	0.3	0.24	Attention deficit hyperactivity disorder;	chr12:103802526	chr12:103746315~103768858:-
LUAD	cis	rs1426063	1	rs10030850	ENSG00000249717.1	RP11-44F21.3	5.45	7.9e-08	2.54e-05	0.37	0.24	QT interval;	chr4:75099199	chr4:74955974~74970362:-
LUAD	cis	rs1426063	1	rs9993589	ENSG00000249717.1	RP11-44F21.3	5.45	7.9e-08	2.54e-05	0.37	0.24	QT interval;	chr4:75099556	chr4:74955974~74970362:-
LUAD	cis	rs2280018	1	rs2280018	ENSG00000188599.16	NPIPP1	-5.45	7.92e-08	2.55e-05	-0.2	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056976	chr16:15104312~15123498:-
LUAD	cis	rs853679	0.769	rs17720293	ENSG00000204709.4	LINC01556	5.45	7.92e-08	2.55e-05	0.46	0.24	Depression;	chr6:28246920	chr6:28943877~28944537:+
LUAD	cis	rs17684571	0.7	rs35609883	ENSG00000231441.1	RP11-472M19.2	5.45	7.92e-08	2.55e-05	0.34	0.24	Schizophrenia;	chr6:56807034	chr6:56844002~56864078:+
LUAD	cis	rs4964805	0.913	rs3812803	ENSG00000257681.1	RP11-341G23.4	5.45	7.93e-08	2.55e-05	0.3	0.24	Attention deficit hyperactivity disorder;	chr12:103806682	chr12:103746315~103768858:-
LUAD	cis	rs2832077	0.943	rs11701777	ENSG00000232855.5	AF131217.1	5.45	7.93e-08	2.55e-05	0.27	0.24	Cognitive test performance;	chr21:28783506	chr21:28439346~28674848:-
LUAD	cis	rs1075265	0.756	rs2160931	ENSG00000233266.1	HMGB1P31	5.45	7.94e-08	2.55e-05	0.31	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53712411	chr2:54051334~54051760:+
LUAD	cis	rs6687821	0.515	rs2798677	ENSG00000267734.1	RP4-604K5.3	-5.45	7.94e-08	2.55e-05	-0.29	-0.24	Yeast infection;	chr1:87086740	chr1:86932199~86934891:-
LUAD	cis	rs9516	0.544	rs681179	ENSG00000254974.1	RP11-702H23.2	5.45	7.94e-08	2.56e-05	0.28	0.24	Facial morphology (factor 15, philtrum width);	chr11:74475791	chr11:74485580~74486051:-
LUAD	cis	rs1823874	0.71	rs8042933	ENSG00000182397.13	DNM1P46	5.45	7.95e-08	2.56e-05	0.3	0.24	IgG glycosylation;	chr15:99824641	chr15:99790156~99806927:-
LUAD	cis	rs2933343	1	rs2933343	ENSG00000261159.1	RP11-723O4.9	5.45	7.95e-08	2.56e-05	0.3	0.24	IgG glycosylation;	chr3:128939649	chr3:128859716~128860526:-
LUAD	cis	rs6687821	0.515	rs2798676	ENSG00000267734.1	RP4-604K5.3	5.45	7.96e-08	2.56e-05	0.29	0.24	Yeast infection;	chr1:87086066	chr1:86932199~86934891:-
LUAD	cis	rs10129255	0.536	rs8004835	ENSG00000211967.3	IGHV3-53	-5.45	7.96e-08	2.56e-05	-0.17	-0.24	Kawasaki disease;	chr14:106686361	chr14:106592676~106593347:-
LUAD	cis	rs997295	0.675	rs17242605	ENSG00000270964.1	RP11-502I4.3	-5.45	7.96e-08	2.56e-05	-0.25	-0.24	Motion sickness;	chr15:67671098	chr15:67541072~67542604:-
LUAD	cis	rs116095464	1	rs10475185	ENSG00000277812.1	AC021087.1	5.45	7.96e-08	2.56e-05	0.69	0.24	Breast cancer;	chr5:306866	chr5:262769~262881:+
LUAD	cis	rs1876905	0.68	rs354540	ENSG00000272356.1	RP5-1112D6.8	-5.45	7.97e-08	2.56e-05	-0.26	-0.24	Mean corpuscular hemoglobin;	chr6:111195827	chr6:111309203~111313517:+
LUAD	cis	rs732716	0.889	rs11666856	ENSG00000267980.1	AC007292.6	-5.45	7.97e-08	2.56e-05	-0.28	-0.24	Mean corpuscular volume;	chr19:4437453	chr19:4363789~4364640:+
LUAD	cis	rs516805	0.63	rs696650	ENSG00000279453.1	RP3-425C14.4	-5.45	7.97e-08	2.56e-05	-0.32	-0.24	Lymphocyte counts;	chr6:122261316	chr6:122436789~122439223:-
LUAD	cis	rs867371	1	rs7166570	ENSG00000259429.4	UBE2Q2P2	-5.45	7.97e-08	2.56e-05	-0.21	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173880	chr15:82355142~82420075:+
LUAD	cis	rs1707322	0.964	rs7512395	ENSG00000234329.1	RP11-767N6.2	5.45	7.98e-08	2.57e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45895505	chr1:45651039~45651826:-
LUAD	cis	rs10761482	0.5	rs1892546	ENSG00000254271.1	RP11-131N11.4	5.45	7.98e-08	2.57e-05	0.27	0.24	Schizophrenia;	chr10:60534258	chr10:60734342~60741828:+
LUAD	cis	rs2562456	0.876	rs11085468	ENSG00000268081.1	RP11-678G14.2	5.45	7.99e-08	2.57e-05	0.36	0.24	Pain;	chr19:21569087	chr19:21554640~21569237:-
LUAD	cis	rs2919009	0.544	rs7920943	ENSG00000271670.1	RP11-95I16.4	5.45	7.99e-08	2.57e-05	0.3	0.24	Obesity-related traits;	chr10:120923456	chr10:120879256~120880667:-
LUAD	cis	rs858239	0.6	rs2072368	ENSG00000230042.1	AK3P3	-5.45	8e-08	2.57e-05	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23129178~23129841:+
LUAD	cis	rs9595908	0.609	rs733487	ENSG00000212293.1	SNORA16	5.45	8.01e-08	2.58e-05	0.26	0.24	Body mass index;	chr13:32741068	chr13:32420390~32420516:-
LUAD	cis	rs1707322	1	rs785490	ENSG00000280836.1	AL355480.1	5.45	8.03e-08	2.58e-05	0.32	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46111452	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs785493	ENSG00000280836.1	AL355480.1	5.45	8.03e-08	2.58e-05	0.32	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46119187	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.964	rs785496	ENSG00000280836.1	AL355480.1	5.45	8.03e-08	2.58e-05	0.32	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46122334	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs785497	ENSG00000280836.1	AL355480.1	5.45	8.03e-08	2.58e-05	0.32	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126231	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.964	rs785499	ENSG00000280836.1	AL355480.1	5.45	8.03e-08	2.58e-05	0.32	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126748	chr1:45581219~45581321:-
LUAD	cis	rs4908768	0.52	rs6681362	ENSG00000232912.4	RP5-1115A15.1	5.45	8.03e-08	2.58e-05	0.22	0.24	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8598468	chr1:8424645~8434838:+
LUAD	cis	rs4908768	0.539	rs1318218	ENSG00000232912.4	RP5-1115A15.1	5.45	8.03e-08	2.58e-05	0.22	0.24	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8598653	chr1:8424645~8434838:+
LUAD	cis	rs9928842	0.765	rs2870467	ENSG00000280152.1	RP11-331F4.5	5.45	8.03e-08	2.58e-05	0.28	0.24	Alcoholic chronic pancreatitis;	chr16:75189983	chr16:75245994~75250077:-
LUAD	cis	rs7618501	0.602	rs34831713	ENSG00000234667.1	ACTBP13	5.45	8.04e-08	2.58e-05	0.27	0.24	Intelligence (multi-trait analysis);	chr3:50081315	chr3:49873347~49877980:-
LUAD	cis	rs453301	0.658	rs6983877	ENSG00000253981.4	ALG1L13P	-5.45	8.04e-08	2.58e-05	-0.28	-0.24	Joint mobility (Beighton score);	chr8:9047129	chr8:8236003~8244667:-
LUAD	cis	rs6687821	0.666	rs566334	ENSG00000267734.1	RP4-604K5.3	5.45	8.05e-08	2.59e-05	0.29	0.24	Yeast infection;	chr1:86785396	chr1:86932199~86934891:-
LUAD	cis	rs4604732	0.536	rs12058821	ENSG00000227135.1	GCSAML-AS1	-5.45	8.05e-08	2.59e-05	-0.38	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247486349	chr1:247524679~247526752:-
LUAD	cis	rs516805	0.667	rs2045352	ENSG00000279453.1	RP3-425C14.4	-5.45	8.05e-08	2.59e-05	-0.33	-0.24	Lymphocyte counts;	chr6:122119694	chr6:122436789~122439223:-
LUAD	cis	rs10129255	0.957	rs10140904	ENSG00000211974.3	IGHV2-70	5.45	8.05e-08	2.59e-05	0.26	0.24	Kawasaki disease;	chr14:106776558	chr14:106723574~106724093:-
LUAD	cis	rs4835473	0.932	rs5016158	ENSG00000251600.4	RP11-673E1.1	-5.45	8.06e-08	2.59e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143738472	chr4:143912331~143982454:+
LUAD	cis	rs6964587	0.773	rs12740	ENSG00000188693.7	CYP51A1-AS1	-5.45	8.06e-08	2.59e-05	-0.28	-0.24	Breast cancer;	chr7:92399988	chr7:92134604~92180725:+
LUAD	cis	rs7617773	0.817	rs13059037	ENSG00000228638.1	FCF1P2	-5.45	8.07e-08	2.59e-05	-0.29	-0.24	Coronary artery disease;	chr3:48246389	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.817	rs35414021	ENSG00000228638.1	FCF1P2	-5.45	8.07e-08	2.59e-05	-0.29	-0.24	Coronary artery disease;	chr3:48252034	chr3:48290793~48291375:-
LUAD	cis	rs9543976	0.623	rs6562915	ENSG00000261553.4	RP11-29G8.3	5.45	8.07e-08	2.59e-05	0.32	0.24	Diabetic retinopathy;	chr13:75596750	chr13:75549773~75807120:+
LUAD	cis	rs10129255	0.5	rs8022547	ENSG00000211967.3	IGHV3-53	-5.45	8.07e-08	2.59e-05	-0.17	-0.24	Kawasaki disease;	chr14:106781985	chr14:106592676~106593347:-
LUAD	cis	rs1832886	1	rs1832886	ENSG00000236493.2	EIF2S2P3	5.45	8.07e-08	2.59e-05	0.28	0.24	Body mass index;	chr10:92717782	chr10:92668745~92669743:-
LUAD	cis	rs1075265	0.836	rs1421622	ENSG00000233266.1	HMGB1P31	-5.45	8.07e-08	2.59e-05	-0.3	-0.24	Chronotype;Morning vs. evening chronotype;	chr2:54062644	chr2:54051334~54051760:+
LUAD	cis	rs453301	0.538	rs7830804	ENSG00000253893.2	FAM85B	5.45	8.08e-08	2.6e-05	0.31	0.24	Joint mobility (Beighton score);	chr8:9113252	chr8:8167819~8226614:-
LUAD	cis	rs964184	0.564	rs2266788	ENSG00000254851.1	RP11-109L13.1	-5.45	8.08e-08	2.6e-05	-0.51	-0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116789970	chr11:117135528~117138582:+
LUAD	cis	rs2303759	0.874	rs8108669	ENSG00000268686.1	AC010524.2	-5.45	8.09e-08	2.6e-05	-0.34	-0.24	Multiple sclerosis;	chr19:49342638	chr19:49368705~49388081:-
LUAD	cis	rs17684571	0.7	rs17684784	ENSG00000231441.1	RP11-472M19.2	-5.45	8.09e-08	2.6e-05	-0.35	-0.24	Schizophrenia;	chr6:56813644	chr6:56844002~56864078:+
LUAD	cis	rs801193	0.569	rs2659907	ENSG00000237310.1	GS1-124K5.4	5.45	8.09e-08	2.6e-05	0.26	0.24	Aortic root size;	chr7:66699045	chr7:66493706~66495474:+
LUAD	cis	rs1012068	0.624	rs4820997	ENSG00000236132.1	CTA-440B3.1	-5.45	8.1e-08	2.6e-05	-0.3	-0.24	Chronic hepatitis C infection;	chr22:31928154	chr22:31816379~31817491:-
LUAD	cis	rs7181230	0.885	rs9919974	ENSG00000275636.1	RP11-521C20.5	5.45	8.1e-08	2.6e-05	0.32	0.24	Dehydroepiandrosterone sulphate levels;	chr15:40045261	chr15:40078892~40079347:+
LUAD	cis	rs875971	0.862	rs6955837	ENSG00000232559.3	GS1-124K5.12	-5.45	8.12e-08	2.61e-05	-0.29	-0.24	Aortic root size;	chr7:66578155	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.825	rs10281499	ENSG00000232559.3	GS1-124K5.12	-5.45	8.12e-08	2.61e-05	-0.29	-0.24	Aortic root size;	chr7:66583979	chr7:66554588~66576923:-
LUAD	cis	rs7017914	0.69	rs4074908	ENSG00000223220.1	Y_RNA	-5.45	8.12e-08	2.61e-05	-0.28	-0.24	Bone mineral density;	chr8:71043097	chr8:70780914~70781008:-
LUAD	cis	rs9309473	0.66	rs17349321	ENSG00000163016.8	ALMS1P	5.45	8.12e-08	2.61e-05	0.35	0.24	Metabolite levels;	chr2:73416625	chr2:73644919~73685576:+
LUAD	cis	rs11742741	0.539	rs13189556	ENSG00000248874.4	C5orf17	-5.45	8.12e-08	2.61e-05	-0.3	-0.24	Educational attainment;	chr5:24103701	chr5:23951348~24178263:+
LUAD	cis	rs9928842	0.712	rs8057843	ENSG00000280152.1	RP11-331F4.5	5.45	8.12e-08	2.61e-05	0.28	0.24	Alcoholic chronic pancreatitis;	chr16:75187657	chr16:75245994~75250077:-
LUAD	cis	rs1823913	0.892	rs35596292	ENSG00000230611.1	HMGB1P27	-5.45	8.12e-08	2.61e-05	-0.3	-0.24	Obesity-related traits;	chr2:191246890	chr2:191174233~191174835:+
LUAD	cis	rs1823913	0.927	rs35530564	ENSG00000230611.1	HMGB1P27	-5.45	8.12e-08	2.61e-05	-0.3	-0.24	Obesity-related traits;	chr2:191247324	chr2:191174233~191174835:+
LUAD	cis	rs673078	0.607	rs111607725	ENSG00000275409.1	RP11-131L12.4	-5.45	8.12e-08	2.61e-05	-0.33	-0.24	Glucose homeostasis traits;	chr12:118442957	chr12:118430147~118430699:+
LUAD	cis	rs8100891	0.734	rs4804990	ENSG00000267213.4	AC007773.2	-5.45	8.12e-08	2.61e-05	-0.29	-0.24	Neuroticism;	chr19:32346523	chr19:32390050~32405560:-
LUAD	cis	rs35740288	0.822	rs17636864	ENSG00000202081.1	RNU6-1280P	5.45	8.12e-08	2.61e-05	0.3	0.24	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85691358	chr15:85651522~85651628:-
LUAD	cis	rs2404602	0.735	rs56246286	ENSG00000259422.1	RP11-593F23.1	-5.45	8.13e-08	2.61e-05	-0.31	-0.24	Blood metabolite levels;	chr15:76398390	chr15:76174891~76181486:-
LUAD	cis	rs12554020	0.681	rs74816254	ENSG00000227603.1	RP11-165J3.6	5.45	8.13e-08	2.61e-05	0.46	0.24	Schizophrenia;	chr9:93486661	chr9:93435332~93437121:-
LUAD	cis	rs12554020	0.786	rs79068125	ENSG00000227603.1	RP11-165J3.6	5.45	8.13e-08	2.61e-05	0.46	0.24	Schizophrenia;	chr9:93486957	chr9:93435332~93437121:-
LUAD	cis	rs12554020	0.786	rs79330192	ENSG00000227603.1	RP11-165J3.6	5.45	8.13e-08	2.61e-05	0.46	0.24	Schizophrenia;	chr9:93487542	chr9:93435332~93437121:-
LUAD	cis	rs9652601	0.691	rs12708717	ENSG00000274038.1	RP11-66H6.4	-5.45	8.14e-08	2.61e-05	-0.29	-0.24	Systemic lupus erythematosus;	chr16:11098522	chr16:11056556~11057034:+
LUAD	cis	rs9652601	0.608	rs8061826	ENSG00000274038.1	RP11-66H6.4	-5.45	8.14e-08	2.61e-05	-0.29	-0.24	Systemic lupus erythematosus;	chr16:11098930	chr16:11056556~11057034:+
LUAD	cis	rs950169	0.84	rs62029595	ENSG00000259295.5	CSPG4P12	5.45	8.14e-08	2.61e-05	0.35	0.24	Schizophrenia;	chr15:84400603	chr15:85191438~85213905:+
LUAD	cis	rs9287719	0.649	rs6722126	ENSG00000243819.4	RN7SL832P	5.45	8.17e-08	2.62e-05	0.26	0.24	Prostate cancer;	chr2:10581516	chr2:10690344~10692099:+
LUAD	cis	rs7826238	0.623	rs2976893	ENSG00000253893.2	FAM85B	5.45	8.17e-08	2.62e-05	0.29	0.24	Systolic blood pressure;	chr8:8480709	chr8:8167819~8226614:-
LUAD	cis	rs270601	0.721	rs270621	ENSG00000233006.5	AC034220.3	5.45	8.17e-08	2.62e-05	0.23	0.24	Acylcarnitine levels;	chr5:132270128	chr5:132311285~132369916:-
LUAD	cis	rs7017914	0.69	rs10504492	ENSG00000223220.1	Y_RNA	5.45	8.18e-08	2.63e-05	0.28	0.24	Bone mineral density;	chr8:71065724	chr8:70780914~70781008:-
LUAD	cis	rs2439831	0.85	rs12441861	ENSG00000249839.1	AC011330.5	-5.45	8.19e-08	2.63e-05	-0.46	-0.24	Lung cancer in ever smokers;	chr15:43768685	chr15:43663654~43684339:-
LUAD	cis	rs2599510	0.755	rs67257914	ENSG00000276334.1	AL133243.1	5.45	8.19e-08	2.63e-05	0.29	0.24	Interleukin-18 levels;	chr2:32578951	chr2:32521927~32523547:+
LUAD	cis	rs10246939	0.543	rs11765106	ENSG00000228775.6	WEE2-AS1	5.45	8.2e-08	2.63e-05	0.32	0.24	Bitter taste perception;	chr7:141902676	chr7:141704338~141738346:-
LUAD	cis	rs10246939	0.543	rs7786202	ENSG00000228775.6	WEE2-AS1	5.45	8.2e-08	2.63e-05	0.32	0.24	Bitter taste perception;	chr7:141906099	chr7:141704338~141738346:-
LUAD	cis	rs10246939	0.543	rs7802271	ENSG00000228775.6	WEE2-AS1	5.45	8.2e-08	2.63e-05	0.32	0.24	Bitter taste perception;	chr7:141909624	chr7:141704338~141738346:-
LUAD	cis	rs10246939	0.52	rs7782886	ENSG00000228775.6	WEE2-AS1	5.45	8.2e-08	2.63e-05	0.32	0.24	Bitter taste perception;	chr7:141909958	chr7:141704338~141738346:-
LUAD	cis	rs10246939	0.543	rs994808	ENSG00000228775.6	WEE2-AS1	5.45	8.2e-08	2.63e-05	0.32	0.24	Bitter taste perception;	chr7:141911091	chr7:141704338~141738346:-
LUAD	cis	rs10246939	0.543	rs7808421	ENSG00000228775.6	WEE2-AS1	5.45	8.2e-08	2.63e-05	0.32	0.24	Bitter taste perception;	chr7:141911592	chr7:141704338~141738346:-
LUAD	cis	rs10246939	0.543	rs7789123	ENSG00000228775.6	WEE2-AS1	5.45	8.2e-08	2.63e-05	0.32	0.24	Bitter taste perception;	chr7:141911699	chr7:141704338~141738346:-
LUAD	cis	rs10246939	0.543	rs11767947	ENSG00000228775.6	WEE2-AS1	5.45	8.2e-08	2.63e-05	0.32	0.24	Bitter taste perception;	chr7:141912821	chr7:141704338~141738346:-
LUAD	cis	rs10246939	0.543	rs11769089	ENSG00000228775.6	WEE2-AS1	5.45	8.2e-08	2.63e-05	0.32	0.24	Bitter taste perception;	chr7:141914310	chr7:141704338~141738346:-
LUAD	cis	rs10246939	0.543	rs11765974	ENSG00000228775.6	WEE2-AS1	5.45	8.2e-08	2.63e-05	0.32	0.24	Bitter taste perception;	chr7:141914390	chr7:141704338~141738346:-
LUAD	cis	rs507080	0.733	rs7108144	ENSG00000278376.1	RP11-158I9.8	-5.45	8.21e-08	2.63e-05	-0.26	-0.24	Serum metabolite levels;	chr11:118698985	chr11:118791254~118793137:+
LUAD	cis	rs10895987	0.531	rs2282498	ENSG00000254614.2	AP003068.23	5.45	8.21e-08	2.63e-05	0.32	0.24	Blood protein levels;	chr11:65088514	chr11:65177606~65181834:-
LUAD	cis	rs2255336	0.938	rs2733840	ENSG00000245648.1	RP11-277P12.20	5.45	8.21e-08	2.63e-05	0.38	0.24	Blood protein levels;	chr12:10393326	chr12:10363769~10398506:+
LUAD	cis	rs7968440	1	rs2731434	ENSG00000200428.1	Y_RNA	-5.45	8.21e-08	2.64e-05	-0.3	-0.24	Fibrinogen;	chr12:50716092	chr12:50743568~50743684:+
LUAD	cis	rs7246657	0.722	rs1291	ENSG00000276846.1	CTD-3220F14.3	-5.45	8.22e-08	2.64e-05	-0.32	-0.24	Coronary artery calcification;	chr19:37738477	chr19:37314868~37315620:-
LUAD	cis	rs6496044	0.963	rs7165300	ENSG00000202081.1	RNU6-1280P	5.45	8.23e-08	2.64e-05	0.28	0.24	Interstitial lung disease;	chr15:85526838	chr15:85651522~85651628:-
LUAD	cis	rs10129255	0.5	rs8006888	ENSG00000211967.3	IGHV3-53	-5.45	8.23e-08	2.64e-05	-0.17	-0.24	Kawasaki disease;	chr14:106782219	chr14:106592676~106593347:-
LUAD	cis	rs10129255	0.536	rs10142951	ENSG00000211967.3	IGHV3-53	-5.45	8.23e-08	2.64e-05	-0.17	-0.24	Kawasaki disease;	chr14:106782337	chr14:106592676~106593347:-
LUAD	cis	rs55665837	0.701	rs12787709	ENSG00000251991.1	RNU7-49P	5.45	8.24e-08	2.65e-05	0.29	0.24	Vitamin D levels;	chr11:14617711	chr11:14478892~14478953:+
LUAD	cis	rs66887589	0.967	rs59516282	ENSG00000245958.5	RP11-33B1.1	5.45	8.25e-08	2.65e-05	0.19	0.24	Diastolic blood pressure;	chr4:119580861	chr4:119454791~119552025:+
LUAD	cis	rs1322639	0.618	rs9505942	ENSG00000261039.2	RP11-417E7.2	-5.45	8.25e-08	2.65e-05	-0.38	-0.24	Pulse pressure;	chr6:169191698	chr6:169175304~169182740:-
LUAD	cis	rs916888	0.773	rs538628	ENSG00000261575.2	RP11-259G18.1	5.45	8.25e-08	2.65e-05	0.38	0.24	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46267037~46268694:+
LUAD	cis	rs9914544	0.628	rs9908821	ENSG00000273018.4	CTD-2303H24.2	-5.45	8.26e-08	2.65e-05	-0.29	-0.24	Educational attainment (years of education);	chr17:18776091	chr17:18511221~18551705:-
LUAD	cis	rs950027	0.538	rs635205	ENSG00000259520.4	CTD-2651B20.3	-5.45	8.26e-08	2.65e-05	-0.28	-0.24	Response to fenofibrate (adiponectin levels);	chr15:45656186	chr15:45251580~45279251:-
LUAD	cis	rs673078	0.607	rs17512483	ENSG00000275409.1	RP11-131L12.4	5.45	8.27e-08	2.65e-05	0.38	0.24	Glucose homeostasis traits;	chr12:118312380	chr12:118430147~118430699:+
LUAD	cis	rs9595908	0.758	rs9591219	ENSG00000212293.1	SNORA16	5.45	8.28e-08	2.65e-05	0.26	0.24	Body mass index;	chr13:32653020	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.758	rs9591220	ENSG00000212293.1	SNORA16	5.45	8.28e-08	2.65e-05	0.26	0.24	Body mass index;	chr13:32653059	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.785	rs12428283	ENSG00000212293.1	SNORA16	5.45	8.28e-08	2.65e-05	0.26	0.24	Body mass index;	chr13:32653775	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.785	rs9596035	ENSG00000212293.1	SNORA16	5.45	8.28e-08	2.65e-05	0.26	0.24	Body mass index;	chr13:32654803	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.785	rs9591226	ENSG00000212293.1	SNORA16	5.45	8.28e-08	2.65e-05	0.26	0.24	Body mass index;	chr13:32655322	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.785	rs7335546	ENSG00000212293.1	SNORA16	5.45	8.28e-08	2.65e-05	0.26	0.24	Body mass index;	chr13:32658197	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.785	rs9591228	ENSG00000212293.1	SNORA16	5.45	8.28e-08	2.65e-05	0.26	0.24	Body mass index;	chr13:32658632	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.785	rs9591230	ENSG00000212293.1	SNORA16	5.45	8.28e-08	2.65e-05	0.26	0.24	Body mass index;	chr13:32663944	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.785	rs2874282	ENSG00000212293.1	SNORA16	5.45	8.28e-08	2.65e-05	0.26	0.24	Body mass index;	chr13:32665876	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.785	rs9596051	ENSG00000212293.1	SNORA16	5.45	8.28e-08	2.65e-05	0.26	0.24	Body mass index;	chr13:32666528	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.785	rs9596057	ENSG00000212293.1	SNORA16	5.45	8.28e-08	2.65e-05	0.26	0.24	Body mass index;	chr13:32669831	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.785	rs9596059	ENSG00000212293.1	SNORA16	5.45	8.28e-08	2.65e-05	0.26	0.24	Body mass index;	chr13:32670145	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.785	rs9596060	ENSG00000212293.1	SNORA16	5.45	8.28e-08	2.65e-05	0.26	0.24	Body mass index;	chr13:32670467	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.785	rs7317147	ENSG00000212293.1	SNORA16	5.45	8.28e-08	2.65e-05	0.26	0.24	Body mass index;	chr13:32670838	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.785	rs6561499	ENSG00000212293.1	SNORA16	5.45	8.28e-08	2.65e-05	0.26	0.24	Body mass index;	chr13:32681075	chr13:32420390~32420516:-
LUAD	cis	rs2337406	1	rs17095456	ENSG00000211972.2	IGHV3-66	5.44	8.28e-08	2.66e-05	0.27	0.24	Alzheimer's disease (late onset);	chr14:106676559	chr14:106675017~106675544:-
LUAD	cis	rs11157436	1	rs12587166	ENSG00000211813.2	TRAV34	5.44	8.28e-08	2.66e-05	0.31	0.24	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22165492	chr14:22207522~22208129:+
LUAD	cis	rs9595908	0.785	rs4942829	ENSG00000212293.1	SNORA16	5.44	8.29e-08	2.66e-05	0.26	0.24	Body mass index;	chr13:32708994	chr13:32420390~32420516:-
LUAD	cis	rs2179367	0.632	rs2341774	ENSG00000231760.4	RP11-350J20.5	5.44	8.29e-08	2.66e-05	0.34	0.24	Dupuytren's disease;	chr6:149425014	chr6:149796151~149826294:-
LUAD	cis	rs7829975	0.742	rs12547493	ENSG00000173295.6	FAM86B3P	-5.44	8.29e-08	2.66e-05	-0.26	-0.24	Mood instability;	chr8:8804024	chr8:8228595~8244865:+
LUAD	cis	rs34787248	1	rs34787248	ENSG00000219392.1	RP1-265C24.5	-5.44	8.29e-08	2.66e-05	-0.35	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28230108	chr6:28115628~28116551:+
LUAD	cis	rs2599510	0.811	rs2710628	ENSG00000276334.1	AL133243.1	5.44	8.3e-08	2.66e-05	0.28	0.24	Interleukin-18 levels;	chr2:32533286	chr2:32521927~32523547:+
LUAD	cis	rs858239	0.601	rs11982002	ENSG00000230042.1	AK3P3	-5.44	8.31e-08	2.66e-05	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23129178~23129841:+
LUAD	cis	rs801193	0.839	rs12534943	ENSG00000224316.1	RP11-479O9.2	-5.44	8.31e-08	2.66e-05	-0.24	-0.24	Aortic root size;	chr7:66605533	chr7:65773620~65802067:+
LUAD	cis	rs10129255	0.5	rs988134	ENSG00000254174.1	IGHV1-12	5.44	8.31e-08	2.66e-05	0.16	0.24	Kawasaki disease;	chr14:106776698	chr14:106122420~106122709:-
LUAD	cis	rs10129255	0.5	rs988133	ENSG00000254174.1	IGHV1-12	5.44	8.31e-08	2.66e-05	0.16	0.24	Kawasaki disease;	chr14:106776724	chr14:106122420~106122709:-
LUAD	cis	rs1075265	0.901	rs7591194	ENSG00000233266.1	HMGB1P31	-5.44	8.31e-08	2.67e-05	-0.3	-0.24	Chronotype;Morning vs. evening chronotype;	chr2:54086699	chr2:54051334~54051760:+
LUAD	cis	rs9813712	0.526	rs13065659	ENSG00000249846.5	RP11-77P16.4	-5.44	8.32e-08	2.67e-05	-0.28	-0.24	Response to amphetamines;	chr3:130231945	chr3:130112550~130120579:+
LUAD	cis	rs7617773	0.817	rs3731497	ENSG00000228638.1	FCF1P2	-5.44	8.33e-08	2.67e-05	-0.29	-0.24	Coronary artery disease;	chr3:48185063	chr3:48290793~48291375:-
LUAD	cis	rs6564219	1	rs6564219	ENSG00000280152.1	RP11-331F4.5	5.44	8.33e-08	2.67e-05	0.28	0.24	Alcoholic chronic pancreatitis;	chr16:75188108	chr16:75245994~75250077:-
LUAD	cis	rs875971	1	rs3735148	ENSG00000237310.1	GS1-124K5.4	5.44	8.33e-08	2.67e-05	0.26	0.24	Aortic root size;	chr7:66506022	chr7:66493706~66495474:+
LUAD	cis	rs673078	0.66	rs2280711	ENSG00000275409.1	RP11-131L12.4	-5.44	8.34e-08	2.67e-05	-0.32	-0.24	Glucose homeostasis traits;	chr12:118212149	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.615	rs73222058	ENSG00000275409.1	RP11-131L12.4	-5.44	8.34e-08	2.67e-05	-0.32	-0.24	Glucose homeostasis traits;	chr12:118221066	chr12:118430147~118430699:+
LUAD	cis	rs748404	0.666	rs12908460	ENSG00000205771.5	CATSPER2P1	-5.44	8.34e-08	2.67e-05	-0.36	-0.24	Lung cancer;	chr15:43413472	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.666	rs2230451	ENSG00000205771.5	CATSPER2P1	-5.44	8.34e-08	2.67e-05	-0.36	-0.24	Lung cancer;	chr15:43415610	chr15:43726918~43747094:-
LUAD	cis	rs1707322	1	rs6677777	ENSG00000234329.1	RP11-767N6.2	5.44	8.34e-08	2.67e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46010164	chr1:45651039~45651826:-
LUAD	cis	rs10129255	0.5	rs7161740	ENSG00000254174.1	IGHV1-12	5.44	8.34e-08	2.67e-05	0.16	0.24	Kawasaki disease;	chr14:106776119	chr14:106122420~106122709:-
LUAD	cis	rs10129255	0.556	rs6576222	ENSG00000254174.1	IGHV1-12	5.44	8.34e-08	2.67e-05	0.16	0.24	Kawasaki disease;	chr14:106776442	chr14:106122420~106122709:-
LUAD	cis	rs10129255	0.536	rs6576223	ENSG00000254174.1	IGHV1-12	5.44	8.34e-08	2.67e-05	0.16	0.24	Kawasaki disease;	chr14:106776448	chr14:106122420~106122709:-
LUAD	cis	rs7948661	1	rs9332793	ENSG00000278376.1	RP11-158I9.8	5.44	8.34e-08	2.67e-05	0.52	0.24	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118483743	chr11:118791254~118793137:+
LUAD	cis	rs2404602	0.967	rs12148805	ENSG00000259422.1	RP11-593F23.1	5.44	8.34e-08	2.67e-05	0.28	0.24	Blood metabolite levels;	chr15:76508318	chr15:76174891~76181486:-
LUAD	cis	rs9309473	0.615	rs62153183	ENSG00000163016.8	ALMS1P	5.44	8.36e-08	2.68e-05	0.37	0.24	Metabolite levels;	chr2:73536239	chr2:73644919~73685576:+
LUAD	cis	rs9506514	0.722	rs10400670	ENSG00000238286.1	SLC35E1P1	5.44	8.36e-08	2.68e-05	0.26	0.24	Coronary artery calcification;	chr13:20679350	chr13:20607268~20608131:+
LUAD	cis	rs4718428	0.705	rs2901311	ENSG00000273142.1	RP11-458F8.4	-5.44	8.37e-08	2.68e-05	-0.18	-0.24	Corneal structure;	chr7:66950082	chr7:66902857~66906297:+
LUAD	cis	rs7617773	0.817	rs11710861	ENSG00000228638.1	FCF1P2	-5.44	8.37e-08	2.68e-05	-0.28	-0.24	Coronary artery disease;	chr3:48256070	chr3:48290793~48291375:-
LUAD	cis	rs8040855	0.599	rs6496800	ENSG00000259774.1	RP11-182J1.13	-5.44	8.38e-08	2.68e-05	-0.28	-0.24	Bulimia nervosa;	chr15:85185055	chr15:84422618~84425882:+
LUAD	cis	rs673078	0.607	rs2036314	ENSG00000275409.1	RP11-131L12.4	-5.44	8.38e-08	2.68e-05	-0.32	-0.24	Glucose homeostasis traits;	chr12:118367132	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs61943369	ENSG00000275409.1	RP11-131L12.4	-5.44	8.38e-08	2.68e-05	-0.32	-0.24	Glucose homeostasis traits;	chr12:118368145	chr12:118430147~118430699:+
LUAD	cis	rs559928	0.692	rs876064	ENSG00000236935.1	AP003774.1	5.44	8.38e-08	2.68e-05	0.35	0.24	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64269561	chr11:64325050~64329504:-
LUAD	cis	rs2111504	0.806	rs2903738	ENSG00000267213.4	AC007773.2	-5.44	8.38e-08	2.69e-05	-0.34	-0.24	Bipolar disorder;	chr19:32455137	chr19:32390050~32405560:-
LUAD	cis	rs2562456	0.917	rs2681376	ENSG00000268081.1	RP11-678G14.2	-5.44	8.39e-08	2.69e-05	-0.37	-0.24	Pain;	chr19:21532723	chr19:21554640~21569237:-
LUAD	cis	rs4568518	0.53	rs10950690	ENSG00000279048.1	RP11-511H23.2	5.44	8.39e-08	2.69e-05	0.2	0.24	Measles;	chr7:17941687	chr7:17940503~17942922:+
LUAD	cis	rs875971	0.862	rs801194	ENSG00000232559.3	GS1-124K5.12	-5.44	8.39e-08	2.69e-05	-0.29	-0.24	Aortic root size;	chr7:66563508	chr7:66554588~66576923:-
LUAD	cis	rs3096299	0.933	rs28608022	ENSG00000182376.2	RP5-1142A6.8	5.44	8.4e-08	2.69e-05	0.25	0.24	Multiple myeloma (IgH translocation);	chr16:89387884	chr16:88742767~88745748:+
LUAD	cis	rs2115536	0.73	rs4573897	ENSG00000278600.1	RP11-81A1.6	-5.44	8.4e-08	2.69e-05	-0.2	-0.24	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79894883	chr15:79920195~79922455:-
LUAD	cis	rs17818399	0.781	rs13024534	ENSG00000279254.1	RP11-536C12.1	-5.44	8.41e-08	2.69e-05	-0.28	-0.24	Height;	chr2:46632247	chr2:46668870~46670778:+
LUAD	cis	rs35740288	0.895	rs3743332	ENSG00000202081.1	RNU6-1280P	5.44	8.41e-08	2.69e-05	0.3	0.24	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85760520	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.929	rs11635081	ENSG00000202081.1	RNU6-1280P	5.44	8.41e-08	2.69e-05	0.3	0.24	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85761029	chr15:85651522~85651628:-
LUAD	cis	rs2455601	0.671	rs10840135	ENSG00000254860.4	TMEM9B-AS1	5.44	8.42e-08	2.69e-05	0.31	0.24	Schizophrenia;	chr11:8858247	chr11:8964675~8977527:+
LUAD	cis	rs4568518	0.53	rs6967917	ENSG00000279048.1	RP11-511H23.2	5.44	8.42e-08	2.7e-05	0.2	0.24	Measles;	chr7:17944674	chr7:17940503~17942922:+
LUAD	cis	rs2111504	0.806	rs10421787	ENSG00000267213.4	AC007773.2	-5.44	8.43e-08	2.7e-05	-0.34	-0.24	Bipolar disorder;	chr19:32460316	chr19:32390050~32405560:-
LUAD	cis	rs6543140	0.693	rs7579737	ENSG00000234389.1	AC007278.3	5.44	8.43e-08	2.7e-05	0.24	0.24	Blood protein levels;	chr2:102370901	chr2:102438713~102440475:+
LUAD	cis	rs858239	0.601	rs11984129	ENSG00000230042.1	AK3P3	-5.44	8.43e-08	2.7e-05	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23113058	chr7:23129178~23129841:+
LUAD	cis	rs7208859	0.623	rs73269923	ENSG00000263603.1	CTD-2349P21.5	-5.44	8.44e-08	2.7e-05	-0.43	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30729469~30731202:+
LUAD	cis	rs896854	0.684	rs10099059	ENSG00000253528.2	RP11-347C18.4	5.44	8.44e-08	2.7e-05	0.23	0.24	Type 2 diabetes;	chr8:94974744	chr8:94974573~94974853:-
LUAD	cis	rs896854	0.684	rs10099941	ENSG00000253528.2	RP11-347C18.4	5.44	8.44e-08	2.7e-05	0.23	0.24	Type 2 diabetes;	chr8:94974780	chr8:94974573~94974853:-
LUAD	cis	rs4835473	0.932	rs5016157	ENSG00000251600.4	RP11-673E1.1	-5.44	8.45e-08	2.71e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143738587	chr4:143912331~143982454:+
LUAD	cis	rs7618501	0.602	rs2624853	ENSG00000234667.1	ACTBP13	5.44	8.45e-08	2.71e-05	0.27	0.24	Intelligence (multi-trait analysis);	chr3:50091460	chr3:49873347~49877980:-
LUAD	cis	rs9309473	0.66	rs79370894	ENSG00000163016.8	ALMS1P	5.44	8.46e-08	2.71e-05	0.36	0.24	Metabolite levels;	chr2:73456388	chr2:73644919~73685576:+
LUAD	cis	rs453301	0.658	rs12114954	ENSG00000253981.4	ALG1L13P	-5.44	8.46e-08	2.71e-05	-0.28	-0.24	Joint mobility (Beighton score);	chr8:9047352	chr8:8236003~8244667:-
LUAD	cis	rs7208859	0.623	rs3794796	ENSG00000263603.1	CTD-2349P21.5	-5.44	8.47e-08	2.71e-05	-0.42	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30729469~30731202:+
LUAD	cis	rs801193	0.805	rs12532355	ENSG00000224316.1	RP11-479O9.2	-5.44	8.48e-08	2.71e-05	-0.24	-0.24	Aortic root size;	chr7:66605597	chr7:65773620~65802067:+
LUAD	cis	rs7618501	0.602	rs2526754	ENSG00000234667.1	ACTBP13	5.44	8.48e-08	2.71e-05	0.27	0.24	Intelligence (multi-trait analysis);	chr3:50088563	chr3:49873347~49877980:-
LUAD	cis	rs1075265	0.756	rs3821081	ENSG00000233266.1	HMGB1P31	-5.44	8.48e-08	2.71e-05	-0.3	-0.24	Chronotype;Morning vs. evening chronotype;	chr2:53738252	chr2:54051334~54051760:+
LUAD	cis	rs2303759	0.914	rs2288481	ENSG00000268686.1	AC010524.2	-5.44	8.49e-08	2.72e-05	-0.37	-0.24	Multiple sclerosis;	chr19:49374939	chr19:49368705~49388081:-
LUAD	cis	rs6570726	0.934	rs430003	ENSG00000235652.6	RP11-545I5.3	5.44	8.49e-08	2.72e-05	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145498370	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs395948	ENSG00000235652.6	RP11-545I5.3	5.44	8.49e-08	2.72e-05	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145499049	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs452552	ENSG00000235652.6	RP11-545I5.3	5.44	8.49e-08	2.72e-05	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145499645	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs451349	ENSG00000235652.6	RP11-545I5.3	5.44	8.49e-08	2.72e-05	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145499758	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.905	rs406799	ENSG00000235652.6	RP11-545I5.3	5.44	8.49e-08	2.72e-05	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145500701	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs1883406	ENSG00000235652.6	RP11-545I5.3	5.44	8.49e-08	2.72e-05	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145502069	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.87	rs370653	ENSG00000235652.6	RP11-545I5.3	5.44	8.49e-08	2.72e-05	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145502506	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs391524	ENSG00000235652.6	RP11-545I5.3	5.44	8.49e-08	2.72e-05	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145502708	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs429306	ENSG00000235652.6	RP11-545I5.3	5.44	8.49e-08	2.72e-05	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145505880	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs428659	ENSG00000235652.6	RP11-545I5.3	5.44	8.49e-08	2.72e-05	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145505903	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs376991	ENSG00000235652.6	RP11-545I5.3	5.44	8.49e-08	2.72e-05	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145506937	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs401888	ENSG00000235652.6	RP11-545I5.3	5.44	8.49e-08	2.72e-05	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145510399	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs414646	ENSG00000235652.6	RP11-545I5.3	5.44	8.49e-08	2.72e-05	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145510549	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs454614	ENSG00000235652.6	RP11-545I5.3	5.44	8.49e-08	2.72e-05	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145511497	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.846	rs411468	ENSG00000235652.6	RP11-545I5.3	5.44	8.49e-08	2.72e-05	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145511656	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs425731	ENSG00000235652.6	RP11-545I5.3	5.44	8.49e-08	2.72e-05	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145513015	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs421690	ENSG00000235652.6	RP11-545I5.3	5.44	8.49e-08	2.72e-05	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145513458	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs399169	ENSG00000235652.6	RP11-545I5.3	5.44	8.49e-08	2.72e-05	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145515217	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs377130	ENSG00000235652.6	RP11-545I5.3	5.44	8.49e-08	2.72e-05	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145515496	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs408723	ENSG00000235652.6	RP11-545I5.3	5.44	8.49e-08	2.72e-05	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145517399	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs425717	ENSG00000235652.6	RP11-545I5.3	5.44	8.49e-08	2.72e-05	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145517484	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs424263	ENSG00000235652.6	RP11-545I5.3	5.44	8.49e-08	2.72e-05	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145518937	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.905	rs419575	ENSG00000235652.6	RP11-545I5.3	5.44	8.49e-08	2.72e-05	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145519038	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs409725	ENSG00000235652.6	RP11-545I5.3	5.44	8.49e-08	2.72e-05	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145519204	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs386823	ENSG00000235652.6	RP11-545I5.3	5.44	8.49e-08	2.72e-05	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145520229	chr6:145799409~145886585:+
LUAD	cis	rs673078	0.607	rs17512763	ENSG00000275409.1	RP11-131L12.4	-5.44	8.5e-08	2.72e-05	-0.33	-0.24	Glucose homeostasis traits;	chr12:118400974	chr12:118430147~118430699:+
LUAD	cis	rs2404602	0.692	rs34272342	ENSG00000259422.1	RP11-593F23.1	5.44	8.5e-08	2.72e-05	0.28	0.24	Blood metabolite levels;	chr15:76719935	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.692	rs67570291	ENSG00000259422.1	RP11-593F23.1	5.44	8.5e-08	2.72e-05	0.28	0.24	Blood metabolite levels;	chr15:76728161	chr15:76174891~76181486:-
LUAD	cis	rs6570726	0.935	rs379164	ENSG00000235652.6	RP11-545I5.3	5.44	8.51e-08	2.72e-05	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145507957	chr6:145799409~145886585:+
LUAD	cis	rs9652601	0.691	rs12922303	ENSG00000274038.1	RP11-66H6.4	-5.44	8.51e-08	2.72e-05	-0.29	-0.24	Systemic lupus erythematosus;	chr16:11099608	chr16:11056556~11057034:+
LUAD	cis	rs8098244	0.516	rs60464408	ENSG00000264745.1	TTC39C-AS1	5.44	8.51e-08	2.72e-05	0.25	0.24	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23692874	chr18:23994213~24015339:-
LUAD	cis	rs62432291	0.614	rs452112	ENSG00000235086.1	FNDC1-IT1	-5.44	8.51e-08	2.72e-05	-0.42	-0.24	Joint mobility (Beighton score);	chr6:159236996	chr6:159240786~159243329:+
LUAD	cis	rs62432291	0.681	rs417719	ENSG00000235086.1	FNDC1-IT1	-5.44	8.51e-08	2.72e-05	-0.42	-0.24	Joint mobility (Beighton score);	chr6:159237010	chr6:159240786~159243329:+
LUAD	cis	rs9813712	0.571	rs9855777	ENSG00000249846.5	RP11-77P16.4	5.44	8.53e-08	2.73e-05	0.28	0.24	Response to amphetamines;	chr3:130214805	chr3:130112550~130120579:+
LUAD	cis	rs453301	0.686	rs3989373	ENSG00000253981.4	ALG1L13P	-5.44	8.53e-08	2.73e-05	-0.27	-0.24	Joint mobility (Beighton score);	chr8:9053798	chr8:8236003~8244667:-
LUAD	cis	rs2562456	1	rs2359155	ENSG00000268081.1	RP11-678G14.2	-5.44	8.54e-08	2.73e-05	-0.36	-0.24	Pain;	chr19:21489067	chr19:21554640~21569237:-
LUAD	cis	rs950169	0.724	rs11632668	ENSG00000259295.5	CSPG4P12	5.44	8.54e-08	2.73e-05	0.35	0.24	Schizophrenia;	chr15:84393989	chr15:85191438~85213905:+
LUAD	cis	rs9287719	0.614	rs10929679	ENSG00000243819.4	RN7SL832P	5.44	8.55e-08	2.73e-05	0.25	0.24	Prostate cancer;	chr2:10582982	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.614	rs10929680	ENSG00000243819.4	RN7SL832P	5.44	8.55e-08	2.73e-05	0.25	0.24	Prostate cancer;	chr2:10583000	chr2:10690344~10692099:+
LUAD	cis	rs1707322	1	rs785478	ENSG00000234329.1	RP11-767N6.2	-5.44	8.55e-08	2.73e-05	-0.25	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46025963	chr1:45651039~45651826:-
LUAD	cis	rs8040855	0.599	rs6496791	ENSG00000259774.1	RP11-182J1.13	-5.44	8.55e-08	2.73e-05	-0.28	-0.24	Bulimia nervosa;	chr15:85182428	chr15:84422618~84425882:+
LUAD	cis	rs748404	0.666	rs12913977	ENSG00000205771.5	CATSPER2P1	-5.44	8.55e-08	2.73e-05	-0.36	-0.24	Lung cancer;	chr15:43438913	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.666	rs12914122	ENSG00000205771.5	CATSPER2P1	-5.44	8.55e-08	2.73e-05	-0.36	-0.24	Lung cancer;	chr15:43438956	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.666	rs34697113	ENSG00000205771.5	CATSPER2P1	-5.44	8.55e-08	2.73e-05	-0.36	-0.24	Lung cancer;	chr15:43442041	chr15:43726918~43747094:-
LUAD	cis	rs12468226	0.873	rs12470401	ENSG00000272966.1	RP11-686O6.1	5.44	8.56e-08	2.73e-05	0.42	0.24	Urate levels;	chr2:202236436	chr2:202336739~202337200:+
LUAD	cis	rs287982	1	rs287982	ENSG00000269973.1	RP11-95D17.1	5.44	8.56e-08	2.74e-05	0.29	0.24	Nonsyndromic cleft lip with cleft palate;	chr2:9832313	chr2:9936360~9939590:+
LUAD	cis	rs957448	0.748	rs12680342	ENSG00000253704.1	RP11-267M23.4	5.44	8.56e-08	2.74e-05	0.32	0.24	Nonsyndromic cleft lip with cleft palate;	chr8:94347410	chr8:94553722~94569745:+
LUAD	cis	rs699371	0.507	rs10149787	ENSG00000270000.1	RP3-449M8.9	-5.44	8.56e-08	2.74e-05	-0.27	-0.24	Height;	chr14:74458749	chr14:74471930~74472360:-
LUAD	cis	rs889398	1	rs889398	ENSG00000226232.7	RP11-419C5.2	5.44	8.56e-08	2.74e-05	0.21	0.24	Body mass index;	chr16:69522812	chr16:69976388~69996188:-
LUAD	cis	rs12468226	0.679	rs6435133	ENSG00000272966.1	RP11-686O6.1	-5.44	8.56e-08	2.74e-05	-0.4	-0.24	Urate levels;	chr2:202209237	chr2:202336739~202337200:+
LUAD	cis	rs875971	0.619	rs2302918	ENSG00000237310.1	GS1-124K5.4	5.44	8.57e-08	2.74e-05	0.26	0.24	Aortic root size;	chr7:66535945	chr7:66493706~66495474:+
LUAD	cis	rs516805	0.667	rs2606609	ENSG00000279453.1	RP3-425C14.4	5.44	8.59e-08	2.75e-05	0.32	0.24	Lymphocyte counts;	chr6:122190346	chr6:122436789~122439223:-
LUAD	cis	rs1707322	0.721	rs10789468	ENSG00000280836.1	AL355480.1	-5.44	8.6e-08	2.75e-05	-0.32	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658886	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.721	rs6429574	ENSG00000280836.1	AL355480.1	-5.44	8.6e-08	2.75e-05	-0.32	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668382	chr1:45581219~45581321:-
LUAD	cis	rs6570726	0.935	rs408768	ENSG00000235652.6	RP11-545I5.3	5.44	8.6e-08	2.75e-05	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145550599	chr6:145799409~145886585:+
LUAD	cis	rs2404602	0.692	rs4360890	ENSG00000259422.1	RP11-593F23.1	5.44	8.6e-08	2.75e-05	0.28	0.24	Blood metabolite levels;	chr15:76880954	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.669	rs12916324	ENSG00000259422.1	RP11-593F23.1	5.44	8.6e-08	2.75e-05	0.28	0.24	Blood metabolite levels;	chr15:76887262	chr15:76174891~76181486:-
LUAD	cis	rs11603023	0.874	rs577396	ENSG00000255239.1	AP002954.6	5.44	8.6e-08	2.75e-05	0.28	0.24	Cholesterol, total;	chr11:118628753	chr11:118688039~118690600:-
LUAD	cis	rs11603023	0.874	rs11216934	ENSG00000255239.1	AP002954.6	5.44	8.6e-08	2.75e-05	0.28	0.24	Cholesterol, total;	chr11:118630742	chr11:118688039~118690600:-
LUAD	cis	rs2404602	0.716	rs7174953	ENSG00000259422.1	RP11-593F23.1	5.44	8.61e-08	2.75e-05	0.28	0.24	Blood metabolite levels;	chr15:76614506	chr15:76174891~76181486:-
LUAD	cis	rs7044106	0.537	rs10818474	ENSG00000238181.2	AHCYP2	-5.44	8.61e-08	2.75e-05	-0.33	-0.24	Hip circumference adjusted for BMI;	chr9:120727686	chr9:120720673~120721972:+
LUAD	cis	rs6543140	0.964	rs4851592	ENSG00000234389.1	AC007278.3	5.44	8.61e-08	2.75e-05	0.24	0.24	Blood protein levels;	chr2:102471181	chr2:102438713~102440475:+
LUAD	cis	rs7968440	1	rs2700485	ENSG00000200428.1	Y_RNA	-5.44	8.61e-08	2.75e-05	-0.3	-0.24	Fibrinogen;	chr12:50710209	chr12:50743568~50743684:+
LUAD	cis	rs7968440	1	rs2250752	ENSG00000200428.1	Y_RNA	-5.44	8.61e-08	2.75e-05	-0.3	-0.24	Fibrinogen;	chr12:50712308	chr12:50743568~50743684:+
LUAD	cis	rs9807989	0.839	rs4988957	ENSG00000234389.1	AC007278.3	-5.44	8.62e-08	2.75e-05	-0.23	-0.24	Asthma;	chr2:102351615	chr2:102438713~102440475:+
LUAD	cis	rs6543140	0.964	rs6761350	ENSG00000234389.1	AC007278.3	5.44	8.63e-08	2.76e-05	0.24	0.24	Blood protein levels;	chr2:102414316	chr2:102438713~102440475:+
LUAD	cis	rs6543140	0.929	rs7602207	ENSG00000234389.1	AC007278.3	5.44	8.63e-08	2.76e-05	0.24	0.24	Blood protein levels;	chr2:102415906	chr2:102438713~102440475:+
LUAD	cis	rs6543140	0.964	rs2160200	ENSG00000234389.1	AC007278.3	5.44	8.63e-08	2.76e-05	0.24	0.24	Blood protein levels;	chr2:102417503	chr2:102438713~102440475:+
LUAD	cis	rs673078	0.607	rs2393418	ENSG00000275409.1	RP11-131L12.4	-5.44	8.63e-08	2.76e-05	-0.33	-0.24	Glucose homeostasis traits;	chr12:118445995	chr12:118430147~118430699:+
LUAD	cis	rs9859260	0.614	rs493661	ENSG00000231464.1	AC024937.4	-5.44	8.65e-08	2.76e-05	-0.28	-0.24	Mean corpuscular volume;	chr3:196059618	chr3:195996738~195998233:+
LUAD	cis	rs10129255	0.957	rs12590799	ENSG00000211972.2	IGHV3-66	5.44	8.65e-08	2.76e-05	0.21	0.24	Kawasaki disease;	chr14:106779713	chr14:106675017~106675544:-
LUAD	cis	rs4835473	0.932	rs3872	ENSG00000251600.4	RP11-673E1.1	5.44	8.66e-08	2.77e-05	0.29	0.24	Immature fraction of reticulocytes;	chr4:143968788	chr4:143912331~143982454:+
LUAD	cis	rs8040855	0.756	rs2342118	ENSG00000259774.1	RP11-182J1.13	-5.44	8.66e-08	2.77e-05	-0.3	-0.24	Bulimia nervosa;	chr15:85149785	chr15:84422618~84425882:+
LUAD	cis	rs957448	1	rs2381882	ENSG00000253704.1	RP11-267M23.4	5.44	8.66e-08	2.77e-05	0.31	0.24	Nonsyndromic cleft lip with cleft palate;	chr8:94535496	chr8:94553722~94569745:+
LUAD	cis	rs12908161	0.96	rs11633450	ENSG00000225151.9	GOLGA2P7	-5.44	8.66e-08	2.77e-05	-0.33	-0.24	Schizophrenia;	chr15:84764056	chr15:84199311~84230136:-
LUAD	cis	rs11157436	1	rs61972228	ENSG00000211813.2	TRAV34	5.44	8.68e-08	2.77e-05	0.31	0.24	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22179460	chr14:22207522~22208129:+
LUAD	cis	rs7430456	0.967	rs6780021	ENSG00000228221.4	LINC00578	5.44	8.68e-08	2.77e-05	0.28	0.24	Breast cancer;	chr3:177739677	chr3:177441921~177752305:+
LUAD	cis	rs7208859	0.673	rs216440	ENSG00000263603.1	CTD-2349P21.5	-5.44	8.68e-08	2.77e-05	-0.36	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30601291	chr17:30729469~30731202:+
LUAD	cis	rs193541	0.632	rs2910135	ENSG00000263432.2	RN7SL689P	5.44	8.68e-08	2.77e-05	0.32	0.24	Glucose homeostasis traits;	chr5:122894095	chr5:123022487~123022783:-
LUAD	cis	rs801193	0.569	rs10950050	ENSG00000232559.3	GS1-124K5.12	5.44	8.69e-08	2.77e-05	0.28	0.24	Aortic root size;	chr7:66774601	chr7:66554588~66576923:-
LUAD	cis	rs7017914	0.605	rs55865599	ENSG00000223220.1	Y_RNA	5.44	8.7e-08	2.78e-05	0.28	0.24	Bone mineral density;	chr8:70792351	chr8:70780914~70781008:-
LUAD	cis	rs7927592	0.763	rs10896326	ENSG00000212093.1	AP000807.1	5.44	8.71e-08	2.78e-05	0.25	0.24	Total body bone mineral density;	chr11:68467103	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.763	rs10896327	ENSG00000212093.1	AP000807.1	5.44	8.71e-08	2.78e-05	0.25	0.24	Total body bone mineral density;	chr11:68467807	chr11:68506083~68506166:-
LUAD	cis	rs9923856	0.519	rs9923455	ENSG00000274038.1	RP11-66H6.4	-5.43	8.73e-08	2.79e-05	-0.29	-0.24	Atopic dermatitis;Adult asthma;	chr16:11038007	chr16:11056556~11057034:+
LUAD	cis	rs2404602	0.692	rs1471780	ENSG00000259422.1	RP11-593F23.1	5.43	8.73e-08	2.79e-05	0.28	0.24	Blood metabolite levels;	chr15:76734185	chr15:76174891~76181486:-
LUAD	cis	rs7580658	0.724	rs7568261	ENSG00000236682.1	AC068282.3	-5.43	8.73e-08	2.79e-05	-0.31	-0.24	Protein C levels;	chr2:127359748	chr2:127389130~127400580:+
LUAD	cis	rs35160687	0.712	rs6745235	ENSG00000273080.1	RP11-301O19.1	-5.43	8.74e-08	2.79e-05	-0.27	-0.24	Night sleep phenotypes;	chr2:86259960	chr2:86195590~86196049:+
LUAD	cis	rs35160687	0.712	rs7568971	ENSG00000273080.1	RP11-301O19.1	-5.43	8.74e-08	2.79e-05	-0.27	-0.24	Night sleep phenotypes;	chr2:86260917	chr2:86195590~86196049:+
LUAD	cis	rs35160687	0.712	rs12476826	ENSG00000273080.1	RP11-301O19.1	-5.43	8.74e-08	2.79e-05	-0.27	-0.24	Night sleep phenotypes;	chr2:86262397	chr2:86195590~86196049:+
LUAD	cis	rs35160687	0.712	rs4832270	ENSG00000273080.1	RP11-301O19.1	-5.43	8.74e-08	2.79e-05	-0.27	-0.24	Night sleep phenotypes;	chr2:86263065	chr2:86195590~86196049:+
LUAD	cis	rs35160687	0.712	rs6547668	ENSG00000273080.1	RP11-301O19.1	-5.43	8.74e-08	2.79e-05	-0.27	-0.24	Night sleep phenotypes;	chr2:86263538	chr2:86195590~86196049:+
LUAD	cis	rs453301	0.686	rs6601280	ENSG00000233609.3	RP11-62H7.2	5.43	8.74e-08	2.79e-05	0.21	0.24	Joint mobility (Beighton score);	chr8:9051726	chr8:8961200~8979025:+
LUAD	cis	rs10761482	0.5	rs10821779	ENSG00000254271.1	RP11-131N11.4	5.43	8.74e-08	2.79e-05	0.27	0.24	Schizophrenia;	chr10:60514767	chr10:60734342~60741828:+
LUAD	cis	rs9500256	0.711	rs6588685	ENSG00000215190.7	LINC00680	-5.43	8.75e-08	2.79e-05	-0.32	-0.24	Eosinophilic esophagitis (pediatric);	chr6:57993375	chr6:57946074~57961501:-
LUAD	cis	rs7927592	0.763	rs7129248	ENSG00000212093.1	AP000807.1	5.43	8.75e-08	2.79e-05	0.25	0.24	Total body bone mineral density;	chr11:68495808	chr11:68506083~68506166:-
LUAD	cis	rs4835473	0.864	rs2323418	ENSG00000251600.4	RP11-673E1.1	5.43	8.76e-08	2.79e-05	0.29	0.24	Immature fraction of reticulocytes;	chr4:143969141	chr4:143912331~143982454:+
LUAD	cis	rs6991838	0.725	rs6995134	ENSG00000200714.1	Y_RNA	5.43	8.76e-08	2.79e-05	0.28	0.24	Intelligence (multi-trait analysis);	chr8:65555472	chr8:65592731~65592820:+
LUAD	cis	rs712039	0.687	rs11656455	ENSG00000276054.1	RP11-378E13.3	5.43	8.76e-08	2.79e-05	0.36	0.24	Tuberculosis;	chr17:37411798	chr17:37386886~37387926:+
LUAD	cis	rs1707322	0.686	rs1547924	ENSG00000280836.1	AL355480.1	-5.43	8.76e-08	2.8e-05	-0.32	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619440	chr1:45581219~45581321:-
LUAD	cis	rs6543140	0.964	rs10193485	ENSG00000234389.1	AC007278.3	5.43	8.77e-08	2.8e-05	0.24	0.24	Blood protein levels;	chr2:102473114	chr2:102438713~102440475:+
LUAD	cis	rs6543140	0.964	rs10196334	ENSG00000234389.1	AC007278.3	5.43	8.77e-08	2.8e-05	0.24	0.24	Blood protein levels;	chr2:102473582	chr2:102438713~102440475:+
LUAD	cis	rs6543140	0.964	rs10200081	ENSG00000234389.1	AC007278.3	5.43	8.77e-08	2.8e-05	0.24	0.24	Blood protein levels;	chr2:102475097	chr2:102438713~102440475:+
LUAD	cis	rs516805	0.563	rs2816083	ENSG00000279453.1	RP3-425C14.4	-5.43	8.77e-08	2.8e-05	-0.32	-0.24	Lymphocyte counts;	chr6:122101611	chr6:122436789~122439223:-
LUAD	cis	rs11742741	0.579	rs1593895	ENSG00000248874.4	C5orf17	-5.43	8.78e-08	2.8e-05	-0.3	-0.24	Educational attainment;	chr5:24115865	chr5:23951348~24178263:+
LUAD	cis	rs11976180	1	rs6464573	ENSG00000204959.4	ARHGEF34P	-5.43	8.78e-08	2.8e-05	-0.3	-0.24	Obesity-related traits;	chr7:144051005	chr7:144272445~144286966:-
LUAD	cis	rs7221109	0.677	rs4890092	ENSG00000278834.1	RP11-458J1.1	5.43	8.78e-08	2.8e-05	0.28	0.24	Type 1 diabetes;	chr17:40630199	chr17:40648300~40649718:+
LUAD	cis	rs4713118	0.539	rs510987	ENSG00000219392.1	RP1-265C24.5	-5.43	8.8e-08	2.81e-05	-0.32	-0.24	Parkinson's disease;	chr6:27879739	chr6:28115628~28116551:+
LUAD	cis	rs17301853	0.908	rs7411689	ENSG00000227373.4	RP11-160H22.5	5.43	8.82e-08	2.81e-05	0.48	0.24	Migraine without aura;Migraine - clinic-based;	chr1:174826202	chr1:174115300~174160004:-
LUAD	cis	rs7617773	0.784	rs11715799	ENSG00000228638.1	FCF1P2	-5.43	8.83e-08	2.82e-05	-0.29	-0.24	Coronary artery disease;	chr3:48213730	chr3:48290793~48291375:-
LUAD	cis	rs9435732	0.832	rs7531163	ENSG00000235241.1	RP11-108M9.5	5.43	8.84e-08	2.82e-05	0.31	0.24	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16986959	chr1:16889095~16889602:+
LUAD	cis	rs1823874	0.71	rs2085086	ENSG00000182397.13	DNM1P46	-5.43	8.84e-08	2.82e-05	-0.29	-0.24	IgG glycosylation;	chr15:99819887	chr15:99790156~99806927:-
LUAD	cis	rs1667284	1	rs1667284	ENSG00000266521.1	RP11-650P15.1	-5.43	8.85e-08	2.82e-05	-0.28	-0.24	Problematic alcohol use in trauma-exposed individuals;	chr18:31646245	chr18:31496645~31497195:-
LUAD	cis	rs55665837	0.539	rs12794714	ENSG00000251991.1	RNU7-49P	5.43	8.85e-08	2.82e-05	0.27	0.24	Vitamin D levels;	chr11:14892029	chr11:14478892~14478953:+
LUAD	cis	rs67311347	0.544	rs7644181	ENSG00000223797.4	ENTPD3-AS1	-5.43	8.86e-08	2.82e-05	-0.25	-0.24	Renal cell carcinoma;	chr3:40314174	chr3:40313802~40453329:-
LUAD	cis	rs4308124	0.708	rs6749633	ENSG00000227992.1	AC108463.2	5.43	8.86e-08	2.83e-05	0.32	0.24	Vitiligo;	chr2:111230439	chr2:111203964~111206215:-
LUAD	cis	rs516805	0.781	rs574462	ENSG00000279453.1	RP3-425C14.4	-5.43	8.86e-08	2.83e-05	-0.31	-0.24	Lymphocyte counts;	chr6:122404863	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.748	rs492250	ENSG00000279453.1	RP3-425C14.4	-5.43	8.87e-08	2.83e-05	-0.31	-0.24	Lymphocyte counts;	chr6:122421808	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.748	rs9320872	ENSG00000279453.1	RP3-425C14.4	-5.43	8.87e-08	2.83e-05	-0.31	-0.24	Lymphocyte counts;	chr6:122425438	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.63	rs505749	ENSG00000279453.1	RP3-425C14.4	-5.43	8.87e-08	2.83e-05	-0.31	-0.24	Lymphocyte counts;	chr6:122425751	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.748	rs502252	ENSG00000279453.1	RP3-425C14.4	-5.43	8.87e-08	2.83e-05	-0.31	-0.24	Lymphocyte counts;	chr6:122436330	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.706	rs577049	ENSG00000279453.1	RP3-425C14.4	-5.43	8.87e-08	2.83e-05	-0.31	-0.24	Lymphocyte counts;	chr6:122438204	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.748	rs577838	ENSG00000279453.1	RP3-425C14.4	-5.43	8.87e-08	2.83e-05	-0.31	-0.24	Lymphocyte counts;	chr6:122438270	chr6:122436789~122439223:-
LUAD	cis	rs2179367	0.509	rs9485390	ENSG00000231760.4	RP11-350J20.5	5.43	8.87e-08	2.83e-05	0.34	0.24	Dupuytren's disease;	chr6:149421004	chr6:149796151~149826294:-
LUAD	cis	rs6750795	0.502	rs11685196	ENSG00000181798.2	LINC00471	-5.43	8.87e-08	2.83e-05	-0.27	-0.24	Height;	chr2:231516587	chr2:231508426~231514339:-
LUAD	cis	rs8072100	0.817	rs9912101	ENSG00000228782.6	CTD-2026D20.3	5.43	8.89e-08	2.83e-05	0.25	0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469712	chr17:47450568~47492492:-
LUAD	cis	rs12699921	0.599	rs6973480	ENSG00000279048.1	RP11-511H23.2	5.43	8.89e-08	2.83e-05	0.19	0.24	Fibrinogen levels;	chr7:17938506	chr7:17940503~17942922:+
LUAD	cis	rs2439831	0.85	rs16977798	ENSG00000205771.5	CATSPER2P1	-5.43	8.89e-08	2.84e-05	-0.47	-0.24	Lung cancer in ever smokers;	chr15:43859750	chr15:43726918~43747094:-
LUAD	cis	rs72634501	0.716	rs2036465	ENSG00000228060.1	RP11-69E11.8	5.43	8.9e-08	2.84e-05	0.25	0.24	HDL cholesterol;	chr1:39110310	chr1:39565160~39573203:+
LUAD	cis	rs9652601	0.691	rs7186145	ENSG00000274038.1	RP11-66H6.4	-5.43	8.91e-08	2.84e-05	-0.3	-0.24	Systemic lupus erythematosus;	chr16:11117021	chr16:11056556~11057034:+
LUAD	cis	rs853679	0.517	rs9283884	ENSG00000204709.4	LINC01556	-5.43	8.91e-08	2.84e-05	-0.33	-0.24	Depression;	chr6:28167882	chr6:28943877~28944537:+
LUAD	cis	rs2880765	0.835	rs6497206	ENSG00000259295.5	CSPG4P12	5.43	8.91e-08	2.84e-05	0.27	0.24	Coronary artery disease;	chr15:85485994	chr15:85191438~85213905:+
LUAD	cis	rs853679	0.76	rs2299029	ENSG00000219392.1	RP1-265C24.5	-5.43	8.91e-08	2.84e-05	-0.35	-0.24	Depression;	chr6:28231053	chr6:28115628~28116551:+
LUAD	cis	rs10895987	0.531	rs11227120	ENSG00000254614.2	AP003068.23	5.43	8.91e-08	2.84e-05	0.32	0.24	Blood protein levels;	chr11:65097387	chr11:65177606~65181834:-
LUAD	cis	rs1962636	1	rs1962636	ENSG00000260306.1	RP11-645C24.5	-5.43	8.92e-08	2.84e-05	-0.22	-0.24	Schizophrenia;	chr16:22053074	chr16:21794095~21795759:-
LUAD	cis	rs77204473	0.744	rs12420200	ENSG00000254851.1	RP11-109L13.1	-5.43	8.92e-08	2.84e-05	-0.52	-0.24	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117127590	chr11:117135528~117138582:+
LUAD	cis	rs2283792	0.73	rs56398890	ENSG00000224086.5	LL22NC03-86G7.1	-5.43	8.92e-08	2.84e-05	-0.23	-0.24	Multiple sclerosis;	chr22:21836496	chr22:21938293~21977632:+
LUAD	cis	rs67311347	0.544	rs2278929	ENSG00000223797.4	ENTPD3-AS1	-5.43	8.92e-08	2.84e-05	-0.25	-0.24	Renal cell carcinoma;	chr3:40309517	chr3:40313802~40453329:-
LUAD	cis	rs11651753	0.561	rs17616603	ENSG00000264920.1	RP11-6N17.4	-5.43	8.93e-08	2.84e-05	-0.3	-0.24	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47882254	chr17:47891255~47895812:-
LUAD	cis	rs7617773	0.743	rs13081633	ENSG00000228638.1	FCF1P2	-5.43	8.93e-08	2.84e-05	-0.29	-0.24	Coronary artery disease;	chr3:48315791	chr3:48290793~48291375:-
LUAD	cis	rs1876905	0.524	rs1084639	ENSG00000272356.1	RP5-1112D6.8	-5.43	8.94e-08	2.85e-05	-0.27	-0.24	Mean corpuscular hemoglobin;	chr6:111165240	chr6:111309203~111313517:+
LUAD	cis	rs11157436	0.958	rs2075494	ENSG00000211813.2	TRAV34	5.43	8.94e-08	2.85e-05	0.31	0.24	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22202564	chr14:22207522~22208129:+
LUAD	cis	rs11157436	0.958	rs2242542	ENSG00000211813.2	TRAV34	5.43	8.94e-08	2.85e-05	0.31	0.24	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22203081	chr14:22207522~22208129:+
LUAD	cis	rs1045529	0.524	rs34251783	ENSG00000253981.4	ALG1L13P	-5.43	8.94e-08	2.85e-05	-0.29	-0.24	Myopia (pathological);Myopia;	chr8:9033866	chr8:8236003~8244667:-
LUAD	cis	rs453301	0.719	rs34004903	ENSG00000253981.4	ALG1L13P	-5.43	8.94e-08	2.85e-05	-0.29	-0.24	Joint mobility (Beighton score);	chr8:9035094	chr8:8236003~8244667:-
LUAD	cis	rs9506514	0.712	rs11838795	ENSG00000238286.1	SLC35E1P1	5.43	8.95e-08	2.85e-05	0.26	0.24	Coronary artery calcification;	chr13:20684189	chr13:20607268~20608131:+
LUAD	cis	rs875971	0.522	rs781144	ENSG00000164669.11	INTS4P1	-5.43	8.96e-08	2.85e-05	-0.29	-0.24	Aortic root size;	chr7:65975357	chr7:65141225~65234216:+
LUAD	cis	rs11976180	0.569	rs12703565	ENSG00000228960.5	OR2A9P	-5.43	8.97e-08	2.86e-05	-0.4	-0.24	Obesity-related traits;	chr7:144057308	chr7:144294480~144300934:+
LUAD	cis	rs6570726	0.577	rs406868	ENSG00000235652.6	RP11-545I5.3	5.43	8.98e-08	2.86e-05	0.25	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145488847	chr6:145799409~145886585:+
LUAD	cis	rs453301	0.686	rs6748	ENSG00000253981.4	ALG1L13P	-5.43	8.98e-08	2.86e-05	-0.29	-0.24	Joint mobility (Beighton score);	chr8:9033292	chr8:8236003~8244667:-
LUAD	cis	rs394563	0.726	rs6906384	ENSG00000231760.4	RP11-350J20.5	-5.43	8.98e-08	2.86e-05	-0.3	-0.24	Dupuytren's disease;	chr6:149343404	chr6:149796151~149826294:-
LUAD	cis	rs6687821	0.515	rs2096286	ENSG00000267734.1	RP4-604K5.3	-5.43	8.99e-08	2.86e-05	-0.29	-0.24	Yeast infection;	chr1:87075298	chr1:86932199~86934891:-
LUAD	cis	rs6687821	0.515	rs2040064	ENSG00000267734.1	RP4-604K5.3	-5.43	8.99e-08	2.86e-05	-0.29	-0.24	Yeast infection;	chr1:87088226	chr1:86932199~86934891:-
LUAD	cis	rs7617773	0.71	rs36064160	ENSG00000228638.1	FCF1P2	-5.43	9.01e-08	2.87e-05	-0.29	-0.24	Coronary artery disease;	chr3:48201611	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.817	rs34728236	ENSG00000228638.1	FCF1P2	-5.43	9.01e-08	2.87e-05	-0.29	-0.24	Coronary artery disease;	chr3:48217618	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.817	rs79310258	ENSG00000228638.1	FCF1P2	-5.43	9.01e-08	2.87e-05	-0.29	-0.24	Coronary artery disease;	chr3:48218177	chr3:48290793~48291375:-
LUAD	cis	rs2665103	0.632	rs3902959	ENSG00000278603.1	RP13-608F4.5	5.43	9.01e-08	2.87e-05	0.28	0.24	Intelligence (multi-trait analysis);	chr15:82252586	chr15:82472203~82472426:+
LUAD	cis	rs1075232	0.826	rs16956738	ENSG00000215302.7	CTD-3092A11.1	5.43	9.01e-08	2.87e-05	0.48	0.24	Survival in colorectal cancer (non-distant metastatic);	chr15:31444028	chr15:30470779~30507623:+
LUAD	cis	rs10246939	0.543	rs11765575	ENSG00000270923.1	TAS2R6P	-5.43	9.02e-08	2.87e-05	-0.26	-0.24	Bitter taste perception;	chr7:141838168	chr7:141787815~141788640:+
LUAD	cis	rs2439831	0.85	rs2277531	ENSG00000205771.5	CATSPER2P1	-5.43	9.02e-08	2.87e-05	-0.46	-0.24	Lung cancer in ever smokers;	chr15:43776871	chr15:43726918~43747094:-
LUAD	cis	rs394563	0.591	rs237012	ENSG00000231760.4	RP11-350J20.5	5.43	9.04e-08	2.88e-05	0.29	0.24	Dupuytren's disease;	chr6:149408062	chr6:149796151~149826294:-
LUAD	cis	rs7618501	0.633	rs9861216	ENSG00000234667.1	ACTBP13	5.43	9.05e-08	2.88e-05	0.27	0.24	Intelligence (multi-trait analysis);	chr3:50021906	chr3:49873347~49877980:-
LUAD	cis	rs2919009	0.62	rs11199664	ENSG00000271670.1	RP11-95I16.4	5.43	9.05e-08	2.88e-05	0.31	0.24	Obesity-related traits;	chr10:120936790	chr10:120879256~120880667:-
LUAD	cis	rs11976180	1	rs2961128	ENSG00000170356.8	OR2A20P	-5.43	9.06e-08	2.88e-05	-0.3	-0.24	Obesity-related traits;	chr7:144066390	chr7:144250045~144252957:-
LUAD	cis	rs11976180	1	rs2371248	ENSG00000170356.8	OR2A20P	-5.43	9.06e-08	2.88e-05	-0.3	-0.24	Obesity-related traits;	chr7:144067096	chr7:144250045~144252957:-
LUAD	cis	rs189798	0.592	rs10111263	ENSG00000173295.6	FAM86B3P	-5.43	9.06e-08	2.88e-05	-0.25	-0.24	Myopia (pathological);	chr8:9111923	chr8:8228595~8244865:+
LUAD	cis	rs7299940	0.967	rs10848243	ENSG00000256299.1	RP11-989F5.3	-5.43	9.07e-08	2.89e-05	-0.26	-0.24	Panic disorder;	chr12:130894769	chr12:130810821~130812622:-
LUAD	cis	rs9425766	0.591	rs2049991	ENSG00000227373.4	RP11-160H22.5	5.43	9.07e-08	2.89e-05	0.3	0.24	Life satisfaction;	chr1:174356428	chr1:174115300~174160004:-
LUAD	cis	rs801193	0.548	rs6975044	ENSG00000237310.1	GS1-124K5.4	5.43	9.07e-08	2.89e-05	0.26	0.24	Aortic root size;	chr7:66762495	chr7:66493706~66495474:+
LUAD	cis	rs12699921	0.632	rs2691617	ENSG00000279048.1	RP11-511H23.2	-5.43	9.08e-08	2.89e-05	-0.19	-0.24	Fibrinogen levels;	chr7:17782704	chr7:17940503~17942922:+
LUAD	cis	rs2288884	0.767	rs58329304	ENSG00000275055.1	CTC-471J1.11	-5.43	9.09e-08	2.89e-05	-0.34	-0.24	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52031919	chr19:52049007~52049754:+
LUAD	cis	rs7804306	0.826	rs12113109	ENSG00000233264.2	AC006042.8	5.43	9.09e-08	2.89e-05	0.39	0.24	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7979920	chr7:7980312~7982228:+
LUAD	cis	rs6568401	0.508	rs4946685	ENSG00000219088.1	RP3-359N14.1	-5.43	9.09e-08	2.89e-05	-0.32	-0.24	Primary tooth development (time to first tooth eruption);	chr6:105726315	chr6:105666326~105667998:+
LUAD	cis	rs4938303	0.756	rs4938301	ENSG00000254851.1	RP11-109L13.1	5.43	9.09e-08	2.89e-05	0.34	0.24	Triglycerides;	chr11:116704757	chr11:117135528~117138582:+
LUAD	cis	rs11168351	0.75	rs11168366	ENSG00000240399.1	RP1-228P16.1	-5.43	9.1e-08	2.89e-05	-0.24	-0.24	Bipolar disorder and schizophrenia;	chr12:48027990	chr12:48054813~48055591:-
LUAD	cis	rs875971	0.862	rs2024192	ENSG00000232559.3	GS1-124K5.12	-5.43	9.1e-08	2.89e-05	-0.28	-0.24	Aortic root size;	chr7:66576460	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs4718377	ENSG00000232559.3	GS1-124K5.12	-5.43	9.1e-08	2.89e-05	-0.28	-0.24	Aortic root size;	chr7:66584691	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs10278014	ENSG00000232559.3	GS1-124K5.12	-5.43	9.1e-08	2.89e-05	-0.28	-0.24	Aortic root size;	chr7:66586277	chr7:66554588~66576923:-
LUAD	cis	rs10129255	0.957	rs11847726	ENSG00000211974.3	IGHV2-70	5.43	9.11e-08	2.9e-05	0.25	0.24	Kawasaki disease;	chr14:106779116	chr14:106723574~106724093:-
LUAD	cis	rs807029	0.577	rs3740490	ENSG00000272572.1	RP11-179B2.2	-5.43	9.11e-08	2.9e-05	-0.34	-0.24	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100996986	chr10:100911103~100912739:-
LUAD	cis	rs4698412	0.874	rs3213710	ENSG00000214846.4	RP11-115L11.1	-5.43	9.11e-08	2.9e-05	-0.3	-0.24	Parkinson's disease;	chr4:15715698	chr4:15730962~15731627:-
LUAD	cis	rs17507216	0.588	rs28864981	ENSG00000255769.6	GOLGA2P10	-5.43	9.12e-08	2.9e-05	-0.31	-0.24	Excessive daytime sleepiness;	chr15:82695420	chr15:82472993~82513950:-
LUAD	cis	rs17507216	0.628	rs8032321	ENSG00000255769.6	GOLGA2P10	-5.43	9.12e-08	2.9e-05	-0.31	-0.24	Excessive daytime sleepiness;	chr15:82698956	chr15:82472993~82513950:-
LUAD	cis	rs17507216	0.628	rs8040488	ENSG00000255769.6	GOLGA2P10	-5.43	9.12e-08	2.9e-05	-0.31	-0.24	Excessive daytime sleepiness;	chr15:82699081	chr15:82472993~82513950:-
LUAD	cis	rs35740288	0.685	rs12899481	ENSG00000202081.1	RNU6-1280P	5.43	9.12e-08	2.9e-05	0.3	0.24	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85765739	chr15:85651522~85651628:-
LUAD	cis	rs7617773	0.817	rs13072018	ENSG00000228638.1	FCF1P2	-5.43	9.13e-08	2.9e-05	-0.29	-0.24	Coronary artery disease;	chr3:48278842	chr3:48290793~48291375:-
LUAD	cis	rs4538475	0.556	rs4263397	ENSG00000214846.4	RP11-115L11.1	-5.43	9.14e-08	2.9e-05	-0.35	-0.24	Parkinson's disease;	chr4:15737767	chr4:15730962~15731627:-
LUAD	cis	rs2562456	0.837	rs62110205	ENSG00000268081.1	RP11-678G14.2	5.43	9.14e-08	2.9e-05	0.36	0.24	Pain;	chr19:21577269	chr19:21554640~21569237:-
LUAD	cis	rs8098244	0.557	rs7229859	ENSG00000264745.1	TTC39C-AS1	5.43	9.14e-08	2.91e-05	0.25	0.24	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23716812	chr18:23994213~24015339:-
LUAD	cis	rs8098244	0.557	rs12957301	ENSG00000264745.1	TTC39C-AS1	5.43	9.14e-08	2.91e-05	0.25	0.24	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23717906	chr18:23994213~24015339:-
LUAD	cis	rs950169	0.92	rs34672825	ENSG00000259728.4	LINC00933	5.43	9.15e-08	2.91e-05	0.38	0.24	Schizophrenia;	chr15:84034718	chr15:84570649~84580175:+
LUAD	cis	rs394563	0.726	rs366905	ENSG00000231760.4	RP11-350J20.5	5.43	9.16e-08	2.91e-05	0.3	0.24	Dupuytren's disease;	chr6:149413961	chr6:149796151~149826294:-
LUAD	cis	rs4143844	0.867	rs12915585	ENSG00000259251.2	RP11-643M14.1	5.43	9.16e-08	2.91e-05	0.43	0.24	Bipolar disorder and schizophrenia;	chr15:61962693	chr15:62060503~62062434:+
LUAD	cis	rs7829975	0.511	rs2976906	ENSG00000253981.4	ALG1L13P	5.43	9.16e-08	2.91e-05	0.27	0.24	Mood instability;	chr8:8484905	chr8:8236003~8244667:-
LUAD	cis	rs897984	0.684	rs6950	ENSG00000260911.2	RP11-196G11.2	-5.43	9.17e-08	2.91e-05	-0.22	-0.24	Dementia with Lewy bodies;	chr16:30984348	chr16:31043150~31049868:+
LUAD	cis	rs897984	0.645	rs9938550	ENSG00000260911.2	RP11-196G11.2	-5.43	9.17e-08	2.91e-05	-0.22	-0.24	Dementia with Lewy bodies;	chr16:30987821	chr16:31043150~31049868:+
LUAD	cis	rs897984	0.762	rs2305880	ENSG00000260911.2	RP11-196G11.2	-5.43	9.17e-08	2.91e-05	-0.22	-0.24	Dementia with Lewy bodies;	chr16:30988141	chr16:31043150~31049868:+
LUAD	cis	rs4964805	0.526	rs934845	ENSG00000257681.1	RP11-341G23.4	5.43	9.18e-08	2.92e-05	0.25	0.24	Attention deficit hyperactivity disorder;	chr12:103791479	chr12:103746315~103768858:-
LUAD	cis	rs997295	0.713	rs17243334	ENSG00000270964.1	RP11-502I4.3	-5.43	9.19e-08	2.92e-05	-0.25	-0.24	Motion sickness;	chr15:67720741	chr15:67541072~67542604:-
LUAD	cis	rs732716	0.785	rs11666453	ENSG00000267980.1	AC007292.6	-5.43	9.19e-08	2.92e-05	-0.28	-0.24	Mean corpuscular volume;	chr19:4368800	chr19:4363789~4364640:+
LUAD	cis	rs1275468	0.731	rs1795380	ENSG00000257497.2	RP11-585P4.5	-5.43	9.2e-08	2.92e-05	-0.36	-0.24	Polycystic ovary syndrome;	chr12:75559432	chr12:75483454~75489820:-
LUAD	cis	rs1275468	0.678	rs2620687	ENSG00000257497.2	RP11-585P4.5	-5.43	9.2e-08	2.92e-05	-0.36	-0.24	Polycystic ovary syndrome;	chr12:75560395	chr12:75483454~75489820:-
LUAD	cis	rs4908768	0.539	rs1381928	ENSG00000232912.4	RP5-1115A15.1	5.42	9.2e-08	2.92e-05	0.22	0.24	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8630874	chr1:8424645~8434838:+
LUAD	cis	rs2115536	0.967	rs934137	ENSG00000278600.1	RP11-81A1.6	-5.42	9.2e-08	2.92e-05	-0.2	-0.24	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79919426	chr15:79920195~79922455:-
LUAD	cis	rs67311347	0.544	rs12633295	ENSG00000223797.4	ENTPD3-AS1	-5.42	9.21e-08	2.93e-05	-0.25	-0.24	Renal cell carcinoma;	chr3:40293801	chr3:40313802~40453329:-
LUAD	cis	rs12699921	0.632	rs2691552	ENSG00000279048.1	RP11-511H23.2	-5.42	9.21e-08	2.93e-05	-0.2	-0.24	Fibrinogen levels;	chr7:17884121	chr7:17940503~17942922:+
LUAD	cis	rs9487094	0.813	rs34131679	ENSG00000260273.1	RP11-425D10.10	5.42	9.21e-08	2.93e-05	0.34	0.24	Height;	chr6:109375848	chr6:109382795~109383666:+
LUAD	cis	rs270601	0.77	rs61352298	ENSG00000233006.5	AC034220.3	5.42	9.21e-08	2.93e-05	0.22	0.24	Acylcarnitine levels;	chr5:132264896	chr5:132311285~132369916:-
LUAD	cis	rs270601	0.739	rs1979981	ENSG00000233006.5	AC034220.3	5.42	9.21e-08	2.93e-05	0.22	0.24	Acylcarnitine levels;	chr5:132266027	chr5:132311285~132369916:-
LUAD	cis	rs270601	0.77	rs1007602	ENSG00000233006.5	AC034220.3	5.42	9.21e-08	2.93e-05	0.22	0.24	Acylcarnitine levels;	chr5:132266473	chr5:132311285~132369916:-
LUAD	cis	rs270601	0.71	rs4705852	ENSG00000233006.5	AC034220.3	5.42	9.21e-08	2.93e-05	0.22	0.24	Acylcarnitine levels;	chr5:132267114	chr5:132311285~132369916:-
LUAD	cis	rs897984	0.762	rs4889599	ENSG00000260911.2	RP11-196G11.2	-5.42	9.22e-08	2.93e-05	-0.21	-0.24	Dementia with Lewy bodies;	chr16:30957268	chr16:31043150~31049868:+
LUAD	cis	rs897984	0.721	rs2305884	ENSG00000260911.2	RP11-196G11.2	-5.42	9.22e-08	2.93e-05	-0.21	-0.24	Dementia with Lewy bodies;	chr16:30959420	chr16:31043150~31049868:+
LUAD	cis	rs7617773	0.78	rs3731489	ENSG00000228638.1	FCF1P2	-5.42	9.22e-08	2.93e-05	-0.29	-0.24	Coronary artery disease;	chr3:48187416	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.779	rs3731487	ENSG00000228638.1	FCF1P2	-5.42	9.22e-08	2.93e-05	-0.29	-0.24	Coronary artery disease;	chr3:48188134	chr3:48290793~48291375:-
LUAD	cis	rs394563	0.591	rs6570963	ENSG00000231760.4	RP11-350J20.5	-5.42	9.23e-08	2.93e-05	-0.3	-0.24	Dupuytren's disease;	chr6:149370219	chr6:149796151~149826294:-
LUAD	cis	rs2933343	0.679	rs789254	ENSG00000261159.1	RP11-723O4.9	5.42	9.24e-08	2.93e-05	0.26	0.24	IgG glycosylation;	chr3:128855750	chr3:128859716~128860526:-
LUAD	cis	rs11105298	0.891	rs12369685	ENSG00000258302.2	RP11-981P6.1	5.42	9.25e-08	2.94e-05	0.31	0.24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89535128	chr12:89561129~89594878:+
LUAD	cis	rs8072100	0.512	rs3809863	ENSG00000228782.6	CTD-2026D20.3	5.42	9.25e-08	2.94e-05	0.26	0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47307646	chr17:47450568~47492492:-
LUAD	cis	rs2455601	0.608	rs11042104	ENSG00000254860.4	TMEM9B-AS1	-5.42	9.26e-08	2.94e-05	-0.3	-0.24	Schizophrenia;	chr11:8869377	chr11:8964675~8977527:+
LUAD	cis	rs9595908	0.785	rs969703	ENSG00000212293.1	SNORA16	5.42	9.26e-08	2.94e-05	0.25	0.24	Body mass index;	chr13:32708264	chr13:32420390~32420516:-
LUAD	cis	rs2018683	0.6	rs6948880	ENSG00000228421.2	AC005013.5	5.42	9.27e-08	2.94e-05	0.27	0.24	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28963862	chr7:28957667~28959345:+
LUAD	cis	rs858239	0.6	rs6967475	ENSG00000230042.1	AK3P3	-5.42	9.27e-08	2.95e-05	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23089363	chr7:23129178~23129841:+
LUAD	cis	rs516805	0.528	rs2606633	ENSG00000279453.1	RP3-425C14.4	-5.42	9.28e-08	2.95e-05	-0.33	-0.24	Lymphocyte counts;	chr6:122100131	chr6:122436789~122439223:-
LUAD	cis	rs4568518	0.53	rs4721672	ENSG00000279048.1	RP11-511H23.2	5.42	9.28e-08	2.95e-05	0.2	0.24	Measles;	chr7:17946475	chr7:17940503~17942922:+
LUAD	cis	rs7122539	0.646	rs682842	ENSG00000213409.4	RP11-658F2.3	5.42	9.29e-08	2.95e-05	0.28	0.24	HIV-1 susceptibility;	chr11:66801472	chr11:66761575~66762399:-
LUAD	cis	rs2337406	1	rs10459466	ENSG00000211974.3	IGHV2-70	-5.42	9.29e-08	2.95e-05	-0.35	-0.24	Alzheimer's disease (late onset);	chr14:106689255	chr14:106723574~106724093:-
LUAD	cis	rs1113500	0.933	rs11185259	ENSG00000226822.1	RP11-356N1.2	-5.42	9.3e-08	2.95e-05	-0.28	-0.24	Growth-regulated protein alpha levels;	chr1:108092440	chr1:108071482~108074519:+
LUAD	cis	rs7208859	0.623	rs55811708	ENSG00000263603.1	CTD-2349P21.5	-5.42	9.3e-08	2.95e-05	-0.42	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30729469~30731202:+
LUAD	cis	rs853679	0.882	rs9380069	ENSG00000219392.1	RP1-265C24.5	-5.42	9.3e-08	2.95e-05	-0.4	-0.24	Depression;	chr6:28235522	chr6:28115628~28116551:+
LUAD	cis	rs673078	0.607	rs7309484	ENSG00000275409.1	RP11-131L12.4	-5.42	9.31e-08	2.96e-05	-0.33	-0.24	Glucose homeostasis traits;	chr12:118400833	chr12:118430147~118430699:+
LUAD	cis	rs7617773	0.78	rs77044321	ENSG00000228638.1	FCF1P2	-5.42	9.32e-08	2.96e-05	-0.29	-0.24	Coronary artery disease;	chr3:48307824	chr3:48290793~48291375:-
LUAD	cis	rs673078	0.66	rs9943819	ENSG00000275409.1	RP11-131L12.4	-5.42	9.33e-08	2.96e-05	-0.31	-0.24	Glucose homeostasis traits;	chr12:118298917	chr12:118430147~118430699:+
LUAD	cis	rs7617773	0.746	rs6796343	ENSG00000228638.1	FCF1P2	-5.42	9.33e-08	2.96e-05	-0.29	-0.24	Coronary artery disease;	chr3:48240531	chr3:48290793~48291375:-
LUAD	cis	rs801193	0.569	rs35070132	ENSG00000237310.1	GS1-124K5.4	5.42	9.33e-08	2.96e-05	0.26	0.24	Aortic root size;	chr7:66773096	chr7:66493706~66495474:+
LUAD	cis	rs2404602	0.692	rs12595586	ENSG00000259422.1	RP11-593F23.1	5.42	9.35e-08	2.97e-05	0.28	0.24	Blood metabolite levels;	chr15:76879869	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.692	rs58889902	ENSG00000259422.1	RP11-593F23.1	5.42	9.35e-08	2.97e-05	0.28	0.24	Blood metabolite levels;	chr15:76880729	chr15:76174891~76181486:-
LUAD	cis	rs11089937	0.597	rs4821772	ENSG00000211638.2	IGLV8-61	5.42	9.36e-08	2.97e-05	0.27	0.24	Periodontitis (PAL4Q3);	chr22:22131383	chr22:22098700~22099212:+
LUAD	cis	rs867371	1	rs7181655	ENSG00000259429.4	UBE2Q2P2	-5.42	9.37e-08	2.97e-05	-0.21	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163275	chr15:82355142~82420075:+
LUAD	cis	rs867371	1	rs7180584	ENSG00000259429.4	UBE2Q2P2	-5.42	9.37e-08	2.97e-05	-0.21	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163493	chr15:82355142~82420075:+
LUAD	cis	rs867371	1	rs6495642	ENSG00000259429.4	UBE2Q2P2	-5.42	9.37e-08	2.97e-05	-0.21	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82165156	chr15:82355142~82420075:+
LUAD	cis	rs875971	0.508	rs10950045	ENSG00000224316.1	RP11-479O9.2	-5.42	9.38e-08	2.98e-05	-0.24	-0.24	Aortic root size;	chr7:66601386	chr7:65773620~65802067:+
LUAD	cis	rs801193	0.839	rs6968619	ENSG00000224316.1	RP11-479O9.2	-5.42	9.38e-08	2.98e-05	-0.24	-0.24	Aortic root size;	chr7:66603880	chr7:65773620~65802067:+
LUAD	cis	rs4143844	0.867	rs11638455	ENSG00000259251.2	RP11-643M14.1	5.42	9.39e-08	2.98e-05	0.42	0.24	Bipolar disorder and schizophrenia;	chr15:61870969	chr15:62060503~62062434:+
LUAD	cis	rs150992	0.53	rs2927646	ENSG00000248489.1	CTD-2007H13.3	5.42	9.4e-08	2.98e-05	0.26	0.24	Body mass index;	chr5:98989462	chr5:98929171~98995013:+
LUAD	cis	rs11157436	0.958	rs61972229	ENSG00000211813.2	TRAV34	5.42	9.41e-08	2.98e-05	0.31	0.24	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22189754	chr14:22207522~22208129:+
LUAD	cis	rs11157436	0.958	rs17183301	ENSG00000211813.2	TRAV34	5.42	9.41e-08	2.98e-05	0.31	0.24	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22190003	chr14:22207522~22208129:+
LUAD	cis	rs10895987	0.531	rs11227118	ENSG00000254614.2	AP003068.23	5.42	9.41e-08	2.99e-05	0.32	0.24	Blood protein levels;	chr11:65093183	chr11:65177606~65181834:-
LUAD	cis	rs7804306	0.826	rs56073406	ENSG00000233264.2	AC006042.8	5.42	9.42e-08	2.99e-05	0.42	0.24	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7981025	chr7:7980312~7982228:+
LUAD	cis	rs9287719	0.649	rs12476554	ENSG00000243819.4	RN7SL832P	5.42	9.42e-08	2.99e-05	0.25	0.24	Prostate cancer;	chr2:10587621	chr2:10690344~10692099:+
LUAD	cis	rs7017914	0.69	rs62506036	ENSG00000223220.1	Y_RNA	5.42	9.42e-08	2.99e-05	0.28	0.24	Bone mineral density;	chr8:71066890	chr8:70780914~70781008:-
LUAD	cis	rs11976180	1	rs2371247	ENSG00000170356.8	OR2A20P	-5.42	9.43e-08	2.99e-05	-0.3	-0.24	Obesity-related traits;	chr7:144067086	chr7:144250045~144252957:-
LUAD	cis	rs1345301	0.587	rs12464251	ENSG00000234389.1	AC007278.3	-5.42	9.43e-08	2.99e-05	-0.23	-0.24	Waist circumference;	chr2:102250748	chr2:102438713~102440475:+
LUAD	cis	rs1345301	0.609	rs56389410	ENSG00000234389.1	AC007278.3	-5.42	9.43e-08	2.99e-05	-0.23	-0.24	Waist circumference;	chr2:102251203	chr2:102438713~102440475:+
LUAD	cis	rs6570726	0.935	rs432086	ENSG00000235652.6	RP11-545I5.3	-5.42	9.44e-08	2.99e-05	-0.24	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145520457	chr6:145799409~145886585:+
LUAD	cis	rs7617773	0.817	rs11130162	ENSG00000228638.1	FCF1P2	-5.42	9.44e-08	2.99e-05	-0.27	-0.24	Coronary artery disease;	chr3:48256121	chr3:48290793~48291375:-
LUAD	cis	rs9309711	0.736	rs13412581	ENSG00000225234.1	TRAPPC12-AS1	-5.42	9.44e-08	3e-05	-0.32	-0.24	Neurofibrillary tangles;	chr2:3493416	chr2:3481242~3482409:-
LUAD	cis	rs1799949	0.965	rs11080034	ENSG00000267681.1	CTD-3199J23.6	-5.42	9.44e-08	3e-05	-0.28	-0.24	Menopause (age at onset);	chr17:43365646	chr17:43144956~43145255:+
LUAD	cis	rs4722166	1	rs4722166	ENSG00000179428.2	AC073072.5	-5.42	9.45e-08	3e-05	-0.31	-0.24	Lung cancer;	chr7:22699143	chr7:22725395~22727620:-
LUAD	cis	rs1275468	0.731	rs1383098	ENSG00000257497.2	RP11-585P4.5	-5.42	9.45e-08	3e-05	-0.35	-0.24	Polycystic ovary syndrome;	chr12:75588107	chr12:75483454~75489820:-
LUAD	cis	rs9287719	0.649	rs6717431	ENSG00000243819.4	RN7SL832P	5.42	9.47e-08	3e-05	0.25	0.24	Prostate cancer;	chr2:10585920	chr2:10690344~10692099:+
LUAD	cis	rs7927592	0.731	rs10896350	ENSG00000212093.1	AP000807.1	5.42	9.48e-08	3.01e-05	0.25	0.24	Total body bone mineral density;	chr11:68618905	chr11:68506083~68506166:-
LUAD	cis	rs853679	0.628	rs9368560	ENSG00000219392.1	RP1-265C24.5	-5.42	9.49e-08	3.01e-05	-0.35	-0.24	Depression;	chr6:28192182	chr6:28115628~28116551:+
LUAD	cis	rs2404602	0.608	rs12911035	ENSG00000259422.1	RP11-593F23.1	5.42	9.49e-08	3.01e-05	0.27	0.24	Blood metabolite levels;	chr15:76314250	chr15:76174891~76181486:-
LUAD	cis	rs858239	0.932	rs1637190	ENSG00000226816.2	AC005082.12	5.42	9.49e-08	3.01e-05	0.31	0.24	Cerebrospinal fluid biomarker levels;	chr7:23229446	chr7:23206013~23208045:+
LUAD	cis	rs36093844	0.848	rs2084079	ENSG00000279742.1	RP11-700A24.1	-5.42	9.5e-08	3.01e-05	-0.29	-0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85879393	chr11:85852557~85854943:-
LUAD	cis	rs1320333	0.772	rs2903491	ENSG00000233296.1	AC092159.2	5.42	9.5e-08	3.01e-05	0.43	0.24	Obesity-related traits;	chr2:686688	chr2:677186~697371:+
LUAD	cis	rs72615157	0.634	rs11762932	ENSG00000242294.5	STAG3L5P	-5.42	9.5e-08	3.01e-05	-0.21	-0.24	Lung function (FEV1/FVC);	chr7:100195043	chr7:100336079~100351900:+
LUAD	cis	rs2404602	0.735	rs4886493	ENSG00000259422.1	RP11-593F23.1	-5.42	9.5e-08	3.01e-05	-0.31	-0.24	Blood metabolite levels;	chr15:76386685	chr15:76174891~76181486:-
LUAD	cis	rs35740288	0.929	rs11556865	ENSG00000202081.1	RNU6-1280P	5.42	9.5e-08	3.01e-05	0.3	0.24	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85759949	chr15:85651522~85651628:-
LUAD	cis	rs9487094	0.961	rs12528822	ENSG00000260273.1	RP11-425D10.10	5.42	9.5e-08	3.01e-05	0.32	0.24	Height;	chr6:109340338	chr6:109382795~109383666:+
LUAD	cis	rs7927592	0.763	rs1193699	ENSG00000212093.1	AP000807.1	5.42	9.5e-08	3.01e-05	0.25	0.24	Total body bone mineral density;	chr11:68482012	chr11:68506083~68506166:-
LUAD	cis	rs2243480	0.522	rs1638736	ENSG00000232546.1	RP11-458F8.1	-5.42	9.51e-08	3.01e-05	-0.36	-0.24	Diabetic kidney disease;	chr7:66627321	chr7:66848496~66858136:+
LUAD	cis	rs783540	0.5	rs1313494	ENSG00000278603.1	RP13-608F4.5	-5.42	9.51e-08	3.01e-05	-0.31	-0.24	Schizophrenia;	chr15:82605530	chr15:82472203~82472426:+
LUAD	cis	rs7430456	0.901	rs9824206	ENSG00000228221.4	LINC00578	5.42	9.51e-08	3.01e-05	0.28	0.24	Breast cancer;	chr3:177742093	chr3:177441921~177752305:+
LUAD	cis	rs6142102	0.625	rs6141431	ENSG00000275784.1	RP5-1125A11.6	-5.42	9.51e-08	3.01e-05	-0.26	-0.24	Skin pigmentation;	chr20:33952508	chr20:33989480~33991818:-
LUAD	cis	rs948562	0.519	rs7112590	ENSG00000280010.1	AP001350.4	5.42	9.51e-08	3.01e-05	0.34	0.24	Lymphoma;	chr11:58276151	chr11:58627435~58628528:+
LUAD	cis	rs10091374	0.874	rs28507404	ENSG00000253967.1	RP11-333A23.4	-5.42	9.52e-08	3.02e-05	-0.27	-0.24	Cardiac Troponin-T levels;	chr8:70474169	chr8:70471134~70485687:+
LUAD	cis	rs6890270	1	rs6890270	ENSG00000271828.1	CTD-2310F14.1	5.42	9.52e-08	3.02e-05	0.35	0.24	Breast cancer;	chr5:56964779	chr5:56927874~56929573:+
LUAD	cis	rs66887589	0.934	rs12648182	ENSG00000245958.5	RP11-33B1.1	5.42	9.53e-08	3.02e-05	0.19	0.24	Diastolic blood pressure;	chr4:119582736	chr4:119454791~119552025:+
LUAD	cis	rs7804306	0.826	rs6975218	ENSG00000233264.2	AC006042.8	5.42	9.53e-08	3.02e-05	0.42	0.24	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7981982	chr7:7980312~7982228:+
LUAD	cis	rs2742234	0.59	rs2505506	ENSG00000273008.1	RP11-351D16.3	-5.42	9.53e-08	3.02e-05	-0.27	-0.24	Hirschsprung disease;	chr10:43150406	chr10:43136824~43138334:-
LUAD	cis	rs2732480	0.577	rs2732457	ENSG00000257735.1	RP11-370I10.6	-5.42	9.54e-08	3.02e-05	-0.3	-0.24	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48364596	chr12:48350945~48442411:+
LUAD	cis	rs812925	0.512	rs7558954	ENSG00000271889.1	RP11-493E12.1	5.42	9.54e-08	3.02e-05	0.28	0.24	Immature fraction of reticulocytes;	chr2:61157771	chr2:61151433~61162105:-
LUAD	cis	rs7617773	0.746	rs4371540	ENSG00000228638.1	FCF1P2	-5.42	9.55e-08	3.03e-05	-0.29	-0.24	Coronary artery disease;	chr3:48312053	chr3:48290793~48291375:-
LUAD	cis	rs9287719	0.578	rs10175555	ENSG00000243819.4	RN7SL832P	5.42	9.57e-08	3.03e-05	0.26	0.24	Prostate cancer;	chr2:10563107	chr2:10690344~10692099:+
LUAD	cis	rs2288884	0.767	rs12462359	ENSG00000275055.1	CTC-471J1.11	-5.42	9.57e-08	3.03e-05	-0.33	-0.24	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52032168	chr19:52049007~52049754:+
LUAD	cis	rs2288884	0.767	rs12460118	ENSG00000275055.1	CTC-471J1.11	-5.42	9.57e-08	3.03e-05	-0.33	-0.24	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52032550	chr19:52049007~52049754:+
LUAD	cis	rs643506	0.817	rs1940392	ENSG00000230911.1	PPIHP1	-5.42	9.57e-08	3.03e-05	-0.3	-0.24	Breast cancer;	chr11:111906122	chr11:112029858~112030367:-
LUAD	cis	rs11976180	1	rs2951354	ENSG00000170356.8	OR2A20P	-5.42	9.57e-08	3.03e-05	-0.3	-0.24	Obesity-related traits;	chr7:144063908	chr7:144250045~144252957:-
LUAD	cis	rs11976180	1	rs2961125	ENSG00000170356.8	OR2A20P	-5.42	9.57e-08	3.03e-05	-0.3	-0.24	Obesity-related traits;	chr7:144064677	chr7:144250045~144252957:-
LUAD	cis	rs11976180	1	rs2961126	ENSG00000170356.8	OR2A20P	-5.42	9.57e-08	3.03e-05	-0.3	-0.24	Obesity-related traits;	chr7:144065643	chr7:144250045~144252957:-
LUAD	cis	rs11976180	0.953	rs2961127	ENSG00000170356.8	OR2A20P	-5.42	9.57e-08	3.03e-05	-0.3	-0.24	Obesity-related traits;	chr7:144065644	chr7:144250045~144252957:-
LUAD	cis	rs11976180	1	rs1919948	ENSG00000170356.8	OR2A20P	-5.42	9.57e-08	3.03e-05	-0.3	-0.24	Obesity-related traits;	chr7:144065750	chr7:144250045~144252957:-
LUAD	cis	rs807029	0.577	rs11190786	ENSG00000272572.1	RP11-179B2.2	-5.42	9.57e-08	3.03e-05	-0.34	-0.24	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100997685	chr10:100911103~100912739:-
LUAD	cis	rs807029	0.577	rs7902510	ENSG00000272572.1	RP11-179B2.2	-5.42	9.57e-08	3.03e-05	-0.34	-0.24	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100998177	chr10:100911103~100912739:-
LUAD	cis	rs807029	0.577	rs7903239	ENSG00000272572.1	RP11-179B2.2	-5.42	9.57e-08	3.03e-05	-0.34	-0.24	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100998580	chr10:100911103~100912739:-
LUAD	cis	rs2790457	0.917	rs1265831	ENSG00000254635.4	WAC-AS1	-5.42	9.58e-08	3.04e-05	-0.26	-0.24	Multiple myeloma;	chr10:28623921	chr10:28522652~28532743:-
LUAD	cis	rs4604732	0.536	rs12049066	ENSG00000227135.1	GCSAML-AS1	-5.42	9.59e-08	3.04e-05	-0.37	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247479353	chr1:247524679~247526752:-
LUAD	cis	rs10129255	0.518	rs8010020	ENSG00000254174.1	IGHV1-12	5.42	9.59e-08	3.04e-05	0.16	0.24	Kawasaki disease;	chr14:106778016	chr14:106122420~106122709:-
LUAD	cis	rs10129255	0.5	rs6576225	ENSG00000254174.1	IGHV1-12	5.42	9.59e-08	3.04e-05	0.16	0.24	Kawasaki disease;	chr14:106778120	chr14:106122420~106122709:-
LUAD	cis	rs10129255	0.5	rs6576226	ENSG00000254174.1	IGHV1-12	5.42	9.59e-08	3.04e-05	0.16	0.24	Kawasaki disease;	chr14:106778135	chr14:106122420~106122709:-
LUAD	cis	rs12468226	0.873	rs3181153	ENSG00000272966.1	RP11-686O6.1	-5.42	9.59e-08	3.04e-05	-0.4	-0.24	Urate levels;	chr2:202205155	chr2:202336739~202337200:+
LUAD	cis	rs10800713	0.954	rs6673474	ENSG00000260088.1	RP11-92G12.3	-5.42	9.6e-08	3.04e-05	-0.34	-0.24	Tandem gait;	chr1:200594991	chr1:200669507~200694250:+
LUAD	cis	rs2919009	0.882	rs2919008	ENSG00000271670.1	RP11-95I16.4	5.42	9.6e-08	3.04e-05	0.31	0.24	Obesity-related traits;	chr10:120838163	chr10:120879256~120880667:-
LUAD	cis	rs17684571	0.7	rs61601344	ENSG00000231441.1	RP11-472M19.2	5.42	9.6e-08	3.04e-05	0.34	0.24	Schizophrenia;	chr6:56797356	chr6:56844002~56864078:+
LUAD	cis	rs3738443	0.817	rs61840052	ENSG00000259865.1	RP11-488L18.10	5.42	9.61e-08	3.04e-05	0.25	0.24	Alcohol dependence;	chr1:247204036	chr1:247187281~247188526:-
LUAD	cis	rs4366055	1	rs4366055	ENSG00000253704.1	RP11-267M23.4	5.42	9.61e-08	3.04e-05	0.3	0.24	Body mass index;	chr8:94495100	chr8:94553722~94569745:+
LUAD	cis	rs11976180	1	rs2951308	ENSG00000170356.8	OR2A20P	5.42	9.61e-08	3.04e-05	0.3	0.24	Obesity-related traits;	chr7:144070056	chr7:144250045~144252957:-
LUAD	cis	rs10091374	0.736	rs7460301	ENSG00000253967.1	RP11-333A23.4	-5.42	9.61e-08	3.04e-05	-0.27	-0.24	Cardiac Troponin-T levels;	chr8:70474130	chr8:70471134~70485687:+
LUAD	cis	rs7176527	0.747	rs28363946	ENSG00000188388.10	GOLGA6L3	5.42	9.63e-08	3.05e-05	0.35	0.24	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84829244	chr15:85240472~85247170:+
LUAD	cis	rs516805	0.64	rs55768410	ENSG00000279453.1	RP3-425C14.4	5.42	9.63e-08	3.05e-05	0.32	0.24	Lymphocyte counts;	chr6:122358588	chr6:122436789~122439223:-
LUAD	cis	rs80028505	0.908	rs56413204	ENSG00000271304.1	DPRXP2	5.42	9.64e-08	3.05e-05	0.49	0.24	Foot ulcer in diabetes and neuropathy;	chr6:36037125	chr6:35989515~35990436:-
LUAD	cis	rs4835473	0.864	rs56084830	ENSG00000251600.4	RP11-673E1.1	-5.42	9.64e-08	3.05e-05	-0.3	-0.24	Immature fraction of reticulocytes;	chr4:143791943	chr4:143912331~143982454:+
LUAD	cis	rs17826219	0.706	rs8075357	ENSG00000263603.1	CTD-2349P21.5	-5.42	9.65e-08	3.05e-05	-0.41	-0.24	Body mass index;	chr17:30730179	chr17:30729469~30731202:+
LUAD	cis	rs17826219	0.706	rs61643715	ENSG00000263603.1	CTD-2349P21.5	-5.42	9.65e-08	3.05e-05	-0.41	-0.24	Body mass index;	chr17:30730744	chr17:30729469~30731202:+
LUAD	cis	rs17826219	0.636	rs8080829	ENSG00000263603.1	CTD-2349P21.5	-5.42	9.65e-08	3.05e-05	-0.41	-0.24	Body mass index;	chr17:30731712	chr17:30729469~30731202:+
LUAD	cis	rs80028505	0.808	rs61195139	ENSG00000271304.1	DPRXP2	5.42	9.65e-08	3.06e-05	0.49	0.24	Foot ulcer in diabetes and neuropathy;	chr6:36078449	chr6:35989515~35990436:-
LUAD	cis	rs80028505	0.908	rs7748078	ENSG00000271304.1	DPRXP2	5.42	9.65e-08	3.06e-05	0.49	0.24	Foot ulcer in diabetes and neuropathy;	chr6:36080233	chr6:35989515~35990436:-
LUAD	cis	rs80028505	0.71	rs80032177	ENSG00000271304.1	DPRXP2	5.42	9.65e-08	3.06e-05	0.49	0.24	Foot ulcer in diabetes and neuropathy;	chr6:36081939	chr6:35989515~35990436:-
LUAD	cis	rs9287719	0.614	rs12329184	ENSG00000243819.4	RN7SL832P	5.42	9.66e-08	3.06e-05	0.25	0.24	Prostate cancer;	chr2:10582638	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.614	rs10929681	ENSG00000243819.4	RN7SL832P	5.42	9.66e-08	3.06e-05	0.25	0.24	Prostate cancer;	chr2:10583157	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.614	rs6711473	ENSG00000243819.4	RN7SL832P	5.42	9.66e-08	3.06e-05	0.25	0.24	Prostate cancer;	chr2:10583248	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.624	rs10211190	ENSG00000243819.4	RN7SL832P	5.42	9.66e-08	3.06e-05	0.25	0.24	Prostate cancer;	chr2:10585302	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.649	rs10166765	ENSG00000243819.4	RN7SL832P	5.42	9.66e-08	3.06e-05	0.25	0.24	Prostate cancer;	chr2:10585547	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.649	rs6720112	ENSG00000243819.4	RN7SL832P	5.42	9.66e-08	3.06e-05	0.25	0.24	Prostate cancer;	chr2:10585593	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.649	rs6730247	ENSG00000243819.4	RN7SL832P	5.42	9.66e-08	3.06e-05	0.25	0.24	Prostate cancer;	chr2:10585762	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.6	rs10197187	ENSG00000243819.4	RN7SL832P	5.42	9.66e-08	3.06e-05	0.25	0.24	Prostate cancer;	chr2:10586513	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.624	rs10199635	ENSG00000243819.4	RN7SL832P	5.42	9.66e-08	3.06e-05	0.25	0.24	Prostate cancer;	chr2:10586514	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.624	rs10199831	ENSG00000243819.4	RN7SL832P	5.42	9.66e-08	3.06e-05	0.25	0.24	Prostate cancer;	chr2:10586737	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.624	rs10187659	ENSG00000243819.4	RN7SL832P	5.42	9.66e-08	3.06e-05	0.25	0.24	Prostate cancer;	chr2:10586834	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.649	rs10202370	ENSG00000243819.4	RN7SL832P	5.42	9.66e-08	3.06e-05	0.25	0.24	Prostate cancer;	chr2:10586917	chr2:10690344~10692099:+
LUAD	cis	rs13256369	0.951	rs12679360	ENSG00000253893.2	FAM85B	5.42	9.66e-08	3.06e-05	0.33	0.24	Obesity-related traits;	chr8:8708759	chr8:8167819~8226614:-
LUAD	cis	rs453301	0.624	rs6987558	ENSG00000173295.6	FAM86B3P	5.42	9.69e-08	3.07e-05	0.26	0.24	Joint mobility (Beighton score);	chr8:9005011	chr8:8228595~8244865:+
LUAD	cis	rs889398	0.933	rs6499240	ENSG00000226232.7	RP11-419C5.2	-5.42	9.69e-08	3.07e-05	-0.21	-0.24	Body mass index;	chr16:69653009	chr16:69976388~69996188:-
LUAD	cis	rs73219805	0.671	rs13267955	ENSG00000228451.3	SDAD1P1	-5.41	9.7e-08	3.07e-05	-0.36	-0.24	Schizophrenia;	chr8:26367077	chr8:26379259~26382953:-
LUAD	cis	rs2015599	0.525	rs10743656	ENSG00000275476.1	RP11-996F15.4	5.41	9.71e-08	3.07e-05	0.26	0.24	Platelet count;Mean platelet volume;	chr12:29332516	chr12:29277397~29277882:-
LUAD	cis	rs1318937	0.764	rs2129945	ENSG00000224660.1	SH3BP5-AS1	5.41	9.71e-08	3.07e-05	0.18	0.24	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15197706	chr3:15254184~15264493:+
LUAD	cis	rs748404	0.697	rs1814323	ENSG00000249839.1	AC011330.5	5.41	9.71e-08	3.07e-05	0.31	0.24	Lung cancer;	chr15:43271039	chr15:43663654~43684339:-
LUAD	cis	rs2688608	0.592	rs12253482	ENSG00000271816.1	BMS1P4	5.41	9.71e-08	3.07e-05	0.2	0.24	Inflammatory bowel disease;	chr10:73736372	chr10:73699151~73730487:-
LUAD	cis	rs35740288	0.822	rs2241268	ENSG00000202081.1	RNU6-1280P	5.41	9.72e-08	3.07e-05	0.31	0.24	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85735078	chr15:85651522~85651628:-
LUAD	cis	rs997295	0.675	rs12912974	ENSG00000270964.1	RP11-502I4.3	-5.41	9.72e-08	3.07e-05	-0.25	-0.24	Motion sickness;	chr15:67682041	chr15:67541072~67542604:-
LUAD	cis	rs997295	0.713	rs8042567	ENSG00000270964.1	RP11-502I4.3	-5.41	9.72e-08	3.07e-05	-0.25	-0.24	Motion sickness;	chr15:67683261	chr15:67541072~67542604:-
LUAD	cis	rs80028505	0.908	rs73730459	ENSG00000271304.1	DPRXP2	5.41	9.72e-08	3.07e-05	0.48	0.24	Foot ulcer in diabetes and neuropathy;	chr6:36117226	chr6:35989515~35990436:-
LUAD	cis	rs1318937	0.679	rs9310471	ENSG00000224660.1	SH3BP5-AS1	5.41	9.72e-08	3.08e-05	0.18	0.24	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15195342	chr3:15254184~15264493:+
LUAD	cis	rs7299940	0.967	rs9738957	ENSG00000256299.1	RP11-989F5.3	5.41	9.73e-08	3.08e-05	0.26	0.24	Panic disorder;	chr12:130904256	chr12:130810821~130812622:-
LUAD	cis	rs1275468	0.731	rs1679384	ENSG00000257497.2	RP11-585P4.5	-5.41	9.73e-08	3.08e-05	-0.36	-0.24	Polycystic ovary syndrome;	chr12:75567552	chr12:75483454~75489820:-
LUAD	cis	rs875971	0.66	rs801217	ENSG00000237310.1	GS1-124K5.4	-5.41	9.74e-08	3.08e-05	-0.26	-0.24	Aortic root size;	chr7:66545590	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.638	rs801216	ENSG00000237310.1	GS1-124K5.4	-5.41	9.74e-08	3.08e-05	-0.26	-0.24	Aortic root size;	chr7:66546680	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.66	rs801211	ENSG00000237310.1	GS1-124K5.4	-5.41	9.74e-08	3.08e-05	-0.26	-0.24	Aortic root size;	chr7:66550702	chr7:66493706~66495474:+
LUAD	cis	rs853679	0.546	rs200949	ENSG00000219392.1	RP1-265C24.5	-5.41	9.74e-08	3.08e-05	-0.44	-0.24	Depression;	chr6:27867657	chr6:28115628~28116551:+
LUAD	cis	rs732716	0.853	rs1127888	ENSG00000267980.1	AC007292.6	-5.41	9.74e-08	3.08e-05	-0.28	-0.24	Mean corpuscular volume;	chr19:4454086	chr19:4363789~4364640:+
LUAD	cis	rs732716	0.853	rs12459922	ENSG00000267980.1	AC007292.6	-5.41	9.74e-08	3.08e-05	-0.28	-0.24	Mean corpuscular volume;	chr19:4455865	chr19:4363789~4364640:+
LUAD	cis	rs925255	0.817	rs12624279	ENSG00000270210.1	RP11-373D23.3	-5.41	9.75e-08	3.08e-05	-0.29	-0.24	Inflammatory bowel disease;Crohn's disease;	chr2:28411923	chr2:28425945~28426719:+
LUAD	cis	rs997295	0.713	rs12905509	ENSG00000270964.1	RP11-502I4.3	-5.41	9.75e-08	3.08e-05	-0.25	-0.24	Motion sickness;	chr15:67701770	chr15:67541072~67542604:-
LUAD	cis	rs11105298	0.891	rs10858881	ENSG00000258302.2	RP11-981P6.1	5.41	9.76e-08	3.08e-05	0.3	0.24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89497697	chr12:89561129~89594878:+
LUAD	cis	rs7662987	0.793	rs78790289	ENSG00000272777.1	RP11-571L19.8	5.41	9.76e-08	3.09e-05	0.38	0.24	Smoking initiation;	chr4:99066736	chr4:99067256~99068125:-
LUAD	cis	rs1275468	0.68	rs1697753	ENSG00000257497.2	RP11-585P4.5	-5.41	9.77e-08	3.09e-05	-0.37	-0.24	Polycystic ovary syndrome;	chr12:75562074	chr12:75483454~75489820:-
LUAD	cis	rs6125961	0.629	rs6125971	ENSG00000224397.4	LINC01272	5.41	9.77e-08	3.09e-05	0.29	0.24	Granulocyte percentage of myeloid white cells;Monocyte count;	chr20:50299229	chr20:50267486~50279795:+
LUAD	cis	rs1707322	0.963	rs6429581	ENSG00000234329.1	RP11-767N6.2	5.41	9.77e-08	3.09e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853424	chr1:45651039~45651826:-
LUAD	cis	rs180730	0.561	rs2892917	ENSG00000251609.2	SETP12	-5.41	9.77e-08	3.09e-05	-0.3	-0.24	Fasting plasma glucose;	chr4:120898600	chr4:120895494~120897083:-
LUAD	cis	rs2880765	0.835	rs7180213	ENSG00000259295.5	CSPG4P12	5.41	9.78e-08	3.09e-05	0.27	0.24	Coronary artery disease;	chr15:85477956	chr15:85191438~85213905:+
LUAD	cis	rs8072100	0.967	rs4239162	ENSG00000228782.6	CTD-2026D20.3	5.41	9.78e-08	3.09e-05	0.25	0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47678444	chr17:47450568~47492492:-
LUAD	cis	rs8072100	0.967	rs4239163	ENSG00000228782.6	CTD-2026D20.3	5.41	9.78e-08	3.09e-05	0.25	0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47678588	chr17:47450568~47492492:-
LUAD	cis	rs2880765	0.835	rs4842886	ENSG00000259295.5	CSPG4P12	5.41	9.79e-08	3.1e-05	0.27	0.24	Coronary artery disease;	chr15:85492542	chr15:85191438~85213905:+
LUAD	cis	rs2880765	0.835	rs4842887	ENSG00000259295.5	CSPG4P12	5.41	9.79e-08	3.1e-05	0.27	0.24	Coronary artery disease;	chr15:85492579	chr15:85191438~85213905:+
LUAD	cis	rs950169	0.922	rs62029585	ENSG00000259295.5	CSPG4P12	5.41	9.8e-08	3.1e-05	0.35	0.24	Schizophrenia;	chr15:84397176	chr15:85191438~85213905:+
LUAD	cis	rs6570726	0.935	rs12663204	ENSG00000235652.6	RP11-545I5.3	5.41	9.8e-08	3.1e-05	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145497237	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs12663205	ENSG00000235652.6	RP11-545I5.3	5.41	9.8e-08	3.1e-05	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145497242	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs12663211	ENSG00000235652.6	RP11-545I5.3	5.41	9.8e-08	3.1e-05	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145497291	chr6:145799409~145886585:+
LUAD	cis	rs4835473	0.662	rs4340756	ENSG00000251600.4	RP11-673E1.1	5.41	9.81e-08	3.1e-05	0.29	0.24	Immature fraction of reticulocytes;	chr4:144017063	chr4:143912331~143982454:+
LUAD	cis	rs12701220	0.655	rs7799656	ENSG00000229043.2	AC091729.9	-5.41	9.81e-08	3.1e-05	-0.3	-0.24	Bronchopulmonary dysplasia;	chr7:1100879	chr7:1160374~1165267:+
LUAD	cis	rs11976180	1	rs2961119	ENSG00000170356.8	OR2A20P	-5.41	9.83e-08	3.1e-05	-0.3	-0.24	Obesity-related traits;	chr7:144058759	chr7:144250045~144252957:-
LUAD	cis	rs10761482	0.5	rs1938538	ENSG00000254271.1	RP11-131N11.4	5.41	9.83e-08	3.11e-05	0.27	0.24	Schizophrenia;	chr10:60538475	chr10:60734342~60741828:+
LUAD	cis	rs10761482	0.5	rs7080540	ENSG00000254271.1	RP11-131N11.4	5.41	9.83e-08	3.11e-05	0.27	0.24	Schizophrenia;	chr10:60538828	chr10:60734342~60741828:+
LUAD	cis	rs6570726	0.935	rs372378	ENSG00000235652.6	RP11-545I5.3	5.41	9.83e-08	3.11e-05	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145495091	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.905	rs388728	ENSG00000235652.6	RP11-545I5.3	5.41	9.83e-08	3.11e-05	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145495283	chr6:145799409~145886585:+
LUAD	cis	rs910316	1	rs8017642	ENSG00000259138.1	RP11-950C14.7	5.41	9.83e-08	3.11e-05	0.26	0.24	Height;	chr14:75124119	chr14:75127153~75136930:+
LUAD	cis	rs801193	0.844	rs732465	ENSG00000237310.1	GS1-124K5.4	5.41	9.86e-08	3.12e-05	0.25	0.24	Aortic root size;	chr7:66533463	chr7:66493706~66495474:+
LUAD	cis	rs7662987	0.793	rs12697	ENSG00000272777.1	RP11-571L19.8	-5.41	9.86e-08	3.12e-05	-0.37	-0.24	Smoking initiation;	chr4:99072225	chr4:99067256~99068125:-
LUAD	cis	rs7911264	1	rs10786052	ENSG00000236493.2	EIF2S2P3	5.41	9.87e-08	3.12e-05	0.26	0.24	Inflammatory bowel disease;	chr10:92686878	chr10:92668745~92669743:-
LUAD	cis	rs858239	0.669	rs10950940	ENSG00000226816.2	AC005082.12	-5.41	9.88e-08	3.12e-05	-0.31	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23157197	chr7:23206013~23208045:+
LUAD	cis	rs12468226	0.873	rs59293950	ENSG00000272966.1	RP11-686O6.1	5.41	9.88e-08	3.12e-05	0.42	0.24	Urate levels;	chr2:202214069	chr2:202336739~202337200:+
LUAD	cis	rs2599510	0.807	rs176416	ENSG00000276334.1	AL133243.1	-5.41	9.88e-08	3.12e-05	-0.27	-0.24	Interleukin-18 levels;	chr2:32427155	chr2:32521927~32523547:+
LUAD	cis	rs7617773	0.78	rs34523942	ENSG00000228638.1	FCF1P2	-5.41	9.88e-08	3.12e-05	-0.28	-0.24	Coronary artery disease;	chr3:48301179	chr3:48290793~48291375:-
LUAD	cis	rs1862618	0.525	rs832403	ENSG00000271828.1	CTD-2310F14.1	-5.41	9.9e-08	3.12e-05	-0.37	-0.24	Initial pursuit acceleration;	chr5:56970165	chr5:56927874~56929573:+
LUAD	cis	rs7712401	0.56	rs13168225	ENSG00000263432.2	RN7SL689P	-5.41	9.9e-08	3.12e-05	-0.32	-0.24	Mean platelet volume;	chr5:123011569	chr5:123022487~123022783:-
LUAD	cis	rs2919009	0.544	rs12267610	ENSG00000271670.1	RP11-95I16.4	5.41	9.9e-08	3.13e-05	0.3	0.24	Obesity-related traits;	chr10:120851275	chr10:120879256~120880667:-
LUAD	cis	rs673078	0.607	rs7958551	ENSG00000275409.1	RP11-131L12.4	-5.41	9.91e-08	3.13e-05	-0.33	-0.24	Glucose homeostasis traits;	chr12:118442585	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs7958652	ENSG00000275409.1	RP11-131L12.4	-5.41	9.91e-08	3.13e-05	-0.33	-0.24	Glucose homeostasis traits;	chr12:118442630	chr12:118430147~118430699:+
LUAD	cis	rs6543140	0.964	rs4851578	ENSG00000234389.1	AC007278.3	5.41	9.91e-08	3.13e-05	0.24	0.24	Blood protein levels;	chr2:102412491	chr2:102438713~102440475:+
LUAD	cis	rs9813712	0.526	rs13065659	ENSG00000228252.7	COL6A4P2	-5.41	9.91e-08	3.13e-05	-0.23	-0.24	Response to amphetamines;	chr3:130231945	chr3:130212823~130273806:+
LUAD	cis	rs4835473	0.932	rs7683686	ENSG00000251600.4	RP11-673E1.1	-5.41	9.91e-08	3.13e-05	-0.27	-0.24	Immature fraction of reticulocytes;	chr4:143784352	chr4:143912331~143982454:+
LUAD	cis	rs8031584	0.56	rs1056118	ENSG00000260382.1	RP11-540B6.2	-5.41	9.92e-08	3.13e-05	-0.27	-0.24	Huntington's disease progression;	chr15:30911583	chr15:30882267~30883231:-
LUAD	cis	rs17711722	0.701	rs781145	ENSG00000164669.11	INTS4P1	-5.41	9.92e-08	3.13e-05	-0.29	-0.24	Calcium levels;	chr7:65975383	chr7:65141225~65234216:+
LUAD	cis	rs72634501	0.568	rs590214	ENSG00000228060.1	RP11-69E11.8	-5.41	9.94e-08	3.14e-05	-0.22	-0.24	HDL cholesterol;	chr1:39146821	chr1:39565160~39573203:+
LUAD	cis	rs2832077	1	rs9983229	ENSG00000232855.5	AF131217.1	-5.41	9.94e-08	3.14e-05	-0.27	-0.24	Cognitive test performance;	chr21:28765352	chr21:28439346~28674848:-
LUAD	cis	rs2404602	0.692	rs59088060	ENSG00000259422.1	RP11-593F23.1	5.41	9.94e-08	3.14e-05	0.28	0.24	Blood metabolite levels;	chr15:76567633	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.716	rs12902174	ENSG00000259422.1	RP11-593F23.1	5.41	9.94e-08	3.14e-05	0.28	0.24	Blood metabolite levels;	chr15:76571199	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.716	rs12438077	ENSG00000259422.1	RP11-593F23.1	5.41	9.94e-08	3.14e-05	0.28	0.24	Blood metabolite levels;	chr15:76571260	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.716	rs12441550	ENSG00000259422.1	RP11-593F23.1	5.41	9.94e-08	3.14e-05	0.28	0.24	Blood metabolite levels;	chr15:76571341	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.716	rs1874944	ENSG00000259422.1	RP11-593F23.1	5.41	9.94e-08	3.14e-05	0.28	0.24	Blood metabolite levels;	chr15:76571587	chr15:76174891~76181486:-
LUAD	cis	rs1075265	0.73	rs4413193	ENSG00000233266.1	HMGB1P31	5.41	9.95e-08	3.14e-05	0.31	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53710901	chr2:54051334~54051760:+
LUAD	cis	rs9652601	0.691	rs3893661	ENSG00000274038.1	RP11-66H6.4	-5.41	9.96e-08	3.14e-05	-0.29	-0.24	Systemic lupus erythematosus;	chr16:11100023	chr16:11056556~11057034:+
LUAD	cis	rs2562456	0.917	rs2650804	ENSG00000268081.1	RP11-678G14.2	5.41	9.96e-08	3.14e-05	0.36	0.24	Pain;	chr19:21497382	chr19:21554640~21569237:-
LUAD	cis	rs2980439	0.87	rs2945230	ENSG00000173295.6	FAM86B3P	5.41	9.96e-08	3.14e-05	0.25	0.24	Neuroticism;	chr8:8252414	chr8:8228595~8244865:+
LUAD	cis	rs11976180	1	rs2951353	ENSG00000170356.8	OR2A20P	-5.41	9.96e-08	3.14e-05	-0.3	-0.24	Obesity-related traits;	chr7:144064023	chr7:144250045~144252957:-
LUAD	cis	rs896854	0.654	rs13274945	ENSG00000253528.2	RP11-347C18.4	5.41	9.96e-08	3.14e-05	0.23	0.24	Type 2 diabetes;	chr8:94974398	chr8:94974573~94974853:-
LUAD	cis	rs1707322	0.752	rs4660880	ENSG00000280836.1	AL355480.1	-5.41	9.96e-08	3.14e-05	-0.32	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645368	chr1:45581219~45581321:-
LUAD	cis	rs2933343	1	rs1680790	ENSG00000261159.1	RP11-723O4.9	5.41	9.96e-08	3.14e-05	0.29	0.24	IgG glycosylation;	chr3:128907010	chr3:128859716~128860526:-
LUAD	cis	rs2933343	1	rs876755	ENSG00000261159.1	RP11-723O4.9	5.41	9.96e-08	3.14e-05	0.29	0.24	IgG glycosylation;	chr3:128909090	chr3:128859716~128860526:-
LUAD	cis	rs10800713	0.954	rs6660637	ENSG00000260088.1	RP11-92G12.3	-5.41	9.97e-08	3.15e-05	-0.35	-0.24	Tandem gait;	chr1:200550893	chr1:200669507~200694250:+
LUAD	cis	rs10800713	0.954	rs10737572	ENSG00000260088.1	RP11-92G12.3	-5.41	9.97e-08	3.15e-05	-0.35	-0.24	Tandem gait;	chr1:200552003	chr1:200669507~200694250:+
LUAD	cis	rs3931020	0.626	rs277402	ENSG00000272864.1	RP11-17E13.2	5.41	9.98e-08	3.15e-05	0.34	0.24	Resistin levels;	chr1:74722637	chr1:74698769~74699333:-
LUAD	cis	rs964184	0.63	rs2160669	ENSG00000254851.1	RP11-109L13.1	-5.41	9.98e-08	3.15e-05	-0.5	-0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116776891	chr11:117135528~117138582:+
LUAD	cis	rs7617773	0.78	rs35411187	ENSG00000228638.1	FCF1P2	-5.41	9.99e-08	3.15e-05	-0.29	-0.24	Coronary artery disease;	chr3:48318527	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.78	rs11714176	ENSG00000228638.1	FCF1P2	-5.41	9.99e-08	3.15e-05	-0.29	-0.24	Coronary artery disease;	chr3:48319372	chr3:48290793~48291375:-
LUAD	cis	rs7927592	0.763	rs624003	ENSG00000212093.1	AP000807.1	5.41	9.99e-08	3.15e-05	0.25	0.24	Total body bone mineral density;	chr11:68463772	chr11:68506083~68506166:-
LUAD	cis	rs1061377	0.965	rs12504238	ENSG00000249685.1	RP11-360F5.3	5.41	1e-07	3.15e-05	0.3	0.24	Uric acid levels;	chr4:39142824	chr4:39133913~39135608:+
LUAD	cis	rs6142102	0.58	rs9753679	ENSG00000275784.1	RP5-1125A11.6	-5.41	1e-07	3.15e-05	-0.26	-0.24	Skin pigmentation;	chr20:33953054	chr20:33989480~33991818:-
LUAD	cis	rs11673344	0.642	rs73025481	ENSG00000226686.6	LINC01535	5.41	1e-07	3.15e-05	0.31	0.24	Obesity-related traits;	chr19:37346437	chr19:37251912~37265535:+
LUAD	cis	rs2404602	0.669	rs12438540	ENSG00000259422.1	RP11-593F23.1	5.41	1e-07	3.16e-05	0.28	0.24	Blood metabolite levels;	chr15:76650872	chr15:76174891~76181486:-
LUAD	cis	rs17684571	0.7	rs17752002	ENSG00000231441.1	RP11-472M19.2	5.41	1e-07	3.16e-05	0.35	0.24	Schizophrenia;	chr6:56812209	chr6:56844002~56864078:+
LUAD	cis	rs10129255	0.957	rs1024349	ENSG00000224373.3	IGHV4-59	5.41	1e-07	3.16e-05	0.16	0.24	Kawasaki disease;	chr14:106689997	chr14:106627249~106627825:-
LUAD	cis	rs1707322	0.717	rs1972410	ENSG00000280836.1	AL355480.1	-5.41	1e-07	3.16e-05	-0.32	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615275	chr1:45581219~45581321:-
LUAD	cis	rs9928842	0.765	rs6564220	ENSG00000280152.1	RP11-331F4.5	5.41	1e-07	3.16e-05	0.28	0.24	Alcoholic chronic pancreatitis;	chr16:75190296	chr16:75245994~75250077:-
LUAD	cis	rs2404602	0.698	rs12909656	ENSG00000259422.1	RP11-593F23.1	-5.41	1e-07	3.17e-05	-0.31	-0.24	Blood metabolite levels;	chr15:76372037	chr15:76174891~76181486:-
LUAD	cis	rs10800713	0.862	rs7533417	ENSG00000260088.1	RP11-92G12.3	-5.41	1e-07	3.17e-05	-0.35	-0.24	Tandem gait;	chr1:200558177	chr1:200669507~200694250:+
LUAD	cis	rs10800713	0.826	rs6427834	ENSG00000260088.1	RP11-92G12.3	-5.41	1e-07	3.17e-05	-0.35	-0.24	Tandem gait;	chr1:200561936	chr1:200669507~200694250:+
LUAD	cis	rs2404602	0.692	rs4442773	ENSG00000259422.1	RP11-593F23.1	5.41	1.01e-07	3.17e-05	0.28	0.24	Blood metabolite levels;	chr15:76739292	chr15:76174891~76181486:-
LUAD	cis	rs4604732	0.527	rs7539082	ENSG00000227135.1	GCSAML-AS1	-5.41	1.01e-07	3.17e-05	-0.37	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463958	chr1:247524679~247526752:-
LUAD	cis	rs516805	0.528	rs2606637	ENSG00000279453.1	RP3-425C14.4	-5.41	1.01e-07	3.18e-05	-0.32	-0.24	Lymphocyte counts;	chr6:122101832	chr6:122436789~122439223:-
LUAD	cis	rs948562	0.519	rs55983896	ENSG00000280010.1	AP001350.4	5.41	1.01e-07	3.18e-05	0.34	0.24	Lymphoma;	chr11:58291866	chr11:58627435~58628528:+
LUAD	cis	rs4141404	0.512	rs1018490	ENSG00000236132.1	CTA-440B3.1	-5.41	1.01e-07	3.18e-05	-0.28	-0.24	Paclitaxel-induced neuropathy;	chr22:31600639	chr22:31816379~31817491:-
LUAD	cis	rs6543140	0.964	rs4851593	ENSG00000234389.1	AC007278.3	-5.41	1.01e-07	3.18e-05	-0.24	-0.24	Blood protein levels;	chr2:102472767	chr2:102438713~102440475:+
LUAD	cis	rs11157436	0.958	rs2204963	ENSG00000211813.2	TRAV34	5.41	1.01e-07	3.18e-05	0.31	0.24	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22187871	chr14:22207522~22208129:+
LUAD	cis	rs916888	0.773	rs199448	ENSG00000261575.2	RP11-259G18.1	5.41	1.01e-07	3.18e-05	0.37	0.24	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46267037~46268694:+
LUAD	cis	rs812925	0.533	rs60997156	ENSG00000271889.1	RP11-493E12.1	5.41	1.01e-07	3.19e-05	0.29	0.24	Immature fraction of reticulocytes;	chr2:61169404	chr2:61151433~61162105:-
LUAD	cis	rs35740288	0.822	rs4843090	ENSG00000202081.1	RNU6-1280P	5.41	1.01e-07	3.19e-05	0.3	0.24	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85677398	chr15:85651522~85651628:-
LUAD	cis	rs4964805	1	rs11111791	ENSG00000257681.1	RP11-341G23.4	5.41	1.01e-07	3.19e-05	0.3	0.24	Attention deficit hyperactivity disorder;	chr12:103799493	chr12:103746315~103768858:-
LUAD	cis	rs8100891	0.734	rs741445	ENSG00000267213.4	AC007773.2	-5.41	1.01e-07	3.19e-05	-0.29	-0.24	Neuroticism;	chr19:32345686	chr19:32390050~32405560:-
LUAD	cis	rs867371	1	rs1174543	ENSG00000259429.4	UBE2Q2P2	5.41	1.01e-07	3.19e-05	0.21	0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82155732	chr15:82355142~82420075:+
LUAD	cis	rs4664293	0.967	rs13020365	ENSG00000226266.5	AC009961.3	-5.41	1.01e-07	3.2e-05	-0.33	-0.24	Monocyte percentage of white cells;	chr2:159619893	chr2:159670708~159712435:-
LUAD	cis	rs812925	0.533	rs35507645	ENSG00000271889.1	RP11-493E12.1	5.41	1.01e-07	3.2e-05	0.29	0.24	Immature fraction of reticulocytes;	chr2:61169631	chr2:61151433~61162105:-
LUAD	cis	rs10129255	0.957	rs12590735	ENSG00000211974.3	IGHV2-70	5.41	1.02e-07	3.2e-05	0.25	0.24	Kawasaki disease;	chr14:106779660	chr14:106723574~106724093:-
LUAD	cis	rs55665837	0.54	rs10128681	ENSG00000251991.1	RNU7-49P	5.41	1.02e-07	3.2e-05	0.27	0.24	Vitamin D levels;	chr11:14680030	chr11:14478892~14478953:+
LUAD	cis	rs55665837	0.54	rs7938266	ENSG00000251991.1	RNU7-49P	5.41	1.02e-07	3.2e-05	0.27	0.24	Vitamin D levels;	chr11:14687778	chr11:14478892~14478953:+
LUAD	cis	rs9992667	0.955	rs28664852	ENSG00000231160.8	KLF3-AS1	5.41	1.02e-07	3.2e-05	0.3	0.24	Eosinophil percentage of granulocytes;	chr4:38644479	chr4:38612701~38664883:-
LUAD	cis	rs7968440	1	rs2731443	ENSG00000200428.1	Y_RNA	-5.41	1.02e-07	3.2e-05	-0.3	-0.24	Fibrinogen;	chr12:50700355	chr12:50743568~50743684:+
LUAD	cis	rs853679	0.527	rs9461443	ENSG00000204709.4	LINC01556	5.41	1.02e-07	3.2e-05	0.32	0.24	Depression;	chr6:28226851	chr6:28943877~28944537:+
LUAD	cis	rs2836950	0.561	rs34705151	ENSG00000255568.3	BRWD1-AS2	-5.41	1.02e-07	3.2e-05	-0.23	-0.24	Menarche (age at onset);	chr21:39181418	chr21:39313935~39314962:+
LUAD	cis	rs6772849	1	rs2712373	ENSG00000242551.2	POU5F1P6	-5.41	1.02e-07	3.21e-05	-0.27	-0.24	Monocyte percentage of white cells;Monocyte count;	chr3:128589212	chr3:128674735~128677005:-
LUAD	cis	rs6772849	1	rs2734037	ENSG00000242551.2	POU5F1P6	-5.41	1.02e-07	3.21e-05	-0.27	-0.24	Monocyte percentage of white cells;Monocyte count;	chr3:128590041	chr3:128674735~128677005:-
LUAD	cis	rs6772849	0.965	rs67790930	ENSG00000242551.2	POU5F1P6	-5.41	1.02e-07	3.21e-05	-0.27	-0.24	Monocyte percentage of white cells;Monocyte count;	chr3:128591193	chr3:128674735~128677005:-
LUAD	cis	rs6772849	0.965	rs4286447	ENSG00000242551.2	POU5F1P6	-5.41	1.02e-07	3.21e-05	-0.27	-0.24	Monocyte percentage of white cells;Monocyte count;	chr3:128591746	chr3:128674735~128677005:-
LUAD	cis	rs7618501	0.573	rs2624824	ENSG00000234667.1	ACTBP13	5.41	1.02e-07	3.21e-05	0.26	0.24	Intelligence (multi-trait analysis);	chr3:50050833	chr3:49873347~49877980:-
LUAD	cis	rs1707322	0.752	rs6662164	ENSG00000280836.1	AL355480.1	-5.41	1.02e-07	3.21e-05	-0.32	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680558	chr1:45581219~45581321:-
LUAD	cis	rs9646944	0.519	rs1041973	ENSG00000234389.1	AC007278.3	-5.41	1.02e-07	3.21e-05	-0.24	-0.24	Blood protein levels;	chr2:102339008	chr2:102438713~102440475:+
LUAD	cis	rs67311347	0.544	rs6804545	ENSG00000223797.4	ENTPD3-AS1	5.41	1.02e-07	3.21e-05	0.25	0.24	Renal cell carcinoma;	chr3:40312549	chr3:40313802~40453329:-
LUAD	cis	rs67311347	1	rs9332450	ENSG00000223797.4	ENTPD3-AS1	-5.41	1.02e-07	3.21e-05	-0.25	-0.24	Renal cell carcinoma;	chr3:40416550	chr3:40313802~40453329:-
LUAD	cis	rs2836950	0.565	rs3171465	ENSG00000255568.3	BRWD1-AS2	-5.41	1.02e-07	3.21e-05	-0.23	-0.24	Menarche (age at onset);	chr21:39180381	chr21:39313935~39314962:+
LUAD	cis	rs2404602	0.669	rs8036703	ENSG00000259422.1	RP11-593F23.1	5.41	1.02e-07	3.21e-05	0.28	0.24	Blood metabolite levels;	chr15:76658699	chr15:76174891~76181486:-
LUAD	cis	rs875971	0.66	rs2013222	ENSG00000237310.1	GS1-124K5.4	-5.41	1.02e-07	3.21e-05	-0.25	-0.24	Aortic root size;	chr7:66570949	chr7:66493706~66495474:+
LUAD	cis	rs1275468	0.731	rs1630753	ENSG00000257497.2	RP11-585P4.5	-5.4	1.02e-07	3.22e-05	-0.36	-0.24	Polycystic ovary syndrome;	chr12:75569518	chr12:75483454~75489820:-
LUAD	cis	rs7017914	0.69	rs4623462	ENSG00000223220.1	Y_RNA	-5.4	1.02e-07	3.22e-05	-0.28	-0.24	Bone mineral density;	chr8:71034149	chr8:70780914~70781008:-
LUAD	cis	rs7617773	0.78	rs3731550	ENSG00000228638.1	FCF1P2	-5.4	1.02e-07	3.22e-05	-0.29	-0.24	Coronary artery disease;	chr3:48165093	chr3:48290793~48291375:-
LUAD	cis	rs2404602	0.692	rs36070630	ENSG00000259422.1	RP11-593F23.1	5.4	1.02e-07	3.22e-05	0.28	0.24	Blood metabolite levels;	chr15:76656918	chr15:76174891~76181486:-
LUAD	cis	rs55665837	0.54	rs11023302	ENSG00000251991.1	RNU7-49P	5.4	1.02e-07	3.22e-05	0.27	0.24	Vitamin D levels;	chr11:14672389	chr11:14478892~14478953:+
LUAD	cis	rs4604732	0.631	rs75600450	ENSG00000227135.1	GCSAML-AS1	-5.4	1.02e-07	3.22e-05	-0.37	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247462190	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.631	rs74154672	ENSG00000227135.1	GCSAML-AS1	-5.4	1.02e-07	3.22e-05	-0.37	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247462323	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.631	rs74154673	ENSG00000227135.1	GCSAML-AS1	-5.4	1.02e-07	3.22e-05	-0.37	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247462327	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.678	rs74154674	ENSG00000227135.1	GCSAML-AS1	-5.4	1.02e-07	3.22e-05	-0.37	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247462383	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.631	rs11490198	ENSG00000227135.1	GCSAML-AS1	-5.4	1.02e-07	3.22e-05	-0.37	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247462401	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.631	rs11490199	ENSG00000227135.1	GCSAML-AS1	-5.4	1.02e-07	3.22e-05	-0.37	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247462435	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.631	rs74154675	ENSG00000227135.1	GCSAML-AS1	-5.4	1.02e-07	3.22e-05	-0.37	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247462534	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.631	rs74154676	ENSG00000227135.1	GCSAML-AS1	-5.4	1.02e-07	3.22e-05	-0.37	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247462592	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.631	rs11490200	ENSG00000227135.1	GCSAML-AS1	-5.4	1.02e-07	3.22e-05	-0.37	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247462613	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.631	rs56704806	ENSG00000227135.1	GCSAML-AS1	-5.4	1.02e-07	3.22e-05	-0.37	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247462846	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.588	rs74154678	ENSG00000227135.1	GCSAML-AS1	-5.4	1.02e-07	3.22e-05	-0.37	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247462900	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.631	rs11490201	ENSG00000227135.1	GCSAML-AS1	-5.4	1.02e-07	3.22e-05	-0.37	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247462960	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.589	rs78689516	ENSG00000227135.1	GCSAML-AS1	-5.4	1.02e-07	3.22e-05	-0.37	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247462972	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.631	rs76761880	ENSG00000227135.1	GCSAML-AS1	-5.4	1.02e-07	3.22e-05	-0.37	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463075	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.536	rs78019731	ENSG00000227135.1	GCSAML-AS1	-5.4	1.02e-07	3.22e-05	-0.37	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463128	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.527	rs77361748	ENSG00000227135.1	GCSAML-AS1	-5.4	1.02e-07	3.22e-05	-0.37	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463173	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.527	rs79329288	ENSG00000227135.1	GCSAML-AS1	-5.4	1.02e-07	3.22e-05	-0.37	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463211	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.578	rs79203328	ENSG00000227135.1	GCSAML-AS1	-5.4	1.02e-07	3.22e-05	-0.37	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463279	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.631	rs75320597	ENSG00000227135.1	GCSAML-AS1	-5.4	1.02e-07	3.22e-05	-0.37	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463449	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.631	rs35046441	ENSG00000227135.1	GCSAML-AS1	-5.4	1.02e-07	3.22e-05	-0.37	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463510	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.631	rs80319072	ENSG00000227135.1	GCSAML-AS1	-5.4	1.02e-07	3.22e-05	-0.37	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463533	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.631	rs34330532	ENSG00000227135.1	GCSAML-AS1	-5.4	1.02e-07	3.22e-05	-0.37	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463542	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.631	rs10925043	ENSG00000227135.1	GCSAML-AS1	-5.4	1.02e-07	3.22e-05	-0.37	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463699	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.631	rs10925044	ENSG00000227135.1	GCSAML-AS1	-5.4	1.02e-07	3.22e-05	-0.37	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463769	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.631	rs10802509	ENSG00000227135.1	GCSAML-AS1	-5.4	1.02e-07	3.22e-05	-0.37	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463856	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.631	rs7546720	ENSG00000227135.1	GCSAML-AS1	-5.4	1.02e-07	3.22e-05	-0.37	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463927	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.578	rs7525209	ENSG00000227135.1	GCSAML-AS1	-5.4	1.02e-07	3.22e-05	-0.37	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247464102	chr1:247524679~247526752:-
LUAD	cis	rs11976180	1	rs2961118	ENSG00000170356.8	OR2A20P	-5.4	1.02e-07	3.22e-05	-0.3	-0.24	Obesity-related traits;	chr7:144058350	chr7:144250045~144252957:-
LUAD	cis	rs673078	0.607	rs7967900	ENSG00000275409.1	RP11-131L12.4	5.4	1.02e-07	3.22e-05	0.33	0.24	Glucose homeostasis traits;	chr12:118381902	chr12:118430147~118430699:+
LUAD	cis	rs7580658	0.676	rs58475809	ENSG00000236682.1	AC068282.3	-5.4	1.03e-07	3.23e-05	-0.31	-0.24	Protein C levels;	chr2:127245074	chr2:127389130~127400580:+
LUAD	cis	rs11051970	0.559	rs11051928	ENSG00000274964.1	RP11-817I4.1	-5.4	1.03e-07	3.23e-05	-0.31	-0.24	Response to tocilizumab in rheumatoid arthritis;	chr12:32319580	chr12:32339368~32340724:+
LUAD	cis	rs11051970	0.559	rs11051929	ENSG00000274964.1	RP11-817I4.1	-5.4	1.03e-07	3.23e-05	-0.31	-0.24	Response to tocilizumab in rheumatoid arthritis;	chr12:32319617	chr12:32339368~32340724:+
LUAD	cis	rs11051970	0.592	rs58926489	ENSG00000274964.1	RP11-817I4.1	-5.4	1.03e-07	3.23e-05	-0.31	-0.24	Response to tocilizumab in rheumatoid arthritis;	chr12:32319949	chr12:32339368~32340724:+
LUAD	cis	rs11051970	0.592	rs58236386	ENSG00000274964.1	RP11-817I4.1	-5.4	1.03e-07	3.23e-05	-0.31	-0.24	Response to tocilizumab in rheumatoid arthritis;	chr12:32320143	chr12:32339368~32340724:+
LUAD	cis	rs11051970	0.559	rs11051932	ENSG00000274964.1	RP11-817I4.1	-5.4	1.03e-07	3.23e-05	-0.31	-0.24	Response to tocilizumab in rheumatoid arthritis;	chr12:32320701	chr12:32339368~32340724:+
LUAD	cis	rs801193	1	rs10252765	ENSG00000237310.1	GS1-124K5.4	5.4	1.03e-07	3.23e-05	0.26	0.24	Aortic root size;	chr7:66763745	chr7:66493706~66495474:+
LUAD	cis	rs301901	0.698	rs4869505	ENSG00000250155.1	CTD-2353F22.1	5.4	1.03e-07	3.23e-05	0.25	0.24	Height;	chr5:37425888	chr5:36666214~36725195:-
LUAD	cis	rs9287719	0.649	rs12618726	ENSG00000243819.4	RN7SL832P	5.4	1.03e-07	3.23e-05	0.25	0.24	Prostate cancer;	chr2:10588249	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.649	rs6714787	ENSG00000243819.4	RN7SL832P	5.4	1.03e-07	3.23e-05	0.25	0.24	Prostate cancer;	chr2:10588906	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.649	rs2024432	ENSG00000243819.4	RN7SL832P	5.4	1.03e-07	3.23e-05	0.25	0.24	Prostate cancer;	chr2:10591348	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.649	rs2024433	ENSG00000243819.4	RN7SL832P	5.4	1.03e-07	3.23e-05	0.25	0.24	Prostate cancer;	chr2:10591378	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.649	rs12104950	ENSG00000243819.4	RN7SL832P	5.4	1.03e-07	3.23e-05	0.25	0.24	Prostate cancer;	chr2:10591979	chr2:10690344~10692099:+
LUAD	cis	rs964184	0.688	rs1558860	ENSG00000254851.1	RP11-109L13.1	-5.4	1.03e-07	3.23e-05	-0.51	-0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116736652	chr11:117135528~117138582:+
LUAD	cis	rs964184	0.63	rs1558861	ENSG00000254851.1	RP11-109L13.1	-5.4	1.03e-07	3.23e-05	-0.51	-0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116736721	chr11:117135528~117138582:+
LUAD	cis	rs4835473	0.932	rs1450250	ENSG00000251600.4	RP11-673E1.1	5.4	1.03e-07	3.23e-05	0.3	0.24	Immature fraction of reticulocytes;	chr4:143731873	chr4:143912331~143982454:+
LUAD	cis	rs10129255	0.5	rs6576232	ENSG00000211967.3	IGHV3-53	-5.4	1.03e-07	3.24e-05	-0.17	-0.24	Kawasaki disease;	chr14:106787090	chr14:106592676~106593347:-
LUAD	cis	rs10754283	0.934	rs6428563	ENSG00000231613.1	RP5-943J3.1	5.4	1.03e-07	3.24e-05	0.24	0.24	Amyotrophic lateral sclerosis (sporadic);	chr1:89646024	chr1:89788914~89790492:+
LUAD	cis	rs7968440	0.933	rs2684889	ENSG00000200428.1	Y_RNA	-5.4	1.03e-07	3.24e-05	-0.3	-0.24	Fibrinogen;	chr12:50686091	chr12:50743568~50743684:+
LUAD	cis	rs7968440	1	rs2700482	ENSG00000200428.1	Y_RNA	-5.4	1.03e-07	3.24e-05	-0.3	-0.24	Fibrinogen;	chr12:50689482	chr12:50743568~50743684:+
LUAD	cis	rs8081395	0.576	rs1292032	ENSG00000266992.1	DHX40P1	5.4	1.03e-07	3.24e-05	0.28	0.24	White blood cell count;	chr17:59914982	chr17:59976009~60002384:-
LUAD	cis	rs4664293	1	rs13014418	ENSG00000226266.5	AC009961.3	-5.4	1.03e-07	3.24e-05	-0.33	-0.24	Monocyte percentage of white cells;	chr2:159627174	chr2:159670708~159712435:-
LUAD	cis	rs944990	0.597	rs61707921	ENSG00000227603.1	RP11-165J3.6	5.4	1.03e-07	3.24e-05	0.27	0.24	Body mass index;	chr9:93475813	chr9:93435332~93437121:-
LUAD	cis	rs11157436	0.958	rs17183356	ENSG00000211813.2	TRAV34	5.4	1.03e-07	3.24e-05	0.32	0.24	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22219101	chr14:22207522~22208129:+
LUAD	cis	rs7017914	0.652	rs11992027	ENSG00000223220.1	Y_RNA	5.4	1.03e-07	3.24e-05	0.27	0.24	Bone mineral density;	chr8:70776635	chr8:70780914~70781008:-
LUAD	cis	rs4964805	0.586	rs934846	ENSG00000257681.1	RP11-341G23.4	5.4	1.03e-07	3.25e-05	0.25	0.24	Attention deficit hyperactivity disorder;	chr12:103791519	chr12:103746315~103768858:-
LUAD	cis	rs12468226	0.873	rs12472035	ENSG00000272966.1	RP11-686O6.1	5.4	1.03e-07	3.25e-05	0.42	0.24	Urate levels;	chr2:202221970	chr2:202336739~202337200:+
LUAD	cis	rs4947019	0.609	rs2275649	ENSG00000260273.1	RP11-425D10.10	5.4	1.03e-07	3.25e-05	0.53	0.24	Hematological parameters;	chr6:109370125	chr6:109382795~109383666:+
LUAD	cis	rs2599510	0.811	rs2243844	ENSG00000276334.1	AL133243.1	5.4	1.03e-07	3.25e-05	0.27	0.24	Interleukin-18 levels;	chr2:32550917	chr2:32521927~32523547:+
LUAD	cis	rs783540	0.542	rs62009945	ENSG00000276710.3	CSPG4P8	5.4	1.03e-07	3.25e-05	0.25	0.24	Schizophrenia;	chr15:82631205	chr15:82459472~82477258:+
LUAD	cis	rs10129255	0.5	rs34326748	ENSG00000211967.3	IGHV3-53	-5.4	1.03e-07	3.25e-05	-0.17	-0.24	Kawasaki disease;	chr14:106782523	chr14:106592676~106593347:-
LUAD	cis	rs10129255	0.5	rs10143385	ENSG00000211967.3	IGHV3-53	-5.4	1.03e-07	3.25e-05	-0.17	-0.24	Kawasaki disease;	chr14:106782559	chr14:106592676~106593347:-
LUAD	cis	rs2562456	0.917	rs6511253	ENSG00000268081.1	RP11-678G14.2	-5.4	1.04e-07	3.26e-05	-0.35	-0.24	Pain;	chr19:21495996	chr19:21554640~21569237:-
LUAD	cis	rs2018683	0.624	rs6462119	ENSG00000228421.2	AC005013.5	5.4	1.04e-07	3.26e-05	0.27	0.24	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28964109	chr7:28957667~28959345:+
LUAD	cis	rs113835537	1	rs113835537	ENSG00000255517.5	CTD-3074O7.5	-5.4	1.04e-07	3.26e-05	-0.33	-0.24	Airway imaging phenotypes;	chr11:66572168	chr11:66473490~66480233:-
LUAD	cis	rs2836950	0.545	rs2836922	ENSG00000255568.3	BRWD1-AS2	-5.4	1.04e-07	3.26e-05	-0.24	-0.24	Menarche (age at onset);	chr21:39144382	chr21:39313935~39314962:+
LUAD	cis	rs997295	0.713	rs12904982	ENSG00000270964.1	RP11-502I4.3	-5.4	1.04e-07	3.26e-05	-0.25	-0.24	Motion sickness;	chr15:67713941	chr15:67541072~67542604:-
LUAD	cis	rs9341808	0.556	rs1535075	ENSG00000272129.1	RP11-250B2.6	5.4	1.04e-07	3.26e-05	0.3	0.24	Sitting height ratio;	chr6:80325089	chr6:80355424~80356859:+
LUAD	cis	rs7804306	1	rs715377	ENSG00000233264.2	AC006042.8	5.4	1.04e-07	3.27e-05	0.39	0.24	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7980303	chr7:7980312~7982228:+
LUAD	cis	rs3738443	0.868	rs35229190	ENSG00000259865.1	RP11-488L18.10	5.4	1.04e-07	3.27e-05	0.25	0.24	Alcohol dependence;	chr1:247202339	chr1:247187281~247188526:-
LUAD	cis	rs2790457	0.958	rs2807754	ENSG00000254635.4	WAC-AS1	-5.4	1.04e-07	3.27e-05	-0.26	-0.24	Multiple myeloma;	chr10:28598263	chr10:28522652~28532743:-
LUAD	cis	rs10754283	0.967	rs7546410	ENSG00000231613.1	RP5-943J3.1	5.4	1.04e-07	3.27e-05	0.24	0.24	Amyotrophic lateral sclerosis (sporadic);	chr1:89644256	chr1:89788914~89790492:+
LUAD	cis	rs12468226	1	rs115170232	ENSG00000226261.1	AC064836.3	5.4	1.04e-07	3.27e-05	0.38	0.24	Urate levels;	chr2:202416790	chr2:202336024~202336727:-
LUAD	cis	rs12468226	1	rs16839149	ENSG00000226261.1	AC064836.3	5.4	1.04e-07	3.27e-05	0.38	0.24	Urate levels;	chr2:202427621	chr2:202336024~202336727:-
LUAD	cis	rs4835473	0.932	rs34950821	ENSG00000251600.4	RP11-673E1.1	-5.4	1.04e-07	3.27e-05	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143738174	chr4:143912331~143982454:+
LUAD	cis	rs11651753	0.561	rs60580012	ENSG00000264920.1	RP11-6N17.4	-5.4	1.04e-07	3.27e-05	-0.29	-0.24	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47892442	chr17:47891255~47895812:-
LUAD	cis	rs11651753	0.561	rs61422354	ENSG00000264920.1	RP11-6N17.4	-5.4	1.04e-07	3.27e-05	-0.29	-0.24	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47892443	chr17:47891255~47895812:-
LUAD	cis	rs858239	0.601	rs6969733	ENSG00000230042.1	AK3P3	-5.4	1.04e-07	3.27e-05	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23128758	chr7:23129178~23129841:+
LUAD	cis	rs4908768	0.539	rs6675443	ENSG00000232912.4	RP5-1115A15.1	5.4	1.04e-07	3.27e-05	0.22	0.24	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8591523	chr1:8424645~8434838:+
LUAD	cis	rs944289	0.553	rs1169135	ENSG00000257826.1	RP11-116N8.4	-5.4	1.04e-07	3.27e-05	-0.27	-0.24	Thyroid cancer;	chr14:36155696	chr14:36061026~36067190:-
LUAD	cis	rs2933343	1	rs789237	ENSG00000261159.1	RP11-723O4.9	5.4	1.04e-07	3.27e-05	0.29	0.24	IgG glycosylation;	chr3:128918118	chr3:128859716~128860526:-
LUAD	cis	rs6570726	0.935	rs422540	ENSG00000235652.6	RP11-545I5.3	5.4	1.04e-07	3.27e-05	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145516679	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs409121	ENSG00000235652.6	RP11-545I5.3	5.4	1.04e-07	3.27e-05	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145518657	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs380883	ENSG00000235652.6	RP11-545I5.3	5.4	1.04e-07	3.28e-05	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145501856	chr6:145799409~145886585:+
LUAD	cis	rs516805	0.665	rs517427	ENSG00000279453.1	RP3-425C14.4	-5.4	1.04e-07	3.28e-05	-0.32	-0.24	Lymphocyte counts;	chr6:122291180	chr6:122436789~122439223:-
LUAD	cis	rs8031584	0.697	rs8036176	ENSG00000259845.1	HERC2P10	5.4	1.04e-07	3.28e-05	0.29	0.24	Huntington's disease progression;	chr15:30883066	chr15:30815271~30844153:+
LUAD	cis	rs35160687	0.712	rs12052607	ENSG00000273080.1	RP11-301O19.1	-5.4	1.04e-07	3.28e-05	-0.27	-0.24	Night sleep phenotypes;	chr2:86279394	chr2:86195590~86196049:+
LUAD	cis	rs35160687	0.712	rs1863059	ENSG00000273080.1	RP11-301O19.1	-5.4	1.04e-07	3.28e-05	-0.27	-0.24	Night sleep phenotypes;	chr2:86282265	chr2:86195590~86196049:+
LUAD	cis	rs807029	0.577	rs3740489	ENSG00000272572.1	RP11-179B2.2	-5.4	1.05e-07	3.28e-05	-0.34	-0.24	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100994481	chr10:100911103~100912739:-
LUAD	cis	rs17666538	0.792	rs1979174	ENSG00000254207.1	RP11-43A14.1	5.4	1.05e-07	3.28e-05	0.5	0.24	IgG glycosylation;	chr8:642274	chr8:725188~725877:-
LUAD	cis	rs9952991	0.941	rs34920518	ENSG00000260302.1	RP11-973H7.1	5.4	1.05e-07	3.29e-05	0.45	0.24	Inflammatory skin disease;	chr18:12783087	chr18:12774651~12775923:-
LUAD	cis	rs755249	0.835	rs4660877	ENSG00000228060.1	RP11-69E11.8	-5.4	1.05e-07	3.29e-05	-0.24	-0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39613574	chr1:39565160~39573203:+
LUAD	cis	rs4664293	1	rs6432540	ENSG00000226266.5	AC009961.3	-5.4	1.05e-07	3.29e-05	-0.33	-0.24	Monocyte percentage of white cells;	chr2:159594192	chr2:159670708~159712435:-
LUAD	cis	rs858239	0.6	rs61292332	ENSG00000230042.1	AK3P3	-5.4	1.05e-07	3.3e-05	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23092243	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.6	rs59073109	ENSG00000230042.1	AK3P3	-5.4	1.05e-07	3.3e-05	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23093607	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.6	rs7788821	ENSG00000230042.1	AK3P3	-5.4	1.05e-07	3.3e-05	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23094026	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.6	rs6956595	ENSG00000230042.1	AK3P3	-5.4	1.05e-07	3.3e-05	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23094637	chr7:23129178~23129841:+
LUAD	cis	rs10050311	0.932	rs55670248	ENSG00000251411.1	RP11-397E7.4	-5.4	1.05e-07	3.3e-05	-0.35	-0.24	Insulin-related traits;	chr4:86804830	chr4:86913266~86914817:-
LUAD	cis	rs9287719	0.601	rs9287718	ENSG00000243819.4	RN7SL832P	-5.4	1.05e-07	3.3e-05	-0.25	-0.24	Prostate cancer;	chr2:10561503	chr2:10690344~10692099:+
LUAD	cis	rs9847710	0.67	rs36051354	ENSG00000242142.1	SERBP1P3	5.4	1.05e-07	3.3e-05	0.27	0.24	Ulcerative colitis;	chr3:52951996	chr3:53064283~53065091:-
LUAD	cis	rs10754283	0.905	rs7519969	ENSG00000231613.1	RP5-943J3.1	5.4	1.05e-07	3.3e-05	0.24	0.24	Amyotrophic lateral sclerosis (sporadic);	chr1:89643162	chr1:89788914~89790492:+
LUAD	cis	rs10754283	0.967	rs7519971	ENSG00000231613.1	RP5-943J3.1	5.4	1.05e-07	3.3e-05	0.24	0.24	Amyotrophic lateral sclerosis (sporadic);	chr1:89643184	chr1:89788914~89790492:+
LUAD	cis	rs10754283	0.967	rs7515375	ENSG00000231613.1	RP5-943J3.1	5.4	1.05e-07	3.3e-05	0.24	0.24	Amyotrophic lateral sclerosis (sporadic);	chr1:89644295	chr1:89788914~89790492:+
LUAD	cis	rs10754283	0.901	rs6663526	ENSG00000231613.1	RP5-943J3.1	5.4	1.05e-07	3.3e-05	0.24	0.24	Amyotrophic lateral sclerosis (sporadic);	chr1:89645303	chr1:89788914~89790492:+
LUAD	cis	rs10754283	0.934	rs7529653	ENSG00000231613.1	RP5-943J3.1	5.4	1.05e-07	3.3e-05	0.24	0.24	Amyotrophic lateral sclerosis (sporadic);	chr1:89646292	chr1:89788914~89790492:+
LUAD	cis	rs10754283	0.87	rs2390764	ENSG00000231613.1	RP5-943J3.1	5.4	1.05e-07	3.3e-05	0.24	0.24	Amyotrophic lateral sclerosis (sporadic);	chr1:89647268	chr1:89788914~89790492:+
LUAD	cis	rs10754283	0.901	rs4520403	ENSG00000231613.1	RP5-943J3.1	5.4	1.05e-07	3.3e-05	0.24	0.24	Amyotrophic lateral sclerosis (sporadic);	chr1:89647281	chr1:89788914~89790492:+
LUAD	cis	rs10754283	0.967	rs4658130	ENSG00000231613.1	RP5-943J3.1	5.4	1.05e-07	3.3e-05	0.24	0.24	Amyotrophic lateral sclerosis (sporadic);	chr1:89647888	chr1:89788914~89790492:+
LUAD	cis	rs10754283	0.934	rs10754284	ENSG00000231613.1	RP5-943J3.1	5.4	1.05e-07	3.3e-05	0.24	0.24	Amyotrophic lateral sclerosis (sporadic);	chr1:89648143	chr1:89788914~89790492:+
LUAD	cis	rs10754283	0.967	rs10801759	ENSG00000231613.1	RP5-943J3.1	5.4	1.05e-07	3.3e-05	0.24	0.24	Amyotrophic lateral sclerosis (sporadic);	chr1:89648186	chr1:89788914~89790492:+
LUAD	cis	rs10754283	0.967	rs10801760	ENSG00000231613.1	RP5-943J3.1	5.4	1.05e-07	3.3e-05	0.24	0.24	Amyotrophic lateral sclerosis (sporadic);	chr1:89648265	chr1:89788914~89790492:+
LUAD	cis	rs10754283	0.967	rs7528433	ENSG00000231613.1	RP5-943J3.1	5.4	1.05e-07	3.3e-05	0.24	0.24	Amyotrophic lateral sclerosis (sporadic);	chr1:89648512	chr1:89788914~89790492:+
LUAD	cis	rs858239	0.6	rs6461692	ENSG00000230042.1	AK3P3	-5.4	1.05e-07	3.3e-05	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23100076	chr7:23129178~23129841:+
LUAD	cis	rs891378	0.92	rs4611012	ENSG00000274245.1	RP11-357P18.2	-5.4	1.05e-07	3.3e-05	-0.29	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207263470	chr1:207372559~207373252:+
LUAD	cis	rs891378	1	rs6540896	ENSG00000274245.1	RP11-357P18.2	-5.4	1.05e-07	3.3e-05	-0.29	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207267506	chr1:207372559~207373252:+
LUAD	cis	rs12468226	0.873	rs3769817	ENSG00000272966.1	RP11-686O6.1	-5.4	1.05e-07	3.3e-05	-0.4	-0.24	Urate levels;	chr2:202214584	chr2:202336739~202337200:+
LUAD	cis	rs12468226	0.873	rs6435134	ENSG00000272966.1	RP11-686O6.1	-5.4	1.05e-07	3.3e-05	-0.4	-0.24	Urate levels;	chr2:202214857	chr2:202336739~202337200:+
LUAD	cis	rs72615157	0.595	rs112241539	ENSG00000242294.5	STAG3L5P	5.4	1.05e-07	3.3e-05	0.21	0.24	Lung function (FEV1/FVC);	chr7:100249614	chr7:100336079~100351900:+
LUAD	cis	rs10129255	0.5	rs8004923	ENSG00000211967.3	IGHV3-53	-5.4	1.05e-07	3.31e-05	-0.17	-0.24	Kawasaki disease;	chr14:106785926	chr14:106592676~106593347:-
LUAD	cis	rs7727544	1	rs7727038	ENSG00000233006.5	AC034220.3	5.4	1.05e-07	3.31e-05	0.21	0.24	Blood metabolite levels;	chr5:132254564	chr5:132311285~132369916:-
LUAD	cis	rs7727544	1	rs7727544	ENSG00000233006.5	AC034220.3	5.4	1.05e-07	3.31e-05	0.21	0.24	Blood metabolite levels;	chr5:132254841	chr5:132311285~132369916:-
LUAD	cis	rs5758511	0.689	rs55906806	ENSG00000205702.9	CYP2D7	5.4	1.05e-07	3.31e-05	0.26	0.24	Birth weight;	chr22:42248465	chr22:42140203~42144577:-
LUAD	cis	rs7617773	0.78	rs71323396	ENSG00000228638.1	FCF1P2	-5.4	1.05e-07	3.31e-05	-0.29	-0.24	Coronary artery disease;	chr3:48333244	chr3:48290793~48291375:-
LUAD	cis	rs858239	0.571	rs6953020	ENSG00000230042.1	AK3P3	-5.4	1.06e-07	3.31e-05	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23129178~23129841:+
LUAD	cis	rs11742741	0.539	rs34635633	ENSG00000248874.4	C5orf17	-5.4	1.06e-07	3.31e-05	-0.3	-0.24	Educational attainment;	chr5:24105391	chr5:23951348~24178263:+
LUAD	cis	rs516805	0.667	rs2606617	ENSG00000279453.1	RP3-425C14.4	-5.4	1.06e-07	3.31e-05	-0.32	-0.24	Lymphocyte counts;	chr6:122182619	chr6:122436789~122439223:-
LUAD	cis	rs2976388	0.609	rs1469811	ENSG00000253741.1	CTD-2292P10.4	-5.4	1.06e-07	3.32e-05	-0.27	-0.24	Urinary tract infection frequency;	chr8:142706581	chr8:142702252~142726973:-
LUAD	cis	rs950169	0.656	rs748455	ENSG00000259295.5	CSPG4P12	5.4	1.06e-07	3.32e-05	0.35	0.24	Schizophrenia;	chr15:84606344	chr15:85191438~85213905:+
LUAD	cis	rs891378	1	rs10864175	ENSG00000274245.1	RP11-357P18.2	-5.4	1.06e-07	3.32e-05	-0.29	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207260004	chr1:207372559~207373252:+
LUAD	cis	rs897984	0.762	rs11150601	ENSG00000260911.2	RP11-196G11.2	-5.4	1.06e-07	3.32e-05	-0.21	-0.24	Dementia with Lewy bodies;	chr16:30966478	chr16:31043150~31049868:+
LUAD	cis	rs7617773	0.817	rs17647717	ENSG00000228638.1	FCF1P2	-5.4	1.06e-07	3.32e-05	-0.29	-0.24	Coronary artery disease;	chr3:48263966	chr3:48290793~48291375:-
LUAD	cis	rs9309473	0.66	rs10496192	ENSG00000163016.8	ALMS1P	5.4	1.06e-07	3.32e-05	0.35	0.24	Metabolite levels;	chr2:73452739	chr2:73644919~73685576:+
LUAD	cis	rs9287719	0.601	rs13427815	ENSG00000243819.4	RN7SL832P	5.4	1.06e-07	3.32e-05	0.25	0.24	Prostate cancer;	chr2:10567859	chr2:10690344~10692099:+
LUAD	cis	rs858239	0.601	rs10278700	ENSG00000230042.1	AK3P3	-5.4	1.06e-07	3.33e-05	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.601	rs10263110	ENSG00000230042.1	AK3P3	-5.4	1.06e-07	3.33e-05	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23129178~23129841:+
LUAD	cis	rs62246343	0.719	rs62246308	ENSG00000254485.4	RP11-380O24.1	5.4	1.06e-07	3.33e-05	0.35	0.24	Fibrinogen levels;	chr3:9427603	chr3:9292588~9363303:-
LUAD	cis	rs2948294	0.566	rs13261997	ENSG00000173295.6	FAM86B3P	5.4	1.06e-07	3.33e-05	0.26	0.24	Red cell distribution width;	chr8:8254773	chr8:8228595~8244865:+
LUAD	cis	rs74233809	1	rs12412038	ENSG00000213277.3	MARCKSL1P1	5.4	1.06e-07	3.33e-05	0.42	0.24	Birth weight;	chr10:103096405	chr10:103175554~103176094:+
LUAD	cis	rs2439831	0.85	rs3816792	ENSG00000205771.5	CATSPER2P1	5.4	1.06e-07	3.34e-05	0.47	0.24	Lung cancer in ever smokers;	chr15:43824788	chr15:43726918~43747094:-
LUAD	cis	rs2404602	0.692	rs7163397	ENSG00000259422.1	RP11-593F23.1	5.4	1.06e-07	3.34e-05	0.28	0.24	Blood metabolite levels;	chr15:76647974	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.692	rs34287706	ENSG00000259422.1	RP11-593F23.1	5.4	1.06e-07	3.34e-05	0.28	0.24	Blood metabolite levels;	chr15:76650061	chr15:76174891~76181486:-
LUAD	cis	rs1707322	1	rs11211217	ENSG00000234329.1	RP11-767N6.2	5.4	1.07e-07	3.34e-05	0.24	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45882557	chr1:45651039~45651826:-
LUAD	cis	rs812925	0.515	rs1177308	ENSG00000271889.1	RP11-493E12.1	5.4	1.07e-07	3.34e-05	0.28	0.24	Immature fraction of reticulocytes;	chr2:61160119	chr2:61151433~61162105:-
LUAD	cis	rs812925	0.553	rs1177307	ENSG00000271889.1	RP11-493E12.1	5.4	1.07e-07	3.34e-05	0.28	0.24	Immature fraction of reticulocytes;	chr2:61160253	chr2:61151433~61162105:-
LUAD	cis	rs812925	0.512	rs1729674	ENSG00000271889.1	RP11-493E12.1	5.4	1.07e-07	3.34e-05	0.28	0.24	Immature fraction of reticulocytes;	chr2:61162602	chr2:61151433~61162105:-
LUAD	cis	rs11089937	0.597	rs4145535	ENSG00000211638.2	IGLV8-61	-5.4	1.07e-07	3.34e-05	-0.28	-0.24	Periodontitis (PAL4Q3);	chr22:22143981	chr22:22098700~22099212:+
LUAD	cis	rs9813712	0.596	rs2587988	ENSG00000249846.5	RP11-77P16.4	-5.4	1.07e-07	3.35e-05	-0.28	-0.24	Response to amphetamines;	chr3:130201415	chr3:130112550~130120579:+
LUAD	cis	rs17711722	0.565	rs4275112	ENSG00000224316.1	RP11-479O9.2	-5.4	1.07e-07	3.35e-05	-0.24	-0.24	Calcium levels;	chr7:65733651	chr7:65773620~65802067:+
LUAD	cis	rs4835473	0.897	rs2089835	ENSG00000251600.4	RP11-673E1.1	5.4	1.07e-07	3.35e-05	0.3	0.24	Immature fraction of reticulocytes;	chr4:143965127	chr4:143912331~143982454:+
LUAD	cis	rs7617773	0.817	rs745116	ENSG00000228638.1	FCF1P2	-5.4	1.07e-07	3.35e-05	-0.28	-0.24	Coronary artery disease;	chr3:48231046	chr3:48290793~48291375:-
LUAD	cis	rs4664293	0.967	rs12611922	ENSG00000226266.5	AC009961.3	-5.4	1.07e-07	3.35e-05	-0.33	-0.24	Monocyte percentage of white cells;	chr2:159606238	chr2:159670708~159712435:-
LUAD	cis	rs17507216	0.718	rs4779033	ENSG00000255769.6	GOLGA2P10	5.4	1.07e-07	3.35e-05	0.31	0.24	Excessive daytime sleepiness;	chr15:82576634	chr15:82472993~82513950:-
LUAD	cis	rs73219805	0.536	rs17055142	ENSG00000228451.3	SDAD1P1	5.4	1.07e-07	3.36e-05	0.52	0.24	Schizophrenia;	chr8:26344085	chr8:26379259~26382953:-
LUAD	cis	rs7927592	0.763	rs7120876	ENSG00000212093.1	AP000807.1	5.4	1.07e-07	3.36e-05	0.24	0.24	Total body bone mineral density;	chr11:68493930	chr11:68506083~68506166:-
LUAD	cis	rs17507216	0.958	rs28648832	ENSG00000255769.6	GOLGA2P10	-5.4	1.07e-07	3.36e-05	-0.29	-0.24	Excessive daytime sleepiness;	chr15:82567642	chr15:82472993~82513950:-
LUAD	cis	rs10246939	0.579	rs6969430	ENSG00000270923.1	TAS2R6P	-5.4	1.07e-07	3.36e-05	-0.26	-0.24	Bitter taste perception;	chr7:141831340	chr7:141787815~141788640:+
LUAD	cis	rs17711722	0.522	rs6957759	ENSG00000224316.1	RP11-479O9.2	5.4	1.07e-07	3.36e-05	0.24	0.24	Calcium levels;	chr7:65806798	chr7:65773620~65802067:+
LUAD	cis	rs8081395	0.603	rs1292047	ENSG00000266992.1	DHX40P1	5.4	1.07e-07	3.36e-05	0.3	0.24	White blood cell count;	chr17:59877805	chr17:59976009~60002384:-
LUAD	cis	rs9309473	0.606	rs77962988	ENSG00000163016.8	ALMS1P	5.4	1.07e-07	3.37e-05	0.36	0.24	Metabolite levels;	chr2:73658963	chr2:73644919~73685576:+
LUAD	cis	rs7968440	0.931	rs2251024	ENSG00000200428.1	Y_RNA	-5.4	1.07e-07	3.37e-05	-0.3	-0.24	Fibrinogen;	chr12:50709850	chr12:50743568~50743684:+
LUAD	cis	rs9287719	0.649	rs10929683	ENSG00000243819.4	RN7SL832P	-5.4	1.08e-07	3.37e-05	-0.25	-0.24	Prostate cancer;	chr2:10592082	chr2:10690344~10692099:+
LUAD	cis	rs673078	0.66	rs73220119	ENSG00000275409.1	RP11-131L12.4	-5.4	1.08e-07	3.37e-05	-0.35	-0.24	Glucose homeostasis traits;	chr12:118159864	chr12:118430147~118430699:+
LUAD	cis	rs858239	0.57	rs10235467	ENSG00000230042.1	AK3P3	-5.4	1.08e-07	3.37e-05	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23129178~23129841:+
LUAD	cis	rs875971	0.862	rs6460307	ENSG00000232559.3	GS1-124K5.12	5.4	1.08e-07	3.37e-05	0.28	0.24	Aortic root size;	chr7:66595884	chr7:66554588~66576923:-
LUAD	cis	rs67311347	1	rs9842564	ENSG00000223797.4	ENTPD3-AS1	-5.39	1.08e-07	3.37e-05	-0.25	-0.24	Renal cell carcinoma;	chr3:40364319	chr3:40313802~40453329:-
LUAD	cis	rs2880765	0.835	rs4536419	ENSG00000259295.5	CSPG4P12	5.39	1.08e-07	3.38e-05	0.27	0.24	Coronary artery disease;	chr15:85496240	chr15:85191438~85213905:+
LUAD	cis	rs9287719	0.601	rs759401	ENSG00000243819.4	RN7SL832P	5.39	1.08e-07	3.39e-05	0.25	0.24	Prostate cancer;	chr2:10569796	chr2:10690344~10692099:+
LUAD	cis	rs7617773	0.817	rs11130163	ENSG00000228638.1	FCF1P2	-5.39	1.08e-07	3.39e-05	-0.27	-0.24	Coronary artery disease;	chr3:48271168	chr3:48290793~48291375:-
LUAD	cis	rs783540	0.656	rs783538	ENSG00000278603.1	RP13-608F4.5	-5.39	1.08e-07	3.39e-05	-0.3	-0.24	Schizophrenia;	chr15:82584394	chr15:82472203~82472426:+
LUAD	cis	rs17507216	1	rs3850610	ENSG00000255769.6	GOLGA2P10	5.39	1.08e-07	3.4e-05	0.28	0.24	Excessive daytime sleepiness;	chr15:82552642	chr15:82472993~82513950:-
LUAD	cis	rs4143844	0.867	rs34646089	ENSG00000259251.2	RP11-643M14.1	5.39	1.09e-07	3.4e-05	0.43	0.24	Bipolar disorder and schizophrenia;	chr15:61978298	chr15:62060503~62062434:+
LUAD	cis	rs7208859	0.623	rs56018041	ENSG00000263603.1	CTD-2349P21.5	-5.39	1.09e-07	3.4e-05	-0.41	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732967	chr17:30729469~30731202:+
LUAD	cis	rs897984	0.542	rs73530203	ENSG00000260911.2	RP11-196G11.2	5.39	1.09e-07	3.4e-05	0.22	0.24	Dementia with Lewy bodies;	chr16:31088538	chr16:31043150~31049868:+
LUAD	cis	rs7727544	0.684	rs272874	ENSG00000233006.5	AC034220.3	-5.39	1.09e-07	3.41e-05	-0.23	-0.24	Blood metabolite levels;	chr5:132339353	chr5:132311285~132369916:-
LUAD	cis	rs17666538	0.585	rs336437	ENSG00000254207.1	RP11-43A14.1	5.39	1.09e-07	3.41e-05	0.48	0.24	IgG glycosylation;	chr8:686251	chr8:725188~725877:-
LUAD	cis	rs36093844	0.752	rs34106192	ENSG00000279742.1	RP11-700A24.1	-5.39	1.09e-07	3.41e-05	-0.31	-0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85845056	chr11:85852557~85854943:-
LUAD	cis	rs10129255	0.518	rs12590732	ENSG00000254174.1	IGHV1-12	-5.39	1.09e-07	3.41e-05	-0.16	-0.24	Kawasaki disease;	chr14:106779612	chr14:106122420~106122709:-
LUAD	cis	rs2562456	0.833	rs2968078	ENSG00000268081.1	RP11-678G14.2	-5.39	1.09e-07	3.41e-05	-0.37	-0.24	Pain;	chr19:21458942	chr19:21554640~21569237:-
LUAD	cis	rs1707322	1	rs12077974	ENSG00000234329.1	RP11-767N6.2	5.39	1.09e-07	3.41e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45918469	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.964	rs10890358	ENSG00000234329.1	RP11-767N6.2	5.39	1.09e-07	3.41e-05	0.24	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853353	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs7531911	ENSG00000234329.1	RP11-767N6.2	5.39	1.09e-07	3.41e-05	0.24	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864751	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs10890359	ENSG00000234329.1	RP11-767N6.2	5.39	1.09e-07	3.41e-05	0.24	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45870963	chr1:45651039~45651826:-
LUAD	cis	rs7968440	0.736	rs1561422	ENSG00000200428.1	Y_RNA	5.39	1.09e-07	3.42e-05	0.3	0.24	Fibrinogen;	chr12:50794614	chr12:50743568~50743684:+
LUAD	cis	rs673078	0.607	rs17513013	ENSG00000275409.1	RP11-131L12.4	-5.39	1.09e-07	3.42e-05	-0.33	-0.24	Glucose homeostasis traits;	chr12:118442070	chr12:118430147~118430699:+
LUAD	cis	rs7017914	0.69	rs11779364	ENSG00000223220.1	Y_RNA	-5.39	1.09e-07	3.42e-05	-0.28	-0.24	Bone mineral density;	chr8:71042361	chr8:70780914~70781008:-
LUAD	cis	rs9309473	0.66	rs62151564	ENSG00000163016.8	ALMS1P	5.39	1.09e-07	3.42e-05	0.35	0.24	Metabolite levels;	chr2:73388321	chr2:73644919~73685576:+
LUAD	cis	rs910316	1	rs7145159	ENSG00000259138.1	RP11-950C14.7	5.39	1.09e-07	3.42e-05	0.25	0.24	Height;	chr14:75116565	chr14:75127153~75136930:+
LUAD	cis	rs853679	0.585	rs201004	ENSG00000219392.1	RP1-265C24.5	-5.39	1.09e-07	3.42e-05	-0.34	-0.24	Depression;	chr6:27837156	chr6:28115628~28116551:+
LUAD	cis	rs2948294	0.524	rs13270062	ENSG00000253981.4	ALG1L13P	5.39	1.1e-07	3.43e-05	0.29	0.24	Red cell distribution width;	chr8:8255128	chr8:8236003~8244667:-
LUAD	cis	rs4604732	0.631	rs12036460	ENSG00000227135.1	GCSAML-AS1	-5.39	1.1e-07	3.43e-05	-0.37	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463626	chr1:247524679~247526752:-
LUAD	cis	rs8180040	0.676	rs66564457	ENSG00000271161.1	BOLA2P2	5.39	1.1e-07	3.44e-05	0.23	0.24	Colorectal cancer;	chr3:46978582	chr3:47499841~47500407:+
LUAD	cis	rs301901	0.686	rs158795	ENSG00000250155.1	CTD-2353F22.1	-5.39	1.1e-07	3.44e-05	-0.28	-0.24	Height;	chr5:36882886	chr5:36666214~36725195:-
LUAD	cis	rs11143230	1	rs62564005	ENSG00000225434.2	LINC01504	-5.39	1.1e-07	3.44e-05	-0.28	-0.24	Suicidal ideation;	chr9:72273467	chr9:72305430~72343210:+
LUAD	cis	rs748404	0.666	rs16957730	ENSG00000205771.5	CATSPER2P1	-5.39	1.1e-07	3.45e-05	-0.36	-0.24	Lung cancer;	chr15:43438288	chr15:43726918~43747094:-
LUAD	cis	rs4835473	0.932	rs13147386	ENSG00000251600.4	RP11-673E1.1	5.39	1.1e-07	3.45e-05	0.29	0.24	Immature fraction of reticulocytes;	chr4:143736586	chr4:143912331~143982454:+
LUAD	cis	rs891378	1	rs7522701	ENSG00000274245.1	RP11-357P18.2	-5.39	1.1e-07	3.45e-05	-0.29	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207237620	chr1:207372559~207373252:+
LUAD	cis	rs858239	0.932	rs858275	ENSG00000226816.2	AC005082.12	5.39	1.1e-07	3.45e-05	0.3	0.24	Cerebrospinal fluid biomarker levels;	chr7:23254525	chr7:23206013~23208045:+
LUAD	cis	rs1707322	1	rs4298677	ENSG00000234329.1	RP11-767N6.2	5.39	1.1e-07	3.45e-05	0.24	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45840947	chr1:45651039~45651826:-
LUAD	cis	rs7017914	0.652	rs62508770	ENSG00000223220.1	Y_RNA	5.39	1.1e-07	3.45e-05	0.27	0.24	Bone mineral density;	chr8:70780269	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs55862702	ENSG00000223220.1	Y_RNA	5.39	1.1e-07	3.45e-05	0.27	0.24	Bone mineral density;	chr8:70781502	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.628	rs6998989	ENSG00000223220.1	Y_RNA	5.39	1.1e-07	3.45e-05	0.27	0.24	Bone mineral density;	chr8:70782296	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.628	rs6981149	ENSG00000223220.1	Y_RNA	5.39	1.1e-07	3.45e-05	0.27	0.24	Bone mineral density;	chr8:70782447	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs1596565	ENSG00000223220.1	Y_RNA	5.39	1.1e-07	3.45e-05	0.27	0.24	Bone mineral density;	chr8:70786597	chr8:70780914~70781008:-
LUAD	cis	rs394563	0.591	rs11155641	ENSG00000231760.4	RP11-350J20.5	-5.39	1.11e-07	3.46e-05	-0.29	-0.24	Dupuytren's disease;	chr6:149327459	chr6:149796151~149826294:-
LUAD	cis	rs7176527	0.796	rs72630464	ENSG00000188388.10	GOLGA6L3	5.39	1.11e-07	3.46e-05	0.34	0.24	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84754895	chr15:85240472~85247170:+
LUAD	cis	rs8098244	0.537	rs7236794	ENSG00000264745.1	TTC39C-AS1	5.39	1.11e-07	3.46e-05	0.25	0.24	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23697706	chr18:23994213~24015339:-
LUAD	cis	rs10129255	0.556	rs8010005	ENSG00000254174.1	IGHV1-12	5.39	1.11e-07	3.46e-05	0.16	0.24	Kawasaki disease;	chr14:106777987	chr14:106122420~106122709:-
LUAD	cis	rs10129255	0.556	rs6576224	ENSG00000254174.1	IGHV1-12	5.39	1.11e-07	3.46e-05	0.16	0.24	Kawasaki disease;	chr14:106777997	chr14:106122420~106122709:-
LUAD	cis	rs732716	0.813	rs760369	ENSG00000267980.1	AC007292.6	5.39	1.11e-07	3.46e-05	0.27	0.24	Mean corpuscular volume;	chr19:4449290	chr19:4363789~4364640:+
LUAD	cis	rs889398	0.9	rs4783722	ENSG00000226232.7	RP11-419C5.2	5.39	1.11e-07	3.46e-05	0.2	0.24	Body mass index;	chr16:69548009	chr16:69976388~69996188:-
LUAD	cis	rs559928	0.692	rs12146487	ENSG00000236935.1	AP003774.1	5.39	1.11e-07	3.46e-05	0.35	0.24	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64259167	chr11:64325050~64329504:-
LUAD	cis	rs4664293	0.967	rs9646765	ENSG00000226266.5	AC009961.3	-5.39	1.11e-07	3.46e-05	-0.33	-0.24	Monocyte percentage of white cells;	chr2:159709137	chr2:159670708~159712435:-
LUAD	cis	rs12928939	0.859	rs11670	ENSG00000260886.1	TAT-AS1	5.39	1.11e-07	3.46e-05	0.3	0.24	Post bronchodilator FEV1;	chr16:71645124	chr16:71565789~71578187:+
LUAD	cis	rs507080	0.663	rs523793	ENSG00000278376.1	RP11-158I9.8	-5.39	1.11e-07	3.46e-05	-0.26	-0.24	Serum metabolite levels;	chr11:118699988	chr11:118791254~118793137:+
LUAD	cis	rs507080	0.736	rs659564	ENSG00000278376.1	RP11-158I9.8	-5.39	1.11e-07	3.46e-05	-0.26	-0.24	Serum metabolite levels;	chr11:118700205	chr11:118791254~118793137:+
LUAD	cis	rs507080	0.736	rs642224	ENSG00000278376.1	RP11-158I9.8	-5.39	1.11e-07	3.46e-05	-0.26	-0.24	Serum metabolite levels;	chr11:118700210	chr11:118791254~118793137:+
LUAD	cis	rs507080	0.733	rs541631	ENSG00000278376.1	RP11-158I9.8	-5.39	1.11e-07	3.46e-05	-0.26	-0.24	Serum metabolite levels;	chr11:118700314	chr11:118791254~118793137:+
LUAD	cis	rs507080	0.736	rs658676	ENSG00000278376.1	RP11-158I9.8	-5.39	1.11e-07	3.46e-05	-0.26	-0.24	Serum metabolite levels;	chr11:118700414	chr11:118791254~118793137:+
LUAD	cis	rs507080	0.733	rs488141	ENSG00000278376.1	RP11-158I9.8	-5.39	1.11e-07	3.46e-05	-0.26	-0.24	Serum metabolite levels;	chr11:118700459	chr11:118791254~118793137:+
LUAD	cis	rs507080	0.733	rs657769	ENSG00000278376.1	RP11-158I9.8	-5.39	1.11e-07	3.46e-05	-0.26	-0.24	Serum metabolite levels;	chr11:118700607	chr11:118791254~118793137:+
LUAD	cis	rs507080	0.733	rs544452	ENSG00000278376.1	RP11-158I9.8	-5.39	1.11e-07	3.46e-05	-0.26	-0.24	Serum metabolite levels;	chr11:118700648	chr11:118791254~118793137:+
LUAD	cis	rs9516	0.544	rs664679	ENSG00000254974.1	RP11-702H23.2	5.39	1.11e-07	3.46e-05	0.28	0.24	Facial morphology (factor 15, philtrum width);	chr11:74475254	chr11:74485580~74486051:-
LUAD	cis	rs12468226	0.574	rs4675271	ENSG00000226261.1	AC064836.3	-5.39	1.11e-07	3.47e-05	-0.34	-0.24	Urate levels;	chr2:202170967	chr2:202336024~202336727:-
LUAD	cis	rs1320333	0.772	rs35181861	ENSG00000233296.1	AC092159.2	5.39	1.11e-07	3.47e-05	0.45	0.24	Obesity-related traits;	chr2:679483	chr2:677186~697371:+
LUAD	cis	rs2115630	0.875	rs8039472	ENSG00000229212.6	RP11-561C5.4	5.39	1.11e-07	3.47e-05	0.28	0.24	P wave terminal force;	chr15:84818413	chr15:85205440~85234795:-
LUAD	cis	rs7119038	0.509	rs10790261	ENSG00000255422.1	AP002954.4	-5.39	1.11e-07	3.47e-05	-0.37	-0.24	Sjögren's syndrome;	chr11:118709038	chr11:118704607~118750263:+
LUAD	cis	rs12908161	0.959	rs61074241	ENSG00000259728.4	LINC00933	5.39	1.11e-07	3.48e-05	0.37	0.24	Schizophrenia;	chr15:84790165	chr15:84570649~84580175:+
LUAD	cis	rs35740288	0.822	rs56322219	ENSG00000202081.1	RNU6-1280P	5.39	1.11e-07	3.48e-05	0.31	0.24	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85733109	chr15:85651522~85651628:-
LUAD	cis	rs375066	0.935	rs454559	ENSG00000267058.1	RP11-15A1.3	-5.39	1.11e-07	3.48e-05	-0.27	-0.24	Breast cancer;	chr19:43924968	chr19:43891804~43901805:-
LUAD	cis	rs35740288	0.822	rs11630549	ENSG00000202081.1	RNU6-1280P	5.39	1.11e-07	3.48e-05	0.31	0.24	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85732565	chr15:85651522~85651628:-
LUAD	cis	rs875971	0.862	rs2460432	ENSG00000237310.1	GS1-124K5.4	-5.39	1.12e-07	3.48e-05	-0.26	-0.24	Aortic root size;	chr7:66089398	chr7:66493706~66495474:+
LUAD	cis	rs7618915	1	rs34569561	ENSG00000243224.1	RP5-1157M23.2	-5.39	1.12e-07	3.48e-05	-0.25	-0.24	Bipolar disorder;	chr3:52253277	chr3:52239258~52241097:+
LUAD	cis	rs516805	0.748	rs512063	ENSG00000279453.1	RP3-425C14.4	-5.39	1.12e-07	3.49e-05	-0.31	-0.24	Lymphocyte counts;	chr6:122409206	chr6:122436789~122439223:-
LUAD	cis	rs1799949	0.965	rs9646418	ENSG00000267681.1	CTD-3199J23.6	-5.39	1.12e-07	3.49e-05	-0.27	-0.24	Menopause (age at onset);	chr17:43348533	chr17:43144956~43145255:+
LUAD	cis	rs8177876	0.822	rs12443549	ENSG00000261061.1	RP11-303E16.2	5.39	1.12e-07	3.49e-05	0.41	0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81070596	chr16:81030770~81031485:+
LUAD	cis	rs67180937	0.553	rs2936020	ENSG00000272750.1	RP11-378J18.8	5.39	1.12e-07	3.49e-05	0.29	0.24	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222655754	chr1:222658867~222661512:-
LUAD	cis	rs7712401	0.601	rs35479600	ENSG00000263432.2	RN7SL689P	-5.39	1.12e-07	3.49e-05	-0.31	-0.24	Mean platelet volume;	chr5:122988775	chr5:123022487~123022783:-
LUAD	cis	rs9807989	0.839	rs1974675	ENSG00000234389.1	AC007278.3	5.39	1.12e-07	3.49e-05	0.23	0.24	Asthma;	chr2:102369915	chr2:102438713~102440475:+
LUAD	cis	rs853679	0.825	rs8180562	ENSG00000219392.1	RP1-265C24.5	-5.39	1.12e-07	3.49e-05	-0.41	-0.24	Depression;	chr6:28173682	chr6:28115628~28116551:+
LUAD	cis	rs55665837	0.54	rs4757261	ENSG00000251991.1	RNU7-49P	5.39	1.12e-07	3.49e-05	0.27	0.24	Vitamin D levels;	chr11:14648256	chr11:14478892~14478953:+
LUAD	cis	rs2688482	0.512	rs3103953	ENSG00000224769.1	AC069213.1	-5.39	1.12e-07	3.5e-05	-0.42	-0.24	Lung disease severity in cystic fibrosis;	chr3:195793726	chr3:195614947~195620233:+
LUAD	cis	rs2836950	0.545	rs11700449	ENSG00000255568.3	BRWD1-AS2	-5.39	1.12e-07	3.5e-05	-0.24	-0.24	Menarche (age at onset);	chr21:39150493	chr21:39313935~39314962:+
LUAD	cis	rs380904	0.519	rs10102146	ENSG00000254859.1	RP11-661A12.5	5.39	1.12e-07	3.5e-05	0.39	0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:143566986	chr8:143541973~143549729:-
LUAD	cis	rs2212361	0.558	rs11020812	ENSG00000255893.1	RP11-685N10.1	5.39	1.12e-07	3.5e-05	0.31	0.24	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94533951	chr11:94472908~94473570:-
LUAD	cis	rs858239	0.601	rs1558313	ENSG00000230042.1	AK3P3	-5.39	1.12e-07	3.51e-05	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.601	rs6962526	ENSG00000230042.1	AK3P3	-5.39	1.12e-07	3.51e-05	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.539	rs6971673	ENSG00000230042.1	AK3P3	-5.39	1.12e-07	3.51e-05	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23129178~23129841:+
LUAD	cis	rs453301	0.686	rs3989373	ENSG00000253893.2	FAM85B	5.39	1.12e-07	3.51e-05	0.29	0.24	Joint mobility (Beighton score);	chr8:9053798	chr8:8167819~8226614:-
LUAD	cis	rs36093844	0.898	rs80079882	ENSG00000279742.1	RP11-700A24.1	-5.39	1.12e-07	3.51e-05	-0.28	-0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85879912	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.898	rs11234457	ENSG00000279742.1	RP11-700A24.1	-5.39	1.12e-07	3.51e-05	-0.28	-0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85879998	chr11:85852557~85854943:-
LUAD	cis	rs2919009	0.579	rs12258778	ENSG00000271670.1	RP11-95I16.4	-5.39	1.12e-07	3.51e-05	-0.29	-0.24	Obesity-related traits;	chr10:120868873	chr10:120879256~120880667:-
LUAD	cis	rs4767841	0.552	rs2893796	ENSG00000248636.5	RP11-768F21.1	-5.39	1.12e-07	3.51e-05	-0.28	-0.24	Urgency urinary incontinence;	chr12:119613464	chr12:119387987~119668079:-
LUAD	cis	rs2243480	0.615	rs34363376	ENSG00000230295.1	RP11-458F8.2	-5.39	1.12e-07	3.51e-05	-0.29	-0.24	Diabetic kidney disease;	chr7:66474549	chr7:66880708~66882981:+
LUAD	cis	rs6570726	0.935	rs382910	ENSG00000235652.6	RP11-545I5.3	5.39	1.12e-07	3.51e-05	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145544805	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs447818	ENSG00000235652.6	RP11-545I5.3	5.39	1.12e-07	3.51e-05	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145547860	chr6:145799409~145886585:+
LUAD	cis	rs4835473	0.932	rs5016159	ENSG00000251600.4	RP11-673E1.1	5.39	1.13e-07	3.51e-05	0.29	0.24	Immature fraction of reticulocytes;	chr4:143738362	chr4:143912331~143982454:+
LUAD	cis	rs11157436	1	rs12587157	ENSG00000211813.2	TRAV34	5.39	1.13e-07	3.52e-05	0.31	0.24	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22181476	chr14:22207522~22208129:+
LUAD	cis	rs4835473	0.932	rs35655934	ENSG00000251600.4	RP11-673E1.1	-5.39	1.13e-07	3.52e-05	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143734697	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.897	rs35515006	ENSG00000251600.4	RP11-673E1.1	-5.39	1.13e-07	3.52e-05	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143734705	chr4:143912331~143982454:+
LUAD	cis	rs516805	0.59	rs13371	ENSG00000279453.1	RP3-425C14.4	-5.39	1.13e-07	3.52e-05	-0.31	-0.24	Lymphocyte counts;	chr6:122443881	chr6:122436789~122439223:-
LUAD	cis	rs2562456	0.833	rs516519	ENSG00000268081.1	RP11-678G14.2	-5.39	1.13e-07	3.52e-05	-0.36	-0.24	Pain;	chr19:21298730	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.833	rs552800	ENSG00000268081.1	RP11-678G14.2	-5.39	1.13e-07	3.52e-05	-0.36	-0.24	Pain;	chr19:21301840	chr19:21554640~21569237:-
LUAD	cis	rs2439831	0.541	rs12440854	ENSG00000205771.5	CATSPER2P1	-5.39	1.13e-07	3.52e-05	-0.51	-0.24	Lung cancer in ever smokers;	chr15:43318474	chr15:43726918~43747094:-
LUAD	cis	rs72615157	0.561	rs113401658	ENSG00000242294.5	STAG3L5P	5.39	1.13e-07	3.52e-05	0.21	0.24	Lung function (FEV1/FVC);	chr7:100260882	chr7:100336079~100351900:+
LUAD	cis	rs6969780	0.841	rs10246712	ENSG00000233429.8	HOTAIRM1	5.39	1.13e-07	3.52e-05	0.36	0.24	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27159241	chr7:27095647~27100265:+
LUAD	cis	rs17684571	0.637	rs17751966	ENSG00000231441.1	RP11-472M19.2	5.39	1.13e-07	3.52e-05	0.35	0.24	Schizophrenia;	chr6:56804850	chr6:56844002~56864078:+
LUAD	cis	rs12554020	0.892	rs59483310	ENSG00000227603.1	RP11-165J3.6	5.39	1.13e-07	3.52e-05	0.37	0.24	Schizophrenia;	chr9:93503318	chr9:93435332~93437121:-
LUAD	cis	rs1707322	1	rs10890381	ENSG00000280836.1	AL355480.1	-5.39	1.13e-07	3.52e-05	-0.31	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986099	chr1:45581219~45581321:-
LUAD	cis	rs10246939	0.543	rs35836873	ENSG00000270923.1	TAS2R6P	-5.39	1.13e-07	3.52e-05	-0.26	-0.24	Bitter taste perception;	chr7:141844010	chr7:141787815~141788640:+
LUAD	cis	rs10246939	0.543	rs9640358	ENSG00000270923.1	TAS2R6P	-5.39	1.13e-07	3.52e-05	-0.26	-0.24	Bitter taste perception;	chr7:141844082	chr7:141787815~141788640:+
LUAD	cis	rs1075265	0.704	rs805405	ENSG00000233266.1	HMGB1P31	5.39	1.13e-07	3.53e-05	0.3	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53891014	chr2:54051334~54051760:+
LUAD	cis	rs1722141	0.67	rs2965073	ENSG00000229628.1	AC073115.7	5.39	1.13e-07	3.53e-05	0.38	0.24	Sitting height ratio;	chr7:45941524	chr7:45990905~46000898:+
LUAD	cis	rs1722141	0.6	rs1525819	ENSG00000229628.1	AC073115.7	5.39	1.13e-07	3.53e-05	0.38	0.24	Sitting height ratio;	chr7:45945301	chr7:45990905~46000898:+
LUAD	cis	rs7615952	0.576	rs4646748	ENSG00000171084.14	FAM86JP	5.39	1.13e-07	3.53e-05	0.35	0.24	Blood pressure (smoking interaction);	chr3:126107486	chr3:125916620~125930024:+
LUAD	cis	rs712039	0.652	rs829163	ENSG00000276054.1	RP11-378E13.3	5.39	1.13e-07	3.53e-05	0.36	0.24	Tuberculosis;	chr17:37405936	chr17:37386886~37387926:+
LUAD	cis	rs6496044	0.507	rs62022863	ENSG00000259407.1	RP11-158M2.3	5.39	1.13e-07	3.54e-05	0.22	0.24	Interstitial lung disease;	chr15:85618822	chr15:85744109~85750281:-
LUAD	cis	rs8050896	1	rs13332030	ENSG00000260695.1	RP11-513N24.1	-5.39	1.13e-07	3.54e-05	-0.4	-0.24	Response to antipsychotic treatment;	chr16:66125761	chr16:65861112~65863784:-
LUAD	cis	rs2255336	0.938	rs2617151	ENSG00000245648.1	RP11-277P12.20	5.39	1.13e-07	3.54e-05	0.35	0.24	Blood protein levels;	chr12:10379835	chr12:10363769~10398506:+
LUAD	cis	rs896854	0.654	rs13248607	ENSG00000253528.2	RP11-347C18.4	5.38	1.14e-07	3.54e-05	0.23	0.24	Type 2 diabetes;	chr8:94974409	chr8:94974573~94974853:-
LUAD	cis	rs9923856	0.519	rs720130	ENSG00000274038.1	RP11-66H6.4	5.38	1.14e-07	3.54e-05	0.28	0.24	Atopic dermatitis;Adult asthma;	chr16:11038776	chr16:11056556~11057034:+
LUAD	cis	rs2880765	0.835	rs11638498	ENSG00000259295.5	CSPG4P12	5.38	1.14e-07	3.54e-05	0.27	0.24	Coronary artery disease;	chr15:85479787	chr15:85191438~85213905:+
LUAD	cis	rs36093844	0.8	rs17817355	ENSG00000279742.1	RP11-700A24.1	-5.38	1.14e-07	3.55e-05	-0.32	-0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85888902	chr11:85852557~85854943:-
LUAD	cis	rs2898681	0.618	rs79471207	ENSG00000248375.1	RP11-177B4.1	-5.38	1.14e-07	3.55e-05	-0.43	-0.24	Optic nerve measurement (cup area);	chr4:52872357	chr4:52720081~52720831:-
LUAD	cis	rs11976180	0.953	rs2951355	ENSG00000170356.8	OR2A20P	-5.38	1.14e-07	3.55e-05	-0.3	-0.24	Obesity-related traits;	chr7:144063469	chr7:144250045~144252957:-
LUAD	cis	rs34375054	0.66	rs12578446	ENSG00000279233.1	RP11-158L12.4	5.38	1.14e-07	3.55e-05	0.21	0.24	Post bronchodilator FEV1/FVC ratio;	chr12:125121341	chr12:125138245~125141711:+
LUAD	cis	rs4964805	1	rs73192052	ENSG00000257681.1	RP11-341G23.4	5.38	1.14e-07	3.55e-05	0.3	0.24	Attention deficit hyperactivity disorder;	chr12:103797076	chr12:103746315~103768858:-
LUAD	cis	rs17684571	0.751	rs10498813	ENSG00000231441.1	RP11-472M19.2	5.38	1.14e-07	3.55e-05	0.35	0.24	Schizophrenia;	chr6:56819921	chr6:56844002~56864078:+
LUAD	cis	rs12468226	0.817	rs12693965	ENSG00000272966.1	RP11-686O6.1	-5.38	1.14e-07	3.55e-05	-0.4	-0.24	Urate levels;	chr2:202210188	chr2:202336739~202337200:+
LUAD	cis	rs4835473	0.897	rs1450249	ENSG00000251600.4	RP11-673E1.1	5.38	1.14e-07	3.55e-05	0.3	0.24	Immature fraction of reticulocytes;	chr4:143724425	chr4:143912331~143982454:+
LUAD	cis	rs11051970	0.559	rs11051925	ENSG00000274964.1	RP11-817I4.1	-5.38	1.14e-07	3.55e-05	-0.31	-0.24	Response to tocilizumab in rheumatoid arthritis;	chr12:32314860	chr12:32339368~32340724:+
LUAD	cis	rs4938303	0.718	rs3212282	ENSG00000280143.1	AP000892.6	5.38	1.14e-07	3.55e-05	0.33	0.24	Triglycerides;	chr11:116731229	chr11:117204967~117210292:+
LUAD	cis	rs10129255	1	rs11621409	ENSG00000224373.3	IGHV4-59	5.38	1.14e-07	3.55e-05	0.16	0.24	Kawasaki disease;	chr14:106695603	chr14:106627249~106627825:-
LUAD	cis	rs2404602	0.735	rs2454450	ENSG00000259422.1	RP11-593F23.1	-5.38	1.14e-07	3.55e-05	-0.31	-0.24	Blood metabolite levels;	chr15:76538895	chr15:76174891~76181486:-
LUAD	cis	rs453301	0.658	rs3855900	ENSG00000253893.2	FAM85B	5.38	1.14e-07	3.55e-05	0.3	0.24	Joint mobility (Beighton score);	chr8:9044411	chr8:8167819~8226614:-
LUAD	cis	rs442309	0.553	rs10761660	ENSG00000238280.1	RP11-436D10.3	-5.38	1.14e-07	3.56e-05	-0.3	-0.24	Vogt-Koyanagi-Harada syndrome;	chr10:62756546	chr10:62793562~62805887:-
LUAD	cis	rs2404602	0.967	rs7174096	ENSG00000259422.1	RP11-593F23.1	5.38	1.14e-07	3.56e-05	0.28	0.24	Blood metabolite levels;	chr15:76780059	chr15:76174891~76181486:-
LUAD	cis	rs6964587	0.773	rs13236026	ENSG00000188693.7	CYP51A1-AS1	-5.38	1.14e-07	3.56e-05	-0.28	-0.24	Breast cancer;	chr7:92256559	chr7:92134604~92180725:+
LUAD	cis	rs516805	0.706	rs572674	ENSG00000279453.1	RP3-425C14.4	-5.38	1.14e-07	3.56e-05	-0.31	-0.24	Lymphocyte counts;	chr6:122411239	chr6:122436789~122439223:-
LUAD	cis	rs673078	0.607	rs61944661	ENSG00000275409.1	RP11-131L12.4	-5.38	1.14e-07	3.56e-05	-0.33	-0.24	Glucose homeostasis traits;	chr12:118445514	chr12:118430147~118430699:+
LUAD	cis	rs12468226	0.873	rs6761131	ENSG00000272966.1	RP11-686O6.1	-5.38	1.14e-07	3.56e-05	-0.4	-0.24	Urate levels;	chr2:202237675	chr2:202336739~202337200:+
LUAD	cis	rs6543140	0.964	rs6734203	ENSG00000234389.1	AC007278.3	5.38	1.15e-07	3.57e-05	0.24	0.24	Blood protein levels;	chr2:102463606	chr2:102438713~102440475:+
LUAD	cis	rs6543140	0.964	rs6543142	ENSG00000234389.1	AC007278.3	5.38	1.15e-07	3.57e-05	0.24	0.24	Blood protein levels;	chr2:102465546	chr2:102438713~102440475:+
LUAD	cis	rs6543140	0.929	rs6742530	ENSG00000234389.1	AC007278.3	5.38	1.15e-07	3.57e-05	0.24	0.24	Blood protein levels;	chr2:102465820	chr2:102438713~102440475:+
LUAD	cis	rs889398	0.967	rs35967356	ENSG00000226232.7	RP11-419C5.2	5.38	1.15e-07	3.57e-05	0.2	0.24	Body mass index;	chr16:69547451	chr16:69976388~69996188:-
LUAD	cis	rs7829975	0.806	rs2428	ENSG00000253893.2	FAM85B	-5.38	1.15e-07	3.57e-05	-0.29	-0.24	Mood instability;	chr8:8783635	chr8:8167819~8226614:-
LUAD	cis	rs712039	0.652	rs853222	ENSG00000276054.1	RP11-378E13.3	5.38	1.15e-07	3.58e-05	0.36	0.24	Tuberculosis;	chr17:37429923	chr17:37386886~37387926:+
LUAD	cis	rs2337406	0.925	rs2011167	ENSG00000223648.3	IGHV3-64	5.38	1.15e-07	3.58e-05	0.3	0.24	Alzheimer's disease (late onset);	chr14:106680831	chr14:106643132~106658258:-
LUAD	cis	rs35160687	0.688	rs12466728	ENSG00000273080.1	RP11-301O19.1	-5.38	1.15e-07	3.59e-05	-0.26	-0.24	Night sleep phenotypes;	chr2:86256976	chr2:86195590~86196049:+
LUAD	cis	rs35160687	0.666	rs36104799	ENSG00000273080.1	RP11-301O19.1	-5.38	1.15e-07	3.59e-05	-0.26	-0.24	Night sleep phenotypes;	chr2:86257000	chr2:86195590~86196049:+
LUAD	cis	rs35160687	0.666	rs7583074	ENSG00000273080.1	RP11-301O19.1	-5.38	1.15e-07	3.59e-05	-0.26	-0.24	Night sleep phenotypes;	chr2:86257069	chr2:86195590~86196049:+
LUAD	cis	rs7208859	0.573	rs55661352	ENSG00000263603.1	CTD-2349P21.5	-5.38	1.15e-07	3.59e-05	-0.43	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30729469~30731202:+
LUAD	cis	rs925255	0.747	rs6547850	ENSG00000270210.1	RP11-373D23.3	-5.38	1.15e-07	3.59e-05	-0.27	-0.24	Inflammatory bowel disease;Crohn's disease;	chr2:28406476	chr2:28425945~28426719:+
LUAD	cis	rs189798	1	rs189798	ENSG00000254340.1	RP11-10A14.3	-5.38	1.15e-07	3.59e-05	-0.3	-0.24	Myopia (pathological);	chr8:9133067	chr8:9141424~9145435:+
LUAD	cis	rs113835537	0.735	rs519380	ENSG00000255517.5	CTD-3074O7.5	-5.38	1.15e-07	3.59e-05	-0.3	-0.24	Airway imaging phenotypes;	chr11:66641938	chr11:66473490~66480233:-
LUAD	cis	rs4835473	0.832	rs35398499	ENSG00000251600.4	RP11-673E1.1	-5.38	1.15e-07	3.59e-05	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143737715	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.832	rs35763177	ENSG00000251600.4	RP11-673E1.1	-5.38	1.15e-07	3.59e-05	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143737717	chr4:143912331~143982454:+
LUAD	cis	rs673078	0.66	rs61945212	ENSG00000275409.1	RP11-131L12.4	-5.38	1.15e-07	3.59e-05	-0.35	-0.24	Glucose homeostasis traits;	chr12:118252351	chr12:118430147~118430699:+
LUAD	cis	rs867371	1	rs11855089	ENSG00000259429.4	UBE2Q2P2	-5.38	1.15e-07	3.59e-05	-0.21	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82154924	chr15:82355142~82420075:+
LUAD	cis	rs7580658	0.676	rs4150407	ENSG00000236682.1	AC068282.3	5.38	1.15e-07	3.59e-05	0.3	0.24	Protein C levels;	chr2:127292055	chr2:127389130~127400580:+
LUAD	cis	rs889398	0.9	rs62052815	ENSG00000226232.7	RP11-419C5.2	5.38	1.15e-07	3.59e-05	0.21	0.24	Body mass index;	chr16:69527923	chr16:69976388~69996188:-
LUAD	cis	rs2439831	0.85	rs16965120	ENSG00000249839.1	AC011330.5	-5.38	1.15e-07	3.59e-05	-0.46	-0.24	Lung cancer in ever smokers;	chr15:43808144	chr15:43663654~43684339:-
LUAD	cis	rs12439619	1	rs35152457	ENSG00000276710.3	CSPG4P8	-5.38	1.15e-07	3.6e-05	-0.24	-0.24	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82459472~82477258:+
LUAD	cis	rs673078	0.615	rs61943528	ENSG00000275409.1	RP11-131L12.4	-5.38	1.15e-07	3.6e-05	-0.35	-0.24	Glucose homeostasis traits;	chr12:118163134	chr12:118430147~118430699:+
LUAD	cis	rs1075265	0.933	rs7607066	ENSG00000233266.1	HMGB1P31	5.38	1.16e-07	3.61e-05	0.3	0.24	Chronotype;Morning vs. evening chronotype;	chr2:54110054	chr2:54051334~54051760:+
LUAD	cis	rs6687758	0.687	rs12123928	ENSG00000228437.4	RP11-400N13.2	5.38	1.16e-07	3.62e-05	0.34	0.24	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221948533	chr1:221966341~221984964:+
LUAD	cis	rs57339844	1	rs57339844	ENSG00000273080.1	RP11-301O19.1	-5.38	1.16e-07	3.62e-05	-0.26	-0.24	Mean platelet volume;	chr2:85891155	chr2:86195590~86196049:+
LUAD	cis	rs17214007	0.877	rs1569300	ENSG00000263335.1	AF001548.5	-5.38	1.16e-07	3.62e-05	-0.34	-0.24	Cognitive function;	chr16:15776891	chr16:15726674~15732993:+
LUAD	cis	rs1322639	0.697	rs12661910	ENSG00000261039.2	RP11-417E7.2	-5.38	1.16e-07	3.62e-05	-0.38	-0.24	Pulse pressure;	chr6:169184293	chr6:169175304~169182740:-
LUAD	cis	rs62246343	0.719	rs56782786	ENSG00000254485.4	RP11-380O24.1	5.38	1.16e-07	3.62e-05	0.35	0.24	Fibrinogen levels;	chr3:9425388	chr3:9292588~9363303:-
LUAD	cis	rs35740288	0.822	rs4843092	ENSG00000202081.1	RNU6-1280P	5.38	1.16e-07	3.62e-05	0.3	0.24	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85689949	chr15:85651522~85651628:-
LUAD	cis	rs1707322	1	rs11211204	ENSG00000234329.1	RP11-767N6.2	5.38	1.16e-07	3.62e-05	0.24	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45852192	chr1:45651039~45651826:-
LUAD	cis	rs2404602	1	rs2056544	ENSG00000259422.1	RP11-593F23.1	5.38	1.16e-07	3.62e-05	0.28	0.24	Blood metabolite levels;	chr15:76533662	chr15:76174891~76181486:-
LUAD	cis	rs763512	0.504	rs11652399	ENSG00000276054.1	RP11-378E13.3	5.38	1.16e-07	3.62e-05	0.37	0.24	3-hydroxypropylmercapturic acid levels in smokers;	chr17:37509679	chr17:37386886~37387926:+
LUAD	cis	rs7826238	0.601	rs2976907	ENSG00000253981.4	ALG1L13P	5.38	1.16e-07	3.63e-05	0.27	0.24	Systolic blood pressure;	chr8:8487658	chr8:8236003~8244667:-
LUAD	cis	rs858239	0.539	rs1358442	ENSG00000230042.1	AK3P3	-5.38	1.16e-07	3.63e-05	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23150120	chr7:23129178~23129841:+
LUAD	cis	rs1707322	0.721	rs4660314	ENSG00000280836.1	AL355480.1	-5.38	1.16e-07	3.63e-05	-0.32	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764213	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.721	rs12069121	ENSG00000280836.1	AL355480.1	-5.38	1.16e-07	3.63e-05	-0.32	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45766312	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.686	rs61784833	ENSG00000280836.1	AL355480.1	-5.38	1.16e-07	3.63e-05	-0.32	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45768100	chr1:45581219~45581321:-
LUAD	cis	rs2880765	0.835	rs6497202	ENSG00000259295.5	CSPG4P12	5.38	1.17e-07	3.63e-05	0.27	0.24	Coronary artery disease;	chr15:85478144	chr15:85191438~85213905:+
LUAD	cis	rs948562	0.947	rs2298607	ENSG00000280010.1	AP001350.4	5.38	1.17e-07	3.64e-05	0.36	0.24	Lymphoma;	chr11:58637026	chr11:58627435~58628528:+
LUAD	cis	rs516805	0.63	rs499825	ENSG00000279453.1	RP3-425C14.4	-5.38	1.17e-07	3.64e-05	-0.31	-0.24	Lymphocyte counts;	chr6:122454050	chr6:122436789~122439223:-
LUAD	cis	rs2243480	1	rs6964530	ENSG00000230295.1	RP11-458F8.2	5.38	1.17e-07	3.64e-05	0.29	0.24	Diabetic kidney disease;	chr7:66253864	chr7:66880708~66882981:+
LUAD	cis	rs673078	0.607	rs61944671	ENSG00000275409.1	RP11-131L12.4	-5.38	1.17e-07	3.64e-05	-0.33	-0.24	Glucose homeostasis traits;	chr12:118450046	chr12:118430147~118430699:+
LUAD	cis	rs7617773	0.817	rs936426	ENSG00000228638.1	FCF1P2	-5.38	1.17e-07	3.64e-05	-0.27	-0.24	Coronary artery disease;	chr3:48173763	chr3:48290793~48291375:-
LUAD	cis	rs858239	1	rs156425	ENSG00000226816.2	AC005082.12	-5.38	1.17e-07	3.64e-05	-0.31	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23206013~23208045:+
LUAD	cis	rs9992667	1	rs9992667	ENSG00000231160.8	KLF3-AS1	5.38	1.17e-07	3.64e-05	0.3	0.24	Eosinophil percentage of granulocytes;	chr4:38678565	chr4:38612701~38664883:-
LUAD	cis	rs2404602	0.692	rs60658665	ENSG00000259422.1	RP11-593F23.1	5.38	1.17e-07	3.64e-05	0.27	0.24	Blood metabolite levels;	chr15:76750167	chr15:76174891~76181486:-
LUAD	cis	rs12701220	0.895	rs12534778	ENSG00000229043.2	AC091729.9	5.38	1.17e-07	3.64e-05	0.32	0.24	Bronchopulmonary dysplasia;	chr7:1026225	chr7:1160374~1165267:+
LUAD	cis	rs7208859	0.573	rs7222803	ENSG00000263603.1	CTD-2349P21.5	-5.38	1.17e-07	3.64e-05	-0.41	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30729469~30731202:+
LUAD	cis	rs8177376	0.906	rs487450	ENSG00000254905.1	RP11-712L6.7	5.38	1.17e-07	3.64e-05	0.36	0.24	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126188474	chr11:126292922~126294254:-
LUAD	cis	rs270601	0.77	rs4361510	ENSG00000233006.5	AC034220.3	5.38	1.17e-07	3.65e-05	0.22	0.24	Acylcarnitine levels;	chr5:132263954	chr5:132311285~132369916:-
LUAD	cis	rs7617773	0.817	rs6806112	ENSG00000228638.1	FCF1P2	-5.38	1.17e-07	3.65e-05	-0.27	-0.24	Coronary artery disease;	chr3:48234587	chr3:48290793~48291375:-
LUAD	cis	rs2688482	0.557	rs3103952	ENSG00000224769.1	AC069213.1	5.38	1.17e-07	3.65e-05	0.42	0.24	Lung disease severity in cystic fibrosis;	chr3:195795819	chr3:195614947~195620233:+
LUAD	cis	rs897984	0.762	rs897986	ENSG00000260911.2	RP11-196G11.2	-5.38	1.17e-07	3.65e-05	-0.21	-0.24	Dementia with Lewy bodies;	chr16:30969581	chr16:31043150~31049868:+
LUAD	cis	rs897984	0.721	rs28360557	ENSG00000260911.2	RP11-196G11.2	-5.38	1.17e-07	3.65e-05	-0.21	-0.24	Dementia with Lewy bodies;	chr16:30971939	chr16:31043150~31049868:+
LUAD	cis	rs897984	0.721	rs4889525	ENSG00000260911.2	RP11-196G11.2	-5.38	1.17e-07	3.65e-05	-0.21	-0.24	Dementia with Lewy bodies;	chr16:30978537	chr16:31043150~31049868:+
LUAD	cis	rs67311347	0.544	rs2278930	ENSG00000223797.4	ENTPD3-AS1	5.38	1.17e-07	3.65e-05	0.25	0.24	Renal cell carcinoma;	chr3:40309601	chr3:40313802~40453329:-
LUAD	cis	rs2562456	0.876	rs11085467	ENSG00000268081.1	RP11-678G14.2	5.38	1.17e-07	3.65e-05	0.36	0.24	Pain;	chr19:21569041	chr19:21554640~21569237:-
LUAD	cis	rs72615157	0.645	rs76281814	ENSG00000242294.5	STAG3L5P	5.38	1.17e-07	3.65e-05	0.21	0.24	Lung function (FEV1/FVC);	chr7:100248791	chr7:100336079~100351900:+
LUAD	cis	rs4835473	0.932	rs7664248	ENSG00000251600.4	RP11-673E1.1	5.38	1.17e-07	3.65e-05	0.3	0.24	Immature fraction of reticulocytes;	chr4:143732554	chr4:143912331~143982454:+
LUAD	cis	rs394563	0.591	rs237016	ENSG00000231760.4	RP11-350J20.5	5.38	1.17e-07	3.65e-05	0.29	0.24	Dupuytren's disease;	chr6:149423723	chr6:149796151~149826294:-
LUAD	cis	rs910316	0.839	rs35977276	ENSG00000259138.1	RP11-950C14.7	-5.38	1.17e-07	3.66e-05	-0.25	-0.24	Height;	chr14:75170656	chr14:75127153~75136930:+
LUAD	cis	rs9601248	0.627	rs2876741	ENSG00000227354.5	RBM26-AS1	-5.38	1.18e-07	3.66e-05	-0.27	-0.24	Major depressive disorder;	chr13:79612577	chr13:79406309~79424328:+
LUAD	cis	rs867371	0.502	rs2047679	ENSG00000278603.1	RP13-608F4.5	5.38	1.18e-07	3.66e-05	0.27	0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82239540	chr15:82472203~82472426:+
LUAD	cis	rs2665103	0.687	rs11633000	ENSG00000278603.1	RP13-608F4.5	5.38	1.18e-07	3.66e-05	0.28	0.24	Intelligence (multi-trait analysis);	chr15:82269320	chr15:82472203~82472426:+
LUAD	cis	rs11157436	0.958	rs17255537	ENSG00000211813.2	TRAV34	5.38	1.18e-07	3.66e-05	0.31	0.24	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22208225	chr14:22207522~22208129:+
LUAD	cis	rs9992667	0.955	rs9992076	ENSG00000231160.8	KLF3-AS1	5.38	1.18e-07	3.66e-05	0.3	0.24	Eosinophil percentage of granulocytes;	chr4:38643046	chr4:38612701~38664883:-
LUAD	cis	rs12468226	0.873	rs6435138	ENSG00000272966.1	RP11-686O6.1	-5.38	1.18e-07	3.66e-05	-0.4	-0.24	Urate levels;	chr2:202234310	chr2:202336739~202337200:+
LUAD	cis	rs3738443	0.817	rs61840053	ENSG00000259865.1	RP11-488L18.10	5.38	1.18e-07	3.67e-05	0.25	0.24	Alcohol dependence;	chr1:247204038	chr1:247187281~247188526:-
LUAD	cis	rs2933343	1	rs876756	ENSG00000261159.1	RP11-723O4.9	5.38	1.18e-07	3.67e-05	0.29	0.24	IgG glycosylation;	chr3:128908780	chr3:128859716~128860526:-
LUAD	cis	rs301901	0.734	rs216386	ENSG00000250155.1	CTD-2353F22.1	-5.38	1.18e-07	3.67e-05	-0.25	-0.24	Height;	chr5:37276224	chr5:36666214~36725195:-
LUAD	cis	rs2337406	0.925	rs76288499	ENSG00000211972.2	IGHV3-66	5.38	1.18e-07	3.67e-05	0.27	0.24	Alzheimer's disease (late onset);	chr14:106686309	chr14:106675017~106675544:-
LUAD	cis	rs732716	0.889	rs62129355	ENSG00000267980.1	AC007292.6	-5.38	1.18e-07	3.67e-05	-0.27	-0.24	Mean corpuscular volume;	chr19:4397037	chr19:4363789~4364640:+
LUAD	cis	rs2015599	0.549	rs7956305	ENSG00000275476.1	RP11-996F15.4	5.38	1.18e-07	3.68e-05	0.26	0.24	Platelet count;Mean platelet volume;	chr12:29308639	chr12:29277397~29277882:-
LUAD	cis	rs2015599	0.543	rs6487807	ENSG00000275476.1	RP11-996F15.4	5.38	1.18e-07	3.68e-05	0.26	0.24	Platelet count;Mean platelet volume;	chr12:29309291	chr12:29277397~29277882:-
LUAD	cis	rs2404602	0.692	rs7174673	ENSG00000259422.1	RP11-593F23.1	5.38	1.18e-07	3.68e-05	0.27	0.24	Blood metabolite levels;	chr15:76779657	chr15:76174891~76181486:-
LUAD	cis	rs7927592	0.83	rs7120635	ENSG00000212093.1	AP000807.1	5.38	1.18e-07	3.68e-05	0.26	0.24	Total body bone mineral density;	chr11:68493825	chr11:68506083~68506166:-
LUAD	cis	rs11051970	0.513	rs7972023	ENSG00000274964.1	RP11-817I4.1	-5.38	1.18e-07	3.68e-05	-0.31	-0.24	Response to tocilizumab in rheumatoid arthritis;	chr12:32312174	chr12:32339368~32340724:+
LUAD	cis	rs7617773	0.78	rs7653152	ENSG00000228638.1	FCF1P2	-5.38	1.18e-07	3.68e-05	-0.29	-0.24	Coronary artery disease;	chr3:48320607	chr3:48290793~48291375:-
LUAD	cis	rs1707322	0.964	rs7546237	ENSG00000234329.1	RP11-767N6.2	5.38	1.18e-07	3.68e-05	0.24	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45819938	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.964	rs6697830	ENSG00000234329.1	RP11-767N6.2	5.38	1.18e-07	3.68e-05	0.24	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45824805	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs12060274	ENSG00000234329.1	RP11-767N6.2	5.38	1.18e-07	3.68e-05	0.24	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825390	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.963	rs11211202	ENSG00000234329.1	RP11-767N6.2	5.38	1.18e-07	3.68e-05	0.24	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45826710	chr1:45651039~45651826:-
LUAD	cis	rs950169	0.84	rs4842854	ENSG00000259295.5	CSPG4P12	5.38	1.19e-07	3.69e-05	0.35	0.24	Schizophrenia;	chr15:84387641	chr15:85191438~85213905:+
LUAD	cis	rs858239	0.932	rs1728313	ENSG00000226816.2	AC005082.12	5.38	1.19e-07	3.69e-05	0.3	0.24	Cerebrospinal fluid biomarker levels;	chr7:23231412	chr7:23206013~23208045:+
LUAD	cis	rs11051970	0.559	rs2291420	ENSG00000274964.1	RP11-817I4.1	-5.38	1.19e-07	3.69e-05	-0.3	-0.24	Response to tocilizumab in rheumatoid arthritis;	chr12:32334816	chr12:32339368~32340724:+
LUAD	cis	rs4713118	0.539	rs200988	ENSG00000219392.1	RP1-265C24.5	-5.38	1.19e-07	3.69e-05	-0.31	-0.24	Parkinson's disease;	chr6:27851575	chr6:28115628~28116551:+
LUAD	cis	rs4927850	1	rs10881564	ENSG00000242086.7	LINC00969	5.38	1.19e-07	3.69e-05	0.21	0.24	Pancreatic cancer;	chr3:196023455	chr3:195658062~195739964:+
LUAD	cis	rs8103033	0.786	rs7245574	ENSG00000226025.8	LGALS17A	-5.38	1.19e-07	3.69e-05	-0.27	-0.24	Obesity-related traits;	chr19:39657462	chr19:39679374~39686373:+
LUAD	cis	rs2404602	0.692	rs1867197	ENSG00000259422.1	RP11-593F23.1	-5.38	1.19e-07	3.69e-05	-0.27	-0.24	Blood metabolite levels;	chr15:76617690	chr15:76174891~76181486:-
LUAD	cis	rs10800713	0.866	rs6703783	ENSG00000260088.1	RP11-92G12.3	-5.38	1.19e-07	3.69e-05	-0.35	-0.24	Tandem gait;	chr1:200544290	chr1:200669507~200694250:+
LUAD	cis	rs2439831	0.702	rs8033995	ENSG00000249839.1	AC011330.5	-5.38	1.19e-07	3.69e-05	-0.47	-0.24	Lung cancer in ever smokers;	chr15:43721311	chr15:43663654~43684339:-
LUAD	cis	rs10129255	0.957	rs8009948	ENSG00000224373.3	IGHV4-59	5.38	1.19e-07	3.69e-05	0.16	0.24	Kawasaki disease;	chr14:106805607	chr14:106627249~106627825:-
LUAD	cis	rs9860428	0.935	rs6787688	ENSG00000242770.2	RP11-180K7.1	-5.38	1.19e-07	3.69e-05	-0.24	-0.24	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112832131	chr3:112802478~112812819:+
LUAD	cis	rs5758659	1	rs134882	ENSG00000182057.4	OGFRP1	5.38	1.19e-07	3.69e-05	0.28	0.24	Cognitive function;	chr22:42274959	chr22:42269753~42275196:+
LUAD	cis	rs2337406	1	rs17095456	ENSG00000223648.3	IGHV3-64	5.38	1.19e-07	3.69e-05	0.3	0.24	Alzheimer's disease (late onset);	chr14:106676559	chr14:106643132~106658258:-
LUAD	cis	rs4908760	0.864	rs1953827	ENSG00000232912.4	RP5-1115A15.1	5.38	1.19e-07	3.7e-05	0.22	0.24	Vitiligo;	chr1:8619789	chr1:8424645~8434838:+
LUAD	cis	rs7208859	0.623	rs56325146	ENSG00000263603.1	CTD-2349P21.5	-5.38	1.19e-07	3.7e-05	-0.41	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824006	chr17:30729469~30731202:+
LUAD	cis	rs897984	0.542	rs8061047	ENSG00000260911.2	RP11-196G11.2	5.38	1.19e-07	3.7e-05	0.22	0.24	Dementia with Lewy bodies;	chr16:31057639	chr16:31043150~31049868:+
LUAD	cis	rs600231	0.665	rs1626021	ENSG00000245532.5	NEAT1	5.38	1.19e-07	3.7e-05	0.19	0.24	Bone mineral density;	chr11:65458716	chr11:65422774~65445540:+
LUAD	cis	rs11157436	0.958	rs61972231	ENSG00000211813.2	TRAV34	5.38	1.19e-07	3.7e-05	0.31	0.24	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22206508	chr14:22207522~22208129:+
LUAD	cis	rs7208859	0.623	rs73269913	ENSG00000263603.1	CTD-2349P21.5	-5.38	1.19e-07	3.7e-05	-0.41	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765165	chr17:30729469~30731202:+
LUAD	cis	rs1075265	0.572	rs3770405	ENSG00000233266.1	HMGB1P31	5.38	1.19e-07	3.7e-05	0.3	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53694884	chr2:54051334~54051760:+
LUAD	cis	rs4660214	0.724	rs2484751	ENSG00000228060.1	RP11-69E11.8	5.38	1.19e-07	3.7e-05	0.22	0.24	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39282867	chr1:39565160~39573203:+
LUAD	cis	rs875971	0.54	rs1723268	ENSG00000236529.1	RP13-254B10.1	5.38	1.19e-07	3.71e-05	0.24	0.24	Aortic root size;	chr7:66008093	chr7:65840212~65840596:+
LUAD	cis	rs11976180	1	rs2371244	ENSG00000170356.8	OR2A20P	-5.38	1.19e-07	3.71e-05	-0.3	-0.24	Obesity-related traits;	chr7:144060518	chr7:144250045~144252957:-
LUAD	cis	rs11976180	1	rs4726669	ENSG00000170356.8	OR2A20P	-5.38	1.19e-07	3.71e-05	-0.3	-0.24	Obesity-related traits;	chr7:144061098	chr7:144250045~144252957:-
LUAD	cis	rs12701220	0.553	rs13245507	ENSG00000229043.2	AC091729.9	-5.37	1.2e-07	3.72e-05	-0.31	-0.24	Bronchopulmonary dysplasia;	chr7:1124058	chr7:1160374~1165267:+
LUAD	cis	rs10754283	0.967	rs12058749	ENSG00000231613.1	RP5-943J3.1	5.37	1.2e-07	3.72e-05	0.25	0.24	Amyotrophic lateral sclerosis (sporadic);	chr1:89640045	chr1:89788914~89790492:+
LUAD	cis	rs2562456	0.682	rs11085464	ENSG00000268081.1	RP11-678G14.2	5.37	1.2e-07	3.72e-05	0.36	0.24	Pain;	chr19:21568976	chr19:21554640~21569237:-
LUAD	cis	rs673078	0.66	rs11068917	ENSG00000275409.1	RP11-131L12.4	-5.37	1.2e-07	3.72e-05	-0.31	-0.24	Glucose homeostasis traits;	chr12:118353315	chr12:118430147~118430699:+
LUAD	cis	rs453301	0.631	rs17700611	ENSG00000253981.4	ALG1L13P	-5.37	1.2e-07	3.73e-05	-0.28	-0.24	Joint mobility (Beighton score);	chr8:8936144	chr8:8236003~8244667:-
LUAD	cis	rs35740288	0.753	rs4843095	ENSG00000202081.1	RNU6-1280P	5.37	1.2e-07	3.73e-05	0.3	0.24	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85731900	chr15:85651522~85651628:-
LUAD	cis	rs4722166	0.645	rs1404006	ENSG00000179428.2	AC073072.5	-5.37	1.2e-07	3.73e-05	-0.29	-0.24	Lung cancer;	chr7:22755458	chr7:22725395~22727620:-
LUAD	cis	rs7208859	0.673	rs216418	ENSG00000263603.1	CTD-2349P21.5	-5.37	1.2e-07	3.73e-05	-0.36	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30609519	chr17:30729469~30731202:+
LUAD	cis	rs7617773	0.743	rs11716371	ENSG00000228638.1	FCF1P2	-5.37	1.2e-07	3.74e-05	-0.29	-0.24	Coronary artery disease;	chr3:48321260	chr3:48290793~48291375:-
LUAD	cis	rs2980439	0.87	rs2945230	ENSG00000253981.4	ALG1L13P	5.37	1.2e-07	3.74e-05	0.27	0.24	Neuroticism;	chr8:8252414	chr8:8236003~8244667:-
LUAD	cis	rs9813712	0.571	rs9855777	ENSG00000228252.7	COL6A4P2	5.37	1.2e-07	3.74e-05	0.22	0.24	Response to amphetamines;	chr3:130214805	chr3:130212823~130273806:+
LUAD	cis	rs6496932	0.874	rs2003294	ENSG00000202081.1	RNU6-1280P	5.37	1.2e-07	3.74e-05	0.32	0.24	Central corneal thickness;Corneal structure;	chr15:85274141	chr15:85651522~85651628:-
LUAD	cis	rs8050896	1	rs8056781	ENSG00000260695.1	RP11-513N24.1	-5.37	1.2e-07	3.74e-05	-0.4	-0.24	Response to antipsychotic treatment;	chr16:66123904	chr16:65861112~65863784:-
LUAD	cis	rs8050896	1	rs16969780	ENSG00000260695.1	RP11-513N24.1	-5.37	1.2e-07	3.74e-05	-0.4	-0.24	Response to antipsychotic treatment;	chr16:66123985	chr16:65861112~65863784:-
LUAD	cis	rs8050896	1	rs59544104	ENSG00000260695.1	RP11-513N24.1	-5.37	1.2e-07	3.74e-05	-0.4	-0.24	Response to antipsychotic treatment;	chr16:66124034	chr16:65861112~65863784:-
LUAD	cis	rs8050896	1	rs7198106	ENSG00000260695.1	RP11-513N24.1	-5.37	1.2e-07	3.74e-05	-0.4	-0.24	Response to antipsychotic treatment;	chr16:66124175	chr16:65861112~65863784:-
LUAD	cis	rs8050896	1	rs7199238	ENSG00000260695.1	RP11-513N24.1	-5.37	1.2e-07	3.74e-05	-0.4	-0.24	Response to antipsychotic treatment;	chr16:66124251	chr16:65861112~65863784:-
LUAD	cis	rs9652601	0.691	rs3862468	ENSG00000274038.1	RP11-66H6.4	5.37	1.2e-07	3.74e-05	0.28	0.24	Systemic lupus erythematosus;	chr16:11100161	chr16:11056556~11057034:+
LUAD	cis	rs763567	0.605	rs647438	ENSG00000271811.1	RP1-79C4.4	-5.37	1.21e-07	3.75e-05	-0.27	-0.24	Tonsillectomy;	chr1:170608094	chr1:170667381~170669425:+
LUAD	cis	rs9287719	0.649	rs10184776	ENSG00000243819.4	RN7SL832P	5.37	1.21e-07	3.75e-05	0.25	0.24	Prostate cancer;	chr2:10586320	chr2:10690344~10692099:+
LUAD	cis	rs853679	0.76	rs11962305	ENSG00000219392.1	RP1-265C24.5	-5.37	1.21e-07	3.75e-05	-0.35	-0.24	Depression;	chr6:28232159	chr6:28115628~28116551:+
LUAD	cis	rs7618501	0.633	rs2008877	ENSG00000234667.1	ACTBP13	5.37	1.21e-07	3.75e-05	0.27	0.24	Intelligence (multi-trait analysis);	chr3:50124858	chr3:49873347~49877980:-
LUAD	cis	rs12935418	0.887	rs3743503	ENSG00000261061.1	RP11-303E16.2	-5.37	1.21e-07	3.76e-05	-0.36	-0.24	Mean corpuscular volume;	chr16:81022836	chr16:81030770~81031485:+
LUAD	cis	rs8098244	0.557	rs10445487	ENSG00000264745.1	TTC39C-AS1	5.37	1.21e-07	3.76e-05	0.25	0.24	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23723728	chr18:23994213~24015339:-
LUAD	cis	rs7208859	0.562	rs8078897	ENSG00000263603.1	CTD-2349P21.5	-5.37	1.21e-07	3.76e-05	-0.41	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs9914499	ENSG00000263603.1	CTD-2349P21.5	-5.37	1.21e-07	3.76e-05	-0.41	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs12006	ENSG00000263603.1	CTD-2349P21.5	-5.37	1.21e-07	3.76e-05	-0.41	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs3752021	ENSG00000263603.1	CTD-2349P21.5	-5.37	1.21e-07	3.76e-05	-0.41	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs1061342	ENSG00000263603.1	CTD-2349P21.5	-5.37	1.21e-07	3.76e-05	-0.41	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs55938328	ENSG00000263603.1	CTD-2349P21.5	-5.37	1.21e-07	3.76e-05	-0.41	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs55961983	ENSG00000263603.1	CTD-2349P21.5	-5.37	1.21e-07	3.76e-05	-0.41	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30729469~30731202:+
LUAD	cis	rs17826219	0.568	rs7213925	ENSG00000263603.1	CTD-2349P21.5	-5.37	1.21e-07	3.76e-05	-0.41	-0.24	Body mass index;	chr17:30794616	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs11658945	ENSG00000263603.1	CTD-2349P21.5	-5.37	1.21e-07	3.76e-05	-0.41	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs11657990	ENSG00000263603.1	CTD-2349P21.5	-5.37	1.21e-07	3.76e-05	-0.41	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs11650982	ENSG00000263603.1	CTD-2349P21.5	-5.37	1.21e-07	3.76e-05	-0.41	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs9915546	ENSG00000263603.1	CTD-2349P21.5	-5.37	1.21e-07	3.76e-05	-0.41	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs9895815	ENSG00000263603.1	CTD-2349P21.5	-5.37	1.21e-07	3.76e-05	-0.41	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30729469~30731202:+
LUAD	cis	rs17826219	0.706	rs73271850	ENSG00000263603.1	CTD-2349P21.5	-5.37	1.21e-07	3.76e-05	-0.41	-0.24	Body mass index;	chr17:30815122	chr17:30729469~30731202:+
LUAD	cis	rs17826219	0.636	rs79565452	ENSG00000263603.1	CTD-2349P21.5	-5.37	1.21e-07	3.76e-05	-0.41	-0.24	Body mass index;	chr17:30815823	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs7208088	ENSG00000263603.1	CTD-2349P21.5	-5.37	1.21e-07	3.76e-05	-0.41	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30729469~30731202:+
LUAD	cis	rs11157436	0.958	rs17183308	ENSG00000211813.2	TRAV34	5.37	1.21e-07	3.76e-05	0.31	0.24	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22195090	chr14:22207522~22208129:+
LUAD	cis	rs66887589	0.934	rs41464847	ENSG00000245958.5	RP11-33B1.1	5.37	1.21e-07	3.76e-05	0.19	0.24	Diastolic blood pressure;	chr4:119611246	chr4:119454791~119552025:+
LUAD	cis	rs10129255	0.957	rs12589190	ENSG00000224373.3	IGHV4-59	5.37	1.21e-07	3.76e-05	0.15	0.24	Kawasaki disease;	chr14:106783079	chr14:106627249~106627825:-
LUAD	cis	rs10129255	0.957	rs7493713	ENSG00000224373.3	IGHV4-59	5.37	1.21e-07	3.76e-05	0.15	0.24	Kawasaki disease;	chr14:106783685	chr14:106627249~106627825:-
LUAD	cis	rs10129255	0.912	rs35468694	ENSG00000224373.3	IGHV4-59	5.37	1.21e-07	3.76e-05	0.15	0.24	Kawasaki disease;	chr14:106784199	chr14:106627249~106627825:-
LUAD	cis	rs10129255	0.957	rs8019272	ENSG00000224373.3	IGHV4-59	5.37	1.21e-07	3.76e-05	0.15	0.24	Kawasaki disease;	chr14:106784709	chr14:106627249~106627825:-
LUAD	cis	rs9287719	0.615	rs12613769	ENSG00000243819.4	RN7SL832P	5.37	1.21e-07	3.76e-05	0.26	0.24	Prostate cancer;	chr2:10602164	chr2:10690344~10692099:+
LUAD	cis	rs10129255	0.509	rs756583	ENSG00000211967.3	IGHV3-53	-5.37	1.21e-07	3.77e-05	-0.17	-0.24	Kawasaki disease;	chr14:106680002	chr14:106592676~106593347:-
LUAD	cis	rs8072100	0.967	rs11871606	ENSG00000228782.6	CTD-2026D20.3	-5.37	1.22e-07	3.77e-05	-0.24	-0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47655408	chr17:47450568~47492492:-
LUAD	cis	rs10091374	0.901	rs12678139	ENSG00000253967.1	RP11-333A23.4	5.37	1.22e-07	3.77e-05	0.27	0.24	Cardiac Troponin-T levels;	chr8:70481515	chr8:70471134~70485687:+
LUAD	cis	rs10129255	1	rs4612959	ENSG00000224373.3	IGHV4-59	5.37	1.22e-07	3.77e-05	0.15	0.24	Kawasaki disease;	chr14:106767055	chr14:106627249~106627825:-
LUAD	cis	rs8098244	0.536	rs10445488	ENSG00000264745.1	TTC39C-AS1	5.37	1.22e-07	3.78e-05	0.25	0.24	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23725402	chr18:23994213~24015339:-
LUAD	cis	rs7968440	0.736	rs10747592	ENSG00000200428.1	Y_RNA	5.37	1.22e-07	3.78e-05	0.3	0.24	Fibrinogen;	chr12:50788339	chr12:50743568~50743684:+
LUAD	cis	rs8050896	1	rs7198326	ENSG00000260695.1	RP11-513N24.1	-5.37	1.22e-07	3.78e-05	-0.4	-0.24	Response to antipsychotic treatment;	chr16:66124311	chr16:65861112~65863784:-
LUAD	cis	rs13423976	0.78	rs6720282	ENSG00000231367.4	AC016995.3	-5.37	1.22e-07	3.78e-05	-0.3	-0.24	Gut microbiome composition (summer);	chr2:38545045	chr2:38406719~38515740:-
LUAD	cis	rs1707322	0.686	rs1250	ENSG00000280836.1	AL355480.1	-5.37	1.22e-07	3.79e-05	-0.32	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628355	chr1:45581219~45581321:-
LUAD	cis	rs4273100	1	rs16960499	ENSG00000228157.4	AC007952.5	5.37	1.22e-07	3.79e-05	0.39	0.24	Schizophrenia;	chr17:19299719	chr17:19092974~19096837:+
LUAD	cis	rs67311347	0.544	rs1454492	ENSG00000223797.4	ENTPD3-AS1	5.37	1.22e-07	3.79e-05	0.25	0.24	Renal cell carcinoma;	chr3:40311393	chr3:40313802~40453329:-
LUAD	cis	rs4908760	0.792	rs10864361	ENSG00000232912.4	RP5-1115A15.1	-5.37	1.22e-07	3.79e-05	-0.22	-0.24	Vitiligo;	chr1:8666662	chr1:8424645~8434838:+
LUAD	cis	rs9595908	0.746	rs7985640	ENSG00000212293.1	SNORA16	5.37	1.23e-07	3.8e-05	0.25	0.24	Body mass index;	chr13:32698228	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.785	rs9591252	ENSG00000212293.1	SNORA16	5.37	1.23e-07	3.8e-05	0.25	0.24	Body mass index;	chr13:32698297	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.785	rs9596083	ENSG00000212293.1	SNORA16	5.37	1.23e-07	3.8e-05	0.25	0.24	Body mass index;	chr13:32700494	chr13:32420390~32420516:-
LUAD	cis	rs2439831	0.85	rs12442129	ENSG00000249839.1	AC011330.5	-5.37	1.23e-07	3.8e-05	-0.48	-0.24	Lung cancer in ever smokers;	chr15:43763658	chr15:43663654~43684339:-
LUAD	cis	rs17666538	0.591	rs7818950	ENSG00000254207.1	RP11-43A14.1	5.37	1.23e-07	3.8e-05	0.45	0.24	IgG glycosylation;	chr8:693831	chr8:725188~725877:-
LUAD	cis	rs1075265	0.783	rs805424	ENSG00000233266.1	HMGB1P31	5.37	1.23e-07	3.8e-05	0.3	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53901098	chr2:54051334~54051760:+
LUAD	cis	rs950169	0.881	rs4842852	ENSG00000259295.5	CSPG4P12	5.37	1.23e-07	3.8e-05	0.35	0.24	Schizophrenia;	chr15:84387263	chr15:85191438~85213905:+
LUAD	cis	rs950169	0.84	rs4842853	ENSG00000259295.5	CSPG4P12	5.37	1.23e-07	3.8e-05	0.35	0.24	Schizophrenia;	chr15:84387606	chr15:85191438~85213905:+
LUAD	cis	rs950169	0.922	rs4842946	ENSG00000259295.5	CSPG4P12	5.37	1.23e-07	3.8e-05	0.35	0.24	Schizophrenia;	chr15:84387633	chr15:85191438~85213905:+
LUAD	cis	rs950169	0.887	rs3860265	ENSG00000259295.5	CSPG4P12	5.37	1.23e-07	3.8e-05	0.35	0.24	Schizophrenia;	chr15:84390487	chr15:85191438~85213905:+
LUAD	cis	rs6714710	0.603	rs7421146	ENSG00000230606.9	AC159540.1	-5.37	1.23e-07	3.8e-05	-0.26	-0.24	Posterior cortical atrophy and Alzheimer's disease;	chr2:97935808	chr2:97416165~97433527:-
LUAD	cis	rs10761482	0.5	rs10740030	ENSG00000254271.1	RP11-131N11.4	5.37	1.23e-07	3.81e-05	0.27	0.24	Schizophrenia;	chr10:60532054	chr10:60734342~60741828:+
LUAD	cis	rs858239	0.6	rs4321896	ENSG00000230042.1	AK3P3	-5.37	1.23e-07	3.81e-05	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23088437	chr7:23129178~23129841:+
LUAD	cis	rs997295	0.675	rs12902804	ENSG00000270964.1	RP11-502I4.3	-5.37	1.23e-07	3.81e-05	-0.25	-0.24	Motion sickness;	chr15:67696320	chr15:67541072~67542604:-
LUAD	cis	rs9952991	0.882	rs2847274	ENSG00000260302.1	RP11-973H7.1	-5.37	1.23e-07	3.82e-05	-0.42	-0.24	Inflammatory skin disease;	chr18:12777604	chr18:12774651~12775923:-
LUAD	cis	rs9952991	0.941	rs2847278	ENSG00000260302.1	RP11-973H7.1	-5.37	1.23e-07	3.82e-05	-0.42	-0.24	Inflammatory skin disease;	chr18:12778716	chr18:12774651~12775923:-
LUAD	cis	rs7617773	0.817	rs3729577	ENSG00000228638.1	FCF1P2	-5.37	1.23e-07	3.82e-05	-0.28	-0.24	Coronary artery disease;	chr3:48187504	chr3:48290793~48291375:-
LUAD	cis	rs2412819	0.52	rs17727763	ENSG00000249839.1	AC011330.5	-5.37	1.23e-07	3.82e-05	-0.42	-0.24	Lung cancer;	chr15:43623873	chr15:43663654~43684339:-
LUAD	cis	rs12468226	0.817	rs6435135	ENSG00000272966.1	RP11-686O6.1	-5.37	1.23e-07	3.82e-05	-0.4	-0.24	Urate levels;	chr2:202217469	chr2:202336739~202337200:+
LUAD	cis	rs9287719	0.649	rs6732429	ENSG00000243819.4	RN7SL832P	-5.37	1.23e-07	3.82e-05	-0.25	-0.24	Prostate cancer;	chr2:10618846	chr2:10690344~10692099:+
LUAD	cis	rs2439831	0.85	rs8023458	ENSG00000205771.5	CATSPER2P1	-5.37	1.23e-07	3.83e-05	-0.46	-0.24	Lung cancer in ever smokers;	chr15:43788741	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.85	rs16963953	ENSG00000205771.5	CATSPER2P1	-5.37	1.23e-07	3.83e-05	-0.46	-0.24	Lung cancer in ever smokers;	chr15:43789521	chr15:43726918~43747094:-
LUAD	cis	rs6570726	0.935	rs434298	ENSG00000235652.6	RP11-545I5.3	5.37	1.24e-07	3.83e-05	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145525737	chr6:145799409~145886585:+
LUAD	cis	rs2404602	0.692	rs57178708	ENSG00000259422.1	RP11-593F23.1	5.37	1.24e-07	3.83e-05	0.28	0.24	Blood metabolite levels;	chr15:76611728	chr15:76174891~76181486:-
LUAD	cis	rs1275468	0.689	rs1795382	ENSG00000257497.2	RP11-585P4.5	-5.37	1.24e-07	3.83e-05	-0.35	-0.24	Polycystic ovary syndrome;	chr12:75586113	chr12:75483454~75489820:-
LUAD	cis	rs2688608	0.592	rs7923045	ENSG00000271816.1	BMS1P4	5.37	1.24e-07	3.83e-05	0.2	0.24	Inflammatory bowel disease;	chr10:73727740	chr10:73699151~73730487:-
LUAD	cis	rs2404602	0.735	rs2048856	ENSG00000259422.1	RP11-593F23.1	-5.37	1.24e-07	3.83e-05	-0.3	-0.24	Blood metabolite levels;	chr15:76507742	chr15:76174891~76181486:-
LUAD	cis	rs875971	0.577	rs35072105	ENSG00000237310.1	GS1-124K5.4	-5.37	1.24e-07	3.83e-05	-0.26	-0.24	Aortic root size;	chr7:66144830	chr7:66493706~66495474:+
LUAD	cis	rs732716	0.853	rs72990643	ENSG00000267980.1	AC007292.6	-5.37	1.24e-07	3.83e-05	-0.28	-0.24	Mean corpuscular volume;	chr19:4454739	chr19:4363789~4364640:+
LUAD	cis	rs11295209	1	rs11295209	ENSG00000245958.5	RP11-33B1.1	5.37	1.24e-07	3.84e-05	0.19	0.24	Plateletcrit;	chr4:119559079	chr4:119454791~119552025:+
LUAD	cis	rs7131987	0.65	rs67146951	ENSG00000257176.2	RP11-996F15.2	-5.37	1.24e-07	3.84e-05	-0.27	-0.24	QT interval;	chr12:29297620	chr12:29280418~29317848:-
LUAD	cis	rs7131987	0.65	rs10843382	ENSG00000257176.2	RP11-996F15.2	-5.37	1.24e-07	3.84e-05	-0.27	-0.24	QT interval;	chr12:29298788	chr12:29280418~29317848:-
LUAD	cis	rs4713118	0.662	rs149970	ENSG00000204709.4	LINC01556	5.37	1.24e-07	3.84e-05	0.32	0.24	Parkinson's disease;	chr6:28012442	chr6:28943877~28944537:+
LUAD	cis	rs6772849	1	rs2712379	ENSG00000242551.2	POU5F1P6	-5.37	1.24e-07	3.84e-05	-0.28	-0.24	Monocyte percentage of white cells;Monocyte count;	chr3:128590217	chr3:128674735~128677005:-
LUAD	cis	rs2404602	0.709	rs11072591	ENSG00000259422.1	RP11-593F23.1	5.37	1.24e-07	3.84e-05	0.3	0.24	Blood metabolite levels;	chr15:76357221	chr15:76174891~76181486:-
LUAD	cis	rs1008375	0.864	rs4698196	ENSG00000249502.1	AC006160.5	-5.37	1.24e-07	3.84e-05	-0.24	-0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17573112	chr4:17587467~17614571:-
LUAD	cis	rs4713118	0.581	rs200504	ENSG00000219392.1	RP1-265C24.5	-5.37	1.24e-07	3.84e-05	-0.34	-0.24	Parkinson's disease;	chr6:27818042	chr6:28115628~28116551:+
LUAD	cis	rs7777677	0.925	rs6969951	ENSG00000244273.1	PGBD4P1	5.37	1.24e-07	3.85e-05	0.26	0.24	Alcoholic chronic pancreatitis;	chr7:142661753	chr7:142722358~142722764:+
LUAD	cis	rs172166	0.694	rs203884	ENSG00000204709.4	LINC01556	5.37	1.24e-07	3.85e-05	0.31	0.24	Cardiac Troponin-T levels;	chr6:28109596	chr6:28943877~28944537:+
LUAD	cis	rs6772849	1	rs2712378	ENSG00000242551.2	POU5F1P6	-5.37	1.24e-07	3.85e-05	-0.27	-0.24	Monocyte percentage of white cells;Monocyte count;	chr3:128589951	chr3:128674735~128677005:-
LUAD	cis	rs950169	0.544	rs12913702	ENSG00000259295.5	CSPG4P12	5.37	1.24e-07	3.85e-05	0.34	0.24	Schizophrenia;	chr15:84609953	chr15:85191438~85213905:+
LUAD	cis	rs950169	0.509	rs71395455	ENSG00000259295.5	CSPG4P12	5.37	1.24e-07	3.85e-05	0.34	0.24	Schizophrenia;	chr15:84610573	chr15:85191438~85213905:+
LUAD	cis	rs997295	0.638	rs11854197	ENSG00000270964.1	RP11-502I4.3	-5.37	1.24e-07	3.85e-05	-0.25	-0.24	Motion sickness;	chr15:67685046	chr15:67541072~67542604:-
LUAD	cis	rs516805	0.748	rs511279	ENSG00000279453.1	RP3-425C14.4	-5.37	1.24e-07	3.85e-05	-0.31	-0.24	Lymphocyte counts;	chr6:122451385	chr6:122436789~122439223:-
LUAD	cis	rs9341808	0.556	rs10455370	ENSG00000272129.1	RP11-250B2.6	-5.37	1.25e-07	3.86e-05	-0.29	-0.24	Sitting height ratio;	chr6:80331150	chr6:80355424~80356859:+
LUAD	cis	rs910316	1	rs12897094	ENSG00000259138.1	RP11-950C14.7	5.37	1.25e-07	3.86e-05	0.25	0.24	Height;	chr14:75112713	chr14:75127153~75136930:+
LUAD	cis	rs4664293	0.967	rs3940435	ENSG00000226266.5	AC009961.3	-5.37	1.25e-07	3.86e-05	-0.33	-0.24	Monocyte percentage of white cells;	chr2:159638272	chr2:159670708~159712435:-
LUAD	cis	rs2933343	0.953	rs2933344	ENSG00000231305.3	RP11-723O4.2	5.37	1.25e-07	3.86e-05	0.28	0.24	IgG glycosylation;	chr3:128939872	chr3:128861313~128871540:-
LUAD	cis	rs10129255	0.518	rs8009594	ENSG00000254174.1	IGHV1-12	5.37	1.25e-07	3.86e-05	0.16	0.24	Kawasaki disease;	chr14:106777494	chr14:106122420~106122709:-
LUAD	cis	rs507080	0.733	rs4486664	ENSG00000278376.1	RP11-158I9.8	-5.37	1.25e-07	3.86e-05	-0.26	-0.24	Serum metabolite levels;	chr11:118698358	chr11:118791254~118793137:+
LUAD	cis	rs394563	0.591	rs805026	ENSG00000231760.4	RP11-350J20.5	5.37	1.25e-07	3.86e-05	0.29	0.24	Dupuytren's disease;	chr6:149407118	chr6:149796151~149826294:-
LUAD	cis	rs875971	0.54	rs1723268	ENSG00000224316.1	RP11-479O9.2	5.37	1.25e-07	3.86e-05	0.24	0.24	Aortic root size;	chr7:66008093	chr7:65773620~65802067:+
LUAD	cis	rs3020264	0.579	rs2454517	ENSG00000271743.1	CTD-2541M15.3	-5.37	1.25e-07	3.87e-05	-0.32	-0.24	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6616237	chr8:6615604~6617198:-
LUAD	cis	rs2288884	0.731	rs11673450	ENSG00000275055.1	CTC-471J1.11	-5.37	1.25e-07	3.87e-05	-0.33	-0.24	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52037441	chr19:52049007~52049754:+
LUAD	cis	rs2288884	0.731	rs11673398	ENSG00000275055.1	CTC-471J1.11	-5.37	1.25e-07	3.87e-05	-0.33	-0.24	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52037444	chr19:52049007~52049754:+
LUAD	cis	rs36093844	0.706	rs79907592	ENSG00000279742.1	RP11-700A24.1	-5.37	1.25e-07	3.87e-05	-0.32	-0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85847024	chr11:85852557~85854943:-
LUAD	cis	rs1722141	0.67	rs1722148	ENSG00000229628.1	AC073115.7	5.37	1.25e-07	3.87e-05	0.38	0.24	Sitting height ratio;	chr7:45953897	chr7:45990905~46000898:+
LUAD	cis	rs1722141	0.67	rs788766	ENSG00000229628.1	AC073115.7	5.37	1.25e-07	3.87e-05	0.38	0.24	Sitting height ratio;	chr7:45957944	chr7:45990905~46000898:+
LUAD	cis	rs1722141	0.67	rs788768	ENSG00000229628.1	AC073115.7	5.37	1.25e-07	3.87e-05	0.38	0.24	Sitting height ratio;	chr7:45960955	chr7:45990905~46000898:+
LUAD	cis	rs10129255	0.957	rs12590667	ENSG00000224373.3	IGHV4-59	-5.37	1.25e-07	3.87e-05	-0.15	-0.24	Kawasaki disease;	chr14:106779223	chr14:106627249~106627825:-
LUAD	cis	rs6860806	0.507	rs2631372	ENSG00000233006.5	AC034220.3	5.37	1.25e-07	3.88e-05	0.24	0.24	Breast cancer;	chr5:132367886	chr5:132311285~132369916:-
LUAD	cis	rs1499614	0.522	rs13247442	ENSG00000226824.5	RP4-756H11.3	-5.37	1.25e-07	3.88e-05	-0.52	-0.24	Gout;	chr7:66723871	chr7:66654538~66669855:+
LUAD	cis	rs10129255	0.5	rs2105989	ENSG00000211967.3	IGHV3-53	-5.37	1.25e-07	3.88e-05	-0.17	-0.24	Kawasaki disease;	chr14:106682199	chr14:106592676~106593347:-
LUAD	cis	rs4835473	0.897	rs11931330	ENSG00000251600.4	RP11-673E1.1	5.37	1.26e-07	3.89e-05	0.29	0.24	Immature fraction of reticulocytes;	chr4:143970808	chr4:143912331~143982454:+
LUAD	cis	rs7829975	0.742	rs1533058	ENSG00000173295.6	FAM86B3P	5.37	1.26e-07	3.89e-05	0.25	0.24	Mood instability;	chr8:8827680	chr8:8228595~8244865:+
LUAD	cis	rs6687821	0.515	rs2764425	ENSG00000267734.1	RP4-604K5.3	-5.37	1.26e-07	3.89e-05	-0.29	-0.24	Yeast infection;	chr1:87083076	chr1:86932199~86934891:-
LUAD	cis	rs950169	0.763	rs35372971	ENSG00000259295.5	CSPG4P12	5.37	1.26e-07	3.89e-05	0.34	0.24	Schizophrenia;	chr15:84387097	chr15:85191438~85213905:+
LUAD	cis	rs7712401	0.623	rs7723798	ENSG00000263432.2	RN7SL689P	5.37	1.26e-07	3.9e-05	0.3	0.24	Mean platelet volume;	chr5:123034022	chr5:123022487~123022783:-
LUAD	cis	rs7580658	0.676	rs12465955	ENSG00000236682.1	AC068282.3	-5.37	1.26e-07	3.9e-05	-0.31	-0.24	Protein C levels;	chr2:127249498	chr2:127389130~127400580:+
LUAD	cis	rs1707322	1	rs785510	ENSG00000280836.1	AL355480.1	5.37	1.26e-07	3.9e-05	0.32	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062946	chr1:45581219~45581321:-
LUAD	cis	rs4654783	0.671	rs1474647	ENSG00000228397.1	RP1-224A6.3	5.36	1.26e-07	3.9e-05	0.3	0.24	Endometriosis;	chr1:22115372	chr1:22023994~22024968:-
LUAD	cis	rs11976180	1	rs6464573	ENSG00000170356.8	OR2A20P	5.36	1.26e-07	3.9e-05	0.3	0.24	Obesity-related traits;	chr7:144051005	chr7:144250045~144252957:-
LUAD	cis	rs10129255	0.83	rs61997609	ENSG00000224373.3	IGHV4-59	5.36	1.26e-07	3.9e-05	0.16	0.24	Kawasaki disease;	chr14:106692376	chr14:106627249~106627825:-
LUAD	cis	rs41307935	0.778	rs78533482	ENSG00000260063.1	RP5-968P14.2	-5.36	1.26e-07	3.91e-05	-0.44	-0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26715851	chr1:26692132~26694131:-
LUAD	cis	rs11051970	0.559	rs3789975	ENSG00000274964.1	RP11-817I4.1	-5.36	1.26e-07	3.91e-05	-0.3	-0.24	Response to tocilizumab in rheumatoid arthritis;	chr12:32331469	chr12:32339368~32340724:+
LUAD	cis	rs561341	0.882	rs72825748	ENSG00000265798.5	RP11-271K11.5	5.36	1.27e-07	3.91e-05	0.38	0.24	Hip circumference adjusted for BMI;	chr17:32040377	chr17:31038575~31059121:-
LUAD	cis	rs11976180	1	rs1533268	ENSG00000170356.8	OR2A20P	-5.36	1.27e-07	3.92e-05	-0.3	-0.24	Obesity-related traits;	chr7:144069265	chr7:144250045~144252957:-
LUAD	cis	rs11976180	1	rs1533267	ENSG00000170356.8	OR2A20P	-5.36	1.27e-07	3.92e-05	-0.3	-0.24	Obesity-related traits;	chr7:144069347	chr7:144250045~144252957:-
LUAD	cis	rs74233809	1	rs12217501	ENSG00000213277.3	MARCKSL1P1	5.36	1.27e-07	3.92e-05	0.42	0.24	Birth weight;	chr10:103092132	chr10:103175554~103176094:+
LUAD	cis	rs55665837	0.701	rs1522633	ENSG00000251991.1	RNU7-49P	5.36	1.27e-07	3.93e-05	0.28	0.24	Vitamin D levels;	chr11:14623692	chr11:14478892~14478953:+
LUAD	cis	rs7811142	1	rs28490152	ENSG00000078319.8	PMS2P1	-5.36	1.27e-07	3.93e-05	-0.27	-0.24	Platelet count;	chr7:100423359	chr7:100320992~100341908:-
LUAD	cis	rs6676180	0.555	rs12060730	ENSG00000231365.4	RP11-418J17.1	-5.36	1.27e-07	3.93e-05	-0.28	-0.24	Monobrow;	chr1:119228079	chr1:119140396~119275973:+
LUAD	cis	rs748404	0.589	rs62020616	ENSG00000205771.5	CATSPER2P1	-5.36	1.27e-07	3.93e-05	-0.36	-0.24	Lung cancer;	chr15:43558554	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.626	rs60367691	ENSG00000205771.5	CATSPER2P1	-5.36	1.27e-07	3.93e-05	-0.36	-0.24	Lung cancer;	chr15:43559201	chr15:43726918~43747094:-
LUAD	cis	rs10129255	0.518	rs8009612	ENSG00000254174.1	IGHV1-12	5.36	1.27e-07	3.93e-05	0.16	0.24	Kawasaki disease;	chr14:106777510	chr14:106122420~106122709:-
LUAD	cis	rs11671005	0.735	rs11670871	ENSG00000268912.1	CTD-2619J13.17	5.36	1.27e-07	3.94e-05	0.31	0.24	Mean platelet volume;	chr19:58429147	chr19:58428632~58431148:-
LUAD	cis	rs2599510	0.84	rs466146	ENSG00000276334.1	AL133243.1	5.36	1.28e-07	3.94e-05	0.27	0.24	Interleukin-18 levels;	chr2:32314167	chr2:32521927~32523547:+
LUAD	cis	rs10129255	0.913	rs10140943	ENSG00000211974.3	IGHV2-70	5.36	1.28e-07	3.94e-05	0.26	0.24	Kawasaki disease;	chr14:106767441	chr14:106723574~106724093:-
LUAD	cis	rs2919009	0.62	rs17501806	ENSG00000271670.1	RP11-95I16.4	5.36	1.28e-07	3.95e-05	0.3	0.24	Obesity-related traits;	chr10:120868905	chr10:120879256~120880667:-
LUAD	cis	rs1862618	0.573	rs185220	ENSG00000271828.1	CTD-2310F14.1	5.36	1.28e-07	3.95e-05	0.35	0.24	Initial pursuit acceleration;	chr5:56909530	chr5:56927874~56929573:+
LUAD	cis	rs2404602	0.692	rs1838048	ENSG00000259422.1	RP11-593F23.1	5.36	1.28e-07	3.95e-05	0.28	0.24	Blood metabolite levels;	chr15:76639338	chr15:76174891~76181486:-
LUAD	cis	rs6669008	1	rs1891969	ENSG00000232450.1	RP4-730K3.3	-5.36	1.28e-07	3.95e-05	-0.28	-0.24	Bacteremia;	chr1:113643233	chr1:113698884~113699631:-
LUAD	cis	rs2898681	0.561	rs6855240	ENSG00000248375.1	RP11-177B4.1	-5.36	1.28e-07	3.96e-05	-0.43	-0.24	Optic nerve measurement (cup area);	chr4:52874620	chr4:52720081~52720831:-
LUAD	cis	rs2898681	0.521	rs6833350	ENSG00000248375.1	RP11-177B4.1	-5.36	1.28e-07	3.96e-05	-0.43	-0.24	Optic nerve measurement (cup area);	chr4:52874701	chr4:52720081~52720831:-
LUAD	cis	rs1876905	0.597	rs1215964	ENSG00000272356.1	RP5-1112D6.8	-5.36	1.28e-07	3.96e-05	-0.27	-0.24	Mean corpuscular hemoglobin;	chr6:111225666	chr6:111309203~111313517:+
LUAD	cis	rs1263173	0.566	rs4225	ENSG00000280143.1	AP000892.6	5.36	1.28e-07	3.96e-05	0.27	0.24	HDL cholesterol;	chr11:116832955	chr11:117204967~117210292:+
LUAD	cis	rs4908760	0.864	rs6701331	ENSG00000232912.4	RP5-1115A15.1	5.36	1.28e-07	3.96e-05	0.22	0.24	Vitiligo;	chr1:8610147	chr1:8424645~8434838:+
LUAD	cis	rs2439831	0.702	rs3759791	ENSG00000205771.5	CATSPER2P1	-5.36	1.28e-07	3.96e-05	-0.47	-0.24	Lung cancer in ever smokers;	chr15:43798600	chr15:43726918~43747094:-
LUAD	cis	rs17747401	0.507	rs12360399	ENSG00000213731.2	RAB5CP1	-5.36	1.28e-07	3.96e-05	-0.25	-0.24	Hypospadias;	chr10:74687338	chr10:74423435~74424014:-
LUAD	cis	rs858239	0.539	rs10280815	ENSG00000230042.1	AK3P3	-5.36	1.28e-07	3.97e-05	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23148751	chr7:23129178~23129841:+
LUAD	cis	rs1075265	0.575	rs2692531	ENSG00000233266.1	HMGB1P31	5.36	1.28e-07	3.97e-05	0.3	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53776640	chr2:54051334~54051760:+
LUAD	cis	rs1799949	1	rs8070085	ENSG00000236383.6	LINC00854	5.36	1.28e-07	3.97e-05	0.2	0.24	Menopause (age at onset);	chr17:43189967	chr17:43216941~43305976:-
LUAD	cis	rs9326248	0.53	rs6589576	ENSG00000280143.1	AP000892.6	-5.36	1.29e-07	3.97e-05	-0.35	-0.24	Blood protein levels;	chr11:116865072	chr11:117204967~117210292:+
LUAD	cis	rs10754283	0.967	rs1320563	ENSG00000231613.1	RP5-943J3.1	5.36	1.29e-07	3.97e-05	0.24	0.24	Amyotrophic lateral sclerosis (sporadic);	chr1:89655473	chr1:89788914~89790492:+
LUAD	cis	rs910316	0.967	rs2024653	ENSG00000259138.1	RP11-950C14.7	5.36	1.29e-07	3.97e-05	0.25	0.24	Height;	chr14:75128451	chr14:75127153~75136930:+
LUAD	cis	rs4835473	0.615	rs6857432	ENSG00000251600.4	RP11-673E1.1	5.36	1.29e-07	3.98e-05	0.29	0.24	Immature fraction of reticulocytes;	chr4:143971912	chr4:143912331~143982454:+
LUAD	cis	rs600231	0.719	rs7114809	ENSG00000245532.5	NEAT1	5.36	1.29e-07	3.98e-05	0.19	0.24	Bone mineral density;	chr11:65483973	chr11:65422774~65445540:+
LUAD	cis	rs16863064	0.866	rs9855318	ENSG00000279891.1	FLJ42393	5.36	1.29e-07	3.98e-05	0.33	0.24	Schizophrenia;	chr3:188169593	chr3:188178543~188180812:+
LUAD	cis	rs853679	0.882	rs9468300	ENSG00000219392.1	RP1-265C24.5	-5.36	1.29e-07	3.98e-05	-0.41	-0.24	Depression;	chr6:28159062	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.882	rs9380064	ENSG00000219392.1	RP1-265C24.5	-5.36	1.29e-07	3.98e-05	-0.41	-0.24	Depression;	chr6:28175340	chr6:28115628~28116551:+
LUAD	cis	rs301807	0.533	rs1466655	ENSG00000232912.4	RP5-1115A15.1	5.36	1.29e-07	3.98e-05	0.22	0.24	Vitiligo;Sum eosinophil basophil counts;	chr1:8315782	chr1:8424645~8434838:+
LUAD	cis	rs6570726	0.935	rs369214	ENSG00000235652.6	RP11-545I5.3	5.36	1.29e-07	3.98e-05	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145535573	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs390252	ENSG00000235652.6	RP11-545I5.3	5.36	1.29e-07	3.98e-05	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145535760	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.875	rs373313	ENSG00000235652.6	RP11-545I5.3	5.36	1.29e-07	3.98e-05	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145536655	chr6:145799409~145886585:+
LUAD	cis	rs2404602	0.716	rs4886817	ENSG00000259422.1	RP11-593F23.1	5.36	1.29e-07	3.98e-05	0.28	0.24	Blood metabolite levels;	chr15:76585361	chr15:76174891~76181486:-
LUAD	cis	rs673078	0.562	rs56347775	ENSG00000275409.1	RP11-131L12.4	-5.36	1.29e-07	3.98e-05	-0.33	-0.24	Glucose homeostasis traits;	chr12:118438002	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs2393416	ENSG00000275409.1	RP11-131L12.4	-5.36	1.29e-07	3.98e-05	-0.33	-0.24	Glucose homeostasis traits;	chr12:118439968	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.56	rs4406856	ENSG00000275409.1	RP11-131L12.4	-5.36	1.29e-07	3.98e-05	-0.33	-0.24	Glucose homeostasis traits;	chr12:118440094	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs4457791	ENSG00000275409.1	RP11-131L12.4	-5.36	1.29e-07	3.98e-05	-0.33	-0.24	Glucose homeostasis traits;	chr12:118440144	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs61943456	ENSG00000275409.1	RP11-131L12.4	-5.36	1.29e-07	3.98e-05	-0.33	-0.24	Glucose homeostasis traits;	chr12:118440326	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs17513006	ENSG00000275409.1	RP11-131L12.4	-5.36	1.29e-07	3.98e-05	-0.33	-0.24	Glucose homeostasis traits;	chr12:118440383	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.56	rs61943457	ENSG00000275409.1	RP11-131L12.4	-5.36	1.29e-07	3.98e-05	-0.33	-0.24	Glucose homeostasis traits;	chr12:118440487	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.562	rs55883417	ENSG00000275409.1	RP11-131L12.4	-5.36	1.29e-07	3.98e-05	-0.33	-0.24	Glucose homeostasis traits;	chr12:118440801	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs55842338	ENSG00000275409.1	RP11-131L12.4	-5.36	1.29e-07	3.98e-05	-0.33	-0.24	Glucose homeostasis traits;	chr12:118441259	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.518	rs17441251	ENSG00000275409.1	RP11-131L12.4	-5.36	1.29e-07	3.98e-05	-0.33	-0.24	Glucose homeostasis traits;	chr12:118441361	chr12:118430147~118430699:+
LUAD	cis	rs7617773	0.817	rs13094727	ENSG00000228638.1	FCF1P2	-5.36	1.29e-07	3.98e-05	-0.29	-0.24	Coronary artery disease;	chr3:48281999	chr3:48290793~48291375:-
LUAD	cis	rs6570726	0.935	rs585292	ENSG00000235652.6	RP11-545I5.3	5.36	1.29e-07	3.99e-05	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145541092	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.837	rs419991	ENSG00000235652.6	RP11-545I5.3	5.36	1.29e-07	3.99e-05	0.24	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145543076	chr6:145799409~145886585:+
LUAD	cis	rs7017914	0.524	rs35544920	ENSG00000223220.1	Y_RNA	5.36	1.29e-07	3.99e-05	0.27	0.24	Bone mineral density;	chr8:70687552	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs34719517	ENSG00000223220.1	Y_RNA	5.36	1.29e-07	3.99e-05	0.27	0.24	Bone mineral density;	chr8:70687866	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.667	rs34972504	ENSG00000223220.1	Y_RNA	5.36	1.29e-07	3.99e-05	0.27	0.24	Bone mineral density;	chr8:70689486	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs12681588	ENSG00000223220.1	Y_RNA	5.36	1.29e-07	3.99e-05	0.27	0.24	Bone mineral density;	chr8:70689652	chr8:70780914~70781008:-
LUAD	cis	rs7580658	0.637	rs1566822	ENSG00000236682.1	AC068282.3	-5.36	1.29e-07	4e-05	-0.31	-0.24	Protein C levels;	chr2:127229815	chr2:127389130~127400580:+
LUAD	cis	rs875971	0.54	rs4717275	ENSG00000164669.11	INTS4P1	5.36	1.29e-07	4e-05	0.29	0.24	Aortic root size;	chr7:65800193	chr7:65141225~65234216:+
LUAD	cis	rs6687758	1	rs12739936	ENSG00000228437.4	RP11-400N13.2	5.36	1.29e-07	4e-05	0.35	0.24	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222009847	chr1:221966341~221984964:+
LUAD	cis	rs2153535	0.606	rs11243253	ENSG00000230939.1	RP11-314C16.1	5.36	1.3e-07	4e-05	0.28	0.24	Motion sickness;	chr6:8379960	chr6:8784178~8785445:+
LUAD	cis	rs6570726	0.935	rs369458	ENSG00000235652.6	RP11-545I5.3	5.36	1.3e-07	4e-05	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145491673	chr6:145799409~145886585:+
LUAD	cis	rs9309473	0.66	rs56131703	ENSG00000163016.8	ALMS1P	5.36	1.3e-07	4e-05	0.35	0.24	Metabolite levels;	chr2:73620133	chr2:73644919~73685576:+
LUAD	cis	rs643506	0.874	rs618421	ENSG00000230911.1	PPIHP1	-5.36	1.3e-07	4.01e-05	-0.3	-0.24	Breast cancer;	chr11:111778085	chr11:112029858~112030367:-
LUAD	cis	rs8055190	1	rs8055190	ENSG00000280214.1	CTD-2012K14.5	-5.36	1.3e-07	4.01e-05	-0.31	-0.24	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr16:67357715	chr16:67550815~67552935:-
LUAD	cis	rs4835473	0.897	rs4835333	ENSG00000251600.4	RP11-673E1.1	-5.36	1.3e-07	4.01e-05	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143703174	chr4:143912331~143982454:+
LUAD	cis	rs6570726	0.577	rs403345	ENSG00000235652.6	RP11-545I5.3	5.36	1.3e-07	4.02e-05	0.25	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145524035	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs447247	ENSG00000235652.6	RP11-545I5.3	5.36	1.3e-07	4.02e-05	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145491542	chr6:145799409~145886585:+
LUAD	cis	rs2179367	0.568	rs11155647	ENSG00000231760.4	RP11-350J20.5	5.36	1.3e-07	4.02e-05	0.34	0.24	Dupuytren's disease;	chr6:149384499	chr6:149796151~149826294:-
LUAD	cis	rs910316	1	rs2268617	ENSG00000259138.1	RP11-950C14.7	5.36	1.31e-07	4.03e-05	0.25	0.24	Height;	chr14:75142025	chr14:75127153~75136930:+
LUAD	cis	rs62246343	0.719	rs73115804	ENSG00000254485.4	RP11-380O24.1	5.36	1.31e-07	4.03e-05	0.35	0.24	Fibrinogen levels;	chr3:9399858	chr3:9292588~9363303:-
LUAD	cis	rs62246343	0.719	rs62246276	ENSG00000254485.4	RP11-380O24.1	5.36	1.31e-07	4.03e-05	0.35	0.24	Fibrinogen levels;	chr3:9403489	chr3:9292588~9363303:-
LUAD	cis	rs7017914	0.69	rs62506037	ENSG00000223220.1	Y_RNA	5.36	1.31e-07	4.03e-05	0.27	0.24	Bone mineral density;	chr8:71066959	chr8:70780914~70781008:-
LUAD	cis	rs875971	0.522	rs9530	ENSG00000164669.11	INTS4P1	-5.36	1.31e-07	4.03e-05	-0.29	-0.24	Aortic root size;	chr7:65960907	chr7:65141225~65234216:+
LUAD	cis	rs9399135	0.517	rs1883354	ENSG00000232876.1	CTA-212D2.2	5.36	1.31e-07	4.03e-05	0.28	0.24	Red blood cell count;	chr6:135136403	chr6:135055033~135060550:+
LUAD	cis	rs7617773	0.779	rs11718329	ENSG00000228638.1	FCF1P2	-5.36	1.31e-07	4.03e-05	-0.27	-0.24	Coronary artery disease;	chr3:48268338	chr3:48290793~48291375:-
LUAD	cis	rs2562456	0.874	rs2562417	ENSG00000268081.1	RP11-678G14.2	-5.36	1.31e-07	4.04e-05	-0.36	-0.24	Pain;	chr19:21528400	chr19:21554640~21569237:-
LUAD	cis	rs7617773	0.817	rs13100815	ENSG00000228638.1	FCF1P2	-5.36	1.31e-07	4.04e-05	-0.29	-0.24	Coronary artery disease;	chr3:48245959	chr3:48290793~48291375:-
LUAD	cis	rs897984	0.759	rs13708	ENSG00000260911.2	RP11-196G11.2	-5.36	1.31e-07	4.04e-05	-0.21	-0.24	Dementia with Lewy bodies;	chr16:30989488	chr16:31043150~31049868:+
LUAD	cis	rs1816752	0.87	rs73469543	ENSG00000273628.1	RP11-756A22.7	5.36	1.31e-07	4.04e-05	0.27	0.24	Obesity-related traits;	chr13:24424832	chr13:24933006~24936796:+
LUAD	cis	rs12468226	1	rs74766638	ENSG00000226261.1	AC064836.3	5.36	1.31e-07	4.04e-05	0.38	0.24	Urate levels;	chr2:202445168	chr2:202336024~202336727:-
LUAD	cis	rs4835473	0.9	rs35311036	ENSG00000251600.4	RP11-673E1.1	-5.36	1.31e-07	4.04e-05	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143734397	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs35906127	ENSG00000251600.4	RP11-673E1.1	-5.36	1.31e-07	4.04e-05	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143734400	chr4:143912331~143982454:+
LUAD	cis	rs36093844	0.8	rs17744711	ENSG00000279742.1	RP11-700A24.1	-5.36	1.31e-07	4.04e-05	-0.32	-0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85889681	chr11:85852557~85854943:-
LUAD	cis	rs4964805	0.954	rs10861104	ENSG00000257681.1	RP11-341G23.4	5.36	1.31e-07	4.04e-05	0.3	0.24	Attention deficit hyperactivity disorder;	chr12:103796145	chr12:103746315~103768858:-
LUAD	cis	rs6772849	1	rs6772849	ENSG00000242551.2	POU5F1P6	-5.36	1.31e-07	4.05e-05	-0.27	-0.24	Monocyte percentage of white cells;Monocyte count;	chr3:128587575	chr3:128674735~128677005:-
LUAD	cis	rs10129255	0.5	rs59939897	ENSG00000211967.3	IGHV3-53	-5.36	1.31e-07	4.05e-05	-0.17	-0.24	Kawasaki disease;	chr14:106783414	chr14:106592676~106593347:-
LUAD	cis	rs10129255	0.5	rs8014529	ENSG00000211967.3	IGHV3-53	-5.36	1.31e-07	4.05e-05	-0.17	-0.24	Kawasaki disease;	chr14:106784065	chr14:106592676~106593347:-
LUAD	cis	rs10129255	0.5	rs12101190	ENSG00000211967.3	IGHV3-53	-5.36	1.31e-07	4.05e-05	-0.17	-0.24	Kawasaki disease;	chr14:106784149	chr14:106592676~106593347:-
LUAD	cis	rs10129255	0.518	rs8004895	ENSG00000211967.3	IGHV3-53	-5.36	1.31e-07	4.05e-05	-0.17	-0.24	Kawasaki disease;	chr14:106785139	chr14:106592676~106593347:-
LUAD	cis	rs17711722	0.522	rs62469933	ENSG00000224316.1	RP11-479O9.2	5.36	1.31e-07	4.05e-05	0.23	0.24	Calcium levels;	chr7:65800652	chr7:65773620~65802067:+
LUAD	cis	rs807029	0.544	rs55646950	ENSG00000272572.1	RP11-179B2.2	-5.36	1.31e-07	4.05e-05	-0.34	-0.24	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101001239	chr10:100911103~100912739:-
LUAD	cis	rs807029	0.577	rs750866	ENSG00000272572.1	RP11-179B2.2	-5.36	1.31e-07	4.05e-05	-0.34	-0.24	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101001701	chr10:100911103~100912739:-
LUAD	cis	rs910316	1	rs4903289	ENSG00000259138.1	RP11-950C14.7	-5.36	1.31e-07	4.05e-05	-0.25	-0.24	Height;	chr14:75157285	chr14:75127153~75136930:+
LUAD	cis	rs1816752	0.748	rs6490912	ENSG00000273628.1	RP11-756A22.7	5.36	1.31e-07	4.05e-05	0.27	0.24	Obesity-related traits;	chr13:24408941	chr13:24933006~24936796:+
LUAD	cis	rs394563	0.591	rs6570964	ENSG00000231760.4	RP11-350J20.5	-5.36	1.31e-07	4.05e-05	-0.29	-0.24	Dupuytren's disease;	chr6:149370723	chr6:149796151~149826294:-
LUAD	cis	rs7617773	0.78	rs11718350	ENSG00000228638.1	FCF1P2	-5.36	1.31e-07	4.05e-05	-0.29	-0.24	Coronary artery disease;	chr3:48319502	chr3:48290793~48291375:-
LUAD	cis	rs7927592	0.717	rs7126451	ENSG00000212093.1	AP000807.1	-5.36	1.31e-07	4.05e-05	-0.24	-0.24	Total body bone mineral density;	chr11:68489918	chr11:68506083~68506166:-
LUAD	cis	rs9952991	0.941	rs2542151	ENSG00000260302.1	RP11-973H7.1	-5.36	1.32e-07	4.06e-05	-0.41	-0.24	Inflammatory skin disease;	chr18:12779948	chr18:12774651~12775923:-
LUAD	cis	rs950169	0.922	rs2033284	ENSG00000259295.5	CSPG4P12	5.36	1.32e-07	4.06e-05	0.35	0.24	Schizophrenia;	chr15:84391575	chr15:85191438~85213905:+
LUAD	cis	rs4604732	0.578	rs12038656	ENSG00000227135.1	GCSAML-AS1	-5.36	1.32e-07	4.06e-05	-0.37	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247460514	chr1:247524679~247526752:-
LUAD	cis	rs453301	0.686	rs10217044	ENSG00000173295.6	FAM86B3P	-5.36	1.32e-07	4.06e-05	-0.26	-0.24	Joint mobility (Beighton score);	chr8:9037242	chr8:8228595~8244865:+
LUAD	cis	rs910316	0.935	rs3742771	ENSG00000259138.1	RP11-950C14.7	5.36	1.32e-07	4.06e-05	0.25	0.24	Height;	chr14:75132944	chr14:75127153~75136930:+
LUAD	cis	rs67311347	0.544	rs9833640	ENSG00000223797.4	ENTPD3-AS1	5.36	1.32e-07	4.06e-05	0.25	0.24	Renal cell carcinoma;	chr3:40313450	chr3:40313802~40453329:-
LUAD	cis	rs67311347	0.544	rs6762121	ENSG00000223797.4	ENTPD3-AS1	5.36	1.32e-07	4.06e-05	0.25	0.24	Renal cell carcinoma;	chr3:40313822	chr3:40313802~40453329:-
LUAD	cis	rs67311347	0.544	rs6787516	ENSG00000223797.4	ENTPD3-AS1	5.36	1.32e-07	4.06e-05	0.25	0.24	Renal cell carcinoma;	chr3:40314125	chr3:40313802~40453329:-
LUAD	cis	rs67311347	0.524	rs7649168	ENSG00000223797.4	ENTPD3-AS1	5.36	1.32e-07	4.06e-05	0.25	0.24	Renal cell carcinoma;	chr3:40314667	chr3:40313802~40453329:-
LUAD	cis	rs9652601	0.622	rs7194305	ENSG00000274038.1	RP11-66H6.4	-5.36	1.32e-07	4.07e-05	-0.28	-0.24	Systemic lupus erythematosus;	chr16:11005850	chr16:11056556~11057034:+
LUAD	cis	rs4927850	0.881	rs7630489	ENSG00000242086.7	LINC00969	5.36	1.32e-07	4.07e-05	0.21	0.24	Pancreatic cancer;	chr3:196026530	chr3:195658062~195739964:+
LUAD	cis	rs1707322	0.506	rs2991983	ENSG00000280836.1	AL355480.1	5.36	1.32e-07	4.07e-05	0.31	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613719	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.717	rs3014249	ENSG00000280836.1	AL355480.1	5.36	1.32e-07	4.07e-05	0.31	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613821	chr1:45581219~45581321:-
LUAD	cis	rs11671005	0.651	rs35117909	ENSG00000268912.1	CTD-2619J13.17	-5.36	1.32e-07	4.07e-05	-0.33	-0.24	Mean platelet volume;	chr19:58401539	chr19:58428632~58431148:-
LUAD	cis	rs1707322	1	rs6672115	ENSG00000280836.1	AL355480.1	-5.36	1.32e-07	4.07e-05	-0.31	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807207	chr1:45581219~45581321:-
LUAD	cis	rs7829975	0.511	rs2976902	ENSG00000253981.4	ALG1L13P	5.36	1.32e-07	4.07e-05	0.27	0.24	Mood instability;	chr8:8483595	chr8:8236003~8244667:-
LUAD	cis	rs7615952	0.599	rs6438955	ENSG00000171084.14	FAM86JP	5.36	1.32e-07	4.07e-05	0.32	0.24	Blood pressure (smoking interaction);	chr3:126011490	chr3:125916620~125930024:+
LUAD	cis	rs293748	0.771	rs158798	ENSG00000250155.1	CTD-2353F22.1	-5.36	1.32e-07	4.07e-05	-0.32	-0.24	Obesity-related traits;	chr5:36869157	chr5:36666214~36725195:-
LUAD	cis	rs35740288	0.787	rs11637768	ENSG00000202081.1	RNU6-1280P	5.36	1.32e-07	4.08e-05	0.3	0.24	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85680179	chr15:85651522~85651628:-
LUAD	cis	rs4964805	1	rs12228207	ENSG00000257681.1	RP11-341G23.4	5.36	1.32e-07	4.08e-05	0.3	0.24	Attention deficit hyperactivity disorder;	chr12:103802956	chr12:103746315~103768858:-
LUAD	cis	rs61270009	0.955	rs11743103	ENSG00000247828.6	TMEM161B-AS1	-5.36	1.32e-07	4.08e-05	-0.27	-0.24	Depressive symptoms;	chr5:88380145	chr5:88268895~88436685:+
LUAD	cis	rs2032366	0.606	rs1452597	ENSG00000267279.1	RP11-879F14.2	-5.36	1.33e-07	4.09e-05	-0.31	-0.24	Obesity-related traits;	chr18:61590985	chr18:61585746~61606916:-
LUAD	cis	rs56080343	0.688	rs10083190	ENSG00000275409.1	RP11-131L12.4	-5.36	1.33e-07	4.09e-05	-0.29	-0.24	Neuroticism;	chr12:118365385	chr12:118430147~118430699:+
LUAD	cis	rs17747401	0.507	rs11001105	ENSG00000213731.2	RAB5CP1	-5.36	1.33e-07	4.09e-05	-0.25	-0.24	Hypospadias;	chr10:74672050	chr10:74423435~74424014:-
LUAD	cis	rs2440129	0.611	rs1042356	ENSG00000215067.8	ALOX12-AS1	5.35	1.33e-07	4.09e-05	0.24	0.24	Tonsillectomy;	chr17:6999424	chr17:6876635~7012349:-
LUAD	cis	rs4835473	0.9	rs67600034	ENSG00000251600.4	RP11-673E1.1	-5.35	1.33e-07	4.09e-05	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143734670	chr4:143912331~143982454:+
LUAD	cis	rs2599510	0.811	rs2754520	ENSG00000276334.1	AL133243.1	5.35	1.33e-07	4.09e-05	0.27	0.24	Interleukin-18 levels;	chr2:32585226	chr2:32521927~32523547:+
LUAD	cis	rs2288884	0.779	rs10411428	ENSG00000275055.1	CTC-471J1.11	-5.35	1.33e-07	4.1e-05	-0.33	-0.24	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52104512	chr19:52049007~52049754:+
LUAD	cis	rs7208859	0.673	rs1347359	ENSG00000263531.1	RP13-753N3.1	5.35	1.33e-07	4.1e-05	0.41	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587511	chr17:30863921~30864940:-
LUAD	cis	rs116175783	0.557	rs1146024	ENSG00000227403.1	AC009299.3	5.35	1.33e-07	4.1e-05	0.43	0.24	Intelligence (multi-trait analysis);	chr2:161282740	chr2:161244739~161249050:+
LUAD	cis	rs7829975	0.623	rs7010753	ENSG00000253893.2	FAM85B	-5.35	1.33e-07	4.1e-05	-0.3	-0.24	Mood instability;	chr8:8516446	chr8:8167819~8226614:-
LUAD	cis	rs6964587	0.773	rs10488514	ENSG00000188693.7	CYP51A1-AS1	-5.35	1.33e-07	4.1e-05	-0.28	-0.24	Breast cancer;	chr7:92322528	chr7:92134604~92180725:+
LUAD	cis	rs12701220	0.655	rs12702117	ENSG00000229043.2	AC091729.9	-5.35	1.33e-07	4.1e-05	-0.29	-0.24	Bronchopulmonary dysplasia;	chr7:1109066	chr7:1160374~1165267:+
LUAD	cis	rs12701220	0.655	rs34344742	ENSG00000229043.2	AC091729.9	-5.35	1.33e-07	4.1e-05	-0.29	-0.24	Bronchopulmonary dysplasia;	chr7:1109652	chr7:1160374~1165267:+
LUAD	cis	rs12701220	0.604	rs12702122	ENSG00000229043.2	AC091729.9	-5.35	1.33e-07	4.1e-05	-0.29	-0.24	Bronchopulmonary dysplasia;	chr7:1109858	chr7:1160374~1165267:+
LUAD	cis	rs7948661	1	rs9332809	ENSG00000278376.1	RP11-158I9.8	5.35	1.33e-07	4.1e-05	0.51	0.24	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118490757	chr11:118791254~118793137:+
LUAD	cis	rs7948661	1	rs2276045	ENSG00000278376.1	RP11-158I9.8	5.35	1.33e-07	4.1e-05	0.51	0.24	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118494453	chr11:118791254~118793137:+
LUAD	cis	rs858239	0.796	rs433395	ENSG00000226816.2	AC005082.12	5.35	1.33e-07	4.1e-05	0.31	0.24	Cerebrospinal fluid biomarker levels;	chr7:23362336	chr7:23206013~23208045:+
LUAD	cis	rs2380205	0.546	rs633928	ENSG00000232807.2	RP11-536K7.3	-5.35	1.33e-07	4.1e-05	-0.24	-0.24	Breast cancer;	chr10:5902547	chr10:5934270~5945900:-
LUAD	cis	rs9584850	0.834	rs17574378	ENSG00000231194.1	FARP1-AS1	5.35	1.33e-07	4.11e-05	0.29	0.24	Neuroticism;	chr13:98464130	chr13:98435405~98435840:-
LUAD	cis	rs7923837	0.893	rs10882104	ENSG00000236493.2	EIF2S2P3	5.35	1.34e-07	4.11e-05	0.27	0.24	Multiple sclerosis;Body mass index;	chr10:92710758	chr10:92668745~92669743:-
LUAD	cis	rs9595908	0.785	rs7326809	ENSG00000212293.1	SNORA16	5.35	1.34e-07	4.11e-05	0.25	0.24	Body mass index;	chr13:32662135	chr13:32420390~32420516:-
LUAD	cis	rs7811142	0.943	rs28660238	ENSG00000078319.8	PMS2P1	-5.35	1.34e-07	4.11e-05	-0.27	-0.24	Platelet count;	chr7:100425685	chr7:100320992~100341908:-
LUAD	cis	rs301901	0.698	rs11948801	ENSG00000250155.1	CTD-2353F22.1	5.35	1.34e-07	4.12e-05	0.25	0.24	Height;	chr5:37430113	chr5:36666214~36725195:-
LUAD	cis	rs12550612	1	rs12550612	ENSG00000253616.4	RP11-875O11.3	5.35	1.34e-07	4.12e-05	0.35	0.24	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23109256	chr8:23071377~23074488:-
LUAD	cis	rs2880765	0.835	rs11074276	ENSG00000259295.5	CSPG4P12	5.35	1.34e-07	4.12e-05	0.27	0.24	Coronary artery disease;	chr15:85487132	chr15:85191438~85213905:+
LUAD	cis	rs442309	0.553	rs7088592	ENSG00000238280.1	RP11-436D10.3	-5.35	1.34e-07	4.12e-05	-0.3	-0.24	Vogt-Koyanagi-Harada syndrome;	chr10:62721530	chr10:62793562~62805887:-
LUAD	cis	rs858239	0.539	rs10225608	ENSG00000230042.1	AK3P3	-5.35	1.34e-07	4.12e-05	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23149289	chr7:23129178~23129841:+
LUAD	cis	rs858239	1	rs156421	ENSG00000226816.2	AC005082.12	5.35	1.34e-07	4.12e-05	0.31	0.24	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23206013~23208045:+
LUAD	cis	rs891378	1	rs6703857	ENSG00000274245.1	RP11-357P18.2	-5.35	1.34e-07	4.13e-05	-0.29	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207270208	chr1:207372559~207373252:+
LUAD	cis	rs875971	0.522	rs2949690	ENSG00000236529.1	RP13-254B10.1	-5.35	1.34e-07	4.13e-05	-0.24	-0.24	Aortic root size;	chr7:66018255	chr7:65840212~65840596:+
LUAD	cis	rs984222	0.538	rs1106529	ENSG00000226172.2	RP4-712E4.1	-5.35	1.34e-07	4.13e-05	-0.29	-0.24	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118988874	chr1:119000344~119001392:-
LUAD	cis	rs7615952	0.641	rs4490307	ENSG00000171084.14	FAM86JP	5.35	1.34e-07	4.13e-05	0.33	0.24	Blood pressure (smoking interaction);	chr3:125993833	chr3:125916620~125930024:+
LUAD	cis	rs11763147	1	rs11763147	ENSG00000164669.11	INTS4P1	5.35	1.34e-07	4.14e-05	0.28	0.24	Corneal structure;	chr7:65861834	chr7:65141225~65234216:+
LUAD	cis	rs11742741	0.523	rs17444026	ENSG00000248874.4	C5orf17	-5.35	1.34e-07	4.14e-05	-0.3	-0.24	Educational attainment;	chr5:24099713	chr5:23951348~24178263:+
LUAD	cis	rs11742741	0.539	rs11955340	ENSG00000248874.4	C5orf17	-5.35	1.34e-07	4.14e-05	-0.3	-0.24	Educational attainment;	chr5:24100036	chr5:23951348~24178263:+
LUAD	cis	rs17214007	0.735	rs8045778	ENSG00000263335.1	AF001548.5	5.35	1.35e-07	4.14e-05	0.33	0.24	Cognitive function;	chr16:15784395	chr16:15726674~15732993:+
LUAD	cis	rs4664293	1	rs6432542	ENSG00000226266.5	AC009961.3	-5.35	1.35e-07	4.14e-05	-0.33	-0.24	Monocyte percentage of white cells;	chr2:159624025	chr2:159670708~159712435:-
LUAD	cis	rs7826238	0.653	rs2979202	ENSG00000253981.4	ALG1L13P	5.35	1.35e-07	4.15e-05	0.27	0.24	Systolic blood pressure;	chr8:8486617	chr8:8236003~8244667:-
LUAD	cis	rs17711722	0.727	rs2658585	ENSG00000164669.11	INTS4P1	-5.35	1.35e-07	4.15e-05	-0.28	-0.24	Calcium levels;	chr7:65996954	chr7:65141225~65234216:+
LUAD	cis	rs9287719	0.649	rs10929684	ENSG00000243819.4	RN7SL832P	-5.35	1.35e-07	4.15e-05	-0.25	-0.24	Prostate cancer;	chr2:10592098	chr2:10690344~10692099:+
LUAD	cis	rs10246939	0.543	rs9640204	ENSG00000228775.6	WEE2-AS1	5.35	1.35e-07	4.15e-05	0.28	0.24	Bitter taste perception;	chr7:141844300	chr7:141704338~141738346:-
LUAD	cis	rs10246939	0.543	rs9640359	ENSG00000228775.6	WEE2-AS1	5.35	1.35e-07	4.15e-05	0.28	0.24	Bitter taste perception;	chr7:141844399	chr7:141704338~141738346:-
LUAD	cis	rs748404	0.626	rs57938858	ENSG00000205771.5	CATSPER2P1	-5.35	1.35e-07	4.15e-05	-0.36	-0.24	Lung cancer;	chr15:43520259	chr15:43726918~43747094:-
LUAD	cis	rs10129255	0.957	rs10136560	ENSG00000211974.3	IGHV2-70	5.35	1.35e-07	4.15e-05	0.25	0.24	Kawasaki disease;	chr14:106787630	chr14:106723574~106724093:-
LUAD	cis	rs867371	1	rs7181655	ENSG00000276710.3	CSPG4P8	-5.35	1.35e-07	4.16e-05	-0.23	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163275	chr15:82459472~82477258:+
LUAD	cis	rs867371	1	rs7180584	ENSG00000276710.3	CSPG4P8	-5.35	1.35e-07	4.16e-05	-0.23	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163493	chr15:82459472~82477258:+
LUAD	cis	rs867371	1	rs6495642	ENSG00000276710.3	CSPG4P8	-5.35	1.35e-07	4.16e-05	-0.23	-0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82165156	chr15:82459472~82477258:+
LUAD	cis	rs897984	0.542	rs7197717	ENSG00000260911.2	RP11-196G11.2	5.35	1.35e-07	4.16e-05	0.21	0.24	Dementia with Lewy bodies;	chr16:31071754	chr16:31043150~31049868:+
LUAD	cis	rs11157436	0.918	rs1983520	ENSG00000211812.1	TRAV26-2	-5.35	1.35e-07	4.16e-05	-0.25	-0.24	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22150390	chr14:22202583~22203368:+
LUAD	cis	rs11157436	0.918	rs1983522	ENSG00000211812.1	TRAV26-2	-5.35	1.35e-07	4.16e-05	-0.25	-0.24	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22150588	chr14:22202583~22203368:+
LUAD	cis	rs853679	0.55	rs34477097	ENSG00000204709.4	LINC01556	5.35	1.35e-07	4.16e-05	0.32	0.24	Depression;	chr6:28229408	chr6:28943877~28944537:+
LUAD	cis	rs7948661	1	rs73615909	ENSG00000278376.1	RP11-158I9.8	5.35	1.35e-07	4.16e-05	0.46	0.24	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118451773	chr11:118791254~118793137:+
LUAD	cis	rs11157436	0.918	rs12586393	ENSG00000211812.1	TRAV26-2	-5.35	1.35e-07	4.17e-05	-0.26	-0.24	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22150815	chr14:22202583~22203368:+
LUAD	cis	rs11157436	0.83	rs61972214	ENSG00000211812.1	TRAV26-2	-5.35	1.35e-07	4.17e-05	-0.26	-0.24	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22152416	chr14:22202583~22203368:+
LUAD	cis	rs2404602	0.692	rs12910382	ENSG00000259422.1	RP11-593F23.1	5.35	1.35e-07	4.17e-05	0.27	0.24	Blood metabolite levels;	chr15:76761101	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.692	rs12911902	ENSG00000259422.1	RP11-593F23.1	5.35	1.35e-07	4.17e-05	0.27	0.24	Blood metabolite levels;	chr15:76761234	chr15:76174891~76181486:-
LUAD	cis	rs9322193	0.962	rs2065664	ENSG00000268592.3	RAET1E-AS1	5.35	1.35e-07	4.17e-05	0.3	0.24	Lung cancer;	chr6:149762485	chr6:149863494~149919507:+
LUAD	cis	rs5758659	0.845	rs5758645	ENSG00000182057.4	OGFRP1	5.35	1.36e-07	4.17e-05	0.29	0.24	Cognitive function;	chr22:42202945	chr22:42269753~42275196:+
LUAD	cis	rs7617773	0.817	rs6787500	ENSG00000228638.1	FCF1P2	-5.35	1.36e-07	4.17e-05	-0.27	-0.24	Coronary artery disease;	chr3:48257949	chr3:48290793~48291375:-
LUAD	cis	rs7176527	0.848	rs72630461	ENSG00000188388.10	GOLGA6L3	5.35	1.36e-07	4.17e-05	0.35	0.24	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84696913	chr15:85240472~85247170:+
LUAD	cis	rs2288884	0.806	rs17779439	ENSG00000275055.1	CTC-471J1.11	-5.35	1.36e-07	4.17e-05	-0.37	-0.24	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52080738	chr19:52049007~52049754:+
LUAD	cis	rs4713118	0.539	rs200951	ENSG00000219392.1	RP1-265C24.5	-5.35	1.36e-07	4.17e-05	-0.31	-0.24	Parkinson's disease;	chr6:27868152	chr6:28115628~28116551:+
LUAD	cis	rs600231	0.708	rs1784860	ENSG00000245532.5	NEAT1	5.35	1.36e-07	4.18e-05	0.18	0.24	Bone mineral density;	chr11:65473241	chr11:65422774~65445540:+
LUAD	cis	rs1707322	1	rs34694458	ENSG00000234329.1	RP11-767N6.2	5.35	1.36e-07	4.18e-05	0.24	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867024	chr1:45651039~45651826:-
LUAD	cis	rs1876905	1	rs1876905	ENSG00000272356.1	RP5-1112D6.8	-5.35	1.36e-07	4.18e-05	-0.26	-0.24	Mean corpuscular hemoglobin;	chr6:111096756	chr6:111309203~111313517:+
LUAD	cis	rs516805	0.706	rs1034060	ENSG00000279453.1	RP3-425C14.4	5.35	1.36e-07	4.18e-05	0.31	0.24	Lymphocyte counts;	chr6:122319181	chr6:122436789~122439223:-
LUAD	cis	rs2880765	0.835	rs7169429	ENSG00000259295.5	CSPG4P12	5.35	1.36e-07	4.18e-05	0.27	0.24	Coronary artery disease;	chr15:85493417	chr15:85191438~85213905:+
LUAD	cis	rs2337406	1	rs11845269	ENSG00000211972.2	IGHV3-66	5.35	1.36e-07	4.18e-05	0.25	0.24	Alzheimer's disease (late onset);	chr14:106683851	chr14:106675017~106675544:-
LUAD	cis	rs1075265	0.783	rs805359	ENSG00000233266.1	HMGB1P31	5.35	1.36e-07	4.18e-05	0.3	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53935317	chr2:54051334~54051760:+
LUAD	cis	rs516805	0.748	rs577744	ENSG00000279453.1	RP3-425C14.4	-5.35	1.36e-07	4.18e-05	-0.3	-0.24	Lymphocyte counts;	chr6:122447712	chr6:122436789~122439223:-
LUAD	cis	rs1707322	1	rs1707317	ENSG00000280836.1	AL355480.1	5.35	1.36e-07	4.19e-05	0.31	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044970	chr1:45581219~45581321:-
LUAD	cis	rs6840360	0.901	rs1561915	ENSG00000270265.1	RP11-731D1.4	-5.35	1.36e-07	4.19e-05	-0.24	-0.24	Intelligence (multi-trait analysis);	chr4:151558572	chr4:151333775~151353224:-
LUAD	cis	rs4852324	0.536	rs17009553	ENSG00000217702.2	RP11-287D1.4	-5.35	1.36e-07	4.19e-05	-0.56	-0.24	Systemic lupus erythematosus;	chr2:73992908	chr2:74130583~74135395:+
LUAD	cis	rs875971	0.862	rs1167408	ENSG00000237310.1	GS1-124K5.4	-5.35	1.36e-07	4.19e-05	-0.26	-0.24	Aortic root size;	chr7:66091121	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.83	rs1167406	ENSG00000237310.1	GS1-124K5.4	-5.35	1.36e-07	4.19e-05	-0.26	-0.24	Aortic root size;	chr7:66091949	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs709609	ENSG00000237310.1	GS1-124K5.4	-5.35	1.36e-07	4.19e-05	-0.26	-0.24	Aortic root size;	chr7:66095574	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs1167399	ENSG00000237310.1	GS1-124K5.4	-5.35	1.36e-07	4.19e-05	-0.26	-0.24	Aortic root size;	chr7:66096890	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs57866200	ENSG00000237310.1	GS1-124K5.4	-5.35	1.36e-07	4.19e-05	-0.26	-0.24	Aortic root size;	chr7:66100405	chr7:66493706~66495474:+
LUAD	cis	rs36093844	0.898	rs11512932	ENSG00000279742.1	RP11-700A24.1	-5.35	1.37e-07	4.2e-05	-0.28	-0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85880087	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.898	rs11234458	ENSG00000279742.1	RP11-700A24.1	-5.35	1.37e-07	4.2e-05	-0.28	-0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85880327	chr11:85852557~85854943:-
LUAD	cis	rs4835473	0.831	rs7689328	ENSG00000251600.4	RP11-673E1.1	5.35	1.37e-07	4.2e-05	0.29	0.24	Immature fraction of reticulocytes;	chr4:143973768	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.831	rs7694353	ENSG00000251600.4	RP11-673E1.1	5.35	1.37e-07	4.2e-05	0.29	0.24	Immature fraction of reticulocytes;	chr4:143973787	chr4:143912331~143982454:+
LUAD	cis	rs5850	0.557	rs10270788	ENSG00000230042.1	AK3P3	-5.35	1.37e-07	4.2e-05	-0.3	-0.24	Blood protein levels;	chr7:23149381	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.539	rs28716381	ENSG00000230042.1	AK3P3	-5.35	1.37e-07	4.2e-05	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23149396	chr7:23129178~23129841:+
LUAD	cis	rs673078	0.66	rs17512177	ENSG00000275409.1	RP11-131L12.4	-5.35	1.37e-07	4.21e-05	-0.34	-0.24	Glucose homeostasis traits;	chr12:118192335	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.66	rs17512198	ENSG00000275409.1	RP11-131L12.4	-5.35	1.37e-07	4.21e-05	-0.34	-0.24	Glucose homeostasis traits;	chr12:118194217	chr12:118430147~118430699:+
LUAD	cis	rs6570726	0.577	rs9497315	ENSG00000235652.6	RP11-545I5.3	-5.35	1.37e-07	4.21e-05	-0.25	-0.24	Lobe attachment (rater-scored or self-reported);	chr6:145470831	chr6:145799409~145886585:+
LUAD	cis	rs2735413	0.599	rs112375862	ENSG00000276007.1	RP11-358L22.3	5.35	1.37e-07	4.21e-05	0.32	0.24	Systolic blood pressure (alcohol consumption interaction);	chr16:78045340	chr16:78123243~78124332:+
LUAD	cis	rs7923837	1	rs10786053	ENSG00000236493.2	EIF2S2P3	5.35	1.37e-07	4.21e-05	0.27	0.24	Multiple sclerosis;Body mass index;	chr10:92714340	chr10:92668745~92669743:-
LUAD	cis	rs7923837	0.928	rs10882105	ENSG00000236493.2	EIF2S2P3	5.35	1.37e-07	4.21e-05	0.27	0.24	Multiple sclerosis;Body mass index;	chr10:92714354	chr10:92668745~92669743:-
LUAD	cis	rs1062177	0.855	rs6884630	ENSG00000253921.1	CTB-113P19.3	-5.35	1.37e-07	4.21e-05	-0.34	-0.24	Preschool internalizing problems;	chr5:151889436	chr5:151753992~151767247:+
LUAD	cis	rs2404602	1	rs12594212	ENSG00000259422.1	RP11-593F23.1	5.35	1.37e-07	4.21e-05	0.28	0.24	Blood metabolite levels;	chr15:76509673	chr15:76174891~76181486:-
LUAD	cis	rs7804306	1	rs7804306	ENSG00000233264.2	AC006042.8	5.35	1.37e-07	4.22e-05	0.42	0.24	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7978549	chr7:7980312~7982228:+
LUAD	cis	rs712039	0.652	rs8069062	ENSG00000276054.1	RP11-378E13.3	5.35	1.37e-07	4.22e-05	0.36	0.24	Tuberculosis;	chr17:37469202	chr17:37386886~37387926:+
LUAD	cis	rs712039	0.652	rs60112577	ENSG00000276054.1	RP11-378E13.3	5.35	1.37e-07	4.22e-05	0.36	0.24	Tuberculosis;	chr17:37473105	chr17:37386886~37387926:+
LUAD	cis	rs380904	0.517	rs11775744	ENSG00000254859.1	RP11-661A12.5	-5.35	1.37e-07	4.22e-05	-0.37	-0.24	Venous thromboembolism (SNP x SNP interaction);	chr8:143567022	chr8:143541973~143549729:-
LUAD	cis	rs2657294	0.62	rs7903537	ENSG00000226051.5	ZNF503-AS1	-5.35	1.38e-07	4.22e-05	-0.32	-0.24	Pneumonia;	chr10:75087732	chr10:75269819~75373500:+
LUAD	cis	rs2657294	0.62	rs2395136	ENSG00000226051.5	ZNF503-AS1	-5.35	1.38e-07	4.22e-05	-0.32	-0.24	Pneumonia;	chr10:75088213	chr10:75269819~75373500:+
LUAD	cis	rs6676180	0.555	rs871665	ENSG00000231365.4	RP11-418J17.1	-5.35	1.38e-07	4.22e-05	-0.28	-0.24	Monobrow;	chr1:119230040	chr1:119140396~119275973:+
LUAD	cis	rs2933343	0.7	rs1680778	ENSG00000261159.1	RP11-723O4.9	5.35	1.38e-07	4.22e-05	0.26	0.24	IgG glycosylation;	chr3:128895342	chr3:128859716~128860526:-
LUAD	cis	rs71636778	0.509	rs11555809	ENSG00000260063.1	RP5-968P14.2	-5.35	1.38e-07	4.22e-05	-0.43	-0.24	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26890178	chr1:26692132~26694131:-
LUAD	cis	rs7617773	0.78	rs13082158	ENSG00000228638.1	FCF1P2	-5.35	1.38e-07	4.23e-05	-0.29	-0.24	Coronary artery disease;	chr3:48330980	chr3:48290793~48291375:-
LUAD	cis	rs6714710	0.627	rs11680883	ENSG00000230606.9	AC159540.1	-5.35	1.38e-07	4.23e-05	-0.26	-0.24	Posterior cortical atrophy and Alzheimer's disease;	chr2:97856147	chr2:97416165~97433527:-
LUAD	cis	rs9487094	0.813	rs3799835	ENSG00000260273.1	RP11-425D10.10	5.35	1.38e-07	4.23e-05	0.33	0.24	Height;	chr6:109372084	chr6:109382795~109383666:+
LUAD	cis	rs17711722	0.701	rs781143	ENSG00000164669.11	INTS4P1	-5.35	1.38e-07	4.23e-05	-0.28	-0.24	Calcium levels;	chr7:65974892	chr7:65141225~65234216:+
LUAD	cis	rs673078	0.607	rs7295288	ENSG00000275409.1	RP11-131L12.4	-5.35	1.38e-07	4.23e-05	-0.32	-0.24	Glucose homeostasis traits;	chr12:118418008	chr12:118430147~118430699:+
LUAD	cis	rs10246939	0.579	rs9640205	ENSG00000270923.1	TAS2R6P	-5.35	1.38e-07	4.23e-05	-0.26	-0.24	Bitter taste perception;	chr7:141844400	chr7:141787815~141788640:+
LUAD	cis	rs7968440	0.966	rs1521516	ENSG00000200428.1	Y_RNA	-5.35	1.38e-07	4.23e-05	-0.29	-0.24	Fibrinogen;	chr12:50661925	chr12:50743568~50743684:+
LUAD	cis	rs7714584	1	rs11743488	ENSG00000197083.10	ZNF300P1	5.35	1.38e-07	4.23e-05	0.5	0.24	Crohn's disease;	chr5:150899656	chr5:150930645~150946289:-
LUAD	cis	rs1426063	1	rs10022814	ENSG00000249717.1	RP11-44F21.3	5.35	1.38e-07	4.24e-05	0.36	0.24	QT interval;	chr4:75094704	chr4:74955974~74970362:-
LUAD	cis	rs1426063	1	rs10029141	ENSG00000249717.1	RP11-44F21.3	5.35	1.38e-07	4.24e-05	0.36	0.24	QT interval;	chr4:75097437	chr4:74955974~74970362:-
LUAD	cis	rs10761482	0.5	rs4540900	ENSG00000254271.1	RP11-131N11.4	5.35	1.38e-07	4.24e-05	0.27	0.24	Schizophrenia;	chr10:60548976	chr10:60734342~60741828:+
LUAD	cis	rs10129255	0.957	rs12590799	ENSG00000224373.3	IGHV4-59	5.35	1.38e-07	4.24e-05	0.15	0.24	Kawasaki disease;	chr14:106779713	chr14:106627249~106627825:-
LUAD	cis	rs853679	0.599	rs149949	ENSG00000204709.4	LINC01556	5.35	1.38e-07	4.24e-05	0.41	0.24	Depression;	chr6:28043738	chr6:28943877~28944537:+
LUAD	cis	rs2086824	0.702	rs3114891	ENSG00000274627.1	RP11-104N10.2	5.35	1.38e-07	4.24e-05	0.22	0.24	Multiple myeloma (IgH translocation);	chr16:89333047	chr16:89516797~89522217:+
LUAD	cis	rs957448	1	rs1023767	ENSG00000253704.1	RP11-267M23.4	5.35	1.38e-07	4.25e-05	0.29	0.24	Nonsyndromic cleft lip with cleft palate;	chr8:94518741	chr8:94553722~94569745:+
LUAD	cis	rs858239	0.863	rs274058	ENSG00000226816.2	AC005082.12	5.35	1.38e-07	4.25e-05	0.31	0.24	Cerebrospinal fluid biomarker levels;	chr7:23351890	chr7:23206013~23208045:+
LUAD	cis	rs2115536	1	rs11637477	ENSG00000278600.1	RP11-81A1.6	-5.35	1.38e-07	4.25e-05	-0.19	-0.24	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79900953	chr15:79920195~79922455:-
LUAD	cis	rs75920871	0.748	rs7106662	ENSG00000254851.1	RP11-109L13.1	5.35	1.38e-07	4.25e-05	0.34	0.24	Subjective well-being;	chr11:117080669	chr11:117135528~117138582:+
LUAD	cis	rs7927592	0.731	rs11228275	ENSG00000212093.1	AP000807.1	-5.35	1.38e-07	4.25e-05	-0.24	-0.24	Total body bone mineral density;	chr11:68536512	chr11:68506083~68506166:-
LUAD	cis	rs2562456	0.793	rs2562474	ENSG00000268081.1	RP11-678G14.2	-5.35	1.39e-07	4.25e-05	-0.37	-0.24	Pain;	chr19:21463480	chr19:21554640~21569237:-
LUAD	cis	rs1667284	0.935	rs1791171	ENSG00000266521.1	RP11-650P15.1	5.35	1.39e-07	4.25e-05	0.28	0.24	Problematic alcohol use in trauma-exposed individuals;	chr18:31636194	chr18:31496645~31497195:-
LUAD	cis	rs1799810	0.523	rs11683986	ENSG00000236682.1	AC068282.3	5.35	1.39e-07	4.26e-05	0.3	0.24	Self-rated health;	chr2:127438822	chr2:127389130~127400580:+
LUAD	cis	rs4835473	0.932	rs13130345	ENSG00000251600.4	RP11-673E1.1	5.35	1.39e-07	4.26e-05	0.29	0.24	Immature fraction of reticulocytes;	chr4:143920939	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.864	rs5015762	ENSG00000251600.4	RP11-673E1.1	-5.35	1.39e-07	4.26e-05	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143737773	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.864	rs5015761	ENSG00000251600.4	RP11-673E1.1	-5.35	1.39e-07	4.26e-05	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143737791	chr4:143912331~143982454:+
LUAD	cis	rs7727544	0.904	rs58835386	ENSG00000233006.5	AC034220.3	5.35	1.39e-07	4.26e-05	0.2	0.24	Blood metabolite levels;	chr5:132264866	chr5:132311285~132369916:-
LUAD	cis	rs875971	0.66	rs28698552	ENSG00000237310.1	GS1-124K5.4	5.35	1.39e-07	4.26e-05	0.25	0.24	Aortic root size;	chr7:66540031	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.66	rs62465434	ENSG00000237310.1	GS1-124K5.4	5.35	1.39e-07	4.26e-05	0.25	0.24	Aortic root size;	chr7:66540165	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.66	rs13224319	ENSG00000237310.1	GS1-124K5.4	5.35	1.39e-07	4.26e-05	0.25	0.24	Aortic root size;	chr7:66542376	chr7:66493706~66495474:+
LUAD	cis	rs8031584	0.958	rs3512	ENSG00000270015.1	RP11-540B6.6	-5.35	1.39e-07	4.26e-05	-0.17	-0.24	Huntington's disease progression;	chr15:30942802	chr15:30926514~30928407:+
LUAD	cis	rs1707322	1	rs7538978	ENSG00000234329.1	RP11-767N6.2	-5.35	1.39e-07	4.27e-05	-0.24	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039382	chr1:45651039~45651826:-
LUAD	cis	rs10129255	0.557	rs4043727	ENSG00000211967.3	IGHV3-53	-5.35	1.39e-07	4.27e-05	-0.19	-0.24	Kawasaki disease;	chr14:106649820	chr14:106592676~106593347:-
LUAD	cis	rs4722166	0.695	rs56061963	ENSG00000179428.2	AC073072.5	-5.35	1.39e-07	4.27e-05	-0.28	-0.24	Lung cancer;	chr7:22760778	chr7:22725395~22727620:-
LUAD	cis	rs6669008	1	rs55912359	ENSG00000232450.1	RP4-730K3.3	-5.35	1.39e-07	4.27e-05	-0.28	-0.24	Bacteremia;	chr1:113624477	chr1:113698884~113699631:-
LUAD	cis	rs1667284	1	rs1667275	ENSG00000266521.1	RP11-650P15.1	5.35	1.4e-07	4.28e-05	0.27	0.24	Problematic alcohol use in trauma-exposed individuals;	chr18:31633302	chr18:31496645~31497195:-
LUAD	cis	rs7017914	0.714	rs3110264	ENSG00000223220.1	Y_RNA	5.35	1.4e-07	4.28e-05	0.28	0.24	Bone mineral density;	chr8:71032045	chr8:70780914~70781008:-
LUAD	cis	rs2134046	0.555	rs11854483	ENSG00000255769.6	GOLGA2P10	-5.35	1.4e-07	4.28e-05	-0.26	-0.24	Cognitive ability;	chr15:82267217	chr15:82472993~82513950:-
LUAD	cis	rs7826238	0.526	rs876955	ENSG00000253893.2	FAM85B	-5.35	1.4e-07	4.28e-05	-0.32	-0.24	Systolic blood pressure;	chr8:8453374	chr8:8167819~8226614:-
LUAD	cis	rs7617773	0.817	rs4131362	ENSG00000228638.1	FCF1P2	-5.35	1.4e-07	4.28e-05	-0.28	-0.24	Coronary artery disease;	chr3:48287546	chr3:48290793~48291375:-
LUAD	cis	rs712039	0.617	rs853201	ENSG00000276054.1	RP11-378E13.3	5.35	1.4e-07	4.29e-05	0.36	0.24	Tuberculosis;	chr17:37444086	chr17:37386886~37387926:+
LUAD	cis	rs35740288	0.929	rs3858927	ENSG00000202081.1	RNU6-1280P	5.34	1.4e-07	4.29e-05	0.3	0.24	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85758385	chr15:85651522~85651628:-
LUAD	cis	rs7208859	0.623	rs60890550	ENSG00000263603.1	CTD-2349P21.5	-5.34	1.4e-07	4.29e-05	-0.43	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30703843	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs11653955	ENSG00000263603.1	CTD-2349P21.5	-5.34	1.4e-07	4.29e-05	-0.43	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30706274	chr17:30729469~30731202:+
LUAD	cis	rs1008375	0.931	rs10939733	ENSG00000249502.1	AC006160.5	-5.34	1.4e-07	4.3e-05	-0.24	-0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17569035	chr4:17587467~17614571:-
LUAD	cis	rs4927850	1	rs7627706	ENSG00000242086.7	LINC00969	5.34	1.4e-07	4.3e-05	0.21	0.24	Pancreatic cancer;	chr3:196026482	chr3:195658062~195739964:+
LUAD	cis	rs3738443	0.953	rs61839997	ENSG00000259865.1	RP11-488L18.10	5.34	1.4e-07	4.3e-05	0.26	0.24	Alcohol dependence;	chr1:247197867	chr1:247187281~247188526:-
LUAD	cis	rs1008375	0.931	rs7435102	ENSG00000249502.1	AC006160.5	-5.34	1.4e-07	4.3e-05	-0.24	-0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17569857	chr4:17587467~17614571:-
LUAD	cis	rs8098244	0.557	rs11662031	ENSG00000264745.1	TTC39C-AS1	5.34	1.4e-07	4.3e-05	0.25	0.24	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23707799	chr18:23994213~24015339:-
LUAD	cis	rs453301	0.606	rs7462373	ENSG00000173295.6	FAM86B3P	-5.34	1.4e-07	4.3e-05	-0.25	-0.24	Joint mobility (Beighton score);	chr8:9041808	chr8:8228595~8244865:+
LUAD	cis	rs6570726	0.902	rs373321	ENSG00000235652.6	RP11-545I5.3	5.34	1.4e-07	4.31e-05	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145533014	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.967	rs374728	ENSG00000235652.6	RP11-545I5.3	5.34	1.4e-07	4.31e-05	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145533462	chr6:145799409~145886585:+
LUAD	cis	rs910316	0.692	rs7156586	ENSG00000279594.1	RP11-950C14.10	5.34	1.41e-07	4.31e-05	0.28	0.24	Height;	chr14:75039527	chr14:75011269~75012851:-
LUAD	cis	rs55665837	0.52	rs10766189	ENSG00000251991.1	RNU7-49P	5.34	1.41e-07	4.31e-05	0.27	0.24	Vitamin D levels;	chr11:14712377	chr11:14478892~14478953:+
LUAD	cis	rs2749592	0.531	rs1208559	ENSG00000263064.2	RP11-291L22.7	-5.34	1.41e-07	4.31e-05	-0.25	-0.24	Age-related hearing impairment (SNP x SNP interaction);	chr10:37932442	chr10:38448689~38448949:+
LUAD	cis	rs948562	0.69	rs11229371	ENSG00000280010.1	AP001350.4	5.34	1.41e-07	4.33e-05	0.36	0.24	Lymphoma;	chr11:58344227	chr11:58627435~58628528:+
LUAD	cis	rs7621025	0.5	rs1965107	ENSG00000239213.4	NCK1-AS1	5.34	1.41e-07	4.33e-05	0.3	0.24	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136929801	chr3:136841726~136862054:-
LUAD	cis	rs6772849	1	rs6798431	ENSG00000242551.2	POU5F1P6	-5.34	1.41e-07	4.33e-05	-0.27	-0.24	Monocyte percentage of white cells;Monocyte count;	chr3:128584530	chr3:128674735~128677005:-
LUAD	cis	rs6772849	1	rs9836257	ENSG00000242551.2	POU5F1P6	-5.34	1.41e-07	4.33e-05	-0.27	-0.24	Monocyte percentage of white cells;Monocyte count;	chr3:128584640	chr3:128674735~128677005:-
LUAD	cis	rs11976180	1	rs1533266	ENSG00000170356.8	OR2A20P	-5.34	1.41e-07	4.33e-05	-0.3	-0.24	Obesity-related traits;	chr7:144069621	chr7:144250045~144252957:-
LUAD	cis	rs66887589	0.934	rs4834792	ENSG00000245958.5	RP11-33B1.1	5.34	1.41e-07	4.33e-05	0.19	0.24	Diastolic blood pressure;	chr4:119634541	chr4:119454791~119552025:+
LUAD	cis	rs61270009	0.955	rs10514299	ENSG00000247828.6	TMEM161B-AS1	5.34	1.41e-07	4.33e-05	0.28	0.24	Depressive symptoms;	chr5:88367793	chr5:88268895~88436685:+
LUAD	cis	rs2408955	0.521	rs1476607	ENSG00000257735.1	RP11-370I10.6	-5.34	1.41e-07	4.33e-05	-0.29	-0.24	Glycated hemoglobin levels;	chr12:48131021	chr12:48350945~48442411:+
LUAD	cis	rs4964805	0.913	rs11111793	ENSG00000257681.1	RP11-341G23.4	5.34	1.42e-07	4.34e-05	0.29	0.24	Attention deficit hyperactivity disorder;	chr12:103804340	chr12:103746315~103768858:-
LUAD	cis	rs2880765	0.835	rs12708553	ENSG00000259295.5	CSPG4P12	-5.34	1.42e-07	4.34e-05	-0.27	-0.24	Coronary artery disease;	chr15:85503602	chr15:85191438~85213905:+
LUAD	cis	rs1426063	0.858	rs10004802	ENSG00000249717.1	RP11-44F21.3	5.34	1.42e-07	4.34e-05	0.34	0.24	QT interval;	chr4:75084413	chr4:74955974~74970362:-
LUAD	cis	rs600231	0.683	rs588298	ENSG00000245532.5	NEAT1	5.34	1.42e-07	4.34e-05	0.18	0.24	Bone mineral density;	chr11:65486103	chr11:65422774~65445540:+
LUAD	cis	rs7617773	0.676	rs13060020	ENSG00000228638.1	FCF1P2	-5.34	1.42e-07	4.34e-05	-0.29	-0.24	Coronary artery disease;	chr3:48331156	chr3:48290793~48291375:-
LUAD	cis	rs35740288	0.822	rs11630179	ENSG00000202081.1	RNU6-1280P	5.34	1.42e-07	4.34e-05	0.3	0.24	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85739703	chr15:85651522~85651628:-
LUAD	cis	rs2380205	0.546	rs635532	ENSG00000232807.2	RP11-536K7.3	-5.34	1.42e-07	4.34e-05	-0.25	-0.24	Breast cancer;	chr10:5928365	chr10:5934270~5945900:-
LUAD	cis	rs6543140	0.865	rs6760275	ENSG00000234389.1	AC007278.3	5.34	1.42e-07	4.35e-05	0.24	0.24	Blood protein levels;	chr2:102463147	chr2:102438713~102440475:+
LUAD	cis	rs67311347	0.544	rs13097602	ENSG00000223797.4	ENTPD3-AS1	-5.34	1.42e-07	4.35e-05	-0.24	-0.24	Renal cell carcinoma;	chr3:40297756	chr3:40313802~40453329:-
LUAD	cis	rs6772849	1	rs2713605	ENSG00000242551.2	POU5F1P6	-5.34	1.42e-07	4.35e-05	-0.27	-0.24	Monocyte percentage of white cells;Monocyte count;	chr3:128588617	chr3:128674735~128677005:-
LUAD	cis	rs2439831	0.702	rs7171750	ENSG00000249839.1	AC011330.5	-5.34	1.42e-07	4.35e-05	-0.47	-0.24	Lung cancer in ever smokers;	chr15:43733660	chr15:43663654~43684339:-
LUAD	cis	rs2439831	0.85	rs11070408	ENSG00000249839.1	AC011330.5	-5.34	1.42e-07	4.35e-05	-0.47	-0.24	Lung cancer in ever smokers;	chr15:43742590	chr15:43663654~43684339:-
LUAD	cis	rs11098499	0.874	rs28452522	ENSG00000248280.1	RP11-33B1.2	5.34	1.42e-07	4.35e-05	0.31	0.24	Corneal astigmatism;	chr4:119189629	chr4:119440561~119450157:-
LUAD	cis	rs1113500	0.614	rs11185243	ENSG00000226822.1	RP11-356N1.2	5.34	1.42e-07	4.36e-05	0.31	0.24	Growth-regulated protein alpha levels;	chr1:108054519	chr1:108071482~108074519:+
LUAD	cis	rs2439831	0.85	rs7168158	ENSG00000249839.1	AC011330.5	-5.34	1.42e-07	4.36e-05	-0.47	-0.24	Lung cancer in ever smokers;	chr15:43758178	chr15:43663654~43684339:-
LUAD	cis	rs2439831	0.85	rs7174208	ENSG00000249839.1	AC011330.5	-5.34	1.42e-07	4.36e-05	-0.47	-0.24	Lung cancer in ever smokers;	chr15:43760484	chr15:43663654~43684339:-
LUAD	cis	rs2439831	0.85	rs12101756	ENSG00000249839.1	AC011330.5	-5.34	1.42e-07	4.36e-05	-0.47	-0.24	Lung cancer in ever smokers;	chr15:43761689	chr15:43663654~43684339:-
LUAD	cis	rs6964587	0.677	rs62467839	ENSG00000188693.7	CYP51A1-AS1	-5.34	1.42e-07	4.36e-05	-0.29	-0.24	Breast cancer;	chr7:92338057	chr7:92134604~92180725:+
LUAD	cis	rs7188445	0.736	rs4243177	ENSG00000261390.4	RP11-345M22.2	5.34	1.43e-07	4.37e-05	0.29	0.24	Urate levels;	chr16:79669932	chr16:79715232~79770563:-
LUAD	cis	rs72807246	0.54	rs72807258	ENSG00000228701.1	TNKS2-AS1	5.34	1.43e-07	4.37e-05	0.52	0.24	Breast cancer;	chr10:92209153	chr10:91782839~91798291:-
LUAD	cis	rs2455601	0.608	rs59025804	ENSG00000254860.4	TMEM9B-AS1	5.34	1.43e-07	4.37e-05	0.3	0.24	Schizophrenia;	chr11:8848754	chr11:8964675~8977527:+
LUAD	cis	rs11157436	0.918	rs2178788	ENSG00000211812.1	TRAV26-2	-5.34	1.43e-07	4.37e-05	-0.25	-0.24	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22150916	chr14:22202583~22203368:+
LUAD	cis	rs9494145	0.68	rs35959442	ENSG00000232876.1	CTA-212D2.2	-5.34	1.43e-07	4.37e-05	-0.32	-0.24	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135103041	chr6:135055033~135060550:+
LUAD	cis	rs516805	0.63	rs2606641	ENSG00000279453.1	RP3-425C14.4	-5.34	1.43e-07	4.38e-05	-0.32	-0.24	Lymphocyte counts;	chr6:122103704	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.63	rs2606643	ENSG00000279453.1	RP3-425C14.4	-5.34	1.43e-07	4.38e-05	-0.32	-0.24	Lymphocyte counts;	chr6:122104352	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.596	rs2606644	ENSG00000279453.1	RP3-425C14.4	-5.34	1.43e-07	4.38e-05	-0.32	-0.24	Lymphocyte counts;	chr6:122104734	chr6:122436789~122439223:-
LUAD	cis	rs2134046	0.587	rs11854289	ENSG00000255769.6	GOLGA2P10	5.34	1.43e-07	4.38e-05	0.25	0.24	Cognitive ability;	chr15:82266461	chr15:82472993~82513950:-
LUAD	cis	rs2404602	0.692	rs4383105	ENSG00000259422.1	RP11-593F23.1	5.34	1.43e-07	4.38e-05	0.27	0.24	Blood metabolite levels;	chr15:76763169	chr15:76174891~76181486:-
LUAD	cis	rs748404	0.589	rs62020612	ENSG00000205771.5	CATSPER2P1	-5.34	1.43e-07	4.38e-05	-0.36	-0.24	Lung cancer;	chr15:43525881	chr15:43726918~43747094:-
LUAD	cis	rs17684571	0.7	rs62411376	ENSG00000231441.1	RP11-472M19.2	5.34	1.43e-07	4.39e-05	0.35	0.24	Schizophrenia;	chr6:56794436	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.7	rs34228698	ENSG00000231441.1	RP11-472M19.2	5.34	1.43e-07	4.39e-05	0.35	0.24	Schizophrenia;	chr6:56795962	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.637	rs34359353	ENSG00000231441.1	RP11-472M19.2	5.34	1.43e-07	4.39e-05	0.35	0.24	Schizophrenia;	chr6:56800963	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.7	rs13198204	ENSG00000231441.1	RP11-472M19.2	5.34	1.43e-07	4.39e-05	0.35	0.24	Schizophrenia;	chr6:56804057	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.7	rs13201639	ENSG00000231441.1	RP11-472M19.2	5.34	1.43e-07	4.39e-05	0.35	0.24	Schizophrenia;	chr6:56804329	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.7	rs71564861	ENSG00000231441.1	RP11-472M19.2	5.34	1.43e-07	4.39e-05	0.35	0.24	Schizophrenia;	chr6:56806793	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.7	rs35251663	ENSG00000231441.1	RP11-472M19.2	5.34	1.43e-07	4.39e-05	0.35	0.24	Schizophrenia;	chr6:56806940	chr6:56844002~56864078:+
LUAD	cis	rs4835473	0.897	rs7678190	ENSG00000251600.4	RP11-673E1.1	5.34	1.43e-07	4.39e-05	0.3	0.24	Immature fraction of reticulocytes;	chr4:143722421	chr4:143912331~143982454:+
LUAD	cis	rs9287719	0.578	rs7598541	ENSG00000243819.4	RN7SL832P	5.34	1.43e-07	4.39e-05	0.25	0.24	Prostate cancer;	chr2:10560390	chr2:10690344~10692099:+
LUAD	cis	rs7083	1	rs505045	ENSG00000254851.1	RP11-109L13.1	5.34	1.43e-07	4.39e-05	0.3	0.24	Blood protein levels;	chr11:117281824	chr11:117135528~117138582:+
LUAD	cis	rs74233809	1	rs11191607	ENSG00000213277.3	MARCKSL1P1	5.34	1.44e-07	4.39e-05	0.42	0.24	Birth weight;	chr10:103199431	chr10:103175554~103176094:+
LUAD	cis	rs6496932	0.866	rs4842870	ENSG00000202081.1	RNU6-1280P	5.34	1.44e-07	4.4e-05	0.33	0.24	Central corneal thickness;Corneal structure;	chr15:85277568	chr15:85651522~85651628:-
LUAD	cis	rs17264034	0.861	rs11749803	ENSG00000250786.1	SNHG18	5.34	1.44e-07	4.4e-05	0.33	0.24	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9553456	chr5:9546200~9550609:+
LUAD	cis	rs6570726	0.935	rs380433	ENSG00000235652.6	RP11-545I5.3	5.34	1.44e-07	4.4e-05	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145538465	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs367643	ENSG00000235652.6	RP11-545I5.3	5.34	1.44e-07	4.4e-05	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145538466	chr6:145799409~145886585:+
LUAD	cis	rs7829975	0.582	rs6983150	ENSG00000253893.2	FAM85B	5.34	1.44e-07	4.41e-05	0.3	0.24	Mood instability;	chr8:8934916	chr8:8167819~8226614:-
LUAD	cis	rs11671005	0.693	rs11666928	ENSG00000268912.1	CTD-2619J13.17	-5.34	1.44e-07	4.41e-05	-0.33	-0.24	Mean platelet volume;	chr19:58402864	chr19:58428632~58431148:-
LUAD	cis	rs10246939	0.579	rs35647444	ENSG00000228775.6	WEE2-AS1	5.34	1.44e-07	4.41e-05	0.28	0.24	Bitter taste perception;	chr7:141833957	chr7:141704338~141738346:-
LUAD	cis	rs891378	0.883	rs6540888	ENSG00000274245.1	RP11-357P18.2	-5.34	1.44e-07	4.41e-05	-0.29	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207247514	chr1:207372559~207373252:+
LUAD	cis	rs2337406	1	rs4774173	ENSG00000211974.3	IGHV2-70	-5.34	1.44e-07	4.41e-05	-0.3	-0.24	Alzheimer's disease (late onset);	chr14:106682029	chr14:106723574~106724093:-
LUAD	cis	rs1707322	0.752	rs28719889	ENSG00000280836.1	AL355480.1	-5.34	1.44e-07	4.41e-05	-0.31	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736611	chr1:45581219~45581321:-
LUAD	cis	rs301901	0.698	rs62360226	ENSG00000250155.1	CTD-2353F22.1	5.34	1.44e-07	4.41e-05	0.25	0.24	Height;	chr5:37428489	chr5:36666214~36725195:-
LUAD	cis	rs12554020	0.786	rs75395683	ENSG00000227603.1	RP11-165J3.6	5.34	1.45e-07	4.42e-05	0.46	0.24	Schizophrenia;	chr9:93415128	chr9:93435332~93437121:-
LUAD	cis	rs2086824	0.702	rs3114896	ENSG00000274627.1	RP11-104N10.2	-5.34	1.45e-07	4.42e-05	-0.22	-0.24	Multiple myeloma (IgH translocation);	chr16:89327154	chr16:89516797~89522217:+
LUAD	cis	rs55665837	0.54	rs10832294	ENSG00000251991.1	RNU7-49P	5.34	1.45e-07	4.42e-05	0.27	0.24	Vitamin D levels;	chr11:14725881	chr11:14478892~14478953:+
LUAD	cis	rs55665837	0.54	rs10219313	ENSG00000251991.1	RNU7-49P	5.34	1.45e-07	4.42e-05	0.27	0.24	Vitamin D levels;	chr11:14728303	chr11:14478892~14478953:+
LUAD	cis	rs55665837	0.54	rs4144487	ENSG00000251991.1	RNU7-49P	5.34	1.45e-07	4.42e-05	0.27	0.24	Vitamin D levels;	chr11:14728905	chr11:14478892~14478953:+
LUAD	cis	rs55665837	0.519	rs10832297	ENSG00000251991.1	RNU7-49P	5.34	1.45e-07	4.42e-05	0.27	0.24	Vitamin D levels;	chr11:14736191	chr11:14478892~14478953:+
LUAD	cis	rs4835473	0.9	rs5015759	ENSG00000251600.4	RP11-673E1.1	-5.34	1.45e-07	4.42e-05	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143738050	chr4:143912331~143982454:+
LUAD	cis	rs875971	0.545	rs313830	ENSG00000226824.5	RP4-756H11.3	5.34	1.45e-07	4.42e-05	0.36	0.24	Aortic root size;	chr7:66086944	chr7:66654538~66669855:+
LUAD	cis	rs7829975	0.582	rs6982832	ENSG00000253893.2	FAM85B	5.34	1.45e-07	4.42e-05	0.3	0.24	Mood instability;	chr8:8934707	chr8:8167819~8226614:-
LUAD	cis	rs875971	1	rs1167411	ENSG00000237310.1	GS1-124K5.4	-5.34	1.45e-07	4.43e-05	-0.26	-0.24	Aortic root size;	chr7:66074277	chr7:66493706~66495474:+
LUAD	cis	rs4835473	0.9	rs35230778	ENSG00000251600.4	RP11-673E1.1	-5.34	1.45e-07	4.43e-05	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143734336	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs34772566	ENSG00000251600.4	RP11-673E1.1	-5.34	1.45e-07	4.43e-05	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143734355	chr4:143912331~143982454:+
LUAD	cis	rs1707322	1	rs4660335	ENSG00000280836.1	AL355480.1	-5.34	1.45e-07	4.43e-05	-0.31	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46009046	chr1:45581219~45581321:-
LUAD	cis	rs643506	0.874	rs618031	ENSG00000230911.1	PPIHP1	-5.34	1.45e-07	4.43e-05	-0.3	-0.24	Breast cancer;	chr11:111778139	chr11:112029858~112030367:-
LUAD	cis	rs7662987	0.793	rs4699700	ENSG00000272777.1	RP11-571L19.8	5.34	1.45e-07	4.43e-05	0.37	0.24	Smoking initiation;	chr4:99077184	chr4:99067256~99068125:-
LUAD	cis	rs35740288	0.752	rs11635956	ENSG00000202081.1	RNU6-1280P	5.34	1.45e-07	4.43e-05	0.3	0.24	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85736697	chr15:85651522~85651628:-
LUAD	cis	rs867371	0.502	rs7176926	ENSG00000278603.1	RP13-608F4.5	5.34	1.45e-07	4.44e-05	0.27	0.24	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82245753	chr15:82472203~82472426:+
LUAD	cis	rs997295	0.713	rs9302245	ENSG00000270964.1	RP11-502I4.3	-5.34	1.45e-07	4.44e-05	-0.25	-0.24	Motion sickness;	chr15:67728799	chr15:67541072~67542604:-
LUAD	cis	rs4834770	0.765	rs1511016	ENSG00000245958.5	RP11-33B1.1	-5.34	1.45e-07	4.44e-05	-0.22	-0.24	Blood protein levels;	chr4:119249200	chr4:119454791~119552025:+
LUAD	cis	rs116175783	0.557	rs3769968	ENSG00000227403.1	AC009299.3	5.34	1.45e-07	4.44e-05	0.43	0.24	Intelligence (multi-trait analysis);	chr2:161309640	chr2:161244739~161249050:+
LUAD	cis	rs7617773	0.817	rs936427	ENSG00000228638.1	FCF1P2	5.34	1.45e-07	4.45e-05	0.28	0.24	Coronary artery disease;	chr3:48259584	chr3:48290793~48291375:-
LUAD	cis	rs7208859	0.673	rs216420	ENSG00000263531.1	RP13-753N3.1	5.34	1.46e-07	4.45e-05	0.4	0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30611490	chr17:30863921~30864940:-
LUAD	cis	rs1707322	1	rs1612419	ENSG00000280836.1	AL355480.1	5.34	1.46e-07	4.45e-05	0.32	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081273	chr1:45581219~45581321:-
LUAD	cis	rs35160687	0.712	rs6705366	ENSG00000273080.1	RP11-301O19.1	-5.34	1.46e-07	4.45e-05	-0.26	-0.24	Night sleep phenotypes;	chr2:86257659	chr2:86195590~86196049:+
LUAD	cis	rs453301	0.686	rs6987107	ENSG00000253893.2	FAM85B	5.34	1.46e-07	4.45e-05	0.31	0.24	Joint mobility (Beighton score);	chr8:9036071	chr8:8167819~8226614:-
LUAD	cis	rs17684571	0.654	rs4348308	ENSG00000231441.1	RP11-472M19.2	5.34	1.46e-07	4.45e-05	0.35	0.24	Schizophrenia;	chr6:56815545	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.7	rs34640766	ENSG00000231441.1	RP11-472M19.2	5.34	1.46e-07	4.45e-05	0.35	0.24	Schizophrenia;	chr6:56815876	chr6:56844002~56864078:+
LUAD	cis	rs287982	1	rs287975	ENSG00000269973.1	RP11-95D17.1	-5.34	1.46e-07	4.46e-05	-0.28	-0.24	Nonsyndromic cleft lip with cleft palate;	chr2:9829346	chr2:9936360~9939590:+
LUAD	cis	rs673078	0.571	rs61945220	ENSG00000275409.1	RP11-131L12.4	-5.34	1.46e-07	4.46e-05	-0.34	-0.24	Glucose homeostasis traits;	chr12:118272924	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.571	rs61945221	ENSG00000275409.1	RP11-131L12.4	-5.34	1.46e-07	4.46e-05	-0.34	-0.24	Glucose homeostasis traits;	chr12:118272926	chr12:118430147~118430699:+
LUAD	cis	rs1799949	0.587	rs1824890	ENSG00000267681.1	CTD-3199J23.6	-5.34	1.46e-07	4.46e-05	-0.32	-0.24	Menopause (age at onset);	chr17:43344536	chr17:43144956~43145255:+
LUAD	cis	rs4143844	0.867	rs12902859	ENSG00000259251.2	RP11-643M14.1	5.34	1.46e-07	4.46e-05	0.42	0.24	Bipolar disorder and schizophrenia;	chr15:61884966	chr15:62060503~62062434:+
LUAD	cis	rs7712401	0.562	rs384483	ENSG00000263432.2	RN7SL689P	-5.34	1.46e-07	4.46e-05	-0.29	-0.24	Mean platelet volume;	chr5:122925878	chr5:123022487~123022783:-
LUAD	cis	rs957448	0.561	rs12679785	ENSG00000253704.1	RP11-267M23.4	5.34	1.46e-07	4.46e-05	0.28	0.24	Nonsyndromic cleft lip with cleft palate;	chr8:94593349	chr8:94553722~94569745:+
LUAD	cis	rs957448	0.529	rs9642928	ENSG00000253704.1	RP11-267M23.4	5.34	1.46e-07	4.46e-05	0.28	0.24	Nonsyndromic cleft lip with cleft palate;	chr8:94601698	chr8:94553722~94569745:+
LUAD	cis	rs6687758	1	rs35805428	ENSG00000228437.4	RP11-400N13.2	5.34	1.46e-07	4.46e-05	0.35	0.24	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222015280	chr1:221966341~221984964:+
LUAD	cis	rs7299940	1	rs7299940	ENSG00000256299.1	RP11-989F5.3	-5.34	1.46e-07	4.47e-05	-0.26	-0.24	Panic disorder;	chr12:130906209	chr12:130810821~130812622:-
LUAD	cis	rs17711722	0.727	rs2658585	ENSG00000236529.1	RP13-254B10.1	5.34	1.46e-07	4.47e-05	0.24	0.24	Calcium levels;	chr7:65996954	chr7:65840212~65840596:+
LUAD	cis	rs6687821	0.515	rs7531296	ENSG00000267734.1	RP4-604K5.3	-5.34	1.47e-07	4.48e-05	-0.29	-0.24	Yeast infection;	chr1:87005691	chr1:86932199~86934891:-
LUAD	cis	rs6687821	0.515	rs2798684	ENSG00000267734.1	RP4-604K5.3	-5.34	1.47e-07	4.48e-05	-0.29	-0.24	Yeast infection;	chr1:87108534	chr1:86932199~86934891:-
LUAD	cis	rs2284219	0.565	rs2284217	ENSG00000244480.1	AC005154.7	-5.34	1.47e-07	4.48e-05	-0.2	-0.24	Type 2 diabetes;	chr7:30673992	chr7:30523143~30524535:-
LUAD	cis	rs891378	1	rs10864167	ENSG00000274245.1	RP11-357P18.2	-5.34	1.47e-07	4.48e-05	-0.29	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207248227	chr1:207372559~207373252:+
LUAD	cis	rs1008375	0.966	rs6449313	ENSG00000249502.1	AC006160.5	-5.34	1.47e-07	4.49e-05	-0.23	-0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17586697	chr4:17587467~17614571:-
LUAD	cis	rs8081395	0.775	rs2526355	ENSG00000266992.1	DHX40P1	5.34	1.47e-07	4.49e-05	0.27	0.24	White blood cell count;	chr17:59875872	chr17:59976009~60002384:-
LUAD	cis	rs12530	0.715	rs5749428	ENSG00000230736.2	RP1-149A16.3	-5.34	1.47e-07	4.49e-05	-0.26	-0.24	IgG glycosylation;	chr22:32403709	chr22:32376664~32384343:+
LUAD	cis	rs12530	0.715	rs5998475	ENSG00000230736.2	RP1-149A16.3	-5.34	1.47e-07	4.49e-05	-0.26	-0.24	IgG glycosylation;	chr22:32405345	chr22:32376664~32384343:+
LUAD	cis	rs9847710	0.838	rs2581795	ENSG00000242142.1	SERBP1P3	-5.34	1.47e-07	4.49e-05	-0.25	-0.24	Ulcerative colitis;	chr3:53004770	chr3:53064283~53065091:-
LUAD	cis	rs957448	1	rs957448	ENSG00000253704.1	RP11-267M23.4	5.34	1.47e-07	4.49e-05	0.29	0.24	Nonsyndromic cleft lip with cleft palate;	chr8:94529074	chr8:94553722~94569745:+
LUAD	cis	rs957448	1	rs72674855	ENSG00000253704.1	RP11-267M23.4	5.34	1.47e-07	4.49e-05	0.29	0.24	Nonsyndromic cleft lip with cleft palate;	chr8:94536706	chr8:94553722~94569745:+
LUAD	cis	rs1707322	0.785	rs10890348	ENSG00000280836.1	AL355480.1	-5.34	1.47e-07	4.49e-05	-0.31	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776751	chr1:45581219~45581321:-
LUAD	cis	rs10050311	0.932	rs4693784	ENSG00000251411.1	RP11-397E7.4	-5.34	1.47e-07	4.5e-05	-0.35	-0.24	Insulin-related traits;	chr4:86802935	chr4:86913266~86914817:-
LUAD	cis	rs10050311	0.932	rs2287147	ENSG00000251411.1	RP11-397E7.4	-5.34	1.47e-07	4.5e-05	-0.35	-0.24	Insulin-related traits;	chr4:86811330	chr4:86913266~86914817:-
LUAD	cis	rs10050311	0.932	rs72665795	ENSG00000251411.1	RP11-397E7.4	-5.34	1.47e-07	4.5e-05	-0.35	-0.24	Insulin-related traits;	chr4:86812000	chr4:86913266~86914817:-
LUAD	cis	rs891378	0.959	rs6703860	ENSG00000274245.1	RP11-357P18.2	-5.33	1.47e-07	4.5e-05	-0.29	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207270226	chr1:207372559~207373252:+
LUAD	cis	rs80028505	0.908	rs7752459	ENSG00000271304.1	DPRXP2	5.33	1.47e-07	4.5e-05	0.46	0.24	Foot ulcer in diabetes and neuropathy;	chr6:36116895	chr6:35989515~35990436:-
LUAD	cis	rs1707322	1	rs7539800	ENSG00000280836.1	AL355480.1	5.33	1.48e-07	4.5e-05	0.31	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796457	chr1:45581219~45581321:-
LUAD	cis	rs2439831	0.681	rs28594657	ENSG00000205771.5	CATSPER2P1	-5.33	1.48e-07	4.51e-05	-0.5	-0.24	Lung cancer in ever smokers;	chr15:43296690	chr15:43726918~43747094:-
LUAD	cis	rs4927850	1	rs7627868	ENSG00000242086.7	LINC00969	5.33	1.48e-07	4.51e-05	0.21	0.24	Pancreatic cancer;	chr3:196026602	chr3:195658062~195739964:+
LUAD	cis	rs9487094	0.645	rs34292461	ENSG00000260273.1	RP11-425D10.10	5.33	1.48e-07	4.51e-05	0.36	0.24	Height;	chr6:109352277	chr6:109382795~109383666:+
LUAD	cis	rs2836950	0.502	rs2150411	ENSG00000255568.3	BRWD1-AS2	-5.33	1.48e-07	4.51e-05	-0.23	-0.24	Menarche (age at onset);	chr21:39202626	chr21:39313935~39314962:+
LUAD	cis	rs10214930	0.813	rs10486548	ENSG00000235574.1	AC073150.6	-5.33	1.48e-07	4.51e-05	-0.31	-0.24	Hypospadias;	chr7:27633076	chr7:27491682~27492765:-
LUAD	cis	rs673078	0.571	rs7963464	ENSG00000275409.1	RP11-131L12.4	-5.33	1.48e-07	4.51e-05	-0.32	-0.24	Glucose homeostasis traits;	chr12:118264924	chr12:118430147~118430699:+
LUAD	cis	rs11157436	1	rs75648426	ENSG00000211813.2	TRAV34	5.33	1.48e-07	4.51e-05	0.31	0.24	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22184044	chr14:22207522~22208129:+
LUAD	cis	rs950169	0.84	rs72748702	ENSG00000259295.5	CSPG4P12	5.33	1.48e-07	4.52e-05	0.35	0.24	Schizophrenia;	chr15:84246494	chr15:85191438~85213905:+
LUAD	cis	rs10793273	1	rs10793273	ENSG00000254675.1	RP11-7I15.4	-5.33	1.48e-07	4.52e-05	-0.27	-0.24	Pelvic organ prolapse;	chr11:78031549	chr11:78022933~78023721:+
LUAD	cis	rs193541	0.593	rs246309	ENSG00000263432.2	RN7SL689P	5.33	1.48e-07	4.52e-05	0.31	0.24	Glucose homeostasis traits;	chr5:122934024	chr5:123022487~123022783:-
LUAD	cis	rs4889609	0.834	rs72785520	ENSG00000260911.2	RP11-196G11.2	5.33	1.48e-07	4.53e-05	0.21	0.24	Response to metformin (IC50);	chr16:31059457	chr16:31043150~31049868:+
LUAD	cis	rs2933343	0.649	rs789216	ENSG00000261159.1	RP11-723O4.9	5.33	1.48e-07	4.53e-05	0.26	0.24	IgG glycosylation;	chr3:128875660	chr3:128859716~128860526:-
LUAD	cis	rs1113500	0.614	rs6677839	ENSG00000226822.1	RP11-356N1.2	-5.33	1.48e-07	4.53e-05	-0.3	-0.24	Growth-regulated protein alpha levels;	chr1:108056719	chr1:108071482~108074519:+
LUAD	cis	rs10754283	0.967	rs7546518	ENSG00000231613.1	RP5-943J3.1	5.33	1.48e-07	4.53e-05	0.24	0.24	Amyotrophic lateral sclerosis (sporadic);	chr1:89644397	chr1:89788914~89790492:+
LUAD	cis	rs6921919	0.789	rs1119211	ENSG00000216901.1	AL022393.7	-5.33	1.49e-07	4.53e-05	-0.31	-0.24	Autism spectrum disorder or schizophrenia;	chr6:28341359	chr6:28176188~28176674:+
LUAD	cis	rs9549367	0.577	rs3024711	ENSG00000269125.1	RP11-98F14.11	-5.33	1.49e-07	4.53e-05	-0.34	-0.24	Platelet distribution width;	chr13:113158954	chr13:113165002~113165183:-
LUAD	cis	rs4835473	0.864	rs13117932	ENSG00000251600.4	RP11-673E1.1	-5.33	1.49e-07	4.53e-05	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143735873	chr4:143912331~143982454:+
LUAD	cis	rs1707322	1	rs7547189	ENSG00000234329.1	RP11-767N6.2	5.33	1.49e-07	4.54e-05	0.24	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853842	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs7547284	ENSG00000234329.1	RP11-767N6.2	5.33	1.49e-07	4.54e-05	0.24	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853893	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs11211205	ENSG00000234329.1	RP11-767N6.2	5.33	1.49e-07	4.54e-05	0.24	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45856202	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs6675222	ENSG00000234329.1	RP11-767N6.2	5.33	1.49e-07	4.54e-05	0.24	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45860904	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs4660895	ENSG00000234329.1	RP11-767N6.2	5.33	1.49e-07	4.54e-05	0.24	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864067	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs4660318	ENSG00000234329.1	RP11-767N6.2	5.33	1.49e-07	4.54e-05	0.24	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45869204	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs10890360	ENSG00000234329.1	RP11-767N6.2	5.33	1.49e-07	4.54e-05	0.24	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45872772	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs6682683	ENSG00000234329.1	RP11-767N6.2	5.33	1.49e-07	4.54e-05	0.24	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45876665	chr1:45651039~45651826:-
LUAD	cis	rs858239	0.601	rs987257	ENSG00000230042.1	AK3P3	-5.33	1.49e-07	4.54e-05	-0.29	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23129178~23129841:+
LUAD	cis	rs11051970	0.559	rs10844179	ENSG00000274964.1	RP11-817I4.1	5.33	1.49e-07	4.54e-05	0.31	0.24	Response to tocilizumab in rheumatoid arthritis;	chr12:32316667	chr12:32339368~32340724:+
LUAD	cis	rs4835473	0.897	rs6537167	ENSG00000251600.4	RP11-673E1.1	5.33	1.49e-07	4.55e-05	0.29	0.24	Immature fraction of reticulocytes;	chr4:143691323	chr4:143912331~143982454:+
LUAD	cis	rs875971	0.862	rs2420174	ENSG00000232559.3	GS1-124K5.12	-5.33	1.49e-07	4.55e-05	-0.28	-0.24	Aortic root size;	chr7:66180374	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs2420173	ENSG00000232559.3	GS1-124K5.12	-5.33	1.49e-07	4.55e-05	-0.28	-0.24	Aortic root size;	chr7:66180412	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs4718319	ENSG00000232559.3	GS1-124K5.12	-5.33	1.49e-07	4.55e-05	-0.28	-0.24	Aortic root size;	chr7:66187797	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.723	rs28391294	ENSG00000232559.3	GS1-124K5.12	-5.33	1.49e-07	4.55e-05	-0.28	-0.24	Aortic root size;	chr7:66189328	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.83	rs6967708	ENSG00000232559.3	GS1-124K5.12	-5.33	1.49e-07	4.55e-05	-0.28	-0.24	Aortic root size;	chr7:66192326	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.895	rs7782806	ENSG00000232559.3	GS1-124K5.12	-5.33	1.49e-07	4.55e-05	-0.28	-0.24	Aortic root size;	chr7:66192910	chr7:66554588~66576923:-
LUAD	cis	rs5760092	0.755	rs915589	ENSG00000228039.3	KB-1125A3.10	-5.33	1.49e-07	4.55e-05	-0.35	-0.24	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23963780~23964374:+
LUAD	cis	rs10761482	0.5	rs10994411	ENSG00000254271.1	RP11-131N11.4	5.33	1.49e-07	4.55e-05	0.26	0.24	Schizophrenia;	chr10:60545050	chr10:60734342~60741828:+
LUAD	cis	rs4964805	0.657	rs11111781	ENSG00000257681.1	RP11-341G23.4	5.33	1.49e-07	4.55e-05	0.25	0.24	Attention deficit hyperactivity disorder;	chr12:103793662	chr12:103746315~103768858:-
LUAD	cis	rs1275468	1	rs1795379	ENSG00000257497.2	RP11-585P4.5	-5.33	1.49e-07	4.55e-05	-0.34	-0.24	Polycystic ovary syndrome;	chr12:75547262	chr12:75483454~75489820:-
LUAD	cis	rs35264875	0.898	rs72928701	ENSG00000259799.1	RP11-554A11.9	5.33	1.49e-07	4.56e-05	0.34	0.24	Blond vs. brown hair color;	chr11:69094096	chr11:69155910~69159752:+
LUAD	cis	rs35264875	0.898	rs55648928	ENSG00000259799.1	RP11-554A11.9	5.33	1.49e-07	4.56e-05	0.34	0.24	Blond vs. brown hair color;	chr11:69094123	chr11:69155910~69159752:+
LUAD	cis	rs35264875	0.898	rs56140802	ENSG00000259799.1	RP11-554A11.9	5.33	1.49e-07	4.56e-05	0.34	0.24	Blond vs. brown hair color;	chr11:69094163	chr11:69155910~69159752:+
LUAD	cis	rs9287719	0.649	rs12617968	ENSG00000234818.1	AC092687.5	5.33	1.49e-07	4.56e-05	0.58	0.24	Prostate cancer;	chr2:10581819	chr2:10589166~10604830:+
LUAD	cis	rs11105298	0.891	rs4842661	ENSG00000258302.2	RP11-981P6.1	5.33	1.5e-07	4.57e-05	0.31	0.24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89536622	chr12:89561129~89594878:+
LUAD	cis	rs6687758	1	rs11118926	ENSG00000228437.4	RP11-400N13.2	5.33	1.5e-07	4.57e-05	0.35	0.24	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222013781	chr1:221966341~221984964:+
LUAD	cis	rs6687758	1	rs17495159	ENSG00000228437.4	RP11-400N13.2	5.33	1.5e-07	4.57e-05	0.35	0.24	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222016251	chr1:221966341~221984964:+
LUAD	cis	rs6687758	1	rs35212520	ENSG00000228437.4	RP11-400N13.2	5.33	1.5e-07	4.57e-05	0.35	0.24	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222016322	chr1:221966341~221984964:+
LUAD	cis	rs7131987	0.65	rs3782509	ENSG00000257176.2	RP11-996F15.2	-5.33	1.5e-07	4.57e-05	-0.27	-0.24	QT interval;	chr12:29300845	chr12:29280418~29317848:-
LUAD	cis	rs10754283	0.934	rs1934043	ENSG00000231613.1	RP5-943J3.1	5.33	1.5e-07	4.58e-05	0.24	0.24	Amyotrophic lateral sclerosis (sporadic);	chr1:89641086	chr1:89788914~89790492:+
LUAD	cis	rs10754283	0.967	rs2185195	ENSG00000231613.1	RP5-943J3.1	5.33	1.5e-07	4.58e-05	0.24	0.24	Amyotrophic lateral sclerosis (sporadic);	chr1:89641138	chr1:89788914~89790492:+
LUAD	cis	rs10754283	0.967	rs6657988	ENSG00000231613.1	RP5-943J3.1	5.33	1.5e-07	4.58e-05	0.24	0.24	Amyotrophic lateral sclerosis (sporadic);	chr1:89641186	chr1:89788914~89790492:+
LUAD	cis	rs10754283	0.967	rs6698273	ENSG00000231613.1	RP5-943J3.1	5.33	1.5e-07	4.58e-05	0.24	0.24	Amyotrophic lateral sclerosis (sporadic);	chr1:89641232	chr1:89788914~89790492:+
LUAD	cis	rs394563	0.559	rs13219868	ENSG00000231760.4	RP11-350J20.5	-5.33	1.5e-07	4.58e-05	-0.29	-0.24	Dupuytren's disease;	chr6:149365382	chr6:149796151~149826294:-
LUAD	cis	rs2337406	0.925	rs2011167	ENSG00000211972.2	IGHV3-66	5.33	1.51e-07	4.59e-05	0.26	0.24	Alzheimer's disease (late onset);	chr14:106680831	chr14:106675017~106675544:-
LUAD	cis	rs7712401	0.601	rs30029	ENSG00000263432.2	RN7SL689P	-5.33	1.51e-07	4.59e-05	-0.29	-0.24	Mean platelet volume;	chr5:122947475	chr5:123022487~123022783:-
LUAD	cis	rs4819052	0.788	rs35323494	ENSG00000215447.6	BX322557.10	-5.33	1.51e-07	4.6e-05	-0.29	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45283824	chr21:45288052~45291738:+
LUAD	cis	rs8180040	0.726	rs4234465	ENSG00000271161.1	BOLA2P2	5.33	1.51e-07	4.6e-05	0.23	0.24	Colorectal cancer;	chr3:46985395	chr3:47499841~47500407:+
LUAD	cis	rs12188164	0.61	rs6555242	ENSG00000225138.6	CTD-2228K2.7	5.33	1.51e-07	4.6e-05	0.22	0.24	Cystic fibrosis severity;	chr5:416431	chr5:473236~480884:+
LUAD	cis	rs375066	0.935	rs399098	ENSG00000267058.1	RP11-15A1.3	-5.33	1.51e-07	4.6e-05	-0.27	-0.24	Breast cancer;	chr19:43914672	chr19:43891804~43901805:-
LUAD	cis	rs3809863	0.602	rs6504833	ENSG00000228782.6	CTD-2026D20.3	5.33	1.51e-07	4.61e-05	0.25	0.24	Glaucoma (primary open-angle);	chr17:47318721	chr17:47450568~47492492:-
LUAD	cis	rs2735413	0.564	rs74316728	ENSG00000276007.1	RP11-358L22.3	5.33	1.51e-07	4.61e-05	0.34	0.24	Systolic blood pressure (alcohol consumption interaction);	chr16:78065756	chr16:78123243~78124332:+
LUAD	cis	rs2836950	0.545	rs4818001	ENSG00000255568.3	BRWD1-AS2	-5.33	1.51e-07	4.61e-05	-0.23	-0.24	Menarche (age at onset);	chr21:39203162	chr21:39313935~39314962:+
LUAD	cis	rs4964805	0.954	rs4964812	ENSG00000257681.1	RP11-341G23.4	5.33	1.51e-07	4.61e-05	0.28	0.24	Attention deficit hyperactivity disorder;	chr12:103795837	chr12:103746315~103768858:-
LUAD	cis	rs1707322	1	rs4660889	ENSG00000234329.1	RP11-767N6.2	5.33	1.51e-07	4.61e-05	0.24	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45831659	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs10890353	ENSG00000234329.1	RP11-767N6.2	5.33	1.51e-07	4.61e-05	0.24	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45832711	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs10890355	ENSG00000234329.1	RP11-767N6.2	5.33	1.51e-07	4.61e-05	0.24	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45851676	chr1:45651039~45651826:-
LUAD	cis	rs4835473	0.868	rs4629390	ENSG00000251600.4	RP11-673E1.1	-5.33	1.51e-07	4.61e-05	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143735302	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.838	rs4583708	ENSG00000251600.4	RP11-673E1.1	-5.33	1.51e-07	4.61e-05	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143735610	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs34257944	ENSG00000251600.4	RP11-673E1.1	-5.33	1.51e-07	4.61e-05	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143736443	chr4:143912331~143982454:+
LUAD	cis	rs116139393	0.656	rs10244591	ENSG00000187953.9	PMS2CL	-5.33	1.52e-07	4.62e-05	-0.29	-0.24	Alzheimer's disease (APOE e4 interaction);	chr7:6731467	chr7:6710128~6753862:+
LUAD	cis	rs2404602	0.692	rs4641709	ENSG00000259422.1	RP11-593F23.1	-5.33	1.52e-07	4.62e-05	-0.27	-0.24	Blood metabolite levels;	chr15:76755395	chr15:76174891~76181486:-
LUAD	cis	rs17684571	0.751	rs35081015	ENSG00000231441.1	RP11-472M19.2	5.33	1.52e-07	4.62e-05	0.35	0.24	Schizophrenia;	chr6:56819757	chr6:56844002~56864078:+
LUAD	cis	rs858239	0.539	rs28624974	ENSG00000230042.1	AK3P3	-5.33	1.52e-07	4.62e-05	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23149317	chr7:23129178~23129841:+
LUAD	cis	rs11319879	1	rs11319879	ENSG00000236493.2	EIF2S2P3	5.33	1.52e-07	4.62e-05	0.26	0.24	Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;	chr10:92693719	chr10:92668745~92669743:-
LUAD	cis	rs17666538	0.585	rs1703927	ENSG00000254207.1	RP11-43A14.1	-5.33	1.52e-07	4.62e-05	-0.46	-0.24	IgG glycosylation;	chr8:663620	chr8:725188~725877:-
LUAD	cis	rs7829975	0.742	rs1533058	ENSG00000253981.4	ALG1L13P	5.33	1.52e-07	4.63e-05	0.27	0.24	Mood instability;	chr8:8827680	chr8:8236003~8244667:-
LUAD	cis	rs4713118	0.696	rs2394002	ENSG00000219392.1	RP1-265C24.5	-5.33	1.52e-07	4.63e-05	-0.32	-0.24	Parkinson's disease;	chr6:27780236	chr6:28115628~28116551:+
LUAD	cis	rs2288884	0.806	rs12460587	ENSG00000275055.1	CTC-471J1.11	-5.33	1.52e-07	4.63e-05	-0.37	-0.24	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52083666	chr19:52049007~52049754:+
LUAD	cis	rs71636778	0.509	rs34460334	ENSG00000260063.1	RP5-968P14.2	-5.33	1.52e-07	4.63e-05	-0.43	-0.24	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26888588	chr1:26692132~26694131:-
LUAD	cis	rs7927592	0.763	rs7119422	ENSG00000212093.1	AP000807.1	-5.33	1.52e-07	4.63e-05	-0.24	-0.24	Total body bone mineral density;	chr11:68563686	chr11:68506083~68506166:-
LUAD	cis	rs10129255	0.536	rs3944157	ENSG00000211967.3	IGHV3-53	-5.33	1.52e-07	4.64e-05	-0.17	-0.24	Kawasaki disease;	chr14:106682286	chr14:106592676~106593347:-
LUAD	cis	rs2115536	0.967	rs3826008	ENSG00000278600.1	RP11-81A1.6	-5.33	1.53e-07	4.64e-05	-0.19	-0.24	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79897463	chr15:79920195~79922455:-
LUAD	cis	rs2115536	1	rs2115540	ENSG00000278600.1	RP11-81A1.6	-5.33	1.53e-07	4.64e-05	-0.19	-0.24	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79897966	chr15:79920195~79922455:-
LUAD	cis	rs2688608	0.592	rs11000759	ENSG00000271816.1	BMS1P4	5.33	1.53e-07	4.64e-05	0.2	0.24	Inflammatory bowel disease;	chr10:73733968	chr10:73699151~73730487:-
LUAD	cis	rs17711722	0.74	rs7809991	ENSG00000236529.1	RP13-254B10.1	5.33	1.53e-07	4.64e-05	0.24	0.24	Calcium levels;	chr7:65941231	chr7:65840212~65840596:+
LUAD	cis	rs66823261	0.741	rs7841786	ENSG00000253166.2	RP11-585F1.6	-5.33	1.53e-07	4.65e-05	-0.33	-0.24	Breast cancer (estrogen-receptor negative);Breast cancer;	chr8:241746	chr8:202660~202897:-
LUAD	cis	rs10246939	0.553	rs34894166	ENSG00000228775.6	WEE2-AS1	5.33	1.53e-07	4.65e-05	0.29	0.24	Bitter taste perception;	chr7:141852158	chr7:141704338~141738346:-
LUAD	cis	rs17264034	1	rs414829	ENSG00000250786.1	SNHG18	5.33	1.53e-07	4.65e-05	0.33	0.24	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9552413	chr5:9546200~9550609:+
LUAD	cis	rs4835473	0.932	rs34525847	ENSG00000251600.4	RP11-673E1.1	-5.33	1.53e-07	4.65e-05	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143734970	chr4:143912331~143982454:+
LUAD	cis	rs9595908	0.708	rs12429740	ENSG00000212293.1	SNORA16	5.33	1.53e-07	4.65e-05	0.26	0.24	Body mass index;	chr13:32684928	chr13:32420390~32420516:-
LUAD	cis	rs2404602	0.967	rs7167613	ENSG00000259422.1	RP11-593F23.1	5.33	1.53e-07	4.65e-05	0.28	0.24	Blood metabolite levels;	chr15:76748851	chr15:76174891~76181486:-
LUAD	cis	rs2735413	0.564	rs78769909	ENSG00000276007.1	RP11-358L22.3	5.33	1.53e-07	4.65e-05	0.33	0.24	Systolic blood pressure (alcohol consumption interaction);	chr16:78070105	chr16:78123243~78124332:+
LUAD	cis	rs2115536	1	rs2903105	ENSG00000278600.1	RP11-81A1.6	-5.33	1.53e-07	4.66e-05	-0.19	-0.24	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79897181	chr15:79920195~79922455:-
LUAD	cis	rs4819052	0.788	rs13049700	ENSG00000215447.6	BX322557.10	-5.33	1.53e-07	4.66e-05	-0.29	-0.24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45281994	chr21:45288052~45291738:+
LUAD	cis	rs516805	0.63	rs2816077	ENSG00000279453.1	RP3-425C14.4	-5.33	1.53e-07	4.66e-05	-0.31	-0.24	Lymphocyte counts;	chr6:122105669	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.63	rs2816075	ENSG00000279453.1	RP3-425C14.4	-5.33	1.53e-07	4.66e-05	-0.31	-0.24	Lymphocyte counts;	chr6:122106110	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.63	rs2816073	ENSG00000279453.1	RP3-425C14.4	-5.33	1.53e-07	4.66e-05	-0.31	-0.24	Lymphocyte counts;	chr6:122106794	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.63	rs2816072	ENSG00000279453.1	RP3-425C14.4	-5.33	1.53e-07	4.66e-05	-0.31	-0.24	Lymphocyte counts;	chr6:122106871	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.666	rs2816071	ENSG00000279453.1	RP3-425C14.4	-5.33	1.53e-07	4.66e-05	-0.31	-0.24	Lymphocyte counts;	chr6:122106995	chr6:122436789~122439223:-
LUAD	cis	rs4908768	0.535	rs2661868	ENSG00000232912.4	RP5-1115A15.1	-5.33	1.53e-07	4.66e-05	-0.24	-0.24	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8409729	chr1:8424645~8434838:+
LUAD	cis	rs2439831	0.85	rs28718261	ENSG00000249839.1	AC011330.5	-5.33	1.53e-07	4.66e-05	-0.47	-0.24	Lung cancer in ever smokers;	chr15:43751595	chr15:43663654~43684339:-
LUAD	cis	rs10800713	0.954	rs6665951	ENSG00000260088.1	RP11-92G12.3	-5.33	1.53e-07	4.66e-05	-0.33	-0.24	Tandem gait;	chr1:200589235	chr1:200669507~200694250:+
LUAD	cis	rs2790457	0.958	rs2790455	ENSG00000254635.4	WAC-AS1	-5.33	1.53e-07	4.67e-05	-0.26	-0.24	Multiple myeloma;	chr10:28558148	chr10:28522652~28532743:-
LUAD	cis	rs1823913	0.538	rs13432697	ENSG00000227542.1	AC092614.2	5.33	1.53e-07	4.67e-05	0.29	0.24	Obesity-related traits;	chr2:191345944	chr2:191229165~191246172:-
LUAD	cis	rs673078	0.66	rs61943524	ENSG00000275409.1	RP11-131L12.4	-5.33	1.53e-07	4.67e-05	-0.35	-0.24	Glucose homeostasis traits;	chr12:118151530	chr12:118430147~118430699:+
LUAD	cis	rs17684571	0.637	rs35566812	ENSG00000231441.1	RP11-472M19.2	5.33	1.53e-07	4.67e-05	0.34	0.24	Schizophrenia;	chr6:56792077	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.7	rs62411375	ENSG00000231441.1	RP11-472M19.2	5.33	1.53e-07	4.67e-05	0.34	0.24	Schizophrenia;	chr6:56794361	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.7	rs13220851	ENSG00000231441.1	RP11-472M19.2	5.33	1.53e-07	4.67e-05	0.34	0.24	Schizophrenia;	chr6:56796753	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.7	rs59432342	ENSG00000231441.1	RP11-472M19.2	5.33	1.53e-07	4.67e-05	0.34	0.24	Schizophrenia;	chr6:56797506	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.7	rs34171958	ENSG00000231441.1	RP11-472M19.2	5.33	1.53e-07	4.67e-05	0.34	0.24	Schizophrenia;	chr6:56800000	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.7	rs13201733	ENSG00000231441.1	RP11-472M19.2	5.33	1.53e-07	4.67e-05	0.34	0.24	Schizophrenia;	chr6:56804226	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.7	rs17684730	ENSG00000231441.1	RP11-472M19.2	5.33	1.53e-07	4.67e-05	0.34	0.24	Schizophrenia;	chr6:56804425	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.7	rs4371846	ENSG00000231441.1	RP11-472M19.2	5.33	1.53e-07	4.67e-05	0.34	0.24	Schizophrenia;	chr6:56805767	chr6:56844002~56864078:+
LUAD	cis	rs2836950	0.565	rs7276046	ENSG00000255568.3	BRWD1-AS2	-5.33	1.54e-07	4.67e-05	-0.23	-0.24	Menarche (age at onset);	chr21:39209367	chr21:39313935~39314962:+
LUAD	cis	rs2836950	0.545	rs8132143	ENSG00000255568.3	BRWD1-AS2	-5.33	1.54e-07	4.67e-05	-0.23	-0.24	Menarche (age at onset);	chr21:39212332	chr21:39313935~39314962:+
LUAD	cis	rs10129255	0.5	rs10131875	ENSG00000211967.3	IGHV3-53	-5.33	1.54e-07	4.67e-05	-0.17	-0.24	Kawasaki disease;	chr14:106792798	chr14:106592676~106593347:-
LUAD	cis	rs2599510	0.811	rs2710615	ENSG00000276334.1	AL133243.1	5.33	1.54e-07	4.67e-05	0.28	0.24	Interleukin-18 levels;	chr2:32566155	chr2:32521927~32523547:+
LUAD	cis	rs600231	0.708	rs661403	ENSG00000245532.5	NEAT1	5.33	1.54e-07	4.67e-05	0.18	0.24	Bone mineral density;	chr11:65475007	chr11:65422774~65445540:+
LUAD	cis	rs4835473	0.864	rs12507633	ENSG00000251600.4	RP11-673E1.1	5.33	1.54e-07	4.68e-05	0.29	0.24	Immature fraction of reticulocytes;	chr4:143962730	chr4:143912331~143982454:+
LUAD	cis	rs4654783	0.505	rs7544210	ENSG00000228397.1	RP1-224A6.3	-5.33	1.54e-07	4.68e-05	-0.28	-0.24	Endometriosis;	chr1:22128649	chr1:22023994~22024968:-
LUAD	cis	rs2599510	0.811	rs62136345	ENSG00000276334.1	AL133243.1	5.33	1.54e-07	4.68e-05	0.27	0.24	Interleukin-18 levels;	chr2:32582156	chr2:32521927~32523547:+
LUAD	cis	rs516805	0.63	rs720205	ENSG00000279453.1	RP3-425C14.4	-5.33	1.54e-07	4.69e-05	-0.32	-0.24	Lymphocyte counts;	chr6:122107329	chr6:122436789~122439223:-
LUAD	cis	rs35740288	0.822	rs10520599	ENSG00000202081.1	RNU6-1280P	5.33	1.54e-07	4.69e-05	0.29	0.24	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85679866	chr15:85651522~85651628:-
LUAD	cis	rs9652601	0.648	rs7197422	ENSG00000274038.1	RP11-66H6.4	-5.33	1.54e-07	4.69e-05	-0.28	-0.24	Systemic lupus erythematosus;	chr16:11027214	chr16:11056556~11057034:+
LUAD	cis	rs7621025	0.5	rs12629000	ENSG00000239213.4	NCK1-AS1	5.33	1.54e-07	4.69e-05	0.29	0.24	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136924729	chr3:136841726~136862054:-
LUAD	cis	rs75920871	0.528	rs10082609	ENSG00000254851.1	RP11-109L13.1	5.33	1.54e-07	4.7e-05	0.34	0.24	Subjective well-being;	chr11:117078358	chr11:117135528~117138582:+
LUAD	cis	rs7208859	0.623	rs28556733	ENSG00000263603.1	CTD-2349P21.5	-5.33	1.55e-07	4.7e-05	-0.4	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30756927	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs28433704	ENSG00000263603.1	CTD-2349P21.5	-5.33	1.55e-07	4.7e-05	-0.4	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757267	chr17:30729469~30731202:+
LUAD	cis	rs17826219	0.706	rs55764512	ENSG00000263603.1	CTD-2349P21.5	-5.33	1.55e-07	4.7e-05	-0.4	-0.24	Body mass index;	chr17:30758740	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs12103508	ENSG00000263603.1	CTD-2349P21.5	-5.33	1.55e-07	4.7e-05	-0.4	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759763	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.524	rs11653605	ENSG00000263603.1	CTD-2349P21.5	-5.33	1.55e-07	4.7e-05	-0.4	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30729469~30731202:+
LUAD	cis	rs7617773	0.779	rs9833309	ENSG00000228638.1	FCF1P2	-5.33	1.55e-07	4.7e-05	-0.28	-0.24	Coronary artery disease;	chr3:48285960	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.817	rs9853804	ENSG00000228638.1	FCF1P2	-5.33	1.55e-07	4.7e-05	-0.28	-0.24	Coronary artery disease;	chr3:48286239	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.817	rs9834095	ENSG00000228638.1	FCF1P2	-5.33	1.55e-07	4.7e-05	-0.28	-0.24	Coronary artery disease;	chr3:48286261	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.817	rs4131361	ENSG00000228638.1	FCF1P2	-5.33	1.55e-07	4.7e-05	-0.28	-0.24	Coronary artery disease;	chr3:48287322	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.817	rs6791930	ENSG00000228638.1	FCF1P2	-5.33	1.55e-07	4.7e-05	-0.28	-0.24	Coronary artery disease;	chr3:48288410	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.817	rs6794644	ENSG00000228638.1	FCF1P2	-5.33	1.55e-07	4.7e-05	-0.28	-0.24	Coronary artery disease;	chr3:48288547	chr3:48290793~48291375:-
LUAD	cis	rs17684571	0.7	rs13200166	ENSG00000231441.1	RP11-472M19.2	5.33	1.55e-07	4.7e-05	0.34	0.24	Schizophrenia;	chr6:56816414	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.7	rs17752046	ENSG00000231441.1	RP11-472M19.2	5.33	1.55e-07	4.7e-05	0.34	0.24	Schizophrenia;	chr6:56816550	chr6:56844002~56864078:+
LUAD	cis	rs4938330	0.739	rs11216266	ENSG00000254851.1	RP11-109L13.1	5.33	1.55e-07	4.71e-05	0.34	0.24	Blood protein levels;	chr11:117079434	chr11:117135528~117138582:+
LUAD	cis	rs11051970	0.559	rs10431283	ENSG00000274964.1	RP11-817I4.1	-5.33	1.55e-07	4.71e-05	-0.31	-0.24	Response to tocilizumab in rheumatoid arthritis;	chr12:32315070	chr12:32339368~32340724:+
LUAD	cis	rs11051970	0.559	rs10431225	ENSG00000274964.1	RP11-817I4.1	-5.33	1.55e-07	4.71e-05	-0.31	-0.24	Response to tocilizumab in rheumatoid arthritis;	chr12:32315177	chr12:32339368~32340724:+
LUAD	cis	rs5758511	0.514	rs5758626	ENSG00000205702.9	CYP2D7	5.33	1.55e-07	4.71e-05	0.24	0.24	Birth weight;	chr22:42176357	chr22:42140203~42144577:-
LUAD	cis	rs1065852	0.861	rs5758627	ENSG00000205702.9	CYP2D7	5.33	1.55e-07	4.71e-05	0.24	0.24	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42176541	chr22:42140203~42144577:-
LUAD	cis	rs10800713	0.56	rs10800706	ENSG00000260088.1	RP11-92G12.3	-5.33	1.55e-07	4.71e-05	-0.39	-0.24	Tandem gait;	chr1:200526967	chr1:200669507~200694250:+
LUAD	cis	rs9309473	0.687	rs6748040	ENSG00000163016.8	ALMS1P	-5.33	1.55e-07	4.71e-05	-0.26	-0.24	Metabolite levels;	chr2:73382800	chr2:73644919~73685576:+
LUAD	cis	rs6687758	0.687	rs7520544	ENSG00000228437.4	RP11-400N13.2	5.33	1.55e-07	4.71e-05	0.34	0.24	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221943856	chr1:221966341~221984964:+
LUAD	cis	rs6570726	0.818	rs398812	ENSG00000235652.6	RP11-545I5.3	5.33	1.55e-07	4.71e-05	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145496135	chr6:145799409~145886585:+
LUAD	cis	rs7617773	0.78	rs7645425	ENSG00000228638.1	FCF1P2	-5.32	1.55e-07	4.72e-05	-0.28	-0.24	Coronary artery disease;	chr3:48320879	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.78	rs6793223	ENSG00000228638.1	FCF1P2	-5.32	1.55e-07	4.72e-05	-0.28	-0.24	Coronary artery disease;	chr3:48322611	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.78	rs4541431	ENSG00000228638.1	FCF1P2	-5.32	1.55e-07	4.72e-05	-0.28	-0.24	Coronary artery disease;	chr3:48323728	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.78	rs11714944	ENSG00000228638.1	FCF1P2	-5.32	1.55e-07	4.72e-05	-0.28	-0.24	Coronary artery disease;	chr3:48325481	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.743	rs13071960	ENSG00000228638.1	FCF1P2	-5.32	1.55e-07	4.72e-05	-0.28	-0.24	Coronary artery disease;	chr3:48326047	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.743	rs4632568	ENSG00000228638.1	FCF1P2	-5.32	1.55e-07	4.72e-05	-0.28	-0.24	Coronary artery disease;	chr3:48326329	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.78	rs11130164	ENSG00000228638.1	FCF1P2	-5.32	1.55e-07	4.72e-05	-0.28	-0.24	Coronary artery disease;	chr3:48327544	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.78	rs7653336	ENSG00000228638.1	FCF1P2	-5.32	1.55e-07	4.72e-05	-0.28	-0.24	Coronary artery disease;	chr3:48327974	chr3:48290793~48291375:-
LUAD	cis	rs891378	0.92	rs10864156	ENSG00000274245.1	RP11-357P18.2	-5.32	1.56e-07	4.72e-05	-0.28	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207240416	chr1:207372559~207373252:+
LUAD	cis	rs56080343	0.515	rs73222056	ENSG00000275409.1	RP11-131L12.4	-5.32	1.56e-07	4.73e-05	-0.37	-0.24	Neuroticism;	chr12:118215875	chr12:118430147~118430699:+
LUAD	cis	rs891378	1	rs10864178	ENSG00000274245.1	RP11-357P18.2	-5.32	1.56e-07	4.73e-05	-0.29	-0.24	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207272333	chr1:207372559~207373252:+
LUAD	cis	rs1707322	0.964	rs6675259	ENSG00000280836.1	AL355480.1	5.32	1.56e-07	4.73e-05	0.31	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46036623	chr1:45581219~45581321:-
LUAD	cis	rs4664293	0.902	rs13391919	ENSG00000226266.5	AC009961.3	-5.32	1.56e-07	4.73e-05	-0.33	-0.24	Monocyte percentage of white cells;	chr2:159703649	chr2:159670708~159712435:-
LUAD	cis	rs1292048	1	rs1292048	ENSG00000266992.1	DHX40P1	5.32	1.56e-07	4.73e-05	0.27	0.24	Red cell distribution width;	chr17:59877710	chr17:59976009~60002384:-
LUAD	cis	rs75920871	0.528	rs7124872	ENSG00000254851.1	RP11-109L13.1	-5.32	1.56e-07	4.74e-05	-0.34	-0.24	Subjective well-being;	chr11:117057235	chr11:117135528~117138582:+
LUAD	cis	rs7580658	0.637	rs3902960	ENSG00000236682.1	AC068282.3	-5.32	1.56e-07	4.74e-05	-0.31	-0.24	Protein C levels;	chr2:127230666	chr2:127389130~127400580:+
LUAD	cis	rs11157436	0.958	rs6572313	ENSG00000211813.2	TRAV34	5.32	1.56e-07	4.74e-05	0.31	0.24	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22214070	chr14:22207522~22208129:+
LUAD	cis	rs17711722	0.528	rs73138179	ENSG00000234585.5	CCT6P3	5.32	1.56e-07	4.75e-05	0.22	0.24	Calcium levels;	chr7:65829495	chr7:65038354~65074713:+
LUAD	cis	rs2288884	0.806	rs60193983	ENSG00000275055.1	CTC-471J1.11	-5.32	1.56e-07	4.75e-05	-0.37	-0.24	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52082659	chr19:52049007~52049754:+
LUAD	cis	rs11651753	0.561	rs4794261	ENSG00000264920.1	RP11-6N17.4	-5.32	1.56e-07	4.75e-05	-0.29	-0.24	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47904980	chr17:47891255~47895812:-
LUAD	cis	rs11651753	0.561	rs1108833	ENSG00000264920.1	RP11-6N17.4	-5.32	1.56e-07	4.75e-05	-0.29	-0.24	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47905431	chr17:47891255~47895812:-
LUAD	cis	rs11651753	0.561	rs7211859	ENSG00000264920.1	RP11-6N17.4	-5.32	1.56e-07	4.75e-05	-0.29	-0.24	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47908916	chr17:47891255~47895812:-
LUAD	cis	rs6568401	0.6	rs1508360	ENSG00000219088.1	RP3-359N14.1	-5.32	1.56e-07	4.75e-05	-0.31	-0.24	Primary tooth development (time to first tooth eruption);	chr6:105729226	chr6:105666326~105667998:+
LUAD	cis	rs12554020	0.892	rs78046549	ENSG00000227603.1	RP11-165J3.6	5.32	1.56e-07	4.75e-05	0.44	0.24	Schizophrenia;	chr9:93506196	chr9:93435332~93437121:-
LUAD	cis	rs6570726	0.935	rs421268	ENSG00000235652.6	RP11-545I5.3	5.32	1.57e-07	4.75e-05	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145524422	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs384519	ENSG00000235652.6	RP11-545I5.3	5.32	1.57e-07	4.75e-05	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145524881	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs454370	ENSG00000235652.6	RP11-545I5.3	5.32	1.57e-07	4.75e-05	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145525593	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs416987	ENSG00000235652.6	RP11-545I5.3	5.32	1.57e-07	4.75e-05	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145525869	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.905	rs452770	ENSG00000235652.6	RP11-545I5.3	5.32	1.57e-07	4.75e-05	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145526026	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs442254	ENSG00000235652.6	RP11-545I5.3	5.32	1.57e-07	4.75e-05	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145527982	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.846	rs441575	ENSG00000235652.6	RP11-545I5.3	5.32	1.57e-07	4.75e-05	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145528069	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs436212	ENSG00000235652.6	RP11-545I5.3	5.32	1.57e-07	4.75e-05	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145528264	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs414222	ENSG00000235652.6	RP11-545I5.3	5.32	1.57e-07	4.75e-05	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145529346	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs385134	ENSG00000235652.6	RP11-545I5.3	5.32	1.57e-07	4.75e-05	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145529869	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs415590	ENSG00000235652.6	RP11-545I5.3	5.32	1.57e-07	4.75e-05	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145530108	chr6:145799409~145886585:+
LUAD	cis	rs4927850	0.881	rs7624638	ENSG00000242086.7	LINC00969	5.32	1.57e-07	4.75e-05	0.21	0.24	Pancreatic cancer;	chr3:196021858	chr3:195658062~195739964:+
LUAD	cis	rs11157436	0.871	rs8003190	ENSG00000211813.2	TRAV34	5.32	1.57e-07	4.75e-05	0.31	0.24	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22212096	chr14:22207522~22208129:+
LUAD	cis	rs4835473	0.932	rs35277115	ENSG00000251600.4	RP11-673E1.1	-5.32	1.57e-07	4.75e-05	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143735001	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs34653324	ENSG00000251600.4	RP11-673E1.1	-5.32	1.57e-07	4.75e-05	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143735058	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs35947648	ENSG00000251600.4	RP11-673E1.1	-5.32	1.57e-07	4.75e-05	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143735092	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs66474962	ENSG00000251600.4	RP11-673E1.1	-5.32	1.57e-07	4.75e-05	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143735145	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.838	rs35800634	ENSG00000251600.4	RP11-673E1.1	-5.32	1.57e-07	4.75e-05	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143735199	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.838	rs34505330	ENSG00000251600.4	RP11-673E1.1	-5.32	1.57e-07	4.75e-05	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143735206	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs4597770	ENSG00000251600.4	RP11-673E1.1	-5.32	1.57e-07	4.75e-05	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143735239	chr4:143912331~143982454:+
LUAD	cis	rs7083	1	rs507880	ENSG00000254851.1	RP11-109L13.1	5.32	1.57e-07	4.76e-05	0.3	0.24	Blood protein levels;	chr11:117266539	chr11:117135528~117138582:+
LUAD	cis	rs1707322	0.686	rs11211179	ENSG00000280836.1	AL355480.1	-5.32	1.57e-07	4.76e-05	-0.31	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762410	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.721	rs10157795	ENSG00000280836.1	AL355480.1	-5.32	1.57e-07	4.76e-05	-0.31	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762520	chr1:45581219~45581321:-
LUAD	cis	rs12468226	0.938	rs10931993	ENSG00000226261.1	AC064836.3	5.32	1.57e-07	4.76e-05	0.38	0.24	Urate levels;	chr2:202243017	chr2:202336024~202336727:-
LUAD	cis	rs516805	0.667	rs1456706	ENSG00000279453.1	RP3-425C14.4	-5.32	1.57e-07	4.76e-05	-0.32	-0.24	Lymphocyte counts;	chr6:122134801	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.667	rs2606651	ENSG00000279453.1	RP3-425C14.4	-5.32	1.57e-07	4.76e-05	-0.32	-0.24	Lymphocyte counts;	chr6:122136475	chr6:122436789~122439223:-
LUAD	cis	rs9910055	1	rs9895423	ENSG00000267080.4	ASB16-AS1	-5.32	1.57e-07	4.76e-05	-0.23	-0.24	Total body bone mineral density;	chr17:44208372	chr17:44175973~44186717:-
LUAD	cis	rs1075265	0.933	rs929734	ENSG00000233266.1	HMGB1P31	5.32	1.57e-07	4.76e-05	0.3	0.24	Chronotype;Morning vs. evening chronotype;	chr2:54111158	chr2:54051334~54051760:+
LUAD	cis	rs896854	0.684	rs2340534	ENSG00000253528.2	RP11-347C18.4	5.32	1.57e-07	4.76e-05	0.23	0.24	Type 2 diabetes;	chr8:94980102	chr8:94974573~94974853:-
LUAD	cis	rs950169	0.887	rs35986397	ENSG00000259295.5	CSPG4P12	5.32	1.57e-07	4.77e-05	0.34	0.24	Schizophrenia;	chr15:84400409	chr15:85191438~85213905:+
LUAD	cis	rs712039	0.652	rs2680719	ENSG00000276054.1	RP11-378E13.3	5.32	1.57e-07	4.77e-05	0.36	0.24	Tuberculosis;	chr17:37451351	chr17:37386886~37387926:+
LUAD	cis	rs7829975	0.514	rs2979139	ENSG00000253893.2	FAM85B	-5.32	1.57e-07	4.77e-05	-0.29	-0.24	Mood instability;	chr8:8410803	chr8:8167819~8226614:-
LUAD	cis	rs7617773	0.815	rs9825637	ENSG00000228638.1	FCF1P2	-5.32	1.57e-07	4.77e-05	-0.28	-0.24	Coronary artery disease;	chr3:48330792	chr3:48290793~48291375:-
LUAD	cis	rs11976180	1	rs1320893	ENSG00000170356.8	OR2A20P	-5.32	1.57e-07	4.77e-05	-0.3	-0.24	Obesity-related traits;	chr7:144055019	chr7:144250045~144252957:-
LUAD	cis	rs7176527	0.848	rs17600128	ENSG00000188388.10	GOLGA6L3	5.32	1.57e-07	4.77e-05	0.34	0.24	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84744141	chr15:85240472~85247170:+
LUAD	cis	rs6570726	0.935	rs449377	ENSG00000235652.6	RP11-545I5.3	5.32	1.57e-07	4.78e-05	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145531301	chr6:145799409~145886585:+
LUAD	cis	rs66887589	0.934	rs7681980	ENSG00000245958.5	RP11-33B1.1	5.32	1.58e-07	4.78e-05	0.19	0.24	Diastolic blood pressure;	chr4:119612068	chr4:119454791~119552025:+
LUAD	cis	rs11089937	0.597	rs4821770	ENSG00000211638.2	IGLV8-61	-5.32	1.58e-07	4.78e-05	-0.27	-0.24	Periodontitis (PAL4Q3);	chr22:22131281	chr22:22098700~22099212:+
LUAD	cis	rs11089937	0.568	rs4821771	ENSG00000211638.2	IGLV8-61	-5.32	1.58e-07	4.78e-05	-0.27	-0.24	Periodontitis (PAL4Q3);	chr22:22131287	chr22:22098700~22099212:+
LUAD	cis	rs11742741	0.572	rs4701425	ENSG00000248874.4	C5orf17	-5.32	1.58e-07	4.78e-05	-0.29	-0.24	Educational attainment;	chr5:24172342	chr5:23951348~24178263:+
LUAD	cis	rs12908161	1	rs11638290	ENSG00000275120.1	RP11-182J1.17	5.32	1.58e-07	4.79e-05	0.36	0.24	Schizophrenia;	chr15:84684405	chr15:84599434~84606463:-
LUAD	cis	rs12908161	0.959	rs34028043	ENSG00000275120.1	RP11-182J1.17	5.32	1.58e-07	4.79e-05	0.36	0.24	Schizophrenia;	chr15:84688354	chr15:84599434~84606463:-
LUAD	cis	rs12908161	0.959	rs34784022	ENSG00000275120.1	RP11-182J1.17	5.32	1.58e-07	4.79e-05	0.36	0.24	Schizophrenia;	chr15:84688675	chr15:84599434~84606463:-
LUAD	cis	rs12908161	0.959	rs12908699	ENSG00000275120.1	RP11-182J1.17	5.32	1.58e-07	4.79e-05	0.36	0.24	Schizophrenia;	chr15:84697172	chr15:84599434~84606463:-
LUAD	cis	rs875971	0.666	rs13242072	ENSG00000237310.1	GS1-124K5.4	-5.32	1.58e-07	4.79e-05	-0.26	-0.24	Aortic root size;	chr7:66301001	chr7:66493706~66495474:+
LUAD	cis	rs10050311	0.932	rs17694112	ENSG00000251411.1	RP11-397E7.4	-5.32	1.58e-07	4.79e-05	-0.35	-0.24	Insulin-related traits;	chr4:86807523	chr4:86913266~86914817:-
LUAD	cis	rs10129255	0.784	rs7147210	ENSG00000224373.3	IGHV4-59	5.32	1.58e-07	4.79e-05	0.16	0.24	Kawasaki disease;	chr14:106705271	chr14:106627249~106627825:-
LUAD	cis	rs12745968	0.594	rs10735781	ENSG00000223787.2	RP4-593M8.1	-5.32	1.58e-07	4.79e-05	-0.27	-0.24	Bipolar disorder and schizophrenia;	chr1:92655550	chr1:92580476~92580821:-
LUAD	cis	rs62246343	0.719	rs6767213	ENSG00000254485.4	RP11-380O24.1	5.32	1.58e-07	4.79e-05	0.35	0.24	Fibrinogen levels;	chr3:9415588	chr3:9292588~9363303:-
LUAD	cis	rs62246343	0.719	rs62246305	ENSG00000254485.4	RP11-380O24.1	5.32	1.58e-07	4.79e-05	0.35	0.24	Fibrinogen levels;	chr3:9416565	chr3:9292588~9363303:-
LUAD	cis	rs875971	0.862	rs2460432	ENSG00000232559.3	GS1-124K5.12	-5.32	1.58e-07	4.8e-05	-0.28	-0.24	Aortic root size;	chr7:66089398	chr7:66554588~66576923:-
LUAD	cis	rs858239	0.541	rs4624924	ENSG00000230042.1	AK3P3	-5.32	1.58e-07	4.8e-05	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23129178~23129841:+
LUAD	cis	rs72615157	0.606	rs941288	ENSG00000242294.5	STAG3L5P	5.32	1.58e-07	4.8e-05	0.2	0.24	Lung function (FEV1/FVC);	chr7:100179185	chr7:100336079~100351900:+
LUAD	cis	rs11157436	0.915	rs11622938	ENSG00000211813.2	TRAV34	5.32	1.58e-07	4.8e-05	0.31	0.24	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22183456	chr14:22207522~22208129:+
LUAD	cis	rs763512	0.504	rs1051838	ENSG00000276054.1	RP11-378E13.3	5.32	1.58e-07	4.8e-05	0.36	0.24	3-hydroxypropylmercapturic acid levels in smokers;	chr17:37510731	chr17:37386886~37387926:+
LUAD	cis	rs2790457	0.833	rs1265843	ENSG00000254635.4	WAC-AS1	-5.32	1.59e-07	4.81e-05	-0.26	-0.24	Multiple myeloma;	chr10:28636088	chr10:28522652~28532743:-
LUAD	cis	rs36093844	0.752	rs17744606	ENSG00000279742.1	RP11-700A24.1	-5.32	1.59e-07	4.81e-05	-0.31	-0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85854407	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.752	rs74404559	ENSG00000279742.1	RP11-700A24.1	-5.32	1.59e-07	4.81e-05	-0.31	-0.24	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85854626	chr11:85852557~85854943:-
LUAD	cis	rs712039	0.652	rs853227	ENSG00000276054.1	RP11-378E13.3	5.32	1.59e-07	4.81e-05	0.36	0.24	Tuberculosis;	chr17:37437428	chr17:37386886~37387926:+
LUAD	cis	rs11671005	0.693	rs34023391	ENSG00000268912.1	CTD-2619J13.17	-5.32	1.59e-07	4.82e-05	-0.33	-0.24	Mean platelet volume;	chr19:58402001	chr19:58428632~58431148:-
LUAD	cis	rs1707322	1	rs1622208	ENSG00000280836.1	AL355480.1	5.32	1.59e-07	4.82e-05	0.31	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46032703	chr1:45581219~45581321:-
LUAD	cis	rs12439619	1	rs12439619	ENSG00000276710.3	CSPG4P8	-5.32	1.59e-07	4.83e-05	-0.23	-0.24	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82459472~82477258:+
LUAD	cis	rs2562456	0.792	rs2562398	ENSG00000268081.1	RP11-678G14.2	-5.32	1.59e-07	4.83e-05	-0.36	-0.24	Pain;	chr19:21540147	chr19:21554640~21569237:-
LUAD	cis	rs2015599	0.525	rs7298031	ENSG00000275476.1	RP11-996F15.4	5.32	1.59e-07	4.83e-05	0.25	0.24	Platelet count;Mean platelet volume;	chr12:29317333	chr12:29277397~29277882:-
LUAD	cis	rs2015599	0.525	rs2016832	ENSG00000275476.1	RP11-996F15.4	5.32	1.59e-07	4.83e-05	0.25	0.24	Platelet count;Mean platelet volume;	chr12:29318199	chr12:29277397~29277882:-
LUAD	cis	rs61270009	0.955	rs2305104	ENSG00000247828.6	TMEM161B-AS1	-5.32	1.6e-07	4.83e-05	-0.27	-0.24	Depressive symptoms;	chr5:88324853	chr5:88268895~88436685:+
LUAD	cis	rs6570726	0.935	rs906774	ENSG00000235652.6	RP11-545I5.3	5.32	1.6e-07	4.84e-05	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145492634	chr6:145799409~145886585:+
LUAD	cis	rs1667284	0.967	rs895888	ENSG00000266521.1	RP11-650P15.1	5.32	1.6e-07	4.84e-05	0.28	0.24	Problematic alcohol use in trauma-exposed individuals;	chr18:31648224	chr18:31496645~31497195:-
LUAD	cis	rs858239	0.601	rs6948469	ENSG00000230042.1	AK3P3	-5.32	1.6e-07	4.84e-05	-0.3	-0.24	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23129178~23129841:+
LUAD	cis	rs6570726	0.935	rs366308	ENSG00000235652.6	RP11-545I5.3	5.32	1.6e-07	4.84e-05	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145493396	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs384806	ENSG00000235652.6	RP11-545I5.3	5.32	1.6e-07	4.84e-05	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145493753	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs385185	ENSG00000235652.6	RP11-545I5.3	5.32	1.6e-07	4.84e-05	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145493856	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs384453	ENSG00000235652.6	RP11-545I5.3	5.32	1.6e-07	4.84e-05	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145494009	chr6:145799409~145886585:+
LUAD	cis	rs889398	0.935	rs1364063	ENSG00000226232.7	RP11-419C5.2	5.32	1.6e-07	4.84e-05	0.2	0.24	Body mass index;	chr16:69554669	chr16:69976388~69996188:-
LUAD	cis	rs193541	0.632	rs34486978	ENSG00000263432.2	RN7SL689P	-5.32	1.6e-07	4.85e-05	-0.31	-0.24	Glucose homeostasis traits;	chr5:122976848	chr5:123022487~123022783:-
LUAD	cis	rs7617773	0.78	rs11710257	ENSG00000228638.1	FCF1P2	-5.32	1.6e-07	4.85e-05	-0.29	-0.24	Coronary artery disease;	chr3:48331724	chr3:48290793~48291375:-
LUAD	cis	rs1876905	0.597	rs354546	ENSG00000272356.1	RP5-1112D6.8	-5.32	1.6e-07	4.85e-05	-0.27	-0.24	Mean corpuscular hemoglobin;	chr6:111211927	chr6:111309203~111313517:+
LUAD	cis	rs35264875	0.851	rs72930611	ENSG00000259799.1	RP11-554A11.9	5.32	1.6e-07	4.85e-05	0.34	0.24	Blond vs. brown hair color;	chr11:69096191	chr11:69155910~69159752:+
LUAD	cis	rs10246939	0.579	rs10464444	ENSG00000270923.1	TAS2R6P	5.32	1.6e-07	4.85e-05	0.25	0.24	Bitter taste perception;	chr7:141832387	chr7:141787815~141788640:+
LUAD	cis	rs9322193	0.884	rs11155675	ENSG00000268592.3	RAET1E-AS1	5.32	1.6e-07	4.85e-05	0.31	0.24	Lung cancer;	chr6:149742883	chr6:149863494~149919507:+
LUAD	cis	rs2688608	0.592	rs7909544	ENSG00000271816.1	BMS1P4	5.32	1.6e-07	4.85e-05	0.2	0.24	Inflammatory bowel disease;	chr10:73724246	chr10:73699151~73730487:-
LUAD	cis	rs1823913	0.66	rs1454752	ENSG00000227542.1	AC092614.2	-5.32	1.6e-07	4.85e-05	-0.29	-0.24	Obesity-related traits;	chr2:191298668	chr2:191229165~191246172:-
LUAD	cis	rs801193	1	rs17566701	ENSG00000237310.1	GS1-124K5.4	5.32	1.6e-07	4.85e-05	0.26	0.24	Aortic root size;	chr7:66728196	chr7:66493706~66495474:+
LUAD	cis	rs35264875	0.851	rs72930621	ENSG00000259799.1	RP11-554A11.9	5.32	1.6e-07	4.86e-05	0.34	0.24	Blond vs. brown hair color;	chr11:69099277	chr11:69155910~69159752:+
LUAD	cis	rs1667284	0.967	rs1667281	ENSG00000266521.1	RP11-650P15.1	5.32	1.61e-07	4.86e-05	0.28	0.24	Problematic alcohol use in trauma-exposed individuals;	chr18:31640793	chr18:31496645~31497195:-
LUAD	cis	rs1667284	1	rs1612691	ENSG00000266521.1	RP11-650P15.1	5.32	1.61e-07	4.86e-05	0.28	0.24	Problematic alcohol use in trauma-exposed individuals;	chr18:31640955	chr18:31496645~31497195:-
LUAD	cis	rs6570726	0.935	rs366621	ENSG00000235652.6	RP11-545I5.3	5.32	1.61e-07	4.86e-05	0.23	0.24	Lobe attachment (rater-scored or self-reported);	chr6:145540139	chr6:145799409~145886585:+
LUAD	cis	rs2015599	0.525	rs10743656	ENSG00000257176.2	RP11-996F15.2	5.32	1.61e-07	4.87e-05	0.25	0.24	Platelet count;Mean platelet volume;	chr12:29332516	chr12:29280418~29317848:-
LUAD	cis	rs2439831	0.681	rs1095386	ENSG00000249839.1	AC011330.5	-5.32	1.61e-07	4.87e-05	-0.41	-0.24	Lung cancer in ever smokers;	chr15:43317311	chr15:43663654~43684339:-
LUAD	cis	rs2734839	0.507	rs2002453	ENSG00000270179.1	RP11-159N11.4	-5.32	1.61e-07	4.87e-05	-0.26	-0.24	Information processing speed;	chr11:113418576	chr11:113368478~113369117:+
LUAD	cis	rs9807989	0.839	rs7603730	ENSG00000234389.1	AC007278.3	5.32	1.61e-07	4.88e-05	0.22	0.24	Asthma;	chr2:102357911	chr2:102438713~102440475:+
LUAD	cis	rs8098244	0.557	rs11082712	ENSG00000264745.1	TTC39C-AS1	5.32	1.61e-07	4.88e-05	0.24	0.24	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23718286	chr18:23994213~24015339:-
LUAD	cis	rs172166	0.585	rs149963	ENSG00000219392.1	RP1-265C24.5	-5.32	1.61e-07	4.88e-05	-0.29	-0.24	Cardiac Troponin-T levels;	chr6:28049354	chr6:28115628~28116551:+
LUAD	cis	rs673078	0.607	rs4766900	ENSG00000275409.1	RP11-131L12.4	-5.32	1.61e-07	4.88e-05	-0.33	-0.24	Glucose homeostasis traits;	chr12:118375139	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs884844	ENSG00000275409.1	RP11-131L12.4	-5.32	1.61e-07	4.88e-05	-0.33	-0.24	Glucose homeostasis traits;	chr12:118377033	chr12:118430147~118430699:+
LUAD	cis	rs7580658	0.637	rs9636235	ENSG00000236682.1	AC068282.3	-5.32	1.61e-07	4.88e-05	-0.3	-0.24	Protein C levels;	chr2:127223975	chr2:127389130~127400580:+
LUAD	cis	rs6750795	0.542	rs1797388	ENSG00000181798.2	LINC00471	-5.32	1.61e-07	4.88e-05	-0.27	-0.24	Height;	chr2:231551270	chr2:231508426~231514339:-
LUAD	cis	rs847577	0.715	rs4729402	ENSG00000272950.1	RP11-307C18.1	5.32	1.61e-07	4.88e-05	0.3	0.24	Breast cancer;	chr7:98078419	chr7:98322853~98323430:+
LUAD	cis	rs516805	0.528	rs2816085	ENSG00000279453.1	RP3-425C14.4	-5.32	1.62e-07	4.89e-05	-0.31	-0.24	Lymphocyte counts;	chr6:122097324	chr6:122436789~122439223:-
LUAD	cis	rs35160687	0.623	rs35408390	ENSG00000273080.1	RP11-301O19.1	-5.32	1.62e-07	4.89e-05	-0.26	-0.24	Night sleep phenotypes;	chr2:86244659	chr2:86195590~86196049:+
LUAD	cis	rs8072100	0.875	rs7208530	ENSG00000228782.6	CTD-2026D20.3	5.32	1.62e-07	4.89e-05	0.25	0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47466741	chr17:47450568~47492492:-
LUAD	cis	rs8072100	0.875	rs12451409	ENSG00000228782.6	CTD-2026D20.3	5.32	1.62e-07	4.89e-05	0.25	0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47467490	chr17:47450568~47492492:-
LUAD	cis	rs2243480	0.522	rs778717	ENSG00000232546.1	RP11-458F8.1	-5.32	1.62e-07	4.9e-05	-0.36	-0.24	Diabetic kidney disease;	chr7:66383164	chr7:66848496~66858136:+
LUAD	cis	rs2239547	0.603	rs17304995	ENSG00000242142.1	SERBP1P3	5.32	1.62e-07	4.9e-05	0.29	0.24	Schizophrenia;	chr3:53036739	chr3:53064283~53065091:-
LUAD	cis	rs1823913	0.503	rs6706578	ENSG00000280083.1	RP11-317J9.1	-5.32	1.62e-07	4.9e-05	-0.29	-0.24	Obesity-related traits;	chr2:191346992	chr2:191154118~191156070:-
LUAD	cis	rs9923856	0.542	rs11859698	ENSG00000274038.1	RP11-66H6.4	-5.32	1.62e-07	4.9e-05	-0.28	-0.24	Atopic dermatitis;Adult asthma;	chr16:11032878	chr16:11056556~11057034:+
LUAD	cis	rs2179367	0.552	rs11155652	ENSG00000231760.4	RP11-350J20.5	5.32	1.62e-07	4.9e-05	0.34	0.24	Dupuytren's disease;	chr6:149417849	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs12209364	ENSG00000231760.4	RP11-350J20.5	5.32	1.62e-07	4.9e-05	0.34	0.24	Dupuytren's disease;	chr6:149418062	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs9498348	ENSG00000231760.4	RP11-350J20.5	5.32	1.62e-07	4.9e-05	0.34	0.24	Dupuytren's disease;	chr6:149418352	chr6:149796151~149826294:-
LUAD	cis	rs2179367	0.632	rs9322179	ENSG00000231760.4	RP11-350J20.5	5.32	1.62e-07	4.9e-05	0.34	0.24	Dupuytren's disease;	chr6:149418664	chr6:149796151~149826294:-
LUAD	cis	rs9494145	1	rs9494145	ENSG00000232876.1	CTA-212D2.2	-5.32	1.62e-07	4.9e-05	-0.34	-0.24	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135111414	chr6:135055033~135060550:+
LUAD	cis	rs13256369	0.774	rs13260303	ENSG00000253893.2	FAM85B	-5.32	1.62e-07	4.9e-05	-0.33	-0.24	Obesity-related traits;	chr8:8729832	chr8:8167819~8226614:-
LUAD	cis	rs8031584	0.958	rs11293	ENSG00000270015.1	RP11-540B6.6	-5.32	1.62e-07	4.9e-05	-0.17	-0.24	Huntington's disease progression;	chr15:30942778	chr15:30926514~30928407:+
LUAD	cis	rs55665837	0.54	rs1007392	ENSG00000251991.1	RNU7-49P	5.32	1.62e-07	4.91e-05	0.26	0.24	Vitamin D levels;	chr11:14753045	chr11:14478892~14478953:+
LUAD	cis	rs9595908	0.733	rs9315175	ENSG00000212293.1	SNORA16	5.32	1.62e-07	4.91e-05	0.25	0.24	Body mass index;	chr13:32649581	chr13:32420390~32420516:-
LUAD	cis	rs7208859	0.623	rs216423	ENSG00000263603.1	CTD-2349P21.5	-5.32	1.62e-07	4.91e-05	-0.35	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30615091	chr17:30729469~30731202:+
LUAD	cis	rs2562456	0.876	rs62110163	ENSG00000268081.1	RP11-678G14.2	5.32	1.62e-07	4.91e-05	0.36	0.24	Pain;	chr19:21546020	chr19:21554640~21569237:-
LUAD	cis	rs1075265	0.783	rs718872	ENSG00000233266.1	HMGB1P31	5.32	1.62e-07	4.91e-05	0.3	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53946569	chr2:54051334~54051760:+
LUAD	cis	rs6840360	0.904	rs6825241	ENSG00000270265.1	RP11-731D1.4	-5.32	1.63e-07	4.91e-05	-0.24	-0.24	Intelligence (multi-trait analysis);	chr4:151622631	chr4:151333775~151353224:-
LUAD	cis	rs2380205	0.538	rs11255774	ENSG00000232807.2	RP11-536K7.3	5.32	1.63e-07	4.92e-05	0.26	0.24	Breast cancer;	chr10:5897096	chr10:5934270~5945900:-
LUAD	cis	rs507080	0.733	rs4393358	ENSG00000278376.1	RP11-158I9.8	-5.32	1.63e-07	4.92e-05	-0.25	-0.24	Serum metabolite levels;	chr11:118698388	chr11:118791254~118793137:+
LUAD	cis	rs1008375	0.9	rs4698622	ENSG00000249502.1	AC006160.5	-5.32	1.63e-07	4.92e-05	-0.24	-0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17587934	chr4:17587467~17614571:-
LUAD	cis	rs1075265	0.756	rs805367	ENSG00000233266.1	HMGB1P31	5.32	1.63e-07	4.92e-05	0.3	0.24	Chronotype;Morning vs. evening chronotype;	chr2:53943956	chr2:54051334~54051760:+
LUAD	cis	rs7968440	1	rs2251603	ENSG00000200428.1	Y_RNA	5.32	1.63e-07	4.92e-05	0.29	0.24	Fibrinogen;	chr12:50655870	chr12:50743568~50743684:+
LUAD	cis	rs7208859	0.623	rs7217984	ENSG00000263603.1	CTD-2349P21.5	-5.32	1.63e-07	4.92e-05	-0.41	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765748	chr17:30729469~30731202:+
LUAD	cis	rs35160687	0.712	rs2303359	ENSG00000273080.1	RP11-301O19.1	-5.32	1.63e-07	4.93e-05	-0.26	-0.24	Night sleep phenotypes;	chr2:86251547	chr2:86195590~86196049:+
LUAD	cis	rs11673344	0.801	rs56343212	ENSG00000226686.6	LINC01535	5.32	1.63e-07	4.93e-05	0.32	0.24	Obesity-related traits;	chr19:37167684	chr19:37251912~37265535:+
LUAD	cis	rs12701220	0.655	rs10241018	ENSG00000229043.2	AC091729.9	-5.32	1.63e-07	4.93e-05	-0.29	-0.24	Bronchopulmonary dysplasia;	chr7:1105138	chr7:1160374~1165267:+
LUAD	cis	rs889398	0.904	rs4783721	ENSG00000226232.7	RP11-419C5.2	5.32	1.63e-07	4.94e-05	0.2	0.24	Body mass index;	chr16:69527253	chr16:69976388~69996188:-
LUAD	cis	rs875971	0.619	rs12533585	ENSG00000237310.1	GS1-124K5.4	5.32	1.63e-07	4.94e-05	0.25	0.24	Aortic root size;	chr7:66519618	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.66	rs12698534	ENSG00000237310.1	GS1-124K5.4	5.32	1.63e-07	4.94e-05	0.25	0.24	Aortic root size;	chr7:66521858	chr7:66493706~66495474:+
LUAD	cis	rs442309	0.553	rs10995281	ENSG00000238280.1	RP11-436D10.3	-5.32	1.63e-07	4.94e-05	-0.3	-0.24	Vogt-Koyanagi-Harada syndrome;	chr10:62707416	chr10:62793562~62805887:-
LUAD	cis	rs9914544	0.602	rs4924929	ENSG00000273018.4	CTD-2303H24.2	-5.32	1.63e-07	4.94e-05	-0.28	-0.24	Educational attainment (years of education);	chr17:18810928	chr17:18511221~18551705:-
LUAD	cis	rs8177876	0.658	rs12444747	ENSG00000261061.1	RP11-303E16.2	-5.32	1.63e-07	4.94e-05	-0.43	-0.24	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81041299	chr16:81030770~81031485:+
LUAD	cis	rs950169	0.8	rs4842847	ENSG00000259295.5	CSPG4P12	5.32	1.63e-07	4.94e-05	0.35	0.24	Schizophrenia;	chr15:84262447	chr15:85191438~85213905:+
LUAD	cis	rs4835473	0.897	rs28701142	ENSG00000251600.4	RP11-673E1.1	5.32	1.63e-07	4.94e-05	0.29	0.24	Immature fraction of reticulocytes;	chr4:143945730	chr4:143912331~143982454:+
LUAD	cis	rs10129255	0.5	rs2105991	ENSG00000254174.1	IGHV1-12	5.32	1.63e-07	4.94e-05	0.16	0.24	Kawasaki disease;	chr14:106682022	chr14:106122420~106122709:-
LUAD	cis	rs7617773	0.78	rs35297486	ENSG00000228638.1	FCF1P2	-5.31	1.64e-07	4.94e-05	-0.29	-0.24	Coronary artery disease;	chr3:48336657	chr3:48290793~48291375:-
LUAD	cis	rs17684571	0.7	rs17684748	ENSG00000231441.1	RP11-472M19.2	5.31	1.64e-07	4.94e-05	0.34	0.24	Schizophrenia;	chr6:56809419	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.7	rs17751977	ENSG00000231441.1	RP11-472M19.2	5.31	1.64e-07	4.94e-05	0.34	0.24	Schizophrenia;	chr6:56809820	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.7	rs17684772	ENSG00000231441.1	RP11-472M19.2	5.31	1.64e-07	4.94e-05	0.34	0.24	Schizophrenia;	chr6:56810415	chr6:56844002~56864078:+
LUAD	cis	rs2688608	0.56	rs10128354	ENSG00000271816.1	BMS1P4	5.31	1.64e-07	4.94e-05	0.2	0.24	Inflammatory bowel disease;	chr10:73710287	chr10:73699151~73730487:-
LUAD	cis	rs712039	0.652	rs1102920	ENSG00000276054.1	RP11-378E13.3	5.31	1.64e-07	4.94e-05	0.35	0.24	Tuberculosis;	chr17:37400850	chr17:37386886~37387926:+
LUAD	cis	rs17684571	0.7	rs36022925	ENSG00000231441.1	RP11-472M19.2	5.31	1.64e-07	4.96e-05	0.34	0.24	Schizophrenia;	chr6:56818169	chr6:56844002~56864078:+
LUAD	cis	rs1008375	0.931	rs6449309	ENSG00000249502.1	AC006160.5	-5.31	1.64e-07	4.97e-05	-0.24	-0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17571585	chr4:17587467~17614571:-
LUAD	cis	rs1874124	0.836	rs17596947	ENSG00000272823.1	RP11-295M18.6	5.31	1.64e-07	4.97e-05	0.34	0.24	Cholesterol, total;	chr1:220820122	chr1:220828676~220829211:-
LUAD	cis	rs7617773	0.707	rs13061269	ENSG00000228638.1	FCF1P2	-5.31	1.65e-07	4.97e-05	-0.29	-0.24	Coronary artery disease;	chr3:48331853	chr3:48290793~48291375:-
LUAD	cis	rs2948294	0.524	rs13270062	ENSG00000173295.6	FAM86B3P	5.31	1.65e-07	4.98e-05	0.26	0.24	Red cell distribution width;	chr8:8255128	chr8:8228595~8244865:+
LUAD	cis	rs2243480	0.522	rs12698511	ENSG00000226824.5	RP4-756H11.3	-5.31	1.65e-07	4.99e-05	-0.5	-0.24	Diabetic kidney disease;	chr7:66009932	chr7:66654538~66669855:+
LUAD	cis	rs17818399	0.815	rs35837037	ENSG00000279254.1	RP11-536C12.1	-5.31	1.65e-07	4.99e-05	-0.27	-0.24	Height;	chr2:46634161	chr2:46668870~46670778:+
LUAD	cis	rs7829975	0.714	rs6994038	ENSG00000173295.6	FAM86B3P	5.31	1.65e-07	4.99e-05	0.25	0.24	Mood instability;	chr8:8803028	chr8:8228595~8244865:+
LUAD	cis	rs4604732	0.588	rs12045675	ENSG00000227135.1	GCSAML-AS1	-5.31	1.65e-07	4.99e-05	-0.36	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247460613	chr1:247524679~247526752:-
LUAD	cis	rs7617773	0.747	rs34076262	ENSG00000228638.1	FCF1P2	-5.31	1.66e-07	5e-05	-0.28	-0.24	Coronary artery disease;	chr3:48328926	chr3:48290793~48291375:-
LUAD	cis	rs875971	0.522	rs10807697	ENSG00000236529.1	RP13-254B10.1	5.31	1.66e-07	5e-05	0.24	0.24	Aortic root size;	chr7:65951183	chr7:65840212~65840596:+
LUAD	cis	rs4664293	1	rs10184034	ENSG00000226266.5	AC009961.3	-5.31	1.66e-07	5e-05	-0.32	-0.24	Monocyte percentage of white cells;	chr2:159648916	chr2:159670708~159712435:-
LUAD	cis	rs4664293	1	rs4664293	ENSG00000226266.5	AC009961.3	-5.31	1.66e-07	5e-05	-0.32	-0.24	Monocyte percentage of white cells;	chr2:159649241	chr2:159670708~159712435:-
LUAD	cis	rs4664293	1	rs10193402	ENSG00000226266.5	AC009961.3	-5.31	1.66e-07	5e-05	-0.32	-0.24	Monocyte percentage of white cells;	chr2:159651271	chr2:159670708~159712435:-
LUAD	cis	rs4664293	1	rs11676412	ENSG00000226266.5	AC009961.3	-5.31	1.66e-07	5e-05	-0.32	-0.24	Monocyte percentage of white cells;	chr2:159651560	chr2:159670708~159712435:-
LUAD	cis	rs270601	0.69	rs162904	ENSG00000233006.5	AC034220.3	-5.31	1.66e-07	5e-05	-0.22	-0.24	Acylcarnitine levels;	chr5:132260091	chr5:132311285~132369916:-
LUAD	cis	rs4141404	0.748	rs2232170	ENSG00000236132.1	CTA-440B3.1	5.31	1.66e-07	5.01e-05	0.29	0.24	Paclitaxel-induced neuropathy;	chr22:31141136	chr22:31816379~31817491:-
LUAD	cis	rs6714710	0.603	rs34503448	ENSG00000230606.9	AC159540.1	-5.31	1.66e-07	5.01e-05	-0.25	-0.24	Posterior cortical atrophy and Alzheimer's disease;	chr2:97970825	chr2:97416165~97433527:-
LUAD	cis	rs6714710	0.603	rs953320	ENSG00000230606.9	AC159540.1	-5.31	1.66e-07	5.01e-05	-0.25	-0.24	Posterior cortical atrophy and Alzheimer's disease;	chr2:97990307	chr2:97416165~97433527:-
LUAD	cis	rs12908161	1	rs12911736	ENSG00000275120.1	RP11-182J1.17	5.31	1.66e-07	5.01e-05	0.36	0.24	Schizophrenia;	chr15:84696777	chr15:84599434~84606463:-
LUAD	cis	rs950169	0.84	rs2896002	ENSG00000259295.5	CSPG4P12	5.31	1.66e-07	5.01e-05	0.34	0.24	Schizophrenia;	chr15:84390423	chr15:85191438~85213905:+
LUAD	cis	rs2880765	0.546	rs11637726	ENSG00000259295.5	CSPG4P12	-5.31	1.66e-07	5.02e-05	-0.29	-0.24	Coronary artery disease;	chr15:85516040	chr15:85191438~85213905:+
LUAD	cis	rs748404	0.666	rs16957715	ENSG00000205771.5	CATSPER2P1	-5.31	1.66e-07	5.02e-05	-0.35	-0.24	Lung cancer;	chr15:43416539	chr15:43726918~43747094:-
LUAD	cis	rs4908760	0.792	rs6577515	ENSG00000232912.4	RP5-1115A15.1	5.31	1.66e-07	5.02e-05	0.21	0.24	Vitiligo;	chr1:8654143	chr1:8424645~8434838:+
LUAD	cis	rs848490	0.674	rs6971555	ENSG00000214293.7	APTR	5.31	1.67e-07	5.03e-05	0.27	0.24	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77777422	chr7:77657660~77696265:-
LUAD	cis	rs2836950	0.565	rs2836930	ENSG00000255568.3	BRWD1-AS2	-5.31	1.67e-07	5.03e-05	-0.23	-0.24	Menarche (age at onset);	chr21:39173730	chr21:39313935~39314962:+
LUAD	cis	rs4713118	1	rs4713118	ENSG00000219392.1	RP1-265C24.5	-5.31	1.67e-07	5.03e-05	-0.32	-0.24	Parkinson's disease;	chr6:27709015	chr6:28115628~28116551:+
LUAD	cis	rs4713118	1	rs13215072	ENSG00000219392.1	RP1-265C24.5	-5.31	1.67e-07	5.03e-05	-0.32	-0.24	Parkinson's disease;	chr6:27709949	chr6:28115628~28116551:+
LUAD	cis	rs155076	0.666	rs2015241	ENSG00000233325.3	MIPEPP3	-5.31	1.67e-07	5.03e-05	-0.35	-0.24	White matter hyperintensity burden;	chr13:21314115	chr13:21298139~21306373:+
LUAD	cis	rs9487094	0.961	rs3778475	ENSG00000260273.1	RP11-425D10.10	5.31	1.67e-07	5.03e-05	0.32	0.24	Height;	chr6:109375003	chr6:109382795~109383666:+
LUAD	cis	rs7580658	0.637	rs9636236	ENSG00000236682.1	AC068282.3	-5.31	1.67e-07	5.04e-05	-0.31	-0.24	Protein C levels;	chr2:127225365	chr2:127389130~127400580:+
LUAD	cis	rs5758659	0.819	rs134871	ENSG00000182057.4	OGFRP1	5.31	1.67e-07	5.04e-05	0.27	0.24	Cognitive function;	chr22:42256710	chr22:42269753~42275196:+
LUAD	cis	rs67180937	0.504	rs3008625	ENSG00000272750.1	RP11-378J18.8	5.31	1.67e-07	5.04e-05	0.29	0.24	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222646680	chr1:222658867~222661512:-
LUAD	cis	rs5758511	0.514	rs5758622	ENSG00000205702.9	CYP2D7	5.31	1.67e-07	5.05e-05	0.24	0.24	Birth weight;	chr22:42167927	chr22:42140203~42144577:-
LUAD	cis	rs1065852	0.906	rs5751232	ENSG00000205702.9	CYP2D7	5.31	1.67e-07	5.05e-05	0.24	0.24	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42168298	chr22:42140203~42144577:-
LUAD	cis	rs5758511	0.514	rs9607882	ENSG00000205702.9	CYP2D7	5.31	1.67e-07	5.05e-05	0.24	0.24	Birth weight;	chr22:42171445	chr22:42140203~42144577:-
LUAD	cis	rs9595908	0.785	rs9596058	ENSG00000212293.1	SNORA16	5.31	1.67e-07	5.05e-05	0.25	0.24	Body mass index;	chr13:32669938	chr13:32420390~32420516:-
LUAD	cis	rs7829975	0.593	rs2921051	ENSG00000253981.4	ALG1L13P	5.31	1.67e-07	5.05e-05	0.27	0.24	Mood instability;	chr8:8462594	chr8:8236003~8244667:-
LUAD	cis	rs8098244	0.66	rs1560281	ENSG00000264745.1	TTC39C-AS1	-5.31	1.67e-07	5.05e-05	-0.24	-0.24	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23913711	chr18:23994213~24015339:-
LUAD	cis	rs17264034	0.861	rs56344213	ENSG00000250786.1	SNHG18	5.31	1.68e-07	5.05e-05	0.33	0.24	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9553756	chr5:9546200~9550609:+
LUAD	cis	rs9650657	0.513	rs7005884	ENSG00000255046.1	RP11-297N6.4	5.31	1.68e-07	5.06e-05	0.29	0.24	Neuroticism;	chr8:10938962	chr8:11797928~11802568:-
LUAD	cis	rs8062405	0.573	rs6565300	ENSG00000251417.2	RP11-1348G14.4	-5.31	1.68e-07	5.06e-05	-0.25	-0.24	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28981728	chr16:28802743~28817828:+
LUAD	cis	rs453301	0.653	rs7853	ENSG00000253893.2	FAM85B	-5.31	1.68e-07	5.07e-05	-0.31	-0.24	Joint mobility (Beighton score);	chr8:9033304	chr8:8167819~8226614:-
LUAD	cis	rs950169	0.922	rs4338765	ENSG00000259295.5	CSPG4P12	5.31	1.68e-07	5.07e-05	0.34	0.24	Schizophrenia;	chr15:84248084	chr15:85191438~85213905:+
LUAD	cis	rs71636778	0.642	rs12752833	ENSG00000260063.1	RP5-968P14.2	-5.31	1.68e-07	5.07e-05	-0.42	-0.24	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26747433	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs115772301	ENSG00000260063.1	RP5-968P14.2	-5.31	1.68e-07	5.07e-05	-0.42	-0.24	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26749193	chr1:26692132~26694131:-
LUAD	cis	rs9952991	0.941	rs2542149	ENSG00000260302.1	RP11-973H7.1	-5.31	1.68e-07	5.07e-05	-0.41	-0.24	Inflammatory skin disease;	chr18:12779019	chr18:12774651~12775923:-
LUAD	cis	rs9952991	0.941	rs2847280	ENSG00000260302.1	RP11-973H7.1	-5.31	1.68e-07	5.07e-05	-0.41	-0.24	Inflammatory skin disease;	chr18:12779343	chr18:12774651~12775923:-
LUAD	cis	rs9952991	0.941	rs2542150	ENSG00000260302.1	RP11-973H7.1	-5.31	1.68e-07	5.07e-05	-0.41	-0.24	Inflammatory skin disease;	chr18:12779764	chr18:12774651~12775923:-
LUAD	cis	rs10129255	0.5	rs11628999	ENSG00000211967.3	IGHV3-53	-5.31	1.68e-07	5.08e-05	-0.17	-0.24	Kawasaki disease;	chr14:106800208	chr14:106592676~106593347:-
LUAD	cis	rs4927850	1	rs7630875	ENSG00000242086.7	LINC00969	5.31	1.68e-07	5.08e-05	0.2	0.24	Pancreatic cancer;	chr3:196026895	chr3:195658062~195739964:+
LUAD	cis	rs9487094	0.813	rs11753645	ENSG00000260273.1	RP11-425D10.10	5.31	1.68e-07	5.08e-05	0.33	0.24	Height;	chr6:109373851	chr6:109382795~109383666:+
LUAD	cis	rs4835473	0.549	rs11940719	ENSG00000251600.4	RP11-673E1.1	5.31	1.68e-07	5.08e-05	0.29	0.24	Immature fraction of reticulocytes;	chr4:143970855	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.83	rs7692672	ENSG00000251600.4	RP11-673E1.1	5.31	1.68e-07	5.08e-05	0.29	0.24	Immature fraction of reticulocytes;	chr4:143971048	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.766	rs6537222	ENSG00000251600.4	RP11-673E1.1	5.31	1.68e-07	5.08e-05	0.29	0.24	Immature fraction of reticulocytes;	chr4:143971459	chr4:143912331~143982454:+
LUAD	cis	rs2015599	0.525	rs10771514	ENSG00000275476.1	RP11-996F15.4	5.31	1.68e-07	5.08e-05	0.25	0.24	Platelet count;Mean platelet volume;	chr12:29315751	chr12:29277397~29277882:-
LUAD	cis	rs600231	0.571	rs10896000	ENSG00000245532.5	NEAT1	5.31	1.69e-07	5.08e-05	0.19	0.24	Bone mineral density;	chr11:65450547	chr11:65422774~65445540:+
LUAD	cis	rs7260598	0.535	rs13343732	ENSG00000269421.1	ZNF92P3	-5.31	1.69e-07	5.09e-05	-0.32	-0.24	Response to taxane treatment (placlitaxel);	chr19:23928479	chr19:23935220~23936173:+
LUAD	cis	rs67311347	0.544	rs9864601	ENSG00000223797.4	ENTPD3-AS1	5.31	1.69e-07	5.09e-05	0.24	0.24	Renal cell carcinoma;	chr3:40303827	chr3:40313802~40453329:-
LUAD	cis	rs4908760	0.792	rs4908505	ENSG00000232912.4	RP5-1115A15.1	5.31	1.69e-07	5.09e-05	0.21	0.24	Vitiligo;	chr1:8668805	chr1:8424645~8434838:+
LUAD	cis	rs6687821	0.515	rs1778012	ENSG00000267734.1	RP4-604K5.3	-5.31	1.69e-07	5.09e-05	-0.28	-0.24	Yeast infection;	chr1:87088873	chr1:86932199~86934891:-
LUAD	cis	rs6687821	0.515	rs1419131	ENSG00000267734.1	RP4-604K5.3	-5.31	1.69e-07	5.09e-05	-0.28	-0.24	Yeast infection;	chr1:87089482	chr1:86932199~86934891:-
LUAD	cis	rs11098499	1	rs1011054	ENSG00000248280.1	RP11-33B1.2	-5.31	1.69e-07	5.09e-05	-0.3	-0.24	Corneal astigmatism;	chr4:119281232	chr4:119440561~119450157:-
LUAD	cis	rs2286503	0.839	rs1054471	ENSG00000221740.1	SNORD93	5.31	1.69e-07	5.09e-05	0.27	0.24	Fibrinogen;	chr7:22813024	chr7:22856613~22856686:+
LUAD	cis	rs2286503	0.839	rs2240726	ENSG00000221740.1	SNORD93	5.31	1.69e-07	5.09e-05	0.27	0.24	Fibrinogen;	chr7:22813516	chr7:22856613~22856686:+
LUAD	cis	rs75422866	0.51	rs75424057	ENSG00000257433.4	RP1-197B17.3	5.31	1.69e-07	5.09e-05	0.48	0.24	Pneumonia;	chr12:47737294	chr12:47706085~47742294:+
LUAD	cis	rs7829975	0.593	rs2921061	ENSG00000253981.4	ALG1L13P	5.31	1.69e-07	5.09e-05	0.27	0.24	Mood instability;	chr8:8460105	chr8:8236003~8244667:-
LUAD	cis	rs950169	0.519	rs7237	ENSG00000275120.1	RP11-182J1.17	5.31	1.69e-07	5.1e-05	0.36	0.24	Schizophrenia;	chr15:84643346	chr15:84599434~84606463:-
LUAD	cis	rs10129255	0.957	rs4387509	ENSG00000224373.3	IGHV4-59	5.31	1.69e-07	5.11e-05	0.16	0.24	Kawasaki disease;	chr14:106704386	chr14:106627249~106627825:-
LUAD	cis	rs12908161	1	rs35316992	ENSG00000275120.1	RP11-182J1.17	5.31	1.69e-07	5.11e-05	0.36	0.24	Schizophrenia;	chr15:84704902	chr15:84599434~84606463:-
LUAD	cis	rs12908161	1	rs4643294	ENSG00000275120.1	RP11-182J1.17	5.31	1.69e-07	5.11e-05	0.36	0.24	Schizophrenia;	chr15:84707022	chr15:84599434~84606463:-
LUAD	cis	rs12908161	1	rs62021219	ENSG00000275120.1	RP11-182J1.17	5.31	1.69e-07	5.11e-05	0.36	0.24	Schizophrenia;	chr15:84712928	chr15:84599434~84606463:-
LUAD	cis	rs12908161	1	rs34900908	ENSG00000275120.1	RP11-182J1.17	5.31	1.69e-07	5.11e-05	0.36	0.24	Schizophrenia;	chr15:84714368	chr15:84599434~84606463:-
LUAD	cis	rs12908161	1	rs35524990	ENSG00000275120.1	RP11-182J1.17	5.31	1.69e-07	5.11e-05	0.36	0.24	Schizophrenia;	chr15:84714972	chr15:84599434~84606463:-
LUAD	cis	rs1707322	0.721	rs6699418	ENSG00000280836.1	AL355480.1	-5.31	1.7e-07	5.11e-05	-0.31	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634509	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.721	rs4431884	ENSG00000280836.1	AL355480.1	-5.31	1.7e-07	5.11e-05	-0.31	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45635651	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.65	rs4660879	ENSG00000280836.1	AL355480.1	-5.31	1.7e-07	5.11e-05	-0.31	-0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45639729	chr1:45581219~45581321:-
LUAD	cis	rs7208859	0.524	rs60114476	ENSG00000263603.1	CTD-2349P21.5	-5.31	1.7e-07	5.11e-05	-0.4	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770649	chr17:30729469~30731202:+
LUAD	cis	rs17826219	0.636	rs2449770	ENSG00000263603.1	CTD-2349P21.5	-5.31	1.7e-07	5.11e-05	-0.4	-0.24	Body mass index;	chr17:30774046	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.524	rs59913838	ENSG00000263603.1	CTD-2349P21.5	-5.31	1.7e-07	5.11e-05	-0.4	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774545	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs8067338	ENSG00000263603.1	CTD-2349P21.5	-5.31	1.7e-07	5.11e-05	-0.4	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775327	chr17:30729469~30731202:+
LUAD	cis	rs6687821	0.684	rs691531	ENSG00000267734.1	RP4-604K5.3	5.31	1.7e-07	5.11e-05	0.27	0.24	Yeast infection;	chr1:86779595	chr1:86932199~86934891:-
LUAD	cis	rs17747401	0.507	rs11001107	ENSG00000213731.2	RAB5CP1	-5.31	1.7e-07	5.11e-05	-0.25	-0.24	Hypospadias;	chr10:74673397	chr10:74423435~74424014:-
LUAD	cis	rs4664293	1	rs2357382	ENSG00000226266.5	AC009961.3	-5.31	1.7e-07	5.12e-05	-0.32	-0.24	Monocyte percentage of white cells;	chr2:159636614	chr2:159670708~159712435:-
LUAD	cis	rs4927850	0.709	rs6783079	ENSG00000207650.1	MIR570	5.31	1.7e-07	5.12e-05	0.26	0.24	Pancreatic cancer;	chr3:195925837	chr3:195699401~195699497:+
LUAD	cis	rs4927850	0.709	rs6765762	ENSG00000207650.1	MIR570	5.31	1.7e-07	5.12e-05	0.26	0.24	Pancreatic cancer;	chr3:195925980	chr3:195699401~195699497:+
LUAD	cis	rs7829975	0.84	rs572366	ENSG00000253893.2	FAM85B	-5.31	1.7e-07	5.12e-05	-0.29	-0.24	Mood instability;	chr8:8721284	chr8:8167819~8226614:-
LUAD	cis	rs71636778	0.509	rs12760759	ENSG00000260063.1	RP5-968P14.2	5.31	1.7e-07	5.12e-05	0.41	0.24	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26831853	chr1:26692132~26694131:-
LUAD	cis	rs1113500	0.614	rs1343192	ENSG00000226822.1	RP11-356N1.2	5.31	1.7e-07	5.12e-05	0.31	0.24	Growth-regulated protein alpha levels;	chr1:108071266	chr1:108071482~108074519:+
LUAD	cis	rs71636778	0.509	rs12731749	ENSG00000260063.1	RP5-968P14.2	-5.31	1.7e-07	5.12e-05	-0.42	-0.24	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26759071	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs34885854	ENSG00000260063.1	RP5-968P14.2	-5.31	1.7e-07	5.12e-05	-0.42	-0.24	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26759758	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs71636777	ENSG00000260063.1	RP5-968P14.2	-5.31	1.7e-07	5.12e-05	-0.42	-0.24	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26761777	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs34681611	ENSG00000260063.1	RP5-968P14.2	-5.31	1.7e-07	5.12e-05	-0.42	-0.24	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26762955	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs74825034	ENSG00000260063.1	RP5-968P14.2	-5.31	1.7e-07	5.12e-05	-0.42	-0.24	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26768641	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.73	rs34951175	ENSG00000260063.1	RP5-968P14.2	-5.31	1.7e-07	5.12e-05	-0.42	-0.24	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26778568	chr1:26692132~26694131:-
LUAD	cis	rs41307935	0.908	rs60798877	ENSG00000260063.1	RP5-968P14.2	-5.31	1.7e-07	5.12e-05	-0.42	-0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26781648	chr1:26692132~26694131:-
LUAD	cis	rs41307935	0.915	rs12685	ENSG00000260063.1	RP5-968P14.2	-5.31	1.7e-07	5.12e-05	-0.42	-0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26781754	chr1:26692132~26694131:-
LUAD	cis	rs41307935	0.818	rs71636779	ENSG00000260063.1	RP5-968P14.2	-5.31	1.7e-07	5.12e-05	-0.42	-0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26787521	chr1:26692132~26694131:-
LUAD	cis	rs41307935	0.915	rs57189461	ENSG00000260063.1	RP5-968P14.2	-5.31	1.7e-07	5.12e-05	-0.42	-0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26798054	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs12748152	ENSG00000260063.1	RP5-968P14.2	-5.31	1.7e-07	5.12e-05	-0.42	-0.24	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26811902	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs71636783	ENSG00000260063.1	RP5-968P14.2	-5.31	1.7e-07	5.12e-05	-0.42	-0.24	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26813370	chr1:26692132~26694131:-
LUAD	cis	rs41307935	0.73	rs34716450	ENSG00000260063.1	RP5-968P14.2	-5.31	1.7e-07	5.12e-05	-0.42	-0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26817084	chr1:26692132~26694131:-
LUAD	cis	rs34381861	0.52	rs74382390	ENSG00000260886.1	TAT-AS1	5.31	1.7e-07	5.12e-05	0.39	0.24	Post bronchodilator FEV1;	chr16:71424623	chr16:71565789~71578187:+
LUAD	cis	rs875971	0.505	rs1723275	ENSG00000236529.1	RP13-254B10.1	-5.31	1.7e-07	5.13e-05	-0.24	-0.24	Aortic root size;	chr7:66039646	chr7:65840212~65840596:+
LUAD	cis	rs2348418	0.765	rs6487665	ENSG00000247934.4	RP11-967K21.1	5.31	1.7e-07	5.13e-05	0.27	0.24	Lung function (FEV1);Lung function (FVC);	chr12:28177726	chr12:28163298~28190738:-
LUAD	cis	rs4835473	0.9	rs5015758	ENSG00000251600.4	RP11-673E1.1	-5.31	1.7e-07	5.13e-05	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143738052	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs34569841	ENSG00000251600.4	RP11-673E1.1	-5.31	1.7e-07	5.13e-05	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143738060	chr4:143912331~143982454:+
LUAD	cis	rs8072100	0.817	rs6505049	ENSG00000228782.6	CTD-2026D20.3	-5.31	1.7e-07	5.13e-05	-0.25	-0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47598415	chr17:47450568~47492492:-
LUAD	cis	rs11976180	1	rs2951368	ENSG00000170356.8	OR2A20P	-5.31	1.71e-07	5.14e-05	-0.3	-0.24	Obesity-related traits;	chr7:144055728	chr7:144250045~144252957:-
LUAD	cis	rs11976180	1	rs2961115	ENSG00000170356.8	OR2A20P	-5.31	1.71e-07	5.14e-05	-0.3	-0.24	Obesity-related traits;	chr7:144056278	chr7:144250045~144252957:-
LUAD	cis	rs6751744	0.855	rs7585513	ENSG00000226266.5	AC009961.3	-5.31	1.71e-07	5.14e-05	-0.33	-0.24	Dysphagia;	chr2:159550379	chr2:159670708~159712435:-
LUAD	cis	rs7208859	0.673	rs216420	ENSG00000263603.1	CTD-2349P21.5	-5.31	1.71e-07	5.14e-05	-0.35	-0.24	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30611490	chr17:30729469~30731202:+
LUAD	cis	rs74233809	1	rs11191514	ENSG00000213277.3	MARCKSL1P1	5.31	1.71e-07	5.15e-05	0.41	0.24	Birth weight;	chr10:103013607	chr10:103175554~103176094:+
LUAD	cis	rs2688608	0.592	rs3933085	ENSG00000271816.1	BMS1P4	5.31	1.71e-07	5.15e-05	0.2	0.24	Inflammatory bowel disease;	chr10:73723573	chr10:73699151~73730487:-
LUAD	cis	rs4143844	0.867	rs11629559	ENSG00000259251.2	RP11-643M14.1	5.31	1.71e-07	5.15e-05	0.41	0.24	Bipolar disorder and schizophrenia;	chr15:61871348	chr15:62060503~62062434:+
LUAD	cis	rs1707322	0.963	rs12145287	ENSG00000234329.1	RP11-767N6.2	5.31	1.71e-07	5.16e-05	0.25	0.24	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45859330	chr1:45651039~45651826:-
LUAD	cis	rs2179367	0.568	rs6932778	ENSG00000231760.4	RP11-350J20.5	5.31	1.71e-07	5.16e-05	0.36	0.24	Dupuytren's disease;	chr6:149328293	chr6:149796151~149826294:-
LUAD	cis	rs8072100	0.967	rs4794001	ENSG00000228782.6	CTD-2026D20.3	5.31	1.71e-07	5.16e-05	0.24	0.24	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47643483	chr17:47450568~47492492:-
LUAD	cis	rs2412819	0.571	rs66903736	ENSG00000249839.1	AC011330.5	-5.31	1.72e-07	5.17e-05	-0.4	-0.24	Lung cancer;	chr15:43619435	chr15:43663654~43684339:-
LUAD	cis	rs2412819	0.571	rs66749753	ENSG00000249839.1	AC011330.5	-5.31	1.72e-07	5.17e-05	-0.4	-0.24	Lung cancer;	chr15:43619601	chr15:43663654~43684339:-
LUAD	cis	rs61270009	0.955	rs12653830	ENSG00000247828.6	TMEM161B-AS1	5.31	1.72e-07	5.17e-05	0.27	0.24	Depressive symptoms;	chr5:88353712	chr5:88268895~88436685:+
LUAD	cis	rs35740288	0.822	rs11629690	ENSG00000202081.1	RNU6-1280P	5.31	1.72e-07	5.17e-05	0.3	0.24	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85744493	chr15:85651522~85651628:-
LUAD	cis	rs910316	1	rs12589815	ENSG00000259138.1	RP11-950C14.7	5.31	1.72e-07	5.18e-05	0.25	0.24	Height;	chr14:75077398	chr14:75127153~75136930:+
LUAD	cis	rs55665837	0.523	rs10832301	ENSG00000251991.1	RNU7-49P	5.31	1.72e-07	5.18e-05	0.26	0.24	Vitamin D levels;	chr11:14767418	chr11:14478892~14478953:+
LUAD	cis	rs9652601	0.622	rs6498143	ENSG00000274038.1	RP11-66H6.4	-5.3	1.72e-07	5.19e-05	-0.28	-0.24	Systemic lupus erythematosus;	chr16:11001179	chr16:11056556~11057034:+
LUAD	cis	rs600231	0.708	rs2957269	ENSG00000245532.5	NEAT1	5.3	1.72e-07	5.19e-05	0.18	0.24	Bone mineral density;	chr11:65475536	chr11:65422774~65445540:+
LUAD	cis	rs600231	0.708	rs2957268	ENSG00000245532.5	NEAT1	5.3	1.72e-07	5.19e-05	0.18	0.24	Bone mineral density;	chr11:65478345	chr11:65422774~65445540:+
LUAD	cis	rs748404	0.706	rs57728767	ENSG00000205771.5	CATSPER2P1	-5.3	1.72e-07	5.19e-05	-0.37	-0.24	Lung cancer;	chr15:43473639	chr15:43726918~43747094:-
LUAD	cis	rs4604732	0.527	rs12031949	ENSG00000227135.1	GCSAML-AS1	-5.3	1.73e-07	5.2e-05	-0.36	-0.24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247461161	chr1:247524679~247526752:-
LUAD	cis	rs11089937	0.568	rs35626600	ENSG00000211638.2	IGLV8-61	-5.3	1.73e-07	5.2e-05	-0.27	-0.24	Periodontitis (PAL4Q3);	chr22:22130811	chr22:22098700~22099212:+
LUAD	cis	rs11089937	0.539	rs34228957	ENSG00000211638.2	IGLV8-61	-5.3	1.73e-07	5.2e-05	-0.27	-0.24	Periodontitis (PAL4Q3);	chr22:22130838	chr22:22098700~22099212:+
LUAD	cis	rs11089937	0.512	rs13054756	ENSG00000211638.2	IGLV8-61	-5.3	1.73e-07	5.2e-05	-0.27	-0.24	Periodontitis (PAL4Q3);	chr22:22130948	chr22:22098700~22099212:+
LUAD	cis	rs11089937	0.597	rs4821768	ENSG00000211638.2	IGLV8-61	-5.3	1.73e-07	5.2e-05	-0.27	-0.24	Periodontitis (PAL4Q3);	chr22:22131047	chr22:22098700~22099212:+
LUAD	cis	rs910316	1	rs1047418	ENSG00000259138.1	RP11-950C14.7	5.3	1.73e-07	5.2e-05	0.25	0.24	Height;	chr14:75139089	chr14:75127153~75136930:+
LUAD	cis	rs11157436	0.958	rs12433649	ENSG00000211813.2	TRAV34	5.3	1.73e-07	5.2e-05	0.31	0.24	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22231828	chr14:22207522~22208129:+
LUAD	cis	rs1008375	0.866	rs12233712	ENSG00000249502.1	AC006160.5	-5.3	1.73e-07	5.2e-05	-0.23	-0.24	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17568440	chr4:17587467~17614571:-
LUAD	cis	rs4938303	0.671	rs2008915	ENSG00000280143.1	AP000892.6	5.3	1.73e-07	5.21e-05	0.33	0.24	Triglycerides;	chr11:116732418	chr11:117204967~117210292:+
LUAD	cis	rs6496044	0.507	rs8034676	ENSG00000259407.1	RP11-158M2.3	-5.3	1.73e-07	5.22e-05	-0.21	-0.24	Interstitial lung disease;	chr15:85616031	chr15:85744109~85750281:-
LUAD	cis	rs997295	0.713	rs9302246	ENSG00000270964.1	RP11-502I4.3	-5.3	1.73e-07	5.22e-05	-0.25	-0.24	Motion sickness;	chr15:67728942	chr15:67541072~67542604:-
LUAD	cis	rs801193	1	rs2055682	ENSG00000237310.1	GS1-124K5.4	5.3	1.74e-07	5.22e-05	0.26	0.24	Aortic root size;	chr7:66795302	chr7:66493706~66495474:+
LUAD	cis	rs8103033	0.676	rs993983	ENSG00000226025.8	LGALS17A	-5.3	1.74e-07	5.22e-05	-0.26	-0.24	Obesity-related traits;	chr19:39660840	chr19:39679374~39686373:+
LUAD	cis	rs17711722	0.701	rs781143	ENSG00000236529.1	RP13-254B10.1	5.3	1.74e-07	5.22e-05	0.24	0.24	Calcium levels;	chr7:65974892	chr7:65840212~65840596:+
LUAD	cis	rs7181230	0.922	rs4924410	ENSG00000275636.1	RP11-521C20.5	-5.3	1.74e-07	5.22e-05	-0.31	-0.24	Dehydroepiandrosterone sulphate levels;	chr15:40047293	chr15:40078892~40079347:+
LUAD	cis	rs875971	0.505	rs6955582	ENSG00000164669.11	INTS4P1	-5.3	1.74e-07	5.22e-05	-0.28	-0.24	Aortic root size;	chr7:65966699	chr7:65141225~65234216:+
LUAD	cis	rs2735413	0.564	rs7191314	ENSG00000276007.1	RP11-358L22.3	5.3	1.74e-07	5.22e-05	0.33	0.24	Systolic blood pressure (alcohol consumption interaction);	chr16:78050339	chr16:78123243~78124332:+
LUAD	cis	rs8098244	0.536	rs7232217	ENSG00000264745.1	TTC39C-AS1	5.3	1.74e-07	5.22e-05	0.25	0.24	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23699115	chr18:23994213~24015339:-
LUAD	cis	rs914615	0.508	rs7535292	ENSG00000160766.13	GBAP1	-5.3	1.74e-07	5.23e-05	-0.24	-0.24	Urinary albumin-to-creatinine ratio;	chr1:155155273	chr1:155213821~155227422:-
LUAD	cis	rs7617773	0.78	rs71323395	ENSG00000228638.1	FCF1P2	-5.3	1.74e-07	5.23e-05	-0.29	-0.24	Coronary artery disease;	chr3:48332587	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.743	rs71323397	ENSG00000228638.1	FCF1P2	-5.3	1.74e-07	5.23e-05	-0.29	-0.24	Coronary artery disease;	chr3:48333384	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.778	rs11715776	ENSG00000228638.1	FCF1P2	-5.3	1.74e-07	5.23e-05	-0.29	-0.24	Coronary artery disease;	chr3:48336121	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.778	rs11707997	ENSG00000228638.1	FCF1P2	-5.3	1.74e-07	5.23e-05	-0.29	-0.24	Coronary artery disease;	chr3:48336385	chr3:48290793~48291375:-
LUAD	cis	rs238295	0.696	rs6053451	ENSG00000230563.2	RP5-828H9.1	5.3	1.74e-07	5.23e-05	0.32	0.24	Occipital cortical area (total cortical area interaction);	chr20:5513258	chr20:5471207~5475182:+
LUAD	cis	rs12188164	0.61	rs57433159	ENSG00000225138.6	CTD-2228K2.7	5.3	1.74e-07	5.23e-05	0.22	0.24	Cystic fibrosis severity;	chr5:418610	chr5:473236~480884:+
LUAD	cis	rs7804306	0.826	rs67343471	ENSG00000233264.2	AC006042.8	5.3	1.74e-07	5.24e-05	0.41	0.24	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7979532	chr7:7980312~7982228:+
LUAD	cis	rs4835473	0.9	rs35419968	ENSG00000251600.4	RP11-673E1.1	-5.3	1.74e-07	5.24e-05	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143734583	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.868	rs66634585	ENSG00000251600.4	RP11-673E1.1	-5.3	1.74e-07	5.24e-05	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143734608	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.868	rs35016507	ENSG00000251600.4	RP11-673E1.1	-5.3	1.74e-07	5.24e-05	-0.29	-0.24	Immature fraction of reticulocytes;	chr4:143734617	chr4:143912331~143982454:+
LUAD	cis	rs11976180	1	rs2951372	ENSG00000170356.8	OR2A20P	-5.3	1.74e-07	5.24e-05	-0.3	-0.24	Obesity-related traits;	chr7:144052410	chr7:144250045~144252957:-
LUAD	cis	rs41307935	0.643	rs34909427	ENSG00000260063.1	RP5-968P14.2	-5.3	1.74e-07	5.24e-05	-0.42	-0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26750763	chr1:26692132~26694131:-
LUAD	cis	rs41307935	0.908	rs12735646	ENSG00000260063.1	RP5-968P14.2	-5.3	1.74e-07	5.24e-05	-0.42	-0.24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26751875	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs59715866	ENSG00000260063.1	RP5-968P14.2	-5.3	1.74e-07	5.24e-05	-0.42	-0.24	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26752685	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs12737946	ENSG00000260063.1	RP5-968P14.2	-5.3	1.74e-07	5.24e-05	-0.42	-0.24	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26753403	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs12742115	ENSG00000260063.1	RP5-968P14.2	-5.3	1.74e-07	5.24e-05	-0.42	-0.24	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26753440	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.57	rs71636776	ENSG00000260063.1	RP5-968P14.2	-5.3	1.74e-07	5.24e-05	-0.42	-0.24	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26756557	chr1:26692132~26694131:-
LUAD	cis	rs7617773	0.817	rs11720622	ENSG00000228638.1	FCF1P2	-5.3	1.75e-07	5.25e-05	-0.27	-0.23	Coronary artery disease;	chr3:48205189	chr3:48290793~48291375:-
LUAD	cis	rs11157436	0.958	rs764161	ENSG00000211813.2	TRAV34	5.3	1.75e-07	5.25e-05	0.31	0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22231182	chr14:22207522~22208129:+
LUAD	cis	rs910316	1	rs10138183	ENSG00000259138.1	RP11-950C14.7	5.3	1.75e-07	5.26e-05	0.25	0.23	Height;	chr14:75148524	chr14:75127153~75136930:+
LUAD	cis	rs9652601	0.676	rs9926615	ENSG00000274038.1	RP11-66H6.4	-5.3	1.75e-07	5.26e-05	-0.28	-0.23	Systemic lupus erythematosus;	chr16:11009303	chr16:11056556~11057034:+
LUAD	cis	rs875971	0.862	rs1167390	ENSG00000237310.1	GS1-124K5.4	-5.3	1.75e-07	5.26e-05	-0.26	-0.23	Aortic root size;	chr7:66110906	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.862	rs35034167	ENSG00000237310.1	GS1-124K5.4	-5.3	1.75e-07	5.26e-05	-0.26	-0.23	Aortic root size;	chr7:66115179	chr7:66493706~66495474:+
LUAD	cis	rs2404602	0.735	rs2468130	ENSG00000259422.1	RP11-593F23.1	-5.3	1.75e-07	5.26e-05	-0.3	-0.23	Blood metabolite levels;	chr15:76504155	chr15:76174891~76181486:-
LUAD	cis	rs10129255	0.5	rs6576230	ENSG00000254174.1	IGHV1-12	5.3	1.75e-07	5.26e-05	0.16	0.23	Kawasaki disease;	chr14:106778539	chr14:106122420~106122709:-
LUAD	cis	rs10129255	0.518	rs11847766	ENSG00000254174.1	IGHV1-12	5.3	1.75e-07	5.26e-05	0.16	0.23	Kawasaki disease;	chr14:106779186	chr14:106122420~106122709:-
LUAD	cis	rs950169	0.922	rs62028133	ENSG00000259295.5	CSPG4P12	5.3	1.75e-07	5.26e-05	0.34	0.23	Schizophrenia;	chr15:84250623	chr15:85191438~85213905:+
LUAD	cis	rs516805	0.63	rs225087	ENSG00000279453.1	RP3-425C14.4	-5.3	1.75e-07	5.26e-05	-0.32	-0.23	Lymphocyte counts;	chr6:122277884	chr6:122436789~122439223:-
LUAD	cis	rs10129255	0.5	rs2027903	ENSG00000254174.1	IGHV1-12	5.3	1.75e-07	5.27e-05	0.16	0.23	Kawasaki disease;	chr14:106807047	chr14:106122420~106122709:-
LUAD	cis	rs10129255	0.518	rs28378320	ENSG00000254174.1	IGHV1-12	5.3	1.75e-07	5.27e-05	0.16	0.23	Kawasaki disease;	chr14:106808609	chr14:106122420~106122709:-
LUAD	cis	rs7618501	0.699	rs1317154	ENSG00000234667.1	ACTBP13	-5.3	1.75e-07	5.27e-05	-0.27	-0.23	Intelligence (multi-trait analysis);	chr3:49872651	chr3:49873347~49877980:-
LUAD	cis	rs516805	0.63	rs2315814	ENSG00000279453.1	RP3-425C14.4	-5.3	1.75e-07	5.27e-05	-0.32	-0.23	Lymphocyte counts;	chr6:122102712	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.596	rs2606640	ENSG00000279453.1	RP3-425C14.4	-5.3	1.75e-07	5.27e-05	-0.32	-0.23	Lymphocyte counts;	chr6:122102901	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.63	rs2262318	ENSG00000279453.1	RP3-425C14.4	-5.3	1.75e-07	5.27e-05	-0.32	-0.23	Lymphocyte counts;	chr6:122102980	chr6:122436789~122439223:-
LUAD	cis	rs35160687	0.623	rs7569654	ENSG00000273080.1	RP11-301O19.1	-5.3	1.75e-07	5.27e-05	-0.26	-0.23	Night sleep phenotypes;	chr2:86250899	chr2:86195590~86196049:+
LUAD	cis	rs394563	0.591	rs11964335	ENSG00000231760.4	RP11-350J20.5	-5.3	1.75e-07	5.27e-05	-0.29	-0.23	Dupuytren's disease;	chr6:149336965	chr6:149796151~149826294:-
LUAD	cis	rs7617773	0.743	rs6804986	ENSG00000228638.1	FCF1P2	-5.3	1.75e-07	5.27e-05	-0.28	-0.23	Coronary artery disease;	chr3:48322105	chr3:48290793~48291375:-
LUAD	cis	rs2404602	0.692	rs56193230	ENSG00000259422.1	RP11-593F23.1	5.3	1.76e-07	5.28e-05	0.27	0.23	Blood metabolite levels;	chr15:76642131	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.692	rs35077207	ENSG00000259422.1	RP11-593F23.1	5.3	1.76e-07	5.28e-05	0.27	0.23	Blood metabolite levels;	chr15:76642965	chr15:76174891~76181486:-
LUAD	cis	rs6570726	0.791	rs392612	ENSG00000235652.6	RP11-545I5.3	-5.3	1.76e-07	5.29e-05	-0.24	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145560450	chr6:145799409~145886585:+
LUAD	cis	rs3096299	0.748	rs3102339	ENSG00000182376.2	RP5-1142A6.8	5.3	1.76e-07	5.3e-05	0.25	0.23	Multiple myeloma (IgH translocation);	chr16:89376303	chr16:88742767~88745748:+
LUAD	cis	rs3096299	0.967	rs2911255	ENSG00000182376.2	RP5-1142A6.8	5.3	1.76e-07	5.3e-05	0.24	0.23	Multiple myeloma (IgH translocation);	chr16:89420729	chr16:88742767~88745748:+
LUAD	cis	rs2919009	0.825	rs7099949	ENSG00000271670.1	RP11-95I16.4	5.3	1.77e-07	5.3e-05	0.31	0.23	Obesity-related traits;	chr10:120839119	chr10:120879256~120880667:-
LUAD	cis	rs11976180	1	rs2961134	ENSG00000170356.8	OR2A20P	-5.3	1.77e-07	5.3e-05	-0.29	-0.23	Obesity-related traits;	chr7:144073969	chr7:144250045~144252957:-
LUAD	cis	rs10129255	0.5	rs10131875	ENSG00000254174.1	IGHV1-12	5.3	1.77e-07	5.31e-05	0.16	0.23	Kawasaki disease;	chr14:106792798	chr14:106122420~106122709:-
LUAD	cis	rs6545883	0.524	rs7561697	ENSG00000271889.1	RP11-493E12.1	-5.3	1.77e-07	5.31e-05	-0.27	-0.23	Tuberculosis;	chr2:61292030	chr2:61151433~61162105:-
LUAD	cis	rs2832077	0.506	rs2832081	ENSG00000232855.5	AF131217.1	-5.3	1.77e-07	5.31e-05	-0.23	-0.23	Cognitive test performance;	chr21:28780670	chr21:28439346~28674848:-
LUAD	cis	rs2408955	0.522	rs3997	ENSG00000257735.1	RP11-370I10.6	-5.3	1.77e-07	5.32e-05	-0.29	-0.23	Glycated hemoglobin levels;	chr12:48087804	chr12:48350945~48442411:+
LUAD	cis	rs1707322	1	rs6429580	ENSG00000234329.1	RP11-767N6.2	5.3	1.77e-07	5.32e-05	0.24	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809976	chr1:45651039~45651826:-
LUAD	cis	rs4835473	0.9	rs6537223	ENSG00000251600.4	RP11-673E1.1	5.3	1.77e-07	5.32e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143971541	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.798	rs34353812	ENSG00000251600.4	RP11-673E1.1	5.3	1.77e-07	5.32e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143973949	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.831	rs10428468	ENSG00000251600.4	RP11-673E1.1	5.3	1.77e-07	5.32e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143974104	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.75	rs57610804	ENSG00000251600.4	RP11-673E1.1	5.3	1.77e-07	5.32e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143974341	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs13148097	ENSG00000251600.4	RP11-673E1.1	5.3	1.77e-07	5.32e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143976238	chr4:143912331~143982454:+
LUAD	cis	rs11976180	1	rs1320894	ENSG00000170356.8	OR2A20P	-5.3	1.77e-07	5.32e-05	-0.3	-0.23	Obesity-related traits;	chr7:144054709	chr7:144250045~144252957:-
LUAD	cis	rs11976180	1	rs2951369	ENSG00000170356.8	OR2A20P	-5.3	1.77e-07	5.32e-05	-0.3	-0.23	Obesity-related traits;	chr7:144055545	chr7:144250045~144252957:-
LUAD	cis	rs11098499	0.739	rs951570	ENSG00000248280.1	RP11-33B1.2	-5.3	1.77e-07	5.32e-05	-0.3	-0.23	Corneal astigmatism;	chr4:119229312	chr4:119440561~119450157:-
LUAD	cis	rs9595908	0.746	rs17516171	ENSG00000212293.1	SNORA16	5.3	1.77e-07	5.33e-05	0.25	0.23	Body mass index;	chr13:32694914	chr13:32420390~32420516:-
LUAD	cis	rs2276314	0.857	rs28530656	ENSG00000278986.1	RP11-723J4.3	5.3	1.78e-07	5.34e-05	0.28	0.23	Endometriosis;Drug-induced torsades de pointes;	chr18:36008737	chr18:35972151~35973916:+
LUAD	cis	rs7714584	1	rs4579248	ENSG00000197083.10	ZNF300P1	5.3	1.78e-07	5.34e-05	0.49	0.23	Crohn's disease;	chr5:150888589	chr5:150930645~150946289:-
LUAD	cis	rs7617773	0.851	rs7647817	ENSG00000228638.1	FCF1P2	-5.3	1.78e-07	5.34e-05	-0.28	-0.23	Coronary artery disease;	chr3:48195017	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.817	rs11707606	ENSG00000228638.1	FCF1P2	-5.3	1.78e-07	5.34e-05	-0.28	-0.23	Coronary artery disease;	chr3:48195597	chr3:48290793~48291375:-
LUAD	cis	rs2015599	0.525	rs7959145	ENSG00000275476.1	RP11-996F15.4	5.3	1.78e-07	5.34e-05	0.25	0.23	Platelet count;Mean platelet volume;	chr12:29330850	chr12:29277397~29277882:-
LUAD	cis	rs2015599	0.525	rs7961943	ENSG00000275476.1	RP11-996F15.4	5.3	1.78e-07	5.34e-05	0.25	0.23	Platelet count;Mean platelet volume;	chr12:29331146	chr12:29277397~29277882:-
LUAD	cis	rs1823874	0.71	rs1840298	ENSG00000182397.13	DNM1P46	-5.3	1.78e-07	5.34e-05	-0.29	-0.23	IgG glycosylation;	chr15:99821889	chr15:99790156~99806927:-
LUAD	cis	rs875971	0.651	rs313829	ENSG00000237310.1	GS1-124K5.4	-5.3	1.78e-07	5.35e-05	-0.29	-0.23	Aortic root size;	chr7:66087510	chr7:66493706~66495474:+
LUAD	cis	rs1113500	0.614	rs61797342	ENSG00000226822.1	RP11-356N1.2	5.3	1.78e-07	5.35e-05	0.31	0.23	Growth-regulated protein alpha levels;	chr1:108065763	chr1:108071482~108074519:+
LUAD	cis	rs1823874	0.71	rs3919790	ENSG00000182397.13	DNM1P46	-5.3	1.78e-07	5.35e-05	-0.29	-0.23	IgG glycosylation;	chr15:99821130	chr15:99790156~99806927:-
LUAD	cis	rs1707322	0.963	rs6429581	ENSG00000280836.1	AL355480.1	-5.3	1.78e-07	5.35e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853424	chr1:45581219~45581321:-
LUAD	cis	rs17507216	1	rs17158413	ENSG00000255769.6	GOLGA2P10	-5.3	1.78e-07	5.35e-05	-0.29	-0.23	Excessive daytime sleepiness;	chr15:82566658	chr15:82472993~82513950:-
LUAD	cis	rs270601	0.683	rs81598	ENSG00000233006.5	AC034220.3	5.3	1.78e-07	5.35e-05	0.22	0.23	Acylcarnitine levels;	chr5:132252267	chr5:132311285~132369916:-
LUAD	cis	rs71636778	0.509	rs34576193	ENSG00000260063.1	RP5-968P14.2	-5.3	1.78e-07	5.35e-05	-0.43	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26728289	chr1:26692132~26694131:-
LUAD	cis	rs7115242	0.858	rs6589592	ENSG00000280143.1	AP000892.6	5.3	1.78e-07	5.35e-05	0.42	0.23	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117087191	chr11:117204967~117210292:+
LUAD	cis	rs2032366	0.606	rs7226896	ENSG00000267279.1	RP11-879F14.2	-5.3	1.78e-07	5.35e-05	-0.3	-0.23	Obesity-related traits;	chr18:61608946	chr18:61585746~61606916:-
LUAD	cis	rs2032366	0.606	rs9783923	ENSG00000267279.1	RP11-879F14.2	-5.3	1.78e-07	5.35e-05	-0.3	-0.23	Obesity-related traits;	chr18:61635518	chr18:61585746~61606916:-
LUAD	cis	rs11976180	1	rs6464574	ENSG00000204959.4	ARHGEF34P	5.3	1.78e-07	5.35e-05	0.3	0.23	Obesity-related traits;	chr7:144051164	chr7:144272445~144286966:-
LUAD	cis	rs9532669	0.926	rs2039119	ENSG00000168852.11	TPTE2P5	-5.3	1.78e-07	5.35e-05	-0.23	-0.23	Cervical cancer;	chr13:40872432	chr13:40822296~40921749:-
LUAD	cis	rs2921036	0.503	rs7817832	ENSG00000253893.2	FAM85B	-5.3	1.79e-07	5.36e-05	-0.32	-0.23	Neuroticism;	chr8:8523311	chr8:8167819~8226614:-
LUAD	cis	rs11105298	0.891	rs10858879	ENSG00000258302.2	RP11-981P6.1	-5.3	1.79e-07	5.36e-05	-0.3	-0.23	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89492801	chr12:89561129~89594878:+
LUAD	cis	rs7617773	0.78	rs13066044	ENSG00000228638.1	FCF1P2	-5.3	1.79e-07	5.37e-05	-0.29	-0.23	Coronary artery disease;	chr3:48335786	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.78	rs11716848	ENSG00000228638.1	FCF1P2	-5.3	1.79e-07	5.37e-05	-0.29	-0.23	Coronary artery disease;	chr3:48337010	chr3:48290793~48291375:-
LUAD	cis	rs2179367	0.632	rs12197598	ENSG00000231760.4	RP11-350J20.5	5.3	1.79e-07	5.37e-05	0.33	0.23	Dupuytren's disease;	chr6:149385418	chr6:149796151~149826294:-
LUAD	cis	rs11089937	0.626	rs737840	ENSG00000211638.2	IGLV8-61	-5.3	1.79e-07	5.37e-05	-0.28	-0.23	Periodontitis (PAL4Q3);	chr22:22162743	chr22:22098700~22099212:+
LUAD	cis	rs948562	0.627	rs12364387	ENSG00000280010.1	AP001350.4	5.3	1.79e-07	5.37e-05	0.34	0.23	Lymphoma;	chr11:58311817	chr11:58627435~58628528:+
LUAD	cis	rs4664293	1	rs12692554	ENSG00000226266.5	AC009961.3	-5.3	1.79e-07	5.37e-05	-0.32	-0.23	Monocyte percentage of white cells;	chr2:159594777	chr2:159670708~159712435:-
LUAD	cis	rs4835473	0.897	rs12505617	ENSG00000251600.4	RP11-673E1.1	5.3	1.79e-07	5.38e-05	0.3	0.23	Immature fraction of reticulocytes;	chr4:143723522	chr4:143912331~143982454:+
LUAD	cis	rs673078	0.66	rs78690826	ENSG00000275409.1	RP11-131L12.4	-5.3	1.79e-07	5.38e-05	-0.36	-0.23	Glucose homeostasis traits;	chr12:118176693	chr12:118430147~118430699:+
LUAD	cis	rs2288884	0.708	rs12460617	ENSG00000275055.1	CTC-471J1.11	-5.3	1.79e-07	5.38e-05	-0.32	-0.23	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52032581	chr19:52049007~52049754:+
LUAD	cis	rs1426063	1	rs11941556	ENSG00000249717.1	RP11-44F21.3	5.3	1.79e-07	5.38e-05	0.36	0.23	QT interval;	chr4:75093825	chr4:74955974~74970362:-
LUAD	cis	rs394563	0.559	rs7753269	ENSG00000231760.4	RP11-350J20.5	-5.3	1.79e-07	5.38e-05	-0.29	-0.23	Dupuytren's disease;	chr6:149350224	chr6:149796151~149826294:-
LUAD	cis	rs35160687	0.623	rs11689971	ENSG00000273080.1	RP11-301O19.1	-5.3	1.8e-07	5.39e-05	-0.26	-0.23	Night sleep phenotypes;	chr2:86247348	chr2:86195590~86196049:+
LUAD	cis	rs35160687	0.623	rs11127021	ENSG00000273080.1	RP11-301O19.1	-5.3	1.8e-07	5.39e-05	-0.26	-0.23	Night sleep phenotypes;	chr2:86247796	chr2:86195590~86196049:+
LUAD	cis	rs8098244	0.557	rs12185288	ENSG00000264745.1	TTC39C-AS1	5.3	1.8e-07	5.39e-05	0.24	0.23	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23732782	chr18:23994213~24015339:-
LUAD	cis	rs932287	1	rs932287	ENSG00000254860.4	TMEM9B-AS1	5.3	1.8e-07	5.39e-05	0.27	0.23	Colonoscopy-negative controls vs population controls;	chr11:9023220	chr11:8964675~8977527:+
LUAD	cis	rs948562	0.545	rs11229345	ENSG00000280010.1	AP001350.4	5.3	1.8e-07	5.4e-05	0.34	0.23	Lymphoma;	chr11:58298795	chr11:58627435~58628528:+
LUAD	cis	rs10129255	0.5	rs7157975	ENSG00000211967.3	IGHV3-53	-5.3	1.8e-07	5.4e-05	-0.17	-0.23	Kawasaki disease;	chr14:106804049	chr14:106592676~106593347:-
LUAD	cis	rs348196	0.767	rs12744132	ENSG00000225855.5	RUSC1-AS1	5.3	1.8e-07	5.41e-05	0.17	0.23	Breast cancer;	chr1:155693535	chr1:155316863~155324176:-
LUAD	cis	rs9601248	0.711	rs9530937	ENSG00000227676.3	LINC01068	-5.3	1.81e-07	5.41e-05	-0.29	-0.23	Major depressive disorder;	chr13:79603701	chr13:79566727~79571436:+
LUAD	cis	rs875971	0.825	rs59466412	ENSG00000237310.1	GS1-124K5.4	-5.3	1.81e-07	5.42e-05	-0.26	-0.23	Aortic root size;	chr7:66100371	chr7:66493706~66495474:+
LUAD	cis	rs10129255	1	rs10141557	ENSG00000211974.3	IGHV2-70	5.3	1.81e-07	5.42e-05	0.25	0.23	Kawasaki disease;	chr14:106767990	chr14:106723574~106724093:-
LUAD	cis	rs394563	0.559	rs7752555	ENSG00000231760.4	RP11-350J20.5	-5.3	1.81e-07	5.42e-05	-0.29	-0.23	Dupuytren's disease;	chr6:149349980	chr6:149796151~149826294:-
LUAD	cis	rs8040855	0.579	rs6496797	ENSG00000259774.1	RP11-182J1.13	-5.3	1.81e-07	5.42e-05	-0.27	-0.23	Bulimia nervosa;	chr15:85183624	chr15:84422618~84425882:+
LUAD	cis	rs1075265	0.783	rs698858	ENSG00000233266.1	HMGB1P31	5.3	1.81e-07	5.42e-05	0.3	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53943333	chr2:54051334~54051760:+
LUAD	cis	rs74233809	1	rs11191454	ENSG00000213277.3	MARCKSL1P1	5.3	1.81e-07	5.42e-05	0.37	0.23	Birth weight;	chr10:102900247	chr10:103175554~103176094:+
LUAD	cis	rs2404602	0.735	rs12906143	ENSG00000259422.1	RP11-593F23.1	-5.3	1.81e-07	5.43e-05	-0.3	-0.23	Blood metabolite levels;	chr15:76417182	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.735	rs11632222	ENSG00000259422.1	RP11-593F23.1	-5.3	1.81e-07	5.43e-05	-0.3	-0.23	Blood metabolite levels;	chr15:76420586	chr15:76174891~76181486:-
LUAD	cis	rs7208859	0.524	rs77498725	ENSG00000263603.1	CTD-2349P21.5	-5.3	1.81e-07	5.43e-05	-0.42	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30736968	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.573	rs73267865	ENSG00000263603.1	CTD-2349P21.5	-5.3	1.81e-07	5.43e-05	-0.42	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737186	chr17:30729469~30731202:+
LUAD	cis	rs1823913	0.538	rs11892998	ENSG00000227542.1	AC092614.2	5.3	1.81e-07	5.43e-05	0.29	0.23	Obesity-related traits;	chr2:191340159	chr2:191229165~191246172:-
LUAD	cis	rs71636778	0.509	rs34026879	ENSG00000260063.1	RP5-968P14.2	-5.3	1.81e-07	5.43e-05	-0.42	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26741747	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs34693293	ENSG00000260063.1	RP5-968P14.2	-5.3	1.81e-07	5.43e-05	-0.42	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26742480	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs35560426	ENSG00000260063.1	RP5-968P14.2	-5.3	1.81e-07	5.43e-05	-0.42	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26742678	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs58421016	ENSG00000260063.1	RP5-968P14.2	-5.3	1.81e-07	5.43e-05	-0.42	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26744038	chr1:26692132~26694131:-
LUAD	cis	rs17818399	0.817	rs17767994	ENSG00000279254.1	RP11-536C12.1	5.29	1.81e-07	5.44e-05	0.27	0.23	Height;	chr2:46632940	chr2:46668870~46670778:+
LUAD	cis	rs17747401	0.507	rs61862570	ENSG00000213731.2	RAB5CP1	-5.29	1.82e-07	5.44e-05	-0.25	-0.23	Hypospadias;	chr10:74687113	chr10:74423435~74424014:-
LUAD	cis	rs1075265	0.933	rs2287642	ENSG00000233266.1	HMGB1P31	5.29	1.82e-07	5.45e-05	0.29	0.23	Chronotype;Morning vs. evening chronotype;	chr2:54108447	chr2:54051334~54051760:+
LUAD	cis	rs3002142	0.908	rs3008606	ENSG00000272750.1	RP11-378J18.8	-5.29	1.82e-07	5.45e-05	-0.31	-0.23	LDL peak particle diameter (total fat intake interaction);	chr1:222611351	chr1:222658867~222661512:-
LUAD	cis	rs4835473	0.932	rs11730929	ENSG00000251600.4	RP11-673E1.1	-5.29	1.82e-07	5.45e-05	-0.3	-0.23	Immature fraction of reticulocytes;	chr4:143834795	chr4:143912331~143982454:+
LUAD	cis	rs1707322	1	rs4606257	ENSG00000234329.1	RP11-767N6.2	5.29	1.82e-07	5.45e-05	0.25	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45841596	chr1:45651039~45651826:-
LUAD	cis	rs1707322	0.721	rs11211178	ENSG00000280836.1	AL355480.1	-5.29	1.82e-07	5.45e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45761894	chr1:45581219~45581321:-
LUAD	cis	rs12468226	0.935	rs75597391	ENSG00000226261.1	AC064836.3	5.29	1.82e-07	5.45e-05	0.38	0.23	Urate levels;	chr2:202398850	chr2:202336024~202336727:-
LUAD	cis	rs4835473	0.932	rs7667092	ENSG00000251600.4	RP11-673E1.1	5.29	1.82e-07	5.46e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143968604	chr4:143912331~143982454:+
LUAD	cis	rs712039	0.652	rs2946340	ENSG00000276054.1	RP11-378E13.3	5.29	1.82e-07	5.46e-05	0.35	0.23	Tuberculosis;	chr17:37392762	chr17:37386886~37387926:+
LUAD	cis	rs7208859	0.623	rs7220289	ENSG00000263603.1	CTD-2349P21.5	-5.29	1.82e-07	5.46e-05	-0.41	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30776744	chr17:30729469~30731202:+
LUAD	cis	rs561341	0.941	rs72825746	ENSG00000265798.5	RP11-271K11.5	5.29	1.82e-07	5.46e-05	0.37	0.23	Hip circumference adjusted for BMI;	chr17:32037591	chr17:31038575~31059121:-
LUAD	cis	rs11976180	1	rs2951363	ENSG00000170356.8	OR2A20P	-5.29	1.82e-07	5.46e-05	-0.3	-0.23	Obesity-related traits;	chr7:144057631	chr7:144250045~144252957:-
LUAD	cis	rs5758511	0.689	rs17478227	ENSG00000205702.9	CYP2D7	-5.29	1.83e-07	5.47e-05	-0.26	-0.23	Birth weight;	chr22:42258321	chr22:42140203~42144577:-
LUAD	cis	rs4908760	0.827	rs1463053	ENSG00000232912.4	RP5-1115A15.1	5.29	1.83e-07	5.47e-05	0.21	0.23	Vitiligo;	chr1:8644978	chr1:8424645~8434838:+
LUAD	cis	rs41307935	0.818	rs80036989	ENSG00000260063.1	RP5-968P14.2	-5.29	1.83e-07	5.47e-05	-0.43	-0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26721033	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs12756074	ENSG00000260063.1	RP5-968P14.2	-5.29	1.83e-07	5.47e-05	-0.43	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26721402	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs35617712	ENSG00000260063.1	RP5-968P14.2	-5.29	1.83e-07	5.47e-05	-0.43	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26724732	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs71636773	ENSG00000260063.1	RP5-968P14.2	-5.29	1.83e-07	5.47e-05	-0.43	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26724828	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs60401377	ENSG00000260063.1	RP5-968P14.2	-5.29	1.83e-07	5.47e-05	-0.43	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26725756	chr1:26692132~26694131:-
LUAD	cis	rs41307935	0.818	rs35145624	ENSG00000260063.1	RP5-968P14.2	-5.29	1.83e-07	5.47e-05	-0.43	-0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26726121	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs35256560	ENSG00000260063.1	RP5-968P14.2	-5.29	1.83e-07	5.47e-05	-0.43	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26727525	chr1:26692132~26694131:-
LUAD	cis	rs287982	0.8	rs9973905	ENSG00000269973.1	RP11-95D17.1	-5.29	1.83e-07	5.47e-05	-0.29	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9820726	chr2:9936360~9939590:+
LUAD	cis	rs2337406	0.81	rs7161739	ENSG00000211972.2	IGHV3-66	5.29	1.83e-07	5.48e-05	0.26	0.23	Alzheimer's disease (late onset);	chr14:106776118	chr14:106675017~106675544:-
LUAD	cis	rs4835473	0.932	rs5015757	ENSG00000251600.4	RP11-673E1.1	5.29	1.83e-07	5.48e-05	0.28	0.23	Immature fraction of reticulocytes;	chr4:143738144	chr4:143912331~143982454:+
LUAD	cis	rs600231	0.665	rs1784859	ENSG00000245532.5	NEAT1	-5.29	1.84e-07	5.49e-05	-0.18	-0.23	Bone mineral density;	chr11:65453278	chr11:65422774~65445540:+
LUAD	cis	rs1707322	0.686	rs3014251	ENSG00000280836.1	AL355480.1	5.29	1.84e-07	5.5e-05	0.31	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45611756	chr1:45581219~45581321:-
LUAD	cis	rs3809863	0.602	rs11650072	ENSG00000228782.6	CTD-2026D20.3	5.29	1.84e-07	5.5e-05	0.25	0.23	Glaucoma (primary open-angle);	chr17:47316299	chr17:47450568~47492492:-
LUAD	cis	rs6687821	0.635	rs954119	ENSG00000267734.1	RP4-604K5.3	-5.29	1.84e-07	5.5e-05	-0.28	-0.23	Yeast infection;	chr1:86825532	chr1:86932199~86934891:-
LUAD	cis	rs1707322	1	rs10158032	ENSG00000234329.1	RP11-767N6.2	5.29	1.84e-07	5.5e-05	0.24	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867029	chr1:45651039~45651826:-
LUAD	cis	rs4835473	0.831	rs4125544	ENSG00000251600.4	RP11-673E1.1	5.29	1.84e-07	5.5e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143962542	chr4:143912331~143982454:+
LUAD	cis	rs6570726	0.577	rs867056	ENSG00000235652.6	RP11-545I5.3	-5.29	1.84e-07	5.5e-05	-0.24	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145463669	chr6:145799409~145886585:+
LUAD	cis	rs1707322	0.827	rs10890347	ENSG00000280836.1	AL355480.1	5.29	1.84e-07	5.51e-05	0.3	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776660	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.752	rs11211152	ENSG00000280836.1	AL355480.1	-5.29	1.84e-07	5.51e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648485	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.752	rs4607935	ENSG00000280836.1	AL355480.1	-5.29	1.84e-07	5.51e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651489	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.681	rs12048866	ENSG00000280836.1	AL355480.1	-5.29	1.84e-07	5.51e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651820	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.752	rs3811436	ENSG00000280836.1	AL355480.1	-5.29	1.84e-07	5.51e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660208	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.752	rs12024590	ENSG00000280836.1	AL355480.1	-5.29	1.84e-07	5.51e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45661824	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.752	rs12027622	ENSG00000280836.1	AL355480.1	-5.29	1.84e-07	5.51e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664580	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.721	rs4415615	ENSG00000280836.1	AL355480.1	-5.29	1.84e-07	5.51e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45666437	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.752	rs7529699	ENSG00000280836.1	AL355480.1	-5.29	1.84e-07	5.51e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668962	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.716	rs6699444	ENSG00000280836.1	AL355480.1	-5.29	1.84e-07	5.51e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669448	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.752	rs10430105	ENSG00000280836.1	AL355480.1	-5.29	1.84e-07	5.51e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45673204	chr1:45581219~45581321:-
LUAD	cis	rs7829975	0.564	rs2921060	ENSG00000253981.4	ALG1L13P	-5.29	1.84e-07	5.51e-05	-0.27	-0.23	Mood instability;	chr8:8460307	chr8:8236003~8244667:-
LUAD	cis	rs2239547	0.522	rs9311485	ENSG00000242142.1	SERBP1P3	-5.29	1.84e-07	5.51e-05	-0.27	-0.23	Schizophrenia;	chr3:52953629	chr3:53064283~53065091:-
LUAD	cis	rs1345301	0.552	rs1558626	ENSG00000234389.1	AC007278.3	-5.29	1.84e-07	5.51e-05	-0.22	-0.23	Waist circumference;	chr2:102245610	chr2:102438713~102440475:+
LUAD	cis	rs1345301	0.518	rs1558624	ENSG00000234389.1	AC007278.3	-5.29	1.84e-07	5.51e-05	-0.22	-0.23	Waist circumference;	chr2:102245773	chr2:102438713~102440475:+
LUAD	cis	rs17711722	0.727	rs1880555	ENSG00000164669.11	INTS4P1	-5.29	1.84e-07	5.52e-05	-0.28	-0.23	Calcium levels;	chr7:65967580	chr7:65141225~65234216:+
LUAD	cis	rs3096299	0.869	rs748941	ENSG00000182376.2	RP5-1142A6.8	5.29	1.85e-07	5.52e-05	0.25	0.23	Multiple myeloma (IgH translocation);	chr16:89374346	chr16:88742767~88745748:+
LUAD	cis	rs2404602	0.735	rs12903874	ENSG00000259422.1	RP11-593F23.1	-5.29	1.85e-07	5.52e-05	-0.3	-0.23	Blood metabolite levels;	chr15:76400977	chr15:76174891~76181486:-
LUAD	cis	rs1876905	0.539	rs62420362	ENSG00000272356.1	RP5-1112D6.8	-5.29	1.85e-07	5.52e-05	-0.27	-0.23	Mean corpuscular hemoglobin;	chr6:111224167	chr6:111309203~111313517:+
LUAD	cis	rs889398	0.967	rs62052816	ENSG00000226232.7	RP11-419C5.2	5.29	1.85e-07	5.53e-05	0.2	0.23	Body mass index;	chr16:69529503	chr16:69976388~69996188:-
LUAD	cis	rs889398	0.967	rs12929503	ENSG00000226232.7	RP11-419C5.2	5.29	1.85e-07	5.53e-05	0.2	0.23	Body mass index;	chr16:69531558	chr16:69976388~69996188:-
LUAD	cis	rs889398	0.935	rs12933292	ENSG00000226232.7	RP11-419C5.2	5.29	1.85e-07	5.53e-05	0.2	0.23	Body mass index;	chr16:69532406	chr16:69976388~69996188:-
LUAD	cis	rs7617773	0.817	rs9847953	ENSG00000228638.1	FCF1P2	-5.29	1.85e-07	5.53e-05	-0.27	-0.23	Coronary artery disease;	chr3:48241205	chr3:48290793~48291375:-
LUAD	cis	rs783540	0.867	rs10906984	ENSG00000278603.1	RP13-608F4.5	5.29	1.85e-07	5.53e-05	0.27	0.23	Schizophrenia;	chr15:82697544	chr15:82472203~82472426:+
LUAD	cis	rs1823874	0.71	rs2085087	ENSG00000182397.13	DNM1P46	-5.29	1.85e-07	5.53e-05	-0.29	-0.23	IgG glycosylation;	chr15:99819938	chr15:99790156~99806927:-
LUAD	cis	rs4927850	1	rs7625570	ENSG00000242086.7	LINC00969	5.29	1.85e-07	5.53e-05	0.21	0.23	Pancreatic cancer;	chr3:196020527	chr3:195658062~195739964:+
LUAD	cis	rs6723226	0.803	rs176415	ENSG00000276334.1	AL133243.1	-5.29	1.85e-07	5.54e-05	-0.28	-0.23	Intelligence (multi-trait analysis);	chr2:32424710	chr2:32521927~32523547:+
LUAD	cis	rs673078	0.66	rs75752792	ENSG00000275409.1	RP11-131L12.4	-5.29	1.85e-07	5.54e-05	-0.33	-0.23	Glucose homeostasis traits;	chr12:118187005	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.66	rs75571641	ENSG00000275409.1	RP11-131L12.4	-5.29	1.85e-07	5.54e-05	-0.33	-0.23	Glucose homeostasis traits;	chr12:118187012	chr12:118430147~118430699:+
LUAD	cis	rs516805	0.667	rs17729938	ENSG00000279453.1	RP3-425C14.4	5.29	1.86e-07	5.55e-05	0.3	0.23	Lymphocyte counts;	chr6:122340364	chr6:122436789~122439223:-
LUAD	cis	rs875971	0.545	rs313828	ENSG00000226824.5	RP4-756H11.3	5.29	1.86e-07	5.55e-05	0.35	0.23	Aortic root size;	chr7:66087627	chr7:66654538~66669855:+
LUAD	cis	rs643506	0.845	rs7114594	ENSG00000230911.1	PPIHP1	-5.29	1.86e-07	5.56e-05	-0.3	-0.23	Breast cancer;	chr11:111897389	chr11:112029858~112030367:-
LUAD	cis	rs1707322	1	rs4660334	ENSG00000234329.1	RP11-767N6.2	5.29	1.86e-07	5.56e-05	0.24	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45996454	chr1:45651039~45651826:-
LUAD	cis	rs287982	1	rs1119633	ENSG00000269973.1	RP11-95D17.1	-5.29	1.86e-07	5.56e-05	-0.28	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9827403	chr2:9936360~9939590:+
LUAD	cis	rs287982	0.935	rs1119632	ENSG00000269973.1	RP11-95D17.1	-5.29	1.86e-07	5.56e-05	-0.28	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9827535	chr2:9936360~9939590:+
LUAD	cis	rs6751744	0.513	rs6738215	ENSG00000226266.5	AC009961.3	-5.29	1.86e-07	5.57e-05	-0.32	-0.23	Dysphagia;	chr2:159596794	chr2:159670708~159712435:-
LUAD	cis	rs8098244	0.638	rs12373237	ENSG00000264745.1	TTC39C-AS1	-5.29	1.86e-07	5.57e-05	-0.24	-0.23	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23845972	chr18:23994213~24015339:-
LUAD	cis	rs67311347	0.544	rs9864664	ENSG00000223797.4	ENTPD3-AS1	5.29	1.86e-07	5.57e-05	0.25	0.23	Renal cell carcinoma;	chr3:40294735	chr3:40313802~40453329:-
LUAD	cis	rs41307935	0.908	rs4579782	ENSG00000260063.1	RP5-968P14.2	-5.29	1.87e-07	5.58e-05	-0.43	-0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26700496	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs57217461	ENSG00000260063.1	RP5-968P14.2	-5.29	1.87e-07	5.58e-05	-0.43	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26701425	chr1:26692132~26694131:-
LUAD	cis	rs896854	0.684	rs10098778	ENSG00000253528.2	RP11-347C18.4	5.29	1.87e-07	5.58e-05	0.22	0.23	Type 2 diabetes;	chr8:94979792	chr8:94974573~94974853:-
LUAD	cis	rs7208859	0.673	rs2470251	ENSG00000263531.1	RP13-753N3.1	5.29	1.87e-07	5.58e-05	0.4	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30768043	chr17:30863921~30864940:-
LUAD	cis	rs1707322	1	rs4606257	ENSG00000280836.1	AL355480.1	-5.29	1.87e-07	5.58e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45841596	chr1:45581219~45581321:-
LUAD	cis	rs950169	0.723	rs17589320	ENSG00000259295.5	CSPG4P12	5.29	1.87e-07	5.58e-05	0.34	0.23	Schizophrenia;	chr15:84251244	chr15:85191438~85213905:+
LUAD	cis	rs950169	0.845	rs4502182	ENSG00000259295.5	CSPG4P12	5.29	1.87e-07	5.58e-05	0.34	0.23	Schizophrenia;	chr15:84254768	chr15:85191438~85213905:+
LUAD	cis	rs17507216	1	rs17507216	ENSG00000255769.6	GOLGA2P10	5.29	1.87e-07	5.59e-05	0.3	0.23	Excessive daytime sleepiness;	chr15:82558175	chr15:82472993~82513950:-
LUAD	cis	rs1823874	0.71	rs67068917	ENSG00000182397.13	DNM1P46	-5.29	1.87e-07	5.59e-05	-0.29	-0.23	IgG glycosylation;	chr15:99822310	chr15:99790156~99806927:-
LUAD	cis	rs516805	0.63	rs2606642	ENSG00000279453.1	RP3-425C14.4	5.29	1.87e-07	5.59e-05	0.32	0.23	Lymphocyte counts;	chr6:122103758	chr6:122436789~122439223:-
LUAD	cis	rs17711722	0.522	rs62469933	ENSG00000234585.5	CCT6P3	5.29	1.87e-07	5.59e-05	0.22	0.23	Calcium levels;	chr7:65800652	chr7:65038354~65074713:+
LUAD	cis	rs875971	0.502	rs2946580	ENSG00000226824.5	RP4-756H11.3	5.29	1.88e-07	5.6e-05	0.35	0.23	Aortic root size;	chr7:66066855	chr7:66654538~66669855:+
LUAD	cis	rs6723226	0.557	rs62136260	ENSG00000276334.1	AL133243.1	-5.29	1.88e-07	5.6e-05	-0.26	-0.23	Intelligence (multi-trait analysis);	chr2:32350379	chr2:32521927~32523547:+
LUAD	cis	rs801193	1	rs10252765	ENSG00000236529.1	RP13-254B10.1	5.29	1.88e-07	5.6e-05	0.24	0.23	Aortic root size;	chr7:66763745	chr7:65840212~65840596:+
LUAD	cis	rs4835473	0.932	rs11100824	ENSG00000251600.4	RP11-673E1.1	5.29	1.88e-07	5.6e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143964845	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.592	rs11100825	ENSG00000251600.4	RP11-673E1.1	5.29	1.88e-07	5.6e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143964903	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.864	rs2089837	ENSG00000251600.4	RP11-673E1.1	5.29	1.88e-07	5.6e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143965038	chr4:143912331~143982454:+
LUAD	cis	rs66887589	0.934	rs2389873	ENSG00000245958.5	RP11-33B1.1	5.29	1.88e-07	5.61e-05	0.19	0.23	Diastolic blood pressure;	chr4:119633559	chr4:119454791~119552025:+
LUAD	cis	rs71636778	0.57	rs12728091	ENSG00000260063.1	RP5-968P14.2	-5.29	1.88e-07	5.62e-05	-0.42	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26817022	chr1:26692132~26694131:-
LUAD	cis	rs453301	0.682	rs2929451	ENSG00000173295.6	FAM86B3P	5.29	1.88e-07	5.62e-05	0.24	0.23	Joint mobility (Beighton score);	chr8:9227785	chr8:8228595~8244865:+
LUAD	cis	rs2665103	0.715	rs11639440	ENSG00000278603.1	RP13-608F4.5	5.29	1.88e-07	5.62e-05	0.27	0.23	Intelligence (multi-trait analysis);	chr15:82278705	chr15:82472203~82472426:+
LUAD	cis	rs7727544	0.904	rs7736102	ENSG00000233006.5	AC034220.3	5.29	1.89e-07	5.62e-05	0.2	0.23	Blood metabolite levels;	chr5:132268564	chr5:132311285~132369916:-
LUAD	cis	rs7727544	0.904	rs6897575	ENSG00000233006.5	AC034220.3	5.29	1.89e-07	5.62e-05	0.2	0.23	Blood metabolite levels;	chr5:132268842	chr5:132311285~132369916:-
LUAD	cis	rs4908768	0.581	rs2784739	ENSG00000232912.4	RP5-1115A15.1	-5.29	1.89e-07	5.63e-05	-0.25	-0.23	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8437498	chr1:8424645~8434838:+
LUAD	cis	rs755249	0.501	rs2484133	ENSG00000228060.1	RP11-69E11.8	-5.29	1.89e-07	5.63e-05	-0.22	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39188322	chr1:39565160~39573203:+
LUAD	cis	rs67311347	0.544	rs12635762	ENSG00000223797.4	ENTPD3-AS1	-5.29	1.89e-07	5.63e-05	-0.24	-0.23	Renal cell carcinoma;	chr3:40291268	chr3:40313802~40453329:-
LUAD	cis	rs1816752	0.905	rs1050112	ENSG00000273628.1	RP11-756A22.7	5.29	1.89e-07	5.63e-05	0.27	0.23	Obesity-related traits;	chr13:24435159	chr13:24933006~24936796:+
LUAD	cis	rs720475	0.732	rs62483106	ENSG00000204959.4	ARHGEF34P	-5.29	1.89e-07	5.64e-05	-0.32	-0.23	Breast cancer;	chr7:144439533	chr7:144272445~144286966:-
LUAD	cis	rs875971	0.862	rs12537823	ENSG00000232559.3	GS1-124K5.12	5.29	1.89e-07	5.64e-05	0.28	0.23	Aortic root size;	chr7:66255897	chr7:66554588~66576923:-
LUAD	cis	rs7208859	0.673	rs7211776	ENSG00000263531.1	RP13-753N3.1	5.29	1.89e-07	5.64e-05	0.4	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793178	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs9912122	ENSG00000263531.1	RP13-753N3.1	5.29	1.89e-07	5.64e-05	0.4	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813698	chr17:30863921~30864940:-
LUAD	cis	rs7083	1	rs673738	ENSG00000254851.1	RP11-109L13.1	5.29	1.89e-07	5.65e-05	0.3	0.23	Blood protein levels;	chr11:117272865	chr11:117135528~117138582:+
LUAD	cis	rs10246939	0.505	rs892354	ENSG00000228775.6	WEE2-AS1	5.29	1.89e-07	5.65e-05	0.3	0.23	Bitter taste perception;	chr7:141844934	chr7:141704338~141738346:-
LUAD	cis	rs755249	0.529	rs3768299	ENSG00000228060.1	RP11-69E11.8	-5.29	1.89e-07	5.65e-05	-0.24	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39391520	chr1:39565160~39573203:+
LUAD	cis	rs9813712	0.571	rs9855426	ENSG00000228252.7	COL6A4P2	5.29	1.9e-07	5.65e-05	0.22	0.23	Response to amphetamines;	chr3:130214475	chr3:130212823~130273806:+
LUAD	cis	rs897984	0.76	rs11076	ENSG00000260911.2	RP11-196G11.2	-5.29	1.9e-07	5.65e-05	-0.21	-0.23	Dementia with Lewy bodies;	chr16:30984207	chr16:31043150~31049868:+
LUAD	cis	rs11976180	1	rs2951364	ENSG00000170356.8	OR2A20P	-5.29	1.9e-07	5.65e-05	-0.3	-0.23	Obesity-related traits;	chr7:144057390	chr7:144250045~144252957:-
LUAD	cis	rs875971	0.571	rs160647	ENSG00000226824.5	RP4-756H11.3	5.29	1.9e-07	5.66e-05	0.35	0.23	Aortic root size;	chr7:66089365	chr7:66654538~66669855:+
LUAD	cis	rs375066	0.934	rs411803	ENSG00000267058.1	RP11-15A1.3	5.29	1.9e-07	5.66e-05	0.27	0.23	Breast cancer;	chr19:43928688	chr19:43891804~43901805:-
LUAD	cis	rs10129255	0.869	rs7150549	ENSG00000224373.3	IGHV4-59	5.29	1.9e-07	5.66e-05	0.16	0.23	Kawasaki disease;	chr14:106705441	chr14:106627249~106627825:-
LUAD	cis	rs875971	0.522	rs709604	ENSG00000236529.1	RP13-254B10.1	-5.29	1.9e-07	5.67e-05	-0.24	-0.23	Aortic root size;	chr7:66032447	chr7:65840212~65840596:+
LUAD	cis	rs9287719	0.649	rs10803724	ENSG00000243819.4	RN7SL832P	5.29	1.9e-07	5.67e-05	0.25	0.23	Prostate cancer;	chr2:10592197	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.649	rs10803725	ENSG00000243819.4	RN7SL832P	5.29	1.9e-07	5.67e-05	0.25	0.23	Prostate cancer;	chr2:10592220	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.649	rs10929685	ENSG00000243819.4	RN7SL832P	5.29	1.9e-07	5.67e-05	0.25	0.23	Prostate cancer;	chr2:10592673	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.649	rs10183359	ENSG00000243819.4	RN7SL832P	5.29	1.9e-07	5.67e-05	0.25	0.23	Prostate cancer;	chr2:10592918	chr2:10690344~10692099:+
LUAD	cis	rs1426063	0.614	rs17000264	ENSG00000249717.1	RP11-44F21.3	5.29	1.9e-07	5.67e-05	0.43	0.23	QT interval;	chr4:75108962	chr4:74955974~74970362:-
LUAD	cis	rs8103033	0.786	rs2190912	ENSG00000226025.8	LGALS17A	-5.29	1.9e-07	5.67e-05	-0.26	-0.23	Obesity-related traits;	chr19:39656982	chr19:39679374~39686373:+
LUAD	cis	rs8103033	0.786	rs2190913	ENSG00000226025.8	LGALS17A	-5.29	1.9e-07	5.67e-05	-0.26	-0.23	Obesity-related traits;	chr19:39656984	chr19:39679374~39686373:+
LUAD	cis	rs7849270	1	rs7855278	ENSG00000268707.1	RP11-247A12.7	5.29	1.9e-07	5.67e-05	0.27	0.23	Blood metabolite ratios;	chr9:129159086	chr9:129170434~129170940:+
LUAD	cis	rs270601	0.739	rs3900945	ENSG00000233006.5	AC034220.3	5.29	1.9e-07	5.67e-05	0.21	0.23	Acylcarnitine levels;	chr5:132257177	chr5:132311285~132369916:-
LUAD	cis	rs875971	0.825	rs1129531	ENSG00000232559.3	GS1-124K5.12	-5.29	1.9e-07	5.68e-05	-0.28	-0.23	Aortic root size;	chr7:66154117	chr7:66554588~66576923:-
LUAD	cis	rs6496044	0.507	rs2467096	ENSG00000259407.1	RP11-158M2.3	5.29	1.9e-07	5.68e-05	0.21	0.23	Interstitial lung disease;	chr15:85667447	chr15:85744109~85750281:-
LUAD	cis	rs4835473	0.771	rs4835097	ENSG00000251600.4	RP11-673E1.1	5.29	1.91e-07	5.68e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143960687	chr4:143912331~143982454:+
LUAD	cis	rs71403859	0.57	rs78972826	ENSG00000260886.1	TAT-AS1	5.29	1.91e-07	5.68e-05	0.37	0.23	Post bronchodilator FEV1;	chr16:71420361	chr16:71565789~71578187:+
LUAD	cis	rs17684571	0.938	rs4262190	ENSG00000231441.1	RP11-472M19.2	5.29	1.91e-07	5.68e-05	0.31	0.23	Schizophrenia;	chr6:56702404	chr6:56844002~56864078:+
LUAD	cis	rs2032366	0.606	rs9965972	ENSG00000267279.1	RP11-879F14.2	-5.29	1.91e-07	5.68e-05	-0.31	-0.23	Obesity-related traits;	chr18:61609468	chr18:61585746~61606916:-
LUAD	cis	rs7404843	0.777	rs6498552	ENSG00000207425.1	Y_RNA	5.28	1.91e-07	5.69e-05	0.45	0.23	Testicular germ cell tumor;	chr16:15446044	chr16:14915457~14915556:-
LUAD	cis	rs7404843	0.85	rs6498553	ENSG00000207425.1	Y_RNA	5.28	1.91e-07	5.69e-05	0.45	0.23	Testicular germ cell tumor;	chr16:15446045	chr16:14915457~14915556:-
LUAD	cis	rs4713118	0.669	rs200997	ENSG00000219392.1	RP1-265C24.5	-5.28	1.91e-07	5.69e-05	-0.29	-0.23	Parkinson's disease;	chr6:27844037	chr6:28115628~28116551:+
LUAD	cis	rs699371	0.507	rs10149538	ENSG00000270000.1	RP3-449M8.9	5.28	1.91e-07	5.69e-05	0.27	0.23	Height;	chr14:74458694	chr14:74471930~74472360:-
LUAD	cis	rs71520386	0.607	rs28617621	ENSG00000228649.7	AC005682.5	-5.28	1.91e-07	5.7e-05	-0.32	-0.23	Fibrinogen levels;	chr7:22818063	chr7:22854178~22861579:+
LUAD	cis	rs1150668	0.699	rs1531681	ENSG00000219392.1	RP1-265C24.5	-5.28	1.91e-07	5.7e-05	-0.29	-0.23	Pubertal anthropometrics;	chr6:28259100	chr6:28115628~28116551:+
LUAD	cis	rs2337406	0.925	rs11851094	ENSG00000211974.3	IGHV2-70	-5.28	1.91e-07	5.7e-05	-0.3	-0.23	Alzheimer's disease (late onset);	chr14:106688967	chr14:106723574~106724093:-
LUAD	cis	rs41307935	0.818	rs35738294	ENSG00000260063.1	RP5-968P14.2	-5.28	1.91e-07	5.7e-05	-0.43	-0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26693642	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs71636769	ENSG00000260063.1	RP5-968P14.2	-5.28	1.91e-07	5.7e-05	-0.43	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26694100	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs71636770	ENSG00000260063.1	RP5-968P14.2	-5.28	1.91e-07	5.7e-05	-0.43	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26694624	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.57	rs12744003	ENSG00000260063.1	RP5-968P14.2	-5.28	1.91e-07	5.7e-05	-0.43	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26701808	chr1:26692132~26694131:-
LUAD	cis	rs41307935	0.908	rs77408691	ENSG00000260063.1	RP5-968P14.2	-5.28	1.91e-07	5.7e-05	-0.43	-0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26707898	chr1:26692132~26694131:-
LUAD	cis	rs41307935	0.73	rs12724159	ENSG00000260063.1	RP5-968P14.2	-5.28	1.91e-07	5.7e-05	-0.43	-0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26709637	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs12729444	ENSG00000260063.1	RP5-968P14.2	-5.28	1.91e-07	5.7e-05	-0.43	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26710663	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs12726081	ENSG00000260063.1	RP5-968P14.2	-5.28	1.91e-07	5.7e-05	-0.43	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26711084	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs12730386	ENSG00000260063.1	RP5-968P14.2	-5.28	1.91e-07	5.7e-05	-0.43	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26711498	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs79568175	ENSG00000260063.1	RP5-968P14.2	-5.28	1.91e-07	5.7e-05	-0.43	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26711725	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs12726287	ENSG00000260063.1	RP5-968P14.2	-5.28	1.91e-07	5.7e-05	-0.43	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26712737	chr1:26692132~26694131:-
LUAD	cis	rs41307935	0.908	rs12756154	ENSG00000260063.1	RP5-968P14.2	-5.28	1.91e-07	5.7e-05	-0.43	-0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26714018	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs35407375	ENSG00000260063.1	RP5-968P14.2	-5.28	1.91e-07	5.7e-05	-0.43	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26714727	chr1:26692132~26694131:-
LUAD	cis	rs516805	0.665	rs2606648	ENSG00000279453.1	RP3-425C14.4	-5.28	1.91e-07	5.7e-05	-0.32	-0.23	Lymphocyte counts;	chr6:122119554	chr6:122436789~122439223:-
LUAD	cis	rs4713118	0.619	rs200486	ENSG00000219392.1	RP1-265C24.5	-5.28	1.92e-07	5.71e-05	-0.33	-0.23	Parkinson's disease;	chr6:27811728	chr6:28115628~28116551:+
LUAD	cis	rs7829975	0.54	rs2976909	ENSG00000253893.2	FAM85B	5.28	1.92e-07	5.71e-05	0.29	0.23	Mood instability;	chr8:8489180	chr8:8167819~8226614:-
LUAD	cis	rs11098499	0.739	rs6534130	ENSG00000248280.1	RP11-33B1.2	-5.28	1.92e-07	5.71e-05	-0.3	-0.23	Corneal astigmatism;	chr4:119210184	chr4:119440561~119450157:-
LUAD	cis	rs9287719	0.624	rs6740245	ENSG00000243819.4	RN7SL832P	5.28	1.92e-07	5.71e-05	0.25	0.23	Prostate cancer;	chr2:10620776	chr2:10690344~10692099:+
LUAD	cis	rs4664293	0.715	rs13002625	ENSG00000226266.5	AC009961.3	5.28	1.92e-07	5.72e-05	0.31	0.23	Monocyte percentage of white cells;	chr2:159648114	chr2:159670708~159712435:-
LUAD	cis	rs559928	0.549	rs57831436	ENSG00000236935.1	AP003774.1	5.28	1.92e-07	5.72e-05	0.34	0.23	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64239825	chr11:64325050~64329504:-
LUAD	cis	rs41307935	0.818	rs34339345	ENSG00000260063.1	RP5-968P14.2	-5.28	1.92e-07	5.72e-05	-0.43	-0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26899598	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs12739698	ENSG00000260063.1	RP5-968P14.2	-5.28	1.92e-07	5.72e-05	-0.43	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26903542	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs78581866	ENSG00000260063.1	RP5-968P14.2	-5.28	1.92e-07	5.72e-05	-0.43	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26921075	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs11538549	ENSG00000260063.1	RP5-968P14.2	-5.28	1.92e-07	5.72e-05	-0.43	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26921792	chr1:26692132~26694131:-
LUAD	cis	rs4835473	0.932	rs13117421	ENSG00000251600.4	RP11-673E1.1	-5.28	1.92e-07	5.72e-05	-0.3	-0.23	Immature fraction of reticulocytes;	chr4:143769405	chr4:143912331~143982454:+
LUAD	cis	rs7727544	1	rs10076701	ENSG00000233006.5	AC034220.3	5.28	1.92e-07	5.73e-05	0.2	0.23	Blood metabolite levels;	chr5:132260726	chr5:132311285~132369916:-
LUAD	cis	rs10754283	0.967	rs10754285	ENSG00000231613.1	RP5-943J3.1	5.28	1.93e-07	5.73e-05	0.24	0.23	Amyotrophic lateral sclerosis (sporadic);	chr1:89651028	chr1:89788914~89790492:+
LUAD	cis	rs67340775	0.541	rs200973	ENSG00000219392.1	RP1-265C24.5	-5.28	1.93e-07	5.73e-05	-0.38	-0.23	Lung cancer in ever smokers;	chr6:27890643	chr6:28115628~28116551:+
LUAD	cis	rs17711722	0.522	rs6957759	ENSG00000234585.5	CCT6P3	5.28	1.93e-07	5.75e-05	0.22	0.23	Calcium levels;	chr7:65806798	chr7:65038354~65074713:+
LUAD	cis	rs1075265	1	rs1075265	ENSG00000233266.1	HMGB1P31	5.28	1.93e-07	5.76e-05	0.3	0.23	Chronotype;Morning vs. evening chronotype;	chr2:54127790	chr2:54051334~54051760:+
LUAD	cis	rs67311347	0.544	rs9821440	ENSG00000223797.4	ENTPD3-AS1	5.28	1.93e-07	5.76e-05	0.24	0.23	Renal cell carcinoma;	chr3:40300856	chr3:40313802~40453329:-
LUAD	cis	rs9425766	0.566	rs10912773	ENSG00000227373.4	RP11-160H22.5	5.28	1.94e-07	5.76e-05	0.29	0.23	Life satisfaction;	chr1:174374567	chr1:174115300~174160004:-
LUAD	cis	rs2562456	0.754	rs55771551	ENSG00000268081.1	RP11-678G14.2	5.28	1.94e-07	5.77e-05	0.36	0.23	Pain;	chr19:21563578	chr19:21554640~21569237:-
LUAD	cis	rs7811142	0.943	rs28578163	ENSG00000078319.8	PMS2P1	-5.28	1.94e-07	5.77e-05	-0.27	-0.23	Platelet count;	chr7:100447131	chr7:100320992~100341908:-
LUAD	cis	rs11157436	0.918	rs1983518	ENSG00000211812.1	TRAV26-2	-5.28	1.94e-07	5.77e-05	-0.25	-0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22149336	chr14:22202583~22203368:+
LUAD	cis	rs1816752	0.837	rs9318530	ENSG00000273628.1	RP11-756A22.7	-5.28	1.94e-07	5.77e-05	-0.26	-0.23	Obesity-related traits;	chr13:24424419	chr13:24933006~24936796:+
LUAD	cis	rs55665837	0.54	rs10766192	ENSG00000251991.1	RNU7-49P	5.28	1.94e-07	5.77e-05	0.26	0.23	Vitamin D levels;	chr11:14790140	chr11:14478892~14478953:+
LUAD	cis	rs9847710	0.524	rs11712910	ENSG00000242142.1	SERBP1P3	5.28	1.94e-07	5.78e-05	0.27	0.23	Ulcerative colitis;	chr3:53060178	chr3:53064283~53065091:-
LUAD	cis	rs11250098	0.642	rs4841460	ENSG00000255046.1	RP11-297N6.4	5.28	1.94e-07	5.78e-05	0.29	0.23	Morning vs. evening chronotype;	chr8:10931983	chr8:11797928~11802568:-
LUAD	cis	rs2739330	0.734	rs2000467	ENSG00000206090.4	AP000350.7	-5.28	1.94e-07	5.78e-05	-0.28	-0.23	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23939998~23942798:+
LUAD	cis	rs11976180	1	rs2951363	ENSG00000204959.4	ARHGEF34P	5.28	1.94e-07	5.78e-05	0.29	0.23	Obesity-related traits;	chr7:144057631	chr7:144272445~144286966:-
LUAD	cis	rs910316	1	rs10136948	ENSG00000259138.1	RP11-950C14.7	5.28	1.94e-07	5.79e-05	0.24	0.23	Height;	chr14:75044372	chr14:75127153~75136930:+
LUAD	cis	rs11159086	0.793	rs1029702	ENSG00000259005.1	RP3-449M8.6	5.28	1.95e-07	5.79e-05	0.3	0.23	Advanced glycation end-product levels;	chr14:74473909	chr14:74474007~74474864:-
LUAD	cis	rs7924176	0.643	rs1908339	ENSG00000213731.2	RAB5CP1	5.28	1.95e-07	5.79e-05	0.25	0.23	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74083342	chr10:74423435~74424014:-
LUAD	cis	rs7657257	1	rs16892283	ENSG00000214846.4	RP11-115L11.1	5.28	1.95e-07	5.8e-05	0.58	0.23	Blood protein levels;	chr4:15729911	chr4:15730962~15731627:-
LUAD	cis	rs1263173	0.696	rs1263172	ENSG00000280143.1	AP000892.6	5.28	1.95e-07	5.8e-05	0.28	0.23	HDL cholesterol;	chr11:116810202	chr11:117204967~117210292:+
LUAD	cis	rs1707322	1	rs12124847	ENSG00000280836.1	AL355480.1	-5.28	1.95e-07	5.8e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45915178	chr1:45581219~45581321:-
LUAD	cis	rs55665837	0.54	rs12416696	ENSG00000251991.1	RNU7-49P	5.28	1.95e-07	5.8e-05	0.26	0.23	Vitamin D levels;	chr11:14769343	chr11:14478892~14478953:+
LUAD	cis	rs7923837	1	rs10748582	ENSG00000236493.2	EIF2S2P3	5.28	1.95e-07	5.81e-05	0.27	0.23	Multiple sclerosis;Body mass index;	chr10:92717462	chr10:92668745~92669743:-
LUAD	cis	rs7580658	0.676	rs4662717	ENSG00000236682.1	AC068282.3	-5.28	1.95e-07	5.81e-05	-0.3	-0.23	Protein C levels;	chr2:127255928	chr2:127389130~127400580:+
LUAD	cis	rs875971	0.522	rs6960048	ENSG00000164669.11	INTS4P1	-5.28	1.95e-07	5.81e-05	-0.28	-0.23	Aortic root size;	chr7:65943052	chr7:65141225~65234216:+
LUAD	cis	rs5769707	0.632	rs135871	ENSG00000235111.1	RP1-29C18.8	-5.28	1.95e-07	5.81e-05	-0.28	-0.23	Monocyte percentage of white cells;Monocyte count;	chr22:49615321	chr22:49612657~49615716:-
LUAD	cis	rs891378	1	rs12095015	ENSG00000274245.1	RP11-357P18.2	5.28	1.96e-07	5.81e-05	0.3	0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207283129	chr1:207372559~207373252:+
LUAD	cis	rs2562456	0.876	rs2681370	ENSG00000268081.1	RP11-678G14.2	5.28	1.96e-07	5.82e-05	0.36	0.23	Pain;	chr19:21554036	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.876	rs11668606	ENSG00000268081.1	RP11-678G14.2	5.28	1.96e-07	5.82e-05	0.36	0.23	Pain;	chr19:21554618	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.876	rs2681395	ENSG00000268081.1	RP11-678G14.2	5.28	1.96e-07	5.82e-05	0.36	0.23	Pain;	chr19:21555338	chr19:21554640~21569237:-
LUAD	cis	rs287982	0.8	rs13429581	ENSG00000269973.1	RP11-95D17.1	-5.28	1.96e-07	5.82e-05	-0.29	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9823314	chr2:9936360~9939590:+
LUAD	cis	rs7945705	0.52	rs1984791	ENSG00000254860.4	TMEM9B-AS1	-5.28	1.96e-07	5.83e-05	-0.29	-0.23	Hemoglobin concentration;	chr11:9013480	chr11:8964675~8977527:+
LUAD	cis	rs1075265	0.73	rs7559380	ENSG00000233266.1	HMGB1P31	5.28	1.96e-07	5.83e-05	0.3	0.23	Chronotype;Morning vs. evening chronotype;	chr2:54129660	chr2:54051334~54051760:+
LUAD	cis	rs4591358	0.68	rs7568240	ENSG00000223466.1	AC064834.2	-5.28	1.96e-07	5.83e-05	-0.32	-0.23	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195428263	chr2:195533035~195538681:+
LUAD	cis	rs9435732	0.778	rs6662202	ENSG00000235241.1	RP11-108M9.5	5.28	1.96e-07	5.83e-05	0.33	0.23	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:17009758	chr1:16889095~16889602:+
LUAD	cis	rs732716	0.785	rs9973266	ENSG00000267980.1	AC007292.6	-5.28	1.96e-07	5.84e-05	-0.28	-0.23	Mean corpuscular volume;	chr19:4392718	chr19:4363789~4364640:+
LUAD	cis	rs2239547	0.522	rs6445550	ENSG00000242142.1	SERBP1P3	5.28	1.97e-07	5.84e-05	0.28	0.23	Schizophrenia;	chr3:52949418	chr3:53064283~53065091:-
LUAD	cis	rs1707322	0.662	rs11211160	ENSG00000280836.1	AL355480.1	-5.28	1.97e-07	5.84e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680557	chr1:45581219~45581321:-
LUAD	cis	rs75920871	0.528	rs2513094	ENSG00000254851.1	RP11-109L13.1	5.28	1.97e-07	5.85e-05	0.35	0.23	Subjective well-being;	chr11:116935696	chr11:117135528~117138582:+
LUAD	cis	rs516805	0.63	rs2816082	ENSG00000279453.1	RP3-425C14.4	-5.28	1.97e-07	5.85e-05	-0.31	-0.23	Lymphocyte counts;	chr6:122102489	chr6:122436789~122439223:-
LUAD	cis	rs7804306	0.655	rs17508185	ENSG00000233264.2	AC006042.8	5.28	1.97e-07	5.85e-05	0.5	0.23	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8015622	chr7:7980312~7982228:+
LUAD	cis	rs9435732	0.778	rs2076604	ENSG00000235241.1	RP11-108M9.5	5.28	1.97e-07	5.85e-05	0.32	0.23	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16991570	chr1:16889095~16889602:+
LUAD	cis	rs10895987	0.531	rs7943007	ENSG00000254614.2	AP003068.23	-5.28	1.97e-07	5.85e-05	-0.31	-0.23	Blood protein levels;	chr11:65089626	chr11:65177606~65181834:-
LUAD	cis	rs2404602	1	rs12443137	ENSG00000259422.1	RP11-593F23.1	5.28	1.97e-07	5.86e-05	0.28	0.23	Blood metabolite levels;	chr15:76548491	chr15:76174891~76181486:-
LUAD	cis	rs891378	1	rs1835307	ENSG00000274245.1	RP11-357P18.2	-5.28	1.97e-07	5.86e-05	-0.28	-0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207253220	chr1:207372559~207373252:+
LUAD	cis	rs7829975	0.871	rs7829826	ENSG00000253893.2	FAM85B	5.28	1.97e-07	5.87e-05	0.3	0.23	Mood instability;	chr8:8720610	chr8:8167819~8226614:-
LUAD	cis	rs1546924	0.57	rs197412	ENSG00000227811.2	FAM212B-AS1	-5.28	1.98e-07	5.87e-05	-0.29	-0.23	Body mass index;	chr1:111766331	chr1:111739841~111747798:+
LUAD	cis	rs11157436	0.874	rs35951144	ENSG00000211812.1	TRAV26-2	-5.28	1.98e-07	5.87e-05	-0.25	-0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22149973	chr14:22202583~22203368:+
LUAD	cis	rs7829975	0.711	rs1039916	ENSG00000173295.6	FAM86B3P	5.28	1.98e-07	5.87e-05	0.24	0.23	Mood instability;	chr8:8828344	chr8:8228595~8244865:+
LUAD	cis	rs61270009	0.955	rs4916904	ENSG00000247828.6	TMEM161B-AS1	5.28	1.98e-07	5.87e-05	0.27	0.23	Depressive symptoms;	chr5:88338780	chr5:88268895~88436685:+
LUAD	cis	rs8180040	0.726	rs6774733	ENSG00000271161.1	BOLA2P2	5.28	1.98e-07	5.87e-05	0.22	0.23	Colorectal cancer;	chr3:46949751	chr3:47499841~47500407:+
LUAD	cis	rs6772849	1	rs9839508	ENSG00000242551.2	POU5F1P6	5.28	1.98e-07	5.87e-05	0.27	0.23	Monocyte percentage of white cells;Monocyte count;	chr3:128591951	chr3:128674735~128677005:-
LUAD	cis	rs1707322	1	rs10789485	ENSG00000280836.1	AL355480.1	-5.28	1.98e-07	5.89e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941636	chr1:45581219~45581321:-
LUAD	cis	rs2408955	0.522	rs11168408	ENSG00000257735.1	RP11-370I10.6	-5.28	1.98e-07	5.89e-05	-0.28	-0.23	Glycated hemoglobin levels;	chr12:48104544	chr12:48350945~48442411:+
LUAD	cis	rs910316	1	rs2098297	ENSG00000259138.1	RP11-950C14.7	-5.28	1.98e-07	5.89e-05	-0.25	-0.23	Height;	chr14:75152415	chr14:75127153~75136930:+
LUAD	cis	rs2337406	1	rs4774173	ENSG00000223648.3	IGHV3-64	5.28	1.98e-07	5.9e-05	0.28	0.23	Alzheimer's disease (late onset);	chr14:106682029	chr14:106643132~106658258:-
LUAD	cis	rs516805	0.528	rs2606627	ENSG00000279453.1	RP3-425C14.4	-5.28	1.99e-07	5.9e-05	-0.31	-0.23	Lymphocyte counts;	chr6:122097129	chr6:122436789~122439223:-
LUAD	cis	rs2439831	0.702	rs7175032	ENSG00000249839.1	AC011330.5	-5.28	1.99e-07	5.9e-05	-0.46	-0.23	Lung cancer in ever smokers;	chr15:43768038	chr15:43663654~43684339:-
LUAD	cis	rs2439831	0.85	rs3862142	ENSG00000249839.1	AC011330.5	-5.28	1.99e-07	5.9e-05	-0.46	-0.23	Lung cancer in ever smokers;	chr15:43772608	chr15:43663654~43684339:-
LUAD	cis	rs2439831	0.702	rs2788	ENSG00000249839.1	AC011330.5	-5.28	1.99e-07	5.9e-05	-0.46	-0.23	Lung cancer in ever smokers;	chr15:43772688	chr15:43663654~43684339:-
LUAD	cis	rs2439831	0.85	rs28891769	ENSG00000249839.1	AC011330.5	-5.28	1.99e-07	5.9e-05	-0.46	-0.23	Lung cancer in ever smokers;	chr15:43780662	chr15:43663654~43684339:-
LUAD	cis	rs2439831	0.85	rs28578398	ENSG00000249839.1	AC011330.5	-5.28	1.99e-07	5.9e-05	-0.46	-0.23	Lung cancer in ever smokers;	chr15:43782848	chr15:43663654~43684339:-
LUAD	cis	rs9487094	0.961	rs12193493	ENSG00000260273.1	RP11-425D10.10	5.28	1.99e-07	5.9e-05	0.32	0.23	Height;	chr6:109371573	chr6:109382795~109383666:+
LUAD	cis	rs2562456	0.761	rs35008138	ENSG00000268081.1	RP11-678G14.2	5.28	1.99e-07	5.9e-05	0.36	0.23	Pain;	chr19:21548822	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.833	rs2681388	ENSG00000268081.1	RP11-678G14.2	5.28	1.99e-07	5.9e-05	0.36	0.23	Pain;	chr19:21549451	chr19:21554640~21569237:-
LUAD	cis	rs516805	0.781	rs502103	ENSG00000279453.1	RP3-425C14.4	-5.28	1.99e-07	5.91e-05	-0.3	-0.23	Lymphocyte counts;	chr6:122446062	chr6:122436789~122439223:-
LUAD	cis	rs10129255	0.5	rs4774189	ENSG00000254174.1	IGHV1-12	5.28	1.99e-07	5.91e-05	0.16	0.23	Kawasaki disease;	chr14:106768275	chr14:106122420~106122709:-
LUAD	cis	rs9322193	0.884	rs10872647	ENSG00000268592.3	RAET1E-AS1	5.28	1.99e-07	5.91e-05	0.31	0.23	Lung cancer;	chr6:149758687	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.884	rs10872648	ENSG00000268592.3	RAET1E-AS1	5.28	1.99e-07	5.91e-05	0.31	0.23	Lung cancer;	chr6:149758699	chr6:149863494~149919507:+
LUAD	cis	rs75920871	0.528	rs7484045	ENSG00000254851.1	RP11-109L13.1	5.28	1.99e-07	5.92e-05	0.33	0.23	Subjective well-being;	chr11:117076174	chr11:117135528~117138582:+
LUAD	cis	rs80028505	0.908	rs56156688	ENSG00000271304.1	DPRXP2	5.28	1.99e-07	5.92e-05	0.48	0.23	Foot ulcer in diabetes and neuropathy;	chr6:36027856	chr6:35989515~35990436:-
LUAD	cis	rs4835473	0.932	rs7693772	ENSG00000251600.4	RP11-673E1.1	5.28	2e-07	5.92e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143965614	chr4:143912331~143982454:+
LUAD	cis	rs453301	0.658	rs13271797	ENSG00000253981.4	ALG1L13P	-5.28	2e-07	5.93e-05	-0.28	-0.23	Joint mobility (Beighton score);	chr8:9028444	chr8:8236003~8244667:-
LUAD	cis	rs4835473	0.742	rs1838519	ENSG00000251600.4	RP11-673E1.1	5.28	2e-07	5.93e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143972242	chr4:143912331~143982454:+
LUAD	cis	rs1707322	1	rs10890376	ENSG00000280836.1	AL355480.1	-5.28	2e-07	5.93e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940910	chr1:45581219~45581321:-
LUAD	cis	rs7811142	0.943	rs67196635	ENSG00000078319.8	PMS2P1	-5.28	2e-07	5.93e-05	-0.27	-0.23	Platelet count;	chr7:100427941	chr7:100320992~100341908:-
LUAD	cis	rs7811142	1	rs6962151	ENSG00000078319.8	PMS2P1	-5.28	2e-07	5.93e-05	-0.27	-0.23	Platelet count;	chr7:100430861	chr7:100320992~100341908:-
LUAD	cis	rs7811142	0.943	rs67483801	ENSG00000078319.8	PMS2P1	-5.28	2e-07	5.93e-05	-0.27	-0.23	Platelet count;	chr7:100434135	chr7:100320992~100341908:-
LUAD	cis	rs7811142	1	rs11761784	ENSG00000078319.8	PMS2P1	-5.28	2e-07	5.93e-05	-0.27	-0.23	Platelet count;	chr7:100442347	chr7:100320992~100341908:-
LUAD	cis	rs7811142	1	rs112317829	ENSG00000078319.8	PMS2P1	-5.28	2e-07	5.93e-05	-0.27	-0.23	Platelet count;	chr7:100445550	chr7:100320992~100341908:-
LUAD	cis	rs7811142	1	rs67239991	ENSG00000078319.8	PMS2P1	-5.28	2e-07	5.93e-05	-0.27	-0.23	Platelet count;	chr7:100448881	chr7:100320992~100341908:-
LUAD	cis	rs7811142	0.943	rs111493473	ENSG00000078319.8	PMS2P1	-5.28	2e-07	5.93e-05	-0.27	-0.23	Platelet count;	chr7:100452119	chr7:100320992~100341908:-
LUAD	cis	rs10761482	0.5	rs1938535	ENSG00000254271.1	RP11-131N11.4	5.28	2e-07	5.93e-05	0.26	0.23	Schizophrenia;	chr10:60514142	chr10:60734342~60741828:+
LUAD	cis	rs453301	0.686	rs4840389	ENSG00000253981.4	ALG1L13P	-5.28	2e-07	5.94e-05	-0.28	-0.23	Joint mobility (Beighton score);	chr8:9026993	chr8:8236003~8244667:-
LUAD	cis	rs9595908	0.785	rs2183873	ENSG00000212293.1	SNORA16	5.28	2e-07	5.94e-05	0.25	0.23	Body mass index;	chr13:32710508	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.785	rs9591261	ENSG00000212293.1	SNORA16	5.28	2e-07	5.94e-05	0.25	0.23	Body mass index;	chr13:32710989	chr13:32420390~32420516:-
LUAD	cis	rs2562456	0.724	rs58001930	ENSG00000268081.1	RP11-678G14.2	5.28	2.01e-07	5.96e-05	0.36	0.23	Pain;	chr19:21560061	chr19:21554640~21569237:-
LUAD	cis	rs1707322	1	rs785467	ENSG00000280836.1	AL355480.1	5.28	2.01e-07	5.96e-05	0.31	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055887	chr1:45581219~45581321:-
LUAD	cis	rs7017914	0.652	rs11987148	ENSG00000223220.1	Y_RNA	5.28	2.01e-07	5.96e-05	0.27	0.23	Bone mineral density;	chr8:70749075	chr8:70780914~70781008:-
LUAD	cis	rs75920871	0.528	rs11216245	ENSG00000254851.1	RP11-109L13.1	5.28	2.01e-07	5.96e-05	0.34	0.23	Subjective well-being;	chr11:117042486	chr11:117135528~117138582:+
LUAD	cis	rs6095360	0.727	rs17378391	ENSG00000222365.1	SNORD12B	-5.28	2.01e-07	5.96e-05	-0.26	-0.23	Intelligence (multi-trait analysis);	chr20:49156064	chr20:49280319~49280409:+
LUAD	cis	rs748404	0.65	rs556851	ENSG00000249839.1	AC011330.5	-5.27	2.01e-07	5.97e-05	-0.3	-0.23	Lung cancer;	chr15:43279021	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.697	rs567357	ENSG00000249839.1	AC011330.5	-5.27	2.01e-07	5.97e-05	-0.3	-0.23	Lung cancer;	chr15:43279192	chr15:43663654~43684339:-
LUAD	cis	rs10214930	0.671	rs9639553	ENSG00000235574.1	AC073150.6	5.27	2.01e-07	5.97e-05	0.28	0.23	Hypospadias;	chr7:27538548	chr7:27491682~27492765:-
LUAD	cis	rs61270009	0.908	rs780405	ENSG00000247828.6	TMEM161B-AS1	-5.27	2.01e-07	5.97e-05	-0.27	-0.23	Depressive symptoms;	chr5:88260522	chr5:88268895~88436685:+
LUAD	cis	rs7777677	0.925	rs4726546	ENSG00000244273.1	PGBD4P1	-5.27	2.01e-07	5.97e-05	-0.25	-0.23	Alcoholic chronic pancreatitis;	chr7:142660485	chr7:142722358~142722764:+
LUAD	cis	rs7777677	0.925	rs6956756	ENSG00000244273.1	PGBD4P1	-5.27	2.01e-07	5.97e-05	-0.25	-0.23	Alcoholic chronic pancreatitis;	chr7:142661832	chr7:142722358~142722764:+
LUAD	cis	rs7777677	0.889	rs6975391	ENSG00000244273.1	PGBD4P1	-5.27	2.01e-07	5.97e-05	-0.25	-0.23	Alcoholic chronic pancreatitis;	chr7:142662001	chr7:142722358~142722764:+
LUAD	cis	rs7777677	0.925	rs9655661	ENSG00000244273.1	PGBD4P1	-5.27	2.01e-07	5.97e-05	-0.25	-0.23	Alcoholic chronic pancreatitis;	chr7:142662291	chr7:142722358~142722764:+
LUAD	cis	rs7777677	0.888	rs9655574	ENSG00000244273.1	PGBD4P1	-5.27	2.01e-07	5.97e-05	-0.25	-0.23	Alcoholic chronic pancreatitis;	chr7:142662412	chr7:142722358~142722764:+
LUAD	cis	rs7777677	0.963	rs4726550	ENSG00000244273.1	PGBD4P1	-5.27	2.01e-07	5.97e-05	-0.25	-0.23	Alcoholic chronic pancreatitis;	chr7:142662932	chr7:142722358~142722764:+
LUAD	cis	rs7777677	0.963	rs7796324	ENSG00000244273.1	PGBD4P1	-5.27	2.01e-07	5.97e-05	-0.25	-0.23	Alcoholic chronic pancreatitis;	chr7:142663708	chr7:142722358~142722764:+
LUAD	cis	rs7617773	0.817	rs9818937	ENSG00000228638.1	FCF1P2	-5.27	2.01e-07	5.97e-05	-0.28	-0.23	Coronary artery disease;	chr3:48283791	chr3:48290793~48291375:-
LUAD	cis	rs6095360	0.727	rs34841991	ENSG00000222365.1	SNORD12B	-5.27	2.01e-07	5.97e-05	-0.26	-0.23	Intelligence (multi-trait analysis);	chr20:49130437	chr20:49280319~49280409:+
LUAD	cis	rs71636778	0.509	rs41303629	ENSG00000260063.1	RP5-968P14.2	-5.27	2.01e-07	5.97e-05	-0.43	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26731130	chr1:26692132~26694131:-
LUAD	cis	rs12468226	1	rs75040639	ENSG00000226261.1	AC064836.3	5.27	2.02e-07	5.98e-05	0.38	0.23	Urate levels;	chr2:202486973	chr2:202336024~202336727:-
LUAD	cis	rs2880765	0.805	rs11858817	ENSG00000259295.5	CSPG4P12	5.27	2.02e-07	5.98e-05	0.27	0.23	Coronary artery disease;	chr15:85488029	chr15:85191438~85213905:+
LUAD	cis	rs2880765	0.835	rs28874135	ENSG00000259295.5	CSPG4P12	5.27	2.02e-07	5.98e-05	0.27	0.23	Coronary artery disease;	chr15:85488272	chr15:85191438~85213905:+
LUAD	cis	rs2880765	0.835	rs11633604	ENSG00000259295.5	CSPG4P12	5.27	2.02e-07	5.98e-05	0.27	0.23	Coronary artery disease;	chr15:85488348	chr15:85191438~85213905:+
LUAD	cis	rs2880765	0.835	rs7164106	ENSG00000259295.5	CSPG4P12	5.27	2.02e-07	5.98e-05	0.27	0.23	Coronary artery disease;	chr15:85489359	chr15:85191438~85213905:+
LUAD	cis	rs2880765	0.835	rs1872074	ENSG00000259295.5	CSPG4P12	5.27	2.02e-07	5.98e-05	0.27	0.23	Coronary artery disease;	chr15:85489953	chr15:85191438~85213905:+
LUAD	cis	rs2880765	0.835	rs4842884	ENSG00000259295.5	CSPG4P12	5.27	2.02e-07	5.98e-05	0.27	0.23	Coronary artery disease;	chr15:85491943	chr15:85191438~85213905:+
LUAD	cis	rs17507216	0.628	rs4627310	ENSG00000255769.6	GOLGA2P10	-5.27	2.02e-07	5.98e-05	-0.31	-0.23	Excessive daytime sleepiness;	chr15:82708330	chr15:82472993~82513950:-
LUAD	cis	rs7083	1	rs655023	ENSG00000254851.1	RP11-109L13.1	5.27	2.02e-07	5.98e-05	0.3	0.23	Blood protein levels;	chr11:117256904	chr11:117135528~117138582:+
LUAD	cis	rs12468226	1	rs12472408	ENSG00000226261.1	AC064836.3	5.27	2.02e-07	5.98e-05	0.38	0.23	Urate levels;	chr2:202413973	chr2:202336024~202336727:-
LUAD	cis	rs910316	1	rs175512	ENSG00000259138.1	RP11-950C14.7	-5.27	2.02e-07	5.99e-05	-0.24	-0.23	Height;	chr14:75056679	chr14:75127153~75136930:+
LUAD	cis	rs61270009	0.955	rs12514004	ENSG00000247828.6	TMEM161B-AS1	5.27	2.02e-07	5.99e-05	0.27	0.23	Depressive symptoms;	chr5:88269979	chr5:88268895~88436685:+
LUAD	cis	rs2280018	0.963	rs11075255	ENSG00000188599.16	NPIPP1	-5.27	2.02e-07	5.99e-05	-0.19	-0.23	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072375	chr16:15104312~15123498:-
LUAD	cis	rs193541	0.586	rs11241662	ENSG00000263432.2	RN7SL689P	-5.27	2.02e-07	5.99e-05	-0.3	-0.23	Glucose homeostasis traits;	chr5:122846280	chr5:123022487~123022783:-
LUAD	cis	rs4143844	1	rs11071644	ENSG00000259251.2	RP11-643M14.1	5.27	2.02e-07	5.99e-05	0.41	0.23	Bipolar disorder and schizophrenia;	chr15:61969565	chr15:62060503~62062434:+
LUAD	cis	rs9807989	0.801	rs10176664	ENSG00000234389.1	AC007278.3	5.27	2.02e-07	6e-05	0.23	0.23	Asthma;	chr2:102359712	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.839	rs6543123	ENSG00000234389.1	AC007278.3	5.27	2.02e-07	6e-05	0.23	0.23	Asthma;	chr2:102360736	chr2:102438713~102440475:+
LUAD	cis	rs11089937	0.626	rs5757051	ENSG00000211638.2	IGLV8-61	5.27	2.02e-07	6e-05	0.26	0.23	Periodontitis (PAL4Q3);	chr22:22141753	chr22:22098700~22099212:+
LUAD	cis	rs600231	0.708	rs682845	ENSG00000245532.5	NEAT1	5.27	2.02e-07	6e-05	0.18	0.23	Bone mineral density;	chr11:65486730	chr11:65422774~65445540:+
LUAD	cis	rs67311347	0.544	rs9868700	ENSG00000223797.4	ENTPD3-AS1	5.27	2.03e-07	6e-05	0.24	0.23	Renal cell carcinoma;	chr3:40303917	chr3:40313802~40453329:-
LUAD	cis	rs5758511	0.514	rs5751240	ENSG00000205702.9	CYP2D7	5.27	2.03e-07	6e-05	0.24	0.23	Birth weight;	chr22:42199252	chr22:42140203~42144577:-
LUAD	cis	rs240993	0.909	rs11153279	ENSG00000271789.1	RP5-1112D6.7	5.27	2.03e-07	6.01e-05	0.27	0.23	Inflammatory skin disease;Psoriasis;	chr6:111266063	chr6:111297126~111298510:+
LUAD	cis	rs35160687	0.644	rs4832264	ENSG00000273080.1	RP11-301O19.1	-5.27	2.03e-07	6.01e-05	-0.26	-0.23	Night sleep phenotypes;	chr2:86259711	chr2:86195590~86196049:+
LUAD	cis	rs35160687	0.644	rs4832265	ENSG00000273080.1	RP11-301O19.1	-5.27	2.03e-07	6.01e-05	-0.26	-0.23	Night sleep phenotypes;	chr2:86261142	chr2:86195590~86196049:+
LUAD	cis	rs1816752	0.875	rs1050110	ENSG00000273628.1	RP11-756A22.7	5.27	2.03e-07	6.02e-05	0.27	0.23	Obesity-related traits;	chr13:24435347	chr13:24933006~24936796:+
LUAD	cis	rs7968440	0.808	rs2554862	ENSG00000200428.1	Y_RNA	-5.27	2.03e-07	6.02e-05	-0.3	-0.23	Fibrinogen;	chr12:50808263	chr12:50743568~50743684:+
LUAD	cis	rs10761482	0.5	rs2393644	ENSG00000254271.1	RP11-131N11.4	5.27	2.03e-07	6.02e-05	0.26	0.23	Schizophrenia;	chr10:60551516	chr10:60734342~60741828:+
LUAD	cis	rs2688608	0.592	rs7076585	ENSG00000271816.1	BMS1P4	5.27	2.03e-07	6.02e-05	0.2	0.23	Inflammatory bowel disease;	chr10:73743934	chr10:73699151~73730487:-
LUAD	cis	rs9992667	0.911	rs12332031	ENSG00000231160.8	KLF3-AS1	5.27	2.03e-07	6.02e-05	0.3	0.23	Eosinophil percentage of granulocytes;	chr4:38651881	chr4:38612701~38664883:-
LUAD	cis	rs2562456	0.874	rs2562408	ENSG00000268081.1	RP11-678G14.2	-5.27	2.03e-07	6.02e-05	-0.36	-0.23	Pain;	chr19:21527079	chr19:21554640~21569237:-
LUAD	cis	rs7044106	0.648	rs2031369	ENSG00000238181.2	AHCYP2	-5.27	2.03e-07	6.02e-05	-0.3	-0.23	Hip circumference adjusted for BMI;	chr9:120598016	chr9:120720673~120721972:+
LUAD	cis	rs867371	1	rs13380317	ENSG00000276710.3	CSPG4P8	5.27	2.03e-07	6.02e-05	0.22	0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214449	chr15:82459472~82477258:+
LUAD	cis	rs11669181	1	rs11669181	ENSG00000267147.2	CTC-548K16.1	5.27	2.04e-07	6.03e-05	0.27	0.23	Conotruncal heart defects (maternal effects);	chr19:14334326	chr19:14333743~14343916:+
LUAD	cis	rs944990	0.576	rs10821126	ENSG00000227603.1	RP11-165J3.6	5.27	2.04e-07	6.03e-05	0.26	0.23	Body mass index;	chr9:93436451	chr9:93435332~93437121:-
LUAD	cis	rs944990	0.576	rs10992731	ENSG00000227603.1	RP11-165J3.6	5.27	2.04e-07	6.03e-05	0.26	0.23	Body mass index;	chr9:93436816	chr9:93435332~93437121:-
LUAD	cis	rs17507216	0.718	rs4779034	ENSG00000255769.6	GOLGA2P10	-5.27	2.04e-07	6.04e-05	-0.29	-0.23	Excessive daytime sleepiness;	chr15:82576799	chr15:82472993~82513950:-
LUAD	cis	rs9992667	0.955	rs66709517	ENSG00000231160.8	KLF3-AS1	5.27	2.04e-07	6.04e-05	0.29	0.23	Eosinophil percentage of granulocytes;	chr4:38647772	chr4:38612701~38664883:-
LUAD	cis	rs9595908	0.746	rs9596075	ENSG00000212293.1	SNORA16	5.27	2.04e-07	6.04e-05	0.25	0.23	Body mass index;	chr13:32692147	chr13:32420390~32420516:-
LUAD	cis	rs9807989	0.729	rs10170583	ENSG00000234389.1	AC007278.3	5.27	2.04e-07	6.05e-05	0.22	0.23	Asthma;	chr2:102358304	chr2:102438713~102440475:+
LUAD	cis	rs10129255	0.5	rs34326748	ENSG00000254174.1	IGHV1-12	5.27	2.04e-07	6.05e-05	0.16	0.23	Kawasaki disease;	chr14:106782523	chr14:106122420~106122709:-
LUAD	cis	rs10129255	0.5	rs10143385	ENSG00000254174.1	IGHV1-12	5.27	2.04e-07	6.05e-05	0.16	0.23	Kawasaki disease;	chr14:106782559	chr14:106122420~106122709:-
LUAD	cis	rs2404602	1	rs12594541	ENSG00000259422.1	RP11-593F23.1	5.27	2.04e-07	6.05e-05	0.28	0.23	Blood metabolite levels;	chr15:76542027	chr15:76174891~76181486:-
LUAD	cis	rs10761482	0.5	rs7098650	ENSG00000254271.1	RP11-131N11.4	5.27	2.04e-07	6.05e-05	0.26	0.23	Schizophrenia;	chr10:60517921	chr10:60734342~60741828:+
LUAD	cis	rs2439831	0.85	rs60883262	ENSG00000249839.1	AC011330.5	-5.27	2.04e-07	6.05e-05	-0.46	-0.23	Lung cancer in ever smokers;	chr15:43784305	chr15:43663654~43684339:-
LUAD	cis	rs11651753	0.598	rs4794286	ENSG00000264920.1	RP11-6N17.4	-5.27	2.04e-07	6.05e-05	-0.29	-0.23	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47913231	chr17:47891255~47895812:-
LUAD	cis	rs875971	0.895	rs4145009	ENSG00000232559.3	GS1-124K5.12	-5.27	2.05e-07	6.06e-05	-0.28	-0.23	Aortic root size;	chr7:66261628	chr7:66554588~66576923:-
LUAD	cis	rs8031584	0.678	rs798086	ENSG00000270015.1	RP11-540B6.6	5.27	2.05e-07	6.06e-05	0.18	0.23	Huntington's disease progression;	chr15:30837008	chr15:30926514~30928407:+
LUAD	cis	rs7617773	0.817	rs3731513	ENSG00000228638.1	FCF1P2	-5.27	2.05e-07	6.06e-05	-0.28	-0.23	Coronary artery disease;	chr3:48178047	chr3:48290793~48291375:-
LUAD	cis	rs948562	0.69	rs17152616	ENSG00000280010.1	AP001350.4	5.27	2.05e-07	6.06e-05	0.35	0.23	Lymphoma;	chr11:58300849	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.69	rs58085299	ENSG00000280010.1	AP001350.4	5.27	2.05e-07	6.06e-05	0.35	0.23	Lymphoma;	chr11:58302836	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.637	rs12361789	ENSG00000280010.1	AP001350.4	5.27	2.05e-07	6.06e-05	0.35	0.23	Lymphoma;	chr11:58309816	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.69	rs113456492	ENSG00000280010.1	AP001350.4	5.27	2.05e-07	6.06e-05	0.35	0.23	Lymphoma;	chr11:58311351	chr11:58627435~58628528:+
LUAD	cis	rs7017914	0.69	rs17699685	ENSG00000223220.1	Y_RNA	5.27	2.05e-07	6.07e-05	0.27	0.23	Bone mineral density;	chr8:71066769	chr8:70780914~70781008:-
LUAD	cis	rs9341808	0.556	rs2223875	ENSG00000272129.1	RP11-250B2.6	5.27	2.05e-07	6.07e-05	0.29	0.23	Sitting height ratio;	chr6:80335735	chr6:80355424~80356859:+
LUAD	cis	rs9341808	0.587	rs3805859	ENSG00000272129.1	RP11-250B2.6	5.27	2.05e-07	6.07e-05	0.29	0.23	Sitting height ratio;	chr6:80339229	chr6:80355424~80356859:+
LUAD	cis	rs8100891	0.665	rs7259259	ENSG00000267213.4	AC007773.2	-5.27	2.05e-07	6.07e-05	-0.28	-0.23	Neuroticism;	chr19:32328935	chr19:32390050~32405560:-
LUAD	cis	rs4237845	0.611	rs10877036	ENSG00000257159.1	RP11-58A17.3	-5.27	2.05e-07	6.07e-05	-0.27	-0.23	Intelligence (multi-trait analysis);	chr12:57927867	chr12:57967058~57968399:+
LUAD	cis	rs9341808	0.5	rs2223873	ENSG00000272129.1	RP11-250B2.6	5.27	2.05e-07	6.07e-05	0.29	0.23	Sitting height ratio;	chr6:80338571	chr6:80355424~80356859:+
LUAD	cis	rs11976180	1	rs2951368	ENSG00000204959.4	ARHGEF34P	5.27	2.05e-07	6.07e-05	0.29	0.23	Obesity-related traits;	chr7:144055728	chr7:144272445~144286966:-
LUAD	cis	rs11976180	1	rs2961115	ENSG00000204959.4	ARHGEF34P	5.27	2.05e-07	6.07e-05	0.29	0.23	Obesity-related traits;	chr7:144056278	chr7:144272445~144286966:-
LUAD	cis	rs12468226	0.872	rs115187557	ENSG00000226261.1	AC064836.3	5.27	2.05e-07	6.07e-05	0.38	0.23	Urate levels;	chr2:202495351	chr2:202336024~202336727:-
LUAD	cis	rs6750795	0.87	rs6754952	ENSG00000181798.2	LINC00471	5.27	2.05e-07	6.08e-05	0.26	0.23	Height;	chr2:231516534	chr2:231508426~231514339:-
LUAD	cis	rs9926296	0.712	rs447735	ENSG00000260259.1	RP11-368I7.4	5.27	2.05e-07	6.08e-05	0.23	0.23	Vitiligo;	chr16:89667941	chr16:89682620~89686569:-
LUAD	cis	rs7580658	0.637	rs4662710	ENSG00000236682.1	AC068282.3	-5.27	2.06e-07	6.08e-05	-0.3	-0.23	Protein C levels;	chr2:127219241	chr2:127389130~127400580:+
LUAD	cis	rs1150668	0.799	rs1736891	ENSG00000219392.1	RP1-265C24.5	-5.27	2.06e-07	6.08e-05	-0.29	-0.23	Pubertal anthropometrics;	chr6:28219323	chr6:28115628~28116551:+
LUAD	cis	rs7208859	0.623	rs11657662	ENSG00000263603.1	CTD-2349P21.5	5.27	2.06e-07	6.09e-05	0.42	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30729469~30731202:+
LUAD	cis	rs11159086	0.793	rs1029703	ENSG00000259005.1	RP3-449M8.6	5.27	2.06e-07	6.09e-05	0.3	0.23	Advanced glycation end-product levels;	chr14:74473899	chr14:74474007~74474864:-
LUAD	cis	rs6570726	0.935	rs397418	ENSG00000235652.6	RP11-545I5.3	5.27	2.06e-07	6.09e-05	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145521226	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs419854	ENSG00000235652.6	RP11-545I5.3	5.27	2.06e-07	6.09e-05	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145522949	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs365658	ENSG00000235652.6	RP11-545I5.3	5.27	2.06e-07	6.09e-05	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145523452	chr6:145799409~145886585:+
LUAD	cis	rs2295359	0.892	rs11209004	ENSG00000275678.1	RP4-547N15.3	-5.27	2.06e-07	6.09e-05	-0.25	-0.23	Psoriasis;	chr1:67148249	chr1:67121605~67123956:-
LUAD	cis	rs11098499	0.71	rs6851130	ENSG00000248280.1	RP11-33B1.2	-5.27	2.06e-07	6.09e-05	-0.3	-0.23	Corneal astigmatism;	chr4:119212557	chr4:119440561~119450157:-
LUAD	cis	rs9595908	0.746	rs2301391	ENSG00000212293.1	SNORA16	5.27	2.06e-07	6.1e-05	0.25	0.23	Body mass index;	chr13:32668398	chr13:32420390~32420516:-
LUAD	cis	rs35740288	0.822	rs17637142	ENSG00000202081.1	RNU6-1280P	5.27	2.06e-07	6.1e-05	0.3	0.23	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85697272	chr15:85651522~85651628:-
LUAD	cis	rs2404602	0.583	rs2469542	ENSG00000259422.1	RP11-593F23.1	-5.27	2.06e-07	6.1e-05	-0.26	-0.23	Blood metabolite levels;	chr15:76265135	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.583	rs2456076	ENSG00000259422.1	RP11-593F23.1	-5.27	2.06e-07	6.1e-05	-0.26	-0.23	Blood metabolite levels;	chr15:76265212	chr15:76174891~76181486:-
LUAD	cis	rs71636778	0.509	rs56932185	ENSG00000260063.1	RP5-968P14.2	-5.27	2.06e-07	6.11e-05	-0.43	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26730152	chr1:26692132~26694131:-
LUAD	cis	rs1345301	0.518	rs56238602	ENSG00000234389.1	AC007278.3	-5.27	2.06e-07	6.11e-05	-0.22	-0.23	Waist circumference;	chr2:102246635	chr2:102438713~102440475:+
LUAD	cis	rs2562456	0.917	rs2562466	ENSG00000268081.1	RP11-678G14.2	-5.27	2.07e-07	6.11e-05	-0.36	-0.23	Pain;	chr19:21531402	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.917	rs2562468	ENSG00000268081.1	RP11-678G14.2	-5.27	2.07e-07	6.11e-05	-0.36	-0.23	Pain;	chr19:21532048	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.917	rs2562471	ENSG00000268081.1	RP11-678G14.2	-5.27	2.07e-07	6.11e-05	-0.36	-0.23	Pain;	chr19:21533017	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.917	rs2681377	ENSG00000268081.1	RP11-678G14.2	-5.27	2.07e-07	6.11e-05	-0.36	-0.23	Pain;	chr19:21533718	chr19:21554640~21569237:-
LUAD	cis	rs7122539	0.646	rs543191	ENSG00000213409.4	RP11-658F2.3	-5.27	2.07e-07	6.11e-05	-0.28	-0.23	HIV-1 susceptibility;	chr11:66816308	chr11:66761575~66762399:-
LUAD	cis	rs1707322	1	rs4074225	ENSG00000280836.1	AL355480.1	-5.27	2.07e-07	6.11e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45926692	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs4134387	ENSG00000280836.1	AL355480.1	-5.27	2.07e-07	6.11e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45929486	chr1:45581219~45581321:-
LUAD	cis	rs2243480	1	rs160655	ENSG00000230295.1	RP11-458F8.2	-5.27	2.07e-07	6.11e-05	-0.28	-0.23	Diabetic kidney disease;	chr7:66068227	chr7:66880708~66882981:+
LUAD	cis	rs12554020	0.792	rs79419498	ENSG00000227603.1	RP11-165J3.6	5.27	2.07e-07	6.13e-05	0.43	0.23	Schizophrenia;	chr9:93504701	chr9:93435332~93437121:-
LUAD	cis	rs7772486	0.754	rs697055	ENSG00000235652.6	RP11-545I5.3	5.27	2.07e-07	6.13e-05	0.24	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145682654	chr6:145799409~145886585:+
LUAD	cis	rs875971	0.522	rs1880556	ENSG00000164669.11	INTS4P1	-5.27	2.07e-07	6.13e-05	-0.28	-0.23	Aortic root size;	chr7:65967557	chr7:65141225~65234216:+
LUAD	cis	rs12468226	1	rs79919139	ENSG00000226261.1	AC064836.3	5.27	2.07e-07	6.13e-05	0.37	0.23	Urate levels;	chr2:202382786	chr2:202336024~202336727:-
LUAD	cis	rs673078	0.66	rs61945224	ENSG00000275409.1	RP11-131L12.4	-5.27	2.07e-07	6.13e-05	-0.36	-0.23	Glucose homeostasis traits;	chr12:118288623	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.66	rs61945225	ENSG00000275409.1	RP11-131L12.4	-5.27	2.07e-07	6.13e-05	-0.36	-0.23	Glucose homeostasis traits;	chr12:118288960	chr12:118430147~118430699:+
LUAD	cis	rs155076	0.711	rs4770129	ENSG00000233325.3	MIPEPP3	-5.27	2.08e-07	6.14e-05	-0.34	-0.23	White matter hyperintensity burden;	chr13:21307920	chr13:21298139~21306373:+
LUAD	cis	rs1345301	0.518	rs1558623	ENSG00000234389.1	AC007278.3	-5.27	2.08e-07	6.14e-05	-0.22	-0.23	Waist circumference;	chr2:102245942	chr2:102438713~102440475:+
LUAD	cis	rs2880765	0.835	rs4843063	ENSG00000259295.5	CSPG4P12	5.27	2.08e-07	6.14e-05	0.27	0.23	Coronary artery disease;	chr15:85505517	chr15:85191438~85213905:+
LUAD	cis	rs910316	1	rs4899544	ENSG00000259138.1	RP11-950C14.7	5.27	2.08e-07	6.14e-05	0.25	0.23	Height;	chr14:75079853	chr14:75127153~75136930:+
LUAD	cis	rs910316	1	rs4903279	ENSG00000259138.1	RP11-950C14.7	5.27	2.08e-07	6.14e-05	0.25	0.23	Height;	chr14:75079880	chr14:75127153~75136930:+
LUAD	cis	rs4143844	0.867	rs978141	ENSG00000259251.2	RP11-643M14.1	5.27	2.08e-07	6.15e-05	0.42	0.23	Bipolar disorder and schizophrenia;	chr15:61974584	chr15:62060503~62062434:+
LUAD	cis	rs910316	1	rs3742773	ENSG00000259138.1	RP11-950C14.7	5.27	2.08e-07	6.15e-05	0.25	0.23	Height;	chr14:75112940	chr14:75127153~75136930:+
LUAD	cis	rs11098499	0.739	rs9884728	ENSG00000248280.1	RP11-33B1.2	-5.27	2.08e-07	6.16e-05	-0.29	-0.23	Corneal astigmatism;	chr4:119205924	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.739	rs2203039	ENSG00000248280.1	RP11-33B1.2	-5.27	2.08e-07	6.16e-05	-0.29	-0.23	Corneal astigmatism;	chr4:119211192	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.739	rs7441137	ENSG00000248280.1	RP11-33B1.2	-5.27	2.08e-07	6.16e-05	-0.29	-0.23	Corneal astigmatism;	chr4:119212066	chr4:119440561~119450157:-
LUAD	cis	rs3750965	0.806	rs7107680	ENSG00000260895.1	RP11-554A11.7	5.27	2.09e-07	6.16e-05	0.27	0.23	Hair color;	chr11:69092426	chr11:69103493~69109094:+
LUAD	cis	rs4835473	0.801	rs76574827	ENSG00000251600.4	RP11-673E1.1	-5.27	2.09e-07	6.16e-05	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143737303	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.832	rs62337616	ENSG00000251600.4	RP11-673E1.1	-5.27	2.09e-07	6.16e-05	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143737307	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.832	rs66717029	ENSG00000251600.4	RP11-673E1.1	-5.27	2.09e-07	6.16e-05	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143737318	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.864	rs17750354	ENSG00000251600.4	RP11-673E1.1	-5.27	2.09e-07	6.16e-05	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143737352	chr4:143912331~143982454:+
LUAD	cis	rs75422866	0.51	rs73105845	ENSG00000257433.4	RP1-197B17.3	5.27	2.09e-07	6.17e-05	0.51	0.23	Pneumonia;	chr12:47741824	chr12:47706085~47742294:+
LUAD	cis	rs4835473	0.932	rs1849112	ENSG00000251600.4	RP11-673E1.1	5.27	2.09e-07	6.17e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143962502	chr4:143912331~143982454:+
LUAD	cis	rs4722166	0.599	rs7776857	ENSG00000179428.2	AC073072.5	-5.27	2.09e-07	6.17e-05	-0.31	-0.23	Lung cancer;	chr7:22715149	chr7:22725395~22727620:-
LUAD	cis	rs875971	0.543	rs801191	ENSG00000237310.1	GS1-124K5.4	-5.27	2.09e-07	6.18e-05	-0.24	-0.23	Aortic root size;	chr7:66567968	chr7:66493706~66495474:+
LUAD	cis	rs4835473	0.864	rs1597446	ENSG00000251600.4	RP11-673E1.1	5.27	2.09e-07	6.18e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143708338	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.835	rs1450247	ENSG00000251600.4	RP11-673E1.1	5.27	2.09e-07	6.18e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143708529	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.897	rs6537171	ENSG00000251600.4	RP11-673E1.1	5.27	2.09e-07	6.18e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143709222	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.897	rs6832722	ENSG00000251600.4	RP11-673E1.1	5.27	2.09e-07	6.18e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143709430	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.897	rs6832749	ENSG00000251600.4	RP11-673E1.1	5.27	2.09e-07	6.18e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143709473	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.897	rs6831477	ENSG00000251600.4	RP11-673E1.1	5.27	2.09e-07	6.18e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143709487	chr4:143912331~143982454:+
LUAD	cis	rs516805	0.528	rs2606628	ENSG00000279453.1	RP3-425C14.4	-5.27	2.09e-07	6.18e-05	-0.31	-0.23	Lymphocyte counts;	chr6:122097460	chr6:122436789~122439223:-
LUAD	cis	rs9487094	0.961	rs9480957	ENSG00000260273.1	RP11-425D10.10	5.27	2.09e-07	6.18e-05	0.32	0.23	Height;	chr6:109430398	chr6:109382795~109383666:+
LUAD	cis	rs1008375	0.866	rs2109518	ENSG00000249502.1	AC006160.5	-5.27	2.09e-07	6.19e-05	-0.23	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17570539	chr4:17587467~17614571:-
LUAD	cis	rs2404602	0.735	rs1607017	ENSG00000259422.1	RP11-593F23.1	-5.27	2.1e-07	6.19e-05	-0.3	-0.23	Blood metabolite levels;	chr15:76434124	chr15:76174891~76181486:-
LUAD	cis	rs7826238	0.539	rs2945891	ENSG00000253981.4	ALG1L13P	5.27	2.1e-07	6.21e-05	0.27	0.23	Systolic blood pressure;	chr8:8297953	chr8:8236003~8244667:-
LUAD	cis	rs2919009	0.664	rs7906521	ENSG00000271670.1	RP11-95I16.4	5.27	2.11e-07	6.22e-05	0.31	0.23	Obesity-related traits;	chr10:120927034	chr10:120879256~120880667:-
LUAD	cis	rs2562456	0.755	rs2914646	ENSG00000268081.1	RP11-678G14.2	-5.27	2.11e-07	6.22e-05	-0.36	-0.23	Pain;	chr19:21454359	chr19:21554640~21569237:-
LUAD	cis	rs193541	0.593	rs30042	ENSG00000263432.2	RN7SL689P	5.27	2.11e-07	6.22e-05	0.31	0.23	Glucose homeostasis traits;	chr5:122936946	chr5:123022487~123022783:-
LUAD	cis	rs6687821	0.515	rs10873819	ENSG00000267734.1	RP4-604K5.3	5.27	2.11e-07	6.22e-05	0.28	0.23	Yeast infection;	chr1:87069512	chr1:86932199~86934891:-
LUAD	cis	rs6543140	0.964	rs1523206	ENSG00000234389.1	AC007278.3	5.27	2.11e-07	6.22e-05	0.23	0.23	Blood protein levels;	chr2:102453715	chr2:102438713~102440475:+
LUAD	cis	rs6543140	0.964	rs1523205	ENSG00000234389.1	AC007278.3	5.27	2.11e-07	6.22e-05	0.23	0.23	Blood protein levels;	chr2:102453716	chr2:102438713~102440475:+
LUAD	cis	rs9595908	0.606	rs7988462	ENSG00000212293.1	SNORA16	5.27	2.11e-07	6.23e-05	0.25	0.23	Body mass index;	chr13:32806701	chr13:32420390~32420516:-
LUAD	cis	rs67311347	0.568	rs9864544	ENSG00000223797.4	ENTPD3-AS1	5.27	2.11e-07	6.23e-05	0.25	0.23	Renal cell carcinoma;	chr3:40294713	chr3:40313802~40453329:-
LUAD	cis	rs1008375	0.966	rs7658240	ENSG00000249502.1	AC006160.5	5.27	2.11e-07	6.23e-05	0.23	0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17587327	chr4:17587467~17614571:-
LUAD	cis	rs2524005	1	rs2524005	ENSG00000281831.1	HCP5B	5.27	2.11e-07	6.23e-05	0.33	0.23	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29871895~29873783:-
LUAD	cis	rs11603023	0.967	rs494560	ENSG00000255239.1	AP002954.6	-5.27	2.11e-07	6.24e-05	-0.27	-0.23	Cholesterol, total;	chr11:118650844	chr11:118688039~118690600:-
LUAD	cis	rs155076	0.711	rs4769158	ENSG00000233325.3	MIPEPP3	-5.27	2.12e-07	6.24e-05	-0.34	-0.23	White matter hyperintensity burden;	chr13:21307836	chr13:21298139~21306373:+
LUAD	cis	rs155076	0.625	rs4769159	ENSG00000233325.3	MIPEPP3	-5.27	2.12e-07	6.24e-05	-0.34	-0.23	White matter hyperintensity burden;	chr13:21307839	chr13:21298139~21306373:+
LUAD	cis	rs11089937	0.597	rs5757007	ENSG00000211638.2	IGLV8-61	-5.26	2.12e-07	6.26e-05	-0.28	-0.23	Periodontitis (PAL4Q3);	chr22:22135167	chr22:22098700~22099212:+
LUAD	cis	rs1707322	1	rs34444543	ENSG00000234329.1	RP11-767N6.2	5.26	2.12e-07	6.26e-05	0.24	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893190	chr1:45651039~45651826:-
LUAD	cis	rs12554020	0.786	rs79804179	ENSG00000227603.1	RP11-165J3.6	5.26	2.12e-07	6.26e-05	0.45	0.23	Schizophrenia;	chr9:93486200	chr9:93435332~93437121:-
LUAD	cis	rs61270009	0.955	rs2410766	ENSG00000247828.6	TMEM161B-AS1	5.26	2.12e-07	6.26e-05	0.27	0.23	Depressive symptoms;	chr5:88405666	chr5:88268895~88436685:+
LUAD	cis	rs875971	0.597	rs11771318	ENSG00000237310.1	GS1-124K5.4	-5.26	2.12e-07	6.26e-05	-0.26	-0.23	Aortic root size;	chr7:66597493	chr7:66493706~66495474:+
LUAD	cis	rs6921919	0.789	rs17301128	ENSG00000216901.1	AL022393.7	5.26	2.12e-07	6.26e-05	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28340257	chr6:28176188~28176674:+
LUAD	cis	rs35740288	0.77	rs67253156	ENSG00000202081.1	RNU6-1280P	5.26	2.12e-07	6.26e-05	0.28	0.23	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85561814	chr15:85651522~85651628:-
LUAD	cis	rs7927592	0.763	rs10791982	ENSG00000212093.1	AP000807.1	-5.26	2.12e-07	6.26e-05	-0.23	-0.23	Total body bone mineral density;	chr11:68570196	chr11:68506083~68506166:-
LUAD	cis	rs1062177	1	rs892006	ENSG00000253921.1	CTB-113P19.3	-5.26	2.12e-07	6.26e-05	-0.34	-0.23	Preschool internalizing problems;	chr5:151801329	chr5:151753992~151767247:+
LUAD	cis	rs858239	0.6	rs4409314	ENSG00000230042.1	AK3P3	-5.26	2.12e-07	6.27e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23129178~23129841:+
LUAD	cis	rs6687758	1	rs12135286	ENSG00000228437.4	RP11-400N13.2	5.26	2.12e-07	6.27e-05	0.35	0.23	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222045419	chr1:221966341~221984964:+
LUAD	cis	rs9900062	1	rs2521879	ENSG00000270714.1	MINOS1P2	-5.26	2.13e-07	6.27e-05	-0.35	-0.23	QT interval;	chr17:64746560	chr17:64747264~64747492:-
LUAD	cis	rs9595908	0.671	rs12428598	ENSG00000212293.1	SNORA16	5.26	2.13e-07	6.28e-05	0.25	0.23	Body mass index;	chr13:32684839	chr13:32420390~32420516:-
LUAD	cis	rs783540	0.5	rs783541	ENSG00000255769.6	GOLGA2P10	5.26	2.13e-07	6.28e-05	0.28	0.23	Schizophrenia;	chr15:82586310	chr15:82472993~82513950:-
LUAD	cis	rs4713118	1	rs1139226	ENSG00000219392.1	RP1-265C24.5	-5.26	2.13e-07	6.28e-05	-0.31	-0.23	Parkinson's disease;	chr6:27707511	chr6:28115628~28116551:+
LUAD	cis	rs9549367	0.756	rs3861723	ENSG00000269125.1	RP11-98F14.11	-5.26	2.13e-07	6.28e-05	-0.29	-0.23	Platelet distribution width;	chr13:113256612	chr13:113165002~113165183:-
LUAD	cis	rs1823874	0.677	rs4381582	ENSG00000182397.13	DNM1P46	-5.26	2.13e-07	6.28e-05	-0.29	-0.23	IgG glycosylation;	chr15:99820308	chr15:99790156~99806927:-
LUAD	cis	rs10129255	0.5	rs8022547	ENSG00000254174.1	IGHV1-12	5.26	2.13e-07	6.29e-05	0.16	0.23	Kawasaki disease;	chr14:106781985	chr14:106122420~106122709:-
LUAD	cis	rs1075265	0.933	rs11888384	ENSG00000233266.1	HMGB1P31	5.26	2.13e-07	6.29e-05	0.29	0.23	Chronotype;Morning vs. evening chronotype;	chr2:54110984	chr2:54051334~54051760:+
LUAD	cis	rs7017914	0.644	rs55970604	ENSG00000223220.1	Y_RNA	5.26	2.13e-07	6.29e-05	0.27	0.23	Bone mineral density;	chr8:71065538	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.644	rs6472564	ENSG00000223220.1	Y_RNA	5.26	2.13e-07	6.29e-05	0.27	0.23	Bone mineral density;	chr8:71066165	chr8:70780914~70781008:-
LUAD	cis	rs1546924	0.57	rs197413	ENSG00000227811.2	FAM212B-AS1	-5.26	2.13e-07	6.29e-05	-0.29	-0.23	Body mass index;	chr1:111766350	chr1:111739841~111747798:+
LUAD	cis	rs2688608	0.592	rs10762559	ENSG00000271816.1	BMS1P4	5.26	2.13e-07	6.29e-05	0.2	0.23	Inflammatory bowel disease;	chr10:73726695	chr10:73699151~73730487:-
LUAD	cis	rs12908161	0.959	rs17534709	ENSG00000225151.9	GOLGA2P7	-5.26	2.13e-07	6.29e-05	-0.32	-0.23	Schizophrenia;	chr15:84771166	chr15:84199311~84230136:-
LUAD	cis	rs9928842	0.765	rs8055472	ENSG00000280152.1	RP11-331F4.5	5.26	2.13e-07	6.3e-05	0.26	0.23	Alcoholic chronic pancreatitis;	chr16:75191650	chr16:75245994~75250077:-
LUAD	cis	rs1707322	1	rs12097761	ENSG00000280836.1	AL355480.1	-5.26	2.13e-07	6.3e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825490	chr1:45581219~45581321:-
LUAD	cis	rs875971	0.522	rs2949690	ENSG00000224316.1	RP11-479O9.2	-5.26	2.14e-07	6.3e-05	-0.24	-0.23	Aortic root size;	chr7:66018255	chr7:65773620~65802067:+
LUAD	cis	rs17826219	0.561	rs562840	ENSG00000263603.1	CTD-2349P21.5	-5.26	2.14e-07	6.31e-05	-0.34	-0.23	Body mass index;	chr17:30622372	chr17:30729469~30731202:+
LUAD	cis	rs8177876	0.915	rs8059692	ENSG00000261061.1	RP11-303E16.2	-5.26	2.14e-07	6.31e-05	-0.37	-0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81096889	chr16:81030770~81031485:+
LUAD	cis	rs6570726	0.902	rs396681	ENSG00000235652.6	RP11-545I5.3	5.26	2.14e-07	6.32e-05	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145532467	chr6:145799409~145886585:+
LUAD	cis	rs1008375	0.932	rs6449315	ENSG00000249502.1	AC006160.5	-5.26	2.14e-07	6.32e-05	-0.23	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17588596	chr4:17587467~17614571:-
LUAD	cis	rs6543140	0.964	rs62154972	ENSG00000234389.1	AC007278.3	5.26	2.14e-07	6.32e-05	0.23	0.23	Blood protein levels;	chr2:102432278	chr2:102438713~102440475:+
LUAD	cis	rs11976180	1	rs2951372	ENSG00000204959.4	ARHGEF34P	5.26	2.14e-07	6.32e-05	0.29	0.23	Obesity-related traits;	chr7:144052410	chr7:144272445~144286966:-
LUAD	cis	rs2255336	0.817	rs12318583	ENSG00000245648.1	RP11-277P12.20	-5.26	2.14e-07	6.32e-05	-0.36	-0.23	Blood protein levels;	chr12:10426485	chr12:10363769~10398506:+
LUAD	cis	rs2735413	0.599	rs76440854	ENSG00000276007.1	RP11-358L22.3	5.26	2.15e-07	6.33e-05	0.33	0.23	Systolic blood pressure (alcohol consumption interaction);	chr16:78046986	chr16:78123243~78124332:+
LUAD	cis	rs17772222	0.958	rs1816372	ENSG00000258983.2	RP11-507K2.2	5.26	2.15e-07	6.34e-05	0.29	0.23	Coronary artery calcification;	chr14:88507033	chr14:88499334~88515502:+
LUAD	cis	rs2880765	0.835	rs4360874	ENSG00000259295.5	CSPG4P12	5.26	2.15e-07	6.34e-05	0.27	0.23	Coronary artery disease;	chr15:85497589	chr15:85191438~85213905:+
LUAD	cis	rs875971	0.862	rs11763189	ENSG00000232559.3	GS1-124K5.12	5.26	2.15e-07	6.34e-05	0.28	0.23	Aortic root size;	chr7:66518542	chr7:66554588~66576923:-
LUAD	cis	rs1502844	0.525	rs3114606	ENSG00000250682.4	LINC00491	-5.26	2.15e-07	6.35e-05	-0.28	-0.23	Schizophrenia;	chr5:102636062	chr5:102609156~102671559:-
LUAD	cis	rs10754283	0.967	rs7523046	ENSG00000231613.1	RP5-943J3.1	5.26	2.16e-07	6.35e-05	0.24	0.23	Amyotrophic lateral sclerosis (sporadic);	chr1:89643940	chr1:89788914~89790492:+
LUAD	cis	rs10754283	0.967	rs7523518	ENSG00000231613.1	RP5-943J3.1	5.26	2.16e-07	6.35e-05	0.24	0.23	Amyotrophic lateral sclerosis (sporadic);	chr1:89644451	chr1:89788914~89790492:+
LUAD	cis	rs673078	0.66	rs61945190	ENSG00000275409.1	RP11-131L12.4	-5.26	2.16e-07	6.36e-05	-0.33	-0.23	Glucose homeostasis traits;	chr12:118231345	chr12:118430147~118430699:+
LUAD	cis	rs891378	0.959	rs11120586	ENSG00000274245.1	RP11-357P18.2	-5.26	2.16e-07	6.36e-05	-0.28	-0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207268152	chr1:207372559~207373252:+
LUAD	cis	rs846111	1	rs846111	ENSG00000225077.2	LINC00337	-5.26	2.16e-07	6.36e-05	-0.27	-0.23	QT interval;	chr1:6219310	chr1:6236240~6239444:+
LUAD	cis	rs2980439	0.607	rs2980419	ENSG00000253981.4	ALG1L13P	5.26	2.16e-07	6.36e-05	0.27	0.23	Neuroticism;	chr8:8256619	chr8:8236003~8244667:-
LUAD	cis	rs10129255	0.5	rs8006888	ENSG00000254174.1	IGHV1-12	5.26	2.16e-07	6.37e-05	0.16	0.23	Kawasaki disease;	chr14:106782219	chr14:106122420~106122709:-
LUAD	cis	rs10129255	0.536	rs10142951	ENSG00000254174.1	IGHV1-12	5.26	2.16e-07	6.37e-05	0.16	0.23	Kawasaki disease;	chr14:106782337	chr14:106122420~106122709:-
LUAD	cis	rs10246939	0.543	rs9640204	ENSG00000270923.1	TAS2R6P	-5.26	2.16e-07	6.37e-05	-0.25	-0.23	Bitter taste perception;	chr7:141844300	chr7:141787815~141788640:+
LUAD	cis	rs10246939	0.543	rs9640359	ENSG00000270923.1	TAS2R6P	-5.26	2.16e-07	6.37e-05	-0.25	-0.23	Bitter taste perception;	chr7:141844399	chr7:141787815~141788640:+
LUAD	cis	rs853679	0.607	rs200489	ENSG00000219392.1	RP1-265C24.5	-5.26	2.17e-07	6.38e-05	-0.45	-0.23	Depression;	chr6:27830479	chr6:28115628~28116551:+
LUAD	cis	rs7829975	0.714	rs7823757	ENSG00000173295.6	FAM86B3P	5.26	2.17e-07	6.38e-05	0.24	0.23	Mood instability;	chr8:8812667	chr8:8228595~8244865:+
LUAD	cis	rs801193	0.901	rs4273746	ENSG00000237310.1	GS1-124K5.4	-5.26	2.17e-07	6.39e-05	-0.26	-0.23	Aortic root size;	chr7:66836124	chr7:66493706~66495474:+
LUAD	cis	rs4604732	0.631	rs12091081	ENSG00000227135.1	GCSAML-AS1	-5.26	2.17e-07	6.39e-05	-0.38	-0.23	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247459762	chr1:247524679~247526752:-
LUAD	cis	rs875971	0.54	rs1723268	ENSG00000164669.11	INTS4P1	-5.26	2.17e-07	6.39e-05	-0.28	-0.23	Aortic root size;	chr7:66008093	chr7:65141225~65234216:+
LUAD	cis	rs9500256	0.625	rs1936228	ENSG00000266579.1	RP1-71H19.2	-5.26	2.17e-07	6.4e-05	-0.28	-0.23	Eosinophilic esophagitis (pediatric);	chr6:58018478	chr6:57493855~57497691:+
LUAD	cis	rs673078	0.607	rs61943451	ENSG00000275409.1	RP11-131L12.4	-5.26	2.17e-07	6.4e-05	-0.32	-0.23	Glucose homeostasis traits;	chr12:118438929	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.518	rs61943452	ENSG00000275409.1	RP11-131L12.4	-5.26	2.17e-07	6.4e-05	-0.32	-0.23	Glucose homeostasis traits;	chr12:118438990	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs61943454	ENSG00000275409.1	RP11-131L12.4	-5.26	2.17e-07	6.4e-05	-0.32	-0.23	Glucose homeostasis traits;	chr12:118439140	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.517	rs61943455	ENSG00000275409.1	RP11-131L12.4	-5.26	2.17e-07	6.4e-05	-0.32	-0.23	Glucose homeostasis traits;	chr12:118439414	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs73207566	ENSG00000275409.1	RP11-131L12.4	-5.26	2.17e-07	6.4e-05	-0.32	-0.23	Glucose homeostasis traits;	chr12:118439471	chr12:118430147~118430699:+
LUAD	cis	rs4835473	0.897	rs4054616	ENSG00000251600.4	RP11-673E1.1	5.26	2.17e-07	6.4e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143837472	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.897	rs2323325	ENSG00000251600.4	RP11-673E1.1	5.26	2.17e-07	6.4e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143837561	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.8	rs4835330	ENSG00000251600.4	RP11-673E1.1	5.26	2.17e-07	6.4e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143846303	chr4:143912331~143982454:+
LUAD	cis	rs858239	0.636	rs28706766	ENSG00000226816.2	AC005082.12	5.26	2.17e-07	6.4e-05	0.3	0.23	Cerebrospinal fluid biomarker levels;	chr7:23130215	chr7:23206013~23208045:+
LUAD	cis	rs7829975	0.714	rs59046059	ENSG00000253893.2	FAM85B	-5.26	2.17e-07	6.4e-05	-0.3	-0.23	Mood instability;	chr8:8813226	chr8:8167819~8226614:-
LUAD	cis	rs2562456	1	rs2562456	ENSG00000268081.1	RP11-678G14.2	5.26	2.18e-07	6.41e-05	0.34	0.23	Pain;	chr19:21483408	chr19:21554640~21569237:-
LUAD	cis	rs4908768	0.535	rs2784738	ENSG00000232912.4	RP5-1115A15.1	-5.26	2.18e-07	6.41e-05	-0.24	-0.23	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8406157	chr1:8424645~8434838:+
LUAD	cis	rs4908768	0.535	rs2748456	ENSG00000232912.4	RP5-1115A15.1	-5.26	2.18e-07	6.41e-05	-0.24	-0.23	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8406690	chr1:8424645~8434838:+
LUAD	cis	rs10754283	0.967	rs2002883	ENSG00000231613.1	RP5-943J3.1	5.26	2.18e-07	6.42e-05	0.23	0.23	Amyotrophic lateral sclerosis (sporadic);	chr1:89640279	chr1:89788914~89790492:+
LUAD	cis	rs556990	0.574	rs473598	ENSG00000269125.1	RP11-98F14.11	-5.26	2.19e-07	6.43e-05	-0.31	-0.23	Blood protein levels;	chr13:113146875	chr13:113165002~113165183:-
LUAD	cis	rs7122539	0.646	rs569818	ENSG00000213409.4	RP11-658F2.3	-5.26	2.19e-07	6.43e-05	-0.28	-0.23	HIV-1 susceptibility;	chr11:66803278	chr11:66761575~66762399:-
LUAD	cis	rs9992667	1	rs68191221	ENSG00000231160.8	KLF3-AS1	5.26	2.19e-07	6.44e-05	0.3	0.23	Eosinophil percentage of granulocytes;	chr4:38675441	chr4:38612701~38664883:-
LUAD	cis	rs9860428	0.564	rs9821278	ENSG00000242770.2	RP11-180K7.1	5.26	2.19e-07	6.44e-05	0.24	0.23	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112797037	chr3:112802478~112812819:+
LUAD	cis	rs67311347	0.544	rs13098483	ENSG00000223797.4	ENTPD3-AS1	5.26	2.19e-07	6.45e-05	0.24	0.23	Renal cell carcinoma;	chr3:40301252	chr3:40313802~40453329:-
LUAD	cis	rs80028505	0.908	rs16884919	ENSG00000271304.1	DPRXP2	-5.26	2.19e-07	6.45e-05	-0.46	-0.23	Foot ulcer in diabetes and neuropathy;	chr6:36103740	chr6:35989515~35990436:-
LUAD	cis	rs67311347	0.635	rs73071706	ENSG00000223797.4	ENTPD3-AS1	5.26	2.19e-07	6.46e-05	0.25	0.23	Renal cell carcinoma;	chr3:40246699	chr3:40313802~40453329:-
LUAD	cis	rs67311347	0.668	rs73071710	ENSG00000223797.4	ENTPD3-AS1	5.26	2.19e-07	6.46e-05	0.25	0.23	Renal cell carcinoma;	chr3:40247096	chr3:40313802~40453329:-
LUAD	cis	rs4591358	0.549	rs10200021	ENSG00000223466.1	AC064834.2	-5.26	2.19e-07	6.46e-05	-0.32	-0.23	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195549863	chr2:195533035~195538681:+
LUAD	cis	rs1008375	0.931	rs10939734	ENSG00000249502.1	AC006160.5	-5.26	2.2e-07	6.46e-05	-0.23	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17569086	chr4:17587467~17614571:-
LUAD	cis	rs910316	1	rs12435391	ENSG00000259138.1	RP11-950C14.7	5.26	2.2e-07	6.48e-05	0.25	0.23	Height;	chr14:75135034	chr14:75127153~75136930:+
LUAD	cis	rs80028505	1	rs80028505	ENSG00000271304.1	DPRXP2	5.26	2.2e-07	6.48e-05	0.47	0.23	Foot ulcer in diabetes and neuropathy;	chr6:36030611	chr6:35989515~35990436:-
LUAD	cis	rs80028505	0.908	rs6932598	ENSG00000271304.1	DPRXP2	5.26	2.2e-07	6.48e-05	0.47	0.23	Foot ulcer in diabetes and neuropathy;	chr6:36031303	chr6:35989515~35990436:-
LUAD	cis	rs7811142	0.943	rs111757992	ENSG00000078319.8	PMS2P1	-5.26	2.2e-07	6.48e-05	-0.27	-0.23	Platelet count;	chr7:100418731	chr7:100320992~100341908:-
LUAD	cis	rs17711722	0.51	rs11767457	ENSG00000234585.5	CCT6P3	5.26	2.2e-07	6.48e-05	0.22	0.23	Calcium levels;	chr7:65825628	chr7:65038354~65074713:+
LUAD	cis	rs453301	0.653	rs7005133	ENSG00000253893.2	FAM85B	-5.26	2.21e-07	6.49e-05	-0.29	-0.23	Joint mobility (Beighton score);	chr8:9043712	chr8:8167819~8226614:-
LUAD	cis	rs71636778	0.509	rs34216334	ENSG00000260063.1	RP5-968P14.2	-5.26	2.21e-07	6.49e-05	-0.42	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26736928	chr1:26692132~26694131:-
LUAD	cis	rs10246939	0.579	rs17133534	ENSG00000228775.6	WEE2-AS1	5.26	2.21e-07	6.49e-05	0.28	0.23	Bitter taste perception;	chr7:141860855	chr7:141704338~141738346:-
LUAD	cis	rs10754283	0.967	rs4658302	ENSG00000231613.1	RP5-943J3.1	5.26	2.21e-07	6.5e-05	0.23	0.23	Amyotrophic lateral sclerosis (sporadic);	chr1:89637777	chr1:89788914~89790492:+
LUAD	cis	rs10754283	0.967	rs7513928	ENSG00000231613.1	RP5-943J3.1	5.26	2.21e-07	6.5e-05	0.23	0.23	Amyotrophic lateral sclerosis (sporadic);	chr1:89639275	chr1:89788914~89790492:+
LUAD	cis	rs7829975	0.593	rs2979241	ENSG00000253893.2	FAM85B	-5.26	2.21e-07	6.5e-05	-0.29	-0.23	Mood instability;	chr8:8445843	chr8:8167819~8226614:-
LUAD	cis	rs875971	0.862	rs6944374	ENSG00000222364.1	RNU6-96P	5.26	2.21e-07	6.5e-05	0.26	0.23	Aortic root size;	chr7:66221942	chr7:66395191~66395286:+
LUAD	cis	rs2286503	0.752	rs6461669	ENSG00000226329.2	AC005682.6	5.26	2.21e-07	6.5e-05	0.3	0.23	Fibrinogen;	chr7:22818447	chr7:22863874~22881350:-
LUAD	cis	rs9341808	0.586	rs3805869	ENSG00000272129.1	RP11-250B2.6	5.26	2.21e-07	6.51e-05	0.29	0.23	Sitting height ratio;	chr6:80336200	chr6:80355424~80356859:+
LUAD	cis	rs4706831	0.663	rs1984242	ENSG00000272129.1	RP11-250B2.6	5.26	2.21e-07	6.51e-05	0.29	0.23	Joint mobility (Beighton score);	chr6:80341528	chr6:80355424~80356859:+
LUAD	cis	rs10754283	0.967	rs1317864	ENSG00000231613.1	RP5-943J3.1	5.26	2.21e-07	6.51e-05	0.23	0.23	Amyotrophic lateral sclerosis (sporadic);	chr1:89639889	chr1:89788914~89790492:+
LUAD	cis	rs10754283	0.967	rs2390763	ENSG00000231613.1	RP5-943J3.1	5.26	2.21e-07	6.51e-05	0.23	0.23	Amyotrophic lateral sclerosis (sporadic);	chr1:89640129	chr1:89788914~89790492:+
LUAD	cis	rs875971	0.862	rs1612452	ENSG00000237310.1	GS1-124K5.4	-5.26	2.21e-07	6.51e-05	-0.26	-0.23	Aortic root size;	chr7:66108909	chr7:66493706~66495474:+
LUAD	cis	rs394563	0.589	rs1900300	ENSG00000231760.4	RP11-350J20.5	-5.26	2.21e-07	6.51e-05	-0.29	-0.23	Dupuytren's disease;	chr6:149320491	chr6:149796151~149826294:-
LUAD	cis	rs2439831	0.85	rs10438303	ENSG00000249839.1	AC011330.5	-5.26	2.21e-07	6.51e-05	-0.47	-0.23	Lung cancer in ever smokers;	chr15:43724219	chr15:43663654~43684339:-
LUAD	cis	rs41307935	0.73	rs12753968	ENSG00000260063.1	RP5-968P14.2	-5.26	2.22e-07	6.52e-05	-0.43	-0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26870872	chr1:26692132~26694131:-
LUAD	cis	rs61270009	0.955	rs768705	ENSG00000247828.6	TMEM161B-AS1	5.26	2.22e-07	6.52e-05	0.26	0.23	Depressive symptoms;	chr5:88272893	chr5:88268895~88436685:+
LUAD	cis	rs6570726	0.599	rs9403725	ENSG00000235652.6	RP11-545I5.3	-5.26	2.22e-07	6.52e-05	-0.25	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145576486	chr6:145799409~145886585:+
LUAD	cis	rs4141404	0.781	rs4820945	ENSG00000236132.1	CTA-440B3.1	5.26	2.22e-07	6.52e-05	0.29	0.23	Paclitaxel-induced neuropathy;	chr22:31153169	chr22:31816379~31817491:-
LUAD	cis	rs4141404	0.701	rs5753483	ENSG00000236132.1	CTA-440B3.1	5.26	2.22e-07	6.52e-05	0.29	0.23	Paclitaxel-induced neuropathy;	chr22:31153595	chr22:31816379~31817491:-
LUAD	cis	rs4908760	0.864	rs12136766	ENSG00000232912.4	RP5-1115A15.1	5.26	2.22e-07	6.52e-05	0.21	0.23	Vitiligo;	chr1:8603762	chr1:8424645~8434838:+
LUAD	cis	rs6095360	0.727	rs13037813	ENSG00000222365.1	SNORD12B	-5.26	2.22e-07	6.52e-05	-0.26	-0.23	Intelligence (multi-trait analysis);	chr20:49134051	chr20:49280319~49280409:+
LUAD	cis	rs2115630	0.846	rs8024538	ENSG00000229212.6	RP11-561C5.4	5.26	2.22e-07	6.53e-05	0.27	0.23	P wave terminal force;	chr15:84825188	chr15:85205440~85234795:-
LUAD	cis	rs8180040	0.615	rs13062681	ENSG00000271161.1	BOLA2P2	5.26	2.22e-07	6.54e-05	0.22	0.23	Colorectal cancer;	chr3:46979634	chr3:47499841~47500407:+
LUAD	cis	rs712039	0.652	rs853224	ENSG00000276054.1	RP11-378E13.3	5.26	2.22e-07	6.54e-05	0.35	0.23	Tuberculosis;	chr17:37431229	chr17:37386886~37387926:+
LUAD	cis	rs896854	0.846	rs7845219	ENSG00000253528.2	RP11-347C18.4	5.26	2.23e-07	6.54e-05	0.22	0.23	Type 2 diabetes;	chr8:94925274	chr8:94974573~94974853:-
LUAD	cis	rs7617773	0.78	rs11720026	ENSG00000228638.1	FCF1P2	-5.26	2.23e-07	6.54e-05	-0.29	-0.23	Coronary artery disease;	chr3:48336431	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.743	rs11715876	ENSG00000228638.1	FCF1P2	-5.26	2.23e-07	6.54e-05	-0.29	-0.23	Coronary artery disease;	chr3:48336432	chr3:48290793~48291375:-
LUAD	cis	rs875971	0.522	rs1701760	ENSG00000164669.11	INTS4P1	-5.26	2.23e-07	6.55e-05	-0.28	-0.23	Aortic root size;	chr7:66008701	chr7:65141225~65234216:+
LUAD	cis	rs12908161	0.959	rs2175567	ENSG00000275120.1	RP11-182J1.17	5.25	2.23e-07	6.55e-05	0.35	0.23	Schizophrenia;	chr15:84657715	chr15:84599434~84606463:-
LUAD	cis	rs1546924	0.669	rs197439	ENSG00000227811.2	FAM212B-AS1	-5.25	2.23e-07	6.55e-05	-0.28	-0.23	Body mass index;	chr1:111738368	chr1:111739841~111747798:+
LUAD	cis	rs4789693	1	rs4789693	ENSG00000265458.1	RP13-20L14.6	5.25	2.23e-07	6.55e-05	0.31	0.23	Glucocorticoid-induced osteonecrosis;	chr17:82463994	chr17:82454273~82458521:-
LUAD	cis	rs7927592	0.701	rs12226585	ENSG00000212093.1	AP000807.1	-5.25	2.23e-07	6.55e-05	-0.23	-0.23	Total body bone mineral density;	chr11:68490393	chr11:68506083~68506166:-
LUAD	cis	rs2832077	0.943	rs2832099	ENSG00000232855.5	AF131217.1	5.25	2.23e-07	6.55e-05	0.25	0.23	Cognitive test performance;	chr21:28801137	chr21:28439346~28674848:-
LUAD	cis	rs6714710	0.603	rs956039	ENSG00000230606.9	AC159540.1	-5.25	2.23e-07	6.56e-05	-0.25	-0.23	Posterior cortical atrophy and Alzheimer's disease;	chr2:97800385	chr2:97416165~97433527:-
LUAD	cis	rs6714710	0.603	rs717417	ENSG00000230606.9	AC159540.1	-5.25	2.23e-07	6.56e-05	-0.25	-0.23	Posterior cortical atrophy and Alzheimer's disease;	chr2:97800387	chr2:97416165~97433527:-
LUAD	cis	rs4295623	0.559	rs2409836	ENSG00000255046.1	RP11-297N6.4	-5.25	2.24e-07	6.56e-05	-0.28	-0.23	Morning vs. evening chronotype;	chr8:11831719	chr8:11797928~11802568:-
LUAD	cis	rs4835473	0.736	rs6851661	ENSG00000251600.4	RP11-673E1.1	5.25	2.24e-07	6.57e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143850587	chr4:143912331~143982454:+
LUAD	cis	rs4460629	0.905	rs4971077	ENSG00000160766.13	GBAP1	-5.25	2.24e-07	6.57e-05	-0.24	-0.23	Serum magnesium levels;	chr1:155156241	chr1:155213821~155227422:-
LUAD	cis	rs1707322	0.752	rs28545085	ENSG00000280836.1	AL355480.1	-5.25	2.24e-07	6.57e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736278	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.752	rs28812624	ENSG00000280836.1	AL355480.1	-5.25	2.24e-07	6.57e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45738064	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.752	rs28507722	ENSG00000280836.1	AL355480.1	-5.25	2.24e-07	6.57e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45740868	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.752	rs28568986	ENSG00000280836.1	AL355480.1	-5.25	2.24e-07	6.57e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45742071	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.717	rs28396194	ENSG00000280836.1	AL355480.1	-5.25	2.24e-07	6.57e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747555	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.717	rs28752166	ENSG00000280836.1	AL355480.1	-5.25	2.24e-07	6.57e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747637	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.717	rs10890345	ENSG00000280836.1	AL355480.1	-5.25	2.24e-07	6.57e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45748255	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.721	rs10789471	ENSG00000280836.1	AL355480.1	-5.25	2.24e-07	6.57e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45749947	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.752	rs11211173	ENSG00000280836.1	AL355480.1	-5.25	2.24e-07	6.57e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45753704	chr1:45581219~45581321:-
LUAD	cis	rs11089937	0.626	rs5757014	ENSG00000211638.2	IGLV8-61	-5.25	2.24e-07	6.57e-05	-0.27	-0.23	Periodontitis (PAL4Q3);	chr22:22135612	chr22:22098700~22099212:+
LUAD	cis	rs4604732	0.631	rs12080860	ENSG00000227135.1	GCSAML-AS1	-5.25	2.24e-07	6.57e-05	-0.36	-0.23	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247459751	chr1:247524679~247526752:-
LUAD	cis	rs7083	1	rs588763	ENSG00000254851.1	RP11-109L13.1	5.25	2.24e-07	6.58e-05	0.3	0.23	Blood protein levels;	chr11:117246065	chr11:117135528~117138582:+
LUAD	cis	rs9595908	0.746	rs12427832	ENSG00000212293.1	SNORA16	-5.25	2.24e-07	6.58e-05	-0.25	-0.23	Body mass index;	chr13:32644896	chr13:32420390~32420516:-
LUAD	cis	rs1874124	0.895	rs34621709	ENSG00000238078.1	LINC01352	-5.25	2.24e-07	6.58e-05	-0.35	-0.23	Cholesterol, total;	chr1:220806736	chr1:220829255~220832429:+
LUAD	cis	rs11098499	0.739	rs4833612	ENSG00000248280.1	RP11-33B1.2	-5.25	2.24e-07	6.58e-05	-0.29	-0.23	Corneal astigmatism;	chr4:119226441	chr4:119440561~119450157:-
LUAD	cis	rs11098499	0.739	rs10013032	ENSG00000248280.1	RP11-33B1.2	-5.25	2.24e-07	6.58e-05	-0.29	-0.23	Corneal astigmatism;	chr4:119228264	chr4:119440561~119450157:-
LUAD	cis	rs1546924	0.692	rs197374	ENSG00000227811.2	FAM212B-AS1	-5.25	2.24e-07	6.59e-05	-0.28	-0.23	Body mass index;	chr1:111747361	chr1:111739841~111747798:+
LUAD	cis	rs8180040	0.726	rs4682837	ENSG00000271161.1	BOLA2P2	5.25	2.25e-07	6.59e-05	0.22	0.23	Colorectal cancer;	chr3:46958217	chr3:47499841~47500407:+
LUAD	cis	rs9595908	0.746	rs9591229	ENSG00000212293.1	SNORA16	5.25	2.25e-07	6.59e-05	0.25	0.23	Body mass index;	chr13:32658870	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.746	rs4942792	ENSG00000212293.1	SNORA16	5.25	2.25e-07	6.59e-05	0.25	0.23	Body mass index;	chr13:32663326	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.746	rs9596048	ENSG00000212293.1	SNORA16	5.25	2.25e-07	6.59e-05	0.25	0.23	Body mass index;	chr13:32664595	chr13:32420390~32420516:-
LUAD	cis	rs4908768	0.52	rs11121216	ENSG00000232912.4	RP5-1115A15.1	5.25	2.25e-07	6.59e-05	0.21	0.23	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8678885	chr1:8424645~8434838:+
LUAD	cis	rs10129255	0.518	rs7143784	ENSG00000254174.1	IGHV1-12	5.25	2.25e-07	6.59e-05	0.16	0.23	Kawasaki disease;	chr14:106687277	chr14:106122420~106122709:-
LUAD	cis	rs7772486	0.713	rs1986729	ENSG00000235652.6	RP11-545I5.3	5.25	2.25e-07	6.59e-05	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145873695	chr6:145799409~145886585:+
LUAD	cis	rs12022452	1	rs12034162	ENSG00000238287.1	RP11-656D10.3	-5.25	2.25e-07	6.59e-05	-0.43	-0.23	Age-related hearing impairment (SNP x SNP interaction);	chr1:40498933	chr1:40493157~40508661:-
LUAD	cis	rs516805	0.781	rs477425	ENSG00000279453.1	RP3-425C14.4	-5.25	2.25e-07	6.6e-05	-0.3	-0.23	Lymphocyte counts;	chr6:122393627	chr6:122436789~122439223:-
LUAD	cis	rs12928939	0.815	rs1345868	ENSG00000260886.1	TAT-AS1	5.25	2.25e-07	6.6e-05	0.28	0.23	Post bronchodilator FEV1;	chr16:71635721	chr16:71565789~71578187:+
LUAD	cis	rs8180040	0.652	rs13077398	ENSG00000271161.1	BOLA2P2	5.25	2.25e-07	6.6e-05	0.22	0.23	Colorectal cancer;	chr3:46969630	chr3:47499841~47500407:+
LUAD	cis	rs897984	0.647	rs8060857	ENSG00000260911.2	RP11-196G11.2	-5.25	2.25e-07	6.6e-05	-0.21	-0.23	Dementia with Lewy bodies;	chr16:30991399	chr16:31043150~31049868:+
LUAD	cis	rs11673344	0.832	rs76470527	ENSG00000226686.6	LINC01535	5.25	2.25e-07	6.61e-05	0.31	0.23	Obesity-related traits;	chr19:37035981	chr19:37251912~37265535:+
LUAD	cis	rs4835473	0.838	rs34521499	ENSG00000251600.4	RP11-673E1.1	-5.25	2.25e-07	6.61e-05	-0.3	-0.23	Immature fraction of reticulocytes;	chr4:143777628	chr4:143912331~143982454:+
LUAD	cis	rs6772849	0.901	rs9849126	ENSG00000242551.2	POU5F1P6	5.25	2.26e-07	6.62e-05	0.26	0.23	Monocyte percentage of white cells;Monocyte count;	chr3:128593226	chr3:128674735~128677005:-
LUAD	cis	rs11051970	0.559	rs2036304	ENSG00000274964.1	RP11-817I4.1	-5.25	2.26e-07	6.62e-05	-0.3	-0.23	Response to tocilizumab in rheumatoid arthritis;	chr12:32325441	chr12:32339368~32340724:+
LUAD	cis	rs8031584	0.918	rs61997138	ENSG00000270015.1	RP11-540B6.6	-5.25	2.26e-07	6.62e-05	-0.17	-0.23	Huntington's disease progression;	chr15:30978573	chr15:30926514~30928407:+
LUAD	cis	rs8031584	0.918	rs61997140	ENSG00000270015.1	RP11-540B6.6	-5.25	2.26e-07	6.62e-05	-0.17	-0.23	Huntington's disease progression;	chr15:30985109	chr15:30926514~30928407:+
LUAD	cis	rs1823874	0.71	rs55947799	ENSG00000182397.13	DNM1P46	-5.25	2.26e-07	6.63e-05	-0.29	-0.23	IgG glycosylation;	chr15:99820700	chr15:99790156~99806927:-
LUAD	cis	rs1823874	0.71	rs4965543	ENSG00000182397.13	DNM1P46	-5.25	2.26e-07	6.63e-05	-0.29	-0.23	IgG glycosylation;	chr15:99821050	chr15:99790156~99806927:-
LUAD	cis	rs11976180	1	rs2951364	ENSG00000204959.4	ARHGEF34P	5.25	2.26e-07	6.63e-05	0.29	0.23	Obesity-related traits;	chr7:144057390	chr7:144272445~144286966:-
LUAD	cis	rs9435732	0.778	rs9435665	ENSG00000235241.1	RP11-108M9.5	5.25	2.26e-07	6.63e-05	0.32	0.23	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16998042	chr1:16889095~16889602:+
LUAD	cis	rs1862618	0.573	rs1550821	ENSG00000271828.1	CTD-2310F14.1	-5.25	2.26e-07	6.63e-05	-0.35	-0.23	Initial pursuit acceleration;	chr5:56946496	chr5:56927874~56929573:+
LUAD	cis	rs4835473	0.897	rs6835827	ENSG00000251600.4	RP11-673E1.1	5.25	2.26e-07	6.63e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143712803	chr4:143912331~143982454:+
LUAD	cis	rs6568401	0.6	rs9386465	ENSG00000219088.1	RP3-359N14.1	-5.25	2.26e-07	6.63e-05	-0.32	-0.23	Primary tooth development (time to first tooth eruption);	chr6:105714510	chr6:105666326~105667998:+
LUAD	cis	rs17711722	0.565	rs73372653	ENSG00000226002.1	RP11-460N20.5	5.25	2.26e-07	6.63e-05	0.26	0.23	Calcium levels;	chr7:65977808	chr7:65084103~65100232:+
LUAD	cis	rs4654783	0.671	rs3765351	ENSG00000228397.1	RP1-224A6.3	5.25	2.26e-07	6.64e-05	0.28	0.23	Endometriosis;	chr1:22119498	chr1:22023994~22024968:-
LUAD	cis	rs75920871	0.528	rs11216244	ENSG00000254851.1	RP11-109L13.1	5.25	2.27e-07	6.64e-05	0.34	0.23	Subjective well-being;	chr11:117042014	chr11:117135528~117138582:+
LUAD	cis	rs17711722	0.701	rs781145	ENSG00000236529.1	RP13-254B10.1	5.25	2.27e-07	6.65e-05	0.24	0.23	Calcium levels;	chr7:65975383	chr7:65840212~65840596:+
LUAD	cis	rs875971	0.825	rs59466412	ENSG00000232559.3	GS1-124K5.12	-5.25	2.27e-07	6.65e-05	-0.28	-0.23	Aortic root size;	chr7:66100371	chr7:66554588~66576923:-
LUAD	cis	rs516805	0.528	rs2198863	ENSG00000279453.1	RP3-425C14.4	-5.25	2.27e-07	6.66e-05	-0.31	-0.23	Lymphocyte counts;	chr6:122091576	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.528	rs2684243	ENSG00000279453.1	RP3-425C14.4	-5.25	2.27e-07	6.66e-05	-0.31	-0.23	Lymphocyte counts;	chr6:122092700	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.528	rs2684244	ENSG00000279453.1	RP3-425C14.4	-5.25	2.27e-07	6.66e-05	-0.31	-0.23	Lymphocyte counts;	chr6:122092734	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.528	rs2606604	ENSG00000279453.1	RP3-425C14.4	-5.25	2.27e-07	6.66e-05	-0.31	-0.23	Lymphocyte counts;	chr6:122093150	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.528	rs2606611	ENSG00000279453.1	RP3-425C14.4	-5.25	2.27e-07	6.66e-05	-0.31	-0.23	Lymphocyte counts;	chr6:122094502	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.528	rs1402537	ENSG00000279453.1	RP3-425C14.4	-5.25	2.27e-07	6.66e-05	-0.31	-0.23	Lymphocyte counts;	chr6:122094962	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.528	rs2606622	ENSG00000279453.1	RP3-425C14.4	-5.25	2.27e-07	6.66e-05	-0.31	-0.23	Lymphocyte counts;	chr6:122096367	chr6:122436789~122439223:-
LUAD	cis	rs853679	0.76	rs9468317	ENSG00000219392.1	RP1-265C24.5	-5.25	2.27e-07	6.66e-05	-0.34	-0.23	Depression;	chr6:28230678	chr6:28115628~28116551:+
LUAD	cis	rs1707322	1	rs10890350	ENSG00000234329.1	RP11-767N6.2	5.25	2.27e-07	6.66e-05	0.24	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796706	chr1:45651039~45651826:-
LUAD	cis	rs1823913	0.503	rs6434464	ENSG00000227542.1	AC092614.2	-5.25	2.27e-07	6.66e-05	-0.29	-0.23	Obesity-related traits;	chr2:191341120	chr2:191229165~191246172:-
LUAD	cis	rs9595908	0.785	rs3783267	ENSG00000212293.1	SNORA16	5.25	2.27e-07	6.66e-05	0.25	0.23	Body mass index;	chr13:32670719	chr13:32420390~32420516:-
LUAD	cis	rs1707322	0.721	rs10890341	ENSG00000280836.1	AL355480.1	-5.25	2.28e-07	6.67e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45681568	chr1:45581219~45581321:-
LUAD	cis	rs9287719	0.649	rs11684537	ENSG00000243819.4	RN7SL832P	5.25	2.28e-07	6.67e-05	0.25	0.23	Prostate cancer;	chr2:10594706	chr2:10690344~10692099:+
LUAD	cis	rs2337406	1	rs74090714	ENSG00000223648.3	IGHV3-64	5.25	2.28e-07	6.67e-05	0.29	0.23	Alzheimer's disease (late onset);	chr14:106691225	chr14:106643132~106658258:-
LUAD	cis	rs1799949	0.931	rs34410138	ENSG00000236383.6	LINC00854	-5.25	2.28e-07	6.68e-05	-0.19	-0.23	Menopause (age at onset);	chr17:43127753	chr17:43216941~43305976:-
LUAD	cis	rs10246939	0.579	rs17133534	ENSG00000270923.1	TAS2R6P	-5.25	2.28e-07	6.68e-05	-0.26	-0.23	Bitter taste perception;	chr7:141860855	chr7:141787815~141788640:+
LUAD	cis	rs8180040	0.701	rs11130111	ENSG00000271161.1	BOLA2P2	5.25	2.28e-07	6.68e-05	0.22	0.23	Colorectal cancer;	chr3:46968315	chr3:47499841~47500407:+
LUAD	cis	rs8180040	0.701	rs11917474	ENSG00000271161.1	BOLA2P2	5.25	2.28e-07	6.68e-05	0.22	0.23	Colorectal cancer;	chr3:46969001	chr3:47499841~47500407:+
LUAD	cis	rs8180040	0.676	rs7633698	ENSG00000271161.1	BOLA2P2	5.25	2.28e-07	6.68e-05	0.22	0.23	Colorectal cancer;	chr3:46971962	chr3:47499841~47500407:+
LUAD	cis	rs8180040	0.676	rs7636252	ENSG00000271161.1	BOLA2P2	5.25	2.28e-07	6.68e-05	0.22	0.23	Colorectal cancer;	chr3:46972052	chr3:47499841~47500407:+
LUAD	cis	rs1707322	0.752	rs11211145	ENSG00000280836.1	AL355480.1	-5.25	2.28e-07	6.68e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642819	chr1:45581219~45581321:-
LUAD	cis	rs964184	0.63	rs10750096	ENSG00000254851.1	RP11-109L13.1	-5.25	2.28e-07	6.69e-05	-0.5	-0.23	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116786072	chr11:117135528~117138582:+
LUAD	cis	rs72772090	0.71	rs11750400	ENSG00000248734.2	CTD-2260A17.1	-5.25	2.28e-07	6.69e-05	-0.34	-0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96742264	chr5:96784777~96785999:+
LUAD	cis	rs72772090	0.71	rs10515244	ENSG00000248734.2	CTD-2260A17.1	-5.25	2.28e-07	6.69e-05	-0.34	-0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96742633	chr5:96784777~96785999:+
LUAD	cis	rs72772090	0.71	rs1559085	ENSG00000248734.2	CTD-2260A17.1	-5.25	2.28e-07	6.69e-05	-0.34	-0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96742998	chr5:96784777~96785999:+
LUAD	cis	rs5758511	0.524	rs738257	ENSG00000205702.9	CYP2D7	5.25	2.28e-07	6.69e-05	0.23	0.23	Birth weight;	chr22:42173292	chr22:42140203~42144577:-
LUAD	cis	rs2015599	0.525	rs10771514	ENSG00000257176.2	RP11-996F15.2	5.25	2.29e-07	6.7e-05	0.25	0.23	Platelet count;Mean platelet volume;	chr12:29315751	chr12:29280418~29317848:-
LUAD	cis	rs1032726	0.536	rs1488591	ENSG00000242770.2	RP11-180K7.1	5.25	2.29e-07	6.7e-05	0.24	0.23	Sum eosinophil basophil counts;Eosinophil counts;	chr3:112802672	chr3:112802478~112812819:+
LUAD	cis	rs9923856	0.519	rs2867168	ENSG00000274038.1	RP11-66H6.4	-5.25	2.29e-07	6.7e-05	-0.27	-0.23	Atopic dermatitis;Adult asthma;	chr16:11029932	chr16:11056556~11057034:+
LUAD	cis	rs2018683	0.624	rs2286219	ENSG00000228421.2	AC005013.5	5.25	2.29e-07	6.7e-05	0.26	0.23	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959047	chr7:28957667~28959345:+
LUAD	cis	rs2018683	0.624	rs2286220	ENSG00000228421.2	AC005013.5	5.25	2.29e-07	6.7e-05	0.26	0.23	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959083	chr7:28957667~28959345:+
LUAD	cis	rs375066	0.901	rs368316	ENSG00000267058.1	RP11-15A1.3	-5.25	2.29e-07	6.71e-05	-0.27	-0.23	Breast cancer;	chr19:43927742	chr19:43891804~43901805:-
LUAD	cis	rs2933343	1	rs1683776	ENSG00000261159.1	RP11-723O4.9	5.25	2.29e-07	6.71e-05	0.29	0.23	IgG glycosylation;	chr3:128903917	chr3:128859716~128860526:-
LUAD	cis	rs2933343	1	rs2630252	ENSG00000261159.1	RP11-723O4.9	5.25	2.29e-07	6.71e-05	0.29	0.23	IgG glycosylation;	chr3:128905929	chr3:128859716~128860526:-
LUAD	cis	rs7122539	0.646	rs627330	ENSG00000213409.4	RP11-658F2.3	-5.25	2.29e-07	6.72e-05	-0.28	-0.23	HIV-1 susceptibility;	chr11:66834628	chr11:66761575~66762399:-
LUAD	cis	rs11143230	1	rs17628494	ENSG00000225434.2	LINC01504	-5.25	2.3e-07	6.72e-05	-0.28	-0.23	Suicidal ideation;	chr9:72274251	chr9:72305430~72343210:+
LUAD	cis	rs4591358	0.608	rs72927762	ENSG00000223466.1	AC064834.2	-5.25	2.3e-07	6.72e-05	-0.42	-0.23	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195544921	chr2:195533035~195538681:+
LUAD	cis	rs11098499	0.739	rs9996382	ENSG00000248280.1	RP11-33B1.2	5.25	2.3e-07	6.73e-05	0.29	0.23	Corneal astigmatism;	chr4:119229857	chr4:119440561~119450157:-
LUAD	cis	rs7712401	0.502	rs30066	ENSG00000263432.2	RN7SL689P	5.25	2.3e-07	6.73e-05	0.3	0.23	Mean platelet volume;	chr5:122958007	chr5:123022487~123022783:-
LUAD	cis	rs193541	0.632	rs30063	ENSG00000263432.2	RN7SL689P	5.25	2.3e-07	6.73e-05	0.3	0.23	Glucose homeostasis traits;	chr5:122959998	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.601	rs30038	ENSG00000263432.2	RN7SL689P	5.25	2.3e-07	6.73e-05	0.3	0.23	Mean platelet volume;	chr5:122941667	chr5:123022487~123022783:-
LUAD	cis	rs7777677	0.925	rs73543808	ENSG00000244273.1	PGBD4P1	-5.25	2.3e-07	6.73e-05	-0.25	-0.23	Alcoholic chronic pancreatitis;	chr7:142660024	chr7:142722358~142722764:+
LUAD	cis	rs812925	0.511	rs11886950	ENSG00000271889.1	RP11-493E12.1	5.25	2.3e-07	6.73e-05	0.28	0.23	Immature fraction of reticulocytes;	chr2:61172182	chr2:61151433~61162105:-
LUAD	cis	rs11971779	0.68	rs11764236	ENSG00000273391.1	RP11-634H22.1	5.25	2.3e-07	6.74e-05	0.24	0.23	Diisocyanate-induced asthma;	chr7:139433768	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.648	rs66463279	ENSG00000273391.1	RP11-634H22.1	5.25	2.3e-07	6.74e-05	0.24	0.23	Diisocyanate-induced asthma;	chr7:139433915	chr7:139359032~139359566:-
LUAD	cis	rs287982	1	rs56154233	ENSG00000269973.1	RP11-95D17.1	-5.25	2.31e-07	6.75e-05	-0.28	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9829098	chr2:9936360~9939590:+
LUAD	cis	rs2288884	0.767	rs28379522	ENSG00000275055.1	CTC-471J1.11	-5.25	2.31e-07	6.75e-05	-0.32	-0.23	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52036234	chr19:52049007~52049754:+
LUAD	cis	rs2243480	1	rs383402	ENSG00000230295.1	RP11-458F8.2	5.25	2.31e-07	6.76e-05	0.28	0.23	Diabetic kidney disease;	chr7:66121666	chr7:66880708~66882981:+
LUAD	cis	rs9807989	0.839	rs1420099	ENSG00000234389.1	AC007278.3	5.25	2.31e-07	6.76e-05	0.22	0.23	Asthma;	chr2:102364083	chr2:102438713~102440475:+
LUAD	cis	rs1707322	0.752	rs4586014	ENSG00000280836.1	AL355480.1	-5.25	2.31e-07	6.76e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684771	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.648	rs4439382	ENSG00000280836.1	AL355480.1	-5.25	2.31e-07	6.76e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45685133	chr1:45581219~45581321:-
LUAD	cis	rs11157436	0.958	rs12432733	ENSG00000211812.1	TRAV26-2	-5.25	2.31e-07	6.77e-05	-0.27	-0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22230741	chr14:22202583~22203368:+
LUAD	cis	rs4803480	1	rs4803480	ENSG00000270164.1	LINC01480	-5.25	2.31e-07	6.77e-05	-0.23	-0.23	Schizophrenia;	chr19:41559909	chr19:41535183~41536904:+
LUAD	cis	rs6543140	0.964	rs918000	ENSG00000234389.1	AC007278.3	5.25	2.31e-07	6.77e-05	0.23	0.23	Blood protein levels;	chr2:102451402	chr2:102438713~102440475:+
LUAD	cis	rs6543140	0.927	rs917999	ENSG00000234389.1	AC007278.3	5.25	2.31e-07	6.77e-05	0.23	0.23	Blood protein levels;	chr2:102451409	chr2:102438713~102440475:+
LUAD	cis	rs6687821	0.515	rs2798682	ENSG00000267734.1	RP4-604K5.3	-5.25	2.31e-07	6.77e-05	-0.29	-0.23	Yeast infection;	chr1:87108280	chr1:86932199~86934891:-
LUAD	cis	rs875971	0.862	rs6460306	ENSG00000232559.3	GS1-124K5.12	-5.25	2.32e-07	6.78e-05	-0.28	-0.23	Aortic root size;	chr7:66595806	chr7:66554588~66576923:-
LUAD	cis	rs2280018	0.609	rs2941253	ENSG00000207425.1	Y_RNA	5.25	2.32e-07	6.78e-05	0.28	0.23	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15079889	chr16:14915457~14915556:-
LUAD	cis	rs673078	0.66	rs16948193	ENSG00000275409.1	RP11-131L12.4	-5.25	2.32e-07	6.78e-05	-0.33	-0.23	Glucose homeostasis traits;	chr12:118227115	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.66	rs61945187	ENSG00000275409.1	RP11-131L12.4	-5.25	2.32e-07	6.78e-05	-0.33	-0.23	Glucose homeostasis traits;	chr12:118228989	chr12:118430147~118430699:+
LUAD	cis	rs2933343	0.601	rs1680759	ENSG00000261159.1	RP11-723O4.9	5.25	2.32e-07	6.78e-05	0.25	0.23	IgG glycosylation;	chr3:128876053	chr3:128859716~128860526:-
LUAD	cis	rs2933343	0.601	rs1680758	ENSG00000261159.1	RP11-723O4.9	5.25	2.32e-07	6.78e-05	0.25	0.23	IgG glycosylation;	chr3:128876054	chr3:128859716~128860526:-
LUAD	cis	rs2933343	0.649	rs789214	ENSG00000261159.1	RP11-723O4.9	5.25	2.32e-07	6.78e-05	0.25	0.23	IgG glycosylation;	chr3:128876152	chr3:128859716~128860526:-
LUAD	cis	rs2933343	0.729	rs789224	ENSG00000261159.1	RP11-723O4.9	5.25	2.32e-07	6.78e-05	0.25	0.23	IgG glycosylation;	chr3:128879388	chr3:128859716~128860526:-
LUAD	cis	rs2933343	0.761	rs789225	ENSG00000261159.1	RP11-723O4.9	5.25	2.32e-07	6.78e-05	0.25	0.23	IgG glycosylation;	chr3:128881386	chr3:128859716~128860526:-
LUAD	cis	rs35160687	0.644	rs10165626	ENSG00000273080.1	RP11-301O19.1	-5.25	2.32e-07	6.78e-05	-0.26	-0.23	Night sleep phenotypes;	chr2:86309584	chr2:86195590~86196049:+
LUAD	cis	rs516805	0.667	rs2606600	ENSG00000279453.1	RP3-425C14.4	5.25	2.32e-07	6.78e-05	0.33	0.23	Lymphocyte counts;	chr6:122204398	chr6:122436789~122439223:-
LUAD	cis	rs1546924	0.57	rs197415	ENSG00000227811.2	FAM212B-AS1	-5.25	2.32e-07	6.79e-05	-0.29	-0.23	Body mass index;	chr1:111768971	chr1:111739841~111747798:+
LUAD	cis	rs7727544	0.618	rs2631367	ENSG00000233006.5	AC034220.3	-5.25	2.32e-07	6.79e-05	-0.21	-0.23	Blood metabolite levels;	chr5:132369766	chr5:132311285~132369916:-
LUAD	cis	rs375066	0.901	rs438517	ENSG00000267058.1	RP11-15A1.3	-5.25	2.32e-07	6.79e-05	-0.26	-0.23	Breast cancer;	chr19:43915506	chr19:43891804~43901805:-
LUAD	cis	rs375066	0.935	rs446674	ENSG00000267058.1	RP11-15A1.3	-5.25	2.32e-07	6.79e-05	-0.26	-0.23	Breast cancer;	chr19:43916855	chr19:43891804~43901805:-
LUAD	cis	rs7617773	0.817	rs6800492	ENSG00000228638.1	FCF1P2	-5.25	2.32e-07	6.8e-05	-0.28	-0.23	Coronary artery disease;	chr3:48282400	chr3:48290793~48291375:-
LUAD	cis	rs11089937	0.626	rs5757011	ENSG00000211638.2	IGLV8-61	-5.25	2.32e-07	6.8e-05	-0.27	-0.23	Periodontitis (PAL4Q3);	chr22:22135336	chr22:22098700~22099212:+
LUAD	cis	rs7017914	0.653	rs3098882	ENSG00000223220.1	Y_RNA	5.25	2.32e-07	6.8e-05	0.27	0.23	Bone mineral density;	chr8:71027859	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.653	rs3110260	ENSG00000223220.1	Y_RNA	5.25	2.32e-07	6.8e-05	0.27	0.23	Bone mineral density;	chr8:71028253	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.69	rs3110261	ENSG00000223220.1	Y_RNA	5.25	2.32e-07	6.8e-05	0.27	0.23	Bone mineral density;	chr8:71029216	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.69	rs3110262	ENSG00000223220.1	Y_RNA	5.25	2.32e-07	6.8e-05	0.27	0.23	Bone mineral density;	chr8:71029395	chr8:70780914~70781008:-
LUAD	cis	rs9494145	0.68	rs4895440	ENSG00000232876.1	CTA-212D2.2	-5.25	2.32e-07	6.8e-05	-0.31	-0.23	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135105420	chr6:135055033~135060550:+
LUAD	cis	rs35740288	1	rs11637212	ENSG00000202081.1	RNU6-1280P	-5.25	2.33e-07	6.8e-05	-0.3	-0.23	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85749866	chr15:85651522~85651628:-
LUAD	cis	rs2404602	0.679	rs12908421	ENSG00000259422.1	RP11-593F23.1	5.25	2.33e-07	6.81e-05	0.27	0.23	Blood metabolite levels;	chr15:76589453	chr15:76174891~76181486:-
LUAD	cis	rs10129255	0.826	rs7150693	ENSG00000224373.3	IGHV4-59	5.25	2.33e-07	6.81e-05	0.15	0.23	Kawasaki disease;	chr14:106705382	chr14:106627249~106627825:-
LUAD	cis	rs8098244	0.557	rs12954712	ENSG00000264745.1	TTC39C-AS1	5.25	2.33e-07	6.82e-05	0.24	0.23	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23707144	chr18:23994213~24015339:-
LUAD	cis	rs8098244	0.557	rs4347707	ENSG00000264745.1	TTC39C-AS1	5.25	2.33e-07	6.82e-05	0.24	0.23	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23710362	chr18:23994213~24015339:-
LUAD	cis	rs9322193	0.607	rs9322229	ENSG00000223701.3	RAET1E-AS1	5.25	2.33e-07	6.83e-05	0.31	0.23	Lung cancer;	chr6:149908949	chr6:149884431~149919508:+
LUAD	cis	rs8098244	0.638	rs867448	ENSG00000264745.1	TTC39C-AS1	5.25	2.34e-07	6.83e-05	0.24	0.23	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23857757	chr18:23994213~24015339:-
LUAD	cis	rs10129255	0.5	rs8011115	ENSG00000254174.1	IGHV1-12	5.25	2.34e-07	6.83e-05	0.16	0.23	Kawasaki disease;	chr14:106786292	chr14:106122420~106122709:-
LUAD	cis	rs1816752	0.905	rs9511266	ENSG00000273628.1	RP11-756A22.7	5.25	2.34e-07	6.83e-05	0.27	0.23	Obesity-related traits;	chr13:24438366	chr13:24933006~24936796:+
LUAD	cis	rs1816752	0.817	rs7985394	ENSG00000273628.1	RP11-756A22.7	5.25	2.34e-07	6.83e-05	0.27	0.23	Obesity-related traits;	chr13:24438714	chr13:24933006~24936796:+
LUAD	cis	rs1816752	0.789	rs7986037	ENSG00000273628.1	RP11-756A22.7	5.25	2.34e-07	6.83e-05	0.27	0.23	Obesity-related traits;	chr13:24438715	chr13:24933006~24936796:+
LUAD	cis	rs9500256	0.967	rs1012500	ENSG00000215190.7	LINC00680	-5.25	2.34e-07	6.83e-05	-0.28	-0.23	Eosinophilic esophagitis (pediatric);	chr6:57978391	chr6:57946074~57961501:-
LUAD	cis	rs910316	1	rs11845639	ENSG00000259138.1	RP11-950C14.7	5.25	2.34e-07	6.84e-05	0.25	0.23	Height;	chr14:75103590	chr14:75127153~75136930:+
LUAD	cis	rs4835473	0.9	rs71612420	ENSG00000251600.4	RP11-673E1.1	-5.25	2.34e-07	6.84e-05	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143779107	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs13134869	ENSG00000251600.4	RP11-673E1.1	-5.25	2.34e-07	6.84e-05	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143782301	chr4:143912331~143982454:+
LUAD	cis	rs17772222	0.958	rs17203789	ENSG00000258983.2	RP11-507K2.2	5.25	2.34e-07	6.84e-05	0.28	0.23	Coronary artery calcification;	chr14:88541362	chr14:88499334~88515502:+
LUAD	cis	rs10129255	0.518	rs10136903	ENSG00000254174.1	IGHV1-12	5.25	2.34e-07	6.84e-05	0.16	0.23	Kawasaki disease;	chr14:106778866	chr14:106122420~106122709:-
LUAD	cis	rs7017914	0.652	rs7842091	ENSG00000223220.1	Y_RNA	5.25	2.34e-07	6.85e-05	0.27	0.23	Bone mineral density;	chr8:70702546	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs1477945	ENSG00000223220.1	Y_RNA	5.25	2.34e-07	6.85e-05	0.27	0.23	Bone mineral density;	chr8:70703318	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs17760532	ENSG00000223220.1	Y_RNA	5.25	2.34e-07	6.85e-05	0.27	0.23	Bone mineral density;	chr8:70708052	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs56173818	ENSG00000223220.1	Y_RNA	5.25	2.34e-07	6.85e-05	0.27	0.23	Bone mineral density;	chr8:70710138	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs34643336	ENSG00000223220.1	Y_RNA	5.25	2.34e-07	6.85e-05	0.27	0.23	Bone mineral density;	chr8:70715718	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.629	rs35621553	ENSG00000223220.1	Y_RNA	5.25	2.34e-07	6.85e-05	0.27	0.23	Bone mineral density;	chr8:70715840	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.628	rs78322467	ENSG00000223220.1	Y_RNA	5.25	2.34e-07	6.85e-05	0.27	0.23	Bone mineral density;	chr8:70716439	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.605	rs13269410	ENSG00000223220.1	Y_RNA	5.25	2.34e-07	6.85e-05	0.27	0.23	Bone mineral density;	chr8:70725773	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.583	rs11986334	ENSG00000223220.1	Y_RNA	5.25	2.34e-07	6.85e-05	0.27	0.23	Bone mineral density;	chr8:70732239	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs2290702	ENSG00000223220.1	Y_RNA	5.25	2.34e-07	6.85e-05	0.27	0.23	Bone mineral density;	chr8:70734745	chr8:70780914~70781008:-
LUAD	cis	rs858239	0.965	rs156429	ENSG00000226816.2	AC005082.12	5.25	2.34e-07	6.85e-05	0.3	0.23	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23206013~23208045:+
LUAD	cis	rs7923609	0.846	rs10761739	ENSG00000232075.1	MRPL35P2	5.25	2.34e-07	6.85e-05	0.29	0.23	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63302248	chr10:63634317~63634827:-
LUAD	cis	rs2688608	0.592	rs11000757	ENSG00000271816.1	BMS1P4	5.25	2.34e-07	6.85e-05	0.2	0.23	Inflammatory bowel disease;	chr10:73727057	chr10:73699151~73730487:-
LUAD	cis	rs2688608	0.62	rs12253408	ENSG00000271816.1	BMS1P4	5.25	2.34e-07	6.85e-05	0.2	0.23	Inflammatory bowel disease;	chr10:73736198	chr10:73699151~73730487:-
LUAD	cis	rs6570726	0.791	rs4335004	ENSG00000235652.6	RP11-545I5.3	5.25	2.35e-07	6.85e-05	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145583628	chr6:145799409~145886585:+
LUAD	cis	rs2439831	0.867	rs496584	ENSG00000249839.1	AC011330.5	-5.25	2.35e-07	6.86e-05	-0.42	-0.23	Lung cancer in ever smokers;	chr15:43539725	chr15:43663654~43684339:-
LUAD	cis	rs875971	0.522	rs2008188	ENSG00000164669.11	INTS4P1	-5.24	2.35e-07	6.86e-05	-0.28	-0.23	Aortic root size;	chr7:65964026	chr7:65141225~65234216:+
LUAD	cis	rs7772486	0.79	rs2265474	ENSG00000235652.6	RP11-545I5.3	5.24	2.35e-07	6.86e-05	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145860956	chr6:145799409~145886585:+
LUAD	cis	rs858239	0.669	rs1006709	ENSG00000226816.2	AC005082.12	5.24	2.35e-07	6.87e-05	0.3	0.23	Cerebrospinal fluid biomarker levels;	chr7:23100480	chr7:23206013~23208045:+
LUAD	cis	rs11098499	0.644	rs10009566	ENSG00000248280.1	RP11-33B1.2	5.24	2.35e-07	6.87e-05	0.29	0.23	Corneal astigmatism;	chr4:119637453	chr4:119440561~119450157:-
LUAD	cis	rs8098244	0.557	rs11662720	ENSG00000264745.1	TTC39C-AS1	-5.24	2.35e-07	6.87e-05	-0.24	-0.23	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23722127	chr18:23994213~24015339:-
LUAD	cis	rs4835473	0.932	rs12509642	ENSG00000251600.4	RP11-673E1.1	-5.24	2.35e-07	6.87e-05	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143737080	chr4:143912331~143982454:+
LUAD	cis	rs2439831	0.85	rs7169988	ENSG00000249839.1	AC011330.5	-5.24	2.35e-07	6.87e-05	-0.46	-0.23	Lung cancer in ever smokers;	chr15:43768237	chr15:43663654~43684339:-
LUAD	cis	rs11089937	0.626	rs5757017	ENSG00000211638.2	IGLV8-61	-5.24	2.35e-07	6.87e-05	-0.26	-0.23	Periodontitis (PAL4Q3);	chr22:22135947	chr22:22098700~22099212:+
LUAD	cis	rs11089937	0.568	rs59356111	ENSG00000211638.2	IGLV8-61	-5.24	2.35e-07	6.87e-05	-0.26	-0.23	Periodontitis (PAL4Q3);	chr22:22136175	chr22:22098700~22099212:+
LUAD	cis	rs11089937	0.626	rs5757019	ENSG00000211638.2	IGLV8-61	-5.24	2.35e-07	6.87e-05	-0.26	-0.23	Periodontitis (PAL4Q3);	chr22:22136286	chr22:22098700~22099212:+
LUAD	cis	rs11089937	0.597	rs5750579	ENSG00000211638.2	IGLV8-61	-5.24	2.35e-07	6.87e-05	-0.26	-0.23	Periodontitis (PAL4Q3);	chr22:22136581	chr22:22098700~22099212:+
LUAD	cis	rs11089937	0.597	rs11089925	ENSG00000211638.2	IGLV8-61	-5.24	2.35e-07	6.87e-05	-0.26	-0.23	Periodontitis (PAL4Q3);	chr22:22137267	chr22:22098700~22099212:+
LUAD	cis	rs11089937	0.597	rs5757024	ENSG00000211638.2	IGLV8-61	-5.24	2.35e-07	6.87e-05	-0.26	-0.23	Periodontitis (PAL4Q3);	chr22:22137415	chr22:22098700~22099212:+
LUAD	cis	rs11089937	0.597	rs5757026	ENSG00000211638.2	IGLV8-61	-5.24	2.35e-07	6.87e-05	-0.26	-0.23	Periodontitis (PAL4Q3);	chr22:22137556	chr22:22098700~22099212:+
LUAD	cis	rs11089937	0.597	rs2213156	ENSG00000211638.2	IGLV8-61	-5.24	2.35e-07	6.87e-05	-0.26	-0.23	Periodontitis (PAL4Q3);	chr22:22137852	chr22:22098700~22099212:+
LUAD	cis	rs11089937	0.626	rs9622955	ENSG00000211638.2	IGLV8-61	-5.24	2.35e-07	6.87e-05	-0.26	-0.23	Periodontitis (PAL4Q3);	chr22:22138343	chr22:22098700~22099212:+
LUAD	cis	rs11089937	0.626	rs4821781	ENSG00000211638.2	IGLV8-61	-5.24	2.35e-07	6.87e-05	-0.26	-0.23	Periodontitis (PAL4Q3);	chr22:22138845	chr22:22098700~22099212:+
LUAD	cis	rs11089937	0.626	rs5750589	ENSG00000211638.2	IGLV8-61	-5.24	2.35e-07	6.87e-05	-0.26	-0.23	Periodontitis (PAL4Q3);	chr22:22139655	chr22:22098700~22099212:+
LUAD	cis	rs11089937	0.626	rs5757038	ENSG00000211638.2	IGLV8-61	-5.24	2.35e-07	6.87e-05	-0.26	-0.23	Periodontitis (PAL4Q3);	chr22:22140149	chr22:22098700~22099212:+
LUAD	cis	rs11976180	1	rs2961144	ENSG00000204959.4	ARHGEF34P	-5.24	2.35e-07	6.87e-05	-0.28	-0.23	Obesity-related traits;	chr7:144050777	chr7:144272445~144286966:-
LUAD	cis	rs67311347	0.544	rs35112505	ENSG00000223797.4	ENTPD3-AS1	5.24	2.35e-07	6.87e-05	0.24	0.23	Renal cell carcinoma;	chr3:40295584	chr3:40313802~40453329:-
LUAD	cis	rs67311347	0.544	rs67533651	ENSG00000223797.4	ENTPD3-AS1	5.24	2.35e-07	6.87e-05	0.24	0.23	Renal cell carcinoma;	chr3:40296876	chr3:40313802~40453329:-
LUAD	cis	rs673078	0.66	rs117091919	ENSG00000275409.1	RP11-131L12.4	-5.24	2.35e-07	6.88e-05	-0.36	-0.23	Glucose homeostasis traits;	chr12:118273228	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.66	rs7314987	ENSG00000275409.1	RP11-131L12.4	-5.24	2.35e-07	6.88e-05	-0.36	-0.23	Glucose homeostasis traits;	chr12:118274072	chr12:118430147~118430699:+
LUAD	cis	rs7968440	0.808	rs6580769	ENSG00000200428.1	Y_RNA	-5.24	2.36e-07	6.88e-05	-0.3	-0.23	Fibrinogen;	chr12:50801738	chr12:50743568~50743684:+
LUAD	cis	rs7968440	0.808	rs66838741	ENSG00000200428.1	Y_RNA	-5.24	2.36e-07	6.88e-05	-0.3	-0.23	Fibrinogen;	chr12:50805231	chr12:50743568~50743684:+
LUAD	cis	rs9287719	0.601	rs6755281	ENSG00000243819.4	RN7SL832P	5.24	2.36e-07	6.89e-05	0.25	0.23	Prostate cancer;	chr2:10629729	chr2:10690344~10692099:+
LUAD	cis	rs9322193	0.884	rs9397036	ENSG00000268592.3	RAET1E-AS1	5.24	2.36e-07	6.89e-05	0.29	0.23	Lung cancer;	chr6:149851787	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.884	rs9383864	ENSG00000268592.3	RAET1E-AS1	5.24	2.36e-07	6.89e-05	0.29	0.23	Lung cancer;	chr6:149851969	chr6:149863494~149919507:+
LUAD	cis	rs9992667	0.955	rs6858772	ENSG00000231160.8	KLF3-AS1	5.24	2.36e-07	6.89e-05	0.29	0.23	Eosinophil percentage of granulocytes;	chr4:38649382	chr4:38612701~38664883:-
LUAD	cis	rs4664293	0.967	rs35975814	ENSG00000226266.5	AC009961.3	-5.24	2.36e-07	6.89e-05	-0.32	-0.23	Monocyte percentage of white cells;	chr2:159691280	chr2:159670708~159712435:-
LUAD	cis	rs7927592	0.731	rs488381	ENSG00000212093.1	AP000807.1	-5.24	2.36e-07	6.89e-05	-0.23	-0.23	Total body bone mineral density;	chr11:68524225	chr11:68506083~68506166:-
LUAD	cis	rs1320333	0.772	rs111825088	ENSG00000233296.1	AC092159.2	5.24	2.36e-07	6.89e-05	0.42	0.23	Obesity-related traits;	chr2:695785	chr2:677186~697371:+
LUAD	cis	rs673078	0.66	rs10507286	ENSG00000275409.1	RP11-131L12.4	-5.24	2.36e-07	6.9e-05	-0.33	-0.23	Glucose homeostasis traits;	chr12:118197101	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.66	rs61945180	ENSG00000275409.1	RP11-131L12.4	-5.24	2.36e-07	6.9e-05	-0.33	-0.23	Glucose homeostasis traits;	chr12:118216335	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.66	rs61945181	ENSG00000275409.1	RP11-131L12.4	-5.24	2.36e-07	6.9e-05	-0.33	-0.23	Glucose homeostasis traits;	chr12:118216651	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.66	rs61945183	ENSG00000275409.1	RP11-131L12.4	-5.24	2.36e-07	6.9e-05	-0.33	-0.23	Glucose homeostasis traits;	chr12:118221966	chr12:118430147~118430699:+
LUAD	cis	rs8103033	0.793	rs35604304	ENSG00000226025.8	LGALS17A	-5.24	2.36e-07	6.9e-05	-0.26	-0.23	Obesity-related traits;	chr19:39631468	chr19:39679374~39686373:+
LUAD	cis	rs854462	1	rs854465	ENSG00000274767.1	AC131056.3	-5.24	2.36e-07	6.9e-05	-0.35	-0.23	Blood protein levels;	chr17:36059516	chr17:36183235~36196471:+
LUAD	cis	rs948562	0.519	rs7111679	ENSG00000280010.1	AP001350.4	5.24	2.36e-07	6.9e-05	0.33	0.23	Lymphoma;	chr11:58284885	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.519	rs7128629	ENSG00000280010.1	AP001350.4	5.24	2.36e-07	6.9e-05	0.33	0.23	Lymphoma;	chr11:58285262	chr11:58627435~58628528:+
LUAD	cis	rs17772222	0.958	rs12436326	ENSG00000258983.2	RP11-507K2.2	5.24	2.37e-07	6.91e-05	0.28	0.23	Coronary artery calcification;	chr14:88533632	chr14:88499334~88515502:+
LUAD	cis	rs7017914	0.69	rs11987409	ENSG00000223220.1	Y_RNA	5.24	2.37e-07	6.91e-05	0.27	0.23	Bone mineral density;	chr8:71067825	chr8:70780914~70781008:-
LUAD	cis	rs957448	0.561	rs13258635	ENSG00000253704.1	RP11-267M23.4	5.24	2.37e-07	6.91e-05	0.27	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94595629	chr8:94553722~94569745:+
LUAD	cis	rs957448	0.561	rs7459558	ENSG00000253704.1	RP11-267M23.4	5.24	2.37e-07	6.91e-05	0.27	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94598618	chr8:94553722~94569745:+
LUAD	cis	rs957448	0.561	rs34471170	ENSG00000253704.1	RP11-267M23.4	5.24	2.37e-07	6.91e-05	0.27	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94601135	chr8:94553722~94569745:+
LUAD	cis	rs957448	0.561	rs9642927	ENSG00000253704.1	RP11-267M23.4	5.24	2.37e-07	6.91e-05	0.27	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94601414	chr8:94553722~94569745:+
LUAD	cis	rs957448	0.561	rs1808488	ENSG00000253704.1	RP11-267M23.4	5.24	2.37e-07	6.91e-05	0.27	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94602636	chr8:94553722~94569745:+
LUAD	cis	rs957448	0.583	rs754275	ENSG00000253704.1	RP11-267M23.4	5.24	2.37e-07	6.91e-05	0.27	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94602741	chr8:94553722~94569745:+
LUAD	cis	rs957448	0.561	rs1426172	ENSG00000253704.1	RP11-267M23.4	5.24	2.37e-07	6.91e-05	0.27	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94602988	chr8:94553722~94569745:+
LUAD	cis	rs10129255	0.5	rs4774008	ENSG00000254174.1	IGHV1-12	5.24	2.37e-07	6.92e-05	0.16	0.23	Kawasaki disease;	chr14:106681273	chr14:106122420~106122709:-
LUAD	cis	rs6687758	0.732	rs72740077	ENSG00000228437.4	RP11-400N13.2	5.24	2.37e-07	6.92e-05	0.34	0.23	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221940827	chr1:221966341~221984964:+
LUAD	cis	rs75422866	0.51	rs35784744	ENSG00000257433.4	RP1-197B17.3	5.24	2.37e-07	6.92e-05	0.47	0.23	Pneumonia;	chr12:47729646	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.541	rs12425816	ENSG00000257433.4	RP1-197B17.3	5.24	2.37e-07	6.92e-05	0.47	0.23	Pneumonia;	chr12:47731419	chr12:47706085~47742294:+
LUAD	cis	rs10754283	0.967	rs10922679	ENSG00000231613.1	RP5-943J3.1	5.24	2.37e-07	6.93e-05	0.23	0.23	Amyotrophic lateral sclerosis (sporadic);	chr1:89635366	chr1:89788914~89790492:+
LUAD	cis	rs10754283	0.935	rs10801756	ENSG00000231613.1	RP5-943J3.1	5.24	2.37e-07	6.93e-05	0.23	0.23	Amyotrophic lateral sclerosis (sporadic);	chr1:89636273	chr1:89788914~89790492:+
LUAD	cis	rs10754283	0.934	rs6684676	ENSG00000231613.1	RP5-943J3.1	5.24	2.37e-07	6.93e-05	0.23	0.23	Amyotrophic lateral sclerosis (sporadic);	chr1:89636614	chr1:89788914~89790492:+
LUAD	cis	rs10754283	0.967	rs6428561	ENSG00000231613.1	RP5-943J3.1	5.24	2.37e-07	6.93e-05	0.23	0.23	Amyotrophic lateral sclerosis (sporadic);	chr1:89637060	chr1:89788914~89790492:+
LUAD	cis	rs10754283	0.967	rs6428562	ENSG00000231613.1	RP5-943J3.1	5.24	2.37e-07	6.93e-05	0.23	0.23	Amyotrophic lateral sclerosis (sporadic);	chr1:89637106	chr1:89788914~89790492:+
LUAD	cis	rs6687758	1	rs17442058	ENSG00000228437.4	RP11-400N13.2	5.24	2.37e-07	6.93e-05	0.35	0.23	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222006808	chr1:221966341~221984964:+
LUAD	cis	rs8031584	0.958	rs61997079	ENSG00000270015.1	RP11-540B6.6	-5.24	2.37e-07	6.93e-05	-0.17	-0.23	Huntington's disease progression;	chr15:30946068	chr15:30926514~30928407:+
LUAD	cis	rs8031584	0.958	rs11637469	ENSG00000270015.1	RP11-540B6.6	-5.24	2.37e-07	6.93e-05	-0.17	-0.23	Huntington's disease progression;	chr15:30946580	chr15:30926514~30928407:+
LUAD	cis	rs75920871	0.528	rs7109649	ENSG00000254851.1	RP11-109L13.1	5.24	2.37e-07	6.93e-05	0.33	0.23	Subjective well-being;	chr11:117072828	chr11:117135528~117138582:+
LUAD	cis	rs75920871	0.528	rs1531706	ENSG00000254851.1	RP11-109L13.1	5.24	2.37e-07	6.93e-05	0.33	0.23	Subjective well-being;	chr11:117073236	chr11:117135528~117138582:+
LUAD	cis	rs17507216	0.628	rs28371837	ENSG00000255769.6	GOLGA2P10	-5.24	2.37e-07	6.93e-05	-0.3	-0.23	Excessive daytime sleepiness;	chr15:82714435	chr15:82472993~82513950:-
LUAD	cis	rs11089937	0.597	rs5750582	ENSG00000211638.2	IGLV8-61	-5.24	2.38e-07	6.94e-05	-0.26	-0.23	Periodontitis (PAL4Q3);	chr22:22137690	chr22:22098700~22099212:+
LUAD	cis	rs11089937	0.626	rs5757028	ENSG00000211638.2	IGLV8-61	-5.24	2.38e-07	6.94e-05	-0.26	-0.23	Periodontitis (PAL4Q3);	chr22:22137699	chr22:22098700~22099212:+
LUAD	cis	rs9992667	0.955	rs6819274	ENSG00000231160.8	KLF3-AS1	5.24	2.38e-07	6.94e-05	0.28	0.23	Eosinophil percentage of granulocytes;	chr4:38614306	chr4:38612701~38664883:-
LUAD	cis	rs6921919	1	rs6922111	ENSG00000216901.1	AL022393.7	5.24	2.38e-07	6.94e-05	0.32	0.23	Autism spectrum disorder or schizophrenia;	chr6:28357531	chr6:28176188~28176674:+
LUAD	cis	rs7712401	0.584	rs28373879	ENSG00000263432.2	RN7SL689P	5.24	2.38e-07	6.94e-05	0.31	0.23	Mean platelet volume;	chr5:123036707	chr5:123022487~123022783:-
LUAD	cis	rs2337406	0.925	rs76288499	ENSG00000223648.3	IGHV3-64	5.24	2.38e-07	6.94e-05	0.29	0.23	Alzheimer's disease (late onset);	chr14:106686309	chr14:106643132~106658258:-
LUAD	cis	rs2239547	0.522	rs2336669	ENSG00000242142.1	SERBP1P3	-5.24	2.38e-07	6.95e-05	-0.27	-0.23	Schizophrenia;	chr3:52960122	chr3:53064283~53065091:-
LUAD	cis	rs75920871	0.528	rs1531707	ENSG00000254851.1	RP11-109L13.1	5.24	2.38e-07	6.95e-05	0.33	0.23	Subjective well-being;	chr11:117073996	chr11:117135528~117138582:+
LUAD	cis	rs643506	0.817	rs658373	ENSG00000230911.1	PPIHP1	-5.24	2.38e-07	6.95e-05	-0.3	-0.23	Breast cancer;	chr11:111812267	chr11:112029858~112030367:-
LUAD	cis	rs643506	0.874	rs673679	ENSG00000230911.1	PPIHP1	-5.24	2.38e-07	6.95e-05	-0.3	-0.23	Breast cancer;	chr11:111816076	chr11:112029858~112030367:-
LUAD	cis	rs643506	0.845	rs607327	ENSG00000230911.1	PPIHP1	-5.24	2.38e-07	6.95e-05	-0.3	-0.23	Breast cancer;	chr11:111824985	chr11:112029858~112030367:-
LUAD	cis	rs1823874	0.71	rs56160817	ENSG00000182397.13	DNM1P46	-5.24	2.38e-07	6.96e-05	-0.29	-0.23	IgG glycosylation;	chr15:99820472	chr15:99790156~99806927:-
LUAD	cis	rs1823874	0.71	rs56186545	ENSG00000182397.13	DNM1P46	-5.24	2.38e-07	6.96e-05	-0.29	-0.23	IgG glycosylation;	chr15:99820554	chr15:99790156~99806927:-
LUAD	cis	rs11976180	1	rs1320894	ENSG00000204959.4	ARHGEF34P	5.24	2.39e-07	6.96e-05	0.29	0.23	Obesity-related traits;	chr7:144054709	chr7:144272445~144286966:-
LUAD	cis	rs11976180	1	rs2951369	ENSG00000204959.4	ARHGEF34P	5.24	2.39e-07	6.96e-05	0.29	0.23	Obesity-related traits;	chr7:144055545	chr7:144272445~144286966:-
LUAD	cis	rs9595908	0.669	rs9591303	ENSG00000212293.1	SNORA16	5.24	2.39e-07	6.97e-05	0.25	0.23	Body mass index;	chr13:32748278	chr13:32420390~32420516:-
LUAD	cis	rs67311347	0.544	rs6599088	ENSG00000223797.4	ENTPD3-AS1	5.24	2.39e-07	6.97e-05	0.24	0.23	Renal cell carcinoma;	chr3:40287797	chr3:40313802~40453329:-
LUAD	cis	rs67311347	0.544	rs9877105	ENSG00000223797.4	ENTPD3-AS1	5.24	2.39e-07	6.97e-05	0.24	0.23	Renal cell carcinoma;	chr3:40291875	chr3:40313802~40453329:-
LUAD	cis	rs4835473	0.897	rs1553070	ENSG00000251600.4	RP11-673E1.1	5.24	2.39e-07	6.97e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143715981	chr4:143912331~143982454:+
LUAD	cis	rs4268898	0.722	rs7564420	ENSG00000242628.4	AC009228.1	5.24	2.39e-07	6.97e-05	0.29	0.23	Asthma;	chr2:24191133	chr2:24214381~24221516:+
LUAD	cis	rs4713118	0.738	rs200465	ENSG00000219392.1	RP1-265C24.5	-5.24	2.39e-07	6.97e-05	-0.3	-0.23	Parkinson's disease;	chr6:27789875	chr6:28115628~28116551:+
LUAD	cis	rs7208859	0.573	rs7214313	ENSG00000263603.1	CTD-2349P21.5	-5.24	2.39e-07	6.97e-05	-0.4	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811578	chr17:30729469~30731202:+
LUAD	cis	rs17711722	1	rs17711722	ENSG00000164669.11	INTS4P1	5.24	2.39e-07	6.98e-05	0.28	0.23	Calcium levels;	chr7:65806210	chr7:65141225~65234216:+
LUAD	cis	rs17711722	0.675	rs6947132	ENSG00000164669.11	INTS4P1	5.24	2.39e-07	6.98e-05	0.28	0.23	Calcium levels;	chr7:65808508	chr7:65141225~65234216:+
LUAD	cis	rs287982	1	rs287980	ENSG00000269973.1	RP11-95D17.1	5.24	2.39e-07	6.98e-05	0.28	0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9831237	chr2:9936360~9939590:+
LUAD	cis	rs1862618	0.573	rs832532	ENSG00000271828.1	CTD-2310F14.1	5.24	2.39e-07	6.98e-05	0.34	0.23	Initial pursuit acceleration;	chr5:56926111	chr5:56927874~56929573:+
LUAD	cis	rs1113500	0.614	rs12565953	ENSG00000226822.1	RP11-356N1.2	5.24	2.39e-07	6.98e-05	0.3	0.23	Growth-regulated protein alpha levels;	chr1:108064465	chr1:108071482~108074519:+
LUAD	cis	rs4964805	0.954	rs11111785	ENSG00000257681.1	RP11-341G23.4	5.24	2.39e-07	6.98e-05	0.28	0.23	Attention deficit hyperactivity disorder;	chr12:103795278	chr12:103746315~103768858:-
LUAD	cis	rs4964805	0.954	rs11111786	ENSG00000257681.1	RP11-341G23.4	5.24	2.39e-07	6.98e-05	0.28	0.23	Attention deficit hyperactivity disorder;	chr12:103795279	chr12:103746315~103768858:-
LUAD	cis	rs1707322	0.964	rs10437063	ENSG00000234329.1	RP11-767N6.2	5.24	2.4e-07	7e-05	0.24	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807994	chr1:45651039~45651826:-
LUAD	cis	rs1707322	1	rs6676982	ENSG00000234329.1	RP11-767N6.2	5.24	2.4e-07	7e-05	0.24	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809729	chr1:45651039~45651826:-
LUAD	cis	rs2255336	0.938	rs2126888	ENSG00000245648.1	RP11-277P12.20	5.24	2.4e-07	7e-05	0.35	0.23	Blood protein levels;	chr12:10393789	chr12:10363769~10398506:+
LUAD	cis	rs35264875	0.846	rs72930625	ENSG00000259799.1	RP11-554A11.9	5.24	2.4e-07	7e-05	0.35	0.23	Blond vs. brown hair color;	chr11:69099652	chr11:69155910~69159752:+
LUAD	cis	rs35264875	0.846	rs72930627	ENSG00000259799.1	RP11-554A11.9	5.24	2.4e-07	7e-05	0.35	0.23	Blond vs. brown hair color;	chr11:69099653	chr11:69155910~69159752:+
LUAD	cis	rs6570726	0.837	rs636894	ENSG00000235652.6	RP11-545I5.3	5.24	2.4e-07	7e-05	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145542986	chr6:145799409~145886585:+
LUAD	cis	rs4835473	0.932	rs7697916	ENSG00000251600.4	RP11-673E1.1	-5.24	2.4e-07	7.01e-05	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143765628	chr4:143912331~143982454:+
LUAD	cis	rs1816752	0.819	rs1981276	ENSG00000273628.1	RP11-756A22.7	5.24	2.41e-07	7.01e-05	0.26	0.23	Obesity-related traits;	chr13:24409361	chr13:24933006~24936796:+
LUAD	cis	rs1816752	0.837	rs57052031	ENSG00000273628.1	RP11-756A22.7	5.24	2.41e-07	7.01e-05	0.26	0.23	Obesity-related traits;	chr13:24409730	chr13:24933006~24936796:+
LUAD	cis	rs673078	0.66	rs17440315	ENSG00000275409.1	RP11-131L12.4	-5.24	2.41e-07	7.01e-05	-0.34	-0.23	Glucose homeostasis traits;	chr12:118158819	chr12:118430147~118430699:+
LUAD	cis	rs12908161	0.959	rs11637728	ENSG00000275120.1	RP11-182J1.17	5.24	2.41e-07	7.02e-05	0.35	0.23	Schizophrenia;	chr15:84660161	chr15:84599434~84606463:-
LUAD	cis	rs75920871	0.528	rs12279066	ENSG00000254851.1	RP11-109L13.1	5.24	2.41e-07	7.02e-05	0.34	0.23	Subjective well-being;	chr11:117043193	chr11:117135528~117138582:+
LUAD	cis	rs1005277	0.557	rs2983338	ENSG00000263064.2	RP11-291L22.7	5.24	2.41e-07	7.02e-05	0.25	0.23	Extrinsic epigenetic age acceleration;	chr10:38261806	chr10:38448689~38448949:+
LUAD	cis	rs7131987	0.718	rs7976961	ENSG00000257176.2	RP11-996F15.2	-5.24	2.41e-07	7.03e-05	-0.26	-0.23	QT interval;	chr12:29310155	chr12:29280418~29317848:-
LUAD	cis	rs9652601	0.959	rs741172	ENSG00000274038.1	RP11-66H6.4	-5.24	2.41e-07	7.03e-05	-0.29	-0.23	Systemic lupus erythematosus;	chr16:11106941	chr16:11056556~11057034:+
LUAD	cis	rs67311347	0.568	rs57287242	ENSG00000223797.4	ENTPD3-AS1	5.24	2.41e-07	7.03e-05	0.24	0.23	Renal cell carcinoma;	chr3:40294047	chr3:40313802~40453329:-
LUAD	cis	rs2946504	0.861	rs2946501	ENSG00000251468.2	RP11-369K16.1	5.24	2.42e-07	7.04e-05	0.29	0.23	Type 2 diabetes;	chr8:12955922	chr8:12958387~12962200:+
LUAD	cis	rs7615952	0.599	rs12485717	ENSG00000171084.14	FAM86JP	-5.24	2.42e-07	7.05e-05	-0.34	-0.23	Blood pressure (smoking interaction);	chr3:125988232	chr3:125916620~125930024:+
LUAD	cis	rs301901	0.729	rs217781	ENSG00000250155.1	CTD-2353F22.1	-5.24	2.42e-07	7.05e-05	-0.25	-0.23	Height;	chr5:37344444	chr5:36666214~36725195:-
LUAD	cis	rs1816752	0.87	rs8000215	ENSG00000273628.1	RP11-756A22.7	5.24	2.42e-07	7.05e-05	0.27	0.23	Obesity-related traits;	chr13:24435648	chr13:24933006~24936796:+
LUAD	cis	rs6750795	0.569	rs1797387	ENSG00000181798.2	LINC00471	-5.24	2.42e-07	7.06e-05	-0.26	-0.23	Height;	chr2:231549981	chr2:231508426~231514339:-
LUAD	cis	rs875971	0.862	rs801195	ENSG00000232559.3	GS1-124K5.12	-5.24	2.42e-07	7.06e-05	-0.28	-0.23	Aortic root size;	chr7:66561128	chr7:66554588~66576923:-
LUAD	cis	rs516805	0.748	rs11154070	ENSG00000279453.1	RP3-425C14.4	5.24	2.42e-07	7.06e-05	0.3	0.23	Lymphocyte counts;	chr6:122362886	chr6:122436789~122439223:-
LUAD	cis	rs673078	0.66	rs61945217	ENSG00000275409.1	RP11-131L12.4	-5.24	2.42e-07	7.06e-05	-0.36	-0.23	Glucose homeostasis traits;	chr12:118261194	chr12:118430147~118430699:+
LUAD	cis	rs1707322	0.685	rs56177313	ENSG00000280836.1	AL355480.1	-5.24	2.43e-07	7.07e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760134	chr1:45581219~45581321:-
LUAD	cis	rs7615952	0.576	rs17523380	ENSG00000171084.14	FAM86JP	5.24	2.43e-07	7.08e-05	0.32	0.23	Blood pressure (smoking interaction);	chr3:126084031	chr3:125916620~125930024:+
LUAD	cis	rs4835473	0.897	rs7681914	ENSG00000251600.4	RP11-673E1.1	5.24	2.43e-07	7.08e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143708838	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.864	rs7682096	ENSG00000251600.4	RP11-673E1.1	5.24	2.43e-07	7.08e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143708892	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.897	rs7682128	ENSG00000251600.4	RP11-673E1.1	5.24	2.43e-07	7.08e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143708950	chr4:143912331~143982454:+
LUAD	cis	rs875971	0.862	rs1167408	ENSG00000232559.3	GS1-124K5.12	-5.24	2.43e-07	7.08e-05	-0.28	-0.23	Aortic root size;	chr7:66091121	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.83	rs1167406	ENSG00000232559.3	GS1-124K5.12	-5.24	2.43e-07	7.08e-05	-0.28	-0.23	Aortic root size;	chr7:66091949	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs709609	ENSG00000232559.3	GS1-124K5.12	-5.24	2.43e-07	7.08e-05	-0.28	-0.23	Aortic root size;	chr7:66095574	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs1167399	ENSG00000232559.3	GS1-124K5.12	-5.24	2.43e-07	7.08e-05	-0.28	-0.23	Aortic root size;	chr7:66096890	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs57866200	ENSG00000232559.3	GS1-124K5.12	-5.24	2.43e-07	7.08e-05	-0.28	-0.23	Aortic root size;	chr7:66100405	chr7:66554588~66576923:-
LUAD	cis	rs2288884	0.708	rs59104696	ENSG00000275055.1	CTC-471J1.11	-5.24	2.43e-07	7.08e-05	-0.33	-0.23	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52051917	chr19:52049007~52049754:+
LUAD	cis	rs2404602	0.669	rs9788684	ENSG00000259422.1	RP11-593F23.1	5.24	2.43e-07	7.09e-05	0.27	0.23	Blood metabolite levels;	chr15:76902497	chr15:76174891~76181486:-
LUAD	cis	rs11089937	0.512	rs34963809	ENSG00000211638.2	IGLV8-61	-5.24	2.43e-07	7.09e-05	-0.27	-0.23	Periodontitis (PAL4Q3);	chr22:22130737	chr22:22098700~22099212:+
LUAD	cis	rs5753618	0.583	rs2273249	ENSG00000236132.1	CTA-440B3.1	-5.24	2.43e-07	7.09e-05	-0.28	-0.23	Colorectal cancer;	chr22:31440500	chr22:31816379~31817491:-
LUAD	cis	rs12439619	0.693	rs7165536	ENSG00000276710.3	CSPG4P8	-5.24	2.43e-07	7.09e-05	-0.26	-0.23	Intelligence (multi-trait analysis);	chr15:82273743	chr15:82459472~82477258:+
LUAD	cis	rs11157436	0.918	rs3811285	ENSG00000211812.1	TRAV26-2	-5.24	2.43e-07	7.09e-05	-0.25	-0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22155322	chr14:22202583~22203368:+
LUAD	cis	rs10129255	0.5	rs59939897	ENSG00000254174.1	IGHV1-12	5.24	2.44e-07	7.09e-05	0.16	0.23	Kawasaki disease;	chr14:106783414	chr14:106122420~106122709:-
LUAD	cis	rs10129255	0.5	rs8014529	ENSG00000254174.1	IGHV1-12	5.24	2.44e-07	7.09e-05	0.16	0.23	Kawasaki disease;	chr14:106784065	chr14:106122420~106122709:-
LUAD	cis	rs10129255	0.5	rs12101190	ENSG00000254174.1	IGHV1-12	5.24	2.44e-07	7.09e-05	0.16	0.23	Kawasaki disease;	chr14:106784149	chr14:106122420~106122709:-
LUAD	cis	rs10129255	0.518	rs8004895	ENSG00000254174.1	IGHV1-12	5.24	2.44e-07	7.09e-05	0.16	0.23	Kawasaki disease;	chr14:106785139	chr14:106122420~106122709:-
LUAD	cis	rs6921919	0.789	rs6456814	ENSG00000216901.1	AL022393.7	5.24	2.44e-07	7.09e-05	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28338035	chr6:28176188~28176674:+
LUAD	cis	rs4713118	1	rs9468195	ENSG00000219392.1	RP1-265C24.5	-5.24	2.44e-07	7.09e-05	-0.31	-0.23	Parkinson's disease;	chr6:27708530	chr6:28115628~28116551:+
LUAD	cis	rs9595908	0.785	rs7328827	ENSG00000212293.1	SNORA16	5.24	2.44e-07	7.1e-05	0.25	0.23	Body mass index;	chr13:32686650	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.785	rs3858846	ENSG00000212293.1	SNORA16	5.24	2.44e-07	7.1e-05	0.25	0.23	Body mass index;	chr13:32687408	chr13:32420390~32420516:-
LUAD	cis	rs4591358	0.731	rs13036252	ENSG00000223466.1	AC064834.2	-5.24	2.44e-07	7.1e-05	-0.32	-0.23	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195425834	chr2:195533035~195538681:+
LUAD	cis	rs783540	0.542	rs62009945	ENSG00000255769.6	GOLGA2P10	5.24	2.44e-07	7.11e-05	0.28	0.23	Schizophrenia;	chr15:82631205	chr15:82472993~82513950:-
LUAD	cis	rs1823913	0.538	rs11892998	ENSG00000280083.1	RP11-317J9.1	-5.24	2.44e-07	7.11e-05	-0.28	-0.23	Obesity-related traits;	chr2:191340159	chr2:191154118~191156070:-
LUAD	cis	rs1345301	0.518	rs12468355	ENSG00000234389.1	AC007278.3	-5.24	2.44e-07	7.11e-05	-0.22	-0.23	Waist circumference;	chr2:102244790	chr2:102438713~102440475:+
LUAD	cis	rs891378	0.848	rs1579484	ENSG00000274245.1	RP11-357P18.2	-5.24	2.44e-07	7.11e-05	-0.28	-0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207262484	chr1:207372559~207373252:+
LUAD	cis	rs10027350	0.765	rs6838393	ENSG00000281501.1	SEPSECS-AS1	5.24	2.44e-07	7.11e-05	0.29	0.23	Childhood ear infection;	chr4:25172629	chr4:25160641~25201440:+
LUAD	cis	rs1799949	0.965	rs8067269	ENSG00000267681.1	CTD-3199J23.6	-5.24	2.44e-07	7.11e-05	-0.27	-0.23	Menopause (age at onset);	chr17:43083782	chr17:43144956~43145255:+
LUAD	cis	rs7804306	0.826	rs17566854	ENSG00000233264.2	AC006042.8	5.24	2.44e-07	7.11e-05	0.45	0.23	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:7993887	chr7:7980312~7982228:+
LUAD	cis	rs74233809	0.901	rs3824754	ENSG00000213277.3	MARCKSL1P1	5.24	2.45e-07	7.13e-05	0.4	0.23	Birth weight;	chr10:102854593	chr10:103175554~103176094:+
LUAD	cis	rs2283792	0.624	rs2876981	ENSG00000224086.5	LL22NC03-86G7.1	-5.24	2.45e-07	7.13e-05	-0.22	-0.23	Multiple sclerosis;	chr22:21851322	chr22:21938293~21977632:+
LUAD	cis	rs35160687	0.712	rs11691807	ENSG00000273080.1	RP11-301O19.1	-5.24	2.46e-07	7.15e-05	-0.26	-0.23	Night sleep phenotypes;	chr2:86255898	chr2:86195590~86196049:+
LUAD	cis	rs891378	0.959	rs7533825	ENSG00000274245.1	RP11-357P18.2	-5.24	2.46e-07	7.15e-05	-0.28	-0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207248817	chr1:207372559~207373252:+
LUAD	cis	rs638893	0.673	rs538645	ENSG00000278376.1	RP11-158I9.8	5.24	2.46e-07	7.15e-05	0.28	0.23	Vitiligo;	chr11:118840360	chr11:118791254~118793137:+
LUAD	cis	rs559928	0.692	rs915987	ENSG00000236935.1	AP003774.1	5.24	2.46e-07	7.15e-05	0.34	0.23	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64260416	chr11:64325050~64329504:-
LUAD	cis	rs2439831	0.85	rs8023458	ENSG00000249839.1	AC011330.5	-5.24	2.46e-07	7.15e-05	-0.46	-0.23	Lung cancer in ever smokers;	chr15:43788741	chr15:43663654~43684339:-
LUAD	cis	rs2439831	0.85	rs16963953	ENSG00000249839.1	AC011330.5	-5.24	2.46e-07	7.15e-05	-0.46	-0.23	Lung cancer in ever smokers;	chr15:43789521	chr15:43663654~43684339:-
LUAD	cis	rs9807989	0.801	rs11123925	ENSG00000234389.1	AC007278.3	5.24	2.46e-07	7.15e-05	0.22	0.23	Asthma;	chr2:102361051	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.839	rs10204837	ENSG00000234389.1	AC007278.3	5.24	2.46e-07	7.15e-05	0.22	0.23	Asthma;	chr2:102361270	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.839	rs3755276	ENSG00000234389.1	AC007278.3	5.24	2.46e-07	7.15e-05	0.22	0.23	Asthma;	chr2:102361999	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.839	rs9308857	ENSG00000234389.1	AC007278.3	5.24	2.46e-07	7.15e-05	0.22	0.23	Asthma;	chr2:102363164	chr2:102438713~102440475:+
LUAD	cis	rs2562456	0.958	rs2562508	ENSG00000268081.1	RP11-678G14.2	-5.24	2.46e-07	7.16e-05	-0.36	-0.23	Pain;	chr19:21543479	chr19:21554640~21569237:-
LUAD	cis	rs7829975	0.511	rs2921028	ENSG00000253981.4	ALG1L13P	5.24	2.46e-07	7.16e-05	0.26	0.23	Mood instability;	chr8:8482967	chr8:8236003~8244667:-
LUAD	cis	rs910316	1	rs12588240	ENSG00000259138.1	RP11-950C14.7	5.24	2.46e-07	7.16e-05	0.25	0.23	Height;	chr14:75145380	chr14:75127153~75136930:+
LUAD	cis	rs875971	0.522	rs4502988	ENSG00000236529.1	RP13-254B10.1	5.24	2.46e-07	7.16e-05	0.24	0.23	Aortic root size;	chr7:65832759	chr7:65840212~65840596:+
LUAD	cis	rs8180040	0.726	rs11130110	ENSG00000271161.1	BOLA2P2	5.24	2.46e-07	7.16e-05	0.22	0.23	Colorectal cancer;	chr3:46959116	chr3:47499841~47500407:+
LUAD	cis	rs41307935	0.822	rs71636786	ENSG00000260063.1	RP5-968P14.2	-5.24	2.47e-07	7.17e-05	-0.42	-0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26851434	chr1:26692132~26694131:-
LUAD	cis	rs1816752	0.905	rs13428	ENSG00000273628.1	RP11-756A22.7	5.24	2.47e-07	7.18e-05	0.27	0.23	Obesity-related traits;	chr13:24435303	chr13:24933006~24936796:+
LUAD	cis	rs7208859	0.673	rs11652370	ENSG00000263531.1	RP13-753N3.1	5.23	2.47e-07	7.18e-05	0.4	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770205	chr17:30863921~30864940:-
LUAD	cis	rs11105298	0.891	rs4842662	ENSG00000258302.2	RP11-981P6.1	5.23	2.47e-07	7.19e-05	0.29	0.23	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539669	chr12:89561129~89594878:+
LUAD	cis	rs11105298	0.891	rs3741898	ENSG00000258302.2	RP11-981P6.1	5.23	2.47e-07	7.19e-05	0.29	0.23	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539986	chr12:89561129~89594878:+
LUAD	cis	rs2295359	0.892	rs11209005	ENSG00000275678.1	RP4-547N15.3	-5.23	2.48e-07	7.2e-05	-0.25	-0.23	Psoriasis;	chr1:67152995	chr1:67121605~67123956:-
LUAD	cis	rs12928939	0.815	rs10500560	ENSG00000260886.1	TAT-AS1	5.23	2.48e-07	7.2e-05	0.29	0.23	Post bronchodilator FEV1;	chr16:71647250	chr16:71565789~71578187:+
LUAD	cis	rs867371	1	rs13380319	ENSG00000276710.3	CSPG4P8	-5.23	2.48e-07	7.21e-05	-0.21	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214526	chr15:82459472~82477258:+
LUAD	cis	rs10740039	1	rs10761541	ENSG00000254271.1	RP11-131N11.4	5.23	2.48e-07	7.21e-05	0.26	0.23	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60655383	chr10:60734342~60741828:+
LUAD	cis	rs7017914	0.652	rs7831507	ENSG00000223220.1	Y_RNA	5.23	2.48e-07	7.22e-05	0.27	0.23	Bone mineral density;	chr8:70682991	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs13256093	ENSG00000223220.1	Y_RNA	5.23	2.48e-07	7.22e-05	0.27	0.23	Bone mineral density;	chr8:70684142	chr8:70780914~70781008:-
LUAD	cis	rs7617773	0.709	rs4404473	ENSG00000228638.1	FCF1P2	-5.23	2.49e-07	7.22e-05	-0.28	-0.23	Coronary artery disease;	chr3:48312136	chr3:48290793~48291375:-
LUAD	cis	rs1707322	1	rs6677777	ENSG00000280836.1	AL355480.1	-5.23	2.49e-07	7.23e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46010164	chr1:45581219~45581321:-
LUAD	cis	rs891378	1	rs877049	ENSG00000274245.1	RP11-357P18.2	-5.23	2.49e-07	7.23e-05	-0.28	-0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207249651	chr1:207372559~207373252:+
LUAD	cis	rs6102185	0.624	rs6129697	ENSG00000229771.2	RP4-644L1.2	-5.23	2.49e-07	7.23e-05	-0.28	-0.23	IgG glycosylation;	chr20:40887371	chr20:40696499~40698616:-
LUAD	cis	rs1823874	0.677	rs8042705	ENSG00000182397.13	DNM1P46	-5.23	2.49e-07	7.23e-05	-0.28	-0.23	IgG glycosylation;	chr15:99824501	chr15:99790156~99806927:-
LUAD	cis	rs9900062	1	rs9900062	ENSG00000270714.1	MINOS1P2	-5.23	2.49e-07	7.23e-05	-0.34	-0.23	QT interval;	chr17:64743456	chr17:64747264~64747492:-
LUAD	cis	rs1707322	0.963	rs10789478	ENSG00000280836.1	AL355480.1	-5.23	2.49e-07	7.23e-05	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45884834	chr1:45581219~45581321:-
LUAD	cis	rs7968440	1	rs7307815	ENSG00000200428.1	Y_RNA	-5.23	2.49e-07	7.23e-05	-0.29	-0.23	Fibrinogen;	chr12:50528927	chr12:50743568~50743684:+
LUAD	cis	rs7618501	0.602	rs2071207	ENSG00000234667.1	ACTBP13	5.23	2.49e-07	7.25e-05	0.26	0.23	Intelligence (multi-trait analysis);	chr3:50122411	chr3:49873347~49877980:-
LUAD	cis	rs7829975	0.714	rs4840362	ENSG00000253893.2	FAM85B	5.23	2.49e-07	7.25e-05	0.29	0.23	Mood instability;	chr8:8812572	chr8:8167819~8226614:-
LUAD	cis	rs643506	0.874	rs645411	ENSG00000230911.1	PPIHP1	-5.23	2.5e-07	7.25e-05	-0.29	-0.23	Breast cancer;	chr11:111823766	chr11:112029858~112030367:-
LUAD	cis	rs301901	0.663	rs217847	ENSG00000250155.1	CTD-2353F22.1	5.23	2.5e-07	7.25e-05	0.25	0.23	Height;	chr5:37367135	chr5:36666214~36725195:-
LUAD	cis	rs948562	0.69	rs73481989	ENSG00000280010.1	AP001350.4	5.23	2.5e-07	7.26e-05	0.35	0.23	Lymphoma;	chr11:58310587	chr11:58627435~58628528:+
LUAD	cis	rs4947019	0.609	rs4946972	ENSG00000260273.1	RP11-425D10.10	5.23	2.5e-07	7.26e-05	0.48	0.23	Hematological parameters;	chr6:109400025	chr6:109382795~109383666:+
LUAD	cis	rs12701220	0.655	rs6955290	ENSG00000229043.2	AC091729.9	5.23	2.5e-07	7.26e-05	0.28	0.23	Bronchopulmonary dysplasia;	chr7:1111430	chr7:1160374~1165267:+
LUAD	cis	rs2688608	0.592	rs11814282	ENSG00000271816.1	BMS1P4	5.23	2.5e-07	7.26e-05	0.2	0.23	Inflammatory bowel disease;	chr10:73730459	chr10:73699151~73730487:-
LUAD	cis	rs2688608	0.53	rs71507081	ENSG00000271816.1	BMS1P4	5.23	2.5e-07	7.26e-05	0.2	0.23	Inflammatory bowel disease;	chr10:73733378	chr10:73699151~73730487:-
LUAD	cis	rs2675662	0.525	rs12264025	ENSG00000271816.1	BMS1P4	5.23	2.5e-07	7.26e-05	0.2	0.23	Psoriasis vulgaris;Psoriasis;	chr10:73734692	chr10:73699151~73730487:-
LUAD	cis	rs2688608	0.592	rs12253429	ENSG00000271816.1	BMS1P4	5.23	2.5e-07	7.26e-05	0.2	0.23	Inflammatory bowel disease;	chr10:73736403	chr10:73699151~73730487:-
LUAD	cis	rs6751744	0.513	rs10173538	ENSG00000226266.5	AC009961.3	-5.23	2.5e-07	7.27e-05	-0.32	-0.23	Dysphagia;	chr2:159712765	chr2:159670708~159712435:-
LUAD	cis	rs8098244	0.617	rs12957168	ENSG00000264745.1	TTC39C-AS1	-5.23	2.5e-07	7.27e-05	-0.24	-0.23	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23821960	chr18:23994213~24015339:-
LUAD	cis	rs17826219	0.706	rs28469200	ENSG00000263603.1	CTD-2349P21.5	-5.23	2.5e-07	7.27e-05	-0.4	-0.23	Body mass index;	chr17:30806554	chr17:30729469~30731202:+
LUAD	cis	rs67311347	0.544	rs2887965	ENSG00000223797.4	ENTPD3-AS1	-5.23	2.51e-07	7.28e-05	-0.24	-0.23	Renal cell carcinoma;	chr3:40292663	chr3:40313802~40453329:-
LUAD	cis	rs36093844	0.706	rs11828105	ENSG00000279742.1	RP11-700A24.1	-5.23	2.51e-07	7.28e-05	-0.31	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85839341	chr11:85852557~85854943:-
LUAD	cis	rs748404	0.697	rs493444	ENSG00000249839.1	AC011330.5	-5.23	2.51e-07	7.28e-05	-0.3	-0.23	Lung cancer;	chr15:43274272	chr15:43663654~43684339:-
LUAD	cis	rs9487094	0.885	rs1358997	ENSG00000260273.1	RP11-425D10.10	5.23	2.51e-07	7.28e-05	0.32	0.23	Height;	chr6:109380457	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.885	rs3799839	ENSG00000260273.1	RP11-425D10.10	5.23	2.51e-07	7.28e-05	0.32	0.23	Height;	chr6:109380990	chr6:109382795~109383666:+
LUAD	cis	rs2765539	0.851	rs1891141	ENSG00000226172.2	RP4-712E4.1	-5.23	2.51e-07	7.28e-05	-0.29	-0.23	Waist-hip ratio;	chr1:119034787	chr1:119000344~119001392:-
LUAD	cis	rs61270009	0.955	rs12657757	ENSG00000247828.6	TMEM161B-AS1	-5.23	2.51e-07	7.28e-05	-0.28	-0.23	Depressive symptoms;	chr5:88280952	chr5:88268895~88436685:+
LUAD	cis	rs6570726	0.791	rs12208812	ENSG00000235652.6	RP11-545I5.3	5.23	2.51e-07	7.28e-05	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145579788	chr6:145799409~145886585:+
LUAD	cis	rs10129255	0.518	rs10150460	ENSG00000254174.1	IGHV1-12	-5.23	2.51e-07	7.29e-05	-0.16	-0.23	Kawasaki disease;	chr14:106677179	chr14:106122420~106122709:-
LUAD	cis	rs7772486	0.754	rs9399561	ENSG00000235652.6	RP11-545I5.3	5.23	2.51e-07	7.29e-05	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145634551	chr6:145799409~145886585:+
LUAD	cis	rs4273100	0.834	rs59415593	ENSG00000228157.4	AC007952.5	5.23	2.51e-07	7.3e-05	0.39	0.23	Schizophrenia;	chr17:19319911	chr17:19092974~19096837:+
LUAD	cis	rs4835473	0.932	rs12505628	ENSG00000251600.4	RP11-673E1.1	-5.23	2.51e-07	7.3e-05	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143758468	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs12505663	ENSG00000251600.4	RP11-673E1.1	-5.23	2.51e-07	7.3e-05	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143758491	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.868	rs12513078	ENSG00000251600.4	RP11-673E1.1	-5.23	2.51e-07	7.3e-05	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143758494	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs12505665	ENSG00000251600.4	RP11-673E1.1	-5.23	2.51e-07	7.3e-05	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143758515	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs12509716	ENSG00000251600.4	RP11-673E1.1	-5.23	2.51e-07	7.3e-05	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143758520	chr4:143912331~143982454:+
LUAD	cis	rs600231	0.708	rs3132767	ENSG00000245532.5	NEAT1	5.23	2.52e-07	7.31e-05	0.18	0.23	Bone mineral density;	chr11:65467389	chr11:65422774~65445540:+
LUAD	cis	rs516805	0.667	rs2606624	ENSG00000279453.1	RP3-425C14.4	-5.23	2.52e-07	7.31e-05	-0.31	-0.23	Lymphocyte counts;	chr6:122168693	chr6:122436789~122439223:-
LUAD	cis	rs7580658	0.637	rs12463909	ENSG00000236682.1	AC068282.3	5.23	2.52e-07	7.31e-05	0.3	0.23	Protein C levels;	chr2:127214162	chr2:127389130~127400580:+
LUAD	cis	rs7968440	0.75	rs67356137	ENSG00000200428.1	Y_RNA	-5.23	2.52e-07	7.32e-05	-0.29	-0.23	Fibrinogen;	chr12:50778044	chr12:50743568~50743684:+
LUAD	cis	rs7927592	0.731	rs643609	ENSG00000212093.1	AP000807.1	5.23	2.52e-07	7.32e-05	0.23	0.23	Total body bone mineral density;	chr11:68474365	chr11:68506083~68506166:-
LUAD	cis	rs1914816	0.653	rs480672	ENSG00000196274.5	Metazoa_SRP	5.23	2.53e-07	7.33e-05	0.3	0.23	Response to tocilizumab in rheumatoid arthritis;	chr15:76489589	chr15:76230048~76230390:-
LUAD	cis	rs11976180	1	rs1540894	ENSG00000170356.8	OR2A20P	-5.23	2.53e-07	7.34e-05	-0.29	-0.23	Obesity-related traits;	chr7:144070583	chr7:144250045~144252957:-
LUAD	cis	rs2404602	0.967	rs2083762	ENSG00000259422.1	RP11-593F23.1	5.23	2.53e-07	7.34e-05	0.28	0.23	Blood metabolite levels;	chr15:76615035	chr15:76174891~76181486:-
LUAD	cis	rs293748	0.771	rs151947	ENSG00000250155.1	CTD-2353F22.1	-5.23	2.53e-07	7.34e-05	-0.32	-0.23	Obesity-related traits;	chr5:36865491	chr5:36666214~36725195:-
LUAD	cis	rs1150668	0.745	rs213238	ENSG00000219392.1	RP1-265C24.5	-5.23	2.53e-07	7.35e-05	-0.29	-0.23	Pubertal anthropometrics;	chr6:28354216	chr6:28115628~28116551:+
LUAD	cis	rs12681366	0.881	rs12682038	ENSG00000253704.1	RP11-267M23.4	5.23	2.53e-07	7.35e-05	0.29	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94393252	chr8:94553722~94569745:+
LUAD	cis	rs6772849	0.708	rs12491942	ENSG00000242551.2	POU5F1P6	-5.23	2.53e-07	7.35e-05	-0.28	-0.23	Monocyte percentage of white cells;Monocyte count;	chr3:128702626	chr3:128674735~128677005:-
LUAD	cis	rs4835473	0.932	rs17695782	ENSG00000251600.4	RP11-673E1.1	-5.23	2.53e-07	7.35e-05	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143830311	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs34917094	ENSG00000251600.4	RP11-673E1.1	-5.23	2.53e-07	7.35e-05	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143832003	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs11736609	ENSG00000251600.4	RP11-673E1.1	-5.23	2.53e-07	7.35e-05	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143832876	chr4:143912331~143982454:+
LUAD	cis	rs2933343	0.679	rs789221	ENSG00000261159.1	RP11-723O4.9	5.23	2.53e-07	7.35e-05	0.25	0.23	IgG glycosylation;	chr3:128872782	chr3:128859716~128860526:-
LUAD	cis	rs3096299	0.935	rs3102387	ENSG00000182376.2	RP5-1142A6.8	5.23	2.53e-07	7.36e-05	0.24	0.23	Multiple myeloma (IgH translocation);	chr16:89365868	chr16:88742767~88745748:+
LUAD	cis	rs8040855	0.794	rs4843024	ENSG00000259774.1	RP11-182J1.13	-5.23	2.54e-07	7.36e-05	-0.29	-0.23	Bulimia nervosa;	chr15:85162669	chr15:84422618~84425882:+
LUAD	cis	rs6964587	0.773	rs59242586	ENSG00000188693.7	CYP51A1-AS1	-5.23	2.54e-07	7.37e-05	-0.28	-0.23	Breast cancer;	chr7:92288831	chr7:92134604~92180725:+
LUAD	cis	rs8031584	0.706	rs798084	ENSG00000270015.1	RP11-540B6.6	-5.23	2.54e-07	7.37e-05	-0.18	-0.23	Huntington's disease progression;	chr15:30834732	chr15:30926514~30928407:+
LUAD	cis	rs4927850	1	rs10881563	ENSG00000242086.7	LINC00969	5.23	2.54e-07	7.37e-05	0.21	0.23	Pancreatic cancer;	chr3:196023354	chr3:195658062~195739964:+
LUAD	cis	rs7662987	0.793	rs28730632	ENSG00000272777.1	RP11-571L19.8	5.23	2.54e-07	7.37e-05	0.37	0.23	Smoking initiation;	chr4:99074552	chr4:99067256~99068125:-
LUAD	cis	rs748404	0.666	rs34591748	ENSG00000205771.5	CATSPER2P1	-5.23	2.54e-07	7.38e-05	-0.35	-0.23	Lung cancer;	chr15:43334917	chr15:43726918~43747094:-
LUAD	cis	rs516805	0.634	rs2816159	ENSG00000279453.1	RP3-425C14.4	-5.23	2.54e-07	7.38e-05	-0.32	-0.23	Lymphocyte counts;	chr6:122121982	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.63	rs1379098	ENSG00000279453.1	RP3-425C14.4	-5.23	2.54e-07	7.38e-05	-0.32	-0.23	Lymphocyte counts;	chr6:122121672	chr6:122436789~122439223:-
LUAD	cis	rs17772222	0.958	rs10134008	ENSG00000258983.2	RP11-507K2.2	5.23	2.54e-07	7.38e-05	0.28	0.23	Coronary artery calcification;	chr14:88549183	chr14:88499334~88515502:+
LUAD	cis	rs17772222	0.958	rs891750	ENSG00000258983.2	RP11-507K2.2	5.23	2.54e-07	7.38e-05	0.28	0.23	Coronary artery calcification;	chr14:88550856	chr14:88499334~88515502:+
LUAD	cis	rs17772222	0.958	rs891749	ENSG00000258983.2	RP11-507K2.2	5.23	2.54e-07	7.38e-05	0.28	0.23	Coronary artery calcification;	chr14:88550893	chr14:88499334~88515502:+
LUAD	cis	rs2404602	0.735	rs4886800	ENSG00000259422.1	RP11-593F23.1	-5.23	2.55e-07	7.38e-05	-0.29	-0.23	Blood metabolite levels;	chr15:76386351	chr15:76174891~76181486:-
LUAD	cis	rs7911264	1	rs10882100	ENSG00000236493.2	EIF2S2P3	5.23	2.55e-07	7.39e-05	0.26	0.23	Inflammatory bowel disease;	chr10:92700930	chr10:92668745~92669743:-
LUAD	cis	rs7617773	0.78	rs13067450	ENSG00000228638.1	FCF1P2	-5.23	2.55e-07	7.39e-05	-0.28	-0.23	Coronary artery disease;	chr3:48295716	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.78	rs4479622	ENSG00000228638.1	FCF1P2	-5.23	2.55e-07	7.39e-05	-0.28	-0.23	Coronary artery disease;	chr3:48296683	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.78	rs34946886	ENSG00000228638.1	FCF1P2	-5.23	2.55e-07	7.39e-05	-0.28	-0.23	Coronary artery disease;	chr3:48296997	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.78	rs34589064	ENSG00000228638.1	FCF1P2	-5.23	2.55e-07	7.39e-05	-0.28	-0.23	Coronary artery disease;	chr3:48298059	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.78	rs2541	ENSG00000228638.1	FCF1P2	-5.23	2.55e-07	7.39e-05	-0.28	-0.23	Coronary artery disease;	chr3:48298128	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.78	rs13085251	ENSG00000228638.1	FCF1P2	-5.23	2.55e-07	7.39e-05	-0.28	-0.23	Coronary artery disease;	chr3:48298555	chr3:48290793~48291375:-
LUAD	cis	rs516805	0.748	rs563084	ENSG00000279453.1	RP3-425C14.4	5.23	2.55e-07	7.39e-05	0.3	0.23	Lymphocyte counts;	chr6:122397105	chr6:122436789~122439223:-
LUAD	cis	rs4323050	0.546	rs13124157	ENSG00000251600.4	RP11-673E1.1	5.23	2.55e-07	7.39e-05	0.29	0.23	High light scatter reticulocyte percentage of red cells;	chr4:143975741	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs13147170	ENSG00000251600.4	RP11-673E1.1	5.23	2.55e-07	7.39e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143975848	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs13147184	ENSG00000251600.4	RP11-673E1.1	5.23	2.55e-07	7.39e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143975873	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.8	rs13124170	ENSG00000251600.4	RP11-673E1.1	5.23	2.55e-07	7.39e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143975951	chr4:143912331~143982454:+
LUAD	cis	rs6543140	0.964	rs10169192	ENSG00000234389.1	AC007278.3	5.23	2.55e-07	7.39e-05	0.23	0.23	Blood protein levels;	chr2:102455751	chr2:102438713~102440475:+
LUAD	cis	rs6543140	0.964	rs11886793	ENSG00000234389.1	AC007278.3	5.23	2.55e-07	7.39e-05	0.23	0.23	Blood protein levels;	chr2:102455760	chr2:102438713~102440475:+
LUAD	cis	rs6543140	0.964	rs2310301	ENSG00000234389.1	AC007278.3	5.23	2.55e-07	7.39e-05	0.23	0.23	Blood protein levels;	chr2:102456475	chr2:102438713~102440475:+
LUAD	cis	rs6543140	1	rs6543140	ENSG00000234389.1	AC007278.3	5.23	2.55e-07	7.39e-05	0.23	0.23	Blood protein levels;	chr2:102457814	chr2:102438713~102440475:+
LUAD	cis	rs6543140	0.964	rs13390895	ENSG00000234389.1	AC007278.3	5.23	2.55e-07	7.39e-05	0.23	0.23	Blood protein levels;	chr2:102459039	chr2:102438713~102440475:+
LUAD	cis	rs6543140	0.855	rs4851591	ENSG00000234389.1	AC007278.3	5.23	2.55e-07	7.39e-05	0.23	0.23	Blood protein levels;	chr2:102460963	chr2:102438713~102440475:+
LUAD	cis	rs6543140	0.964	rs7561351	ENSG00000234389.1	AC007278.3	5.23	2.55e-07	7.39e-05	0.23	0.23	Blood protein levels;	chr2:102461320	chr2:102438713~102440475:+
LUAD	cis	rs6543140	0.964	rs13393175	ENSG00000234389.1	AC007278.3	5.23	2.55e-07	7.39e-05	0.23	0.23	Blood protein levels;	chr2:102462389	chr2:102438713~102440475:+
LUAD	cis	rs12530	0.715	rs2294311	ENSG00000230736.2	RP1-149A16.3	-5.23	2.55e-07	7.4e-05	-0.26	-0.23	IgG glycosylation;	chr22:32397282	chr22:32376664~32384343:+
LUAD	cis	rs867371	1	rs8037224	ENSG00000276710.3	CSPG4P8	-5.23	2.55e-07	7.4e-05	-0.22	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82172189	chr15:82459472~82477258:+
LUAD	cis	rs453301	0.592	rs4841084	ENSG00000253893.2	FAM85B	-5.23	2.55e-07	7.4e-05	-0.3	-0.23	Joint mobility (Beighton score);	chr8:9026395	chr8:8167819~8226614:-
LUAD	cis	rs1707322	0.686	rs2050376	ENSG00000280836.1	AL355480.1	-5.23	2.55e-07	7.4e-05	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45612958	chr1:45581219~45581321:-
LUAD	cis	rs7617773	0.78	rs13090538	ENSG00000228638.1	FCF1P2	-5.23	2.55e-07	7.41e-05	-0.28	-0.23	Coronary artery disease;	chr3:48329279	chr3:48290793~48291375:-
LUAD	cis	rs453301	0.653	rs7005133	ENSG00000173295.6	FAM86B3P	5.23	2.56e-07	7.41e-05	0.24	0.23	Joint mobility (Beighton score);	chr8:9043712	chr8:8228595~8244865:+
LUAD	cis	rs8072100	0.817	rs7213086	ENSG00000228782.6	CTD-2026D20.3	5.23	2.56e-07	7.41e-05	0.25	0.23	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47674944	chr17:47450568~47492492:-
LUAD	cis	rs559928	0.606	rs12419038	ENSG00000236935.1	AP003774.1	5.23	2.56e-07	7.42e-05	0.32	0.23	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64145264	chr11:64325050~64329504:-
LUAD	cis	rs9494145	0.838	rs9483788	ENSG00000232876.1	CTA-212D2.2	-5.23	2.56e-07	7.43e-05	-0.33	-0.23	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135114363	chr6:135055033~135060550:+
LUAD	cis	rs17684571	0.751	rs6934714	ENSG00000231441.1	RP11-472M19.2	5.23	2.56e-07	7.43e-05	0.33	0.23	Schizophrenia;	chr6:56821811	chr6:56844002~56864078:+
LUAD	cis	rs2288884	0.767	rs3450	ENSG00000275055.1	CTC-471J1.11	-5.23	2.56e-07	7.43e-05	-0.33	-0.23	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52049746	chr19:52049007~52049754:+
LUAD	cis	rs7968440	0.736	rs10735827	ENSG00000200428.1	Y_RNA	-5.23	2.56e-07	7.43e-05	-0.29	-0.23	Fibrinogen;	chr12:50788629	chr12:50743568~50743684:+
LUAD	cis	rs7819412	0.765	rs7000132	ENSG00000255046.1	RP11-297N6.4	5.23	2.56e-07	7.43e-05	0.28	0.23	Triglycerides;	chr8:11173426	chr8:11797928~11802568:-
LUAD	cis	rs2179367	0.6	rs9498355	ENSG00000231760.4	RP11-350J20.5	-5.23	2.56e-07	7.43e-05	-0.35	-0.23	Dupuytren's disease;	chr6:149442274	chr6:149796151~149826294:-
LUAD	cis	rs10740039	1	rs10740039	ENSG00000254271.1	RP11-131N11.4	5.23	2.57e-07	7.44e-05	0.25	0.23	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60654924	chr10:60734342~60741828:+
LUAD	cis	rs10246939	0.505	rs9640203	ENSG00000228775.6	WEE2-AS1	5.23	2.57e-07	7.45e-05	0.3	0.23	Bitter taste perception;	chr7:141844295	chr7:141704338~141738346:-
LUAD	cis	rs944289	0.576	rs1820604	ENSG00000257826.1	RP11-116N8.4	5.23	2.57e-07	7.45e-05	0.25	0.23	Thyroid cancer;	chr14:36170000	chr14:36061026~36067190:-
LUAD	cis	rs17684571	0.7	rs13220618	ENSG00000231441.1	RP11-472M19.2	5.23	2.57e-07	7.45e-05	0.34	0.23	Schizophrenia;	chr6:56819388	chr6:56844002~56864078:+
LUAD	cis	rs10129255	1	rs10129255	ENSG00000224373.3	IGHV4-59	-5.23	2.57e-07	7.45e-05	-0.15	-0.23	Kawasaki disease;	chr14:106767970	chr14:106627249~106627825:-
LUAD	cis	rs7829975	0.617	rs4841072	ENSG00000253893.2	FAM85B	5.23	2.57e-07	7.45e-05	0.29	0.23	Mood instability;	chr8:8933743	chr8:8167819~8226614:-
LUAD	cis	rs2522056	1	rs1003533	ENSG00000233006.5	AC034220.3	-5.23	2.57e-07	7.45e-05	-0.25	-0.23	Fibrinogen;Lymphocyte counts;	chr5:132419959	chr5:132311285~132369916:-
LUAD	cis	rs4268898	0.722	rs6723257	ENSG00000242628.4	AC009228.1	-5.23	2.57e-07	7.46e-05	-0.3	-0.23	Asthma;	chr2:24168260	chr2:24214381~24221516:+
LUAD	cis	rs916888	0.821	rs199505	ENSG00000261575.2	RP11-259G18.1	-5.23	2.57e-07	7.46e-05	-0.36	-0.23	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46267037~46268694:+
LUAD	cis	rs916888	0.821	rs70602	ENSG00000261575.2	RP11-259G18.1	-5.23	2.57e-07	7.46e-05	-0.36	-0.23	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46267037~46268694:+
LUAD	cis	rs4268898	0.722	rs11680491	ENSG00000242628.4	AC009228.1	-5.23	2.57e-07	7.46e-05	-0.29	-0.23	Asthma;	chr2:24193423	chr2:24214381~24221516:+
LUAD	cis	rs6487679	0.614	rs6487668	ENSG00000111788.10	RP11-22B23.1	5.23	2.57e-07	7.46e-05	0.24	0.23	Non-alcoholic fatty liver disease histology (AST);	chr12:9200312	chr12:9277235~9313241:+
LUAD	cis	rs8031584	0.541	rs2959037	ENSG00000260382.1	RP11-540B6.2	-5.23	2.57e-07	7.46e-05	-0.27	-0.23	Huntington's disease progression;	chr15:30925961	chr15:30882267~30883231:-
LUAD	cis	rs4835473	0.9	rs34264936	ENSG00000251600.4	RP11-673E1.1	-5.23	2.57e-07	7.46e-05	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143780294	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs13140028	ENSG00000251600.4	RP11-673E1.1	-5.23	2.57e-07	7.46e-05	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143782195	chr4:143912331~143982454:+
LUAD	cis	rs7968440	1	rs2684900	ENSG00000200428.1	Y_RNA	-5.23	2.58e-07	7.46e-05	-0.29	-0.23	Fibrinogen;	chr12:50625773	chr12:50743568~50743684:+
LUAD	cis	rs875971	0.862	rs1968126	ENSG00000232559.3	GS1-124K5.12	-5.23	2.58e-07	7.47e-05	-0.27	-0.23	Aortic root size;	chr7:66592017	chr7:66554588~66576923:-
LUAD	cis	rs867371	1	rs1501372	ENSG00000276710.3	CSPG4P8	-5.23	2.58e-07	7.47e-05	-0.22	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176114	chr15:82459472~82477258:+
LUAD	cis	rs867371	1	rs1846911	ENSG00000276710.3	CSPG4P8	-5.23	2.58e-07	7.47e-05	-0.22	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176309	chr15:82459472~82477258:+
LUAD	cis	rs8062405	0.573	rs8045689	ENSG00000251417.2	RP11-1348G14.4	5.23	2.58e-07	7.47e-05	0.25	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28976948	chr16:28802743~28817828:+
LUAD	cis	rs1707322	1	rs11211190	ENSG00000234329.1	RP11-767N6.2	5.23	2.58e-07	7.47e-05	0.24	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800583	chr1:45651039~45651826:-
LUAD	cis	rs11976180	1	rs2961144	ENSG00000170356.8	OR2A20P	5.23	2.58e-07	7.48e-05	0.29	0.23	Obesity-related traits;	chr7:144050777	chr7:144250045~144252957:-
LUAD	cis	rs2295359	0.892	rs4655686	ENSG00000275678.1	RP4-547N15.3	-5.23	2.58e-07	7.48e-05	-0.25	-0.23	Psoriasis;	chr1:67172321	chr1:67121605~67123956:-
LUAD	cis	rs9595908	0.785	rs17515873	ENSG00000212293.1	SNORA16	5.23	2.58e-07	7.48e-05	0.25	0.23	Body mass index;	chr13:32647711	chr13:32420390~32420516:-
LUAD	cis	rs2286503	0.901	rs10950922	ENSG00000221740.1	SNORD93	5.23	2.59e-07	7.49e-05	0.26	0.23	Fibrinogen;	chr7:22814387	chr7:22856613~22856686:+
LUAD	cis	rs7968440	0.933	rs2700480	ENSG00000200428.1	Y_RNA	-5.23	2.59e-07	7.5e-05	-0.29	-0.23	Fibrinogen;	chr12:50628648	chr12:50743568~50743684:+
LUAD	cis	rs3738443	1	rs75028588	ENSG00000259865.1	RP11-488L18.10	5.23	2.59e-07	7.5e-05	0.25	0.23	Alcohol dependence;	chr1:247208350	chr1:247187281~247188526:-
LUAD	cis	rs4835473	0.897	rs17693768	ENSG00000251600.4	RP11-673E1.1	-5.23	2.59e-07	7.51e-05	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143737503	chr4:143912331~143982454:+
LUAD	cis	rs7777677	0.925	rs4726542	ENSG00000244273.1	PGBD4P1	-5.23	2.59e-07	7.51e-05	-0.25	-0.23	Alcoholic chronic pancreatitis;	chr7:142659516	chr7:142722358~142722764:+
LUAD	cis	rs1008375	0.898	rs9998130	ENSG00000249502.1	AC006160.5	-5.23	2.6e-07	7.52e-05	-0.23	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17592282	chr4:17587467~17614571:-
LUAD	cis	rs2239547	0.522	rs6771610	ENSG00000242142.1	SERBP1P3	5.23	2.6e-07	7.52e-05	0.27	0.23	Schizophrenia;	chr3:52992088	chr3:53064283~53065091:-
LUAD	cis	rs61270009	0.955	rs11741675	ENSG00000247828.6	TMEM161B-AS1	5.23	2.6e-07	7.52e-05	0.27	0.23	Depressive symptoms;	chr5:88332984	chr5:88268895~88436685:+
LUAD	cis	rs4835473	0.864	rs4835343	ENSG00000251600.4	RP11-673E1.1	5.23	2.6e-07	7.52e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143866038	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.831	rs1579816	ENSG00000251600.4	RP11-673E1.1	5.23	2.6e-07	7.52e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143866772	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs4240334	ENSG00000251600.4	RP11-673E1.1	5.23	2.6e-07	7.52e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143871352	chr4:143912331~143982454:+
LUAD	cis	rs867371	0.929	rs7176075	ENSG00000276710.3	CSPG4P8	-5.22	2.6e-07	7.53e-05	-0.22	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82178998	chr15:82459472~82477258:+
LUAD	cis	rs287982	1	rs287979	ENSG00000269973.1	RP11-95D17.1	5.22	2.6e-07	7.53e-05	0.28	0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9830838	chr2:9936360~9939590:+
LUAD	cis	rs673078	0.66	rs7977403	ENSG00000275409.1	RP11-131L12.4	-5.22	2.6e-07	7.53e-05	-0.33	-0.23	Glucose homeostasis traits;	chr12:118233446	chr12:118430147~118430699:+
LUAD	cis	rs4141404	0.512	rs2070274	ENSG00000236132.1	CTA-440B3.1	5.22	2.6e-07	7.53e-05	0.27	0.23	Paclitaxel-induced neuropathy;	chr22:31603237	chr22:31816379~31817491:-
LUAD	cis	rs1707322	0.721	rs56255771	ENSG00000280836.1	AL355480.1	-5.22	2.6e-07	7.54e-05	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758647	chr1:45581219~45581321:-
LUAD	cis	rs6723226	0.721	rs10172510	ENSG00000276334.1	AL133243.1	5.22	2.6e-07	7.54e-05	0.25	0.23	Intelligence (multi-trait analysis);	chr2:32395820	chr2:32521927~32523547:+
LUAD	cis	rs12701220	0.655	rs6463317	ENSG00000229043.2	AC091729.9	-5.22	2.61e-07	7.54e-05	-0.28	-0.23	Bronchopulmonary dysplasia;	chr7:1119607	chr7:1160374~1165267:+
LUAD	cis	rs274567	0.599	rs11242110	ENSG00000233006.5	AC034220.3	-5.22	2.61e-07	7.54e-05	-0.21	-0.23	Blood metabolite levels;	chr5:132408085	chr5:132311285~132369916:-
LUAD	cis	rs4835473	0.9	rs6834494	ENSG00000251600.4	RP11-673E1.1	-5.22	2.61e-07	7.55e-05	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143822257	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs11734290	ENSG00000251600.4	RP11-673E1.1	-5.22	2.61e-07	7.55e-05	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143823636	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs11734383	ENSG00000251600.4	RP11-673E1.1	-5.22	2.61e-07	7.55e-05	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143824093	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.868	rs11735295	ENSG00000251600.4	RP11-673E1.1	-5.22	2.61e-07	7.55e-05	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143824150	chr4:143912331~143982454:+
LUAD	cis	rs891378	1	rs2564978	ENSG00000274245.1	RP11-357P18.2	-5.22	2.61e-07	7.55e-05	-0.3	-0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207321071	chr1:207372559~207373252:+
LUAD	cis	rs2562456	0.755	rs2650773	ENSG00000268081.1	RP11-678G14.2	-5.22	2.61e-07	7.55e-05	-0.37	-0.23	Pain;	chr19:21461286	chr19:21554640~21569237:-
LUAD	cis	rs10129255	0.5	rs11628999	ENSG00000254174.1	IGHV1-12	5.22	2.61e-07	7.55e-05	0.16	0.23	Kawasaki disease;	chr14:106800208	chr14:106122420~106122709:-
LUAD	cis	rs4908760	0.827	rs6692693	ENSG00000232912.4	RP5-1115A15.1	5.22	2.61e-07	7.56e-05	0.21	0.23	Vitiligo;	chr1:8647057	chr1:8424645~8434838:+
LUAD	cis	rs6570726	0.738	rs7746330	ENSG00000235652.6	RP11-545I5.3	5.22	2.61e-07	7.56e-05	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145578121	chr6:145799409~145886585:+
LUAD	cis	rs6142102	0.517	rs6142050	ENSG00000275784.1	RP5-1125A11.6	-5.22	2.61e-07	7.56e-05	-0.25	-0.23	Skin pigmentation;	chr20:33939322	chr20:33989480~33991818:-
LUAD	cis	rs1008375	0.9	rs1003413	ENSG00000249502.1	AC006160.5	5.22	2.61e-07	7.56e-05	0.23	0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17580819	chr4:17587467~17614571:-
LUAD	cis	rs7829975	0.511	rs2980426	ENSG00000173295.6	FAM86B3P	5.22	2.61e-07	7.56e-05	0.26	0.23	Mood instability;	chr8:8288087	chr8:8228595~8244865:+
LUAD	cis	rs2734839	0.507	rs1076562	ENSG00000270179.1	RP11-159N11.4	-5.22	2.61e-07	7.57e-05	-0.26	-0.23	Information processing speed;	chr11:113425286	chr11:113368478~113369117:+
LUAD	cis	rs4835473	0.932	rs35017645	ENSG00000251600.4	RP11-673E1.1	-5.22	2.62e-07	7.57e-05	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143760196	chr4:143912331~143982454:+
LUAD	cis	rs4865169	0.934	rs3796531	ENSG00000269949.1	RP11-738E22.3	-5.22	2.62e-07	7.57e-05	-0.29	-0.23	Breast cancer;	chr4:56984680	chr4:56960927~56961373:-
LUAD	cis	rs1008375	0.931	rs4479701	ENSG00000249502.1	AC006160.5	-5.22	2.62e-07	7.57e-05	-0.23	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17569873	chr4:17587467~17614571:-
LUAD	cis	rs9309473	0.687	rs12465867	ENSG00000163016.8	ALMS1P	5.22	2.62e-07	7.57e-05	0.26	0.23	Metabolite levels;	chr2:73384974	chr2:73644919~73685576:+
LUAD	cis	rs9309473	0.583	rs35885918	ENSG00000163016.8	ALMS1P	5.22	2.62e-07	7.57e-05	0.26	0.23	Metabolite levels;	chr2:73385106	chr2:73644919~73685576:+
LUAD	cis	rs3747113	1	rs1041748	ENSG00000128262.7	POM121L9P	-5.22	2.62e-07	7.57e-05	-0.25	-0.23	Gut microbiome composition (summer);	chr22:24304886	chr22:24251828~24265525:+
LUAD	cis	rs1075265	0.626	rs805412	ENSG00000233266.1	HMGB1P31	5.22	2.62e-07	7.58e-05	0.29	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53893683	chr2:54051334~54051760:+
LUAD	cis	rs638893	0.617	rs4938558	ENSG00000278376.1	RP11-158I9.8	-5.22	2.62e-07	7.58e-05	-0.28	-0.23	Vitiligo;	chr11:118847220	chr11:118791254~118793137:+
LUAD	cis	rs8098244	0.638	rs17797660	ENSG00000264745.1	TTC39C-AS1	5.22	2.62e-07	7.58e-05	0.24	0.23	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23853074	chr18:23994213~24015339:-
LUAD	cis	rs8098244	0.638	rs12955347	ENSG00000264745.1	TTC39C-AS1	5.22	2.62e-07	7.58e-05	0.24	0.23	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23853232	chr18:23994213~24015339:-
LUAD	cis	rs12745968	0.623	rs10874732	ENSG00000223787.2	RP4-593M8.1	-5.22	2.62e-07	7.59e-05	-0.27	-0.23	Bipolar disorder and schizophrenia;	chr1:92658002	chr1:92580476~92580821:-
LUAD	cis	rs113835537	0.935	rs3867133	ENSG00000255517.5	CTD-3074O7.5	5.22	2.62e-07	7.59e-05	0.32	0.23	Airway imaging phenotypes;	chr11:66684491	chr11:66473490~66480233:-
LUAD	cis	rs7083	1	rs7083	ENSG00000254851.1	RP11-109L13.1	5.22	2.62e-07	7.59e-05	0.29	0.23	Blood protein levels;	chr11:117285836	chr11:117135528~117138582:+
LUAD	cis	rs11976180	1	rs1919949	ENSG00000170356.8	OR2A20P	-5.22	2.63e-07	7.6e-05	-0.29	-0.23	Obesity-related traits;	chr7:144070630	chr7:144250045~144252957:-
LUAD	cis	rs875971	0.66	rs10263935	ENSG00000237310.1	GS1-124K5.4	5.22	2.63e-07	7.6e-05	0.25	0.23	Aortic root size;	chr7:66631041	chr7:66493706~66495474:+
LUAD	cis	rs9595908	0.746	rs9596076	ENSG00000212293.1	SNORA16	5.22	2.63e-07	7.6e-05	0.25	0.23	Body mass index;	chr13:32693515	chr13:32420390~32420516:-
LUAD	cis	rs2688608	0.592	rs11000760	ENSG00000271816.1	BMS1P4	5.22	2.63e-07	7.6e-05	0.2	0.23	Inflammatory bowel disease;	chr10:73733976	chr10:73699151~73730487:-
LUAD	cis	rs7131987	0.621	rs6487805	ENSG00000257176.2	RP11-996F15.2	5.22	2.63e-07	7.6e-05	0.26	0.23	QT interval;	chr12:29304617	chr12:29280418~29317848:-
LUAD	cis	rs287982	1	rs287981	ENSG00000269973.1	RP11-95D17.1	5.22	2.63e-07	7.61e-05	0.28	0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9831433	chr2:9936360~9939590:+
LUAD	cis	rs61270009	0.955	rs4916719	ENSG00000247828.6	TMEM161B-AS1	5.22	2.63e-07	7.61e-05	0.27	0.23	Depressive symptoms;	chr5:88327844	chr5:88268895~88436685:+
LUAD	cis	rs8031584	0.958	rs8034856	ENSG00000270015.1	RP11-540B6.6	-5.22	2.63e-07	7.61e-05	-0.17	-0.23	Huntington's disease progression;	chr15:30948754	chr15:30926514~30928407:+
LUAD	cis	rs12439619	0.693	rs4778989	ENSG00000276710.3	CSPG4P8	-5.22	2.63e-07	7.62e-05	-0.26	-0.23	Intelligence (multi-trait analysis);	chr15:82276963	chr15:82459472~82477258:+
LUAD	cis	rs1707322	0.752	rs12062535	ENSG00000280836.1	AL355480.1	-5.22	2.64e-07	7.62e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45757208	chr1:45581219~45581321:-
LUAD	cis	rs4664293	0.967	rs12999124	ENSG00000226266.5	AC009961.3	-5.22	2.64e-07	7.63e-05	-0.32	-0.23	Monocyte percentage of white cells;	chr2:159674817	chr2:159670708~159712435:-
LUAD	cis	rs7968440	0.722	rs11609941	ENSG00000200428.1	Y_RNA	-5.22	2.64e-07	7.63e-05	-0.3	-0.23	Fibrinogen;	chr12:50773835	chr12:50743568~50743684:+
LUAD	cis	rs7968440	0.808	rs66947035	ENSG00000200428.1	Y_RNA	-5.22	2.64e-07	7.63e-05	-0.3	-0.23	Fibrinogen;	chr12:50781260	chr12:50743568~50743684:+
LUAD	cis	rs11673344	0.642	rs55755939	ENSG00000226686.6	LINC01535	5.22	2.64e-07	7.63e-05	0.3	0.23	Obesity-related traits;	chr19:37353723	chr19:37251912~37265535:+
LUAD	cis	rs1874124	0.836	rs7549963	ENSG00000272823.1	RP11-295M18.6	-5.22	2.64e-07	7.63e-05	-0.34	-0.23	Cholesterol, total;	chr1:220814918	chr1:220828676~220829211:-
LUAD	cis	rs875971	1	rs1183245	ENSG00000237310.1	GS1-124K5.4	-5.22	2.64e-07	7.64e-05	-0.25	-0.23	Aortic root size;	chr7:66076198	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs1144895	ENSG00000237310.1	GS1-124K5.4	-5.22	2.64e-07	7.64e-05	-0.25	-0.23	Aortic root size;	chr7:66076320	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs1144894	ENSG00000237310.1	GS1-124K5.4	-5.22	2.64e-07	7.64e-05	-0.25	-0.23	Aortic root size;	chr7:66077907	chr7:66493706~66495474:+
LUAD	cis	rs910316	0.967	rs10142770	ENSG00000259138.1	RP11-950C14.7	5.22	2.64e-07	7.64e-05	0.25	0.23	Height;	chr14:75058746	chr14:75127153~75136930:+
LUAD	cis	rs7208859	0.614	rs216474	ENSG00000263531.1	RP13-753N3.1	-5.22	2.64e-07	7.64e-05	-0.45	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30538073	chr17:30863921~30864940:-
LUAD	cis	rs6142102	0.625	rs6142051	ENSG00000275784.1	RP5-1125A11.6	-5.22	2.64e-07	7.64e-05	-0.25	-0.23	Skin pigmentation;	chr20:33945212	chr20:33989480~33991818:-
LUAD	cis	rs12289961	0.526	rs11229362	ENSG00000280010.1	AP001350.4	-5.22	2.65e-07	7.65e-05	-0.38	-0.23	Lymphoma;	chr11:58323142	chr11:58627435~58628528:+
LUAD	cis	rs1707322	0.686	rs2230658	ENSG00000280836.1	AL355480.1	5.22	2.65e-07	7.65e-05	0.31	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613182	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.686	rs2230659	ENSG00000280836.1	AL355480.1	5.22	2.65e-07	7.65e-05	0.31	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613212	chr1:45581219~45581321:-
LUAD	cis	rs4660214	0.666	rs4660550	ENSG00000228060.1	RP11-69E11.8	5.22	2.65e-07	7.65e-05	0.21	0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222787	chr1:39565160~39573203:+
LUAD	cis	rs8050896	0.793	rs2014885	ENSG00000260695.1	RP11-513N24.1	-5.22	2.65e-07	7.65e-05	-0.39	-0.23	Response to antipsychotic treatment;	chr16:66123012	chr16:65861112~65863784:-
LUAD	cis	rs75920871	0.528	rs12274388	ENSG00000254851.1	RP11-109L13.1	5.22	2.65e-07	7.65e-05	0.33	0.23	Subjective well-being;	chr11:117075522	chr11:117135528~117138582:+
LUAD	cis	rs889398	0.934	rs12923231	ENSG00000226232.7	RP11-419C5.2	5.22	2.65e-07	7.66e-05	0.2	0.23	Body mass index;	chr16:69538989	chr16:69976388~69996188:-
LUAD	cis	rs6570726	0.599	rs455001	ENSG00000235652.6	RP11-545I5.3	5.22	2.65e-07	7.66e-05	0.24	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145533314	chr6:145799409~145886585:+
LUAD	cis	rs2832077	0.506	rs2832085	ENSG00000232855.5	AF131217.1	5.22	2.65e-07	7.67e-05	0.23	0.23	Cognitive test performance;	chr21:28782936	chr21:28439346~28674848:-
LUAD	cis	rs67311347	0.544	rs13062243	ENSG00000223797.4	ENTPD3-AS1	5.22	2.66e-07	7.68e-05	0.24	0.23	Renal cell carcinoma;	chr3:40295298	chr3:40313802~40453329:-
LUAD	cis	rs67311347	0.544	rs12054197	ENSG00000223797.4	ENTPD3-AS1	5.22	2.66e-07	7.68e-05	0.24	0.23	Renal cell carcinoma;	chr3:40296071	chr3:40313802~40453329:-
LUAD	cis	rs4604732	0.631	rs12031721	ENSG00000227135.1	GCSAML-AS1	-5.22	2.66e-07	7.68e-05	-0.36	-0.23	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247460471	chr1:247524679~247526752:-
LUAD	cis	rs5769707	0.592	rs6009783	ENSG00000235111.1	RP1-29C18.8	-5.22	2.66e-07	7.68e-05	-0.27	-0.23	Monocyte percentage of white cells;Monocyte count;	chr22:49617353	chr22:49612657~49615716:-
LUAD	cis	rs6496932	0.913	rs4843037	ENSG00000202081.1	RNU6-1280P	5.22	2.66e-07	7.68e-05	0.32	0.23	Central corneal thickness;Corneal structure;	chr15:85274674	chr15:85651522~85651628:-
LUAD	cis	rs3738443	1	rs61839991	ENSG00000259865.1	RP11-488L18.10	5.22	2.66e-07	7.69e-05	0.25	0.23	Alcohol dependence;	chr1:247186284	chr1:247187281~247188526:-
LUAD	cis	rs3738443	0.953	rs56065612	ENSG00000259865.1	RP11-488L18.10	5.22	2.66e-07	7.69e-05	0.25	0.23	Alcohol dependence;	chr1:247194812	chr1:247187281~247188526:-
LUAD	cis	rs875971	0.522	rs2008188	ENSG00000236529.1	RP13-254B10.1	5.22	2.66e-07	7.69e-05	0.23	0.23	Aortic root size;	chr7:65964026	chr7:65840212~65840596:+
LUAD	cis	rs4143844	0.867	rs11071640	ENSG00000259251.2	RP11-643M14.1	5.22	2.66e-07	7.69e-05	0.41	0.23	Bipolar disorder and schizophrenia;	chr15:61918305	chr15:62060503~62062434:+
LUAD	cis	rs4143844	0.867	rs12907567	ENSG00000259251.2	RP11-643M14.1	5.22	2.66e-07	7.69e-05	0.41	0.23	Bipolar disorder and schizophrenia;	chr15:61922408	chr15:62060503~62062434:+
LUAD	cis	rs4143844	0.867	rs34853395	ENSG00000259251.2	RP11-643M14.1	5.22	2.66e-07	7.69e-05	0.41	0.23	Bipolar disorder and schizophrenia;	chr15:61923024	chr15:62060503~62062434:+
LUAD	cis	rs3020264	1	rs3020264	ENSG00000271743.1	CTD-2541M15.3	5.22	2.66e-07	7.69e-05	0.32	0.23	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6631056	chr8:6615604~6617198:-
LUAD	cis	rs2734839	0.507	rs2005313	ENSG00000270179.1	RP11-159N11.4	-5.22	2.66e-07	7.69e-05	-0.26	-0.23	Information processing speed;	chr11:113419327	chr11:113368478~113369117:+
LUAD	cis	rs7937890	1	rs2970335	ENSG00000254418.1	RP11-21L19.1	5.22	2.66e-07	7.69e-05	0.27	0.23	Mitochondrial DNA levels;	chr11:14303855	chr11:14262846~14273691:-
LUAD	cis	rs875971	0.66	rs801192	ENSG00000237310.1	GS1-124K5.4	-5.22	2.66e-07	7.69e-05	-0.25	-0.23	Aortic root size;	chr7:66566965	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.66	rs801190	ENSG00000237310.1	GS1-124K5.4	-5.22	2.66e-07	7.69e-05	-0.25	-0.23	Aortic root size;	chr7:66568046	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.66	rs3857686	ENSG00000237310.1	GS1-124K5.4	-5.22	2.66e-07	7.69e-05	-0.25	-0.23	Aortic root size;	chr7:66571204	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.638	rs3898855	ENSG00000237310.1	GS1-124K5.4	-5.22	2.66e-07	7.69e-05	-0.25	-0.23	Aortic root size;	chr7:66571411	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.638	rs10278816	ENSG00000237310.1	GS1-124K5.4	-5.22	2.66e-07	7.69e-05	-0.25	-0.23	Aortic root size;	chr7:66572000	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.66	rs10281080	ENSG00000237310.1	GS1-124K5.4	-5.22	2.66e-07	7.69e-05	-0.25	-0.23	Aortic root size;	chr7:66577454	chr7:66493706~66495474:+
LUAD	cis	rs67311347	0.544	rs4974047	ENSG00000223797.4	ENTPD3-AS1	5.22	2.67e-07	7.7e-05	0.24	0.23	Renal cell carcinoma;	chr3:40298162	chr3:40313802~40453329:-
LUAD	cis	rs7115242	1	rs7115242	ENSG00000280143.1	AP000892.6	-5.22	2.67e-07	7.7e-05	-0.39	-0.23	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117037567	chr11:117204967~117210292:+
LUAD	cis	rs7617773	0.744	rs2125482	ENSG00000228638.1	FCF1P2	-5.22	2.67e-07	7.7e-05	-0.28	-0.23	Coronary artery disease;	chr3:48281643	chr3:48290793~48291375:-
LUAD	cis	rs287982	1	rs287977	ENSG00000269973.1	RP11-95D17.1	5.22	2.67e-07	7.71e-05	0.28	0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9829889	chr2:9936360~9939590:+
LUAD	cis	rs2948294	0.588	rs7011221	ENSG00000253981.4	ALG1L13P	5.22	2.67e-07	7.71e-05	0.28	0.23	Red cell distribution width;	chr8:8256724	chr8:8236003~8244667:-
LUAD	cis	rs2295359	0.892	rs72676058	ENSG00000275678.1	RP4-547N15.3	-5.22	2.67e-07	7.71e-05	-0.25	-0.23	Psoriasis;	chr1:67161998	chr1:67121605~67123956:-
LUAD	cis	rs2239547	0.522	rs6770957	ENSG00000242142.1	SERBP1P3	5.22	2.67e-07	7.72e-05	0.27	0.23	Schizophrenia;	chr3:52961400	chr3:53064283~53065091:-
LUAD	cis	rs875971	0.862	rs28470208	ENSG00000232559.3	GS1-124K5.12	-5.22	2.68e-07	7.73e-05	-0.28	-0.23	Aortic root size;	chr7:66119713	chr7:66554588~66576923:-
LUAD	cis	rs6687821	0.515	rs1199680	ENSG00000267734.1	RP4-604K5.3	-5.22	2.68e-07	7.73e-05	-0.28	-0.23	Yeast infection;	chr1:87099993	chr1:86932199~86934891:-
LUAD	cis	rs6687821	0.515	rs7536241	ENSG00000267734.1	RP4-604K5.3	-5.22	2.68e-07	7.73e-05	-0.28	-0.23	Yeast infection;	chr1:87101030	chr1:86932199~86934891:-
LUAD	cis	rs1707322	0.721	rs10890343	ENSG00000280836.1	AL355480.1	-5.22	2.68e-07	7.73e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692250	chr1:45581219~45581321:-
LUAD	cis	rs2661868	0.788	rs2708631	ENSG00000232912.4	RP5-1115A15.1	-5.22	2.68e-07	7.74e-05	-0.24	-0.23	Life satisfaction;	chr1:8403450	chr1:8424645~8434838:+
LUAD	cis	rs2439831	0.85	rs7183809	ENSG00000205771.5	CATSPER2P1	-5.22	2.68e-07	7.75e-05	-0.45	-0.23	Lung cancer in ever smokers;	chr15:43828670	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.85	rs3759790	ENSG00000205771.5	CATSPER2P1	-5.22	2.68e-07	7.75e-05	-0.45	-0.23	Lung cancer in ever smokers;	chr15:43828832	chr15:43726918~43747094:-
LUAD	cis	rs11673344	0.832	rs112380313	ENSG00000226686.6	LINC01535	5.22	2.69e-07	7.75e-05	0.31	0.23	Obesity-related traits;	chr19:37027979	chr19:37251912~37265535:+
LUAD	cis	rs4835473	0.868	rs35809032	ENSG00000251600.4	RP11-673E1.1	-5.22	2.69e-07	7.76e-05	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143824797	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs17763107	ENSG00000251600.4	RP11-673E1.1	-5.22	2.69e-07	7.76e-05	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143828512	chr4:143912331~143982454:+
LUAD	cis	rs200986	1	rs200986	ENSG00000219392.1	RP1-265C24.5	-5.22	2.69e-07	7.76e-05	-0.3	-0.23	Autism spectrum disorder or schizophrenia;	chr6:27856988	chr6:28115628~28116551:+
LUAD	cis	rs17507216	0.718	rs28587782	ENSG00000255769.6	GOLGA2P10	-5.22	2.69e-07	7.77e-05	-0.3	-0.23	Excessive daytime sleepiness;	chr15:82576881	chr15:82472993~82513950:-
LUAD	cis	rs1707322	0.963	rs34907901	ENSG00000234329.1	RP11-767N6.2	5.22	2.69e-07	7.77e-05	0.25	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45939542	chr1:45651039~45651826:-
LUAD	cis	rs12022452	1	rs12031278	ENSG00000238287.1	RP11-656D10.3	-5.22	2.69e-07	7.77e-05	-0.44	-0.23	Age-related hearing impairment (SNP x SNP interaction);	chr1:40511246	chr1:40493157~40508661:-
LUAD	cis	rs1707322	0.821	rs10749857	ENSG00000280836.1	AL355480.1	-5.22	2.7e-07	7.78e-05	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782471	chr1:45581219~45581321:-
LUAD	cis	rs4908760	0.827	rs7556169	ENSG00000270282.1	RP5-1115A15.2	-5.22	2.7e-07	7.79e-05	-0.25	-0.23	Vitiligo;	chr1:8681342	chr1:8512653~8513021:+
LUAD	cis	rs7923837	0.964	rs10882106	ENSG00000236493.2	EIF2S2P3	5.22	2.7e-07	7.79e-05	0.27	0.23	Multiple sclerosis;Body mass index;	chr10:92720577	chr10:92668745~92669743:-
LUAD	cis	rs7580658	0.637	rs4580338	ENSG00000236682.1	AC068282.3	-5.22	2.7e-07	7.79e-05	-0.3	-0.23	Protein C levels;	chr2:127217361	chr2:127389130~127400580:+
LUAD	cis	rs2295359	0.892	rs10889657	ENSG00000275678.1	RP4-547N15.3	-5.22	2.7e-07	7.79e-05	-0.24	-0.23	Psoriasis;	chr1:67149804	chr1:67121605~67123956:-
LUAD	cis	rs867371	0.656	rs2665103	ENSG00000255769.6	GOLGA2P10	5.22	2.7e-07	7.79e-05	0.24	0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82140374	chr15:82472993~82513950:-
LUAD	cis	rs6687821	0.587	rs6656882	ENSG00000267734.1	RP4-604K5.3	-5.22	2.7e-07	7.79e-05	-0.28	-0.23	Yeast infection;	chr1:86827231	chr1:86932199~86934891:-
LUAD	cis	rs858239	0.712	rs199650	ENSG00000226816.2	AC005082.12	-5.22	2.7e-07	7.8e-05	-0.3	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23327570	chr7:23206013~23208045:+
LUAD	cis	rs4835473	0.897	rs3874	ENSG00000251600.4	RP11-673E1.1	5.22	2.71e-07	7.8e-05	0.28	0.23	Immature fraction of reticulocytes;	chr4:143968795	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs2323417	ENSG00000251600.4	RP11-673E1.1	5.22	2.71e-07	7.8e-05	0.28	0.23	Immature fraction of reticulocytes;	chr4:143969108	chr4:143912331~143982454:+
LUAD	cis	rs2348418	0.733	rs7137557	ENSG00000247934.4	RP11-967K21.1	5.22	2.71e-07	7.8e-05	0.27	0.23	Lung function (FEV1);Lung function (FVC);	chr12:28221259	chr12:28163298~28190738:-
LUAD	cis	rs2348418	0.733	rs12425200	ENSG00000247934.4	RP11-967K21.1	5.22	2.71e-07	7.8e-05	0.27	0.23	Lung function (FEV1);Lung function (FVC);	chr12:28237896	chr12:28163298~28190738:-
LUAD	cis	rs116175783	0.793	rs1267044	ENSG00000227403.1	AC009299.3	5.22	2.71e-07	7.8e-05	0.42	0.23	Intelligence (multi-trait analysis);	chr2:161271100	chr2:161244739~161249050:+
LUAD	cis	rs9287719	0.578	rs13425171	ENSG00000243819.4	RN7SL832P	5.22	2.71e-07	7.81e-05	0.25	0.23	Prostate cancer;	chr2:10591840	chr2:10690344~10692099:+
LUAD	cis	rs116175783	0.557	rs1146025	ENSG00000227403.1	AC009299.3	5.22	2.71e-07	7.81e-05	0.42	0.23	Intelligence (multi-trait analysis);	chr2:161283301	chr2:161244739~161249050:+
LUAD	cis	rs61270009	0.955	rs11748768	ENSG00000247828.6	TMEM161B-AS1	5.22	2.71e-07	7.82e-05	0.27	0.23	Depressive symptoms;	chr5:88354818	chr5:88268895~88436685:+
LUAD	cis	rs61270009	0.955	rs11750391	ENSG00000247828.6	TMEM161B-AS1	5.22	2.71e-07	7.82e-05	0.27	0.23	Depressive symptoms;	chr5:88356255	chr5:88268895~88436685:+
LUAD	cis	rs7968440	1	rs11609231	ENSG00000200428.1	Y_RNA	-5.22	2.71e-07	7.82e-05	-0.29	-0.23	Fibrinogen;	chr12:50538647	chr12:50743568~50743684:+
LUAD	cis	rs1707322	0.682	rs10890334	ENSG00000280836.1	AL355480.1	-5.22	2.71e-07	7.82e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634706	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.682	rs10890335	ENSG00000280836.1	AL355480.1	-5.22	2.71e-07	7.82e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634722	chr1:45581219~45581321:-
LUAD	cis	rs67311347	0.544	rs4974040	ENSG00000223797.4	ENTPD3-AS1	5.22	2.71e-07	7.83e-05	0.24	0.23	Renal cell carcinoma;	chr3:40289568	chr3:40313802~40453329:-
LUAD	cis	rs67311347	0.544	rs1902073	ENSG00000223797.4	ENTPD3-AS1	5.22	2.71e-07	7.83e-05	0.24	0.23	Renal cell carcinoma;	chr3:40292006	chr3:40313802~40453329:-
LUAD	cis	rs1707322	0.827	rs6694302	ENSG00000280836.1	AL355480.1	-5.22	2.71e-07	7.83e-05	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45779973	chr1:45581219~45581321:-
LUAD	cis	rs2115630	0.936	rs8033459	ENSG00000229212.6	RP11-561C5.4	5.22	2.72e-07	7.83e-05	0.27	0.23	P wave terminal force;	chr15:84710027	chr15:85205440~85234795:-
LUAD	cis	rs7927592	0.731	rs2840367	ENSG00000212093.1	AP000807.1	-5.22	2.72e-07	7.83e-05	-0.23	-0.23	Total body bone mineral density;	chr11:68534633	chr11:68506083~68506166:-
LUAD	cis	rs2243480	0.522	rs431168	ENSG00000232546.1	RP11-458F8.1	-5.22	2.72e-07	7.84e-05	-0.35	-0.23	Diabetic kidney disease;	chr7:66046617	chr7:66848496~66858136:+
LUAD	cis	rs889398	0.967	rs7359336	ENSG00000226232.7	RP11-419C5.2	-5.22	2.72e-07	7.84e-05	-0.2	-0.23	Body mass index;	chr16:69699557	chr16:69976388~69996188:-
LUAD	cis	rs1862618	0.573	rs2034245	ENSG00000271828.1	CTD-2310F14.1	-5.22	2.72e-07	7.85e-05	-0.35	-0.23	Initial pursuit acceleration;	chr5:56947858	chr5:56927874~56929573:+
LUAD	cis	rs5758511	0.514	rs2899354	ENSG00000205702.9	CYP2D7	5.22	2.72e-07	7.85e-05	0.23	0.23	Birth weight;	chr22:42158403	chr22:42140203~42144577:-
LUAD	cis	rs4268898	0.722	rs35520052	ENSG00000242628.4	AC009228.1	-5.22	2.72e-07	7.85e-05	-0.29	-0.23	Asthma;	chr2:24192408	chr2:24214381~24221516:+
LUAD	cis	rs858239	0.614	rs2014816	ENSG00000226816.2	AC005082.12	5.22	2.72e-07	7.85e-05	0.3	0.23	Cerebrospinal fluid biomarker levels;	chr7:23083417	chr7:23206013~23208045:+
LUAD	cis	rs2933343	0.7	rs789233	ENSG00000261159.1	RP11-723O4.9	5.22	2.73e-07	7.85e-05	0.25	0.23	IgG glycosylation;	chr3:128884307	chr3:128859716~128860526:-
LUAD	cis	rs11105298	0.891	rs10858906	ENSG00000258302.2	RP11-981P6.1	5.22	2.73e-07	7.86e-05	0.29	0.23	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89540697	chr12:89561129~89594878:+
LUAD	cis	rs394563	0.775	rs399673	ENSG00000231760.4	RP11-350J20.5	5.22	2.73e-07	7.87e-05	0.29	0.23	Dupuytren's disease;	chr6:149462085	chr6:149796151~149826294:-
LUAD	cis	rs11671005	0.695	rs8106061	ENSG00000268912.1	CTD-2619J13.17	-5.22	2.73e-07	7.88e-05	-0.31	-0.23	Mean platelet volume;	chr19:58406623	chr19:58428632~58431148:-
LUAD	cis	rs7829975	0.511	rs1543238	ENSG00000173295.6	FAM86B3P	5.22	2.74e-07	7.88e-05	0.25	0.23	Mood instability;	chr8:8277287	chr8:8228595~8244865:+
LUAD	cis	rs2098713	0.561	rs57015453	ENSG00000250155.1	CTD-2353F22.1	5.21	2.74e-07	7.89e-05	0.24	0.23	Telomere length;	chr5:37596878	chr5:36666214~36725195:-
LUAD	cis	rs11089937	0.597	rs4821773	ENSG00000211638.2	IGLV8-61	-5.21	2.74e-07	7.89e-05	-0.27	-0.23	Periodontitis (PAL4Q3);	chr22:22131434	chr22:22098700~22099212:+
LUAD	cis	rs9500256	0.967	rs4928431	ENSG00000215190.7	LINC00680	5.21	2.74e-07	7.89e-05	0.27	0.23	Eosinophilic esophagitis (pediatric);	chr6:57979980	chr6:57946074~57961501:-
LUAD	cis	rs516805	0.667	rs7752093	ENSG00000279453.1	RP3-425C14.4	5.21	2.74e-07	7.89e-05	0.31	0.23	Lymphocyte counts;	chr6:122301265	chr6:122436789~122439223:-
LUAD	cis	rs3096299	0.9	rs4785663	ENSG00000182376.2	RP5-1142A6.8	5.21	2.74e-07	7.89e-05	0.24	0.23	Multiple myeloma (IgH translocation);	chr16:89368480	chr16:88742767~88745748:+
LUAD	cis	rs712039	0.652	rs853232	ENSG00000276054.1	RP11-378E13.3	5.21	2.74e-07	7.9e-05	0.33	0.23	Tuberculosis;	chr17:37481076	chr17:37386886~37387926:+
LUAD	cis	rs4803480	0.872	rs10420470	ENSG00000270164.1	LINC01480	-5.21	2.74e-07	7.9e-05	-0.23	-0.23	Schizophrenia;	chr19:41567075	chr19:41535183~41536904:+
LUAD	cis	rs4908760	0.965	rs7542312	ENSG00000270282.1	RP5-1115A15.2	5.21	2.74e-07	7.9e-05	0.25	0.23	Vitiligo;	chr1:8513412	chr1:8512653~8513021:+
LUAD	cis	rs6095360	0.7	rs7262349	ENSG00000222365.1	SNORD12B	-5.21	2.74e-07	7.9e-05	-0.26	-0.23	Intelligence (multi-trait analysis);	chr20:49178768	chr20:49280319~49280409:+
LUAD	cis	rs6095360	0.689	rs35667796	ENSG00000222365.1	SNORD12B	-5.21	2.74e-07	7.9e-05	-0.26	-0.23	Intelligence (multi-trait analysis);	chr20:49186764	chr20:49280319~49280409:+
LUAD	cis	rs9595908	0.746	rs3848087	ENSG00000212293.1	SNORA16	5.21	2.74e-07	7.9e-05	0.25	0.23	Body mass index;	chr13:32697637	chr13:32420390~32420516:-
LUAD	cis	rs62344088	0.744	rs76038312	ENSG00000277812.1	AC021087.1	5.21	2.74e-07	7.9e-05	0.67	0.23	Asthma (childhood onset);	chr5:228890	chr5:262769~262881:+
LUAD	cis	rs453301	0.686	rs6601280	ENSG00000173295.6	FAM86B3P	5.21	2.74e-07	7.91e-05	0.25	0.23	Joint mobility (Beighton score);	chr8:9051726	chr8:8228595~8244865:+
LUAD	cis	rs80028505	0.908	rs56056710	ENSG00000271304.1	DPRXP2	5.21	2.74e-07	7.91e-05	0.47	0.23	Foot ulcer in diabetes and neuropathy;	chr6:36068575	chr6:35989515~35990436:-
LUAD	cis	rs80028505	0.908	rs58237753	ENSG00000271304.1	DPRXP2	5.21	2.74e-07	7.91e-05	0.47	0.23	Foot ulcer in diabetes and neuropathy;	chr6:36068578	chr6:35989515~35990436:-
LUAD	cis	rs516805	0.631	rs2606647	ENSG00000279453.1	RP3-425C14.4	-5.21	2.75e-07	7.91e-05	-0.32	-0.23	Lymphocyte counts;	chr6:122118967	chr6:122436789~122439223:-
LUAD	cis	rs9322193	0.607	rs6557165	ENSG00000223701.3	RAET1E-AS1	-5.21	2.75e-07	7.91e-05	-0.32	-0.23	Lung cancer;	chr6:149906883	chr6:149884431~149919508:+
LUAD	cis	rs9532669	0.89	rs4941999	ENSG00000168852.11	TPTE2P5	5.21	2.75e-07	7.91e-05	0.23	0.23	Cervical cancer;	chr13:40859926	chr13:40822296~40921749:-
LUAD	cis	rs6543140	0.964	rs4851589	ENSG00000234389.1	AC007278.3	5.21	2.75e-07	7.91e-05	0.23	0.23	Blood protein levels;	chr2:102460685	chr2:102438713~102440475:+
LUAD	cis	rs910316	0.904	rs7156089	ENSG00000259138.1	RP11-950C14.7	-5.21	2.75e-07	7.92e-05	-0.25	-0.23	Height;	chr14:75178824	chr14:75127153~75136930:+
LUAD	cis	rs4835473	0.897	rs35598237	ENSG00000251600.4	RP11-673E1.1	-5.21	2.75e-07	7.92e-05	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143735961	chr4:143912331~143982454:+
LUAD	cis	rs453301	0.653	rs1562211	ENSG00000253893.2	FAM85B	5.21	2.75e-07	7.92e-05	0.29	0.23	Joint mobility (Beighton score);	chr8:9044914	chr8:8167819~8226614:-
LUAD	cis	rs11089937	0.626	rs9619811	ENSG00000211638.2	IGLV8-61	-5.21	2.75e-07	7.92e-05	-0.27	-0.23	Periodontitis (PAL4Q3);	chr22:22159186	chr22:22098700~22099212:+
LUAD	cis	rs7131987	0.65	rs7957339	ENSG00000257176.2	RP11-996F15.2	-5.21	2.75e-07	7.92e-05	-0.26	-0.23	QT interval;	chr12:29303562	chr12:29280418~29317848:-
LUAD	cis	rs748404	0.697	rs546170	ENSG00000249839.1	AC011330.5	-5.21	2.75e-07	7.93e-05	-0.3	-0.23	Lung cancer;	chr15:43272651	chr15:43663654~43684339:-
LUAD	cis	rs11603023	0.967	rs4245184	ENSG00000255239.1	AP002954.6	-5.21	2.76e-07	7.94e-05	-0.27	-0.23	Cholesterol, total;	chr11:118639844	chr11:118688039~118690600:-
LUAD	cis	rs891378	1	rs6664815	ENSG00000274245.1	RP11-357P18.2	-5.21	2.76e-07	7.94e-05	-0.28	-0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207242218	chr1:207372559~207373252:+
LUAD	cis	rs712039	0.652	rs11656503	ENSG00000276054.1	RP11-378E13.3	5.21	2.76e-07	7.94e-05	0.35	0.23	Tuberculosis;	chr17:37411934	chr17:37386886~37387926:+
LUAD	cis	rs3002142	1	rs3008607	ENSG00000272750.1	RP11-378J18.8	-5.21	2.76e-07	7.94e-05	-0.31	-0.23	LDL peak particle diameter (total fat intake interaction);	chr1:222612350	chr1:222658867~222661512:-
LUAD	cis	rs4835473	0.897	rs7687317	ENSG00000251600.4	RP11-673E1.1	5.21	2.76e-07	7.94e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143709010	chr4:143912331~143982454:+
LUAD	cis	rs12908161	0.92	rs12904605	ENSG00000275120.1	RP11-182J1.17	5.21	2.76e-07	7.95e-05	0.35	0.23	Schizophrenia;	chr15:84658188	chr15:84599434~84606463:-
LUAD	cis	rs11157436	1	rs2293731	ENSG00000211813.2	TRAV34	5.21	2.76e-07	7.95e-05	0.31	0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22148880	chr14:22207522~22208129:+
LUAD	cis	rs12680842	0.842	rs34691145	ENSG00000253704.1	RP11-267M23.4	5.21	2.76e-07	7.95e-05	0.27	0.23	Body mass index;	chr8:94597715	chr8:94553722~94569745:+
LUAD	cis	rs12681366	0.839	rs2931632	ENSG00000253704.1	RP11-267M23.4	5.21	2.76e-07	7.95e-05	0.28	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94406560	chr8:94553722~94569745:+
LUAD	cis	rs11700536	1	rs4919965	ENSG00000236663.1	AP001631.9	-5.21	2.76e-07	7.95e-05	-0.27	-0.23	Interleukin-18 levels;	chr21:43137961	chr21:43140523~43141092:-
LUAD	cis	rs1707322	0.716	rs10890342	ENSG00000280836.1	AL355480.1	-5.21	2.76e-07	7.95e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45691415	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.752	rs6658700	ENSG00000280836.1	AL355480.1	-5.21	2.76e-07	7.95e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45694588	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.752	rs12047629	ENSG00000280836.1	AL355480.1	-5.21	2.76e-07	7.95e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697130	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.752	rs11211169	ENSG00000280836.1	AL355480.1	-5.21	2.76e-07	7.95e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701037	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.752	rs11211171	ENSG00000280836.1	AL355480.1	-5.21	2.76e-07	7.95e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45702970	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.752	rs28623463	ENSG00000280836.1	AL355480.1	-5.21	2.76e-07	7.95e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45705086	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.716	rs28370457	ENSG00000280836.1	AL355480.1	-5.21	2.76e-07	7.95e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706390	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.752	rs28890893	ENSG00000280836.1	AL355480.1	-5.21	2.76e-07	7.95e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720904	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.752	rs28550303	ENSG00000280836.1	AL355480.1	-5.21	2.76e-07	7.95e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723242	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.716	rs28375469	ENSG00000280836.1	AL355480.1	-5.21	2.76e-07	7.95e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45729703	chr1:45581219~45581321:-
LUAD	cis	rs6543140	0.964	rs6543138	ENSG00000234389.1	AC007278.3	5.21	2.77e-07	7.96e-05	0.23	0.23	Blood protein levels;	chr2:102449672	chr2:102438713~102440475:+
LUAD	cis	rs1008375	0.9	rs6851783	ENSG00000249502.1	AC006160.5	-5.21	2.77e-07	7.96e-05	-0.23	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17576846	chr4:17587467~17614571:-
LUAD	cis	rs1008375	0.9	rs7658447	ENSG00000249502.1	AC006160.5	-5.21	2.77e-07	7.96e-05	-0.23	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17577792	chr4:17587467~17614571:-
LUAD	cis	rs1707322	0.963	rs12145287	ENSG00000280836.1	AL355480.1	-5.21	2.77e-07	7.97e-05	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45859330	chr1:45581219~45581321:-
LUAD	cis	rs12699921	0.526	rs12699916	ENSG00000279048.1	RP11-511H23.2	-5.21	2.77e-07	7.97e-05	-0.19	-0.23	Fibrinogen levels;	chr7:17868923	chr7:17940503~17942922:+
LUAD	cis	rs2243480	0.522	rs73150635	ENSG00000226824.5	RP4-756H11.3	-5.21	2.77e-07	7.97e-05	-0.51	-0.23	Diabetic kidney disease;	chr7:66507503	chr7:66654538~66669855:+
LUAD	cis	rs9435732	0.725	rs10437047	ENSG00000235241.1	RP11-108M9.5	5.21	2.77e-07	7.97e-05	0.32	0.23	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16994933	chr1:16889095~16889602:+
LUAD	cis	rs9652601	0.622	rs17804470	ENSG00000274038.1	RP11-66H6.4	-5.21	2.77e-07	7.98e-05	-0.28	-0.23	Systemic lupus erythematosus;	chr16:11006111	chr16:11056556~11057034:+
LUAD	cis	rs287982	0.935	rs287978	ENSG00000269973.1	RP11-95D17.1	5.21	2.78e-07	7.99e-05	0.28	0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9830405	chr2:9936360~9939590:+
LUAD	cis	rs3750965	0.959	rs4930264	ENSG00000260895.1	RP11-554A11.7	5.21	2.78e-07	7.99e-05	0.26	0.23	Hair color;	chr11:69084713	chr11:69103493~69109094:+
LUAD	cis	rs1707322	0.752	rs11488313	ENSG00000280836.1	AL355480.1	-5.21	2.78e-07	7.99e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45759108	chr1:45581219~45581321:-
LUAD	cis	rs9322193	0.884	rs9383865	ENSG00000268592.3	RAET1E-AS1	5.21	2.78e-07	7.99e-05	0.29	0.23	Lung cancer;	chr6:149852043	chr6:149863494~149919507:+
LUAD	cis	rs910316	1	rs7147118	ENSG00000259138.1	RP11-950C14.7	5.21	2.78e-07	7.99e-05	0.25	0.23	Height;	chr14:75143467	chr14:75127153~75136930:+
LUAD	cis	rs2286503	0.966	rs2286507	ENSG00000221740.1	SNORD93	5.21	2.78e-07	7.99e-05	0.26	0.23	Fibrinogen;	chr7:22815141	chr7:22856613~22856686:+
LUAD	cis	rs17301853	1	rs17301125	ENSG00000227373.4	RP11-160H22.5	5.21	2.78e-07	7.99e-05	0.45	0.23	Migraine without aura;Migraine - clinic-based;	chr1:174374755	chr1:174115300~174160004:-
LUAD	cis	rs17301853	1	rs78326521	ENSG00000227373.4	RP11-160H22.5	5.21	2.78e-07	7.99e-05	0.45	0.23	Migraine without aura;Migraine - clinic-based;	chr1:174377714	chr1:174115300~174160004:-
LUAD	cis	rs11673344	0.704	rs484001	ENSG00000226686.6	LINC01535	5.21	2.78e-07	7.99e-05	0.28	0.23	Obesity-related traits;	chr19:36931320	chr19:37251912~37265535:+
LUAD	cis	rs7208859	0.673	rs450585	ENSG00000263603.1	CTD-2349P21.5	-5.21	2.78e-07	8e-05	-0.34	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624021	chr17:30729469~30731202:+
LUAD	cis	rs4835473	0.897	rs4835095	ENSG00000251600.4	RP11-673E1.1	5.21	2.78e-07	8e-05	0.28	0.23	Immature fraction of reticulocytes;	chr4:143960431	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.831	rs2667353	ENSG00000251600.4	RP11-673E1.1	5.21	2.78e-07	8e-05	0.28	0.23	Immature fraction of reticulocytes;	chr4:143960462	chr4:143912331~143982454:+
LUAD	cis	rs10129255	0.5	rs10143242	ENSG00000254174.1	IGHV1-12	5.21	2.78e-07	8.01e-05	0.16	0.23	Kawasaki disease;	chr14:106681814	chr14:106122420~106122709:-
LUAD	cis	rs2933343	0.649	rs789219	ENSG00000261159.1	RP11-723O4.9	5.21	2.78e-07	8.01e-05	0.25	0.23	IgG glycosylation;	chr3:128873677	chr3:128859716~128860526:-
LUAD	cis	rs6570726	0.935	rs386344	ENSG00000235652.6	RP11-545I5.3	5.21	2.79e-07	8.01e-05	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145534486	chr6:145799409~145886585:+
LUAD	cis	rs516805	0.562	rs2816156	ENSG00000279453.1	RP3-425C14.4	-5.21	2.79e-07	8.02e-05	-0.32	-0.23	Lymphocyte counts;	chr6:122124569	chr6:122436789~122439223:-
LUAD	cis	rs71403859	0.57	rs76231867	ENSG00000260886.1	TAT-AS1	5.21	2.79e-07	8.02e-05	0.37	0.23	Post bronchodilator FEV1;	chr16:71416023	chr16:71565789~71578187:+
LUAD	cis	rs1816752	0.905	rs7339140	ENSG00000273628.1	RP11-756A22.7	5.21	2.79e-07	8.02e-05	0.26	0.23	Obesity-related traits;	chr13:24437764	chr13:24933006~24936796:+
LUAD	cis	rs1816752	0.87	rs9511261	ENSG00000273628.1	RP11-756A22.7	5.21	2.79e-07	8.02e-05	0.26	0.23	Obesity-related traits;	chr13:24437880	chr13:24933006~24936796:+
LUAD	cis	rs1816752	0.905	rs9511262	ENSG00000273628.1	RP11-756A22.7	5.21	2.79e-07	8.02e-05	0.26	0.23	Obesity-related traits;	chr13:24437885	chr13:24933006~24936796:+
LUAD	cis	rs7727544	0.716	rs72793283	ENSG00000233006.5	AC034220.3	5.21	2.79e-07	8.03e-05	0.2	0.23	Blood metabolite levels;	chr5:132231248	chr5:132311285~132369916:-
LUAD	cis	rs6088590	0.965	rs6058108	ENSG00000276073.1	RP5-1125A11.7	-5.21	2.79e-07	8.03e-05	-0.23	-0.23	Coronary artery disease;	chr20:34700851	chr20:33985617~33988989:-
LUAD	cis	rs9341808	0.739	rs4706831	ENSG00000272129.1	RP11-250B2.6	5.21	2.79e-07	8.03e-05	0.28	0.23	Sitting height ratio;	chr6:80297982	chr6:80355424~80356859:+
LUAD	cis	rs11089937	0.597	rs5757027	ENSG00000211638.2	IGLV8-61	-5.21	2.79e-07	8.03e-05	-0.26	-0.23	Periodontitis (PAL4Q3);	chr22:22137683	chr22:22098700~22099212:+
LUAD	cis	rs875971	0.638	rs801205	ENSG00000237310.1	GS1-124K5.4	-5.21	2.8e-07	8.04e-05	-0.25	-0.23	Aortic root size;	chr7:66557157	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.617	rs810400	ENSG00000237310.1	GS1-124K5.4	-5.21	2.8e-07	8.04e-05	-0.25	-0.23	Aortic root size;	chr7:66557902	chr7:66493706~66495474:+
LUAD	cis	rs4964805	0.865	rs11111796	ENSG00000257681.1	RP11-341G23.4	5.21	2.8e-07	8.04e-05	0.28	0.23	Attention deficit hyperactivity disorder;	chr12:103812150	chr12:103746315~103768858:-
LUAD	cis	rs11089937	0.626	rs5757013	ENSG00000211638.2	IGLV8-61	-5.21	2.8e-07	8.05e-05	-0.27	-0.23	Periodontitis (PAL4Q3);	chr22:22135544	chr22:22098700~22099212:+
LUAD	cis	rs925255	0.743	rs7600164	ENSG00000270210.1	RP11-373D23.3	5.21	2.8e-07	8.05e-05	0.28	0.23	Inflammatory bowel disease;Crohn's disease;	chr2:28421995	chr2:28425945~28426719:+
LUAD	cis	rs7017914	0.652	rs62532068	ENSG00000223220.1	Y_RNA	5.21	2.8e-07	8.05e-05	0.26	0.23	Bone mineral density;	chr8:70750952	chr8:70780914~70781008:-
LUAD	cis	rs11157436	1	rs3811278	ENSG00000211813.2	TRAV34	5.21	2.8e-07	8.05e-05	0.31	0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22186227	chr14:22207522~22208129:+
LUAD	cis	rs9322193	0.607	rs6925151	ENSG00000223701.3	RAET1E-AS1	5.21	2.8e-07	8.05e-05	0.31	0.23	Lung cancer;	chr6:149889587	chr6:149884431~149919508:+
LUAD	cis	rs6687758	1	rs12121134	ENSG00000228437.4	RP11-400N13.2	5.21	2.8e-07	8.05e-05	0.34	0.23	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222021538	chr1:221966341~221984964:+
LUAD	cis	rs6687758	1	rs56170536	ENSG00000228437.4	RP11-400N13.2	5.21	2.8e-07	8.05e-05	0.34	0.23	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222024527	chr1:221966341~221984964:+
LUAD	cis	rs6687758	1	rs66732677	ENSG00000228437.4	RP11-400N13.2	5.21	2.8e-07	8.05e-05	0.34	0.23	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222026325	chr1:221966341~221984964:+
LUAD	cis	rs11157436	1	rs11157436	ENSG00000211813.2	TRAV34	-5.21	2.8e-07	8.06e-05	-0.3	-0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22168978	chr14:22207522~22208129:+
LUAD	cis	rs2239547	0.603	rs34230854	ENSG00000242142.1	SERBP1P3	5.21	2.81e-07	8.08e-05	0.28	0.23	Schizophrenia;	chr3:53044574	chr3:53064283~53065091:-
LUAD	cis	rs2919009	0.712	rs2241847	ENSG00000271670.1	RP11-95I16.4	5.21	2.81e-07	8.08e-05	0.29	0.23	Obesity-related traits;	chr10:120858159	chr10:120879256~120880667:-
LUAD	cis	rs7017914	0.714	rs2732119	ENSG00000223220.1	Y_RNA	5.21	2.81e-07	8.09e-05	0.27	0.23	Bone mineral density;	chr8:70996142	chr8:70780914~70781008:-
LUAD	cis	rs10246939	0.505	rs34726057	ENSG00000228775.6	WEE2-AS1	5.21	2.81e-07	8.09e-05	0.29	0.23	Bitter taste perception;	chr7:141832117	chr7:141704338~141738346:-
LUAD	cis	rs2239547	0.522	rs7652131	ENSG00000242142.1	SERBP1P3	5.21	2.81e-07	8.09e-05	0.27	0.23	Schizophrenia;	chr3:52963138	chr3:53064283~53065091:-
LUAD	cis	rs61270009	0.955	rs454830	ENSG00000247828.6	TMEM161B-AS1	-5.21	2.82e-07	8.09e-05	-0.27	-0.23	Depressive symptoms;	chr5:88254678	chr5:88268895~88436685:+
LUAD	cis	rs4964805	1	rs11111792	ENSG00000257681.1	RP11-341G23.4	5.21	2.82e-07	8.1e-05	0.28	0.23	Attention deficit hyperactivity disorder;	chr12:103801079	chr12:103746315~103768858:-
LUAD	cis	rs12188164	0.515	rs17562461	ENSG00000225138.6	CTD-2228K2.7	5.21	2.82e-07	8.1e-05	0.22	0.23	Cystic fibrosis severity;	chr5:411246	chr5:473236~480884:+
LUAD	cis	rs4908760	0.827	rs10864362	ENSG00000232912.4	RP5-1115A15.1	5.21	2.82e-07	8.1e-05	0.21	0.23	Vitiligo;	chr1:8672395	chr1:8424645~8434838:+
LUAD	cis	rs9487094	0.645	rs1322818	ENSG00000260273.1	RP11-425D10.10	5.21	2.82e-07	8.11e-05	0.36	0.23	Height;	chr6:109369898	chr6:109382795~109383666:+
LUAD	cis	rs673078	0.607	rs2055534	ENSG00000275409.1	RP11-131L12.4	-5.21	2.82e-07	8.11e-05	-0.33	-0.23	Glucose homeostasis traits;	chr12:118386527	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs56157623	ENSG00000275409.1	RP11-131L12.4	-5.21	2.82e-07	8.11e-05	-0.33	-0.23	Glucose homeostasis traits;	chr12:118388162	chr12:118430147~118430699:+
LUAD	cis	rs950169	0.881	rs150965	ENSG00000259295.5	CSPG4P12	5.21	2.82e-07	8.11e-05	0.34	0.23	Schizophrenia;	chr15:84537296	chr15:85191438~85213905:+
LUAD	cis	rs875971	0.522	rs1917563	ENSG00000224316.1	RP11-479O9.2	-5.21	2.82e-07	8.11e-05	-0.23	-0.23	Aortic root size;	chr7:65950660	chr7:65773620~65802067:+
LUAD	cis	rs9910055	1	rs2071167	ENSG00000267080.4	ASB16-AS1	5.21	2.83e-07	8.12e-05	0.22	0.23	Total body bone mineral density;	chr17:44210151	chr17:44175973~44186717:-
LUAD	cis	rs6952407	1	rs6952407	ENSG00000237310.1	GS1-124K5.4	-5.21	2.83e-07	8.12e-05	-0.25	-0.23	Cotinine glucuronidation;	chr7:66580525	chr7:66493706~66495474:+
LUAD	cis	rs1823874	0.71	rs2902472	ENSG00000182397.13	DNM1P46	-5.21	2.83e-07	8.12e-05	-0.28	-0.23	IgG glycosylation;	chr15:99824257	chr15:99790156~99806927:-
LUAD	cis	rs9595908	0.746	rs1029306	ENSG00000212293.1	SNORA16	5.21	2.83e-07	8.12e-05	0.25	0.23	Body mass index;	chr13:32707695	chr13:32420390~32420516:-
LUAD	cis	rs910316	0.967	rs175502	ENSG00000259138.1	RP11-950C14.7	-5.21	2.83e-07	8.12e-05	-0.24	-0.23	Height;	chr14:75066976	chr14:75127153~75136930:+
LUAD	cis	rs41307935	0.915	rs34696599	ENSG00000260063.1	RP5-968P14.2	-5.21	2.83e-07	8.12e-05	-0.43	-0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26877237	chr1:26692132~26694131:-
LUAD	cis	rs4908768	0.501	rs1922983	ENSG00000270282.1	RP5-1115A15.2	5.21	2.83e-07	8.13e-05	0.25	0.23	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8471266	chr1:8512653~8513021:+
LUAD	cis	rs2880765	0.835	rs7168860	ENSG00000259295.5	CSPG4P12	5.21	2.83e-07	8.13e-05	0.27	0.23	Coronary artery disease;	chr15:85493799	chr15:85191438~85213905:+
LUAD	cis	rs2288884	0.767	rs17835716	ENSG00000275055.1	CTC-471J1.11	-5.21	2.83e-07	8.13e-05	-0.33	-0.23	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52047789	chr19:52049007~52049754:+
LUAD	cis	rs2288884	0.767	rs3752119	ENSG00000275055.1	CTC-471J1.11	-5.21	2.83e-07	8.13e-05	-0.33	-0.23	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52048245	chr19:52049007~52049754:+
LUAD	cis	rs910316	0.967	rs4903285	ENSG00000259138.1	RP11-950C14.7	5.21	2.83e-07	8.14e-05	0.25	0.23	Height;	chr14:75142565	chr14:75127153~75136930:+
LUAD	cis	rs1387259	0.931	rs1107654	ENSG00000257735.1	RP11-370I10.6	5.21	2.83e-07	8.14e-05	0.28	0.23	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48287314	chr12:48350945~48442411:+
LUAD	cis	rs5769707	0.632	rs6009782	ENSG00000235111.1	RP1-29C18.8	-5.21	2.84e-07	8.14e-05	-0.27	-0.23	Monocyte percentage of white cells;Monocyte count;	chr22:49617164	chr22:49612657~49615716:-
LUAD	cis	rs6687758	1	rs17442323	ENSG00000228437.4	RP11-400N13.2	5.21	2.84e-07	8.14e-05	0.34	0.23	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222019622	chr1:221966341~221984964:+
LUAD	cis	rs2098713	0.561	rs62359058	ENSG00000250155.1	CTD-2353F22.1	5.21	2.84e-07	8.15e-05	0.24	0.23	Telomere length;	chr5:37592593	chr5:36666214~36725195:-
LUAD	cis	rs2098713	0.561	rs12655908	ENSG00000250155.1	CTD-2353F22.1	5.21	2.84e-07	8.15e-05	0.24	0.23	Telomere length;	chr5:37595793	chr5:36666214~36725195:-
LUAD	cis	rs2098713	0.561	rs4869530	ENSG00000250155.1	CTD-2353F22.1	5.21	2.84e-07	8.15e-05	0.24	0.23	Telomere length;	chr5:37598468	chr5:36666214~36725195:-
LUAD	cis	rs2098713	0.561	rs11949124	ENSG00000250155.1	CTD-2353F22.1	5.21	2.84e-07	8.15e-05	0.24	0.23	Telomere length;	chr5:37590362	chr5:36666214~36725195:-
LUAD	cis	rs997295	0.592	rs7162320	ENSG00000270964.1	RP11-502I4.3	-5.21	2.84e-07	8.16e-05	-0.24	-0.23	Motion sickness;	chr15:67473700	chr15:67541072~67542604:-
LUAD	cis	rs7968440	0.838	rs7979165	ENSG00000200428.1	Y_RNA	-5.21	2.84e-07	8.16e-05	-0.3	-0.23	Fibrinogen;	chr12:50754774	chr12:50743568~50743684:+
LUAD	cis	rs7968440	0.808	rs67218241	ENSG00000200428.1	Y_RNA	-5.21	2.84e-07	8.16e-05	-0.3	-0.23	Fibrinogen;	chr12:50761639	chr12:50743568~50743684:+
LUAD	cis	rs3750965	0.959	rs2253658	ENSG00000260895.1	RP11-554A11.7	5.21	2.84e-07	8.16e-05	0.26	0.23	Hair color;	chr11:69089336	chr11:69103493~69109094:+
LUAD	cis	rs2098713	0.561	rs4869440	ENSG00000250155.1	CTD-2353F22.1	5.21	2.84e-07	8.16e-05	0.24	0.23	Telomere length;	chr5:37600839	chr5:36666214~36725195:-
LUAD	cis	rs875971	0.505	rs2462573	ENSG00000236529.1	RP13-254B10.1	-5.21	2.84e-07	8.17e-05	-0.23	-0.23	Aortic root size;	chr7:66042405	chr7:65840212~65840596:+
LUAD	cis	rs116095464	1	rs3777237	ENSG00000277812.1	AC021087.1	5.21	2.85e-07	8.17e-05	0.68	0.23	Breast cancer;	chr5:307526	chr5:262769~262881:+
LUAD	cis	rs2337406	1	rs4774173	ENSG00000211972.2	IGHV3-66	5.21	2.85e-07	8.18e-05	0.25	0.23	Alzheimer's disease (late onset);	chr14:106682029	chr14:106675017~106675544:-
LUAD	cis	rs2880765	0.805	rs34598679	ENSG00000259295.5	CSPG4P12	5.21	2.85e-07	8.19e-05	0.27	0.23	Coronary artery disease;	chr15:85498974	chr15:85191438~85213905:+
LUAD	cis	rs2880765	0.835	rs4344688	ENSG00000259295.5	CSPG4P12	5.21	2.85e-07	8.19e-05	0.27	0.23	Coronary artery disease;	chr15:85499776	chr15:85191438~85213905:+
LUAD	cis	rs2880765	0.835	rs4280192	ENSG00000259295.5	CSPG4P12	5.21	2.85e-07	8.19e-05	0.27	0.23	Coronary artery disease;	chr15:85499789	chr15:85191438~85213905:+
LUAD	cis	rs2880765	0.835	rs7162502	ENSG00000259295.5	CSPG4P12	5.21	2.85e-07	8.19e-05	0.27	0.23	Coronary artery disease;	chr15:85501242	chr15:85191438~85213905:+
LUAD	cis	rs2880765	0.835	rs7169632	ENSG00000259295.5	CSPG4P12	5.21	2.85e-07	8.19e-05	0.27	0.23	Coronary artery disease;	chr15:85501436	chr15:85191438~85213905:+
LUAD	cis	rs2880765	0.835	rs7163958	ENSG00000259295.5	CSPG4P12	5.21	2.85e-07	8.19e-05	0.27	0.23	Coronary artery disease;	chr15:85501984	chr15:85191438~85213905:+
LUAD	cis	rs2880765	0.835	rs12910373	ENSG00000259295.5	CSPG4P12	5.21	2.85e-07	8.19e-05	0.27	0.23	Coronary artery disease;	chr15:85503571	chr15:85191438~85213905:+
LUAD	cis	rs11089937	0.609	rs2213158	ENSG00000211638.2	IGLV8-61	-5.21	2.85e-07	8.19e-05	-0.27	-0.23	Periodontitis (PAL4Q3);	chr22:22138099	chr22:22098700~22099212:+
LUAD	cis	rs11089937	0.637	rs2213159	ENSG00000211638.2	IGLV8-61	-5.21	2.85e-07	8.19e-05	-0.27	-0.23	Periodontitis (PAL4Q3);	chr22:22138100	chr22:22098700~22099212:+
LUAD	cis	rs2380205	0.5	rs688388	ENSG00000232807.2	RP11-536K7.3	-5.21	2.85e-07	8.19e-05	-0.24	-0.23	Breast cancer;	chr10:5918667	chr10:5934270~5945900:-
LUAD	cis	rs11098499	0.71	rs4145952	ENSG00000248280.1	RP11-33B1.2	5.21	2.86e-07	8.2e-05	0.27	0.23	Corneal astigmatism;	chr4:119234651	chr4:119440561~119450157:-
LUAD	cis	rs875971	0.862	rs880166	ENSG00000232559.3	GS1-124K5.12	-5.21	2.86e-07	8.21e-05	-0.27	-0.23	Aortic root size;	chr7:66205775	chr7:66554588~66576923:-
LUAD	cis	rs1062177	1	rs2964584	ENSG00000253921.1	CTB-113P19.3	-5.21	2.86e-07	8.21e-05	-0.34	-0.23	Preschool internalizing problems;	chr5:151763317	chr5:151753992~151767247:+
LUAD	cis	rs2880765	0.835	rs4514633	ENSG00000259295.5	CSPG4P12	5.21	2.86e-07	8.21e-05	0.27	0.23	Coronary artery disease;	chr15:85497786	chr15:85191438~85213905:+
LUAD	cis	rs867371	1	rs7166570	ENSG00000276710.3	CSPG4P8	-5.21	2.86e-07	8.21e-05	-0.22	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173880	chr15:82459472~82477258:+
LUAD	cis	rs7617773	0.817	rs9311421	ENSG00000228638.1	FCF1P2	-5.21	2.86e-07	8.21e-05	-0.27	-0.23	Coronary artery disease;	chr3:48251588	chr3:48290793~48291375:-
LUAD	cis	rs875971	0.522	rs2949690	ENSG00000164669.11	INTS4P1	5.21	2.86e-07	8.22e-05	0.28	0.23	Aortic root size;	chr7:66018255	chr7:65141225~65234216:+
LUAD	cis	rs516805	0.667	rs2606650	ENSG00000279453.1	RP3-425C14.4	-5.21	2.87e-07	8.22e-05	-0.31	-0.23	Lymphocyte counts;	chr6:122123443	chr6:122436789~122439223:-
LUAD	cis	rs1816752	0.905	rs8002215	ENSG00000273628.1	RP11-756A22.7	5.21	2.87e-07	8.22e-05	0.26	0.23	Obesity-related traits;	chr13:24416229	chr13:24933006~24936796:+
LUAD	cis	rs516805	0.63	rs2315816	ENSG00000279453.1	RP3-425C14.4	-5.21	2.87e-07	8.22e-05	-0.31	-0.23	Lymphocyte counts;	chr6:122102793	chr6:122436789~122439223:-
LUAD	cis	rs3002142	0.908	rs3008608	ENSG00000272750.1	RP11-378J18.8	-5.21	2.87e-07	8.23e-05	-0.31	-0.23	LDL peak particle diameter (total fat intake interaction);	chr1:222612656	chr1:222658867~222661512:-
LUAD	cis	rs867371	1	rs2088858	ENSG00000276710.3	CSPG4P8	-5.21	2.87e-07	8.23e-05	-0.22	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182408	chr15:82459472~82477258:+
LUAD	cis	rs867371	1	rs4778982	ENSG00000276710.3	CSPG4P8	-5.21	2.87e-07	8.23e-05	-0.22	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182931	chr15:82459472~82477258:+
LUAD	cis	rs867371	1	rs2867579	ENSG00000276710.3	CSPG4P8	-5.21	2.87e-07	8.23e-05	-0.22	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183043	chr15:82459472~82477258:+
LUAD	cis	rs867371	1	rs881308	ENSG00000276710.3	CSPG4P8	-5.21	2.87e-07	8.23e-05	-0.22	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183456	chr15:82459472~82477258:+
LUAD	cis	rs875971	0.505	rs1723275	ENSG00000224316.1	RP11-479O9.2	-5.21	2.87e-07	8.23e-05	-0.23	-0.23	Aortic root size;	chr7:66039646	chr7:65773620~65802067:+
LUAD	cis	rs453301	0.653	rs7853	ENSG00000173295.6	FAM86B3P	5.21	2.87e-07	8.23e-05	0.25	0.23	Joint mobility (Beighton score);	chr8:9033304	chr8:8228595~8244865:+
LUAD	cis	rs3738443	1	rs61840059	ENSG00000259865.1	RP11-488L18.10	5.21	2.87e-07	8.24e-05	0.25	0.23	Alcohol dependence;	chr1:247207676	chr1:247187281~247188526:-
LUAD	cis	rs748404	0.666	rs72709871	ENSG00000205771.5	CATSPER2P1	-5.21	2.87e-07	8.24e-05	-0.34	-0.23	Lung cancer;	chr15:43499025	chr15:43726918~43747094:-
LUAD	cis	rs62246343	0.654	rs7631372	ENSG00000254485.4	RP11-380O24.1	5.21	2.88e-07	8.25e-05	0.34	0.23	Fibrinogen levels;	chr3:9451631	chr3:9292588~9363303:-
LUAD	cis	rs62246343	0.719	rs73130116	ENSG00000254485.4	RP11-380O24.1	5.21	2.88e-07	8.25e-05	0.34	0.23	Fibrinogen levels;	chr3:9452827	chr3:9292588~9363303:-
LUAD	cis	rs7811142	1	rs7809801	ENSG00000078319.8	PMS2P1	-5.21	2.88e-07	8.25e-05	-0.27	-0.23	Platelet count;	chr7:100474408	chr7:100320992~100341908:-
LUAD	cis	rs7811142	1	rs11766752	ENSG00000078319.8	PMS2P1	-5.21	2.88e-07	8.25e-05	-0.27	-0.23	Platelet count;	chr7:100475669	chr7:100320992~100341908:-
LUAD	cis	rs891378	1	rs891378	ENSG00000274245.1	RP11-357P18.2	-5.21	2.88e-07	8.25e-05	-0.3	-0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207316974	chr1:207372559~207373252:+
LUAD	cis	rs4237845	0.586	rs4760174	ENSG00000257159.1	RP11-58A17.3	5.2	2.88e-07	8.26e-05	0.28	0.23	Intelligence (multi-trait analysis);	chr12:57926653	chr12:57967058~57968399:+
LUAD	cis	rs7777677	0.925	rs6960743	ENSG00000244273.1	PGBD4P1	-5.2	2.88e-07	8.26e-05	-0.25	-0.23	Alcoholic chronic pancreatitis;	chr7:142661768	chr7:142722358~142722764:+
LUAD	cis	rs9992667	0.91	rs10019144	ENSG00000231160.8	KLF3-AS1	5.2	2.88e-07	8.26e-05	0.29	0.23	Eosinophil percentage of granulocytes;	chr4:38684784	chr4:38612701~38664883:-
LUAD	cis	rs11089937	0.568	rs12160317	ENSG00000211638.2	IGLV8-61	-5.2	2.88e-07	8.26e-05	-0.27	-0.23	Periodontitis (PAL4Q3);	chr22:22131619	chr22:22098700~22099212:+
LUAD	cis	rs2742234	0.59	rs2505557	ENSG00000273008.1	RP11-351D16.3	-5.2	2.88e-07	8.26e-05	-0.27	-0.23	Hirschsprung disease;	chr10:43170568	chr10:43136824~43138334:-
LUAD	cis	rs9287719	0.624	rs10172926	ENSG00000243819.4	RN7SL832P	5.2	2.88e-07	8.26e-05	0.24	0.23	Prostate cancer;	chr2:10593128	chr2:10690344~10692099:+
LUAD	cis	rs6687821	0.531	rs10873816	ENSG00000267734.1	RP4-604K5.3	-5.2	2.88e-07	8.26e-05	-0.3	-0.23	Yeast infection;	chr1:87035316	chr1:86932199~86934891:-
LUAD	cis	rs6687821	0.563	rs1936282	ENSG00000267734.1	RP4-604K5.3	-5.2	2.88e-07	8.26e-05	-0.3	-0.23	Yeast infection;	chr1:87039275	chr1:86932199~86934891:-
LUAD	cis	rs6687821	0.5	rs6693974	ENSG00000267734.1	RP4-604K5.3	-5.2	2.88e-07	8.26e-05	-0.3	-0.23	Yeast infection;	chr1:87040438	chr1:86932199~86934891:-
LUAD	cis	rs6687821	0.531	rs6696540	ENSG00000267734.1	RP4-604K5.3	-5.2	2.88e-07	8.26e-05	-0.3	-0.23	Yeast infection;	chr1:87040444	chr1:86932199~86934891:-
LUAD	cis	rs10129255	0.957	rs8009638	ENSG00000211967.3	IGHV3-53	-5.2	2.88e-07	8.27e-05	-0.18	-0.23	Kawasaki disease;	chr14:106777570	chr14:106592676~106593347:-
LUAD	cis	rs867371	1	rs7173339	ENSG00000259429.4	UBE2Q2P2	-5.2	2.88e-07	8.27e-05	-0.2	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82175253	chr15:82355142~82420075:+
LUAD	cis	rs11089937	0.597	rs4821774	ENSG00000211638.2	IGLV8-61	-5.2	2.88e-07	8.27e-05	-0.27	-0.23	Periodontitis (PAL4Q3);	chr22:22131536	chr22:22098700~22099212:+
LUAD	cis	rs7937890	0.559	rs2597187	ENSG00000251991.1	RNU7-49P	5.2	2.89e-07	8.27e-05	0.24	0.23	Mitochondrial DNA levels;	chr11:14495473	chr11:14478892~14478953:+
LUAD	cis	rs7591472	1	rs7591472	ENSG00000183308.6	AC005037.3	5.2	2.89e-07	8.28e-05	0.37	0.23	Triptolide cytotoxicity;	chr2:201025028	chr2:200963263~201009102:+
LUAD	cis	rs2018683	0.803	rs12700920	ENSG00000228421.2	AC005013.5	5.2	2.89e-07	8.28e-05	0.26	0.23	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28945307	chr7:28957667~28959345:+
LUAD	cis	rs2018683	0.933	rs12536127	ENSG00000228421.2	AC005013.5	5.2	2.89e-07	8.28e-05	0.26	0.23	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28946350	chr7:28957667~28959345:+
LUAD	cis	rs7968440	1	rs2700479	ENSG00000200428.1	Y_RNA	-5.2	2.89e-07	8.28e-05	-0.29	-0.23	Fibrinogen;	chr12:50626688	chr12:50743568~50743684:+
LUAD	cis	rs2734839	0.507	rs2245805	ENSG00000270179.1	RP11-159N11.4	-5.2	2.89e-07	8.28e-05	-0.25	-0.23	Information processing speed;	chr11:113419977	chr11:113368478~113369117:+
LUAD	cis	rs7829975	0.714	rs12544992	ENSG00000253893.2	FAM85B	-5.2	2.89e-07	8.28e-05	-0.29	-0.23	Mood instability;	chr8:8804171	chr8:8167819~8226614:-
LUAD	cis	rs6543140	0.964	rs6543136	ENSG00000234389.1	AC007278.3	5.2	2.89e-07	8.29e-05	0.23	0.23	Blood protein levels;	chr2:102449087	chr2:102438713~102440475:+
LUAD	cis	rs11603023	0.967	rs7936556	ENSG00000255239.1	AP002954.6	-5.2	2.89e-07	8.29e-05	-0.27	-0.23	Cholesterol, total;	chr11:118630582	chr11:118688039~118690600:-
LUAD	cis	rs516805	0.748	rs6930548	ENSG00000279453.1	RP3-425C14.4	-5.2	2.89e-07	8.29e-05	-0.3	-0.23	Lymphocyte counts;	chr6:122375807	chr6:122436789~122439223:-
LUAD	cis	rs1198872	0.558	rs10929699	ENSG00000272275.1	RP11-791G15.2	-5.2	2.89e-07	8.29e-05	-0.32	-0.23	Cardiac Troponin-T levels;	chr2:10778083	chr2:10767875~10770058:-
LUAD	cis	rs45509595	0.749	rs401763	ENSG00000219392.1	RP1-265C24.5	-5.2	2.9e-07	8.3e-05	-0.44	-0.23	Breast cancer;	chr6:27814750	chr6:28115628~28116551:+
LUAD	cis	rs45509595	0.659	rs390764	ENSG00000219392.1	RP1-265C24.5	-5.2	2.9e-07	8.3e-05	-0.44	-0.23	Breast cancer;	chr6:27814757	chr6:28115628~28116551:+
LUAD	cis	rs45509595	0.841	rs401754	ENSG00000219392.1	RP1-265C24.5	-5.2	2.9e-07	8.3e-05	-0.44	-0.23	Breast cancer;	chr6:27814760	chr6:28115628~28116551:+
LUAD	cis	rs4835473	0.637	rs1825040	ENSG00000251600.4	RP11-673E1.1	-5.2	2.9e-07	8.31e-05	-0.26	-0.23	Immature fraction of reticulocytes;	chr4:143794417	chr4:143912331~143982454:+
LUAD	cis	rs4819052	0.788	rs9978857	ENSG00000215447.6	BX322557.10	-5.2	2.9e-07	8.31e-05	-0.28	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285240	chr21:45288052~45291738:+
LUAD	cis	rs2404602	0.552	rs11072613	ENSG00000259422.1	RP11-593F23.1	-5.2	2.9e-07	8.31e-05	-0.33	-0.23	Blood metabolite levels;	chr15:76669185	chr15:76174891~76181486:-
LUAD	cis	rs12681366	0.801	rs2919668	ENSG00000253704.1	RP11-267M23.4	5.2	2.9e-07	8.31e-05	0.29	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94449193	chr8:94553722~94569745:+
LUAD	cis	rs910316	1	rs28626045	ENSG00000259138.1	RP11-950C14.7	5.2	2.9e-07	8.32e-05	0.24	0.23	Height;	chr14:75122492	chr14:75127153~75136930:+
LUAD	cis	rs1707322	0.717	rs11211161	ENSG00000280836.1	AL355480.1	-5.2	2.9e-07	8.32e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45682466	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.752	rs61784793	ENSG00000280836.1	AL355480.1	-5.2	2.9e-07	8.32e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45683613	chr1:45581219~45581321:-
LUAD	cis	rs889398	0.967	rs2032912	ENSG00000226232.7	RP11-419C5.2	5.2	2.9e-07	8.32e-05	0.2	0.23	Body mass index;	chr16:69534400	chr16:69976388~69996188:-
LUAD	cis	rs193541	0.564	rs407230	ENSG00000263432.2	RN7SL689P	-5.2	2.91e-07	8.33e-05	-0.31	-0.23	Glucose homeostasis traits;	chr5:123010032	chr5:123022487~123022783:-
LUAD	cis	rs2732480	0.5	rs12829841	ENSG00000257735.1	RP11-370I10.6	5.2	2.91e-07	8.33e-05	0.29	0.23	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48234956	chr12:48350945~48442411:+
LUAD	cis	rs2732480	0.523	rs34286639	ENSG00000257735.1	RP11-370I10.6	5.2	2.91e-07	8.33e-05	0.29	0.23	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48235261	chr12:48350945~48442411:+
LUAD	cis	rs1387259	0.929	rs11168484	ENSG00000257735.1	RP11-370I10.6	5.2	2.91e-07	8.33e-05	0.29	0.23	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48239806	chr12:48350945~48442411:+
LUAD	cis	rs6714710	0.603	rs12995673	ENSG00000230606.9	AC159540.1	-5.2	2.91e-07	8.33e-05	-0.25	-0.23	Posterior cortical atrophy and Alzheimer's disease;	chr2:97792583	chr2:97416165~97433527:-
LUAD	cis	rs3750965	0.959	rs11228490	ENSG00000260895.1	RP11-554A11.7	-5.2	2.91e-07	8.33e-05	-0.27	-0.23	Hair color;	chr11:69093404	chr11:69103493~69109094:+
LUAD	cis	rs12468226	0.689	rs17651413	ENSG00000226261.1	AC064836.3	5.2	2.91e-07	8.33e-05	0.37	0.23	Urate levels;	chr2:202104086	chr2:202336024~202336727:-
LUAD	cis	rs9807989	0.801	rs10173193	ENSG00000234389.1	AC007278.3	5.2	2.91e-07	8.34e-05	0.22	0.23	Asthma;	chr2:102358590	chr2:102438713~102440475:+
LUAD	cis	rs2028299	0.919	rs3759831	ENSG00000259677.1	RP11-493E3.1	5.2	2.91e-07	8.34e-05	0.28	0.23	Type 2 diabetes;	chr15:89871410	chr15:89876540~89877285:+
LUAD	cis	rs9287719	0.614	rs10929678	ENSG00000243819.4	RN7SL832P	5.2	2.92e-07	8.35e-05	0.25	0.23	Prostate cancer;	chr2:10582969	chr2:10690344~10692099:+
LUAD	cis	rs453301	0.631	rs7843789	ENSG00000253981.4	ALG1L13P	-5.2	2.92e-07	8.35e-05	-0.27	-0.23	Joint mobility (Beighton score);	chr8:8943051	chr8:8236003~8244667:-
LUAD	cis	rs2380205	0.517	rs12781700	ENSG00000232807.2	RP11-536K7.3	5.2	2.92e-07	8.36e-05	0.25	0.23	Breast cancer;	chr10:5894462	chr10:5934270~5945900:-
LUAD	cis	rs587080	0.624	rs512715	ENSG00000245532.5	NEAT1	-5.2	2.92e-07	8.36e-05	-0.19	-0.23	Plateletcrit;	chr11:65423737	chr11:65422774~65445540:+
LUAD	cis	rs8098244	0.557	rs11659490	ENSG00000264745.1	TTC39C-AS1	-5.2	2.92e-07	8.37e-05	-0.24	-0.23	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23722343	chr18:23994213~24015339:-
LUAD	cis	rs12908161	1	rs35808647	ENSG00000275120.1	RP11-182J1.17	5.2	2.92e-07	8.37e-05	0.36	0.23	Schizophrenia;	chr15:84834210	chr15:84599434~84606463:-
LUAD	cis	rs9584850	0.718	rs6491427	ENSG00000231194.1	FARP1-AS1	5.2	2.93e-07	8.38e-05	0.29	0.23	Neuroticism;	chr13:98460912	chr13:98435405~98435840:-
LUAD	cis	rs4835473	0.932	rs1877235	ENSG00000251600.4	RP11-673E1.1	-5.2	2.93e-07	8.38e-05	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143986961	chr4:143912331~143982454:+
LUAD	cis	rs7208859	0.673	rs73263981	ENSG00000263531.1	RP13-753N3.1	5.2	2.93e-07	8.38e-05	0.4	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593484	chr17:30863921~30864940:-
LUAD	cis	rs748404	0.697	rs546722	ENSG00000249839.1	AC011330.5	-5.2	2.93e-07	8.38e-05	-0.3	-0.23	Lung cancer;	chr15:43288621	chr15:43663654~43684339:-
LUAD	cis	rs6570726	0.791	rs9399558	ENSG00000235652.6	RP11-545I5.3	5.2	2.93e-07	8.38e-05	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145590594	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.791	rs9376953	ENSG00000235652.6	RP11-545I5.3	5.2	2.93e-07	8.38e-05	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145591090	chr6:145799409~145886585:+
LUAD	cis	rs7937890	1	rs2970334	ENSG00000254418.1	RP11-21L19.1	-5.2	2.93e-07	8.38e-05	-0.27	-0.23	Mitochondrial DNA levels;	chr11:14307809	chr11:14262846~14273691:-
LUAD	cis	rs7208859	0.524	rs59923796	ENSG00000263603.1	CTD-2349P21.5	-5.2	2.93e-07	8.38e-05	-0.41	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737901	chr17:30729469~30731202:+
LUAD	cis	rs17826219	0.5	rs57005940	ENSG00000263603.1	CTD-2349P21.5	-5.2	2.93e-07	8.38e-05	-0.41	-0.23	Body mass index;	chr17:30739311	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.573	rs73267872	ENSG00000263603.1	CTD-2349P21.5	-5.2	2.93e-07	8.38e-05	-0.41	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30740189	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs56812022	ENSG00000263603.1	CTD-2349P21.5	-5.2	2.93e-07	8.38e-05	-0.41	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741715	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.524	rs57670615	ENSG00000263603.1	CTD-2349P21.5	-5.2	2.93e-07	8.38e-05	-0.41	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30742480	chr17:30729469~30731202:+
LUAD	cis	rs17826219	0.5	rs2874724	ENSG00000263603.1	CTD-2349P21.5	-5.2	2.93e-07	8.38e-05	-0.41	-0.23	Body mass index;	chr17:30745415	chr17:30729469~30731202:+
LUAD	cis	rs17826219	0.568	rs9898097	ENSG00000263603.1	CTD-2349P21.5	-5.2	2.93e-07	8.38e-05	-0.41	-0.23	Body mass index;	chr17:30745654	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs9911490	ENSG00000263603.1	CTD-2349P21.5	-5.2	2.93e-07	8.38e-05	-0.41	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30745995	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs7503542	ENSG00000263603.1	CTD-2349P21.5	-5.2	2.93e-07	8.38e-05	-0.41	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746812	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.573	rs11656278	ENSG00000263603.1	CTD-2349P21.5	-5.2	2.93e-07	8.38e-05	-0.41	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748170	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs6505207	ENSG00000263603.1	CTD-2349P21.5	-5.2	2.93e-07	8.38e-05	-0.41	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749553	chr17:30729469~30731202:+
LUAD	cis	rs12468226	0.873	rs76552560	ENSG00000272966.1	RP11-686O6.1	5.2	2.93e-07	8.38e-05	0.4	0.23	Urate levels;	chr2:202173123	chr2:202336739~202337200:+
LUAD	cis	rs2404602	0.735	rs2461871	ENSG00000259422.1	RP11-593F23.1	-5.2	2.93e-07	8.38e-05	-0.29	-0.23	Blood metabolite levels;	chr15:76530077	chr15:76174891~76181486:-
LUAD	cis	rs225245	0.541	rs321613	ENSG00000267592.1	CTC-507E2.2	5.2	2.93e-07	8.39e-05	0.27	0.23	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr17:35554699	chr17:35596904~35597128:-
LUAD	cis	rs2688608	0.587	rs2894040	ENSG00000271816.1	BMS1P4	5.2	2.93e-07	8.39e-05	0.2	0.23	Inflammatory bowel disease;	chr10:73718401	chr10:73699151~73730487:-
LUAD	cis	rs2688608	0.592	rs3849967	ENSG00000271816.1	BMS1P4	5.2	2.93e-07	8.39e-05	0.2	0.23	Inflammatory bowel disease;	chr10:73723608	chr10:73699151~73730487:-
LUAD	cis	rs2688608	0.592	rs7909802	ENSG00000271816.1	BMS1P4	5.2	2.93e-07	8.39e-05	0.2	0.23	Inflammatory bowel disease;	chr10:73724428	chr10:73699151~73730487:-
LUAD	cis	rs2688608	0.592	rs11000758	ENSG00000271816.1	BMS1P4	5.2	2.93e-07	8.39e-05	0.2	0.23	Inflammatory bowel disease;	chr10:73733852	chr10:73699151~73730487:-
LUAD	cis	rs2688608	0.592	rs10762560	ENSG00000271816.1	BMS1P4	5.2	2.93e-07	8.39e-05	0.2	0.23	Inflammatory bowel disease;	chr10:73735647	chr10:73699151~73730487:-
LUAD	cis	rs3096299	0.606	rs2965960	ENSG00000274627.1	RP11-104N10.2	5.2	2.93e-07	8.39e-05	0.24	0.23	Multiple myeloma (IgH translocation);	chr16:89475387	chr16:89516797~89522217:+
LUAD	cis	rs4835473	0.897	rs55635947	ENSG00000251600.4	RP11-673E1.1	-5.2	2.93e-07	8.39e-05	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143736218	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs55862664	ENSG00000251600.4	RP11-673E1.1	-5.2	2.93e-07	8.39e-05	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143736311	chr4:143912331~143982454:+
LUAD	cis	rs643506	0.874	rs663511	ENSG00000230911.1	PPIHP1	-5.2	2.94e-07	8.4e-05	-0.29	-0.23	Breast cancer;	chr11:111839311	chr11:112029858~112030367:-
LUAD	cis	rs66887589	0.87	rs59590064	ENSG00000245958.5	RP11-33B1.1	5.2	2.94e-07	8.4e-05	0.18	0.23	Diastolic blood pressure;	chr4:119618598	chr4:119454791~119552025:+
LUAD	cis	rs4143844	1	rs17271291	ENSG00000259251.2	RP11-643M14.1	5.2	2.94e-07	8.4e-05	0.41	0.23	Bipolar disorder and schizophrenia;	chr15:61982818	chr15:62060503~62062434:+
LUAD	cis	rs10740039	1	rs10994460	ENSG00000254271.1	RP11-131N11.4	5.2	2.94e-07	8.4e-05	0.26	0.23	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60659033	chr10:60734342~60741828:+
LUAD	cis	rs1387259	0.929	rs2634666	ENSG00000257735.1	RP11-370I10.6	5.2	2.94e-07	8.41e-05	0.28	0.23	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48269887	chr12:48350945~48442411:+
LUAD	cis	rs7777677	1	rs7777677	ENSG00000244273.1	PGBD4P1	-5.2	2.94e-07	8.41e-05	-0.25	-0.23	Alcoholic chronic pancreatitis;	chr7:142663616	chr7:142722358~142722764:+
LUAD	cis	rs9923856	0.523	rs11642631	ENSG00000274038.1	RP11-66H6.4	-5.2	2.94e-07	8.41e-05	-0.28	-0.23	Atopic dermatitis;Adult asthma;	chr16:11104978	chr16:11056556~11057034:+
LUAD	cis	rs17684571	0.7	rs35440822	ENSG00000231441.1	RP11-472M19.2	5.2	2.94e-07	8.41e-05	0.34	0.23	Schizophrenia;	chr6:56801006	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.575	rs71564855	ENSG00000231441.1	RP11-472M19.2	5.2	2.94e-07	8.41e-05	0.34	0.23	Schizophrenia;	chr6:56801117	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.7	rs13218913	ENSG00000231441.1	RP11-472M19.2	5.2	2.94e-07	8.41e-05	0.34	0.23	Schizophrenia;	chr6:56801247	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.7	rs71564856	ENSG00000231441.1	RP11-472M19.2	5.2	2.94e-07	8.41e-05	0.34	0.23	Schizophrenia;	chr6:56803447	chr6:56844002~56864078:+
LUAD	cis	rs12554020	0.786	rs17532098	ENSG00000227603.1	RP11-165J3.6	5.2	2.94e-07	8.42e-05	0.45	0.23	Schizophrenia;	chr9:93500443	chr9:93435332~93437121:-
LUAD	cis	rs7617773	0.694	rs13099560	ENSG00000228638.1	FCF1P2	5.2	2.94e-07	8.42e-05	0.26	0.23	Coronary artery disease;	chr3:48163278	chr3:48290793~48291375:-
LUAD	cis	rs210138	0.882	rs407710	ENSG00000197251.3	LINC00336	5.2	2.94e-07	8.42e-05	0.37	0.23	Testicular germ cell tumor;	chr6:33586480	chr6:33586106~33593338:-
LUAD	cis	rs10129255	0.5	rs2105989	ENSG00000254174.1	IGHV1-12	5.2	2.95e-07	8.43e-05	0.16	0.23	Kawasaki disease;	chr14:106682199	chr14:106122420~106122709:-
LUAD	cis	rs11159086	0.793	rs11621693	ENSG00000259005.1	RP3-449M8.6	5.2	2.95e-07	8.43e-05	0.3	0.23	Advanced glycation end-product levels;	chr14:74472631	chr14:74474007~74474864:-
LUAD	cis	rs1275468	0.731	rs2652022	ENSG00000257497.2	RP11-585P4.5	-5.2	2.95e-07	8.43e-05	-0.34	-0.23	Polycystic ovary syndrome;	chr12:75586771	chr12:75483454~75489820:-
LUAD	cis	rs4908768	0.52	rs4908507	ENSG00000232912.4	RP5-1115A15.1	5.2	2.95e-07	8.43e-05	0.21	0.23	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8678878	chr1:8424645~8434838:+
LUAD	cis	rs14027	0.921	rs13262434	ENSG00000279347.1	RP11-85I17.2	-5.2	2.95e-07	8.44e-05	-0.21	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119733423	chr8:119838736~119840385:-
LUAD	cis	rs516805	0.63	rs699405	ENSG00000279453.1	RP3-425C14.4	-5.2	2.95e-07	8.44e-05	-0.3	-0.23	Lymphocyte counts;	chr6:122274145	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.596	rs225088	ENSG00000279453.1	RP3-425C14.4	-5.2	2.95e-07	8.44e-05	-0.3	-0.23	Lymphocyte counts;	chr6:122277898	chr6:122436789~122439223:-
LUAD	cis	rs10246939	0.553	rs34894166	ENSG00000270923.1	TAS2R6P	-5.2	2.95e-07	8.44e-05	-0.26	-0.23	Bitter taste perception;	chr7:141852158	chr7:141787815~141788640:+
LUAD	cis	rs11250098	0.583	rs66724331	ENSG00000255046.1	RP11-297N6.4	5.2	2.95e-07	8.44e-05	0.29	0.23	Morning vs. evening chronotype;	chr8:10931835	chr8:11797928~11802568:-
LUAD	cis	rs6687758	1	rs12731064	ENSG00000228437.4	RP11-400N13.2	5.2	2.95e-07	8.44e-05	0.34	0.23	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222016779	chr1:221966341~221984964:+
LUAD	cis	rs1707322	0.752	rs6703748	ENSG00000280836.1	AL355480.1	-5.2	2.95e-07	8.44e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45630304	chr1:45581219~45581321:-
LUAD	cis	rs394563	0.591	rs237019	ENSG00000231760.4	RP11-350J20.5	5.2	2.95e-07	8.45e-05	0.28	0.23	Dupuytren's disease;	chr6:149405928	chr6:149796151~149826294:-
LUAD	cis	rs673078	0.607	rs7309671	ENSG00000275409.1	RP11-131L12.4	-5.2	2.96e-07	8.45e-05	-0.34	-0.23	Glucose homeostasis traits;	chr12:118313188	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs17512525	ENSG00000275409.1	RP11-131L12.4	-5.2	2.96e-07	8.45e-05	-0.34	-0.23	Glucose homeostasis traits;	chr12:118315467	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs17440774	ENSG00000275409.1	RP11-131L12.4	-5.2	2.96e-07	8.45e-05	-0.34	-0.23	Glucose homeostasis traits;	chr12:118316155	chr12:118430147~118430699:+
LUAD	cis	rs55665837	0.502	rs4757269	ENSG00000251991.1	RNU7-49P	5.2	2.96e-07	8.45e-05	0.26	0.23	Vitamin D levels;	chr11:14814646	chr11:14478892~14478953:+
LUAD	cis	rs507080	0.883	rs692750	ENSG00000278376.1	RP11-158I9.8	-5.2	2.96e-07	8.45e-05	-0.25	-0.23	Serum metabolite levels;	chr11:118667599	chr11:118791254~118793137:+
LUAD	cis	rs11976180	0.569	rs12703565	ENSG00000204959.4	ARHGEF34P	5.2	2.96e-07	8.46e-05	0.36	0.23	Obesity-related traits;	chr7:144057308	chr7:144272445~144286966:-
LUAD	cis	rs867371	1	rs8041868	ENSG00000276710.3	CSPG4P8	-5.2	2.96e-07	8.46e-05	-0.21	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82179985	chr15:82459472~82477258:+
LUAD	cis	rs4835473	0.838	rs6838981	ENSG00000251600.4	RP11-673E1.1	-5.2	2.96e-07	8.46e-05	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143826484	chr4:143912331~143982454:+
LUAD	cis	rs17826219	0.789	rs4794873	ENSG00000263531.1	RP13-753N3.1	5.2	2.96e-07	8.47e-05	0.45	0.23	Body mass index;	chr17:30421334	chr17:30863921~30864940:-
LUAD	cis	rs9309473	1	rs13384952	ENSG00000163016.8	ALMS1P	-5.2	2.96e-07	8.47e-05	-0.33	-0.23	Metabolite levels;	chr2:73496832	chr2:73644919~73685576:+
LUAD	cis	rs891378	1	rs2782828	ENSG00000274245.1	RP11-357P18.2	-5.2	2.96e-07	8.47e-05	-0.3	-0.23	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207323654	chr1:207372559~207373252:+
LUAD	cis	rs12908161	0.96	rs34452033	ENSG00000275120.1	RP11-182J1.17	5.2	2.97e-07	8.47e-05	0.35	0.23	Schizophrenia;	chr15:84678762	chr15:84599434~84606463:-
LUAD	cis	rs7829975	0.714	rs12544992	ENSG00000173295.6	FAM86B3P	5.2	2.97e-07	8.47e-05	0.24	0.23	Mood instability;	chr8:8804171	chr8:8228595~8244865:+
LUAD	cis	rs453301	0.653	rs2956244	ENSG00000253893.2	FAM85B	-5.2	2.97e-07	8.48e-05	-0.3	-0.23	Joint mobility (Beighton score);	chr8:9027656	chr8:8167819~8226614:-
LUAD	cis	rs7083	0.935	rs2509211	ENSG00000254851.1	RP11-109L13.1	5.2	2.97e-07	8.48e-05	0.29	0.23	Blood protein levels;	chr11:117266917	chr11:117135528~117138582:+
LUAD	cis	rs7083	1	rs524085	ENSG00000254851.1	RP11-109L13.1	5.2	2.97e-07	8.48e-05	0.29	0.23	Blood protein levels;	chr11:117266931	chr11:117135528~117138582:+
LUAD	cis	rs7189233	0.531	rs8049033	ENSG00000279344.1	RP11-44F14.7	5.2	2.97e-07	8.49e-05	0.19	0.23	Intelligence (multi-trait analysis);	chr16:53479143	chr16:53478957~53481550:-
LUAD	cis	rs860295	0.58	rs6672284	ENSG00000225855.5	RUSC1-AS1	5.2	2.97e-07	8.49e-05	0.16	0.23	Body mass index;	chr1:155308172	chr1:155316863~155324176:-
LUAD	cis	rs6687821	0.5	rs6702601	ENSG00000267734.1	RP4-604K5.3	-5.2	2.97e-07	8.49e-05	-0.3	-0.23	Yeast infection;	chr1:87047875	chr1:86932199~86934891:-
LUAD	cis	rs875971	0.508	rs6947808	ENSG00000237310.1	GS1-124K5.4	-5.2	2.97e-07	8.49e-05	-0.24	-0.23	Aortic root size;	chr7:66580095	chr7:66493706~66495474:+
LUAD	cis	rs6669008	1	rs6669008	ENSG00000232450.1	RP4-730K3.3	-5.2	2.97e-07	8.5e-05	-0.28	-0.23	Bacteremia;	chr1:113623939	chr1:113698884~113699631:-
LUAD	cis	rs9545047	0.567	rs7321186	ENSG00000227354.5	RBM26-AS1	5.2	2.98e-07	8.5e-05	0.25	0.23	Schizophrenia;	chr13:79383403	chr13:79406309~79424328:+
LUAD	cis	rs2742234	0.59	rs2257767	ENSG00000273008.1	RP11-351D16.3	-5.2	2.98e-07	8.5e-05	-0.27	-0.23	Hirschsprung disease;	chr10:43162363	chr10:43136824~43138334:-
LUAD	cis	rs4835473	0.639	rs28674022	ENSG00000251600.4	RP11-673E1.1	5.2	2.98e-07	8.5e-05	0.28	0.23	Immature fraction of reticulocytes;	chr4:143966409	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.864	rs28423022	ENSG00000251600.4	RP11-673E1.1	5.2	2.98e-07	8.5e-05	0.28	0.23	Immature fraction of reticulocytes;	chr4:143966416	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.864	rs35888177	ENSG00000251600.4	RP11-673E1.1	5.2	2.98e-07	8.5e-05	0.28	0.23	Immature fraction of reticulocytes;	chr4:143966863	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs10033382	ENSG00000251600.4	RP11-673E1.1	5.2	2.98e-07	8.5e-05	0.28	0.23	Immature fraction of reticulocytes;	chr4:143967103	chr4:143912331~143982454:+
LUAD	cis	rs12745968	0.623	rs10874733	ENSG00000223787.2	RP4-593M8.1	-5.2	2.98e-07	8.5e-05	-0.27	-0.23	Bipolar disorder and schizophrenia;	chr1:92658176	chr1:92580476~92580821:-
LUAD	cis	rs7083	1	rs664011	ENSG00000254851.1	RP11-109L13.1	5.2	2.98e-07	8.51e-05	0.3	0.23	Blood protein levels;	chr11:117237602	chr11:117135528~117138582:+
LUAD	cis	rs875971	1	rs2220626	ENSG00000237310.1	GS1-124K5.4	-5.2	2.98e-07	8.51e-05	-0.25	-0.23	Aortic root size;	chr7:66081075	chr7:66493706~66495474:+
LUAD	cis	rs807029	0.533	rs3824783	ENSG00000272572.1	RP11-179B2.2	-5.2	2.98e-07	8.51e-05	-0.33	-0.23	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:100991094	chr10:100911103~100912739:-
LUAD	cis	rs35160687	0.623	rs11127019	ENSG00000273080.1	RP11-301O19.1	-5.2	2.98e-07	8.51e-05	-0.26	-0.23	Night sleep phenotypes;	chr2:86240495	chr2:86195590~86196049:+
LUAD	cis	rs2239547	0.522	rs9865094	ENSG00000242142.1	SERBP1P3	-5.2	2.98e-07	8.52e-05	-0.27	-0.23	Schizophrenia;	chr3:52951303	chr3:53064283~53065091:-
LUAD	cis	rs2239547	0.522	rs9831409	ENSG00000242142.1	SERBP1P3	-5.2	2.98e-07	8.52e-05	-0.27	-0.23	Schizophrenia;	chr3:52951695	chr3:53064283~53065091:-
LUAD	cis	rs673078	0.607	rs882927	ENSG00000275409.1	RP11-131L12.4	-5.2	2.98e-07	8.52e-05	-0.31	-0.23	Glucose homeostasis traits;	chr12:118406737	chr12:118430147~118430699:+
LUAD	cis	rs14027	0.921	rs13270831	ENSG00000279347.1	RP11-85I17.2	-5.2	2.99e-07	8.52e-05	-0.2	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119755071	chr8:119838736~119840385:-
LUAD	cis	rs14027	0.921	rs16893113	ENSG00000279347.1	RP11-85I17.2	-5.2	2.99e-07	8.52e-05	-0.2	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119756447	chr8:119838736~119840385:-
LUAD	cis	rs14027	0.921	rs2326377	ENSG00000279347.1	RP11-85I17.2	-5.2	2.99e-07	8.52e-05	-0.2	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119756696	chr8:119838736~119840385:-
LUAD	cis	rs14027	0.921	rs13257002	ENSG00000279347.1	RP11-85I17.2	-5.2	2.99e-07	8.52e-05	-0.2	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119757489	chr8:119838736~119840385:-
LUAD	cis	rs14027	0.921	rs62526565	ENSG00000279347.1	RP11-85I17.2	-5.2	2.99e-07	8.52e-05	-0.2	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119759301	chr8:119838736~119840385:-
LUAD	cis	rs11976180	1	rs2961118	ENSG00000204959.4	ARHGEF34P	5.2	2.99e-07	8.53e-05	0.28	0.23	Obesity-related traits;	chr7:144058350	chr7:144272445~144286966:-
LUAD	cis	rs394563	0.619	rs4895787	ENSG00000231760.4	RP11-350J20.5	-5.2	2.99e-07	8.54e-05	-0.29	-0.23	Dupuytren's disease;	chr6:149325364	chr6:149796151~149826294:-
LUAD	cis	rs7208859	0.673	rs450585	ENSG00000263531.1	RP13-753N3.1	5.2	2.99e-07	8.55e-05	0.38	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624021	chr17:30863921~30864940:-
LUAD	cis	rs4835473	0.932	rs4835279	ENSG00000251600.4	RP11-673E1.1	-5.2	3e-07	8.55e-05	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143788917	chr4:143912331~143982454:+
LUAD	cis	rs1707322	0.721	rs10890336	ENSG00000280836.1	AL355480.1	-5.2	3e-07	8.56e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645384	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.721	rs11211151	ENSG00000280836.1	AL355480.1	-5.2	3e-07	8.56e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45647080	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.721	rs12045096	ENSG00000280836.1	AL355480.1	-5.2	3e-07	8.56e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648756	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.721	rs4609469	ENSG00000280836.1	AL355480.1	-5.2	3e-07	8.56e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651513	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.721	rs12049027	ENSG00000280836.1	AL355480.1	-5.2	3e-07	8.56e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45652512	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.752	rs10789467	ENSG00000280836.1	AL355480.1	-5.2	3e-07	8.56e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45653073	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.721	rs10890337	ENSG00000280836.1	AL355480.1	-5.2	3e-07	8.56e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658855	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.752	rs3811435	ENSG00000280836.1	AL355480.1	-5.2	3e-07	8.56e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660118	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.721	rs9793568	ENSG00000280836.1	AL355480.1	-5.2	3e-07	8.56e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664701	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.721	rs11211157	ENSG00000280836.1	AL355480.1	-5.2	3e-07	8.56e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667172	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.721	rs11211158	ENSG00000280836.1	AL355480.1	-5.2	3e-07	8.56e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667178	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.721	rs6429575	ENSG00000280836.1	AL355480.1	-5.2	3e-07	8.56e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668544	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.685	rs6690926	ENSG00000280836.1	AL355480.1	-5.2	3e-07	8.56e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669306	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.752	rs8179402	ENSG00000280836.1	AL355480.1	-5.2	3e-07	8.56e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45676794	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.752	rs8179296	ENSG00000280836.1	AL355480.1	-5.2	3e-07	8.56e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45678119	chr1:45581219~45581321:-
LUAD	cis	rs516805	0.63	rs2606656	ENSG00000279453.1	RP3-425C14.4	-5.2	3e-07	8.56e-05	-0.32	-0.23	Lymphocyte counts;	chr6:122153088	chr6:122436789~122439223:-
LUAD	cis	rs9322193	0.923	rs9371486	ENSG00000268592.3	RAET1E-AS1	5.2	3e-07	8.56e-05	0.3	0.23	Lung cancer;	chr6:149832090	chr6:149863494~149919507:+
LUAD	cis	rs11089937	0.568	rs12160318	ENSG00000211638.2	IGLV8-61	-5.2	3e-07	8.56e-05	-0.27	-0.23	Periodontitis (PAL4Q3);	chr22:22131627	chr22:22098700~22099212:+
LUAD	cis	rs11089937	0.568	rs12159174	ENSG00000211638.2	IGLV8-61	-5.2	3e-07	8.56e-05	-0.27	-0.23	Periodontitis (PAL4Q3);	chr22:22131639	chr22:22098700~22099212:+
LUAD	cis	rs11089937	0.568	rs11089919	ENSG00000211638.2	IGLV8-61	-5.2	3e-07	8.56e-05	-0.27	-0.23	Periodontitis (PAL4Q3);	chr22:22131648	chr22:22098700~22099212:+
LUAD	cis	rs4268898	0.722	rs7563958	ENSG00000242628.4	AC009228.1	-5.2	3e-07	8.57e-05	-0.29	-0.23	Asthma;	chr2:24199512	chr2:24214381~24221516:+
LUAD	cis	rs4664293	1	rs10204535	ENSG00000226266.5	AC009961.3	-5.2	3e-07	8.57e-05	-0.31	-0.23	Monocyte percentage of white cells;	chr2:159607181	chr2:159670708~159712435:-
LUAD	cis	rs4803480	1	rs7255679	ENSG00000270164.1	LINC01480	-5.2	3e-07	8.57e-05	-0.23	-0.23	Schizophrenia;	chr19:41557611	chr19:41535183~41536904:+
LUAD	cis	rs7829975	0.606	rs6422352	ENSG00000253893.2	FAM85B	5.2	3e-07	8.57e-05	0.29	0.23	Mood instability;	chr8:8936683	chr8:8167819~8226614:-
LUAD	cis	rs748404	0.697	rs530188	ENSG00000249839.1	AC011330.5	-5.2	3e-07	8.57e-05	-0.3	-0.23	Lung cancer;	chr15:43253116	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.697	rs475227	ENSG00000249839.1	AC011330.5	-5.2	3e-07	8.57e-05	-0.3	-0.23	Lung cancer;	chr15:43254248	chr15:43663654~43684339:-
LUAD	cis	rs2946504	0.861	rs2954171	ENSG00000251468.2	RP11-369K16.1	-5.2	3e-07	8.57e-05	-0.3	-0.23	Type 2 diabetes;	chr8:12956087	chr8:12958387~12962200:+
LUAD	cis	rs944990	0.597	rs4607675	ENSG00000227603.1	RP11-165J3.6	5.2	3.01e-07	8.58e-05	0.26	0.23	Body mass index;	chr9:93454127	chr9:93435332~93437121:-
LUAD	cis	rs9928842	0.771	rs2870471	ENSG00000280152.1	RP11-331F4.5	-5.2	3.01e-07	8.58e-05	-0.24	-0.23	Alcoholic chronic pancreatitis;	chr16:75240384	chr16:75245994~75250077:-
LUAD	cis	rs7712401	0.584	rs4836382	ENSG00000263432.2	RN7SL689P	5.2	3.01e-07	8.59e-05	0.31	0.23	Mean platelet volume;	chr5:123040946	chr5:123022487~123022783:-
LUAD	cis	rs6714710	0.603	rs1470483	ENSG00000230606.9	AC159540.1	-5.2	3.01e-07	8.59e-05	-0.25	-0.23	Posterior cortical atrophy and Alzheimer's disease;	chr2:97777431	chr2:97416165~97433527:-
LUAD	cis	rs9595908	0.785	rs7981925	ENSG00000212293.1	SNORA16	5.2	3.01e-07	8.59e-05	0.25	0.23	Body mass index;	chr13:32693706	chr13:32420390~32420516:-
LUAD	cis	rs67311347	0.544	rs9814779	ENSG00000223797.4	ENTPD3-AS1	5.2	3.01e-07	8.59e-05	0.24	0.23	Renal cell carcinoma;	chr3:40298940	chr3:40313802~40453329:-
LUAD	cis	rs8031584	0.678	rs4779790	ENSG00000259845.1	HERC2P10	5.2	3.01e-07	8.6e-05	0.28	0.23	Huntington's disease progression;	chr15:30872392	chr15:30815271~30844153:+
LUAD	cis	rs7208859	0.524	rs73988172	ENSG00000263603.1	CTD-2349P21.5	-5.2	3.02e-07	8.6e-05	-0.39	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30729469~30731202:+
LUAD	cis	rs6772849	0.768	rs4521246	ENSG00000242551.2	POU5F1P6	5.2	3.02e-07	8.6e-05	0.28	0.23	Monocyte percentage of white cells;Monocyte count;	chr3:128702323	chr3:128674735~128677005:-
LUAD	cis	rs12468226	1	rs76528043	ENSG00000226261.1	AC064836.3	5.2	3.02e-07	8.61e-05	0.37	0.23	Urate levels;	chr2:202466116	chr2:202336024~202336727:-
LUAD	cis	rs673078	0.607	rs17440669	ENSG00000275409.1	RP11-131L12.4	-5.2	3.02e-07	8.61e-05	-0.34	-0.23	Glucose homeostasis traits;	chr12:118310397	chr12:118430147~118430699:+
LUAD	cis	rs7131987	0.65	rs11050208	ENSG00000257176.2	RP11-996F15.2	-5.2	3.02e-07	8.61e-05	-0.28	-0.23	QT interval;	chr12:29357436	chr12:29280418~29317848:-
LUAD	cis	rs9322193	0.884	rs11155679	ENSG00000268592.3	RAET1E-AS1	5.2	3.02e-07	8.61e-05	0.3	0.23	Lung cancer;	chr6:149758881	chr6:149863494~149919507:+
LUAD	cis	rs4835473	0.897	rs56334914	ENSG00000251600.4	RP11-673E1.1	-5.2	3.03e-07	8.63e-05	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143736291	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.897	rs56324738	ENSG00000251600.4	RP11-673E1.1	-5.2	3.03e-07	8.63e-05	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143736297	chr4:143912331~143982454:+
LUAD	cis	rs909685	1	rs909685	ENSG00000280216.1	RP3-333H23.9	5.2	3.03e-07	8.63e-05	0.25	0.23	Rheumatoid arthritis;	chr22:39351666	chr22:39379610~39380015:+
LUAD	cis	rs1707322	0.964	rs7512395	ENSG00000280836.1	AL355480.1	-5.19	3.03e-07	8.64e-05	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45895505	chr1:45581219~45581321:-
LUAD	cis	rs9910055	0.659	rs7216294	ENSG00000267080.4	ASB16-AS1	-5.19	3.03e-07	8.64e-05	-0.21	-0.23	Total body bone mineral density;	chr17:44173727	chr17:44175973~44186717:-
LUAD	cis	rs2976388	1	rs1045574	ENSG00000253741.1	CTD-2292P10.4	5.19	3.04e-07	8.65e-05	0.26	0.23	Urinary tract infection frequency;	chr8:142682540	chr8:142702252~142726973:-
LUAD	cis	rs225245	0.541	rs321612	ENSG00000267592.1	CTC-507E2.2	5.19	3.04e-07	8.66e-05	0.27	0.23	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr17:35554612	chr17:35596904~35597128:-
LUAD	cis	rs9992667	0.955	rs922334	ENSG00000231160.8	KLF3-AS1	5.19	3.04e-07	8.66e-05	0.27	0.23	Eosinophil percentage of granulocytes;	chr4:38615137	chr4:38612701~38664883:-
LUAD	cis	rs2599510	0.703	rs762023	ENSG00000276334.1	AL133243.1	5.19	3.04e-07	8.66e-05	0.26	0.23	Interleukin-18 levels;	chr2:32488103	chr2:32521927~32523547:+
LUAD	cis	rs240993	0.812	rs9487639	ENSG00000230177.1	RP5-1112D6.4	-5.19	3.04e-07	8.66e-05	-0.23	-0.23	Inflammatory skin disease;Psoriasis;	chr6:111426791	chr6:111277932~111278742:+
LUAD	cis	rs1008375	0.9	rs6812675	ENSG00000249502.1	AC006160.5	-5.19	3.04e-07	8.67e-05	-0.23	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17595926	chr4:17587467~17614571:-
LUAD	cis	rs1008375	0.9	rs4698625	ENSG00000249502.1	AC006160.5	-5.19	3.04e-07	8.67e-05	-0.23	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17597877	chr4:17587467~17614571:-
LUAD	cis	rs1707322	0.691	rs11211175	ENSG00000280836.1	AL355480.1	-5.19	3.04e-07	8.67e-05	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755212	chr1:45581219~45581321:-
LUAD	cis	rs7712401	0.601	rs30039	ENSG00000263432.2	RN7SL689P	-5.19	3.04e-07	8.67e-05	-0.3	-0.23	Mean platelet volume;	chr5:122941484	chr5:123022487~123022783:-
LUAD	cis	rs10754283	0.967	rs10801757	ENSG00000231613.1	RP5-943J3.1	5.19	3.04e-07	8.67e-05	0.23	0.23	Amyotrophic lateral sclerosis (sporadic);	chr1:89637521	chr1:89788914~89790492:+
LUAD	cis	rs2921036	0.529	rs2979192	ENSG00000253893.2	FAM85B	-5.19	3.04e-07	8.67e-05	-0.29	-0.23	Neuroticism;	chr8:8480637	chr8:8167819~8226614:-
LUAD	cis	rs748404	0.723	rs512431	ENSG00000249839.1	AC011330.5	5.19	3.04e-07	8.67e-05	0.3	0.23	Lung cancer;	chr15:43249741	chr15:43663654~43684339:-
LUAD	cis	rs2284378	0.506	rs6142059	ENSG00000275784.1	RP5-1125A11.6	-5.19	3.04e-07	8.67e-05	-0.24	-0.23	Breast cancer;	chr20:33956521	chr20:33989480~33991818:-
LUAD	cis	rs561341	0.943	rs508566	ENSG00000265798.5	RP11-271K11.5	5.19	3.05e-07	8.68e-05	0.37	0.23	Hip circumference adjusted for BMI;	chr17:31962842	chr17:31038575~31059121:-
LUAD	cis	rs2998286	0.862	rs2993981	ENSG00000254635.4	WAC-AS1	-5.19	3.05e-07	8.68e-05	-0.28	-0.23	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28506552	chr10:28522652~28532743:-
LUAD	cis	rs2998286	0.862	rs2993982	ENSG00000254635.4	WAC-AS1	-5.19	3.05e-07	8.68e-05	-0.28	-0.23	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28506559	chr10:28522652~28532743:-
LUAD	cis	rs763567	1	rs6677540	ENSG00000271811.1	RP1-79C4.4	-5.19	3.05e-07	8.69e-05	-0.28	-0.23	Tonsillectomy;	chr1:170614370	chr1:170667381~170669425:+
LUAD	cis	rs763567	0.967	rs6690642	ENSG00000271811.1	RP1-79C4.4	-5.19	3.05e-07	8.69e-05	-0.28	-0.23	Tonsillectomy;	chr1:170614803	chr1:170667381~170669425:+
LUAD	cis	rs12468226	0.938	rs10931993	ENSG00000272966.1	RP11-686O6.1	5.19	3.05e-07	8.7e-05	0.38	0.23	Urate levels;	chr2:202243017	chr2:202336739~202337200:+
LUAD	cis	rs673078	0.66	rs73205512	ENSG00000275409.1	RP11-131L12.4	-5.19	3.05e-07	8.7e-05	-0.33	-0.23	Glucose homeostasis traits;	chr12:118235770	chr12:118430147~118430699:+
LUAD	cis	rs1075265	0.73	rs805392	ENSG00000233266.1	HMGB1P31	5.19	3.06e-07	8.7e-05	0.29	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53877594	chr2:54051334~54051760:+
LUAD	cis	rs9928842	0.765	rs6564222	ENSG00000280152.1	RP11-331F4.5	5.19	3.06e-07	8.7e-05	0.27	0.23	Alcoholic chronic pancreatitis;	chr16:75191146	chr16:75245994~75250077:-
LUAD	cis	rs12468226	0.808	rs77251002	ENSG00000226261.1	AC064836.3	5.19	3.06e-07	8.71e-05	0.38	0.23	Urate levels;	chr2:202150236	chr2:202336024~202336727:-
LUAD	cis	rs7621025	0.5	rs16844241	ENSG00000239213.4	NCK1-AS1	-5.19	3.06e-07	8.71e-05	-0.29	-0.23	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136916329	chr3:136841726~136862054:-
LUAD	cis	rs55665837	0.54	rs12290926	ENSG00000251991.1	RNU7-49P	5.19	3.06e-07	8.71e-05	0.26	0.23	Vitamin D levels;	chr11:14673500	chr11:14478892~14478953:+
LUAD	cis	rs9992667	0.955	rs9998440	ENSG00000231160.8	KLF3-AS1	-5.19	3.06e-07	8.72e-05	-0.27	-0.23	Eosinophil percentage of granulocytes;	chr4:38606180	chr4:38612701~38664883:-
LUAD	cis	rs7017914	0.622	rs34022947	ENSG00000223220.1	Y_RNA	5.19	3.06e-07	8.73e-05	0.27	0.23	Bone mineral density;	chr8:71072373	chr8:70780914~70781008:-
LUAD	cis	rs453301	0.686	rs11787026	ENSG00000173295.6	FAM86B3P	5.19	3.07e-07	8.73e-05	0.25	0.23	Joint mobility (Beighton score);	chr8:9044861	chr8:8228595~8244865:+
LUAD	cis	rs7017914	0.69	rs3098875	ENSG00000223220.1	Y_RNA	5.19	3.07e-07	8.73e-05	0.27	0.23	Bone mineral density;	chr8:71022453	chr8:70780914~70781008:-
LUAD	cis	rs516805	0.667	rs9482234	ENSG00000279453.1	RP3-425C14.4	5.19	3.07e-07	8.73e-05	0.31	0.23	Lymphocyte counts;	chr6:122313998	chr6:122436789~122439223:-
LUAD	cis	rs1816752	0.87	rs7320102	ENSG00000273628.1	RP11-756A22.7	5.19	3.07e-07	8.73e-05	0.26	0.23	Obesity-related traits;	chr13:24437435	chr13:24933006~24936796:+
LUAD	cis	rs673078	0.607	rs61943403	ENSG00000275409.1	RP11-131L12.4	-5.19	3.07e-07	8.74e-05	-0.31	-0.23	Glucose homeostasis traits;	chr12:118399887	chr12:118430147~118430699:+
LUAD	cis	rs11157436	0.918	rs1076546	ENSG00000211813.2	TRAV34	5.19	3.08e-07	8.75e-05	0.28	0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22159015	chr14:22207522~22208129:+
LUAD	cis	rs7131987	0.65	rs7973786	ENSG00000257176.2	RP11-996F15.2	-5.19	3.08e-07	8.76e-05	-0.26	-0.23	QT interval;	chr12:29309811	chr12:29280418~29317848:-
LUAD	cis	rs2790457	0.958	rs2790454	ENSG00000254635.4	WAC-AS1	-5.19	3.08e-07	8.77e-05	-0.25	-0.23	Multiple myeloma;	chr10:28553103	chr10:28522652~28532743:-
LUAD	cis	rs875971	0.505	rs1167386	ENSG00000236529.1	RP13-254B10.1	-5.19	3.08e-07	8.77e-05	-0.23	-0.23	Aortic root size;	chr7:66048109	chr7:65840212~65840596:+
LUAD	cis	rs875971	0.505	rs1167385	ENSG00000236529.1	RP13-254B10.1	-5.19	3.08e-07	8.77e-05	-0.23	-0.23	Aortic root size;	chr7:66048321	chr7:65840212~65840596:+
LUAD	cis	rs7772486	0.754	rs4896838	ENSG00000235652.6	RP11-545I5.3	-5.19	3.08e-07	8.77e-05	-0.23	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145694315	chr6:145799409~145886585:+
LUAD	cis	rs897984	0.574	rs11647284	ENSG00000260911.2	RP11-196G11.2	5.19	3.08e-07	8.78e-05	0.21	0.23	Dementia with Lewy bodies;	chr16:31066014	chr16:31043150~31049868:+
LUAD	cis	rs11976180	1	rs1533268	ENSG00000204959.4	ARHGEF34P	5.19	3.08e-07	8.78e-05	0.28	0.23	Obesity-related traits;	chr7:144069265	chr7:144272445~144286966:-
LUAD	cis	rs11976180	1	rs1533267	ENSG00000204959.4	ARHGEF34P	5.19	3.08e-07	8.78e-05	0.28	0.23	Obesity-related traits;	chr7:144069347	chr7:144272445~144286966:-
LUAD	cis	rs957448	0.539	rs9643346	ENSG00000253704.1	RP11-267M23.4	5.19	3.09e-07	8.78e-05	0.27	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94601587	chr8:94553722~94569745:+
LUAD	cis	rs11157436	0.697	rs4334205	ENSG00000211812.1	TRAV26-2	5.19	3.09e-07	8.79e-05	0.22	0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22155699	chr14:22202583~22203368:+
LUAD	cis	rs2098713	0.535	rs1126290	ENSG00000250155.1	CTD-2353F22.1	5.19	3.09e-07	8.79e-05	0.24	0.23	Telomere length;	chr5:37588398	chr5:36666214~36725195:-
LUAD	cis	rs4143844	1	rs34424197	ENSG00000259251.2	RP11-643M14.1	5.19	3.09e-07	8.79e-05	0.4	0.23	Bipolar disorder and schizophrenia;	chr15:61996620	chr15:62060503~62062434:+
LUAD	cis	rs875971	0.505	rs2462573	ENSG00000164669.11	INTS4P1	5.19	3.09e-07	8.79e-05	0.28	0.23	Aortic root size;	chr7:66042405	chr7:65141225~65234216:+
LUAD	cis	rs4141404	0.851	rs9606833	ENSG00000236132.1	CTA-440B3.1	-5.19	3.09e-07	8.8e-05	-0.32	-0.23	Paclitaxel-induced neuropathy;	chr22:31354027	chr22:31816379~31817491:-
LUAD	cis	rs1061377	0.965	rs7690465	ENSG00000249685.1	RP11-360F5.3	5.19	3.09e-07	8.8e-05	0.29	0.23	Uric acid levels;	chr4:39147015	chr4:39133913~39135608:+
LUAD	cis	rs4908760	0.827	rs7513420	ENSG00000232912.4	RP5-1115A15.1	5.19	3.09e-07	8.8e-05	0.21	0.23	Vitiligo;	chr1:8620985	chr1:8424645~8434838:+
LUAD	cis	rs12022452	0.818	rs11810978	ENSG00000238287.1	RP11-656D10.3	-5.19	3.09e-07	8.8e-05	-0.4	-0.23	Age-related hearing impairment (SNP x SNP interaction);	chr1:40554175	chr1:40493157~40508661:-
LUAD	cis	rs2946504	0.861	rs2946502	ENSG00000251468.2	RP11-369K16.1	-5.19	3.09e-07	8.8e-05	-0.3	-0.23	Type 2 diabetes;	chr8:12955445	chr8:12958387~12962200:+
LUAD	cis	rs150992	0.504	rs152036	ENSG00000248489.1	CTD-2007H13.3	5.19	3.09e-07	8.8e-05	0.3	0.23	Body mass index;	chr5:98981729	chr5:98929171~98995013:+
LUAD	cis	rs11105298	0.891	rs4842664	ENSG00000258302.2	RP11-981P6.1	5.19	3.1e-07	8.8e-05	0.3	0.23	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89544253	chr12:89561129~89594878:+
LUAD	cis	rs11105298	0.891	rs11105325	ENSG00000258302.2	RP11-981P6.1	5.19	3.1e-07	8.8e-05	0.3	0.23	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89544813	chr12:89561129~89594878:+
LUAD	cis	rs875971	0.54	rs736270	ENSG00000164669.11	INTS4P1	-5.19	3.1e-07	8.81e-05	-0.28	-0.23	Aortic root size;	chr7:65963835	chr7:65141225~65234216:+
LUAD	cis	rs944990	0.576	rs10821135	ENSG00000227603.1	RP11-165J3.6	5.19	3.1e-07	8.81e-05	0.26	0.23	Body mass index;	chr9:93476296	chr9:93435332~93437121:-
LUAD	cis	rs875971	0.505	rs1167386	ENSG00000164669.11	INTS4P1	5.19	3.1e-07	8.81e-05	0.28	0.23	Aortic root size;	chr7:66048109	chr7:65141225~65234216:+
LUAD	cis	rs875971	0.505	rs1167385	ENSG00000164669.11	INTS4P1	5.19	3.1e-07	8.81e-05	0.28	0.23	Aortic root size;	chr7:66048321	chr7:65141225~65234216:+
LUAD	cis	rs875971	0.825	rs1860472	ENSG00000232559.3	GS1-124K5.12	-5.19	3.1e-07	8.81e-05	-0.27	-0.23	Aortic root size;	chr7:66617736	chr7:66554588~66576923:-
LUAD	cis	rs6772849	1	rs9848975	ENSG00000242551.2	POU5F1P6	-5.19	3.1e-07	8.81e-05	-0.26	-0.23	Monocyte percentage of white cells;Monocyte count;	chr3:128593140	chr3:128674735~128677005:-
LUAD	cis	rs4908768	0.52	rs7520025	ENSG00000232912.4	RP5-1115A15.1	5.19	3.1e-07	8.81e-05	0.21	0.23	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8638218	chr1:8424645~8434838:+
LUAD	cis	rs2688608	0.588	rs10128205	ENSG00000271816.1	BMS1P4	5.19	3.1e-07	8.82e-05	0.2	0.23	Inflammatory bowel disease;	chr10:73709890	chr10:73699151~73730487:-
LUAD	cis	rs4835473	0.714	rs10013005	ENSG00000251600.4	RP11-673E1.1	5.19	3.1e-07	8.82e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143711351	chr4:143912331~143982454:+
LUAD	cis	rs755249	0.501	rs2484749	ENSG00000228060.1	RP11-69E11.8	5.19	3.1e-07	8.82e-05	0.21	0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39293283	chr1:39565160~39573203:+
LUAD	cis	rs10129255	0.5	rs11627315	ENSG00000254174.1	IGHV1-12	5.19	3.1e-07	8.83e-05	0.16	0.23	Kawasaki disease;	chr14:106802182	chr14:106122420~106122709:-
LUAD	cis	rs7176527	1	rs3762168	ENSG00000229212.6	RP11-561C5.4	5.19	3.1e-07	8.83e-05	0.34	0.23	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84599416	chr15:85205440~85234795:-
LUAD	cis	rs6570726	0.791	rs9403734	ENSG00000235652.6	RP11-545I5.3	5.19	3.11e-07	8.83e-05	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145610323	chr6:145799409~145886585:+
LUAD	cis	rs2015599	0.549	rs7956305	ENSG00000257176.2	RP11-996F15.2	5.19	3.11e-07	8.83e-05	0.24	0.23	Platelet count;Mean platelet volume;	chr12:29308639	chr12:29280418~29317848:-
LUAD	cis	rs2015599	0.543	rs6487807	ENSG00000257176.2	RP11-996F15.2	5.19	3.11e-07	8.83e-05	0.24	0.23	Platelet count;Mean platelet volume;	chr12:29309291	chr12:29280418~29317848:-
LUAD	cis	rs12681366	0.881	rs2931631	ENSG00000253704.1	RP11-267M23.4	5.19	3.11e-07	8.83e-05	0.28	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94401415	chr8:94553722~94569745:+
LUAD	cis	rs2337406	1	rs3858878	ENSG00000211974.3	IGHV2-70	-5.19	3.11e-07	8.83e-05	-0.3	-0.23	Alzheimer's disease (late onset);	chr14:106688061	chr14:106723574~106724093:-
LUAD	cis	rs12554020	0.581	rs4255201	ENSG00000227603.1	RP11-165J3.6	5.19	3.11e-07	8.84e-05	0.46	0.23	Schizophrenia;	chr9:93401055	chr9:93435332~93437121:-
LUAD	cis	rs1707322	1	rs4660332	ENSG00000280836.1	AL355480.1	-5.19	3.11e-07	8.85e-05	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995746	chr1:45581219~45581321:-
LUAD	cis	rs8031584	0.918	rs34693097	ENSG00000270015.1	RP11-540B6.6	-5.19	3.11e-07	8.85e-05	-0.17	-0.23	Huntington's disease progression;	chr15:30961781	chr15:30926514~30928407:+
LUAD	cis	rs8031584	0.918	rs35784593	ENSG00000270015.1	RP11-540B6.6	-5.19	3.11e-07	8.85e-05	-0.17	-0.23	Huntington's disease progression;	chr15:30962385	chr15:30926514~30928407:+
LUAD	cis	rs2980439	0.807	rs2980438	ENSG00000173295.6	FAM86B3P	5.19	3.11e-07	8.85e-05	0.24	0.23	Neuroticism;	chr8:8237303	chr8:8228595~8244865:+
LUAD	cis	rs10129255	0.536	rs3944157	ENSG00000254174.1	IGHV1-12	5.19	3.11e-07	8.85e-05	0.16	0.23	Kawasaki disease;	chr14:106682286	chr14:106122420~106122709:-
LUAD	cis	rs2239547	0.562	rs35380116	ENSG00000242142.1	SERBP1P3	-5.19	3.11e-07	8.85e-05	-0.27	-0.23	Schizophrenia;	chr3:52945162	chr3:53064283~53065091:-
LUAD	cis	rs4835473	0.742	rs7654409	ENSG00000251600.4	RP11-673E1.1	5.19	3.12e-07	8.85e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143956842	chr4:143912331~143982454:+
LUAD	cis	rs1012068	0.581	rs5749339	ENSG00000236132.1	CTA-440B3.1	5.19	3.12e-07	8.85e-05	0.3	0.23	Chronic hepatitis C infection;	chr22:31919749	chr22:31816379~31817491:-
LUAD	cis	rs4664293	0.967	rs7597482	ENSG00000226266.5	AC009961.3	-5.19	3.12e-07	8.86e-05	-0.32	-0.23	Monocyte percentage of white cells;	chr2:159690580	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.967	rs7597488	ENSG00000226266.5	AC009961.3	-5.19	3.12e-07	8.86e-05	-0.32	-0.23	Monocyte percentage of white cells;	chr2:159690585	chr2:159670708~159712435:-
LUAD	cis	rs9487094	0.922	rs2275650	ENSG00000260273.1	RP11-425D10.10	5.19	3.12e-07	8.86e-05	0.32	0.23	Height;	chr6:109347085	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.885	rs3818934	ENSG00000260273.1	RP11-425D10.10	5.19	3.12e-07	8.86e-05	0.32	0.23	Height;	chr6:109347277	chr6:109382795~109383666:+
LUAD	cis	rs17507216	0.718	rs17158403	ENSG00000255769.6	GOLGA2P10	-5.19	3.12e-07	8.86e-05	-0.29	-0.23	Excessive daytime sleepiness;	chr15:82572478	chr15:82472993~82513950:-
LUAD	cis	rs73242632	0.881	rs1713965	ENSG00000269949.1	RP11-738E22.3	-5.19	3.12e-07	8.86e-05	-0.53	-0.23	Congenital heart disease (maternal effect);	chr4:57055370	chr4:56960927~56961373:-
LUAD	cis	rs73242632	0.881	rs1713964	ENSG00000269949.1	RP11-738E22.3	-5.19	3.12e-07	8.86e-05	-0.53	-0.23	Congenital heart disease (maternal effect);	chr4:57055505	chr4:56960927~56961373:-
LUAD	cis	rs6750795	0.569	rs1667308	ENSG00000181798.2	LINC00471	-5.19	3.12e-07	8.87e-05	-0.26	-0.23	Height;	chr2:231541633	chr2:231508426~231514339:-
LUAD	cis	rs2439831	0.85	rs2277531	ENSG00000249839.1	AC011330.5	-5.19	3.12e-07	8.87e-05	-0.46	-0.23	Lung cancer in ever smokers;	chr15:43776871	chr15:43663654~43684339:-
LUAD	cis	rs2015599	0.525	rs7298031	ENSG00000257176.2	RP11-996F15.2	5.19	3.12e-07	8.87e-05	0.25	0.23	Platelet count;Mean platelet volume;	chr12:29317333	chr12:29280418~29317848:-
LUAD	cis	rs2015599	0.525	rs2016832	ENSG00000257176.2	RP11-996F15.2	5.19	3.12e-07	8.87e-05	0.25	0.23	Platelet count;Mean platelet volume;	chr12:29318199	chr12:29280418~29317848:-
LUAD	cis	rs17507216	0.718	rs72751662	ENSG00000255769.6	GOLGA2P10	-5.19	3.12e-07	8.87e-05	-0.31	-0.23	Excessive daytime sleepiness;	chr15:82594705	chr15:82472993~82513950:-
LUAD	cis	rs910316	0.692	rs7156586	ENSG00000259138.1	RP11-950C14.7	5.19	3.12e-07	8.88e-05	0.25	0.23	Height;	chr14:75039527	chr14:75127153~75136930:+
LUAD	cis	rs7772486	0.79	rs2253654	ENSG00000235652.6	RP11-545I5.3	5.19	3.12e-07	8.88e-05	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145878309	chr6:145799409~145886585:+
LUAD	cis	rs10971721	0.643	rs10971699	ENSG00000260947.1	RP11-384P7.7	5.19	3.13e-07	8.88e-05	0.54	0.23	Body mass index;	chr9:33777186	chr9:33697459~33700986:+
LUAD	cis	rs1816752	0.905	rs11839006	ENSG00000273628.1	RP11-756A22.7	5.19	3.13e-07	8.89e-05	0.27	0.23	Obesity-related traits;	chr13:24435893	chr13:24933006~24936796:+
LUAD	cis	rs3747113	1	rs3747113	ENSG00000128262.7	POM121L9P	5.19	3.13e-07	8.89e-05	0.24	0.23	Gut microbiome composition (summer);	chr22:24321550	chr22:24251828~24265525:+
LUAD	cis	rs2295359	0.892	rs2064689	ENSG00000275678.1	RP4-547N15.3	-5.19	3.13e-07	8.89e-05	-0.24	-0.23	Psoriasis;	chr1:67187327	chr1:67121605~67123956:-
LUAD	cis	rs9900062	0.586	rs6504250	ENSG00000270714.1	MINOS1P2	-5.19	3.13e-07	8.89e-05	-0.32	-0.23	QT interval;	chr17:64684435	chr17:64747264~64747492:-
LUAD	cis	rs875971	0.522	rs4718285	ENSG00000164669.11	INTS4P1	-5.19	3.13e-07	8.89e-05	-0.27	-0.23	Aortic root size;	chr7:65827018	chr7:65141225~65234216:+
LUAD	cis	rs875971	0.522	rs4718286	ENSG00000164669.11	INTS4P1	-5.19	3.13e-07	8.89e-05	-0.27	-0.23	Aortic root size;	chr7:65827777	chr7:65141225~65234216:+
LUAD	cis	rs80028505	0.908	rs61763101	ENSG00000271304.1	DPRXP2	5.19	3.13e-07	8.89e-05	0.47	0.23	Foot ulcer in diabetes and neuropathy;	chr6:36028636	chr6:35989515~35990436:-
LUAD	cis	rs17711722	0.565	rs4275112	ENSG00000234585.5	CCT6P3	-5.19	3.14e-07	8.91e-05	-0.21	-0.23	Calcium levels;	chr7:65733651	chr7:65038354~65074713:+
LUAD	cis	rs897984	0.762	rs8062719	ENSG00000260911.2	RP11-196G11.2	-5.19	3.14e-07	8.92e-05	-0.21	-0.23	Dementia with Lewy bodies;	chr16:30991343	chr16:31043150~31049868:+
LUAD	cis	rs9549367	0.577	rs3024713	ENSG00000269125.1	RP11-98F14.11	-5.19	3.14e-07	8.92e-05	-0.33	-0.23	Platelet distribution width;	chr13:113159007	chr13:113165002~113165183:-
LUAD	cis	rs453301	0.598	rs1025395	ENSG00000253893.2	FAM85B	-5.19	3.14e-07	8.92e-05	-0.29	-0.23	Joint mobility (Beighton score);	chr8:8979093	chr8:8167819~8226614:-
LUAD	cis	rs2212361	0.558	rs16924599	ENSG00000255893.1	RP11-685N10.1	-5.19	3.14e-07	8.92e-05	-0.31	-0.23	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94523265	chr11:94472908~94473570:-
LUAD	cis	rs8180040	0.62	rs11917361	ENSG00000271161.1	BOLA2P2	-5.19	3.14e-07	8.92e-05	-0.22	-0.23	Colorectal cancer;	chr3:47029007	chr3:47499841~47500407:+
LUAD	cis	rs1816752	0.719	rs11843470	ENSG00000273628.1	RP11-756A22.7	5.19	3.14e-07	8.93e-05	0.26	0.23	Obesity-related traits;	chr13:24423561	chr13:24933006~24936796:+
LUAD	cis	rs4964805	0.865	rs67825151	ENSG00000257681.1	RP11-341G23.4	5.19	3.15e-07	8.93e-05	0.29	0.23	Attention deficit hyperactivity disorder;	chr12:103811666	chr12:103746315~103768858:-
LUAD	cis	rs9322193	0.607	rs10457852	ENSG00000223701.3	RAET1E-AS1	5.19	3.15e-07	8.93e-05	0.33	0.23	Lung cancer;	chr6:149880584	chr6:149884431~149919508:+
LUAD	cis	rs950169	0.922	rs12906983	ENSG00000259295.5	CSPG4P12	5.19	3.15e-07	8.94e-05	0.34	0.23	Schizophrenia;	chr15:84262270	chr15:85191438~85213905:+
LUAD	cis	rs2911132	0.714	rs13167972	ENSG00000248734.2	CTD-2260A17.1	5.19	3.15e-07	8.94e-05	0.23	0.23	Urate levels (BMI interaction);	chr5:96761124	chr5:96784777~96785999:+
LUAD	cis	rs858239	0.509	rs6962213	ENSG00000230042.1	AK3P3	-5.19	3.15e-07	8.94e-05	-0.29	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23148490	chr7:23129178~23129841:+
LUAD	cis	rs9487094	0.961	rs7773095	ENSG00000260273.1	RP11-425D10.10	-5.19	3.15e-07	8.94e-05	-0.31	-0.23	Height;	chr6:109405874	chr6:109382795~109383666:+
LUAD	cis	rs4604732	0.536	rs4925674	ENSG00000227135.1	GCSAML-AS1	-5.19	3.15e-07	8.95e-05	-0.35	-0.23	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247473604	chr1:247524679~247526752:-
LUAD	cis	rs7777677	0.925	rs4726540	ENSG00000244273.1	PGBD4P1	-5.19	3.15e-07	8.95e-05	-0.25	-0.23	Alcoholic chronic pancreatitis;	chr7:142658771	chr7:142722358~142722764:+
LUAD	cis	rs916888	0.821	rs415430	ENSG00000261575.2	RP11-259G18.1	-5.19	3.15e-07	8.95e-05	-0.35	-0.23	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46267037~46268694:+
LUAD	cis	rs916888	0.779	rs430685	ENSG00000261575.2	RP11-259G18.1	-5.19	3.15e-07	8.95e-05	-0.35	-0.23	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46267037~46268694:+
LUAD	cis	rs875971	0.789	rs7808013	ENSG00000232559.3	GS1-124K5.12	-5.19	3.15e-07	8.95e-05	-0.27	-0.23	Aortic root size;	chr7:66606209	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.825	rs7384021	ENSG00000232559.3	GS1-124K5.12	-5.19	3.15e-07	8.95e-05	-0.27	-0.23	Aortic root size;	chr7:66612917	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.825	rs66981195	ENSG00000232559.3	GS1-124K5.12	-5.19	3.15e-07	8.95e-05	-0.27	-0.23	Aortic root size;	chr7:66614048	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs3926380	ENSG00000232559.3	GS1-124K5.12	-5.19	3.15e-07	8.95e-05	-0.27	-0.23	Aortic root size;	chr7:66615658	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.767	rs61348003	ENSG00000232559.3	GS1-124K5.12	5.19	3.16e-07	8.96e-05	0.28	0.23	Aortic root size;	chr7:66540947	chr7:66554588~66576923:-
LUAD	cis	rs1387259	0.929	rs2956703	ENSG00000257735.1	RP11-370I10.6	5.19	3.16e-07	8.97e-05	0.28	0.23	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48276511	chr12:48350945~48442411:+
LUAD	cis	rs12745968	0.653	rs11164791	ENSG00000223787.2	RP4-593M8.1	-5.19	3.16e-07	8.97e-05	-0.27	-0.23	Bipolar disorder and schizophrenia;	chr1:92654077	chr1:92580476~92580821:-
LUAD	cis	rs4295623	0.559	rs4841600	ENSG00000255046.1	RP11-297N6.4	-5.19	3.16e-07	8.97e-05	-0.28	-0.23	Morning vs. evening chronotype;	chr8:11830639	chr8:11797928~11802568:-
LUAD	cis	rs948562	0.947	rs60767173	ENSG00000280010.1	AP001350.4	5.19	3.16e-07	8.97e-05	0.35	0.23	Lymphoma;	chr11:58634074	chr11:58627435~58628528:+
LUAD	cis	rs6545883	0.524	rs2694619	ENSG00000271889.1	RP11-493E12.1	-5.19	3.16e-07	8.97e-05	-0.27	-0.23	Tuberculosis;	chr2:61309766	chr2:61151433~61162105:-
LUAD	cis	rs12022452	1	rs75936657	ENSG00000238287.1	RP11-656D10.3	-5.19	3.16e-07	8.97e-05	-0.43	-0.23	Age-related hearing impairment (SNP x SNP interaction);	chr1:40536017	chr1:40493157~40508661:-
LUAD	cis	rs6700559	0.647	rs11801159	ENSG00000260088.1	RP11-92G12.3	5.19	3.16e-07	8.97e-05	0.29	0.23	Coronary artery disease;	chr1:200623974	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.605	rs11802836	ENSG00000260088.1	RP11-92G12.3	5.19	3.16e-07	8.97e-05	0.29	0.23	Coronary artery disease;	chr1:200624027	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.692	rs12744809	ENSG00000260088.1	RP11-92G12.3	5.19	3.16e-07	8.97e-05	0.29	0.23	Coronary artery disease;	chr1:200624197	chr1:200669507~200694250:+
LUAD	cis	rs11976180	1	rs2371244	ENSG00000204959.4	ARHGEF34P	5.19	3.16e-07	8.97e-05	0.28	0.23	Obesity-related traits;	chr7:144060518	chr7:144272445~144286966:-
LUAD	cis	rs11976180	1	rs4726669	ENSG00000204959.4	ARHGEF34P	5.19	3.16e-07	8.97e-05	0.28	0.23	Obesity-related traits;	chr7:144061098	chr7:144272445~144286966:-
LUAD	cis	rs73186030	0.546	rs6791616	ENSG00000272758.4	RP11-299J3.8	5.19	3.16e-07	8.98e-05	0.28	0.23	Serum parathyroid hormone levels;	chr3:122388388	chr3:122416207~122443180:+
LUAD	cis	rs673078	0.607	rs56080343	ENSG00000275409.1	RP11-131L12.4	-5.19	3.17e-07	8.99e-05	-0.29	-0.23	Glucose homeostasis traits;	chr12:118439113	chr12:118430147~118430699:+
LUAD	cis	rs2286503	0.901	rs2286505	ENSG00000221740.1	SNORD93	5.19	3.17e-07	8.99e-05	0.26	0.23	Fibrinogen;	chr7:22815221	chr7:22856613~22856686:+
LUAD	cis	rs12468226	1	rs2350809	ENSG00000226261.1	AC064836.3	5.19	3.17e-07	8.99e-05	0.37	0.23	Urate levels;	chr2:202464210	chr2:202336024~202336727:-
LUAD	cis	rs6570726	0.935	rs368848	ENSG00000235652.6	RP11-545I5.3	5.19	3.17e-07	8.99e-05	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145534145	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs374000	ENSG00000235652.6	RP11-545I5.3	5.19	3.17e-07	8.99e-05	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145534154	chr6:145799409~145886585:+
LUAD	cis	rs9992667	0.955	rs11096953	ENSG00000231160.8	KLF3-AS1	-5.19	3.17e-07	9e-05	-0.28	-0.23	Eosinophil percentage of granulocytes;	chr4:38642171	chr4:38612701~38664883:-
LUAD	cis	rs875971	0.522	rs7784623	ENSG00000164669.11	INTS4P1	-5.19	3.18e-07	9.01e-05	-0.27	-0.23	Aortic root size;	chr7:65930047	chr7:65141225~65234216:+
LUAD	cis	rs875971	0.522	rs34973832	ENSG00000164669.11	INTS4P1	-5.19	3.18e-07	9.01e-05	-0.27	-0.23	Aortic root size;	chr7:65931217	chr7:65141225~65234216:+
LUAD	cis	rs17818399	0.89	rs34752561	ENSG00000279254.1	RP11-536C12.1	-5.19	3.18e-07	9.02e-05	-0.27	-0.23	Height;	chr2:46623011	chr2:46668870~46670778:+
LUAD	cis	rs897984	0.683	rs8050330	ENSG00000232748.3	RP11-196G11.6	-5.19	3.18e-07	9.02e-05	-0.29	-0.23	Dementia with Lewy bodies;	chr16:30813649	chr16:31056460~31062803:+
LUAD	cis	rs867371	0.964	rs7169961	ENSG00000276710.3	CSPG4P8	-5.19	3.19e-07	9.04e-05	-0.21	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186588	chr15:82459472~82477258:+
LUAD	cis	rs867371	1	rs6495643	ENSG00000276710.3	CSPG4P8	-5.19	3.19e-07	9.04e-05	-0.21	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186913	chr15:82459472~82477258:+
LUAD	cis	rs2286503	1	rs2286503	ENSG00000221740.1	SNORD93	5.18	3.19e-07	9.04e-05	0.26	0.23	Fibrinogen;	chr7:22816987	chr7:22856613~22856686:+
LUAD	cis	rs875971	0.756	rs2901210	ENSG00000232559.3	GS1-124K5.12	-5.18	3.19e-07	9.05e-05	-0.27	-0.23	Aortic root size;	chr7:66552518	chr7:66554588~66576923:-
LUAD	cis	rs453301	0.598	rs10104303	ENSG00000253893.2	FAM85B	-5.18	3.19e-07	9.05e-05	-0.29	-0.23	Joint mobility (Beighton score);	chr8:8977018	chr8:8167819~8226614:-
LUAD	cis	rs2880765	0.835	rs7161880	ENSG00000259295.5	CSPG4P12	5.18	3.19e-07	9.05e-05	0.26	0.23	Coronary artery disease;	chr15:85475515	chr15:85191438~85213905:+
LUAD	cis	rs2562456	0.793	rs2650819	ENSG00000268081.1	RP11-678G14.2	-5.18	3.19e-07	9.05e-05	-0.36	-0.23	Pain;	chr19:21456071	chr19:21554640~21569237:-
LUAD	cis	rs516805	0.63	rs170422	ENSG00000279453.1	RP3-425C14.4	-5.18	3.19e-07	9.06e-05	-0.3	-0.23	Lymphocyte counts;	chr6:122261422	chr6:122436789~122439223:-
LUAD	cis	rs800160	0.777	rs2521284	ENSG00000236264.4	RPL26P30	5.18	3.19e-07	9.06e-05	0.31	0.23	Bacteremia;	chr11:2320447	chr11:2335132~2335776:-
LUAD	cis	rs61270009	0.955	rs12655529	ENSG00000247828.6	TMEM161B-AS1	5.18	3.2e-07	9.06e-05	0.26	0.23	Depressive symptoms;	chr5:88280980	chr5:88268895~88436685:+
LUAD	cis	rs910316	0.935	rs11159119	ENSG00000259138.1	RP11-950C14.7	-5.18	3.2e-07	9.07e-05	-0.24	-0.23	Height;	chr14:75170264	chr14:75127153~75136930:+
LUAD	cis	rs4835473	0.897	rs11727223	ENSG00000251600.4	RP11-673E1.1	5.18	3.2e-07	9.07e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143707090	chr4:143912331~143982454:+
LUAD	cis	rs11105298	0.891	rs3741899	ENSG00000258302.2	RP11-981P6.1	5.18	3.2e-07	9.07e-05	0.29	0.23	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89540154	chr12:89561129~89594878:+
LUAD	cis	rs867371	1	rs8041924	ENSG00000276710.3	CSPG4P8	-5.18	3.21e-07	9.09e-05	-0.21	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82181320	chr15:82459472~82477258:+
LUAD	cis	rs950169	0.58	rs11634320	ENSG00000275120.1	RP11-182J1.17	-5.18	3.21e-07	9.09e-05	-0.35	-0.23	Schizophrenia;	chr15:84628952	chr15:84599434~84606463:-
LUAD	cis	rs193541	0.556	rs30024	ENSG00000263432.2	RN7SL689P	5.18	3.21e-07	9.09e-05	0.3	0.23	Glucose homeostasis traits;	chr5:122949465	chr5:123022487~123022783:-
LUAD	cis	rs3002131	0.688	rs3008650	ENSG00000272750.1	RP11-378J18.8	-5.18	3.21e-07	9.09e-05	-0.29	-0.23	Interleukin-10 levels;	chr1:222589873	chr1:222658867~222661512:-
LUAD	cis	rs12681366	0.881	rs12674614	ENSG00000253704.1	RP11-267M23.4	5.18	3.21e-07	9.11e-05	0.28	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94396605	chr8:94553722~94569745:+
LUAD	cis	rs12681366	0.881	rs3019155	ENSG00000253704.1	RP11-267M23.4	5.18	3.21e-07	9.11e-05	0.28	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94405359	chr8:94553722~94569745:+
LUAD	cis	rs7131987	0.621	rs3782506	ENSG00000257176.2	RP11-996F15.2	5.18	3.22e-07	9.12e-05	0.26	0.23	QT interval;	chr12:29292489	chr12:29280418~29317848:-
LUAD	cis	rs1387259	0.79	rs2732445	ENSG00000257735.1	RP11-370I10.6	5.18	3.22e-07	9.13e-05	0.29	0.23	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48251750	chr12:48350945~48442411:+
LUAD	cis	rs858239	0.601	rs6980224	ENSG00000230042.1	AK3P3	-5.18	3.22e-07	9.13e-05	-0.29	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23129178~23129841:+
LUAD	cis	rs2032366	0.606	rs1377171	ENSG00000267279.1	RP11-879F14.2	-5.18	3.22e-07	9.13e-05	-0.3	-0.23	Obesity-related traits;	chr18:61606810	chr18:61585746~61606916:-
LUAD	cis	rs61270009	0.955	rs12654702	ENSG00000247828.6	TMEM161B-AS1	5.18	3.22e-07	9.13e-05	0.27	0.23	Depressive symptoms;	chr5:88402882	chr5:88268895~88436685:+
LUAD	cis	rs61270009	0.955	rs6874182	ENSG00000247828.6	TMEM161B-AS1	5.18	3.22e-07	9.13e-05	0.27	0.23	Depressive symptoms;	chr5:88407268	chr5:88268895~88436685:+
LUAD	cis	rs61270009	0.955	rs12523282	ENSG00000247828.6	TMEM161B-AS1	5.18	3.22e-07	9.13e-05	0.27	0.23	Depressive symptoms;	chr5:88407679	chr5:88268895~88436685:+
LUAD	cis	rs61270009	0.955	rs12651891	ENSG00000247828.6	TMEM161B-AS1	5.18	3.22e-07	9.13e-05	0.27	0.23	Depressive symptoms;	chr5:88408187	chr5:88268895~88436685:+
LUAD	cis	rs1075265	0.73	rs6713088	ENSG00000233266.1	HMGB1P31	5.18	3.23e-07	9.14e-05	0.29	0.23	Chronotype;Morning vs. evening chronotype;	chr2:54118332	chr2:54051334~54051760:+
LUAD	cis	rs910316	1	rs910316	ENSG00000259138.1	RP11-950C14.7	5.18	3.23e-07	9.15e-05	0.24	0.23	Height;	chr14:75159339	chr14:75127153~75136930:+
LUAD	cis	rs910316	0.874	rs61980828	ENSG00000259138.1	RP11-950C14.7	-5.18	3.23e-07	9.15e-05	-0.24	-0.23	Height;	chr14:75163675	chr14:75127153~75136930:+
LUAD	cis	rs896854	0.875	rs4735333	ENSG00000253528.2	RP11-347C18.4	5.18	3.23e-07	9.15e-05	0.22	0.23	Type 2 diabetes;	chr8:94942846	chr8:94974573~94974853:-
LUAD	cis	rs11976180	0.953	rs2951355	ENSG00000204959.4	ARHGEF34P	5.18	3.23e-07	9.15e-05	0.28	0.23	Obesity-related traits;	chr7:144063469	chr7:144272445~144286966:-
LUAD	cis	rs4835473	0.932	rs6849896	ENSG00000251600.4	RP11-673E1.1	-5.18	3.23e-07	9.16e-05	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143794927	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.838	rs35998817	ENSG00000251600.4	RP11-673E1.1	-5.18	3.23e-07	9.16e-05	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143795355	chr4:143912331~143982454:+
LUAD	cis	rs7618501	0.602	rs2013208	ENSG00000234667.1	ACTBP13	5.18	3.24e-07	9.16e-05	0.26	0.23	Intelligence (multi-trait analysis);	chr3:50091966	chr3:49873347~49877980:-
LUAD	cis	rs875971	0.54	rs4717275	ENSG00000236529.1	RP13-254B10.1	-5.18	3.24e-07	9.17e-05	-0.23	-0.23	Aortic root size;	chr7:65800193	chr7:65840212~65840596:+
LUAD	cis	rs11976180	1	rs11975942	ENSG00000170356.8	OR2A20P	-5.18	3.24e-07	9.17e-05	-0.3	-0.23	Obesity-related traits;	chr7:144043487	chr7:144250045~144252957:-
LUAD	cis	rs71520386	0.632	rs10269414	ENSG00000228649.7	AC005682.5	-5.18	3.24e-07	9.17e-05	-0.31	-0.23	Fibrinogen levels;	chr7:22816674	chr7:22854178~22861579:+
LUAD	cis	rs1707322	0.691	rs11211174	ENSG00000280836.1	AL355480.1	-5.18	3.24e-07	9.17e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755144	chr1:45581219~45581321:-
LUAD	cis	rs910316	1	rs12589876	ENSG00000259138.1	RP11-950C14.7	5.18	3.24e-07	9.18e-05	0.24	0.23	Height;	chr14:75077486	chr14:75127153~75136930:+
LUAD	cis	rs1005277	0.579	rs2103938	ENSG00000263064.2	RP11-291L22.7	5.18	3.24e-07	9.18e-05	0.25	0.23	Extrinsic epigenetic age acceleration;	chr10:38205070	chr10:38448689~38448949:+
LUAD	cis	rs9652601	0.622	rs1985372	ENSG00000274038.1	RP11-66H6.4	-5.18	3.24e-07	9.18e-05	-0.27	-0.23	Systemic lupus erythematosus;	chr16:11020982	chr16:11056556~11057034:+
LUAD	cis	rs2524005	1	rs2524005	ENSG00000235821.1	IFITM4P	-5.18	3.24e-07	9.18e-05	-0.29	-0.23	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29750729~29751148:-
LUAD	cis	rs7131987	0.65	rs7954871	ENSG00000257176.2	RP11-996F15.2	-5.18	3.24e-07	9.18e-05	-0.26	-0.23	QT interval;	chr12:29306799	chr12:29280418~29317848:-
LUAD	cis	rs8177876	0.749	rs10459871	ENSG00000261061.1	RP11-303E16.2	-5.18	3.24e-07	9.18e-05	-0.41	-0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81059462	chr16:81030770~81031485:+
LUAD	cis	rs12681366	0.881	rs10464877	ENSG00000253704.1	RP11-267M23.4	5.18	3.24e-07	9.19e-05	0.28	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94385615	chr8:94553722~94569745:+
LUAD	cis	rs1707322	1	rs10890382	ENSG00000280836.1	AL355480.1	-5.18	3.25e-07	9.19e-05	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46004002	chr1:45581219~45581321:-
LUAD	cis	rs4835473	0.897	rs2219912	ENSG00000251600.4	RP11-673E1.1	5.18	3.25e-07	9.19e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143707909	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.897	rs6537172	ENSG00000251600.4	RP11-673E1.1	5.18	3.25e-07	9.19e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143710612	chr4:143912331~143982454:+
LUAD	cis	rs10246939	0.505	rs6967189	ENSG00000228775.6	WEE2-AS1	5.18	3.25e-07	9.2e-05	0.29	0.23	Bitter taste perception;	chr7:141826220	chr7:141704338~141738346:-
LUAD	cis	rs2455601	0.507	rs7948452	ENSG00000254860.4	TMEM9B-AS1	5.18	3.25e-07	9.2e-05	0.29	0.23	Schizophrenia;	chr11:8856157	chr11:8964675~8977527:+
LUAD	cis	rs3747113	1	rs9624447	ENSG00000128262.7	POM121L9P	-5.18	3.25e-07	9.2e-05	-0.24	-0.23	Gut microbiome composition (summer);	chr22:24285587	chr22:24251828~24265525:+
LUAD	cis	rs17507216	0.671	rs4779035	ENSG00000255769.6	GOLGA2P10	-5.18	3.25e-07	9.2e-05	-0.3	-0.23	Excessive daytime sleepiness;	chr15:82591686	chr15:82472993~82513950:-
LUAD	cis	rs1816752	0.905	rs7400631	ENSG00000273628.1	RP11-756A22.7	5.18	3.25e-07	9.21e-05	0.26	0.23	Obesity-related traits;	chr13:24415927	chr13:24933006~24936796:+
LUAD	cis	rs516805	0.597	rs2816157	ENSG00000279453.1	RP3-425C14.4	-5.18	3.25e-07	9.21e-05	-0.31	-0.23	Lymphocyte counts;	chr6:122124400	chr6:122436789~122439223:-
LUAD	cis	rs6496932	0.913	rs7403354	ENSG00000202081.1	RNU6-1280P	5.18	3.26e-07	9.21e-05	0.31	0.23	Central corneal thickness;Corneal structure;	chr15:85277624	chr15:85651522~85651628:-
LUAD	cis	rs11157436	0.918	rs12433895	ENSG00000211812.1	TRAV26-2	-5.18	3.26e-07	9.22e-05	-0.25	-0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22154577	chr14:22202583~22203368:+
LUAD	cis	rs4908768	0.539	rs7526171	ENSG00000232912.4	RP5-1115A15.1	5.18	3.26e-07	9.22e-05	0.21	0.23	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8590126	chr1:8424645~8434838:+
LUAD	cis	rs193541	0.632	rs246276	ENSG00000263432.2	RN7SL689P	5.18	3.26e-07	9.23e-05	0.31	0.23	Glucose homeostasis traits;	chr5:122904262	chr5:123022487~123022783:-
LUAD	cis	rs9807989	0.839	rs3771166	ENSG00000234389.1	AC007278.3	5.18	3.26e-07	9.24e-05	0.22	0.23	Asthma;	chr2:102369762	chr2:102438713~102440475:+
LUAD	cis	rs55665837	0.54	rs3206554	ENSG00000251991.1	RNU7-49P	5.18	3.26e-07	9.24e-05	0.26	0.23	Vitamin D levels;	chr11:14776399	chr11:14478892~14478953:+
LUAD	cis	rs7968440	0.707	rs1109726	ENSG00000200428.1	Y_RNA	-5.18	3.27e-07	9.26e-05	-0.29	-0.23	Fibrinogen;	chr12:50764765	chr12:50743568~50743684:+
LUAD	cis	rs9992667	0.955	rs28560778	ENSG00000231160.8	KLF3-AS1	5.18	3.28e-07	9.27e-05	0.28	0.23	Eosinophil percentage of granulocytes;	chr4:38609668	chr4:38612701~38664883:-
LUAD	cis	rs875971	0.522	rs709604	ENSG00000164669.11	INTS4P1	5.18	3.28e-07	9.27e-05	0.27	0.23	Aortic root size;	chr7:66032447	chr7:65141225~65234216:+
LUAD	cis	rs7017914	0.652	rs10957533	ENSG00000223220.1	Y_RNA	-5.18	3.28e-07	9.27e-05	-0.26	-0.23	Bone mineral density;	chr8:70912872	chr8:70780914~70781008:-
LUAD	cis	rs10214930	0.813	rs1404282	ENSG00000235574.1	AC073150.6	-5.18	3.28e-07	9.27e-05	-0.3	-0.23	Hypospadias;	chr7:27545832	chr7:27491682~27492765:-
LUAD	cis	rs897984	0.683	rs729482	ENSG00000260911.2	RP11-196G11.2	5.18	3.28e-07	9.28e-05	0.21	0.23	Dementia with Lewy bodies;	chr16:31005649	chr16:31043150~31049868:+
LUAD	cis	rs7083	1	rs644215	ENSG00000254851.1	RP11-109L13.1	5.18	3.28e-07	9.28e-05	0.29	0.23	Blood protein levels;	chr11:117275202	chr11:117135528~117138582:+
LUAD	cis	rs4964805	1	rs1866295	ENSG00000257681.1	RP11-341G23.4	5.18	3.28e-07	9.28e-05	0.28	0.23	Attention deficit hyperactivity disorder;	chr12:103793168	chr12:103746315~103768858:-
LUAD	cis	rs643506	0.874	rs4245045	ENSG00000230911.1	PPIHP1	-5.18	3.29e-07	9.29e-05	-0.29	-0.23	Breast cancer;	chr11:111789200	chr11:112029858~112030367:-
LUAD	cis	rs7968440	1	rs67701624	ENSG00000200428.1	Y_RNA	-5.18	3.29e-07	9.3e-05	-0.29	-0.23	Fibrinogen;	chr12:50535155	chr12:50743568~50743684:+
LUAD	cis	rs7968440	0.966	rs68171620	ENSG00000200428.1	Y_RNA	-5.18	3.29e-07	9.3e-05	-0.29	-0.23	Fibrinogen;	chr12:50543755	chr12:50743568~50743684:+
LUAD	cis	rs9287719	0.601	rs1861299	ENSG00000243819.4	RN7SL832P	5.18	3.29e-07	9.3e-05	0.25	0.23	Prostate cancer;	chr2:10623631	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.601	rs1861300	ENSG00000243819.4	RN7SL832P	5.18	3.29e-07	9.3e-05	0.25	0.23	Prostate cancer;	chr2:10623835	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.601	rs10084172	ENSG00000243819.4	RN7SL832P	5.18	3.29e-07	9.3e-05	0.25	0.23	Prostate cancer;	chr2:10631102	chr2:10690344~10692099:+
LUAD	cis	rs12022452	0.908	rs4660423	ENSG00000238287.1	RP11-656D10.3	-5.18	3.29e-07	9.31e-05	-0.43	-0.23	Age-related hearing impairment (SNP x SNP interaction);	chr1:40554632	chr1:40493157~40508661:-
LUAD	cis	rs17772222	0.958	rs76559451	ENSG00000258983.2	RP11-507K2.2	5.18	3.29e-07	9.31e-05	0.28	0.23	Coronary artery calcification;	chr14:88523193	chr14:88499334~88515502:+
LUAD	cis	rs12439619	0.693	rs9944185	ENSG00000276710.3	CSPG4P8	-5.18	3.29e-07	9.31e-05	-0.25	-0.23	Intelligence (multi-trait analysis);	chr15:82157927	chr15:82459472~82477258:+
LUAD	cis	rs7829975	0.711	rs12682352	ENSG00000253893.2	FAM85B	-5.18	3.29e-07	9.32e-05	-0.28	-0.23	Mood instability;	chr8:8788736	chr8:8167819~8226614:-
LUAD	cis	rs964184	0.63	rs9326246	ENSG00000254851.1	RP11-109L13.1	-5.18	3.3e-07	9.32e-05	-0.49	-0.23	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116741017	chr11:117135528~117138582:+
LUAD	cis	rs9287719	0.601	rs6751436	ENSG00000243819.4	RN7SL832P	5.18	3.3e-07	9.32e-05	0.25	0.23	Prostate cancer;	chr2:10583736	chr2:10690344~10692099:+
LUAD	cis	rs875971	0.825	rs801202	ENSG00000232559.3	GS1-124K5.12	-5.18	3.3e-07	9.32e-05	-0.27	-0.23	Aortic root size;	chr7:66558942	chr7:66554588~66576923:-
LUAD	cis	rs4835473	0.868	rs62337303	ENSG00000251600.4	RP11-673E1.1	-5.18	3.3e-07	9.32e-05	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143824967	chr4:143912331~143982454:+
LUAD	cis	rs916888	0.697	rs199516	ENSG00000261575.2	RP11-259G18.1	-5.18	3.3e-07	9.32e-05	-0.35	-0.23	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46267037~46268694:+
LUAD	cis	rs453301	0.682	rs2929451	ENSG00000253981.4	ALG1L13P	5.18	3.3e-07	9.32e-05	0.26	0.23	Joint mobility (Beighton score);	chr8:9227785	chr8:8236003~8244667:-
LUAD	cis	rs1707322	1	rs10789479	ENSG00000280836.1	AL355480.1	-5.18	3.3e-07	9.34e-05	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886828	chr1:45581219~45581321:-
LUAD	cis	rs270601	0.77	rs932019	ENSG00000233006.5	AC034220.3	5.18	3.3e-07	9.34e-05	0.21	0.23	Acylcarnitine levels;	chr5:132263677	chr5:132311285~132369916:-
LUAD	cis	rs3750965	0.959	rs3376	ENSG00000260895.1	RP11-554A11.7	5.18	3.3e-07	9.34e-05	0.26	0.23	Hair color;	chr11:69089212	chr11:69103493~69109094:+
LUAD	cis	rs12468226	1	rs116635509	ENSG00000226261.1	AC064836.3	5.18	3.31e-07	9.35e-05	0.37	0.23	Urate levels;	chr2:202460027	chr2:202336024~202336727:-
LUAD	cis	rs950169	0.649	rs12901010	ENSG00000225151.9	GOLGA2P7	-5.18	3.31e-07	9.36e-05	-0.35	-0.23	Schizophrenia;	chr15:84030282	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.69	rs12901166	ENSG00000225151.9	GOLGA2P7	-5.18	3.31e-07	9.36e-05	-0.35	-0.23	Schizophrenia;	chr15:84030361	chr15:84199311~84230136:-
LUAD	cis	rs1062177	1	rs2915880	ENSG00000253921.1	CTB-113P19.3	-5.18	3.31e-07	9.36e-05	-0.34	-0.23	Preschool internalizing problems;	chr5:151767773	chr5:151753992~151767247:+
LUAD	cis	rs7017914	0.69	rs17699710	ENSG00000223220.1	Y_RNA	5.18	3.31e-07	9.36e-05	0.27	0.23	Bone mineral density;	chr8:71067975	chr8:70780914~70781008:-
LUAD	cis	rs10129255	0.5	rs8004923	ENSG00000254174.1	IGHV1-12	5.18	3.31e-07	9.36e-05	0.15	0.23	Kawasaki disease;	chr14:106785926	chr14:106122420~106122709:-
LUAD	cis	rs10129255	0.912	rs61997792	ENSG00000211974.3	IGHV2-70	5.18	3.31e-07	9.37e-05	0.25	0.23	Kawasaki disease;	chr14:106799304	chr14:106723574~106724093:-
LUAD	cis	rs720475	0.732	rs17195725	ENSG00000204959.4	ARHGEF34P	5.18	3.32e-07	9.37e-05	0.31	0.23	Breast cancer;	chr7:144440044	chr7:144272445~144286966:-
LUAD	cis	rs4908768	0.535	rs2708628	ENSG00000232912.4	RP5-1115A15.1	-5.18	3.32e-07	9.37e-05	-0.23	-0.23	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8390388	chr1:8424645~8434838:+
LUAD	cis	rs2439831	0.85	rs28504496	ENSG00000249839.1	AC011330.5	-5.18	3.32e-07	9.37e-05	-0.46	-0.23	Lung cancer in ever smokers;	chr15:43724685	chr15:43663654~43684339:-
LUAD	cis	rs6095360	0.69	rs35649484	ENSG00000222365.1	SNORD12B	-5.18	3.32e-07	9.37e-05	-0.26	-0.23	Intelligence (multi-trait analysis);	chr20:49138625	chr20:49280319~49280409:+
LUAD	cis	rs7500321	1	rs7500321	ENSG00000251417.2	RP11-1348G14.4	5.18	3.32e-07	9.38e-05	0.26	0.23	Intelligence (multi-trait analysis);	chr16:28965699	chr16:28802743~28817828:+
LUAD	cis	rs2976388	0.609	rs2572899	ENSG00000253741.1	CTD-2292P10.4	-5.18	3.32e-07	9.38e-05	-0.26	-0.23	Urinary tract infection frequency;	chr8:142704131	chr8:142702252~142726973:-
LUAD	cis	rs6545883	0.524	rs12713435	ENSG00000271889.1	RP11-493E12.1	-5.18	3.32e-07	9.38e-05	-0.27	-0.23	Tuberculosis;	chr2:61272654	chr2:61151433~61162105:-
LUAD	cis	rs12908161	1	rs12905057	ENSG00000275120.1	RP11-182J1.17	5.18	3.32e-07	9.38e-05	0.35	0.23	Schizophrenia;	chr15:84667534	chr15:84599434~84606463:-
LUAD	cis	rs11742741	0.64	rs62347897	ENSG00000248874.4	C5orf17	-5.18	3.32e-07	9.39e-05	-0.29	-0.23	Educational attainment;	chr5:24214756	chr5:23951348~24178263:+
LUAD	cis	rs800160	0.777	rs2173888	ENSG00000236264.4	RPL26P30	-5.18	3.32e-07	9.39e-05	-0.31	-0.23	Bacteremia;	chr11:2335878	chr11:2335132~2335776:-
LUAD	cis	rs800160	0.777	rs2106606	ENSG00000236264.4	RPL26P30	-5.18	3.32e-07	9.39e-05	-0.31	-0.23	Bacteremia;	chr11:2336333	chr11:2335132~2335776:-
LUAD	cis	rs1075265	0.597	rs10490471	ENSG00000233266.1	HMGB1P31	5.18	3.32e-07	9.39e-05	0.29	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53769446	chr2:54051334~54051760:+
LUAD	cis	rs12745968	0.589	rs6697491	ENSG00000223787.2	RP4-593M8.1	-5.18	3.32e-07	9.39e-05	-0.27	-0.23	Bipolar disorder and schizophrenia;	chr1:92567157	chr1:92580476~92580821:-
LUAD	cis	rs7621025	0.5	rs4678275	ENSG00000239213.4	NCK1-AS1	5.18	3.33e-07	9.4e-05	0.29	0.23	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136934841	chr3:136841726~136862054:-
LUAD	cis	rs2998286	0.862	rs4237390	ENSG00000254635.4	WAC-AS1	-5.18	3.33e-07	9.4e-05	-0.28	-0.23	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28504497	chr10:28522652~28532743:-
LUAD	cis	rs2239547	0.522	rs2581779	ENSG00000242142.1	SERBP1P3	-5.18	3.33e-07	9.4e-05	-0.28	-0.23	Schizophrenia;	chr3:53022183	chr3:53064283~53065091:-
LUAD	cis	rs2028299	0.959	rs893617	ENSG00000259677.1	RP11-493E3.1	5.18	3.33e-07	9.41e-05	0.28	0.23	Type 2 diabetes;	chr15:89838046	chr15:89876540~89877285:+
LUAD	cis	rs1816752	0.87	rs9581025	ENSG00000273628.1	RP11-756A22.7	5.18	3.33e-07	9.41e-05	0.26	0.23	Obesity-related traits;	chr13:24423687	chr13:24933006~24936796:+
LUAD	cis	rs1816752	0.87	rs9581027	ENSG00000273628.1	RP11-756A22.7	5.18	3.33e-07	9.41e-05	0.26	0.23	Obesity-related traits;	chr13:24423790	chr13:24933006~24936796:+
LUAD	cis	rs17684571	0.938	rs13205013	ENSG00000231441.1	RP11-472M19.2	5.18	3.33e-07	9.42e-05	0.3	0.23	Schizophrenia;	chr6:56692546	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.938	rs35637749	ENSG00000231441.1	RP11-472M19.2	5.18	3.33e-07	9.42e-05	0.3	0.23	Schizophrenia;	chr6:56692613	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.938	rs7767128	ENSG00000231441.1	RP11-472M19.2	5.18	3.33e-07	9.42e-05	0.3	0.23	Schizophrenia;	chr6:56694489	chr6:56844002~56864078:+
LUAD	cis	rs2337406	1	rs10459466	ENSG00000211972.2	IGHV3-66	5.18	3.33e-07	9.42e-05	0.28	0.23	Alzheimer's disease (late onset);	chr14:106689255	chr14:106675017~106675544:-
LUAD	cis	rs1914816	0.653	rs157763	ENSG00000196274.5	Metazoa_SRP	5.18	3.34e-07	9.42e-05	0.29	0.23	Response to tocilizumab in rheumatoid arthritis;	chr15:76500498	chr15:76230048~76230390:-
LUAD	cis	rs7208859	0.623	rs8067035	ENSG00000263603.1	CTD-2349P21.5	-5.18	3.34e-07	9.42e-05	-0.39	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775170	chr17:30729469~30731202:+
LUAD	cis	rs2742234	0.518	rs1254967	ENSG00000273008.1	RP11-351D16.3	5.18	3.34e-07	9.43e-05	0.27	0.23	Hirschsprung disease;	chr10:43194943	chr10:43136824~43138334:-
LUAD	cis	rs2018683	1	rs740252	ENSG00000228421.2	AC005013.5	5.18	3.34e-07	9.43e-05	0.25	0.23	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28958149	chr7:28957667~28959345:+
LUAD	cis	rs7580658	0.614	rs2896888	ENSG00000236682.1	AC068282.3	-5.18	3.34e-07	9.44e-05	-0.3	-0.23	Protein C levels;	chr2:127208235	chr2:127389130~127400580:+
LUAD	cis	rs7617773	0.78	rs13079728	ENSG00000228638.1	FCF1P2	-5.18	3.34e-07	9.44e-05	-0.28	-0.23	Coronary artery disease;	chr3:48297870	chr3:48290793~48291375:-
LUAD	cis	rs7208859	0.623	rs7219361	ENSG00000263603.1	CTD-2349P21.5	-5.18	3.34e-07	9.44e-05	-0.41	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30729469~30731202:+
LUAD	cis	rs287982	0.932	rs9973577	ENSG00000269973.1	RP11-95D17.1	-5.18	3.35e-07	9.45e-05	-0.28	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9820574	chr2:9936360~9939590:+
LUAD	cis	rs1799949	1	rs8176220	ENSG00000236383.6	LINC00854	-5.18	3.35e-07	9.45e-05	-0.18	-0.23	Menopause (age at onset);	chr17:43070445	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs1799966	ENSG00000236383.6	LINC00854	-5.18	3.35e-07	9.45e-05	-0.18	-0.23	Menopause (age at onset);	chr17:43071077	chr17:43216941~43305976:-
LUAD	cis	rs1062177	1	rs6890099	ENSG00000253921.1	CTB-113P19.3	-5.18	3.35e-07	9.46e-05	-0.33	-0.23	Preschool internalizing problems;	chr5:151772401	chr5:151753992~151767247:+
LUAD	cis	rs875971	0.862	rs908915	ENSG00000232559.3	GS1-124K5.12	-5.18	3.35e-07	9.46e-05	-0.27	-0.23	Aortic root size;	chr7:66149664	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs7809814	ENSG00000232559.3	GS1-124K5.12	-5.18	3.35e-07	9.46e-05	-0.27	-0.23	Aortic root size;	chr7:66150410	chr7:66554588~66576923:-
LUAD	cis	rs1322639	0.657	rs9355135	ENSG00000261039.2	RP11-417E7.2	-5.18	3.35e-07	9.46e-05	-0.38	-0.23	Pulse pressure;	chr6:169172911	chr6:169175304~169182740:-
LUAD	cis	rs7017914	0.629	rs2732120	ENSG00000223220.1	Y_RNA	5.18	3.35e-07	9.47e-05	0.26	0.23	Bone mineral density;	chr8:70992758	chr8:70780914~70781008:-
LUAD	cis	rs7208859	0.614	rs216477	ENSG00000263531.1	RP13-753N3.1	-5.17	3.36e-07	9.48e-05	-0.43	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30539726	chr17:30863921~30864940:-
LUAD	cis	rs889398	1	rs889399	ENSG00000226232.7	RP11-419C5.2	5.17	3.36e-07	9.48e-05	0.2	0.23	Body mass index;	chr16:69522680	chr16:69976388~69996188:-
LUAD	cis	rs1546924	0.669	rs6687953	ENSG00000227811.2	FAM212B-AS1	-5.17	3.36e-07	9.48e-05	-0.28	-0.23	Body mass index;	chr1:111750890	chr1:111739841~111747798:+
LUAD	cis	rs801193	1	rs2420824	ENSG00000237310.1	GS1-124K5.4	-5.17	3.36e-07	9.49e-05	-0.25	-0.23	Aortic root size;	chr7:66666129	chr7:66493706~66495474:+
LUAD	cis	rs1707322	0.721	rs11211149	ENSG00000280836.1	AL355480.1	-5.17	3.36e-07	9.49e-05	-0.31	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45646546	chr1:45581219~45581321:-
LUAD	cis	rs62432291	0.681	rs436277	ENSG00000235086.1	FNDC1-IT1	5.17	3.37e-07	9.5e-05	0.39	0.23	Joint mobility (Beighton score);	chr6:159213110	chr6:159240786~159243329:+
LUAD	cis	rs4268898	0.722	rs2288072	ENSG00000242628.4	AC009228.1	-5.17	3.37e-07	9.5e-05	-0.29	-0.23	Asthma;	chr2:24167648	chr2:24214381~24221516:+
LUAD	cis	rs638893	0.588	rs2156755	ENSG00000278376.1	RP11-158I9.8	-5.17	3.37e-07	9.5e-05	-0.28	-0.23	Vitiligo;	chr11:118855521	chr11:118791254~118793137:+
LUAD	cis	rs9992667	0.955	rs10025499	ENSG00000231160.8	KLF3-AS1	5.17	3.37e-07	9.51e-05	0.28	0.23	Eosinophil percentage of granulocytes;	chr4:38619373	chr4:38612701~38664883:-
LUAD	cis	rs2948294	0.566	rs13274039	ENSG00000253981.4	ALG1L13P	5.17	3.37e-07	9.51e-05	0.28	0.23	Red cell distribution width;	chr8:8254137	chr8:8236003~8244667:-
LUAD	cis	rs801193	0.967	rs2420827	ENSG00000237310.1	GS1-124K5.4	-5.17	3.37e-07	9.51e-05	-0.25	-0.23	Aortic root size;	chr7:66682114	chr7:66493706~66495474:+
LUAD	cis	rs2018683	0.584	rs4722880	ENSG00000228421.2	AC005013.5	5.17	3.37e-07	9.51e-05	0.26	0.23	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959581	chr7:28957667~28959345:+
LUAD	cis	rs80028505	0.908	rs79062678	ENSG00000271304.1	DPRXP2	5.17	3.37e-07	9.52e-05	0.46	0.23	Foot ulcer in diabetes and neuropathy;	chr6:36090426	chr6:35989515~35990436:-
LUAD	cis	rs287982	0.932	rs58521916	ENSG00000269973.1	RP11-95D17.1	-5.17	3.38e-07	9.52e-05	-0.28	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9826341	chr2:9936360~9939590:+
LUAD	cis	rs193541	0.632	rs30023	ENSG00000263432.2	RN7SL689P	5.17	3.38e-07	9.53e-05	0.3	0.23	Glucose homeostasis traits;	chr5:122949604	chr5:123022487~123022783:-
LUAD	cis	rs1707322	1	rs11211232	ENSG00000280836.1	AL355480.1	-5.17	3.38e-07	9.53e-05	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45945474	chr1:45581219~45581321:-
LUAD	cis	rs867371	1	rs1392976	ENSG00000276710.3	CSPG4P8	5.17	3.38e-07	9.53e-05	0.22	0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82153834	chr15:82459472~82477258:+
LUAD	cis	rs867371	1	rs9944197	ENSG00000276710.3	CSPG4P8	-5.17	3.38e-07	9.53e-05	-0.22	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82158261	chr15:82459472~82477258:+
LUAD	cis	rs875971	0.862	rs6460302	ENSG00000232559.3	GS1-124K5.12	5.17	3.38e-07	9.53e-05	0.28	0.23	Aortic root size;	chr7:66495270	chr7:66554588~66576923:-
LUAD	cis	rs7968440	1	rs7305655	ENSG00000200428.1	Y_RNA	5.17	3.38e-07	9.55e-05	0.28	0.23	Fibrinogen;	chr12:50611506	chr12:50743568~50743684:+
LUAD	cis	rs10246939	0.529	rs60165685	ENSG00000270923.1	TAS2R6P	-5.17	3.39e-07	9.55e-05	-0.26	-0.23	Bitter taste perception;	chr7:141861190	chr7:141787815~141788640:+
LUAD	cis	rs2439831	0.867	rs2447211	ENSG00000249839.1	AC011330.5	-5.17	3.39e-07	9.55e-05	-0.42	-0.23	Lung cancer in ever smokers;	chr15:43644153	chr15:43663654~43684339:-
LUAD	cis	rs875971	0.516	rs6945322	ENSG00000236529.1	RP13-254B10.1	5.17	3.39e-07	9.55e-05	0.23	0.23	Aortic root size;	chr7:65871069	chr7:65840212~65840596:+
LUAD	cis	rs17711722	0.701	rs55773927	ENSG00000236529.1	RP13-254B10.1	5.17	3.39e-07	9.55e-05	0.23	0.23	Calcium levels;	chr7:65872915	chr7:65840212~65840596:+
LUAD	cis	rs17711722	0.727	rs35850374	ENSG00000236529.1	RP13-254B10.1	5.17	3.39e-07	9.55e-05	0.23	0.23	Calcium levels;	chr7:65892789	chr7:65840212~65840596:+
LUAD	cis	rs11603023	0.967	rs644273	ENSG00000255239.1	AP002954.6	-5.17	3.39e-07	9.56e-05	-0.27	-0.23	Cholesterol, total;	chr11:118640634	chr11:118688039~118690600:-
LUAD	cis	rs4835473	0.932	rs13129993	ENSG00000251600.4	RP11-673E1.1	-5.17	3.39e-07	9.56e-05	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143763076	chr4:143912331~143982454:+
LUAD	cis	rs9549367	0.577	rs776904	ENSG00000269125.1	RP11-98F14.11	-5.17	3.39e-07	9.57e-05	-0.34	-0.23	Platelet distribution width;	chr13:113156228	chr13:113165002~113165183:-
LUAD	cis	rs867371	1	rs867370	ENSG00000259429.4	UBE2Q2P2	5.17	3.39e-07	9.57e-05	0.2	0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82145921	chr15:82355142~82420075:+
LUAD	cis	rs867371	1	rs867371	ENSG00000259429.4	UBE2Q2P2	5.17	3.39e-07	9.57e-05	0.2	0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82146005	chr15:82355142~82420075:+
LUAD	cis	rs763567	0.933	rs623752	ENSG00000271811.1	RP1-79C4.4	5.17	3.39e-07	9.57e-05	0.27	0.23	Tonsillectomy;	chr1:170649150	chr1:170667381~170669425:+
LUAD	cis	rs12022452	1	rs3738471	ENSG00000238287.1	RP11-656D10.3	-5.17	3.4e-07	9.58e-05	-0.43	-0.23	Age-related hearing impairment (SNP x SNP interaction);	chr1:40540873	chr1:40493157~40508661:-
LUAD	cis	rs12022452	0.73	rs2297755	ENSG00000238287.1	RP11-656D10.3	-5.17	3.4e-07	9.58e-05	-0.43	-0.23	Age-related hearing impairment (SNP x SNP interaction);	chr1:40547343	chr1:40493157~40508661:-
LUAD	cis	rs35160687	0.712	rs4832262	ENSG00000273080.1	RP11-301O19.1	-5.17	3.4e-07	9.58e-05	-0.25	-0.23	Night sleep phenotypes;	chr2:86258011	chr2:86195590~86196049:+
LUAD	cis	rs11051970	0.527	rs7977938	ENSG00000274964.1	RP11-817I4.1	-5.17	3.4e-07	9.58e-05	-0.3	-0.23	Response to tocilizumab in rheumatoid arthritis;	chr12:32322406	chr12:32339368~32340724:+
LUAD	cis	rs8177876	0.749	rs2278024	ENSG00000261061.1	RP11-303E16.2	-5.17	3.4e-07	9.58e-05	-0.39	-0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81045628	chr16:81030770~81031485:+
LUAD	cis	rs4143844	1	rs34556569	ENSG00000259251.2	RP11-643M14.1	5.17	3.4e-07	9.58e-05	0.41	0.23	Bipolar disorder and schizophrenia;	chr15:61989619	chr15:62060503~62062434:+
LUAD	cis	rs4143844	1	rs62007791	ENSG00000259251.2	RP11-643M14.1	5.17	3.4e-07	9.58e-05	0.41	0.23	Bipolar disorder and schizophrenia;	chr15:61992487	chr15:62060503~62062434:+
LUAD	cis	rs4143844	0.867	rs35259011	ENSG00000259251.2	RP11-643M14.1	5.17	3.4e-07	9.58e-05	0.41	0.23	Bipolar disorder and schizophrenia;	chr15:61993260	chr15:62060503~62062434:+
LUAD	cis	rs2337406	1	rs17112416	ENSG00000211972.2	IGHV3-66	-5.17	3.4e-07	9.59e-05	-0.25	-0.23	Alzheimer's disease (late onset);	chr14:106686773	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.5	rs6576231	ENSG00000211967.3	IGHV3-53	-5.17	3.4e-07	9.59e-05	-0.17	-0.23	Kawasaki disease;	chr14:106783693	chr14:106592676~106593347:-
LUAD	cis	rs10740039	0.961	rs2083696	ENSG00000254271.1	RP11-131N11.4	5.17	3.4e-07	9.59e-05	0.26	0.23	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60656430	chr10:60734342~60741828:+
LUAD	cis	rs10740039	1	rs10821818	ENSG00000254271.1	RP11-131N11.4	5.17	3.4e-07	9.59e-05	0.26	0.23	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60657178	chr10:60734342~60741828:+
LUAD	cis	rs10740039	0.883	rs6479722	ENSG00000254271.1	RP11-131N11.4	5.17	3.4e-07	9.59e-05	0.26	0.23	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60657923	chr10:60734342~60741828:+
LUAD	cis	rs10740039	1	rs6479723	ENSG00000254271.1	RP11-131N11.4	5.17	3.4e-07	9.59e-05	0.26	0.23	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60658127	chr10:60734342~60741828:+
LUAD	cis	rs10740039	1	rs10761545	ENSG00000254271.1	RP11-131N11.4	5.17	3.4e-07	9.59e-05	0.26	0.23	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60658811	chr10:60734342~60741828:+
LUAD	cis	rs4938303	0.589	rs11216100	ENSG00000254851.1	RP11-109L13.1	5.17	3.4e-07	9.59e-05	0.31	0.23	Triglycerides;	chr11:116701814	chr11:117135528~117138582:+
LUAD	cis	rs7948661	1	rs9332871	ENSG00000278376.1	RP11-158I9.8	5.17	3.4e-07	9.59e-05	0.49	0.23	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118523141	chr11:118791254~118793137:+
LUAD	cis	rs6570726	0.935	rs388394	ENSG00000235652.6	RP11-545I5.3	5.17	3.4e-07	9.59e-05	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145531553	chr6:145799409~145886585:+
LUAD	cis	rs6940116	1	rs6940116	ENSG00000219392.1	RP1-265C24.5	-5.17	3.4e-07	9.59e-05	-0.34	-0.23	Intelligence (multi-trait analysis);Autism spectrum disorder or schizophrenia;	chr6:27740953	chr6:28115628~28116551:+
LUAD	cis	rs4835473	0.8	rs1849133	ENSG00000251600.4	RP11-673E1.1	5.17	3.4e-07	9.6e-05	0.28	0.23	Immature fraction of reticulocytes;	chr4:143958262	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.864	rs1849132	ENSG00000251600.4	RP11-673E1.1	5.17	3.4e-07	9.6e-05	0.28	0.23	Immature fraction of reticulocytes;	chr4:143958309	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs13123407	ENSG00000251600.4	RP11-673E1.1	5.17	3.4e-07	9.6e-05	0.28	0.23	Immature fraction of reticulocytes;	chr4:143958713	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.897	rs61611095	ENSG00000251600.4	RP11-673E1.1	5.17	3.4e-07	9.6e-05	0.28	0.23	Immature fraction of reticulocytes;	chr4:143958802	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs4835449	ENSG00000251600.4	RP11-673E1.1	5.17	3.4e-07	9.6e-05	0.28	0.23	Immature fraction of reticulocytes;	chr4:143958830	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1838516	ENSG00000251600.4	RP11-673E1.1	5.17	3.4e-07	9.6e-05	0.28	0.23	Immature fraction of reticulocytes;	chr4:143962082	chr4:143912331~143982454:+
LUAD	cis	rs9928842	0.823	rs889514	ENSG00000280152.1	RP11-331F4.5	5.17	3.41e-07	9.6e-05	0.24	0.23	Alcoholic chronic pancreatitis;	chr16:75238614	chr16:75245994~75250077:-
LUAD	cis	rs1823874	0.677	rs2100446	ENSG00000182397.13	DNM1P46	-5.17	3.41e-07	9.6e-05	-0.29	-0.23	IgG glycosylation;	chr15:99820169	chr15:99790156~99806927:-
LUAD	cis	rs1823874	0.677	rs2100447	ENSG00000182397.13	DNM1P46	-5.17	3.41e-07	9.6e-05	-0.29	-0.23	IgG glycosylation;	chr15:99820188	chr15:99790156~99806927:-
LUAD	cis	rs9595908	0.785	rs7326314	ENSG00000212293.1	SNORA16	5.17	3.41e-07	9.61e-05	0.24	0.23	Body mass index;	chr13:32706422	chr13:32420390~32420516:-
LUAD	cis	rs916888	0.821	rs199506	ENSG00000261575.2	RP11-259G18.1	-5.17	3.41e-07	9.61e-05	-0.36	-0.23	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46267037~46268694:+
LUAD	cis	rs7208859	0.623	rs7220999	ENSG00000263603.1	CTD-2349P21.5	-5.17	3.41e-07	9.61e-05	-0.41	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822280	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs55638872	ENSG00000263603.1	CTD-2349P21.5	-5.17	3.41e-07	9.61e-05	-0.41	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822534	chr17:30729469~30731202:+
LUAD	cis	rs17684571	0.7	rs34520435	ENSG00000231441.1	RP11-472M19.2	5.17	3.41e-07	9.61e-05	0.33	0.23	Schizophrenia;	chr6:56818319	chr6:56844002~56864078:+
LUAD	cis	rs6840258	0.66	rs10516786	ENSG00000251411.1	RP11-397E7.4	-5.17	3.41e-07	9.61e-05	-0.31	-0.23	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86971189	chr4:86913266~86914817:-
LUAD	cis	rs453301	0.606	rs7462373	ENSG00000253893.2	FAM85B	5.17	3.41e-07	9.61e-05	0.28	0.23	Joint mobility (Beighton score);	chr8:9041808	chr8:8167819~8226614:-
LUAD	cis	rs9595908	0.746	rs2301393	ENSG00000212293.1	SNORA16	5.17	3.41e-07	9.62e-05	0.24	0.23	Body mass index;	chr13:32658298	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.785	rs7985656	ENSG00000212293.1	SNORA16	5.17	3.41e-07	9.62e-05	0.24	0.23	Body mass index;	chr13:32664414	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.785	rs9596056	ENSG00000212293.1	SNORA16	5.17	3.41e-07	9.62e-05	0.24	0.23	Body mass index;	chr13:32669402	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.785	rs60088097	ENSG00000212293.1	SNORA16	5.17	3.41e-07	9.62e-05	0.24	0.23	Body mass index;	chr13:32678043	chr13:32420390~32420516:-
LUAD	cis	rs7923837	1	rs7923837	ENSG00000236493.2	EIF2S2P3	5.17	3.41e-07	9.62e-05	0.26	0.23	Multiple sclerosis;Body mass index;	chr10:92722160	chr10:92668745~92669743:-
LUAD	cis	rs4835473	0.708	rs7655939	ENSG00000251600.4	RP11-673E1.1	5.17	3.41e-07	9.62e-05	0.29	0.23	Immature fraction of reticulocytes;	chr4:143956889	chr4:143912331~143982454:+
LUAD	cis	rs2028299	1	rs3960018	ENSG00000259677.1	RP11-493E3.1	5.17	3.41e-07	9.62e-05	0.28	0.23	Type 2 diabetes;	chr15:89840075	chr15:89876540~89877285:+
LUAD	cis	rs2028299	1	rs2351706	ENSG00000259677.1	RP11-493E3.1	5.17	3.41e-07	9.62e-05	0.28	0.23	Type 2 diabetes;	chr15:89840883	chr15:89876540~89877285:+
LUAD	cis	rs9545047	0.584	rs12871015	ENSG00000227354.5	RBM26-AS1	-5.17	3.41e-07	9.62e-05	-0.24	-0.23	Schizophrenia;	chr13:79333564	chr13:79406309~79424328:+
LUAD	cis	rs4835473	0.897	rs2590034	ENSG00000251600.4	RP11-673E1.1	5.17	3.41e-07	9.62e-05	0.28	0.23	Immature fraction of reticulocytes;	chr4:143926778	chr4:143912331~143982454:+
LUAD	cis	rs1707322	0.721	rs61784800	ENSG00000280836.1	AL355480.1	5.17	3.42e-07	9.62e-05	0.3	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712440	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.721	rs6665808	ENSG00000280836.1	AL355480.1	-5.17	3.42e-07	9.62e-05	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45696611	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.682	rs28508523	ENSG00000280836.1	AL355480.1	-5.17	3.42e-07	9.62e-05	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723953	chr1:45581219~45581321:-
LUAD	cis	rs6570726	0.791	rs12208019	ENSG00000235652.6	RP11-545I5.3	5.17	3.42e-07	9.63e-05	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145614436	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.791	rs11155435	ENSG00000235652.6	RP11-545I5.3	5.17	3.42e-07	9.63e-05	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145617409	chr6:145799409~145886585:+
LUAD	cis	rs4308124	0.708	rs2137168	ENSG00000227992.1	AC108463.2	-5.17	3.42e-07	9.63e-05	-0.31	-0.23	Vitiligo;	chr2:111228932	chr2:111203964~111206215:-
LUAD	cis	rs7119	0.717	rs12917175	ENSG00000259362.2	RP11-307C19.1	-5.17	3.42e-07	9.63e-05	-0.29	-0.23	Type 2 diabetes;	chr15:77525851	chr15:77525540~77534110:+
LUAD	cis	rs7208859	0.623	rs216434	ENSG00000263603.1	CTD-2349P21.5	-5.17	3.42e-07	9.63e-05	-0.42	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595317	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs216436	ENSG00000263603.1	CTD-2349P21.5	-5.17	3.42e-07	9.63e-05	-0.42	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595882	chr17:30729469~30731202:+
LUAD	cis	rs11673344	0.555	rs502546	ENSG00000226686.6	LINC01535	-5.17	3.42e-07	9.64e-05	-0.3	-0.23	Obesity-related traits;	chr19:37361788	chr19:37251912~37265535:+
LUAD	cis	rs1799949	0.628	rs4474733	ENSG00000267681.1	CTD-3199J23.6	-5.17	3.42e-07	9.64e-05	-0.3	-0.23	Menopause (age at onset);	chr17:43356292	chr17:43144956~43145255:+
LUAD	cis	rs7829975	0.871	rs572307	ENSG00000253893.2	FAM85B	5.17	3.42e-07	9.64e-05	0.29	0.23	Mood instability;	chr8:8721301	chr8:8167819~8226614:-
LUAD	cis	rs763567	1	rs3903239	ENSG00000271811.1	RP1-79C4.4	-5.17	3.43e-07	9.65e-05	-0.28	-0.23	Tonsillectomy;	chr1:170600176	chr1:170667381~170669425:+
LUAD	cis	rs763567	1	rs12760630	ENSG00000271811.1	RP1-79C4.4	-5.17	3.43e-07	9.65e-05	-0.28	-0.23	Tonsillectomy;	chr1:170600548	chr1:170667381~170669425:+
LUAD	cis	rs763567	1	rs10919437	ENSG00000271811.1	RP1-79C4.4	-5.17	3.43e-07	9.65e-05	-0.28	-0.23	Tonsillectomy;	chr1:170603805	chr1:170667381~170669425:+
LUAD	cis	rs763567	1	rs2206062	ENSG00000271811.1	RP1-79C4.4	-5.17	3.43e-07	9.65e-05	-0.28	-0.23	Tonsillectomy;	chr1:170606966	chr1:170667381~170669425:+
LUAD	cis	rs17214007	0.877	rs2075515	ENSG00000263335.1	AF001548.5	-5.17	3.43e-07	9.65e-05	-0.32	-0.23	Cognitive function;	chr16:15778462	chr16:15726674~15732993:+
LUAD	cis	rs1823913	0.538	rs13432697	ENSG00000280083.1	RP11-317J9.1	-5.17	3.43e-07	9.65e-05	-0.28	-0.23	Obesity-related traits;	chr2:191345944	chr2:191154118~191156070:-
LUAD	cis	rs9487094	0.813	rs3799840	ENSG00000260273.1	RP11-425D10.10	5.17	3.43e-07	9.65e-05	0.32	0.23	Height;	chr6:109381443	chr6:109382795~109383666:+
LUAD	cis	rs172166	0.561	rs149976	ENSG00000219392.1	RP1-265C24.5	5.17	3.43e-07	9.65e-05	0.28	0.23	Cardiac Troponin-T levels;	chr6:28019998	chr6:28115628~28116551:+
LUAD	cis	rs11105298	0.891	rs12369195	ENSG00000258302.2	RP11-981P6.1	5.17	3.43e-07	9.65e-05	0.29	0.23	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89541195	chr12:89561129~89594878:+
LUAD	cis	rs6751744	0.514	rs12386214	ENSG00000226266.5	AC009961.3	-5.17	3.43e-07	9.66e-05	-0.31	-0.23	Dysphagia;	chr2:159675012	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.932	rs4665104	ENSG00000226266.5	AC009961.3	-5.17	3.43e-07	9.66e-05	-0.31	-0.23	Monocyte percentage of white cells;	chr2:159675847	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.967	rs7595639	ENSG00000226266.5	AC009961.3	-5.17	3.43e-07	9.66e-05	-0.31	-0.23	Monocyte percentage of white cells;	chr2:159676533	chr2:159670708~159712435:-
LUAD	cis	rs12681366	0.881	rs3019145	ENSG00000253704.1	RP11-267M23.4	5.17	3.43e-07	9.66e-05	0.28	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94401324	chr8:94553722~94569745:+
LUAD	cis	rs2380205	0.546	rs649537	ENSG00000232807.2	RP11-536K7.3	-5.17	3.43e-07	9.67e-05	-0.24	-0.23	Breast cancer;	chr10:5903709	chr10:5934270~5945900:-
LUAD	cis	rs7772486	0.79	rs2485632	ENSG00000235652.6	RP11-545I5.3	5.17	3.43e-07	9.67e-05	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145872092	chr6:145799409~145886585:+
LUAD	cis	rs9992667	0.911	rs28360925	ENSG00000231160.8	KLF3-AS1	5.17	3.44e-07	9.67e-05	0.28	0.23	Eosinophil percentage of granulocytes;	chr4:38615676	chr4:38612701~38664883:-
LUAD	cis	rs8098244	0.638	rs12955083	ENSG00000264745.1	TTC39C-AS1	-5.17	3.44e-07	9.67e-05	-0.24	-0.23	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23853002	chr18:23994213~24015339:-
LUAD	cis	rs42490	0.528	rs1032516	ENSG00000251136.7	RP11-37B2.1	5.17	3.44e-07	9.68e-05	0.23	0.23	Leprosy;	chr8:89670055	chr8:89609409~89757727:-
LUAD	cis	rs17826219	0.561	rs562840	ENSG00000263531.1	RP13-753N3.1	5.17	3.44e-07	9.68e-05	0.39	0.23	Body mass index;	chr17:30622372	chr17:30863921~30864940:-
LUAD	cis	rs910316	0.967	rs10246	ENSG00000259138.1	RP11-950C14.7	5.17	3.44e-07	9.69e-05	0.24	0.23	Height;	chr14:75077767	chr14:75127153~75136930:+
LUAD	cis	rs8180040	0.69	rs7640397	ENSG00000271161.1	BOLA2P2	5.17	3.44e-07	9.69e-05	0.22	0.23	Colorectal cancer;	chr3:46948338	chr3:47499841~47500407:+
LUAD	cis	rs9435732	0.832	rs2076602	ENSG00000235241.1	RP11-108M9.5	5.17	3.44e-07	9.69e-05	0.32	0.23	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16996703	chr1:16889095~16889602:+
LUAD	cis	rs7772486	0.79	rs2253307	ENSG00000235652.6	RP11-545I5.3	5.17	3.45e-07	9.7e-05	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145875045	chr6:145799409~145886585:+
LUAD	cis	rs11089937	0.626	rs737841	ENSG00000211638.2	IGLV8-61	-5.17	3.45e-07	9.7e-05	-0.28	-0.23	Periodontitis (PAL4Q3);	chr22:22162769	chr22:22098700~22099212:+
LUAD	cis	rs4964805	1	rs4964806	ENSG00000257681.1	RP11-341G23.4	5.17	3.45e-07	9.71e-05	0.28	0.23	Attention deficit hyperactivity disorder;	chr12:103798982	chr12:103746315~103768858:-
LUAD	cis	rs4964805	1	rs4964794	ENSG00000257681.1	RP11-341G23.4	5.17	3.45e-07	9.71e-05	0.28	0.23	Attention deficit hyperactivity disorder;	chr12:103800640	chr12:103746315~103768858:-
LUAD	cis	rs875971	1	rs1167612	ENSG00000237310.1	GS1-124K5.4	-5.17	3.45e-07	9.72e-05	-0.25	-0.23	Aortic root size;	chr7:66102989	chr7:66493706~66495474:+
LUAD	cis	rs17027258	0.609	rs4851005	ENSG00000234389.1	AC007278.3	-5.17	3.45e-07	9.72e-05	-0.22	-0.23	White blood cell types;	chr2:102395092	chr2:102438713~102440475:+
LUAD	cis	rs2562456	0.833	rs8106025	ENSG00000268081.1	RP11-678G14.2	-5.17	3.46e-07	9.72e-05	-0.36	-0.23	Pain;	chr19:21451922	chr19:21554640~21569237:-
LUAD	cis	rs10129255	0.5	rs6576232	ENSG00000254174.1	IGHV1-12	5.17	3.46e-07	9.74e-05	0.15	0.23	Kawasaki disease;	chr14:106787090	chr14:106122420~106122709:-
LUAD	cis	rs6088590	0.61	rs6120663	ENSG00000276073.1	RP5-1125A11.7	5.17	3.46e-07	9.75e-05	0.23	0.23	Coronary artery disease;	chr20:34494101	chr20:33985617~33988989:-
LUAD	cis	rs11159086	0.793	rs28612392	ENSG00000259005.1	RP3-449M8.6	5.17	3.47e-07	9.75e-05	0.3	0.23	Advanced glycation end-product levels;	chr14:74467894	chr14:74474007~74474864:-
LUAD	cis	rs1062177	1	rs41494545	ENSG00000253921.1	CTB-113P19.3	5.17	3.47e-07	9.76e-05	0.33	0.23	Preschool internalizing problems;	chr5:151855533	chr5:151753992~151767247:+
LUAD	cis	rs1008375	0.931	rs6449310	ENSG00000249502.1	AC006160.5	-5.17	3.47e-07	9.77e-05	-0.23	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17573907	chr4:17587467~17614571:-
LUAD	cis	rs1707322	1	rs10890350	ENSG00000280836.1	AL355480.1	-5.17	3.47e-07	9.77e-05	-0.29	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796706	chr1:45581219~45581321:-
LUAD	cis	rs11976180	1	rs2961119	ENSG00000204959.4	ARHGEF34P	5.17	3.47e-07	9.77e-05	0.28	0.23	Obesity-related traits;	chr7:144058759	chr7:144272445~144286966:-
LUAD	cis	rs2657294	0.62	rs7903537	ENSG00000233313.2	HMGA1P5	-5.17	3.48e-07	9.78e-05	-0.29	-0.23	Pneumonia;	chr10:75087732	chr10:75276376~75276646:-
LUAD	cis	rs2657294	0.62	rs2395136	ENSG00000233313.2	HMGA1P5	-5.17	3.48e-07	9.78e-05	-0.29	-0.23	Pneumonia;	chr10:75088213	chr10:75276376~75276646:-
LUAD	cis	rs7083	1	rs535602	ENSG00000254851.1	RP11-109L13.1	5.17	3.48e-07	9.78e-05	0.3	0.23	Blood protein levels;	chr11:117237059	chr11:117135528~117138582:+
LUAD	cis	rs1707322	1	rs4390216	ENSG00000234329.1	RP11-767N6.2	5.17	3.48e-07	9.78e-05	0.24	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800784	chr1:45651039~45651826:-
LUAD	cis	rs7617773	0.817	rs9819094	ENSG00000228638.1	FCF1P2	-5.17	3.48e-07	9.78e-05	-0.26	-0.23	Coronary artery disease;	chr3:48278068	chr3:48290793~48291375:-
LUAD	cis	rs67311347	0.544	rs2278927	ENSG00000223797.4	ENTPD3-AS1	5.17	3.48e-07	9.78e-05	0.24	0.23	Renal cell carcinoma;	chr3:40308956	chr3:40313802~40453329:-
LUAD	cis	rs74233809	1	rs11191551	ENSG00000213277.3	MARCKSL1P1	5.17	3.48e-07	9.78e-05	0.41	0.23	Birth weight;	chr10:103091078	chr10:103175554~103176094:+
LUAD	cis	rs74233809	1	rs17094683	ENSG00000213277.3	MARCKSL1P1	5.17	3.48e-07	9.78e-05	0.41	0.23	Birth weight;	chr10:103091544	chr10:103175554~103176094:+
LUAD	cis	rs8031584	0.736	rs11635775	ENSG00000270015.1	RP11-540B6.6	-5.17	3.48e-07	9.78e-05	-0.18	-0.23	Huntington's disease progression;	chr15:30868437	chr15:30926514~30928407:+
LUAD	cis	rs6964587	0.773	rs13223564	ENSG00000188693.7	CYP51A1-AS1	-5.17	3.48e-07	9.79e-05	-0.28	-0.23	Breast cancer;	chr7:92303352	chr7:92134604~92180725:+
LUAD	cis	rs6095360	0.727	rs10485609	ENSG00000222365.1	SNORD12B	-5.17	3.48e-07	9.79e-05	-0.26	-0.23	Intelligence (multi-trait analysis);	chr20:49049075	chr20:49280319~49280409:+
LUAD	cis	rs6095360	0.727	rs35843274	ENSG00000222365.1	SNORD12B	-5.17	3.48e-07	9.79e-05	-0.26	-0.23	Intelligence (multi-trait analysis);	chr20:49049366	chr20:49280319~49280409:+
LUAD	cis	rs7208859	0.623	rs170051	ENSG00000263603.1	CTD-2349P21.5	-5.17	3.48e-07	9.79e-05	-0.41	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587135	chr17:30729469~30731202:+
LUAD	cis	rs12699921	0.632	rs1830006	ENSG00000279048.1	RP11-511H23.2	-5.17	3.48e-07	9.79e-05	-0.19	-0.23	Fibrinogen levels;	chr7:17788261	chr7:17940503~17942922:+
LUAD	cis	rs7208859	0.623	rs9899268	ENSG00000263603.1	CTD-2349P21.5	-5.17	3.48e-07	9.8e-05	-0.4	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30823237	chr17:30729469~30731202:+
LUAD	cis	rs11976180	1	rs1919950	ENSG00000204959.4	ARHGEF34P	5.17	3.48e-07	9.8e-05	0.28	0.23	Obesity-related traits;	chr7:144070805	chr7:144272445~144286966:-
LUAD	cis	rs4789693	0.679	rs7217570	ENSG00000265458.1	RP13-20L14.6	-5.17	3.48e-07	9.8e-05	-0.31	-0.23	Glucocorticoid-induced osteonecrosis;	chr17:82421456	chr17:82454273~82458521:-
LUAD	cis	rs1062753	0.771	rs932376	ENSG00000227370.1	RP4-669P10.19	5.17	3.49e-07	9.81e-05	0.23	0.23	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42218356	chr22:42132543~42132998:+
LUAD	cis	rs2688608	0.592	rs7080579	ENSG00000271816.1	BMS1P4	5.17	3.49e-07	9.81e-05	0.2	0.23	Inflammatory bowel disease;	chr10:73744271	chr10:73699151~73730487:-
LUAD	cis	rs7772486	0.754	rs6932863	ENSG00000235652.6	RP11-545I5.3	-5.17	3.49e-07	9.82e-05	-0.23	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145700119	chr6:145799409~145886585:+
LUAD	cis	rs801193	0.66	rs1962050	ENSG00000237310.1	GS1-124K5.4	-5.17	3.49e-07	9.82e-05	-0.24	-0.23	Aortic root size;	chr7:66775021	chr7:66493706~66495474:+
LUAD	cis	rs1008375	0.966	rs3775927	ENSG00000249502.1	AC006160.5	-5.17	3.5e-07	9.84e-05	-0.22	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17598271	chr4:17587467~17614571:-
LUAD	cis	rs1426063	0.858	rs11931653	ENSG00000249717.1	RP11-44F21.3	5.17	3.5e-07	9.84e-05	0.33	0.23	QT interval;	chr4:75080856	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.858	rs55775471	ENSG00000249717.1	RP11-44F21.3	5.17	3.5e-07	9.84e-05	0.33	0.23	QT interval;	chr4:75081074	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.858	rs9990627	ENSG00000249717.1	RP11-44F21.3	5.17	3.5e-07	9.84e-05	0.33	0.23	QT interval;	chr4:75081244	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.858	rs10026994	ENSG00000249717.1	RP11-44F21.3	5.17	3.5e-07	9.84e-05	0.33	0.23	QT interval;	chr4:75081551	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.858	rs6830936	ENSG00000249717.1	RP11-44F21.3	5.17	3.5e-07	9.84e-05	0.33	0.23	QT interval;	chr4:75083952	chr4:74955974~74970362:-
LUAD	cis	rs2790457	0.958	rs2532741	ENSG00000254635.4	WAC-AS1	-5.17	3.5e-07	9.84e-05	-0.26	-0.23	Multiple myeloma;	chr10:28574879	chr10:28522652~28532743:-
LUAD	cis	rs875971	0.862	rs35378740	ENSG00000232559.3	GS1-124K5.12	5.17	3.51e-07	9.85e-05	0.27	0.23	Aortic root size;	chr7:66522725	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs10950043	ENSG00000232559.3	GS1-124K5.12	5.17	3.51e-07	9.85e-05	0.27	0.23	Aortic root size;	chr7:66523623	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs17747530	ENSG00000232559.3	GS1-124K5.12	5.17	3.51e-07	9.85e-05	0.27	0.23	Aortic root size;	chr7:66529742	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs13226170	ENSG00000232559.3	GS1-124K5.12	5.17	3.51e-07	9.85e-05	0.27	0.23	Aortic root size;	chr7:66534311	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs2420611	ENSG00000232559.3	GS1-124K5.12	5.17	3.51e-07	9.85e-05	0.27	0.23	Aortic root size;	chr7:66534333	chr7:66554588~66576923:-
LUAD	cis	rs2980439	0.525	rs2980508	ENSG00000253893.2	FAM85B	-5.17	3.51e-07	9.85e-05	-0.28	-0.23	Neuroticism;	chr8:8314210	chr8:8167819~8226614:-
LUAD	cis	rs2919009	0.664	rs11815788	ENSG00000271670.1	RP11-95I16.4	5.17	3.51e-07	9.86e-05	0.3	0.23	Obesity-related traits;	chr10:120924582	chr10:120879256~120880667:-
LUAD	cis	rs2599510	0.811	rs2710625	ENSG00000276334.1	AL133243.1	5.17	3.51e-07	9.86e-05	0.27	0.23	Interleukin-18 levels;	chr2:32597890	chr2:32521927~32523547:+
LUAD	cis	rs1150668	0.796	rs728122	ENSG00000219392.1	RP1-265C24.5	-5.17	3.51e-07	9.87e-05	-0.28	-0.23	Pubertal anthropometrics;	chr6:28431347	chr6:28115628~28116551:+
LUAD	cis	rs4835473	0.932	rs35055653	ENSG00000251600.4	RP11-673E1.1	-5.17	3.51e-07	9.87e-05	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143754836	chr4:143912331~143982454:+
LUAD	cis	rs12745968	0.589	rs6682801	ENSG00000223787.2	RP4-593M8.1	-5.17	3.52e-07	9.88e-05	-0.27	-0.23	Bipolar disorder and schizophrenia;	chr1:92608984	chr1:92580476~92580821:-
LUAD	cis	rs7772486	0.701	rs11155438	ENSG00000235652.6	RP11-545I5.3	5.17	3.52e-07	9.88e-05	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145628976	chr6:145799409~145886585:+
LUAD	cis	rs2295359	0.892	rs4655687	ENSG00000275678.1	RP4-547N15.3	-5.17	3.52e-07	9.89e-05	-0.24	-0.23	Psoriasis;	chr1:67184263	chr1:67121605~67123956:-
LUAD	cis	rs875971	0.508	rs10258739	ENSG00000224316.1	RP11-479O9.2	-5.17	3.52e-07	9.9e-05	-0.23	-0.23	Aortic root size;	chr7:66597948	chr7:65773620~65802067:+
LUAD	cis	rs7968440	1	rs7977690	ENSG00000200428.1	Y_RNA	-5.17	3.52e-07	9.9e-05	-0.28	-0.23	Fibrinogen;	chr12:50736631	chr12:50743568~50743684:+
LUAD	cis	rs9910055	0.659	rs7214540	ENSG00000267080.4	ASB16-AS1	-5.17	3.52e-07	9.9e-05	-0.21	-0.23	Total body bone mineral density;	chr17:44179236	chr17:44175973~44186717:-
LUAD	cis	rs1008375	0.898	rs4698623	ENSG00000249502.1	AC006160.5	-5.17	3.53e-07	9.9e-05	-0.22	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17593079	chr4:17587467~17614571:-
LUAD	cis	rs2015599	0.525	rs7959145	ENSG00000257176.2	RP11-996F15.2	5.17	3.53e-07	9.91e-05	0.24	0.23	Platelet count;Mean platelet volume;	chr12:29330850	chr12:29280418~29317848:-
LUAD	cis	rs2015599	0.525	rs7961943	ENSG00000257176.2	RP11-996F15.2	5.17	3.53e-07	9.91e-05	0.24	0.23	Platelet count;Mean platelet volume;	chr12:29331146	chr12:29280418~29317848:-
LUAD	cis	rs7772486	0.754	rs4896839	ENSG00000235652.6	RP11-545I5.3	-5.16	3.53e-07	9.91e-05	-0.23	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145698553	chr6:145799409~145886585:+
LUAD	cis	rs465969	0.793	rs34288099	ENSG00000255389.1	C6orf3	-5.16	3.53e-07	9.92e-05	-0.4	-0.23	Psoriasis;	chr6:111424034	chr6:111599875~111602295:+
LUAD	cis	rs7138803	0.51	rs10875969	ENSG00000257464.1	RP11-161H23.8	-5.16	3.53e-07	9.92e-05	-0.22	-0.23	Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index;	chr12:49812940	chr12:49442424~49442652:-
LUAD	cis	rs4143844	0.867	rs34257602	ENSG00000259251.2	RP11-643M14.1	5.16	3.53e-07	9.92e-05	0.41	0.23	Bipolar disorder and schizophrenia;	chr15:61993548	chr15:62060503~62062434:+
LUAD	cis	rs12681366	0.801	rs72674819	ENSG00000253704.1	RP11-267M23.4	5.16	3.53e-07	9.92e-05	0.28	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94468072	chr8:94553722~94569745:+
LUAD	cis	rs11157436	1	rs11157440	ENSG00000211813.2	TRAV34	5.16	3.54e-07	9.93e-05	0.3	0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22181757	chr14:22207522~22208129:+
LUAD	cis	rs5769707	0.609	rs739247	ENSG00000235111.1	RP1-29C18.8	-5.16	3.54e-07	9.93e-05	-0.27	-0.23	Monocyte percentage of white cells;Monocyte count;	chr22:49603009	chr22:49612657~49615716:-
LUAD	cis	rs889398	0.967	rs1437134	ENSG00000226232.7	RP11-419C5.2	-5.16	3.54e-07	9.94e-05	-0.19	-0.23	Body mass index;	chr16:69696523	chr16:69976388~69996188:-
LUAD	cis	rs1275468	0.798	rs1275474	ENSG00000257497.2	RP11-585P4.5	-5.16	3.54e-07	9.94e-05	-0.32	-0.23	Polycystic ovary syndrome;	chr12:75525870	chr12:75483454~75489820:-
LUAD	cis	rs875971	0.522	rs4718285	ENSG00000236529.1	RP13-254B10.1	5.16	3.54e-07	9.94e-05	0.23	0.23	Aortic root size;	chr7:65827018	chr7:65840212~65840596:+
LUAD	cis	rs875971	0.522	rs4718286	ENSG00000236529.1	RP13-254B10.1	5.16	3.54e-07	9.94e-05	0.23	0.23	Aortic root size;	chr7:65827777	chr7:65840212~65840596:+
LUAD	cis	rs12745968	0.62	rs7535490	ENSG00000223787.2	RP4-593M8.1	-5.16	3.54e-07	9.94e-05	-0.27	-0.23	Bipolar disorder and schizophrenia;	chr1:92596292	chr1:92580476~92580821:-
LUAD	cis	rs11976180	1	rs2951354	ENSG00000204959.4	ARHGEF34P	5.16	3.54e-07	9.95e-05	0.28	0.23	Obesity-related traits;	chr7:144063908	chr7:144272445~144286966:-
LUAD	cis	rs11976180	1	rs2961125	ENSG00000204959.4	ARHGEF34P	5.16	3.54e-07	9.95e-05	0.28	0.23	Obesity-related traits;	chr7:144064677	chr7:144272445~144286966:-
LUAD	cis	rs11976180	1	rs2961126	ENSG00000204959.4	ARHGEF34P	5.16	3.54e-07	9.95e-05	0.28	0.23	Obesity-related traits;	chr7:144065643	chr7:144272445~144286966:-
LUAD	cis	rs11976180	0.953	rs2961127	ENSG00000204959.4	ARHGEF34P	5.16	3.54e-07	9.95e-05	0.28	0.23	Obesity-related traits;	chr7:144065644	chr7:144272445~144286966:-
LUAD	cis	rs11976180	1	rs1919948	ENSG00000204959.4	ARHGEF34P	5.16	3.54e-07	9.95e-05	0.28	0.23	Obesity-related traits;	chr7:144065750	chr7:144272445~144286966:-
LUAD	cis	rs227932	0.867	rs116981	ENSG00000234286.1	AC006026.13	-5.16	3.54e-07	9.95e-05	-0.38	-0.23	Schizophrenia;	chr7:23590849	chr7:23680195~23680786:-
LUAD	cis	rs116139393	0.536	rs13247186	ENSG00000187953.9	PMS2CL	-5.16	3.55e-07	9.96e-05	-0.28	-0.23	Alzheimer's disease (APOE e4 interaction);	chr7:6729524	chr7:6710128~6753862:+
LUAD	cis	rs10754283	0.967	rs1934045	ENSG00000231613.1	RP5-943J3.1	-5.16	3.55e-07	9.97e-05	-0.23	-0.23	Amyotrophic lateral sclerosis (sporadic);	chr1:89642240	chr1:89788914~89790492:+
LUAD	cis	rs7017914	0.653	rs13273718	ENSG00000223220.1	Y_RNA	5.16	3.55e-07	9.97e-05	0.26	0.23	Bone mineral density;	chr8:70757485	chr8:70780914~70781008:-
LUAD	cis	rs875971	0.522	rs7784623	ENSG00000236529.1	RP13-254B10.1	5.16	3.55e-07	9.97e-05	0.23	0.23	Aortic root size;	chr7:65930047	chr7:65840212~65840596:+
LUAD	cis	rs875971	0.522	rs34973832	ENSG00000236529.1	RP13-254B10.1	5.16	3.55e-07	9.97e-05	0.23	0.23	Aortic root size;	chr7:65931217	chr7:65840212~65840596:+
LUAD	cis	rs9992667	0.955	rs1962053	ENSG00000231160.8	KLF3-AS1	5.16	3.56e-07	9.98e-05	0.28	0.23	Eosinophil percentage of granulocytes;	chr4:38610736	chr4:38612701~38664883:-
LUAD	cis	rs7131987	0.621	rs11050181	ENSG00000257176.2	RP11-996F15.2	-5.16	3.56e-07	9.98e-05	-0.26	-0.23	QT interval;	chr12:29314736	chr12:29280418~29317848:-
LUAD	cis	rs7131987	0.65	rs10843384	ENSG00000257176.2	RP11-996F15.2	-5.16	3.56e-07	9.98e-05	-0.26	-0.23	QT interval;	chr12:29319476	chr12:29280418~29317848:-
LUAD	cis	rs7131987	0.65	rs11050188	ENSG00000257176.2	RP11-996F15.2	-5.16	3.56e-07	9.98e-05	-0.26	-0.23	QT interval;	chr12:29320175	chr12:29280418~29317848:-
LUAD	cis	rs7131987	0.683	rs12366505	ENSG00000257176.2	RP11-996F15.2	-5.16	3.56e-07	9.98e-05	-0.26	-0.23	QT interval;	chr12:29321177	chr12:29280418~29317848:-
LUAD	cis	rs7131987	0.65	rs12366527	ENSG00000257176.2	RP11-996F15.2	-5.16	3.56e-07	9.98e-05	-0.26	-0.23	QT interval;	chr12:29321323	chr12:29280418~29317848:-
LUAD	cis	rs7131987	0.65	rs7311912	ENSG00000257176.2	RP11-996F15.2	-5.16	3.56e-07	9.98e-05	-0.26	-0.23	QT interval;	chr12:29322770	chr12:29280418~29317848:-
LUAD	cis	rs8100891	0.734	rs8104048	ENSG00000267213.4	AC007773.2	-5.16	3.56e-07	9.98e-05	-0.27	-0.23	Neuroticism;	chr19:32338400	chr19:32390050~32405560:-
LUAD	cis	rs61270009	0.913	rs373845	ENSG00000247828.6	TMEM161B-AS1	-5.16	3.56e-07	9.98e-05	-0.26	-0.23	Depressive symptoms;	chr5:88253893	chr5:88268895~88436685:+
LUAD	cis	rs948562	0.519	rs7107808	ENSG00000280010.1	AP001350.4	5.16	3.56e-07	9.99e-05	0.32	0.23	Lymphoma;	chr11:58283606	chr11:58627435~58628528:+
LUAD	cis	rs673078	0.66	rs58113338	ENSG00000275409.1	RP11-131L12.4	-5.16	3.56e-07	9.99e-05	-0.33	-0.23	Glucose homeostasis traits;	chr12:118251335	chr12:118430147~118430699:+
LUAD	cis	rs7580658	0.895	rs62157549	ENSG00000236682.1	AC068282.3	-5.16	3.56e-07	1e-04	-0.31	-0.23	Protein C levels;	chr2:127308431	chr2:127389130~127400580:+
LUAD	cis	rs875971	0.965	rs697968	ENSG00000237310.1	GS1-124K5.4	-5.16	3.57e-07	1e-04	-0.25	-0.23	Aortic root size;	chr7:66070046	chr7:66493706~66495474:+
LUAD	cis	rs193541	0.632	rs154504	ENSG00000263432.2	RN7SL689P	5.16	3.57e-07	1e-04	0.3	0.23	Glucose homeostasis traits;	chr5:122868391	chr5:123022487~123022783:-
LUAD	cis	rs889398	0.933	rs244418	ENSG00000226232.7	RP11-419C5.2	5.16	3.57e-07	1e-04	0.19	0.23	Body mass index;	chr16:69588859	chr16:69976388~69996188:-
LUAD	cis	rs10895987	0.83	rs12292693	ENSG00000254614.2	AP003068.23	-5.16	3.57e-07	1e-04	-0.36	-0.23	Blood protein levels;	chr11:65169248	chr11:65177606~65181834:-
LUAD	cis	rs4835473	0.932	rs1849136	ENSG00000251600.4	RP11-673E1.1	-5.16	3.57e-07	1e-04	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143912380	chr4:143912331~143982454:+
LUAD	cis	rs41307935	0.643	rs34533568	ENSG00000260063.1	RP5-968P14.2	-5.16	3.57e-07	1e-04	-0.5	-0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26984148	chr1:26692132~26694131:-
LUAD	cis	rs41307935	0.643	rs12750643	ENSG00000260063.1	RP5-968P14.2	-5.16	3.57e-07	1e-04	-0.5	-0.23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26991003	chr1:26692132~26694131:-
LUAD	cis	rs4835473	0.897	rs28825455	ENSG00000251600.4	RP11-673E1.1	5.16	3.58e-07	1e-04	0.28	0.23	Immature fraction of reticulocytes;	chr4:143707593	chr4:143912331~143982454:+
LUAD	cis	rs7580658	0.676	rs2174270	ENSG00000236682.1	AC068282.3	-5.16	3.58e-07	1e-04	-0.3	-0.23	Protein C levels;	chr2:127248502	chr2:127389130~127400580:+
LUAD	cis	rs11157436	1	rs72638482	ENSG00000211813.2	TRAV34	5.16	3.58e-07	1e-04	0.3	0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22153322	chr14:22207522~22208129:+
LUAD	cis	rs7772486	0.727	rs6941429	ENSG00000235652.6	RP11-545I5.3	5.16	3.58e-07	1e-04	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145631147	chr6:145799409~145886585:+
LUAD	cis	rs11603023	0.967	rs654423	ENSG00000255239.1	AP002954.6	-5.16	3.58e-07	1e-04	-0.26	-0.23	Cholesterol, total;	chr11:118641039	chr11:118688039~118690600:-
LUAD	cis	rs4835473	0.932	rs7670010	ENSG00000251600.4	RP11-673E1.1	5.16	3.58e-07	0.000101	0.28	0.23	Immature fraction of reticulocytes;	chr4:143821679	chr4:143912331~143982454:+
LUAD	cis	rs7618501	0.633	rs11925192	ENSG00000234667.1	ACTBP13	-5.16	3.59e-07	0.000101	-0.26	-0.23	Intelligence (multi-trait analysis);	chr3:50001231	chr3:49873347~49877980:-
LUAD	cis	rs7618501	0.572	rs4688756	ENSG00000234667.1	ACTBP13	-5.16	3.59e-07	0.000101	-0.26	-0.23	Intelligence (multi-trait analysis);	chr3:50002761	chr3:49873347~49877980:-
LUAD	cis	rs7017914	0.616	rs55855305	ENSG00000223220.1	Y_RNA	5.16	3.59e-07	0.000101	0.26	0.23	Bone mineral density;	chr8:70790642	chr8:70780914~70781008:-
LUAD	cis	rs673078	0.66	rs61943362	ENSG00000275409.1	RP11-131L12.4	-5.16	3.59e-07	0.000101	-0.36	-0.23	Glucose homeostasis traits;	chr12:118322042	chr12:118430147~118430699:+
LUAD	cis	rs1045529	0.524	rs34251783	ENSG00000253893.2	FAM85B	5.16	3.59e-07	0.000101	0.3	0.23	Myopia (pathological);Myopia;	chr8:9033866	chr8:8167819~8226614:-
LUAD	cis	rs453301	0.719	rs34004903	ENSG00000253893.2	FAM85B	5.16	3.59e-07	0.000101	0.3	0.23	Joint mobility (Beighton score);	chr8:9035094	chr8:8167819~8226614:-
LUAD	cis	rs7299940	0.694	rs12296337	ENSG00000256250.1	RP11-989F5.1	5.16	3.59e-07	0.000101	0.26	0.23	Panic disorder;	chr12:130891406	chr12:130810606~130812438:+
LUAD	cis	rs9487094	0.961	rs34202013	ENSG00000260273.1	RP11-425D10.10	5.16	3.59e-07	0.000101	0.31	0.23	Height;	chr6:109353355	chr6:109382795~109383666:+
LUAD	cis	rs8103033	0.786	rs4802053	ENSG00000226025.8	LGALS17A	-5.16	3.6e-07	0.000101	-0.26	-0.23	Obesity-related traits;	chr19:39656599	chr19:39679374~39686373:+
LUAD	cis	rs957448	0.561	rs4734282	ENSG00000253704.1	RP11-267M23.4	5.16	3.6e-07	0.000101	0.27	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94603827	chr8:94553722~94569745:+
LUAD	cis	rs763567	0.967	rs10919444	ENSG00000271811.1	RP1-79C4.4	-5.16	3.6e-07	0.000101	-0.28	-0.23	Tonsillectomy;	chr1:170612493	chr1:170667381~170669425:+
LUAD	cis	rs763567	0.967	rs1952675	ENSG00000271811.1	RP1-79C4.4	-5.16	3.6e-07	0.000101	-0.28	-0.23	Tonsillectomy;	chr1:170613434	chr1:170667381~170669425:+
LUAD	cis	rs7131987	0.65	rs11050187	ENSG00000257176.2	RP11-996F15.2	-5.16	3.6e-07	0.000101	-0.26	-0.23	QT interval;	chr12:29319943	chr12:29280418~29317848:-
LUAD	cis	rs11976180	1	rs2961132	ENSG00000170356.8	OR2A20P	-5.16	3.6e-07	0.000101	-0.29	-0.23	Obesity-related traits;	chr7:144071035	chr7:144250045~144252957:-
LUAD	cis	rs4835473	0.897	rs35599924	ENSG00000251600.4	RP11-673E1.1	5.16	3.6e-07	0.000101	0.28	0.23	Immature fraction of reticulocytes;	chr4:143980602	chr4:143912331~143982454:+
LUAD	cis	rs1150668	0.768	rs1150716	ENSG00000219392.1	RP1-265C24.5	-5.16	3.6e-07	0.000101	-0.28	-0.23	Pubertal anthropometrics;	chr6:28294921	chr6:28115628~28116551:+
LUAD	cis	rs11157436	0.958	rs12432733	ENSG00000211813.2	TRAV34	5.16	3.61e-07	0.000101	0.3	0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22230741	chr14:22207522~22208129:+
LUAD	cis	rs498872	1	rs498872	ENSG00000255239.1	AP002954.6	5.16	3.61e-07	0.000101	0.28	0.23	Glioma;	chr11:118606652	chr11:118688039~118690600:-
LUAD	cis	rs950169	0.656	rs748455	ENSG00000275120.1	RP11-182J1.17	5.16	3.61e-07	0.000101	0.36	0.23	Schizophrenia;	chr15:84606344	chr15:84599434~84606463:-
LUAD	cis	rs7829975	0.633	rs2979181	ENSG00000173295.6	FAM86B3P	5.16	3.61e-07	0.000101	0.24	0.23	Mood instability;	chr8:8465578	chr8:8228595~8244865:+
LUAD	cis	rs6687821	0.531	rs4656137	ENSG00000267734.1	RP4-604K5.3	-5.16	3.61e-07	0.000101	-0.3	-0.23	Yeast infection;	chr1:87030164	chr1:86932199~86934891:-
LUAD	cis	rs6687821	0.531	rs6576861	ENSG00000267734.1	RP4-604K5.3	-5.16	3.61e-07	0.000101	-0.3	-0.23	Yeast infection;	chr1:87030538	chr1:86932199~86934891:-
LUAD	cis	rs2018683	1	rs4719962	ENSG00000228421.2	AC005013.5	5.16	3.61e-07	0.000101	0.25	0.23	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959621	chr7:28957667~28959345:+
LUAD	cis	rs2980439	0.607	rs2980419	ENSG00000173295.6	FAM86B3P	5.16	3.62e-07	0.000101	0.25	0.23	Neuroticism;	chr8:8256619	chr8:8228595~8244865:+
LUAD	cis	rs1707322	0.927	rs11211194	ENSG00000234329.1	RP11-767N6.2	5.16	3.62e-07	0.000101	0.23	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45816412	chr1:45651039~45651826:-
LUAD	cis	rs858239	0.863	rs466225	ENSG00000226816.2	AC005082.12	5.16	3.62e-07	0.000101	0.3	0.23	Cerebrospinal fluid biomarker levels;	chr7:23292784	chr7:23206013~23208045:+
LUAD	cis	rs7017914	0.69	rs9650238	ENSG00000223220.1	Y_RNA	5.16	3.62e-07	0.000101	0.27	0.23	Bone mineral density;	chr8:71080471	chr8:70780914~70781008:-
LUAD	cis	rs2404602	0.716	rs284895	ENSG00000259422.1	RP11-593F23.1	-5.16	3.62e-07	0.000102	-0.25	-0.23	Blood metabolite levels;	chr15:76458884	chr15:76174891~76181486:-
LUAD	cis	rs10129255	0.917	rs7142373	ENSG00000224373.3	IGHV4-59	5.16	3.63e-07	0.000102	0.15	0.23	Kawasaki disease;	chr14:106708947	chr14:106627249~106627825:-
LUAD	cis	rs55665837	0.519	rs1451677	ENSG00000251991.1	RNU7-49P	5.16	3.63e-07	0.000102	0.26	0.23	Vitamin D levels;	chr11:14724466	chr11:14478892~14478953:+
LUAD	cis	rs1062177	1	rs2915877	ENSG00000253921.1	CTB-113P19.3	-5.16	3.63e-07	0.000102	-0.33	-0.23	Preschool internalizing problems;	chr5:151771040	chr5:151753992~151767247:+
LUAD	cis	rs1062177	1	rs2964576	ENSG00000253921.1	CTB-113P19.3	-5.16	3.63e-07	0.000102	-0.33	-0.23	Preschool internalizing problems;	chr5:151771041	chr5:151753992~151767247:+
LUAD	cis	rs12439619	0.693	rs28689861	ENSG00000276710.3	CSPG4P8	-5.16	3.63e-07	0.000102	-0.25	-0.23	Intelligence (multi-trait analysis);	chr15:82206369	chr15:82459472~82477258:+
LUAD	cis	rs453301	0.686	rs6748	ENSG00000253893.2	FAM85B	5.16	3.63e-07	0.000102	0.3	0.23	Joint mobility (Beighton score);	chr8:9033292	chr8:8167819~8226614:-
LUAD	cis	rs896854	0.902	rs726816	ENSG00000253528.2	RP11-347C18.4	5.16	3.63e-07	0.000102	0.22	0.23	Type 2 diabetes;	chr8:94956185	chr8:94974573~94974853:-
LUAD	cis	rs2919009	0.664	rs55968513	ENSG00000271670.1	RP11-95I16.4	5.16	3.63e-07	0.000102	0.29	0.23	Obesity-related traits;	chr10:120859067	chr10:120879256~120880667:-
LUAD	cis	rs394563	0.775	rs412894	ENSG00000231760.4	RP11-350J20.5	5.16	3.64e-07	0.000102	0.29	0.23	Dupuytren's disease;	chr6:149460039	chr6:149796151~149826294:-
LUAD	cis	rs1707322	0.682	rs28490344	ENSG00000280836.1	AL355480.1	-5.16	3.64e-07	0.000102	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45732276	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.721	rs28501477	ENSG00000280836.1	AL355480.1	-5.16	3.64e-07	0.000102	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45733412	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.721	rs28641748	ENSG00000280836.1	AL355480.1	-5.16	3.64e-07	0.000102	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747164	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.721	rs6697821	ENSG00000280836.1	AL355480.1	-5.16	3.64e-07	0.000102	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751050	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.721	rs4330955	ENSG00000280836.1	AL355480.1	-5.16	3.64e-07	0.000102	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751813	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.691	rs12031182	ENSG00000280836.1	AL355480.1	-5.16	3.64e-07	0.000102	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755327	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.721	rs10430123	ENSG00000280836.1	AL355480.1	-5.16	3.64e-07	0.000102	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755768	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.716	rs6694889	ENSG00000280836.1	AL355480.1	-5.16	3.64e-07	0.000102	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45636134	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.682	rs12041197	ENSG00000280836.1	AL355480.1	-5.16	3.64e-07	0.000102	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638792	chr1:45581219~45581321:-
LUAD	cis	rs853679	1	rs735765	ENSG00000204709.4	LINC01556	5.16	3.64e-07	0.000102	0.39	0.23	Depression;	chr6:28202519	chr6:28943877~28944537:+
LUAD	cis	rs4908768	0.501	rs12061328	ENSG00000270282.1	RP5-1115A15.2	5.16	3.64e-07	0.000102	0.25	0.23	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8471903	chr1:8512653~8513021:+
LUAD	cis	rs2115630	0.936	rs6496318	ENSG00000229212.6	RP11-561C5.4	5.16	3.64e-07	0.000102	0.27	0.23	P wave terminal force;	chr15:84671998	chr15:85205440~85234795:-
LUAD	cis	rs2115630	0.902	rs8023276	ENSG00000229212.6	RP11-561C5.4	5.16	3.64e-07	0.000102	0.27	0.23	P wave terminal force;	chr15:84676407	chr15:85205440~85234795:-
LUAD	cis	rs7727544	0.836	rs10463892	ENSG00000233006.5	AC034220.3	5.16	3.64e-07	0.000102	0.2	0.23	Blood metabolite levels;	chr5:132263012	chr5:132311285~132369916:-
LUAD	cis	rs67517081	1	rs67517081	ENSG00000260911.2	RP11-196G11.2	-5.16	3.64e-07	0.000102	-0.21	-0.23	Mean corpuscular hemoglobin;	chr16:30976060	chr16:31043150~31049868:+
LUAD	cis	rs7131987	0.622	rs7294598	ENSG00000257176.2	RP11-996F15.2	5.16	3.65e-07	0.000102	0.26	0.23	QT interval;	chr12:29379056	chr12:29280418~29317848:-
LUAD	cis	rs2243480	0.522	rs12698511	ENSG00000232546.1	RP11-458F8.1	-5.16	3.65e-07	0.000102	-0.34	-0.23	Diabetic kidney disease;	chr7:66009932	chr7:66848496~66858136:+
LUAD	cis	rs12699921	0.933	rs6942635	ENSG00000279048.1	RP11-511H23.2	5.16	3.65e-07	0.000102	0.19	0.23	Fibrinogen levels;	chr7:17948242	chr7:17940503~17942922:+
LUAD	cis	rs8031584	0.678	rs8035703	ENSG00000259845.1	HERC2P10	5.16	3.65e-07	0.000102	0.27	0.23	Huntington's disease progression;	chr15:30876269	chr15:30815271~30844153:+
LUAD	cis	rs1345301	0.518	rs1035131	ENSG00000234389.1	AC007278.3	-5.16	3.65e-07	0.000102	-0.22	-0.23	Waist circumference;	chr2:102246181	chr2:102438713~102440475:+
LUAD	cis	rs875971	0.862	rs13536	ENSG00000232559.3	GS1-124K5.12	-5.16	3.65e-07	0.000102	-0.27	-0.23	Aortic root size;	chr7:66554203	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs801209	ENSG00000232559.3	GS1-124K5.12	-5.16	3.65e-07	0.000102	-0.27	-0.23	Aortic root size;	chr7:66554403	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs801206	ENSG00000232559.3	GS1-124K5.12	-5.16	3.65e-07	0.000102	-0.27	-0.23	Aortic root size;	chr7:66556979	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs801204	ENSG00000232559.3	GS1-124K5.12	-5.16	3.65e-07	0.000102	-0.27	-0.23	Aortic root size;	chr7:66557934	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs801203	ENSG00000232559.3	GS1-124K5.12	-5.16	3.65e-07	0.000102	-0.27	-0.23	Aortic root size;	chr7:66558025	chr7:66554588~66576923:-
LUAD	cis	rs4835473	0.932	rs1580002	ENSG00000251600.4	RP11-673E1.1	-5.16	3.66e-07	0.000102	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143766507	chr4:143912331~143982454:+
LUAD	cis	rs61270009	0.955	rs410354	ENSG00000247828.6	TMEM161B-AS1	-5.16	3.66e-07	0.000102	-0.26	-0.23	Depressive symptoms;	chr5:88254467	chr5:88268895~88436685:+
LUAD	cis	rs61270009	0.955	rs780404	ENSG00000247828.6	TMEM161B-AS1	-5.16	3.66e-07	0.000102	-0.26	-0.23	Depressive symptoms;	chr5:88256675	chr5:88268895~88436685:+
LUAD	cis	rs61270009	0.955	rs375514	ENSG00000247828.6	TMEM161B-AS1	-5.16	3.66e-07	0.000102	-0.26	-0.23	Depressive symptoms;	chr5:88259477	chr5:88268895~88436685:+
LUAD	cis	rs61270009	0.955	rs377958	ENSG00000247828.6	TMEM161B-AS1	-5.16	3.66e-07	0.000102	-0.26	-0.23	Depressive symptoms;	chr5:88267571	chr5:88268895~88436685:+
LUAD	cis	rs61270009	0.913	rs402114	ENSG00000247828.6	TMEM161B-AS1	-5.16	3.66e-07	0.000102	-0.26	-0.23	Depressive symptoms;	chr5:88268106	chr5:88268895~88436685:+
LUAD	cis	rs17818399	0.815	rs17768132	ENSG00000279254.1	RP11-536C12.1	5.16	3.66e-07	0.000102	0.27	0.23	Height;	chr2:46636110	chr2:46668870~46670778:+
LUAD	cis	rs6095360	0.7	rs2295026	ENSG00000222365.1	SNORD12B	-5.16	3.66e-07	0.000103	-0.26	-0.23	Intelligence (multi-trait analysis);	chr20:48966248	chr20:49280319~49280409:+
LUAD	cis	rs2562456	0.876	rs62110202	ENSG00000268081.1	RP11-678G14.2	5.16	3.66e-07	0.000103	0.34	0.23	Pain;	chr19:21571799	chr19:21554640~21569237:-
LUAD	cis	rs7829975	0.606	rs891570	ENSG00000253893.2	FAM85B	5.16	3.67e-07	0.000103	0.29	0.23	Mood instability;	chr8:8936944	chr8:8167819~8226614:-
LUAD	cis	rs11971779	0.648	rs59791374	ENSG00000273391.1	RP11-634H22.1	5.16	3.67e-07	0.000103	0.24	0.23	Diisocyanate-induced asthma;	chr7:139432216	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.59	rs59602547	ENSG00000273391.1	RP11-634H22.1	5.16	3.67e-07	0.000103	0.24	0.23	Diisocyanate-induced asthma;	chr7:139432277	chr7:139359032~139359566:-
LUAD	cis	rs12439619	0.739	rs4778988	ENSG00000276710.3	CSPG4P8	-5.16	3.67e-07	0.000103	-0.23	-0.23	Intelligence (multi-trait analysis);	chr15:82247996	chr15:82459472~82477258:+
LUAD	cis	rs2348418	0.669	rs7959641	ENSG00000247934.4	RP11-967K21.1	5.16	3.67e-07	0.000103	0.27	0.23	Lung function (FEV1);Lung function (FVC);	chr12:28237267	chr12:28163298~28190738:-
LUAD	cis	rs17507216	0.718	rs72751657	ENSG00000255769.6	GOLGA2P10	-5.16	3.67e-07	0.000103	-0.3	-0.23	Excessive daytime sleepiness;	chr15:82581259	chr15:82472993~82513950:-
LUAD	cis	rs7083	0.935	rs529470	ENSG00000254851.1	RP11-109L13.1	5.16	3.67e-07	0.000103	0.29	0.23	Blood protein levels;	chr11:117262092	chr11:117135528~117138582:+
LUAD	cis	rs7083	0.935	rs529471	ENSG00000254851.1	RP11-109L13.1	5.16	3.67e-07	0.000103	0.29	0.23	Blood protein levels;	chr11:117262093	chr11:117135528~117138582:+
LUAD	cis	rs7083	0.935	rs7111678	ENSG00000254851.1	RP11-109L13.1	5.16	3.67e-07	0.000103	0.29	0.23	Blood protein levels;	chr11:117265090	chr11:117135528~117138582:+
LUAD	cis	rs7083	1	rs2509210	ENSG00000254851.1	RP11-109L13.1	5.16	3.67e-07	0.000103	0.29	0.23	Blood protein levels;	chr11:117265354	chr11:117135528~117138582:+
LUAD	cis	rs7083	0.967	rs558590	ENSG00000254851.1	RP11-109L13.1	5.16	3.67e-07	0.000103	0.29	0.23	Blood protein levels;	chr11:117268405	chr11:117135528~117138582:+
LUAD	cis	rs7083	1	rs495438	ENSG00000254851.1	RP11-109L13.1	5.16	3.67e-07	0.000103	0.29	0.23	Blood protein levels;	chr11:117274011	chr11:117135528~117138582:+
LUAD	cis	rs7083	0.935	rs492151	ENSG00000254851.1	RP11-109L13.1	5.16	3.67e-07	0.000103	0.29	0.23	Blood protein levels;	chr11:117275099	chr11:117135528~117138582:+
LUAD	cis	rs6687821	0.587	rs4282790	ENSG00000267734.1	RP4-604K5.3	-5.16	3.68e-07	0.000103	-0.28	-0.23	Yeast infection;	chr1:86828222	chr1:86932199~86934891:-
LUAD	cis	rs11976180	1	rs1919950	ENSG00000170356.8	OR2A20P	-5.16	3.68e-07	0.000103	-0.29	-0.23	Obesity-related traits;	chr7:144070805	chr7:144250045~144252957:-
LUAD	cis	rs11742741	0.579	rs17444609	ENSG00000248874.4	C5orf17	5.16	3.68e-07	0.000103	0.28	0.23	Educational attainment;	chr5:24110244	chr5:23951348~24178263:+
LUAD	cis	rs17711722	0.585	rs6942660	ENSG00000236529.1	RP13-254B10.1	5.16	3.68e-07	0.000103	0.23	0.23	Calcium levels;	chr7:65837419	chr7:65840212~65840596:+
LUAD	cis	rs17711722	0.64	rs13237956	ENSG00000236529.1	RP13-254B10.1	5.16	3.68e-07	0.000103	0.23	0.23	Calcium levels;	chr7:65853042	chr7:65840212~65840596:+
LUAD	cis	rs30380	0.573	rs469783	ENSG00000248734.2	CTD-2260A17.1	5.16	3.68e-07	0.000103	0.23	0.23	Cerebrospinal fluid biomarker levels;	chr5:96785820	chr5:96784777~96785999:+
LUAD	cis	rs984222	0.838	rs6428789	ENSG00000226172.2	RP4-712E4.1	-5.16	3.68e-07	0.000103	-0.25	-0.23	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119007857	chr1:119000344~119001392:-
LUAD	cis	rs11089937	0.54	rs9622920	ENSG00000211638.2	IGLV8-61	5.16	3.68e-07	0.000103	0.26	0.23	Periodontitis (PAL4Q3);	chr22:22133024	chr22:22098700~22099212:+
LUAD	cis	rs867371	0.892	rs4344697	ENSG00000259429.4	UBE2Q2P2	-5.16	3.68e-07	0.000103	-0.2	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82252873	chr15:82355142~82420075:+
LUAD	cis	rs7968440	0.715	rs7967954	ENSG00000272368.2	RP4-605O3.4	-5.16	3.69e-07	0.000103	-0.26	-0.23	Fibrinogen;	chr12:50279701	chr12:50112197~50165618:+
LUAD	cis	rs1707322	0.721	rs4559551	ENSG00000280836.1	AL355480.1	-5.16	3.69e-07	0.000103	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701861	chr1:45581219~45581321:-
LUAD	cis	rs9341808	0.727	rs9361599	ENSG00000272129.1	RP11-250B2.6	5.16	3.69e-07	0.000103	0.28	0.23	Sitting height ratio;	chr6:80315525	chr6:80355424~80356859:+
LUAD	cis	rs9341808	0.754	rs9352817	ENSG00000272129.1	RP11-250B2.6	5.16	3.69e-07	0.000103	0.28	0.23	Sitting height ratio;	chr6:80316162	chr6:80355424~80356859:+
LUAD	cis	rs2295359	0.892	rs12029362	ENSG00000275678.1	RP4-547N15.3	-5.16	3.69e-07	0.000103	-0.24	-0.23	Psoriasis;	chr1:67158548	chr1:67121605~67123956:-
LUAD	cis	rs14027	0.921	rs13261032	ENSG00000279347.1	RP11-85I17.2	-5.16	3.69e-07	0.000103	-0.2	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119733117	chr8:119838736~119840385:-
LUAD	cis	rs14027	0.921	rs2048239	ENSG00000279347.1	RP11-85I17.2	-5.16	3.69e-07	0.000103	-0.2	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119735701	chr8:119838736~119840385:-
LUAD	cis	rs12550612	0.83	rs9918919	ENSG00000253616.4	RP11-875O11.3	5.16	3.69e-07	0.000103	0.34	0.23	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23109777	chr8:23071377~23074488:-
LUAD	cis	rs2998286	0.862	rs2807728	ENSG00000254635.4	WAC-AS1	5.16	3.69e-07	0.000103	0.27	0.23	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28526504	chr10:28522652~28532743:-
LUAD	cis	rs2243480	0.522	rs73150635	ENSG00000232546.1	RP11-458F8.1	-5.16	3.7e-07	0.000103	-0.35	-0.23	Diabetic kidney disease;	chr7:66507503	chr7:66848496~66858136:+
LUAD	cis	rs7826238	0.566	rs2945886	ENSG00000173295.6	FAM86B3P	5.16	3.7e-07	0.000103	0.25	0.23	Systolic blood pressure;	chr8:8290748	chr8:8228595~8244865:+
LUAD	cis	rs10771431	0.713	rs17794353	ENSG00000111788.10	RP11-22B23.1	-5.16	3.7e-07	0.000103	-0.2	-0.23	Breast size;	chr12:9209187	chr12:9277235~9313241:+
LUAD	cis	rs875971	0.825	rs4587224	ENSG00000232559.3	GS1-124K5.12	-5.16	3.7e-07	0.000103	-0.27	-0.23	Aortic root size;	chr7:66271195	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.792	rs6971752	ENSG00000232559.3	GS1-124K5.12	-5.16	3.7e-07	0.000103	-0.27	-0.23	Aortic root size;	chr7:66272999	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs10950033	ENSG00000232559.3	GS1-124K5.12	-5.16	3.7e-07	0.000103	-0.27	-0.23	Aortic root size;	chr7:66274686	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs11760844	ENSG00000232559.3	GS1-124K5.12	-5.16	3.7e-07	0.000103	-0.27	-0.23	Aortic root size;	chr7:66274896	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs4149461	ENSG00000232559.3	GS1-124K5.12	-5.16	3.7e-07	0.000103	-0.27	-0.23	Aortic root size;	chr7:66279745	chr7:66554588~66576923:-
LUAD	cis	rs7811142	1	rs68116612	ENSG00000078319.8	PMS2P1	-5.16	3.7e-07	0.000103	-0.27	-0.23	Platelet count;	chr7:100408870	chr7:100320992~100341908:-
LUAD	cis	rs193541	0.632	rs1460040	ENSG00000263432.2	RN7SL689P	5.16	3.7e-07	0.000103	0.3	0.23	Glucose homeostasis traits;	chr5:122769537	chr5:123022487~123022783:-
LUAD	cis	rs11976180	1	rs2961128	ENSG00000204959.4	ARHGEF34P	5.16	3.7e-07	0.000103	0.28	0.23	Obesity-related traits;	chr7:144066390	chr7:144272445~144286966:-
LUAD	cis	rs11976180	1	rs2371248	ENSG00000204959.4	ARHGEF34P	5.16	3.7e-07	0.000103	0.28	0.23	Obesity-related traits;	chr7:144067096	chr7:144272445~144286966:-
LUAD	cis	rs7712401	0.601	rs246285	ENSG00000263432.2	RN7SL689P	-5.16	3.7e-07	0.000104	-0.28	-0.23	Mean platelet volume;	chr5:122909273	chr5:123022487~123022783:-
LUAD	cis	rs1062177	0.855	rs919263	ENSG00000253921.1	CTB-113P19.3	-5.16	3.71e-07	0.000104	-0.32	-0.23	Preschool internalizing problems;	chr5:151886292	chr5:151753992~151767247:+
LUAD	cis	rs896854	0.967	rs13257021	ENSG00000253528.2	RP11-347C18.4	5.16	3.71e-07	0.000104	0.22	0.23	Type 2 diabetes;	chr8:94953467	chr8:94974573~94974853:-
LUAD	cis	rs896854	0.967	rs10808671	ENSG00000253528.2	RP11-347C18.4	5.16	3.71e-07	0.000104	0.22	0.23	Type 2 diabetes;	chr8:94955144	chr8:94974573~94974853:-
LUAD	cis	rs896854	0.967	rs10956933	ENSG00000253528.2	RP11-347C18.4	5.16	3.71e-07	0.000104	0.22	0.23	Type 2 diabetes;	chr8:94955460	chr8:94974573~94974853:-
LUAD	cis	rs858239	1	rs199347	ENSG00000226816.2	AC005082.12	5.16	3.71e-07	0.000104	0.3	0.23	Cerebrospinal fluid biomarker levels;	chr7:23254127	chr7:23206013~23208045:+
LUAD	cis	rs394563	0.717	rs548848	ENSG00000231760.4	RP11-350J20.5	5.15	3.71e-07	0.000104	0.29	0.23	Dupuytren's disease;	chr6:149460873	chr6:149796151~149826294:-
LUAD	cis	rs1707322	0.789	rs7540578	ENSG00000280836.1	AL355480.1	-5.15	3.71e-07	0.000104	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45786472	chr1:45581219~45581321:-
LUAD	cis	rs4908768	0.501	rs6668508	ENSG00000270282.1	RP5-1115A15.2	5.15	3.72e-07	0.000104	0.25	0.23	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8514059	chr1:8512653~8513021:+
LUAD	cis	rs4908768	0.501	rs6577494	ENSG00000270282.1	RP5-1115A15.2	5.15	3.72e-07	0.000104	0.25	0.23	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8516866	chr1:8512653~8513021:+
LUAD	cis	rs6496044	0.507	rs410522	ENSG00000259407.1	RP11-158M2.3	5.15	3.72e-07	0.000104	0.21	0.23	Interstitial lung disease;	chr15:85663813	chr15:85744109~85750281:-
LUAD	cis	rs7017914	0.69	rs13263370	ENSG00000223220.1	Y_RNA	5.15	3.72e-07	0.000104	0.27	0.23	Bone mineral density;	chr8:71057299	chr8:70780914~70781008:-
LUAD	cis	rs2028299	0.959	rs748508	ENSG00000259677.1	RP11-493E3.1	5.15	3.72e-07	0.000104	0.28	0.23	Type 2 diabetes;	chr15:89838026	chr15:89876540~89877285:+
LUAD	cis	rs3750965	0.959	rs4930265	ENSG00000260895.1	RP11-554A11.7	5.15	3.72e-07	0.000104	0.26	0.23	Hair color;	chr11:69088486	chr11:69103493~69109094:+
LUAD	cis	rs910316	1	rs2300601	ENSG00000259138.1	RP11-950C14.7	5.15	3.73e-07	0.000104	0.24	0.23	Height;	chr14:75172868	chr14:75127153~75136930:+
LUAD	cis	rs858239	0.539	rs4504540	ENSG00000230042.1	AK3P3	-5.15	3.73e-07	0.000104	-0.29	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23146579	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.509	rs6975524	ENSG00000230042.1	AK3P3	-5.15	3.73e-07	0.000104	-0.29	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23146833	chr7:23129178~23129841:+
LUAD	cis	rs910316	0.836	rs6574212	ENSG00000259138.1	RP11-950C14.7	-5.15	3.73e-07	0.000104	-0.24	-0.23	Height;	chr14:75204956	chr14:75127153~75136930:+
LUAD	cis	rs72807246	1	rs72807246	ENSG00000228701.1	TNKS2-AS1	5.15	3.73e-07	0.000104	0.51	0.23	Breast cancer;	chr10:92172529	chr10:91782839~91798291:-
LUAD	cis	rs11159086	0.793	rs11625502	ENSG00000259005.1	RP3-449M8.6	5.15	3.73e-07	0.000104	0.3	0.23	Advanced glycation end-product levels;	chr14:74468309	chr14:74474007~74474864:-
LUAD	cis	rs1426063	0.858	rs7666182	ENSG00000249717.1	RP11-44F21.3	5.15	3.73e-07	0.000104	0.33	0.23	QT interval;	chr4:75090989	chr4:74955974~74970362:-
LUAD	cis	rs7811142	1	rs4472444	ENSG00000078319.8	PMS2P1	-5.15	3.73e-07	0.000104	-0.27	-0.23	Platelet count;	chr7:100473135	chr7:100320992~100341908:-
LUAD	cis	rs867371	1	rs1174543	ENSG00000276710.3	CSPG4P8	5.15	3.73e-07	0.000104	0.22	0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82155732	chr15:82459472~82477258:+
LUAD	cis	rs2976388	0.609	rs2585152	ENSG00000253741.1	CTD-2292P10.4	-5.15	3.74e-07	0.000104	-0.26	-0.23	Urinary tract infection frequency;	chr8:142704796	chr8:142702252~142726973:-
LUAD	cis	rs1012068	1	rs1012068	ENSG00000236132.1	CTA-440B3.1	-5.15	3.74e-07	0.000104	-0.29	-0.23	Chronic hepatitis C infection;	chr22:31869917	chr22:31816379~31817491:-
LUAD	cis	rs4664293	0.836	rs13032500	ENSG00000226266.5	AC009961.3	-5.15	3.74e-07	0.000104	-0.32	-0.23	Monocyte percentage of white cells;	chr2:159749740	chr2:159670708~159712435:-
LUAD	cis	rs1876905	0.68	rs354527	ENSG00000272356.1	RP5-1112D6.8	-5.15	3.74e-07	0.000104	-0.27	-0.23	Mean corpuscular hemoglobin;	chr6:111217390	chr6:111309203~111313517:+
LUAD	cis	rs71403859	0.502	rs75986475	ENSG00000260886.1	TAT-AS1	5.15	3.74e-07	0.000105	0.4	0.23	Post bronchodilator FEV1;	chr16:71430155	chr16:71565789~71578187:+
LUAD	cis	rs7968440	0.778	rs111941917	ENSG00000200428.1	Y_RNA	-5.15	3.74e-07	0.000105	-0.3	-0.23	Fibrinogen;	chr12:50764479	chr12:50743568~50743684:+
LUAD	cis	rs4722166	0.695	rs4722177	ENSG00000179428.2	AC073072.5	-5.15	3.75e-07	0.000105	-0.27	-0.23	Lung cancer;	chr7:22758912	chr7:22725395~22727620:-
LUAD	cis	rs4604732	0.631	rs60311891	ENSG00000227135.1	GCSAML-AS1	-5.15	3.75e-07	0.000105	-0.36	-0.23	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247459825	chr1:247524679~247526752:-
LUAD	cis	rs62246343	0.719	rs62246275	ENSG00000254485.4	RP11-380O24.1	5.15	3.75e-07	0.000105	0.34	0.23	Fibrinogen levels;	chr3:9399496	chr3:9292588~9363303:-
LUAD	cis	rs7017914	0.69	rs35201629	ENSG00000223220.1	Y_RNA	5.15	3.76e-07	0.000105	0.26	0.23	Bone mineral density;	chr8:71062264	chr8:70780914~70781008:-
LUAD	cis	rs6714710	0.603	rs13034929	ENSG00000230606.9	AC159540.1	-5.15	3.76e-07	0.000105	-0.25	-0.23	Posterior cortical atrophy and Alzheimer's disease;	chr2:97786309	chr2:97416165~97433527:-
LUAD	cis	rs6687821	0.531	rs2390217	ENSG00000267734.1	RP4-604K5.3	-5.15	3.76e-07	0.000105	-0.3	-0.23	Yeast infection;	chr1:87033896	chr1:86932199~86934891:-
LUAD	cis	rs853679	0.546	rs200954	ENSG00000219392.1	RP1-265C24.5	-5.15	3.76e-07	0.000105	-0.44	-0.23	Depression;	chr6:27870986	chr6:28115628~28116551:+
LUAD	cis	rs7819412	0.74	rs7844536	ENSG00000255046.1	RP11-297N6.4	5.15	3.76e-07	0.000105	0.27	0.23	Triglycerides;	chr8:11176519	chr8:11797928~11802568:-
LUAD	cis	rs9309473	0.687	rs7576824	ENSG00000163016.8	ALMS1P	-5.15	3.76e-07	0.000105	-0.26	-0.23	Metabolite levels;	chr2:73384153	chr2:73644919~73685576:+
LUAD	cis	rs6921919	0.789	rs13210258	ENSG00000216901.1	AL022393.7	5.15	3.76e-07	0.000105	0.3	0.23	Autism spectrum disorder or schizophrenia;	chr6:28340894	chr6:28176188~28176674:+
LUAD	cis	rs4938303	0.589	rs11601584	ENSG00000254851.1	RP11-109L13.1	5.15	3.76e-07	0.000105	0.31	0.23	Triglycerides;	chr11:116700568	chr11:117135528~117138582:+
LUAD	cis	rs673078	0.66	rs7970481	ENSG00000275409.1	RP11-131L12.4	-5.15	3.76e-07	0.000105	-0.32	-0.23	Glucose homeostasis traits;	chr12:118242112	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.66	rs61945206	ENSG00000275409.1	RP11-131L12.4	-5.15	3.76e-07	0.000105	-0.32	-0.23	Glucose homeostasis traits;	chr12:118238295	chr12:118430147~118430699:+
LUAD	cis	rs4835473	0.897	rs12508285	ENSG00000251600.4	RP11-673E1.1	-5.15	3.77e-07	0.000105	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143792642	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs7667544	ENSG00000251600.4	RP11-673E1.1	-5.15	3.77e-07	0.000105	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143793802	chr4:143912331~143982454:+
LUAD	cis	rs2880765	0.835	rs4281668	ENSG00000259295.5	CSPG4P12	5.15	3.77e-07	0.000105	0.27	0.23	Coronary artery disease;	chr15:85504055	chr15:85191438~85213905:+
LUAD	cis	rs17711722	0.585	rs6942660	ENSG00000164669.11	INTS4P1	-5.15	3.77e-07	0.000105	-0.27	-0.23	Calcium levels;	chr7:65837419	chr7:65141225~65234216:+
LUAD	cis	rs17711722	0.64	rs13237956	ENSG00000164669.11	INTS4P1	-5.15	3.77e-07	0.000105	-0.27	-0.23	Calcium levels;	chr7:65853042	chr7:65141225~65234216:+
LUAD	cis	rs875971	0.54	rs781152	ENSG00000164669.11	INTS4P1	-5.15	3.77e-07	0.000105	-0.28	-0.23	Aortic root size;	chr7:66014585	chr7:65141225~65234216:+
LUAD	cis	rs17711722	0.727	rs781151	ENSG00000164669.11	INTS4P1	-5.15	3.77e-07	0.000105	-0.28	-0.23	Calcium levels;	chr7:66014891	chr7:65141225~65234216:+
LUAD	cis	rs1075265	0.669	rs805317	ENSG00000233266.1	HMGB1P31	5.15	3.78e-07	0.000105	0.28	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53907867	chr2:54051334~54051760:+
LUAD	cis	rs1075265	0.692	rs805318	ENSG00000233266.1	HMGB1P31	5.15	3.78e-07	0.000105	0.28	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53907915	chr2:54051334~54051760:+
LUAD	cis	rs61270009	0.955	rs12515274	ENSG00000247828.6	TMEM161B-AS1	5.15	3.78e-07	0.000105	0.27	0.23	Depressive symptoms;	chr5:88359845	chr5:88268895~88436685:+
LUAD	cis	rs875971	0.522	rs1701760	ENSG00000224316.1	RP11-479O9.2	5.15	3.78e-07	0.000105	0.23	0.23	Aortic root size;	chr7:66008701	chr7:65773620~65802067:+
LUAD	cis	rs6921919	0.848	rs56131013	ENSG00000216901.1	AL022393.7	5.15	3.78e-07	0.000105	0.31	0.23	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:28176188~28176674:+
LUAD	cis	rs9900062	0.535	rs753917	ENSG00000270714.1	MINOS1P2	-5.15	3.78e-07	0.000105	-0.31	-0.23	QT interval;	chr17:64677018	chr17:64747264~64747492:-
LUAD	cis	rs643506	0.874	rs625477	ENSG00000230911.1	PPIHP1	-5.15	3.78e-07	0.000106	-0.29	-0.23	Breast cancer;	chr11:111790962	chr11:112029858~112030367:-
LUAD	cis	rs2548724	0.536	rs55912935	ENSG00000250682.4	LINC00491	5.15	3.79e-07	0.000106	0.27	0.23	Type 2 diabetes;	chr5:102475250	chr5:102609156~102671559:-
LUAD	cis	rs2976388	0.609	rs2585153	ENSG00000253741.1	CTD-2292P10.4	-5.15	3.79e-07	0.000106	-0.26	-0.23	Urinary tract infection frequency;	chr8:142703927	chr8:142702252~142726973:-
LUAD	cis	rs12530	0.715	rs2294313	ENSG00000230736.2	RP1-149A16.3	-5.15	3.79e-07	0.000106	-0.25	-0.23	IgG glycosylation;	chr22:32398452	chr22:32376664~32384343:+
LUAD	cis	rs9487094	0.961	rs9487100	ENSG00000260273.1	RP11-425D10.10	5.15	3.79e-07	0.000106	0.31	0.23	Height;	chr6:109429207	chr6:109382795~109383666:+
LUAD	cis	rs9322193	0.923	rs10872651	ENSG00000268592.3	RAET1E-AS1	5.15	3.8e-07	0.000106	0.29	0.23	Lung cancer;	chr6:149768273	chr6:149863494~149919507:+
LUAD	cis	rs875971	0.893	rs62465470	ENSG00000232559.3	GS1-124K5.12	-5.15	3.8e-07	0.000106	-0.27	-0.23	Aortic root size;	chr7:66136231	chr7:66554588~66576923:-
LUAD	cis	rs673078	0.66	rs73205531	ENSG00000275409.1	RP11-131L12.4	-5.15	3.8e-07	0.000106	-0.33	-0.23	Glucose homeostasis traits;	chr12:118282063	chr12:118430147~118430699:+
LUAD	cis	rs9992667	0.955	rs28510735	ENSG00000231160.8	KLF3-AS1	5.15	3.8e-07	0.000106	0.28	0.23	Eosinophil percentage of granulocytes;	chr4:38612320	chr4:38612701~38664883:-
LUAD	cis	rs1318937	0.679	rs9849394	ENSG00000224660.1	SH3BP5-AS1	5.15	3.8e-07	0.000106	0.17	0.23	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15183135	chr3:15254184~15264493:+
LUAD	cis	rs6570726	0.791	rs13202312	ENSG00000235652.6	RP11-545I5.3	5.15	3.8e-07	0.000106	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145591957	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.791	rs7765675	ENSG00000235652.6	RP11-545I5.3	5.15	3.8e-07	0.000106	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145593941	chr6:145799409~145886585:+
LUAD	cis	rs17507216	0.628	rs4513065	ENSG00000255769.6	GOLGA2P10	-5.15	3.8e-07	0.000106	-0.3	-0.23	Excessive daytime sleepiness;	chr15:82712096	chr15:82472993~82513950:-
LUAD	cis	rs17684571	0.872	rs3002004	ENSG00000231441.1	RP11-472M19.2	5.15	3.8e-07	0.000106	0.32	0.23	Schizophrenia;	chr6:56743331	chr6:56844002~56864078:+
LUAD	cis	rs42490	0.966	rs39505	ENSG00000251136.7	RP11-37B2.1	-5.15	3.81e-07	0.000106	-0.24	-0.23	Leprosy;	chr8:89779838	chr8:89609409~89757727:-
LUAD	cis	rs42490	1	rs39506	ENSG00000251136.7	RP11-37B2.1	-5.15	3.81e-07	0.000106	-0.24	-0.23	Leprosy;	chr8:89779899	chr8:89609409~89757727:-
LUAD	cis	rs1113500	0.548	rs11185271	ENSG00000226822.1	RP11-356N1.2	5.15	3.81e-07	0.000106	0.32	0.23	Growth-regulated protein alpha levels;	chr1:108117311	chr1:108071482~108074519:+
LUAD	cis	rs875971	0.577	rs34888281	ENSG00000224316.1	RP11-479O9.2	-5.15	3.81e-07	0.000106	-0.23	-0.23	Aortic root size;	chr7:66120784	chr7:65773620~65802067:+
LUAD	cis	rs2032366	0.606	rs713485	ENSG00000267279.1	RP11-879F14.2	-5.15	3.81e-07	0.000106	-0.3	-0.23	Obesity-related traits;	chr18:61603692	chr18:61585746~61606916:-
LUAD	cis	rs42490	1	rs40545	ENSG00000251136.7	RP11-37B2.1	-5.15	3.81e-07	0.000106	-0.24	-0.23	Leprosy;	chr8:89777483	chr8:89609409~89757727:-
LUAD	cis	rs1799949	1	rs35668327	ENSG00000236383.6	LINC00854	-5.15	3.82e-07	0.000106	-0.18	-0.23	Menopause (age at onset);	chr17:43121078	chr17:43216941~43305976:-
LUAD	cis	rs6687821	0.635	rs494577	ENSG00000267734.1	RP4-604K5.3	5.15	3.82e-07	0.000106	0.27	0.23	Yeast infection;	chr1:86794394	chr1:86932199~86934891:-
LUAD	cis	rs896854	0.818	rs13262110	ENSG00000253528.2	RP11-347C18.4	5.15	3.82e-07	0.000106	0.22	0.23	Type 2 diabetes;	chr8:94914662	chr8:94974573~94974853:-
LUAD	cis	rs453301	0.631	rs11780774	ENSG00000253981.4	ALG1L13P	-5.15	3.82e-07	0.000106	-0.27	-0.23	Joint mobility (Beighton score);	chr8:8941601	chr8:8236003~8244667:-
LUAD	cis	rs2011013	0.6	rs17370572	ENSG00000259570.1	RP11-671M22.4	-5.15	3.82e-07	0.000106	-0.39	-0.23	Sitting height ratio;	chr15:83947961	chr15:84394512~84395514:+
LUAD	cis	rs1707322	0.686	rs2275085	ENSG00000280836.1	AL355480.1	5.15	3.82e-07	0.000106	0.3	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620180	chr1:45581219~45581321:-
LUAD	cis	rs4835473	0.932	rs4585249	ENSG00000251600.4	RP11-673E1.1	-5.15	3.82e-07	0.000106	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143981173	chr4:143912331~143982454:+
LUAD	cis	rs867371	1	rs11855089	ENSG00000276710.3	CSPG4P8	-5.15	3.82e-07	0.000106	-0.21	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82154924	chr15:82459472~82477258:+
LUAD	cis	rs1799949	1	rs4793194	ENSG00000236383.6	LINC00854	-5.15	3.82e-07	0.000106	-0.18	-0.23	Menopause (age at onset);	chr17:43066316	chr17:43216941~43305976:-
LUAD	cis	rs7927592	0.673	rs498782	ENSG00000212093.1	AP000807.1	5.15	3.82e-07	0.000106	0.23	0.23	Total body bone mineral density;	chr11:68508383	chr11:68506083~68506166:-
LUAD	cis	rs7674212	0.833	rs61075040	ENSG00000246560.2	RP11-10L12.4	5.15	3.82e-07	0.000107	0.3	0.23	Type 2 diabetes;	chr4:103052804	chr4:102828055~102844075:+
LUAD	cis	rs1707322	0.721	rs10430124	ENSG00000280836.1	AL355480.1	-5.15	3.82e-07	0.000107	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755945	chr1:45581219~45581321:-
LUAD	cis	rs287982	0.932	rs11887231	ENSG00000269973.1	RP11-95D17.1	-5.15	3.83e-07	0.000107	-0.28	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9826987	chr2:9936360~9939590:+
LUAD	cis	rs287982	1	rs13404815	ENSG00000269973.1	RP11-95D17.1	-5.15	3.83e-07	0.000107	-0.28	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9827637	chr2:9936360~9939590:+
LUAD	cis	rs287982	1	rs2656329	ENSG00000269973.1	RP11-95D17.1	-5.15	3.83e-07	0.000107	-0.28	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9828215	chr2:9936360~9939590:+
LUAD	cis	rs7017914	0.628	rs2279128	ENSG00000223220.1	Y_RNA	5.15	3.83e-07	0.000107	0.26	0.23	Bone mineral density;	chr8:70669324	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.583	rs1477943	ENSG00000223220.1	Y_RNA	5.15	3.83e-07	0.000107	0.26	0.23	Bone mineral density;	chr8:70670528	chr8:70780914~70781008:-
LUAD	cis	rs875971	0.755	rs76288834	ENSG00000232559.3	GS1-124K5.12	-5.15	3.83e-07	0.000107	-0.27	-0.23	Aortic root size;	chr7:66604815	chr7:66554588~66576923:-
LUAD	cis	rs73186030	0.546	rs55780469	ENSG00000272758.4	RP11-299J3.8	5.15	3.83e-07	0.000107	0.29	0.23	Serum parathyroid hormone levels;	chr3:122388590	chr3:122416207~122443180:+
LUAD	cis	rs910316	0.934	rs4903278	ENSG00000259138.1	RP11-950C14.7	5.15	3.83e-07	0.000107	0.24	0.23	Height;	chr14:75068316	chr14:75127153~75136930:+
LUAD	cis	rs2408955	0.501	rs8716	ENSG00000257735.1	RP11-370I10.6	5.15	3.83e-07	0.000107	0.27	0.23	Glycated hemoglobin levels;	chr12:48145699	chr12:48350945~48442411:+
LUAD	cis	rs1005277	0.579	rs1740735	ENSG00000263064.2	RP11-291L22.7	5.15	3.84e-07	0.000107	0.24	0.23	Extrinsic epigenetic age acceleration;	chr10:38208849	chr10:38448689~38448949:+
LUAD	cis	rs1062177	0.855	rs1346489	ENSG00000253921.1	CTB-113P19.3	-5.15	3.84e-07	0.000107	-0.32	-0.23	Preschool internalizing problems;	chr5:151886973	chr5:151753992~151767247:+
LUAD	cis	rs7246657	0.722	rs3095726	ENSG00000276846.1	CTD-3220F14.3	-5.15	3.84e-07	0.000107	-0.34	-0.23	Coronary artery calcification;	chr19:37738923	chr19:37314868~37315620:-
LUAD	cis	rs80028505	0.908	rs7766032	ENSG00000271304.1	DPRXP2	5.15	3.84e-07	0.000107	0.46	0.23	Foot ulcer in diabetes and neuropathy;	chr6:36101212	chr6:35989515~35990436:-
LUAD	cis	rs800160	0.72	rs2651791	ENSG00000236264.4	RPL26P30	-5.15	3.84e-07	0.000107	-0.3	-0.23	Bacteremia;	chr11:2337324	chr11:2335132~2335776:-
LUAD	cis	rs4835473	0.838	rs12507468	ENSG00000251600.4	RP11-673E1.1	-5.15	3.85e-07	0.000107	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143908061	chr4:143912331~143982454:+
LUAD	cis	rs9287719	0.601	rs10178751	ENSG00000243819.4	RN7SL832P	5.15	3.85e-07	0.000107	0.24	0.23	Prostate cancer;	chr2:10594077	chr2:10690344~10692099:+
LUAD	cis	rs4908760	0.827	rs10864362	ENSG00000270282.1	RP5-1115A15.2	5.15	3.85e-07	0.000107	0.25	0.23	Vitiligo;	chr1:8672395	chr1:8512653~8513021:+
LUAD	cis	rs35160687	0.623	rs13005014	ENSG00000273080.1	RP11-301O19.1	-5.15	3.85e-07	0.000107	-0.25	-0.23	Night sleep phenotypes;	chr2:86260093	chr2:86195590~86196049:+
LUAD	cis	rs35160687	0.644	rs1863056	ENSG00000273080.1	RP11-301O19.1	-5.15	3.85e-07	0.000107	-0.25	-0.23	Night sleep phenotypes;	chr2:86264122	chr2:86195590~86196049:+
LUAD	cis	rs1816752	0.905	rs7571	ENSG00000273628.1	RP11-756A22.7	5.15	3.85e-07	0.000107	0.26	0.23	Obesity-related traits;	chr13:24426479	chr13:24933006~24936796:+
LUAD	cis	rs875971	0.522	rs6960048	ENSG00000236529.1	RP13-254B10.1	5.15	3.85e-07	0.000107	0.23	0.23	Aortic root size;	chr7:65943052	chr7:65840212~65840596:+
LUAD	cis	rs6687821	0.515	rs2390215	ENSG00000267734.1	RP4-604K5.3	-5.15	3.86e-07	0.000107	-0.28	-0.23	Yeast infection;	chr1:87023130	chr1:86932199~86934891:-
LUAD	cis	rs71636778	0.509	rs34556682	ENSG00000260063.1	RP5-968P14.2	-5.15	3.86e-07	0.000107	-0.41	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26859658	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs34889971	ENSG00000260063.1	RP5-968P14.2	-5.15	3.86e-07	0.000107	-0.41	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26861566	chr1:26692132~26694131:-
LUAD	cis	rs7968440	0.736	rs7978559	ENSG00000200428.1	Y_RNA	-5.15	3.86e-07	0.000107	-0.3	-0.23	Fibrinogen;	chr12:50794855	chr12:50743568~50743684:+
LUAD	cis	rs7968440	0.808	rs7958114	ENSG00000200428.1	Y_RNA	-5.15	3.86e-07	0.000107	-0.3	-0.23	Fibrinogen;	chr12:50796909	chr12:50743568~50743684:+
LUAD	cis	rs9650657	0.504	rs10108347	ENSG00000255046.1	RP11-297N6.4	5.15	3.86e-07	0.000107	0.28	0.23	Neuroticism;	chr8:11176008	chr8:11797928~11802568:-
LUAD	cis	rs9650657	0.504	rs10109167	ENSG00000255046.1	RP11-297N6.4	5.15	3.86e-07	0.000107	0.28	0.23	Neuroticism;	chr8:11176016	chr8:11797928~11802568:-
LUAD	cis	rs80028505	1	rs7770183	ENSG00000271304.1	DPRXP2	5.15	3.86e-07	0.000107	0.46	0.23	Foot ulcer in diabetes and neuropathy;	chr6:36114796	chr6:35989515~35990436:-
LUAD	cis	rs80028505	0.908	rs56044978	ENSG00000271304.1	DPRXP2	5.15	3.86e-07	0.000107	0.46	0.23	Foot ulcer in diabetes and neuropathy;	chr6:36115327	chr6:35989515~35990436:-
LUAD	cis	rs6539288	0.933	rs10778513	ENSG00000260329.1	RP11-412D9.4	-5.15	3.87e-07	0.000108	-0.25	-0.23	Total body bone mineral density;	chr12:106908405	chr12:106954029~106955497:-
LUAD	cis	rs2522056	1	rs10900807	ENSG00000233006.5	AC034220.3	-5.15	3.87e-07	0.000108	-0.26	-0.23	Fibrinogen;Lymphocyte counts;	chr5:132421788	chr5:132311285~132369916:-
LUAD	cis	rs17301853	0.908	rs78683861	ENSG00000227373.4	RP11-160H22.5	5.15	3.87e-07	0.000108	0.45	0.23	Migraine without aura;Migraine - clinic-based;	chr1:174333802	chr1:174115300~174160004:-
LUAD	cis	rs875971	0.66	rs10950044	ENSG00000237310.1	GS1-124K5.4	-5.15	3.87e-07	0.000108	-0.24	-0.23	Aortic root size;	chr7:66577989	chr7:66493706~66495474:+
LUAD	cis	rs42490	1	rs402886	ENSG00000251136.7	RP11-37B2.1	-5.15	3.87e-07	0.000108	-0.24	-0.23	Leprosy;	chr8:89760272	chr8:89609409~89757727:-
LUAD	cis	rs42490	0.966	rs39500	ENSG00000251136.7	RP11-37B2.1	-5.15	3.87e-07	0.000108	-0.24	-0.23	Leprosy;	chr8:89760437	chr8:89609409~89757727:-
LUAD	cis	rs42490	0.966	rs39761	ENSG00000251136.7	RP11-37B2.1	-5.15	3.87e-07	0.000108	-0.24	-0.23	Leprosy;	chr8:89760692	chr8:89609409~89757727:-
LUAD	cis	rs42490	0.934	rs43225	ENSG00000251136.7	RP11-37B2.1	-5.15	3.87e-07	0.000108	-0.24	-0.23	Leprosy;	chr8:89760776	chr8:89609409~89757727:-
LUAD	cis	rs42490	0.966	rs39503	ENSG00000251136.7	RP11-37B2.1	-5.15	3.87e-07	0.000108	-0.24	-0.23	Leprosy;	chr8:89767579	chr8:89609409~89757727:-
LUAD	cis	rs42490	1	rs447618	ENSG00000251136.7	RP11-37B2.1	-5.15	3.87e-07	0.000108	-0.24	-0.23	Leprosy;	chr8:89773457	chr8:89609409~89757727:-
LUAD	cis	rs875971	0.66	rs10215132	ENSG00000237310.1	GS1-124K5.4	-5.15	3.87e-07	0.000108	-0.24	-0.23	Aortic root size;	chr7:66589419	chr7:66493706~66495474:+
LUAD	cis	rs75422866	0.51	rs73105803	ENSG00000257433.4	RP1-197B17.3	5.15	3.87e-07	0.000108	0.48	0.23	Pneumonia;	chr12:47722135	chr12:47706085~47742294:+
LUAD	cis	rs8127691	0.935	rs2876932	ENSG00000237604.1	AP001056.1	5.15	3.87e-07	0.000108	0.27	0.23	Inflammatory bowel disease;	chr21:44198653	chr21:44175489~44176453:+
LUAD	cis	rs9584850	0.834	rs3803253	ENSG00000231194.1	FARP1-AS1	5.15	3.88e-07	0.000108	0.28	0.23	Neuroticism;	chr13:98464895	chr13:98435405~98435840:-
LUAD	cis	rs950169	0.544	rs12913702	ENSG00000275120.1	RP11-182J1.17	5.15	3.88e-07	0.000108	0.35	0.23	Schizophrenia;	chr15:84609953	chr15:84599434~84606463:-
LUAD	cis	rs950169	0.509	rs71395455	ENSG00000275120.1	RP11-182J1.17	5.15	3.88e-07	0.000108	0.35	0.23	Schizophrenia;	chr15:84610573	chr15:84599434~84606463:-
LUAD	cis	rs12928939	0.815	rs7185575	ENSG00000260886.1	TAT-AS1	5.15	3.88e-07	0.000108	0.28	0.23	Post bronchodilator FEV1;	chr16:71638666	chr16:71565789~71578187:+
LUAD	cis	rs1823913	0.538	rs6732537	ENSG00000280083.1	RP11-317J9.1	-5.15	3.88e-07	0.000108	-0.28	-0.23	Obesity-related traits;	chr2:191346755	chr2:191154118~191156070:-
LUAD	cis	rs1150668	0.796	rs2247002	ENSG00000219392.1	RP1-265C24.5	-5.15	3.88e-07	0.000108	-0.28	-0.23	Pubertal anthropometrics;	chr6:28430174	chr6:28115628~28116551:+
LUAD	cis	rs30380	1	rs30378	ENSG00000272109.1	CTD-2260A17.3	-5.15	3.89e-07	0.000108	-0.25	-0.23	Cerebrospinal fluid biomarker levels;	chr5:96786290	chr5:96804353~96806105:+
LUAD	cis	rs11763147	1	rs11763147	ENSG00000236529.1	RP13-254B10.1	-5.15	3.89e-07	0.000108	-0.23	-0.23	Corneal structure;	chr7:65861834	chr7:65840212~65840596:+
LUAD	cis	rs453301	0.605	rs7843024	ENSG00000253981.4	ALG1L13P	-5.15	3.89e-07	0.000108	-0.27	-0.23	Joint mobility (Beighton score);	chr8:8942466	chr8:8236003~8244667:-
LUAD	cis	rs4143844	0.867	rs62007764	ENSG00000259251.2	RP11-643M14.1	5.15	3.89e-07	0.000108	0.4	0.23	Bipolar disorder and schizophrenia;	chr15:61948855	chr15:62060503~62062434:+
LUAD	cis	rs4143844	0.867	rs12912477	ENSG00000259251.2	RP11-643M14.1	5.15	3.89e-07	0.000108	0.4	0.23	Bipolar disorder and schizophrenia;	chr15:61949909	chr15:62060503~62062434:+
LUAD	cis	rs7937890	0.559	rs2575837	ENSG00000251991.1	RNU7-49P	5.15	3.89e-07	0.000108	0.24	0.23	Mitochondrial DNA levels;	chr11:14476455	chr11:14478892~14478953:+
LUAD	cis	rs7937890	0.559	rs2575838	ENSG00000251991.1	RNU7-49P	5.15	3.89e-07	0.000108	0.24	0.23	Mitochondrial DNA levels;	chr11:14476675	chr11:14478892~14478953:+
LUAD	cis	rs7937890	0.559	rs2167160	ENSG00000251991.1	RNU7-49P	5.15	3.89e-07	0.000108	0.24	0.23	Mitochondrial DNA levels;	chr11:14485903	chr11:14478892~14478953:+
LUAD	cis	rs7937890	0.559	rs2597217	ENSG00000251991.1	RNU7-49P	5.15	3.89e-07	0.000108	0.24	0.23	Mitochondrial DNA levels;	chr11:14511337	chr11:14478892~14478953:+
LUAD	cis	rs1799949	0.965	rs12950779	ENSG00000236383.6	LINC00854	-5.15	3.89e-07	0.000108	-0.19	-0.23	Menopause (age at onset);	chr17:43154506	chr17:43216941~43305976:-
LUAD	cis	rs2286503	0.78	rs1304431	ENSG00000226329.2	AC005682.6	5.15	3.89e-07	0.000108	0.3	0.23	Fibrinogen;	chr7:22825793	chr7:22863874~22881350:-
LUAD	cis	rs8031584	0.872	rs11634761	ENSG00000270015.1	RP11-540B6.6	-5.15	3.9e-07	0.000108	-0.17	-0.23	Huntington's disease progression;	chr15:30950970	chr15:30926514~30928407:+
LUAD	cis	rs1816752	0.87	rs9318529	ENSG00000273628.1	RP11-756A22.7	5.15	3.9e-07	0.000108	0.26	0.23	Obesity-related traits;	chr13:24424190	chr13:24933006~24936796:+
LUAD	cis	rs11051970	0.559	rs4316592	ENSG00000274964.1	RP11-817I4.1	-5.15	3.9e-07	0.000108	-0.3	-0.23	Response to tocilizumab in rheumatoid arthritis;	chr12:32331076	chr12:32339368~32340724:+
LUAD	cis	rs7116495	1	rs7103210	ENSG00000254682.1	RP11-660L16.2	5.15	3.9e-07	0.000108	0.46	0.23	Severe influenza A (H1N1) infection;	chr11:71937920	chr11:71448674~71452157:+
LUAD	cis	rs6095360	0.727	rs35393280	ENSG00000222365.1	SNORD12B	-5.15	3.9e-07	0.000108	-0.26	-0.23	Intelligence (multi-trait analysis);	chr20:48927097	chr20:49280319~49280409:+
LUAD	cis	rs1823874	0.677	rs56096943	ENSG00000182397.13	DNM1P46	-5.14	3.9e-07	0.000109	-0.29	-0.23	IgG glycosylation;	chr15:99820513	chr15:99790156~99806927:-
LUAD	cis	rs2933343	0.649	rs728839	ENSG00000261159.1	RP11-723O4.9	5.14	3.91e-07	0.000109	0.25	0.23	IgG glycosylation;	chr3:128870516	chr3:128859716~128860526:-
LUAD	cis	rs62432291	0.681	rs1699442	ENSG00000235086.1	FNDC1-IT1	5.14	3.91e-07	0.000109	0.39	0.23	Joint mobility (Beighton score);	chr6:159234886	chr6:159240786~159243329:+
LUAD	cis	rs2243480	1	rs160634	ENSG00000232546.1	RP11-458F8.1	5.14	3.91e-07	0.000109	0.28	0.23	Diabetic kidney disease;	chr7:66063677	chr7:66848496~66858136:+
LUAD	cis	rs2880765	0.835	rs7174323	ENSG00000259295.5	CSPG4P12	5.14	3.91e-07	0.000109	0.26	0.23	Coronary artery disease;	chr15:85506488	chr15:85191438~85213905:+
LUAD	cis	rs74233809	1	rs3740390	ENSG00000213277.3	MARCKSL1P1	5.14	3.91e-07	0.000109	0.36	0.23	Birth weight;	chr10:102878723	chr10:103175554~103176094:+
LUAD	cis	rs2765539	0.887	rs1325933	ENSG00000226172.2	RP4-712E4.1	-5.14	3.91e-07	0.000109	-0.29	-0.23	Waist-hip ratio;	chr1:119013136	chr1:119000344~119001392:-
LUAD	cis	rs7567389	0.583	rs11683427	ENSG00000236682.1	AC068282.3	-5.14	3.91e-07	0.000109	-0.33	-0.23	Self-rated health;	chr2:127198967	chr2:127389130~127400580:+
LUAD	cis	rs71520386	0.632	rs2286500	ENSG00000228649.7	AC005682.5	-5.14	3.91e-07	0.000109	-0.31	-0.23	Fibrinogen levels;	chr7:22817185	chr7:22854178~22861579:+
LUAD	cis	rs2548724	0.587	rs59399361	ENSG00000250682.4	LINC00491	5.14	3.92e-07	0.000109	0.27	0.23	Type 2 diabetes;	chr5:102413414	chr5:102609156~102671559:-
LUAD	cis	rs4604732	0.527	rs60444724	ENSG00000227135.1	GCSAML-AS1	-5.14	3.92e-07	0.000109	-0.36	-0.23	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247459862	chr1:247524679~247526752:-
LUAD	cis	rs12554020	0.786	rs12553389	ENSG00000227603.1	RP11-165J3.6	5.14	3.92e-07	0.000109	0.43	0.23	Schizophrenia;	chr9:93500979	chr9:93435332~93437121:-
LUAD	cis	rs12554020	0.786	rs78865387	ENSG00000227603.1	RP11-165J3.6	5.14	3.92e-07	0.000109	0.43	0.23	Schizophrenia;	chr9:93501827	chr9:93435332~93437121:-
LUAD	cis	rs17826219	0.636	rs4055314	ENSG00000263603.1	CTD-2349P21.5	-5.14	3.92e-07	0.000109	-0.41	-0.23	Body mass index;	chr17:30752751	chr17:30729469~30731202:+
LUAD	cis	rs17507216	0.718	rs72751675	ENSG00000255769.6	GOLGA2P10	-5.14	3.92e-07	0.000109	-0.3	-0.23	Excessive daytime sleepiness;	chr15:82630452	chr15:82472993~82513950:-
LUAD	cis	rs3738443	0.868	rs2892054	ENSG00000259865.1	RP11-488L18.10	5.14	3.92e-07	0.000109	0.24	0.23	Alcohol dependence;	chr1:247203803	chr1:247187281~247188526:-
LUAD	cis	rs6700559	0.692	rs4915447	ENSG00000260088.1	RP11-92G12.3	5.14	3.92e-07	0.000109	0.28	0.23	Coronary artery disease;	chr1:200624340	chr1:200669507~200694250:+
LUAD	cis	rs948562	0.947	rs2186381	ENSG00000280010.1	AP001350.4	5.14	3.92e-07	0.000109	0.34	0.23	Lymphoma;	chr11:58630320	chr11:58627435~58628528:+
LUAD	cis	rs944289	0.6	rs2774166	ENSG00000257826.1	RP11-116N8.4	5.14	3.93e-07	0.000109	0.24	0.23	Thyroid cancer;	chr14:36169449	chr14:36061026~36067190:-
LUAD	cis	rs11051970	0.559	rs11051941	ENSG00000274964.1	RP11-817I4.1	-5.14	3.93e-07	0.000109	-0.3	-0.23	Response to tocilizumab in rheumatoid arthritis;	chr12:32330338	chr12:32339368~32340724:+
LUAD	cis	rs11051970	0.559	rs11051942	ENSG00000274964.1	RP11-817I4.1	-5.14	3.93e-07	0.000109	-0.3	-0.23	Response to tocilizumab in rheumatoid arthritis;	chr12:32330344	chr12:32339368~32340724:+
LUAD	cis	rs7181230	1	rs28587891	ENSG00000275636.1	RP11-521C20.5	5.14	3.93e-07	0.000109	0.28	0.23	Dehydroepiandrosterone sulphate levels;	chr15:40072905	chr15:40078892~40079347:+
LUAD	cis	rs13113518	0.783	rs12504300	ENSG00000223305.1	RN7SKP30	5.14	3.93e-07	0.000109	0.28	0.23	Height;	chr4:55482360	chr4:55540502~55540835:-
LUAD	cis	rs897984	0.806	rs1458202	ENSG00000260911.2	RP11-196G11.2	5.14	3.94e-07	0.000109	0.2	0.23	Dementia with Lewy bodies;	chr16:30941881	chr16:31043150~31049868:+
LUAD	cis	rs17711722	0.565	rs4717276	ENSG00000234585.5	CCT6P3	5.14	3.94e-07	0.000109	0.21	0.23	Calcium levels;	chr7:65829754	chr7:65038354~65074713:+
LUAD	cis	rs36093844	0.706	rs2084080	ENSG00000279742.1	RP11-700A24.1	-5.14	3.95e-07	0.00011	-0.33	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85879322	chr11:85852557~85854943:-
LUAD	cis	rs2243480	0.803	rs160649	ENSG00000230295.1	RP11-458F8.2	-5.14	3.95e-07	0.00011	-0.27	-0.23	Diabetic kidney disease;	chr7:66078212	chr7:66880708~66882981:+
LUAD	cis	rs2243480	1	rs160648	ENSG00000230295.1	RP11-458F8.2	-5.14	3.95e-07	0.00011	-0.27	-0.23	Diabetic kidney disease;	chr7:66078397	chr7:66880708~66882981:+
LUAD	cis	rs9487094	0.961	rs1040284	ENSG00000260273.1	RP11-425D10.10	5.14	3.95e-07	0.00011	0.31	0.23	Height;	chr6:109352730	chr6:109382795~109383666:+
LUAD	cis	rs7017914	0.69	rs17699455	ENSG00000223220.1	Y_RNA	5.14	3.95e-07	0.00011	0.26	0.23	Bone mineral density;	chr8:71060138	chr8:70780914~70781008:-
LUAD	cis	rs73242632	0.881	rs17182939	ENSG00000269949.1	RP11-738E22.3	5.14	3.95e-07	0.00011	0.56	0.23	Congenital heart disease (maternal effect);	chr4:57060625	chr4:56960927~56961373:-
LUAD	cis	rs11105298	0.891	rs3825330	ENSG00000258302.2	RP11-981P6.1	5.14	3.96e-07	0.00011	0.29	0.23	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539933	chr12:89561129~89594878:+
LUAD	cis	rs12530	0.715	rs2294314	ENSG00000230736.2	RP1-149A16.3	-5.14	3.96e-07	0.00011	-0.25	-0.23	IgG glycosylation;	chr22:32398616	chr22:32376664~32384343:+
LUAD	cis	rs4604732	0.631	rs1106719	ENSG00000227135.1	GCSAML-AS1	5.14	3.96e-07	0.00011	0.36	0.23	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247461411	chr1:247524679~247526752:-
LUAD	cis	rs948562	0.681	rs10750901	ENSG00000280010.1	AP001350.4	5.14	3.96e-07	0.00011	0.32	0.23	Lymphoma;	chr11:58660110	chr11:58627435~58628528:+
LUAD	cis	rs9322193	0.566	rs6912330	ENSG00000223701.3	RAET1E-AS1	-5.14	3.96e-07	0.00011	-0.32	-0.23	Lung cancer;	chr6:149908811	chr6:149884431~149919508:+
LUAD	cis	rs673078	0.66	rs7973455	ENSG00000275409.1	RP11-131L12.4	-5.14	3.96e-07	0.00011	-0.32	-0.23	Glucose homeostasis traits;	chr12:118247490	chr12:118430147~118430699:+
LUAD	cis	rs1065852	0.51	rs5758666	ENSG00000227370.1	RP4-669P10.19	5.14	3.97e-07	0.00011	0.24	0.23	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42236827	chr22:42132543~42132998:+
LUAD	cis	rs9322193	0.607	rs12527391	ENSG00000223701.3	RAET1E-AS1	5.14	3.97e-07	0.00011	0.33	0.23	Lung cancer;	chr6:149882156	chr6:149884431~149919508:+
LUAD	cis	rs9595908	0.746	rs9591222	ENSG00000212293.1	SNORA16	5.14	3.97e-07	0.00011	0.25	0.23	Body mass index;	chr13:32653261	chr13:32420390~32420516:-
LUAD	cis	rs4664293	0.967	rs1006192	ENSG00000226266.5	AC009961.3	-5.14	3.97e-07	0.00011	-0.32	-0.23	Monocyte percentage of white cells;	chr2:159711078	chr2:159670708~159712435:-
LUAD	cis	rs889398	0.874	rs2917677	ENSG00000226232.7	RP11-419C5.2	5.14	3.97e-07	0.00011	0.19	0.23	Body mass index;	chr16:69716946	chr16:69976388~69996188:-
LUAD	cis	rs11742741	0.714	rs1428203	ENSG00000248874.4	C5orf17	-5.14	3.97e-07	0.00011	-0.29	-0.23	Educational attainment;	chr5:24164504	chr5:23951348~24178263:+
LUAD	cis	rs2933343	0.909	rs1683817	ENSG00000261159.1	RP11-723O4.9	5.14	3.97e-07	0.00011	0.28	0.23	IgG glycosylation;	chr3:128932693	chr3:128859716~128860526:-
LUAD	cis	rs1075265	0.54	rs2542587	ENSG00000233266.1	HMGB1P31	5.14	3.97e-07	0.00011	0.29	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53788839	chr2:54051334~54051760:+
LUAD	cis	rs1075265	0.563	rs2692537	ENSG00000233266.1	HMGB1P31	5.14	3.97e-07	0.00011	0.29	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53788840	chr2:54051334~54051760:+
LUAD	cis	rs10129255	0.536	rs6576201	ENSG00000254174.1	IGHV1-12	-5.14	3.97e-07	0.00011	-0.15	-0.23	Kawasaki disease;	chr14:106683696	chr14:106122420~106122709:-
LUAD	cis	rs55665837	0.502	rs12795794	ENSG00000251991.1	RNU7-49P	5.14	3.98e-07	0.00011	0.26	0.23	Vitamin D levels;	chr11:14825327	chr11:14478892~14478953:+
LUAD	cis	rs10129255	0.5	rs1024350	ENSG00000254174.1	IGHV1-12	5.14	3.98e-07	0.00011	0.15	0.23	Kawasaki disease;	chr14:106685105	chr14:106122420~106122709:-
LUAD	cis	rs7937890	0.559	rs2575836	ENSG00000251991.1	RNU7-49P	5.14	3.98e-07	0.000111	0.24	0.23	Mitochondrial DNA levels;	chr11:14476318	chr11:14478892~14478953:+
LUAD	cis	rs7937890	0.531	rs2575859	ENSG00000251991.1	RNU7-49P	5.14	3.98e-07	0.000111	0.24	0.23	Mitochondrial DNA levels;	chr11:14489190	chr11:14478892~14478953:+
LUAD	cis	rs7937890	0.559	rs2597188	ENSG00000251991.1	RNU7-49P	5.14	3.98e-07	0.000111	0.24	0.23	Mitochondrial DNA levels;	chr11:14495360	chr11:14478892~14478953:+
LUAD	cis	rs7937890	0.504	rs2575822	ENSG00000251991.1	RNU7-49P	5.14	3.98e-07	0.000111	0.24	0.23	Mitochondrial DNA levels;	chr11:14498305	chr11:14478892~14478953:+
LUAD	cis	rs7937890	0.559	rs2575823	ENSG00000251991.1	RNU7-49P	5.14	3.98e-07	0.000111	0.24	0.23	Mitochondrial DNA levels;	chr11:14499808	chr11:14478892~14478953:+
LUAD	cis	rs7937890	0.559	rs2597221	ENSG00000251991.1	RNU7-49P	5.14	3.98e-07	0.000111	0.24	0.23	Mitochondrial DNA levels;	chr11:14505529	chr11:14478892~14478953:+
LUAD	cis	rs7937890	0.559	rs6486197	ENSG00000251991.1	RNU7-49P	5.14	3.98e-07	0.000111	0.24	0.23	Mitochondrial DNA levels;	chr11:14508328	chr11:14478892~14478953:+
LUAD	cis	rs7937890	0.559	rs2597219	ENSG00000251991.1	RNU7-49P	5.14	3.98e-07	0.000111	0.24	0.23	Mitochondrial DNA levels;	chr11:14509320	chr11:14478892~14478953:+
LUAD	cis	rs7937890	0.559	rs2575852	ENSG00000251991.1	RNU7-49P	5.14	3.98e-07	0.000111	0.24	0.23	Mitochondrial DNA levels;	chr11:14511822	chr11:14478892~14478953:+
LUAD	cis	rs7937890	0.531	rs2597216	ENSG00000251991.1	RNU7-49P	5.14	3.98e-07	0.000111	0.24	0.23	Mitochondrial DNA levels;	chr11:14512370	chr11:14478892~14478953:+
LUAD	cis	rs7937890	0.559	rs1548074	ENSG00000251991.1	RNU7-49P	5.14	3.98e-07	0.000111	0.24	0.23	Mitochondrial DNA levels;	chr11:14513279	chr11:14478892~14478953:+
LUAD	cis	rs7937890	0.561	rs2575849	ENSG00000251991.1	RNU7-49P	5.14	3.98e-07	0.000111	0.24	0.23	Mitochondrial DNA levels;	chr11:14518093	chr11:14478892~14478953:+
LUAD	cis	rs2072438	0.503	rs2146838	ENSG00000226752.6	PSMD5-AS1	5.14	3.99e-07	0.000111	0.24	0.23	Rheumatoid arthritis;	chr9:121114027	chr9:120824828~120854385:+
LUAD	cis	rs9487094	0.813	rs12524502	ENSG00000260273.1	RP11-425D10.10	5.14	3.99e-07	0.000111	0.32	0.23	Height;	chr6:109333018	chr6:109382795~109383666:+
LUAD	cis	rs875971	0.862	rs10256544	ENSG00000237310.1	GS1-124K5.4	5.14	3.99e-07	0.000111	0.25	0.23	Aortic root size;	chr7:66210141	chr7:66493706~66495474:+
LUAD	cis	rs10246939	0.505	rs12703409	ENSG00000228775.6	WEE2-AS1	5.14	3.99e-07	0.000111	0.29	0.23	Bitter taste perception;	chr7:141812058	chr7:141704338~141738346:-
LUAD	cis	rs9487094	0.813	rs13203252	ENSG00000260273.1	RP11-425D10.10	5.14	3.99e-07	0.000111	0.32	0.23	Height;	chr6:109351533	chr6:109382795~109383666:+
LUAD	cis	rs2790457	1	rs2790457	ENSG00000254635.4	WAC-AS1	-5.14	3.99e-07	0.000111	-0.25	-0.23	Multiple myeloma;	chr10:28567890	chr10:28522652~28532743:-
LUAD	cis	rs442309	0.553	rs10995299	ENSG00000238280.1	RP11-436D10.3	-5.14	3.99e-07	0.000111	-0.29	-0.23	Vogt-Koyanagi-Harada syndrome;	chr10:62744443	chr10:62793562~62805887:-
LUAD	cis	rs897984	0.683	rs72799316	ENSG00000232748.3	RP11-196G11.6	-5.14	3.99e-07	0.000111	-0.28	-0.23	Dementia with Lewy bodies;	chr16:30815884	chr16:31056460~31062803:+
LUAD	cis	rs1062177	1	rs2964578	ENSG00000253921.1	CTB-113P19.3	-5.14	3.99e-07	0.000111	-0.34	-0.23	Preschool internalizing problems;	chr5:151767637	chr5:151753992~151767247:+
LUAD	cis	rs6687821	0.689	rs372830	ENSG00000267734.1	RP4-604K5.3	5.14	4e-07	0.000111	0.27	0.23	Yeast infection;	chr1:86739569	chr1:86932199~86934891:-
LUAD	cis	rs6687821	0.689	rs372828	ENSG00000267734.1	RP4-604K5.3	5.14	4e-07	0.000111	0.27	0.23	Yeast infection;	chr1:86739570	chr1:86932199~86934891:-
LUAD	cis	rs1345301	0.518	rs2110661	ENSG00000234389.1	AC007278.3	-5.14	4e-07	0.000111	-0.22	-0.23	Waist circumference;	chr2:102246761	chr2:102438713~102440475:+
LUAD	cis	rs1005277	0.579	rs2800485	ENSG00000263064.2	RP11-291L22.7	5.14	4e-07	0.000111	0.25	0.23	Extrinsic epigenetic age acceleration;	chr10:38253660	chr10:38448689~38448949:+
LUAD	cis	rs7829975	0.591	rs12677543	ENSG00000253893.2	FAM85B	-5.14	4e-07	0.000111	-0.29	-0.23	Mood instability;	chr8:8786764	chr8:8167819~8226614:-
LUAD	cis	rs11051970	0.559	rs11051940	ENSG00000274964.1	RP11-817I4.1	-5.14	4e-07	0.000111	-0.29	-0.23	Response to tocilizumab in rheumatoid arthritis;	chr12:32330187	chr12:32339368~32340724:+
LUAD	cis	rs2337406	0.925	rs11851094	ENSG00000223648.3	IGHV3-64	5.14	4.01e-07	0.000111	0.28	0.23	Alzheimer's disease (late onset);	chr14:106688967	chr14:106643132~106658258:-
LUAD	cis	rs6088590	1	rs2378256	ENSG00000276073.1	RP5-1125A11.7	-5.14	4.01e-07	0.000111	-0.23	-0.23	Coronary artery disease;	chr20:34704323	chr20:33985617~33988989:-
LUAD	cis	rs6088590	0.965	rs910869	ENSG00000276073.1	RP5-1125A11.7	-5.14	4.01e-07	0.000111	-0.23	-0.23	Coronary artery disease;	chr20:34704973	chr20:33985617~33988989:-
LUAD	cis	rs1707322	0.752	rs11211168	ENSG00000280836.1	AL355480.1	-5.14	4.01e-07	0.000111	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697975	chr1:45581219~45581321:-
LUAD	cis	rs7120173	0.915	rs12786797	ENSG00000254851.1	RP11-109L13.1	-5.14	4.01e-07	0.000111	-0.36	-0.23	Visceral adipose tissue adjusted for BMI;	chr11:117017035	chr11:117135528~117138582:+
LUAD	cis	rs875971	0.964	rs697969	ENSG00000237310.1	GS1-124K5.4	-5.14	4.01e-07	0.000111	-0.25	-0.23	Aortic root size;	chr7:66093491	chr7:66493706~66495474:+
LUAD	cis	rs875971	1	rs1182882	ENSG00000237310.1	GS1-124K5.4	-5.14	4.01e-07	0.000111	-0.25	-0.23	Aortic root size;	chr7:66097076	chr7:66493706~66495474:+
LUAD	cis	rs7829975	0.617	rs4841071	ENSG00000253893.2	FAM85B	-5.14	4.02e-07	0.000111	-0.28	-0.23	Mood instability;	chr8:8933634	chr8:8167819~8226614:-
LUAD	cis	rs712039	0.652	rs866465	ENSG00000276054.1	RP11-378E13.3	5.14	4.02e-07	0.000111	0.35	0.23	Tuberculosis;	chr17:37499298	chr17:37386886~37387926:+
LUAD	cis	rs2032366	0.967	rs9965804	ENSG00000267279.1	RP11-879F14.2	-5.14	4.02e-07	0.000111	-0.28	-0.23	Obesity-related traits;	chr18:61602021	chr18:61585746~61606916:-
LUAD	cis	rs7772486	0.754	rs857881	ENSG00000235652.6	RP11-545I5.3	-5.14	4.02e-07	0.000112	-0.23	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145649657	chr6:145799409~145886585:+
LUAD	cis	rs17684571	0.751	rs16888184	ENSG00000231441.1	RP11-472M19.2	5.14	4.02e-07	0.000112	0.34	0.23	Schizophrenia;	chr6:56861347	chr6:56844002~56864078:+
LUAD	cis	rs75422866	0.51	rs73104197	ENSG00000257433.4	RP1-197B17.3	5.14	4.02e-07	0.000112	0.48	0.23	Pneumonia;	chr12:47717273	chr12:47706085~47742294:+
LUAD	cis	rs9487094	0.744	rs2275652	ENSG00000260273.1	RP11-425D10.10	5.14	4.02e-07	0.000112	0.32	0.23	Height;	chr6:109382480	chr6:109382795~109383666:+
LUAD	cis	rs9928842	0.765	rs6564223	ENSG00000280152.1	RP11-331F4.5	5.14	4.03e-07	0.000112	0.27	0.23	Alcoholic chronic pancreatitis;	chr16:75192001	chr16:75245994~75250077:-
LUAD	cis	rs9584850	0.834	rs7339274	ENSG00000231194.1	FARP1-AS1	-5.14	4.03e-07	0.000112	-0.28	-0.23	Neuroticism;	chr13:98468018	chr13:98435405~98435840:-
LUAD	cis	rs897984	0.762	rs7204459	ENSG00000260911.2	RP11-196G11.2	-5.14	4.03e-07	0.000112	-0.2	-0.23	Dementia with Lewy bodies;	chr16:30972891	chr16:31043150~31049868:+
LUAD	cis	rs7119038	0.509	rs11216960	ENSG00000255422.1	AP002954.4	5.14	4.03e-07	0.000112	0.35	0.23	Sjögren's syndrome;	chr11:118707164	chr11:118704607~118750263:+
LUAD	cis	rs7119038	0.509	rs10892256	ENSG00000255422.1	AP002954.4	5.14	4.03e-07	0.000112	0.35	0.23	Sjögren's syndrome;	chr11:118707996	chr11:118704607~118750263:+
LUAD	cis	rs7119038	0.509	rs10892257	ENSG00000255422.1	AP002954.4	5.14	4.03e-07	0.000112	0.35	0.23	Sjögren's syndrome;	chr11:118708618	chr11:118704607~118750263:+
LUAD	cis	rs7119038	0.509	rs11216961	ENSG00000255422.1	AP002954.4	5.14	4.03e-07	0.000112	0.35	0.23	Sjögren's syndrome;	chr11:118709629	chr11:118704607~118750263:+
LUAD	cis	rs4964805	0.954	rs10861105	ENSG00000257681.1	RP11-341G23.4	5.14	4.04e-07	0.000112	0.27	0.23	Attention deficit hyperactivity disorder;	chr12:103796221	chr12:103746315~103768858:-
LUAD	cis	rs2732480	0.5	rs2450986	ENSG00000257735.1	RP11-370I10.6	5.14	4.04e-07	0.000112	0.28	0.23	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48267905	chr12:48350945~48442411:+
LUAD	cis	rs7829975	0.714	rs4841040	ENSG00000253893.2	FAM85B	-5.14	4.04e-07	0.000112	-0.29	-0.23	Mood instability;	chr8:8797017	chr8:8167819~8226614:-
LUAD	cis	rs875971	0.619	rs10278371	ENSG00000237310.1	GS1-124K5.4	-5.14	4.04e-07	0.000112	-0.24	-0.23	Aortic root size;	chr7:66586553	chr7:66493706~66495474:+
LUAD	cis	rs1707322	0.826	rs10890349	ENSG00000280836.1	AL355480.1	-5.14	4.04e-07	0.000112	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784283	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.758	rs10789474	ENSG00000280836.1	AL355480.1	-5.14	4.04e-07	0.000112	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784368	chr1:45581219~45581321:-
LUAD	cis	rs10246939	0.511	rs62475469	ENSG00000228775.6	WEE2-AS1	5.14	4.05e-07	0.000112	0.28	0.23	Bitter taste perception;	chr7:141864846	chr7:141704338~141738346:-
LUAD	cis	rs1032726	0.617	rs7432373	ENSG00000242770.2	RP11-180K7.1	-5.14	4.05e-07	0.000112	-0.26	-0.23	Sum eosinophil basophil counts;Eosinophil counts;	chr3:112927852	chr3:112802478~112812819:+
LUAD	cis	rs7968440	1	rs66644594	ENSG00000200428.1	Y_RNA	-5.14	4.05e-07	0.000112	-0.29	-0.23	Fibrinogen;	chr12:50539200	chr12:50743568~50743684:+
LUAD	cis	rs55665837	0.54	rs12788030	ENSG00000251991.1	RNU7-49P	5.14	4.05e-07	0.000112	0.26	0.23	Vitamin D levels;	chr11:14743138	chr11:14478892~14478953:+
LUAD	cis	rs11023332	0.832	rs10832289	ENSG00000251991.1	RNU7-49P	-5.14	4.06e-07	0.000112	-0.25	-0.23	Vitamin D levels;Adiponectin levels;	chr11:14647950	chr11:14478892~14478953:+
LUAD	cis	rs1816752	0.638	rs9578730	ENSG00000273628.1	RP11-756A22.7	5.14	4.06e-07	0.000112	0.26	0.23	Obesity-related traits;	chr13:24425545	chr13:24933006~24936796:+
LUAD	cis	rs875971	0.522	rs10807697	ENSG00000164669.11	INTS4P1	-5.14	4.06e-07	0.000112	-0.27	-0.23	Aortic root size;	chr7:65951183	chr7:65141225~65234216:+
LUAD	cis	rs9341808	0.528	rs2322753	ENSG00000272129.1	RP11-250B2.6	5.14	4.06e-07	0.000113	0.28	0.23	Sitting height ratio;	chr6:80333148	chr6:80355424~80356859:+
LUAD	cis	rs6687821	0.515	rs2390220	ENSG00000267734.1	RP4-604K5.3	-5.14	4.06e-07	0.000113	-0.27	-0.23	Yeast infection;	chr1:86989235	chr1:86932199~86934891:-
LUAD	cis	rs71636778	0.509	rs17162311	ENSG00000260063.1	RP5-968P14.2	5.14	4.06e-07	0.000113	0.39	0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26848475	chr1:26692132~26694131:-
LUAD	cis	rs875971	0.862	rs4368860	ENSG00000232559.3	GS1-124K5.12	-5.14	4.06e-07	0.000113	-0.27	-0.23	Aortic root size;	chr7:66143495	chr7:66554588~66576923:-
LUAD	cis	rs17826219	0.706	rs609472	ENSG00000263531.1	RP13-753N3.1	5.14	4.07e-07	0.000113	0.38	0.23	Body mass index;	chr17:30624409	chr17:30863921~30864940:-
LUAD	cis	rs7924176	0.601	rs1874152	ENSG00000213731.2	RAB5CP1	-5.14	4.07e-07	0.000113	-0.24	-0.23	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74076361	chr10:74423435~74424014:-
LUAD	cis	rs34375054	0.66	rs900411	ENSG00000279233.1	RP11-158L12.4	5.14	4.07e-07	0.000113	0.2	0.23	Post bronchodilator FEV1/FVC ratio;	chr12:125128293	chr12:125138245~125141711:+
LUAD	cis	rs36093844	0.898	rs12363602	ENSG00000279742.1	RP11-700A24.1	-5.14	4.07e-07	0.000113	-0.27	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85885358	chr11:85852557~85854943:-
LUAD	cis	rs2946504	0.861	rs2977085	ENSG00000251468.2	RP11-369K16.1	-5.14	4.07e-07	0.000113	-0.29	-0.23	Type 2 diabetes;	chr8:12956237	chr8:12958387~12962200:+
LUAD	cis	rs11976180	1	rs1533266	ENSG00000204959.4	ARHGEF34P	5.14	4.07e-07	0.000113	0.28	0.23	Obesity-related traits;	chr7:144069621	chr7:144272445~144286966:-
LUAD	cis	rs2028299	1	rs2351707	ENSG00000259677.1	RP11-493E3.1	5.14	4.08e-07	0.000113	0.28	0.23	Type 2 diabetes;	chr15:89840813	chr15:89876540~89877285:+
LUAD	cis	rs1707322	0.647	rs6686944	ENSG00000280836.1	AL355480.1	-5.14	4.08e-07	0.000113	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690636	chr1:45581219~45581321:-
LUAD	cis	rs7131987	0.65	rs16934135	ENSG00000257176.2	RP11-996F15.2	-5.14	4.08e-07	0.000113	-0.26	-0.23	QT interval;	chr12:29331030	chr12:29280418~29317848:-
LUAD	cis	rs10129255	0.834	rs10139893	ENSG00000224373.3	IGHV4-59	5.14	4.08e-07	0.000113	0.15	0.23	Kawasaki disease;	chr14:106711377	chr14:106627249~106627825:-
LUAD	cis	rs875971	0.505	rs1723275	ENSG00000164669.11	INTS4P1	5.14	4.08e-07	0.000113	0.27	0.23	Aortic root size;	chr7:66039646	chr7:65141225~65234216:+
LUAD	cis	rs516805	0.667	rs225074	ENSG00000279453.1	RP3-425C14.4	-5.14	4.09e-07	0.000113	-0.31	-0.23	Lymphocyte counts;	chr6:122265102	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.665	rs225077	ENSG00000279453.1	RP3-425C14.4	-5.14	4.09e-07	0.000113	-0.31	-0.23	Lymphocyte counts;	chr6:122269794	chr6:122436789~122439223:-
LUAD	cis	rs7665090	0.806	rs434644	ENSG00000246560.2	RP11-10L12.4	-5.14	4.09e-07	0.000113	-0.28	-0.23	Primary biliary cholangitis;	chr4:102662032	chr4:102828055~102844075:+
LUAD	cis	rs7665090	0.806	rs413967	ENSG00000246560.2	RP11-10L12.4	-5.14	4.09e-07	0.000113	-0.28	-0.23	Primary biliary cholangitis;	chr4:102662039	chr4:102828055~102844075:+
LUAD	cis	rs7665090	0.806	rs404574	ENSG00000246560.2	RP11-10L12.4	-5.14	4.09e-07	0.000113	-0.28	-0.23	Primary biliary cholangitis;	chr4:102662051	chr4:102828055~102844075:+
LUAD	cis	rs9438901	0.592	rs1293259	ENSG00000224183.1	SDHDP6	5.14	4.09e-07	0.000113	0.47	0.23	Red cell distribution width;	chr1:25369344	chr1:25294164~25294643:-
LUAD	cis	rs1823913	0.503	rs6706578	ENSG00000227542.1	AC092614.2	5.14	4.09e-07	0.000113	0.29	0.23	Obesity-related traits;	chr2:191346992	chr2:191229165~191246172:-
LUAD	cis	rs375066	0.935	rs368089	ENSG00000267058.1	RP11-15A1.3	-5.14	4.1e-07	0.000113	-0.26	-0.23	Breast cancer;	chr19:43894932	chr19:43891804~43901805:-
LUAD	cis	rs6687758	1	rs12125368	ENSG00000228437.4	RP11-400N13.2	5.14	4.1e-07	0.000114	0.34	0.23	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222025330	chr1:221966341~221984964:+
LUAD	cis	rs11971779	0.68	rs11768023	ENSG00000273391.1	RP11-634H22.1	5.14	4.1e-07	0.000114	0.23	0.23	Diisocyanate-induced asthma;	chr7:139369649	chr7:139359032~139359566:-
LUAD	cis	rs17772222	0.917	rs7157149	ENSG00000258983.2	RP11-507K2.2	5.14	4.1e-07	0.000114	0.28	0.23	Coronary artery calcification;	chr14:88765501	chr14:88499334~88515502:+
LUAD	cis	rs4835473	0.831	rs4452380	ENSG00000251600.4	RP11-673E1.1	5.14	4.1e-07	0.000114	0.28	0.23	Immature fraction of reticulocytes;	chr4:143972856	chr4:143912331~143982454:+
LUAD	cis	rs1075265	0.587	rs2949812	ENSG00000233266.1	HMGB1P31	5.13	4.11e-07	0.000114	0.29	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53797190	chr2:54051334~54051760:+
LUAD	cis	rs75422866	0.51	rs73105812	ENSG00000257433.4	RP1-197B17.3	5.13	4.11e-07	0.000114	0.48	0.23	Pneumonia;	chr12:47724404	chr12:47706085~47742294:+
LUAD	cis	rs910316	1	rs12589376	ENSG00000259138.1	RP11-950C14.7	5.13	4.11e-07	0.000114	0.24	0.23	Height;	chr14:75094449	chr14:75127153~75136930:+
LUAD	cis	rs910316	0.967	rs1071989	ENSG00000259138.1	RP11-950C14.7	5.13	4.11e-07	0.000114	0.24	0.23	Height;	chr14:75097956	chr14:75127153~75136930:+
LUAD	cis	rs910316	1	rs9805979	ENSG00000259138.1	RP11-950C14.7	5.13	4.11e-07	0.000114	0.24	0.23	Height;	chr14:75099506	chr14:75127153~75136930:+
LUAD	cis	rs61270009	0.955	rs16903057	ENSG00000247828.6	TMEM161B-AS1	5.13	4.11e-07	0.000114	0.27	0.23	Depressive symptoms;	chr5:88292603	chr5:88268895~88436685:+
LUAD	cis	rs453301	0.658	rs6983877	ENSG00000253893.2	FAM85B	5.13	4.11e-07	0.000114	0.29	0.23	Joint mobility (Beighton score);	chr8:9047129	chr8:8167819~8226614:-
LUAD	cis	rs17264034	0.861	rs414396	ENSG00000250786.1	SNHG18	5.13	4.12e-07	0.000114	0.33	0.23	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9550596	chr5:9546200~9550609:+
LUAD	cis	rs9890032	0.581	rs62070592	ENSG00000266490.1	CTD-2349P21.9	5.13	4.12e-07	0.000114	0.22	0.23	Hip circumference adjusted for BMI;	chr17:30695531	chr17:30792372~30792833:+
LUAD	cis	rs4908768	0.501	rs2045820	ENSG00000232912.4	RP5-1115A15.1	5.13	4.12e-07	0.000114	0.21	0.23	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8678076	chr1:8424645~8434838:+
LUAD	cis	rs12681366	0.881	rs2381793	ENSG00000253704.1	RP11-267M23.4	5.13	4.12e-07	0.000114	0.28	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94388167	chr8:94553722~94569745:+
LUAD	cis	rs2243480	1	rs1404147	ENSG00000232559.3	GS1-124K5.12	5.13	4.12e-07	0.000114	0.36	0.23	Diabetic kidney disease;	chr7:65799537	chr7:66554588~66576923:-
LUAD	cis	rs2976388	0.609	rs2244152	ENSG00000253741.1	CTD-2292P10.4	-5.13	4.12e-07	0.000114	-0.26	-0.23	Urinary tract infection frequency;	chr8:142703467	chr8:142702252~142726973:-
LUAD	cis	rs75920871	0.528	rs3886960	ENSG00000254851.1	RP11-109L13.1	5.13	4.12e-07	0.000114	0.33	0.23	Subjective well-being;	chr11:117054274	chr11:117135528~117138582:+
LUAD	cis	rs75920871	0.528	rs723955	ENSG00000254851.1	RP11-109L13.1	5.13	4.12e-07	0.000114	0.33	0.23	Subjective well-being;	chr11:117054326	chr11:117135528~117138582:+
LUAD	cis	rs75920871	0.528	rs7108912	ENSG00000254851.1	RP11-109L13.1	5.13	4.12e-07	0.000114	0.33	0.23	Subjective well-being;	chr11:117055280	chr11:117135528~117138582:+
LUAD	cis	rs2919009	0.563	rs55761976	ENSG00000271670.1	RP11-95I16.4	5.13	4.12e-07	0.000114	0.3	0.23	Obesity-related traits;	chr10:120935030	chr10:120879256~120880667:-
LUAD	cis	rs1005277	0.529	rs1780125	ENSG00000263064.2	RP11-291L22.7	5.13	4.12e-07	0.000114	0.25	0.23	Extrinsic epigenetic age acceleration;	chr10:38242448	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.502	rs2800484	ENSG00000263064.2	RP11-291L22.7	5.13	4.12e-07	0.000114	0.25	0.23	Extrinsic epigenetic age acceleration;	chr10:38253487	chr10:38448689~38448949:+
LUAD	cis	rs7617773	0.746	rs4130995	ENSG00000228638.1	FCF1P2	-5.13	4.12e-07	0.000114	-0.26	-0.23	Coronary artery disease;	chr3:48316765	chr3:48290793~48291375:-
LUAD	cis	rs875971	0.862	rs1167390	ENSG00000232559.3	GS1-124K5.12	-5.13	4.13e-07	0.000114	-0.27	-0.23	Aortic root size;	chr7:66110906	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs35034167	ENSG00000232559.3	GS1-124K5.12	-5.13	4.13e-07	0.000114	-0.27	-0.23	Aortic root size;	chr7:66115179	chr7:66554588~66576923:-
LUAD	cis	rs61270009	0.955	rs390856	ENSG00000247828.6	TMEM161B-AS1	5.13	4.13e-07	0.000114	0.26	0.23	Depressive symptoms;	chr5:88251742	chr5:88268895~88436685:+
LUAD	cis	rs3761847	0.651	rs1323472	ENSG00000226752.6	PSMD5-AS1	-5.13	4.13e-07	0.000114	-0.24	-0.23	Rheumatoid arthritis;	chr9:121064057	chr9:120824828~120854385:+
LUAD	cis	rs2732480	0.5	rs2932093	ENSG00000257735.1	RP11-370I10.6	5.13	4.13e-07	0.000114	0.28	0.23	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48254488	chr12:48350945~48442411:+
LUAD	cis	rs7017914	0.69	rs7825815	ENSG00000223220.1	Y_RNA	5.13	4.13e-07	0.000114	0.26	0.23	Bone mineral density;	chr8:71074170	chr8:70780914~70781008:-
LUAD	cis	rs875971	0.861	rs801215	ENSG00000232559.3	GS1-124K5.12	-5.13	4.14e-07	0.000114	-0.27	-0.23	Aortic root size;	chr7:66546951	chr7:66554588~66576923:-
LUAD	cis	rs10050311	0.698	rs67867077	ENSG00000251411.1	RP11-397E7.4	-5.13	4.14e-07	0.000114	-0.31	-0.23	Insulin-related traits;	chr4:86722593	chr4:86913266~86914817:-
LUAD	cis	rs916888	0.738	rs199515	ENSG00000261575.2	RP11-259G18.1	-5.13	4.14e-07	0.000114	-0.34	-0.23	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46267037~46268694:+
LUAD	cis	rs9322193	1	rs58189451	ENSG00000268592.3	RAET1E-AS1	5.13	4.14e-07	0.000115	0.29	0.23	Lung cancer;	chr6:149600252	chr6:149863494~149919507:+
LUAD	cis	rs10483853	0.525	rs10138789	ENSG00000258695.2	RP3-414A15.2	-5.13	4.14e-07	0.000115	-0.32	-0.23	Coronary artery calcification;	chr14:73497574	chr14:73522878~73530610:+
LUAD	cis	rs910316	0.935	rs2268620	ENSG00000259138.1	RP11-950C14.7	-5.13	4.14e-07	0.000115	-0.24	-0.23	Height;	chr14:75173700	chr14:75127153~75136930:+
LUAD	cis	rs7937890	0.967	rs963212	ENSG00000254418.1	RP11-21L19.1	-5.13	4.15e-07	0.000115	-0.26	-0.23	Mitochondrial DNA levels;	chr11:14303186	chr11:14262846~14273691:-
LUAD	cis	rs12554020	1	rs12335532	ENSG00000227603.1	RP11-165J3.6	5.13	4.15e-07	0.000115	0.33	0.23	Schizophrenia;	chr9:93431673	chr9:93435332~93437121:-
LUAD	cis	rs11157436	0.958	rs6572313	ENSG00000211812.1	TRAV26-2	-5.13	4.15e-07	0.000115	-0.26	-0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22214070	chr14:22202583~22203368:+
LUAD	cis	rs6095360	0.727	rs755588	ENSG00000222365.1	SNORD12B	-5.13	4.15e-07	0.000115	-0.26	-0.23	Intelligence (multi-trait analysis);	chr20:49104491	chr20:49280319~49280409:+
LUAD	cis	rs1799949	1	rs8176234	ENSG00000236383.6	LINC00854	-5.13	4.15e-07	0.000115	-0.18	-0.23	Menopause (age at onset);	chr17:43067763	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs8176233	ENSG00000236383.6	LINC00854	-5.13	4.15e-07	0.000115	-0.18	-0.23	Menopause (age at onset);	chr17:43067787	chr17:43216941~43305976:-
LUAD	cis	rs7714584	1	rs73282234	ENSG00000197083.10	ZNF300P1	5.13	4.16e-07	0.000115	0.49	0.23	Crohn's disease;	chr5:150816362	chr5:150930645~150946289:-
LUAD	cis	rs11673344	0.832	rs11540540	ENSG00000226686.6	LINC01535	5.13	4.16e-07	0.000115	0.31	0.23	Obesity-related traits;	chr19:37129629	chr19:37251912~37265535:+
LUAD	cis	rs9847710	0.696	rs62253605	ENSG00000242142.1	SERBP1P3	5.13	4.16e-07	0.000115	0.26	0.23	Ulcerative colitis;	chr3:52944402	chr3:53064283~53065091:-
LUAD	cis	rs61270009	0.863	rs35339529	ENSG00000247828.6	TMEM161B-AS1	5.13	4.16e-07	0.000115	0.27	0.23	Depressive symptoms;	chr5:88360284	chr5:88268895~88436685:+
LUAD	cis	rs10091374	1	rs10091374	ENSG00000253967.1	RP11-333A23.4	-5.13	4.16e-07	0.000115	-0.26	-0.23	Cardiac Troponin-T levels;	chr8:70474669	chr8:70471134~70485687:+
LUAD	cis	rs950169	0.544	rs2036949	ENSG00000275120.1	RP11-182J1.17	5.13	4.16e-07	0.000115	0.35	0.23	Schizophrenia;	chr15:84620374	chr15:84599434~84606463:-
LUAD	cis	rs1799949	0.93	rs3765640	ENSG00000236383.6	LINC00854	-5.13	4.17e-07	0.000115	-0.19	-0.23	Menopause (age at onset);	chr17:43124230	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs8176077	ENSG00000236383.6	LINC00854	-5.13	4.17e-07	0.000115	-0.19	-0.23	Menopause (age at onset);	chr17:43124331	chr17:43216941~43305976:-
LUAD	cis	rs1799949	0.965	rs12947782	ENSG00000236383.6	LINC00854	-5.13	4.17e-07	0.000115	-0.19	-0.23	Menopause (age at onset);	chr17:43127865	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs33945274	ENSG00000236383.6	LINC00854	-5.13	4.17e-07	0.000115	-0.19	-0.23	Menopause (age at onset);	chr17:43128056	chr17:43216941~43305976:-
LUAD	cis	rs1799949	0.965	rs33925201	ENSG00000236383.6	LINC00854	-5.13	4.17e-07	0.000115	-0.19	-0.23	Menopause (age at onset);	chr17:43128665	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs11653069	ENSG00000236383.6	LINC00854	-5.13	4.17e-07	0.000115	-0.19	-0.23	Menopause (age at onset);	chr17:43131360	chr17:43216941~43305976:-
LUAD	cis	rs6687821	0.515	rs2390221	ENSG00000267734.1	RP4-604K5.3	-5.13	4.18e-07	0.000116	-0.28	-0.23	Yeast infection;	chr1:86990333	chr1:86932199~86934891:-
LUAD	cis	rs442309	0.687	rs10822054	ENSG00000238280.1	RP11-436D10.3	-5.13	4.18e-07	0.000116	-0.28	-0.23	Vogt-Koyanagi-Harada syndrome;	chr10:62720492	chr10:62793562~62805887:-
LUAD	cis	rs7017914	0.69	rs3098869	ENSG00000223220.1	Y_RNA	5.13	4.19e-07	0.000116	0.26	0.23	Bone mineral density;	chr8:71017597	chr8:70780914~70781008:-
LUAD	cis	rs7826238	0.601	rs2979206	ENSG00000253981.4	ALG1L13P	5.13	4.19e-07	0.000116	0.26	0.23	Systolic blood pressure;	chr8:8488071	chr8:8236003~8244667:-
LUAD	cis	rs75422866	0.51	rs74733564	ENSG00000257433.4	RP1-197B17.3	5.13	4.19e-07	0.000116	0.48	0.23	Pneumonia;	chr12:47724644	chr12:47706085~47742294:+
LUAD	cis	rs75422866	0.51	rs73105814	ENSG00000257433.4	RP1-197B17.3	5.13	4.19e-07	0.000116	0.48	0.23	Pneumonia;	chr12:47725817	chr12:47706085~47742294:+
LUAD	cis	rs4964805	1	rs73192053	ENSG00000257681.1	RP11-341G23.4	5.13	4.19e-07	0.000116	0.28	0.23	Attention deficit hyperactivity disorder;	chr12:103797077	chr12:103746315~103768858:-
LUAD	cis	rs4964805	1	rs11111789	ENSG00000257681.1	RP11-341G23.4	5.13	4.19e-07	0.000116	0.28	0.23	Attention deficit hyperactivity disorder;	chr12:103797762	chr12:103746315~103768858:-
LUAD	cis	rs9487094	0.778	rs11757877	ENSG00000260273.1	RP11-425D10.10	5.13	4.19e-07	0.000116	0.32	0.23	Height;	chr6:109360679	chr6:109382795~109383666:+
LUAD	cis	rs55665837	0.54	rs10832299	ENSG00000251991.1	RNU7-49P	5.13	4.19e-07	0.000116	0.26	0.23	Vitamin D levels;	chr11:14747846	chr11:14478892~14478953:+
LUAD	cis	rs984222	0.741	rs1886914	ENSG00000226172.2	RP4-712E4.1	-5.13	4.19e-07	0.000116	-0.24	-0.23	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118998829	chr1:119000344~119001392:-
LUAD	cis	rs6687821	0.531	rs4518960	ENSG00000267734.1	RP4-604K5.3	-5.13	4.19e-07	0.000116	-0.3	-0.23	Yeast infection;	chr1:87048746	chr1:86932199~86934891:-
LUAD	cis	rs7617773	0.817	rs6796490	ENSG00000228638.1	FCF1P2	-5.13	4.2e-07	0.000116	-0.26	-0.23	Coronary artery disease;	chr3:48195614	chr3:48290793~48291375:-
LUAD	cis	rs4835473	0.932	rs13134808	ENSG00000251600.4	RP11-673E1.1	-5.13	4.2e-07	0.000116	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143798339	chr4:143912331~143982454:+
LUAD	cis	rs7017914	0.652	rs12681420	ENSG00000223220.1	Y_RNA	5.13	4.2e-07	0.000116	0.26	0.23	Bone mineral density;	chr8:70680963	chr8:70780914~70781008:-
LUAD	cis	rs66887589	0.934	rs7672519	ENSG00000245958.5	RP11-33B1.1	5.13	4.2e-07	0.000116	0.18	0.23	Diastolic blood pressure;	chr4:119622957	chr4:119454791~119552025:+
LUAD	cis	rs12439619	0.693	rs17269819	ENSG00000276710.3	CSPG4P8	-5.13	4.2e-07	0.000116	-0.25	-0.23	Intelligence (multi-trait analysis);	chr15:82174660	chr15:82459472~82477258:+
LUAD	cis	rs858239	0.539	rs57864591	ENSG00000230042.1	AK3P3	-5.13	4.2e-07	0.000116	-0.29	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23144805	chr7:23129178~23129841:+
LUAD	cis	rs4835473	0.77	rs4835096	ENSG00000251600.4	RP11-673E1.1	5.13	4.2e-07	0.000116	0.28	0.23	Immature fraction of reticulocytes;	chr4:143960685	chr4:143912331~143982454:+
LUAD	cis	rs7017914	0.558	rs4526394	ENSG00000223220.1	Y_RNA	5.13	4.21e-07	0.000116	0.26	0.23	Bone mineral density;	chr8:71076092	chr8:70780914~70781008:-
LUAD	cis	rs1062177	1	rs2915878	ENSG00000253921.1	CTB-113P19.3	-5.13	4.21e-07	0.000116	-0.33	-0.23	Preschool internalizing problems;	chr5:151770101	chr5:151753992~151767247:+
LUAD	cis	rs7208859	0.573	rs216442	ENSG00000263603.1	CTD-2349P21.5	-5.13	4.21e-07	0.000116	-0.41	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604179	chr17:30729469~30731202:+
LUAD	cis	rs11673344	0.704	rs510757	ENSG00000226686.6	LINC01535	-5.13	4.21e-07	0.000116	-0.28	-0.23	Obesity-related traits;	chr19:36931900	chr19:37251912~37265535:+
LUAD	cis	rs516805	0.63	rs696651	ENSG00000279453.1	RP3-425C14.4	-5.13	4.21e-07	0.000116	-0.3	-0.23	Lymphocyte counts;	chr6:122280069	chr6:122436789~122439223:-
LUAD	cis	rs17772222	0.958	rs1123421	ENSG00000258983.2	RP11-507K2.2	5.13	4.21e-07	0.000116	0.28	0.23	Coronary artery calcification;	chr14:88524651	chr14:88499334~88515502:+
LUAD	cis	rs4664293	1	rs4665083	ENSG00000226266.5	AC009961.3	5.13	4.21e-07	0.000116	0.31	0.23	Monocyte percentage of white cells;	chr2:159573616	chr2:159670708~159712435:-
LUAD	cis	rs8100891	1	rs8100891	ENSG00000267213.4	AC007773.2	-5.13	4.21e-07	0.000116	-0.3	-0.23	Neuroticism;	chr19:32338607	chr19:32390050~32405560:-
LUAD	cis	rs35264875	1	rs7110274	ENSG00000259799.1	RP11-554A11.9	5.13	4.22e-07	0.000116	0.33	0.23	Blond vs. brown hair color;	chr11:69075236	chr11:69155910~69159752:+
LUAD	cis	rs12468226	0.752	rs116078354	ENSG00000226261.1	AC064836.3	5.13	4.22e-07	0.000116	0.36	0.23	Urate levels;	chr2:202136356	chr2:202336024~202336727:-
LUAD	cis	rs7208859	0.573	rs7223803	ENSG00000263603.1	CTD-2349P21.5	-5.13	4.22e-07	0.000117	-0.41	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750175	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs55814012	ENSG00000263603.1	CTD-2349P21.5	-5.13	4.22e-07	0.000117	-0.41	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750679	chr17:30729469~30731202:+
LUAD	cis	rs17826219	0.5	rs2449749	ENSG00000263603.1	CTD-2349P21.5	-5.13	4.22e-07	0.000117	-0.41	-0.23	Body mass index;	chr17:30751280	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs9894709	ENSG00000263603.1	CTD-2349P21.5	-5.13	4.22e-07	0.000117	-0.41	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751436	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs9896603	ENSG00000263603.1	CTD-2349P21.5	-5.13	4.22e-07	0.000117	-0.41	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751494	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs8080882	ENSG00000263603.1	CTD-2349P21.5	-5.13	4.22e-07	0.000117	-0.41	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30754128	chr17:30729469~30731202:+
LUAD	cis	rs1799949	1	rs35330014	ENSG00000236383.6	LINC00854	-5.13	4.23e-07	0.000117	-0.18	-0.23	Menopause (age at onset);	chr17:43060530	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs3092994	ENSG00000236383.6	LINC00854	-5.13	4.23e-07	0.000117	-0.18	-0.23	Menopause (age at onset);	chr17:43063808	chr17:43216941~43305976:-
LUAD	cis	rs7948661	0.661	rs7116876	ENSG00000278376.1	RP11-158I9.8	5.13	4.23e-07	0.000117	0.5	0.23	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118500310	chr11:118791254~118793137:+
LUAD	cis	rs875971	0.862	rs1612452	ENSG00000232559.3	GS1-124K5.12	-5.13	4.23e-07	0.000117	-0.27	-0.23	Aortic root size;	chr7:66108909	chr7:66554588~66576923:-
LUAD	cis	rs1322639	0.668	rs9766666	ENSG00000261039.2	RP11-417E7.2	-5.13	4.23e-07	0.000117	-0.3	-0.23	Pulse pressure;	chr6:169213446	chr6:169175304~169182740:-
LUAD	cis	rs1318937	0.831	rs9851648	ENSG00000224660.1	SH3BP5-AS1	5.13	4.23e-07	0.000117	0.16	0.23	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15259292	chr3:15254184~15264493:+
LUAD	cis	rs11976180	1	rs2961132	ENSG00000204959.4	ARHGEF34P	5.13	4.23e-07	0.000117	0.28	0.23	Obesity-related traits;	chr7:144071035	chr7:144272445~144286966:-
LUAD	cis	rs7968440	0.808	rs1613835	ENSG00000200428.1	Y_RNA	-5.13	4.23e-07	0.000117	-0.3	-0.23	Fibrinogen;	chr12:50811283	chr12:50743568~50743684:+
LUAD	cis	rs7968440	0.808	rs1659387	ENSG00000200428.1	Y_RNA	-5.13	4.23e-07	0.000117	-0.3	-0.23	Fibrinogen;	chr12:50811284	chr12:50743568~50743684:+
LUAD	cis	rs1008375	0.966	rs3733576	ENSG00000249502.1	AC006160.5	-5.13	4.24e-07	0.000117	-0.23	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17585080	chr4:17587467~17614571:-
LUAD	cis	rs17711722	0.701	rs4467826	ENSG00000164669.11	INTS4P1	-5.13	4.24e-07	0.000117	-0.27	-0.23	Calcium levels;	chr7:65903721	chr7:65141225~65234216:+
LUAD	cis	rs4713118	0.568	rs9468213	ENSG00000219392.1	RP1-265C24.5	-5.13	4.24e-07	0.000117	-0.28	-0.23	Parkinson's disease;	chr6:27738401	chr6:28115628~28116551:+
LUAD	cis	rs9326246	0.643	rs651821	ENSG00000254851.1	RP11-109L13.1	-5.13	4.25e-07	0.000117	-0.45	-0.23	Coronary artery disease;	chr11:116791863	chr11:117135528~117138582:+
LUAD	cis	rs673078	0.66	rs11068891	ENSG00000275409.1	RP11-131L12.4	5.13	4.25e-07	0.000117	0.29	0.23	Glucose homeostasis traits;	chr12:118259814	chr12:118430147~118430699:+
LUAD	cis	rs10129255	0.956	rs10137268	ENSG00000224373.3	IGHV4-59	5.13	4.25e-07	0.000117	0.15	0.23	Kawasaki disease;	chr14:106697402	chr14:106627249~106627825:-
LUAD	cis	rs948562	0.573	rs4459322	ENSG00000280010.1	AP001350.4	-5.13	4.25e-07	0.000117	-0.34	-0.23	Lymphoma;	chr11:58295694	chr11:58627435~58628528:+
LUAD	cis	rs1799949	0.965	rs6503726	ENSG00000267681.1	CTD-3199J23.6	-5.13	4.25e-07	0.000117	-0.26	-0.23	Menopause (age at onset);	chr17:43132725	chr17:43144956~43145255:+
LUAD	cis	rs748404	0.697	rs498227	ENSG00000249839.1	AC011330.5	-5.13	4.25e-07	0.000117	-0.29	-0.23	Lung cancer;	chr15:43280854	chr15:43663654~43684339:-
LUAD	cis	rs10050311	0.586	rs2054592	ENSG00000251411.1	RP11-397E7.4	-5.13	4.25e-07	0.000117	-0.32	-0.23	Insulin-related traits;	chr4:86752292	chr4:86913266~86914817:-
LUAD	cis	rs10050311	0.746	rs17454662	ENSG00000251411.1	RP11-397E7.4	-5.13	4.25e-07	0.000117	-0.32	-0.23	Insulin-related traits;	chr4:86752611	chr4:86913266~86914817:-
LUAD	cis	rs10129255	0.536	rs17113249	ENSG00000254174.1	IGHV1-12	5.13	4.26e-07	0.000117	0.15	0.23	Kawasaki disease;	chr14:106678273	chr14:106122420~106122709:-
LUAD	cis	rs516805	0.706	rs11752939	ENSG00000279453.1	RP3-425C14.4	5.13	4.26e-07	0.000117	0.3	0.23	Lymphocyte counts;	chr6:122350062	chr6:122436789~122439223:-
LUAD	cis	rs1799949	1	rs36036395	ENSG00000236383.6	LINC00854	-5.13	4.26e-07	0.000117	-0.19	-0.23	Menopause (age at onset);	chr17:43029280	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs72829113	ENSG00000236383.6	LINC00854	-5.13	4.26e-07	0.000117	-0.19	-0.23	Menopause (age at onset);	chr17:43029818	chr17:43216941~43305976:-
LUAD	cis	rs2933343	0.951	rs789217	ENSG00000231305.3	RP11-723O4.2	5.13	4.26e-07	0.000117	0.27	0.23	IgG glycosylation;	chr3:128874358	chr3:128861313~128871540:-
LUAD	cis	rs66887589	0.934	rs6817317	ENSG00000245958.5	RP11-33B1.1	5.13	4.26e-07	0.000118	0.18	0.23	Diastolic blood pressure;	chr4:119621672	chr4:119454791~119552025:+
LUAD	cis	rs1062177	0.951	rs2915876	ENSG00000253921.1	CTB-113P19.3	-5.13	4.26e-07	0.000118	-0.33	-0.23	Preschool internalizing problems;	chr5:151771184	chr5:151753992~151767247:+
LUAD	cis	rs1008375	0.966	rs3796813	ENSG00000249502.1	AC006160.5	-5.13	4.26e-07	0.000118	-0.23	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17590025	chr4:17587467~17614571:-
LUAD	cis	rs42490	1	rs40452	ENSG00000251136.7	RP11-37B2.1	-5.13	4.26e-07	0.000118	-0.24	-0.23	Leprosy;	chr8:89765931	chr8:89609409~89757727:-
LUAD	cis	rs6088590	0.93	rs6087618	ENSG00000276073.1	RP5-1125A11.7	-5.13	4.26e-07	0.000118	-0.23	-0.23	Coronary artery disease;	chr20:34700603	chr20:33985617~33988989:-
LUAD	cis	rs1426063	0.858	rs11936768	ENSG00000249717.1	RP11-44F21.3	5.13	4.27e-07	0.000118	0.33	0.23	QT interval;	chr4:75084506	chr4:74955974~74970362:-
LUAD	cis	rs71636778	0.509	rs34585496	ENSG00000260063.1	RP5-968P14.2	-5.13	4.27e-07	0.000118	-0.41	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26699449	chr1:26692132~26694131:-
LUAD	cis	rs1124609	0.527	rs11632154	ENSG00000244879.4	GABPB1-AS1	5.13	4.27e-07	0.000118	0.31	0.23	Subjective well-being;	chr15:50204321	chr15:50354959~50372202:+
LUAD	cis	rs2998286	0.862	rs2993980	ENSG00000254635.4	WAC-AS1	-5.13	4.27e-07	0.000118	-0.28	-0.23	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28506286	chr10:28522652~28532743:-
LUAD	cis	rs10129255	0.556	rs9324093	ENSG00000254174.1	IGHV1-12	5.13	4.28e-07	0.000118	0.15	0.23	Kawasaki disease;	chr14:106683893	chr14:106122420~106122709:-
LUAD	cis	rs9660180	0.62	rs3817856	ENSG00000231050.1	RP1-140A9.1	-5.13	4.28e-07	0.000118	-0.25	-0.23	Body mass index;	chr1:1732392	chr1:1891471~1892658:+
LUAD	cis	rs4835473	0.808	rs6836630	ENSG00000251600.4	RP11-673E1.1	-5.13	4.28e-07	0.000118	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143801068	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs13101541	ENSG00000251600.4	RP11-673E1.1	-5.13	4.28e-07	0.000118	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143806590	chr4:143912331~143982454:+
LUAD	cis	rs6772849	1	rs60228913	ENSG00000242551.2	POU5F1P6	-5.13	4.28e-07	0.000118	-0.26	-0.23	Monocyte percentage of white cells;Monocyte count;	chr3:128592488	chr3:128674735~128677005:-
LUAD	cis	rs12701220	0.655	rs10215292	ENSG00000229043.2	AC091729.9	-5.13	4.29e-07	0.000118	-0.29	-0.23	Bronchopulmonary dysplasia;	chr7:1095627	chr7:1160374~1165267:+
LUAD	cis	rs1707322	0.789	rs10789473	ENSG00000280836.1	AL355480.1	-5.13	4.29e-07	0.000118	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782459	chr1:45581219~45581321:-
LUAD	cis	rs36093844	0.752	rs7127501	ENSG00000279742.1	RP11-700A24.1	-5.13	4.29e-07	0.000118	-0.31	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85853262	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.752	rs17817254	ENSG00000279742.1	RP11-700A24.1	-5.13	4.29e-07	0.000118	-0.31	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85853783	chr11:85852557~85854943:-
LUAD	cis	rs8100891	0.614	rs6510243	ENSG00000267213.4	AC007773.2	-5.13	4.29e-07	0.000118	-0.27	-0.23	Neuroticism;	chr19:32342765	chr19:32390050~32405560:-
LUAD	cis	rs853679	0.546	rs200989	ENSG00000219392.1	RP1-265C24.5	-5.13	4.29e-07	0.000118	-0.43	-0.23	Depression;	chr6:27848664	chr6:28115628~28116551:+
LUAD	cis	rs66823261	0.778	rs2906332	ENSG00000253166.2	RP11-585F1.6	-5.13	4.29e-07	0.000118	-0.33	-0.23	Breast cancer (estrogen-receptor negative);Breast cancer;	chr8:244943	chr8:202660~202897:-
LUAD	cis	rs17265703	0.524	rs12107092	ENSG00000272758.4	RP11-299J3.8	5.13	4.29e-07	0.000118	0.28	0.23	Phosphorus levels;	chr3:122405001	chr3:122416207~122443180:+
LUAD	cis	rs4908768	0.501	rs6577499	ENSG00000270282.1	RP5-1115A15.2	-5.13	4.29e-07	0.000118	-0.25	-0.23	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8552045	chr1:8512653~8513021:+
LUAD	cis	rs6570726	0.791	rs9497357	ENSG00000235652.6	RP11-545I5.3	5.13	4.29e-07	0.000118	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145591752	chr6:145799409~145886585:+
LUAD	cis	rs1275468	0.731	rs1480002	ENSG00000257497.2	RP11-585P4.5	-5.13	4.29e-07	0.000118	-0.34	-0.23	Polycystic ovary syndrome;	chr12:75587184	chr12:75483454~75489820:-
LUAD	cis	rs7017914	0.667	rs2732098	ENSG00000223220.1	Y_RNA	5.13	4.29e-07	0.000118	0.27	0.23	Bone mineral density;	chr8:71008762	chr8:70780914~70781008:-
LUAD	cis	rs6570726	0.643	rs9403735	ENSG00000235652.6	RP11-545I5.3	5.13	4.29e-07	0.000118	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145615455	chr6:145799409~145886585:+
LUAD	cis	rs71403859	0.502	rs8053720	ENSG00000260886.1	TAT-AS1	5.13	4.3e-07	0.000118	0.36	0.23	Post bronchodilator FEV1;	chr16:71422239	chr16:71565789~71578187:+
LUAD	cis	rs6545883	0.507	rs4672427	ENSG00000271889.1	RP11-493E12.1	-5.13	4.3e-07	0.000118	-0.26	-0.23	Tuberculosis;	chr2:61242115	chr2:61151433~61162105:-
LUAD	cis	rs17772222	0.917	rs61984683	ENSG00000258983.2	RP11-507K2.2	5.13	4.3e-07	0.000119	0.28	0.23	Coronary artery calcification;	chr14:88553162	chr14:88499334~88515502:+
LUAD	cis	rs1799949	1	rs12936816	ENSG00000236383.6	LINC00854	-5.13	4.3e-07	0.000119	-0.19	-0.23	Menopause (age at onset);	chr17:43149692	chr17:43216941~43305976:-
LUAD	cis	rs1816752	0.905	rs4770666	ENSG00000273628.1	RP11-756A22.7	5.13	4.31e-07	0.000119	0.26	0.23	Obesity-related traits;	chr13:24414891	chr13:24933006~24936796:+
LUAD	cis	rs4964805	0.913	rs12830701	ENSG00000257681.1	RP11-341G23.4	5.13	4.31e-07	0.000119	0.28	0.23	Attention deficit hyperactivity disorder;	chr12:103807904	chr12:103746315~103768858:-
LUAD	cis	rs7772486	0.754	rs1055212	ENSG00000235652.6	RP11-545I5.3	-5.13	4.31e-07	0.000119	-0.23	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145737179	chr6:145799409~145886585:+
LUAD	cis	rs7017914	0.714	rs13273979	ENSG00000223220.1	Y_RNA	5.13	4.32e-07	0.000119	0.26	0.23	Bone mineral density;	chr8:70825087	chr8:70780914~70781008:-
LUAD	cis	rs61270009	0.955	rs75214722	ENSG00000247828.6	TMEM161B-AS1	5.13	4.32e-07	0.000119	0.26	0.23	Depressive symptoms;	chr5:88269908	chr5:88268895~88436685:+
LUAD	cis	rs61270009	0.955	rs895295	ENSG00000247828.6	TMEM161B-AS1	5.13	4.32e-07	0.000119	0.26	0.23	Depressive symptoms;	chr5:88271529	chr5:88268895~88436685:+
LUAD	cis	rs61270009	0.913	rs16903040	ENSG00000247828.6	TMEM161B-AS1	5.13	4.32e-07	0.000119	0.26	0.23	Depressive symptoms;	chr5:88273220	chr5:88268895~88436685:+
LUAD	cis	rs11673344	0.77	rs7257135	ENSG00000226686.6	LINC01535	5.13	4.32e-07	0.000119	0.3	0.23	Obesity-related traits;	chr19:37088726	chr19:37251912~37265535:+
LUAD	cis	rs858239	0.676	rs274032	ENSG00000226816.2	AC005082.12	5.13	4.32e-07	0.000119	0.3	0.23	Cerebrospinal fluid biomarker levels;	chr7:23334940	chr7:23206013~23208045:+
LUAD	cis	rs643506	0.874	rs687152	ENSG00000230911.1	PPIHP1	-5.12	4.32e-07	0.000119	-0.29	-0.23	Breast cancer;	chr11:111850950	chr11:112029858~112030367:-
LUAD	cis	rs643506	0.874	rs4936786	ENSG00000230911.1	PPIHP1	-5.12	4.32e-07	0.000119	-0.29	-0.23	Breast cancer;	chr11:111856504	chr11:112029858~112030367:-
LUAD	cis	rs2404602	1	rs2896954	ENSG00000259422.1	RP11-593F23.1	5.12	4.33e-07	0.000119	0.27	0.23	Blood metabolite levels;	chr15:76559351	chr15:76174891~76181486:-
LUAD	cis	rs11976180	1	rs11976180	ENSG00000170356.8	OR2A20P	-5.12	4.33e-07	0.000119	-0.29	-0.23	Obesity-related traits;	chr7:144044487	chr7:144250045~144252957:-
LUAD	cis	rs910316	1	rs11623413	ENSG00000259138.1	RP11-950C14.7	-5.12	4.33e-07	0.000119	-0.24	-0.23	Height;	chr14:75122121	chr14:75127153~75136930:+
LUAD	cis	rs1005277	0.579	rs1740732	ENSG00000263064.2	RP11-291L22.7	5.12	4.33e-07	0.000119	0.25	0.23	Extrinsic epigenetic age acceleration;	chr10:38202457	chr10:38448689~38448949:+
LUAD	cis	rs11673344	0.801	rs76806623	ENSG00000226686.6	LINC01535	5.12	4.33e-07	0.000119	0.31	0.23	Obesity-related traits;	chr19:37132525	chr19:37251912~37265535:+
LUAD	cis	rs763567	1	rs12755237	ENSG00000271811.1	RP1-79C4.4	-5.12	4.33e-07	0.000119	-0.28	-0.23	Tonsillectomy;	chr1:170599573	chr1:170667381~170669425:+
LUAD	cis	rs763567	1	rs12742164	ENSG00000271811.1	RP1-79C4.4	-5.12	4.33e-07	0.000119	-0.28	-0.23	Tonsillectomy;	chr1:170599755	chr1:170667381~170669425:+
LUAD	cis	rs6088590	1	rs6088615	ENSG00000276073.1	RP5-1125A11.7	5.12	4.33e-07	0.000119	0.23	0.23	Coronary artery disease;	chr20:34812671	chr20:33985617~33988989:-
LUAD	cis	rs4819052	0.788	rs13049700	ENSG00000223768.1	LINC00205	-5.12	4.34e-07	0.000119	-0.28	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45281994	chr21:45293285~45297354:+
LUAD	cis	rs2562456	0.833	rs2968076	ENSG00000268081.1	RP11-678G14.2	-5.12	4.34e-07	0.000119	-0.35	-0.23	Pain;	chr19:21454299	chr19:21554640~21569237:-
LUAD	cis	rs858239	0.539	rs4294098	ENSG00000230042.1	AK3P3	-5.12	4.34e-07	0.000119	-0.29	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23146376	chr7:23129178~23129841:+
LUAD	cis	rs17772222	0.958	rs2274737	ENSG00000258983.2	RP11-507K2.2	5.12	4.34e-07	0.00012	0.28	0.23	Coronary artery calcification;	chr14:88469307	chr14:88499334~88515502:+
LUAD	cis	rs1150668	0.796	rs2531825	ENSG00000219392.1	RP1-265C24.5	-5.12	4.34e-07	0.00012	-0.28	-0.23	Pubertal anthropometrics;	chr6:28381487	chr6:28115628~28116551:+
LUAD	cis	rs11023332	1	rs11023332	ENSG00000251991.1	RNU7-49P	5.12	4.35e-07	0.00012	0.26	0.23	Vitamin D levels;Adiponectin levels;	chr11:14762564	chr11:14478892~14478953:+
LUAD	cis	rs950169	0.58	rs11635597	ENSG00000275120.1	RP11-182J1.17	5.12	4.35e-07	0.00012	0.35	0.23	Schizophrenia;	chr15:84622468	chr15:84599434~84606463:-
LUAD	cis	rs7937890	0.507	rs4463820	ENSG00000251991.1	RNU7-49P	5.12	4.35e-07	0.00012	0.24	0.23	Mitochondrial DNA levels;	chr11:14534796	chr11:14478892~14478953:+
LUAD	cis	rs867371	0.896	rs6495647	ENSG00000276710.3	CSPG4P8	-5.12	4.35e-07	0.00012	-0.21	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82244708	chr15:82459472~82477258:+
LUAD	cis	rs7580658	0.895	rs9636237	ENSG00000236682.1	AC068282.3	-5.12	4.35e-07	0.00012	-0.31	-0.23	Protein C levels;	chr2:127318446	chr2:127389130~127400580:+
LUAD	cis	rs7829975	0.509	rs2945269	ENSG00000173295.6	FAM86B3P	5.12	4.36e-07	0.00012	0.24	0.23	Mood instability;	chr8:8258056	chr8:8228595~8244865:+
LUAD	cis	rs10129255	1	rs10129407	ENSG00000224373.3	IGHV4-59	5.12	4.36e-07	0.00012	0.15	0.23	Kawasaki disease;	chr14:106767956	chr14:106627249~106627825:-
LUAD	cis	rs916888	0.779	rs199498	ENSG00000261575.2	RP11-259G18.1	5.12	4.36e-07	0.00012	0.34	0.23	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46267037~46268694:+
LUAD	cis	rs7017914	0.69	rs7013793	ENSG00000223220.1	Y_RNA	5.12	4.36e-07	0.00012	0.26	0.23	Bone mineral density;	chr8:71061317	chr8:70780914~70781008:-
LUAD	cis	rs1823913	0.503	rs6434464	ENSG00000280083.1	RP11-317J9.1	5.12	4.36e-07	0.00012	0.27	0.23	Obesity-related traits;	chr2:191341120	chr2:191154118~191156070:-
LUAD	cis	rs2998286	0.715	rs2993985	ENSG00000254635.4	WAC-AS1	-5.12	4.36e-07	0.00012	-0.28	-0.23	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28510311	chr10:28522652~28532743:-
LUAD	cis	rs1816752	0.87	rs2033955	ENSG00000273628.1	RP11-756A22.7	5.12	4.37e-07	0.00012	0.26	0.23	Obesity-related traits;	chr13:24436406	chr13:24933006~24936796:+
LUAD	cis	rs1816752	0.87	rs2033954	ENSG00000273628.1	RP11-756A22.7	5.12	4.37e-07	0.00012	0.26	0.23	Obesity-related traits;	chr13:24436429	chr13:24933006~24936796:+
LUAD	cis	rs7824557	0.505	rs2736313	ENSG00000255046.1	RP11-297N6.4	-5.12	4.37e-07	0.00012	-0.27	-0.23	Retinal vascular caliber;	chr8:11229433	chr8:11797928~11802568:-
LUAD	cis	rs1707322	0.752	rs11211146	ENSG00000280836.1	AL355480.1	-5.12	4.37e-07	0.00012	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644122	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.752	rs11211147	ENSG00000280836.1	AL355480.1	-5.12	4.37e-07	0.00012	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644422	chr1:45581219~45581321:-
LUAD	cis	rs7208859	0.562	rs216408	ENSG00000263531.1	RP13-753N3.1	-5.12	4.37e-07	0.00012	-0.39	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30580739	chr17:30863921~30864940:-
LUAD	cis	rs2439831	0.85	rs3816792	ENSG00000249839.1	AC011330.5	5.12	4.38e-07	0.00012	0.46	0.23	Lung cancer in ever smokers;	chr15:43824788	chr15:43663654~43684339:-
LUAD	cis	rs2919009	0.607	rs56004902	ENSG00000271670.1	RP11-95I16.4	5.12	4.38e-07	0.00012	0.3	0.23	Obesity-related traits;	chr10:120938378	chr10:120879256~120880667:-
LUAD	cis	rs2919009	0.551	rs61872771	ENSG00000271670.1	RP11-95I16.4	5.12	4.38e-07	0.00012	0.3	0.23	Obesity-related traits;	chr10:120939465	chr10:120879256~120880667:-
LUAD	cis	rs2976388	0.609	rs2717601	ENSG00000253741.1	CTD-2292P10.4	-5.12	4.38e-07	0.00012	-0.26	-0.23	Urinary tract infection frequency;	chr8:142726506	chr8:142702252~142726973:-
LUAD	cis	rs9322193	0.607	rs7764677	ENSG00000223701.3	RAET1E-AS1	5.12	4.38e-07	0.000121	0.31	0.23	Lung cancer;	chr6:149906197	chr6:149884431~149919508:+
LUAD	cis	rs7829975	0.774	rs35039922	ENSG00000253893.2	FAM85B	-5.12	4.39e-07	0.000121	-0.29	-0.23	Mood instability;	chr8:8817815	chr8:8167819~8226614:-
LUAD	cis	rs7772486	0.754	rs702319	ENSG00000235652.6	RP11-545I5.3	-5.12	4.39e-07	0.000121	-0.23	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145684981	chr6:145799409~145886585:+
LUAD	cis	rs10129255	1	rs10134517	ENSG00000224373.3	IGHV4-59	5.12	4.39e-07	0.000121	0.15	0.23	Kawasaki disease;	chr14:106718498	chr14:106627249~106627825:-
LUAD	cis	rs858239	0.932	rs858272	ENSG00000226816.2	AC005082.12	5.12	4.39e-07	0.000121	0.29	0.23	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23206013~23208045:+
LUAD	cis	rs1154275	0.537	rs9875150	ENSG00000242770.2	RP11-180K7.1	5.12	4.39e-07	0.000121	0.23	0.23	Takotsubo syndrome;	chr3:112796937	chr3:112802478~112812819:+
LUAD	cis	rs7208859	0.623	rs609063	ENSG00000263603.1	CTD-2349P21.5	-5.12	4.39e-07	0.000121	-0.4	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs383436	ENSG00000263603.1	CTD-2349P21.5	-5.12	4.39e-07	0.000121	-0.4	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30632161	chr17:30729469~30731202:+
LUAD	cis	rs4835473	0.897	rs924234	ENSG00000251600.4	RP11-673E1.1	5.12	4.39e-07	0.000121	0.28	0.23	Immature fraction of reticulocytes;	chr4:143706799	chr4:143912331~143982454:+
LUAD	cis	rs11089937	0.539	rs6001075	ENSG00000211638.2	IGLV8-61	-5.12	4.4e-07	0.000121	-0.26	-0.23	Periodontitis (PAL4Q3);	chr22:22133765	chr22:22098700~22099212:+
LUAD	cis	rs11089937	0.597	rs6001076	ENSG00000211638.2	IGLV8-61	-5.12	4.4e-07	0.000121	-0.26	-0.23	Periodontitis (PAL4Q3);	chr22:22133873	chr22:22098700~22099212:+
LUAD	cis	rs11089937	0.597	rs5995560	ENSG00000211638.2	IGLV8-61	-5.12	4.4e-07	0.000121	-0.26	-0.23	Periodontitis (PAL4Q3);	chr22:22133989	chr22:22098700~22099212:+
LUAD	cis	rs4835473	0.897	rs34380794	ENSG00000251600.4	RP11-673E1.1	-5.12	4.4e-07	0.000121	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143735800	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.75	rs56372690	ENSG00000251600.4	RP11-673E1.1	-5.12	4.4e-07	0.000121	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143735816	chr4:143912331~143982454:+
LUAD	cis	rs6570726	0.791	rs435671	ENSG00000235652.6	RP11-545I5.3	5.12	4.4e-07	0.000121	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145560079	chr6:145799409~145886585:+
LUAD	cis	rs2115630	1	rs2115630	ENSG00000229212.6	RP11-561C5.4	5.12	4.4e-07	0.000121	0.26	0.23	P wave terminal force;	chr15:84821285	chr15:85205440~85234795:-
LUAD	cis	rs1914816	0.653	rs190771	ENSG00000196274.5	Metazoa_SRP	5.12	4.41e-07	0.000121	0.29	0.23	Response to tocilizumab in rheumatoid arthritis;	chr15:76489681	chr15:76230048~76230390:-
LUAD	cis	rs2018683	0.87	rs13232487	ENSG00000228421.2	AC005013.5	5.12	4.41e-07	0.000121	0.25	0.23	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28945502	chr7:28957667~28959345:+
LUAD	cis	rs8050896	1	rs8051967	ENSG00000260695.1	RP11-513N24.1	-5.12	4.41e-07	0.000121	-0.38	-0.23	Response to antipsychotic treatment;	chr16:66125186	chr16:65861112~65863784:-
LUAD	cis	rs858239	0.539	rs6955726	ENSG00000230042.1	AK3P3	-5.12	4.42e-07	0.000121	-0.29	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23147072	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.539	rs6976957	ENSG00000230042.1	AK3P3	-5.12	4.42e-07	0.000121	-0.29	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23147714	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.539	rs6956828	ENSG00000230042.1	AK3P3	-5.12	4.42e-07	0.000121	-0.29	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23147728	chr7:23129178~23129841:+
LUAD	cis	rs2408955	0.568	rs12099462	ENSG00000257735.1	RP11-370I10.6	-5.12	4.42e-07	0.000121	-0.27	-0.23	Glycated hemoglobin levels;	chr12:48109321	chr12:48350945~48442411:+
LUAD	cis	rs916888	0.821	rs199513	ENSG00000261575.2	RP11-259G18.1	-5.12	4.42e-07	0.000121	-0.34	-0.23	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46267037~46268694:+
LUAD	cis	rs57502260	0.704	rs17149179	ENSG00000212093.1	AP000807.1	5.12	4.42e-07	0.000121	0.32	0.23	Total body bone mineral density (age 45-60);	chr11:68584254	chr11:68506083~68506166:-
LUAD	cis	rs4835473	0.932	rs1849135	ENSG00000251600.4	RP11-673E1.1	-5.12	4.42e-07	0.000121	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143912279	chr4:143912331~143982454:+
LUAD	cis	rs950169	0.922	rs62021167	ENSG00000259295.5	CSPG4P12	5.12	4.42e-07	0.000121	0.33	0.23	Schizophrenia;	chr15:84574820	chr15:85191438~85213905:+
LUAD	cis	rs12439619	0.693	rs8034801	ENSG00000276710.3	CSPG4P8	-5.12	4.42e-07	0.000121	-0.25	-0.23	Intelligence (multi-trait analysis);	chr15:82183996	chr15:82459472~82477258:+
LUAD	cis	rs12681366	0.763	rs3019277	ENSG00000253704.1	RP11-267M23.4	5.12	4.43e-07	0.000122	0.28	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94428195	chr8:94553722~94569745:+
LUAD	cis	rs875971	0.54	rs35510581	ENSG00000237310.1	GS1-124K5.4	-5.12	4.43e-07	0.000122	-0.25	-0.23	Aortic root size;	chr7:66113790	chr7:66493706~66495474:+
LUAD	cis	rs7396835	0.537	rs10892035	ENSG00000280143.1	AP000892.6	5.12	4.43e-07	0.000122	0.3	0.23	Quantitative traits;	chr11:116824222	chr11:117204967~117210292:+
LUAD	cis	rs2239547	0.522	rs2581780	ENSG00000242142.1	SERBP1P3	-5.12	4.44e-07	0.000122	-0.27	-0.23	Schizophrenia;	chr3:53024944	chr3:53064283~53065091:-
LUAD	cis	rs7772486	0.692	rs2265915	ENSG00000235652.6	RP11-545I5.3	5.12	4.44e-07	0.000122	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145873196	chr6:145799409~145886585:+
LUAD	cis	rs138249	0.505	rs138218	ENSG00000273253.2	RP3-402G11.26	-5.12	4.44e-07	0.000122	-0.21	-0.23	Gestational age at birth in labor-initiated deliveries (child effect);	chr22:50109129	chr22:50199090~50200837:-
LUAD	cis	rs10129255	0.834	rs10139893	ENSG00000211974.3	IGHV2-70	5.12	4.44e-07	0.000122	0.25	0.23	Kawasaki disease;	chr14:106711377	chr14:106723574~106724093:-
LUAD	cis	rs375066	0.935	rs425221	ENSG00000267058.1	RP11-15A1.3	5.12	4.44e-07	0.000122	0.26	0.23	Breast cancer;	chr19:43914392	chr19:43891804~43901805:-
LUAD	cis	rs2337406	1	rs17113276	ENSG00000223648.3	IGHV3-64	-5.12	4.44e-07	0.000122	-0.27	-0.23	Alzheimer's disease (late onset);	chr14:106683485	chr14:106643132~106658258:-
LUAD	cis	rs1318937	0.764	rs735659	ENSG00000224660.1	SH3BP5-AS1	5.12	4.45e-07	0.000122	0.17	0.23	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15182487	chr3:15254184~15264493:+
LUAD	cis	rs7260359	0.518	rs344816	ENSG00000242675.1	RPS16P9	5.12	4.45e-07	0.000122	0.24	0.23	Intelligence (multi-trait analysis);	chr19:45322368	chr19:45332698~45333124:-
LUAD	cis	rs897984	0.762	rs4889604	ENSG00000260911.2	RP11-196G11.2	-5.12	4.45e-07	0.000122	-0.2	-0.23	Dementia with Lewy bodies;	chr16:30974673	chr16:31043150~31049868:+
LUAD	cis	rs897984	0.762	rs12931046	ENSG00000260911.2	RP11-196G11.2	-5.12	4.45e-07	0.000122	-0.2	-0.23	Dementia with Lewy bodies;	chr16:30975823	chr16:31043150~31049868:+
LUAD	cis	rs2880765	0.835	rs900573	ENSG00000259295.5	CSPG4P12	-5.12	4.45e-07	0.000122	-0.26	-0.23	Coronary artery disease;	chr15:85494762	chr15:85191438~85213905:+
LUAD	cis	rs1031391	0.716	rs10772416	ENSG00000247157.5	LINC01252	-5.12	4.45e-07	0.000122	-0.31	-0.23	Bitter taste perception;	chr12:11017488	chr12:11548030~11590369:+
LUAD	cis	rs10129255	0.912	rs8009135	ENSG00000211967.3	IGHV3-53	-5.12	4.46e-07	0.000122	-0.17	-0.23	Kawasaki disease;	chr14:106777528	chr14:106592676~106593347:-
LUAD	cis	rs17507216	0.671	rs28582623	ENSG00000255769.6	GOLGA2P10	-5.12	4.46e-07	0.000122	-0.29	-0.23	Excessive daytime sleepiness;	chr15:82577381	chr15:82472993~82513950:-
LUAD	cis	rs7819412	0.623	rs7833435	ENSG00000255046.1	RP11-297N6.4	5.12	4.46e-07	0.000123	0.29	0.23	Triglycerides;	chr8:10943627	chr8:11797928~11802568:-
LUAD	cis	rs7208859	0.623	rs9898084	ENSG00000263603.1	CTD-2349P21.5	-5.12	4.46e-07	0.000123	-0.39	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30729469~30731202:+
LUAD	cis	rs5758659	0.935	rs134879	ENSG00000182057.4	OGFRP1	5.12	4.47e-07	0.000123	0.27	0.23	Cognitive function;	chr22:42268195	chr22:42269753~42275196:+
LUAD	cis	rs4835473	0.932	rs62337619	ENSG00000251600.4	RP11-673E1.1	-5.12	4.47e-07	0.000123	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143742083	chr4:143912331~143982454:+
LUAD	cis	rs35934224	0.504	rs7288631	ENSG00000232926.1	AC000078.5	5.12	4.47e-07	0.000123	0.29	0.23	Glaucoma (primary open-angle);	chr22:19848625	chr22:19887289~19887970:+
LUAD	cis	rs4948102	0.551	rs4275190	ENSG00000273720.1	RP11-613E4.4	-5.12	4.47e-07	0.000123	-0.28	-0.23	Plasma homocysteine levels (post-methionine load test);	chr7:56036695	chr7:55743073~55743457:+
LUAD	cis	rs1707322	0.721	rs11211163	ENSG00000280836.1	AL355480.1	-5.12	4.47e-07	0.000123	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45687876	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.721	rs12037803	ENSG00000280836.1	AL355480.1	-5.12	4.47e-07	0.000123	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690820	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.721	rs10789470	ENSG00000280836.1	AL355480.1	-5.12	4.47e-07	0.000123	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692659	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.721	rs61784796	ENSG00000280836.1	AL355480.1	-5.12	4.47e-07	0.000123	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697584	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.721	rs10749856	ENSG00000280836.1	AL355480.1	-5.12	4.47e-07	0.000123	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45699174	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.721	rs10890344	ENSG00000280836.1	AL355480.1	-5.12	4.47e-07	0.000123	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45700418	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.721	rs4564187	ENSG00000280836.1	AL355480.1	-5.12	4.47e-07	0.000123	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701189	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.752	rs28438704	ENSG00000280836.1	AL355480.1	-5.12	4.47e-07	0.000123	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45704872	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.721	rs28442079	ENSG00000280836.1	AL355480.1	-5.12	4.47e-07	0.000123	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706329	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.721	rs28817701	ENSG00000280836.1	AL355480.1	-5.12	4.47e-07	0.000123	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720378	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.691	rs28495425	ENSG00000280836.1	AL355480.1	-5.12	4.47e-07	0.000123	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45721648	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.685	rs28617418	ENSG00000280836.1	AL355480.1	-5.12	4.47e-07	0.000123	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723854	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.691	rs61784803	ENSG00000280836.1	AL355480.1	5.12	4.47e-07	0.000123	0.3	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45713599	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.663	rs3935296	ENSG00000280836.1	AL355480.1	5.12	4.47e-07	0.000123	0.3	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45714798	chr1:45581219~45581321:-
LUAD	cis	rs4664293	0.707	rs7563956	ENSG00000226266.5	AC009961.3	5.12	4.47e-07	0.000123	0.3	0.23	Monocyte percentage of white cells;	chr2:159815943	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.74	rs12464577	ENSG00000226266.5	AC009961.3	5.12	4.47e-07	0.000123	0.3	0.23	Monocyte percentage of white cells;	chr2:159816321	chr2:159670708~159712435:-
LUAD	cis	rs7324557	0.683	rs9510884	ENSG00000205861.10	C1QTNF9B-AS1	5.12	4.47e-07	0.000123	0.3	0.23	Visceral adipose tissue adjusted for BMI;	chr13:23830873	chr13:23888889~23897263:+
LUAD	cis	rs7017914	0.652	rs62508777	ENSG00000223220.1	Y_RNA	5.12	4.48e-07	0.000123	0.26	0.23	Bone mineral density;	chr8:70782769	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs6986479	ENSG00000223220.1	Y_RNA	5.12	4.48e-07	0.000123	0.26	0.23	Bone mineral density;	chr8:70785323	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs35115647	ENSG00000223220.1	Y_RNA	5.12	4.48e-07	0.000123	0.26	0.23	Bone mineral density;	chr8:70785777	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs1444339	ENSG00000223220.1	Y_RNA	5.12	4.48e-07	0.000123	0.26	0.23	Bone mineral density;	chr8:70788407	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.628	rs7822474	ENSG00000223220.1	Y_RNA	5.12	4.48e-07	0.000123	0.26	0.23	Bone mineral density;	chr8:70793498	chr8:70780914~70781008:-
LUAD	cis	rs1008375	0.966	rs10939735	ENSG00000249502.1	AC006160.5	-5.12	4.48e-07	0.000123	-0.23	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17577268	chr4:17587467~17614571:-
LUAD	cis	rs4835473	0.932	rs1450235	ENSG00000251600.4	RP11-673E1.1	5.12	4.48e-07	0.000123	0.29	0.23	Immature fraction of reticulocytes;	chr4:143782927	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs34324222	ENSG00000251600.4	RP11-673E1.1	-5.12	4.48e-07	0.000123	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143784572	chr4:143912331~143982454:+
LUAD	cis	rs801193	0.935	rs11772264	ENSG00000237310.1	GS1-124K5.4	5.12	4.48e-07	0.000123	0.25	0.23	Aortic root size;	chr7:66711400	chr7:66493706~66495474:+
LUAD	cis	rs17826219	0.714	rs11650821	ENSG00000263603.1	CTD-2349P21.5	-5.12	4.49e-07	0.000123	-0.4	-0.23	Body mass index;	chr17:30641132	chr17:30729469~30731202:+
LUAD	cis	rs1707322	1	rs785507	ENSG00000280836.1	AL355480.1	5.12	4.49e-07	0.000123	0.3	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46075886	chr1:45581219~45581321:-
LUAD	cis	rs1799949	1	rs11653253	ENSG00000236383.6	LINC00854	-5.12	4.49e-07	0.000123	-0.19	-0.23	Menopause (age at onset);	chr17:43030645	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs12951869	ENSG00000236383.6	LINC00854	-5.12	4.49e-07	0.000123	-0.19	-0.23	Menopause (age at onset);	chr17:43035550	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs11654452	ENSG00000236383.6	LINC00854	-5.12	4.49e-07	0.000123	-0.19	-0.23	Menopause (age at onset);	chr17:43037366	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs2175957	ENSG00000236383.6	LINC00854	-5.12	4.49e-07	0.000123	-0.18	-0.23	Menopause (age at onset);	chr17:43134805	chr17:43216941~43305976:-
LUAD	cis	rs1799949	0.965	rs33988650	ENSG00000236383.6	LINC00854	-5.12	4.49e-07	0.000123	-0.18	-0.23	Menopause (age at onset);	chr17:43135863	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs11656097	ENSG00000236383.6	LINC00854	-5.12	4.49e-07	0.000123	-0.18	-0.23	Menopause (age at onset);	chr17:43138596	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs11658754	ENSG00000236383.6	LINC00854	-5.12	4.49e-07	0.000123	-0.18	-0.23	Menopause (age at onset);	chr17:43140722	chr17:43216941~43305976:-
LUAD	cis	rs12745968	0.561	rs10874726	ENSG00000223787.2	RP4-593M8.1	-5.12	4.49e-07	0.000123	-0.27	-0.23	Bipolar disorder and schizophrenia;	chr1:92637542	chr1:92580476~92580821:-
LUAD	cis	rs12745968	0.589	rs10782937	ENSG00000223787.2	RP4-593M8.1	-5.12	4.49e-07	0.000123	-0.27	-0.23	Bipolar disorder and schizophrenia;	chr1:92637644	chr1:92580476~92580821:-
LUAD	cis	rs9322193	0.607	rs4869755	ENSG00000223701.3	RAET1E-AS1	5.12	4.5e-07	0.000123	0.33	0.23	Lung cancer;	chr6:149886347	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.639	rs4869756	ENSG00000223701.3	RAET1E-AS1	5.12	4.5e-07	0.000123	0.33	0.23	Lung cancer;	chr6:149886360	chr6:149884431~149919508:+
LUAD	cis	rs2032366	0.591	rs7241479	ENSG00000267279.1	RP11-879F14.2	-5.12	4.5e-07	0.000123	-0.29	-0.23	Obesity-related traits;	chr18:61631923	chr18:61585746~61606916:-
LUAD	cis	rs2032366	0.654	rs7227661	ENSG00000267279.1	RP11-879F14.2	-5.12	4.5e-07	0.000123	-0.29	-0.23	Obesity-related traits;	chr18:61632275	chr18:61585746~61606916:-
LUAD	cis	rs240993	0.812	rs28770304	ENSG00000230177.1	RP5-1112D6.4	5.12	4.5e-07	0.000123	0.23	0.23	Inflammatory skin disease;Psoriasis;	chr6:111461586	chr6:111277932~111278742:+
LUAD	cis	rs7302981	0.934	rs7532	ENSG00000272368.2	RP4-605O3.4	-5.12	4.5e-07	0.000123	-0.27	-0.23	Systolic blood pressure;	chr12:50130181	chr12:50112197~50165618:+
LUAD	cis	rs1008375	0.966	rs28441502	ENSG00000249502.1	AC006160.5	-5.12	4.5e-07	0.000123	-0.22	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17596761	chr4:17587467~17614571:-
LUAD	cis	rs516805	0.563	rs571706	ENSG00000279453.1	RP3-425C14.4	-5.12	4.5e-07	0.000123	-0.3	-0.23	Lymphocyte counts;	chr6:122393787	chr6:122436789~122439223:-
LUAD	cis	rs7772486	0.754	rs9373475	ENSG00000235652.6	RP11-545I5.3	5.12	4.5e-07	0.000123	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145805283	chr6:145799409~145886585:+
LUAD	cis	rs673078	0.607	rs61943393	ENSG00000275409.1	RP11-131L12.4	-5.12	4.51e-07	0.000123	-0.32	-0.23	Glucose homeostasis traits;	chr12:118383650	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.607	rs73205576	ENSG00000275409.1	RP11-131L12.4	-5.12	4.51e-07	0.000123	-0.32	-0.23	Glucose homeostasis traits;	chr12:118384268	chr12:118430147~118430699:+
LUAD	cis	rs9500256	0.966	rs1322446	ENSG00000215190.7	LINC00680	-5.12	4.51e-07	0.000124	-0.27	-0.23	Eosinophilic esophagitis (pediatric);	chr6:57985672	chr6:57946074~57961501:-
LUAD	cis	rs11051970	0.559	rs11051939	ENSG00000274964.1	RP11-817I4.1	5.12	4.51e-07	0.000124	0.29	0.23	Response to tocilizumab in rheumatoid arthritis;	chr12:32330107	chr12:32339368~32340724:+
LUAD	cis	rs17772222	0.958	rs2297128	ENSG00000258983.2	RP11-507K2.2	5.12	4.51e-07	0.000124	0.28	0.23	Coronary artery calcification;	chr14:88469910	chr14:88499334~88515502:+
LUAD	cis	rs2919009	0.664	rs55848502	ENSG00000271670.1	RP11-95I16.4	5.12	4.51e-07	0.000124	0.29	0.23	Obesity-related traits;	chr10:120925258	chr10:120879256~120880667:-
LUAD	cis	rs1799949	1	rs2298862	ENSG00000236383.6	LINC00854	-5.12	4.51e-07	0.000124	-0.19	-0.23	Menopause (age at onset);	chr17:43024671	chr17:43216941~43305976:-
LUAD	cis	rs1799949	0.93	rs2298861	ENSG00000236383.6	LINC00854	-5.12	4.51e-07	0.000124	-0.19	-0.23	Menopause (age at onset);	chr17:43024814	chr17:43216941~43305976:-
LUAD	cis	rs673078	0.607	rs7304342	ENSG00000275409.1	RP11-131L12.4	-5.12	4.51e-07	0.000124	-0.31	-0.23	Glucose homeostasis traits;	chr12:118390166	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.615	rs61943397	ENSG00000275409.1	RP11-131L12.4	-5.12	4.51e-07	0.000124	-0.31	-0.23	Glucose homeostasis traits;	chr12:118390996	chr12:118430147~118430699:+
LUAD	cis	rs10246939	0.579	rs58093678	ENSG00000270923.1	TAS2R6P	-5.12	4.51e-07	0.000124	-0.25	-0.23	Bitter taste perception;	chr7:141856719	chr7:141787815~141788640:+
LUAD	cis	rs948562	0.657	rs11229358	ENSG00000280010.1	AP001350.4	5.12	4.51e-07	0.000124	0.35	0.23	Lymphoma;	chr11:58314088	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.69	rs11229359	ENSG00000280010.1	AP001350.4	5.12	4.51e-07	0.000124	0.35	0.23	Lymphoma;	chr11:58314613	chr11:58627435~58628528:+
LUAD	cis	rs763567	0.933	rs608930	ENSG00000271811.1	RP1-79C4.4	5.12	4.52e-07	0.000124	0.27	0.23	Tonsillectomy;	chr1:170648165	chr1:170667381~170669425:+
LUAD	cis	rs7772486	0.79	rs2249386	ENSG00000235652.6	RP11-545I5.3	5.12	4.52e-07	0.000124	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145865475	chr6:145799409~145886585:+
LUAD	cis	rs2439831	0.85	rs28595038	ENSG00000249839.1	AC011330.5	-5.12	4.52e-07	0.000124	-0.45	-0.23	Lung cancer in ever smokers;	chr15:43752661	chr15:43663654~43684339:-
LUAD	cis	rs2439831	0.85	rs10163054	ENSG00000249839.1	AC011330.5	-5.12	4.52e-07	0.000124	-0.45	-0.23	Lung cancer in ever smokers;	chr15:43755440	chr15:43663654~43684339:-
LUAD	cis	rs7017914	0.667	rs2639925	ENSG00000223220.1	Y_RNA	5.12	4.53e-07	0.000124	0.26	0.23	Bone mineral density;	chr8:70991937	chr8:70780914~70781008:-
LUAD	cis	rs2661868	0.918	rs2636314	ENSG00000232912.4	RP5-1115A15.1	-5.12	4.53e-07	0.000124	-0.23	-0.23	Life satisfaction;	chr1:8380583	chr1:8424645~8434838:+
LUAD	cis	rs516805	0.633	rs9490414	ENSG00000279453.1	RP3-425C14.4	5.12	4.53e-07	0.000124	0.3	0.23	Lymphocyte counts;	chr6:122245612	chr6:122436789~122439223:-
LUAD	cis	rs6604026	0.555	rs34221961	ENSG00000223787.2	RP4-593M8.1	5.12	4.54e-07	0.000124	0.31	0.23	Multiple sclerosis;	chr1:92615337	chr1:92580476~92580821:-
LUAD	cis	rs9309473	0.558	rs11679042	ENSG00000163016.8	ALMS1P	5.12	4.54e-07	0.000124	0.34	0.23	Metabolite levels;	chr2:73680184	chr2:73644919~73685576:+
LUAD	cis	rs10129255	0.518	rs12590732	ENSG00000211967.3	IGHV3-53	5.12	4.54e-07	0.000124	0.16	0.23	Kawasaki disease;	chr14:106779612	chr14:106592676~106593347:-
LUAD	cis	rs7017914	0.69	rs7013495	ENSG00000223220.1	Y_RNA	5.11	4.54e-07	0.000124	0.26	0.23	Bone mineral density;	chr8:70781282	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.69	rs10429277	ENSG00000223220.1	Y_RNA	5.11	4.54e-07	0.000124	0.26	0.23	Bone mineral density;	chr8:70789156	chr8:70780914~70781008:-
LUAD	cis	rs7927592	0.763	rs596494	ENSG00000212093.1	AP000807.1	5.11	4.54e-07	0.000124	0.23	0.23	Total body bone mineral density;	chr11:68483586	chr11:68506083~68506166:-
LUAD	cis	rs6570726	0.791	rs9403729	ENSG00000235652.6	RP11-545I5.3	5.11	4.54e-07	0.000124	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145585871	chr6:145799409~145886585:+
LUAD	cis	rs10129255	0.5	rs2027902	ENSG00000211967.3	IGHV3-53	-5.11	4.54e-07	0.000124	-0.16	-0.23	Kawasaki disease;	chr14:106807157	chr14:106592676~106593347:-
LUAD	cis	rs853679	0.546	rs200981	ENSG00000219392.1	RP1-265C24.5	-5.11	4.55e-07	0.000125	-0.44	-0.23	Depression;	chr6:27865396	chr6:28115628~28116551:+
LUAD	cis	rs7208859	0.623	rs216423	ENSG00000263531.1	RP13-753N3.1	5.11	4.55e-07	0.000125	0.39	0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30615091	chr17:30863921~30864940:-
LUAD	cis	rs875971	0.83	rs12673450	ENSG00000232559.3	GS1-124K5.12	5.11	4.56e-07	0.000125	0.28	0.23	Aortic root size;	chr7:66544233	chr7:66554588~66576923:-
LUAD	cis	rs2032366	0.63	rs6567226	ENSG00000267279.1	RP11-879F14.2	-5.11	4.56e-07	0.000125	-0.29	-0.23	Obesity-related traits;	chr18:61635689	chr18:61585746~61606916:-
LUAD	cis	rs2098713	0.535	rs56044522	ENSG00000250155.1	CTD-2353F22.1	5.11	4.56e-07	0.000125	0.24	0.23	Telomere length;	chr5:37582698	chr5:36666214~36725195:-
LUAD	cis	rs8177876	0.822	rs79926943	ENSG00000261061.1	RP11-303E16.2	-5.11	4.56e-07	0.000125	-0.4	-0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81072005	chr16:81030770~81031485:+
LUAD	cis	rs7580658	0.857	rs11890187	ENSG00000236682.1	AC068282.3	-5.11	4.56e-07	0.000125	-0.31	-0.23	Protein C levels;	chr2:127326162	chr2:127389130~127400580:+
LUAD	cis	rs73186030	0.546	rs73188388	ENSG00000272758.4	RP11-299J3.8	5.11	4.56e-07	0.000125	0.29	0.23	Serum parathyroid hormone levels;	chr3:122399229	chr3:122416207~122443180:+
LUAD	cis	rs61270009	0.955	rs430943	ENSG00000247828.6	TMEM161B-AS1	-5.11	4.56e-07	0.000125	-0.26	-0.23	Depressive symptoms;	chr5:88251306	chr5:88268895~88436685:+
LUAD	cis	rs42490	0.903	rs218900	ENSG00000251136.7	RP11-37B2.1	-5.11	4.57e-07	0.000125	-0.23	-0.23	Leprosy;	chr8:89718678	chr8:89609409~89757727:-
LUAD	cis	rs858239	0.539	rs7791200	ENSG00000230042.1	AK3P3	-5.11	4.57e-07	0.000125	-0.29	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23142502	chr7:23129178~23129841:+
LUAD	cis	rs683257	0.673	rs72990126	ENSG00000234147.1	RP3-460G2.2	-5.11	4.57e-07	0.000125	-0.36	-0.23	Facial emotion recognition (angry faces);	chr6:140850534	chr6:140845958~140852924:-
LUAD	cis	rs4143844	0.867	rs77585482	ENSG00000259251.2	RP11-643M14.1	5.11	4.57e-07	0.000125	0.4	0.23	Bipolar disorder and schizophrenia;	chr15:61925442	chr15:62060503~62062434:+
LUAD	cis	rs4143844	0.867	rs62009109	ENSG00000259251.2	RP11-643M14.1	5.11	4.57e-07	0.000125	0.4	0.23	Bipolar disorder and schizophrenia;	chr15:61927032	chr15:62060503~62062434:+
LUAD	cis	rs755249	0.501	rs2455648	ENSG00000228060.1	RP11-69E11.8	-5.11	4.57e-07	0.000125	-0.21	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39178040	chr1:39565160~39573203:+
LUAD	cis	rs17711722	0.522	rs4642526	ENSG00000234585.5	CCT6P3	5.11	4.57e-07	0.000125	0.21	0.23	Calcium levels;	chr7:65751755	chr7:65038354~65074713:+
LUAD	cis	rs17711722	0.74	rs7809991	ENSG00000164669.11	INTS4P1	-5.11	4.58e-07	0.000125	-0.27	-0.23	Calcium levels;	chr7:65941231	chr7:65141225~65234216:+
LUAD	cis	rs853679	1	rs11965538	ENSG00000204709.4	LINC01556	5.11	4.58e-07	0.000125	0.35	0.23	Depression;	chr6:28272137	chr6:28943877~28944537:+
LUAD	cis	rs7017914	0.677	rs1973364	ENSG00000223220.1	Y_RNA	-5.11	4.58e-07	0.000125	-0.26	-0.23	Bone mineral density;	chr8:70955007	chr8:70780914~70781008:-
LUAD	cis	rs1876905	0.597	rs191631	ENSG00000272356.1	RP5-1112D6.8	-5.11	4.58e-07	0.000125	-0.27	-0.23	Mean corpuscular hemoglobin;	chr6:111226862	chr6:111309203~111313517:+
LUAD	cis	rs10246939	0.505	rs9640203	ENSG00000270923.1	TAS2R6P	-5.11	4.58e-07	0.000125	-0.27	-0.23	Bitter taste perception;	chr7:141844295	chr7:141787815~141788640:+
LUAD	cis	rs11089937	0.512	rs6001073	ENSG00000211638.2	IGLV8-61	-5.11	4.58e-07	0.000125	-0.26	-0.23	Periodontitis (PAL4Q3);	chr22:22133650	chr22:22098700~22099212:+
LUAD	cis	rs559928	1	rs471584	ENSG00000236935.1	AP003774.1	-5.11	4.59e-07	0.000126	-0.29	-0.23	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64381780	chr11:64325050~64329504:-
LUAD	cis	rs853679	0.546	rs200990	ENSG00000219392.1	RP1-265C24.5	-5.11	4.59e-07	0.000126	-0.43	-0.23	Depression;	chr6:27848045	chr6:28115628~28116551:+
LUAD	cis	rs7772486	0.79	rs2253768	ENSG00000235652.6	RP11-545I5.3	5.11	4.6e-07	0.000126	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145878786	chr6:145799409~145886585:+
LUAD	cis	rs17711722	1	rs17711722	ENSG00000236529.1	RP13-254B10.1	-5.11	4.6e-07	0.000126	-0.23	-0.23	Calcium levels;	chr7:65806210	chr7:65840212~65840596:+
LUAD	cis	rs17711722	0.675	rs6947132	ENSG00000236529.1	RP13-254B10.1	-5.11	4.6e-07	0.000126	-0.23	-0.23	Calcium levels;	chr7:65808508	chr7:65840212~65840596:+
LUAD	cis	rs673078	0.607	rs7302387	ENSG00000275409.1	RP11-131L12.4	-5.11	4.6e-07	0.000126	-0.35	-0.23	Glucose homeostasis traits;	chr12:118316546	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.66	rs7961312	ENSG00000275409.1	RP11-131L12.4	-5.11	4.6e-07	0.000126	-0.35	-0.23	Glucose homeostasis traits;	chr12:118324431	chr12:118430147~118430699:+
LUAD	cis	rs12681366	0.839	rs3019278	ENSG00000253704.1	RP11-267M23.4	5.11	4.6e-07	0.000126	0.28	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94434339	chr8:94553722~94569745:+
LUAD	cis	rs12681366	0.839	rs2930964	ENSG00000253704.1	RP11-267M23.4	5.11	4.6e-07	0.000126	0.28	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94435906	chr8:94553722~94569745:+
LUAD	cis	rs801193	1	rs7782320	ENSG00000237310.1	GS1-124K5.4	5.11	4.6e-07	0.000126	0.25	0.23	Aortic root size;	chr7:66712111	chr7:66493706~66495474:+
LUAD	cis	rs2286503	0.752	rs6461669	ENSG00000221740.1	SNORD93	5.11	4.6e-07	0.000126	0.26	0.23	Fibrinogen;	chr7:22818447	chr7:22856613~22856686:+
LUAD	cis	rs763567	0.967	rs7412231	ENSG00000271811.1	RP1-79C4.4	-5.11	4.6e-07	0.000126	-0.28	-0.23	Tonsillectomy;	chr1:170601358	chr1:170667381~170669425:+
LUAD	cis	rs2098713	0.535	rs4869538	ENSG00000250155.1	CTD-2353F22.1	5.11	4.61e-07	0.000126	0.24	0.23	Telomere length;	chr5:37624065	chr5:36666214~36725195:-
LUAD	cis	rs2239547	0.563	rs4687699	ENSG00000242142.1	SERBP1P3	5.11	4.61e-07	0.000126	0.26	0.23	Schizophrenia;	chr3:53067208	chr3:53064283~53065091:-
LUAD	cis	rs240993	0.812	rs9487632	ENSG00000230177.1	RP5-1112D6.4	-5.11	4.61e-07	0.000126	-0.23	-0.23	Inflammatory skin disease;Psoriasis;	chr6:111417970	chr6:111277932~111278742:+
LUAD	cis	rs240993	0.812	rs11153295	ENSG00000230177.1	RP5-1112D6.4	-5.11	4.61e-07	0.000126	-0.23	-0.23	Inflammatory skin disease;Psoriasis;	chr6:111420164	chr6:111277932~111278742:+
LUAD	cis	rs240993	0.812	rs6915753	ENSG00000230177.1	RP5-1112D6.4	-5.11	4.61e-07	0.000126	-0.23	-0.23	Inflammatory skin disease;Psoriasis;	chr6:111420476	chr6:111277932~111278742:+
LUAD	cis	rs240993	0.812	rs4620159	ENSG00000230177.1	RP5-1112D6.4	-5.11	4.61e-07	0.000126	-0.23	-0.23	Inflammatory skin disease;Psoriasis;	chr6:111423532	chr6:111277932~111278742:+
LUAD	cis	rs12701220	0.655	rs9638973	ENSG00000229043.2	AC091729.9	-5.11	4.62e-07	0.000126	-0.29	-0.23	Bronchopulmonary dysplasia;	chr7:1094042	chr7:1160374~1165267:+
LUAD	cis	rs9807989	0.839	rs4988955	ENSG00000234389.1	AC007278.3	5.11	4.62e-07	0.000126	0.22	0.23	Asthma;	chr2:102351468	chr2:102438713~102440475:+
LUAD	cis	rs8098244	0.537	rs11877880	ENSG00000264745.1	TTC39C-AS1	5.11	4.62e-07	0.000126	0.24	0.23	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23716401	chr18:23994213~24015339:-
LUAD	cis	rs12554020	0.786	rs7857183	ENSG00000227603.1	RP11-165J3.6	5.11	4.62e-07	0.000126	0.35	0.23	Schizophrenia;	chr9:93569762	chr9:93435332~93437121:-
LUAD	cis	rs984222	0.775	rs2645294	ENSG00000226172.2	RP4-712E4.1	-5.11	4.62e-07	0.000126	-0.24	-0.23	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119031964	chr1:119000344~119001392:-
LUAD	cis	rs2708377	0.789	rs3911150	ENSG00000212125.2	TAS2R15P	-5.11	4.63e-07	0.000127	-0.33	-0.23	Bitter taste perception;	chr12:11049649	chr12:10964425~10965352:-
LUAD	cis	rs2742234	0.59	rs2435338	ENSG00000273008.1	RP11-351D16.3	-5.11	4.63e-07	0.000127	-0.26	-0.23	Hirschsprung disease;	chr10:43146667	chr10:43136824~43138334:-
LUAD	cis	rs2742234	0.59	rs2435339	ENSG00000273008.1	RP11-351D16.3	-5.11	4.63e-07	0.000127	-0.26	-0.23	Hirschsprung disease;	chr10:43146725	chr10:43136824~43138334:-
LUAD	cis	rs4835473	0.897	rs7662736	ENSG00000251600.4	RP11-673E1.1	5.11	4.63e-07	0.000127	0.28	0.23	Immature fraction of reticulocytes;	chr4:143958036	chr4:143912331~143982454:+
LUAD	cis	rs453301	0.658	rs12114954	ENSG00000253893.2	FAM85B	5.11	4.64e-07	0.000127	0.29	0.23	Joint mobility (Beighton score);	chr8:9047352	chr8:8167819~8226614:-
LUAD	cis	rs7580658	0.864	rs4150454	ENSG00000236682.1	AC068282.3	-5.11	4.64e-07	0.000127	-0.3	-0.23	Protein C levels;	chr2:127280968	chr2:127389130~127400580:+
LUAD	cis	rs925255	0.591	rs7559046	ENSG00000270210.1	RP11-373D23.3	5.11	4.64e-07	0.000127	0.27	0.23	Inflammatory bowel disease;Crohn's disease;	chr2:28421803	chr2:28425945~28426719:+
LUAD	cis	rs10050311	0.932	rs17012072	ENSG00000251411.1	RP11-397E7.4	-5.11	4.64e-07	0.000127	-0.34	-0.23	Insulin-related traits;	chr4:86783816	chr4:86913266~86914817:-
LUAD	cis	rs75422866	0.51	rs73105818	ENSG00000257433.4	RP1-197B17.3	5.11	4.65e-07	0.000127	0.47	0.23	Pneumonia;	chr12:47726538	chr12:47706085~47742294:+
LUAD	cis	rs5758659	0.967	rs5758670	ENSG00000227370.1	RP4-669P10.19	-5.11	4.65e-07	0.000127	-0.21	-0.23	Cognitive function;	chr22:42240681	chr22:42132543~42132998:+
LUAD	cis	rs2836950	0.565	rs8130320	ENSG00000255568.3	BRWD1-AS2	-5.11	4.66e-07	0.000127	-0.22	-0.23	Menarche (age at onset);	chr21:39208332	chr21:39313935~39314962:+
LUAD	cis	rs8098244	0.638	rs12953820	ENSG00000264745.1	TTC39C-AS1	5.11	4.66e-07	0.000127	0.23	0.23	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23878760	chr18:23994213~24015339:-
LUAD	cis	rs14027	0.921	rs16893101	ENSG00000279347.1	RP11-85I17.2	-5.11	4.66e-07	0.000127	-0.2	-0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119750669	chr8:119838736~119840385:-
LUAD	cis	rs6095360	0.7	rs79941596	ENSG00000222365.1	SNORD12B	-5.11	4.66e-07	0.000127	-0.26	-0.23	Intelligence (multi-trait analysis);	chr20:49177259	chr20:49280319~49280409:+
LUAD	cis	rs6095360	0.689	rs7274851	ENSG00000222365.1	SNORD12B	-5.11	4.66e-07	0.000127	-0.26	-0.23	Intelligence (multi-trait analysis);	chr20:49177818	chr20:49280319~49280409:+
LUAD	cis	rs9309473	0.687	rs6747145	ENSG00000163016.8	ALMS1P	5.11	4.66e-07	0.000127	0.26	0.23	Metabolite levels;	chr2:73382049	chr2:73644919~73685576:+
LUAD	cis	rs11976180	1	rs1919951	ENSG00000170356.8	OR2A20P	-5.11	4.66e-07	0.000127	-0.29	-0.23	Obesity-related traits;	chr7:144071798	chr7:144250045~144252957:-
LUAD	cis	rs1005277	0.579	rs1621040	ENSG00000263064.2	RP11-291L22.7	5.11	4.66e-07	0.000127	0.24	0.23	Extrinsic epigenetic age acceleration;	chr10:38208304	chr10:38448689~38448949:+
LUAD	cis	rs1426063	0.858	rs6823982	ENSG00000249717.1	RP11-44F21.3	5.11	4.68e-07	0.000128	0.33	0.23	QT interval;	chr4:75084961	chr4:74955974~74970362:-
LUAD	cis	rs6687821	0.515	rs2753275	ENSG00000267734.1	RP4-604K5.3	5.11	4.68e-07	0.000128	0.28	0.23	Yeast infection;	chr1:86956377	chr1:86932199~86934891:-
LUAD	cis	rs1816752	0.87	rs9581029	ENSG00000273628.1	RP11-756A22.7	5.11	4.68e-07	0.000128	0.25	0.23	Obesity-related traits;	chr13:24425147	chr13:24933006~24936796:+
LUAD	cis	rs1816752	0.905	rs9511249	ENSG00000273628.1	RP11-756A22.7	5.11	4.68e-07	0.000128	0.25	0.23	Obesity-related traits;	chr13:24425457	chr13:24933006~24936796:+
LUAD	cis	rs673078	0.517	rs73205578	ENSG00000275409.1	RP11-131L12.4	-5.11	4.68e-07	0.000128	-0.33	-0.23	Glucose homeostasis traits;	chr12:118385113	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.66	rs73205579	ENSG00000275409.1	RP11-131L12.4	-5.11	4.68e-07	0.000128	-0.33	-0.23	Glucose homeostasis traits;	chr12:118385125	chr12:118430147~118430699:+
LUAD	cis	rs950169	0.881	rs34117475	ENSG00000259295.5	CSPG4P12	5.11	4.69e-07	0.000128	0.32	0.23	Schizophrenia;	chr15:84565212	chr15:85191438~85213905:+
LUAD	cis	rs17711722	0.565	rs73372653	ENSG00000234585.5	CCT6P3	5.11	4.69e-07	0.000128	0.21	0.23	Calcium levels;	chr7:65977808	chr7:65038354~65074713:+
LUAD	cis	rs35851103	0.506	rs4841659	ENSG00000255046.1	RP11-297N6.4	-5.11	4.69e-07	0.000128	-0.28	-0.23	Neuroticism;	chr8:11970691	chr8:11797928~11802568:-
LUAD	cis	rs2898681	0.618	rs7677726	ENSG00000248375.1	RP11-177B4.1	5.11	4.69e-07	0.000128	0.4	0.23	Optic nerve measurement (cup area);	chr4:52873095	chr4:52720081~52720831:-
LUAD	cis	rs7772486	0.754	rs4896841	ENSG00000235652.6	RP11-545I5.3	-5.11	4.69e-07	0.000128	-0.23	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145720386	chr6:145799409~145886585:+
LUAD	cis	rs17666538	0.535	rs7822126	ENSG00000254207.1	RP11-43A14.1	5.11	4.69e-07	0.000128	0.41	0.23	IgG glycosylation;	chr8:693810	chr8:725188~725877:-
LUAD	cis	rs1799949	0.896	rs8176086	ENSG00000236383.6	LINC00854	-5.11	4.69e-07	0.000128	-0.18	-0.23	Menopause (age at onset);	chr17:43122761	chr17:43216941~43305976:-
LUAD	cis	rs6570726	0.738	rs4495284	ENSG00000235652.6	RP11-545I5.3	5.11	4.69e-07	0.000128	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145595481	chr6:145799409~145886585:+
LUAD	cis	rs4835473	0.618	rs12499429	ENSG00000251600.4	RP11-673E1.1	-5.11	4.69e-07	0.000128	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143889914	chr4:143912331~143982454:+
LUAD	cis	rs673078	0.66	rs61945219	ENSG00000275409.1	RP11-131L12.4	-5.11	4.7e-07	0.000128	-0.3	-0.23	Glucose homeostasis traits;	chr12:118272916	chr12:118430147~118430699:+
LUAD	cis	rs4908760	0.613	rs4908511	ENSG00000270282.1	RP5-1115A15.2	-5.11	4.7e-07	0.000128	-0.25	-0.23	Vitiligo;	chr1:8752331	chr1:8512653~8513021:+
LUAD	cis	rs8062405	0.573	rs7140	ENSG00000251417.2	RP11-1348G14.4	5.11	4.7e-07	0.000128	0.25	0.23	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28984436	chr16:28802743~28817828:+
LUAD	cis	rs10754283	0.901	rs10047070	ENSG00000231613.1	RP5-943J3.1	5.11	4.7e-07	0.000128	0.23	0.23	Amyotrophic lateral sclerosis (sporadic);	chr1:89633156	chr1:89788914~89790492:+
LUAD	cis	rs8098244	0.638	rs3745027	ENSG00000264745.1	TTC39C-AS1	5.11	4.71e-07	0.000129	0.23	0.23	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23893999	chr18:23994213~24015339:-
LUAD	cis	rs453301	0.624	rs330049	ENSG00000253981.4	ALG1L13P	5.11	4.71e-07	0.000129	0.27	0.23	Joint mobility (Beighton score);	chr8:9229789	chr8:8236003~8244667:-
LUAD	cis	rs12681366	0.761	rs2930963	ENSG00000253704.1	RP11-267M23.4	5.11	4.71e-07	0.000129	0.28	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94434892	chr8:94553722~94569745:+
LUAD	cis	rs4713118	0.591	rs2056924	ENSG00000219392.1	RP1-265C24.5	-5.11	4.71e-07	0.000129	-0.28	-0.23	Parkinson's disease;	chr6:27722395	chr6:28115628~28116551:+
LUAD	cis	rs6102185	0.572	rs6129698	ENSG00000229771.2	RP4-644L1.2	-5.11	4.71e-07	0.000129	-0.28	-0.23	IgG glycosylation;	chr20:40889786	chr20:40696499~40698616:-
LUAD	cis	rs10129255	0.957	rs10138532	ENSG00000211974.3	IGHV2-70	5.11	4.71e-07	0.000129	0.24	0.23	Kawasaki disease;	chr14:106803901	chr14:106723574~106724093:-
LUAD	cis	rs75422866	0.51	rs73105819	ENSG00000257433.4	RP1-197B17.3	5.11	4.71e-07	0.000129	0.47	0.23	Pneumonia;	chr12:47727190	chr12:47706085~47742294:+
LUAD	cis	rs2098713	0.599	rs12652658	ENSG00000250155.1	CTD-2353F22.1	5.11	4.71e-07	0.000129	0.23	0.23	Telomere length;	chr5:37555461	chr5:36666214~36725195:-
LUAD	cis	rs11976180	1	rs2961120	ENSG00000204959.4	ARHGEF34P	5.11	4.71e-07	0.000129	0.28	0.23	Obesity-related traits;	chr7:144059492	chr7:144272445~144286966:-
LUAD	cis	rs11976180	1	rs2951360	ENSG00000204959.4	ARHGEF34P	5.11	4.71e-07	0.000129	0.28	0.23	Obesity-related traits;	chr7:144060256	chr7:144272445~144286966:-
LUAD	cis	rs4908760	0.86	rs11121202	ENSG00000232912.4	RP5-1115A15.1	5.11	4.72e-07	0.000129	0.21	0.23	Vitiligo;	chr1:8579298	chr1:8424645~8434838:+
LUAD	cis	rs11089937	0.626	rs2213157	ENSG00000211638.2	IGLV8-61	-5.11	4.72e-07	0.000129	-0.26	-0.23	Periodontitis (PAL4Q3);	chr22:22137997	chr22:22098700~22099212:+
LUAD	cis	rs11009175	0.556	rs2093345	ENSG00000273038.2	RP11-479G22.8	-5.11	4.72e-07	0.000129	-0.28	-0.23	Depression (quantitative trait);	chr10:33037255	chr10:32887255~32889311:-
LUAD	cis	rs559928	0.569	rs7103915	ENSG00000236935.1	AP003774.1	-5.11	4.72e-07	0.000129	-0.31	-0.23	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64176898	chr11:64325050~64329504:-
LUAD	cis	rs2790457	0.958	rs2790444	ENSG00000254635.4	WAC-AS1	-5.11	4.72e-07	0.000129	-0.25	-0.23	Multiple myeloma;	chr10:28536760	chr10:28522652~28532743:-
LUAD	cis	rs9992667	0.91	rs28681431	ENSG00000231160.8	KLF3-AS1	5.11	4.72e-07	0.000129	0.29	0.23	Eosinophil percentage of granulocytes;	chr4:38686307	chr4:38612701~38664883:-
LUAD	cis	rs2337406	1	rs17113276	ENSG00000211974.3	IGHV2-70	5.11	4.72e-07	0.000129	0.29	0.23	Alzheimer's disease (late onset);	chr14:106683485	chr14:106723574~106724093:-
LUAD	cis	rs7826238	0.72	rs12546760	ENSG00000173295.6	FAM86B3P	-5.11	4.72e-07	0.000129	-0.24	-0.23	Systolic blood pressure;	chr8:8517326	chr8:8228595~8244865:+
LUAD	cis	rs3761847	0.622	rs10818500	ENSG00000226752.6	PSMD5-AS1	5.11	4.72e-07	0.000129	0.24	0.23	Rheumatoid arthritis;	chr9:121048605	chr9:120824828~120854385:+
LUAD	cis	rs12701220	0.553	rs9639882	ENSG00000229043.2	AC091729.9	-5.11	4.72e-07	0.000129	-0.29	-0.23	Bronchopulmonary dysplasia;	chr7:1094095	chr7:1160374~1165267:+
LUAD	cis	rs9309473	0.718	rs10175529	ENSG00000163016.8	ALMS1P	5.11	4.73e-07	0.000129	0.26	0.23	Metabolite levels;	chr2:73378965	chr2:73644919~73685576:+
LUAD	cis	rs1501911	0.588	rs709389	ENSG00000248489.1	CTD-2007H13.3	5.11	4.73e-07	0.000129	0.27	0.23	Lung function (FEV1/FVC);	chr5:98994011	chr5:98929171~98995013:+
LUAD	cis	rs600231	0.623	rs587080	ENSG00000245532.5	NEAT1	5.11	4.73e-07	0.000129	0.18	0.23	Bone mineral density;	chr11:65486329	chr11:65422774~65445540:+
LUAD	cis	rs9322193	0.886	rs2065663	ENSG00000268592.3	RAET1E-AS1	5.11	4.73e-07	0.000129	0.29	0.23	Lung cancer;	chr6:149760331	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.923	rs12205092	ENSG00000268592.3	RAET1E-AS1	5.11	4.73e-07	0.000129	0.29	0.23	Lung cancer;	chr6:149761375	chr6:149863494~149919507:+
LUAD	cis	rs9487094	0.961	rs9480948	ENSG00000260273.1	RP11-425D10.10	5.11	4.73e-07	0.000129	0.31	0.23	Height;	chr6:109407148	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.961	rs11967108	ENSG00000260273.1	RP11-425D10.10	5.11	4.73e-07	0.000129	0.31	0.23	Height;	chr6:109354040	chr6:109382795~109383666:+
LUAD	cis	rs9652601	0.959	rs12927355	ENSG00000274038.1	RP11-66H6.4	-5.11	4.74e-07	0.000129	-0.28	-0.23	Systemic lupus erythematosus;	chr16:11100914	chr16:11056556~11057034:+
LUAD	cis	rs7017914	0.652	rs35323776	ENSG00000223220.1	Y_RNA	5.11	4.74e-07	0.000129	0.26	0.23	Bone mineral density;	chr8:70797931	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.69	rs35767277	ENSG00000223220.1	Y_RNA	5.11	4.74e-07	0.000129	0.26	0.23	Bone mineral density;	chr8:70806262	chr8:70780914~70781008:-
LUAD	cis	rs9807989	0.839	rs10182710	ENSG00000234389.1	AC007278.3	5.11	4.74e-07	0.000129	0.22	0.23	Asthma;	chr2:102364846	chr2:102438713~102440475:+
LUAD	cis	rs9807989	0.839	rs13392100	ENSG00000234389.1	AC007278.3	5.11	4.74e-07	0.000129	0.22	0.23	Asthma;	chr2:102365634	chr2:102438713~102440475:+
LUAD	cis	rs1075265	0.572	rs62139835	ENSG00000233266.1	HMGB1P31	5.11	4.75e-07	0.000129	0.29	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53682307	chr2:54051334~54051760:+
LUAD	cis	rs7829975	0.593	rs2979241	ENSG00000253981.4	ALG1L13P	5.11	4.75e-07	0.000129	0.26	0.23	Mood instability;	chr8:8445843	chr8:8236003~8244667:-
LUAD	cis	rs4664293	0.967	rs2357526	ENSG00000226266.5	AC009961.3	5.11	4.75e-07	0.000129	0.31	0.23	Monocyte percentage of white cells;	chr2:159668085	chr2:159670708~159712435:-
LUAD	cis	rs2599510	0.703	rs58852184	ENSG00000276334.1	AL133243.1	5.11	4.75e-07	0.000129	0.27	0.23	Interleukin-18 levels;	chr2:32504696	chr2:32521927~32523547:+
LUAD	cis	rs1816752	0.905	rs9581026	ENSG00000273628.1	RP11-756A22.7	5.11	4.75e-07	0.000129	0.26	0.23	Obesity-related traits;	chr13:24423788	chr13:24933006~24936796:+
LUAD	cis	rs1729951	0.575	rs1654926	ENSG00000239213.4	NCK1-AS1	5.11	4.75e-07	0.000129	0.25	0.23	Neuroticism;	chr3:136991082	chr3:136841726~136862054:-
LUAD	cis	rs3096299	0.606	rs8052103	ENSG00000274627.1	RP11-104N10.2	-5.11	4.76e-07	0.00013	-0.24	-0.23	Multiple myeloma (IgH translocation);	chr16:89474835	chr16:89516797~89522217:+
LUAD	cis	rs950169	0.922	rs17531523	ENSG00000259295.5	CSPG4P12	5.11	4.76e-07	0.00013	0.33	0.23	Schizophrenia;	chr15:84589218	chr15:85191438~85213905:+
LUAD	cis	rs3177980	0.529	rs549002	ENSG00000239494.2	RN7SL333P	-5.11	4.76e-07	0.00013	-0.22	-0.23	Amyotrophic lateral sclerosis;	chr1:169920900	chr1:169859756~169860052:+
LUAD	cis	rs1707322	1	rs7538978	ENSG00000280836.1	AL355480.1	5.11	4.76e-07	0.00013	0.29	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039382	chr1:45581219~45581321:-
LUAD	cis	rs113835537	0.808	rs10896128	ENSG00000255517.5	CTD-3074O7.5	-5.11	4.76e-07	0.00013	-0.32	-0.23	Airway imaging phenotypes;	chr11:66557058	chr11:66473490~66480233:-
LUAD	cis	rs7829975	0.623	rs10092965	ENSG00000253893.2	FAM85B	-5.11	4.76e-07	0.00013	-0.29	-0.23	Mood instability;	chr8:8515975	chr8:8167819~8226614:-
LUAD	cis	rs1005277	0.579	rs1780133	ENSG00000263064.2	RP11-291L22.7	5.11	4.76e-07	0.00013	0.24	0.23	Extrinsic epigenetic age acceleration;	chr10:38210581	chr10:38448689~38448949:+
LUAD	cis	rs875971	0.508	rs10242423	ENSG00000237310.1	GS1-124K5.4	-5.11	4.76e-07	0.00013	-0.24	-0.23	Aortic root size;	chr7:66594188	chr7:66493706~66495474:+
LUAD	cis	rs4538475	0.53	rs6449168	ENSG00000214846.4	RP11-115L11.1	5.11	4.77e-07	0.00013	0.33	0.23	Parkinson's disease;	chr4:15726090	chr4:15730962~15731627:-
LUAD	cis	rs449789	0.857	rs9355713	ENSG00000235086.1	FNDC1-IT1	-5.11	4.77e-07	0.00013	-0.31	-0.23	Pulse pressure;	chr6:159301516	chr6:159240786~159243329:+
LUAD	cis	rs12681366	0.881	rs3019150	ENSG00000253704.1	RP11-267M23.4	5.11	4.77e-07	0.00013	0.28	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94420055	chr8:94553722~94569745:+
LUAD	cis	rs17684571	0.808	rs6938003	ENSG00000231441.1	RP11-472M19.2	5.11	4.77e-07	0.00013	0.31	0.23	Schizophrenia;	chr6:56753365	chr6:56844002~56864078:+
LUAD	cis	rs8040855	0.894	rs6496770	ENSG00000259774.1	RP11-182J1.13	-5.1	4.77e-07	0.00013	-0.27	-0.23	Bulimia nervosa;	chr15:85161890	chr15:84422618~84425882:+
LUAD	cis	rs453301	0.653	rs2956244	ENSG00000173295.6	FAM86B3P	5.1	4.78e-07	0.00013	0.25	0.23	Joint mobility (Beighton score);	chr8:9027656	chr8:8228595~8244865:+
LUAD	cis	rs35160687	0.623	rs4832263	ENSG00000273080.1	RP11-301O19.1	-5.1	4.78e-07	0.00013	-0.25	-0.23	Night sleep phenotypes;	chr2:86258034	chr2:86195590~86196049:+
LUAD	cis	rs2732480	0.5	rs2732461	ENSG00000257735.1	RP11-370I10.6	5.1	4.78e-07	0.00013	0.28	0.23	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48299019	chr12:48350945~48442411:+
LUAD	cis	rs807029	0.577	rs701834	ENSG00000272572.1	RP11-179B2.2	-5.1	4.78e-07	0.00013	-0.33	-0.23	Ejection fraction in Tripanosoma cruzi seropositivity;	chr10:101002044	chr10:100911103~100912739:-
LUAD	cis	rs8031584	0.958	rs34294266	ENSG00000270015.1	RP11-540B6.6	-5.1	4.78e-07	0.00013	-0.17	-0.23	Huntington's disease progression;	chr15:30954637	chr15:30926514~30928407:+
LUAD	cis	rs7968440	1	rs7968440	ENSG00000200428.1	Y_RNA	-5.1	4.78e-07	0.00013	-0.28	-0.23	Fibrinogen;	chr12:50740958	chr12:50743568~50743684:+
LUAD	cis	rs4143844	0.867	rs12901055	ENSG00000259251.2	RP11-643M14.1	5.1	4.78e-07	0.00013	0.4	0.23	Bipolar disorder and schizophrenia;	chr15:61880708	chr15:62060503~62062434:+
LUAD	cis	rs4143844	0.867	rs17303915	ENSG00000259251.2	RP11-643M14.1	5.1	4.78e-07	0.00013	0.4	0.23	Bipolar disorder and schizophrenia;	chr15:61882695	chr15:62060503~62062434:+
LUAD	cis	rs4143844	0.867	rs35559361	ENSG00000259251.2	RP11-643M14.1	5.1	4.78e-07	0.00013	0.4	0.23	Bipolar disorder and schizophrenia;	chr15:61891318	chr15:62060503~62062434:+
LUAD	cis	rs4143844	0.867	rs36056548	ENSG00000259251.2	RP11-643M14.1	5.1	4.78e-07	0.00013	0.4	0.23	Bipolar disorder and schizophrenia;	chr15:61904187	chr15:62060503~62062434:+
LUAD	cis	rs7829975	0.742	rs7832968	ENSG00000253893.2	FAM85B	-5.1	4.78e-07	0.00013	-0.28	-0.23	Mood instability;	chr8:8795379	chr8:8167819~8226614:-
LUAD	cis	rs35264875	0.796	rs72928657	ENSG00000259799.1	RP11-554A11.9	5.1	4.78e-07	0.00013	0.33	0.23	Blond vs. brown hair color;	chr11:69084868	chr11:69155910~69159752:+
LUAD	cis	rs7829975	0.508	rs4841006	ENSG00000173295.6	FAM86B3P	-5.1	4.79e-07	0.00013	-0.24	-0.23	Mood instability;	chr8:8643964	chr8:8228595~8244865:+
LUAD	cis	rs7826238	0.509	rs2948288	ENSG00000173295.6	FAM86B3P	5.1	4.79e-07	0.00013	0.24	0.23	Systolic blood pressure;	chr8:8257782	chr8:8228595~8244865:+
LUAD	cis	rs12701220	0.604	rs34904312	ENSG00000229043.2	AC091729.9	-5.1	4.79e-07	0.00013	-0.29	-0.23	Bronchopulmonary dysplasia;	chr7:1096247	chr7:1160374~1165267:+
LUAD	cis	rs4835473	0.897	rs17693780	ENSG00000251600.4	RP11-673E1.1	-5.1	4.79e-07	0.00013	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143737563	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.897	rs35556180	ENSG00000251600.4	RP11-673E1.1	-5.1	4.79e-07	0.00013	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143737595	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.897	rs35377051	ENSG00000251600.4	RP11-673E1.1	-5.1	4.79e-07	0.00013	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143737627	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.864	rs17018131	ENSG00000251600.4	RP11-673E1.1	-5.1	4.79e-07	0.00013	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143737647	chr4:143912331~143982454:+
LUAD	cis	rs1799949	1	rs12944458	ENSG00000236383.6	LINC00854	-5.1	4.79e-07	0.00013	-0.19	-0.23	Menopause (age at onset);	chr17:43028755	chr17:43216941~43305976:-
LUAD	cis	rs1707322	0.964	rs10437063	ENSG00000280836.1	AL355480.1	-5.1	4.79e-07	0.00013	-0.29	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807994	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs6676982	ENSG00000280836.1	AL355480.1	-5.1	4.79e-07	0.00013	-0.29	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809729	chr1:45581219~45581321:-
LUAD	cis	rs1816752	0.905	rs9511264	ENSG00000273628.1	RP11-756A22.7	-5.1	4.79e-07	0.00013	-0.25	-0.23	Obesity-related traits;	chr13:24438079	chr13:24933006~24936796:+
LUAD	cis	rs997295	0.592	rs8026627	ENSG00000270964.1	RP11-502I4.3	5.1	4.79e-07	0.000131	0.23	0.23	Motion sickness;	chr15:67477968	chr15:67541072~67542604:-
LUAD	cis	rs9813712	0.571	rs9824426	ENSG00000228252.7	COL6A4P2	-5.1	4.79e-07	0.000131	-0.21	-0.23	Response to amphetamines;	chr3:130226115	chr3:130212823~130273806:+
LUAD	cis	rs75920871	0.528	rs11216241	ENSG00000254851.1	RP11-109L13.1	5.1	4.8e-07	0.000131	0.33	0.23	Subjective well-being;	chr11:117028533	chr11:117135528~117138582:+
LUAD	cis	rs875971	0.522	rs1880556	ENSG00000224316.1	RP11-479O9.2	5.1	4.8e-07	0.000131	0.23	0.23	Aortic root size;	chr7:65967557	chr7:65773620~65802067:+
LUAD	cis	rs1707322	0.721	rs11211165	ENSG00000280836.1	AL355480.1	-5.1	4.8e-07	0.000131	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692234	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.721	rs11211166	ENSG00000280836.1	AL355480.1	-5.1	4.8e-07	0.000131	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692270	chr1:45581219~45581321:-
LUAD	cis	rs240993	0.812	rs10214442	ENSG00000230177.1	RP5-1112D6.4	-5.1	4.8e-07	0.000131	-0.23	-0.23	Inflammatory skin disease;Psoriasis;	chr6:111431857	chr6:111277932~111278742:+
LUAD	cis	rs7302981	0.934	rs7279	ENSG00000272368.2	RP4-605O3.4	-5.1	4.8e-07	0.000131	-0.27	-0.23	Systolic blood pressure;	chr12:50130164	chr12:50112197~50165618:+
LUAD	cis	rs1914816	0.653	rs157776	ENSG00000196274.5	Metazoa_SRP	5.1	4.8e-07	0.000131	0.3	0.23	Response to tocilizumab in rheumatoid arthritis;	chr15:76464362	chr15:76230048~76230390:-
LUAD	cis	rs7923837	1	rs4933736	ENSG00000236493.2	EIF2S2P3	5.1	4.8e-07	0.000131	0.26	0.23	Multiple sclerosis;Body mass index;	chr10:92711838	chr10:92668745~92669743:-
LUAD	cis	rs4604234	0.708	rs11966262	ENSG00000272129.1	RP11-250B2.6	-5.1	4.8e-07	0.000131	-0.51	-0.23	Cancer;	chr6:80294867	chr6:80355424~80356859:+
LUAD	cis	rs516805	0.528	rs2606626	ENSG00000279453.1	RP3-425C14.4	-5.1	4.8e-07	0.000131	-0.31	-0.23	Lymphocyte counts;	chr6:122096882	chr6:122436789~122439223:-
LUAD	cis	rs10050311	0.746	rs72665791	ENSG00000251411.1	RP11-397E7.4	-5.1	4.81e-07	0.000131	-0.32	-0.23	Insulin-related traits;	chr4:86757634	chr4:86913266~86914817:-
LUAD	cis	rs4908760	0.864	rs1463052	ENSG00000232912.4	RP5-1115A15.1	5.1	4.81e-07	0.000131	0.21	0.23	Vitiligo;	chr1:8641172	chr1:8424645~8434838:+
LUAD	cis	rs6570726	0.935	rs453609	ENSG00000235652.6	RP11-545I5.3	5.1	4.81e-07	0.000131	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145491196	chr6:145799409~145886585:+
LUAD	cis	rs7849270	0.801	rs6478868	ENSG00000268707.1	RP11-247A12.7	5.1	4.81e-07	0.000131	0.27	0.23	Blood metabolite ratios;	chr9:129164813	chr9:129170434~129170940:+
LUAD	cis	rs1799949	1	rs11655505	ENSG00000236383.6	LINC00854	-5.1	4.81e-07	0.000131	-0.18	-0.23	Menopause (age at onset);	chr17:43126360	chr17:43216941~43305976:-
LUAD	cis	rs1799949	0.965	rs4793204	ENSG00000236383.6	LINC00854	-5.1	4.81e-07	0.000131	-0.18	-0.23	Menopause (age at onset);	chr17:43127281	chr17:43216941~43305976:-
LUAD	cis	rs17301853	0.908	rs76087688	ENSG00000227373.4	RP11-160H22.5	5.1	4.81e-07	0.000131	0.45	0.23	Migraine without aura;Migraine - clinic-based;	chr1:174482430	chr1:174115300~174160004:-
LUAD	cis	rs17301853	1	rs6674797	ENSG00000227373.4	RP11-160H22.5	5.1	4.81e-07	0.000131	0.45	0.23	Migraine without aura;Migraine - clinic-based;	chr1:174487105	chr1:174115300~174160004:-
LUAD	cis	rs867371	0.929	rs1045508	ENSG00000259429.4	UBE2Q2P2	5.1	4.81e-07	0.000131	0.2	0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82157565	chr15:82355142~82420075:+
LUAD	cis	rs193541	0.632	rs7735618	ENSG00000263432.2	RN7SL689P	5.1	4.81e-07	0.000131	0.3	0.23	Glucose homeostasis traits;	chr5:122840550	chr5:123022487~123022783:-
LUAD	cis	rs4835473	0.9	rs12503074	ENSG00000251600.4	RP11-673E1.1	-5.1	4.81e-07	0.000131	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143812560	chr4:143912331~143982454:+
LUAD	cis	rs1062177	0.906	rs2964573	ENSG00000253921.1	CTB-113P19.3	-5.1	4.82e-07	0.000131	-0.34	-0.23	Preschool internalizing problems;	chr5:151780561	chr5:151753992~151767247:+
LUAD	cis	rs17508449	0.69	rs4839333	ENSG00000232450.1	RP4-730K3.3	-5.1	4.82e-07	0.000131	-0.4	-0.23	Leprosy;	chr1:113676539	chr1:113698884~113699631:-
LUAD	cis	rs11673344	0.832	rs56080874	ENSG00000226686.6	LINC01535	5.1	4.82e-07	0.000131	0.3	0.23	Obesity-related traits;	chr19:37085487	chr19:37251912~37265535:+
LUAD	cis	rs10754283	0.967	rs7552896	ENSG00000231613.1	RP5-943J3.1	5.1	4.82e-07	0.000131	0.23	0.23	Amyotrophic lateral sclerosis (sporadic);	chr1:89637635	chr1:89788914~89790492:+
LUAD	cis	rs17301853	0.915	rs7545388	ENSG00000227373.4	RP11-160H22.5	5.1	4.82e-07	0.000131	0.45	0.23	Migraine without aura;Migraine - clinic-based;	chr1:174296285	chr1:174115300~174160004:-
LUAD	cis	rs42490	0.903	rs218901	ENSG00000251136.7	RP11-37B2.1	-5.1	4.83e-07	0.000131	-0.23	-0.23	Leprosy;	chr8:89719089	chr8:89609409~89757727:-
LUAD	cis	rs6545883	0.507	rs6545855	ENSG00000271889.1	RP11-493E12.1	-5.1	4.83e-07	0.000131	-0.26	-0.23	Tuberculosis;	chr2:61305725	chr2:61151433~61162105:-
LUAD	cis	rs7208859	0.623	rs11651857	ENSG00000263603.1	CTD-2349P21.5	-5.1	4.83e-07	0.000131	-0.41	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30599344	chr17:30729469~30731202:+
LUAD	cis	rs35740288	0.929	rs11630585	ENSG00000202081.1	RNU6-1280P	5.1	4.83e-07	0.000131	0.29	0.23	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85762773	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.929	rs11636821	ENSG00000202081.1	RNU6-1280P	5.1	4.83e-07	0.000131	0.29	0.23	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85762774	chr15:85651522~85651628:-
LUAD	cis	rs35740288	0.929	rs11630684	ENSG00000202081.1	RNU6-1280P	5.1	4.83e-07	0.000131	0.29	0.23	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85763025	chr15:85651522~85651628:-
LUAD	cis	rs2998286	0.723	rs332177	ENSG00000254635.4	WAC-AS1	-5.1	4.83e-07	0.000131	-0.3	-0.23	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28618221	chr10:28522652~28532743:-
LUAD	cis	rs9595908	0.785	rs9596032	ENSG00000212293.1	SNORA16	5.1	4.83e-07	0.000131	0.24	0.23	Body mass index;	chr13:32654708	chr13:32420390~32420516:-
LUAD	cis	rs6921919	0.848	rs6903823	ENSG00000216901.1	AL022393.7	5.1	4.83e-07	0.000132	0.3	0.23	Autism spectrum disorder or schizophrenia;	chr6:28354519	chr6:28176188~28176674:+
LUAD	cis	rs603446	1	rs603446	ENSG00000254851.1	RP11-109L13.1	-5.1	4.84e-07	0.000132	-0.28	-0.23	Triglycerides;	chr11:116783719	chr11:117135528~117138582:+
LUAD	cis	rs9322193	0.607	rs3798763	ENSG00000223701.3	RAET1E-AS1	5.1	4.84e-07	0.000132	0.33	0.23	Lung cancer;	chr6:149889964	chr6:149884431~149919508:+
LUAD	cis	rs6570726	0.791	rs2096201	ENSG00000235652.6	RP11-545I5.3	5.1	4.84e-07	0.000132	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145613137	chr6:145799409~145886585:+
LUAD	cis	rs2440129	0.611	rs434473	ENSG00000215067.8	ALOX12-AS1	-5.1	4.85e-07	0.000132	-0.23	-0.23	Tonsillectomy;	chr17:7001615	chr17:6876635~7012349:-
LUAD	cis	rs4664293	1	rs6753181	ENSG00000226266.5	AC009961.3	-5.1	4.85e-07	0.000132	-0.32	-0.23	Monocyte percentage of white cells;	chr2:159635927	chr2:159670708~159712435:-
LUAD	cis	rs9601248	0.627	rs2146593	ENSG00000227354.5	RBM26-AS1	5.1	4.85e-07	0.000132	0.26	0.23	Major depressive disorder;	chr13:79605977	chr13:79406309~79424328:+
LUAD	cis	rs13256369	0.901	rs12681298	ENSG00000253893.2	FAM85B	5.1	4.85e-07	0.000132	0.31	0.23	Obesity-related traits;	chr8:8708725	chr8:8167819~8226614:-
LUAD	cis	rs2286503	0.839	rs4722188	ENSG00000226329.2	AC005682.6	5.1	4.86e-07	0.000132	0.29	0.23	Fibrinogen;	chr7:22820592	chr7:22863874~22881350:-
LUAD	cis	rs6687821	0.5	rs6703683	ENSG00000267734.1	RP4-604K5.3	-5.1	4.86e-07	0.000132	-0.3	-0.23	Yeast infection;	chr1:87042656	chr1:86932199~86934891:-
LUAD	cis	rs910316	1	rs10149880	ENSG00000259138.1	RP11-950C14.7	-5.1	4.86e-07	0.000132	-0.24	-0.23	Height;	chr14:75166305	chr14:75127153~75136930:+
LUAD	cis	rs875971	0.66	rs79009421	ENSG00000237310.1	GS1-124K5.4	-5.1	4.86e-07	0.000132	-0.24	-0.23	Aortic root size;	chr7:66603522	chr7:66493706~66495474:+
LUAD	cis	rs1816752	0.755	rs1981277	ENSG00000273628.1	RP11-756A22.7	5.1	4.86e-07	0.000132	0.26	0.23	Obesity-related traits;	chr13:24409375	chr13:24933006~24936796:+
LUAD	cis	rs1816752	0.712	rs9507335	ENSG00000273628.1	RP11-756A22.7	5.1	4.86e-07	0.000132	0.26	0.23	Obesity-related traits;	chr13:24409766	chr13:24933006~24936796:+
LUAD	cis	rs1816752	0.811	rs9507337	ENSG00000273628.1	RP11-756A22.7	5.1	4.86e-07	0.000132	0.26	0.23	Obesity-related traits;	chr13:24410807	chr13:24933006~24936796:+
LUAD	cis	rs453301	0.658	rs12114954	ENSG00000173295.6	FAM86B3P	-5.1	4.86e-07	0.000132	-0.24	-0.23	Joint mobility (Beighton score);	chr8:9047352	chr8:8228595~8244865:+
LUAD	cis	rs10935480	1	rs10935480	ENSG00000249274.1	PDLIM1P4	-5.1	4.87e-07	0.000132	-0.24	-0.23	Blood protein levels;	chr3:98713142	chr3:98782188~98783193:+
LUAD	cis	rs4835473	0.932	rs7669198	ENSG00000251600.4	RP11-673E1.1	-5.1	4.87e-07	0.000132	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143821229	chr4:143912331~143982454:+
LUAD	cis	rs8177876	0.822	rs55939311	ENSG00000261061.1	RP11-303E16.2	-5.1	4.87e-07	0.000132	-0.4	-0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81075493	chr16:81030770~81031485:+
LUAD	cis	rs8177876	0.822	rs12444137	ENSG00000261061.1	RP11-303E16.2	-5.1	4.87e-07	0.000132	-0.4	-0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81076746	chr16:81030770~81031485:+
LUAD	cis	rs801193	0.967	rs3800823	ENSG00000237310.1	GS1-124K5.4	-5.1	4.87e-07	0.000132	-0.25	-0.23	Aortic root size;	chr7:66682123	chr7:66493706~66495474:+
LUAD	cis	rs17508449	0.819	rs79220465	ENSG00000232450.1	RP4-730K3.3	-5.1	4.87e-07	0.000132	-0.38	-0.23	Leprosy;	chr1:113628719	chr1:113698884~113699631:-
LUAD	cis	rs11742741	0.714	rs61442687	ENSG00000248874.4	C5orf17	-5.1	4.87e-07	0.000132	-0.29	-0.23	Educational attainment;	chr5:24189306	chr5:23951348~24178263:+
LUAD	cis	rs763567	1	rs1928715	ENSG00000271811.1	RP1-79C4.4	-5.1	4.87e-07	0.000133	-0.28	-0.23	Tonsillectomy;	chr1:170598296	chr1:170667381~170669425:+
LUAD	cis	rs2933343	1	rs789213	ENSG00000231305.3	RP11-723O4.2	-5.1	4.88e-07	0.000133	-0.27	-0.23	IgG glycosylation;	chr3:128897516	chr3:128861313~128871540:-
LUAD	cis	rs875971	0.66	rs6460308	ENSG00000237310.1	GS1-124K5.4	-5.1	4.88e-07	0.000133	-0.24	-0.23	Aortic root size;	chr7:66619753	chr7:66493706~66495474:+
LUAD	cis	rs1729407	0.933	rs1729405	ENSG00000280143.1	AP000892.6	5.1	4.88e-07	0.000133	0.26	0.23	Apolipoprotein A-IV levels;	chr11:116808044	chr11:117204967~117210292:+
LUAD	cis	rs8072100	0.79	rs6505048	ENSG00000228782.6	CTD-2026D20.3	-5.1	4.88e-07	0.000133	-0.24	-0.23	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47597632	chr17:47450568~47492492:-
LUAD	cis	rs10129255	0.957	rs6576233	ENSG00000211972.2	IGHV3-66	5.1	4.88e-07	0.000133	0.19	0.23	Kawasaki disease;	chr14:106787239	chr14:106675017~106675544:-
LUAD	cis	rs3096299	0.838	rs3096319	ENSG00000182376.2	RP5-1142A6.8	5.1	4.88e-07	0.000133	0.23	0.23	Multiple myeloma (IgH translocation);	chr16:89336226	chr16:88742767~88745748:+
LUAD	cis	rs7617773	0.746	rs7619865	ENSG00000228638.1	FCF1P2	-5.1	4.88e-07	0.000133	-0.26	-0.23	Coronary artery disease;	chr3:48329090	chr3:48290793~48291375:-
LUAD	cis	rs950169	0.58	rs35516100	ENSG00000275120.1	RP11-182J1.17	5.1	4.89e-07	0.000133	0.35	0.23	Schizophrenia;	chr15:84652199	chr15:84599434~84606463:-
LUAD	cis	rs950169	0.58	rs62021208	ENSG00000275120.1	RP11-182J1.17	5.1	4.89e-07	0.000133	0.35	0.23	Schizophrenia;	chr15:84653013	chr15:84599434~84606463:-
LUAD	cis	rs442309	0.532	rs10995276	ENSG00000238280.1	RP11-436D10.3	5.1	4.9e-07	0.000133	0.29	0.23	Vogt-Koyanagi-Harada syndrome;	chr10:62694301	chr10:62793562~62805887:-
LUAD	cis	rs4141404	0.561	rs5994376	ENSG00000236132.1	CTA-440B3.1	5.1	4.9e-07	0.000133	0.25	0.23	Paclitaxel-induced neuropathy;	chr22:31167569	chr22:31816379~31817491:-
LUAD	cis	rs453301	0.653	rs11784393	ENSG00000173295.6	FAM86B3P	5.1	4.9e-07	0.000133	0.24	0.23	Joint mobility (Beighton score);	chr8:9045624	chr8:8228595~8244865:+
LUAD	cis	rs12681366	0.801	rs6981551	ENSG00000253704.1	RP11-267M23.4	5.1	4.9e-07	0.000133	0.28	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94466421	chr8:94553722~94569745:+
LUAD	cis	rs7727544	0.716	rs11955347	ENSG00000233006.5	AC034220.3	5.1	4.9e-07	0.000133	0.2	0.23	Blood metabolite levels;	chr5:132232231	chr5:132311285~132369916:-
LUAD	cis	rs55726902	0.553	rs2525052	ENSG00000276691.1	RP5-1057I20.5	5.1	4.9e-07	0.000133	0.22	0.23	Allergic disease (asthma, hay fever or eczema);	chr12:47801641	chr12:47788426~47788971:+
LUAD	cis	rs10129255	0.5	rs1974468	ENSG00000254174.1	IGHV1-12	5.1	4.91e-07	0.000133	0.15	0.23	Kawasaki disease;	chr14:106686149	chr14:106122420~106122709:-
LUAD	cis	rs2239547	0.563	rs2581820	ENSG00000242142.1	SERBP1P3	-5.1	4.91e-07	0.000133	-0.26	-0.23	Schizophrenia;	chr3:52986528	chr3:53064283~53065091:-
LUAD	cis	rs7727544	0.901	rs55633655	ENSG00000233006.5	AC034220.3	5.1	4.91e-07	0.000133	0.2	0.23	Blood metabolite levels;	chr5:132263063	chr5:132311285~132369916:-
LUAD	cis	rs11742741	0.69	rs35311965	ENSG00000248874.4	C5orf17	-5.1	4.91e-07	0.000134	-0.28	-0.23	Educational attainment;	chr5:24176027	chr5:23951348~24178263:+
LUAD	cis	rs2948294	0.566	rs13261997	ENSG00000253981.4	ALG1L13P	5.1	4.92e-07	0.000134	0.27	0.23	Red cell distribution width;	chr8:8254773	chr8:8236003~8244667:-
LUAD	cis	rs1707322	0.827	rs12125508	ENSG00000280836.1	AL355480.1	-5.1	4.92e-07	0.000134	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45780338	chr1:45581219~45581321:-
LUAD	cis	rs4835473	0.801	rs28715976	ENSG00000251600.4	RP11-673E1.1	-5.1	4.92e-07	0.000134	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143891603	chr4:143912331~143982454:+
LUAD	cis	rs7923837	1	rs7923866	ENSG00000236493.2	EIF2S2P3	5.1	4.92e-07	0.000134	0.26	0.23	Multiple sclerosis;Body mass index;	chr10:92722319	chr10:92668745~92669743:-
LUAD	cis	rs4143844	0.867	rs35324423	ENSG00000259251.2	RP11-643M14.1	5.1	4.92e-07	0.000134	0.41	0.23	Bipolar disorder and schizophrenia;	chr15:62019946	chr15:62060503~62062434:+
LUAD	cis	rs4143844	0.867	rs4143845	ENSG00000259251.2	RP11-643M14.1	5.1	4.92e-07	0.000134	0.41	0.23	Bipolar disorder and schizophrenia;	chr15:62020894	chr15:62060503~62062434:+
LUAD	cis	rs9595908	0.785	rs9315177	ENSG00000212293.1	SNORA16	5.1	4.92e-07	0.000134	0.24	0.23	Body mass index;	chr13:32696214	chr13:32420390~32420516:-
LUAD	cis	rs9595908	0.785	rs9596081	ENSG00000212293.1	SNORA16	5.1	4.92e-07	0.000134	0.24	0.23	Body mass index;	chr13:32698405	chr13:32420390~32420516:-
LUAD	cis	rs7772486	0.754	rs12199362	ENSG00000235652.6	RP11-545I5.3	5.1	4.92e-07	0.000134	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145797089	chr6:145799409~145886585:+
LUAD	cis	rs2911132	0.511	rs7063	ENSG00000248734.2	CTD-2260A17.1	5.1	4.92e-07	0.000134	0.25	0.23	Urate levels (BMI interaction);	chr5:96774507	chr5:96784777~96785999:+
LUAD	cis	rs74233809	1	rs11191502	ENSG00000213277.3	MARCKSL1P1	5.1	4.93e-07	0.000134	0.39	0.23	Birth weight;	chr10:103005737	chr10:103175554~103176094:+
LUAD	cis	rs74233809	1	rs74444347	ENSG00000213277.3	MARCKSL1P1	5.1	4.93e-07	0.000134	0.39	0.23	Birth weight;	chr10:103009518	chr10:103175554~103176094:+
LUAD	cis	rs74233809	1	rs12221335	ENSG00000213277.3	MARCKSL1P1	5.1	4.93e-07	0.000134	0.39	0.23	Birth weight;	chr10:103009635	chr10:103175554~103176094:+
LUAD	cis	rs7083	1	rs678837	ENSG00000254851.1	RP11-109L13.1	5.1	4.94e-07	0.000134	0.29	0.23	Blood protein levels;	chr11:117238554	chr11:117135528~117138582:+
LUAD	cis	rs11673344	0.668	rs7248693	ENSG00000226686.6	LINC01535	5.1	4.94e-07	0.000134	0.3	0.23	Obesity-related traits;	chr19:36991864	chr19:37251912~37265535:+
LUAD	cis	rs889398	0.967	rs244415	ENSG00000226232.7	RP11-419C5.2	5.1	4.94e-07	0.000134	0.19	0.23	Body mass index;	chr16:69632780	chr16:69976388~69996188:-
LUAD	cis	rs11157436	0.918	rs11157426	ENSG00000211812.1	TRAV26-2	-5.1	4.94e-07	0.000134	-0.24	-0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22153691	chr14:22202583~22203368:+
LUAD	cis	rs11157436	0.918	rs11157427	ENSG00000211812.1	TRAV26-2	-5.1	4.94e-07	0.000134	-0.24	-0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22154291	chr14:22202583~22203368:+
LUAD	cis	rs11157436	0.792	rs12433875	ENSG00000211812.1	TRAV26-2	-5.1	4.94e-07	0.000134	-0.24	-0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22154490	chr14:22202583~22203368:+
LUAD	cis	rs35160687	0.644	rs11676515	ENSG00000273080.1	RP11-301O19.1	-5.1	4.95e-07	0.000134	-0.25	-0.23	Night sleep phenotypes;	chr2:86268934	chr2:86195590~86196049:+
LUAD	cis	rs867371	1	rs8042464	ENSG00000259429.4	UBE2Q2P2	-5.1	4.95e-07	0.000134	-0.2	-0.23	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173195	chr15:82355142~82420075:+
LUAD	cis	rs7208859	0.614	rs7216394	ENSG00000263531.1	RP13-753N3.1	-5.1	4.95e-07	0.000134	-0.43	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30498738	chr17:30863921~30864940:-
LUAD	cis	rs1318937	0.764	rs2077619	ENSG00000224660.1	SH3BP5-AS1	5.1	4.95e-07	0.000135	0.17	0.23	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15182835	chr3:15254184~15264493:+
LUAD	cis	rs10800713	0.954	rs4504918	ENSG00000260088.1	RP11-92G12.3	5.1	4.95e-07	0.000135	0.32	0.23	Tandem gait;	chr1:200588639	chr1:200669507~200694250:+
LUAD	cis	rs12935418	0.832	rs79957369	ENSG00000261061.1	RP11-303E16.2	-5.1	4.95e-07	0.000135	-0.34	-0.23	Mean corpuscular volume;	chr16:81025654	chr16:81030770~81031485:+
LUAD	cis	rs2255336	0.873	rs7397310	ENSG00000245648.1	RP11-277P12.20	5.1	4.96e-07	0.000135	0.34	0.23	Blood protein levels;	chr12:10368394	chr12:10363769~10398506:+
LUAD	cis	rs1426063	0.858	rs6837969	ENSG00000249717.1	RP11-44F21.3	5.1	4.96e-07	0.000135	0.33	0.23	QT interval;	chr4:75085005	chr4:74955974~74970362:-
LUAD	cis	rs1426063	0.858	rs6843217	ENSG00000249717.1	RP11-44F21.3	5.1	4.96e-07	0.000135	0.33	0.23	QT interval;	chr4:75085201	chr4:74955974~74970362:-
LUAD	cis	rs7017914	0.652	rs13264053	ENSG00000223220.1	Y_RNA	5.1	4.96e-07	0.000135	0.26	0.23	Bone mineral density;	chr8:71079101	chr8:70780914~70781008:-
LUAD	cis	rs17684571	0.613	rs4587171	ENSG00000231441.1	RP11-472M19.2	5.1	4.96e-07	0.000135	0.32	0.23	Schizophrenia;	chr6:56805465	chr6:56844002~56864078:+
LUAD	cis	rs10246939	0.579	rs6969430	ENSG00000228775.6	WEE2-AS1	5.1	4.97e-07	0.000135	0.27	0.23	Bitter taste perception;	chr7:141831340	chr7:141704338~141738346:-
LUAD	cis	rs7968440	1	rs11832315	ENSG00000200428.1	Y_RNA	-5.1	4.97e-07	0.000135	-0.28	-0.23	Fibrinogen;	chr12:50550149	chr12:50743568~50743684:+
LUAD	cis	rs875971	0.862	rs6971059	ENSG00000232559.3	GS1-124K5.12	-5.1	4.97e-07	0.000135	-0.27	-0.23	Aortic root size;	chr7:66602045	chr7:66554588~66576923:-
LUAD	cis	rs4908760	0.899	rs61783642	ENSG00000270282.1	RP5-1115A15.2	5.1	4.97e-07	0.000135	0.25	0.23	Vitiligo;	chr1:8531338	chr1:8512653~8513021:+
LUAD	cis	rs2933343	0.951	rs789218	ENSG00000261159.1	RP11-723O4.9	5.1	4.98e-07	0.000135	0.28	0.23	IgG glycosylation;	chr3:128873827	chr3:128859716~128860526:-
LUAD	cis	rs1799949	1	rs3950989	ENSG00000236383.6	LINC00854	-5.1	4.98e-07	0.000135	-0.18	-0.23	Menopause (age at onset);	chr17:43085936	chr17:43216941~43305976:-
LUAD	cis	rs875971	0.66	rs801193	ENSG00000237310.1	GS1-124K5.4	-5.1	4.98e-07	0.000135	-0.24	-0.23	Aortic root size;	chr7:66565625	chr7:66493706~66495474:+
LUAD	cis	rs11089937	0.626	rs4820337	ENSG00000211638.2	IGLV8-61	5.1	4.98e-07	0.000135	0.26	0.23	Periodontitis (PAL4Q3);	chr22:22164374	chr22:22098700~22099212:+
LUAD	cis	rs2286503	1	rs2286501	ENSG00000221740.1	SNORD93	5.1	4.98e-07	0.000135	0.25	0.23	Fibrinogen;	chr7:22817166	chr7:22856613~22856686:+
LUAD	cis	rs7665090	0.87	rs227361	ENSG00000246560.2	RP11-10L12.4	5.1	4.98e-07	0.000135	0.27	0.23	Primary biliary cholangitis;	chr4:102665820	chr4:102828055~102844075:+
LUAD	cis	rs2948294	0.588	rs7011221	ENSG00000173295.6	FAM86B3P	5.1	4.98e-07	0.000135	0.25	0.23	Red cell distribution width;	chr8:8256724	chr8:8228595~8244865:+
LUAD	cis	rs7176527	0.706	rs35641144	ENSG00000188388.10	GOLGA6L3	5.1	4.99e-07	0.000135	0.33	0.23	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84723543	chr15:85240472~85247170:+
LUAD	cis	rs453301	0.657	rs36056437	ENSG00000253893.2	FAM85B	5.1	4.99e-07	0.000135	0.29	0.23	Joint mobility (Beighton score);	chr8:8935355	chr8:8167819~8226614:-
LUAD	cis	rs2911132	0.564	rs1057569	ENSG00000248734.2	CTD-2260A17.1	5.1	4.99e-07	0.000135	0.25	0.23	Urate levels (BMI interaction);	chr5:96773906	chr5:96784777~96785999:+
LUAD	cis	rs73173548	0.502	rs4144466	ENSG00000247828.6	TMEM161B-AS1	5.1	5e-07	0.000136	0.28	0.23	Macular telangiectasia type 2;	chr5:88412379	chr5:88268895~88436685:+
LUAD	cis	rs875971	0.522	rs1701760	ENSG00000236529.1	RP13-254B10.1	5.1	5e-07	0.000136	0.23	0.23	Aortic root size;	chr7:66008701	chr7:65840212~65840596:+
LUAD	cis	rs301901	0.772	rs301867	ENSG00000250155.1	CTD-2353F22.1	-5.1	5e-07	0.000136	-0.24	-0.23	Height;	chr5:37130754	chr5:36666214~36725195:-
LUAD	cis	rs61270009	0.955	rs34241164	ENSG00000247828.6	TMEM161B-AS1	5.1	5e-07	0.000136	0.26	0.23	Depressive symptoms;	chr5:88293189	chr5:88268895~88436685:+
LUAD	cis	rs13177755	1	rs13177755	ENSG00000247828.6	TMEM161B-AS1	5.1	5e-07	0.000136	0.26	0.23	Depressive symptoms (multi-trait analysis);	chr5:88296420	chr5:88268895~88436685:+
LUAD	cis	rs61270009	0.955	rs13159835	ENSG00000247828.6	TMEM161B-AS1	5.1	5e-07	0.000136	0.26	0.23	Depressive symptoms;	chr5:88305576	chr5:88268895~88436685:+
LUAD	cis	rs4948102	0.599	rs2230197	ENSG00000273720.1	RP11-613E4.4	-5.1	5e-07	0.000136	-0.28	-0.23	Plasma homocysteine levels (post-methionine load test);	chr7:56058667	chr7:55743073~55743457:+
LUAD	cis	rs2439831	0.681	rs825739	ENSG00000249839.1	AC011330.5	-5.1	5.01e-07	0.000136	-0.4	-0.23	Lung cancer in ever smokers;	chr15:43300230	chr15:43663654~43684339:-
LUAD	cis	rs10129255	0.744	rs28517388	ENSG00000224373.3	IGHV4-59	5.1	5.01e-07	0.000136	0.15	0.23	Kawasaki disease;	chr14:106704323	chr14:106627249~106627825:-
LUAD	cis	rs172166	0.538	rs149956	ENSG00000219392.1	RP1-265C24.5	-5.1	5.01e-07	0.000136	-0.28	-0.23	Cardiac Troponin-T levels;	chr6:28068473	chr6:28115628~28116551:+
LUAD	cis	rs11157436	0.958	rs3811277	ENSG00000211813.2	TRAV34	5.1	5.01e-07	0.000136	0.3	0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22190419	chr14:22207522~22208129:+
LUAD	cis	rs3002142	0.908	rs3002143	ENSG00000272750.1	RP11-378J18.8	-5.1	5.02e-07	0.000136	-0.29	-0.23	LDL peak particle diameter (total fat intake interaction);	chr1:222615512	chr1:222658867~222661512:-
LUAD	cis	rs7968440	0.715	rs7957659	ENSG00000272368.2	RP4-605O3.4	-5.1	5.02e-07	0.000136	-0.25	-0.23	Fibrinogen;	chr12:50245027	chr12:50112197~50165618:+
LUAD	cis	rs2976388	0.609	rs2164308	ENSG00000253741.1	CTD-2292P10.4	5.09	5.02e-07	0.000136	0.26	0.23	Urinary tract infection frequency;	chr8:142704241	chr8:142702252~142726973:-
LUAD	cis	rs11089937	0.553	rs35336247	ENSG00000211638.2	IGLV8-61	-5.09	5.02e-07	0.000136	-0.26	-0.23	Periodontitis (PAL4Q3);	chr22:22131593	chr22:22098700~22099212:+
LUAD	cis	rs11089937	0.553	rs34088081	ENSG00000211638.2	IGLV8-61	-5.09	5.02e-07	0.000136	-0.26	-0.23	Periodontitis (PAL4Q3);	chr22:22131601	chr22:22098700~22099212:+
LUAD	cis	rs9322193	0.962	rs12175575	ENSG00000268592.3	RAET1E-AS1	5.09	5.02e-07	0.000136	0.28	0.23	Lung cancer;	chr6:149763351	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.962	rs4869966	ENSG00000268592.3	RAET1E-AS1	5.09	5.02e-07	0.000136	0.28	0.23	Lung cancer;	chr6:149763714	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.962	rs1112730	ENSG00000268592.3	RAET1E-AS1	5.09	5.02e-07	0.000136	0.28	0.23	Lung cancer;	chr6:149766383	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.923	rs1112729	ENSG00000268592.3	RAET1E-AS1	5.09	5.02e-07	0.000136	0.28	0.23	Lung cancer;	chr6:149766491	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.962	rs10452626	ENSG00000268592.3	RAET1E-AS1	5.09	5.02e-07	0.000136	0.28	0.23	Lung cancer;	chr6:149767481	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.923	rs62441303	ENSG00000268592.3	RAET1E-AS1	5.09	5.02e-07	0.000136	0.28	0.23	Lung cancer;	chr6:149767547	chr6:149863494~149919507:+
LUAD	cis	rs1707322	0.691	rs61784799	ENSG00000280836.1	AL355480.1	5.09	5.02e-07	0.000136	0.3	0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712076	chr1:45581219~45581321:-
LUAD	cis	rs4660456	0.572	rs7519348	ENSG00000237899.1	RP4-739H11.3	-5.09	5.03e-07	0.000136	-0.26	-0.23	Platelet count;	chr1:40694532	chr1:40669089~40687588:-
LUAD	cis	rs12681366	0.801	rs2011246	ENSG00000253704.1	RP11-267M23.4	5.09	5.03e-07	0.000136	0.28	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94450846	chr8:94553722~94569745:+
LUAD	cis	rs12681366	0.801	rs55963151	ENSG00000253704.1	RP11-267M23.4	5.09	5.03e-07	0.000136	0.28	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94466198	chr8:94553722~94569745:+
LUAD	cis	rs172166	0.56	rs203878	ENSG00000219392.1	RP1-265C24.5	-5.09	5.03e-07	0.000136	-0.28	-0.23	Cardiac Troponin-T levels;	chr6:28081218	chr6:28115628~28116551:+
LUAD	cis	rs4268898	0.722	rs12185638	ENSG00000242628.4	AC009228.1	-5.09	5.03e-07	0.000136	-0.29	-0.23	Asthma;	chr2:24159160	chr2:24214381~24221516:+
LUAD	cis	rs4268898	0.722	rs4665253	ENSG00000242628.4	AC009228.1	-5.09	5.03e-07	0.000136	-0.29	-0.23	Asthma;	chr2:24159676	chr2:24214381~24221516:+
LUAD	cis	rs4835473	0.897	rs7682204	ENSG00000251600.4	RP11-673E1.1	5.09	5.04e-07	0.000137	0.28	0.23	Immature fraction of reticulocytes;	chr4:143966306	chr4:143912331~143982454:+
LUAD	cis	rs897984	0.683	rs9932572	ENSG00000232748.3	RP11-196G11.6	-5.09	5.04e-07	0.000137	-0.28	-0.23	Dementia with Lewy bodies;	chr16:30830321	chr16:31056460~31062803:+
LUAD	cis	rs12745968	0.589	rs10874710	ENSG00000223787.2	RP4-593M8.1	-5.09	5.04e-07	0.000137	-0.27	-0.23	Bipolar disorder and schizophrenia;	chr1:92552206	chr1:92580476~92580821:-
LUAD	cis	rs12745968	0.589	rs10874711	ENSG00000223787.2	RP4-593M8.1	-5.09	5.04e-07	0.000137	-0.27	-0.23	Bipolar disorder and schizophrenia;	chr1:92552431	chr1:92580476~92580821:-
LUAD	cis	rs6095360	0.69	rs35888516	ENSG00000222365.1	SNORD12B	-5.09	5.04e-07	0.000137	-0.25	-0.23	Intelligence (multi-trait analysis);	chr20:49147738	chr20:49280319~49280409:+
LUAD	cis	rs6095360	0.727	rs35752040	ENSG00000222365.1	SNORD12B	-5.09	5.04e-07	0.000137	-0.26	-0.23	Intelligence (multi-trait analysis);	chr20:49008063	chr20:49280319~49280409:+
LUAD	cis	rs301901	0.766	rs12521993	ENSG00000250155.1	CTD-2353F22.1	5.09	5.04e-07	0.000137	0.24	0.23	Height;	chr5:37488095	chr5:36666214~36725195:-
LUAD	cis	rs11051970	0.559	rs7956708	ENSG00000274964.1	RP11-817I4.1	-5.09	5.04e-07	0.000137	-0.3	-0.23	Response to tocilizumab in rheumatoid arthritis;	chr12:32315908	chr12:32339368~32340724:+
LUAD	cis	rs1799949	0.965	rs8176161	ENSG00000236383.6	LINC00854	-5.09	5.04e-07	0.000137	-0.18	-0.23	Menopause (age at onset);	chr17:43089373	chr17:43216941~43305976:-
LUAD	cis	rs1799949	0.894	rs8176160	ENSG00000236383.6	LINC00854	-5.09	5.04e-07	0.000137	-0.18	-0.23	Menopause (age at onset);	chr17:43089486	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs2070834	ENSG00000236383.6	LINC00854	-5.09	5.04e-07	0.000137	-0.18	-0.23	Menopause (age at onset);	chr17:43090268	chr17:43216941~43305976:-
LUAD	cis	rs4835473	0.932	rs17695238	ENSG00000251600.4	RP11-673E1.1	-5.09	5.04e-07	0.000137	-0.29	-0.23	Immature fraction of reticulocytes;	chr4:143820720	chr4:143912331~143982454:+
LUAD	cis	rs1426063	0.858	rs72662426	ENSG00000249717.1	RP11-44F21.3	5.09	5.05e-07	0.000137	0.33	0.23	QT interval;	chr4:75084828	chr4:74955974~74970362:-
LUAD	cis	rs17711722	0.727	rs1880555	ENSG00000224316.1	RP11-479O9.2	5.09	5.05e-07	0.000137	0.23	0.23	Calcium levels;	chr7:65967580	chr7:65773620~65802067:+
LUAD	cis	rs875971	0.862	rs4718330	ENSG00000232559.3	GS1-124K5.12	-5.09	5.06e-07	0.000137	-0.27	-0.23	Aortic root size;	chr7:66250256	chr7:66554588~66576923:-
LUAD	cis	rs2657294	0.62	rs9783273	ENSG00000233313.2	HMGA1P5	-5.09	5.06e-07	0.000137	-0.28	-0.23	Pneumonia;	chr10:75081982	chr10:75276376~75276646:-
LUAD	cis	rs2657294	0.62	rs4746259	ENSG00000233313.2	HMGA1P5	-5.09	5.06e-07	0.000137	-0.28	-0.23	Pneumonia;	chr10:75082310	chr10:75276376~75276646:-
LUAD	cis	rs17818399	0.926	rs35682608	ENSG00000279254.1	RP11-536C12.1	-5.09	5.06e-07	0.000137	-0.26	-0.23	Height;	chr2:46609403	chr2:46668870~46670778:+
LUAD	cis	rs7772486	0.72	rs6901888	ENSG00000235652.6	RP11-545I5.3	-5.09	5.06e-07	0.000137	-0.22	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145702008	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.72	rs6931553	ENSG00000235652.6	RP11-545I5.3	-5.09	5.07e-07	0.000137	-0.23	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145791212	chr6:145799409~145886585:+
LUAD	cis	rs516805	0.667	rs7771090	ENSG00000279453.1	RP3-425C14.4	-5.09	5.07e-07	0.000137	-0.3	-0.23	Lymphocyte counts;	chr6:122339732	chr6:122436789~122439223:-
LUAD	cis	rs4908768	0.501	rs12046643	ENSG00000270282.1	RP5-1115A15.2	5.09	5.07e-07	0.000137	0.25	0.23	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8487806	chr1:8512653~8513021:+
LUAD	cis	rs4908760	0.965	rs10864353	ENSG00000270282.1	RP5-1115A15.2	5.09	5.07e-07	0.000137	0.25	0.23	Vitiligo;	chr1:8489656	chr1:8512653~8513021:+
LUAD	cis	rs4908768	0.501	rs6677736	ENSG00000270282.1	RP5-1115A15.2	5.09	5.07e-07	0.000137	0.25	0.23	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8492744	chr1:8512653~8513021:+
LUAD	cis	rs4908768	0.501	rs7527389	ENSG00000270282.1	RP5-1115A15.2	5.09	5.07e-07	0.000137	0.25	0.23	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8496485	chr1:8512653~8513021:+
LUAD	cis	rs4908768	0.501	rs7518608	ENSG00000270282.1	RP5-1115A15.2	5.09	5.07e-07	0.000137	0.25	0.23	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8497260	chr1:8512653~8513021:+
LUAD	cis	rs4908760	0.965	rs10864356	ENSG00000270282.1	RP5-1115A15.2	5.09	5.07e-07	0.000137	0.25	0.23	Vitiligo;	chr1:8509812	chr1:8512653~8513021:+
LUAD	cis	rs5758659	0.967	rs5751250	ENSG00000227370.1	RP4-669P10.19	-5.09	5.07e-07	0.000137	-0.2	-0.23	Cognitive function;	chr22:42243639	chr22:42132543~42132998:+
LUAD	cis	rs2911132	0.511	rs3198304	ENSG00000248734.2	CTD-2260A17.1	5.09	5.08e-07	0.000137	0.25	0.23	Urate levels (BMI interaction);	chr5:96775524	chr5:96784777~96785999:+
LUAD	cis	rs2911132	0.511	rs13160562	ENSG00000248734.2	CTD-2260A17.1	5.09	5.08e-07	0.000137	0.25	0.23	Urate levels (BMI interaction);	chr5:96775667	chr5:96784777~96785999:+
LUAD	cis	rs453301	0.658	rs6983877	ENSG00000173295.6	FAM86B3P	-5.09	5.08e-07	0.000138	-0.24	-0.23	Joint mobility (Beighton score);	chr8:9047129	chr8:8228595~8244865:+
LUAD	cis	rs61270009	0.955	rs10942528	ENSG00000247828.6	TMEM161B-AS1	5.09	5.08e-07	0.000138	0.27	0.23	Depressive symptoms;	chr5:88314098	chr5:88268895~88436685:+
LUAD	cis	rs61270009	0.913	rs13190179	ENSG00000247828.6	TMEM161B-AS1	5.09	5.08e-07	0.000138	0.27	0.23	Depressive symptoms;	chr5:88314755	chr5:88268895~88436685:+
LUAD	cis	rs61270009	0.955	rs11738675	ENSG00000247828.6	TMEM161B-AS1	5.09	5.08e-07	0.000138	0.27	0.23	Depressive symptoms;	chr5:88315360	chr5:88268895~88436685:+
LUAD	cis	rs61270009	0.955	rs60331678	ENSG00000247828.6	TMEM161B-AS1	5.09	5.08e-07	0.000138	0.27	0.23	Depressive symptoms;	chr5:88315547	chr5:88268895~88436685:+
LUAD	cis	rs61270009	0.955	rs10462333	ENSG00000247828.6	TMEM161B-AS1	5.09	5.08e-07	0.000138	0.27	0.23	Depressive symptoms;	chr5:88315871	chr5:88268895~88436685:+
LUAD	cis	rs61270009	0.955	rs6872897	ENSG00000247828.6	TMEM161B-AS1	5.09	5.08e-07	0.000138	0.27	0.23	Depressive symptoms;	chr5:88322248	chr5:88268895~88436685:+
LUAD	cis	rs61270009	0.908	rs16903077	ENSG00000247828.6	TMEM161B-AS1	5.09	5.08e-07	0.000138	0.27	0.23	Depressive symptoms;	chr5:88323008	chr5:88268895~88436685:+
LUAD	cis	rs4835473	0.797	rs34585546	ENSG00000251600.4	RP11-673E1.1	-5.09	5.08e-07	0.000138	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143680693	chr4:143912331~143982454:+
LUAD	cis	rs61270009	0.955	rs4269995	ENSG00000247828.6	TMEM161B-AS1	5.09	5.09e-07	0.000138	0.26	0.23	Depressive symptoms;	chr5:88405406	chr5:88268895~88436685:+
LUAD	cis	rs61270009	0.955	rs1367233	ENSG00000247828.6	TMEM161B-AS1	5.09	5.09e-07	0.000138	0.26	0.23	Depressive symptoms;	chr5:88301195	chr5:88268895~88436685:+
LUAD	cis	rs61270009	0.955	rs11740776	ENSG00000247828.6	TMEM161B-AS1	5.09	5.09e-07	0.000138	0.26	0.23	Depressive symptoms;	chr5:88303489	chr5:88268895~88436685:+
LUAD	cis	rs61270009	0.955	rs4916717	ENSG00000247828.6	TMEM161B-AS1	5.09	5.09e-07	0.000138	0.26	0.23	Depressive symptoms;	chr5:88305802	chr5:88268895~88436685:+
LUAD	cis	rs4835473	0.663	rs4835115	ENSG00000251600.4	RP11-673E1.1	5.09	5.09e-07	0.000138	0.28	0.23	Immature fraction of reticulocytes;	chr4:143979308	chr4:143912331~143982454:+
LUAD	cis	rs7083	1	rs512188	ENSG00000254851.1	RP11-109L13.1	-5.09	5.1e-07	0.000138	-0.28	-0.23	Blood protein levels;	chr11:117255994	chr11:117135528~117138582:+
LUAD	cis	rs712039	0.617	rs36081240	ENSG00000276054.1	RP11-378E13.3	5.09	5.11e-07	0.000138	0.34	0.23	Tuberculosis;	chr17:37424955	chr17:37386886~37387926:+
LUAD	cis	rs875971	0.895	rs6460278	ENSG00000232559.3	GS1-124K5.12	-5.09	5.11e-07	0.000138	-0.27	-0.23	Aortic root size;	chr7:66197749	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs6460279	ENSG00000232559.3	GS1-124K5.12	-5.09	5.11e-07	0.000138	-0.27	-0.23	Aortic root size;	chr7:66197774	chr7:66554588~66576923:-
LUAD	cis	rs7017914	0.69	rs3098878	ENSG00000223220.1	Y_RNA	5.09	5.11e-07	0.000138	0.26	0.23	Bone mineral density;	chr8:71025234	chr8:70780914~70781008:-
LUAD	cis	rs1799949	1	rs12952790	ENSG00000236383.6	LINC00854	-5.09	5.11e-07	0.000138	-0.18	-0.23	Menopause (age at onset);	chr17:43147590	chr17:43216941~43305976:-
LUAD	cis	rs42490	1	rs405734	ENSG00000251136.7	RP11-37B2.1	-5.09	5.12e-07	0.000138	-0.23	-0.23	Leprosy;	chr8:89756211	chr8:89609409~89757727:-
LUAD	cis	rs2286503	0.966	rs6949233	ENSG00000221740.1	SNORD93	5.09	5.12e-07	0.000138	0.25	0.23	Fibrinogen;	chr7:22818572	chr7:22856613~22856686:+
LUAD	cis	rs5758511	0.68	rs5758657	ENSG00000205702.9	CYP2D7	5.09	5.12e-07	0.000139	0.22	0.23	Birth weight;	chr22:42222663	chr22:42140203~42144577:-
LUAD	cis	rs5758511	0.68	rs1033459	ENSG00000205702.9	CYP2D7	5.09	5.12e-07	0.000139	0.22	0.23	Birth weight;	chr22:42223061	chr22:42140203~42144577:-
LUAD	cis	rs11673344	0.642	rs11083420	ENSG00000226686.6	LINC01535	5.09	5.12e-07	0.000139	0.29	0.23	Obesity-related traits;	chr19:37317901	chr19:37251912~37265535:+
LUAD	cis	rs2688608	0.592	rs2306328	ENSG00000271816.1	BMS1P4	5.09	5.12e-07	0.000139	0.19	0.23	Inflammatory bowel disease;	chr10:73819752	chr10:73699151~73730487:-
LUAD	cis	rs1816752	0.633	rs9578729	ENSG00000273628.1	RP11-756A22.7	5.09	5.13e-07	0.000139	0.25	0.23	Obesity-related traits;	chr13:24425106	chr13:24933006~24936796:+
LUAD	cis	rs7772486	0.754	rs9497401	ENSG00000235652.6	RP11-545I5.3	-5.09	5.13e-07	0.000139	-0.23	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145730135	chr6:145799409~145886585:+
LUAD	cis	rs1005277	0.579	rs1780136	ENSG00000263064.2	RP11-291L22.7	5.09	5.13e-07	0.000139	0.24	0.23	Extrinsic epigenetic age acceleration;	chr10:38212525	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.579	rs1780138	ENSG00000263064.2	RP11-291L22.7	5.09	5.13e-07	0.000139	0.24	0.23	Extrinsic epigenetic age acceleration;	chr10:38212726	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.579	rs1780139	ENSG00000263064.2	RP11-291L22.7	5.09	5.13e-07	0.000139	0.24	0.23	Extrinsic epigenetic age acceleration;	chr10:38214090	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.602	rs1780141	ENSG00000263064.2	RP11-291L22.7	5.09	5.13e-07	0.000139	0.24	0.23	Extrinsic epigenetic age acceleration;	chr10:38215371	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.541	rs1740741	ENSG00000263064.2	RP11-291L22.7	5.09	5.13e-07	0.000139	0.24	0.23	Extrinsic epigenetic age acceleration;	chr10:38226406	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.528	rs2057228	ENSG00000263064.2	RP11-291L22.7	5.09	5.13e-07	0.000139	0.24	0.23	Extrinsic epigenetic age acceleration;	chr10:38226838	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.579	rs1740742	ENSG00000263064.2	RP11-291L22.7	5.09	5.13e-07	0.000139	0.24	0.23	Extrinsic epigenetic age acceleration;	chr10:38229932	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.602	rs1740743	ENSG00000263064.2	RP11-291L22.7	5.09	5.13e-07	0.000139	0.24	0.23	Extrinsic epigenetic age acceleration;	chr10:38230294	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.579	rs1740745	ENSG00000263064.2	RP11-291L22.7	5.09	5.13e-07	0.000139	0.24	0.23	Extrinsic epigenetic age acceleration;	chr10:38231128	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.579	rs1740747	ENSG00000263064.2	RP11-291L22.7	5.09	5.13e-07	0.000139	0.24	0.23	Extrinsic epigenetic age acceleration;	chr10:38231537	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.579	rs1740749	ENSG00000263064.2	RP11-291L22.7	5.09	5.13e-07	0.000139	0.24	0.23	Extrinsic epigenetic age acceleration;	chr10:38232718	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.579	rs1780115	ENSG00000263064.2	RP11-291L22.7	5.09	5.13e-07	0.000139	0.24	0.23	Extrinsic epigenetic age acceleration;	chr10:38235845	chr10:38448689~38448949:+
LUAD	cis	rs1799949	1	rs2292595	ENSG00000236383.6	LINC00854	-5.09	5.13e-07	0.000139	-0.18	-0.23	Menopause (age at onset);	chr17:43138657	chr17:43216941~43305976:-
LUAD	cis	rs1387259	0.57	rs12368659	ENSG00000257735.1	RP11-370I10.6	5.09	5.13e-07	0.000139	0.26	0.23	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48168516	chr12:48350945~48442411:+
LUAD	cis	rs9595908	0.785	rs7331393	ENSG00000212293.1	SNORA16	-5.09	5.13e-07	0.000139	-0.25	-0.23	Body mass index;	chr13:32647065	chr13:32420390~32420516:-
LUAD	cis	rs1799949	1	rs16942	ENSG00000236383.6	LINC00854	-5.09	5.13e-07	0.000139	-0.18	-0.23	Menopause (age at onset);	chr17:43091983	chr17:43216941~43305976:-
LUAD	cis	rs7727544	0.669	rs113823725	ENSG00000233006.5	AC034220.3	5.09	5.13e-07	0.000139	0.2	0.23	Blood metabolite levels;	chr5:132227808	chr5:132311285~132369916:-
LUAD	cis	rs4908760	0.899	rs6577496	ENSG00000270282.1	RP5-1115A15.2	5.09	5.14e-07	0.000139	0.25	0.23	Vitiligo;	chr1:8521168	chr1:8512653~8513021:+
LUAD	cis	rs2522056	1	rs2106854	ENSG00000233006.5	AC034220.3	-5.09	5.14e-07	0.000139	-0.24	-0.23	Fibrinogen;Lymphocyte counts;	chr5:132433482	chr5:132311285~132369916:-
LUAD	cis	rs7521902	0.508	rs12038474	ENSG00000228397.1	RP1-224A6.3	-5.09	5.15e-07	0.000139	-0.39	-0.23	Endometriosis;Ovarian cancer;Bone mineral density;Hip circumference adjusted for BMI;	chr1:22076864	chr1:22023994~22024968:-
LUAD	cis	rs4660456	0.619	rs753753	ENSG00000237899.1	RP4-739H11.3	-5.09	5.15e-07	0.000139	-0.26	-0.23	Platelet count;	chr1:40771716	chr1:40669089~40687588:-
LUAD	cis	rs4845875	0.53	rs4846048	ENSG00000242349.4	NPPA-AS1	-5.09	5.15e-07	0.000139	-0.24	-0.23	Midregional pro atrial natriuretic peptide levels;	chr1:11786195	chr1:11841017~11848079:+
LUAD	cis	rs7017914	0.69	rs2732117	ENSG00000223220.1	Y_RNA	5.09	5.16e-07	0.000139	0.26	0.23	Bone mineral density;	chr8:70996843	chr8:70780914~70781008:-
LUAD	cis	rs910316	0.967	rs12890371	ENSG00000259138.1	RP11-950C14.7	5.09	5.16e-07	0.000139	0.24	0.23	Height;	chr14:75127136	chr14:75127153~75136930:+
LUAD	cis	rs910316	1	rs12889309	ENSG00000259138.1	RP11-950C14.7	5.09	5.16e-07	0.000139	0.24	0.23	Height;	chr14:75127199	chr14:75127153~75136930:+
LUAD	cis	rs12468226	1	rs75040639	ENSG00000272966.1	RP11-686O6.1	5.09	5.16e-07	0.000139	0.38	0.23	Urate levels;	chr2:202486973	chr2:202336739~202337200:+
LUAD	cis	rs875971	0.862	rs7786892	ENSG00000232559.3	GS1-124K5.12	-5.09	5.16e-07	0.000139	-0.27	-0.23	Aortic root size;	chr7:66163889	chr7:66554588~66576923:-
LUAD	cis	rs1707322	1	rs10158032	ENSG00000280836.1	AL355480.1	-5.09	5.16e-07	0.000139	-0.29	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867029	chr1:45581219~45581321:-
LUAD	cis	rs8103033	0.786	rs2270028	ENSG00000226025.8	LGALS17A	-5.09	5.16e-07	0.00014	-0.25	-0.23	Obesity-related traits;	chr19:39642185	chr19:39679374~39686373:+
LUAD	cis	rs8103033	0.786	rs2270029	ENSG00000226025.8	LGALS17A	-5.09	5.16e-07	0.00014	-0.25	-0.23	Obesity-related traits;	chr19:39642360	chr19:39679374~39686373:+
LUAD	cis	rs7968440	0.591	rs6580732	ENSG00000272368.2	RP4-605O3.4	-5.09	5.17e-07	0.00014	-0.25	-0.23	Fibrinogen;	chr12:50252496	chr12:50112197~50165618:+
LUAD	cis	rs36093844	0.706	rs1445501	ENSG00000279742.1	RP11-700A24.1	-5.09	5.17e-07	0.00014	-0.31	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85831833	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.706	rs78680968	ENSG00000279742.1	RP11-700A24.1	-5.09	5.17e-07	0.00014	-0.31	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85832437	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.706	rs76852274	ENSG00000279742.1	RP11-700A24.1	-5.09	5.17e-07	0.00014	-0.31	-0.23	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85832717	chr11:85852557~85854943:-
LUAD	cis	rs17023223	0.537	rs12086	ENSG00000231365.4	RP11-418J17.1	-5.09	5.17e-07	0.00014	-0.33	-0.23	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119031237	chr1:119140396~119275973:+
LUAD	cis	rs7138803	0.538	rs11169162	ENSG00000257464.1	RP11-161H23.8	-5.09	5.18e-07	0.00014	-0.22	-0.23	Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index;	chr12:49813343	chr12:49442424~49442652:-
LUAD	cis	rs4789693	0.679	rs7213057	ENSG00000265458.1	RP13-20L14.6	5.09	5.18e-07	0.00014	0.31	0.23	Glucocorticoid-induced osteonecrosis;	chr17:82421063	chr17:82454273~82458521:-
LUAD	cis	rs1799949	1	rs12950607	ENSG00000236383.6	LINC00854	-5.09	5.18e-07	0.00014	-0.18	-0.23	Menopause (age at onset);	chr17:43147911	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs11079056	ENSG00000236383.6	LINC00854	-5.09	5.18e-07	0.00014	-0.18	-0.23	Menopause (age at onset);	chr17:43148782	chr17:43216941~43305976:-
LUAD	cis	rs11976180	1	rs2951353	ENSG00000204959.4	ARHGEF34P	5.09	5.18e-07	0.00014	0.28	0.23	Obesity-related traits;	chr7:144064023	chr7:144272445~144286966:-
LUAD	cis	rs11742741	0.676	rs34415514	ENSG00000248874.4	C5orf17	-5.09	5.19e-07	0.00014	-0.28	-0.23	Educational attainment;	chr5:24196173	chr5:23951348~24178263:+
LUAD	cis	rs950169	0.922	rs67804993	ENSG00000259295.5	CSPG4P12	5.09	5.19e-07	0.00014	0.32	0.23	Schizophrenia;	chr15:84560799	chr15:85191438~85213905:+
LUAD	cis	rs4835473	0.932	rs28377887	ENSG00000251600.4	RP11-673E1.1	5.09	5.19e-07	0.00014	0.28	0.23	Immature fraction of reticulocytes;	chr4:143977075	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs6826862	ENSG00000251600.4	RP11-673E1.1	5.09	5.19e-07	0.00014	0.28	0.23	Immature fraction of reticulocytes;	chr4:143978180	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.864	rs4257604	ENSG00000251600.4	RP11-673E1.1	5.09	5.19e-07	0.00014	0.28	0.23	Immature fraction of reticulocytes;	chr4:143980261	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs4516663	ENSG00000251600.4	RP11-673E1.1	5.09	5.19e-07	0.00014	0.28	0.23	Immature fraction of reticulocytes;	chr4:143980791	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.8	rs2089839	ENSG00000251600.4	RP11-673E1.1	5.09	5.19e-07	0.00014	0.28	0.23	Immature fraction of reticulocytes;	chr4:143980955	chr4:143912331~143982454:+
LUAD	cis	rs8180040	0.764	rs2132173	ENSG00000271161.1	BOLA2P2	-5.09	5.19e-07	0.00014	-0.21	-0.23	Colorectal cancer;	chr3:47205570	chr3:47499841~47500407:+
LUAD	cis	rs875971	0.505	rs2462573	ENSG00000224316.1	RP11-479O9.2	-5.09	5.2e-07	0.00014	-0.23	-0.23	Aortic root size;	chr7:66042405	chr7:65773620~65802067:+
LUAD	cis	rs9376098	0.698	rs7756303	ENSG00000232876.1	CTA-212D2.2	-5.09	5.2e-07	0.00014	-0.26	-0.23	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135148846	chr6:135055033~135060550:+
LUAD	cis	rs7727544	0.606	rs2631360	ENSG00000233006.5	AC034220.3	5.09	5.2e-07	0.000141	0.2	0.23	Blood metabolite levels;	chr5:132371737	chr5:132311285~132369916:-
LUAD	cis	rs1914816	0.702	rs157779	ENSG00000196274.5	Metazoa_SRP	5.09	5.21e-07	0.000141	0.3	0.23	Response to tocilizumab in rheumatoid arthritis;	chr15:76468965	chr15:76230048~76230390:-
LUAD	cis	rs55726902	0.553	rs2525053	ENSG00000276691.1	RP5-1057I20.5	5.09	5.21e-07	0.000141	0.22	0.23	Allergic disease (asthma, hay fever or eczema);	chr12:47801565	chr12:47788426~47788971:+
LUAD	cis	rs910316	1	rs7156105	ENSG00000259138.1	RP11-950C14.7	5.09	5.21e-07	0.000141	0.24	0.23	Height;	chr14:75075251	chr14:75127153~75136930:+
LUAD	cis	rs9487094	0.848	rs7372	ENSG00000260273.1	RP11-425D10.10	5.09	5.21e-07	0.000141	0.31	0.23	Height;	chr6:109366911	chr6:109382795~109383666:+
LUAD	cis	rs1876905	0.764	rs6934341	ENSG00000272356.1	RP5-1112D6.8	-5.09	5.22e-07	0.000141	-0.26	-0.23	Mean corpuscular hemoglobin;	chr6:111098387	chr6:111309203~111313517:+
LUAD	cis	rs116175783	0.557	rs62197071	ENSG00000227403.1	AC009299.3	5.09	5.22e-07	0.000141	0.41	0.23	Intelligence (multi-trait analysis);	chr2:161292703	chr2:161244739~161249050:+
LUAD	cis	rs116175783	0.557	rs16845757	ENSG00000227403.1	AC009299.3	5.09	5.22e-07	0.000141	0.41	0.23	Intelligence (multi-trait analysis);	chr2:161299749	chr2:161244739~161249050:+
LUAD	cis	rs3750965	0.839	rs921670	ENSG00000260895.1	RP11-554A11.7	5.09	5.22e-07	0.000141	0.26	0.23	Hair color;	chr11:69104171	chr11:69103493~69109094:+
LUAD	cis	rs453301	0.592	rs4841084	ENSG00000173295.6	FAM86B3P	5.09	5.22e-07	0.000141	0.25	0.23	Joint mobility (Beighton score);	chr8:9026395	chr8:8228595~8244865:+
LUAD	cis	rs10246939	0.543	rs11765575	ENSG00000228775.6	WEE2-AS1	5.09	5.23e-07	0.000141	0.27	0.23	Bitter taste perception;	chr7:141838168	chr7:141704338~141738346:-
LUAD	cis	rs7017914	0.652	rs7014185	ENSG00000223220.1	Y_RNA	5.09	5.23e-07	0.000141	0.26	0.23	Bone mineral density;	chr8:71082558	chr8:70780914~70781008:-
LUAD	cis	rs910316	1	rs3742778	ENSG00000259138.1	RP11-950C14.7	-5.09	5.23e-07	0.000141	-0.24	-0.23	Height;	chr14:75071514	chr14:75127153~75136930:+
LUAD	cis	rs7772486	0.754	rs9386134	ENSG00000235652.6	RP11-545I5.3	5.09	5.23e-07	0.000141	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145824372	chr6:145799409~145886585:+
LUAD	cis	rs7617773	0.817	rs11928691	ENSG00000228638.1	FCF1P2	-5.09	5.23e-07	0.000141	-0.26	-0.23	Coronary artery disease;	chr3:48245275	chr3:48290793~48291375:-
LUAD	cis	rs4835473	0.897	rs1545437	ENSG00000251600.4	RP11-673E1.1	-5.09	5.23e-07	0.000141	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143696689	chr4:143912331~143982454:+
LUAD	cis	rs7772486	0.719	rs702307	ENSG00000235652.6	RP11-545I5.3	-5.09	5.23e-07	0.000141	-0.23	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145672318	chr6:145799409~145886585:+
LUAD	cis	rs801193	0.839	rs12534943	ENSG00000237310.1	GS1-124K5.4	-5.09	5.23e-07	0.000141	-0.24	-0.23	Aortic root size;	chr7:66605533	chr7:66493706~66495474:+
LUAD	cis	rs673078	0.66	rs17512407	ENSG00000275409.1	RP11-131L12.4	-5.09	5.23e-07	0.000141	-0.35	-0.23	Glucose homeostasis traits;	chr12:118292705	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.66	rs61946064	ENSG00000275409.1	RP11-131L12.4	-5.09	5.23e-07	0.000141	-0.35	-0.23	Glucose homeostasis traits;	chr12:118294495	chr12:118430147~118430699:+
LUAD	cis	rs17711722	0.727	rs2658585	ENSG00000224316.1	RP11-479O9.2	5.09	5.24e-07	0.000141	0.23	0.23	Calcium levels;	chr7:65996954	chr7:65773620~65802067:+
LUAD	cis	rs10129255	0.536	rs8004835	ENSG00000254174.1	IGHV1-12	5.09	5.24e-07	0.000142	0.15	0.23	Kawasaki disease;	chr14:106686361	chr14:106122420~106122709:-
LUAD	cis	rs4142995	0.962	rs6461354	ENSG00000279048.1	RP11-511H23.2	-5.09	5.24e-07	0.000142	-0.18	-0.23	HDL cholesterol;HDL cholesterol levels;	chr7:17874977	chr7:17940503~17942922:+
LUAD	cis	rs7017914	0.652	rs62530770	ENSG00000223220.1	Y_RNA	5.09	5.24e-07	0.000142	0.26	0.23	Bone mineral density;	chr8:70688761	chr8:70780914~70781008:-
LUAD	cis	rs9910055	0.683	rs7220138	ENSG00000267080.4	ASB16-AS1	-5.09	5.25e-07	0.000142	-0.21	-0.23	Total body bone mineral density;	chr17:44176643	chr17:44175973~44186717:-
LUAD	cis	rs9910055	0.639	rs7217858	ENSG00000267080.4	ASB16-AS1	-5.09	5.25e-07	0.000142	-0.21	-0.23	Total body bone mineral density;	chr17:44177159	chr17:44175973~44186717:-
LUAD	cis	rs9584850	0.794	rs72655609	ENSG00000231194.1	FARP1-AS1	5.09	5.25e-07	0.000142	0.28	0.23	Neuroticism;	chr13:98476368	chr13:98435405~98435840:-
LUAD	cis	rs8180040	0.764	rs12630534	ENSG00000271161.1	BOLA2P2	5.09	5.25e-07	0.000142	0.21	0.23	Colorectal cancer;	chr3:46959553	chr3:47499841~47500407:+
LUAD	cis	rs875971	0.862	rs778720	ENSG00000232559.3	GS1-124K5.12	-5.09	5.26e-07	0.000142	-0.27	-0.23	Aortic root size;	chr7:66381288	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs10282433	ENSG00000232559.3	GS1-124K5.12	-5.09	5.26e-07	0.000142	-0.27	-0.23	Aortic root size;	chr7:66256452	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.756	rs4718328	ENSG00000232559.3	GS1-124K5.12	-5.09	5.26e-07	0.000142	-0.27	-0.23	Aortic root size;	chr7:66228350	chr7:66554588~66576923:-
LUAD	cis	rs10129255	0.5	rs6576231	ENSG00000254174.1	IGHV1-12	5.09	5.26e-07	0.000142	0.15	0.23	Kawasaki disease;	chr14:106783693	chr14:106122420~106122709:-
LUAD	cis	rs1012068	0.541	rs11703587	ENSG00000236132.1	CTA-440B3.1	-5.09	5.26e-07	0.000142	-0.3	-0.23	Chronic hepatitis C infection;	chr22:31926428	chr22:31816379~31817491:-
LUAD	cis	rs7208859	0.51	rs216402	ENSG00000263603.1	CTD-2349P21.5	-5.09	5.27e-07	0.000142	-0.41	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30590108	chr17:30729469~30731202:+
LUAD	cis	rs2239547	0.522	rs2581815	ENSG00000242142.1	SERBP1P3	5.09	5.27e-07	0.000142	0.26	0.23	Schizophrenia;	chr3:52948143	chr3:53064283~53065091:-
LUAD	cis	rs2018683	0.899	rs10269454	ENSG00000228421.2	AC005013.5	5.09	5.27e-07	0.000142	0.25	0.23	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28938783	chr7:28957667~28959345:+
LUAD	cis	rs301901	0.743	rs10073054	ENSG00000250155.1	CTD-2353F22.1	-5.09	5.27e-07	0.000142	-0.24	-0.23	Height;	chr5:37172281	chr5:36666214~36725195:-
LUAD	cis	rs7772486	0.701	rs697056	ENSG00000235652.6	RP11-545I5.3	-5.08	5.28e-07	0.000142	-0.23	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145682761	chr6:145799409~145886585:+
LUAD	cis	rs4664293	0.867	rs7565297	ENSG00000226266.5	AC009961.3	-5.08	5.28e-07	0.000142	-0.31	-0.23	Monocyte percentage of white cells;	chr2:159716008	chr2:159670708~159712435:-
LUAD	cis	rs643506	0.874	rs648544	ENSG00000230911.1	PPIHP1	-5.08	5.29e-07	0.000143	-0.28	-0.23	Breast cancer;	chr11:111795404	chr11:112029858~112030367:-
LUAD	cis	rs2337406	0.925	rs11851094	ENSG00000211972.2	IGHV3-66	5.08	5.29e-07	0.000143	0.24	0.23	Alzheimer's disease (late onset);	chr14:106688967	chr14:106675017~106675544:-
LUAD	cis	rs1799949	1	rs4793189	ENSG00000236383.6	LINC00854	-5.08	5.29e-07	0.000143	-0.18	-0.23	Menopause (age at onset);	chr17:43038698	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs11657053	ENSG00000236383.6	LINC00854	-5.08	5.29e-07	0.000143	-0.18	-0.23	Menopause (age at onset);	chr17:43039112	chr17:43216941~43305976:-
LUAD	cis	rs858239	0.6	rs10488077	ENSG00000230042.1	AK3P3	-5.08	5.29e-07	0.000143	-0.28	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23129178~23129841:+
LUAD	cis	rs801193	0.805	rs12532355	ENSG00000237310.1	GS1-124K5.4	-5.08	5.29e-07	0.000143	-0.24	-0.23	Aortic root size;	chr7:66605597	chr7:66493706~66495474:+
LUAD	cis	rs748404	0.666	rs12900259	ENSG00000205771.5	CATSPER2P1	-5.08	5.29e-07	0.000143	-0.34	-0.23	Lung cancer;	chr15:43427369	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.666	rs34921640	ENSG00000205771.5	CATSPER2P1	-5.08	5.29e-07	0.000143	-0.34	-0.23	Lung cancer;	chr15:43429187	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.666	rs62020574	ENSG00000205771.5	CATSPER2P1	-5.08	5.29e-07	0.000143	-0.34	-0.23	Lung cancer;	chr15:43429380	chr15:43726918~43747094:-
LUAD	cis	rs9660180	0.62	rs34298494	ENSG00000231050.1	RP1-140A9.1	-5.08	5.3e-07	0.000143	-0.26	-0.23	Body mass index;	chr1:1731963	chr1:1891471~1892658:+
LUAD	cis	rs2976388	0.625	rs2257840	ENSG00000253741.1	CTD-2292P10.4	-5.08	5.3e-07	0.000143	-0.26	-0.23	Urinary tract infection frequency;	chr8:142727775	chr8:142702252~142726973:-
LUAD	cis	rs7017914	0.642	rs2732143	ENSG00000223220.1	Y_RNA	5.08	5.3e-07	0.000143	0.26	0.23	Bone mineral density;	chr8:70963007	chr8:70780914~70781008:-
LUAD	cis	rs1816752	0.837	rs7139748	ENSG00000273628.1	RP11-756A22.7	5.08	5.3e-07	0.000143	0.26	0.23	Obesity-related traits;	chr13:24411531	chr13:24933006~24936796:+
LUAD	cis	rs1008375	0.898	rs7678654	ENSG00000249502.1	AC006160.5	-5.08	5.31e-07	0.000143	-0.23	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17573753	chr4:17587467~17614571:-
LUAD	cis	rs507080	0.961	rs642530	ENSG00000278376.1	RP11-158I9.8	-5.08	5.31e-07	0.000143	-0.24	-0.23	Serum metabolite levels;	chr11:118680047	chr11:118791254~118793137:+
LUAD	cis	rs4604732	0.631	rs34924545	ENSG00000227135.1	GCSAML-AS1	-5.08	5.31e-07	0.000143	-0.34	-0.23	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463590	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.631	rs34443739	ENSG00000227135.1	GCSAML-AS1	-5.08	5.31e-07	0.000143	-0.34	-0.23	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247463611	chr1:247524679~247526752:-
LUAD	cis	rs453301	0.598	rs2921383	ENSG00000253893.2	FAM85B	-5.08	5.31e-07	0.000143	-0.29	-0.23	Joint mobility (Beighton score);	chr8:9034711	chr8:8167819~8226614:-
LUAD	cis	rs4664293	0.967	rs10803758	ENSG00000226266.5	AC009961.3	-5.08	5.31e-07	0.000143	-0.31	-0.23	Monocyte percentage of white cells;	chr2:159691708	chr2:159670708~159712435:-
LUAD	cis	rs9487094	0.813	rs61233650	ENSG00000260273.1	RP11-425D10.10	5.08	5.31e-07	0.000143	0.32	0.23	Height;	chr6:109365409	chr6:109382795~109383666:+
LUAD	cis	rs7772486	0.754	rs697053	ENSG00000235652.6	RP11-545I5.3	-5.08	5.31e-07	0.000143	-0.23	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145668671	chr6:145799409~145886585:+
LUAD	cis	rs9309473	0.687	rs11693531	ENSG00000163016.8	ALMS1P	5.08	5.31e-07	0.000143	0.26	0.23	Metabolite levels;	chr2:73381486	chr2:73644919~73685576:+
LUAD	cis	rs2032366	0.967	rs6650736	ENSG00000267279.1	RP11-879F14.2	-5.08	5.32e-07	0.000143	-0.28	-0.23	Obesity-related traits;	chr18:61601711	chr18:61585746~61606916:-
LUAD	cis	rs2239547	0.522	rs2581797	ENSG00000242142.1	SERBP1P3	-5.08	5.32e-07	0.000143	-0.26	-0.23	Schizophrenia;	chr3:52938452	chr3:53064283~53065091:-
LUAD	cis	rs1075265	0.756	rs809280	ENSG00000233266.1	HMGB1P31	5.08	5.32e-07	0.000143	0.28	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53921270	chr2:54051334~54051760:+
LUAD	cis	rs1876905	0.68	rs9384787	ENSG00000272356.1	RP5-1112D6.8	5.08	5.32e-07	0.000143	0.23	0.23	Mean corpuscular hemoglobin;	chr6:111113707	chr6:111309203~111313517:+
LUAD	cis	rs193541	0.632	rs119449	ENSG00000263432.2	RN7SL689P	5.08	5.32e-07	0.000144	0.3	0.23	Glucose homeostasis traits;	chr5:122948046	chr5:123022487~123022783:-
LUAD	cis	rs1861353	0.863	rs16952252	ENSG00000279344.1	RP11-44F14.7	5.08	5.33e-07	0.000144	0.19	0.23	Intelligence (multi-trait analysis);	chr16:53450068	chr16:53478957~53481550:-
LUAD	cis	rs10129255	0.785	rs10150044	ENSG00000211972.2	IGHV3-66	5.08	5.33e-07	0.000144	0.2	0.23	Kawasaki disease;	chr14:106775695	chr14:106675017~106675544:-
LUAD	cis	rs10129255	0.957	rs10137980	ENSG00000211972.2	IGHV3-66	5.08	5.33e-07	0.000144	0.2	0.23	Kawasaki disease;	chr14:106775735	chr14:106675017~106675544:-
LUAD	cis	rs7580658	0.857	rs17015199	ENSG00000236682.1	AC068282.3	-5.08	5.33e-07	0.000144	-0.31	-0.23	Protein C levels;	chr2:127336477	chr2:127389130~127400580:+
LUAD	cis	rs853679	0.76	rs9357067	ENSG00000219392.1	RP1-265C24.5	-5.08	5.33e-07	0.000144	-0.33	-0.23	Depression;	chr6:28242515	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.76	rs967005	ENSG00000219392.1	RP1-265C24.5	-5.08	5.33e-07	0.000144	-0.33	-0.23	Depression;	chr6:28242910	chr6:28115628~28116551:+
LUAD	cis	rs17818399	0.781	rs34449783	ENSG00000279254.1	RP11-536C12.1	-5.08	5.33e-07	0.000144	-0.26	-0.23	Height;	chr2:46636416	chr2:46668870~46670778:+
LUAD	cis	rs11671005	0.735	rs11671591	ENSG00000268912.1	CTD-2619J13.17	5.08	5.33e-07	0.000144	0.3	0.23	Mean platelet volume;	chr19:58406970	chr19:58428632~58431148:-
LUAD	cis	rs12745968	0.589	rs3936944	ENSG00000223787.2	RP4-593M8.1	-5.08	5.33e-07	0.000144	-0.27	-0.23	Bipolar disorder and schizophrenia;	chr1:92641401	chr1:92580476~92580821:-
LUAD	cis	rs1075265	0.587	rs2542585	ENSG00000233266.1	HMGB1P31	5.08	5.34e-07	0.000144	0.29	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53786407	chr2:54051334~54051760:+
LUAD	cis	rs193541	0.593	rs154499	ENSG00000263432.2	RN7SL689P	5.08	5.34e-07	0.000144	0.3	0.23	Glucose homeostasis traits;	chr5:122883971	chr5:123022487~123022783:-
LUAD	cis	rs2303759	0.67	rs45549132	ENSG00000268686.1	AC010524.2	-5.08	5.35e-07	0.000144	-0.33	-0.23	Multiple sclerosis;	chr19:49290771	chr19:49368705~49388081:-
LUAD	cis	rs13113518	0.812	rs12648271	ENSG00000223305.1	RN7SKP30	5.08	5.35e-07	0.000144	0.27	0.23	Height;	chr4:55501955	chr4:55540502~55540835:-
LUAD	cis	rs875971	0.505	rs1167386	ENSG00000224316.1	RP11-479O9.2	-5.08	5.35e-07	0.000144	-0.23	-0.23	Aortic root size;	chr7:66048109	chr7:65773620~65802067:+
LUAD	cis	rs875971	0.505	rs1167385	ENSG00000224316.1	RP11-479O9.2	-5.08	5.35e-07	0.000144	-0.23	-0.23	Aortic root size;	chr7:66048321	chr7:65773620~65802067:+
LUAD	cis	rs7772486	0.754	rs6915718	ENSG00000235652.6	RP11-545I5.3	-5.08	5.35e-07	0.000144	-0.23	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145779540	chr6:145799409~145886585:+
LUAD	cis	rs1008375	0.966	rs3775925	ENSG00000249502.1	AC006160.5	-5.08	5.35e-07	0.000144	-0.22	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17586814	chr4:17587467~17614571:-
LUAD	cis	rs875971	0.638	rs10249404	ENSG00000237310.1	GS1-124K5.4	-5.08	5.36e-07	0.000144	-0.24	-0.23	Aortic root size;	chr7:66581737	chr7:66493706~66495474:+
LUAD	cis	rs7712401	0.54	rs27617	ENSG00000263432.2	RN7SL689P	5.08	5.36e-07	0.000144	0.29	0.23	Mean platelet volume;	chr5:122900839	chr5:123022487~123022783:-
LUAD	cis	rs6095360	0.727	rs7274221	ENSG00000222365.1	SNORD12B	-5.08	5.36e-07	0.000144	-0.26	-0.23	Intelligence (multi-trait analysis);	chr20:49006961	chr20:49280319~49280409:+
LUAD	cis	rs1799949	1	rs33946455	ENSG00000236383.6	LINC00854	-5.08	5.36e-07	0.000145	-0.18	-0.23	Menopause (age at onset);	chr17:43169829	chr17:43216941~43305976:-
LUAD	cis	rs2337406	1	rs17113276	ENSG00000211972.2	IGHV3-66	-5.08	5.37e-07	0.000145	-0.24	-0.23	Alzheimer's disease (late onset);	chr14:106683485	chr14:106675017~106675544:-
LUAD	cis	rs12745968	0.569	rs7521752	ENSG00000223787.2	RP4-593M8.1	-5.08	5.37e-07	0.000145	-0.27	-0.23	Bipolar disorder and schizophrenia;	chr1:92551584	chr1:92580476~92580821:-
LUAD	cis	rs10129255	0.5	rs9324092	ENSG00000254174.1	IGHV1-12	-5.08	5.37e-07	0.000145	-0.15	-0.23	Kawasaki disease;	chr14:106683806	chr14:106122420~106122709:-
LUAD	cis	rs916888	0.821	rs199514	ENSG00000261575.2	RP11-259G18.1	-5.08	5.38e-07	0.000145	-0.35	-0.23	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46267037~46268694:+
LUAD	cis	rs9487094	0.961	rs11153174	ENSG00000260273.1	RP11-425D10.10	5.08	5.38e-07	0.000145	0.31	0.23	Height;	chr6:109352852	chr6:109382795~109383666:+
LUAD	cis	rs5769707	0.656	rs135875	ENSG00000235111.1	RP1-29C18.8	-5.08	5.38e-07	0.000145	-0.27	-0.23	Monocyte percentage of white cells;Monocyte count;	chr22:49618771	chr22:49612657~49615716:-
LUAD	cis	rs7829975	0.714	rs6994038	ENSG00000253893.2	FAM85B	-5.08	5.38e-07	0.000145	-0.28	-0.23	Mood instability;	chr8:8803028	chr8:8167819~8226614:-
LUAD	cis	rs7727544	0.625	rs3091338	ENSG00000233006.5	AC034220.3	5.08	5.38e-07	0.000145	0.2	0.23	Blood metabolite levels;	chr5:132067045	chr5:132311285~132369916:-
LUAD	cis	rs950169	0.58	rs1061737	ENSG00000259295.5	CSPG4P12	5.08	5.38e-07	0.000145	0.32	0.23	Schizophrenia;	chr15:84640559	chr15:85191438~85213905:+
LUAD	cis	rs6750795	0.569	rs1667305	ENSG00000181798.2	LINC00471	-5.08	5.38e-07	0.000145	-0.25	-0.23	Height;	chr2:231539118	chr2:231508426~231514339:-
LUAD	cis	rs12908161	1	rs58416181	ENSG00000275120.1	RP11-182J1.17	5.08	5.38e-07	0.000145	0.34	0.23	Schizophrenia;	chr15:84721230	chr15:84599434~84606463:-
LUAD	cis	rs7567389	0.626	rs11683344	ENSG00000236682.1	AC068282.3	-5.08	5.38e-07	0.000145	-0.33	-0.23	Self-rated health;	chr2:127198676	chr2:127389130~127400580:+
LUAD	cis	rs7580658	0.864	rs4150441	ENSG00000236682.1	AC068282.3	-5.08	5.38e-07	0.000145	-0.3	-0.23	Protein C levels;	chr2:127283339	chr2:127389130~127400580:+
LUAD	cis	rs1799949	1	rs8176103	ENSG00000236383.6	LINC00854	-5.08	5.39e-07	0.000145	-0.18	-0.23	Menopause (age at onset);	chr17:43115033	chr17:43216941~43305976:-
LUAD	cis	rs3750965	0.919	rs12280942	ENSG00000260895.1	RP11-554A11.7	-5.08	5.39e-07	0.000145	-0.25	-0.23	Hair color;	chr11:69092215	chr11:69103493~69109094:+
LUAD	cis	rs599083	0.573	rs3018713	ENSG00000212093.1	AP000807.1	5.08	5.39e-07	0.000145	0.24	0.23	Bone mineral density (spine);	chr11:68623518	chr11:68506083~68506166:-
LUAD	cis	rs1062177	1	rs17741826	ENSG00000253921.1	CTB-113P19.3	5.08	5.39e-07	0.000145	0.31	0.23	Preschool internalizing problems;	chr5:151769701	chr5:151753992~151767247:+
LUAD	cis	rs4908760	0.792	rs4908505	ENSG00000270282.1	RP5-1115A15.2	5.08	5.39e-07	0.000145	0.25	0.23	Vitiligo;	chr1:8668805	chr1:8512653~8513021:+
LUAD	cis	rs2239547	0.603	rs4687698	ENSG00000242142.1	SERBP1P3	5.08	5.39e-07	0.000145	0.27	0.23	Schizophrenia;	chr3:53063092	chr3:53064283~53065091:-
LUAD	cis	rs1546924	0.549	rs127204	ENSG00000227811.2	FAM212B-AS1	-5.08	5.39e-07	0.000145	-0.28	-0.23	Body mass index;	chr1:111735071	chr1:111739841~111747798:+
LUAD	cis	rs9322193	0.962	rs3805752	ENSG00000268592.3	RAET1E-AS1	5.08	5.39e-07	0.000145	0.29	0.23	Lung cancer;	chr6:149795490	chr6:149863494~149919507:+
LUAD	cis	rs4908760	0.965	rs12080583	ENSG00000270282.1	RP5-1115A15.2	5.08	5.4e-07	0.000145	0.25	0.23	Vitiligo;	chr1:8464817	chr1:8512653~8513021:+
LUAD	cis	rs2098713	0.535	rs2176478	ENSG00000250155.1	CTD-2353F22.1	5.08	5.4e-07	0.000145	0.24	0.23	Telomere length;	chr5:37626939	chr5:36666214~36725195:-
LUAD	cis	rs14027	0.921	rs2289011	ENSG00000279347.1	RP11-85I17.2	5.08	5.4e-07	0.000145	0.2	0.23	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119744768	chr8:119838736~119840385:-
LUAD	cis	rs1150668	0.699	rs13408	ENSG00000219392.1	RP1-265C24.5	-5.08	5.4e-07	0.000145	-0.29	-0.23	Pubertal anthropometrics;	chr6:28244970	chr6:28115628~28116551:+
LUAD	cis	rs910316	1	rs11159117	ENSG00000259138.1	RP11-950C14.7	5.08	5.4e-07	0.000145	0.24	0.23	Height;	chr14:75118164	chr14:75127153~75136930:+
LUAD	cis	rs7772486	0.754	rs697054	ENSG00000235652.6	RP11-545I5.3	5.08	5.41e-07	0.000146	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145682634	chr6:145799409~145886585:+
LUAD	cis	rs5760092	0.755	rs915589	ENSG00000206090.4	AP000350.7	-5.08	5.41e-07	0.000146	-0.31	-0.23	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23939998~23942798:+
LUAD	cis	rs3096299	0.509	rs4785691	ENSG00000182376.2	RP5-1142A6.8	5.08	5.41e-07	0.000146	0.23	0.23	Multiple myeloma (IgH translocation);	chr16:89530813	chr16:88742767~88745748:+
LUAD	cis	rs1075265	0.621	rs2542593	ENSG00000233266.1	HMGB1P31	5.08	5.41e-07	0.000146	0.29	0.23	Chronotype;Morning vs. evening chronotype;	chr2:53804299	chr2:54051334~54051760:+
LUAD	cis	rs17772222	0.958	rs74074098	ENSG00000258983.2	RP11-507K2.2	5.08	5.41e-07	0.000146	0.28	0.23	Coronary artery calcification;	chr14:88484213	chr14:88499334~88515502:+
LUAD	cis	rs4142995	0.626	rs77555266	ENSG00000279048.1	RP11-511H23.2	-5.08	5.41e-07	0.000146	-0.19	-0.23	HDL cholesterol;HDL cholesterol levels;	chr7:17869891	chr7:17940503~17942922:+
LUAD	cis	rs11976180	1	rs2371247	ENSG00000204959.4	ARHGEF34P	5.08	5.41e-07	0.000146	0.28	0.23	Obesity-related traits;	chr7:144067086	chr7:144272445~144286966:-
LUAD	cis	rs10129255	0.957	rs12590667	ENSG00000274576.2	IGHV2-70	-5.08	5.41e-07	0.000146	-0.19	-0.23	Kawasaki disease;	chr14:106779223	chr14:106770577~106771020:-
LUAD	cis	rs4664293	0.769	rs1365798	ENSG00000226266.5	AC009961.3	5.08	5.42e-07	0.000146	0.32	0.23	Monocyte percentage of white cells;	chr2:159795853	chr2:159670708~159712435:-
LUAD	cis	rs61542988	0.797	rs4329182	ENSG00000228649.7	AC005682.5	5.08	5.42e-07	0.000146	0.32	0.23	Fibrinogen levels;	chr7:22843002	chr7:22854178~22861579:+
LUAD	cis	rs7714584	1	rs17800886	ENSG00000197083.10	ZNF300P1	5.08	5.42e-07	0.000146	0.44	0.23	Crohn's disease;	chr5:150929977	chr5:150930645~150946289:-
LUAD	cis	rs875971	1	rs697970	ENSG00000232559.3	GS1-124K5.12	-5.08	5.42e-07	0.000146	-0.27	-0.23	Aortic root size;	chr7:66095065	chr7:66554588~66576923:-
LUAD	cis	rs4763879	0.502	rs11052552	ENSG00000256582.1	RP11-75L1.1	5.08	5.42e-07	0.000146	0.23	0.23	Type 1 diabetes;	chr12:9703362	chr12:9704077~9709350:+
LUAD	cis	rs897984	0.683	rs8046001	ENSG00000232748.3	RP11-196G11.6	-5.08	5.42e-07	0.000146	-0.28	-0.23	Dementia with Lewy bodies;	chr16:30822000	chr16:31056460~31062803:+
LUAD	cis	rs1799949	0.93	rs3092987	ENSG00000236383.6	LINC00854	-5.08	5.42e-07	0.000146	-0.18	-0.23	Menopause (age at onset);	chr17:43070706	chr17:43216941~43305976:-
LUAD	cis	rs3096299	0.967	rs2911257	ENSG00000182376.2	RP5-1142A6.8	5.08	5.42e-07	0.000146	0.23	0.23	Multiple myeloma (IgH translocation);	chr16:89417726	chr16:88742767~88745748:+
LUAD	cis	rs3738443	0.951	rs61840056	ENSG00000259865.1	RP11-488L18.10	5.08	5.42e-07	0.000146	0.24	0.23	Alcohol dependence;	chr1:247205930	chr1:247187281~247188526:-
LUAD	cis	rs7772486	0.754	rs6570708	ENSG00000235652.6	RP11-545I5.3	-5.08	5.42e-07	0.000146	-0.22	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145668292	chr6:145799409~145886585:+
LUAD	cis	rs1799949	1	rs4793190	ENSG00000236383.6	LINC00854	-5.08	5.43e-07	0.000146	-0.18	-0.23	Menopause (age at onset);	chr17:43048092	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs8176297	ENSG00000236383.6	LINC00854	-5.08	5.43e-07	0.000146	-0.18	-0.23	Menopause (age at onset);	chr17:43051308	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs8176296	ENSG00000236383.6	LINC00854	-5.08	5.43e-07	0.000146	-0.18	-0.23	Menopause (age at onset);	chr17:43051574	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs4793191	ENSG00000236383.6	LINC00854	-5.08	5.43e-07	0.000146	-0.18	-0.23	Menopause (age at onset);	chr17:43052360	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs4793192	ENSG00000236383.6	LINC00854	-5.08	5.43e-07	0.000146	-0.18	-0.23	Menopause (age at onset);	chr17:43052373	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs8176289	ENSG00000236383.6	LINC00854	-5.08	5.43e-07	0.000146	-0.18	-0.23	Menopause (age at onset);	chr17:43054039	chr17:43216941~43305976:-
LUAD	cis	rs9659323	0.67	rs6701378	ENSG00000231365.4	RP11-418J17.1	-5.08	5.43e-07	0.000146	-0.27	-0.23	Body mass index;	chr1:119095930	chr1:119140396~119275973:+
LUAD	cis	rs763567	1	rs763567	ENSG00000271811.1	RP1-79C4.4	-5.08	5.43e-07	0.000146	-0.28	-0.23	Tonsillectomy;	chr1:170596864	chr1:170667381~170669425:+
LUAD	cis	rs763512	0.504	rs1045013	ENSG00000276054.1	RP11-378E13.3	5.08	5.43e-07	0.000146	0.36	0.23	3-hydroxypropylmercapturic acid levels in smokers;	chr17:37518790	chr17:37386886~37387926:+
LUAD	cis	rs453301	0.686	rs4840389	ENSG00000253893.2	FAM85B	5.08	5.44e-07	0.000146	0.29	0.23	Joint mobility (Beighton score);	chr8:9026993	chr8:8167819~8226614:-
LUAD	cis	rs732716	0.889	rs55637375	ENSG00000267980.1	AC007292.6	-5.08	5.44e-07	0.000146	-0.26	-0.23	Mean corpuscular volume;	chr19:4386848	chr19:4363789~4364640:+
LUAD	cis	rs11742741	0.676	rs13155915	ENSG00000248874.4	C5orf17	-5.08	5.44e-07	0.000146	-0.28	-0.23	Educational attainment;	chr5:24191881	chr5:23951348~24178263:+
LUAD	cis	rs11742741	0.702	rs13154927	ENSG00000248874.4	C5orf17	-5.08	5.44e-07	0.000146	-0.28	-0.23	Educational attainment;	chr5:24191972	chr5:23951348~24178263:+
LUAD	cis	rs7772486	0.754	rs13214277	ENSG00000235652.6	RP11-545I5.3	5.08	5.44e-07	0.000146	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145814989	chr6:145799409~145886585:+
LUAD	cis	rs2286503	0.78	rs2286506	ENSG00000221740.1	SNORD93	5.08	5.44e-07	0.000146	0.26	0.23	Fibrinogen;	chr7:22815196	chr7:22856613~22856686:+
LUAD	cis	rs2286503	0.752	rs2286504	ENSG00000221740.1	SNORD93	5.08	5.44e-07	0.000146	0.26	0.23	Fibrinogen;	chr7:22815228	chr7:22856613~22856686:+
LUAD	cis	rs1320333	0.685	rs6710875	ENSG00000233296.1	AC092159.2	-5.08	5.45e-07	0.000146	-0.39	-0.23	Obesity-related traits;	chr2:699976	chr2:677186~697371:+
LUAD	cis	rs4835473	0.932	rs12503900	ENSG00000251600.4	RP11-673E1.1	-5.08	5.45e-07	0.000146	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143812459	chr4:143912331~143982454:+
LUAD	cis	rs17508449	0.819	rs17359281	ENSG00000232450.1	RP4-730K3.3	5.08	5.45e-07	0.000147	0.38	0.23	Leprosy;	chr1:113643337	chr1:113698884~113699631:-
LUAD	cis	rs12701220	0.503	rs12702024	ENSG00000229043.2	AC091729.9	-5.08	5.45e-07	0.000147	-0.31	-0.23	Bronchopulmonary dysplasia;	chr7:1090184	chr7:1160374~1165267:+
LUAD	cis	rs712039	0.652	rs736424	ENSG00000276054.1	RP11-378E13.3	5.08	5.45e-07	0.000147	0.32	0.23	Tuberculosis;	chr17:37429263	chr17:37386886~37387926:+
LUAD	cis	rs1075232	0.826	rs12438813	ENSG00000215302.7	CTD-3092A11.1	-5.08	5.45e-07	0.000147	-0.51	-0.23	Survival in colorectal cancer (non-distant metastatic);	chr15:31413710	chr15:30470779~30507623:+
LUAD	cis	rs1075232	1	rs34959140	ENSG00000215302.7	CTD-3092A11.1	-5.08	5.45e-07	0.000147	-0.51	-0.23	Survival in colorectal cancer (non-distant metastatic);	chr15:31433020	chr15:30470779~30507623:+
LUAD	cis	rs2412819	0.559	rs8040336	ENSG00000249839.1	AC011330.5	-5.08	5.45e-07	0.000147	-0.27	-0.23	Lung cancer;	chr15:43761419	chr15:43663654~43684339:-
LUAD	cis	rs4143844	0.609	rs11632560	ENSG00000259251.2	RP11-643M14.1	5.08	5.45e-07	0.000147	0.41	0.23	Bipolar disorder and schizophrenia;	chr15:62009299	chr15:62060503~62062434:+
LUAD	cis	rs2439831	0.867	rs933941	ENSG00000249839.1	AC011330.5	-5.08	5.45e-07	0.000147	-0.41	-0.23	Lung cancer in ever smokers;	chr15:43340028	chr15:43663654~43684339:-
LUAD	cis	rs10740039	1	rs10740040	ENSG00000254271.1	RP11-131N11.4	5.08	5.45e-07	0.000147	0.25	0.23	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60654985	chr10:60734342~60741828:+
LUAD	cis	rs2408955	0.521	rs10875749	ENSG00000257735.1	RP11-370I10.6	-5.08	5.46e-07	0.000147	-0.27	-0.23	Glycated hemoglobin levels;	chr12:48138134	chr12:48350945~48442411:+
LUAD	cis	rs7580658	0.817	rs6761447	ENSG00000236682.1	AC068282.3	-5.08	5.46e-07	0.000147	-0.3	-0.23	Protein C levels;	chr2:127316997	chr2:127389130~127400580:+
LUAD	cis	rs7302981	0.967	rs2178173	ENSG00000272368.2	RP4-605O3.4	-5.08	5.46e-07	0.000147	-0.26	-0.23	Systolic blood pressure;	chr12:50124146	chr12:50112197~50165618:+
LUAD	cis	rs7302981	0.967	rs7297421	ENSG00000272368.2	RP4-605O3.4	-5.08	5.46e-07	0.000147	-0.26	-0.23	Systolic blood pressure;	chr12:50125143	chr12:50112197~50165618:+
LUAD	cis	rs12701220	0.655	rs34696066	ENSG00000229043.2	AC091729.9	-5.08	5.46e-07	0.000147	-0.29	-0.23	Bronchopulmonary dysplasia;	chr7:1101283	chr7:1160374~1165267:+
LUAD	cis	rs11105298	0.891	rs10858909	ENSG00000258302.2	RP11-981P6.1	5.08	5.46e-07	0.000147	0.29	0.23	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89541610	chr12:89561129~89594878:+
LUAD	cis	rs11673344	0.563	rs256744	ENSG00000226686.6	LINC01535	-5.08	5.47e-07	0.000147	-0.29	-0.23	Obesity-related traits;	chr19:37364586	chr19:37251912~37265535:+
LUAD	cis	rs950169	0.58	rs11634322	ENSG00000259295.5	CSPG4P12	5.08	5.47e-07	0.000147	0.32	0.23	Schizophrenia;	chr15:84628978	chr15:85191438~85213905:+
LUAD	cis	rs950169	0.58	rs4603535	ENSG00000259295.5	CSPG4P12	5.08	5.47e-07	0.000147	0.32	0.23	Schizophrenia;	chr15:84630641	chr15:85191438~85213905:+
LUAD	cis	rs10129255	0.5	rs7157975	ENSG00000254174.1	IGHV1-12	5.08	5.47e-07	0.000147	0.15	0.23	Kawasaki disease;	chr14:106804049	chr14:106122420~106122709:-
LUAD	cis	rs6687821	0.515	rs1621247	ENSG00000267734.1	RP4-604K5.3	-5.08	5.47e-07	0.000147	-0.28	-0.23	Yeast infection;	chr1:87104715	chr1:86932199~86934891:-
LUAD	cis	rs73186030	0.546	rs55857899	ENSG00000272758.4	RP11-299J3.8	5.08	5.47e-07	0.000147	0.29	0.23	Serum parathyroid hormone levels;	chr3:122390705	chr3:122416207~122443180:+
LUAD	cis	rs1062177	0.826	rs2915879	ENSG00000253921.1	CTB-113P19.3	-5.08	5.48e-07	0.000147	-0.33	-0.23	Preschool internalizing problems;	chr5:151767881	chr5:151753992~151767247:+
LUAD	cis	rs643506	0.874	rs609007	ENSG00000230911.1	PPIHP1	5.08	5.48e-07	0.000147	0.28	0.23	Breast cancer;	chr11:111848870	chr11:112029858~112030367:-
LUAD	cis	rs2404602	0.536	rs12915248	ENSG00000259422.1	RP11-593F23.1	5.08	5.48e-07	0.000147	0.25	0.23	Blood metabolite levels;	chr15:76473274	chr15:76174891~76181486:-
LUAD	cis	rs12701220	0.655	rs11489405	ENSG00000229043.2	AC091729.9	-5.08	5.48e-07	0.000147	-0.29	-0.23	Bronchopulmonary dysplasia;	chr7:1100256	chr7:1160374~1165267:+
LUAD	cis	rs453301	0.658	rs13271797	ENSG00000253893.2	FAM85B	5.08	5.48e-07	0.000147	0.29	0.23	Joint mobility (Beighton score);	chr8:9028444	chr8:8167819~8226614:-
LUAD	cis	rs4660214	0.666	rs625384	ENSG00000228060.1	RP11-69E11.8	-5.08	5.48e-07	0.000147	-0.2	-0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39427421	chr1:39565160~39573203:+
LUAD	cis	rs2286503	0.78	rs12113458	ENSG00000221740.1	SNORD93	5.08	5.49e-07	0.000147	0.26	0.23	Fibrinogen;	chr7:22816009	chr7:22856613~22856686:+
LUAD	cis	rs35264875	0.95	rs72928659	ENSG00000259799.1	RP11-554A11.9	5.08	5.49e-07	0.000147	0.33	0.23	Blond vs. brown hair color;	chr11:69084890	chr11:69155910~69159752:+
LUAD	cis	rs287982	0.932	rs9973654	ENSG00000269973.1	RP11-95D17.1	-5.08	5.5e-07	0.000148	-0.27	-0.23	Nonsyndromic cleft lip with cleft palate;	chr2:9822439	chr2:9936360~9939590:+
LUAD	cis	rs9487094	0.961	rs11153175	ENSG00000260273.1	RP11-425D10.10	5.08	5.5e-07	0.000148	0.31	0.23	Height;	chr6:109361318	chr6:109382795~109383666:+
LUAD	cis	rs7580658	0.895	rs4662722	ENSG00000236682.1	AC068282.3	-5.08	5.5e-07	0.000148	-0.31	-0.23	Protein C levels;	chr2:127344993	chr2:127389130~127400580:+
LUAD	cis	rs7580658	0.895	rs4662580	ENSG00000236682.1	AC068282.3	-5.08	5.5e-07	0.000148	-0.31	-0.23	Protein C levels;	chr2:127345230	chr2:127389130~127400580:+
LUAD	cis	rs4143844	1	rs34173668	ENSG00000259251.2	RP11-643M14.1	5.08	5.5e-07	0.000148	0.4	0.23	Bipolar disorder and schizophrenia;	chr15:62013385	chr15:62060503~62062434:+
LUAD	cis	rs4143844	1	rs11629645	ENSG00000259251.2	RP11-643M14.1	5.08	5.5e-07	0.000148	0.4	0.23	Bipolar disorder and schizophrenia;	chr15:62014275	chr15:62060503~62062434:+
LUAD	cis	rs1008375	0.931	rs10008337	ENSG00000249502.1	AC006160.5	-5.08	5.5e-07	0.000148	-0.22	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17592226	chr4:17587467~17614571:-
LUAD	cis	rs1008375	0.898	rs61047804	ENSG00000249502.1	AC006160.5	-5.08	5.5e-07	0.000148	-0.22	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17592342	chr4:17587467~17614571:-
LUAD	cis	rs1008375	0.898	rs10008445	ENSG00000249502.1	AC006160.5	-5.08	5.5e-07	0.000148	-0.22	-0.23	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17592355	chr4:17587467~17614571:-
LUAD	cis	rs496547	0.52	rs11216963	ENSG00000255422.1	AP002954.4	5.08	5.5e-07	0.000148	0.34	0.23	Hip minimal joint space width;	chr11:118710105	chr11:118704607~118750263:+
LUAD	cis	rs7119038	0.509	rs11216964	ENSG00000255422.1	AP002954.4	5.08	5.5e-07	0.000148	0.34	0.23	Sjögren's syndrome;	chr11:118711186	chr11:118704607~118750263:+
LUAD	cis	rs6687821	0.643	rs10446	ENSG00000267734.1	RP4-604K5.3	5.08	5.51e-07	0.000148	0.27	0.23	Yeast infection;	chr1:86747316	chr1:86932199~86934891:-
LUAD	cis	rs6687821	0.555	rs263497	ENSG00000267734.1	RP4-604K5.3	5.08	5.51e-07	0.000148	0.27	0.23	Yeast infection;	chr1:86748465	chr1:86932199~86934891:-
LUAD	cis	rs12745968	0.532	rs10874724	ENSG00000223787.2	RP4-593M8.1	-5.08	5.51e-07	0.000148	-0.27	-0.23	Bipolar disorder and schizophrenia;	chr1:92622626	chr1:92580476~92580821:-
LUAD	cis	rs375066	0.935	rs388685	ENSG00000267058.1	RP11-15A1.3	-5.08	5.51e-07	0.000148	-0.25	-0.23	Breast cancer;	chr19:43914528	chr19:43891804~43901805:-
LUAD	cis	rs858239	0.67	rs6967526	ENSG00000226816.2	AC005082.12	5.08	5.51e-07	0.000148	0.29	0.23	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23206013~23208045:+
LUAD	cis	rs4819052	0.788	rs9978857	ENSG00000223768.1	LINC00205	-5.08	5.51e-07	0.000148	-0.27	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285240	chr21:45293285~45297354:+
LUAD	cis	rs42490	0.903	rs7824932	ENSG00000251136.7	RP11-37B2.1	5.08	5.52e-07	0.000148	0.23	0.23	Leprosy;	chr8:89703848	chr8:89609409~89757727:-
LUAD	cis	rs11105298	0.891	rs11105319	ENSG00000258302.2	RP11-981P6.1	5.08	5.53e-07	0.000148	0.29	0.23	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89533400	chr12:89561129~89594878:+
LUAD	cis	rs30380	1	rs27529	ENSG00000272109.1	CTD-2260A17.3	-5.08	5.53e-07	0.000148	-0.24	-0.23	Cerebrospinal fluid biomarker levels;	chr5:96790605	chr5:96804353~96806105:+
LUAD	cis	rs2832077	0.943	rs2832100	ENSG00000232855.5	AF131217.1	5.08	5.53e-07	0.000149	0.24	0.23	Cognitive test performance;	chr21:28803305	chr21:28439346~28674848:-
LUAD	cis	rs4143844	0.867	rs36126734	ENSG00000259251.2	RP11-643M14.1	5.08	5.53e-07	0.000149	0.41	0.23	Bipolar disorder and schizophrenia;	chr15:62022710	chr15:62060503~62062434:+
LUAD	cis	rs4143844	0.867	rs34088392	ENSG00000259251.2	RP11-643M14.1	5.08	5.53e-07	0.000149	0.41	0.23	Bipolar disorder and schizophrenia;	chr15:62022843	chr15:62060503~62062434:+
LUAD	cis	rs375066	0.935	rs388706	ENSG00000267058.1	RP11-15A1.3	-5.08	5.53e-07	0.000149	-0.25	-0.23	Breast cancer;	chr19:43914541	chr19:43891804~43901805:-
LUAD	cis	rs1062177	1	rs2964585	ENSG00000253921.1	CTB-113P19.3	-5.08	5.53e-07	0.000149	-0.33	-0.23	Preschool internalizing problems;	chr5:151762334	chr5:151753992~151767247:+
LUAD	cis	rs6714710	0.603	rs895438	ENSG00000230606.9	AC159540.1	-5.08	5.53e-07	0.000149	-0.24	-0.23	Posterior cortical atrophy and Alzheimer's disease;	chr2:97766423	chr2:97416165~97433527:-
LUAD	cis	rs2439831	0.681	rs498837	ENSG00000249839.1	AC011330.5	-5.08	5.53e-07	0.000149	-0.4	-0.23	Lung cancer in ever smokers;	chr15:43315826	chr15:43663654~43684339:-
LUAD	cis	rs2439831	0.681	rs540031	ENSG00000249839.1	AC011330.5	-5.08	5.53e-07	0.000149	-0.4	-0.23	Lung cancer in ever smokers;	chr15:43316657	chr15:43663654~43684339:-
LUAD	cis	rs1876905	0.68	rs9400468	ENSG00000272356.1	RP5-1112D6.8	-5.08	5.53e-07	0.000149	-0.25	-0.23	Mean corpuscular hemoglobin;	chr6:111138766	chr6:111309203~111313517:+
LUAD	cis	rs6687821	0.834	rs7805	ENSG00000267734.1	RP4-604K5.3	5.08	5.54e-07	0.000149	0.26	0.23	Yeast infection;	chr1:86743270	chr1:86932199~86934891:-
LUAD	cis	rs732716	0.853	rs62129349	ENSG00000267980.1	AC007292.6	-5.08	5.54e-07	0.000149	-0.26	-0.23	Mean corpuscular volume;	chr19:4385662	chr19:4363789~4364640:+
LUAD	cis	rs732716	0.889	rs11085074	ENSG00000267980.1	AC007292.6	-5.08	5.54e-07	0.000149	-0.26	-0.23	Mean corpuscular volume;	chr19:4386355	chr19:4363789~4364640:+
LUAD	cis	rs62432291	0.681	rs400477	ENSG00000235086.1	FNDC1-IT1	5.08	5.54e-07	0.000149	0.37	0.23	Joint mobility (Beighton score);	chr6:159214911	chr6:159240786~159243329:+
LUAD	cis	rs2834288	0.618	rs9977699	ENSG00000237945.6	LINC00649	-5.08	5.54e-07	0.000149	-0.28	-0.23	Gut microbiota (bacterial taxa);	chr21:33978601	chr21:33915534~33977691:+
LUAD	cis	rs6570726	0.764	rs4263604	ENSG00000235652.6	RP11-545I5.3	5.08	5.55e-07	0.000149	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145595561	chr6:145799409~145886585:+
LUAD	cis	rs4865169	1	rs4865169	ENSG00000269949.1	RP11-738E22.3	-5.07	5.55e-07	0.000149	-0.28	-0.23	Breast cancer;	chr4:57013626	chr4:56960927~56961373:-
LUAD	cis	rs6687821	0.715	rs691774	ENSG00000267734.1	RP4-604K5.3	5.07	5.55e-07	0.000149	0.27	0.23	Yeast infection;	chr1:86779067	chr1:86932199~86934891:-
LUAD	cis	rs858239	0.539	rs6955969	ENSG00000230042.1	AK3P3	-5.07	5.55e-07	0.000149	-0.29	-0.23	Cerebrospinal fluid biomarker levels;	chr7:23147080	chr7:23129178~23129841:+
LUAD	cis	rs75920871	0.502	rs7124996	ENSG00000254851.1	RP11-109L13.1	5.07	5.55e-07	0.000149	0.33	0.23	Subjective well-being;	chr11:117057290	chr11:117135528~117138582:+
LUAD	cis	rs4938330	0.68	rs4938329	ENSG00000254851.1	RP11-109L13.1	5.07	5.55e-07	0.000149	0.33	0.23	Blood protein levels;	chr11:117057396	chr11:117135528~117138582:+
LUAD	cis	rs1816752	0.777	rs6490915	ENSG00000273628.1	RP11-756A22.7	5.07	5.56e-07	0.000149	0.26	0.23	Obesity-related traits;	chr13:24413724	chr13:24933006~24936796:+
LUAD	cis	rs7208859	0.623	rs216445	ENSG00000263603.1	CTD-2349P21.5	-5.07	5.56e-07	0.000149	-0.41	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606558	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs216446	ENSG00000263603.1	CTD-2349P21.5	-5.07	5.56e-07	0.000149	-0.41	-0.23	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606700	chr17:30729469~30731202:+
LUAD	cis	rs11671005	0.735	rs56292587	ENSG00000268912.1	CTD-2619J13.17	-5.07	5.56e-07	0.000149	-0.3	-0.23	Mean platelet volume;	chr19:58407699	chr19:58428632~58431148:-
LUAD	cis	rs11671005	0.735	rs56290606	ENSG00000268912.1	CTD-2619J13.17	-5.07	5.56e-07	0.000149	-0.3	-0.23	Mean platelet volume;	chr19:58407953	chr19:58428632~58431148:-
LUAD	cis	rs11671005	0.735	rs11878198	ENSG00000268912.1	CTD-2619J13.17	-5.07	5.56e-07	0.000149	-0.3	-0.23	Mean platelet volume;	chr19:58408935	chr19:58428632~58431148:-
LUAD	cis	rs11671005	0.735	rs11666716	ENSG00000268912.1	CTD-2619J13.17	-5.07	5.56e-07	0.000149	-0.3	-0.23	Mean platelet volume;	chr19:58409585	chr19:58428632~58431148:-
LUAD	cis	rs11671005	0.735	rs34511020	ENSG00000268912.1	CTD-2619J13.17	-5.07	5.56e-07	0.000149	-0.3	-0.23	Mean platelet volume;	chr19:58409929	chr19:58428632~58431148:-
LUAD	cis	rs11671005	0.735	rs11666303	ENSG00000268912.1	CTD-2619J13.17	-5.07	5.56e-07	0.000149	-0.3	-0.23	Mean platelet volume;	chr19:58411135	chr19:58428632~58431148:-
LUAD	cis	rs11671005	0.735	rs34152946	ENSG00000268912.1	CTD-2619J13.17	-5.07	5.56e-07	0.000149	-0.3	-0.23	Mean platelet volume;	chr19:58411896	chr19:58428632~58431148:-
LUAD	cis	rs71520386	0.607	rs28660425	ENSG00000228649.7	AC005682.5	-5.07	5.56e-07	0.000149	-0.31	-0.23	Fibrinogen levels;	chr7:22818532	chr7:22854178~22861579:+
LUAD	cis	rs7083	0.967	rs477269	ENSG00000254851.1	RP11-109L13.1	5.07	5.57e-07	0.000149	0.29	0.23	Blood protein levels;	chr11:117267575	chr11:117135528~117138582:+
LUAD	cis	rs1816752	0.905	rs9511260	ENSG00000273628.1	RP11-756A22.7	5.07	5.57e-07	0.000149	0.26	0.23	Obesity-related traits;	chr13:24437038	chr13:24933006~24936796:+
LUAD	cis	rs748404	0.697	rs572959	ENSG00000249839.1	AC011330.5	-5.07	5.57e-07	0.00015	-0.29	-0.23	Lung cancer;	chr15:43258304	chr15:43663654~43684339:-
LUAD	cis	rs4865169	0.871	rs9918067	ENSG00000269949.1	RP11-738E22.3	-5.07	5.57e-07	0.00015	-0.28	-0.23	Breast cancer;	chr4:57004378	chr4:56960927~56961373:-
LUAD	cis	rs6723226	0.679	rs116617324	ENSG00000276334.1	AL133243.1	-5.07	5.58e-07	0.00015	-0.25	-0.23	Intelligence (multi-trait analysis);	chr2:32397641	chr2:32521927~32523547:+
LUAD	cis	rs673078	0.66	rs61943525	ENSG00000275409.1	RP11-131L12.4	-5.07	5.58e-07	0.00015	-0.35	-0.23	Glucose homeostasis traits;	chr12:118152927	chr12:118430147~118430699:+
LUAD	cis	rs5769707	0.609	rs135861	ENSG00000235111.1	RP1-29C18.8	-5.07	5.58e-07	0.00015	-0.27	-0.23	Monocyte percentage of white cells;Monocyte count;	chr22:49604470	chr22:49612657~49615716:-
LUAD	cis	rs7083	0.875	rs536648	ENSG00000254851.1	RP11-109L13.1	5.07	5.58e-07	0.00015	0.28	0.23	Blood protein levels;	chr11:117272469	chr11:117135528~117138582:+
LUAD	cis	rs172166	0.538	rs1150686	ENSG00000219392.1	RP1-265C24.5	-5.07	5.59e-07	0.00015	-0.28	-0.23	Cardiac Troponin-T levels;	chr6:28193493	chr6:28115628~28116551:+
LUAD	cis	rs4908768	0.501	rs7520617	ENSG00000270282.1	RP5-1115A15.2	5.07	5.59e-07	0.00015	0.25	0.23	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8513658	chr1:8512653~8513021:+
LUAD	cis	rs7017914	0.652	rs17778232	ENSG00000223220.1	Y_RNA	5.07	5.59e-07	0.00015	0.26	0.23	Bone mineral density;	chr8:71079283	chr8:70780914~70781008:-
LUAD	cis	rs75920871	0.528	rs10466590	ENSG00000254851.1	RP11-109L13.1	5.07	5.59e-07	0.00015	0.33	0.23	Subjective well-being;	chr11:117023697	chr11:117135528~117138582:+
LUAD	cis	rs720475	0.732	rs62483107	ENSG00000204959.4	ARHGEF34P	-5.07	5.59e-07	0.00015	-0.31	-0.23	Breast cancer;	chr7:144442144	chr7:144272445~144286966:-
LUAD	cis	rs720475	0.695	rs62483108	ENSG00000204959.4	ARHGEF34P	-5.07	5.59e-07	0.00015	-0.31	-0.23	Breast cancer;	chr7:144442326	chr7:144272445~144286966:-
LUAD	cis	rs301901	0.698	rs217837	ENSG00000250155.1	CTD-2353F22.1	5.07	5.6e-07	0.00015	0.24	0.23	Height;	chr5:37376570	chr5:36666214~36725195:-
LUAD	cis	rs4591358	0.731	rs12693768	ENSG00000223466.1	AC064834.2	-5.07	5.6e-07	0.00015	-0.31	-0.23	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195451897	chr2:195533035~195538681:+
LUAD	cis	rs4908768	0.501	rs11121201	ENSG00000270282.1	RP5-1115A15.2	5.07	5.6e-07	0.00015	0.25	0.23	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8572732	chr1:8512653~8513021:+
LUAD	cis	rs683257	0.636	rs6918856	ENSG00000234147.1	RP3-460G2.2	-5.07	5.6e-07	0.00015	-0.37	-0.23	Facial emotion recognition (angry faces);	chr6:140851609	chr6:140845958~140852924:-
LUAD	cis	rs11157436	0.958	rs1041859	ENSG00000211813.2	TRAV34	5.07	5.6e-07	0.00015	0.3	0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22204878	chr14:22207522~22208129:+
LUAD	cis	rs11157436	0.958	rs1041860	ENSG00000211813.2	TRAV34	5.07	5.6e-07	0.00015	0.3	0.23	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22204897	chr14:22207522~22208129:+
LUAD	cis	rs801193	0.548	rs2659904	ENSG00000237310.1	GS1-124K5.4	5.07	5.61e-07	0.00015	0.25	0.23	Aortic root size;	chr7:66713615	chr7:66493706~66495474:+
LUAD	cis	rs1823874	0.886	rs2123933	ENSG00000182397.13	DNM1P46	-5.07	5.61e-07	0.00015	-0.26	-0.23	IgG glycosylation;	chr15:99824131	chr15:99790156~99806927:-
LUAD	cis	rs2836950	0.545	rs8132424	ENSG00000255568.3	BRWD1-AS2	5.07	5.62e-07	0.000151	0.22	0.23	Menarche (age at onset);	chr21:39212486	chr21:39313935~39314962:+
LUAD	cis	rs2239547	0.521	rs9682464	ENSG00000242142.1	SERBP1P3	5.07	5.62e-07	0.000151	0.26	0.23	Schizophrenia;	chr3:52854469	chr3:53064283~53065091:-
LUAD	cis	rs4143844	0.867	rs11631273	ENSG00000259251.2	RP11-643M14.1	5.07	5.62e-07	0.000151	0.41	0.23	Bipolar disorder and schizophrenia;	chr15:61985871	chr15:62060503~62062434:+
LUAD	cis	rs12935418	0.83	rs12448368	ENSG00000261061.1	RP11-303E16.2	5.07	5.62e-07	0.000151	0.32	0.23	Mean corpuscular volume;	chr16:81011342	chr16:81030770~81031485:+
LUAD	cis	rs7829975	0.508	rs4841006	ENSG00000253893.2	FAM85B	5.07	5.62e-07	0.000151	0.28	0.23	Mood instability;	chr8:8643964	chr8:8167819~8226614:-
LUAD	cis	rs5758511	0.68	rs5751243	ENSG00000226450.2	CYP2D8P	5.07	5.63e-07	0.000151	0.21	0.23	Birth weight;	chr22:42221171	chr22:42149886~42155001:-
LUAD	cis	rs5758511	0.637	rs5751244	ENSG00000226450.2	CYP2D8P	5.07	5.63e-07	0.000151	0.21	0.23	Birth weight;	chr22:42221405	chr22:42149886~42155001:-
LUAD	cis	rs4835473	0.897	rs36083752	ENSG00000251600.4	RP11-673E1.1	-5.07	5.63e-07	0.000151	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143693377	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.897	rs35162238	ENSG00000251600.4	RP11-673E1.1	-5.07	5.63e-07	0.000151	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143693518	chr4:143912331~143982454:+
LUAD	cis	rs748404	0.697	rs554001	ENSG00000249839.1	AC011330.5	-5.07	5.63e-07	0.000151	-0.29	-0.23	Lung cancer;	chr15:43259721	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.697	rs501884	ENSG00000249839.1	AC011330.5	-5.07	5.63e-07	0.000151	-0.29	-0.23	Lung cancer;	chr15:43261784	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.697	rs504417	ENSG00000249839.1	AC011330.5	-5.07	5.63e-07	0.000151	-0.29	-0.23	Lung cancer;	chr15:43262028	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.723	rs560134	ENSG00000249839.1	AC011330.5	-5.07	5.63e-07	0.000151	-0.29	-0.23	Lung cancer;	chr15:43263501	chr15:43663654~43684339:-
LUAD	cis	rs875971	0.522	rs1617484	ENSG00000164669.11	INTS4P1	-5.07	5.63e-07	0.000151	-0.27	-0.23	Aortic root size;	chr7:65998108	chr7:65141225~65234216:+
LUAD	cis	rs2239557	0.614	rs73303112	ENSG00000259065.1	RP5-1021I20.1	-5.07	5.64e-07	0.000151	-0.29	-0.23	Common traits (Other);	chr14:74013433	chr14:73787360~73803270:+
LUAD	cis	rs2554380	0.628	rs7177929	ENSG00000230373.7	GOLGA6L5P	-5.07	5.64e-07	0.000151	-0.24	-0.23	Height;	chr15:83809927	chr15:84507885~84516814:-
LUAD	cis	rs11673344	0.77	rs34729406	ENSG00000226686.6	LINC01535	5.07	5.65e-07	0.000151	0.3	0.23	Obesity-related traits;	chr19:37012764	chr19:37251912~37265535:+
LUAD	cis	rs8177876	0.731	rs76093926	ENSG00000261061.1	RP11-303E16.2	-5.07	5.65e-07	0.000151	-0.41	-0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078920	chr16:81030770~81031485:+
LUAD	cis	rs11089937	0.597	rs5757005	ENSG00000211638.2	IGLV8-61	-5.07	5.65e-07	0.000151	-0.26	-0.23	Periodontitis (PAL4Q3);	chr22:22134775	chr22:22098700~22099212:+
LUAD	cis	rs4273100	1	rs12602286	ENSG00000228157.4	AC007952.5	-5.07	5.65e-07	0.000151	-0.35	-0.23	Schizophrenia;	chr17:19333641	chr17:19092974~19096837:+
LUAD	cis	rs2933343	0.621	rs789242	ENSG00000261159.1	RP11-723O4.9	5.07	5.65e-07	0.000152	0.25	0.23	IgG glycosylation;	chr3:128866864	chr3:128859716~128860526:-
LUAD	cis	rs9813712	0.571	rs6795143	ENSG00000228252.7	COL6A4P2	-5.07	5.66e-07	0.000152	-0.21	-0.23	Response to amphetamines;	chr3:130224355	chr3:130212823~130273806:+
LUAD	cis	rs9813712	0.571	rs9289366	ENSG00000228252.7	COL6A4P2	-5.07	5.66e-07	0.000152	-0.21	-0.23	Response to amphetamines;	chr3:130225267	chr3:130212823~130273806:+
LUAD	cis	rs9813712	0.571	rs9289367	ENSG00000228252.7	COL6A4P2	-5.07	5.66e-07	0.000152	-0.21	-0.23	Response to amphetamines;	chr3:130225286	chr3:130212823~130273806:+
LUAD	cis	rs9813712	0.571	rs9289368	ENSG00000228252.7	COL6A4P2	-5.07	5.66e-07	0.000152	-0.21	-0.23	Response to amphetamines;	chr3:130225562	chr3:130212823~130273806:+
LUAD	cis	rs9813712	0.571	rs6774141	ENSG00000228252.7	COL6A4P2	-5.07	5.66e-07	0.000152	-0.21	-0.23	Response to amphetamines;	chr3:130225599	chr3:130212823~130273806:+
LUAD	cis	rs2562456	0.833	rs2928211	ENSG00000268081.1	RP11-678G14.2	-5.07	5.66e-07	0.000152	-0.34	-0.23	Pain;	chr19:21358495	chr19:21554640~21569237:-
LUAD	cis	rs4908768	0.501	rs4908761	ENSG00000270282.1	RP5-1115A15.2	5.07	5.66e-07	0.000152	0.25	0.23	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8492159	chr1:8512653~8513021:+
LUAD	cis	rs1345301	0.552	rs67880537	ENSG00000234389.1	AC007278.3	-5.07	5.67e-07	0.000152	-0.21	-0.23	Waist circumference;	chr2:102247646	chr2:102438713~102440475:+
LUAD	cis	rs9992667	0.955	rs12331049	ENSG00000231160.8	KLF3-AS1	5.07	5.67e-07	0.000152	0.28	0.23	Eosinophil percentage of granulocytes;	chr4:38654151	chr4:38612701~38664883:-
LUAD	cis	rs9487094	0.848	rs1322816	ENSG00000260273.1	RP11-425D10.10	5.07	5.68e-07	0.000152	0.31	0.23	Height;	chr6:109382524	chr6:109382795~109383666:+
LUAD	cis	rs6687821	0.736	rs263436	ENSG00000267734.1	RP4-604K5.3	5.07	5.69e-07	0.000152	0.26	0.23	Yeast infection;	chr1:86706719	chr1:86932199~86934891:-
LUAD	cis	rs6687821	0.531	rs4623671	ENSG00000267734.1	RP4-604K5.3	-5.07	5.69e-07	0.000152	-0.29	-0.23	Yeast infection;	chr1:87018537	chr1:86932199~86934891:-
LUAD	cis	rs7131987	0.617	rs3764953	ENSG00000257176.2	RP11-996F15.2	-5.07	5.69e-07	0.000152	-0.26	-0.23	QT interval;	chr12:29349303	chr12:29280418~29317848:-
LUAD	cis	rs2380205	0.517	rs56369297	ENSG00000232807.2	RP11-536K7.3	5.07	5.7e-07	0.000153	0.25	0.23	Breast cancer;	chr10:5904680	chr10:5934270~5945900:-
LUAD	cis	rs7160336	0.628	rs12893501	ENSG00000259065.1	RP5-1021I20.1	5.07	5.7e-07	0.000153	0.28	0.23	Blood protein levels;	chr14:73990459	chr14:73787360~73803270:+
LUAD	cis	rs4819052	0.788	rs35323494	ENSG00000223768.1	LINC00205	-5.07	5.7e-07	0.000153	-0.28	-0.23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45283824	chr21:45293285~45297354:+
LUAD	cis	rs61776719	0.52	rs17465651	ENSG00000212541.1	RNU6-510P	-5.07	5.7e-07	0.000153	-0.27	-0.23	Coronary artery disease;	chr1:37952824	chr1:37991462~37991569:+
LUAD	cis	rs6570726	0.935	rs430561	ENSG00000235652.6	RP11-545I5.3	5.07	5.71e-07	0.000153	0.22	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145492004	chr6:145799409~145886585:+
LUAD	cis	rs2599510	0.783	rs2710626	ENSG00000276334.1	AL133243.1	5.07	5.71e-07	0.000153	0.26	0.23	Interleukin-18 levels;	chr2:32533687	chr2:32521927~32523547:+
LUAD	cis	rs4964805	0.865	rs35371470	ENSG00000257681.1	RP11-341G23.4	5.07	5.71e-07	0.000153	0.28	0.23	Attention deficit hyperactivity disorder;	chr12:103809942	chr12:103746315~103768858:-
LUAD	cis	rs4964805	0.865	rs4964289	ENSG00000257681.1	RP11-341G23.4	5.07	5.71e-07	0.000153	0.28	0.23	Attention deficit hyperactivity disorder;	chr12:103810413	chr12:103746315~103768858:-
LUAD	cis	rs9322193	0.923	rs12176034	ENSG00000268592.3	RAET1E-AS1	5.07	5.71e-07	0.000153	0.29	0.23	Lung cancer;	chr6:149800557	chr6:149863494~149919507:+
LUAD	cis	rs11673344	0.67	rs73039188	ENSG00000226686.6	LINC01535	5.07	5.71e-07	0.000153	0.29	0.23	Obesity-related traits;	chr19:36922449	chr19:37251912~37265535:+
LUAD	cis	rs11051970	0.559	rs16919727	ENSG00000274964.1	RP11-817I4.1	-5.07	5.72e-07	0.000153	-0.29	-0.23	Response to tocilizumab in rheumatoid arthritis;	chr12:32329976	chr12:32339368~32340724:+
LUAD	cis	rs3761847	0.622	rs4837807	ENSG00000226752.6	PSMD5-AS1	-5.07	5.72e-07	0.000153	-0.24	-0.23	Rheumatoid arthritis;	chr9:121029727	chr9:120824828~120854385:+
LUAD	cis	rs7743045	0.504	rs4946382	ENSG00000253194.1	RP11-351A11.1	5.07	5.72e-07	0.000153	0.3	0.23	Mean platelet volume;	chr6:118979312	chr6:118934785~119031541:+
LUAD	cis	rs755249	0.565	rs3768320	ENSG00000228060.1	RP11-69E11.8	5.07	5.72e-07	0.000153	0.2	0.23	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39566567	chr1:39565160~39573203:+
LUAD	cis	rs9322193	0.962	rs3805749	ENSG00000268592.3	RAET1E-AS1	5.07	5.72e-07	0.000153	0.29	0.23	Lung cancer;	chr6:149772546	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.847	rs9505972	ENSG00000268592.3	RAET1E-AS1	5.07	5.72e-07	0.000153	0.29	0.23	Lung cancer;	chr6:149775255	chr6:149863494~149919507:+
LUAD	cis	rs875971	0.862	rs11773628	ENSG00000232559.3	GS1-124K5.12	-5.07	5.73e-07	0.000153	-0.27	-0.23	Aortic root size;	chr7:66517644	chr7:66554588~66576923:-
LUAD	cis	rs10246939	0.505	rs34726057	ENSG00000270923.1	TAS2R6P	-5.07	5.73e-07	0.000153	-0.26	-0.23	Bitter taste perception;	chr7:141832117	chr7:141787815~141788640:+
LUAD	cis	rs1876905	0.68	rs434034	ENSG00000272356.1	RP5-1112D6.8	-5.07	5.73e-07	0.000153	-0.26	-0.23	Mean corpuscular hemoglobin;	chr6:111204180	chr6:111309203~111313517:+
LUAD	cis	rs12681366	0.843	rs3019156	ENSG00000253704.1	RP11-267M23.4	5.07	5.73e-07	0.000153	0.28	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94409552	chr8:94553722~94569745:+
LUAD	cis	rs12681366	0.843	rs3019147	ENSG00000253704.1	RP11-267M23.4	5.07	5.73e-07	0.000153	0.28	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94412804	chr8:94553722~94569745:+
LUAD	cis	rs35264875	1	rs35264875	ENSG00000259799.1	RP11-554A11.9	5.07	5.73e-07	0.000153	0.33	0.23	Blond vs. brown hair color;	chr11:69078931	chr11:69155910~69159752:+
LUAD	cis	rs748404	0.697	rs505249	ENSG00000249839.1	AC011330.5	-5.07	5.74e-07	0.000154	-0.29	-0.23	Lung cancer;	chr15:43267762	chr15:43663654~43684339:-
LUAD	cis	rs7923837	0.963	rs11187141	ENSG00000236493.2	EIF2S2P3	5.07	5.74e-07	0.000154	0.26	0.23	Multiple sclerosis;Body mass index;	chr10:92707388	chr10:92668745~92669743:-
LUAD	cis	rs5758659	0.714	rs5758578	ENSG00000227370.1	RP4-669P10.19	5.07	5.74e-07	0.000154	0.2	0.23	Cognitive function;	chr22:42094288	chr22:42132543~42132998:+
LUAD	cis	rs4143844	0.867	rs62006964	ENSG00000259251.2	RP11-643M14.1	5.07	5.74e-07	0.000154	0.39	0.23	Bipolar disorder and schizophrenia;	chr15:61995424	chr15:62060503~62062434:+
LUAD	cis	rs10246939	0.579	rs13232651	ENSG00000228775.6	WEE2-AS1	5.07	5.75e-07	0.000154	0.27	0.23	Bitter taste perception;	chr7:141862624	chr7:141704338~141738346:-
LUAD	cis	rs2404602	1	rs12441433	ENSG00000259422.1	RP11-593F23.1	5.07	5.75e-07	0.000154	0.26	0.23	Blood metabolite levels;	chr15:76523674	chr15:76174891~76181486:-
LUAD	cis	rs42490	0.868	rs12675281	ENSG00000251136.7	RP11-37B2.1	5.07	5.75e-07	0.000154	0.23	0.23	Leprosy;	chr8:89681561	chr8:89609409~89757727:-
LUAD	cis	rs896854	0.53	rs10956934	ENSG00000253528.2	RP11-347C18.4	5.07	5.75e-07	0.000154	0.22	0.23	Type 2 diabetes;	chr8:94980245	chr8:94974573~94974853:-
LUAD	cis	rs4591358	0.731	rs10208012	ENSG00000223466.1	AC064834.2	5.07	5.75e-07	0.000154	0.31	0.23	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195452137	chr2:195533035~195538681:+
LUAD	cis	rs8177876	0.731	rs10514512	ENSG00000261061.1	RP11-303E16.2	-5.07	5.76e-07	0.000154	-0.41	-0.23	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080350	chr16:81030770~81031485:+
LUAD	cis	rs2286503	0.839	rs2270105	ENSG00000226329.2	AC005682.6	5.07	5.77e-07	0.000154	0.29	0.23	Fibrinogen;	chr7:22822848	chr7:22863874~22881350:-
LUAD	cis	rs2032366	1	rs8088329	ENSG00000267279.1	RP11-879F14.2	-5.07	5.77e-07	0.000154	-0.28	-0.23	Obesity-related traits;	chr18:61595758	chr18:61585746~61606916:-
LUAD	cis	rs7430456	0.81	rs6443489	ENSG00000225790.1	RP11-2L8.1	-5.07	5.78e-07	0.000154	-0.27	-0.23	Breast cancer;	chr3:177737489	chr3:177934823~177937662:+
LUAD	cis	rs1729951	0.575	rs835641	ENSG00000239213.4	NCK1-AS1	5.07	5.78e-07	0.000155	0.25	0.23	Neuroticism;	chr3:136984632	chr3:136841726~136862054:-
LUAD	cis	rs1729951	0.575	rs16844362	ENSG00000239213.4	NCK1-AS1	5.07	5.78e-07	0.000155	0.25	0.23	Neuroticism;	chr3:136985166	chr3:136841726~136862054:-
LUAD	cis	rs2749097	0.825	rs11208260	ENSG00000244256.3	RN7SL130P	-5.07	5.78e-07	0.000155	-0.27	-0.23	Alcohol consumption (transferrin glycosylation);	chr1:63657608	chr1:63655743~63656047:+
LUAD	cis	rs42490	0.837	rs218916	ENSG00000251136.7	RP11-37B2.1	-5.07	5.79e-07	0.000155	-0.23	-0.23	Leprosy;	chr8:89688709	chr8:89609409~89757727:-
LUAD	cis	rs6570726	0.791	rs383841	ENSG00000235652.6	RP11-545I5.3	-5.07	5.79e-07	0.000155	-0.22	-0.23	Lobe attachment (rater-scored or self-reported);	chr6:145567193	chr6:145799409~145886585:+
LUAD	cis	rs2998286	0.862	rs2486637	ENSG00000254635.4	WAC-AS1	-5.07	5.8e-07	0.000155	-0.28	-0.23	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28505085	chr10:28522652~28532743:-
LUAD	cis	rs4143844	0.867	rs17303887	ENSG00000259251.2	RP11-643M14.1	5.07	5.8e-07	0.000155	0.4	0.23	Bipolar disorder and schizophrenia;	chr15:61873354	chr15:62060503~62062434:+
LUAD	cis	rs1914816	0.653	rs403656	ENSG00000196274.5	Metazoa_SRP	5.07	5.8e-07	0.000155	0.29	0.23	Response to tocilizumab in rheumatoid arthritis;	chr15:76463165	chr15:76230048~76230390:-
LUAD	cis	rs1387259	0.859	rs2054905	ENSG00000257735.1	RP11-370I10.6	5.07	5.8e-07	0.000155	0.28	0.23	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48294168	chr12:48350945~48442411:+
LUAD	cis	rs748404	0.65	rs518234	ENSG00000249839.1	AC011330.5	-5.07	5.8e-07	0.000155	-0.29	-0.23	Lung cancer;	chr15:43281223	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.65	rs518261	ENSG00000249839.1	AC011330.5	-5.07	5.8e-07	0.000155	-0.29	-0.23	Lung cancer;	chr15:43281231	chr15:43663654~43684339:-
LUAD	cis	rs4664293	0.967	rs13032135	ENSG00000226266.5	AC009961.3	-5.07	5.8e-07	0.000155	-0.31	-0.23	Monocyte percentage of white cells;	chr2:159675588	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.934	rs4380179	ENSG00000226266.5	AC009961.3	-5.07	5.8e-07	0.000155	-0.31	-0.23	Monocyte percentage of white cells;	chr2:159685064	chr2:159670708~159712435:-
LUAD	cis	rs2735413	0.563	rs11646833	ENSG00000276007.1	RP11-358L22.3	5.07	5.8e-07	0.000155	0.33	0.23	Systolic blood pressure (alcohol consumption interaction);	chr16:78023482	chr16:78123243~78124332:+
LUAD	cis	rs71636778	0.509	rs12741472	ENSG00000260063.1	RP5-968P14.2	-5.07	5.8e-07	0.000155	-0.4	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26895118	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.57	rs34026565	ENSG00000260063.1	RP5-968P14.2	-5.07	5.8e-07	0.000155	-0.4	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26903485	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs35108146	ENSG00000260063.1	RP5-968P14.2	-5.07	5.8e-07	0.000155	-0.4	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26921949	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs12752711	ENSG00000260063.1	RP5-968P14.2	-5.07	5.8e-07	0.000155	-0.4	-0.23	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26923767	chr1:26692132~26694131:-
LUAD	cis	rs3096299	0.781	rs2170839	ENSG00000182376.2	RP5-1142A6.8	5.07	5.81e-07	0.000155	0.23	0.23	Multiple myeloma (IgH translocation);	chr16:89343044	chr16:88742767~88745748:+
LUAD	cis	rs4835473	0.897	rs11100802	ENSG00000251600.4	RP11-673E1.1	-5.07	5.81e-07	0.000155	-0.28	-0.23	Immature fraction of reticulocytes;	chr4:143700046	chr4:143912331~143982454:+
LUAD	cis	rs11159086	0.729	rs8015872	ENSG00000259005.1	RP3-449M8.6	5.07	5.81e-07	0.000155	0.29	0.23	Advanced glycation end-product levels;	chr14:74475529	chr14:74474007~74474864:-
LUAD	cis	rs8180040	0.62	rs2278963	ENSG00000271161.1	BOLA2P2	-5.07	5.81e-07	0.000155	-0.22	-0.23	Colorectal cancer;	chr3:47013379	chr3:47499841~47500407:+
LUAD	cis	rs847577	0.677	rs951988	ENSG00000272950.1	RP11-307C18.1	-5.07	5.81e-07	0.000155	-0.29	-0.23	Breast cancer;	chr7:98133162	chr7:98322853~98323430:+
LUAD	cis	rs11742741	0.676	rs34323137	ENSG00000248874.4	C5orf17	-5.07	5.81e-07	0.000155	-0.28	-0.23	Educational attainment;	chr5:24196120	chr5:23951348~24178263:+
LUAD	cis	rs2283792	0.646	rs9610317	ENSG00000224086.5	LL22NC03-86G7.1	-5.07	5.82e-07	0.000155	-0.22	-0.23	Multiple sclerosis;	chr22:21785601	chr22:21938293~21977632:+
LUAD	cis	rs6570726	0.791	rs10457788	ENSG00000235652.6	RP11-545I5.3	5.07	5.82e-07	0.000156	0.23	0.23	Lobe attachment (rater-scored or self-reported);	chr6:145600000	chr6:145799409~145886585:+
LUAD	cis	rs2255336	0.938	rs2045876	ENSG00000245648.1	RP11-277P12.20	5.07	5.82e-07	0.000156	0.33	0.23	Blood protein levels;	chr12:10389233	chr12:10363769~10398506:+
LUAD	cis	rs2239547	0.522	rs9846976	ENSG00000242142.1	SERBP1P3	5.07	5.82e-07	0.000156	0.26	0.23	Schizophrenia;	chr3:52973979	chr3:53064283~53065091:-
LUAD	cis	rs75920871	0.528	rs11216240	ENSG00000254851.1	RP11-109L13.1	5.07	5.82e-07	0.000156	0.33	0.23	Subjective well-being;	chr11:117028532	chr11:117135528~117138582:+
LUAD	cis	rs75920871	0.528	rs11600552	ENSG00000254851.1	RP11-109L13.1	5.07	5.82e-07	0.000156	0.33	0.23	Subjective well-being;	chr11:117030231	chr11:117135528~117138582:+
LUAD	cis	rs75920871	0.528	rs7941428	ENSG00000254851.1	RP11-109L13.1	5.07	5.82e-07	0.000156	0.33	0.23	Subjective well-being;	chr11:117032668	chr11:117135528~117138582:+
LUAD	cis	rs643506	0.715	rs11214031	ENSG00000230911.1	PPIHP1	-5.07	5.82e-07	0.000156	-0.28	-0.23	Breast cancer;	chr11:111895315	chr11:112029858~112030367:-
LUAD	cis	rs643506	0.774	rs11214033	ENSG00000230911.1	PPIHP1	5.07	5.82e-07	0.000156	0.28	0.23	Breast cancer;	chr11:111898978	chr11:112029858~112030367:-
LUAD	cis	rs12681366	0.839	rs3019282	ENSG00000253704.1	RP11-267M23.4	5.07	5.83e-07	0.000156	0.28	0.23	Nonsyndromic cleft lip with cleft palate;	chr8:94439898	chr8:94553722~94569745:+
LUAD	cis	rs73186030	0.546	rs73188327	ENSG00000272758.4	RP11-299J3.8	5.07	5.83e-07	0.000156	0.29	0.23	Serum parathyroid hormone levels;	chr3:122394819	chr3:122416207~122443180:+
LUAD	cis	rs875971	0.651	rs2420596	ENSG00000232559.3	GS1-124K5.12	5.06	5.83e-07	0.000156	0.27	0.23	Aortic root size;	chr7:66450996	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.52	rs2420597	ENSG00000232559.3	GS1-124K5.12	5.06	5.83e-07	0.000156	0.27	0.23	Aortic root size;	chr7:66450999	chr7:66554588~66576923:-
LUAD	cis	rs2742234	0.59	rs2742237	ENSG00000273008.1	RP11-351D16.3	-5.06	5.83e-07	0.000156	-0.26	-0.23	Hirschsprung disease;	chr10:43125875	chr10:43136824~43138334:-
LUAD	cis	rs875971	0.577	rs35072105	ENSG00000236529.1	RP13-254B10.1	-5.06	5.83e-07	0.000156	-0.23	-0.23	Aortic root size;	chr7:66144830	chr7:65840212~65840596:+
LUAD	cis	rs6964587	0.967	rs10953065	ENSG00000188693.7	CYP51A1-AS1	5.06	5.83e-07	0.000156	0.27	0.23	Breast cancer;	chr7:92179601	chr7:92134604~92180725:+
LUAD	cis	rs875971	0.862	rs10276077	ENSG00000232559.3	GS1-124K5.12	-5.06	5.83e-07	0.000156	-0.27	-0.23	Aortic root size;	chr7:66263424	chr7:66554588~66576923:-
LUAD	cis	rs2998286	0.723	rs332161	ENSG00000254635.4	WAC-AS1	5.06	5.84e-07	0.000156	0.3	0.23	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28599911	chr10:28522652~28532743:-
LUAD	cis	rs2439831	0.85	rs7183809	ENSG00000249839.1	AC011330.5	-5.06	5.84e-07	0.000156	-0.45	-0.23	Lung cancer in ever smokers;	chr15:43828670	chr15:43663654~43684339:-
LUAD	cis	rs2439831	0.85	rs3759790	ENSG00000249839.1	AC011330.5	-5.06	5.84e-07	0.000156	-0.45	-0.23	Lung cancer in ever smokers;	chr15:43828832	chr15:43663654~43684339:-
LUAD	cis	rs67340775	0.541	rs200975	ENSG00000219392.1	RP1-265C24.5	-5.06	5.84e-07	0.000156	-0.37	-0.23	Lung cancer in ever smokers;	chr6:27887847	chr6:28115628~28116551:+
LUAD	cis	rs67340775	0.541	rs200974	ENSG00000219392.1	RP1-265C24.5	-5.06	5.84e-07	0.000156	-0.37	-0.23	Lung cancer in ever smokers;	chr6:27888067	chr6:28115628~28116551:+
LUAD	cis	rs3738443	0.951	rs4269806	ENSG00000259865.1	RP11-488L18.10	5.06	5.84e-07	0.000156	0.24	0.23	Alcohol dependence;	chr1:247211721	chr1:247187281~247188526:-
LUAD	cis	rs1707322	0.721	rs12043945	ENSG00000280836.1	AL355480.1	-5.06	5.84e-07	0.000156	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45641250	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.721	rs12091503	ENSG00000280836.1	AL355480.1	-5.06	5.84e-07	0.000156	-0.3	-0.23	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642196	chr1:45581219~45581321:-
LUAD	cis	rs875971	0.862	rs13232191	ENSG00000232559.3	GS1-124K5.12	5.06	5.85e-07	0.000156	0.27	0.22	Aortic root size;	chr7:66521661	chr7:66554588~66576923:-
LUAD	cis	rs12468226	1	rs12468226	ENSG00000226261.1	AC064836.3	5.06	5.85e-07	0.000156	0.36	0.22	Urate levels;	chr2:202472278	chr2:202336024~202336727:-
LUAD	cis	rs12468226	1	rs74508472	ENSG00000226261.1	AC064836.3	5.06	5.85e-07	0.000156	0.36	0.22	Urate levels;	chr2:202517290	chr2:202336024~202336727:-
LUAD	cis	rs12468226	0.702	rs114634431	ENSG00000226261.1	AC064836.3	5.06	5.85e-07	0.000156	0.36	0.22	Urate levels;	chr2:202142530	chr2:202336024~202336727:-
LUAD	cis	rs4141404	0.748	rs2232176	ENSG00000236132.1	CTA-440B3.1	5.06	5.85e-07	0.000156	0.29	0.22	Paclitaxel-induced neuropathy;	chr22:31140147	chr22:31816379~31817491:-
LUAD	cis	rs2286492	0.881	rs78433057	ENSG00000228649.7	AC005682.5	-5.06	5.85e-07	0.000156	-0.44	-0.22	Bipolar disorder;	chr7:22890619	chr7:22854178~22861579:+
LUAD	cis	rs17684571	0.7	rs6904535	ENSG00000231441.1	RP11-472M19.2	5.06	5.85e-07	0.000156	0.31	0.22	Schizophrenia;	chr6:56767178	chr6:56844002~56864078:+
LUAD	cis	rs9322193	0.566	rs9397070	ENSG00000223701.3	RAET1E-AS1	-5.06	5.86e-07	0.000156	-0.31	-0.22	Lung cancer;	chr6:149922073	chr6:149884431~149919508:+
LUAD	cis	rs35264875	1	rs72928636	ENSG00000259799.1	RP11-554A11.9	5.06	5.86e-07	0.000156	0.33	0.22	Blond vs. brown hair color;	chr11:69080918	chr11:69155910~69159752:+
LUAD	cis	rs35264875	1	rs72928644	ENSG00000259799.1	RP11-554A11.9	5.06	5.86e-07	0.000156	0.33	0.22	Blond vs. brown hair color;	chr11:69082377	chr11:69155910~69159752:+
LUAD	cis	rs35264875	1	rs1542334	ENSG00000259799.1	RP11-554A11.9	5.06	5.86e-07	0.000156	0.33	0.22	Blond vs. brown hair color;	chr11:69083305	chr11:69155910~69159752:+
LUAD	cis	rs35264875	1	rs72928652	ENSG00000259799.1	RP11-554A11.9	5.06	5.86e-07	0.000156	0.33	0.22	Blond vs. brown hair color;	chr11:69084079	chr11:69155910~69159752:+
LUAD	cis	rs2274459	0.591	rs16868575	ENSG00000224796.1	RPL32P1	-5.06	5.86e-07	0.000156	-0.24	-0.22	Obesity (extreme);	chr6:33661269	chr6:33079451~33079860:+
LUAD	cis	rs42490	0.873	rs218903	ENSG00000251136.7	RP11-37B2.1	-5.06	5.86e-07	0.000157	-0.23	-0.22	Leprosy;	chr8:89721458	chr8:89609409~89757727:-
LUAD	cis	rs875971	0.638	rs6460305	ENSG00000237310.1	GS1-124K5.4	-5.06	5.87e-07	0.000157	-0.24	-0.22	Aortic root size;	chr7:66595421	chr7:66493706~66495474:+
LUAD	cis	rs897984	0.537	rs8045637	ENSG00000232748.3	RP11-196G11.6	-5.06	5.87e-07	0.000157	-0.28	-0.22	Dementia with Lewy bodies;	chr16:30807341	chr16:31056460~31062803:+
LUAD	cis	rs6840360	1	rs1105535	ENSG00000270265.1	RP11-731D1.4	-5.06	5.87e-07	0.000157	-0.23	-0.22	Intelligence (multi-trait analysis);	chr4:151684018	chr4:151333775~151353224:-
LUAD	cis	rs2735413	0.564	rs11863954	ENSG00000276007.1	RP11-358L22.3	-5.06	5.87e-07	0.000157	-0.33	-0.22	Systolic blood pressure (alcohol consumption interaction);	chr16:78093252	chr16:78123243~78124332:+
LUAD	cis	rs6840360	1	rs1105536	ENSG00000270265.1	RP11-731D1.4	-5.06	5.88e-07	0.000157	-0.23	-0.22	Intelligence (multi-trait analysis);	chr4:151683875	chr4:151333775~151353224:-
LUAD	cis	rs875971	0.508	rs10950045	ENSG00000237310.1	GS1-124K5.4	-5.06	5.88e-07	0.000157	-0.24	-0.22	Aortic root size;	chr7:66601386	chr7:66493706~66495474:+
LUAD	cis	rs801193	0.839	rs6968619	ENSG00000237310.1	GS1-124K5.4	-5.06	5.88e-07	0.000157	-0.24	-0.22	Aortic root size;	chr7:66603880	chr7:66493706~66495474:+
LUAD	cis	rs950169	0.541	rs10795	ENSG00000259295.5	CSPG4P12	5.06	5.88e-07	0.000157	0.32	0.22	Schizophrenia;	chr15:84634066	chr15:85191438~85213905:+
LUAD	cis	rs950169	0.58	rs36126054	ENSG00000259295.5	CSPG4P12	5.06	5.88e-07	0.000157	0.32	0.22	Schizophrenia;	chr15:84634492	chr15:85191438~85213905:+
LUAD	cis	rs11159086	0.793	rs12432412	ENSG00000259005.1	RP3-449M8.6	5.06	5.88e-07	0.000157	0.29	0.22	Advanced glycation end-product levels;	chr14:74474294	chr14:74474007~74474864:-
LUAD	cis	rs11159086	0.793	rs1029700	ENSG00000259005.1	RP3-449M8.6	5.06	5.88e-07	0.000157	0.29	0.22	Advanced glycation end-product levels;	chr14:74474309	chr14:74474007~74474864:-
LUAD	cis	rs11159086	0.793	rs1029699	ENSG00000259005.1	RP3-449M8.6	5.06	5.88e-07	0.000157	0.29	0.22	Advanced glycation end-product levels;	chr14:74474790	chr14:74474007~74474864:-
LUAD	cis	rs9435732	0.62	rs12045097	ENSG00000235241.1	RP11-108M9.5	5.06	5.89e-07	0.000157	0.31	0.22	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:17019382	chr1:16889095~16889602:+
LUAD	cis	rs6088590	0.55	rs12624640	ENSG00000276073.1	RP5-1125A11.7	-5.06	5.89e-07	0.000157	-0.23	-0.22	Coronary artery disease;	chr20:34364319	chr20:33985617~33988989:-
LUAD	cis	rs6496044	0.963	rs6496050	ENSG00000202081.1	RNU6-1280P	5.06	5.89e-07	0.000157	0.26	0.22	Interstitial lung disease;	chr15:85526019	chr15:85651522~85651628:-
LUAD	cis	rs73186030	0.546	rs73188320	ENSG00000272758.4	RP11-299J3.8	5.06	5.9e-07	0.000157	0.29	0.22	Serum parathyroid hormone levels;	chr3:122391694	chr3:122416207~122443180:+
LUAD	cis	rs6095360	0.674	rs7269912	ENSG00000222365.1	SNORD12B	-5.06	5.9e-07	0.000157	-0.26	-0.22	Intelligence (multi-trait analysis);	chr20:49039661	chr20:49280319~49280409:+
LUAD	cis	rs6095360	0.7	rs13042443	ENSG00000222365.1	SNORD12B	-5.06	5.9e-07	0.000157	-0.26	-0.22	Intelligence (multi-trait analysis);	chr20:49047217	chr20:49280319~49280409:+
LUAD	cis	rs6095360	0.727	rs2227946	ENSG00000222365.1	SNORD12B	-5.06	5.9e-07	0.000157	-0.26	-0.22	Intelligence (multi-trait analysis);	chr20:49068783	chr20:49280319~49280409:+
LUAD	cis	rs12928939	0.954	rs8057568	ENSG00000260886.1	TAT-AS1	5.06	5.9e-07	0.000157	0.29	0.22	Post bronchodilator FEV1;	chr16:71778092	chr16:71565789~71578187:+
LUAD	cis	rs116175783	0.557	rs10490567	ENSG00000227403.1	AC009299.3	5.06	5.9e-07	0.000158	0.4	0.22	Intelligence (multi-trait analysis);	chr2:161317267	chr2:161244739~161249050:+
LUAD	cis	rs4142995	0.962	rs10282707	ENSG00000279048.1	RP11-511H23.2	-5.06	5.9e-07	0.000158	-0.17	-0.22	HDL cholesterol;HDL cholesterol levels;	chr7:17871415	chr7:17940503~17942922:+
LUAD	cis	rs6687821	0.5	rs7519975	ENSG00000267734.1	RP4-604K5.3	-5.06	5.9e-07	0.000158	-0.29	-0.22	Yeast infection;	chr1:87021355	chr1:86932199~86934891:-
LUAD	cis	rs6840360	1	rs7439465	ENSG00000270265.1	RP11-731D1.4	5.06	5.9e-07	0.000158	0.23	0.22	Intelligence (multi-trait analysis);	chr4:151673662	chr4:151333775~151353224:-
LUAD	cis	rs561341	1	rs72823785	ENSG00000265798.5	RP11-271K11.5	5.06	5.91e-07	0.000158	0.36	0.22	Hip circumference adjusted for BMI;	chr17:31946765	chr17:31038575~31059121:-
LUAD	cis	rs561341	1	rs55978022	ENSG00000265798.5	RP11-271K11.5	5.06	5.91e-07	0.000158	0.36	0.22	Hip circumference adjusted for BMI;	chr17:31948918	chr17:31038575~31059121:-
LUAD	cis	rs4268898	0.722	rs10445893	ENSG00000242628.4	AC009228.1	-5.06	5.91e-07	0.000158	-0.29	-0.22	Asthma;	chr2:24184259	chr2:24214381~24221516:+
LUAD	cis	rs11157436	0.958	rs764160	ENSG00000211813.2	TRAV34	5.06	5.91e-07	0.000158	0.29	0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22231098	chr14:22207522~22208129:+
LUAD	cis	rs1707322	0.721	rs10890346	ENSG00000280836.1	AL355480.1	5.06	5.91e-07	0.000158	0.3	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758220	chr1:45581219~45581321:-
LUAD	cis	rs9532669	0.926	rs9525438	ENSG00000239827.7	SUGT1P3	-5.06	5.92e-07	0.000158	-0.26	-0.22	Cervical cancer;	chr13:40964123	chr13:40908159~40921774:-
LUAD	cis	rs9341808	0.727	rs9352809	ENSG00000272129.1	RP11-250B2.6	5.06	5.92e-07	0.000158	0.28	0.22	Sitting height ratio;	chr6:80289599	chr6:80355424~80356859:+
LUAD	cis	rs301901	1	rs158622	ENSG00000250155.1	CTD-2353F22.1	5.06	5.92e-07	0.000158	0.23	0.22	Height;	chr5:36887793	chr5:36666214~36725195:-
LUAD	cis	rs11051970	0.559	rs2270786	ENSG00000274964.1	RP11-817I4.1	-5.06	5.92e-07	0.000158	-0.31	-0.22	Response to tocilizumab in rheumatoid arthritis;	chr12:32337830	chr12:32339368~32340724:+
LUAD	cis	rs7208859	0.623	rs216439	ENSG00000263603.1	CTD-2349P21.5	-5.06	5.92e-07	0.000158	-0.41	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30600866	chr17:30729469~30731202:+
LUAD	cis	rs2032366	1	rs10439023	ENSG00000267279.1	RP11-879F14.2	-5.06	5.92e-07	0.000158	-0.28	-0.22	Obesity-related traits;	chr18:61597073	chr18:61585746~61606916:-
LUAD	cis	rs853679	0.546	rs34295134	ENSG00000219392.1	RP1-265C24.5	-5.06	5.94e-07	0.000158	-0.43	-0.22	Depression;	chr6:27860373	chr6:28115628~28116551:+
LUAD	cis	rs8177876	1	rs8177876	ENSG00000261061.1	RP11-303E16.2	-5.06	5.94e-07	0.000159	-0.44	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81090670	chr16:81030770~81031485:+
LUAD	cis	rs12025262	0.546	rs10754539	ENSG00000227671.4	RP11-488L18.4	-5.06	5.94e-07	0.000159	-0.15	-0.22	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr1:247202128	chr1:247189851~247210856:-
LUAD	cis	rs2286503	0.839	rs2270108	ENSG00000226329.2	AC005682.6	5.06	5.94e-07	0.000159	0.29	0.22	Fibrinogen;	chr7:22822512	chr7:22863874~22881350:-
LUAD	cis	rs2286503	0.839	rs2270107	ENSG00000226329.2	AC005682.6	5.06	5.94e-07	0.000159	0.29	0.22	Fibrinogen;	chr7:22822564	chr7:22863874~22881350:-
LUAD	cis	rs2286503	0.839	rs2270103	ENSG00000226329.2	AC005682.6	5.06	5.94e-07	0.000159	0.29	0.22	Fibrinogen;	chr7:22823103	chr7:22863874~22881350:-
LUAD	cis	rs2286503	0.839	rs10276099	ENSG00000226329.2	AC005682.6	5.06	5.94e-07	0.000159	0.29	0.22	Fibrinogen;	chr7:22823331	chr7:22863874~22881350:-
LUAD	cis	rs7208859	0.623	rs79607958	ENSG00000263603.1	CTD-2349P21.5	-5.06	5.95e-07	0.000159	-0.42	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607530	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs75136574	ENSG00000263603.1	CTD-2349P21.5	-5.06	5.95e-07	0.000159	-0.42	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607531	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs77544470	ENSG00000263603.1	CTD-2349P21.5	-5.06	5.95e-07	0.000159	-0.42	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607532	chr17:30729469~30731202:+
LUAD	cis	rs763567	0.967	rs736791	ENSG00000271811.1	RP1-79C4.4	-5.06	5.95e-07	0.000159	-0.27	-0.22	Tonsillectomy;	chr1:170617174	chr1:170667381~170669425:+
LUAD	cis	rs6723226	0.572	rs176404	ENSG00000276334.1	AL133243.1	-5.06	5.96e-07	0.000159	-0.25	-0.22	Intelligence (multi-trait analysis);	chr2:32413778	chr2:32521927~32523547:+
LUAD	cis	rs1075265	0.636	rs2193683	ENSG00000233266.1	HMGB1P31	5.06	5.96e-07	0.000159	0.28	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53695319	chr2:54051334~54051760:+
LUAD	cis	rs1075265	0.611	rs11684084	ENSG00000233266.1	HMGB1P31	5.06	5.96e-07	0.000159	0.28	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53695806	chr2:54051334~54051760:+
LUAD	cis	rs3761847	0.622	rs10818498	ENSG00000226752.6	PSMD5-AS1	-5.06	5.98e-07	0.000159	-0.24	-0.22	Rheumatoid arthritis;	chr9:121025288	chr9:120824828~120854385:+
LUAD	cis	rs7208859	0.524	rs8069400	ENSG00000263603.1	CTD-2349P21.5	-5.06	5.98e-07	0.000159	-0.41	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748949	chr17:30729469~30731202:+
LUAD	cis	rs673078	0.607	rs2784	ENSG00000275409.1	RP11-131L12.4	-5.06	5.98e-07	0.000159	-0.35	-0.22	Glucose homeostasis traits;	chr12:118311745	chr12:118430147~118430699:+
LUAD	cis	rs10129255	0.536	rs6576201	ENSG00000211967.3	IGHV3-53	5.06	5.98e-07	0.000159	0.16	0.22	Kawasaki disease;	chr14:106683696	chr14:106592676~106593347:-
LUAD	cis	rs916888	0.821	rs199512	ENSG00000261575.2	RP11-259G18.1	-5.06	5.98e-07	0.000159	-0.34	-0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46267037~46268694:+
LUAD	cis	rs916888	0.821	rs199509	ENSG00000261575.2	RP11-259G18.1	-5.06	5.98e-07	0.000159	-0.34	-0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46267037~46268694:+
LUAD	cis	rs916888	0.821	rs199507	ENSG00000261575.2	RP11-259G18.1	-5.06	5.98e-07	0.000159	-0.34	-0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46267037~46268694:+
LUAD	cis	rs42490	0.868	rs4961158	ENSG00000251136.7	RP11-37B2.1	5.06	5.98e-07	0.000159	0.23	0.22	Leprosy;	chr8:89685607	chr8:89609409~89757727:-
LUAD	cis	rs301901	0.772	rs10061157	ENSG00000250155.1	CTD-2353F22.1	5.06	5.99e-07	0.00016	0.23	0.22	Height;	chr5:37161516	chr5:36666214~36725195:-
LUAD	cis	rs394563	0.967	rs447025	ENSG00000231760.4	RP11-350J20.5	5.06	5.99e-07	0.00016	0.28	0.22	Dupuytren's disease;	chr6:149477992	chr6:149796151~149826294:-
LUAD	cis	rs11673344	0.864	rs79407399	ENSG00000226686.6	LINC01535	5.06	5.99e-07	0.00016	0.31	0.22	Obesity-related traits;	chr19:37000004	chr19:37251912~37265535:+
LUAD	cis	rs561341	1	rs498391	ENSG00000265798.5	RP11-271K11.5	5.06	5.99e-07	0.00016	0.36	0.22	Hip circumference adjusted for BMI;	chr17:32001685	chr17:31038575~31059121:-
LUAD	cis	rs7712401	0.541	rs6867714	ENSG00000263432.2	RN7SL689P	5.06	5.99e-07	0.00016	0.3	0.22	Mean platelet volume;	chr5:123046364	chr5:123022487~123022783:-
LUAD	cis	rs301901	0.772	rs6860727	ENSG00000250155.1	CTD-2353F22.1	-5.06	5.99e-07	0.00016	-0.23	-0.22	Height;	chr5:37179239	chr5:36666214~36725195:-
LUAD	cis	rs867371	1	rs7173339	ENSG00000276710.3	CSPG4P8	-5.06	6e-07	0.00016	-0.21	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82175253	chr15:82459472~82477258:+
LUAD	cis	rs1075232	1	rs72722861	ENSG00000215302.7	CTD-3092A11.1	-5.06	6e-07	0.00016	-0.51	-0.22	Survival in colorectal cancer (non-distant metastatic);	chr15:31412085	chr15:30470779~30507623:+
LUAD	cis	rs2286503	0.78	rs12113458	ENSG00000226329.2	AC005682.6	5.06	6e-07	0.00016	0.29	0.22	Fibrinogen;	chr7:22816009	chr7:22863874~22881350:-
LUAD	cis	rs12745968	0.62	rs7520630	ENSG00000223787.2	RP4-593M8.1	-5.06	6e-07	0.00016	-0.28	-0.22	Bipolar disorder and schizophrenia;	chr1:92493404	chr1:92580476~92580821:-
LUAD	cis	rs7181230	0.885	rs8026641	ENSG00000275636.1	RP11-521C20.5	-5.06	6e-07	0.00016	-0.29	-0.22	Dehydroepiandrosterone sulphate levels;	chr15:40046660	chr15:40078892~40079347:+
LUAD	cis	rs950169	0.512	rs4374136	ENSG00000259728.4	LINC00933	5.06	6.01e-07	0.00016	0.34	0.22	Schizophrenia;	chr15:83976255	chr15:84570649~84580175:+
LUAD	cis	rs2404602	0.735	rs11629888	ENSG00000259422.1	RP11-593F23.1	-5.06	6.01e-07	0.00016	-0.29	-0.22	Blood metabolite levels;	chr15:76427539	chr15:76174891~76181486:-
LUAD	cis	rs875971	0.522	rs1968127	ENSG00000237310.1	GS1-124K5.4	-5.06	6.01e-07	0.00016	-0.24	-0.22	Aortic root size;	chr7:66591816	chr7:66493706~66495474:+
LUAD	cis	rs11089937	0.597	rs9619812	ENSG00000211638.2	IGLV8-61	-5.06	6.01e-07	0.00016	-0.26	-0.22	Periodontitis (PAL4Q3);	chr22:22163945	chr22:22098700~22099212:+
LUAD	cis	rs7208859	0.673	rs423151	ENSG00000280069.1	CTD-2349P21.3	-5.06	6.01e-07	0.00016	-0.26	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30625268	chr17:30738182~30740275:+
LUAD	cis	rs7829975	0.714	rs11784052	ENSG00000173295.6	FAM86B3P	5.06	6.01e-07	0.00016	0.24	0.22	Mood instability;	chr8:8814452	chr8:8228595~8244865:+
LUAD	cis	rs1062177	1	rs2016409	ENSG00000253921.1	CTB-113P19.3	5.06	6.01e-07	0.00016	0.33	0.22	Preschool internalizing problems;	chr5:151746763	chr5:151753992~151767247:+
LUAD	cis	rs35264875	1	rs6591370	ENSG00000259799.1	RP11-554A11.9	5.06	6.01e-07	0.00016	0.33	0.22	Blond vs. brown hair color;	chr11:69075535	chr11:69155910~69159752:+
LUAD	cis	rs75422866	0.558	rs73104190	ENSG00000257433.4	RP1-197B17.3	5.06	6.02e-07	0.00016	0.47	0.22	Pneumonia;	chr12:47716040	chr12:47706085~47742294:+
LUAD	cis	rs2286503	0.839	rs4722189	ENSG00000226329.2	AC005682.6	5.06	6.02e-07	0.00016	0.29	0.22	Fibrinogen;	chr7:22820855	chr7:22863874~22881350:-
LUAD	cis	rs2286503	0.809	rs4719716	ENSG00000226329.2	AC005682.6	5.06	6.02e-07	0.00016	0.29	0.22	Fibrinogen;	chr7:22821750	chr7:22863874~22881350:-
LUAD	cis	rs2286503	0.78	rs981792	ENSG00000226329.2	AC005682.6	5.06	6.02e-07	0.00016	0.29	0.22	Fibrinogen;	chr7:22822020	chr7:22863874~22881350:-
LUAD	cis	rs4908760	0.613	rs12024032	ENSG00000232912.4	RP5-1115A15.1	-5.06	6.02e-07	0.00016	-0.21	-0.22	Vitiligo;	chr1:8748126	chr1:8424645~8434838:+
LUAD	cis	rs12554020	0.892	rs6479494	ENSG00000227603.1	RP11-165J3.6	-5.06	6.02e-07	0.00016	-0.34	-0.22	Schizophrenia;	chr9:93568217	chr9:93435332~93437121:-
LUAD	cis	rs7017914	0.652	rs2639911	ENSG00000223220.1	Y_RNA	5.06	6.02e-07	0.00016	0.26	0.22	Bone mineral density;	chr8:70948477	chr8:70780914~70781008:-
LUAD	cis	rs4143844	1	rs12905264	ENSG00000259251.2	RP11-643M14.1	5.06	6.02e-07	0.00016	0.39	0.22	Bipolar disorder and schizophrenia;	chr15:61994464	chr15:62060503~62062434:+
LUAD	cis	rs2337406	1	rs3858878	ENSG00000223648.3	IGHV3-64	5.06	6.02e-07	0.00016	0.27	0.22	Alzheimer's disease (late onset);	chr14:106688061	chr14:106643132~106658258:-
LUAD	cis	rs10129255	0.957	rs10136781	ENSG00000274576.2	IGHV2-70	5.06	6.03e-07	0.000161	0.2	0.22	Kawasaki disease;	chr14:106780451	chr14:106770577~106771020:-
LUAD	cis	rs10129255	0.957	rs8022165	ENSG00000274576.2	IGHV2-70	5.06	6.03e-07	0.000161	0.2	0.22	Kawasaki disease;	chr14:106781682	chr14:106770577~106771020:-
LUAD	cis	rs10129255	0.917	rs8022493	ENSG00000274576.2	IGHV2-70	5.06	6.03e-07	0.000161	0.2	0.22	Kawasaki disease;	chr14:106781820	chr14:106770577~106771020:-
LUAD	cis	rs4722166	0.695	rs35779989	ENSG00000179428.2	AC073072.5	-5.06	6.03e-07	0.000161	-0.26	-0.22	Lung cancer;	chr7:22760695	chr7:22725395~22727620:-
LUAD	cis	rs4835473	0.715	rs1849124	ENSG00000251600.4	RP11-673E1.1	5.06	6.03e-07	0.000161	0.28	0.22	Immature fraction of reticulocytes;	chr4:143978494	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.689	rs1849123	ENSG00000251600.4	RP11-673E1.1	5.06	6.03e-07	0.000161	0.28	0.22	Immature fraction of reticulocytes;	chr4:143978495	chr4:143912331~143982454:+
LUAD	cis	rs11742741	0.714	rs11744373	ENSG00000248874.4	C5orf17	-5.06	6.04e-07	0.000161	-0.28	-0.22	Educational attainment;	chr5:24156562	chr5:23951348~24178263:+
LUAD	cis	rs2337406	0.866	rs79901786	ENSG00000211972.2	IGHV3-66	5.06	6.04e-07	0.000161	0.24	0.22	Alzheimer's disease (late onset);	chr14:106777623	chr14:106675017~106675544:-
LUAD	cis	rs35264875	0.95	rs35337391	ENSG00000259799.1	RP11-554A11.9	5.06	6.04e-07	0.000161	0.32	0.22	Blond vs. brown hair color;	chr11:69086544	chr11:69155910~69159752:+
LUAD	cis	rs2562456	0.833	rs2562507	ENSG00000268081.1	RP11-678G14.2	-5.06	6.04e-07	0.000161	-0.34	-0.22	Pain;	chr19:21543535	chr19:21554640~21569237:-
LUAD	cis	rs2239557	1	rs2358628	ENSG00000259065.1	RP5-1021I20.1	5.06	6.04e-07	0.000161	0.26	0.22	Common traits (Other);	chr14:74165054	chr14:73787360~73803270:+
LUAD	cis	rs1150668	0.796	rs9468372	ENSG00000219392.1	RP1-265C24.5	-5.06	6.04e-07	0.000161	-0.28	-0.22	Pubertal anthropometrics;	chr6:28411584	chr6:28115628~28116551:+
LUAD	cis	rs293748	0.713	rs2937116	ENSG00000250155.1	CTD-2353F22.1	-5.06	6.05e-07	0.000161	-0.31	-0.22	Obesity-related traits;	chr5:36824900	chr5:36666214~36725195:-
LUAD	cis	rs875971	0.767	rs12668005	ENSG00000232559.3	GS1-124K5.12	5.06	6.05e-07	0.000161	0.27	0.22	Aortic root size;	chr7:66444034	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs11765791	ENSG00000232559.3	GS1-124K5.12	5.06	6.05e-07	0.000161	0.27	0.22	Aortic root size;	chr7:66471587	chr7:66554588~66576923:-
LUAD	cis	rs4819052	1	rs4819052	ENSG00000215447.6	BX322557.10	-5.06	6.05e-07	0.000161	-0.29	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45279862	chr21:45288052~45291738:+
LUAD	cis	rs12928939	0.815	rs61753635	ENSG00000260886.1	TAT-AS1	5.06	6.05e-07	0.000161	0.27	0.22	Post bronchodilator FEV1;	chr16:71626501	chr16:71565789~71578187:+
LUAD	cis	rs9341808	0.754	rs6907729	ENSG00000272129.1	RP11-250B2.6	-5.06	6.05e-07	0.000161	-0.28	-0.22	Sitting height ratio;	chr6:80295205	chr6:80355424~80356859:+
LUAD	cis	rs4908768	0.501	rs6577488	ENSG00000270282.1	RP5-1115A15.2	5.06	6.05e-07	0.000161	0.25	0.22	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8474469	chr1:8512653~8513021:+
LUAD	cis	rs4908768	0.501	rs4351668	ENSG00000270282.1	RP5-1115A15.2	5.06	6.05e-07	0.000161	0.25	0.22	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8475758	chr1:8512653~8513021:+
LUAD	cis	rs4908768	0.501	rs7551849	ENSG00000270282.1	RP5-1115A15.2	5.06	6.05e-07	0.000161	0.25	0.22	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8479403	chr1:8512653~8513021:+
LUAD	cis	rs1799949	0.929	rs12937015	ENSG00000236383.6	LINC00854	-5.06	6.06e-07	0.000161	-0.18	-0.22	Menopause (age at onset);	chr17:43155456	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs4340367	ENSG00000236383.6	LINC00854	-5.06	6.06e-07	0.000161	-0.18	-0.22	Menopause (age at onset);	chr17:43155755	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs4792981	ENSG00000236383.6	LINC00854	-5.06	6.06e-07	0.000161	-0.18	-0.22	Menopause (age at onset);	chr17:43156257	chr17:43216941~43305976:-
LUAD	cis	rs1799949	0.965	rs35521261	ENSG00000236383.6	LINC00854	-5.06	6.06e-07	0.000161	-0.18	-0.22	Menopause (age at onset);	chr17:43161595	chr17:43216941~43305976:-
LUAD	cis	rs1799949	0.896	rs33933393	ENSG00000236383.6	LINC00854	-5.06	6.06e-07	0.000161	-0.18	-0.22	Menopause (age at onset);	chr17:43165415	chr17:43216941~43305976:-
LUAD	cis	rs5769707	0.632	rs1476037	ENSG00000235111.1	RP1-29C18.8	-5.06	6.07e-07	0.000161	-0.26	-0.22	Monocyte percentage of white cells;Monocyte count;	chr22:49597729	chr22:49612657~49615716:-
LUAD	cis	rs12701220	0.901	rs12701708	ENSG00000229043.2	AC091729.9	-5.06	6.07e-07	0.000162	-0.29	-0.22	Bronchopulmonary dysplasia;	chr7:1050697	chr7:1160374~1165267:+
LUAD	cis	rs1150668	0.83	rs213240	ENSG00000219392.1	RP1-265C24.5	-5.06	6.07e-07	0.000162	-0.28	-0.22	Pubertal anthropometrics;	chr6:28348098	chr6:28115628~28116551:+
LUAD	cis	rs7829975	0.744	rs2409092	ENSG00000253981.4	ALG1L13P	5.06	6.07e-07	0.000162	0.26	0.22	Mood instability;	chr8:8824682	chr8:8236003~8244667:-
LUAD	cis	rs6921919	0.848	rs6903652	ENSG00000216901.1	AL022393.7	5.06	6.07e-07	0.000162	0.3	0.22	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:28176188~28176674:+
LUAD	cis	rs1799949	1	rs33926631	ENSG00000236383.6	LINC00854	-5.06	6.07e-07	0.000162	-0.18	-0.22	Menopause (age at onset);	chr17:43152446	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs1960605	ENSG00000236383.6	LINC00854	-5.06	6.07e-07	0.000162	-0.18	-0.22	Menopause (age at onset);	chr17:43153380	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs2037076	ENSG00000236383.6	LINC00854	-5.06	6.07e-07	0.000162	-0.18	-0.22	Menopause (age at onset);	chr17:43153866	chr17:43216941~43305976:-
LUAD	cis	rs6921919	1	rs35875412	ENSG00000216901.1	AL022393.7	5.06	6.07e-07	0.000162	0.31	0.22	Autism spectrum disorder or schizophrenia;	chr6:28364041	chr6:28176188~28176674:+
LUAD	cis	rs2283792	0.646	rs7292584	ENSG00000224086.5	LL22NC03-86G7.1	-5.06	6.07e-07	0.000162	-0.22	-0.22	Multiple sclerosis;	chr22:21768458	chr22:21938293~21977632:+
LUAD	cis	rs42490	0.934	rs218946	ENSG00000251136.7	RP11-37B2.1	-5.06	6.08e-07	0.000162	-0.23	-0.22	Leprosy;	chr8:89704478	chr8:89609409~89757727:-
LUAD	cis	rs2408955	0.522	rs4760679	ENSG00000257735.1	RP11-370I10.6	-5.06	6.08e-07	0.000162	-0.27	-0.22	Glycated hemoglobin levels;	chr12:48067852	chr12:48350945~48442411:+
LUAD	cis	rs699371	0.55	rs11851117	ENSG00000270000.1	RP3-449M8.9	5.06	6.08e-07	0.000162	0.26	0.22	Height;	chr14:74454856	chr14:74471930~74472360:-
LUAD	cis	rs2742234	0.518	rs2505514	ENSG00000273008.1	RP11-351D16.3	-5.06	6.08e-07	0.000162	-0.26	-0.22	Hirschsprung disease;	chr10:43137800	chr10:43136824~43138334:-
LUAD	cis	rs9322193	0.923	rs62439840	ENSG00000268592.3	RAET1E-AS1	5.06	6.08e-07	0.000162	0.28	0.22	Lung cancer;	chr6:149674639	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.962	rs9393175	ENSG00000268592.3	RAET1E-AS1	5.06	6.08e-07	0.000162	0.28	0.22	Lung cancer;	chr6:149677587	chr6:149863494~149919507:+
LUAD	cis	rs6539247	0.509	rs4275717	ENSG00000257890.1	RP11-114F10.2	-5.06	6.09e-07	0.000162	-0.24	-0.22	Attention function in attention deficit hyperactive disorder;	chr12:106052074	chr12:106050961~106058254:-
LUAD	cis	rs6142102	0.886	rs6142098	ENSG00000275784.1	RP5-1125A11.6	-5.06	6.09e-07	0.000162	-0.24	-0.22	Skin pigmentation;	chr20:34100488	chr20:33989480~33991818:-
LUAD	cis	rs2836950	0.52	rs8133927	ENSG00000255568.3	BRWD1-AS2	-5.06	6.09e-07	0.000162	-0.22	-0.22	Menarche (age at onset);	chr21:39318035	chr21:39313935~39314962:+
LUAD	cis	rs2836950	0.52	rs8133928	ENSG00000255568.3	BRWD1-AS2	-5.06	6.09e-07	0.000162	-0.22	-0.22	Menarche (age at onset);	chr21:39318037	chr21:39313935~39314962:+
LUAD	cis	rs9549328	0.8	rs1317507	ENSG00000267868.1	RP11-120K24.3	5.06	6.09e-07	0.000162	0.26	0.22	Systolic blood pressure;	chr13:112977466	chr13:112964835~112966131:-
LUAD	cis	rs2439831	0.702	rs2467402	ENSG00000249839.1	AC011330.5	5.06	6.1e-07	0.000162	0.41	0.22	Lung cancer in ever smokers;	chr15:43732292	chr15:43663654~43684339:-
LUAD	cis	rs1320333	0.772	rs17786111	ENSG00000233296.1	AC092159.2	5.06	6.1e-07	0.000162	0.41	0.22	Obesity-related traits;	chr2:700562	chr2:677186~697371:+
LUAD	cis	rs2098713	0.535	rs1589116	ENSG00000250155.1	CTD-2353F22.1	5.06	6.1e-07	0.000162	0.24	0.22	Telomere length;	chr5:37629567	chr5:36666214~36725195:-
LUAD	cis	rs673078	0.66	rs7965350	ENSG00000275409.1	RP11-131L12.4	-5.06	6.11e-07	0.000162	-0.32	-0.22	Glucose homeostasis traits;	chr12:118266710	chr12:118430147~118430699:+
LUAD	cis	rs4835473	0.863	rs7696828	ENSG00000251600.4	RP11-673E1.1	5.06	6.11e-07	0.000163	0.28	0.22	Immature fraction of reticulocytes;	chr4:143700846	chr4:143912331~143982454:+
LUAD	cis	rs17666538	0.71	rs1703941	ENSG00000254207.1	RP11-43A14.1	5.06	6.11e-07	0.000163	0.46	0.22	IgG glycosylation;	chr8:708447	chr8:725188~725877:-
LUAD	cis	rs12681366	0.801	rs12549544	ENSG00000253704.1	RP11-267M23.4	5.06	6.12e-07	0.000163	0.28	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94471329	chr8:94553722~94569745:+
LUAD	cis	rs7116495	1	rs6592450	ENSG00000254682.1	RP11-660L16.2	5.06	6.12e-07	0.000163	0.45	0.22	Severe influenza A (H1N1) infection;	chr11:71960120	chr11:71448674~71452157:+
LUAD	cis	rs1862618	0.627	rs744023	ENSG00000271828.1	CTD-2310F14.1	5.05	6.13e-07	0.000163	0.34	0.22	Initial pursuit acceleration;	chr5:56901251	chr5:56927874~56929573:+
LUAD	cis	rs7580658	0.864	rs10928761	ENSG00000236682.1	AC068282.3	-5.05	6.13e-07	0.000163	-0.3	-0.22	Protein C levels;	chr2:127245671	chr2:127389130~127400580:+
LUAD	cis	rs30380	0.553	rs152280	ENSG00000272109.1	CTD-2260A17.3	-5.05	6.13e-07	0.000163	-0.28	-0.22	Cerebrospinal fluid biomarker levels;	chr5:96826239	chr5:96804353~96806105:+
LUAD	cis	rs2919009	1	rs2919009	ENSG00000271670.1	RP11-95I16.4	5.05	6.14e-07	0.000163	0.29	0.22	Obesity-related traits;	chr10:120831861	chr10:120879256~120880667:-
LUAD	cis	rs875971	0.638	rs6960778	ENSG00000237310.1	GS1-124K5.4	-5.05	6.14e-07	0.000163	-0.24	-0.22	Aortic root size;	chr7:66606610	chr7:66493706~66495474:+
LUAD	cis	rs12534093	0.602	rs11765452	ENSG00000234286.1	AC006026.13	-5.05	6.14e-07	0.000163	-0.29	-0.22	Infant length;Height;	chr7:23542936	chr7:23680195~23680786:-
LUAD	cis	rs11976180	1	rs13226728	ENSG00000170356.8	OR2A20P	-5.05	6.14e-07	0.000163	-0.28	-0.22	Obesity-related traits;	chr7:144049485	chr7:144250045~144252957:-
LUAD	cis	rs2239547	0.562	rs6794389	ENSG00000242142.1	SERBP1P3	5.05	6.15e-07	0.000163	0.27	0.22	Schizophrenia;	chr3:53062378	chr3:53064283~53065091:-
LUAD	cis	rs17826219	0.562	rs719600	ENSG00000263531.1	RP13-753N3.1	-5.05	6.15e-07	0.000164	-0.44	-0.22	Body mass index;	chr17:30404244	chr17:30863921~30864940:-
LUAD	cis	rs1799949	1	rs8176242	ENSG00000236383.6	LINC00854	-5.05	6.15e-07	0.000164	-0.18	-0.22	Menopause (age at onset);	chr17:43065857	chr17:43216941~43305976:-
LUAD	cis	rs7017914	0.714	rs13268251	ENSG00000223220.1	Y_RNA	-5.05	6.15e-07	0.000164	-0.25	-0.22	Bone mineral density;	chr8:71066579	chr8:70780914~70781008:-
LUAD	cis	rs2032366	1	rs1840047	ENSG00000267279.1	RP11-879F14.2	-5.05	6.15e-07	0.000164	-0.27	-0.22	Obesity-related traits;	chr18:61591312	chr18:61585746~61606916:-
LUAD	cis	rs4908760	0.827	rs7556169	ENSG00000232912.4	RP5-1115A15.1	-5.05	6.16e-07	0.000164	-0.21	-0.22	Vitiligo;	chr1:8681342	chr1:8424645~8434838:+
LUAD	cis	rs6687821	0.654	rs11161896	ENSG00000267734.1	RP4-604K5.3	-5.05	6.16e-07	0.000164	-0.27	-0.22	Yeast infection;	chr1:86820541	chr1:86932199~86934891:-
LUAD	cis	rs6095360	0.727	rs13040426	ENSG00000222365.1	SNORD12B	-5.05	6.16e-07	0.000164	-0.25	-0.22	Intelligence (multi-trait analysis);	chr20:49097916	chr20:49280319~49280409:+
LUAD	cis	rs11976180	1	rs11976037	ENSG00000170356.8	OR2A20P	-5.05	6.16e-07	0.000164	-0.29	-0.22	Obesity-related traits;	chr7:144043931	chr7:144250045~144252957:-
LUAD	cis	rs1707322	1	rs946527	ENSG00000280836.1	AL355480.1	-5.05	6.17e-07	0.000164	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46020298	chr1:45581219~45581321:-
LUAD	cis	rs10800713	0.908	rs6686605	ENSG00000260088.1	RP11-92G12.3	-5.05	6.17e-07	0.000164	-0.33	-0.22	Tandem gait;	chr1:200539440	chr1:200669507~200694250:+
LUAD	cis	rs7806994	1	rs7806994	ENSG00000275875.1	RP11-613E4.5	-5.05	6.17e-07	0.000164	-0.32	-0.22	PR interval in Tripanosoma cruzi seropositivity;	chr7:56071812	chr7:55741525~55741869:+
LUAD	cis	rs17264034	0.861	rs431288	ENSG00000250786.1	SNHG18	5.05	6.17e-07	0.000164	0.32	0.22	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9549347	chr5:9546200~9550609:+
LUAD	cis	rs1707322	0.752	rs4660313	ENSG00000280836.1	AL355480.1	5.05	6.17e-07	0.000164	0.3	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645169	chr1:45581219~45581321:-
LUAD	cis	rs875971	0.798	rs57739047	ENSG00000232559.3	GS1-124K5.12	5.05	6.17e-07	0.000164	0.27	0.22	Aortic root size;	chr7:66507579	chr7:66554588~66576923:-
LUAD	cis	rs9287719	0.578	rs62127189	ENSG00000243819.4	RN7SL832P	5.05	6.17e-07	0.000164	0.24	0.22	Prostate cancer;	chr2:10621200	chr2:10690344~10692099:+
LUAD	cis	rs2645288	1	rs2645288	ENSG00000226172.2	RP4-712E4.1	-5.05	6.17e-07	0.000164	-0.31	-0.22	Breast size;	chr1:118957860	chr1:119000344~119001392:-
LUAD	cis	rs4722166	0.568	rs1880241	ENSG00000179428.2	AC073072.5	-5.05	6.17e-07	0.000164	-0.25	-0.22	Lung cancer;	chr7:22719850	chr7:22725395~22727620:-
LUAD	cis	rs2295359	0.892	rs72676067	ENSG00000275678.1	RP4-547N15.3	-5.05	6.18e-07	0.000164	-0.24	-0.22	Psoriasis;	chr1:67193120	chr1:67121605~67123956:-
LUAD	cis	rs2295359	0.892	rs72676069	ENSG00000275678.1	RP4-547N15.3	-5.05	6.18e-07	0.000164	-0.24	-0.22	Psoriasis;	chr1:67193271	chr1:67121605~67123956:-
LUAD	cis	rs6545883	0.524	rs2694618	ENSG00000271889.1	RP11-493E12.1	5.05	6.19e-07	0.000164	0.26	0.22	Tuberculosis;	chr2:61309849	chr2:61151433~61162105:-
LUAD	cis	rs7083	0.905	rs11216338	ENSG00000254851.1	RP11-109L13.1	5.05	6.19e-07	0.000164	0.28	0.22	Blood protein levels;	chr11:117261003	chr11:117135528~117138582:+
LUAD	cis	rs7083	1	rs619772	ENSG00000254851.1	RP11-109L13.1	5.05	6.19e-07	0.000164	0.28	0.22	Blood protein levels;	chr11:117268120	chr11:117135528~117138582:+
LUAD	cis	rs7083	1	rs493139	ENSG00000254851.1	RP11-109L13.1	5.05	6.19e-07	0.000164	0.28	0.22	Blood protein levels;	chr11:117275233	chr11:117135528~117138582:+
LUAD	cis	rs853679	1	rs2799077	ENSG00000219392.1	RP1-265C24.5	-5.05	6.19e-07	0.000164	-0.34	-0.22	Depression;	chr6:28266819	chr6:28115628~28116551:+
LUAD	cis	rs875971	0.508	rs10253883	ENSG00000237310.1	GS1-124K5.4	-5.05	6.19e-07	0.000165	-0.24	-0.22	Aortic root size;	chr7:66596151	chr7:66493706~66495474:+
LUAD	cis	rs4664293	0.867	rs6432553	ENSG00000226266.5	AC009961.3	-5.05	6.2e-07	0.000165	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159720499	chr2:159670708~159712435:-
LUAD	cis	rs507080	0.845	rs481903	ENSG00000278376.1	RP11-158I9.8	-5.05	6.2e-07	0.000165	-0.24	-0.22	Serum metabolite levels;	chr11:118697024	chr11:118791254~118793137:+
LUAD	cis	rs4143844	1	rs34042779	ENSG00000259251.2	RP11-643M14.1	5.05	6.2e-07	0.000165	0.4	0.22	Bipolar disorder and schizophrenia;	chr15:61990899	chr15:62060503~62062434:+
LUAD	cis	rs73242632	0.881	rs1277296	ENSG00000269949.1	RP11-738E22.3	-5.05	6.2e-07	0.000165	-0.51	-0.22	Congenital heart disease (maternal effect);	chr4:57062164	chr4:56960927~56961373:-
LUAD	cis	rs5758511	0.68	rs5751243	ENSG00000205702.9	CYP2D7	5.05	6.21e-07	0.000165	0.22	0.22	Birth weight;	chr22:42221171	chr22:42140203~42144577:-
LUAD	cis	rs5758511	0.637	rs5751244	ENSG00000205702.9	CYP2D7	5.05	6.21e-07	0.000165	0.22	0.22	Birth weight;	chr22:42221405	chr22:42140203~42144577:-
LUAD	cis	rs453301	0.686	rs3989373	ENSG00000173295.6	FAM86B3P	-5.05	6.21e-07	0.000165	-0.23	-0.22	Joint mobility (Beighton score);	chr8:9053798	chr8:8228595~8244865:+
LUAD	cis	rs453301	0.598	rs2921383	ENSG00000173295.6	FAM86B3P	5.05	6.21e-07	0.000165	0.24	0.22	Joint mobility (Beighton score);	chr8:9034711	chr8:8228595~8244865:+
LUAD	cis	rs2348418	0.733	rs2169752	ENSG00000247934.4	RP11-967K21.1	-5.05	6.21e-07	0.000165	-0.25	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28239279	chr12:28163298~28190738:-
LUAD	cis	rs1150688	1	rs1150688	ENSG00000219392.1	RP1-265C24.5	-5.05	6.21e-07	0.000165	-0.28	-0.22	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28115628~28116551:+
LUAD	cis	rs7017914	0.69	rs12674838	ENSG00000223220.1	Y_RNA	5.05	6.21e-07	0.000165	0.26	0.22	Bone mineral density;	chr8:71078045	chr8:70780914~70781008:-
LUAD	cis	rs61270009	0.955	rs11748798	ENSG00000247828.6	TMEM161B-AS1	5.05	6.22e-07	0.000165	0.26	0.22	Depressive symptoms;	chr5:88354925	chr5:88268895~88436685:+
LUAD	cis	rs61270009	0.955	rs11740836	ENSG00000247828.6	TMEM161B-AS1	5.05	6.22e-07	0.000165	0.26	0.22	Depressive symptoms;	chr5:88356311	chr5:88268895~88436685:+
LUAD	cis	rs61270009	0.913	rs13154590	ENSG00000247828.6	TMEM161B-AS1	5.05	6.22e-07	0.000165	0.26	0.22	Depressive symptoms;	chr5:88357208	chr5:88268895~88436685:+
LUAD	cis	rs71520386	0.632	rs1474349	ENSG00000228649.7	AC005682.5	-5.05	6.22e-07	0.000165	-0.31	-0.22	Fibrinogen levels;	chr7:22814146	chr7:22854178~22861579:+
LUAD	cis	rs2976388	1	rs2976388	ENSG00000253741.1	CTD-2292P10.4	5.05	6.22e-07	0.000165	0.25	0.22	Urinary tract infection frequency;	chr8:142678838	chr8:142702252~142726973:-
LUAD	cis	rs1722141	0.599	rs2342395	ENSG00000229628.1	AC073115.7	5.05	6.22e-07	0.000165	0.37	0.22	Sitting height ratio;	chr7:45935616	chr7:45990905~46000898:+
LUAD	cis	rs7302981	0.967	rs7972842	ENSG00000272368.2	RP4-605O3.4	-5.05	6.22e-07	0.000165	-0.26	-0.22	Systolic blood pressure;	chr12:50122540	chr12:50112197~50165618:+
LUAD	cis	rs2098713	0.561	rs55960353	ENSG00000250155.1	CTD-2353F22.1	5.05	6.23e-07	0.000165	0.24	0.22	Telomere length;	chr5:37599484	chr5:36666214~36725195:-
LUAD	cis	rs1008375	0.966	rs4698621	ENSG00000249502.1	AC006160.5	-5.05	6.23e-07	0.000165	-0.22	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17585942	chr4:17587467~17614571:-
LUAD	cis	rs10129255	0.5	rs11627315	ENSG00000211967.3	IGHV3-53	-5.05	6.23e-07	0.000165	-0.16	-0.22	Kawasaki disease;	chr14:106802182	chr14:106592676~106593347:-
LUAD	cis	rs2554380	0.628	rs6602993	ENSG00000230373.7	GOLGA6L5P	-5.05	6.23e-07	0.000165	-0.24	-0.22	Height;	chr15:83813610	chr15:84507885~84516814:-
LUAD	cis	rs10246939	0.579	rs10464444	ENSG00000228775.6	WEE2-AS1	-5.05	6.23e-07	0.000165	-0.26	-0.22	Bitter taste perception;	chr7:141832387	chr7:141704338~141738346:-
LUAD	cis	rs6095360	0.727	rs34385643	ENSG00000222365.1	SNORD12B	-5.05	6.23e-07	0.000165	-0.25	-0.22	Intelligence (multi-trait analysis);	chr20:48956879	chr20:49280319~49280409:+
LUAD	cis	rs875971	0.862	rs1875057	ENSG00000232559.3	GS1-124K5.12	-5.05	6.23e-07	0.000165	-0.27	-0.22	Aortic root size;	chr7:66266868	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs6960446	ENSG00000232559.3	GS1-124K5.12	-5.05	6.23e-07	0.000165	-0.27	-0.22	Aortic root size;	chr7:66268272	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.789	rs10260426	ENSG00000232559.3	GS1-124K5.12	-5.05	6.23e-07	0.000165	-0.27	-0.22	Aortic root size;	chr7:66271055	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs7796162	ENSG00000232559.3	GS1-124K5.12	-5.05	6.23e-07	0.000165	-0.27	-0.22	Aortic root size;	chr7:66280771	chr7:66554588~66576923:-
LUAD	cis	rs7819412	0.525	rs10086521	ENSG00000255046.1	RP11-297N6.4	5.05	6.24e-07	0.000166	0.29	0.22	Triglycerides;	chr8:10926259	chr8:11797928~11802568:-
LUAD	cis	rs7208859	0.623	rs9906957	ENSG00000280069.1	CTD-2349P21.3	-5.05	6.24e-07	0.000166	-0.31	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30830737	chr17:30738182~30740275:+
LUAD	cis	rs17818399	0.815	rs17768138	ENSG00000279254.1	RP11-536C12.1	-5.05	6.24e-07	0.000166	-0.26	-0.22	Height;	chr2:46641078	chr2:46668870~46670778:+
LUAD	cis	rs7580658	0.864	rs1566823	ENSG00000236682.1	AC068282.3	-5.05	6.24e-07	0.000166	-0.3	-0.22	Protein C levels;	chr2:127260616	chr2:127389130~127400580:+
LUAD	cis	rs2933343	0.621	rs789249	ENSG00000261159.1	RP11-723O4.9	5.05	6.24e-07	0.000166	0.24	0.22	IgG glycosylation;	chr3:128859610	chr3:128859716~128860526:-
LUAD	cis	rs6142102	0.961	rs6087557	ENSG00000275784.1	RP5-1125A11.6	-5.05	6.24e-07	0.000166	-0.24	-0.22	Skin pigmentation;	chr20:34110469	chr20:33989480~33991818:-
LUAD	cis	rs12468226	1	rs7597156	ENSG00000272966.1	RP11-686O6.1	5.05	6.24e-07	0.000166	0.36	0.22	Urate levels;	chr2:202329339	chr2:202336739~202337200:+
LUAD	cis	rs17508449	0.865	rs4838994	ENSG00000232450.1	RP4-730K3.3	5.05	6.25e-07	0.000166	0.36	0.22	Leprosy;	chr1:113608984	chr1:113698884~113699631:-
LUAD	cis	rs75920871	0.528	rs11216255	ENSG00000254851.1	RP11-109L13.1	5.05	6.25e-07	0.000166	0.32	0.22	Subjective well-being;	chr11:117059279	chr11:117135528~117138582:+
LUAD	cis	rs950169	0.65	rs12902052	ENSG00000259295.5	CSPG4P12	5.05	6.25e-07	0.000166	0.33	0.22	Schizophrenia;	chr15:84582607	chr15:85191438~85213905:+
LUAD	cis	rs6840360	1	rs2840130	ENSG00000270265.1	RP11-731D1.4	-5.05	6.25e-07	0.000166	-0.23	-0.22	Intelligence (multi-trait analysis);	chr4:151679547	chr4:151333775~151353224:-
LUAD	cis	rs6840360	1	rs907237	ENSG00000270265.1	RP11-731D1.4	-5.05	6.25e-07	0.000166	-0.23	-0.22	Intelligence (multi-trait analysis);	chr4:151679994	chr4:151333775~151353224:-
LUAD	cis	rs1707322	0.927	rs6690386	ENSG00000280836.1	AL355480.1	-5.05	6.25e-07	0.000166	-0.3	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45787339	chr1:45581219~45581321:-
LUAD	cis	rs910316	0.875	rs12588099	ENSG00000259138.1	RP11-950C14.7	5.05	6.25e-07	0.000166	0.24	0.22	Height;	chr14:75127759	chr14:75127153~75136930:+
LUAD	cis	rs801193	1	rs4717319	ENSG00000236529.1	RP13-254B10.1	5.05	6.26e-07	0.000166	0.23	0.22	Aortic root size;	chr7:66777606	chr7:65840212~65840596:+
LUAD	cis	rs801193	0.904	rs4718403	ENSG00000236529.1	RP13-254B10.1	5.05	6.26e-07	0.000166	0.23	0.22	Aortic root size;	chr7:66777742	chr7:65840212~65840596:+
LUAD	cis	rs6723226	0.721	rs3769600	ENSG00000276334.1	AL133243.1	-5.05	6.26e-07	0.000166	-0.25	-0.22	Intelligence (multi-trait analysis);	chr2:32391811	chr2:32521927~32523547:+
LUAD	cis	rs875971	0.862	rs1695820	ENSG00000232559.3	GS1-124K5.12	5.05	6.26e-07	0.000166	0.27	0.22	Aortic root size;	chr7:66379576	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.83	rs778715	ENSG00000232559.3	GS1-124K5.12	5.05	6.26e-07	0.000166	0.27	0.22	Aortic root size;	chr7:66384222	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.83	rs809025	ENSG00000232559.3	GS1-124K5.12	5.05	6.26e-07	0.000166	0.27	0.22	Aortic root size;	chr7:66384832	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs778702	ENSG00000232559.3	GS1-124K5.12	5.05	6.26e-07	0.000166	0.27	0.22	Aortic root size;	chr7:66399848	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs1643375	ENSG00000232559.3	GS1-124K5.12	5.05	6.26e-07	0.000166	0.27	0.22	Aortic root size;	chr7:66407690	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs6962717	ENSG00000232559.3	GS1-124K5.12	5.05	6.26e-07	0.000166	0.27	0.22	Aortic root size;	chr7:66418748	chr7:66554588~66576923:-
LUAD	cis	rs116095464	1	rs111646826	ENSG00000277812.1	AC021087.1	5.05	6.27e-07	0.000166	0.67	0.22	Breast cancer;	chr5:328237	chr5:262769~262881:+
LUAD	cis	rs301901	0.772	rs301863	ENSG00000250155.1	CTD-2353F22.1	-5.05	6.27e-07	0.000166	-0.24	-0.22	Height;	chr5:37133456	chr5:36666214~36725195:-
LUAD	cis	rs301901	0.772	rs301873	ENSG00000250155.1	CTD-2353F22.1	-5.05	6.27e-07	0.000166	-0.24	-0.22	Height;	chr5:37136896	chr5:36666214~36725195:-
LUAD	cis	rs1799949	0.896	rs8176098	ENSG00000236383.6	LINC00854	-5.05	6.27e-07	0.000166	-0.18	-0.22	Menopause (age at onset);	chr17:43116189	chr17:43216941~43305976:-
LUAD	cis	rs2295359	0.892	rs10789224	ENSG00000275678.1	RP4-547N15.3	5.05	6.27e-07	0.000166	0.23	0.22	Psoriasis;	chr1:67139451	chr1:67121605~67123956:-
LUAD	cis	rs1707322	0.963	rs10890373	ENSG00000280836.1	AL355480.1	-5.05	6.27e-07	0.000166	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45928083	chr1:45581219~45581321:-
LUAD	cis	rs61270009	0.955	rs10462472	ENSG00000247828.6	TMEM161B-AS1	5.05	6.28e-07	0.000166	0.26	0.22	Depressive symptoms;	chr5:88346652	chr5:88268895~88436685:+
LUAD	cis	rs9322193	0.607	rs9383941	ENSG00000223701.3	RAET1E-AS1	-5.05	6.28e-07	0.000167	-0.31	-0.22	Lung cancer;	chr6:149912100	chr6:149884431~149919508:+
LUAD	cis	rs6539288	0.933	rs1822736	ENSG00000260329.1	RP11-412D9.4	5.05	6.28e-07	0.000167	0.24	0.22	Total body bone mineral density;	chr12:106915481	chr12:106954029~106955497:-
LUAD	cis	rs4835473	0.9	rs10027246	ENSG00000251600.4	RP11-673E1.1	-5.05	6.28e-07	0.000167	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143935069	chr4:143912331~143982454:+
LUAD	cis	rs2836974	0.544	rs8128919	ENSG00000255568.3	BRWD1-AS2	5.05	6.29e-07	0.000167	0.22	0.22	Cognitive function;	chr21:39339936	chr21:39313935~39314962:+
LUAD	cis	rs6570726	0.935	rs446242	ENSG00000235652.6	RP11-545I5.3	5.05	6.29e-07	0.000167	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145522730	chr6:145799409~145886585:+
LUAD	cis	rs42490	0.903	rs184302	ENSG00000251136.7	RP11-37B2.1	-5.05	6.29e-07	0.000167	-0.23	-0.22	Leprosy;	chr8:89704396	chr8:89609409~89757727:-
LUAD	cis	rs9322193	0.566	rs4870118	ENSG00000223701.3	RAET1E-AS1	-5.05	6.29e-07	0.000167	-0.31	-0.22	Lung cancer;	chr6:149923877	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.566	rs4869767	ENSG00000223701.3	RAET1E-AS1	-5.05	6.29e-07	0.000167	-0.31	-0.22	Lung cancer;	chr6:149923974	chr6:149884431~149919508:+
LUAD	cis	rs9322193	0.566	rs4869768	ENSG00000223701.3	RAET1E-AS1	-5.05	6.29e-07	0.000167	-0.31	-0.22	Lung cancer;	chr6:149924067	chr6:149884431~149919508:+
LUAD	cis	rs7727544	0.647	rs72793280	ENSG00000233006.5	AC034220.3	5.05	6.29e-07	0.000167	0.2	0.22	Blood metabolite levels;	chr5:132227207	chr5:132311285~132369916:-
LUAD	cis	rs801193	1	rs2659909	ENSG00000237310.1	GS1-124K5.4	5.05	6.29e-07	0.000167	0.24	0.22	Aortic root size;	chr7:66695292	chr7:66493706~66495474:+
LUAD	cis	rs1816752	0.905	rs4769352	ENSG00000273628.1	RP11-756A22.7	5.05	6.3e-07	0.000167	0.25	0.22	Obesity-related traits;	chr13:24426237	chr13:24933006~24936796:+
LUAD	cis	rs1816752	0.805	rs4769353	ENSG00000273628.1	RP11-756A22.7	5.05	6.3e-07	0.000167	0.25	0.22	Obesity-related traits;	chr13:24426318	chr13:24933006~24936796:+
LUAD	cis	rs7017914	0.69	rs62508859	ENSG00000223220.1	Y_RNA	5.05	6.31e-07	0.000167	0.26	0.22	Bone mineral density;	chr8:70828699	chr8:70780914~70781008:-
LUAD	cis	rs7937890	0.869	rs2915404	ENSG00000254418.1	RP11-21L19.1	5.05	6.31e-07	0.000167	0.26	0.22	Mitochondrial DNA levels;	chr11:14383279	chr11:14262846~14273691:-
LUAD	cis	rs858239	1	rs858240	ENSG00000226816.2	AC005082.12	5.05	6.32e-07	0.000167	0.29	0.22	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23206013~23208045:+
LUAD	cis	rs2408955	0.541	rs11168428	ENSG00000257735.1	RP11-370I10.6	-5.05	6.32e-07	0.000167	-0.26	-0.22	Glycated hemoglobin levels;	chr12:48153345	chr12:48350945~48442411:+
LUAD	cis	rs858239	0.862	rs1728292	ENSG00000226816.2	AC005082.12	5.05	6.32e-07	0.000168	0.28	0.22	Cerebrospinal fluid biomarker levels;	chr7:23223855	chr7:23206013~23208045:+
LUAD	cis	rs2976388	0.609	rs2572909	ENSG00000253741.1	CTD-2292P10.4	-5.05	6.32e-07	0.000168	-0.26	-0.22	Urinary tract infection frequency;	chr8:142725046	chr8:142702252~142726973:-
LUAD	cis	rs2976388	0.609	rs2585140	ENSG00000253741.1	CTD-2292P10.4	-5.05	6.32e-07	0.000168	-0.26	-0.22	Urinary tract infection frequency;	chr8:142725478	chr8:142702252~142726973:-
LUAD	cis	rs7119038	0.509	rs11216960	ENSG00000255239.1	AP002954.6	-5.05	6.33e-07	0.000168	-0.33	-0.22	Sjögren's syndrome;	chr11:118707164	chr11:118688039~118690600:-
LUAD	cis	rs7119038	0.509	rs10892256	ENSG00000255239.1	AP002954.6	-5.05	6.33e-07	0.000168	-0.33	-0.22	Sjögren's syndrome;	chr11:118707996	chr11:118688039~118690600:-
LUAD	cis	rs7119038	0.509	rs10892257	ENSG00000255239.1	AP002954.6	-5.05	6.33e-07	0.000168	-0.33	-0.22	Sjögren's syndrome;	chr11:118708618	chr11:118688039~118690600:-
LUAD	cis	rs7119038	0.509	rs11216961	ENSG00000255239.1	AP002954.6	-5.05	6.33e-07	0.000168	-0.33	-0.22	Sjögren's syndrome;	chr11:118709629	chr11:118688039~118690600:-
LUAD	cis	rs2749097	0.825	rs10889436	ENSG00000244256.3	RN7SL130P	-5.05	6.33e-07	0.000168	-0.27	-0.22	Alcohol consumption (transferrin glycosylation);	chr1:63658226	chr1:63655743~63656047:+
LUAD	cis	rs1799949	0.965	rs8176193	ENSG00000236383.6	LINC00854	-5.05	6.33e-07	0.000168	-0.18	-0.22	Menopause (age at onset);	chr17:43079499	chr17:43216941~43305976:-
LUAD	cis	rs7208859	0.673	rs216418	ENSG00000263531.1	RP13-753N3.1	5.05	6.33e-07	0.000168	0.38	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30609519	chr17:30863921~30864940:-
LUAD	cis	rs3750965	0.92	rs10896420	ENSG00000260895.1	RP11-554A11.7	5.05	6.33e-07	0.000168	0.26	0.22	Hair color;	chr11:69095579	chr11:69103493~69109094:+
LUAD	cis	rs3750965	0.92	rs10896421	ENSG00000260895.1	RP11-554A11.7	5.05	6.33e-07	0.000168	0.26	0.22	Hair color;	chr11:69095580	chr11:69103493~69109094:+
LUAD	cis	rs7580658	0.864	rs34832797	ENSG00000236682.1	AC068282.3	-5.05	6.34e-07	0.000168	-0.3	-0.22	Protein C levels;	chr2:127361865	chr2:127389130~127400580:+
LUAD	cis	rs2239547	0.523	rs6803486	ENSG00000242142.1	SERBP1P3	5.05	6.34e-07	0.000168	0.27	0.22	Schizophrenia;	chr3:53064193	chr3:53064283~53065091:-
LUAD	cis	rs8098244	0.638	rs9951784	ENSG00000264745.1	TTC39C-AS1	5.05	6.35e-07	0.000168	0.23	0.22	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23882709	chr18:23994213~24015339:-
LUAD	cis	rs4835473	0.897	rs1391189	ENSG00000251600.4	RP11-673E1.1	-5.05	6.35e-07	0.000168	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143690951	chr4:143912331~143982454:+
LUAD	cis	rs12468226	1	rs76021735	ENSG00000226261.1	AC064836.3	5.05	6.35e-07	0.000168	0.36	0.22	Urate levels;	chr2:202511476	chr2:202336024~202336727:-
LUAD	cis	rs6570726	0.764	rs9403733	ENSG00000235652.6	RP11-545I5.3	5.05	6.35e-07	0.000168	0.23	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145591175	chr6:145799409~145886585:+
LUAD	cis	rs875971	0.83	rs6950137	ENSG00000232559.3	GS1-124K5.12	5.05	6.36e-07	0.000168	0.27	0.22	Aortic root size;	chr7:66511623	chr7:66554588~66576923:-
LUAD	cis	rs4908760	0.864	rs6674832	ENSG00000232912.4	RP5-1115A15.1	5.05	6.36e-07	0.000168	0.2	0.22	Vitiligo;	chr1:8631820	chr1:8424645~8434838:+
LUAD	cis	rs984222	0.967	rs10923713	ENSG00000226172.2	RP4-712E4.1	-5.05	6.36e-07	0.000168	-0.24	-0.22	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118967864	chr1:119000344~119001392:-
LUAD	cis	rs9900062	0.586	rs6504249	ENSG00000270714.1	MINOS1P2	-5.05	6.36e-07	0.000169	-0.3	-0.22	QT interval;	chr17:64680031	chr17:64747264~64747492:-
LUAD	cis	rs453301	0.658	rs3855900	ENSG00000173295.6	FAM86B3P	-5.05	6.37e-07	0.000169	-0.24	-0.22	Joint mobility (Beighton score);	chr8:9044411	chr8:8228595~8244865:+
LUAD	cis	rs950169	0.887	rs220333	ENSG00000259295.5	CSPG4P12	5.05	6.37e-07	0.000169	0.32	0.22	Schizophrenia;	chr15:84547902	chr15:85191438~85213905:+
LUAD	cis	rs1876905	0.597	rs1150076	ENSG00000272356.1	RP5-1112D6.8	-5.05	6.37e-07	0.000169	-0.26	-0.22	Mean corpuscular hemoglobin;	chr6:111227227	chr6:111309203~111313517:+
LUAD	cis	rs2933343	0.7	rs789238	ENSG00000261159.1	RP11-723O4.9	5.05	6.37e-07	0.000169	0.24	0.22	IgG glycosylation;	chr3:128917872	chr3:128859716~128860526:-
LUAD	cis	rs11168351	0.864	rs12228750	ENSG00000257735.1	RP11-370I10.6	-5.05	6.37e-07	0.000169	-0.27	-0.22	Bipolar disorder and schizophrenia;	chr12:48103214	chr12:48350945~48442411:+
LUAD	cis	rs11168351	0.864	rs10875743	ENSG00000257735.1	RP11-370I10.6	-5.05	6.37e-07	0.000169	-0.27	-0.22	Bipolar disorder and schizophrenia;	chr12:48104630	chr12:48350945~48442411:+
LUAD	cis	rs9376098	0.698	rs6924521	ENSG00000232876.1	CTA-212D2.2	-5.05	6.38e-07	0.000169	-0.26	-0.22	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135146277	chr6:135055033~135060550:+
LUAD	cis	rs6545883	0.524	rs4599092	ENSG00000271889.1	RP11-493E12.1	-5.05	6.38e-07	0.000169	-0.26	-0.22	Tuberculosis;	chr2:61271833	chr2:61151433~61162105:-
LUAD	cis	rs561341	1	rs117029332	ENSG00000265798.5	RP11-271K11.5	5.05	6.38e-07	0.000169	0.36	0.22	Hip circumference adjusted for BMI;	chr17:31939066	chr17:31038575~31059121:-
LUAD	cis	rs561341	1	rs72821971	ENSG00000265798.5	RP11-271K11.5	5.05	6.38e-07	0.000169	0.36	0.22	Hip circumference adjusted for BMI;	chr17:31942324	chr17:31038575~31059121:-
LUAD	cis	rs853679	0.76	rs9393910	ENSG00000219392.1	RP1-265C24.5	-5.05	6.38e-07	0.000169	-0.33	-0.22	Depression;	chr6:28240414	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.76	rs9368563	ENSG00000219392.1	RP1-265C24.5	-5.05	6.38e-07	0.000169	-0.33	-0.22	Depression;	chr6:28240780	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.76	rs9295768	ENSG00000219392.1	RP1-265C24.5	-5.05	6.38e-07	0.000169	-0.33	-0.22	Depression;	chr6:28241324	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.699	rs9468318	ENSG00000219392.1	RP1-265C24.5	-5.05	6.38e-07	0.000169	-0.33	-0.22	Depression;	chr6:28241753	chr6:28115628~28116551:+
LUAD	cis	rs673078	0.66	rs73205551	ENSG00000275409.1	RP11-131L12.4	-5.05	6.38e-07	0.000169	-0.29	-0.22	Glucose homeostasis traits;	chr12:118330808	chr12:118430147~118430699:+
LUAD	cis	rs1154275	0.524	rs9832446	ENSG00000242770.2	RP11-180K7.1	5.05	6.39e-07	0.000169	0.24	0.22	Takotsubo syndrome;	chr3:112783850	chr3:112802478~112812819:+
LUAD	cis	rs8072100	0.79	rs7222225	ENSG00000228782.6	CTD-2026D20.3	-5.05	6.39e-07	0.000169	-0.24	-0.22	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47616131	chr17:47450568~47492492:-
LUAD	cis	rs2439831	0.85	rs28590651	ENSG00000205771.5	CATSPER2P1	-5.05	6.39e-07	0.000169	-0.43	-0.22	Lung cancer in ever smokers;	chr15:43820818	chr15:43726918~43747094:-
LUAD	cis	rs8031584	0.918	rs34331396	ENSG00000270015.1	RP11-540B6.6	-5.05	6.39e-07	0.000169	-0.16	-0.22	Huntington's disease progression;	chr15:30956533	chr15:30926514~30928407:+
LUAD	cis	rs2439831	0.85	rs12441127	ENSG00000249839.1	AC011330.5	-5.05	6.39e-07	0.000169	-0.44	-0.22	Lung cancer in ever smokers;	chr15:43728977	chr15:43663654~43684339:-
LUAD	cis	rs2018683	0.835	rs7782264	ENSG00000228421.2	AC005013.5	-5.05	6.39e-07	0.000169	-0.25	-0.22	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28939369	chr7:28957667~28959345:+
LUAD	cis	rs950169	0.734	rs67119537	ENSG00000259728.4	LINC00933	5.05	6.39e-07	0.000169	0.31	0.22	Schizophrenia;	chr15:84395671	chr15:84570649~84580175:+
LUAD	cis	rs4803480	0.578	rs7252454	ENSG00000270164.1	LINC01480	-5.05	6.4e-07	0.000169	-0.21	-0.22	Schizophrenia;	chr19:41527343	chr19:41535183~41536904:+
LUAD	cis	rs7619708	1	rs7619708	ENSG00000231464.1	AC024937.4	-5.05	6.4e-07	0.000169	-0.3	-0.22	Red cell distribution width;	chr3:196083316	chr3:195996738~195998233:+
LUAD	cis	rs2337406	1	rs3858878	ENSG00000211972.2	IGHV3-66	5.05	6.4e-07	0.000169	0.24	0.22	Alzheimer's disease (late onset);	chr14:106688061	chr14:106675017~106675544:-
LUAD	cis	rs4835473	0.932	rs9685306	ENSG00000251600.4	RP11-673E1.1	-5.05	6.4e-07	0.000169	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143748843	chr4:143912331~143982454:+
LUAD	cis	rs800160	0.777	rs2521282	ENSG00000236264.4	RPL26P30	-5.05	6.4e-07	0.000169	-0.32	-0.22	Bacteremia;	chr11:2318507	chr11:2335132~2335776:-
LUAD	cis	rs783540	0.542	rs62009945	ENSG00000278603.1	RP13-608F4.5	-5.05	6.41e-07	0.00017	-0.29	-0.22	Schizophrenia;	chr15:82631205	chr15:82472203~82472426:+
LUAD	cis	rs950169	0.58	rs1061737	ENSG00000275120.1	RP11-182J1.17	5.05	6.41e-07	0.00017	0.34	0.22	Schizophrenia;	chr15:84640559	chr15:84599434~84606463:-
LUAD	cis	rs853679	0.882	rs2743555	ENSG00000204709.4	LINC01556	5.05	6.41e-07	0.00017	0.34	0.22	Depression;	chr6:28273304	chr6:28943877~28944537:+
LUAD	cis	rs4908760	0.86	rs11121202	ENSG00000270282.1	RP5-1115A15.2	5.05	6.41e-07	0.00017	0.25	0.22	Vitiligo;	chr1:8579298	chr1:8512653~8513021:+
LUAD	cis	rs2688608	0.653	rs12775558	ENSG00000271816.1	BMS1P4	5.05	6.41e-07	0.00017	0.19	0.22	Inflammatory bowel disease;	chr10:73811110	chr10:73699151~73730487:-
LUAD	cis	rs673078	0.607	rs11068906	ENSG00000275409.1	RP11-131L12.4	-5.05	6.41e-07	0.00017	-0.31	-0.22	Glucose homeostasis traits;	chr12:118315098	chr12:118430147~118430699:+
LUAD	cis	rs8040855	0.93	rs6496767	ENSG00000259774.1	RP11-182J1.13	-5.05	6.41e-07	0.00017	-0.27	-0.22	Bulimia nervosa;	chr15:85159522	chr15:84422618~84425882:+
LUAD	cis	rs7580658	0.521	rs2404535	ENSG00000236682.1	AC068282.3	5.05	6.42e-07	0.00017	0.29	0.22	Protein C levels;	chr2:127190133	chr2:127389130~127400580:+
LUAD	cis	rs2599510	0.729	rs1135484	ENSG00000276334.1	AL133243.1	5.05	6.42e-07	0.00017	0.26	0.22	Interleukin-18 levels;	chr2:32523993	chr2:32521927~32523547:+
LUAD	cis	rs12681366	0.801	rs1372048	ENSG00000253704.1	RP11-267M23.4	5.05	6.42e-07	0.00017	0.28	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94455013	chr8:94553722~94569745:+
LUAD	cis	rs77204473	1	rs12292278	ENSG00000254851.1	RP11-109L13.1	-5.05	6.42e-07	0.00017	-0.52	-0.22	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116887977	chr11:117135528~117138582:+
LUAD	cis	rs6687821	0.834	rs263481	ENSG00000267734.1	RP4-604K5.3	5.05	6.42e-07	0.00017	0.26	0.22	Yeast infection;	chr1:86737560	chr1:86932199~86934891:-
LUAD	cis	rs12928939	0.769	rs1056303	ENSG00000260886.1	TAT-AS1	5.05	6.42e-07	0.00017	0.27	0.22	Post bronchodilator FEV1;	chr16:71636163	chr16:71565789~71578187:+
LUAD	cis	rs875971	0.862	rs778686	ENSG00000232559.3	GS1-124K5.12	5.05	6.42e-07	0.00017	0.27	0.22	Aortic root size;	chr7:66370923	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs778684	ENSG00000232559.3	GS1-124K5.12	5.05	6.42e-07	0.00017	0.27	0.22	Aortic root size;	chr7:66371416	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs778680	ENSG00000232559.3	GS1-124K5.12	5.05	6.42e-07	0.00017	0.27	0.22	Aortic root size;	chr7:66375427	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs11769079	ENSG00000232559.3	GS1-124K5.12	5.05	6.42e-07	0.00017	0.27	0.22	Aortic root size;	chr7:66377141	chr7:66554588~66576923:-
LUAD	cis	rs1009115	0.692	rs4720778	ENSG00000272328.1	RP4-594A5.1	5.05	6.42e-07	0.00017	0.28	0.22	Post bronchodilator FEV1;	chr7:8385295	chr7:8303741~8341343:+
LUAD	cis	rs4664293	0.967	rs1346325	ENSG00000226266.5	AC009961.3	-5.05	6.42e-07	0.00017	-0.31	-0.22	Monocyte percentage of white cells;	chr2:159685995	chr2:159670708~159712435:-
LUAD	cis	rs7727544	0.716	rs2089855	ENSG00000233006.5	AC034220.3	5.05	6.43e-07	0.00017	0.2	0.22	Blood metabolite levels;	chr5:132237836	chr5:132311285~132369916:-
LUAD	cis	rs2933343	1	rs1680795	ENSG00000261159.1	RP11-723O4.9	5.05	6.43e-07	0.00017	0.28	0.22	IgG glycosylation;	chr3:128901545	chr3:128859716~128860526:-
LUAD	cis	rs875971	0.54	rs781152	ENSG00000237310.1	GS1-124K5.4	5.05	6.44e-07	0.00017	0.24	0.22	Aortic root size;	chr7:66014585	chr7:66493706~66495474:+
LUAD	cis	rs17711722	0.727	rs781151	ENSG00000237310.1	GS1-124K5.4	5.05	6.44e-07	0.00017	0.24	0.22	Calcium levels;	chr7:66014891	chr7:66493706~66495474:+
LUAD	cis	rs7017914	0.644	rs1159724	ENSG00000223220.1	Y_RNA	5.04	6.46e-07	0.000171	0.26	0.22	Bone mineral density;	chr8:71087586	chr8:70780914~70781008:-
LUAD	cis	rs1707322	0.927	rs11211194	ENSG00000280836.1	AL355480.1	-5.04	6.46e-07	0.000171	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45816412	chr1:45581219~45581321:-
LUAD	cis	rs1075265	0.692	rs805358	ENSG00000233266.1	HMGB1P31	5.04	6.46e-07	0.000171	0.28	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53934885	chr2:54051334~54051760:+
LUAD	cis	rs9376098	0.698	rs9494155	ENSG00000232876.1	CTA-212D2.2	-5.04	6.47e-07	0.000171	-0.26	-0.22	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135147753	chr6:135055033~135060550:+
LUAD	cis	rs12468226	0.872	rs1061157	ENSG00000272966.1	RP11-686O6.1	5.04	6.47e-07	0.000171	0.38	0.22	Urate levels;	chr2:202556476	chr2:202336739~202337200:+
LUAD	cis	rs116095464	1	rs10054850	ENSG00000277812.1	AC021087.1	5.04	6.48e-07	0.000171	0.67	0.22	Breast cancer;	chr5:335712	chr5:262769~262881:+
LUAD	cis	rs116095464	0.85	rs10057272	ENSG00000277812.1	AC021087.1	5.04	6.48e-07	0.000171	0.67	0.22	Breast cancer;	chr5:340073	chr5:262769~262881:+
LUAD	cis	rs116095464	0.85	rs62330058	ENSG00000277812.1	AC021087.1	5.04	6.48e-07	0.000171	0.67	0.22	Breast cancer;	chr5:343449	chr5:262769~262881:+
LUAD	cis	rs889398	0.967	rs244417	ENSG00000226232.7	RP11-419C5.2	5.04	6.48e-07	0.000171	0.19	0.22	Body mass index;	chr16:69629616	chr16:69976388~69996188:-
LUAD	cis	rs189798	0.807	rs330905	ENSG00000254340.1	RP11-10A14.3	5.04	6.48e-07	0.000171	0.3	0.22	Myopia (pathological);	chr8:9136041	chr8:9141424~9145435:+
LUAD	cis	rs4268898	0.686	rs2042468	ENSG00000242628.4	AC009228.1	-5.04	6.48e-07	0.000171	-0.29	-0.22	Asthma;	chr2:24175577	chr2:24214381~24221516:+
LUAD	cis	rs4722166	0.695	rs7808122	ENSG00000179428.2	AC073072.5	-5.04	6.49e-07	0.000171	-0.26	-0.22	Lung cancer;	chr7:22758461	chr7:22725395~22727620:-
LUAD	cis	rs4604732	0.631	rs12038880	ENSG00000227135.1	GCSAML-AS1	-5.04	6.49e-07	0.000171	-0.36	-0.22	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247461301	chr1:247524679~247526752:-
LUAD	cis	rs858239	0.601	rs10239760	ENSG00000230042.1	AK3P3	-5.04	6.49e-07	0.000172	-0.28	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23110331	chr7:23129178~23129841:+
LUAD	cis	rs4568518	0.501	rs12699920	ENSG00000279048.1	RP11-511H23.2	5.04	6.49e-07	0.000172	0.19	0.22	Measles;	chr7:17953326	chr7:17940503~17942922:+
LUAD	cis	rs4568518	0.53	rs4721674	ENSG00000279048.1	RP11-511H23.2	5.04	6.49e-07	0.000172	0.19	0.22	Measles;	chr7:17953754	chr7:17940503~17942922:+
LUAD	cis	rs7208859	0.673	rs216440	ENSG00000263531.1	RP13-753N3.1	5.04	6.49e-07	0.000172	0.38	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30601291	chr17:30863921~30864940:-
LUAD	cis	rs11159086	0.793	rs10139122	ENSG00000259005.1	RP3-449M8.6	5.04	6.5e-07	0.000172	0.29	0.22	Advanced glycation end-product levels;	chr14:74492353	chr14:74474007~74474864:-
LUAD	cis	rs4908760	0.669	rs4908506	ENSG00000232912.4	RP5-1115A15.1	5.04	6.5e-07	0.000172	0.2	0.22	Vitiligo;	chr1:8668919	chr1:8424645~8434838:+
LUAD	cis	rs1876905	0.597	rs354526	ENSG00000272356.1	RP5-1112D6.8	-5.04	6.51e-07	0.000172	-0.26	-0.22	Mean corpuscular hemoglobin;	chr6:111216278	chr6:111309203~111313517:+
LUAD	cis	rs2976388	0.506	rs2572902	ENSG00000253741.1	CTD-2292P10.4	-5.04	6.51e-07	0.000172	-0.26	-0.22	Urinary tract infection frequency;	chr8:142709969	chr8:142702252~142726973:-
LUAD	cis	rs2976388	0.609	rs2572904	ENSG00000253741.1	CTD-2292P10.4	-5.04	6.51e-07	0.000172	-0.26	-0.22	Urinary tract infection frequency;	chr8:142710775	chr8:142702252~142726973:-
LUAD	cis	rs2976388	0.609	rs2585150	ENSG00000253741.1	CTD-2292P10.4	-5.04	6.51e-07	0.000172	-0.26	-0.22	Urinary tract infection frequency;	chr8:142711251	chr8:142702252~142726973:-
LUAD	cis	rs2976388	0.609	rs2585149	ENSG00000253741.1	CTD-2292P10.4	-5.04	6.51e-07	0.000172	-0.26	-0.22	Urinary tract infection frequency;	chr8:142711902	chr8:142702252~142726973:-
LUAD	cis	rs9890032	0.52	rs2321926	ENSG00000266490.1	CTD-2349P21.9	5.04	6.51e-07	0.000172	0.21	0.22	Hip circumference adjusted for BMI;	chr17:30714534	chr17:30792372~30792833:+
LUAD	cis	rs2239547	0.522	rs2581801	ENSG00000242142.1	SERBP1P3	-5.04	6.51e-07	0.000172	-0.27	-0.22	Schizophrenia;	chr3:52938891	chr3:53064283~53065091:-
LUAD	cis	rs7927592	0.546	rs497261	ENSG00000212093.1	AP000807.1	5.04	6.51e-07	0.000172	0.24	0.22	Total body bone mineral density;	chr11:68424776	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.546	rs599083	ENSG00000212093.1	AP000807.1	5.04	6.51e-07	0.000172	0.24	0.22	Total body bone mineral density;	chr11:68424878	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.546	rs683978	ENSG00000212093.1	AP000807.1	5.04	6.51e-07	0.000172	0.24	0.22	Total body bone mineral density;	chr11:68424953	chr11:68506083~68506166:-
LUAD	cis	rs783540	0.521	rs1259176	ENSG00000278603.1	RP13-608F4.5	-5.04	6.51e-07	0.000172	-0.29	-0.22	Schizophrenia;	chr15:82602149	chr15:82472203~82472426:+
LUAD	cis	rs116139393	0.54	rs13224907	ENSG00000187953.9	PMS2CL	-5.04	6.51e-07	0.000172	-0.29	-0.22	Alzheimer's disease (APOE e4 interaction);	chr7:6734261	chr7:6710128~6753862:+
LUAD	cis	rs1008375	0.966	rs12509962	ENSG00000249502.1	AC006160.5	-5.04	6.52e-07	0.000172	-0.21	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17678669	chr4:17587467~17614571:-
LUAD	cis	rs2239547	0.603	rs59989280	ENSG00000242142.1	SERBP1P3	5.04	6.52e-07	0.000172	0.27	0.22	Schizophrenia;	chr3:53064859	chr3:53064283~53065091:-
LUAD	cis	rs2239547	0.603	rs6789219	ENSG00000242142.1	SERBP1P3	5.04	6.52e-07	0.000172	0.27	0.22	Schizophrenia;	chr3:53064922	chr3:53064283~53065091:-
LUAD	cis	rs875971	0.522	rs709604	ENSG00000224316.1	RP11-479O9.2	-5.04	6.52e-07	0.000172	-0.23	-0.22	Aortic root size;	chr7:66032447	chr7:65773620~65802067:+
LUAD	cis	rs6687821	0.773	rs12097495	ENSG00000267734.1	RP4-604K5.3	5.04	6.52e-07	0.000172	0.3	0.22	Yeast infection;	chr1:86749925	chr1:86932199~86934891:-
LUAD	cis	rs950169	0.922	rs11631096	ENSG00000259295.5	CSPG4P12	5.04	6.53e-07	0.000172	0.32	0.22	Schizophrenia;	chr15:84557698	chr15:85191438~85213905:+
LUAD	cis	rs375066	0.967	rs436249	ENSG00000267058.1	RP11-15A1.3	-5.04	6.53e-07	0.000172	-0.25	-0.22	Breast cancer;	chr19:43895413	chr19:43891804~43901805:-
LUAD	cis	rs801193	0.761	rs2659888	ENSG00000236529.1	RP13-254B10.1	5.04	6.53e-07	0.000173	0.23	0.22	Aortic root size;	chr7:66765184	chr7:65840212~65840596:+
LUAD	cis	rs853679	1	rs1778511	ENSG00000219392.1	RP1-265C24.5	5.04	6.53e-07	0.000173	0.34	0.22	Depression;	chr6:28261633	chr6:28115628~28116551:+
LUAD	cis	rs6772849	1	rs66910450	ENSG00000242551.2	POU5F1P6	-5.04	6.53e-07	0.000173	-0.26	-0.22	Monocyte percentage of white cells;Monocyte count;	chr3:128585050	chr3:128674735~128677005:-
LUAD	cis	rs2919009	0.537	rs11199606	ENSG00000271670.1	RP11-95I16.4	5.04	6.53e-07	0.000173	0.27	0.22	Obesity-related traits;	chr10:120866005	chr10:120879256~120880667:-
LUAD	cis	rs11051970	0.559	rs11051938	ENSG00000274964.1	RP11-817I4.1	-5.04	6.54e-07	0.000173	-0.29	-0.22	Response to tocilizumab in rheumatoid arthritis;	chr12:32329882	chr12:32339368~32340724:+
LUAD	cis	rs4845875	0.559	rs4846047	ENSG00000242349.4	NPPA-AS1	5.04	6.55e-07	0.000173	0.24	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11783575	chr1:11841017~11848079:+
LUAD	cis	rs17772222	0.958	rs60878614	ENSG00000258983.2	RP11-507K2.2	5.04	6.55e-07	0.000173	0.28	0.22	Coronary artery calcification;	chr14:88513871	chr14:88499334~88515502:+
LUAD	cis	rs12681366	0.881	rs3019149	ENSG00000253704.1	RP11-267M23.4	5.04	6.55e-07	0.000173	0.28	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94418351	chr8:94553722~94569745:+
LUAD	cis	rs6687821	0.834	rs166415	ENSG00000267734.1	RP4-604K5.3	5.04	6.55e-07	0.000173	0.26	0.22	Yeast infection;	chr1:86742117	chr1:86932199~86934891:-
LUAD	cis	rs748404	0.666	rs34515241	ENSG00000205771.5	CATSPER2P1	-5.04	6.55e-07	0.000173	-0.35	-0.22	Lung cancer;	chr15:43342011	chr15:43726918~43747094:-
LUAD	cis	rs71520386	0.632	rs2286509	ENSG00000228649.7	AC005682.5	-5.04	6.56e-07	0.000173	-0.3	-0.22	Fibrinogen levels;	chr7:22814832	chr7:22854178~22861579:+
LUAD	cis	rs11671005	0.735	rs11668420	ENSG00000268912.1	CTD-2619J13.17	-5.04	6.56e-07	0.000173	-0.3	-0.22	Mean platelet volume;	chr19:58426469	chr19:58428632~58431148:-
LUAD	cis	rs1062177	0.855	rs919262	ENSG00000253921.1	CTB-113P19.3	5.04	6.56e-07	0.000173	0.32	0.22	Preschool internalizing problems;	chr5:151886523	chr5:151753992~151767247:+
LUAD	cis	rs61270009	0.955	rs2115884	ENSG00000247828.6	TMEM161B-AS1	5.04	6.56e-07	0.000173	0.27	0.22	Depressive symptoms;	chr5:88358839	chr5:88268895~88436685:+
LUAD	cis	rs4835473	0.864	rs61427459	ENSG00000251600.4	RP11-673E1.1	-5.04	6.56e-07	0.000173	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143699605	chr4:143912331~143982454:+
LUAD	cis	rs1707322	1	rs34444543	ENSG00000280836.1	AL355480.1	-5.04	6.56e-07	0.000173	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893190	chr1:45581219~45581321:-
LUAD	cis	rs5758511	0.68	rs5758651	ENSG00000205702.9	CYP2D7	5.04	6.57e-07	0.000173	0.22	0.22	Birth weight;	chr22:42213142	chr22:42140203~42144577:-
LUAD	cis	rs5758511	0.68	rs5758652	ENSG00000205702.9	CYP2D7	5.04	6.57e-07	0.000173	0.22	0.22	Birth weight;	chr22:42216402	chr22:42140203~42144577:-
LUAD	cis	rs11671005	0.651	rs11878203	ENSG00000268912.1	CTD-2619J13.17	-5.04	6.57e-07	0.000173	-0.3	-0.22	Mean platelet volume;	chr19:58408683	chr19:58428632~58431148:-
LUAD	cis	rs74233809	1	rs11191499	ENSG00000213277.3	MARCKSL1P1	5.04	6.57e-07	0.000173	0.36	0.22	Birth weight;	chr10:103004514	chr10:103175554~103176094:+
LUAD	cis	rs10935480	0.935	rs4857414	ENSG00000249274.1	PDLIM1P4	-5.04	6.57e-07	0.000173	-0.24	-0.22	Blood protein levels;	chr3:98713715	chr3:98782188~98783193:+
LUAD	cis	rs11671005	0.57	rs73062110	ENSG00000268912.1	CTD-2619J13.17	-5.04	6.58e-07	0.000174	-0.3	-0.22	Mean platelet volume;	chr19:58425275	chr19:58428632~58431148:-
LUAD	cis	rs673078	0.607	rs7294498	ENSG00000275409.1	RP11-131L12.4	-5.04	6.58e-07	0.000174	-0.29	-0.22	Glucose homeostasis traits;	chr12:118321680	chr12:118430147~118430699:+
LUAD	cis	rs9322193	0.926	rs9689036	ENSG00000268592.3	RAET1E-AS1	5.04	6.58e-07	0.000174	0.28	0.22	Lung cancer;	chr6:149780563	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.962	rs9322218	ENSG00000268592.3	RAET1E-AS1	5.04	6.58e-07	0.000174	0.28	0.22	Lung cancer;	chr6:149782183	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.962	rs9322219	ENSG00000268592.3	RAET1E-AS1	5.04	6.58e-07	0.000174	0.28	0.22	Lung cancer;	chr6:149782263	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.962	rs9322223	ENSG00000268592.3	RAET1E-AS1	5.04	6.58e-07	0.000174	0.28	0.22	Lung cancer;	chr6:149801509	chr6:149863494~149919507:+
LUAD	cis	rs2836950	0.501	rs11702505	ENSG00000255568.3	BRWD1-AS2	-5.04	6.58e-07	0.000174	-0.22	-0.22	Menarche (age at onset);	chr21:39328688	chr21:39313935~39314962:+
LUAD	cis	rs2836950	0.501	rs2836985	ENSG00000255568.3	BRWD1-AS2	-5.04	6.58e-07	0.000174	-0.22	-0.22	Menarche (age at onset);	chr21:39329243	chr21:39313935~39314962:+
LUAD	cis	rs5758659	0.904	rs134877	ENSG00000182057.4	OGFRP1	5.04	6.58e-07	0.000174	0.26	0.22	Cognitive function;	chr22:42266365	chr22:42269753~42275196:+
LUAD	cis	rs896854	0.818	rs896855	ENSG00000253528.2	RP11-347C18.4	5.04	6.58e-07	0.000174	0.22	0.22	Type 2 diabetes;	chr8:94947580	chr8:94974573~94974853:-
LUAD	cis	rs896854	0.936	rs10108430	ENSG00000253528.2	RP11-347C18.4	5.04	6.58e-07	0.000174	0.22	0.22	Type 2 diabetes;	chr8:94949566	chr8:94974573~94974853:-
LUAD	cis	rs394563	0.726	rs6942381	ENSG00000231760.4	RP11-350J20.5	-5.04	6.58e-07	0.000174	-0.27	-0.22	Dupuytren's disease;	chr6:149341855	chr6:149796151~149826294:-
LUAD	cis	rs1729951	0.575	rs361237	ENSG00000239213.4	NCK1-AS1	5.04	6.59e-07	0.000174	0.25	0.22	Neuroticism;	chr3:136983572	chr3:136841726~136862054:-
LUAD	cis	rs36093844	0.66	rs1445500	ENSG00000279742.1	RP11-700A24.1	-5.04	6.59e-07	0.000174	-0.31	-0.22	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85831439	chr11:85852557~85854943:-
LUAD	cis	rs6543140	0.964	rs6543144	ENSG00000234389.1	AC007278.3	5.04	6.59e-07	0.000174	0.22	0.22	Blood protein levels;	chr2:102476116	chr2:102438713~102440475:+
LUAD	cis	rs11089937	0.568	rs6001078	ENSG00000211638.2	IGLV8-61	-5.04	6.6e-07	0.000174	-0.26	-0.22	Periodontitis (PAL4Q3);	chr22:22134365	chr22:22098700~22099212:+
LUAD	cis	rs4664293	0.764	rs1425044	ENSG00000226266.5	AC009961.3	-5.04	6.6e-07	0.000174	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159618426	chr2:159670708~159712435:-
LUAD	cis	rs453301	0.686	rs1045527	ENSG00000253893.2	FAM85B	5.04	6.6e-07	0.000174	0.29	0.22	Joint mobility (Beighton score);	chr8:9032531	chr8:8167819~8226614:-
LUAD	cis	rs2933343	0.7	rs789240	ENSG00000261159.1	RP11-723O4.9	5.04	6.6e-07	0.000174	0.24	0.22	IgG glycosylation;	chr3:128911792	chr3:128859716~128860526:-
LUAD	cis	rs1062177	1	rs2915882	ENSG00000253921.1	CTB-113P19.3	-5.04	6.6e-07	0.000174	-0.33	-0.22	Preschool internalizing problems;	chr5:151765875	chr5:151753992~151767247:+
LUAD	cis	rs8050896	1	rs7191644	ENSG00000260695.1	RP11-513N24.1	-5.04	6.6e-07	0.000174	-0.37	-0.22	Response to antipsychotic treatment;	chr16:66124591	chr16:65861112~65863784:-
LUAD	cis	rs8050896	1	rs6499062	ENSG00000260695.1	RP11-513N24.1	-5.04	6.6e-07	0.000174	-0.37	-0.22	Response to antipsychotic treatment;	chr16:66124758	chr16:65861112~65863784:-
LUAD	cis	rs7208859	0.623	rs73271869	ENSG00000280069.1	CTD-2349P21.3	-5.04	6.6e-07	0.000174	-0.31	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825203	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs73271872	ENSG00000280069.1	CTD-2349P21.3	-5.04	6.6e-07	0.000174	-0.31	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825210	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs56146117	ENSG00000280069.1	CTD-2349P21.3	-5.04	6.6e-07	0.000174	-0.31	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826307	chr17:30738182~30740275:+
LUAD	cis	rs17826219	0.568	rs9907834	ENSG00000280069.1	CTD-2349P21.3	-5.04	6.6e-07	0.000174	-0.31	-0.22	Body mass index;	chr17:30826995	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs73271887	ENSG00000280069.1	CTD-2349P21.3	-5.04	6.6e-07	0.000174	-0.31	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827917	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs9898858	ENSG00000280069.1	CTD-2349P21.3	-5.04	6.6e-07	0.000174	-0.31	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829193	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs55658077	ENSG00000280069.1	CTD-2349P21.3	-5.04	6.6e-07	0.000174	-0.31	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829501	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs9899692	ENSG00000280069.1	CTD-2349P21.3	-5.04	6.6e-07	0.000174	-0.31	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829921	chr17:30738182~30740275:+
LUAD	cis	rs477895	1	rs477895	ENSG00000236935.1	AP003774.1	5.04	6.61e-07	0.000174	0.26	0.22	Mean platelet volume;	chr11:64281440	chr11:64325050~64329504:-
LUAD	cis	rs4141404	0.74	rs4820946	ENSG00000236132.1	CTA-440B3.1	-5.04	6.61e-07	0.000174	-0.28	-0.22	Paclitaxel-induced neuropathy;	chr22:31155174	chr22:31816379~31817491:-
LUAD	cis	rs56318008	0.773	rs3754496	ENSG00000228397.1	RP1-224A6.3	-5.04	6.61e-07	0.000174	-0.38	-0.22	Total body bone mineral density;Gestational age at birth (maternal effect);	chr1:22052387	chr1:22023994~22024968:-
LUAD	cis	rs36093844	0.752	rs79516304	ENSG00000279742.1	RP11-700A24.1	-5.04	6.61e-07	0.000174	-0.3	-0.22	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85836192	chr11:85852557~85854943:-
LUAD	cis	rs11673344	0.932	rs76350084	ENSG00000226686.6	LINC01535	5.04	6.62e-07	0.000175	0.29	0.22	Obesity-related traits;	chr19:37187917	chr19:37251912~37265535:+
LUAD	cis	rs10129255	0.536	rs10139058	ENSG00000254174.1	IGHV1-12	5.04	6.62e-07	0.000175	0.15	0.22	Kawasaki disease;	chr14:106685899	chr14:106122420~106122709:-
LUAD	cis	rs7923837	1	rs7087591	ENSG00000236493.2	EIF2S2P3	5.04	6.62e-07	0.000175	0.26	0.22	Multiple sclerosis;Body mass index;	chr10:92713872	chr10:92668745~92669743:-
LUAD	cis	rs12745968	0.62	rs11164607	ENSG00000223787.2	RP4-593M8.1	-5.04	6.63e-07	0.000175	-0.28	-0.22	Bipolar disorder and schizophrenia;	chr1:92481581	chr1:92580476~92580821:-
LUAD	cis	rs1816752	0.905	rs7991450	ENSG00000273628.1	RP11-756A22.7	5.04	6.63e-07	0.000175	0.25	0.22	Obesity-related traits;	chr13:24425898	chr13:24933006~24936796:+
LUAD	cis	rs1816752	0.774	rs7986162	ENSG00000273628.1	RP11-756A22.7	5.04	6.63e-07	0.000175	0.25	0.22	Obesity-related traits;	chr13:24425941	chr13:24933006~24936796:+
LUAD	cis	rs1075265	0.553	rs2692532	ENSG00000233266.1	HMGB1P31	5.04	6.64e-07	0.000175	0.29	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53778962	chr2:54051334~54051760:+
LUAD	cis	rs875971	0.66	rs10229345	ENSG00000237310.1	GS1-124K5.4	5.04	6.64e-07	0.000175	0.24	0.22	Aortic root size;	chr7:66517181	chr7:66493706~66495474:+
LUAD	cis	rs9322193	0.923	rs6913486	ENSG00000268592.3	RAET1E-AS1	-5.04	6.64e-07	0.000175	-0.28	-0.22	Lung cancer;	chr6:149705060	chr6:149863494~149919507:+
LUAD	cis	rs2880765	0.546	rs8042776	ENSG00000259416.2	RP11-158M2.5	5.04	6.65e-07	0.000175	0.24	0.22	Coronary artery disease;	chr15:85512398	chr15:85754941~85756237:-
LUAD	cis	rs1799949	0.93	rs33968979	ENSG00000236383.6	LINC00854	-5.04	6.65e-07	0.000175	-0.18	-0.22	Menopause (age at onset);	chr17:43145975	chr17:43216941~43305976:-
LUAD	cis	rs8098244	0.66	rs12970745	ENSG00000264745.1	TTC39C-AS1	5.04	6.65e-07	0.000175	0.23	0.22	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23908142	chr18:23994213~24015339:-
LUAD	cis	rs7017914	0.549	rs3098863	ENSG00000223220.1	Y_RNA	5.04	6.65e-07	0.000175	0.26	0.22	Bone mineral density;	chr8:70965931	chr8:70780914~70781008:-
LUAD	cis	rs7829975	0.659	rs4382480	ENSG00000173295.6	FAM86B3P	5.04	6.66e-07	0.000176	0.23	0.22	Mood instability;	chr8:8863963	chr8:8228595~8244865:+
LUAD	cis	rs17826219	0.585	rs8064302	ENSG00000263531.1	RP13-753N3.1	-5.04	6.66e-07	0.000176	-0.44	-0.22	Body mass index;	chr17:30397920	chr17:30863921~30864940:-
LUAD	cis	rs891378	1	rs7545125	ENSG00000274245.1	RP11-357P18.2	-5.04	6.67e-07	0.000176	-0.29	-0.22	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207251382	chr1:207372559~207373252:+
LUAD	cis	rs172166	0.516	rs1150670	ENSG00000219392.1	RP1-265C24.5	-5.04	6.67e-07	0.000176	-0.28	-0.22	Cardiac Troponin-T levels;	chr6:28162781	chr6:28115628~28116551:+
LUAD	cis	rs172166	0.516	rs2021826	ENSG00000219392.1	RP1-265C24.5	-5.04	6.67e-07	0.000176	-0.28	-0.22	Cardiac Troponin-T levels;	chr6:28164978	chr6:28115628~28116551:+
LUAD	cis	rs2295359	0.892	rs12401432	ENSG00000275678.1	RP4-547N15.3	-5.04	6.67e-07	0.000176	-0.24	-0.22	Psoriasis;	chr1:67191248	chr1:67121605~67123956:-
LUAD	cis	rs875971	0.862	rs4718383	ENSG00000232559.3	GS1-124K5.12	-5.04	6.67e-07	0.000176	-0.27	-0.22	Aortic root size;	chr7:66643422	chr7:66554588~66576923:-
LUAD	cis	rs1345301	0.518	rs17689452	ENSG00000234389.1	AC007278.3	-5.04	6.67e-07	0.000176	-0.21	-0.22	Waist circumference;	chr2:102248221	chr2:102438713~102440475:+
LUAD	cis	rs1799949	1	rs8176109	ENSG00000236383.6	LINC00854	-5.04	6.68e-07	0.000176	-0.18	-0.22	Menopause (age at onset);	chr17:43113759	chr17:43216941~43305976:-
LUAD	cis	rs11671005	0.735	rs11667591	ENSG00000268912.1	CTD-2619J13.17	-5.04	6.69e-07	0.000176	-0.3	-0.22	Mean platelet volume;	chr19:58426270	chr19:58428632~58431148:-
LUAD	cis	rs4908760	0.965	rs301814	ENSG00000270282.1	RP5-1115A15.2	5.04	6.69e-07	0.000176	0.25	0.22	Vitiligo;	chr1:8450517	chr1:8512653~8513021:+
LUAD	cis	rs7937890	0.559	rs2575829	ENSG00000251991.1	RNU7-49P	5.04	6.7e-07	0.000176	0.24	0.22	Mitochondrial DNA levels;	chr11:14463475	chr11:14478892~14478953:+
LUAD	cis	rs7937890	0.559	rs2597200	ENSG00000251991.1	RNU7-49P	5.04	6.7e-07	0.000176	0.24	0.22	Mitochondrial DNA levels;	chr11:14464054	chr11:14478892~14478953:+
LUAD	cis	rs7937890	0.559	rs2575830	ENSG00000251991.1	RNU7-49P	5.04	6.7e-07	0.000176	0.24	0.22	Mitochondrial DNA levels;	chr11:14464056	chr11:14478892~14478953:+
LUAD	cis	rs7937890	0.559	rs2575831	ENSG00000251991.1	RNU7-49P	5.04	6.7e-07	0.000176	0.24	0.22	Mitochondrial DNA levels;	chr11:14464648	chr11:14478892~14478953:+
LUAD	cis	rs7937890	0.559	rs2597197	ENSG00000251991.1	RNU7-49P	5.04	6.7e-07	0.000176	0.24	0.22	Mitochondrial DNA levels;	chr11:14468286	chr11:14478892~14478953:+
LUAD	cis	rs2286503	0.966	rs6949233	ENSG00000226329.2	AC005682.6	5.04	6.7e-07	0.000176	0.28	0.22	Fibrinogen;	chr7:22818572	chr7:22863874~22881350:-
LUAD	cis	rs8077577	0.747	rs62072509	ENSG00000273018.4	CTD-2303H24.2	-5.04	6.7e-07	0.000176	-0.31	-0.22	Obesity-related traits;	chr17:18279079	chr17:18511221~18551705:-
LUAD	cis	rs12745968	0.589	rs10747446	ENSG00000223787.2	RP4-593M8.1	-5.04	6.7e-07	0.000176	-0.26	-0.22	Bipolar disorder and schizophrenia;	chr1:92642845	chr1:92580476~92580821:-
LUAD	cis	rs2404602	0.536	rs17364330	ENSG00000259422.1	RP11-593F23.1	5.04	6.7e-07	0.000177	0.25	0.22	Blood metabolite levels;	chr15:76473044	chr15:76174891~76181486:-
LUAD	cis	rs950169	0.763	rs35372971	ENSG00000229212.6	RP11-561C5.4	-5.04	6.7e-07	0.000177	-0.32	-0.22	Schizophrenia;	chr15:84387097	chr15:85205440~85234795:-
LUAD	cis	rs853679	0.538	rs13199081	ENSG00000216901.1	AL022393.7	5.04	6.7e-07	0.000177	0.28	0.22	Depression;	chr6:28364057	chr6:28176188~28176674:+
LUAD	cis	rs2028299	0.919	rs12440156	ENSG00000259677.1	RP11-493E3.1	5.04	6.71e-07	0.000177	0.27	0.22	Type 2 diabetes;	chr15:89877441	chr15:89876540~89877285:+
LUAD	cis	rs36093844	0.706	rs7931771	ENSG00000279742.1	RP11-700A24.1	-5.04	6.71e-07	0.000177	-0.3	-0.22	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85838845	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.752	rs7931698	ENSG00000279742.1	RP11-700A24.1	-5.04	6.71e-07	0.000177	-0.3	-0.22	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85838883	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.706	rs76407487	ENSG00000279742.1	RP11-700A24.1	-5.04	6.71e-07	0.000177	-0.3	-0.22	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85839589	chr11:85852557~85854943:-
LUAD	cis	rs858239	0.6	rs10241208	ENSG00000230042.1	AK3P3	-5.04	6.71e-07	0.000177	-0.28	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23129178~23129841:+
LUAD	cis	rs950169	0.58	rs17532346	ENSG00000275120.1	RP11-182J1.17	5.04	6.71e-07	0.000177	0.34	0.22	Schizophrenia;	chr15:84628264	chr15:84599434~84606463:-
LUAD	cis	rs2911132	0.66	rs754615	ENSG00000248734.2	CTD-2260A17.1	5.04	6.72e-07	0.000177	0.22	0.22	Urate levels (BMI interaction);	chr5:96750630	chr5:96784777~96785999:+
LUAD	cis	rs6687758	0.687	rs11118902	ENSG00000228437.4	RP11-400N13.2	5.04	6.72e-07	0.000177	0.32	0.22	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221932275	chr1:221966341~221984964:+
LUAD	cis	rs11155671	0.53	rs4458704	ENSG00000268592.3	RAET1E-AS1	5.04	6.72e-07	0.000177	0.27	0.22	Testicular germ cell tumor;	chr6:149911743	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.961	rs9767713	ENSG00000268592.3	RAET1E-AS1	5.04	6.72e-07	0.000177	0.28	0.22	Lung cancer;	chr6:149588241	chr6:149863494~149919507:+
LUAD	cis	rs1816752	0.719	rs11841989	ENSG00000273628.1	RP11-756A22.7	5.04	6.72e-07	0.000177	0.25	0.22	Obesity-related traits;	chr13:24423560	chr13:24933006~24936796:+
LUAD	cis	rs12681366	0.761	rs2197003	ENSG00000253704.1	RP11-267M23.4	5.04	6.73e-07	0.000177	0.27	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94444758	chr8:94553722~94569745:+
LUAD	cis	rs12681366	0.801	rs2921386	ENSG00000253704.1	RP11-267M23.4	5.04	6.73e-07	0.000177	0.27	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94446672	chr8:94553722~94569745:+
LUAD	cis	rs1816752	0.583	rs6490918	ENSG00000273628.1	RP11-756A22.7	-5.04	6.73e-07	0.000177	-0.26	-0.22	Obesity-related traits;	chr13:24427977	chr13:24933006~24936796:+
LUAD	cis	rs7772486	0.754	rs2328709	ENSG00000235652.6	RP11-545I5.3	-5.04	6.73e-07	0.000177	-0.22	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145785683	chr6:145799409~145886585:+
LUAD	cis	rs7208859	0.623	rs55724095	ENSG00000280069.1	CTD-2349P21.3	-5.04	6.74e-07	0.000177	-0.3	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826040	chr17:30738182~30740275:+
LUAD	cis	rs17826219	0.568	rs9903854	ENSG00000280069.1	CTD-2349P21.3	-5.04	6.74e-07	0.000177	-0.3	-0.22	Body mass index;	chr17:30826980	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs80355557	ENSG00000280069.1	CTD-2349P21.3	-5.04	6.74e-07	0.000177	-0.3	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827403	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs9911173	ENSG00000280069.1	CTD-2349P21.3	-5.04	6.74e-07	0.000177	-0.3	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827732	chr17:30738182~30740275:+
LUAD	cis	rs5758659	0.714	rs6002607	ENSG00000227370.1	RP4-669P10.19	5.04	6.74e-07	0.000178	0.2	0.22	Cognitive function;	chr22:42100502	chr22:42132543~42132998:+
LUAD	cis	rs4835473	0.932	rs12512652	ENSG00000251600.4	RP11-673E1.1	-5.04	6.74e-07	0.000178	-0.27	-0.22	Immature fraction of reticulocytes;	chr4:143736787	chr4:143912331~143982454:+
LUAD	cis	rs3738443	0.951	rs61840467	ENSG00000259865.1	RP11-488L18.10	5.04	6.75e-07	0.000178	0.24	0.22	Alcohol dependence;	chr1:247216936	chr1:247187281~247188526:-
LUAD	cis	rs712039	0.565	rs1714988	ENSG00000276054.1	RP11-378E13.3	5.04	6.75e-07	0.000178	0.34	0.22	Tuberculosis;	chr17:37387113	chr17:37386886~37387926:+
LUAD	cis	rs4835473	0.932	rs13107719	ENSG00000251600.4	RP11-673E1.1	-5.04	6.75e-07	0.000178	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143752034	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.897	rs2323194	ENSG00000251600.4	RP11-673E1.1	-5.04	6.75e-07	0.000178	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143752879	chr4:143912331~143982454:+
LUAD	cis	rs34779708	0.931	rs10437420	ENSG00000271335.4	RP11-324I22.4	-5.04	6.76e-07	0.000178	-0.23	-0.22	Inflammatory bowel disease;Crohn's disease;	chr10:35046116	chr10:35314552~35336401:-
LUAD	cis	rs9987353	0.589	rs1053036	ENSG00000253893.2	FAM85B	5.04	6.76e-07	0.000178	0.28	0.22	Recombination measurement;	chr8:9202567	chr8:8167819~8226614:-
LUAD	cis	rs910316	1	rs4322591	ENSG00000259138.1	RP11-950C14.7	5.04	6.76e-07	0.000178	0.24	0.22	Height;	chr14:75133994	chr14:75127153~75136930:+
LUAD	cis	rs7017914	0.523	rs10504497	ENSG00000223220.1	Y_RNA	-5.04	6.76e-07	0.000178	-0.26	-0.22	Bone mineral density;	chr8:71096652	chr8:70780914~70781008:-
LUAD	cis	rs12745968	0.623	rs4847432	ENSG00000223787.2	RP4-593M8.1	-5.04	6.76e-07	0.000178	-0.26	-0.22	Bipolar disorder and schizophrenia;	chr1:92653327	chr1:92580476~92580821:-
LUAD	cis	rs1816752	0.837	rs7324645	ENSG00000273628.1	RP11-756A22.7	5.04	6.77e-07	0.000178	0.25	0.22	Obesity-related traits;	chr13:24426717	chr13:24933006~24936796:+
LUAD	cis	rs12468226	1	rs57080353	ENSG00000226261.1	AC064836.3	5.03	6.77e-07	0.000178	0.36	0.22	Urate levels;	chr2:202511824	chr2:202336024~202336727:-
LUAD	cis	rs12468226	0.81	rs3736578	ENSG00000226261.1	AC064836.3	5.03	6.77e-07	0.000178	0.36	0.22	Urate levels;	chr2:202519989	chr2:202336024~202336727:-
LUAD	cis	rs12468226	1	rs116439150	ENSG00000226261.1	AC064836.3	5.03	6.77e-07	0.000178	0.36	0.22	Urate levels;	chr2:202523814	chr2:202336024~202336727:-
LUAD	cis	rs12468226	1	rs12467409	ENSG00000226261.1	AC064836.3	5.03	6.77e-07	0.000178	0.36	0.22	Urate levels;	chr2:202529625	chr2:202336024~202336727:-
LUAD	cis	rs12468226	0.81	rs77090459	ENSG00000226261.1	AC064836.3	5.03	6.77e-07	0.000178	0.36	0.22	Urate levels;	chr2:202542132	chr2:202336024~202336727:-
LUAD	cis	rs11157436	0.918	rs12437004	ENSG00000211812.1	TRAV26-2	-5.03	6.78e-07	0.000178	-0.24	-0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22149461	chr14:22202583~22203368:+
LUAD	cis	rs4908768	0.501	rs11121199	ENSG00000270282.1	RP5-1115A15.2	5.03	6.78e-07	0.000178	0.25	0.22	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8540133	chr1:8512653~8513021:+
LUAD	cis	rs1150668	0.835	rs1233696	ENSG00000219392.1	RP1-265C24.5	-5.03	6.78e-07	0.000179	-0.28	-0.22	Pubertal anthropometrics;	chr6:28175232	chr6:28115628~28116551:+
LUAD	cis	rs763567	1	rs61217505	ENSG00000271811.1	RP1-79C4.4	-5.03	6.79e-07	0.000179	-0.27	-0.22	Tonsillectomy;	chr1:170604117	chr1:170667381~170669425:+
LUAD	cis	rs11700536	0.54	rs8132259	ENSG00000236663.1	AP001631.9	5.03	6.79e-07	0.000179	0.25	0.22	Interleukin-18 levels;	chr21:43129548	chr21:43140523~43141092:-
LUAD	cis	rs17818399	0.926	rs1824050	ENSG00000279254.1	RP11-536C12.1	-5.03	6.79e-07	0.000179	-0.26	-0.22	Height;	chr2:46612338	chr2:46668870~46670778:+
LUAD	cis	rs17818399	0.926	rs1378764	ENSG00000279254.1	RP11-536C12.1	-5.03	6.79e-07	0.000179	-0.26	-0.22	Height;	chr2:46612542	chr2:46668870~46670778:+
LUAD	cis	rs7208859	0.524	rs73263982	ENSG00000263531.1	RP13-753N3.1	5.03	6.79e-07	0.000179	0.38	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593606	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.623	rs216433	ENSG00000263531.1	RP13-753N3.1	5.03	6.79e-07	0.000179	0.38	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30594842	chr17:30863921~30864940:-
LUAD	cis	rs7208859	0.673	rs216435	ENSG00000263531.1	RP13-753N3.1	5.03	6.79e-07	0.000179	0.38	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595719	chr17:30863921~30864940:-
LUAD	cis	rs910316	1	rs10146482	ENSG00000259138.1	RP11-950C14.7	5.03	6.79e-07	0.000179	0.24	0.22	Height;	chr14:75107384	chr14:75127153~75136930:+
LUAD	cis	rs950169	0.58	rs11630887	ENSG00000275120.1	RP11-182J1.17	5.03	6.79e-07	0.000179	0.34	0.22	Schizophrenia;	chr15:84649784	chr15:84599434~84606463:-
LUAD	cis	rs12468226	0.873	rs2350358	ENSG00000272966.1	RP11-686O6.1	-5.03	6.8e-07	0.000179	-0.36	-0.22	Urate levels;	chr2:202199771	chr2:202336739~202337200:+
LUAD	cis	rs1799949	1	rs8176273	ENSG00000236383.6	LINC00854	-5.03	6.8e-07	0.000179	-0.18	-0.22	Menopause (age at onset);	chr17:43059636	chr17:43216941~43305976:-
LUAD	cis	rs6504249	0.893	rs2521827	ENSG00000270714.1	MINOS1P2	-5.03	6.8e-07	0.000179	-0.31	-0.22	Joint mobility (Beighton score);	chr17:64696610	chr17:64747264~64747492:-
LUAD	cis	rs12745968	0.652	rs10782912	ENSG00000223787.2	RP4-593M8.1	-5.03	6.8e-07	0.000179	-0.28	-0.22	Bipolar disorder and schizophrenia;	chr1:92491355	chr1:92580476~92580821:-
LUAD	cis	rs61270009	0.955	rs10214154	ENSG00000247828.6	TMEM161B-AS1	-5.03	6.8e-07	0.000179	-0.25	-0.22	Depressive symptoms;	chr5:88249502	chr5:88268895~88436685:+
LUAD	cis	rs4835473	0.864	rs57137521	ENSG00000251600.4	RP11-673E1.1	-5.03	6.8e-07	0.000179	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143704045	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.897	rs55945293	ENSG00000251600.4	RP11-673E1.1	-5.03	6.8e-07	0.000179	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143704766	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.897	rs7695328	ENSG00000251600.4	RP11-673E1.1	5.03	6.8e-07	0.000179	0.28	0.22	Immature fraction of reticulocytes;	chr4:143703768	chr4:143912331~143982454:+
LUAD	cis	rs2749097	0.825	rs35477997	ENSG00000244256.3	RN7SL130P	-5.03	6.8e-07	0.000179	-0.27	-0.22	Alcohol consumption (transferrin glycosylation);	chr1:63656834	chr1:63655743~63656047:+
LUAD	cis	rs9322193	0.923	rs55993747	ENSG00000268592.3	RAET1E-AS1	5.03	6.81e-07	0.000179	0.28	0.22	Lung cancer;	chr6:149622016	chr6:149863494~149919507:+
LUAD	cis	rs5758659	1	rs134873	ENSG00000182057.4	OGFRP1	5.03	6.81e-07	0.000179	0.26	0.22	Cognitive function;	chr22:42261560	chr22:42269753~42275196:+
LUAD	cis	rs9322193	0.962	rs9689447	ENSG00000268592.3	RAET1E-AS1	5.03	6.81e-07	0.000179	0.28	0.22	Lung cancer;	chr6:149789350	chr6:149863494~149919507:+
LUAD	cis	rs2286503	0.839	rs2240728	ENSG00000221740.1	SNORD93	5.03	6.82e-07	0.000179	0.26	0.22	Fibrinogen;	chr7:22812880	chr7:22856613~22856686:+
LUAD	cis	rs7116495	1	rs3018301	ENSG00000254682.1	RP11-660L16.2	5.03	6.82e-07	0.000179	0.44	0.22	Severe influenza A (H1N1) infection;	chr11:72081025	chr11:71448674~71452157:+
LUAD	cis	rs875971	0.862	rs1860469	ENSG00000232559.3	GS1-124K5.12	-5.03	6.82e-07	0.000179	-0.27	-0.22	Aortic root size;	chr7:66641888	chr7:66554588~66576923:-
LUAD	cis	rs6723226	0.698	rs13409142	ENSG00000276334.1	AL133243.1	5.03	6.82e-07	0.000179	0.26	0.22	Intelligence (multi-trait analysis);	chr2:32441069	chr2:32521927~32523547:+
LUAD	cis	rs7937890	0.559	rs2597201	ENSG00000251991.1	RNU7-49P	5.03	6.82e-07	0.000179	0.24	0.22	Mitochondrial DNA levels;	chr11:14463858	chr11:14478892~14478953:+
LUAD	cis	rs7937890	0.532	rs2575832	ENSG00000251991.1	RNU7-49P	5.03	6.82e-07	0.000179	0.24	0.22	Mitochondrial DNA levels;	chr11:14467264	chr11:14478892~14478953:+
LUAD	cis	rs36093844	0.706	rs17817230	ENSG00000279742.1	RP11-700A24.1	-5.03	6.83e-07	0.000179	-0.3	-0.22	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85843014	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.706	rs76504433	ENSG00000279742.1	RP11-700A24.1	-5.03	6.83e-07	0.000179	-0.3	-0.22	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85843217	chr11:85852557~85854943:-
LUAD	cis	rs1008375	0.966	rs2315645	ENSG00000249502.1	AC006160.5	-5.03	6.83e-07	0.00018	-0.22	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17578055	chr4:17587467~17614571:-
LUAD	cis	rs3747113	1	rs13056719	ENSG00000128262.7	POM121L9P	-5.03	6.83e-07	0.00018	-0.25	-0.22	Gut microbiome composition (summer);	chr22:24328131	chr22:24251828~24265525:+
LUAD	cis	rs3738443	0.951	rs4582838	ENSG00000259865.1	RP11-488L18.10	5.03	6.84e-07	0.00018	0.25	0.22	Alcohol dependence;	chr1:247210269	chr1:247187281~247188526:-
LUAD	cis	rs12468226	0.752	rs79058237	ENSG00000226261.1	AC064836.3	5.03	6.84e-07	0.00018	0.36	0.22	Urate levels;	chr2:202140247	chr2:202336024~202336727:-
LUAD	cis	rs36093844	0.706	rs7102361	ENSG00000279742.1	RP11-700A24.1	-5.03	6.85e-07	0.00018	-0.3	-0.22	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85849096	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.706	rs75217143	ENSG00000279742.1	RP11-700A24.1	-5.03	6.85e-07	0.00018	-0.3	-0.22	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85851227	chr11:85852557~85854943:-
LUAD	cis	rs2898290	0.5	rs11998678	ENSG00000255046.1	RP11-297N6.4	5.03	6.85e-07	0.00018	0.28	0.22	Systolic blood pressure;	chr8:11972641	chr8:11797928~11802568:-
LUAD	cis	rs2115536	1	rs2115536	ENSG00000278600.1	RP11-81A1.6	-5.03	6.85e-07	0.00018	-0.18	-0.22	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79901905	chr15:79920195~79922455:-
LUAD	cis	rs6840360	0.593	rs4696103	ENSG00000270265.1	RP11-731D1.4	-5.03	6.86e-07	0.00018	-0.25	-0.22	Intelligence (multi-trait analysis);	chr4:151643459	chr4:151333775~151353224:-
LUAD	cis	rs7937890	0.532	rs2575833	ENSG00000251991.1	RNU7-49P	5.03	6.86e-07	0.00018	0.24	0.22	Mitochondrial DNA levels;	chr11:14470959	chr11:14478892~14478953:+
LUAD	cis	rs9322193	0.884	rs9371201	ENSG00000268592.3	RAET1E-AS1	5.03	6.87e-07	0.00018	0.3	0.22	Lung cancer;	chr6:149823865	chr6:149863494~149919507:+
LUAD	cis	rs736801	0.808	rs2522057	ENSG00000233006.5	AC034220.3	5.03	6.87e-07	0.000181	0.2	0.22	Mosquito bite size;Breast cancer;	chr5:132466255	chr5:132311285~132369916:-
LUAD	cis	rs7829975	0.774	rs57312668	ENSG00000253981.4	ALG1L13P	5.03	6.87e-07	0.000181	0.26	0.22	Mood instability;	chr8:8822967	chr8:8236003~8244667:-
LUAD	cis	rs116095464	1	rs62330028	ENSG00000277812.1	AC021087.1	5.03	6.88e-07	0.000181	0.67	0.22	Breast cancer;	chr5:319042	chr5:262769~262881:+
LUAD	cis	rs6570726	0.818	rs437978	ENSG00000235652.6	RP11-545I5.3	5.03	6.88e-07	0.000181	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145487998	chr6:145799409~145886585:+
LUAD	cis	rs4835473	0.932	rs6826665	ENSG00000251600.4	RP11-673E1.1	-5.03	6.88e-07	0.000181	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143795140	chr4:143912331~143982454:+
LUAD	cis	rs2836950	0.501	rs2836980	ENSG00000255568.3	BRWD1-AS2	-5.03	6.88e-07	0.000181	-0.22	-0.22	Menarche (age at onset);	chr21:39315692	chr21:39313935~39314962:+
LUAD	cis	rs2836950	0.501	rs11088470	ENSG00000255568.3	BRWD1-AS2	-5.03	6.88e-07	0.000181	-0.22	-0.22	Menarche (age at onset);	chr21:39317236	chr21:39313935~39314962:+
LUAD	cis	rs2836950	0.501	rs2836983	ENSG00000255568.3	BRWD1-AS2	-5.03	6.88e-07	0.000181	-0.22	-0.22	Menarche (age at onset);	chr21:39317410	chr21:39313935~39314962:+
LUAD	cis	rs12745968	0.589	rs12025792	ENSG00000223787.2	RP4-593M8.1	-5.03	6.89e-07	0.000181	-0.26	-0.22	Bipolar disorder and schizophrenia;	chr1:92641851	chr1:92580476~92580821:-
LUAD	cis	rs1008375	1	rs10440301	ENSG00000249502.1	AC006160.5	-5.03	6.89e-07	0.000181	-0.21	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17661576	chr4:17587467~17614571:-
LUAD	cis	rs61270009	0.955	rs6872223	ENSG00000247828.6	TMEM161B-AS1	5.03	6.89e-07	0.000181	0.25	0.22	Depressive symptoms;	chr5:88306555	chr5:88268895~88436685:+
LUAD	cis	rs10129255	0.5	rs988132	ENSG00000254174.1	IGHV1-12	5.03	6.89e-07	0.000181	0.15	0.22	Kawasaki disease;	chr14:106776758	chr14:106122420~106122709:-
LUAD	cis	rs7580658	0.895	rs7589451	ENSG00000236682.1	AC068282.3	-5.03	6.89e-07	0.000181	-0.3	-0.22	Protein C levels;	chr2:127371199	chr2:127389130~127400580:+
LUAD	cis	rs9807989	0.839	rs1362348	ENSG00000234389.1	AC007278.3	5.03	6.9e-07	0.000181	0.22	0.22	Asthma;	chr2:102368164	chr2:102438713~102440475:+
LUAD	cis	rs10129255	0.833	rs7156689	ENSG00000211967.3	IGHV3-53	-5.03	6.9e-07	0.000181	-0.17	-0.22	Kawasaki disease;	chr14:106816039	chr14:106592676~106593347:-
LUAD	cis	rs9309473	0.687	rs6710659	ENSG00000163016.8	ALMS1P	5.03	6.91e-07	0.000181	0.25	0.22	Metabolite levels;	chr2:73380382	chr2:73644919~73685576:+
LUAD	cis	rs8077577	0.747	rs62072511	ENSG00000273018.4	CTD-2303H24.2	-5.03	6.91e-07	0.000181	-0.31	-0.22	Obesity-related traits;	chr17:18289843	chr17:18511221~18551705:-
LUAD	cis	rs7302981	0.967	rs11831413	ENSG00000272368.2	RP4-605O3.4	5.03	6.91e-07	0.000181	0.26	0.22	Systolic blood pressure;	chr12:50156600	chr12:50112197~50165618:+
LUAD	cis	rs9400467	0.508	rs11153283	ENSG00000271789.1	RP5-1112D6.7	-5.03	6.91e-07	0.000181	-0.23	-0.22	Amino acid levels;Blood metabolite levels;	chr6:111275940	chr6:111297126~111298510:+
LUAD	cis	rs561341	1	rs117979353	ENSG00000265798.5	RP11-271K11.5	5.03	6.91e-07	0.000182	0.36	0.22	Hip circumference adjusted for BMI;	chr17:31945847	chr17:31038575~31059121:-
LUAD	cis	rs9487094	0.813	rs67857472	ENSG00000260273.1	RP11-425D10.10	5.03	6.91e-07	0.000182	0.31	0.22	Height;	chr6:109359125	chr6:109382795~109383666:+
LUAD	cis	rs1008375	0.931	rs1860592	ENSG00000249502.1	AC006160.5	-5.03	6.92e-07	0.000182	-0.22	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17575405	chr4:17587467~17614571:-
LUAD	cis	rs116175783	0.557	rs2042487	ENSG00000227403.1	AC009299.3	5.03	6.92e-07	0.000182	0.41	0.22	Intelligence (multi-trait analysis);	chr2:161293734	chr2:161244739~161249050:+
LUAD	cis	rs116175783	0.557	rs62197075	ENSG00000227403.1	AC009299.3	5.03	6.92e-07	0.000182	0.41	0.22	Intelligence (multi-trait analysis);	chr2:161312613	chr2:161244739~161249050:+
LUAD	cis	rs4908760	0.931	rs1463049	ENSG00000270282.1	RP5-1115A15.2	5.03	6.93e-07	0.000182	0.25	0.22	Vitiligo;	chr1:8537049	chr1:8512653~8513021:+
LUAD	cis	rs12908161	0.92	rs35738019	ENSG00000275120.1	RP11-182J1.17	5.03	6.93e-07	0.000182	0.34	0.22	Schizophrenia;	chr15:84736979	chr15:84599434~84606463:-
LUAD	cis	rs12908161	1	rs34570071	ENSG00000275120.1	RP11-182J1.17	5.03	6.93e-07	0.000182	0.34	0.22	Schizophrenia;	chr15:84736981	chr15:84599434~84606463:-
LUAD	cis	rs7621025	0.5	rs71630059	ENSG00000239213.4	NCK1-AS1	-5.03	6.93e-07	0.000182	-0.29	-0.22	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136862769	chr3:136841726~136862054:-
LUAD	cis	rs950169	0.922	rs12915832	ENSG00000259295.5	CSPG4P12	5.03	6.94e-07	0.000182	0.32	0.22	Schizophrenia;	chr15:84568226	chr15:85191438~85213905:+
LUAD	cis	rs875971	0.516	rs6945322	ENSG00000164669.11	INTS4P1	-5.03	6.94e-07	0.000182	-0.27	-0.22	Aortic root size;	chr7:65871069	chr7:65141225~65234216:+
LUAD	cis	rs17711722	0.701	rs55773927	ENSG00000164669.11	INTS4P1	-5.03	6.94e-07	0.000182	-0.27	-0.22	Calcium levels;	chr7:65872915	chr7:65141225~65234216:+
LUAD	cis	rs17711722	0.727	rs35850374	ENSG00000164669.11	INTS4P1	-5.03	6.94e-07	0.000182	-0.27	-0.22	Calcium levels;	chr7:65892789	chr7:65141225~65234216:+
LUAD	cis	rs9487094	0.744	rs13220304	ENSG00000260273.1	RP11-425D10.10	5.03	6.94e-07	0.000182	0.31	0.22	Height;	chr6:109331033	chr6:109382795~109383666:+
LUAD	cis	rs14027	0.883	rs28486074	ENSG00000279347.1	RP11-85I17.2	-5.03	6.95e-07	0.000182	-0.2	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119720762	chr8:119838736~119840385:-
LUAD	cis	rs14027	0.842	rs28634937	ENSG00000279347.1	RP11-85I17.2	-5.03	6.95e-07	0.000182	-0.2	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119720877	chr8:119838736~119840385:-
LUAD	cis	rs1008375	0.966	rs7675735	ENSG00000249502.1	AC006160.5	-5.03	6.95e-07	0.000182	-0.22	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17585514	chr4:17587467~17614571:-
LUAD	cis	rs1008375	0.898	rs4698620	ENSG00000249502.1	AC006160.5	-5.03	6.95e-07	0.000182	-0.22	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17585738	chr4:17587467~17614571:-
LUAD	cis	rs61270009	0.818	rs6452786	ENSG00000247828.6	TMEM161B-AS1	5.03	6.95e-07	0.000183	0.26	0.22	Depressive symptoms;	chr5:88409022	chr5:88268895~88436685:+
LUAD	cis	rs2688608	0.592	rs10762563	ENSG00000271816.1	BMS1P4	5.03	6.96e-07	0.000183	0.19	0.22	Inflammatory bowel disease;	chr10:73765044	chr10:73699151~73730487:-
LUAD	cis	rs2243480	1	rs313814	ENSG00000164669.11	INTS4P1	5.03	6.96e-07	0.000183	0.4	0.22	Diabetic kidney disease;	chr7:66038306	chr7:65141225~65234216:+
LUAD	cis	rs6687821	0.834	rs263463	ENSG00000267734.1	RP4-604K5.3	5.03	6.97e-07	0.000183	0.26	0.22	Yeast infection;	chr1:86723198	chr1:86932199~86934891:-
LUAD	cis	rs67311347	0.544	rs7644643	ENSG00000223797.4	ENTPD3-AS1	-5.03	6.97e-07	0.000183	-0.23	-0.22	Renal cell carcinoma;	chr3:40308718	chr3:40313802~40453329:-
LUAD	cis	rs9322193	0.962	rs4552	ENSG00000268592.3	RAET1E-AS1	5.03	6.97e-07	0.000183	0.28	0.22	Lung cancer;	chr6:149811183	chr6:149863494~149919507:+
LUAD	cis	rs2998286	0.723	rs332172	ENSG00000254635.4	WAC-AS1	-5.03	6.97e-07	0.000183	-0.3	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28610394	chr10:28522652~28532743:-
LUAD	cis	rs394563	0.81	rs480870	ENSG00000231760.4	RP11-350J20.5	5.03	6.97e-07	0.000183	0.28	0.22	Dupuytren's disease;	chr6:149463682	chr6:149796151~149826294:-
LUAD	cis	rs394563	0.775	rs420430	ENSG00000231760.4	RP11-350J20.5	5.03	6.97e-07	0.000183	0.28	0.22	Dupuytren's disease;	chr6:149464403	chr6:149796151~149826294:-
LUAD	cis	rs394563	0.775	rs448420	ENSG00000231760.4	RP11-350J20.5	5.03	6.97e-07	0.000183	0.28	0.22	Dupuytren's disease;	chr6:149464666	chr6:149796151~149826294:-
LUAD	cis	rs4964805	0.683	rs12424737	ENSG00000257681.1	RP11-341G23.4	5.03	6.98e-07	0.000183	0.24	0.22	Attention deficit hyperactivity disorder;	chr12:103802443	chr12:103746315~103768858:-
LUAD	cis	rs7927592	0.763	rs10896351	ENSG00000212093.1	AP000807.1	5.03	6.98e-07	0.000183	0.23	0.22	Total body bone mineral density;	chr11:68619428	chr11:68506083~68506166:-
LUAD	cis	rs7968440	1	rs66597435	ENSG00000200428.1	Y_RNA	-5.03	6.98e-07	0.000183	-0.28	-0.22	Fibrinogen;	chr12:50551486	chr12:50743568~50743684:+
LUAD	cis	rs561341	0.783	rs512698	ENSG00000265798.5	RP11-271K11.5	5.03	6.99e-07	0.000183	0.35	0.22	Hip circumference adjusted for BMI;	chr17:31965488	chr17:31038575~31059121:-
LUAD	cis	rs4964805	0.657	rs11111787	ENSG00000257681.1	RP11-341G23.4	5.03	6.99e-07	0.000183	0.24	0.22	Attention deficit hyperactivity disorder;	chr12:103795721	chr12:103746315~103768858:-
LUAD	cis	rs6545883	0.56	rs11677776	ENSG00000271889.1	RP11-493E12.1	-5.03	6.99e-07	0.000183	-0.26	-0.22	Tuberculosis;	chr2:61275978	chr2:61151433~61162105:-
LUAD	cis	rs11143230	1	rs11143230	ENSG00000225434.2	LINC01504	5.03	6.99e-07	0.000183	0.27	0.22	Suicidal ideation;	chr9:72272787	chr9:72305430~72343210:+
LUAD	cis	rs1387259	0.899	rs7307566	ENSG00000257735.1	RP11-370I10.6	5.03	7e-07	0.000184	0.27	0.22	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48210899	chr12:48350945~48442411:+
LUAD	cis	rs2919009	0.664	rs57078496	ENSG00000271670.1	RP11-95I16.4	5.03	7e-07	0.000184	0.3	0.22	Obesity-related traits;	chr10:120881877	chr10:120879256~120880667:-
LUAD	cis	rs36093844	0.752	rs56202113	ENSG00000279742.1	RP11-700A24.1	-5.03	7e-07	0.000184	-0.3	-0.22	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85842515	chr11:85852557~85854943:-
LUAD	cis	rs2380205	0.517	rs11255780	ENSG00000232807.2	RP11-536K7.3	-5.03	7e-07	0.000184	-0.24	-0.22	Breast cancer;	chr10:5897865	chr10:5934270~5945900:-
LUAD	cis	rs750134	0.901	rs118023614	ENSG00000257221.1	RP11-689B22.2	-5.03	7e-07	0.000184	-0.34	-0.22	Low high density lipoprotein cholesterol levels;	chr12:108795286	chr12:108628687~108641318:+
LUAD	cis	rs11742741	0.702	rs3924719	ENSG00000248874.4	C5orf17	-5.03	7e-07	0.000184	-0.29	-0.22	Educational attainment;	chr5:24206968	chr5:23951348~24178263:+
LUAD	cis	rs1816752	0.905	rs7995492	ENSG00000273628.1	RP11-756A22.7	5.03	7e-07	0.000184	0.25	0.22	Obesity-related traits;	chr13:24438885	chr13:24933006~24936796:+
LUAD	cis	rs10761482	0.5	rs2153525	ENSG00000254271.1	RP11-131N11.4	-5.03	7.01e-07	0.000184	-0.25	-0.22	Schizophrenia;	chr10:60509816	chr10:60734342~60741828:+
LUAD	cis	rs4538475	1	rs4538475	ENSG00000214846.4	RP11-115L11.1	5.03	7.01e-07	0.000184	0.38	0.22	Parkinson's disease;	chr4:15736314	chr4:15730962~15731627:-
LUAD	cis	rs17301853	1	rs75402546	ENSG00000227373.4	RP11-160H22.5	5.03	7.01e-07	0.000184	0.45	0.22	Migraine without aura;Migraine - clinic-based;	chr1:174172092	chr1:174115300~174160004:-
LUAD	cis	rs442309	0.687	rs11815005	ENSG00000238280.1	RP11-436D10.3	-5.03	7.02e-07	0.000184	-0.28	-0.22	Vogt-Koyanagi-Harada syndrome;	chr10:62696987	chr10:62793562~62805887:-
LUAD	cis	rs8062405	0.573	rs11645306	ENSG00000251417.2	RP11-1348G14.4	5.03	7.02e-07	0.000184	0.24	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28972615	chr16:28802743~28817828:+
LUAD	cis	rs6095360	0.727	rs13040292	ENSG00000222365.1	SNORD12B	-5.03	7.02e-07	0.000184	-0.25	-0.22	Intelligence (multi-trait analysis);	chr20:49105045	chr20:49280319~49280409:+
LUAD	cis	rs2836950	0.501	rs13047518	ENSG00000255568.3	BRWD1-AS2	-5.03	7.02e-07	0.000184	-0.22	-0.22	Menarche (age at onset);	chr21:39335381	chr21:39313935~39314962:+
LUAD	cis	rs11159086	1	rs11159086	ENSG00000259005.1	RP3-449M8.6	5.03	7.02e-07	0.000184	0.29	0.22	Advanced glycation end-product levels;	chr14:74495572	chr14:74474007~74474864:-
LUAD	cis	rs516805	0.564	rs2679658	ENSG00000279453.1	RP3-425C14.4	-5.03	7.03e-07	0.000184	-0.31	-0.22	Lymphocyte counts;	chr6:122109293	chr6:122436789~122439223:-
LUAD	cis	rs875971	0.964	rs160635	ENSG00000237310.1	GS1-124K5.4	5.03	7.03e-07	0.000184	0.24	0.22	Aortic root size;	chr7:66063931	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.798	rs12698522	ENSG00000232559.3	GS1-124K5.12	5.03	7.04e-07	0.000184	0.27	0.22	Aortic root size;	chr7:66502354	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.83	rs28714531	ENSG00000232559.3	GS1-124K5.12	5.03	7.04e-07	0.000184	0.27	0.22	Aortic root size;	chr7:66503250	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs12698526	ENSG00000232559.3	GS1-124K5.12	5.03	7.04e-07	0.000184	0.27	0.22	Aortic root size;	chr7:66504118	chr7:66554588~66576923:-
LUAD	cis	rs1799949	1	rs2271574	ENSG00000236383.6	LINC00854	-5.03	7.04e-07	0.000185	-0.18	-0.22	Menopause (age at onset);	chr17:43175631	chr17:43216941~43305976:-
LUAD	cis	rs4964805	0.773	rs4964623	ENSG00000257681.1	RP11-341G23.4	5.03	7.04e-07	0.000185	0.28	0.22	Attention deficit hyperactivity disorder;	chr12:103828964	chr12:103746315~103768858:-
LUAD	cis	rs4964805	0.773	rs35746861	ENSG00000257681.1	RP11-341G23.4	5.03	7.04e-07	0.000185	0.28	0.22	Attention deficit hyperactivity disorder;	chr12:103831506	chr12:103746315~103768858:-
LUAD	cis	rs853679	0.546	rs200948	ENSG00000219392.1	RP1-265C24.5	-5.03	7.05e-07	0.000185	-0.43	-0.22	Depression;	chr6:27867494	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.546	rs200950	ENSG00000219392.1	RP1-265C24.5	-5.03	7.05e-07	0.000185	-0.43	-0.22	Depression;	chr6:27867994	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.546	rs200952	ENSG00000219392.1	RP1-265C24.5	-5.03	7.05e-07	0.000185	-0.43	-0.22	Depression;	chr6:27869198	chr6:28115628~28116551:+
LUAD	cis	rs4776970	0.632	rs8030996	ENSG00000270964.1	RP11-502I4.3	-5.03	7.05e-07	0.000185	-0.23	-0.22	Body mass index;Waist circumference;	chr15:67739068	chr15:67541072~67542604:-
LUAD	cis	rs875971	1	rs697970	ENSG00000237310.1	GS1-124K5.4	-5.03	7.05e-07	0.000185	-0.24	-0.22	Aortic root size;	chr7:66095065	chr7:66493706~66495474:+
LUAD	cis	rs9287719	0.578	rs10168852	ENSG00000243819.4	RN7SL832P	5.03	7.05e-07	0.000185	0.24	0.22	Prostate cancer;	chr2:10606197	chr2:10690344~10692099:+
LUAD	cis	rs11157436	0.958	rs17255510	ENSG00000211813.2	TRAV34	-5.03	7.06e-07	0.000185	-0.29	-0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22194962	chr14:22207522~22208129:+
LUAD	cis	rs7665090	0.846	rs4496586	ENSG00000246560.2	RP11-10L12.4	5.03	7.06e-07	0.000185	0.27	0.22	Primary biliary cholangitis;	chr4:102636154	chr4:102828055~102844075:+
LUAD	cis	rs56318008	0.773	rs2268177	ENSG00000228397.1	RP1-224A6.3	5.03	7.07e-07	0.000185	0.39	0.22	Total body bone mineral density;Gestational age at birth (maternal effect);	chr1:22088917	chr1:22023994~22024968:-
LUAD	cis	rs375066	0.806	rs415168	ENSG00000267058.1	RP11-15A1.3	-5.03	7.07e-07	0.000185	-0.25	-0.22	Breast cancer;	chr19:43898422	chr19:43891804~43901805:-
LUAD	cis	rs10985070	0.507	rs12551347	ENSG00000226752.6	PSMD5-AS1	-5.03	7.07e-07	0.000185	-0.23	-0.22	Rheumatoid arthritis;	chr9:121174316	chr9:120824828~120854385:+
LUAD	cis	rs7618501	0.699	rs9821675	ENSG00000234667.1	ACTBP13	-5.03	7.08e-07	0.000185	-0.26	-0.22	Intelligence (multi-trait analysis);	chr3:49865111	chr3:49873347~49877980:-
LUAD	cis	rs172166	0.637	rs1233708	ENSG00000204709.4	LINC01556	5.03	7.08e-07	0.000185	0.28	0.22	Cardiac Troponin-T levels;	chr6:28205441	chr6:28943877~28944537:+
LUAD	cis	rs2976388	0.609	rs2717550	ENSG00000253741.1	CTD-2292P10.4	-5.03	7.08e-07	0.000185	-0.26	-0.22	Urinary tract infection frequency;	chr8:142706390	chr8:142702252~142726973:-
LUAD	cis	rs2976388	0.609	rs1594999	ENSG00000253741.1	CTD-2292P10.4	-5.03	7.08e-07	0.000185	-0.26	-0.22	Urinary tract infection frequency;	chr8:142709156	chr8:142702252~142726973:-
LUAD	cis	rs1426063	1	rs10026801	ENSG00000249717.1	RP11-44F21.3	5.03	7.08e-07	0.000186	0.33	0.22	QT interval;	chr4:75103167	chr4:74955974~74970362:-
LUAD	cis	rs2032366	1	rs2032366	ENSG00000267279.1	RP11-879F14.2	-5.03	7.08e-07	0.000186	-0.27	-0.22	Obesity-related traits;	chr18:61599138	chr18:61585746~61606916:-
LUAD	cis	rs11155671	0.53	rs9371215	ENSG00000268592.3	RAET1E-AS1	5.03	7.08e-07	0.000186	0.28	0.22	Testicular germ cell tumor;	chr6:149873162	chr6:149863494~149919507:+
LUAD	cis	rs720475	0.732	rs17172978	ENSG00000204959.4	ARHGEF34P	-5.03	7.09e-07	0.000186	-0.3	-0.22	Breast cancer;	chr7:144429551	chr7:144272445~144286966:-
LUAD	cis	rs42490	0.51	rs4961157	ENSG00000251136.7	RP11-37B2.1	-5.03	7.1e-07	0.000186	-0.22	-0.22	Leprosy;	chr8:89684800	chr8:89609409~89757727:-
LUAD	cis	rs6687821	0.834	rs263466	ENSG00000267734.1	RP4-604K5.3	5.03	7.1e-07	0.000186	0.26	0.22	Yeast infection;	chr1:86717873	chr1:86932199~86934891:-
LUAD	cis	rs4835473	0.808	rs6831401	ENSG00000251600.4	RP11-673E1.1	-5.03	7.1e-07	0.000186	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143801038	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.778	rs6853798	ENSG00000251600.4	RP11-673E1.1	-5.03	7.1e-07	0.000186	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143801153	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs12502940	ENSG00000251600.4	RP11-673E1.1	-5.03	7.1e-07	0.000186	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143812117	chr4:143912331~143982454:+
LUAD	cis	rs453301	0.538	rs7830804	ENSG00000253981.4	ALG1L13P	-5.03	7.1e-07	0.000186	-0.26	-0.22	Joint mobility (Beighton score);	chr8:9113252	chr8:8236003~8244667:-
LUAD	cis	rs12701220	0.696	rs12112029	ENSG00000229043.2	AC091729.9	-5.03	7.1e-07	0.000186	-0.28	-0.22	Bronchopulmonary dysplasia;	chr7:1098253	chr7:1160374~1165267:+
LUAD	cis	rs875971	0.505	rs6955582	ENSG00000236529.1	RP13-254B10.1	5.03	7.11e-07	0.000186	0.23	0.22	Aortic root size;	chr7:65966699	chr7:65840212~65840596:+
LUAD	cis	rs7772486	0.701	rs7772717	ENSG00000235652.6	RP11-545I5.3	5.02	7.12e-07	0.000186	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145633718	chr6:145799409~145886585:+
LUAD	cis	rs6545883	0.56	rs11677775	ENSG00000271889.1	RP11-493E12.1	-5.02	7.12e-07	0.000187	-0.26	-0.22	Tuberculosis;	chr2:61275975	chr2:61151433~61162105:-
LUAD	cis	rs2295359	0.892	rs6688383	ENSG00000275678.1	RP4-547N15.3	5.02	7.13e-07	0.000187	0.23	0.22	Psoriasis;	chr1:67190271	chr1:67121605~67123956:-
LUAD	cis	rs17826219	0.568	rs59858012	ENSG00000263603.1	CTD-2349P21.5	-5.02	7.13e-07	0.000187	-0.44	-0.22	Body mass index;	chr17:30751564	chr17:30729469~30731202:+
LUAD	cis	rs2836950	0.565	rs2836945	ENSG00000255568.3	BRWD1-AS2	-5.02	7.13e-07	0.000187	-0.22	-0.22	Menarche (age at onset);	chr21:39224831	chr21:39313935~39314962:+
LUAD	cis	rs2255336	0.938	rs1382264	ENSG00000245648.1	RP11-277P12.20	-5.02	7.14e-07	0.000187	-0.33	-0.22	Blood protein levels;	chr12:10390740	chr12:10363769~10398506:+
LUAD	cis	rs6095360	0.727	rs35640549	ENSG00000222365.1	SNORD12B	-5.02	7.14e-07	0.000187	-0.25	-0.22	Intelligence (multi-trait analysis);	chr20:49040009	chr20:49280319~49280409:+
LUAD	cis	rs11051970	0.797	rs4540912	ENSG00000274964.1	RP11-817I4.1	-5.02	7.14e-07	0.000187	-0.25	-0.22	Response to tocilizumab in rheumatoid arthritis;	chr12:32314259	chr12:32339368~32340724:+
LUAD	cis	rs35851103	0.507	rs6601649	ENSG00000255046.1	RP11-297N6.4	5.02	7.14e-07	0.000187	0.28	0.22	Neuroticism;	chr8:11999808	chr8:11797928~11802568:-
LUAD	cis	rs2933343	0.7	rs1683779	ENSG00000261159.1	RP11-723O4.9	5.02	7.14e-07	0.000187	0.24	0.22	IgG glycosylation;	chr3:128923205	chr3:128859716~128860526:-
LUAD	cis	rs240993	0.812	rs7751272	ENSG00000230177.1	RP5-1112D6.4	-5.02	7.14e-07	0.000187	-0.23	-0.22	Inflammatory skin disease;Psoriasis;	chr6:111419068	chr6:111277932~111278742:+
LUAD	cis	rs1816752	0.905	rs9511242	ENSG00000273628.1	RP11-756A22.7	5.02	7.14e-07	0.000187	0.26	0.22	Obesity-related traits;	chr13:24419261	chr13:24933006~24936796:+
LUAD	cis	rs875971	0.79	rs10257911	ENSG00000232559.3	GS1-124K5.12	-5.02	7.14e-07	0.000187	-0.27	-0.22	Aortic root size;	chr7:66278783	chr7:66554588~66576923:-
LUAD	cis	rs7927592	0.546	rs554734	ENSG00000212093.1	AP000807.1	5.02	7.15e-07	0.000187	0.24	0.22	Total body bone mineral density;	chr11:68425050	chr11:68506083~68506166:-
LUAD	cis	rs10853057	0.717	rs4791242	ENSG00000214174.7	AMZ2P1	-5.02	7.16e-07	0.000187	-0.38	-0.22	White matter microstructure (global fractional anisotropy);	chr17:65061533	chr17:64966550~64975576:-
LUAD	cis	rs10935480	0.771	rs7634817	ENSG00000249274.1	PDLIM1P4	5.02	7.16e-07	0.000187	0.24	0.22	Blood protein levels;	chr3:98743681	chr3:98782188~98783193:+
LUAD	cis	rs4908760	0.613	rs4908511	ENSG00000232912.4	RP5-1115A15.1	-5.02	7.16e-07	0.000187	-0.2	-0.22	Vitiligo;	chr1:8752331	chr1:8424645~8434838:+
LUAD	cis	rs4664293	0.934	rs7604482	ENSG00000226266.5	AC009961.3	-5.02	7.16e-07	0.000187	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159657315	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.967	rs10176436	ENSG00000226266.5	AC009961.3	-5.02	7.16e-07	0.000187	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159658883	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.967	rs7559127	ENSG00000226266.5	AC009961.3	-5.02	7.16e-07	0.000187	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159659424	chr2:159670708~159712435:-
LUAD	cis	rs7772486	0.754	rs6906258	ENSG00000235652.6	RP11-545I5.3	-5.02	7.16e-07	0.000187	-0.23	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145768220	chr6:145799409~145886585:+
LUAD	cis	rs7208859	0.673	rs9915139	ENSG00000280069.1	CTD-2349P21.3	-5.02	7.16e-07	0.000187	-0.29	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831497	chr17:30738182~30740275:+
LUAD	cis	rs9659323	0.67	rs12096179	ENSG00000231365.4	RP11-418J17.1	-5.02	7.17e-07	0.000188	-0.26	-0.22	Body mass index;	chr1:119093100	chr1:119140396~119275973:+
LUAD	cis	rs240993	0.812	rs9387013	ENSG00000230177.1	RP5-1112D6.4	5.02	7.17e-07	0.000188	0.23	0.22	Inflammatory skin disease;Psoriasis;	chr6:111512517	chr6:111277932~111278742:+
LUAD	cis	rs11742741	0.676	rs62347896	ENSG00000248874.4	C5orf17	-5.02	7.17e-07	0.000188	-0.28	-0.22	Educational attainment;	chr5:24204990	chr5:23951348~24178263:+
LUAD	cis	rs2980436	1	rs2980436	ENSG00000233609.3	RP11-62H7.2	-5.02	7.17e-07	0.000188	-0.19	-0.22	Schizophrenia;	chr8:8234503	chr8:8961200~8979025:+
LUAD	cis	rs11976180	1	rs1540894	ENSG00000204959.4	ARHGEF34P	5.02	7.17e-07	0.000188	0.27	0.22	Obesity-related traits;	chr7:144070583	chr7:144272445~144286966:-
LUAD	cis	rs17772222	0.917	rs61984684	ENSG00000258983.2	RP11-507K2.2	5.02	7.17e-07	0.000188	0.28	0.22	Coronary artery calcification;	chr14:88559104	chr14:88499334~88515502:+
LUAD	cis	rs12681366	0.881	rs2960121	ENSG00000253704.1	RP11-267M23.4	5.02	7.17e-07	0.000188	0.28	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94417678	chr8:94553722~94569745:+
LUAD	cis	rs891378	1	rs2802217	ENSG00000274245.1	RP11-357P18.2	-5.02	7.18e-07	0.000188	-0.29	-0.22	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207309625	chr1:207372559~207373252:+
LUAD	cis	rs113835537	0.935	rs11550057	ENSG00000255517.5	CTD-3074O7.5	-5.02	7.18e-07	0.000188	-0.33	-0.22	Airway imaging phenotypes;	chr11:66625409	chr11:66473490~66480233:-
LUAD	cis	rs113835537	0.935	rs15969	ENSG00000255517.5	CTD-3074O7.5	-5.02	7.18e-07	0.000188	-0.33	-0.22	Airway imaging phenotypes;	chr11:66626916	chr11:66473490~66480233:-
LUAD	cis	rs113835537	0.935	rs117480267	ENSG00000255517.5	CTD-3074O7.5	-5.02	7.18e-07	0.000188	-0.33	-0.22	Airway imaging phenotypes;	chr11:66631125	chr11:66473490~66480233:-
LUAD	cis	rs875971	0.638	rs7793569	ENSG00000237310.1	GS1-124K5.4	-5.02	7.18e-07	0.000188	-0.24	-0.22	Aortic root size;	chr7:66651646	chr7:66493706~66495474:+
LUAD	cis	rs8177376	0.906	rs522486	ENSG00000254905.1	RP11-712L6.7	5.02	7.18e-07	0.000188	0.33	0.22	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126190054	chr11:126292922~126294254:-
LUAD	cis	rs858239	0.6	rs4628176	ENSG00000230042.1	AK3P3	-5.02	7.18e-07	0.000188	-0.28	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23129178~23129841:+
LUAD	cis	rs61270009	0.955	rs4916898	ENSG00000247828.6	TMEM161B-AS1	5.02	7.18e-07	0.000188	0.25	0.22	Depressive symptoms;	chr5:88290245	chr5:88268895~88436685:+
LUAD	cis	rs2239557	0.645	rs3742810	ENSG00000259065.1	RP5-1021I20.1	5.02	7.18e-07	0.000188	0.28	0.22	Common traits (Other);	chr14:74010785	chr14:73787360~73803270:+
LUAD	cis	rs9322193	0.847	rs868375	ENSG00000268592.3	RAET1E-AS1	5.02	7.18e-07	0.000188	0.28	0.22	Lung cancer;	chr6:149844905	chr6:149863494~149919507:+
LUAD	cis	rs7923837	1	rs11187144	ENSG00000236493.2	EIF2S2P3	5.02	7.18e-07	0.000188	0.25	0.22	Multiple sclerosis;Body mass index;	chr10:92710223	chr10:92668745~92669743:-
LUAD	cis	rs17264034	0.821	rs374218	ENSG00000250786.1	SNHG18	5.02	7.19e-07	0.000188	0.32	0.22	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9548331	chr5:9546200~9550609:+
LUAD	cis	rs2976388	0.609	rs2263092	ENSG00000253741.1	CTD-2292P10.4	-5.02	7.19e-07	0.000188	-0.26	-0.22	Urinary tract infection frequency;	chr8:142708548	chr8:142702252~142726973:-
LUAD	cis	rs12468226	1	rs6739198	ENSG00000226261.1	AC064836.3	5.02	7.19e-07	0.000188	0.34	0.22	Urate levels;	chr2:202492273	chr2:202336024~202336727:-
LUAD	cis	rs1275468	0.731	rs1480001	ENSG00000257497.2	RP11-585P4.5	-5.02	7.2e-07	0.000188	-0.33	-0.22	Polycystic ovary syndrome;	chr12:75586939	chr12:75483454~75489820:-
LUAD	cis	rs6095360	0.727	rs7264419	ENSG00000222365.1	SNORD12B	-5.02	7.2e-07	0.000188	-0.25	-0.22	Intelligence (multi-trait analysis);	chr20:49084772	chr20:49280319~49280409:+
LUAD	cis	rs891378	1	rs971318	ENSG00000274245.1	RP11-357P18.2	5.02	7.2e-07	0.000188	0.29	0.22	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207302251	chr1:207372559~207373252:+
LUAD	cis	rs7208859	0.614	rs4794874	ENSG00000263531.1	RP13-753N3.1	-5.02	7.2e-07	0.000188	-0.42	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30514300	chr17:30863921~30864940:-
LUAD	cis	rs4142995	0.962	rs10242866	ENSG00000279048.1	RP11-511H23.2	-5.02	7.2e-07	0.000188	-0.18	-0.22	HDL cholesterol;HDL cholesterol levels;	chr7:17880990	chr7:17940503~17942922:+
LUAD	cis	rs9487094	0.961	rs12206928	ENSG00000260273.1	RP11-425D10.10	5.02	7.2e-07	0.000188	0.3	0.22	Height;	chr6:109357908	chr6:109382795~109383666:+
LUAD	cis	rs2408955	0.521	rs7301003	ENSG00000257735.1	RP11-370I10.6	5.02	7.2e-07	0.000188	0.26	0.22	Glycated hemoglobin levels;	chr12:48156444	chr12:48350945~48442411:+
LUAD	cis	rs11976020	1	rs11976020	ENSG00000205578.5	POM121B	-5.02	7.21e-07	0.000188	-0.31	-0.22	Educational attainment (years of education);	chr7:72782785	chr7:73293497~73301161:+
LUAD	cis	rs2239547	0.522	rs2581805	ENSG00000242142.1	SERBP1P3	-5.02	7.21e-07	0.000188	-0.26	-0.22	Schizophrenia;	chr3:52945034	chr3:53064283~53065091:-
LUAD	cis	rs673078	1	rs673078	ENSG00000275409.1	RP11-131L12.4	5.02	7.21e-07	0.000189	0.29	0.22	Glucose homeostasis traits;	chr12:118353636	chr12:118430147~118430699:+
LUAD	cis	rs2688608	0.617	rs6480709	ENSG00000271816.1	BMS1P4	5.02	7.22e-07	0.000189	0.19	0.22	Inflammatory bowel disease;	chr10:73719367	chr10:73699151~73730487:-
LUAD	cis	rs673078	0.607	rs61943398	ENSG00000275409.1	RP11-131L12.4	-5.02	7.22e-07	0.000189	-0.31	-0.22	Glucose homeostasis traits;	chr12:118393280	chr12:118430147~118430699:+
LUAD	cis	rs1707322	0.721	rs10890333	ENSG00000280836.1	AL355480.1	-5.02	7.22e-07	0.000189	-0.3	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634650	chr1:45581219~45581321:-
LUAD	cis	rs9900062	0.546	rs2428352	ENSG00000270714.1	MINOS1P2	5.02	7.22e-07	0.000189	0.3	0.22	QT interval;	chr17:64698620	chr17:64747264~64747492:-
LUAD	cis	rs1008375	0.966	rs1860591	ENSG00000249502.1	AC006160.5	-5.02	7.23e-07	0.000189	-0.22	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17575706	chr4:17587467~17614571:-
LUAD	cis	rs1707322	1	rs1613296	ENSG00000280836.1	AL355480.1	5.02	7.23e-07	0.000189	0.29	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081180	chr1:45581219~45581321:-
LUAD	cis	rs7017914	0.714	rs1481796	ENSG00000223220.1	Y_RNA	-5.02	7.23e-07	0.000189	-0.25	-0.22	Bone mineral density;	chr8:71082115	chr8:70780914~70781008:-
LUAD	cis	rs7772486	0.719	rs2206141	ENSG00000235652.6	RP11-545I5.3	-5.02	7.23e-07	0.000189	-0.23	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145765056	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.754	rs6570718	ENSG00000235652.6	RP11-545I5.3	-5.02	7.23e-07	0.000189	-0.23	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145767307	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.654	rs6906402	ENSG00000235652.6	RP11-545I5.3	-5.02	7.23e-07	0.000189	-0.23	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145768171	chr6:145799409~145886585:+
LUAD	cis	rs748404	0.626	rs72707530	ENSG00000205771.5	CATSPER2P1	-5.02	7.23e-07	0.000189	-0.34	-0.22	Lung cancer;	chr15:43353622	chr15:43726918~43747094:-
LUAD	cis	rs896854	1	rs13255935	ENSG00000253528.2	RP11-347C18.4	5.02	7.23e-07	0.000189	0.22	0.22	Type 2 diabetes;	chr8:94953457	chr8:94974573~94974853:-
LUAD	cis	rs763512	0.504	rs853216	ENSG00000276054.1	RP11-378E13.3	5.02	7.24e-07	0.000189	0.34	0.22	3-hydroxypropylmercapturic acid levels in smokers;	chr17:37502902	chr17:37386886~37387926:+
LUAD	cis	rs5758659	0.714	rs2413668	ENSG00000227370.1	RP4-669P10.19	5.02	7.24e-07	0.000189	0.2	0.22	Cognitive function;	chr22:42109837	chr22:42132543~42132998:+
LUAD	cis	rs5758659	0.657	rs5758587	ENSG00000227370.1	RP4-669P10.19	5.02	7.24e-07	0.000189	0.2	0.22	Cognitive function;	chr22:42121632	chr22:42132543~42132998:+
LUAD	cis	rs800160	0.582	rs2521286	ENSG00000236264.4	RPL26P30	-5.02	7.24e-07	0.000189	-0.3	-0.22	Bacteremia;	chr11:2320741	chr11:2335132~2335776:-
LUAD	cis	rs17772222	0.917	rs12588535	ENSG00000258983.2	RP11-507K2.2	5.02	7.24e-07	0.000189	0.28	0.22	Coronary artery calcification;	chr14:88781900	chr14:88499334~88515502:+
LUAD	cis	rs1729951	0.575	rs361248	ENSG00000239213.4	NCK1-AS1	5.02	7.25e-07	0.000189	0.24	0.22	Neuroticism;	chr3:136990224	chr3:136841726~136862054:-
LUAD	cis	rs1799949	0.965	rs8176323	ENSG00000236383.6	LINC00854	-5.02	7.25e-07	0.000189	-0.18	-0.22	Menopause (age at onset);	chr17:43043694	chr17:43216941~43305976:-
LUAD	cis	rs2832077	0.506	rs2832093	ENSG00000232855.5	AF131217.1	5.02	7.25e-07	0.000189	0.22	0.22	Cognitive test performance;	chr21:28792533	chr21:28439346~28674848:-
LUAD	cis	rs875971	0.522	rs1917563	ENSG00000164669.11	INTS4P1	5.02	7.26e-07	0.00019	0.27	0.22	Aortic root size;	chr7:65950660	chr7:65141225~65234216:+
LUAD	cis	rs7017914	0.69	rs7844508	ENSG00000223220.1	Y_RNA	5.02	7.26e-07	0.00019	0.26	0.22	Bone mineral density;	chr8:70690760	chr8:70780914~70781008:-
LUAD	cis	rs7208859	0.623	rs73269916	ENSG00000263603.1	CTD-2349P21.5	-5.02	7.26e-07	0.00019	-0.38	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30769308	chr17:30729469~30731202:+
LUAD	cis	rs1707322	0.963	rs4630155	ENSG00000280836.1	AL355480.1	-5.02	7.27e-07	0.00019	-0.3	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45791438	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.963	rs4508055	ENSG00000280836.1	AL355480.1	-5.02	7.27e-07	0.00019	-0.3	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792059	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.963	rs12076580	ENSG00000280836.1	AL355480.1	-5.02	7.27e-07	0.00019	-0.3	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792487	chr1:45581219~45581321:-
LUAD	cis	rs10800713	0.56	rs10919967	ENSG00000260088.1	RP11-92G12.3	5.02	7.27e-07	0.00019	0.35	0.22	Tandem gait;	chr1:200533543	chr1:200669507~200694250:+
LUAD	cis	rs875971	0.793	rs460678	ENSG00000237310.1	GS1-124K5.4	5.02	7.27e-07	0.00019	0.24	0.22	Aortic root size;	chr7:66062213	chr7:66493706~66495474:+
LUAD	cis	rs801193	1	rs4717319	ENSG00000237310.1	GS1-124K5.4	5.02	7.28e-07	0.00019	0.24	0.22	Aortic root size;	chr7:66777606	chr7:66493706~66495474:+
LUAD	cis	rs801193	0.904	rs4718403	ENSG00000237310.1	GS1-124K5.4	5.02	7.28e-07	0.00019	0.24	0.22	Aortic root size;	chr7:66777742	chr7:66493706~66495474:+
LUAD	cis	rs944722	0.526	rs2297516	ENSG00000266786.1	LGALS9DP	5.02	7.29e-07	0.00019	0.26	0.22	Fractional exhaled nitric oxide (childhood);	chr17:27768704	chr17:27746132~27754954:+
LUAD	cis	rs2408955	0.521	rs11168437	ENSG00000257735.1	RP11-370I10.6	5.02	7.29e-07	0.00019	0.27	0.22	Glycated hemoglobin levels;	chr12:48172373	chr12:48350945~48442411:+
LUAD	cis	rs11673344	0.74	rs113752815	ENSG00000226686.6	LINC01535	5.02	7.29e-07	0.00019	0.3	0.22	Obesity-related traits;	chr19:37043829	chr19:37251912~37265535:+
LUAD	cis	rs865483	0.63	rs7215774	ENSG00000276054.1	RP11-378E13.3	-5.02	7.3e-07	0.000191	-0.26	-0.22	Monocyte count;	chr17:37383917	chr17:37386886~37387926:+
LUAD	cis	rs453301	0.653	rs1562211	ENSG00000173295.6	FAM86B3P	-5.02	7.3e-07	0.000191	-0.23	-0.22	Joint mobility (Beighton score);	chr8:9044914	chr8:8228595~8244865:+
LUAD	cis	rs11159086	0.793	rs8015894	ENSG00000259005.1	RP3-449M8.6	5.02	7.3e-07	0.000191	0.29	0.22	Advanced glycation end-product levels;	chr14:74491917	chr14:74474007~74474864:-
LUAD	cis	rs9650657	0.504	rs7813802	ENSG00000255046.1	RP11-297N6.4	-5.02	7.32e-07	0.000191	-0.27	-0.22	Neuroticism;	chr8:11176467	chr8:11797928~11802568:-
LUAD	cis	rs916888	0.531	rs183211	ENSG00000261575.2	RP11-259G18.1	5.02	7.32e-07	0.000191	0.3	0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46267037~46268694:+
LUAD	cis	rs853679	1	rs11965538	ENSG00000219392.1	RP1-265C24.5	-5.02	7.32e-07	0.000191	-0.34	-0.22	Depression;	chr6:28272137	chr6:28115628~28116551:+
LUAD	cis	rs471144	0.881	rs12081541	ENSG00000237975.5	FLG-AS1	-5.02	7.32e-07	0.000191	-0.43	-0.22	Inflammatory skin disease;	chr1:152468890	chr1:152168125~152445456:+
LUAD	cis	rs17508449	0.821	rs1419231	ENSG00000232450.1	RP4-730K3.3	-5.02	7.32e-07	0.000191	-0.38	-0.22	Leprosy;	chr1:113583596	chr1:113698884~113699631:-
LUAD	cis	rs17826219	0.706	rs609472	ENSG00000263603.1	CTD-2349P21.5	-5.02	7.32e-07	0.000191	-0.33	-0.22	Body mass index;	chr17:30624409	chr17:30729469~30731202:+
LUAD	cis	rs2408955	0.522	rs973398	ENSG00000257735.1	RP11-370I10.6	-5.02	7.33e-07	0.000191	-0.26	-0.22	Glycated hemoglobin levels;	chr12:48097265	chr12:48350945~48442411:+
LUAD	cis	rs4268898	0.697	rs10445892	ENSG00000242628.4	AC009228.1	-5.02	7.33e-07	0.000191	-0.28	-0.22	Asthma;	chr2:24184089	chr2:24214381~24221516:+
LUAD	cis	rs9532669	0.926	rs9525418	ENSG00000168852.11	TPTE2P5	-5.02	7.34e-07	0.000191	-0.22	-0.22	Cervical cancer;	chr13:40879081	chr13:40822296~40921749:-
LUAD	cis	rs4664293	0.867	rs7579206	ENSG00000226266.5	AC009961.3	-5.02	7.34e-07	0.000191	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159715992	chr2:159670708~159712435:-
LUAD	cis	rs7208859	0.573	rs73267829	ENSG00000263603.1	CTD-2349P21.5	-5.02	7.34e-07	0.000192	-0.4	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30676921	chr17:30729469~30731202:+
LUAD	cis	rs2749097	0.808	rs855355	ENSG00000244256.3	RN7SL130P	-5.02	7.34e-07	0.000192	-0.29	-0.22	Alcohol consumption (transferrin glycosylation);	chr1:63656206	chr1:63655743~63656047:+
LUAD	cis	rs875971	0.798	rs6460304	ENSG00000232559.3	GS1-124K5.12	5.02	7.34e-07	0.000192	0.27	0.22	Aortic root size;	chr7:66499741	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs6945775	ENSG00000232559.3	GS1-124K5.12	5.02	7.34e-07	0.000192	0.27	0.22	Aortic root size;	chr7:66503987	chr7:66554588~66576923:-
LUAD	cis	rs6840360	1	rs6833368	ENSG00000270265.1	RP11-731D1.4	5.02	7.35e-07	0.000192	0.22	0.22	Intelligence (multi-trait analysis);	chr4:151682025	chr4:151333775~151353224:-
LUAD	cis	rs7772486	0.754	rs4895682	ENSG00000235652.6	RP11-545I5.3	-5.02	7.35e-07	0.000192	-0.23	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145741725	chr6:145799409~145886585:+
LUAD	cis	rs66887589	0.934	rs2715016	ENSG00000245958.5	RP11-33B1.1	5.02	7.35e-07	0.000192	0.18	0.22	Diastolic blood pressure;	chr4:119531201	chr4:119454791~119552025:+
LUAD	cis	rs17772222	0.876	rs12587528	ENSG00000258983.2	RP11-507K2.2	5.02	7.36e-07	0.000192	0.27	0.22	Coronary artery calcification;	chr14:88487652	chr14:88499334~88515502:+
LUAD	cis	rs17772222	0.837	rs1864748	ENSG00000258983.2	RP11-507K2.2	5.02	7.36e-07	0.000192	0.27	0.22	Coronary artery calcification;	chr14:88488847	chr14:88499334~88515502:+
LUAD	cis	rs858239	0.601	rs764534	ENSG00000230042.1	AK3P3	-5.02	7.36e-07	0.000192	-0.28	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.601	rs2068459	ENSG00000230042.1	AK3P3	-5.02	7.36e-07	0.000192	-0.28	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.601	rs73272053	ENSG00000230042.1	AK3P3	-5.02	7.36e-07	0.000192	-0.28	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23115906	chr7:23129178~23129841:+
LUAD	cis	rs471144	0.881	rs12089980	ENSG00000237975.5	FLG-AS1	-5.02	7.37e-07	0.000192	-0.43	-0.22	Inflammatory skin disease;	chr1:152459455	chr1:152168125~152445456:+
LUAD	cis	rs853679	0.546	rs200490	ENSG00000219392.1	RP1-265C24.5	-5.02	7.37e-07	0.000192	-0.43	-0.22	Depression;	chr6:27829157	chr6:28115628~28116551:+
LUAD	cis	rs2281558	0.517	rs16987966	ENSG00000125804.12	FAM182A	-5.02	7.37e-07	0.000192	-0.35	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25662778	chr20:26054655~26086917:+
LUAD	cis	rs1816752	0.905	rs7317850	ENSG00000273628.1	RP11-756A22.7	5.02	7.38e-07	0.000192	0.26	0.22	Obesity-related traits;	chr13:24419899	chr13:24933006~24936796:+
LUAD	cis	rs4908768	0.501	rs6669503	ENSG00000270282.1	RP5-1115A15.2	5.02	7.38e-07	0.000192	0.25	0.22	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8504241	chr1:8512653~8513021:+
LUAD	cis	rs2836950	0.501	rs2836984	ENSG00000255568.3	BRWD1-AS2	-5.02	7.38e-07	0.000193	-0.22	-0.22	Menarche (age at onset);	chr21:39329023	chr21:39313935~39314962:+
LUAD	cis	rs9341808	0.754	rs9352808	ENSG00000272129.1	RP11-250B2.6	5.02	7.39e-07	0.000193	0.28	0.22	Sitting height ratio;	chr6:80287625	chr6:80355424~80356859:+
LUAD	cis	rs4568518	0.619	rs13238312	ENSG00000279048.1	RP11-511H23.2	5.02	7.39e-07	0.000193	0.18	0.22	Measles;	chr7:17968821	chr7:17940503~17942922:+
LUAD	cis	rs2919009	0.607	rs59153085	ENSG00000271670.1	RP11-95I16.4	5.02	7.4e-07	0.000193	0.3	0.22	Obesity-related traits;	chr10:120931782	chr10:120879256~120880667:-
LUAD	cis	rs896854	0.846	rs2340584	ENSG00000253528.2	RP11-347C18.4	5.02	7.4e-07	0.000193	0.21	0.22	Type 2 diabetes;	chr8:94904583	chr8:94974573~94974853:-
LUAD	cis	rs3750965	0.959	rs3168115	ENSG00000260895.1	RP11-554A11.7	-5.02	7.4e-07	0.000193	-0.25	-0.22	Hair color;	chr11:69090622	chr11:69103493~69109094:+
LUAD	cis	rs4789693	0.938	rs4789694	ENSG00000265458.1	RP13-20L14.6	-5.02	7.4e-07	0.000193	-0.3	-0.22	Glucocorticoid-induced osteonecrosis;	chr17:82470223	chr17:82454273~82458521:-
LUAD	cis	rs12928939	0.769	rs34680964	ENSG00000260886.1	TAT-AS1	5.02	7.4e-07	0.000193	0.27	0.22	Post bronchodilator FEV1;	chr16:71624691	chr16:71565789~71578187:+
LUAD	cis	rs2836950	0.565	rs2836942	ENSG00000255568.3	BRWD1-AS2	-5.02	7.4e-07	0.000193	-0.22	-0.22	Menarche (age at onset);	chr21:39219455	chr21:39313935~39314962:+
LUAD	cis	rs6496044	1	rs6496044	ENSG00000202081.1	RNU6-1280P	5.02	7.41e-07	0.000193	0.26	0.22	Interstitial lung disease;	chr15:85524075	chr15:85651522~85651628:-
LUAD	cis	rs910316	1	rs8003506	ENSG00000259138.1	RP11-950C14.7	-5.02	7.41e-07	0.000193	-0.24	-0.22	Height;	chr14:75119585	chr14:75127153~75136930:+
LUAD	cis	rs4908768	0.501	rs35865480	ENSG00000270282.1	RP5-1115A15.2	5.02	7.42e-07	0.000193	0.25	0.22	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8543718	chr1:8512653~8513021:+
LUAD	cis	rs2380205	0.517	rs12785055	ENSG00000232807.2	RP11-536K7.3	5.02	7.42e-07	0.000193	0.24	0.22	Breast cancer;	chr10:5899167	chr10:5934270~5945900:-
LUAD	cis	rs875971	0.54	rs35510581	ENSG00000236529.1	RP13-254B10.1	-5.02	7.42e-07	0.000193	-0.23	-0.22	Aortic root size;	chr7:66113790	chr7:65840212~65840596:+
LUAD	cis	rs984222	1	rs984222	ENSG00000226172.2	RP4-712E4.1	-5.02	7.42e-07	0.000193	-0.24	-0.22	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118961220	chr1:119000344~119001392:-
LUAD	cis	rs984222	0.967	rs984225	ENSG00000226172.2	RP4-712E4.1	-5.02	7.42e-07	0.000193	-0.24	-0.22	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118961661	chr1:119000344~119001392:-
LUAD	cis	rs984222	0.967	rs10923712	ENSG00000226172.2	RP4-712E4.1	-5.02	7.42e-07	0.000193	-0.24	-0.22	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118962811	chr1:119000344~119001392:-
LUAD	cis	rs4865169	0.967	rs10023088	ENSG00000269949.1	RP11-738E22.3	5.02	7.42e-07	0.000193	0.28	0.22	Breast cancer;	chr4:57018269	chr4:56960927~56961373:-
LUAD	cis	rs11671005	0.693	rs11669665	ENSG00000268912.1	CTD-2619J13.17	-5.02	7.42e-07	0.000193	-0.3	-0.22	Mean platelet volume;	chr19:58420518	chr19:58428632~58431148:-
LUAD	cis	rs11671005	0.735	rs11084543	ENSG00000268912.1	CTD-2619J13.17	-5.02	7.42e-07	0.000193	-0.3	-0.22	Mean platelet volume;	chr19:58421334	chr19:58428632~58431148:-
LUAD	cis	rs11671005	0.735	rs11881000	ENSG00000268912.1	CTD-2619J13.17	-5.02	7.42e-07	0.000193	-0.3	-0.22	Mean platelet volume;	chr19:58421421	chr19:58428632~58431148:-
LUAD	cis	rs11671005	0.735	rs12981875	ENSG00000268912.1	CTD-2619J13.17	-5.02	7.42e-07	0.000193	-0.3	-0.22	Mean platelet volume;	chr19:58423763	chr19:58428632~58431148:-
LUAD	cis	rs950169	0.58	rs11636189	ENSG00000275120.1	RP11-182J1.17	5.02	7.42e-07	0.000193	0.34	0.22	Schizophrenia;	chr15:84650323	chr15:84599434~84606463:-
LUAD	cis	rs1008375	0.966	rs3796812	ENSG00000249502.1	AC006160.5	-5.02	7.42e-07	0.000194	-0.22	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17580428	chr4:17587467~17614571:-
LUAD	cis	rs3177980	0.529	rs516793	ENSG00000239494.2	RN7SL333P	-5.02	7.42e-07	0.000194	-0.22	-0.22	Amyotrophic lateral sclerosis;	chr1:169938074	chr1:169859756~169860052:+
LUAD	cis	rs61270009	0.955	rs4916897	ENSG00000247828.6	TMEM161B-AS1	5.02	7.42e-07	0.000194	0.25	0.22	Depressive symptoms;	chr5:88285771	chr5:88268895~88436685:+
LUAD	cis	rs4908768	0.501	rs1463050	ENSG00000270282.1	RP5-1115A15.2	5.02	7.43e-07	0.000194	0.25	0.22	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8536983	chr1:8512653~8513021:+
LUAD	cis	rs7727544	0.716	rs6863213	ENSG00000233006.5	AC034220.3	5.02	7.44e-07	0.000194	0.2	0.22	Blood metabolite levels;	chr5:132240239	chr5:132311285~132369916:-
LUAD	cis	rs2688608	0.592	rs10824032	ENSG00000271816.1	BMS1P4	5.02	7.44e-07	0.000194	0.19	0.22	Inflammatory bowel disease;	chr10:73768372	chr10:73699151~73730487:-
LUAD	cis	rs17507216	0.628	rs28737193	ENSG00000255769.6	GOLGA2P10	-5.02	7.44e-07	0.000194	-0.28	-0.22	Excessive daytime sleepiness;	chr15:82701318	chr15:82472993~82513950:-
LUAD	cis	rs7430456	0.837	rs7651130	ENSG00000228221.4	LINC00578	5.02	7.45e-07	0.000194	0.26	0.22	Breast cancer;	chr3:177719720	chr3:177441921~177752305:+
LUAD	cis	rs950169	0.544	rs2036949	ENSG00000259295.5	CSPG4P12	5.02	7.45e-07	0.000194	0.32	0.22	Schizophrenia;	chr15:84620374	chr15:85191438~85213905:+
LUAD	cis	rs17711722	0.522	rs4642526	ENSG00000224316.1	RP11-479O9.2	5.02	7.46e-07	0.000194	0.22	0.22	Calcium levels;	chr7:65751755	chr7:65773620~65802067:+
LUAD	cis	rs7829975	0.782	rs6990746	ENSG00000253893.2	FAM85B	5.02	7.47e-07	0.000195	0.28	0.22	Mood instability;	chr8:8690301	chr8:8167819~8226614:-
LUAD	cis	rs113835537	0.877	rs57127845	ENSG00000255517.5	CTD-3074O7.5	-5.02	7.47e-07	0.000195	-0.33	-0.22	Airway imaging phenotypes;	chr11:66550854	chr11:66473490~66480233:-
LUAD	cis	rs875971	0.522	rs4502988	ENSG00000164669.11	INTS4P1	-5.01	7.48e-07	0.000195	-0.27	-0.22	Aortic root size;	chr7:65832759	chr7:65141225~65234216:+
LUAD	cis	rs2749097	0.825	rs6671606	ENSG00000244256.3	RN7SL130P	-5.01	7.48e-07	0.000195	-0.27	-0.22	Alcohol consumption (transferrin glycosylation);	chr1:63658197	chr1:63655743~63656047:+
LUAD	cis	rs2749097	0.825	rs11208261	ENSG00000244256.3	RN7SL130P	-5.01	7.48e-07	0.000195	-0.27	-0.22	Alcohol consumption (transferrin glycosylation);	chr1:63658331	chr1:63655743~63656047:+
LUAD	cis	rs375066	0.935	rs408549	ENSG00000267058.1	RP11-15A1.3	-5.01	7.48e-07	0.000195	-0.25	-0.22	Breast cancer;	chr19:43921467	chr19:43891804~43901805:-
LUAD	cis	rs375066	0.935	rs398388	ENSG00000267058.1	RP11-15A1.3	-5.01	7.48e-07	0.000195	-0.25	-0.22	Breast cancer;	chr19:43921530	chr19:43891804~43901805:-
LUAD	cis	rs375066	0.935	rs403137	ENSG00000267058.1	RP11-15A1.3	-5.01	7.48e-07	0.000195	-0.25	-0.22	Breast cancer;	chr19:43923474	chr19:43891804~43901805:-
LUAD	cis	rs375066	0.869	rs379785	ENSG00000267058.1	RP11-15A1.3	-5.01	7.48e-07	0.000195	-0.25	-0.22	Breast cancer;	chr19:43923949	chr19:43891804~43901805:-
LUAD	cis	rs375066	0.935	rs428505	ENSG00000267058.1	RP11-15A1.3	-5.01	7.48e-07	0.000195	-0.25	-0.22	Breast cancer;	chr19:43924759	chr19:43891804~43901805:-
LUAD	cis	rs375066	0.935	rs367741	ENSG00000267058.1	RP11-15A1.3	-5.01	7.48e-07	0.000195	-0.25	-0.22	Breast cancer;	chr19:43925028	chr19:43891804~43901805:-
LUAD	cis	rs6687821	0.834	rs34389199	ENSG00000267734.1	RP4-604K5.3	5.01	7.48e-07	0.000195	0.26	0.22	Yeast infection;	chr1:86725224	chr1:86932199~86934891:-
LUAD	cis	rs4591358	0.731	rs12693769	ENSG00000223466.1	AC064834.2	-5.01	7.48e-07	0.000195	-0.31	-0.22	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195453722	chr2:195533035~195538681:+
LUAD	cis	rs2408955	0.5	rs12816820	ENSG00000257735.1	RP11-370I10.6	5.01	7.5e-07	0.000195	0.26	0.22	Glycated hemoglobin levels;	chr12:48164542	chr12:48350945~48442411:+
LUAD	cis	rs4591358	0.731	rs13031745	ENSG00000223466.1	AC064834.2	-5.01	7.5e-07	0.000195	-0.31	-0.22	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195440458	chr2:195533035~195538681:+
LUAD	cis	rs4835473	0.932	rs1849113	ENSG00000251600.4	RP11-673E1.1	-5.01	7.51e-07	0.000195	-0.27	-0.22	Immature fraction of reticulocytes;	chr4:143962512	chr4:143912331~143982454:+
LUAD	cis	rs847577	0.575	rs41278842	ENSG00000272950.1	RP11-307C18.1	-5.01	7.51e-07	0.000196	-0.29	-0.22	Breast cancer;	chr7:98186687	chr7:98322853~98323430:+
LUAD	cis	rs2732480	0.577	rs2634684	ENSG00000257735.1	RP11-370I10.6	-5.01	7.51e-07	0.000196	-0.27	-0.22	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48337092	chr12:48350945~48442411:+
LUAD	cis	rs2933343	0.951	rs796862	ENSG00000231305.3	RP11-723O4.2	5.01	7.51e-07	0.000196	0.27	0.22	IgG glycosylation;	chr3:128874197	chr3:128861313~128871540:-
LUAD	cis	rs2562456	0.793	rs61445561	ENSG00000268081.1	RP11-678G14.2	5.01	7.52e-07	0.000196	0.37	0.22	Pain;	chr19:21321230	chr19:21554640~21569237:-
LUAD	cis	rs7829975	0.774	rs11775523	ENSG00000173295.6	FAM86B3P	5.01	7.52e-07	0.000196	0.24	0.22	Mood instability;	chr8:8821666	chr8:8228595~8244865:+
LUAD	cis	rs7829975	0.774	rs1039915	ENSG00000173295.6	FAM86B3P	5.01	7.52e-07	0.000196	0.24	0.22	Mood instability;	chr8:8822104	chr8:8228595~8244865:+
LUAD	cis	rs2439831	0.85	rs28590651	ENSG00000249839.1	AC011330.5	-5.01	7.52e-07	0.000196	-0.44	-0.22	Lung cancer in ever smokers;	chr15:43820818	chr15:43663654~43684339:-
LUAD	cis	rs673078	0.66	rs17512142	ENSG00000275409.1	RP11-131L12.4	-5.01	7.52e-07	0.000196	-0.34	-0.22	Glucose homeostasis traits;	chr12:118186186	chr12:118430147~118430699:+
LUAD	cis	rs4835473	0.932	rs13152443	ENSG00000251600.4	RP11-673E1.1	-5.01	7.52e-07	0.000196	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143742492	chr4:143912331~143982454:+
LUAD	cis	rs858239	0.601	rs6971002	ENSG00000230042.1	AK3P3	-5.01	7.53e-07	0.000196	-0.28	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23129178~23129841:+
LUAD	cis	rs7665090	0.87	rs228627	ENSG00000246560.2	RP11-10L12.4	-5.01	7.53e-07	0.000196	-0.28	-0.22	Primary biliary cholangitis;	chr4:102651925	chr4:102828055~102844075:+
LUAD	cis	rs11976180	1	rs1919949	ENSG00000204959.4	ARHGEF34P	5.01	7.53e-07	0.000196	0.27	0.22	Obesity-related traits;	chr7:144070630	chr7:144272445~144286966:-
LUAD	cis	rs910316	0.575	rs12889133	ENSG00000259138.1	RP11-950C14.7	5.01	7.54e-07	0.000196	0.25	0.22	Height;	chr14:74998386	chr14:75127153~75136930:+
LUAD	cis	rs2976388	1	rs2976396	ENSG00000253741.1	CTD-2292P10.4	-5.01	7.54e-07	0.000196	-0.25	-0.22	Urinary tract infection frequency;	chr8:142682583	chr8:142702252~142726973:-
LUAD	cis	rs8091660	0.624	rs9948328	ENSG00000278983.1	RP11-426J5.3	5.01	7.55e-07	0.000196	0.27	0.22	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48569613	chr18:48564795~48568342:+
LUAD	cis	rs2749097	0.825	rs6670731	ENSG00000244256.3	RN7SL130P	-5.01	7.55e-07	0.000197	-0.27	-0.22	Alcohol consumption (transferrin glycosylation);	chr1:63657487	chr1:63655743~63656047:+
LUAD	cis	rs8098244	0.565	rs11664777	ENSG00000264745.1	TTC39C-AS1	5.01	7.55e-07	0.000197	0.23	0.22	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23731793	chr18:23994213~24015339:-
LUAD	cis	rs2337406	1	rs10459466	ENSG00000223648.3	IGHV3-64	5.01	7.55e-07	0.000197	0.3	0.22	Alzheimer's disease (late onset);	chr14:106689255	chr14:106643132~106658258:-
LUAD	cis	rs8177876	0.658	rs16954513	ENSG00000261061.1	RP11-303E16.2	-5.01	7.56e-07	0.000197	-0.44	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81043599	chr16:81030770~81031485:+
LUAD	cis	rs853679	0.882	rs2743555	ENSG00000219392.1	RP1-265C24.5	-5.01	7.56e-07	0.000197	-0.34	-0.22	Depression;	chr6:28273304	chr6:28115628~28116551:+
LUAD	cis	rs75920871	0.528	rs682048	ENSG00000254851.1	RP11-109L13.1	5.01	7.57e-07	0.000197	0.33	0.22	Subjective well-being;	chr11:116957604	chr11:117135528~117138582:+
LUAD	cis	rs2243480	1	rs427044	ENSG00000226002.1	RP11-460N20.5	-5.01	7.57e-07	0.000197	-0.38	-0.22	Diabetic kidney disease;	chr7:66043558	chr7:65084103~65100232:+
LUAD	cis	rs62445005	1	rs62445005	ENSG00000211699.2	TRGV3	5.01	7.57e-07	0.000197	0.26	0.22	Shingles;	chr7:38346957	chr7:38358512~38359162:-
LUAD	cis	rs7968440	0.801	rs7960015	ENSG00000200428.1	Y_RNA	-5.01	7.57e-07	0.000197	-0.29	-0.22	Fibrinogen;	chr12:50751411	chr12:50743568~50743684:+
LUAD	cis	rs11671005	0.735	rs12986387	ENSG00000268912.1	CTD-2619J13.17	-5.01	7.58e-07	0.000197	-0.3	-0.22	Mean platelet volume;	chr19:58415848	chr19:58428632~58431148:-
LUAD	cis	rs11671005	0.735	rs11667723	ENSG00000268912.1	CTD-2619J13.17	-5.01	7.58e-07	0.000197	-0.3	-0.22	Mean platelet volume;	chr19:58416122	chr19:58428632~58431148:-
LUAD	cis	rs11671005	0.735	rs11668789	ENSG00000268912.1	CTD-2619J13.17	-5.01	7.58e-07	0.000197	-0.3	-0.22	Mean platelet volume;	chr19:58416942	chr19:58428632~58431148:-
LUAD	cis	rs11671005	0.735	rs35652377	ENSG00000268912.1	CTD-2619J13.17	-5.01	7.58e-07	0.000197	-0.3	-0.22	Mean platelet volume;	chr19:58417833	chr19:58428632~58431148:-
LUAD	cis	rs11671005	0.735	rs3764532	ENSG00000268912.1	CTD-2619J13.17	-5.01	7.58e-07	0.000197	-0.3	-0.22	Mean platelet volume;	chr19:58417855	chr19:58428632~58431148:-
LUAD	cis	rs11671005	0.735	rs3088284	ENSG00000268912.1	CTD-2619J13.17	-5.01	7.58e-07	0.000197	-0.3	-0.22	Mean platelet volume;	chr19:58418060	chr19:58428632~58431148:-
LUAD	cis	rs11671005	0.735	rs12981649	ENSG00000268912.1	CTD-2619J13.17	-5.01	7.58e-07	0.000197	-0.3	-0.22	Mean platelet volume;	chr19:58418676	chr19:58428632~58431148:-
LUAD	cis	rs7829975	0.711	rs1039916	ENSG00000253981.4	ALG1L13P	5.01	7.58e-07	0.000197	0.25	0.22	Mood instability;	chr8:8828344	chr8:8236003~8244667:-
LUAD	cis	rs3177980	0.529	rs659476	ENSG00000239494.2	RN7SL333P	-5.01	7.59e-07	0.000197	-0.22	-0.22	Amyotrophic lateral sclerosis;	chr1:169938352	chr1:169859756~169860052:+
LUAD	cis	rs42490	0.903	rs218899	ENSG00000251136.7	RP11-37B2.1	-5.01	7.59e-07	0.000198	-0.23	-0.22	Leprosy;	chr8:89717279	chr8:89609409~89757727:-
LUAD	cis	rs867371	0.762	rs12905578	ENSG00000259429.4	UBE2Q2P2	5.01	7.59e-07	0.000198	0.2	0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82288923	chr15:82355142~82420075:+
LUAD	cis	rs2948294	0.545	rs11776397	ENSG00000253981.4	ALG1L13P	5.01	7.59e-07	0.000198	0.27	0.22	Red cell distribution width;	chr8:8257639	chr8:8236003~8244667:-
LUAD	cis	rs67340775	0.541	rs200968	ENSG00000219392.1	RP1-265C24.5	-5.01	7.59e-07	0.000198	-0.37	-0.22	Lung cancer in ever smokers;	chr6:27891790	chr6:28115628~28116551:+
LUAD	cis	rs42490	0.903	rs218948	ENSG00000251136.7	RP11-37B2.1	-5.01	7.59e-07	0.000198	-0.23	-0.22	Leprosy;	chr8:89705617	chr8:89609409~89757727:-
LUAD	cis	rs56114371	0.53	rs2056923	ENSG00000219392.1	RP1-265C24.5	-5.01	7.6e-07	0.000198	-0.34	-0.22	Breast cancer;	chr6:27722160	chr6:28115628~28116551:+
LUAD	cis	rs2657294	0.62	rs2395132	ENSG00000233313.2	HMGA1P5	-5.01	7.6e-07	0.000198	-0.28	-0.22	Pneumonia;	chr10:75080840	chr10:75276376~75276646:-
LUAD	cis	rs7116495	1	rs7121260	ENSG00000254682.1	RP11-660L16.2	5.01	7.61e-07	0.000198	0.43	0.22	Severe influenza A (H1N1) infection;	chr11:71989520	chr11:71448674~71452157:+
LUAD	cis	rs7937890	0.535	rs2575857	ENSG00000251991.1	RNU7-49P	5.01	7.61e-07	0.000198	0.24	0.22	Mitochondrial DNA levels;	chr11:14479750	chr11:14478892~14478953:+
LUAD	cis	rs950169	0.544	rs62021193	ENSG00000275120.1	RP11-182J1.17	5.01	7.62e-07	0.000198	0.34	0.22	Schizophrenia;	chr15:84627352	chr15:84599434~84606463:-
LUAD	cis	rs8081395	0.741	rs1292053	ENSG00000266992.1	DHX40P1	-5.01	7.62e-07	0.000198	-0.25	-0.22	White blood cell count;	chr17:59886176	chr17:59976009~60002384:-
LUAD	cis	rs516805	0.528	rs2684245	ENSG00000279453.1	RP3-425C14.4	-5.01	7.62e-07	0.000198	-0.31	-0.22	Lymphocyte counts;	chr6:122092990	chr6:122436789~122439223:-
LUAD	cis	rs17684571	0.872	rs13210876	ENSG00000231441.1	RP11-472M19.2	-5.01	7.62e-07	0.000198	-0.3	-0.22	Schizophrenia;	chr6:56739425	chr6:56844002~56864078:+
LUAD	cis	rs12701220	0.744	rs2030958	ENSG00000229043.2	AC091729.9	-5.01	7.62e-07	0.000198	-0.3	-0.22	Bronchopulmonary dysplasia;	chr7:1036374	chr7:1160374~1165267:+
LUAD	cis	rs6496044	0.963	rs11853972	ENSG00000202081.1	RNU6-1280P	5.01	7.62e-07	0.000198	0.26	0.22	Interstitial lung disease;	chr15:85519209	chr15:85651522~85651628:-
LUAD	cis	rs2018683	0.899	rs10479816	ENSG00000228421.2	AC005013.5	5.01	7.63e-07	0.000198	0.25	0.22	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28938404	chr7:28957667~28959345:+
LUAD	cis	rs2286503	0.839	rs2270105	ENSG00000221740.1	SNORD93	5.01	7.63e-07	0.000198	0.25	0.22	Fibrinogen;	chr7:22822848	chr7:22856613~22856686:+
LUAD	cis	rs3738443	0.868	rs17269923	ENSG00000259865.1	RP11-488L18.10	5.01	7.63e-07	0.000198	0.23	0.22	Alcohol dependence;	chr1:247208861	chr1:247187281~247188526:-
LUAD	cis	rs7017914	0.69	rs13255849	ENSG00000223220.1	Y_RNA	5.01	7.63e-07	0.000198	0.26	0.22	Bone mineral density;	chr8:70840518	chr8:70780914~70781008:-
LUAD	cis	rs75920871	0.528	rs7128772	ENSG00000254851.1	RP11-109L13.1	5.01	7.63e-07	0.000198	0.32	0.22	Subjective well-being;	chr11:117018695	chr11:117135528~117138582:+
LUAD	cis	rs516805	0.667	rs225080	ENSG00000279453.1	RP3-425C14.4	-5.01	7.64e-07	0.000199	-0.29	-0.22	Lymphocyte counts;	chr6:122295949	chr6:122436789~122439223:-
LUAD	cis	rs12701220	0.5	rs6463224	ENSG00000229043.2	AC091729.9	-5.01	7.65e-07	0.000199	-0.28	-0.22	Bronchopulmonary dysplasia;	chr7:1100782	chr7:1160374~1165267:+
LUAD	cis	rs1555322	0.53	rs2297789	ENSG00000126005.14	MMP24-AS1	-5.01	7.65e-07	0.000199	-0.31	-0.22	Attention deficit hyperactivity disorder;	chr20:35279445	chr20:35216462~35278131:-
LUAD	cis	rs2243480	1	rs313799	ENSG00000226002.1	RP11-460N20.5	-5.01	7.66e-07	0.000199	-0.37	-0.22	Diabetic kidney disease;	chr7:66029343	chr7:65084103~65100232:+
LUAD	cis	rs1075265	0.611	rs3770403	ENSG00000233266.1	HMGB1P31	5.01	7.66e-07	0.000199	0.29	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53695688	chr2:54051334~54051760:+
LUAD	cis	rs7829975	0.517	rs12542733	ENSG00000253893.2	FAM85B	5.01	7.66e-07	0.000199	0.27	0.22	Mood instability;	chr8:8967348	chr8:8167819~8226614:-
LUAD	cis	rs2554380	0.628	rs890311	ENSG00000230373.7	GOLGA6L5P	-5.01	7.66e-07	0.000199	-0.23	-0.22	Height;	chr15:83772200	chr15:84507885~84516814:-
LUAD	cis	rs6088590	0.965	rs6087619	ENSG00000276073.1	RP5-1125A11.7	-5.01	7.66e-07	0.000199	-0.23	-0.22	Coronary artery disease;	chr20:34700707	chr20:33985617~33988989:-
LUAD	cis	rs2295359	0.824	rs12060309	ENSG00000275678.1	RP4-547N15.3	-5.01	7.67e-07	0.000199	-0.24	-0.22	Psoriasis;	chr1:67138536	chr1:67121605~67123956:-
LUAD	cis	rs160451	0.966	rs28374917	ENSG00000251136.7	RP11-37B2.1	5.01	7.67e-07	0.000199	0.22	0.22	Leprosy;	chr8:89666525	chr8:89609409~89757727:-
LUAD	cis	rs2732480	0.5	rs11168468	ENSG00000257735.1	RP11-370I10.6	5.01	7.67e-07	0.000199	0.27	0.22	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48218682	chr12:48350945~48442411:+
LUAD	cis	rs4835473	0.8	rs1849134	ENSG00000251600.4	RP11-673E1.1	5.01	7.67e-07	0.000199	0.27	0.22	Immature fraction of reticulocytes;	chr4:143958260	chr4:143912331~143982454:+
LUAD	cis	rs2933343	0.729	rs1680794	ENSG00000261159.1	RP11-723O4.9	5.01	7.68e-07	0.000199	0.24	0.22	IgG glycosylation;	chr3:128901547	chr3:128859716~128860526:-
LUAD	cis	rs2933343	0.7	rs1683777	ENSG00000261159.1	RP11-723O4.9	5.01	7.68e-07	0.000199	0.24	0.22	IgG glycosylation;	chr3:128906037	chr3:128859716~128860526:-
LUAD	cis	rs2933343	0.7	rs1680788	ENSG00000261159.1	RP11-723O4.9	5.01	7.68e-07	0.000199	0.24	0.22	IgG glycosylation;	chr3:128906475	chr3:128859716~128860526:-
LUAD	cis	rs7829975	0.774	rs13259216	ENSG00000253893.2	FAM85B	-5.01	7.68e-07	2e-04	-0.28	-0.22	Mood instability;	chr8:8816091	chr8:8167819~8226614:-
LUAD	cis	rs867371	0.892	rs4344697	ENSG00000276710.3	CSPG4P8	-5.01	7.68e-07	2e-04	-0.21	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82252873	chr15:82459472~82477258:+
LUAD	cis	rs875971	0.66	rs10272357	ENSG00000237310.1	GS1-124K5.4	-5.01	7.68e-07	2e-04	-0.24	-0.22	Aortic root size;	chr7:66598087	chr7:66493706~66495474:+
LUAD	cis	rs3738443	1	rs56340510	ENSG00000259865.1	RP11-488L18.10	5.01	7.68e-07	2e-04	0.24	0.22	Alcohol dependence;	chr1:247208707	chr1:247187281~247188526:-
LUAD	cis	rs11020821	0.828	rs16924603	ENSG00000255893.1	RP11-685N10.1	-5.01	7.69e-07	2e-04	-0.29	-0.22	Response to angiotensin II receptor blocker therapy;Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94522093	chr11:94472908~94473570:-
LUAD	cis	rs12745968	0.589	rs7417452	ENSG00000223787.2	RP4-593M8.1	-5.01	7.69e-07	2e-04	-0.26	-0.22	Bipolar disorder and schizophrenia;	chr1:92566496	chr1:92580476~92580821:-
LUAD	cis	rs3002142	1	rs3002142	ENSG00000272750.1	RP11-378J18.8	-5.01	7.69e-07	2e-04	-0.28	-0.22	LDL peak particle diameter (total fat intake interaction);	chr1:222614720	chr1:222658867~222661512:-
LUAD	cis	rs2998286	0.678	rs332114	ENSG00000254635.4	WAC-AS1	5.01	7.69e-07	2e-04	0.29	0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28636772	chr10:28522652~28532743:-
LUAD	cis	rs17345786	1	rs11715368	ENSG00000244119.1	PDCL3P4	5.01	7.69e-07	2e-04	0.24	0.22	Colonoscopy-negative controls vs population controls;	chr3:101617536	chr3:101712472~101713191:+
LUAD	cis	rs6545883	0.507	rs10169662	ENSG00000271889.1	RP11-493E12.1	-5.01	7.69e-07	2e-04	-0.26	-0.22	Tuberculosis;	chr2:61280801	chr2:61151433~61162105:-
LUAD	cis	rs11976180	1	rs13243677	ENSG00000170356.8	OR2A20P	-5.01	7.7e-07	2e-04	-0.28	-0.22	Obesity-related traits;	chr7:144049479	chr7:144250045~144252957:-
LUAD	cis	rs4908768	0.581	rs2784740	ENSG00000232912.4	RP5-1115A15.1	-5.01	7.7e-07	2e-04	-0.24	-0.22	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8440997	chr1:8424645~8434838:+
LUAD	cis	rs7102710	0.557	rs61884000	ENSG00000254418.1	RP11-21L19.1	5.01	7.71e-07	2e-04	0.58	0.22	Glucagon levels in response to oral glucose tolerance test (fasting);	chr11:14324626	chr11:14262846~14273691:-
LUAD	cis	rs11673344	0.526	rs35153242	ENSG00000226686.6	LINC01535	-5.01	7.71e-07	2e-04	-0.28	-0.22	Obesity-related traits;	chr19:37660841	chr19:37251912~37265535:+
LUAD	cis	rs1799949	1	rs8176145	ENSG00000236383.6	LINC00854	-5.01	7.71e-07	2e-04	-0.18	-0.22	Menopause (age at onset);	chr17:43097077	chr17:43216941~43305976:-
LUAD	cis	rs1799949	0.965	rs8176140	ENSG00000236383.6	LINC00854	-5.01	7.71e-07	2e-04	-0.18	-0.22	Menopause (age at onset);	chr17:43099629	chr17:43216941~43305976:-
LUAD	cis	rs6687821	0.684	rs10782585	ENSG00000267734.1	RP4-604K5.3	-5.01	7.71e-07	2e-04	-0.26	-0.22	Yeast infection;	chr1:86821913	chr1:86932199~86934891:-
LUAD	cis	rs9322193	0.884	rs1108889	ENSG00000268592.3	RAET1E-AS1	5.01	7.71e-07	2e-04	0.29	0.22	Lung cancer;	chr6:149845433	chr6:149863494~149919507:+
LUAD	cis	rs1707322	1	rs10789486	ENSG00000280836.1	AL355480.1	-5.01	7.72e-07	2e-04	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45942995	chr1:45581219~45581321:-
LUAD	cis	rs561341	1	rs55736640	ENSG00000265798.5	RP11-271K11.5	5.01	7.72e-07	2e-04	0.37	0.22	Hip circumference adjusted for BMI;	chr17:32006829	chr17:31038575~31059121:-
LUAD	cis	rs3893377	0.848	rs10222984	ENSG00000214846.4	RP11-115L11.1	5.01	7.72e-07	2e-04	0.34	0.22	Current cigarettes per day in chronic obstructive pulmonary disease;	chr4:15740080	chr4:15730962~15731627:-
LUAD	cis	rs12468226	0.872	rs115187557	ENSG00000272966.1	RP11-686O6.1	5.01	7.72e-07	0.000201	0.37	0.22	Urate levels;	chr2:202495351	chr2:202336739~202337200:+
LUAD	cis	rs910316	1	rs4903281	ENSG00000259138.1	RP11-950C14.7	5.01	7.72e-07	0.000201	0.24	0.22	Height;	chr14:75087658	chr14:75127153~75136930:+
LUAD	cis	rs2836950	0.509	rs4816618	ENSG00000255568.3	BRWD1-AS2	-5.01	7.73e-07	0.000201	-0.22	-0.22	Menarche (age at onset);	chr21:39227603	chr21:39313935~39314962:+
LUAD	cis	rs2836950	0.527	rs2836948	ENSG00000255568.3	BRWD1-AS2	-5.01	7.73e-07	0.000201	-0.22	-0.22	Menarche (age at onset);	chr21:39227751	chr21:39313935~39314962:+
LUAD	cis	rs7208859	0.623	rs8081299	ENSG00000263603.1	CTD-2349P21.5	-5.01	7.73e-07	0.000201	-0.38	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777278	chr17:30729469~30731202:+
LUAD	cis	rs1005277	0.563	rs2505215	ENSG00000263064.2	RP11-291L22.7	5.01	7.74e-07	0.000201	0.24	0.22	Extrinsic epigenetic age acceleration;	chr10:38192345	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.563	rs2505216	ENSG00000263064.2	RP11-291L22.7	5.01	7.74e-07	0.000201	0.24	0.22	Extrinsic epigenetic age acceleration;	chr10:38193902	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.563	rs2800550	ENSG00000263064.2	RP11-291L22.7	5.01	7.74e-07	0.000201	0.24	0.22	Extrinsic epigenetic age acceleration;	chr10:38194001	chr10:38448689~38448949:+
LUAD	cis	rs7617773	0.817	rs9830016	ENSG00000228638.1	FCF1P2	-5.01	7.74e-07	0.000201	-0.25	-0.22	Coronary artery disease;	chr3:48241004	chr3:48290793~48291375:-
LUAD	cis	rs17684571	0.872	rs3002008	ENSG00000231441.1	RP11-472M19.2	5.01	7.74e-07	0.000201	0.31	0.22	Schizophrenia;	chr6:56757527	chr6:56844002~56864078:+
LUAD	cis	rs7727544	0.716	rs11949055	ENSG00000233006.5	AC034220.3	5.01	7.75e-07	0.000201	0.2	0.22	Blood metabolite levels;	chr5:132241044	chr5:132311285~132369916:-
LUAD	cis	rs1799949	1	rs12516	ENSG00000236383.6	LINC00854	-5.01	7.75e-07	0.000201	-0.18	-0.22	Menopause (age at onset);	chr17:43044391	chr17:43216941~43305976:-
LUAD	cis	rs7712401	0.58	rs10066632	ENSG00000263432.2	RN7SL689P	5.01	7.75e-07	0.000201	0.3	0.22	Mean platelet volume;	chr5:123028988	chr5:123022487~123022783:-
LUAD	cis	rs7712401	0.58	rs10076327	ENSG00000263432.2	RN7SL689P	5.01	7.75e-07	0.000201	0.3	0.22	Mean platelet volume;	chr5:123031652	chr5:123022487~123022783:-
LUAD	cis	rs950169	0.541	rs10795	ENSG00000275120.1	RP11-182J1.17	5.01	7.75e-07	0.000201	0.34	0.22	Schizophrenia;	chr15:84634066	chr15:84599434~84606463:-
LUAD	cis	rs950169	0.58	rs36126054	ENSG00000275120.1	RP11-182J1.17	5.01	7.75e-07	0.000201	0.34	0.22	Schizophrenia;	chr15:84634492	chr15:84599434~84606463:-
LUAD	cis	rs6687758	1	rs6695584	ENSG00000228437.4	RP11-400N13.2	5.01	7.75e-07	0.000201	0.32	0.22	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221988647	chr1:221966341~221984964:+
LUAD	cis	rs4841134	0.655	rs12234997	ENSG00000233609.3	RP11-62H7.2	-5.01	7.76e-07	0.000201	-0.18	-0.22	Age-related disease endophenotypes;	chr8:9380198	chr8:8961200~8979025:+
LUAD	cis	rs4819052	0.704	rs2297283	ENSG00000223768.1	LINC00205	-5.01	7.76e-07	0.000201	-0.26	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263675	chr21:45293285~45297354:+
LUAD	cis	rs12745968	0.589	rs3936945	ENSG00000223787.2	RP4-593M8.1	-5.01	7.77e-07	0.000202	-0.28	-0.22	Bipolar disorder and schizophrenia;	chr1:92641314	chr1:92580476~92580821:-
LUAD	cis	rs853679	1	rs1778508	ENSG00000204709.4	LINC01556	-5.01	7.77e-07	0.000202	-0.33	-0.22	Depression;	chr6:28262103	chr6:28943877~28944537:+
LUAD	cis	rs875971	0.862	rs2909688	ENSG00000232559.3	GS1-124K5.12	5.01	7.77e-07	0.000202	0.27	0.22	Aortic root size;	chr7:66376625	chr7:66554588~66576923:-
LUAD	cis	rs61270009	0.955	rs13171573	ENSG00000247828.6	TMEM161B-AS1	5.01	7.77e-07	0.000202	0.26	0.22	Depressive symptoms;	chr5:88383625	chr5:88268895~88436685:+
LUAD	cis	rs9322193	0.607	rs12209310	ENSG00000223701.3	RAET1E-AS1	5.01	7.77e-07	0.000202	0.32	0.22	Lung cancer;	chr6:149904882	chr6:149884431~149919508:+
LUAD	cis	rs10129255	0.957	rs8009073	ENSG00000211974.3	IGHV2-70	5.01	7.78e-07	0.000202	0.24	0.22	Kawasaki disease;	chr14:106777278	chr14:106723574~106724093:-
LUAD	cis	rs7017914	0.652	rs2732138	ENSG00000223220.1	Y_RNA	5.01	7.78e-07	0.000202	0.26	0.22	Bone mineral density;	chr8:70971372	chr8:70780914~70781008:-
LUAD	cis	rs4835473	0.8	rs1849122	ENSG00000251600.4	RP11-673E1.1	5.01	7.78e-07	0.000202	0.27	0.22	Immature fraction of reticulocytes;	chr4:143978699	chr4:143912331~143982454:+
LUAD	cis	rs9650657	0.515	rs6601560	ENSG00000255046.1	RP11-297N6.4	5.01	7.79e-07	0.000202	0.27	0.22	Neuroticism;	chr8:11093356	chr8:11797928~11802568:-
LUAD	cis	rs1850744	0.702	rs55813730	ENSG00000163612.10	FAM86KP	5.01	7.79e-07	0.000202	0.68	0.22	Economic and political preferences;	chr4:9593994	chr4:9153296~9165451:+
LUAD	cis	rs2028299	1	rs7111	ENSG00000259677.1	RP11-493E3.1	5.01	7.79e-07	0.000202	0.27	0.22	Type 2 diabetes;	chr15:89830641	chr15:89876540~89877285:+
LUAD	cis	rs2028299	1	rs2028299	ENSG00000259677.1	RP11-493E3.1	5.01	7.79e-07	0.000202	0.27	0.22	Type 2 diabetes;	chr15:89831025	chr15:89876540~89877285:+
LUAD	cis	rs13256369	0.851	rs13267036	ENSG00000253893.2	FAM85B	-5.01	7.79e-07	0.000202	-0.31	-0.22	Obesity-related traits;	chr8:8709175	chr8:8167819~8226614:-
LUAD	cis	rs7017914	0.652	rs7015947	ENSG00000223220.1	Y_RNA	5.01	7.79e-07	0.000202	0.25	0.22	Bone mineral density;	chr8:70748711	chr8:70780914~70781008:-
LUAD	cis	rs801193	0.844	rs2244022	ENSG00000224316.1	RP11-479O9.2	5.01	7.79e-07	0.000202	0.22	0.22	Aortic root size;	chr7:66737443	chr7:65773620~65802067:+
LUAD	cis	rs4835473	0.669	rs56112476	ENSG00000251600.4	RP11-673E1.1	-5.01	7.8e-07	0.000202	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143948716	chr4:143912331~143982454:+
LUAD	cis	rs13256369	0.851	rs13258283	ENSG00000253893.2	FAM85B	-5.01	7.8e-07	0.000202	-0.31	-0.22	Obesity-related traits;	chr8:8706120	chr8:8167819~8226614:-
LUAD	cis	rs13256369	0.851	rs13249700	ENSG00000253893.2	FAM85B	-5.01	7.8e-07	0.000202	-0.31	-0.22	Obesity-related traits;	chr8:8706127	chr8:8167819~8226614:-
LUAD	cis	rs4664293	0.801	rs6432552	ENSG00000230783.1	AC009961.2	-5.01	7.8e-07	0.000202	-0.27	-0.22	Monocyte percentage of white cells;	chr2:159717613	chr2:159689217~159690291:-
LUAD	cis	rs442309	0.574	rs7895364	ENSG00000238280.1	RP11-436D10.3	-5.01	7.8e-07	0.000202	-0.27	-0.22	Vogt-Koyanagi-Harada syndrome;	chr10:62725053	chr10:62793562~62805887:-
LUAD	cis	rs801193	1	rs13239306	ENSG00000236529.1	RP13-254B10.1	-5.01	7.8e-07	0.000202	-0.23	-0.22	Aortic root size;	chr7:66671030	chr7:65840212~65840596:+
LUAD	cis	rs17772222	0.917	rs17188046	ENSG00000258983.2	RP11-507K2.2	5.01	7.8e-07	0.000202	0.27	0.22	Coronary artery calcification;	chr14:88624417	chr14:88499334~88515502:+
LUAD	cis	rs7829975	0.606	rs10112585	ENSG00000253893.2	FAM85B	5.01	7.8e-07	0.000202	0.28	0.22	Mood instability;	chr8:8937520	chr8:8167819~8226614:-
LUAD	cis	rs2661868	0.51	rs9645401	ENSG00000232912.4	RP5-1115A15.1	-5.01	7.8e-07	0.000202	-0.24	-0.22	Life satisfaction;	chr1:8326598	chr1:8424645~8434838:+
LUAD	cis	rs11159086	0.793	rs1029701	ENSG00000259005.1	RP3-449M8.6	5.01	7.81e-07	0.000202	0.28	0.22	Advanced glycation end-product levels;	chr14:74474112	chr14:74474007~74474864:-
LUAD	cis	rs2378497	1	rs3121626	ENSG00000232679.1	RP11-400N13.3	5.01	7.82e-07	0.000203	0.34	0.22	Serum thyroid-stimulating hormone levels;	chr1:222017218	chr1:222041705~222064763:-
LUAD	cis	rs1799949	0.773	rs2137990	ENSG00000236383.6	LINC00854	5.01	7.82e-07	0.000203	0.17	0.22	Menopause (age at onset);	chr17:43165879	chr17:43216941~43305976:-
LUAD	cis	rs720475	0.732	rs73159066	ENSG00000204959.4	ARHGEF34P	-5.01	7.83e-07	0.000203	-0.3	-0.22	Breast cancer;	chr7:144426495	chr7:144272445~144286966:-
LUAD	cis	rs10985070	0.504	rs2296077	ENSG00000226752.6	PSMD5-AS1	-5.01	7.83e-07	0.000203	-0.23	-0.22	Rheumatoid arthritis;	chr9:121182665	chr9:120824828~120854385:+
LUAD	cis	rs875971	0.928	rs2036263	ENSG00000232559.3	GS1-124K5.12	-5.01	7.83e-07	0.000203	-0.26	-0.22	Aortic root size;	chr7:66335210	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs10240949	ENSG00000232559.3	GS1-124K5.12	-5.01	7.83e-07	0.000203	-0.26	-0.22	Aortic root size;	chr7:66339430	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs7782704	ENSG00000232559.3	GS1-124K5.12	-5.01	7.83e-07	0.000203	-0.26	-0.22	Aortic root size;	chr7:66340379	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs6959268	ENSG00000232559.3	GS1-124K5.12	-5.01	7.83e-07	0.000203	-0.26	-0.22	Aortic root size;	chr7:66347979	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs28491091	ENSG00000232559.3	GS1-124K5.12	-5.01	7.84e-07	0.000203	-0.26	-0.22	Aortic root size;	chr7:66204077	chr7:66554588~66576923:-
LUAD	cis	rs5758659	1	rs134902	ENSG00000273366.1	CTA-989H11.1	-5.01	7.84e-07	0.000203	-0.25	-0.22	Cognitive function;	chr22:42287991	chr22:42278188~42278846:+
LUAD	cis	rs516805	0.667	rs7767993	ENSG00000279453.1	RP3-425C14.4	5.01	7.84e-07	0.000203	0.29	0.22	Lymphocyte counts;	chr6:122343192	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.667	rs10457432	ENSG00000279453.1	RP3-425C14.4	5.01	7.84e-07	0.000203	0.29	0.22	Lymphocyte counts;	chr6:122344699	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.673	rs12201010	ENSG00000279453.1	RP3-425C14.4	5.01	7.84e-07	0.000203	0.29	0.22	Lymphocyte counts;	chr6:122345675	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.64	rs12208084	ENSG00000279453.1	RP3-425C14.4	5.01	7.84e-07	0.000203	0.29	0.22	Lymphocyte counts;	chr6:122345745	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.706	rs17662514	ENSG00000279453.1	RP3-425C14.4	5.01	7.84e-07	0.000203	0.29	0.22	Lymphocyte counts;	chr6:122346013	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.706	rs9320863	ENSG00000279453.1	RP3-425C14.4	5.01	7.84e-07	0.000203	0.29	0.22	Lymphocyte counts;	chr6:122347086	chr6:122436789~122439223:-
LUAD	cis	rs2732480	0.5	rs1387257	ENSG00000257735.1	RP11-370I10.6	5.01	7.84e-07	0.000203	0.27	0.22	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48242883	chr12:48350945~48442411:+
LUAD	cis	rs801193	1	rs3778909	ENSG00000236529.1	RP13-254B10.1	5.01	7.84e-07	0.000203	0.23	0.22	Aortic root size;	chr7:66790659	chr7:65840212~65840596:+
LUAD	cis	rs2098713	0.599	rs62359042	ENSG00000250155.1	CTD-2353F22.1	5.01	7.85e-07	0.000203	0.24	0.22	Telomere length;	chr5:37577604	chr5:36666214~36725195:-
LUAD	cis	rs375066	0.935	rs373168	ENSG00000267058.1	RP11-15A1.3	-5.01	7.85e-07	0.000203	-0.25	-0.22	Breast cancer;	chr19:43926717	chr19:43891804~43901805:-
LUAD	cis	rs67340775	0.541	rs200979	ENSG00000219392.1	RP1-265C24.5	-5	7.86e-07	0.000204	-0.37	-0.22	Lung cancer in ever smokers;	chr6:27884579	chr6:28115628~28116551:+
LUAD	cis	rs561341	1	rs113115092	ENSG00000265798.5	RP11-271K11.5	5	7.86e-07	0.000204	0.35	0.22	Hip circumference adjusted for BMI;	chr17:31957145	chr17:31038575~31059121:-
LUAD	cis	rs561341	1	rs555629	ENSG00000265798.5	RP11-271K11.5	5	7.86e-07	0.000204	0.35	0.22	Hip circumference adjusted for BMI;	chr17:31967117	chr17:31038575~31059121:-
LUAD	cis	rs1707322	0.963	rs6666763	ENSG00000280836.1	AL355480.1	-5	7.86e-07	0.000204	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45970779	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs4489497	ENSG00000280836.1	AL355480.1	-5	7.86e-07	0.000204	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45973026	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs11211235	ENSG00000280836.1	AL355480.1	-5	7.86e-07	0.000204	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45974703	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.893	rs9919275	ENSG00000280836.1	AL355480.1	-5	7.86e-07	0.000204	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45975688	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs11211236	ENSG00000280836.1	AL355480.1	-5	7.86e-07	0.000204	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45978095	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs4660328	ENSG00000280836.1	AL355480.1	-5	7.86e-07	0.000204	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45979159	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.928	rs61785614	ENSG00000280836.1	AL355480.1	-5	7.86e-07	0.000204	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45980375	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs9793167	ENSG00000280836.1	AL355480.1	-5	7.86e-07	0.000204	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981128	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs11211237	ENSG00000280836.1	AL355480.1	-5	7.86e-07	0.000204	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981657	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.963	rs11211238	ENSG00000280836.1	AL355480.1	-5	7.86e-07	0.000204	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983743	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs4460583	ENSG00000280836.1	AL355480.1	-5	7.86e-07	0.000204	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45984246	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.963	rs4459051	ENSG00000280836.1	AL355480.1	-5	7.86e-07	0.000204	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45985531	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs11211239	ENSG00000280836.1	AL355480.1	-5	7.86e-07	0.000204	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986275	chr1:45581219~45581321:-
LUAD	cis	rs875971	0.83	rs778711	ENSG00000232559.3	GS1-124K5.12	5	7.86e-07	0.000204	0.27	0.22	Aortic root size;	chr7:66386670	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs1083554	ENSG00000232559.3	GS1-124K5.12	5	7.86e-07	0.000204	0.27	0.22	Aortic root size;	chr7:66387354	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs778707	ENSG00000232559.3	GS1-124K5.12	5	7.86e-07	0.000204	0.27	0.22	Aortic root size;	chr7:66392040	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs778705	ENSG00000232559.3	GS1-124K5.12	5	7.86e-07	0.000204	0.27	0.22	Aortic root size;	chr7:66396128	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs778697	ENSG00000232559.3	GS1-124K5.12	5	7.86e-07	0.000204	0.27	0.22	Aortic root size;	chr7:66405439	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.798	rs7789615	ENSG00000232559.3	GS1-124K5.12	5	7.86e-07	0.000204	0.27	0.22	Aortic root size;	chr7:66413674	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs6978028	ENSG00000232559.3	GS1-124K5.12	5	7.86e-07	0.000204	0.27	0.22	Aortic root size;	chr7:66421313	chr7:66554588~66576923:-
LUAD	cis	rs34375054	0.66	rs58624919	ENSG00000279233.1	RP11-158L12.4	5	7.86e-07	0.000204	0.2	0.22	Post bronchodilator FEV1/FVC ratio;	chr12:125111912	chr12:125138245~125141711:+
LUAD	cis	rs1065852	0.51	rs5751247	ENSG00000227370.1	RP4-669P10.19	5	7.86e-07	0.000204	0.23	0.22	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42237048	chr22:42132543~42132998:+
LUAD	cis	rs2688608	0.618	rs28553894	ENSG00000271816.1	BMS1P4	5	7.86e-07	0.000204	0.19	0.22	Inflammatory bowel disease;	chr10:73730085	chr10:73699151~73730487:-
LUAD	cis	rs2688608	0.618	rs28718766	ENSG00000271816.1	BMS1P4	5	7.86e-07	0.000204	0.19	0.22	Inflammatory bowel disease;	chr10:73730086	chr10:73699151~73730487:-
LUAD	cis	rs925255	0.743	rs7589485	ENSG00000270210.1	RP11-373D23.3	5	7.87e-07	0.000204	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr2:28422253	chr2:28425945~28426719:+
LUAD	cis	rs7727544	0.606	rs200838	ENSG00000233006.5	AC034220.3	-5	7.87e-07	0.000204	-0.2	-0.22	Blood metabolite levels;	chr5:132374707	chr5:132311285~132369916:-
LUAD	cis	rs4776997	0.545	rs12592195	ENSG00000270964.1	RP11-502I4.3	5	7.87e-07	0.000204	0.25	0.22	Verbal declarative memory;	chr15:67848266	chr15:67541072~67542604:-
LUAD	cis	rs2742234	0.541	rs10793426	ENSG00000273008.1	RP11-351D16.3	5	7.87e-07	0.000204	0.26	0.22	Hirschsprung disease;	chr10:43249832	chr10:43136824~43138334:-
LUAD	cis	rs13256369	0.802	rs35382339	ENSG00000253893.2	FAM85B	-5	7.87e-07	0.000204	-0.31	-0.22	Obesity-related traits;	chr8:8701745	chr8:8167819~8226614:-
LUAD	cis	rs13256369	0.802	rs11781257	ENSG00000253893.2	FAM85B	-5	7.87e-07	0.000204	-0.31	-0.22	Obesity-related traits;	chr8:8702153	chr8:8167819~8226614:-
LUAD	cis	rs17684571	0.751	rs7758867	ENSG00000231441.1	RP11-472M19.2	5	7.87e-07	0.000204	0.32	0.22	Schizophrenia;	chr6:56836000	chr6:56844002~56864078:+
LUAD	cis	rs12745968	0.652	rs4970703	ENSG00000223787.2	RP4-593M8.1	-5	7.88e-07	0.000204	-0.28	-0.22	Bipolar disorder and schizophrenia;	chr1:92492298	chr1:92580476~92580821:-
LUAD	cis	rs7119038	0.509	rs10892258	ENSG00000255422.1	AP002954.4	-5	7.89e-07	0.000204	-0.33	-0.22	Sjögren's syndrome;	chr11:118709156	chr11:118704607~118750263:+
LUAD	cis	rs875971	0.54	rs4717275	ENSG00000224316.1	RP11-479O9.2	-5	7.89e-07	0.000204	-0.23	-0.22	Aortic root size;	chr7:65800193	chr7:65773620~65802067:+
LUAD	cis	rs240993	0.909	rs11153279	ENSG00000272356.1	RP5-1112D6.8	5	7.89e-07	0.000204	0.2	0.22	Inflammatory skin disease;Psoriasis;	chr6:111266063	chr6:111309203~111313517:+
LUAD	cis	rs17406451	0.655	rs6713844	ENSG00000279873.2	LINC01126	5	7.89e-07	0.000204	0.19	0.22	Mitochondrial DNA levels;	chr2:43523126	chr2:43227210~43228855:+
LUAD	cis	rs4142995	1	rs4142995	ENSG00000279048.1	RP11-511H23.2	-5	7.89e-07	0.000204	-0.17	-0.22	HDL cholesterol;HDL cholesterol levels;	chr7:17879635	chr7:17940503~17942922:+
LUAD	cis	rs7829975	0.774	rs57312668	ENSG00000173295.6	FAM86B3P	5	7.9e-07	0.000205	0.24	0.22	Mood instability;	chr8:8822967	chr8:8228595~8244865:+
LUAD	cis	rs4664293	0.801	rs7590595	ENSG00000230783.1	AC009961.2	-5	7.9e-07	0.000205	-0.27	-0.22	Monocyte percentage of white cells;	chr2:159715198	chr2:159689217~159690291:-
LUAD	cis	rs2274459	0.591	rs10947427	ENSG00000224796.1	RPL32P1	5	7.91e-07	0.000205	0.24	0.22	Obesity (extreme);	chr6:33676476	chr6:33079451~33079860:+
LUAD	cis	rs7937890	0.531	rs2575828	ENSG00000251991.1	RNU7-49P	5	7.91e-07	0.000205	0.24	0.22	Mitochondrial DNA levels;	chr11:14462646	chr11:14478892~14478953:+
LUAD	cis	rs172166	0.516	rs2791333	ENSG00000219392.1	RP1-265C24.5	-5	7.92e-07	0.000205	-0.28	-0.22	Cardiac Troponin-T levels;	chr6:28143336	chr6:28115628~28116551:+
LUAD	cis	rs858239	0.932	rs1728320	ENSG00000226816.2	AC005082.12	5	7.92e-07	0.000205	0.29	0.22	Cerebrospinal fluid biomarker levels;	chr7:23280170	chr7:23206013~23208045:+
LUAD	cis	rs875971	0.83	rs427973	ENSG00000237310.1	GS1-124K5.4	5	7.92e-07	0.000205	0.24	0.22	Aortic root size;	chr7:66061661	chr7:66493706~66495474:+
LUAD	cis	rs36093844	0.904	rs4631905	ENSG00000279742.1	RP11-700A24.1	-5	7.93e-07	0.000205	-0.25	-0.22	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85878375	chr11:85852557~85854943:-
LUAD	cis	rs7432375	0.566	rs835636	ENSG00000239213.4	NCK1-AS1	5	7.93e-07	0.000205	0.24	0.22	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136955658	chr3:136841726~136862054:-
LUAD	cis	rs2286503	0.839	rs2270108	ENSG00000221740.1	SNORD93	5	7.93e-07	0.000205	0.25	0.22	Fibrinogen;	chr7:22822512	chr7:22856613~22856686:+
LUAD	cis	rs2286503	0.839	rs2270107	ENSG00000221740.1	SNORD93	5	7.93e-07	0.000205	0.25	0.22	Fibrinogen;	chr7:22822564	chr7:22856613~22856686:+
LUAD	cis	rs2286503	0.839	rs2270103	ENSG00000221740.1	SNORD93	5	7.93e-07	0.000205	0.25	0.22	Fibrinogen;	chr7:22823103	chr7:22856613~22856686:+
LUAD	cis	rs2286503	0.839	rs10276099	ENSG00000221740.1	SNORD93	5	7.93e-07	0.000205	0.25	0.22	Fibrinogen;	chr7:22823331	chr7:22856613~22856686:+
LUAD	cis	rs1799949	1	rs4793212	ENSG00000236383.6	LINC00854	-5	7.93e-07	0.000205	-0.18	-0.22	Menopause (age at onset);	chr17:43150733	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs34534709	ENSG00000236383.6	LINC00854	-5	7.93e-07	0.000205	-0.18	-0.22	Menopause (age at onset);	chr17:43150923	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs34059614	ENSG00000236383.6	LINC00854	-5	7.93e-07	0.000205	-0.18	-0.22	Menopause (age at onset);	chr17:43151054	chr17:43216941~43305976:-
LUAD	cis	rs42490	0.873	rs218895	ENSG00000251136.7	RP11-37B2.1	-5	7.93e-07	0.000205	-0.23	-0.22	Leprosy;	chr8:89714320	chr8:89609409~89757727:-
LUAD	cis	rs2281558	0.583	rs7260957	ENSG00000125804.12	FAM182A	-5	7.94e-07	0.000205	-0.35	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25741826	chr20:26054655~26086917:+
LUAD	cis	rs4713118	0.615	rs57252182	ENSG00000219392.1	RP1-265C24.5	-5	7.94e-07	0.000205	-0.27	-0.22	Parkinson's disease;	chr6:27752470	chr6:28115628~28116551:+
LUAD	cis	rs56114371	0.53	rs169262	ENSG00000219392.1	RP1-265C24.5	-5	7.94e-07	0.000205	-0.31	-0.22	Breast cancer;	chr6:27803112	chr6:28115628~28116551:+
LUAD	cis	rs4819052	1	rs2297286	ENSG00000215447.6	BX322557.10	-5	7.94e-07	0.000205	-0.29	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45287982	chr21:45288052~45291738:+
LUAD	cis	rs1707322	1	rs6671754	ENSG00000280836.1	AL355480.1	-5	7.94e-07	0.000206	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968318	chr1:45581219~45581321:-
LUAD	cis	rs9309473	0.687	rs6706235	ENSG00000163016.8	ALMS1P	5	7.95e-07	0.000206	0.25	0.22	Metabolite levels;	chr2:73386430	chr2:73644919~73685576:+
LUAD	cis	rs8055167	1	rs8055167	ENSG00000280152.1	RP11-331F4.5	5	7.95e-07	0.000206	0.21	0.22	Alcoholic chronic pancreatitis;	chr16:75220991	chr16:75245994~75250077:-
LUAD	cis	rs1862618	0.525	rs2662016	ENSG00000271828.1	CTD-2310F14.1	-5	7.95e-07	0.000206	-0.33	-0.22	Initial pursuit acceleration;	chr5:56973220	chr5:56927874~56929573:+
LUAD	cis	rs7017914	0.653	rs6472548	ENSG00000223220.1	Y_RNA	5	7.95e-07	0.000206	0.25	0.22	Bone mineral density;	chr8:70842064	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.69	rs1156956	ENSG00000223220.1	Y_RNA	5	7.95e-07	0.000206	0.25	0.22	Bone mineral density;	chr8:70842803	chr8:70780914~70781008:-
LUAD	cis	rs2998286	0.723	rs332186	ENSG00000254635.4	WAC-AS1	-5	7.95e-07	0.000206	-0.29	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28624674	chr10:28522652~28532743:-
LUAD	cis	rs2998286	0.723	rs332187	ENSG00000254635.4	WAC-AS1	-5	7.95e-07	0.000206	-0.29	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28624887	chr10:28522652~28532743:-
LUAD	cis	rs2028299	1	rs4932148	ENSG00000259677.1	RP11-493E3.1	5	7.95e-07	0.000206	0.26	0.22	Type 2 diabetes;	chr15:89851124	chr15:89876540~89877285:+
LUAD	cis	rs6095360	0.727	rs17450430	ENSG00000222365.1	SNORD12B	-5	7.96e-07	0.000206	-0.25	-0.22	Intelligence (multi-trait analysis);	chr20:49155727	chr20:49280319~49280409:+
LUAD	cis	rs42490	0.868	rs4961155	ENSG00000251136.7	RP11-37B2.1	5	7.96e-07	0.000206	0.23	0.22	Leprosy;	chr8:89666035	chr8:89609409~89757727:-
LUAD	cis	rs8177876	0.822	rs77475047	ENSG00000261061.1	RP11-303E16.2	-5	7.96e-07	0.000206	-0.4	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81073355	chr16:81030770~81031485:+
LUAD	cis	rs950169	0.922	rs11630507	ENSG00000259295.5	CSPG4P12	5	7.96e-07	0.000206	0.32	0.22	Schizophrenia;	chr15:84552494	chr15:85191438~85213905:+
LUAD	cis	rs2380205	0.517	rs6602330	ENSG00000232807.2	RP11-536K7.3	5	7.96e-07	0.000206	0.24	0.22	Breast cancer;	chr10:5902270	chr10:5934270~5945900:-
LUAD	cis	rs7208859	0.623	rs3752019	ENSG00000280069.1	CTD-2349P21.3	-5	7.97e-07	0.000206	-0.31	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824687	chr17:30738182~30740275:+
LUAD	cis	rs7302981	0.667	rs7308692	ENSG00000272368.2	RP4-605O3.4	-5	7.97e-07	0.000206	-0.25	-0.22	Systolic blood pressure;	chr12:50233871	chr12:50112197~50165618:+
LUAD	cis	rs4664293	0.867	rs7606046	ENSG00000226266.5	AC009961.3	-5	7.97e-07	0.000206	-0.31	-0.22	Monocyte percentage of white cells;	chr2:159719647	chr2:159670708~159712435:-
LUAD	cis	rs2286503	1	rs2286498	ENSG00000226329.2	AC005682.6	-5	7.97e-07	0.000206	-0.28	-0.22	Fibrinogen;	chr7:22817885	chr7:22863874~22881350:-
LUAD	cis	rs2599510	0.744	rs2254106	ENSG00000276334.1	AL133243.1	5	7.97e-07	0.000206	0.25	0.22	Interleukin-18 levels;	chr2:32543730	chr2:32521927~32523547:+
LUAD	cis	rs8077577	0.747	rs3817992	ENSG00000273018.4	CTD-2303H24.2	-5	7.98e-07	0.000206	-0.31	-0.22	Obesity-related traits;	chr17:18290697	chr17:18511221~18551705:-
LUAD	cis	rs8077577	0.747	rs2294913	ENSG00000273018.4	CTD-2303H24.2	-5	7.98e-07	0.000206	-0.31	-0.22	Obesity-related traits;	chr17:18299682	chr17:18511221~18551705:-
LUAD	cis	rs2562456	0.793	rs57299552	ENSG00000268081.1	RP11-678G14.2	5	7.98e-07	0.000206	0.36	0.22	Pain;	chr19:21321326	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.754	rs76688173	ENSG00000268081.1	RP11-678G14.2	5	7.98e-07	0.000206	0.36	0.22	Pain;	chr19:21321856	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.833	rs74711277	ENSG00000268081.1	RP11-678G14.2	5	7.98e-07	0.000206	0.36	0.22	Pain;	chr19:21322641	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.833	rs62107479	ENSG00000268081.1	RP11-678G14.2	5	7.98e-07	0.000206	0.36	0.22	Pain;	chr19:21323962	chr19:21554640~21569237:-
LUAD	cis	rs74233809	1	rs10883808	ENSG00000213277.3	MARCKSL1P1	5	7.98e-07	0.000206	0.38	0.22	Birth weight;	chr10:102961369	chr10:103175554~103176094:+
LUAD	cis	rs74233809	1	rs11191479	ENSG00000213277.3	MARCKSL1P1	5	7.98e-07	0.000206	0.38	0.22	Birth weight;	chr10:102963863	chr10:103175554~103176094:+
LUAD	cis	rs916888	0.779	rs199526	ENSG00000261575.2	RP11-259G18.1	-5	7.98e-07	0.000207	-0.31	-0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:46267037~46268694:+
LUAD	cis	rs17711722	0.701	rs4467826	ENSG00000236529.1	RP13-254B10.1	5	7.98e-07	0.000207	0.22	0.22	Calcium levels;	chr7:65903721	chr7:65840212~65840596:+
LUAD	cis	rs73186030	0.546	rs67931976	ENSG00000272758.4	RP11-299J3.8	5	7.99e-07	0.000207	0.28	0.22	Serum parathyroid hormone levels;	chr3:122386868	chr3:122416207~122443180:+
LUAD	cis	rs7829975	0.714	rs11777085	ENSG00000173295.6	FAM86B3P	5	7.99e-07	0.000207	0.23	0.22	Mood instability;	chr8:8814919	chr8:8228595~8244865:+
LUAD	cis	rs875971	0.83	rs427973	ENSG00000232559.3	GS1-124K5.12	5	7.99e-07	0.000207	0.26	0.22	Aortic root size;	chr7:66061661	chr7:66554588~66576923:-
LUAD	cis	rs2976388	0.609	rs2585145	ENSG00000253741.1	CTD-2292P10.4	-5	7.99e-07	0.000207	-0.25	-0.22	Urinary tract infection frequency;	chr8:142718039	chr8:142702252~142726973:-
LUAD	cis	rs6570726	0.818	rs399516	ENSG00000235652.6	RP11-545I5.3	5	7.99e-07	0.000207	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145489713	chr6:145799409~145886585:+
LUAD	cis	rs36093844	0.752	rs7943104	ENSG00000279742.1	RP11-700A24.1	-5	7.99e-07	0.000207	-0.3	-0.22	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85834137	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.752	rs80323143	ENSG00000279742.1	RP11-700A24.1	-5	7.99e-07	0.000207	-0.3	-0.22	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85835053	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.651	rs55978615	ENSG00000279742.1	RP11-700A24.1	-5	7.99e-07	0.000207	-0.3	-0.22	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85835348	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.752	rs77197861	ENSG00000279742.1	RP11-700A24.1	-5	7.99e-07	0.000207	-0.3	-0.22	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85836362	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.752	rs1445511	ENSG00000279742.1	RP11-700A24.1	-5	7.99e-07	0.000207	-0.3	-0.22	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85837006	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.698	rs55951560	ENSG00000279742.1	RP11-700A24.1	-5	7.99e-07	0.000207	-0.3	-0.22	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85837299	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.752	rs56036199	ENSG00000279742.1	RP11-700A24.1	-5	7.99e-07	0.000207	-0.3	-0.22	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85837720	chr11:85852557~85854943:-
LUAD	cis	rs42490	0.834	rs10102245	ENSG00000251136.7	RP11-37B2.1	5	7.99e-07	0.000207	0.23	0.22	Leprosy;	chr8:89638317	chr8:89609409~89757727:-
LUAD	cis	rs2562456	0.652	rs62110214	ENSG00000268081.1	RP11-678G14.2	5	7.99e-07	0.000207	0.35	0.22	Pain;	chr19:21592406	chr19:21554640~21569237:-
LUAD	cis	rs6102185	0.572	rs6102201	ENSG00000229771.2	RP4-644L1.2	-5	8e-07	0.000207	-0.27	-0.22	IgG glycosylation;	chr20:40891166	chr20:40696499~40698616:-
LUAD	cis	rs442309	0.687	rs10995282	ENSG00000238280.1	RP11-436D10.3	-5	8.01e-07	0.000207	-0.28	-0.22	Vogt-Koyanagi-Harada syndrome;	chr10:62711531	chr10:62793562~62805887:-
LUAD	cis	rs2933343	0.7	rs2624910	ENSG00000261159.1	RP11-723O4.9	5	8.01e-07	0.000207	0.24	0.22	IgG glycosylation;	chr3:128931432	chr3:128859716~128860526:-
LUAD	cis	rs8031584	0.918	rs1425292	ENSG00000270015.1	RP11-540B6.6	-5	8.01e-07	0.000207	-0.16	-0.22	Huntington's disease progression;	chr15:30993219	chr15:30926514~30928407:+
LUAD	cis	rs853679	0.546	rs200953	ENSG00000219392.1	RP1-265C24.5	-5	8.02e-07	0.000207	-0.43	-0.22	Depression;	chr6:27869489	chr6:28115628~28116551:+
LUAD	cis	rs8127691	0.967	rs2838520	ENSG00000237604.1	AP001056.1	5	8.02e-07	0.000207	0.26	0.22	Inflammatory bowel disease;	chr21:44196013	chr21:44175489~44176453:+
LUAD	cis	rs2255336	0.938	rs1478309	ENSG00000245648.1	RP11-277P12.20	5	8.03e-07	0.000207	0.33	0.22	Blood protein levels;	chr12:10389146	chr12:10363769~10398506:+
LUAD	cis	rs73198271	0.737	rs565203	ENSG00000253893.2	FAM85B	5	8.03e-07	0.000207	0.28	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8775447	chr8:8167819~8226614:-
LUAD	cis	rs673078	0.66	rs16948197	ENSG00000275409.1	RP11-131L12.4	5	8.04e-07	0.000208	0.31	0.22	Glucose homeostasis traits;	chr12:118239135	chr12:118430147~118430699:+
LUAD	cis	rs9341808	0.754	rs6916405	ENSG00000272129.1	RP11-250B2.6	5	8.04e-07	0.000208	0.27	0.22	Sitting height ratio;	chr6:80314471	chr6:80355424~80356859:+
LUAD	cis	rs7829975	0.681	rs2271342	ENSG00000253893.2	FAM85B	-5	8.04e-07	0.000208	-0.28	-0.22	Mood instability;	chr8:8786428	chr8:8167819~8226614:-
LUAD	cis	rs12699921	0.536	rs2177652	ENSG00000279048.1	RP11-511H23.2	-5	8.04e-07	0.000208	-0.18	-0.22	Fibrinogen levels;	chr7:17855310	chr7:17940503~17942922:+
LUAD	cis	rs7017914	0.652	rs6994488	ENSG00000223220.1	Y_RNA	5	8.05e-07	0.000208	0.25	0.22	Bone mineral density;	chr8:70741229	chr8:70780914~70781008:-
LUAD	cis	rs116095464	1	rs3936676	ENSG00000277812.1	AC021087.1	5	8.05e-07	0.000208	0.62	0.22	Breast cancer;	chr5:353562	chr5:262769~262881:+
LUAD	cis	rs1850744	0.59	rs35509001	ENSG00000163612.10	FAM86KP	5	8.05e-07	0.000208	0.68	0.22	Economic and political preferences;	chr4:9593247	chr4:9153296~9165451:+
LUAD	cis	rs4591358	0.68	rs12693771	ENSG00000223466.1	AC064834.2	-5	8.06e-07	0.000208	-0.31	-0.22	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195461651	chr2:195533035~195538681:+
LUAD	cis	rs4908768	0.501	rs2016084	ENSG00000270282.1	RP5-1115A15.2	5	8.06e-07	0.000208	0.24	0.22	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8553359	chr1:8512653~8513021:+
LUAD	cis	rs6751744	0.924	rs13386318	ENSG00000226266.5	AC009961.3	-5	8.06e-07	0.000208	-0.34	-0.22	Dysphagia;	chr2:159541846	chr2:159670708~159712435:-
LUAD	cis	rs559928	0.642	rs2286615	ENSG00000236935.1	AP003774.1	5	8.07e-07	0.000208	0.33	0.22	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64271703	chr11:64325050~64329504:-
LUAD	cis	rs561341	1	rs72823787	ENSG00000265798.5	RP11-271K11.5	5	8.07e-07	0.000209	0.35	0.22	Hip circumference adjusted for BMI;	chr17:31956790	chr17:31038575~31059121:-
LUAD	cis	rs561341	1	rs72823789	ENSG00000265798.5	RP11-271K11.5	5	8.07e-07	0.000209	0.35	0.22	Hip circumference adjusted for BMI;	chr17:31957065	chr17:31038575~31059121:-
LUAD	cis	rs561341	1	rs2470243	ENSG00000265798.5	RP11-271K11.5	5	8.07e-07	0.000209	0.35	0.22	Hip circumference adjusted for BMI;	chr17:31963936	chr17:31038575~31059121:-
LUAD	cis	rs561341	1	rs483301	ENSG00000265798.5	RP11-271K11.5	5	8.07e-07	0.000209	0.35	0.22	Hip circumference adjusted for BMI;	chr17:31966379	chr17:31038575~31059121:-
LUAD	cis	rs561341	1	rs1681718	ENSG00000265798.5	RP11-271K11.5	5	8.07e-07	0.000209	0.35	0.22	Hip circumference adjusted for BMI;	chr17:31969426	chr17:31038575~31059121:-
LUAD	cis	rs4591358	0.68	rs12995102	ENSG00000223466.1	AC064834.2	-5	8.07e-07	0.000209	-0.31	-0.22	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195447752	chr2:195533035~195538681:+
LUAD	cis	rs3738443	0.951	rs55914345	ENSG00000259865.1	RP11-488L18.10	5	8.07e-07	0.000209	0.24	0.22	Alcohol dependence;	chr1:247216105	chr1:247187281~247188526:-
LUAD	cis	rs783540	0.521	rs28719490	ENSG00000278603.1	RP13-608F4.5	5	8.07e-07	0.000209	0.29	0.22	Schizophrenia;	chr15:82720688	chr15:82472203~82472426:+
LUAD	cis	rs453301	0.686	rs6601281	ENSG00000253893.2	FAM85B	5	8.08e-07	0.000209	0.28	0.22	Joint mobility (Beighton score);	chr8:9053494	chr8:8167819~8226614:-
LUAD	cis	rs4601821	0.635	rs12282356	ENSG00000270179.1	RP11-159N11.4	-5	8.08e-07	0.000209	-0.22	-0.22	Alcoholic chronic pancreatitis;	chr11:113337660	chr11:113368478~113369117:+
LUAD	cis	rs643506	0.874	rs582465	ENSG00000230911.1	PPIHP1	-5	8.08e-07	0.000209	-0.28	-0.22	Breast cancer;	chr11:111797861	chr11:112029858~112030367:-
LUAD	cis	rs9928842	0.664	rs8053265	ENSG00000280152.1	RP11-331F4.5	5	8.08e-07	0.000209	0.23	0.22	Alcoholic chronic pancreatitis;	chr16:75187953	chr16:75245994~75250077:-
LUAD	cis	rs240993	0.812	rs9481160	ENSG00000230177.1	RP5-1112D6.4	5	8.09e-07	0.000209	0.23	0.22	Inflammatory skin disease;Psoriasis;	chr6:111517317	chr6:111277932~111278742:+
LUAD	cis	rs4660214	0.666	rs1180376	ENSG00000228060.1	RP11-69E11.8	-5	8.09e-07	0.000209	-0.2	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39418761	chr1:39565160~39573203:+
LUAD	cis	rs1387259	0.931	rs11168474	ENSG00000257735.1	RP11-370I10.6	5	8.09e-07	0.000209	0.27	0.22	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48227601	chr12:48350945~48442411:+
LUAD	cis	rs55665837	0.539	rs10832310	ENSG00000251991.1	RNU7-49P	5	8.1e-07	0.000209	0.25	0.22	Vitamin D levels;	chr11:14856896	chr11:14478892~14478953:+
LUAD	cis	rs55665837	0.539	rs10832311	ENSG00000251991.1	RNU7-49P	5	8.1e-07	0.000209	0.25	0.22	Vitamin D levels;	chr11:14860380	chr11:14478892~14478953:+
LUAD	cis	rs950169	0.922	rs11633534	ENSG00000259295.5	CSPG4P12	5	8.1e-07	0.000209	0.33	0.22	Schizophrenia;	chr15:84581411	chr15:85191438~85213905:+
LUAD	cis	rs854462	0.925	rs854461	ENSG00000274767.1	AC131056.3	-5	8.11e-07	0.00021	-0.36	-0.22	Blood protein levels;	chr17:36057850	chr17:36183235~36196471:+
LUAD	cis	rs6142102	0.961	rs2268089	ENSG00000275784.1	RP5-1125A11.6	-5	8.11e-07	0.00021	-0.24	-0.22	Skin pigmentation;	chr20:34079492	chr20:33989480~33991818:-
LUAD	cis	rs858239	0.601	rs12539331	ENSG00000230042.1	AK3P3	-5	8.12e-07	0.00021	-0.28	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23111711	chr7:23129178~23129841:+
LUAD	cis	rs2033711	0.84	rs10423138	ENSG00000268912.1	CTD-2619J13.17	-5	8.12e-07	0.00021	-0.23	-0.22	Uric acid clearance;	chr19:58416935	chr19:58428632~58431148:-
LUAD	cis	rs2033711	0.87	rs3764534	ENSG00000268912.1	CTD-2619J13.17	-5	8.12e-07	0.00021	-0.23	-0.22	Uric acid clearance;	chr19:58417769	chr19:58428632~58431148:-
LUAD	cis	rs7131987	0.65	rs7301398	ENSG00000257176.2	RP11-996F15.2	-5	8.12e-07	0.00021	-0.25	-0.22	QT interval;	chr12:29302457	chr12:29280418~29317848:-
LUAD	cis	rs7131987	0.65	rs7301188	ENSG00000257176.2	RP11-996F15.2	-5	8.12e-07	0.00021	-0.25	-0.22	QT interval;	chr12:29302458	chr12:29280418~29317848:-
LUAD	cis	rs7017914	0.652	rs950903	ENSG00000223220.1	Y_RNA	5	8.13e-07	0.00021	0.25	0.22	Bone mineral density;	chr8:70988539	chr8:70780914~70781008:-
LUAD	cis	rs9322193	0.566	rs12528243	ENSG00000223701.3	RAET1E-AS1	5	8.13e-07	0.00021	0.32	0.22	Lung cancer;	chr6:149898491	chr6:149884431~149919508:+
LUAD	cis	rs7772486	0.754	rs9386132	ENSG00000235652.6	RP11-545I5.3	5	8.13e-07	0.00021	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145819615	chr6:145799409~145886585:+
LUAD	cis	rs1799949	0.896	rs35908185	ENSG00000236383.6	LINC00854	-5	8.13e-07	0.00021	-0.18	-0.22	Menopause (age at onset);	chr17:43103094	chr17:43216941~43305976:-
LUAD	cis	rs8177876	0.841	rs117310590	ENSG00000261061.1	RP11-303E16.2	-5	8.14e-07	0.00021	-0.43	-0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81094790	chr16:81030770~81031485:+
LUAD	cis	rs3177980	0.56	rs16862745	ENSG00000239494.2	RN7SL333P	-5	8.14e-07	0.00021	-0.22	-0.22	Amyotrophic lateral sclerosis;	chr1:169891058	chr1:169859756~169860052:+
LUAD	cis	rs4908768	0.501	rs12756257	ENSG00000270282.1	RP5-1115A15.2	5	8.15e-07	0.00021	0.24	0.22	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8556874	chr1:8512653~8513021:+
LUAD	cis	rs3761847	0.593	rs1468673	ENSG00000226752.6	PSMD5-AS1	-5	8.15e-07	0.00021	-0.23	-0.22	Rheumatoid arthritis;	chr9:121047612	chr9:120824828~120854385:+
LUAD	cis	rs2665103	0.715	rs7403041	ENSG00000278603.1	RP13-608F4.5	-5	8.15e-07	0.00021	-0.26	-0.22	Intelligence (multi-trait analysis);	chr15:82287841	chr15:82472203~82472426:+
LUAD	cis	rs910316	0.967	rs175498	ENSG00000259138.1	RP11-950C14.7	-5	8.15e-07	0.000211	-0.23	-0.22	Height;	chr14:75069666	chr14:75127153~75136930:+
LUAD	cis	rs67340775	0.541	rs200966	ENSG00000219392.1	RP1-265C24.5	-5	8.15e-07	0.000211	-0.37	-0.22	Lung cancer in ever smokers;	chr6:27894374	chr6:28115628~28116551:+
LUAD	cis	rs6539288	0.933	rs1444583	ENSG00000260329.1	RP11-412D9.4	5	8.16e-07	0.000211	0.23	0.22	Total body bone mineral density;	chr12:106919068	chr12:106954029~106955497:-
LUAD	cis	rs7119038	0.509	rs10892259	ENSG00000255422.1	AP002954.4	5	8.16e-07	0.000211	0.34	0.22	Sjögren's syndrome;	chr11:118712293	chr11:118704607~118750263:+
LUAD	cis	rs7208859	0.673	rs999798	ENSG00000280069.1	CTD-2349P21.3	-5	8.16e-07	0.000211	-0.26	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831822	chr17:30738182~30740275:+
LUAD	cis	rs72772090	0.71	rs17479052	ENSG00000248734.2	CTD-2260A17.1	-5	8.16e-07	0.000211	-0.33	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96729932	chr5:96784777~96785999:+
LUAD	cis	rs72772090	0.71	rs17400741	ENSG00000248734.2	CTD-2260A17.1	-5	8.16e-07	0.000211	-0.33	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96730872	chr5:96784777~96785999:+
LUAD	cis	rs7208859	0.623	rs8068645	ENSG00000263603.1	CTD-2349P21.5	-5	8.16e-07	0.000211	-0.38	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777324	chr17:30729469~30731202:+
LUAD	cis	rs465969	1	rs465969	ENSG00000255389.1	C6orf3	-5	8.16e-07	0.000211	-0.4	-0.22	Psoriasis;	chr6:111334327	chr6:111599875~111602295:+
LUAD	cis	rs17826219	0.733	rs7221691	ENSG00000263531.1	RP13-753N3.1	-5	8.16e-07	0.000211	-0.44	-0.22	Body mass index;	chr17:30396601	chr17:30863921~30864940:-
LUAD	cis	rs673078	0.607	rs16948230	ENSG00000275409.1	RP11-131L12.4	-5	8.16e-07	0.000211	-0.3	-0.22	Glucose homeostasis traits;	chr12:118277086	chr12:118430147~118430699:+
LUAD	cis	rs7302981	0.667	rs7136648	ENSG00000272368.2	RP4-605O3.4	5	8.17e-07	0.000211	0.25	0.22	Systolic blood pressure;	chr12:50231039	chr12:50112197~50165618:+
LUAD	cis	rs7937890	0.532	rs2575827	ENSG00000251991.1	RNU7-49P	5	8.17e-07	0.000211	0.24	0.22	Mitochondrial DNA levels;	chr11:14453969	chr11:14478892~14478953:+
LUAD	cis	rs7937890	0.532	rs2256884	ENSG00000251991.1	RNU7-49P	5	8.17e-07	0.000211	0.24	0.22	Mitochondrial DNA levels;	chr11:14454856	chr11:14478892~14478953:+
LUAD	cis	rs6687821	0.643	rs263495	ENSG00000267734.1	RP4-604K5.3	5	8.17e-07	0.000211	0.27	0.22	Yeast infection;	chr1:86753048	chr1:86932199~86934891:-
LUAD	cis	rs6570726	0.791	rs11759979	ENSG00000235652.6	RP11-545I5.3	5	8.17e-07	0.000211	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145597745	chr6:145799409~145886585:+
LUAD	cis	rs67340775	0.541	rs169287	ENSG00000219392.1	RP1-265C24.5	-5	8.17e-07	0.000211	-0.37	-0.22	Lung cancer in ever smokers;	chr6:27886982	chr6:28115628~28116551:+
LUAD	cis	rs4835473	0.868	rs1822841	ENSG00000251600.4	RP11-673E1.1	5	8.17e-07	0.000211	0.28	0.22	Immature fraction of reticulocytes;	chr4:143921485	chr4:143912331~143982454:+
LUAD	cis	rs7122539	0.646	rs608248	ENSG00000213409.4	RP11-658F2.3	5	8.17e-07	0.000211	0.26	0.22	HIV-1 susceptibility;	chr11:66794777	chr11:66761575~66762399:-
LUAD	cis	rs9549328	0.731	rs55804996	ENSG00000267868.1	RP11-120K24.3	5	8.18e-07	0.000211	0.27	0.22	Systolic blood pressure;	chr13:112971053	chr13:112964835~112966131:-
LUAD	cis	rs9813712	0.571	rs9824426	ENSG00000249846.5	RP11-77P16.4	-5	8.18e-07	0.000211	-0.26	-0.22	Response to amphetamines;	chr3:130226115	chr3:130112550~130120579:+
LUAD	cis	rs720475	0.732	rs17195725	ENSG00000170356.8	OR2A20P	-5	8.18e-07	0.000211	-0.31	-0.22	Breast cancer;	chr7:144440044	chr7:144250045~144252957:-
LUAD	cis	rs12681366	0.801	rs2043988	ENSG00000253704.1	RP11-267M23.4	5	8.18e-07	0.000211	0.28	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94457327	chr8:94553722~94569745:+
LUAD	cis	rs12681366	0.801	rs2919658	ENSG00000253704.1	RP11-267M23.4	5	8.18e-07	0.000211	0.28	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94459550	chr8:94553722~94569745:+
LUAD	cis	rs12681366	0.801	rs2930956	ENSG00000253704.1	RP11-267M23.4	5	8.18e-07	0.000211	0.28	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94460840	chr8:94553722~94569745:+
LUAD	cis	rs6519955	0.866	rs9626920	ENSG00000231711.2	LINC00899	-5	8.18e-07	0.000211	-0.2	-0.22	Dupuytren's disease;	chr22:46033113	chr22:46039907~46044853:-
LUAD	cis	rs3738443	0.951	rs41315860	ENSG00000259865.1	RP11-488L18.10	5	8.18e-07	0.000211	0.24	0.22	Alcohol dependence;	chr1:247212558	chr1:247187281~247188526:-
LUAD	cis	rs4660214	0.666	rs11205839	ENSG00000228060.1	RP11-69E11.8	5	8.18e-07	0.000211	0.2	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39268061	chr1:39565160~39573203:+
LUAD	cis	rs847577	0.677	rs1495525	ENSG00000272950.1	RP11-307C18.1	-5	8.19e-07	0.000211	-0.29	-0.22	Breast cancer;	chr7:98196920	chr7:98322853~98323430:+
LUAD	cis	rs858239	0.539	rs10270695	ENSG00000230042.1	AK3P3	5	8.19e-07	0.000211	0.28	0.22	Cerebrospinal fluid biomarker levels;	chr7:23149369	chr7:23129178~23129841:+
LUAD	cis	rs375066	0.935	rs387689	ENSG00000267058.1	RP11-15A1.3	-5	8.2e-07	0.000211	-0.25	-0.22	Breast cancer;	chr19:43915959	chr19:43891804~43901805:-
LUAD	cis	rs375066	0.935	rs398193	ENSG00000267058.1	RP11-15A1.3	-5	8.2e-07	0.000211	-0.25	-0.22	Breast cancer;	chr19:43916268	chr19:43891804~43901805:-
LUAD	cis	rs375066	0.868	rs378112	ENSG00000267058.1	RP11-15A1.3	-5	8.2e-07	0.000211	-0.25	-0.22	Breast cancer;	chr19:43917777	chr19:43891804~43901805:-
LUAD	cis	rs375066	0.868	rs378109	ENSG00000267058.1	RP11-15A1.3	-5	8.2e-07	0.000211	-0.25	-0.22	Breast cancer;	chr19:43917785	chr19:43891804~43901805:-
LUAD	cis	rs375066	0.935	rs450308	ENSG00000267058.1	RP11-15A1.3	-5	8.2e-07	0.000211	-0.25	-0.22	Breast cancer;	chr19:43918206	chr19:43891804~43901805:-
LUAD	cis	rs375066	0.935	rs424729	ENSG00000267058.1	RP11-15A1.3	-5	8.2e-07	0.000211	-0.25	-0.22	Breast cancer;	chr19:43918650	chr19:43891804~43901805:-
LUAD	cis	rs375066	0.935	rs423320	ENSG00000267058.1	RP11-15A1.3	-5	8.2e-07	0.000211	-0.25	-0.22	Breast cancer;	chr19:43918830	chr19:43891804~43901805:-
LUAD	cis	rs375066	0.935	rs423752	ENSG00000267058.1	RP11-15A1.3	-5	8.2e-07	0.000211	-0.25	-0.22	Breast cancer;	chr19:43919043	chr19:43891804~43901805:-
LUAD	cis	rs6604026	0.624	rs35705463	ENSG00000223787.2	RP4-593M8.1	5	8.21e-07	0.000212	0.3	0.22	Multiple sclerosis;	chr1:92767766	chr1:92580476~92580821:-
LUAD	cis	rs763567	0.81	rs638704	ENSG00000271811.1	RP1-79C4.4	5	8.21e-07	0.000212	0.27	0.22	Tonsillectomy;	chr1:170629046	chr1:170667381~170669425:+
LUAD	cis	rs7829975	0.846	rs11779061	ENSG00000253893.2	FAM85B	5	8.22e-07	0.000212	0.28	0.22	Mood instability;	chr8:8691922	chr8:8167819~8226614:-
LUAD	cis	rs896854	0.812	rs12546365	ENSG00000253528.2	RP11-347C18.4	5	8.22e-07	0.000212	0.21	0.22	Type 2 diabetes;	chr8:94899249	chr8:94974573~94974853:-
LUAD	cis	rs7923609	0.818	rs10761716	ENSG00000232075.1	MRPL35P2	-5	8.22e-07	0.000212	-0.28	-0.22	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63122540	chr10:63634317~63634827:-
LUAD	cis	rs6570726	0.738	rs6917199	ENSG00000235652.6	RP11-545I5.3	5	8.22e-07	0.000212	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145597184	chr6:145799409~145886585:+
LUAD	cis	rs755249	0.501	rs2490945	ENSG00000228060.1	RP11-69E11.8	-5	8.22e-07	0.000212	-0.2	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39371672	chr1:39565160~39573203:+
LUAD	cis	rs925255	0.776	rs2279990	ENSG00000270210.1	RP11-373D23.3	5	8.22e-07	0.000212	0.26	0.22	Inflammatory bowel disease;Crohn's disease;	chr2:28413873	chr2:28425945~28426719:+
LUAD	cis	rs6597981	0.604	rs7945912	ENSG00000255284.1	AP006621.5	5	8.22e-07	0.000212	0.21	0.22	Breast cancer;	chr11:750849	chr11:777578~784297:+
LUAD	cis	rs2286503	1	rs2286499	ENSG00000221740.1	SNORD93	5	8.23e-07	0.000212	0.25	0.22	Fibrinogen;	chr7:22817858	chr7:22856613~22856686:+
LUAD	cis	rs889398	0.935	rs244420	ENSG00000226232.7	RP11-419C5.2	5	8.23e-07	0.000212	0.19	0.22	Body mass index;	chr16:69624093	chr16:69976388~69996188:-
LUAD	cis	rs5758511	0.68	rs1033460	ENSG00000205702.9	CYP2D7	5	8.23e-07	0.000212	0.22	0.22	Birth weight;	chr22:42223302	chr22:42140203~42144577:-
LUAD	cis	rs4835473	0.932	rs17750042	ENSG00000251600.4	RP11-673E1.1	-5	8.23e-07	0.000212	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143726691	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1375989	ENSG00000251600.4	RP11-673E1.1	-5	8.23e-07	0.000212	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143726893	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs35598827	ENSG00000251600.4	RP11-673E1.1	-5	8.23e-07	0.000212	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143729605	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs34570929	ENSG00000251600.4	RP11-673E1.1	-5	8.23e-07	0.000212	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143730766	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs17750172	ENSG00000251600.4	RP11-673E1.1	-5	8.23e-07	0.000212	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143731094	chr4:143912331~143982454:+
LUAD	cis	rs11155671	0.53	rs9397398	ENSG00000268592.3	RAET1E-AS1	5	8.24e-07	0.000213	0.27	0.22	Testicular germ cell tumor;	chr6:149872467	chr6:149863494~149919507:+
LUAD	cis	rs9341808	0.754	rs9294173	ENSG00000272129.1	RP11-250B2.6	4.99	8.25e-07	0.000213	0.27	0.22	Sitting height ratio;	chr6:80281913	chr6:80355424~80356859:+
LUAD	cis	rs36423	0.702	rs36393	ENSG00000266869.1	RP6-114E22.1	-4.99	8.25e-07	0.000213	-0.33	-0.22	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71896009	chr14:71848606~71908430:+
LUAD	cis	rs36423	0.748	rs36392	ENSG00000266869.1	RP6-114E22.1	-4.99	8.25e-07	0.000213	-0.33	-0.22	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71896044	chr14:71848606~71908430:+
LUAD	cis	rs12745968	0.589	rs10874725	ENSG00000223787.2	RP4-593M8.1	-4.99	8.25e-07	0.000213	-0.26	-0.22	Bipolar disorder and schizophrenia;	chr1:92625293	chr1:92580476~92580821:-
LUAD	cis	rs4568518	0.53	rs6970593	ENSG00000279048.1	RP11-511H23.2	-4.99	8.25e-07	0.000213	-0.18	-0.22	Measles;	chr7:17949736	chr7:17940503~17942922:+
LUAD	cis	rs10754283	0.967	rs1934044	ENSG00000231613.1	RP5-943J3.1	-4.99	8.26e-07	0.000213	-0.23	-0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89641942	chr1:89788914~89790492:+
LUAD	cis	rs7017914	0.652	rs2639947	ENSG00000223220.1	Y_RNA	4.99	8.26e-07	0.000213	0.26	0.22	Bone mineral density;	chr8:70999202	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs2732145	ENSG00000223220.1	Y_RNA	4.99	8.26e-07	0.000213	0.26	0.22	Bone mineral density;	chr8:70999834	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs2732146	ENSG00000223220.1	Y_RNA	4.99	8.26e-07	0.000213	0.26	0.22	Bone mineral density;	chr8:70999883	chr8:70780914~70781008:-
LUAD	cis	rs7829975	0.572	rs7005000	ENSG00000253893.2	FAM85B	4.99	8.26e-07	0.000213	0.28	0.22	Mood instability;	chr8:8939092	chr8:8167819~8226614:-
LUAD	cis	rs6751744	1	rs6751744	ENSG00000226266.5	AC009961.3	-4.99	8.26e-07	0.000213	-0.33	-0.22	Dysphagia;	chr2:159550974	chr2:159670708~159712435:-
LUAD	cis	rs1799949	0.965	rs33961729	ENSG00000236383.6	LINC00854	-4.99	8.27e-07	0.000213	-0.18	-0.22	Menopause (age at onset);	chr17:43135907	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs11657835	ENSG00000236383.6	LINC00854	-4.99	8.27e-07	0.000213	-0.18	-0.22	Menopause (age at onset);	chr17:43139936	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs1135214	ENSG00000236383.6	LINC00854	-4.99	8.27e-07	0.000213	-0.18	-0.22	Menopause (age at onset);	chr17:43140306	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs11652332	ENSG00000236383.6	LINC00854	-4.99	8.27e-07	0.000213	-0.18	-0.22	Menopause (age at onset);	chr17:43143472	chr17:43216941~43305976:-
LUAD	cis	rs61542988	0.756	rs5013587	ENSG00000228649.7	AC005682.5	4.99	8.27e-07	0.000213	0.32	0.22	Fibrinogen levels;	chr7:22843041	chr7:22854178~22861579:+
LUAD	cis	rs12908161	1	rs35960805	ENSG00000275120.1	RP11-182J1.17	4.99	8.27e-07	0.000213	0.33	0.22	Schizophrenia;	chr15:84800749	chr15:84599434~84606463:-
LUAD	cis	rs12908161	1	rs12912388	ENSG00000275120.1	RP11-182J1.17	4.99	8.27e-07	0.000213	0.33	0.22	Schizophrenia;	chr15:84801319	chr15:84599434~84606463:-
LUAD	cis	rs12460587	0.587	rs10415150	ENSG00000275055.1	CTC-471J1.11	-4.99	8.28e-07	0.000213	-0.25	-0.22	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52101372	chr19:52049007~52049754:+
LUAD	cis	rs61270009	0.955	rs4916907	ENSG00000247828.6	TMEM161B-AS1	4.99	8.28e-07	0.000213	0.26	0.22	Depressive symptoms;	chr5:88364163	chr5:88268895~88436685:+
LUAD	cis	rs61270009	0.955	rs12657776	ENSG00000247828.6	TMEM161B-AS1	4.99	8.28e-07	0.000213	0.26	0.22	Depressive symptoms;	chr5:88365776	chr5:88268895~88436685:+
LUAD	cis	rs42490	0.966	rs218936	ENSG00000251136.7	RP11-37B2.1	4.99	8.29e-07	0.000214	0.23	0.22	Leprosy;	chr8:89743186	chr8:89609409~89757727:-
LUAD	cis	rs4591358	0.731	rs12693772	ENSG00000223466.1	AC064834.2	-4.99	8.29e-07	0.000214	-0.31	-0.22	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195473636	chr2:195533035~195538681:+
LUAD	cis	rs17818399	0.815	rs62136873	ENSG00000279254.1	RP11-536C12.1	-4.99	8.3e-07	0.000214	-0.26	-0.22	Height;	chr2:46634098	chr2:46668870~46670778:+
LUAD	cis	rs561341	1	rs497479	ENSG00000265798.5	RP11-271K11.5	4.99	8.3e-07	0.000214	0.35	0.22	Hip circumference adjusted for BMI;	chr17:32001586	chr17:31038575~31059121:-
LUAD	cis	rs2239547	0.603	rs9870898	ENSG00000242142.1	SERBP1P3	4.99	8.3e-07	0.000214	0.27	0.22	Schizophrenia;	chr3:53058359	chr3:53064283~53065091:-
LUAD	cis	rs7714584	1	rs4958842	ENSG00000197083.10	ZNF300P1	4.99	8.31e-07	0.000214	0.45	0.22	Crohn's disease;	chr5:150845315	chr5:150930645~150946289:-
LUAD	cis	rs7937890	0.504	rs2575847	ENSG00000251991.1	RNU7-49P	4.99	8.31e-07	0.000214	0.24	0.22	Mitochondrial DNA levels;	chr11:14449626	chr11:14478892~14478953:+
LUAD	cis	rs7937890	0.559	rs2575825	ENSG00000251991.1	RNU7-49P	4.99	8.31e-07	0.000214	0.24	0.22	Mitochondrial DNA levels;	chr11:14450550	chr11:14478892~14478953:+
LUAD	cis	rs7772486	0.754	rs2328707	ENSG00000235652.6	RP11-545I5.3	-4.99	8.31e-07	0.000214	-0.22	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145732362	chr6:145799409~145886585:+
LUAD	cis	rs6728642	0.901	rs7584641	ENSG00000230606.9	AC159540.1	4.99	8.31e-07	0.000214	0.35	0.22	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96941918	chr2:97416165~97433527:-
LUAD	cis	rs17711722	0.701	rs781143	ENSG00000224316.1	RP11-479O9.2	4.99	8.31e-07	0.000214	0.22	0.22	Calcium levels;	chr7:65974892	chr7:65773620~65802067:+
LUAD	cis	rs4835473	0.778	rs2622380	ENSG00000251600.4	RP11-673E1.1	-4.99	8.31e-07	0.000214	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143814571	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs35792820	ENSG00000251600.4	RP11-673E1.1	-4.99	8.31e-07	0.000214	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143814806	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.864	rs62337300	ENSG00000251600.4	RP11-673E1.1	-4.99	8.31e-07	0.000214	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143815897	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs7697498	ENSG00000251600.4	RP11-673E1.1	-4.99	8.31e-07	0.000214	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143816854	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs7656455	ENSG00000251600.4	RP11-673E1.1	-4.99	8.31e-07	0.000214	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143817005	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs13133239	ENSG00000251600.4	RP11-673E1.1	-4.99	8.31e-07	0.000214	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143818894	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.9	rs13106488	ENSG00000251600.4	RP11-673E1.1	-4.99	8.31e-07	0.000214	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143818969	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs13105102	ENSG00000251600.4	RP11-673E1.1	-4.99	8.31e-07	0.000214	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143819046	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.868	rs13105118	ENSG00000251600.4	RP11-673E1.1	-4.99	8.31e-07	0.000214	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143819077	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs35271123	ENSG00000251600.4	RP11-673E1.1	-4.99	8.31e-07	0.000214	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143819629	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1383443	ENSG00000251600.4	RP11-673E1.1	-4.99	8.31e-07	0.000214	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143819940	chr4:143912331~143982454:+
LUAD	cis	rs2367970	0.57	rs7123583	ENSG00000280143.1	AP000892.6	-4.99	8.31e-07	0.000214	-0.28	-0.22	HDL cholesterol;	chr11:116729305	chr11:117204967~117210292:+
LUAD	cis	rs8077577	0.747	rs62072507	ENSG00000273018.4	CTD-2303H24.2	-4.99	8.31e-07	0.000214	-0.31	-0.22	Obesity-related traits;	chr17:18269021	chr17:18511221~18551705:-
LUAD	cis	rs13256369	0.802	rs13281933	ENSG00000253893.2	FAM85B	-4.99	8.32e-07	0.000214	-0.31	-0.22	Obesity-related traits;	chr8:8705155	chr8:8167819~8226614:-
LUAD	cis	rs496547	0.52	rs11216963	ENSG00000255239.1	AP002954.6	-4.99	8.32e-07	0.000214	-0.32	-0.22	Hip minimal joint space width;	chr11:118710105	chr11:118688039~118690600:-
LUAD	cis	rs7119038	0.509	rs11216964	ENSG00000255239.1	AP002954.6	-4.99	8.32e-07	0.000214	-0.32	-0.22	Sjögren's syndrome;	chr11:118711186	chr11:118688039~118690600:-
LUAD	cis	rs1707322	1	rs4660334	ENSG00000280836.1	AL355480.1	-4.99	8.33e-07	0.000214	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45996454	chr1:45581219~45581321:-
LUAD	cis	rs477895	1	rs66968227	ENSG00000236935.1	AP003774.1	-4.99	8.33e-07	0.000214	-0.29	-0.22	Mean platelet volume;	chr11:64303458	chr11:64325050~64329504:-
LUAD	cis	rs7017914	0.69	rs6992048	ENSG00000223220.1	Y_RNA	4.99	8.33e-07	0.000215	0.25	0.22	Bone mineral density;	chr8:70911636	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.69	rs6984663	ENSG00000223220.1	Y_RNA	4.99	8.33e-07	0.000215	0.25	0.22	Bone mineral density;	chr8:70915430	chr8:70780914~70781008:-
LUAD	cis	rs13256369	0.802	rs11249885	ENSG00000253893.2	FAM85B	-4.99	8.34e-07	0.000215	-0.29	-0.22	Obesity-related traits;	chr8:8704498	chr8:8167819~8226614:-
LUAD	cis	rs240993	0.812	rs4945881	ENSG00000230177.1	RP5-1112D6.4	4.99	8.34e-07	0.000215	0.22	0.22	Inflammatory skin disease;Psoriasis;	chr6:111470260	chr6:111277932~111278742:+
LUAD	cis	rs35160687	0.623	rs718292	ENSG00000273080.1	RP11-301O19.1	4.99	8.34e-07	0.000215	0.25	0.22	Night sleep phenotypes;	chr2:86246617	chr2:86195590~86196049:+
LUAD	cis	rs2033711	0.755	rs4801587	ENSG00000268912.1	CTD-2619J13.17	-4.99	8.35e-07	0.000215	-0.23	-0.22	Uric acid clearance;	chr19:58425312	chr19:58428632~58431148:-
LUAD	cis	rs3096299	0.658	rs4785679	ENSG00000182376.2	RP5-1142A6.8	4.99	8.35e-07	0.000215	0.23	0.22	Multiple myeloma (IgH translocation);	chr16:89499705	chr16:88742767~88745748:+
LUAD	cis	rs7829975	0.714	rs7823757	ENSG00000253981.4	ALG1L13P	4.99	8.36e-07	0.000215	0.25	0.22	Mood instability;	chr8:8812667	chr8:8236003~8244667:-
LUAD	cis	rs7017914	0.69	rs55915640	ENSG00000223220.1	Y_RNA	4.99	8.37e-07	0.000215	0.26	0.22	Bone mineral density;	chr8:71052423	chr8:70780914~70781008:-
LUAD	cis	rs2933343	0.649	rs2638845	ENSG00000261159.1	RP11-723O4.9	4.99	8.37e-07	0.000216	0.24	0.22	IgG glycosylation;	chr3:128868526	chr3:128859716~128860526:-
LUAD	cis	rs2732480	0.5	rs2450991	ENSG00000257735.1	RP11-370I10.6	4.99	8.37e-07	0.000216	0.27	0.22	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48257838	chr12:48350945~48442411:+
LUAD	cis	rs14027	0.921	rs67905698	ENSG00000279347.1	RP11-85I17.2	-4.99	8.37e-07	0.000216	-0.19	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119792186	chr8:119838736~119840385:-
LUAD	cis	rs14027	0.921	rs28756749	ENSG00000279347.1	RP11-85I17.2	-4.99	8.37e-07	0.000216	-0.19	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119803164	chr8:119838736~119840385:-
LUAD	cis	rs11971779	0.715	rs10954646	ENSG00000273391.1	RP11-634H22.1	-4.99	8.37e-07	0.000216	-0.23	-0.22	Diisocyanate-induced asthma;	chr7:139376323	chr7:139359032~139359566:-
LUAD	cis	rs897984	0.806	rs12924903	ENSG00000260911.2	RP11-196G11.2	4.99	8.38e-07	0.000216	0.2	0.22	Dementia with Lewy bodies;	chr16:30917649	chr16:31043150~31049868:+
LUAD	cis	rs36093844	0.752	rs56261432	ENSG00000279742.1	RP11-700A24.1	-4.99	8.38e-07	0.000216	-0.3	-0.22	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85837338	chr11:85852557~85854943:-
LUAD	cis	rs61270009	0.955	rs78909929	ENSG00000247828.6	TMEM161B-AS1	4.99	8.38e-07	0.000216	0.25	0.22	Depressive symptoms;	chr5:88344154	chr5:88268895~88436685:+
LUAD	cis	rs6687758	1	rs66666316	ENSG00000228437.4	RP11-400N13.2	4.99	8.39e-07	0.000216	0.34	0.22	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222018592	chr1:221966341~221984964:+
LUAD	cis	rs9322193	0.923	rs11155683	ENSG00000268592.3	RAET1E-AS1	4.99	8.4e-07	0.000216	0.27	0.22	Lung cancer;	chr6:149779341	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.923	rs9372044	ENSG00000268592.3	RAET1E-AS1	4.99	8.4e-07	0.000216	0.27	0.22	Lung cancer;	chr6:149780867	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.962	rs11155685	ENSG00000268592.3	RAET1E-AS1	4.99	8.4e-07	0.000216	0.27	0.22	Lung cancer;	chr6:149781649	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.962	rs9689269	ENSG00000268592.3	RAET1E-AS1	4.99	8.4e-07	0.000216	0.27	0.22	Lung cancer;	chr6:149791861	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.962	rs62441335	ENSG00000268592.3	RAET1E-AS1	4.99	8.4e-07	0.000216	0.27	0.22	Lung cancer;	chr6:149792658	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.962	rs4816	ENSG00000268592.3	RAET1E-AS1	4.99	8.4e-07	0.000216	0.27	0.22	Lung cancer;	chr6:149793609	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.926	rs952166	ENSG00000268592.3	RAET1E-AS1	4.99	8.4e-07	0.000216	0.27	0.22	Lung cancer;	chr6:149798774	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.962	rs952165	ENSG00000268592.3	RAET1E-AS1	4.99	8.4e-07	0.000216	0.27	0.22	Lung cancer;	chr6:149798900	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.926	rs9285525	ENSG00000268592.3	RAET1E-AS1	4.99	8.4e-07	0.000216	0.27	0.22	Lung cancer;	chr6:149801253	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.884	rs2342858	ENSG00000268592.3	RAET1E-AS1	4.99	8.4e-07	0.000216	0.27	0.22	Lung cancer;	chr6:149805967	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.884	rs2095375	ENSG00000268592.3	RAET1E-AS1	4.99	8.4e-07	0.000216	0.27	0.22	Lung cancer;	chr6:149807037	chr6:149863494~149919507:+
LUAD	cis	rs2439831	0.85	rs2228368	ENSG00000249839.1	AC011330.5	-4.99	8.4e-07	0.000216	-0.44	-0.22	Lung cancer in ever smokers;	chr15:43809812	chr15:43663654~43684339:-
LUAD	cis	rs1707322	1	rs4660906	ENSG00000280836.1	AL355480.1	-4.99	8.4e-07	0.000216	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46005188	chr1:45581219~45581321:-
LUAD	cis	rs673078	0.607	rs7307393	ENSG00000275409.1	RP11-131L12.4	-4.99	8.4e-07	0.000216	-0.33	-0.22	Glucose homeostasis traits;	chr12:118308537	chr12:118430147~118430699:+
LUAD	cis	rs9322193	0.847	rs12191643	ENSG00000268592.3	RAET1E-AS1	4.99	8.4e-07	0.000216	0.27	0.22	Lung cancer;	chr6:149628912	chr6:149863494~149919507:+
LUAD	cis	rs73173548	0.502	rs6865693	ENSG00000247828.6	TMEM161B-AS1	4.99	8.41e-07	0.000216	0.27	0.22	Macular telangiectasia type 2;	chr5:88419422	chr5:88268895~88436685:+
LUAD	cis	rs6751744	0.513	rs7563368	ENSG00000226266.5	AC009961.3	4.99	8.41e-07	0.000216	0.3	0.22	Dysphagia;	chr2:159600564	chr2:159670708~159712435:-
LUAD	cis	rs910316	0.967	rs4899545	ENSG00000259138.1	RP11-950C14.7	4.99	8.41e-07	0.000216	0.24	0.22	Height;	chr14:75101435	chr14:75127153~75136930:+
LUAD	cis	rs4835473	0.524	rs4404495	ENSG00000251600.4	RP11-673E1.1	4.99	8.41e-07	0.000216	0.27	0.22	Immature fraction of reticulocytes;	chr4:143979791	chr4:143912331~143982454:+
LUAD	cis	rs1823913	0.503	rs34689696	ENSG00000280083.1	RP11-317J9.1	-4.99	8.42e-07	0.000217	-0.28	-0.22	Obesity-related traits;	chr2:191355247	chr2:191154118~191156070:-
LUAD	cis	rs13315649	0.562	rs6439137	ENSG00000242551.2	POU5F1P6	-4.99	8.42e-07	0.000217	-0.28	-0.22	Sum eosinophil basophil counts;	chr3:128668107	chr3:128674735~128677005:-
LUAD	cis	rs6142102	0.961	rs6120519	ENSG00000275784.1	RP5-1125A11.6	-4.99	8.42e-07	0.000217	-0.24	-0.22	Skin pigmentation;	chr20:34100307	chr20:33989480~33991818:-
LUAD	cis	rs11976180	1	rs2961117	ENSG00000204959.4	ARHGEF34P	4.99	8.42e-07	0.000217	0.27	0.22	Obesity-related traits;	chr7:144058160	chr7:144272445~144286966:-
LUAD	cis	rs9322193	0.962	rs6914319	ENSG00000268592.3	RAET1E-AS1	4.99	8.42e-07	0.000217	0.27	0.22	Lung cancer;	chr6:149806304	chr6:149863494~149919507:+
LUAD	cis	rs1275468	1	rs1148000	ENSG00000257497.2	RP11-585P4.5	-4.99	8.42e-07	0.000217	-0.31	-0.22	Polycystic ovary syndrome;	chr12:75542521	chr12:75483454~75489820:-
LUAD	cis	rs673078	0.66	rs16948234	ENSG00000275409.1	RP11-131L12.4	4.99	8.43e-07	0.000217	0.31	0.22	Glucose homeostasis traits;	chr12:118282464	chr12:118430147~118430699:+
LUAD	cis	rs8077577	0.747	rs12449313	ENSG00000273018.4	CTD-2303H24.2	-4.99	8.43e-07	0.000217	-0.31	-0.22	Obesity-related traits;	chr17:18317696	chr17:18511221~18551705:-
LUAD	cis	rs9322193	0.962	rs3805753	ENSG00000268592.3	RAET1E-AS1	4.99	8.43e-07	0.000217	0.27	0.22	Lung cancer;	chr6:149795662	chr6:149863494~149919507:+
LUAD	cis	rs6604026	0.555	rs34734076	ENSG00000223787.2	RP4-593M8.1	4.99	8.44e-07	0.000217	0.31	0.22	Multiple sclerosis;	chr1:92613901	chr1:92580476~92580821:-
LUAD	cis	rs6604026	0.555	rs11807962	ENSG00000223787.2	RP4-593M8.1	4.99	8.44e-07	0.000217	0.31	0.22	Multiple sclerosis;	chr1:92614721	chr1:92580476~92580821:-
LUAD	cis	rs6604026	0.555	rs11589122	ENSG00000223787.2	RP4-593M8.1	4.99	8.44e-07	0.000217	0.31	0.22	Multiple sclerosis;	chr1:92618346	chr1:92580476~92580821:-
LUAD	cis	rs7172677	0.768	rs72730586	ENSG00000260269.4	CTD-2323K18.1	4.99	8.45e-07	0.000217	0.3	0.22	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75061824	chr15:75527150~75601205:-
LUAD	cis	rs14027	0.883	rs10087723	ENSG00000279347.1	RP11-85I17.2	-4.99	8.45e-07	0.000217	-0.2	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119711014	chr8:119838736~119840385:-
LUAD	cis	rs11976180	1	rs13243677	ENSG00000204959.4	ARHGEF34P	4.99	8.45e-07	0.000217	0.28	0.22	Obesity-related traits;	chr7:144049479	chr7:144272445~144286966:-
LUAD	cis	rs875971	0.619	rs2302918	ENSG00000224316.1	RP11-479O9.2	4.99	8.46e-07	0.000218	0.23	0.22	Aortic root size;	chr7:66535945	chr7:65773620~65802067:+
LUAD	cis	rs2933343	0.672	rs1872545	ENSG00000261159.1	RP11-723O4.9	4.99	8.46e-07	0.000218	0.24	0.22	IgG glycosylation;	chr3:128926196	chr3:128859716~128860526:-
LUAD	cis	rs2836950	0.501	rs62223052	ENSG00000255568.3	BRWD1-AS2	-4.99	8.46e-07	0.000218	-0.22	-0.22	Menarche (age at onset);	chr21:39336776	chr21:39313935~39314962:+
LUAD	cis	rs6964587	0.507	rs12539439	ENSG00000188693.7	CYP51A1-AS1	-4.99	8.46e-07	0.000218	-0.27	-0.22	Breast cancer;	chr7:92288051	chr7:92134604~92180725:+
LUAD	cis	rs36093844	0.752	rs78820266	ENSG00000279742.1	RP11-700A24.1	-4.99	8.47e-07	0.000218	-0.3	-0.22	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85847214	chr11:85852557~85854943:-
LUAD	cis	rs6993244	1	rs6993244	ENSG00000173295.6	FAM86B3P	4.99	8.48e-07	0.000218	0.24	0.22	Mean corpuscular hemoglobin;	chr8:9005549	chr8:8228595~8244865:+
LUAD	cis	rs1707322	1	rs6687301	ENSG00000280836.1	AL355480.1	-4.99	8.48e-07	0.000218	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45917180	chr1:45581219~45581321:-
LUAD	cis	rs720475	0.732	rs62483106	ENSG00000170356.8	OR2A20P	4.99	8.49e-07	0.000218	0.31	0.22	Breast cancer;	chr7:144439533	chr7:144250045~144252957:-
LUAD	cis	rs301901	1	rs6875748	ENSG00000250155.1	CTD-2353F22.1	4.99	8.49e-07	0.000218	0.23	0.22	Height;	chr5:37041491	chr5:36666214~36725195:-
LUAD	cis	rs42490	1	rs1003843	ENSG00000251136.7	RP11-37B2.1	-4.99	8.49e-07	0.000218	-0.23	-0.22	Leprosy;	chr8:89727252	chr8:89609409~89757727:-
LUAD	cis	rs7773456	0.711	rs9358277	ENSG00000228412.5	RP4-625H18.2	-4.99	8.49e-07	0.000218	-0.3	-0.22	Lupus nephritis in systemic lupus erythematosus;	chr6:19816398	chr6:19802164~19804752:-
LUAD	cis	rs2286503	0.839	rs4722189	ENSG00000221740.1	SNORD93	4.99	8.49e-07	0.000218	0.25	0.22	Fibrinogen;	chr7:22820855	chr7:22856613~22856686:+
LUAD	cis	rs2286503	0.809	rs4719716	ENSG00000221740.1	SNORD93	4.99	8.49e-07	0.000218	0.25	0.22	Fibrinogen;	chr7:22821750	chr7:22856613~22856686:+
LUAD	cis	rs2286503	0.78	rs981792	ENSG00000221740.1	SNORD93	4.99	8.49e-07	0.000218	0.25	0.22	Fibrinogen;	chr7:22822020	chr7:22856613~22856686:+
LUAD	cis	rs3750965	1	rs731974	ENSG00000260895.1	RP11-554A11.7	4.99	8.49e-07	0.000218	0.26	0.22	Hair color;	chr11:69079688	chr11:69103493~69109094:+
LUAD	cis	rs9828933	0.938	rs9809432	ENSG00000280620.1	SCAANT1	4.99	8.49e-07	0.000218	0.32	0.22	Type 2 diabetes;	chr3:64017277	chr3:63911518~63911772:-
LUAD	cis	rs950169	0.58	rs17598114	ENSG00000259295.5	CSPG4P12	4.99	8.5e-07	0.000218	0.31	0.22	Schizophrenia;	chr15:84628086	chr15:85191438~85213905:+
LUAD	cis	rs12699921	0.935	rs6461363	ENSG00000279048.1	RP11-511H23.2	4.99	8.5e-07	0.000218	0.19	0.22	Fibrinogen levels;	chr7:17952527	chr7:17940503~17942922:+
LUAD	cis	rs2732480	0.5	rs7297824	ENSG00000257735.1	RP11-370I10.6	4.99	8.51e-07	0.000219	0.27	0.22	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48204867	chr12:48350945~48442411:+
LUAD	cis	rs35160687	0.644	rs11687392	ENSG00000273080.1	RP11-301O19.1	-4.99	8.51e-07	0.000219	-0.25	-0.22	Night sleep phenotypes;	chr2:86275540	chr2:86195590~86196049:+
LUAD	cis	rs193541	0.555	rs2438151	ENSG00000263432.2	RN7SL689P	4.99	8.51e-07	0.000219	0.29	0.22	Glucose homeostasis traits;	chr5:122863502	chr5:123022487~123022783:-
LUAD	cis	rs11673344	0.966	rs56330606	ENSG00000226686.6	LINC01535	4.99	8.52e-07	0.000219	0.28	0.22	Obesity-related traits;	chr19:37183051	chr19:37251912~37265535:+
LUAD	cis	rs7120173	0.693	rs12799198	ENSG00000254851.1	RP11-109L13.1	-4.99	8.52e-07	0.000219	-0.35	-0.22	Visceral adipose tissue adjusted for BMI;	chr11:116930706	chr11:117135528~117138582:+
LUAD	cis	rs997295	0.592	rs12594849	ENSG00000270964.1	RP11-502I4.3	-4.99	8.53e-07	0.000219	-0.23	-0.22	Motion sickness;	chr15:67424234	chr15:67541072~67542604:-
LUAD	cis	rs4835473	0.932	rs4835471	ENSG00000251600.4	RP11-673E1.1	4.99	8.53e-07	0.000219	0.27	0.22	Immature fraction of reticulocytes;	chr4:143982153	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.897	rs4835119	ENSG00000251600.4	RP11-673E1.1	4.99	8.53e-07	0.000219	0.27	0.22	Immature fraction of reticulocytes;	chr4:143982210	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs4835472	ENSG00000251600.4	RP11-673E1.1	4.99	8.53e-07	0.000219	0.27	0.22	Immature fraction of reticulocytes;	chr4:143982398	chr4:143912331~143982454:+
LUAD	cis	rs4835473	1	rs4835473	ENSG00000251600.4	RP11-673E1.1	4.99	8.53e-07	0.000219	0.27	0.22	Immature fraction of reticulocytes;	chr4:143982419	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs6847869	ENSG00000251600.4	RP11-673E1.1	4.99	8.53e-07	0.000219	0.27	0.22	Immature fraction of reticulocytes;	chr4:143982881	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.897	rs6846984	ENSG00000251600.4	RP11-673E1.1	4.99	8.53e-07	0.000219	0.27	0.22	Immature fraction of reticulocytes;	chr4:143983098	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs34617134	ENSG00000251600.4	RP11-673E1.1	4.99	8.53e-07	0.000219	0.27	0.22	Immature fraction of reticulocytes;	chr4:143983606	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs4260486	ENSG00000251600.4	RP11-673E1.1	4.99	8.53e-07	0.000219	0.27	0.22	Immature fraction of reticulocytes;	chr4:143987556	chr4:143912331~143982454:+
LUAD	cis	rs4664293	0.867	rs6761145	ENSG00000226266.5	AC009961.3	-4.99	8.54e-07	0.000219	-0.31	-0.22	Monocyte percentage of white cells;	chr2:159725673	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs6732987	ENSG00000226266.5	AC009961.3	-4.99	8.54e-07	0.000219	-0.31	-0.22	Monocyte percentage of white cells;	chr2:159725918	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs7589941	ENSG00000226266.5	AC009961.3	-4.99	8.54e-07	0.000219	-0.31	-0.22	Monocyte percentage of white cells;	chr2:159727589	chr2:159670708~159712435:-
LUAD	cis	rs875971	0.767	rs1643394	ENSG00000232559.3	GS1-124K5.12	4.99	8.54e-07	0.000219	0.26	0.22	Aortic root size;	chr7:66371107	chr7:66554588~66576923:-
LUAD	cis	rs12745968	0.589	rs10874727	ENSG00000223787.2	RP4-593M8.1	-4.99	8.54e-07	0.000219	-0.26	-0.22	Bipolar disorder and schizophrenia;	chr1:92637595	chr1:92580476~92580821:-
LUAD	cis	rs7727544	0.716	rs10058655	ENSG00000233006.5	AC034220.3	4.99	8.54e-07	0.000219	0.2	0.22	Blood metabolite levels;	chr5:132235203	chr5:132311285~132369916:-
LUAD	cis	rs8072100	0.656	rs2610367	ENSG00000228782.6	CTD-2026D20.3	4.99	8.56e-07	0.00022	0.24	0.22	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47492449	chr17:47450568~47492492:-
LUAD	cis	rs7772486	0.754	rs1415747	ENSG00000235652.6	RP11-545I5.3	4.99	8.56e-07	0.00022	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145756113	chr6:145799409~145886585:+
LUAD	cis	rs9322193	0.962	rs9765929	ENSG00000268592.3	RAET1E-AS1	4.99	8.56e-07	0.00022	0.27	0.22	Lung cancer;	chr6:149769680	chr6:149863494~149919507:+
LUAD	cis	rs287982	1	rs287976	ENSG00000269973.1	RP11-95D17.1	4.99	8.57e-07	0.00022	0.25	0.22	Nonsyndromic cleft lip with cleft palate;	chr2:9829559	chr2:9936360~9939590:+
LUAD	cis	rs1816752	0.74	rs6490924	ENSG00000273628.1	RP11-756A22.7	-4.99	8.58e-07	0.00022	-0.25	-0.22	Obesity-related traits;	chr13:24432914	chr13:24933006~24936796:+
LUAD	cis	rs638893	0.617	rs7103314	ENSG00000278376.1	RP11-158I9.8	-4.99	8.58e-07	0.00022	-0.26	-0.22	Vitiligo;	chr11:118852828	chr11:118791254~118793137:+
LUAD	cis	rs1864400	0.645	rs2249005	ENSG00000273008.1	RP11-351D16.3	-4.99	8.58e-07	0.00022	-0.26	-0.22	Hirschsprung disease;	chr10:43131832	chr10:43136824~43138334:-
LUAD	cis	rs1387259	0.929	rs11168460	ENSG00000257735.1	RP11-370I10.6	4.99	8.58e-07	0.00022	0.27	0.22	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48203582	chr12:48350945~48442411:+
LUAD	cis	rs2933343	0.621	rs789241	ENSG00000261159.1	RP11-723O4.9	4.99	8.59e-07	0.000221	0.24	0.22	IgG glycosylation;	chr3:128866909	chr3:128859716~128860526:-
LUAD	cis	rs9322193	0.607	rs915140	ENSG00000223701.3	RAET1E-AS1	4.99	8.59e-07	0.000221	0.32	0.22	Lung cancer;	chr6:149899674	chr6:149884431~149919508:+
LUAD	cis	rs2732480	0.5	rs1552550	ENSG00000257735.1	RP11-370I10.6	4.99	8.59e-07	0.000221	0.27	0.22	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48249568	chr12:48350945~48442411:+
LUAD	cis	rs875971	0.522	rs1968127	ENSG00000236529.1	RP13-254B10.1	-4.99	8.59e-07	0.000221	-0.22	-0.22	Aortic root size;	chr7:66591816	chr7:65840212~65840596:+
LUAD	cis	rs9322193	0.884	rs1125	ENSG00000268592.3	RAET1E-AS1	4.99	8.6e-07	0.000221	0.29	0.22	Lung cancer;	chr6:149658280	chr6:149863494~149919507:+
LUAD	cis	rs858239	0.601	rs10224327	ENSG00000230042.1	AK3P3	-4.99	8.61e-07	0.000221	-0.28	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23122201	chr7:23129178~23129841:+
LUAD	cis	rs9649213	0.574	rs7802560	ENSG00000272950.1	RP11-307C18.1	-4.99	8.61e-07	0.000221	-0.29	-0.22	Prostate cancer (SNP x SNP interaction);	chr7:98274494	chr7:98322853~98323430:+
LUAD	cis	rs8077577	0.562	rs8081042	ENSG00000273018.4	CTD-2303H24.2	-4.99	8.61e-07	0.000221	-0.31	-0.22	Obesity-related traits;	chr17:18295753	chr17:18511221~18551705:-
LUAD	cis	rs2239547	0.522	rs2564947	ENSG00000242142.1	SERBP1P3	-4.99	8.62e-07	0.000221	-0.25	-0.22	Schizophrenia;	chr3:53012200	chr3:53064283~53065091:-
LUAD	cis	rs2933343	1	rs2929859	ENSG00000231305.3	RP11-723O4.2	4.99	8.62e-07	0.000221	0.27	0.22	IgG glycosylation;	chr3:128889498	chr3:128861313~128871540:-
LUAD	cis	rs9309473	0.718	rs6546829	ENSG00000163016.8	ALMS1P	4.99	8.62e-07	0.000221	0.25	0.22	Metabolite levels;	chr2:73386661	chr2:73644919~73685576:+
LUAD	cis	rs6687821	0.643	rs451660	ENSG00000267734.1	RP4-604K5.3	4.99	8.62e-07	0.000221	0.26	0.22	Yeast infection;	chr1:86725028	chr1:86932199~86934891:-
LUAD	cis	rs6687821	0.643	rs440018	ENSG00000267734.1	RP4-604K5.3	4.99	8.62e-07	0.000221	0.26	0.22	Yeast infection;	chr1:86725031	chr1:86932199~86934891:-
LUAD	cis	rs9900062	0.586	rs12600679	ENSG00000270714.1	MINOS1P2	-4.99	8.62e-07	0.000221	-0.3	-0.22	QT interval;	chr17:64691209	chr17:64747264~64747492:-
LUAD	cis	rs2976388	0.587	rs2717606	ENSG00000253741.1	CTD-2292P10.4	-4.99	8.62e-07	0.000221	-0.25	-0.22	Urinary tract infection frequency;	chr8:142718078	chr8:142702252~142726973:-
LUAD	cis	rs2976388	0.609	rs2585144	ENSG00000253741.1	CTD-2292P10.4	-4.99	8.62e-07	0.000221	-0.25	-0.22	Urinary tract infection frequency;	chr8:142718851	chr8:142702252~142726973:-
LUAD	cis	rs2976388	0.609	rs2717603	ENSG00000253741.1	CTD-2292P10.4	-4.99	8.62e-07	0.000221	-0.25	-0.22	Urinary tract infection frequency;	chr8:142721775	chr8:142702252~142726973:-
LUAD	cis	rs7017914	0.714	rs12155783	ENSG00000223220.1	Y_RNA	-4.99	8.62e-07	0.000221	-0.25	-0.22	Bone mineral density;	chr8:71086891	chr8:70780914~70781008:-
LUAD	cis	rs1387259	0.839	rs7487682	ENSG00000257735.1	RP11-370I10.6	-4.99	8.62e-07	0.000221	-0.26	-0.22	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48185882	chr12:48350945~48442411:+
LUAD	cis	rs4835473	0.808	rs11725413	ENSG00000251600.4	RP11-673E1.1	-4.99	8.63e-07	0.000221	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143943366	chr4:143912331~143982454:+
LUAD	cis	rs2072438	0.503	rs4837810	ENSG00000226752.6	PSMD5-AS1	-4.99	8.63e-07	0.000221	-0.23	-0.22	Rheumatoid arthritis;	chr9:121118921	chr9:120824828~120854385:+
LUAD	cis	rs673078	0.66	rs11068910	ENSG00000275409.1	RP11-131L12.4	-4.99	8.63e-07	0.000221	-0.29	-0.22	Glucose homeostasis traits;	chr12:118336076	chr12:118430147~118430699:+
LUAD	cis	rs9400467	0.528	rs10872066	ENSG00000271789.1	RP5-1112D6.7	-4.99	8.63e-07	0.000221	-0.23	-0.22	Amino acid levels;Blood metabolite levels;	chr6:111272408	chr6:111297126~111298510:+
LUAD	cis	rs6840258	1	rs6819155	ENSG00000251411.1	RP11-397E7.4	-4.99	8.63e-07	0.000222	-0.29	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87055026	chr4:86913266~86914817:-
LUAD	cis	rs11673344	0.665	rs74435359	ENSG00000226686.6	LINC01535	4.99	8.63e-07	0.000222	0.3	0.22	Obesity-related traits;	chr19:36955252	chr19:37251912~37265535:+
LUAD	cis	rs875971	0.66	rs7807930	ENSG00000237310.1	GS1-124K5.4	-4.99	8.64e-07	0.000222	-0.24	-0.22	Aortic root size;	chr7:66622178	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.66	rs7807944	ENSG00000237310.1	GS1-124K5.4	-4.99	8.64e-07	0.000222	-0.24	-0.22	Aortic root size;	chr7:66622208	chr7:66493706~66495474:+
LUAD	cis	rs7017914	0.652	rs2933859	ENSG00000223220.1	Y_RNA	4.99	8.64e-07	0.000222	0.25	0.22	Bone mineral density;	chr8:70993894	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs2933858	ENSG00000223220.1	Y_RNA	4.99	8.64e-07	0.000222	0.25	0.22	Bone mineral density;	chr8:70994109	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs2639948	ENSG00000223220.1	Y_RNA	4.99	8.64e-07	0.000222	0.25	0.22	Bone mineral density;	chr8:70996251	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs2732118	ENSG00000223220.1	Y_RNA	4.99	8.64e-07	0.000222	0.25	0.22	Bone mineral density;	chr8:70996430	chr8:70780914~70781008:-
LUAD	cis	rs2408955	0.522	rs2051851	ENSG00000257735.1	RP11-370I10.6	-4.99	8.64e-07	0.000222	-0.26	-0.22	Glycated hemoglobin levels;	chr12:48092157	chr12:48350945~48442411:+
LUAD	cis	rs10129255	0.509	rs756583	ENSG00000254174.1	IGHV1-12	4.99	8.64e-07	0.000222	0.15	0.22	Kawasaki disease;	chr14:106680002	chr14:106122420~106122709:-
LUAD	cis	rs3096299	0.658	rs3934737	ENSG00000182376.2	RP5-1142A6.8	4.99	8.65e-07	0.000222	0.23	0.22	Multiple myeloma (IgH translocation);	chr16:89493801	chr16:88742767~88745748:+
LUAD	cis	rs2303759	0.507	rs35042238	ENSG00000268686.1	AC010524.2	-4.99	8.65e-07	0.000222	-0.42	-0.22	Multiple sclerosis;	chr19:49369684	chr19:49368705~49388081:-
LUAD	cis	rs2439831	0.681	rs478104	ENSG00000249839.1	AC011330.5	-4.99	8.65e-07	0.000222	-0.39	-0.22	Lung cancer in ever smokers;	chr15:43302702	chr15:43663654~43684339:-
LUAD	cis	rs12468226	0.938	rs10166594	ENSG00000272966.1	RP11-686O6.1	4.99	8.66e-07	0.000222	0.35	0.22	Urate levels;	chr2:202250262	chr2:202336739~202337200:+
LUAD	cis	rs853679	1	rs1419183	ENSG00000219392.1	RP1-265C24.5	-4.99	8.66e-07	0.000222	-0.34	-0.22	Depression;	chr6:28275017	chr6:28115628~28116551:+
LUAD	cis	rs2408955	0.522	rs7139330	ENSG00000257735.1	RP11-370I10.6	-4.98	8.67e-07	0.000222	-0.26	-0.22	Glycated hemoglobin levels;	chr12:48089701	chr12:48350945~48442411:+
LUAD	cis	rs9900062	0.586	rs11653958	ENSG00000270714.1	MINOS1P2	-4.98	8.67e-07	0.000222	-0.3	-0.22	QT interval;	chr17:64690612	chr17:64747264~64747492:-
LUAD	cis	rs516805	0.748	rs155461	ENSG00000279453.1	RP3-425C14.4	-4.98	8.67e-07	0.000222	-0.32	-0.22	Lymphocyte counts;	chr6:122499547	chr6:122436789~122439223:-
LUAD	cis	rs643506	0.874	rs613292	ENSG00000230911.1	PPIHP1	-4.98	8.67e-07	0.000222	-0.28	-0.22	Breast cancer;	chr11:111798081	chr11:112029858~112030367:-
LUAD	cis	rs516805	0.706	rs9490427	ENSG00000279453.1	RP3-425C14.4	4.98	8.68e-07	0.000223	0.29	0.22	Lymphocyte counts;	chr6:122353084	chr6:122436789~122439223:-
LUAD	cis	rs561341	1	rs72825740	ENSG00000265798.5	RP11-271K11.5	4.98	8.68e-07	0.000223	0.36	0.22	Hip circumference adjusted for BMI;	chr17:32011337	chr17:31038575~31059121:-
LUAD	cis	rs4664293	0.967	rs10202187	ENSG00000226266.5	AC009961.3	-4.98	8.68e-07	0.000223	-0.32	-0.22	Monocyte percentage of white cells;	chr2:159571135	chr2:159670708~159712435:-
LUAD	cis	rs875971	0.522	rs781144	ENSG00000237310.1	GS1-124K5.4	4.98	8.69e-07	0.000223	0.24	0.22	Aortic root size;	chr7:65975357	chr7:66493706~66495474:+
LUAD	cis	rs116175783	0.557	rs1733180	ENSG00000227403.1	AC009299.3	-4.98	8.69e-07	0.000223	-0.38	-0.22	Intelligence (multi-trait analysis);	chr2:161277119	chr2:161244739~161249050:+
LUAD	cis	rs35160687	0.644	rs36079379	ENSG00000273080.1	RP11-301O19.1	-4.98	8.69e-07	0.000223	-0.25	-0.22	Night sleep phenotypes;	chr2:86318837	chr2:86195590~86196049:+
LUAD	cis	rs1045529	0.524	rs34251783	ENSG00000173295.6	FAM86B3P	-4.98	8.69e-07	0.000223	-0.24	-0.22	Myopia (pathological);Myopia;	chr8:9033866	chr8:8228595~8244865:+
LUAD	cis	rs453301	0.719	rs34004903	ENSG00000173295.6	FAM86B3P	-4.98	8.69e-07	0.000223	-0.24	-0.22	Joint mobility (Beighton score);	chr8:9035094	chr8:8228595~8244865:+
LUAD	cis	rs453301	0.686	rs6748	ENSG00000173295.6	FAM86B3P	-4.98	8.69e-07	0.000223	-0.24	-0.22	Joint mobility (Beighton score);	chr8:9033292	chr8:8228595~8244865:+
LUAD	cis	rs5760092	0.618	rs5996631	ENSG00000228039.3	KB-1125A3.10	-4.98	8.7e-07	0.000223	-0.31	-0.22	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23963780~23964374:+
LUAD	cis	rs4835473	0.591	rs6822129	ENSG00000251600.4	RP11-673E1.1	-4.98	8.71e-07	0.000223	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:144058755	chr4:143912331~143982454:+
LUAD	cis	rs7772486	0.806	rs2253648	ENSG00000235652.6	RP11-545I5.3	4.98	8.71e-07	0.000223	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145878160	chr6:145799409~145886585:+
LUAD	cis	rs4908768	0.501	rs6702060	ENSG00000270282.1	RP5-1115A15.2	4.98	8.71e-07	0.000223	0.24	0.22	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8546965	chr1:8512653~8513021:+
LUAD	cis	rs4908768	0.501	rs6577502	ENSG00000270282.1	RP5-1115A15.2	4.98	8.71e-07	0.000223	0.24	0.22	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8555518	chr1:8512653~8513021:+
LUAD	cis	rs4908768	0.501	rs1473420	ENSG00000270282.1	RP5-1115A15.2	4.98	8.71e-07	0.000223	0.24	0.22	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8556779	chr1:8512653~8513021:+
LUAD	cis	rs7017914	0.69	rs4446768	ENSG00000223220.1	Y_RNA	4.98	8.72e-07	0.000224	0.25	0.22	Bone mineral density;	chr8:70865354	chr8:70780914~70781008:-
LUAD	cis	rs17345786	1	rs17345786	ENSG00000244119.1	PDCL3P4	-4.98	8.72e-07	0.000224	-0.24	-0.22	Colonoscopy-negative controls vs population controls;	chr3:101599474	chr3:101712472~101713191:+
LUAD	cis	rs1005277	0.579	rs2749612	ENSG00000263064.2	RP11-291L22.7	4.98	8.73e-07	0.000224	0.24	0.22	Extrinsic epigenetic age acceleration;	chr10:38199682	chr10:38448689~38448949:+
LUAD	cis	rs6604026	0.589	rs11800848	ENSG00000223787.2	RP4-593M8.1	4.98	8.73e-07	0.000224	0.31	0.22	Multiple sclerosis;	chr1:92662370	chr1:92580476~92580821:-
LUAD	cis	rs875971	0.522	rs1880556	ENSG00000237310.1	GS1-124K5.4	4.98	8.73e-07	0.000224	0.24	0.22	Aortic root size;	chr7:65967557	chr7:66493706~66495474:+
LUAD	cis	rs6687758	1	rs12125383	ENSG00000228437.4	RP11-400N13.2	4.98	8.74e-07	0.000224	0.34	0.22	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221995092	chr1:221966341~221984964:+
LUAD	cis	rs394563	0.726	rs6922130	ENSG00000231760.4	RP11-350J20.5	-4.98	8.74e-07	0.000224	-0.26	-0.22	Dupuytren's disease;	chr6:149351239	chr6:149796151~149826294:-
LUAD	cis	rs1150668	0.799	rs1150705	ENSG00000219392.1	RP1-265C24.5	-4.98	8.75e-07	0.000224	-0.28	-0.22	Pubertal anthropometrics;	chr6:28226008	chr6:28115628~28116551:+
LUAD	cis	rs925255	0.81	rs2048240	ENSG00000270210.1	RP11-373D23.3	4.98	8.75e-07	0.000224	0.27	0.22	Inflammatory bowel disease;Crohn's disease;	chr2:28417460	chr2:28425945~28426719:+
LUAD	cis	rs2439831	0.867	rs11856184	ENSG00000249839.1	AC011330.5	-4.98	8.75e-07	0.000224	-0.41	-0.22	Lung cancer in ever smokers;	chr15:43626964	chr15:43663654~43684339:-
LUAD	cis	rs2439831	0.571	rs2470121	ENSG00000249839.1	AC011330.5	-4.98	8.75e-07	0.000224	-0.41	-0.22	Lung cancer in ever smokers;	chr15:43645420	chr15:43663654~43684339:-
LUAD	cis	rs1799949	1	rs3092988	ENSG00000236383.6	LINC00854	-4.98	8.76e-07	0.000224	-0.18	-0.22	Menopause (age at onset);	chr17:43049685	chr17:43216941~43305976:-
LUAD	cis	rs35160687	0.712	rs1863057	ENSG00000273080.1	RP11-301O19.1	-4.98	8.76e-07	0.000224	-0.25	-0.22	Night sleep phenotypes;	chr2:86274978	chr2:86195590~86196049:+
LUAD	cis	rs4143844	1	rs62006969	ENSG00000259251.2	RP11-643M14.1	4.98	8.76e-07	0.000225	0.39	0.22	Bipolar disorder and schizophrenia;	chr15:62001213	chr15:62060503~62062434:+
LUAD	cis	rs4143844	0.867	rs11634077	ENSG00000259251.2	RP11-643M14.1	4.98	8.76e-07	0.000225	0.39	0.22	Bipolar disorder and schizophrenia;	chr15:62001376	chr15:62060503~62062434:+
LUAD	cis	rs2303759	0.551	rs7249040	ENSG00000268686.1	AC010524.2	-4.98	8.76e-07	0.000225	-0.31	-0.22	Multiple sclerosis;	chr19:49287345	chr19:49368705~49388081:-
LUAD	cis	rs6545883	0.501	rs935860	ENSG00000271889.1	RP11-493E12.1	4.98	8.76e-07	0.000225	0.26	0.22	Tuberculosis;	chr2:61179426	chr2:61151433~61162105:-
LUAD	cis	rs61270009	0.955	rs12163987	ENSG00000247828.6	TMEM161B-AS1	4.98	8.76e-07	0.000225	0.25	0.22	Depressive symptoms;	chr5:88276209	chr5:88268895~88436685:+
LUAD	cis	rs1799949	1	rs1060915	ENSG00000236383.6	LINC00854	-4.98	8.77e-07	0.000225	-0.18	-0.22	Menopause (age at onset);	chr17:43082453	chr17:43216941~43305976:-
LUAD	cis	rs7829975	0.846	rs7005216	ENSG00000253893.2	FAM85B	4.98	8.77e-07	0.000225	0.27	0.22	Mood instability;	chr8:8689600	chr8:8167819~8226614:-
LUAD	cis	rs7302981	0.967	rs6580729	ENSG00000272368.2	RP4-605O3.4	4.98	8.77e-07	0.000225	0.26	0.22	Systolic blood pressure;	chr12:50153255	chr12:50112197~50165618:+
LUAD	cis	rs12701220	0.503	rs12702047	ENSG00000229043.2	AC091729.9	-4.98	8.78e-07	0.000225	-0.31	-0.22	Bronchopulmonary dysplasia;	chr7:1093084	chr7:1160374~1165267:+
LUAD	cis	rs61270009	0.955	rs780401	ENSG00000247828.6	TMEM161B-AS1	-4.98	8.79e-07	0.000225	-0.25	-0.22	Depressive symptoms;	chr5:88244393	chr5:88268895~88436685:+
LUAD	cis	rs4372836	0.93	rs7607844	ENSG00000226833.4	AC097724.3	4.98	8.79e-07	0.000225	0.26	0.22	Body mass index;	chr2:28748872	chr2:28708953~28736205:-
LUAD	cis	rs17711722	0.653	rs2460421	ENSG00000236529.1	RP13-254B10.1	-4.98	8.79e-07	0.000225	-0.22	-0.22	Calcium levels;	chr7:66026136	chr7:65840212~65840596:+
LUAD	cis	rs41307935	0.908	rs111707709	ENSG00000260063.1	RP5-968P14.2	-4.98	8.8e-07	0.000225	-0.39	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26848285	chr1:26692132~26694131:-
LUAD	cis	rs2280018	0.526	rs2966129	ENSG00000207425.1	Y_RNA	-4.98	8.8e-07	0.000225	-0.28	-0.22	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059070	chr16:14915457~14915556:-
LUAD	cis	rs17684571	0.872	rs3002011	ENSG00000231441.1	RP11-472M19.2	4.98	8.8e-07	0.000225	0.31	0.22	Schizophrenia;	chr6:56760325	chr6:56844002~56864078:+
LUAD	cis	rs1799949	0.93	rs8176194	ENSG00000236383.6	LINC00854	-4.98	8.8e-07	0.000226	-0.18	-0.22	Menopause (age at onset);	chr17:43079204	chr17:43216941~43305976:-
LUAD	cis	rs9601248	0.756	rs7997134	ENSG00000227354.5	RBM26-AS1	-4.98	8.8e-07	0.000226	-0.25	-0.22	Major depressive disorder;	chr13:79619594	chr13:79406309~79424328:+
LUAD	cis	rs2283792	0.646	rs9610271	ENSG00000224086.5	LL22NC03-86G7.1	-4.98	8.81e-07	0.000226	-0.22	-0.22	Multiple sclerosis;	chr22:21758238	chr22:21938293~21977632:+
LUAD	cis	rs7017914	0.652	rs958605	ENSG00000223220.1	Y_RNA	4.98	8.81e-07	0.000226	0.25	0.22	Bone mineral density;	chr8:70988356	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs2732122	ENSG00000223220.1	Y_RNA	4.98	8.81e-07	0.000226	0.25	0.22	Bone mineral density;	chr8:70988908	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs2639926	ENSG00000223220.1	Y_RNA	4.98	8.81e-07	0.000226	0.25	0.22	Bone mineral density;	chr8:70988976	chr8:70780914~70781008:-
LUAD	cis	rs7598759	0.588	rs6737291	ENSG00000181798.2	LINC00471	-4.98	8.81e-07	0.000226	-0.24	-0.22	Noise-induced hearing loss;	chr2:231464848	chr2:231508426~231514339:-
LUAD	cis	rs1816752	0.774	rs2862895	ENSG00000273628.1	RP11-756A22.7	4.98	8.82e-07	0.000226	0.25	0.22	Obesity-related traits;	chr13:24410328	chr13:24933006~24936796:+
LUAD	cis	rs1075265	0.692	rs805361	ENSG00000233266.1	HMGB1P31	4.98	8.82e-07	0.000226	0.28	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53938709	chr2:54051334~54051760:+
LUAD	cis	rs193541	0.632	rs39821	ENSG00000263432.2	RN7SL689P	4.98	8.82e-07	0.000226	0.3	0.22	Glucose homeostasis traits;	chr5:122959777	chr5:123022487~123022783:-
LUAD	cis	rs875971	0.638	rs6460305	ENSG00000236529.1	RP13-254B10.1	-4.98	8.82e-07	0.000226	-0.22	-0.22	Aortic root size;	chr7:66595421	chr7:65840212~65840596:+
LUAD	cis	rs2378497	1	rs12136244	ENSG00000232679.1	RP11-400N13.3	4.98	8.82e-07	0.000226	0.34	0.22	Serum thyroid-stimulating hormone levels;	chr1:222016059	chr1:222041705~222064763:-
LUAD	cis	rs4835473	0.863	rs11735239	ENSG00000251600.4	RP11-673E1.1	-4.98	8.82e-07	0.000226	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143689372	chr4:143912331~143982454:+
LUAD	cis	rs7208859	0.623	rs56325146	ENSG00000266490.1	CTD-2349P21.9	4.98	8.83e-07	0.000226	0.32	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824006	chr17:30792372~30792833:+
LUAD	cis	rs6723226	0.806	rs2249109	ENSG00000276334.1	AL133243.1	4.98	8.83e-07	0.000226	0.25	0.22	Intelligence (multi-trait analysis);	chr2:32525812	chr2:32521927~32523547:+
LUAD	cis	rs7208859	0.673	rs216409	ENSG00000263531.1	RP13-753N3.1	-4.98	8.84e-07	0.000226	-0.38	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30579251	chr17:30863921~30864940:-
LUAD	cis	rs7665090	0.87	rs228616	ENSG00000246560.2	RP11-10L12.4	-4.98	8.84e-07	0.000226	-0.27	-0.22	Primary biliary cholangitis;	chr4:102658534	chr4:102828055~102844075:+
LUAD	cis	rs10754283	0.967	rs10922680	ENSG00000231613.1	RP5-943J3.1	-4.98	8.84e-07	0.000226	-0.23	-0.22	Amyotrophic lateral sclerosis (sporadic);	chr1:89635767	chr1:89788914~89790492:+
LUAD	cis	rs17508449	0.819	rs74524050	ENSG00000232450.1	RP4-730K3.3	-4.98	8.84e-07	0.000226	-0.38	-0.22	Leprosy;	chr1:113688585	chr1:113698884~113699631:-
LUAD	cis	rs3738443	0.951	rs4551629	ENSG00000259865.1	RP11-488L18.10	4.98	8.85e-07	0.000227	0.24	0.22	Alcohol dependence;	chr1:247211748	chr1:247187281~247188526:-
LUAD	cis	rs2408955	0.561	rs9971924	ENSG00000257735.1	RP11-370I10.6	-4.98	8.85e-07	0.000227	-0.26	-0.22	Glycated hemoglobin levels;	chr12:48086049	chr12:48350945~48442411:+
LUAD	cis	rs9322193	0.884	rs11155689	ENSG00000268592.3	RAET1E-AS1	4.98	8.85e-07	0.000227	0.27	0.22	Lung cancer;	chr6:149808470	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.884	rs933055	ENSG00000268592.3	RAET1E-AS1	4.98	8.85e-07	0.000227	0.27	0.22	Lung cancer;	chr6:149809701	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.962	rs4869731	ENSG00000268592.3	RAET1E-AS1	4.98	8.85e-07	0.000227	0.27	0.22	Lung cancer;	chr6:149810072	chr6:149863494~149919507:+
LUAD	cis	rs7727544	0.606	rs11950562	ENSG00000233006.5	AC034220.3	4.98	8.86e-07	0.000227	0.2	0.22	Blood metabolite levels;	chr5:132316836	chr5:132311285~132369916:-
LUAD	cis	rs2898681	1	rs62336823	ENSG00000248375.1	RP11-177B4.1	-4.98	8.86e-07	0.000227	-0.33	-0.22	Optic nerve measurement (cup area);	chr4:52891494	chr4:52720081~52720831:-
LUAD	cis	rs453301	0.686	rs10217044	ENSG00000253893.2	FAM85B	4.98	8.86e-07	0.000227	0.29	0.22	Joint mobility (Beighton score);	chr8:9037242	chr8:8167819~8226614:-
LUAD	cis	rs7772486	0.72	rs4896837	ENSG00000235652.6	RP11-545I5.3	-4.98	8.87e-07	0.000227	-0.23	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145693032	chr6:145799409~145886585:+
LUAD	cis	rs4660214	0.666	rs663892	ENSG00000228060.1	RP11-69E11.8	-4.98	8.87e-07	0.000227	-0.2	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39424005	chr1:39565160~39573203:+
LUAD	cis	rs4660214	0.666	rs1180384	ENSG00000228060.1	RP11-69E11.8	-4.98	8.87e-07	0.000227	-0.2	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39427102	chr1:39565160~39573203:+
LUAD	cis	rs73186030	0.591	rs28630628	ENSG00000272758.4	RP11-299J3.8	4.98	8.87e-07	0.000227	0.28	0.22	Serum parathyroid hormone levels;	chr3:122386769	chr3:122416207~122443180:+
LUAD	cis	rs7772486	0.754	rs702318	ENSG00000235652.6	RP11-545I5.3	-4.98	8.87e-07	0.000227	-0.22	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145684737	chr6:145799409~145886585:+
LUAD	cis	rs1005277	0.579	rs1780121	ENSG00000263064.2	RP11-291L22.7	4.98	8.87e-07	0.000227	0.24	0.22	Extrinsic epigenetic age acceleration;	chr10:38240509	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.579	rs1780122	ENSG00000263064.2	RP11-291L22.7	4.98	8.87e-07	0.000227	0.24	0.22	Extrinsic epigenetic age acceleration;	chr10:38240581	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.579	rs1780145	ENSG00000263064.2	RP11-291L22.7	4.98	8.87e-07	0.000227	0.24	0.22	Extrinsic epigenetic age acceleration;	chr10:38248142	chr10:38448689~38448949:+
LUAD	cis	rs9860428	0.844	rs12490586	ENSG00000242770.2	RP11-180K7.1	4.98	8.87e-07	0.000227	0.24	0.22	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112904386	chr3:112802478~112812819:+
LUAD	cis	rs9860428	0.844	rs12487198	ENSG00000242770.2	RP11-180K7.1	4.98	8.87e-07	0.000227	0.24	0.22	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112904423	chr3:112802478~112812819:+
LUAD	cis	rs1707322	1	rs4390216	ENSG00000280836.1	AL355480.1	-4.98	8.88e-07	0.000227	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800784	chr1:45581219~45581321:-
LUAD	cis	rs7937890	0.559	rs1116739	ENSG00000251991.1	RNU7-49P	4.98	8.88e-07	0.000227	0.23	0.22	Mitochondrial DNA levels;	chr11:14467636	chr11:14478892~14478953:+
LUAD	cis	rs2742234	0.59	rs2503863	ENSG00000273008.1	RP11-351D16.3	-4.98	8.88e-07	0.000227	-0.26	-0.22	Hirschsprung disease;	chr10:43171950	chr10:43136824~43138334:-
LUAD	cis	rs2742234	0.59	rs2503848	ENSG00000273008.1	RP11-351D16.3	-4.98	8.88e-07	0.000227	-0.26	-0.22	Hirschsprung disease;	chr10:43177337	chr10:43136824~43138334:-
LUAD	cis	rs2742234	0.59	rs2435383	ENSG00000273008.1	RP11-351D16.3	-4.98	8.88e-07	0.000227	-0.26	-0.22	Hirschsprung disease;	chr10:43180223	chr10:43136824~43138334:-
LUAD	cis	rs2742234	0.541	rs1059484	ENSG00000273008.1	RP11-351D16.3	-4.98	8.88e-07	0.000227	-0.26	-0.22	Hirschsprung disease;	chr10:43184352	chr10:43136824~43138334:-
LUAD	cis	rs875971	0.638	rs10249404	ENSG00000236529.1	RP13-254B10.1	-4.98	8.88e-07	0.000227	-0.22	-0.22	Aortic root size;	chr7:66581737	chr7:65840212~65840596:+
LUAD	cis	rs9584850	0.794	rs17470961	ENSG00000231194.1	FARP1-AS1	4.98	8.89e-07	0.000227	0.27	0.22	Neuroticism;	chr13:98483060	chr13:98435405~98435840:-
LUAD	cis	rs42490	0.528	rs1040327	ENSG00000251136.7	RP11-37B2.1	4.98	8.89e-07	0.000228	0.22	0.22	Leprosy;	chr8:89669585	chr8:89609409~89757727:-
LUAD	cis	rs42490	0.528	rs2840206	ENSG00000251136.7	RP11-37B2.1	4.98	8.89e-07	0.000228	0.22	0.22	Leprosy;	chr8:89670184	chr8:89609409~89757727:-
LUAD	cis	rs1008375	1	rs7673500	ENSG00000249502.1	AC006160.5	-4.98	8.9e-07	0.000228	-0.21	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17619760	chr4:17587467~17614571:-
LUAD	cis	rs4789693	0.938	rs8078595	ENSG00000265458.1	RP13-20L14.6	4.98	8.9e-07	0.000228	0.3	0.22	Glucocorticoid-induced osteonecrosis;	chr17:82469112	chr17:82454273~82458521:-
LUAD	cis	rs800160	0.777	rs11022289	ENSG00000236264.4	RPL26P30	-4.98	8.9e-07	0.000228	-0.29	-0.22	Bacteremia;	chr11:2324187	chr11:2335132~2335776:-
LUAD	cis	rs800160	0.777	rs11022291	ENSG00000236264.4	RPL26P30	-4.98	8.9e-07	0.000228	-0.29	-0.22	Bacteremia;	chr11:2324391	chr11:2335132~2335776:-
LUAD	cis	rs800160	0.777	rs2651781	ENSG00000236264.4	RPL26P30	-4.98	8.9e-07	0.000228	-0.29	-0.22	Bacteremia;	chr11:2324447	chr11:2335132~2335776:-
LUAD	cis	rs9341808	0.754	rs3793000	ENSG00000272129.1	RP11-250B2.6	4.98	8.91e-07	0.000228	0.27	0.22	Sitting height ratio;	chr6:80285420	chr6:80355424~80356859:+
LUAD	cis	rs2239547	0.522	rs2710345	ENSG00000242142.1	SERBP1P3	-4.98	8.91e-07	0.000228	-0.26	-0.22	Schizophrenia;	chr3:52942059	chr3:53064283~53065091:-
LUAD	cis	rs6570726	0.791	rs370654	ENSG00000235652.6	RP11-545I5.3	4.98	8.92e-07	0.000228	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145557869	chr6:145799409~145886585:+
LUAD	cis	rs875971	0.793	rs460678	ENSG00000232559.3	GS1-124K5.12	4.98	8.92e-07	0.000228	0.26	0.22	Aortic root size;	chr7:66062213	chr7:66554588~66576923:-
LUAD	cis	rs2919009	0.607	rs41287984	ENSG00000271670.1	RP11-95I16.4	4.98	8.92e-07	0.000228	0.3	0.22	Obesity-related traits;	chr10:120852958	chr10:120879256~120880667:-
LUAD	cis	rs4908768	0.501	rs11121194	ENSG00000270282.1	RP5-1115A15.2	4.98	8.92e-07	0.000228	0.24	0.22	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8509847	chr1:8512653~8513021:+
LUAD	cis	rs1075265	0.62	rs2542584	ENSG00000233266.1	HMGB1P31	4.98	8.92e-07	0.000228	0.28	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53782707	chr2:54051334~54051760:+
LUAD	cis	rs10992756	0.551	rs883784	ENSG00000227603.1	RP11-165J3.6	4.98	8.93e-07	0.000228	0.25	0.22	Intelligence (multi-trait analysis);	chr9:93519954	chr9:93435332~93437121:-
LUAD	cis	rs944990	0.557	rs7019001	ENSG00000227603.1	RP11-165J3.6	4.98	8.93e-07	0.000228	0.25	0.22	Body mass index;	chr9:93528942	chr9:93435332~93437121:-
LUAD	cis	rs2880765	0.835	rs4360875	ENSG00000259295.5	CSPG4P12	4.98	8.94e-07	0.000229	0.26	0.22	Coronary artery disease;	chr15:85497163	chr15:85191438~85213905:+
LUAD	cis	rs2562456	0.755	rs2562421	ENSG00000268081.1	RP11-678G14.2	-4.98	8.94e-07	0.000229	-0.34	-0.22	Pain;	chr19:21448502	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.793	rs2562420	ENSG00000268081.1	RP11-678G14.2	-4.98	8.94e-07	0.000229	-0.34	-0.22	Pain;	chr19:21448503	chr19:21554640~21569237:-
LUAD	cis	rs2011013	0.6	rs34047645	ENSG00000259570.1	RP11-671M22.4	-4.98	8.94e-07	0.000229	-0.38	-0.22	Sitting height ratio;	chr15:83942615	chr15:84394512~84395514:+
LUAD	cis	rs2562456	0.833	rs62107531	ENSG00000268081.1	RP11-678G14.2	4.98	8.94e-07	0.000229	0.36	0.22	Pain;	chr19:21326263	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.833	rs55756795	ENSG00000268081.1	RP11-678G14.2	4.98	8.94e-07	0.000229	0.36	0.22	Pain;	chr19:21327257	chr19:21554640~21569237:-
LUAD	cis	rs7772486	0.754	rs9386133	ENSG00000235652.6	RP11-545I5.3	4.98	8.95e-07	0.000229	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145820077	chr6:145799409~145886585:+
LUAD	cis	rs1707322	1	rs6429580	ENSG00000280836.1	AL355480.1	-4.98	8.96e-07	0.000229	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809976	chr1:45581219~45581321:-
LUAD	cis	rs910316	0.967	rs7146523	ENSG00000259138.1	RP11-950C14.7	-4.98	8.97e-07	0.000229	-0.23	-0.22	Height;	chr14:75193177	chr14:75127153~75136930:+
LUAD	cis	rs9487094	0.922	rs12208933	ENSG00000260273.1	RP11-425D10.10	4.98	8.98e-07	0.00023	0.31	0.22	Height;	chr6:109582583	chr6:109382795~109383666:+
LUAD	cis	rs10129255	0.518	rs2006284	ENSG00000254174.1	IGHV1-12	4.98	8.98e-07	0.00023	0.15	0.22	Kawasaki disease;	chr14:106676185	chr14:106122420~106122709:-
LUAD	cis	rs2933343	0.7	rs789239	ENSG00000261159.1	RP11-723O4.9	4.98	8.99e-07	0.00023	0.24	0.22	IgG glycosylation;	chr3:128914965	chr3:128859716~128860526:-
LUAD	cis	rs10129255	0.957	rs10141052	ENSG00000211967.3	IGHV3-53	-4.98	8.99e-07	0.00023	-0.17	-0.22	Kawasaki disease;	chr14:106776528	chr14:106592676~106593347:-
LUAD	cis	rs1075265	0.626	rs805320	ENSG00000233266.1	HMGB1P31	4.98	8.99e-07	0.00023	0.28	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53911305	chr2:54051334~54051760:+
LUAD	cis	rs2018683	0.932	rs4386882	ENSG00000228421.2	AC005013.5	4.98	8.99e-07	0.00023	0.25	0.22	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28949653	chr7:28957667~28959345:+
LUAD	cis	rs2239547	0.522	rs2581823	ENSG00000242142.1	SERBP1P3	-4.98	9e-07	0.00023	-0.25	-0.22	Schizophrenia;	chr3:52988060	chr3:53064283~53065091:-
LUAD	cis	rs7017914	0.69	rs17699084	ENSG00000223220.1	Y_RNA	-4.98	9.01e-07	0.00023	-0.26	-0.22	Bone mineral density;	chr8:71051176	chr8:70780914~70781008:-
LUAD	cis	rs9545047	0.604	rs1324870	ENSG00000227354.5	RBM26-AS1	-4.98	9.01e-07	0.00023	-0.23	-0.22	Schizophrenia;	chr13:79297911	chr13:79406309~79424328:+
LUAD	cis	rs2976388	0.609	rs2257796	ENSG00000253741.1	CTD-2292P10.4	-4.98	9.01e-07	0.00023	-0.25	-0.22	Urinary tract infection frequency;	chr8:142727249	chr8:142702252~142726973:-
LUAD	cis	rs950169	0.58	rs17598114	ENSG00000275120.1	RP11-182J1.17	4.98	9.02e-07	0.00023	0.34	0.22	Schizophrenia;	chr15:84628086	chr15:84599434~84606463:-
LUAD	cis	rs561341	0.769	rs559228	ENSG00000265798.5	RP11-271K11.5	4.98	9.02e-07	0.00023	0.35	0.22	Hip circumference adjusted for BMI;	chr17:31967508	chr17:31038575~31059121:-
LUAD	cis	rs673078	0.66	rs11068908	ENSG00000275409.1	RP11-131L12.4	-4.98	9.02e-07	0.000231	-0.3	-0.22	Glucose homeostasis traits;	chr12:118327265	chr12:118430147~118430699:+
LUAD	cis	rs6604026	0.555	rs11805007	ENSG00000223787.2	RP4-593M8.1	4.98	9.02e-07	0.000231	0.3	0.22	Multiple sclerosis;	chr1:92616633	chr1:92580476~92580821:-
LUAD	cis	rs193541	0.642	rs42538	ENSG00000263432.2	RN7SL689P	4.98	9.02e-07	0.000231	0.3	0.22	Glucose homeostasis traits;	chr5:122956657	chr5:123022487~123022783:-
LUAD	cis	rs944990	0.557	rs13292712	ENSG00000227603.1	RP11-165J3.6	4.98	9.03e-07	0.000231	0.25	0.22	Body mass index;	chr9:93534438	chr9:93435332~93437121:-
LUAD	cis	rs950169	0.58	rs11634322	ENSG00000275120.1	RP11-182J1.17	4.98	9.04e-07	0.000231	0.34	0.22	Schizophrenia;	chr15:84628978	chr15:84599434~84606463:-
LUAD	cis	rs950169	0.58	rs4603535	ENSG00000275120.1	RP11-182J1.17	4.98	9.04e-07	0.000231	0.34	0.22	Schizophrenia;	chr15:84630641	chr15:84599434~84606463:-
LUAD	cis	rs8072100	0.79	rs3760371	ENSG00000228782.6	CTD-2026D20.3	-4.98	9.04e-07	0.000231	-0.23	-0.22	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47618548	chr17:47450568~47492492:-
LUAD	cis	rs8103033	0.748	rs8101868	ENSG00000226025.8	LGALS17A	-4.98	9.04e-07	0.000231	-0.25	-0.22	Obesity-related traits;	chr19:39646090	chr19:39679374~39686373:+
LUAD	cis	rs8103033	0.781	rs7248699	ENSG00000226025.8	LGALS17A	-4.98	9.04e-07	0.000231	-0.25	-0.22	Obesity-related traits;	chr19:39649338	chr19:39679374~39686373:+
LUAD	cis	rs8103033	0.781	rs7248784	ENSG00000226025.8	LGALS17A	-4.98	9.04e-07	0.000231	-0.25	-0.22	Obesity-related traits;	chr19:39649347	chr19:39679374~39686373:+
LUAD	cis	rs55665837	0.539	rs731042	ENSG00000251991.1	RNU7-49P	4.98	9.04e-07	0.000231	0.25	0.22	Vitamin D levels;	chr11:14853429	chr11:14478892~14478953:+
LUAD	cis	rs891378	1	rs971317	ENSG00000274245.1	RP11-357P18.2	-4.98	9.04e-07	0.000231	-0.29	-0.22	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207302695	chr1:207372559~207373252:+
LUAD	cis	rs7017914	0.652	rs35931247	ENSG00000223220.1	Y_RNA	4.98	9.05e-07	0.000231	0.25	0.22	Bone mineral density;	chr8:70743849	chr8:70780914~70781008:-
LUAD	cis	rs2562456	0.833	rs11669790	ENSG00000268081.1	RP11-678G14.2	4.98	9.05e-07	0.000231	0.36	0.22	Pain;	chr19:21328980	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.833	rs62107534	ENSG00000268081.1	RP11-678G14.2	4.98	9.05e-07	0.000231	0.36	0.22	Pain;	chr19:21329389	chr19:21554640~21569237:-
LUAD	cis	rs7119038	0.509	rs10892258	ENSG00000255239.1	AP002954.6	4.98	9.05e-07	0.000231	0.32	0.22	Sjögren's syndrome;	chr11:118709156	chr11:118688039~118690600:-
LUAD	cis	rs17684571	0.751	rs1903332	ENSG00000231441.1	RP11-472M19.2	-4.98	9.06e-07	0.000231	-0.31	-0.22	Schizophrenia;	chr6:56857437	chr6:56844002~56864078:+
LUAD	cis	rs875971	0.862	rs1983372	ENSG00000232559.3	GS1-124K5.12	-4.98	9.06e-07	0.000231	-0.26	-0.22	Aortic root size;	chr7:66146364	chr7:66554588~66576923:-
LUAD	cis	rs5758659	1	rs134869	ENSG00000182057.4	OGFRP1	4.98	9.06e-07	0.000231	0.26	0.22	Cognitive function;	chr22:42256068	chr22:42269753~42275196:+
LUAD	cis	rs561341	0.941	rs17780080	ENSG00000265798.5	RP11-271K11.5	4.98	9.07e-07	0.000232	0.36	0.22	Hip circumference adjusted for BMI;	chr17:32016127	chr17:31038575~31059121:-
LUAD	cis	rs561341	0.941	rs17780086	ENSG00000265798.5	RP11-271K11.5	4.98	9.07e-07	0.000232	0.36	0.22	Hip circumference adjusted for BMI;	chr17:32016263	chr17:31038575~31059121:-
LUAD	cis	rs10483853	0.579	rs66992833	ENSG00000258695.2	RP3-414A15.2	-4.98	9.07e-07	0.000232	-0.32	-0.22	Coronary artery calcification;	chr14:73471638	chr14:73522878~73530610:+
LUAD	cis	rs12745968	0.652	rs11164608	ENSG00000223787.2	RP4-593M8.1	-4.98	9.07e-07	0.000232	-0.28	-0.22	Bipolar disorder and schizophrenia;	chr1:92481870	chr1:92580476~92580821:-
LUAD	cis	rs240993	0.812	rs118202	ENSG00000230177.1	RP5-1112D6.4	-4.98	9.08e-07	0.000232	-0.22	-0.22	Inflammatory skin disease;Psoriasis;	chr6:111337168	chr6:111277932~111278742:+
LUAD	cis	rs240993	0.812	rs240955	ENSG00000230177.1	RP5-1112D6.4	-4.98	9.08e-07	0.000232	-0.22	-0.22	Inflammatory skin disease;Psoriasis;	chr6:111339440	chr6:111277932~111278742:+
LUAD	cis	rs240993	0.761	rs453776	ENSG00000230177.1	RP5-1112D6.4	-4.98	9.08e-07	0.000232	-0.22	-0.22	Inflammatory skin disease;Psoriasis;	chr6:111342260	chr6:111277932~111278742:+
LUAD	cis	rs9487094	0.885	rs1590306	ENSG00000260273.1	RP11-425D10.10	4.98	9.08e-07	0.000232	0.3	0.22	Height;	chr6:109359747	chr6:109382795~109383666:+
LUAD	cis	rs1008375	0.966	rs6825133	ENSG00000249502.1	AC006160.5	-4.98	9.09e-07	0.000232	-0.22	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17576153	chr4:17587467~17614571:-
LUAD	cis	rs42490	0.7	rs40459	ENSG00000251136.7	RP11-37B2.1	4.98	9.09e-07	0.000232	0.23	0.22	Leprosy;	chr8:89833998	chr8:89609409~89757727:-
LUAD	cis	rs9900062	0.586	rs2676307	ENSG00000270714.1	MINOS1P2	-4.98	9.1e-07	0.000232	-0.3	-0.22	QT interval;	chr17:64694595	chr17:64747264~64747492:-
LUAD	cis	rs8062405	0.573	rs7187575	ENSG00000251417.2	RP11-1348G14.4	4.97	9.1e-07	0.000232	0.24	0.22	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28978780	chr16:28802743~28817828:+
LUAD	cis	rs12908161	0.96	rs11633450	ENSG00000275120.1	RP11-182J1.17	4.97	9.1e-07	0.000232	0.34	0.22	Schizophrenia;	chr15:84764056	chr15:84599434~84606463:-
LUAD	cis	rs6604026	0.555	rs12743520	ENSG00000223787.2	RP4-593M8.1	4.97	9.11e-07	0.000233	0.3	0.22	Multiple sclerosis;	chr1:92571555	chr1:92580476~92580821:-
LUAD	cis	rs1799949	1	rs8176269	ENSG00000236383.6	LINC00854	-4.97	9.12e-07	0.000233	-0.18	-0.22	Menopause (age at onset);	chr17:43061609	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs8176265	ENSG00000236383.6	LINC00854	-4.97	9.12e-07	0.000233	-0.18	-0.22	Menopause (age at onset);	chr17:43061979	chr17:43216941~43305976:-
LUAD	cis	rs2033711	0.622	rs975947	ENSG00000268912.1	CTD-2619J13.17	-4.97	9.12e-07	0.000233	-0.25	-0.22	Uric acid clearance;	chr19:58386826	chr19:58428632~58431148:-
LUAD	cis	rs7598759	0.712	rs6727372	ENSG00000181798.2	LINC00471	-4.97	9.12e-07	0.000233	-0.24	-0.22	Noise-induced hearing loss;	chr2:231467195	chr2:231508426~231514339:-
LUAD	cis	rs4664293	0.867	rs7594329	ENSG00000226266.5	AC009961.3	-4.97	9.13e-07	0.000233	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159716207	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs7582124	ENSG00000226266.5	AC009961.3	-4.97	9.13e-07	0.000233	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159716326	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.802	rs13025347	ENSG00000226266.5	AC009961.3	-4.97	9.13e-07	0.000233	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159721056	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs6432554	ENSG00000226266.5	AC009961.3	-4.97	9.13e-07	0.000233	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159722573	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs6760485	ENSG00000226266.5	AC009961.3	-4.97	9.13e-07	0.000233	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159723179	chr2:159670708~159712435:-
LUAD	cis	rs453301	0.686	rs6987107	ENSG00000173295.6	FAM86B3P	-4.97	9.13e-07	0.000233	-0.24	-0.22	Joint mobility (Beighton score);	chr8:9036071	chr8:8228595~8244865:+
LUAD	cis	rs910316	1	rs876403	ENSG00000259138.1	RP11-950C14.7	4.97	9.13e-07	0.000233	0.23	0.22	Height;	chr14:75136131	chr14:75127153~75136930:+
LUAD	cis	rs4835473	0.9	rs10003922	ENSG00000251600.4	RP11-673E1.1	-4.97	9.13e-07	0.000233	-0.27	-0.22	Immature fraction of reticulocytes;	chr4:143921235	chr4:143912331~143982454:+
LUAD	cis	rs6095360	0.7	rs36098998	ENSG00000222365.1	SNORD12B	-4.97	9.14e-07	0.000233	-0.25	-0.22	Intelligence (multi-trait analysis);	chr20:49071572	chr20:49280319~49280409:+
LUAD	cis	rs57502260	0.79	rs7128942	ENSG00000212093.1	AP000807.1	4.97	9.14e-07	0.000233	0.29	0.22	Total body bone mineral density (age 45-60);	chr11:68620516	chr11:68506083~68506166:-
LUAD	cis	rs801193	1	rs2707854	ENSG00000237310.1	GS1-124K5.4	4.97	9.14e-07	0.000233	0.24	0.22	Aortic root size;	chr7:66747610	chr7:66493706~66495474:+
LUAD	cis	rs2742234	0.578	rs2435354	ENSG00000273008.1	RP11-351D16.3	-4.97	9.14e-07	0.000233	-0.26	-0.22	Hirschsprung disease;	chr10:43156997	chr10:43136824~43138334:-
LUAD	cis	rs2836974	0.545	rs8128901	ENSG00000255568.3	BRWD1-AS2	4.97	9.14e-07	0.000233	0.21	0.22	Cognitive function;	chr21:39338493	chr21:39313935~39314962:+
LUAD	cis	rs1707322	1	rs785480	ENSG00000234329.1	RP11-767N6.2	4.97	9.15e-07	0.000233	0.23	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46026492	chr1:45651039~45651826:-
LUAD	cis	rs7017914	0.652	rs2639943	ENSG00000223220.1	Y_RNA	4.97	9.15e-07	0.000233	0.26	0.22	Bone mineral density;	chr8:71000905	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.606	rs2639941	ENSG00000223220.1	Y_RNA	4.97	9.15e-07	0.000233	0.26	0.22	Bone mineral density;	chr8:71001670	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.644	rs2639940	ENSG00000223220.1	Y_RNA	4.97	9.15e-07	0.000233	0.26	0.22	Bone mineral density;	chr8:71001686	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.606	rs2639939	ENSG00000223220.1	Y_RNA	4.97	9.15e-07	0.000233	0.26	0.22	Bone mineral density;	chr8:71001688	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.628	rs2035925	ENSG00000223220.1	Y_RNA	4.97	9.15e-07	0.000233	0.26	0.22	Bone mineral density;	chr8:71001981	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs2639938	ENSG00000223220.1	Y_RNA	4.97	9.15e-07	0.000233	0.26	0.22	Bone mineral density;	chr8:71002117	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs2639937	ENSG00000223220.1	Y_RNA	4.97	9.15e-07	0.000233	0.26	0.22	Bone mineral density;	chr8:71002121	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs2035924	ENSG00000223220.1	Y_RNA	4.97	9.15e-07	0.000233	0.26	0.22	Bone mineral density;	chr8:71002218	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs36162059	ENSG00000223220.1	Y_RNA	4.97	9.15e-07	0.000233	0.26	0.22	Bone mineral density;	chr8:71002471	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.583	rs2639936	ENSG00000223220.1	Y_RNA	4.97	9.15e-07	0.000233	0.26	0.22	Bone mineral density;	chr8:71002500	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.628	rs2732089	ENSG00000223220.1	Y_RNA	4.97	9.15e-07	0.000233	0.26	0.22	Bone mineral density;	chr8:71002929	chr8:70780914~70781008:-
LUAD	cis	rs1862618	0.526	rs2591963	ENSG00000271828.1	CTD-2310F14.1	-4.97	9.15e-07	0.000233	-0.33	-0.22	Initial pursuit acceleration;	chr5:56941308	chr5:56927874~56929573:+
LUAD	cis	rs1862618	0.573	rs2591962	ENSG00000271828.1	CTD-2310F14.1	-4.97	9.15e-07	0.000233	-0.33	-0.22	Initial pursuit acceleration;	chr5:56941328	chr5:56927874~56929573:+
LUAD	cis	rs4835473	0.932	rs11724752	ENSG00000251600.4	RP11-673E1.1	-4.97	9.17e-07	0.000234	-0.27	-0.22	Immature fraction of reticulocytes;	chr4:143769473	chr4:143912331~143982454:+
LUAD	cis	rs9322193	0.884	rs880245	ENSG00000268592.3	RAET1E-AS1	-4.97	9.17e-07	0.000234	-0.28	-0.22	Lung cancer;	chr6:149846262	chr6:149863494~149919507:+
LUAD	cis	rs891378	1	rs2802236	ENSG00000274245.1	RP11-357P18.2	4.97	9.17e-07	0.000234	0.29	0.22	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207298844	chr1:207372559~207373252:+
LUAD	cis	rs17684571	0.872	rs13191164	ENSG00000231441.1	RP11-472M19.2	4.97	9.18e-07	0.000234	0.29	0.22	Schizophrenia;	chr6:56701832	chr6:56844002~56864078:+
LUAD	cis	rs2439831	0.681	rs540388	ENSG00000249839.1	AC011330.5	-4.97	9.18e-07	0.000234	-0.39	-0.22	Lung cancer in ever smokers;	chr15:43314296	chr15:43663654~43684339:-
LUAD	cis	rs858239	1	rs199351	ENSG00000226816.2	AC005082.12	4.97	9.18e-07	0.000234	0.29	0.22	Cerebrospinal fluid biomarker levels;	chr7:23260430	chr7:23206013~23208045:+
LUAD	cis	rs858239	0.6	rs13438188	ENSG00000230042.1	AK3P3	4.97	9.18e-07	0.000234	0.27	0.22	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23129178~23129841:+
LUAD	cis	rs8050896	1	rs59093487	ENSG00000260695.1	RP11-513N24.1	-4.97	9.18e-07	0.000234	-0.42	-0.22	Response to antipsychotic treatment;	chr16:66125410	chr16:65861112~65863784:-
LUAD	cis	rs8050896	1	rs16969792	ENSG00000260695.1	RP11-513N24.1	-4.97	9.18e-07	0.000234	-0.42	-0.22	Response to antipsychotic treatment;	chr16:66125508	chr16:65861112~65863784:-
LUAD	cis	rs7937890	0.559	rs2034480	ENSG00000251991.1	RNU7-49P	4.97	9.18e-07	0.000234	0.23	0.22	Mitochondrial DNA levels;	chr11:14445377	chr11:14478892~14478953:+
LUAD	cis	rs6840258	1	rs6840258	ENSG00000251411.1	RP11-397E7.4	-4.97	9.19e-07	0.000234	-0.29	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87052516	chr4:86913266~86914817:-
LUAD	cis	rs7432375	0.61	rs28458819	ENSG00000239213.4	NCK1-AS1	4.97	9.2e-07	0.000235	0.23	0.22	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136803472	chr3:136841726~136862054:-
LUAD	cis	rs7432375	0.58	rs4678441	ENSG00000239213.4	NCK1-AS1	4.97	9.2e-07	0.000235	0.23	0.22	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136813986	chr3:136841726~136862054:-
LUAD	cis	rs7432375	0.58	rs4678442	ENSG00000239213.4	NCK1-AS1	4.97	9.2e-07	0.000235	0.23	0.22	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136814129	chr3:136841726~136862054:-
LUAD	cis	rs4143844	0.867	rs957348	ENSG00000259251.2	RP11-643M14.1	4.97	9.21e-07	0.000235	0.38	0.22	Bipolar disorder and schizophrenia;	chr15:61935700	chr15:62060503~62062434:+
LUAD	cis	rs8072100	0.79	rs34200664	ENSG00000228782.6	CTD-2026D20.3	-4.97	9.22e-07	0.000235	-0.23	-0.22	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47667286	chr17:47450568~47492492:-
LUAD	cis	rs3930017	1	rs3930017	ENSG00000242435.1	UPK3BP1	4.97	9.22e-07	0.000235	0.23	0.22	Body mass index;	chr7:77091265	chr7:77004662~77005774:+
LUAD	cis	rs61270009	0.955	rs4916905	ENSG00000247828.6	TMEM161B-AS1	4.97	9.22e-07	0.000235	0.26	0.22	Depressive symptoms;	chr5:88362244	chr5:88268895~88436685:+
LUAD	cis	rs9322193	0.962	rs35031906	ENSG00000268592.3	RAET1E-AS1	4.97	9.22e-07	0.000235	0.27	0.22	Lung cancer;	chr6:149677438	chr6:149863494~149919507:+
LUAD	cis	rs7017914	0.652	rs56099911	ENSG00000223220.1	Y_RNA	4.97	9.22e-07	0.000235	0.25	0.22	Bone mineral density;	chr8:70710156	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs6987515	ENSG00000223220.1	Y_RNA	4.97	9.22e-07	0.000235	0.25	0.22	Bone mineral density;	chr8:70728067	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs56156614	ENSG00000223220.1	Y_RNA	4.97	9.22e-07	0.000235	0.25	0.22	Bone mineral density;	chr8:70730816	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs56094661	ENSG00000223220.1	Y_RNA	4.97	9.22e-07	0.000235	0.25	0.22	Bone mineral density;	chr8:70732493	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.592	rs6980835	ENSG00000223220.1	Y_RNA	4.97	9.22e-07	0.000235	0.25	0.22	Bone mineral density;	chr8:70733691	chr8:70780914~70781008:-
LUAD	cis	rs1799949	0.965	rs8176130	ENSG00000236383.6	LINC00854	-4.97	9.22e-07	0.000235	-0.18	-0.22	Menopause (age at onset);	chr17:43106026	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs8176120	ENSG00000236383.6	LINC00854	-4.97	9.22e-07	0.000235	-0.18	-0.22	Menopause (age at onset);	chr17:43109216	chr17:43216941~43305976:-
LUAD	cis	rs7580658	0.521	rs35577992	ENSG00000236682.1	AC068282.3	-4.97	9.23e-07	0.000235	-0.29	-0.22	Protein C levels;	chr2:127183748	chr2:127389130~127400580:+
LUAD	cis	rs6728642	0.908	rs6576996	ENSG00000230606.9	AC159540.1	4.97	9.23e-07	0.000235	0.33	0.22	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96957575	chr2:97416165~97433527:-
LUAD	cis	rs41307935	0.555	rs35427438	ENSG00000260063.1	RP5-968P14.2	-4.97	9.23e-07	0.000235	-0.47	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26976355	chr1:26692132~26694131:-
LUAD	cis	rs41307935	0.643	rs7555729	ENSG00000260063.1	RP5-968P14.2	-4.97	9.23e-07	0.000235	-0.47	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26982540	chr1:26692132~26694131:-
LUAD	cis	rs41307935	0.643	rs34370737	ENSG00000260063.1	RP5-968P14.2	-4.97	9.23e-07	0.000235	-0.47	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26985113	chr1:26692132~26694131:-
LUAD	cis	rs41307935	0.643	rs12726806	ENSG00000260063.1	RP5-968P14.2	-4.97	9.23e-07	0.000235	-0.47	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26991061	chr1:26692132~26694131:-
LUAD	cis	rs891378	1	rs10864181	ENSG00000274245.1	RP11-357P18.2	-4.97	9.23e-07	0.000235	-0.29	-0.22	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207274706	chr1:207372559~207373252:+
LUAD	cis	rs1707322	0.929	rs785513	ENSG00000280836.1	AL355480.1	4.97	9.23e-07	0.000235	0.29	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46072648	chr1:45581219~45581321:-
LUAD	cis	rs4819052	1	rs9306123	ENSG00000215447.6	BX322557.10	-4.97	9.23e-07	0.000235	-0.29	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45290007	chr21:45288052~45291738:+
LUAD	cis	rs853679	0.607	rs201002	ENSG00000219392.1	RP1-265C24.5	-4.97	9.24e-07	0.000236	-0.4	-0.22	Depression;	chr6:27840414	chr6:28115628~28116551:+
LUAD	cis	rs8098244	0.638	rs9948008	ENSG00000264745.1	TTC39C-AS1	4.97	9.24e-07	0.000236	0.23	0.22	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23906049	chr18:23994213~24015339:-
LUAD	cis	rs7829975	0.774	rs13259216	ENSG00000173295.6	FAM86B3P	4.97	9.24e-07	0.000236	0.23	0.22	Mood instability;	chr8:8816091	chr8:8228595~8244865:+
LUAD	cis	rs2276314	0.512	rs17562898	ENSG00000278986.1	RP11-723J4.3	4.97	9.24e-07	0.000236	0.41	0.22	Endometriosis;Drug-induced torsades de pointes;	chr18:35997212	chr18:35972151~35973916:+
LUAD	cis	rs4835473	0.897	rs1450246	ENSG00000251600.4	RP11-673E1.1	4.97	9.24e-07	0.000236	0.27	0.22	Immature fraction of reticulocytes;	chr4:143702954	chr4:143912331~143982454:+
LUAD	cis	rs293748	1	rs293748	ENSG00000250155.1	CTD-2353F22.1	-4.97	9.25e-07	0.000236	-0.29	-0.22	Obesity-related traits;	chr5:36900741	chr5:36666214~36725195:-
LUAD	cis	rs6604026	0.589	rs67026262	ENSG00000223787.2	RP4-593M8.1	4.97	9.25e-07	0.000236	0.3	0.22	Multiple sclerosis;	chr1:92646070	chr1:92580476~92580821:-
LUAD	cis	rs6604026	0.589	rs67876779	ENSG00000223787.2	RP4-593M8.1	4.97	9.25e-07	0.000236	0.3	0.22	Multiple sclerosis;	chr1:92646308	chr1:92580476~92580821:-
LUAD	cis	rs6604026	0.555	rs11591094	ENSG00000223787.2	RP4-593M8.1	4.97	9.25e-07	0.000236	0.3	0.22	Multiple sclerosis;	chr1:92649899	chr1:92580476~92580821:-
LUAD	cis	rs7923609	0.778	rs7075195	ENSG00000232075.1	MRPL35P2	-4.97	9.25e-07	0.000236	-0.27	-0.22	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63290899	chr10:63634317~63634827:-
LUAD	cis	rs227275	0.554	rs6810668	ENSG00000251288.2	RP11-10L12.2	-4.97	9.25e-07	0.000236	-0.27	-0.22	Allergic disease (asthma, hay fever or eczema);	chr4:102987574	chr4:102751401~102752641:+
LUAD	cis	rs5758511	0.68	rs5758687	ENSG00000226450.2	CYP2D8P	4.97	9.25e-07	0.000236	0.21	0.22	Birth weight;	chr22:42260582	chr22:42149886~42155001:-
LUAD	cis	rs896854	0.846	rs13254283	ENSG00000253528.2	RP11-347C18.4	4.97	9.27e-07	0.000236	0.21	0.22	Type 2 diabetes;	chr8:94901875	chr8:94974573~94974853:-
LUAD	cis	rs763567	1	rs2022372	ENSG00000271811.1	RP1-79C4.4	-4.97	9.27e-07	0.000236	-0.27	-0.22	Tonsillectomy;	chr1:170620769	chr1:170667381~170669425:+
LUAD	cis	rs853679	0.567	rs7774981	ENSG00000216901.1	AL022393.7	4.97	9.27e-07	0.000236	0.27	0.22	Depression;	chr6:28379133	chr6:28176188~28176674:+
LUAD	cis	rs853679	0.567	rs7754960	ENSG00000216901.1	AL022393.7	4.97	9.27e-07	0.000236	0.27	0.22	Depression;	chr6:28379168	chr6:28176188~28176674:+
LUAD	cis	rs643506	0.79	rs688095	ENSG00000230911.1	PPIHP1	-4.97	9.27e-07	0.000236	-0.28	-0.22	Breast cancer;	chr11:111808047	chr11:112029858~112030367:-
LUAD	cis	rs73173548	0.502	rs12187348	ENSG00000247828.6	TMEM161B-AS1	4.97	9.28e-07	0.000236	0.27	0.22	Macular telangiectasia type 2;	chr5:88424724	chr5:88268895~88436685:+
LUAD	cis	rs2742234	0.59	rs2435337	ENSG00000273008.1	RP11-351D16.3	-4.97	9.28e-07	0.000236	-0.26	-0.22	Hirschsprung disease;	chr10:43166388	chr10:43136824~43138334:-
LUAD	cis	rs17508449	0.865	rs75419513	ENSG00000232450.1	RP4-730K3.3	-4.97	9.28e-07	0.000236	-0.38	-0.22	Leprosy;	chr1:113590174	chr1:113698884~113699631:-
LUAD	cis	rs17508449	0.819	rs4839329	ENSG00000232450.1	RP4-730K3.3	-4.97	9.28e-07	0.000236	-0.38	-0.22	Leprosy;	chr1:113593083	chr1:113698884~113699631:-
LUAD	cis	rs7191700	0.644	rs918738	ENSG00000262703.1	RP11-485G7.6	-4.97	9.28e-07	0.000237	-0.19	-0.22	Multiple sclerosis;	chr16:11345822	chr16:11348143~11349321:-
LUAD	cis	rs4819052	0.62	rs421619	ENSG00000223768.1	LINC00205	-4.97	9.29e-07	0.000237	-0.3	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45126200	chr21:45293285~45297354:+
LUAD	cis	rs11159086	0.793	rs1860108	ENSG00000259005.1	RP3-449M8.6	4.97	9.3e-07	0.000237	0.28	0.22	Advanced glycation end-product levels;	chr14:74478562	chr14:74474007~74474864:-
LUAD	cis	rs11159086	0.793	rs3784035	ENSG00000259005.1	RP3-449M8.6	4.97	9.3e-07	0.000237	0.28	0.22	Advanced glycation end-product levels;	chr14:74482221	chr14:74474007~74474864:-
LUAD	cis	rs11159086	0.793	rs12433382	ENSG00000259005.1	RP3-449M8.6	4.97	9.3e-07	0.000237	0.28	0.22	Advanced glycation end-product levels;	chr14:74482940	chr14:74474007~74474864:-
LUAD	cis	rs11159086	0.793	rs10148268	ENSG00000259005.1	RP3-449M8.6	4.97	9.3e-07	0.000237	0.28	0.22	Advanced glycation end-product levels;	chr14:74484261	chr14:74474007~74474864:-
LUAD	cis	rs801193	1	rs2707850	ENSG00000237310.1	GS1-124K5.4	4.97	9.3e-07	0.000237	0.24	0.22	Aortic root size;	chr7:66738883	chr7:66493706~66495474:+
LUAD	cis	rs801193	0.967	rs1110414	ENSG00000237310.1	GS1-124K5.4	4.97	9.3e-07	0.000237	0.24	0.22	Aortic root size;	chr7:66740595	chr7:66493706~66495474:+
LUAD	cis	rs801193	1	rs7783924	ENSG00000237310.1	GS1-124K5.4	4.97	9.3e-07	0.000237	0.24	0.22	Aortic root size;	chr7:66744070	chr7:66493706~66495474:+
LUAD	cis	rs801193	1	rs7789184	ENSG00000237310.1	GS1-124K5.4	4.97	9.3e-07	0.000237	0.24	0.22	Aortic root size;	chr7:66745208	chr7:66493706~66495474:+
LUAD	cis	rs7116495	1	rs541022	ENSG00000254682.1	RP11-660L16.2	4.97	9.3e-07	0.000237	0.46	0.22	Severe influenza A (H1N1) infection;	chr11:72072010	chr11:71448674~71452157:+
LUAD	cis	rs4873772	0.837	rs11782572	ENSG00000253330.1	RP11-697N18.3	4.97	9.3e-07	0.000237	0.25	0.22	Lobe attachment (rater-scored or self-reported);	chr8:47558483	chr8:47511034~47512141:-
LUAD	cis	rs42490	0.528	rs10956209	ENSG00000251136.7	RP11-37B2.1	4.97	9.3e-07	0.000237	0.22	0.22	Leprosy;	chr8:89670923	chr8:89609409~89757727:-
LUAD	cis	rs6570726	0.791	rs443628	ENSG00000235652.6	RP11-545I5.3	4.97	9.31e-07	0.000237	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145562348	chr6:145799409~145886585:+
LUAD	cis	rs9992667	0.955	rs6855993	ENSG00000231160.8	KLF3-AS1	4.97	9.31e-07	0.000237	0.26	0.22	Eosinophil percentage of granulocytes;	chr4:38607291	chr4:38612701~38664883:-
LUAD	cis	rs7017914	0.652	rs13262205	ENSG00000223220.1	Y_RNA	4.97	9.31e-07	0.000237	0.25	0.22	Bone mineral density;	chr8:70659690	chr8:70780914~70781008:-
LUAD	cis	rs4664293	0.867	rs34392518	ENSG00000226266.5	AC009961.3	-4.97	9.31e-07	0.000237	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159749367	chr2:159670708~159712435:-
LUAD	cis	rs13256369	0.802	rs12681326	ENSG00000253893.2	FAM85B	-4.97	9.32e-07	0.000237	-0.31	-0.22	Obesity-related traits;	chr8:8708879	chr8:8167819~8226614:-
LUAD	cis	rs11009175	0.746	rs11009203	ENSG00000273038.2	RP11-479G22.8	-4.97	9.33e-07	0.000237	-0.31	-0.22	Depression (quantitative trait);	chr10:33059205	chr10:32887255~32889311:-
LUAD	cis	rs36093844	0.799	rs7124956	ENSG00000279742.1	RP11-700A24.1	-4.97	9.34e-07	0.000238	-0.25	-0.22	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85877776	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.904	rs1445502	ENSG00000279742.1	RP11-700A24.1	-4.97	9.34e-07	0.000238	-0.25	-0.22	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85878255	chr11:85852557~85854943:-
LUAD	cis	rs301901	0.743	rs301872	ENSG00000250155.1	CTD-2353F22.1	-4.97	9.34e-07	0.000238	-0.23	-0.22	Height;	chr5:37137756	chr5:36666214~36725195:-
LUAD	cis	rs301901	0.714	rs301869	ENSG00000250155.1	CTD-2353F22.1	-4.97	9.34e-07	0.000238	-0.23	-0.22	Height;	chr5:37140495	chr5:36666214~36725195:-
LUAD	cis	rs301901	0.772	rs2098713	ENSG00000250155.1	CTD-2353F22.1	-4.97	9.34e-07	0.000238	-0.23	-0.22	Height;	chr5:37144472	chr5:36666214~36725195:-
LUAD	cis	rs7937890	0.559	rs4369365	ENSG00000251991.1	RNU7-49P	4.97	9.34e-07	0.000238	0.24	0.22	Mitochondrial DNA levels;	chr11:14422969	chr11:14478892~14478953:+
LUAD	cis	rs9928842	0.664	rs7205074	ENSG00000280152.1	RP11-331F4.5	-4.97	9.34e-07	0.000238	-0.23	-0.22	Alcoholic chronic pancreatitis;	chr16:75186111	chr16:75245994~75250077:-
LUAD	cis	rs8077577	0.747	rs1925	ENSG00000273018.4	CTD-2303H24.2	-4.97	9.34e-07	0.000238	-0.31	-0.22	Obesity-related traits;	chr17:18274401	chr17:18511221~18551705:-
LUAD	cis	rs72772090	0.71	rs11739280	ENSG00000248734.2	CTD-2260A17.1	4.97	9.35e-07	0.000238	0.31	0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96738443	chr5:96784777~96785999:+
LUAD	cis	rs4835473	0.771	rs4261935	ENSG00000251600.4	RP11-673E1.1	4.97	9.35e-07	0.000238	0.27	0.22	Immature fraction of reticulocytes;	chr4:143979751	chr4:143912331~143982454:+
LUAD	cis	rs11671005	0.695	rs11673069	ENSG00000268912.1	CTD-2619J13.17	-4.97	9.35e-07	0.000238	-0.3	-0.22	Mean platelet volume;	chr19:58423551	chr19:58428632~58431148:-
LUAD	cis	rs42490	0.903	rs218902	ENSG00000251136.7	RP11-37B2.1	4.97	9.36e-07	0.000238	0.23	0.22	Leprosy;	chr8:89719986	chr8:89609409~89757727:-
LUAD	cis	rs673078	0.66	rs17433217	ENSG00000275409.1	RP11-131L12.4	-4.97	9.36e-07	0.000238	-0.31	-0.22	Glucose homeostasis traits;	chr12:118269076	chr12:118430147~118430699:+
LUAD	cis	rs12022452	0.822	rs6600343	ENSG00000238287.1	RP11-656D10.3	-4.97	9.36e-07	0.000238	-0.34	-0.22	Age-related hearing impairment (SNP x SNP interaction);	chr1:40562538	chr1:40493157~40508661:-
LUAD	cis	rs1008375	0.966	rs3775924	ENSG00000249502.1	AC006160.5	-4.97	9.37e-07	0.000238	-0.22	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17584361	chr4:17587467~17614571:-
LUAD	cis	rs1816752	0.87	rs3825449	ENSG00000273628.1	RP11-756A22.7	4.97	9.38e-07	0.000239	0.25	0.22	Obesity-related traits;	chr13:24440303	chr13:24933006~24936796:+
LUAD	cis	rs11168351	0.833	rs6580652	ENSG00000257735.1	RP11-370I10.6	-4.97	9.38e-07	0.000239	-0.26	-0.22	Bipolar disorder and schizophrenia;	chr12:48053322	chr12:48350945~48442411:+
LUAD	cis	rs1707322	1	rs12077546	ENSG00000280836.1	AL355480.1	-4.97	9.38e-07	0.000239	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966134	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs12124291	ENSG00000280836.1	AL355480.1	-4.97	9.38e-07	0.000239	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966460	chr1:45581219~45581321:-
LUAD	cis	rs6687821	0.784	rs263476	ENSG00000267734.1	RP4-604K5.3	4.97	9.38e-07	0.000239	0.26	0.22	Yeast infection;	chr1:86743975	chr1:86932199~86934891:-
LUAD	cis	rs11051970	0.559	rs3748276	ENSG00000274964.1	RP11-817I4.1	-4.97	9.38e-07	0.000239	-0.28	-0.22	Response to tocilizumab in rheumatoid arthritis;	chr12:32328643	chr12:32339368~32340724:+
LUAD	cis	rs7017914	0.629	rs2956611	ENSG00000223220.1	Y_RNA	4.97	9.38e-07	0.000239	0.25	0.22	Bone mineral density;	chr8:70985633	chr8:70780914~70781008:-
LUAD	cis	rs801193	1	rs3778909	ENSG00000237310.1	GS1-124K5.4	4.97	9.39e-07	0.000239	0.24	0.22	Aortic root size;	chr7:66790659	chr7:66493706~66495474:+
LUAD	cis	rs7044106	0.887	rs1359328	ENSG00000238181.2	AHCYP2	-4.97	9.39e-07	0.000239	-0.31	-0.22	Hip circumference adjusted for BMI;	chr9:120608544	chr9:120720673~120721972:+
LUAD	cis	rs4835473	0.932	rs4835118	ENSG00000251600.4	RP11-673E1.1	4.97	9.39e-07	0.000239	0.27	0.22	Immature fraction of reticulocytes;	chr4:143981994	chr4:143912331~143982454:+
LUAD	cis	rs6687758	0.945	rs12033415	ENSG00000228437.4	RP11-400N13.2	4.97	9.39e-07	0.000239	0.32	0.22	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221981726	chr1:221966341~221984964:+
LUAD	cis	rs2378497	1	rs2378497	ENSG00000232679.1	RP11-400N13.3	4.97	9.39e-07	0.000239	0.34	0.22	Serum thyroid-stimulating hormone levels;	chr1:222021660	chr1:222041705~222064763:-
LUAD	cis	rs2378497	1	rs55756813	ENSG00000232679.1	RP11-400N13.3	4.97	9.39e-07	0.000239	0.34	0.22	Serum thyroid-stimulating hormone levels;	chr1:222021677	chr1:222041705~222064763:-
LUAD	cis	rs507080	0.961	rs600969	ENSG00000278376.1	RP11-158I9.8	-4.97	9.4e-07	0.000239	-0.24	-0.22	Serum metabolite levels;	chr11:118675087	chr11:118791254~118793137:+
LUAD	cis	rs507080	0.961	rs673770	ENSG00000278376.1	RP11-158I9.8	-4.97	9.4e-07	0.000239	-0.24	-0.22	Serum metabolite levels;	chr11:118679892	chr11:118791254~118793137:+
LUAD	cis	rs916888	0.821	rs199504	ENSG00000261575.2	RP11-259G18.1	-4.97	9.4e-07	0.000239	-0.34	-0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46267037~46268694:+
LUAD	cis	rs9659323	0.67	rs17023223	ENSG00000231365.4	RP11-418J17.1	-4.97	9.4e-07	0.000239	-0.26	-0.22	Body mass index;	chr1:119088551	chr1:119140396~119275973:+
LUAD	cis	rs755249	0.501	rs4660669	ENSG00000228060.1	RP11-69E11.8	4.97	9.41e-07	0.000239	0.2	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39341786	chr1:39565160~39573203:+
LUAD	cis	rs9860428	0.844	rs9863580	ENSG00000242770.2	RP11-180K7.1	4.97	9.41e-07	0.000239	0.24	0.22	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112905883	chr3:112802478~112812819:+
LUAD	cis	rs9860428	0.844	rs9877803	ENSG00000242770.2	RP11-180K7.1	4.97	9.41e-07	0.000239	0.24	0.22	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112906290	chr3:112802478~112812819:+
LUAD	cis	rs2933343	0.7	rs883602	ENSG00000261159.1	RP11-723O4.9	4.97	9.43e-07	0.00024	0.24	0.22	IgG glycosylation;	chr3:128935109	chr3:128859716~128860526:-
LUAD	cis	rs7923609	0.905	rs7088799	ENSG00000232075.1	MRPL35P2	-4.97	9.43e-07	0.00024	-0.27	-0.22	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63256414	chr10:63634317~63634827:-
LUAD	cis	rs7017914	0.617	rs34917985	ENSG00000223220.1	Y_RNA	4.97	9.43e-07	0.00024	0.25	0.22	Bone mineral density;	chr8:70662426	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs6993326	ENSG00000223220.1	Y_RNA	4.97	9.43e-07	0.00024	0.25	0.22	Bone mineral density;	chr8:70663365	chr8:70780914~70781008:-
LUAD	cis	rs9438901	0.655	rs609320	ENSG00000224183.1	SDHDP6	4.97	9.43e-07	0.00024	0.42	0.22	Red cell distribution width;	chr1:25390874	chr1:25294164~25294643:-
LUAD	cis	rs2732480	0.5	rs12828309	ENSG00000257735.1	RP11-370I10.6	4.97	9.44e-07	0.00024	0.27	0.22	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48247377	chr12:48350945~48442411:+
LUAD	cis	rs12681366	0.801	rs2919657	ENSG00000253704.1	RP11-267M23.4	4.97	9.44e-07	0.00024	0.27	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94460724	chr8:94553722~94569745:+
LUAD	cis	rs12928939	0.911	rs8051878	ENSG00000260886.1	TAT-AS1	4.97	9.44e-07	0.00024	0.28	0.22	Post bronchodilator FEV1;	chr16:71784528	chr16:71565789~71578187:+
LUAD	cis	rs12928939	0.911	rs7202840	ENSG00000260886.1	TAT-AS1	4.97	9.44e-07	0.00024	0.28	0.22	Post bronchodilator FEV1;	chr16:71790811	chr16:71565789~71578187:+
LUAD	cis	rs889398	0.869	rs862320	ENSG00000226232.7	RP11-419C5.2	4.97	9.44e-07	0.00024	0.19	0.22	Body mass index;	chr16:69617963	chr16:69976388~69996188:-
LUAD	cis	rs8098244	0.66	rs28409401	ENSG00000264745.1	TTC39C-AS1	4.97	9.45e-07	0.00024	0.23	0.22	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23910400	chr18:23994213~24015339:-
LUAD	cis	rs853679	0.769	rs17720293	ENSG00000219392.1	RP1-265C24.5	-4.97	9.45e-07	0.00024	-0.42	-0.22	Depression;	chr6:28246920	chr6:28115628~28116551:+
LUAD	cis	rs8031584	0.958	rs7176569	ENSG00000270015.1	RP11-540B6.6	4.97	9.46e-07	0.000241	0.16	0.22	Huntington's disease progression;	chr15:30952292	chr15:30926514~30928407:+
LUAD	cis	rs2933343	0.621	rs728838	ENSG00000261159.1	RP11-723O4.9	4.97	9.46e-07	0.000241	0.24	0.22	IgG glycosylation;	chr3:128870170	chr3:128859716~128860526:-
LUAD	cis	rs9910055	0.573	rs113184718	ENSG00000267080.4	ASB16-AS1	4.97	9.47e-07	0.000241	0.2	0.22	Total body bone mineral density;	chr17:44129175	chr17:44175973~44186717:-
LUAD	cis	rs7208859	0.573	rs8070182	ENSG00000263603.1	CTD-2349P21.5	-4.97	9.47e-07	0.000241	-0.37	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30729469~30731202:+
LUAD	cis	rs2911132	0.506	rs7705827	ENSG00000248734.2	CTD-2260A17.1	4.97	9.47e-07	0.000241	0.23	0.22	Urate levels (BMI interaction);	chr5:96746729	chr5:96784777~96785999:+
LUAD	cis	rs1275468	1	rs1275469	ENSG00000257497.2	RP11-585P4.5	-4.97	9.48e-07	0.000241	-0.31	-0.22	Polycystic ovary syndrome;	chr12:75541450	chr12:75483454~75489820:-
LUAD	cis	rs11089937	0.54	rs2329931	ENSG00000211638.2	IGLV8-61	-4.97	9.49e-07	0.000241	-0.26	-0.22	Periodontitis (PAL4Q3);	chr22:22131994	chr22:22098700~22099212:+
LUAD	cis	rs11089937	0.568	rs2876996	ENSG00000211638.2	IGLV8-61	-4.97	9.49e-07	0.000241	-0.26	-0.22	Periodontitis (PAL4Q3);	chr22:22132006	chr22:22098700~22099212:+
LUAD	cis	rs7598759	0.712	rs6740474	ENSG00000181798.2	LINC00471	-4.97	9.49e-07	0.000241	-0.24	-0.22	Noise-induced hearing loss;	chr2:231467120	chr2:231508426~231514339:-
LUAD	cis	rs7598759	0.712	rs6727510	ENSG00000181798.2	LINC00471	-4.97	9.49e-07	0.000241	-0.24	-0.22	Noise-induced hearing loss;	chr2:231467305	chr2:231508426~231514339:-
LUAD	cis	rs7598759	0.675	rs6727530	ENSG00000181798.2	LINC00471	-4.97	9.49e-07	0.000241	-0.24	-0.22	Noise-induced hearing loss;	chr2:231467347	chr2:231508426~231514339:-
LUAD	cis	rs7598759	0.712	rs10933372	ENSG00000181798.2	LINC00471	-4.97	9.49e-07	0.000241	-0.24	-0.22	Noise-induced hearing loss;	chr2:231467614	chr2:231508426~231514339:-
LUAD	cis	rs7598759	0.712	rs997400	ENSG00000181798.2	LINC00471	-4.97	9.49e-07	0.000241	-0.24	-0.22	Noise-induced hearing loss;	chr2:231468136	chr2:231508426~231514339:-
LUAD	cis	rs6570726	0.791	rs400329	ENSG00000235652.6	RP11-545I5.3	4.97	9.5e-07	0.000241	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145558306	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.764	rs367065	ENSG00000235652.6	RP11-545I5.3	4.97	9.5e-07	0.000241	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145561173	chr6:145799409~145886585:+
LUAD	cis	rs1707322	1	rs785478	ENSG00000280836.1	AL355480.1	4.97	9.5e-07	0.000242	0.28	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46025963	chr1:45581219~45581321:-
LUAD	cis	rs7772486	0.754	rs864148	ENSG00000235652.6	RP11-545I5.3	-4.97	9.5e-07	0.000242	-0.22	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145655539	chr6:145799409~145886585:+
LUAD	cis	rs801193	1	rs6975195	ENSG00000237310.1	GS1-124K5.4	-4.97	9.5e-07	0.000242	-0.24	-0.22	Aortic root size;	chr7:66659787	chr7:66493706~66495474:+
LUAD	cis	rs801193	1	rs3857688	ENSG00000237310.1	GS1-124K5.4	-4.97	9.5e-07	0.000242	-0.24	-0.22	Aortic root size;	chr7:66662819	chr7:66493706~66495474:+
LUAD	cis	rs801193	1	rs2286684	ENSG00000237310.1	GS1-124K5.4	-4.97	9.5e-07	0.000242	-0.24	-0.22	Aortic root size;	chr7:66664843	chr7:66493706~66495474:+
LUAD	cis	rs801193	0.935	rs2286683	ENSG00000237310.1	GS1-124K5.4	-4.97	9.5e-07	0.000242	-0.24	-0.22	Aortic root size;	chr7:66664856	chr7:66493706~66495474:+
LUAD	cis	rs801193	1	rs10274773	ENSG00000237310.1	GS1-124K5.4	-4.97	9.5e-07	0.000242	-0.24	-0.22	Aortic root size;	chr7:66668591	chr7:66493706~66495474:+
LUAD	cis	rs12908161	1	rs12908161	ENSG00000275120.1	RP11-182J1.17	4.97	9.51e-07	0.000242	0.34	0.22	Schizophrenia;	chr15:84664594	chr15:84599434~84606463:-
LUAD	cis	rs748404	0.666	rs7183708	ENSG00000205771.5	CATSPER2P1	-4.97	9.51e-07	0.000242	-0.33	-0.22	Lung cancer;	chr15:43355226	chr15:43726918~43747094:-
LUAD	cis	rs4835473	0.863	rs13146607	ENSG00000251600.4	RP11-673E1.1	-4.97	9.52e-07	0.000242	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143687283	chr4:143912331~143982454:+
LUAD	cis	rs3761847	0.622	rs10435888	ENSG00000226752.6	PSMD5-AS1	-4.97	9.53e-07	0.000242	-0.23	-0.22	Rheumatoid arthritis;	chr9:121057325	chr9:120824828~120854385:+
LUAD	cis	rs3761847	0.593	rs10985140	ENSG00000226752.6	PSMD5-AS1	-4.97	9.53e-07	0.000242	-0.23	-0.22	Rheumatoid arthritis;	chr9:121060559	chr9:120824828~120854385:+
LUAD	cis	rs3761847	0.622	rs1323471	ENSG00000226752.6	PSMD5-AS1	-4.97	9.53e-07	0.000242	-0.23	-0.22	Rheumatoid arthritis;	chr9:121064037	chr9:120824828~120854385:+
LUAD	cis	rs4819052	0.788	rs2236449	ENSG00000215447.6	BX322557.10	-4.97	9.53e-07	0.000242	-0.27	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45282591	chr21:45288052~45291738:+
LUAD	cis	rs9322193	0.923	rs12175504	ENSG00000268592.3	RAET1E-AS1	4.97	9.53e-07	0.000242	0.27	0.22	Lung cancer;	chr6:149664079	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.962	rs62439843	ENSG00000268592.3	RAET1E-AS1	4.97	9.53e-07	0.000242	0.27	0.22	Lung cancer;	chr6:149676521	chr6:149863494~149919507:+
LUAD	cis	rs5758511	0.68	rs5758681	ENSG00000205702.9	CYP2D7	4.97	9.53e-07	0.000242	0.21	0.22	Birth weight;	chr22:42249085	chr22:42140203~42144577:-
LUAD	cis	rs7221109	1	rs7221109	ENSG00000278834.1	RP11-458J1.1	4.97	9.53e-07	0.000242	0.25	0.22	Type 1 diabetes;	chr17:40614034	chr17:40648300~40649718:+
LUAD	cis	rs4835473	0.618	rs7685385	ENSG00000251600.4	RP11-673E1.1	-4.97	9.54e-07	0.000242	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:144029851	chr4:143912331~143982454:+
LUAD	cis	rs1012068	0.924	rs5994449	ENSG00000236132.1	CTA-440B3.1	-4.97	9.54e-07	0.000242	-0.28	-0.22	Chronic hepatitis C infection;	chr22:31908193	chr22:31816379~31817491:-
LUAD	cis	rs1012068	0.924	rs5998173	ENSG00000236132.1	CTA-440B3.1	-4.97	9.54e-07	0.000242	-0.28	-0.22	Chronic hepatitis C infection;	chr22:31909985	chr22:31816379~31817491:-
LUAD	cis	rs2243480	1	rs313809	ENSG00000164669.11	INTS4P1	4.97	9.54e-07	0.000242	0.39	0.22	Diabetic kidney disease;	chr7:66034996	chr7:65141225~65234216:+
LUAD	cis	rs11671005	0.693	rs11668757	ENSG00000268912.1	CTD-2619J13.17	-4.97	9.54e-07	0.000242	-0.3	-0.22	Mean platelet volume;	chr19:58416932	chr19:58428632~58431148:-
LUAD	cis	rs3095008	0.614	rs3095212	ENSG00000243004.4	AC005062.2	-4.97	9.55e-07	0.000243	-0.25	-0.22	Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide);	chr7:20196513	chr7:19918981~20140453:-
LUAD	cis	rs17772222	0.74	rs61975278	ENSG00000258789.1	RP11-507K2.3	-4.97	9.55e-07	0.000243	-0.29	-0.22	Coronary artery calcification;	chr14:88511223	chr14:88551597~88552493:+
LUAD	cis	rs7829975	0.774	rs35431455	ENSG00000173295.6	FAM86B3P	4.97	9.55e-07	0.000243	0.23	0.22	Mood instability;	chr8:8816226	chr8:8228595~8244865:+
LUAD	cis	rs10129255	0.957	rs8009464	ENSG00000211967.3	IGHV3-53	-4.97	9.55e-07	0.000243	-0.17	-0.22	Kawasaki disease;	chr14:106777611	chr14:106592676~106593347:-
LUAD	cis	rs35160687	0.644	rs4832276	ENSG00000273080.1	RP11-301O19.1	4.97	9.55e-07	0.000243	0.24	0.22	Night sleep phenotypes;	chr2:86317895	chr2:86195590~86196049:+
LUAD	cis	rs847577	0.677	rs10242903	ENSG00000272950.1	RP11-307C18.1	-4.96	9.56e-07	0.000243	-0.28	-0.22	Breast cancer;	chr7:98112483	chr7:98322853~98323430:+
LUAD	cis	rs2742234	0.59	rs2503864	ENSG00000273008.1	RP11-351D16.3	-4.96	9.56e-07	0.000243	-0.26	-0.22	Hirschsprung disease;	chr10:43171319	chr10:43136824~43138334:-
LUAD	cis	rs2562456	0.793	rs7258473	ENSG00000268081.1	RP11-678G14.2	4.96	9.56e-07	0.000243	0.36	0.22	Pain;	chr19:21331795	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.793	rs2219839	ENSG00000268081.1	RP11-678G14.2	4.96	9.56e-07	0.000243	0.36	0.22	Pain;	chr19:21333520	chr19:21554640~21569237:-
LUAD	cis	rs801193	0.569	rs11761542	ENSG00000232559.3	GS1-124K5.12	4.96	9.57e-07	0.000243	0.26	0.22	Aortic root size;	chr7:66753209	chr7:66554588~66576923:-
LUAD	cis	rs11159086	0.793	rs10147316	ENSG00000259005.1	RP3-449M8.6	4.96	9.57e-07	0.000243	0.28	0.22	Advanced glycation end-product levels;	chr14:74475688	chr14:74474007~74474864:-
LUAD	cis	rs11159086	0.793	rs8021664	ENSG00000259005.1	RP3-449M8.6	4.96	9.57e-07	0.000243	0.28	0.22	Advanced glycation end-product levels;	chr14:74476592	chr14:74474007~74474864:-
LUAD	cis	rs875971	0.862	rs949930	ENSG00000232559.3	GS1-124K5.12	-4.96	9.57e-07	0.000243	-0.26	-0.22	Aortic root size;	chr7:66301835	chr7:66554588~66576923:-
LUAD	cis	rs867371	0.762	rs1846910	ENSG00000259429.4	UBE2Q2P2	-4.96	9.57e-07	0.000243	-0.2	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82279439	chr15:82355142~82420075:+
LUAD	cis	rs8098244	0.52	rs12955456	ENSG00000264745.1	TTC39C-AS1	4.96	9.57e-07	0.000243	0.23	0.22	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23677624	chr18:23994213~24015339:-
LUAD	cis	rs17684571	0.872	rs6901176	ENSG00000231441.1	RP11-472M19.2	4.96	9.58e-07	0.000243	0.29	0.22	Schizophrenia;	chr6:56696759	chr6:56844002~56864078:+
LUAD	cis	rs3823536	0.5	rs4728144	ENSG00000275106.1	RP11-309L24.10	-4.96	9.58e-07	0.000243	-0.26	-0.22	Sjögren's syndrome;	chr7:129000280	chr7:128952527~128953316:-
LUAD	cis	rs4664293	0.836	rs10190704	ENSG00000226266.5	AC009961.3	-4.96	9.58e-07	0.000243	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159738451	chr2:159670708~159712435:-
LUAD	cis	rs1009115	0.528	rs4725086	ENSG00000272328.1	RP4-594A5.1	-4.96	9.59e-07	0.000243	-0.28	-0.22	Post bronchodilator FEV1;	chr7:8358937	chr7:8303741~8341343:+
LUAD	cis	rs7829975	0.623	rs7010753	ENSG00000173295.6	FAM86B3P	4.96	9.6e-07	0.000244	0.24	0.22	Mood instability;	chr8:8516446	chr8:8228595~8244865:+
LUAD	cis	rs35160687	0.644	rs2113615	ENSG00000273080.1	RP11-301O19.1	-4.96	9.61e-07	0.000244	-0.25	-0.22	Night sleep phenotypes;	chr2:86290479	chr2:86195590~86196049:+
LUAD	cis	rs867371	0.929	rs7173852	ENSG00000259429.4	UBE2Q2P2	-4.96	9.61e-07	0.000244	-0.19	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82169512	chr15:82355142~82420075:+
LUAD	cis	rs875971	0.577	rs34888281	ENSG00000237310.1	GS1-124K5.4	-4.96	9.61e-07	0.000244	-0.24	-0.22	Aortic root size;	chr7:66120784	chr7:66493706~66495474:+
LUAD	cis	rs7017914	0.652	rs2732141	ENSG00000223220.1	Y_RNA	4.96	9.61e-07	0.000244	0.25	0.22	Bone mineral density;	chr8:70998672	chr8:70780914~70781008:-
LUAD	cis	rs10771431	0.738	rs11049697	ENSG00000111788.10	RP11-22B23.1	4.96	9.61e-07	0.000244	0.2	0.22	Breast size;	chr12:9232743	chr12:9277235~9313241:+
LUAD	cis	rs7923609	0.846	rs7098181	ENSG00000232075.1	MRPL35P2	-4.96	9.61e-07	0.000244	-0.27	-0.22	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63267383	chr10:63634317~63634827:-
LUAD	cis	rs875971	0.862	rs6952182	ENSG00000232559.3	GS1-124K5.12	-4.96	9.62e-07	0.000244	-0.26	-0.22	Aortic root size;	chr7:66218330	chr7:66554588~66576923:-
LUAD	cis	rs1707322	1	rs34694458	ENSG00000280836.1	AL355480.1	-4.96	9.63e-07	0.000244	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867024	chr1:45581219~45581321:-
LUAD	cis	rs4664293	0.867	rs7566584	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159728284	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs7566802	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159728480	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs3732289	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159728887	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs3821299	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159729229	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs13415100	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159729716	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs13415025	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159729799	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs13389662	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159729926	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs7562060	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159730618	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs4665110	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159731014	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs34893664	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159732266	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs34795915	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159732420	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs10204867	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159732674	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs35196716	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159733266	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs6432557	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159735699	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs7603274	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159736179	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.836	rs13403371	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159736603	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs13428679	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159736687	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs12623283	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159736959	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs2098976	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159737264	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs2081723	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159737649	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs2081722	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159737697	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs10166694	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159738380	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs2357529	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159738922	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs12692562	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159739199	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs12998291	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159739392	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs2357532	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159740916	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs16844269	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159742569	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.836	rs4664300	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159743927	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs16822556	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159744392	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs16822558	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159744496	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs1834761	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159745278	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs6432558	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159745397	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.836	rs7567818	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159746186	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs12692563	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159746300	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs12620924	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159746452	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.836	rs13397597	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159747084	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.805	rs7593273	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159749349	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.805	rs6432559	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159750649	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs6432560	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159750758	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs3863924	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159758247	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs11681565	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159760362	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.836	rs11687502	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159760464	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.836	rs13401087	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159760957	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs12692564	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159761326	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs1427328	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159762064	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.613	rs9784044	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159765854	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs4664301	ENSG00000226266.5	AC009961.3	-4.96	9.63e-07	0.000244	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159766855	chr2:159670708~159712435:-
LUAD	cis	rs673078	0.615	rs16948204	ENSG00000275409.1	RP11-131L12.4	-4.96	9.64e-07	0.000245	-0.31	-0.22	Glucose homeostasis traits;	chr12:118258252	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.66	rs7303417	ENSG00000275409.1	RP11-131L12.4	-4.96	9.64e-07	0.000245	-0.31	-0.22	Glucose homeostasis traits;	chr12:118258859	chr12:118430147~118430699:+
LUAD	cis	rs11089937	0.626	rs5757056	ENSG00000211638.2	IGLV8-61	-4.96	9.64e-07	0.000245	-0.25	-0.22	Periodontitis (PAL4Q3);	chr22:22142491	chr22:22098700~22099212:+
LUAD	cis	rs71636778	0.509	rs6656815	ENSG00000260063.1	RP5-968P14.2	-4.96	9.64e-07	0.000245	-0.38	-0.22	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26965971	chr1:26692132~26694131:-
LUAD	cis	rs11159086	0.793	rs10136668	ENSG00000259005.1	RP3-449M8.6	4.96	9.65e-07	0.000245	0.29	0.22	Advanced glycation end-product levels;	chr14:74492183	chr14:74474007~74474864:-
LUAD	cis	rs4964805	0.632	rs9706225	ENSG00000257681.1	RP11-341G23.4	4.96	9.65e-07	0.000245	0.24	0.22	Attention deficit hyperactivity disorder;	chr12:103794308	chr12:103746315~103768858:-
LUAD	cis	rs9860428	0.844	rs7641119	ENSG00000242770.2	RP11-180K7.1	4.96	9.65e-07	0.000245	0.24	0.22	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112891978	chr3:112802478~112812819:+
LUAD	cis	rs7829975	0.742	rs12547493	ENSG00000253893.2	FAM85B	4.96	9.65e-07	0.000245	0.28	0.22	Mood instability;	chr8:8804024	chr8:8167819~8226614:-
LUAD	cis	rs853679	0.882	rs4713140	ENSG00000204709.4	LINC01556	4.96	9.66e-07	0.000245	0.37	0.22	Depression;	chr6:28129415	chr6:28943877~28944537:+
LUAD	cis	rs1008375	0.931	rs3775926	ENSG00000249502.1	AC006160.5	-4.96	9.66e-07	0.000245	-0.21	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17598214	chr4:17587467~17614571:-
LUAD	cis	rs1008375	0.9	rs12650220	ENSG00000249502.1	AC006160.5	-4.96	9.66e-07	0.000245	-0.21	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17593742	chr4:17587467~17614571:-
LUAD	cis	rs9487094	0.553	rs13191995	ENSG00000260273.1	RP11-425D10.10	4.96	9.66e-07	0.000245	0.33	0.22	Height;	chr6:109645257	chr6:109382795~109383666:+
LUAD	cis	rs2239547	0.657	rs7620706	ENSG00000242142.1	SERBP1P3	4.96	9.66e-07	0.000245	0.26	0.22	Schizophrenia;	chr3:52857740	chr3:53064283~53065091:-
LUAD	cis	rs1707322	0.929	rs785500	ENSG00000280836.1	AL355480.1	4.96	9.66e-07	0.000245	0.29	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46127372	chr1:45581219~45581321:-
LUAD	cis	rs11242704	0.508	rs2569866	ENSG00000272279.1	RP11-157J24.2	-4.96	9.67e-07	0.000245	-0.27	-0.22	Response to hepatitis C treatment;	chr6:1529817	chr6:1528364~1528911:-
LUAD	cis	rs7829975	0.626	rs332040	ENSG00000253981.4	ALG1L13P	4.96	9.67e-07	0.000245	0.26	0.22	Mood instability;	chr8:8872978	chr8:8236003~8244667:-
LUAD	cis	rs4908768	0.539	rs7547411	ENSG00000270282.1	RP5-1115A15.2	4.96	9.67e-07	0.000245	0.25	0.22	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8578086	chr1:8512653~8513021:+
LUAD	cis	rs453301	0.653	rs7005133	ENSG00000253981.4	ALG1L13P	4.96	9.68e-07	0.000245	0.25	0.22	Joint mobility (Beighton score);	chr8:9043712	chr8:8236003~8244667:-
LUAD	cis	rs7743045	0.504	rs4946385	ENSG00000253194.1	RP11-351A11.1	4.96	9.68e-07	0.000245	0.29	0.22	Mean platelet volume;	chr6:118985247	chr6:118934785~119031541:+
LUAD	cis	rs4664293	0.867	rs10194483	ENSG00000226266.5	AC009961.3	-4.96	9.69e-07	0.000246	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159739883	chr2:159670708~159712435:-
LUAD	cis	rs7811142	0.943	rs10241492	ENSG00000078319.8	PMS2P1	-4.96	9.69e-07	0.000246	-0.26	-0.22	Platelet count;	chr7:100397190	chr7:100320992~100341908:-
LUAD	cis	rs9487094	1	rs12197114	ENSG00000260273.1	RP11-425D10.10	4.96	9.69e-07	0.000246	0.3	0.22	Height;	chr6:109414295	chr6:109382795~109383666:+
LUAD	cis	rs2933343	0.951	rs1055128	ENSG00000231305.3	RP11-723O4.2	4.96	9.69e-07	0.000246	0.26	0.22	IgG glycosylation;	chr3:128872205	chr3:128861313~128871540:-
LUAD	cis	rs72772090	0.71	rs56122780	ENSG00000248734.2	CTD-2260A17.1	-4.96	9.69e-07	0.000246	-0.33	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96724191	chr5:96784777~96785999:+
LUAD	cis	rs72772090	0.71	rs113710451	ENSG00000248734.2	CTD-2260A17.1	-4.96	9.69e-07	0.000246	-0.33	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96724602	chr5:96784777~96785999:+
LUAD	cis	rs72772090	0.71	rs11745122	ENSG00000248734.2	CTD-2260A17.1	-4.96	9.69e-07	0.000246	-0.33	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96725034	chr5:96784777~96785999:+
LUAD	cis	rs9322193	0.923	rs9800686	ENSG00000268592.3	RAET1E-AS1	4.96	9.7e-07	0.000246	0.28	0.22	Lung cancer;	chr6:149634464	chr6:149863494~149919507:+
LUAD	cis	rs12745968	0.653	rs6604008	ENSG00000223787.2	RP4-593M8.1	-4.96	9.7e-07	0.000246	-0.27	-0.22	Bipolar disorder and schizophrenia;	chr1:92711884	chr1:92580476~92580821:-
LUAD	cis	rs7829975	0.66	rs10093926	ENSG00000253893.2	FAM85B	4.96	9.71e-07	0.000246	0.28	0.22	Mood instability;	chr8:8691510	chr8:8167819~8226614:-
LUAD	cis	rs12188164	0.515	rs2672744	ENSG00000225138.6	CTD-2228K2.7	-4.96	9.71e-07	0.000246	-0.2	-0.22	Cystic fibrosis severity;	chr5:410932	chr5:473236~480884:+
LUAD	cis	rs801193	1	rs11773829	ENSG00000237310.1	GS1-124K5.4	-4.96	9.71e-07	0.000246	-0.24	-0.22	Aortic root size;	chr7:66676087	chr7:66493706~66495474:+
LUAD	cis	rs9322193	0.923	rs2342857	ENSG00000268592.3	RAET1E-AS1	4.96	9.72e-07	0.000246	0.27	0.22	Lung cancer;	chr6:149809537	chr6:149863494~149919507:+
LUAD	cis	rs875971	0.522	rs2008188	ENSG00000224316.1	RP11-479O9.2	4.96	9.72e-07	0.000246	0.22	0.22	Aortic root size;	chr7:65964026	chr7:65773620~65802067:+
LUAD	cis	rs2998286	0.54	rs332158	ENSG00000254635.4	WAC-AS1	-4.96	9.72e-07	0.000247	-0.29	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28595433	chr10:28522652~28532743:-
LUAD	cis	rs2998286	0.784	rs2993987	ENSG00000254635.4	WAC-AS1	-4.96	9.72e-07	0.000247	-0.27	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28511241	chr10:28522652~28532743:-
LUAD	cis	rs2998286	0.862	rs2993989	ENSG00000254635.4	WAC-AS1	-4.96	9.72e-07	0.000247	-0.27	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28512986	chr10:28522652~28532743:-
LUAD	cis	rs7017914	0.667	rs13281864	ENSG00000223220.1	Y_RNA	4.96	9.72e-07	0.000247	0.25	0.22	Bone mineral density;	chr8:70730338	chr8:70780914~70781008:-
LUAD	cis	rs2933343	1	rs789232	ENSG00000231305.3	RP11-723O4.2	4.96	9.73e-07	0.000247	0.26	0.22	IgG glycosylation;	chr3:128884237	chr3:128861313~128871540:-
LUAD	cis	rs2933343	1	rs1683811	ENSG00000231305.3	RP11-723O4.2	4.96	9.73e-07	0.000247	0.26	0.22	IgG glycosylation;	chr3:128893270	chr3:128861313~128871540:-
LUAD	cis	rs6570726	0.791	rs6912079	ENSG00000235652.6	RP11-545I5.3	4.96	9.73e-07	0.000247	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145573813	chr6:145799409~145886585:+
LUAD	cis	rs4266144	0.821	rs56237906	ENSG00000244515.1	KRT18P34	-4.96	9.73e-07	0.000247	-0.3	-0.22	Coronary artery disease;	chr3:157134684	chr3:157162663~157163932:-
LUAD	cis	rs453301	0.653	rs11784393	ENSG00000253893.2	FAM85B	-4.96	9.73e-07	0.000247	-0.28	-0.22	Joint mobility (Beighton score);	chr8:9045624	chr8:8167819~8226614:-
LUAD	cis	rs6840360	1	rs6846114	ENSG00000270265.1	RP11-731D1.4	4.96	9.73e-07	0.000247	0.23	0.22	Intelligence (multi-trait analysis);	chr4:151683406	chr4:151333775~151353224:-
LUAD	cis	rs1972460	0.506	rs62012050	ENSG00000276710.3	CSPG4P8	-4.96	9.74e-07	0.000247	-0.22	-0.22	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82459472~82477258:+
LUAD	cis	rs2455601	1	rs2455601	ENSG00000254860.4	TMEM9B-AS1	4.96	9.74e-07	0.000247	0.34	0.22	Schizophrenia;	chr11:8877853	chr11:8964675~8977527:+
LUAD	cis	rs6095360	0.727	rs35989889	ENSG00000222365.1	SNORD12B	-4.96	9.74e-07	0.000247	-0.25	-0.22	Intelligence (multi-trait analysis);	chr20:49100816	chr20:49280319~49280409:+
LUAD	cis	rs7302981	1	rs7302981	ENSG00000272368.2	RP4-605O3.4	-4.96	9.75e-07	0.000247	-0.25	-0.22	Systolic blood pressure;	chr12:50144032	chr12:50112197~50165618:+
LUAD	cis	rs8098244	0.52	rs12955607	ENSG00000264745.1	TTC39C-AS1	-4.96	9.75e-07	0.000247	-0.23	-0.22	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23677671	chr18:23994213~24015339:-
LUAD	cis	rs12908161	1	rs60957376	ENSG00000275120.1	RP11-182J1.17	4.96	9.75e-07	0.000247	0.33	0.22	Schizophrenia;	chr15:84737561	chr15:84599434~84606463:-
LUAD	cis	rs301901	1	rs292182	ENSG00000250155.1	CTD-2353F22.1	-4.96	9.75e-07	0.000247	-0.23	-0.22	Height;	chr5:36954710	chr5:36666214~36725195:-
LUAD	cis	rs6762	0.748	rs28735718	ENSG00000279672.1	CMB9-55F22.1	4.96	9.75e-07	0.000247	0.24	0.22	Mean platelet volume;	chr11:839629	chr11:779617~780755:+
LUAD	cis	rs6762	0.642	rs28692469	ENSG00000279672.1	CMB9-55F22.1	4.96	9.75e-07	0.000247	0.24	0.22	Mean platelet volume;	chr11:839675	chr11:779617~780755:+
LUAD	cis	rs2337406	0.714	rs115401799	ENSG00000223648.3	IGHV3-64	4.96	9.76e-07	0.000247	0.29	0.22	Alzheimer's disease (late onset);	chr14:106813739	chr14:106643132~106658258:-
LUAD	cis	rs916888	0.61	rs199438	ENSG00000261575.2	RP11-259G18.1	4.96	9.76e-07	0.000247	0.3	0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46267037~46268694:+
LUAD	cis	rs1062177	0.826	rs2915822	ENSG00000253921.1	CTB-113P19.3	4.96	9.77e-07	0.000247	0.32	0.22	Preschool internalizing problems;	chr5:151751340	chr5:151753992~151767247:+
LUAD	cis	rs10129255	0.957	rs10141009	ENSG00000211967.3	IGHV3-53	-4.96	9.77e-07	0.000247	-0.17	-0.22	Kawasaki disease;	chr14:106776695	chr14:106592676~106593347:-
LUAD	cis	rs10129255	0.912	rs6576227	ENSG00000211967.3	IGHV3-53	-4.96	9.77e-07	0.000247	-0.17	-0.22	Kawasaki disease;	chr14:106778202	chr14:106592676~106593347:-
LUAD	cis	rs10129255	0.957	rs6576228	ENSG00000211967.3	IGHV3-53	-4.96	9.77e-07	0.000247	-0.17	-0.22	Kawasaki disease;	chr14:106778401	chr14:106592676~106593347:-
LUAD	cis	rs150992	0.505	rs167798	ENSG00000248489.1	CTD-2007H13.3	4.96	9.77e-07	0.000248	0.28	0.22	Body mass index;	chr5:98972150	chr5:98929171~98995013:+
LUAD	cis	rs12745968	0.589	rs7513775	ENSG00000223787.2	RP4-593M8.1	-4.96	9.77e-07	0.000248	-0.26	-0.22	Bipolar disorder and schizophrenia;	chr1:92538940	chr1:92580476~92580821:-
LUAD	cis	rs73198271	0.737	rs535094	ENSG00000253893.2	FAM85B	4.96	9.77e-07	0.000248	0.28	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8776418	chr8:8167819~8226614:-
LUAD	cis	rs5758511	0.68	rs17002902	ENSG00000205702.9	CYP2D7	4.96	9.77e-07	0.000248	0.22	0.22	Birth weight;	chr22:42229503	chr22:42140203~42144577:-
LUAD	cis	rs5758511	0.68	rs5758662	ENSG00000205702.9	CYP2D7	4.96	9.77e-07	0.000248	0.22	0.22	Birth weight;	chr22:42232082	chr22:42140203~42144577:-
LUAD	cis	rs7580658	0.857	rs2896980	ENSG00000236682.1	AC068282.3	-4.96	9.77e-07	0.000248	-0.3	-0.22	Protein C levels;	chr2:127382383	chr2:127389130~127400580:+
LUAD	cis	rs453301	0.597	rs7001187	ENSG00000253893.2	FAM85B	4.96	9.78e-07	0.000248	0.28	0.22	Joint mobility (Beighton score);	chr8:8935272	chr8:8167819~8226614:-
LUAD	cis	rs9322193	0.923	rs12174035	ENSG00000268592.3	RAET1E-AS1	4.96	9.78e-07	0.000248	0.27	0.22	Lung cancer;	chr6:149763311	chr6:149863494~149919507:+
LUAD	cis	rs7017914	0.69	rs6984056	ENSG00000223220.1	Y_RNA	4.96	9.78e-07	0.000248	0.26	0.22	Bone mineral density;	chr8:70858886	chr8:70780914~70781008:-
LUAD	cis	rs801193	0.935	rs3800820	ENSG00000237310.1	GS1-124K5.4	-4.96	9.78e-07	0.000248	-0.24	-0.22	Aortic root size;	chr7:66682191	chr7:66493706~66495474:+
LUAD	cis	rs9322193	0.923	rs10872645	ENSG00000268592.3	RAET1E-AS1	4.96	9.78e-07	0.000248	0.27	0.22	Lung cancer;	chr6:149742840	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.923	rs12211511	ENSG00000268592.3	RAET1E-AS1	4.96	9.78e-07	0.000248	0.27	0.22	Lung cancer;	chr6:149745206	chr6:149863494~149919507:+
LUAD	cis	rs9987353	0.566	rs34389718	ENSG00000253893.2	FAM85B	4.96	9.78e-07	0.000248	0.3	0.22	Recombination measurement;	chr8:9208015	chr8:8167819~8226614:-
LUAD	cis	rs9322193	0.884	rs2064521	ENSG00000268592.3	RAET1E-AS1	-4.96	9.78e-07	0.000248	-0.27	-0.22	Lung cancer;	chr6:149625336	chr6:149863494~149919507:+
LUAD	cis	rs712039	0.652	rs853196	ENSG00000276054.1	RP11-378E13.3	4.96	9.78e-07	0.000248	0.33	0.22	Tuberculosis;	chr17:37488553	chr17:37386886~37387926:+
LUAD	cis	rs7948661	1	rs9332819	ENSG00000278376.1	RP11-158I9.8	-4.96	9.8e-07	0.000248	-0.42	-0.22	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118494548	chr11:118791254~118793137:+
LUAD	cis	rs2832077	0.506	rs10222093	ENSG00000232855.5	AF131217.1	4.96	9.8e-07	0.000248	0.22	0.22	Cognitive test performance;	chr21:28791196	chr21:28439346~28674848:-
LUAD	cis	rs1012068	0.695	rs5998152	ENSG00000236132.1	CTA-440B3.1	-4.96	9.8e-07	0.000248	-0.29	-0.22	Chronic hepatitis C infection;	chr22:31867176	chr22:31816379~31817491:-
LUAD	cis	rs12745968	0.62	rs6603992	ENSG00000223787.2	RP4-593M8.1	-4.96	9.8e-07	0.000248	-0.27	-0.22	Bipolar disorder and schizophrenia;	chr1:92572885	chr1:92580476~92580821:-
LUAD	cis	rs240993	0.812	rs9487626	ENSG00000230177.1	RP5-1112D6.4	-4.96	9.8e-07	0.000248	-0.22	-0.22	Inflammatory skin disease;Psoriasis;	chr6:111395665	chr6:111277932~111278742:+
LUAD	cis	rs240993	0.715	rs9487627	ENSG00000230177.1	RP5-1112D6.4	-4.96	9.8e-07	0.000248	-0.22	-0.22	Inflammatory skin disease;Psoriasis;	chr6:111408846	chr6:111277932~111278742:+
LUAD	cis	rs2439831	0.867	rs2412780	ENSG00000249839.1	AC011330.5	-4.96	9.81e-07	0.000248	-0.39	-0.22	Lung cancer in ever smokers;	chr15:43363596	chr15:43663654~43684339:-
LUAD	cis	rs2439831	0.867	rs2412779	ENSG00000249839.1	AC011330.5	-4.96	9.81e-07	0.000248	-0.39	-0.22	Lung cancer in ever smokers;	chr15:43363729	chr15:43663654~43684339:-
LUAD	cis	rs2439831	0.867	rs2899082	ENSG00000249839.1	AC011330.5	-4.96	9.81e-07	0.000248	-0.39	-0.22	Lung cancer in ever smokers;	chr15:43363845	chr15:43663654~43684339:-
LUAD	cis	rs2439831	0.867	rs4583210	ENSG00000249839.1	AC011330.5	-4.96	9.81e-07	0.000248	-0.39	-0.22	Lung cancer in ever smokers;	chr15:43368727	chr15:43663654~43684339:-
LUAD	cis	rs2439831	0.867	rs28461955	ENSG00000249839.1	AC011330.5	-4.96	9.81e-07	0.000248	-0.39	-0.22	Lung cancer in ever smokers;	chr15:43369261	chr15:43663654~43684339:-
LUAD	cis	rs4845875	0.564	rs2151655	ENSG00000242349.4	NPPA-AS1	4.96	9.81e-07	0.000249	0.24	0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11785461	chr1:11841017~11848079:+
LUAD	cis	rs477895	1	rs2286614	ENSG00000236935.1	AP003774.1	-4.96	9.82e-07	0.000249	-0.29	-0.22	Mean platelet volume;	chr11:64300838	chr11:64325050~64329504:-
LUAD	cis	rs12908161	1	rs11632465	ENSG00000275120.1	RP11-182J1.17	4.96	9.82e-07	0.000249	0.33	0.22	Schizophrenia;	chr15:84738814	chr15:84599434~84606463:-
LUAD	cis	rs4835473	0.897	rs12649594	ENSG00000251600.4	RP11-673E1.1	4.96	9.82e-07	0.000249	0.27	0.22	Immature fraction of reticulocytes;	chr4:143989307	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.864	rs13101482	ENSG00000251600.4	RP11-673E1.1	4.96	9.82e-07	0.000249	0.27	0.22	Immature fraction of reticulocytes;	chr4:143989463	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.864	rs13135472	ENSG00000251600.4	RP11-673E1.1	4.96	9.82e-07	0.000249	0.27	0.22	Immature fraction of reticulocytes;	chr4:143989465	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1849118	ENSG00000251600.4	RP11-673E1.1	4.96	9.82e-07	0.000249	0.27	0.22	Immature fraction of reticulocytes;	chr4:143989822	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.663	rs1511423	ENSG00000251600.4	RP11-673E1.1	4.96	9.82e-07	0.000249	0.27	0.22	Immature fraction of reticulocytes;	chr4:143990136	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.639	rs5029916	ENSG00000251600.4	RP11-673E1.1	4.96	9.82e-07	0.000249	0.27	0.22	Immature fraction of reticulocytes;	chr4:143990684	chr4:143912331~143982454:+
LUAD	cis	rs2032366	0.63	rs7235404	ENSG00000267279.1	RP11-879F14.2	4.96	9.82e-07	0.000249	0.29	0.22	Obesity-related traits;	chr18:61628753	chr18:61585746~61606916:-
LUAD	cis	rs375066	0.901	rs376069	ENSG00000267058.1	RP11-15A1.3	-4.96	9.82e-07	0.000249	-0.25	-0.22	Breast cancer;	chr19:43913143	chr19:43891804~43901805:-
LUAD	cis	rs17507216	0.718	rs7165690	ENSG00000255769.6	GOLGA2P10	-4.96	9.82e-07	0.000249	-0.29	-0.22	Excessive daytime sleepiness;	chr15:82654804	chr15:82472993~82513950:-
LUAD	cis	rs6840360	1	rs3749563	ENSG00000270265.1	RP11-731D1.4	-4.96	9.83e-07	0.000249	-0.22	-0.22	Intelligence (multi-trait analysis);	chr4:151675356	chr4:151333775~151353224:-
LUAD	cis	rs6840360	1	rs7671651	ENSG00000270265.1	RP11-731D1.4	-4.96	9.83e-07	0.000249	-0.22	-0.22	Intelligence (multi-trait analysis);	chr4:151676050	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.967	rs17027798	ENSG00000270265.1	RP11-731D1.4	-4.96	9.83e-07	0.000249	-0.22	-0.22	Intelligence (multi-trait analysis);	chr4:151676388	chr4:151333775~151353224:-
LUAD	cis	rs7829975	0.774	rs11775523	ENSG00000253981.4	ALG1L13P	4.96	9.84e-07	0.000249	0.26	0.22	Mood instability;	chr8:8821666	chr8:8236003~8244667:-
LUAD	cis	rs7829975	0.774	rs1039915	ENSG00000253981.4	ALG1L13P	4.96	9.84e-07	0.000249	0.26	0.22	Mood instability;	chr8:8822104	chr8:8236003~8244667:-
LUAD	cis	rs2998286	0.723	rs332154	ENSG00000254635.4	WAC-AS1	-4.96	9.84e-07	0.000249	-0.29	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28591465	chr10:28522652~28532743:-
LUAD	cis	rs2998286	0.723	rs332156	ENSG00000254635.4	WAC-AS1	-4.96	9.84e-07	0.000249	-0.29	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28593152	chr10:28522652~28532743:-
LUAD	cis	rs7829975	0.564	rs2976855	ENSG00000173295.6	FAM86B3P	4.96	9.85e-07	0.000249	0.23	0.22	Mood instability;	chr8:8444284	chr8:8228595~8244865:+
LUAD	cis	rs6723226	0.521	rs1991626	ENSG00000276334.1	AL133243.1	-4.96	9.85e-07	0.000249	-0.26	-0.22	Intelligence (multi-trait analysis);	chr2:32377382	chr2:32521927~32523547:+
LUAD	cis	rs2439831	0.867	rs8039638	ENSG00000249839.1	AC011330.5	-4.96	9.85e-07	0.000249	-0.39	-0.22	Lung cancer in ever smokers;	chr15:43342207	chr15:43663654~43684339:-
LUAD	cis	rs2439831	0.867	rs28415933	ENSG00000249839.1	AC011330.5	-4.96	9.85e-07	0.000249	-0.39	-0.22	Lung cancer in ever smokers;	chr15:43343602	chr15:43663654~43684339:-
LUAD	cis	rs2439831	0.867	rs12324572	ENSG00000249839.1	AC011330.5	-4.96	9.85e-07	0.000249	-0.39	-0.22	Lung cancer in ever smokers;	chr15:43344002	chr15:43663654~43684339:-
LUAD	cis	rs4908768	0.501	rs11121186	ENSG00000270282.1	RP5-1115A15.2	4.96	9.86e-07	0.00025	0.24	0.22	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8480281	chr1:8512653~8513021:+
LUAD	cis	rs71636778	0.509	rs35969145	ENSG00000260063.1	RP5-968P14.2	-4.96	9.86e-07	0.00025	-0.39	-0.22	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26932901	chr1:26692132~26694131:-
LUAD	cis	rs6142102	0.517	rs8119076	ENSG00000275784.1	RP5-1125A11.6	-4.96	9.86e-07	0.00025	-0.24	-0.22	Skin pigmentation;	chr20:33937909	chr20:33989480~33991818:-
LUAD	cis	rs6142102	0.517	rs6059577	ENSG00000275784.1	RP5-1125A11.6	-4.96	9.86e-07	0.00025	-0.24	-0.22	Skin pigmentation;	chr20:33939880	chr20:33989480~33991818:-
LUAD	cis	rs9990333	0.562	rs73210005	ENSG00000231464.1	AC024937.4	4.96	9.86e-07	0.00025	0.25	0.22	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100441	chr3:195996738~195998233:+
LUAD	cis	rs9990333	0.562	rs58079878	ENSG00000231464.1	AC024937.4	4.96	9.86e-07	0.00025	0.25	0.22	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100620	chr3:195996738~195998233:+
LUAD	cis	rs9860428	0.844	rs9819621	ENSG00000242770.2	RP11-180K7.1	4.96	9.87e-07	0.00025	0.24	0.22	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112904219	chr3:112802478~112812819:+
LUAD	cis	rs2380205	0.538	rs1976655	ENSG00000232807.2	RP11-536K7.3	4.96	9.87e-07	0.00025	0.25	0.22	Breast cancer;	chr10:5880766	chr10:5934270~5945900:-
LUAD	cis	rs1816752	0.905	rs7995909	ENSG00000273628.1	RP11-756A22.7	4.96	9.87e-07	0.00025	0.25	0.22	Obesity-related traits;	chr13:24439159	chr13:24933006~24936796:+
LUAD	cis	rs1816752	0.905	rs6490927	ENSG00000273628.1	RP11-756A22.7	4.96	9.87e-07	0.00025	0.25	0.22	Obesity-related traits;	chr13:24439802	chr13:24933006~24936796:+
LUAD	cis	rs1816752	0.905	rs6490928	ENSG00000273628.1	RP11-756A22.7	4.96	9.87e-07	0.00025	0.25	0.22	Obesity-related traits;	chr13:24439921	chr13:24933006~24936796:+
LUAD	cis	rs1816752	0.905	rs6490929	ENSG00000273628.1	RP11-756A22.7	4.96	9.87e-07	0.00025	0.25	0.22	Obesity-related traits;	chr13:24440114	chr13:24933006~24936796:+
LUAD	cis	rs1816752	0.87	rs7998797	ENSG00000273628.1	RP11-756A22.7	4.96	9.87e-07	0.00025	0.25	0.22	Obesity-related traits;	chr13:24440850	chr13:24933006~24936796:+
LUAD	cis	rs1816752	0.87	rs7981337	ENSG00000273628.1	RP11-756A22.7	4.96	9.87e-07	0.00025	0.25	0.22	Obesity-related traits;	chr13:24440915	chr13:24933006~24936796:+
LUAD	cis	rs7017914	0.667	rs3098862	ENSG00000223220.1	Y_RNA	4.96	9.87e-07	0.00025	0.25	0.22	Bone mineral density;	chr8:70965706	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs2639914	ENSG00000223220.1	Y_RNA	4.96	9.87e-07	0.00025	0.25	0.22	Bone mineral density;	chr8:70967418	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.628	rs2732139	ENSG00000223220.1	Y_RNA	4.96	9.87e-07	0.00025	0.25	0.22	Bone mineral density;	chr8:70967802	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs2639913	ENSG00000223220.1	Y_RNA	4.96	9.87e-07	0.00025	0.25	0.22	Bone mineral density;	chr8:70967929	chr8:70780914~70781008:-
LUAD	cis	rs4835473	0.897	rs7657088	ENSG00000251600.4	RP11-673E1.1	-4.96	9.87e-07	0.00025	-0.27	-0.22	Immature fraction of reticulocytes;	chr4:143701877	chr4:143912331~143982454:+
LUAD	cis	rs507080	0.922	rs4589335	ENSG00000278376.1	RP11-158I9.8	-4.96	9.88e-07	0.00025	-0.24	-0.22	Serum metabolite levels;	chr11:118668431	chr11:118791254~118793137:+
LUAD	cis	rs35160687	0.623	rs2276625	ENSG00000273080.1	RP11-301O19.1	4.96	9.88e-07	0.00025	0.24	0.22	Night sleep phenotypes;	chr2:86254712	chr2:86195590~86196049:+
LUAD	cis	rs875971	0.83	rs6976714	ENSG00000232559.3	GS1-124K5.12	4.96	9.88e-07	0.00025	0.26	0.22	Aortic root size;	chr7:66426474	chr7:66554588~66576923:-
LUAD	cis	rs1816752	0.819	rs7316961	ENSG00000273628.1	RP11-756A22.7	4.96	9.89e-07	0.00025	0.25	0.22	Obesity-related traits;	chr13:24411039	chr13:24933006~24936796:+
LUAD	cis	rs9287719	0.556	rs10168351	ENSG00000243819.4	RN7SL832P	4.96	9.89e-07	0.00025	0.23	0.22	Prostate cancer;	chr2:10596684	chr2:10690344~10692099:+
LUAD	cis	rs11671005	0.735	rs3826684	ENSG00000268912.1	CTD-2619J13.17	-4.96	9.89e-07	0.00025	-0.3	-0.22	Mean platelet volume;	chr19:58407338	chr19:58428632~58431148:-
LUAD	cis	rs11671005	0.735	rs3826683	ENSG00000268912.1	CTD-2619J13.17	-4.96	9.89e-07	0.00025	-0.3	-0.22	Mean platelet volume;	chr19:58407366	chr19:58428632~58431148:-
LUAD	cis	rs11671005	0.735	rs3826681	ENSG00000268912.1	CTD-2619J13.17	-4.96	9.89e-07	0.00025	-0.3	-0.22	Mean platelet volume;	chr19:58407397	chr19:58428632~58431148:-
LUAD	cis	rs35343117	1	rs35343117	ENSG00000259295.5	CSPG4P12	4.96	9.89e-07	0.00025	0.28	0.22	Psoriasis;	chr15:85535884	chr15:85191438~85213905:+
LUAD	cis	rs1008375	1	rs2058339	ENSG00000249502.1	AC006160.5	-4.96	9.9e-07	0.00025	-0.21	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17676833	chr4:17587467~17614571:-
LUAD	cis	rs2239547	0.603	rs7644973	ENSG00000242142.1	SERBP1P3	4.96	9.91e-07	0.000251	0.26	0.22	Schizophrenia;	chr3:53048921	chr3:53064283~53065091:-
LUAD	cis	rs2239547	0.603	rs71301807	ENSG00000242142.1	SERBP1P3	4.96	9.91e-07	0.000251	0.26	0.22	Schizophrenia;	chr3:53051459	chr3:53064283~53065091:-
LUAD	cis	rs7829975	0.714	rs7823757	ENSG00000253893.2	FAM85B	-4.96	9.91e-07	0.000251	-0.27	-0.22	Mood instability;	chr8:8812667	chr8:8167819~8226614:-
LUAD	cis	rs2243480	1	rs937108	ENSG00000226002.1	RP11-460N20.5	-4.96	9.92e-07	0.000251	-0.36	-0.22	Diabetic kidney disease;	chr7:65963465	chr7:65084103~65100232:+
LUAD	cis	rs1320333	0.772	rs2867136	ENSG00000233296.1	AC092159.2	-4.96	9.93e-07	0.000251	-0.38	-0.22	Obesity-related traits;	chr2:701455	chr2:677186~697371:+
LUAD	cis	rs875971	0.642	rs35526611	ENSG00000237310.1	GS1-124K5.4	-4.96	9.95e-07	0.000251	-0.24	-0.22	Aortic root size;	chr7:66629021	chr7:66493706~66495474:+
LUAD	cis	rs1876905	0.68	rs395564	ENSG00000272356.1	RP5-1112D6.8	-4.96	9.95e-07	0.000251	-0.24	-0.22	Mean corpuscular hemoglobin;	chr6:111176176	chr6:111309203~111313517:+
LUAD	cis	rs7302981	1	rs7308356	ENSG00000272368.2	RP4-605O3.4	-4.96	9.95e-07	0.000252	-0.26	-0.22	Systolic blood pressure;	chr12:50145828	chr12:50112197~50165618:+
LUAD	cis	rs7302981	0.934	rs7301649	ENSG00000272368.2	RP4-605O3.4	-4.96	9.95e-07	0.000252	-0.26	-0.22	Systolic blood pressure;	chr12:50147087	chr12:50112197~50165618:+
LUAD	cis	rs7302981	0.934	rs7294548	ENSG00000272368.2	RP4-605O3.4	-4.96	9.95e-07	0.000252	-0.26	-0.22	Systolic blood pressure;	chr12:50149418	chr12:50112197~50165618:+
LUAD	cis	rs6604026	0.589	rs12738833	ENSG00000223787.2	RP4-593M8.1	4.96	9.95e-07	0.000252	0.3	0.22	Multiple sclerosis;	chr1:92653561	chr1:92580476~92580821:-
LUAD	cis	rs6604026	0.589	rs11578098	ENSG00000223787.2	RP4-593M8.1	4.96	9.95e-07	0.000252	0.3	0.22	Multiple sclerosis;	chr1:92653853	chr1:92580476~92580821:-
LUAD	cis	rs6604026	0.589	rs11800771	ENSG00000223787.2	RP4-593M8.1	4.96	9.95e-07	0.000252	0.3	0.22	Multiple sclerosis;	chr1:92661552	chr1:92580476~92580821:-
LUAD	cis	rs6604026	0.555	rs68160001	ENSG00000223787.2	RP4-593M8.1	4.96	9.95e-07	0.000252	0.3	0.22	Multiple sclerosis;	chr1:92668018	chr1:92580476~92580821:-
LUAD	cis	rs6142102	0.625	rs4911137	ENSG00000275784.1	RP5-1125A11.6	-4.96	9.96e-07	0.000252	-0.24	-0.22	Skin pigmentation;	chr20:33947657	chr20:33989480~33991818:-
LUAD	cis	rs301901	1	rs300061	ENSG00000250155.1	CTD-2353F22.1	-4.96	9.97e-07	0.000252	-0.23	-0.22	Height;	chr5:37022673	chr5:36666214~36725195:-
LUAD	cis	rs7829975	0.593	rs2921077	ENSG00000173295.6	FAM86B3P	4.96	9.98e-07	0.000252	0.23	0.22	Mood instability;	chr8:8446992	chr8:8228595~8244865:+
LUAD	cis	rs2337406	0.714	rs2337463	ENSG00000211974.3	IGHV2-70	-4.96	9.98e-07	0.000252	-0.29	-0.22	Alzheimer's disease (late onset);	chr14:106816066	chr14:106723574~106724093:-
LUAD	cis	rs9322193	0.926	rs3805751	ENSG00000268592.3	RAET1E-AS1	4.96	9.98e-07	0.000252	0.27	0.22	Lung cancer;	chr6:149791193	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.962	rs10872656	ENSG00000268592.3	RAET1E-AS1	4.96	9.98e-07	0.000252	0.27	0.22	Lung cancer;	chr6:149799444	chr6:149863494~149919507:+
LUAD	cis	rs4908768	0.501	rs6577491	ENSG00000270282.1	RP5-1115A15.2	4.96	9.99e-07	0.000252	0.24	0.22	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8514913	chr1:8512653~8513021:+
LUAD	cis	rs8098244	0.638	rs9958787	ENSG00000264745.1	TTC39C-AS1	4.96	9.99e-07	0.000252	0.22	0.22	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23870461	chr18:23994213~24015339:-
LUAD	cis	rs5758511	0.68	rs5758699	ENSG00000205702.9	CYP2D7	4.96	9.99e-07	0.000252	0.22	0.22	Birth weight;	chr22:42292028	chr22:42140203~42144577:-
LUAD	cis	rs4664293	0.801	rs7589771	ENSG00000230783.1	AC009961.2	-4.96	9.99e-07	0.000252	-0.27	-0.22	Monocyte percentage of white cells;	chr2:159727621	chr2:159689217~159690291:-
LUAD	cis	rs13256369	0.755	rs11776987	ENSG00000253893.2	FAM85B	-4.96	9.99e-07	0.000253	-0.31	-0.22	Obesity-related traits;	chr8:8701891	chr8:8167819~8226614:-
LUAD	cis	rs7017914	0.652	rs2639924	ENSG00000223220.1	Y_RNA	4.96	1e-06	0.000253	0.24	0.22	Bone mineral density;	chr8:70993306	chr8:70780914~70781008:-
LUAD	cis	rs12928939	0.815	rs12446005	ENSG00000260886.1	TAT-AS1	4.96	1e-06	0.000253	0.27	0.22	Post bronchodilator FEV1;	chr16:71621132	chr16:71565789~71578187:+
LUAD	cis	rs7714584	1	rs12656538	ENSG00000197083.10	ZNF300P1	4.96	1e-06	0.000253	0.45	0.22	Crohn's disease;	chr5:150871818	chr5:150930645~150946289:-
LUAD	cis	rs2295359	0.892	rs17375018	ENSG00000275678.1	RP4-547N15.3	4.96	1e-06	0.000253	0.23	0.22	Psoriasis;	chr1:67189464	chr1:67121605~67123956:-
LUAD	cis	rs4835473	0.932	rs6852502	ENSG00000251600.4	RP11-673E1.1	4.96	1e-06	0.000253	0.27	0.22	Immature fraction of reticulocytes;	chr4:143987174	chr4:143912331~143982454:+
LUAD	cis	rs193541	0.564	rs62377434	ENSG00000263432.2	RN7SL689P	-4.96	1e-06	0.000253	-0.3	-0.22	Glucose homeostasis traits;	chr5:123004874	chr5:123022487~123022783:-
LUAD	cis	rs875971	0.862	rs6964437	ENSG00000232559.3	GS1-124K5.12	-4.96	1e-06	0.000253	-0.26	-0.22	Aortic root size;	chr7:66221457	chr7:66554588~66576923:-
LUAD	cis	rs4568518	0.53	rs10273476	ENSG00000279048.1	RP11-511H23.2	4.96	1e-06	0.000253	0.19	0.22	Measles;	chr7:17958795	chr7:17940503~17942922:+
LUAD	cis	rs6687821	0.599	rs263496	ENSG00000267734.1	RP4-604K5.3	4.96	1e-06	0.000253	0.28	0.22	Yeast infection;	chr1:86750078	chr1:86932199~86934891:-
LUAD	cis	rs2243480	1	rs160634	ENSG00000232559.3	GS1-124K5.12	-4.95	1e-06	0.000254	-0.36	-0.22	Diabetic kidney disease;	chr7:66063677	chr7:66554588~66576923:-
LUAD	cis	rs10246939	0.544	rs6955562	ENSG00000270923.1	TAS2R6P	-4.95	1e-06	0.000254	-0.25	-0.22	Bitter taste perception;	chr7:141886641	chr7:141787815~141788640:+
LUAD	cis	rs1707322	1	rs7532204	ENSG00000280836.1	AL355480.1	4.95	1e-06	0.000254	0.28	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019403	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.835	rs946525	ENSG00000280836.1	AL355480.1	4.95	1e-06	0.000254	0.28	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021605	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs946524	ENSG00000280836.1	AL355480.1	4.95	1e-06	0.000254	0.28	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021888	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs4660336	ENSG00000280836.1	AL355480.1	4.95	1e-06	0.000254	0.28	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46022304	chr1:45581219~45581321:-
LUAD	cis	rs12681366	0.801	rs12682524	ENSG00000253704.1	RP11-267M23.4	4.95	1e-06	0.000254	0.27	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94472071	chr8:94553722~94569745:+
LUAD	cis	rs6723226	0.593	rs176401	ENSG00000276334.1	AL133243.1	-4.95	1.01e-06	0.000254	-0.25	-0.22	Intelligence (multi-trait analysis);	chr2:32411443	chr2:32521927~32523547:+
LUAD	cis	rs2286503	0.78	rs2240727	ENSG00000221740.1	SNORD93	4.95	1.01e-06	0.000254	0.25	0.22	Fibrinogen;	chr7:22812893	chr7:22856613~22856686:+
LUAD	cis	rs10761482	0.544	rs1934760	ENSG00000254271.1	RP11-131N11.4	4.95	1.01e-06	0.000254	0.25	0.22	Schizophrenia;	chr10:60496987	chr10:60734342~60741828:+
LUAD	cis	rs7727544	0.654	rs4705849	ENSG00000233006.5	AC034220.3	4.95	1.01e-06	0.000254	0.19	0.22	Blood metabolite levels;	chr5:132223506	chr5:132311285~132369916:-
LUAD	cis	rs1816752	0.819	rs4769349	ENSG00000273628.1	RP11-756A22.7	-4.95	1.01e-06	0.000254	-0.25	-0.22	Obesity-related traits;	chr13:24408694	chr13:24933006~24936796:+
LUAD	cis	rs7727544	0.716	rs72793278	ENSG00000233006.5	AC034220.3	4.95	1.01e-06	0.000254	0.19	0.22	Blood metabolite levels;	chr5:132225679	chr5:132311285~132369916:-
LUAD	cis	rs74233809	0.901	rs11191425	ENSG00000213277.3	MARCKSL1P1	4.95	1.01e-06	0.000254	0.36	0.22	Birth weight;	chr10:102866213	chr10:103175554~103176094:+
LUAD	cis	rs801193	0.844	rs2244022	ENSG00000237310.1	GS1-124K5.4	4.95	1.01e-06	0.000254	0.23	0.22	Aortic root size;	chr7:66737443	chr7:66493706~66495474:+
LUAD	cis	rs1707322	1	rs11211204	ENSG00000280836.1	AL355480.1	-4.95	1.01e-06	0.000255	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45852192	chr1:45581219~45581321:-
LUAD	cis	rs7618915	1	rs3852064	ENSG00000243224.1	RP5-1157M23.2	-4.95	1.01e-06	0.000255	-0.24	-0.22	Bipolar disorder;	chr3:52315396	chr3:52239258~52241097:+
LUAD	cis	rs720475	0.732	rs73159066	ENSG00000170356.8	OR2A20P	4.95	1.01e-06	0.000255	0.3	0.22	Breast cancer;	chr7:144426495	chr7:144250045~144252957:-
LUAD	cis	rs7617773	1	rs9832957	ENSG00000228638.1	FCF1P2	4.95	1.01e-06	0.000255	0.25	0.22	Coronary artery disease;	chr3:48143776	chr3:48290793~48291375:-
LUAD	cis	rs17711722	0.74	rs7809991	ENSG00000224316.1	RP11-479O9.2	4.95	1.01e-06	0.000255	0.22	0.22	Calcium levels;	chr7:65941231	chr7:65773620~65802067:+
LUAD	cis	rs2998286	0.723	rs332168	ENSG00000254635.4	WAC-AS1	-4.95	1.01e-06	0.000255	-0.28	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28607488	chr10:28522652~28532743:-
LUAD	cis	rs875971	0.862	rs6947339	ENSG00000232559.3	GS1-124K5.12	4.95	1.01e-06	0.000255	0.26	0.22	Aortic root size;	chr7:66423483	chr7:66554588~66576923:-
LUAD	cis	rs1707322	0.717	rs12023439	ENSG00000280836.1	AL355480.1	-4.95	1.01e-06	0.000255	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638964	chr1:45581219~45581321:-
LUAD	cis	rs8077577	0.747	rs62072540	ENSG00000273018.4	CTD-2303H24.2	-4.95	1.01e-06	0.000255	-0.31	-0.22	Obesity-related traits;	chr17:18321914	chr17:18511221~18551705:-
LUAD	cis	rs11157436	0.914	rs7142794	ENSG00000211813.2	TRAV34	4.95	1.01e-06	0.000255	0.28	0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22238175	chr14:22207522~22208129:+
LUAD	cis	rs6604026	0.555	rs1333743	ENSG00000223787.2	RP4-593M8.1	4.95	1.01e-06	0.000255	0.3	0.22	Multiple sclerosis;	chr1:92600617	chr1:92580476~92580821:-
LUAD	cis	rs6604026	0.555	rs11808092	ENSG00000223787.2	RP4-593M8.1	4.95	1.01e-06	0.000255	0.3	0.22	Multiple sclerosis;	chr1:92607671	chr1:92580476~92580821:-
LUAD	cis	rs10246939	0.579	rs13232651	ENSG00000270923.1	TAS2R6P	-4.95	1.01e-06	0.000255	-0.24	-0.22	Bitter taste perception;	chr7:141862624	chr7:141787815~141788640:+
LUAD	cis	rs6723226	0.75	rs10182170	ENSG00000276334.1	AL133243.1	4.95	1.01e-06	0.000255	0.25	0.22	Intelligence (multi-trait analysis);	chr2:32479118	chr2:32521927~32523547:+
LUAD	cis	rs1008375	0.898	rs2079892	ENSG00000249502.1	AC006160.5	-4.95	1.01e-06	0.000255	-0.22	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17575540	chr4:17587467~17614571:-
LUAD	cis	rs1008375	0.931	rs10019482	ENSG00000249502.1	AC006160.5	-4.95	1.01e-06	0.000255	-0.22	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17576456	chr4:17587467~17614571:-
LUAD	cis	rs801193	1	rs2003301	ENSG00000237310.1	GS1-124K5.4	-4.95	1.01e-06	0.000255	-0.24	-0.22	Aortic root size;	chr7:66682669	chr7:66493706~66495474:+
LUAD	cis	rs9322193	0.962	rs4869730	ENSG00000268592.3	RAET1E-AS1	4.95	1.01e-06	0.000255	0.27	0.22	Lung cancer;	chr6:149808187	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.923	rs2151913	ENSG00000268592.3	RAET1E-AS1	4.95	1.01e-06	0.000255	0.27	0.22	Lung cancer;	chr6:149809506	chr6:149863494~149919507:+
LUAD	cis	rs14027	0.883	rs16893027	ENSG00000279347.1	RP11-85I17.2	-4.95	1.01e-06	0.000255	-0.19	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119701534	chr8:119838736~119840385:-
LUAD	cis	rs1062177	0.774	rs2964574	ENSG00000253921.1	CTB-113P19.3	-4.95	1.01e-06	0.000255	-0.32	-0.22	Preschool internalizing problems;	chr5:151776150	chr5:151753992~151767247:+
LUAD	cis	rs6095360	0.727	rs13044004	ENSG00000222365.1	SNORD12B	-4.95	1.01e-06	0.000255	-0.25	-0.22	Intelligence (multi-trait analysis);	chr20:49101834	chr20:49280319~49280409:+
LUAD	cis	rs11673344	0.764	rs547483	ENSG00000226686.6	LINC01535	-4.95	1.01e-06	0.000256	-0.28	-0.22	Obesity-related traits;	chr19:36950463	chr19:37251912~37265535:+
LUAD	cis	rs801193	1	rs7785213	ENSG00000237310.1	GS1-124K5.4	-4.95	1.01e-06	0.000256	-0.24	-0.22	Aortic root size;	chr7:66673991	chr7:66493706~66495474:+
LUAD	cis	rs9322193	0.851	rs9322194	ENSG00000268592.3	RAET1E-AS1	4.95	1.01e-06	0.000256	0.27	0.22	Lung cancer;	chr6:149599113	chr6:149863494~149919507:+
LUAD	cis	rs10129255	0.957	rs28887506	ENSG00000211974.3	IGHV2-70	4.95	1.01e-06	0.000256	0.24	0.22	Kawasaki disease;	chr14:106785589	chr14:106723574~106724093:-
LUAD	cis	rs2072438	0.503	rs1323474	ENSG00000226752.6	PSMD5-AS1	-4.95	1.01e-06	0.000256	-0.23	-0.22	Rheumatoid arthritis;	chr9:121090581	chr9:120824828~120854385:+
LUAD	cis	rs875971	0.638	rs35986979	ENSG00000237310.1	GS1-124K5.4	-4.95	1.02e-06	0.000256	-0.24	-0.22	Aortic root size;	chr7:66624003	chr7:66493706~66495474:+
LUAD	cis	rs7208859	0.573	rs8078182	ENSG00000280069.1	CTD-2349P21.3	-4.95	1.02e-06	0.000256	-0.26	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822646	chr17:30738182~30740275:+
LUAD	cis	rs8077577	0.747	rs8081155	ENSG00000273018.4	CTD-2303H24.2	-4.95	1.02e-06	0.000256	-0.31	-0.22	Obesity-related traits;	chr17:18288634	chr17:18511221~18551705:-
LUAD	cis	rs948562	0.696	rs11229532	ENSG00000280010.1	AP001350.4	4.95	1.02e-06	0.000256	0.4	0.22	Lymphoma;	chr11:58574877	chr11:58627435~58628528:+
LUAD	cis	rs2617170	0.885	rs2617150	ENSG00000245648.1	RP11-277P12.20	4.95	1.02e-06	0.000256	0.28	0.22	Behcet's disease;	chr12:10376435	chr12:10363769~10398506:+
LUAD	cis	rs7044106	0.708	rs1324472	ENSG00000238181.2	AHCYP2	-4.95	1.02e-06	0.000256	-0.28	-0.22	Hip circumference adjusted for BMI;	chr9:120612832	chr9:120720673~120721972:+
LUAD	cis	rs9322193	0.923	rs57938011	ENSG00000268592.3	RAET1E-AS1	4.95	1.02e-06	0.000256	0.28	0.22	Lung cancer;	chr6:149642969	chr6:149863494~149919507:+
LUAD	cis	rs8127691	0.967	rs2838521	ENSG00000237604.1	AP001056.1	-4.95	1.02e-06	0.000257	-0.25	-0.22	Inflammatory bowel disease;	chr21:44196034	chr21:44175489~44176453:+
LUAD	cis	rs783540	0.5	rs7178459	ENSG00000278603.1	RP13-608F4.5	4.95	1.02e-06	0.000257	0.29	0.22	Schizophrenia;	chr15:82729632	chr15:82472203~82472426:+
LUAD	cis	rs7772486	0.72	rs991507	ENSG00000235652.6	RP11-545I5.3	-4.95	1.02e-06	0.000257	-0.22	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145702473	chr6:145799409~145886585:+
LUAD	cis	rs4835473	0.9	rs3856989	ENSG00000251600.4	RP11-673E1.1	4.95	1.02e-06	0.000257	0.28	0.22	Immature fraction of reticulocytes;	chr4:143921752	chr4:143912331~143982454:+
LUAD	cis	rs5758659	1	rs134900	ENSG00000273366.1	CTA-989H11.1	-4.95	1.02e-06	0.000257	-0.25	-0.22	Cognitive function;	chr22:42287337	chr22:42278188~42278846:+
LUAD	cis	rs2153535	0.562	rs10458225	ENSG00000230939.1	RP11-314C16.1	4.95	1.02e-06	0.000257	0.26	0.22	Motion sickness;	chr6:8385771	chr6:8784178~8785445:+
LUAD	cis	rs1816752	0.633	rs8002387	ENSG00000273628.1	RP11-756A22.7	4.95	1.02e-06	0.000257	0.25	0.22	Obesity-related traits;	chr13:24416306	chr13:24933006~24936796:+
LUAD	cis	rs193541	0.632	rs154512	ENSG00000263432.2	RN7SL689P	4.95	1.02e-06	0.000257	0.29	0.22	Glucose homeostasis traits;	chr5:122859345	chr5:123022487~123022783:-
LUAD	cis	rs71520386	0.632	rs10253651	ENSG00000228649.7	AC005682.5	-4.95	1.02e-06	0.000257	-0.3	-0.22	Fibrinogen levels;	chr7:22830564	chr7:22854178~22861579:+
LUAD	cis	rs10129255	0.833	rs61997797	ENSG00000211967.3	IGHV3-53	-4.95	1.02e-06	0.000257	-0.17	-0.22	Kawasaki disease;	chr14:106815190	chr14:106592676~106593347:-
LUAD	cis	rs1150668	0.799	rs2142730	ENSG00000219392.1	RP1-265C24.5	-4.95	1.02e-06	0.000257	-0.27	-0.22	Pubertal anthropometrics;	chr6:28298372	chr6:28115628~28116551:+
LUAD	cis	rs113835537	0.935	rs79106199	ENSG00000255517.5	CTD-3074O7.5	-4.95	1.02e-06	0.000257	-0.32	-0.22	Airway imaging phenotypes;	chr11:66653047	chr11:66473490~66480233:-
LUAD	cis	rs9813712	0.571	rs9855426	ENSG00000249846.5	RP11-77P16.4	4.95	1.02e-06	0.000257	0.26	0.22	Response to amphetamines;	chr3:130214475	chr3:130112550~130120579:+
LUAD	cis	rs4948102	0.642	rs6593297	ENSG00000273720.1	RP11-613E4.4	4.95	1.02e-06	0.000258	0.27	0.22	Plasma homocysteine levels (post-methionine load test);	chr7:56054365	chr7:55743073~55743457:+
LUAD	cis	rs997295	0.556	rs10468041	ENSG00000270964.1	RP11-502I4.3	-4.95	1.02e-06	0.000258	-0.23	-0.22	Motion sickness;	chr15:67480865	chr15:67541072~67542604:-
LUAD	cis	rs8098244	0.617	rs12969388	ENSG00000264745.1	TTC39C-AS1	4.95	1.02e-06	0.000258	0.23	0.22	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23907089	chr18:23994213~24015339:-
LUAD	cis	rs1075265	0.508	rs12621225	ENSG00000272156.1	RP11-477N3.1	-4.95	1.02e-06	0.000258	-0.27	-0.22	Chronotype;Morning vs. evening chronotype;	chr2:53710040	chr2:54082554~54085066:+
LUAD	cis	rs2742234	0.59	rs2505553	ENSG00000273008.1	RP11-351D16.3	-4.95	1.02e-06	0.000258	-0.26	-0.22	Hirschsprung disease;	chr10:43185803	chr10:43136824~43138334:-
LUAD	cis	rs2742234	0.59	rs2115817	ENSG00000273008.1	RP11-351D16.3	-4.95	1.02e-06	0.000258	-0.26	-0.22	Hirschsprung disease;	chr10:43191104	chr10:43136824~43138334:-
LUAD	cis	rs2742234	0.59	rs1254965	ENSG00000273008.1	RP11-351D16.3	4.95	1.02e-06	0.000258	0.26	0.22	Hirschsprung disease;	chr10:43194405	chr10:43136824~43138334:-
LUAD	cis	rs13256369	0.851	rs13271698	ENSG00000253893.2	FAM85B	-4.95	1.02e-06	0.000258	-0.31	-0.22	Obesity-related traits;	chr8:8710029	chr8:8167819~8226614:-
LUAD	cis	rs13256369	1	rs12550458	ENSG00000253893.2	FAM85B	-4.95	1.02e-06	0.000258	-0.31	-0.22	Obesity-related traits;	chr8:8710322	chr8:8167819~8226614:-
LUAD	cis	rs13256369	1	rs12545771	ENSG00000253893.2	FAM85B	-4.95	1.02e-06	0.000258	-0.31	-0.22	Obesity-related traits;	chr8:8710467	chr8:8167819~8226614:-
LUAD	cis	rs9487094	0.71	rs10499052	ENSG00000260273.1	RP11-425D10.10	4.95	1.02e-06	0.000258	0.33	0.22	Height;	chr6:109564272	chr6:109382795~109383666:+
LUAD	cis	rs11159086	0.793	rs9285594	ENSG00000259005.1	RP3-449M8.6	4.95	1.02e-06	0.000258	0.28	0.22	Advanced glycation end-product levels;	chr14:74489253	chr14:74474007~74474864:-
LUAD	cis	rs11159086	0.793	rs4903229	ENSG00000259005.1	RP3-449M8.6	4.95	1.02e-06	0.000258	0.28	0.22	Advanced glycation end-product levels;	chr14:74489865	chr14:74474007~74474864:-
LUAD	cis	rs11159086	0.793	rs8016972	ENSG00000259005.1	RP3-449M8.6	4.95	1.02e-06	0.000258	0.28	0.22	Advanced glycation end-product levels;	chr14:74491833	chr14:74474007~74474864:-
LUAD	cis	rs4835473	0.712	rs12509607	ENSG00000251600.4	RP11-673E1.1	-4.95	1.02e-06	0.000258	-0.27	-0.22	Immature fraction of reticulocytes;	chr4:143736894	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.712	rs12498218	ENSG00000251600.4	RP11-673E1.1	-4.95	1.02e-06	0.000258	-0.27	-0.22	Immature fraction of reticulocytes;	chr4:143736900	chr4:143912331~143982454:+
LUAD	cis	rs2380205	0.517	rs7082434	ENSG00000232807.2	RP11-536K7.3	4.95	1.02e-06	0.000258	0.24	0.22	Breast cancer;	chr10:5906675	chr10:5934270~5945900:-
LUAD	cis	rs453301	0.686	rs6601280	ENSG00000253981.4	ALG1L13P	4.95	1.03e-06	0.000258	0.27	0.22	Joint mobility (Beighton score);	chr8:9051726	chr8:8236003~8244667:-
LUAD	cis	rs17772222	0.917	rs58550317	ENSG00000258983.2	RP11-507K2.2	4.95	1.03e-06	0.000259	0.27	0.22	Coronary artery calcification;	chr14:88775243	chr14:88499334~88515502:+
LUAD	cis	rs755249	0.51	rs599892	ENSG00000228060.1	RP11-69E11.8	-4.95	1.03e-06	0.000259	-0.2	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39457212	chr1:39565160~39573203:+
LUAD	cis	rs113835537	0.935	rs117131621	ENSG00000255517.5	CTD-3074O7.5	-4.95	1.03e-06	0.000259	-0.32	-0.22	Airway imaging phenotypes;	chr11:66654863	chr11:66473490~66480233:-
LUAD	cis	rs113835537	0.935	rs57043177	ENSG00000255517.5	CTD-3074O7.5	-4.95	1.03e-06	0.000259	-0.32	-0.22	Airway imaging phenotypes;	chr11:66655676	chr11:66473490~66480233:-
LUAD	cis	rs17301013	0.829	rs2006197	ENSG00000227373.4	RP11-160H22.5	4.95	1.03e-06	0.000259	0.27	0.22	Systemic lupus erythematosus;	chr1:174432825	chr1:174115300~174160004:-
LUAD	cis	rs6728642	0.803	rs11891457	ENSG00000230606.9	AC159540.1	4.95	1.03e-06	0.000259	0.33	0.22	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96966712	chr2:97416165~97433527:-
LUAD	cis	rs6728642	0.803	rs11891458	ENSG00000230606.9	AC159540.1	4.95	1.03e-06	0.000259	0.33	0.22	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96966713	chr2:97416165~97433527:-
LUAD	cis	rs7772486	0.754	rs702304	ENSG00000235652.6	RP11-545I5.3	-4.95	1.03e-06	0.000259	-0.22	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145669661	chr6:145799409~145886585:+
LUAD	cis	rs9322193	0.884	rs7743823	ENSG00000268592.3	RAET1E-AS1	4.95	1.03e-06	0.000259	0.28	0.22	Lung cancer;	chr6:149849744	chr6:149863494~149919507:+
LUAD	cis	rs889398	0.967	rs12599391	ENSG00000226232.7	RP11-419C5.2	-4.95	1.03e-06	0.000259	-0.18	-0.22	Body mass index;	chr16:69571446	chr16:69976388~69996188:-
LUAD	cis	rs2239547	0.603	rs2276825	ENSG00000242142.1	SERBP1P3	4.95	1.03e-06	0.000259	0.26	0.22	Schizophrenia;	chr3:52852589	chr3:53064283~53065091:-
LUAD	cis	rs3096299	0.874	rs3102342	ENSG00000182376.2	RP5-1142A6.8	4.95	1.03e-06	0.000259	0.23	0.22	Multiple myeloma (IgH translocation);	chr16:89385167	chr16:88742767~88745748:+
LUAD	cis	rs10129255	1	rs10137758	ENSG00000224373.3	IGHV4-59	4.95	1.03e-06	0.000259	0.15	0.22	Kawasaki disease;	chr14:106697673	chr14:106627249~106627825:-
LUAD	cis	rs875971	0.522	rs10807697	ENSG00000224316.1	RP11-479O9.2	4.95	1.03e-06	0.00026	0.22	0.22	Aortic root size;	chr7:65951183	chr7:65773620~65802067:+
LUAD	cis	rs7849270	0.842	rs12237274	ENSG00000268707.1	RP11-247A12.7	-4.95	1.03e-06	0.00026	-0.25	-0.22	Blood metabolite ratios;	chr9:129169441	chr9:129170434~129170940:+
LUAD	cis	rs2243480	1	rs34970380	ENSG00000164669.11	INTS4P1	4.95	1.03e-06	0.00026	0.4	0.22	Diabetic kidney disease;	chr7:65966506	chr7:65141225~65234216:+
LUAD	cis	rs2243480	0.901	rs73148097	ENSG00000164669.11	INTS4P1	4.95	1.03e-06	0.00026	0.4	0.22	Diabetic kidney disease;	chr7:65966800	chr7:65141225~65234216:+
LUAD	cis	rs4964805	0.657	rs73192049	ENSG00000257681.1	RP11-341G23.4	4.95	1.03e-06	0.00026	0.23	0.22	Attention deficit hyperactivity disorder;	chr12:103794215	chr12:103746315~103768858:-
LUAD	cis	rs17301013	0.507	rs72713512	ENSG00000227373.4	RP11-160H22.5	4.95	1.03e-06	0.00026	0.29	0.22	Systemic lupus erythematosus;	chr1:174283505	chr1:174115300~174160004:-
LUAD	cis	rs11157436	0.918	rs12437004	ENSG00000211813.2	TRAV34	4.95	1.03e-06	0.00026	0.26	0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22149461	chr14:22207522~22208129:+
LUAD	cis	rs8127691	0.967	rs4380337	ENSG00000237604.1	AP001056.1	4.95	1.03e-06	0.00026	0.26	0.22	Inflammatory bowel disease;	chr21:44196166	chr21:44175489~44176453:+
LUAD	cis	rs4789693	0.809	rs8071692	ENSG00000265458.1	RP13-20L14.6	4.95	1.03e-06	0.00026	0.31	0.22	Glucocorticoid-induced osteonecrosis;	chr17:82434457	chr17:82454273~82458521:-
LUAD	cis	rs2337406	0.714	rs115401799	ENSG00000211972.2	IGHV3-66	4.95	1.03e-06	0.00026	0.25	0.22	Alzheimer's disease (late onset);	chr14:106813739	chr14:106675017~106675544:-
LUAD	cis	rs301901	0.861	rs217797	ENSG00000250155.1	CTD-2353F22.1	-4.95	1.03e-06	0.00026	-0.23	-0.22	Height;	chr5:37318193	chr5:36666214~36725195:-
LUAD	cis	rs7712401	0.601	rs36180885	ENSG00000263432.2	RN7SL689P	-4.95	1.03e-06	0.00026	-0.3	-0.22	Mean platelet volume;	chr5:123020708	chr5:123022487~123022783:-
LUAD	cis	rs1816752	0.87	rs7981480	ENSG00000273628.1	RP11-756A22.7	4.95	1.03e-06	0.00026	0.25	0.22	Obesity-related traits;	chr13:24440966	chr13:24933006~24936796:+
LUAD	cis	rs1816752	0.837	rs4769355	ENSG00000273628.1	RP11-756A22.7	4.95	1.03e-06	0.00026	0.25	0.22	Obesity-related traits;	chr13:24441059	chr13:24933006~24936796:+
LUAD	cis	rs1816752	0.905	rs4770680	ENSG00000273628.1	RP11-756A22.7	4.95	1.03e-06	0.00026	0.25	0.22	Obesity-related traits;	chr13:24441110	chr13:24933006~24936796:+
LUAD	cis	rs7590268	0.609	rs67584485	ENSG00000279873.2	LINC01126	4.95	1.03e-06	0.00026	0.21	0.22	Orofacial clefts;	chr2:43535056	chr2:43227210~43228855:+
LUAD	cis	rs9545047	0.604	rs7331872	ENSG00000227354.5	RBM26-AS1	-4.95	1.04e-06	0.000261	-0.23	-0.22	Schizophrenia;	chr13:79388717	chr13:79406309~79424328:+
LUAD	cis	rs219780	0.821	rs219783	ENSG00000233818.1	AP000695.4	4.95	1.04e-06	0.000261	0.26	0.22	Kidney stones;	chr21:36459654	chr21:36445731~36532408:+
LUAD	cis	rs9500256	0.715	rs7769674	ENSG00000266579.1	RP1-71H19.2	4.95	1.04e-06	0.000261	0.27	0.22	Eosinophilic esophagitis (pediatric);	chr6:58020586	chr6:57493855~57497691:+
LUAD	cis	rs763567	0.967	rs1234274	ENSG00000271811.1	RP1-79C4.4	4.95	1.04e-06	0.000261	0.26	0.22	Tonsillectomy;	chr1:170627232	chr1:170667381~170669425:+
LUAD	cis	rs6840360	1	rs10007167	ENSG00000270265.1	RP11-731D1.4	-4.95	1.04e-06	0.000261	-0.23	-0.22	Intelligence (multi-trait analysis);	chr4:151682503	chr4:151333775~151353224:-
LUAD	cis	rs867371	1	rs8042464	ENSG00000276710.3	CSPG4P8	-4.95	1.04e-06	0.000261	-0.21	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173195	chr15:82459472~82477258:+
LUAD	cis	rs6570726	0.689	rs411785	ENSG00000235652.6	RP11-545I5.3	4.95	1.04e-06	0.000261	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145567262	chr6:145799409~145886585:+
LUAD	cis	rs9500256	0.669	rs7770369	ENSG00000266579.1	RP1-71H19.2	4.95	1.04e-06	0.000261	0.27	0.22	Eosinophilic esophagitis (pediatric);	chr6:58021043	chr6:57493855~57497691:+
LUAD	cis	rs301901	1	rs168662	ENSG00000250155.1	CTD-2353F22.1	-4.95	1.04e-06	0.000262	-0.23	-0.22	Height;	chr5:36925633	chr5:36666214~36725195:-
LUAD	cis	rs9890032	0.934	rs3760318	ENSG00000266490.1	CTD-2349P21.9	4.95	1.04e-06	0.000262	0.2	0.22	Hip circumference adjusted for BMI;	chr17:30920697	chr17:30792372~30792833:+
LUAD	cis	rs17772222	0.958	rs17798341	ENSG00000258983.2	RP11-507K2.2	4.95	1.04e-06	0.000262	0.27	0.22	Coronary artery calcification;	chr14:88548201	chr14:88499334~88515502:+
LUAD	cis	rs801193	1	rs2659906	ENSG00000237310.1	GS1-124K5.4	4.95	1.04e-06	0.000262	0.24	0.22	Aortic root size;	chr7:66700323	chr7:66493706~66495474:+
LUAD	cis	rs2880765	0.743	rs7168345	ENSG00000259295.5	CSPG4P12	-4.95	1.04e-06	0.000262	-0.25	-0.22	Coronary artery disease;	chr15:85470370	chr15:85191438~85213905:+
LUAD	cis	rs7250849	0.565	rs7255319	ENSG00000273837.1	LLNLR-470E3.1	4.95	1.04e-06	0.000262	0.27	0.22	Blood protein levels;	chr19:51664653	chr19:51639478~51639931:-
LUAD	cis	rs683257	0.636	rs6934165	ENSG00000234147.1	RP3-460G2.2	-4.95	1.04e-06	0.000262	-0.35	-0.22	Facial emotion recognition (angry faces);	chr6:140851191	chr6:140845958~140852924:-
LUAD	cis	rs683257	0.636	rs56295525	ENSG00000234147.1	RP3-460G2.2	-4.95	1.04e-06	0.000262	-0.35	-0.22	Facial emotion recognition (angry faces);	chr6:140853380	chr6:140845958~140852924:-
LUAD	cis	rs7017914	0.652	rs2639928	ENSG00000223220.1	Y_RNA	4.95	1.04e-06	0.000262	0.25	0.22	Bone mineral density;	chr8:70971414	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs2933847	ENSG00000223220.1	Y_RNA	4.95	1.04e-06	0.000262	0.25	0.22	Bone mineral density;	chr8:70972946	chr8:70780914~70781008:-
LUAD	cis	rs13256369	0.901	rs12679831	ENSG00000253893.2	FAM85B	-4.95	1.04e-06	0.000262	-0.3	-0.22	Obesity-related traits;	chr8:8708901	chr8:8167819~8226614:-
LUAD	cis	rs13256369	0.901	rs12681327	ENSG00000253893.2	FAM85B	-4.95	1.04e-06	0.000262	-0.3	-0.22	Obesity-related traits;	chr8:8708904	chr8:8167819~8226614:-
LUAD	cis	rs4835473	0.868	rs5025156	ENSG00000251600.4	RP11-673E1.1	-4.95	1.04e-06	0.000262	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143738025	chr4:143912331~143982454:+
LUAD	cis	rs9487094	0.961	rs11153177	ENSG00000260273.1	RP11-425D10.10	4.95	1.04e-06	0.000262	0.3	0.22	Height;	chr6:109416225	chr6:109382795~109383666:+
LUAD	cis	rs1008375	0.966	rs4698619	ENSG00000249502.1	AC006160.5	-4.95	1.04e-06	0.000262	-0.22	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17579332	chr4:17587467~17614571:-
LUAD	cis	rs1008375	0.966	rs10939736	ENSG00000249502.1	AC006160.5	-4.95	1.04e-06	0.000262	-0.22	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17579994	chr4:17587467~17614571:-
LUAD	cis	rs1008375	0.966	rs2010053	ENSG00000249502.1	AC006160.5	-4.95	1.04e-06	0.000262	-0.22	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17582183	chr4:17587467~17614571:-
LUAD	cis	rs1008375	0.966	rs1476836	ENSG00000249502.1	AC006160.5	-4.95	1.04e-06	0.000262	-0.22	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17583391	chr4:17587467~17614571:-
LUAD	cis	rs1008375	0.898	rs7670500	ENSG00000249502.1	AC006160.5	-4.95	1.04e-06	0.000262	-0.22	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17585334	chr4:17587467~17614571:-
LUAD	cis	rs2098713	0.535	rs11748123	ENSG00000250155.1	CTD-2353F22.1	4.95	1.04e-06	0.000262	0.23	0.22	Telomere length;	chr5:37575317	chr5:36666214~36725195:-
LUAD	cis	rs673078	0.66	rs73205526	ENSG00000275409.1	RP11-131L12.4	-4.95	1.04e-06	0.000263	-0.31	-0.22	Glucose homeostasis traits;	chr12:118273172	chr12:118430147~118430699:+
LUAD	cis	rs1005277	0.691	rs2474558	ENSG00000263064.2	RP11-291L22.7	-4.95	1.04e-06	0.000263	-0.24	-0.22	Extrinsic epigenetic age acceleration;	chr10:38197213	chr10:38448689~38448949:+
LUAD	cis	rs4964805	0.657	rs11111783	ENSG00000257681.1	RP11-341G23.4	4.95	1.05e-06	0.000263	0.23	0.22	Attention deficit hyperactivity disorder;	chr12:103794745	chr12:103746315~103768858:-
LUAD	cis	rs875971	0.66	rs3764903	ENSG00000237310.1	GS1-124K5.4	-4.95	1.05e-06	0.000263	-0.24	-0.22	Aortic root size;	chr7:66633495	chr7:66493706~66495474:+
LUAD	cis	rs1008375	0.966	rs3775923	ENSG00000249502.1	AC006160.5	-4.95	1.05e-06	0.000263	-0.22	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17584002	chr4:17587467~17614571:-
LUAD	cis	rs7811142	1	rs11771241	ENSG00000078319.8	PMS2P1	-4.95	1.05e-06	0.000263	-0.26	-0.22	Platelet count;	chr7:100397162	chr7:100320992~100341908:-
LUAD	cis	rs7017914	0.818	rs13252808	ENSG00000223220.1	Y_RNA	4.95	1.05e-06	0.000263	0.25	0.22	Bone mineral density;	chr8:70704420	chr8:70780914~70781008:-
LUAD	cis	rs1707322	0.964	rs785483	ENSG00000280836.1	AL355480.1	4.95	1.05e-06	0.000263	0.28	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46093499	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.964	rs796773	ENSG00000280836.1	AL355480.1	4.95	1.05e-06	0.000263	0.28	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46098803	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.896	rs785518	ENSG00000280836.1	AL355480.1	4.95	1.05e-06	0.000263	0.28	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102750	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs785519	ENSG00000280836.1	AL355480.1	4.95	1.05e-06	0.000263	0.28	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102890	chr1:45581219~45581321:-
LUAD	cis	rs11971779	0.941	rs7802779	ENSG00000273391.1	RP11-634H22.1	4.95	1.05e-06	0.000263	0.24	0.22	Diisocyanate-induced asthma;	chr7:139437833	chr7:139359032~139359566:-
LUAD	cis	rs12928939	0.723	rs71403864	ENSG00000260886.1	TAT-AS1	4.95	1.05e-06	0.000263	0.27	0.22	Post bronchodilator FEV1;	chr16:71661127	chr16:71565789~71578187:+
LUAD	cis	rs7017914	0.69	rs10453108	ENSG00000223220.1	Y_RNA	4.95	1.05e-06	0.000264	0.25	0.22	Bone mineral density;	chr8:70870705	chr8:70780914~70781008:-
LUAD	cis	rs1874124	0.895	rs2642420	ENSG00000272823.1	RP11-295M18.6	4.95	1.05e-06	0.000264	0.31	0.22	Cholesterol, total;	chr1:220804308	chr1:220828676~220829211:-
LUAD	cis	rs7430456	0.638	rs13071694	ENSG00000225790.1	RP11-2L8.1	4.95	1.05e-06	0.000264	0.27	0.22	Breast cancer;	chr3:177775198	chr3:177934823~177937662:+
LUAD	cis	rs6723226	0.708	rs2754513	ENSG00000276334.1	AL133243.1	4.95	1.05e-06	0.000264	0.25	0.22	Intelligence (multi-trait analysis);	chr2:32557696	chr2:32521927~32523547:+
LUAD	cis	rs2286503	1	rs2286503	ENSG00000226329.2	AC005682.6	4.95	1.05e-06	0.000264	0.28	0.22	Fibrinogen;	chr7:22816987	chr7:22863874~22881350:-
LUAD	cis	rs3747113	1	rs34949904	ENSG00000128262.7	POM121L9P	-4.95	1.05e-06	0.000265	-0.24	-0.22	Gut microbiome composition (summer);	chr22:24299330	chr22:24251828~24265525:+
LUAD	cis	rs71636778	0.509	rs17162339	ENSG00000260063.1	RP5-968P14.2	4.95	1.05e-06	0.000265	0.37	0.22	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26926332	chr1:26692132~26694131:-
LUAD	cis	rs2562456	0.754	rs62107469	ENSG00000268081.1	RP11-678G14.2	4.95	1.05e-06	0.000265	0.36	0.22	Pain;	chr19:21312699	chr19:21554640~21569237:-
LUAD	cis	rs42490	0.966	rs2735871	ENSG00000251136.7	RP11-37B2.1	4.95	1.05e-06	0.000265	0.23	0.22	Leprosy;	chr8:89731154	chr8:89609409~89757727:-
LUAD	cis	rs42490	0.934	rs10095743	ENSG00000251136.7	RP11-37B2.1	-4.94	1.05e-06	0.000265	-0.23	-0.22	Leprosy;	chr8:89749445	chr8:89609409~89757727:-
LUAD	cis	rs6687758	1	rs12140604	ENSG00000228437.4	RP11-400N13.2	4.94	1.05e-06	0.000265	0.32	0.22	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221985808	chr1:221966341~221984964:+
LUAD	cis	rs375066	0.935	rs417699	ENSG00000267058.1	RP11-15A1.3	-4.94	1.05e-06	0.000265	-0.24	-0.22	Breast cancer;	chr19:43913423	chr19:43891804~43901805:-
LUAD	cis	rs8072100	0.967	rs11079784	ENSG00000228782.6	CTD-2026D20.3	-4.94	1.05e-06	0.000265	-0.23	-0.22	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47624914	chr17:47450568~47492492:-
LUAD	cis	rs7119038	0.509	rs11216956	ENSG00000255239.1	AP002954.6	-4.94	1.05e-06	0.000265	-0.32	-0.22	Sjögren's syndrome;	chr11:118704617	chr11:118688039~118690600:-
LUAD	cis	rs453301	0.653	rs1045529	ENSG00000253893.2	FAM85B	4.94	1.05e-06	0.000265	0.28	0.22	Joint mobility (Beighton score);	chr8:9032588	chr8:8167819~8226614:-
LUAD	cis	rs11671005	0.693	rs11084542	ENSG00000268912.1	CTD-2619J13.17	-4.94	1.06e-06	0.000265	-0.3	-0.22	Mean platelet volume;	chr19:58420732	chr19:58428632~58431148:-
LUAD	cis	rs375066	0.935	rs10406290	ENSG00000267058.1	RP11-15A1.3	-4.94	1.06e-06	0.000265	-0.25	-0.22	Breast cancer;	chr19:43874725	chr19:43891804~43901805:-
LUAD	cis	rs1707322	1	rs4660889	ENSG00000280836.1	AL355480.1	-4.94	1.06e-06	0.000266	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45831659	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs10890353	ENSG00000280836.1	AL355480.1	-4.94	1.06e-06	0.000266	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45832711	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs10890355	ENSG00000280836.1	AL355480.1	-4.94	1.06e-06	0.000266	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45851676	chr1:45581219~45581321:-
LUAD	cis	rs11673344	0.504	rs6510588	ENSG00000276846.1	CTD-3220F14.3	-4.94	1.06e-06	0.000266	-0.24	-0.22	Obesity-related traits;	chr19:37106493	chr19:37314868~37315620:-
LUAD	cis	rs2404602	1	rs2404602	ENSG00000259422.1	RP11-593F23.1	4.94	1.06e-06	0.000266	0.26	0.22	Blood metabolite levels;	chr15:76738451	chr15:76174891~76181486:-
LUAD	cis	rs1707322	1	rs11211248	ENSG00000280836.1	AL355480.1	-4.94	1.06e-06	0.000266	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46011172	chr1:45581219~45581321:-
LUAD	cis	rs72772090	0.71	rs112178674	ENSG00000248734.2	CTD-2260A17.1	-4.94	1.06e-06	0.000266	-0.33	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96724651	chr5:96784777~96785999:+
LUAD	cis	rs6142102	0.961	rs2284389	ENSG00000275784.1	RP5-1125A11.6	-4.94	1.06e-06	0.000266	-0.24	-0.22	Skin pigmentation;	chr20:34069035	chr20:33989480~33991818:-
LUAD	cis	rs801193	1	rs62466793	ENSG00000237310.1	GS1-124K5.4	4.94	1.06e-06	0.000266	0.24	0.22	Aortic root size;	chr7:66726530	chr7:66493706~66495474:+
LUAD	cis	rs5758511	0.689	rs56906457	ENSG00000226450.2	CYP2D8P	4.94	1.06e-06	0.000266	0.22	0.22	Birth weight;	chr22:42232329	chr22:42149886~42155001:-
LUAD	cis	rs853679	1	rs6901575	ENSG00000204709.4	LINC01556	4.94	1.06e-06	0.000266	0.33	0.22	Depression;	chr6:28283207	chr6:28943877~28944537:+
LUAD	cis	rs9860428	0.808	rs6805341	ENSG00000242770.2	RP11-180K7.1	4.94	1.06e-06	0.000266	0.23	0.22	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112899471	chr3:112802478~112812819:+
LUAD	cis	rs9860428	0.808	rs9868922	ENSG00000242770.2	RP11-180K7.1	4.94	1.06e-06	0.000266	0.23	0.22	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112899503	chr3:112802478~112812819:+
LUAD	cis	rs9860428	0.844	rs2399437	ENSG00000242770.2	RP11-180K7.1	4.94	1.06e-06	0.000266	0.23	0.22	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112900369	chr3:112802478~112812819:+
LUAD	cis	rs2735413	0.564	rs78375430	ENSG00000276007.1	RP11-358L22.3	4.94	1.06e-06	0.000266	0.31	0.22	Systolic blood pressure (alcohol consumption interaction);	chr16:78050916	chr16:78123243~78124332:+
LUAD	cis	rs720475	0.732	rs17172978	ENSG00000170356.8	OR2A20P	4.94	1.06e-06	0.000266	0.3	0.22	Breast cancer;	chr7:144429551	chr7:144250045~144252957:-
LUAD	cis	rs74233809	1	rs11191505	ENSG00000213277.3	MARCKSL1P1	4.94	1.06e-06	0.000266	0.39	0.22	Birth weight;	chr10:103007134	chr10:103175554~103176094:+
LUAD	cis	rs1275468	1	rs17115231	ENSG00000257497.2	RP11-585P4.5	-4.94	1.06e-06	0.000266	-0.3	-0.22	Polycystic ovary syndrome;	chr12:75539895	chr12:75483454~75489820:-
LUAD	cis	rs193541	0.632	rs430069	ENSG00000263432.2	RN7SL689P	4.94	1.06e-06	0.000267	0.3	0.22	Glucose homeostasis traits;	chr5:122927656	chr5:123022487~123022783:-
LUAD	cis	rs5758659	1	rs134869	ENSG00000227370.1	RP4-669P10.19	-4.94	1.06e-06	0.000267	-0.2	-0.22	Cognitive function;	chr22:42256068	chr22:42132543~42132998:+
LUAD	cis	rs4776970	0.632	rs12592101	ENSG00000270964.1	RP11-502I4.3	-4.94	1.06e-06	0.000267	-0.23	-0.22	Body mass index;Waist circumference;	chr15:67737232	chr15:67541072~67542604:-
LUAD	cis	rs708547	0.575	rs6847086	ENSG00000269949.1	RP11-738E22.3	-4.94	1.06e-06	0.000267	-0.3	-0.22	Response to bleomycin (chromatid breaks);	chr4:56925698	chr4:56960927~56961373:-
LUAD	cis	rs2562456	0.917	rs11085463	ENSG00000268081.1	RP11-678G14.2	4.94	1.06e-06	0.000267	0.32	0.22	Pain;	chr19:21568500	chr19:21554640~21569237:-
LUAD	cis	rs801193	0.569	rs11772819	ENSG00000232559.3	GS1-124K5.12	4.94	1.06e-06	0.000267	0.26	0.22	Aortic root size;	chr7:66752983	chr7:66554588~66576923:-
LUAD	cis	rs801193	0.569	rs7800620	ENSG00000232559.3	GS1-124K5.12	4.94	1.06e-06	0.000267	0.26	0.22	Aortic root size;	chr7:66758701	chr7:66554588~66576923:-
LUAD	cis	rs301901	0.965	rs159749	ENSG00000250155.1	CTD-2353F22.1	-4.94	1.06e-06	0.000267	-0.23	-0.22	Height;	chr5:36968438	chr5:36666214~36725195:-
LUAD	cis	rs2998286	0.784	rs998362	ENSG00000254635.4	WAC-AS1	-4.94	1.06e-06	0.000267	-0.28	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28528129	chr10:28522652~28532743:-
LUAD	cis	rs13256369	1	rs883648	ENSG00000253893.2	FAM85B	-4.94	1.06e-06	0.000267	-0.31	-0.22	Obesity-related traits;	chr8:8712011	chr8:8167819~8226614:-
LUAD	cis	rs71520386	0.632	rs9692432	ENSG00000228649.7	AC005682.5	-4.94	1.06e-06	0.000267	-0.3	-0.22	Fibrinogen levels;	chr7:22829244	chr7:22854178~22861579:+
LUAD	cis	rs71520386	0.632	rs71520387	ENSG00000228649.7	AC005682.5	-4.94	1.06e-06	0.000267	-0.3	-0.22	Fibrinogen levels;	chr7:22830057	chr7:22854178~22861579:+
LUAD	cis	rs71520386	0.632	rs10224244	ENSG00000228649.7	AC005682.5	-4.94	1.06e-06	0.000267	-0.3	-0.22	Fibrinogen levels;	chr7:22830455	chr7:22854178~22861579:+
LUAD	cis	rs867371	0.722	rs8033050	ENSG00000259429.4	UBE2Q2P2	-4.94	1.06e-06	0.000267	-0.2	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82269648	chr15:82355142~82420075:+
LUAD	cis	rs9959145	0.543	rs11664013	ENSG00000267108.1	RP11-861E21.1	-4.94	1.07e-06	0.000267	-0.24	-0.22	Immune response to smallpox vaccine (IL-6);	chr18:12582789	chr18:12432897~12437635:+
LUAD	cis	rs6604026	0.555	rs4642892	ENSG00000223787.2	RP4-593M8.1	4.94	1.07e-06	0.000268	0.31	0.22	Multiple sclerosis;	chr1:92628570	chr1:92580476~92580821:-
LUAD	cis	rs2439831	0.85	rs68079546	ENSG00000249839.1	AC011330.5	-4.94	1.07e-06	0.000268	-0.45	-0.22	Lung cancer in ever smokers;	chr15:43844759	chr15:43663654~43684339:-
LUAD	cis	rs2439831	0.85	rs56909447	ENSG00000249839.1	AC011330.5	-4.94	1.07e-06	0.000268	-0.45	-0.22	Lung cancer in ever smokers;	chr15:43845420	chr15:43663654~43684339:-
LUAD	cis	rs2439831	0.85	rs28476182	ENSG00000249839.1	AC011330.5	-4.94	1.07e-06	0.000268	-0.45	-0.22	Lung cancer in ever smokers;	chr15:43847445	chr15:43663654~43684339:-
LUAD	cis	rs2439831	0.85	rs28696802	ENSG00000249839.1	AC011330.5	-4.94	1.07e-06	0.000268	-0.45	-0.22	Lung cancer in ever smokers;	chr15:43848197	chr15:43663654~43684339:-
LUAD	cis	rs12022452	0.908	rs11811487	ENSG00000238287.1	RP11-656D10.3	-4.94	1.07e-06	0.000268	-0.39	-0.22	Age-related hearing impairment (SNP x SNP interaction);	chr1:40555398	chr1:40493157~40508661:-
LUAD	cis	rs1816752	0.783	rs7317439	ENSG00000273628.1	RP11-756A22.7	4.94	1.07e-06	0.000268	0.25	0.22	Obesity-related traits;	chr13:24410939	chr13:24933006~24936796:+
LUAD	cis	rs1816752	0.783	rs7139527	ENSG00000273628.1	RP11-756A22.7	4.94	1.07e-06	0.000268	0.25	0.22	Obesity-related traits;	chr13:24411374	chr13:24933006~24936796:+
LUAD	cis	rs1816752	0.819	rs9511240	ENSG00000273628.1	RP11-756A22.7	4.94	1.07e-06	0.000268	0.25	0.22	Obesity-related traits;	chr13:24411768	chr13:24933006~24936796:+
LUAD	cis	rs1816752	0.819	rs7988388	ENSG00000273628.1	RP11-756A22.7	4.94	1.07e-06	0.000268	0.25	0.22	Obesity-related traits;	chr13:24412675	chr13:24933006~24936796:+
LUAD	cis	rs1816752	0.875	rs7993132	ENSG00000273628.1	RP11-756A22.7	4.94	1.07e-06	0.000268	0.25	0.22	Obesity-related traits;	chr13:24412903	chr13:24933006~24936796:+
LUAD	cis	rs1862618	0.525	rs2662019	ENSG00000271828.1	CTD-2310F14.1	-4.94	1.07e-06	0.000268	-0.32	-0.22	Initial pursuit acceleration;	chr5:56967277	chr5:56927874~56929573:+
LUAD	cis	rs2439831	0.85	rs68079546	ENSG00000205771.5	CATSPER2P1	-4.94	1.07e-06	0.000268	-0.44	-0.22	Lung cancer in ever smokers;	chr15:43844759	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.85	rs56909447	ENSG00000205771.5	CATSPER2P1	-4.94	1.07e-06	0.000268	-0.44	-0.22	Lung cancer in ever smokers;	chr15:43845420	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.85	rs28476182	ENSG00000205771.5	CATSPER2P1	-4.94	1.07e-06	0.000268	-0.44	-0.22	Lung cancer in ever smokers;	chr15:43847445	chr15:43726918~43747094:-
LUAD	cis	rs2439831	0.85	rs28696802	ENSG00000205771.5	CATSPER2P1	-4.94	1.07e-06	0.000268	-0.44	-0.22	Lung cancer in ever smokers;	chr15:43848197	chr15:43726918~43747094:-
LUAD	cis	rs36093844	0.752	rs78589744	ENSG00000279742.1	RP11-700A24.1	-4.94	1.07e-06	0.000268	-0.29	-0.22	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85844956	chr11:85852557~85854943:-
LUAD	cis	rs4964805	0.606	rs7312606	ENSG00000257681.1	RP11-341G23.4	4.94	1.07e-06	0.000268	0.23	0.22	Attention deficit hyperactivity disorder;	chr12:103794607	chr12:103746315~103768858:-
LUAD	cis	rs4964805	0.581	rs7312825	ENSG00000257681.1	RP11-341G23.4	4.94	1.07e-06	0.000268	0.23	0.22	Attention deficit hyperactivity disorder;	chr12:103794610	chr12:103746315~103768858:-
LUAD	cis	rs801193	1	rs2659912	ENSG00000237310.1	GS1-124K5.4	4.94	1.07e-06	0.000268	0.24	0.22	Aortic root size;	chr7:66693012	chr7:66493706~66495474:+
LUAD	cis	rs9376098	0.698	rs6929368	ENSG00000232876.1	CTA-212D2.2	4.94	1.07e-06	0.000268	0.26	0.22	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135146587	chr6:135055033~135060550:+
LUAD	cis	rs4568518	0.53	rs7802331	ENSG00000279048.1	RP11-511H23.2	4.94	1.07e-06	0.000268	0.18	0.22	Measles;	chr7:17955352	chr7:17940503~17942922:+
LUAD	cis	rs875971	0.66	rs1860470	ENSG00000237310.1	GS1-124K5.4	-4.94	1.07e-06	0.000268	-0.24	-0.22	Aortic root size;	chr7:66638707	chr7:66493706~66495474:+
LUAD	cis	rs2554380	0.628	rs12914377	ENSG00000230373.7	GOLGA6L5P	-4.94	1.07e-06	0.000268	-0.23	-0.22	Height;	chr15:83791941	chr15:84507885~84516814:-
LUAD	cis	rs1862618	0.529	rs978406	ENSG00000271828.1	CTD-2310F14.1	-4.94	1.07e-06	0.000268	-0.33	-0.22	Initial pursuit acceleration;	chr5:56963981	chr5:56927874~56929573:+
LUAD	cis	rs10935480	0.904	rs13065271	ENSG00000249274.1	PDLIM1P4	-4.94	1.07e-06	0.000268	-0.23	-0.22	Blood protein levels;	chr3:98715649	chr3:98782188~98783193:+
LUAD	cis	rs9659323	0.67	rs61808898	ENSG00000231365.4	RP11-418J17.1	-4.94	1.07e-06	0.000268	-0.26	-0.22	Body mass index;	chr1:119096232	chr1:119140396~119275973:+
LUAD	cis	rs1707322	0.65	rs4553239	ENSG00000280836.1	AL355480.1	-4.94	1.07e-06	0.000269	-0.29	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684814	chr1:45581219~45581321:-
LUAD	cis	rs7017914	0.628	rs7833211	ENSG00000223220.1	Y_RNA	4.94	1.07e-06	0.000269	0.25	0.22	Bone mineral density;	chr8:70691903	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs12156043	ENSG00000223220.1	Y_RNA	4.94	1.07e-06	0.000269	0.25	0.22	Bone mineral density;	chr8:70701808	chr8:70780914~70781008:-
LUAD	cis	rs6762	0.692	rs7928925	ENSG00000279672.1	CMB9-55F22.1	4.94	1.07e-06	0.000269	0.24	0.22	Mean platelet volume;	chr11:839155	chr11:779617~780755:+
LUAD	cis	rs73198271	0.765	rs534103	ENSG00000253893.2	FAM85B	4.94	1.07e-06	0.000269	0.28	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8776559	chr8:8167819~8226614:-
LUAD	cis	rs875971	0.964	rs697969	ENSG00000232559.3	GS1-124K5.12	-4.94	1.07e-06	0.000269	-0.26	-0.22	Aortic root size;	chr7:66093491	chr7:66554588~66576923:-
LUAD	cis	rs875971	1	rs1182882	ENSG00000232559.3	GS1-124K5.12	-4.94	1.07e-06	0.000269	-0.26	-0.22	Aortic root size;	chr7:66097076	chr7:66554588~66576923:-
LUAD	cis	rs7017914	0.652	rs2639931	ENSG00000223220.1	Y_RNA	4.94	1.07e-06	0.000269	0.25	0.22	Bone mineral density;	chr8:70974202	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs2639932	ENSG00000223220.1	Y_RNA	4.94	1.07e-06	0.000269	0.25	0.22	Bone mineral density;	chr8:70974216	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs2956615	ENSG00000223220.1	Y_RNA	4.94	1.07e-06	0.000269	0.25	0.22	Bone mineral density;	chr8:70974519	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.583	rs2732129	ENSG00000223220.1	Y_RNA	4.94	1.07e-06	0.000269	0.25	0.22	Bone mineral density;	chr8:70982734	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs2639912	ENSG00000223220.1	Y_RNA	4.94	1.07e-06	0.000269	0.25	0.22	Bone mineral density;	chr8:70983134	chr8:70780914~70781008:-
LUAD	cis	rs1150668	0.83	rs2023493	ENSG00000219392.1	RP1-265C24.5	-4.94	1.07e-06	0.000269	-0.28	-0.22	Pubertal anthropometrics;	chr6:28432385	chr6:28115628~28116551:+
LUAD	cis	rs9309473	0.615	rs62151562	ENSG00000163016.8	ALMS1P	4.94	1.07e-06	0.000269	0.33	0.22	Metabolite levels;	chr2:73376412	chr2:73644919~73685576:+
LUAD	cis	rs858239	1	rs858239	ENSG00000226816.2	AC005082.12	4.94	1.07e-06	0.000269	0.28	0.22	Cerebrospinal fluid biomarker levels;	chr7:23246696	chr7:23206013~23208045:+
LUAD	cis	rs12468226	0.689	rs17656903	ENSG00000226261.1	AC064836.3	-4.94	1.07e-06	0.000269	-0.35	-0.22	Urate levels;	chr2:202106312	chr2:202336024~202336727:-
LUAD	cis	rs2522056	0.935	rs1981524	ENSG00000233006.5	AC034220.3	-4.94	1.07e-06	0.000269	-0.24	-0.22	Fibrinogen;Lymphocyte counts;	chr5:132420814	chr5:132311285~132369916:-
LUAD	cis	rs1005277	0.579	rs1780116	ENSG00000263064.2	RP11-291L22.7	4.94	1.07e-06	0.000269	0.24	0.22	Extrinsic epigenetic age acceleration;	chr10:38237693	chr10:38448689~38448949:+
LUAD	cis	rs1799949	0.929	rs799905	ENSG00000236383.6	LINC00854	-4.94	1.07e-06	0.00027	-0.18	-0.22	Menopause (age at onset);	chr17:43125170	chr17:43216941~43305976:-
LUAD	cis	rs1275468	0.798	rs10879928	ENSG00000257497.2	RP11-585P4.5	4.94	1.08e-06	0.00027	0.3	0.22	Polycystic ovary syndrome;	chr12:75531996	chr12:75483454~75489820:-
LUAD	cis	rs2933343	0.621	rs883843	ENSG00000261159.1	RP11-723O4.9	-4.94	1.08e-06	0.00027	-0.24	-0.22	IgG glycosylation;	chr3:128848540	chr3:128859716~128860526:-
LUAD	cis	rs910316	0.967	rs35446981	ENSG00000259138.1	RP11-950C14.7	-4.94	1.08e-06	0.00027	-0.23	-0.22	Height;	chr14:75170648	chr14:75127153~75136930:+
LUAD	cis	rs1816752	0.792	rs7330956	ENSG00000273628.1	RP11-756A22.7	4.94	1.08e-06	0.00027	0.25	0.22	Obesity-related traits;	chr13:24413174	chr13:24933006~24936796:+
LUAD	cis	rs7811142	1	rs11771419	ENSG00000078319.8	PMS2P1	-4.94	1.08e-06	0.00027	-0.26	-0.22	Platelet count;	chr7:100390780	chr7:100320992~100341908:-
LUAD	cis	rs4568518	0.53	rs12699921	ENSG00000279048.1	RP11-511H23.2	4.94	1.08e-06	0.00027	0.19	0.22	Measles;	chr7:17954871	chr7:17940503~17942922:+
LUAD	cis	rs9322193	0.962	rs9505974	ENSG00000268592.3	RAET1E-AS1	4.94	1.08e-06	0.00027	0.27	0.22	Lung cancer;	chr6:149779294	chr6:149863494~149919507:+
LUAD	cis	rs1850744	0.702	rs7668469	ENSG00000163612.10	FAM86KP	-4.94	1.08e-06	0.00027	-0.66	-0.22	Economic and political preferences;	chr4:9742906	chr4:9153296~9165451:+
LUAD	cis	rs12468226	0.752	rs77319662	ENSG00000226261.1	AC064836.3	4.94	1.08e-06	0.00027	0.35	0.22	Urate levels;	chr2:202126928	chr2:202336024~202336727:-
LUAD	cis	rs11122895	0.846	rs11692656	ENSG00000236307.2	EEF1E1P1	4.94	1.08e-06	0.00027	0.25	0.22	Allergic sensitization;	chr2:111685147	chr2:111887914~111888741:+
LUAD	cis	rs1707322	1	rs785486	ENSG00000280836.1	AL355480.1	4.94	1.08e-06	0.000271	0.28	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46109476	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.865	rs785501	ENSG00000280836.1	AL355480.1	4.94	1.08e-06	0.000271	0.28	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46113939	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs785504	ENSG00000280836.1	AL355480.1	4.94	1.08e-06	0.000271	0.28	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46130024	chr1:45581219~45581321:-
LUAD	cis	rs6840258	0.825	rs72667751	ENSG00000251411.1	RP11-397E7.4	-4.94	1.08e-06	0.000271	-0.28	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87015227	chr4:86913266~86914817:-
LUAD	cis	rs6840258	1	rs72667753	ENSG00000251411.1	RP11-397E7.4	-4.94	1.08e-06	0.000271	-0.28	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87019860	chr4:86913266~86914817:-
LUAD	cis	rs801193	1	rs1553610	ENSG00000237310.1	GS1-124K5.4	4.94	1.08e-06	0.000271	0.24	0.22	Aortic root size;	chr7:66732246	chr7:66493706~66495474:+
LUAD	cis	rs9425766	0.566	rs12079820	ENSG00000227373.4	RP11-160H22.5	4.94	1.08e-06	0.000271	0.28	0.22	Life satisfaction;	chr1:174240771	chr1:174115300~174160004:-
LUAD	cis	rs748404	0.626	rs17780920	ENSG00000205771.5	CATSPER2P1	-4.94	1.08e-06	0.000271	-0.33	-0.22	Lung cancer;	chr15:43370164	chr15:43726918~43747094:-
LUAD	cis	rs67311347	0.577	rs2887951	ENSG00000223797.4	ENTPD3-AS1	4.94	1.08e-06	0.000271	0.22	0.22	Renal cell carcinoma;	chr3:40240613	chr3:40313802~40453329:-
LUAD	cis	rs12745968	0.589	rs4484938	ENSG00000223787.2	RP4-593M8.1	-4.94	1.08e-06	0.000271	-0.26	-0.22	Bipolar disorder and schizophrenia;	chr1:92490264	chr1:92580476~92580821:-
LUAD	cis	rs301901	1	rs159751	ENSG00000250155.1	CTD-2353F22.1	-4.94	1.08e-06	0.000271	-0.23	-0.22	Height;	chr5:36999896	chr5:36666214~36725195:-
LUAD	cis	rs2239547	0.618	rs3733047	ENSG00000242142.1	SERBP1P3	-4.94	1.08e-06	0.000271	-0.26	-0.22	Schizophrenia;	chr3:52837913	chr3:53064283~53065091:-
LUAD	cis	rs13113518	0.812	rs12500686	ENSG00000223305.1	RN7SKP30	4.94	1.08e-06	0.000271	0.26	0.22	Height;	chr4:55457922	chr4:55540502~55540835:-
LUAD	cis	rs11159086	0.793	rs10139029	ENSG00000259005.1	RP3-449M8.6	4.94	1.08e-06	0.000271	0.28	0.22	Advanced glycation end-product levels;	chr14:74492284	chr14:74474007~74474864:-
LUAD	cis	rs11971779	0.715	rs11772771	ENSG00000273391.1	RP11-634H22.1	4.94	1.08e-06	0.000271	0.23	0.22	Diisocyanate-induced asthma;	chr7:139374057	chr7:139359032~139359566:-
LUAD	cis	rs6840360	1	rs1896883	ENSG00000270265.1	RP11-731D1.4	4.94	1.08e-06	0.000271	0.22	0.22	Intelligence (multi-trait analysis);	chr4:151674221	chr4:151333775~151353224:-
LUAD	cis	rs1799949	1	rs33994002	ENSG00000236383.6	LINC00854	-4.94	1.08e-06	0.000271	-0.18	-0.22	Menopause (age at onset);	chr17:43176801	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs33920795	ENSG00000236383.6	LINC00854	-4.94	1.08e-06	0.000271	-0.18	-0.22	Menopause (age at onset);	chr17:43176993	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs33918839	ENSG00000236383.6	LINC00854	-4.94	1.08e-06	0.000271	-0.18	-0.22	Menopause (age at onset);	chr17:43177155	chr17:43216941~43305976:-
LUAD	cis	rs9487094	0.813	rs12528712	ENSG00000260273.1	RP11-425D10.10	4.94	1.08e-06	0.000271	0.31	0.22	Height;	chr6:109339681	chr6:109382795~109383666:+
LUAD	cis	rs7302981	0.967	rs12815871	ENSG00000272368.2	RP4-605O3.4	4.94	1.08e-06	0.000271	0.26	0.22	Systolic blood pressure;	chr12:50157165	chr12:50112197~50165618:+
LUAD	cis	rs1075265	0.584	rs10164409	ENSG00000233266.1	HMGB1P31	4.94	1.08e-06	0.000271	0.28	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53940867	chr2:54051334~54051760:+
LUAD	cis	rs875971	0.862	rs4236208	ENSG00000232559.3	GS1-124K5.12	-4.94	1.08e-06	0.000271	-0.26	-0.22	Aortic root size;	chr7:66284091	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs10261398	ENSG00000232559.3	GS1-124K5.12	-4.94	1.08e-06	0.000271	-0.26	-0.22	Aortic root size;	chr7:66285177	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs10224872	ENSG00000232559.3	GS1-124K5.12	-4.94	1.08e-06	0.000271	-0.26	-0.22	Aortic root size;	chr7:66294786	chr7:66554588~66576923:-
LUAD	cis	rs6957923	1	rs6956228	ENSG00000230658.1	KLHL7-AS1	4.94	1.08e-06	0.000272	0.26	0.22	Height;	chr7:23448096	chr7:23101228~23105703:-
LUAD	cis	rs801193	0.935	rs2659899	ENSG00000237310.1	GS1-124K5.4	4.94	1.08e-06	0.000272	0.24	0.22	Aortic root size;	chr7:66721734	chr7:66493706~66495474:+
LUAD	cis	rs801193	1	rs62466794	ENSG00000237310.1	GS1-124K5.4	4.94	1.08e-06	0.000272	0.24	0.22	Aortic root size;	chr7:66726592	chr7:66493706~66495474:+
LUAD	cis	rs6840360	1	rs3749562	ENSG00000270265.1	RP11-731D1.4	-4.94	1.08e-06	0.000272	-0.22	-0.22	Intelligence (multi-trait analysis);	chr4:151675388	chr4:151333775~151353224:-
LUAD	cis	rs10246939	0.505	rs13236432	ENSG00000270923.1	TAS2R6P	-4.94	1.08e-06	0.000272	-0.26	-0.22	Bitter taste perception;	chr7:141850980	chr7:141787815~141788640:+
LUAD	cis	rs6570726	0.818	rs437147	ENSG00000235652.6	RP11-545I5.3	4.94	1.08e-06	0.000272	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145554287	chr6:145799409~145886585:+
LUAD	cis	rs1062177	0.826	rs2915873	ENSG00000253921.1	CTB-113P19.3	-4.94	1.08e-06	0.000272	-0.33	-0.22	Preschool internalizing problems;	chr5:151777097	chr5:151753992~151767247:+
LUAD	cis	rs13256369	0.802	rs13280101	ENSG00000253893.2	FAM85B	-4.94	1.09e-06	0.000272	-0.3	-0.22	Obesity-related traits;	chr8:8705263	chr8:8167819~8226614:-
LUAD	cis	rs42490	0.844	rs444078	ENSG00000251136.7	RP11-37B2.1	-4.94	1.09e-06	0.000272	-0.22	-0.22	Leprosy;	chr8:89701558	chr8:89609409~89757727:-
LUAD	cis	rs875971	0.862	rs778724	ENSG00000232559.3	GS1-124K5.12	4.94	1.09e-06	0.000272	0.26	0.22	Aortic root size;	chr7:66364304	chr7:66554588~66576923:-
LUAD	cis	rs75920871	0.528	rs1241655	ENSG00000254851.1	RP11-109L13.1	4.94	1.09e-06	0.000272	0.32	0.22	Subjective well-being;	chr11:116967092	chr11:117135528~117138582:+
LUAD	cis	rs507080	0.961	rs642497	ENSG00000278376.1	RP11-158I9.8	-4.94	1.09e-06	0.000272	-0.23	-0.22	Serum metabolite levels;	chr11:118680075	chr11:118791254~118793137:+
LUAD	cis	rs910316	1	rs4899546	ENSG00000259138.1	RP11-950C14.7	4.94	1.09e-06	0.000272	0.23	0.22	Height;	chr14:75128243	chr14:75127153~75136930:+
LUAD	cis	rs113835537	0.935	rs1127145	ENSG00000255517.5	CTD-3074O7.5	-4.94	1.09e-06	0.000272	-0.32	-0.22	Airway imaging phenotypes;	chr11:66605834	chr11:66473490~66480233:-
LUAD	cis	rs1546924	0.692	rs197379	ENSG00000227811.2	FAM212B-AS1	-4.94	1.09e-06	0.000273	-0.27	-0.22	Body mass index;	chr1:111749681	chr1:111739841~111747798:+
LUAD	cis	rs2439831	0.85	rs9944216	ENSG00000249839.1	AC011330.5	4.94	1.09e-06	0.000273	0.45	0.22	Lung cancer in ever smokers;	chr15:43868575	chr15:43663654~43684339:-
LUAD	cis	rs7829975	0.742	rs882462	ENSG00000253981.4	ALG1L13P	4.94	1.09e-06	0.000273	0.26	0.22	Mood instability;	chr8:8821020	chr8:8236003~8244667:-
LUAD	cis	rs4835473	0.932	rs1988206	ENSG00000251600.4	RP11-673E1.1	4.94	1.09e-06	0.000273	0.27	0.22	Immature fraction of reticulocytes;	chr4:143991344	chr4:143912331~143982454:+
LUAD	cis	rs6687758	1	rs17011200	ENSG00000228437.4	RP11-400N13.2	4.94	1.09e-06	0.000273	0.32	0.22	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222018163	chr1:221966341~221984964:+
LUAD	cis	rs17406451	0.655	rs10188861	ENSG00000279873.2	LINC01126	4.94	1.09e-06	0.000273	0.18	0.22	Mitochondrial DNA levels;	chr2:43538971	chr2:43227210~43228855:+
LUAD	cis	rs8050896	1	rs6499064	ENSG00000260695.1	RP11-513N24.1	-4.94	1.09e-06	0.000273	-0.44	-0.22	Response to antipsychotic treatment;	chr16:66127526	chr16:65861112~65863784:-
LUAD	cis	rs8040855	0.657	rs6496733	ENSG00000259774.1	RP11-182J1.13	-4.94	1.09e-06	0.000273	-0.28	-0.22	Bulimia nervosa;	chr15:85129945	chr15:84422618~84425882:+
LUAD	cis	rs10181042	0.612	rs1177282	ENSG00000271889.1	RP11-493E12.1	4.94	1.09e-06	0.000273	0.27	0.22	Crohn's disease;	chr2:61130642	chr2:61151433~61162105:-
LUAD	cis	rs10246939	0.505	rs892354	ENSG00000270923.1	TAS2R6P	-4.94	1.09e-06	0.000273	-0.26	-0.22	Bitter taste perception;	chr7:141844934	chr7:141787815~141788640:+
LUAD	cis	rs2554380	0.628	rs963690	ENSG00000230373.7	GOLGA6L5P	-4.94	1.09e-06	0.000273	-0.23	-0.22	Height;	chr15:83771068	chr15:84507885~84516814:-
LUAD	cis	rs6840258	1	rs75550773	ENSG00000251411.1	RP11-397E7.4	-4.94	1.09e-06	0.000273	-0.28	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87034271	chr4:86913266~86914817:-
LUAD	cis	rs7017914	0.652	rs17760766	ENSG00000223220.1	Y_RNA	4.94	1.09e-06	0.000273	0.25	0.22	Bone mineral density;	chr8:70758954	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs1444343	ENSG00000223220.1	Y_RNA	4.94	1.09e-06	0.000273	0.25	0.22	Bone mineral density;	chr8:70760749	chr8:70780914~70781008:-
LUAD	cis	rs1914816	0.653	rs157766	ENSG00000196274.5	Metazoa_SRP	-4.94	1.09e-06	0.000274	-0.27	-0.22	Response to tocilizumab in rheumatoid arthritis;	chr15:76495181	chr15:76230048~76230390:-
LUAD	cis	rs12530	0.651	rs2072816	ENSG00000230736.2	RP1-149A16.3	-4.94	1.09e-06	0.000274	-0.24	-0.22	IgG glycosylation;	chr22:32394411	chr22:32376664~32384343:+
LUAD	cis	rs36423	0.748	rs36388	ENSG00000266869.1	RP6-114E22.1	-4.94	1.09e-06	0.000274	-0.33	-0.22	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71898959	chr14:71848606~71908430:+
LUAD	cis	rs2439831	0.85	rs3742982	ENSG00000249839.1	AC011330.5	-4.94	1.09e-06	0.000274	-0.45	-0.22	Lung cancer in ever smokers;	chr15:43884483	chr15:43663654~43684339:-
LUAD	cis	rs4820294	0.669	rs732857	ENSG00000233360.4	Z83844.1	4.94	1.09e-06	0.000274	0.22	0.22	Fat distribution (HIV);	chr22:37664843	chr22:37641832~37658377:-
LUAD	cis	rs36093844	0.898	rs11234463	ENSG00000279742.1	RP11-700A24.1	-4.94	1.09e-06	0.000274	-0.26	-0.22	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85886042	chr11:85852557~85854943:-
LUAD	cis	rs6840258	0.943	rs72667748	ENSG00000251411.1	RP11-397E7.4	-4.94	1.09e-06	0.000274	-0.28	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87005882	chr4:86913266~86914817:-
LUAD	cis	rs17818399	0.926	rs13032670	ENSG00000279254.1	RP11-536C12.1	-4.94	1.1e-06	0.000274	-0.25	-0.22	Height;	chr2:46603655	chr2:46668870~46670778:+
LUAD	cis	rs17818399	0.926	rs13033177	ENSG00000279254.1	RP11-536C12.1	-4.94	1.1e-06	0.000274	-0.25	-0.22	Height;	chr2:46603923	chr2:46668870~46670778:+
LUAD	cis	rs113835537	0.866	rs59566349	ENSG00000255517.5	CTD-3074O7.5	-4.94	1.1e-06	0.000274	-0.32	-0.22	Airway imaging phenotypes;	chr11:66598523	chr11:66473490~66480233:-
LUAD	cis	rs795484	0.507	rs2249624	ENSG00000275759.1	RP11-131L12.3	4.94	1.1e-06	0.000274	0.23	0.22	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118151264	chr12:118428281~118428870:+
LUAD	cis	rs9322193	0.607	rs9371228	ENSG00000223701.3	RAET1E-AS1	-4.94	1.1e-06	0.000274	-0.31	-0.22	Lung cancer;	chr6:149921977	chr6:149884431~149919508:+
LUAD	cis	rs2998286	0.862	rs1416817	ENSG00000254635.4	WAC-AS1	-4.94	1.1e-06	0.000274	-0.27	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28503548	chr10:28522652~28532743:-
LUAD	cis	rs2098713	0.535	rs56288111	ENSG00000250155.1	CTD-2353F22.1	4.94	1.1e-06	0.000274	0.23	0.22	Telomere length;	chr5:37619340	chr5:36666214~36725195:-
LUAD	cis	rs1275468	1	rs1679381	ENSG00000257497.2	RP11-585P4.5	-4.94	1.1e-06	0.000274	-0.3	-0.22	Polycystic ovary syndrome;	chr12:75552344	chr12:75483454~75489820:-
LUAD	cis	rs2732480	0.5	rs7315820	ENSG00000257735.1	RP11-370I10.6	4.94	1.1e-06	0.000274	0.26	0.22	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48205155	chr12:48350945~48442411:+
LUAD	cis	rs55823223	0.648	rs936393	ENSG00000267801.1	RP11-552F3.9	4.94	1.1e-06	0.000274	0.25	0.22	Psoriasis;	chr17:75851532	chr17:75876372~75879546:+
LUAD	cis	rs4908768	0.501	rs1463051	ENSG00000270282.1	RP5-1115A15.2	-4.94	1.1e-06	0.000275	-0.24	-0.22	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8536834	chr1:8512653~8513021:+
LUAD	cis	rs11155671	0.53	rs1334510	ENSG00000268592.3	RAET1E-AS1	4.94	1.1e-06	0.000275	0.27	0.22	Testicular germ cell tumor;	chr6:149880043	chr6:149863494~149919507:+
LUAD	cis	rs11841001	0.556	rs17065026	ENSG00000261105.4	LMO7-AS1	4.94	1.1e-06	0.000275	0.34	0.22	Corneal astigmatism;	chr13:75779020	chr13:75604700~75635994:-
LUAD	cis	rs80028505	0.614	rs3761980	ENSG00000271304.1	DPRXP2	-4.94	1.1e-06	0.000275	-0.4	-0.22	Foot ulcer in diabetes and neuropathy;	chr6:36026129	chr6:35989515~35990436:-
LUAD	cis	rs11976180	1	rs67239267	ENSG00000170356.8	OR2A20P	-4.94	1.1e-06	0.000275	-0.28	-0.22	Obesity-related traits;	chr7:144048023	chr7:144250045~144252957:-
LUAD	cis	rs4835473	0.868	rs4350958	ENSG00000251600.4	RP11-673E1.1	4.94	1.1e-06	0.000275	0.27	0.22	Immature fraction of reticulocytes;	chr4:143744656	chr4:143912331~143982454:+
LUAD	cis	rs2742234	0.59	rs2435376	ENSG00000273008.1	RP11-351D16.3	-4.94	1.1e-06	0.000275	-0.25	-0.22	Hirschsprung disease;	chr10:43189515	chr10:43136824~43138334:-
LUAD	cis	rs2742234	0.579	rs2503881	ENSG00000273008.1	RP11-351D16.3	-4.94	1.1e-06	0.000275	-0.25	-0.22	Hirschsprung disease;	chr10:43190578	chr10:43136824~43138334:-
LUAD	cis	rs7727544	0.716	rs4705926	ENSG00000233006.5	AC034220.3	4.94	1.1e-06	0.000275	0.19	0.22	Blood metabolite levels;	chr5:132226065	chr5:132311285~132369916:-
LUAD	cis	rs910316	1	rs876402	ENSG00000259138.1	RP11-950C14.7	-4.94	1.1e-06	0.000276	-0.23	-0.22	Height;	chr14:75135159	chr14:75127153~75136930:+
LUAD	cis	rs3747113	0.865	rs9620384	ENSG00000128262.7	POM121L9P	-4.94	1.1e-06	0.000276	-0.24	-0.22	Gut microbiome composition (summer);	chr22:24379380	chr22:24251828~24265525:+
LUAD	cis	rs57502260	0.749	rs67446678	ENSG00000212093.1	AP000807.1	4.94	1.1e-06	0.000276	0.29	0.22	Total body bone mineral density (age 45-60);	chr11:68459998	chr11:68506083~68506166:-
LUAD	cis	rs17684571	0.7	rs35642890	ENSG00000231441.1	RP11-472M19.2	4.94	1.1e-06	0.000276	0.3	0.22	Schizophrenia;	chr6:56809919	chr6:56844002~56864078:+
LUAD	cis	rs11673344	0.931	rs7256746	ENSG00000226686.6	LINC01535	4.94	1.1e-06	0.000276	0.25	0.22	Obesity-related traits;	chr19:37175073	chr19:37251912~37265535:+
LUAD	cis	rs6751744	0.889	rs12692553	ENSG00000226266.5	AC009961.3	-4.94	1.1e-06	0.000276	-0.33	-0.22	Dysphagia;	chr2:159534337	chr2:159670708~159712435:-
LUAD	cis	rs4964805	0.657	rs1866293	ENSG00000257681.1	RP11-341G23.4	4.94	1.1e-06	0.000276	0.23	0.22	Attention deficit hyperactivity disorder;	chr12:103792877	chr12:103746315~103768858:-
LUAD	cis	rs4964805	0.657	rs1866294	ENSG00000257681.1	RP11-341G23.4	4.94	1.1e-06	0.000276	0.23	0.22	Attention deficit hyperactivity disorder;	chr12:103793017	chr12:103746315~103768858:-
LUAD	cis	rs4964805	0.71	rs1866296	ENSG00000257681.1	RP11-341G23.4	4.94	1.1e-06	0.000276	0.23	0.22	Attention deficit hyperactivity disorder;	chr12:103793314	chr12:103746315~103768858:-
LUAD	cis	rs3750965	1	rs3750965	ENSG00000260895.1	RP11-554A11.7	4.94	1.11e-06	0.000276	0.26	0.22	Hair color;	chr11:69072692	chr11:69103493~69109094:+
LUAD	cis	rs7829975	0.533	rs1039917	ENSG00000253981.4	ALG1L13P	4.94	1.11e-06	0.000277	0.26	0.22	Mood instability;	chr8:8861340	chr8:8236003~8244667:-
LUAD	cis	rs13315649	0.614	rs7609765	ENSG00000242551.2	POU5F1P6	-4.94	1.11e-06	0.000277	-0.28	-0.22	Sum eosinophil basophil counts;	chr3:128688295	chr3:128674735~128677005:-
LUAD	cis	rs13315649	0.639	rs7612926	ENSG00000242551.2	POU5F1P6	-4.94	1.11e-06	0.000277	-0.28	-0.22	Sum eosinophil basophil counts;	chr3:128689221	chr3:128674735~128677005:-
LUAD	cis	rs9860428	0.844	rs9852286	ENSG00000242770.2	RP11-180K7.1	4.94	1.11e-06	0.000277	0.23	0.22	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112896161	chr3:112802478~112812819:+
LUAD	cis	rs4664293	0.867	rs1126842	ENSG00000226266.5	AC009961.3	-4.94	1.11e-06	0.000277	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159770806	chr2:159670708~159712435:-
LUAD	cis	rs7017914	0.593	rs2732140	ENSG00000223220.1	Y_RNA	4.93	1.11e-06	0.000277	0.25	0.22	Bone mineral density;	chr8:70998491	chr8:70780914~70781008:-
LUAD	cis	rs2115630	0.967	rs7171167	ENSG00000229212.6	RP11-561C5.4	4.93	1.11e-06	0.000277	0.26	0.22	P wave terminal force;	chr15:84695892	chr15:85205440~85234795:-
LUAD	cis	rs498872	0.507	rs10892247	ENSG00000255239.1	AP002954.6	-4.93	1.11e-06	0.000277	-0.32	-0.22	Glioma;	chr11:118619361	chr11:118688039~118690600:-
LUAD	cis	rs6687758	0.687	rs13375176	ENSG00000228437.4	RP11-400N13.2	4.93	1.11e-06	0.000277	0.31	0.22	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221926523	chr1:221966341~221984964:+
LUAD	cis	rs9322193	0.923	rs10782314	ENSG00000268592.3	RAET1E-AS1	4.93	1.11e-06	0.000277	0.27	0.22	Lung cancer;	chr6:149735527	chr6:149863494~149919507:+
LUAD	cis	rs453301	0.606	rs6601279	ENSG00000253893.2	FAM85B	4.93	1.11e-06	0.000277	0.28	0.22	Joint mobility (Beighton score);	chr8:9050721	chr8:8167819~8226614:-
LUAD	cis	rs453301	0.606	rs6981060	ENSG00000253893.2	FAM85B	4.93	1.11e-06	0.000277	0.28	0.22	Joint mobility (Beighton score);	chr8:9050725	chr8:8167819~8226614:-
LUAD	cis	rs116139393	0.561	rs62439737	ENSG00000187953.9	PMS2CL	-4.93	1.11e-06	0.000277	-0.28	-0.22	Alzheimer's disease (APOE e4 interaction);	chr7:6740179	chr7:6710128~6753862:+
LUAD	cis	rs10266483	0.654	rs6962076	ENSG00000271550.1	BNIP3P11	-4.93	1.11e-06	0.000277	-0.26	-0.22	Response to statin therapy;	chr7:64559214	chr7:64678954~64687393:-
LUAD	cis	rs801193	1	rs1553609	ENSG00000237310.1	GS1-124K5.4	4.93	1.11e-06	0.000277	0.24	0.22	Aortic root size;	chr7:66732152	chr7:66493706~66495474:+
LUAD	cis	rs6952407	1	rs6952407	ENSG00000224316.1	RP11-479O9.2	-4.93	1.11e-06	0.000277	-0.22	-0.22	Cotinine glucuronidation;	chr7:66580525	chr7:65773620~65802067:+
LUAD	cis	rs7598759	0.712	rs12991636	ENSG00000181798.2	LINC00471	-4.93	1.11e-06	0.000278	-0.24	-0.22	Noise-induced hearing loss;	chr2:231468955	chr2:231508426~231514339:-
LUAD	cis	rs1113500	0.748	rs1781048	ENSG00000226822.1	RP11-356N1.2	4.93	1.11e-06	0.000278	0.26	0.22	Growth-regulated protein alpha levels;	chr1:108012428	chr1:108071482~108074519:+
LUAD	cis	rs2617170	0.922	rs2733852	ENSG00000245648.1	RP11-277P12.20	-4.93	1.11e-06	0.000278	-0.27	-0.22	Behcet's disease;	chr12:10375969	chr12:10363769~10398506:+
LUAD	cis	rs9322193	0.923	rs9479810	ENSG00000268592.3	RAET1E-AS1	4.93	1.11e-06	0.000278	0.27	0.22	Lung cancer;	chr6:149751359	chr6:149863494~149919507:+
LUAD	cis	rs2286503	0.78	rs2286506	ENSG00000226329.2	AC005682.6	4.93	1.11e-06	0.000278	0.29	0.22	Fibrinogen;	chr7:22815196	chr7:22863874~22881350:-
LUAD	cis	rs2286503	0.752	rs2286504	ENSG00000226329.2	AC005682.6	4.93	1.11e-06	0.000278	0.29	0.22	Fibrinogen;	chr7:22815228	chr7:22863874~22881350:-
LUAD	cis	rs35160687	0.644	rs57270703	ENSG00000273080.1	RP11-301O19.1	-4.93	1.11e-06	0.000278	-0.25	-0.22	Night sleep phenotypes;	chr2:86289750	chr2:86195590~86196049:+
LUAD	cis	rs2018683	1	rs2018683	ENSG00000228421.2	AC005013.5	4.93	1.11e-06	0.000278	0.23	0.22	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28974579	chr7:28957667~28959345:+
LUAD	cis	rs801193	0.548	rs2109297	ENSG00000232559.3	GS1-124K5.12	-4.93	1.11e-06	0.000278	-0.26	-0.22	Aortic root size;	chr7:66657397	chr7:66554588~66576923:-
LUAD	cis	rs801193	0.591	rs721717	ENSG00000232559.3	GS1-124K5.12	-4.93	1.11e-06	0.000278	-0.26	-0.22	Aortic root size;	chr7:66665305	chr7:66554588~66576923:-
LUAD	cis	rs801193	0.569	rs6951302	ENSG00000232559.3	GS1-124K5.12	-4.93	1.11e-06	0.000278	-0.26	-0.22	Aortic root size;	chr7:66667525	chr7:66554588~66576923:-
LUAD	cis	rs1075232	1	rs12438318	ENSG00000215302.7	CTD-3092A11.1	-4.93	1.11e-06	0.000278	-0.5	-0.22	Survival in colorectal cancer (non-distant metastatic);	chr15:31388242	chr15:30470779~30507623:+
LUAD	cis	rs7665090	0.967	rs228611	ENSG00000246560.2	RP11-10L12.4	-4.93	1.11e-06	0.000278	-0.27	-0.22	Primary biliary cholangitis;	chr4:102640552	chr4:102828055~102844075:+
LUAD	cis	rs950169	0.922	rs12912934	ENSG00000259295.5	CSPG4P12	4.93	1.11e-06	0.000278	0.32	0.22	Schizophrenia;	chr15:84571216	chr15:85191438~85213905:+
LUAD	cis	rs2243480	1	rs1039664	ENSG00000226002.1	RP11-460N20.5	-4.93	1.11e-06	0.000278	-0.36	-0.22	Diabetic kidney disease;	chr7:65984729	chr7:65084103~65100232:+
LUAD	cis	rs853679	1	rs7740487	ENSG00000204709.4	LINC01556	4.93	1.11e-06	0.000278	0.35	0.22	Depression;	chr6:28248708	chr6:28943877~28944537:+
LUAD	cis	rs853679	1	rs68141011	ENSG00000204709.4	LINC01556	4.93	1.11e-06	0.000278	0.35	0.22	Depression;	chr6:28250019	chr6:28943877~28944537:+
LUAD	cis	rs853679	1	rs13200462	ENSG00000204709.4	LINC01556	4.93	1.11e-06	0.000278	0.35	0.22	Depression;	chr6:28250421	chr6:28943877~28944537:+
LUAD	cis	rs4568518	0.53	rs7802064	ENSG00000279048.1	RP11-511H23.2	4.93	1.11e-06	0.000278	0.18	0.22	Measles;	chr7:17955230	chr7:17940503~17942922:+
LUAD	cis	rs7430456	0.874	rs7428501	ENSG00000225790.1	RP11-2L8.1	-4.93	1.11e-06	0.000278	-0.26	-0.22	Breast cancer;	chr3:177751974	chr3:177934823~177937662:+
LUAD	cis	rs2998286	0.643	rs332181	ENSG00000254635.4	WAC-AS1	-4.93	1.11e-06	0.000278	-0.29	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28621187	chr10:28522652~28532743:-
LUAD	cis	rs12908161	1	rs36033486	ENSG00000275120.1	RP11-182J1.17	4.93	1.11e-06	0.000278	0.33	0.22	Schizophrenia;	chr15:84776461	chr15:84599434~84606463:-
LUAD	cis	rs12908161	1	rs12908549	ENSG00000275120.1	RP11-182J1.17	4.93	1.11e-06	0.000278	0.33	0.22	Schizophrenia;	chr15:84779120	chr15:84599434~84606463:-
LUAD	cis	rs35160687	0.644	rs2367232	ENSG00000273080.1	RP11-301O19.1	-4.93	1.11e-06	0.000278	-0.25	-0.22	Night sleep phenotypes;	chr2:86314368	chr2:86195590~86196049:+
LUAD	cis	rs61270009	0.955	rs454693	ENSG00000247828.6	TMEM161B-AS1	4.93	1.11e-06	0.000279	0.24	0.22	Depressive symptoms;	chr5:88248396	chr5:88268895~88436685:+
LUAD	cis	rs17818399	0.926	rs35350086	ENSG00000279254.1	RP11-536C12.1	-4.93	1.11e-06	0.000279	-0.25	-0.22	Height;	chr2:46606897	chr2:46668870~46670778:+
LUAD	cis	rs4660214	0.614	rs6688708	ENSG00000228060.1	RP11-69E11.8	4.93	1.12e-06	0.000279	0.2	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39293321	chr1:39565160~39573203:+
LUAD	cis	rs2310173	0.575	rs2071008	ENSG00000281162.1	LINC01127	-4.93	1.12e-06	0.000279	-0.25	-0.22	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:101998817	chr2:101962056~101987167:+
LUAD	cis	rs301901	1	rs184182	ENSG00000250155.1	CTD-2353F22.1	-4.93	1.12e-06	0.000279	-0.23	-0.22	Height;	chr5:37005003	chr5:36666214~36725195:-
LUAD	cis	rs2688608	0.592	rs13013	ENSG00000271816.1	BMS1P4	4.93	1.12e-06	0.000279	0.18	0.22	Inflammatory bowel disease;	chr10:73802403	chr10:73699151~73730487:-
LUAD	cis	rs2742234	0.955	rs1800861	ENSG00000273008.1	RP11-351D16.3	-4.93	1.12e-06	0.000279	-0.24	-0.22	Hirschsprung disease;	chr10:43118395	chr10:43136824~43138334:-
LUAD	cis	rs2742234	0.955	rs2075910	ENSG00000273008.1	RP11-351D16.3	-4.93	1.12e-06	0.000279	-0.24	-0.22	Hirschsprung disease;	chr10:43118782	chr10:43136824~43138334:-
LUAD	cis	rs2028299	0.92	rs2043880	ENSG00000259677.1	RP11-493E3.1	4.93	1.12e-06	0.000279	0.27	0.22	Type 2 diabetes;	chr15:89889294	chr15:89876540~89877285:+
LUAD	cis	rs875971	0.862	rs6958294	ENSG00000232559.3	GS1-124K5.12	-4.93	1.12e-06	0.000279	-0.26	-0.22	Aortic root size;	chr7:66329809	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs2088655	ENSG00000232559.3	GS1-124K5.12	-4.93	1.12e-06	0.000279	-0.26	-0.22	Aortic root size;	chr7:66330724	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.895	rs10447522	ENSG00000232559.3	GS1-124K5.12	-4.93	1.12e-06	0.000279	-0.26	-0.22	Aortic root size;	chr7:66331087	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs2088653	ENSG00000232559.3	GS1-124K5.12	-4.93	1.12e-06	0.000279	-0.26	-0.22	Aortic root size;	chr7:66343621	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs778736	ENSG00000232559.3	GS1-124K5.12	4.93	1.12e-06	0.000279	0.26	0.22	Aortic root size;	chr7:66348861	chr7:66554588~66576923:-
LUAD	cis	rs8180040	0.764	rs13061071	ENSG00000271161.1	BOLA2P2	4.93	1.12e-06	0.000279	0.21	0.22	Colorectal cancer;	chr3:47097218	chr3:47499841~47500407:+
LUAD	cis	rs2404602	1	rs6495206	ENSG00000259422.1	RP11-593F23.1	4.93	1.12e-06	0.000279	0.26	0.22	Blood metabolite levels;	chr15:76578622	chr15:76174891~76181486:-
LUAD	cis	rs2404602	1	rs1117367	ENSG00000259422.1	RP11-593F23.1	4.93	1.12e-06	0.000279	0.26	0.22	Blood metabolite levels;	chr15:76579989	chr15:76174891~76181486:-
LUAD	cis	rs2033711	0.87	rs4801270	ENSG00000268912.1	CTD-2619J13.17	-4.93	1.12e-06	0.000279	-0.23	-0.22	Uric acid clearance;	chr19:58421395	chr19:58428632~58431148:-
LUAD	cis	rs2239547	0.657	rs2071040	ENSG00000242142.1	SERBP1P3	4.93	1.12e-06	0.00028	0.27	0.22	Schizophrenia;	chr3:52830844	chr3:53064283~53065091:-
LUAD	cis	rs7688540	0.8	rs61792060	ENSG00000211553.1	AC253576.2	-4.93	1.12e-06	0.00028	-0.28	-0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:262661	chr4:136461~136568:+
LUAD	cis	rs2310173	0.575	rs757918	ENSG00000281162.1	LINC01127	-4.93	1.12e-06	0.00028	-0.25	-0.22	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:101996837	chr2:101962056~101987167:+
LUAD	cis	rs12468226	1	rs12468226	ENSG00000272966.1	RP11-686O6.1	4.93	1.12e-06	0.00028	0.36	0.22	Urate levels;	chr2:202472278	chr2:202336739~202337200:+
LUAD	cis	rs12468226	1	rs74508472	ENSG00000272966.1	RP11-686O6.1	4.93	1.12e-06	0.00028	0.36	0.22	Urate levels;	chr2:202517290	chr2:202336739~202337200:+
LUAD	cis	rs12908161	1	rs56864281	ENSG00000275120.1	RP11-182J1.17	4.93	1.12e-06	0.00028	0.33	0.22	Schizophrenia;	chr15:84814418	chr15:84599434~84606463:-
LUAD	cis	rs41307935	0.908	rs17162313	ENSG00000260063.1	RP5-968P14.2	4.93	1.12e-06	0.00028	0.39	0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26849628	chr1:26692132~26694131:-
LUAD	cis	rs2243480	1	rs427044	ENSG00000164669.11	INTS4P1	4.93	1.12e-06	0.00028	0.39	0.22	Diabetic kidney disease;	chr7:66043558	chr7:65141225~65234216:+
LUAD	cis	rs17660992	1	rs17660992	ENSG00000273837.1	LLNLR-470E3.1	-4.93	1.12e-06	0.00028	-0.24	-0.22	Blood protein levels;	chr19:51660695	chr19:51639478~51639931:-
LUAD	cis	rs7829975	0.617	rs4841071	ENSG00000173295.6	FAM86B3P	4.93	1.12e-06	0.00028	0.22	0.22	Mood instability;	chr8:8933634	chr8:8228595~8244865:+
LUAD	cis	rs7017914	0.653	rs6983845	ENSG00000223220.1	Y_RNA	4.93	1.12e-06	0.00028	0.25	0.22	Bone mineral density;	chr8:70834245	chr8:70780914~70781008:-
LUAD	cis	rs7829975	0.572	rs28730413	ENSG00000253893.2	FAM85B	4.93	1.12e-06	0.00028	0.28	0.22	Mood instability;	chr8:8937937	chr8:8167819~8226614:-
LUAD	cis	rs1799949	0.965	rs799910	ENSG00000236383.6	LINC00854	-4.93	1.12e-06	0.000281	-0.17	-0.22	Menopause (age at onset);	chr17:43127544	chr17:43216941~43305976:-
LUAD	cis	rs2998286	0.592	rs606044	ENSG00000254635.4	WAC-AS1	-4.93	1.12e-06	0.000281	-0.32	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28671206	chr10:28522652~28532743:-
LUAD	cis	rs875971	0.54	rs736270	ENSG00000236529.1	RP13-254B10.1	4.93	1.12e-06	0.000281	0.22	0.22	Aortic root size;	chr7:65963835	chr7:65840212~65840596:+
LUAD	cis	rs7688540	0.8	rs73793597	ENSG00000211553.1	AC253576.2	-4.93	1.12e-06	0.000281	-0.28	-0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:262116	chr4:136461~136568:+
LUAD	cis	rs14027	0.883	rs13272852	ENSG00000279347.1	RP11-85I17.2	-4.93	1.13e-06	0.000281	-0.19	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119712921	chr8:119838736~119840385:-
LUAD	cis	rs150992	0.603	rs161732	ENSG00000248489.1	CTD-2007H13.3	-4.93	1.13e-06	0.000281	-0.27	-0.22	Body mass index;	chr5:98941418	chr5:98929171~98995013:+
LUAD	cis	rs3738443	0.904	rs12562191	ENSG00000259865.1	RP11-488L18.10	4.93	1.13e-06	0.000281	0.24	0.22	Alcohol dependence;	chr1:247234227	chr1:247187281~247188526:-
LUAD	cis	rs3738443	0.904	rs12569090	ENSG00000259865.1	RP11-488L18.10	4.93	1.13e-06	0.000281	0.24	0.22	Alcohol dependence;	chr1:247234370	chr1:247187281~247188526:-
LUAD	cis	rs8077577	0.689	rs16961133	ENSG00000273018.4	CTD-2303H24.2	-4.93	1.13e-06	0.000281	-0.31	-0.22	Obesity-related traits;	chr17:18320234	chr17:18511221~18551705:-
LUAD	cis	rs8077577	0.747	rs57697650	ENSG00000273018.4	CTD-2303H24.2	-4.93	1.13e-06	0.000281	-0.31	-0.22	Obesity-related traits;	chr17:18321381	chr17:18511221~18551705:-
LUAD	cis	rs12745968	0.623	rs4294424	ENSG00000223787.2	RP4-593M8.1	-4.93	1.13e-06	0.000281	-0.26	-0.22	Bipolar disorder and schizophrenia;	chr1:92673817	chr1:92580476~92580821:-
LUAD	cis	rs7829975	0.774	rs35431455	ENSG00000253981.4	ALG1L13P	4.93	1.13e-06	0.000281	0.25	0.22	Mood instability;	chr8:8816226	chr8:8236003~8244667:-
LUAD	cis	rs2243480	1	rs313813	ENSG00000164669.11	INTS4P1	4.93	1.13e-06	0.000281	0.39	0.22	Diabetic kidney disease;	chr7:66038513	chr7:65141225~65234216:+
LUAD	cis	rs301901	0.772	rs301874	ENSG00000250155.1	CTD-2353F22.1	-4.93	1.13e-06	0.000281	-0.24	-0.22	Height;	chr5:37094189	chr5:36666214~36725195:-
LUAD	cis	rs8040855	0.756	rs12909477	ENSG00000259774.1	RP11-182J1.13	-4.93	1.13e-06	0.000282	-0.29	-0.22	Bulimia nervosa;	chr15:85146644	chr15:84422618~84425882:+
LUAD	cis	rs8031584	0.678	rs4779496	ENSG00000259845.1	HERC2P10	4.93	1.13e-06	0.000282	0.27	0.22	Huntington's disease progression;	chr15:30858851	chr15:30815271~30844153:+
LUAD	cis	rs8031584	0.678	rs4779497	ENSG00000259845.1	HERC2P10	4.93	1.13e-06	0.000282	0.27	0.22	Huntington's disease progression;	chr15:30859162	chr15:30815271~30844153:+
LUAD	cis	rs8031584	0.678	rs8028173	ENSG00000259845.1	HERC2P10	4.93	1.13e-06	0.000282	0.27	0.22	Huntington's disease progression;	chr15:30863546	chr15:30815271~30844153:+
LUAD	cis	rs8031584	0.706	rs2177670	ENSG00000259845.1	HERC2P10	4.93	1.13e-06	0.000282	0.27	0.22	Huntington's disease progression;	chr15:30865548	chr15:30815271~30844153:+
LUAD	cis	rs8031584	0.678	rs36047941	ENSG00000259845.1	HERC2P10	4.93	1.13e-06	0.000282	0.27	0.22	Huntington's disease progression;	chr15:30867032	chr15:30815271~30844153:+
LUAD	cis	rs6840258	1	rs114701347	ENSG00000251411.1	RP11-397E7.4	-4.93	1.13e-06	0.000282	-0.28	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87043849	chr4:86913266~86914817:-
LUAD	cis	rs801193	1	rs2659912	ENSG00000236529.1	RP13-254B10.1	4.93	1.13e-06	0.000282	0.22	0.22	Aortic root size;	chr7:66693012	chr7:65840212~65840596:+
LUAD	cis	rs42490	0.903	rs218944	ENSG00000251136.7	RP11-37B2.1	-4.93	1.13e-06	0.000282	-0.23	-0.22	Leprosy;	chr8:89701839	chr8:89609409~89757727:-
LUAD	cis	rs2836950	0.565	rs2836943	ENSG00000255568.3	BRWD1-AS2	-4.93	1.13e-06	0.000282	-0.21	-0.22	Menarche (age at onset);	chr21:39220685	chr21:39313935~39314962:+
LUAD	cis	rs4143844	0.867	rs11629741	ENSG00000259251.2	RP11-643M14.1	4.93	1.13e-06	0.000282	0.39	0.22	Bipolar disorder and schizophrenia;	chr15:61892783	chr15:62060503~62062434:+
LUAD	cis	rs4143844	0.867	rs34796280	ENSG00000259251.2	RP11-643M14.1	4.93	1.13e-06	0.000282	0.39	0.22	Bipolar disorder and schizophrenia;	chr15:61893680	chr15:62060503~62062434:+
LUAD	cis	rs12908161	1	rs12905057	ENSG00000259295.5	CSPG4P12	4.93	1.13e-06	0.000282	0.31	0.22	Schizophrenia;	chr15:84667534	chr15:85191438~85213905:+
LUAD	cis	rs1707322	1	rs7527079	ENSG00000280836.1	AL355480.1	-4.93	1.13e-06	0.000283	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45947778	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs34446427	ENSG00000280836.1	AL355480.1	-4.93	1.13e-06	0.000283	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45951983	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.963	rs4660900	ENSG00000280836.1	AL355480.1	-4.93	1.13e-06	0.000283	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45953933	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs4454479	ENSG00000280836.1	AL355480.1	-4.93	1.13e-06	0.000283	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45957883	chr1:45581219~45581321:-
LUAD	cis	rs2836950	0.501	rs35994303	ENSG00000255568.3	BRWD1-AS2	-4.93	1.13e-06	0.000283	-0.21	-0.22	Menarche (age at onset);	chr21:39314094	chr21:39313935~39314962:+
LUAD	cis	rs2439831	0.867	rs4075674	ENSG00000249839.1	AC011330.5	-4.93	1.13e-06	0.000283	-0.39	-0.22	Lung cancer in ever smokers;	chr15:43358032	chr15:43663654~43684339:-
LUAD	cis	rs12681366	0.839	rs3019281	ENSG00000253704.1	RP11-267M23.4	4.93	1.13e-06	0.000283	0.27	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94438061	chr8:94553722~94569745:+
LUAD	cis	rs10129255	0.957	rs12590799	ENSG00000274576.2	IGHV2-70	4.93	1.14e-06	0.000283	0.19	0.22	Kawasaki disease;	chr14:106779713	chr14:106770577~106771020:-
LUAD	cis	rs9425766	0.566	rs4447042	ENSG00000227373.4	RP11-160H22.5	4.93	1.14e-06	0.000283	0.28	0.22	Life satisfaction;	chr1:174212747	chr1:174115300~174160004:-
LUAD	cis	rs4835473	0.932	rs13103072	ENSG00000251600.4	RP11-673E1.1	-4.93	1.14e-06	0.000283	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143952116	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.864	rs28609839	ENSG00000251600.4	RP11-673E1.1	-4.93	1.14e-06	0.000283	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143954160	chr4:143912331~143982454:+
LUAD	cis	rs1799949	1	rs8176202	ENSG00000236383.6	LINC00854	-4.93	1.14e-06	0.000283	-0.18	-0.22	Menopause (age at onset);	chr17:43078211	chr17:43216941~43305976:-
LUAD	cis	rs6840258	1	rs72667752	ENSG00000251411.1	RP11-397E7.4	-4.93	1.14e-06	0.000283	-0.28	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87018379	chr4:86913266~86914817:-
LUAD	cis	rs6840258	1	rs72667754	ENSG00000251411.1	RP11-397E7.4	-4.93	1.14e-06	0.000283	-0.28	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87020909	chr4:86913266~86914817:-
LUAD	cis	rs6840258	1	rs56390363	ENSG00000251411.1	RP11-397E7.4	-4.93	1.14e-06	0.000283	-0.28	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87021935	chr4:86913266~86914817:-
LUAD	cis	rs6840258	1	rs56050898	ENSG00000251411.1	RP11-397E7.4	-4.93	1.14e-06	0.000283	-0.28	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87024223	chr4:86913266~86914817:-
LUAD	cis	rs1799949	1	rs16941	ENSG00000236383.6	LINC00854	-4.93	1.14e-06	0.000283	-0.18	-0.22	Menopause (age at onset);	chr17:43092418	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs16940	ENSG00000236383.6	LINC00854	-4.93	1.14e-06	0.000283	-0.18	-0.22	Menopause (age at onset);	chr17:43093220	chr17:43216941~43305976:-
LUAD	cis	rs7615952	0.576	rs1127717	ENSG00000171084.14	FAM86JP	4.93	1.14e-06	0.000283	0.31	0.22	Blood pressure (smoking interaction);	chr3:126107216	chr3:125916620~125930024:+
LUAD	cis	rs17684571	0.938	rs6924375	ENSG00000231441.1	RP11-472M19.2	4.93	1.14e-06	0.000283	0.29	0.22	Schizophrenia;	chr6:56696993	chr6:56844002~56864078:+
LUAD	cis	rs62355901	0.8	rs7709971	ENSG00000271828.1	CTD-2310F14.1	4.93	1.14e-06	0.000284	0.32	0.22	Breast cancer;	chr5:56711512	chr5:56927874~56929573:+
LUAD	cis	rs950169	0.922	rs11630760	ENSG00000259295.5	CSPG4P12	4.93	1.14e-06	0.000284	0.32	0.22	Schizophrenia;	chr15:84570106	chr15:85191438~85213905:+
LUAD	cis	rs950169	0.887	rs71395453	ENSG00000259295.5	CSPG4P12	4.93	1.14e-06	0.000284	0.32	0.22	Schizophrenia;	chr15:84570259	chr15:85191438~85213905:+
LUAD	cis	rs950169	0.922	rs11633075	ENSG00000259295.5	CSPG4P12	4.93	1.14e-06	0.000284	0.32	0.22	Schizophrenia;	chr15:84570741	chr15:85191438~85213905:+
LUAD	cis	rs720475	0.732	rs62483107	ENSG00000170356.8	OR2A20P	4.93	1.14e-06	0.000284	0.31	0.22	Breast cancer;	chr7:144442144	chr7:144250045~144252957:-
LUAD	cis	rs720475	0.695	rs62483108	ENSG00000170356.8	OR2A20P	4.93	1.14e-06	0.000284	0.31	0.22	Breast cancer;	chr7:144442326	chr7:144250045~144252957:-
LUAD	cis	rs2032366	1	rs1894095	ENSG00000267279.1	RP11-879F14.2	-4.93	1.14e-06	0.000284	-0.27	-0.22	Obesity-related traits;	chr18:61605988	chr18:61585746~61606916:-
LUAD	cis	rs17666538	0.642	rs7821983	ENSG00000254207.1	RP11-43A14.1	4.93	1.14e-06	0.000284	0.48	0.22	IgG glycosylation;	chr8:693696	chr8:725188~725877:-
LUAD	cis	rs957448	0.503	rs752460	ENSG00000253704.1	RP11-267M23.4	4.93	1.14e-06	0.000284	0.28	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94477994	chr8:94553722~94569745:+
LUAD	cis	rs12681366	0.801	rs4735293	ENSG00000253704.1	RP11-267M23.4	4.93	1.14e-06	0.000284	0.28	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94478175	chr8:94553722~94569745:+
LUAD	cis	rs34864796	0.547	rs200476	ENSG00000219392.1	RP1-265C24.5	-4.93	1.14e-06	0.000284	-0.31	-0.22	Lung function (FEV1/FVC);Lung function (FVC);Lung function (FEV1);	chr6:27800570	chr6:28115628~28116551:+
LUAD	cis	rs34034915	1	rs34034915	ENSG00000219392.1	RP1-265C24.5	-4.93	1.14e-06	0.000284	-0.27	-0.22	Hepatitis A;	chr6:27752924	chr6:28115628~28116551:+
LUAD	cis	rs4713118	0.527	rs36042294	ENSG00000219392.1	RP1-265C24.5	-4.93	1.14e-06	0.000284	-0.27	-0.22	Parkinson's disease;	chr6:27752933	chr6:28115628~28116551:+
LUAD	cis	rs2286503	0.78	rs929464	ENSG00000226329.2	AC005682.6	4.93	1.14e-06	0.000284	0.29	0.22	Fibrinogen;	chr7:22835151	chr7:22863874~22881350:-
LUAD	cis	rs6840360	1	rs6810860	ENSG00000270265.1	RP11-731D1.4	4.93	1.14e-06	0.000284	0.22	0.22	Intelligence (multi-trait analysis);	chr4:151682012	chr4:151333775~151353224:-
LUAD	cis	rs9322193	0.81	rs62439811	ENSG00000268592.3	RAET1E-AS1	4.93	1.14e-06	0.000284	0.28	0.22	Lung cancer;	chr6:149640416	chr6:149863494~149919507:+
LUAD	cis	rs801193	0.761	rs2659888	ENSG00000237310.1	GS1-124K5.4	4.93	1.14e-06	0.000284	0.23	0.22	Aortic root size;	chr7:66765184	chr7:66493706~66495474:+
LUAD	cis	rs7772486	0.754	rs2064185	ENSG00000235652.6	RP11-545I5.3	-4.93	1.14e-06	0.000284	-0.22	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145745678	chr6:145799409~145886585:+
LUAD	cis	rs11159086	0.793	rs17100414	ENSG00000259005.1	RP3-449M8.6	4.93	1.14e-06	0.000285	0.29	0.22	Advanced glycation end-product levels;	chr14:74467918	chr14:74474007~74474864:-
LUAD	cis	rs9425766	0.566	rs4442420	ENSG00000227373.4	RP11-160H22.5	4.93	1.14e-06	0.000285	0.28	0.22	Life satisfaction;	chr1:174199667	chr1:174115300~174160004:-
LUAD	cis	rs875971	0.522	rs1880556	ENSG00000236529.1	RP13-254B10.1	4.93	1.14e-06	0.000285	0.22	0.22	Aortic root size;	chr7:65967557	chr7:65840212~65840596:+
LUAD	cis	rs453301	0.606	rs7462373	ENSG00000233609.3	RP11-62H7.2	-4.93	1.14e-06	0.000285	-0.18	-0.22	Joint mobility (Beighton score);	chr8:9041808	chr8:8961200~8979025:+
LUAD	cis	rs13134327	0.513	rs7679687	ENSG00000251600.4	RP11-673E1.1	-4.93	1.14e-06	0.000285	-0.28	-0.22	Glycated hemoglobin levels;	chr4:144024031	chr4:143912331~143982454:+
LUAD	cis	rs66887589	0.776	rs10518337	ENSG00000245958.5	RP11-33B1.1	4.93	1.14e-06	0.000285	0.18	0.22	Diastolic blood pressure;	chr4:119653719	chr4:119454791~119552025:+
LUAD	cis	rs9322193	0.607	rs12210822	ENSG00000223701.3	RAET1E-AS1	4.93	1.14e-06	0.000285	0.31	0.22	Lung cancer;	chr6:149905356	chr6:149884431~149919508:+
LUAD	cis	rs9322193	1	rs9322193	ENSG00000268592.3	RAET1E-AS1	4.93	1.15e-06	0.000285	0.27	0.22	Lung cancer;	chr6:149598007	chr6:149863494~149919507:+
LUAD	cis	rs2998286	0.862	rs2998285	ENSG00000254635.4	WAC-AS1	4.93	1.15e-06	0.000285	0.27	0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28504310	chr10:28522652~28532743:-
LUAD	cis	rs1008375	0.931	rs2098151	ENSG00000249502.1	AC006160.5	-4.93	1.15e-06	0.000285	-0.22	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17575867	chr4:17587467~17614571:-
LUAD	cis	rs61270009	0.955	rs13189889	ENSG00000247828.6	TMEM161B-AS1	4.93	1.15e-06	0.000286	0.26	0.22	Depressive symptoms;	chr5:88365589	chr5:88268895~88436685:+
LUAD	cis	rs9910055	0.659	rs3826412	ENSG00000267080.4	ASB16-AS1	-4.93	1.15e-06	0.000286	-0.2	-0.22	Total body bone mineral density;	chr17:44177729	chr17:44175973~44186717:-
LUAD	cis	rs7017914	0.69	rs2639929	ENSG00000223220.1	Y_RNA	4.93	1.15e-06	0.000286	0.25	0.22	Bone mineral density;	chr8:70972413	chr8:70780914~70781008:-
LUAD	cis	rs984222	0.967	rs1409157	ENSG00000226172.2	RP4-712E4.1	-4.93	1.15e-06	0.000286	-0.23	-0.22	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118961864	chr1:119000344~119001392:-
LUAD	cis	rs875971	0.862	rs6460282	ENSG00000232559.3	GS1-124K5.12	-4.93	1.15e-06	0.000286	-0.26	-0.22	Aortic root size;	chr7:66226259	chr7:66554588~66576923:-
LUAD	cis	rs8077577	0.747	rs62072537	ENSG00000273018.4	CTD-2303H24.2	-4.93	1.15e-06	0.000286	-0.31	-0.22	Obesity-related traits;	chr17:18312786	chr17:18511221~18551705:-
LUAD	cis	rs7208859	0.623	rs9899268	ENSG00000266490.1	CTD-2349P21.9	4.93	1.15e-06	0.000286	0.33	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30823237	chr17:30792372~30792833:+
LUAD	cis	rs7618501	0.699	rs2681780	ENSG00000234667.1	ACTBP13	-4.93	1.15e-06	0.000286	-0.25	-0.22	Intelligence (multi-trait analysis);	chr3:49860397	chr3:49873347~49877980:-
LUAD	cis	rs7618501	0.699	rs2777888	ENSG00000234667.1	ACTBP13	-4.93	1.15e-06	0.000286	-0.25	-0.22	Intelligence (multi-trait analysis);	chr3:49860567	chr3:49873347~49877980:-
LUAD	cis	rs7618501	0.699	rs2681781	ENSG00000234667.1	ACTBP13	-4.93	1.15e-06	0.000286	-0.25	-0.22	Intelligence (multi-trait analysis);	chr3:49860840	chr3:49873347~49877980:-
LUAD	cis	rs9450351	0.744	rs75096179	ENSG00000203875.9	SNHG5	-4.93	1.15e-06	0.000286	-0.6	-0.22	Interferon gamma-induced protein 10 levels;	chr6:85580606	chr6:85660950~85678736:-
LUAD	cis	rs9926296	0.744	rs6860	ENSG00000260259.1	RP11-368I7.4	4.93	1.15e-06	0.000286	0.22	0.22	Vitiligo;	chr16:89644712	chr16:89682620~89686569:-
LUAD	cis	rs2749097	0.825	rs2658432	ENSG00000244256.3	RN7SL130P	-4.93	1.15e-06	0.000286	-0.26	-0.22	Alcohol consumption (transferrin glycosylation);	chr1:63659153	chr1:63655743~63656047:+
LUAD	cis	rs507080	0.961	rs4457789	ENSG00000278376.1	RP11-158I9.8	-4.93	1.15e-06	0.000286	-0.24	-0.22	Serum metabolite levels;	chr11:118668461	chr11:118791254~118793137:+
LUAD	cis	rs17508449	0.819	rs76726048	ENSG00000232450.1	RP4-730K3.3	-4.93	1.15e-06	0.000286	-0.37	-0.22	Leprosy;	chr1:113664077	chr1:113698884~113699631:-
LUAD	cis	rs7937890	0.559	rs2575853	ENSG00000251991.1	RNU7-49P	4.93	1.15e-06	0.000286	0.23	0.22	Mitochondrial DNA levels;	chr11:14512417	chr11:14478892~14478953:+
LUAD	cis	rs2933343	1	rs789227	ENSG00000231305.3	RP11-723O4.2	4.93	1.15e-06	0.000286	0.26	0.22	IgG glycosylation;	chr3:128881742	chr3:128861313~128871540:-
LUAD	cis	rs7923609	0.846	rs10761731	ENSG00000232075.1	MRPL35P2	-4.93	1.15e-06	0.000286	-0.27	-0.22	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63267850	chr10:63634317~63634827:-
LUAD	cis	rs2933343	0.649	rs1683786	ENSG00000261159.1	RP11-723O4.9	4.93	1.15e-06	0.000286	0.24	0.22	IgG glycosylation;	chr3:128908109	chr3:128859716~128860526:-
LUAD	cis	rs2933343	0.7	rs876754	ENSG00000261159.1	RP11-723O4.9	4.93	1.15e-06	0.000286	0.24	0.22	IgG glycosylation;	chr3:128908910	chr3:128859716~128860526:-
LUAD	cis	rs4835473	0.771	rs4443231	ENSG00000251600.4	RP11-673E1.1	4.93	1.15e-06	0.000286	0.27	0.22	Immature fraction of reticulocytes;	chr4:143979501	chr4:143912331~143982454:+
LUAD	cis	rs916888	0.61	rs199444	ENSG00000261575.2	RP11-259G18.1	4.93	1.15e-06	0.000286	0.3	0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46267037~46268694:+
LUAD	cis	rs916888	0.61	rs199442	ENSG00000261575.2	RP11-259G18.1	4.93	1.15e-06	0.000286	0.3	0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46267037~46268694:+
LUAD	cis	rs950169	0.922	rs11633534	ENSG00000229212.6	RP11-561C5.4	-4.93	1.15e-06	0.000287	-0.32	-0.22	Schizophrenia;	chr15:84581411	chr15:85205440~85234795:-
LUAD	cis	rs910316	1	rs175426	ENSG00000259138.1	RP11-950C14.7	-4.93	1.15e-06	0.000287	-0.23	-0.22	Height;	chr14:75157431	chr14:75127153~75136930:+
LUAD	cis	rs559928	0.947	rs10792430	ENSG00000236935.1	AP003774.1	4.93	1.15e-06	0.000287	0.3	0.22	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64379642	chr11:64325050~64329504:-
LUAD	cis	rs62432291	0.681	rs385438	ENSG00000235086.1	FNDC1-IT1	-4.93	1.15e-06	0.000287	-0.37	-0.22	Joint mobility (Beighton score);	chr6:159235181	chr6:159240786~159243329:+
LUAD	cis	rs1426063	1	rs10033857	ENSG00000249717.1	RP11-44F21.3	4.93	1.15e-06	0.000287	0.32	0.22	QT interval;	chr4:75103208	chr4:74955974~74970362:-
LUAD	cis	rs6102185	0.549	rs6029415	ENSG00000229771.2	RP4-644L1.2	-4.93	1.15e-06	0.000287	-0.27	-0.22	IgG glycosylation;	chr20:40889551	chr20:40696499~40698616:-
LUAD	cis	rs8050896	1	rs8054823	ENSG00000260695.1	RP11-513N24.1	-4.93	1.15e-06	0.000287	-0.36	-0.22	Response to antipsychotic treatment;	chr16:66123517	chr16:65861112~65863784:-
LUAD	cis	rs4639966	0.569	rs603486	ENSG00000255239.1	AP002954.6	4.93	1.15e-06	0.000288	0.25	0.22	Systemic lupus erythematosus;	chr11:118716638	chr11:118688039~118690600:-
LUAD	cis	rs7017914	0.652	rs2017035	ENSG00000223220.1	Y_RNA	4.93	1.16e-06	0.000288	0.25	0.22	Bone mineral density;	chr8:70929571	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs34366597	ENSG00000223220.1	Y_RNA	4.93	1.16e-06	0.000288	0.25	0.22	Bone mineral density;	chr8:70932658	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs7839977	ENSG00000223220.1	Y_RNA	4.93	1.16e-06	0.000288	0.25	0.22	Bone mineral density;	chr8:70933067	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs1493199	ENSG00000223220.1	Y_RNA	4.93	1.16e-06	0.000288	0.25	0.22	Bone mineral density;	chr8:70934269	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.616	rs17689943	ENSG00000223220.1	Y_RNA	4.93	1.16e-06	0.000288	0.25	0.22	Bone mineral density;	chr8:70936145	chr8:70780914~70781008:-
LUAD	cis	rs1823913	0.538	rs6732537	ENSG00000227542.1	AC092614.2	4.93	1.16e-06	0.000288	0.28	0.22	Obesity-related traits;	chr2:191346755	chr2:191229165~191246172:-
LUAD	cis	rs4776970	0.632	rs3784706	ENSG00000270964.1	RP11-502I4.3	-4.93	1.16e-06	0.000288	-0.23	-0.22	Body mass index;Waist circumference;	chr15:67737411	chr15:67541072~67542604:-
LUAD	cis	rs13113518	0.557	rs13142096	ENSG00000223305.1	RN7SKP30	4.93	1.16e-06	0.000288	0.27	0.22	Height;	chr4:55566291	chr4:55540502~55540835:-
LUAD	cis	rs916888	0.61	rs199529	ENSG00000261575.2	RP11-259G18.1	4.93	1.16e-06	0.000288	0.33	0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46267037~46268694:+
LUAD	cis	rs9545047	0.604	rs11620233	ENSG00000227354.5	RBM26-AS1	-4.93	1.16e-06	0.000288	-0.23	-0.22	Schizophrenia;	chr13:79373871	chr13:79406309~79424328:+
LUAD	cis	rs736801	0.729	rs1050152	ENSG00000233006.5	AC034220.3	4.93	1.16e-06	0.000288	0.2	0.22	Mosquito bite size;Breast cancer;	chr5:132340627	chr5:132311285~132369916:-
LUAD	cis	rs6840258	1	rs17012234	ENSG00000251411.1	RP11-397E7.4	4.93	1.16e-06	0.000288	0.28	0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86990539	chr4:86913266~86914817:-
LUAD	cis	rs7119038	0.509	rs10892259	ENSG00000255239.1	AP002954.6	-4.93	1.16e-06	0.000288	-0.32	-0.22	Sjögren's syndrome;	chr11:118712293	chr11:118688039~118690600:-
LUAD	cis	rs9487094	0.961	rs11153180	ENSG00000260273.1	RP11-425D10.10	4.93	1.16e-06	0.000289	0.3	0.22	Height;	chr6:109423238	chr6:109382795~109383666:+
LUAD	cis	rs783540	0.521	rs28719490	ENSG00000276710.3	CSPG4P8	-4.93	1.16e-06	0.000289	-0.23	-0.22	Schizophrenia;	chr15:82720688	chr15:82459472~82477258:+
LUAD	cis	rs12681366	0.839	rs3019280	ENSG00000253704.1	RP11-267M23.4	4.93	1.16e-06	0.000289	0.27	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94437804	chr8:94553722~94569745:+
LUAD	cis	rs7260359	0.518	rs344815	ENSG00000242675.1	RPS16P9	4.93	1.16e-06	0.000289	0.23	0.22	Intelligence (multi-trait analysis);	chr19:45322996	chr19:45332698~45333124:-
LUAD	cis	rs4835473	0.897	rs4835474	ENSG00000251600.4	RP11-673E1.1	4.93	1.16e-06	0.000289	0.27	0.22	Immature fraction of reticulocytes;	chr4:143982444	chr4:143912331~143982454:+
LUAD	cis	rs748404	0.697	rs1095389	ENSG00000249839.1	AC011330.5	-4.93	1.16e-06	0.000289	-0.28	-0.22	Lung cancer;	chr15:43274473	chr15:43663654~43684339:-
LUAD	cis	rs4143844	0.867	rs11639286	ENSG00000259251.2	RP11-643M14.1	4.92	1.16e-06	0.000289	0.4	0.22	Bipolar disorder and schizophrenia;	chr15:62024397	chr15:62060503~62062434:+
LUAD	cis	rs4143844	0.867	rs34958705	ENSG00000259251.2	RP11-643M14.1	4.92	1.16e-06	0.000289	0.4	0.22	Bipolar disorder and schizophrenia;	chr15:62024558	chr15:62060503~62062434:+
LUAD	cis	rs7131987	0.683	rs3782511	ENSG00000257176.2	RP11-996F15.2	-4.92	1.16e-06	0.000289	-0.25	-0.22	QT interval;	chr12:29343291	chr12:29280418~29317848:-
LUAD	cis	rs11671005	0.735	rs3826682	ENSG00000268912.1	CTD-2619J13.17	-4.92	1.16e-06	0.000289	-0.3	-0.22	Mean platelet volume;	chr19:58407381	chr19:58428632~58431148:-
LUAD	cis	rs7811142	1	rs60478351	ENSG00000078319.8	PMS2P1	-4.92	1.16e-06	0.000289	-0.26	-0.22	Platelet count;	chr7:100491394	chr7:100320992~100341908:-
LUAD	cis	rs2948294	0.545	rs11776397	ENSG00000173295.6	FAM86B3P	4.92	1.16e-06	0.000289	0.24	0.22	Red cell distribution width;	chr8:8257639	chr8:8228595~8244865:+
LUAD	cis	rs5758511	0.68	rs5758686	ENSG00000205702.9	CYP2D7	4.92	1.16e-06	0.00029	0.22	0.22	Birth weight;	chr22:42259371	chr22:42140203~42144577:-
LUAD	cis	rs910316	1	rs175425	ENSG00000259138.1	RP11-950C14.7	-4.92	1.16e-06	0.00029	-0.23	-0.22	Height;	chr14:75159428	chr14:75127153~75136930:+
LUAD	cis	rs910316	0.935	rs175422	ENSG00000259138.1	RP11-950C14.7	-4.92	1.16e-06	0.00029	-0.23	-0.22	Height;	chr14:75160616	chr14:75127153~75136930:+
LUAD	cis	rs1061377	0.71	rs12503506	ENSG00000249685.1	RP11-360F5.3	4.92	1.16e-06	0.00029	0.26	0.22	Uric acid levels;	chr4:39082553	chr4:39133913~39135608:+
LUAD	cis	rs1707322	1	rs10890378	ENSG00000280836.1	AL355480.1	4.92	1.17e-06	0.00029	0.28	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45944985	chr1:45581219~45581321:-
LUAD	cis	rs10129255	0.5	rs2027902	ENSG00000254174.1	IGHV1-12	4.92	1.17e-06	0.00029	0.15	0.22	Kawasaki disease;	chr14:106807157	chr14:106122420~106122709:-
LUAD	cis	rs7621025	0.63	rs1681818	ENSG00000239213.4	NCK1-AS1	-4.92	1.17e-06	0.00029	-0.28	-0.22	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136754831	chr3:136841726~136862054:-
LUAD	cis	rs2243480	1	rs906134	ENSG00000164669.11	INTS4P1	4.92	1.17e-06	0.00029	0.39	0.22	Diabetic kidney disease;	chr7:65979301	chr7:65141225~65234216:+
LUAD	cis	rs950169	0.84	rs62019457	ENSG00000259295.5	CSPG4P12	4.92	1.17e-06	0.00029	0.31	0.22	Schizophrenia;	chr15:84558911	chr15:85191438~85213905:+
LUAD	cis	rs12908161	1	rs17600551	ENSG00000275120.1	RP11-182J1.17	4.92	1.17e-06	0.00029	0.33	0.22	Schizophrenia;	chr15:84776027	chr15:84599434~84606463:-
LUAD	cis	rs12908161	1	rs62019469	ENSG00000275120.1	RP11-182J1.17	4.92	1.17e-06	0.00029	0.33	0.22	Schizophrenia;	chr15:84777989	chr15:84599434~84606463:-
LUAD	cis	rs9341808	0.559	rs7762895	ENSG00000272129.1	RP11-250B2.6	4.92	1.17e-06	0.00029	0.27	0.22	Sitting height ratio;	chr6:80351714	chr6:80355424~80356859:+
LUAD	cis	rs62158211	1	rs62158211	ENSG00000234997.1	AC016745.3	-4.92	1.17e-06	0.00029	-0.28	-0.22	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113348562	chr2:113424495~113425324:+
LUAD	cis	rs875971	0.862	rs10274883	ENSG00000232559.3	GS1-124K5.12	-4.92	1.17e-06	0.00029	-0.26	-0.22	Aortic root size;	chr7:66651104	chr7:66554588~66576923:-
LUAD	cis	rs801193	0.569	rs881285	ENSG00000232559.3	GS1-124K5.12	-4.92	1.17e-06	0.00029	-0.26	-0.22	Aortic root size;	chr7:66654433	chr7:66554588~66576923:-
LUAD	cis	rs801193	0.569	rs3846973	ENSG00000232559.3	GS1-124K5.12	-4.92	1.17e-06	0.00029	-0.26	-0.22	Aortic root size;	chr7:66655048	chr7:66554588~66576923:-
LUAD	cis	rs801193	0.569	rs2013908	ENSG00000232559.3	GS1-124K5.12	-4.92	1.17e-06	0.00029	-0.26	-0.22	Aortic root size;	chr7:66656082	chr7:66554588~66576923:-
LUAD	cis	rs13315649	0.642	rs9811914	ENSG00000242551.2	POU5F1P6	-4.92	1.17e-06	0.00029	-0.28	-0.22	Sum eosinophil basophil counts;	chr3:128676517	chr3:128674735~128677005:-
LUAD	cis	rs875971	0.54	rs781152	ENSG00000224316.1	RP11-479O9.2	4.92	1.17e-06	0.00029	0.22	0.22	Aortic root size;	chr7:66014585	chr7:65773620~65802067:+
LUAD	cis	rs17711722	0.727	rs781151	ENSG00000224316.1	RP11-479O9.2	4.92	1.17e-06	0.00029	0.22	0.22	Calcium levels;	chr7:66014891	chr7:65773620~65802067:+
LUAD	cis	rs4964805	1	rs4964805	ENSG00000257681.1	RP11-341G23.4	4.92	1.17e-06	0.000291	0.26	0.22	Attention deficit hyperactivity disorder;	chr12:103799046	chr12:103746315~103768858:-
LUAD	cis	rs75920871	0.528	rs7935834	ENSG00000254851.1	RP11-109L13.1	4.92	1.17e-06	0.000291	0.31	0.22	Subjective well-being;	chr11:117073721	chr11:117135528~117138582:+
LUAD	cis	rs780096	0.526	rs7602534	ENSG00000234072.1	AC074117.10	-4.92	1.17e-06	0.000291	-0.17	-0.22	Total body bone mineral density;	chr2:27369556	chr2:27356246~27367622:+
LUAD	cis	rs301901	0.734	rs10941321	ENSG00000250155.1	CTD-2353F22.1	-4.92	1.17e-06	0.000291	-0.23	-0.22	Height;	chr5:37213248	chr5:36666214~36725195:-
LUAD	cis	rs1707322	1	rs7547189	ENSG00000280836.1	AL355480.1	-4.92	1.17e-06	0.000291	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853842	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs7547284	ENSG00000280836.1	AL355480.1	-4.92	1.17e-06	0.000291	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853893	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs11211205	ENSG00000280836.1	AL355480.1	-4.92	1.17e-06	0.000291	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45856202	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs6675222	ENSG00000280836.1	AL355480.1	-4.92	1.17e-06	0.000291	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45860904	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs4660895	ENSG00000280836.1	AL355480.1	-4.92	1.17e-06	0.000291	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864067	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs4660318	ENSG00000280836.1	AL355480.1	-4.92	1.17e-06	0.000291	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45869204	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs10890360	ENSG00000280836.1	AL355480.1	-4.92	1.17e-06	0.000291	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45872772	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs6682683	ENSG00000280836.1	AL355480.1	-4.92	1.17e-06	0.000291	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45876665	chr1:45581219~45581321:-
LUAD	cis	rs950169	0.544	rs62021193	ENSG00000259295.5	CSPG4P12	4.92	1.17e-06	0.000291	0.31	0.22	Schizophrenia;	chr15:84627352	chr15:85191438~85213905:+
LUAD	cis	rs13256369	0.826	rs12678414	ENSG00000253893.2	FAM85B	-4.92	1.17e-06	0.000291	-0.3	-0.22	Obesity-related traits;	chr8:8728506	chr8:8167819~8226614:-
LUAD	cis	rs10129255	0.957	rs10136817	ENSG00000211974.3	IGHV2-70	4.92	1.17e-06	0.000291	0.24	0.22	Kawasaki disease;	chr14:106787730	chr14:106723574~106724093:-
LUAD	cis	rs4601821	0.789	rs7123797	ENSG00000270179.1	RP11-159N11.4	-4.92	1.17e-06	0.000291	-0.23	-0.22	Alcoholic chronic pancreatitis;	chr11:113391849	chr11:113368478~113369117:+
LUAD	cis	rs12701220	0.522	rs868833	ENSG00000229043.2	AC091729.9	-4.92	1.17e-06	0.000291	-0.25	-0.22	Bronchopulmonary dysplasia;	chr7:1015337	chr7:1160374~1165267:+
LUAD	cis	rs891378	1	rs2802238	ENSG00000274245.1	RP11-357P18.2	-4.92	1.17e-06	0.000291	-0.29	-0.22	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207302796	chr1:207372559~207373252:+
LUAD	cis	rs1012068	0.881	rs5998168	ENSG00000236132.1	CTA-440B3.1	-4.92	1.17e-06	0.000291	-0.29	-0.22	Chronic hepatitis C infection;	chr22:31901310	chr22:31816379~31817491:-
LUAD	cis	rs6568401	0.6	rs1508361	ENSG00000219088.1	RP3-359N14.1	-4.92	1.17e-06	0.000292	-0.28	-0.22	Primary tooth development (time to first tooth eruption);	chr6:105729410	chr6:105666326~105667998:+
LUAD	cis	rs2281558	0.583	rs11087526	ENSG00000125804.12	FAM182A	-4.92	1.17e-06	0.000292	-0.35	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25667380	chr20:26054655~26086917:+
LUAD	cis	rs170183	0.934	rs35734452	ENSG00000233818.1	AP000695.4	-4.92	1.18e-06	0.000292	-0.21	-0.22	Bone mineral density;	chr21:36483703	chr21:36445731~36532408:+
LUAD	cis	rs2404602	0.692	rs3110382	ENSG00000259422.1	RP11-593F23.1	-4.92	1.18e-06	0.000292	-0.25	-0.22	Blood metabolite levels;	chr15:76856347	chr15:76174891~76181486:-
LUAD	cis	rs4142995	0.962	rs17138358	ENSG00000279048.1	RP11-511H23.2	-4.92	1.18e-06	0.000292	-0.17	-0.22	HDL cholesterol;HDL cholesterol levels;	chr7:17880630	chr7:17940503~17942922:+
LUAD	cis	rs599083	0.59	rs10791984	ENSG00000212093.1	AP000807.1	-4.92	1.18e-06	0.000292	-0.23	-0.22	Bone mineral density (spine);	chr11:68640367	chr11:68506083~68506166:-
LUAD	cis	rs853679	0.505	rs200992	ENSG00000219392.1	RP1-265C24.5	-4.92	1.18e-06	0.000292	-0.43	-0.22	Depression;	chr6:27846899	chr6:28115628~28116551:+
LUAD	cis	rs948562	0.947	rs7945889	ENSG00000280010.1	AP001350.4	4.92	1.18e-06	0.000292	0.33	0.22	Lymphoma;	chr11:58609262	chr11:58627435~58628528:+
LUAD	cis	rs7829975	0.742	rs882462	ENSG00000173295.6	FAM86B3P	4.92	1.18e-06	0.000293	0.23	0.22	Mood instability;	chr8:8821020	chr8:8228595~8244865:+
LUAD	cis	rs748404	0.666	rs514438	ENSG00000205771.5	CATSPER2P1	-4.92	1.18e-06	0.000293	-0.32	-0.22	Lung cancer;	chr15:43328245	chr15:43726918~43747094:-
LUAD	cis	rs4268898	0.697	rs6714652	ENSG00000242628.4	AC009228.1	-4.92	1.18e-06	0.000293	-0.28	-0.22	Asthma;	chr2:24160189	chr2:24214381~24221516:+
LUAD	cis	rs4568518	0.501	rs6966247	ENSG00000279048.1	RP11-511H23.2	4.92	1.18e-06	0.000293	0.18	0.22	Measles;	chr7:17949624	chr7:17940503~17942922:+
LUAD	cis	rs7923609	0.875	rs10761741	ENSG00000232075.1	MRPL35P2	-4.92	1.18e-06	0.000293	-0.27	-0.22	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63306426	chr10:63634317~63634827:-
LUAD	cis	rs1707322	1	rs11211200	ENSG00000280836.1	AL355480.1	-4.92	1.18e-06	0.000294	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45822680	chr1:45581219~45581321:-
LUAD	cis	rs783540	0.5	rs7163840	ENSG00000276710.3	CSPG4P8	4.92	1.18e-06	0.000294	0.23	0.22	Schizophrenia;	chr15:82729551	chr15:82459472~82477258:+
LUAD	cis	rs1167827	0.68	rs1167796	ENSG00000223705.8	NSUN5P1	-4.92	1.18e-06	0.000294	-0.15	-0.22	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75410322~75416787:+
LUAD	cis	rs2243480	0.522	rs12698511	ENSG00000226002.1	RP11-460N20.5	-4.92	1.18e-06	0.000294	-0.42	-0.22	Diabetic kidney disease;	chr7:66009932	chr7:65084103~65100232:+
LUAD	cis	rs7138803	0.51	rs4898530	ENSG00000257464.1	RP11-161H23.8	-4.92	1.18e-06	0.000294	-0.21	-0.22	Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index;	chr12:49810926	chr12:49442424~49442652:-
LUAD	cis	rs17711722	0.523	rs313812	ENSG00000226002.1	RP11-460N20.5	-4.92	1.18e-06	0.000294	-0.24	-0.22	Calcium levels;	chr7:66040056	chr7:65084103~65100232:+
LUAD	cis	rs2998286	0.723	rs332146	ENSG00000254635.4	WAC-AS1	-4.92	1.18e-06	0.000294	-0.29	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28580255	chr10:28522652~28532743:-
LUAD	cis	rs75920871	0.512	rs6589583	ENSG00000254851.1	RP11-109L13.1	4.92	1.18e-06	0.000294	0.32	0.22	Subjective well-being;	chr11:116993050	chr11:117135528~117138582:+
LUAD	cis	rs75920871	0.528	rs7930264	ENSG00000254851.1	RP11-109L13.1	4.92	1.18e-06	0.000294	0.32	0.22	Subjective well-being;	chr11:117000050	chr11:117135528~117138582:+
LUAD	cis	rs801193	0.569	rs13226966	ENSG00000232559.3	GS1-124K5.12	4.92	1.18e-06	0.000294	0.26	0.22	Aortic root size;	chr7:66768636	chr7:66554588~66576923:-
LUAD	cis	rs4268898	0.722	rs11691212	ENSG00000242628.4	AC009228.1	-4.92	1.19e-06	0.000294	-0.28	-0.22	Asthma;	chr2:24181864	chr2:24214381~24221516:+
LUAD	cis	rs867371	0.717	rs3858954	ENSG00000259429.4	UBE2Q2P2	-4.92	1.19e-06	0.000294	-0.2	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82265693	chr15:82355142~82420075:+
LUAD	cis	rs853679	0.567	rs3799499	ENSG00000216901.1	AL022393.7	4.92	1.19e-06	0.000294	0.27	0.22	Depression;	chr6:28386473	chr6:28176188~28176674:+
LUAD	cis	rs2032366	0.606	rs6567225	ENSG00000267279.1	RP11-879F14.2	4.92	1.19e-06	0.000295	0.29	0.22	Obesity-related traits;	chr18:61607418	chr18:61585746~61606916:-
LUAD	cis	rs7937890	0.559	rs2597206	ENSG00000251991.1	RNU7-49P	4.92	1.19e-06	0.000295	0.23	0.22	Mitochondrial DNA levels;	chr11:14455992	chr11:14478892~14478953:+
LUAD	cis	rs3096299	0.617	rs2353030	ENSG00000182376.2	RP5-1142A6.8	-4.92	1.19e-06	0.000295	-0.22	-0.22	Multiple myeloma (IgH translocation);	chr16:89339419	chr16:88742767~88745748:+
LUAD	cis	rs2832077	0.506	rs2832088	ENSG00000232855.5	AF131217.1	4.92	1.19e-06	0.000295	0.22	0.22	Cognitive test performance;	chr21:28786298	chr21:28439346~28674848:-
LUAD	cis	rs12701220	0.553	rs34062359	ENSG00000229043.2	AC091729.9	-4.92	1.19e-06	0.000295	-0.3	-0.22	Bronchopulmonary dysplasia;	chr7:1099440	chr7:1160374~1165267:+
LUAD	cis	rs1546924	0.57	rs197419	ENSG00000227811.2	FAM212B-AS1	4.92	1.19e-06	0.000295	0.27	0.22	Body mass index;	chr1:111772828	chr1:111739841~111747798:+
LUAD	cis	rs2404602	0.563	rs12914005	ENSG00000259422.1	RP11-593F23.1	4.92	1.19e-06	0.000295	0.24	0.22	Blood metabolite levels;	chr15:76473326	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.536	rs7163946	ENSG00000259422.1	RP11-593F23.1	4.92	1.19e-06	0.000295	0.24	0.22	Blood metabolite levels;	chr15:76473708	chr15:76174891~76181486:-
LUAD	cis	rs2404602	0.536	rs7165025	ENSG00000259422.1	RP11-593F23.1	4.92	1.19e-06	0.000295	0.24	0.22	Blood metabolite levels;	chr15:76474093	chr15:76174891~76181486:-
LUAD	cis	rs944990	0.686	rs6479485	ENSG00000227603.1	RP11-165J3.6	4.92	1.19e-06	0.000295	0.25	0.22	Body mass index;	chr9:93456969	chr9:93435332~93437121:-
LUAD	cis	rs812925	0.512	rs1177309	ENSG00000271889.1	RP11-493E12.1	4.92	1.19e-06	0.000295	0.26	0.22	Immature fraction of reticulocytes;	chr2:61158113	chr2:61151433~61162105:-
LUAD	cis	rs2286503	0.78	rs929464	ENSG00000221740.1	SNORD93	4.92	1.19e-06	0.000295	0.25	0.22	Fibrinogen;	chr7:22835151	chr7:22856613~22856686:+
LUAD	cis	rs7927592	0.673	rs2510392	ENSG00000212093.1	AP000807.1	4.92	1.19e-06	0.000295	0.23	0.22	Total body bone mineral density;	chr11:68626989	chr11:68506083~68506166:-
LUAD	cis	rs6840258	1	rs56395939	ENSG00000251411.1	RP11-397E7.4	-4.92	1.19e-06	0.000296	-0.28	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87042481	chr4:86913266~86914817:-
LUAD	cis	rs2933343	0.859	rs789247	ENSG00000231305.3	RP11-723O4.2	4.92	1.19e-06	0.000296	0.26	0.22	IgG glycosylation;	chr3:128861742	chr3:128861313~128871540:-
LUAD	cis	rs2933343	0.903	rs2638846	ENSG00000231305.3	RP11-723O4.2	4.92	1.19e-06	0.000296	0.26	0.22	IgG glycosylation;	chr3:128868320	chr3:128861313~128871540:-
LUAD	cis	rs2439831	0.681	rs825740	ENSG00000249839.1	AC011330.5	-4.92	1.19e-06	0.000296	-0.4	-0.22	Lung cancer in ever smokers;	chr15:43300210	chr15:43663654~43684339:-
LUAD	cis	rs7017914	0.69	rs1838392	ENSG00000223220.1	Y_RNA	4.92	1.19e-06	0.000296	0.25	0.22	Bone mineral density;	chr8:70770348	chr8:70780914~70781008:-
LUAD	cis	rs516805	0.667	rs1339532	ENSG00000279453.1	RP3-425C14.4	4.92	1.19e-06	0.000296	0.29	0.22	Lymphocyte counts;	chr6:122345249	chr6:122436789~122439223:-
LUAD	cis	rs7772486	0.72	rs702320	ENSG00000235652.6	RP11-545I5.3	-4.92	1.19e-06	0.000296	-0.22	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145685518	chr6:145799409~145886585:+
LUAD	cis	rs17684571	0.872	rs34429594	ENSG00000231441.1	RP11-472M19.2	4.92	1.19e-06	0.000296	0.3	0.22	Schizophrenia;	chr6:56714954	chr6:56844002~56864078:+
LUAD	cis	rs7017914	0.652	rs2732147	ENSG00000223220.1	Y_RNA	4.92	1.19e-06	0.000296	0.25	0.22	Bone mineral density;	chr8:71000179	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs2639946	ENSG00000223220.1	Y_RNA	4.92	1.19e-06	0.000296	0.25	0.22	Bone mineral density;	chr8:71000265	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.628	rs2732149	ENSG00000223220.1	Y_RNA	4.92	1.19e-06	0.000296	0.25	0.22	Bone mineral density;	chr8:71000267	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs2639945	ENSG00000223220.1	Y_RNA	4.92	1.19e-06	0.000296	0.25	0.22	Bone mineral density;	chr8:71000304	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.54	rs2639944	ENSG00000223220.1	Y_RNA	4.92	1.19e-06	0.000296	0.25	0.22	Bone mineral density;	chr8:71000512	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs2732088	ENSG00000223220.1	Y_RNA	4.92	1.19e-06	0.000296	0.25	0.22	Bone mineral density;	chr8:71000542	chr8:70780914~70781008:-
LUAD	cis	rs800160	0.777	rs2651779	ENSG00000236264.4	RPL26P30	-4.92	1.19e-06	0.000296	-0.29	-0.22	Bacteremia;	chr11:2323040	chr11:2335132~2335776:-
LUAD	cis	rs910316	0.967	rs4384542	ENSG00000259138.1	RP11-950C14.7	-4.92	1.2e-06	0.000297	-0.23	-0.22	Height;	chr14:75191310	chr14:75127153~75136930:+
LUAD	cis	rs4789693	0.546	rs7220204	ENSG00000265458.1	RP13-20L14.6	4.92	1.2e-06	0.000297	0.3	0.22	Glucocorticoid-induced osteonecrosis;	chr17:82418254	chr17:82454273~82458521:-
LUAD	cis	rs5769707	0.706	rs763128	ENSG00000235111.1	RP1-29C18.8	-4.92	1.2e-06	0.000297	-0.26	-0.22	Monocyte percentage of white cells;Monocyte count;	chr22:49624397	chr22:49612657~49615716:-
LUAD	cis	rs375066	0.935	rs413093	ENSG00000267058.1	RP11-15A1.3	-4.92	1.2e-06	0.000297	-0.25	-0.22	Breast cancer;	chr19:43922113	chr19:43891804~43901805:-
LUAD	cis	rs4664293	0.801	rs7607143	ENSG00000230783.1	AC009961.2	-4.92	1.2e-06	0.000297	-0.26	-0.22	Monocyte percentage of white cells;	chr2:159728250	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.833	rs10170336	ENSG00000230783.1	AC009961.2	-4.92	1.2e-06	0.000297	-0.26	-0.22	Monocyte percentage of white cells;	chr2:159732832	chr2:159689217~159690291:-
LUAD	cis	rs673078	0.607	rs61946067	ENSG00000275409.1	RP11-131L12.4	-4.92	1.2e-06	0.000297	-0.33	-0.22	Glucose homeostasis traits;	chr12:118303152	chr12:118430147~118430699:+
LUAD	cis	rs4664293	0.867	rs12617546	ENSG00000226266.5	AC009961.3	-4.92	1.2e-06	0.000297	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159767079	chr2:159670708~159712435:-
LUAD	cis	rs71636778	0.509	rs41307935	ENSG00000260063.1	RP5-968P14.2	-4.92	1.2e-06	0.000297	-0.39	-0.22	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26854576	chr1:26692132~26694131:-
LUAD	cis	rs9487094	0.553	rs11968891	ENSG00000260273.1	RP11-425D10.10	4.92	1.2e-06	0.000297	0.34	0.22	Height;	chr6:109548647	chr6:109382795~109383666:+
LUAD	cis	rs5769707	0.632	rs135872	ENSG00000235111.1	RP1-29C18.8	-4.92	1.2e-06	0.000297	-0.26	-0.22	Monocyte percentage of white cells;Monocyte count;	chr22:49615652	chr22:49612657~49615716:-
LUAD	cis	rs801193	0.591	rs4506088	ENSG00000232559.3	GS1-124K5.12	-4.92	1.2e-06	0.000297	-0.26	-0.22	Aortic root size;	chr7:66670470	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs6460293	ENSG00000232559.3	GS1-124K5.12	-4.92	1.2e-06	0.000297	-0.26	-0.22	Aortic root size;	chr7:66345205	chr7:66554588~66576923:-
LUAD	cis	rs9473147	0.543	rs9296558	ENSG00000270761.1	RP11-385F7.1	-4.92	1.2e-06	0.000297	-0.25	-0.22	Platelet distribution width;Mean platelet volume;	chr6:47484147	chr6:47477243~47477572:-
LUAD	cis	rs7829975	0.688	rs7827182	ENSG00000173295.6	FAM86B3P	4.92	1.2e-06	0.000297	0.23	0.22	Mood instability;	chr8:8522961	chr8:8228595~8244865:+
LUAD	cis	rs9322193	0.962	rs7740784	ENSG00000268592.3	RAET1E-AS1	4.92	1.2e-06	0.000297	0.28	0.22	Lung cancer;	chr6:149833364	chr6:149863494~149919507:+
LUAD	cis	rs14027	0.921	rs1567359	ENSG00000279347.1	RP11-85I17.2	-4.92	1.2e-06	0.000297	-0.19	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119778378	chr8:119838736~119840385:-
LUAD	cis	rs14027	0.921	rs2043430	ENSG00000279347.1	RP11-85I17.2	-4.92	1.2e-06	0.000297	-0.19	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119779741	chr8:119838736~119840385:-
LUAD	cis	rs14027	0.921	rs12543087	ENSG00000279347.1	RP11-85I17.2	-4.92	1.2e-06	0.000297	-0.19	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119784207	chr8:119838736~119840385:-
LUAD	cis	rs14027	0.921	rs10101278	ENSG00000279347.1	RP11-85I17.2	-4.92	1.2e-06	0.000297	-0.19	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119784799	chr8:119838736~119840385:-
LUAD	cis	rs14027	0.921	rs1976575	ENSG00000279347.1	RP11-85I17.2	-4.92	1.2e-06	0.000297	-0.19	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119788618	chr8:119838736~119840385:-
LUAD	cis	rs14027	0.921	rs7837589	ENSG00000279347.1	RP11-85I17.2	-4.92	1.2e-06	0.000297	-0.19	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119789401	chr8:119838736~119840385:-
LUAD	cis	rs14027	0.921	rs4871634	ENSG00000279347.1	RP11-85I17.2	-4.92	1.2e-06	0.000297	-0.19	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119806243	chr8:119838736~119840385:-
LUAD	cis	rs801193	1	rs2707845	ENSG00000237310.1	GS1-124K5.4	4.92	1.2e-06	0.000297	0.24	0.22	Aortic root size;	chr7:66733811	chr7:66493706~66495474:+
LUAD	cis	rs2243480	1	rs2961102	ENSG00000164669.11	INTS4P1	4.92	1.2e-06	0.000298	0.39	0.22	Diabetic kidney disease;	chr7:65959671	chr7:65141225~65234216:+
LUAD	cis	rs7324557	0.683	rs9507167	ENSG00000205861.10	C1QTNF9B-AS1	4.92	1.2e-06	0.000298	0.29	0.22	Visceral adipose tissue adjusted for BMI;	chr13:23829525	chr13:23888889~23897263:+
LUAD	cis	rs9487094	0.922	rs11153181	ENSG00000260273.1	RP11-425D10.10	4.92	1.2e-06	0.000298	0.3	0.22	Height;	chr6:109428824	chr6:109382795~109383666:+
LUAD	cis	rs5758659	1	rs5751255	ENSG00000182057.4	OGFRP1	4.92	1.2e-06	0.000298	0.26	0.22	Cognitive function;	chr22:42252402	chr22:42269753~42275196:+
LUAD	cis	rs17508449	0.865	rs76308249	ENSG00000232450.1	RP4-730K3.3	-4.92	1.2e-06	0.000298	-0.37	-0.22	Leprosy;	chr1:113605059	chr1:113698884~113699631:-
LUAD	cis	rs17508449	0.865	rs80348557	ENSG00000232450.1	RP4-730K3.3	-4.92	1.2e-06	0.000298	-0.37	-0.22	Leprosy;	chr1:113608494	chr1:113698884~113699631:-
LUAD	cis	rs9425766	0.679	rs10912761	ENSG00000227373.4	RP11-160H22.5	4.92	1.2e-06	0.000298	0.28	0.22	Life satisfaction;	chr1:174312466	chr1:174115300~174160004:-
LUAD	cis	rs6095360	0.727	rs2075677	ENSG00000222365.1	SNORD12B	-4.92	1.2e-06	0.000298	-0.25	-0.22	Intelligence (multi-trait analysis);	chr20:49084487	chr20:49280319~49280409:+
LUAD	cis	rs7017914	0.69	rs7845516	ENSG00000223220.1	Y_RNA	-4.92	1.2e-06	0.000298	-0.25	-0.22	Bone mineral density;	chr8:70773587	chr8:70780914~70781008:-
LUAD	cis	rs17772222	0.917	rs4635267	ENSG00000258983.2	RP11-507K2.2	4.92	1.2e-06	0.000298	0.27	0.22	Coronary artery calcification;	chr14:88621922	chr14:88499334~88515502:+
LUAD	cis	rs17772222	0.876	rs56144430	ENSG00000258983.2	RP11-507K2.2	4.92	1.2e-06	0.000298	0.27	0.22	Coronary artery calcification;	chr14:88622013	chr14:88499334~88515502:+
LUAD	cis	rs453301	0.653	rs1562211	ENSG00000253981.4	ALG1L13P	-4.92	1.2e-06	0.000299	-0.25	-0.22	Joint mobility (Beighton score);	chr8:9044914	chr8:8236003~8244667:-
LUAD	cis	rs13256369	0.802	rs34762800	ENSG00000253893.2	FAM85B	-4.92	1.2e-06	0.000299	-0.31	-0.22	Obesity-related traits;	chr8:8701784	chr8:8167819~8226614:-
LUAD	cis	rs950169	0.58	rs2271431	ENSG00000275120.1	RP11-182J1.17	4.92	1.21e-06	0.000299	0.33	0.22	Schizophrenia;	chr15:84646233	chr15:84599434~84606463:-
LUAD	cis	rs4664293	0.867	rs2357531	ENSG00000226266.5	AC009961.3	-4.92	1.21e-06	0.000299	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159740907	chr2:159670708~159712435:-
LUAD	cis	rs2299587	0.689	rs2299588	ENSG00000253671.1	RP11-806O11.1	-4.92	1.21e-06	0.000299	-0.25	-0.22	Economic and political preferences;	chr8:17944216	chr8:17808941~17820868:+
LUAD	cis	rs74233809	0.901	rs11191416	ENSG00000213277.3	MARCKSL1P1	-4.92	1.21e-06	0.000299	-0.36	-0.22	Birth weight;	chr10:102845159	chr10:103175554~103176094:+
LUAD	cis	rs795484	0.507	rs795482	ENSG00000275759.1	RP11-131L12.3	4.92	1.21e-06	0.000299	0.23	0.22	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118153011	chr12:118428281~118428870:+
LUAD	cis	rs561341	1	rs501957	ENSG00000265798.5	RP11-271K11.5	4.92	1.21e-06	0.000299	0.35	0.22	Hip circumference adjusted for BMI;	chr17:31987485	chr17:31038575~31059121:-
LUAD	cis	rs4841134	1	rs4841134	ENSG00000233609.3	RP11-62H7.2	4.92	1.21e-06	0.000299	0.17	0.22	Age-related disease endophenotypes;	chr8:9329014	chr8:8961200~8979025:+
LUAD	cis	rs5758659	0.716	rs5758661	ENSG00000182057.4	OGFRP1	4.92	1.21e-06	0.000299	0.26	0.22	Cognitive function;	chr22:42228439	chr22:42269753~42275196:+
LUAD	cis	rs71520386	0.632	rs9691076	ENSG00000228649.7	AC005682.5	-4.92	1.21e-06	0.000299	-0.3	-0.22	Fibrinogen levels;	chr7:22829742	chr7:22854178~22861579:+
LUAD	cis	rs193541	0.593	rs154517	ENSG00000263432.2	RN7SL689P	4.92	1.21e-06	3e-04	0.29	0.22	Glucose homeostasis traits;	chr5:122854130	chr5:123022487~123022783:-
LUAD	cis	rs853679	0.567	rs2232427	ENSG00000216901.1	AL022393.7	4.92	1.21e-06	3e-04	0.27	0.22	Depression;	chr6:28391932	chr6:28176188~28176674:+
LUAD	cis	rs5758659	0.714	rs133373	ENSG00000227370.1	RP4-669P10.19	-4.92	1.21e-06	3e-04	-0.19	-0.22	Cognitive function;	chr22:42069784	chr22:42132543~42132998:+
LUAD	cis	rs4908760	0.792	rs10864361	ENSG00000270282.1	RP5-1115A15.2	-4.92	1.21e-06	3e-04	-0.24	-0.22	Vitiligo;	chr1:8666662	chr1:8512653~8513021:+
LUAD	cis	rs12745968	0.62	rs4847267	ENSG00000223787.2	RP4-593M8.1	4.92	1.21e-06	3e-04	0.25	0.22	Bipolar disorder and schizophrenia;	chr1:92689790	chr1:92580476~92580821:-
LUAD	cis	rs1816752	0.819	rs4770664	ENSG00000273628.1	RP11-756A22.7	4.92	1.21e-06	3e-04	0.25	0.22	Obesity-related traits;	chr13:24414695	chr13:24933006~24936796:+
LUAD	cis	rs1529102	1	rs1529102	ENSG00000225889.6	AC074289.1	-4.92	1.21e-06	3e-04	-0.21	-0.22	Breast size;	chr2:64268493	chr2:64143239~64252859:+
LUAD	cis	rs301901	1	rs188541	ENSG00000250155.1	CTD-2353F22.1	-4.92	1.21e-06	3e-04	-0.23	-0.22	Height;	chr5:37061159	chr5:36666214~36725195:-
LUAD	cis	rs4835473	0.932	rs4305468	ENSG00000251600.4	RP11-673E1.1	-4.92	1.21e-06	3e-04	-0.27	-0.22	Immature fraction of reticulocytes;	chr4:143987315	chr4:143912331~143982454:+
LUAD	cis	rs1075265	0.587	rs2949811	ENSG00000233266.1	HMGB1P31	4.92	1.21e-06	3e-04	0.28	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53797028	chr2:54051334~54051760:+
LUAD	cis	rs9322193	0.632	rs3828700	ENSG00000268592.3	RAET1E-AS1	4.92	1.21e-06	3e-04	0.27	0.22	Lung cancer;	chr6:149791033	chr6:149863494~149919507:+
LUAD	cis	rs9532669	0.926	rs9532690	ENSG00000239827.7	SUGT1P3	-4.92	1.21e-06	3e-04	-0.25	-0.22	Cervical cancer;	chr13:40968654	chr13:40908159~40921774:-
LUAD	cis	rs12701220	0.901	rs12701710	ENSG00000229043.2	AC091729.9	4.92	1.21e-06	3e-04	0.28	0.22	Bronchopulmonary dysplasia;	chr7:1050760	chr7:1160374~1165267:+
LUAD	cis	rs12468226	0.935	rs75597391	ENSG00000272966.1	RP11-686O6.1	4.92	1.21e-06	3e-04	0.36	0.22	Urate levels;	chr2:202398850	chr2:202336739~202337200:+
LUAD	cis	rs950169	0.58	rs11635597	ENSG00000259295.5	CSPG4P12	4.92	1.21e-06	3e-04	0.31	0.22	Schizophrenia;	chr15:84622468	chr15:85191438~85213905:+
LUAD	cis	rs10129255	0.785	rs10150044	ENSG00000211967.3	IGHV3-53	-4.92	1.21e-06	3e-04	-0.17	-0.22	Kawasaki disease;	chr14:106775695	chr14:106592676~106593347:-
LUAD	cis	rs10129255	0.957	rs10137980	ENSG00000211967.3	IGHV3-53	-4.92	1.21e-06	3e-04	-0.17	-0.22	Kawasaki disease;	chr14:106775735	chr14:106592676~106593347:-
LUAD	cis	rs3096299	0.591	rs748940	ENSG00000182376.2	RP5-1142A6.8	4.92	1.21e-06	3e-04	0.23	0.22	Multiple myeloma (IgH translocation);	chr16:89374349	chr16:88742767~88745748:+
LUAD	cis	rs7299940	0.967	rs10848243	ENSG00000256250.1	RP11-989F5.1	-4.92	1.21e-06	0.000301	-0.24	-0.22	Panic disorder;	chr12:130894769	chr12:130810606~130812438:+
LUAD	cis	rs7119038	0.509	rs10892260	ENSG00000255422.1	AP002954.4	4.92	1.21e-06	0.000301	0.34	0.22	Sjögren's syndrome;	chr11:118712816	chr11:118704607~118750263:+
LUAD	cis	rs17772222	0.917	rs61984708	ENSG00000258983.2	RP11-507K2.2	4.92	1.22e-06	0.000301	0.27	0.22	Coronary artery calcification;	chr14:88565523	chr14:88499334~88515502:+
LUAD	cis	rs9322193	0.962	rs9688412	ENSG00000268592.3	RAET1E-AS1	-4.92	1.22e-06	0.000301	-0.27	-0.22	Lung cancer;	chr6:149803147	chr6:149863494~149919507:+
LUAD	cis	rs7017914	0.69	rs11989644	ENSG00000223220.1	Y_RNA	4.92	1.22e-06	0.000301	0.25	0.22	Bone mineral density;	chr8:70728961	chr8:70780914~70781008:-
LUAD	cis	rs2998286	0.862	rs1416816	ENSG00000254635.4	WAC-AS1	-4.92	1.22e-06	0.000301	-0.26	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28503491	chr10:28522652~28532743:-
LUAD	cis	rs56046484	0.778	rs1606119	ENSG00000259295.5	CSPG4P12	4.92	1.22e-06	0.000301	0.28	0.22	Testicular germ cell tumor;	chr15:85128148	chr15:85191438~85213905:+
LUAD	cis	rs17711722	0.523	rs365896	ENSG00000226002.1	RP11-460N20.5	-4.92	1.22e-06	0.000301	-0.24	-0.22	Calcium levels;	chr7:66045710	chr7:65084103~65100232:+
LUAD	cis	rs910316	1	rs175449	ENSG00000259138.1	RP11-950C14.7	-4.92	1.22e-06	0.000302	-0.23	-0.22	Height;	chr14:75124143	chr14:75127153~75136930:+
LUAD	cis	rs910316	0.935	rs175448	ENSG00000259138.1	RP11-950C14.7	-4.92	1.22e-06	0.000302	-0.23	-0.22	Height;	chr14:75124368	chr14:75127153~75136930:+
LUAD	cis	rs1799949	0.757	rs9915489	ENSG00000267681.1	CTD-3199J23.6	-4.92	1.22e-06	0.000302	-0.25	-0.22	Menopause (age at onset);	chr17:43021209	chr17:43144956~43145255:+
LUAD	cis	rs7598759	0.679	rs6740843	ENSG00000181798.2	LINC00471	-4.92	1.22e-06	0.000302	-0.24	-0.22	Noise-induced hearing loss;	chr2:231467428	chr2:231508426~231514339:-
LUAD	cis	rs2554380	0.628	rs2081541	ENSG00000230373.7	GOLGA6L5P	-4.92	1.22e-06	0.000302	-0.23	-0.22	Height;	chr15:83774934	chr15:84507885~84516814:-
LUAD	cis	rs2554380	0.628	rs919069	ENSG00000230373.7	GOLGA6L5P	-4.92	1.22e-06	0.000302	-0.23	-0.22	Height;	chr15:83775776	chr15:84507885~84516814:-
LUAD	cis	rs10129255	1	rs4612959	ENSG00000274576.2	IGHV2-70	4.92	1.22e-06	0.000302	0.19	0.22	Kawasaki disease;	chr14:106767055	chr14:106770577~106771020:-
LUAD	cis	rs2115630	1	rs6496441	ENSG00000229212.6	RP11-561C5.4	4.91	1.22e-06	0.000302	0.25	0.22	P wave terminal force;	chr15:84820117	chr15:85205440~85234795:-
LUAD	cis	rs9487094	0.778	rs13214717	ENSG00000260273.1	RP11-425D10.10	4.91	1.22e-06	0.000302	0.32	0.22	Height;	chr6:109573151	chr6:109382795~109383666:+
LUAD	cis	rs4604732	0.536	rs61184655	ENSG00000227135.1	GCSAML-AS1	-4.91	1.22e-06	0.000302	-0.33	-0.22	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247488040	chr1:247524679~247526752:-
LUAD	cis	rs720475	1	rs720475	ENSG00000228960.5	OR2A9P	-4.91	1.22e-06	0.000303	-0.3	-0.22	Breast cancer;	chr7:144377836	chr7:144294480~144300934:+
LUAD	cis	rs7811142	1	rs67040465	ENSG00000078319.8	PMS2P1	-4.91	1.22e-06	0.000303	-0.26	-0.22	Platelet count;	chr7:100485455	chr7:100320992~100341908:-
LUAD	cis	rs2115630	0.967	rs10438428	ENSG00000229212.6	RP11-561C5.4	4.91	1.22e-06	0.000303	0.25	0.22	P wave terminal force;	chr15:84787514	chr15:85205440~85234795:-
LUAD	cis	rs11673344	0.526	rs73035160	ENSG00000226686.6	LINC01535	4.91	1.22e-06	0.000303	0.27	0.22	Obesity-related traits;	chr19:37655135	chr19:37251912~37265535:+
LUAD	cis	rs11673344	0.526	rs1871196	ENSG00000226686.6	LINC01535	4.91	1.22e-06	0.000303	0.27	0.22	Obesity-related traits;	chr19:37656022	chr19:37251912~37265535:+
LUAD	cis	rs5758659	0.714	rs5758574	ENSG00000227370.1	RP4-669P10.19	4.91	1.22e-06	0.000303	0.19	0.22	Cognitive function;	chr22:42085396	chr22:42132543~42132998:+
LUAD	cis	rs2548724	0.617	rs62369302	ENSG00000250682.4	LINC00491	4.91	1.22e-06	0.000303	0.27	0.22	Type 2 diabetes;	chr5:102372089	chr5:102609156~102671559:-
LUAD	cis	rs1707322	1	rs3922887	ENSG00000280836.1	AL355480.1	-4.91	1.23e-06	0.000303	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008130	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs3922886	ENSG00000280836.1	AL355480.1	-4.91	1.23e-06	0.000303	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008230	chr1:45581219~45581321:-
LUAD	cis	rs8077577	0.747	rs16961153	ENSG00000273018.4	CTD-2303H24.2	4.91	1.23e-06	0.000303	0.31	0.22	Obesity-related traits;	chr17:18323787	chr17:18511221~18551705:-
LUAD	cis	rs301901	1	rs292184	ENSG00000250155.1	CTD-2353F22.1	-4.91	1.23e-06	0.000303	-0.23	-0.22	Height;	chr5:36963703	chr5:36666214~36725195:-
LUAD	cis	rs5758511	0.68	rs5758687	ENSG00000205702.9	CYP2D7	4.91	1.23e-06	0.000304	0.21	0.22	Birth weight;	chr22:42260582	chr22:42140203~42144577:-
LUAD	cis	rs301901	1	rs301859	ENSG00000250155.1	CTD-2353F22.1	-4.91	1.23e-06	0.000304	-0.23	-0.22	Height;	chr5:37045739	chr5:36666214~36725195:-
LUAD	cis	rs7829975	0.511	rs2948286	ENSG00000173295.6	FAM86B3P	4.91	1.23e-06	0.000304	0.24	0.22	Mood instability;	chr8:8272638	chr8:8228595~8244865:+
LUAD	cis	rs2742234	0.541	rs1879310	ENSG00000273008.1	RP11-351D16.3	4.91	1.23e-06	0.000304	0.25	0.22	Hirschsprung disease;	chr10:43239327	chr10:43136824~43138334:-
LUAD	cis	rs950169	0.84	rs62029595	ENSG00000229212.6	RP11-561C5.4	-4.91	1.23e-06	0.000304	-0.31	-0.22	Schizophrenia;	chr15:84400603	chr15:85205440~85234795:-
LUAD	cis	rs1707322	1	rs11211219	ENSG00000280836.1	AL355480.1	-4.91	1.23e-06	0.000304	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893806	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs11211222	ENSG00000280836.1	AL355480.1	-4.91	1.23e-06	0.000304	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45902085	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.963	rs9787412	ENSG00000280836.1	AL355480.1	-4.91	1.23e-06	0.000304	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45905924	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs4660896	ENSG00000280836.1	AL355480.1	-4.91	1.23e-06	0.000304	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45906744	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs12133129	ENSG00000280836.1	AL355480.1	-4.91	1.23e-06	0.000304	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907676	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.963	rs4553121	ENSG00000280836.1	AL355480.1	-4.91	1.23e-06	0.000304	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45909581	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.963	rs6690652	ENSG00000280836.1	AL355480.1	-4.91	1.23e-06	0.000304	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45911020	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs6695421	ENSG00000280836.1	AL355480.1	-4.91	1.23e-06	0.000304	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914535	chr1:45581219~45581321:-
LUAD	cis	rs4660214	0.666	rs7554206	ENSG00000228060.1	RP11-69E11.8	4.91	1.23e-06	0.000304	0.2	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39463568	chr1:39565160~39573203:+
LUAD	cis	rs36093844	0.699	rs4015260	ENSG00000279742.1	RP11-700A24.1	-4.91	1.23e-06	0.000304	-0.3	-0.22	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85847844	chr11:85852557~85854943:-
LUAD	cis	rs2998286	0.862	rs2790448	ENSG00000254635.4	WAC-AS1	-4.91	1.23e-06	0.000304	-0.28	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28512828	chr10:28522652~28532743:-
LUAD	cis	rs2998286	0.822	rs2807734	ENSG00000254635.4	WAC-AS1	-4.91	1.23e-06	0.000304	-0.28	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28513036	chr10:28522652~28532743:-
LUAD	cis	rs6496932	0.874	rs11074061	ENSG00000202081.1	RNU6-1280P	4.91	1.23e-06	0.000304	0.31	0.22	Central corneal thickness;Corneal structure;	chr15:85274962	chr15:85651522~85651628:-
LUAD	cis	rs301901	1	rs159913	ENSG00000250155.1	CTD-2353F22.1	-4.91	1.23e-06	0.000304	-0.23	-0.22	Height;	chr5:37053881	chr5:36666214~36725195:-
LUAD	cis	rs2243480	1	rs35820085	ENSG00000164669.11	INTS4P1	4.91	1.23e-06	0.000304	0.39	0.22	Diabetic kidney disease;	chr7:65977771	chr7:65141225~65234216:+
LUAD	cis	rs7208859	0.623	rs7220999	ENSG00000266490.1	CTD-2349P21.9	4.91	1.23e-06	0.000304	0.33	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822280	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs55638872	ENSG00000266490.1	CTD-2349P21.9	4.91	1.23e-06	0.000304	0.33	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822534	chr17:30792372~30792833:+
LUAD	cis	rs896854	0.631	rs10097617	ENSG00000253528.2	RP11-347C18.4	4.91	1.23e-06	0.000304	0.21	0.22	Type 2 diabetes;	chr8:94949398	chr8:94974573~94974853:-
LUAD	cis	rs1075265	0.563	rs2542588	ENSG00000233266.1	HMGB1P31	-4.91	1.23e-06	0.000305	-0.28	-0.22	Chronotype;Morning vs. evening chronotype;	chr2:53791787	chr2:54051334~54051760:+
LUAD	cis	rs12745968	0.589	rs6695638	ENSG00000223787.2	RP4-593M8.1	-4.91	1.23e-06	0.000305	-0.26	-0.22	Bipolar disorder and schizophrenia;	chr1:92557929	chr1:92580476~92580821:-
LUAD	cis	rs2439831	0.681	rs1549523	ENSG00000249839.1	AC011330.5	-4.91	1.23e-06	0.000305	-0.38	-0.22	Lung cancer in ever smokers;	chr15:43331991	chr15:43663654~43684339:-
LUAD	cis	rs7017914	0.617	rs111678999	ENSG00000223220.1	Y_RNA	4.91	1.24e-06	0.000305	0.25	0.22	Bone mineral density;	chr8:70755748	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.69	rs35074484	ENSG00000223220.1	Y_RNA	4.91	1.24e-06	0.000305	0.25	0.22	Bone mineral density;	chr8:70762526	chr8:70780914~70781008:-
LUAD	cis	rs7968440	0.808	rs67934435	ENSG00000200428.1	Y_RNA	-4.91	1.24e-06	0.000306	-0.28	-0.22	Fibrinogen;	chr12:50823401	chr12:50743568~50743684:+
LUAD	cis	rs9910055	0.615	rs189049	ENSG00000267080.4	ASB16-AS1	4.91	1.24e-06	0.000306	0.2	0.22	Total body bone mineral density;	chr17:44119845	chr17:44175973~44186717:-
LUAD	cis	rs7665090	0.87	rs228615	ENSG00000246560.2	RP11-10L12.4	-4.91	1.24e-06	0.000306	-0.27	-0.22	Primary biliary cholangitis;	chr4:102658303	chr4:102828055~102844075:+
LUAD	cis	rs7017914	0.652	rs35318824	ENSG00000223220.1	Y_RNA	4.91	1.24e-06	0.000306	0.25	0.22	Bone mineral density;	chr8:70820387	chr8:70780914~70781008:-
LUAD	cis	rs6604026	0.624	rs35311203	ENSG00000223787.2	RP4-593M8.1	4.91	1.24e-06	0.000306	0.3	0.22	Multiple sclerosis;	chr1:92712910	chr1:92580476~92580821:-
LUAD	cis	rs7772486	0.754	rs702306	ENSG00000235652.6	RP11-545I5.3	-4.91	1.24e-06	0.000306	-0.22	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145669893	chr6:145799409~145886585:+
LUAD	cis	rs896854	1	rs896854	ENSG00000253528.2	RP11-347C18.4	4.91	1.24e-06	0.000306	0.21	0.22	Type 2 diabetes;	chr8:94948283	chr8:94974573~94974853:-
LUAD	cis	rs896854	0.902	rs896852	ENSG00000253528.2	RP11-347C18.4	4.91	1.24e-06	0.000306	0.21	0.22	Type 2 diabetes;	chr8:94948658	chr8:94974573~94974853:-
LUAD	cis	rs896854	1	rs7003387	ENSG00000253528.2	RP11-347C18.4	4.91	1.24e-06	0.000306	0.21	0.22	Type 2 diabetes;	chr8:94949751	chr8:94974573~94974853:-
LUAD	cis	rs12745968	0.62	rs7514156	ENSG00000223787.2	RP4-593M8.1	-4.91	1.24e-06	0.000306	-0.26	-0.22	Bipolar disorder and schizophrenia;	chr1:92504652	chr1:92580476~92580821:-
LUAD	cis	rs2790457	0.792	rs1265845	ENSG00000254635.4	WAC-AS1	-4.91	1.24e-06	0.000306	-0.24	-0.22	Multiple myeloma;	chr10:28638294	chr10:28522652~28532743:-
LUAD	cis	rs801193	0.967	rs2707853	ENSG00000237310.1	GS1-124K5.4	4.91	1.24e-06	0.000307	0.24	0.22	Aortic root size;	chr7:66749023	chr7:66493706~66495474:+
LUAD	cis	rs801193	1	rs2659889	ENSG00000237310.1	GS1-124K5.4	4.91	1.24e-06	0.000307	0.24	0.22	Aortic root size;	chr7:66752125	chr7:66493706~66495474:+
LUAD	cis	rs12681366	0.881	rs12675415	ENSG00000253704.1	RP11-267M23.4	4.91	1.24e-06	0.000307	0.27	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94371332	chr8:94553722~94569745:+
LUAD	cis	rs6840258	0.825	rs79998318	ENSG00000251411.1	RP11-397E7.4	-4.91	1.24e-06	0.000307	-0.28	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87033014	chr4:86913266~86914817:-
LUAD	cis	rs1707322	1	rs6657720	ENSG00000280836.1	AL355480.1	-4.91	1.24e-06	0.000307	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45920597	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs7519181	ENSG00000280836.1	AL355480.1	-4.91	1.24e-06	0.000307	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45922157	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs7526369	ENSG00000280836.1	AL355480.1	-4.91	1.24e-06	0.000307	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45924888	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.963	rs10890371	ENSG00000280836.1	AL355480.1	-4.91	1.24e-06	0.000307	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925225	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs10890372	ENSG00000280836.1	AL355480.1	-4.91	1.24e-06	0.000307	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925348	chr1:45581219~45581321:-
LUAD	cis	rs8077577	0.731	rs11869952	ENSG00000273018.4	CTD-2303H24.2	-4.91	1.24e-06	0.000308	-0.31	-0.22	Obesity-related traits;	chr17:18318399	chr17:18511221~18551705:-
LUAD	cis	rs35828350	1	rs35828350	ENSG00000275120.1	RP11-182J1.17	4.91	1.25e-06	0.000308	0.33	0.22	Autism spectrum disorder or schizophrenia;	chr15:84812610	chr15:84599434~84606463:-
LUAD	cis	rs2255336	0.706	rs4415856	ENSG00000245648.1	RP11-277P12.20	-4.91	1.25e-06	0.000308	-0.3	-0.22	Blood protein levels;	chr12:10448069	chr12:10363769~10398506:+
LUAD	cis	rs61270009	0.955	rs415302	ENSG00000247828.6	TMEM161B-AS1	-4.91	1.25e-06	0.000308	-0.24	-0.22	Depressive symptoms;	chr5:88231628	chr5:88268895~88436685:+
LUAD	cis	rs61270009	0.955	rs780398	ENSG00000247828.6	TMEM161B-AS1	-4.91	1.25e-06	0.000308	-0.24	-0.22	Depressive symptoms;	chr5:88234112	chr5:88268895~88436685:+
LUAD	cis	rs2948294	0.588	rs12544596	ENSG00000173295.6	FAM86B3P	4.91	1.25e-06	0.000308	0.24	0.22	Red cell distribution width;	chr8:8258824	chr8:8228595~8244865:+
LUAD	cis	rs1150668	0.764	rs9368565	ENSG00000219392.1	RP1-265C24.5	4.91	1.25e-06	0.000308	0.27	0.22	Pubertal anthropometrics;	chr6:28377433	chr6:28115628~28116551:+
LUAD	cis	rs1150668	0.796	rs1052215	ENSG00000219392.1	RP1-265C24.5	4.91	1.25e-06	0.000308	0.27	0.22	Pubertal anthropometrics;	chr6:28380381	chr6:28115628~28116551:+
LUAD	cis	rs17807185	0.676	rs4273781	ENSG00000214293.7	APTR	4.91	1.25e-06	0.000309	0.24	0.22	Height;	chr7:77671806	chr7:77657660~77696265:-
LUAD	cis	rs11051970	0.559	rs4931012	ENSG00000274964.1	RP11-817I4.1	-4.91	1.25e-06	0.000309	-0.29	-0.22	Response to tocilizumab in rheumatoid arthritis;	chr12:32328970	chr12:32339368~32340724:+
LUAD	cis	rs7615952	0.576	rs17523380	ENSG00000250012.1	RP11-124N2.1	-4.91	1.25e-06	0.000309	-0.29	-0.22	Blood pressure (smoking interaction);	chr3:126084031	chr3:126084220~126095349:+
LUAD	cis	rs875971	0.862	rs709596	ENSG00000232559.3	GS1-124K5.12	4.91	1.25e-06	0.000309	0.26	0.22	Aortic root size;	chr7:66360926	chr7:66554588~66576923:-
LUAD	cis	rs847577	0.832	rs1799068	ENSG00000272950.1	RP11-307C18.1	-4.91	1.25e-06	0.000309	-0.28	-0.22	Breast cancer;	chr7:98077757	chr7:98322853~98323430:+
LUAD	cis	rs12908161	1	rs11637142	ENSG00000275120.1	RP11-182J1.17	4.91	1.25e-06	0.000309	0.33	0.22	Schizophrenia;	chr15:84752696	chr15:84599434~84606463:-
LUAD	cis	rs3738443	1	rs3738443	ENSG00000259865.1	RP11-488L18.10	-4.91	1.25e-06	0.000309	-0.24	-0.22	Alcohol dependence;	chr1:247184887	chr1:247187281~247188526:-
LUAD	cis	rs1816752	0.819	rs4770665	ENSG00000273628.1	RP11-756A22.7	4.91	1.25e-06	0.000309	0.25	0.22	Obesity-related traits;	chr13:24414810	chr13:24933006~24936796:+
LUAD	cis	rs1816752	0.749	rs77832754	ENSG00000273628.1	RP11-756A22.7	4.91	1.25e-06	0.000309	0.25	0.22	Obesity-related traits;	chr13:24416016	chr13:24933006~24936796:+
LUAD	cis	rs1707322	1	rs10890380	ENSG00000280836.1	AL355480.1	-4.91	1.25e-06	0.000309	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983797	chr1:45581219~45581321:-
LUAD	cis	rs16944613	0.588	rs6496697	ENSG00000259212.1	CTD-3065B20.2	-4.91	1.25e-06	0.00031	-0.33	-0.22	Colorectal cancer;	chr15:90588600	chr15:90595840~90596447:-
LUAD	cis	rs375066	0.935	rs430308	ENSG00000267058.1	RP11-15A1.3	-4.91	1.25e-06	0.00031	-0.25	-0.22	Breast cancer;	chr19:43896223	chr19:43891804~43901805:-
LUAD	cis	rs748404	0.697	rs530683	ENSG00000249839.1	AC011330.5	4.91	1.26e-06	0.00031	0.28	0.22	Lung cancer;	chr15:43276801	chr15:43663654~43684339:-
LUAD	cis	rs1008375	1	rs2058338	ENSG00000249502.1	AC006160.5	4.91	1.26e-06	0.00031	0.2	0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17676977	chr4:17587467~17614571:-
LUAD	cis	rs116095464	1	rs61079948	ENSG00000277812.1	AC021087.1	4.91	1.26e-06	0.00031	0.63	0.22	Breast cancer;	chr5:325388	chr5:262769~262881:+
LUAD	cis	rs7017914	0.652	rs3098858	ENSG00000223220.1	Y_RNA	4.91	1.26e-06	0.00031	0.25	0.22	Bone mineral density;	chr8:70951038	chr8:70780914~70781008:-
LUAD	cis	rs9487094	0.645	rs12529505	ENSG00000260273.1	RP11-425D10.10	-4.91	1.26e-06	0.00031	-0.31	-0.22	Height;	chr6:109625358	chr6:109382795~109383666:+
LUAD	cis	rs7772486	0.754	rs6937661	ENSG00000235652.6	RP11-545I5.3	-4.91	1.26e-06	0.00031	-0.22	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145792163	chr6:145799409~145886585:+
LUAD	cis	rs7674212	0.865	rs13149311	ENSG00000246560.2	RP11-10L12.4	4.91	1.26e-06	0.00031	0.28	0.22	Type 2 diabetes;	chr4:103056543	chr4:102828055~102844075:+
LUAD	cis	rs875971	0.66	rs10950044	ENSG00000224316.1	RP11-479O9.2	-4.91	1.26e-06	0.00031	-0.22	-0.22	Aortic root size;	chr7:66577989	chr7:65773620~65802067:+
LUAD	cis	rs8031584	1	rs35811129	ENSG00000270015.1	RP11-540B6.6	-4.91	1.26e-06	0.00031	-0.17	-0.22	Huntington's disease progression;	chr15:30949143	chr15:30926514~30928407:+
LUAD	cis	rs172166	0.561	rs149971	ENSG00000219392.1	RP1-265C24.5	-4.91	1.26e-06	0.00031	-0.27	-0.22	Cardiac Troponin-T levels;	chr6:28014374	chr6:28115628~28116551:+
LUAD	cis	rs12468226	1	rs2350809	ENSG00000272966.1	RP11-686O6.1	4.91	1.26e-06	0.00031	0.36	0.22	Urate levels;	chr2:202464210	chr2:202336739~202337200:+
LUAD	cis	rs375066	0.935	rs407731	ENSG00000267058.1	RP11-15A1.3	4.91	1.26e-06	0.00031	0.25	0.22	Breast cancer;	chr19:43913925	chr19:43891804~43901805:-
LUAD	cis	rs13256369	0.851	rs13255061	ENSG00000253893.2	FAM85B	-4.91	1.26e-06	0.000311	-0.3	-0.22	Obesity-related traits;	chr8:8706324	chr8:8167819~8226614:-
LUAD	cis	rs13256369	0.851	rs12541477	ENSG00000253893.2	FAM85B	-4.91	1.26e-06	0.000311	-0.3	-0.22	Obesity-related traits;	chr8:8706385	chr8:8167819~8226614:-
LUAD	cis	rs13256369	0.851	rs13266562	ENSG00000253893.2	FAM85B	-4.91	1.26e-06	0.000311	-0.3	-0.22	Obesity-related traits;	chr8:8706555	chr8:8167819~8226614:-
LUAD	cis	rs2688608	0.62	rs7098444	ENSG00000271816.1	BMS1P4	4.91	1.26e-06	0.000311	0.18	0.22	Inflammatory bowel disease;	chr10:73820284	chr10:73699151~73730487:-
LUAD	cis	rs877356	1	rs35520957	ENSG00000250378.1	RP11-119J18.1	-4.91	1.26e-06	0.000311	-0.39	-0.22	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (dichotomous);	chr5:135827618	chr5:135812667~135826582:+
LUAD	cis	rs875971	0.66	rs10950044	ENSG00000236529.1	RP13-254B10.1	-4.91	1.26e-06	0.000311	-0.22	-0.22	Aortic root size;	chr7:66577989	chr7:65840212~65840596:+
LUAD	cis	rs11671005	0.735	rs11084544	ENSG00000268912.1	CTD-2619J13.17	-4.91	1.26e-06	0.000311	-0.29	-0.22	Mean platelet volume;	chr19:58428760	chr19:58428632~58431148:-
LUAD	cis	rs7714584	1	rs59531858	ENSG00000197083.10	ZNF300P1	4.91	1.26e-06	0.000311	0.44	0.22	Crohn's disease;	chr5:150867501	chr5:150930645~150946289:-
LUAD	cis	rs61270009	0.687	rs10942530	ENSG00000247828.6	TMEM161B-AS1	4.91	1.26e-06	0.000311	0.27	0.22	Depressive symptoms;	chr5:88414221	chr5:88268895~88436685:+
LUAD	cis	rs7772486	0.719	rs702317	ENSG00000235652.6	RP11-545I5.3	-4.91	1.26e-06	0.000311	-0.22	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145683874	chr6:145799409~145886585:+
LUAD	cis	rs453301	0.686	rs1045527	ENSG00000173295.6	FAM86B3P	-4.91	1.26e-06	0.000311	-0.24	-0.22	Joint mobility (Beighton score);	chr8:9032531	chr8:8228595~8244865:+
LUAD	cis	rs6142102	0.923	rs3787230	ENSG00000275784.1	RP5-1125A11.6	-4.91	1.26e-06	0.000311	-0.24	-0.22	Skin pigmentation;	chr20:34052466	chr20:33989480~33991818:-
LUAD	cis	rs4789693	0.544	rs4789770	ENSG00000265458.1	RP13-20L14.6	4.91	1.26e-06	0.000311	0.3	0.22	Glucocorticoid-induced osteonecrosis;	chr17:82418779	chr17:82454273~82458521:-
LUAD	cis	rs875971	1	rs11974264	ENSG00000232559.3	GS1-124K5.12	-4.91	1.26e-06	0.000311	-0.25	-0.22	Aortic root size;	chr7:66182595	chr7:66554588~66576923:-
LUAD	cis	rs875971	1	rs1540651	ENSG00000232559.3	GS1-124K5.12	-4.91	1.26e-06	0.000311	-0.25	-0.22	Aortic root size;	chr7:66185134	chr7:66554588~66576923:-
LUAD	cis	rs2562456	0.833	rs62107540	ENSG00000268081.1	RP11-678G14.2	4.91	1.26e-06	0.000311	0.35	0.22	Pain;	chr19:21335693	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.833	rs62107541	ENSG00000268081.1	RP11-678G14.2	4.91	1.26e-06	0.000311	0.35	0.22	Pain;	chr19:21335733	chr19:21554640~21569237:-
LUAD	cis	rs875971	0.66	rs10215132	ENSG00000224316.1	RP11-479O9.2	-4.91	1.26e-06	0.000311	-0.22	-0.22	Aortic root size;	chr7:66589419	chr7:65773620~65802067:+
LUAD	cis	rs42490	1	rs13252917	ENSG00000251136.7	RP11-37B2.1	-4.91	1.26e-06	0.000312	-0.22	-0.22	Leprosy;	chr8:89747202	chr8:89609409~89757727:-
LUAD	cis	rs42490	1	rs10112852	ENSG00000251136.7	RP11-37B2.1	-4.91	1.26e-06	0.000312	-0.22	-0.22	Leprosy;	chr8:89749257	chr8:89609409~89757727:-
LUAD	cis	rs6604026	0.503	rs4847311	ENSG00000223787.2	RP4-593M8.1	-4.91	1.26e-06	0.000312	-0.27	-0.22	Multiple sclerosis;	chr1:92758297	chr1:92580476~92580821:-
LUAD	cis	rs9487094	0.885	rs13212766	ENSG00000260273.1	RP11-425D10.10	4.91	1.26e-06	0.000312	0.3	0.22	Height;	chr6:109384228	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.961	rs3757234	ENSG00000260273.1	RP11-425D10.10	4.91	1.26e-06	0.000312	0.3	0.22	Height;	chr6:109385087	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.961	rs1923725	ENSG00000260273.1	RP11-425D10.10	4.91	1.26e-06	0.000312	0.3	0.22	Height;	chr6:109387685	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.961	rs12524639	ENSG00000260273.1	RP11-425D10.10	4.91	1.26e-06	0.000312	0.3	0.22	Height;	chr6:109388256	chr6:109382795~109383666:+
LUAD	cis	rs7829975	0.714	rs11777085	ENSG00000253981.4	ALG1L13P	4.91	1.26e-06	0.000312	0.25	0.22	Mood instability;	chr8:8814919	chr8:8236003~8244667:-
LUAD	cis	rs7772486	0.79	rs9485024	ENSG00000235652.6	RP11-545I5.3	-4.91	1.26e-06	0.000312	-0.22	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145821351	chr6:145799409~145886585:+
LUAD	cis	rs2115630	0.967	rs28595395	ENSG00000229212.6	RP11-561C5.4	4.91	1.26e-06	0.000312	0.26	0.22	P wave terminal force;	chr15:84791721	chr15:85205440~85234795:-
LUAD	cis	rs2998286	0.723	rs332142	ENSG00000254635.4	WAC-AS1	-4.91	1.27e-06	0.000312	-0.29	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28575026	chr10:28522652~28532743:-
LUAD	cis	rs2998286	0.723	rs332143	ENSG00000254635.4	WAC-AS1	-4.91	1.27e-06	0.000312	-0.29	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28575777	chr10:28522652~28532743:-
LUAD	cis	rs1707322	0.896	rs809774	ENSG00000280836.1	AL355480.1	4.91	1.27e-06	0.000313	0.28	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46094572	chr1:45581219~45581321:-
LUAD	cis	rs219780	0.784	rs219778	ENSG00000233818.1	AP000695.4	4.91	1.27e-06	0.000313	0.25	0.22	Kidney stones;	chr21:36462343	chr21:36445731~36532408:+
LUAD	cis	rs219780	0.784	rs219776	ENSG00000233818.1	AP000695.4	4.91	1.27e-06	0.000313	0.25	0.22	Kidney stones;	chr21:36462537	chr21:36445731~36532408:+
LUAD	cis	rs219780	0.75	rs2835363	ENSG00000233818.1	AP000695.4	4.91	1.27e-06	0.000313	0.25	0.22	Kidney stones;	chr21:36462616	chr21:36445731~36532408:+
LUAD	cis	rs219780	0.75	rs219775	ENSG00000233818.1	AP000695.4	4.91	1.27e-06	0.000313	0.25	0.22	Kidney stones;	chr21:36462646	chr21:36445731~36532408:+
LUAD	cis	rs9322193	0.884	rs7769115	ENSG00000268592.3	RAET1E-AS1	4.91	1.27e-06	0.000313	0.28	0.22	Lung cancer;	chr6:149848796	chr6:149863494~149919507:+
LUAD	cis	rs1008375	0.797	rs6843530	ENSG00000249502.1	AC006160.5	-4.91	1.27e-06	0.000313	-0.22	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17591982	chr4:17587467~17614571:-
LUAD	cis	rs948562	0.519	rs12295189	ENSG00000280010.1	AP001350.4	4.91	1.27e-06	0.000313	0.31	0.22	Lymphoma;	chr11:58292254	chr11:58627435~58628528:+
LUAD	cis	rs14027	0.883	rs35449013	ENSG00000279347.1	RP11-85I17.2	-4.91	1.27e-06	0.000313	-0.19	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119729239	chr8:119838736~119840385:-
LUAD	cis	rs14027	0.705	rs13265683	ENSG00000279347.1	RP11-85I17.2	-4.91	1.27e-06	0.000313	-0.19	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119729926	chr8:119838736~119840385:-
LUAD	cis	rs210138	0.832	rs375555	ENSG00000197251.3	LINC00336	4.91	1.27e-06	0.000313	0.37	0.22	Testicular germ cell tumor;	chr6:33589964	chr6:33586106~33593338:-
LUAD	cis	rs12468226	0.872	rs1061157	ENSG00000226261.1	AC064836.3	4.91	1.27e-06	0.000313	0.36	0.22	Urate levels;	chr2:202556476	chr2:202336024~202336727:-
LUAD	cis	rs8040855	0.659	rs8037886	ENSG00000259774.1	RP11-182J1.13	-4.91	1.27e-06	0.000313	-0.29	-0.22	Bulimia nervosa;	chr15:85143533	chr15:84422618~84425882:+
LUAD	cis	rs7017914	0.69	rs13269690	ENSG00000223220.1	Y_RNA	4.91	1.27e-06	0.000314	0.25	0.22	Bone mineral density;	chr8:70732572	chr8:70780914~70781008:-
LUAD	cis	rs801193	0.569	rs2659893	ENSG00000232559.3	GS1-124K5.12	4.91	1.27e-06	0.000314	0.26	0.22	Aortic root size;	chr7:66735006	chr7:66554588~66576923:-
LUAD	cis	rs801193	0.569	rs2659892	ENSG00000232559.3	GS1-124K5.12	4.91	1.27e-06	0.000314	0.26	0.22	Aortic root size;	chr7:66735318	chr7:66554588~66576923:-
LUAD	cis	rs801193	0.548	rs2659891	ENSG00000232559.3	GS1-124K5.12	4.91	1.27e-06	0.000314	0.26	0.22	Aortic root size;	chr7:66736127	chr7:66554588~66576923:-
LUAD	cis	rs801193	0.569	rs2707847	ENSG00000232559.3	GS1-124K5.12	4.91	1.27e-06	0.000314	0.26	0.22	Aortic root size;	chr7:66737884	chr7:66554588~66576923:-
LUAD	cis	rs801193	0.548	rs7805152	ENSG00000232559.3	GS1-124K5.12	4.91	1.27e-06	0.000314	0.26	0.22	Aortic root size;	chr7:66744266	chr7:66554588~66576923:-
LUAD	cis	rs9322193	0.923	rs11155670	ENSG00000268592.3	RAET1E-AS1	4.91	1.27e-06	0.000314	0.27	0.22	Lung cancer;	chr6:149644992	chr6:149863494~149919507:+
LUAD	cis	rs7772486	0.754	rs9390356	ENSG00000235652.6	RP11-545I5.3	-4.91	1.27e-06	0.000314	-0.21	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145797847	chr6:145799409~145886585:+
LUAD	cis	rs7811142	1	rs11559117	ENSG00000078319.8	PMS2P1	-4.91	1.27e-06	0.000314	-0.26	-0.22	Platelet count;	chr7:100478991	chr7:100320992~100341908:-
LUAD	cis	rs7811142	1	rs2406253	ENSG00000078319.8	PMS2P1	-4.91	1.27e-06	0.000314	-0.26	-0.22	Platelet count;	chr7:100479650	chr7:100320992~100341908:-
LUAD	cis	rs7811142	1	rs4463351	ENSG00000078319.8	PMS2P1	-4.91	1.27e-06	0.000314	-0.26	-0.22	Platelet count;	chr7:100480603	chr7:100320992~100341908:-
LUAD	cis	rs7811142	1	rs60844404	ENSG00000078319.8	PMS2P1	-4.91	1.27e-06	0.000314	-0.26	-0.22	Platelet count;	chr7:100482851	chr7:100320992~100341908:-
LUAD	cis	rs7811142	1	rs113738841	ENSG00000078319.8	PMS2P1	-4.91	1.27e-06	0.000314	-0.26	-0.22	Platelet count;	chr7:100483683	chr7:100320992~100341908:-
LUAD	cis	rs7811142	1	rs11763511	ENSG00000078319.8	PMS2P1	-4.91	1.27e-06	0.000314	-0.26	-0.22	Platelet count;	chr7:100484321	chr7:100320992~100341908:-
LUAD	cis	rs7811142	1	rs2897358	ENSG00000078319.8	PMS2P1	-4.91	1.27e-06	0.000314	-0.26	-0.22	Platelet count;	chr7:100491017	chr7:100320992~100341908:-
LUAD	cis	rs860295	0.651	rs6692183	ENSG00000225855.5	RUSC1-AS1	4.91	1.27e-06	0.000314	0.15	0.22	Body mass index;	chr1:155334536	chr1:155316863~155324176:-
LUAD	cis	rs1707322	1	rs1707303	ENSG00000280836.1	AL355480.1	4.91	1.27e-06	0.000314	0.29	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46132601	chr1:45581219~45581321:-
LUAD	cis	rs1874124	0.895	rs34621709	ENSG00000272823.1	RP11-295M18.6	-4.91	1.27e-06	0.000314	-0.33	-0.22	Cholesterol, total;	chr1:220806736	chr1:220828676~220829211:-
LUAD	cis	rs2243480	1	rs316315	ENSG00000230295.1	RP11-458F8.2	4.91	1.27e-06	0.000314	0.23	0.22	Diabetic kidney disease;	chr7:66126218	chr7:66880708~66882981:+
LUAD	cis	rs5758659	0.714	rs2284087	ENSG00000227370.1	RP4-669P10.19	4.91	1.28e-06	0.000314	0.19	0.22	Cognitive function;	chr22:42089667	chr22:42132543~42132998:+
LUAD	cis	rs7636293	1	rs7636293	ENSG00000270773.1	RP13-685P2.7	-4.91	1.28e-06	0.000314	-0.26	-0.22	Height;	chr3:129327063	chr3:129345411~129346164:+
LUAD	cis	rs9322193	0.962	rs35443312	ENSG00000268592.3	RAET1E-AS1	4.91	1.28e-06	0.000315	0.27	0.22	Lung cancer;	chr6:149670625	chr6:149863494~149919507:+
LUAD	cis	rs9487094	0.885	rs2208209	ENSG00000260273.1	RP11-425D10.10	4.91	1.28e-06	0.000315	0.3	0.22	Height;	chr6:109581800	chr6:109382795~109383666:+
LUAD	cis	rs7017914	0.629	rs2732126	ENSG00000223220.1	Y_RNA	4.91	1.28e-06	0.000315	0.25	0.22	Bone mineral density;	chr8:70986257	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.629	rs2732125	ENSG00000223220.1	Y_RNA	4.91	1.28e-06	0.000315	0.25	0.22	Bone mineral density;	chr8:70986266	chr8:70780914~70781008:-
LUAD	cis	rs2072438	0.503	rs10739590	ENSG00000226752.6	PSMD5-AS1	-4.91	1.28e-06	0.000315	-0.23	-0.22	Rheumatoid arthritis;	chr9:121109203	chr9:120824828~120854385:+
LUAD	cis	rs7131987	0.621	rs57803026	ENSG00000257176.2	RP11-996F15.2	-4.91	1.28e-06	0.000315	-0.25	-0.22	QT interval;	chr12:29344573	chr12:29280418~29317848:-
LUAD	cis	rs875971	0.619	rs10278371	ENSG00000224316.1	RP11-479O9.2	-4.91	1.28e-06	0.000315	-0.22	-0.22	Aortic root size;	chr7:66586553	chr7:65773620~65802067:+
LUAD	cis	rs12745968	0.652	rs6603986	ENSG00000223787.2	RP4-593M8.1	-4.91	1.28e-06	0.000315	-0.27	-0.22	Bipolar disorder and schizophrenia;	chr1:92551664	chr1:92580476~92580821:-
LUAD	cis	rs8396	1	rs9918016	ENSG00000271817.2	U3	4.91	1.28e-06	0.000315	0.27	0.22	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158700845	chr4:158700691~158700909:+
LUAD	cis	rs12928939	0.911	rs12917983	ENSG00000260886.1	TAT-AS1	4.91	1.28e-06	0.000315	0.28	0.22	Post bronchodilator FEV1;	chr16:71801340	chr16:71565789~71578187:+
LUAD	cis	rs35740288	1	rs35740288	ENSG00000202081.1	RNU6-1280P	4.91	1.28e-06	0.000315	0.27	0.22	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85753854	chr15:85651522~85651628:-
LUAD	cis	rs35740288	1	rs17577449	ENSG00000202081.1	RNU6-1280P	4.91	1.28e-06	0.000315	0.27	0.22	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85753954	chr15:85651522~85651628:-
LUAD	cis	rs7302981	0.9	rs836180	ENSG00000272368.2	RP4-605O3.4	4.91	1.28e-06	0.000315	0.26	0.22	Systolic blood pressure;	chr12:50109486	chr12:50112197~50165618:+
LUAD	cis	rs910316	1	rs175436	ENSG00000259138.1	RP11-950C14.7	-4.91	1.28e-06	0.000315	-0.23	-0.22	Height;	chr14:75141980	chr14:75127153~75136930:+
LUAD	cis	rs6142102	0.961	rs1883524	ENSG00000275784.1	RP5-1125A11.6	-4.91	1.28e-06	0.000315	-0.24	-0.22	Skin pigmentation;	chr20:34038301	chr20:33989480~33991818:-
LUAD	cis	rs17772222	0.958	rs59136503	ENSG00000258983.2	RP11-507K2.2	4.91	1.28e-06	0.000315	0.27	0.22	Coronary artery calcification;	chr14:88501921	chr14:88499334~88515502:+
LUAD	cis	rs7404843	0.925	rs12600043	ENSG00000263335.1	AF001548.5	4.91	1.28e-06	0.000315	0.48	0.22	Testicular germ cell tumor;	chr16:15446095	chr16:15726674~15732993:+
LUAD	cis	rs71520386	0.632	rs10224533	ENSG00000228649.7	AC005682.5	-4.9	1.28e-06	0.000316	-0.3	-0.22	Fibrinogen levels;	chr7:22821522	chr7:22854178~22861579:+
LUAD	cis	rs71520386	0.632	rs35353454	ENSG00000228649.7	AC005682.5	-4.9	1.28e-06	0.000316	-0.3	-0.22	Fibrinogen levels;	chr7:22822120	chr7:22854178~22861579:+
LUAD	cis	rs848490	0.855	rs67745553	ENSG00000214293.7	APTR	4.9	1.28e-06	0.000316	0.28	0.22	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77674781	chr7:77657660~77696265:-
LUAD	cis	rs9322193	0.923	rs9688350	ENSG00000268592.3	RAET1E-AS1	4.9	1.28e-06	0.000316	0.27	0.22	Lung cancer;	chr6:149730977	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.923	rs9767652	ENSG00000268592.3	RAET1E-AS1	4.9	1.28e-06	0.000316	0.27	0.22	Lung cancer;	chr6:149734502	chr6:149863494~149919507:+
LUAD	cis	rs804292	0.695	rs804279	ENSG00000255046.1	RP11-297N6.4	4.9	1.28e-06	0.000316	0.31	0.22	Nicotine use;Alcohol dependence;	chr8:11766380	chr8:11797928~11802568:-
LUAD	cis	rs375066	0.935	rs406968	ENSG00000267058.1	RP11-15A1.3	-4.9	1.28e-06	0.000316	-0.25	-0.22	Breast cancer;	chr19:43914191	chr19:43891804~43901805:-
LUAD	cis	rs1707322	1	rs11211217	ENSG00000280836.1	AL355480.1	-4.9	1.28e-06	0.000316	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45882557	chr1:45581219~45581321:-
LUAD	cis	rs748404	0.666	rs35158584	ENSG00000205771.5	CATSPER2P1	-4.9	1.28e-06	0.000316	-0.34	-0.22	Lung cancer;	chr15:43392876	chr15:43726918~43747094:-
LUAD	cis	rs2404602	0.647	rs7181506	ENSG00000259422.1	RP11-593F23.1	4.9	1.28e-06	0.000316	0.28	0.22	Blood metabolite levels;	chr15:76643336	chr15:76174891~76181486:-
LUAD	cis	rs801193	1	rs2707854	ENSG00000236529.1	RP13-254B10.1	4.9	1.28e-06	0.000316	0.22	0.22	Aortic root size;	chr7:66747610	chr7:65840212~65840596:+
LUAD	cis	rs9287719	0.649	rs10207885	ENSG00000243819.4	RN7SL832P	4.9	1.28e-06	0.000316	0.23	0.22	Prostate cancer;	chr2:10593062	chr2:10690344~10692099:+
LUAD	cis	rs2522056	0.808	rs1016988	ENSG00000233006.5	AC034220.3	-4.9	1.29e-06	0.000317	-0.25	-0.22	Fibrinogen;Lymphocyte counts;	chr5:132408882	chr5:132311285~132369916:-
LUAD	cis	rs7119038	0.509	rs10790261	ENSG00000255239.1	AP002954.6	4.9	1.29e-06	0.000317	0.32	0.22	Sjögren's syndrome;	chr11:118709038	chr11:118688039~118690600:-
LUAD	cis	rs12745968	0.653	rs1003116	ENSG00000223787.2	RP4-593M8.1	-4.9	1.29e-06	0.000317	-0.26	-0.22	Bipolar disorder and schizophrenia;	chr1:92700844	chr1:92580476~92580821:-
LUAD	cis	rs6840360	0.681	rs4519779	ENSG00000270265.1	RP11-731D1.4	-4.9	1.29e-06	0.000317	-0.23	-0.22	Intelligence (multi-trait analysis);	chr4:151380033	chr4:151333775~151353224:-
LUAD	cis	rs7017914	0.69	rs7003794	ENSG00000223220.1	Y_RNA	4.9	1.29e-06	0.000317	0.25	0.22	Bone mineral density;	chr8:70876911	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.714	rs1982884	ENSG00000223220.1	Y_RNA	4.9	1.29e-06	0.000317	0.25	0.22	Bone mineral density;	chr8:70877318	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.69	rs13255749	ENSG00000223220.1	Y_RNA	4.9	1.29e-06	0.000317	0.25	0.22	Bone mineral density;	chr8:70889586	chr8:70780914~70781008:-
LUAD	cis	rs11051970	0.559	rs3748275	ENSG00000274964.1	RP11-817I4.1	-4.9	1.29e-06	0.000317	-0.29	-0.22	Response to tocilizumab in rheumatoid arthritis;	chr12:32328159	chr12:32339368~32340724:+
LUAD	cis	rs5758659	0.714	rs5751216	ENSG00000227370.1	RP4-669P10.19	4.9	1.29e-06	0.000317	0.19	0.22	Cognitive function;	chr22:42112933	chr22:42132543~42132998:+
LUAD	cis	rs4664293	0.51	rs3903306	ENSG00000226266.5	AC009961.3	4.9	1.29e-06	0.000317	0.3	0.22	Monocyte percentage of white cells;	chr2:159592171	chr2:159670708~159712435:-
LUAD	cis	rs12468226	1	rs79919139	ENSG00000272966.1	RP11-686O6.1	4.9	1.29e-06	0.000317	0.36	0.22	Urate levels;	chr2:202382786	chr2:202336739~202337200:+
LUAD	cis	rs9910055	0.607	rs13726	ENSG00000267080.4	ASB16-AS1	-4.9	1.29e-06	0.000317	-0.2	-0.22	Total body bone mineral density;	chr17:44162193	chr17:44175973~44186717:-
LUAD	cis	rs875971	0.66	rs10215132	ENSG00000236529.1	RP13-254B10.1	-4.9	1.29e-06	0.000317	-0.22	-0.22	Aortic root size;	chr7:66589419	chr7:65840212~65840596:+
LUAD	cis	rs9584850	0.794	rs17574433	ENSG00000231194.1	FARP1-AS1	-4.9	1.29e-06	0.000317	-0.28	-0.22	Neuroticism;	chr13:98485803	chr13:98435405~98435840:-
LUAD	cis	rs6723226	0.708	rs2710627	ENSG00000276334.1	AL133243.1	4.9	1.29e-06	0.000317	0.25	0.22	Intelligence (multi-trait analysis);	chr2:32533560	chr2:32521927~32523547:+
LUAD	cis	rs1012068	0.581	rs5753817	ENSG00000236132.1	CTA-440B3.1	-4.9	1.29e-06	0.000317	-0.29	-0.22	Chronic hepatitis C infection;	chr22:31917741	chr22:31816379~31817491:-
LUAD	cis	rs5769707	0.616	rs6009786	ENSG00000235111.1	RP1-29C18.8	-4.9	1.29e-06	0.000317	-0.26	-0.22	Monocyte percentage of white cells;Monocyte count;	chr22:49621497	chr22:49612657~49615716:-
LUAD	cis	rs453301	0.686	rs6601281	ENSG00000233609.3	RP11-62H7.2	-4.9	1.29e-06	0.000317	-0.18	-0.22	Joint mobility (Beighton score);	chr8:9053494	chr8:8961200~8979025:+
LUAD	cis	rs453301	0.631	rs13250781	ENSG00000253893.2	FAM85B	4.9	1.29e-06	0.000318	0.28	0.22	Joint mobility (Beighton score);	chr8:8935833	chr8:8167819~8226614:-
LUAD	cis	rs748404	0.666	rs35326382	ENSG00000205771.5	CATSPER2P1	-4.9	1.29e-06	0.000318	-0.33	-0.22	Lung cancer;	chr15:43338686	chr15:43726918~43747094:-
LUAD	cis	rs948562	0.895	rs7484263	ENSG00000280010.1	AP001350.4	4.9	1.29e-06	0.000318	0.33	0.22	Lymphoma;	chr11:58608080	chr11:58627435~58628528:+
LUAD	cis	rs4835473	0.897	rs11723113	ENSG00000251600.4	RP11-673E1.1	4.9	1.29e-06	0.000318	0.27	0.22	Immature fraction of reticulocytes;	chr4:143707283	chr4:143912331~143982454:+
LUAD	cis	rs2337406	1	rs17112416	ENSG00000223648.3	IGHV3-64	-4.9	1.29e-06	0.000318	-0.27	-0.22	Alzheimer's disease (late onset);	chr14:106686773	chr14:106643132~106658258:-
LUAD	cis	rs61270009	0.955	rs35300532	ENSG00000247828.6	TMEM161B-AS1	4.9	1.29e-06	0.000318	0.25	0.22	Depressive symptoms;	chr5:88293219	chr5:88268895~88436685:+
LUAD	cis	rs61270009	0.955	rs12659252	ENSG00000247828.6	TMEM161B-AS1	4.9	1.29e-06	0.000318	0.25	0.22	Depressive symptoms;	chr5:88297472	chr5:88268895~88436685:+
LUAD	cis	rs4964805	0.657	rs4964813	ENSG00000257681.1	RP11-341G23.4	4.9	1.29e-06	0.000318	0.23	0.22	Attention deficit hyperactivity disorder;	chr12:103795776	chr12:103746315~103768858:-
LUAD	cis	rs73173548	0.502	rs71639110	ENSG00000247828.6	TMEM161B-AS1	4.9	1.29e-06	0.000318	0.27	0.22	Macular telangiectasia type 2;	chr5:88422222	chr5:88268895~88436685:+
LUAD	cis	rs7302981	0.899	rs4883481	ENSG00000272368.2	RP4-605O3.4	-4.9	1.29e-06	0.000318	-0.26	-0.22	Systolic blood pressure;	chr12:50180528	chr12:50112197~50165618:+
LUAD	cis	rs783540	0.609	rs803686	ENSG00000276710.3	CSPG4P8	4.9	1.29e-06	0.000318	0.23	0.22	Schizophrenia;	chr15:82550590	chr15:82459472~82477258:+
LUAD	cis	rs67981189	0.647	rs36555	ENSG00000269927.1	RP6-91H8.3	-4.9	1.29e-06	0.000318	-0.29	-0.22	Schizophrenia;	chr14:70897844	chr14:71141125~71143253:-
LUAD	cis	rs4835473	0.736	rs11724009	ENSG00000251600.4	RP11-673E1.1	4.9	1.29e-06	0.000318	0.27	0.22	Immature fraction of reticulocytes;	chr4:143984291	chr4:143912331~143982454:+
LUAD	cis	rs4323050	0.514	rs28647406	ENSG00000251600.4	RP11-673E1.1	4.9	1.29e-06	0.000318	0.27	0.22	High light scatter reticulocyte percentage of red cells;	chr4:143984437	chr4:143912331~143982454:+
LUAD	cis	rs9860428	0.844	rs9820561	ENSG00000242770.2	RP11-180K7.1	4.9	1.29e-06	0.000318	0.23	0.22	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112897693	chr3:112802478~112812819:+
LUAD	cis	rs6687758	0.687	rs12140529	ENSG00000228437.4	RP11-400N13.2	4.9	1.29e-06	0.000318	0.31	0.22	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221925411	chr1:221966341~221984964:+
LUAD	cis	rs375066	0.868	rs370190	ENSG00000267058.1	RP11-15A1.3	-4.9	1.29e-06	0.000318	-0.25	-0.22	Breast cancer;	chr19:43920102	chr19:43891804~43901805:-
LUAD	cis	rs10050311	0.746	rs17420607	ENSG00000251411.1	RP11-397E7.4	-4.9	1.29e-06	0.000318	-0.3	-0.22	Insulin-related traits;	chr4:86749048	chr4:86913266~86914817:-
LUAD	cis	rs17826219	0.706	rs57698184	ENSG00000263603.1	CTD-2349P21.5	-4.9	1.29e-06	0.000319	-0.38	-0.22	Body mass index;	chr17:30737900	chr17:30729469~30731202:+
LUAD	cis	rs17826219	0.706	rs9893922	ENSG00000263603.1	CTD-2349P21.5	-4.9	1.29e-06	0.000319	-0.38	-0.22	Body mass index;	chr17:30741407	chr17:30729469~30731202:+
LUAD	cis	rs17826219	0.5	rs9891256	ENSG00000263603.1	CTD-2349P21.5	-4.9	1.29e-06	0.000319	-0.38	-0.22	Body mass index;	chr17:30745674	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs7503335	ENSG00000263603.1	CTD-2349P21.5	-4.9	1.29e-06	0.000319	-0.38	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30729469~30731202:+
LUAD	cis	rs875971	0.564	rs313804	ENSG00000232559.3	GS1-124K5.12	4.9	1.3e-06	0.000319	0.26	0.22	Aortic root size;	chr7:66049635	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.662	rs448725	ENSG00000232559.3	GS1-124K5.12	4.9	1.3e-06	0.000319	0.26	0.22	Aortic root size;	chr7:66049641	chr7:66554588~66576923:-
LUAD	cis	rs853679	0.723	rs9366718	ENSG00000219392.1	RP1-265C24.5	-4.9	1.3e-06	0.000319	-0.32	-0.22	Depression;	chr6:28237724	chr6:28115628~28116551:+
LUAD	cis	rs516805	0.561	rs2816096	ENSG00000279453.1	RP3-425C14.4	-4.9	1.3e-06	0.000319	-0.29	-0.22	Lymphocyte counts;	chr6:122075731	chr6:122436789~122439223:-
LUAD	cis	rs2243480	1	rs35396113	ENSG00000164669.11	INTS4P1	4.9	1.3e-06	0.000319	0.39	0.22	Diabetic kidney disease;	chr7:66030474	chr7:65141225~65234216:+
LUAD	cis	rs4660214	0.789	rs1180375	ENSG00000228060.1	RP11-69E11.8	-4.9	1.3e-06	0.000319	-0.2	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39415368	chr1:39565160~39573203:+
LUAD	cis	rs75920871	0.528	rs2513097	ENSG00000254851.1	RP11-109L13.1	4.9	1.3e-06	0.000319	0.32	0.22	Subjective well-being;	chr11:116965496	chr11:117135528~117138582:+
LUAD	cis	rs11155671	0.53	rs9968871	ENSG00000268592.3	RAET1E-AS1	4.9	1.3e-06	0.000319	0.28	0.22	Testicular germ cell tumor;	chr6:149888060	chr6:149863494~149919507:+
LUAD	cis	rs11155671	0.53	rs9969044	ENSG00000268592.3	RAET1E-AS1	4.9	1.3e-06	0.000319	0.28	0.22	Testicular germ cell tumor;	chr6:149888068	chr6:149863494~149919507:+
LUAD	cis	rs4706831	0.625	rs638056	ENSG00000272129.1	RP11-250B2.6	-4.9	1.3e-06	0.000319	-0.27	-0.22	Joint mobility (Beighton score);	chr6:80271091	chr6:80355424~80356859:+
LUAD	cis	rs8070463	0.515	rs11655943	ENSG00000228782.6	CTD-2026D20.3	4.9	1.3e-06	0.00032	0.23	0.22	Multiple sclerosis;Ankylosing spondylitis;	chr17:47308274	chr17:47450568~47492492:-
LUAD	cis	rs2998286	0.862	rs2185293	ENSG00000254635.4	WAC-AS1	-4.9	1.3e-06	0.00032	-0.27	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28519170	chr10:28522652~28532743:-
LUAD	cis	rs7811142	1	rs6979335	ENSG00000078319.8	PMS2P1	-4.9	1.3e-06	0.00032	-0.26	-0.22	Platelet count;	chr7:100492237	chr7:100320992~100341908:-
LUAD	cis	rs7811142	1	rs73405353	ENSG00000078319.8	PMS2P1	-4.9	1.3e-06	0.00032	-0.26	-0.22	Platelet count;	chr7:100493592	chr7:100320992~100341908:-
LUAD	cis	rs1707322	1	rs785498	ENSG00000280836.1	AL355480.1	4.9	1.3e-06	0.00032	0.28	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126742	chr1:45581219~45581321:-
LUAD	cis	rs2098713	0.535	rs10941358	ENSG00000250155.1	CTD-2353F22.1	4.9	1.3e-06	0.00032	0.23	0.22	Telomere length;	chr5:37637276	chr5:36666214~36725195:-
LUAD	cis	rs11976180	1	rs7777389	ENSG00000170356.8	OR2A20P	-4.9	1.3e-06	0.000321	-0.28	-0.22	Obesity-related traits;	chr7:144047709	chr7:144250045~144252957:-
LUAD	cis	rs2742234	0.541	rs10899786	ENSG00000273008.1	RP11-351D16.3	4.9	1.3e-06	0.000321	0.26	0.22	Hirschsprung disease;	chr10:43249135	chr10:43136824~43138334:-
LUAD	cis	rs2742234	0.541	rs61845684	ENSG00000273008.1	RP11-351D16.3	4.9	1.3e-06	0.000321	0.26	0.22	Hirschsprung disease;	chr10:43249535	chr10:43136824~43138334:-
LUAD	cis	rs950169	0.922	rs62028133	ENSG00000229212.6	RP11-561C5.4	-4.9	1.3e-06	0.000321	-0.32	-0.22	Schizophrenia;	chr15:84250623	chr15:85205440~85234795:-
LUAD	cis	rs5758511	0.68	rs1107553	ENSG00000205702.9	CYP2D7	4.9	1.3e-06	0.000321	0.21	0.22	Birth weight;	chr22:42271467	chr22:42140203~42144577:-
LUAD	cis	rs375066	1	rs375066	ENSG00000267058.1	RP11-15A1.3	-4.9	1.3e-06	0.000321	-0.25	-0.22	Breast cancer;	chr19:43919418	chr19:43891804~43901805:-
LUAD	cis	rs9543976	0.623	rs6562914	ENSG00000261553.4	RP11-29G8.3	4.9	1.3e-06	0.000321	0.28	0.22	Diabetic retinopathy;	chr13:75593401	chr13:75549773~75807120:+
LUAD	cis	rs2742234	0.541	rs12416428	ENSG00000273008.1	RP11-351D16.3	4.9	1.31e-06	0.000321	0.26	0.22	Hirschsprung disease;	chr10:43213550	chr10:43136824~43138334:-
LUAD	cis	rs2742234	0.541	rs11238476	ENSG00000273008.1	RP11-351D16.3	4.9	1.31e-06	0.000321	0.26	0.22	Hirschsprung disease;	chr10:43215988	chr10:43136824~43138334:-
LUAD	cis	rs4819052	1	rs2297284	ENSG00000215447.6	BX322557.10	-4.9	1.31e-06	0.000321	-0.28	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285430	chr21:45288052~45291738:+
LUAD	cis	rs71520386	0.579	rs4394299	ENSG00000228649.7	AC005682.5	-4.9	1.31e-06	0.000321	-0.3	-0.22	Fibrinogen levels;	chr7:22825763	chr7:22854178~22861579:+
LUAD	cis	rs2300747	0.872	rs1034920	ENSG00000177173.5	NAP1L4P1	-4.9	1.31e-06	0.000321	-0.35	-0.22	Primary biliary cholangitis;Multiple sclerosis;	chr1:116533777	chr1:116532936~116534092:-
LUAD	cis	rs2300747	0.872	rs1034921	ENSG00000177173.5	NAP1L4P1	-4.9	1.31e-06	0.000321	-0.35	-0.22	Primary biliary cholangitis;Multiple sclerosis;	chr1:116533781	chr1:116532936~116534092:-
LUAD	cis	rs2300747	0.872	rs10802192	ENSG00000177173.5	NAP1L4P1	-4.9	1.31e-06	0.000321	-0.35	-0.22	Primary biliary cholangitis;Multiple sclerosis;	chr1:116533839	chr1:116532936~116534092:-
LUAD	cis	rs1008375	0.966	rs2302393	ENSG00000249502.1	AC006160.5	-4.9	1.31e-06	0.000321	-0.21	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17652718	chr4:17587467~17614571:-
LUAD	cis	rs7017914	0.652	rs1845217	ENSG00000223220.1	Y_RNA	4.9	1.31e-06	0.000321	0.25	0.22	Bone mineral density;	chr8:70985016	chr8:70780914~70781008:-
LUAD	cis	rs2933343	0.7	rs6787833	ENSG00000261159.1	RP11-723O4.9	4.9	1.31e-06	0.000321	0.24	0.22	IgG glycosylation;	chr3:128937341	chr3:128859716~128860526:-
LUAD	cis	rs875971	0.825	rs6951503	ENSG00000232559.3	GS1-124K5.12	-4.9	1.31e-06	0.000321	-0.26	-0.22	Aortic root size;	chr7:66253949	chr7:66554588~66576923:-
LUAD	cis	rs5758659	0.904	rs5758653	ENSG00000182057.4	OGFRP1	4.9	1.31e-06	0.000321	0.26	0.22	Cognitive function;	chr22:42217479	chr22:42269753~42275196:+
LUAD	cis	rs950169	0.922	rs11638445	ENSG00000275120.1	RP11-182J1.17	4.9	1.31e-06	0.000321	0.34	0.22	Schizophrenia;	chr15:84594463	chr15:84599434~84606463:-
LUAD	cis	rs9926296	0.712	rs2437957	ENSG00000260259.1	RP11-368I7.4	4.9	1.31e-06	0.000321	0.22	0.22	Vitiligo;	chr16:89649240	chr16:89682620~89686569:-
LUAD	cis	rs2522056	0.932	rs2522064	ENSG00000233006.5	AC034220.3	-4.9	1.31e-06	0.000322	-0.24	-0.22	Fibrinogen;Lymphocyte counts;	chr5:132470796	chr5:132311285~132369916:-
LUAD	cis	rs4835473	0.83	rs75309663	ENSG00000251600.4	RP11-673E1.1	-4.9	1.31e-06	0.000322	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143675647	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.864	rs57648439	ENSG00000251600.4	RP11-673E1.1	-4.9	1.31e-06	0.000322	-0.27	-0.22	Immature fraction of reticulocytes;	chr4:143691519	chr4:143912331~143982454:+
LUAD	cis	rs2439831	0.85	rs28858500	ENSG00000249839.1	AC011330.5	-4.9	1.31e-06	0.000322	-0.46	-0.22	Lung cancer in ever smokers;	chr15:43864744	chr15:43663654~43684339:-
LUAD	cis	rs2243480	1	rs160634	ENSG00000230295.1	RP11-458F8.2	4.9	1.31e-06	0.000322	0.25	0.22	Diabetic kidney disease;	chr7:66063677	chr7:66880708~66882981:+
LUAD	cis	rs6604026	0.557	rs72724515	ENSG00000223787.2	RP4-593M8.1	4.9	1.31e-06	0.000322	0.29	0.22	Multiple sclerosis;	chr1:92585519	chr1:92580476~92580821:-
LUAD	cis	rs2749097	0.825	rs2819176	ENSG00000244256.3	RN7SL130P	-4.9	1.31e-06	0.000322	-0.27	-0.22	Alcohol consumption (transferrin glycosylation);	chr1:63659159	chr1:63655743~63656047:+
LUAD	cis	rs7923609	0.756	rs7080386	ENSG00000232075.1	MRPL35P2	-4.9	1.31e-06	0.000322	-0.27	-0.22	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63288546	chr10:63634317~63634827:-
LUAD	cis	rs561341	1	rs554078	ENSG00000265798.5	RP11-271K11.5	4.9	1.31e-06	0.000322	0.35	0.22	Hip circumference adjusted for BMI;	chr17:32003090	chr17:31038575~31059121:-
LUAD	cis	rs561341	0.941	rs72825736	ENSG00000265798.5	RP11-271K11.5	4.9	1.31e-06	0.000322	0.35	0.22	Hip circumference adjusted for BMI;	chr17:32003267	chr17:31038575~31059121:-
LUAD	cis	rs561341	0.941	rs8081016	ENSG00000265798.5	RP11-271K11.5	4.9	1.31e-06	0.000322	0.35	0.22	Hip circumference adjusted for BMI;	chr17:32004732	chr17:31038575~31059121:-
LUAD	cis	rs2742234	0.955	rs2503849	ENSG00000273008.1	RP11-351D16.3	-4.9	1.31e-06	0.000322	-0.24	-0.22	Hirschsprung disease;	chr10:43177328	chr10:43136824~43138334:-
LUAD	cis	rs2742234	0.955	rs2435384	ENSG00000273008.1	RP11-351D16.3	-4.9	1.31e-06	0.000322	-0.24	-0.22	Hirschsprung disease;	chr10:43178283	chr10:43136824~43138334:-
LUAD	cis	rs5758511	0.68	rs739146	ENSG00000226450.2	CYP2D8P	4.9	1.31e-06	0.000322	0.2	0.22	Birth weight;	chr22:42264408	chr22:42149886~42155001:-
LUAD	cis	rs9584850	0.789	rs7988345	ENSG00000231194.1	FARP1-AS1	4.9	1.31e-06	0.000322	0.27	0.22	Neuroticism;	chr13:98465431	chr13:98435405~98435840:-
LUAD	cis	rs13256369	0.851	rs11249890	ENSG00000253893.2	FAM85B	-4.9	1.31e-06	0.000322	-0.3	-0.22	Obesity-related traits;	chr8:8707735	chr8:8167819~8226614:-
LUAD	cis	rs1729951	0.575	rs75976	ENSG00000239213.4	NCK1-AS1	4.9	1.31e-06	0.000322	0.24	0.22	Neuroticism;	chr3:136981613	chr3:136841726~136862054:-
LUAD	cis	rs875971	0.825	rs28480509	ENSG00000232559.3	GS1-124K5.12	-4.9	1.31e-06	0.000322	-0.26	-0.22	Aortic root size;	chr7:66634237	chr7:66554588~66576923:-
LUAD	cis	rs2028299	1	rs8031576	ENSG00000259677.1	RP11-493E3.1	4.9	1.31e-06	0.000322	0.27	0.22	Type 2 diabetes;	chr15:89836982	chr15:89876540~89877285:+
LUAD	cis	rs12908161	0.92	rs35758837	ENSG00000275120.1	RP11-182J1.17	4.9	1.31e-06	0.000322	0.32	0.22	Schizophrenia;	chr15:84768151	chr15:84599434~84606463:-
LUAD	cis	rs12468226	1	rs76528043	ENSG00000272966.1	RP11-686O6.1	4.9	1.31e-06	0.000323	0.36	0.22	Urate levels;	chr2:202466116	chr2:202336739~202337200:+
LUAD	cis	rs6453278	1	rs6453279	ENSG00000250802.5	ZBED3-AS1	-4.9	1.31e-06	0.000323	-0.25	-0.22	Autism;	chr5:77121249	chr5:77086740~77166909:+
LUAD	cis	rs2688608	0.592	rs7908825	ENSG00000271816.1	BMS1P4	-4.9	1.31e-06	0.000323	-0.18	-0.22	Inflammatory bowel disease;	chr10:73794783	chr10:73699151~73730487:-
LUAD	cis	rs8031584	0.723	rs711224	ENSG00000270015.1	RP11-540B6.6	4.9	1.31e-06	0.000323	0.17	0.22	Huntington's disease progression;	chr15:30835718	chr15:30926514~30928407:+
LUAD	cis	rs1707322	1	rs7553924	ENSG00000280836.1	AL355480.1	-4.9	1.32e-06	0.000323	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886952	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs4641257	ENSG00000280836.1	AL355480.1	-4.9	1.32e-06	0.000323	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45887917	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs6693336	ENSG00000280836.1	AL355480.1	-4.9	1.32e-06	0.000323	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45888923	chr1:45581219~45581321:-
LUAD	cis	rs896854	0.967	rs896853	ENSG00000253528.2	RP11-347C18.4	4.9	1.32e-06	0.000323	0.21	0.22	Type 2 diabetes;	chr8:94948627	chr8:94974573~94974853:-
LUAD	cis	rs193541	0.632	rs154503	ENSG00000263432.2	RN7SL689P	4.9	1.32e-06	0.000324	0.3	0.22	Glucose homeostasis traits;	chr5:122868804	chr5:123022487~123022783:-
LUAD	cis	rs7811142	1	rs7787620	ENSG00000078319.8	PMS2P1	-4.9	1.32e-06	0.000324	-0.26	-0.22	Platelet count;	chr7:100491611	chr7:100320992~100341908:-
LUAD	cis	rs7811142	1	rs11769700	ENSG00000078319.8	PMS2P1	-4.9	1.32e-06	0.000324	-0.26	-0.22	Platelet count;	chr7:100492426	chr7:100320992~100341908:-
LUAD	cis	rs7017914	0.628	rs1389198	ENSG00000223220.1	Y_RNA	4.9	1.32e-06	0.000324	0.25	0.22	Bone mineral density;	chr8:70921872	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs7814774	ENSG00000223220.1	Y_RNA	4.9	1.32e-06	0.000324	0.25	0.22	Bone mineral density;	chr8:70934881	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs62506898	ENSG00000223220.1	Y_RNA	4.9	1.32e-06	0.000324	0.25	0.22	Bone mineral density;	chr8:70935267	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs17689989	ENSG00000223220.1	Y_RNA	4.9	1.32e-06	0.000324	0.25	0.22	Bone mineral density;	chr8:70936769	chr8:70780914~70781008:-
LUAD	cis	rs950169	0.686	rs12906474	ENSG00000259295.5	CSPG4P12	4.9	1.32e-06	0.000324	0.31	0.22	Schizophrenia;	chr15:84566006	chr15:85191438~85213905:+
LUAD	cis	rs950169	0.81	rs2879976	ENSG00000259295.5	CSPG4P12	4.9	1.32e-06	0.000324	0.31	0.22	Schizophrenia;	chr15:84566347	chr15:85191438~85213905:+
LUAD	cis	rs12908161	1	rs12903134	ENSG00000275120.1	RP11-182J1.17	4.9	1.32e-06	0.000324	0.32	0.22	Schizophrenia;	chr15:84794468	chr15:84599434~84606463:-
LUAD	cis	rs12908161	1	rs35726233	ENSG00000275120.1	RP11-182J1.17	4.9	1.32e-06	0.000324	0.32	0.22	Schizophrenia;	chr15:84794569	chr15:84599434~84606463:-
LUAD	cis	rs2657294	0.62	rs9783273	ENSG00000226051.5	ZNF503-AS1	-4.9	1.32e-06	0.000324	-0.29	-0.22	Pneumonia;	chr10:75081982	chr10:75269819~75373500:+
LUAD	cis	rs2657294	0.62	rs4746259	ENSG00000226051.5	ZNF503-AS1	-4.9	1.32e-06	0.000324	-0.29	-0.22	Pneumonia;	chr10:75082310	chr10:75269819~75373500:+
LUAD	cis	rs5758659	0.714	rs133376	ENSG00000227370.1	RP4-669P10.19	-4.9	1.32e-06	0.000325	-0.2	-0.22	Cognitive function;	chr22:42070901	chr22:42132543~42132998:+
LUAD	cis	rs2998286	0.862	rs946594	ENSG00000254635.4	WAC-AS1	-4.9	1.32e-06	0.000325	-0.27	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28503318	chr10:28522652~28532743:-
LUAD	cis	rs12745968	0.56	rs1325434	ENSG00000223787.2	RP4-593M8.1	-4.9	1.32e-06	0.000325	-0.26	-0.22	Bipolar disorder and schizophrenia;	chr1:92495775	chr1:92580476~92580821:-
LUAD	cis	rs9650657	0.571	rs11783247	ENSG00000255046.1	RP11-297N6.4	4.9	1.32e-06	0.000325	0.27	0.22	Neuroticism;	chr8:10931365	chr8:11797928~11802568:-
LUAD	cis	rs35740288	0.77	rs17635450	ENSG00000202081.1	RNU6-1280P	-4.9	1.32e-06	0.000325	-0.28	-0.22	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85655818	chr15:85651522~85651628:-
LUAD	cis	rs4964805	0.865	rs4964780	ENSG00000257681.1	RP11-341G23.4	4.9	1.32e-06	0.000325	0.27	0.22	Attention deficit hyperactivity disorder;	chr12:103813081	chr12:103746315~103768858:-
LUAD	cis	rs2288884	1	rs17779301	ENSG00000269959.1	SPACA6P-AS	4.9	1.32e-06	0.000325	0.28	0.22	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52035990	chr19:51685363~51693456:-
LUAD	cis	rs3096299	0.563	rs4600467	ENSG00000182376.2	RP5-1142A6.8	4.9	1.32e-06	0.000325	0.23	0.22	Multiple myeloma (IgH translocation);	chr16:89496108	chr16:88742767~88745748:+
LUAD	cis	rs8127691	1	rs762421	ENSG00000237604.1	AP001056.1	-4.9	1.32e-06	0.000325	-0.26	-0.22	Inflammatory bowel disease;	chr21:44195678	chr21:44175489~44176453:+
LUAD	cis	rs10050311	0.698	rs10516778	ENSG00000251411.1	RP11-397E7.4	-4.9	1.32e-06	0.000325	-0.3	-0.22	Insulin-related traits;	chr4:86714898	chr4:86913266~86914817:-
LUAD	cis	rs11742741	0.652	rs66527927	ENSG00000248874.4	C5orf17	-4.9	1.32e-06	0.000325	-0.28	-0.22	Educational attainment;	chr5:24226579	chr5:23951348~24178263:+
LUAD	cis	rs875971	0.862	rs6460290	ENSG00000232559.3	GS1-124K5.12	-4.9	1.32e-06	0.000325	-0.26	-0.22	Aortic root size;	chr7:66344119	chr7:66554588~66576923:-
LUAD	cis	rs7017914	0.69	rs13261146	ENSG00000223220.1	Y_RNA	4.9	1.33e-06	0.000325	0.25	0.22	Bone mineral density;	chr8:70814684	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs13263047	ENSG00000223220.1	Y_RNA	4.9	1.33e-06	0.000325	0.25	0.22	Bone mineral density;	chr8:70815061	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs62508827	ENSG00000223220.1	Y_RNA	4.9	1.33e-06	0.000325	0.25	0.22	Bone mineral density;	chr8:70815820	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs62508828	ENSG00000223220.1	Y_RNA	4.9	1.33e-06	0.000325	0.25	0.22	Bone mineral density;	chr8:70815974	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs56108781	ENSG00000223220.1	Y_RNA	4.9	1.33e-06	0.000325	0.25	0.22	Bone mineral density;	chr8:70816519	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs34751830	ENSG00000223220.1	Y_RNA	4.9	1.33e-06	0.000325	0.25	0.22	Bone mineral density;	chr8:70818239	chr8:70780914~70781008:-
LUAD	cis	rs42490	0.966	rs6992985	ENSG00000251136.7	RP11-37B2.1	-4.9	1.33e-06	0.000326	-0.22	-0.22	Leprosy;	chr8:89746330	chr8:89609409~89757727:-
LUAD	cis	rs73173548	0.502	rs10942531	ENSG00000247828.6	TMEM161B-AS1	4.9	1.33e-06	0.000326	0.27	0.22	Macular telangiectasia type 2;	chr5:88414280	chr5:88268895~88436685:+
LUAD	cis	rs763121	0.776	rs4820346	ENSG00000225450.1	RP3-508I15.14	4.9	1.33e-06	0.000326	0.21	0.22	Menopause (age at onset);	chr22:38729069	chr22:38739003~38749041:+
LUAD	cis	rs1322639	0.657	rs12203887	ENSG00000261039.2	RP11-417E7.2	-4.9	1.33e-06	0.000326	-0.36	-0.22	Pulse pressure;	chr6:169172157	chr6:169175304~169182740:-
LUAD	cis	rs2028299	1	rs6496609	ENSG00000259677.1	RP11-493E3.1	4.9	1.33e-06	0.000326	0.27	0.22	Type 2 diabetes;	chr15:89836400	chr15:89876540~89877285:+
LUAD	cis	rs6604026	0.555	rs56044027	ENSG00000223787.2	RP4-593M8.1	4.9	1.33e-06	0.000326	0.3	0.22	Multiple sclerosis;	chr1:92617137	chr1:92580476~92580821:-
LUAD	cis	rs1005277	0.579	rs1740737	ENSG00000263064.2	RP11-291L22.7	4.9	1.33e-06	0.000326	0.24	0.22	Extrinsic epigenetic age acceleration;	chr10:38210437	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.579	rs1614236	ENSG00000263064.2	RP11-291L22.7	4.9	1.33e-06	0.000326	0.24	0.22	Extrinsic epigenetic age acceleration;	chr10:38214068	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.579	rs2749616	ENSG00000263064.2	RP11-291L22.7	4.9	1.33e-06	0.000326	0.24	0.22	Extrinsic epigenetic age acceleration;	chr10:38222065	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.579	rs1780146	ENSG00000263064.2	RP11-291L22.7	4.9	1.33e-06	0.000326	0.24	0.22	Extrinsic epigenetic age acceleration;	chr10:38228946	chr10:38448689~38448949:+
LUAD	cis	rs4835473	0.8	rs1849117	ENSG00000251600.4	RP11-673E1.1	4.9	1.33e-06	0.000326	0.27	0.22	Immature fraction of reticulocytes;	chr4:143989791	chr4:143912331~143982454:+
LUAD	cis	rs301901	0.796	rs4869527	ENSG00000250155.1	CTD-2353F22.1	4.9	1.33e-06	0.000326	0.23	0.22	Height;	chr5:37533964	chr5:36666214~36725195:-
LUAD	cis	rs301901	0.796	rs6872681	ENSG00000250155.1	CTD-2353F22.1	4.9	1.33e-06	0.000326	0.23	0.22	Height;	chr5:37535278	chr5:36666214~36725195:-
LUAD	cis	rs1426063	1	rs17000242	ENSG00000249717.1	RP11-44F21.3	4.9	1.33e-06	0.000326	0.32	0.22	QT interval;	chr4:75103857	chr4:74955974~74970362:-
LUAD	cis	rs1426063	1	rs7666371	ENSG00000249717.1	RP11-44F21.3	4.9	1.33e-06	0.000326	0.32	0.22	QT interval;	chr4:75104325	chr4:74955974~74970362:-
LUAD	cis	rs1426063	1	rs6829858	ENSG00000249717.1	RP11-44F21.3	4.9	1.33e-06	0.000326	0.32	0.22	QT interval;	chr4:75105202	chr4:74955974~74970362:-
LUAD	cis	rs8098244	0.638	rs1109949	ENSG00000264745.1	TTC39C-AS1	4.9	1.33e-06	0.000326	0.22	0.22	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23834136	chr18:23994213~24015339:-
LUAD	cis	rs2836950	0.502	rs12627205	ENSG00000255568.3	BRWD1-AS2	-4.9	1.33e-06	0.000326	-0.21	-0.22	Menarche (age at onset);	chr21:39258101	chr21:39313935~39314962:+
LUAD	cis	rs801193	1	rs2707850	ENSG00000236529.1	RP13-254B10.1	4.9	1.33e-06	0.000326	0.22	0.22	Aortic root size;	chr7:66738883	chr7:65840212~65840596:+
LUAD	cis	rs801193	0.967	rs1110414	ENSG00000236529.1	RP13-254B10.1	4.9	1.33e-06	0.000326	0.22	0.22	Aortic root size;	chr7:66740595	chr7:65840212~65840596:+
LUAD	cis	rs801193	1	rs7783924	ENSG00000236529.1	RP13-254B10.1	4.9	1.33e-06	0.000326	0.22	0.22	Aortic root size;	chr7:66744070	chr7:65840212~65840596:+
LUAD	cis	rs801193	1	rs7789184	ENSG00000236529.1	RP13-254B10.1	4.9	1.33e-06	0.000326	0.22	0.22	Aortic root size;	chr7:66745208	chr7:65840212~65840596:+
LUAD	cis	rs1062177	0.855	rs62395861	ENSG00000253921.1	CTB-113P19.3	-4.9	1.33e-06	0.000326	-0.33	-0.22	Preschool internalizing problems;	chr5:151889709	chr5:151753992~151767247:+
LUAD	cis	rs1062177	0.95	rs59580263	ENSG00000253921.1	CTB-113P19.3	-4.9	1.33e-06	0.000326	-0.33	-0.22	Preschool internalizing problems;	chr5:151890016	chr5:151753992~151767247:+
LUAD	cis	rs4835473	0.897	rs34425128	ENSG00000251600.4	RP11-673E1.1	-4.9	1.33e-06	0.000326	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143725191	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.897	rs62337587	ENSG00000251600.4	RP11-673E1.1	-4.9	1.33e-06	0.000326	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143725839	chr4:143912331~143982454:+
LUAD	cis	rs5758659	0.633	rs762995	ENSG00000182057.4	OGFRP1	4.9	1.33e-06	0.000327	0.26	0.22	Cognitive function;	chr22:42276118	chr22:42269753~42275196:+
LUAD	cis	rs858239	0.539	rs2390757	ENSG00000230042.1	AK3P3	-4.9	1.33e-06	0.000327	-0.28	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23151873	chr7:23129178~23129841:+
LUAD	cis	rs7138803	0.51	rs7977112	ENSG00000257464.1	RP11-161H23.8	-4.9	1.33e-06	0.000327	-0.21	-0.22	Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index;	chr12:49815835	chr12:49442424~49442652:-
LUAD	cis	rs1529102	0.844	rs2698533	ENSG00000225889.6	AC074289.1	-4.9	1.33e-06	0.000327	-0.21	-0.22	Breast size;	chr2:64271271	chr2:64143239~64252859:+
LUAD	cis	rs875971	0.508	rs10258739	ENSG00000237310.1	GS1-124K5.4	-4.9	1.33e-06	0.000327	-0.23	-0.22	Aortic root size;	chr7:66597948	chr7:66493706~66495474:+
LUAD	cis	rs755249	0.529	rs604316	ENSG00000228060.1	RP11-69E11.8	-4.9	1.33e-06	0.000327	-0.2	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39413694	chr1:39565160~39573203:+
LUAD	cis	rs7208859	0.673	rs9911989	ENSG00000263603.1	CTD-2349P21.5	4.9	1.33e-06	0.000327	0.39	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30729469~30731202:+
LUAD	cis	rs1707322	0.964	rs7546237	ENSG00000280836.1	AL355480.1	-4.9	1.33e-06	0.000327	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45819938	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.964	rs6697830	ENSG00000280836.1	AL355480.1	-4.9	1.33e-06	0.000327	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45824805	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs12060274	ENSG00000280836.1	AL355480.1	-4.9	1.33e-06	0.000327	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825390	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.963	rs11211202	ENSG00000280836.1	AL355480.1	-4.9	1.33e-06	0.000327	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45826710	chr1:45581219~45581321:-
LUAD	cis	rs13256369	0.708	rs11783670	ENSG00000253893.2	FAM85B	-4.9	1.33e-06	0.000327	-0.3	-0.22	Obesity-related traits;	chr8:8701884	chr8:8167819~8226614:-
LUAD	cis	rs160451	0.899	rs218887	ENSG00000251136.7	RP11-37B2.1	4.9	1.33e-06	0.000327	0.22	0.22	Leprosy;	chr8:89679295	chr8:89609409~89757727:-
LUAD	cis	rs75422866	0.51	rs73105845	ENSG00000276691.1	RP5-1057I20.5	4.9	1.33e-06	0.000327	0.38	0.22	Pneumonia;	chr12:47741824	chr12:47788426~47788971:+
LUAD	cis	rs2976388	1	rs1045605	ENSG00000253741.1	CTD-2292P10.4	4.9	1.33e-06	0.000327	0.24	0.22	Urinary tract infection frequency;	chr8:142682683	chr8:142702252~142726973:-
LUAD	cis	rs62355901	0.8	rs10461612	ENSG00000271828.1	CTD-2310F14.1	4.9	1.34e-06	0.000328	0.32	0.22	Breast cancer;	chr5:56708004	chr5:56927874~56929573:+
LUAD	cis	rs875971	0.54	rs781152	ENSG00000236529.1	RP13-254B10.1	4.9	1.34e-06	0.000328	0.22	0.22	Aortic root size;	chr7:66014585	chr7:65840212~65840596:+
LUAD	cis	rs17711722	0.727	rs781151	ENSG00000236529.1	RP13-254B10.1	4.9	1.34e-06	0.000328	0.22	0.22	Calcium levels;	chr7:66014891	chr7:65840212~65840596:+
LUAD	cis	rs42490	1	rs6470366	ENSG00000251136.7	RP11-37B2.1	-4.9	1.34e-06	0.000328	-0.22	-0.22	Leprosy;	chr8:89747760	chr8:89609409~89757727:-
LUAD	cis	rs9500256	0.903	rs726783	ENSG00000215190.7	LINC00680	-4.9	1.34e-06	0.000328	-0.26	-0.22	Eosinophilic esophagitis (pediatric);	chr6:58006583	chr6:57946074~57961501:-
LUAD	cis	rs867371	0.826	rs2047678	ENSG00000259429.4	UBE2Q2P2	-4.9	1.34e-06	0.000328	-0.2	-0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82205857	chr15:82355142~82420075:+
LUAD	cis	rs1799949	0.965	rs35954893	ENSG00000236383.6	LINC00854	-4.9	1.34e-06	0.000328	-0.18	-0.22	Menopause (age at onset);	chr17:43181769	chr17:43216941~43305976:-
LUAD	cis	rs1864400	0.696	rs2742239	ENSG00000273008.1	RP11-351D16.3	-4.9	1.34e-06	0.000328	-0.25	-0.22	Hirschsprung disease;	chr10:43126264	chr10:43136824~43138334:-
LUAD	cis	rs301901	1	rs388098	ENSG00000250155.1	CTD-2353F22.1	-4.9	1.34e-06	0.000328	-0.23	-0.22	Height;	chr5:37068442	chr5:36666214~36725195:-
LUAD	cis	rs74233809	1	rs10883815	ENSG00000213277.3	MARCKSL1P1	4.9	1.34e-06	0.000328	0.38	0.22	Birth weight;	chr10:102979422	chr10:103175554~103176094:+
LUAD	cis	rs74233809	1	rs112390216	ENSG00000213277.3	MARCKSL1P1	4.9	1.34e-06	0.000328	0.38	0.22	Birth weight;	chr10:102981274	chr10:103175554~103176094:+
LUAD	cis	rs35160687	0.644	rs1863061	ENSG00000273080.1	RP11-301O19.1	-4.9	1.34e-06	0.000328	-0.24	-0.22	Night sleep phenotypes;	chr2:86285784	chr2:86195590~86196049:+
LUAD	cis	rs35160687	0.644	rs4832272	ENSG00000273080.1	RP11-301O19.1	-4.9	1.34e-06	0.000328	-0.24	-0.22	Night sleep phenotypes;	chr2:86289088	chr2:86195590~86196049:+
LUAD	cis	rs7017914	0.69	rs11985482	ENSG00000223220.1	Y_RNA	4.9	1.34e-06	0.000328	0.25	0.22	Bone mineral density;	chr8:70898343	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.583	rs7838671	ENSG00000223220.1	Y_RNA	4.9	1.34e-06	0.000328	0.25	0.22	Bone mineral density;	chr8:70899057	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.69	rs13248937	ENSG00000223220.1	Y_RNA	4.9	1.34e-06	0.000328	0.25	0.22	Bone mineral density;	chr8:70906514	chr8:70780914~70781008:-
LUAD	cis	rs1850744	0.826	rs7659176	ENSG00000163612.10	FAM86KP	-4.9	1.34e-06	0.000329	-0.65	-0.22	Economic and political preferences;	chr4:9719442	chr4:9153296~9165451:+
LUAD	cis	rs72772090	0.71	rs11750399	ENSG00000248734.2	CTD-2260A17.1	-4.9	1.34e-06	0.000329	-0.32	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96742236	chr5:96784777~96785999:+
LUAD	cis	rs801193	1	rs3800812	ENSG00000237310.1	GS1-124K5.4	4.9	1.34e-06	0.000329	0.23	0.22	Aortic root size;	chr7:66758474	chr7:66493706~66495474:+
LUAD	cis	rs801193	1	rs4279493	ENSG00000237310.1	GS1-124K5.4	4.9	1.34e-06	0.000329	0.23	0.22	Aortic root size;	chr7:66761633	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.619	rs10278371	ENSG00000236529.1	RP13-254B10.1	-4.9	1.34e-06	0.000329	-0.22	-0.22	Aortic root size;	chr7:66586553	chr7:65840212~65840596:+
LUAD	cis	rs7017914	0.652	rs3098859	ENSG00000223220.1	Y_RNA	4.9	1.34e-06	0.000329	0.25	0.22	Bone mineral density;	chr8:70952797	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.545	rs3110268	ENSG00000223220.1	Y_RNA	4.9	1.34e-06	0.000329	0.25	0.22	Bone mineral density;	chr8:70953933	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.617	rs2732144	ENSG00000223220.1	Y_RNA	4.9	1.34e-06	0.000329	0.25	0.22	Bone mineral density;	chr8:70954384	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.617	rs2639949	ENSG00000223220.1	Y_RNA	4.9	1.34e-06	0.000329	0.25	0.22	Bone mineral density;	chr8:70954781	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.617	rs2639950	ENSG00000223220.1	Y_RNA	4.9	1.34e-06	0.000329	0.25	0.22	Bone mineral density;	chr8:70954823	chr8:70780914~70781008:-
LUAD	cis	rs4938303	0.718	rs4938300	ENSG00000254851.1	RP11-109L13.1	4.9	1.34e-06	0.000329	0.34	0.22	Triglycerides;	chr11:116696903	chr11:117135528~117138582:+
LUAD	cis	rs7560272	0.695	rs10190002	ENSG00000163016.8	ALMS1P	4.9	1.34e-06	0.000329	0.23	0.22	Schizophrenia;	chr2:73566927	chr2:73644919~73685576:+
LUAD	cis	rs1707322	0.928	rs10732844	ENSG00000280836.1	AL355480.1	-4.9	1.34e-06	0.000329	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907016	chr1:45581219~45581321:-
LUAD	cis	rs4835473	0.897	rs11728121	ENSG00000251600.4	RP11-673E1.1	4.9	1.34e-06	0.000329	0.28	0.22	Immature fraction of reticulocytes;	chr4:143707079	chr4:143912331~143982454:+
LUAD	cis	rs42490	0.966	rs2735878	ENSG00000251136.7	RP11-37B2.1	-4.9	1.34e-06	0.000329	-0.22	-0.22	Leprosy;	chr8:89742720	chr8:89609409~89757727:-
LUAD	cis	rs42490	0.966	rs6993133	ENSG00000251136.7	RP11-37B2.1	-4.9	1.34e-06	0.000329	-0.22	-0.22	Leprosy;	chr8:89746396	chr8:89609409~89757727:-
LUAD	cis	rs2933343	0.859	rs789245	ENSG00000261159.1	RP11-723O4.9	4.9	1.34e-06	0.000329	0.27	0.22	IgG glycosylation;	chr3:128864737	chr3:128859716~128860526:-
LUAD	cis	rs950169	0.922	rs4338765	ENSG00000229212.6	RP11-561C5.4	-4.9	1.34e-06	0.000329	-0.32	-0.22	Schizophrenia;	chr15:84248084	chr15:85205440~85234795:-
LUAD	cis	rs987724	0.727	rs6776157	ENSG00000240875.4	LINC00886	-4.9	1.34e-06	0.000329	-0.24	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156825693	chr3:156747346~156817062:-
LUAD	cis	rs4568518	0.53	rs10226084	ENSG00000279048.1	RP11-511H23.2	4.9	1.34e-06	0.000329	0.18	0.22	Measles;	chr7:17957989	chr7:17940503~17942922:+
LUAD	cis	rs6570726	0.791	rs6918814	ENSG00000235652.6	RP11-545I5.3	4.89	1.34e-06	0.000329	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145584892	chr6:145799409~145886585:+
LUAD	cis	rs7937890	0.559	rs6486193	ENSG00000251991.1	RNU7-49P	4.89	1.34e-06	0.00033	0.23	0.22	Mitochondrial DNA levels;	chr11:14416061	chr11:14478892~14478953:+
LUAD	cis	rs2439831	0.681	rs956391	ENSG00000249839.1	AC011330.5	4.89	1.34e-06	0.00033	0.37	0.22	Lung cancer in ever smokers;	chr15:43325295	chr15:43663654~43684339:-
LUAD	cis	rs2115630	1	rs4633690	ENSG00000229212.6	RP11-561C5.4	4.89	1.35e-06	0.000331	0.25	0.22	P wave terminal force;	chr15:84818729	chr15:85205440~85234795:-
LUAD	cis	rs7727544	0.606	rs10060615	ENSG00000233006.5	AC034220.3	4.89	1.35e-06	0.000331	0.2	0.22	Blood metabolite levels;	chr5:132373185	chr5:132311285~132369916:-
LUAD	cis	rs957448	1	rs1023767	ENSG00000254315.1	RP11-267M23.3	4.89	1.35e-06	0.000331	0.27	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94518741	chr8:94533628~94534391:+
LUAD	cis	rs72717009	0.825	rs9427398	ENSG00000225217.1	HSPA7	-4.89	1.35e-06	0.000331	-0.31	-0.22	Rheumatoid arthritis;	chr1:161506415	chr1:161606291~161608217:+
LUAD	cis	rs4964805	0.913	rs35945096	ENSG00000257681.1	RP11-341G23.4	4.89	1.35e-06	0.000331	0.27	0.22	Attention deficit hyperactivity disorder;	chr12:103808151	chr12:103746315~103768858:-
LUAD	cis	rs1707322	1	rs4539075	ENSG00000280836.1	AL355480.1	-4.89	1.35e-06	0.000332	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45892338	chr1:45581219~45581321:-
LUAD	cis	rs2998286	0.723	rs332162	ENSG00000254635.4	WAC-AS1	-4.89	1.35e-06	0.000332	-0.29	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28599960	chr10:28522652~28532743:-
LUAD	cis	rs41307935	0.818	rs35576939	ENSG00000260063.1	RP5-968P14.2	-4.89	1.35e-06	0.000332	-0.39	-0.22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26947604	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs17340509	ENSG00000260063.1	RP5-968P14.2	-4.89	1.35e-06	0.000332	-0.39	-0.22	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26948209	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs17360994	ENSG00000260063.1	RP5-968P14.2	-4.89	1.35e-06	0.000332	-0.39	-0.22	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26952082	chr1:26692132~26694131:-
LUAD	cis	rs219780	0.784	rs219779	ENSG00000233818.1	AP000695.4	4.89	1.35e-06	0.000332	0.25	0.22	Kidney stones;	chr21:36461453	chr21:36445731~36532408:+
LUAD	cis	rs9341808	0.754	rs3805885	ENSG00000272129.1	RP11-250B2.6	-4.89	1.35e-06	0.000332	-0.26	-0.22	Sitting height ratio;	chr6:80287034	chr6:80355424~80356859:+
LUAD	cis	rs6604026	0.624	rs35038369	ENSG00000223787.2	RP4-593M8.1	4.89	1.35e-06	0.000332	0.3	0.22	Multiple sclerosis;	chr1:92765411	chr1:92580476~92580821:-
LUAD	cis	rs6604026	0.624	rs11585590	ENSG00000223787.2	RP4-593M8.1	4.89	1.35e-06	0.000332	0.3	0.22	Multiple sclerosis;	chr1:92766823	chr1:92580476~92580821:-
LUAD	cis	rs4908760	0.613	rs12028160	ENSG00000270282.1	RP5-1115A15.2	-4.89	1.36e-06	0.000332	-0.24	-0.22	Vitiligo;	chr1:8752155	chr1:8512653~8513021:+
LUAD	cis	rs172166	0.516	rs2622322	ENSG00000219392.1	RP1-265C24.5	-4.89	1.36e-06	0.000332	-0.27	-0.22	Cardiac Troponin-T levels;	chr6:28149665	chr6:28115628~28116551:+
LUAD	cis	rs13631	0.728	rs10118245	ENSG00000268996.3	MAN1B1-AS1	4.89	1.36e-06	0.000332	0.27	0.22	Cerebrospinal fluid biomarker levels;	chr9:137085140	chr9:137084946~137086817:-
LUAD	cis	rs848490	0.722	rs6976860	ENSG00000214293.7	APTR	4.89	1.36e-06	0.000332	0.25	0.22	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77822829	chr7:77657660~77696265:-
LUAD	cis	rs116175783	0.557	rs1267058	ENSG00000227403.1	AC009299.3	-4.89	1.36e-06	0.000332	-0.38	-0.22	Intelligence (multi-trait analysis);	chr2:161264934	chr2:161244739~161249050:+
LUAD	cis	rs748404	0.706	rs35975365	ENSG00000205771.5	CATSPER2P1	-4.89	1.36e-06	0.000333	-0.35	-0.22	Lung cancer;	chr15:43379347	chr15:43726918~43747094:-
LUAD	cis	rs2281636	0.63	rs12355655	ENSG00000233690.1	EBAG9P1	4.89	1.36e-06	0.000333	0.23	0.22	Obesity-related traits;	chr10:99616982	chr10:99697407~99697949:-
LUAD	cis	rs4072980	0.527	rs11210825	ENSG00000212541.1	RNU6-510P	-4.89	1.36e-06	0.000333	-0.26	-0.22	Coronary artery disease;	chr1:37981314	chr1:37991462~37991569:+
LUAD	cis	rs950169	0.8	rs34302901	ENSG00000259295.5	CSPG4P12	4.89	1.36e-06	0.000333	0.31	0.22	Schizophrenia;	chr15:84567712	chr15:85191438~85213905:+
LUAD	cis	rs9322193	0.736	rs10457851	ENSG00000268592.3	RAET1E-AS1	4.89	1.36e-06	0.000333	0.27	0.22	Lung cancer;	chr6:149775216	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.886	rs10872652	ENSG00000268592.3	RAET1E-AS1	4.89	1.36e-06	0.000333	0.27	0.22	Lung cancer;	chr6:149775303	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.886	rs17672976	ENSG00000268592.3	RAET1E-AS1	4.89	1.36e-06	0.000333	0.27	0.22	Lung cancer;	chr6:149776207	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.923	rs2184369	ENSG00000268592.3	RAET1E-AS1	4.89	1.36e-06	0.000333	0.27	0.22	Lung cancer;	chr6:149776681	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.962	rs2342861	ENSG00000268592.3	RAET1E-AS1	4.89	1.36e-06	0.000333	0.27	0.22	Lung cancer;	chr6:149777561	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.926	rs2342860	ENSG00000268592.3	RAET1E-AS1	4.89	1.36e-06	0.000333	0.27	0.22	Lung cancer;	chr6:149777641	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.962	rs10872653	ENSG00000268592.3	RAET1E-AS1	4.89	1.36e-06	0.000333	0.27	0.22	Lung cancer;	chr6:149778907	chr6:149863494~149919507:+
LUAD	cis	rs6687758	0.645	rs949618	ENSG00000228437.4	RP11-400N13.2	4.89	1.36e-06	0.000333	0.3	0.22	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221940598	chr1:221966341~221984964:+
LUAD	cis	rs11992162	0.967	rs10112888	ENSG00000255046.1	RP11-297N6.4	-4.89	1.36e-06	0.000334	-0.26	-0.22	Monocyte count;	chr8:11972699	chr8:11797928~11802568:-
LUAD	cis	rs11673344	0.704	rs1667384	ENSG00000226686.6	LINC01535	4.89	1.36e-06	0.000334	0.27	0.22	Obesity-related traits;	chr19:36925852	chr19:37251912~37265535:+
LUAD	cis	rs516805	0.561	rs2684239	ENSG00000279453.1	RP3-425C14.4	-4.89	1.36e-06	0.000334	-0.29	-0.22	Lymphocyte counts;	chr6:122086976	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.561	rs2679640	ENSG00000279453.1	RP3-425C14.4	-4.89	1.36e-06	0.000334	-0.29	-0.22	Lymphocyte counts;	chr6:122087013	chr6:122436789~122439223:-
LUAD	cis	rs3930017	1	rs3930016	ENSG00000242435.1	UPK3BP1	4.89	1.37e-06	0.000334	0.23	0.22	Body mass index;	chr7:77091132	chr7:77004662~77005774:+
LUAD	cis	rs4664293	0.528	rs72960224	ENSG00000226266.5	AC009961.3	4.89	1.37e-06	0.000334	0.31	0.22	Monocyte percentage of white cells;	chr2:159563993	chr2:159670708~159712435:-
LUAD	cis	rs763567	0.845	rs492804	ENSG00000271811.1	RP1-79C4.4	4.89	1.37e-06	0.000335	0.26	0.22	Tonsillectomy;	chr1:170643121	chr1:170667381~170669425:+
LUAD	cis	rs763567	0.967	rs593560	ENSG00000271811.1	RP1-79C4.4	4.89	1.37e-06	0.000335	0.26	0.22	Tonsillectomy;	chr1:170646776	chr1:170667381~170669425:+
LUAD	cis	rs56114371	0.777	rs200483	ENSG00000219392.1	RP1-265C24.5	-4.89	1.37e-06	0.000335	-0.39	-0.22	Breast cancer;	chr6:27807046	chr6:28115628~28116551:+
LUAD	cis	rs2998286	0.822	rs2095901	ENSG00000254635.4	WAC-AS1	-4.89	1.37e-06	0.000335	-0.27	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28514790	chr10:28522652~28532743:-
LUAD	cis	rs5758659	0.845	rs5758645	ENSG00000227370.1	RP4-669P10.19	-4.89	1.37e-06	0.000335	-0.2	-0.22	Cognitive function;	chr22:42202945	chr22:42132543~42132998:+
LUAD	cis	rs6723226	0.764	rs176403	ENSG00000276334.1	AL133243.1	-4.89	1.37e-06	0.000335	-0.25	-0.22	Intelligence (multi-trait analysis);	chr2:32412796	chr2:32521927~32523547:+
LUAD	cis	rs9860428	0.723	rs1354055	ENSG00000242770.2	RP11-180K7.1	4.89	1.37e-06	0.000335	0.23	0.22	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112896099	chr3:112802478~112812819:+
LUAD	cis	rs853679	0.599	rs149949	ENSG00000219392.1	RP1-265C24.5	-4.89	1.37e-06	0.000335	-0.37	-0.22	Depression;	chr6:28043738	chr6:28115628~28116551:+
LUAD	cis	rs1816752	0.774	rs55888616	ENSG00000273628.1	RP11-756A22.7	4.89	1.37e-06	0.000335	0.25	0.22	Obesity-related traits;	chr13:24441954	chr13:24933006~24936796:+
LUAD	cis	rs9926296	0.744	rs460984	ENSG00000260259.1	RP11-368I7.4	4.89	1.37e-06	0.000335	0.22	0.22	Vitiligo;	chr16:89646766	chr16:89682620~89686569:-
LUAD	cis	rs3096299	0.685	rs4785676	ENSG00000182376.2	RP5-1142A6.8	4.89	1.37e-06	0.000335	0.23	0.22	Multiple myeloma (IgH translocation);	chr16:89487216	chr16:88742767~88745748:+
LUAD	cis	rs490608	0.628	rs678157	ENSG00000225855.5	RUSC1-AS1	4.89	1.37e-06	0.000335	0.15	0.22	Inflammatory bowel disease;	chr1:155688550	chr1:155316863~155324176:-
LUAD	cis	rs9549328	0.8	rs9549617	ENSG00000267868.1	RP11-120K24.3	4.89	1.37e-06	0.000336	0.26	0.22	Systolic blood pressure;	chr13:112973756	chr13:112964835~112966131:-
LUAD	cis	rs7017914	0.616	rs12681114	ENSG00000223220.1	Y_RNA	4.89	1.37e-06	0.000336	0.25	0.22	Bone mineral density;	chr8:70750263	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.616	rs12679132	ENSG00000223220.1	Y_RNA	4.89	1.37e-06	0.000336	0.25	0.22	Bone mineral density;	chr8:70750270	chr8:70780914~70781008:-
LUAD	cis	rs8098244	0.617	rs12969104	ENSG00000264745.1	TTC39C-AS1	4.89	1.37e-06	0.000336	0.22	0.22	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23832275	chr18:23994213~24015339:-
LUAD	cis	rs944990	0.557	rs952288	ENSG00000227603.1	RP11-165J3.6	4.89	1.37e-06	0.000336	0.24	0.22	Body mass index;	chr9:93502629	chr9:93435332~93437121:-
LUAD	cis	rs2562456	0.833	rs1626404	ENSG00000268081.1	RP11-678G14.2	4.89	1.37e-06	0.000336	0.35	0.22	Pain;	chr19:21300986	chr19:21554640~21569237:-
LUAD	cis	rs7829975	0.774	rs13259216	ENSG00000253981.4	ALG1L13P	4.89	1.37e-06	0.000336	0.25	0.22	Mood instability;	chr8:8816091	chr8:8236003~8244667:-
LUAD	cis	rs301901	0.761	rs1533521	ENSG00000250155.1	CTD-2353F22.1	4.89	1.37e-06	0.000336	0.23	0.22	Height;	chr5:37540355	chr5:36666214~36725195:-
LUAD	cis	rs57561814	0.51	rs1524107	ENSG00000179428.2	AC073072.5	-4.89	1.37e-06	0.000336	-0.46	-0.22	Tonsillectomy;	chr7:22728600	chr7:22725395~22727620:-
LUAD	cis	rs4660214	0.666	rs10888788	ENSG00000228060.1	RP11-69E11.8	4.89	1.37e-06	0.000336	0.2	0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39472024	chr1:39565160~39573203:+
LUAD	cis	rs6723226	0.552	rs62136336	ENSG00000276334.1	AL133243.1	4.89	1.37e-06	0.000336	0.25	0.22	Intelligence (multi-trait analysis);	chr2:32579039	chr2:32521927~32523547:+
LUAD	cis	rs9500256	0.934	rs1343391	ENSG00000215190.7	LINC00680	-4.89	1.38e-06	0.000337	-0.26	-0.22	Eosinophilic esophagitis (pediatric);	chr6:58017876	chr6:57946074~57961501:-
LUAD	cis	rs874460	0.932	rs313841	ENSG00000211513.4	MIR320E	4.89	1.38e-06	0.000337	0.35	0.22	Chronic lymphocytic leukemia;	chr19:46720692	chr19:46709271~46709382:-
LUAD	cis	rs7017914	0.69	rs2732133	ENSG00000223220.1	Y_RNA	4.89	1.38e-06	0.000337	0.25	0.22	Bone mineral density;	chr8:70978741	chr8:70780914~70781008:-
LUAD	cis	rs4722166	0.695	rs7793125	ENSG00000179428.2	AC073072.5	-4.89	1.38e-06	0.000337	-0.25	-0.22	Lung cancer;	chr7:22769541	chr7:22725395~22727620:-
LUAD	cis	rs301901	1	rs300058	ENSG00000250155.1	CTD-2353F22.1	-4.89	1.38e-06	0.000337	-0.23	-0.22	Height;	chr5:37053874	chr5:36666214~36725195:-
LUAD	cis	rs875971	0.522	rs1617484	ENSG00000236529.1	RP13-254B10.1	4.89	1.38e-06	0.000337	0.22	0.22	Aortic root size;	chr7:65998108	chr7:65840212~65840596:+
LUAD	cis	rs1062177	0.855	rs6896664	ENSG00000253921.1	CTB-113P19.3	-4.89	1.38e-06	0.000337	-0.31	-0.22	Preschool internalizing problems;	chr5:151885713	chr5:151753992~151767247:+
LUAD	cis	rs8077577	0.689	rs16961114	ENSG00000273018.4	CTD-2303H24.2	-4.89	1.38e-06	0.000337	-0.31	-0.22	Obesity-related traits;	chr17:18312025	chr17:18511221~18551705:-
LUAD	cis	rs4835473	0.604	rs11938387	ENSG00000251600.4	RP11-673E1.1	4.89	1.38e-06	0.000337	0.27	0.22	Immature fraction of reticulocytes;	chr4:143984476	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.798	rs11100829	ENSG00000251600.4	RP11-673E1.1	4.89	1.38e-06	0.000337	0.27	0.22	Immature fraction of reticulocytes;	chr4:143984761	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1511425	ENSG00000251600.4	RP11-673E1.1	4.89	1.38e-06	0.000337	0.27	0.22	Immature fraction of reticulocytes;	chr4:143985122	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1849120	ENSG00000251600.4	RP11-673E1.1	4.89	1.38e-06	0.000337	0.27	0.22	Immature fraction of reticulocytes;	chr4:143985337	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs4835476	ENSG00000251600.4	RP11-673E1.1	4.89	1.38e-06	0.000337	0.27	0.22	Immature fraction of reticulocytes;	chr4:143985517	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1828502	ENSG00000251600.4	RP11-673E1.1	4.89	1.38e-06	0.000337	0.27	0.22	Immature fraction of reticulocytes;	chr4:143985797	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs7668698	ENSG00000251600.4	RP11-673E1.1	4.89	1.38e-06	0.000337	0.27	0.22	Immature fraction of reticulocytes;	chr4:143986333	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs6537231	ENSG00000251600.4	RP11-673E1.1	4.89	1.38e-06	0.000337	0.27	0.22	Immature fraction of reticulocytes;	chr4:143986489	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1877234	ENSG00000251600.4	RP11-673E1.1	4.89	1.38e-06	0.000337	0.27	0.22	Immature fraction of reticulocytes;	chr4:143986774	chr4:143912331~143982454:+
LUAD	cis	rs17684571	0.872	rs36068365	ENSG00000231441.1	RP11-472M19.2	4.89	1.38e-06	0.000337	0.3	0.22	Schizophrenia;	chr6:56716358	chr6:56844002~56864078:+
LUAD	cis	rs7208859	0.725	rs9891656	ENSG00000280069.1	CTD-2349P21.3	-4.89	1.38e-06	0.000337	-0.26	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916337	chr17:30738182~30740275:+
LUAD	cis	rs34435647	1	rs34435647	ENSG00000226266.5	AC009961.3	-4.89	1.38e-06	0.000338	-0.3	-0.22	Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;	chr2:159661779	chr2:159670708~159712435:-
LUAD	cis	rs113835537	0.866	rs59320108	ENSG00000255517.5	CTD-3074O7.5	-4.89	1.38e-06	0.000338	-0.32	-0.22	Airway imaging phenotypes;	chr11:66598525	chr11:66473490~66480233:-
LUAD	cis	rs1799949	1	rs915945	ENSG00000236383.6	LINC00854	-4.89	1.38e-06	0.000338	-0.18	-0.22	Menopause (age at onset);	chr17:43027847	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs12942277	ENSG00000236383.6	LINC00854	-4.89	1.38e-06	0.000338	-0.18	-0.22	Menopause (age at onset);	chr17:43035957	chr17:43216941~43305976:-
LUAD	cis	rs1799949	0.965	rs34616041	ENSG00000236383.6	LINC00854	-4.89	1.38e-06	0.000338	-0.18	-0.22	Menopause (age at onset);	chr17:43036769	chr17:43216941~43305976:-
LUAD	cis	rs1008375	1	rs4698635	ENSG00000249502.1	AC006160.5	-4.89	1.38e-06	0.000338	-0.21	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17628619	chr4:17587467~17614571:-
LUAD	cis	rs17301853	1	rs6658917	ENSG00000227373.4	RP11-160H22.5	4.89	1.38e-06	0.000338	0.42	0.22	Migraine without aura;Migraine - clinic-based;	chr1:174821673	chr1:174115300~174160004:-
LUAD	cis	rs394563	0.601	rs431978	ENSG00000231760.4	RP11-350J20.5	-4.89	1.38e-06	0.000338	-0.28	-0.22	Dupuytren's disease;	chr6:149471864	chr6:149796151~149826294:-
LUAD	cis	rs9322193	0.923	rs35830138	ENSG00000268592.3	RAET1E-AS1	4.89	1.38e-06	0.000338	0.27	0.22	Lung cancer;	chr6:149668635	chr6:149863494~149919507:+
LUAD	cis	rs2295359	0.892	rs56920441	ENSG00000275678.1	RP4-547N15.3	-4.89	1.38e-06	0.000338	-0.23	-0.22	Psoriasis;	chr1:67186329	chr1:67121605~67123956:-
LUAD	cis	rs7119	0.651	rs8041398	ENSG00000259362.2	RP11-307C19.1	-4.89	1.38e-06	0.000338	-0.28	-0.22	Type 2 diabetes;	chr15:77546831	chr15:77525540~77534110:+
LUAD	cis	rs516805	0.748	rs197680	ENSG00000279453.1	RP3-425C14.4	-4.89	1.39e-06	0.000338	-0.31	-0.22	Lymphocyte counts;	chr6:122548987	chr6:122436789~122439223:-
LUAD	cis	rs301901	1	rs159755	ENSG00000250155.1	CTD-2353F22.1	-4.89	1.39e-06	0.000339	-0.23	-0.22	Height;	chr5:36995103	chr5:36666214~36725195:-
LUAD	cis	rs858239	0.6	rs10266123	ENSG00000230042.1	AK3P3	-4.89	1.39e-06	0.000339	-0.28	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23129178~23129841:+
LUAD	cis	rs801193	0.569	rs35070132	ENSG00000232559.3	GS1-124K5.12	4.89	1.39e-06	0.000339	0.26	0.22	Aortic root size;	chr7:66773096	chr7:66554588~66576923:-
LUAD	cis	rs3747113	1	rs35303215	ENSG00000128262.7	POM121L9P	-4.89	1.39e-06	0.000339	-0.24	-0.22	Gut microbiome composition (summer);	chr22:24405567	chr22:24251828~24265525:+
LUAD	cis	rs8180040	0.701	rs7625067	ENSG00000271161.1	BOLA2P2	4.89	1.39e-06	0.000339	0.21	0.22	Colorectal cancer;	chr3:47053815	chr3:47499841~47500407:+
LUAD	cis	rs8180040	0.764	rs6794193	ENSG00000271161.1	BOLA2P2	4.89	1.39e-06	0.000339	0.21	0.22	Colorectal cancer;	chr3:47073414	chr3:47499841~47500407:+
LUAD	cis	rs8072100	0.79	rs1962307	ENSG00000228782.6	CTD-2026D20.3	4.89	1.39e-06	0.00034	0.23	0.22	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47630505	chr17:47450568~47492492:-
LUAD	cis	rs10129255	0.957	rs61997760	ENSG00000224373.3	IGHV4-59	4.89	1.39e-06	0.00034	0.14	0.22	Kawasaki disease;	chr14:106716993	chr14:106627249~106627825:-
LUAD	cis	rs13256369	0.802	rs2280560	ENSG00000253893.2	FAM85B	-4.89	1.39e-06	0.00034	-0.3	-0.22	Obesity-related traits;	chr8:8703092	chr8:8167819~8226614:-
LUAD	cis	rs13256369	0.802	rs12153	ENSG00000253893.2	FAM85B	-4.89	1.39e-06	0.00034	-0.3	-0.22	Obesity-related traits;	chr8:8703399	chr8:8167819~8226614:-
LUAD	cis	rs74233809	1	rs77860422	ENSG00000213277.3	MARCKSL1P1	4.89	1.39e-06	0.00034	0.38	0.22	Birth weight;	chr10:102988252	chr10:103175554~103176094:+
LUAD	cis	rs801193	0.967	rs34356500	ENSG00000236529.1	RP13-254B10.1	4.89	1.39e-06	0.00034	0.22	0.22	Aortic root size;	chr7:66771620	chr7:65840212~65840596:+
LUAD	cis	rs2255336	0.817	rs10743889	ENSG00000245648.1	RP11-277P12.20	4.89	1.39e-06	0.00034	0.33	0.22	Blood protein levels;	chr12:10368790	chr12:10363769~10398506:+
LUAD	cis	rs5758659	0.714	rs5758589	ENSG00000227370.1	RP4-669P10.19	4.89	1.39e-06	0.00034	0.19	0.22	Cognitive function;	chr22:42122378	chr22:42132543~42132998:+
LUAD	cis	rs14027	0.921	rs2136374	ENSG00000279347.1	RP11-85I17.2	-4.89	1.39e-06	0.00034	-0.19	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119765046	chr8:119838736~119840385:-
LUAD	cis	rs14027	0.881	rs4871578	ENSG00000279347.1	RP11-85I17.2	-4.89	1.39e-06	0.00034	-0.19	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119767615	chr8:119838736~119840385:-
LUAD	cis	rs14027	0.921	rs10110601	ENSG00000279347.1	RP11-85I17.2	-4.89	1.39e-06	0.00034	-0.19	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119774866	chr8:119838736~119840385:-
LUAD	cis	rs61270009	0.955	rs4916899	ENSG00000247828.6	TMEM161B-AS1	4.89	1.39e-06	0.00034	0.25	0.22	Depressive symptoms;	chr5:88292209	chr5:88268895~88436685:+
LUAD	cis	rs748404	0.697	rs473554	ENSG00000249839.1	AC011330.5	-4.89	1.4e-06	0.000341	-0.28	-0.22	Lung cancer;	chr15:43276009	chr15:43663654~43684339:-
LUAD	cis	rs301901	1	rs300064	ENSG00000250155.1	CTD-2353F22.1	4.89	1.4e-06	0.000341	0.22	0.22	Height;	chr5:37025769	chr5:36666214~36725195:-
LUAD	cis	rs2554380	0.628	rs6602990	ENSG00000230373.7	GOLGA6L5P	-4.89	1.4e-06	0.000341	-0.23	-0.22	Height;	chr15:83783470	chr15:84507885~84516814:-
LUAD	cis	rs34421088	0.623	rs2572433	ENSG00000255046.1	RP11-297N6.4	-4.89	1.4e-06	0.000341	-0.27	-0.22	Neuroticism;	chr8:11243532	chr8:11797928~11802568:-
LUAD	cis	rs1426063	1	rs28515115	ENSG00000249717.1	RP11-44F21.3	4.89	1.4e-06	0.000341	0.32	0.22	QT interval;	chr4:75101904	chr4:74955974~74970362:-
LUAD	cis	rs1799949	1	rs67060599	ENSG00000236383.6	LINC00854	-4.89	1.4e-06	0.000341	-0.18	-0.22	Menopause (age at onset);	chr17:43103085	chr17:43216941~43305976:-
LUAD	cis	rs301901	1	rs150380	ENSG00000250155.1	CTD-2353F22.1	-4.89	1.4e-06	0.000341	-0.22	-0.22	Height;	chr5:36880769	chr5:36666214~36725195:-
LUAD	cis	rs9650657	0.515	rs7820860	ENSG00000255046.1	RP11-297N6.4	4.89	1.4e-06	0.000341	0.27	0.22	Neuroticism;	chr8:11092886	chr8:11797928~11802568:-
LUAD	cis	rs2836950	0.501	rs4818018	ENSG00000255568.3	BRWD1-AS2	-4.89	1.4e-06	0.000341	-0.21	-0.22	Menarche (age at onset);	chr21:39322146	chr21:39313935~39314962:+
LUAD	cis	rs2836950	0.501	rs4818019	ENSG00000255568.3	BRWD1-AS2	-4.89	1.4e-06	0.000341	-0.21	-0.22	Menarche (age at onset);	chr21:39322530	chr21:39313935~39314962:+
LUAD	cis	rs71636778	0.509	rs34667713	ENSG00000260063.1	RP5-968P14.2	-4.89	1.4e-06	0.000341	-0.39	-0.22	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26966187	chr1:26692132~26694131:-
LUAD	cis	rs2239547	0.522	rs2336162	ENSG00000242142.1	SERBP1P3	-4.89	1.4e-06	0.000341	-0.26	-0.22	Schizophrenia;	chr3:52917503	chr3:53064283~53065091:-
LUAD	cis	rs7829975	0.606	rs11776838	ENSG00000253893.2	FAM85B	4.89	1.4e-06	0.000341	0.27	0.22	Mood instability;	chr8:8937291	chr8:8167819~8226614:-
LUAD	cis	rs1044826	0.957	rs4683799	ENSG00000214280.3	RP11-553K23.2	-4.89	1.4e-06	0.000341	-0.25	-0.22	Obesity-related traits;	chr3:139491416	chr3:139582928~139583593:-
LUAD	cis	rs11992162	0.967	rs7836456	ENSG00000255046.1	RP11-297N6.4	-4.89	1.4e-06	0.000341	-0.26	-0.22	Monocyte count;	chr8:11971666	chr8:11797928~11802568:-
LUAD	cis	rs6570726	0.791	rs1280276	ENSG00000235652.6	RP11-545I5.3	4.89	1.4e-06	0.000342	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145571214	chr6:145799409~145886585:+
LUAD	cis	rs2933343	0.951	rs789251	ENSG00000231305.3	RP11-723O4.2	4.89	1.4e-06	0.000342	0.26	0.22	IgG glycosylation;	chr3:128857927	chr3:128861313~128871540:-
LUAD	cis	rs6840360	1	rs4571	ENSG00000270265.1	RP11-731D1.4	-4.89	1.4e-06	0.000342	-0.22	-0.22	Intelligence (multi-trait analysis);	chr4:151671039	chr4:151333775~151353224:-
LUAD	cis	rs1150668	0.796	rs2531832	ENSG00000219392.1	RP1-265C24.5	-4.89	1.4e-06	0.000342	-0.27	-0.22	Pubertal anthropometrics;	chr6:28421445	chr6:28115628~28116551:+
LUAD	cis	rs2243480	1	rs313813	ENSG00000226002.1	RP11-460N20.5	-4.89	1.4e-06	0.000343	-0.37	-0.22	Diabetic kidney disease;	chr7:66038513	chr7:65084103~65100232:+
LUAD	cis	rs7017914	0.568	rs13272884	ENSG00000223220.1	Y_RNA	4.89	1.4e-06	0.000343	0.25	0.22	Bone mineral density;	chr8:70729413	chr8:70780914~70781008:-
LUAD	cis	rs7819412	0.668	rs920047	ENSG00000255046.1	RP11-297N6.4	4.89	1.4e-06	0.000343	0.26	0.22	Triglycerides;	chr8:11229966	chr8:11797928~11802568:-
LUAD	cis	rs36423	0.702	rs36383	ENSG00000266869.1	RP6-114E22.1	-4.89	1.41e-06	0.000343	-0.33	-0.22	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71902385	chr14:71848606~71908430:+
LUAD	cis	rs36423	0.748	rs36381	ENSG00000266869.1	RP6-114E22.1	-4.89	1.41e-06	0.000343	-0.33	-0.22	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71903833	chr14:71848606~71908430:+
LUAD	cis	rs36423	0.748	rs36380	ENSG00000266869.1	RP6-114E22.1	-4.89	1.41e-06	0.000343	-0.33	-0.22	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71904545	chr14:71848606~71908430:+
LUAD	cis	rs61270009	0.818	rs4916718	ENSG00000247828.6	TMEM161B-AS1	4.89	1.41e-06	0.000343	0.25	0.22	Depressive symptoms;	chr5:88316825	chr5:88268895~88436685:+
LUAD	cis	rs9341808	0.754	rs10733162	ENSG00000272129.1	RP11-250B2.6	4.89	1.41e-06	0.000343	0.27	0.22	Sitting height ratio;	chr6:80313672	chr6:80355424~80356859:+
LUAD	cis	rs2836950	0.545	rs2836952	ENSG00000255568.3	BRWD1-AS2	-4.89	1.41e-06	0.000343	-0.21	-0.22	Menarche (age at onset);	chr21:39244725	chr21:39313935~39314962:+
LUAD	cis	rs11155671	0.53	rs4869763	ENSG00000268592.3	RAET1E-AS1	4.89	1.41e-06	0.000343	0.27	0.22	Testicular germ cell tumor;	chr6:149890548	chr6:149863494~149919507:+
LUAD	cis	rs2492286	0.518	rs2712418	ENSG00000242551.2	POU5F1P6	-4.89	1.41e-06	0.000344	-0.27	-0.22	Eosinophil counts;	chr3:128624793	chr3:128674735~128677005:-
LUAD	cis	rs944990	0.513	rs10821144	ENSG00000227603.1	RP11-165J3.6	4.89	1.41e-06	0.000344	0.24	0.22	Body mass index;	chr9:93502976	chr9:93435332~93437121:-
LUAD	cis	rs4664293	0.718	rs4477859	ENSG00000226266.5	AC009961.3	4.89	1.41e-06	0.000344	0.29	0.22	Monocyte percentage of white cells;	chr2:159738616	chr2:159670708~159712435:-
LUAD	cis	rs6142102	0.961	rs1055857	ENSG00000275784.1	RP5-1125A11.6	-4.88	1.41e-06	0.000344	-0.24	-0.22	Skin pigmentation;	chr20:34026067	chr20:33989480~33991818:-
LUAD	cis	rs1150668	0.699	rs12214383	ENSG00000219392.1	RP1-265C24.5	4.88	1.41e-06	0.000344	0.27	0.22	Pubertal anthropometrics;	chr6:28255953	chr6:28115628~28116551:+
LUAD	cis	rs950169	0.686	rs12906474	ENSG00000229212.6	RP11-561C5.4	-4.88	1.41e-06	0.000344	-0.31	-0.22	Schizophrenia;	chr15:84566006	chr15:85205440~85234795:-
LUAD	cis	rs950169	0.81	rs2879976	ENSG00000229212.6	RP11-561C5.4	-4.88	1.41e-06	0.000344	-0.31	-0.22	Schizophrenia;	chr15:84566347	chr15:85205440~85234795:-
LUAD	cis	rs27524	0.734	rs27037	ENSG00000248734.2	CTD-2260A17.1	4.88	1.41e-06	0.000344	0.23	0.22	Hodgkin's lymphoma;Psoriasis;	chr5:96758990	chr5:96784777~96785999:+
LUAD	cis	rs375066	0.762	rs17656688	ENSG00000267058.1	RP11-15A1.3	4.88	1.41e-06	0.000344	0.24	0.22	Breast cancer;	chr19:43920925	chr19:43891804~43901805:-
LUAD	cis	rs7017914	0.667	rs13262350	ENSG00000223220.1	Y_RNA	4.88	1.41e-06	0.000344	0.25	0.22	Bone mineral density;	chr8:71069371	chr8:70780914~70781008:-
LUAD	cis	rs30380	1	rs30378	ENSG00000248734.2	CTD-2260A17.1	4.88	1.41e-06	0.000344	0.23	0.22	Cerebrospinal fluid biomarker levels;	chr5:96786290	chr5:96784777~96785999:+
LUAD	cis	rs7017914	0.628	rs55740254	ENSG00000223220.1	Y_RNA	4.88	1.41e-06	0.000345	0.25	0.22	Bone mineral density;	chr8:70928325	chr8:70780914~70781008:-
LUAD	cis	rs4948102	0.667	rs7811270	ENSG00000273720.1	RP11-613E4.4	-4.88	1.41e-06	0.000345	-0.27	-0.22	Plasma homocysteine levels (post-methionine load test);	chr7:56072297	chr7:55743073~55743457:+
LUAD	cis	rs2562456	0.793	rs11667103	ENSG00000268081.1	RP11-678G14.2	4.88	1.42e-06	0.000345	0.35	0.22	Pain;	chr19:21303839	chr19:21554640~21569237:-
LUAD	cis	rs7924176	0.544	rs10824218	ENSG00000213731.2	RAB5CP1	4.88	1.42e-06	0.000345	0.23	0.22	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74661458	chr10:74423435~74424014:-
LUAD	cis	rs1478897	0.898	rs2249040	ENSG00000270154.1	RP11-419I17.1	-4.88	1.42e-06	0.000345	-0.25	-0.22	Systemic lupus erythematosus;	chr8:11533270	chr8:12476462~12477122:+
LUAD	cis	rs2562456	0.833	rs1781867	ENSG00000268081.1	RP11-678G14.2	4.88	1.42e-06	0.000345	0.35	0.22	Pain;	chr19:21304368	chr19:21554640~21569237:-
LUAD	cis	rs9992667	0.956	rs73232890	ENSG00000231160.8	KLF3-AS1	4.88	1.42e-06	0.000345	0.28	0.22	Eosinophil percentage of granulocytes;	chr4:38683420	chr4:38612701~38664883:-
LUAD	cis	rs12701220	0.901	rs12701713	ENSG00000229043.2	AC091729.9	-4.88	1.42e-06	0.000345	-0.29	-0.22	Bronchopulmonary dysplasia;	chr7:1050869	chr7:1160374~1165267:+
LUAD	cis	rs9928842	0.712	rs10871304	ENSG00000280152.1	RP11-331F4.5	4.88	1.42e-06	0.000345	0.23	0.22	Alcoholic chronic pancreatitis;	chr16:75189593	chr16:75245994~75250077:-
LUAD	cis	rs71520386	0.632	rs12532922	ENSG00000228649.7	AC005682.5	-4.88	1.42e-06	0.000346	-0.3	-0.22	Fibrinogen levels;	chr7:22820796	chr7:22854178~22861579:+
LUAD	cis	rs2286503	0.78	rs2240727	ENSG00000226329.2	AC005682.6	4.88	1.42e-06	0.000346	0.28	0.22	Fibrinogen;	chr7:22812893	chr7:22863874~22881350:-
LUAD	cis	rs8098244	0.617	rs12965616	ENSG00000264745.1	TTC39C-AS1	4.88	1.42e-06	0.000346	0.22	0.22	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23831262	chr18:23994213~24015339:-
LUAD	cis	rs6496932	0.913	rs34896088	ENSG00000202081.1	RNU6-1280P	4.88	1.42e-06	0.000346	0.31	0.22	Central corneal thickness;Corneal structure;	chr15:85278393	chr15:85651522~85651628:-
LUAD	cis	rs875971	0.755	rs10228885	ENSG00000232559.3	GS1-124K5.12	-4.88	1.42e-06	0.000346	-0.26	-0.22	Aortic root size;	chr7:66315542	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs3893216	ENSG00000232559.3	GS1-124K5.12	-4.88	1.42e-06	0.000346	-0.26	-0.22	Aortic root size;	chr7:66325720	chr7:66554588~66576923:-
LUAD	cis	rs638893	0.617	rs4938564	ENSG00000278376.1	RP11-158I9.8	-4.88	1.42e-06	0.000346	-0.26	-0.22	Vitiligo;	chr11:118849881	chr11:118791254~118793137:+
LUAD	cis	rs638893	0.588	rs4936440	ENSG00000278376.1	RP11-158I9.8	-4.88	1.42e-06	0.000346	-0.26	-0.22	Vitiligo;	chr11:118849975	chr11:118791254~118793137:+
LUAD	cis	rs638893	0.588	rs4938566	ENSG00000278376.1	RP11-158I9.8	-4.88	1.42e-06	0.000346	-0.26	-0.22	Vitiligo;	chr11:118850480	chr11:118791254~118793137:+
LUAD	cis	rs638893	0.617	rs4938567	ENSG00000278376.1	RP11-158I9.8	-4.88	1.42e-06	0.000346	-0.26	-0.22	Vitiligo;	chr11:118850540	chr11:118791254~118793137:+
LUAD	cis	rs638893	0.617	rs11217059	ENSG00000278376.1	RP11-158I9.8	-4.88	1.42e-06	0.000346	-0.26	-0.22	Vitiligo;	chr11:118852378	chr11:118791254~118793137:+
LUAD	cis	rs6687821	0.531	rs4357505	ENSG00000267734.1	RP4-604K5.3	4.88	1.42e-06	0.000346	0.28	0.22	Yeast infection;	chr1:87018785	chr1:86932199~86934891:-
LUAD	cis	rs6714710	0.603	rs17488897	ENSG00000230606.9	AC159540.1	-4.88	1.42e-06	0.000346	-0.24	-0.22	Posterior cortical atrophy and Alzheimer's disease;	chr2:97748701	chr2:97416165~97433527:-
LUAD	cis	rs736801	0.704	rs56399423	ENSG00000233006.5	AC034220.3	4.88	1.42e-06	0.000346	0.2	0.22	Mosquito bite size;Breast cancer;	chr5:132336964	chr5:132311285~132369916:-
LUAD	cis	rs17772222	0.876	rs61983303	ENSG00000258983.2	RP11-507K2.2	4.88	1.42e-06	0.000346	0.27	0.22	Coronary artery calcification;	chr14:88764459	chr14:88499334~88515502:+
LUAD	cis	rs17772222	0.917	rs2224333	ENSG00000258983.2	RP11-507K2.2	4.88	1.42e-06	0.000346	0.27	0.22	Coronary artery calcification;	chr14:88768748	chr14:88499334~88515502:+
LUAD	cis	rs17772222	0.917	rs12590826	ENSG00000258983.2	RP11-507K2.2	4.88	1.42e-06	0.000346	0.27	0.22	Coronary artery calcification;	chr14:88769357	chr14:88499334~88515502:+
LUAD	cis	rs17772222	0.917	rs57889459	ENSG00000258983.2	RP11-507K2.2	4.88	1.42e-06	0.000346	0.27	0.22	Coronary artery calcification;	chr14:88770820	chr14:88499334~88515502:+
LUAD	cis	rs17772222	0.917	rs61982733	ENSG00000258983.2	RP11-507K2.2	4.88	1.42e-06	0.000346	0.27	0.22	Coronary artery calcification;	chr14:88776244	chr14:88499334~88515502:+
LUAD	cis	rs17772222	0.917	rs2145120	ENSG00000258983.2	RP11-507K2.2	4.88	1.42e-06	0.000346	0.27	0.22	Coronary artery calcification;	chr14:88777699	chr14:88499334~88515502:+
LUAD	cis	rs42490	0.966	rs218932	ENSG00000251136.7	RP11-37B2.1	-4.88	1.42e-06	0.000346	-0.22	-0.22	Leprosy;	chr8:89740725	chr8:89609409~89757727:-
LUAD	cis	rs1008375	1	rs7694020	ENSG00000249502.1	AC006160.5	-4.88	1.42e-06	0.000346	-0.2	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17680974	chr4:17587467~17614571:-
LUAD	cis	rs801193	1	rs7788576	ENSG00000237310.1	GS1-124K5.4	-4.88	1.42e-06	0.000347	-0.23	-0.22	Aortic root size;	chr7:66683315	chr7:66493706~66495474:+
LUAD	cis	rs801193	0.935	rs2659916	ENSG00000237310.1	GS1-124K5.4	4.88	1.42e-06	0.000347	0.23	0.22	Aortic root size;	chr7:66686365	chr7:66493706~66495474:+
LUAD	cis	rs801193	1	rs6958520	ENSG00000237310.1	GS1-124K5.4	4.88	1.42e-06	0.000347	0.23	0.22	Aortic root size;	chr7:66686466	chr7:66493706~66495474:+
LUAD	cis	rs801193	0.967	rs2707849	ENSG00000237310.1	GS1-124K5.4	4.88	1.42e-06	0.000347	0.23	0.22	Aortic root size;	chr7:66687725	chr7:66493706~66495474:+
LUAD	cis	rs12908161	1	rs11638290	ENSG00000259295.5	CSPG4P12	4.88	1.42e-06	0.000347	0.31	0.22	Schizophrenia;	chr15:84684405	chr15:85191438~85213905:+
LUAD	cis	rs12908161	0.959	rs34028043	ENSG00000259295.5	CSPG4P12	4.88	1.42e-06	0.000347	0.31	0.22	Schizophrenia;	chr15:84688354	chr15:85191438~85213905:+
LUAD	cis	rs12908161	0.959	rs34784022	ENSG00000259295.5	CSPG4P12	4.88	1.42e-06	0.000347	0.31	0.22	Schizophrenia;	chr15:84688675	chr15:85191438~85213905:+
LUAD	cis	rs12908161	0.959	rs12908699	ENSG00000259295.5	CSPG4P12	4.88	1.42e-06	0.000347	0.31	0.22	Schizophrenia;	chr15:84697172	chr15:85191438~85213905:+
LUAD	cis	rs7727544	0.716	rs3844312	ENSG00000233006.5	AC034220.3	4.88	1.42e-06	0.000347	0.19	0.22	Blood metabolite levels;	chr5:132246663	chr5:132311285~132369916:-
LUAD	cis	rs301901	0.772	rs7711452	ENSG00000250155.1	CTD-2353F22.1	-4.88	1.43e-06	0.000347	-0.23	-0.22	Height;	chr5:37216735	chr5:36666214~36725195:-
LUAD	cis	rs6921919	1	rs6921919	ENSG00000216901.1	AL022393.7	4.88	1.43e-06	0.000347	0.29	0.22	Autism spectrum disorder or schizophrenia;	chr6:28357424	chr6:28176188~28176674:+
LUAD	cis	rs193541	0.632	rs168913	ENSG00000263432.2	RN7SL689P	4.88	1.43e-06	0.000348	0.29	0.22	Glucose homeostasis traits;	chr5:122890098	chr5:123022487~123022783:-
LUAD	cis	rs11122895	0.791	rs7559932	ENSG00000236307.2	EEF1E1P1	4.88	1.43e-06	0.000348	0.24	0.22	Allergic sensitization;	chr2:111709555	chr2:111887914~111888741:+
LUAD	cis	rs12745968	0.532	rs4970704	ENSG00000223787.2	RP4-593M8.1	-4.88	1.43e-06	0.000348	-0.26	-0.22	Bipolar disorder and schizophrenia;	chr1:92506145	chr1:92580476~92580821:-
LUAD	cis	rs7923609	0.846	rs9787438	ENSG00000232075.1	MRPL35P2	-4.88	1.43e-06	0.000348	-0.27	-0.22	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63278270	chr10:63634317~63634827:-
LUAD	cis	rs301901	0.772	rs301878	ENSG00000250155.1	CTD-2353F22.1	-4.88	1.43e-06	0.000348	-0.23	-0.22	Height;	chr5:37097036	chr5:36666214~36725195:-
LUAD	cis	rs35934224	0.783	rs7284106	ENSG00000232926.1	AC000078.5	4.88	1.43e-06	0.000348	0.23	0.22	Glaucoma (primary open-angle);	chr22:19870026	chr22:19887289~19887970:+
LUAD	cis	rs6095360	0.7	rs11908024	ENSG00000222365.1	SNORD12B	-4.88	1.43e-06	0.000349	-0.24	-0.22	Intelligence (multi-trait analysis);	chr20:49081649	chr20:49280319~49280409:+
LUAD	cis	rs3750965	1	rs7937006	ENSG00000260895.1	RP11-554A11.7	4.88	1.43e-06	0.000349	0.25	0.22	Hair color;	chr11:69076464	chr11:69103493~69109094:+
LUAD	cis	rs74233809	1	rs35125602	ENSG00000213277.3	MARCKSL1P1	4.88	1.43e-06	0.000349	0.36	0.22	Birth weight;	chr10:102896282	chr10:103175554~103176094:+
LUAD	cis	rs2380205	0.546	rs636578	ENSG00000232807.2	RP11-536K7.3	-4.88	1.43e-06	0.000349	-0.23	-0.22	Breast cancer;	chr10:5896581	chr10:5934270~5945900:-
LUAD	cis	rs2554380	0.628	rs7175491	ENSG00000230373.7	GOLGA6L5P	-4.88	1.44e-06	0.000349	-0.23	-0.22	Height;	chr15:83806187	chr15:84507885~84516814:-
LUAD	cis	rs5758511	0.68	rs5758667	ENSG00000205702.9	CYP2D7	4.88	1.44e-06	0.000349	0.21	0.22	Birth weight;	chr22:42237198	chr22:42140203~42144577:-
LUAD	cis	rs3822625	1	rs16886448	ENSG00000271828.1	CTD-2310F14.1	4.88	1.44e-06	0.000349	0.5	0.22	Breast cancer (early onset);	chr5:56874986	chr5:56927874~56929573:+
LUAD	cis	rs9341808	0.727	rs4706834	ENSG00000272129.1	RP11-250B2.6	4.88	1.44e-06	0.000349	0.27	0.22	Sitting height ratio;	chr6:80302888	chr6:80355424~80356859:+
LUAD	cis	rs8050896	1	rs73586297	ENSG00000260695.1	RP11-513N24.1	-4.88	1.44e-06	0.000349	-0.43	-0.22	Response to antipsychotic treatment;	chr16:66128477	chr16:65861112~65863784:-
LUAD	cis	rs12468226	1	rs116635509	ENSG00000272966.1	RP11-686O6.1	4.88	1.44e-06	0.00035	0.36	0.22	Urate levels;	chr2:202460027	chr2:202336739~202337200:+
LUAD	cis	rs2522056	1	rs2057655	ENSG00000233006.5	AC034220.3	4.88	1.44e-06	0.00035	0.23	0.22	Fibrinogen;Lymphocyte counts;	chr5:132471932	chr5:132311285~132369916:-
LUAD	cis	rs2834288	0.645	rs2032313	ENSG00000237945.6	LINC00649	4.88	1.44e-06	0.00035	0.27	0.22	Gut microbiota (bacterial taxa);	chr21:33981946	chr21:33915534~33977691:+
LUAD	cis	rs7208859	0.673	rs216411	ENSG00000263531.1	RP13-753N3.1	-4.88	1.44e-06	0.00035	-0.37	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576475	chr17:30863921~30864940:-
LUAD	cis	rs1707322	1	rs4073847	ENSG00000280836.1	AL355480.1	4.88	1.44e-06	0.00035	0.28	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45997340	chr1:45581219~45581321:-
LUAD	cis	rs875971	1	rs2220626	ENSG00000232559.3	GS1-124K5.12	-4.88	1.44e-06	0.00035	-0.26	-0.22	Aortic root size;	chr7:66081075	chr7:66554588~66576923:-
LUAD	cis	rs375066	0.935	rs397913	ENSG00000267058.1	RP11-15A1.3	4.88	1.44e-06	0.00035	0.24	0.22	Breast cancer;	chr19:43894788	chr19:43891804~43901805:-
LUAD	cis	rs4835473	0.722	rs34106992	ENSG00000251600.4	RP11-673E1.1	-4.88	1.44e-06	0.000351	-0.27	-0.22	Immature fraction of reticulocytes;	chr4:143736844	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.722	rs34261585	ENSG00000251600.4	RP11-673E1.1	-4.88	1.44e-06	0.000351	-0.27	-0.22	Immature fraction of reticulocytes;	chr4:143736846	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.722	rs35770552	ENSG00000251600.4	RP11-673E1.1	-4.88	1.44e-06	0.000351	-0.27	-0.22	Immature fraction of reticulocytes;	chr4:143736848	chr4:143912331~143982454:+
LUAD	cis	rs6088590	1	rs6119512	ENSG00000276073.1	RP5-1125A11.7	-4.88	1.44e-06	0.000351	-0.22	-0.22	Coronary artery disease;	chr20:34719100	chr20:33985617~33988989:-
LUAD	cis	rs7017914	0.652	rs13281838	ENSG00000223220.1	Y_RNA	4.88	1.44e-06	0.000351	0.25	0.22	Bone mineral density;	chr8:70822207	chr8:70780914~70781008:-
LUAD	cis	rs10050311	0.698	rs3775238	ENSG00000251411.1	RP11-397E7.4	-4.88	1.44e-06	0.000351	-0.31	-0.22	Insulin-related traits;	chr4:86712231	chr4:86913266~86914817:-
LUAD	cis	rs4835473	0.897	rs1817027	ENSG00000251600.4	RP11-673E1.1	-4.88	1.44e-06	0.000351	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143713336	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.801	rs999049	ENSG00000251600.4	RP11-673E1.1	-4.88	1.44e-06	0.000351	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143715440	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.897	rs11735341	ENSG00000251600.4	RP11-673E1.1	-4.88	1.44e-06	0.000351	-0.28	-0.22	Immature fraction of reticulocytes;	chr4:143716030	chr4:143912331~143982454:+
LUAD	cis	rs189798	0.807	rs9949	ENSG00000173295.6	FAM86B3P	4.88	1.44e-06	0.000351	0.27	0.22	Myopia (pathological);	chr8:9137002	chr8:8228595~8244865:+
LUAD	cis	rs34375054	0.526	rs883315	ENSG00000279233.1	RP11-158L12.4	4.88	1.44e-06	0.000351	0.19	0.22	Post bronchodilator FEV1/FVC ratio;	chr12:125192343	chr12:125138245~125141711:+
LUAD	cis	rs6125597	0.967	rs6067048	ENSG00000230758.1	SNAP23P	4.88	1.44e-06	0.000351	0.22	0.22	Intelligence (multi-trait analysis);	chr20:49310024	chr20:49038357~49038602:-
LUAD	cis	rs74233809	1	rs10883806	ENSG00000213277.3	MARCKSL1P1	4.88	1.44e-06	0.000351	0.38	0.22	Birth weight;	chr10:102953319	chr10:103175554~103176094:+
LUAD	cis	rs74233809	1	rs78260931	ENSG00000213277.3	MARCKSL1P1	4.88	1.44e-06	0.000351	0.38	0.22	Birth weight;	chr10:102962205	chr10:103175554~103176094:+
LUAD	cis	rs875971	0.83	rs427575	ENSG00000232559.3	GS1-124K5.12	4.88	1.44e-06	0.000351	0.25	0.22	Aortic root size;	chr7:66054232	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.8	rs427557	ENSG00000232559.3	GS1-124K5.12	4.88	1.44e-06	0.000351	0.25	0.22	Aortic root size;	chr7:66054263	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.83	rs587360	ENSG00000232559.3	GS1-124K5.12	4.88	1.44e-06	0.000351	0.25	0.22	Aortic root size;	chr7:66057711	chr7:66554588~66576923:-
LUAD	cis	rs42490	0.51	rs218890	ENSG00000251136.7	RP11-37B2.1	-4.88	1.44e-06	0.000351	-0.22	-0.22	Leprosy;	chr8:89680848	chr8:89609409~89757727:-
LUAD	cis	rs801193	1	rs13239306	ENSG00000237310.1	GS1-124K5.4	-4.88	1.44e-06	0.000351	-0.24	-0.22	Aortic root size;	chr7:66671030	chr7:66493706~66495474:+
LUAD	cis	rs1008375	1	rs56974987	ENSG00000249502.1	AC006160.5	-4.88	1.44e-06	0.000351	-0.21	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17626233	chr4:17587467~17614571:-
LUAD	cis	rs8040855	0.69	rs8041189	ENSG00000259774.1	RP11-182J1.13	-4.88	1.44e-06	0.000351	-0.29	-0.22	Bulimia nervosa;	chr15:85143096	chr15:84422618~84425882:+
LUAD	cis	rs8127691	1	rs743479	ENSG00000237604.1	AP001056.1	4.88	1.45e-06	0.000352	0.26	0.22	Inflammatory bowel disease;	chr21:44192067	chr21:44175489~44176453:+
LUAD	cis	rs9487094	0.744	rs13204787	ENSG00000260273.1	RP11-425D10.10	4.88	1.45e-06	0.000352	0.32	0.22	Height;	chr6:109618283	chr6:109382795~109383666:+
LUAD	cis	rs7017914	0.652	rs17768191	ENSG00000223220.1	Y_RNA	4.88	1.45e-06	0.000352	0.25	0.22	Bone mineral density;	chr8:70939642	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.629	rs17690181	ENSG00000223220.1	Y_RNA	4.88	1.45e-06	0.000352	0.25	0.22	Bone mineral density;	chr8:70942231	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs13273873	ENSG00000223220.1	Y_RNA	4.88	1.45e-06	0.000352	0.25	0.22	Bone mineral density;	chr8:70942984	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs13280740	ENSG00000223220.1	Y_RNA	4.88	1.45e-06	0.000352	0.25	0.22	Bone mineral density;	chr8:70946286	chr8:70780914~70781008:-
LUAD	cis	rs6570726	0.791	rs446362	ENSG00000235652.6	RP11-545I5.3	4.88	1.45e-06	0.000352	0.22	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145557580	chr6:145799409~145886585:+
LUAD	cis	rs944289	0.538	rs1169150	ENSG00000257826.1	RP11-116N8.4	-4.88	1.45e-06	0.000352	-0.24	-0.22	Thyroid cancer;	chr14:36171384	chr14:36061026~36067190:-
LUAD	cis	rs4908760	0.795	rs6693009	ENSG00000270282.1	RP5-1115A15.2	4.88	1.45e-06	0.000352	0.24	0.22	Vitiligo;	chr1:8683651	chr1:8512653~8513021:+
LUAD	cis	rs875971	0.825	rs1000464	ENSG00000232559.3	GS1-124K5.12	-4.88	1.45e-06	0.000352	-0.26	-0.22	Aortic root size;	chr7:66312922	chr7:66554588~66576923:-
LUAD	cis	rs7819412	0.807	rs4840542	ENSG00000255046.1	RP11-297N6.4	4.88	1.45e-06	0.000353	0.27	0.22	Triglycerides;	chr8:11087299	chr8:11797928~11802568:-
LUAD	cis	rs10863681	0.738	rs12140558	ENSG00000228437.4	RP11-400N13.2	4.88	1.45e-06	0.000353	0.27	0.22	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222100978	chr1:221966341~221984964:+
LUAD	cis	rs7937890	1	rs6486190	ENSG00000254418.1	RP11-21L19.1	4.88	1.45e-06	0.000353	0.26	0.22	Mitochondrial DNA levels;	chr11:14379670	chr11:14262846~14273691:-
LUAD	cis	rs1799949	0.965	rs8176322	ENSG00000236383.6	LINC00854	-4.88	1.45e-06	0.000353	-0.17	-0.22	Menopause (age at onset);	chr17:43043756	chr17:43216941~43305976:-
LUAD	cis	rs2284378	0.515	rs6059579	ENSG00000275784.1	RP5-1125A11.6	-4.88	1.45e-06	0.000353	-0.24	-0.22	Breast cancer;	chr20:33940059	chr20:33989480~33991818:-
LUAD	cis	rs2033711	0.728	rs4801586	ENSG00000268912.1	CTD-2619J13.17	-4.88	1.45e-06	0.000353	-0.23	-0.22	Uric acid clearance;	chr19:58423161	chr19:58428632~58431148:-
LUAD	cis	rs4568518	0.619	rs34058374	ENSG00000279048.1	RP11-511H23.2	4.88	1.45e-06	0.000353	0.18	0.22	Measles;	chr7:17968959	chr7:17940503~17942922:+
LUAD	cis	rs36423	0.748	rs36395	ENSG00000266869.1	RP6-114E22.1	-4.88	1.45e-06	0.000353	-0.33	-0.22	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71895714	chr14:71848606~71908430:+
LUAD	cis	rs36423	0.748	rs36394	ENSG00000266869.1	RP6-114E22.1	-4.88	1.45e-06	0.000353	-0.33	-0.22	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71895899	chr14:71848606~71908430:+
LUAD	cis	rs4664293	0.625	rs3821300	ENSG00000226266.5	AC009961.3	4.88	1.45e-06	0.000353	0.29	0.22	Monocyte percentage of white cells;	chr2:159710719	chr2:159670708~159712435:-
LUAD	cis	rs453301	0.653	rs1045529	ENSG00000173295.6	FAM86B3P	-4.88	1.45e-06	0.000353	-0.23	-0.22	Joint mobility (Beighton score);	chr8:9032588	chr8:8228595~8244865:+
LUAD	cis	rs11122895	0.72	rs7559924	ENSG00000236307.2	EEF1E1P1	4.88	1.45e-06	0.000353	0.24	0.22	Allergic sensitization;	chr2:111709541	chr2:111887914~111888741:+
LUAD	cis	rs453301	0.631	rs28572014	ENSG00000253981.4	ALG1L13P	-4.88	1.45e-06	0.000353	-0.25	-0.22	Joint mobility (Beighton score);	chr8:8936097	chr8:8236003~8244667:-
LUAD	cis	rs10050311	0.8	rs17420966	ENSG00000251411.1	RP11-397E7.4	-4.88	1.45e-06	0.000354	-0.32	-0.22	Insulin-related traits;	chr4:86770976	chr4:86913266~86914817:-
LUAD	cis	rs2404602	0.569	rs2469249	ENSG00000259422.1	RP11-593F23.1	-4.88	1.46e-06	0.000354	-0.29	-0.22	Blood metabolite levels;	chr15:76479721	chr15:76174891~76181486:-
LUAD	cis	rs7432375	0.61	rs60574021	ENSG00000239213.4	NCK1-AS1	4.88	1.46e-06	0.000354	0.23	0.22	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136801439	chr3:136841726~136862054:-
LUAD	cis	rs6604026	0.555	rs34812295	ENSG00000223787.2	RP4-593M8.1	4.88	1.46e-06	0.000354	0.29	0.22	Multiple sclerosis;	chr1:92606712	chr1:92580476~92580821:-
LUAD	cis	rs4460629	0.901	rs4745	ENSG00000160766.13	GBAP1	4.88	1.46e-06	0.000354	0.22	0.22	Serum magnesium levels;	chr1:155133751	chr1:155213821~155227422:-
LUAD	cis	rs1707322	0.896	rs946528	ENSG00000280836.1	AL355480.1	4.88	1.46e-06	0.000354	0.28	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019890	chr1:45581219~45581321:-
LUAD	cis	rs801193	0.967	rs2707841	ENSG00000237310.1	GS1-124K5.4	4.88	1.46e-06	0.000354	0.23	0.22	Aortic root size;	chr7:66692033	chr7:66493706~66495474:+
LUAD	cis	rs1729951	0.575	rs747842	ENSG00000239213.4	NCK1-AS1	4.88	1.46e-06	0.000354	0.24	0.22	Neuroticism;	chr3:136984279	chr3:136841726~136862054:-
LUAD	cis	rs1729951	0.575	rs747843	ENSG00000239213.4	NCK1-AS1	4.88	1.46e-06	0.000354	0.24	0.22	Neuroticism;	chr3:136984288	chr3:136841726~136862054:-
LUAD	cis	rs1729951	0.575	rs835642	ENSG00000239213.4	NCK1-AS1	4.88	1.46e-06	0.000354	0.24	0.22	Neuroticism;	chr3:136984523	chr3:136841726~136862054:-
LUAD	cis	rs2380205	0.517	rs2387092	ENSG00000232807.2	RP11-536K7.3	4.88	1.46e-06	0.000355	0.24	0.22	Breast cancer;	chr10:5918246	chr10:5934270~5945900:-
LUAD	cis	rs375066	0.762	rs17713001	ENSG00000267058.1	RP11-15A1.3	4.88	1.46e-06	0.000355	0.24	0.22	Breast cancer;	chr19:43917073	chr19:43891804~43901805:-
LUAD	cis	rs375066	0.762	rs2284245	ENSG00000267058.1	RP11-15A1.3	4.88	1.46e-06	0.000355	0.24	0.22	Breast cancer;	chr19:43918437	chr19:43891804~43901805:-
LUAD	cis	rs1198872	0.526	rs57282335	ENSG00000272275.1	RP11-791G15.2	-4.88	1.46e-06	0.000355	-0.31	-0.22	Cardiac Troponin-T levels;	chr2:10788081	chr2:10767875~10770058:-
LUAD	cis	rs8180040	0.701	rs13066214	ENSG00000271161.1	BOLA2P2	4.88	1.46e-06	0.000355	0.21	0.22	Colorectal cancer;	chr3:46992447	chr3:47499841~47500407:+
LUAD	cis	rs2617170	0.885	rs7975996	ENSG00000245648.1	RP11-277P12.20	4.88	1.46e-06	0.000355	0.28	0.22	Behcet's disease;	chr12:10372324	chr12:10363769~10398506:+
LUAD	cis	rs7829975	0.714	rs11784052	ENSG00000253981.4	ALG1L13P	4.88	1.46e-06	0.000355	0.25	0.22	Mood instability;	chr8:8814452	chr8:8236003~8244667:-
LUAD	cis	rs9987353	0.62	rs34455383	ENSG00000253893.2	FAM85B	4.88	1.46e-06	0.000355	0.29	0.22	Recombination measurement;	chr8:9208948	chr8:8167819~8226614:-
LUAD	cis	rs2898681	1	rs4864690	ENSG00000248375.1	RP11-177B4.1	-4.88	1.46e-06	0.000355	-0.33	-0.22	Optic nerve measurement (cup area);	chr4:52884604	chr4:52720081~52720831:-
LUAD	cis	rs7208859	0.623	rs9899268	ENSG00000280069.1	CTD-2349P21.3	-4.88	1.46e-06	0.000355	-0.3	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30823237	chr17:30738182~30740275:+
LUAD	cis	rs507080	0.922	rs7114458	ENSG00000278376.1	RP11-158I9.8	-4.88	1.46e-06	0.000355	-0.24	-0.22	Serum metabolite levels;	chr11:118695466	chr11:118791254~118793137:+
LUAD	cis	rs507080	0.922	rs7114216	ENSG00000278376.1	RP11-158I9.8	-4.88	1.46e-06	0.000355	-0.24	-0.22	Serum metabolite levels;	chr11:118695525	chr11:118791254~118793137:+
LUAD	cis	rs7119	0.651	rs17394732	ENSG00000259362.2	RP11-307C19.1	4.88	1.46e-06	0.000355	0.27	0.22	Type 2 diabetes;	chr15:77543315	chr15:77525540~77534110:+
LUAD	cis	rs35160687	0.644	rs4610056	ENSG00000273080.1	RP11-301O19.1	-4.88	1.46e-06	0.000355	-0.24	-0.22	Night sleep phenotypes;	chr2:86326127	chr2:86195590~86196049:+
LUAD	cis	rs10091374	0.967	rs6472531	ENSG00000253967.1	RP11-333A23.4	-4.88	1.46e-06	0.000355	-0.25	-0.22	Cardiac Troponin-T levels;	chr8:70474246	chr8:70471134~70485687:+
LUAD	cis	rs10091374	1	rs7838853	ENSG00000253967.1	RP11-333A23.4	-4.88	1.46e-06	0.000355	-0.25	-0.22	Cardiac Troponin-T levels;	chr8:70474462	chr8:70471134~70485687:+
LUAD	cis	rs2380205	0.517	rs7067928	ENSG00000232807.2	RP11-536K7.3	4.88	1.46e-06	0.000356	0.24	0.22	Breast cancer;	chr10:5910891	chr10:5934270~5945900:-
LUAD	cis	rs12908161	0.959	rs1051168	ENSG00000275120.1	RP11-182J1.17	4.88	1.46e-06	0.000356	0.33	0.22	Schizophrenia;	chr15:84657289	chr15:84599434~84606463:-
LUAD	cis	rs13256369	0.951	rs13260947	ENSG00000253893.2	FAM85B	-4.88	1.47e-06	0.000356	-0.3	-0.22	Obesity-related traits;	chr8:8708373	chr8:8167819~8226614:-
LUAD	cis	rs13256369	0.951	rs13259955	ENSG00000253893.2	FAM85B	-4.88	1.47e-06	0.000356	-0.3	-0.22	Obesity-related traits;	chr8:8708375	chr8:8167819~8226614:-
LUAD	cis	rs950169	0.58	rs11636189	ENSG00000259295.5	CSPG4P12	4.88	1.47e-06	0.000356	0.31	0.22	Schizophrenia;	chr15:84650323	chr15:85191438~85213905:+
LUAD	cis	rs1707322	1	rs4524994	ENSG00000280836.1	AL355480.1	-4.88	1.47e-06	0.000356	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45904591	chr1:45581219~45581321:-
LUAD	cis	rs7968440	0.651	rs7309519	ENSG00000272368.2	RP4-605O3.4	-4.88	1.47e-06	0.000356	-0.24	-0.22	Fibrinogen;	chr12:50258497	chr12:50112197~50165618:+
LUAD	cis	rs116095464	1	rs6879758	ENSG00000277812.1	AC021087.1	4.88	1.47e-06	0.000357	0.58	0.22	Breast cancer;	chr5:350162	chr5:262769~262881:+
LUAD	cis	rs9545047	0.604	rs9565487	ENSG00000227354.5	RBM26-AS1	-4.88	1.47e-06	0.000357	-0.23	-0.22	Schizophrenia;	chr13:79332742	chr13:79406309~79424328:+
LUAD	cis	rs2976388	0.647	rs2244163	ENSG00000253741.1	CTD-2292P10.4	-4.88	1.47e-06	0.000357	-0.25	-0.22	Urinary tract infection frequency;	chr8:142703082	chr8:142702252~142726973:-
LUAD	cis	rs3096299	0.933	rs889576	ENSG00000182376.2	RP5-1142A6.8	-4.88	1.47e-06	0.000357	-0.22	-0.22	Multiple myeloma (IgH translocation);	chr16:89363245	chr16:88742767~88745748:+
LUAD	cis	rs116139393	0.611	rs7792579	ENSG00000187953.9	PMS2CL	-4.88	1.47e-06	0.000357	-0.28	-0.22	Alzheimer's disease (APOE e4 interaction);	chr7:6725962	chr7:6710128~6753862:+
LUAD	cis	rs7017914	0.652	rs2639910	ENSG00000223220.1	Y_RNA	4.88	1.47e-06	0.000357	0.25	0.22	Bone mineral density;	chr8:70949649	chr8:70780914~70781008:-
LUAD	cis	rs6604026	0.555	rs67646822	ENSG00000223787.2	RP4-593M8.1	4.88	1.47e-06	0.000357	0.3	0.22	Multiple sclerosis;	chr1:92643406	chr1:92580476~92580821:-
LUAD	cis	rs7829975	0.714	rs4841040	ENSG00000173295.6	FAM86B3P	4.88	1.47e-06	0.000357	0.23	0.22	Mood instability;	chr8:8797017	chr8:8228595~8244865:+
LUAD	cis	rs914615	0.508	rs4390169	ENSG00000160766.13	GBAP1	4.88	1.47e-06	0.000357	0.22	0.22	Urinary albumin-to-creatinine ratio;	chr1:155133578	chr1:155213821~155227422:-
LUAD	cis	rs1799949	1	rs4793215	ENSG00000236383.6	LINC00854	-4.88	1.47e-06	0.000357	-0.18	-0.22	Menopause (age at onset);	chr17:43166915	chr17:43216941~43305976:-
LUAD	cis	rs11673344	0.734	rs1667343	ENSG00000226686.6	LINC01535	4.88	1.47e-06	0.000357	0.28	0.22	Obesity-related traits;	chr19:36978196	chr19:37251912~37265535:+
LUAD	cis	rs10129255	0.917	rs7142373	ENSG00000211974.3	IGHV2-70	4.88	1.47e-06	0.000357	0.24	0.22	Kawasaki disease;	chr14:106708947	chr14:106723574~106724093:-
LUAD	cis	rs11157436	0.918	rs1076546	ENSG00000211812.1	TRAV26-2	-4.88	1.47e-06	0.000358	-0.23	-0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22159015	chr14:22202583~22203368:+
LUAD	cis	rs111315781	1	rs111315781	ENSG00000183308.6	AC005037.3	4.88	1.47e-06	0.000358	0.39	0.22	Triptolide cytotoxicity;	chr2:200874001	chr2:200963263~201009102:+
LUAD	cis	rs449789	0.817	rs1875814	ENSG00000235086.1	FNDC1-IT1	-4.88	1.47e-06	0.000358	-0.31	-0.22	Pulse pressure;	chr6:159299234	chr6:159240786~159243329:+
LUAD	cis	rs449789	0.857	rs1875816	ENSG00000235086.1	FNDC1-IT1	-4.88	1.47e-06	0.000358	-0.31	-0.22	Pulse pressure;	chr6:159299282	chr6:159240786~159243329:+
LUAD	cis	rs14027	0.883	rs1469755	ENSG00000279347.1	RP11-85I17.2	-4.88	1.47e-06	0.000358	-0.19	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119728107	chr8:119838736~119840385:-
LUAD	cis	rs1729951	0.575	rs361239	ENSG00000239213.4	NCK1-AS1	4.88	1.48e-06	0.000358	0.24	0.22	Neuroticism;	chr3:136982453	chr3:136841726~136862054:-
LUAD	cis	rs507080	0.922	rs558781	ENSG00000278376.1	RP11-158I9.8	-4.88	1.48e-06	0.000358	-0.24	-0.22	Serum metabolite levels;	chr11:118693688	chr11:118791254~118793137:+
LUAD	cis	rs2742234	0.91	rs2503866	ENSG00000273008.1	RP11-351D16.3	-4.88	1.48e-06	0.000358	-0.23	-0.22	Hirschsprung disease;	chr10:43150813	chr10:43136824~43138334:-
LUAD	cis	rs4664293	0.867	rs3771718	ENSG00000226266.5	AC009961.3	-4.88	1.48e-06	0.000358	-0.3	-0.22	Monocyte percentage of white cells;	chr2:159780397	chr2:159670708~159712435:-
LUAD	cis	rs71520386	0.632	rs10279864	ENSG00000228649.7	AC005682.5	-4.88	1.48e-06	0.000358	-0.3	-0.22	Fibrinogen levels;	chr7:22824205	chr7:22854178~22861579:+
LUAD	cis	rs219780	0.768	rs219784	ENSG00000233818.1	AP000695.4	4.88	1.48e-06	0.000358	0.26	0.22	Kidney stones;	chr21:36459569	chr21:36445731~36532408:+
LUAD	cis	rs4908760	0.868	rs12131864	ENSG00000270282.1	RP5-1115A15.2	4.88	1.48e-06	0.000359	0.24	0.22	Vitiligo;	chr1:8531103	chr1:8512653~8513021:+
LUAD	cis	rs4865169	0.623	rs6838975	ENSG00000269949.1	RP11-738E22.3	-4.88	1.48e-06	0.000359	-0.3	-0.22	Breast cancer;	chr4:56873650	chr4:56960927~56961373:-
LUAD	cis	rs708547	0.541	rs6554392	ENSG00000269949.1	RP11-738E22.3	-4.88	1.48e-06	0.000359	-0.3	-0.22	Response to bleomycin (chromatid breaks);	chr4:56873782	chr4:56960927~56961373:-
LUAD	cis	rs9309473	0.514	rs62149630	ENSG00000163016.8	ALMS1P	4.88	1.48e-06	0.000359	0.33	0.22	Metabolite levels;	chr2:73354627	chr2:73644919~73685576:+
LUAD	cis	rs13256369	0.802	rs11995449	ENSG00000253893.2	FAM85B	-4.88	1.48e-06	0.000359	-0.3	-0.22	Obesity-related traits;	chr8:8702388	chr8:8167819~8226614:-
LUAD	cis	rs507080	0.922	rs12577485	ENSG00000278376.1	RP11-158I9.8	-4.88	1.48e-06	0.000359	-0.23	-0.22	Serum metabolite levels;	chr11:118676793	chr11:118791254~118793137:+
LUAD	cis	rs9322193	0.923	rs7753812	ENSG00000268592.3	RAET1E-AS1	4.88	1.48e-06	0.000359	0.27	0.22	Lung cancer;	chr6:149690150	chr6:149863494~149919507:+
LUAD	cis	rs1707322	1	rs12403666	ENSG00000280836.1	AL355480.1	-4.88	1.48e-06	0.000359	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45965949	chr1:45581219~45581321:-
LUAD	cis	rs925255	0.901	rs906805	ENSG00000270210.1	RP11-373D23.3	4.88	1.48e-06	0.000359	0.24	0.22	Inflammatory bowel disease;Crohn's disease;	chr2:28382012	chr2:28425945~28426719:+
LUAD	cis	rs10129255	1	rs10129407	ENSG00000274576.2	IGHV2-70	4.88	1.48e-06	0.000359	0.19	0.22	Kawasaki disease;	chr14:106767956	chr14:106770577~106771020:-
LUAD	cis	rs12745968	0.525	rs6603997	ENSG00000223787.2	RP4-593M8.1	-4.88	1.48e-06	0.000359	-0.25	-0.22	Bipolar disorder and schizophrenia;	chr1:92597054	chr1:92580476~92580821:-
LUAD	cis	rs301901	1	rs300060	ENSG00000250155.1	CTD-2353F22.1	-4.87	1.48e-06	0.000359	-0.22	-0.22	Height;	chr5:37019252	chr5:36666214~36725195:-
LUAD	cis	rs875971	0.66	rs801217	ENSG00000236529.1	RP13-254B10.1	-4.87	1.48e-06	0.000359	-0.22	-0.22	Aortic root size;	chr7:66545590	chr7:65840212~65840596:+
LUAD	cis	rs875971	0.638	rs801216	ENSG00000236529.1	RP13-254B10.1	-4.87	1.48e-06	0.000359	-0.22	-0.22	Aortic root size;	chr7:66546680	chr7:65840212~65840596:+
LUAD	cis	rs875971	0.66	rs801211	ENSG00000236529.1	RP13-254B10.1	-4.87	1.48e-06	0.000359	-0.22	-0.22	Aortic root size;	chr7:66550702	chr7:65840212~65840596:+
LUAD	cis	rs301901	1	rs300055	ENSG00000250155.1	CTD-2353F22.1	-4.87	1.48e-06	0.000359	-0.22	-0.22	Height;	chr5:37072722	chr5:36666214~36725195:-
LUAD	cis	rs442309	0.532	rs10995301	ENSG00000238280.1	RP11-436D10.3	4.87	1.48e-06	0.00036	0.28	0.22	Vogt-Koyanagi-Harada syndrome;	chr10:62747535	chr10:62793562~62805887:-
LUAD	cis	rs8031584	0.578	rs1088473	ENSG00000259845.1	HERC2P10	-4.87	1.48e-06	0.00036	-0.26	-0.22	Huntington's disease progression;	chr15:30847095	chr15:30815271~30844153:+
LUAD	cis	rs301901	0.772	rs7715883	ENSG00000250155.1	CTD-2353F22.1	-4.87	1.48e-06	0.00036	-0.23	-0.22	Height;	chr5:37238160	chr5:36666214~36725195:-
LUAD	cis	rs1062753	0.771	rs5751245	ENSG00000227370.1	RP4-669P10.19	4.87	1.48e-06	0.00036	0.22	0.22	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42224934	chr22:42132543~42132998:+
LUAD	cis	rs2749097	0.825	rs11208265	ENSG00000244256.3	RN7SL130P	-4.87	1.48e-06	0.00036	-0.26	-0.22	Alcohol consumption (transferrin glycosylation);	chr1:63659563	chr1:63655743~63656047:+
LUAD	cis	rs7189233	0.531	rs9941254	ENSG00000279344.1	RP11-44F14.7	4.87	1.48e-06	0.00036	0.18	0.22	Intelligence (multi-trait analysis);	chr16:53453306	chr16:53478957~53481550:-
LUAD	cis	rs7176527	0.519	rs12148368	ENSG00000188388.10	GOLGA6L3	4.87	1.48e-06	0.00036	0.26	0.22	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84563274	chr15:85240472~85247170:+
LUAD	cis	rs2243480	1	rs1723270	ENSG00000164669.11	INTS4P1	4.87	1.49e-06	0.00036	0.39	0.22	Diabetic kidney disease;	chr7:66004843	chr7:65141225~65234216:+
LUAD	cis	rs7017914	0.652	rs62533063	ENSG00000223220.1	Y_RNA	4.87	1.49e-06	0.00036	0.25	0.22	Bone mineral density;	chr8:70673824	chr8:70780914~70781008:-
LUAD	cis	rs453301	0.657	rs36056437	ENSG00000173295.6	FAM86B3P	-4.87	1.49e-06	0.00036	-0.24	-0.22	Joint mobility (Beighton score);	chr8:8935355	chr8:8228595~8244865:+
LUAD	cis	rs35160687	0.644	rs4832036	ENSG00000273080.1	RP11-301O19.1	-4.87	1.49e-06	0.00036	-0.24	-0.22	Night sleep phenotypes;	chr2:86324179	chr2:86195590~86196049:+
LUAD	cis	rs160451	0.966	rs12216864	ENSG00000251136.7	RP11-37B2.1	4.87	1.49e-06	0.00036	0.22	0.22	Leprosy;	chr8:89665895	chr8:89609409~89757727:-
LUAD	cis	rs801193	0.569	rs7782587	ENSG00000232559.3	GS1-124K5.12	4.87	1.49e-06	0.00036	0.26	0.22	Aortic root size;	chr7:66701485	chr7:66554588~66576923:-
LUAD	cis	rs801193	0.569	rs4717315	ENSG00000232559.3	GS1-124K5.12	4.87	1.49e-06	0.00036	0.26	0.22	Aortic root size;	chr7:66713338	chr7:66554588~66576923:-
LUAD	cis	rs801193	0.527	rs2707837	ENSG00000232559.3	GS1-124K5.12	4.87	1.49e-06	0.00036	0.26	0.22	Aortic root size;	chr7:66716086	chr7:66554588~66576923:-
LUAD	cis	rs442309	0.551	rs10995305	ENSG00000238280.1	RP11-436D10.3	-4.87	1.49e-06	0.000361	-0.27	-0.22	Vogt-Koyanagi-Harada syndrome;	chr10:62781150	chr10:62793562~62805887:-
LUAD	cis	rs7829975	0.714	rs11777085	ENSG00000253893.2	FAM85B	-4.87	1.49e-06	0.000361	-0.27	-0.22	Mood instability;	chr8:8814919	chr8:8167819~8226614:-
LUAD	cis	rs61270009	0.955	rs780399	ENSG00000247828.6	TMEM161B-AS1	-4.87	1.49e-06	0.000361	-0.24	-0.22	Depressive symptoms;	chr5:88237160	chr5:88268895~88436685:+
LUAD	cis	rs61270009	0.913	rs380670	ENSG00000247828.6	TMEM161B-AS1	-4.87	1.49e-06	0.000361	-0.24	-0.22	Depressive symptoms;	chr5:88243132	chr5:88268895~88436685:+
LUAD	cis	rs61270009	0.955	rs379430	ENSG00000247828.6	TMEM161B-AS1	-4.87	1.49e-06	0.000361	-0.24	-0.22	Depressive symptoms;	chr5:88243275	chr5:88268895~88436685:+
LUAD	cis	rs61270009	0.955	rs383385	ENSG00000247828.6	TMEM161B-AS1	-4.87	1.49e-06	0.000361	-0.24	-0.22	Depressive symptoms;	chr5:88246065	chr5:88268895~88436685:+
LUAD	cis	rs61270009	0.955	rs396702	ENSG00000247828.6	TMEM161B-AS1	-4.87	1.49e-06	0.000361	-0.24	-0.22	Depressive symptoms;	chr5:88247486	chr5:88268895~88436685:+
LUAD	cis	rs1816752	0.721	rs7399656	ENSG00000273628.1	RP11-756A22.7	4.87	1.49e-06	0.000361	0.24	0.22	Obesity-related traits;	chr13:24415708	chr13:24933006~24936796:+
LUAD	cis	rs2742234	0.868	rs2505512	ENSG00000273008.1	RP11-351D16.3	-4.87	1.49e-06	0.000361	-0.23	-0.22	Hirschsprung disease;	chr10:43138148	chr10:43136824~43138334:-
LUAD	cis	rs2742234	0.91	rs2505511	ENSG00000273008.1	RP11-351D16.3	-4.87	1.49e-06	0.000361	-0.23	-0.22	Hirschsprung disease;	chr10:43145581	chr10:43136824~43138334:-
LUAD	cis	rs875971	0.522	rs1617484	ENSG00000224316.1	RP11-479O9.2	4.87	1.49e-06	0.000361	0.22	0.22	Aortic root size;	chr7:65998108	chr7:65773620~65802067:+
LUAD	cis	rs2032366	0.591	rs9783921	ENSG00000267279.1	RP11-879F14.2	4.87	1.49e-06	0.000361	0.27	0.22	Obesity-related traits;	chr18:61635219	chr18:61585746~61606916:-
LUAD	cis	rs712039	0.652	rs853197	ENSG00000276054.1	RP11-378E13.3	4.87	1.49e-06	0.000361	0.33	0.22	Tuberculosis;	chr17:37488610	chr17:37386886~37387926:+
LUAD	cis	rs673078	0.66	rs61943365	ENSG00000275409.1	RP11-131L12.4	-4.87	1.49e-06	0.000362	-0.28	-0.22	Glucose homeostasis traits;	chr12:118339166	chr12:118430147~118430699:+
LUAD	cis	rs7119	0.717	rs11634174	ENSG00000259362.2	RP11-307C19.1	-4.87	1.49e-06	0.000362	-0.27	-0.22	Type 2 diabetes;	chr15:77518890	chr15:77525540~77534110:+
LUAD	cis	rs7119	0.717	rs12904348	ENSG00000259362.2	RP11-307C19.1	-4.87	1.49e-06	0.000362	-0.27	-0.22	Type 2 diabetes;	chr15:77523396	chr15:77525540~77534110:+
LUAD	cis	rs13113518	0.812	rs12505880	ENSG00000223305.1	RN7SKP30	4.87	1.49e-06	0.000362	0.25	0.22	Height;	chr4:55440988	chr4:55540502~55540835:-
LUAD	cis	rs910316	1	rs10142865	ENSG00000259138.1	RP11-950C14.7	4.87	1.49e-06	0.000362	0.23	0.22	Height;	chr14:75088921	chr14:75127153~75136930:+
LUAD	cis	rs910316	1	rs10142626	ENSG00000259138.1	RP11-950C14.7	4.87	1.49e-06	0.000362	0.23	0.22	Height;	chr14:75088933	chr14:75127153~75136930:+
LUAD	cis	rs950169	0.58	rs11630887	ENSG00000259295.5	CSPG4P12	4.87	1.49e-06	0.000362	0.31	0.22	Schizophrenia;	chr15:84649784	chr15:85191438~85213905:+
LUAD	cis	rs8031584	0.678	rs798127	ENSG00000259845.1	HERC2P10	-4.87	1.5e-06	0.000362	-0.27	-0.22	Huntington's disease progression;	chr15:30825200	chr15:30815271~30844153:+
LUAD	cis	rs875971	0.862	rs778734	ENSG00000232559.3	GS1-124K5.12	4.87	1.5e-06	0.000362	0.26	0.22	Aortic root size;	chr7:66349862	chr7:66554588~66576923:-
LUAD	cis	rs9322193	0.962	rs2342764	ENSG00000268592.3	RAET1E-AS1	4.87	1.5e-06	0.000362	0.27	0.22	Lung cancer;	chr6:149835068	chr6:149863494~149919507:+
LUAD	cis	rs3893377	0.848	rs3893376	ENSG00000214846.4	RP11-115L11.1	4.87	1.5e-06	0.000362	0.33	0.22	Current cigarettes per day in chronic obstructive pulmonary disease;	chr4:15740451	chr4:15730962~15731627:-
LUAD	cis	rs61270009	0.863	rs6452782	ENSG00000247828.6	TMEM161B-AS1	4.87	1.5e-06	0.000363	0.25	0.22	Depressive symptoms;	chr5:88376887	chr5:88268895~88436685:+
LUAD	cis	rs2032366	0.63	rs1377172	ENSG00000267279.1	RP11-879F14.2	-4.87	1.5e-06	0.000363	-0.28	-0.22	Obesity-related traits;	chr18:61629148	chr18:61585746~61606916:-
LUAD	cis	rs2032366	0.63	rs12457579	ENSG00000267279.1	RP11-879F14.2	-4.87	1.5e-06	0.000363	-0.28	-0.22	Obesity-related traits;	chr18:61629575	chr18:61585746~61606916:-
LUAD	cis	rs4722166	0.695	rs6946509	ENSG00000179428.2	AC073072.5	-4.87	1.5e-06	0.000363	-0.25	-0.22	Lung cancer;	chr7:22769871	chr7:22725395~22727620:-
LUAD	cis	rs16873450	0.506	rs4566942	ENSG00000234800.2	PCMTD1P3	-4.87	1.5e-06	0.000363	-0.25	-0.22	Verbal memory performance (residualized delayed recall level);	chr7:23759488	chr7:23721311~23721782:-
LUAD	cis	rs16873450	0.527	rs28406908	ENSG00000234800.2	PCMTD1P3	-4.87	1.5e-06	0.000363	-0.25	-0.22	Verbal memory performance (residualized delayed recall level);	chr7:23759574	chr7:23721311~23721782:-
LUAD	cis	rs8091660	0.624	rs2175565	ENSG00000278983.1	RP11-426J5.3	-4.87	1.5e-06	0.000363	-0.27	-0.22	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48553481	chr18:48564795~48568342:+
LUAD	cis	rs847577	0.646	rs10270222	ENSG00000272950.1	RP11-307C18.1	-4.87	1.5e-06	0.000364	-0.28	-0.22	Breast cancer;	chr7:98152487	chr7:98322853~98323430:+
LUAD	cis	rs1062177	0.901	rs1549622	ENSG00000253921.1	CTB-113P19.3	-4.87	1.5e-06	0.000364	-0.33	-0.22	Preschool internalizing problems;	chr5:151886488	chr5:151753992~151767247:+
LUAD	cis	rs516805	0.748	rs155467	ENSG00000279453.1	RP3-425C14.4	-4.87	1.5e-06	0.000364	-0.3	-0.22	Lymphocyte counts;	chr6:122512451	chr6:122436789~122439223:-
LUAD	cis	rs1275468	0.554	rs1147994	ENSG00000257497.2	RP11-585P4.5	-4.87	1.5e-06	0.000364	-0.32	-0.22	Polycystic ovary syndrome;	chr12:75566186	chr12:75483454~75489820:-
LUAD	cis	rs13256369	0.802	rs13255789	ENSG00000253893.2	FAM85B	-4.87	1.5e-06	0.000364	-0.3	-0.22	Obesity-related traits;	chr8:8705281	chr8:8167819~8226614:-
LUAD	cis	rs449789	0.857	rs4708817	ENSG00000235086.1	FNDC1-IT1	-4.87	1.5e-06	0.000364	-0.3	-0.22	Pulse pressure;	chr6:159299608	chr6:159240786~159243329:+
LUAD	cis	rs2832077	0.527	rs2250141	ENSG00000232855.5	AF131217.1	-4.87	1.5e-06	0.000364	-0.22	-0.22	Cognitive test performance;	chr21:28869662	chr21:28439346~28674848:-
LUAD	cis	rs2742234	0.955	rs2435385	ENSG00000273008.1	RP11-351D16.3	-4.87	1.51e-06	0.000365	-0.24	-0.22	Hirschsprung disease;	chr10:43170302	chr10:43136824~43138334:-
LUAD	cis	rs6840258	1	rs55787557	ENSG00000251411.1	RP11-397E7.4	-4.87	1.51e-06	0.000365	-0.28	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87029673	chr4:86913266~86914817:-
LUAD	cis	rs6840258	1	rs72667759	ENSG00000251411.1	RP11-397E7.4	-4.87	1.51e-06	0.000365	-0.28	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87031047	chr4:86913266~86914817:-
LUAD	cis	rs507080	0.961	rs607527	ENSG00000278376.1	RP11-158I9.8	4.87	1.51e-06	0.000365	0.23	0.22	Serum metabolite levels;	chr11:118667478	chr11:118791254~118793137:+
LUAD	cis	rs7122539	0.603	rs508443	ENSG00000213409.4	RP11-658F2.3	4.87	1.51e-06	0.000365	0.26	0.22	HIV-1 susceptibility;	chr11:66741898	chr11:66761575~66762399:-
LUAD	cis	rs7937890	0.598	rs10734225	ENSG00000251991.1	RNU7-49P	4.87	1.51e-06	0.000365	0.25	0.22	Mitochondrial DNA levels;	chr11:14421448	chr11:14478892~14478953:+
LUAD	cis	rs12745968	0.624	rs6675753	ENSG00000223787.2	RP4-593M8.1	-4.87	1.51e-06	0.000365	-0.26	-0.22	Bipolar disorder and schizophrenia;	chr1:92750039	chr1:92580476~92580821:-
LUAD	cis	rs1816752	0.819	rs7317504	ENSG00000273628.1	RP11-756A22.7	4.87	1.51e-06	0.000366	0.25	0.22	Obesity-related traits;	chr13:24411287	chr13:24933006~24936796:+
LUAD	cis	rs1816752	0.783	rs7317712	ENSG00000273628.1	RP11-756A22.7	4.87	1.51e-06	0.000366	0.25	0.22	Obesity-related traits;	chr13:24411365	chr13:24933006~24936796:+
LUAD	cis	rs9376098	0.698	rs2050020	ENSG00000232876.1	CTA-212D2.2	-4.87	1.51e-06	0.000366	-0.25	-0.22	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135142915	chr6:135055033~135060550:+
LUAD	cis	rs14027	0.921	rs12542706	ENSG00000279347.1	RP11-85I17.2	-4.87	1.51e-06	0.000366	-0.19	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119831539	chr8:119838736~119840385:-
LUAD	cis	rs14027	0.921	rs10505374	ENSG00000279347.1	RP11-85I17.2	-4.87	1.51e-06	0.000366	-0.19	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119832350	chr8:119838736~119840385:-
LUAD	cis	rs9928842	0.765	rs6564221	ENSG00000280152.1	RP11-331F4.5	4.87	1.51e-06	0.000366	0.25	0.22	Alcoholic chronic pancreatitis;	chr16:75191073	chr16:75245994~75250077:-
LUAD	cis	rs875971	1	rs1167612	ENSG00000232559.3	GS1-124K5.12	-4.87	1.52e-06	0.000367	-0.26	-0.22	Aortic root size;	chr7:66102989	chr7:66554588~66576923:-
LUAD	cis	rs2115630	0.936	rs6496318	ENSG00000225151.9	GOLGA2P7	4.87	1.52e-06	0.000367	0.25	0.22	P wave terminal force;	chr15:84671998	chr15:84199311~84230136:-
LUAD	cis	rs2115630	0.902	rs8023276	ENSG00000225151.9	GOLGA2P7	4.87	1.52e-06	0.000367	0.25	0.22	P wave terminal force;	chr15:84676407	chr15:84199311~84230136:-
LUAD	cis	rs6095360	0.727	rs8118101	ENSG00000222365.1	SNORD12B	-4.87	1.52e-06	0.000367	-0.24	-0.22	Intelligence (multi-trait analysis);	chr20:49073301	chr20:49280319~49280409:+
LUAD	cis	rs6095360	0.727	rs7271812	ENSG00000222365.1	SNORD12B	-4.87	1.52e-06	0.000367	-0.24	-0.22	Intelligence (multi-trait analysis);	chr20:49076496	chr20:49280319~49280409:+
LUAD	cis	rs12908161	0.959	rs3748376	ENSG00000275120.1	RP11-182J1.17	4.87	1.52e-06	0.000367	0.33	0.22	Schizophrenia;	chr15:84785121	chr15:84599434~84606463:-
LUAD	cis	rs12908161	1	rs62019464	ENSG00000275120.1	RP11-182J1.17	4.87	1.52e-06	0.000367	0.32	0.22	Schizophrenia;	chr15:84751238	chr15:84599434~84606463:-
LUAD	cis	rs1799949	0.93	rs66499067	ENSG00000236383.6	LINC00854	-4.87	1.52e-06	0.000367	-0.18	-0.22	Menopause (age at onset);	chr17:43096467	chr17:43216941~43305976:-
LUAD	cis	rs7493	1	rs12026	ENSG00000233942.1	AC004012.1	4.87	1.52e-06	0.000367	0.32	0.22	Yu-Zhi constitution type in type 2 diabetes;	chr7:95411704	chr7:95471835~95473998:+
LUAD	cis	rs14027	0.883	rs1433953	ENSG00000279347.1	RP11-85I17.2	-4.87	1.52e-06	0.000367	-0.19	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119704754	chr8:119838736~119840385:-
LUAD	cis	rs2562456	0.793	rs279807	ENSG00000268081.1	RP11-678G14.2	4.87	1.52e-06	0.000367	0.35	0.22	Pain;	chr19:21283020	chr19:21554640~21569237:-
LUAD	cis	rs6604026	0.59	rs12749480	ENSG00000223787.2	RP4-593M8.1	4.87	1.52e-06	0.000367	0.3	0.22	Multiple sclerosis;	chr1:92714968	chr1:92580476~92580821:-
LUAD	cis	rs2235642	0.533	rs2076436	ENSG00000280231.1	LA16c-380F5.3	-4.87	1.52e-06	0.000367	-0.33	-0.22	Coronary artery disease;	chr16:1558081	chr16:1553655~1554130:-
LUAD	cis	rs7829975	0.714	rs60315134	ENSG00000253893.2	FAM85B	-4.87	1.52e-06	0.000368	-0.27	-0.22	Mood instability;	chr8:8813089	chr8:8167819~8226614:-
LUAD	cis	rs875971	0.638	rs10249404	ENSG00000224316.1	RP11-479O9.2	-4.87	1.52e-06	0.000368	-0.22	-0.22	Aortic root size;	chr7:66581737	chr7:65773620~65802067:+
LUAD	cis	rs8072100	0.79	rs11079783	ENSG00000228782.6	CTD-2026D20.3	-4.87	1.52e-06	0.000368	-0.23	-0.22	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47608650	chr17:47450568~47492492:-
LUAD	cis	rs12745968	0.589	rs7541942	ENSG00000223787.2	RP4-593M8.1	-4.87	1.52e-06	0.000368	-0.25	-0.22	Bipolar disorder and schizophrenia;	chr1:92555807	chr1:92580476~92580821:-
LUAD	cis	rs5758511	0.679	rs55867855	ENSG00000205702.9	CYP2D7	4.87	1.52e-06	0.000368	0.21	0.22	Birth weight;	chr22:42227252	chr22:42140203~42144577:-
LUAD	cis	rs1707322	1	rs6661500	ENSG00000280836.1	AL355480.1	-4.87	1.52e-06	0.000368	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45999990	chr1:45581219~45581321:-
LUAD	cis	rs34375054	0.66	rs57491100	ENSG00000279233.1	RP11-158L12.4	4.87	1.52e-06	0.000369	0.2	0.22	Post bronchodilator FEV1/FVC ratio;	chr12:125108464	chr12:125138245~125141711:+
LUAD	cis	rs34375054	0.66	rs57031290	ENSG00000279233.1	RP11-158L12.4	4.87	1.52e-06	0.000369	0.2	0.22	Post bronchodilator FEV1/FVC ratio;	chr12:125108507	chr12:125138245~125141711:+
LUAD	cis	rs6687758	0.735	rs12032653	ENSG00000228437.4	RP11-400N13.2	4.87	1.52e-06	0.000369	0.31	0.22	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221975457	chr1:221966341~221984964:+
LUAD	cis	rs6687758	0.679	rs12029332	ENSG00000228437.4	RP11-400N13.2	4.87	1.52e-06	0.000369	0.31	0.22	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221975480	chr1:221966341~221984964:+
LUAD	cis	rs13256369	0.951	rs10503394	ENSG00000253893.2	FAM85B	-4.87	1.53e-06	0.000369	-0.3	-0.22	Obesity-related traits;	chr8:8708265	chr8:8167819~8226614:-
LUAD	cis	rs1062177	0.826	rs2053063	ENSG00000253921.1	CTB-113P19.3	-4.87	1.53e-06	0.000369	-0.32	-0.22	Preschool internalizing problems;	chr5:151787203	chr5:151753992~151767247:+
LUAD	cis	rs8127691	0.967	rs762423	ENSG00000237604.1	AP001056.1	4.87	1.53e-06	0.000369	0.25	0.22	Inflammatory bowel disease;	chr21:44195803	chr21:44175489~44176453:+
LUAD	cis	rs394563	0.625	rs394526	ENSG00000231760.4	RP11-350J20.5	4.87	1.53e-06	0.000369	0.28	0.22	Dupuytren's disease;	chr6:149475839	chr6:149796151~149826294:-
LUAD	cis	rs71520386	0.632	rs12532938	ENSG00000228649.7	AC005682.5	-4.87	1.53e-06	0.000369	-0.3	-0.22	Fibrinogen levels;	chr7:22820876	chr7:22854178~22861579:+
LUAD	cis	rs2898681	1	rs2046364	ENSG00000248375.1	RP11-177B4.1	-4.87	1.53e-06	0.000369	-0.33	-0.22	Optic nerve measurement (cup area);	chr4:52877051	chr4:52720081~52720831:-
LUAD	cis	rs875971	0.638	rs7793569	ENSG00000236529.1	RP13-254B10.1	-4.87	1.53e-06	0.000369	-0.22	-0.22	Aortic root size;	chr7:66651646	chr7:65840212~65840596:+
LUAD	cis	rs2337406	0.852	rs12050239	ENSG00000211972.2	IGHV3-66	4.87	1.53e-06	0.000369	0.23	0.22	Alzheimer's disease (late onset);	chr14:106781132	chr14:106675017~106675544:-
LUAD	cis	rs4835473	0.932	rs1849115	ENSG00000251600.4	RP11-673E1.1	4.87	1.53e-06	0.000369	0.27	0.22	Immature fraction of reticulocytes;	chr4:143989687	chr4:143912331~143982454:+
LUAD	cis	rs2098713	0.599	rs12152831	ENSG00000250155.1	CTD-2353F22.1	4.87	1.53e-06	0.000369	0.22	0.22	Telomere length;	chr5:37555215	chr5:36666214~36725195:-
LUAD	cis	rs1799949	1	rs11653231	ENSG00000236383.6	LINC00854	-4.87	1.53e-06	0.000369	-0.17	-0.22	Menopause (age at onset);	chr17:43179443	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs1399323	ENSG00000236383.6	LINC00854	-4.87	1.53e-06	0.000369	-0.17	-0.22	Menopause (age at onset);	chr17:43180313	chr17:43216941~43305976:-
LUAD	cis	rs1799949	0.93	rs4445938	ENSG00000236383.6	LINC00854	-4.87	1.53e-06	0.000369	-0.17	-0.22	Menopause (age at onset);	chr17:43185883	chr17:43216941~43305976:-
LUAD	cis	rs7763441	0.545	rs9501844	ENSG00000272465.1	RP1-136B1.1	-4.87	1.53e-06	0.000369	-0.26	-0.22	Monobrow;	chr6:2452706	chr6:2437549~2438249:+
LUAD	cis	rs1075232	1	rs56396205	ENSG00000215302.7	CTD-3092A11.1	-4.87	1.53e-06	0.000369	-0.49	-0.22	Survival in colorectal cancer (non-distant metastatic);	chr15:31386182	chr15:30470779~30507623:+
LUAD	cis	rs1075232	1	rs4450360	ENSG00000215302.7	CTD-3092A11.1	-4.87	1.53e-06	0.000369	-0.49	-0.22	Survival in colorectal cancer (non-distant metastatic);	chr15:31389827	chr15:30470779~30507623:+
LUAD	cis	rs1075232	1	rs72722847	ENSG00000215302.7	CTD-3092A11.1	-4.87	1.53e-06	0.000369	-0.49	-0.22	Survival in colorectal cancer (non-distant metastatic);	chr15:31390143	chr15:30470779~30507623:+
LUAD	cis	rs875971	0.862	rs10263690	ENSG00000232559.3	GS1-124K5.12	-4.87	1.53e-06	0.00037	-0.26	-0.22	Aortic root size;	chr7:66301466	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs10250544	ENSG00000232559.3	GS1-124K5.12	-4.87	1.53e-06	0.00037	-0.26	-0.22	Aortic root size;	chr7:66301574	chr7:66554588~66576923:-
LUAD	cis	rs910316	0.967	rs8013444	ENSG00000259138.1	RP11-950C14.7	-4.87	1.53e-06	0.00037	-0.23	-0.22	Height;	chr14:75195278	chr14:75127153~75136930:+
LUAD	cis	rs2274273	0.529	rs7149965	ENSG00000258413.1	RP11-665C16.6	-4.87	1.53e-06	0.00037	-0.28	-0.22	Protein biomarker;	chr14:55041473	chr14:55262767~55272075:-
LUAD	cis	rs2998286	0.862	rs1339704	ENSG00000254635.4	WAC-AS1	-4.87	1.53e-06	0.00037	-0.26	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28527400	chr10:28522652~28532743:-
LUAD	cis	rs673078	0.571	rs7954330	ENSG00000275409.1	RP11-131L12.4	-4.87	1.53e-06	0.00037	-0.3	-0.22	Glucose homeostasis traits;	chr12:118275284	chr12:118430147~118430699:+
LUAD	cis	rs2732480	0.538	rs1387260	ENSG00000257735.1	RP11-370I10.6	4.87	1.53e-06	0.00037	0.27	0.22	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309308	chr12:48350945~48442411:+
LUAD	cis	rs7302981	0.967	rs35549836	ENSG00000272368.2	RP4-605O3.4	4.87	1.54e-06	0.000371	0.25	0.22	Systolic blood pressure;	chr12:50159419	chr12:50112197~50165618:+
LUAD	cis	rs1062177	1	rs2964571	ENSG00000253921.1	CTB-113P19.3	-4.87	1.54e-06	0.000371	-0.33	-0.22	Preschool internalizing problems;	chr5:151791695	chr5:151753992~151767247:+
LUAD	cis	rs1062177	1	rs2915869	ENSG00000253921.1	CTB-113P19.3	-4.87	1.54e-06	0.000371	-0.33	-0.22	Preschool internalizing problems;	chr5:151791948	chr5:151753992~151767247:+
LUAD	cis	rs2243480	0.901	rs313808	ENSG00000164669.11	INTS4P1	4.87	1.54e-06	0.000371	0.39	0.22	Diabetic kidney disease;	chr7:66034886	chr7:65141225~65234216:+
LUAD	cis	rs12681366	0.806	rs72672679	ENSG00000253704.1	RP11-267M23.4	4.87	1.54e-06	0.000372	0.27	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94368956	chr8:94553722~94569745:+
LUAD	cis	rs9341808	0.529	rs2322765	ENSG00000272129.1	RP11-250B2.6	4.87	1.54e-06	0.000372	0.27	0.22	Sitting height ratio;	chr6:80354879	chr6:80355424~80356859:+
LUAD	cis	rs36423	0.748	rs36391	ENSG00000266869.1	RP6-114E22.1	-4.87	1.54e-06	0.000372	-0.33	-0.22	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71898402	chr14:71848606~71908430:+
LUAD	cis	rs1799949	0.93	rs1554063	ENSG00000236383.6	LINC00854	-4.87	1.54e-06	0.000372	-0.17	-0.22	Menopause (age at onset);	chr17:43135128	chr17:43216941~43305976:-
LUAD	cis	rs2304003	1	rs980231	ENSG00000235192.1	AC009495.2	4.87	1.54e-06	0.000372	0.25	0.22	Social communication problems;	chr2:165824612	chr2:165794851~165810010:+
LUAD	cis	rs2898681	1	rs6833096	ENSG00000248375.1	RP11-177B4.1	-4.87	1.54e-06	0.000372	-0.33	-0.22	Optic nerve measurement (cup area);	chr4:52878108	chr4:52720081~52720831:-
LUAD	cis	rs301901	1	rs159753	ENSG00000250155.1	CTD-2353F22.1	-4.87	1.54e-06	0.000373	-0.22	-0.22	Height;	chr5:37007527	chr5:36666214~36725195:-
LUAD	cis	rs301901	1	rs300063	ENSG00000250155.1	CTD-2353F22.1	-4.87	1.54e-06	0.000373	-0.22	-0.22	Height;	chr5:37023796	chr5:36666214~36725195:-
LUAD	cis	rs2295359	0.824	rs11209003	ENSG00000275678.1	RP4-547N15.3	-4.87	1.54e-06	0.000373	-0.23	-0.22	Psoriasis;	chr1:67135449	chr1:67121605~67123956:-
LUAD	cis	rs7829975	0.626	rs332040	ENSG00000253893.2	FAM85B	-4.87	1.54e-06	0.000373	-0.27	-0.22	Mood instability;	chr8:8872978	chr8:8167819~8226614:-
LUAD	cis	rs9322193	0.962	rs3805748	ENSG00000268592.3	RAET1E-AS1	4.87	1.54e-06	0.000373	0.27	0.22	Lung cancer;	chr6:149772542	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.886	rs12525871	ENSG00000268592.3	RAET1E-AS1	4.87	1.54e-06	0.000373	0.27	0.22	Lung cancer;	chr6:149775882	chr6:149863494~149919507:+
LUAD	cis	rs62158211	1	rs4618068	ENSG00000234997.1	AC016745.3	-4.87	1.54e-06	0.000373	-0.28	-0.22	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113351778	chr2:113424495~113425324:+
LUAD	cis	rs4761702	0.857	rs1135400	ENSG00000257252.4	RP11-486A14.2	4.87	1.55e-06	0.000373	0.27	0.22	Immature fraction of reticulocytes;	chr12:93315763	chr12:93317135~93377736:-
LUAD	cis	rs950169	0.579	rs11633088	ENSG00000225151.9	GOLGA2P7	4.87	1.55e-06	0.000373	0.3	0.22	Schizophrenia;	chr15:84003429	chr15:84199311~84230136:-
LUAD	cis	rs7937890	0.874	rs6486191	ENSG00000254418.1	RP11-21L19.1	4.87	1.55e-06	0.000373	0.25	0.22	Mitochondrial DNA levels;	chr11:14382193	chr11:14262846~14273691:-
LUAD	cis	rs61270009	0.955	rs17548339	ENSG00000247828.6	TMEM161B-AS1	4.87	1.55e-06	0.000374	0.25	0.22	Depressive symptoms;	chr5:88391761	chr5:88268895~88436685:+
LUAD	cis	rs61270009	0.955	rs16903122	ENSG00000247828.6	TMEM161B-AS1	4.87	1.55e-06	0.000374	0.25	0.22	Depressive symptoms;	chr5:88397744	chr5:88268895~88436685:+
LUAD	cis	rs17123764	0.71	rs933738	ENSG00000257464.1	RP11-161H23.8	-4.87	1.55e-06	0.000374	-0.27	-0.22	Intelligence (multi-trait analysis);	chr12:49549339	chr12:49442424~49442652:-
LUAD	cis	rs3738443	1	rs61840057	ENSG00000259865.1	RP11-488L18.10	4.87	1.55e-06	0.000374	0.23	0.22	Alcohol dependence;	chr1:247206054	chr1:247187281~247188526:-
LUAD	cis	rs599083	0.829	rs23691	ENSG00000212093.1	AP000807.1	-4.87	1.55e-06	0.000374	-0.23	-0.22	Bone mineral density (spine);	chr11:68411200	chr11:68506083~68506166:-
LUAD	cis	rs599083	0.829	rs314751	ENSG00000212093.1	AP000807.1	-4.87	1.55e-06	0.000374	-0.23	-0.22	Bone mineral density (spine);	chr11:68412092	chr11:68506083~68506166:-
LUAD	cis	rs17508449	0.736	rs76038270	ENSG00000232450.1	RP4-730K3.3	-4.87	1.55e-06	0.000374	-0.37	-0.22	Leprosy;	chr1:113696298	chr1:113698884~113699631:-
LUAD	cis	rs71636778	0.509	rs17356923	ENSG00000260063.1	RP5-968P14.2	-4.87	1.55e-06	0.000375	-0.38	-0.22	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26956185	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs12742376	ENSG00000260063.1	RP5-968P14.2	-4.87	1.55e-06	0.000375	-0.38	-0.22	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26958704	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs34514856	ENSG00000260063.1	RP5-968P14.2	-4.87	1.55e-06	0.000375	-0.38	-0.22	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26961069	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs60340200	ENSG00000260063.1	RP5-968P14.2	-4.87	1.55e-06	0.000375	-0.38	-0.22	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26961225	chr1:26692132~26694131:-
LUAD	cis	rs9549328	0.8	rs9549326	ENSG00000267868.1	RP11-120K24.3	4.87	1.55e-06	0.000375	0.26	0.22	Systolic blood pressure;	chr13:112976139	chr13:112964835~112966131:-
LUAD	cis	rs1707322	1	rs11211243	ENSG00000280836.1	AL355480.1	-4.87	1.55e-06	0.000375	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45989761	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs11211244	ENSG00000280836.1	AL355480.1	-4.87	1.55e-06	0.000375	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991001	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs4660903	ENSG00000280836.1	AL355480.1	-4.87	1.55e-06	0.000375	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991929	chr1:45581219~45581321:-
LUAD	cis	rs950169	0.58	rs35516100	ENSG00000259295.5	CSPG4P12	4.87	1.55e-06	0.000375	0.31	0.22	Schizophrenia;	chr15:84652199	chr15:85191438~85213905:+
LUAD	cis	rs950169	0.58	rs62021208	ENSG00000259295.5	CSPG4P12	4.87	1.55e-06	0.000375	0.31	0.22	Schizophrenia;	chr15:84653013	chr15:85191438~85213905:+
LUAD	cis	rs9322193	0.884	rs62439837	ENSG00000268592.3	RAET1E-AS1	4.87	1.55e-06	0.000375	0.27	0.22	Lung cancer;	chr6:149670380	chr6:149863494~149919507:+
LUAD	cis	rs2243480	1	rs958550	ENSG00000230295.1	RP11-458F8.2	4.87	1.55e-06	0.000375	0.24	0.22	Diabetic kidney disease;	chr7:66170692	chr7:66880708~66882981:+
LUAD	cis	rs6723226	0.732	rs390480	ENSG00000276334.1	AL133243.1	-4.86	1.55e-06	0.000375	-0.24	-0.22	Intelligence (multi-trait analysis);	chr2:32285003	chr2:32521927~32523547:+
LUAD	cis	rs113835537	0.877	rs2229456	ENSG00000255517.5	CTD-3074O7.5	-4.86	1.55e-06	0.000375	-0.3	-0.22	Airway imaging phenotypes;	chr11:66561270	chr11:66473490~66480233:-
LUAD	cis	rs35160687	0.644	rs7595785	ENSG00000273080.1	RP11-301O19.1	-4.86	1.56e-06	0.000375	-0.24	-0.22	Night sleep phenotypes;	chr2:86329282	chr2:86195590~86196049:+
LUAD	cis	rs944990	0.576	rs883782	ENSG00000227603.1	RP11-165J3.6	4.86	1.56e-06	0.000375	0.24	0.22	Body mass index;	chr9:93520003	chr9:93435332~93437121:-
LUAD	cis	rs944990	0.557	rs7035504	ENSG00000227603.1	RP11-165J3.6	4.86	1.56e-06	0.000375	0.24	0.22	Body mass index;	chr9:93528639	chr9:93435332~93437121:-
LUAD	cis	rs8031584	0.697	rs798080	ENSG00000270015.1	RP11-540B6.6	4.86	1.56e-06	0.000375	0.17	0.22	Huntington's disease progression;	chr15:30829966	chr15:30926514~30928407:+
LUAD	cis	rs453301	0.631	rs28572014	ENSG00000253893.2	FAM85B	4.86	1.56e-06	0.000375	0.28	0.22	Joint mobility (Beighton score);	chr8:8936097	chr8:8167819~8226614:-
LUAD	cis	rs2288884	0.943	rs75722407	ENSG00000269959.1	SPACA6P-AS	-4.86	1.56e-06	0.000376	-0.29	-0.22	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52021989	chr19:51685363~51693456:-
LUAD	cis	rs17772222	0.917	rs1998670	ENSG00000258983.2	RP11-507K2.2	4.86	1.56e-06	0.000376	0.27	0.22	Coronary artery calcification;	chr14:88504581	chr14:88499334~88515502:+
LUAD	cis	rs1008375	0.863	rs10003291	ENSG00000249502.1	AC006160.5	-4.86	1.56e-06	0.000376	-0.22	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17599105	chr4:17587467~17614571:-
LUAD	cis	rs4803480	0.63	rs16975338	ENSG00000270164.1	LINC01480	4.86	1.56e-06	0.000376	0.32	0.22	Schizophrenia;	chr19:41551655	chr19:41535183~41536904:+
LUAD	cis	rs1008375	1	rs6846238	ENSG00000249502.1	AC006160.5	-4.86	1.56e-06	0.000376	-0.21	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17628316	chr4:17587467~17614571:-
LUAD	cis	rs2286503	1	rs2286498	ENSG00000221740.1	SNORD93	-4.86	1.56e-06	0.000377	-0.24	-0.22	Fibrinogen;	chr7:22817885	chr7:22856613~22856686:+
LUAD	cis	rs561341	1	rs508192	ENSG00000265798.5	RP11-271K11.5	-4.86	1.56e-06	0.000377	-0.34	-0.22	Hip circumference adjusted for BMI;	chr17:31988128	chr17:31038575~31059121:-
LUAD	cis	rs338389	0.586	rs338387	ENSG00000260657.2	RP11-315D16.4	4.86	1.56e-06	0.000377	0.26	0.22	Survival in rectal cancer;	chr15:67968644	chr15:68267792~68277994:-
LUAD	cis	rs301901	0.698	rs217838	ENSG00000250155.1	CTD-2353F22.1	4.86	1.56e-06	0.000377	0.23	0.22	Height;	chr5:37376194	chr5:36666214~36725195:-
LUAD	cis	rs7200786	0.692	rs1700818	ENSG00000274038.1	RP11-66H6.4	-4.86	1.56e-06	0.000377	-0.26	-0.22	Systemic lupus erythematosus;Multiple sclerosis;	chr16:10963412	chr16:11056556~11057034:+
LUAD	cis	rs61270009	0.955	rs415449	ENSG00000247828.6	TMEM161B-AS1	-4.86	1.56e-06	0.000377	-0.24	-0.22	Depressive symptoms;	chr5:88231533	chr5:88268895~88436685:+
LUAD	cis	rs7829975	0.774	rs35431455	ENSG00000253893.2	FAM85B	-4.86	1.57e-06	0.000378	-0.27	-0.22	Mood instability;	chr8:8816226	chr8:8167819~8226614:-
LUAD	cis	rs831571	1	rs166230	ENSG00000280620.1	SCAANT1	-4.86	1.57e-06	0.000378	-0.3	-0.22	Type 2 diabetes;	chr3:64067531	chr3:63911518~63911772:-
LUAD	cis	rs1426063	1	rs1426063	ENSG00000249717.1	RP11-44F21.3	-4.86	1.57e-06	0.000378	-0.31	-0.22	QT interval;	chr4:75105711	chr4:74955974~74970362:-
LUAD	cis	rs1707322	0.963	rs1768815	ENSG00000280836.1	AL355480.1	4.86	1.57e-06	0.000378	0.28	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062931	chr1:45581219~45581321:-
LUAD	cis	rs10895987	0.955	rs11227136	ENSG00000254614.2	AP003068.23	4.86	1.57e-06	0.000378	0.35	0.22	Blood protein levels;	chr11:65164493	chr11:65177606~65181834:-
LUAD	cis	rs2492286	0.597	rs6802078	ENSG00000242551.2	POU5F1P6	-4.86	1.57e-06	0.000378	-0.29	-0.22	Eosinophil counts;	chr3:128639910	chr3:128674735~128677005:-
LUAD	cis	rs875971	0.522	rs9530	ENSG00000224316.1	RP11-479O9.2	4.86	1.57e-06	0.000378	0.22	0.22	Aortic root size;	chr7:65960907	chr7:65773620~65802067:+
LUAD	cis	rs12745968	0.589	rs7540564	ENSG00000223787.2	RP4-593M8.1	-4.86	1.57e-06	0.000378	-0.26	-0.22	Bipolar disorder and schizophrenia;	chr1:92492269	chr1:92580476~92580821:-
LUAD	cis	rs7119	0.651	rs12917044	ENSG00000259362.2	RP11-307C19.1	4.86	1.57e-06	0.000378	0.26	0.22	Type 2 diabetes;	chr15:77557804	chr15:77525540~77534110:+
LUAD	cis	rs2404602	1	rs12898430	ENSG00000259422.1	RP11-593F23.1	4.86	1.57e-06	0.000378	0.26	0.22	Blood metabolite levels;	chr15:76582582	chr15:76174891~76181486:-
LUAD	cis	rs2286503	0.752	rs59538378	ENSG00000226329.2	AC005682.6	4.86	1.57e-06	0.000379	0.29	0.22	Fibrinogen;	chr7:22837478	chr7:22863874~22881350:-
LUAD	cis	rs7829975	0.755	rs3789849	ENSG00000253981.4	ALG1L13P	4.86	1.57e-06	0.000379	0.25	0.22	Mood instability;	chr8:8829544	chr8:8236003~8244667:-
LUAD	cis	rs42490	1	rs218913	ENSG00000251136.7	RP11-37B2.1	-4.86	1.57e-06	0.000379	-0.22	-0.22	Leprosy;	chr8:89732206	chr8:89609409~89757727:-
LUAD	cis	rs35160687	0.644	rs1863058	ENSG00000273080.1	RP11-301O19.1	-4.86	1.57e-06	0.000379	-0.24	-0.22	Night sleep phenotypes;	chr2:86282144	chr2:86195590~86196049:+
LUAD	cis	rs1799949	1	rs8176318	ENSG00000236383.6	LINC00854	-4.86	1.57e-06	0.000379	-0.17	-0.22	Menopause (age at onset);	chr17:43045257	chr17:43216941~43305976:-
LUAD	cis	rs561341	1	rs501312	ENSG00000265798.5	RP11-271K11.5	4.86	1.57e-06	0.000379	0.35	0.22	Hip circumference adjusted for BMI;	chr17:32002047	chr17:31038575~31059121:-
LUAD	cis	rs875971	0.895	rs12531677	ENSG00000232559.3	GS1-124K5.12	-4.86	1.57e-06	0.00038	-0.26	-0.22	Aortic root size;	chr7:66304099	chr7:66554588~66576923:-
LUAD	cis	rs2439831	0.867	rs6493085	ENSG00000249839.1	AC011330.5	-4.86	1.57e-06	0.00038	-0.39	-0.22	Lung cancer in ever smokers;	chr15:43361984	chr15:43663654~43684339:-
LUAD	cis	rs2439831	0.867	rs2412778	ENSG00000249839.1	AC011330.5	-4.86	1.57e-06	0.00038	-0.39	-0.22	Lung cancer in ever smokers;	chr15:43368784	chr15:43663654~43684339:-
LUAD	cis	rs875971	0.862	rs7798630	ENSG00000232559.3	GS1-124K5.12	-4.86	1.57e-06	0.00038	-0.26	-0.22	Aortic root size;	chr7:66306492	chr7:66554588~66576923:-
LUAD	cis	rs17772222	0.876	rs61986665	ENSG00000258789.1	RP11-507K2.3	-4.86	1.57e-06	0.00038	-0.29	-0.22	Coronary artery calcification;	chr14:88711354	chr14:88551597~88552493:+
LUAD	cis	rs7017914	0.69	rs10090471	ENSG00000223220.1	Y_RNA	4.86	1.58e-06	0.00038	0.25	0.22	Bone mineral density;	chr8:70885034	chr8:70780914~70781008:-
LUAD	cis	rs6604026	0.661	rs72724555	ENSG00000223787.2	RP4-593M8.1	4.86	1.58e-06	0.00038	0.3	0.22	Multiple sclerosis;	chr1:92645318	chr1:92580476~92580821:-
LUAD	cis	rs10246939	0.505	rs10952508	ENSG00000270923.1	TAS2R6P	-4.86	1.58e-06	0.00038	-0.26	-0.22	Bitter taste perception;	chr7:141879415	chr7:141787815~141788640:+
LUAD	cis	rs1799949	1	rs1973646	ENSG00000236383.6	LINC00854	-4.86	1.58e-06	0.00038	-0.18	-0.22	Menopause (age at onset);	chr17:43158478	chr17:43216941~43305976:-
LUAD	cis	rs7208859	0.623	rs7220999	ENSG00000280069.1	CTD-2349P21.3	-4.86	1.58e-06	0.00038	-0.3	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822280	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs55638872	ENSG00000280069.1	CTD-2349P21.3	-4.86	1.58e-06	0.00038	-0.3	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822534	chr17:30738182~30740275:+
LUAD	cis	rs10050311	0.698	rs17454154	ENSG00000251411.1	RP11-397E7.4	-4.86	1.58e-06	0.00038	-0.3	-0.22	Insulin-related traits;	chr4:86715007	chr4:86913266~86914817:-
LUAD	cis	rs10050311	0.698	rs78818211	ENSG00000251411.1	RP11-397E7.4	-4.86	1.58e-06	0.00038	-0.3	-0.22	Insulin-related traits;	chr4:86715235	chr4:86913266~86914817:-
LUAD	cis	rs375066	0.935	rs371875	ENSG00000267058.1	RP11-15A1.3	-4.86	1.58e-06	0.00038	-0.24	-0.22	Breast cancer;	chr19:43889105	chr19:43891804~43901805:-
LUAD	cis	rs507080	0.961	rs34413584	ENSG00000278376.1	RP11-158I9.8	-4.86	1.58e-06	0.000381	-0.23	-0.22	Serum metabolite levels;	chr11:118675072	chr11:118791254~118793137:+
LUAD	cis	rs2239547	0.522	rs6768844	ENSG00000242142.1	SERBP1P3	-4.86	1.58e-06	0.000381	-0.25	-0.22	Schizophrenia;	chr3:52970604	chr3:53064283~53065091:-
LUAD	cis	rs4964805	0.913	rs36034617	ENSG00000257681.1	RP11-341G23.4	4.86	1.58e-06	0.000381	0.26	0.22	Attention deficit hyperactivity disorder;	chr12:103809837	chr12:103746315~103768858:-
LUAD	cis	rs72634501	0.517	rs6684217	ENSG00000228060.1	RP11-69E11.8	4.86	1.58e-06	0.000381	0.2	0.22	HDL cholesterol;	chr1:39121606	chr1:39565160~39573203:+
LUAD	cis	rs2115630	0.936	rs11073663	ENSG00000229212.6	RP11-561C5.4	4.86	1.58e-06	0.000381	0.25	0.22	P wave terminal force;	chr15:84717037	chr15:85205440~85234795:-
LUAD	cis	rs10246939	0.505	rs6967189	ENSG00000270923.1	TAS2R6P	-4.86	1.58e-06	0.000381	-0.25	-0.22	Bitter taste perception;	chr7:141826220	chr7:141787815~141788640:+
LUAD	cis	rs7826238	0.539	rs2945891	ENSG00000173295.6	FAM86B3P	4.86	1.58e-06	0.000381	0.23	0.22	Systolic blood pressure;	chr8:8297953	chr8:8228595~8244865:+
LUAD	cis	rs2439831	0.867	rs6493082	ENSG00000249839.1	AC011330.5	-4.86	1.58e-06	0.000381	-0.39	-0.22	Lung cancer in ever smokers;	chr15:43342610	chr15:43663654~43684339:-
LUAD	cis	rs2439831	0.867	rs8041132	ENSG00000249839.1	AC011330.5	-4.86	1.58e-06	0.000381	-0.39	-0.22	Lung cancer in ever smokers;	chr15:43342938	chr15:43663654~43684339:-
LUAD	cis	rs2439831	0.867	rs16957627	ENSG00000249839.1	AC011330.5	-4.86	1.58e-06	0.000381	-0.39	-0.22	Lung cancer in ever smokers;	chr15:43350459	chr15:43663654~43684339:-
LUAD	cis	rs2439831	0.717	rs7165471	ENSG00000249839.1	AC011330.5	-4.86	1.58e-06	0.000381	-0.39	-0.22	Lung cancer in ever smokers;	chr15:43352590	chr15:43663654~43684339:-
LUAD	cis	rs9487094	0.744	rs13199519	ENSG00000260273.1	RP11-425D10.10	4.86	1.58e-06	0.000382	0.31	0.22	Height;	chr6:109387972	chr6:109382795~109383666:+
LUAD	cis	rs71520386	0.634	rs13240023	ENSG00000228649.7	AC005682.5	-4.86	1.58e-06	0.000382	-0.3	-0.22	Fibrinogen levels;	chr7:22827874	chr7:22854178~22861579:+
LUAD	cis	rs13256369	0.756	rs13282580	ENSG00000253893.2	FAM85B	-4.86	1.58e-06	0.000382	-0.3	-0.22	Obesity-related traits;	chr8:8705393	chr8:8167819~8226614:-
LUAD	cis	rs13256369	0.802	rs13256404	ENSG00000253893.2	FAM85B	-4.86	1.58e-06	0.000382	-0.3	-0.22	Obesity-related traits;	chr8:8705464	chr8:8167819~8226614:-
LUAD	cis	rs13256369	0.756	rs13280759	ENSG00000253893.2	FAM85B	-4.86	1.58e-06	0.000382	-0.3	-0.22	Obesity-related traits;	chr8:8705485	chr8:8167819~8226614:-
LUAD	cis	rs507080	0.922	rs592280	ENSG00000278376.1	RP11-158I9.8	-4.86	1.59e-06	0.000382	-0.23	-0.22	Serum metabolite levels;	chr11:118682509	chr11:118791254~118793137:+
LUAD	cis	rs13256369	0.851	rs13254997	ENSG00000253893.2	FAM85B	-4.86	1.59e-06	0.000382	-0.3	-0.22	Obesity-related traits;	chr8:8706243	chr8:8167819~8226614:-
LUAD	cis	rs2735413	0.522	rs2075737	ENSG00000276007.1	RP11-358L22.3	4.86	1.59e-06	0.000382	0.29	0.22	Systolic blood pressure (alcohol consumption interaction);	chr16:78023077	chr16:78123243~78124332:+
LUAD	cis	rs867371	1	rs867370	ENSG00000276710.3	CSPG4P8	4.86	1.59e-06	0.000382	0.21	0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82145921	chr15:82459472~82477258:+
LUAD	cis	rs867371	1	rs867371	ENSG00000276710.3	CSPG4P8	4.86	1.59e-06	0.000382	0.21	0.22	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82146005	chr15:82459472~82477258:+
LUAD	cis	rs6840258	0.941	rs7665282	ENSG00000251411.1	RP11-397E7.4	-4.86	1.59e-06	0.000382	-0.28	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86979698	chr4:86913266~86914817:-
LUAD	cis	rs301901	1	rs158623	ENSG00000250155.1	CTD-2353F22.1	-4.86	1.59e-06	0.000382	-0.22	-0.22	Height;	chr5:36882917	chr5:36666214~36725195:-
LUAD	cis	rs2562456	0.833	rs62110071	ENSG00000268081.1	RP11-678G14.2	4.86	1.59e-06	0.000382	0.35	0.22	Pain;	chr19:21288101	chr19:21554640~21569237:-
LUAD	cis	rs13256369	0.851	rs13256611	ENSG00000253893.2	FAM85B	-4.86	1.59e-06	0.000383	-0.3	-0.22	Obesity-related traits;	chr8:8706831	chr8:8167819~8226614:-
LUAD	cis	rs13256369	0.802	rs11249888	ENSG00000253893.2	FAM85B	-4.86	1.59e-06	0.000383	-0.3	-0.22	Obesity-related traits;	chr8:8707424	chr8:8167819~8226614:-
LUAD	cis	rs13256369	0.851	rs11249889	ENSG00000253893.2	FAM85B	-4.86	1.59e-06	0.000383	-0.3	-0.22	Obesity-related traits;	chr8:8707482	chr8:8167819~8226614:-
LUAD	cis	rs599083	0.793	rs314750	ENSG00000212093.1	AP000807.1	-4.86	1.59e-06	0.000383	-0.23	-0.22	Bone mineral density (spine);	chr11:68414560	chr11:68506083~68506166:-
LUAD	cis	rs1707322	0.928	rs6681068	ENSG00000280836.1	AL355480.1	-4.86	1.59e-06	0.000383	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45932710	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs11211228	ENSG00000280836.1	AL355480.1	-4.86	1.59e-06	0.000383	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934168	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.963	rs11211229	ENSG00000280836.1	AL355480.1	-4.86	1.59e-06	0.000383	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934845	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs9803784	ENSG00000280836.1	AL355480.1	-4.86	1.59e-06	0.000383	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45936235	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.963	rs12022335	ENSG00000280836.1	AL355480.1	-4.86	1.59e-06	0.000383	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45937060	chr1:45581219~45581321:-
LUAD	cis	rs801193	0.569	rs2707824	ENSG00000232559.3	GS1-124K5.12	4.86	1.59e-06	0.000383	0.26	0.22	Aortic root size;	chr7:66724256	chr7:66554588~66576923:-
LUAD	cis	rs7829975	0.711	rs4841051	ENSG00000253893.2	FAM85B	4.86	1.59e-06	0.000383	0.26	0.22	Mood instability;	chr8:8828136	chr8:8167819~8226614:-
LUAD	cis	rs7017914	0.616	rs11987260	ENSG00000223220.1	Y_RNA	4.86	1.59e-06	0.000383	0.25	0.22	Bone mineral density;	chr8:70861647	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs11994581	ENSG00000223220.1	Y_RNA	4.86	1.59e-06	0.000383	0.25	0.22	Bone mineral density;	chr8:70862172	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs34301443	ENSG00000223220.1	Y_RNA	4.86	1.59e-06	0.000383	0.25	0.22	Bone mineral density;	chr8:70863161	chr8:70780914~70781008:-
LUAD	cis	rs507080	0.845	rs667982	ENSG00000278376.1	RP11-158I9.8	-4.86	1.59e-06	0.000384	-0.23	-0.22	Serum metabolite levels;	chr11:118692058	chr11:118791254~118793137:+
LUAD	cis	rs8180040	0.587	rs1466741	ENSG00000271161.1	BOLA2P2	-4.86	1.59e-06	0.000384	-0.21	-0.22	Colorectal cancer;	chr3:47205724	chr3:47499841~47500407:+
LUAD	cis	rs599083	0.744	rs603129	ENSG00000212093.1	AP000807.1	-4.86	1.59e-06	0.000384	-0.24	-0.22	Bone mineral density (spine);	chr11:68419201	chr11:68506083~68506166:-
LUAD	cis	rs42490	0.966	rs2644033	ENSG00000251136.7	RP11-37B2.1	4.86	1.6e-06	0.000384	0.22	0.22	Leprosy;	chr8:89739196	chr8:89609409~89757727:-
LUAD	cis	rs42490	0.966	rs218914	ENSG00000251136.7	RP11-37B2.1	-4.86	1.6e-06	0.000384	-0.22	-0.22	Leprosy;	chr8:89733130	chr8:89609409~89757727:-
LUAD	cis	rs10129255	1	rs10134517	ENSG00000274576.2	IGHV2-70	4.86	1.6e-06	0.000384	0.19	0.22	Kawasaki disease;	chr14:106718498	chr14:106770577~106771020:-
LUAD	cis	rs910316	1	rs8017642	ENSG00000279594.1	RP11-950C14.10	4.86	1.6e-06	0.000384	0.25	0.22	Height;	chr14:75124119	chr14:75011269~75012851:-
LUAD	cis	rs7574070	0.567	rs4853546	ENSG00000280083.1	RP11-317J9.1	-4.86	1.6e-06	0.000384	-0.28	-0.22	Behcet's disease;	chr2:191144926	chr2:191154118~191156070:-
LUAD	cis	rs11051970	0.559	rs11536026	ENSG00000274964.1	RP11-817I4.1	-4.86	1.6e-06	0.000384	-0.3	-0.22	Response to tocilizumab in rheumatoid arthritis;	chr12:32316593	chr12:32339368~32340724:+
LUAD	cis	rs2286503	1	rs2286501	ENSG00000226329.2	AC005682.6	4.86	1.6e-06	0.000384	0.27	0.22	Fibrinogen;	chr7:22817166	chr7:22863874~22881350:-
LUAD	cis	rs875971	0.965	rs697968	ENSG00000232559.3	GS1-124K5.12	-4.86	1.6e-06	0.000384	-0.26	-0.22	Aortic root size;	chr7:66070046	chr7:66554588~66576923:-
LUAD	cis	rs7849270	0.801	rs10819474	ENSG00000268707.1	RP11-247A12.7	-4.86	1.6e-06	0.000385	-0.26	-0.22	Blood metabolite ratios;	chr9:129168215	chr9:129170434~129170940:+
LUAD	cis	rs7324557	0.684	rs58663560	ENSG00000205861.10	C1QTNF9B-AS1	-4.86	1.6e-06	0.000385	-0.29	-0.22	Visceral adipose tissue adjusted for BMI;	chr13:23830800	chr13:23888889~23897263:+
LUAD	cis	rs30380	1	rs151964	ENSG00000248734.2	CTD-2260A17.1	4.86	1.6e-06	0.000385	0.22	0.22	Cerebrospinal fluid biomarker levels;	chr5:96787963	chr5:96784777~96785999:+
LUAD	cis	rs2439831	0.681	rs1549525	ENSG00000249839.1	AC011330.5	-4.86	1.6e-06	0.000385	-0.38	-0.22	Lung cancer in ever smokers;	chr15:43335657	chr15:43663654~43684339:-
LUAD	cis	rs2439831	0.681	rs7175434	ENSG00000249839.1	AC011330.5	-4.86	1.6e-06	0.000385	-0.38	-0.22	Lung cancer in ever smokers;	chr15:43336344	chr15:43663654~43684339:-
LUAD	cis	rs12468226	1	rs76021735	ENSG00000272966.1	RP11-686O6.1	4.86	1.6e-06	0.000385	0.36	0.22	Urate levels;	chr2:202511476	chr2:202336739~202337200:+
LUAD	cis	rs2239557	1	rs7157566	ENSG00000259065.1	RP5-1021I20.1	4.86	1.6e-06	0.000385	0.25	0.22	Common traits (Other);	chr14:74182426	chr14:73787360~73803270:+
LUAD	cis	rs1729951	0.514	rs75977	ENSG00000239213.4	NCK1-AS1	4.86	1.6e-06	0.000385	0.24	0.22	Neuroticism;	chr3:136981707	chr3:136841726~136862054:-
LUAD	cis	rs17301013	0.861	rs10218528	ENSG00000227373.4	RP11-160H22.5	4.86	1.6e-06	0.000385	0.27	0.22	Systemic lupus erythematosus;	chr1:174478450	chr1:174115300~174160004:-
LUAD	cis	rs1799949	1	rs8074136	ENSG00000236383.6	LINC00854	-4.86	1.6e-06	0.000385	-0.17	-0.22	Menopause (age at onset);	chr17:43190296	chr17:43216941~43305976:-
LUAD	cis	rs6723226	0.572	rs176411	ENSG00000276334.1	AL133243.1	4.86	1.6e-06	0.000385	0.24	0.22	Intelligence (multi-trait analysis);	chr2:32418460	chr2:32521927~32523547:+
LUAD	cis	rs9322193	0.923	rs12195866	ENSG00000268592.3	RAET1E-AS1	4.86	1.6e-06	0.000385	0.27	0.22	Lung cancer;	chr6:149693334	chr6:149863494~149919507:+
LUAD	cis	rs193541	0.593	rs1035372	ENSG00000263432.2	RN7SL689P	4.86	1.6e-06	0.000385	0.29	0.22	Glucose homeostasis traits;	chr5:122833753	chr5:123022487~123022783:-
LUAD	cis	rs17826219	0.636	rs7221463	ENSG00000263603.1	CTD-2349P21.5	-4.86	1.6e-06	0.000385	-0.38	-0.22	Body mass index;	chr17:30753533	chr17:30729469~30731202:+
LUAD	cis	rs6558530	0.587	rs6986102	ENSG00000253982.1	CTD-2336O2.1	4.86	1.6e-06	0.000386	0.28	0.22	Systolic blood pressure;	chr8:1752474	chr8:1761990~1764502:-
LUAD	cis	rs2098713	0.586	rs61435914	ENSG00000250155.1	CTD-2353F22.1	4.86	1.6e-06	0.000386	0.23	0.22	Telomere length;	chr5:37607239	chr5:36666214~36725195:-
LUAD	cis	rs3002131	0.562	rs2173401	ENSG00000225265.1	TAF1A-AS1	-4.86	1.61e-06	0.000386	-0.35	-0.22	Interleukin-10 levels;	chr1:222575992	chr1:222589825~222593032:+
LUAD	cis	rs6700559	0.565	rs2809341	ENSG00000260088.1	RP11-92G12.3	-4.86	1.61e-06	0.000387	-0.27	-0.22	Coronary artery disease;	chr1:200628560	chr1:200669507~200694250:+
LUAD	cis	rs875971	0.658	rs432667	ENSG00000232559.3	GS1-124K5.12	4.86	1.61e-06	0.000387	0.25	0.22	Aortic root size;	chr7:66049646	chr7:66554588~66576923:-
LUAD	cis	rs2742234	0.59	rs2435377	ENSG00000273008.1	RP11-351D16.3	4.86	1.61e-06	0.000387	0.25	0.22	Hirschsprung disease;	chr10:43188152	chr10:43136824~43138334:-
LUAD	cis	rs10129255	1	rs10129255	ENSG00000274576.2	IGHV2-70	-4.86	1.61e-06	0.000388	-0.19	-0.22	Kawasaki disease;	chr14:106767970	chr14:106770577~106771020:-
LUAD	cis	rs375066	0.736	rs62114649	ENSG00000267058.1	RP11-15A1.3	4.86	1.61e-06	0.000388	0.24	0.22	Breast cancer;	chr19:43912415	chr19:43891804~43901805:-
LUAD	cis	rs442309	0.687	rs7084016	ENSG00000238280.1	RP11-436D10.3	-4.86	1.61e-06	0.000388	-0.27	-0.22	Vogt-Koyanagi-Harada syndrome;	chr10:62720681	chr10:62793562~62805887:-
LUAD	cis	rs9467773	0.804	rs2073526	ENSG00000124549.13	BTN2A3P	-4.86	1.61e-06	0.000388	-0.2	-0.22	Intelligence (multi-trait analysis);	chr6:26374430	chr6:26421391~26432383:+
LUAD	cis	rs1816752	0.819	rs6490917	ENSG00000273628.1	RP11-756A22.7	4.86	1.61e-06	0.000388	0.25	0.22	Obesity-related traits;	chr13:24423119	chr13:24933006~24936796:+
LUAD	cis	rs375066	0.762	rs12610287	ENSG00000267058.1	RP11-15A1.3	4.86	1.61e-06	0.000388	0.24	0.22	Breast cancer;	chr19:43896511	chr19:43891804~43901805:-
LUAD	cis	rs375066	0.762	rs1073654	ENSG00000267058.1	RP11-15A1.3	4.86	1.61e-06	0.000388	0.24	0.22	Breast cancer;	chr19:43907268	chr19:43891804~43901805:-
LUAD	cis	rs375066	0.762	rs1073653	ENSG00000267058.1	RP11-15A1.3	4.86	1.61e-06	0.000388	0.24	0.22	Breast cancer;	chr19:43907391	chr19:43891804~43901805:-
LUAD	cis	rs14027	0.921	rs6469852	ENSG00000279347.1	RP11-85I17.2	4.86	1.61e-06	0.000388	0.19	0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119848495	chr8:119838736~119840385:-
LUAD	cis	rs193541	0.632	rs2407402	ENSG00000263432.2	RN7SL689P	4.86	1.61e-06	0.000388	0.29	0.22	Glucose homeostasis traits;	chr5:122771410	chr5:123022487~123022783:-
LUAD	cis	rs45509595	0.841	rs200501	ENSG00000219392.1	RP1-265C24.5	-4.86	1.61e-06	0.000388	-0.41	-0.22	Breast cancer;	chr6:27821164	chr6:28115628~28116551:+
LUAD	cis	rs2836950	0.545	rs2836959	ENSG00000255568.3	BRWD1-AS2	-4.86	1.61e-06	0.000388	-0.21	-0.22	Menarche (age at onset);	chr21:39251742	chr21:39313935~39314962:+
LUAD	cis	rs73198271	0.751	rs617813	ENSG00000253893.2	FAM85B	4.86	1.61e-06	0.000388	0.27	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8778378	chr8:8167819~8226614:-
LUAD	cis	rs2153535	0.935	rs11243254	ENSG00000230939.1	RP11-314C16.1	4.86	1.62e-06	0.000388	0.24	0.22	Motion sickness;	chr6:8381009	chr6:8784178~8785445:+
LUAD	cis	rs1799949	0.929	rs799906	ENSG00000236383.6	LINC00854	-4.86	1.62e-06	0.000389	-0.17	-0.22	Menopause (age at onset);	chr17:43126099	chr17:43216941~43305976:-
LUAD	cis	rs1799949	0.965	rs799908	ENSG00000236383.6	LINC00854	-4.86	1.62e-06	0.000389	-0.17	-0.22	Menopause (age at onset);	chr17:43126899	chr17:43216941~43305976:-
LUAD	cis	rs643506	0.874	rs634983	ENSG00000230911.1	PPIHP1	-4.86	1.62e-06	0.000389	-0.27	-0.22	Breast cancer;	chr11:111876703	chr11:112029858~112030367:-
LUAD	cis	rs4683346	1	rs12635458	ENSG00000173811.9	CCDC13-AS1	-4.86	1.62e-06	0.000389	-0.24	-0.22	Granulocyte percentage of myeloid white cells;	chr3:42850124	chr3:42732575~42746768:+
LUAD	cis	rs875971	0.862	rs11984115	ENSG00000232559.3	GS1-124K5.12	-4.86	1.62e-06	0.000389	-0.26	-0.22	Aortic root size;	chr7:66308872	chr7:66554588~66576923:-
LUAD	cis	rs7819412	0.594	rs17724226	ENSG00000255046.1	RP11-297N6.4	4.86	1.62e-06	0.000389	0.27	0.22	Triglycerides;	chr8:11111416	chr8:11797928~11802568:-
LUAD	cis	rs42490	0.903	rs393891	ENSG00000251136.7	RP11-37B2.1	-4.86	1.62e-06	0.000389	-0.22	-0.22	Leprosy;	chr8:89701556	chr8:89609409~89757727:-
LUAD	cis	rs4819052	1	rs3746980	ENSG00000215447.6	BX322557.10	-4.86	1.62e-06	0.000389	-0.28	-0.22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291665	chr21:45288052~45291738:+
LUAD	cis	rs7763441	0.506	rs9405168	ENSG00000272465.1	RP1-136B1.1	-4.86	1.62e-06	0.000389	-0.26	-0.22	Monobrow;	chr6:2453561	chr6:2437549~2438249:+
LUAD	cis	rs57502260	0.704	rs72936570	ENSG00000212093.1	AP000807.1	4.86	1.62e-06	0.000389	0.3	0.22	Total body bone mineral density (age 45-60);	chr11:68539671	chr11:68506083~68506166:-
LUAD	cis	rs950169	0.723	rs17589320	ENSG00000229212.6	RP11-561C5.4	-4.86	1.62e-06	0.000389	-0.31	-0.22	Schizophrenia;	chr15:84251244	chr15:85205440~85234795:-
LUAD	cis	rs950169	0.845	rs4502182	ENSG00000229212.6	RP11-561C5.4	-4.86	1.62e-06	0.000389	-0.31	-0.22	Schizophrenia;	chr15:84254768	chr15:85205440~85234795:-
LUAD	cis	rs2378497	1	rs12137305	ENSG00000232679.1	RP11-400N13.3	4.86	1.62e-06	0.000389	0.31	0.22	Serum thyroid-stimulating hormone levels;	chr1:222047359	chr1:222041705~222064763:-
LUAD	cis	rs17711722	0.565	rs4275112	ENSG00000226002.1	RP11-460N20.5	-4.86	1.62e-06	0.000389	-0.24	-0.22	Calcium levels;	chr7:65733651	chr7:65084103~65100232:+
LUAD	cis	rs7811142	0.83	rs73401450	ENSG00000078319.8	PMS2P1	-4.86	1.62e-06	0.00039	-0.26	-0.22	Platelet count;	chr7:100384236	chr7:100320992~100341908:-
LUAD	cis	rs2348418	0.703	rs10843122	ENSG00000247934.4	RP11-967K21.1	-4.86	1.62e-06	0.00039	-0.25	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28174153	chr12:28163298~28190738:-
LUAD	cis	rs7727544	0.606	rs17622208	ENSG00000233006.5	AC034220.3	4.86	1.62e-06	0.00039	0.2	0.22	Blood metabolite levels;	chr5:132381358	chr5:132311285~132369916:-
LUAD	cis	rs4568518	0.53	rs10269921	ENSG00000279048.1	RP11-511H23.2	4.86	1.62e-06	0.00039	0.18	0.22	Measles;	chr7:17958317	chr7:17940503~17942922:+
LUAD	cis	rs12745968	0.62	rs6666831	ENSG00000223787.2	RP4-593M8.1	-4.86	1.62e-06	0.00039	-0.26	-0.22	Bipolar disorder and schizophrenia;	chr1:92757240	chr1:92580476~92580821:-
LUAD	cis	rs1012068	0.92	rs5994443	ENSG00000236132.1	CTA-440B3.1	-4.86	1.63e-06	0.00039	-0.28	-0.22	Chronic hepatitis C infection;	chr22:31879367	chr22:31816379~31817491:-
LUAD	cis	rs7772486	0.727	rs4896843	ENSG00000235652.6	RP11-545I5.3	-4.86	1.63e-06	0.000391	-0.22	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145742315	chr6:145799409~145886585:+
LUAD	cis	rs853679	1	rs1778511	ENSG00000204709.4	LINC01556	-4.86	1.63e-06	0.000391	-0.33	-0.22	Depression;	chr6:28261633	chr6:28943877~28944537:+
LUAD	cis	rs12022452	0.822	rs11208390	ENSG00000238287.1	RP11-656D10.3	-4.86	1.63e-06	0.000391	-0.34	-0.22	Age-related hearing impairment (SNP x SNP interaction);	chr1:40556342	chr1:40493157~40508661:-
LUAD	cis	rs4865762	0.617	rs153119	ENSG00000247796.2	CTD-2366F13.1	-4.86	1.63e-06	0.000392	-0.22	-0.22	Intraocular pressure;	chr5:53232385	chr5:53109842~53115126:+
LUAD	cis	rs7637701	0.818	rs4680305	ENSG00000240875.4	LINC00886	-4.85	1.63e-06	0.000392	-0.23	-0.22	Breast cancer;	chr3:156815614	chr3:156747346~156817062:-
LUAD	cis	rs559928	0.606	rs7941773	ENSG00000236935.1	AP003774.1	4.85	1.63e-06	0.000392	0.31	0.22	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64185287	chr11:64325050~64329504:-
LUAD	cis	rs559928	0.606	rs57021319	ENSG00000236935.1	AP003774.1	4.85	1.63e-06	0.000392	0.31	0.22	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64188630	chr11:64325050~64329504:-
LUAD	cis	rs559928	0.606	rs55970968	ENSG00000236935.1	AP003774.1	4.85	1.63e-06	0.000392	0.31	0.22	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64193961	chr11:64325050~64329504:-
LUAD	cis	rs2239547	0.522	rs9842974	ENSG00000242142.1	SERBP1P3	4.85	1.63e-06	0.000392	0.25	0.22	Schizophrenia;	chr3:52977034	chr3:53064283~53065091:-
LUAD	cis	rs12745968	0.589	rs912796	ENSG00000223787.2	RP4-593M8.1	-4.85	1.63e-06	0.000392	-0.26	-0.22	Bipolar disorder and schizophrenia;	chr1:92495853	chr1:92580476~92580821:-
LUAD	cis	rs2688608	0.62	rs11000767	ENSG00000271816.1	BMS1P4	4.85	1.63e-06	0.000392	0.18	0.22	Inflammatory bowel disease;	chr10:73756868	chr10:73699151~73730487:-
LUAD	cis	rs1008375	1	rs1974624	ENSG00000249502.1	AC006160.5	-4.85	1.63e-06	0.000392	-0.2	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17648658	chr4:17587467~17614571:-
LUAD	cis	rs1008375	0.902	rs6844984	ENSG00000249502.1	AC006160.5	-4.85	1.63e-06	0.000392	-0.2	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17649681	chr4:17587467~17614571:-
LUAD	cis	rs9322193	0.962	rs13215691	ENSG00000268592.3	RAET1E-AS1	4.85	1.63e-06	0.000392	0.27	0.22	Lung cancer;	chr6:149792666	chr6:149863494~149919507:+
LUAD	cis	rs41369048	0.669	rs80327434	ENSG00000238078.1	LINC01352	-4.85	1.63e-06	0.000392	-0.33	-0.22	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220850961	chr1:220829255~220832429:+
LUAD	cis	rs7829975	0.811	rs7011229	ENSG00000253893.2	FAM85B	4.85	1.63e-06	0.000392	0.27	0.22	Mood instability;	chr8:8685814	chr8:8167819~8226614:-
LUAD	cis	rs8180040	0.654	rs11714373	ENSG00000271161.1	BOLA2P2	-4.85	1.63e-06	0.000392	-0.21	-0.22	Colorectal cancer;	chr3:47173327	chr3:47499841~47500407:+
LUAD	cis	rs17508449	0.819	rs75290614	ENSG00000232450.1	RP4-730K3.3	-4.85	1.63e-06	0.000392	-0.37	-0.22	Leprosy;	chr1:113700250	chr1:113698884~113699631:-
LUAD	cis	rs41369048	0.669	rs11586003	ENSG00000238078.1	LINC01352	-4.85	1.63e-06	0.000393	-0.33	-0.22	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220866816	chr1:220829255~220832429:+
LUAD	cis	rs5758511	0.68	rs34107327	ENSG00000205702.9	CYP2D7	4.85	1.64e-06	0.000393	0.21	0.22	Birth weight;	chr22:42252347	chr22:42140203~42144577:-
LUAD	cis	rs4948102	0.642	rs766333	ENSG00000273720.1	RP11-613E4.4	-4.85	1.64e-06	0.000393	-0.26	-0.22	Plasma homocysteine levels (post-methionine load test);	chr7:56059011	chr7:55743073~55743457:+
LUAD	cis	rs1707322	1	rs1707337	ENSG00000280836.1	AL355480.1	4.85	1.64e-06	0.000393	0.28	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46043097	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs1768807	ENSG00000280836.1	AL355480.1	4.85	1.64e-06	0.000393	0.28	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044898	chr1:45581219~45581321:-
LUAD	cis	rs2562456	0.833	rs7246339	ENSG00000268081.1	RP11-678G14.2	4.85	1.64e-06	0.000393	0.35	0.22	Pain;	chr19:21292495	chr19:21554640~21569237:-
LUAD	cis	rs2735413	0.564	rs17776122	ENSG00000276007.1	RP11-358L22.3	4.85	1.64e-06	0.000393	0.3	0.22	Systolic blood pressure (alcohol consumption interaction);	chr16:78072389	chr16:78123243~78124332:+
LUAD	cis	rs4835473	0.897	rs6537170	ENSG00000251600.4	RP11-673E1.1	4.85	1.64e-06	0.000393	0.27	0.22	Immature fraction of reticulocytes;	chr4:143691747	chr4:143912331~143982454:+
LUAD	cis	rs9473147	0.516	rs2151974	ENSG00000270761.1	RP11-385F7.1	-4.85	1.64e-06	0.000394	-0.25	-0.22	Platelet distribution width;Mean platelet volume;	chr6:47547894	chr6:47477243~47477572:-
LUAD	cis	rs6539288	0.933	rs6539291	ENSG00000260329.1	RP11-412D9.4	-4.85	1.64e-06	0.000394	-0.23	-0.22	Total body bone mineral density;	chr12:106916033	chr12:106954029~106955497:-
LUAD	cis	rs9309473	0.687	rs11126399	ENSG00000163016.8	ALMS1P	4.85	1.64e-06	0.000394	0.25	0.22	Metabolite levels;	chr2:73386213	chr2:73644919~73685576:+
LUAD	cis	rs301901	1	rs300065	ENSG00000250155.1	CTD-2353F22.1	-4.85	1.64e-06	0.000394	-0.22	-0.22	Height;	chr5:36997725	chr5:36666214~36725195:-
LUAD	cis	rs453301	0.686	rs11785634	ENSG00000253893.2	FAM85B	4.85	1.64e-06	0.000394	0.28	0.22	Joint mobility (Beighton score);	chr8:9035087	chr8:8167819~8226614:-
LUAD	cis	rs9545047	0.604	rs7332367	ENSG00000227354.5	RBM26-AS1	-4.85	1.64e-06	0.000394	-0.23	-0.22	Schizophrenia;	chr13:79339816	chr13:79406309~79424328:+
LUAD	cis	rs8077577	0.689	rs62072515	ENSG00000273018.4	CTD-2303H24.2	-4.85	1.64e-06	0.000394	-0.3	-0.22	Obesity-related traits;	chr17:18310121	chr17:18511221~18551705:-
LUAD	cis	rs2562456	0.833	rs62107539	ENSG00000268081.1	RP11-678G14.2	4.85	1.64e-06	0.000394	0.35	0.22	Pain;	chr19:21334910	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.833	rs76646508	ENSG00000268081.1	RP11-678G14.2	4.85	1.64e-06	0.000394	0.35	0.22	Pain;	chr19:21335247	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.833	rs77576302	ENSG00000268081.1	RP11-678G14.2	4.85	1.64e-06	0.000394	0.35	0.22	Pain;	chr19:21335385	chr19:21554640~21569237:-
LUAD	cis	rs748404	0.697	rs493177	ENSG00000249839.1	AC011330.5	-4.85	1.64e-06	0.000394	-0.27	-0.22	Lung cancer;	chr15:43251060	chr15:43663654~43684339:-
LUAD	cis	rs9322193	0.923	rs9322214	ENSG00000268592.3	RAET1E-AS1	4.85	1.64e-06	0.000395	0.27	0.22	Lung cancer;	chr6:149703986	chr6:149863494~149919507:+
LUAD	cis	rs6568401	0.6	rs6568400	ENSG00000219088.1	RP3-359N14.1	4.85	1.64e-06	0.000395	0.28	0.22	Primary tooth development (time to first tooth eruption);	chr6:105736410	chr6:105666326~105667998:+
LUAD	cis	rs10129255	0.957	rs8014696	ENSG00000274576.2	IGHV2-70	-4.85	1.64e-06	0.000395	-0.19	-0.22	Kawasaki disease;	chr14:106769752	chr14:106770577~106771020:-
LUAD	cis	rs2439831	0.681	rs3742971	ENSG00000249839.1	AC011330.5	4.85	1.64e-06	0.000395	0.38	0.22	Lung cancer in ever smokers;	chr15:43330718	chr15:43663654~43684339:-
LUAD	cis	rs17508449	0.819	rs78874053	ENSG00000232450.1	RP4-730K3.3	-4.85	1.65e-06	0.000396	-0.37	-0.22	Leprosy;	chr1:113700251	chr1:113698884~113699631:-
LUAD	cis	rs4143844	0.867	rs12907534	ENSG00000259251.2	RP11-643M14.1	4.85	1.65e-06	0.000396	0.37	0.22	Bipolar disorder and schizophrenia;	chr15:61908396	chr15:62060503~62062434:+
LUAD	cis	rs4143844	0.867	rs35607089	ENSG00000259251.2	RP11-643M14.1	4.85	1.65e-06	0.000396	0.37	0.22	Bipolar disorder and schizophrenia;	chr15:61909573	chr15:62060503~62062434:+
LUAD	cis	rs4143844	0.737	rs35984535	ENSG00000259251.2	RP11-643M14.1	4.85	1.65e-06	0.000396	0.37	0.22	Bipolar disorder and schizophrenia;	chr15:61912747	chr15:62060503~62062434:+
LUAD	cis	rs1707322	1	rs11211190	ENSG00000280836.1	AL355480.1	-4.85	1.65e-06	0.000396	-0.28	-0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800583	chr1:45581219~45581321:-
LUAD	cis	rs2408955	0.521	rs10875753	ENSG00000257735.1	RP11-370I10.6	4.85	1.65e-06	0.000396	0.25	0.22	Glycated hemoglobin levels;	chr12:48163358	chr12:48350945~48442411:+
LUAD	cis	rs984222	0.967	rs10802069	ENSG00000226172.2	RP4-712E4.1	-4.85	1.65e-06	0.000396	-0.23	-0.22	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118974734	chr1:119000344~119001392:-
LUAD	cis	rs2998286	0.862	rs2993990	ENSG00000254635.4	WAC-AS1	-4.85	1.65e-06	0.000396	-0.27	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28518041	chr10:28522652~28532743:-
LUAD	cis	rs2404602	1	rs4886818	ENSG00000259422.1	RP11-593F23.1	4.85	1.65e-06	0.000396	0.26	0.22	Blood metabolite levels;	chr15:76588598	chr15:76174891~76181486:-
LUAD	cis	rs2404602	1	rs11072603	ENSG00000259422.1	RP11-593F23.1	4.85	1.65e-06	0.000396	0.26	0.22	Blood metabolite levels;	chr15:76588797	chr15:76174891~76181486:-
LUAD	cis	rs17711722	0.565	rs4717276	ENSG00000226002.1	RP11-460N20.5	4.85	1.65e-06	0.000396	0.24	0.22	Calcium levels;	chr7:65829754	chr7:65084103~65100232:+
LUAD	cis	rs6088590	1	rs6087632	ENSG00000276073.1	RP5-1125A11.7	-4.85	1.65e-06	0.000397	-0.22	-0.22	Coronary artery disease;	chr20:34819901	chr20:33985617~33988989:-
LUAD	cis	rs6088590	0.931	rs6088617	ENSG00000276073.1	RP5-1125A11.7	-4.85	1.65e-06	0.000397	-0.22	-0.22	Coronary artery disease;	chr20:34820233	chr20:33985617~33988989:-
LUAD	cis	rs17507216	0.718	rs7161977	ENSG00000255769.6	GOLGA2P10	-4.85	1.66e-06	0.000397	-0.28	-0.22	Excessive daytime sleepiness;	chr15:82646782	chr15:82472993~82513950:-
LUAD	cis	rs449789	0.857	rs1553482	ENSG00000235086.1	FNDC1-IT1	-4.85	1.66e-06	0.000397	-0.3	-0.22	Pulse pressure;	chr6:159301115	chr6:159240786~159243329:+
LUAD	cis	rs7017914	0.69	rs2008517	ENSG00000223220.1	Y_RNA	4.85	1.66e-06	0.000397	0.25	0.22	Bone mineral density;	chr8:70944285	chr8:70780914~70781008:-
LUAD	cis	rs8030379	0.811	rs7162542	ENSG00000230373.7	GOLGA6L5P	-4.85	1.66e-06	0.000397	-0.2	-0.22	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83845538	chr15:84507885~84516814:-
LUAD	cis	rs950169	0.58	rs11633762	ENSG00000259295.5	CSPG4P12	4.85	1.66e-06	0.000398	0.31	0.22	Schizophrenia;	chr15:84643921	chr15:85191438~85213905:+
LUAD	cis	rs9473147	0.516	rs2151975	ENSG00000270761.1	RP11-385F7.1	-4.85	1.66e-06	0.000398	-0.25	-0.22	Platelet distribution width;Mean platelet volume;	chr6:47547927	chr6:47477243~47477572:-
LUAD	cis	rs6840258	1	rs72667765	ENSG00000251411.1	RP11-397E7.4	-4.85	1.66e-06	0.000398	-0.28	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87044790	chr4:86913266~86914817:-
LUAD	cis	rs8050896	1	rs7205730	ENSG00000260695.1	RP11-513N24.1	-4.85	1.66e-06	0.000398	-0.41	-0.22	Response to antipsychotic treatment;	chr16:66127140	chr16:65861112~65863784:-
LUAD	cis	rs12745968	0.589	rs3903212	ENSG00000223787.2	RP4-593M8.1	-4.85	1.66e-06	0.000398	-0.26	-0.22	Bipolar disorder and schizophrenia;	chr1:92518498	chr1:92580476~92580821:-
LUAD	cis	rs875971	0.83	rs4718358	ENSG00000232559.3	GS1-124K5.12	4.85	1.66e-06	0.000398	0.25	0.22	Aortic root size;	chr7:66508681	chr7:66554588~66576923:-
LUAD	cis	rs6088590	0.965	rs6120730	ENSG00000276073.1	RP5-1125A11.7	-4.85	1.66e-06	0.000398	-0.22	-0.22	Coronary artery disease;	chr20:34797299	chr20:33985617~33988989:-
LUAD	cis	rs7017914	0.653	rs2732130	ENSG00000223220.1	Y_RNA	4.85	1.66e-06	0.000398	0.25	0.22	Bone mineral density;	chr8:70981238	chr8:70780914~70781008:-
LUAD	cis	rs6539288	0.899	rs6539290	ENSG00000260329.1	RP11-412D9.4	-4.85	1.66e-06	0.000398	-0.23	-0.22	Total body bone mineral density;	chr12:106915871	chr12:106954029~106955497:-
LUAD	cis	rs950169	0.579	rs881983	ENSG00000259728.4	LINC00933	4.85	1.66e-06	0.000398	0.33	0.22	Schizophrenia;	chr15:83978556	chr15:84570649~84580175:+
LUAD	cis	rs14027	0.921	rs12707880	ENSG00000279347.1	RP11-85I17.2	-4.85	1.66e-06	0.000399	-0.19	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119829051	chr8:119838736~119840385:-
LUAD	cis	rs5758511	0.633	rs5758689	ENSG00000205702.9	CYP2D7	4.85	1.66e-06	0.000399	0.21	0.22	Birth weight;	chr22:42268966	chr22:42140203~42144577:-
LUAD	cis	rs559928	0.597	rs2186572	ENSG00000236935.1	AP003774.1	4.85	1.66e-06	0.000399	0.32	0.22	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64128415	chr11:64325050~64329504:-
LUAD	cis	rs559928	0.557	rs7122408	ENSG00000236935.1	AP003774.1	4.85	1.66e-06	0.000399	0.32	0.22	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64131354	chr11:64325050~64329504:-
LUAD	cis	rs193541	0.53	rs2045626	ENSG00000263432.2	RN7SL689P	4.85	1.66e-06	0.000399	0.28	0.22	Glucose homeostasis traits;	chr5:122745558	chr5:123022487~123022783:-
LUAD	cis	rs71636778	0.509	rs34976021	ENSG00000260063.1	RP5-968P14.2	-4.85	1.66e-06	0.000399	-0.36	-0.22	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26972073	chr1:26692132~26694131:-
LUAD	cis	rs9376098	0.698	rs6908307	ENSG00000232876.1	CTA-212D2.2	-4.85	1.66e-06	0.000399	-0.26	-0.22	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135141542	chr6:135055033~135060550:+
LUAD	cis	rs8077577	0.747	rs62072541	ENSG00000273018.4	CTD-2303H24.2	-4.85	1.66e-06	0.000399	-0.3	-0.22	Obesity-related traits;	chr17:18323385	chr17:18511221~18551705:-
LUAD	cis	rs801193	1	rs2707845	ENSG00000236529.1	RP13-254B10.1	4.85	1.66e-06	0.000399	0.22	0.22	Aortic root size;	chr7:66733811	chr7:65840212~65840596:+
LUAD	cis	rs193541	0.632	rs1363200	ENSG00000263432.2	RN7SL689P	4.85	1.66e-06	0.000399	0.29	0.22	Glucose homeostasis traits;	chr5:122828107	chr5:123022487~123022783:-
LUAD	cis	rs11673344	0.77	rs74770693	ENSG00000226686.6	LINC01535	4.85	1.66e-06	0.000399	0.29	0.22	Obesity-related traits;	chr19:37135613	chr19:37251912~37265535:+
LUAD	cis	rs11089937	0.626	rs4821784	ENSG00000211638.2	IGLV8-61	-4.85	1.66e-06	0.000399	-0.27	-0.22	Periodontitis (PAL4Q3);	chr22:22143513	chr22:22098700~22099212:+
LUAD	cis	rs7772486	0.806	rs7740785	ENSG00000235652.6	RP11-545I5.3	4.85	1.67e-06	0.000399	0.21	0.22	Lobe attachment (rater-scored or self-reported);	chr6:145850163	chr6:145799409~145886585:+
LUAD	cis	rs2617170	0.883	rs2733851	ENSG00000245648.1	RP11-277P12.20	4.85	1.67e-06	0.000399	0.27	0.22	Behcet's disease;	chr12:10376498	chr12:10363769~10398506:+
LUAD	cis	rs9584850	0.834	rs7985565	ENSG00000231194.1	FARP1-AS1	4.85	1.67e-06	0.000399	0.26	0.22	Neuroticism;	chr13:98461217	chr13:98435405~98435840:-
LUAD	cis	rs7760535	0.763	rs9487666	ENSG00000271789.1	RP5-1112D6.7	-4.85	1.67e-06	4e-04	-0.23	-0.22	Metabolic traits;	chr6:111547821	chr6:111297126~111298510:+
LUAD	cis	rs1799949	1	rs12944597	ENSG00000236383.6	LINC00854	-4.85	1.67e-06	4e-04	-0.18	-0.22	Menopause (age at onset);	chr17:43035667	chr17:43216941~43305976:-
LUAD	cis	rs1707322	0.964	rs785508	ENSG00000280836.1	AL355480.1	4.85	1.67e-06	4e-04	0.28	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061487	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.964	rs785509	ENSG00000280836.1	AL355480.1	4.85	1.67e-06	4e-04	0.28	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061628	chr1:45581219~45581321:-
LUAD	cis	rs736801	0.808	rs2248116	ENSG00000233006.5	AC034220.3	-4.85	1.67e-06	4e-04	-0.19	-0.22	Mosquito bite size;Breast cancer;	chr5:132468655	chr5:132311285~132369916:-
LUAD	cis	rs7017914	0.652	rs62510667	ENSG00000223220.1	Y_RNA	4.85	1.67e-06	4e-04	0.25	0.22	Bone mineral density;	chr8:70850458	chr8:70780914~70781008:-
LUAD	cis	rs858239	0.601	rs2141307	ENSG00000230042.1	AK3P3	-4.85	1.67e-06	4e-04	-0.28	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23151805	chr7:23129178~23129841:+
LUAD	cis	rs800160	0.777	rs10765944	ENSG00000236264.4	RPL26P30	-4.85	1.67e-06	4e-04	-0.3	-0.22	Bacteremia;	chr11:2326964	chr11:2335132~2335776:-
LUAD	cis	rs4947019	1	rs4947015	ENSG00000260273.1	RP11-425D10.10	4.85	1.67e-06	4e-04	0.44	0.22	Hematological parameters;	chr6:109731312	chr6:109382795~109383666:+
LUAD	cis	rs7829975	0.744	rs2409092	ENSG00000173295.6	FAM86B3P	4.85	1.67e-06	0.000401	0.23	0.22	Mood instability;	chr8:8824682	chr8:8228595~8244865:+
LUAD	cis	rs42490	0.966	rs218908	ENSG00000251136.7	RP11-37B2.1	-4.85	1.67e-06	0.000401	-0.22	-0.22	Leprosy;	chr8:89728886	chr8:89609409~89757727:-
LUAD	cis	rs42490	1	rs2735870	ENSG00000251136.7	RP11-37B2.1	4.85	1.67e-06	0.000401	0.22	0.22	Leprosy;	chr8:89730456	chr8:89609409~89757727:-
LUAD	cis	rs2735413	0.564	rs2222897	ENSG00000276007.1	RP11-358L22.3	4.85	1.67e-06	0.000401	0.3	0.22	Systolic blood pressure (alcohol consumption interaction);	chr16:78058138	chr16:78123243~78124332:+
LUAD	cis	rs9322193	0.962	rs7818	ENSG00000268592.3	RAET1E-AS1	4.85	1.67e-06	0.000401	0.26	0.22	Lung cancer;	chr6:149810956	chr6:149863494~149919507:+
LUAD	cis	rs2098713	0.549	rs62359033	ENSG00000250155.1	CTD-2353F22.1	4.85	1.67e-06	0.000401	0.22	0.22	Telomere length;	chr5:37549741	chr5:36666214~36725195:-
LUAD	cis	rs17507216	0.609	rs1431716	ENSG00000255769.6	GOLGA2P10	-4.85	1.67e-06	0.000401	-0.28	-0.22	Excessive daytime sleepiness;	chr15:82676180	chr15:82472993~82513950:-
LUAD	cis	rs5758659	0.714	rs6002626	ENSG00000227370.1	RP4-669P10.19	4.85	1.67e-06	0.000401	0.2	0.22	Cognitive function;	chr22:42121985	chr22:42132543~42132998:+
LUAD	cis	rs10208649	0.572	rs7585466	ENSG00000272156.1	RP11-477N3.1	4.85	1.67e-06	0.000401	0.41	0.22	Body mass index;	chr2:54098988	chr2:54082554~54085066:+
LUAD	cis	rs748404	0.666	rs7180812	ENSG00000205771.5	CATSPER2P1	-4.85	1.67e-06	0.000401	-0.33	-0.22	Lung cancer;	chr15:43403033	chr15:43726918~43747094:-
LUAD	cis	rs957448	0.561	rs71532325	ENSG00000253704.1	RP11-267M23.4	4.85	1.67e-06	0.000401	0.26	0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94615738	chr8:94553722~94569745:+
LUAD	cis	rs9487094	0.922	rs13204102	ENSG00000260273.1	RP11-425D10.10	4.85	1.67e-06	0.000401	0.3	0.22	Height;	chr6:109617741	chr6:109382795~109383666:+
LUAD	cis	rs9487094	0.922	rs10499053	ENSG00000260273.1	RP11-425D10.10	4.85	1.67e-06	0.000401	0.3	0.22	Height;	chr6:109619295	chr6:109382795~109383666:+
LUAD	cis	rs41369048	0.669	rs77986094	ENSG00000238078.1	LINC01352	-4.85	1.67e-06	0.000401	-0.33	-0.22	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220854514	chr1:220829255~220832429:+
LUAD	cis	rs853679	0.567	rs1005126	ENSG00000216901.1	AL022393.7	4.85	1.68e-06	0.000401	0.27	0.22	Depression;	chr6:28399846	chr6:28176188~28176674:+
LUAD	cis	rs11971779	0.68	rs4728467	ENSG00000273391.1	RP11-634H22.1	4.85	1.68e-06	0.000401	0.23	0.22	Diisocyanate-induced asthma;	chr7:139435816	chr7:139359032~139359566:-
LUAD	cis	rs17301013	0.861	rs333418	ENSG00000227373.4	RP11-160H22.5	4.85	1.68e-06	0.000402	0.27	0.22	Systemic lupus erythematosus;	chr1:174707294	chr1:174115300~174160004:-
LUAD	cis	rs17345786	1	rs997739	ENSG00000244119.1	PDCL3P4	4.85	1.68e-06	0.000402	0.23	0.22	Colonoscopy-negative controls vs population controls;	chr3:101595096	chr3:101712472~101713191:+
LUAD	cis	rs17345786	0.954	rs17508319	ENSG00000244119.1	PDCL3P4	4.85	1.68e-06	0.000402	0.23	0.22	Colonoscopy-negative controls vs population controls;	chr3:101600059	chr3:101712472~101713191:+
LUAD	cis	rs17345786	0.953	rs78645744	ENSG00000244119.1	PDCL3P4	4.85	1.68e-06	0.000402	0.23	0.22	Colonoscopy-negative controls vs population controls;	chr3:101608945	chr3:101712472~101713191:+
LUAD	cis	rs17345786	0.817	rs11720560	ENSG00000244119.1	PDCL3P4	4.85	1.68e-06	0.000402	0.23	0.22	Colonoscopy-negative controls vs population controls;	chr3:101609640	chr3:101712472~101713191:+
LUAD	cis	rs2440129	0.611	rs1126667	ENSG00000215067.8	ALOX12-AS1	-4.85	1.68e-06	0.000402	-0.21	-0.22	Tonsillectomy;	chr17:6999441	chr17:6876635~7012349:-
LUAD	cis	rs1075232	1	rs9672214	ENSG00000215302.7	CTD-3092A11.1	-4.85	1.68e-06	0.000402	-0.48	-0.22	Survival in colorectal cancer (non-distant metastatic);	chr15:31385572	chr15:30470779~30507623:+
LUAD	cis	rs916888	0.61	rs199530	ENSG00000261575.2	RP11-259G18.1	-4.85	1.68e-06	0.000402	-0.28	-0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46267037~46268694:+
LUAD	cis	rs8127691	1	rs2838517	ENSG00000237604.1	AP001056.1	4.85	1.68e-06	0.000402	0.25	0.22	Inflammatory bowel disease;	chr21:44193942	chr21:44175489~44176453:+
LUAD	cis	rs7618501	0.699	rs6446187	ENSG00000234667.1	ACTBP13	-4.85	1.68e-06	0.000402	-0.25	-0.22	Intelligence (multi-trait analysis);	chr3:49869678	chr3:49873347~49877980:-
LUAD	cis	rs7208859	0.673	rs9915139	ENSG00000263603.1	CTD-2349P21.5	-4.85	1.68e-06	0.000402	-0.36	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831497	chr17:30729469~30731202:+
LUAD	cis	rs13256369	0.802	rs12681925	ENSG00000253893.2	FAM85B	-4.85	1.68e-06	0.000402	-0.3	-0.22	Obesity-related traits;	chr8:8704139	chr8:8167819~8226614:-
LUAD	cis	rs13256369	0.802	rs12680019	ENSG00000253893.2	FAM85B	-4.85	1.68e-06	0.000402	-0.3	-0.22	Obesity-related traits;	chr8:8704188	chr8:8167819~8226614:-
LUAD	cis	rs9473147	0.516	rs9367284	ENSG00000270761.1	RP11-385F7.1	-4.85	1.68e-06	0.000402	-0.25	-0.22	Platelet distribution width;Mean platelet volume;	chr6:47548633	chr6:47477243~47477572:-
LUAD	cis	rs9473147	0.516	rs9381575	ENSG00000270761.1	RP11-385F7.1	-4.85	1.68e-06	0.000402	-0.25	-0.22	Platelet distribution width;Mean platelet volume;	chr6:47561028	chr6:47477243~47477572:-
LUAD	cis	rs7200786	0.583	rs2302557	ENSG00000274038.1	RP11-66H6.4	-4.85	1.68e-06	0.000403	-0.26	-0.22	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11042191	chr16:11056556~11057034:+
LUAD	cis	rs6142102	0.961	rs6119447	ENSG00000275784.1	RP5-1125A11.6	-4.85	1.68e-06	0.000403	-0.24	-0.22	Skin pigmentation;	chr20:34080770	chr20:33989480~33991818:-
LUAD	cis	rs800160	0.777	rs2521283	ENSG00000236264.4	RPL26P30	-4.85	1.68e-06	0.000403	-0.3	-0.22	Bacteremia;	chr11:2320342	chr11:2335132~2335776:-
LUAD	cis	rs2880765	0.835	rs730372	ENSG00000259295.5	CSPG4P12	-4.85	1.68e-06	0.000403	-0.25	-0.22	Coronary artery disease;	chr15:85494962	chr15:85191438~85213905:+
LUAD	cis	rs67340775	0.541	rs200965	ENSG00000219392.1	RP1-265C24.5	-4.85	1.68e-06	0.000403	-0.37	-0.22	Lung cancer in ever smokers;	chr6:27898606	chr6:28115628~28116551:+
LUAD	cis	rs14027	0.921	rs2634	ENSG00000279347.1	RP11-85I17.2	-4.85	1.68e-06	0.000403	-0.19	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119819869	chr8:119838736~119840385:-
LUAD	cis	rs14027	0.921	rs12542794	ENSG00000279347.1	RP11-85I17.2	-4.85	1.68e-06	0.000403	-0.19	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119826153	chr8:119838736~119840385:-
LUAD	cis	rs755249	0.501	rs621807	ENSG00000228060.1	RP11-69E11.8	-4.85	1.68e-06	0.000403	-0.2	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39376771	chr1:39565160~39573203:+
LUAD	cis	rs875971	0.522	rs781144	ENSG00000236529.1	RP13-254B10.1	4.85	1.68e-06	0.000403	0.22	0.22	Aortic root size;	chr7:65975357	chr7:65840212~65840596:+
LUAD	cis	rs763567	0.967	rs654461	ENSG00000271811.1	RP1-79C4.4	4.85	1.68e-06	0.000403	0.26	0.22	Tonsillectomy;	chr1:170644709	chr1:170667381~170669425:+
LUAD	cis	rs2337406	1	rs74090714	ENSG00000211972.2	IGHV3-66	4.85	1.69e-06	0.000404	0.24	0.22	Alzheimer's disease (late onset);	chr14:106691225	chr14:106675017~106675544:-
LUAD	cis	rs860295	0.651	rs6677385	ENSG00000225855.5	RUSC1-AS1	4.85	1.69e-06	0.000404	0.15	0.22	Body mass index;	chr1:155334790	chr1:155316863~155324176:-
LUAD	cis	rs507080	0.922	rs502601	ENSG00000278376.1	RP11-158I9.8	-4.85	1.69e-06	0.000404	-0.23	-0.22	Serum metabolite levels;	chr11:118694970	chr11:118791254~118793137:+
LUAD	cis	rs9322193	0.961	rs9027	ENSG00000268592.3	RAET1E-AS1	4.85	1.69e-06	0.000404	0.26	0.22	Lung cancer;	chr6:149594921	chr6:149863494~149919507:+
LUAD	cis	rs673078	0.66	rs56708462	ENSG00000275409.1	RP11-131L12.4	-4.85	1.69e-06	0.000404	-0.31	-0.22	Glucose homeostasis traits;	chr12:118284135	chr12:118430147~118430699:+
LUAD	cis	rs673078	0.66	rs7962185	ENSG00000275409.1	RP11-131L12.4	-4.85	1.69e-06	0.000404	-0.31	-0.22	Glucose homeostasis traits;	chr12:118287842	chr12:118430147~118430699:+
LUAD	cis	rs12468226	0.606	rs10445793	ENSG00000272966.1	RP11-686O6.1	4.85	1.69e-06	0.000404	0.34	0.22	Urate levels;	chr2:202190799	chr2:202336739~202337200:+
LUAD	cis	rs1799949	1	rs8176126	ENSG00000236383.6	LINC00854	4.85	1.69e-06	0.000404	0.17	0.22	Menopause (age at onset);	chr17:43107032	chr17:43216941~43305976:-
LUAD	cis	rs858239	0.509	rs57611130	ENSG00000230042.1	AK3P3	-4.85	1.69e-06	0.000404	-0.27	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23144933	chr7:23129178~23129841:+
LUAD	cis	rs9910055	0.529	rs400460	ENSG00000267080.4	ASB16-AS1	4.85	1.69e-06	0.000404	0.2	0.22	Total body bone mineral density;	chr17:44105402	chr17:44175973~44186717:-
LUAD	cis	rs7182621	0.793	rs12904168	ENSG00000259363.4	CTD-2054N24.2	-4.85	1.69e-06	0.000404	-0.26	-0.22	Colonoscopy-negative controls vs population controls;	chr15:99869495	chr15:99807023~99877148:+
LUAD	cis	rs5758659	0.904	rs5758653	ENSG00000227370.1	RP4-669P10.19	-4.85	1.69e-06	0.000404	-0.19	-0.22	Cognitive function;	chr22:42217479	chr22:42132543~42132998:+
LUAD	cis	rs6840258	0.891	rs3733377	ENSG00000251411.1	RP11-397E7.4	4.85	1.69e-06	0.000405	0.27	0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87108330	chr4:86913266~86914817:-
LUAD	cis	rs42490	1	rs2735873	ENSG00000251136.7	RP11-37B2.1	4.85	1.69e-06	0.000405	0.22	0.22	Leprosy;	chr8:89737748	chr8:89609409~89757727:-
LUAD	cis	rs897984	0.77	rs3813020	ENSG00000260911.2	RP11-196G11.2	-4.85	1.69e-06	0.000405	-0.19	-0.22	Dementia with Lewy bodies;	chr16:30922754	chr16:31043150~31049868:+
LUAD	cis	rs17508449	0.779	rs78703286	ENSG00000232450.1	RP4-730K3.3	-4.85	1.69e-06	0.000405	-0.36	-0.22	Leprosy;	chr1:113605493	chr1:113698884~113699631:-
LUAD	cis	rs13256369	0.951	rs13270852	ENSG00000253893.2	FAM85B	-4.85	1.69e-06	0.000405	-0.3	-0.22	Obesity-related traits;	chr8:8709343	chr8:8167819~8226614:-
LUAD	cis	rs17507216	0.681	rs28877110	ENSG00000255769.6	GOLGA2P10	-4.85	1.69e-06	0.000405	-0.28	-0.22	Excessive daytime sleepiness;	chr15:82672111	chr15:82472993~82513950:-
LUAD	cis	rs9500256	0.669	rs7776004	ENSG00000266579.1	RP1-71H19.2	4.85	1.69e-06	0.000405	0.27	0.22	Eosinophilic esophagitis (pediatric);	chr6:58017484	chr6:57493855~57497691:+
LUAD	cis	rs2998286	0.723	rs2772435	ENSG00000254635.4	WAC-AS1	-4.85	1.69e-06	0.000405	-0.29	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28546534	chr10:28522652~28532743:-
LUAD	cis	rs2998286	0.723	rs2807759	ENSG00000254635.4	WAC-AS1	-4.85	1.69e-06	0.000405	-0.29	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28548682	chr10:28522652~28532743:-
LUAD	cis	rs2998286	0.723	rs332121	ENSG00000254635.4	WAC-AS1	-4.85	1.69e-06	0.000405	-0.29	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28552285	chr10:28522652~28532743:-
LUAD	cis	rs2998286	0.572	rs332124	ENSG00000254635.4	WAC-AS1	-4.85	1.69e-06	0.000405	-0.29	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28553545	chr10:28522652~28532743:-
LUAD	cis	rs2998286	0.723	rs332126	ENSG00000254635.4	WAC-AS1	-4.85	1.69e-06	0.000405	-0.29	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28556866	chr10:28522652~28532743:-
LUAD	cis	rs2998286	0.723	rs332128	ENSG00000254635.4	WAC-AS1	-4.85	1.69e-06	0.000405	-0.29	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28559399	chr10:28522652~28532743:-
LUAD	cis	rs2998286	0.723	rs231202	ENSG00000254635.4	WAC-AS1	-4.85	1.69e-06	0.000405	-0.29	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28560111	chr10:28522652~28532743:-
LUAD	cis	rs2998286	0.723	rs332131	ENSG00000254635.4	WAC-AS1	-4.85	1.69e-06	0.000405	-0.29	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28564933	chr10:28522652~28532743:-
LUAD	cis	rs712039	0.652	rs17137970	ENSG00000276054.1	RP11-378E13.3	4.85	1.69e-06	0.000405	0.32	0.22	Tuberculosis;	chr17:37411739	chr17:37386886~37387926:+
LUAD	cis	rs7829975	0.572	rs28446104	ENSG00000253893.2	FAM85B	4.85	1.69e-06	0.000405	0.27	0.22	Mood instability;	chr8:8938391	chr8:8167819~8226614:-
LUAD	cis	rs12468226	1	rs11899836	ENSG00000272966.1	RP11-686O6.1	4.85	1.69e-06	0.000405	0.35	0.22	Urate levels;	chr2:202371316	chr2:202336739~202337200:+
LUAD	cis	rs2933343	0.7	rs2249514	ENSG00000261159.1	RP11-723O4.9	4.85	1.69e-06	0.000405	0.23	0.22	IgG glycosylation;	chr3:128924969	chr3:128859716~128860526:-
LUAD	cis	rs2933343	0.7	rs2630257	ENSG00000261159.1	RP11-723O4.9	4.85	1.69e-06	0.000405	0.23	0.22	IgG glycosylation;	chr3:128925172	chr3:128859716~128860526:-
LUAD	cis	rs2933343	0.729	rs1680785	ENSG00000261159.1	RP11-723O4.9	4.85	1.69e-06	0.000405	0.23	0.22	IgG glycosylation;	chr3:128925973	chr3:128859716~128860526:-
LUAD	cis	rs2933343	0.729	rs1680786	ENSG00000261159.1	RP11-723O4.9	4.85	1.69e-06	0.000405	0.23	0.22	IgG glycosylation;	chr3:128925997	chr3:128859716~128860526:-
LUAD	cis	rs6840258	0.941	rs6854749	ENSG00000251411.1	RP11-397E7.4	-4.85	1.69e-06	0.000405	-0.28	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87047646	chr4:86913266~86914817:-
LUAD	cis	rs9400467	0.528	rs465796	ENSG00000271789.1	RP5-1112D6.7	-4.85	1.69e-06	0.000405	-0.23	-0.22	Amino acid levels;Blood metabolite levels;	chr6:111298522	chr6:111297126~111298510:+
LUAD	cis	rs73198271	0.722	rs488566	ENSG00000253893.2	FAM85B	4.85	1.69e-06	0.000405	0.27	0.22	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8782065	chr8:8167819~8226614:-
LUAD	cis	rs14027	0.921	rs16893140	ENSG00000279347.1	RP11-85I17.2	-4.85	1.69e-06	0.000405	-0.19	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119767007	chr8:119838736~119840385:-
LUAD	cis	rs12468226	1	rs57080353	ENSG00000272966.1	RP11-686O6.1	4.85	1.69e-06	0.000405	0.36	0.22	Urate levels;	chr2:202511824	chr2:202336739~202337200:+
LUAD	cis	rs12468226	0.81	rs3736578	ENSG00000272966.1	RP11-686O6.1	4.85	1.69e-06	0.000405	0.36	0.22	Urate levels;	chr2:202519989	chr2:202336739~202337200:+
LUAD	cis	rs12468226	1	rs116439150	ENSG00000272966.1	RP11-686O6.1	4.85	1.69e-06	0.000405	0.36	0.22	Urate levels;	chr2:202523814	chr2:202336739~202337200:+
LUAD	cis	rs12468226	1	rs12467409	ENSG00000272966.1	RP11-686O6.1	4.85	1.69e-06	0.000405	0.36	0.22	Urate levels;	chr2:202529625	chr2:202336739~202337200:+
LUAD	cis	rs12468226	0.81	rs77090459	ENSG00000272966.1	RP11-686O6.1	4.85	1.69e-06	0.000405	0.36	0.22	Urate levels;	chr2:202542132	chr2:202336739~202337200:+
LUAD	cis	rs6840360	0.869	rs55668815	ENSG00000270265.1	RP11-731D1.4	-4.85	1.7e-06	0.000406	-0.22	-0.22	Intelligence (multi-trait analysis);	chr4:151552676	chr4:151333775~151353224:-
LUAD	cis	rs2998286	0.768	rs332137	ENSG00000254635.4	WAC-AS1	-4.85	1.7e-06	0.000406	-0.29	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28570050	chr10:28522652~28532743:-
LUAD	cis	rs2998286	0.768	rs332140	ENSG00000254635.4	WAC-AS1	-4.85	1.7e-06	0.000406	-0.29	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28570431	chr10:28522652~28532743:-
LUAD	cis	rs7763441	0.545	rs9392392	ENSG00000272465.1	RP1-136B1.1	-4.85	1.7e-06	0.000406	-0.26	-0.22	Monobrow;	chr6:2453199	chr6:2437549~2438249:+
LUAD	cis	rs561341	1	rs550264	ENSG00000265798.5	RP11-271K11.5	4.85	1.7e-06	0.000406	0.35	0.22	Hip circumference adjusted for BMI;	chr17:31990521	chr17:31038575~31059121:-
LUAD	cis	rs561341	1	rs564714	ENSG00000265798.5	RP11-271K11.5	4.85	1.7e-06	0.000406	0.35	0.22	Hip circumference adjusted for BMI;	chr17:31991385	chr17:31038575~31059121:-
LUAD	cis	rs561341	1	rs111454793	ENSG00000265798.5	RP11-271K11.5	4.85	1.7e-06	0.000406	0.35	0.22	Hip circumference adjusted for BMI;	chr17:31992248	chr17:31038575~31059121:-
LUAD	cis	rs561341	1	rs527256	ENSG00000265798.5	RP11-271K11.5	4.85	1.7e-06	0.000406	0.35	0.22	Hip circumference adjusted for BMI;	chr17:31994274	chr17:31038575~31059121:-
LUAD	cis	rs561341	1	rs473356	ENSG00000265798.5	RP11-271K11.5	4.85	1.7e-06	0.000406	0.35	0.22	Hip circumference adjusted for BMI;	chr17:31994743	chr17:31038575~31059121:-
LUAD	cis	rs561341	1	rs576985	ENSG00000265798.5	RP11-271K11.5	4.85	1.7e-06	0.000406	0.35	0.22	Hip circumference adjusted for BMI;	chr17:31996304	chr17:31038575~31059121:-
LUAD	cis	rs561341	1	rs510264	ENSG00000265798.5	RP11-271K11.5	4.85	1.7e-06	0.000406	0.35	0.22	Hip circumference adjusted for BMI;	chr17:31996395	chr17:31038575~31059121:-
LUAD	cis	rs561341	1	rs15654	ENSG00000265798.5	RP11-271K11.5	4.85	1.7e-06	0.000406	0.35	0.22	Hip circumference adjusted for BMI;	chr17:31999341	chr17:31038575~31059121:-
LUAD	cis	rs561341	1	rs550923	ENSG00000265798.5	RP11-271K11.5	4.85	1.7e-06	0.000406	0.35	0.22	Hip circumference adjusted for BMI;	chr17:31999994	chr17:31038575~31059121:-
LUAD	cis	rs2562456	0.55	rs4809143	ENSG00000268081.1	RP11-678G14.2	4.85	1.7e-06	0.000406	0.34	0.22	Pain;	chr19:21589926	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.583	rs4809144	ENSG00000268081.1	RP11-678G14.2	4.85	1.7e-06	0.000406	0.34	0.22	Pain;	chr19:21589928	chr19:21554640~21569237:-
LUAD	cis	rs1876905	0.764	rs9398265	ENSG00000272356.1	RP5-1112D6.8	-4.85	1.7e-06	0.000406	-0.24	-0.22	Mean corpuscular hemoglobin;	chr6:111101399	chr6:111309203~111313517:+
LUAD	cis	rs193541	0.632	rs152038	ENSG00000263432.2	RN7SL689P	4.85	1.7e-06	0.000407	0.29	0.22	Glucose homeostasis traits;	chr5:122860151	chr5:123022487~123022783:-
LUAD	cis	rs75422866	0.51	rs73105829	ENSG00000276691.1	RP5-1057I20.5	4.85	1.7e-06	0.000407	0.36	0.22	Pneumonia;	chr12:47734162	chr12:47788426~47788971:+
LUAD	cis	rs916888	0.647	rs199449	ENSG00000261575.2	RP11-259G18.1	4.85	1.7e-06	0.000407	0.29	0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46267037~46268694:+
LUAD	cis	rs9322193	0.923	rs9285524	ENSG00000268592.3	RAET1E-AS1	4.85	1.7e-06	0.000407	0.27	0.22	Lung cancer;	chr6:149694122	chr6:149863494~149919507:+
LUAD	cis	rs72717009	0.825	rs10494360	ENSG00000225217.1	HSPA7	-4.85	1.7e-06	0.000407	-0.31	-0.22	Rheumatoid arthritis;	chr1:161505960	chr1:161606291~161608217:+
LUAD	cis	rs9425766	0.679	rs4650989	ENSG00000227373.4	RP11-160H22.5	4.85	1.7e-06	0.000407	0.27	0.22	Life satisfaction;	chr1:174289739	chr1:174115300~174160004:-
LUAD	cis	rs8031584	0.678	rs798127	ENSG00000270015.1	RP11-540B6.6	4.85	1.7e-06	0.000407	0.17	0.22	Huntington's disease progression;	chr15:30825200	chr15:30926514~30928407:+
LUAD	cis	rs2153535	0.585	rs980083	ENSG00000230939.1	RP11-314C16.1	4.85	1.7e-06	0.000407	0.24	0.22	Motion sickness;	chr6:8589683	chr6:8784178~8785445:+
LUAD	cis	rs801193	1	rs2707836	ENSG00000237310.1	GS1-124K5.4	4.85	1.7e-06	0.000407	0.23	0.22	Aortic root size;	chr7:66695448	chr7:66493706~66495474:+
LUAD	cis	rs801193	0.844	rs7779971	ENSG00000237310.1	GS1-124K5.4	4.85	1.7e-06	0.000407	0.23	0.22	Aortic root size;	chr7:66696803	chr7:66493706~66495474:+
LUAD	cis	rs17345786	1	rs17345528	ENSG00000244119.1	PDCL3P4	-4.85	1.7e-06	0.000407	-0.23	-0.22	Colonoscopy-negative controls vs population controls;	chr3:101575986	chr3:101712472~101713191:+
LUAD	cis	rs7017914	0.652	rs754846	ENSG00000223220.1	Y_RNA	4.85	1.7e-06	0.000407	0.25	0.22	Bone mineral density;	chr8:70832304	chr8:70780914~70781008:-
LUAD	cis	rs559928	0.597	rs947939	ENSG00000236935.1	AP003774.1	4.85	1.7e-06	0.000407	0.32	0.22	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64117815	chr11:64325050~64329504:-
LUAD	cis	rs7302981	0.967	rs35998534	ENSG00000272368.2	RP4-605O3.4	4.85	1.7e-06	0.000407	0.25	0.22	Systolic blood pressure;	chr12:50162999	chr12:50112197~50165618:+
LUAD	cis	rs4908760	0.792	rs6577515	ENSG00000270282.1	RP5-1115A15.2	4.85	1.7e-06	0.000408	0.23	0.22	Vitiligo;	chr1:8654143	chr1:8512653~8513021:+
LUAD	cis	rs6840258	1	rs56201818	ENSG00000251411.1	RP11-397E7.4	-4.85	1.71e-06	0.000408	-0.28	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87031481	chr4:86913266~86914817:-
LUAD	cis	rs7714584	1	rs931058	ENSG00000197083.10	ZNF300P1	4.85	1.71e-06	0.000408	0.49	0.22	Crohn's disease;	chr5:150954136	chr5:150930645~150946289:-
LUAD	cis	rs2243480	1	rs313807	ENSG00000164669.11	INTS4P1	4.85	1.71e-06	0.000408	0.38	0.22	Diabetic kidney disease;	chr7:66034494	chr7:65141225~65234216:+
LUAD	cis	rs2028299	0.959	rs2165069	ENSG00000259677.1	RP11-493E3.1	4.85	1.71e-06	0.000408	0.26	0.22	Type 2 diabetes;	chr15:89863887	chr15:89876540~89877285:+
LUAD	cis	rs301901	0.965	rs292195	ENSG00000250155.1	CTD-2353F22.1	-4.85	1.71e-06	0.000408	-0.22	-0.22	Height;	chr5:36941456	chr5:36666214~36725195:-
LUAD	cis	rs7688540	0.8	rs6857106	ENSG00000211553.1	AC253576.2	4.85	1.71e-06	0.000408	0.27	0.22	Facial morphology (factor 6, height of vermillion lower lip);	chr4:255641	chr4:136461~136568:+
LUAD	cis	rs453301	0.631	rs7843789	ENSG00000173295.6	FAM86B3P	-4.85	1.71e-06	0.000408	-0.23	-0.22	Joint mobility (Beighton score);	chr8:8943051	chr8:8228595~8244865:+
LUAD	cis	rs8127691	0.967	rs762422	ENSG00000237604.1	AP001056.1	-4.85	1.71e-06	0.000408	-0.25	-0.22	Inflammatory bowel disease;	chr21:44195755	chr21:44175489~44176453:+
LUAD	cis	rs801193	0.569	rs6978178	ENSG00000232559.3	GS1-124K5.12	-4.85	1.71e-06	0.000408	-0.26	-0.22	Aortic root size;	chr7:66658097	chr7:66554588~66576923:-
LUAD	cis	rs507080	0.885	rs7926959	ENSG00000278376.1	RP11-158I9.8	-4.84	1.71e-06	0.000409	-0.23	-0.22	Serum metabolite levels;	chr11:118689157	chr11:118791254~118793137:+
LUAD	cis	rs507080	0.663	rs7926970	ENSG00000278376.1	RP11-158I9.8	-4.84	1.71e-06	0.000409	-0.23	-0.22	Serum metabolite levels;	chr11:118689172	chr11:118791254~118793137:+
LUAD	cis	rs12745968	0.587	rs1034218	ENSG00000223787.2	RP4-593M8.1	-4.84	1.71e-06	0.000409	-0.25	-0.22	Bipolar disorder and schizophrenia;	chr1:92583574	chr1:92580476~92580821:-
LUAD	cis	rs4266290	0.671	rs884474	ENSG00000214846.4	RP11-115L11.1	4.84	1.71e-06	0.000409	0.32	0.22	Parkinson's disease;	chr4:15754647	chr4:15730962~15731627:-
LUAD	cis	rs7777677	0.925	rs2156964	ENSG00000244273.1	PGBD4P1	-4.84	1.71e-06	0.000409	-0.23	-0.22	Alcoholic chronic pancreatitis;	chr7:142664755	chr7:142722358~142722764:+
LUAD	cis	rs1008375	1	rs2315556	ENSG00000249502.1	AC006160.5	-4.84	1.71e-06	0.000409	-0.2	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17669238	chr4:17587467~17614571:-
LUAD	cis	rs1008375	1	rs555	ENSG00000249502.1	AC006160.5	-4.84	1.71e-06	0.000409	-0.2	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17624035	chr4:17587467~17614571:-
LUAD	cis	rs875971	0.522	rs781144	ENSG00000224316.1	RP11-479O9.2	4.84	1.71e-06	0.00041	0.22	0.22	Aortic root size;	chr7:65975357	chr7:65773620~65802067:+
LUAD	cis	rs763121	0.889	rs9610971	ENSG00000228274.3	RP3-508I15.9	-4.84	1.72e-06	0.00041	-0.22	-0.22	Menopause (age at onset);	chr22:38514805	chr22:38667585~38681820:-
LUAD	cis	rs72717009	0.825	rs9427399	ENSG00000225217.1	HSPA7	-4.84	1.72e-06	0.00041	-0.31	-0.22	Rheumatoid arthritis;	chr1:161506743	chr1:161606291~161608217:+
LUAD	cis	rs72717009	0.825	rs7515174	ENSG00000225217.1	HSPA7	-4.84	1.72e-06	0.00041	-0.31	-0.22	Rheumatoid arthritis;	chr1:161507159	chr1:161606291~161608217:+
LUAD	cis	rs72717009	0.825	rs7539468	ENSG00000225217.1	HSPA7	-4.84	1.72e-06	0.00041	-0.31	-0.22	Rheumatoid arthritis;	chr1:161507276	chr1:161606291~161608217:+
LUAD	cis	rs72717009	0.778	rs9427400	ENSG00000225217.1	HSPA7	-4.84	1.72e-06	0.00041	-0.31	-0.22	Rheumatoid arthritis;	chr1:161507414	chr1:161606291~161608217:+
LUAD	cis	rs72717009	0.825	rs6671753	ENSG00000225217.1	HSPA7	-4.84	1.72e-06	0.00041	-0.31	-0.22	Rheumatoid arthritis;	chr1:161508918	chr1:161606291~161608217:+
LUAD	cis	rs4660456	0.597	rs7518568	ENSG00000237899.1	RP4-739H11.3	4.84	1.72e-06	0.00041	0.25	0.22	Platelet count;	chr1:40708508	chr1:40669089~40687588:-
LUAD	cis	rs7210086	0.808	rs4331375	ENSG00000263893.2	CTD-3010D24.3	4.84	1.72e-06	0.00041	0.3	0.22	Ulcerative colitis;	chr17:72643943	chr17:72642731~72644490:+
LUAD	cis	rs6957923	0.934	rs9969137	ENSG00000230658.1	KLHL7-AS1	4.84	1.72e-06	0.00041	0.26	0.22	Height;	chr7:23438669	chr7:23101228~23105703:-
LUAD	cis	rs673078	0.66	rs61946068	ENSG00000275409.1	RP11-131L12.4	-4.84	1.72e-06	0.00041	-0.32	-0.22	Glucose homeostasis traits;	chr12:118305861	chr12:118430147~118430699:+
LUAD	cis	rs11673344	0.704	rs1644710	ENSG00000226686.6	LINC01535	4.84	1.72e-06	0.000411	0.27	0.22	Obesity-related traits;	chr19:36926160	chr19:37251912~37265535:+
LUAD	cis	rs17772222	0.876	rs58655091	ENSG00000258983.2	RP11-507K2.2	4.84	1.72e-06	0.000411	0.26	0.22	Coronary artery calcification;	chr14:88748567	chr14:88499334~88515502:+
LUAD	cis	rs2998286	0.862	rs2790460	ENSG00000254635.4	WAC-AS1	-4.84	1.72e-06	0.000412	-0.26	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28502093	chr10:28522652~28532743:-
LUAD	cis	rs2239547	0.657	rs6445538	ENSG00000242142.1	SERBP1P3	4.84	1.72e-06	0.000412	0.25	0.22	Schizophrenia;	chr3:52840272	chr3:53064283~53065091:-
LUAD	cis	rs58785573	0.624	rs2126526	ENSG00000231160.8	KLF3-AS1	-4.84	1.72e-06	0.000412	-0.21	-0.22	Lymphocyte percentage of white cells;	chr4:38617068	chr4:38612701~38664883:-
LUAD	cis	rs12908161	0.96	rs62019463	ENSG00000259295.5	CSPG4P12	4.84	1.72e-06	0.000412	0.3	0.22	Schizophrenia;	chr15:84744856	chr15:85191438~85213905:+
LUAD	cis	rs875971	0.862	rs9791712	ENSG00000232559.3	GS1-124K5.12	-4.84	1.72e-06	0.000412	-0.26	-0.22	Aortic root size;	chr7:66640176	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs9791713	ENSG00000232559.3	GS1-124K5.12	-4.84	1.72e-06	0.000412	-0.26	-0.22	Aortic root size;	chr7:66640211	chr7:66554588~66576923:-
LUAD	cis	rs17772222	0.874	rs78077739	ENSG00000258983.2	RP11-507K2.2	4.84	1.73e-06	0.000412	0.26	0.22	Coronary artery calcification;	chr14:88741176	chr14:88499334~88515502:+
LUAD	cis	rs2243480	1	rs13247184	ENSG00000164669.11	INTS4P1	4.84	1.73e-06	0.000412	0.39	0.22	Diabetic kidney disease;	chr7:65893941	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs35283677	ENSG00000164669.11	INTS4P1	4.84	1.73e-06	0.000412	0.39	0.22	Diabetic kidney disease;	chr7:65894246	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs35421653	ENSG00000164669.11	INTS4P1	4.84	1.73e-06	0.000412	0.39	0.22	Diabetic kidney disease;	chr7:65898442	chr7:65141225~65234216:+
LUAD	cis	rs2742234	0.59	rs2075912	ENSG00000273008.1	RP11-351D16.3	-4.84	1.73e-06	0.000412	-0.25	-0.22	Hirschsprung disease;	chr10:43126769	chr10:43136824~43138334:-
LUAD	cis	rs4908768	0.501	rs6577492	ENSG00000270282.1	RP5-1115A15.2	4.84	1.73e-06	0.000413	0.24	0.22	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8515005	chr1:8512653~8513021:+
LUAD	cis	rs13256369	0.802	rs11249887	ENSG00000253893.2	FAM85B	-4.84	1.73e-06	0.000413	-0.3	-0.22	Obesity-related traits;	chr8:8704674	chr8:8167819~8226614:-
LUAD	cis	rs13256369	0.755	rs12550057	ENSG00000253893.2	FAM85B	-4.84	1.73e-06	0.000413	-0.3	-0.22	Obesity-related traits;	chr8:8704758	chr8:8167819~8226614:-
LUAD	cis	rs4664293	0.528	rs56027129	ENSG00000226266.5	AC009961.3	4.84	1.73e-06	0.000413	0.3	0.22	Monocyte percentage of white cells;	chr2:159600091	chr2:159670708~159712435:-
LUAD	cis	rs763567	0.904	rs544478	ENSG00000271811.1	RP1-79C4.4	4.84	1.73e-06	0.000413	0.26	0.22	Tonsillectomy;	chr1:170644901	chr1:170667381~170669425:+
LUAD	cis	rs453301	0.624	rs330060	ENSG00000253981.4	ALG1L13P	-4.84	1.73e-06	0.000413	-0.25	-0.22	Joint mobility (Beighton score);	chr8:9233392	chr8:8236003~8244667:-
LUAD	cis	rs889398	0.741	rs2362642	ENSG00000226232.7	RP11-419C5.2	-4.84	1.73e-06	0.000413	-0.19	-0.22	Body mass index;	chr16:69897555	chr16:69976388~69996188:-
LUAD	cis	rs603446	0.967	rs3741301	ENSG00000254851.1	RP11-109L13.1	-4.84	1.73e-06	0.000414	-0.27	-0.22	Triglycerides;	chr11:116760675	chr11:117135528~117138582:+
LUAD	cis	rs507080	0.922	rs533646	ENSG00000278376.1	RP11-158I9.8	-4.84	1.73e-06	0.000414	-0.24	-0.22	Serum metabolite levels;	chr11:118696037	chr11:118791254~118793137:+
LUAD	cis	rs6840360	1	rs6838966	ENSG00000270265.1	RP11-731D1.4	-4.84	1.73e-06	0.000414	-0.22	-0.22	Intelligence (multi-trait analysis);	chr4:151682323	chr4:151333775~151353224:-
LUAD	cis	rs2018683	1	rs160837	ENSG00000228421.2	AC005013.5	4.84	1.74e-06	0.000414	0.24	0.22	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28973116	chr7:28957667~28959345:+
LUAD	cis	rs950169	0.58	rs17532346	ENSG00000259295.5	CSPG4P12	4.84	1.74e-06	0.000414	0.3	0.22	Schizophrenia;	chr15:84628264	chr15:85191438~85213905:+
LUAD	cis	rs8054556	0.647	rs11863174	ENSG00000214725.6	CDIPT-AS1	-4.84	1.74e-06	0.000414	-0.25	-0.22	Autism spectrum disorder or schizophrenia;	chr16:30008054	chr16:29863593~29868053:+
LUAD	cis	rs4789693	0.938	rs12952655	ENSG00000265458.1	RP13-20L14.6	-4.84	1.74e-06	0.000414	-0.29	-0.22	Glucocorticoid-induced osteonecrosis;	chr17:82463263	chr17:82454273~82458521:-
LUAD	cis	rs9322193	0.683	rs113281309	ENSG00000268592.3	RAET1E-AS1	4.84	1.74e-06	0.000414	0.27	0.22	Lung cancer;	chr6:149787289	chr6:149863494~149919507:+
LUAD	cis	rs801193	1	rs11773829	ENSG00000236529.1	RP13-254B10.1	-4.84	1.74e-06	0.000414	-0.22	-0.22	Aortic root size;	chr7:66676087	chr7:65840212~65840596:+
LUAD	cis	rs301901	1	rs158624	ENSG00000250155.1	CTD-2353F22.1	-4.84	1.74e-06	0.000415	-0.22	-0.22	Height;	chr5:36865567	chr5:36666214~36725195:-
LUAD	cis	rs875971	1	rs709597	ENSG00000232559.3	GS1-124K5.12	-4.84	1.74e-06	0.000415	-0.25	-0.22	Aortic root size;	chr7:66360996	chr7:66554588~66576923:-
LUAD	cis	rs375066	0.935	rs4803662	ENSG00000267058.1	RP11-15A1.3	-4.84	1.74e-06	0.000415	-0.24	-0.22	Breast cancer;	chr19:43855412	chr19:43891804~43901805:-
LUAD	cis	rs375066	0.901	rs1050054	ENSG00000267058.1	RP11-15A1.3	-4.84	1.74e-06	0.000415	-0.24	-0.22	Breast cancer;	chr19:43872529	chr19:43891804~43901805:-
LUAD	cis	rs9487094	0.885	rs12524273	ENSG00000260273.1	RP11-425D10.10	4.84	1.74e-06	0.000415	0.3	0.22	Height;	chr6:109395761	chr6:109382795~109383666:+
LUAD	cis	rs1008375	1	rs4698634	ENSG00000249502.1	AC006160.5	4.84	1.74e-06	0.000415	0.2	0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17628569	chr4:17587467~17614571:-
LUAD	cis	rs801193	1	rs6975195	ENSG00000236529.1	RP13-254B10.1	-4.84	1.74e-06	0.000415	-0.22	-0.22	Aortic root size;	chr7:66659787	chr7:65840212~65840596:+
LUAD	cis	rs801193	1	rs3857688	ENSG00000236529.1	RP13-254B10.1	-4.84	1.74e-06	0.000415	-0.22	-0.22	Aortic root size;	chr7:66662819	chr7:65840212~65840596:+
LUAD	cis	rs801193	1	rs2286684	ENSG00000236529.1	RP13-254B10.1	-4.84	1.74e-06	0.000415	-0.22	-0.22	Aortic root size;	chr7:66664843	chr7:65840212~65840596:+
LUAD	cis	rs801193	0.935	rs2286683	ENSG00000236529.1	RP13-254B10.1	-4.84	1.74e-06	0.000415	-0.22	-0.22	Aortic root size;	chr7:66664856	chr7:65840212~65840596:+
LUAD	cis	rs801193	1	rs10274773	ENSG00000236529.1	RP13-254B10.1	-4.84	1.74e-06	0.000415	-0.22	-0.22	Aortic root size;	chr7:66668591	chr7:65840212~65840596:+
LUAD	cis	rs950169	0.84	rs72748702	ENSG00000229212.6	RP11-561C5.4	-4.84	1.74e-06	0.000416	-0.31	-0.22	Schizophrenia;	chr15:84246494	chr15:85205440~85234795:-
LUAD	cis	rs13113518	0.729	rs12641881	ENSG00000223305.1	RN7SKP30	4.84	1.74e-06	0.000416	0.27	0.22	Height;	chr4:55401306	chr4:55540502~55540835:-
LUAD	cis	rs2998286	0.862	rs2807732	ENSG00000254635.4	WAC-AS1	-4.84	1.74e-06	0.000416	-0.26	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28520318	chr10:28522652~28532743:-
LUAD	cis	rs1005277	0.602	rs1831315	ENSG00000263064.2	RP11-291L22.7	4.84	1.74e-06	0.000416	0.24	0.22	Extrinsic epigenetic age acceleration;	chr10:38184425	chr10:38448689~38448949:+
LUAD	cis	rs42490	1	rs218907	ENSG00000251136.7	RP11-37B2.1	-4.84	1.74e-06	0.000416	-0.22	-0.22	Leprosy;	chr8:89728164	chr8:89609409~89757727:-
LUAD	cis	rs7119038	0.509	rs10892260	ENSG00000255239.1	AP002954.6	-4.84	1.74e-06	0.000416	-0.32	-0.22	Sjögren's syndrome;	chr11:118712816	chr11:118688039~118690600:-
LUAD	cis	rs950169	0.881	rs34591918	ENSG00000229212.6	RP11-561C5.4	-4.84	1.74e-06	0.000416	-0.31	-0.22	Schizophrenia;	chr15:84396135	chr15:85205440~85234795:-
LUAD	cis	rs801193	1	rs4717310	ENSG00000237310.1	GS1-124K5.4	4.84	1.74e-06	0.000416	0.23	0.22	Aortic root size;	chr7:66696020	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.66	rs10272357	ENSG00000236529.1	RP13-254B10.1	-4.84	1.74e-06	0.000416	-0.22	-0.22	Aortic root size;	chr7:66598087	chr7:65840212~65840596:+
LUAD	cis	rs13434995	0.842	rs62309759	ENSG00000273257.1	RP11-177J6.1	-4.84	1.75e-06	0.000416	-0.35	-0.22	Adiponectin levels;	chr4:55557826	chr4:55387949~55388271:+
LUAD	cis	rs9322193	0.962	rs9322220	ENSG00000268592.3	RAET1E-AS1	4.84	1.75e-06	0.000416	0.27	0.22	Lung cancer;	chr6:149782897	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.962	rs10214845	ENSG00000268592.3	RAET1E-AS1	4.84	1.75e-06	0.000416	0.27	0.22	Lung cancer;	chr6:149783124	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.962	rs9767122	ENSG00000268592.3	RAET1E-AS1	4.84	1.75e-06	0.000416	0.27	0.22	Lung cancer;	chr6:149783553	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.923	rs1413654	ENSG00000268592.3	RAET1E-AS1	4.84	1.75e-06	0.000416	0.27	0.22	Lung cancer;	chr6:149783956	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.962	rs9688809	ENSG00000268592.3	RAET1E-AS1	4.84	1.75e-06	0.000416	0.27	0.22	Lung cancer;	chr6:149787920	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.962	rs9689242	ENSG00000268592.3	RAET1E-AS1	4.84	1.75e-06	0.000416	0.27	0.22	Lung cancer;	chr6:149787970	chr6:149863494~149919507:+
LUAD	cis	rs9322193	1	rs9767077	ENSG00000268592.3	RAET1E-AS1	4.84	1.75e-06	0.000416	0.27	0.22	Lung cancer;	chr6:149788479	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.923	rs9688938	ENSG00000268592.3	RAET1E-AS1	4.84	1.75e-06	0.000416	0.27	0.22	Lung cancer;	chr6:149788941	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.962	rs9688940	ENSG00000268592.3	RAET1E-AS1	4.84	1.75e-06	0.000416	0.27	0.22	Lung cancer;	chr6:149788977	chr6:149863494~149919507:+
LUAD	cis	rs7811142	0.943	rs3900792	ENSG00000078319.8	PMS2P1	-4.84	1.75e-06	0.000416	-0.25	-0.22	Platelet count;	chr7:100406954	chr7:100320992~100341908:-
LUAD	cis	rs7017914	0.652	rs7841286	ENSG00000223220.1	Y_RNA	4.84	1.75e-06	0.000416	0.25	0.22	Bone mineral density;	chr8:70890908	chr8:70780914~70781008:-
LUAD	cis	rs1501911	0.588	rs819227	ENSG00000248489.1	CTD-2007H13.3	-4.84	1.75e-06	0.000417	-0.26	-0.22	Lung function (FEV1/FVC);	chr5:98994161	chr5:98929171~98995013:+
LUAD	cis	rs4908768	0.501	rs7530745	ENSG00000270282.1	RP5-1115A15.2	4.84	1.75e-06	0.000417	0.24	0.22	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8497631	chr1:8512653~8513021:+
LUAD	cis	rs67340775	0.541	rs200964	ENSG00000219392.1	RP1-265C24.5	-4.84	1.75e-06	0.000417	-0.37	-0.22	Lung cancer in ever smokers;	chr6:27899165	chr6:28115628~28116551:+
LUAD	cis	rs6088590	1	rs6058111	ENSG00000276073.1	RP5-1125A11.7	-4.84	1.75e-06	0.000417	-0.22	-0.22	Coronary artery disease;	chr20:34723195	chr20:33985617~33988989:-
LUAD	cis	rs5769707	0.732	rs135865	ENSG00000235111.1	RP1-29C18.8	-4.84	1.75e-06	0.000417	-0.25	-0.22	Monocyte percentage of white cells;Monocyte count;	chr22:49611181	chr22:49612657~49615716:-
LUAD	cis	rs950169	0.8	rs34302901	ENSG00000229212.6	RP11-561C5.4	-4.84	1.75e-06	0.000417	-0.31	-0.22	Schizophrenia;	chr15:84567712	chr15:85205440~85234795:-
LUAD	cis	rs7615952	0.576	rs2276729	ENSG00000171084.14	FAM86JP	4.84	1.75e-06	0.000417	0.3	0.22	Blood pressure (smoking interaction);	chr3:126107371	chr3:125916620~125930024:+
LUAD	cis	rs643506	0.845	rs2850245	ENSG00000230911.1	PPIHP1	-4.84	1.75e-06	0.000417	-0.27	-0.22	Breast cancer;	chr11:111890014	chr11:112029858~112030367:-
LUAD	cis	rs6723226	0.842	rs2754522	ENSG00000276334.1	AL133243.1	4.84	1.75e-06	0.000417	0.25	0.22	Intelligence (multi-trait analysis);	chr2:32576190	chr2:32521927~32523547:+
LUAD	cis	rs1823913	0.538	rs6731901	ENSG00000227542.1	AC092614.2	4.84	1.75e-06	0.000417	0.28	0.22	Obesity-related traits;	chr2:191353609	chr2:191229165~191246172:-
LUAD	cis	rs6687758	0.687	rs12123928	ENSG00000200033.1	RNU6-403P	4.84	1.75e-06	0.000417	0.29	0.22	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221948533	chr1:221837334~221837437:-
LUAD	cis	rs507080	0.922	rs625513	ENSG00000278376.1	RP11-158I9.8	-4.84	1.75e-06	0.000417	-0.23	-0.22	Serum metabolite levels;	chr11:118685010	chr11:118791254~118793137:+
LUAD	cis	rs507080	0.922	rs514143	ENSG00000278376.1	RP11-158I9.8	-4.84	1.75e-06	0.000417	-0.23	-0.22	Serum metabolite levels;	chr11:118687740	chr11:118791254~118793137:+
LUAD	cis	rs6840258	1	rs72667750	ENSG00000251411.1	RP11-397E7.4	-4.84	1.75e-06	0.000417	-0.29	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87009273	chr4:86913266~86914817:-
LUAD	cis	rs6840258	1	rs56406125	ENSG00000251411.1	RP11-397E7.4	-4.84	1.75e-06	0.000417	-0.29	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87019053	chr4:86913266~86914817:-
LUAD	cis	rs1075265	0.605	rs805418	ENSG00000233266.1	HMGB1P31	4.84	1.75e-06	0.000417	0.27	0.22	Chronotype;Morning vs. evening chronotype;	chr2:53898634	chr2:54051334~54051760:+
LUAD	cis	rs944990	0.557	rs4743927	ENSG00000227603.1	RP11-165J3.6	4.84	1.75e-06	0.000418	0.24	0.22	Body mass index;	chr9:93510364	chr9:93435332~93437121:-
LUAD	cis	rs944990	0.576	rs6479492	ENSG00000227603.1	RP11-165J3.6	4.84	1.75e-06	0.000418	0.24	0.22	Body mass index;	chr9:93513684	chr9:93435332~93437121:-
LUAD	cis	rs950169	0.545	rs4842841	ENSG00000259728.4	LINC00933	4.84	1.75e-06	0.000418	0.33	0.22	Schizophrenia;	chr15:83972373	chr15:84570649~84580175:+
LUAD	cis	rs442309	0.687	rs10995283	ENSG00000238280.1	RP11-436D10.3	-4.84	1.75e-06	0.000418	-0.27	-0.22	Vogt-Koyanagi-Harada syndrome;	chr10:62714628	chr10:62793562~62805887:-
LUAD	cis	rs1799949	1	rs8176133	ENSG00000236383.6	LINC00854	-4.84	1.75e-06	0.000418	-0.18	-0.22	Menopause (age at onset);	chr17:43105441	chr17:43216941~43305976:-
LUAD	cis	rs1667284	0.58	rs4799589	ENSG00000266521.1	RP11-650P15.1	-4.84	1.76e-06	0.000418	-0.25	-0.22	Problematic alcohol use in trauma-exposed individuals;	chr18:31656293	chr18:31496645~31497195:-
LUAD	cis	rs12908161	1	rs12910012	ENSG00000275120.1	RP11-182J1.17	4.84	1.76e-06	0.000419	0.32	0.22	Schizophrenia;	chr15:84755431	chr15:84599434~84606463:-
LUAD	cis	rs12908161	1	rs12899981	ENSG00000275120.1	RP11-182J1.17	4.84	1.76e-06	0.000419	0.32	0.22	Schizophrenia;	chr15:84759142	chr15:84599434~84606463:-
LUAD	cis	rs71636778	0.509	rs17162387	ENSG00000260063.1	RP5-968P14.2	-4.84	1.76e-06	0.000419	-0.36	-0.22	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26966865	chr1:26692132~26694131:-
LUAD	cis	rs801193	1	rs7785213	ENSG00000236529.1	RP13-254B10.1	-4.84	1.76e-06	0.000419	-0.22	-0.22	Aortic root size;	chr7:66673991	chr7:65840212~65840596:+
LUAD	cis	rs910316	1	rs12590452	ENSG00000259138.1	RP11-950C14.7	4.84	1.76e-06	0.000419	0.23	0.22	Height;	chr14:75082053	chr14:75127153~75136930:+
LUAD	cis	rs910316	1	rs1043674	ENSG00000259138.1	RP11-950C14.7	4.84	1.76e-06	0.000419	0.23	0.22	Height;	chr14:75082667	chr14:75127153~75136930:+
LUAD	cis	rs910316	0.967	rs2010678	ENSG00000259138.1	RP11-950C14.7	4.84	1.76e-06	0.000419	0.23	0.22	Height;	chr14:75100475	chr14:75127153~75136930:+
LUAD	cis	rs17772222	0.917	rs1956406	ENSG00000258983.2	RP11-507K2.2	4.84	1.76e-06	0.000419	0.26	0.22	Coronary artery calcification;	chr14:88749711	chr14:88499334~88515502:+
LUAD	cis	rs7819412	0.811	rs2409691	ENSG00000255046.1	RP11-297N6.4	4.84	1.76e-06	0.000419	0.26	0.22	Triglycerides;	chr8:11085766	chr8:11797928~11802568:-
LUAD	cis	rs17508449	0.819	rs79667495	ENSG00000232450.1	RP4-730K3.3	-4.84	1.76e-06	0.000419	-0.37	-0.22	Leprosy;	chr1:113648707	chr1:113698884~113699631:-
LUAD	cis	rs11976180	1	rs13226728	ENSG00000204959.4	ARHGEF34P	4.84	1.76e-06	0.000419	0.27	0.22	Obesity-related traits;	chr7:144049485	chr7:144272445~144286966:-
LUAD	cis	rs10266483	0.739	rs679966	ENSG00000227986.1	TRIM60P18	-4.84	1.76e-06	0.000419	-0.26	-0.22	Response to statin therapy;	chr7:64306688	chr7:64355078~64356199:+
LUAD	cis	rs2348418	0.733	rs7294486	ENSG00000247934.4	RP11-967K21.1	-4.84	1.76e-06	0.000419	-0.24	-0.22	Lung function (FEV1);Lung function (FVC);	chr12:28181989	chr12:28163298~28190738:-
LUAD	cis	rs4664293	0.764	rs10195287	ENSG00000226266.5	AC009961.3	-4.84	1.76e-06	0.000419	-0.29	-0.22	Monocyte percentage of white cells;	chr2:159604967	chr2:159670708~159712435:-
LUAD	cis	rs2976388	0.967	rs2976395	ENSG00000253741.1	CTD-2292P10.4	4.84	1.76e-06	0.00042	0.24	0.22	Urinary tract infection frequency;	chr8:142682332	chr8:142702252~142726973:-
LUAD	cis	rs2976388	1	rs1045547	ENSG00000253741.1	CTD-2292P10.4	4.84	1.76e-06	0.00042	0.24	0.22	Urinary tract infection frequency;	chr8:142682339	chr8:142702252~142726973:-
LUAD	cis	rs17772222	0.917	rs61986670	ENSG00000258983.2	RP11-507K2.2	4.84	1.76e-06	0.00042	0.26	0.22	Coronary artery calcification;	chr14:88730875	chr14:88499334~88515502:+
LUAD	cis	rs17772222	0.917	rs61986671	ENSG00000258983.2	RP11-507K2.2	4.84	1.76e-06	0.00042	0.26	0.22	Coronary artery calcification;	chr14:88732917	chr14:88499334~88515502:+
LUAD	cis	rs2281636	0.691	rs11190218	ENSG00000233690.1	EBAG9P1	4.84	1.76e-06	0.00042	0.22	0.22	Obesity-related traits;	chr10:99650305	chr10:99697407~99697949:-
LUAD	cis	rs875971	0.964	rs160635	ENSG00000232559.3	GS1-124K5.12	4.84	1.76e-06	0.00042	0.25	0.22	Aortic root size;	chr7:66063931	chr7:66554588~66576923:-
LUAD	cis	rs2948294	0.588	rs12544596	ENSG00000253981.4	ALG1L13P	4.84	1.76e-06	0.00042	0.26	0.22	Red cell distribution width;	chr8:8258824	chr8:8236003~8244667:-
LUAD	cis	rs7119	0.717	rs8032405	ENSG00000259362.2	RP11-307C19.1	-4.84	1.76e-06	0.00042	-0.27	-0.22	Type 2 diabetes;	chr15:77533002	chr15:77525540~77534110:+
LUAD	cis	rs6102185	0.55	rs6124287	ENSG00000229771.2	RP4-644L1.2	-4.84	1.77e-06	0.000421	-0.27	-0.22	IgG glycosylation;	chr20:40888129	chr20:40696499~40698616:-
LUAD	cis	rs1005277	0.579	rs1780130	ENSG00000263064.2	RP11-291L22.7	4.84	1.77e-06	0.000421	0.23	0.22	Extrinsic epigenetic age acceleration;	chr10:38196450	chr10:38448689~38448949:+
LUAD	cis	rs17772222	0.74	rs61975276	ENSG00000258789.1	RP11-507K2.3	-4.84	1.77e-06	0.000421	-0.28	-0.22	Coronary artery calcification;	chr14:88511193	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.74	rs61975277	ENSG00000258789.1	RP11-507K2.3	-4.84	1.77e-06	0.000421	-0.28	-0.22	Coronary artery calcification;	chr14:88511202	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.74	rs61984675	ENSG00000258789.1	RP11-507K2.3	-4.84	1.77e-06	0.000421	-0.28	-0.22	Coronary artery calcification;	chr14:88511236	chr14:88551597~88552493:+
LUAD	cis	rs6840360	1	rs4696109	ENSG00000270265.1	RP11-731D1.4	-4.84	1.77e-06	0.000421	-0.22	-0.22	Intelligence (multi-trait analysis);	chr4:151747633	chr4:151333775~151353224:-
LUAD	cis	rs877356	0.831	rs17169187	ENSG00000250378.1	RP11-119J18.1	-4.84	1.77e-06	0.000421	-0.39	-0.22	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (dichotomous);	chr5:135828069	chr5:135812667~135826582:+
LUAD	cis	rs17684571	0.872	rs16888135	ENSG00000231441.1	RP11-472M19.2	4.84	1.77e-06	0.000421	0.3	0.22	Schizophrenia;	chr6:56734969	chr6:56844002~56864078:+
LUAD	cis	rs17711722	0.701	rs781145	ENSG00000224316.1	RP11-479O9.2	4.84	1.77e-06	0.000421	0.22	0.22	Calcium levels;	chr7:65975383	chr7:65773620~65802067:+
LUAD	cis	rs2032366	0.63	rs1894094	ENSG00000267279.1	RP11-879F14.2	-4.84	1.77e-06	0.000421	-0.28	-0.22	Obesity-related traits;	chr18:61606390	chr18:61585746~61606916:-
LUAD	cis	rs5758659	0.967	rs5751250	ENSG00000182057.4	OGFRP1	4.84	1.77e-06	0.000421	0.26	0.22	Cognitive function;	chr22:42243639	chr22:42269753~42275196:+
LUAD	cis	rs3750965	1	rs7950657	ENSG00000260895.1	RP11-554A11.7	4.84	1.77e-06	0.000421	0.25	0.22	Hair color;	chr11:69067363	chr11:69103493~69109094:+
LUAD	cis	rs1113500	0.58	rs1781058	ENSG00000226822.1	RP11-356N1.2	4.84	1.77e-06	0.000422	0.26	0.22	Growth-regulated protein alpha levels;	chr1:108021437	chr1:108071482~108074519:+
LUAD	cis	rs62432291	0.681	rs365045	ENSG00000235086.1	FNDC1-IT1	4.84	1.77e-06	0.000422	0.36	0.22	Joint mobility (Beighton score);	chr6:159211218	chr6:159240786~159243329:+
LUAD	cis	rs2562456	0.752	rs279809	ENSG00000268081.1	RP11-678G14.2	4.84	1.77e-06	0.000422	0.35	0.22	Pain;	chr19:21284729	chr19:21554640~21569237:-
LUAD	cis	rs11673344	0.704	rs1726719	ENSG00000226686.6	LINC01535	4.84	1.77e-06	0.000422	0.27	0.22	Obesity-related traits;	chr19:36927130	chr19:37251912~37265535:+
LUAD	cis	rs7017914	0.652	rs3098865	ENSG00000223220.1	Y_RNA	4.84	1.77e-06	0.000422	0.25	0.22	Bone mineral density;	chr8:71003749	chr8:70780914~70781008:-
LUAD	cis	rs516805	0.781	rs560717	ENSG00000279453.1	RP3-425C14.4	-4.84	1.77e-06	0.000422	-0.29	-0.22	Lymphocyte counts;	chr6:122482909	chr6:122436789~122439223:-
LUAD	cis	rs2239547	0.522	rs6792578	ENSG00000242142.1	SERBP1P3	4.84	1.77e-06	0.000422	0.25	0.22	Schizophrenia;	chr3:52970588	chr3:53064283~53065091:-
LUAD	cis	rs7017914	0.652	rs11991584	ENSG00000223220.1	Y_RNA	4.84	1.77e-06	0.000422	0.25	0.22	Bone mineral density;	chr8:70859112	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs11991605	ENSG00000223220.1	Y_RNA	4.84	1.77e-06	0.000422	0.25	0.22	Bone mineral density;	chr8:70859117	chr8:70780914~70781008:-
LUAD	cis	rs2286492	1	rs2286492	ENSG00000228649.7	AC005682.5	4.84	1.78e-06	0.000422	0.38	0.22	Bipolar disorder;	chr7:22945391	chr7:22854178~22861579:+
LUAD	cis	rs172166	0.561	rs149973	ENSG00000219392.1	RP1-265C24.5	-4.84	1.78e-06	0.000422	-0.26	-0.22	Cardiac Troponin-T levels;	chr6:28015835	chr6:28115628~28116551:+
LUAD	cis	rs172166	0.561	rs149974	ENSG00000219392.1	RP1-265C24.5	-4.84	1.78e-06	0.000422	-0.26	-0.22	Cardiac Troponin-T levels;	chr6:28017318	chr6:28115628~28116551:+
LUAD	cis	rs801193	0.548	rs6975044	ENSG00000232559.3	GS1-124K5.12	4.84	1.78e-06	0.000423	0.26	0.22	Aortic root size;	chr7:66762495	chr7:66554588~66576923:-
LUAD	cis	rs2243480	0.901	rs313808	ENSG00000226002.1	RP11-460N20.5	-4.84	1.78e-06	0.000423	-0.36	-0.22	Diabetic kidney disease;	chr7:66034886	chr7:65084103~65100232:+
LUAD	cis	rs7772486	0.719	rs7753770	ENSG00000235652.6	RP11-545I5.3	-4.84	1.78e-06	0.000423	-0.22	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145745025	chr6:145799409~145886585:+
LUAD	cis	rs2243480	1	rs781150	ENSG00000164669.11	INTS4P1	4.84	1.78e-06	0.000423	0.39	0.22	Diabetic kidney disease;	chr7:66015986	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs313798	ENSG00000164669.11	INTS4P1	4.84	1.78e-06	0.000423	0.39	0.22	Diabetic kidney disease;	chr7:66028044	chr7:65141225~65234216:+
LUAD	cis	rs950169	0.84	rs2896002	ENSG00000229212.6	RP11-561C5.4	-4.84	1.78e-06	0.000423	-0.31	-0.22	Schizophrenia;	chr15:84390423	chr15:85205440~85234795:-
LUAD	cis	rs1008375	0.932	rs9291660	ENSG00000249502.1	AC006160.5	-4.84	1.78e-06	0.000423	-0.21	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17661791	chr4:17587467~17614571:-
LUAD	cis	rs1008375	1	rs1008374	ENSG00000249502.1	AC006160.5	-4.84	1.78e-06	0.000423	-0.2	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17681596	chr4:17587467~17614571:-
LUAD	cis	rs7138803	0.51	rs2336448	ENSG00000257464.1	RP11-161H23.8	-4.84	1.78e-06	0.000423	-0.21	-0.22	Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index;	chr12:49818845	chr12:49442424~49442652:-
LUAD	cis	rs6840258	1	rs767315	ENSG00000251411.1	RP11-397E7.4	-4.84	1.78e-06	0.000423	-0.28	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87039283	chr4:86913266~86914817:-
LUAD	cis	rs11971779	0.715	rs55714903	ENSG00000273391.1	RP11-634H22.1	4.84	1.78e-06	0.000424	0.23	0.22	Diisocyanate-induced asthma;	chr7:139389844	chr7:139359032~139359566:-
LUAD	cis	rs11157436	0.846	rs12435431	ENSG00000211813.2	TRAV34	4.84	1.78e-06	0.000424	0.26	0.22	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22230301	chr14:22207522~22208129:+
LUAD	cis	rs9650657	0.53	rs6982381	ENSG00000255046.1	RP11-297N6.4	4.84	1.78e-06	0.000424	0.26	0.22	Neuroticism;	chr8:11094990	chr8:11797928~11802568:-
LUAD	cis	rs3893377	0.848	rs11933202	ENSG00000214846.4	RP11-115L11.1	4.84	1.78e-06	0.000424	0.32	0.22	Current cigarettes per day in chronic obstructive pulmonary disease;	chr4:15742905	chr4:15730962~15731627:-
LUAD	cis	rs2439831	0.681	rs484846	ENSG00000249839.1	AC011330.5	-4.84	1.78e-06	0.000424	-0.38	-0.22	Lung cancer in ever smokers;	chr15:43308605	chr15:43663654~43684339:-
LUAD	cis	rs7829975	0.714	rs60315134	ENSG00000173295.6	FAM86B3P	4.84	1.78e-06	0.000424	0.23	0.22	Mood instability;	chr8:8813089	chr8:8228595~8244865:+
LUAD	cis	rs7017914	0.652	rs34768553	ENSG00000223220.1	Y_RNA	4.84	1.78e-06	0.000424	0.25	0.22	Bone mineral density;	chr8:70864755	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs35343840	ENSG00000223220.1	Y_RNA	4.84	1.78e-06	0.000424	0.25	0.22	Bone mineral density;	chr8:70865160	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.628	rs7015825	ENSG00000223220.1	Y_RNA	4.84	1.78e-06	0.000424	0.25	0.22	Bone mineral density;	chr8:70866438	chr8:70780914~70781008:-
LUAD	cis	rs4722166	0.704	rs4321884	ENSG00000179428.2	AC073072.5	-4.84	1.78e-06	0.000424	-0.24	-0.22	Lung cancer;	chr7:22701840	chr7:22725395~22727620:-
LUAD	cis	rs763567	0.967	rs473832	ENSG00000271811.1	RP1-79C4.4	4.84	1.78e-06	0.000424	0.26	0.22	Tonsillectomy;	chr1:170640049	chr1:170667381~170669425:+
LUAD	cis	rs948562	0.519	rs12288500	ENSG00000280010.1	AP001350.4	4.84	1.78e-06	0.000424	0.3	0.22	Lymphoma;	chr11:58292412	chr11:58627435~58628528:+
LUAD	cis	rs950169	0.58	rs11634320	ENSG00000259295.5	CSPG4P12	-4.84	1.79e-06	0.000425	-0.3	-0.22	Schizophrenia;	chr15:84628952	chr15:85191438~85213905:+
LUAD	cis	rs9322193	0.923	rs9480031	ENSG00000268592.3	RAET1E-AS1	4.84	1.79e-06	0.000425	0.26	0.22	Lung cancer;	chr6:149758875	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.923	rs10872649	ENSG00000268592.3	RAET1E-AS1	4.84	1.79e-06	0.000425	0.26	0.22	Lung cancer;	chr6:149759454	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.923	rs10872650	ENSG00000268592.3	RAET1E-AS1	4.84	1.79e-06	0.000425	0.26	0.22	Lung cancer;	chr6:149760959	chr6:149863494~149919507:+
LUAD	cis	rs6840258	1	rs17604480	ENSG00000251411.1	RP11-397E7.4	-4.84	1.79e-06	0.000425	-0.28	-0.22	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87048975	chr4:86913266~86914817:-
LUAD	cis	rs17684571	0.872	rs3002003	ENSG00000231441.1	RP11-472M19.2	4.84	1.79e-06	0.000425	0.29	0.22	Schizophrenia;	chr6:56743274	chr6:56844002~56864078:+
LUAD	cis	rs507080	0.922	rs4938524	ENSG00000278376.1	RP11-158I9.8	-4.84	1.79e-06	0.000425	-0.23	-0.22	Serum metabolite levels;	chr11:118681365	chr11:118791254~118793137:+
LUAD	cis	rs858239	0.899	rs858271	ENSG00000226816.2	AC005082.12	4.84	1.79e-06	0.000425	0.28	0.22	Cerebrospinal fluid biomarker levels;	chr7:23238664	chr7:23206013~23208045:+
LUAD	cis	rs2735413	0.599	rs77209133	ENSG00000276007.1	RP11-358L22.3	4.84	1.79e-06	0.000425	0.29	0.22	Systolic blood pressure (alcohol consumption interaction);	chr16:78042827	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.599	rs79414963	ENSG00000276007.1	RP11-358L22.3	4.84	1.79e-06	0.000425	0.29	0.22	Systolic blood pressure (alcohol consumption interaction);	chr16:78043132	chr16:78123243~78124332:+
LUAD	cis	rs14027	0.921	rs1433951	ENSG00000279347.1	RP11-85I17.2	-4.84	1.79e-06	0.000425	-0.19	-0.22	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119777362	chr8:119838736~119840385:-
LUAD	cis	rs5769707	0.609	rs2007024	ENSG00000235111.1	RP1-29C18.8	-4.84	1.79e-06	0.000425	-0.25	-0.22	Monocyte percentage of white cells;Monocyte count;	chr22:49595167	chr22:49612657~49615716:-
LUAD	cis	rs11089937	0.597	rs6001072	ENSG00000211638.2	IGLV8-61	-4.84	1.79e-06	0.000425	-0.25	-0.22	Periodontitis (PAL4Q3);	chr22:22133629	chr22:22098700~22099212:+
LUAD	cis	rs8031584	0.652	rs2691683	ENSG00000259845.1	HERC2P10	-4.84	1.79e-06	0.000426	-0.26	-0.22	Huntington's disease progression;	chr15:30842857	chr15:30815271~30844153:+
LUAD	cis	rs7208859	0.614	rs216412	ENSG00000280069.1	CTD-2349P21.3	4.83	1.8e-06	0.000427	0.25	0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576376	chr17:30738182~30740275:+
LUAD	cis	rs7621025	0.63	rs1681816	ENSG00000239213.4	NCK1-AS1	-4.83	1.8e-06	0.000427	-0.27	-0.22	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136755920	chr3:136841726~136862054:-
LUAD	cis	rs2252586	0.916	rs7793272	ENSG00000176826.14	FKBP9P1	-4.83	1.8e-06	0.000427	-0.29	-0.22	Glioma;	chr7:54898366	chr7:55681074~55713252:-
LUAD	cis	rs57502260	0.79	rs7129320	ENSG00000212093.1	AP000807.1	4.83	1.8e-06	0.000427	0.29	0.22	Total body bone mineral density (age 45-60);	chr11:68620752	chr11:68506083~68506166:-
LUAD	cis	rs3096299	0.9	rs2911258	ENSG00000182376.2	RP5-1142A6.8	4.83	1.8e-06	0.000427	0.22	0.22	Multiple myeloma (IgH translocation);	chr16:89414352	chr16:88742767~88745748:+
LUAD	cis	rs17772222	0.917	rs8018755	ENSG00000258983.2	RP11-507K2.2	4.83	1.8e-06	0.000427	0.26	0.22	Coronary artery calcification;	chr14:88714249	chr14:88499334~88515502:+
LUAD	cis	rs17772222	0.917	rs8018630	ENSG00000258983.2	RP11-507K2.2	4.83	1.8e-06	0.000427	0.26	0.22	Coronary artery calcification;	chr14:88714250	chr14:88499334~88515502:+
LUAD	cis	rs17772222	0.917	rs8020072	ENSG00000258983.2	RP11-507K2.2	4.83	1.8e-06	0.000427	0.26	0.22	Coronary artery calcification;	chr14:88714332	chr14:88499334~88515502:+
LUAD	cis	rs17772222	0.917	rs12589982	ENSG00000258983.2	RP11-507K2.2	4.83	1.8e-06	0.000427	0.26	0.22	Coronary artery calcification;	chr14:88716861	chr14:88499334~88515502:+
LUAD	cis	rs1555322	0.53	rs6058224	ENSG00000126005.14	MMP24-AS1	-4.83	1.8e-06	0.000428	-0.29	-0.22	Attention deficit hyperactivity disorder;	chr20:35293971	chr20:35216462~35278131:-
LUAD	cis	rs7017914	0.677	rs67781030	ENSG00000223220.1	Y_RNA	4.83	1.8e-06	0.000428	0.25	0.22	Bone mineral density;	chr8:70836619	chr8:70780914~70781008:-
LUAD	cis	rs9910055	0.659	rs721769	ENSG00000267080.4	ASB16-AS1	-4.83	1.8e-06	0.000428	-0.2	-0.22	Total body bone mineral density;	chr17:44184220	chr17:44175973~44186717:-
LUAD	cis	rs7181230	1	rs7181230	ENSG00000275636.1	RP11-521C20.5	4.83	1.8e-06	0.000428	0.26	0.22	Dehydroepiandrosterone sulphate levels;	chr15:40068540	chr15:40078892~40079347:+
LUAD	cis	rs800160	0.777	rs11600971	ENSG00000236264.4	RPL26P30	-4.83	1.8e-06	0.000428	-0.28	-0.22	Bacteremia;	chr11:2322211	chr11:2335132~2335776:-
LUAD	cis	rs9601248	0.756	rs2146592	ENSG00000227354.5	RBM26-AS1	-4.83	1.8e-06	0.000428	-0.24	-0.22	Major depressive disorder;	chr13:79606146	chr13:79406309~79424328:+
LUAD	cis	rs858239	0.6	rs6461691	ENSG00000230042.1	AK3P3	-4.83	1.8e-06	0.000429	-0.27	-0.22	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23129178~23129841:+
LUAD	cis	rs6957923	0.935	rs13226524	ENSG00000230658.1	KLHL7-AS1	4.83	1.81e-06	0.000429	0.26	0.22	Height;	chr7:23442258	chr7:23101228~23105703:-
LUAD	cis	rs7829975	0.742	rs1533059	ENSG00000253981.4	ALG1L13P	-4.83	1.81e-06	0.000429	-0.25	-0.22	Mood instability;	chr8:8827443	chr8:8236003~8244667:-
LUAD	cis	rs6142102	0.961	rs6120487	ENSG00000275784.1	RP5-1125A11.6	-4.83	1.81e-06	0.000429	-0.24	-0.22	Skin pigmentation;	chr20:34034802	chr20:33989480~33991818:-
LUAD	cis	rs10050311	0.698	rs4693780	ENSG00000251411.1	RP11-397E7.4	4.83	1.81e-06	0.000429	0.29	0.22	Insulin-related traits;	chr4:86720066	chr4:86913266~86914817:-
LUAD	cis	rs74233809	1	rs11191453	ENSG00000213277.3	MARCKSL1P1	4.83	1.81e-06	0.00043	0.36	0.22	Birth weight;	chr10:102900095	chr10:103175554~103176094:+
LUAD	cis	rs801193	1	rs3800812	ENSG00000236529.1	RP13-254B10.1	4.83	1.81e-06	0.00043	0.22	0.22	Aortic root size;	chr7:66758474	chr7:65840212~65840596:+
LUAD	cis	rs801193	1	rs4279493	ENSG00000236529.1	RP13-254B10.1	4.83	1.81e-06	0.00043	0.22	0.22	Aortic root size;	chr7:66761633	chr7:65840212~65840596:+
LUAD	cis	rs1008375	1	rs3933453	ENSG00000249502.1	AC006160.5	-4.83	1.81e-06	0.00043	-0.2	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17634696	chr4:17587467~17614571:-
LUAD	cis	rs9287719	0.601	rs12692412	ENSG00000243819.4	RN7SL832P	-4.83	1.81e-06	0.00043	-0.23	-0.22	Prostate cancer;	chr2:10579928	chr2:10690344~10692099:+
LUAD	cis	rs7208859	0.623	rs7219712	ENSG00000263603.1	CTD-2349P21.5	-4.83	1.81e-06	0.00043	-0.37	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753552	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.573	rs8078656	ENSG00000263603.1	CTD-2349P21.5	-4.83	1.81e-06	0.00043	-0.37	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753953	chr17:30729469~30731202:+
LUAD	cis	rs950169	0.887	rs35986397	ENSG00000229212.6	RP11-561C5.4	-4.83	1.81e-06	0.00043	-0.31	-0.22	Schizophrenia;	chr15:84400409	chr15:85205440~85234795:-
LUAD	cis	rs301901	0.772	rs6451313	ENSG00000250155.1	CTD-2353F22.1	-4.83	1.81e-06	0.00043	-0.23	-0.22	Height;	chr5:37182208	chr5:36666214~36725195:-
LUAD	cis	rs7636293	0.897	rs7623428	ENSG00000270773.1	RP13-685P2.7	4.83	1.81e-06	0.00043	0.26	0.22	Height;	chr3:129330050	chr3:129345411~129346164:+
LUAD	cis	rs916888	0.61	rs199453	ENSG00000261575.2	RP11-259G18.1	4.83	1.81e-06	0.00043	0.29	0.22	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46267037~46268694:+
LUAD	cis	rs34375054	0.526	rs2343638	ENSG00000279233.1	RP11-158L12.4	4.83	1.81e-06	0.000431	0.19	0.22	Post bronchodilator FEV1/FVC ratio;	chr12:125192576	chr12:125138245~125141711:+
LUAD	cis	rs847577	0.715	rs12665986	ENSG00000272950.1	RP11-307C18.1	-4.83	1.81e-06	0.000431	-0.28	-0.22	Breast cancer;	chr7:98090364	chr7:98322853~98323430:+
LUAD	cis	rs6701713	0.959	rs4844610	ENSG00000274245.1	RP11-357P18.2	-4.83	1.81e-06	0.000431	-0.36	-0.22	Alzheimer's disease (late onset);	chr1:207629207	chr1:207372559~207373252:+
LUAD	cis	rs957448	0.561	rs4735302	ENSG00000253704.1	RP11-267M23.4	-4.83	1.81e-06	0.000431	-0.25	-0.22	Nonsyndromic cleft lip with cleft palate;	chr8:94604752	chr8:94553722~94569745:+
LUAD	cis	rs4845875	0.53	rs6667720	ENSG00000242349.4	NPPA-AS1	-4.83	1.81e-06	0.000431	-0.23	-0.22	Midregional pro atrial natriuretic peptide levels;	chr1:11771558	chr1:11841017~11848079:+
LUAD	cis	rs301901	1	rs296962	ENSG00000250155.1	CTD-2353F22.1	-4.83	1.81e-06	0.000431	-0.22	-0.22	Height;	chr5:36990381	chr5:36666214~36725195:-
LUAD	cis	rs1799949	0.965	rs11650132	ENSG00000236383.6	LINC00854	-4.83	1.81e-06	0.000431	-0.18	-0.22	Menopause (age at onset);	chr17:43174070	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs11654731	ENSG00000236383.6	LINC00854	-4.83	1.81e-06	0.000431	-0.18	-0.22	Menopause (age at onset);	chr17:43174923	chr17:43216941~43305976:-
LUAD	cis	rs6496044	0.547	rs8039929	ENSG00000259295.5	CSPG4P12	4.83	1.82e-06	0.000431	0.25	0.22	Interstitial lung disease;	chr15:85537731	chr15:85191438~85213905:+
LUAD	cis	rs1555322	0.53	rs2425047	ENSG00000126005.14	MMP24-AS1	4.83	1.82e-06	0.000431	0.29	0.22	Attention deficit hyperactivity disorder;	chr20:35283872	chr20:35216462~35278131:-
LUAD	cis	rs113835537	0.935	rs75863187	ENSG00000255517.5	CTD-3074O7.5	-4.83	1.82e-06	0.000432	-0.32	-0.22	Airway imaging phenotypes;	chr11:66675990	chr11:66473490~66480233:-
LUAD	cis	rs5769707	0.568	rs2011097	ENSG00000235111.1	RP1-29C18.8	-4.83	1.82e-06	0.000432	-0.26	-0.22	Monocyte percentage of white cells;Monocyte count;	chr22:49624421	chr22:49612657~49615716:-
LUAD	cis	rs2243480	1	rs937108	ENSG00000164669.11	INTS4P1	4.83	1.82e-06	0.000432	0.38	0.22	Diabetic kidney disease;	chr7:65963465	chr7:65141225~65234216:+
LUAD	cis	rs7017914	0.677	rs7010889	ENSG00000223220.1	Y_RNA	4.83	1.82e-06	0.000432	0.24	0.22	Bone mineral density;	chr8:70741136	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.69	rs7016334	ENSG00000223220.1	Y_RNA	4.83	1.82e-06	0.000432	0.24	0.22	Bone mineral density;	chr8:70742171	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.714	rs28376252	ENSG00000223220.1	Y_RNA	4.83	1.82e-06	0.000432	0.24	0.22	Bone mineral density;	chr8:70747652	chr8:70780914~70781008:-
LUAD	cis	rs55823223	0.618	rs11867339	ENSG00000267801.1	RP11-552F3.9	4.83	1.82e-06	0.000432	0.25	0.22	Psoriasis;	chr17:75866012	chr17:75876372~75879546:+
LUAD	cis	rs453301	0.624	rs330056	ENSG00000253981.4	ALG1L13P	-4.83	1.82e-06	0.000432	-0.25	-0.22	Joint mobility (Beighton score);	chr8:9232185	chr8:8236003~8244667:-
LUAD	cis	rs6142102	0.812	rs4911375	ENSG00000275784.1	RP5-1125A11.6	-4.83	1.82e-06	0.000432	-0.24	-0.22	Skin pigmentation;	chr20:33928216	chr20:33989480~33991818:-
LUAD	cis	rs910316	1	rs2300601	ENSG00000279594.1	RP11-950C14.10	4.83	1.82e-06	0.000433	0.25	0.22	Height;	chr14:75172868	chr14:75011269~75012851:-
LUAD	cis	rs7017914	0.652	rs1822651	ENSG00000223220.1	Y_RNA	4.83	1.82e-06	0.000433	0.25	0.22	Bone mineral density;	chr8:70824426	chr8:70780914~70781008:-
LUAD	cis	rs8177876	0.915	rs1563072	ENSG00000261061.1	RP11-303E16.2	4.83	1.82e-06	0.000433	0.36	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81095811	chr16:81030770~81031485:+
LUAD	cis	rs8177876	0.841	rs874437	ENSG00000261061.1	RP11-303E16.2	4.83	1.82e-06	0.000433	0.36	0.22	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81095890	chr16:81030770~81031485:+
LUAD	cis	rs950169	0.84	rs62019457	ENSG00000229212.6	RP11-561C5.4	-4.83	1.82e-06	0.000433	-0.31	-0.22	Schizophrenia;	chr15:84558911	chr15:85205440~85234795:-
LUAD	cis	rs8127691	0.904	rs7282490	ENSG00000237604.1	AP001056.1	4.83	1.82e-06	0.000433	0.25	0.22	Inflammatory bowel disease;	chr21:44195858	chr21:44175489~44176453:+
LUAD	cis	rs6142102	0.961	rs2300204	ENSG00000275784.1	RP5-1125A11.6	-4.83	1.82e-06	0.000433	-0.24	-0.22	Skin pigmentation;	chr20:34000967	chr20:33989480~33991818:-
LUAD	cis	rs2998286	0.815	rs332132	ENSG00000254635.4	WAC-AS1	-4.83	1.82e-06	0.000433	-0.28	-0.22	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28565185	chr10:28522652~28532743:-
LUAD	cis	rs11673344	0.562	rs256740	ENSG00000226686.6	LINC01535	-4.83	1.83e-06	0.000433	-0.27	-0.22	Obesity-related traits;	chr19:37365451	chr19:37251912~37265535:+
LUAD	cis	rs42490	0.51	rs218885	ENSG00000251136.7	RP11-37B2.1	4.83	1.83e-06	0.000433	0.21	0.22	Leprosy;	chr8:89678313	chr8:89609409~89757727:-
LUAD	cis	rs875971	0.83	rs427575	ENSG00000237310.1	GS1-124K5.4	4.83	1.83e-06	0.000434	0.23	0.22	Aortic root size;	chr7:66054232	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.8	rs427557	ENSG00000237310.1	GS1-124K5.4	4.83	1.83e-06	0.000434	0.23	0.22	Aortic root size;	chr7:66054263	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.83	rs587360	ENSG00000237310.1	GS1-124K5.4	4.83	1.83e-06	0.000434	0.23	0.22	Aortic root size;	chr7:66057711	chr7:66493706~66495474:+
LUAD	cis	rs673078	0.66	rs12229607	ENSG00000275409.1	RP11-131L12.4	-4.83	1.83e-06	0.000434	-0.29	-0.22	Glucose homeostasis traits;	chr12:118338333	chr12:118430147~118430699:+
LUAD	cis	rs7829975	0.591	rs12677543	ENSG00000173295.6	FAM86B3P	4.83	1.83e-06	0.000434	0.23	0.22	Mood instability;	chr8:8786764	chr8:8228595~8244865:+
LUAD	cis	rs875971	1	rs1565531	ENSG00000232559.3	GS1-124K5.12	-4.83	1.83e-06	0.000434	-0.25	-0.22	Aortic root size;	chr7:66198126	chr7:66554588~66576923:-
LUAD	cis	rs3822625	1	rs79953845	ENSG00000271828.1	CTD-2310F14.1	4.83	1.83e-06	0.000434	0.49	0.22	Breast cancer (early onset);	chr5:56828967	chr5:56927874~56929573:+
LUAD	cis	rs3822625	1	rs56822906	ENSG00000271828.1	CTD-2310F14.1	4.83	1.83e-06	0.000434	0.49	0.22	Breast cancer (early onset);	chr5:56870087	chr5:56927874~56929573:+
LUAD	cis	rs3822625	1	rs9686160	ENSG00000271828.1	CTD-2310F14.1	4.83	1.83e-06	0.000434	0.49	0.22	Breast cancer (early onset);	chr5:56876174	chr5:56927874~56929573:+
LUAD	cis	rs3822625	1	rs9687226	ENSG00000271828.1	CTD-2310F14.1	4.83	1.83e-06	0.000434	0.49	0.22	Breast cancer (early onset);	chr5:56880619	chr5:56927874~56929573:+
LUAD	cis	rs3822625	1	rs16877026	ENSG00000271828.1	CTD-2310F14.1	4.83	1.83e-06	0.000434	0.49	0.22	Breast cancer (early onset);	chr5:56889099	chr5:56927874~56929573:+
LUAD	cis	rs3822625	1	rs76058858	ENSG00000271828.1	CTD-2310F14.1	4.83	1.83e-06	0.000434	0.49	0.22	Breast cancer (early onset);	chr5:56890612	chr5:56927874~56929573:+
LUAD	cis	rs7017914	0.652	rs1156955	ENSG00000223220.1	Y_RNA	4.83	1.83e-06	0.000434	0.25	0.22	Bone mineral density;	chr8:70842724	chr8:70780914~70781008:-
LUAD	cis	rs6604026	0.522	rs12756786	ENSG00000223787.2	RP4-593M8.1	4.83	1.83e-06	0.000434	0.29	0.22	Multiple sclerosis;	chr1:92579398	chr1:92580476~92580821:-
LUAD	cis	rs4660214	0.666	rs1775656	ENSG00000228060.1	RP11-69E11.8	-4.83	1.83e-06	0.000434	-0.19	-0.22	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39445329	chr1:39565160~39573203:+
LUAD	cis	rs831571	0.519	rs13059603	ENSG00000280620.1	SCAANT1	-4.83	1.83e-06	0.000434	-0.25	-0.22	Type 2 diabetes;	chr3:63841705	chr3:63911518~63911772:-
LUAD	cis	rs9473147	0.516	rs6904764	ENSG00000270761.1	RP11-385F7.1	-4.83	1.83e-06	0.000434	-0.25	-0.22	Platelet distribution width;Mean platelet volume;	chr6:47535761	chr6:47477243~47477572:-
LUAD	cis	rs9369695	0.883	rs9473128	ENSG00000270761.1	RP11-385F7.1	-4.83	1.83e-06	0.000434	-0.25	-0.22	Reticulocyte count;	chr6:47537274	chr6:47477243~47477572:-
LUAD	cis	rs7772486	0.655	rs2142981	ENSG00000235652.6	RP11-545I5.3	-4.83	1.83e-06	0.000434	-0.22	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145750559	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.72	rs6570713	ENSG00000235652.6	RP11-545I5.3	-4.83	1.83e-06	0.000434	-0.22	-0.22	Lobe attachment (rater-scored or self-reported);	chr6:145753949	chr6:145799409~145886585:+
LUAD	cis	rs5769707	0.632	rs135877	ENSG00000235111.1	RP1-29C18.8	-4.83	1.83e-06	0.000435	-0.26	-0.22	Monocyte percentage of white cells;Monocyte count;	chr22:49620354	chr22:49612657~49615716:-
LUAD	cis	rs5758659	0.935	rs134879	ENSG00000227370.1	RP4-669P10.19	-4.83	1.83e-06	0.000435	-0.19	-0.22	Cognitive function;	chr22:42268195	chr22:42132543~42132998:+
LUAD	cis	rs4948102	0.642	rs4948104	ENSG00000273720.1	RP11-613E4.4	-4.83	1.83e-06	0.000435	-0.27	-0.22	Plasma homocysteine levels (post-methionine load test);	chr7:56074826	chr7:55743073~55743457:+
LUAD	cis	rs2337406	0.866	rs8003852	ENSG00000211972.2	IGHV3-66	4.83	1.83e-06	0.000435	0.23	0.22	Alzheimer's disease (late onset);	chr14:106776648	chr14:106675017~106675544:-
LUAD	cis	rs2337406	0.866	rs988131	ENSG00000211972.2	IGHV3-66	4.83	1.83e-06	0.000435	0.23	0.22	Alzheimer's disease (late onset);	chr14:106776833	chr14:106675017~106675544:-
LUAD	cis	rs2337406	0.866	rs8005518	ENSG00000211972.2	IGHV3-66	4.83	1.83e-06	0.000435	0.23	0.22	Alzheimer's disease (late onset);	chr14:106777009	chr14:106675017~106675544:-
LUAD	cis	rs2337406	0.866	rs57684263	ENSG00000211972.2	IGHV3-66	4.83	1.83e-06	0.000435	0.23	0.22	Alzheimer's disease (late onset);	chr14:106777263	chr14:106675017~106675544:-
LUAD	cis	rs2337406	0.866	rs7152809	ENSG00000211972.2	IGHV3-66	4.83	1.83e-06	0.000435	0.23	0.22	Alzheimer's disease (late onset);	chr14:106778385	chr14:106675017~106675544:-
LUAD	cis	rs2337406	0.866	rs7152832	ENSG00000211972.2	IGHV3-66	4.83	1.83e-06	0.000435	0.23	0.22	Alzheimer's disease (late onset);	chr14:106778427	chr14:106675017~106675544:-
LUAD	cis	rs2337406	0.5	rs7152934	ENSG00000211972.2	IGHV3-66	4.83	1.83e-06	0.000435	0.23	0.22	Alzheimer's disease (late onset);	chr14:106778702	chr14:106675017~106675544:-
LUAD	cis	rs2337406	0.789	rs12050392	ENSG00000211972.2	IGHV3-66	4.83	1.83e-06	0.000435	0.23	0.22	Alzheimer's disease (late onset);	chr14:106779073	chr14:106675017~106675544:-
LUAD	cis	rs2337406	0.866	rs74092505	ENSG00000211972.2	IGHV3-66	4.83	1.83e-06	0.000435	0.23	0.22	Alzheimer's disease (late onset);	chr14:106779163	chr14:106675017~106675544:-
LUAD	cis	rs2337406	0.789	rs74092507	ENSG00000211972.2	IGHV3-66	4.83	1.83e-06	0.000435	0.23	0.22	Alzheimer's disease (late onset);	chr14:106779174	chr14:106675017~106675544:-
LUAD	cis	rs2337406	0.866	rs74092511	ENSG00000211972.2	IGHV3-66	4.83	1.83e-06	0.000435	0.23	0.22	Alzheimer's disease (late onset);	chr14:106779234	chr14:106675017~106675544:-
LUAD	cis	rs910316	0.523	rs4026175	ENSG00000259138.1	RP11-950C14.7	4.83	1.83e-06	0.000435	0.24	0.22	Height;	chr14:75035537	chr14:75127153~75136930:+
LUAD	cis	rs2554380	0.628	rs4843158	ENSG00000230373.7	GOLGA6L5P	-4.83	1.83e-06	0.000435	-0.23	-0.22	Height;	chr15:83802884	chr15:84507885~84516814:-
LUAD	cis	rs2439831	0.867	rs2927072	ENSG00000249839.1	AC011330.5	-4.83	1.83e-06	0.000435	-0.4	-0.22	Lung cancer in ever smokers;	chr15:43630200	chr15:43663654~43684339:-
LUAD	cis	rs2439831	0.867	rs2920781	ENSG00000249839.1	AC011330.5	-4.83	1.83e-06	0.000435	-0.4	-0.22	Lung cancer in ever smokers;	chr15:43632484	chr15:43663654~43684339:-
LUAD	cis	rs2439831	0.764	rs2447193	ENSG00000249839.1	AC011330.5	-4.83	1.83e-06	0.000435	-0.4	-0.22	Lung cancer in ever smokers;	chr15:43637535	chr15:43663654~43684339:-
LUAD	cis	rs858239	1	rs199348	ENSG00000226816.2	AC005082.12	4.83	1.84e-06	0.000435	0.28	0.22	Cerebrospinal fluid biomarker levels;	chr7:23253479	chr7:23206013~23208045:+
LUAD	cis	rs35160687	0.623	rs1863060	ENSG00000273080.1	RP11-301O19.1	-4.83	1.84e-06	0.000435	-0.24	-0.22	Night sleep phenotypes;	chr2:86284333	chr2:86195590~86196049:+
LUAD	cis	rs910316	0.967	rs2268619	ENSG00000259138.1	RP11-950C14.7	-4.83	1.84e-06	0.000436	-0.23	-0.22	Height;	chr14:75173651	chr14:75127153~75136930:+
LUAD	cis	rs6539288	1	rs6539288	ENSG00000260329.1	RP11-412D9.4	-4.83	1.84e-06	0.000436	-0.23	-0.22	Total body bone mineral density;	chr12:106904084	chr12:106954029~106955497:-
LUAD	cis	rs2337406	0.866	rs988130	ENSG00000211972.2	IGHV3-66	4.83	1.84e-06	0.000436	0.23	0.22	Alzheimer's disease (late onset);	chr14:106777154	chr14:106675017~106675544:-
LUAD	cis	rs950169	0.881	rs150965	ENSG00000229212.6	RP11-561C5.4	-4.83	1.84e-06	0.000436	-0.31	-0.22	Schizophrenia;	chr15:84537296	chr15:85205440~85234795:-
LUAD	cis	rs2286503	0.839	rs4722188	ENSG00000221740.1	SNORD93	4.83	1.84e-06	0.000436	0.25	0.22	Fibrinogen;	chr7:22820592	chr7:22856613~22856686:+
LUAD	cis	rs7712401	0.58	rs4288111	ENSG00000263432.2	RN7SL689P	-4.83	1.84e-06	0.000436	-0.27	-0.22	Mean platelet volume;	chr5:123052487	chr5:123022487~123022783:-
LUAD	cis	rs7923609	0.846	rs7073753	ENSG00000232075.1	MRPL35P2	-4.83	1.84e-06	0.000436	-0.26	-0.22	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63303060	chr10:63634317~63634827:-
LUAD	cis	rs2243480	0.808	rs12698508	ENSG00000164669.11	INTS4P1	4.83	1.84e-06	0.000436	0.39	0.22	Diabetic kidney disease;	chr7:65946971	chr7:65141225~65234216:+
LUAD	cis	rs11159086	1	rs4903233	ENSG00000259005.1	RP3-449M8.6	4.83	1.84e-06	0.000436	0.28	0.22	Advanced glycation end-product levels;	chr14:74497291	chr14:74474007~74474864:-
LUAD	cis	rs4713118	0.615	rs9348772	ENSG00000219392.1	RP1-265C24.5	-4.83	1.84e-06	0.000436	-0.26	-0.22	Parkinson's disease;	chr6:27688311	chr6:28115628~28116551:+
LUAD	cis	rs853679	1	rs1419183	ENSG00000204709.4	LINC01556	4.83	1.84e-06	0.000436	0.33	0.22	Depression;	chr6:28275017	chr6:28943877~28944537:+
LUAD	cis	rs5758511	0.68	rs739146	ENSG00000205702.9	CYP2D7	4.83	1.84e-06	0.000436	0.21	0.22	Birth weight;	chr22:42264408	chr22:42140203~42144577:-
LUAD	cis	rs12468226	1	rs111542497	ENSG00000272966.1	RP11-686O6.1	4.83	1.84e-06	0.000436	0.32	0.22	Urate levels;	chr2:202330369	chr2:202336739~202337200:+
LUAD	cis	rs7208859	0.562	rs11650923	ENSG00000263603.1	CTD-2349P21.5	-4.83	1.84e-06	0.000437	-0.39	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30681149	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs56378576	ENSG00000263603.1	CTD-2349P21.5	-4.83	1.84e-06	0.000437	-0.39	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30683102	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs35916850	ENSG00000263603.1	CTD-2349P21.5	-4.83	1.84e-06	0.000437	-0.39	-0.22	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30684155	chr17:30729469~30731202:+
LUAD	cis	rs2898681	0.561	rs7699960	ENSG00000248375.1	RP11-177B4.1	-4.83	1.84e-06	0.000437	-0.36	-0.22	Optic nerve measurement (cup area);	chr4:52869494	chr4:52720081~52720831:-
LUAD	cis	rs4835473	0.831	rs4323050	ENSG00000251600.4	RP11-673E1.1	4.83	1.84e-06	0.000437	0.27	0.22	Immature fraction of reticulocytes;	chr4:143992106	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1849128	ENSG00000251600.4	RP11-673E1.1	4.83	1.84e-06	0.000437	0.27	0.22	Immature fraction of reticulocytes;	chr4:143992582	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.715	rs4538428	ENSG00000251600.4	RP11-673E1.1	4.83	1.84e-06	0.000437	0.27	0.22	Immature fraction of reticulocytes;	chr4:143992751	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.771	rs2175452	ENSG00000251600.4	RP11-673E1.1	4.83	1.84e-06	0.000437	0.27	0.22	Immature fraction of reticulocytes;	chr4:143992887	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.8	rs2175451	ENSG00000251600.4	RP11-673E1.1	4.83	1.84e-06	0.000437	0.27	0.22	Immature fraction of reticulocytes;	chr4:143992964	chr4:143912331~143982454:+
LUAD	cis	rs4323050	0.51	rs4254715	ENSG00000251600.4	RP11-673E1.1	4.83	1.84e-06	0.000437	0.27	0.22	High light scatter reticulocyte percentage of red cells;	chr4:143993140	chr4:143912331~143982454:+
LUAD	cis	rs4323050	0.51	rs4273414	ENSG00000251600.4	RP11-673E1.1	4.83	1.84e-06	0.000437	0.27	0.22	High light scatter reticulocyte percentage of red cells;	chr4:143993142	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.831	rs1912743	ENSG00000251600.4	RP11-673E1.1	4.83	1.84e-06	0.000437	0.27	0.22	Immature fraction of reticulocytes;	chr4:143993705	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.614	rs4487293	ENSG00000251600.4	RP11-673E1.1	4.83	1.84e-06	0.000437	0.27	0.22	Immature fraction of reticulocytes;	chr4:143993880	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.742	rs6537238	ENSG00000251600.4	RP11-673E1.1	4.83	1.84e-06	0.000437	0.27	0.22	Immature fraction of reticulocytes;	chr4:143996463	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs1473055	ENSG00000251600.4	RP11-673E1.1	4.83	1.84e-06	0.000437	0.27	0.22	Immature fraction of reticulocytes;	chr4:143997714	chr4:143912331~143982454:+
LUAD	cis	rs7819412	0.745	rs2898260	ENSG00000255046.1	RP11-297N6.4	4.83	1.85e-06	0.000437	0.26	0.22	Triglycerides;	chr8:11081980	chr8:11797928~11802568:-
LUAD	cis	rs1008375	0.932	rs964012	ENSG00000249502.1	AC006160.5	-4.83	1.85e-06	0.000437	-0.21	-0.22	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17617561	chr4:17587467~17614571:-
LUAD	cis	rs2617170	0.922	rs1351113	ENSG00000245648.1	RP11-277P12.20	-4.83	1.85e-06	0.000437	-0.27	-0.22	Behcet's disease;	chr12:10373045	chr12:10363769~10398506:+
LUAD	cis	rs2765539	0.851	rs8928	ENSG00000226172.2	RP4-712E4.1	-4.83	1.85e-06	0.000438	-0.27	-0.22	Waist-hip ratio;	chr1:119031451	chr1:119000344~119001392:-
LUAD	cis	rs5758659	0.714	rs5751220	ENSG00000227370.1	RP4-669P10.19	4.83	1.85e-06	0.000438	0.2	0.22	Cognitive function;	chr22:42120201	chr22:42132543~42132998:+
LUAD	cis	rs17684571	0.688	rs35440408	ENSG00000231441.1	RP11-472M19.2	4.83	1.85e-06	0.000438	0.32	0.22	Schizophrenia;	chr6:56866055	chr6:56844002~56864078:+
LUAD	cis	rs7829975	0.567	rs6601273	ENSG00000253893.2	FAM85B	4.83	1.85e-06	0.000438	0.27	0.22	Mood instability;	chr8:8939009	chr8:8167819~8226614:-
LUAD	cis	rs4143844	0.867	rs12185103	ENSG00000259251.2	RP11-643M14.1	4.83	1.85e-06	0.000438	0.38	0.22	Bipolar disorder and schizophrenia;	chr15:61889092	chr15:62060503~62062434:+
LUAD	cis	rs4143844	0.867	rs71411468	ENSG00000259251.2	RP11-643M14.1	4.83	1.85e-06	0.000438	0.38	0.22	Bipolar disorder and schizophrenia;	chr15:61894514	chr15:62060503~62062434:+
LUAD	cis	rs1707322	0.964	rs1768802	ENSG00000280836.1	AL355480.1	4.83	1.85e-06	0.000438	0.28	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46082196	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs1588663	ENSG00000280836.1	AL355480.1	4.83	1.85e-06	0.000438	0.28	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083153	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs1768801	ENSG00000280836.1	AL355480.1	4.83	1.85e-06	0.000438	0.28	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083465	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs1768800	ENSG00000280836.1	AL355480.1	4.83	1.85e-06	0.000438	0.28	0.22	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083516	chr1:45581219~45581321:-
LUAD	cis	rs7726354	0.546	rs77982563	ENSG00000271828.1	CTD-2310F14.1	4.83	1.85e-06	0.000438	0.46	0.22	Breast cancer (early onset);	chr5:56897840	chr5:56927874~56929573:+
LUAD	cis	rs3822625	0.867	rs76418981	ENSG00000271828.1	CTD-2310F14.1	4.83	1.85e-06	0.000438	0.49	0.22	Breast cancer (early onset);	chr5:56834707	chr5:56927874~56929573:+
LUAD	cis	rs3822625	1	rs16886397	ENSG00000271828.1	CTD-2310F14.1	4.83	1.85e-06	0.000438	0.49	0.22	Breast cancer (early onset);	chr5:56838449	chr5:56927874~56929573:+
LUAD	cis	rs3822625	1	rs16886420	ENSG00000271828.1	CTD-2310F14.1	4.83	1.85e-06	0.000438	0.49	0.22	Breast cancer (early onset);	chr5:56847172	chr5:56927874~56929573:+
LUAD	cis	rs9926296	0.712	rs258332	ENSG00000260259.1	RP11-368I7.4	4.83	1.85e-06	0.000438	0.21	0.22	Vitiligo;	chr16:89661275	chr16:89682620~89686569:-
LUAD	cis	rs507080	0.922	rs519848	ENSG00000278376.1	RP11-158I9.8	-4.83	1.85e-06	0.000439	-0.23	-0.21	Serum metabolite levels;	chr11:118682006	chr11:118791254~118793137:+
LUAD	cis	rs17772222	0.793	rs7143853	ENSG00000258983.2	RP11-507K2.2	4.83	1.85e-06	0.000439	0.26	0.21	Coronary artery calcification;	chr14:88578477	chr14:88499334~88515502:+
LUAD	cis	rs41307935	0.643	rs57215361	ENSG00000260063.1	RP5-968P14.2	-4.83	1.86e-06	0.000439	-0.42	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26988323	chr1:26692132~26694131:-
LUAD	cis	rs684603	1	rs684603	ENSG00000246174.6	KCTD21-AS1	-4.83	1.86e-06	0.000439	-0.33	-0.21	Number of common colds;	chr11:78102803	chr11:78139771~78175323:+
LUAD	cis	rs9322193	0.607	rs12204653	ENSG00000223701.3	RAET1E-AS1	4.83	1.86e-06	0.000439	0.31	0.21	Lung cancer;	chr6:149891885	chr6:149884431~149919508:+
LUAD	cis	rs5758511	0.68	rs58654759	ENSG00000205702.9	CYP2D7	4.83	1.86e-06	0.00044	0.21	0.21	Birth weight;	chr22:42246570	chr22:42140203~42144577:-
LUAD	cis	rs9473147	0.516	rs9296564	ENSG00000270761.1	RP11-385F7.1	-4.83	1.86e-06	0.00044	-0.25	-0.21	Platelet distribution width;Mean platelet volume;	chr6:47527023	chr6:47477243~47477572:-
LUAD	cis	rs12745968	0.718	rs911523	ENSG00000223787.2	RP4-593M8.1	-4.83	1.86e-06	0.00044	-0.27	-0.21	Bipolar disorder and schizophrenia;	chr1:92696163	chr1:92580476~92580821:-
LUAD	cis	rs7493	1	rs3735586	ENSG00000233942.1	AC004012.1	4.83	1.86e-06	0.00044	0.31	0.21	Yu-Zhi constitution type in type 2 diabetes;	chr7:95406270	chr7:95471835~95473998:+
LUAD	cis	rs240993	0.812	rs7766610	ENSG00000230177.1	RP5-1112D6.4	-4.83	1.86e-06	0.000441	-0.23	-0.21	Inflammatory skin disease;Psoriasis;	chr6:111386618	chr6:111277932~111278742:+
LUAD	cis	rs9659323	0.67	rs10157346	ENSG00000231365.4	RP11-418J17.1	-4.83	1.86e-06	0.000441	-0.25	-0.21	Body mass index;	chr1:119090924	chr1:119140396~119275973:+
LUAD	cis	rs7131987	0.683	rs7954278	ENSG00000257176.2	RP11-996F15.2	-4.83	1.86e-06	0.000441	-0.24	-0.21	QT interval;	chr12:29306357	chr12:29280418~29317848:-
LUAD	cis	rs12745968	0.652	rs942753	ENSG00000223787.2	RP4-593M8.1	-4.83	1.86e-06	0.000441	-0.27	-0.21	Bipolar disorder and schizophrenia;	chr1:92476909	chr1:92580476~92580821:-
LUAD	cis	rs8127691	0.967	rs4456788	ENSG00000237604.1	AP001056.1	4.83	1.86e-06	0.000441	0.25	0.21	Inflammatory bowel disease;	chr21:44196441	chr21:44175489~44176453:+
LUAD	cis	rs1150668	0.835	rs203869	ENSG00000219392.1	RP1-265C24.5	-4.83	1.86e-06	0.000441	-0.27	-0.21	Pubertal anthropometrics;	chr6:28073041	chr6:28115628~28116551:+
LUAD	cis	rs6558530	0.666	rs7005699	ENSG00000253982.1	CTD-2336O2.1	4.83	1.86e-06	0.000441	0.28	0.21	Systolic blood pressure;	chr8:1752454	chr8:1761990~1764502:-
LUAD	cis	rs6570726	0.791	rs427128	ENSG00000235652.6	RP11-545I5.3	4.83	1.86e-06	0.000441	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145544781	chr6:145799409~145886585:+
LUAD	cis	rs875971	0.862	rs7783779	ENSG00000232559.3	GS1-124K5.12	-4.83	1.86e-06	0.000441	-0.26	-0.21	Aortic root size;	chr7:66331639	chr7:66554588~66576923:-
LUAD	cis	rs262150	0.659	rs2527237	ENSG00000231419.5	LINC00689	4.83	1.86e-06	0.000441	0.26	0.21	Facial morphology (factor 20);	chr7:159005803	chr7:159006522~159030195:+
LUAD	cis	rs42490	1	rs218929	ENSG00000251136.7	RP11-37B2.1	-4.83	1.86e-06	0.000441	-0.22	-0.21	Leprosy;	chr8:89739091	chr8:89609409~89757727:-
LUAD	cis	rs2554380	0.657	rs4530091	ENSG00000230373.7	GOLGA6L5P	-4.83	1.87e-06	0.000442	-0.24	-0.21	Height;	chr15:83814026	chr15:84507885~84516814:-
LUAD	cis	rs7937890	0.81	rs10734224	ENSG00000254418.1	RP11-21L19.1	4.83	1.87e-06	0.000442	0.25	0.21	Mitochondrial DNA levels;	chr11:14402578	chr11:14262846~14273691:-
LUAD	cis	rs1008375	0.932	rs12500912	ENSG00000249502.1	AC006160.5	-4.83	1.87e-06	0.000442	-0.21	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17601695	chr4:17587467~17614571:-
LUAD	cis	rs1008375	0.932	rs12500947	ENSG00000249502.1	AC006160.5	-4.83	1.87e-06	0.000442	-0.21	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17601801	chr4:17587467~17614571:-
LUAD	cis	rs6840258	1	rs10516788	ENSG00000251411.1	RP11-397E7.4	-4.83	1.87e-06	0.000443	-0.28	-0.21	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87039705	chr4:86913266~86914817:-
LUAD	cis	rs453301	0.624	rs330058	ENSG00000253981.4	ALG1L13P	-4.83	1.87e-06	0.000443	-0.25	-0.21	Joint mobility (Beighton score);	chr8:9232299	chr8:8236003~8244667:-
LUAD	cis	rs7923609	0.846	rs7896518	ENSG00000232075.1	MRPL35P2	-4.83	1.87e-06	0.000443	-0.26	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63344740	chr10:63634317~63634827:-
LUAD	cis	rs7637701	0.818	rs10936038	ENSG00000240875.4	LINC00886	-4.83	1.87e-06	0.000443	-0.23	-0.21	Breast cancer;	chr3:156814877	chr3:156747346~156817062:-
LUAD	cis	rs7637701	0.818	rs11711674	ENSG00000240875.4	LINC00886	-4.83	1.87e-06	0.000443	-0.23	-0.21	Breast cancer;	chr3:156815164	chr3:156747346~156817062:-
LUAD	cis	rs7637701	0.818	rs1560415	ENSG00000240875.4	LINC00886	-4.83	1.87e-06	0.000443	-0.23	-0.21	Breast cancer;	chr3:156819569	chr3:156747346~156817062:-
LUAD	cis	rs7637701	0.818	rs1560416	ENSG00000240875.4	LINC00886	-4.83	1.87e-06	0.000443	-0.23	-0.21	Breast cancer;	chr3:156819630	chr3:156747346~156817062:-
LUAD	cis	rs7637701	0.818	rs9837271	ENSG00000240875.4	LINC00886	-4.83	1.87e-06	0.000443	-0.23	-0.21	Breast cancer;	chr3:156820949	chr3:156747346~156817062:-
LUAD	cis	rs7017914	0.69	rs13274981	ENSG00000223220.1	Y_RNA	4.83	1.87e-06	0.000443	0.25	0.21	Bone mineral density;	chr8:70853045	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs6985251	ENSG00000223220.1	Y_RNA	4.83	1.87e-06	0.000443	0.25	0.21	Bone mineral density;	chr8:70853620	chr8:70780914~70781008:-
LUAD	cis	rs7727544	0.571	rs12521097	ENSG00000233006.5	AC034220.3	4.83	1.87e-06	0.000443	0.19	0.21	Blood metabolite levels;	chr5:132239645	chr5:132311285~132369916:-
LUAD	cis	rs150992	0.536	rs179053	ENSG00000248489.1	CTD-2007H13.3	4.83	1.88e-06	0.000445	0.27	0.21	Body mass index;	chr5:98979890	chr5:98929171~98995013:+
LUAD	cis	rs801193	1	rs2003301	ENSG00000236529.1	RP13-254B10.1	-4.83	1.88e-06	0.000445	-0.22	-0.21	Aortic root size;	chr7:66682669	chr7:65840212~65840596:+
LUAD	cis	rs42490	1	rs67143546	ENSG00000251136.7	RP11-37B2.1	-4.83	1.88e-06	0.000445	-0.22	-0.21	Leprosy;	chr8:89753950	chr8:89609409~89757727:-
LUAD	cis	rs42490	0.966	rs385524	ENSG00000251136.7	RP11-37B2.1	-4.83	1.88e-06	0.000445	-0.22	-0.21	Leprosy;	chr8:89754242	chr8:89609409~89757727:-
LUAD	cis	rs4835473	0.932	rs4835120	ENSG00000251600.4	RP11-673E1.1	4.82	1.88e-06	0.000445	0.26	0.21	Immature fraction of reticulocytes;	chr4:143982370	chr4:143912331~143982454:+
LUAD	cis	rs5758659	1	rs134902	ENSG00000227370.1	RP4-669P10.19	-4.82	1.88e-06	0.000446	-0.19	-0.21	Cognitive function;	chr22:42287991	chr22:42132543~42132998:+
LUAD	cis	rs111756027	0.51	rs11862602	ENSG00000260922.1	RP11-538I12.3	4.82	1.88e-06	0.000446	0.26	0.21	Bone mineral density (Ward's triangle area);	chr16:77233519	chr16:77234877~77290934:+
LUAD	cis	rs5758511	0.68	rs5758698	ENSG00000205702.9	CYP2D7	4.82	1.89e-06	0.000446	0.21	0.21	Birth weight;	chr22:42288812	chr22:42140203~42144577:-
LUAD	cis	rs1707322	0.963	rs10789484	ENSG00000280836.1	AL355480.1	-4.82	1.89e-06	0.000446	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941306	chr1:45581219~45581321:-
LUAD	cis	rs4268898	0.722	rs34565113	ENSG00000242628.4	AC009228.1	-4.82	1.89e-06	0.000446	-0.27	-0.21	Asthma;	chr2:24200207	chr2:24214381~24221516:+
LUAD	cis	rs559928	0.606	rs11231726	ENSG00000236935.1	AP003774.1	4.82	1.89e-06	0.000446	0.31	0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64219867	chr11:64325050~64329504:-
LUAD	cis	rs11976180	1	rs2951308	ENSG00000204959.4	ARHGEF34P	-4.82	1.89e-06	0.000447	-0.26	-0.21	Obesity-related traits;	chr7:144070056	chr7:144272445~144286966:-
LUAD	cis	rs12908161	0.959	rs17534709	ENSG00000275120.1	RP11-182J1.17	4.82	1.89e-06	0.000447	0.33	0.21	Schizophrenia;	chr15:84771166	chr15:84599434~84606463:-
LUAD	cis	rs12928939	0.911	rs77823468	ENSG00000260886.1	TAT-AS1	4.82	1.89e-06	0.000447	0.27	0.21	Post bronchodilator FEV1;	chr16:71794713	chr16:71565789~71578187:+
LUAD	cis	rs12928939	0.954	rs34998650	ENSG00000260886.1	TAT-AS1	4.82	1.89e-06	0.000447	0.27	0.21	Post bronchodilator FEV1;	chr16:71795426	chr16:71565789~71578187:+
LUAD	cis	rs2235642	0.533	rs17135391	ENSG00000280231.1	LA16c-380F5.3	-4.82	1.89e-06	0.000447	-0.32	-0.21	Coronary artery disease;	chr16:1555605	chr16:1553655~1554130:-
LUAD	cis	rs160451	0.933	rs2088198	ENSG00000251136.7	RP11-37B2.1	4.82	1.89e-06	0.000447	0.22	0.21	Leprosy;	chr8:89678693	chr8:89609409~89757727:-
LUAD	cis	rs853679	1	rs1679709	ENSG00000219392.1	RP1-265C24.5	4.82	1.89e-06	0.000447	0.33	0.21	Depression;	chr6:28260564	chr6:28115628~28116551:+
LUAD	cis	rs7119	0.745	rs11632602	ENSG00000259362.2	RP11-307C19.1	-4.82	1.89e-06	0.000447	-0.27	-0.21	Type 2 diabetes;	chr15:77517422	chr15:77525540~77534110:+
LUAD	cis	rs7208859	0.673	rs11657270	ENSG00000263603.1	CTD-2349P21.5	-4.82	1.89e-06	0.000447	-0.39	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887369	chr17:30729469~30731202:+
LUAD	cis	rs896854	0.967	rs2879813	ENSG00000253528.2	RP11-347C18.4	4.82	1.89e-06	0.000447	0.21	0.21	Type 2 diabetes;	chr8:94948719	chr8:94974573~94974853:-
LUAD	cis	rs801193	0.935	rs3800820	ENSG00000236529.1	RP13-254B10.1	-4.82	1.89e-06	0.000447	-0.22	-0.21	Aortic root size;	chr7:66682191	chr7:65840212~65840596:+
LUAD	cis	rs6088590	1	rs910870	ENSG00000276073.1	RP5-1125A11.7	-4.82	1.89e-06	0.000447	-0.22	-0.21	Coronary artery disease;	chr20:34705089	chr20:33985617~33988989:-
LUAD	cis	rs6840258	1	rs17701999	ENSG00000251411.1	RP11-397E7.4	-4.82	1.89e-06	0.000447	-0.28	-0.21	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87034392	chr4:86913266~86914817:-
LUAD	cis	rs4938303	0.587	rs10892017	ENSG00000254851.1	RP11-109L13.1	4.82	1.89e-06	0.000448	0.3	0.21	Triglycerides;	chr11:116697165	chr11:117135528~117138582:+
LUAD	cis	rs7430456	0.901	rs9824206	ENSG00000225790.1	RP11-2L8.1	-4.82	1.89e-06	0.000448	-0.25	-0.21	Breast cancer;	chr3:177742093	chr3:177934823~177937662:+
LUAD	cis	rs9828933	1	rs9828933	ENSG00000280620.1	SCAANT1	4.82	1.89e-06	0.000448	0.3	0.21	Type 2 diabetes;	chr3:64017221	chr3:63911518~63911772:-
LUAD	cis	rs9828933	0.938	rs7617036	ENSG00000280620.1	SCAANT1	4.82	1.89e-06	0.000448	0.3	0.21	Type 2 diabetes;	chr3:64017319	chr3:63911518~63911772:-
LUAD	cis	rs2153535	0.585	rs1033803	ENSG00000230939.1	RP11-314C16.1	-4.82	1.9e-06	0.000448	-0.24	-0.21	Motion sickness;	chr6:8674779	chr6:8784178~8785445:+
LUAD	cis	rs9467773	0.62	rs2101582	ENSG00000241549.7	GUSBP2	4.82	1.9e-06	0.000449	0.23	0.21	Intelligence (multi-trait analysis);	chr6:26622506	chr6:26871484~26956554:-
LUAD	cis	rs7017914	0.652	rs6982838	ENSG00000223220.1	Y_RNA	4.82	1.9e-06	0.000449	0.25	0.21	Bone mineral density;	chr8:70830504	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs1457198	ENSG00000223220.1	Y_RNA	4.82	1.9e-06	0.000449	0.25	0.21	Bone mineral density;	chr8:70834934	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs35921782	ENSG00000223220.1	Y_RNA	4.82	1.9e-06	0.000449	0.25	0.21	Bone mineral density;	chr8:70836689	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs35380538	ENSG00000223220.1	Y_RNA	4.82	1.9e-06	0.000449	0.25	0.21	Bone mineral density;	chr8:70845432	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.628	rs10957532	ENSG00000223220.1	Y_RNA	4.82	1.9e-06	0.000449	0.25	0.21	Bone mineral density;	chr8:70845775	chr8:70780914~70781008:-
LUAD	cis	rs9926296	0.712	rs258319	ENSG00000260259.1	RP11-368I7.4	4.82	1.9e-06	0.000449	0.21	0.21	Vitiligo;	chr16:89665616	chr16:89682620~89686569:-
LUAD	cis	rs8073060	0.859	rs17550268	ENSG00000267592.1	CTC-507E2.2	-4.82	1.9e-06	0.000449	-0.29	-0.21	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35547659	chr17:35596904~35597128:-
LUAD	cis	rs34375054	0.526	rs7302475	ENSG00000279233.1	RP11-158L12.4	4.82	1.9e-06	0.000449	0.18	0.21	Post bronchodilator FEV1/FVC ratio;	chr12:125193340	chr12:125138245~125141711:+
LUAD	cis	rs116175783	0.557	rs2303318	ENSG00000227403.1	AC009299.3	4.82	1.9e-06	0.000449	0.4	0.21	Intelligence (multi-trait analysis);	chr2:161367984	chr2:161244739~161249050:+
LUAD	cis	rs5758511	0.68	rs5758688	ENSG00000205702.9	CYP2D7	4.82	1.9e-06	0.000449	0.21	0.21	Birth weight;	chr22:42266495	chr22:42140203~42144577:-
LUAD	cis	rs9425766	0.655	rs6666767	ENSG00000227373.4	RP11-160H22.5	4.82	1.9e-06	0.000449	0.27	0.21	Life satisfaction;	chr1:174357564	chr1:174115300~174160004:-
LUAD	cis	rs875971	0.522	rs7784623	ENSG00000224316.1	RP11-479O9.2	4.82	1.9e-06	0.000449	0.21	0.21	Aortic root size;	chr7:65930047	chr7:65773620~65802067:+
LUAD	cis	rs875971	0.522	rs34973832	ENSG00000224316.1	RP11-479O9.2	4.82	1.9e-06	0.000449	0.21	0.21	Aortic root size;	chr7:65931217	chr7:65773620~65802067:+
LUAD	cis	rs193541	0.632	rs1903260	ENSG00000263432.2	RN7SL689P	4.82	1.9e-06	0.00045	0.29	0.21	Glucose homeostasis traits;	chr5:122799493	chr5:123022487~123022783:-
LUAD	cis	rs62432291	0.681	rs397476	ENSG00000235086.1	FNDC1-IT1	-4.82	1.91e-06	0.00045	-0.34	-0.21	Joint mobility (Beighton score);	chr6:159218252	chr6:159240786~159243329:+
LUAD	cis	rs36423	0.748	rs36387	ENSG00000266869.1	RP6-114E22.1	-4.82	1.91e-06	0.000451	-0.32	-0.21	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71900629	chr14:71848606~71908430:+
LUAD	cis	rs36423	0.748	rs36385	ENSG00000266869.1	RP6-114E22.1	-4.82	1.91e-06	0.000451	-0.32	-0.21	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71901594	chr14:71848606~71908430:+
LUAD	cis	rs36423	0.66	rs36384	ENSG00000266869.1	RP6-114E22.1	-4.82	1.91e-06	0.000451	-0.32	-0.21	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71901638	chr14:71848606~71908430:+
LUAD	cis	rs6840360	0.87	rs7680604	ENSG00000270265.1	RP11-731D1.4	-4.82	1.91e-06	0.000451	-0.22	-0.21	Intelligence (multi-trait analysis);	chr4:151548765	chr4:151333775~151353224:-
LUAD	cis	rs1707322	1	rs10890375	ENSG00000280836.1	AL355480.1	-4.82	1.91e-06	0.000451	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940909	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs10890377	ENSG00000280836.1	AL355480.1	-4.82	1.91e-06	0.000451	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940922	chr1:45581219~45581321:-
LUAD	cis	rs9400467	0.528	rs11153280	ENSG00000271789.1	RP5-1112D6.7	-4.82	1.91e-06	0.000451	-0.22	-0.21	Amino acid levels;Blood metabolite levels;	chr6:111268090	chr6:111297126~111298510:+
LUAD	cis	rs944289	0.6	rs1834855	ENSG00000257826.1	RP11-116N8.4	-4.82	1.91e-06	0.000451	-0.24	-0.21	Thyroid cancer;	chr14:36171432	chr14:36061026~36067190:-
LUAD	cis	rs875971	0.66	rs10229345	ENSG00000224316.1	RP11-479O9.2	4.82	1.91e-06	0.000451	0.22	0.21	Aortic root size;	chr7:66517181	chr7:65773620~65802067:+
LUAD	cis	rs7580658	0.534	rs2089109	ENSG00000236682.1	AC068282.3	-4.82	1.91e-06	0.000451	-0.27	-0.21	Protein C levels;	chr2:127193882	chr2:127389130~127400580:+
LUAD	cis	rs2933343	0.7	rs1683787	ENSG00000261159.1	RP11-723O4.9	-4.82	1.91e-06	0.000451	-0.23	-0.21	IgG glycosylation;	chr3:128908178	chr3:128859716~128860526:-
LUAD	cis	rs73173548	0.502	rs12189343	ENSG00000247828.6	TMEM161B-AS1	4.82	1.91e-06	0.000451	0.27	0.21	Macular telangiectasia type 2;	chr5:88447510	chr5:88268895~88436685:+
LUAD	cis	rs2998286	0.723	rs332191	ENSG00000254635.4	WAC-AS1	-4.82	1.91e-06	0.000451	-0.29	-0.21	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28632196	chr10:28522652~28532743:-
LUAD	cis	rs34375054	1	rs3751178	ENSG00000279233.1	RP11-158L12.4	-4.82	1.91e-06	0.000452	-0.18	-0.21	Post bronchodilator FEV1/FVC ratio;	chr12:125179811	chr12:125138245~125141711:+
LUAD	cis	rs2239557	1	rs11159067	ENSG00000259065.1	RP5-1021I20.1	-4.82	1.91e-06	0.000452	-0.24	-0.21	Common traits (Other);	chr14:74170741	chr14:73787360~73803270:+
LUAD	cis	rs17508449	0.819	rs4839332	ENSG00000232450.1	RP4-730K3.3	-4.82	1.91e-06	0.000452	-0.37	-0.21	Leprosy;	chr1:113619569	chr1:113698884~113699631:-
LUAD	cis	rs801193	0.569	rs2659908	ENSG00000232559.3	GS1-124K5.12	4.82	1.91e-06	0.000452	0.25	0.21	Aortic root size;	chr7:66695835	chr7:66554588~66576923:-
LUAD	cis	rs875971	1	rs6979382	ENSG00000232559.3	GS1-124K5.12	4.82	1.91e-06	0.000452	0.25	0.21	Aortic root size;	chr7:66421388	chr7:66554588~66576923:-
LUAD	cis	rs875971	1	rs6961990	ENSG00000232559.3	GS1-124K5.12	4.82	1.91e-06	0.000452	0.25	0.21	Aortic root size;	chr7:66423583	chr7:66554588~66576923:-
LUAD	cis	rs9425766	0.541	rs4652274	ENSG00000227373.4	RP11-160H22.5	4.82	1.92e-06	0.000452	0.27	0.21	Life satisfaction;	chr1:174249434	chr1:174115300~174160004:-
LUAD	cis	rs17826219	0.706	rs2322197	ENSG00000263603.1	CTD-2349P21.5	-4.82	1.92e-06	0.000453	-0.37	-0.21	Body mass index;	chr17:30778787	chr17:30729469~30731202:+
LUAD	cis	rs453301	0.682	rs2929308	ENSG00000173295.6	FAM86B3P	-4.82	1.92e-06	0.000453	-0.22	-0.21	Joint mobility (Beighton score);	chr8:9226611	chr8:8228595~8244865:+
LUAD	cis	rs2028299	0.839	rs3844575	ENSG00000259677.1	RP11-493E3.1	4.82	1.92e-06	0.000453	0.26	0.21	Type 2 diabetes;	chr15:89900515	chr15:89876540~89877285:+
LUAD	cis	rs2028299	0.839	rs2279848	ENSG00000259677.1	RP11-493E3.1	4.82	1.92e-06	0.000453	0.26	0.21	Type 2 diabetes;	chr15:89901449	chr15:89876540~89877285:+
LUAD	cis	rs2976388	0.647	rs2585138	ENSG00000253741.1	CTD-2292P10.4	-4.82	1.92e-06	0.000453	-0.25	-0.21	Urinary tract infection frequency;	chr8:142727533	chr8:142702252~142726973:-
LUAD	cis	rs2115630	1	rs11854291	ENSG00000229212.6	RP11-561C5.4	4.82	1.92e-06	0.000453	0.25	0.21	P wave terminal force;	chr15:84820477	chr15:85205440~85234795:-
LUAD	cis	rs301901	0.772	rs301909	ENSG00000250155.1	CTD-2353F22.1	-4.82	1.92e-06	0.000454	-0.23	-0.21	Height;	chr5:37102525	chr5:36666214~36725195:-
LUAD	cis	rs301901	0.772	rs301908	ENSG00000250155.1	CTD-2353F22.1	-4.82	1.92e-06	0.000454	-0.23	-0.21	Height;	chr5:37103704	chr5:36666214~36725195:-
LUAD	cis	rs8077577	0.747	rs2071242	ENSG00000273018.4	CTD-2303H24.2	-4.82	1.92e-06	0.000454	-0.31	-0.21	Obesity-related traits;	chr17:18251196	chr17:18511221~18551705:-
LUAD	cis	rs7119	0.717	rs12901732	ENSG00000259362.2	RP11-307C19.1	-4.82	1.92e-06	0.000454	-0.27	-0.21	Type 2 diabetes;	chr15:77526591	chr15:77525540~77534110:+
LUAD	cis	rs9584850	0.708	rs4411372	ENSG00000231194.1	FARP1-AS1	4.82	1.92e-06	0.000454	0.26	0.21	Neuroticism;	chr13:98478169	chr13:98435405~98435840:-
LUAD	cis	rs7829975	0.682	rs7013471	ENSG00000253981.4	ALG1L13P	-4.82	1.92e-06	0.000454	-0.24	-0.21	Mood instability;	chr8:8829815	chr8:8236003~8244667:-
LUAD	cis	rs3096299	0.658	rs4291902	ENSG00000182376.2	RP5-1142A6.8	4.82	1.93e-06	0.000455	0.22	0.21	Multiple myeloma (IgH translocation);	chr16:89493907	chr16:88742767~88745748:+
LUAD	cis	rs2243480	1	rs11538349	ENSG00000226002.1	RP11-460N20.5	-4.82	1.93e-06	0.000455	-0.36	-0.21	Diabetic kidney disease;	chr7:65956884	chr7:65084103~65100232:+
LUAD	cis	rs11641365	1	rs11641365	ENSG00000278341.1	RP5-1142A6.10	-4.82	1.93e-06	0.000455	-0.29	-0.21	Autism spectrum disorder-related traits;	chr16:88707485	chr16:88708956~88710437:-
LUAD	cis	rs42490	1	rs218905	ENSG00000251136.7	RP11-37B2.1	-4.82	1.93e-06	0.000455	-0.22	-0.21	Leprosy;	chr8:89723661	chr8:89609409~89757727:-
LUAD	cis	rs8127691	0.967	rs743478	ENSG00000237604.1	AP001056.1	4.82	1.93e-06	0.000455	0.26	0.21	Inflammatory bowel disease;	chr21:44191803	chr21:44175489~44176453:+
LUAD	cis	rs16873450	0.527	rs6461738	ENSG00000234800.2	PCMTD1P3	4.82	1.93e-06	0.000455	0.24	0.21	Verbal memory performance (residualized delayed recall level);	chr7:23789557	chr7:23721311~23721782:-
LUAD	cis	rs193541	0.632	rs6595413	ENSG00000263432.2	RN7SL689P	4.82	1.93e-06	0.000455	0.29	0.21	Glucose homeostasis traits;	chr5:122821254	chr5:123022487~123022783:-
LUAD	cis	rs11105298	0.891	rs11105302	ENSG00000258302.2	RP11-981P6.1	-4.82	1.93e-06	0.000455	-0.26	-0.21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89497589	chr12:89561129~89594878:+
LUAD	cis	rs712039	0.583	rs853223	ENSG00000276054.1	RP11-378E13.3	4.82	1.93e-06	0.000455	0.32	0.21	Tuberculosis;	chr17:37431050	chr17:37386886~37387926:+
LUAD	cis	rs11971779	0.68	rs66491565	ENSG00000273391.1	RP11-634H22.1	4.82	1.93e-06	0.000455	0.22	0.21	Diisocyanate-induced asthma;	chr7:139404231	chr7:139359032~139359566:-
LUAD	cis	rs9926296	0.687	rs258317	ENSG00000260259.1	RP11-368I7.4	4.82	1.93e-06	0.000456	0.21	0.21	Vitiligo;	chr16:89665830	chr16:89682620~89686569:-
LUAD	cis	rs66887589	0.87	rs2389875	ENSG00000245958.5	RP11-33B1.1	4.82	1.93e-06	0.000456	0.17	0.21	Diastolic blood pressure;	chr4:119635859	chr4:119454791~119552025:+
LUAD	cis	rs8072100	0.967	rs8072644	ENSG00000228782.6	CTD-2026D20.3	-4.82	1.93e-06	0.000456	-0.22	-0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47575998	chr17:47450568~47492492:-
LUAD	cis	rs17508449	0.775	rs4839336	ENSG00000232450.1	RP4-730K3.3	-4.82	1.93e-06	0.000456	-0.36	-0.21	Leprosy;	chr1:113691523	chr1:113698884~113699631:-
LUAD	cis	rs17508449	0.819	rs77551704	ENSG00000232450.1	RP4-730K3.3	-4.82	1.93e-06	0.000456	-0.36	-0.21	Leprosy;	chr1:113692564	chr1:113698884~113699631:-
LUAD	cis	rs9322193	0.926	rs9383546	ENSG00000268592.3	RAET1E-AS1	4.82	1.93e-06	0.000456	0.27	0.21	Lung cancer;	chr6:149822743	chr6:149863494~149919507:+
LUAD	cis	rs720064	0.618	rs4800171	ENSG00000264745.1	TTC39C-AS1	4.82	1.94e-06	0.000456	0.24	0.21	Strep throat;	chr18:23952495	chr18:23994213~24015339:-
LUAD	cis	rs4660214	0.666	rs10493087	ENSG00000228060.1	RP11-69E11.8	4.82	1.94e-06	0.000457	0.19	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39251584	chr1:39565160~39573203:+
LUAD	cis	rs4660214	0.666	rs11205828	ENSG00000228060.1	RP11-69E11.8	4.82	1.94e-06	0.000457	0.19	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39253674	chr1:39565160~39573203:+
LUAD	cis	rs1707322	1	rs7517560	ENSG00000280836.1	AL355480.1	-4.82	1.94e-06	0.000457	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45960271	chr1:45581219~45581321:-
LUAD	cis	rs516805	0.596	rs4326267	ENSG00000279453.1	RP3-425C14.4	-4.82	1.94e-06	0.000458	-0.3	-0.21	Lymphocyte counts;	chr6:122106476	chr6:122436789~122439223:-
LUAD	cis	rs7119	0.689	rs12907630	ENSG00000259362.2	RP11-307C19.1	-4.82	1.94e-06	0.000458	-0.27	-0.21	Type 2 diabetes;	chr15:77520564	chr15:77525540~77534110:+
LUAD	cis	rs72717009	0.825	rs9427397	ENSG00000225217.1	HSPA7	-4.82	1.94e-06	0.000458	-0.31	-0.21	Rheumatoid arthritis;	chr1:161506414	chr1:161606291~161608217:+
LUAD	cis	rs42490	0.934	rs218925	ENSG00000251136.7	RP11-37B2.1	-4.82	1.94e-06	0.000458	-0.22	-0.21	Leprosy;	chr8:89737352	chr8:89609409~89757727:-
LUAD	cis	rs2921073	0.604	rs2979140	ENSG00000253893.2	FAM85B	-4.82	1.94e-06	0.000458	-0.27	-0.21	Parkinson's disease;	chr8:8409692	chr8:8167819~8226614:-
LUAD	cis	rs7017914	0.69	rs7838421	ENSG00000223220.1	Y_RNA	4.82	1.94e-06	0.000458	0.24	0.21	Bone mineral density;	chr8:70760088	chr8:70780914~70781008:-
LUAD	cis	rs375066	0.901	rs12977303	ENSG00000267058.1	RP11-15A1.3	-4.82	1.94e-06	0.000458	-0.24	-0.21	Breast cancer;	chr19:43873517	chr19:43891804~43901805:-
LUAD	cis	rs7804306	0.522	rs11981425	ENSG00000233264.2	AC006042.8	4.82	1.94e-06	0.000458	0.29	0.21	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8045298	chr7:7980312~7982228:+
LUAD	cis	rs2836974	0.583	rs2735307	ENSG00000255568.3	BRWD1-AS2	4.82	1.94e-06	0.000458	0.21	0.21	Cognitive function;	chr21:39341432	chr21:39313935~39314962:+
LUAD	cis	rs6604026	0.555	rs36114576	ENSG00000223787.2	RP4-593M8.1	4.82	1.94e-06	0.000458	0.3	0.21	Multiple sclerosis;	chr1:92671999	chr1:92580476~92580821:-
LUAD	cis	rs4683346	1	rs4683344	ENSG00000173811.9	CCDC13-AS1	-4.82	1.94e-06	0.000458	-0.23	-0.21	Granulocyte percentage of myeloid white cells;	chr3:42842712	chr3:42732575~42746768:+
LUAD	cis	rs2832077	0.943	rs4816332	ENSG00000232855.5	AF131217.1	4.82	1.95e-06	0.000459	0.24	0.21	Cognitive test performance;	chr21:28829384	chr21:28439346~28674848:-
LUAD	cis	rs2832077	0.824	rs4816333	ENSG00000232855.5	AF131217.1	4.82	1.95e-06	0.000459	0.24	0.21	Cognitive test performance;	chr21:28829455	chr21:28439346~28674848:-
LUAD	cis	rs227275	0.554	rs223363	ENSG00000251288.2	RP11-10L12.2	-4.82	1.95e-06	0.000459	-0.26	-0.21	Allergic disease (asthma, hay fever or eczema);	chr4:102846182	chr4:102751401~102752641:+
LUAD	cis	rs9322193	0.887	rs9767113	ENSG00000268592.3	RAET1E-AS1	4.82	1.95e-06	0.000459	0.27	0.21	Lung cancer;	chr6:149718157	chr6:149863494~149919507:+
LUAD	cis	rs10129255	1	rs10129319	ENSG00000274576.2	IGHV2-70	4.82	1.95e-06	0.000459	0.19	0.21	Kawasaki disease;	chr14:106767996	chr14:106770577~106771020:-
LUAD	cis	rs1008375	1	rs4698641	ENSG00000249502.1	AC006160.5	-4.82	1.95e-06	0.000459	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17641007	chr4:17587467~17614571:-
LUAD	cis	rs7829975	0.714	rs4840362	ENSG00000173295.6	FAM86B3P	-4.82	1.95e-06	0.000459	-0.22	-0.21	Mood instability;	chr8:8812572	chr8:8228595~8244865:+
LUAD	cis	rs5758511	0.68	rs5758682	ENSG00000205702.9	CYP2D7	4.82	1.95e-06	0.00046	0.21	0.21	Birth weight;	chr22:42249196	chr22:42140203~42144577:-
LUAD	cis	rs3750965	1	rs1466222	ENSG00000260895.1	RP11-554A11.7	4.82	1.95e-06	0.00046	0.25	0.21	Hair color;	chr11:69065380	chr11:69103493~69109094:+
LUAD	cis	rs875971	0.658	rs432667	ENSG00000237310.1	GS1-124K5.4	4.82	1.95e-06	0.00046	0.23	0.21	Aortic root size;	chr7:66049646	chr7:66493706~66495474:+
LUAD	cis	rs7829975	0.535	rs4841005	ENSG00000173295.6	FAM86B3P	-4.82	1.95e-06	0.00046	-0.23	-0.21	Mood instability;	chr8:8643720	chr8:8228595~8244865:+
LUAD	cis	rs17772222	0.682	rs7142053	ENSG00000258789.1	RP11-507K2.3	-4.82	1.95e-06	0.00046	-0.26	-0.21	Coronary artery calcification;	chr14:88511594	chr14:88551597~88552493:+
LUAD	cis	rs2562456	0.833	rs1781872	ENSG00000268081.1	RP11-678G14.2	4.82	1.95e-06	0.00046	0.35	0.21	Pain;	chr19:21294601	chr19:21554640~21569237:-
LUAD	cis	rs56318008	0.773	rs2268179	ENSG00000228397.1	RP1-224A6.3	-4.82	1.95e-06	0.00046	-0.37	-0.21	Total body bone mineral density;Gestational age at birth (maternal effect);	chr1:22088292	chr1:22023994~22024968:-
LUAD	cis	rs9322193	0.962	rs3763162	ENSG00000268592.3	RAET1E-AS1	-4.82	1.95e-06	0.000461	-0.27	-0.21	Lung cancer;	chr6:149819674	chr6:149863494~149919507:+
LUAD	cis	rs875971	0.522	rs4502988	ENSG00000224316.1	RP11-479O9.2	4.82	1.95e-06	0.000461	0.22	0.21	Aortic root size;	chr7:65832759	chr7:65773620~65802067:+
LUAD	cis	rs6088590	1	rs6087623	ENSG00000276073.1	RP5-1125A11.7	-4.82	1.96e-06	0.000461	-0.22	-0.21	Coronary artery disease;	chr20:34729858	chr20:33985617~33988989:-
LUAD	cis	rs5769707	0.632	rs135876	ENSG00000235111.1	RP1-29C18.8	-4.82	1.96e-06	0.000461	-0.26	-0.21	Monocyte percentage of white cells;Monocyte count;	chr22:49619925	chr22:49612657~49615716:-
LUAD	cis	rs9322193	0.962	rs6903998	ENSG00000268592.3	RAET1E-AS1	4.82	1.96e-06	0.000461	0.27	0.21	Lung cancer;	chr6:149831357	chr6:149863494~149919507:+
LUAD	cis	rs7829975	0.742	rs7832968	ENSG00000173295.6	FAM86B3P	4.82	1.96e-06	0.000461	0.22	0.21	Mood instability;	chr8:8795379	chr8:8228595~8244865:+
LUAD	cis	rs7937890	0.631	rs7118886	ENSG00000254418.1	RP11-21L19.1	4.82	1.96e-06	0.000461	0.25	0.21	Mitochondrial DNA levels;	chr11:14405971	chr11:14262846~14273691:-
LUAD	cis	rs2243480	1	rs781156	ENSG00000226002.1	RP11-460N20.5	-4.82	1.96e-06	0.000462	-0.36	-0.21	Diabetic kidney disease;	chr7:66014154	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs781149	ENSG00000226002.1	RP11-460N20.5	-4.82	1.96e-06	0.000462	-0.36	-0.21	Diabetic kidney disease;	chr7:66016297	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs451396	ENSG00000226002.1	RP11-460N20.5	-4.82	1.96e-06	0.000462	-0.36	-0.21	Diabetic kidney disease;	chr7:66019087	chr7:65084103~65100232:+
LUAD	cis	rs2243480	0.901	rs58207111	ENSG00000226002.1	RP11-460N20.5	-4.82	1.96e-06	0.000462	-0.36	-0.21	Diabetic kidney disease;	chr7:66021736	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs1167613	ENSG00000226002.1	RP11-460N20.5	-4.82	1.96e-06	0.000462	-0.36	-0.21	Diabetic kidney disease;	chr7:66022452	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs1715235	ENSG00000226002.1	RP11-460N20.5	-4.82	1.96e-06	0.000462	-0.36	-0.21	Diabetic kidney disease;	chr7:66023407	chr7:65084103~65100232:+
LUAD	cis	rs1501911	0.611	rs10041261	ENSG00000248489.1	CTD-2007H13.3	-4.82	1.96e-06	0.000462	-0.26	-0.21	Lung function (FEV1/FVC);	chr5:99023435	chr5:98929171~98995013:+
LUAD	cis	rs5758659	0.653	rs133383	ENSG00000227370.1	RP4-669P10.19	-4.82	1.96e-06	0.000462	-0.19	-0.21	Cognitive function;	chr22:42077599	chr22:42132543~42132998:+
LUAD	cis	rs36093844	0.752	rs4296062	ENSG00000279742.1	RP11-700A24.1	-4.82	1.96e-06	0.000462	-0.32	-0.21	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85818140	chr11:85852557~85854943:-
LUAD	cis	rs9309473	0.514	rs62149659	ENSG00000163016.8	ALMS1P	4.82	1.96e-06	0.000462	0.32	0.21	Metabolite levels;	chr2:73358068	chr2:73644919~73685576:+
LUAD	cis	rs7160336	0.604	rs4903150	ENSG00000259065.1	RP5-1021I20.1	4.82	1.96e-06	0.000463	0.25	0.21	Blood protein levels;	chr14:73844725	chr14:73787360~73803270:+
LUAD	cis	rs2098713	0.599	rs1812818	ENSG00000250155.1	CTD-2353F22.1	4.82	1.97e-06	0.000463	0.22	0.21	Telomere length;	chr5:37546652	chr5:36666214~36725195:-
LUAD	cis	rs17772222	0.917	rs17188228	ENSG00000258983.2	RP11-507K2.2	4.82	1.97e-06	0.000463	0.26	0.21	Coronary artery calcification;	chr14:88738921	chr14:88499334~88515502:+
LUAD	cis	rs2280018	0.526	rs2966128	ENSG00000207425.1	Y_RNA	4.82	1.97e-06	0.000463	0.27	0.21	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059532	chr16:14915457~14915556:-
LUAD	cis	rs6061231	0.624	rs8668	ENSG00000273619.1	RP5-908M14.9	4.82	1.97e-06	0.000463	0.2	0.21	Colorectal cancer;	chr20:62389008	chr20:62386303~62386970:-
LUAD	cis	rs193541	0.632	rs26370	ENSG00000263432.2	RN7SL689P	4.82	1.97e-06	0.000463	0.29	0.21	Glucose homeostasis traits;	chr5:122899497	chr5:123022487~123022783:-
LUAD	cis	rs875971	0.862	rs2901152	ENSG00000232559.3	GS1-124K5.12	-4.82	1.97e-06	0.000464	-0.26	-0.21	Aortic root size;	chr7:66300017	chr7:66554588~66576923:-
LUAD	cis	rs957448	0.561	rs58663902	ENSG00000253704.1	RP11-267M23.4	4.82	1.97e-06	0.000464	0.25	0.21	Nonsyndromic cleft lip with cleft palate;	chr8:94610177	chr8:94553722~94569745:+
LUAD	cis	rs6840258	1	rs7695426	ENSG00000251411.1	RP11-397E7.4	-4.82	1.97e-06	0.000464	-0.28	-0.21	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87000125	chr4:86913266~86914817:-
LUAD	cis	rs7189233	0.531	rs7204758	ENSG00000279344.1	RP11-44F14.7	4.82	1.97e-06	0.000464	0.18	0.21	Intelligence (multi-trait analysis);	chr16:53448453	chr16:53478957~53481550:-
LUAD	cis	rs7189233	0.531	rs9921627	ENSG00000279344.1	RP11-44F14.7	4.82	1.97e-06	0.000464	0.18	0.21	Intelligence (multi-trait analysis);	chr16:53448780	chr16:53478957~53481550:-
LUAD	cis	rs193541	0.632	rs400207	ENSG00000263432.2	RN7SL689P	-4.82	1.97e-06	0.000464	-0.29	-0.21	Glucose homeostasis traits;	chr5:122982802	chr5:123022487~123022783:-
LUAD	cis	rs193541	0.632	rs415417	ENSG00000263432.2	RN7SL689P	-4.82	1.97e-06	0.000464	-0.29	-0.21	Glucose homeostasis traits;	chr5:122987189	chr5:123022487~123022783:-
LUAD	cis	rs193541	0.632	rs62377425	ENSG00000263432.2	RN7SL689P	-4.82	1.97e-06	0.000464	-0.29	-0.21	Glucose homeostasis traits;	chr5:122996930	chr5:123022487~123022783:-
LUAD	cis	rs193541	0.632	rs34714850	ENSG00000263432.2	RN7SL689P	-4.82	1.97e-06	0.000464	-0.29	-0.21	Glucose homeostasis traits;	chr5:122997000	chr5:123022487~123022783:-
LUAD	cis	rs42490	0.966	rs419754	ENSG00000251136.7	RP11-37B2.1	-4.82	1.97e-06	0.000465	-0.22	-0.21	Leprosy;	chr8:89755452	chr8:89609409~89757727:-
LUAD	cis	rs2439831	0.85	rs12442297	ENSG00000249839.1	AC011330.5	-4.81	1.98e-06	0.000465	-0.46	-0.21	Lung cancer in ever smokers;	chr15:43876272	chr15:43663654~43684339:-
LUAD	cis	rs897984	0.806	rs9319588	ENSG00000260911.2	RP11-196G11.2	-4.81	1.98e-06	0.000465	-0.19	-0.21	Dementia with Lewy bodies;	chr16:30919662	chr16:31043150~31049868:+
LUAD	cis	rs897984	0.77	rs12930657	ENSG00000260911.2	RP11-196G11.2	-4.81	1.98e-06	0.000465	-0.19	-0.21	Dementia with Lewy bodies;	chr16:30920647	chr16:31043150~31049868:+
LUAD	cis	rs9322193	0.923	rs9322209	ENSG00000268592.3	RAET1E-AS1	4.81	1.98e-06	0.000465	0.26	0.21	Lung cancer;	chr6:149691226	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.962	rs1413655	ENSG00000268592.3	RAET1E-AS1	4.81	1.98e-06	0.000465	0.27	0.21	Lung cancer;	chr6:149821815	chr6:149863494~149919507:+
LUAD	cis	rs2617170	0.922	rs1049172	ENSG00000245648.1	RP11-277P12.20	4.81	1.98e-06	0.000466	0.27	0.21	Behcet's disease;	chr12:10373141	chr12:10363769~10398506:+
LUAD	cis	rs9659323	0.67	rs12095067	ENSG00000231365.4	RP11-418J17.1	-4.81	1.98e-06	0.000466	-0.25	-0.21	Body mass index;	chr1:119093110	chr1:119140396~119275973:+
LUAD	cis	rs17772222	0.917	rs61986664	ENSG00000258789.1	RP11-507K2.3	-4.81	1.98e-06	0.000466	-0.29	-0.21	Coronary artery calcification;	chr14:88711251	chr14:88551597~88552493:+
LUAD	cis	rs7208859	0.673	rs423151	ENSG00000263531.1	RP13-753N3.1	4.81	1.98e-06	0.000466	0.36	0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30625268	chr17:30863921~30864940:-
LUAD	cis	rs950169	0.887	rs12903946	ENSG00000229212.6	RP11-561C5.4	-4.81	1.98e-06	0.000466	-0.31	-0.21	Schizophrenia;	chr15:84399732	chr15:85205440~85234795:-
LUAD	cis	rs950169	0.887	rs62029593	ENSG00000229212.6	RP11-561C5.4	-4.81	1.98e-06	0.000466	-0.31	-0.21	Schizophrenia;	chr15:84400482	chr15:85205440~85234795:-
LUAD	cis	rs950169	0.81	rs62029594	ENSG00000229212.6	RP11-561C5.4	-4.81	1.98e-06	0.000466	-0.31	-0.21	Schizophrenia;	chr15:84400554	chr15:85205440~85234795:-
LUAD	cis	rs950169	0.881	rs62029596	ENSG00000229212.6	RP11-561C5.4	-4.81	1.98e-06	0.000466	-0.31	-0.21	Schizophrenia;	chr15:84400736	chr15:85205440~85234795:-
LUAD	cis	rs950169	0.881	rs4081123	ENSG00000229212.6	RP11-561C5.4	-4.81	1.98e-06	0.000466	-0.31	-0.21	Schizophrenia;	chr15:84401537	chr15:85205440~85234795:-
LUAD	cis	rs950169	0.881	rs62029599	ENSG00000229212.6	RP11-561C5.4	-4.81	1.98e-06	0.000466	-0.31	-0.21	Schizophrenia;	chr15:84401867	chr15:85205440~85234795:-
LUAD	cis	rs950169	0.8	rs4099846	ENSG00000229212.6	RP11-561C5.4	-4.81	1.98e-06	0.000466	-0.31	-0.21	Schizophrenia;	chr15:84402196	chr15:85205440~85234795:-
LUAD	cis	rs7120173	0.571	rs634044	ENSG00000254851.1	RP11-109L13.1	-4.81	1.98e-06	0.000467	-0.36	-0.21	Visceral adipose tissue adjusted for BMI;	chr11:116881842	chr11:117135528~117138582:+
LUAD	cis	rs7819412	1	rs7819412	ENSG00000255046.1	RP11-297N6.4	-4.81	1.98e-06	0.000467	-0.26	-0.21	Triglycerides;	chr8:11187652	chr8:11797928~11802568:-
LUAD	cis	rs5758659	1	rs5758660	ENSG00000227370.1	RP4-669P10.19	-4.81	1.98e-06	0.000467	-0.19	-0.21	Cognitive function;	chr22:42227712	chr22:42132543~42132998:+
LUAD	cis	rs150992	0.571	rs34488	ENSG00000248489.1	CTD-2007H13.3	4.81	1.98e-06	0.000467	0.27	0.21	Body mass index;	chr5:98977773	chr5:98929171~98995013:+
LUAD	cis	rs3738443	1	rs74152976	ENSG00000259865.1	RP11-488L18.10	4.81	1.99e-06	0.000467	0.23	0.21	Alcohol dependence;	chr1:247183504	chr1:247187281~247188526:-
LUAD	cis	rs12908161	1	rs12908161	ENSG00000259295.5	CSPG4P12	4.81	1.99e-06	0.000467	0.3	0.21	Schizophrenia;	chr15:84664594	chr15:85191438~85213905:+
LUAD	cis	rs2243480	1	rs1723269	ENSG00000164669.11	INTS4P1	4.81	1.99e-06	0.000468	0.38	0.21	Diabetic kidney disease;	chr7:66007799	chr7:65141225~65234216:+
LUAD	cis	rs375066	0.762	rs62114648	ENSG00000267058.1	RP11-15A1.3	4.81	1.99e-06	0.000468	0.24	0.21	Breast cancer;	chr19:43910664	chr19:43891804~43901805:-
LUAD	cis	rs11122895	0.839	rs12999970	ENSG00000236307.2	EEF1E1P1	4.81	1.99e-06	0.000468	0.24	0.21	Allergic sensitization;	chr2:111689254	chr2:111887914~111888741:+
LUAD	cis	rs7712401	0.562	rs2407403	ENSG00000263432.2	RN7SL689P	4.81	1.99e-06	0.000468	0.26	0.21	Mean platelet volume;	chr5:122838336	chr5:123022487~123022783:-
LUAD	cis	rs16873450	0.527	rs12536714	ENSG00000234800.2	PCMTD1P3	4.81	1.99e-06	0.000468	0.25	0.21	Verbal memory performance (residualized delayed recall level);	chr7:23801194	chr7:23721311~23721782:-
LUAD	cis	rs4660214	0.666	rs1537818	ENSG00000228060.1	RP11-69E11.8	4.81	1.99e-06	0.000468	0.19	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39181366	chr1:39565160~39573203:+
LUAD	cis	rs12468226	1	rs7565875	ENSG00000226261.1	AC064836.3	4.81	1.99e-06	0.000468	0.32	0.21	Urate levels;	chr2:202516412	chr2:202336024~202336727:-
LUAD	cis	rs17818399	0.815	rs17819022	ENSG00000279254.1	RP11-536C12.1	-4.81	1.99e-06	0.000468	-0.25	-0.21	Height;	chr2:46623432	chr2:46668870~46670778:+
LUAD	cis	rs2348418	0.733	rs2019011	ENSG00000247934.4	RP11-967K21.1	4.81	1.99e-06	0.000468	0.25	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28228144	chr12:28163298~28190738:-
LUAD	cis	rs12022452	1	rs12022452	ENSG00000238287.1	RP11-656D10.3	-4.81	1.99e-06	0.000469	-0.41	-0.21	Age-related hearing impairment (SNP x SNP interaction);	chr1:40487628	chr1:40493157~40508661:-
LUAD	cis	rs193541	0.632	rs7729834	ENSG00000263432.2	RN7SL689P	4.81	1.99e-06	0.000469	0.29	0.21	Glucose homeostasis traits;	chr5:122786464	chr5:123022487~123022783:-
LUAD	cis	rs11098499	0.739	rs10031033	ENSG00000248280.1	RP11-33B1.2	4.81	1.99e-06	0.000469	0.27	0.21	Corneal astigmatism;	chr4:119230297	chr4:119440561~119450157:-
LUAD	cis	rs2243480	1	rs160652	ENSG00000164669.11	INTS4P1	4.81	1.99e-06	0.000469	0.38	0.21	Diabetic kidney disease;	chr7:66073444	chr7:65141225~65234216:+
LUAD	cis	rs75422866	0.51	rs35784744	ENSG00000276691.1	RP5-1057I20.5	4.81	1.99e-06	0.000469	0.35	0.21	Pneumonia;	chr12:47729646	chr12:47788426~47788971:+
LUAD	cis	rs75422866	0.541	rs12425816	ENSG00000276691.1	RP5-1057I20.5	4.81	1.99e-06	0.000469	0.35	0.21	Pneumonia;	chr12:47731419	chr12:47788426~47788971:+
LUAD	cis	rs7210086	0.808	rs6501558	ENSG00000263893.2	CTD-3010D24.3	4.81	1.99e-06	0.000469	0.3	0.21	Ulcerative colitis;	chr17:72643349	chr17:72642731~72644490:+
LUAD	cis	rs17608059	0.524	rs9897978	ENSG00000236088.8	COX10-AS1	4.81	2e-06	0.000469	0.25	0.21	Temperament;	chr17:13996939	chr17:13756478~14069495:-
LUAD	cis	rs914615	0.552	rs4460629	ENSG00000160766.13	GBAP1	-4.81	2e-06	0.000469	-0.22	-0.21	Urinary albumin-to-creatinine ratio;	chr1:155162859	chr1:155213821~155227422:-
LUAD	cis	rs914615	0.552	rs12752585	ENSG00000160766.13	GBAP1	-4.81	2e-06	0.000469	-0.22	-0.21	Urinary albumin-to-creatinine ratio;	chr1:155162930	chr1:155213821~155227422:-
LUAD	cis	rs7829975	0.742	rs12547493	ENSG00000253981.4	ALG1L13P	-4.81	2e-06	0.00047	-0.25	-0.21	Mood instability;	chr8:8804024	chr8:8236003~8244667:-
LUAD	cis	rs2880765	0.546	rs11639291	ENSG00000259295.5	CSPG4P12	4.81	2e-06	0.00047	0.26	0.21	Coronary artery disease;	chr15:85520899	chr15:85191438~85213905:+
LUAD	cis	rs2439831	0.681	rs528517	ENSG00000249839.1	AC011330.5	-4.81	2e-06	0.00047	-0.39	-0.21	Lung cancer in ever smokers;	chr15:43320727	chr15:43663654~43684339:-
LUAD	cis	rs13256369	0.851	rs11786125	ENSG00000253893.2	FAM85B	-4.81	2e-06	0.00047	-0.3	-0.21	Obesity-related traits;	chr8:8707060	chr8:8167819~8226614:-
LUAD	cis	rs17772222	0.74	rs3783885	ENSG00000258789.1	RP11-507K2.3	-4.81	2e-06	0.000471	-0.28	-0.21	Coronary artery calcification;	chr14:88510714	chr14:88551597~88552493:+
LUAD	cis	rs9990333	0.562	rs56038600	ENSG00000231464.1	AC024937.4	4.81	2e-06	0.000471	0.24	0.21	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196090109	chr3:195996738~195998233:+
LUAD	cis	rs1008375	1	rs10012335	ENSG00000249502.1	AC006160.5	-4.81	2e-06	0.000471	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17627007	chr4:17587467~17614571:-
LUAD	cis	rs473651	0.692	rs579511	ENSG00000229915.1	AC016999.2	-4.81	2e-06	0.000471	-0.28	-0.21	Multiple system atrophy;	chr2:238426273	chr2:238427077~238427729:-
LUAD	cis	rs2243480	1	rs313807	ENSG00000226002.1	RP11-460N20.5	-4.81	2e-06	0.000471	-0.36	-0.21	Diabetic kidney disease;	chr7:66034494	chr7:65084103~65100232:+
LUAD	cis	rs9322193	0.923	rs35961297	ENSG00000268592.3	RAET1E-AS1	4.81	2.01e-06	0.000472	0.26	0.21	Lung cancer;	chr6:149667929	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.923	rs35967444	ENSG00000268592.3	RAET1E-AS1	4.81	2.01e-06	0.000472	0.26	0.21	Lung cancer;	chr6:149675588	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.923	rs62439842	ENSG00000268592.3	RAET1E-AS1	4.81	2.01e-06	0.000472	0.26	0.21	Lung cancer;	chr6:149675847	chr6:149863494~149919507:+
LUAD	cis	rs6840360	1	rs6839074	ENSG00000270265.1	RP11-731D1.4	4.81	2.01e-06	0.000472	0.22	0.21	Intelligence (multi-trait analysis);	chr4:151682205	chr4:151333775~151353224:-
LUAD	cis	rs9487094	0.922	rs1048203	ENSG00000260273.1	RP11-425D10.10	4.81	2.01e-06	0.000472	0.29	0.21	Height;	chr6:109441033	chr6:109382795~109383666:+
LUAD	cis	rs301901	0.664	rs4504403	ENSG00000250155.1	CTD-2353F22.1	4.81	2.01e-06	0.000472	0.22	0.21	Height;	chr5:37481330	chr5:36666214~36725195:-
LUAD	cis	rs17301853	1	rs17373189	ENSG00000227373.4	RP11-160H22.5	-4.81	2.01e-06	0.000472	-0.41	-0.21	Migraine without aura;Migraine - clinic-based;	chr1:174400629	chr1:174115300~174160004:-
LUAD	cis	rs57502260	0.679	rs72936524	ENSG00000212093.1	AP000807.1	4.81	2.01e-06	0.000472	0.3	0.21	Total body bone mineral density (age 45-60);	chr11:68508430	chr11:68506083~68506166:-
LUAD	cis	rs5760092	0.618	rs5996631	ENSG00000206090.4	AP000350.7	-4.81	2.01e-06	0.000473	-0.28	-0.21	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23939998~23942798:+
LUAD	cis	rs867371	0.82	rs7164362	ENSG00000259429.4	UBE2Q2P2	-4.81	2.01e-06	0.000473	-0.2	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82194401	chr15:82355142~82420075:+
LUAD	cis	rs2976388	0.609	rs2717602	ENSG00000253741.1	CTD-2292P10.4	-4.81	2.01e-06	0.000473	-0.25	-0.21	Urinary tract infection frequency;	chr8:142724265	chr8:142702252~142726973:-
LUAD	cis	rs507080	0.922	rs642662	ENSG00000278376.1	RP11-158I9.8	-4.81	2.01e-06	0.000473	-0.24	-0.21	Serum metabolite levels;	chr11:118696311	chr11:118791254~118793137:+
LUAD	cis	rs1334894	0.901	rs72899772	ENSG00000228559.1	RP3-340B19.3	-4.81	2.01e-06	0.000473	-0.42	-0.21	Coronary artery disease;	chr6:35533552	chr6:35544632~35545669:+
LUAD	cis	rs9322193	0.962	rs9397022	ENSG00000268592.3	RAET1E-AS1	4.81	2.01e-06	0.000473	0.27	0.21	Lung cancer;	chr6:149812052	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.962	rs9397357	ENSG00000268592.3	RAET1E-AS1	4.81	2.01e-06	0.000473	0.27	0.21	Lung cancer;	chr6:149812465	chr6:149863494~149919507:+
LUAD	cis	rs12908161	1	rs35316992	ENSG00000259295.5	CSPG4P12	4.81	2.01e-06	0.000473	0.31	0.21	Schizophrenia;	chr15:84704902	chr15:85191438~85213905:+
LUAD	cis	rs12908161	1	rs4643294	ENSG00000259295.5	CSPG4P12	4.81	2.01e-06	0.000473	0.31	0.21	Schizophrenia;	chr15:84707022	chr15:85191438~85213905:+
LUAD	cis	rs12908161	1	rs62021219	ENSG00000259295.5	CSPG4P12	4.81	2.01e-06	0.000473	0.31	0.21	Schizophrenia;	chr15:84712928	chr15:85191438~85213905:+
LUAD	cis	rs12908161	1	rs34900908	ENSG00000259295.5	CSPG4P12	4.81	2.01e-06	0.000473	0.31	0.21	Schizophrenia;	chr15:84714368	chr15:85191438~85213905:+
LUAD	cis	rs12908161	1	rs35524990	ENSG00000259295.5	CSPG4P12	4.81	2.01e-06	0.000473	0.31	0.21	Schizophrenia;	chr15:84714972	chr15:85191438~85213905:+
LUAD	cis	rs6687758	0.687	rs12140498	ENSG00000228437.4	RP11-400N13.2	4.81	2.02e-06	0.000473	0.3	0.21	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221925348	chr1:221966341~221984964:+
LUAD	cis	rs4664293	0.867	rs2303550	ENSG00000226266.5	AC009961.3	-4.81	2.02e-06	0.000474	-0.29	-0.21	Monocyte percentage of white cells;	chr2:159781110	chr2:159670708~159712435:-
LUAD	cis	rs8127691	0.904	rs2070552	ENSG00000237604.1	AP001056.1	4.81	2.02e-06	0.000474	0.25	0.21	Inflammatory bowel disease;	chr21:44197186	chr21:44175489~44176453:+
LUAD	cis	rs801193	1	rs2659906	ENSG00000236529.1	RP13-254B10.1	4.81	2.02e-06	0.000474	0.22	0.21	Aortic root size;	chr7:66700323	chr7:65840212~65840596:+
LUAD	cis	rs6088590	1	rs6087625	ENSG00000276073.1	RP5-1125A11.7	4.81	2.02e-06	0.000474	0.22	0.21	Coronary artery disease;	chr20:34754674	chr20:33985617~33988989:-
LUAD	cis	rs875971	0.66	rs28698552	ENSG00000236529.1	RP13-254B10.1	4.81	2.02e-06	0.000474	0.22	0.21	Aortic root size;	chr7:66540031	chr7:65840212~65840596:+
LUAD	cis	rs875971	0.66	rs62465434	ENSG00000236529.1	RP13-254B10.1	4.81	2.02e-06	0.000474	0.22	0.21	Aortic root size;	chr7:66540165	chr7:65840212~65840596:+
LUAD	cis	rs875971	0.66	rs13224319	ENSG00000236529.1	RP13-254B10.1	4.81	2.02e-06	0.000474	0.22	0.21	Aortic root size;	chr7:66542376	chr7:65840212~65840596:+
LUAD	cis	rs7119	0.717	rs12902925	ENSG00000259362.2	RP11-307C19.1	-4.81	2.02e-06	0.000474	-0.27	-0.21	Type 2 diabetes;	chr15:77526799	chr15:77525540~77534110:+
LUAD	cis	rs1008375	1	rs10027755	ENSG00000249502.1	AC006160.5	-4.81	2.02e-06	0.000474	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17614331	chr4:17587467~17614571:-
LUAD	cis	rs763567	0.933	rs531007	ENSG00000271811.1	RP1-79C4.4	4.81	2.02e-06	0.000474	0.25	0.21	Tonsillectomy;	chr1:170649241	chr1:170667381~170669425:+
LUAD	cis	rs301901	0.965	rs3104057	ENSG00000250155.1	CTD-2353F22.1	-4.81	2.02e-06	0.000474	-0.22	-0.21	Height;	chr5:36982949	chr5:36666214~36725195:-
LUAD	cis	rs2380205	0.517	rs12774886	ENSG00000232807.2	RP11-536K7.3	4.81	2.02e-06	0.000475	0.24	0.21	Breast cancer;	chr10:5929489	chr10:5934270~5945900:-
LUAD	cis	rs2688608	0.592	rs10824031	ENSG00000271816.1	BMS1P4	4.81	2.02e-06	0.000475	0.18	0.21	Inflammatory bowel disease;	chr10:73749515	chr10:73699151~73730487:-
LUAD	cis	rs9549328	0.731	rs7983602	ENSG00000267868.1	RP11-120K24.3	4.81	2.02e-06	0.000475	0.25	0.21	Systolic blood pressure;	chr13:112966168	chr13:112964835~112966131:-
LUAD	cis	rs1008375	0.897	rs6820164	ENSG00000249502.1	AC006160.5	-4.81	2.02e-06	0.000475	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17628492	chr4:17587467~17614571:-
LUAD	cis	rs9322193	0.884	rs7744105	ENSG00000268592.3	RAET1E-AS1	4.81	2.03e-06	0.000475	0.27	0.21	Lung cancer;	chr6:149849308	chr6:149863494~149919507:+
LUAD	cis	rs2880765	0.546	rs35316253	ENSG00000259295.5	CSPG4P12	4.81	2.03e-06	0.000476	0.26	0.21	Coronary artery disease;	chr15:85522329	chr15:85191438~85213905:+
LUAD	cis	rs1008375	1	rs12648232	ENSG00000249502.1	AC006160.5	4.81	2.03e-06	0.000476	0.21	0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17610914	chr4:17587467~17614571:-
LUAD	cis	rs7430456	0.87	rs9864169	ENSG00000225790.1	RP11-2L8.1	-4.81	2.03e-06	0.000476	-0.25	-0.21	Breast cancer;	chr3:177746841	chr3:177934823~177937662:+
LUAD	cis	rs7430456	0.901	rs12696448	ENSG00000225790.1	RP11-2L8.1	-4.81	2.03e-06	0.000476	-0.25	-0.21	Breast cancer;	chr3:177746860	chr3:177934823~177937662:+
LUAD	cis	rs2617170	0.961	rs2734565	ENSG00000245648.1	RP11-277P12.20	4.81	2.03e-06	0.000476	0.26	0.21	Behcet's disease;	chr12:10407992	chr12:10363769~10398506:+
LUAD	cis	rs3743772	0.5	rs11859135	ENSG00000279722.1	RP11-44F14.6	4.81	2.03e-06	0.000476	0.3	0.21	Depressive symptoms (SSRI exposure interaction);	chr16:53404267	chr16:53487607~53489943:-
LUAD	cis	rs113835537	0.877	rs77239910	ENSG00000255517.5	CTD-3074O7.5	-4.81	2.03e-06	0.000477	-0.31	-0.21	Airway imaging phenotypes;	chr11:66562168	chr11:66473490~66480233:-
LUAD	cis	rs12468226	1	rs115170232	ENSG00000272966.1	RP11-686O6.1	4.81	2.03e-06	0.000477	0.35	0.21	Urate levels;	chr2:202416790	chr2:202336739~202337200:+
LUAD	cis	rs12468226	1	rs16839149	ENSG00000272966.1	RP11-686O6.1	4.81	2.03e-06	0.000477	0.35	0.21	Urate levels;	chr2:202427621	chr2:202336739~202337200:+
LUAD	cis	rs2439831	0.681	rs11858152	ENSG00000249839.1	AC011330.5	-4.81	2.03e-06	0.000477	-0.36	-0.21	Lung cancer in ever smokers;	chr15:43341998	chr15:43663654~43684339:-
LUAD	cis	rs9322193	0.566	rs5024811	ENSG00000223701.3	RAET1E-AS1	-4.81	2.03e-06	0.000477	-0.29	-0.21	Lung cancer;	chr6:149924898	chr6:149884431~149919508:+
LUAD	cis	rs71636778	0.509	rs56139710	ENSG00000260063.1	RP5-968P14.2	-4.81	2.03e-06	0.000477	-0.36	-0.21	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26943297	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs11807824	ENSG00000260063.1	RP5-968P14.2	-4.81	2.03e-06	0.000477	-0.36	-0.21	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26943847	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs34473788	ENSG00000260063.1	RP5-968P14.2	-4.81	2.03e-06	0.000477	-0.36	-0.21	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26945028	chr1:26692132~26694131:-
LUAD	cis	rs9309473	0.607	rs7604588	ENSG00000163016.8	ALMS1P	4.81	2.03e-06	0.000477	0.24	0.21	Metabolite levels;	chr2:73344289	chr2:73644919~73685576:+
LUAD	cis	rs6687758	0.687	rs12137323	ENSG00000200033.1	RNU6-403P	4.81	2.04e-06	0.000477	0.3	0.21	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221952186	chr1:221837334~221837437:-
LUAD	cis	rs12745968	0.652	rs4970714	ENSG00000223787.2	RP4-593M8.1	-4.81	2.04e-06	0.000478	-0.27	-0.21	Bipolar disorder and schizophrenia;	chr1:92475800	chr1:92580476~92580821:-
LUAD	cis	rs643506	0.874	rs680096	ENSG00000230911.1	PPIHP1	-4.81	2.04e-06	0.000478	-0.26	-0.21	Breast cancer;	chr11:111837945	chr11:112029858~112030367:-
LUAD	cis	rs6604026	0.555	rs3790450	ENSG00000223787.2	RP4-593M8.1	4.81	2.04e-06	0.000478	0.29	0.21	Multiple sclerosis;	chr1:92625508	chr1:92580476~92580821:-
LUAD	cis	rs7017914	0.559	rs12056347	ENSG00000223220.1	Y_RNA	4.81	2.04e-06	0.000478	0.25	0.21	Bone mineral density;	chr8:71072374	chr8:70780914~70781008:-
LUAD	cis	rs4835473	0.932	rs4092718	ENSG00000251600.4	RP11-673E1.1	-4.81	2.04e-06	0.000478	-0.26	-0.21	Immature fraction of reticulocytes;	chr4:143799637	chr4:143912331~143982454:+
LUAD	cis	rs12908161	0.96	rs34452033	ENSG00000259295.5	CSPG4P12	4.81	2.04e-06	0.000479	0.3	0.21	Schizophrenia;	chr15:84678762	chr15:85191438~85213905:+
LUAD	cis	rs17772222	0.917	rs17260408	ENSG00000258983.2	RP11-507K2.2	4.81	2.04e-06	0.000479	0.26	0.21	Coronary artery calcification;	chr14:88715464	chr14:88499334~88515502:+
LUAD	cis	rs17772222	0.917	rs8021690	ENSG00000258983.2	RP11-507K2.2	4.81	2.04e-06	0.000479	0.26	0.21	Coronary artery calcification;	chr14:88717806	chr14:88499334~88515502:+
LUAD	cis	rs442309	0.687	rs10995294	ENSG00000238280.1	RP11-436D10.3	-4.81	2.04e-06	0.000479	-0.27	-0.21	Vogt-Koyanagi-Harada syndrome;	chr10:62723157	chr10:62793562~62805887:-
LUAD	cis	rs4835473	0.932	rs12509579	ENSG00000251600.4	RP11-673E1.1	-4.81	2.04e-06	0.000479	-0.27	-0.21	Immature fraction of reticulocytes;	chr4:143736821	chr4:143912331~143982454:+
LUAD	cis	rs2832077	0.527	rs2738953	ENSG00000232855.5	AF131217.1	-4.81	2.04e-06	0.000479	-0.22	-0.21	Cognitive test performance;	chr21:28866041	chr21:28439346~28674848:-
LUAD	cis	rs11122895	0.791	rs12623828	ENSG00000236307.2	EEF1E1P1	-4.81	2.04e-06	0.000479	-0.24	-0.21	Allergic sensitization;	chr2:111706782	chr2:111887914~111888741:+
LUAD	cis	rs2742234	0.541	rs2742235	ENSG00000273008.1	RP11-351D16.3	-4.81	2.05e-06	0.00048	-0.25	-0.21	Hirschsprung disease;	chr10:43120877	chr10:43136824~43138334:-
LUAD	cis	rs17684571	0.872	rs11961141	ENSG00000231441.1	RP11-472M19.2	4.81	2.05e-06	0.00048	0.3	0.21	Schizophrenia;	chr6:56717580	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.81	rs60498201	ENSG00000231441.1	RP11-472M19.2	4.81	2.05e-06	0.00048	0.3	0.21	Schizophrenia;	chr6:56718021	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.872	rs35807277	ENSG00000231441.1	RP11-472M19.2	4.81	2.05e-06	0.00048	0.3	0.21	Schizophrenia;	chr6:56718783	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.872	rs34812826	ENSG00000231441.1	RP11-472M19.2	4.81	2.05e-06	0.00048	0.3	0.21	Schizophrenia;	chr6:56721893	chr6:56844002~56864078:+
LUAD	cis	rs875971	1	rs1183245	ENSG00000232559.3	GS1-124K5.12	-4.81	2.05e-06	0.00048	-0.25	-0.21	Aortic root size;	chr7:66076198	chr7:66554588~66576923:-
LUAD	cis	rs875971	1	rs1144895	ENSG00000232559.3	GS1-124K5.12	-4.81	2.05e-06	0.00048	-0.25	-0.21	Aortic root size;	chr7:66076320	chr7:66554588~66576923:-
LUAD	cis	rs875971	1	rs1144894	ENSG00000232559.3	GS1-124K5.12	-4.81	2.05e-06	0.00048	-0.25	-0.21	Aortic root size;	chr7:66077907	chr7:66554588~66576923:-
LUAD	cis	rs9910055	1	rs9910055	ENSG00000267080.4	ASB16-AS1	-4.81	2.05e-06	0.00048	-0.21	-0.21	Total body bone mineral density;	chr17:44205669	chr17:44175973~44186717:-
LUAD	cis	rs2300747	0.932	rs1016140	ENSG00000177173.5	NAP1L4P1	-4.81	2.05e-06	0.00048	-0.34	-0.21	Primary biliary cholangitis;Multiple sclerosis;	chr1:116533925	chr1:116532936~116534092:-
LUAD	cis	rs2836974	0.545	rs3167757	ENSG00000255568.3	BRWD1-AS2	4.81	2.05e-06	0.00048	0.2	0.21	Cognitive function;	chr21:39342552	chr21:39313935~39314962:+
LUAD	cis	rs6964587	0.773	rs62467797	ENSG00000188693.7	CYP51A1-AS1	-4.81	2.05e-06	0.000481	-0.26	-0.21	Breast cancer;	chr7:92260408	chr7:92134604~92180725:+
LUAD	cis	rs4819052	1	rs2297285	ENSG00000215447.6	BX322557.10	4.81	2.05e-06	0.000481	0.28	0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285706	chr21:45288052~45291738:+
LUAD	cis	rs301901	1	rs292194	ENSG00000250155.1	CTD-2353F22.1	4.81	2.05e-06	0.000481	0.22	0.21	Height;	chr5:36941665	chr5:36666214~36725195:-
LUAD	cis	rs801193	0.967	rs2707841	ENSG00000236529.1	RP13-254B10.1	4.81	2.05e-06	0.000481	0.22	0.21	Aortic root size;	chr7:66692033	chr7:65840212~65840596:+
LUAD	cis	rs6728642	0.519	rs4260285	ENSG00000230606.9	AC159540.1	4.81	2.05e-06	0.000481	0.31	0.21	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96904344	chr2:97416165~97433527:-
LUAD	cis	rs875971	0.522	rs6960048	ENSG00000224316.1	RP11-479O9.2	4.81	2.05e-06	0.000482	0.21	0.21	Aortic root size;	chr7:65943052	chr7:65773620~65802067:+
LUAD	cis	rs62158211	1	rs1807282	ENSG00000234997.1	AC016745.3	-4.81	2.05e-06	0.000482	-0.27	-0.21	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113352459	chr2:113424495~113425324:+
LUAD	cis	rs375066	0.935	rs384329	ENSG00000267058.1	RP11-15A1.3	-4.81	2.06e-06	0.000482	-0.24	-0.21	Breast cancer;	chr19:43919829	chr19:43891804~43901805:-
LUAD	cis	rs9322193	1	rs9377229	ENSG00000268592.3	RAET1E-AS1	4.81	2.06e-06	0.000482	0.26	0.21	Lung cancer;	chr6:149607655	chr6:149863494~149919507:+
LUAD	cis	rs7948661	1	rs7941217	ENSG00000278376.1	RP11-158I9.8	-4.81	2.06e-06	0.000482	-0.4	-0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118478532	chr11:118791254~118793137:+
LUAD	cis	rs9473147	0.543	rs1004173	ENSG00000270761.1	RP11-385F7.1	-4.81	2.06e-06	0.000482	-0.25	-0.21	Platelet distribution width;Mean platelet volume;	chr6:47477281	chr6:47477243~47477572:-
LUAD	cis	rs36423	0.748	rs36386	ENSG00000266869.1	RP6-114E22.1	4.81	2.06e-06	0.000482	0.32	0.21	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71901187	chr14:71848606~71908430:+
LUAD	cis	rs1075265	0.756	rs6751105	ENSG00000233266.1	HMGB1P31	4.81	2.06e-06	0.000483	0.27	0.21	Chronotype;Morning vs. evening chronotype;	chr2:54129214	chr2:54051334~54051760:+
LUAD	cis	rs11157436	0.918	rs1983519	ENSG00000211813.2	TRAV34	4.81	2.06e-06	0.000483	0.29	0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22150310	chr14:22207522~22208129:+
LUAD	cis	rs4908768	0.501	rs2045820	ENSG00000270282.1	RP5-1115A15.2	4.81	2.06e-06	0.000483	0.24	0.21	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8678076	chr1:8512653~8513021:+
LUAD	cis	rs2562456	0.793	rs11667392	ENSG00000268081.1	RP11-678G14.2	4.81	2.06e-06	0.000483	0.35	0.21	Pain;	chr19:21289806	chr19:21554640~21569237:-
LUAD	cis	rs13256369	0.95	rs12548792	ENSG00000253893.2	FAM85B	-4.81	2.06e-06	0.000483	-0.3	-0.21	Obesity-related traits;	chr8:8710521	chr8:8167819~8226614:-
LUAD	cis	rs13256369	0.901	rs13251887	ENSG00000253893.2	FAM85B	-4.81	2.06e-06	0.000483	-0.3	-0.21	Obesity-related traits;	chr8:8711168	chr8:8167819~8226614:-
LUAD	cis	rs875971	0.651	rs313829	ENSG00000164669.11	INTS4P1	4.81	2.06e-06	0.000483	0.29	0.21	Aortic root size;	chr7:66087510	chr7:65141225~65234216:+
LUAD	cis	rs1334894	0.901	rs7765792	ENSG00000228559.1	RP3-340B19.3	-4.81	2.06e-06	0.000483	-0.42	-0.21	Coronary artery disease;	chr6:35529731	chr6:35544632~35545669:+
LUAD	cis	rs853679	0.567	rs9969098	ENSG00000216901.1	AL022393.7	4.81	2.06e-06	0.000483	0.27	0.21	Depression;	chr6:28430971	chr6:28176188~28176674:+
LUAD	cis	rs853679	0.567	rs16894106	ENSG00000216901.1	AL022393.7	4.81	2.06e-06	0.000483	0.27	0.21	Depression;	chr6:28432562	chr6:28176188~28176674:+
LUAD	cis	rs7923609	0.875	rs10740118	ENSG00000232075.1	MRPL35P2	4.81	2.06e-06	0.000484	0.26	0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63341447	chr10:63634317~63634827:-
LUAD	cis	rs801193	1	rs1553609	ENSG00000236529.1	RP13-254B10.1	4.81	2.06e-06	0.000484	0.22	0.21	Aortic root size;	chr7:66732152	chr7:65840212~65840596:+
LUAD	cis	rs12935418	0.733	rs12448615	ENSG00000261061.1	RP11-303E16.2	-4.81	2.07e-06	0.000484	-0.3	-0.21	Mean corpuscular volume;	chr16:80947132	chr16:81030770~81031485:+
LUAD	cis	rs6088590	1	rs2295354	ENSG00000276073.1	RP5-1125A11.7	-4.81	2.07e-06	0.000484	-0.22	-0.21	Coronary artery disease;	chr20:34768738	chr20:33985617~33988989:-
LUAD	cis	rs9545047	0.553	rs7332004	ENSG00000227354.5	RBM26-AS1	-4.81	2.07e-06	0.000484	-0.22	-0.21	Schizophrenia;	chr13:79364128	chr13:79406309~79424328:+
LUAD	cis	rs8098244	0.617	rs11872810	ENSG00000264745.1	TTC39C-AS1	4.81	2.07e-06	0.000484	0.22	0.21	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23823416	chr18:23994213~24015339:-
LUAD	cis	rs11976180	1	rs11976037	ENSG00000204959.4	ARHGEF34P	4.81	2.07e-06	0.000484	0.27	0.21	Obesity-related traits;	chr7:144043931	chr7:144272445~144286966:-
LUAD	cis	rs2742234	0.503	rs1254968	ENSG00000273008.1	RP11-351D16.3	4.81	2.07e-06	0.000484	0.25	0.21	Hirschsprung disease;	chr10:43196243	chr10:43136824~43138334:-
LUAD	cis	rs13113518	1	rs11133388	ENSG00000272969.1	RP11-528I4.2	-4.81	2.07e-06	0.000484	-0.22	-0.21	Height;	chr4:55477866	chr4:55547112~55547889:+
LUAD	cis	rs9341808	0.754	rs3812126	ENSG00000272129.1	RP11-250B2.6	-4.81	2.07e-06	0.000484	-0.26	-0.21	Sitting height ratio;	chr6:80242984	chr6:80355424~80356859:+
LUAD	cis	rs301901	0.796	rs62361483	ENSG00000250155.1	CTD-2353F22.1	4.81	2.07e-06	0.000485	0.22	0.21	Height;	chr5:37468413	chr5:36666214~36725195:-
LUAD	cis	rs2115630	0.967	rs8027779	ENSG00000229212.6	RP11-561C5.4	4.81	2.07e-06	0.000485	0.25	0.21	P wave terminal force;	chr15:84712154	chr15:85205440~85234795:-
LUAD	cis	rs9584850	0.834	rs745639	ENSG00000231194.1	FARP1-AS1	4.81	2.07e-06	0.000485	0.26	0.21	Neuroticism;	chr13:98467025	chr13:98435405~98435840:-
LUAD	cis	rs801193	1	rs7788576	ENSG00000236529.1	RP13-254B10.1	-4.81	2.07e-06	0.000485	-0.22	-0.21	Aortic root size;	chr7:66683315	chr7:65840212~65840596:+
LUAD	cis	rs801193	0.935	rs2659916	ENSG00000236529.1	RP13-254B10.1	4.81	2.07e-06	0.000485	0.22	0.21	Aortic root size;	chr7:66686365	chr7:65840212~65840596:+
LUAD	cis	rs801193	1	rs6958520	ENSG00000236529.1	RP13-254B10.1	4.81	2.07e-06	0.000485	0.22	0.21	Aortic root size;	chr7:66686466	chr7:65840212~65840596:+
LUAD	cis	rs801193	0.967	rs2707849	ENSG00000236529.1	RP13-254B10.1	4.81	2.07e-06	0.000485	0.22	0.21	Aortic root size;	chr7:66687725	chr7:65840212~65840596:+
LUAD	cis	rs2252586	0.916	rs7793297	ENSG00000176826.14	FKBP9P1	-4.81	2.07e-06	0.000485	-0.29	-0.21	Glioma;	chr7:54898410	chr7:55681074~55713252:-
LUAD	cis	rs2439831	0.867	rs2447208	ENSG00000249839.1	AC011330.5	-4.8	2.07e-06	0.000485	-0.39	-0.21	Lung cancer in ever smokers;	chr15:43641697	chr15:43663654~43684339:-
LUAD	cis	rs801193	0.935	rs2659899	ENSG00000236529.1	RP13-254B10.1	4.8	2.07e-06	0.000485	0.22	0.21	Aortic root size;	chr7:66721734	chr7:65840212~65840596:+
LUAD	cis	rs801193	1	rs62466794	ENSG00000236529.1	RP13-254B10.1	4.8	2.07e-06	0.000485	0.22	0.21	Aortic root size;	chr7:66726592	chr7:65840212~65840596:+
LUAD	cis	rs7665090	0.87	rs228613	ENSG00000246560.2	RP11-10L12.4	-4.8	2.07e-06	0.000485	-0.27	-0.21	Primary biliary cholangitis;	chr4:102656308	chr4:102828055~102844075:+
LUAD	cis	rs172166	0.516	rs1225715	ENSG00000219392.1	RP1-265C24.5	4.8	2.07e-06	0.000486	0.27	0.21	Cardiac Troponin-T levels;	chr6:28145595	chr6:28115628~28116551:+
LUAD	cis	rs80028505	0.908	rs16883860	ENSG00000271304.1	DPRXP2	-4.8	2.08e-06	0.000486	-0.39	-0.21	Foot ulcer in diabetes and neuropathy;	chr6:36034685	chr6:35989515~35990436:-
LUAD	cis	rs442309	0.64	rs11597299	ENSG00000238280.1	RP11-436D10.3	-4.8	2.08e-06	0.000486	-0.26	-0.21	Vogt-Koyanagi-Harada syndrome;	chr10:62706515	chr10:62793562~62805887:-
LUAD	cis	rs442309	0.687	rs11599754	ENSG00000238280.1	RP11-436D10.3	-4.8	2.08e-06	0.000486	-0.26	-0.21	Vogt-Koyanagi-Harada syndrome;	chr10:62706891	chr10:62793562~62805887:-
LUAD	cis	rs2662776	0.521	rs2815268	ENSG00000232995.6	RGS5	-4.8	2.08e-06	0.000486	-0.2	-0.21	Lead levels in blood;	chr1:163190945	chr1:163244505~163321894:-
LUAD	cis	rs765787	0.53	rs12909987	ENSG00000259520.4	CTD-2651B20.3	4.8	2.08e-06	0.000486	0.27	0.21	Uric acid levels;	chr15:45220009	chr15:45251580~45279251:-
LUAD	cis	rs7763441	0.545	rs9391949	ENSG00000272465.1	RP1-136B1.1	4.8	2.08e-06	0.000487	0.25	0.21	Monobrow;	chr6:2451790	chr6:2437549~2438249:+
LUAD	cis	rs1075265	0.933	rs918357	ENSG00000233266.1	HMGB1P31	4.8	2.08e-06	0.000487	0.27	0.21	Chronotype;Morning vs. evening chronotype;	chr2:54108826	chr2:54051334~54051760:+
LUAD	cis	rs3096299	0.967	rs28689480	ENSG00000182376.2	RP5-1142A6.8	4.8	2.08e-06	0.000487	0.22	0.21	Multiple myeloma (IgH translocation);	chr16:89393685	chr16:88742767~88745748:+
LUAD	cis	rs9341808	0.754	rs6918172	ENSG00000272129.1	RP11-250B2.6	4.8	2.08e-06	0.000487	0.26	0.21	Sitting height ratio;	chr6:80309525	chr6:80355424~80356859:+
LUAD	cis	rs56318008	0.773	rs17837951	ENSG00000228397.1	RP1-224A6.3	-4.8	2.08e-06	0.000487	-0.37	-0.21	Total body bone mineral density;Gestational age at birth (maternal effect);	chr1:22062379	chr1:22023994~22024968:-
LUAD	cis	rs2243480	1	rs1964692	ENSG00000226002.1	RP11-460N20.5	-4.8	2.08e-06	0.000487	-0.36	-0.21	Diabetic kidney disease;	chr7:65989196	chr7:65084103~65100232:+
LUAD	cis	rs9813712	0.571	rs6795143	ENSG00000249846.5	RP11-77P16.4	-4.8	2.08e-06	0.000487	-0.25	-0.21	Response to amphetamines;	chr3:130224355	chr3:130112550~130120579:+
LUAD	cis	rs9813712	0.571	rs9289366	ENSG00000249846.5	RP11-77P16.4	-4.8	2.08e-06	0.000487	-0.25	-0.21	Response to amphetamines;	chr3:130225267	chr3:130112550~130120579:+
LUAD	cis	rs9813712	0.571	rs9289367	ENSG00000249846.5	RP11-77P16.4	-4.8	2.08e-06	0.000487	-0.25	-0.21	Response to amphetamines;	chr3:130225286	chr3:130112550~130120579:+
LUAD	cis	rs9813712	0.571	rs9289368	ENSG00000249846.5	RP11-77P16.4	-4.8	2.08e-06	0.000487	-0.25	-0.21	Response to amphetamines;	chr3:130225562	chr3:130112550~130120579:+
LUAD	cis	rs9813712	0.571	rs6774141	ENSG00000249846.5	RP11-77P16.4	-4.8	2.08e-06	0.000487	-0.25	-0.21	Response to amphetamines;	chr3:130225599	chr3:130112550~130120579:+
LUAD	cis	rs8072100	0.713	rs11079776	ENSG00000228782.6	CTD-2026D20.3	4.8	2.08e-06	0.000487	0.23	0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469527	chr17:47450568~47492492:-
LUAD	cis	rs950169	0.724	rs11632668	ENSG00000229212.6	RP11-561C5.4	-4.8	2.08e-06	0.000487	-0.31	-0.21	Schizophrenia;	chr15:84393989	chr15:85205440~85234795:-
LUAD	cis	rs7772486	0.79	rs9403749	ENSG00000235652.6	RP11-545I5.3	4.8	2.08e-06	0.000488	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145841103	chr6:145799409~145886585:+
LUAD	cis	rs11122895	0.791	rs12373588	ENSG00000236307.2	EEF1E1P1	4.8	2.09e-06	0.000488	0.24	0.21	Allergic sensitization;	chr2:111708688	chr2:111887914~111888741:+
LUAD	cis	rs2998286	0.666	rs2491251	ENSG00000254635.4	WAC-AS1	-4.8	2.09e-06	0.000488	-0.26	-0.21	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28525363	chr10:28522652~28532743:-
LUAD	cis	rs867371	0.519	rs1566560	ENSG00000276710.3	CSPG4P8	-4.8	2.09e-06	0.000488	-0.2	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232116	chr15:82459472~82477258:+
LUAD	cis	rs867371	0.519	rs1566559	ENSG00000276710.3	CSPG4P8	-4.8	2.09e-06	0.000488	-0.2	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232120	chr15:82459472~82477258:+
LUAD	cis	rs897984	0.806	rs10782002	ENSG00000260911.2	RP11-196G11.2	-4.8	2.09e-06	0.000488	-0.19	-0.21	Dementia with Lewy bodies;	chr16:30935185	chr16:31043150~31049868:+
LUAD	cis	rs8072100	0.738	rs9900123	ENSG00000228782.6	CTD-2026D20.3	4.8	2.09e-06	0.000489	0.23	0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47471689	chr17:47450568~47492492:-
LUAD	cis	rs16873450	0.571	rs10268973	ENSG00000234800.2	PCMTD1P3	4.8	2.09e-06	0.000489	0.24	0.21	Verbal memory performance (residualized delayed recall level);	chr7:23763696	chr7:23721311~23721782:-
LUAD	cis	rs55665837	0.539	rs10500804	ENSG00000251991.1	RNU7-49P	4.8	2.09e-06	0.000489	0.24	0.21	Vitamin D levels;	chr11:14888727	chr11:14478892~14478953:+
LUAD	cis	rs801193	1	rs62466793	ENSG00000236529.1	RP13-254B10.1	4.8	2.09e-06	0.000489	0.22	0.21	Aortic root size;	chr7:66726530	chr7:65840212~65840596:+
LUAD	cis	rs910316	1	rs7142235	ENSG00000259138.1	RP11-950C14.7	4.8	2.09e-06	0.000489	0.23	0.21	Height;	chr14:75093260	chr14:75127153~75136930:+
LUAD	cis	rs875971	0.66	rs801192	ENSG00000236529.1	RP13-254B10.1	-4.8	2.09e-06	0.000489	-0.22	-0.21	Aortic root size;	chr7:66566965	chr7:65840212~65840596:+
LUAD	cis	rs875971	0.66	rs801190	ENSG00000236529.1	RP13-254B10.1	-4.8	2.09e-06	0.000489	-0.22	-0.21	Aortic root size;	chr7:66568046	chr7:65840212~65840596:+
LUAD	cis	rs875971	0.66	rs3857686	ENSG00000236529.1	RP13-254B10.1	-4.8	2.09e-06	0.000489	-0.22	-0.21	Aortic root size;	chr7:66571204	chr7:65840212~65840596:+
LUAD	cis	rs875971	0.638	rs3898855	ENSG00000236529.1	RP13-254B10.1	-4.8	2.09e-06	0.000489	-0.22	-0.21	Aortic root size;	chr7:66571411	chr7:65840212~65840596:+
LUAD	cis	rs875971	0.638	rs10278816	ENSG00000236529.1	RP13-254B10.1	-4.8	2.09e-06	0.000489	-0.22	-0.21	Aortic root size;	chr7:66572000	chr7:65840212~65840596:+
LUAD	cis	rs875971	0.66	rs10281080	ENSG00000236529.1	RP13-254B10.1	-4.8	2.09e-06	0.000489	-0.22	-0.21	Aortic root size;	chr7:66577454	chr7:65840212~65840596:+
LUAD	cis	rs240993	0.761	rs9400480	ENSG00000230177.1	RP5-1112D6.4	4.8	2.09e-06	0.000489	0.22	0.21	Inflammatory skin disease;Psoriasis;	chr6:111529394	chr6:111277932~111278742:+
LUAD	cis	rs2243480	1	rs73142166	ENSG00000164669.11	INTS4P1	4.8	2.09e-06	0.00049	0.39	0.21	Diabetic kidney disease;	chr7:65910845	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs3885839	ENSG00000164669.11	INTS4P1	4.8	2.1e-06	0.000491	0.39	0.21	Diabetic kidney disease;	chr7:65825416	chr7:65141225~65234216:+
LUAD	cis	rs2243480	0.901	rs3813708	ENSG00000164669.11	INTS4P1	4.8	2.1e-06	0.000491	0.39	0.21	Diabetic kidney disease;	chr7:65840645	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs73142122	ENSG00000164669.11	INTS4P1	4.8	2.1e-06	0.000491	0.39	0.21	Diabetic kidney disease;	chr7:65846311	chr7:65141225~65234216:+
LUAD	cis	rs2243480	0.901	rs73142137	ENSG00000164669.11	INTS4P1	4.8	2.1e-06	0.000491	0.39	0.21	Diabetic kidney disease;	chr7:65878455	chr7:65141225~65234216:+
LUAD	cis	rs301901	0.828	rs4304095	ENSG00000250155.1	CTD-2353F22.1	4.8	2.1e-06	0.000491	0.22	0.21	Height;	chr5:37454360	chr5:36666214~36725195:-
LUAD	cis	rs2732480	0.5	rs11168464	ENSG00000257735.1	RP11-370I10.6	4.8	2.1e-06	0.000491	0.26	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48208332	chr12:48350945~48442411:+
LUAD	cis	rs7246657	0.525	rs1667351	ENSG00000276846.1	CTD-3220F14.3	4.8	2.1e-06	0.000491	0.28	0.21	Coronary artery calcification;	chr19:36987125	chr19:37314868~37315620:-
LUAD	cis	rs9601248	0.756	rs9601251	ENSG00000227354.5	RBM26-AS1	-4.8	2.1e-06	0.000491	-0.23	-0.21	Major depressive disorder;	chr13:79615582	chr13:79406309~79424328:+
LUAD	cis	rs7829975	0.714	rs6994038	ENSG00000253981.4	ALG1L13P	4.8	2.1e-06	0.000491	0.24	0.21	Mood instability;	chr8:8803028	chr8:8236003~8244667:-
LUAD	cis	rs2153535	0.585	rs1041279	ENSG00000230939.1	RP11-314C16.1	-4.8	2.1e-06	0.000491	-0.24	-0.21	Motion sickness;	chr6:8650293	chr6:8784178~8785445:+
LUAD	cis	rs950169	0.881	rs4842852	ENSG00000229212.6	RP11-561C5.4	-4.8	2.1e-06	0.000492	-0.31	-0.21	Schizophrenia;	chr15:84387263	chr15:85205440~85234795:-
LUAD	cis	rs950169	0.84	rs4842853	ENSG00000229212.6	RP11-561C5.4	-4.8	2.1e-06	0.000492	-0.31	-0.21	Schizophrenia;	chr15:84387606	chr15:85205440~85234795:-
LUAD	cis	rs950169	0.922	rs4842946	ENSG00000229212.6	RP11-561C5.4	-4.8	2.1e-06	0.000492	-0.31	-0.21	Schizophrenia;	chr15:84387633	chr15:85205440~85234795:-
LUAD	cis	rs950169	0.887	rs3860265	ENSG00000229212.6	RP11-561C5.4	-4.8	2.1e-06	0.000492	-0.31	-0.21	Schizophrenia;	chr15:84390487	chr15:85205440~85234795:-
LUAD	cis	rs9322193	0.543	rs9371533	ENSG00000268592.3	RAET1E-AS1	4.8	2.1e-06	0.000492	0.27	0.21	Lung cancer;	chr6:149889545	chr6:149863494~149919507:+
LUAD	cis	rs9487094	0.961	rs9487068	ENSG00000260273.1	RP11-425D10.10	4.8	2.1e-06	0.000492	0.29	0.21	Height;	chr6:109350642	chr6:109382795~109383666:+
LUAD	cis	rs13434995	0.755	rs1488941	ENSG00000273257.1	RP11-177J6.1	-4.8	2.1e-06	0.000492	-0.33	-0.21	Adiponectin levels;	chr4:55517799	chr4:55387949~55388271:+
LUAD	cis	rs720475	0.732	rs7784282	ENSG00000204959.4	ARHGEF34P	-4.8	2.1e-06	0.000492	-0.28	-0.21	Breast cancer;	chr7:144431561	chr7:144272445~144286966:-
LUAD	cis	rs3750965	1	rs61881024	ENSG00000260895.1	RP11-554A11.7	4.8	2.1e-06	0.000492	0.25	0.21	Hair color;	chr11:69070326	chr11:69103493~69109094:+
LUAD	cis	rs7396835	0.741	rs7396851	ENSG00000280143.1	AP000892.6	-4.8	2.11e-06	0.000492	-0.31	-0.21	Quantitative traits;	chr11:116813448	chr11:117204967~117210292:+
LUAD	cis	rs16873450	0.527	rs1017192	ENSG00000234800.2	PCMTD1P3	-4.8	2.11e-06	0.000492	-0.24	-0.21	Verbal memory performance (residualized delayed recall level);	chr7:23770067	chr7:23721311~23721782:-
LUAD	cis	rs9840812	0.577	rs503973	ENSG00000239213.4	NCK1-AS1	-4.8	2.11e-06	0.000492	-0.28	-0.21	Fibrinogen levels;	chr3:136340695	chr3:136841726~136862054:-
LUAD	cis	rs17301013	0.861	rs170768	ENSG00000227373.4	RP11-160H22.5	4.8	2.11e-06	0.000493	0.27	0.21	Systemic lupus erythematosus;	chr1:174720787	chr1:174115300~174160004:-
LUAD	cis	rs8127691	1	rs8127691	ENSG00000237604.1	AP001056.1	4.8	2.11e-06	0.000493	0.25	0.21	Inflammatory bowel disease;	chr21:44194977	chr21:44175489~44176453:+
LUAD	cis	rs2998286	0.862	rs2807763	ENSG00000254635.4	WAC-AS1	4.8	2.11e-06	0.000493	0.27	0.21	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28528702	chr10:28522652~28532743:-
LUAD	cis	rs2243480	0.711	rs1626926	ENSG00000226002.1	RP11-460N20.5	-4.8	2.11e-06	0.000493	-0.36	-0.21	Diabetic kidney disease;	chr7:65970805	chr7:65084103~65100232:+
LUAD	cis	rs17345786	1	rs55641278	ENSG00000244119.1	PDCL3P4	4.8	2.11e-06	0.000493	0.24	0.21	Colonoscopy-negative controls vs population controls;	chr3:101571733	chr3:101712472~101713191:+
LUAD	cis	rs4142110	0.658	rs371824	ENSG00000271216.1	LINC01050	4.8	2.11e-06	0.000493	0.25	0.21	Nephrolithiasis;	chr13:42224498	chr13:42810366~42812562:-
LUAD	cis	rs2286503	0.533	rs1880239	ENSG00000226329.2	AC005682.6	4.8	2.11e-06	0.000493	0.31	0.21	Fibrinogen;	chr7:22832065	chr7:22863874~22881350:-
LUAD	cis	rs950169	0.922	rs11630507	ENSG00000229212.6	RP11-561C5.4	-4.8	2.11e-06	0.000493	-0.3	-0.21	Schizophrenia;	chr15:84552494	chr15:85205440~85234795:-
LUAD	cis	rs2998286	0.636	rs332112	ENSG00000254635.4	WAC-AS1	4.8	2.11e-06	0.000493	0.28	0.21	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28633879	chr10:28522652~28532743:-
LUAD	cis	rs7302981	0.9	rs836179	ENSG00000272368.2	RP4-605O3.4	4.8	2.11e-06	0.000493	0.25	0.21	Systolic blood pressure;	chr12:50109299	chr12:50112197~50165618:+
LUAD	cis	rs17772222	0.74	rs11159857	ENSG00000258789.1	RP11-507K2.3	-4.8	2.11e-06	0.000493	-0.28	-0.21	Coronary artery calcification;	chr14:88510796	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.74	rs4390529	ENSG00000258789.1	RP11-507K2.3	-4.8	2.11e-06	0.000493	-0.28	-0.21	Coronary artery calcification;	chr14:88510853	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.771	rs4516145	ENSG00000258789.1	RP11-507K2.3	-4.8	2.11e-06	0.000493	-0.28	-0.21	Coronary artery calcification;	chr14:88510953	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.74	rs4594187	ENSG00000258789.1	RP11-507K2.3	-4.8	2.11e-06	0.000493	-0.28	-0.21	Coronary artery calcification;	chr14:88511071	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.74	rs4514599	ENSG00000258789.1	RP11-507K2.3	-4.8	2.11e-06	0.000493	-0.28	-0.21	Coronary artery calcification;	chr14:88511083	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.74	rs73317739	ENSG00000258789.1	RP11-507K2.3	-4.8	2.11e-06	0.000493	-0.28	-0.21	Coronary artery calcification;	chr14:88511400	chr14:88551597~88552493:+
LUAD	cis	rs11155671	0.53	rs9322228	ENSG00000268592.3	RAET1E-AS1	4.8	2.11e-06	0.000493	0.26	0.21	Testicular germ cell tumor;	chr6:149888173	chr6:149863494~149919507:+
LUAD	cis	rs11155671	0.53	rs7774787	ENSG00000268592.3	RAET1E-AS1	4.8	2.11e-06	0.000493	0.26	0.21	Testicular germ cell tumor;	chr6:149888296	chr6:149863494~149919507:+
LUAD	cis	rs11155671	0.53	rs2342767	ENSG00000268592.3	RAET1E-AS1	4.8	2.11e-06	0.000493	0.26	0.21	Testicular germ cell tumor;	chr6:149888581	chr6:149863494~149919507:+
LUAD	cis	rs11155671	0.53	rs7764376	ENSG00000268592.3	RAET1E-AS1	4.8	2.11e-06	0.000493	0.26	0.21	Testicular germ cell tumor;	chr6:149889208	chr6:149863494~149919507:+
LUAD	cis	rs11155671	0.53	rs6933882	ENSG00000268592.3	RAET1E-AS1	4.8	2.11e-06	0.000493	0.26	0.21	Testicular germ cell tumor;	chr6:149889666	chr6:149863494~149919507:+
LUAD	cis	rs11155671	0.53	rs6939761	ENSG00000268592.3	RAET1E-AS1	4.8	2.11e-06	0.000493	0.26	0.21	Testicular germ cell tumor;	chr6:149889858	chr6:149863494~149919507:+
LUAD	cis	rs11155671	0.53	rs3823021	ENSG00000268592.3	RAET1E-AS1	4.8	2.11e-06	0.000493	0.26	0.21	Testicular germ cell tumor;	chr6:149889863	chr6:149863494~149919507:+
LUAD	cis	rs11155671	0.53	rs4869764	ENSG00000268592.3	RAET1E-AS1	4.8	2.11e-06	0.000493	0.26	0.21	Testicular germ cell tumor;	chr6:149890692	chr6:149863494~149919507:+
LUAD	cis	rs7189233	0.531	rs16952246	ENSG00000279344.1	RP11-44F14.7	4.8	2.11e-06	0.000494	0.18	0.21	Intelligence (multi-trait analysis);	chr16:53446797	chr16:53478957~53481550:-
LUAD	cis	rs301901	1	rs301901	ENSG00000250155.1	CTD-2353F22.1	-4.8	2.11e-06	0.000494	-0.22	-0.21	Height;	chr5:37046524	chr5:36666214~36725195:-
LUAD	cis	rs1707322	1	rs11211223	ENSG00000280836.1	AL355480.1	-4.8	2.11e-06	0.000494	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914933	chr1:45581219~45581321:-
LUAD	cis	rs61270009	0.913	rs3733809	ENSG00000247828.6	TMEM161B-AS1	4.8	2.11e-06	0.000494	0.25	0.21	Depressive symptoms;	chr5:88410112	chr5:88268895~88436685:+
LUAD	cis	rs7674212	0.772	rs13113099	ENSG00000246560.2	RP11-10L12.4	4.8	2.11e-06	0.000494	0.27	0.21	Type 2 diabetes;	chr4:103052965	chr4:102828055~102844075:+
LUAD	cis	rs7937890	0.505	rs4403769	ENSG00000251991.1	RNU7-49P	4.8	2.11e-06	0.000494	0.23	0.21	Mitochondrial DNA levels;	chr11:14428630	chr11:14478892~14478953:+
LUAD	cis	rs9322193	0.923	rs9322197	ENSG00000268592.3	RAET1E-AS1	4.8	2.12e-06	0.000494	0.26	0.21	Lung cancer;	chr6:149622577	chr6:149863494~149919507:+
LUAD	cis	rs2239547	0.562	rs2581810	ENSG00000242142.1	SERBP1P3	-4.8	2.12e-06	0.000494	-0.25	-0.21	Schizophrenia;	chr3:52926843	chr3:53064283~53065091:-
LUAD	cis	rs1355223	0.902	rs836467	ENSG00000271369.1	RP11-350D17.3	-4.8	2.12e-06	0.000494	-0.25	-0.21	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34715885	chr11:34709600~34710161:+
LUAD	cis	rs4664293	0.609	rs10209829	ENSG00000226266.5	AC009961.3	-4.8	2.12e-06	0.000495	-0.28	-0.21	Monocyte percentage of white cells;	chr2:159591113	chr2:159670708~159712435:-
LUAD	cis	rs4713118	0.615	rs9295747	ENSG00000219392.1	RP1-265C24.5	4.8	2.12e-06	0.000495	0.26	0.21	Parkinson's disease;	chr6:27769214	chr6:28115628~28116551:+
LUAD	cis	rs12554020	0.892	rs12341488	ENSG00000227603.1	RP11-165J3.6	4.8	2.12e-06	0.000495	0.33	0.21	Schizophrenia;	chr9:93568889	chr9:93435332~93437121:-
LUAD	cis	rs2115630	1	rs2879828	ENSG00000229212.6	RP11-561C5.4	4.8	2.12e-06	0.000495	0.24	0.21	P wave terminal force;	chr15:84818746	chr15:85205440~85234795:-
LUAD	cis	rs116139393	0.611	rs62439722	ENSG00000187953.9	PMS2CL	-4.8	2.12e-06	0.000495	-0.28	-0.21	Alzheimer's disease (APOE e4 interaction);	chr7:6725309	chr7:6710128~6753862:+
LUAD	cis	rs10266483	0.739	rs679966	ENSG00000228653.2	HNRNPCP7	-4.8	2.12e-06	0.000495	-0.26	-0.21	Response to statin therapy;	chr7:64306688	chr7:64500825~64501729:+
LUAD	cis	rs6840258	0.941	rs72667757	ENSG00000251411.1	RP11-397E7.4	-4.8	2.12e-06	0.000495	-0.29	-0.21	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87025842	chr4:86913266~86914817:-
LUAD	cis	rs8180040	1	rs2302278	ENSG00000271161.1	BOLA2P2	-4.8	2.12e-06	0.000495	-0.2	-0.21	Colorectal cancer;	chr3:47319592	chr3:47499841~47500407:+
LUAD	cis	rs643506	0.874	rs631318	ENSG00000230911.1	PPIHP1	4.8	2.12e-06	0.000495	0.26	0.21	Breast cancer;	chr11:111806971	chr11:112029858~112030367:-
LUAD	cis	rs12908161	0.853	rs12912342	ENSG00000259295.5	CSPG4P12	4.8	2.12e-06	0.000495	0.28	0.21	Schizophrenia;	chr15:84704985	chr15:85191438~85213905:+
LUAD	cis	rs801193	1	rs7782320	ENSG00000236529.1	RP13-254B10.1	4.8	2.12e-06	0.000496	0.22	0.21	Aortic root size;	chr7:66712111	chr7:65840212~65840596:+
LUAD	cis	rs467650	0.553	rs149508	ENSG00000248489.1	CTD-2007H13.3	4.8	2.12e-06	0.000496	0.24	0.21	Venous thromboembolism (SNP x SNP interaction);	chr5:98642741	chr5:98929171~98995013:+
LUAD	cis	rs467650	0.553	rs40807	ENSG00000248489.1	CTD-2007H13.3	4.8	2.12e-06	0.000496	0.24	0.21	Venous thromboembolism (SNP x SNP interaction);	chr5:98646095	chr5:98929171~98995013:+
LUAD	cis	rs467650	0.553	rs27706	ENSG00000248489.1	CTD-2007H13.3	4.8	2.12e-06	0.000496	0.24	0.21	Venous thromboembolism (SNP x SNP interaction);	chr5:98646475	chr5:98929171~98995013:+
LUAD	cis	rs467650	0.553	rs40173	ENSG00000248489.1	CTD-2007H13.3	4.8	2.12e-06	0.000496	0.24	0.21	Venous thromboembolism (SNP x SNP interaction);	chr5:98647713	chr5:98929171~98995013:+
LUAD	cis	rs467650	0.553	rs27020	ENSG00000248489.1	CTD-2007H13.3	4.8	2.12e-06	0.000496	0.24	0.21	Venous thromboembolism (SNP x SNP interaction);	chr5:98647962	chr5:98929171~98995013:+
LUAD	cis	rs12908161	1	rs35630683	ENSG00000275120.1	RP11-182J1.17	4.8	2.12e-06	0.000496	0.32	0.21	Schizophrenia;	chr15:84806000	chr15:84599434~84606463:-
LUAD	cis	rs1075265	0.669	rs805330	ENSG00000233266.1	HMGB1P31	4.8	2.12e-06	0.000496	0.27	0.21	Chronotype;Morning vs. evening chronotype;	chr2:53921194	chr2:54051334~54051760:+
LUAD	cis	rs2554380	0.628	rs4843156	ENSG00000230373.7	GOLGA6L5P	-4.8	2.12e-06	0.000496	-0.22	-0.21	Height;	chr15:83788593	chr15:84507885~84516814:-
LUAD	cis	rs9910055	0.659	rs7212573	ENSG00000267080.4	ASB16-AS1	-4.8	2.12e-06	0.000496	-0.2	-0.21	Total body bone mineral density;	chr17:44176913	chr17:44175973~44186717:-
LUAD	cis	rs763567	0.933	rs567328	ENSG00000271811.1	RP1-79C4.4	4.8	2.12e-06	0.000496	0.26	0.21	Tonsillectomy;	chr1:170644728	chr1:170667381~170669425:+
LUAD	cis	rs62025270	0.688	rs62025272	ENSG00000202081.1	RNU6-1280P	-4.8	2.12e-06	0.000496	-0.3	-0.21	Idiopathic pulmonary fibrosis;	chr15:85770391	chr15:85651522~85651628:-
LUAD	cis	rs801193	1	rs1553610	ENSG00000236529.1	RP13-254B10.1	4.8	2.13e-06	0.000497	0.22	0.21	Aortic root size;	chr7:66732246	chr7:65840212~65840596:+
LUAD	cis	rs72717009	0.825	rs61802846	ENSG00000225217.1	HSPA7	-4.8	2.13e-06	0.000497	-0.31	-0.21	Rheumatoid arthritis;	chr1:161504083	chr1:161606291~161608217:+
LUAD	cis	rs8098244	0.617	rs34511347	ENSG00000264745.1	TTC39C-AS1	4.8	2.13e-06	0.000497	0.22	0.21	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23822920	chr18:23994213~24015339:-
LUAD	cis	rs4664293	0.867	rs3771721	ENSG00000226266.5	AC009961.3	-4.8	2.13e-06	0.000497	-0.29	-0.21	Monocyte percentage of white cells;	chr2:159771644	chr2:159670708~159712435:-
LUAD	cis	rs2378497	1	rs12117316	ENSG00000232679.1	RP11-400N13.3	4.8	2.13e-06	0.000497	0.32	0.21	Serum thyroid-stimulating hormone levels;	chr1:222012627	chr1:222041705~222064763:-
LUAD	cis	rs7617773	0.925	rs34513961	ENSG00000228638.1	FCF1P2	-4.8	2.13e-06	0.000497	-0.26	-0.21	Coronary artery disease;	chr3:48132163	chr3:48290793~48291375:-
LUAD	cis	rs2033711	0.783	rs8113810	ENSG00000268912.1	CTD-2619J13.17	-4.8	2.13e-06	0.000497	-0.23	-0.21	Uric acid clearance;	chr19:58420739	chr19:58428632~58431148:-
LUAD	cis	rs2028299	0.839	rs2279849	ENSG00000259677.1	RP11-493E3.1	4.8	2.13e-06	0.000498	0.26	0.21	Type 2 diabetes;	chr15:89901407	chr15:89876540~89877285:+
LUAD	cis	rs2380205	0.538	rs11255698	ENSG00000232807.2	RP11-536K7.3	4.8	2.13e-06	0.000498	0.24	0.21	Breast cancer;	chr10:5878930	chr10:5934270~5945900:-
LUAD	cis	rs2243480	1	rs781157	ENSG00000226002.1	RP11-460N20.5	-4.8	2.13e-06	0.000498	-0.36	-0.21	Diabetic kidney disease;	chr7:66013324	chr7:65084103~65100232:+
LUAD	cis	rs9650657	0.529	rs10108618	ENSG00000255046.1	RP11-297N6.4	4.8	2.13e-06	0.000498	0.26	0.21	Neuroticism;	chr8:11095582	chr8:11797928~11802568:-
LUAD	cis	rs8072100	0.582	rs3826536	ENSG00000228782.6	CTD-2026D20.3	4.8	2.14e-06	0.000498	0.23	0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47424601	chr17:47450568~47492492:-
LUAD	cis	rs8072100	0.676	rs9908049	ENSG00000228782.6	CTD-2026D20.3	4.8	2.14e-06	0.000498	0.23	0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47424730	chr17:47450568~47492492:-
LUAD	cis	rs17406451	0.633	rs13422268	ENSG00000279873.2	LINC01126	4.8	2.14e-06	0.000498	0.18	0.21	Mitochondrial DNA levels;	chr2:43534919	chr2:43227210~43228855:+
LUAD	cis	rs2554380	0.628	rs7179507	ENSG00000230373.7	GOLGA6L5P	-4.8	2.14e-06	0.000499	-0.22	-0.21	Height;	chr15:83804779	chr15:84507885~84516814:-
LUAD	cis	rs6088590	1	rs55753039	ENSG00000276073.1	RP5-1125A11.7	-4.8	2.14e-06	0.000499	-0.22	-0.21	Coronary artery disease;	chr20:34807137	chr20:33985617~33988989:-
LUAD	cis	rs7083	0.84	rs509565	ENSG00000254851.1	RP11-109L13.1	4.8	2.14e-06	0.000499	0.27	0.21	Blood protein levels;	chr11:117249757	chr11:117135528~117138582:+
LUAD	cis	rs801193	0.935	rs11772264	ENSG00000236529.1	RP13-254B10.1	4.8	2.14e-06	0.000499	0.22	0.21	Aortic root size;	chr7:66711400	chr7:65840212~65840596:+
LUAD	cis	rs910316	0.934	rs7141705	ENSG00000259138.1	RP11-950C14.7	-4.8	2.14e-06	0.000499	-0.23	-0.21	Height;	chr14:75188649	chr14:75127153~75136930:+
LUAD	cis	rs71520386	0.561	rs10274260	ENSG00000228649.7	AC005682.5	-4.8	2.14e-06	0.000499	-0.29	-0.21	Fibrinogen levels;	chr7:22805227	chr7:22854178~22861579:+
LUAD	cis	rs516805	0.748	rs12212981	ENSG00000279453.1	RP3-425C14.4	4.8	2.14e-06	5e-04	0.31	0.21	Lymphocyte counts;	chr6:122580854	chr6:122436789~122439223:-
LUAD	cis	rs9322193	0.923	rs12660304	ENSG00000268592.3	RAET1E-AS1	4.8	2.14e-06	5e-04	0.26	0.21	Lung cancer;	chr6:149739647	chr6:149863494~149919507:+
LUAD	cis	rs1707322	0.964	rs10890358	ENSG00000280836.1	AL355480.1	-4.8	2.14e-06	5e-04	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853353	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs7531911	ENSG00000280836.1	AL355480.1	-4.8	2.14e-06	5e-04	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864751	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs10890359	ENSG00000280836.1	AL355480.1	-4.8	2.14e-06	5e-04	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45870963	chr1:45581219~45581321:-
LUAD	cis	rs763121	0.853	rs5757181	ENSG00000228274.3	RP3-508I15.9	-4.8	2.14e-06	5e-04	-0.22	-0.21	Menopause (age at onset);	chr22:38617517	chr22:38667585~38681820:-
LUAD	cis	rs2018683	0.899	rs10479817	ENSG00000228421.2	AC005013.5	4.8	2.14e-06	5e-04	0.24	0.21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28938531	chr7:28957667~28959345:+
LUAD	cis	rs453301	0.686	rs11785634	ENSG00000173295.6	FAM86B3P	-4.8	2.14e-06	5e-04	-0.23	-0.21	Joint mobility (Beighton score);	chr8:9035087	chr8:8228595~8244865:+
LUAD	cis	rs2976388	0.967	rs2976397	ENSG00000253741.1	CTD-2292P10.4	4.8	2.14e-06	5e-04	0.25	0.21	Urinary tract infection frequency;	chr8:142683195	chr8:142702252~142726973:-
LUAD	cis	rs9322193	0.847	rs56103941	ENSG00000268592.3	RAET1E-AS1	4.8	2.14e-06	5e-04	0.27	0.21	Lung cancer;	chr6:149816095	chr6:149863494~149919507:+
LUAD	cis	rs2554380	0.628	rs2401130	ENSG00000230373.7	GOLGA6L5P	-4.8	2.14e-06	5e-04	-0.23	-0.21	Height;	chr15:83801983	chr15:84507885~84516814:-
LUAD	cis	rs2554380	0.628	rs2401131	ENSG00000230373.7	GOLGA6L5P	-4.8	2.14e-06	5e-04	-0.23	-0.21	Height;	chr15:83802144	chr15:84507885~84516814:-
LUAD	cis	rs9287719	0.699	rs4669602	ENSG00000234818.1	AC092687.5	4.8	2.15e-06	0.000501	0.26	0.21	Prostate cancer;	chr2:10647841	chr2:10589166~10604830:+
LUAD	cis	rs712039	0.617	rs60118041	ENSG00000276054.1	RP11-378E13.3	4.8	2.15e-06	0.000501	0.32	0.21	Tuberculosis;	chr17:37443151	chr17:37386886~37387926:+
LUAD	cis	rs712039	0.652	rs1829453	ENSG00000276054.1	RP11-378E13.3	4.8	2.15e-06	0.000501	0.32	0.21	Tuberculosis;	chr17:37449741	chr17:37386886~37387926:+
LUAD	cis	rs2732480	0.557	rs2409004	ENSG00000240399.1	RP1-228P16.1	4.8	2.15e-06	0.000501	0.21	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48327668	chr12:48054813~48055591:-
LUAD	cis	rs9425766	0.566	rs56188862	ENSG00000227373.4	RP11-160H22.5	4.8	2.15e-06	0.000501	0.27	0.21	Life satisfaction;	chr1:174220131	chr1:174115300~174160004:-
LUAD	cis	rs35934224	0.783	rs34593728	ENSG00000232926.1	AC000078.5	4.8	2.15e-06	0.000501	0.23	0.21	Glaucoma (primary open-angle);	chr22:19869966	chr22:19887289~19887970:+
LUAD	cis	rs4664293	0.51	rs57575372	ENSG00000226266.5	AC009961.3	4.8	2.15e-06	0.000501	0.29	0.21	Monocyte percentage of white cells;	chr2:159569253	chr2:159670708~159712435:-
LUAD	cis	rs2524005	1	rs2524005	ENSG00000227262.3	HCG4B	-4.8	2.15e-06	0.000501	-0.28	-0.21	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29925983~29926973:-
LUAD	cis	rs2243480	0.803	rs35480979	ENSG00000229886.1	RP5-1132H15.3	4.8	2.15e-06	0.000502	0.38	0.21	Diabetic kidney disease;	chr7:65892097	chr7:66025126~66031544:-
LUAD	cis	rs1008375	1	rs12507142	ENSG00000249502.1	AC006160.5	-4.8	2.15e-06	0.000502	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17654480	chr4:17587467~17614571:-
LUAD	cis	rs950169	0.887	rs220333	ENSG00000229212.6	RP11-561C5.4	-4.8	2.15e-06	0.000502	-0.3	-0.21	Schizophrenia;	chr15:84547902	chr15:85205440~85234795:-
LUAD	cis	rs875971	0.522	rs1968127	ENSG00000224316.1	RP11-479O9.2	-4.8	2.15e-06	0.000502	-0.21	-0.21	Aortic root size;	chr7:66591816	chr7:65773620~65802067:+
LUAD	cis	rs6728642	0.908	rs6731522	ENSG00000230606.9	AC159540.1	4.8	2.16e-06	0.000503	0.33	0.21	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96982260	chr2:97416165~97433527:-
LUAD	cis	rs875971	0.66	rs801192	ENSG00000224316.1	RP11-479O9.2	-4.8	2.16e-06	0.000503	-0.21	-0.21	Aortic root size;	chr7:66566965	chr7:65773620~65802067:+
LUAD	cis	rs875971	0.66	rs801190	ENSG00000224316.1	RP11-479O9.2	-4.8	2.16e-06	0.000503	-0.21	-0.21	Aortic root size;	chr7:66568046	chr7:65773620~65802067:+
LUAD	cis	rs875971	0.66	rs3857686	ENSG00000224316.1	RP11-479O9.2	-4.8	2.16e-06	0.000503	-0.21	-0.21	Aortic root size;	chr7:66571204	chr7:65773620~65802067:+
LUAD	cis	rs875971	0.638	rs3898855	ENSG00000224316.1	RP11-479O9.2	-4.8	2.16e-06	0.000503	-0.21	-0.21	Aortic root size;	chr7:66571411	chr7:65773620~65802067:+
LUAD	cis	rs875971	0.638	rs10278816	ENSG00000224316.1	RP11-479O9.2	-4.8	2.16e-06	0.000503	-0.21	-0.21	Aortic root size;	chr7:66572000	chr7:65773620~65802067:+
LUAD	cis	rs875971	0.66	rs10281080	ENSG00000224316.1	RP11-479O9.2	-4.8	2.16e-06	0.000503	-0.21	-0.21	Aortic root size;	chr7:66577454	chr7:65773620~65802067:+
LUAD	cis	rs875971	0.638	rs801205	ENSG00000236529.1	RP13-254B10.1	-4.8	2.16e-06	0.000503	-0.22	-0.21	Aortic root size;	chr7:66557157	chr7:65840212~65840596:+
LUAD	cis	rs875971	0.617	rs810400	ENSG00000236529.1	RP13-254B10.1	-4.8	2.16e-06	0.000503	-0.22	-0.21	Aortic root size;	chr7:66557902	chr7:65840212~65840596:+
LUAD	cis	rs5758511	0.68	rs5758684	ENSG00000205702.9	CYP2D7	4.8	2.16e-06	0.000503	0.21	0.21	Birth weight;	chr22:42253503	chr22:42140203~42144577:-
LUAD	cis	rs561341	0.882	rs2428337	ENSG00000265798.5	RP11-271K11.5	4.8	2.16e-06	0.000503	0.34	0.21	Hip circumference adjusted for BMI;	chr17:31972448	chr17:31038575~31059121:-
LUAD	cis	rs116175783	0.557	rs72876083	ENSG00000227403.1	AC009299.3	4.8	2.16e-06	0.000503	0.4	0.21	Intelligence (multi-trait analysis);	chr2:161327527	chr2:161244739~161249050:+
LUAD	cis	rs11673344	0.698	rs56161518	ENSG00000226686.6	LINC01535	4.8	2.16e-06	0.000503	0.29	0.21	Obesity-related traits;	chr19:36978555	chr19:37251912~37265535:+
LUAD	cis	rs673078	0.66	rs17440364	ENSG00000275409.1	RP11-131L12.4	-4.8	2.16e-06	0.000504	-0.31	-0.21	Glucose homeostasis traits;	chr12:118186613	chr12:118430147~118430699:+
LUAD	cis	rs74233809	1	rs5011520	ENSG00000213277.3	MARCKSL1P1	4.8	2.16e-06	0.000504	0.37	0.21	Birth weight;	chr10:102937759	chr10:103175554~103176094:+
LUAD	cis	rs9322193	0.847	rs12210605	ENSG00000268592.3	RAET1E-AS1	4.8	2.16e-06	0.000504	0.27	0.21	Lung cancer;	chr6:149817267	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.923	rs9371199	ENSG00000268592.3	RAET1E-AS1	4.8	2.16e-06	0.000504	0.27	0.21	Lung cancer;	chr6:149817526	chr6:149863494~149919507:+
LUAD	cis	rs17772222	0.917	rs61984737	ENSG00000258983.2	RP11-507K2.2	4.8	2.16e-06	0.000504	0.26	0.21	Coronary artery calcification;	chr14:88637028	chr14:88499334~88515502:+
LUAD	cis	rs4664293	0.867	rs11681245	ENSG00000226266.5	AC009961.3	-4.8	2.16e-06	0.000504	-0.29	-0.21	Monocyte percentage of white cells;	chr2:159772882	chr2:159670708~159712435:-
LUAD	cis	rs6088590	1	rs3787222	ENSG00000276073.1	RP5-1125A11.7	-4.8	2.16e-06	0.000504	-0.22	-0.21	Coronary artery disease;	chr20:34745236	chr20:33985617~33988989:-
LUAD	cis	rs516805	0.528	rs2684241	ENSG00000279453.1	RP3-425C14.4	-4.8	2.16e-06	0.000505	-0.28	-0.21	Lymphocyte counts;	chr6:122089903	chr6:122436789~122439223:-
LUAD	cis	rs2836950	0.565	rs7278297	ENSG00000255568.3	BRWD1-AS2	-4.8	2.17e-06	0.000505	-0.21	-0.21	Menarche (age at onset);	chr21:39253826	chr21:39313935~39314962:+
LUAD	cis	rs7937890	0.559	rs2597196	ENSG00000251991.1	RNU7-49P	-4.8	2.17e-06	0.000505	-0.22	-0.21	Mitochondrial DNA levels;	chr11:14470055	chr11:14478892~14478953:+
LUAD	cis	rs8072100	0.581	rs4267364	ENSG00000228782.6	CTD-2026D20.3	4.8	2.17e-06	0.000506	0.23	0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47703898	chr17:47450568~47492492:-
LUAD	cis	rs4835473	0.932	rs4287958	ENSG00000251600.4	RP11-673E1.1	4.8	2.17e-06	0.000506	0.26	0.21	Immature fraction of reticulocytes;	chr4:143987719	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs4125545	ENSG00000251600.4	RP11-673E1.1	4.8	2.17e-06	0.000506	0.26	0.21	Immature fraction of reticulocytes;	chr4:143988650	chr4:143912331~143982454:+
LUAD	cis	rs875971	0.638	rs801205	ENSG00000224316.1	RP11-479O9.2	-4.8	2.17e-06	0.000506	-0.21	-0.21	Aortic root size;	chr7:66557157	chr7:65773620~65802067:+
LUAD	cis	rs875971	0.617	rs810400	ENSG00000224316.1	RP11-479O9.2	-4.8	2.17e-06	0.000506	-0.21	-0.21	Aortic root size;	chr7:66557902	chr7:65773620~65802067:+
LUAD	cis	rs4664293	0.528	rs12477092	ENSG00000226266.5	AC009961.3	4.8	2.17e-06	0.000506	0.29	0.21	Monocyte percentage of white cells;	chr2:159577170	chr2:159670708~159712435:-
LUAD	cis	rs12745968	0.653	rs10874736	ENSG00000223787.2	RP4-593M8.1	-4.8	2.17e-06	0.000506	-0.25	-0.21	Bipolar disorder and schizophrenia;	chr1:92714639	chr1:92580476~92580821:-
LUAD	cis	rs73173548	0.502	rs34933255	ENSG00000247828.6	TMEM161B-AS1	4.8	2.17e-06	0.000506	0.26	0.21	Macular telangiectasia type 2;	chr5:88446492	chr5:88268895~88436685:+
LUAD	cis	rs73173548	0.502	rs12188494	ENSG00000247828.6	TMEM161B-AS1	4.8	2.17e-06	0.000506	0.26	0.21	Macular telangiectasia type 2;	chr5:88447747	chr5:88268895~88436685:+
LUAD	cis	rs9487094	0.677	rs4428538	ENSG00000260273.1	RP11-425D10.10	4.79	2.17e-06	0.000507	0.33	0.21	Height;	chr6:109409645	chr6:109382795~109383666:+
LUAD	cis	rs638893	0.617	rs2156750	ENSG00000278376.1	RP11-158I9.8	-4.79	2.18e-06	0.000507	-0.25	-0.21	Vitiligo;	chr11:118848545	chr11:118791254~118793137:+
LUAD	cis	rs638893	0.561	rs2156749	ENSG00000278376.1	RP11-158I9.8	-4.79	2.18e-06	0.000507	-0.25	-0.21	Vitiligo;	chr11:118848696	chr11:118791254~118793137:+
LUAD	cis	rs453301	0.686	rs11787026	ENSG00000233609.3	RP11-62H7.2	4.79	2.18e-06	0.000507	0.18	0.21	Joint mobility (Beighton score);	chr8:9044861	chr8:8961200~8979025:+
LUAD	cis	rs1008375	0.932	rs9283698	ENSG00000249502.1	AC006160.5	-4.79	2.18e-06	0.000507	-0.21	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17660848	chr4:17587467~17614571:-
LUAD	cis	rs375066	0.935	rs423765	ENSG00000267058.1	RP11-15A1.3	-4.79	2.18e-06	0.000508	-0.24	-0.21	Breast cancer;	chr19:43912047	chr19:43891804~43901805:-
LUAD	cis	rs5758511	0.689	rs17478227	ENSG00000226450.2	CYP2D8P	-4.79	2.18e-06	0.000508	-0.23	-0.21	Birth weight;	chr22:42258321	chr22:42149886~42155001:-
LUAD	cis	rs2562456	0.833	rs55899865	ENSG00000268081.1	RP11-678G14.2	4.79	2.18e-06	0.000508	0.35	0.21	Pain;	chr19:21298933	chr19:21554640~21569237:-
LUAD	cis	rs5758659	1	rs5758659	ENSG00000227370.1	RP4-669P10.19	-4.79	2.18e-06	0.000508	-0.19	-0.21	Cognitive function;	chr22:42225997	chr22:42132543~42132998:+
LUAD	cis	rs6687758	0.687	rs7520544	ENSG00000200033.1	RNU6-403P	4.79	2.18e-06	0.000508	0.29	0.21	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221943856	chr1:221837334~221837437:-
LUAD	cis	rs1008375	0.872	rs6831115	ENSG00000249502.1	AC006160.5	-4.79	2.18e-06	0.000508	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17638840	chr4:17587467~17614571:-
LUAD	cis	rs1008375	1	rs6811887	ENSG00000249502.1	AC006160.5	-4.79	2.18e-06	0.000508	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17639235	chr4:17587467~17614571:-
LUAD	cis	rs1008375	1	rs28501187	ENSG00000249502.1	AC006160.5	-4.79	2.18e-06	0.000508	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17641997	chr4:17587467~17614571:-
LUAD	cis	rs11122895	0.72	rs3860381	ENSG00000236307.2	EEF1E1P1	4.79	2.18e-06	0.000509	0.24	0.21	Allergic sensitization;	chr2:111707072	chr2:111887914~111888741:+
LUAD	cis	rs1008375	1	rs28552744	ENSG00000249502.1	AC006160.5	-4.79	2.19e-06	0.000509	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17618542	chr4:17587467~17614571:-
LUAD	cis	rs875971	0.66	rs2013222	ENSG00000224316.1	RP11-479O9.2	-4.79	2.19e-06	0.000509	-0.21	-0.21	Aortic root size;	chr7:66570949	chr7:65773620~65802067:+
LUAD	cis	rs1062177	0.855	rs6892117	ENSG00000253921.1	CTB-113P19.3	4.79	2.19e-06	0.000509	0.29	0.21	Preschool internalizing problems;	chr5:151885424	chr5:151753992~151767247:+
LUAD	cis	rs1964356	0.967	rs2953802	ENSG00000173295.6	FAM86B3P	4.79	2.19e-06	0.000509	0.24	0.21	Mean corpuscular volume;	chr8:8994371	chr8:8228595~8244865:+
LUAD	cis	rs7246657	0.722	rs958305	ENSG00000276846.1	CTD-3220F14.3	-4.79	2.19e-06	0.00051	-0.28	-0.21	Coronary artery calcification;	chr19:37698539	chr19:37314868~37315620:-
LUAD	cis	rs9813712	0.574	rs11718032	ENSG00000249846.5	RP11-77P16.4	4.79	2.19e-06	0.00051	0.25	0.21	Response to amphetamines;	chr3:130257749	chr3:130112550~130120579:+
LUAD	cis	rs2657294	0.62	rs2395132	ENSG00000226051.5	ZNF503-AS1	-4.79	2.19e-06	0.00051	-0.28	-0.21	Pneumonia;	chr10:75080840	chr10:75269819~75373500:+
LUAD	cis	rs160451	0.899	rs218918	ENSG00000251136.7	RP11-37B2.1	-4.79	2.19e-06	0.00051	-0.22	-0.21	Leprosy;	chr8:89690153	chr8:89609409~89757727:-
LUAD	cis	rs9545047	0.604	rs7988784	ENSG00000227354.5	RBM26-AS1	-4.79	2.19e-06	0.00051	-0.22	-0.21	Schizophrenia;	chr13:79335337	chr13:79406309~79424328:+
LUAD	cis	rs34779708	0.966	rs1148245	ENSG00000271335.4	RP11-324I22.4	4.79	2.19e-06	0.00051	0.22	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35222966	chr10:35314552~35336401:-
LUAD	cis	rs12701220	0.948	rs12690826	ENSG00000229043.2	AC091729.9	-4.79	2.19e-06	0.00051	-0.28	-0.21	Bronchopulmonary dysplasia;	chr7:1041982	chr7:1160374~1165267:+
LUAD	cis	rs1816752	0.805	rs61614647	ENSG00000273628.1	RP11-756A22.7	4.79	2.19e-06	0.00051	0.24	0.21	Obesity-related traits;	chr13:24441829	chr13:24933006~24936796:+
LUAD	cis	rs6687758	0.945	rs17011182	ENSG00000228437.4	RP11-400N13.2	4.79	2.19e-06	0.000511	0.31	0.21	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221990985	chr1:221966341~221984964:+
LUAD	cis	rs2732480	0.557	rs2732441	ENSG00000257735.1	RP11-370I10.6	4.79	2.19e-06	0.000511	0.26	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48329541	chr12:48350945~48442411:+
LUAD	cis	rs910316	0.967	rs11159116	ENSG00000259138.1	RP11-950C14.7	4.79	2.19e-06	0.000511	0.23	0.21	Height;	chr14:75083881	chr14:75127153~75136930:+
LUAD	cis	rs9322193	0.923	rs10747276	ENSG00000268592.3	RAET1E-AS1	4.79	2.2e-06	0.000511	0.26	0.21	Lung cancer;	chr6:149758739	chr6:149863494~149919507:+
LUAD	cis	rs2742234	0.915	rs2742233	ENSG00000273008.1	RP11-351D16.3	-4.79	2.2e-06	0.000512	-0.23	-0.21	Hirschsprung disease;	chr10:43115110	chr10:43136824~43138334:-
LUAD	cis	rs2948294	0.588	rs4840913	ENSG00000173295.6	FAM86B3P	4.79	2.2e-06	0.000512	0.24	0.21	Red cell distribution width;	chr8:8259384	chr8:8228595~8244865:+
LUAD	cis	rs2018683	0.711	rs1874977	ENSG00000228421.2	AC005013.5	4.79	2.2e-06	0.000512	0.24	0.21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28928466	chr7:28957667~28959345:+
LUAD	cis	rs6969780	0.722	rs983185	ENSG00000233429.8	HOTAIRM1	-4.79	2.2e-06	0.000512	-0.32	-0.21	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27148988	chr7:27095647~27100265:+
LUAD	cis	rs1387259	0.839	rs7486941	ENSG00000257735.1	RP11-370I10.6	-4.79	2.2e-06	0.000512	-0.24	-0.21	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48184848	chr12:48350945~48442411:+
LUAD	cis	rs4664293	0.867	rs1427329	ENSG00000226266.5	AC009961.3	-4.79	2.2e-06	0.000512	-0.3	-0.21	Monocyte percentage of white cells;	chr2:159748301	chr2:159670708~159712435:-
LUAD	cis	rs1008375	1	rs2872958	ENSG00000249502.1	AC006160.5	-4.79	2.2e-06	0.000513	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17663409	chr4:17587467~17614571:-
LUAD	cis	rs5760092	0.618	rs5996631	ENSG00000099984.9	GSTT2	4.79	2.2e-06	0.000513	0.29	0.21	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23980123~23983911:+
LUAD	cis	rs13256369	0.708	rs11249886	ENSG00000253893.2	FAM85B	-4.79	2.2e-06	0.000513	-0.3	-0.21	Obesity-related traits;	chr8:8704511	chr8:8167819~8226614:-
LUAD	cis	rs9910055	0.573	rs228768	ENSG00000267080.4	ASB16-AS1	-4.79	2.2e-06	0.000513	-0.19	-0.21	Total body bone mineral density;	chr17:44114525	chr17:44175973~44186717:-
LUAD	cis	rs1008375	1	rs10939743	ENSG00000249502.1	AC006160.5	-4.79	2.21e-06	0.000513	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17661108	chr4:17587467~17614571:-
LUAD	cis	rs2898681	1	rs2003198	ENSG00000248375.1	RP11-177B4.1	-4.79	2.21e-06	0.000513	-0.32	-0.21	Optic nerve measurement (cup area);	chr4:52882416	chr4:52720081~52720831:-
LUAD	cis	rs13256369	0.802	rs1060107	ENSG00000253893.2	FAM85B	-4.79	2.21e-06	0.000513	-0.3	-0.21	Obesity-related traits;	chr8:8703889	chr8:8167819~8226614:-
LUAD	cis	rs13256369	0.802	rs4840350	ENSG00000253893.2	FAM85B	-4.79	2.21e-06	0.000513	-0.3	-0.21	Obesity-related traits;	chr8:8703932	chr8:8167819~8226614:-
LUAD	cis	rs13256369	0.802	rs1060106	ENSG00000253893.2	FAM85B	-4.79	2.21e-06	0.000513	-0.3	-0.21	Obesity-related traits;	chr8:8703942	chr8:8167819~8226614:-
LUAD	cis	rs13256369	0.802	rs11249883	ENSG00000253893.2	FAM85B	-4.79	2.21e-06	0.000513	-0.3	-0.21	Obesity-related traits;	chr8:8704027	chr8:8167819~8226614:-
LUAD	cis	rs9322193	0.962	rs9322206	ENSG00000268592.3	RAET1E-AS1	4.79	2.21e-06	0.000513	0.26	0.21	Lung cancer;	chr6:149641481	chr6:149863494~149919507:+
LUAD	cis	rs7017914	0.69	rs10090230	ENSG00000223220.1	Y_RNA	4.79	2.21e-06	0.000513	0.25	0.21	Bone mineral density;	chr8:70884778	chr8:70780914~70781008:-
LUAD	cis	rs11051970	0.659	rs2728674	ENSG00000274964.1	RP11-817I4.1	-4.79	2.21e-06	0.000514	-0.24	-0.21	Response to tocilizumab in rheumatoid arthritis;	chr12:32434531	chr12:32339368~32340724:+
LUAD	cis	rs2919009	0.551	rs7080781	ENSG00000271670.1	RP11-95I16.4	4.79	2.21e-06	0.000514	0.28	0.21	Obesity-related traits;	chr10:120962171	chr10:120879256~120880667:-
LUAD	cis	rs853679	0.882	rs9461432	ENSG00000204709.4	LINC01556	4.79	2.21e-06	0.000514	0.36	0.21	Depression;	chr6:28119105	chr6:28943877~28944537:+
LUAD	cis	rs2243480	1	rs4718270	ENSG00000164669.11	INTS4P1	4.79	2.21e-06	0.000514	0.38	0.21	Diabetic kidney disease;	chr7:65737415	chr7:65141225~65234216:+
LUAD	cis	rs2243480	0.901	rs2900904	ENSG00000164669.11	INTS4P1	4.79	2.21e-06	0.000514	0.38	0.21	Diabetic kidney disease;	chr7:65739282	chr7:65141225~65234216:+
LUAD	cis	rs638893	0.617	rs7116715	ENSG00000278376.1	RP11-158I9.8	-4.79	2.21e-06	0.000514	-0.25	-0.21	Vitiligo;	chr11:118849033	chr11:118791254~118793137:+
LUAD	cis	rs12468226	1	rs7597156	ENSG00000226261.1	AC064836.3	4.79	2.21e-06	0.000514	0.33	0.21	Urate levels;	chr2:202329339	chr2:202336024~202336727:-
LUAD	cis	rs7119	0.717	rs12915548	ENSG00000259362.2	RP11-307C19.1	-4.79	2.21e-06	0.000514	-0.27	-0.21	Type 2 diabetes;	chr15:77525700	chr15:77525540~77534110:+
LUAD	cis	rs7119	0.717	rs12917314	ENSG00000259362.2	RP11-307C19.1	-4.79	2.21e-06	0.000514	-0.27	-0.21	Type 2 diabetes;	chr15:77525943	chr15:77525540~77534110:+
LUAD	cis	rs7119	0.717	rs12916822	ENSG00000259362.2	RP11-307C19.1	-4.79	2.21e-06	0.000514	-0.27	-0.21	Type 2 diabetes;	chr15:77526206	chr15:77525540~77534110:+
LUAD	cis	rs910316	1	rs876402	ENSG00000279594.1	RP11-950C14.10	-4.79	2.21e-06	0.000514	-0.24	-0.21	Height;	chr14:75135159	chr14:75011269~75012851:-
LUAD	cis	rs7811142	0.83	rs6945952	ENSG00000078319.8	PMS2P1	-4.79	2.21e-06	0.000515	-0.26	-0.21	Platelet count;	chr7:100384152	chr7:100320992~100341908:-
LUAD	cis	rs7811142	0.83	rs73401451	ENSG00000078319.8	PMS2P1	-4.79	2.21e-06	0.000515	-0.26	-0.21	Platelet count;	chr7:100384272	chr7:100320992~100341908:-
LUAD	cis	rs875971	0.638	rs6460305	ENSG00000224316.1	RP11-479O9.2	-4.79	2.21e-06	0.000515	-0.21	-0.21	Aortic root size;	chr7:66595421	chr7:65773620~65802067:+
LUAD	cis	rs950169	0.84	rs12905223	ENSG00000259295.5	CSPG4P12	4.79	2.21e-06	0.000515	0.31	0.21	Schizophrenia;	chr15:84571037	chr15:85191438~85213905:+
LUAD	cis	rs2288884	0.943	rs11084131	ENSG00000269959.1	SPACA6P-AS	-4.79	2.22e-06	0.000515	-0.28	-0.21	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52011193	chr19:51685363~51693456:-
LUAD	cis	rs2288884	0.943	rs11084132	ENSG00000269959.1	SPACA6P-AS	-4.79	2.22e-06	0.000515	-0.28	-0.21	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52011327	chr19:51685363~51693456:-
LUAD	cis	rs1426063	1	rs10022563	ENSG00000249717.1	RP11-44F21.3	4.79	2.22e-06	0.000515	0.31	0.21	QT interval;	chr4:75100989	chr4:74955974~74970362:-
LUAD	cis	rs7302981	0.741	rs4459386	ENSG00000272368.2	RP4-605O3.4	-4.79	2.22e-06	0.000515	-0.24	-0.21	Systolic blood pressure;	chr12:50201164	chr12:50112197~50165618:+
LUAD	cis	rs9910055	0.96	rs9911991	ENSG00000267080.4	ASB16-AS1	-4.79	2.22e-06	0.000516	-0.2	-0.21	Total body bone mineral density;	chr17:44201548	chr17:44175973~44186717:-
LUAD	cis	rs10971721	0.643	rs41315997	ENSG00000260947.1	RP11-384P7.7	4.79	2.22e-06	0.000516	0.49	0.21	Body mass index;	chr9:33798840	chr9:33697459~33700986:+
LUAD	cis	rs6957923	0.818	rs12538407	ENSG00000230658.1	KLHL7-AS1	4.79	2.22e-06	0.000516	0.25	0.21	Height;	chr7:23481697	chr7:23101228~23105703:-
LUAD	cis	rs9652601	0.779	rs12935413	ENSG00000274038.1	RP11-66H6.4	-4.79	2.22e-06	0.000516	-0.26	-0.21	Systemic lupus erythematosus;	chr16:11116590	chr16:11056556~11057034:+
LUAD	cis	rs36093844	0.642	rs17148574	ENSG00000279742.1	RP11-700A24.1	-4.79	2.22e-06	0.000516	-0.22	-0.21	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85897231	chr11:85852557~85854943:-
LUAD	cis	rs5758659	0.679	rs134870	ENSG00000182057.4	OGFRP1	4.79	2.22e-06	0.000516	0.25	0.21	Cognitive function;	chr22:42256311	chr22:42269753~42275196:+
LUAD	cis	rs11673344	0.764	rs16971873	ENSG00000226686.6	LINC01535	4.79	2.22e-06	0.000516	0.27	0.21	Obesity-related traits;	chr19:36978521	chr19:37251912~37265535:+
LUAD	cis	rs6570726	0.791	rs436498	ENSG00000235652.6	RP11-545I5.3	4.79	2.22e-06	0.000516	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145555211	chr6:145799409~145886585:+
LUAD	cis	rs12908161	1	rs17601029	ENSG00000275120.1	RP11-182J1.17	4.79	2.22e-06	0.000517	0.32	0.21	Schizophrenia;	chr15:84804478	chr15:84599434~84606463:-
LUAD	cis	rs559928	1	rs72926038	ENSG00000236935.1	AP003774.1	4.79	2.22e-06	0.000517	0.3	0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64374919	chr11:64325050~64329504:-
LUAD	cis	rs559928	0.947	rs56339474	ENSG00000236935.1	AP003774.1	4.79	2.22e-06	0.000517	0.3	0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64375006	chr11:64325050~64329504:-
LUAD	cis	rs761746	0.582	rs7287054	ENSG00000236132.1	CTA-440B3.1	-4.79	2.22e-06	0.000517	-0.28	-0.21	Intelligence;	chr22:31844735	chr22:31816379~31817491:-
LUAD	cis	rs8072100	0.967	rs8078880	ENSG00000228782.6	CTD-2026D20.3	-4.79	2.22e-06	0.000517	-0.22	-0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47599160	chr17:47450568~47492492:-
LUAD	cis	rs1008375	1	rs11724495	ENSG00000249502.1	AC006160.5	-4.79	2.22e-06	0.000517	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17619687	chr4:17587467~17614571:-
LUAD	cis	rs6570726	0.791	rs414600	ENSG00000235652.6	RP11-545I5.3	4.79	2.23e-06	0.000517	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145558470	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.791	rs6915094	ENSG00000235652.6	RP11-545I5.3	4.79	2.23e-06	0.000517	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145562404	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.791	rs365869	ENSG00000235652.6	RP11-545I5.3	4.79	2.23e-06	0.000517	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145563615	chr6:145799409~145886585:+
LUAD	cis	rs9322193	0.924	rs9322189	ENSG00000268592.3	RAET1E-AS1	4.79	2.23e-06	0.000518	0.26	0.21	Lung cancer;	chr6:149588797	chr6:149863494~149919507:+
LUAD	cis	rs73173548	0.502	rs6865869	ENSG00000247828.6	TMEM161B-AS1	4.79	2.23e-06	0.000518	0.26	0.21	Macular telangiectasia type 2;	chr5:88449645	chr5:88268895~88436685:+
LUAD	cis	rs853679	1	rs9986596	ENSG00000204709.4	LINC01556	4.79	2.23e-06	0.000518	0.33	0.21	Depression;	chr6:28251883	chr6:28943877~28944537:+
LUAD	cis	rs2492286	0.673	rs17255991	ENSG00000242551.2	POU5F1P6	4.79	2.23e-06	0.000518	0.35	0.21	Eosinophil counts;	chr3:128637371	chr3:128674735~128677005:-
LUAD	cis	rs950169	0.84	rs4842854	ENSG00000229212.6	RP11-561C5.4	-4.79	2.23e-06	0.000518	-0.31	-0.21	Schizophrenia;	chr15:84387641	chr15:85205440~85234795:-
LUAD	cis	rs2521295	1	rs2521295	ENSG00000236264.4	RPL26P30	-4.79	2.23e-06	0.000518	-0.29	-0.21	Monocyte count;	chr11:2327630	chr11:2335132~2335776:-
LUAD	cis	rs477895	0.838	rs7111278	ENSG00000236935.1	AP003774.1	-4.79	2.23e-06	0.000518	-0.26	-0.21	Mean platelet volume;	chr11:64248812	chr11:64325050~64329504:-
LUAD	cis	rs477895	0.838	rs2001003	ENSG00000236935.1	AP003774.1	-4.79	2.23e-06	0.000518	-0.26	-0.21	Mean platelet volume;	chr11:64251215	chr11:64325050~64329504:-
LUAD	cis	rs477895	0.878	rs7478730	ENSG00000236935.1	AP003774.1	-4.79	2.23e-06	0.000518	-0.26	-0.21	Mean platelet volume;	chr11:64251355	chr11:64325050~64329504:-
LUAD	cis	rs11009175	0.746	rs17230579	ENSG00000273038.2	RP11-479G22.8	4.79	2.23e-06	0.000519	0.3	0.21	Depression (quantitative trait);	chr10:33059117	chr10:32887255~32889311:-
LUAD	cis	rs6714710	0.535	rs13006932	ENSG00000230606.9	AC159540.1	-4.79	2.23e-06	0.000519	-0.23	-0.21	Posterior cortical atrophy and Alzheimer's disease;	chr2:97754235	chr2:97416165~97433527:-
LUAD	cis	rs8127691	0.967	rs8134436	ENSG00000237604.1	AP001056.1	4.79	2.23e-06	0.000519	0.25	0.21	Inflammatory bowel disease;	chr21:44196614	chr21:44175489~44176453:+
LUAD	cis	rs11700536	1	rs2839636	ENSG00000236663.1	AP001631.9	4.79	2.24e-06	0.00052	0.26	0.21	Interleukin-18 levels;	chr21:43139085	chr21:43140523~43141092:-
LUAD	cis	rs12468226	1	rs77435512	ENSG00000272966.1	RP11-686O6.1	4.79	2.24e-06	0.00052	0.32	0.21	Urate levels;	chr2:202334165	chr2:202336739~202337200:+
LUAD	cis	rs7937890	1	rs7937890	ENSG00000254418.1	RP11-21L19.1	4.79	2.24e-06	0.00052	0.25	0.21	Mitochondrial DNA levels;	chr11:14374939	chr11:14262846~14273691:-
LUAD	cis	rs11667325	1	rs11667325	ENSG00000268316.1	AC006272.2	4.79	2.24e-06	0.00052	0.22	0.21	Neutrophil percentage of granulocytes;	chr19:51797810	chr19:51839771~51840945:-
LUAD	cis	rs875971	0.522	rs7784623	ENSG00000237310.1	GS1-124K5.4	4.79	2.24e-06	0.00052	0.23	0.21	Aortic root size;	chr7:65930047	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.522	rs34973832	ENSG00000237310.1	GS1-124K5.4	4.79	2.24e-06	0.00052	0.23	0.21	Aortic root size;	chr7:65931217	chr7:66493706~66495474:+
LUAD	cis	rs2439831	0.867	rs3101443	ENSG00000249839.1	AC011330.5	-4.79	2.24e-06	0.00052	-0.4	-0.21	Lung cancer in ever smokers;	chr15:43620174	chr15:43663654~43684339:-
LUAD	cis	rs17406451	0.655	rs6708660	ENSG00000279873.2	LINC01126	4.79	2.24e-06	0.00052	0.18	0.21	Mitochondrial DNA levels;	chr2:43525243	chr2:43227210~43228855:+
LUAD	cis	rs2734839	0.507	rs2471850	ENSG00000270179.1	RP11-159N11.4	-4.79	2.24e-06	0.00052	-0.24	-0.21	Information processing speed;	chr11:113430544	chr11:113368478~113369117:+
LUAD	cis	rs7119	0.651	rs8041520	ENSG00000259362.2	RP11-307C19.1	-4.79	2.24e-06	0.00052	-0.27	-0.21	Type 2 diabetes;	chr15:77546827	chr15:77525540~77534110:+
LUAD	cis	rs301901	1	rs158796	ENSG00000250155.1	CTD-2353F22.1	-4.79	2.24e-06	0.00052	-0.22	-0.21	Height;	chr5:36878678	chr5:36666214~36725195:-
LUAD	cis	rs5758659	0.716	rs2143138	ENSG00000182057.4	OGFRP1	4.79	2.24e-06	0.000521	0.25	0.21	Cognitive function;	chr22:42222334	chr22:42269753~42275196:+
LUAD	cis	rs638893	0.617	rs4938561	ENSG00000278376.1	RP11-158I9.8	-4.79	2.24e-06	0.000521	-0.25	-0.21	Vitiligo;	chr11:118847776	chr11:118791254~118793137:+
LUAD	cis	rs8031584	0.678	rs798125	ENSG00000259845.1	HERC2P10	-4.79	2.24e-06	0.000521	-0.26	-0.21	Huntington's disease progression;	chr15:30824597	chr15:30815271~30844153:+
LUAD	cis	rs189798	0.592	rs10111263	ENSG00000253981.4	ALG1L13P	-4.79	2.24e-06	0.000521	-0.24	-0.21	Myopia (pathological);	chr8:9111923	chr8:8236003~8244667:-
LUAD	cis	rs9659323	0.64	rs11800444	ENSG00000231365.4	RP11-418J17.1	-4.79	2.25e-06	0.000522	-0.25	-0.21	Body mass index;	chr1:119097052	chr1:119140396~119275973:+
LUAD	cis	rs4660456	0.572	rs1008204	ENSG00000237899.1	RP4-739H11.3	4.79	2.25e-06	0.000522	0.24	0.21	Platelet count;	chr1:40700189	chr1:40669089~40687588:-
LUAD	cis	rs7208859	0.614	rs73265646	ENSG00000263603.1	CTD-2349P21.5	-4.79	2.25e-06	0.000522	-0.39	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917005	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs58908911	ENSG00000263603.1	CTD-2349P21.5	-4.79	2.25e-06	0.000522	-0.39	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917540	chr17:30729469~30731202:+
LUAD	cis	rs7937890	0.559	rs2597208	ENSG00000251991.1	RNU7-49P	4.79	2.25e-06	0.000522	0.23	0.21	Mitochondrial DNA levels;	chr11:14450783	chr11:14478892~14478953:+
LUAD	cis	rs17711722	0.727	rs2658585	ENSG00000237310.1	GS1-124K5.4	4.79	2.25e-06	0.000522	0.23	0.21	Calcium levels;	chr7:65996954	chr7:66493706~66495474:+
LUAD	cis	rs1850744	0.826	rs9291607	ENSG00000163612.10	FAM86KP	4.79	2.25e-06	0.000522	0.55	0.21	Economic and political preferences;	chr4:9707174	chr4:9153296~9165451:+
LUAD	cis	rs13315649	0.639	rs73196928	ENSG00000242551.2	POU5F1P6	-4.79	2.25e-06	0.000522	-0.26	-0.21	Sum eosinophil basophil counts;	chr3:128670583	chr3:128674735~128677005:-
LUAD	cis	rs4968361	0.892	rs58003080	ENSG00000266992.1	DHX40P1	4.79	2.25e-06	0.000522	0.39	0.21	Schizophrenia;	chr17:59437596	chr17:59976009~60002384:-
LUAD	cis	rs801193	0.967	rs2707853	ENSG00000236529.1	RP13-254B10.1	4.79	2.25e-06	0.000523	0.22	0.21	Aortic root size;	chr7:66749023	chr7:65840212~65840596:+
LUAD	cis	rs801193	1	rs2659889	ENSG00000236529.1	RP13-254B10.1	4.79	2.25e-06	0.000523	0.22	0.21	Aortic root size;	chr7:66752125	chr7:65840212~65840596:+
LUAD	cis	rs7208859	0.673	rs28588622	ENSG00000263603.1	CTD-2349P21.5	-4.79	2.25e-06	0.000523	-0.39	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30918681	chr17:30729469~30731202:+
LUAD	cis	rs17508449	0.865	rs4839330	ENSG00000232450.1	RP4-730K3.3	-4.79	2.25e-06	0.000523	-0.36	-0.21	Leprosy;	chr1:113594960	chr1:113698884~113699631:-
LUAD	cis	rs17508449	0.865	rs75296543	ENSG00000232450.1	RP4-730K3.3	-4.79	2.25e-06	0.000523	-0.36	-0.21	Leprosy;	chr1:113595664	chr1:113698884~113699631:-
LUAD	cis	rs12745968	0.652	rs4970702	ENSG00000223787.2	RP4-593M8.1	-4.79	2.25e-06	0.000523	-0.27	-0.21	Bipolar disorder and schizophrenia;	chr1:92479437	chr1:92580476~92580821:-
LUAD	cis	rs8180040	0.62	rs6442055	ENSG00000271161.1	BOLA2P2	4.79	2.26e-06	0.000524	0.21	0.21	Colorectal cancer;	chr3:47069232	chr3:47499841~47500407:+
LUAD	cis	rs1062177	1	rs2347596	ENSG00000253921.1	CTB-113P19.3	-4.79	2.26e-06	0.000524	-0.32	-0.21	Preschool internalizing problems;	chr5:151799638	chr5:151753992~151767247:+
LUAD	cis	rs2378497	1	rs56236427	ENSG00000232679.1	RP11-400N13.3	4.79	2.26e-06	0.000524	0.34	0.21	Serum thyroid-stimulating hormone levels;	chr1:221988852	chr1:222041705~222064763:-
LUAD	cis	rs16944613	0.588	rs6416553	ENSG00000259212.1	CTD-3065B20.2	-4.79	2.26e-06	0.000524	-0.34	-0.21	Colorectal cancer;	chr15:90592179	chr15:90595840~90596447:-
LUAD	cis	rs6570726	0.791	rs408443	ENSG00000235652.6	RP11-545I5.3	4.79	2.26e-06	0.000524	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145553507	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.791	rs436156	ENSG00000235652.6	RP11-545I5.3	4.79	2.26e-06	0.000524	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145553737	chr6:145799409~145886585:+
LUAD	cis	rs13256369	1	rs13266699	ENSG00000253893.2	FAM85B	4.79	2.26e-06	0.000524	0.3	0.21	Obesity-related traits;	chr8:8712803	chr8:8167819~8226614:-
LUAD	cis	rs9322193	0.736	rs3828701	ENSG00000268592.3	RAET1E-AS1	4.79	2.26e-06	0.000524	0.26	0.21	Lung cancer;	chr6:149791063	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.736	rs3805750	ENSG00000268592.3	RAET1E-AS1	4.79	2.26e-06	0.000524	0.26	0.21	Lung cancer;	chr6:149791065	chr6:149863494~149919507:+
LUAD	cis	rs950169	0.922	rs62029585	ENSG00000229212.6	RP11-561C5.4	-4.79	2.26e-06	0.000524	-0.31	-0.21	Schizophrenia;	chr15:84397176	chr15:85205440~85234795:-
LUAD	cis	rs4664293	0.51	rs2113861	ENSG00000226266.5	AC009961.3	4.79	2.26e-06	0.000525	0.29	0.21	Monocyte percentage of white cells;	chr2:159585233	chr2:159670708~159712435:-
LUAD	cis	rs1707322	0.928	rs7527244	ENSG00000280836.1	AL355480.1	-4.79	2.26e-06	0.000525	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45903100	chr1:45581219~45581321:-
LUAD	cis	rs8072100	0.79	rs11656856	ENSG00000228782.6	CTD-2026D20.3	-4.79	2.26e-06	0.000525	-0.23	-0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47637305	chr17:47450568~47492492:-
LUAD	cis	rs950169	0.922	rs11638445	ENSG00000259295.5	CSPG4P12	4.79	2.26e-06	0.000525	0.31	0.21	Schizophrenia;	chr15:84594463	chr15:85191438~85213905:+
LUAD	cis	rs7017914	0.69	rs2732127	ENSG00000223220.1	Y_RNA	4.79	2.27e-06	0.000526	0.24	0.21	Bone mineral density;	chr8:70984584	chr8:70780914~70781008:-
LUAD	cis	rs6496044	0.547	rs7173125	ENSG00000259295.5	CSPG4P12	-4.79	2.27e-06	0.000526	-0.25	-0.21	Interstitial lung disease;	chr15:85512214	chr15:85191438~85213905:+
LUAD	cis	rs6565180	1	rs11862806	ENSG00000273724.1	RP11-347C12.12	-4.79	2.27e-06	0.000526	-0.23	-0.21	Tonsillectomy;	chr16:30352750	chr16:30336400~30343336:+
LUAD	cis	rs7493	0.95	rs17880101	ENSG00000233942.1	AC004012.1	4.79	2.27e-06	0.000526	0.31	0.21	Yu-Zhi constitution type in type 2 diabetes;	chr7:95402145	chr7:95471835~95473998:+
LUAD	cis	rs9532669	0.926	rs9532689	ENSG00000239827.7	SUGT1P3	-4.79	2.27e-06	0.000526	-0.25	-0.21	Cervical cancer;	chr13:40957990	chr13:40908159~40921774:-
LUAD	cis	rs7829975	0.5	rs7841082	ENSG00000253893.2	FAM85B	4.79	2.27e-06	0.000526	0.25	0.21	Mood instability;	chr8:8311465	chr8:8167819~8226614:-
LUAD	cis	rs2688608	0.62	rs7076525	ENSG00000271816.1	BMS1P4	4.79	2.27e-06	0.000526	0.18	0.21	Inflammatory bowel disease;	chr10:73753039	chr10:73699151~73730487:-
LUAD	cis	rs944289	0.711	rs7148603	ENSG00000257826.1	RP11-116N8.4	-4.79	2.27e-06	0.000526	-0.23	-0.21	Thyroid cancer;	chr14:36214573	chr14:36061026~36067190:-
LUAD	cis	rs5758659	0.714	rs7245	ENSG00000227370.1	RP4-669P10.19	4.79	2.27e-06	0.000526	0.19	0.21	Cognitive function;	chr22:42085845	chr22:42132543~42132998:+
LUAD	cis	rs12908161	1	rs58416181	ENSG00000259295.5	CSPG4P12	4.79	2.27e-06	0.000527	0.3	0.21	Schizophrenia;	chr15:84721230	chr15:85191438~85213905:+
LUAD	cis	rs73173548	0.502	rs10505857	ENSG00000247828.6	TMEM161B-AS1	4.79	2.27e-06	0.000527	0.26	0.21	Macular telangiectasia type 2;	chr5:88420376	chr5:88268895~88436685:+
LUAD	cis	rs950169	0.8	rs4842847	ENSG00000229212.6	RP11-561C5.4	-4.79	2.27e-06	0.000527	-0.31	-0.21	Schizophrenia;	chr15:84262447	chr15:85205440~85234795:-
LUAD	cis	rs442309	0.553	rs7073430	ENSG00000238280.1	RP11-436D10.3	-4.79	2.27e-06	0.000527	-0.27	-0.21	Vogt-Koyanagi-Harada syndrome;	chr10:62695121	chr10:62793562~62805887:-
LUAD	cis	rs8180040	0.627	rs6442059	ENSG00000271161.1	BOLA2P2	4.79	2.27e-06	0.000527	0.2	0.21	Colorectal cancer;	chr3:47145585	chr3:47499841~47500407:+
LUAD	cis	rs8180040	0.681	rs9818382	ENSG00000271161.1	BOLA2P2	4.79	2.27e-06	0.000527	0.2	0.21	Colorectal cancer;	chr3:47151544	chr3:47499841~47500407:+
LUAD	cis	rs8180040	0.654	rs6766230	ENSG00000271161.1	BOLA2P2	4.79	2.27e-06	0.000527	0.2	0.21	Colorectal cancer;	chr3:47154719	chr3:47499841~47500407:+
LUAD	cis	rs8180040	0.627	rs9821119	ENSG00000271161.1	BOLA2P2	4.79	2.27e-06	0.000527	0.2	0.21	Colorectal cancer;	chr3:47156947	chr3:47499841~47500407:+
LUAD	cis	rs875971	0.558	rs4433015	ENSG00000237310.1	GS1-124K5.4	-4.79	2.27e-06	0.000527	-0.23	-0.21	Aortic root size;	chr7:66174736	chr7:66493706~66495474:+
LUAD	cis	rs7727544	0.547	rs56083751	ENSG00000233006.5	AC034220.3	4.79	2.27e-06	0.000527	0.19	0.21	Blood metabolite levels;	chr5:132328945	chr5:132311285~132369916:-
LUAD	cis	rs73173548	0.528	rs13161403	ENSG00000247828.6	TMEM161B-AS1	4.79	2.27e-06	0.000527	0.27	0.21	Macular telangiectasia type 2;	chr5:88471144	chr5:88268895~88436685:+
LUAD	cis	rs4819052	0.679	rs2838860	ENSG00000223768.1	LINC00205	-4.79	2.27e-06	0.000527	-0.25	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45264989	chr21:45293285~45297354:+
LUAD	cis	rs116175783	0.557	rs62188138	ENSG00000227403.1	AC009299.3	4.79	2.27e-06	0.000528	0.39	0.21	Intelligence (multi-trait analysis);	chr2:161410935	chr2:161244739~161249050:+
LUAD	cis	rs116175783	0.557	rs6710414	ENSG00000227403.1	AC009299.3	4.79	2.27e-06	0.000528	0.39	0.21	Intelligence (multi-trait analysis);	chr2:161412004	chr2:161244739~161249050:+
LUAD	cis	rs9473147	0.543	rs9473122	ENSG00000270761.1	RP11-385F7.1	-4.79	2.28e-06	0.000528	-0.25	-0.21	Platelet distribution width;Mean platelet volume;	chr6:47507226	chr6:47477243~47477572:-
LUAD	cis	rs9473147	0.543	rs13211285	ENSG00000270761.1	RP11-385F7.1	-4.79	2.28e-06	0.000528	-0.25	-0.21	Platelet distribution width;Mean platelet volume;	chr6:47511882	chr6:47477243~47477572:-
LUAD	cis	rs9473147	0.543	rs1872505	ENSG00000270761.1	RP11-385F7.1	-4.79	2.28e-06	0.000528	-0.25	-0.21	Platelet distribution width;Mean platelet volume;	chr6:47513239	chr6:47477243~47477572:-
LUAD	cis	rs9473147	0.516	rs9296561	ENSG00000270761.1	RP11-385F7.1	-4.79	2.28e-06	0.000528	-0.25	-0.21	Platelet distribution width;Mean platelet volume;	chr6:47521202	chr6:47477243~47477572:-
LUAD	cis	rs9473147	0.516	rs7749167	ENSG00000270761.1	RP11-385F7.1	-4.79	2.28e-06	0.000528	-0.25	-0.21	Platelet distribution width;Mean platelet volume;	chr6:47526204	chr6:47477243~47477572:-
LUAD	cis	rs7493	1	rs6961773	ENSG00000233942.1	AC004012.1	4.79	2.28e-06	0.000528	0.31	0.21	Yu-Zhi constitution type in type 2 diabetes;	chr7:95408406	chr7:95471835~95473998:+
LUAD	cis	rs2115630	0.755	rs7169629	ENSG00000229212.6	RP11-561C5.4	-4.79	2.28e-06	0.000528	-0.25	-0.21	P wave terminal force;	chr15:84648043	chr15:85205440~85234795:-
LUAD	cis	rs5758511	0.689	rs55906806	ENSG00000226450.2	CYP2D8P	4.79	2.28e-06	0.000528	0.22	0.21	Birth weight;	chr22:42248465	chr22:42149886~42155001:-
LUAD	cis	rs7618501	0.516	rs2856236	ENSG00000234667.1	ACTBP13	4.79	2.28e-06	0.000528	0.24	0.21	Intelligence (multi-trait analysis);	chr3:50124284	chr3:49873347~49877980:-
LUAD	cis	rs7208859	0.623	rs9914242	ENSG00000263603.1	CTD-2349P21.5	-4.78	2.28e-06	0.000528	-0.39	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889227	chr17:30729469~30731202:+
LUAD	cis	rs4819052	1	rs4819052	ENSG00000223768.1	LINC00205	-4.78	2.28e-06	0.000529	-0.27	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45279862	chr21:45293285~45297354:+
LUAD	cis	rs62355901	0.545	rs6882255	ENSG00000271828.1	CTD-2310F14.1	4.78	2.28e-06	0.000529	0.36	0.21	Breast cancer;	chr5:56762344	chr5:56927874~56929573:+
LUAD	cis	rs62355900	0.636	rs12654584	ENSG00000271828.1	CTD-2310F14.1	4.78	2.28e-06	0.000529	0.36	0.21	Endometriosis;	chr5:56762588	chr5:56927874~56929573:+
LUAD	cis	rs5758511	0.68	rs1107554	ENSG00000205702.9	CYP2D7	4.78	2.28e-06	0.000529	0.21	0.21	Birth weight;	chr22:42271588	chr22:42140203~42144577:-
LUAD	cis	rs14027	0.843	rs1828238	ENSG00000279347.1	RP11-85I17.2	4.78	2.28e-06	0.000529	0.19	0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119848105	chr8:119838736~119840385:-
LUAD	cis	rs14027	0.921	rs1960438	ENSG00000279347.1	RP11-85I17.2	4.78	2.28e-06	0.000529	0.19	0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119848193	chr8:119838736~119840385:-
LUAD	cis	rs860295	0.702	rs475550	ENSG00000225855.5	RUSC1-AS1	4.78	2.28e-06	0.000529	0.15	0.21	Body mass index;	chr1:155682290	chr1:155316863~155324176:-
LUAD	cis	rs7772486	0.72	rs1890171	ENSG00000235652.6	RP11-545I5.3	-4.78	2.28e-06	0.000529	-0.21	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145750978	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.72	rs4896844	ENSG00000235652.6	RP11-545I5.3	-4.78	2.28e-06	0.000529	-0.21	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145754088	chr6:145799409~145886585:+
LUAD	cis	rs2880765	0.743	rs16940052	ENSG00000259295.5	CSPG4P12	4.78	2.28e-06	0.00053	0.24	0.21	Coronary artery disease;	chr15:85463443	chr15:85191438~85213905:+
LUAD	cis	rs7178375	1	rs1474382	ENSG00000270015.1	RP11-540B6.6	4.78	2.28e-06	0.00053	0.2	0.21	Hypertriglyceridemia;	chr15:30922446	chr15:30926514~30928407:+
LUAD	cis	rs507080	0.922	rs555356	ENSG00000278376.1	RP11-158I9.8	-4.78	2.28e-06	0.00053	-0.23	-0.21	Serum metabolite levels;	chr11:118687369	chr11:118791254~118793137:+
LUAD	cis	rs9473147	0.516	rs1931837	ENSG00000270761.1	RP11-385F7.1	-4.78	2.29e-06	0.00053	-0.25	-0.21	Platelet distribution width;Mean platelet volume;	chr6:47474641	chr6:47477243~47477572:-
LUAD	cis	rs13434995	0.842	rs55869433	ENSG00000273257.1	RP11-177J6.1	-4.78	2.29e-06	0.00053	-0.34	-0.21	Adiponectin levels;	chr4:55544770	chr4:55387949~55388271:+
LUAD	cis	rs1008375	0.932	rs6841784	ENSG00000249502.1	AC006160.5	-4.78	2.29e-06	0.000531	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17624795	chr4:17587467~17614571:-
LUAD	cis	rs6604026	0.624	rs34305407	ENSG00000223787.2	RP4-593M8.1	4.78	2.29e-06	0.000531	0.29	0.21	Multiple sclerosis;	chr1:92708658	chr1:92580476~92580821:-
LUAD	cis	rs2243480	0.908	rs4718273	ENSG00000164669.11	INTS4P1	-4.78	2.29e-06	0.000531	-0.38	-0.21	Diabetic kidney disease;	chr7:65751112	chr7:65141225~65234216:+
LUAD	cis	rs2378497	1	rs17011253	ENSG00000232679.1	RP11-400N13.3	4.78	2.29e-06	0.000531	0.31	0.21	Serum thyroid-stimulating hormone levels;	chr1:222040714	chr1:222041705~222064763:-
LUAD	cis	rs34779708	0.931	rs2244100	ENSG00000271335.4	RP11-324I22.4	-4.78	2.29e-06	0.000531	-0.22	-0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35034708	chr10:35314552~35336401:-
LUAD	cis	rs12554020	0.892	rs10217595	ENSG00000227603.1	RP11-165J3.6	4.78	2.3e-06	0.000532	0.35	0.21	Schizophrenia;	chr9:93418609	chr9:93435332~93437121:-
LUAD	cis	rs7777677	0.925	rs6956269	ENSG00000244273.1	PGBD4P1	-4.78	2.3e-06	0.000532	-0.23	-0.21	Alcoholic chronic pancreatitis;	chr7:142661303	chr7:142722358~142722764:+
LUAD	cis	rs7777677	0.925	rs4726547	ENSG00000244273.1	PGBD4P1	-4.78	2.3e-06	0.000532	-0.23	-0.21	Alcoholic chronic pancreatitis;	chr7:142662750	chr7:142722358~142722764:+
LUAD	cis	rs12745968	0.586	rs2065915	ENSG00000223787.2	RP4-593M8.1	-4.78	2.3e-06	0.000532	-0.26	-0.21	Bipolar disorder and schizophrenia;	chr1:92735925	chr1:92580476~92580821:-
LUAD	cis	rs12745968	0.718	rs10782941	ENSG00000223787.2	RP4-593M8.1	-4.78	2.3e-06	0.000532	-0.26	-0.21	Bipolar disorder and schizophrenia;	chr1:92744283	chr1:92580476~92580821:-
LUAD	cis	rs507080	0.922	rs525485	ENSG00000278376.1	RP11-158I9.8	-4.78	2.3e-06	0.000533	-0.23	-0.21	Serum metabolite levels;	chr11:118685045	chr11:118791254~118793137:+
LUAD	cis	rs9322193	0.962	rs6899661	ENSG00000268592.3	RAET1E-AS1	4.78	2.3e-06	0.000533	0.26	0.21	Lung cancer;	chr6:149818093	chr6:149863494~149919507:+
LUAD	cis	rs1707322	0.89	rs2297883	ENSG00000280836.1	AL355480.1	4.78	2.3e-06	0.000533	0.27	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46045815	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs1707338	ENSG00000280836.1	AL355480.1	4.78	2.3e-06	0.000533	0.27	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46046309	chr1:45581219~45581321:-
LUAD	cis	rs1707322	0.964	rs1707339	ENSG00000280836.1	AL355480.1	4.78	2.3e-06	0.000533	0.27	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46047507	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs1768818	ENSG00000280836.1	AL355480.1	4.78	2.3e-06	0.000533	0.27	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048614	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs1768817	ENSG00000280836.1	AL355480.1	4.78	2.3e-06	0.000533	0.27	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048862	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs785470	ENSG00000280836.1	AL355480.1	4.78	2.3e-06	0.000533	0.27	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46053950	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs785469	ENSG00000280836.1	AL355480.1	4.78	2.3e-06	0.000533	0.27	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055419	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs785468	ENSG00000280836.1	AL355480.1	4.78	2.3e-06	0.000533	0.27	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055845	chr1:45581219~45581321:-
LUAD	cis	rs17345786	1	rs73863360	ENSG00000244119.1	PDCL3P4	4.78	2.3e-06	0.000533	0.23	0.21	Colonoscopy-negative controls vs population controls;	chr3:101597993	chr3:101712472~101713191:+
LUAD	cis	rs17345786	0.911	rs10936707	ENSG00000244119.1	PDCL3P4	4.78	2.3e-06	0.000533	0.23	0.21	Colonoscopy-negative controls vs population controls;	chr3:101605219	chr3:101712472~101713191:+
LUAD	cis	rs11155671	0.53	rs7742993	ENSG00000268592.3	RAET1E-AS1	4.78	2.3e-06	0.000533	0.26	0.21	Testicular germ cell tumor;	chr6:149883959	chr6:149863494~149919507:+
LUAD	cis	rs9545047	0.604	rs9318634	ENSG00000227354.5	RBM26-AS1	-4.78	2.3e-06	0.000533	-0.23	-0.21	Schizophrenia;	chr13:79369303	chr13:79406309~79424328:+
LUAD	cis	rs4143844	0.867	rs34589937	ENSG00000259251.2	RP11-643M14.1	4.78	2.3e-06	0.000533	0.36	0.21	Bipolar disorder and schizophrenia;	chr15:61876196	chr15:62060503~62062434:+
LUAD	cis	rs7824557	0.524	rs7835318	ENSG00000255046.1	RP11-297N6.4	4.78	2.3e-06	0.000533	0.26	0.21	Retinal vascular caliber;	chr8:11096364	chr8:11797928~11802568:-
LUAD	cis	rs6723226	0.772	rs2366894	ENSG00000276334.1	AL133243.1	4.78	2.3e-06	0.000533	0.24	0.21	Intelligence (multi-trait analysis);	chr2:32488639	chr2:32521927~32523547:+
LUAD	cis	rs8031584	0.697	rs798080	ENSG00000259845.1	HERC2P10	-4.78	2.3e-06	0.000534	-0.26	-0.21	Huntington's disease progression;	chr15:30829966	chr15:30815271~30844153:+
LUAD	cis	rs9473147	0.516	rs7749271	ENSG00000270761.1	RP11-385F7.1	-4.78	2.31e-06	0.000534	-0.25	-0.21	Platelet distribution width;Mean platelet volume;	chr6:47517266	chr6:47477243~47477572:-
LUAD	cis	rs2439831	0.717	rs2470132	ENSG00000249839.1	AC011330.5	-4.78	2.31e-06	0.000534	-0.38	-0.21	Lung cancer in ever smokers;	chr15:43543283	chr15:43663654~43684339:-
LUAD	cis	rs2439831	0.867	rs2255051	ENSG00000249839.1	AC011330.5	-4.78	2.31e-06	0.000534	-0.38	-0.21	Lung cancer in ever smokers;	chr15:43553963	chr15:43663654~43684339:-
LUAD	cis	rs16873450	0.527	rs10215408	ENSG00000234800.2	PCMTD1P3	4.78	2.31e-06	0.000535	0.24	0.21	Verbal memory performance (residualized delayed recall level);	chr7:23796267	chr7:23721311~23721782:-
LUAD	cis	rs2976388	0.609	rs2585148	ENSG00000253741.1	CTD-2292P10.4	-4.78	2.31e-06	0.000535	-0.25	-0.21	Urinary tract infection frequency;	chr8:142714775	chr8:142702252~142726973:-
LUAD	cis	rs1008375	1	rs9991307	ENSG00000249502.1	AC006160.5	-4.78	2.31e-06	0.000535	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17660785	chr4:17587467~17614571:-
LUAD	cis	rs17345786	1	rs58907984	ENSG00000244119.1	PDCL3P4	4.78	2.31e-06	0.000535	0.23	0.21	Colonoscopy-negative controls vs population controls;	chr3:101586326	chr3:101712472~101713191:+
LUAD	cis	rs17772222	0.917	rs61983300	ENSG00000258983.2	RP11-507K2.2	4.78	2.31e-06	0.000535	0.26	0.21	Coronary artery calcification;	chr14:88754047	chr14:88499334~88515502:+
LUAD	cis	rs17772222	0.876	rs78068036	ENSG00000258983.2	RP11-507K2.2	4.78	2.31e-06	0.000535	0.26	0.21	Coronary artery calcification;	chr14:88754817	chr14:88499334~88515502:+
LUAD	cis	rs17772222	0.917	rs11159868	ENSG00000258983.2	RP11-507K2.2	4.78	2.31e-06	0.000535	0.26	0.21	Coronary artery calcification;	chr14:88760528	chr14:88499334~88515502:+
LUAD	cis	rs12745968	0.589	rs4970707	ENSG00000223787.2	RP4-593M8.1	-4.78	2.31e-06	0.000535	-0.25	-0.21	Bipolar disorder and schizophrenia;	chr1:92520889	chr1:92580476~92580821:-
LUAD	cis	rs9341808	0.754	rs9341811	ENSG00000272129.1	RP11-250B2.6	4.78	2.31e-06	0.000536	0.26	0.21	Sitting height ratio;	chr6:80272984	chr6:80355424~80356859:+
LUAD	cis	rs6088590	1	rs6088590	ENSG00000276073.1	RP5-1125A11.7	-4.78	2.31e-06	0.000536	-0.21	-0.21	Coronary artery disease;	chr20:34725762	chr20:33985617~33988989:-
LUAD	cis	rs13315649	0.724	rs28787069	ENSG00000242551.2	POU5F1P6	-4.78	2.31e-06	0.000536	-0.27	-0.21	Sum eosinophil basophil counts;	chr3:128695613	chr3:128674735~128677005:-
LUAD	cis	rs2742234	0.91	rs2505513	ENSG00000273008.1	RP11-351D16.3	-4.78	2.32e-06	0.000536	-0.22	-0.21	Hirschsprung disease;	chr10:43138089	chr10:43136824~43138334:-
LUAD	cis	rs6840360	1	rs6535814	ENSG00000270265.1	RP11-731D1.4	-4.78	2.32e-06	0.000537	-0.22	-0.21	Intelligence (multi-trait analysis);	chr4:151688542	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.967	rs6535815	ENSG00000270265.1	RP11-731D1.4	-4.78	2.32e-06	0.000537	-0.22	-0.21	Intelligence (multi-trait analysis);	chr4:151688548	chr4:151333775~151353224:-
LUAD	cis	rs301901	0.772	rs6887958	ENSG00000250155.1	CTD-2353F22.1	-4.78	2.32e-06	0.000537	-0.23	-0.21	Height;	chr5:37189717	chr5:36666214~36725195:-
LUAD	cis	rs301901	0.514	rs11954689	ENSG00000250155.1	CTD-2353F22.1	-4.78	2.32e-06	0.000537	-0.24	-0.21	Height;	chr5:37269214	chr5:36666214~36725195:-
LUAD	cis	rs7772486	0.79	rs7753833	ENSG00000235652.6	RP11-545I5.3	4.78	2.32e-06	0.000537	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145840296	chr6:145799409~145886585:+
LUAD	cis	rs800160	0.777	rs2521294	ENSG00000236264.4	RPL26P30	-4.78	2.32e-06	0.000537	-0.29	-0.21	Bacteremia;	chr11:2327548	chr11:2335132~2335776:-
LUAD	cis	rs12468226	1	rs76284304	ENSG00000272966.1	RP11-686O6.1	4.78	2.32e-06	0.000537	0.35	0.21	Urate levels;	chr2:202427116	chr2:202336739~202337200:+
LUAD	cis	rs2239547	0.657	rs12496077	ENSG00000242142.1	SERBP1P3	4.78	2.32e-06	0.000537	0.25	0.21	Schizophrenia;	chr3:52852225	chr3:53064283~53065091:-
LUAD	cis	rs6539288	0.77	rs1468908	ENSG00000260329.1	RP11-412D9.4	-4.78	2.32e-06	0.000537	-0.23	-0.21	Total body bone mineral density;	chr12:106904539	chr12:106954029~106955497:-
LUAD	cis	rs6539288	0.933	rs1470380	ENSG00000260329.1	RP11-412D9.4	-4.78	2.32e-06	0.000537	-0.23	-0.21	Total body bone mineral density;	chr12:106904961	chr12:106954029~106955497:-
LUAD	cis	rs4964805	0.657	rs4964814	ENSG00000257681.1	RP11-341G23.4	-4.78	2.32e-06	0.000537	-0.23	-0.21	Attention deficit hyperactivity disorder;	chr12:103795606	chr12:103746315~103768858:-
LUAD	cis	rs720475	0.732	rs7784282	ENSG00000170356.8	OR2A20P	4.78	2.32e-06	0.000537	0.29	0.21	Breast cancer;	chr7:144431561	chr7:144250045~144252957:-
LUAD	cis	rs2732480	0.577	rs2732448	ENSG00000257735.1	RP11-370I10.6	4.78	2.32e-06	0.000537	0.26	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48336817	chr12:48350945~48442411:+
LUAD	cis	rs17508449	0.819	rs17359378	ENSG00000232450.1	RP4-730K3.3	-4.78	2.32e-06	0.000537	-0.36	-0.21	Leprosy;	chr1:113674087	chr1:113698884~113699631:-
LUAD	cis	rs17508449	0.819	rs17274627	ENSG00000232450.1	RP4-730K3.3	-4.78	2.32e-06	0.000537	-0.36	-0.21	Leprosy;	chr1:113674773	chr1:113698884~113699631:-
LUAD	cis	rs193541	0.53	rs9327272	ENSG00000263432.2	RN7SL689P	4.78	2.32e-06	0.000537	0.28	0.21	Glucose homeostasis traits;	chr5:122737853	chr5:123022487~123022783:-
LUAD	cis	rs7017914	0.69	rs7837005	ENSG00000223220.1	Y_RNA	4.78	2.32e-06	0.000538	0.25	0.21	Bone mineral density;	chr8:71086797	chr8:70780914~70781008:-
LUAD	cis	rs4143844	0.867	rs17303894	ENSG00000259251.2	RP11-643M14.1	4.78	2.32e-06	0.000538	0.36	0.21	Bipolar disorder and schizophrenia;	chr15:61873378	chr15:62060503~62062434:+
LUAD	cis	rs2281636	0.723	rs11190245	ENSG00000233690.1	EBAG9P1	4.78	2.32e-06	0.000538	0.22	0.21	Obesity-related traits;	chr10:99691502	chr10:99697407~99697949:-
LUAD	cis	rs2257011	1	rs1896797	ENSG00000230373.7	GOLGA6L5P	4.78	2.33e-06	0.000538	0.2	0.21	Height;	chr15:83605839	chr15:84507885~84516814:-
LUAD	cis	rs12701220	0.69	rs10243973	ENSG00000229043.2	AC091729.9	-4.78	2.33e-06	0.000539	-0.27	-0.21	Bronchopulmonary dysplasia;	chr7:1025347	chr7:1160374~1165267:+
LUAD	cis	rs35934224	0.783	rs58714937	ENSG00000232926.1	AC000078.5	4.78	2.33e-06	0.000539	0.23	0.21	Glaucoma (primary open-angle);	chr22:19869187	chr22:19887289~19887970:+
LUAD	cis	rs7017914	0.628	rs12156041	ENSG00000223220.1	Y_RNA	4.78	2.33e-06	0.000539	0.24	0.21	Bone mineral density;	chr8:70914690	chr8:70780914~70781008:-
LUAD	cis	rs1062177	0.95	rs892005	ENSG00000253921.1	CTB-113P19.3	-4.78	2.33e-06	0.000539	-0.32	-0.21	Preschool internalizing problems;	chr5:151801060	chr5:151753992~151767247:+
LUAD	cis	rs8127691	0.967	rs4317019	ENSG00000237604.1	AP001056.1	4.78	2.33e-06	0.000539	0.25	0.21	Inflammatory bowel disease;	chr21:44196392	chr21:44175489~44176453:+
LUAD	cis	rs375066	0.71	rs11881193	ENSG00000267058.1	RP11-15A1.3	4.78	2.33e-06	0.00054	0.24	0.21	Breast cancer;	chr19:43917364	chr19:43891804~43901805:-
LUAD	cis	rs1729951	0.575	rs168635	ENSG00000239213.4	NCK1-AS1	4.78	2.33e-06	0.00054	0.23	0.21	Neuroticism;	chr3:136980236	chr3:136841726~136862054:-
LUAD	cis	rs61270009	0.738	rs12659772	ENSG00000247828.6	TMEM161B-AS1	4.78	2.34e-06	0.00054	0.26	0.21	Depressive symptoms;	chr5:88451917	chr5:88268895~88436685:+
LUAD	cis	rs368187	0.517	rs17836290	ENSG00000257826.1	RP11-116N8.4	-4.78	2.34e-06	0.000541	-0.23	-0.21	Thyroid cancer;	chr14:36021066	chr14:36061026~36067190:-
LUAD	cis	rs1979679	0.842	rs7316299	ENSG00000278733.1	RP11-425D17.1	4.78	2.34e-06	0.000541	0.27	0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28179757	chr12:28185625~28186190:-
LUAD	cis	rs13256369	0.755	rs12680167	ENSG00000253893.2	FAM85B	-4.78	2.34e-06	0.000542	-0.29	-0.21	Obesity-related traits;	chr8:8704957	chr8:8167819~8226614:-
LUAD	cis	rs6496932	0.774	rs12901648	ENSG00000202081.1	RNU6-1280P	-4.78	2.34e-06	0.000542	-0.33	-0.21	Central corneal thickness;Corneal structure;	chr15:85408487	chr15:85651522~85651628:-
LUAD	cis	rs6539288	0.866	rs6539286	ENSG00000260329.1	RP11-412D9.4	-4.78	2.34e-06	0.000542	-0.23	-0.21	Total body bone mineral density;	chr12:106903845	chr12:106954029~106955497:-
LUAD	cis	rs6539288	0.899	rs6539287	ENSG00000260329.1	RP11-412D9.4	-4.78	2.34e-06	0.000542	-0.23	-0.21	Total body bone mineral density;	chr12:106903872	chr12:106954029~106955497:-
LUAD	cis	rs2998286	0.822	rs2807737	ENSG00000254635.4	WAC-AS1	-4.78	2.34e-06	0.000542	-0.26	-0.21	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28501052	chr10:28522652~28532743:-
LUAD	cis	rs950169	0.922	rs11635505	ENSG00000229212.6	RP11-561C5.4	4.78	2.34e-06	0.000542	0.3	0.21	Schizophrenia;	chr15:84553803	chr15:85205440~85234795:-
LUAD	cis	rs30380	1	rs27529	ENSG00000248734.2	CTD-2260A17.1	4.78	2.34e-06	0.000542	0.21	0.21	Cerebrospinal fluid biomarker levels;	chr5:96790605	chr5:96784777~96785999:+
LUAD	cis	rs17772222	0.917	rs1950806	ENSG00000258983.2	RP11-507K2.2	4.78	2.34e-06	0.000542	0.27	0.21	Coronary artery calcification;	chr14:88774412	chr14:88499334~88515502:+
LUAD	cis	rs8177876	0.658	rs12456	ENSG00000261061.1	RP11-303E16.2	-4.78	2.34e-06	0.000542	-0.33	-0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81031454	chr16:81030770~81031485:+
LUAD	cis	rs7665090	1	rs3733202	ENSG00000246560.2	RP11-10L12.4	4.78	2.34e-06	0.000542	0.26	0.21	Primary biliary cholangitis;	chr4:102635704	chr4:102828055~102844075:+
LUAD	cis	rs6095360	0.727	rs1556876	ENSG00000222365.1	SNORD12B	-4.78	2.34e-06	0.000542	-0.24	-0.21	Intelligence (multi-trait analysis);	chr20:49099914	chr20:49280319~49280409:+
LUAD	cis	rs950169	0.881	rs72750843	ENSG00000259295.5	CSPG4P12	4.78	2.34e-06	0.000542	0.31	0.21	Schizophrenia;	chr15:84592552	chr15:85191438~85213905:+
LUAD	cis	rs875971	1	rs6961717	ENSG00000232559.3	GS1-124K5.12	-4.78	2.35e-06	0.000543	-0.25	-0.21	Aortic root size;	chr7:66122550	chr7:66554588~66576923:-
LUAD	cis	rs10091374	1	rs34684538	ENSG00000253967.1	RP11-333A23.4	-4.78	2.35e-06	0.000543	-0.24	-0.21	Cardiac Troponin-T levels;	chr8:70472639	chr8:70471134~70485687:+
LUAD	cis	rs7948661	1	rs7948661	ENSG00000278376.1	RP11-158I9.8	4.78	2.35e-06	0.000543	0.4	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118470934	chr11:118791254~118793137:+
LUAD	cis	rs9473147	0.516	rs4715018	ENSG00000270761.1	RP11-385F7.1	-4.78	2.35e-06	0.000543	-0.25	-0.21	Platelet distribution width;Mean platelet volume;	chr6:47474135	chr6:47477243~47477572:-
LUAD	cis	rs11779988	0.528	rs208029	ENSG00000253671.1	RP11-806O11.1	-4.78	2.35e-06	0.000543	-0.25	-0.21	Breast cancer;	chr8:17983478	chr8:17808941~17820868:+
LUAD	cis	rs453301	0.571	rs330057	ENSG00000253981.4	ALG1L13P	-4.78	2.35e-06	0.000543	-0.25	-0.21	Joint mobility (Beighton score);	chr8:9232283	chr8:8236003~8244667:-
LUAD	cis	rs2832077	0.527	rs2705690	ENSG00000232855.5	AF131217.1	-4.78	2.35e-06	0.000543	-0.21	-0.21	Cognitive test performance;	chr21:28866923	chr21:28439346~28674848:-
LUAD	cis	rs17666538	0.71	rs7834337	ENSG00000254207.1	RP11-43A14.1	4.78	2.35e-06	0.000543	0.4	0.21	IgG glycosylation;	chr8:705828	chr8:725188~725877:-
LUAD	cis	rs516805	0.63	rs4245520	ENSG00000279453.1	RP3-425C14.4	-4.78	2.35e-06	0.000543	-0.3	-0.21	Lymphocyte counts;	chr6:122106477	chr6:122436789~122439223:-
LUAD	cis	rs8031584	1	rs35607976	ENSG00000270015.1	RP11-540B6.6	-4.78	2.35e-06	0.000543	-0.17	-0.21	Huntington's disease progression;	chr15:30985585	chr15:30926514~30928407:+
LUAD	cis	rs5758659	0.967	rs5758670	ENSG00000182057.4	OGFRP1	4.78	2.35e-06	0.000543	0.25	0.21	Cognitive function;	chr22:42240681	chr22:42269753~42275196:+
LUAD	cis	rs2295359	0.824	rs4655679	ENSG00000275678.1	RP4-547N15.3	4.78	2.35e-06	0.000544	0.23	0.21	Psoriasis;	chr1:67133974	chr1:67121605~67123956:-
LUAD	cis	rs2742234	0.59	rs741968	ENSG00000273008.1	RP11-351D16.3	-4.78	2.35e-06	0.000544	-0.25	-0.21	Hirschsprung disease;	chr10:43116260	chr10:43136824~43138334:-
LUAD	cis	rs875971	0.516	rs6945322	ENSG00000224316.1	RP11-479O9.2	4.78	2.35e-06	0.000544	0.21	0.21	Aortic root size;	chr7:65871069	chr7:65773620~65802067:+
LUAD	cis	rs17711722	0.701	rs55773927	ENSG00000224316.1	RP11-479O9.2	4.78	2.35e-06	0.000544	0.21	0.21	Calcium levels;	chr7:65872915	chr7:65773620~65802067:+
LUAD	cis	rs17711722	0.727	rs35850374	ENSG00000224316.1	RP11-479O9.2	4.78	2.35e-06	0.000544	0.21	0.21	Calcium levels;	chr7:65892789	chr7:65773620~65802067:+
LUAD	cis	rs853679	1	rs7740487	ENSG00000219392.1	RP1-265C24.5	-4.78	2.35e-06	0.000544	-0.34	-0.21	Depression;	chr6:28248708	chr6:28115628~28116551:+
LUAD	cis	rs853679	1	rs68141011	ENSG00000219392.1	RP1-265C24.5	-4.78	2.35e-06	0.000544	-0.34	-0.21	Depression;	chr6:28250019	chr6:28115628~28116551:+
LUAD	cis	rs853679	1	rs13200462	ENSG00000219392.1	RP1-265C24.5	-4.78	2.35e-06	0.000544	-0.34	-0.21	Depression;	chr6:28250421	chr6:28115628~28116551:+
LUAD	cis	rs72772090	1	rs72772092	ENSG00000248734.2	CTD-2260A17.1	-4.78	2.35e-06	0.000544	-0.3	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96711208	chr5:96784777~96785999:+
LUAD	cis	rs6952407	1	rs6952407	ENSG00000236529.1	RP13-254B10.1	-4.78	2.35e-06	0.000544	-0.22	-0.21	Cotinine glucuronidation;	chr7:66580525	chr7:65840212~65840596:+
LUAD	cis	rs2439831	0.867	rs2255042	ENSG00000249839.1	AC011330.5	4.78	2.35e-06	0.000544	0.38	0.21	Lung cancer in ever smokers;	chr15:43542120	chr15:43663654~43684339:-
LUAD	cis	rs12908161	0.959	rs34342559	ENSG00000275120.1	RP11-182J1.17	4.78	2.36e-06	0.000545	0.32	0.21	Schizophrenia;	chr15:84788040	chr15:84599434~84606463:-
LUAD	cis	rs12908161	0.959	rs35557864	ENSG00000275120.1	RP11-182J1.17	4.78	2.36e-06	0.000545	0.32	0.21	Schizophrenia;	chr15:84788398	chr15:84599434~84606463:-
LUAD	cis	rs42490	0.8	rs56291556	ENSG00000251136.7	RP11-37B2.1	4.78	2.36e-06	0.000545	0.22	0.21	Leprosy;	chr8:89662546	chr8:89609409~89757727:-
LUAD	cis	rs643506	0.874	rs615642	ENSG00000230911.1	PPIHP1	-4.78	2.36e-06	0.000545	-0.26	-0.21	Breast cancer;	chr11:111778697	chr11:112029858~112030367:-
LUAD	cis	rs16873450	0.527	rs7777127	ENSG00000234800.2	PCMTD1P3	4.78	2.36e-06	0.000545	0.24	0.21	Verbal memory performance (residualized delayed recall level);	chr7:23794582	chr7:23721311~23721782:-
LUAD	cis	rs761746	0.542	rs7290856	ENSG00000236132.1	CTA-440B3.1	-4.78	2.36e-06	0.000545	-0.28	-0.21	Intelligence;	chr22:31834930	chr22:31816379~31817491:-
LUAD	cis	rs55823223	0.648	rs72860389	ENSG00000267801.1	RP11-552F3.9	4.78	2.36e-06	0.000545	0.25	0.21	Psoriasis;	chr17:75869990	chr17:75876372~75879546:+
LUAD	cis	rs375066	0.762	rs171238	ENSG00000267058.1	RP11-15A1.3	-4.78	2.36e-06	0.000546	-0.24	-0.21	Breast cancer;	chr19:43875402	chr19:43891804~43901805:-
LUAD	cis	rs801193	0.904	rs4718405	ENSG00000237310.1	GS1-124K5.4	4.78	2.36e-06	0.000546	0.23	0.21	Aortic root size;	chr7:66789659	chr7:66493706~66495474:+
LUAD	cis	rs1008375	1	rs10939744	ENSG00000249502.1	AC006160.5	-4.78	2.36e-06	0.000546	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17662850	chr4:17587467~17614571:-
LUAD	cis	rs6539288	0.933	rs6539285	ENSG00000260329.1	RP11-412D9.4	-4.78	2.36e-06	0.000546	-0.23	-0.21	Total body bone mineral density;	chr12:106903683	chr12:106954029~106955497:-
LUAD	cis	rs2337406	1	rs74090714	ENSG00000211974.3	IGHV2-70	-4.78	2.36e-06	0.000546	-0.28	-0.21	Alzheimer's disease (late onset);	chr14:106691225	chr14:106723574~106724093:-
LUAD	cis	rs1009115	0.551	rs6965848	ENSG00000272328.1	RP4-594A5.1	-4.78	2.36e-06	0.000546	-0.27	-0.21	Post bronchodilator FEV1;	chr7:8373021	chr7:8303741~8341343:+
LUAD	cis	rs9545047	0.547	rs1590465	ENSG00000227354.5	RBM26-AS1	-4.78	2.36e-06	0.000546	-0.23	-0.21	Schizophrenia;	chr13:79393998	chr13:79406309~79424328:+
LUAD	cis	rs2732480	0.5	rs2450989	ENSG00000257735.1	RP11-370I10.6	-4.78	2.37e-06	0.000546	-0.26	-0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48259625	chr12:48350945~48442411:+
LUAD	cis	rs2732480	0.538	rs1387259	ENSG00000257735.1	RP11-370I10.6	-4.78	2.37e-06	0.000546	-0.27	-0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309739	chr12:48350945~48442411:+
LUAD	cis	rs71636778	0.509	rs35962879	ENSG00000260063.1	RP5-968P14.2	-4.78	2.37e-06	0.000547	-0.36	-0.21	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26956965	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.509	rs61457762	ENSG00000260063.1	RP5-968P14.2	-4.78	2.37e-06	0.000547	-0.36	-0.21	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26957666	chr1:26692132~26694131:-
LUAD	cis	rs875971	1	rs1544549	ENSG00000232559.3	GS1-124K5.12	-4.78	2.37e-06	0.000547	-0.25	-0.21	Aortic root size;	chr7:66625676	chr7:66554588~66576923:-
LUAD	cis	rs11159086	1	rs3759745	ENSG00000259005.1	RP3-449M8.6	4.78	2.37e-06	0.000547	0.28	0.21	Advanced glycation end-product levels;	chr14:74495967	chr14:74474007~74474864:-
LUAD	cis	rs11159086	1	rs4903232	ENSG00000259005.1	RP3-449M8.6	4.78	2.37e-06	0.000547	0.28	0.21	Advanced glycation end-product levels;	chr14:74496585	chr14:74474007~74474864:-
LUAD	cis	rs2243480	1	rs313814	ENSG00000226002.1	RP11-460N20.5	-4.78	2.37e-06	0.000547	-0.36	-0.21	Diabetic kidney disease;	chr7:66038306	chr7:65084103~65100232:+
LUAD	cis	rs2153535	0.609	rs2146159	ENSG00000230939.1	RP11-314C16.1	-4.78	2.37e-06	0.000547	-0.24	-0.21	Motion sickness;	chr6:8667222	chr6:8784178~8785445:+
LUAD	cis	rs7119	0.717	rs11639293	ENSG00000259362.2	RP11-307C19.1	-4.78	2.37e-06	0.000547	-0.27	-0.21	Type 2 diabetes;	chr15:77518503	chr15:77525540~77534110:+
LUAD	cis	rs7119	0.717	rs7181283	ENSG00000259362.2	RP11-307C19.1	-4.78	2.37e-06	0.000547	-0.27	-0.21	Type 2 diabetes;	chr15:77522202	chr15:77525540~77534110:+
LUAD	cis	rs7119	0.717	rs12899390	ENSG00000259362.2	RP11-307C19.1	-4.78	2.37e-06	0.000547	-0.27	-0.21	Type 2 diabetes;	chr15:77522896	chr15:77525540~77534110:+
LUAD	cis	rs7119	0.717	rs12901100	ENSG00000259362.2	RP11-307C19.1	-4.78	2.37e-06	0.000547	-0.27	-0.21	Type 2 diabetes;	chr15:77523216	chr15:77525540~77534110:+
LUAD	cis	rs7119	0.717	rs12904212	ENSG00000259362.2	RP11-307C19.1	-4.78	2.37e-06	0.000547	-0.27	-0.21	Type 2 diabetes;	chr15:77523491	chr15:77525540~77534110:+
LUAD	cis	rs7119	0.717	rs12904584	ENSG00000259362.2	RP11-307C19.1	-4.78	2.37e-06	0.000547	-0.27	-0.21	Type 2 diabetes;	chr15:77523649	chr15:77525540~77534110:+
LUAD	cis	rs7119	0.717	rs11636529	ENSG00000259362.2	RP11-307C19.1	-4.78	2.37e-06	0.000547	-0.27	-0.21	Type 2 diabetes;	chr15:77523878	chr15:77525540~77534110:+
LUAD	cis	rs7119	0.717	rs11631274	ENSG00000259362.2	RP11-307C19.1	-4.78	2.37e-06	0.000547	-0.27	-0.21	Type 2 diabetes;	chr15:77524089	chr15:77525540~77534110:+
LUAD	cis	rs7119	0.717	rs7176307	ENSG00000259362.2	RP11-307C19.1	-4.78	2.37e-06	0.000547	-0.27	-0.21	Type 2 diabetes;	chr15:77524342	chr15:77525540~77534110:+
LUAD	cis	rs7119	0.717	rs12909645	ENSG00000259362.2	RP11-307C19.1	-4.78	2.37e-06	0.000547	-0.27	-0.21	Type 2 diabetes;	chr15:77524477	chr15:77525540~77534110:+
LUAD	cis	rs7119	0.679	rs12909808	ENSG00000259362.2	RP11-307C19.1	-4.78	2.37e-06	0.000547	-0.27	-0.21	Type 2 diabetes;	chr15:77524602	chr15:77525540~77534110:+
LUAD	cis	rs7119	0.717	rs12910594	ENSG00000259362.2	RP11-307C19.1	-4.78	2.37e-06	0.000547	-0.27	-0.21	Type 2 diabetes;	chr15:77524761	chr15:77525540~77534110:+
LUAD	cis	rs7119	0.717	rs12910513	ENSG00000259362.2	RP11-307C19.1	-4.78	2.37e-06	0.000547	-0.27	-0.21	Type 2 diabetes;	chr15:77524916	chr15:77525540~77534110:+
LUAD	cis	rs7119	0.717	rs12911854	ENSG00000259362.2	RP11-307C19.1	-4.78	2.37e-06	0.000547	-0.27	-0.21	Type 2 diabetes;	chr15:77524946	chr15:77525540~77534110:+
LUAD	cis	rs7119	0.717	rs12910975	ENSG00000259362.2	RP11-307C19.1	-4.78	2.37e-06	0.000547	-0.27	-0.21	Type 2 diabetes;	chr15:77525145	chr15:77525540~77534110:+
LUAD	cis	rs7119	0.717	rs12912386	ENSG00000259362.2	RP11-307C19.1	-4.78	2.37e-06	0.000547	-0.27	-0.21	Type 2 diabetes;	chr15:77525298	chr15:77525540~77534110:+
LUAD	cis	rs7119	0.717	rs62009069	ENSG00000259362.2	RP11-307C19.1	-4.78	2.37e-06	0.000547	-0.27	-0.21	Type 2 diabetes;	chr15:77525535	chr15:77525540~77534110:+
LUAD	cis	rs7119	0.717	rs62009070	ENSG00000259362.2	RP11-307C19.1	-4.78	2.37e-06	0.000547	-0.27	-0.21	Type 2 diabetes;	chr15:77525542	chr15:77525540~77534110:+
LUAD	cis	rs7119	0.717	rs62009071	ENSG00000259362.2	RP11-307C19.1	-4.78	2.37e-06	0.000547	-0.27	-0.21	Type 2 diabetes;	chr15:77525544	chr15:77525540~77534110:+
LUAD	cis	rs7119	0.717	rs12916642	ENSG00000259362.2	RP11-307C19.1	-4.78	2.37e-06	0.000547	-0.27	-0.21	Type 2 diabetes;	chr15:77526084	chr15:77525540~77534110:+
LUAD	cis	rs1008375	0.8	rs28754811	ENSG00000249502.1	AC006160.5	-4.78	2.37e-06	0.000547	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17610689	chr4:17587467~17614571:-
LUAD	cis	rs11159086	0.793	rs11845370	ENSG00000259005.1	RP3-449M8.6	4.78	2.37e-06	0.000547	0.27	0.21	Advanced glycation end-product levels;	chr14:74481587	chr14:74474007~74474864:-
LUAD	cis	rs507080	0.883	rs656575	ENSG00000278376.1	RP11-158I9.8	-4.78	2.37e-06	0.000547	-0.23	-0.21	Serum metabolite levels;	chr11:118679199	chr11:118791254~118793137:+
LUAD	cis	rs507080	0.961	rs656505	ENSG00000278376.1	RP11-158I9.8	-4.78	2.37e-06	0.000547	-0.23	-0.21	Serum metabolite levels;	chr11:118679245	chr11:118791254~118793137:+
LUAD	cis	rs507080	0.961	rs660489	ENSG00000278376.1	RP11-158I9.8	-4.78	2.37e-06	0.000547	-0.23	-0.21	Serum metabolite levels;	chr11:118679255	chr11:118791254~118793137:+
LUAD	cis	rs507080	0.961	rs543327	ENSG00000278376.1	RP11-158I9.8	-4.78	2.37e-06	0.000547	-0.23	-0.21	Serum metabolite levels;	chr11:118679276	chr11:118791254~118793137:+
LUAD	cis	rs507080	0.961	rs543413	ENSG00000278376.1	RP11-158I9.8	-4.78	2.37e-06	0.000547	-0.23	-0.21	Serum metabolite levels;	chr11:118679308	chr11:118791254~118793137:+
LUAD	cis	rs12439619	0.921	rs56042848	ENSG00000276710.3	CSPG4P8	-4.78	2.37e-06	0.000547	-0.22	-0.21	Intelligence (multi-trait analysis);	chr15:82235244	chr15:82459472~82477258:+
LUAD	cis	rs5758511	0.68	rs5758681	ENSG00000226450.2	CYP2D8P	4.78	2.37e-06	0.000547	0.2	0.21	Birth weight;	chr22:42249085	chr22:42149886~42155001:-
LUAD	cis	rs1876905	0.68	rs7767302	ENSG00000272356.1	RP5-1112D6.8	4.78	2.37e-06	0.000547	0.23	0.21	Mean corpuscular hemoglobin;	chr6:111143942	chr6:111309203~111313517:+
LUAD	cis	rs6570726	0.935	rs371744	ENSG00000235652.6	RP11-545I5.3	4.78	2.37e-06	0.000548	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145519888	chr6:145799409~145886585:+
LUAD	cis	rs2255336	0.616	rs6488285	ENSG00000245648.1	RP11-277P12.20	4.78	2.37e-06	0.000548	0.35	0.21	Blood protein levels;	chr12:10366107	chr12:10363769~10398506:+
LUAD	cis	rs2255336	0.608	rs7957681	ENSG00000245648.1	RP11-277P12.20	4.78	2.37e-06	0.000548	0.35	0.21	Blood protein levels;	chr12:10366223	chr12:10363769~10398506:+
LUAD	cis	rs2255336	0.608	rs7958658	ENSG00000245648.1	RP11-277P12.20	4.78	2.37e-06	0.000548	0.35	0.21	Blood protein levels;	chr12:10366229	chr12:10363769~10398506:+
LUAD	cis	rs997295	0.737	rs11631474	ENSG00000270964.1	RP11-502I4.3	4.78	2.37e-06	0.000548	0.22	0.21	Motion sickness;	chr15:67641829	chr15:67541072~67542604:-
LUAD	cis	rs2439831	0.702	rs9989313	ENSG00000249839.1	AC011330.5	-4.78	2.37e-06	0.000548	-0.46	-0.21	Lung cancer in ever smokers;	chr15:43860619	chr15:43663654~43684339:-
LUAD	cis	rs8031584	0.678	rs798125	ENSG00000270015.1	RP11-540B6.6	4.78	2.38e-06	0.000549	0.16	0.21	Huntington's disease progression;	chr15:30824597	chr15:30926514~30928407:+
LUAD	cis	rs2976388	0.692	rs2585175	ENSG00000253741.1	CTD-2292P10.4	-4.78	2.38e-06	0.000549	-0.25	-0.21	Urinary tract infection frequency;	chr8:142699871	chr8:142702252~142726973:-
LUAD	cis	rs17301013	0.861	rs10912824	ENSG00000227373.4	RP11-160H22.5	4.78	2.38e-06	0.000549	0.27	0.21	Systemic lupus erythematosus;	chr1:174625846	chr1:174115300~174160004:-
LUAD	cis	rs7829975	0.533	rs1039917	ENSG00000253893.2	FAM85B	-4.78	2.38e-06	0.000549	-0.27	-0.21	Mood instability;	chr8:8861340	chr8:8167819~8226614:-
LUAD	cis	rs2243480	0.522	rs431168	ENSG00000226002.1	RP11-460N20.5	-4.78	2.38e-06	0.000549	-0.41	-0.21	Diabetic kidney disease;	chr7:66046617	chr7:65084103~65100232:+
LUAD	cis	rs13256369	0.708	rs10903310	ENSG00000253893.2	FAM85B	4.78	2.38e-06	0.000549	0.3	0.21	Obesity-related traits;	chr8:8732177	chr8:8167819~8226614:-
LUAD	cis	rs14027	0.921	rs10109901	ENSG00000279347.1	RP11-85I17.2	-4.78	2.38e-06	0.000549	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119817287	chr8:119838736~119840385:-
LUAD	cis	rs14027	0.921	rs10109951	ENSG00000279347.1	RP11-85I17.2	-4.78	2.38e-06	0.000549	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119817519	chr8:119838736~119840385:-
LUAD	cis	rs14027	0.883	rs4871642	ENSG00000279347.1	RP11-85I17.2	-4.78	2.38e-06	0.000549	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119818813	chr8:119838736~119840385:-
LUAD	cis	rs14027	0.921	rs4870955	ENSG00000279347.1	RP11-85I17.2	-4.78	2.38e-06	0.000549	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119821929	chr8:119838736~119840385:-
LUAD	cis	rs14027	0.921	rs34718068	ENSG00000279347.1	RP11-85I17.2	-4.78	2.38e-06	0.000549	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119822368	chr8:119838736~119840385:-
LUAD	cis	rs763567	0.933	rs588837	ENSG00000271811.1	RP1-79C4.4	4.78	2.38e-06	0.000549	0.25	0.21	Tonsillectomy;	chr1:170653968	chr1:170667381~170669425:+
LUAD	cis	rs375066	0.935	rs421512	ENSG00000267058.1	RP11-15A1.3	-4.78	2.38e-06	0.000549	-0.24	-0.21	Breast cancer;	chr19:43911428	chr19:43891804~43901805:-
LUAD	cis	rs2933343	0.951	rs7648327	ENSG00000231305.3	RP11-723O4.2	4.78	2.38e-06	0.000549	0.26	0.21	IgG glycosylation;	chr3:128851865	chr3:128861313~128871540:-
LUAD	cis	rs6802315	0.573	rs7635993	ENSG00000272087.1	RP11-379F4.7	4.78	2.38e-06	0.00055	0.23	0.21	Periodontitis (CDC/AAP);	chr3:158742187	chr3:158693120~158693768:-
LUAD	cis	rs561341	1	rs542132	ENSG00000265798.5	RP11-271K11.5	4.78	2.38e-06	0.00055	0.34	0.21	Hip circumference adjusted for BMI;	chr17:31980174	chr17:31038575~31059121:-
LUAD	cis	rs8072100	0.967	rs11656855	ENSG00000228782.6	CTD-2026D20.3	-4.78	2.38e-06	0.00055	-0.22	-0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47637289	chr17:47450568~47492492:-
LUAD	cis	rs12908161	0.96	rs62019463	ENSG00000275120.1	RP11-182J1.17	4.78	2.38e-06	0.00055	0.32	0.21	Schizophrenia;	chr15:84744856	chr15:84599434~84606463:-
LUAD	cis	rs7086627	0.515	rs10887903	ENSG00000226659.1	RP11-137H2.4	-4.78	2.38e-06	0.00055	-0.28	-0.21	Post bronchodilator FEV1;	chr10:80450885	chr10:80529597~80535942:-
LUAD	cis	rs9584850	0.834	rs9584854	ENSG00000231194.1	FARP1-AS1	4.78	2.39e-06	0.000551	0.26	0.21	Neuroticism;	chr13:98466336	chr13:98435405~98435840:-
LUAD	cis	rs1799949	1	rs11659028	ENSG00000236383.6	LINC00854	-4.78	2.39e-06	0.000551	-0.17	-0.21	Menopause (age at onset);	chr17:43043008	chr17:43216941~43305976:-
LUAD	cis	rs2439831	0.85	rs28524541	ENSG00000249839.1	AC011330.5	-4.78	2.39e-06	0.000551	-0.45	-0.21	Lung cancer in ever smokers;	chr15:43832633	chr15:43663654~43684339:-
LUAD	cis	rs2243480	1	rs1723270	ENSG00000232559.3	GS1-124K5.12	4.78	2.39e-06	0.000551	0.37	0.21	Diabetic kidney disease;	chr7:66004843	chr7:66554588~66576923:-
LUAD	cis	rs561341	0.882	rs2521594	ENSG00000265798.5	RP11-271K11.5	4.77	2.39e-06	0.000551	0.34	0.21	Hip circumference adjusted for BMI;	chr17:31975068	chr17:31038575~31059121:-
LUAD	cis	rs1061377	0.748	rs13117988	ENSG00000249685.1	RP11-360F5.3	4.77	2.39e-06	0.000552	0.26	0.21	Uric acid levels;	chr4:39092219	chr4:39133913~39135608:+
LUAD	cis	rs6840360	1	rs4696291	ENSG00000270265.1	RP11-731D1.4	-4.77	2.39e-06	0.000552	-0.22	-0.21	Intelligence (multi-trait analysis);	chr4:151710485	chr4:151333775~151353224:-
LUAD	cis	rs7743045	0.504	rs10499090	ENSG00000253194.1	RP11-351A11.1	4.77	2.39e-06	0.000552	0.28	0.21	Mean platelet volume;	chr6:119000386	chr6:118934785~119031541:+
LUAD	cis	rs9473147	0.503	rs9473123	ENSG00000270761.1	RP11-385F7.1	-4.77	2.39e-06	0.000552	-0.25	-0.21	Platelet distribution width;Mean platelet volume;	chr6:47507603	chr6:47477243~47477572:-
LUAD	cis	rs12745968	0.653	rs12123935	ENSG00000223787.2	RP4-593M8.1	-4.77	2.39e-06	0.000552	-0.25	-0.21	Bipolar disorder and schizophrenia;	chr1:92710257	chr1:92580476~92580821:-
LUAD	cis	rs12745968	0.589	rs722356	ENSG00000223787.2	RP4-593M8.1	-4.77	2.39e-06	0.000552	-0.25	-0.21	Bipolar disorder and schizophrenia;	chr1:92516848	chr1:92580476~92580821:-
LUAD	cis	rs57502260	0.704	rs72936599	ENSG00000212093.1	AP000807.1	4.77	2.39e-06	0.000552	0.3	0.21	Total body bone mineral density (age 45-60);	chr11:68552937	chr11:68506083~68506166:-
LUAD	cis	rs67311347	0.524	rs11129869	ENSG00000223797.4	ENTPD3-AS1	4.77	2.39e-06	0.000552	0.22	0.21	Renal cell carcinoma;	chr3:40218247	chr3:40313802~40453329:-
LUAD	cis	rs6088590	1	rs6120705	ENSG00000276073.1	RP5-1125A11.7	-4.77	2.4e-06	0.000553	-0.22	-0.21	Coronary artery disease;	chr20:34725936	chr20:33985617~33988989:-
LUAD	cis	rs1816752	0.806	rs3816218	ENSG00000273628.1	RP11-756A22.7	4.77	2.4e-06	0.000553	0.24	0.21	Obesity-related traits;	chr13:24443033	chr13:24933006~24936796:+
LUAD	cis	rs1816752	0.666	rs7994022	ENSG00000273628.1	RP11-756A22.7	4.77	2.4e-06	0.000553	0.24	0.21	Obesity-related traits;	chr13:24443092	chr13:24933006~24936796:+
LUAD	cis	rs1816752	0.712	rs6490932	ENSG00000273628.1	RP11-756A22.7	4.77	2.4e-06	0.000553	0.24	0.21	Obesity-related traits;	chr13:24443313	chr13:24933006~24936796:+
LUAD	cis	rs1816752	0.713	rs7336357	ENSG00000273628.1	RP11-756A22.7	4.77	2.4e-06	0.000553	0.24	0.21	Obesity-related traits;	chr13:24443452	chr13:24933006~24936796:+
LUAD	cis	rs1816752	0.683	rs7330532	ENSG00000273628.1	RP11-756A22.7	4.77	2.4e-06	0.000553	0.24	0.21	Obesity-related traits;	chr13:24443453	chr13:24933006~24936796:+
LUAD	cis	rs1816752	0.59	rs61947036	ENSG00000273628.1	RP11-756A22.7	4.77	2.4e-06	0.000553	0.24	0.21	Obesity-related traits;	chr13:24443544	chr13:24933006~24936796:+
LUAD	cis	rs2742234	0.578	rs2742241	ENSG00000273008.1	RP11-351D16.3	-4.77	2.4e-06	0.000553	-0.25	-0.21	Hirschsprung disease;	chr10:43129775	chr10:43136824~43138334:-
LUAD	cis	rs11671005	0.735	rs1122955	ENSG00000268912.1	CTD-2619J13.17	-4.77	2.4e-06	0.000553	-0.29	-0.21	Mean platelet volume;	chr19:58434836	chr19:58428632~58431148:-
LUAD	cis	rs11671005	0.735	rs11668814	ENSG00000268912.1	CTD-2619J13.17	-4.77	2.4e-06	0.000553	-0.29	-0.21	Mean platelet volume;	chr19:58435466	chr19:58428632~58431148:-
LUAD	cis	rs71520386	0.632	rs1029738	ENSG00000228649.7	AC005682.5	-4.77	2.4e-06	0.000553	-0.29	-0.21	Fibrinogen levels;	chr7:22834428	chr7:22854178~22861579:+
LUAD	cis	rs5758659	1	rs134873	ENSG00000227370.1	RP4-669P10.19	-4.77	2.4e-06	0.000553	-0.19	-0.21	Cognitive function;	chr22:42261560	chr22:42132543~42132998:+
LUAD	cis	rs67311347	0.544	rs6769627	ENSG00000223797.4	ENTPD3-AS1	4.77	2.4e-06	0.000553	0.22	0.21	Renal cell carcinoma;	chr3:40286354	chr3:40313802~40453329:-
LUAD	cis	rs6142102	0.961	rs2284386	ENSG00000275784.1	RP5-1125A11.6	-4.77	2.4e-06	0.000553	-0.23	-0.21	Skin pigmentation;	chr20:34056590	chr20:33989480~33991818:-
LUAD	cis	rs9650657	0.537	rs11250092	ENSG00000255046.1	RP11-297N6.4	-4.77	2.4e-06	0.000554	-0.26	-0.21	Neuroticism;	chr8:10929033	chr8:11797928~11802568:-
LUAD	cis	rs453301	0.686	rs11787026	ENSG00000253893.2	FAM85B	-4.77	2.4e-06	0.000554	-0.27	-0.21	Joint mobility (Beighton score);	chr8:9044861	chr8:8167819~8226614:-
LUAD	cis	rs17684571	0.751	rs6910414	ENSG00000231441.1	RP11-472M19.2	4.77	2.4e-06	0.000554	0.3	0.21	Schizophrenia;	chr6:56861939	chr6:56844002~56864078:+
LUAD	cis	rs9322193	0.923	rs9377230	ENSG00000268592.3	RAET1E-AS1	4.77	2.4e-06	0.000554	0.26	0.21	Lung cancer;	chr6:149613607	chr6:149863494~149919507:+
LUAD	cis	rs6840360	1	rs1355413	ENSG00000270265.1	RP11-731D1.4	-4.77	2.4e-06	0.000554	-0.22	-0.21	Intelligence (multi-trait analysis);	chr4:151712515	chr4:151333775~151353224:-
LUAD	cis	rs72717009	0.825	rs11810143	ENSG00000225217.1	HSPA7	-4.77	2.4e-06	0.000554	-0.3	-0.21	Rheumatoid arthritis;	chr1:161510859	chr1:161606291~161608217:+
LUAD	cis	rs9860428	0.844	rs9858931	ENSG00000242770.2	RP11-180K7.1	-4.77	2.4e-06	0.000554	-0.23	-0.21	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112897933	chr3:112802478~112812819:+
LUAD	cis	rs7302981	0.967	rs7136570	ENSG00000272368.2	RP4-605O3.4	-4.77	2.4e-06	0.000555	-0.25	-0.21	Systolic blood pressure;	chr12:50136153	chr12:50112197~50165618:+
LUAD	cis	rs293748	0.771	rs66868318	ENSG00000250155.1	CTD-2353F22.1	-4.77	2.4e-06	0.000555	-0.29	-0.21	Obesity-related traits;	chr5:36826119	chr5:36666214~36725195:-
LUAD	cis	rs375066	0.762	rs239939	ENSG00000267058.1	RP11-15A1.3	-4.77	2.41e-06	0.000555	-0.24	-0.21	Breast cancer;	chr19:43883815	chr19:43891804~43901805:-
LUAD	cis	rs375066	0.762	rs239938	ENSG00000267058.1	RP11-15A1.3	-4.77	2.41e-06	0.000555	-0.24	-0.21	Breast cancer;	chr19:43886153	chr19:43891804~43901805:-
LUAD	cis	rs1816752	0.819	rs7985478	ENSG00000273628.1	RP11-756A22.7	4.77	2.41e-06	0.000555	0.24	0.21	Obesity-related traits;	chr13:24417135	chr13:24933006~24936796:+
LUAD	cis	rs11992162	0.967	rs4840601	ENSG00000255046.1	RP11-297N6.4	-4.77	2.41e-06	0.000555	-0.26	-0.21	Monocyte count;	chr8:11971221	chr8:11797928~11802568:-
LUAD	cis	rs67311347	0.577	rs2371129	ENSG00000223797.4	ENTPD3-AS1	-4.77	2.41e-06	0.000555	-0.22	-0.21	Renal cell carcinoma;	chr3:40206902	chr3:40313802~40453329:-
LUAD	cis	rs9322193	0.962	rs17673294	ENSG00000268592.3	RAET1E-AS1	4.77	2.41e-06	0.000555	0.26	0.21	Lung cancer;	chr6:149813857	chr6:149863494~149919507:+
LUAD	cis	rs2310173	0.575	rs13022757	ENSG00000281162.1	LINC01127	-4.77	2.41e-06	0.000555	-0.24	-0.21	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:101997084	chr2:101962056~101987167:+
LUAD	cis	rs12928939	0.911	rs12919271	ENSG00000260886.1	TAT-AS1	4.77	2.41e-06	0.000555	0.27	0.21	Post bronchodilator FEV1;	chr16:71758793	chr16:71565789~71578187:+
LUAD	cis	rs17508449	0.865	rs4838993	ENSG00000232450.1	RP4-730K3.3	-4.77	2.41e-06	0.000555	-0.36	-0.21	Leprosy;	chr1:113592511	chr1:113698884~113699631:-
LUAD	cis	rs453301	0.522	rs1964356	ENSG00000173295.6	FAM86B3P	4.77	2.41e-06	0.000556	0.24	0.21	Joint mobility (Beighton score);	chr8:8995760	chr8:8228595~8244865:+
LUAD	cis	rs2281636	0.723	rs11190255	ENSG00000233690.1	EBAG9P1	4.77	2.41e-06	0.000556	0.22	0.21	Obesity-related traits;	chr10:99714742	chr10:99697407~99697949:-
LUAD	cis	rs7189233	0.531	rs7204496	ENSG00000279344.1	RP11-44F14.7	-4.77	2.41e-06	0.000556	-0.17	-0.21	Intelligence (multi-trait analysis);	chr16:53462686	chr16:53478957~53481550:-
LUAD	cis	rs2976388	0.647	rs2585154	ENSG00000253741.1	CTD-2292P10.4	-4.77	2.41e-06	0.000556	-0.25	-0.21	Urinary tract infection frequency;	chr8:142702067	chr8:142702252~142726973:-
LUAD	cis	rs6840360	0.515	rs11099811	ENSG00000270265.1	RP11-731D1.4	-4.77	2.41e-06	0.000556	-0.22	-0.21	Intelligence (multi-trait analysis);	chr4:151399380	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.582	rs7691601	ENSG00000270265.1	RP11-731D1.4	-4.77	2.41e-06	0.000556	-0.22	-0.21	Intelligence (multi-trait analysis);	chr4:151400479	chr4:151333775~151353224:-
LUAD	cis	rs2239547	0.563	rs4687560	ENSG00000242142.1	SERBP1P3	4.77	2.41e-06	0.000556	0.25	0.21	Schizophrenia;	chr3:52864105	chr3:53064283~53065091:-
LUAD	cis	rs11673344	0.615	rs2921561	ENSG00000226686.6	LINC01535	4.77	2.41e-06	0.000556	0.26	0.21	Obesity-related traits;	chr19:37348969	chr19:37251912~37265535:+
LUAD	cis	rs6751744	0.855	rs1425045	ENSG00000226266.5	AC009961.3	-4.77	2.41e-06	0.000557	-0.32	-0.21	Dysphagia;	chr2:159508236	chr2:159670708~159712435:-
LUAD	cis	rs6840360	0.582	rs4696260	ENSG00000270265.1	RP11-731D1.4	-4.77	2.41e-06	0.000557	-0.22	-0.21	Intelligence (multi-trait analysis);	chr4:151397772	chr4:151333775~151353224:-
LUAD	cis	rs6088590	1	rs10048849	ENSG00000276073.1	RP5-1125A11.7	-4.77	2.41e-06	0.000557	-0.22	-0.21	Coronary artery disease;	chr20:34831877	chr20:33985617~33988989:-
LUAD	cis	rs2378497	0.938	rs1339869	ENSG00000232679.1	RP11-400N13.3	4.77	2.42e-06	0.000557	0.33	0.21	Serum thyroid-stimulating hormone levels;	chr1:222006591	chr1:222041705~222064763:-
LUAD	cis	rs11992162	0.967	rs10088415	ENSG00000255046.1	RP11-297N6.4	4.77	2.42e-06	0.000557	0.26	0.21	Monocyte count;	chr8:11973316	chr8:11797928~11802568:-
LUAD	cis	rs1816752	0.712	rs2862898	ENSG00000273628.1	RP11-756A22.7	4.77	2.42e-06	0.000557	0.24	0.21	Obesity-related traits;	chr13:24414323	chr13:24933006~24936796:+
LUAD	cis	rs1816752	0.652	rs2902356	ENSG00000273628.1	RP11-756A22.7	4.77	2.42e-06	0.000557	0.24	0.21	Obesity-related traits;	chr13:24414333	chr13:24933006~24936796:+
LUAD	cis	rs6840360	0.571	rs4696278	ENSG00000270265.1	RP11-731D1.4	-4.77	2.42e-06	0.000557	-0.24	-0.21	Intelligence (multi-trait analysis);	chr4:151637826	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.571	rs4696279	ENSG00000270265.1	RP11-731D1.4	-4.77	2.42e-06	0.000557	-0.24	-0.21	Intelligence (multi-trait analysis);	chr4:151639297	chr4:151333775~151353224:-
LUAD	cis	rs71520386	0.632	rs10254365	ENSG00000228649.7	AC005682.5	-4.77	2.42e-06	0.000557	-0.29	-0.21	Fibrinogen levels;	chr7:22825135	chr7:22854178~22861579:+
LUAD	cis	rs6496044	0.591	rs979825	ENSG00000259295.5	CSPG4P12	4.77	2.42e-06	0.000558	0.25	0.21	Interstitial lung disease;	chr15:85537394	chr15:85191438~85213905:+
LUAD	cis	rs2408955	0.522	rs10875721	ENSG00000257735.1	RP11-370I10.6	-4.77	2.42e-06	0.000558	-0.26	-0.21	Glycated hemoglobin levels;	chr12:48019810	chr12:48350945~48442411:+
LUAD	cis	rs4664293	0.667	rs2042782	ENSG00000226266.5	AC009961.3	4.77	2.42e-06	0.000558	0.28	0.21	Monocyte percentage of white cells;	chr2:159789781	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.642	rs6732598	ENSG00000226266.5	AC009961.3	4.77	2.42e-06	0.000558	0.28	0.21	Monocyte percentage of white cells;	chr2:159790370	chr2:159670708~159712435:-
LUAD	cis	rs9652601	1	rs9652601	ENSG00000274038.1	RP11-66H6.4	-4.77	2.42e-06	0.000558	-0.26	-0.21	Systemic lupus erythematosus;	chr16:11080508	chr16:11056556~11057034:+
LUAD	cis	rs1864400	0.69	rs2565200	ENSG00000273008.1	RP11-351D16.3	-4.77	2.42e-06	0.000559	-0.24	-0.21	Hirschsprung disease;	chr10:43127485	chr10:43136824~43138334:-
LUAD	cis	rs2243480	1	rs1723267	ENSG00000226002.1	RP11-460N20.5	-4.77	2.42e-06	0.000559	-0.35	-0.21	Diabetic kidney disease;	chr7:66008327	chr7:65084103~65100232:+
LUAD	cis	rs2732480	0.577	rs1489109	ENSG00000257735.1	RP11-370I10.6	4.77	2.42e-06	0.000559	0.26	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344997	chr12:48350945~48442411:+
LUAD	cis	rs2732480	0.577	rs1489108	ENSG00000257735.1	RP11-370I10.6	4.77	2.42e-06	0.000559	0.26	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344998	chr12:48350945~48442411:+
LUAD	cis	rs7017914	0.652	rs10504487	ENSG00000223220.1	Y_RNA	4.77	2.42e-06	0.000559	0.24	0.21	Bone mineral density;	chr8:70931364	chr8:70780914~70781008:-
LUAD	cis	rs10129255	1	rs11627342	ENSG00000211974.3	IGHV2-70	4.77	2.42e-06	0.000559	0.23	0.21	Kawasaki disease;	chr14:106675823	chr14:106723574~106724093:-
LUAD	cis	rs7923837	0.65	rs10882098	ENSG00000236493.2	EIF2S2P3	4.77	2.42e-06	0.000559	0.24	0.21	Multiple sclerosis;Body mass index;	chr10:92685036	chr10:92668745~92669743:-
LUAD	cis	rs800160	0.844	rs2651784	ENSG00000236264.4	RPL26P30	-4.77	2.43e-06	0.000559	-0.29	-0.21	Bacteremia;	chr11:2326319	chr11:2335132~2335776:-
LUAD	cis	rs2243480	1	rs313809	ENSG00000226002.1	RP11-460N20.5	-4.77	2.43e-06	0.000559	-0.36	-0.21	Diabetic kidney disease;	chr7:66034996	chr7:65084103~65100232:+
LUAD	cis	rs111580313	0.71	rs77733759	ENSG00000270020.1	RP11-463O9.9	4.77	2.43e-06	0.000559	0.45	0.21	Systemic juvenile idiopathic arthritis;	chr16:86590513	chr16:86520383~86523897:-
LUAD	cis	rs4061073	0.961	rs9012	ENSG00000198711.5	SSBP3-AS1	-4.77	2.43e-06	0.000559	-0.19	-0.21	Body mass index;	chr1:54225792	chr1:54236440~54239063:+
LUAD	cis	rs1707322	1	rs2458400	ENSG00000280836.1	AL355480.1	4.77	2.43e-06	0.000559	0.28	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46065126	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs9429186	ENSG00000280836.1	AL355480.1	4.77	2.43e-06	0.000559	0.28	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074015	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs785506	ENSG00000280836.1	AL355480.1	4.77	2.43e-06	0.000559	0.28	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074980	chr1:45581219~45581321:-
LUAD	cis	rs4908760	0.965	rs1884352	ENSG00000270282.1	RP5-1115A15.2	4.77	2.43e-06	0.000559	0.23	0.21	Vitiligo;	chr1:8477229	chr1:8512653~8513021:+
LUAD	cis	rs9322193	0.923	rs11155677	ENSG00000268592.3	RAET1E-AS1	4.77	2.43e-06	0.000559	0.26	0.21	Lung cancer;	chr6:149756953	chr6:149863494~149919507:+
LUAD	cis	rs4841097	0.876	rs6601288	ENSG00000253893.2	FAM85B	-4.77	2.43e-06	0.00056	-0.28	-0.21	Platelet distribution width;	chr8:9085920	chr8:8167819~8226614:-
LUAD	cis	rs2562456	0.754	rs11666213	ENSG00000268081.1	RP11-678G14.2	4.77	2.43e-06	0.00056	0.35	0.21	Pain;	chr19:21422843	chr19:21554640~21569237:-
LUAD	cis	rs7302981	0.741	rs8181679	ENSG00000272368.2	RP4-605O3.4	-4.77	2.43e-06	0.00056	-0.24	-0.21	Systolic blood pressure;	chr12:50217237	chr12:50112197~50165618:+
LUAD	cis	rs2554380	0.6	rs6602986	ENSG00000230373.7	GOLGA6L5P	-4.77	2.43e-06	0.00056	-0.22	-0.21	Height;	chr15:83778347	chr15:84507885~84516814:-
LUAD	cis	rs4489787	1	rs11168576	ENSG00000240399.1	RP1-228P16.1	-4.77	2.43e-06	0.00056	-0.32	-0.21	Prostate cancer (SNP x SNP interaction);	chr12:48446635	chr12:48054813~48055591:-
LUAD	cis	rs673078	0.607	rs1060964	ENSG00000275409.1	RP11-131L12.4	-4.77	2.43e-06	0.000561	-0.28	-0.21	Glucose homeostasis traits;	chr12:118414906	chr12:118430147~118430699:+
LUAD	cis	rs57502260	0.704	rs60538784	ENSG00000212093.1	AP000807.1	4.77	2.43e-06	0.000561	0.29	0.21	Total body bone mineral density (age 45-60);	chr11:68619267	chr11:68506083~68506166:-
LUAD	cis	rs16873450	0.527	rs11982624	ENSG00000234800.2	PCMTD1P3	4.77	2.43e-06	0.000561	0.24	0.21	Verbal memory performance (residualized delayed recall level);	chr7:23834815	chr7:23721311~23721782:-
LUAD	cis	rs9322193	0.884	rs9688858	ENSG00000268592.3	RAET1E-AS1	4.77	2.43e-06	0.000561	0.26	0.21	Lung cancer;	chr6:149637911	chr6:149863494~149919507:+
LUAD	cis	rs910316	0.87	rs7147712	ENSG00000259138.1	RP11-950C14.7	-4.77	2.43e-06	0.000561	-0.22	-0.21	Height;	chr14:75204004	chr14:75127153~75136930:+
LUAD	cis	rs11168618	0.904	rs11495273	ENSG00000240399.1	RP1-228P16.1	4.77	2.43e-06	0.000561	0.2	0.21	Adiponectin levels;	chr12:48535407	chr12:48054813~48055591:-
LUAD	cis	rs1816752	0.776	rs9511268	ENSG00000273628.1	RP11-756A22.7	4.77	2.44e-06	0.000561	0.25	0.21	Obesity-related traits;	chr13:24444182	chr13:24933006~24936796:+
LUAD	cis	rs7727544	0.606	rs10058074	ENSG00000233006.5	AC034220.3	4.77	2.44e-06	0.000561	0.19	0.21	Blood metabolite levels;	chr5:132350453	chr5:132311285~132369916:-
LUAD	cis	rs561341	1	rs548957	ENSG00000265798.5	RP11-271K11.5	4.77	2.44e-06	0.000561	0.34	0.21	Hip circumference adjusted for BMI;	chr17:31975392	chr17:31038575~31059121:-
LUAD	cis	rs561341	1	rs484175	ENSG00000265798.5	RP11-271K11.5	4.77	2.44e-06	0.000561	0.34	0.21	Hip circumference adjusted for BMI;	chr17:31982022	chr17:31038575~31059121:-
LUAD	cis	rs561341	0.941	rs4525554	ENSG00000265798.5	RP11-271K11.5	4.77	2.44e-06	0.000561	0.34	0.21	Hip circumference adjusted for BMI;	chr17:31985800	chr17:31038575~31059121:-
LUAD	cis	rs561341	1	rs530209	ENSG00000265798.5	RP11-271K11.5	4.77	2.44e-06	0.000561	0.34	0.21	Hip circumference adjusted for BMI;	chr17:31988268	chr17:31038575~31059121:-
LUAD	cis	rs561341	1	rs72825712	ENSG00000265798.5	RP11-271K11.5	4.77	2.44e-06	0.000561	0.34	0.21	Hip circumference adjusted for BMI;	chr17:31989100	chr17:31038575~31059121:-
LUAD	cis	rs561341	1	rs561341	ENSG00000265798.5	RP11-271K11.5	4.77	2.44e-06	0.000561	0.34	0.21	Hip circumference adjusted for BMI;	chr17:31989366	chr17:31038575~31059121:-
LUAD	cis	rs11159086	0.838	rs10147963	ENSG00000259005.1	RP3-449M8.6	4.77	2.44e-06	0.000561	0.27	0.21	Advanced glycation end-product levels;	chr14:74476091	chr14:74474007~74474864:-
LUAD	cis	rs12745968	0.589	rs6603989	ENSG00000223787.2	RP4-593M8.1	-4.77	2.44e-06	0.000561	-0.25	-0.21	Bipolar disorder and schizophrenia;	chr1:92561371	chr1:92580476~92580821:-
LUAD	cis	rs45509595	0.841	rs9368531	ENSG00000219392.1	RP1-265C24.5	-4.77	2.44e-06	0.000561	-0.4	-0.21	Breast cancer;	chr6:27814094	chr6:28115628~28116551:+
LUAD	cis	rs45509595	0.841	rs2747054	ENSG00000219392.1	RP1-265C24.5	-4.77	2.44e-06	0.000561	-0.4	-0.21	Breast cancer;	chr6:27815581	chr6:28115628~28116551:+
LUAD	cis	rs1387259	0.931	rs11168474	ENSG00000240399.1	RP1-228P16.1	4.77	2.44e-06	0.000561	0.21	0.21	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48227601	chr12:48054813~48055591:-
LUAD	cis	rs4660214	0.666	rs587404	ENSG00000228060.1	RP11-69E11.8	-4.77	2.44e-06	0.000561	-0.19	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39442834	chr1:39565160~39573203:+
LUAD	cis	rs8072100	0.713	rs8075058	ENSG00000228782.6	CTD-2026D20.3	4.77	2.44e-06	0.000562	0.23	0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47405491	chr17:47450568~47492492:-
LUAD	cis	rs875971	0.895	rs7788984	ENSG00000232559.3	GS1-124K5.12	4.77	2.44e-06	0.000562	0.25	0.21	Aortic root size;	chr7:66450629	chr7:66554588~66576923:-
LUAD	cis	rs8062405	0.824	rs4788085	ENSG00000251417.2	RP11-1348G14.4	-4.77	2.44e-06	0.000562	-0.21	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28802743~28817828:+
LUAD	cis	rs8062405	0.824	rs28772958	ENSG00000251417.2	RP11-1348G14.4	-4.77	2.44e-06	0.000562	-0.21	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28802743~28817828:+
LUAD	cis	rs795484	0.507	rs1726407	ENSG00000275759.1	RP11-131L12.3	4.77	2.44e-06	0.000562	0.22	0.21	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118145921	chr12:118428281~118428870:+
LUAD	cis	rs7119	0.717	rs12910512	ENSG00000259362.2	RP11-307C19.1	-4.77	2.44e-06	0.000562	-0.26	-0.21	Type 2 diabetes;	chr15:77524911	chr15:77525540~77534110:+
LUAD	cis	rs5758659	1	rs5758677	ENSG00000227370.1	RP4-669P10.19	-4.77	2.44e-06	0.000562	-0.19	-0.21	Cognitive function;	chr22:42247033	chr22:42132543~42132998:+
LUAD	cis	rs7210086	0.808	rs3935122	ENSG00000263893.2	CTD-3010D24.3	4.77	2.44e-06	0.000562	0.29	0.21	Ulcerative colitis;	chr17:72645176	chr17:72642731~72644490:+
LUAD	cis	rs10129255	1	rs9324091	ENSG00000211974.3	IGHV2-70	4.77	2.44e-06	0.000562	0.23	0.21	Kawasaki disease;	chr14:106676625	chr14:106723574~106724093:-
LUAD	cis	rs2243480	1	rs56016656	ENSG00000164669.11	INTS4P1	4.77	2.44e-06	0.000562	0.39	0.21	Diabetic kidney disease;	chr7:65918494	chr7:65141225~65234216:+
LUAD	cis	rs2243480	0.803	rs55700941	ENSG00000164669.11	INTS4P1	4.77	2.44e-06	0.000562	0.39	0.21	Diabetic kidney disease;	chr7:65924813	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs56291018	ENSG00000164669.11	INTS4P1	4.77	2.44e-06	0.000562	0.39	0.21	Diabetic kidney disease;	chr7:65925352	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs36033484	ENSG00000164669.11	INTS4P1	4.77	2.44e-06	0.000562	0.39	0.21	Diabetic kidney disease;	chr7:65925571	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs34193460	ENSG00000164669.11	INTS4P1	4.77	2.44e-06	0.000562	0.39	0.21	Diabetic kidney disease;	chr7:65928123	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs34560516	ENSG00000164669.11	INTS4P1	4.77	2.44e-06	0.000562	0.39	0.21	Diabetic kidney disease;	chr7:65939105	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs57057549	ENSG00000164669.11	INTS4P1	4.77	2.44e-06	0.000562	0.39	0.21	Diabetic kidney disease;	chr7:65940751	chr7:65141225~65234216:+
LUAD	cis	rs8127691	0.967	rs4635612	ENSG00000237604.1	AP001056.1	4.77	2.44e-06	0.000562	0.25	0.21	Inflammatory bowel disease;	chr21:44196080	chr21:44175489~44176453:+
LUAD	cis	rs2115630	0.905	rs1975277	ENSG00000229212.6	RP11-561C5.4	4.77	2.44e-06	0.000562	0.25	0.21	P wave terminal force;	chr15:84786327	chr15:85205440~85234795:-
LUAD	cis	rs2880765	0.743	rs4551990	ENSG00000259295.5	CSPG4P12	4.77	2.44e-06	0.000563	0.25	0.21	Coronary artery disease;	chr15:85472056	chr15:85191438~85213905:+
LUAD	cis	rs7772486	0.754	rs1415746	ENSG00000235652.6	RP11-545I5.3	-4.77	2.44e-06	0.000563	-0.21	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145755971	chr6:145799409~145886585:+
LUAD	cis	rs4660214	0.789	rs1984142	ENSG00000228060.1	RP11-69E11.8	4.77	2.44e-06	0.000563	0.19	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39279936	chr1:39565160~39573203:+
LUAD	cis	rs1008375	1	rs10032326	ENSG00000249502.1	AC006160.5	-4.77	2.44e-06	0.000563	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17629094	chr4:17587467~17614571:-
LUAD	cis	rs7208859	0.573	rs56031503	ENSG00000263603.1	CTD-2349P21.5	-4.77	2.45e-06	0.000563	-0.37	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30729469~30731202:+
LUAD	cis	rs9813712	0.526	rs62281641	ENSG00000249846.5	RP11-77P16.4	-4.77	2.45e-06	0.000563	-0.25	-0.21	Response to amphetamines;	chr3:130235668	chr3:130112550~130120579:+
LUAD	cis	rs2252586	0.833	rs77799804	ENSG00000176826.14	FKBP9P1	-4.77	2.45e-06	0.000563	-0.29	-0.21	Glioma;	chr7:54897151	chr7:55681074~55713252:-
LUAD	cis	rs2548724	0.588	rs62371034	ENSG00000250682.4	LINC00491	4.77	2.45e-06	0.000563	0.27	0.21	Type 2 diabetes;	chr5:102489780	chr5:102609156~102671559:-
LUAD	cis	rs2742234	0.59	rs2565201	ENSG00000273008.1	RP11-351D16.3	-4.77	2.45e-06	0.000563	-0.25	-0.21	Hirschsprung disease;	chr10:43123036	chr10:43136824~43138334:-
LUAD	cis	rs950169	0.881	rs72750843	ENSG00000229212.6	RP11-561C5.4	-4.77	2.45e-06	0.000564	-0.31	-0.21	Schizophrenia;	chr15:84592552	chr15:85205440~85234795:-
LUAD	cis	rs875971	1	rs1981798	ENSG00000232559.3	GS1-124K5.12	4.77	2.45e-06	0.000564	0.25	0.21	Aortic root size;	chr7:66489916	chr7:66554588~66576923:-
LUAD	cis	rs36423	0.748	rs36399	ENSG00000266869.1	RP6-114E22.1	-4.77	2.45e-06	0.000564	-0.32	-0.21	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71893616	chr14:71848606~71908430:+
LUAD	cis	rs36423	0.748	rs36398	ENSG00000266869.1	RP6-114E22.1	-4.77	2.45e-06	0.000564	-0.32	-0.21	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71893710	chr14:71848606~71908430:+
LUAD	cis	rs150992	0.536	rs10479348	ENSG00000248489.1	CTD-2007H13.3	-4.77	2.45e-06	0.000564	-0.27	-0.21	Body mass index;	chr5:99013022	chr5:98929171~98995013:+
LUAD	cis	rs2524005	1	rs2524005	ENSG00000243753.4	HLA-L	-4.77	2.45e-06	0.000564	-0.29	-0.21	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:30259584~30293014:+
LUAD	cis	rs1167827	0.71	rs1167836	ENSG00000223705.8	NSUN5P1	4.77	2.45e-06	0.000564	0.15	0.21	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75539580	chr7:75410322~75416787:+
LUAD	cis	rs7493	0.95	rs12704794	ENSG00000233942.1	AC004012.1	4.77	2.45e-06	0.000564	0.31	0.21	Yu-Zhi constitution type in type 2 diabetes;	chr7:95406821	chr7:95471835~95473998:+
LUAD	cis	rs7493	1	rs12155103	ENSG00000233942.1	AC004012.1	4.77	2.45e-06	0.000564	0.31	0.21	Yu-Zhi constitution type in type 2 diabetes;	chr7:95407819	chr7:95471835~95473998:+
LUAD	cis	rs7493	0.95	rs6961624	ENSG00000233942.1	AC004012.1	4.77	2.45e-06	0.000564	0.31	0.21	Yu-Zhi constitution type in type 2 diabetes;	chr7:95408349	chr7:95471835~95473998:+
LUAD	cis	rs7493	1	rs2286232	ENSG00000233942.1	AC004012.1	4.77	2.45e-06	0.000564	0.31	0.21	Yu-Zhi constitution type in type 2 diabetes;	chr7:95410133	chr7:95471835~95473998:+
LUAD	cis	rs507080	0.883	rs558593	ENSG00000278376.1	RP11-158I9.8	-4.77	2.45e-06	0.000565	-0.23	-0.21	Serum metabolite levels;	chr11:118691811	chr11:118791254~118793137:+
LUAD	cis	rs1062177	0.756	rs2964588	ENSG00000253921.1	CTB-113P19.3	4.77	2.45e-06	0.000565	0.3	0.21	Preschool internalizing problems;	chr5:151738825	chr5:151753992~151767247:+
LUAD	cis	rs1707322	1	rs6429588	ENSG00000280836.1	AL355480.1	-4.77	2.46e-06	0.000565	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45988386	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs4660331	ENSG00000280836.1	AL355480.1	-4.77	2.46e-06	0.000565	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45993111	chr1:45581219~45581321:-
LUAD	cis	rs1707322	1	rs12097799	ENSG00000280836.1	AL355480.1	-4.77	2.46e-06	0.000565	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45994214	chr1:45581219~45581321:-
LUAD	cis	rs9500256	1	rs9500256	ENSG00000215190.7	LINC00680	-4.77	2.46e-06	0.000565	-0.25	-0.21	Eosinophilic esophagitis (pediatric);	chr6:57982677	chr6:57946074~57961501:-
LUAD	cis	rs2933343	1	rs1680784	ENSG00000231305.3	RP11-723O4.2	4.77	2.46e-06	0.000565	0.26	0.21	IgG glycosylation;	chr3:128925615	chr3:128861313~128871540:-
LUAD	cis	rs6088590	1	rs2295353	ENSG00000276073.1	RP5-1125A11.7	-4.77	2.46e-06	0.000566	-0.22	-0.21	Coronary artery disease;	chr20:34768708	chr20:33985617~33988989:-
LUAD	cis	rs12701220	0.847	rs10272002	ENSG00000229043.2	AC091729.9	-4.77	2.46e-06	0.000566	-0.29	-0.21	Bronchopulmonary dysplasia;	chr7:1007979	chr7:1160374~1165267:+
LUAD	cis	rs6687758	0.687	rs17011146	ENSG00000228437.4	RP11-400N13.2	4.77	2.46e-06	0.000567	0.3	0.21	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221940306	chr1:221966341~221984964:+
LUAD	cis	rs35160687	0.644	rs4832274	ENSG00000273080.1	RP11-301O19.1	-4.77	2.46e-06	0.000567	-0.24	-0.21	Night sleep phenotypes;	chr2:86301961	chr2:86195590~86196049:+
LUAD	cis	rs2243480	1	rs73142162	ENSG00000164669.11	INTS4P1	4.77	2.46e-06	0.000567	0.39	0.21	Diabetic kidney disease;	chr7:65909309	chr7:65141225~65234216:+
LUAD	cis	rs6088590	1	rs6088595	ENSG00000276073.1	RP5-1125A11.7	-4.77	2.47e-06	0.000567	-0.23	-0.21	Coronary artery disease;	chr20:34770696	chr20:33985617~33988989:-
LUAD	cis	rs7811142	0.943	rs11769886	ENSG00000078319.8	PMS2P1	-4.77	2.47e-06	0.000567	-0.26	-0.21	Platelet count;	chr7:100400984	chr7:100320992~100341908:-
LUAD	cis	rs2239547	0.618	rs2071041	ENSG00000242142.1	SERBP1P3	4.77	2.47e-06	0.000567	0.25	0.21	Schizophrenia;	chr3:52830677	chr3:53064283~53065091:-
LUAD	cis	rs875971	0.54	rs4717275	ENSG00000237310.1	GS1-124K5.4	-4.77	2.47e-06	0.000567	-0.23	-0.21	Aortic root size;	chr7:65800193	chr7:66493706~66495474:+
LUAD	cis	rs1555322	0.53	rs2250205	ENSG00000126005.14	MMP24-AS1	-4.77	2.47e-06	0.000568	-0.3	-0.21	Attention deficit hyperactivity disorder;	chr20:35280121	chr20:35216462~35278131:-
LUAD	cis	rs7580658	0.545	rs885276	ENSG00000236682.1	AC068282.3	-4.77	2.47e-06	0.000568	-0.27	-0.21	Protein C levels;	chr2:127193328	chr2:127389130~127400580:+
LUAD	cis	rs12745968	0.589	rs7530780	ENSG00000223787.2	RP4-593M8.1	-4.77	2.47e-06	0.000568	-0.25	-0.21	Bipolar disorder and schizophrenia;	chr1:92664711	chr1:92580476~92580821:-
LUAD	cis	rs4660456	0.572	rs10789191	ENSG00000237899.1	RP4-739H11.3	4.77	2.47e-06	0.000568	0.25	0.21	Platelet count;	chr1:40690819	chr1:40669089~40687588:-
LUAD	cis	rs11157436	0.602	rs11157435	ENSG00000211813.2	TRAV34	4.77	2.47e-06	0.000568	0.24	0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22168888	chr14:22207522~22208129:+
LUAD	cis	rs3813579	1	rs3813579	ENSG00000261390.4	RP11-345M22.2	-4.77	2.47e-06	0.000569	-0.26	-0.21	Thyroid volume;	chr16:79715379	chr16:79715232~79770563:-
LUAD	cis	rs34779708	0.966	rs2126984	ENSG00000271335.4	RP11-324I22.4	4.77	2.47e-06	0.000569	0.22	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35121363	chr10:35314552~35336401:-
LUAD	cis	rs4664293	0.667	rs10169681	ENSG00000226266.5	AC009961.3	4.77	2.47e-06	0.000569	0.28	0.21	Monocyte percentage of white cells;	chr2:159782065	chr2:159670708~159712435:-
LUAD	cis	rs2243480	1	rs73150014	ENSG00000164669.11	INTS4P1	4.77	2.47e-06	0.000569	0.38	0.21	Diabetic kidney disease;	chr7:65985932	chr7:65141225~65234216:+
LUAD	cis	rs172166	0.516	rs1225618	ENSG00000219392.1	RP1-265C24.5	-4.77	2.47e-06	0.000569	-0.27	-0.21	Cardiac Troponin-T levels;	chr6:28161935	chr6:28115628~28116551:+
LUAD	cis	rs9545047	0.604	rs9545085	ENSG00000227354.5	RBM26-AS1	4.77	2.47e-06	0.000569	0.22	0.21	Schizophrenia;	chr13:79363969	chr13:79406309~79424328:+
LUAD	cis	rs7684253	1	rs7684253	ENSG00000269949.1	RP11-738E22.3	4.77	2.47e-06	0.000569	0.27	0.21	Migraine;	chr4:56861145	chr4:56960927~56961373:-
LUAD	cis	rs1707322	1	rs4298677	ENSG00000280836.1	AL355480.1	-4.77	2.47e-06	0.000569	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45840947	chr1:45581219~45581321:-
LUAD	cis	rs875971	0.522	rs4718285	ENSG00000224316.1	RP11-479O9.2	4.77	2.48e-06	0.000569	0.21	0.21	Aortic root size;	chr7:65827018	chr7:65773620~65802067:+
LUAD	cis	rs875971	0.522	rs4718286	ENSG00000224316.1	RP11-479O9.2	4.77	2.48e-06	0.000569	0.21	0.21	Aortic root size;	chr7:65827777	chr7:65773620~65802067:+
LUAD	cis	rs7017914	0.629	rs35762981	ENSG00000223220.1	Y_RNA	4.77	2.48e-06	0.000569	0.24	0.21	Bone mineral density;	chr8:70889405	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs4629903	ENSG00000223220.1	Y_RNA	4.77	2.48e-06	0.000569	0.24	0.21	Bone mineral density;	chr8:70892897	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs13271286	ENSG00000223220.1	Y_RNA	4.77	2.48e-06	0.000569	0.24	0.21	Bone mineral density;	chr8:70894364	chr8:70780914~70781008:-
LUAD	cis	rs57502260	0.68	rs55654976	ENSG00000212093.1	AP000807.1	4.77	2.48e-06	0.000569	0.29	0.21	Total body bone mineral density (age 45-60);	chr11:68626073	chr11:68506083~68506166:-
LUAD	cis	rs11673344	0.734	rs2551047	ENSG00000226686.6	LINC01535	4.77	2.48e-06	0.000569	0.26	0.21	Obesity-related traits;	chr19:36935174	chr19:37251912~37265535:+
LUAD	cis	rs11673344	0.704	rs551717	ENSG00000226686.6	LINC01535	4.77	2.48e-06	0.000569	0.26	0.21	Obesity-related traits;	chr19:36936977	chr19:37251912~37265535:+
LUAD	cis	rs11673344	0.704	rs826290	ENSG00000226686.6	LINC01535	4.77	2.48e-06	0.000569	0.26	0.21	Obesity-related traits;	chr19:36937543	chr19:37251912~37265535:+
LUAD	cis	rs11673344	0.67	rs35011739	ENSG00000226686.6	LINC01535	4.77	2.48e-06	0.000569	0.26	0.21	Obesity-related traits;	chr19:36943328	chr19:37251912~37265535:+
LUAD	cis	rs11673344	0.704	rs540451	ENSG00000226686.6	LINC01535	4.77	2.48e-06	0.000569	0.26	0.21	Obesity-related traits;	chr19:36944619	chr19:37251912~37265535:+
LUAD	cis	rs3743772	0.5	rs8045574	ENSG00000279722.1	RP11-44F14.6	-4.77	2.48e-06	0.00057	-0.28	-0.21	Depressive symptoms (SSRI exposure interaction);	chr16:53395293	chr16:53487607~53489943:-
LUAD	cis	rs17772222	0.917	rs8006652	ENSG00000258983.2	RP11-507K2.2	4.77	2.48e-06	0.00057	0.26	0.21	Coronary artery calcification;	chr14:88631290	chr14:88499334~88515502:+
LUAD	cis	rs2378497	1	rs2970199	ENSG00000232679.1	RP11-400N13.3	-4.77	2.48e-06	0.00057	-0.3	-0.21	Serum thyroid-stimulating hormone levels;	chr1:222004112	chr1:222041705~222064763:-
LUAD	cis	rs7430456	0.674	rs9814974	ENSG00000225790.1	RP11-2L8.1	-4.77	2.49e-06	0.000571	-0.27	-0.21	Breast cancer;	chr3:177774073	chr3:177934823~177937662:+
LUAD	cis	rs9549328	0.8	rs9549616	ENSG00000267868.1	RP11-120K24.3	4.77	2.49e-06	0.000572	0.26	0.21	Systolic blood pressure;	chr13:112973448	chr13:112964835~112966131:-
LUAD	cis	rs507080	0.922	rs582630	ENSG00000278376.1	RP11-158I9.8	-4.77	2.49e-06	0.000572	-0.23	-0.21	Serum metabolite levels;	chr11:118692090	chr11:118791254~118793137:+
LUAD	cis	rs507080	0.883	rs527475	ENSG00000278376.1	RP11-158I9.8	-4.77	2.49e-06	0.000572	-0.23	-0.21	Serum metabolite levels;	chr11:118692530	chr11:118791254~118793137:+
LUAD	cis	rs4660214	0.666	rs7553009	ENSG00000228060.1	RP11-69E11.8	4.77	2.49e-06	0.000572	0.19	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39247441	chr1:39565160~39573203:+
LUAD	cis	rs6088590	1	rs6119524	ENSG00000276073.1	RP5-1125A11.7	-4.77	2.49e-06	0.000572	-0.21	-0.21	Coronary artery disease;	chr20:34786010	chr20:33985617~33988989:-
LUAD	cis	rs17684571	0.872	rs2967960	ENSG00000231441.1	RP11-472M19.2	4.77	2.49e-06	0.000573	0.29	0.21	Schizophrenia;	chr6:56745971	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.872	rs3002007	ENSG00000231441.1	RP11-472M19.2	4.77	2.49e-06	0.000573	0.29	0.21	Schizophrenia;	chr6:56753962	chr6:56844002~56864078:+
LUAD	cis	rs1150668	0.699	rs1736895	ENSG00000219392.1	RP1-265C24.5	-4.77	2.49e-06	0.000573	-0.26	-0.21	Pubertal anthropometrics;	chr6:28252048	chr6:28115628~28116551:+
LUAD	cis	rs7829975	0.846	rs1879957	ENSG00000253893.2	FAM85B	4.77	2.49e-06	0.000573	0.26	0.21	Mood instability;	chr8:8687298	chr8:8167819~8226614:-
LUAD	cis	rs4664293	0.667	rs3815876	ENSG00000226266.5	AC009961.3	-4.77	2.49e-06	0.000573	-0.28	-0.21	Monocyte percentage of white cells;	chr2:159783640	chr2:159670708~159712435:-
LUAD	cis	rs453301	0.653	rs11784393	ENSG00000253981.4	ALG1L13P	4.77	2.49e-06	0.000573	0.24	0.21	Joint mobility (Beighton score);	chr8:9045624	chr8:8236003~8244667:-
LUAD	cis	rs11671005	0.735	rs45617039	ENSG00000268912.1	CTD-2619J13.17	-4.77	2.5e-06	0.000573	-0.29	-0.21	Mean platelet volume;	chr19:58439729	chr19:58428632~58431148:-
LUAD	cis	rs6751744	0.855	rs35019796	ENSG00000226266.5	AC009961.3	-4.77	2.5e-06	0.000573	-0.32	-0.21	Dysphagia;	chr2:159510644	chr2:159670708~159712435:-
LUAD	cis	rs9487094	0.744	rs13192476	ENSG00000260273.1	RP11-425D10.10	4.77	2.5e-06	0.000574	0.3	0.21	Height;	chr6:109403951	chr6:109382795~109383666:+
LUAD	cis	rs4908760	0.613	rs12403640	ENSG00000232912.4	RP5-1115A15.1	4.77	2.5e-06	0.000574	0.2	0.21	Vitiligo;	chr1:8757804	chr1:8424645~8434838:+
LUAD	cis	rs4819052	0.565	rs35776291	ENSG00000223768.1	LINC00205	-4.77	2.5e-06	0.000574	-0.25	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45286227	chr21:45293285~45297354:+
LUAD	cis	rs910316	1	rs11845639	ENSG00000279594.1	RP11-950C14.10	4.77	2.5e-06	0.000574	0.25	0.21	Height;	chr14:75103590	chr14:75011269~75012851:-
LUAD	cis	rs193541	0.632	rs173481	ENSG00000263432.2	RN7SL689P	4.77	2.5e-06	0.000574	0.29	0.21	Glucose homeostasis traits;	chr5:122918857	chr5:123022487~123022783:-
LUAD	cis	rs2408955	0.522	rs6580650	ENSG00000257735.1	RP11-370I10.6	-4.77	2.5e-06	0.000575	-0.26	-0.21	Glycated hemoglobin levels;	chr12:48024773	chr12:48350945~48442411:+
LUAD	cis	rs896854	0.548	rs574183	ENSG00000253528.2	RP11-347C18.4	-4.77	2.5e-06	0.000575	-0.22	-0.21	Type 2 diabetes;	chr8:94961588	chr8:94974573~94974853:-
LUAD	cis	rs9890032	0.532	rs1808257	ENSG00000266490.1	CTD-2349P21.9	4.76	2.51e-06	0.000575	0.2	0.21	Hip circumference adjusted for BMI;	chr17:30712948	chr17:30792372~30792833:+
LUAD	cis	rs9309473	0.632	rs11885217	ENSG00000163016.8	ALMS1P	4.76	2.51e-06	0.000576	0.24	0.21	Metabolite levels;	chr2:73326080	chr2:73644919~73685576:+
LUAD	cis	rs9584850	0.834	rs4294654	ENSG00000231194.1	FARP1-AS1	4.76	2.51e-06	0.000576	0.26	0.21	Neuroticism;	chr13:98467353	chr13:98435405~98435840:-
LUAD	cis	rs12908161	0.959	rs62019472	ENSG00000275120.1	RP11-182J1.17	4.76	2.51e-06	0.000576	0.32	0.21	Schizophrenia;	chr15:84788262	chr15:84599434~84606463:-
LUAD	cis	rs5758511	0.68	rs5758657	ENSG00000226450.2	CYP2D8P	4.76	2.51e-06	0.000576	0.2	0.21	Birth weight;	chr22:42222663	chr22:42149886~42155001:-
LUAD	cis	rs5758511	0.68	rs1033459	ENSG00000226450.2	CYP2D8P	4.76	2.51e-06	0.000576	0.2	0.21	Birth weight;	chr22:42223061	chr22:42149886~42155001:-
LUAD	cis	rs6088590	1	rs6087626	ENSG00000276073.1	RP5-1125A11.7	-4.76	2.51e-06	0.000576	-0.22	-0.21	Coronary artery disease;	chr20:34759525	chr20:33985617~33988989:-
LUAD	cis	rs453301	0.653	rs2956244	ENSG00000253981.4	ALG1L13P	4.76	2.51e-06	0.000576	0.25	0.21	Joint mobility (Beighton score);	chr8:9027656	chr8:8236003~8244667:-
LUAD	cis	rs4268898	0.679	rs2543666	ENSG00000242628.4	AC009228.1	-4.76	2.51e-06	0.000576	-0.3	-0.21	Asthma;	chr2:24223173	chr2:24214381~24221516:+
LUAD	cis	rs12908161	1	rs62019464	ENSG00000259295.5	CSPG4P12	4.76	2.51e-06	0.000576	0.3	0.21	Schizophrenia;	chr15:84751238	chr15:85191438~85213905:+
LUAD	cis	rs853679	0.599	rs202906	ENSG00000219392.1	RP1-265C24.5	4.76	2.51e-06	0.000576	0.34	0.21	Depression;	chr6:28043874	chr6:28115628~28116551:+
LUAD	cis	rs950169	0.65	rs12902052	ENSG00000229212.6	RP11-561C5.4	-4.76	2.51e-06	0.000576	-0.31	-0.21	Schizophrenia;	chr15:84582607	chr15:85205440~85234795:-
LUAD	cis	rs7181230	1	rs9972424	ENSG00000275636.1	RP11-521C20.5	4.76	2.51e-06	0.000577	0.26	0.21	Dehydroepiandrosterone sulphate levels;	chr15:40073650	chr15:40078892~40079347:+
LUAD	cis	rs910316	1	rs13099	ENSG00000259138.1	RP11-950C14.7	-4.76	2.51e-06	0.000577	-0.22	-0.21	Height;	chr14:75132452	chr14:75127153~75136930:+
LUAD	cis	rs4489787	1	rs12298871	ENSG00000240399.1	RP1-228P16.1	4.76	2.52e-06	0.000577	0.33	0.21	Prostate cancer (SNP x SNP interaction);	chr12:48395194	chr12:48054813~48055591:-
LUAD	cis	rs10129255	0.957	rs8009948	ENSG00000211974.3	IGHV2-70	4.76	2.52e-06	0.000577	0.23	0.21	Kawasaki disease;	chr14:106805607	chr14:106723574~106724093:-
LUAD	cis	rs853679	0.527	rs707907	ENSG00000219392.1	RP1-265C24.5	-4.76	2.52e-06	0.000578	-0.27	-0.21	Depression;	chr6:28323463	chr6:28115628~28116551:+
LUAD	cis	rs4568518	0.561	rs4579426	ENSG00000279048.1	RP11-511H23.2	4.76	2.52e-06	0.000578	0.18	0.21	Measles;	chr7:17968636	chr7:17940503~17942922:+
LUAD	cis	rs4699052	0.537	rs1580278	ENSG00000246560.2	RP11-10L12.4	-4.76	2.52e-06	0.000578	-0.27	-0.21	Testicular germ cell tumor;	chr4:103219691	chr4:102828055~102844075:+
LUAD	cis	rs8127691	1	rs7276302	ENSG00000237604.1	AP001056.1	4.76	2.52e-06	0.000578	0.25	0.21	Inflammatory bowel disease;	chr21:44194276	chr21:44175489~44176453:+
LUAD	cis	rs6545883	0.507	rs2123111	ENSG00000271889.1	RP11-493E12.1	-4.76	2.52e-06	0.000578	-0.25	-0.21	Tuberculosis;	chr2:61223319	chr2:61151433~61162105:-
LUAD	cis	rs12022452	0.822	rs7545012	ENSG00000238287.1	RP11-656D10.3	4.76	2.52e-06	0.000578	0.33	0.21	Age-related hearing impairment (SNP x SNP interaction);	chr1:40562178	chr1:40493157~40508661:-
LUAD	cis	rs8180040	0.654	rs6791062	ENSG00000271161.1	BOLA2P2	4.76	2.52e-06	0.000578	0.2	0.21	Colorectal cancer;	chr3:47132853	chr3:47499841~47500407:+
LUAD	cis	rs1707322	1	rs785480	ENSG00000280836.1	AL355480.1	-4.76	2.52e-06	0.000578	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46026492	chr1:45581219~45581321:-
LUAD	cis	rs8180040	0.593	rs4018905	ENSG00000271161.1	BOLA2P2	4.76	2.52e-06	0.000578	0.2	0.21	Colorectal cancer;	chr3:47096680	chr3:47499841~47500407:+
LUAD	cis	rs8180040	0.545	rs9311403	ENSG00000271161.1	BOLA2P2	4.76	2.52e-06	0.000578	0.2	0.21	Colorectal cancer;	chr3:47097388	chr3:47499841~47500407:+
LUAD	cis	rs875971	0.66	rs1860468	ENSG00000237310.1	GS1-124K5.4	-4.76	2.52e-06	0.000578	-0.23	-0.21	Aortic root size;	chr7:66642265	chr7:66493706~66495474:+
LUAD	cis	rs7772486	0.692	rs1577916	ENSG00000235652.6	RP11-545I5.3	-4.76	2.52e-06	0.000579	-0.21	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145748653	chr6:145799409~145886585:+
LUAD	cis	rs1799949	0.683	rs55737636	ENSG00000236383.6	LINC00854	-4.76	2.52e-06	0.000579	-0.17	-0.21	Menopause (age at onset);	chr17:43112722	chr17:43216941~43305976:-
LUAD	cis	rs2115630	0.641	rs11073613	ENSG00000229212.6	RP11-561C5.4	4.76	2.52e-06	0.000579	0.25	0.21	P wave terminal force;	chr15:84642662	chr15:85205440~85234795:-
LUAD	cis	rs6088590	1	rs6088607	ENSG00000276073.1	RP5-1125A11.7	-4.76	2.52e-06	0.000579	-0.21	-0.21	Coronary artery disease;	chr20:34790930	chr20:33985617~33988989:-
LUAD	cis	rs2378497	1	rs2800860	ENSG00000232679.1	RP11-400N13.3	4.76	2.53e-06	0.00058	0.31	0.21	Serum thyroid-stimulating hormone levels;	chr1:222009884	chr1:222041705~222064763:-
LUAD	cis	rs2732480	0.557	rs923397	ENSG00000240399.1	RP1-228P16.1	4.76	2.53e-06	0.00058	0.21	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48326609	chr12:48054813~48055591:-
LUAD	cis	rs7017914	0.652	rs6984618	ENSG00000223220.1	Y_RNA	4.76	2.53e-06	0.00058	0.24	0.21	Bone mineral density;	chr8:70883334	chr8:70780914~70781008:-
LUAD	cis	rs6088590	0.965	rs6088620	ENSG00000276073.1	RP5-1125A11.7	-4.76	2.53e-06	0.00058	-0.22	-0.21	Coronary artery disease;	chr20:34824219	chr20:33985617~33988989:-
LUAD	cis	rs2300747	0.932	rs12141411	ENSG00000177173.5	NAP1L4P1	-4.76	2.53e-06	0.00058	-0.34	-0.21	Primary biliary cholangitis;Multiple sclerosis;	chr1:116541788	chr1:116532936~116534092:-
LUAD	cis	rs17711722	1	rs17711722	ENSG00000224316.1	RP11-479O9.2	-4.76	2.53e-06	0.000581	-0.21	-0.21	Calcium levels;	chr7:65806210	chr7:65773620~65802067:+
LUAD	cis	rs17711722	0.675	rs6947132	ENSG00000224316.1	RP11-479O9.2	-4.76	2.53e-06	0.000581	-0.21	-0.21	Calcium levels;	chr7:65808508	chr7:65773620~65802067:+
LUAD	cis	rs9813712	0.595	rs1453239	ENSG00000249846.5	RP11-77P16.4	-4.76	2.53e-06	0.000581	-0.25	-0.21	Response to amphetamines;	chr3:130288915	chr3:130112550~130120579:+
LUAD	cis	rs916888	0.61	rs199436	ENSG00000261575.2	RP11-259G18.1	-4.76	2.53e-06	0.000581	-0.28	-0.21	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46267037~46268694:+
LUAD	cis	rs6840360	0.571	rs62327277	ENSG00000270265.1	RP11-731D1.4	-4.76	2.53e-06	0.000581	-0.24	-0.21	Intelligence (multi-trait analysis);	chr4:151634753	chr4:151333775~151353224:-
LUAD	cis	rs7119	0.689	rs12901765	ENSG00000259362.2	RP11-307C19.1	-4.76	2.54e-06	0.000582	-0.26	-0.21	Type 2 diabetes;	chr15:77526761	chr15:77525540~77534110:+
LUAD	cis	rs507080	0.922	rs585039	ENSG00000278376.1	RP11-158I9.8	-4.76	2.54e-06	0.000582	-0.23	-0.21	Serum metabolite levels;	chr11:118692672	chr11:118791254~118793137:+
LUAD	cis	rs8031584	0.958	rs1043742	ENSG00000270015.1	RP11-540B6.6	-4.76	2.54e-06	0.000582	-0.15	-0.21	Huntington's disease progression;	chr15:30940378	chr15:30926514~30928407:+
LUAD	cis	rs2378497	1	rs61823902	ENSG00000232679.1	RP11-400N13.3	4.76	2.54e-06	0.000583	0.34	0.21	Serum thyroid-stimulating hormone levels;	chr1:221990788	chr1:222041705~222064763:-
LUAD	cis	rs2378497	1	rs61823903	ENSG00000232679.1	RP11-400N13.3	4.76	2.54e-06	0.000583	0.34	0.21	Serum thyroid-stimulating hormone levels;	chr1:221991095	chr1:222041705~222064763:-
LUAD	cis	rs67311347	0.713	rs9861194	ENSG00000223797.4	ENTPD3-AS1	4.76	2.54e-06	0.000583	0.23	0.21	Renal cell carcinoma;	chr3:40267734	chr3:40313802~40453329:-
LUAD	cis	rs17772222	0.696	rs28666030	ENSG00000258789.1	RP11-507K2.3	-4.76	2.54e-06	0.000583	-0.27	-0.21	Coronary artery calcification;	chr14:88511463	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.74	rs28493481	ENSG00000258789.1	RP11-507K2.3	-4.76	2.54e-06	0.000583	-0.27	-0.21	Coronary artery calcification;	chr14:88511491	chr14:88551597~88552493:+
LUAD	cis	rs897984	0.683	rs12447534	ENSG00000260911.2	RP11-196G11.2	-4.76	2.55e-06	0.000584	-0.19	-0.21	Dementia with Lewy bodies;	chr16:30792936	chr16:31043150~31049868:+
LUAD	cis	rs17684571	0.872	rs11968575	ENSG00000231441.1	RP11-472M19.2	4.76	2.55e-06	0.000584	0.29	0.21	Schizophrenia;	chr6:56728107	chr6:56844002~56864078:+
LUAD	cis	rs516805	0.667	rs9632500	ENSG00000279453.1	RP3-425C14.4	4.76	2.55e-06	0.000584	0.28	0.21	Lymphocyte counts;	chr6:122251472	chr6:122436789~122439223:-
LUAD	cis	rs7122539	0.646	rs594313	ENSG00000213409.4	RP11-658F2.3	-4.76	2.55e-06	0.000584	-0.25	-0.21	HIV-1 susceptibility;	chr11:66841520	chr11:66761575~66762399:-
LUAD	cis	rs10863681	0.738	rs12561821	ENSG00000228437.4	RP11-400N13.2	4.76	2.55e-06	0.000584	0.26	0.21	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222087887	chr1:221966341~221984964:+
LUAD	cis	rs6840360	1	rs6817586	ENSG00000270265.1	RP11-731D1.4	-4.76	2.55e-06	0.000584	-0.22	-0.21	Intelligence (multi-trait analysis);	chr4:151722032	chr4:151333775~151353224:-
LUAD	cis	rs7208859	0.562	rs11650923	ENSG00000266490.1	CTD-2349P21.9	4.76	2.55e-06	0.000584	0.32	0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30681149	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs56378576	ENSG00000266490.1	CTD-2349P21.9	4.76	2.55e-06	0.000584	0.32	0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30683102	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs35916850	ENSG00000266490.1	CTD-2349P21.9	4.76	2.55e-06	0.000584	0.32	0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30684155	chr17:30792372~30792833:+
LUAD	cis	rs12122100	0.507	rs1925343	ENSG00000244371.2	PFN1P8	4.76	2.55e-06	0.000584	0.24	0.21	HIV-1 control;	chr1:147033981	chr1:146957117~146957659:-
LUAD	cis	rs3743772	0.5	rs9924562	ENSG00000279722.1	RP11-44F14.6	4.76	2.55e-06	0.000584	0.3	0.21	Depressive symptoms (SSRI exposure interaction);	chr16:53415152	chr16:53487607~53489943:-
LUAD	cis	rs6496932	0.635	rs2200214	ENSG00000259630.2	CTD-2262B20.1	-4.76	2.55e-06	0.000584	-0.27	-0.21	Central corneal thickness;Corneal structure;	chr15:85383745	chr15:85415228~85415633:+
LUAD	cis	rs1799949	1	rs2037075	ENSG00000236383.6	LINC00854	-4.76	2.55e-06	0.000585	-0.17	-0.21	Menopause (age at onset);	chr17:43153809	chr17:43216941~43305976:-
LUAD	cis	rs1420585	1	rs12597905	ENSG00000260052.1	CTC-527H23.3	4.76	2.55e-06	0.000585	0.32	0.21	Pursuit maintenance gain;	chr16:48968092	chr16:48637143~48638719:+
LUAD	cis	rs950169	0.545	rs4354897	ENSG00000259728.4	LINC00933	4.76	2.55e-06	0.000585	0.33	0.21	Schizophrenia;	chr15:83976219	chr15:84570649~84580175:+
LUAD	cis	rs2976388	1	rs2920298	ENSG00000253741.1	CTD-2292P10.4	4.76	2.56e-06	0.000586	0.24	0.21	Urinary tract infection frequency;	chr8:142681625	chr8:142702252~142726973:-
LUAD	cis	rs2976388	1	rs2920297	ENSG00000253741.1	CTD-2292P10.4	4.76	2.56e-06	0.000586	0.24	0.21	Urinary tract infection frequency;	chr8:142681665	chr8:142702252~142726973:-
LUAD	cis	rs2976388	1	rs2920296	ENSG00000253741.1	CTD-2292P10.4	4.76	2.56e-06	0.000586	0.24	0.21	Urinary tract infection frequency;	chr8:142681691	chr8:142702252~142726973:-
LUAD	cis	rs2976388	1	rs1045531	ENSG00000253741.1	CTD-2292P10.4	4.76	2.56e-06	0.000586	0.24	0.21	Urinary tract infection frequency;	chr8:142682129	chr8:142702252~142726973:-
LUAD	cis	rs2976388	1	rs2976394	ENSG00000253741.1	CTD-2292P10.4	4.76	2.56e-06	0.000586	0.24	0.21	Urinary tract infection frequency;	chr8:142682204	chr8:142702252~142726973:-
LUAD	cis	rs853679	0.882	rs9468287	ENSG00000204709.4	LINC01556	4.76	2.56e-06	0.000586	0.36	0.21	Depression;	chr6:28111963	chr6:28943877~28944537:+
LUAD	cis	rs2749097	0.825	rs11208264	ENSG00000244256.3	RN7SL130P	-4.76	2.56e-06	0.000586	-0.26	-0.21	Alcohol consumption (transferrin glycosylation);	chr1:63659401	chr1:63655743~63656047:+
LUAD	cis	rs5758511	0.508	rs2413667	ENSG00000205702.9	CYP2D7	4.76	2.56e-06	0.000586	0.22	0.21	Birth weight;	chr22:42076233	chr22:42140203~42144577:-
LUAD	cis	rs172166	0.637	rs1071893	ENSG00000216901.1	AL022393.7	4.76	2.56e-06	0.000586	0.25	0.21	Cardiac Troponin-T levels;	chr6:28199857	chr6:28176188~28176674:+
LUAD	cis	rs7017914	0.652	rs13250391	ENSG00000223220.1	Y_RNA	4.76	2.56e-06	0.000586	0.24	0.21	Bone mineral density;	chr8:70885537	chr8:70780914~70781008:-
LUAD	cis	rs4660214	0.666	rs6698791	ENSG00000228060.1	RP11-69E11.8	4.76	2.56e-06	0.000587	0.19	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39469104	chr1:39565160~39573203:+
LUAD	cis	rs2919009	0.545	rs11199680	ENSG00000271670.1	RP11-95I16.4	-4.76	2.56e-06	0.000587	-0.25	-0.21	Obesity-related traits;	chr10:120957788	chr10:120879256~120880667:-
LUAD	cis	rs7636293	1	rs9816623	ENSG00000270773.1	RP13-685P2.7	4.76	2.56e-06	0.000587	0.26	0.21	Height;	chr3:129323873	chr3:129345411~129346164:+
LUAD	cis	rs9926296	0.682	rs467357	ENSG00000260259.1	RP11-368I7.4	4.76	2.56e-06	0.000587	0.21	0.21	Vitiligo;	chr16:89650989	chr16:89682620~89686569:-
LUAD	cis	rs2742234	0.541	rs10899782	ENSG00000273008.1	RP11-351D16.3	4.76	2.56e-06	0.000587	0.25	0.21	Hirschsprung disease;	chr10:43240913	chr10:43136824~43138334:-
LUAD	cis	rs8072100	0.764	rs2644349	ENSG00000228782.6	CTD-2026D20.3	-4.76	2.56e-06	0.000587	-0.22	-0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47564377	chr17:47450568~47492492:-
LUAD	cis	rs17772222	0.917	rs17260380	ENSG00000258983.2	RP11-507K2.2	4.76	2.56e-06	0.000587	0.26	0.21	Coronary artery calcification;	chr14:88682142	chr14:88499334~88515502:+
LUAD	cis	rs17772222	0.917	rs58984912	ENSG00000258983.2	RP11-507K2.2	4.76	2.56e-06	0.000587	0.26	0.21	Coronary artery calcification;	chr14:88698172	chr14:88499334~88515502:+
LUAD	cis	rs4908760	0.792	rs11121215	ENSG00000270282.1	RP5-1115A15.2	4.76	2.56e-06	0.000587	0.23	0.21	Vitiligo;	chr1:8673069	chr1:8512653~8513021:+
LUAD	cis	rs4295623	0.789	rs12541318	ENSG00000255046.1	RP11-297N6.4	4.76	2.57e-06	0.000588	0.26	0.21	Morning vs. evening chronotype;	chr8:11737461	chr8:11797928~11802568:-
LUAD	cis	rs7617773	0.925	rs6442105	ENSG00000228638.1	FCF1P2	4.76	2.57e-06	0.000588	0.25	0.21	Coronary artery disease;	chr3:48140836	chr3:48290793~48291375:-
LUAD	cis	rs957448	1	rs957448	ENSG00000254315.1	RP11-267M23.3	4.76	2.57e-06	0.000588	0.26	0.21	Nonsyndromic cleft lip with cleft palate;	chr8:94529074	chr8:94533628~94534391:+
LUAD	cis	rs957448	1	rs72674855	ENSG00000254315.1	RP11-267M23.3	4.76	2.57e-06	0.000588	0.26	0.21	Nonsyndromic cleft lip with cleft palate;	chr8:94536706	chr8:94533628~94534391:+
LUAD	cis	rs2732480	0.5	rs7966829	ENSG00000257735.1	RP11-370I10.6	4.76	2.57e-06	0.000588	0.26	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48221820	chr12:48350945~48442411:+
LUAD	cis	rs17772222	1	rs17772288	ENSG00000258983.2	RP11-507K2.2	4.76	2.57e-06	0.000588	0.25	0.21	Coronary artery calcification;	chr14:88361022	chr14:88499334~88515502:+
LUAD	cis	rs2033711	0.654	rs734380	ENSG00000268912.1	CTD-2619J13.17	-4.76	2.57e-06	0.000588	-0.23	-0.21	Uric acid clearance;	chr19:58387596	chr19:58428632~58431148:-
LUAD	cis	rs17685	0.712	rs6976236	ENSG00000280388.1	RP11-229D13.3	-4.76	2.57e-06	0.000588	-0.2	-0.21	Coffee consumption (cups per day);Coffee consumption;	chr7:76111769	chr7:76043977~76045963:-
LUAD	cis	rs948562	0.519	rs4387363	ENSG00000280010.1	AP001350.4	4.76	2.57e-06	0.000588	0.3	0.21	Lymphoma;	chr11:58293128	chr11:58627435~58628528:+
LUAD	cis	rs12681420	0.754	rs34471605	ENSG00000223220.1	Y_RNA	4.76	2.57e-06	0.000588	0.25	0.21	Erythrocyte cadmium concentration in never smokers;	chr8:70849983	chr8:70780914~70781008:-
LUAD	cis	rs2239547	0.563	rs9876403	ENSG00000242142.1	SERBP1P3	4.76	2.57e-06	0.000588	0.25	0.21	Schizophrenia;	chr3:52882900	chr3:53064283~53065091:-
LUAD	cis	rs7119	0.717	rs12904254	ENSG00000259362.2	RP11-307C19.1	-4.76	2.57e-06	0.000589	-0.26	-0.21	Type 2 diabetes;	chr15:77510243	chr15:77525540~77534110:+
LUAD	cis	rs853679	1	rs6901575	ENSG00000219392.1	RP1-265C24.5	-4.76	2.57e-06	0.000589	-0.32	-0.21	Depression;	chr6:28283207	chr6:28115628~28116551:+
LUAD	cis	rs801193	0.569	rs13242290	ENSG00000232559.3	GS1-124K5.12	-4.76	2.57e-06	0.000589	-0.25	-0.21	Aortic root size;	chr7:66656898	chr7:66554588~66576923:-
LUAD	cis	rs4908760	0.73	rs10779704	ENSG00000232912.4	RP5-1115A15.1	4.76	2.57e-06	0.000589	0.19	0.21	Vitiligo;	chr1:8633478	chr1:8424645~8434838:+
LUAD	cis	rs453301	0.592	rs4841084	ENSG00000253981.4	ALG1L13P	4.76	2.57e-06	0.000589	0.25	0.21	Joint mobility (Beighton score);	chr8:9026395	chr8:8236003~8244667:-
LUAD	cis	rs6088590	1	rs1998028	ENSG00000276073.1	RP5-1125A11.7	-4.76	2.57e-06	0.000589	-0.22	-0.21	Coronary artery disease;	chr20:34756792	chr20:33985617~33988989:-
LUAD	cis	rs7772486	0.641	rs9390374	ENSG00000235652.6	RP11-545I5.3	4.76	2.58e-06	0.00059	0.22	0.21	Lobe attachment (rater-scored or self-reported);	chr6:146047039	chr6:145799409~145886585:+
LUAD	cis	rs9910055	0.531	rs6503490	ENSG00000267080.4	ASB16-AS1	-4.76	2.58e-06	0.00059	-0.19	-0.21	Total body bone mineral density;	chr17:44169288	chr17:44175973~44186717:-
LUAD	cis	rs7119	0.717	rs7180732	ENSG00000259362.2	RP11-307C19.1	-4.76	2.58e-06	0.00059	-0.27	-0.21	Type 2 diabetes;	chr15:77537579	chr15:77525540~77534110:+
LUAD	cis	rs7017914	0.677	rs6472566	ENSG00000223220.1	Y_RNA	4.76	2.58e-06	0.00059	0.25	0.21	Bone mineral density;	chr8:71088249	chr8:70780914~70781008:-
LUAD	cis	rs910316	0.783	rs11850751	ENSG00000279594.1	RP11-950C14.10	4.76	2.58e-06	0.00059	0.24	0.21	Height;	chr14:75123410	chr14:75011269~75012851:-
LUAD	cis	rs14027	0.843	rs6469849	ENSG00000279347.1	RP11-85I17.2	-4.76	2.58e-06	0.00059	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119844929	chr8:119838736~119840385:-
LUAD	cis	rs1864585	0.52	rs17776427	ENSG00000255046.1	RP11-297N6.4	4.76	2.58e-06	0.00059	0.3	0.21	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10815462	chr8:11797928~11802568:-
LUAD	cis	rs12908161	1	rs12910012	ENSG00000259295.5	CSPG4P12	4.76	2.58e-06	0.00059	0.3	0.21	Schizophrenia;	chr15:84755431	chr15:85191438~85213905:+
LUAD	cis	rs12908161	1	rs12899981	ENSG00000259295.5	CSPG4P12	4.76	2.58e-06	0.00059	0.3	0.21	Schizophrenia;	chr15:84759142	chr15:85191438~85213905:+
LUAD	cis	rs7430456	0.674	rs13079337	ENSG00000225790.1	RP11-2L8.1	-4.76	2.58e-06	0.00059	-0.27	-0.21	Breast cancer;	chr3:177776996	chr3:177934823~177937662:+
LUAD	cis	rs7617773	0.925	rs35942721	ENSG00000228638.1	FCF1P2	-4.76	2.58e-06	0.000591	-0.26	-0.21	Coronary artery disease;	chr3:48131579	chr3:48290793~48291375:-
LUAD	cis	rs57502260	0.915	rs75202638	ENSG00000212093.1	AP000807.1	4.76	2.58e-06	0.000591	0.28	0.21	Total body bone mineral density (age 45-60);	chr11:68442953	chr11:68506083~68506166:-
LUAD	cis	rs4865169	0.934	rs12650737	ENSG00000269949.1	RP11-738E22.3	-4.76	2.58e-06	0.000591	-0.27	-0.21	Breast cancer;	chr4:57026309	chr4:56960927~56961373:-
LUAD	cis	rs62355901	0.505	rs62356565	ENSG00000271828.1	CTD-2310F14.1	4.76	2.58e-06	0.000591	0.4	0.21	Breast cancer;	chr5:56948139	chr5:56927874~56929573:+
LUAD	cis	rs875971	1	rs4718307	ENSG00000232559.3	GS1-124K5.12	-4.76	2.58e-06	0.000591	-0.25	-0.21	Aortic root size;	chr7:66146001	chr7:66554588~66576923:-
LUAD	cis	rs7772486	0.754	rs702324	ENSG00000235652.6	RP11-545I5.3	-4.76	2.58e-06	0.000591	-0.21	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145687657	chr6:145799409~145886585:+
LUAD	cis	rs2243480	1	rs6460260	ENSG00000164669.11	INTS4P1	-4.76	2.58e-06	0.000591	-0.38	-0.21	Diabetic kidney disease;	chr7:65750468	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs6460261	ENSG00000164669.11	INTS4P1	-4.76	2.58e-06	0.000591	-0.38	-0.21	Diabetic kidney disease;	chr7:65750593	chr7:65141225~65234216:+
LUAD	cis	rs2933343	0.621	rs6764682	ENSG00000261159.1	RP11-723O4.9	-4.76	2.58e-06	0.000591	-0.23	-0.21	IgG glycosylation;	chr3:128849540	chr3:128859716~128860526:-
LUAD	cis	rs2933343	1	rs1683782	ENSG00000231305.3	RP11-723O4.2	4.76	2.59e-06	0.000592	0.26	0.21	IgG glycosylation;	chr3:128921434	chr3:128861313~128871540:-
LUAD	cis	rs2933343	1	rs6785869	ENSG00000231305.3	RP11-723O4.2	4.76	2.59e-06	0.000592	0.26	0.21	IgG glycosylation;	chr3:128924301	chr3:128861313~128871540:-
LUAD	cis	rs2933343	1	rs1683778	ENSG00000231305.3	RP11-723O4.2	4.76	2.59e-06	0.000592	0.26	0.21	IgG glycosylation;	chr3:128925752	chr3:128861313~128871540:-
LUAD	cis	rs2439831	0.85	rs12440573	ENSG00000249839.1	AC011330.5	-4.76	2.59e-06	0.000592	-0.44	-0.21	Lung cancer in ever smokers;	chr15:43816799	chr15:43663654~43684339:-
LUAD	cis	rs2742234	0.541	rs11528481	ENSG00000273008.1	RP11-351D16.3	4.76	2.59e-06	0.000592	0.25	0.21	Hirschsprung disease;	chr10:43242319	chr10:43136824~43138334:-
LUAD	cis	rs853679	1	rs1679709	ENSG00000204709.4	LINC01556	-4.76	2.59e-06	0.000592	-0.32	-0.21	Depression;	chr6:28260564	chr6:28943877~28944537:+
LUAD	cis	rs7172677	0.768	rs72730587	ENSG00000260269.4	CTD-2323K18.1	4.76	2.59e-06	0.000592	0.28	0.21	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75065712	chr15:75527150~75601205:-
LUAD	cis	rs1150668	0.796	rs213237	ENSG00000219392.1	RP1-265C24.5	-4.76	2.59e-06	0.000592	-0.27	-0.21	Pubertal anthropometrics;	chr6:28356161	chr6:28115628~28116551:+
LUAD	cis	rs9322193	0.923	rs2297928	ENSG00000268592.3	RAET1E-AS1	4.76	2.59e-06	0.000592	0.26	0.21	Lung cancer;	chr6:149718584	chr6:149863494~149919507:+
LUAD	cis	rs55823223	0.648	rs936394	ENSG00000267801.1	RP11-552F3.9	4.76	2.59e-06	0.000593	0.24	0.21	Psoriasis;	chr17:75855927	chr17:75876372~75879546:+
LUAD	cis	rs4819052	0.655	rs2330103	ENSG00000223768.1	LINC00205	-4.76	2.59e-06	0.000593	-0.25	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45274599	chr21:45293285~45297354:+
LUAD	cis	rs9652601	0.649	rs7403919	ENSG00000274038.1	RP11-66H6.4	4.76	2.59e-06	0.000593	0.26	0.21	Systemic lupus erythematosus;	chr16:10992111	chr16:11056556~11057034:+
LUAD	cis	rs2439831	0.85	rs28413704	ENSG00000249839.1	AC011330.5	-4.76	2.59e-06	0.000593	-0.45	-0.21	Lung cancer in ever smokers;	chr15:43856229	chr15:43663654~43684339:-
LUAD	cis	rs7189233	0.531	rs7202621	ENSG00000279344.1	RP11-44F14.7	4.76	2.59e-06	0.000593	0.17	0.21	Intelligence (multi-trait analysis);	chr16:53452125	chr16:53478957~53481550:-
LUAD	cis	rs240993	0.812	rs2025269	ENSG00000230177.1	RP5-1112D6.4	-4.76	2.59e-06	0.000593	-0.22	-0.21	Inflammatory skin disease;Psoriasis;	chr6:111489237	chr6:111277932~111278742:+
LUAD	cis	rs7772486	0.72	rs7752286	ENSG00000235652.6	RP11-545I5.3	-4.76	2.59e-06	0.000593	-0.21	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145751526	chr6:145799409~145886585:+
LUAD	cis	rs10129255	0.872	rs1858683	ENSG00000211974.3	IGHV2-70	4.76	2.59e-06	0.000593	0.23	0.21	Kawasaki disease;	chr14:106670217	chr14:106723574~106724093:-
LUAD	cis	rs41369048	0.669	rs6660867	ENSG00000238078.1	LINC01352	-4.76	2.59e-06	0.000593	-0.31	-0.21	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220864097	chr1:220829255~220832429:+
LUAD	cis	rs9487094	0.813	rs34320275	ENSG00000260273.1	RP11-425D10.10	4.76	2.59e-06	0.000593	0.3	0.21	Height;	chr6:109436760	chr6:109382795~109383666:+
LUAD	cis	rs2880765	0.743	rs11630410	ENSG00000259295.5	CSPG4P12	4.76	2.6e-06	0.000594	0.24	0.21	Coronary artery disease;	chr15:85461510	chr15:85191438~85213905:+
LUAD	cis	rs2880765	0.71	rs11630457	ENSG00000259295.5	CSPG4P12	4.76	2.6e-06	0.000594	0.24	0.21	Coronary artery disease;	chr15:85461570	chr15:85191438~85213905:+
LUAD	cis	rs9473147	0.516	rs9395279	ENSG00000270761.1	RP11-385F7.1	-4.76	2.6e-06	0.000594	-0.24	-0.21	Platelet distribution width;Mean platelet volume;	chr6:47575128	chr6:47477243~47477572:-
LUAD	cis	rs2028299	0.919	rs7174878	ENSG00000259677.1	RP11-493E3.1	4.76	2.6e-06	0.000594	0.26	0.21	Type 2 diabetes;	chr15:89891656	chr15:89876540~89877285:+
LUAD	cis	rs17301013	0.861	rs332799	ENSG00000227373.4	RP11-160H22.5	4.76	2.6e-06	0.000595	0.26	0.21	Systemic lupus erythematosus;	chr1:174731110	chr1:174115300~174160004:-
LUAD	cis	rs8180040	0.764	rs4082155	ENSG00000271161.1	BOLA2P2	4.76	2.6e-06	0.000595	0.2	0.21	Colorectal cancer;	chr3:47083895	chr3:47499841~47500407:+
LUAD	cis	rs6088590	1	rs6120708	ENSG00000276073.1	RP5-1125A11.7	-4.76	2.6e-06	0.000595	-0.21	-0.21	Coronary artery disease;	chr20:34747722	chr20:33985617~33988989:-
LUAD	cis	rs516805	0.748	rs155460	ENSG00000279453.1	RP3-425C14.4	-4.76	2.61e-06	0.000596	-0.29	-0.21	Lymphocyte counts;	chr6:122499180	chr6:122436789~122439223:-
LUAD	cis	rs2303759	0.626	rs12982246	ENSG00000268686.1	AC010524.2	-4.76	2.61e-06	0.000596	-0.32	-0.21	Multiple sclerosis;	chr19:49297912	chr19:49368705~49388081:-
LUAD	cis	rs17772222	0.917	rs2004329	ENSG00000258983.2	RP11-507K2.2	4.76	2.61e-06	0.000597	0.26	0.21	Coronary artery calcification;	chr14:88532965	chr14:88499334~88515502:+
LUAD	cis	rs1799949	0.965	rs799917	ENSG00000236383.6	LINC00854	-4.76	2.61e-06	0.000597	-0.17	-0.21	Menopause (age at onset);	chr17:43092919	chr17:43216941~43305976:-
LUAD	cis	rs6840360	1	rs9995704	ENSG00000270265.1	RP11-731D1.4	-4.76	2.61e-06	0.000597	-0.22	-0.21	Intelligence (multi-trait analysis);	chr4:151697917	chr4:151333775~151353224:-
LUAD	cis	rs6750795	0.507	rs1667320	ENSG00000181798.2	LINC00471	-4.76	2.61e-06	0.000597	-0.24	-0.21	Height;	chr2:231553603	chr2:231508426~231514339:-
LUAD	cis	rs847577	0.677	rs4729403	ENSG00000272950.1	RP11-307C18.1	-4.76	2.61e-06	0.000597	-0.27	-0.21	Breast cancer;	chr7:98078529	chr7:98322853~98323430:+
LUAD	cis	rs2243480	1	rs35542501	ENSG00000226002.1	RP11-460N20.5	-4.76	2.61e-06	0.000597	-0.35	-0.21	Diabetic kidney disease;	chr7:65966228	chr7:65084103~65100232:+
LUAD	cis	rs2243480	0.708	rs781141	ENSG00000226002.1	RP11-460N20.5	-4.76	2.61e-06	0.000597	-0.35	-0.21	Diabetic kidney disease;	chr7:65973566	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs781142	ENSG00000226002.1	RP11-460N20.5	-4.76	2.61e-06	0.000597	-0.35	-0.21	Diabetic kidney disease;	chr7:65973791	chr7:65084103~65100232:+
LUAD	cis	rs8072100	0.875	rs9635762	ENSG00000228782.6	CTD-2026D20.3	-4.76	2.61e-06	0.000598	-0.22	-0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47571080	chr17:47450568~47492492:-
LUAD	cis	rs8091660	0.624	rs6507852	ENSG00000278983.1	RP11-426J5.3	-4.76	2.62e-06	0.000598	-0.26	-0.21	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48548678	chr18:48564795~48568342:+
LUAD	cis	rs9813712	0.571	rs9846596	ENSG00000249846.5	RP11-77P16.4	-4.76	2.62e-06	0.000598	-0.25	-0.21	Response to amphetamines;	chr3:130288318	chr3:130112550~130120579:+
LUAD	cis	rs950169	0.922	rs62021167	ENSG00000229212.6	RP11-561C5.4	-4.76	2.62e-06	0.000598	-0.31	-0.21	Schizophrenia;	chr15:84574820	chr15:85205440~85234795:-
LUAD	cis	rs7772486	0.686	rs9376961	ENSG00000235652.6	RP11-545I5.3	4.76	2.62e-06	0.000598	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145727601	chr6:145799409~145886585:+
LUAD	cis	rs950169	0.579	rs12912716	ENSG00000259728.4	LINC00933	4.76	2.62e-06	0.000598	0.33	0.21	Schizophrenia;	chr15:83995511	chr15:84570649~84580175:+
LUAD	cis	rs73173548	0.502	rs6867204	ENSG00000247828.6	TMEM161B-AS1	4.76	2.62e-06	0.000598	0.26	0.21	Macular telangiectasia type 2;	chr5:88446423	chr5:88268895~88436685:+
LUAD	cis	rs2732480	0.577	rs2732466	ENSG00000257735.1	RP11-370I10.6	4.76	2.62e-06	0.000599	0.26	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48338676	chr12:48350945~48442411:+
LUAD	cis	rs12908161	0.92	rs12904605	ENSG00000259295.5	CSPG4P12	4.76	2.62e-06	0.000599	0.3	0.21	Schizophrenia;	chr15:84658188	chr15:85191438~85213905:+
LUAD	cis	rs12745968	0.653	rs7418336	ENSG00000223787.2	RP4-593M8.1	-4.76	2.62e-06	0.000599	-0.25	-0.21	Bipolar disorder and schizophrenia;	chr1:92697828	chr1:92580476~92580821:-
LUAD	cis	rs8180040	0.654	rs6773521	ENSG00000271161.1	BOLA2P2	-4.76	2.62e-06	0.000599	-0.2	-0.21	Colorectal cancer;	chr3:47192929	chr3:47499841~47500407:+
LUAD	cis	rs8180040	0.647	rs57756484	ENSG00000271161.1	BOLA2P2	-4.76	2.62e-06	0.000599	-0.2	-0.21	Colorectal cancer;	chr3:47197843	chr3:47499841~47500407:+
LUAD	cis	rs8180040	0.654	rs1466740	ENSG00000271161.1	BOLA2P2	-4.76	2.62e-06	0.000599	-0.2	-0.21	Colorectal cancer;	chr3:47204393	chr3:47499841~47500407:+
LUAD	cis	rs516805	0.706	rs1339533	ENSG00000279453.1	RP3-425C14.4	-4.76	2.62e-06	0.000599	-0.26	-0.21	Lymphocyte counts;	chr6:122348687	chr6:122436789~122439223:-
LUAD	cis	rs9926296	0.682	rs645019	ENSG00000260259.1	RP11-368I7.4	4.76	2.62e-06	0.000599	0.21	0.21	Vitiligo;	chr16:89650475	chr16:89682620~89686569:-
LUAD	cis	rs61542988	0.606	rs4722185	ENSG00000228649.7	AC005682.5	4.76	2.63e-06	6e-04	0.32	0.21	Fibrinogen levels;	chr7:22793092	chr7:22854178~22861579:+
LUAD	cis	rs2243480	1	rs34702770	ENSG00000229886.1	RP5-1132H15.3	4.75	2.63e-06	6e-04	0.37	0.21	Diabetic kidney disease;	chr7:65879836	chr7:66025126~66031544:-
LUAD	cis	rs2665103	0.715	rs16973457	ENSG00000278603.1	RP13-608F4.5	4.75	2.63e-06	6e-04	0.25	0.21	Intelligence (multi-trait analysis);	chr15:82271650	chr15:82472203~82472426:+
LUAD	cis	rs7826238	0.564	rs2921053	ENSG00000253981.4	ALG1L13P	4.75	2.63e-06	0.000601	0.24	0.21	Systolic blood pressure;	chr8:8462453	chr8:8236003~8244667:-
LUAD	cis	rs9303029	1	rs12450191	ENSG00000265458.1	RP13-20L14.6	4.75	2.63e-06	0.000601	0.39	0.21	Protein quantitative trait loci;	chr17:82450072	chr17:82454273~82458521:-
LUAD	cis	rs2239547	0.522	rs4519686	ENSG00000242142.1	SERBP1P3	4.75	2.63e-06	0.000601	0.24	0.21	Schizophrenia;	chr3:52963855	chr3:53064283~53065091:-
LUAD	cis	rs7772486	0.641	rs960385	ENSG00000235652.6	RP11-545I5.3	4.75	2.63e-06	0.000601	0.22	0.21	Lobe attachment (rater-scored or self-reported);	chr6:146049938	chr6:145799409~145886585:+
LUAD	cis	rs6840360	1	rs6535809	ENSG00000270265.1	RP11-731D1.4	-4.75	2.63e-06	0.000601	-0.22	-0.21	Intelligence (multi-trait analysis);	chr4:151671781	chr4:151333775~151353224:-
LUAD	cis	rs8177876	0.597	rs1048194	ENSG00000261061.1	RP11-303E16.2	4.75	2.63e-06	0.000601	0.38	0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81031097	chr16:81030770~81031485:+
LUAD	cis	rs453301	0.631	rs13250781	ENSG00000253981.4	ALG1L13P	-4.75	2.63e-06	0.000601	-0.25	-0.21	Joint mobility (Beighton score);	chr8:8935833	chr8:8236003~8244667:-
LUAD	cis	rs8059260	0.541	rs34361212	ENSG00000274038.1	RP11-66H6.4	-4.75	2.63e-06	0.000601	-0.47	-0.21	Alcohol consumption over the past year;	chr16:11145832	chr16:11056556~11057034:+
LUAD	cis	rs6539288	0.933	rs1444581	ENSG00000260329.1	RP11-412D9.4	-4.75	2.63e-06	0.000601	-0.23	-0.21	Total body bone mineral density;	chr12:106920473	chr12:106954029~106955497:-
LUAD	cis	rs4706831	0.647	rs627240	ENSG00000260645.1	RP11-250B2.5	-4.75	2.63e-06	0.000602	-0.2	-0.21	Joint mobility (Beighton score);	chr6:80276168	chr6:80466958~80469080:+
LUAD	cis	rs2976388	0.647	rs2164307	ENSG00000253741.1	CTD-2292P10.4	-4.75	2.63e-06	0.000602	-0.24	-0.21	Urinary tract infection frequency;	chr8:142707413	chr8:142702252~142726973:-
LUAD	cis	rs2976388	0.573	rs1529865	ENSG00000253741.1	CTD-2292P10.4	-4.75	2.63e-06	0.000602	-0.24	-0.21	Urinary tract infection frequency;	chr8:142707753	chr8:142702252~142726973:-
LUAD	cis	rs2976388	0.609	rs1560986	ENSG00000253741.1	CTD-2292P10.4	-4.75	2.63e-06	0.000602	-0.24	-0.21	Urinary tract infection frequency;	chr8:142708357	chr8:142702252~142726973:-
LUAD	cis	rs4908760	0.613	rs2401189	ENSG00000270282.1	RP5-1115A15.2	4.75	2.63e-06	0.000602	0.23	0.21	Vitiligo;	chr1:8758541	chr1:8512653~8513021:+
LUAD	cis	rs228614	0.51	rs223313	ENSG00000251288.2	RP11-10L12.2	-4.75	2.63e-06	0.000602	-0.25	-0.21	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102886563	chr4:102751401~102752641:+
LUAD	cis	rs853679	1	rs2799077	ENSG00000204709.4	LINC01556	4.75	2.64e-06	0.000602	0.32	0.21	Depression;	chr6:28266819	chr6:28943877~28944537:+
LUAD	cis	rs17826219	0.568	rs2626985	ENSG00000263603.1	CTD-2349P21.5	-4.75	2.64e-06	0.000602	-0.36	-0.21	Body mass index;	chr17:30750419	chr17:30729469~30731202:+
LUAD	cis	rs11971779	0.68	rs4728465	ENSG00000273391.1	RP11-634H22.1	4.75	2.64e-06	0.000602	0.22	0.21	Diisocyanate-induced asthma;	chr7:139384315	chr7:139359032~139359566:-
LUAD	cis	rs9860428	0.844	rs2399441	ENSG00000242770.2	RP11-180K7.1	4.75	2.64e-06	0.000603	0.22	0.21	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112868165	chr3:112802478~112812819:+
LUAD	cis	rs1008375	1	rs4698200	ENSG00000249502.1	AC006160.5	-4.75	2.64e-06	0.000603	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17655428	chr4:17587467~17614571:-
LUAD	cis	rs453301	0.605	rs7843024	ENSG00000173295.6	FAM86B3P	-4.75	2.64e-06	0.000603	-0.23	-0.21	Joint mobility (Beighton score);	chr8:8942466	chr8:8228595~8244865:+
LUAD	cis	rs6840360	1	rs3792691	ENSG00000270265.1	RP11-731D1.4	4.75	2.64e-06	0.000603	0.22	0.21	Intelligence (multi-trait analysis);	chr4:151714651	chr4:151333775~151353224:-
LUAD	cis	rs14027	0.921	rs7833112	ENSG00000279347.1	RP11-85I17.2	-4.75	2.64e-06	0.000603	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119835842	chr8:119838736~119840385:-
LUAD	cis	rs950169	0.84	rs12905223	ENSG00000229212.6	RP11-561C5.4	-4.75	2.64e-06	0.000603	-0.3	-0.21	Schizophrenia;	chr15:84571037	chr15:85205440~85234795:-
LUAD	cis	rs2836974	0.604	rs2854727	ENSG00000255568.3	BRWD1-AS2	4.75	2.64e-06	0.000603	0.2	0.21	Cognitive function;	chr21:39341861	chr21:39313935~39314962:+
LUAD	cis	rs7772486	0.641	rs67882056	ENSG00000235652.6	RP11-545I5.3	4.75	2.64e-06	0.000603	0.22	0.21	Lobe attachment (rater-scored or self-reported);	chr6:146095165	chr6:145799409~145886585:+
LUAD	cis	rs4776970	0.632	rs55993790	ENSG00000270964.1	RP11-502I4.3	-4.75	2.64e-06	0.000603	-0.23	-0.21	Body mass index;Waist circumference;	chr15:67734184	chr15:67541072~67542604:-
LUAD	cis	rs683257	0.636	rs17070386	ENSG00000234147.1	RP3-460G2.2	4.75	2.64e-06	0.000603	0.34	0.21	Facial emotion recognition (angry faces);	chr6:140850424	chr6:140845958~140852924:-
LUAD	cis	rs17684571	0.872	rs2967963	ENSG00000231441.1	RP11-472M19.2	4.75	2.64e-06	0.000603	0.29	0.21	Schizophrenia;	chr6:56756819	chr6:56844002~56864078:+
LUAD	cis	rs9545047	0.604	rs7983344	ENSG00000227354.5	RBM26-AS1	-4.75	2.64e-06	0.000603	-0.22	-0.21	Schizophrenia;	chr13:79299295	chr13:79406309~79424328:+
LUAD	cis	rs6840360	0.615	rs62329085	ENSG00000270265.1	RP11-731D1.4	-4.75	2.64e-06	0.000604	-0.24	-0.21	Intelligence (multi-trait analysis);	chr4:151549085	chr4:151333775~151353224:-
LUAD	cis	rs12928939	0.815	rs11648483	ENSG00000260886.1	TAT-AS1	4.75	2.64e-06	0.000604	0.26	0.21	Post bronchodilator FEV1;	chr16:71673495	chr16:71565789~71578187:+
LUAD	cis	rs10129255	0.957	rs4387509	ENSG00000211974.3	IGHV2-70	4.75	2.64e-06	0.000604	0.23	0.21	Kawasaki disease;	chr14:106704386	chr14:106723574~106724093:-
LUAD	cis	rs4789693	0.872	rs28612648	ENSG00000265458.1	RP13-20L14.6	4.75	2.65e-06	0.000604	0.3	0.21	Glucocorticoid-induced osteonecrosis;	chr17:82445510	chr17:82454273~82458521:-
LUAD	cis	rs6762	0.55	rs8672	ENSG00000279672.1	CMB9-55F22.1	4.75	2.65e-06	0.000604	0.23	0.21	Mean platelet volume;	chr11:838634	chr11:779617~780755:+
LUAD	cis	rs12908161	0.959	rs2175567	ENSG00000259295.5	CSPG4P12	4.75	2.65e-06	0.000604	0.3	0.21	Schizophrenia;	chr15:84657715	chr15:85191438~85213905:+
LUAD	cis	rs9860428	0.815	rs9825873	ENSG00000242770.2	RP11-180K7.1	4.75	2.65e-06	0.000604	0.23	0.21	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112905547	chr3:112802478~112812819:+
LUAD	cis	rs11673344	0.764	rs472226	ENSG00000226686.6	LINC01535	4.75	2.65e-06	0.000604	0.27	0.21	Obesity-related traits;	chr19:36967811	chr19:37251912~37265535:+
LUAD	cis	rs6604026	0.59	rs11809055	ENSG00000223787.2	RP4-593M8.1	4.75	2.65e-06	0.000604	0.29	0.21	Multiple sclerosis;	chr1:92675107	chr1:92580476~92580821:-
LUAD	cis	rs9322193	0.926	rs9766562	ENSG00000268592.3	RAET1E-AS1	4.75	2.65e-06	0.000605	0.26	0.21	Lung cancer;	chr6:149788709	chr6:149863494~149919507:+
LUAD	cis	rs8177876	0.841	rs8177851	ENSG00000261061.1	RP11-303E16.2	-4.75	2.65e-06	0.000605	-0.4	-0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81092747	chr16:81030770~81031485:+
LUAD	cis	rs17301013	0.861	rs2038025	ENSG00000227373.4	RP11-160H22.5	4.75	2.65e-06	0.000605	0.27	0.21	Systemic lupus erythematosus;	chr1:174574712	chr1:174115300~174160004:-
LUAD	cis	rs8031584	0.918	rs35396566	ENSG00000270015.1	RP11-540B6.6	-4.75	2.65e-06	0.000605	-0.17	-0.21	Huntington's disease progression;	chr15:30970854	chr15:30926514~30928407:+
LUAD	cis	rs6604026	0.624	rs12756698	ENSG00000223787.2	RP4-593M8.1	4.75	2.65e-06	0.000605	0.29	0.21	Multiple sclerosis;	chr1:92697243	chr1:92580476~92580821:-
LUAD	cis	rs6604026	0.624	rs11803097	ENSG00000223787.2	RP4-593M8.1	4.75	2.65e-06	0.000605	0.29	0.21	Multiple sclerosis;	chr1:92705932	chr1:92580476~92580821:-
LUAD	cis	rs6604026	0.59	rs12749786	ENSG00000223787.2	RP4-593M8.1	4.75	2.65e-06	0.000605	0.29	0.21	Multiple sclerosis;	chr1:92706367	chr1:92580476~92580821:-
LUAD	cis	rs6604026	0.624	rs72724586	ENSG00000223787.2	RP4-593M8.1	4.75	2.65e-06	0.000605	0.29	0.21	Multiple sclerosis;	chr1:92707620	chr1:92580476~92580821:-
LUAD	cis	rs2439831	0.85	rs11856795	ENSG00000249839.1	AC011330.5	-4.75	2.65e-06	0.000606	-0.45	-0.21	Lung cancer in ever smokers;	chr15:43868384	chr15:43663654~43684339:-
LUAD	cis	rs7948661	1	rs9332816	ENSG00000278376.1	RP11-158I9.8	4.75	2.66e-06	0.000606	0.41	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118493689	chr11:118791254~118793137:+
LUAD	cis	rs1005277	0.579	rs1780137	ENSG00000263064.2	RP11-291L22.7	4.75	2.66e-06	0.000607	0.23	0.21	Extrinsic epigenetic age acceleration;	chr10:38212547	chr10:38448689~38448949:+
LUAD	cis	rs2832077	0.943	rs2832097	ENSG00000232855.5	AF131217.1	-4.75	2.66e-06	0.000607	-0.22	-0.21	Cognitive test performance;	chr21:28801017	chr21:28439346~28674848:-
LUAD	cis	rs12554020	0.892	rs75678521	ENSG00000227603.1	RP11-165J3.6	4.75	2.66e-06	0.000607	0.35	0.21	Schizophrenia;	chr9:93600744	chr9:93435332~93437121:-
LUAD	cis	rs11846409	0.799	rs10467899	ENSG00000223648.3	IGHV3-64	4.75	2.66e-06	0.000607	0.25	0.21	Rheumatic heart disease;	chr14:106644012	chr14:106643132~106658258:-
LUAD	cis	rs17508449	0.865	rs76112502	ENSG00000232450.1	RP4-730K3.3	-4.75	2.66e-06	0.000608	-0.35	-0.21	Leprosy;	chr1:113607074	chr1:113698884~113699631:-
LUAD	cis	rs987724	0.519	rs9820830	ENSG00000240875.4	LINC00886	-4.75	2.67e-06	0.000608	-0.23	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156824915	chr3:156747346~156817062:-
LUAD	cis	rs6570726	0.811	rs375873	ENSG00000235652.6	RP11-545I5.3	4.75	2.67e-06	0.000608	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145491235	chr6:145799409~145886585:+
LUAD	cis	rs1799949	0.965	rs6503727	ENSG00000236383.6	LINC00854	-4.75	2.67e-06	0.000609	-0.17	-0.21	Menopause (age at onset);	chr17:43160842	chr17:43216941~43305976:-
LUAD	cis	rs2153535	0.585	rs9406188	ENSG00000230939.1	RP11-314C16.1	-4.75	2.67e-06	0.000609	-0.24	-0.21	Motion sickness;	chr6:8667604	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.585	rs9328501	ENSG00000230939.1	RP11-314C16.1	-4.75	2.67e-06	0.000609	-0.24	-0.21	Motion sickness;	chr6:8669287	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.56	rs9379239	ENSG00000230939.1	RP11-314C16.1	-4.75	2.67e-06	0.000609	-0.24	-0.21	Motion sickness;	chr6:8670263	chr6:8784178~8785445:+
LUAD	cis	rs858239	0.602	rs6953996	ENSG00000230042.1	AK3P3	-4.75	2.67e-06	0.000609	-0.27	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23129178~23129841:+
LUAD	cis	rs7937890	0.56	rs2597194	ENSG00000251991.1	RNU7-49P	4.75	2.67e-06	0.00061	0.23	0.21	Mitochondrial DNA levels;	chr11:14475723	chr11:14478892~14478953:+
LUAD	cis	rs7937890	0.593	rs2597189	ENSG00000251991.1	RNU7-49P	4.75	2.67e-06	0.00061	0.23	0.21	Mitochondrial DNA levels;	chr11:14490514	chr11:14478892~14478953:+
LUAD	cis	rs8031584	0.723	rs711224	ENSG00000259845.1	HERC2P10	-4.75	2.67e-06	0.00061	-0.26	-0.21	Huntington's disease progression;	chr15:30835718	chr15:30815271~30844153:+
LUAD	cis	rs11673344	0.704	rs571340	ENSG00000226686.6	LINC01535	4.75	2.67e-06	0.00061	0.27	0.21	Obesity-related traits;	chr19:36933981	chr19:37251912~37265535:+
LUAD	cis	rs7116495	1	rs531326	ENSG00000254682.1	RP11-660L16.2	-4.75	2.67e-06	0.00061	-0.42	-0.21	Severe influenza A (H1N1) infection;	chr11:71859610	chr11:71448674~71452157:+
LUAD	cis	rs4664293	0.51	rs890096	ENSG00000226266.5	AC009961.3	4.75	2.68e-06	0.00061	0.29	0.21	Monocyte percentage of white cells;	chr2:159604849	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.51	rs747707	ENSG00000226266.5	AC009961.3	4.75	2.68e-06	0.00061	0.29	0.21	Monocyte percentage of white cells;	chr2:159609003	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.51	rs6731277	ENSG00000226266.5	AC009961.3	4.75	2.68e-06	0.00061	0.29	0.21	Monocyte percentage of white cells;	chr2:159610606	chr2:159670708~159712435:-
LUAD	cis	rs375066	0.935	rs432454	ENSG00000267058.1	RP11-15A1.3	-4.75	2.68e-06	0.00061	-0.24	-0.21	Breast cancer;	chr19:43894679	chr19:43891804~43901805:-
LUAD	cis	rs2439831	0.85	rs8042868	ENSG00000249839.1	AC011330.5	-4.75	2.68e-06	0.00061	-0.44	-0.21	Lung cancer in ever smokers;	chr15:43647444	chr15:43663654~43684339:-
LUAD	cis	rs4908760	0.832	rs11121209	ENSG00000232912.4	RP5-1115A15.1	4.75	2.68e-06	0.000611	0.19	0.21	Vitiligo;	chr1:8626803	chr1:8424645~8434838:+
LUAD	cis	rs9545047	0.604	rs7319212	ENSG00000227354.5	RBM26-AS1	-4.75	2.68e-06	0.000611	-0.22	-0.21	Schizophrenia;	chr13:79365404	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs7319252	ENSG00000227354.5	RBM26-AS1	-4.75	2.68e-06	0.000611	-0.22	-0.21	Schizophrenia;	chr13:79365471	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs35476664	ENSG00000227354.5	RBM26-AS1	-4.75	2.68e-06	0.000611	-0.22	-0.21	Schizophrenia;	chr13:79375462	chr13:79406309~79424328:+
LUAD	cis	rs525592	1	rs525592	ENSG00000212093.1	AP000807.1	4.75	2.68e-06	0.000611	0.22	0.21	Bone mineral density;	chr11:68427636	chr11:68506083~68506166:-
LUAD	cis	rs1008375	1	rs2159584	ENSG00000249502.1	AC006160.5	-4.75	2.68e-06	0.000611	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17618945	chr4:17587467~17614571:-
LUAD	cis	rs10129255	0.869	rs7150549	ENSG00000211974.3	IGHV2-70	4.75	2.68e-06	0.000611	0.23	0.21	Kawasaki disease;	chr14:106705441	chr14:106723574~106724093:-
LUAD	cis	rs2404602	0.646	rs3764245	ENSG00000259422.1	RP11-593F23.1	4.75	2.68e-06	0.000611	0.28	0.21	Blood metabolite levels;	chr15:76930835	chr15:76174891~76181486:-
LUAD	cis	rs867371	0.82	rs12443224	ENSG00000259429.4	UBE2Q2P2	-4.75	2.68e-06	0.000612	-0.19	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82203269	chr15:82355142~82420075:+
LUAD	cis	rs6840360	1	rs6535813	ENSG00000270265.1	RP11-731D1.4	-4.75	2.69e-06	0.000612	-0.22	-0.21	Intelligence (multi-trait analysis);	chr4:151678500	chr4:151333775~151353224:-
LUAD	cis	rs6088590	1	rs6119516	ENSG00000276073.1	RP5-1125A11.7	-4.75	2.69e-06	0.000612	-0.21	-0.21	Coronary artery disease;	chr20:34740220	chr20:33985617~33988989:-
LUAD	cis	rs950169	0.959	rs12911210	ENSG00000275120.1	RP11-182J1.17	4.75	2.69e-06	0.000612	0.32	0.21	Schizophrenia;	chr15:84123331	chr15:84599434~84606463:-
LUAD	cis	rs516805	0.667	rs928011	ENSG00000279453.1	RP3-425C14.4	4.75	2.69e-06	0.000613	0.28	0.21	Lymphocyte counts;	chr6:122248991	chr6:122436789~122439223:-
LUAD	cis	rs4664293	0.769	rs2729726	ENSG00000230783.1	AC009961.2	-4.75	2.69e-06	0.000613	-0.26	-0.21	Monocyte percentage of white cells;	chr2:159811597	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.738	rs1549580	ENSG00000230783.1	AC009961.2	-4.75	2.69e-06	0.000613	-0.26	-0.21	Monocyte percentage of white cells;	chr2:159812177	chr2:159689217~159690291:-
LUAD	cis	rs5758511	0.68	rs5758651	ENSG00000226450.2	CYP2D8P	4.75	2.69e-06	0.000613	0.2	0.21	Birth weight;	chr22:42213142	chr22:42149886~42155001:-
LUAD	cis	rs5758511	0.68	rs5758652	ENSG00000226450.2	CYP2D8P	4.75	2.69e-06	0.000613	0.2	0.21	Birth weight;	chr22:42216402	chr22:42149886~42155001:-
LUAD	cis	rs7119	0.623	rs11637932	ENSG00000259362.2	RP11-307C19.1	-4.75	2.69e-06	0.000613	-0.27	-0.21	Type 2 diabetes;	chr15:77555011	chr15:77525540~77534110:+
LUAD	cis	rs7119	0.651	rs12915057	ENSG00000259362.2	RP11-307C19.1	-4.75	2.69e-06	0.000613	-0.27	-0.21	Type 2 diabetes;	chr15:77555403	chr15:77525540~77534110:+
LUAD	cis	rs7119	0.679	rs34075648	ENSG00000259362.2	RP11-307C19.1	-4.75	2.69e-06	0.000613	-0.27	-0.21	Type 2 diabetes;	chr15:77555460	chr15:77525540~77534110:+
LUAD	cis	rs7119	0.651	rs35657172	ENSG00000259362.2	RP11-307C19.1	-4.75	2.69e-06	0.000613	-0.27	-0.21	Type 2 diabetes;	chr15:77555471	chr15:77525540~77534110:+
LUAD	cis	rs7119	0.651	rs34607443	ENSG00000259362.2	RP11-307C19.1	-4.75	2.69e-06	0.000613	-0.27	-0.21	Type 2 diabetes;	chr15:77555550	chr15:77525540~77534110:+
LUAD	cis	rs17684571	0.748	rs3002006	ENSG00000231441.1	RP11-472M19.2	4.75	2.69e-06	0.000613	0.29	0.21	Schizophrenia;	chr6:56750916	chr6:56844002~56864078:+
LUAD	cis	rs10246939	0.544	rs12668089	ENSG00000270923.1	TAS2R6P	-4.75	2.69e-06	0.000613	-0.24	-0.21	Bitter taste perception;	chr7:141875111	chr7:141787815~141788640:+
LUAD	cis	rs7116495	1	rs10751189	ENSG00000254682.1	RP11-660L16.2	-4.75	2.69e-06	0.000614	-0.4	-0.21	Severe influenza A (H1N1) infection;	chr11:71959532	chr11:71448674~71452157:+
LUAD	cis	rs17666538	0.901	rs73177064	ENSG00000254207.1	RP11-43A14.1	-4.75	2.7e-06	0.000614	-0.48	-0.21	IgG glycosylation;	chr8:635293	chr8:725188~725877:-
LUAD	cis	rs17666538	1	rs73177066	ENSG00000254207.1	RP11-43A14.1	-4.75	2.7e-06	0.000614	-0.48	-0.21	IgG glycosylation;	chr8:635750	chr8:725188~725877:-
LUAD	cis	rs801193	1	rs2707856	ENSG00000237310.1	GS1-124K5.4	4.75	2.7e-06	0.000614	0.23	0.21	Aortic root size;	chr7:66746023	chr7:66493706~66495474:+
LUAD	cis	rs6088590	0.965	rs13040449	ENSG00000276073.1	RP5-1125A11.7	-4.75	2.7e-06	0.000615	-0.22	-0.21	Coronary artery disease;	chr20:34771098	chr20:33985617~33988989:-
LUAD	cis	rs1008375	1	rs4235388	ENSG00000249502.1	AC006160.5	-4.75	2.7e-06	0.000615	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17680407	chr4:17587467~17614571:-
LUAD	cis	rs7086627	0.506	rs10749575	ENSG00000226659.1	RP11-137H2.4	-4.75	2.7e-06	0.000615	-0.28	-0.21	Post bronchodilator FEV1;	chr10:80377165	chr10:80529597~80535942:-
LUAD	cis	rs4142110	0.658	rs430080	ENSG00000271216.1	LINC01050	-4.75	2.7e-06	0.000615	-0.25	-0.21	Nephrolithiasis;	chr13:42223850	chr13:42810366~42812562:-
LUAD	cis	rs17508449	0.819	rs4589108	ENSG00000232450.1	RP4-730K3.3	-4.75	2.7e-06	0.000616	-0.37	-0.21	Leprosy;	chr1:113717003	chr1:113698884~113699631:-
LUAD	cis	rs8177876	0.642	rs4454990	ENSG00000261838.4	RP11-303E16.6	-4.75	2.7e-06	0.000616	-0.41	-0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81106550	chr16:81069854~81076598:+
LUAD	cis	rs12468226	1	rs74766638	ENSG00000272966.1	RP11-686O6.1	4.75	2.7e-06	0.000616	0.35	0.21	Urate levels;	chr2:202445168	chr2:202336739~202337200:+
LUAD	cis	rs4604234	0.518	rs73463537	ENSG00000272129.1	RP11-250B2.6	-4.75	2.7e-06	0.000616	-0.46	-0.21	Cancer;	chr6:80275314	chr6:80355424~80356859:+
LUAD	cis	rs4568518	0.53	rs11764965	ENSG00000279048.1	RP11-511H23.2	4.75	2.71e-06	0.000616	0.18	0.21	Measles;	chr7:17959127	chr7:17940503~17942922:+
LUAD	cis	rs17684571	0.872	rs4640889	ENSG00000231441.1	RP11-472M19.2	-4.75	2.71e-06	0.000616	-0.29	-0.21	Schizophrenia;	chr6:56740534	chr6:56844002~56864078:+
LUAD	cis	rs5758659	1	rs5751255	ENSG00000227370.1	RP4-669P10.19	-4.75	2.71e-06	0.000616	-0.19	-0.21	Cognitive function;	chr22:42252402	chr22:42132543~42132998:+
LUAD	cis	rs477895	0.838	rs11605738	ENSG00000236935.1	AP003774.1	-4.75	2.71e-06	0.000617	-0.26	-0.21	Mean platelet volume;	chr11:64245934	chr11:64325050~64329504:-
LUAD	cis	rs948562	0.593	rs74556128	ENSG00000280010.1	AP001350.4	4.75	2.71e-06	0.000617	0.38	0.21	Lymphoma;	chr11:58559704	chr11:58627435~58628528:+
LUAD	cis	rs4660214	0.666	rs683135	ENSG00000228060.1	RP11-69E11.8	-4.75	2.71e-06	0.000617	-0.19	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39429788	chr1:39565160~39573203:+
LUAD	cis	rs17684571	0.872	rs59085778	ENSG00000231441.1	RP11-472M19.2	4.75	2.71e-06	0.000617	0.29	0.21	Schizophrenia;	chr6:56723357	chr6:56844002~56864078:+
LUAD	cis	rs4660456	0.596	rs1534956	ENSG00000237899.1	RP4-739H11.3	4.75	2.71e-06	0.000617	0.24	0.21	Platelet count;	chr1:40720771	chr1:40669089~40687588:-
LUAD	cis	rs848490	0.889	rs17156320	ENSG00000214293.7	APTR	-4.75	2.71e-06	0.000617	-0.27	-0.21	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77670793	chr7:77657660~77696265:-
LUAD	cis	rs17301013	0.861	rs12568655	ENSG00000227373.4	RP11-160H22.5	4.75	2.71e-06	0.000617	0.26	0.21	Systemic lupus erythematosus;	chr1:174465194	chr1:174115300~174160004:-
LUAD	cis	rs193541	0.632	rs10037044	ENSG00000263432.2	RN7SL689P	-4.75	2.71e-06	0.000617	-0.28	-0.21	Glucose homeostasis traits;	chr5:122787604	chr5:123022487~123022783:-
LUAD	cis	rs9400467	0.508	rs1676863	ENSG00000271789.1	RP5-1112D6.7	-4.75	2.71e-06	0.000618	-0.22	-0.21	Amino acid levels;Blood metabolite levels;	chr6:111320387	chr6:111297126~111298510:+
LUAD	cis	rs7829975	0.688	rs6601703	ENSG00000173295.6	FAM86B3P	4.75	2.71e-06	0.000618	0.22	0.21	Mood instability;	chr8:8522714	chr8:8228595~8244865:+
LUAD	cis	rs9322193	0.923	rs9479094	ENSG00000268592.3	RAET1E-AS1	4.75	2.71e-06	0.000618	0.26	0.21	Lung cancer;	chr6:149725083	chr6:149863494~149919507:+
LUAD	cis	rs2976388	0.874	rs2976389	ENSG00000253741.1	CTD-2292P10.4	4.75	2.72e-06	0.000618	0.24	0.21	Urinary tract infection frequency;	chr8:142679003	chr8:142702252~142726973:-
LUAD	cis	rs948562	0.681	rs11822754	ENSG00000280010.1	AP001350.4	4.75	2.72e-06	0.000618	0.29	0.21	Lymphoma;	chr11:58665406	chr11:58627435~58628528:+
LUAD	cis	rs477895	0.838	rs1058735	ENSG00000236935.1	AP003774.1	-4.75	2.72e-06	0.000618	-0.25	-0.21	Mean platelet volume;	chr11:64232938	chr11:64325050~64329504:-
LUAD	cis	rs477895	0.838	rs35090903	ENSG00000236935.1	AP003774.1	-4.75	2.72e-06	0.000618	-0.25	-0.21	Mean platelet volume;	chr11:64233126	chr11:64325050~64329504:-
LUAD	cis	rs1799949	0.757	rs9915489	ENSG00000236383.6	LINC00854	-4.75	2.72e-06	0.000618	-0.17	-0.21	Menopause (age at onset);	chr17:43021209	chr17:43216941~43305976:-
LUAD	cis	rs2976388	0.647	rs2082801	ENSG00000253741.1	CTD-2292P10.4	-4.75	2.72e-06	0.000619	-0.24	-0.21	Urinary tract infection frequency;	chr8:142705043	chr8:142702252~142726973:-
LUAD	cis	rs2439831	0.681	rs511673	ENSG00000249839.1	AC011330.5	-4.75	2.72e-06	0.000619	-0.38	-0.21	Lung cancer in ever smokers;	chr15:43326665	chr15:43663654~43684339:-
LUAD	cis	rs950169	0.922	rs11635505	ENSG00000275120.1	RP11-182J1.17	-4.75	2.72e-06	0.000619	-0.32	-0.21	Schizophrenia;	chr15:84553803	chr15:84599434~84606463:-
LUAD	cis	rs1008375	1	rs9291659	ENSG00000249502.1	AC006160.5	-4.75	2.72e-06	0.00062	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17660737	chr4:17587467~17614571:-
LUAD	cis	rs2348418	0.733	rs1904386	ENSG00000247934.4	RP11-967K21.1	-4.75	2.72e-06	0.00062	-0.24	-0.21	Lung function (FEV1);Lung function (FVC);	chr12:28202321	chr12:28163298~28190738:-
LUAD	cis	rs2348418	0.733	rs1824769	ENSG00000247934.4	RP11-967K21.1	-4.75	2.72e-06	0.00062	-0.24	-0.21	Lung function (FEV1);Lung function (FVC);	chr12:28202322	chr12:28163298~28190738:-
LUAD	cis	rs2348418	0.671	rs2169753	ENSG00000247934.4	RP11-967K21.1	-4.75	2.72e-06	0.00062	-0.24	-0.21	Lung function (FEV1);Lung function (FVC);	chr12:28203481	chr12:28163298~28190738:-
LUAD	cis	rs12701220	0.948	rs10275712	ENSG00000229043.2	AC091729.9	-4.75	2.73e-06	0.00062	-0.28	-0.21	Bronchopulmonary dysplasia;	chr7:1043282	chr7:1160374~1165267:+
LUAD	cis	rs62355900	0.627	rs9292123	ENSG00000271828.1	CTD-2310F14.1	4.75	2.73e-06	0.00062	0.37	0.21	Endometriosis;	chr5:56807982	chr5:56927874~56929573:+
LUAD	cis	rs477895	0.838	rs11607007	ENSG00000236935.1	AP003774.1	-4.75	2.73e-06	0.00062	-0.26	-0.21	Mean platelet volume;	chr11:64240504	chr11:64325050~64329504:-
LUAD	cis	rs6921919	0.789	rs11970439	ENSG00000216901.1	AL022393.7	4.75	2.73e-06	0.00062	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:28176188~28176674:+
LUAD	cis	rs442309	0.687	rs10822058	ENSG00000238280.1	RP11-436D10.3	-4.75	2.73e-06	0.00062	-0.26	-0.21	Vogt-Koyanagi-Harada syndrome;	chr10:62763822	chr10:62793562~62805887:-
LUAD	cis	rs896854	0.967	rs1320164	ENSG00000253528.2	RP11-347C18.4	4.75	2.73e-06	0.000621	0.21	0.21	Type 2 diabetes;	chr8:94948539	chr8:94974573~94974853:-
LUAD	cis	rs950169	0.881	rs34117475	ENSG00000229212.6	RP11-561C5.4	-4.75	2.73e-06	0.000621	-0.3	-0.21	Schizophrenia;	chr15:84565212	chr15:85205440~85234795:-
LUAD	cis	rs9309473	0.528	rs7573275	ENSG00000163016.8	ALMS1P	4.75	2.73e-06	0.000621	0.25	0.21	Metabolite levels;	chr2:73325414	chr2:73644919~73685576:+
LUAD	cis	rs2028299	0.92	rs10852123	ENSG00000259677.1	RP11-493E3.1	4.75	2.73e-06	0.000621	0.26	0.21	Type 2 diabetes;	chr15:89885662	chr15:89876540~89877285:+
LUAD	cis	rs6840360	0.967	rs6535812	ENSG00000270265.1	RP11-731D1.4	-4.75	2.73e-06	0.000621	-0.21	-0.21	Intelligence (multi-trait analysis);	chr4:151678222	chr4:151333775~151353224:-
LUAD	cis	rs12681366	0.881	rs16916760	ENSG00000253704.1	RP11-267M23.4	4.75	2.73e-06	0.000621	0.27	0.21	Nonsyndromic cleft lip with cleft palate;	chr8:94356881	chr8:94553722~94569745:+
LUAD	cis	rs116175783	0.557	rs3731768	ENSG00000227403.1	AC009299.3	4.75	2.73e-06	0.000621	0.39	0.21	Intelligence (multi-trait analysis);	chr2:161250809	chr2:161244739~161249050:+
LUAD	cis	rs7923837	1	rs1112718	ENSG00000236493.2	EIF2S2P3	4.75	2.73e-06	0.000622	0.23	0.21	Multiple sclerosis;Body mass index;	chr10:92719350	chr10:92668745~92669743:-
LUAD	cis	rs8180040	0.577	rs12493425	ENSG00000271161.1	BOLA2P2	4.75	2.73e-06	0.000622	0.2	0.21	Colorectal cancer;	chr3:47135456	chr3:47499841~47500407:+
LUAD	cis	rs7017914	0.606	rs2035926	ENSG00000223220.1	Y_RNA	4.75	2.73e-06	0.000622	0.24	0.21	Bone mineral density;	chr8:71001339	chr8:70780914~70781008:-
LUAD	cis	rs7339483	0.85	rs66673977	ENSG00000268058.1	BNIP3P40	-4.75	2.73e-06	0.000622	-0.38	-0.21	Discordance in emotional problems in monozygotic twins;	chr19:24208302	chr19:24098425~24098980:-
LUAD	cis	rs73173548	0.502	rs4451795	ENSG00000247828.6	TMEM161B-AS1	4.75	2.74e-06	0.000622	0.25	0.21	Macular telangiectasia type 2;	chr5:88422879	chr5:88268895~88436685:+
LUAD	cis	rs7811142	1	rs7803454	ENSG00000078319.8	PMS2P1	-4.75	2.74e-06	0.000623	-0.26	-0.21	Platelet count;	chr7:100393925	chr7:100320992~100341908:-
LUAD	cis	rs9545047	0.604	rs6563100	ENSG00000227354.5	RBM26-AS1	4.75	2.74e-06	0.000623	0.22	0.21	Schizophrenia;	chr13:79382978	chr13:79406309~79424328:+
LUAD	cis	rs11168351	0.926	rs10875719	ENSG00000257735.1	RP11-370I10.6	4.75	2.74e-06	0.000623	0.26	0.21	Bipolar disorder and schizophrenia;	chr12:48017375	chr12:48350945~48442411:+
LUAD	cis	rs4660214	0.666	rs4617393	ENSG00000228060.1	RP11-69E11.8	4.75	2.74e-06	0.000623	0.19	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39474551	chr1:39565160~39573203:+
LUAD	cis	rs948562	0.519	rs12295247	ENSG00000280010.1	AP001350.4	4.75	2.74e-06	0.000623	0.29	0.21	Lymphoma;	chr11:58292321	chr11:58627435~58628528:+
LUAD	cis	rs10897473	0.529	rs10751006	ENSG00000236935.1	AP003774.1	-4.75	2.74e-06	0.000623	-0.21	-0.21	Immature fraction of reticulocytes;	chr11:64084722	chr11:64325050~64329504:-
LUAD	cis	rs911555	0.57	rs11625397	ENSG00000258851.1	RP11-894P9.2	4.75	2.74e-06	0.000623	0.24	0.21	Intelligence (multi-trait analysis);	chr14:103561220	chr14:103553421~103561877:+
LUAD	cis	rs2239557	1	rs11628710	ENSG00000259065.1	RP5-1021I20.1	-4.75	2.74e-06	0.000623	-0.24	-0.21	Common traits (Other);	chr14:74182577	chr14:73787360~73803270:+
LUAD	cis	rs113835537	0.877	rs3867132	ENSG00000255517.5	CTD-3074O7.5	-4.75	2.74e-06	0.000623	-0.31	-0.21	Airway imaging phenotypes;	chr11:66541798	chr11:66473490~66480233:-
LUAD	cis	rs7119	0.717	rs12901471	ENSG00000259362.2	RP11-307C19.1	-4.75	2.74e-06	0.000624	-0.26	-0.21	Type 2 diabetes;	chr15:77526650	chr15:77525540~77534110:+
LUAD	cis	rs2243480	0.803	rs34804747	ENSG00000229886.1	RP5-1132H15.3	4.75	2.74e-06	0.000624	0.37	0.21	Diabetic kidney disease;	chr7:65947955	chr7:66025126~66031544:-
LUAD	cis	rs1799949	0.965	rs799912	ENSG00000236383.6	LINC00854	-4.75	2.74e-06	0.000624	-0.17	-0.21	Menopause (age at onset);	chr17:43105117	chr17:43216941~43305976:-
LUAD	cis	rs55823223	0.564	rs12103594	ENSG00000267801.1	RP11-552F3.9	4.75	2.75e-06	0.000624	0.23	0.21	Psoriasis;	chr17:75859198	chr17:75876372~75879546:+
LUAD	cis	rs1799949	0.965	rs11651623	ENSG00000236383.6	LINC00854	-4.75	2.75e-06	0.000624	-0.17	-0.21	Menopause (age at onset);	chr17:43177830	chr17:43216941~43305976:-
LUAD	cis	rs9322193	0.567	rs7742692	ENSG00000268592.3	RAET1E-AS1	4.75	2.75e-06	0.000624	0.26	0.21	Lung cancer;	chr6:149892363	chr6:149863494~149919507:+
LUAD	cis	rs2836974	0.583	rs2776306	ENSG00000255568.3	BRWD1-AS2	4.75	2.75e-06	0.000625	0.2	0.21	Cognitive function;	chr21:39341828	chr21:39313935~39314962:+
LUAD	cis	rs1008375	1	rs2159583	ENSG00000249502.1	AC006160.5	-4.75	2.75e-06	0.000625	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17657215	chr4:17587467~17614571:-
LUAD	cis	rs7829975	0.714	rs60315134	ENSG00000253981.4	ALG1L13P	4.75	2.75e-06	0.000625	0.24	0.21	Mood instability;	chr8:8813089	chr8:8236003~8244667:-
LUAD	cis	rs10246939	0.543	rs35836873	ENSG00000228775.6	WEE2-AS1	4.75	2.75e-06	0.000625	0.25	0.21	Bitter taste perception;	chr7:141844010	chr7:141704338~141738346:-
LUAD	cis	rs10246939	0.543	rs9640358	ENSG00000228775.6	WEE2-AS1	4.75	2.75e-06	0.000625	0.25	0.21	Bitter taste perception;	chr7:141844082	chr7:141704338~141738346:-
LUAD	cis	rs7829975	0.522	rs6601689	ENSG00000253893.2	FAM85B	-4.75	2.75e-06	0.000625	-0.25	-0.21	Mood instability;	chr8:8314761	chr8:8167819~8226614:-
LUAD	cis	rs2239547	0.618	rs4687663	ENSG00000242142.1	SERBP1P3	4.75	2.75e-06	0.000626	0.25	0.21	Schizophrenia;	chr3:52836602	chr3:53064283~53065091:-
LUAD	cis	rs801193	0.967	rs2420827	ENSG00000236529.1	RP13-254B10.1	-4.75	2.75e-06	0.000626	-0.22	-0.21	Aortic root size;	chr7:66682114	chr7:65840212~65840596:+
LUAD	cis	rs2562456	0.793	rs73537884	ENSG00000268081.1	RP11-678G14.2	4.75	2.75e-06	0.000626	0.34	0.21	Pain;	chr19:21321908	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.793	rs78467454	ENSG00000268081.1	RP11-678G14.2	4.75	2.75e-06	0.000626	0.34	0.21	Pain;	chr19:21321930	chr19:21554640~21569237:-
LUAD	cis	rs11250098	0.548	rs7837038	ENSG00000255046.1	RP11-297N6.4	4.75	2.75e-06	0.000626	0.26	0.21	Morning vs. evening chronotype;	chr8:10925564	chr8:11797928~11802568:-
LUAD	cis	rs6558530	0.692	rs6558522	ENSG00000253982.1	CTD-2336O2.1	-4.74	2.75e-06	0.000626	-0.27	-0.21	Systolic blood pressure;	chr8:1754204	chr8:1761990~1764502:-
LUAD	cis	rs477895	0.713	rs1059440	ENSG00000236935.1	AP003774.1	4.74	2.76e-06	0.000627	0.25	0.21	Mean platelet volume;	chr11:64224329	chr11:64325050~64329504:-
LUAD	cis	rs14027	0.883	rs10102038	ENSG00000279347.1	RP11-85I17.2	-4.74	2.76e-06	0.000627	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119702544	chr8:119838736~119840385:-
LUAD	cis	rs14027	0.883	rs35660840	ENSG00000279347.1	RP11-85I17.2	-4.74	2.76e-06	0.000627	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119704351	chr8:119838736~119840385:-
LUAD	cis	rs12468226	0.606	rs79092351	ENSG00000272966.1	RP11-686O6.1	4.74	2.76e-06	0.000627	0.33	0.21	Urate levels;	chr2:202204388	chr2:202336739~202337200:+
LUAD	cis	rs150992	0.504	rs7723242	ENSG00000248489.1	CTD-2007H13.3	-4.74	2.76e-06	0.000627	-0.27	-0.21	Body mass index;	chr5:99023408	chr5:98929171~98995013:+
LUAD	cis	rs9860428	0.808	rs34147006	ENSG00000242770.2	RP11-180K7.1	4.74	2.76e-06	0.000627	0.22	0.21	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112903063	chr3:112802478~112812819:+
LUAD	cis	rs2524005	1	rs2524005	ENSG00000230795.2	HLA-K	-4.74	2.76e-06	0.000627	-0.3	-0.21	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29926459~29929232:+
LUAD	cis	rs375066	0.935	rs422457	ENSG00000267058.1	RP11-15A1.3	-4.74	2.76e-06	0.000628	-0.24	-0.21	Breast cancer;	chr19:43905259	chr19:43891804~43901805:-
LUAD	cis	rs9322193	0.923	rs11155674	ENSG00000268592.3	RAET1E-AS1	4.74	2.76e-06	0.000628	0.26	0.21	Lung cancer;	chr6:149711111	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.923	rs2185352	ENSG00000268592.3	RAET1E-AS1	4.74	2.76e-06	0.000628	0.26	0.21	Lung cancer;	chr6:149714640	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.923	rs2297932	ENSG00000268592.3	RAET1E-AS1	4.74	2.76e-06	0.000628	0.26	0.21	Lung cancer;	chr6:149718225	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.923	rs2297930	ENSG00000268592.3	RAET1E-AS1	4.74	2.76e-06	0.000628	0.26	0.21	Lung cancer;	chr6:149718360	chr6:149863494~149919507:+
LUAD	cis	rs7829975	0.774	rs11775523	ENSG00000253893.2	FAM85B	-4.74	2.76e-06	0.000628	-0.27	-0.21	Mood instability;	chr8:8821666	chr8:8167819~8226614:-
LUAD	cis	rs7829975	0.774	rs1039915	ENSG00000253893.2	FAM85B	-4.74	2.76e-06	0.000628	-0.27	-0.21	Mood instability;	chr8:8822104	chr8:8167819~8226614:-
LUAD	cis	rs13434995	0.891	rs62309728	ENSG00000273257.1	RP11-177J6.1	-4.74	2.76e-06	0.000628	-0.34	-0.21	Adiponectin levels;	chr4:55530648	chr4:55387949~55388271:+
LUAD	cis	rs4664293	0.647	rs7580539	ENSG00000226266.5	AC009961.3	-4.74	2.77e-06	0.000628	-0.28	-0.21	Monocyte percentage of white cells;	chr2:159589238	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.539	rs7580661	ENSG00000226266.5	AC009961.3	-4.74	2.77e-06	0.000628	-0.28	-0.21	Monocyte percentage of white cells;	chr2:159589326	chr2:159670708~159712435:-
LUAD	cis	rs9341808	0.529	rs4706840	ENSG00000272129.1	RP11-250B2.6	4.74	2.77e-06	0.000628	0.27	0.21	Sitting height ratio;	chr6:80348052	chr6:80355424~80356859:+
LUAD	cis	rs9545047	0.604	rs9318633	ENSG00000227354.5	RBM26-AS1	-4.74	2.77e-06	0.000628	-0.22	-0.21	Schizophrenia;	chr13:79369113	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs12872328	ENSG00000227354.5	RBM26-AS1	-4.74	2.77e-06	0.000628	-0.22	-0.21	Schizophrenia;	chr13:79370489	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs2182010	ENSG00000227354.5	RBM26-AS1	-4.74	2.77e-06	0.000628	-0.22	-0.21	Schizophrenia;	chr13:79370618	chr13:79406309~79424328:+
LUAD	cis	rs559928	0.548	rs11231713	ENSG00000236935.1	AP003774.1	4.74	2.77e-06	0.000629	0.31	0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64164377	chr11:64325050~64329504:-
LUAD	cis	rs559928	0.593	rs112275221	ENSG00000236935.1	AP003774.1	4.74	2.77e-06	0.000629	0.31	0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64169522	chr11:64325050~64329504:-
LUAD	cis	rs1009115	0.62	rs42950	ENSG00000272328.1	RP4-594A5.1	4.74	2.77e-06	0.000629	0.27	0.21	Post bronchodilator FEV1;	chr7:8382756	chr7:8303741~8341343:+
LUAD	cis	rs10995356	0.966	rs10740096	ENSG00000238280.1	RP11-436D10.3	-4.74	2.77e-06	0.000629	-0.26	-0.21	Temperament;	chr10:62915331	chr10:62793562~62805887:-
LUAD	cis	rs2976388	0.609	rs2717605	ENSG00000253741.1	CTD-2292P10.4	-4.74	2.77e-06	0.000629	-0.24	-0.21	Urinary tract infection frequency;	chr8:142719597	chr8:142702252~142726973:-
LUAD	cis	rs2976388	0.609	rs2572907	ENSG00000253741.1	CTD-2292P10.4	-4.74	2.77e-06	0.000629	-0.24	-0.21	Urinary tract infection frequency;	chr8:142720520	chr8:142702252~142726973:-
LUAD	cis	rs2976388	0.609	rs2572908	ENSG00000253741.1	CTD-2292P10.4	-4.74	2.77e-06	0.000629	-0.24	-0.21	Urinary tract infection frequency;	chr8:142721218	chr8:142702252~142726973:-
LUAD	cis	rs910316	1	rs175449	ENSG00000279594.1	RP11-950C14.10	-4.74	2.77e-06	0.000629	-0.24	-0.21	Height;	chr14:75124143	chr14:75011269~75012851:-
LUAD	cis	rs910316	0.935	rs175448	ENSG00000279594.1	RP11-950C14.10	-4.74	2.77e-06	0.000629	-0.24	-0.21	Height;	chr14:75124368	chr14:75011269~75012851:-
LUAD	cis	rs2836950	0.565	rs2150414	ENSG00000255568.3	BRWD1-AS2	-4.74	2.77e-06	0.000629	-0.2	-0.21	Menarche (age at onset);	chr21:39243062	chr21:39313935~39314962:+
LUAD	cis	rs5758511	0.689	rs5758691	ENSG00000205702.9	CYP2D7	4.74	2.77e-06	0.00063	0.21	0.21	Birth weight;	chr22:42272498	chr22:42140203~42144577:-
LUAD	cis	rs5758511	0.68	rs1001586	ENSG00000205702.9	CYP2D7	4.74	2.77e-06	0.00063	0.21	0.21	Birth weight;	chr22:42274287	chr22:42140203~42144577:-
LUAD	cis	rs5758511	0.68	rs739147	ENSG00000205702.9	CYP2D7	4.74	2.77e-06	0.00063	0.21	0.21	Birth weight;	chr22:42275060	chr22:42140203~42144577:-
LUAD	cis	rs1008375	0.966	rs2315553	ENSG00000249502.1	AC006160.5	-4.74	2.78e-06	0.00063	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17625709	chr4:17587467~17614571:-
LUAD	cis	rs35160687	0.644	rs9309635	ENSG00000273080.1	RP11-301O19.1	4.74	2.78e-06	0.000631	0.23	0.21	Night sleep phenotypes;	chr2:86272279	chr2:86195590~86196049:+
LUAD	cis	rs17711722	0.74	rs7809991	ENSG00000237310.1	GS1-124K5.4	4.74	2.78e-06	0.000631	0.22	0.21	Calcium levels;	chr7:65941231	chr7:66493706~66495474:+
LUAD	cis	rs7017914	0.69	rs6991708	ENSG00000223220.1	Y_RNA	4.74	2.78e-06	0.000631	0.24	0.21	Bone mineral density;	chr8:70756293	chr8:70780914~70781008:-
LUAD	cis	rs1499614	0.901	rs2178742	ENSG00000232559.3	GS1-124K5.12	4.74	2.78e-06	0.000631	0.38	0.21	Gout;	chr7:66732812	chr7:66554588~66576923:-
LUAD	cis	rs6762	0.719	rs7936806	ENSG00000279672.1	CMB9-55F22.1	4.74	2.78e-06	0.000631	0.23	0.21	Mean platelet volume;	chr11:839186	chr11:779617~780755:+
LUAD	cis	rs12554020	0.786	rs78619366	ENSG00000227603.1	RP11-165J3.6	4.74	2.78e-06	0.000631	0.42	0.21	Schizophrenia;	chr9:93590541	chr9:93435332~93437121:-
LUAD	cis	rs12554020	0.579	rs78814851	ENSG00000227603.1	RP11-165J3.6	4.74	2.78e-06	0.000631	0.42	0.21	Schizophrenia;	chr9:93590652	chr9:93435332~93437121:-
LUAD	cis	rs75422866	0.51	rs73105819	ENSG00000276691.1	RP5-1057I20.5	4.74	2.78e-06	0.000631	0.35	0.21	Pneumonia;	chr12:47727190	chr12:47788426~47788971:+
LUAD	cis	rs193541	0.632	rs30036	ENSG00000263432.2	RN7SL689P	4.74	2.78e-06	0.000632	0.29	0.21	Glucose homeostasis traits;	chr5:122942565	chr5:123022487~123022783:-
LUAD	cis	rs6723226	0.806	rs6543658	ENSG00000276334.1	AL133243.1	4.74	2.78e-06	0.000632	0.24	0.21	Intelligence (multi-trait analysis);	chr2:32493782	chr2:32521927~32523547:+
LUAD	cis	rs6840360	1	rs6823194	ENSG00000270265.1	RP11-731D1.4	-4.74	2.78e-06	0.000632	-0.22	-0.21	Intelligence (multi-trait analysis);	chr4:151683391	chr4:151333775~151353224:-
LUAD	cis	rs7200786	0.692	rs8055544	ENSG00000274038.1	RP11-66H6.4	4.74	2.78e-06	0.000632	0.26	0.21	Systemic lupus erythematosus;Multiple sclerosis;	chr16:10997704	chr16:11056556~11057034:+
LUAD	cis	rs60180747	0.544	rs11633808	ENSG00000261318.1	RP11-653J6.1	4.74	2.79e-06	0.000632	0.28	0.21	Testicular germ cell tumor;	chr15:66275773	chr15:66278498~66293357:-
LUAD	cis	rs6840360	1	rs6841783	ENSG00000270265.1	RP11-731D1.4	-4.74	2.79e-06	0.000632	-0.21	-0.21	Intelligence (multi-trait analysis);	chr4:151677724	chr4:151333775~151353224:-
LUAD	cis	rs55823223	0.68	rs57287238	ENSG00000267801.1	RP11-552F3.9	4.74	2.79e-06	0.000633	0.24	0.21	Psoriasis;	chr17:75854859	chr17:75876372~75879546:+
LUAD	cis	rs453301	0.631	rs11780774	ENSG00000173295.6	FAM86B3P	-4.74	2.79e-06	0.000633	-0.23	-0.21	Joint mobility (Beighton score);	chr8:8941601	chr8:8228595~8244865:+
LUAD	cis	rs4237845	1	rs4237845	ENSG00000257159.1	RP11-58A17.3	-4.74	2.79e-06	0.000633	-0.25	-0.21	Intelligence (multi-trait analysis);	chr12:57908653	chr12:57967058~57968399:+
LUAD	cis	rs516805	0.748	rs155463	ENSG00000279453.1	RP3-425C14.4	-4.74	2.79e-06	0.000633	-0.29	-0.21	Lymphocyte counts;	chr6:122501474	chr6:122436789~122439223:-
LUAD	cis	rs74233809	1	rs77602510	ENSG00000213277.3	MARCKSL1P1	4.74	2.79e-06	0.000633	0.37	0.21	Birth weight;	chr10:102922845	chr10:103175554~103176094:+
LUAD	cis	rs74233809	1	rs78821730	ENSG00000213277.3	MARCKSL1P1	4.74	2.79e-06	0.000633	0.37	0.21	Birth weight;	chr10:102924787	chr10:103175554~103176094:+
LUAD	cis	rs559928	0.947	rs12417275	ENSG00000236935.1	AP003774.1	4.74	2.79e-06	0.000633	0.29	0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64376302	chr11:64325050~64329504:-
LUAD	cis	rs897984	0.806	rs10782001	ENSG00000260911.2	RP11-196G11.2	-4.74	2.79e-06	0.000633	-0.19	-0.21	Dementia with Lewy bodies;	chr16:30931304	chr16:31043150~31049868:+
LUAD	cis	rs897984	0.806	rs12928852	ENSG00000260911.2	RP11-196G11.2	-4.74	2.79e-06	0.000633	-0.19	-0.21	Dementia with Lewy bodies;	chr16:30932667	chr16:31043150~31049868:+
LUAD	cis	rs910316	0.967	rs8007539	ENSG00000259138.1	RP11-950C14.7	-4.74	2.79e-06	0.000633	-0.22	-0.21	Height;	chr14:75198250	chr14:75127153~75136930:+
LUAD	cis	rs2028299	1	rs1371135	ENSG00000259677.1	RP11-493E3.1	4.74	2.79e-06	0.000633	0.25	0.21	Type 2 diabetes;	chr15:89848038	chr15:89876540~89877285:+
LUAD	cis	rs8127691	0.967	rs2070551	ENSG00000237604.1	AP001056.1	4.74	2.79e-06	0.000634	0.25	0.21	Inflammatory bowel disease;	chr21:44196789	chr21:44175489~44176453:+
LUAD	cis	rs1012068	0.81	rs5998140	ENSG00000236132.1	CTA-440B3.1	-4.74	2.79e-06	0.000634	-0.28	-0.21	Chronic hepatitis C infection;	chr22:31845961	chr22:31816379~31817491:-
LUAD	cis	rs950169	0.922	rs12910334	ENSG00000229212.6	RP11-561C5.4	-4.74	2.79e-06	0.000634	-0.31	-0.21	Schizophrenia;	chr15:84403620	chr15:85205440~85234795:-
LUAD	cis	rs2880765	0.743	rs12906308	ENSG00000259295.5	CSPG4P12	-4.74	2.79e-06	0.000634	-0.24	-0.21	Coronary artery disease;	chr15:85464828	chr15:85191438~85213905:+
LUAD	cis	rs2880765	0.743	rs8039049	ENSG00000259295.5	CSPG4P12	4.74	2.79e-06	0.000634	0.24	0.21	Coronary artery disease;	chr15:85464398	chr15:85191438~85213905:+
LUAD	cis	rs2880765	0.743	rs8039631	ENSG00000259295.5	CSPG4P12	4.74	2.79e-06	0.000634	0.24	0.21	Coronary artery disease;	chr15:85464700	chr15:85191438~85213905:+
LUAD	cis	rs561341	0.556	rs542244	ENSG00000265798.5	RP11-271K11.5	4.74	2.79e-06	0.000634	0.34	0.21	Hip circumference adjusted for BMI;	chr17:31980223	chr17:31038575~31059121:-
LUAD	cis	rs13113518	0.812	rs1522114	ENSG00000223305.1	RN7SKP30	4.74	2.8e-06	0.000634	0.25	0.21	Height;	chr4:55489895	chr4:55540502~55540835:-
LUAD	cis	rs7208859	0.673	rs216409	ENSG00000280069.1	CTD-2349P21.3	4.74	2.8e-06	0.000635	0.25	0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30579251	chr17:30738182~30740275:+
LUAD	cis	rs9287719	0.649	rs10186984	ENSG00000243819.4	RN7SL832P	-4.74	2.8e-06	0.000635	-0.23	-0.21	Prostate cancer;	chr2:10594066	chr2:10690344~10692099:+
LUAD	cis	rs875971	0.54	rs35510581	ENSG00000224316.1	RP11-479O9.2	-4.74	2.8e-06	0.000635	-0.22	-0.21	Aortic root size;	chr7:66113790	chr7:65773620~65802067:+
LUAD	cis	rs9322193	0.962	rs3763163	ENSG00000268592.3	RAET1E-AS1	4.74	2.8e-06	0.000636	0.26	0.21	Lung cancer;	chr6:149819770	chr6:149863494~149919507:+
LUAD	cis	rs7324557	0.93	rs7324545	ENSG00000205861.10	C1QTNF9B-AS1	4.74	2.8e-06	0.000636	0.28	0.21	Visceral adipose tissue adjusted for BMI;	chr13:23722702	chr13:23888889~23897263:+
LUAD	cis	rs559928	1	rs559928	ENSG00000236935.1	AP003774.1	-4.74	2.8e-06	0.000636	-0.25	-0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64382898	chr11:64325050~64329504:-
LUAD	cis	rs2736345	0.516	rs7844858	ENSG00000270154.1	RP11-419I17.1	4.74	2.8e-06	0.000636	0.24	0.21	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11535150	chr8:12476462~12477122:+
LUAD	cis	rs6840360	0.901	rs1443094	ENSG00000270265.1	RP11-731D1.4	-4.74	2.8e-06	0.000636	-0.21	-0.21	Intelligence (multi-trait analysis);	chr4:151535572	chr4:151333775~151353224:-
LUAD	cis	rs9860428	0.844	rs9845041	ENSG00000242770.2	RP11-180K7.1	4.74	2.81e-06	0.000637	0.22	0.21	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112905212	chr3:112802478~112812819:+
LUAD	cis	rs375066	0.901	rs376457	ENSG00000267058.1	RP11-15A1.3	-4.74	2.81e-06	0.000637	-0.24	-0.21	Breast cancer;	chr19:43908605	chr19:43891804~43901805:-
LUAD	cis	rs375066	0.935	rs430667	ENSG00000267058.1	RP11-15A1.3	-4.74	2.81e-06	0.000637	-0.24	-0.21	Breast cancer;	chr19:43909101	chr19:43891804~43901805:-
LUAD	cis	rs375066	0.935	rs398964	ENSG00000267058.1	RP11-15A1.3	-4.74	2.81e-06	0.000637	-0.24	-0.21	Breast cancer;	chr19:43909732	chr19:43891804~43901805:-
LUAD	cis	rs375066	0.935	rs439665	ENSG00000267058.1	RP11-15A1.3	-4.74	2.81e-06	0.000637	-0.24	-0.21	Breast cancer;	chr19:43910315	chr19:43891804~43901805:-
LUAD	cis	rs910316	0.967	rs175479	ENSG00000259138.1	RP11-950C14.7	-4.74	2.81e-06	0.000637	-0.22	-0.21	Height;	chr14:75095168	chr14:75127153~75136930:+
LUAD	cis	rs2153535	0.585	rs9505512	ENSG00000230939.1	RP11-314C16.1	-4.74	2.81e-06	0.000637	-0.24	-0.21	Motion sickness;	chr6:8667337	chr6:8784178~8785445:+
LUAD	cis	rs6840360	1	rs6845944	ENSG00000270265.1	RP11-731D1.4	-4.74	2.81e-06	0.000637	-0.22	-0.21	Intelligence (multi-trait analysis);	chr4:151683368	chr4:151333775~151353224:-
LUAD	cis	rs4835473	0.897	rs13144504	ENSG00000251600.4	RP11-673E1.1	-4.74	2.81e-06	0.000638	-0.27	-0.21	Immature fraction of reticulocytes;	chr4:143707402	chr4:143912331~143982454:+
LUAD	cis	rs8098244	0.617	rs7244406	ENSG00000264745.1	TTC39C-AS1	4.74	2.81e-06	0.000638	0.22	0.21	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23820041	chr18:23994213~24015339:-
LUAD	cis	rs7189233	0.531	rs8055279	ENSG00000279344.1	RP11-44F14.7	4.74	2.81e-06	0.000638	0.17	0.21	Intelligence (multi-trait analysis);	chr16:53488837	chr16:53478957~53481550:-
LUAD	cis	rs375066	0.935	rs426534	ENSG00000267058.1	RP11-15A1.3	-4.74	2.81e-06	0.000638	-0.24	-0.21	Breast cancer;	chr19:43908431	chr19:43891804~43901805:-
LUAD	cis	rs17711722	0.585	rs6942660	ENSG00000224316.1	RP11-479O9.2	4.74	2.82e-06	0.000638	0.21	0.21	Calcium levels;	chr7:65837419	chr7:65773620~65802067:+
LUAD	cis	rs17711722	0.64	rs13237956	ENSG00000224316.1	RP11-479O9.2	4.74	2.82e-06	0.000638	0.21	0.21	Calcium levels;	chr7:65853042	chr7:65773620~65802067:+
LUAD	cis	rs853679	1	rs1679732	ENSG00000204709.4	LINC01556	-4.74	2.82e-06	0.000639	-0.32	-0.21	Depression;	chr6:28253486	chr6:28943877~28944537:+
LUAD	cis	rs6840258	1	rs7682652	ENSG00000251411.1	RP11-397E7.4	-4.74	2.82e-06	0.000639	-0.27	-0.21	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86992292	chr4:86913266~86914817:-
LUAD	cis	rs6570726	0.791	rs621382	ENSG00000235652.6	RP11-545I5.3	4.74	2.82e-06	0.000639	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145478008	chr6:145799409~145886585:+
LUAD	cis	rs61270009	0.874	rs780403	ENSG00000247828.6	TMEM161B-AS1	-4.74	2.82e-06	0.000639	-0.24	-0.21	Depressive symptoms;	chr5:88244989	chr5:88268895~88436685:+
LUAD	cis	rs699371	0.507	rs10149787	ENSG00000259005.1	RP3-449M8.6	-4.74	2.82e-06	0.000639	-0.22	-0.21	Height;	chr14:74458749	chr14:74474007~74474864:-
LUAD	cis	rs9487094	0.813	rs13195517	ENSG00000260273.1	RP11-425D10.10	4.74	2.82e-06	0.00064	0.29	0.21	Height;	chr6:109415050	chr6:109382795~109383666:+
LUAD	cis	rs6751744	0.855	rs10206214	ENSG00000226266.5	AC009961.3	-4.74	2.82e-06	0.00064	-0.32	-0.21	Dysphagia;	chr2:159507781	chr2:159670708~159712435:-
LUAD	cis	rs6496932	0.503	rs7170370	ENSG00000202081.1	RNU6-1280P	-4.74	2.82e-06	0.00064	-0.27	-0.21	Central corneal thickness;Corneal structure;	chr15:85414505	chr15:85651522~85651628:-
LUAD	cis	rs240993	0.715	rs6920798	ENSG00000230177.1	RP5-1112D6.4	4.74	2.82e-06	0.00064	0.21	0.21	Inflammatory skin disease;Psoriasis;	chr6:111526074	chr6:111277932~111278742:+
LUAD	cis	rs6088590	1	rs6119530	ENSG00000276073.1	RP5-1125A11.7	-4.74	2.82e-06	0.00064	-0.22	-0.21	Coronary artery disease;	chr20:34816127	chr20:33985617~33988989:-
LUAD	cis	rs11673344	0.704	rs1644711	ENSG00000226686.6	LINC01535	4.74	2.82e-06	0.00064	0.26	0.21	Obesity-related traits;	chr19:36926420	chr19:37251912~37265535:+
LUAD	cis	rs11673344	0.704	rs826262	ENSG00000226686.6	LINC01535	4.74	2.82e-06	0.00064	0.26	0.21	Obesity-related traits;	chr19:36928540	chr19:37251912~37265535:+
LUAD	cis	rs11673344	0.704	rs485034	ENSG00000226686.6	LINC01535	4.74	2.82e-06	0.00064	0.26	0.21	Obesity-related traits;	chr19:36931455	chr19:37251912~37265535:+
LUAD	cis	rs11673344	0.704	rs517110	ENSG00000226686.6	LINC01535	4.74	2.82e-06	0.00064	0.26	0.21	Obesity-related traits;	chr19:36931492	chr19:37251912~37265535:+
LUAD	cis	rs17301013	0.861	rs332796	ENSG00000227373.4	RP11-160H22.5	4.74	2.82e-06	0.00064	0.26	0.21	Systemic lupus erythematosus;	chr1:174727142	chr1:174115300~174160004:-
LUAD	cis	rs7119	0.717	rs8033654	ENSG00000259362.2	RP11-307C19.1	-4.74	2.82e-06	0.00064	-0.27	-0.21	Type 2 diabetes;	chr15:77532908	chr15:77525540~77534110:+
LUAD	cis	rs7119	0.717	rs8033067	ENSG00000259362.2	RP11-307C19.1	-4.74	2.82e-06	0.00064	-0.27	-0.21	Type 2 diabetes;	chr15:77533153	chr15:77525540~77534110:+
LUAD	cis	rs950169	0.734	rs67119537	ENSG00000229212.6	RP11-561C5.4	-4.74	2.82e-06	0.00064	-0.28	-0.21	Schizophrenia;	chr15:84395671	chr15:85205440~85234795:-
LUAD	cis	rs6687758	1	rs12739936	ENSG00000200033.1	RNU6-403P	4.74	2.83e-06	0.000641	0.29	0.21	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222009847	chr1:221837334~221837437:-
LUAD	cis	rs2735413	0.564	rs11859770	ENSG00000276007.1	RP11-358L22.3	4.74	2.83e-06	0.000641	0.29	0.21	Systolic blood pressure (alcohol consumption interaction);	chr16:78092837	chr16:78123243~78124332:+
LUAD	cis	rs4908760	0.864	rs12136766	ENSG00000270282.1	RP5-1115A15.2	4.74	2.83e-06	0.000641	0.23	0.21	Vitiligo;	chr1:8603762	chr1:8512653~8513021:+
LUAD	cis	rs34783982	0.881	rs2351489	ENSG00000261441.1	RP11-217B1.2	-4.74	2.83e-06	0.000641	-0.27	-0.21	Squamous cell lung carcinoma;	chr15:88958639	chr15:89335053~89336161:+
LUAD	cis	rs2911132	0.621	rs17480169	ENSG00000248734.2	CTD-2260A17.1	4.74	2.83e-06	0.000641	0.23	0.21	Urate levels (BMI interaction);	chr5:96753363	chr5:96784777~96785999:+
LUAD	cis	rs9813712	0.595	rs1993217	ENSG00000249846.5	RP11-77P16.4	-4.74	2.83e-06	0.000641	-0.25	-0.21	Response to amphetamines;	chr3:130284832	chr3:130112550~130120579:+
LUAD	cis	rs875971	0.522	rs10807697	ENSG00000237310.1	GS1-124K5.4	4.74	2.83e-06	0.000641	0.22	0.21	Aortic root size;	chr7:65951183	chr7:66493706~66495474:+
LUAD	cis	rs8072100	0.935	rs12943464	ENSG00000228782.6	CTD-2026D20.3	-4.74	2.83e-06	0.000641	-0.22	-0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47612985	chr17:47450568~47492492:-
LUAD	cis	rs8072100	0.935	rs4793978	ENSG00000228782.6	CTD-2026D20.3	-4.74	2.83e-06	0.000641	-0.22	-0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47620809	chr17:47450568~47492492:-
LUAD	cis	rs9584850	0.834	rs7334078	ENSG00000231194.1	FARP1-AS1	-4.74	2.83e-06	0.000641	-0.25	-0.21	Neuroticism;	chr13:98468230	chr13:98435405~98435840:-
LUAD	cis	rs9303029	1	rs60529510	ENSG00000265458.1	RP13-20L14.6	4.74	2.83e-06	0.000641	0.39	0.21	Protein quantitative trait loci;	chr17:82449604	chr17:82454273~82458521:-
LUAD	cis	rs4927850	1	rs7614767	ENSG00000242086.7	LINC00969	4.74	2.83e-06	0.000641	0.19	0.21	Pancreatic cancer;	chr3:196026580	chr3:195658062~195739964:+
LUAD	cis	rs2153535	0.585	rs9379238	ENSG00000230939.1	RP11-314C16.1	-4.74	2.83e-06	0.000641	-0.24	-0.21	Motion sickness;	chr6:8667806	chr6:8784178~8785445:+
LUAD	cis	rs9473147	0.516	rs13212790	ENSG00000270761.1	RP11-385F7.1	-4.74	2.83e-06	0.000642	-0.24	-0.21	Platelet distribution width;Mean platelet volume;	chr6:47608631	chr6:47477243~47477572:-
LUAD	cis	rs6969780	0.63	rs10238095	ENSG00000233429.8	HOTAIRM1	-4.74	2.83e-06	0.000642	-0.31	-0.21	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27157024	chr7:27095647~27100265:+
LUAD	cis	rs1823913	0.538	rs6731901	ENSG00000280083.1	RP11-317J9.1	-4.74	2.83e-06	0.000642	-0.26	-0.21	Obesity-related traits;	chr2:191353609	chr2:191154118~191156070:-
LUAD	cis	rs8180040	0.62	rs1811652	ENSG00000271161.1	BOLA2P2	-4.74	2.83e-06	0.000642	-0.2	-0.21	Colorectal cancer;	chr3:47167208	chr3:47499841~47500407:+
LUAD	cis	rs8180040	0.654	rs62246451	ENSG00000271161.1	BOLA2P2	-4.74	2.83e-06	0.000642	-0.2	-0.21	Colorectal cancer;	chr3:47170142	chr3:47499841~47500407:+
LUAD	cis	rs375066	0.901	rs372491	ENSG00000267058.1	RP11-15A1.3	-4.74	2.83e-06	0.000642	-0.24	-0.21	Breast cancer;	chr19:43897641	chr19:43891804~43901805:-
LUAD	cis	rs375066	0.868	rs453950	ENSG00000267058.1	RP11-15A1.3	-4.74	2.83e-06	0.000642	-0.24	-0.21	Breast cancer;	chr19:43898903	chr19:43891804~43901805:-
LUAD	cis	rs375066	0.934	rs440784	ENSG00000267058.1	RP11-15A1.3	-4.74	2.83e-06	0.000642	-0.24	-0.21	Breast cancer;	chr19:43900190	chr19:43891804~43901805:-
LUAD	cis	rs375066	0.901	rs374307	ENSG00000267058.1	RP11-15A1.3	-4.74	2.83e-06	0.000642	-0.24	-0.21	Breast cancer;	chr19:43900246	chr19:43891804~43901805:-
LUAD	cis	rs375066	0.967	rs441344	ENSG00000267058.1	RP11-15A1.3	-4.74	2.83e-06	0.000642	-0.24	-0.21	Breast cancer;	chr19:43900530	chr19:43891804~43901805:-
LUAD	cis	rs375066	0.935	rs398099	ENSG00000267058.1	RP11-15A1.3	-4.74	2.83e-06	0.000642	-0.24	-0.21	Breast cancer;	chr19:43901129	chr19:43891804~43901805:-
LUAD	cis	rs375066	0.935	rs385321	ENSG00000267058.1	RP11-15A1.3	-4.74	2.83e-06	0.000642	-0.24	-0.21	Breast cancer;	chr19:43901135	chr19:43891804~43901805:-
LUAD	cis	rs375066	0.967	rs376328	ENSG00000267058.1	RP11-15A1.3	-4.74	2.83e-06	0.000642	-0.24	-0.21	Breast cancer;	chr19:43903335	chr19:43891804~43901805:-
LUAD	cis	rs375066	0.935	rs365556	ENSG00000267058.1	RP11-15A1.3	-4.74	2.83e-06	0.000642	-0.24	-0.21	Breast cancer;	chr19:43904047	chr19:43891804~43901805:-
LUAD	cis	rs375066	0.901	rs451945	ENSG00000267058.1	RP11-15A1.3	-4.74	2.83e-06	0.000642	-0.24	-0.21	Breast cancer;	chr19:43904601	chr19:43891804~43901805:-
LUAD	cis	rs375066	0.934	rs454813	ENSG00000267058.1	RP11-15A1.3	-4.74	2.83e-06	0.000642	-0.24	-0.21	Breast cancer;	chr19:43904821	chr19:43891804~43901805:-
LUAD	cis	rs375066	0.967	rs417400	ENSG00000267058.1	RP11-15A1.3	-4.74	2.83e-06	0.000642	-0.24	-0.21	Breast cancer;	chr19:43906694	chr19:43891804~43901805:-
LUAD	cis	rs7299940	0.967	rs9738957	ENSG00000256250.1	RP11-989F5.1	4.74	2.83e-06	0.000642	0.24	0.21	Panic disorder;	chr12:130904256	chr12:130810606~130812438:+
LUAD	cis	rs9425766	0.541	rs12691474	ENSG00000227373.4	RP11-160H22.5	4.74	2.83e-06	0.000642	0.26	0.21	Life satisfaction;	chr1:174200867	chr1:174115300~174160004:-
LUAD	cis	rs7493	0.901	rs17882539	ENSG00000233942.1	AC004012.1	4.74	2.83e-06	0.000642	0.3	0.21	Yu-Zhi constitution type in type 2 diabetes;	chr7:95397096	chr7:95471835~95473998:+
LUAD	cis	rs10129255	0.957	rs10140904	ENSG00000211967.3	IGHV3-53	-4.74	2.83e-06	0.000642	-0.17	-0.21	Kawasaki disease;	chr14:106776558	chr14:106592676~106593347:-
LUAD	cis	rs4366055	1	rs4366055	ENSG00000254315.1	RP11-267M23.3	4.74	2.83e-06	0.000642	0.26	0.21	Body mass index;	chr8:94495100	chr8:94533628~94534391:+
LUAD	cis	rs12701220	0.817	rs1058729	ENSG00000229043.2	AC091729.9	-4.74	2.83e-06	0.000642	-0.27	-0.21	Bronchopulmonary dysplasia;	chr7:1047647	chr7:1160374~1165267:+
LUAD	cis	rs559928	1	rs641168	ENSG00000236935.1	AP003774.1	-4.74	2.84e-06	0.000642	-0.26	-0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64378817	chr11:64325050~64329504:-
LUAD	cis	rs12022452	0.822	rs11811369	ENSG00000238287.1	RP11-656D10.3	-4.74	2.84e-06	0.000642	-0.33	-0.21	Age-related hearing impairment (SNP x SNP interaction);	chr1:40560611	chr1:40493157~40508661:-
LUAD	cis	rs17772222	0.876	rs12436982	ENSG00000258983.2	RP11-507K2.2	4.74	2.84e-06	0.000643	0.26	0.21	Coronary artery calcification;	chr14:88689862	chr14:88499334~88515502:+
LUAD	cis	rs860295	0.557	rs7534795	ENSG00000225855.5	RUSC1-AS1	4.74	2.84e-06	0.000643	0.15	0.21	Body mass index;	chr1:155305762	chr1:155316863~155324176:-
LUAD	cis	rs7598759	0.679	rs6437018	ENSG00000181798.2	LINC00471	-4.74	2.84e-06	0.000643	-0.24	-0.21	Noise-induced hearing loss;	chr2:231462980	chr2:231508426~231514339:-
LUAD	cis	rs7598759	0.679	rs6437019	ENSG00000181798.2	LINC00471	-4.74	2.84e-06	0.000643	-0.24	-0.21	Noise-induced hearing loss;	chr2:231462996	chr2:231508426~231514339:-
LUAD	cis	rs477895	0.838	rs12794145	ENSG00000236935.1	AP003774.1	-4.74	2.84e-06	0.000643	-0.25	-0.21	Mean platelet volume;	chr11:64239012	chr11:64325050~64329504:-
LUAD	cis	rs30380	1	rs30379	ENSG00000248734.2	CTD-2260A17.1	4.74	2.84e-06	0.000643	0.22	0.21	Cerebrospinal fluid biomarker levels;	chr5:96786556	chr5:96784777~96785999:+
LUAD	cis	rs30380	1	rs30380	ENSG00000248734.2	CTD-2260A17.1	4.74	2.84e-06	0.000643	0.22	0.21	Cerebrospinal fluid biomarker levels;	chr5:96786577	chr5:96784777~96785999:+
LUAD	cis	rs10995356	0.932	rs10995370	ENSG00000238280.1	RP11-436D10.3	-4.74	2.84e-06	0.000644	-0.26	-0.21	Temperament;	chr10:62926803	chr10:62793562~62805887:-
LUAD	cis	rs559928	1	rs72926046	ENSG00000236935.1	AP003774.1	4.74	2.84e-06	0.000644	0.29	0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64375915	chr11:64325050~64329504:-
LUAD	cis	rs559928	1	rs72926050	ENSG00000236935.1	AP003774.1	4.74	2.84e-06	0.000644	0.29	0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64376102	chr11:64325050~64329504:-
LUAD	cis	rs12908161	0.959	rs12906348	ENSG00000275120.1	RP11-182J1.17	4.74	2.84e-06	0.000644	0.32	0.21	Schizophrenia;	chr15:84786190	chr15:84599434~84606463:-
LUAD	cis	rs6088590	0.901	rs6087631	ENSG00000276073.1	RP5-1125A11.7	-4.74	2.84e-06	0.000644	-0.21	-0.21	Coronary artery disease;	chr20:34815706	chr20:33985617~33988989:-
LUAD	cis	rs73242632	0.881	rs7699276	ENSG00000269949.1	RP11-738E22.3	4.74	2.85e-06	0.000645	0.54	0.21	Congenital heart disease (maternal effect);	chr4:57057391	chr4:56960927~56961373:-
LUAD	cis	rs1600249	0.562	rs17153419	ENSG00000270154.1	RP11-419I17.1	-4.74	2.85e-06	0.000645	-0.27	-0.21	Rheumatoid arthritis;	chr8:11536724	chr8:12476462~12477122:+
LUAD	cis	rs1876905	0.68	rs3749867	ENSG00000272356.1	RP5-1112D6.8	-4.74	2.85e-06	0.000645	-0.24	-0.21	Mean corpuscular hemoglobin;	chr6:111103615	chr6:111309203~111313517:+
LUAD	cis	rs9545047	0.604	rs7986306	ENSG00000227354.5	RBM26-AS1	4.74	2.85e-06	0.000645	0.22	0.21	Schizophrenia;	chr13:79392530	chr13:79406309~79424328:+
LUAD	cis	rs7598759	0.679	rs10202701	ENSG00000181798.2	LINC00471	4.74	2.85e-06	0.000645	0.24	0.21	Noise-induced hearing loss;	chr2:231463970	chr2:231508426~231514339:-
LUAD	cis	rs8180040	0.654	rs9837343	ENSG00000271161.1	BOLA2P2	4.74	2.85e-06	0.000645	0.2	0.21	Colorectal cancer;	chr3:47135898	chr3:47499841~47500407:+
LUAD	cis	rs10266483	0.705	rs1111649	ENSG00000228653.2	HNRNPCP7	-4.74	2.85e-06	0.000645	-0.26	-0.21	Response to statin therapy;	chr7:64296435	chr7:64500825~64501729:+
LUAD	cis	rs8180040	0.715	rs6772670	ENSG00000271161.1	BOLA2P2	4.74	2.85e-06	0.000645	0.2	0.21	Colorectal cancer;	chr3:47149859	chr3:47499841~47500407:+
LUAD	cis	rs8180040	0.764	rs11712716	ENSG00000271161.1	BOLA2P2	4.74	2.85e-06	0.000645	0.2	0.21	Colorectal cancer;	chr3:47151942	chr3:47499841~47500407:+
LUAD	cis	rs8180040	0.764	rs12629262	ENSG00000271161.1	BOLA2P2	4.74	2.85e-06	0.000645	0.2	0.21	Colorectal cancer;	chr3:47155090	chr3:47499841~47500407:+
LUAD	cis	rs8180040	0.764	rs11708451	ENSG00000271161.1	BOLA2P2	4.74	2.85e-06	0.000645	0.2	0.21	Colorectal cancer;	chr3:47157336	chr3:47499841~47500407:+
LUAD	cis	rs910316	0.967	rs4903293	ENSG00000259138.1	RP11-950C14.7	-4.74	2.85e-06	0.000645	-0.22	-0.21	Height;	chr14:75189865	chr14:75127153~75136930:+
LUAD	cis	rs2742234	0.91	rs2505505	ENSG00000273008.1	RP11-351D16.3	-4.74	2.85e-06	0.000645	-0.23	-0.21	Hirschsprung disease;	chr10:43152773	chr10:43136824~43138334:-
LUAD	cis	rs4664293	0.51	rs72961751	ENSG00000226266.5	AC009961.3	4.74	2.85e-06	0.000646	0.29	0.21	Monocyte percentage of white cells;	chr2:159738067	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.903	rs10185155	ENSG00000226266.5	AC009961.3	-4.74	2.85e-06	0.000646	-0.3	-0.21	Monocyte percentage of white cells;	chr2:159696717	chr2:159670708~159712435:-
LUAD	cis	rs2243480	0.706	rs34466769	ENSG00000226002.1	RP11-460N20.5	-4.74	2.85e-06	0.000646	-0.31	-0.21	Diabetic kidney disease;	chr7:65988305	chr7:65084103~65100232:+
LUAD	cis	rs34779708	0.966	rs2045915	ENSG00000271335.4	RP11-324I22.4	4.74	2.85e-06	0.000646	0.22	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35129688	chr10:35314552~35336401:-
LUAD	cis	rs9926296	0.712	rs2434872	ENSG00000260259.1	RP11-368I7.4	4.74	2.85e-06	0.000646	0.21	0.21	Vitiligo;	chr16:89650507	chr16:89682620~89686569:-
LUAD	cis	rs9303029	0.8	rs9896620	ENSG00000265458.1	RP13-20L14.6	4.74	2.85e-06	0.000646	0.38	0.21	Protein quantitative trait loci;	chr17:82453331	chr17:82454273~82458521:-
LUAD	cis	rs17772222	0.74	rs11845147	ENSG00000258789.1	RP11-507K2.3	-4.74	2.86e-06	0.000647	-0.28	-0.21	Coronary artery calcification;	chr14:88502804	chr14:88551597~88552493:+
LUAD	cis	rs7772486	0.774	rs6930181	ENSG00000235652.6	RP11-545I5.3	-4.74	2.86e-06	0.000647	-0.21	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145859838	chr6:145799409~145886585:+
LUAD	cis	rs6679677	0.543	rs1230680	ENSG00000232450.1	RP4-730K3.3	-4.74	2.86e-06	0.000647	-0.37	-0.21	Rheumatoid arthritis;Monokine induced by gamma interferon levels;Type 1 diabetes;Hypothyroidism;Systemic lupus erythematosus;Pediatric autoimmune diseases;Crohn's disease;Antineutrophil cytoplasmic antibody-associated vasculitis;	chr1:113754148	chr1:113698884~113699631:-
LUAD	cis	rs7727544	0.716	rs4705928	ENSG00000233006.5	AC034220.3	-4.74	2.86e-06	0.000648	-0.19	-0.21	Blood metabolite levels;	chr5:132242944	chr5:132311285~132369916:-
LUAD	cis	rs2243480	1	rs316313	ENSG00000164669.11	INTS4P1	4.74	2.86e-06	0.000648	0.38	0.21	Diabetic kidney disease;	chr7:66128561	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs316312	ENSG00000164669.11	INTS4P1	4.74	2.86e-06	0.000648	0.38	0.21	Diabetic kidney disease;	chr7:66131504	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs419603	ENSG00000164669.11	INTS4P1	4.74	2.86e-06	0.000648	0.38	0.21	Diabetic kidney disease;	chr7:66132354	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs387676	ENSG00000164669.11	INTS4P1	4.74	2.86e-06	0.000648	0.38	0.21	Diabetic kidney disease;	chr7:66133233	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs13310597	ENSG00000164669.11	INTS4P1	4.74	2.86e-06	0.000648	0.38	0.21	Diabetic kidney disease;	chr7:66133553	chr7:65141225~65234216:+
LUAD	cis	rs6840360	1	rs6535811	ENSG00000270265.1	RP11-731D1.4	-4.74	2.86e-06	0.000648	-0.21	-0.21	Intelligence (multi-trait analysis);	chr4:151677840	chr4:151333775~151353224:-
LUAD	cis	rs7107174	1	rs1385601	ENSG00000251323.2	RP11-452H21.4	4.74	2.86e-06	0.000648	0.26	0.21	Testicular germ cell tumor;	chr11:78225018	chr11:78423982~78429836:-
LUAD	cis	rs6539288	0.834	rs1545097	ENSG00000260329.1	RP11-412D9.4	-4.74	2.87e-06	0.000649	-0.23	-0.21	Total body bone mineral density;	chr12:106919918	chr12:106954029~106955497:-
LUAD	cis	rs6539288	0.899	rs6539292	ENSG00000260329.1	RP11-412D9.4	-4.74	2.87e-06	0.000649	-0.23	-0.21	Total body bone mineral density;	chr12:106919935	chr12:106954029~106955497:-
LUAD	cis	rs2286503	0.78	rs1304431	ENSG00000221740.1	SNORD93	4.74	2.87e-06	0.000649	0.24	0.21	Fibrinogen;	chr7:22825793	chr7:22856613~22856686:+
LUAD	cis	rs6802315	1	rs6802315	ENSG00000272247.1	RP11-379F4.9	-4.74	2.87e-06	0.000649	-0.23	-0.21	Periodontitis (CDC/AAP);	chr3:158796571	chr3:158801257~158801935:-
LUAD	cis	rs453301	0.653	rs1045529	ENSG00000253981.4	ALG1L13P	-4.74	2.87e-06	0.000649	-0.25	-0.21	Joint mobility (Beighton score);	chr8:9032588	chr8:8236003~8244667:-
LUAD	cis	rs1707322	1	rs4660905	ENSG00000280836.1	AL355480.1	4.74	2.87e-06	0.000649	0.27	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995915	chr1:45581219~45581321:-
LUAD	cis	rs17772222	0.917	rs12434935	ENSG00000258983.2	RP11-507K2.2	4.74	2.87e-06	0.00065	0.26	0.21	Coronary artery calcification;	chr14:88645449	chr14:88499334~88515502:+
LUAD	cis	rs2742234	0.955	rs2503865	ENSG00000273008.1	RP11-351D16.3	-4.74	2.87e-06	0.00065	-0.23	-0.21	Hirschsprung disease;	chr10:43164088	chr10:43136824~43138334:-
LUAD	cis	rs2998286	0.723	rs332139	ENSG00000254635.4	WAC-AS1	-4.74	2.87e-06	0.00065	-0.28	-0.21	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28570150	chr10:28522652~28532743:-
LUAD	cis	rs11089937	0.626	rs2213161	ENSG00000211638.2	IGLV8-61	-4.74	2.87e-06	0.00065	-0.26	-0.21	Periodontitis (PAL4Q3);	chr22:22143005	chr22:22098700~22099212:+
LUAD	cis	rs801193	1	rs2659915	ENSG00000236529.1	RP13-254B10.1	4.74	2.87e-06	0.00065	0.22	0.21	Aortic root size;	chr7:66688114	chr7:65840212~65840596:+
LUAD	cis	rs1008375	0.686	rs34338142	ENSG00000249502.1	AC006160.5	-4.74	2.88e-06	0.000651	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17624551	chr4:17587467~17614571:-
LUAD	cis	rs11673344	0.764	rs10424584	ENSG00000226686.6	LINC01535	4.74	2.88e-06	0.000651	0.27	0.21	Obesity-related traits;	chr19:36975986	chr19:37251912~37265535:+
LUAD	cis	rs4908760	0.965	rs10864354	ENSG00000270282.1	RP5-1115A15.2	4.74	2.88e-06	0.000651	0.24	0.21	Vitiligo;	chr1:8489681	chr1:8512653~8513021:+
LUAD	cis	rs9910055	0.659	rs227578	ENSG00000267080.4	ASB16-AS1	4.74	2.88e-06	0.000651	0.19	0.21	Total body bone mineral density;	chr17:44132821	chr17:44175973~44186717:-
LUAD	cis	rs2439831	0.85	rs61390361	ENSG00000249839.1	AC011330.5	-4.74	2.88e-06	0.000651	-0.45	-0.21	Lung cancer in ever smokers;	chr15:43867644	chr15:43663654~43684339:-
LUAD	cis	rs7968440	0.966	rs7977742	ENSG00000200428.1	Y_RNA	-4.74	2.88e-06	0.000651	-0.26	-0.21	Fibrinogen;	chr12:50736424	chr12:50743568~50743684:+
LUAD	cis	rs12681420	0.665	rs67705199	ENSG00000223220.1	Y_RNA	4.74	2.88e-06	0.000651	0.24	0.21	Erythrocyte cadmium concentration in never smokers;	chr8:70695170	chr8:70780914~70781008:-
LUAD	cis	rs8062405	0.789	rs2106480	ENSG00000251417.2	RP11-1348G14.4	-4.74	2.88e-06	0.000651	-0.21	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28802743~28817828:+
LUAD	cis	rs9545047	0.564	rs7336186	ENSG00000227354.5	RBM26-AS1	-4.74	2.88e-06	0.000652	-0.22	-0.21	Schizophrenia;	chr13:79385497	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs2182009	ENSG00000227354.5	RBM26-AS1	-4.74	2.88e-06	0.000652	-0.22	-0.21	Schizophrenia;	chr13:79397781	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs4605023	ENSG00000227354.5	RBM26-AS1	-4.74	2.88e-06	0.000652	-0.22	-0.21	Schizophrenia;	chr13:79398700	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs9565496	ENSG00000227354.5	RBM26-AS1	-4.74	2.88e-06	0.000652	-0.22	-0.21	Schizophrenia;	chr13:79398751	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs12877507	ENSG00000227354.5	RBM26-AS1	-4.74	2.88e-06	0.000652	-0.22	-0.21	Schizophrenia;	chr13:79401822	chr13:79406309~79424328:+
LUAD	cis	rs1008375	1	rs10939742	ENSG00000249502.1	AC006160.5	-4.74	2.88e-06	0.000652	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17658313	chr4:17587467~17614571:-
LUAD	cis	rs6604026	0.59	rs2051841	ENSG00000223787.2	RP4-593M8.1	4.74	2.88e-06	0.000652	0.29	0.21	Multiple sclerosis;	chr1:92690638	chr1:92580476~92580821:-
LUAD	cis	rs6604026	0.59	rs11577426	ENSG00000223787.2	RP4-593M8.1	4.74	2.88e-06	0.000652	0.29	0.21	Multiple sclerosis;	chr1:92694681	chr1:92580476~92580821:-
LUAD	cis	rs42490	0.868	rs1605996	ENSG00000251136.7	RP11-37B2.1	4.73	2.89e-06	0.000653	0.21	0.21	Leprosy;	chr8:89655674	chr8:89609409~89757727:-
LUAD	cis	rs13256369	1	rs4841016	ENSG00000253893.2	FAM85B	-4.73	2.89e-06	0.000653	-0.29	-0.21	Obesity-related traits;	chr8:8715051	chr8:8167819~8226614:-
LUAD	cis	rs13315649	0.525	rs62270822	ENSG00000242551.2	POU5F1P6	-4.73	2.89e-06	0.000653	-0.27	-0.21	Sum eosinophil basophil counts;	chr3:128683677	chr3:128674735~128677005:-
LUAD	cis	rs5758659	1	rs5758677	ENSG00000182057.4	OGFRP1	4.73	2.89e-06	0.000654	0.25	0.21	Cognitive function;	chr22:42247033	chr22:42269753~42275196:+
LUAD	cis	rs9910055	0.529	rs170637	ENSG00000267080.4	ASB16-AS1	4.73	2.89e-06	0.000654	0.2	0.21	Total body bone mineral density;	chr17:44109500	chr17:44175973~44186717:-
LUAD	cis	rs1546924	0.647	rs197422	ENSG00000227811.2	FAM212B-AS1	-4.73	2.89e-06	0.000654	-0.26	-0.21	Body mass index;	chr1:111774890	chr1:111739841~111747798:+
LUAD	cis	rs7116495	1	rs2845857	ENSG00000254682.1	RP11-660L16.2	4.73	2.89e-06	0.000654	0.46	0.21	Severe influenza A (H1N1) infection;	chr11:72004169	chr11:71448674~71452157:+
LUAD	cis	rs7017914	0.644	rs13258800	ENSG00000223220.1	Y_RNA	4.73	2.89e-06	0.000654	0.25	0.21	Bone mineral density;	chr8:70819867	chr8:70780914~70781008:-
LUAD	cis	rs3893377	0.848	rs10023845	ENSG00000214846.4	RP11-115L11.1	-4.73	2.89e-06	0.000654	-0.31	-0.21	Current cigarettes per day in chronic obstructive pulmonary disease;	chr4:15739628	chr4:15730962~15731627:-
LUAD	cis	rs6539288	0.901	rs1444580	ENSG00000260329.1	RP11-412D9.4	-4.73	2.9e-06	0.000655	-0.23	-0.21	Total body bone mineral density;	chr12:106920780	chr12:106954029~106955497:-
LUAD	cis	rs12908161	0.959	rs17598603	ENSG00000259728.4	LINC00933	-4.73	2.9e-06	0.000655	-0.3	-0.21	Schizophrenia;	chr15:84656980	chr15:84570649~84580175:+
LUAD	cis	rs2880765	0.527	rs35184622	ENSG00000259295.5	CSPG4P12	4.73	2.9e-06	0.000655	0.26	0.21	Coronary artery disease;	chr15:85529804	chr15:85191438~85213905:+
LUAD	cis	rs2880765	0.527	rs1483578	ENSG00000259295.5	CSPG4P12	4.73	2.9e-06	0.000655	0.26	0.21	Coronary artery disease;	chr15:85532186	chr15:85191438~85213905:+
LUAD	cis	rs11089937	0.637	rs988200	ENSG00000211638.2	IGLV8-61	-4.73	2.9e-06	0.000655	-0.26	-0.21	Periodontitis (PAL4Q3);	chr22:22154715	chr22:22098700~22099212:+
LUAD	cis	rs6840360	0.967	rs7667197	ENSG00000270265.1	RP11-731D1.4	-4.73	2.9e-06	0.000655	-0.21	-0.21	Intelligence (multi-trait analysis);	chr4:151692800	chr4:151333775~151353224:-
LUAD	cis	rs5758659	1	rs5758660	ENSG00000182057.4	OGFRP1	4.73	2.9e-06	0.000655	0.25	0.21	Cognitive function;	chr22:42227712	chr22:42269753~42275196:+
LUAD	cis	rs7493	0.95	rs17166868	ENSG00000233942.1	AC004012.1	4.73	2.9e-06	0.000656	0.3	0.21	Yu-Zhi constitution type in type 2 diabetes;	chr7:95404104	chr7:95471835~95473998:+
LUAD	cis	rs6012564	1	rs2295714	ENSG00000230758.1	SNAP23P	4.73	2.9e-06	0.000656	0.22	0.21	Anger;	chr20:49123277	chr20:49038357~49038602:-
LUAD	cis	rs2243480	0.901	rs2456483	ENSG00000226002.1	RP11-460N20.5	-4.73	2.9e-06	0.000656	-0.35	-0.21	Diabetic kidney disease;	chr7:65996588	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs1701750	ENSG00000226002.1	RP11-460N20.5	-4.73	2.9e-06	0.000656	-0.35	-0.21	Diabetic kidney disease;	chr7:66002158	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs1701758	ENSG00000226002.1	RP11-460N20.5	-4.73	2.9e-06	0.000656	-0.35	-0.21	Diabetic kidney disease;	chr7:66005214	chr7:65084103~65100232:+
LUAD	cis	rs2243480	0.901	rs1701759	ENSG00000226002.1	RP11-460N20.5	-4.73	2.9e-06	0.000656	-0.35	-0.21	Diabetic kidney disease;	chr7:66005945	chr7:65084103~65100232:+
LUAD	cis	rs2288073	0.965	rs10185445	ENSG00000242628.4	AC009228.1	-4.73	2.9e-06	0.000657	-0.29	-0.21	Venous thromboembolism (SNP x SNP interaction);	chr2:24188107	chr2:24214381~24221516:+
LUAD	cis	rs2976388	0.609	rs2376491	ENSG00000253741.1	CTD-2292P10.4	-4.73	2.91e-06	0.000657	-0.24	-0.21	Urinary tract infection frequency;	chr8:142709516	chr8:142702252~142726973:-
LUAD	cis	rs240993	0.812	rs6929024	ENSG00000230177.1	RP5-1112D6.4	4.73	2.91e-06	0.000657	0.23	0.21	Inflammatory skin disease;Psoriasis;	chr6:111545104	chr6:111277932~111278742:+
LUAD	cis	rs9473147	0.543	rs4711878	ENSG00000270761.1	RP11-385F7.1	-4.73	2.91e-06	0.000658	-0.25	-0.21	Platelet distribution width;Mean platelet volume;	chr6:47488382	chr6:47477243~47477572:-
LUAD	cis	rs9473147	0.516	rs6931478	ENSG00000270761.1	RP11-385F7.1	-4.73	2.91e-06	0.000658	-0.25	-0.21	Platelet distribution width;Mean platelet volume;	chr6:47494177	chr6:47477243~47477572:-
LUAD	cis	rs9369695	0.881	rs9349409	ENSG00000270761.1	RP11-385F7.1	-4.73	2.91e-06	0.000658	-0.25	-0.21	Reticulocyte count;	chr6:47495390	chr6:47477243~47477572:-
LUAD	cis	rs9369695	0.842	rs9395262	ENSG00000270761.1	RP11-385F7.1	-4.73	2.91e-06	0.000658	-0.25	-0.21	Reticulocyte count;	chr6:47497531	chr6:47477243~47477572:-
LUAD	cis	rs7829975	0.714	rs4840362	ENSG00000253981.4	ALG1L13P	-4.73	2.91e-06	0.000658	-0.24	-0.21	Mood instability;	chr8:8812572	chr8:8236003~8244667:-
LUAD	cis	rs6772849	0.901	rs9289330	ENSG00000242551.2	POU5F1P6	-4.73	2.91e-06	0.000658	-0.23	-0.21	Monocyte percentage of white cells;Monocyte count;	chr3:128592224	chr3:128674735~128677005:-
LUAD	cis	rs5758511	0.633	rs5751258	ENSG00000205702.9	CYP2D7	4.73	2.91e-06	0.000658	0.2	0.21	Birth weight;	chr22:42267865	chr22:42140203~42144577:-
LUAD	cis	rs9322193	0.923	rs1984111	ENSG00000268592.3	RAET1E-AS1	4.73	2.91e-06	0.000658	0.26	0.21	Lung cancer;	chr6:149831720	chr6:149863494~149919507:+
LUAD	cis	rs7493	0.851	rs11770903	ENSG00000233942.1	AC004012.1	4.73	2.91e-06	0.000658	0.3	0.21	Yu-Zhi constitution type in type 2 diabetes;	chr7:95397015	chr7:95471835~95473998:+
LUAD	cis	rs160451	0.966	rs1603289	ENSG00000251136.7	RP11-37B2.1	4.73	2.91e-06	0.000658	0.21	0.21	Leprosy;	chr8:89655405	chr8:89609409~89757727:-
LUAD	cis	rs11155671	0.53	rs9397420	ENSG00000268592.3	RAET1E-AS1	-4.73	2.91e-06	0.000658	-0.26	-0.21	Testicular germ cell tumor;	chr6:149885645	chr6:149863494~149919507:+
LUAD	cis	rs73173548	0.502	rs10452479	ENSG00000247828.6	TMEM161B-AS1	4.73	2.91e-06	0.000658	0.25	0.21	Macular telangiectasia type 2;	chr5:88445131	chr5:88268895~88436685:+
LUAD	cis	rs1062177	0.756	rs2915827	ENSG00000253921.1	CTB-113P19.3	4.73	2.91e-06	0.000658	0.3	0.21	Preschool internalizing problems;	chr5:151740144	chr5:151753992~151767247:+
LUAD	cis	rs17772222	0.837	rs57118463	ENSG00000258983.2	RP11-507K2.2	4.73	2.91e-06	0.000658	0.26	0.21	Coronary artery calcification;	chr14:88665822	chr14:88499334~88515502:+
LUAD	cis	rs1707322	1	rs10890365	ENSG00000280836.1	AL355480.1	-4.73	2.91e-06	0.000658	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893676	chr1:45581219~45581321:-
LUAD	cis	rs7208859	0.673	rs9913782	ENSG00000263603.1	CTD-2349P21.5	-4.73	2.92e-06	0.000659	-0.39	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910366	chr17:30729469~30731202:+
LUAD	cis	rs5758511	0.68	rs17002902	ENSG00000226450.2	CYP2D8P	4.73	2.92e-06	0.000659	0.2	0.21	Birth weight;	chr22:42229503	chr22:42149886~42155001:-
LUAD	cis	rs5758511	0.68	rs5758662	ENSG00000226450.2	CYP2D8P	4.73	2.92e-06	0.000659	0.2	0.21	Birth weight;	chr22:42232082	chr22:42149886~42155001:-
LUAD	cis	rs55823223	0.68	rs3744017	ENSG00000267801.1	RP11-552F3.9	4.73	2.92e-06	0.000659	0.25	0.21	Psoriasis;	chr17:75875386	chr17:75876372~75879546:+
LUAD	cis	rs948562	0.523	rs11827480	ENSG00000280010.1	AP001350.4	4.73	2.92e-06	0.000659	0.29	0.21	Lymphoma;	chr11:58665251	chr11:58627435~58628528:+
LUAD	cis	rs1150668	0.83	rs2859365	ENSG00000219392.1	RP1-265C24.5	4.73	2.92e-06	0.00066	0.26	0.21	Pubertal anthropometrics;	chr6:28423688	chr6:28115628~28116551:+
LUAD	cis	rs17711722	0.701	rs4467826	ENSG00000224316.1	RP11-479O9.2	4.73	2.92e-06	0.00066	0.21	0.21	Calcium levels;	chr7:65903721	chr7:65773620~65802067:+
LUAD	cis	rs763121	0.889	rs1837988	ENSG00000228274.3	RP3-508I15.9	-4.73	2.92e-06	0.00066	-0.22	-0.21	Menopause (age at onset);	chr22:38505089	chr22:38667585~38681820:-
LUAD	cis	rs301901	1	rs13176880	ENSG00000250155.1	CTD-2353F22.1	-4.73	2.92e-06	0.00066	-0.22	-0.21	Height;	chr5:37081780	chr5:36666214~36725195:-
LUAD	cis	rs2732480	0.577	rs2450994	ENSG00000240399.1	RP1-228P16.1	4.73	2.92e-06	0.000661	0.21	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48328049	chr12:48054813~48055591:-
LUAD	cis	rs559928	0.606	rs55942618	ENSG00000236935.1	AP003774.1	4.73	2.93e-06	0.000661	0.31	0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64168533	chr11:64325050~64329504:-
LUAD	cis	rs559928	0.606	rs76653616	ENSG00000236935.1	AP003774.1	4.73	2.93e-06	0.000661	0.31	0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64168667	chr11:64325050~64329504:-
LUAD	cis	rs1150668	0.796	rs1124132	ENSG00000219392.1	RP1-265C24.5	-4.73	2.93e-06	0.000661	-0.26	-0.21	Pubertal anthropometrics;	chr6:28412544	chr6:28115628~28116551:+
LUAD	cis	rs559928	1	rs7105178	ENSG00000236935.1	AP003774.1	-4.73	2.93e-06	0.000661	-0.27	-0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64377637	chr11:64325050~64329504:-
LUAD	cis	rs17301013	0.861	rs61826916	ENSG00000227373.4	RP11-160H22.5	4.73	2.93e-06	0.000661	0.27	0.21	Systemic lupus erythematosus;	chr1:174616048	chr1:174115300~174160004:-
LUAD	cis	rs9322193	0.884	rs9480009	ENSG00000268592.3	RAET1E-AS1	4.73	2.93e-06	0.000661	0.26	0.21	Lung cancer;	chr6:149758502	chr6:149863494~149919507:+
LUAD	cis	rs2243480	0.901	rs2949697	ENSG00000226002.1	RP11-460N20.5	-4.73	2.93e-06	0.000662	-0.36	-0.21	Diabetic kidney disease;	chr7:65999249	chr7:65084103~65100232:+
LUAD	cis	rs7829975	0.681	rs2271342	ENSG00000173295.6	FAM86B3P	4.73	2.93e-06	0.000662	0.22	0.21	Mood instability;	chr8:8786428	chr8:8228595~8244865:+
LUAD	cis	rs6687821	0.834	rs263479	ENSG00000267734.1	RP4-604K5.3	4.73	2.93e-06	0.000662	0.25	0.21	Yeast infection;	chr1:86739278	chr1:86932199~86934891:-
LUAD	cis	rs13256369	1	rs885000	ENSG00000253893.2	FAM85B	-4.73	2.93e-06	0.000662	-0.29	-0.21	Obesity-related traits;	chr8:8711365	chr8:8167819~8226614:-
LUAD	cis	rs2348418	0.765	rs4931734	ENSG00000247934.4	RP11-967K21.1	-4.73	2.93e-06	0.000662	-0.24	-0.21	Lung function (FEV1);Lung function (FVC);	chr12:28196661	chr12:28163298~28190738:-
LUAD	cis	rs17301013	0.828	rs332783	ENSG00000227373.4	RP11-160H22.5	4.73	2.93e-06	0.000662	0.26	0.21	Systemic lupus erythematosus;	chr1:174719260	chr1:174115300~174160004:-
LUAD	cis	rs7829975	0.606	rs7819827	ENSG00000253893.2	FAM85B	4.73	2.94e-06	0.000663	0.26	0.21	Mood instability;	chr8:8939545	chr8:8167819~8226614:-
LUAD	cis	rs7829975	0.573	rs7842359	ENSG00000253893.2	FAM85B	4.73	2.94e-06	0.000663	0.26	0.21	Mood instability;	chr8:8939568	chr8:8167819~8226614:-
LUAD	cis	rs160451	0.934	rs34036322	ENSG00000251136.7	RP11-37B2.1	4.73	2.94e-06	0.000663	0.21	0.21	Leprosy;	chr8:89654670	chr8:89609409~89757727:-
LUAD	cis	rs507080	1	rs507080	ENSG00000278376.1	RP11-158I9.8	-4.73	2.94e-06	0.000663	-0.23	-0.21	Serum metabolite levels;	chr11:118678873	chr11:118791254~118793137:+
LUAD	cis	rs1876905	0.539	rs240980	ENSG00000255389.1	C6orf3	-4.73	2.94e-06	0.000663	-0.29	-0.21	Mean corpuscular hemoglobin;	chr6:111288707	chr6:111599875~111602295:+
LUAD	cis	rs7772486	0.738	rs2246334	ENSG00000235652.6	RP11-545I5.3	4.73	2.94e-06	0.000663	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145862499	chr6:145799409~145886585:+
LUAD	cis	rs2243480	1	rs35396113	ENSG00000226002.1	RP11-460N20.5	-4.73	2.94e-06	0.000664	-0.36	-0.21	Diabetic kidney disease;	chr7:66030474	chr7:65084103~65100232:+
LUAD	cis	rs4908760	0.613	rs2401189	ENSG00000232912.4	RP5-1115A15.1	4.73	2.94e-06	0.000664	0.19	0.21	Vitiligo;	chr1:8758541	chr1:8424645~8434838:+
LUAD	cis	rs5769707	0.749	rs8137251	ENSG00000235111.1	RP1-29C18.8	-4.73	2.94e-06	0.000664	-0.24	-0.21	Monocyte percentage of white cells;Monocyte count;	chr22:49643021	chr22:49612657~49615716:-
LUAD	cis	rs72772090	1	rs72772095	ENSG00000248734.2	CTD-2260A17.1	-4.73	2.94e-06	0.000664	-0.31	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96718149	chr5:96784777~96785999:+
LUAD	cis	rs57502260	0.915	rs7106320	ENSG00000212093.1	AP000807.1	4.73	2.94e-06	0.000664	0.28	0.21	Total body bone mineral density (age 45-60);	chr11:68442650	chr11:68506083~68506166:-
LUAD	cis	rs7172677	1	rs7172677	ENSG00000260269.4	CTD-2323K18.1	4.73	2.94e-06	0.000664	0.28	0.21	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75132252	chr15:75527150~75601205:-
LUAD	cis	rs1008375	0.902	rs12503164	ENSG00000249502.1	AC006160.5	-4.73	2.94e-06	0.000664	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17654484	chr4:17587467~17614571:-
LUAD	cis	rs561341	0.882	rs504887	ENSG00000265798.5	RP11-271K11.5	4.73	2.94e-06	0.000664	0.33	0.21	Hip circumference adjusted for BMI;	chr17:31995862	chr17:31038575~31059121:-
LUAD	cis	rs7017914	0.606	rs2035928	ENSG00000223220.1	Y_RNA	4.73	2.94e-06	0.000664	0.24	0.21	Bone mineral density;	chr8:71001320	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.606	rs2035927	ENSG00000223220.1	Y_RNA	4.73	2.94e-06	0.000664	0.24	0.21	Bone mineral density;	chr8:71001325	chr8:70780914~70781008:-
LUAD	cis	rs1008375	1	rs11737138	ENSG00000249502.1	AC006160.5	-4.73	2.94e-06	0.000664	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17656363	chr4:17587467~17614571:-
LUAD	cis	rs1008375	1	rs2109522	ENSG00000249502.1	AC006160.5	-4.73	2.94e-06	0.000664	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17657022	chr4:17587467~17614571:-
LUAD	cis	rs2858942	0.602	rs1211375	ENSG00000268836.1	LA16c-OS12.2	-4.73	2.95e-06	0.000665	-0.2	-0.21	Mean corpuscular hemoglobin;	chr16:190281	chr16:185748~186294:-
LUAD	cis	rs2310173	0.575	rs4851527	ENSG00000281162.1	LINC01127	4.73	2.95e-06	0.000665	0.24	0.21	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:102005914	chr2:101962056~101987167:+
LUAD	cis	rs7493	1	rs2068604	ENSG00000233942.1	AC004012.1	4.73	2.95e-06	0.000666	0.31	0.21	Yu-Zhi constitution type in type 2 diabetes;	chr7:95412230	chr7:95471835~95473998:+
LUAD	cis	rs34779708	0.966	rs12762493	ENSG00000271335.4	RP11-324I22.4	4.73	2.95e-06	0.000666	0.22	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35182945	chr10:35314552~35336401:-
LUAD	cis	rs780096	0.587	rs6760828	ENSG00000234072.1	AC074117.10	-4.73	2.95e-06	0.000666	-0.16	-0.21	Total body bone mineral density;	chr2:27356364	chr2:27356246~27367622:+
LUAD	cis	rs2304003	1	rs10930182	ENSG00000235192.1	AC009495.2	4.73	2.96e-06	0.000667	0.25	0.21	Social communication problems;	chr2:165831678	chr2:165794851~165810010:+
LUAD	cis	rs1008375	0.966	rs11733730	ENSG00000249502.1	AC006160.5	-4.73	2.96e-06	0.000667	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17623586	chr4:17587467~17614571:-
LUAD	cis	rs61270009	0.955	rs780397	ENSG00000247828.6	TMEM161B-AS1	-4.73	2.96e-06	0.000667	-0.24	-0.21	Depressive symptoms;	chr5:88233841	chr5:88268895~88436685:+
LUAD	cis	rs2243480	1	rs316332	ENSG00000164669.11	INTS4P1	4.73	2.96e-06	0.000668	0.37	0.21	Diabetic kidney disease;	chr7:66139312	chr7:65141225~65234216:+
LUAD	cis	rs5769707	0.681	rs135879	ENSG00000235111.1	RP1-29C18.8	-4.73	2.96e-06	0.000668	-0.25	-0.21	Monocyte percentage of white cells;Monocyte count;	chr22:49625003	chr22:49612657~49615716:-
LUAD	cis	rs5769707	0.642	rs135880	ENSG00000235111.1	RP1-29C18.8	-4.73	2.96e-06	0.000668	-0.25	-0.21	Monocyte percentage of white cells;Monocyte count;	chr22:49625006	chr22:49612657~49615716:-
LUAD	cis	rs4660214	0.724	rs10788933	ENSG00000228060.1	RP11-69E11.8	4.73	2.96e-06	0.000668	0.19	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39229483	chr1:39565160~39573203:+
LUAD	cis	rs6061231	1	rs11908473	ENSG00000273619.1	RP5-908M14.9	-4.73	2.96e-06	0.000668	-0.22	-0.21	Colorectal cancer;	chr20:62382714	chr20:62386303~62386970:-
LUAD	cis	rs9322193	0.923	rs9404048	ENSG00000268592.3	RAET1E-AS1	4.73	2.96e-06	0.000668	0.26	0.21	Lung cancer;	chr6:149616188	chr6:149863494~149919507:+
LUAD	cis	rs13113518	0.729	rs13120134	ENSG00000223305.1	RN7SKP30	4.73	2.96e-06	0.000668	0.26	0.21	Height;	chr4:55415153	chr4:55540502~55540835:-
LUAD	cis	rs7017914	0.69	rs13280922	ENSG00000223220.1	Y_RNA	4.73	2.96e-06	0.000668	0.24	0.21	Bone mineral density;	chr8:70713163	chr8:70780914~70781008:-
LUAD	cis	rs10995356	0.932	rs10822084	ENSG00000238280.1	RP11-436D10.3	-4.73	2.96e-06	0.000668	-0.26	-0.21	Temperament;	chr10:62918211	chr10:62793562~62805887:-
LUAD	cis	rs7086627	0.515	rs6585994	ENSG00000226659.1	RP11-137H2.4	-4.73	2.96e-06	0.000668	-0.27	-0.21	Post bronchodilator FEV1;	chr10:80431887	chr10:80529597~80535942:-
LUAD	cis	rs9322193	0.566	rs3922947	ENSG00000223701.3	RAET1E-AS1	-4.73	2.96e-06	0.000669	-0.29	-0.21	Lung cancer;	chr6:149924856	chr6:149884431~149919508:+
LUAD	cis	rs6570726	0.905	rs421032	ENSG00000235652.6	RP11-545I5.3	4.73	2.97e-06	0.000669	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145506635	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs9390329	ENSG00000235652.6	RP11-545I5.3	4.73	2.97e-06	0.000669	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145506890	chr6:145799409~145886585:+
LUAD	cis	rs860295	0.702	rs2048431	ENSG00000225855.5	RUSC1-AS1	4.73	2.97e-06	0.00067	0.15	0.21	Body mass index;	chr1:155648839	chr1:155316863~155324176:-
LUAD	cis	rs9910055	0.529	rs228767	ENSG00000267080.4	ASB16-AS1	4.73	2.97e-06	0.00067	0.19	0.21	Total body bone mineral density;	chr17:44110943	chr17:44175973~44186717:-
LUAD	cis	rs150992	0.603	rs246251	ENSG00000248489.1	CTD-2007H13.3	4.73	2.97e-06	0.00067	0.27	0.21	Body mass index;	chr5:98942362	chr5:98929171~98995013:+
LUAD	cis	rs559928	0.597	rs11600667	ENSG00000236935.1	AP003774.1	4.73	2.97e-06	0.00067	0.3	0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64208711	chr11:64325050~64329504:-
LUAD	cis	rs338389	0.933	rs338398	ENSG00000260657.2	RP11-315D16.4	-4.73	2.97e-06	0.00067	-0.24	-0.21	Survival in rectal cancer;	chr15:67962253	chr15:68267792~68277994:-
LUAD	cis	rs950169	0.922	rs11631096	ENSG00000229212.6	RP11-561C5.4	-4.73	2.97e-06	0.00067	-0.3	-0.21	Schizophrenia;	chr15:84557698	chr15:85205440~85234795:-
LUAD	cis	rs7119	0.651	rs12917431	ENSG00000259362.2	RP11-307C19.1	-4.73	2.97e-06	0.00067	-0.26	-0.21	Type 2 diabetes;	chr15:77557842	chr15:77525540~77534110:+
LUAD	cis	rs9926296	0.712	rs459920	ENSG00000260259.1	RP11-368I7.4	4.73	2.97e-06	0.000671	0.2	0.21	Vitiligo;	chr16:89664419	chr16:89682620~89686569:-
LUAD	cis	rs453301	0.658	rs13271797	ENSG00000173295.6	FAM86B3P	-4.73	2.98e-06	0.000671	-0.23	-0.21	Joint mobility (Beighton score);	chr8:9028444	chr8:8228595~8244865:+
LUAD	cis	rs9473147	0.543	rs4715019	ENSG00000270761.1	RP11-385F7.1	-4.73	2.98e-06	0.000671	-0.25	-0.21	Platelet distribution width;Mean platelet volume;	chr6:47479305	chr6:47477243~47477572:-
LUAD	cis	rs4664293	0.647	rs6714917	ENSG00000226266.5	AC009961.3	-4.73	2.98e-06	0.000672	-0.28	-0.21	Monocyte percentage of white cells;	chr2:159592942	chr2:159670708~159712435:-
LUAD	cis	rs11157436	0.918	rs11157426	ENSG00000211813.2	TRAV34	4.73	2.98e-06	0.000672	0.25	0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22153691	chr14:22207522~22208129:+
LUAD	cis	rs11157436	0.918	rs11157427	ENSG00000211813.2	TRAV34	4.73	2.98e-06	0.000672	0.25	0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22154291	chr14:22207522~22208129:+
LUAD	cis	rs11157436	0.792	rs12433875	ENSG00000211813.2	TRAV34	4.73	2.98e-06	0.000672	0.25	0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22154490	chr14:22207522~22208129:+
LUAD	cis	rs7493	1	rs2299263	ENSG00000233942.1	AC004012.1	-4.73	2.98e-06	0.000672	-0.3	-0.21	Yu-Zhi constitution type in type 2 diabetes;	chr7:95411099	chr7:95471835~95473998:+
LUAD	cis	rs2919009	0.607	rs11199682	ENSG00000271670.1	RP11-95I16.4	4.73	2.98e-06	0.000672	0.27	0.21	Obesity-related traits;	chr10:120958339	chr10:120879256~120880667:-
LUAD	cis	rs897984	0.762	rs7206511	ENSG00000260911.2	RP11-196G11.2	-4.73	2.98e-06	0.000672	-0.19	-0.21	Dementia with Lewy bodies;	chr16:30939031	chr16:31043150~31049868:+
LUAD	cis	rs393155	0.517	rs330050	ENSG00000253981.4	ALG1L13P	-4.73	2.98e-06	0.000672	-0.24	-0.21	Neuroticism;	chr8:9230169	chr8:8236003~8244667:-
LUAD	cis	rs4664293	0.647	rs6711049	ENSG00000226266.5	AC009961.3	-4.73	2.98e-06	0.000672	-0.28	-0.21	Monocyte percentage of white cells;	chr2:159584634	chr2:159670708~159712435:-
LUAD	cis	rs17826219	0.636	rs12946563	ENSG00000263603.1	CTD-2349P21.5	-4.73	2.98e-06	0.000672	-0.37	-0.21	Body mass index;	chr17:30776148	chr17:30729469~30731202:+
LUAD	cis	rs6012564	0.929	rs4810898	ENSG00000230758.1	SNAP23P	-4.73	2.98e-06	0.000673	-0.22	-0.21	Anger;	chr20:48937855	chr20:49038357~49038602:-
LUAD	cis	rs559928	0.948	rs1198984	ENSG00000236935.1	AP003774.1	-4.73	2.99e-06	0.000673	-0.26	-0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64380948	chr11:64325050~64329504:-
LUAD	cis	rs1008375	0.966	rs4698636	ENSG00000249502.1	AC006160.5	-4.73	2.99e-06	0.000673	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17631211	chr4:17587467~17614571:-
LUAD	cis	rs8028182	0.537	rs4371118	ENSG00000260274.1	RP11-817O13.8	-4.73	2.99e-06	0.000673	-0.26	-0.21	Sudden cardiac arrest;	chr15:75606549	chr15:75368155~75369584:+
LUAD	cis	rs7208859	0.573	rs73267873	ENSG00000263603.1	CTD-2349P21.5	-4.73	2.99e-06	0.000673	-0.34	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741439	chr17:30729469~30731202:+
LUAD	cis	rs17826219	0.561	rs4085382	ENSG00000263603.1	CTD-2349P21.5	-4.73	2.99e-06	0.000673	-0.34	-0.21	Body mass index;	chr17:30744184	chr17:30729469~30731202:+
LUAD	cis	rs61542988	0.532	rs10240168	ENSG00000228649.7	AC005682.5	4.73	2.99e-06	0.000674	0.29	0.21	Fibrinogen levels;	chr7:22779715	chr7:22854178~22861579:+
LUAD	cis	rs1008375	1	rs3815414	ENSG00000249502.1	AC006160.5	4.73	2.99e-06	0.000674	0.2	0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17605036	chr4:17587467~17614571:-
LUAD	cis	rs507080	0.961	rs1784298	ENSG00000278376.1	RP11-158I9.8	-4.73	2.99e-06	0.000674	-0.22	-0.21	Serum metabolite levels;	chr11:118677956	chr11:118791254~118793137:+
LUAD	cis	rs507080	0.961	rs4938522	ENSG00000278376.1	RP11-158I9.8	-4.73	2.99e-06	0.000674	-0.22	-0.21	Serum metabolite levels;	chr11:118677962	chr11:118791254~118793137:+
LUAD	cis	rs507080	1	rs659969	ENSG00000278376.1	RP11-158I9.8	-4.73	2.99e-06	0.000674	-0.22	-0.21	Serum metabolite levels;	chr11:118679094	chr11:118791254~118793137:+
LUAD	cis	rs453301	0.686	rs4840389	ENSG00000173295.6	FAM86B3P	-4.73	2.99e-06	0.000674	-0.23	-0.21	Joint mobility (Beighton score);	chr8:9026993	chr8:8228595~8244865:+
LUAD	cis	rs12745968	0.652	rs4970700	ENSG00000223787.2	RP4-593M8.1	4.73	2.99e-06	0.000675	0.26	0.21	Bipolar disorder and schizophrenia;	chr1:92509936	chr1:92580476~92580821:-
LUAD	cis	rs4664293	0.647	rs7587700	ENSG00000226266.5	AC009961.3	-4.73	3e-06	0.000675	-0.28	-0.21	Monocyte percentage of white cells;	chr2:159587809	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.647	rs7595044	ENSG00000226266.5	AC009961.3	-4.73	3e-06	0.000675	-0.28	-0.21	Monocyte percentage of white cells;	chr2:159589694	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.647	rs12623149	ENSG00000226266.5	AC009961.3	-4.73	3e-06	0.000675	-0.28	-0.21	Monocyte percentage of white cells;	chr2:159590835	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.647	rs6432539	ENSG00000226266.5	AC009961.3	-4.73	3e-06	0.000675	-0.28	-0.21	Monocyte percentage of white cells;	chr2:159592209	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.631	rs6714899	ENSG00000226266.5	AC009961.3	-4.73	3e-06	0.000675	-0.28	-0.21	Monocyte percentage of white cells;	chr2:159592895	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.647	rs6734085	ENSG00000226266.5	AC009961.3	-4.73	3e-06	0.000675	-0.28	-0.21	Monocyte percentage of white cells;	chr2:159595711	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.647	rs4665090	ENSG00000226266.5	AC009961.3	-4.73	3e-06	0.000675	-0.28	-0.21	Monocyte percentage of white cells;	chr2:159597396	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.647	rs4635484	ENSG00000226266.5	AC009961.3	-4.73	3e-06	0.000675	-0.28	-0.21	Monocyte percentage of white cells;	chr2:159597619	chr2:159670708~159712435:-
LUAD	cis	rs6840360	1	rs6849050	ENSG00000270265.1	RP11-731D1.4	-4.73	3e-06	0.000675	-0.21	-0.21	Intelligence (multi-trait analysis);	chr4:151678750	chr4:151333775~151353224:-
LUAD	cis	rs5758659	1	rs5758659	ENSG00000182057.4	OGFRP1	4.73	3e-06	0.000675	0.25	0.21	Cognitive function;	chr22:42225997	chr22:42269753~42275196:+
LUAD	cis	rs6840360	1	rs6535818	ENSG00000270265.1	RP11-731D1.4	-4.73	3e-06	0.000675	-0.21	-0.21	Intelligence (multi-trait analysis);	chr4:151729730	chr4:151333775~151353224:-
LUAD	cis	rs6840360	1	rs28637056	ENSG00000270265.1	RP11-731D1.4	-4.73	3e-06	0.000675	-0.21	-0.21	Intelligence (multi-trait analysis);	chr4:151731349	chr4:151333775~151353224:-
LUAD	cis	rs6558530	0.653	rs6984632	ENSG00000253982.1	CTD-2336O2.1	4.73	3e-06	0.000675	0.27	0.21	Systolic blood pressure;	chr8:1752268	chr8:1761990~1764502:-
LUAD	cis	rs925255	0.81	rs7574996	ENSG00000270210.1	RP11-373D23.3	4.73	3e-06	0.000675	0.25	0.21	Inflammatory bowel disease;Crohn's disease;	chr2:28420656	chr2:28425945~28426719:+
LUAD	cis	rs6142102	0.961	rs2235596	ENSG00000275784.1	RP5-1125A11.6	4.73	3e-06	0.000676	0.23	0.21	Skin pigmentation;	chr20:34096503	chr20:33989480~33991818:-
LUAD	cis	rs1008375	1	rs4698198	ENSG00000249502.1	AC006160.5	-4.73	3e-06	0.000676	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17654913	chr4:17587467~17614571:-
LUAD	cis	rs1008375	1	rs4698199	ENSG00000249502.1	AC006160.5	-4.73	3e-06	0.000676	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17655115	chr4:17587467~17614571:-
LUAD	cis	rs7493	1	rs7786401	ENSG00000233942.1	AC004012.1	4.73	3e-06	0.000676	0.3	0.21	Yu-Zhi constitution type in type 2 diabetes;	chr7:95404689	chr7:95471835~95473998:+
LUAD	cis	rs7208859	0.673	rs12103759	ENSG00000263603.1	CTD-2349P21.5	-4.73	3e-06	0.000676	-0.39	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908669	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs59029591	ENSG00000263603.1	CTD-2349P21.5	-4.73	3e-06	0.000676	-0.39	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908728	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs73265633	ENSG00000263603.1	CTD-2349P21.5	-4.73	3e-06	0.000676	-0.39	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30909288	chr17:30729469~30731202:+
LUAD	cis	rs2749097	0.825	rs2749100	ENSG00000244256.3	RN7SL130P	4.73	3e-06	0.000676	0.25	0.21	Alcohol consumption (transferrin glycosylation);	chr1:63659308	chr1:63655743~63656047:+
LUAD	cis	rs12928939	0.862	rs7197104	ENSG00000260886.1	TAT-AS1	4.73	3e-06	0.000676	0.27	0.21	Post bronchodilator FEV1;	chr16:71760158	chr16:71565789~71578187:+
LUAD	cis	rs1555322	0.53	rs2425044	ENSG00000126005.14	MMP24-AS1	-4.73	3e-06	0.000676	-0.3	-0.21	Attention deficit hyperactivity disorder;	chr20:35281932	chr20:35216462~35278131:-
LUAD	cis	rs6840360	1	rs1864300	ENSG00000270265.1	RP11-731D1.4	-4.73	3e-06	0.000676	-0.21	-0.21	Intelligence (multi-trait analysis);	chr4:151742174	chr4:151333775~151353224:-
LUAD	cis	rs6840360	1	rs12331037	ENSG00000270265.1	RP11-731D1.4	-4.73	3e-06	0.000676	-0.21	-0.21	Intelligence (multi-trait analysis);	chr4:151742819	chr4:151333775~151353224:-
LUAD	cis	rs6840360	1	rs28710456	ENSG00000270265.1	RP11-731D1.4	-4.73	3e-06	0.000676	-0.21	-0.21	Intelligence (multi-trait analysis);	chr4:151746019	chr4:151333775~151353224:-
LUAD	cis	rs7826238	0.623	rs2976893	ENSG00000173295.6	FAM86B3P	-4.73	3e-06	0.000677	-0.21	-0.21	Systolic blood pressure;	chr8:8480709	chr8:8228595~8244865:+
LUAD	cis	rs1008375	0.966	rs6833808	ENSG00000249502.1	AC006160.5	-4.73	3.01e-06	0.000677	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17650903	chr4:17587467~17614571:-
LUAD	cis	rs8180040	0.726	rs13094672	ENSG00000271161.1	BOLA2P2	4.73	3.01e-06	0.000678	0.2	0.21	Colorectal cancer;	chr3:47107949	chr3:47499841~47500407:+
LUAD	cis	rs293748	0.657	rs16903342	ENSG00000250155.1	CTD-2353F22.1	-4.73	3.01e-06	0.000678	-0.29	-0.21	Obesity-related traits;	chr5:36792480	chr5:36666214~36725195:-
LUAD	cis	rs4660214	0.666	rs7414381	ENSG00000228060.1	RP11-69E11.8	4.73	3.01e-06	0.000678	0.19	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39275848	chr1:39565160~39573203:+
LUAD	cis	rs4660214	0.666	rs3116387	ENSG00000228060.1	RP11-69E11.8	4.73	3.01e-06	0.000678	0.19	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39277197	chr1:39565160~39573203:+
LUAD	cis	rs2735413	0.564	rs73578735	ENSG00000276007.1	RP11-358L22.3	4.73	3.01e-06	0.000678	0.29	0.21	Systolic blood pressure (alcohol consumption interaction);	chr16:78071039	chr16:78123243~78124332:+
LUAD	cis	rs853679	0.567	rs7740429	ENSG00000216901.1	AL022393.7	4.73	3.01e-06	0.000678	0.27	0.21	Depression;	chr6:28431469	chr6:28176188~28176674:+
LUAD	cis	rs449789	0.502	rs529281	ENSG00000235086.1	FNDC1-IT1	-4.73	3.01e-06	0.000678	-0.29	-0.21	Pulse pressure;	chr6:159287473	chr6:159240786~159243329:+
LUAD	cis	rs449789	0.817	rs534519	ENSG00000235086.1	FNDC1-IT1	-4.73	3.01e-06	0.000678	-0.29	-0.21	Pulse pressure;	chr6:159290897	chr6:159240786~159243329:+
LUAD	cis	rs449789	0.857	rs2501175	ENSG00000235086.1	FNDC1-IT1	-4.73	3.01e-06	0.000678	-0.29	-0.21	Pulse pressure;	chr6:159293380	chr6:159240786~159243329:+
LUAD	cis	rs449789	0.779	rs553197	ENSG00000235086.1	FNDC1-IT1	-4.73	3.01e-06	0.000678	-0.29	-0.21	Pulse pressure;	chr6:159293593	chr6:159240786~159243329:+
LUAD	cis	rs449789	0.857	rs578714	ENSG00000235086.1	FNDC1-IT1	-4.73	3.01e-06	0.000678	-0.29	-0.21	Pulse pressure;	chr6:159294086	chr6:159240786~159243329:+
LUAD	cis	rs449789	0.857	rs579533	ENSG00000235086.1	FNDC1-IT1	-4.73	3.01e-06	0.000678	-0.29	-0.21	Pulse pressure;	chr6:159294171	chr6:159240786~159243329:+
LUAD	cis	rs449789	0.857	rs687314	ENSG00000235086.1	FNDC1-IT1	-4.73	3.01e-06	0.000678	-0.29	-0.21	Pulse pressure;	chr6:159295230	chr6:159240786~159243329:+
LUAD	cis	rs449789	0.857	rs591953	ENSG00000235086.1	FNDC1-IT1	-4.73	3.01e-06	0.000678	-0.29	-0.21	Pulse pressure;	chr6:159295714	chr6:159240786~159243329:+
LUAD	cis	rs449789	0.857	rs606833	ENSG00000235086.1	FNDC1-IT1	-4.73	3.01e-06	0.000678	-0.29	-0.21	Pulse pressure;	chr6:159296744	chr6:159240786~159243329:+
LUAD	cis	rs7119	0.717	rs12916682	ENSG00000259362.2	RP11-307C19.1	-4.73	3.01e-06	0.000678	-0.26	-0.21	Type 2 diabetes;	chr15:77515595	chr15:77525540~77534110:+
LUAD	cis	rs8072100	0.764	rs4794371	ENSG00000228782.6	CTD-2026D20.3	-4.73	3.01e-06	0.000679	-0.22	-0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47550327	chr17:47450568~47492492:-
LUAD	cis	rs984222	0.527	rs2794315	ENSG00000231365.4	RP11-418J17.1	-4.73	3.02e-06	0.000679	-0.24	-0.21	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119035043	chr1:119140396~119275973:+
LUAD	cis	rs984222	0.527	rs2247883	ENSG00000231365.4	RP11-418J17.1	-4.73	3.02e-06	0.000679	-0.24	-0.21	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119035214	chr1:119140396~119275973:+
LUAD	cis	rs240993	0.516	rs240968	ENSG00000230177.1	RP5-1112D6.4	-4.73	3.02e-06	0.00068	-0.23	-0.21	Inflammatory skin disease;Psoriasis;	chr6:111311517	chr6:111277932~111278742:+
LUAD	cis	rs240993	0.812	rs459809	ENSG00000230177.1	RP5-1112D6.4	-4.73	3.02e-06	0.00068	-0.22	-0.21	Inflammatory skin disease;Psoriasis;	chr6:111331964	chr6:111277932~111278742:+
LUAD	cis	rs7829975	0.517	rs12542733	ENSG00000173295.6	FAM86B3P	-4.73	3.02e-06	0.000681	-0.22	-0.21	Mood instability;	chr8:8967348	chr8:8228595~8244865:+
LUAD	cis	rs12701220	0.894	rs8591	ENSG00000229043.2	AC091729.9	-4.73	3.03e-06	0.000681	-0.28	-0.21	Bronchopulmonary dysplasia;	chr7:997163	chr7:1160374~1165267:+
LUAD	cis	rs2832077	0.943	rs2832106	ENSG00000232855.5	AF131217.1	4.72	3.03e-06	0.000681	0.24	0.21	Cognitive test performance;	chr21:28819445	chr21:28439346~28674848:-
LUAD	cis	rs8180040	0.764	rs11130115	ENSG00000271161.1	BOLA2P2	4.72	3.03e-06	0.000681	0.2	0.21	Colorectal cancer;	chr3:47140171	chr3:47499841~47500407:+
LUAD	cis	rs1501911	0.527	rs109843	ENSG00000248489.1	CTD-2007H13.3	4.72	3.03e-06	0.000682	0.23	0.21	Lung function (FEV1/FVC);	chr5:98985233	chr5:98929171~98995013:+
LUAD	cis	rs642803	0.551	rs1308020	ENSG00000255557.1	RP11-770G2.2	-4.72	3.03e-06	0.000682	-0.26	-0.21	Urate levels;	chr11:65730087	chr11:65745729~65771585:+
LUAD	cis	rs2255336	0.702	rs7964772	ENSG00000245648.1	RP11-277P12.20	4.72	3.03e-06	0.000682	0.35	0.21	Blood protein levels;	chr12:10367498	chr12:10363769~10398506:+
LUAD	cis	rs7017914	0.652	rs4532626	ENSG00000223220.1	Y_RNA	-4.72	3.03e-06	0.000682	-0.24	-0.21	Bone mineral density;	chr8:71032660	chr8:70780914~70781008:-
LUAD	cis	rs875971	1	rs7792762	ENSG00000232559.3	GS1-124K5.12	4.72	3.04e-06	0.000683	0.25	0.21	Aortic root size;	chr7:66539151	chr7:66554588~66576923:-
LUAD	cis	rs2732480	0.557	rs2634682	ENSG00000257735.1	RP11-370I10.6	4.72	3.04e-06	0.000683	0.26	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339160	chr12:48350945~48442411:+
LUAD	cis	rs9341808	0.59	rs4706841	ENSG00000272129.1	RP11-250B2.6	4.72	3.04e-06	0.000683	0.27	0.21	Sitting height ratio;	chr6:80348110	chr6:80355424~80356859:+
LUAD	cis	rs897984	0.806	rs11150600	ENSG00000260911.2	RP11-196G11.2	-4.72	3.04e-06	0.000683	-0.19	-0.21	Dementia with Lewy bodies;	chr16:30929010	chr16:31043150~31049868:+
LUAD	cis	rs706293	0.512	rs31916	ENSG00000261360.1	CTD-2165H16.4	4.72	3.04e-06	0.000683	0.19	0.21	Urate levels (BMI interaction);	chr5:14814774	chr5:14661808~14664604:-
LUAD	cis	rs12745968	0.619	rs10874738	ENSG00000223787.2	RP4-593M8.1	-4.72	3.04e-06	0.000683	-0.25	-0.21	Bipolar disorder and schizophrenia;	chr1:92758662	chr1:92580476~92580821:-
LUAD	cis	rs12745968	0.685	rs11164807	ENSG00000223787.2	RP4-593M8.1	-4.72	3.04e-06	0.000683	-0.25	-0.21	Bipolar disorder and schizophrenia;	chr1:92768538	chr1:92580476~92580821:-
LUAD	cis	rs10129255	0.957	rs11846893	ENSG00000274576.2	IGHV2-70	4.72	3.04e-06	0.000684	0.18	0.21	Kawasaki disease;	chr14:106779068	chr14:106770577~106771020:-
LUAD	cis	rs67311347	0.506	rs55962832	ENSG00000223797.4	ENTPD3-AS1	4.72	3.04e-06	0.000684	0.22	0.21	Renal cell carcinoma;	chr3:40202960	chr3:40313802~40453329:-
LUAD	cis	rs6921919	0.789	rs6912584	ENSG00000216901.1	AL022393.7	4.72	3.04e-06	0.000684	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr6:28176188~28176674:+
LUAD	cis	rs2998286	0.723	rs332189	ENSG00000254635.4	WAC-AS1	-4.72	3.04e-06	0.000684	-0.27	-0.21	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28628292	chr10:28522652~28532743:-
LUAD	cis	rs11118620	0.622	rs11118618	ENSG00000257551.1	HLX-AS1	4.72	3.04e-06	0.000684	0.28	0.21	Heart failure;	chr1:220838204	chr1:220832763~220880140:-
LUAD	cis	rs875971	1	rs1167411	ENSG00000232559.3	GS1-124K5.12	-4.72	3.04e-06	0.000685	-0.25	-0.21	Aortic root size;	chr7:66074277	chr7:66554588~66576923:-
LUAD	cis	rs8062405	0.756	rs151182	ENSG00000251417.2	RP11-1348G14.4	-4.72	3.05e-06	0.000685	-0.22	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28484431	chr16:28802743~28817828:+
LUAD	cis	rs4538475	1	rs4273468	ENSG00000214846.4	RP11-115L11.1	-4.72	3.05e-06	0.000685	-0.36	-0.21	Parkinson's disease;	chr4:15736240	chr4:15730962~15731627:-
LUAD	cis	rs61270009	0.731	rs13189022	ENSG00000247828.6	TMEM161B-AS1	4.72	3.05e-06	0.000685	0.26	0.21	Depressive symptoms;	chr5:88445017	chr5:88268895~88436685:+
LUAD	cis	rs7590268	0.52	rs1994706	ENSG00000279873.2	LINC01126	4.72	3.05e-06	0.000685	0.22	0.21	Orofacial clefts;	chr2:43568904	chr2:43227210~43228855:+
LUAD	cis	rs2378497	0.818	rs61823905	ENSG00000232679.1	RP11-400N13.3	4.72	3.05e-06	0.000685	0.33	0.21	Serum thyroid-stimulating hormone levels;	chr1:222019675	chr1:222041705~222064763:-
LUAD	cis	rs4908768	0.539	rs6663123	ENSG00000270282.1	RP5-1115A15.2	4.72	3.05e-06	0.000685	0.23	0.21	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8582872	chr1:8512653~8513021:+
LUAD	cis	rs950169	0.922	rs12915832	ENSG00000229212.6	RP11-561C5.4	-4.72	3.05e-06	0.000686	-0.3	-0.21	Schizophrenia;	chr15:84568226	chr15:85205440~85234795:-
LUAD	cis	rs4835473	0.932	rs4835455	ENSG00000251600.4	RP11-673E1.1	4.72	3.05e-06	0.000686	0.24	0.21	Immature fraction of reticulocytes;	chr4:143962290	chr4:143912331~143982454:+
LUAD	cis	rs4664293	1	rs10432413	ENSG00000226266.5	AC009961.3	-4.72	3.05e-06	0.000686	-0.3	-0.21	Monocyte percentage of white cells;	chr2:159639243	chr2:159670708~159712435:-
LUAD	cis	rs7636293	0.86	rs55862617	ENSG00000270773.1	RP13-685P2.7	4.72	3.05e-06	0.000686	0.25	0.21	Height;	chr3:129330693	chr3:129345411~129346164:+
LUAD	cis	rs7636293	0.86	rs55894447	ENSG00000270773.1	RP13-685P2.7	4.72	3.05e-06	0.000686	0.25	0.21	Height;	chr3:129330694	chr3:129345411~129346164:+
LUAD	cis	rs7636293	0.86	rs55893559	ENSG00000270773.1	RP13-685P2.7	4.72	3.05e-06	0.000686	0.25	0.21	Height;	chr3:129330695	chr3:129345411~129346164:+
LUAD	cis	rs10129255	0.744	rs28517388	ENSG00000211974.3	IGHV2-70	4.72	3.05e-06	0.000686	0.23	0.21	Kawasaki disease;	chr14:106704323	chr14:106723574~106724093:-
LUAD	cis	rs9532669	0.926	rs9532691	ENSG00000239827.7	SUGT1P3	4.72	3.05e-06	0.000686	0.24	0.21	Cervical cancer;	chr13:40969358	chr13:40908159~40921774:-
LUAD	cis	rs1275468	0.724	rs1611928	ENSG00000257497.2	RP11-585P4.5	-4.72	3.05e-06	0.000686	-0.31	-0.21	Polycystic ovary syndrome;	chr12:75561705	chr12:75483454~75489820:-
LUAD	cis	rs12073359	1	rs72694957	ENSG00000223945.2	RP11-458I7.1	-4.72	3.05e-06	0.000686	-0.33	-0.21	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150163093	chr1:150053864~150055034:+
LUAD	cis	rs6957923	0.835	rs4445126	ENSG00000230658.1	KLHL7-AS1	4.72	3.05e-06	0.000687	0.26	0.21	Height;	chr7:23457476	chr7:23101228~23105703:-
LUAD	cis	rs7829975	0.659	rs4382480	ENSG00000253981.4	ALG1L13P	4.72	3.05e-06	0.000687	0.24	0.21	Mood instability;	chr8:8863963	chr8:8236003~8244667:-
LUAD	cis	rs2018683	0.77	rs10951208	ENSG00000228421.2	AC005013.5	4.72	3.06e-06	0.000687	0.24	0.21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28982888	chr7:28957667~28959345:+
LUAD	cis	rs4664293	0.565	rs10165197	ENSG00000226266.5	AC009961.3	4.72	3.06e-06	0.000687	0.28	0.21	Monocyte percentage of white cells;	chr2:159537137	chr2:159670708~159712435:-
LUAD	cis	rs45509595	0.822	rs200484	ENSG00000219392.1	RP1-265C24.5	-4.72	3.06e-06	0.000687	-0.4	-0.21	Breast cancer;	chr6:27807896	chr6:28115628~28116551:+
LUAD	cis	rs17772222	0.917	rs17188207	ENSG00000258983.2	RP11-507K2.2	4.72	3.06e-06	0.000687	0.26	0.21	Coronary artery calcification;	chr14:88699579	chr14:88499334~88515502:+
LUAD	cis	rs9473147	0.516	rs9369695	ENSG00000270761.1	RP11-385F7.1	-4.72	3.06e-06	0.000688	-0.25	-0.21	Platelet distribution width;Mean platelet volume;	chr6:47472829	chr6:47477243~47477572:-
LUAD	cis	rs860295	0.702	rs11264387	ENSG00000225855.5	RUSC1-AS1	4.72	3.06e-06	0.000688	0.14	0.21	Body mass index;	chr1:155593361	chr1:155316863~155324176:-
LUAD	cis	rs5758511	0.634	rs1001587	ENSG00000205702.9	CYP2D7	4.72	3.06e-06	0.000688	0.21	0.21	Birth weight;	chr22:42274105	chr22:42140203~42144577:-
LUAD	cis	rs9860428	0.844	rs6795428	ENSG00000242770.2	RP11-180K7.1	4.72	3.06e-06	0.000688	0.22	0.21	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112896508	chr3:112802478~112812819:+
LUAD	cis	rs2243480	1	rs422164	ENSG00000164669.11	INTS4P1	4.72	3.07e-06	0.000689	0.37	0.21	Diabetic kidney disease;	chr7:66121618	chr7:65141225~65234216:+
LUAD	cis	rs7646881	0.504	rs7617304	ENSG00000240207.5	RP11-379F4.4	-4.72	3.07e-06	0.000689	-0.24	-0.21	Tetralogy of Fallot;	chr3:158745312	chr3:158732263~158784070:+
LUAD	cis	rs7017914	0.652	rs3110263	ENSG00000223220.1	Y_RNA	4.72	3.07e-06	0.00069	0.25	0.21	Bone mineral density;	chr8:71030457	chr8:70780914~70781008:-
LUAD	cis	rs950169	0.922	rs11633534	ENSG00000275120.1	RP11-182J1.17	4.72	3.07e-06	0.00069	0.33	0.21	Schizophrenia;	chr15:84581411	chr15:84599434~84606463:-
LUAD	cis	rs2018683	0.768	rs10282015	ENSG00000228421.2	AC005013.5	4.72	3.07e-06	0.00069	0.24	0.21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28982522	chr7:28957667~28959345:+
LUAD	cis	rs9322193	0.847	rs4870054	ENSG00000268592.3	RAET1E-AS1	4.72	3.07e-06	0.00069	0.28	0.21	Lung cancer;	chr6:149848402	chr6:149863494~149919507:+
LUAD	cis	rs812925	0.502	rs13028833	ENSG00000271889.1	RP11-493E12.1	-4.72	3.07e-06	0.00069	-0.25	-0.21	Immature fraction of reticulocytes;	chr2:61417194	chr2:61151433~61162105:-
LUAD	cis	rs6565180	1	rs6565180	ENSG00000273724.1	RP11-347C12.12	-4.72	3.07e-06	0.00069	-0.23	-0.21	Tonsillectomy;	chr16:30350020	chr16:30336400~30343336:+
LUAD	cis	rs7302981	0.741	rs10783342	ENSG00000272368.2	RP4-605O3.4	4.72	3.08e-06	0.000691	0.23	0.21	Systolic blood pressure;	chr12:50234683	chr12:50112197~50165618:+
LUAD	cis	rs2439831	0.702	rs3759791	ENSG00000249839.1	AC011330.5	-4.72	3.08e-06	0.000691	-0.43	-0.21	Lung cancer in ever smokers;	chr15:43798600	chr15:43663654~43684339:-
LUAD	cis	rs9487094	0.885	rs59906308	ENSG00000260273.1	RP11-425D10.10	4.72	3.08e-06	0.000691	0.29	0.21	Height;	chr6:109438349	chr6:109382795~109383666:+
LUAD	cis	rs9309473	0.632	rs6706179	ENSG00000163016.8	ALMS1P	4.72	3.08e-06	0.000691	0.23	0.21	Metabolite levels;	chr2:73351449	chr2:73644919~73685576:+
LUAD	cis	rs10129255	0.784	rs7147210	ENSG00000211974.3	IGHV2-70	4.72	3.08e-06	0.000691	0.23	0.21	Kawasaki disease;	chr14:106705271	chr14:106723574~106724093:-
LUAD	cis	rs783540	0.5	rs7178459	ENSG00000276710.3	CSPG4P8	-4.72	3.08e-06	0.000692	-0.22	-0.21	Schizophrenia;	chr15:82729632	chr15:82459472~82477258:+
LUAD	cis	rs6957923	1	rs4304239	ENSG00000230658.1	KLHL7-AS1	4.72	3.08e-06	0.000692	0.25	0.21	Height;	chr7:23456342	chr7:23101228~23105703:-
LUAD	cis	rs8180040	0.764	rs13062022	ENSG00000271161.1	BOLA2P2	4.72	3.08e-06	0.000692	0.2	0.21	Colorectal cancer;	chr3:47127885	chr3:47499841~47500407:+
LUAD	cis	rs7208859	0.673	rs56846352	ENSG00000263603.1	CTD-2349P21.5	-4.72	3.08e-06	0.000692	-0.32	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792170	chr17:30729469~30731202:+
LUAD	cis	rs11603023	0.625	rs633683	ENSG00000255239.1	AP002954.6	4.72	3.08e-06	0.000693	0.25	0.21	Cholesterol, total;	chr11:118634025	chr11:118688039~118690600:-
LUAD	cis	rs561341	1	rs560132	ENSG00000265798.5	RP11-271K11.5	4.72	3.08e-06	0.000693	0.34	0.21	Hip circumference adjusted for BMI;	chr17:31993000	chr17:31038575~31059121:-
LUAD	cis	rs1061377	0.674	rs34506243	ENSG00000249685.1	RP11-360F5.3	4.72	3.09e-06	0.000693	0.25	0.21	Uric acid levels;	chr4:39082702	chr4:39133913~39135608:+
LUAD	cis	rs910316	1	rs175442	ENSG00000259138.1	RP11-950C14.7	-4.72	3.09e-06	0.000693	-0.22	-0.21	Height;	chr14:75136861	chr14:75127153~75136930:+
LUAD	cis	rs875971	0.706	rs1643374	ENSG00000224316.1	RP11-479O9.2	4.72	3.09e-06	0.000693	0.22	0.21	Aortic root size;	chr7:66407695	chr7:65773620~65802067:+
LUAD	cis	rs2243480	0.764	rs2460423	ENSG00000164669.11	INTS4P1	4.72	3.09e-06	0.000694	0.37	0.21	Diabetic kidney disease;	chr7:66136229	chr7:65141225~65234216:+
LUAD	cis	rs5758511	0.68	rs1033460	ENSG00000226450.2	CYP2D8P	4.72	3.09e-06	0.000694	0.2	0.21	Birth weight;	chr22:42223302	chr22:42149886~42155001:-
LUAD	cis	rs9929215	1	rs9929215	ENSG00000270020.1	RP11-463O9.9	-4.72	3.09e-06	0.000694	-0.54	-0.21	Colorectal cancer;	chr16:86487884	chr16:86520383~86523897:-
LUAD	cis	rs801193	1	rs2420824	ENSG00000236529.1	RP13-254B10.1	-4.72	3.09e-06	0.000694	-0.21	-0.21	Aortic root size;	chr7:66666129	chr7:65840212~65840596:+
LUAD	cis	rs897984	0.806	rs8052245	ENSG00000260911.2	RP11-196G11.2	-4.72	3.09e-06	0.000694	-0.19	-0.21	Dementia with Lewy bodies;	chr16:30905109	chr16:31043150~31049868:+
LUAD	cis	rs587080	0.624	rs512715	ENSG00000254614.2	AP003068.23	-4.72	3.09e-06	0.000694	-0.32	-0.21	Plateletcrit;	chr11:65423737	chr11:65177606~65181834:-
LUAD	cis	rs7819412	0.875	rs11250121	ENSG00000255046.1	RP11-297N6.4	4.72	3.1e-06	0.000695	0.25	0.21	Triglycerides;	chr8:11202802	chr8:11797928~11802568:-
LUAD	cis	rs7493	0.95	rs7785705	ENSG00000233942.1	AC004012.1	4.72	3.1e-06	0.000695	0.3	0.21	Yu-Zhi constitution type in type 2 diabetes;	chr7:95404491	chr7:95471835~95473998:+
LUAD	cis	rs6840360	0.53	rs12645029	ENSG00000270265.1	RP11-731D1.4	-4.72	3.1e-06	0.000695	-0.24	-0.21	Intelligence (multi-trait analysis);	chr4:151728880	chr4:151333775~151353224:-
LUAD	cis	rs6840258	0.825	rs72667747	ENSG00000251411.1	RP11-397E7.4	-4.72	3.1e-06	0.000695	-0.28	-0.21	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87000911	chr4:86913266~86914817:-
LUAD	cis	rs17508449	1	rs17508449	ENSG00000232450.1	RP4-730K3.3	-4.72	3.1e-06	0.000696	-0.34	-0.21	Leprosy;	chr1:113542523	chr1:113698884~113699631:-
LUAD	cis	rs9425766	0.679	rs2901785	ENSG00000227373.4	RP11-160H22.5	4.72	3.1e-06	0.000696	0.26	0.21	Life satisfaction;	chr1:174135605	chr1:174115300~174160004:-
LUAD	cis	rs35160687	0.644	rs17738058	ENSG00000273080.1	RP11-301O19.1	-4.72	3.1e-06	0.000696	-0.24	-0.21	Night sleep phenotypes;	chr2:86286080	chr2:86195590~86196049:+
LUAD	cis	rs375066	0.935	rs376032	ENSG00000267058.1	RP11-15A1.3	-4.72	3.1e-06	0.000696	-0.24	-0.21	Breast cancer;	chr19:43903412	chr19:43891804~43901805:-
LUAD	cis	rs5758511	0.68	rs5758692	ENSG00000205702.9	CYP2D7	4.72	3.1e-06	0.000696	0.21	0.21	Birth weight;	chr22:42273023	chr22:42140203~42144577:-
LUAD	cis	rs801193	1	rs4717310	ENSG00000236529.1	RP13-254B10.1	4.72	3.1e-06	0.000696	0.21	0.21	Aortic root size;	chr7:66696020	chr7:65840212~65840596:+
LUAD	cis	rs2976388	0.647	rs2572906	ENSG00000253741.1	CTD-2292P10.4	-4.72	3.1e-06	0.000696	-0.24	-0.21	Urinary tract infection frequency;	chr8:142716851	chr8:142702252~142726973:-
LUAD	cis	rs7819412	0.745	rs4841498	ENSG00000255046.1	RP11-297N6.4	4.72	3.1e-06	0.000696	0.26	0.21	Triglycerides;	chr8:11127922	chr8:11797928~11802568:-
LUAD	cis	rs62025270	0.688	rs56388190	ENSG00000202081.1	RNU6-1280P	-4.72	3.1e-06	0.000696	-0.29	-0.21	Idiopathic pulmonary fibrosis;	chr15:85771665	chr15:85651522~85651628:-
LUAD	cis	rs4713118	0.715	rs200480	ENSG00000219392.1	RP1-265C24.5	-4.72	3.1e-06	0.000696	-0.26	-0.21	Parkinson's disease;	chr6:27805886	chr6:28115628~28116551:+
LUAD	cis	rs5758511	0.68	rs5758686	ENSG00000226450.2	CYP2D8P	4.72	3.1e-06	0.000696	0.2	0.21	Birth weight;	chr22:42259371	chr22:42149886~42155001:-
LUAD	cis	rs9473147	0.516	rs9395283	ENSG00000270761.1	RP11-385F7.1	-4.72	3.1e-06	0.000697	-0.24	-0.21	Platelet distribution width;Mean platelet volume;	chr6:47583708	chr6:47477243~47477572:-
LUAD	cis	rs9473147	0.516	rs6903331	ENSG00000270761.1	RP11-385F7.1	-4.72	3.1e-06	0.000697	-0.24	-0.21	Platelet distribution width;Mean platelet volume;	chr6:47595179	chr6:47477243~47477572:-
LUAD	cis	rs2439831	0.85	rs28413881	ENSG00000249839.1	AC011330.5	-4.72	3.11e-06	0.000697	-0.45	-0.21	Lung cancer in ever smokers;	chr15:43881901	chr15:43663654~43684339:-
LUAD	cis	rs7176527	1	rs3762169	ENSG00000229212.6	RP11-561C5.4	4.72	3.11e-06	0.000697	0.3	0.21	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84598728	chr15:85205440~85234795:-
LUAD	cis	rs2239547	0.657	rs3755803	ENSG00000242142.1	SERBP1P3	4.72	3.11e-06	0.000697	0.25	0.21	Schizophrenia;	chr3:52832141	chr3:53064283~53065091:-
LUAD	cis	rs12468226	0.873	rs1474267	ENSG00000226261.1	AC064836.3	-4.72	3.11e-06	0.000697	-0.35	-0.21	Urate levels;	chr2:202178596	chr2:202336024~202336727:-
LUAD	cis	rs1062177	0.724	rs2915828	ENSG00000253921.1	CTB-113P19.3	4.72	3.11e-06	0.000697	0.3	0.21	Preschool internalizing problems;	chr5:151738560	chr5:151753992~151767247:+
LUAD	cis	rs1062177	0.724	rs2964590	ENSG00000253921.1	CTB-113P19.3	4.72	3.11e-06	0.000697	0.3	0.21	Preschool internalizing problems;	chr5:151738585	chr5:151753992~151767247:+
LUAD	cis	rs6565180	1	rs68051857	ENSG00000273724.1	RP11-347C12.12	-4.72	3.11e-06	0.000697	-0.23	-0.21	Tonsillectomy;	chr16:30348690	chr16:30336400~30343336:+
LUAD	cis	rs1707322	0.896	rs785512	ENSG00000280836.1	AL355480.1	4.72	3.11e-06	0.000697	0.28	0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46068871	chr1:45581219~45581321:-
LUAD	cis	rs2288884	1	rs2288884	ENSG00000269959.1	SPACA6P-AS	-4.72	3.11e-06	0.000698	-0.28	-0.21	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52029018	chr19:51685363~51693456:-
LUAD	cis	rs916888	0.61	rs142167	ENSG00000261575.2	RP11-259G18.1	-4.72	3.11e-06	0.000698	-0.28	-0.21	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46267037~46268694:+
LUAD	cis	rs73198271	0.737	rs506960	ENSG00000253893.2	FAM85B	4.72	3.11e-06	0.000698	0.26	0.21	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8772759	chr8:8167819~8226614:-
LUAD	cis	rs67311347	0.577	rs11129870	ENSG00000223797.4	ENTPD3-AS1	4.72	3.11e-06	0.000698	0.22	0.21	Renal cell carcinoma;	chr3:40218915	chr3:40313802~40453329:-
LUAD	cis	rs853679	0.882	rs4713139	ENSG00000204709.4	LINC01556	4.72	3.11e-06	0.000698	0.35	0.21	Depression;	chr6:28124907	chr6:28943877~28944537:+
LUAD	cis	rs7017914	0.628	rs2380691	ENSG00000223220.1	Y_RNA	4.72	3.11e-06	0.000698	0.24	0.21	Bone mineral density;	chr8:70872942	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs6998354	ENSG00000223220.1	Y_RNA	4.72	3.11e-06	0.000698	0.24	0.21	Bone mineral density;	chr8:70873934	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.644	rs12156377	ENSG00000223220.1	Y_RNA	4.72	3.11e-06	0.000698	0.24	0.21	Bone mineral density;	chr8:70875457	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs1908032	ENSG00000223220.1	Y_RNA	4.72	3.11e-06	0.000698	0.24	0.21	Bone mineral density;	chr8:70876735	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs7003788	ENSG00000223220.1	Y_RNA	4.72	3.11e-06	0.000698	0.24	0.21	Bone mineral density;	chr8:70876889	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.628	rs13272343	ENSG00000223220.1	Y_RNA	4.72	3.11e-06	0.000698	0.24	0.21	Bone mineral density;	chr8:70882272	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.69	rs12675094	ENSG00000223220.1	Y_RNA	4.72	3.11e-06	0.000698	0.24	0.21	Bone mineral density;	chr8:70884968	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.628	rs12675116	ENSG00000223220.1	Y_RNA	4.72	3.11e-06	0.000698	0.24	0.21	Bone mineral density;	chr8:70885056	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs13252230	ENSG00000223220.1	Y_RNA	4.72	3.11e-06	0.000698	0.24	0.21	Bone mineral density;	chr8:70886081	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs6996049	ENSG00000223220.1	Y_RNA	4.72	3.11e-06	0.000698	0.24	0.21	Bone mineral density;	chr8:70887771	chr8:70780914~70781008:-
LUAD	cis	rs2239547	0.657	rs6445539	ENSG00000242142.1	SERBP1P3	4.72	3.11e-06	0.000698	0.25	0.21	Schizophrenia;	chr3:52840280	chr3:53064283~53065091:-
LUAD	cis	rs2239547	0.657	rs7638524	ENSG00000242142.1	SERBP1P3	4.72	3.11e-06	0.000698	0.25	0.21	Schizophrenia;	chr3:52840845	chr3:53064283~53065091:-
LUAD	cis	rs3758785	0.623	rs77241189	ENSG00000255893.1	RP11-685N10.1	-4.72	3.11e-06	0.000699	-0.29	-0.21	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94410151	chr11:94472908~94473570:-
LUAD	cis	rs9545047	0.584	rs9565485	ENSG00000227354.5	RBM26-AS1	-4.72	3.12e-06	0.000699	-0.22	-0.21	Schizophrenia;	chr13:79307428	chr13:79406309~79424328:+
LUAD	cis	rs12819124	0.502	rs10875718	ENSG00000240399.1	RP1-228P16.1	4.72	3.12e-06	0.000699	0.21	0.21	Glycated hemoglobin levels;	chr12:48017319	chr12:48054813~48055591:-
LUAD	cis	rs72772090	0.71	rs17400685	ENSG00000248734.2	CTD-2260A17.1	4.72	3.12e-06	7e-04	0.31	0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96730662	chr5:96784777~96785999:+
LUAD	cis	rs7138803	0.51	rs2603111	ENSG00000257464.1	RP11-161H23.8	-4.72	3.12e-06	7e-04	-0.2	-0.21	Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index;	chr12:49806063	chr12:49442424~49442652:-
LUAD	cis	rs160451	0.966	rs183363	ENSG00000251136.7	RP11-37B2.1	4.72	3.12e-06	7e-04	0.22	0.21	Leprosy;	chr8:89665951	chr8:89609409~89757727:-
LUAD	cis	rs7580658	0.509	rs12477653	ENSG00000236682.1	AC068282.3	-4.72	3.12e-06	7e-04	-0.26	-0.21	Protein C levels;	chr2:127194505	chr2:127389130~127400580:+
LUAD	cis	rs7580658	0.545	rs13001179	ENSG00000236682.1	AC068282.3	-4.72	3.12e-06	7e-04	-0.26	-0.21	Protein C levels;	chr2:127194617	chr2:127389130~127400580:+
LUAD	cis	rs7580658	0.545	rs13001184	ENSG00000236682.1	AC068282.3	-4.72	3.12e-06	7e-04	-0.26	-0.21	Protein C levels;	chr2:127194630	chr2:127389130~127400580:+
LUAD	cis	rs11155671	0.53	rs7757984	ENSG00000268592.3	RAET1E-AS1	4.72	3.12e-06	0.000701	0.26	0.21	Testicular germ cell tumor;	chr6:149887515	chr6:149863494~149919507:+
LUAD	cis	rs10129255	1	rs61997605	ENSG00000211974.3	IGHV2-70	4.72	3.12e-06	0.000701	0.22	0.21	Kawasaki disease;	chr14:106678368	chr14:106723574~106724093:-
LUAD	cis	rs10129255	1	rs8012033	ENSG00000211974.3	IGHV2-70	4.72	3.12e-06	0.000701	0.22	0.21	Kawasaki disease;	chr14:106678854	chr14:106723574~106724093:-
LUAD	cis	rs8031584	0.651	rs28664821	ENSG00000270015.1	RP11-540B6.6	4.72	3.12e-06	0.000701	0.15	0.21	Huntington's disease progression;	chr15:30880120	chr15:30926514~30928407:+
LUAD	cis	rs9322193	0.923	rs4870509	ENSG00000268592.3	RAET1E-AS1	4.72	3.13e-06	0.000701	0.26	0.21	Lung cancer;	chr6:149702212	chr6:149863494~149919507:+
LUAD	cis	rs7189233	0.531	rs9929873	ENSG00000279344.1	RP11-44F14.7	4.72	3.13e-06	0.000701	0.17	0.21	Intelligence (multi-trait analysis);	chr16:53456764	chr16:53478957~53481550:-
LUAD	cis	rs801193	1	rs2707836	ENSG00000236529.1	RP13-254B10.1	4.72	3.13e-06	0.000701	0.21	0.21	Aortic root size;	chr7:66695448	chr7:65840212~65840596:+
LUAD	cis	rs801193	0.844	rs7779971	ENSG00000236529.1	RP13-254B10.1	4.72	3.13e-06	0.000701	0.21	0.21	Aortic root size;	chr7:66696803	chr7:65840212~65840596:+
LUAD	cis	rs2919009	0.607	rs72826623	ENSG00000271670.1	RP11-95I16.4	4.72	3.13e-06	0.000702	0.28	0.21	Obesity-related traits;	chr10:120952843	chr10:120879256~120880667:-
LUAD	cis	rs2617170	0.883	rs2086099	ENSG00000245648.1	RP11-277P12.20	4.72	3.13e-06	0.000702	0.26	0.21	Behcet's disease;	chr12:10373939	chr12:10363769~10398506:+
LUAD	cis	rs41369048	0.669	rs11589654	ENSG00000238078.1	LINC01352	-4.72	3.13e-06	0.000702	-0.31	-0.21	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220866646	chr1:220829255~220832429:+
LUAD	cis	rs2243480	0.908	rs4718273	ENSG00000232559.3	GS1-124K5.12	-4.72	3.13e-06	0.000702	-0.37	-0.21	Diabetic kidney disease;	chr7:65751112	chr7:66554588~66576923:-
LUAD	cis	rs10246939	0.543	rs10952509	ENSG00000270923.1	TAS2R6P	-4.72	3.13e-06	0.000702	-0.25	-0.21	Bitter taste perception;	chr7:141890884	chr7:141787815~141788640:+
LUAD	cis	rs10246939	0.543	rs12538701	ENSG00000270923.1	TAS2R6P	-4.72	3.13e-06	0.000702	-0.25	-0.21	Bitter taste perception;	chr7:141893634	chr7:141787815~141788640:+
LUAD	cis	rs9487094	0.922	rs13204500	ENSG00000260273.1	RP11-425D10.10	4.72	3.13e-06	0.000703	0.29	0.21	Height;	chr6:109640682	chr6:109382795~109383666:+
LUAD	cis	rs14027	0.883	rs13255850	ENSG00000279347.1	RP11-85I17.2	-4.72	3.13e-06	0.000703	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119705923	chr8:119838736~119840385:-
LUAD	cis	rs8180040	0.726	rs10461018	ENSG00000271161.1	BOLA2P2	-4.72	3.13e-06	0.000703	-0.2	-0.21	Colorectal cancer;	chr3:46953752	chr3:47499841~47500407:+
LUAD	cis	rs1008375	1	rs7697889	ENSG00000249502.1	AC006160.5	-4.72	3.13e-06	0.000703	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17616338	chr4:17587467~17614571:-
LUAD	cis	rs7819412	0.806	rs6980856	ENSG00000255046.1	RP11-297N6.4	-4.72	3.14e-06	0.000703	-0.26	-0.21	Triglycerides;	chr8:11080750	chr8:11797928~11802568:-
LUAD	cis	rs9322193	0.887	rs3777949	ENSG00000268592.3	RAET1E-AS1	4.72	3.14e-06	0.000703	0.26	0.21	Lung cancer;	chr6:149596021	chr6:149863494~149919507:+
LUAD	cis	rs1008375	1	rs6849704	ENSG00000249502.1	AC006160.5	-4.72	3.14e-06	0.000704	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17650408	chr4:17587467~17614571:-
LUAD	cis	rs1008375	1	rs10805357	ENSG00000249502.1	AC006160.5	-4.72	3.14e-06	0.000704	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17650729	chr4:17587467~17614571:-
LUAD	cis	rs6570726	0.764	rs9399553	ENSG00000235652.6	RP11-545I5.3	4.72	3.14e-06	0.000704	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145552528	chr6:145799409~145886585:+
LUAD	cis	rs12900463	0.813	rs186266	ENSG00000259295.5	CSPG4P12	4.72	3.14e-06	0.000705	0.29	0.21	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);	chr15:84859564	chr15:85191438~85213905:+
LUAD	cis	rs1153858	0.562	rs8025019	ENSG00000259520.4	CTD-2651B20.3	-4.72	3.14e-06	0.000705	-0.45	-0.21	Homoarginine levels;	chr15:45443667	chr15:45251580~45279251:-
LUAD	cis	rs6570726	0.905	rs396492	ENSG00000235652.6	RP11-545I5.3	4.72	3.14e-06	0.000705	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145495044	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs7757387	ENSG00000235652.6	RP11-545I5.3	4.72	3.14e-06	0.000705	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145495590	chr6:145799409~145886585:+
LUAD	cis	rs453301	0.653	rs7853	ENSG00000253981.4	ALG1L13P	4.72	3.15e-06	0.000705	0.25	0.21	Joint mobility (Beighton score);	chr8:9033304	chr8:8236003~8244667:-
LUAD	cis	rs73173548	0.502	rs6452789	ENSG00000247828.6	TMEM161B-AS1	4.72	3.15e-06	0.000705	0.25	0.21	Macular telangiectasia type 2;	chr5:88429498	chr5:88268895~88436685:+
LUAD	cis	rs4908760	0.827	rs6692693	ENSG00000270282.1	RP5-1115A15.2	4.72	3.15e-06	0.000705	0.23	0.21	Vitiligo;	chr1:8647057	chr1:8512653~8513021:+
LUAD	cis	rs736801	0.78	rs2188962	ENSG00000233006.5	AC034220.3	4.72	3.15e-06	0.000705	0.19	0.21	Mosquito bite size;Breast cancer;	chr5:132435113	chr5:132311285~132369916:-
LUAD	cis	rs6539288	0.899	rs4964192	ENSG00000260329.1	RP11-412D9.4	-4.72	3.15e-06	0.000705	-0.23	-0.21	Total body bone mineral density;	chr12:106915014	chr12:106954029~106955497:-
LUAD	cis	rs67311347	0.713	rs4974018	ENSG00000223797.4	ENTPD3-AS1	4.72	3.15e-06	0.000705	0.23	0.21	Renal cell carcinoma;	chr3:40265928	chr3:40313802~40453329:-
LUAD	cis	rs6751744	0.772	rs11901769	ENSG00000226266.5	AC009961.3	-4.72	3.15e-06	0.000705	-0.32	-0.21	Dysphagia;	chr2:159489746	chr2:159670708~159712435:-
LUAD	cis	rs7937890	0.572	rs2597218	ENSG00000251991.1	RNU7-49P	4.72	3.15e-06	0.000705	0.24	0.21	Mitochondrial DNA levels;	chr11:14510792	chr11:14478892~14478953:+
LUAD	cis	rs2018683	0.711	rs917213	ENSG00000228421.2	AC005013.5	4.72	3.15e-06	0.000706	0.24	0.21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28928587	chr7:28957667~28959345:+
LUAD	cis	rs2018683	0.711	rs917214	ENSG00000228421.2	AC005013.5	4.72	3.15e-06	0.000706	0.24	0.21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28928676	chr7:28957667~28959345:+
LUAD	cis	rs9309473	0.607	rs11686504	ENSG00000163016.8	ALMS1P	4.72	3.15e-06	0.000706	0.23	0.21	Metabolite levels;	chr2:73352684	chr2:73644919~73685576:+
LUAD	cis	rs62025270	0.632	rs62022918	ENSG00000202081.1	RNU6-1280P	-4.72	3.15e-06	0.000706	-0.31	-0.21	Idiopathic pulmonary fibrosis;	chr15:85675053	chr15:85651522~85651628:-
LUAD	cis	rs62025270	0.632	rs111906684	ENSG00000202081.1	RNU6-1280P	-4.72	3.15e-06	0.000706	-0.31	-0.21	Idiopathic pulmonary fibrosis;	chr15:85678705	chr15:85651522~85651628:-
LUAD	cis	rs2439831	0.681	rs2278859	ENSG00000249839.1	AC011330.5	-4.72	3.15e-06	0.000706	-0.36	-0.21	Lung cancer in ever smokers;	chr15:43340762	chr15:43663654~43684339:-
LUAD	cis	rs11641365	0.678	rs877579	ENSG00000278341.1	RP5-1142A6.10	4.72	3.15e-06	0.000706	0.28	0.21	Autism spectrum disorder-related traits;	chr16:88704213	chr16:88708956~88710437:-
LUAD	cis	rs13256369	1	rs1109619	ENSG00000253893.2	FAM85B	-4.72	3.16e-06	0.000707	-0.29	-0.21	Obesity-related traits;	chr8:8714106	chr8:8167819~8226614:-
LUAD	cis	rs293748	0.657	rs72732585	ENSG00000250155.1	CTD-2353F22.1	-4.72	3.16e-06	0.000707	-0.29	-0.21	Obesity-related traits;	chr5:36792493	chr5:36666214~36725195:-
LUAD	cis	rs8180040	0.764	rs13084117	ENSG00000271161.1	BOLA2P2	4.72	3.16e-06	0.000707	0.2	0.21	Colorectal cancer;	chr3:47141749	chr3:47499841~47500407:+
LUAD	cis	rs7208859	0.623	rs9912440	ENSG00000280069.1	CTD-2349P21.3	-4.72	3.16e-06	0.000707	-0.29	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30821754	chr17:30738182~30740275:+
LUAD	cis	rs6969780	0.841	rs2301720	ENSG00000233429.8	HOTAIRM1	-4.72	3.16e-06	0.000708	-0.32	-0.21	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27156450	chr7:27095647~27100265:+
LUAD	cis	rs17345786	1	rs3762729	ENSG00000244119.1	PDCL3P4	4.72	3.16e-06	0.000708	0.23	0.21	Colonoscopy-negative controls vs population controls;	chr3:101590030	chr3:101712472~101713191:+
LUAD	cis	rs7189233	0.531	rs8062535	ENSG00000279344.1	RP11-44F14.7	4.72	3.16e-06	0.000708	0.17	0.21	Intelligence (multi-trait analysis);	chr16:53478576	chr16:53478957~53481550:-
LUAD	cis	rs6545883	0.524	rs17482440	ENSG00000271889.1	RP11-493E12.1	-4.72	3.16e-06	0.000708	-0.24	-0.21	Tuberculosis;	chr2:61321722	chr2:61151433~61162105:-
LUAD	cis	rs8177876	0.749	rs2278025	ENSG00000261061.1	RP11-303E16.2	4.72	3.16e-06	0.000708	0.32	0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81045636	chr16:81030770~81031485:+
LUAD	cis	rs10266483	0.661	rs608769	ENSG00000228653.2	HNRNPCP7	-4.72	3.16e-06	0.000708	-0.26	-0.21	Response to statin therapy;	chr7:64292783	chr7:64500825~64501729:+
LUAD	cis	rs2288884	0.806	rs60193983	ENSG00000269959.1	SPACA6P-AS	-4.72	3.16e-06	0.000708	-0.28	-0.21	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52082659	chr19:51685363~51693456:-
LUAD	cis	rs17818399	0.501	rs13413254	ENSG00000279254.1	RP11-536C12.1	-4.72	3.17e-06	0.000709	-0.21	-0.21	Height;	chr2:46575795	chr2:46668870~46670778:+
LUAD	cis	rs878939	0.625	rs61871279	ENSG00000230224.1	PHBP9	-4.72	3.17e-06	0.000709	-0.2	-0.21	Warfarin maintenance dose;	chr10:99583948	chr10:100248271~100249095:+
LUAD	cis	rs9473147	0.516	rs2171089	ENSG00000270761.1	RP11-385F7.1	-4.72	3.17e-06	0.00071	-0.25	-0.21	Platelet distribution width;Mean platelet volume;	chr6:47548075	chr6:47477243~47477572:-
LUAD	cis	rs910316	1	rs28626045	ENSG00000279594.1	RP11-950C14.10	4.72	3.17e-06	0.00071	0.24	0.21	Height;	chr14:75122492	chr14:75011269~75012851:-
LUAD	cis	rs6714710	0.58	rs11692470	ENSG00000230606.9	AC159540.1	-4.71	3.17e-06	0.00071	-0.22	-0.21	Posterior cortical atrophy and Alzheimer's disease;	chr2:97904101	chr2:97416165~97433527:-
LUAD	cis	rs7829975	0.711	rs4841051	ENSG00000253981.4	ALG1L13P	-4.71	3.17e-06	0.00071	-0.24	-0.21	Mood instability;	chr8:8828136	chr8:8236003~8244667:-
LUAD	cis	rs8098244	0.597	rs12960583	ENSG00000264745.1	TTC39C-AS1	4.71	3.17e-06	0.00071	0.21	0.21	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23772629	chr18:23994213~24015339:-
LUAD	cis	rs7493	1	rs6968305	ENSG00000233942.1	AC004012.1	4.71	3.17e-06	0.00071	0.31	0.21	Yu-Zhi constitution type in type 2 diabetes;	chr7:95413217	chr7:95471835~95473998:+
LUAD	cis	rs2836950	0.52	rs2836966	ENSG00000255568.3	BRWD1-AS2	-4.71	3.18e-06	0.000711	-0.2	-0.21	Menarche (age at onset);	chr21:39265595	chr21:39313935~39314962:+
LUAD	cis	rs42490	1	rs43134	ENSG00000251136.7	RP11-37B2.1	4.71	3.18e-06	0.000711	0.22	0.21	Leprosy;	chr8:89775732	chr8:89609409~89757727:-
LUAD	cis	rs55823223	0.618	rs72860390	ENSG00000267801.1	RP11-552F3.9	4.71	3.18e-06	0.000711	0.24	0.21	Psoriasis;	chr17:75873833	chr17:75876372~75879546:+
LUAD	cis	rs507080	0.961	rs520543	ENSG00000278376.1	RP11-158I9.8	-4.71	3.18e-06	0.000711	-0.23	-0.21	Serum metabolite levels;	chr11:118667448	chr11:118791254~118793137:+
LUAD	cis	rs9369695	0.842	rs2396825	ENSG00000270761.1	RP11-385F7.1	-4.71	3.18e-06	0.000712	-0.24	-0.21	Reticulocyte count;	chr6:47600960	chr6:47477243~47477572:-
LUAD	cis	rs2562456	0.641	rs62107468	ENSG00000268081.1	RP11-678G14.2	4.71	3.18e-06	0.000712	0.34	0.21	Pain;	chr19:21307177	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.833	rs2154302	ENSG00000268081.1	RP11-678G14.2	4.71	3.18e-06	0.000712	0.34	0.21	Pain;	chr19:21307609	chr19:21554640~21569237:-
LUAD	cis	rs11673344	0.764	rs10403679	ENSG00000226686.6	LINC01535	4.71	3.18e-06	0.000712	0.27	0.21	Obesity-related traits;	chr19:36980810	chr19:37251912~37265535:+
LUAD	cis	rs11673344	0.764	rs13345491	ENSG00000226686.6	LINC01535	4.71	3.18e-06	0.000712	0.27	0.21	Obesity-related traits;	chr19:36982197	chr19:37251912~37265535:+
LUAD	cis	rs1876905	0.539	rs457497	ENSG00000255389.1	C6orf3	-4.71	3.18e-06	0.000712	-0.29	-0.21	Mean corpuscular hemoglobin;	chr6:111301346	chr6:111599875~111602295:+
LUAD	cis	rs910316	1	rs4903284	ENSG00000279594.1	RP11-950C14.10	4.71	3.18e-06	0.000712	0.24	0.21	Height;	chr14:75125780	chr14:75011269~75012851:-
LUAD	cis	rs7617773	0.963	rs12495221	ENSG00000228638.1	FCF1P2	4.71	3.18e-06	0.000712	0.23	0.21	Coronary artery disease;	chr3:48137688	chr3:48290793~48291375:-
LUAD	cis	rs2919009	0.607	rs61088531	ENSG00000271670.1	RP11-95I16.4	4.71	3.18e-06	0.000713	0.28	0.21	Obesity-related traits;	chr10:120946696	chr10:120879256~120880667:-
LUAD	cis	rs2919009	0.607	rs61872773	ENSG00000271670.1	RP11-95I16.4	4.71	3.18e-06	0.000713	0.28	0.21	Obesity-related traits;	chr10:120946998	chr10:120879256~120880667:-
LUAD	cis	rs12468226	0.808	rs77251002	ENSG00000272966.1	RP11-686O6.1	4.71	3.19e-06	0.000713	0.36	0.21	Urate levels;	chr2:202150236	chr2:202336739~202337200:+
LUAD	cis	rs6539288	0.933	rs6539289	ENSG00000260329.1	RP11-412D9.4	4.71	3.19e-06	0.000713	0.23	0.21	Total body bone mineral density;	chr12:106915538	chr12:106954029~106955497:-
LUAD	cis	rs17684571	0.872	rs13219546	ENSG00000231441.1	RP11-472M19.2	4.71	3.19e-06	0.000713	0.29	0.21	Schizophrenia;	chr6:56741480	chr6:56844002~56864078:+
LUAD	cis	rs9487094	0.813	rs35969918	ENSG00000260273.1	RP11-425D10.10	4.71	3.19e-06	0.000713	0.29	0.21	Height;	chr6:109441837	chr6:109382795~109383666:+
LUAD	cis	rs2439831	0.867	rs2614811	ENSG00000249839.1	AC011330.5	-4.71	3.19e-06	0.000713	-0.4	-0.21	Lung cancer in ever smokers;	chr15:43621289	chr15:43663654~43684339:-
LUAD	cis	rs2439831	0.85	rs28564774	ENSG00000249839.1	AC011330.5	-4.71	3.19e-06	0.000714	-0.45	-0.21	Lung cancer in ever smokers;	chr15:43833277	chr15:43663654~43684339:-
LUAD	cis	rs2439831	0.85	rs12441984	ENSG00000249839.1	AC011330.5	-4.71	3.19e-06	0.000714	-0.45	-0.21	Lung cancer in ever smokers;	chr15:43834087	chr15:43663654~43684339:-
LUAD	cis	rs6539288	0.739	rs7302653	ENSG00000260329.1	RP11-412D9.4	-4.71	3.19e-06	0.000714	-0.23	-0.21	Total body bone mineral density;	chr12:106979744	chr12:106954029~106955497:-
LUAD	cis	rs7819412	0.749	rs11991118	ENSG00000255046.1	RP11-297N6.4	-4.71	3.19e-06	0.000714	-0.25	-0.21	Triglycerides;	chr8:11081763	chr8:11797928~11802568:-
LUAD	cis	rs7829975	0.509	rs7838674	ENSG00000253893.2	FAM85B	4.71	3.19e-06	0.000714	0.27	0.21	Mood instability;	chr8:8939563	chr8:8167819~8226614:-
LUAD	cis	rs875971	1	rs2087647	ENSG00000232559.3	GS1-124K5.12	-4.71	3.19e-06	0.000714	-0.24	-0.21	Aortic root size;	chr7:66128201	chr7:66554588~66576923:-
LUAD	cis	rs875971	1	rs6958484	ENSG00000232559.3	GS1-124K5.12	-4.71	3.19e-06	0.000714	-0.24	-0.21	Aortic root size;	chr7:66134459	chr7:66554588~66576923:-
LUAD	cis	rs1008375	0.932	rs13127157	ENSG00000249502.1	AC006160.5	4.71	3.2e-06	0.000715	0.21	0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17616426	chr4:17587467~17614571:-
LUAD	cis	rs6840360	0.55	rs12651635	ENSG00000270265.1	RP11-731D1.4	-4.71	3.2e-06	0.000715	-0.24	-0.21	Intelligence (multi-trait analysis);	chr4:151636634	chr4:151333775~151353224:-
LUAD	cis	rs11673344	0.931	rs1234251	ENSG00000226686.6	LINC01535	4.71	3.2e-06	0.000715	0.26	0.21	Obesity-related traits;	chr19:37180354	chr19:37251912~37265535:+
LUAD	cis	rs7324557	0.621	rs9507166	ENSG00000205861.10	C1QTNF9B-AS1	4.71	3.2e-06	0.000715	0.28	0.21	Visceral adipose tissue adjusted for BMI;	chr13:23824844	chr13:23888889~23897263:+
LUAD	cis	rs1799949	1	rs11653460	ENSG00000236383.6	LINC00854	-4.71	3.2e-06	0.000715	-0.17	-0.21	Menopause (age at onset);	chr17:43179289	chr17:43216941~43305976:-
LUAD	cis	rs6840360	1	rs9998462	ENSG00000270265.1	RP11-731D1.4	-4.71	3.2e-06	0.000716	-0.21	-0.21	Intelligence (multi-trait analysis);	chr4:151725396	chr4:151333775~151353224:-
LUAD	cis	rs8180040	0.726	rs4682844	ENSG00000271161.1	BOLA2P2	-4.71	3.2e-06	0.000716	-0.2	-0.21	Colorectal cancer;	chr3:46941247	chr3:47499841~47500407:+
LUAD	cis	rs11673344	0.633	rs519606	ENSG00000226686.6	LINC01535	4.71	3.2e-06	0.000716	0.26	0.21	Obesity-related traits;	chr19:36942327	chr19:37251912~37265535:+
LUAD	cis	rs16873450	0.507	rs2390825	ENSG00000234800.2	PCMTD1P3	4.71	3.2e-06	0.000716	0.24	0.21	Verbal memory performance (residualized delayed recall level);	chr7:23837194	chr7:23721311~23721782:-
LUAD	cis	rs867371	0.502	rs8025964	ENSG00000276710.3	CSPG4P8	-4.71	3.2e-06	0.000716	-0.19	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82229429	chr15:82459472~82477258:+
LUAD	cis	rs12025262	0.934	rs10924961	ENSG00000227671.4	RP11-488L18.4	4.71	3.2e-06	0.000716	0.15	0.21	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr1:247198985	chr1:247189851~247210856:-
LUAD	cis	rs957448	1	rs72674866	ENSG00000253175.1	RP11-267M23.6	4.71	3.2e-06	0.000717	0.26	0.21	Nonsyndromic cleft lip with cleft palate;	chr8:94564619	chr8:94565036~94565715:+
LUAD	cis	rs957448	1	rs55897841	ENSG00000253175.1	RP11-267M23.6	4.71	3.2e-06	0.000717	0.26	0.21	Nonsyndromic cleft lip with cleft palate;	chr8:94565042	chr8:94565036~94565715:+
LUAD	cis	rs957448	0.948	rs72674867	ENSG00000253175.1	RP11-267M23.6	4.71	3.2e-06	0.000717	0.26	0.21	Nonsyndromic cleft lip with cleft palate;	chr8:94565973	chr8:94565036~94565715:+
LUAD	cis	rs916888	0.61	rs199454	ENSG00000261575.2	RP11-259G18.1	-4.71	3.2e-06	0.000717	-0.28	-0.21	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46267037~46268694:+
LUAD	cis	rs4873772	0.704	rs12675378	ENSG00000253330.1	RP11-697N18.3	-4.71	3.21e-06	0.000717	-0.24	-0.21	Lobe attachment (rater-scored or self-reported);	chr8:47538132	chr8:47511034~47512141:-
LUAD	cis	rs116175783	0.557	rs62197081	ENSG00000227403.1	AC009299.3	4.71	3.21e-06	0.000717	0.38	0.21	Intelligence (multi-trait analysis);	chr2:161336814	chr2:161244739~161249050:+
LUAD	cis	rs7208859	0.725	rs9897673	ENSG00000280069.1	CTD-2349P21.3	-4.71	3.21e-06	0.000718	-0.25	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916348	chr17:30738182~30740275:+
LUAD	cis	rs9487094	0.778	rs61318425	ENSG00000260273.1	RP11-425D10.10	4.71	3.21e-06	0.000718	0.3	0.21	Height;	chr6:109427303	chr6:109382795~109383666:+
LUAD	cis	rs17655730	0.52	rs2178798	ENSG00000277290.1	RP11-326C3.16	-4.71	3.21e-06	0.000718	-0.19	-0.21	Mean platelet volume;	chr11:254869	chr11:243099~243483:-
LUAD	cis	rs2070074	0.591	rs3739882	ENSG00000230074.1	RP11-195F19.9	4.71	3.21e-06	0.000718	0.48	0.21	CTACK levels;	chr9:34653112	chr9:34665665~34681298:+
LUAD	cis	rs13434995	0.787	rs62303724	ENSG00000273257.1	RP11-177J6.1	-4.71	3.21e-06	0.000718	-0.34	-0.21	Adiponectin levels;	chr4:55485114	chr4:55387949~55388271:+
LUAD	cis	rs13434995	0.842	rs62305269	ENSG00000273257.1	RP11-177J6.1	-4.71	3.21e-06	0.000718	-0.34	-0.21	Adiponectin levels;	chr4:55507237	chr4:55387949~55388271:+
LUAD	cis	rs13434995	0.842	rs73236149	ENSG00000273257.1	RP11-177J6.1	-4.71	3.21e-06	0.000718	-0.34	-0.21	Adiponectin levels;	chr4:55507307	chr4:55387949~55388271:+
LUAD	cis	rs56114371	0.568	rs200468	ENSG00000219392.1	RP1-265C24.5	-4.71	3.21e-06	0.000718	-0.29	-0.21	Breast cancer;	chr6:27790076	chr6:28115628~28116551:+
LUAD	cis	rs9860428	0.844	rs9878913	ENSG00000242770.2	RP11-180K7.1	4.71	3.21e-06	0.000718	0.22	0.21	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112866272	chr3:112802478~112812819:+
LUAD	cis	rs9860428	0.844	rs2399442	ENSG00000242770.2	RP11-180K7.1	4.71	3.21e-06	0.000718	0.22	0.21	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112866426	chr3:112802478~112812819:+
LUAD	cis	rs17684571	0.872	rs4275049	ENSG00000231441.1	RP11-472M19.2	4.71	3.21e-06	0.000719	0.29	0.21	Schizophrenia;	chr6:56737530	chr6:56844002~56864078:+
LUAD	cis	rs10246939	0.543	rs9640357	ENSG00000228775.6	WEE2-AS1	4.71	3.21e-06	0.000719	0.25	0.21	Bitter taste perception;	chr7:141843298	chr7:141704338~141738346:-
LUAD	cis	rs2243480	0.908	rs55876148	ENSG00000164669.11	INTS4P1	4.71	3.21e-06	0.000719	0.38	0.21	Diabetic kidney disease;	chr7:65914813	chr7:65141225~65234216:+
LUAD	cis	rs944990	0.576	rs7040832	ENSG00000227603.1	RP11-165J3.6	4.71	3.22e-06	0.000719	0.24	0.21	Body mass index;	chr9:93436508	chr9:93435332~93437121:-
LUAD	cis	rs7138803	0.616	rs2603105	ENSG00000257464.1	RP11-161H23.8	-4.71	3.22e-06	0.000719	-0.21	-0.21	Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index;	chr12:49794651	chr12:49442424~49442652:-
LUAD	cis	rs853679	0.527	rs853690	ENSG00000219392.1	RP1-265C24.5	-4.71	3.22e-06	0.00072	-0.27	-0.21	Depression;	chr6:28317705	chr6:28115628~28116551:+
LUAD	cis	rs473651	0.904	rs551859	ENSG00000229915.1	AC016999.2	-4.71	3.22e-06	0.00072	-0.28	-0.21	Multiple system atrophy;	chr2:238463195	chr2:238427077~238427729:-
LUAD	cis	rs6921919	0.945	rs7765989	ENSG00000216901.1	AL022393.7	4.71	3.23e-06	0.000721	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28432518	chr6:28176188~28176674:+
LUAD	cis	rs6676180	0.555	rs947430	ENSG00000231365.4	RP11-418J17.1	-4.71	3.23e-06	0.000722	-0.24	-0.21	Monobrow;	chr1:119236111	chr1:119140396~119275973:+
LUAD	cis	rs6714710	0.603	rs11679828	ENSG00000230606.9	AC159540.1	-4.71	3.23e-06	0.000722	-0.22	-0.21	Posterior cortical atrophy and Alzheimer's disease;	chr2:97901163	chr2:97416165~97433527:-
LUAD	cis	rs71520386	0.583	rs28799344	ENSG00000228649.7	AC005682.5	-4.71	3.23e-06	0.000722	-0.28	-0.21	Fibrinogen levels;	chr7:22805647	chr7:22854178~22861579:+
LUAD	cis	rs4664293	0.669	rs35299907	ENSG00000226266.5	AC009961.3	4.71	3.23e-06	0.000722	0.29	0.21	Monocyte percentage of white cells;	chr2:159562142	chr2:159670708~159712435:-
LUAD	cis	rs375066	0.868	rs368079	ENSG00000267058.1	RP11-15A1.3	-4.71	3.23e-06	0.000722	-0.23	-0.21	Breast cancer;	chr19:43889204	chr19:43891804~43901805:-
LUAD	cis	rs2732480	0.577	rs2634680	ENSG00000257735.1	RP11-370I10.6	4.71	3.23e-06	0.000722	0.26	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48340781	chr12:48350945~48442411:+
LUAD	cis	rs2732480	0.577	rs2634678	ENSG00000257735.1	RP11-370I10.6	4.71	3.23e-06	0.000722	0.26	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48341755	chr12:48350945~48442411:+
LUAD	cis	rs1106529	0.515	rs2810935	ENSG00000226172.2	RP4-712E4.1	4.71	3.23e-06	0.000722	0.29	0.21	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);	chr1:118910956	chr1:119000344~119001392:-
LUAD	cis	rs11159086	0.793	rs11850070	ENSG00000259005.1	RP3-449M8.6	4.71	3.23e-06	0.000722	0.27	0.21	Advanced glycation end-product levels;	chr14:74487575	chr14:74474007~74474864:-
LUAD	cis	rs11159086	0.793	rs28378078	ENSG00000259005.1	RP3-449M8.6	4.71	3.23e-06	0.000722	0.27	0.21	Advanced glycation end-product levels;	chr14:74487940	chr14:74474007~74474864:-
LUAD	cis	rs2348418	0.765	rs2078016	ENSG00000247934.4	RP11-967K21.1	-4.71	3.23e-06	0.000722	-0.24	-0.21	Lung function (FEV1);Lung function (FVC);	chr12:28180174	chr12:28163298~28190738:-
LUAD	cis	rs858239	0.508	rs2390754	ENSG00000230042.1	AK3P3	-4.71	3.23e-06	0.000722	-0.27	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23150875	chr7:23129178~23129841:+
LUAD	cis	rs6603134	0.502	rs10411185	ENSG00000267939.1	CTD-2325M2.1	-4.71	3.23e-06	0.000722	-0.24	-0.21	Blood protein levels;	chr19:8038997	chr19:8008729~8016025:+
LUAD	cis	rs9322193	0.923	rs12529698	ENSG00000268592.3	RAET1E-AS1	4.71	3.23e-06	0.000723	0.26	0.21	Lung cancer;	chr6:149650951	chr6:149863494~149919507:+
LUAD	cis	rs2115630	1	rs56074163	ENSG00000229212.6	RP11-561C5.4	4.71	3.23e-06	0.000723	0.24	0.21	P wave terminal force;	chr15:84808101	chr15:85205440~85234795:-
LUAD	cis	rs1799949	0.965	rs9911630	ENSG00000236383.6	LINC00854	-4.71	3.23e-06	0.000723	-0.17	-0.21	Menopause (age at onset);	chr17:43036325	chr17:43216941~43305976:-
LUAD	cis	rs1150668	0.699	rs2394049	ENSG00000219392.1	RP1-265C24.5	-4.71	3.24e-06	0.000723	-0.26	-0.21	Pubertal anthropometrics;	chr6:28271903	chr6:28115628~28116551:+
LUAD	cis	rs73173548	0.502	rs12659818	ENSG00000247828.6	TMEM161B-AS1	4.71	3.24e-06	0.000723	0.26	0.21	Macular telangiectasia type 2;	chr5:88451964	chr5:88268895~88436685:+
LUAD	cis	rs62025270	0.632	rs17636096	ENSG00000202081.1	RNU6-1280P	-4.71	3.24e-06	0.000724	-0.31	-0.21	Idiopathic pulmonary fibrosis;	chr15:85675503	chr15:85651522~85651628:-
LUAD	cis	rs7200786	0.692	rs1700820	ENSG00000274038.1	RP11-66H6.4	4.71	3.24e-06	0.000724	0.25	0.21	Systemic lupus erythematosus;Multiple sclerosis;	chr16:10962761	chr16:11056556~11057034:+
LUAD	cis	rs7309	0.935	rs6432674	ENSG00000227403.1	AC009299.3	-4.71	3.24e-06	0.000724	-0.25	-0.21	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161168811	chr2:161244739~161249050:+
LUAD	cis	rs7324557	0.652	rs7332811	ENSG00000205861.10	C1QTNF9B-AS1	4.71	3.24e-06	0.000724	0.28	0.21	Visceral adipose tissue adjusted for BMI;	chr13:23823066	chr13:23888889~23897263:+
LUAD	cis	rs2380205	0.517	rs12767690	ENSG00000232807.2	RP11-536K7.3	4.71	3.24e-06	0.000724	0.23	0.21	Breast cancer;	chr10:5926008	chr10:5934270~5945900:-
LUAD	cis	rs17345786	1	rs7641261	ENSG00000244119.1	PDCL3P4	4.71	3.24e-06	0.000725	0.23	0.21	Colonoscopy-negative controls vs population controls;	chr3:101560162	chr3:101712472~101713191:+
LUAD	cis	rs559928	0.606	rs56207008	ENSG00000236935.1	AP003774.1	4.71	3.25e-06	0.000725	0.31	0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64115743	chr11:64325050~64329504:-
LUAD	cis	rs801193	0.569	rs2659907	ENSG00000232559.3	GS1-124K5.12	4.71	3.25e-06	0.000725	0.25	0.21	Aortic root size;	chr7:66699045	chr7:66554588~66576923:-
LUAD	cis	rs55823223	0.648	rs11867560	ENSG00000267801.1	RP11-552F3.9	4.71	3.25e-06	0.000725	0.24	0.21	Psoriasis;	chr17:75861125	chr17:75876372~75879546:+
LUAD	cis	rs55823223	0.648	rs11867582	ENSG00000267801.1	RP11-552F3.9	4.71	3.25e-06	0.000725	0.24	0.21	Psoriasis;	chr17:75861225	chr17:75876372~75879546:+
LUAD	cis	rs301901	1	rs300049	ENSG00000250155.1	CTD-2353F22.1	-4.71	3.25e-06	0.000725	-0.22	-0.21	Height;	chr5:37083971	chr5:36666214~36725195:-
LUAD	cis	rs7937890	0.559	rs10766184	ENSG00000251991.1	RNU7-49P	4.71	3.25e-06	0.000725	0.22	0.21	Mitochondrial DNA levels;	chr11:14521031	chr11:14478892~14478953:+
LUAD	cis	rs14027	0.921	rs7813651	ENSG00000279347.1	RP11-85I17.2	-4.71	3.25e-06	0.000726	-0.19	-0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119839119	chr8:119838736~119840385:-
LUAD	cis	rs2439831	0.681	rs7168940	ENSG00000249839.1	AC011330.5	-4.71	3.25e-06	0.000726	-0.36	-0.21	Lung cancer in ever smokers;	chr15:43341136	chr15:43663654~43684339:-
LUAD	cis	rs7923609	0.846	rs7090111	ENSG00000232075.1	MRPL35P2	-4.71	3.25e-06	0.000726	-0.26	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63318234	chr10:63634317~63634827:-
LUAD	cis	rs4908768	0.539	rs7526171	ENSG00000270282.1	RP5-1115A15.2	4.71	3.25e-06	0.000726	0.23	0.21	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8590126	chr1:8512653~8513021:+
LUAD	cis	rs11089937	0.929	rs5757155	ENSG00000211638.2	IGLV8-61	-4.71	3.25e-06	0.000726	-0.21	-0.21	Periodontitis (PAL4Q3);	chr22:22165378	chr22:22098700~22099212:+
LUAD	cis	rs561341	1	rs4795667	ENSG00000265798.5	RP11-271K11.5	4.71	3.25e-06	0.000727	0.33	0.21	Hip circumference adjusted for BMI;	chr17:31917424	chr17:31038575~31059121:-
LUAD	cis	rs6728642	1	rs57035274	ENSG00000230606.9	AC159540.1	4.71	3.25e-06	0.000727	0.34	0.21	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96942387	chr2:97416165~97433527:-
LUAD	cis	rs150992	0.536	rs161729	ENSG00000248489.1	CTD-2007H13.3	4.71	3.26e-06	0.000727	0.27	0.21	Body mass index;	chr5:98982477	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.536	rs161730	ENSG00000248489.1	CTD-2007H13.3	4.71	3.26e-06	0.000727	0.27	0.21	Body mass index;	chr5:98982631	chr5:98929171~98995013:+
LUAD	cis	rs11089937	0.609	rs9622980	ENSG00000211638.2	IGLV8-61	-4.71	3.26e-06	0.000727	-0.26	-0.21	Periodontitis (PAL4Q3);	chr22:22149888	chr22:22098700~22099212:+
LUAD	cis	rs453301	0.686	rs2409120	ENSG00000173295.6	FAM86B3P	-4.71	3.26e-06	0.000728	-0.22	-0.21	Joint mobility (Beighton score);	chr8:9025061	chr8:8228595~8244865:+
LUAD	cis	rs2239557	1	rs10150201	ENSG00000259065.1	RP5-1021I20.1	4.71	3.26e-06	0.000728	0.24	0.21	Common traits (Other);	chr14:74182454	chr14:73787360~73803270:+
LUAD	cis	rs301901	0.772	rs301906	ENSG00000250155.1	CTD-2353F22.1	-4.71	3.26e-06	0.000728	-0.22	-0.21	Height;	chr5:37105504	chr5:36666214~36725195:-
LUAD	cis	rs55823223	0.59	rs11870142	ENSG00000267801.1	RP11-552F3.9	4.71	3.26e-06	0.000728	0.23	0.21	Psoriasis;	chr17:75862921	chr17:75876372~75879546:+
LUAD	cis	rs55823223	0.503	rs55699990	ENSG00000267801.1	RP11-552F3.9	4.71	3.26e-06	0.000728	0.23	0.21	Psoriasis;	chr17:75863105	chr17:75876372~75879546:+
LUAD	cis	rs7829975	0.501	rs2980769	ENSG00000253981.4	ALG1L13P	4.71	3.26e-06	0.000728	0.24	0.21	Mood instability;	chr8:8462781	chr8:8236003~8244667:-
LUAD	cis	rs2239547	0.657	rs4687554	ENSG00000242142.1	SERBP1P3	4.71	3.26e-06	0.000728	0.25	0.21	Schizophrenia;	chr3:52830119	chr3:53064283~53065091:-
LUAD	cis	rs812925	0.502	rs6545868	ENSG00000271889.1	RP11-493E12.1	-4.71	3.26e-06	0.000728	-0.25	-0.21	Immature fraction of reticulocytes;	chr2:61428230	chr2:61151433~61162105:-
LUAD	cis	rs2732480	0.517	rs2634676	ENSG00000257735.1	RP11-370I10.6	4.71	3.26e-06	0.000728	0.26	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344453	chr12:48350945~48442411:+
LUAD	cis	rs7819412	0.594	rs7460507	ENSG00000255046.1	RP11-297N6.4	4.71	3.27e-06	0.000729	0.26	0.21	Triglycerides;	chr8:11111565	chr8:11797928~11802568:-
LUAD	cis	rs9900062	0.546	rs2676294	ENSG00000270714.1	MINOS1P2	4.71	3.27e-06	0.000729	0.28	0.21	QT interval;	chr17:64714646	chr17:64747264~64747492:-
LUAD	cis	rs9322193	0.884	rs10872646	ENSG00000268592.3	RAET1E-AS1	4.71	3.27e-06	0.000729	0.26	0.21	Lung cancer;	chr6:149746539	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.884	rs12528279	ENSG00000268592.3	RAET1E-AS1	4.71	3.27e-06	0.000729	0.26	0.21	Lung cancer;	chr6:149750892	chr6:149863494~149919507:+
LUAD	cis	rs950169	0.723	rs17589320	ENSG00000275120.1	RP11-182J1.17	4.71	3.27e-06	0.000729	0.33	0.21	Schizophrenia;	chr15:84251244	chr15:84599434~84606463:-
LUAD	cis	rs950169	0.845	rs4502182	ENSG00000275120.1	RP11-182J1.17	4.71	3.27e-06	0.000729	0.33	0.21	Schizophrenia;	chr15:84254768	chr15:84599434~84606463:-
LUAD	cis	rs7138803	0.51	rs2603110	ENSG00000257464.1	RP11-161H23.8	-4.71	3.27e-06	0.000729	-0.2	-0.21	Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index;	chr12:49805533	chr12:49442424~49442652:-
LUAD	cis	rs9473147	0.516	rs9395286	ENSG00000270761.1	RP11-385F7.1	-4.71	3.27e-06	0.00073	-0.24	-0.21	Platelet distribution width;Mean platelet volume;	chr6:47607596	chr6:47477243~47477572:-
LUAD	cis	rs113835537	0.877	rs2229455	ENSG00000255517.5	CTD-3074O7.5	-4.71	3.27e-06	0.00073	-0.29	-0.21	Airway imaging phenotypes;	chr11:66560584	chr11:66473490~66480233:-
LUAD	cis	rs7829975	0.688	rs7817376	ENSG00000173295.6	FAM86B3P	-4.71	3.27e-06	0.00073	-0.22	-0.21	Mood instability;	chr8:8523020	chr8:8228595~8244865:+
LUAD	cis	rs1799949	0.965	rs11650913	ENSG00000236383.6	LINC00854	-4.71	3.27e-06	0.00073	-0.17	-0.21	Menopause (age at onset);	chr17:43179580	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs12936831	ENSG00000236383.6	LINC00854	-4.71	3.27e-06	0.00073	-0.17	-0.21	Menopause (age at onset);	chr17:43179799	chr17:43216941~43305976:-
LUAD	cis	rs12701220	0.817	rs7798459	ENSG00000229043.2	AC091729.9	-4.71	3.27e-06	0.00073	-0.26	-0.21	Bronchopulmonary dysplasia;	chr7:1048329	chr7:1160374~1165267:+
LUAD	cis	rs72717009	0.825	rs7529225	ENSG00000225217.1	HSPA7	-4.71	3.27e-06	0.00073	-0.3	-0.21	Rheumatoid arthritis;	chr1:161509562	chr1:161606291~161608217:+
LUAD	cis	rs72717009	0.825	rs7529425	ENSG00000225217.1	HSPA7	-4.71	3.27e-06	0.00073	-0.3	-0.21	Rheumatoid arthritis;	chr1:161509809	chr1:161606291~161608217:+
LUAD	cis	rs1008375	0.966	rs2286773	ENSG00000249502.1	AC006160.5	-4.71	3.27e-06	0.00073	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17614591	chr4:17587467~17614571:-
LUAD	cis	rs2337406	0.866	rs79901786	ENSG00000223648.3	IGHV3-64	4.71	3.27e-06	0.00073	0.25	0.21	Alzheimer's disease (late onset);	chr14:106777623	chr14:106643132~106658258:-
LUAD	cis	rs6802315	0.604	rs9863103	ENSG00000272087.1	RP11-379F4.7	-4.71	3.27e-06	0.00073	-0.23	-0.21	Periodontitis (CDC/AAP);	chr3:158746014	chr3:158693120~158693768:-
LUAD	cis	rs1008375	1	rs56308330	ENSG00000249502.1	AC006160.5	-4.71	3.28e-06	0.000731	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17641427	chr4:17587467~17614571:-
LUAD	cis	rs1008375	1	rs28693609	ENSG00000249502.1	AC006160.5	-4.71	3.28e-06	0.000731	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17643610	chr4:17587467~17614571:-
LUAD	cis	rs73173548	0.502	rs12653074	ENSG00000247828.6	TMEM161B-AS1	4.71	3.28e-06	0.000731	0.26	0.21	Macular telangiectasia type 2;	chr5:88452920	chr5:88268895~88436685:+
LUAD	cis	rs7119	0.717	rs11630916	ENSG00000259362.2	RP11-307C19.1	-4.71	3.28e-06	0.000731	-0.26	-0.21	Type 2 diabetes;	chr15:77528989	chr15:77525540~77534110:+
LUAD	cis	rs1075265	0.563	rs2692536	ENSG00000233266.1	HMGB1P31	4.71	3.28e-06	0.000731	0.27	0.21	Chronotype;Morning vs. evening chronotype;	chr2:53788266	chr2:54051334~54051760:+
LUAD	cis	rs875971	0.564	rs313804	ENSG00000237310.1	GS1-124K5.4	4.71	3.28e-06	0.000731	0.23	0.21	Aortic root size;	chr7:66049635	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.662	rs448725	ENSG00000237310.1	GS1-124K5.4	4.71	3.28e-06	0.000731	0.23	0.21	Aortic root size;	chr7:66049641	chr7:66493706~66495474:+
LUAD	cis	rs4908760	0.516	rs11121232	ENSG00000232912.4	RP5-1115A15.1	4.71	3.28e-06	0.000731	0.19	0.21	Vitiligo;	chr1:8790650	chr1:8424645~8434838:+
LUAD	cis	rs12745968	0.653	rs2107519	ENSG00000223787.2	RP4-593M8.1	-4.71	3.28e-06	0.000731	-0.25	-0.21	Bipolar disorder and schizophrenia;	chr1:92727313	chr1:92580476~92580821:-
LUAD	cis	rs17711722	0.701	rs781143	ENSG00000237310.1	GS1-124K5.4	4.71	3.28e-06	0.000732	0.23	0.21	Calcium levels;	chr7:65974892	chr7:66493706~66495474:+
LUAD	cis	rs950169	0.922	rs2033284	ENSG00000229212.6	RP11-561C5.4	-4.71	3.28e-06	0.000732	-0.3	-0.21	Schizophrenia;	chr15:84391575	chr15:85205440~85234795:-
LUAD	cis	rs35160687	0.644	rs11127024	ENSG00000273080.1	RP11-301O19.1	-4.71	3.28e-06	0.000732	-0.23	-0.21	Night sleep phenotypes;	chr2:86278330	chr2:86195590~86196049:+
LUAD	cis	rs9399135	0.517	rs1041478	ENSG00000232876.1	CTA-212D2.2	-4.71	3.28e-06	0.000732	-0.25	-0.21	Red blood cell count;	chr6:135130059	chr6:135055033~135060550:+
LUAD	cis	rs17189298	0.712	rs4849753	ENSG00000231013.1	AC013275.2	-4.71	3.28e-06	0.000732	-0.22	-0.21	Cerebrospinal T-tau levels;	chr2:119116553	chr2:119476448~119487346:+
LUAD	cis	rs7430456	0.967	rs6780021	ENSG00000225790.1	RP11-2L8.1	-4.71	3.29e-06	0.000733	-0.24	-0.21	Breast cancer;	chr3:177739677	chr3:177934823~177937662:+
LUAD	cis	rs1012068	0.921	rs5994442	ENSG00000236132.1	CTA-440B3.1	-4.71	3.29e-06	0.000733	-0.27	-0.21	Chronic hepatitis C infection;	chr22:31875946	chr22:31816379~31817491:-
LUAD	cis	rs4568518	0.619	rs6946266	ENSG00000279048.1	RP11-511H23.2	4.71	3.29e-06	0.000733	0.17	0.21	Measles;	chr7:17967965	chr7:17940503~17942922:+
LUAD	cis	rs7102710	1	rs7941132	ENSG00000254418.1	RP11-21L19.1	4.71	3.29e-06	0.000733	0.48	0.21	Glucagon levels in response to oral glucose tolerance test (fasting);	chr11:14281210	chr11:14262846~14273691:-
LUAD	cis	rs2243480	1	rs4718269	ENSG00000164669.11	INTS4P1	-4.71	3.29e-06	0.000733	-0.38	-0.21	Diabetic kidney disease;	chr7:65735810	chr7:65141225~65234216:+
LUAD	cis	rs1150668	0.796	rs213236	ENSG00000219392.1	RP1-265C24.5	-4.71	3.29e-06	0.000733	-0.26	-0.21	Pubertal anthropometrics;	chr6:28356620	chr6:28115628~28116551:+
LUAD	cis	rs6840360	0.762	rs62327352	ENSG00000270265.1	RP11-731D1.4	-4.71	3.29e-06	0.000734	-0.21	-0.21	Intelligence (multi-trait analysis);	chr4:151749628	chr4:151333775~151353224:-
LUAD	cis	rs8103033	0.824	rs35457488	ENSG00000226025.8	LGALS17A	-4.71	3.29e-06	0.000734	-0.23	-0.21	Obesity-related traits;	chr19:39646532	chr19:39679374~39686373:+
LUAD	cis	rs17772222	0.917	rs12431548	ENSG00000258983.2	RP11-507K2.2	4.71	3.29e-06	0.000734	0.26	0.21	Coronary artery calcification;	chr14:88635826	chr14:88499334~88515502:+
LUAD	cis	rs1008375	1	rs3815413	ENSG00000249502.1	AC006160.5	-4.71	3.29e-06	0.000734	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17653025	chr4:17587467~17614571:-
LUAD	cis	rs4835473	0.838	rs10024263	ENSG00000251600.4	RP11-673E1.1	4.71	3.29e-06	0.000734	0.26	0.21	Immature fraction of reticulocytes;	chr4:144038174	chr4:143912331~143982454:+
LUAD	cis	rs7819412	0.538	rs4523214	ENSG00000255046.1	RP11-297N6.4	4.71	3.29e-06	0.000734	0.26	0.21	Triglycerides;	chr8:11113263	chr8:11797928~11802568:-
LUAD	cis	rs10897473	0.554	rs7115071	ENSG00000236935.1	AP003774.1	-4.71	3.3e-06	0.000735	-0.21	-0.21	Immature fraction of reticulocytes;	chr11:64084161	chr11:64325050~64329504:-
LUAD	cis	rs9545047	0.604	rs12875039	ENSG00000227354.5	RBM26-AS1	-4.71	3.3e-06	0.000735	-0.22	-0.21	Schizophrenia;	chr13:79327449	chr13:79406309~79424328:+
LUAD	cis	rs3808502	0.549	rs7831039	ENSG00000255046.1	RP11-297N6.4	4.71	3.3e-06	0.000735	0.26	0.21	Neuroticism;	chr8:11570128	chr8:11797928~11802568:-
LUAD	cis	rs2617170	0.961	rs2617171	ENSG00000245648.1	RP11-277P12.20	4.71	3.3e-06	0.000735	0.26	0.21	Behcet's disease;	chr12:10408680	chr12:10363769~10398506:+
LUAD	cis	rs301901	0.796	rs4869520	ENSG00000250155.1	CTD-2353F22.1	4.71	3.3e-06	0.000735	0.22	0.21	Height;	chr5:37508981	chr5:36666214~36725195:-
LUAD	cis	rs301901	0.796	rs1517789	ENSG00000250155.1	CTD-2353F22.1	4.71	3.3e-06	0.000735	0.22	0.21	Height;	chr5:37510578	chr5:36666214~36725195:-
LUAD	cis	rs3809863	0.646	rs9899121	ENSG00000228782.6	CTD-2026D20.3	4.71	3.3e-06	0.000736	0.23	0.21	Glaucoma (primary open-angle);	chr17:47317778	chr17:47450568~47492492:-
LUAD	cis	rs30380	1	rs469758	ENSG00000248734.2	CTD-2260A17.1	4.71	3.3e-06	0.000736	0.22	0.21	Cerebrospinal fluid biomarker levels;	chr5:96786011	chr5:96784777~96785999:+
LUAD	cis	rs4660214	0.724	rs3931300	ENSG00000228060.1	RP11-69E11.8	4.71	3.3e-06	0.000736	0.19	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39195175	chr1:39565160~39573203:+
LUAD	cis	rs375066	0.935	rs384522	ENSG00000267058.1	RP11-15A1.3	-4.71	3.3e-06	0.000736	-0.24	-0.21	Breast cancer;	chr19:43900892	chr19:43891804~43901805:-
LUAD	cis	rs4664293	0.899	rs7588710	ENSG00000226266.5	AC009961.3	-4.71	3.3e-06	0.000736	-0.3	-0.21	Monocyte percentage of white cells;	chr2:159673011	chr2:159670708~159712435:-
LUAD	cis	rs8031584	0.672	rs17815726	ENSG00000270015.1	RP11-540B6.6	4.71	3.3e-06	0.000736	0.17	0.21	Huntington's disease progression;	chr15:31021049	chr15:30926514~30928407:+
LUAD	cis	rs3758785	0.737	rs12270338	ENSG00000255893.1	RP11-685N10.1	4.71	3.3e-06	0.000736	0.28	0.21	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94414298	chr11:94472908~94473570:-
LUAD	cis	rs7172677	0.691	rs12901092	ENSG00000260269.4	CTD-2323K18.1	4.71	3.3e-06	0.000736	0.27	0.21	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75081804	chr15:75527150~75601205:-
LUAD	cis	rs41369048	0.669	rs6660867	ENSG00000272823.1	RP11-295M18.6	-4.71	3.31e-06	0.000737	-0.31	-0.21	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220864097	chr1:220828676~220829211:-
LUAD	cis	rs1062177	0.756	rs2915815	ENSG00000253921.1	CTB-113P19.3	4.71	3.31e-06	0.000737	0.31	0.21	Preschool internalizing problems;	chr5:151736322	chr5:151753992~151767247:+
LUAD	cis	rs3770081	1	rs56104203	ENSG00000273080.1	RP11-301O19.1	-4.71	3.31e-06	0.000738	-0.47	-0.21	Facial emotion recognition (sad faces);	chr2:86109133	chr2:86195590~86196049:+
LUAD	cis	rs2153535	0.585	rs9378565	ENSG00000230939.1	RP11-314C16.1	-4.71	3.31e-06	0.000739	-0.24	-0.21	Motion sickness;	chr6:8664580	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.561	rs9405407	ENSG00000230939.1	RP11-314C16.1	-4.71	3.31e-06	0.000739	-0.24	-0.21	Motion sickness;	chr6:8665199	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.585	rs9378566	ENSG00000230939.1	RP11-314C16.1	-4.71	3.31e-06	0.000739	-0.24	-0.21	Motion sickness;	chr6:8665203	chr6:8784178~8785445:+
LUAD	cis	rs910316	1	rs2268617	ENSG00000279594.1	RP11-950C14.10	4.71	3.32e-06	0.000739	0.24	0.21	Height;	chr14:75142025	chr14:75011269~75012851:-
LUAD	cis	rs7189233	0.531	rs7194730	ENSG00000279344.1	RP11-44F14.7	4.71	3.32e-06	0.000739	0.17	0.21	Intelligence (multi-trait analysis);	chr16:53455278	chr16:53478957~53481550:-
LUAD	cis	rs7189233	0.531	rs13332406	ENSG00000279344.1	RP11-44F14.7	4.71	3.32e-06	0.000739	0.17	0.21	Intelligence (multi-trait analysis);	chr16:53455793	chr16:53478957~53481550:-
LUAD	cis	rs7017914	0.629	rs2732111	ENSG00000223220.1	Y_RNA	4.71	3.32e-06	0.000739	0.24	0.21	Bone mineral density;	chr8:71015194	chr8:70780914~70781008:-
LUAD	cis	rs11159086	0.793	rs10150696	ENSG00000259005.1	RP3-449M8.6	4.71	3.32e-06	0.00074	0.27	0.21	Advanced glycation end-product levels;	chr14:74476723	chr14:74474007~74474864:-
LUAD	cis	rs6142102	0.517	rs6059580	ENSG00000275784.1	RP5-1125A11.6	-4.71	3.32e-06	0.00074	-0.23	-0.21	Skin pigmentation;	chr20:33940067	chr20:33989480~33991818:-
LUAD	cis	rs1790761	0.667	rs658768	ENSG00000184224.3	C11orf72	4.71	3.32e-06	0.00074	0.24	0.21	Mean corpuscular volume;	chr11:67570337	chr11:67602880~67606706:-
LUAD	cis	rs1790761	0.667	rs591434	ENSG00000184224.3	C11orf72	4.71	3.32e-06	0.00074	0.24	0.21	Mean corpuscular volume;	chr11:67570343	chr11:67602880~67606706:-
LUAD	cis	rs7493	0.95	rs7785846	ENSG00000233942.1	AC004012.1	4.71	3.32e-06	0.00074	0.3	0.21	Yu-Zhi constitution type in type 2 diabetes;	chr7:95404529	chr7:95471835~95473998:+
LUAD	cis	rs4964805	0.632	rs11111782	ENSG00000257681.1	RP11-341G23.4	-4.71	3.32e-06	0.00074	-0.22	-0.21	Attention deficit hyperactivity disorder;	chr12:103794698	chr12:103746315~103768858:-
LUAD	cis	rs2708377	0.789	rs3911150	ENSG00000270863.1	DDX55P1	-4.71	3.32e-06	0.00074	-0.36	-0.21	Bitter taste perception;	chr12:11049649	chr12:11512723~11514136:+
LUAD	cis	rs9549328	0.837	rs9549618	ENSG00000267868.1	RP11-120K24.3	4.7	3.32e-06	0.00074	0.26	0.21	Systolic blood pressure;	chr13:112974334	chr13:112964835~112966131:-
LUAD	cis	rs4664293	0.625	rs2114625	ENSG00000226266.5	AC009961.3	-4.7	3.33e-06	0.000741	-0.28	-0.21	Monocyte percentage of white cells;	chr2:159687297	chr2:159670708~159712435:-
LUAD	cis	rs301901	0.828	rs56007618	ENSG00000250155.1	CTD-2353F22.1	4.7	3.33e-06	0.000741	0.22	0.21	Height;	chr5:37475788	chr5:36666214~36725195:-
LUAD	cis	rs301901	0.828	rs55731764	ENSG00000250155.1	CTD-2353F22.1	4.7	3.33e-06	0.000741	0.22	0.21	Height;	chr5:37475789	chr5:36666214~36725195:-
LUAD	cis	rs12701220	0.894	rs12539012	ENSG00000229043.2	AC091729.9	-4.7	3.33e-06	0.000741	-0.28	-0.21	Bronchopulmonary dysplasia;	chr7:1012497	chr7:1160374~1165267:+
LUAD	cis	rs12701220	0.894	rs13224488	ENSG00000229043.2	AC091729.9	-4.7	3.33e-06	0.000741	-0.28	-0.21	Bronchopulmonary dysplasia;	chr7:1012717	chr7:1160374~1165267:+
LUAD	cis	rs2378497	1	rs12137800	ENSG00000232679.1	RP11-400N13.3	4.7	3.33e-06	0.000741	0.33	0.21	Serum thyroid-stimulating hormone levels;	chr1:222005713	chr1:222041705~222064763:-
LUAD	cis	rs12745968	0.653	rs6660136	ENSG00000223787.2	RP4-593M8.1	-4.7	3.33e-06	0.000741	-0.25	-0.21	Bipolar disorder and schizophrenia;	chr1:92699650	chr1:92580476~92580821:-
LUAD	cis	rs12745968	0.623	rs6604007	ENSG00000223787.2	RP4-593M8.1	-4.7	3.33e-06	0.000741	-0.25	-0.21	Bipolar disorder and schizophrenia;	chr1:92705007	chr1:92580476~92580821:-
LUAD	cis	rs10466239	0.614	rs56214316	ENSG00000230555.2	RP11-517P14.2	4.7	3.33e-06	0.000742	0.34	0.21	Telomere length;	chr10:43365658	chr10:43420738~43422100:+
LUAD	cis	rs6840360	0.615	rs6831810	ENSG00000270265.1	RP11-731D1.4	-4.7	3.33e-06	0.000742	-0.24	-0.21	Intelligence (multi-trait analysis);	chr4:151540843	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.615	rs56319216	ENSG00000270265.1	RP11-731D1.4	-4.7	3.33e-06	0.000742	-0.24	-0.21	Intelligence (multi-trait analysis);	chr4:151542564	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.615	rs4696095	ENSG00000270265.1	RP11-731D1.4	-4.7	3.33e-06	0.000742	-0.24	-0.21	Intelligence (multi-trait analysis);	chr4:151546091	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.615	rs72728171	ENSG00000270265.1	RP11-731D1.4	-4.7	3.33e-06	0.000742	-0.24	-0.21	Intelligence (multi-trait analysis);	chr4:151548220	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.615	rs72728173	ENSG00000270265.1	RP11-731D1.4	-4.7	3.33e-06	0.000742	-0.24	-0.21	Intelligence (multi-trait analysis);	chr4:151548221	chr4:151333775~151353224:-
LUAD	cis	rs7119	0.651	rs8025968	ENSG00000259362.2	RP11-307C19.1	-4.7	3.33e-06	0.000742	-0.27	-0.21	Type 2 diabetes;	chr15:77547274	chr15:77525540~77534110:+
LUAD	cis	rs8072100	0.701	rs10163469	ENSG00000228782.6	CTD-2026D20.3	-4.7	3.33e-06	0.000742	-0.22	-0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47610401	chr17:47450568~47492492:-
LUAD	cis	rs219780	0.821	rs219777	ENSG00000233818.1	AP000695.4	4.7	3.34e-06	0.000743	0.25	0.21	Kidney stones;	chr21:36462423	chr21:36445731~36532408:+
LUAD	cis	rs17711722	0.701	rs781145	ENSG00000237310.1	GS1-124K5.4	4.7	3.34e-06	0.000743	0.23	0.21	Calcium levels;	chr7:65975383	chr7:66493706~66495474:+
LUAD	cis	rs301901	0.796	rs62359002	ENSG00000250155.1	CTD-2353F22.1	4.7	3.34e-06	0.000744	0.22	0.21	Height;	chr5:37499677	chr5:36666214~36725195:-
LUAD	cis	rs55823223	0.504	rs56098714	ENSG00000267801.1	RP11-552F3.9	4.7	3.34e-06	0.000744	0.23	0.21	Psoriasis;	chr17:75864222	chr17:75876372~75879546:+
LUAD	cis	rs561341	0.714	rs111760509	ENSG00000265798.5	RP11-271K11.5	4.7	3.34e-06	0.000744	0.34	0.21	Hip circumference adjusted for BMI;	chr17:31977301	chr17:31038575~31059121:-
LUAD	cis	rs736801	0.808	rs4705950	ENSG00000233006.5	AC034220.3	4.7	3.34e-06	0.000744	0.19	0.21	Mosquito bite size;Breast cancer;	chr5:132457594	chr5:132311285~132369916:-
LUAD	cis	rs2337406	0.587	rs916547	ENSG00000211972.2	IGHV3-66	4.7	3.34e-06	0.000744	0.22	0.21	Alzheimer's disease (late onset);	chr14:106646735	chr14:106675017~106675544:-
LUAD	cis	rs477895	0.838	rs72922039	ENSG00000236935.1	AP003774.1	-4.7	3.34e-06	0.000744	-0.26	-0.21	Mean platelet volume;	chr11:64245644	chr11:64325050~64329504:-
LUAD	cis	rs6668108	1	rs6668108	ENSG00000224358.1	RP11-466F5.8	-4.7	3.34e-06	0.000744	-0.37	-0.21	Intraocular pressure;	chr1:165722083	chr1:165768929~165775176:+
LUAD	cis	rs9813712	0.523	rs9866942	ENSG00000249846.5	RP11-77P16.4	-4.7	3.34e-06	0.000744	-0.24	-0.21	Response to amphetamines;	chr3:130297796	chr3:130112550~130120579:+
LUAD	cis	rs8180040	0.62	rs9858443	ENSG00000271161.1	BOLA2P2	4.7	3.35e-06	0.000745	0.2	0.21	Colorectal cancer;	chr3:47044558	chr3:47499841~47500407:+
LUAD	cis	rs8180040	0.62	rs4683322	ENSG00000271161.1	BOLA2P2	4.7	3.35e-06	0.000745	0.2	0.21	Colorectal cancer;	chr3:47051699	chr3:47499841~47500407:+
LUAD	cis	rs9322193	0.923	rs12174349	ENSG00000268592.3	RAET1E-AS1	4.7	3.35e-06	0.000745	0.26	0.21	Lung cancer;	chr6:149718012	chr6:149863494~149919507:+
LUAD	cis	rs2836950	0.52	rs11911087	ENSG00000255568.3	BRWD1-AS2	-4.7	3.35e-06	0.000745	-0.2	-0.21	Menarche (age at onset);	chr21:39293266	chr21:39313935~39314962:+
LUAD	cis	rs875971	0.522	rs6960048	ENSG00000237310.1	GS1-124K5.4	4.7	3.35e-06	0.000745	0.22	0.21	Aortic root size;	chr7:65943052	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.66	rs28698552	ENSG00000224316.1	RP11-479O9.2	4.7	3.35e-06	0.000745	0.21	0.21	Aortic root size;	chr7:66540031	chr7:65773620~65802067:+
LUAD	cis	rs875971	0.66	rs62465434	ENSG00000224316.1	RP11-479O9.2	4.7	3.35e-06	0.000745	0.21	0.21	Aortic root size;	chr7:66540165	chr7:65773620~65802067:+
LUAD	cis	rs875971	0.66	rs13224319	ENSG00000224316.1	RP11-479O9.2	4.7	3.35e-06	0.000745	0.21	0.21	Aortic root size;	chr7:66542376	chr7:65773620~65802067:+
LUAD	cis	rs1799949	0.86	rs8176279	ENSG00000236383.6	LINC00854	-4.7	3.35e-06	0.000746	-0.16	-0.21	Menopause (age at onset);	chr17:43058379	chr17:43216941~43305976:-
LUAD	cis	rs227275	0.554	rs223315	ENSG00000251288.2	RP11-10L12.2	-4.7	3.36e-06	0.000746	-0.25	-0.21	Allergic disease (asthma, hay fever or eczema);	chr4:102884286	chr4:102751401~102752641:+
LUAD	cis	rs1790761	0.692	rs674783	ENSG00000184224.3	C11orf72	4.7	3.36e-06	0.000747	0.24	0.21	Mean corpuscular volume;	chr11:67571605	chr11:67602880~67606706:-
LUAD	cis	rs9473147	0.516	rs9381564	ENSG00000270761.1	RP11-385F7.1	-4.7	3.36e-06	0.000747	-0.25	-0.21	Platelet distribution width;Mean platelet volume;	chr6:47476070	chr6:47477243~47477572:-
LUAD	cis	rs2976388	0.967	rs2585183	ENSG00000253741.1	CTD-2292P10.4	4.7	3.36e-06	0.000747	0.24	0.21	Urinary tract infection frequency;	chr8:142684641	chr8:142702252~142726973:-
LUAD	cis	rs12745968	0.589	rs10782936	ENSG00000223787.2	RP4-593M8.1	-4.7	3.36e-06	0.000747	-0.25	-0.21	Bipolar disorder and schizophrenia;	chr1:92576349	chr1:92580476~92580821:-
LUAD	cis	rs9322193	0.923	rs55849538	ENSG00000268592.3	RAET1E-AS1	4.7	3.36e-06	0.000748	0.27	0.21	Lung cancer;	chr6:149635330	chr6:149863494~149919507:+
LUAD	cis	rs301901	0.662	rs7726960	ENSG00000250155.1	CTD-2353F22.1	4.7	3.36e-06	0.000748	0.22	0.21	Height;	chr5:37490184	chr5:36666214~36725195:-
LUAD	cis	rs227275	0.554	rs223319	ENSG00000251288.2	RP11-10L12.2	-4.7	3.36e-06	0.000748	-0.25	-0.21	Allergic disease (asthma, hay fever or eczema);	chr4:102881157	chr4:102751401~102752641:+
LUAD	cis	rs228614	0.509	rs223318	ENSG00000251288.2	RP11-10L12.2	-4.7	3.36e-06	0.000748	-0.25	-0.21	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102881422	chr4:102751401~102752641:+
LUAD	cis	rs61542988	0.532	rs12673996	ENSG00000228649.7	AC005682.5	4.7	3.37e-06	0.000749	0.3	0.21	Fibrinogen levels;	chr7:22793781	chr7:22854178~22861579:+
LUAD	cis	rs2018683	1	rs4719963	ENSG00000228421.2	AC005013.5	-4.7	3.37e-06	0.000749	-0.23	-0.21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28971448	chr7:28957667~28959345:+
LUAD	cis	rs301901	0.828	rs62361485	ENSG00000250155.1	CTD-2353F22.1	4.7	3.37e-06	0.000749	0.22	0.21	Height;	chr5:37474739	chr5:36666214~36725195:-
LUAD	cis	rs6088590	1	rs2076668	ENSG00000276073.1	RP5-1125A11.7	-4.7	3.37e-06	0.000749	-0.22	-0.21	Coronary artery disease;	chr20:34849818	chr20:33985617~33988989:-
LUAD	cis	rs7119	0.717	rs8040702	ENSG00000259362.2	RP11-307C19.1	-4.7	3.37e-06	0.000749	-0.26	-0.21	Type 2 diabetes;	chr15:77511273	chr15:77525540~77534110:+
LUAD	cis	rs1008375	1	rs1860596	ENSG00000249502.1	AC006160.5	-4.7	3.37e-06	0.000749	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17658459	chr4:17587467~17614571:-
LUAD	cis	rs7119	0.717	rs12916515	ENSG00000259362.2	RP11-307C19.1	-4.7	3.37e-06	0.000749	-0.26	-0.21	Type 2 diabetes;	chr15:77526176	chr15:77525540~77534110:+
LUAD	cis	rs2028299	0.919	rs8026131	ENSG00000259677.1	RP11-493E3.1	4.7	3.37e-06	0.000749	0.25	0.21	Type 2 diabetes;	chr15:89874767	chr15:89876540~89877285:+
LUAD	cis	rs2028299	0.879	rs986505	ENSG00000259677.1	RP11-493E3.1	4.7	3.37e-06	0.000749	0.25	0.21	Type 2 diabetes;	chr15:89875181	chr15:89876540~89877285:+
LUAD	cis	rs77686669	1	rs77686669	ENSG00000242294.5	STAG3L5P	4.7	3.37e-06	0.00075	0.17	0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr7:100146949	chr7:100336079~100351900:+
LUAD	cis	rs11673344	0.864	rs703537	ENSG00000226686.6	LINC01535	4.7	3.37e-06	0.00075	0.27	0.21	Obesity-related traits;	chr19:37016827	chr19:37251912~37265535:+
LUAD	cis	rs3930017	1	rs7783809	ENSG00000242435.1	UPK3BP1	4.7	3.38e-06	0.00075	0.23	0.21	Body mass index;	chr7:77090234	chr7:77004662~77005774:+
LUAD	cis	rs8072100	0.967	rs8075411	ENSG00000228782.6	CTD-2026D20.3	-4.7	3.38e-06	0.000751	-0.22	-0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47599394	chr17:47450568~47492492:-
LUAD	cis	rs9400467	0.528	rs10872066	ENSG00000230177.1	RP5-1112D6.4	-4.7	3.38e-06	0.000751	-0.18	-0.21	Amino acid levels;Blood metabolite levels;	chr6:111272408	chr6:111277932~111278742:+
LUAD	cis	rs5769707	0.681	rs9616329	ENSG00000235111.1	RP1-29C18.8	-4.7	3.38e-06	0.000751	-0.25	-0.21	Monocyte percentage of white cells;Monocyte count;	chr22:49632666	chr22:49612657~49615716:-
LUAD	cis	rs1790761	0.692	rs638140	ENSG00000184224.3	C11orf72	4.7	3.38e-06	0.000751	0.24	0.21	Mean corpuscular volume;	chr11:67566387	chr11:67602880~67606706:-
LUAD	cis	rs1790761	0.692	rs1269981	ENSG00000184224.3	C11orf72	4.7	3.38e-06	0.000751	0.24	0.21	Mean corpuscular volume;	chr11:67567488	chr11:67602880~67606706:-
LUAD	cis	rs1790761	0.658	rs666328	ENSG00000184224.3	C11orf72	4.7	3.38e-06	0.000751	0.24	0.21	Mean corpuscular volume;	chr11:67568067	chr11:67602880~67606706:-
LUAD	cis	rs1790761	0.667	rs11227837	ENSG00000184224.3	C11orf72	4.7	3.38e-06	0.000751	0.24	0.21	Mean corpuscular volume;	chr11:67568953	chr11:67602880~67606706:-
LUAD	cis	rs4660456	0.529	rs61779237	ENSG00000237899.1	RP4-739H11.3	4.7	3.38e-06	0.000751	0.24	0.21	Platelet count;	chr1:40685300	chr1:40669089~40687588:-
LUAD	cis	rs559928	0.606	rs78038516	ENSG00000236935.1	AP003774.1	4.7	3.38e-06	0.000752	0.3	0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64210595	chr11:64325050~64329504:-
LUAD	cis	rs9813712	0.595	rs16825656	ENSG00000249846.5	RP11-77P16.4	-4.7	3.38e-06	0.000752	-0.25	-0.21	Response to amphetamines;	chr3:130286225	chr3:130112550~130120579:+
LUAD	cis	rs948562	0.681	rs10792180	ENSG00000280010.1	AP001350.4	4.7	3.38e-06	0.000752	0.28	0.21	Lymphoma;	chr11:58660116	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.681	rs78570565	ENSG00000280010.1	AP001350.4	4.7	3.38e-06	0.000752	0.28	0.21	Lymphoma;	chr11:58664597	chr11:58627435~58628528:+
LUAD	cis	rs2018683	0.621	rs10261556	ENSG00000228421.2	AC005013.5	4.7	3.38e-06	0.000752	0.23	0.21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28937019	chr7:28957667~28959345:+
LUAD	cis	rs11023332	0.706	rs11023380	ENSG00000251991.1	RNU7-49P	4.7	3.39e-06	0.000752	0.23	0.21	Vitamin D levels;Adiponectin levels;	chr11:14908512	chr11:14478892~14478953:+
LUAD	cis	rs11023332	0.8	rs12271890	ENSG00000251991.1	RNU7-49P	4.7	3.39e-06	0.000752	0.23	0.21	Vitamin D levels;Adiponectin levels;	chr11:14913140	chr11:14478892~14478953:+
LUAD	cis	rs17680741	0.802	rs7088704	ENSG00000226659.1	RP11-137H2.4	-4.7	3.39e-06	0.000752	-0.3	-0.21	Coronary artery disease;	chr10:80482174	chr10:80529597~80535942:-
LUAD	cis	rs1008375	0.966	rs4698638	ENSG00000249502.1	AC006160.5	-4.7	3.39e-06	0.000753	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17631365	chr4:17587467~17614571:-
LUAD	cis	rs1008375	1	rs6818639	ENSG00000249502.1	AC006160.5	-4.7	3.39e-06	0.000753	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17631426	chr4:17587467~17614571:-
LUAD	cis	rs897984	0.806	rs4889571	ENSG00000260911.2	RP11-196G11.2	-4.7	3.39e-06	0.000753	-0.19	-0.21	Dementia with Lewy bodies;	chr16:30937726	chr16:31043150~31049868:+
LUAD	cis	rs897984	0.806	rs11640534	ENSG00000260911.2	RP11-196G11.2	-4.7	3.39e-06	0.000753	-0.19	-0.21	Dementia with Lewy bodies;	chr16:30938194	chr16:31043150~31049868:+
LUAD	cis	rs4908768	0.501	rs1024197	ENSG00000270282.1	RP5-1115A15.2	4.7	3.39e-06	0.000753	0.23	0.21	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8476998	chr1:8512653~8513021:+
LUAD	cis	rs2439831	0.85	rs694985	ENSG00000249839.1	AC011330.5	-4.7	3.39e-06	0.000753	-0.37	-0.21	Lung cancer in ever smokers;	chr15:43521189	chr15:43663654~43684339:-
LUAD	cis	rs12701220	0.522	rs12334290	ENSG00000229043.2	AC091729.9	-4.7	3.39e-06	0.000753	-0.24	-0.21	Bronchopulmonary dysplasia;	chr7:1014881	chr7:1160374~1165267:+
LUAD	cis	rs34375054	0.526	rs34764657	ENSG00000279233.1	RP11-158L12.4	4.7	3.39e-06	0.000753	0.18	0.21	Post bronchodilator FEV1/FVC ratio;	chr12:125195093	chr12:125138245~125141711:+
LUAD	cis	rs8180040	0.726	rs9843075	ENSG00000271161.1	BOLA2P2	4.7	3.39e-06	0.000754	0.2	0.21	Colorectal cancer;	chr3:47154140	chr3:47499841~47500407:+
LUAD	cis	rs10895987	0.955	rs7114094	ENSG00000254614.2	AP003068.23	4.7	3.39e-06	0.000754	0.33	0.21	Blood protein levels;	chr11:65159740	chr11:65177606~65181834:-
LUAD	cis	rs10463554	0.889	rs246911	ENSG00000250682.4	LINC00491	4.7	3.39e-06	0.000754	0.26	0.21	Parkinson's disease;	chr5:103227502	chr5:102609156~102671559:-
LUAD	cis	rs8072100	0.713	rs11651643	ENSG00000228782.6	CTD-2026D20.3	4.7	3.4e-06	0.000754	0.22	0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47405863	chr17:47450568~47492492:-
LUAD	cis	rs8072100	0.713	rs9895776	ENSG00000228782.6	CTD-2026D20.3	4.7	3.4e-06	0.000754	0.22	0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47408637	chr17:47450568~47492492:-
LUAD	cis	rs8072100	0.738	rs3736438	ENSG00000228782.6	CTD-2026D20.3	4.7	3.4e-06	0.000754	0.22	0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47409285	chr17:47450568~47492492:-
LUAD	cis	rs1008375	1	rs1860597	ENSG00000249502.1	AC006160.5	-4.7	3.4e-06	0.000754	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17656027	chr4:17587467~17614571:-
LUAD	cis	rs8072100	0.967	rs4793842	ENSG00000228782.6	CTD-2026D20.3	-4.7	3.4e-06	0.000755	-0.22	-0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47594140	chr17:47450568~47492492:-
LUAD	cis	rs7829975	0.714	rs4841040	ENSG00000253981.4	ALG1L13P	4.7	3.4e-06	0.000755	0.24	0.21	Mood instability;	chr8:8797017	chr8:8236003~8244667:-
LUAD	cis	rs2836950	0.52	rs59916147	ENSG00000255568.3	BRWD1-AS2	-4.7	3.4e-06	0.000755	-0.2	-0.21	Menarche (age at onset);	chr21:39262776	chr21:39313935~39314962:+
LUAD	cis	rs2243480	1	rs431076	ENSG00000164669.11	INTS4P1	4.7	3.4e-06	0.000755	0.37	0.21	Diabetic kidney disease;	chr7:66135333	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs2257790	ENSG00000164669.11	INTS4P1	4.7	3.4e-06	0.000755	0.37	0.21	Diabetic kidney disease;	chr7:66135463	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs2460422	ENSG00000164669.11	INTS4P1	4.7	3.4e-06	0.000755	0.37	0.21	Diabetic kidney disease;	chr7:66136518	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs316334	ENSG00000164669.11	INTS4P1	4.7	3.4e-06	0.000755	0.37	0.21	Diabetic kidney disease;	chr7:66137139	chr7:65141225~65234216:+
LUAD	cis	rs7302981	0.899	rs1862043	ENSG00000272368.2	RP4-605O3.4	-4.7	3.4e-06	0.000755	-0.25	-0.21	Systolic blood pressure;	chr12:50182533	chr12:50112197~50165618:+
LUAD	cis	rs2286503	0.901	rs10950922	ENSG00000226329.2	AC005682.6	4.7	3.4e-06	0.000756	0.27	0.21	Fibrinogen;	chr7:22814387	chr7:22863874~22881350:-
LUAD	cis	rs7017914	0.667	rs1481801	ENSG00000223220.1	Y_RNA	4.7	3.4e-06	0.000756	0.25	0.21	Bone mineral density;	chr8:71077484	chr8:70780914~70781008:-
LUAD	cis	rs6496932	0.635	rs11074191	ENSG00000259630.2	CTD-2262B20.1	-4.7	3.4e-06	0.000756	-0.26	-0.21	Central corneal thickness;Corneal structure;	chr15:85388794	chr15:85415228~85415633:+
LUAD	cis	rs12446632	0.824	rs66674044	ENSG00000261195.1	CTD-2380F24.1	-4.7	3.4e-06	0.000756	-0.3	-0.21	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Menarche (age at onset);Obesity;Childhood body mass index;Waist circumference;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr16:19893022	chr16:19761172~19766099:-
LUAD	cis	rs2378497	0.887	rs12122410	ENSG00000232679.1	RP11-400N13.3	4.7	3.41e-06	0.000756	0.31	0.21	Serum thyroid-stimulating hormone levels;	chr1:222038169	chr1:222041705~222064763:-
LUAD	cis	rs62025270	0.522	rs16943120	ENSG00000202081.1	RNU6-1280P	-4.7	3.41e-06	0.000757	-0.3	-0.21	Idiopathic pulmonary fibrosis;	chr15:85683066	chr15:85651522~85651628:-
LUAD	cis	rs6687758	1	rs12739936	ENSG00000227925.1	RP11-191N8.2	4.7	3.41e-06	0.000757	0.3	0.21	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222009847	chr1:221827666~221840666:-
LUAD	cis	rs1075265	0.522	rs7584474	ENSG00000233266.1	HMGB1P31	4.7	3.41e-06	0.000757	0.27	0.21	Chronotype;Morning vs. evening chronotype;	chr2:53674874	chr2:54051334~54051760:+
LUAD	cis	rs16873450	0.527	rs6461743	ENSG00000234800.2	PCMTD1P3	4.7	3.41e-06	0.000757	0.23	0.21	Verbal memory performance (residualized delayed recall level);	chr7:23831972	chr7:23721311~23721782:-
LUAD	cis	rs16873450	0.527	rs2214236	ENSG00000234800.2	PCMTD1P3	4.7	3.41e-06	0.000757	0.23	0.21	Verbal memory performance (residualized delayed recall level);	chr7:23832790	chr7:23721311~23721782:-
LUAD	cis	rs6088590	0.93	rs6120723	ENSG00000276073.1	RP5-1125A11.7	-4.7	3.41e-06	0.000757	-0.21	-0.21	Coronary artery disease;	chr20:34776852	chr20:33985617~33988989:-
LUAD	cis	rs6088590	0.965	rs6120727	ENSG00000276073.1	RP5-1125A11.7	-4.7	3.41e-06	0.000757	-0.21	-0.21	Coronary artery disease;	chr20:34786299	chr20:33985617~33988989:-
LUAD	cis	rs9860428	0.679	rs1032726	ENSG00000242770.2	RP11-180K7.1	4.7	3.41e-06	0.000757	0.22	0.21	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112967228	chr3:112802478~112812819:+
LUAD	cis	rs6539247	0.509	rs2374584	ENSG00000257890.1	RP11-114F10.2	-4.7	3.41e-06	0.000758	-0.22	-0.21	Attention function in attention deficit hyperactive disorder;	chr12:106052210	chr12:106050961~106058254:-
LUAD	cis	rs9545047	0.604	rs9530906	ENSG00000227354.5	RBM26-AS1	4.7	3.41e-06	0.000758	0.22	0.21	Schizophrenia;	chr13:79372401	chr13:79406309~79424328:+
LUAD	cis	rs8177876	0.822	rs56198248	ENSG00000261061.1	RP11-303E16.2	-4.7	3.42e-06	0.000758	-0.4	-0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074869	chr16:81030770~81031485:+
LUAD	cis	rs6840258	0.941	rs55913164	ENSG00000251411.1	RP11-397E7.4	-4.7	3.42e-06	0.000758	-0.28	-0.21	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86977778	chr4:86913266~86914817:-
LUAD	cis	rs6840258	1	rs17752307	ENSG00000251411.1	RP11-397E7.4	-4.7	3.42e-06	0.000758	-0.28	-0.21	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86978133	chr4:86913266~86914817:-
LUAD	cis	rs4664293	0.632	rs7588230	ENSG00000226266.5	AC009961.3	4.7	3.42e-06	0.000759	0.28	0.21	Monocyte percentage of white cells;	chr2:159797209	chr2:159670708~159712435:-
LUAD	cis	rs916888	0.61	rs199452	ENSG00000261575.2	RP11-259G18.1	4.7	3.42e-06	0.000759	0.28	0.21	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46267037~46268694:+
LUAD	cis	rs2976388	0.934	rs2920279	ENSG00000253741.1	CTD-2292P10.4	4.7	3.42e-06	0.000759	0.23	0.21	Urinary tract infection frequency;	chr8:142680717	chr8:142702252~142726973:-
LUAD	cis	rs2243480	1	rs1796220	ENSG00000232559.3	GS1-124K5.12	4.7	3.42e-06	0.00076	0.37	0.21	Diabetic kidney disease;	chr7:66597113	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs2707831	ENSG00000232559.3	GS1-124K5.12	4.7	3.42e-06	0.00076	0.37	0.21	Diabetic kidney disease;	chr7:66597524	chr7:66554588~66576923:-
LUAD	cis	rs17711722	0.727	rs1880555	ENSG00000237310.1	GS1-124K5.4	4.7	3.42e-06	0.00076	0.23	0.21	Calcium levels;	chr7:65967580	chr7:66493706~66495474:+
LUAD	cis	rs2742234	0.541	rs7073849	ENSG00000273008.1	RP11-351D16.3	4.7	3.43e-06	0.000761	0.24	0.21	Hirschsprung disease;	chr10:43245026	chr10:43136824~43138334:-
LUAD	cis	rs6687758	1	rs11118926	ENSG00000200033.1	RNU6-403P	4.7	3.43e-06	0.000761	0.29	0.21	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222013781	chr1:221837334~221837437:-
LUAD	cis	rs6687758	1	rs17495159	ENSG00000200033.1	RNU6-403P	4.7	3.43e-06	0.000761	0.29	0.21	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222016251	chr1:221837334~221837437:-
LUAD	cis	rs6687758	1	rs35212520	ENSG00000200033.1	RNU6-403P	4.7	3.43e-06	0.000761	0.29	0.21	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222016322	chr1:221837334~221837437:-
LUAD	cis	rs9584850	0.834	rs745638	ENSG00000231194.1	FARP1-AS1	-4.7	3.43e-06	0.000761	-0.25	-0.21	Neuroticism;	chr13:98467053	chr13:98435405~98435840:-
LUAD	cis	rs7208859	0.573	rs73267829	ENSG00000266490.1	CTD-2349P21.9	4.7	3.43e-06	0.000762	0.32	0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30676921	chr17:30792372~30792833:+
LUAD	cis	rs74233809	1	rs74233296	ENSG00000213277.3	MARCKSL1P1	4.7	3.43e-06	0.000762	0.35	0.21	Birth weight;	chr10:102895593	chr10:103175554~103176094:+
LUAD	cis	rs7811142	0.83	rs118119933	ENSG00000078319.8	PMS2P1	-4.7	3.43e-06	0.000762	-0.26	-0.21	Platelet count;	chr7:100341427	chr7:100320992~100341908:-
LUAD	cis	rs2562456	0.754	rs11673234	ENSG00000268081.1	RP11-678G14.2	4.7	3.44e-06	0.000762	0.34	0.21	Pain;	chr19:21324800	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.754	rs11673320	ENSG00000268081.1	RP11-678G14.2	4.7	3.44e-06	0.000762	0.34	0.21	Pain;	chr19:21324801	chr19:21554640~21569237:-
LUAD	cis	rs7618915	1	rs3852063	ENSG00000243224.1	RP5-1157M23.2	-4.7	3.44e-06	0.000763	-0.23	-0.21	Bipolar disorder;	chr3:52315188	chr3:52239258~52241097:+
LUAD	cis	rs2028299	0.92	rs8027198	ENSG00000259677.1	RP11-493E3.1	4.7	3.44e-06	0.000763	0.25	0.21	Type 2 diabetes;	chr15:89883457	chr15:89876540~89877285:+
LUAD	cis	rs11673344	0.764	rs513406	ENSG00000226686.6	LINC01535	4.7	3.44e-06	0.000763	0.27	0.21	Obesity-related traits;	chr19:36948245	chr19:37251912~37265535:+
LUAD	cis	rs11673344	0.734	rs496872	ENSG00000226686.6	LINC01535	4.7	3.44e-06	0.000763	0.27	0.21	Obesity-related traits;	chr19:36948579	chr19:37251912~37265535:+
LUAD	cis	rs2380205	0.651	rs7072283	ENSG00000232807.2	RP11-536K7.3	4.7	3.44e-06	0.000764	0.21	0.21	Breast cancer;	chr10:5876684	chr10:5934270~5945900:-
LUAD	cis	rs6732565	0.966	rs1533299	ENSG00000235721.1	AC013268.3	4.7	3.44e-06	0.000764	0.23	0.21	Rheumatoid arthritis;	chr2:110858564	chr2:110007675~110010783:+
LUAD	cis	rs2033711	0.87	rs7409473	ENSG00000268912.1	CTD-2619J13.17	-4.7	3.44e-06	0.000764	-0.22	-0.21	Uric acid clearance;	chr19:58427798	chr19:58428632~58431148:-
LUAD	cis	rs2033711	0.87	rs7408188	ENSG00000268912.1	CTD-2619J13.17	-4.7	3.44e-06	0.000764	-0.22	-0.21	Uric acid clearance;	chr19:58428022	chr19:58428632~58431148:-
LUAD	cis	rs1707322	1	rs10890370	ENSG00000280836.1	AL355480.1	-4.7	3.45e-06	0.000765	-0.27	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45923545	chr1:45581219~45581321:-
LUAD	cis	rs7493	0.95	rs17879277	ENSG00000233942.1	AC004012.1	4.7	3.45e-06	0.000765	0.3	0.21	Yu-Zhi constitution type in type 2 diabetes;	chr7:95401320	chr7:95471835~95473998:+
LUAD	cis	rs61270009	0.738	rs73171756	ENSG00000247828.6	TMEM161B-AS1	4.7	3.45e-06	0.000765	0.25	0.21	Depressive symptoms;	chr5:88446454	chr5:88268895~88436685:+
LUAD	cis	rs12701220	0.894	rs12701406	ENSG00000229043.2	AC091729.9	-4.7	3.45e-06	0.000765	-0.28	-0.21	Bronchopulmonary dysplasia;	chr7:1010647	chr7:1160374~1165267:+
LUAD	cis	rs897984	0.762	rs12930545	ENSG00000260911.2	RP11-196G11.2	-4.7	3.45e-06	0.000765	-0.19	-0.21	Dementia with Lewy bodies;	chr16:30927490	chr16:31043150~31049868:+
LUAD	cis	rs7493	0.95	rs7802171	ENSG00000233942.1	AC004012.1	4.7	3.45e-06	0.000765	0.31	0.21	Yu-Zhi constitution type in type 2 diabetes;	chr7:95401009	chr7:95471835~95473998:+
LUAD	cis	rs61270009	0.955	rs780402	ENSG00000247828.6	TMEM161B-AS1	-4.7	3.45e-06	0.000765	-0.24	-0.21	Depressive symptoms;	chr5:88244890	chr5:88268895~88436685:+
LUAD	cis	rs875971	0.522	rs2008188	ENSG00000237310.1	GS1-124K5.4	4.7	3.45e-06	0.000766	0.22	0.21	Aortic root size;	chr7:65964026	chr7:66493706~66495474:+
LUAD	cis	rs6840360	1	rs3749561	ENSG00000270265.1	RP11-731D1.4	4.7	3.45e-06	0.000766	0.21	0.21	Intelligence (multi-trait analysis);	chr4:151688965	chr4:151333775~151353224:-
LUAD	cis	rs9545047	0.604	rs7322901	ENSG00000227354.5	RBM26-AS1	4.7	3.45e-06	0.000766	0.22	0.21	Schizophrenia;	chr13:79383505	chr13:79406309~79424328:+
LUAD	cis	rs1012068	0.547	rs5998141	ENSG00000236132.1	CTA-440B3.1	-4.7	3.45e-06	0.000766	-0.28	-0.21	Chronic hepatitis C infection;	chr22:31848254	chr22:31816379~31817491:-
LUAD	cis	rs442309	0.553	rs10995278	ENSG00000238280.1	RP11-436D10.3	-4.7	3.45e-06	0.000766	-0.26	-0.21	Vogt-Koyanagi-Harada syndrome;	chr10:62694737	chr10:62793562~62805887:-
LUAD	cis	rs7176527	0.8	rs56747535	ENSG00000229212.6	RP11-561C5.4	4.7	3.45e-06	0.000766	0.32	0.21	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84632709	chr15:85205440~85234795:-
LUAD	cis	rs6142102	1	rs6142102	ENSG00000275784.1	RP5-1125A11.6	-4.7	3.45e-06	0.000766	-0.23	-0.21	Skin pigmentation;	chr20:34116821	chr20:33989480~33991818:-
LUAD	cis	rs2243480	1	rs34637256	ENSG00000229886.1	RP5-1132H15.3	4.7	3.45e-06	0.000766	0.37	0.21	Diabetic kidney disease;	chr7:65895144	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs35391607	ENSG00000229886.1	RP5-1132H15.3	4.7	3.45e-06	0.000766	0.37	0.21	Diabetic kidney disease;	chr7:65895842	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs13220979	ENSG00000229886.1	RP5-1132H15.3	4.7	3.45e-06	0.000766	0.37	0.21	Diabetic kidney disease;	chr7:65898217	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs34974928	ENSG00000229886.1	RP5-1132H15.3	4.7	3.45e-06	0.000766	0.37	0.21	Diabetic kidney disease;	chr7:65899019	chr7:66025126~66031544:-
LUAD	cis	rs1555322	0.53	rs6060341	ENSG00000126005.14	MMP24-AS1	4.7	3.46e-06	0.000766	0.29	0.21	Attention deficit hyperactivity disorder;	chr20:35275830	chr20:35216462~35278131:-
LUAD	cis	rs9473147	0.516	rs7754282	ENSG00000270761.1	RP11-385F7.1	4.7	3.46e-06	0.000766	0.24	0.21	Platelet distribution width;Mean platelet volume;	chr6:47534288	chr6:47477243~47477572:-
LUAD	cis	rs6088590	1	rs28542147	ENSG00000276073.1	RP5-1125A11.7	-4.7	3.46e-06	0.000766	-0.21	-0.21	Coronary artery disease;	chr20:34788520	chr20:33985617~33988989:-
LUAD	cis	rs2735413	0.563	rs72800918	ENSG00000276007.1	RP11-358L22.3	4.7	3.46e-06	0.000767	0.3	0.21	Systolic blood pressure (alcohol consumption interaction);	chr16:78026834	chr16:78123243~78124332:+
LUAD	cis	rs9910055	0.659	rs186603	ENSG00000267080.4	ASB16-AS1	4.7	3.46e-06	0.000767	0.19	0.21	Total body bone mineral density;	chr17:44130516	chr17:44175973~44186717:-
LUAD	cis	rs3738443	0.904	rs61840474	ENSG00000259865.1	RP11-488L18.10	4.7	3.46e-06	0.000767	0.23	0.21	Alcohol dependence;	chr1:247225109	chr1:247187281~247188526:-
LUAD	cis	rs950169	0.58	rs11633762	ENSG00000275120.1	RP11-182J1.17	4.7	3.46e-06	0.000768	0.32	0.21	Schizophrenia;	chr15:84643921	chr15:84599434~84606463:-
LUAD	cis	rs1008375	1	rs3846357	ENSG00000249502.1	AC006160.5	-4.7	3.46e-06	0.000768	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17634264	chr4:17587467~17614571:-
LUAD	cis	rs1008375	0.966	rs1860599	ENSG00000249502.1	AC006160.5	-4.7	3.46e-06	0.000768	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17637277	chr4:17587467~17614571:-
LUAD	cis	rs5758659	0.904	rs134877	ENSG00000227370.1	RP4-669P10.19	-4.7	3.46e-06	0.000768	-0.19	-0.21	Cognitive function;	chr22:42266365	chr22:42132543~42132998:+
LUAD	cis	rs12908161	0.959	rs61074241	ENSG00000275120.1	RP11-182J1.17	4.7	3.47e-06	0.000768	0.33	0.21	Schizophrenia;	chr15:84790165	chr15:84599434~84606463:-
LUAD	cis	rs9532669	0.926	rs9562254	ENSG00000168852.11	TPTE2P5	-4.7	3.47e-06	0.000769	-0.21	-0.21	Cervical cancer;	chr13:40960902	chr13:40822296~40921749:-
LUAD	cis	rs875971	1	rs6946143	ENSG00000232559.3	GS1-124K5.12	4.7	3.47e-06	0.000769	0.25	0.21	Aortic root size;	chr7:66114735	chr7:66554588~66576923:-
LUAD	cis	rs11122895	0.791	rs11686294	ENSG00000236307.2	EEF1E1P1	4.7	3.47e-06	0.000769	0.23	0.21	Allergic sensitization;	chr2:111713130	chr2:111887914~111888741:+
LUAD	cis	rs10129255	0.957	rs12589190	ENSG00000274576.2	IGHV2-70	4.7	3.47e-06	0.000769	0.18	0.21	Kawasaki disease;	chr14:106783079	chr14:106770577~106771020:-
LUAD	cis	rs10129255	0.957	rs7493713	ENSG00000274576.2	IGHV2-70	4.7	3.47e-06	0.000769	0.18	0.21	Kawasaki disease;	chr14:106783685	chr14:106770577~106771020:-
LUAD	cis	rs10129255	0.912	rs35468694	ENSG00000274576.2	IGHV2-70	4.7	3.47e-06	0.000769	0.18	0.21	Kawasaki disease;	chr14:106784199	chr14:106770577~106771020:-
LUAD	cis	rs10129255	0.957	rs8019272	ENSG00000274576.2	IGHV2-70	4.7	3.47e-06	0.000769	0.18	0.21	Kawasaki disease;	chr14:106784709	chr14:106770577~106771020:-
LUAD	cis	rs7819412	0.521	rs11777887	ENSG00000255046.1	RP11-297N6.4	-4.7	3.47e-06	0.000769	-0.25	-0.21	Triglycerides;	chr8:11179290	chr8:11797928~11802568:-
LUAD	cis	rs8072100	0.967	rs4289035	ENSG00000228782.6	CTD-2026D20.3	4.7	3.47e-06	0.000769	0.22	0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47629845	chr17:47450568~47492492:-
LUAD	cis	rs875971	1	rs11974219	ENSG00000232559.3	GS1-124K5.12	-4.7	3.47e-06	0.00077	-0.24	-0.21	Aortic root size;	chr7:66182423	chr7:66554588~66576923:-
LUAD	cis	rs17508449	0.819	rs79198040	ENSG00000232450.1	RP4-730K3.3	-4.7	3.47e-06	0.00077	-0.36	-0.21	Leprosy;	chr1:113746069	chr1:113698884~113699631:-
LUAD	cis	rs6840360	0.901	rs1946999	ENSG00000270265.1	RP11-731D1.4	-4.7	3.47e-06	0.00077	-0.21	-0.21	Intelligence (multi-trait analysis);	chr4:151534187	chr4:151333775~151353224:-
LUAD	cis	rs17772222	0.916	rs77306894	ENSG00000258983.2	RP11-507K2.2	4.7	3.47e-06	0.00077	0.26	0.21	Coronary artery calcification;	chr14:88494507	chr14:88499334~88515502:+
LUAD	cis	rs2098713	0.562	rs55794983	ENSG00000250155.1	CTD-2353F22.1	4.7	3.47e-06	0.00077	0.22	0.21	Telomere length;	chr5:37549046	chr5:36666214~36725195:-
LUAD	cis	rs2742234	1	rs1864395	ENSG00000273008.1	RP11-351D16.3	-4.7	3.47e-06	0.00077	-0.22	-0.21	Hirschsprung disease;	chr10:43160249	chr10:43136824~43138334:-
LUAD	cis	rs13256369	0.865	rs13277708	ENSG00000253893.2	FAM85B	-4.7	3.48e-06	0.00077	-0.29	-0.21	Obesity-related traits;	chr8:8716426	chr8:8167819~8226614:-
LUAD	cis	rs6840360	0.967	rs6535817	ENSG00000270265.1	RP11-731D1.4	-4.7	3.48e-06	0.000771	-0.21	-0.21	Intelligence (multi-trait analysis);	chr4:151720789	chr4:151333775~151353224:-
LUAD	cis	rs6728642	0.519	rs6721921	ENSG00000230606.9	AC159540.1	4.7	3.48e-06	0.000771	0.3	0.21	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96900764	chr2:97416165~97433527:-
LUAD	cis	rs6728642	0.519	rs59131346	ENSG00000230606.9	AC159540.1	4.7	3.48e-06	0.000771	0.3	0.21	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96901031	chr2:97416165~97433527:-
LUAD	cis	rs10246939	0.579	rs12703413	ENSG00000270923.1	TAS2R6P	4.7	3.48e-06	0.000771	0.23	0.21	Bitter taste perception;	chr7:141847047	chr7:141787815~141788640:+
LUAD	cis	rs2742234	0.554	rs1270015	ENSG00000273008.1	RP11-351D16.3	4.7	3.48e-06	0.000771	0.25	0.21	Hirschsprung disease;	chr10:43202792	chr10:43136824~43138334:-
LUAD	cis	rs9545047	0.604	rs28579970	ENSG00000227354.5	RBM26-AS1	-4.7	3.48e-06	0.000771	-0.22	-0.21	Schizophrenia;	chr13:79308726	chr13:79406309~79424328:+
LUAD	cis	rs9473147	0.543	rs7738044	ENSG00000270761.1	RP11-385F7.1	-4.7	3.48e-06	0.000771	-0.24	-0.21	Platelet distribution width;Mean platelet volume;	chr6:47501537	chr6:47477243~47477572:-
LUAD	cis	rs2212361	0.558	rs72963816	ENSG00000255893.1	RP11-685N10.1	-4.7	3.48e-06	0.000771	-0.29	-0.21	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94539634	chr11:94472908~94473570:-
LUAD	cis	rs73173548	0.502	rs13165428	ENSG00000247828.6	TMEM161B-AS1	-4.69	3.48e-06	0.000772	-0.25	-0.21	Macular telangiectasia type 2;	chr5:88443945	chr5:88268895~88436685:+
LUAD	cis	rs4835473	0.897	rs7676614	ENSG00000251600.4	RP11-673E1.1	-4.69	3.48e-06	0.000772	-0.26	-0.21	Immature fraction of reticulocytes;	chr4:143695213	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.864	rs7681559	ENSG00000251600.4	RP11-673E1.1	-4.69	3.48e-06	0.000772	-0.26	-0.21	Immature fraction of reticulocytes;	chr4:143695248	chr4:143912331~143982454:+
LUAD	cis	rs9322193	0.961	rs2064520	ENSG00000268592.3	RAET1E-AS1	4.69	3.48e-06	0.000772	0.25	0.21	Lung cancer;	chr6:149603650	chr6:149863494~149919507:+
LUAD	cis	rs34779708	0.931	rs7923217	ENSG00000271335.4	RP11-324I22.4	4.69	3.48e-06	0.000772	0.22	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35020661	chr10:35314552~35336401:-
LUAD	cis	rs9545047	0.604	rs1749988	ENSG00000227354.5	RBM26-AS1	4.69	3.49e-06	0.000772	0.22	0.21	Schizophrenia;	chr13:79333103	chr13:79406309~79424328:+
LUAD	cis	rs57502260	0.704	rs55975204	ENSG00000212093.1	AP000807.1	4.69	3.49e-06	0.000772	0.29	0.21	Total body bone mineral density (age 45-60);	chr11:68481656	chr11:68506083~68506166:-
LUAD	cis	rs57502260	0.704	rs12286536	ENSG00000212093.1	AP000807.1	4.69	3.49e-06	0.000772	0.29	0.21	Total body bone mineral density (age 45-60);	chr11:68522766	chr11:68506083~68506166:-
LUAD	cis	rs7772486	0.727	rs10447449	ENSG00000235652.6	RP11-545I5.3	4.69	3.49e-06	0.000773	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145817571	chr6:145799409~145886585:+
LUAD	cis	rs10246939	0.544	rs6957037	ENSG00000270923.1	TAS2R6P	-4.69	3.49e-06	0.000773	-0.23	-0.21	Bitter taste perception;	chr7:141865557	chr7:141787815~141788640:+
LUAD	cis	rs1062177	0.826	rs1549920	ENSG00000253921.1	CTB-113P19.3	-4.69	3.49e-06	0.000773	-0.3	-0.21	Preschool internalizing problems;	chr5:151761283	chr5:151753992~151767247:+
LUAD	cis	rs4819052	0.84	rs914217	ENSG00000215447.6	BX322557.10	-4.69	3.49e-06	0.000773	-0.27	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278384	chr21:45288052~45291738:+
LUAD	cis	rs875971	0.628	rs6974355	ENSG00000224316.1	RP11-479O9.2	4.69	3.49e-06	0.000774	0.21	0.21	Aortic root size;	chr7:66376994	chr7:65773620~65802067:+
LUAD	cis	rs1008375	1	rs4642241	ENSG00000249502.1	AC006160.5	-4.69	3.49e-06	0.000774	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17615488	chr4:17587467~17614571:-
LUAD	cis	rs875971	0.522	rs1617484	ENSG00000237310.1	GS1-124K5.4	4.69	3.49e-06	0.000774	0.23	0.21	Aortic root size;	chr7:65998108	chr7:66493706~66495474:+
LUAD	cis	rs8180040	0.764	rs11718795	ENSG00000271161.1	BOLA2P2	4.69	3.49e-06	0.000774	0.2	0.21	Colorectal cancer;	chr3:47177237	chr3:47499841~47500407:+
LUAD	cis	rs453301	0.653	rs7016139	ENSG00000253981.4	ALG1L13P	-4.69	3.5e-06	0.000774	-0.25	-0.21	Joint mobility (Beighton score);	chr8:9037960	chr8:8236003~8244667:-
LUAD	cis	rs4601821	0.635	rs7114433	ENSG00000270179.1	RP11-159N11.4	-4.69	3.5e-06	0.000775	-0.21	-0.21	Alcoholic chronic pancreatitis;	chr11:113337376	chr11:113368478~113369117:+
LUAD	cis	rs6545883	0.524	rs778159	ENSG00000271889.1	RP11-493E12.1	-4.69	3.5e-06	0.000775	-0.24	-0.21	Tuberculosis;	chr2:61329609	chr2:61151433~61162105:-
LUAD	cis	rs7927592	0.513	rs607887	ENSG00000212093.1	AP000807.1	4.69	3.5e-06	0.000775	0.22	0.21	Total body bone mineral density;	chr11:68429493	chr11:68506083~68506166:-
LUAD	cis	rs6687821	0.531	rs11161930	ENSG00000267734.1	RP4-604K5.3	-4.69	3.5e-06	0.000775	-0.28	-0.21	Yeast infection;	chr1:87056097	chr1:86932199~86934891:-
LUAD	cis	rs8077577	0.747	rs11869582	ENSG00000273018.4	CTD-2303H24.2	-4.69	3.5e-06	0.000775	-0.32	-0.21	Obesity-related traits;	chr17:18233267	chr17:18511221~18551705:-
LUAD	cis	rs7829975	0.511	rs2921028	ENSG00000173295.6	FAM86B3P	4.69	3.5e-06	0.000775	0.22	0.21	Mood instability;	chr8:8482967	chr8:8228595~8244865:+
LUAD	cis	rs2239547	0.657	rs4687672	ENSG00000242142.1	SERBP1P3	4.69	3.5e-06	0.000776	0.24	0.21	Schizophrenia;	chr3:52846527	chr3:53064283~53065091:-
LUAD	cis	rs12554020	0.786	rs12349299	ENSG00000227603.1	RP11-165J3.6	4.69	3.5e-06	0.000776	0.35	0.21	Schizophrenia;	chr9:93412482	chr9:93435332~93437121:-
LUAD	cis	rs34779708	0.931	rs2490663	ENSG00000271335.4	RP11-324I22.4	-4.69	3.5e-06	0.000776	-0.21	-0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35040807	chr10:35314552~35336401:-
LUAD	cis	rs6840360	1	rs2303866	ENSG00000270265.1	RP11-731D1.4	-4.69	3.51e-06	0.000776	-0.21	-0.21	Intelligence (multi-trait analysis);	chr4:151719235	chr4:151333775~151353224:-
LUAD	cis	rs227275	0.525	rs2086499	ENSG00000251288.2	RP11-10L12.2	-4.69	3.51e-06	0.000777	-0.25	-0.21	Allergic disease (asthma, hay fever or eczema);	chr4:103008672	chr4:102751401~102752641:+
LUAD	cis	rs8072100	0.902	rs12051716	ENSG00000228782.6	CTD-2026D20.3	-4.69	3.51e-06	0.000777	-0.21	-0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47505029	chr17:47450568~47492492:-
LUAD	cis	rs8180040	0.726	rs4682842	ENSG00000271161.1	BOLA2P2	-4.69	3.51e-06	0.000777	-0.2	-0.21	Colorectal cancer;	chr3:46941283	chr3:47499841~47500407:+
LUAD	cis	rs875971	0.66	rs801217	ENSG00000224316.1	RP11-479O9.2	-4.69	3.51e-06	0.000777	-0.21	-0.21	Aortic root size;	chr7:66545590	chr7:65773620~65802067:+
LUAD	cis	rs875971	0.638	rs801216	ENSG00000224316.1	RP11-479O9.2	-4.69	3.51e-06	0.000777	-0.21	-0.21	Aortic root size;	chr7:66546680	chr7:65773620~65802067:+
LUAD	cis	rs875971	0.66	rs801211	ENSG00000224316.1	RP11-479O9.2	-4.69	3.51e-06	0.000777	-0.21	-0.21	Aortic root size;	chr7:66550702	chr7:65773620~65802067:+
LUAD	cis	rs1799949	0.965	rs8176087	ENSG00000236383.6	LINC00854	-4.69	3.51e-06	0.000778	-0.17	-0.21	Menopause (age at onset);	chr17:43118649	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs34942571	ENSG00000236383.6	LINC00854	-4.69	3.51e-06	0.000778	-0.17	-0.21	Menopause (age at onset);	chr17:43121362	chr17:43216941~43305976:-
LUAD	cis	rs6570726	0.902	rs406979	ENSG00000235652.6	RP11-545I5.3	4.69	3.51e-06	0.000778	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145517847	chr6:145799409~145886585:+
LUAD	cis	rs7945705	0.875	rs4929914	ENSG00000254860.4	TMEM9B-AS1	4.69	3.51e-06	0.000778	0.23	0.21	Hemoglobin concentration;	chr11:8802841	chr11:8964675~8977527:+
LUAD	cis	rs2732480	0.557	rs2409004	ENSG00000257735.1	RP11-370I10.6	4.69	3.51e-06	0.000778	0.25	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48327668	chr12:48350945~48442411:+
LUAD	cis	rs2281636	0.723	rs11190195	ENSG00000233690.1	EBAG9P1	-4.69	3.52e-06	0.000778	-0.21	-0.21	Obesity-related traits;	chr10:99626710	chr10:99697407~99697949:-
LUAD	cis	rs41307935	0.643	rs35859457	ENSG00000260063.1	RP5-968P14.2	-4.69	3.52e-06	0.000778	-0.45	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26993386	chr1:26692132~26694131:-
LUAD	cis	rs34779708	0.931	rs4934731	ENSG00000271335.4	RP11-324I22.4	4.69	3.52e-06	0.000779	0.22	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35142708	chr10:35314552~35336401:-
LUAD	cis	rs4835473	0.932	rs36018946	ENSG00000251600.4	RP11-673E1.1	-4.69	3.52e-06	0.000779	-0.26	-0.21	Immature fraction of reticulocytes;	chr4:143980942	chr4:143912331~143982454:+
LUAD	cis	rs36423	0.748	rs28138	ENSG00000266869.1	RP6-114E22.1	-4.69	3.52e-06	0.000779	-0.31	-0.21	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71891970	chr14:71848606~71908430:+
LUAD	cis	rs74233809	0.892	rs11191447	ENSG00000213277.3	MARCKSL1P1	4.69	3.52e-06	0.000779	0.35	0.21	Birth weight;	chr10:102892566	chr10:103175554~103176094:+
LUAD	cis	rs12554020	0.579	rs76025942	ENSG00000227603.1	RP11-165J3.6	4.69	3.53e-06	0.000781	0.42	0.21	Schizophrenia;	chr9:93605618	chr9:93435332~93437121:-
LUAD	cis	rs10429558	0.609	rs76290025	ENSG00000227603.1	RP11-165J3.6	4.69	3.53e-06	0.000781	0.42	0.21	Neuroticism;	chr9:93608100	chr9:93435332~93437121:-
LUAD	cis	rs9545047	0.584	rs1619669	ENSG00000227354.5	RBM26-AS1	4.69	3.53e-06	0.000781	0.22	0.21	Schizophrenia;	chr13:79378363	chr13:79406309~79424328:+
LUAD	cis	rs2243480	1	rs431318	ENSG00000164669.11	INTS4P1	4.69	3.53e-06	0.000781	0.37	0.21	Diabetic kidney disease;	chr7:66046610	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs313803	ENSG00000164669.11	INTS4P1	4.69	3.53e-06	0.000781	0.37	0.21	Diabetic kidney disease;	chr7:66049744	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs313802	ENSG00000164669.11	INTS4P1	4.69	3.53e-06	0.000781	0.37	0.21	Diabetic kidney disease;	chr7:66051386	chr7:65141225~65234216:+
LUAD	cis	rs2243480	0.803	rs403089	ENSG00000164669.11	INTS4P1	4.69	3.53e-06	0.000781	0.37	0.21	Diabetic kidney disease;	chr7:66052736	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs458291	ENSG00000164669.11	INTS4P1	4.69	3.53e-06	0.000781	0.37	0.21	Diabetic kidney disease;	chr7:66055492	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs466983	ENSG00000164669.11	INTS4P1	4.69	3.53e-06	0.000781	0.37	0.21	Diabetic kidney disease;	chr7:66055509	chr7:65141225~65234216:+
LUAD	cis	rs17711722	0.701	rs4467826	ENSG00000237310.1	GS1-124K5.4	4.69	3.53e-06	0.000781	0.22	0.21	Calcium levels;	chr7:65903721	chr7:66493706~66495474:+
LUAD	cis	rs12908161	0.92	rs35738019	ENSG00000259295.5	CSPG4P12	4.69	3.53e-06	0.000781	0.29	0.21	Schizophrenia;	chr15:84736979	chr15:85191438~85213905:+
LUAD	cis	rs12908161	1	rs34570071	ENSG00000259295.5	CSPG4P12	4.69	3.53e-06	0.000781	0.29	0.21	Schizophrenia;	chr15:84736981	chr15:85191438~85213905:+
LUAD	cis	rs6125597	0.516	rs6019537	ENSG00000230758.1	SNAP23P	-4.69	3.53e-06	0.000781	-0.22	-0.21	Intelligence (multi-trait analysis);	chr20:48927067	chr20:49038357~49038602:-
LUAD	cis	rs1008375	0.835	rs9760627	ENSG00000249502.1	AC006160.5	-4.69	3.53e-06	0.000781	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17649885	chr4:17587467~17614571:-
LUAD	cis	rs61270009	0.955	rs10514300	ENSG00000247828.6	TMEM161B-AS1	4.69	3.53e-06	0.000781	0.25	0.21	Depressive symptoms;	chr5:88409465	chr5:88268895~88436685:+
LUAD	cis	rs7430456	0.839	rs9824506	ENSG00000225790.1	RP11-2L8.1	4.69	3.53e-06	0.000781	0.25	0.21	Breast cancer;	chr3:177751431	chr3:177934823~177937662:+
LUAD	cis	rs2562456	0.833	rs11666828	ENSG00000268081.1	RP11-678G14.2	4.69	3.53e-06	0.000781	0.34	0.21	Pain;	chr19:21342218	chr19:21554640~21569237:-
LUAD	cis	rs12908161	0.96	rs17599989	ENSG00000259295.5	CSPG4P12	4.69	3.53e-06	0.000782	0.29	0.21	Schizophrenia;	chr15:84742305	chr15:85191438~85213905:+
LUAD	cis	rs9467773	0.869	rs1796520	ENSG00000124549.13	BTN2A3P	-4.69	3.53e-06	0.000782	-0.19	-0.21	Intelligence (multi-trait analysis);	chr6:26410572	chr6:26421391~26432383:+
LUAD	cis	rs9341808	0.529	rs9350851	ENSG00000272129.1	RP11-250B2.6	4.69	3.53e-06	0.000782	0.26	0.21	Sitting height ratio;	chr6:80349471	chr6:80355424~80356859:+
LUAD	cis	rs9341808	0.529	rs9352826	ENSG00000272129.1	RP11-250B2.6	4.69	3.53e-06	0.000782	0.26	0.21	Sitting height ratio;	chr6:80349654	chr6:80355424~80356859:+
LUAD	cis	rs11897432	0.868	rs13008694	ENSG00000279873.2	LINC01126	4.69	3.53e-06	0.000782	0.22	0.21	DNA methylation (variation);	chr2:43615989	chr2:43227210~43228855:+
LUAD	cis	rs6921919	0.887	rs7766356	ENSG00000216901.1	AL022393.7	4.69	3.54e-06	0.000782	0.31	0.21	Autism spectrum disorder or schizophrenia;	chr6:28432761	chr6:28176188~28176674:+
LUAD	cis	rs783540	0.5	rs783541	ENSG00000278603.1	RP13-608F4.5	-4.69	3.54e-06	0.000782	-0.27	-0.21	Schizophrenia;	chr15:82586310	chr15:82472203~82472426:+
LUAD	cis	rs1150668	0.796	rs1005125	ENSG00000219392.1	RP1-265C24.5	-4.69	3.54e-06	0.000782	-0.26	-0.21	Pubertal anthropometrics;	chr6:28399578	chr6:28115628~28116551:+
LUAD	cis	rs9545047	0.604	rs9530915	ENSG00000227354.5	RBM26-AS1	4.69	3.54e-06	0.000782	0.22	0.21	Schizophrenia;	chr13:79396512	chr13:79406309~79424328:+
LUAD	cis	rs1320333	0.772	rs17786120	ENSG00000233296.1	AC092159.2	4.69	3.54e-06	0.000783	0.38	0.21	Obesity-related traits;	chr2:700580	chr2:677186~697371:+
LUAD	cis	rs4664293	0.769	rs1365798	ENSG00000230783.1	AC009961.2	4.69	3.54e-06	0.000783	0.26	0.21	Monocyte percentage of white cells;	chr2:159795853	chr2:159689217~159690291:-
LUAD	cis	rs2033711	0.87	rs1465789	ENSG00000268912.1	CTD-2619J13.17	-4.69	3.54e-06	0.000783	-0.22	-0.21	Uric acid clearance;	chr19:58434689	chr19:58428632~58431148:-
LUAD	cis	rs2998286	0.723	rs332152	ENSG00000254635.4	WAC-AS1	-4.69	3.54e-06	0.000783	-0.27	-0.21	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28585602	chr10:28522652~28532743:-
LUAD	cis	rs1799949	1	rs35070007	ENSG00000236383.6	LINC00854	4.69	3.54e-06	0.000783	0.16	0.21	Menopause (age at onset);	chr17:43164730	chr17:43216941~43305976:-
LUAD	cis	rs2976388	1	rs2294010	ENSG00000253741.1	CTD-2292P10.4	4.69	3.54e-06	0.000783	0.23	0.21	Urinary tract infection frequency;	chr8:142681012	chr8:142702252~142726973:-
LUAD	cis	rs2976388	1	rs2976392	ENSG00000253741.1	CTD-2292P10.4	4.69	3.54e-06	0.000783	0.23	0.21	Urinary tract infection frequency;	chr8:142681514	chr8:142702252~142726973:-
LUAD	cis	rs2976388	1	rs2978982	ENSG00000253741.1	CTD-2292P10.4	4.69	3.54e-06	0.000783	0.23	0.21	Urinary tract infection frequency;	chr8:142682072	chr8:142702252~142726973:-
LUAD	cis	rs2976388	1	rs10216533	ENSG00000253741.1	CTD-2292P10.4	4.69	3.54e-06	0.000783	0.23	0.21	Urinary tract infection frequency;	chr8:142682272	chr8:142702252~142726973:-
LUAD	cis	rs35740288	0.857	rs3803506	ENSG00000259407.1	RP11-158M2.3	-4.69	3.54e-06	0.000784	-0.21	-0.21	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85747709	chr15:85744109~85750281:-
LUAD	cis	rs877356	0.667	rs35114832	ENSG00000250378.1	RP11-119J18.1	-4.69	3.54e-06	0.000784	-0.37	-0.21	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (dichotomous);	chr5:135821799	chr5:135812667~135826582:+
LUAD	cis	rs301901	0.895	rs292172	ENSG00000250155.1	CTD-2353F22.1	-4.69	3.54e-06	0.000784	-0.22	-0.21	Height;	chr5:36817237	chr5:36666214~36725195:-
LUAD	cis	rs4908760	0.613	rs12028160	ENSG00000232912.4	RP5-1115A15.1	-4.69	3.55e-06	0.000784	-0.19	-0.21	Vitiligo;	chr1:8752155	chr1:8424645~8434838:+
LUAD	cis	rs7119	0.678	rs12914098	ENSG00000259362.2	RP11-307C19.1	-4.69	3.55e-06	0.000784	-0.26	-0.21	Type 2 diabetes;	chr15:77530671	chr15:77525540~77534110:+
LUAD	cis	rs7017914	0.667	rs2732124	ENSG00000223220.1	Y_RNA	4.69	3.55e-06	0.000784	0.24	0.21	Bone mineral density;	chr8:70986447	chr8:70780914~70781008:-
LUAD	cis	rs801193	0.904	rs4718405	ENSG00000236529.1	RP13-254B10.1	4.69	3.55e-06	0.000785	0.21	0.21	Aortic root size;	chr7:66789659	chr7:65840212~65840596:+
LUAD	cis	rs944990	0.597	rs10821162	ENSG00000227603.1	RP11-165J3.6	4.69	3.55e-06	0.000785	0.24	0.21	Body mass index;	chr9:93579042	chr9:93435332~93437121:-
LUAD	cis	rs2303759	0.709	rs3760667	ENSG00000268686.1	AC010524.2	-4.69	3.55e-06	0.000785	-0.31	-0.21	Multiple sclerosis;	chr19:49311575	chr19:49368705~49388081:-
LUAD	cis	rs2898681	1	rs2411281	ENSG00000248375.1	RP11-177B4.1	-4.69	3.55e-06	0.000785	-0.31	-0.21	Optic nerve measurement (cup area);	chr4:52890890	chr4:52720081~52720831:-
LUAD	cis	rs7119	0.651	rs12902072	ENSG00000259362.2	RP11-307C19.1	-4.69	3.55e-06	0.000785	-0.27	-0.21	Type 2 diabetes;	chr15:77556390	chr15:77525540~77534110:+
LUAD	cis	rs853679	0.76	rs9393909	ENSG00000219392.1	RP1-265C24.5	4.69	3.55e-06	0.000785	0.32	0.21	Depression;	chr6:28239422	chr6:28115628~28116551:+
LUAD	cis	rs160451	0.966	rs2101854	ENSG00000251136.7	RP11-37B2.1	4.69	3.55e-06	0.000785	0.21	0.21	Leprosy;	chr8:89663517	chr8:89609409~89757727:-
LUAD	cis	rs6687758	1	rs35805428	ENSG00000227925.1	RP11-191N8.2	4.69	3.56e-06	0.000786	0.3	0.21	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222015280	chr1:221827666~221840666:-
LUAD	cis	rs7208859	0.623	rs9895785	ENSG00000266490.1	CTD-2349P21.9	-4.69	3.56e-06	0.000786	-0.31	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30792372~30792833:+
LUAD	cis	rs7404843	0.778	rs72774864	ENSG00000263335.1	AF001548.5	4.69	3.56e-06	0.000787	0.45	0.21	Testicular germ cell tumor;	chr16:15418465	chr16:15726674~15732993:+
LUAD	cis	rs2378497	0.938	rs12140406	ENSG00000232679.1	RP11-400N13.3	4.69	3.56e-06	0.000787	0.33	0.21	Serum thyroid-stimulating hormone levels;	chr1:221985191	chr1:222041705~222064763:-
LUAD	cis	rs17772222	0.74	rs10138309	ENSG00000258789.1	RP11-507K2.3	-4.69	3.56e-06	0.000787	-0.27	-0.21	Coronary artery calcification;	chr14:88510352	chr14:88551597~88552493:+
LUAD	cis	rs9400467	0.528	rs456865	ENSG00000271789.1	RP5-1112D6.7	-4.69	3.56e-06	0.000787	-0.22	-0.21	Amino acid levels;Blood metabolite levels;	chr6:111311725	chr6:111297126~111298510:+
LUAD	cis	rs2836950	0.565	rs2150413	ENSG00000255568.3	BRWD1-AS2	-4.69	3.56e-06	0.000788	-0.2	-0.21	Menarche (age at onset);	chr21:39242952	chr21:39313935~39314962:+
LUAD	cis	rs6687758	1	rs6687758	ENSG00000228437.4	RP11-400N13.2	4.69	3.56e-06	0.000788	0.31	0.21	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221991606	chr1:221966341~221984964:+
LUAD	cis	rs6088590	1	rs2180276	ENSG00000276073.1	RP5-1125A11.7	-4.69	3.56e-06	0.000788	-0.21	-0.21	Coronary artery disease;	chr20:34772982	chr20:33985617~33988989:-
LUAD	cis	rs8180040	0.629	rs7426969	ENSG00000271161.1	BOLA2P2	4.69	3.57e-06	0.000788	0.2	0.21	Colorectal cancer;	chr3:47049865	chr3:47499841~47500407:+
LUAD	cis	rs3096299	0.754	rs3102382	ENSG00000182376.2	RP5-1142A6.8	4.69	3.57e-06	0.000788	0.21	0.21	Multiple myeloma (IgH translocation);	chr16:89343334	chr16:88742767~88745748:+
LUAD	cis	rs234043	1	rs234051	ENSG00000223387.5	RP11-408H1.3	-4.69	3.57e-06	0.000789	-0.27	-0.21	Renal cell carcinoma;	chr3:172593922	chr3:172560888~172595607:-
LUAD	cis	rs7829975	0.711	rs12682352	ENSG00000253981.4	ALG1L13P	4.69	3.57e-06	0.000789	0.23	0.21	Mood instability;	chr8:8788736	chr8:8236003~8244667:-
LUAD	cis	rs10895987	1	rs9971407	ENSG00000254614.2	AP003068.23	4.69	3.57e-06	0.000789	0.33	0.21	Blood protein levels;	chr11:65130754	chr11:65177606~65181834:-
LUAD	cis	rs6095360	0.727	rs1983528	ENSG00000222365.1	SNORD12B	4.69	3.57e-06	0.000789	0.24	0.21	Intelligence (multi-trait analysis);	chr20:49069753	chr20:49280319~49280409:+
LUAD	cis	rs2562456	0.833	rs55790393	ENSG00000268081.1	RP11-678G14.2	4.69	3.57e-06	0.00079	0.34	0.21	Pain;	chr19:21323382	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.793	rs11672341	ENSG00000268081.1	RP11-678G14.2	4.69	3.57e-06	0.00079	0.34	0.21	Pain;	chr19:21324502	chr19:21554640~21569237:-
LUAD	cis	rs4948102	0.597	rs12669623	ENSG00000273720.1	RP11-613E4.4	-4.69	3.57e-06	0.00079	-0.26	-0.21	Plasma homocysteine levels (post-methionine load test);	chr7:56071486	chr7:55743073~55743457:+
LUAD	cis	rs17345786	0.906	rs72944107	ENSG00000244119.1	PDCL3P4	4.69	3.57e-06	0.00079	0.23	0.21	Colonoscopy-negative controls vs population controls;	chr3:101478346	chr3:101712472~101713191:+
LUAD	cis	rs4908760	0.613	rs12403640	ENSG00000270282.1	RP5-1115A15.2	4.69	3.57e-06	0.00079	0.23	0.21	Vitiligo;	chr1:8757804	chr1:8512653~8513021:+
LUAD	cis	rs9545047	0.604	rs7329331	ENSG00000227354.5	RBM26-AS1	4.69	3.57e-06	0.00079	0.22	0.21	Schizophrenia;	chr13:79384986	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs7330479	ENSG00000227354.5	RBM26-AS1	4.69	3.57e-06	0.00079	0.22	0.21	Schizophrenia;	chr13:79385058	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs6563104	ENSG00000227354.5	RBM26-AS1	4.69	3.57e-06	0.00079	0.22	0.21	Schizophrenia;	chr13:79389718	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs7981500	ENSG00000227354.5	RBM26-AS1	4.69	3.57e-06	0.00079	0.22	0.21	Schizophrenia;	chr13:79391461	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs57821487	ENSG00000227354.5	RBM26-AS1	4.69	3.57e-06	0.00079	0.22	0.21	Schizophrenia;	chr13:79392810	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs7323246	ENSG00000227354.5	RBM26-AS1	4.69	3.57e-06	0.00079	0.22	0.21	Schizophrenia;	chr13:79392903	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs7331766	ENSG00000227354.5	RBM26-AS1	4.69	3.57e-06	0.00079	0.22	0.21	Schizophrenia;	chr13:79394076	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs12865187	ENSG00000227354.5	RBM26-AS1	-4.69	3.58e-06	0.00079	-0.22	-0.21	Schizophrenia;	chr13:79316469	chr13:79406309~79424328:+
LUAD	cis	rs7945705	0.967	rs2568090	ENSG00000254860.4	TMEM9B-AS1	-4.69	3.58e-06	0.00079	-0.24	-0.21	Hemoglobin concentration;	chr11:8827948	chr11:8964675~8977527:+
LUAD	cis	rs338389	0.967	rs338385	ENSG00000260657.2	RP11-315D16.4	-4.69	3.58e-06	0.00079	-0.24	-0.21	Survival in rectal cancer;	chr15:67970542	chr15:68267792~68277994:-
LUAD	cis	rs2212361	0.558	rs72963821	ENSG00000255893.1	RP11-685N10.1	-4.69	3.58e-06	0.00079	-0.29	-0.21	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94540820	chr11:94472908~94473570:-
LUAD	cis	rs2212361	0.558	rs72963823	ENSG00000255893.1	RP11-685N10.1	-4.69	3.58e-06	0.00079	-0.29	-0.21	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94540874	chr11:94472908~94473570:-
LUAD	cis	rs8180040	0.966	rs2062278	ENSG00000271161.1	BOLA2P2	4.69	3.58e-06	0.00079	0.2	0.21	Colorectal cancer;	chr3:47375271	chr3:47499841~47500407:+
LUAD	cis	rs6687758	1	rs35805428	ENSG00000200033.1	RNU6-403P	4.69	3.58e-06	0.00079	0.29	0.21	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222015280	chr1:221837334~221837437:-
LUAD	cis	rs2274273	0.554	rs3742564	ENSG00000258413.1	RP11-665C16.6	4.69	3.58e-06	0.000791	0.27	0.21	Protein biomarker;	chr14:55063402	chr14:55262767~55272075:-
LUAD	cis	rs1008375	0.931	rs6813374	ENSG00000249502.1	AC006160.5	-4.69	3.58e-06	0.000791	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17647871	chr4:17587467~17614571:-
LUAD	cis	rs1008375	0.966	rs6813375	ENSG00000249502.1	AC006160.5	-4.69	3.58e-06	0.000791	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17647876	chr4:17587467~17614571:-
LUAD	cis	rs1008375	1	rs1558378	ENSG00000249502.1	AC006160.5	-4.69	3.58e-06	0.000791	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17648728	chr4:17587467~17614571:-
LUAD	cis	rs1008375	1	rs1558377	ENSG00000249502.1	AC006160.5	-4.69	3.58e-06	0.000791	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17649135	chr4:17587467~17614571:-
LUAD	cis	rs1008375	0.966	rs2872957	ENSG00000249502.1	AC006160.5	-4.69	3.58e-06	0.000791	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17650134	chr4:17587467~17614571:-
LUAD	cis	rs1964356	0.967	rs17701675	ENSG00000173295.6	FAM86B3P	-4.69	3.59e-06	0.000792	-0.23	-0.21	Mean corpuscular volume;	chr8:8993123	chr8:8228595~8244865:+
LUAD	cis	rs2032366	0.63	rs7235404	ENSG00000266920.1	ACTBP9	-4.69	3.59e-06	0.000792	-0.23	-0.21	Obesity-related traits;	chr18:61628753	chr18:62442028~62443126:+
LUAD	cis	rs4143844	0.867	rs11637606	ENSG00000259251.2	RP11-643M14.1	-4.69	3.59e-06	0.000792	-0.36	-0.21	Bipolar disorder and schizophrenia;	chr15:61912515	chr15:62060503~62062434:+
LUAD	cis	rs10050311	0.8	rs2230600	ENSG00000251411.1	RP11-397E7.4	4.69	3.59e-06	0.000793	0.29	0.21	Insulin-related traits;	chr4:86769845	chr4:86913266~86914817:-
LUAD	cis	rs9545047	0.588	rs9530913	ENSG00000227354.5	RBM26-AS1	4.69	3.59e-06	0.000793	0.22	0.21	Schizophrenia;	chr13:79384539	chr13:79406309~79424328:+
LUAD	cis	rs11051970	0.838	rs2651369	ENSG00000274964.1	RP11-817I4.1	-4.69	3.59e-06	0.000793	-0.22	-0.21	Response to tocilizumab in rheumatoid arthritis;	chr12:32399835	chr12:32339368~32340724:+
LUAD	cis	rs9487094	0.71	rs71558370	ENSG00000260273.1	RP11-425D10.10	4.69	3.59e-06	0.000793	0.32	0.21	Height;	chr6:109455700	chr6:109382795~109383666:+
LUAD	cis	rs12554020	0.892	rs76488437	ENSG00000227603.1	RP11-165J3.6	4.69	3.59e-06	0.000793	0.35	0.21	Schizophrenia;	chr9:93605514	chr9:93435332~93437121:-
LUAD	cis	rs12554020	0.681	rs80062429	ENSG00000227603.1	RP11-165J3.6	4.69	3.59e-06	0.000793	0.35	0.21	Schizophrenia;	chr9:93608830	chr9:93435332~93437121:-
LUAD	cis	rs950169	0.922	rs12912934	ENSG00000229212.6	RP11-561C5.4	-4.69	3.59e-06	0.000793	-0.3	-0.21	Schizophrenia;	chr15:84571216	chr15:85205440~85234795:-
LUAD	cis	rs2439831	0.85	rs7169322	ENSG00000249839.1	AC011330.5	-4.69	3.59e-06	0.000793	-0.45	-0.21	Lung cancer in ever smokers;	chr15:43838816	chr15:43663654~43684339:-
LUAD	cis	rs2439831	0.85	rs28707214	ENSG00000249839.1	AC011330.5	-4.69	3.59e-06	0.000793	-0.45	-0.21	Lung cancer in ever smokers;	chr15:43839425	chr15:43663654~43684339:-
LUAD	cis	rs4908760	0.613	rs12024032	ENSG00000270282.1	RP5-1115A15.2	-4.69	3.6e-06	0.000794	-0.23	-0.21	Vitiligo;	chr1:8748126	chr1:8512653~8513021:+
LUAD	cis	rs34779708	0.966	rs10508816	ENSG00000271335.4	RP11-324I22.4	4.69	3.6e-06	0.000795	0.22	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35171048	chr10:35314552~35336401:-
LUAD	cis	rs3096299	0.967	rs2911256	ENSG00000182376.2	RP5-1142A6.8	4.69	3.6e-06	0.000795	0.21	0.21	Multiple myeloma (IgH translocation);	chr16:89418688	chr16:88742767~88745748:+
LUAD	cis	rs62229266	0.626	rs7280896	ENSG00000214914.3	RPL23AP3	4.69	3.6e-06	0.000796	0.25	0.21	Mitral valve prolapse;	chr21:36088608	chr21:36016079~36016546:-
LUAD	cis	rs67311347	0.577	rs1880763	ENSG00000223797.4	ENTPD3-AS1	-4.69	3.6e-06	0.000796	-0.21	-0.21	Renal cell carcinoma;	chr3:40241764	chr3:40313802~40453329:-
LUAD	cis	rs17508449	1	rs79381435	ENSG00000232450.1	RP4-730K3.3	-4.69	3.61e-06	0.000797	-0.34	-0.21	Leprosy;	chr1:113543054	chr1:113698884~113699631:-
LUAD	cis	rs7829975	0.572	rs7005000	ENSG00000173295.6	FAM86B3P	-4.69	3.61e-06	0.000797	-0.22	-0.21	Mood instability;	chr8:8939092	chr8:8228595~8244865:+
LUAD	cis	rs11671005	0.693	rs11668821	ENSG00000268912.1	CTD-2619J13.17	-4.69	3.61e-06	0.000797	-0.29	-0.21	Mean platelet volume;	chr19:58444446	chr19:58428632~58431148:-
LUAD	cis	rs11671005	0.616	rs12980907	ENSG00000268912.1	CTD-2619J13.17	-4.69	3.61e-06	0.000797	-0.29	-0.21	Mean platelet volume;	chr19:58444959	chr19:58428632~58431148:-
LUAD	cis	rs9322193	0.923	rs7767622	ENSG00000268592.3	RAET1E-AS1	4.69	3.61e-06	0.000797	0.26	0.21	Lung cancer;	chr6:149681766	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.923	rs4421206	ENSG00000268592.3	RAET1E-AS1	4.69	3.61e-06	0.000797	0.26	0.21	Lung cancer;	chr6:149682891	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.923	rs3798761	ENSG00000268592.3	RAET1E-AS1	4.69	3.61e-06	0.000797	0.26	0.21	Lung cancer;	chr6:149683643	chr6:149863494~149919507:+
LUAD	cis	rs17301013	0.861	rs1793319	ENSG00000227373.4	RP11-160H22.5	4.69	3.61e-06	0.000798	0.26	0.21	Systemic lupus erythematosus;	chr1:174795470	chr1:174115300~174160004:-
LUAD	cis	rs4660214	0.724	rs10888683	ENSG00000228060.1	RP11-69E11.8	-4.69	3.61e-06	0.000798	-0.19	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39157997	chr1:39565160~39573203:+
LUAD	cis	rs6570726	0.791	rs11155426	ENSG00000235652.6	RP11-545I5.3	4.69	3.62e-06	0.000798	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145495994	chr6:145799409~145886585:+
LUAD	cis	rs4664293	0.833	rs3764969	ENSG00000226266.5	AC009961.3	-4.69	3.62e-06	0.000798	-0.29	-0.21	Monocyte percentage of white cells;	chr2:159764337	chr2:159670708~159712435:-
LUAD	cis	rs17772222	0.917	rs61984736	ENSG00000258983.2	RP11-507K2.2	4.69	3.62e-06	0.000798	0.26	0.21	Coronary artery calcification;	chr14:88626359	chr14:88499334~88515502:+
LUAD	cis	rs1499614	1	rs1267818	ENSG00000232559.3	GS1-124K5.12	4.69	3.62e-06	0.000798	0.37	0.21	Gout;	chr7:66642037	chr7:66554588~66576923:-
LUAD	cis	rs2836950	0.545	rs2836956	ENSG00000255568.3	BRWD1-AS2	4.69	3.62e-06	0.000798	0.2	0.21	Menarche (age at onset);	chr21:39251092	chr21:39313935~39314962:+
LUAD	cis	rs8098244	0.603	rs2960580	ENSG00000264745.1	TTC39C-AS1	4.69	3.62e-06	0.000799	0.22	0.21	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23712058	chr18:23994213~24015339:-
LUAD	cis	rs35740288	0.857	rs11630274	ENSG00000259407.1	RP11-158M2.3	-4.69	3.62e-06	0.000799	-0.21	-0.21	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85745156	chr15:85744109~85750281:-
LUAD	cis	rs2742234	0.541	rs11238483	ENSG00000273008.1	RP11-351D16.3	4.69	3.62e-06	0.000799	0.25	0.21	Hirschsprung disease;	chr10:43233332	chr10:43136824~43138334:-
LUAD	cis	rs71520386	0.583	rs35322907	ENSG00000228649.7	AC005682.5	-4.69	3.62e-06	0.000799	-0.28	-0.21	Fibrinogen levels;	chr7:22806592	chr7:22854178~22861579:+
LUAD	cis	rs683257	0.636	rs55942214	ENSG00000234147.1	RP3-460G2.2	-4.69	3.62e-06	0.000799	-0.33	-0.21	Facial emotion recognition (angry faces);	chr6:140827313	chr6:140845958~140852924:-
LUAD	cis	rs36093844	0.904	rs7113656	ENSG00000279742.1	RP11-700A24.1	-4.69	3.62e-06	8e-04	-0.23	-0.21	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85883696	chr11:85852557~85854943:-
LUAD	cis	rs9487094	0.813	rs12528566	ENSG00000260273.1	RP11-425D10.10	4.69	3.62e-06	8e-04	0.29	0.21	Height;	chr6:109416945	chr6:109382795~109383666:+
LUAD	cis	rs55823223	0.564	rs2034947	ENSG00000267801.1	RP11-552F3.9	4.69	3.62e-06	8e-04	0.23	0.21	Psoriasis;	chr17:75867848	chr17:75876372~75879546:+
LUAD	cis	rs9425766	0.692	rs4652294	ENSG00000227373.4	RP11-160H22.5	4.69	3.63e-06	8e-04	0.26	0.21	Life satisfaction;	chr1:174272027	chr1:174115300~174160004:-
LUAD	cis	rs12554020	0.892	rs10117236	ENSG00000227603.1	RP11-165J3.6	4.69	3.63e-06	8e-04	0.35	0.21	Schizophrenia;	chr9:93419731	chr9:93435332~93437121:-
LUAD	cis	rs12554020	0.892	rs7863760	ENSG00000227603.1	RP11-165J3.6	4.69	3.63e-06	8e-04	0.35	0.21	Schizophrenia;	chr9:93420287	chr9:93435332~93437121:-
LUAD	cis	rs11089937	0.626	rs9619800	ENSG00000211638.2	IGLV8-61	-4.69	3.63e-06	8e-04	-0.24	-0.21	Periodontitis (PAL4Q3);	chr22:22141088	chr22:22098700~22099212:+
LUAD	cis	rs1979679	0.842	rs11049380	ENSG00000278733.1	RP11-425D17.1	4.69	3.63e-06	0.000801	0.26	0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28160904	chr12:28185625~28186190:-
LUAD	cis	rs1979679	0.842	rs2035271	ENSG00000278733.1	RP11-425D17.1	4.69	3.63e-06	0.000801	0.26	0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28165638	chr12:28185625~28186190:-
LUAD	cis	rs7829975	0.711	rs12682352	ENSG00000173295.6	FAM86B3P	4.69	3.63e-06	0.000801	0.21	0.21	Mood instability;	chr8:8788736	chr8:8228595~8244865:+
LUAD	cis	rs1008375	1	rs17507481	ENSG00000249502.1	AC006160.5	-4.69	3.63e-06	0.000801	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17618443	chr4:17587467~17614571:-
LUAD	cis	rs7665090	1	rs909349	ENSG00000246560.2	RP11-10L12.4	-4.69	3.63e-06	0.000801	-0.25	-0.21	Primary biliary cholangitis;	chr4:102635159	chr4:102828055~102844075:+
LUAD	cis	rs6840360	0.582	rs59714108	ENSG00000270265.1	RP11-731D1.4	-4.69	3.63e-06	0.000801	-0.21	-0.21	Intelligence (multi-trait analysis);	chr4:151404787	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.582	rs6813735	ENSG00000270265.1	RP11-731D1.4	-4.69	3.63e-06	0.000801	-0.21	-0.21	Intelligence (multi-trait analysis);	chr4:151405838	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.582	rs57585665	ENSG00000270265.1	RP11-731D1.4	-4.69	3.63e-06	0.000801	-0.21	-0.21	Intelligence (multi-trait analysis);	chr4:151405865	chr4:151333775~151353224:-
LUAD	cis	rs5758511	0.514	rs5758626	ENSG00000226450.2	CYP2D8P	4.69	3.63e-06	0.000801	0.2	0.21	Birth weight;	chr22:42176357	chr22:42149886~42155001:-
LUAD	cis	rs1065852	0.861	rs5758627	ENSG00000226450.2	CYP2D8P	4.69	3.63e-06	0.000801	0.2	0.21	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42176541	chr22:42149886~42155001:-
LUAD	cis	rs7811142	1	rs7783159	ENSG00000078319.8	PMS2P1	-4.69	3.63e-06	0.000801	-0.25	-0.21	Platelet count;	chr7:100419831	chr7:100320992~100341908:-
LUAD	cis	rs453301	0.682	rs2929308	ENSG00000253981.4	ALG1L13P	-4.69	3.63e-06	0.000802	-0.24	-0.21	Joint mobility (Beighton score);	chr8:9226611	chr8:8236003~8244667:-
LUAD	cis	rs2562456	0.833	rs1932087	ENSG00000268081.1	RP11-678G14.2	4.69	3.63e-06	0.000802	0.34	0.21	Pain;	chr19:21338625	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.833	rs11671609	ENSG00000268081.1	RP11-678G14.2	4.69	3.63e-06	0.000802	0.34	0.21	Pain;	chr19:21342769	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.793	rs62109212	ENSG00000268081.1	RP11-678G14.2	4.69	3.63e-06	0.000802	0.34	0.21	Pain;	chr19:21343716	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.833	rs57250002	ENSG00000268081.1	RP11-678G14.2	4.69	3.63e-06	0.000802	0.34	0.21	Pain;	chr19:21344048	chr19:21554640~21569237:-
LUAD	cis	rs7829975	0.688	rs7826654	ENSG00000173295.6	FAM86B3P	4.69	3.64e-06	0.000802	0.22	0.21	Mood instability;	chr8:8521596	chr8:8228595~8244865:+
LUAD	cis	rs7829975	0.688	rs7826660	ENSG00000173295.6	FAM86B3P	4.69	3.64e-06	0.000802	0.22	0.21	Mood instability;	chr8:8521597	chr8:8228595~8244865:+
LUAD	cis	rs875971	1	rs2036264	ENSG00000232559.3	GS1-124K5.12	-4.69	3.64e-06	0.000802	-0.25	-0.21	Aortic root size;	chr7:66334917	chr7:66554588~66576923:-
LUAD	cis	rs875971	1	rs7783613	ENSG00000232559.3	GS1-124K5.12	-4.69	3.64e-06	0.000802	-0.25	-0.21	Aortic root size;	chr7:66340274	chr7:66554588~66576923:-
LUAD	cis	rs755249	0.508	rs10888688	ENSG00000228060.1	RP11-69E11.8	4.69	3.64e-06	0.000802	0.19	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39171633	chr1:39565160~39573203:+
LUAD	cis	rs17711722	0.522	rs62469933	ENSG00000226002.1	RP11-460N20.5	4.69	3.64e-06	0.000803	0.23	0.21	Calcium levels;	chr7:65800652	chr7:65084103~65100232:+
LUAD	cis	rs17711722	0.522	rs6957759	ENSG00000226002.1	RP11-460N20.5	4.69	3.64e-06	0.000803	0.23	0.21	Calcium levels;	chr7:65806798	chr7:65084103~65100232:+
LUAD	cis	rs17772222	0.917	rs61986670	ENSG00000258789.1	RP11-507K2.3	-4.69	3.64e-06	0.000803	-0.28	-0.21	Coronary artery calcification;	chr14:88730875	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.917	rs61986671	ENSG00000258789.1	RP11-507K2.3	-4.69	3.64e-06	0.000803	-0.28	-0.21	Coronary artery calcification;	chr14:88732917	chr14:88551597~88552493:+
LUAD	cis	rs4237845	0.591	rs4760344	ENSG00000257159.1	RP11-58A17.3	4.69	3.64e-06	0.000803	0.27	0.21	Intelligence (multi-trait analysis);	chr12:57927000	chr12:57967058~57968399:+
LUAD	cis	rs12025262	0.934	rs10924961	ENSG00000225300.1	RP11-1086F11.1	4.69	3.64e-06	0.000804	0.22	0.21	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr1:247198985	chr1:246605873~246608102:+
LUAD	cis	rs6762	0.748	rs5030780	ENSG00000279672.1	CMB9-55F22.1	4.69	3.64e-06	0.000804	0.22	0.21	Mean platelet volume;	chr11:838110	chr11:779617~780755:+
LUAD	cis	rs16873450	0.548	rs6953133	ENSG00000234800.2	PCMTD1P3	4.69	3.64e-06	0.000804	0.24	0.21	Verbal memory performance (residualized delayed recall level);	chr7:23761171	chr7:23721311~23721782:-
LUAD	cis	rs7189233	0.55	rs13330182	ENSG00000279344.1	RP11-44F14.7	4.69	3.64e-06	0.000804	0.17	0.21	Intelligence (multi-trait analysis);	chr16:53438473	chr16:53478957~53481550:-
LUAD	cis	rs748404	0.666	rs7181634	ENSG00000205771.5	CATSPER2P1	-4.69	3.65e-06	0.000804	-0.32	-0.21	Lung cancer;	chr15:43351703	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.666	rs55748552	ENSG00000205771.5	CATSPER2P1	-4.69	3.65e-06	0.000804	-0.32	-0.21	Lung cancer;	chr15:43359428	chr15:43726918~43747094:-
LUAD	cis	rs2732480	0.577	rs2732486	ENSG00000257735.1	RP11-370I10.6	4.69	3.65e-06	0.000804	0.26	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344051	chr12:48350945~48442411:+
LUAD	cis	rs858239	0.669	rs1990365	ENSG00000226816.2	AC005082.12	4.69	3.65e-06	0.000805	0.27	0.21	Cerebrospinal fluid biomarker levels;	chr7:23076347	chr7:23206013~23208045:+
LUAD	cis	rs30380	1	rs246454	ENSG00000248734.2	CTD-2260A17.1	4.69	3.65e-06	0.000805	0.21	0.21	Cerebrospinal fluid biomarker levels;	chr5:96787561	chr5:96784777~96785999:+
LUAD	cis	rs30380	0.922	rs246453	ENSG00000248734.2	CTD-2260A17.1	4.69	3.65e-06	0.000805	0.21	0.21	Cerebrospinal fluid biomarker levels;	chr5:96787633	chr5:96784777~96785999:+
LUAD	cis	rs4591358	0.636	rs6712400	ENSG00000223466.1	AC064834.2	-4.69	3.65e-06	0.000805	-0.27	-0.21	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195506646	chr2:195533035~195538681:+
LUAD	cis	rs6687758	1	rs11118926	ENSG00000227925.1	RP11-191N8.2	4.68	3.65e-06	0.000805	0.29	0.21	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222013781	chr1:221827666~221840666:-
LUAD	cis	rs6687758	1	rs17495159	ENSG00000227925.1	RP11-191N8.2	4.68	3.65e-06	0.000805	0.29	0.21	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222016251	chr1:221827666~221840666:-
LUAD	cis	rs6687758	1	rs35212520	ENSG00000227925.1	RP11-191N8.2	4.68	3.65e-06	0.000805	0.29	0.21	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222016322	chr1:221827666~221840666:-
LUAD	cis	rs7829975	0.688	rs7837587	ENSG00000173295.6	FAM86B3P	4.68	3.65e-06	0.000805	0.22	0.21	Mood instability;	chr8:8521482	chr8:8228595~8244865:+
LUAD	cis	rs4143844	0.867	rs12916410	ENSG00000259251.2	RP11-643M14.1	4.68	3.65e-06	0.000805	0.37	0.21	Bipolar disorder and schizophrenia;	chr15:62010687	chr15:62060503~62062434:+
LUAD	cis	rs11976180	1	rs7777389	ENSG00000204959.4	ARHGEF34P	4.68	3.65e-06	0.000805	0.26	0.21	Obesity-related traits;	chr7:144047709	chr7:144272445~144286966:-
LUAD	cis	rs11841001	0.556	rs34083520	ENSG00000261105.4	LMO7-AS1	-4.68	3.65e-06	0.000805	-0.33	-0.21	Corneal astigmatism;	chr13:75775622	chr13:75604700~75635994:-
LUAD	cis	rs4664293	0.967	rs13000070	ENSG00000226266.5	AC009961.3	-4.68	3.65e-06	0.000805	-0.3	-0.21	Monocyte percentage of white cells;	chr2:159669263	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.647	rs10199805	ENSG00000226266.5	AC009961.3	-4.68	3.65e-06	0.000805	-0.28	-0.21	Monocyte percentage of white cells;	chr2:159570880	chr2:159670708~159712435:-
LUAD	cis	rs2243480	0.803	rs36004293	ENSG00000164669.11	INTS4P1	4.68	3.65e-06	0.000805	0.37	0.21	Diabetic kidney disease;	chr7:65951525	chr7:65141225~65234216:+
LUAD	cis	rs2243480	0.803	rs35268390	ENSG00000164669.11	INTS4P1	4.68	3.65e-06	0.000805	0.37	0.21	Diabetic kidney disease;	chr7:65951549	chr7:65141225~65234216:+
LUAD	cis	rs1008375	1	rs7671752	ENSG00000249502.1	AC006160.5	-4.68	3.66e-06	0.000806	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17659775	chr4:17587467~17614571:-
LUAD	cis	rs10995356	0.932	rs7902607	ENSG00000238280.1	RP11-436D10.3	-4.68	3.66e-06	0.000806	-0.26	-0.21	Temperament;	chr10:62914708	chr10:62793562~62805887:-
LUAD	cis	rs5758659	1	rs134900	ENSG00000227370.1	RP4-669P10.19	-4.68	3.66e-06	0.000807	-0.19	-0.21	Cognitive function;	chr22:42287337	chr22:42132543~42132998:+
LUAD	cis	rs910316	0.967	rs11159121	ENSG00000259138.1	RP11-950C14.7	-4.68	3.66e-06	0.000808	-0.22	-0.21	Height;	chr14:75199326	chr14:75127153~75136930:+
LUAD	cis	rs9322193	0.923	rs9766004	ENSG00000268592.3	RAET1E-AS1	4.68	3.67e-06	0.000808	0.25	0.21	Lung cancer;	chr6:149754363	chr6:149863494~149919507:+
LUAD	cis	rs1499614	1	rs1267817	ENSG00000232559.3	GS1-124K5.12	4.68	3.67e-06	0.000808	0.37	0.21	Gout;	chr7:66645053	chr7:66554588~66576923:-
LUAD	cis	rs1387259	0.899	rs7307566	ENSG00000240399.1	RP1-228P16.1	4.68	3.67e-06	0.000808	0.21	0.21	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48210899	chr12:48054813~48055591:-
LUAD	cis	rs6957923	0.839	rs58201821	ENSG00000230658.1	KLHL7-AS1	4.68	3.67e-06	0.000809	0.25	0.21	Height;	chr7:23471241	chr7:23101228~23105703:-
LUAD	cis	rs2911132	0.564	rs17401719	ENSG00000248734.2	CTD-2260A17.1	-4.68	3.67e-06	0.000809	-0.22	-0.21	Urate levels (BMI interaction);	chr5:96753342	chr5:96784777~96785999:+
LUAD	cis	rs6921919	0.887	rs16894116	ENSG00000216901.1	AL022393.7	4.68	3.67e-06	0.00081	0.29	0.21	Autism spectrum disorder or schizophrenia;	chr6:28447190	chr6:28176188~28176674:+
LUAD	cis	rs62025270	0.632	rs62022919	ENSG00000202081.1	RNU6-1280P	-4.68	3.67e-06	0.00081	-0.31	-0.21	Idiopathic pulmonary fibrosis;	chr15:85675079	chr15:85651522~85651628:-
LUAD	cis	rs9322193	0.923	rs66516768	ENSG00000268592.3	RAET1E-AS1	4.68	3.68e-06	0.00081	0.26	0.21	Lung cancer;	chr6:149671999	chr6:149863494~149919507:+
LUAD	cis	rs1799949	0.965	rs11657883	ENSG00000236383.6	LINC00854	-4.68	3.68e-06	0.00081	-0.17	-0.21	Menopause (age at onset);	chr17:43178007	chr17:43216941~43305976:-
LUAD	cis	rs1799949	0.965	rs11656945	ENSG00000236383.6	LINC00854	-4.68	3.68e-06	0.00081	-0.17	-0.21	Menopause (age at onset);	chr17:43178248	chr17:43216941~43305976:-
LUAD	cis	rs8177876	0.749	rs2549891	ENSG00000261061.1	RP11-303E16.2	4.68	3.68e-06	0.000811	0.3	0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046761	chr16:81030770~81031485:+
LUAD	cis	rs1555322	0.53	rs2250205	ENSG00000279253.1	RP4-614O4.13	-4.68	3.68e-06	0.000811	-0.26	-0.21	Attention deficit hyperactivity disorder;	chr20:35280121	chr20:35262727~35264187:-
LUAD	cis	rs34779708	0.966	rs11010095	ENSG00000271335.4	RP11-324I22.4	4.68	3.68e-06	0.000812	0.22	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35107020	chr10:35314552~35336401:-
LUAD	cis	rs755249	0.508	rs6703800	ENSG00000228060.1	RP11-69E11.8	4.68	3.69e-06	0.000812	0.19	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39160970	chr1:39565160~39573203:+
LUAD	cis	rs9545047	0.604	rs8001392	ENSG00000227354.5	RBM26-AS1	4.68	3.69e-06	0.000813	0.22	0.21	Schizophrenia;	chr13:79374211	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs4146473	ENSG00000227354.5	RBM26-AS1	4.68	3.69e-06	0.000813	0.22	0.21	Schizophrenia;	chr13:79374548	chr13:79406309~79424328:+
LUAD	cis	rs9633740	0.578	rs11185982	ENSG00000226659.1	RP11-137H2.4	-4.68	3.69e-06	0.000813	-0.36	-0.21	Post bronchodilator FEV1;	chr10:80545871	chr10:80529597~80535942:-
LUAD	cis	rs6604026	0.59	rs11810217	ENSG00000223787.2	RP4-593M8.1	4.68	3.69e-06	0.000813	0.29	0.21	Multiple sclerosis;	chr1:92682820	chr1:92580476~92580821:-
LUAD	cis	rs11810217	0.718	rs114225281	ENSG00000223787.2	RP4-593M8.1	4.68	3.69e-06	0.000813	0.29	0.21	Multiple sclerosis;	chr1:92685669	chr1:92580476~92580821:-
LUAD	cis	rs6604026	0.59	rs111807611	ENSG00000223787.2	RP4-593M8.1	4.68	3.69e-06	0.000813	0.29	0.21	Multiple sclerosis;	chr1:92687707	chr1:92580476~92580821:-
LUAD	cis	rs2380205	0.503	rs685852	ENSG00000232807.2	RP11-536K7.3	-4.68	3.69e-06	0.000813	-0.22	-0.21	Breast cancer;	chr10:5892654	chr10:5934270~5945900:-
LUAD	cis	rs7727544	0.581	rs10075801	ENSG00000233006.5	AC034220.3	4.68	3.69e-06	0.000813	0.19	0.21	Blood metabolite levels;	chr5:132341949	chr5:132311285~132369916:-
LUAD	cis	rs875971	0.577	rs35072105	ENSG00000224316.1	RP11-479O9.2	-4.68	3.69e-06	0.000813	-0.21	-0.21	Aortic root size;	chr7:66144830	chr7:65773620~65802067:+
LUAD	cis	rs7829975	0.626	rs907183	ENSG00000173295.6	FAM86B3P	-4.68	3.69e-06	0.000814	-0.22	-0.21	Mood instability;	chr8:8872251	chr8:8228595~8244865:+
LUAD	cis	rs6969780	0.908	rs6461987	ENSG00000233429.8	HOTAIRM1	4.68	3.7e-06	0.000814	0.37	0.21	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27127337	chr7:27095647~27100265:+
LUAD	cis	rs2348418	0.733	rs2169754	ENSG00000247934.4	RP11-967K21.1	-4.68	3.7e-06	0.000814	-0.24	-0.21	Lung function (FEV1);Lung function (FVC);	chr12:28187712	chr12:28163298~28190738:-
LUAD	cis	rs1816752	0.746	rs9511270	ENSG00000273628.1	RP11-756A22.7	4.68	3.7e-06	0.000814	0.24	0.21	Obesity-related traits;	chr13:24444542	chr13:24933006~24936796:+
LUAD	cis	rs8180040	0.627	rs58956475	ENSG00000271161.1	BOLA2P2	-4.68	3.7e-06	0.000815	-0.2	-0.21	Colorectal cancer;	chr3:47183125	chr3:47499841~47500407:+
LUAD	cis	rs11673344	0.704	rs1726724	ENSG00000226686.6	LINC01535	4.68	3.7e-06	0.000815	0.26	0.21	Obesity-related traits;	chr19:36925890	chr19:37251912~37265535:+
LUAD	cis	rs2286503	0.901	rs2286505	ENSG00000226329.2	AC005682.6	4.68	3.7e-06	0.000815	0.27	0.21	Fibrinogen;	chr7:22815221	chr7:22863874~22881350:-
LUAD	cis	rs9584850	0.834	rs12869627	ENSG00000231194.1	FARP1-AS1	4.68	3.7e-06	0.000815	0.26	0.21	Neuroticism;	chr13:98468198	chr13:98435405~98435840:-
LUAD	cis	rs783540	0.656	rs783538	ENSG00000276710.3	CSPG4P8	4.68	3.7e-06	0.000815	0.21	0.21	Schizophrenia;	chr15:82584394	chr15:82459472~82477258:+
LUAD	cis	rs1008375	0.933	rs6449324	ENSG00000249502.1	AC006160.5	-4.68	3.7e-06	0.000815	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17693257	chr4:17587467~17614571:-
LUAD	cis	rs2378497	0.877	rs12129517	ENSG00000232679.1	RP11-400N13.3	4.68	3.7e-06	0.000816	0.33	0.21	Serum thyroid-stimulating hormone levels;	chr1:221984959	chr1:222041705~222064763:-
LUAD	cis	rs2378497	1	rs56054113	ENSG00000232679.1	RP11-400N13.3	4.68	3.7e-06	0.000816	0.33	0.21	Serum thyroid-stimulating hormone levels;	chr1:221987052	chr1:222041705~222064763:-
LUAD	cis	rs3809863	0.602	rs7225700	ENSG00000228782.6	CTD-2026D20.3	4.68	3.7e-06	0.000816	0.22	0.21	Glaucoma (primary open-angle);	chr17:47314438	chr17:47450568~47492492:-
LUAD	cis	rs2239547	0.618	rs4687658	ENSG00000242142.1	SERBP1P3	4.68	3.7e-06	0.000816	0.25	0.21	Schizophrenia;	chr3:52826350	chr3:53064283~53065091:-
LUAD	cis	rs2239547	0.657	rs2276817	ENSG00000242142.1	SERBP1P3	4.68	3.7e-06	0.000816	0.25	0.21	Schizophrenia;	chr3:52826920	chr3:53064283~53065091:-
LUAD	cis	rs2239547	0.657	rs13072536	ENSG00000242142.1	SERBP1P3	4.68	3.7e-06	0.000816	0.25	0.21	Schizophrenia;	chr3:52827195	chr3:53064283~53065091:-
LUAD	cis	rs2239547	0.657	rs12488303	ENSG00000242142.1	SERBP1P3	4.68	3.7e-06	0.000816	0.25	0.21	Schizophrenia;	chr3:52827987	chr3:53064283~53065091:-
LUAD	cis	rs2239547	0.657	rs2072391	ENSG00000242142.1	SERBP1P3	4.68	3.7e-06	0.000816	0.25	0.21	Schizophrenia;	chr3:52828184	chr3:53064283~53065091:-
LUAD	cis	rs11971779	0.752	rs4732371	ENSG00000273391.1	RP11-634H22.1	4.68	3.7e-06	0.000816	0.22	0.21	Diisocyanate-induced asthma;	chr7:139392571	chr7:139359032~139359566:-
LUAD	cis	rs6088590	0.931	rs6088624	ENSG00000276073.1	RP5-1125A11.7	-4.68	3.71e-06	0.000816	-0.22	-0.21	Coronary artery disease;	chr20:34849049	chr20:33985617~33988989:-
LUAD	cis	rs17772222	1	rs17772222	ENSG00000258983.2	RP11-507K2.2	-4.68	3.71e-06	0.000816	-0.26	-0.21	Coronary artery calcification;	chr14:88360138	chr14:88499334~88515502:+
LUAD	cis	rs4908760	0.539	rs10864367	ENSG00000232912.4	RP5-1115A15.1	4.68	3.71e-06	0.000817	0.19	0.21	Vitiligo;	chr1:8787321	chr1:8424645~8434838:+
LUAD	cis	rs950169	0.579	rs12913054	ENSG00000259728.4	LINC00933	4.68	3.71e-06	0.000817	0.33	0.21	Schizophrenia;	chr15:83995704	chr15:84570649~84580175:+
LUAD	cis	rs1816752	0.819	rs7400583	ENSG00000273628.1	RP11-756A22.7	4.68	3.71e-06	0.000817	0.24	0.21	Obesity-related traits;	chr13:24415916	chr13:24933006~24936796:+
LUAD	cis	rs11155671	0.53	rs7756850	ENSG00000268592.3	RAET1E-AS1	4.68	3.71e-06	0.000817	0.26	0.21	Testicular germ cell tumor;	chr6:149891460	chr6:149863494~149919507:+
LUAD	cis	rs4664293	0.967	rs4665103	ENSG00000226266.5	AC009961.3	-4.68	3.71e-06	0.000817	-0.3	-0.21	Monocyte percentage of white cells;	chr2:159675801	chr2:159670708~159712435:-
LUAD	cis	rs8177876	0.658	rs79603321	ENSG00000261061.1	RP11-303E16.2	-4.68	3.71e-06	0.000817	-0.34	-0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81039139	chr16:81030770~81031485:+
LUAD	cis	rs2303759	0.666	rs66967196	ENSG00000268686.1	AC010524.2	-4.68	3.72e-06	0.000818	-0.31	-0.21	Multiple sclerosis;	chr19:49305637	chr19:49368705~49388081:-
LUAD	cis	rs2243480	1	rs34136756	ENSG00000229886.1	RP5-1132H15.3	4.68	3.72e-06	0.000818	0.36	0.21	Diabetic kidney disease;	chr7:65916269	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs78803505	ENSG00000229886.1	RP5-1132H15.3	4.68	3.72e-06	0.000818	0.36	0.21	Diabetic kidney disease;	chr7:65917585	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs34933526	ENSG00000229886.1	RP5-1132H15.3	4.68	3.72e-06	0.000818	0.36	0.21	Diabetic kidney disease;	chr7:65918212	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs34577383	ENSG00000229886.1	RP5-1132H15.3	4.68	3.72e-06	0.000818	0.36	0.21	Diabetic kidney disease;	chr7:65920739	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs6949812	ENSG00000229886.1	RP5-1132H15.3	4.68	3.72e-06	0.000818	0.36	0.21	Diabetic kidney disease;	chr7:65922114	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs55895244	ENSG00000229886.1	RP5-1132H15.3	4.68	3.72e-06	0.000818	0.36	0.21	Diabetic kidney disease;	chr7:65922691	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs6970243	ENSG00000229886.1	RP5-1132H15.3	4.68	3.72e-06	0.000818	0.36	0.21	Diabetic kidney disease;	chr7:65923503	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs7794661	ENSG00000229886.1	RP5-1132H15.3	4.68	3.72e-06	0.000818	0.36	0.21	Diabetic kidney disease;	chr7:65924743	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs7795242	ENSG00000229886.1	RP5-1132H15.3	4.68	3.72e-06	0.000818	0.36	0.21	Diabetic kidney disease;	chr7:65925107	chr7:66025126~66031544:-
LUAD	cis	rs2243480	0.708	rs35310401	ENSG00000229886.1	RP5-1132H15.3	4.68	3.72e-06	0.000818	0.36	0.21	Diabetic kidney disease;	chr7:65925372	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs35058610	ENSG00000229886.1	RP5-1132H15.3	4.68	3.72e-06	0.000818	0.36	0.21	Diabetic kidney disease;	chr7:65925938	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs2177703	ENSG00000229886.1	RP5-1132H15.3	4.68	3.72e-06	0.000818	0.36	0.21	Diabetic kidney disease;	chr7:65926730	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs35432774	ENSG00000229886.1	RP5-1132H15.3	4.68	3.72e-06	0.000818	0.36	0.21	Diabetic kidney disease;	chr7:65928032	chr7:66025126~66031544:-
LUAD	cis	rs2243480	0.831	rs7806717	ENSG00000229886.1	RP5-1132H15.3	-4.68	3.72e-06	0.000818	-0.36	-0.21	Diabetic kidney disease;	chr7:65928187	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs56985706	ENSG00000229886.1	RP5-1132H15.3	4.68	3.72e-06	0.000818	0.36	0.21	Diabetic kidney disease;	chr7:65929575	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs60683927	ENSG00000229886.1	RP5-1132H15.3	4.68	3.72e-06	0.000818	0.36	0.21	Diabetic kidney disease;	chr7:65929781	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs58062456	ENSG00000229886.1	RP5-1132H15.3	4.68	3.72e-06	0.000818	0.36	0.21	Diabetic kidney disease;	chr7:65929865	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs34529418	ENSG00000229886.1	RP5-1132H15.3	4.68	3.72e-06	0.000818	0.36	0.21	Diabetic kidney disease;	chr7:65938222	chr7:66025126~66031544:-
LUAD	cis	rs2243480	0.901	rs35087093	ENSG00000229886.1	RP5-1132H15.3	4.68	3.72e-06	0.000818	0.36	0.21	Diabetic kidney disease;	chr7:65940221	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs35046236	ENSG00000229886.1	RP5-1132H15.3	4.68	3.72e-06	0.000818	0.36	0.21	Diabetic kidney disease;	chr7:65943626	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs36068983	ENSG00000229886.1	RP5-1132H15.3	4.68	3.72e-06	0.000818	0.36	0.21	Diabetic kidney disease;	chr7:65944004	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs68189316	ENSG00000229886.1	RP5-1132H15.3	4.68	3.72e-06	0.000818	0.36	0.21	Diabetic kidney disease;	chr7:65944182	chr7:66025126~66031544:-
LUAD	cis	rs11673344	0.864	rs2562595	ENSG00000226686.6	LINC01535	4.68	3.72e-06	0.000818	0.27	0.21	Obesity-related traits;	chr19:37023964	chr19:37251912~37265535:+
LUAD	cis	rs11673344	0.832	rs8101407	ENSG00000226686.6	LINC01535	4.68	3.72e-06	0.000818	0.27	0.21	Obesity-related traits;	chr19:37024444	chr19:37251912~37265535:+
LUAD	cis	rs8177876	0.822	rs8043855	ENSG00000261838.4	RP11-303E16.6	4.68	3.72e-06	0.000818	0.4	0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81089256	chr16:81069854~81076598:+
LUAD	cis	rs1075265	0.547	rs7587217	ENSG00000233266.1	HMGB1P31	4.68	3.72e-06	0.000818	0.27	0.21	Chronotype;Morning vs. evening chronotype;	chr2:53675029	chr2:54051334~54051760:+
LUAD	cis	rs6762	0.748	rs7928935	ENSG00000279672.1	CMB9-55F22.1	4.68	3.72e-06	0.000818	0.23	0.21	Mean platelet volume;	chr11:839127	chr11:779617~780755:+
LUAD	cis	rs748404	0.697	rs555001	ENSG00000249839.1	AC011330.5	-4.68	3.72e-06	0.000818	-0.26	-0.21	Lung cancer;	chr15:43253530	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.697	rs475261	ENSG00000249839.1	AC011330.5	-4.68	3.72e-06	0.000818	-0.26	-0.21	Lung cancer;	chr15:43254258	chr15:43663654~43684339:-
LUAD	cis	rs1008375	1	rs6854733	ENSG00000249502.1	AC006160.5	-4.68	3.72e-06	0.000818	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17638903	chr4:17587467~17614571:-
LUAD	cis	rs1008375	1	rs55939327	ENSG00000249502.1	AC006160.5	-4.68	3.72e-06	0.000818	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17641314	chr4:17587467~17614571:-
LUAD	cis	rs1008375	1	rs2286771	ENSG00000249502.1	AC006160.5	-4.68	3.72e-06	0.000818	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17642225	chr4:17587467~17614571:-
LUAD	cis	rs1008375	1	rs28545485	ENSG00000249502.1	AC006160.5	-4.68	3.72e-06	0.000818	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17643753	chr4:17587467~17614571:-
LUAD	cis	rs1008375	1	rs10011865	ENSG00000249502.1	AC006160.5	-4.68	3.72e-06	0.000818	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17644087	chr4:17587467~17614571:-
LUAD	cis	rs442309	0.687	rs10822053	ENSG00000238280.1	RP11-436D10.3	4.68	3.72e-06	0.000819	0.26	0.21	Vogt-Koyanagi-Harada syndrome;	chr10:62701075	chr10:62793562~62805887:-
LUAD	cis	rs6840360	0.967	rs1105534	ENSG00000270265.1	RP11-731D1.4	-4.68	3.72e-06	0.000819	-0.21	-0.21	Intelligence (multi-trait analysis);	chr4:151684160	chr4:151333775~151353224:-
LUAD	cis	rs12030196	0.788	rs2764928	ENSG00000230812.4	LINC01358	-4.68	3.72e-06	0.000819	-0.21	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:58957117	chr1:59020387~59044614:+
LUAD	cis	rs2288884	0.806	rs17779439	ENSG00000269959.1	SPACA6P-AS	-4.68	3.72e-06	0.000819	-0.28	-0.21	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52080738	chr19:51685363~51693456:-
LUAD	cis	rs2018683	0.707	rs917219	ENSG00000228421.2	AC005013.5	4.68	3.72e-06	0.000819	0.23	0.21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28935726	chr7:28957667~28959345:+
LUAD	cis	rs9545047	0.604	rs9574406	ENSG00000227354.5	RBM26-AS1	-4.68	3.73e-06	0.00082	-0.22	-0.21	Schizophrenia;	chr13:79338982	chr13:79406309~79424328:+
LUAD	cis	rs2380205	0.517	rs11255974	ENSG00000232807.2	RP11-536K7.3	4.68	3.73e-06	0.00082	0.23	0.21	Breast cancer;	chr10:5926931	chr10:5934270~5945900:-
LUAD	cis	rs1008375	0.897	rs1006723	ENSG00000249502.1	AC006160.5	-4.68	3.73e-06	0.00082	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17616901	chr4:17587467~17614571:-
LUAD	cis	rs9879311	0.643	rs1473183	ENSG00000240288.6	GHRLOS	4.68	3.73e-06	0.00082	0.21	0.21	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10370143	chr3:10285754~10293449:+
LUAD	cis	rs750134	0.901	rs3741781	ENSG00000257221.1	RP11-689B22.2	-4.68	3.73e-06	0.00082	-0.32	-0.21	Low high density lipoprotein cholesterol levels;	chr12:108784227	chr12:108628687~108641318:+
LUAD	cis	rs4908768	0.501	rs910581	ENSG00000270282.1	RP5-1115A15.2	4.68	3.73e-06	0.00082	0.23	0.21	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8469464	chr1:8512653~8513021:+
LUAD	cis	rs9487094	0.922	rs6916579	ENSG00000260273.1	RP11-425D10.10	4.68	3.73e-06	0.000821	0.28	0.21	Height;	chr6:109530435	chr6:109382795~109383666:+
LUAD	cis	rs10483853	0.579	rs10134243	ENSG00000258695.2	RP3-414A15.2	-4.68	3.73e-06	0.000821	-0.29	-0.21	Coronary artery calcification;	chr14:73478444	chr14:73522878~73530610:+
LUAD	cis	rs2976388	0.565	rs2572905	ENSG00000253741.1	CTD-2292P10.4	-4.68	3.74e-06	0.000822	-0.24	-0.21	Urinary tract infection frequency;	chr8:142715686	chr8:142702252~142726973:-
LUAD	cis	rs6723108	0.603	rs4953938	ENSG00000224043.6	CCNT2-AS1	4.68	3.74e-06	0.000822	0.26	0.21	Type 2 diabetes;	chr2:134937278	chr2:134735464~134918710:-
LUAD	cis	rs2439831	0.85	rs3736180	ENSG00000249839.1	AC011330.5	-4.68	3.74e-06	0.000823	-0.45	-0.21	Lung cancer in ever smokers;	chr15:43814426	chr15:43663654~43684339:-
LUAD	cis	rs2439831	0.85	rs28684672	ENSG00000249839.1	AC011330.5	-4.68	3.74e-06	0.000823	-0.45	-0.21	Lung cancer in ever smokers;	chr15:43815464	chr15:43663654~43684339:-
LUAD	cis	rs1551277	0.877	rs7801465	ENSG00000146666.5	LINC00525	-4.68	3.74e-06	0.000823	-0.23	-0.21	Anxiety disorder;	chr7:47799028	chr7:47761476~47766772:+
LUAD	cis	rs853679	1	rs2799079	ENSG00000204709.4	LINC01556	4.68	3.74e-06	0.000823	0.31	0.21	Depression;	chr6:28267398	chr6:28943877~28944537:+
LUAD	cis	rs34375054	0.573	rs12581367	ENSG00000279233.1	RP11-158L12.4	4.68	3.74e-06	0.000823	0.19	0.21	Post bronchodilator FEV1/FVC ratio;	chr12:125170095	chr12:125138245~125141711:+
LUAD	cis	rs9322193	0.809	rs9479808	ENSG00000268592.3	RAET1E-AS1	4.68	3.75e-06	0.000824	0.25	0.21	Lung cancer;	chr6:149751328	chr6:149863494~149919507:+
LUAD	cis	rs6840360	0.516	rs6535794	ENSG00000270265.1	RP11-731D1.4	-4.68	3.75e-06	0.000824	-0.21	-0.21	Intelligence (multi-trait analysis);	chr4:151381631	chr4:151333775~151353224:-
LUAD	cis	rs72634501	0.517	rs6600289	ENSG00000228060.1	RP11-69E11.8	4.68	3.75e-06	0.000824	0.19	0.21	HDL cholesterol;	chr1:39148140	chr1:39565160~39573203:+
LUAD	cis	rs875971	0.66	rs79009421	ENSG00000236529.1	RP13-254B10.1	-4.68	3.75e-06	0.000824	-0.21	-0.21	Aortic root size;	chr7:66603522	chr7:65840212~65840596:+
LUAD	cis	rs6570726	0.791	rs365747	ENSG00000235652.6	RP11-545I5.3	4.68	3.75e-06	0.000825	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145545648	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.764	rs448258	ENSG00000235652.6	RP11-545I5.3	4.68	3.75e-06	0.000825	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145548009	chr6:145799409~145886585:+
LUAD	cis	rs9322193	0.923	rs10782316	ENSG00000268592.3	RAET1E-AS1	4.68	3.75e-06	0.000825	0.25	0.21	Lung cancer;	chr6:149752755	chr6:149863494~149919507:+
LUAD	cis	rs7176527	0.848	rs3748374	ENSG00000229212.6	RP11-561C5.4	4.68	3.76e-06	0.000825	0.32	0.21	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84641012	chr15:85205440~85234795:-
LUAD	cis	rs6687821	0.531	rs7534656	ENSG00000267734.1	RP4-604K5.3	-4.68	3.76e-06	0.000826	-0.27	-0.21	Yeast infection;	chr1:87045715	chr1:86932199~86934891:-
LUAD	cis	rs7713065	0.531	rs2522051	ENSG00000233006.5	AC034220.3	4.68	3.76e-06	0.000826	0.19	0.21	Lung function (FEV1/FVC);	chr5:132461886	chr5:132311285~132369916:-
LUAD	cis	rs4568518	0.619	rs4470902	ENSG00000279048.1	RP11-511H23.2	-4.68	3.76e-06	0.000826	-0.17	-0.21	Measles;	chr7:17968687	chr7:17940503~17942922:+
LUAD	cis	rs57502260	0.704	rs2186937	ENSG00000212093.1	AP000807.1	4.68	3.76e-06	0.000827	0.29	0.21	Total body bone mineral density (age 45-60);	chr11:68489379	chr11:68506083~68506166:-
LUAD	cis	rs71520386	0.632	rs28526185	ENSG00000228649.7	AC005682.5	-4.68	3.76e-06	0.000827	-0.28	-0.21	Fibrinogen levels;	chr7:22831699	chr7:22854178~22861579:+
LUAD	cis	rs7829975	0.714	rs12544992	ENSG00000253981.4	ALG1L13P	4.68	3.77e-06	0.000827	0.24	0.21	Mood instability;	chr8:8804171	chr8:8236003~8244667:-
LUAD	cis	rs3809863	0.602	rs2317677	ENSG00000228782.6	CTD-2026D20.3	4.68	3.77e-06	0.000828	0.22	0.21	Glaucoma (primary open-angle);	chr17:47316041	chr17:47450568~47492492:-
LUAD	cis	rs61270009	0.955	rs34148755	ENSG00000247828.6	TMEM161B-AS1	4.68	3.77e-06	0.000828	0.24	0.21	Depressive symptoms;	chr5:88394130	chr5:88268895~88436685:+
LUAD	cis	rs57502260	1	rs56312530	ENSG00000212093.1	AP000807.1	4.68	3.77e-06	0.000828	0.28	0.21	Total body bone mineral density (age 45-60);	chr11:68451947	chr11:68506083~68506166:-
LUAD	cis	rs875971	1	rs10244498	ENSG00000232559.3	GS1-124K5.12	4.68	3.77e-06	0.000828	0.24	0.21	Aortic root size;	chr7:66651069	chr7:66554588~66576923:-
LUAD	cis	rs11971779	0.838	rs58074268	ENSG00000273391.1	RP11-634H22.1	4.68	3.77e-06	0.000828	0.23	0.21	Diisocyanate-induced asthma;	chr7:139424179	chr7:139359032~139359566:-
LUAD	cis	rs853679	0.882	rs3757188	ENSG00000204709.4	LINC01556	4.68	3.77e-06	0.000828	0.36	0.21	Depression;	chr6:28139579	chr6:28943877~28944537:+
LUAD	cis	rs375066	0.935	rs425217	ENSG00000267058.1	RP11-15A1.3	-4.68	3.77e-06	0.000828	-0.23	-0.21	Breast cancer;	chr19:43889823	chr19:43891804~43901805:-
LUAD	cis	rs7829975	0.742	rs882462	ENSG00000253893.2	FAM85B	-4.68	3.77e-06	0.000828	-0.26	-0.21	Mood instability;	chr8:8821020	chr8:8167819~8226614:-
LUAD	cis	rs2337406	1	rs11845269	ENSG00000223648.3	IGHV3-64	4.68	3.77e-06	0.000828	0.25	0.21	Alzheimer's disease (late onset);	chr14:106683851	chr14:106643132~106658258:-
LUAD	cis	rs875971	0.66	rs10272357	ENSG00000224316.1	RP11-479O9.2	-4.68	3.77e-06	0.000828	-0.21	-0.21	Aortic root size;	chr7:66598087	chr7:65773620~65802067:+
LUAD	cis	rs2280018	0.526	rs1510148	ENSG00000207425.1	Y_RNA	4.68	3.77e-06	0.000829	0.26	0.21	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15073522	chr16:14915457~14915556:-
LUAD	cis	rs801193	1	rs17566701	ENSG00000236529.1	RP13-254B10.1	4.68	3.77e-06	0.000829	0.22	0.21	Aortic root size;	chr7:66728196	chr7:65840212~65840596:+
LUAD	cis	rs2836950	0.585	rs1029004	ENSG00000255568.3	BRWD1-AS2	-4.68	3.77e-06	0.000829	-0.2	-0.21	Menarche (age at onset);	chr21:39243417	chr21:39313935~39314962:+
LUAD	cis	rs1431005	0.858	rs11132461	ENSG00000250658.1	RP11-138B4.1	-4.68	3.77e-06	0.000829	-0.25	-0.21	Response to statin therapy;	chr4:187509161	chr4:187304083~187309682:-
LUAD	cis	rs7829975	0.511	rs2976902	ENSG00000173295.6	FAM86B3P	4.68	3.77e-06	0.000829	0.22	0.21	Mood instability;	chr8:8483595	chr8:8228595~8244865:+
LUAD	cis	rs442309	0.875	rs224146	ENSG00000238280.1	RP11-436D10.3	-4.68	3.78e-06	0.00083	-0.25	-0.21	Vogt-Koyanagi-Harada syndrome;	chr10:62723179	chr10:62793562~62805887:-
LUAD	cis	rs7493	0.901	rs17879517	ENSG00000233942.1	AC004012.1	4.68	3.78e-06	0.00083	0.3	0.21	Yu-Zhi constitution type in type 2 diabetes;	chr7:95401334	chr7:95471835~95473998:+
LUAD	cis	rs7945705	0.818	rs10769948	ENSG00000254860.4	TMEM9B-AS1	4.68	3.78e-06	0.00083	0.24	0.21	Hemoglobin concentration;	chr11:8740235	chr11:8964675~8977527:+
LUAD	cis	rs8072100	0.738	rs9895509	ENSG00000228782.6	CTD-2026D20.3	-4.68	3.78e-06	0.00083	-0.22	-0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47472252	chr17:47450568~47492492:-
LUAD	cis	rs7324557	0.717	rs7325423	ENSG00000205861.10	C1QTNF9B-AS1	-4.68	3.78e-06	0.00083	-0.27	-0.21	Visceral adipose tissue adjusted for BMI;	chr13:23827670	chr13:23888889~23897263:+
LUAD	cis	rs910316	0.819	rs175461	ENSG00000259138.1	RP11-950C14.7	-4.68	3.78e-06	0.000831	-0.22	-0.21	Height;	chr14:75115113	chr14:75127153~75136930:+
LUAD	cis	rs5758659	0.737	rs10854749	ENSG00000182057.4	OGFRP1	4.68	3.78e-06	0.000831	0.25	0.21	Cognitive function;	chr22:42051337	chr22:42269753~42275196:+
LUAD	cis	rs8177876	0.731	rs74878296	ENSG00000261061.1	RP11-303E16.2	-4.68	3.78e-06	0.000831	-0.41	-0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81071940	chr16:81030770~81031485:+
LUAD	cis	rs7208859	0.623	rs216445	ENSG00000266490.1	CTD-2349P21.9	4.68	3.79e-06	0.000831	0.32	0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606558	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs216446	ENSG00000266490.1	CTD-2349P21.9	4.68	3.79e-06	0.000831	0.32	0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606700	chr17:30792372~30792833:+
LUAD	cis	rs9487094	0.677	rs13203636	ENSG00000260273.1	RP11-425D10.10	4.68	3.79e-06	0.000832	0.32	0.21	Height;	chr6:109741085	chr6:109382795~109383666:+
LUAD	cis	rs17772222	0.74	rs7143642	ENSG00000258789.1	RP11-507K2.3	-4.68	3.79e-06	0.000832	-0.27	-0.21	Coronary artery calcification;	chr14:88507616	chr14:88551597~88552493:+
LUAD	cis	rs8072100	0.713	rs1912486	ENSG00000228782.6	CTD-2026D20.3	4.68	3.79e-06	0.000832	0.22	0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47437801	chr17:47450568~47492492:-
LUAD	cis	rs8072100	0.667	rs1912485	ENSG00000228782.6	CTD-2026D20.3	4.68	3.79e-06	0.000832	0.22	0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47438312	chr17:47450568~47492492:-
LUAD	cis	rs7829975	0.714	rs59046059	ENSG00000173295.6	FAM86B3P	4.68	3.79e-06	0.000832	0.22	0.21	Mood instability;	chr8:8813226	chr8:8228595~8244865:+
LUAD	cis	rs7044106	0.578	rs4837788	ENSG00000238181.2	AHCYP2	-4.68	3.79e-06	0.000832	-0.33	-0.21	Hip circumference adjusted for BMI;	chr9:120634523	chr9:120720673~120721972:+
LUAD	cis	rs11089937	0.626	rs11704092	ENSG00000211638.2	IGLV8-61	-4.68	3.79e-06	0.000833	-0.25	-0.21	Periodontitis (PAL4Q3);	chr22:22135815	chr22:22098700~22099212:+
LUAD	cis	rs11089937	0.667	rs78549985	ENSG00000211638.2	IGLV8-61	-4.68	3.79e-06	0.000833	-0.25	-0.21	Periodontitis (PAL4Q3);	chr22:22139152	chr22:22098700~22099212:+
LUAD	cis	rs6504622	0.875	rs3785888	ENSG00000262879.4	RP11-156P1.3	-4.68	3.8e-06	0.000834	-0.25	-0.21	Orofacial clefts;	chr17:46928337	chr17:46984045~47100323:-
LUAD	cis	rs150992	0.569	rs326482	ENSG00000248489.1	CTD-2007H13.3	4.68	3.8e-06	0.000834	0.27	0.21	Body mass index;	chr5:98951115	chr5:98929171~98995013:+
LUAD	cis	rs2732480	0.577	rs2634691	ENSG00000257735.1	RP11-370I10.6	4.68	3.8e-06	0.000834	0.26	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48314476	chr12:48350945~48442411:+
LUAD	cis	rs6700559	0.692	rs12126676	ENSG00000260088.1	RP11-92G12.3	4.68	3.8e-06	0.000834	0.27	0.21	Coronary artery disease;	chr1:200631692	chr1:200669507~200694250:+
LUAD	cis	rs2933343	0.649	rs789216	ENSG00000231305.3	RP11-723O4.2	4.68	3.8e-06	0.000834	0.22	0.21	IgG glycosylation;	chr3:128875660	chr3:128861313~128871540:-
LUAD	cis	rs1799949	1	rs12944430	ENSG00000236383.6	LINC00854	-4.68	3.8e-06	0.000834	-0.17	-0.21	Menopause (age at onset);	chr17:43178803	chr17:43216941~43305976:-
LUAD	cis	rs1799949	0.965	rs11658499	ENSG00000236383.6	LINC00854	-4.68	3.8e-06	0.000834	-0.17	-0.21	Menopause (age at onset);	chr17:43182732	chr17:43216941~43305976:-
LUAD	cis	rs11464691	1	rs11464691	ENSG00000278834.1	RP11-458J1.1	4.68	3.8e-06	0.000834	0.24	0.21	Allergic disease (asthma, hay fever or eczema);	chr17:40614389	chr17:40648300~40649718:+
LUAD	cis	rs17711722	0.51	rs11767457	ENSG00000189316.3	RP11-797H7.5	-4.68	3.8e-06	0.000835	-0.23	-0.21	Calcium levels;	chr7:65825628	chr7:64888527~64890100:-
LUAD	cis	rs7176527	0.796	rs1057946	ENSG00000229212.6	RP11-561C5.4	4.68	3.8e-06	0.000835	0.32	0.21	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84639555	chr15:85205440~85234795:-
LUAD	cis	rs17772222	0.917	rs12587200	ENSG00000258983.2	RP11-507K2.2	4.68	3.81e-06	0.000835	0.25	0.21	Coronary artery calcification;	chr14:88632060	chr14:88499334~88515502:+
LUAD	cis	rs2439831	1	rs1814538	ENSG00000249839.1	AC011330.5	4.68	3.81e-06	0.000835	0.36	0.21	Lung cancer in ever smokers;	chr15:43467576	chr15:43663654~43684339:-
LUAD	cis	rs11009175	0.725	rs10827173	ENSG00000273038.2	RP11-479G22.8	-4.68	3.81e-06	0.000835	-0.29	-0.21	Depression (quantitative trait);	chr10:33039851	chr10:32887255~32889311:-
LUAD	cis	rs6957923	0.934	rs7788661	ENSG00000230658.1	KLHL7-AS1	4.68	3.81e-06	0.000836	0.25	0.21	Height;	chr7:23451694	chr7:23101228~23105703:-
LUAD	cis	rs559928	0.597	rs2096706	ENSG00000236935.1	AP003774.1	4.68	3.81e-06	0.000836	0.31	0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64156974	chr11:64325050~64329504:-
LUAD	cis	rs14027	0.921	rs35496588	ENSG00000279347.1	RP11-85I17.2	4.68	3.81e-06	0.000836	0.19	0.21	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119842461	chr8:119838736~119840385:-
LUAD	cis	rs1799949	1	rs4793197	ENSG00000236383.6	LINC00854	-4.68	3.81e-06	0.000836	-0.17	-0.21	Menopause (age at onset);	chr17:43079885	chr17:43216941~43305976:-
LUAD	cis	rs1008375	0.863	rs4698632	ENSG00000249502.1	AC006160.5	-4.68	3.81e-06	0.000836	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17613271	chr4:17587467~17614571:-
LUAD	cis	rs11073619	0.773	rs28612692	ENSG00000230373.7	GOLGA6L5P	-4.68	3.81e-06	0.000836	-0.33	-0.21	Positive affect;	chr15:84601836	chr15:84507885~84516814:-
LUAD	cis	rs9545047	0.589	rs9545090	ENSG00000227354.5	RBM26-AS1	4.68	3.81e-06	0.000836	0.22	0.21	Schizophrenia;	chr13:79367276	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs9530902	ENSG00000227354.5	RBM26-AS1	4.68	3.81e-06	0.000836	0.22	0.21	Schizophrenia;	chr13:79367748	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs9545092	ENSG00000227354.5	RBM26-AS1	4.68	3.81e-06	0.000836	0.22	0.21	Schizophrenia;	chr13:79369809	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.611	rs9545093	ENSG00000227354.5	RBM26-AS1	4.68	3.81e-06	0.000836	0.22	0.21	Schizophrenia;	chr13:79371969	chr13:79406309~79424328:+
LUAD	cis	rs2028299	1	rs4932143	ENSG00000259677.1	RP11-493E3.1	4.68	3.81e-06	0.000836	0.26	0.21	Type 2 diabetes;	chr15:89828835	chr15:89876540~89877285:+
LUAD	cis	rs2832077	0.943	rs4816336	ENSG00000232855.5	AF131217.1	4.68	3.81e-06	0.000836	0.24	0.21	Cognitive test performance;	chr21:28821197	chr21:28439346~28674848:-
LUAD	cis	rs1008375	1	rs6449319	ENSG00000249502.1	AC006160.5	-4.68	3.81e-06	0.000836	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17638660	chr4:17587467~17614571:-
LUAD	cis	rs4835473	0.832	rs55935372	ENSG00000251600.4	RP11-673E1.1	-4.68	3.81e-06	0.000837	-0.26	-0.21	Immature fraction of reticulocytes;	chr4:143700626	chr4:143912331~143982454:+
LUAD	cis	rs712039	0.652	rs7226252	ENSG00000276054.1	RP11-378E13.3	4.68	3.81e-06	0.000837	0.31	0.21	Tuberculosis;	chr17:37434812	chr17:37386886~37387926:+
LUAD	cis	rs712039	0.652	rs67879888	ENSG00000276054.1	RP11-378E13.3	4.68	3.81e-06	0.000837	0.31	0.21	Tuberculosis;	chr17:37435211	chr17:37386886~37387926:+
LUAD	cis	rs17508449	0.819	rs3761934	ENSG00000232450.1	RP4-730K3.3	-4.68	3.82e-06	0.000838	-0.36	-0.21	Leprosy;	chr1:113646445	chr1:113698884~113699631:-
LUAD	cis	rs17508449	0.819	rs41352847	ENSG00000232450.1	RP4-730K3.3	-4.68	3.82e-06	0.000838	-0.36	-0.21	Leprosy;	chr1:113647258	chr1:113698884~113699631:-
LUAD	cis	rs17508449	0.819	rs2146018	ENSG00000232450.1	RP4-730K3.3	-4.68	3.82e-06	0.000838	-0.36	-0.21	Leprosy;	chr1:113652708	chr1:113698884~113699631:-
LUAD	cis	rs5769707	0.904	rs7288869	ENSG00000235111.1	RP1-29C18.8	-4.68	3.82e-06	0.000838	-0.23	-0.21	Monocyte percentage of white cells;Monocyte count;	chr22:49621679	chr22:49612657~49615716:-
LUAD	cis	rs780096	0.546	rs7563162	ENSG00000234072.1	AC074117.10	-4.68	3.82e-06	0.000838	-0.16	-0.21	Total body bone mineral density;	chr2:27408324	chr2:27356246~27367622:+
LUAD	cis	rs9928842	0.664	rs9921632	ENSG00000280152.1	RP11-331F4.5	4.68	3.82e-06	0.000838	0.21	0.21	Alcoholic chronic pancreatitis;	chr16:75186365	chr16:75245994~75250077:-
LUAD	cis	rs2239557	1	rs2358633	ENSG00000259065.1	RP5-1021I20.1	4.68	3.82e-06	0.000838	0.24	0.21	Common traits (Other);	chr14:74180715	chr14:73787360~73803270:+
LUAD	cis	rs7102710	1	rs61883963	ENSG00000254418.1	RP11-21L19.1	4.68	3.82e-06	0.000838	0.48	0.21	Glucagon levels in response to oral glucose tolerance test (fasting);	chr11:14317157	chr11:14262846~14273691:-
LUAD	cis	rs4908760	0.539	rs7513880	ENSG00000232912.4	RP5-1115A15.1	4.68	3.82e-06	0.000838	0.19	0.21	Vitiligo;	chr1:8779241	chr1:8424645~8434838:+
LUAD	cis	rs9315786	0.924	rs7323436	ENSG00000168852.11	TPTE2P5	-4.68	3.82e-06	0.000838	-0.21	-0.21	Neutrophil percentage of granulocytes;	chr13:40776843	chr13:40822296~40921749:-
LUAD	cis	rs2310173	0.575	rs4850993	ENSG00000281162.1	LINC01127	-4.68	3.82e-06	0.000838	-0.23	-0.21	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:102006004	chr2:101962056~101987167:+
LUAD	cis	rs7208859	0.573	rs216443	ENSG00000263603.1	CTD-2349P21.5	-4.68	3.82e-06	0.000839	-0.38	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30729469~30731202:+
LUAD	cis	rs2028299	0.959	rs12594808	ENSG00000259677.1	RP11-493E3.1	4.68	3.82e-06	0.000839	0.25	0.21	Type 2 diabetes;	chr15:89857652	chr15:89876540~89877285:+
LUAD	cis	rs6687758	0.732	rs72740077	ENSG00000200033.1	RNU6-403P	4.68	3.82e-06	0.000839	0.28	0.21	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221940827	chr1:221837334~221837437:-
LUAD	cis	rs338389	0.967	rs338399	ENSG00000260657.2	RP11-315D16.4	-4.67	3.82e-06	0.000839	-0.24	-0.21	Survival in rectal cancer;	chr15:67961921	chr15:68267792~68277994:-
LUAD	cis	rs338389	0.967	rs338396	ENSG00000260657.2	RP11-315D16.4	-4.67	3.82e-06	0.000839	-0.24	-0.21	Survival in rectal cancer;	chr15:67962925	chr15:68267792~68277994:-
LUAD	cis	rs950169	0.922	rs11635505	ENSG00000259295.5	CSPG4P12	-4.67	3.82e-06	0.000839	-0.29	-0.21	Schizophrenia;	chr15:84553803	chr15:85191438~85213905:+
LUAD	cis	rs9473147	0.543	rs9367279	ENSG00000270761.1	RP11-385F7.1	-4.67	3.82e-06	0.000839	-0.24	-0.21	Platelet distribution width;Mean platelet volume;	chr6:47480600	chr6:47477243~47477572:-
LUAD	cis	rs9473147	0.543	rs9473119	ENSG00000270761.1	RP11-385F7.1	-4.67	3.82e-06	0.000839	-0.24	-0.21	Platelet distribution width;Mean platelet volume;	chr6:47482882	chr6:47477243~47477572:-
LUAD	cis	rs13113518	1	rs13113518	ENSG00000272969.1	RP11-528I4.2	4.67	3.83e-06	0.000839	0.21	0.21	Height;	chr4:55533481	chr4:55547112~55547889:+
LUAD	cis	rs2243480	1	rs34815098	ENSG00000164669.11	INTS4P1	4.67	3.83e-06	0.000839	0.38	0.21	Diabetic kidney disease;	chr7:65827267	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs4548056	ENSG00000164669.11	INTS4P1	4.67	3.83e-06	0.000839	0.38	0.21	Diabetic kidney disease;	chr7:65833886	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs7456042	ENSG00000164669.11	INTS4P1	4.67	3.83e-06	0.000839	0.38	0.21	Diabetic kidney disease;	chr7:65834791	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs35735127	ENSG00000164669.11	INTS4P1	4.67	3.83e-06	0.000839	0.38	0.21	Diabetic kidney disease;	chr7:65835436	chr7:65141225~65234216:+
LUAD	cis	rs2243480	0.901	rs35256305	ENSG00000164669.11	INTS4P1	4.67	3.83e-06	0.000839	0.38	0.21	Diabetic kidney disease;	chr7:65841418	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs73142121	ENSG00000164669.11	INTS4P1	4.67	3.83e-06	0.000839	0.38	0.21	Diabetic kidney disease;	chr7:65846219	chr7:65141225~65234216:+
LUAD	cis	rs2243480	0.803	rs34004500	ENSG00000164669.11	INTS4P1	4.67	3.83e-06	0.000839	0.38	0.21	Diabetic kidney disease;	chr7:65847191	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs35825738	ENSG00000164669.11	INTS4P1	4.67	3.83e-06	0.000839	0.38	0.21	Diabetic kidney disease;	chr7:65853040	chr7:65141225~65234216:+
LUAD	cis	rs948562	0.545	rs4509786	ENSG00000280010.1	AP001350.4	4.67	3.83e-06	0.000839	0.29	0.21	Lymphoma;	chr11:58293203	chr11:58627435~58628528:+
LUAD	cis	rs2732480	0.557	rs923397	ENSG00000257735.1	RP11-370I10.6	4.67	3.83e-06	0.000839	0.25	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48326609	chr12:48350945~48442411:+
LUAD	cis	rs2998286	0.549	rs675678	ENSG00000254635.4	WAC-AS1	-4.67	3.83e-06	0.000839	-0.3	-0.21	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28656400	chr10:28522652~28532743:-
LUAD	cis	rs7688540	0.8	rs10003142	ENSG00000211553.1	AC253576.2	-4.67	3.83e-06	0.00084	-0.26	-0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:297970	chr4:136461~136568:+
LUAD	cis	rs7688540	0.771	rs11723803	ENSG00000211553.1	AC253576.2	-4.67	3.83e-06	0.00084	-0.26	-0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:298580	chr4:136461~136568:+
LUAD	cis	rs2911132	0.568	rs3797814	ENSG00000248734.2	CTD-2260A17.1	4.67	3.83e-06	0.00084	0.23	0.21	Urate levels (BMI interaction);	chr5:96756222	chr5:96784777~96785999:+
LUAD	cis	rs6539288	0.933	rs7961366	ENSG00000260329.1	RP11-412D9.4	-4.67	3.83e-06	0.00084	-0.23	-0.21	Total body bone mineral density;	chr12:106902263	chr12:106954029~106955497:-
LUAD	cis	rs2304003	0.95	rs1863199	ENSG00000235192.1	AC009495.2	4.67	3.83e-06	0.00084	0.25	0.21	Social communication problems;	chr2:165810140	chr2:165794851~165810010:+
LUAD	cis	rs2212361	0.558	rs113242956	ENSG00000255893.1	RP11-685N10.1	-4.67	3.83e-06	0.00084	-0.29	-0.21	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94539300	chr11:94472908~94473570:-
LUAD	cis	rs12701220	0.725	rs13242971	ENSG00000229043.2	AC091729.9	-4.67	3.83e-06	0.00084	-0.28	-0.21	Bronchopulmonary dysplasia;	chr7:1015879	chr7:1160374~1165267:+
LUAD	cis	rs7615952	0.576	rs2276726	ENSG00000171084.14	FAM86JP	4.67	3.83e-06	0.00084	0.28	0.21	Blood pressure (smoking interaction);	chr3:126107444	chr3:125916620~125930024:+
LUAD	cis	rs9322193	0.923	rs14314	ENSG00000268592.3	RAET1E-AS1	4.67	3.83e-06	0.00084	0.26	0.21	Lung cancer;	chr6:149820395	chr6:149863494~149919507:+
LUAD	cis	rs2239547	0.522	rs6773040	ENSG00000242142.1	SERBP1P3	-4.67	3.83e-06	0.000841	-0.25	-0.21	Schizophrenia;	chr3:52901412	chr3:53064283~53065091:-
LUAD	cis	rs11992162	1	rs11994417	ENSG00000255046.1	RP11-297N6.4	-4.67	3.83e-06	0.000841	-0.26	-0.21	Monocyte count;	chr8:11975753	chr8:11797928~11802568:-
LUAD	cis	rs41369048	0.858	rs11578466	ENSG00000238078.1	LINC01352	-4.67	3.83e-06	0.000841	-0.33	-0.21	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220884397	chr1:220829255~220832429:+
LUAD	cis	rs7396835	1	rs7396835	ENSG00000280143.1	AP000892.6	4.67	3.84e-06	0.000841	0.31	0.21	Quantitative traits;	chr11:116813312	chr11:117204967~117210292:+
LUAD	cis	rs948562	0.519	rs12289961	ENSG00000280010.1	AP001350.4	4.67	3.84e-06	0.000841	0.29	0.21	Lymphoma;	chr11:58292720	chr11:58627435~58628528:+
LUAD	cis	rs9876781	1	rs9812647	ENSG00000229759.1	MRPS18AP1	-4.67	3.84e-06	0.000841	-0.2	-0.21	Longevity;	chr3:48407507	chr3:48256350~48256938:-
LUAD	cis	rs7743045	0.625	rs9387628	ENSG00000253194.1	RP11-351A11.1	-4.67	3.84e-06	0.000842	-0.27	-0.21	Mean platelet volume;	chr6:119031853	chr6:118934785~119031541:+
LUAD	cis	rs12908161	0.96	rs17599989	ENSG00000275120.1	RP11-182J1.17	4.67	3.84e-06	0.000842	0.31	0.21	Schizophrenia;	chr15:84742305	chr15:84599434~84606463:-
LUAD	cis	rs11051970	0.636	rs2733703	ENSG00000274964.1	RP11-817I4.1	-4.67	3.84e-06	0.000842	-0.21	-0.21	Response to tocilizumab in rheumatoid arthritis;	chr12:32408860	chr12:32339368~32340724:+
LUAD	cis	rs4835473	0.618	rs12499907	ENSG00000251600.4	RP11-673E1.1	-4.67	3.84e-06	0.000842	-0.26	-0.21	Immature fraction of reticulocytes;	chr4:143999748	chr4:143912331~143982454:+
LUAD	cis	rs7937890	0.631	rs7118886	ENSG00000251991.1	RNU7-49P	4.67	3.84e-06	0.000842	0.22	0.21	Mitochondrial DNA levels;	chr11:14405971	chr11:14478892~14478953:+
LUAD	cis	rs6840360	1	rs4696285	ENSG00000270265.1	RP11-731D1.4	-4.67	3.84e-06	0.000843	-0.21	-0.21	Intelligence (multi-trait analysis);	chr4:151684297	chr4:151333775~151353224:-
LUAD	cis	rs12701220	0.522	rs12701455	ENSG00000229043.2	AC091729.9	-4.67	3.84e-06	0.000843	-0.24	-0.21	Bronchopulmonary dysplasia;	chr7:1015773	chr7:1160374~1165267:+
LUAD	cis	rs2836950	0.501	rs2056844	ENSG00000255568.3	BRWD1-AS2	-4.67	3.85e-06	0.000843	-0.2	-0.21	Menarche (age at onset);	chr21:39298534	chr21:39313935~39314962:+
LUAD	cis	rs9860428	0.679	rs12494693	ENSG00000242770.2	RP11-180K7.1	4.67	3.85e-06	0.000844	0.21	0.21	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112958682	chr3:112802478~112812819:+
LUAD	cis	rs1799949	0.93	rs35292991	ENSG00000236383.6	LINC00854	-4.67	3.85e-06	0.000844	-0.17	-0.21	Menopause (age at onset);	chr17:43181999	chr17:43216941~43305976:-
LUAD	cis	rs950169	0.922	rs12906983	ENSG00000229212.6	RP11-561C5.4	-4.67	3.85e-06	0.000844	-0.31	-0.21	Schizophrenia;	chr15:84262270	chr15:85205440~85234795:-
LUAD	cis	rs2378497	1	rs75451751	ENSG00000232679.1	RP11-400N13.3	4.67	3.85e-06	0.000845	0.33	0.21	Serum thyroid-stimulating hormone levels;	chr1:221994454	chr1:222041705~222064763:-
LUAD	cis	rs17685	0.523	rs10246583	ENSG00000280388.1	RP11-229D13.3	-4.67	3.86e-06	0.000845	-0.19	-0.21	Coffee consumption (cups per day);Coffee consumption;	chr7:76117349	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.753	rs55812043	ENSG00000280388.1	RP11-229D13.3	-4.67	3.86e-06	0.000845	-0.19	-0.21	Coffee consumption (cups per day);Coffee consumption;	chr7:76117923	chr7:76043977~76045963:-
LUAD	cis	rs202072	0.652	rs453695	ENSG00000272379.1	RP1-257A7.5	-4.67	3.86e-06	0.000845	-0.34	-0.21	HIV-1 viral setpoint;	chr6:13262274	chr6:13290018~13290490:-
LUAD	cis	rs67311347	0.594	rs12629111	ENSG00000223797.4	ENTPD3-AS1	4.67	3.86e-06	0.000845	0.22	0.21	Renal cell carcinoma;	chr3:40243860	chr3:40313802~40453329:-
LUAD	cis	rs453301	0.598	rs2921383	ENSG00000253981.4	ALG1L13P	4.67	3.86e-06	0.000846	0.25	0.21	Joint mobility (Beighton score);	chr8:9034711	chr8:8236003~8244667:-
LUAD	cis	rs1008375	1	rs1008375	ENSG00000249502.1	AC006160.5	-4.67	3.86e-06	0.000846	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17681211	chr4:17587467~17614571:-
LUAD	cis	rs80028505	0.908	rs7761118	ENSG00000271304.1	DPRXP2	4.67	3.86e-06	0.000846	0.37	0.21	Foot ulcer in diabetes and neuropathy;	chr6:36100526	chr6:35989515~35990436:-
LUAD	cis	rs75920871	0.61	rs11216169	ENSG00000254851.1	RP11-109L13.1	-4.67	3.86e-06	0.000846	-0.45	-0.21	Subjective well-being;	chr11:116873673	chr11:117135528~117138582:+
LUAD	cis	rs375066	0.935	rs108775	ENSG00000267058.1	RP11-15A1.3	-4.67	3.86e-06	0.000846	-0.23	-0.21	Breast cancer;	chr19:43901770	chr19:43891804~43901805:-
LUAD	cis	rs6728642	0.519	rs6717064	ENSG00000230606.9	AC159540.1	4.67	3.87e-06	0.000847	0.32	0.21	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96911606	chr2:97416165~97433527:-
LUAD	cis	rs6539288	0.933	rs1037012	ENSG00000260329.1	RP11-412D9.4	-4.67	3.87e-06	0.000847	-0.23	-0.21	Total body bone mineral density;	chr12:106908899	chr12:106954029~106955497:-
LUAD	cis	rs9473147	0.571	rs9369717	ENSG00000270761.1	RP11-385F7.1	-4.67	3.87e-06	0.000847	-0.24	-0.21	Platelet distribution width;Mean platelet volume;	chr6:47586732	chr6:47477243~47477572:-
LUAD	cis	rs2732480	0.577	rs2732481	ENSG00000257735.1	RP11-370I10.6	4.67	3.87e-06	0.000847	0.26	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343202	chr12:48350945~48442411:+
LUAD	cis	rs2732480	0.557	rs2732484	ENSG00000257735.1	RP11-370I10.6	4.67	3.87e-06	0.000847	0.26	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343462	chr12:48350945~48442411:+
LUAD	cis	rs2239547	0.618	rs13083728	ENSG00000242142.1	SERBP1P3	4.67	3.87e-06	0.000847	0.25	0.21	Schizophrenia;	chr3:52834429	chr3:53064283~53065091:-
LUAD	cis	rs2281636	0.691	rs6584306	ENSG00000233690.1	EBAG9P1	4.67	3.87e-06	0.000847	0.21	0.21	Obesity-related traits;	chr10:99662739	chr10:99697407~99697949:-
LUAD	cis	rs7811142	0.83	rs76798830	ENSG00000078319.8	PMS2P1	-4.67	3.87e-06	0.000848	-0.26	-0.21	Platelet count;	chr7:100355205	chr7:100320992~100341908:-
LUAD	cis	rs7811142	0.775	rs6946768	ENSG00000078319.8	PMS2P1	-4.67	3.87e-06	0.000848	-0.26	-0.21	Platelet count;	chr7:100356770	chr7:100320992~100341908:-
LUAD	cis	rs1799949	1	rs8176083	ENSG00000236383.6	LINC00854	-4.67	3.87e-06	0.000848	-0.17	-0.21	Menopause (age at onset);	chr17:43123134	chr17:43216941~43305976:-
LUAD	cis	rs7674212	0.865	rs1481279	ENSG00000246560.2	RP11-10L12.4	-4.67	3.87e-06	0.000848	-0.26	-0.21	Type 2 diabetes;	chr4:103056781	chr4:102828055~102844075:+
LUAD	cis	rs4664293	0.836	rs13016015	ENSG00000226266.5	AC009961.3	-4.67	3.87e-06	0.000848	-0.29	-0.21	Monocyte percentage of white cells;	chr2:159790018	chr2:159670708~159712435:-
LUAD	cis	rs2243480	1	rs34970380	ENSG00000232559.3	GS1-124K5.12	4.67	3.87e-06	0.000848	0.37	0.21	Diabetic kidney disease;	chr7:65966506	chr7:66554588~66576923:-
LUAD	cis	rs2243480	0.901	rs73148097	ENSG00000232559.3	GS1-124K5.12	4.67	3.87e-06	0.000848	0.37	0.21	Diabetic kidney disease;	chr7:65966800	chr7:66554588~66576923:-
LUAD	cis	rs11673344	0.864	rs2263167	ENSG00000226686.6	LINC01535	4.67	3.87e-06	0.000848	0.26	0.21	Obesity-related traits;	chr19:37030025	chr19:37251912~37265535:+
LUAD	cis	rs875971	0.66	rs2013222	ENSG00000236529.1	RP13-254B10.1	-4.67	3.87e-06	0.000848	-0.21	-0.21	Aortic root size;	chr7:66570949	chr7:65840212~65840596:+
LUAD	cis	rs75422866	0.51	rs75424057	ENSG00000276691.1	RP5-1057I20.5	4.67	3.87e-06	0.000848	0.35	0.21	Pneumonia;	chr12:47737294	chr12:47788426~47788971:+
LUAD	cis	rs5758511	0.596	rs55644935	ENSG00000226450.2	CYP2D8P	4.67	3.87e-06	0.000849	0.19	0.21	Birth weight;	chr22:42270063	chr22:42149886~42155001:-
LUAD	cis	rs1008375	0.932	rs3846356	ENSG00000249502.1	AC006160.5	-4.67	3.88e-06	0.000849	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17612553	chr4:17587467~17614571:-
LUAD	cis	rs1008375	0.863	rs4590022	ENSG00000249502.1	AC006160.5	-4.67	3.88e-06	0.000849	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17612811	chr4:17587467~17614571:-
LUAD	cis	rs1008375	0.932	rs4698630	ENSG00000249502.1	AC006160.5	-4.67	3.88e-06	0.000849	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17613069	chr4:17587467~17614571:-
LUAD	cis	rs9926296	0.682	rs258328	ENSG00000260259.1	RP11-368I7.4	4.67	3.88e-06	0.000849	0.2	0.21	Vitiligo;	chr16:89663906	chr16:89682620~89686569:-
LUAD	cis	rs2742234	0.504	rs10899780	ENSG00000273008.1	RP11-351D16.3	4.67	3.88e-06	0.000849	0.25	0.21	Hirschsprung disease;	chr10:43230348	chr10:43136824~43138334:-
LUAD	cis	rs73173548	0.528	rs34182576	ENSG00000247828.6	TMEM161B-AS1	4.67	3.88e-06	0.00085	0.26	0.21	Macular telangiectasia type 2;	chr5:88438321	chr5:88268895~88436685:+
LUAD	cis	rs9487094	0.961	rs1546980	ENSG00000260273.1	RP11-425D10.10	4.67	3.88e-06	0.00085	0.28	0.21	Height;	chr6:109452743	chr6:109382795~109383666:+
LUAD	cis	rs1008375	0.897	rs2315554	ENSG00000249502.1	AC006160.5	-4.67	3.88e-06	0.000851	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17658784	chr4:17587467~17614571:-
LUAD	cis	rs11159086	0.941	rs12434836	ENSG00000259005.1	RP3-449M8.6	4.67	3.88e-06	0.000851	0.29	0.21	Advanced glycation end-product levels;	chr14:74468887	chr14:74474007~74474864:-
LUAD	cis	rs13256369	0.901	rs4841015	ENSG00000253893.2	FAM85B	-4.67	3.89e-06	0.000851	-0.29	-0.21	Obesity-related traits;	chr8:8709630	chr8:8167819~8226614:-
LUAD	cis	rs57502260	0.704	rs923346	ENSG00000212093.1	AP000807.1	4.67	3.89e-06	0.000852	0.27	0.21	Total body bone mineral density (age 45-60);	chr11:68414907	chr11:68506083~68506166:-
LUAD	cis	rs910316	0.967	rs10142770	ENSG00000279594.1	RP11-950C14.10	4.67	3.89e-06	0.000853	0.24	0.21	Height;	chr14:75058746	chr14:75011269~75012851:-
LUAD	cis	rs2562456	0.833	rs62109218	ENSG00000268081.1	RP11-678G14.2	4.67	3.9e-06	0.000853	0.33	0.21	Pain;	chr19:21346059	chr19:21554640~21569237:-
LUAD	cis	rs57502260	0.764	rs3867143	ENSG00000212093.1	AP000807.1	4.67	3.9e-06	0.000853	0.28	0.21	Total body bone mineral density (age 45-60);	chr11:68455606	chr11:68506083~68506166:-
LUAD	cis	rs6687821	0.684	rs690794	ENSG00000267734.1	RP4-604K5.3	-4.67	3.9e-06	0.000853	-0.24	-0.21	Yeast infection;	chr1:86805305	chr1:86932199~86934891:-
LUAD	cis	rs2115630	1	rs55646601	ENSG00000229212.6	RP11-561C5.4	4.67	3.9e-06	0.000853	0.24	0.21	P wave terminal force;	chr15:84780337	chr15:85205440~85234795:-
LUAD	cis	rs867371	0.502	rs7176926	ENSG00000276710.3	CSPG4P8	-4.67	3.9e-06	0.000854	-0.19	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82245753	chr15:82459472~82477258:+
LUAD	cis	rs55823223	0.564	rs936396	ENSG00000267801.1	RP11-552F3.9	4.67	3.9e-06	0.000854	0.23	0.21	Psoriasis;	chr17:75850748	chr17:75876372~75879546:+
LUAD	cis	rs2348418	0.831	rs7137119	ENSG00000244712.1	RP11-874G11.1	4.67	3.9e-06	0.000854	0.24	0.21	Lung function (FEV1);Lung function (FVC);	chr12:28565058	chr12:28564678~28565141:-
LUAD	cis	rs227275	0.554	rs223316	ENSG00000251288.2	RP11-10L12.2	-4.67	3.9e-06	0.000854	-0.25	-0.21	Allergic disease (asthma, hay fever or eczema);	chr4:102881949	chr4:102751401~102752641:+
LUAD	cis	rs10895987	1	rs11227126	ENSG00000254614.2	AP003068.23	4.67	3.9e-06	0.000854	0.33	0.21	Blood protein levels;	chr11:65140591	chr11:65177606~65181834:-
LUAD	cis	rs9341808	0.754	rs6907729	ENSG00000260645.1	RP11-250B2.5	-4.67	3.9e-06	0.000854	-0.2	-0.21	Sitting height ratio;	chr6:80295205	chr6:80466958~80469080:+
LUAD	cis	rs17772222	0.63	rs4904454	ENSG00000258789.1	RP11-507K2.3	4.67	3.91e-06	0.000855	0.25	0.21	Coronary artery calcification;	chr14:88537777	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.63	rs2033418	ENSG00000258789.1	RP11-507K2.3	4.67	3.91e-06	0.000855	0.25	0.21	Coronary artery calcification;	chr14:88539331	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.63	rs10873392	ENSG00000258789.1	RP11-507K2.3	4.67	3.91e-06	0.000855	0.25	0.21	Coronary artery calcification;	chr14:88545124	chr14:88551597~88552493:+
LUAD	cis	rs7493	0.901	rs11767787	ENSG00000233942.1	AC004012.1	4.67	3.91e-06	0.000856	0.29	0.21	Yu-Zhi constitution type in type 2 diabetes;	chr7:95397441	chr7:95471835~95473998:+
LUAD	cis	rs6604026	0.624	rs35526187	ENSG00000223787.2	RP4-593M8.1	4.67	3.91e-06	0.000856	0.29	0.21	Multiple sclerosis;	chr1:92732610	chr1:92580476~92580821:-
LUAD	cis	rs6604026	0.624	rs11805698	ENSG00000223787.2	RP4-593M8.1	4.67	3.91e-06	0.000856	0.29	0.21	Multiple sclerosis;	chr1:92737695	chr1:92580476~92580821:-
LUAD	cis	rs9400467	0.528	rs457492	ENSG00000271789.1	RP5-1112D6.7	-4.67	3.91e-06	0.000856	-0.22	-0.21	Amino acid levels;Blood metabolite levels;	chr6:111320647	chr6:111297126~111298510:+
LUAD	cis	rs7714584	1	rs11167515	ENSG00000197083.10	ZNF300P1	4.67	3.91e-06	0.000856	0.41	0.21	Crohn's disease;	chr5:150859909	chr5:150930645~150946289:-
LUAD	cis	rs8180040	0.701	rs34103310	ENSG00000271161.1	BOLA2P2	4.67	3.91e-06	0.000856	0.2	0.21	Colorectal cancer;	chr3:47031776	chr3:47499841~47500407:+
LUAD	cis	rs13434995	0.842	rs3792603	ENSG00000273257.1	RP11-177J6.1	-4.67	3.91e-06	0.000857	-0.34	-0.21	Adiponectin levels;	chr4:55435891	chr4:55387949~55388271:+
LUAD	cis	rs13434995	0.755	rs62303690	ENSG00000273257.1	RP11-177J6.1	-4.67	3.91e-06	0.000857	-0.34	-0.21	Adiponectin levels;	chr4:55439838	chr4:55387949~55388271:+
LUAD	cis	rs55823223	0.648	rs11869977	ENSG00000267801.1	RP11-552F3.9	4.67	3.91e-06	0.000857	0.24	0.21	Psoriasis;	chr17:75861301	chr17:75876372~75879546:+
LUAD	cis	rs7811142	1	rs7783550	ENSG00000078319.8	PMS2P1	4.67	3.91e-06	0.000857	0.24	0.21	Platelet count;	chr7:100390182	chr7:100320992~100341908:-
LUAD	cis	rs394563	0.901	rs448874	ENSG00000216906.2	RP11-350J20.9	4.67	3.92e-06	0.000857	0.26	0.21	Dupuytren's disease;	chr6:149475831	chr6:149904243~149906418:+
LUAD	cis	rs9400467	0.508	rs11153283	ENSG00000230177.1	RP5-1112D6.4	-4.67	3.92e-06	0.000857	-0.18	-0.21	Amino acid levels;Blood metabolite levels;	chr6:111275940	chr6:111277932~111278742:+
LUAD	cis	rs2243480	1	rs316330	ENSG00000164669.11	INTS4P1	4.67	3.92e-06	0.000857	0.38	0.21	Diabetic kidney disease;	chr7:66140385	chr7:65141225~65234216:+
LUAD	cis	rs8072100	0.713	rs57427906	ENSG00000228782.6	CTD-2026D20.3	4.67	3.92e-06	0.000857	0.22	0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47416648	chr17:47450568~47492492:-
LUAD	cis	rs8072100	0.713	rs4968228	ENSG00000228782.6	CTD-2026D20.3	4.67	3.92e-06	0.000857	0.22	0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47420182	chr17:47450568~47492492:-
LUAD	cis	rs8072100	0.713	rs9899859	ENSG00000228782.6	CTD-2026D20.3	4.67	3.92e-06	0.000857	0.22	0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47435683	chr17:47450568~47492492:-
LUAD	cis	rs6570726	0.791	rs370112	ENSG00000235652.6	RP11-545I5.3	4.67	3.92e-06	0.000858	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145538717	chr6:145799409~145886585:+
LUAD	cis	rs1062177	1	rs12653926	ENSG00000253921.1	CTB-113P19.3	-4.67	3.92e-06	0.000858	-0.31	-0.21	Preschool internalizing problems;	chr5:151870687	chr5:151753992~151767247:+
LUAD	cis	rs4568518	0.619	rs9648238	ENSG00000279048.1	RP11-511H23.2	4.67	3.92e-06	0.000858	0.17	0.21	Measles;	chr7:17965614	chr7:17940503~17942922:+
LUAD	cis	rs2732480	0.5	rs12828309	ENSG00000240399.1	RP1-228P16.1	4.67	3.92e-06	0.000858	0.21	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48247377	chr12:48054813~48055591:-
LUAD	cis	rs6860806	0.661	rs4705927	ENSG00000233006.5	AC034220.3	4.67	3.92e-06	0.000858	0.18	0.21	Breast cancer;	chr5:132242915	chr5:132311285~132369916:-
LUAD	cis	rs6700559	0.74	rs4387211	ENSG00000260088.1	RP11-92G12.3	-4.67	3.92e-06	0.000858	-0.26	-0.21	Coronary artery disease;	chr1:200676810	chr1:200669507~200694250:+
LUAD	cis	rs13113518	0.783	rs11943206	ENSG00000223305.1	RN7SKP30	4.67	3.93e-06	0.000859	0.24	0.21	Height;	chr4:55570843	chr4:55540502~55540835:-
LUAD	cis	rs6840360	0.571	rs17360371	ENSG00000270265.1	RP11-731D1.4	-4.67	3.93e-06	0.000859	-0.24	-0.21	Intelligence (multi-trait analysis);	chr4:151644222	chr4:151333775~151353224:-
LUAD	cis	rs477895	0.838	rs12798333	ENSG00000236935.1	AP003774.1	-4.67	3.93e-06	0.000859	-0.25	-0.21	Mean platelet volume;	chr11:64245312	chr11:64325050~64329504:-
LUAD	cis	rs8180040	0.603	rs9854790	ENSG00000271161.1	BOLA2P2	4.67	3.93e-06	0.00086	0.2	0.21	Colorectal cancer;	chr3:47059816	chr3:47499841~47500407:+
LUAD	cis	rs17684571	0.872	rs3002010	ENSG00000231441.1	RP11-472M19.2	4.67	3.93e-06	0.00086	0.29	0.21	Schizophrenia;	chr6:56760050	chr6:56844002~56864078:+
LUAD	cis	rs11168618	0.904	rs10875829	ENSG00000240399.1	RP1-228P16.1	4.67	3.93e-06	0.00086	0.2	0.21	Adiponectin levels;	chr12:48533414	chr12:48054813~48055591:-
LUAD	cis	rs227275	0.527	rs223308	ENSG00000251288.2	RP11-10L12.2	-4.67	3.93e-06	0.00086	-0.25	-0.21	Allergic disease (asthma, hay fever or eczema);	chr4:102891342	chr4:102751401~102752641:+
LUAD	cis	rs453301	0.624	rs4841083	ENSG00000173295.6	FAM86B3P	4.67	3.94e-06	0.000861	0.23	0.21	Joint mobility (Beighton score);	chr8:9012918	chr8:8228595~8244865:+
LUAD	cis	rs750134	1	rs56389244	ENSG00000257221.1	RP11-689B22.2	-4.67	3.94e-06	0.000861	-0.32	-0.21	Low high density lipoprotein cholesterol levels;	chr12:108683396	chr12:108628687~108641318:+
LUAD	cis	rs848490	0.889	rs11489585	ENSG00000214293.7	APTR	4.67	3.94e-06	0.000861	0.27	0.21	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77685535	chr7:77657660~77696265:-
LUAD	cis	rs71520386	0.632	rs10224419	ENSG00000228649.7	AC005682.5	4.67	3.94e-06	0.000861	0.29	0.21	Fibrinogen levels;	chr7:22830397	chr7:22854178~22861579:+
LUAD	cis	rs7138803	0.511	rs11169163	ENSG00000257464.1	RP11-161H23.8	-4.67	3.94e-06	0.000861	-0.21	-0.21	Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index;	chr12:49814560	chr12:49442424~49442652:-
LUAD	cis	rs2742234	0.541	rs7096500	ENSG00000273008.1	RP11-351D16.3	4.67	3.94e-06	0.000861	0.25	0.21	Hirschsprung disease;	chr10:43216647	chr10:43136824~43138334:-
LUAD	cis	rs2742234	0.541	rs4648313	ENSG00000273008.1	RP11-351D16.3	4.67	3.94e-06	0.000861	0.25	0.21	Hirschsprung disease;	chr10:43221291	chr10:43136824~43138334:-
LUAD	cis	rs2742234	0.541	rs10793424	ENSG00000273008.1	RP11-351D16.3	4.67	3.94e-06	0.000861	0.25	0.21	Hirschsprung disease;	chr10:43221668	chr10:43136824~43138334:-
LUAD	cis	rs2742234	0.541	rs11238479	ENSG00000273008.1	RP11-351D16.3	4.67	3.94e-06	0.000861	0.25	0.21	Hirschsprung disease;	chr10:43221975	chr10:43136824~43138334:-
LUAD	cis	rs2742234	0.541	rs10899778	ENSG00000273008.1	RP11-351D16.3	4.67	3.94e-06	0.000861	0.25	0.21	Hirschsprung disease;	chr10:43223061	chr10:43136824~43138334:-
LUAD	cis	rs2742234	0.541	rs11238481	ENSG00000273008.1	RP11-351D16.3	4.67	3.94e-06	0.000861	0.25	0.21	Hirschsprung disease;	chr10:43223838	chr10:43136824~43138334:-
LUAD	cis	rs2742234	0.541	rs61268333	ENSG00000273008.1	RP11-351D16.3	4.67	3.94e-06	0.000861	0.25	0.21	Hirschsprung disease;	chr10:43225922	chr10:43136824~43138334:-
LUAD	cis	rs2742234	0.541	rs60845448	ENSG00000273008.1	RP11-351D16.3	4.67	3.94e-06	0.000861	0.25	0.21	Hirschsprung disease;	chr10:43226014	chr10:43136824~43138334:-
LUAD	cis	rs2742234	0.541	rs10899779	ENSG00000273008.1	RP11-351D16.3	4.67	3.94e-06	0.000861	0.25	0.21	Hirschsprung disease;	chr10:43228528	chr10:43136824~43138334:-
LUAD	cis	rs375066	0.935	rs367283	ENSG00000267058.1	RP11-15A1.3	-4.67	3.94e-06	0.000861	-0.23	-0.21	Breast cancer;	chr19:43901975	chr19:43891804~43901805:-
LUAD	cis	rs375066	0.935	rs448823	ENSG00000267058.1	RP11-15A1.3	-4.67	3.94e-06	0.000861	-0.23	-0.21	Breast cancer;	chr19:43902139	chr19:43891804~43901805:-
LUAD	cis	rs375066	0.868	rs448829	ENSG00000267058.1	RP11-15A1.3	-4.67	3.94e-06	0.000861	-0.23	-0.21	Breast cancer;	chr19:43902169	chr19:43891804~43901805:-
LUAD	cis	rs11168618	0.567	rs12372687	ENSG00000240399.1	RP1-228P16.1	4.67	3.94e-06	0.000862	0.2	0.21	Adiponectin levels;	chr12:48418016	chr12:48054813~48055591:-
LUAD	cis	rs7119	0.679	rs12914932	ENSG00000259362.2	RP11-307C19.1	-4.67	3.95e-06	0.000863	-0.27	-0.21	Type 2 diabetes;	chr15:77546709	chr15:77525540~77534110:+
LUAD	cis	rs8072100	0.967	rs3760370	ENSG00000228782.6	CTD-2026D20.3	-4.67	3.95e-06	0.000863	-0.22	-0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47618466	chr17:47450568~47492492:-
LUAD	cis	rs1008375	0.933	rs6847966	ENSG00000249502.1	AC006160.5	-4.67	3.95e-06	0.000863	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17632632	chr4:17587467~17614571:-
LUAD	cis	rs1008375	1	rs6848360	ENSG00000249502.1	AC006160.5	-4.67	3.95e-06	0.000863	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17632819	chr4:17587467~17614571:-
LUAD	cis	rs1008375	1	rs7659718	ENSG00000249502.1	AC006160.5	-4.67	3.95e-06	0.000863	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17636397	chr4:17587467~17614571:-
LUAD	cis	rs7665090	0.728	rs228617	ENSG00000251288.2	RP11-10L12.2	4.67	3.95e-06	0.000863	0.25	0.21	Primary biliary cholangitis;	chr4:102659631	chr4:102751401~102752641:+
LUAD	cis	rs11168618	0.904	rs7135125	ENSG00000240399.1	RP1-228P16.1	4.67	3.95e-06	0.000863	0.2	0.21	Adiponectin levels;	chr12:48532485	chr12:48054813~48055591:-
LUAD	cis	rs1008375	1	rs3733579	ENSG00000249502.1	AC006160.5	-4.67	3.95e-06	0.000864	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17693320	chr4:17587467~17614571:-
LUAD	cis	rs5758511	0.68	rs1107553	ENSG00000226450.2	CYP2D8P	4.67	3.95e-06	0.000864	0.19	0.21	Birth weight;	chr22:42271467	chr22:42149886~42155001:-
LUAD	cis	rs17685	0.712	rs6954569	ENSG00000280388.1	RP11-229D13.3	-4.67	3.95e-06	0.000864	-0.19	-0.21	Coffee consumption (cups per day);Coffee consumption;	chr7:76109567	chr7:76043977~76045963:-
LUAD	cis	rs442309	0.583	rs10995307	ENSG00000238280.1	RP11-436D10.3	4.67	3.95e-06	0.000864	0.25	0.21	Vogt-Koyanagi-Harada syndrome;	chr10:62792482	chr10:62793562~62805887:-
LUAD	cis	rs2280018	0.526	rs2941257	ENSG00000207425.1	Y_RNA	4.67	3.95e-06	0.000864	0.26	0.21	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072588	chr16:14915457~14915556:-
LUAD	cis	rs2976388	0.967	rs2976393	ENSG00000253741.1	CTD-2292P10.4	4.67	3.95e-06	0.000864	0.23	0.21	Urinary tract infection frequency;	chr8:142682200	chr8:142702252~142726973:-
LUAD	cis	rs7665090	0.87	rs228614	ENSG00000246560.2	RP11-10L12.4	-4.67	3.95e-06	0.000864	-0.26	-0.21	Primary biliary cholangitis;	chr4:102657480	chr4:102828055~102844075:+
LUAD	cis	rs4819052	0.788	rs2236449	ENSG00000223768.1	LINC00205	-4.67	3.96e-06	0.000865	-0.26	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45282591	chr21:45293285~45297354:+
LUAD	cis	rs9425766	0.64	rs6693423	ENSG00000227373.4	RP11-160H22.5	4.67	3.96e-06	0.000865	0.26	0.21	Life satisfaction;	chr1:174364680	chr1:174115300~174160004:-
LUAD	cis	rs9425766	0.679	rs60363188	ENSG00000227373.4	RP11-160H22.5	4.67	3.96e-06	0.000865	0.26	0.21	Life satisfaction;	chr1:174375959	chr1:174115300~174160004:-
LUAD	cis	rs9425766	0.679	rs12084119	ENSG00000227373.4	RP11-160H22.5	4.67	3.96e-06	0.000865	0.26	0.21	Life satisfaction;	chr1:174377138	chr1:174115300~174160004:-
LUAD	cis	rs72634501	0.568	rs6679564	ENSG00000228060.1	RP11-69E11.8	4.67	3.96e-06	0.000866	0.19	0.21	HDL cholesterol;	chr1:39151408	chr1:39565160~39573203:+
LUAD	cis	rs507080	0.883	rs12798453	ENSG00000278376.1	RP11-158I9.8	-4.67	3.96e-06	0.000866	-0.22	-0.21	Serum metabolite levels;	chr11:118690701	chr11:118791254~118793137:+
LUAD	cis	rs6840360	0.571	rs6811676	ENSG00000270265.1	RP11-731D1.4	-4.67	3.96e-06	0.000866	-0.24	-0.21	Intelligence (multi-trait analysis);	chr4:151641574	chr4:151333775~151353224:-
LUAD	cis	rs9309473	0.554	rs4330127	ENSG00000163016.8	ALMS1P	4.67	3.96e-06	0.000866	0.23	0.21	Metabolite levels;	chr2:73354192	chr2:73644919~73685576:+
LUAD	cis	rs34779708	0.966	rs6481941	ENSG00000271335.4	RP11-324I22.4	4.67	3.97e-06	0.000867	0.22	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35151213	chr10:35314552~35336401:-
LUAD	cis	rs11673344	0.765	rs826296	ENSG00000226686.6	LINC01535	4.67	3.97e-06	0.000867	0.26	0.21	Obesity-related traits;	chr19:36947384	chr19:37251912~37265535:+
LUAD	cis	rs61776719	0.52	rs12569027	ENSG00000212541.1	RNU6-510P	-4.67	3.97e-06	0.000867	-0.25	-0.21	Coronary artery disease;	chr1:37983491	chr1:37991462~37991569:+
LUAD	cis	rs61776719	0.5	rs11210866	ENSG00000212541.1	RNU6-510P	-4.67	3.97e-06	0.000867	-0.25	-0.21	Coronary artery disease;	chr1:37983893	chr1:37991462~37991569:+
LUAD	cis	rs950169	0.922	rs67804993	ENSG00000229212.6	RP11-561C5.4	-4.67	3.97e-06	0.000867	-0.3	-0.21	Schizophrenia;	chr15:84560799	chr15:85205440~85234795:-
LUAD	cis	rs2337406	0.641	rs10133227	ENSG00000223648.3	IGHV3-64	-4.67	3.97e-06	0.000868	-0.25	-0.21	Alzheimer's disease (late onset);	chr14:106814260	chr14:106643132~106658258:-
LUAD	cis	rs7172677	0.768	rs72730583	ENSG00000260269.4	CTD-2323K18.1	4.67	3.97e-06	0.000868	0.28	0.21	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75059289	chr15:75527150~75601205:-
LUAD	cis	rs9309473	0.607	rs7573719	ENSG00000163016.8	ALMS1P	4.67	3.97e-06	0.000868	0.23	0.21	Metabolite levels;	chr2:73355858	chr2:73644919~73685576:+
LUAD	cis	rs7772486	0.764	rs7762562	ENSG00000235652.6	RP11-545I5.3	4.67	3.98e-06	0.000869	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145837858	chr6:145799409~145886585:+
LUAD	cis	rs2243480	1	rs906134	ENSG00000232559.3	GS1-124K5.12	4.67	3.98e-06	0.000869	0.37	0.21	Diabetic kidney disease;	chr7:65979301	chr7:66554588~66576923:-
LUAD	cis	rs6723108	0.581	rs10176573	ENSG00000224043.6	CCNT2-AS1	-4.67	3.98e-06	0.000869	-0.26	-0.21	Type 2 diabetes;	chr2:134899901	chr2:134735464~134918710:-
LUAD	cis	rs9910055	0.659	rs112114764	ENSG00000267080.4	ASB16-AS1	4.67	3.98e-06	0.000869	0.19	0.21	Total body bone mineral density;	chr17:44123673	chr17:44175973~44186717:-
LUAD	cis	rs35740288	1	rs11637212	ENSG00000259407.1	RP11-158M2.3	4.67	3.98e-06	0.00087	0.21	0.21	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85749866	chr15:85744109~85750281:-
LUAD	cis	rs2243480	1	rs313820	ENSG00000164669.11	INTS4P1	4.67	3.98e-06	0.00087	0.37	0.21	Diabetic kidney disease;	chr7:66109479	chr7:65141225~65234216:+
LUAD	cis	rs36093844	0.898	rs895255	ENSG00000279742.1	RP11-700A24.1	4.67	3.98e-06	0.00087	0.23	0.21	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85823503	chr11:85852557~85854943:-
LUAD	cis	rs11976180	1	rs67239267	ENSG00000204959.4	ARHGEF34P	4.67	3.98e-06	0.00087	0.26	0.21	Obesity-related traits;	chr7:144048023	chr7:144272445~144286966:-
LUAD	cis	rs5758511	0.514	rs5751240	ENSG00000226450.2	CYP2D8P	4.67	3.98e-06	0.00087	0.2	0.21	Birth weight;	chr22:42199252	chr22:42149886~42155001:-
LUAD	cis	rs750134	1	rs12580445	ENSG00000257221.1	RP11-689B22.2	-4.67	3.98e-06	0.00087	-0.32	-0.21	Low high density lipoprotein cholesterol levels;	chr12:108681581	chr12:108628687~108641318:+
LUAD	cis	rs4664293	0.546	rs72956113	ENSG00000226266.5	AC009961.3	4.67	3.98e-06	0.00087	0.29	0.21	Monocyte percentage of white cells;	chr2:159631132	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.51	rs66571608	ENSG00000226266.5	AC009961.3	4.67	3.98e-06	0.00087	0.29	0.21	Monocyte percentage of white cells;	chr2:159635851	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.51	rs66589863	ENSG00000226266.5	AC009961.3	4.67	3.98e-06	0.00087	0.29	0.21	Monocyte percentage of white cells;	chr2:159649684	chr2:159670708~159712435:-
LUAD	cis	rs17818399	0.788	rs17818315	ENSG00000279254.1	RP11-536C12.1	-4.67	3.98e-06	0.00087	-0.24	-0.21	Height;	chr2:46591853	chr2:46668870~46670778:+
LUAD	cis	rs780096	0.546	rs715326	ENSG00000234072.1	AC074117.10	4.67	3.98e-06	0.00087	0.16	0.21	Total body bone mineral density;	chr2:27502894	chr2:27356246~27367622:+
LUAD	cis	rs9545047	0.604	rs1980883	ENSG00000227354.5	RBM26-AS1	-4.67	3.99e-06	0.00087	-0.22	-0.21	Schizophrenia;	chr13:79310629	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs9565486	ENSG00000227354.5	RBM26-AS1	-4.67	3.99e-06	0.00087	-0.22	-0.21	Schizophrenia;	chr13:79317469	chr13:79406309~79424328:+
LUAD	cis	rs17508449	0.819	rs78394484	ENSG00000232450.1	RP4-730K3.3	-4.67	3.99e-06	0.00087	-0.36	-0.21	Leprosy;	chr1:113740136	chr1:113698884~113699631:-
LUAD	cis	rs3738443	0.904	rs61840475	ENSG00000259865.1	RP11-488L18.10	4.67	3.99e-06	0.000871	0.23	0.21	Alcohol dependence;	chr1:247225818	chr1:247187281~247188526:-
LUAD	cis	rs507080	0.845	rs613377	ENSG00000278376.1	RP11-158I9.8	-4.67	3.99e-06	0.000871	-0.22	-0.21	Serum metabolite levels;	chr11:118685375	chr11:118791254~118793137:+
LUAD	cis	rs1876905	0.68	rs9384787	ENSG00000230177.1	RP5-1112D6.4	4.67	3.99e-06	0.000871	0.22	0.21	Mean corpuscular hemoglobin;	chr6:111113707	chr6:111277932~111278742:+
LUAD	cis	rs9545047	0.588	rs9530894	ENSG00000227354.5	RBM26-AS1	4.67	3.99e-06	0.000872	0.22	0.21	Schizophrenia;	chr13:79334020	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs9530895	ENSG00000227354.5	RBM26-AS1	4.67	3.99e-06	0.000872	0.22	0.21	Schizophrenia;	chr13:79334877	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.567	rs9530896	ENSG00000227354.5	RBM26-AS1	4.67	3.99e-06	0.000872	0.22	0.21	Schizophrenia;	chr13:79335507	chr13:79406309~79424328:+
LUAD	cis	rs2286503	0.839	rs1054471	ENSG00000226329.2	AC005682.6	4.67	4e-06	0.000872	0.27	0.21	Fibrinogen;	chr7:22813024	chr7:22863874~22881350:-
LUAD	cis	rs2286503	0.839	rs2240726	ENSG00000226329.2	AC005682.6	4.67	4e-06	0.000872	0.27	0.21	Fibrinogen;	chr7:22813516	chr7:22863874~22881350:-
LUAD	cis	rs17685	0.753	rs10264760	ENSG00000280388.1	RP11-229D13.3	-4.67	4e-06	0.000872	-0.19	-0.21	Coffee consumption (cups per day);Coffee consumption;	chr7:76120376	chr7:76043977~76045963:-
LUAD	cis	rs925255	0.711	rs12478126	ENSG00000270210.1	RP11-373D23.3	4.67	4e-06	0.000873	0.24	0.21	Inflammatory bowel disease;Crohn's disease;	chr2:28423081	chr2:28425945~28426719:+
LUAD	cis	rs7116495	0.786	rs1892919	ENSG00000254682.1	RP11-660L16.2	4.67	4e-06	0.000873	0.45	0.21	Severe influenza A (H1N1) infection;	chr11:72001129	chr11:71448674~71452157:+
LUAD	cis	rs6687758	0.687	rs12140529	ENSG00000200033.1	RNU6-403P	4.67	4e-06	0.000873	0.27	0.21	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221925411	chr1:221837334~221837437:-
LUAD	cis	rs6714710	0.603	rs11681535	ENSG00000230606.9	AC159540.1	-4.67	4e-06	0.000874	-0.22	-0.21	Posterior cortical atrophy and Alzheimer's disease;	chr2:97872486	chr2:97416165~97433527:-
LUAD	cis	rs950169	0.922	rs6603022	ENSG00000275120.1	RP11-182J1.17	-4.67	4e-06	0.000874	-0.33	-0.21	Schizophrenia;	chr15:84161418	chr15:84599434~84606463:-
LUAD	cis	rs6957923	0.818	rs10950949	ENSG00000230658.1	KLHL7-AS1	4.67	4e-06	0.000874	0.25	0.21	Height;	chr7:23479641	chr7:23101228~23105703:-
LUAD	cis	rs4604732	0.631	rs12031694	ENSG00000227135.1	GCSAML-AS1	-4.67	4e-06	0.000874	-0.31	-0.21	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247460351	chr1:247524679~247526752:-
LUAD	cis	rs7945705	0.875	rs10769957	ENSG00000254860.4	TMEM9B-AS1	4.66	4.01e-06	0.000874	0.24	0.21	Hemoglobin concentration;	chr11:8787469	chr11:8964675~8977527:+
LUAD	cis	rs9545047	0.604	rs1752649	ENSG00000227354.5	RBM26-AS1	4.66	4.01e-06	0.000875	0.22	0.21	Schizophrenia;	chr13:79331980	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs1749983	ENSG00000227354.5	RBM26-AS1	4.66	4.01e-06	0.000875	0.22	0.21	Schizophrenia;	chr13:79332077	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.567	rs1752648	ENSG00000227354.5	RBM26-AS1	4.66	4.01e-06	0.000875	0.22	0.21	Schizophrenia;	chr13:79332124	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs1752647	ENSG00000227354.5	RBM26-AS1	4.66	4.01e-06	0.000875	0.22	0.21	Schizophrenia;	chr13:79332741	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.532	rs1752646	ENSG00000227354.5	RBM26-AS1	4.66	4.01e-06	0.000875	0.22	0.21	Schizophrenia;	chr13:79332752	chr13:79406309~79424328:+
LUAD	cis	rs875971	0.619	rs12533585	ENSG00000236529.1	RP13-254B10.1	4.66	4.01e-06	0.000875	0.21	0.21	Aortic root size;	chr7:66519618	chr7:65840212~65840596:+
LUAD	cis	rs875971	0.66	rs12698534	ENSG00000236529.1	RP13-254B10.1	4.66	4.01e-06	0.000875	0.21	0.21	Aortic root size;	chr7:66521858	chr7:65840212~65840596:+
LUAD	cis	rs507080	0.807	rs7926944	ENSG00000278376.1	RP11-158I9.8	-4.66	4.01e-06	0.000875	-0.23	-0.21	Serum metabolite levels;	chr11:118689119	chr11:118791254~118793137:+
LUAD	cis	rs9532669	0.511	rs3783164	ENSG00000168852.11	TPTE2P5	-4.66	4.01e-06	0.000875	-0.22	-0.21	Cervical cancer;	chr13:40806227	chr13:40822296~40921749:-
LUAD	cis	rs12554020	0.892	rs75625893	ENSG00000227603.1	RP11-165J3.6	4.66	4.01e-06	0.000876	0.34	0.21	Schizophrenia;	chr9:93605006	chr9:93435332~93437121:-
LUAD	cis	rs858239	0.669	rs10950940	ENSG00000230042.1	AK3P3	4.66	4.01e-06	0.000876	0.26	0.21	Cerebrospinal fluid biomarker levels;	chr7:23157197	chr7:23129178~23129841:+
LUAD	cis	rs9322193	0.962	rs1889473	ENSG00000268592.3	RAET1E-AS1	4.66	4.02e-06	0.000876	0.26	0.21	Lung cancer;	chr6:149825485	chr6:149863494~149919507:+
LUAD	cis	rs71520386	0.53	rs10256628	ENSG00000228649.7	AC005682.5	-4.66	4.02e-06	0.000877	-0.28	-0.21	Fibrinogen levels;	chr7:22843640	chr7:22854178~22861579:+
LUAD	cis	rs2153535	0.585	rs9393057	ENSG00000230939.1	RP11-314C16.1	4.66	4.02e-06	0.000877	0.23	0.21	Motion sickness;	chr6:8668067	chr6:8784178~8785445:+
LUAD	cis	rs6545883	0.524	rs811871	ENSG00000271889.1	RP11-493E12.1	-4.66	4.02e-06	0.000877	-0.24	-0.21	Tuberculosis;	chr2:61350814	chr2:61151433~61162105:-
LUAD	cis	rs7017914	0.652	rs10504480	ENSG00000223220.1	Y_RNA	4.66	4.02e-06	0.000877	0.24	0.21	Bone mineral density;	chr8:70666012	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs11987501	ENSG00000223220.1	Y_RNA	4.66	4.02e-06	0.000877	0.24	0.21	Bone mineral density;	chr8:70666283	chr8:70780914~70781008:-
LUAD	cis	rs6687821	0.531	rs6661530	ENSG00000267734.1	RP4-604K5.3	4.66	4.02e-06	0.000877	0.27	0.21	Yeast infection;	chr1:87020367	chr1:86932199~86934891:-
LUAD	cis	rs812925	0.502	rs2084318	ENSG00000271889.1	RP11-493E12.1	-4.66	4.02e-06	0.000877	-0.25	-0.21	Immature fraction of reticulocytes;	chr2:61425466	chr2:61151433~61162105:-
LUAD	cis	rs4835473	0.897	rs4423826	ENSG00000251600.4	RP11-673E1.1	4.66	4.02e-06	0.000877	0.26	0.21	Immature fraction of reticulocytes;	chr4:143992165	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.932	rs4835126	ENSG00000251600.4	RP11-673E1.1	4.66	4.02e-06	0.000877	0.26	0.21	Immature fraction of reticulocytes;	chr4:143997740	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.699	rs4835127	ENSG00000251600.4	RP11-673E1.1	4.66	4.02e-06	0.000877	0.26	0.21	Immature fraction of reticulocytes;	chr4:143997972	chr4:143912331~143982454:+
LUAD	cis	rs4706831	0.625	rs638056	ENSG00000260645.1	RP11-250B2.5	-4.66	4.02e-06	0.000877	-0.2	-0.21	Joint mobility (Beighton score);	chr6:80271091	chr6:80466958~80469080:+
LUAD	cis	rs12439619	0.739	rs62012046	ENSG00000276710.3	CSPG4P8	-4.66	4.02e-06	0.000878	-0.23	-0.21	Intelligence (multi-trait analysis);	chr15:82236824	chr15:82459472~82477258:+
LUAD	cis	rs12439619	0.774	rs62012047	ENSG00000276710.3	CSPG4P8	-4.66	4.02e-06	0.000878	-0.23	-0.21	Intelligence (multi-trait analysis);	chr15:82236852	chr15:82459472~82477258:+
LUAD	cis	rs12439619	0.81	rs62012049	ENSG00000276710.3	CSPG4P8	-4.66	4.02e-06	0.000878	-0.23	-0.21	Intelligence (multi-trait analysis);	chr15:82237722	chr15:82459472~82477258:+
LUAD	cis	rs853679	0.567	rs13196606	ENSG00000216901.1	AL022393.7	4.66	4.03e-06	0.000878	0.26	0.21	Depression;	chr6:28402301	chr6:28176188~28176674:+
LUAD	cis	rs2732480	0.5	rs2450991	ENSG00000240399.1	RP1-228P16.1	4.66	4.03e-06	0.000879	0.21	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48257838	chr12:48054813~48055591:-
LUAD	cis	rs763512	0.532	rs1416	ENSG00000276054.1	RP11-378E13.3	4.66	4.03e-06	0.000879	0.31	0.21	3-hydroxypropylmercapturic acid levels in smokers;	chr17:37534709	chr17:37386886~37387926:+
LUAD	cis	rs9322193	0.607	rs10457852	ENSG00000268592.3	RAET1E-AS1	4.66	4.03e-06	0.000879	0.31	0.21	Lung cancer;	chr6:149880584	chr6:149863494~149919507:+
LUAD	cis	rs712039	0.652	rs853206	ENSG00000276054.1	RP11-378E13.3	4.66	4.03e-06	0.000879	0.31	0.21	Tuberculosis;	chr17:37464692	chr17:37386886~37387926:+
LUAD	cis	rs2522056	1	rs2522054	ENSG00000233006.5	AC034220.3	-4.66	4.03e-06	0.000879	-0.23	-0.21	Fibrinogen;Lymphocyte counts;	chr5:132463834	chr5:132311285~132369916:-
LUAD	cis	rs11089937	0.597	rs11704434	ENSG00000211638.2	IGLV8-61	-4.66	4.03e-06	0.000879	-0.25	-0.21	Periodontitis (PAL4Q3);	chr22:22131715	chr22:22098700~22099212:+
LUAD	cis	rs801193	0.967	rs34356500	ENSG00000237310.1	GS1-124K5.4	4.66	4.03e-06	0.00088	0.22	0.21	Aortic root size;	chr7:66771620	chr7:66493706~66495474:+
LUAD	cis	rs7927592	0.513	rs3853616	ENSG00000212093.1	AP000807.1	4.66	4.04e-06	0.00088	0.22	0.21	Total body bone mineral density;	chr11:68430784	chr11:68506083~68506166:-
LUAD	cis	rs6591341	0.515	rs599301	ENSG00000212093.1	AP000807.1	4.66	4.04e-06	0.000881	0.22	0.21	Lean body mass;	chr11:68422477	chr11:68506083~68506166:-
LUAD	cis	rs9425766	0.64	rs17301013	ENSG00000227373.4	RP11-160H22.5	4.66	4.04e-06	0.000881	0.26	0.21	Life satisfaction;	chr1:174343675	chr1:174115300~174160004:-
LUAD	cis	rs910316	0.935	rs175076	ENSG00000259138.1	RP11-950C14.7	-4.66	4.04e-06	0.000882	-0.22	-0.21	Height;	chr14:75038783	chr14:75127153~75136930:+
LUAD	cis	rs642803	0.591	rs620088	ENSG00000255557.1	RP11-770G2.2	-4.66	4.04e-06	0.000882	-0.25	-0.21	Urate levels;	chr11:65741515	chr11:65745729~65771585:+
LUAD	cis	rs1799949	0.965	rs2236762	ENSG00000236383.6	LINC00854	-4.66	4.04e-06	0.000882	-0.16	-0.21	Menopause (age at onset);	chr17:43074658	chr17:43216941~43305976:-
LUAD	cis	rs2742234	0.541	rs11238490	ENSG00000273008.1	RP11-351D16.3	4.66	4.05e-06	0.000882	0.24	0.21	Hirschsprung disease;	chr10:43252150	chr10:43136824~43138334:-
LUAD	cis	rs6840360	0.571	rs62327278	ENSG00000270265.1	RP11-731D1.4	-4.66	4.05e-06	0.000882	-0.24	-0.21	Intelligence (multi-trait analysis);	chr4:151637638	chr4:151333775~151353224:-
LUAD	cis	rs2380205	0.517	rs11255971	ENSG00000232807.2	RP11-536K7.3	4.66	4.05e-06	0.000882	0.23	0.21	Breast cancer;	chr10:5925213	chr10:5934270~5945900:-
LUAD	cis	rs11168618	0.567	rs56354789	ENSG00000240399.1	RP1-228P16.1	4.66	4.05e-06	0.000883	0.21	0.21	Adiponectin levels;	chr12:48410160	chr12:48054813~48055591:-
LUAD	cis	rs6728642	1	rs7593754	ENSG00000230606.9	AC159540.1	4.66	4.05e-06	0.000884	0.34	0.21	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96941807	chr2:97416165~97433527:-
LUAD	cis	rs7493	1	rs17166875	ENSG00000233942.1	AC004012.1	4.66	4.05e-06	0.000884	0.31	0.21	Yu-Zhi constitution type in type 2 diabetes;	chr7:95411959	chr7:95471835~95473998:+
LUAD	cis	rs453301	0.624	rs2979256	ENSG00000173295.6	FAM86B3P	4.66	4.06e-06	0.000885	0.23	0.21	Joint mobility (Beighton score);	chr8:9014200	chr8:8228595~8244865:+
LUAD	cis	rs12468226	0.873	rs2350358	ENSG00000226261.1	AC064836.3	-4.66	4.06e-06	0.000885	-0.32	-0.21	Urate levels;	chr2:202199771	chr2:202336024~202336727:-
LUAD	cis	rs7617773	0.963	rs9822496	ENSG00000228638.1	FCF1P2	-4.66	4.06e-06	0.000885	-0.23	-0.21	Coronary artery disease;	chr3:48139843	chr3:48290793~48291375:-
LUAD	cis	rs17772222	0.917	rs17124652	ENSG00000258983.2	RP11-507K2.2	4.66	4.06e-06	0.000885	0.26	0.21	Coronary artery calcification;	chr14:88424384	chr14:88499334~88515502:+
LUAD	cis	rs9309473	0.607	rs6546824	ENSG00000163016.8	ALMS1P	4.66	4.06e-06	0.000885	0.23	0.21	Metabolite levels;	chr2:73360203	chr2:73644919~73685576:+
LUAD	cis	rs9309473	0.607	rs4641966	ENSG00000163016.8	ALMS1P	4.66	4.06e-06	0.000885	0.23	0.21	Metabolite levels;	chr2:73363678	chr2:73644919~73685576:+
LUAD	cis	rs7772486	0.754	rs9373476	ENSG00000235652.6	RP11-545I5.3	4.66	4.06e-06	0.000885	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145818605	chr6:145799409~145886585:+
LUAD	cis	rs6687821	0.834	rs263433	ENSG00000267734.1	RP4-604K5.3	4.66	4.07e-06	0.000886	0.23	0.21	Yeast infection;	chr1:86715206	chr1:86932199~86934891:-
LUAD	cis	rs2243480	0.908	rs313822	ENSG00000164669.11	INTS4P1	4.66	4.07e-06	0.000887	0.37	0.21	Diabetic kidney disease;	chr7:66108952	chr7:65141225~65234216:+
LUAD	cis	rs10129255	0.912	rs8011090	ENSG00000211974.3	IGHV2-70	4.66	4.07e-06	0.000887	0.22	0.21	Kawasaki disease;	chr14:106678896	chr14:106723574~106724093:-
LUAD	cis	rs2243480	1	rs313832	ENSG00000164669.11	INTS4P1	4.66	4.07e-06	0.000887	0.37	0.21	Diabetic kidney disease;	chr7:66085904	chr7:65141225~65234216:+
LUAD	cis	rs17772222	0.74	rs11847417	ENSG00000258789.1	RP11-507K2.3	4.66	4.07e-06	0.000887	0.26	0.21	Coronary artery calcification;	chr14:88510606	chr14:88551597~88552493:+
LUAD	cis	rs17772222	1	rs12433464	ENSG00000258983.2	RP11-507K2.2	4.66	4.07e-06	0.000887	0.25	0.21	Coronary artery calcification;	chr14:88357671	chr14:88499334~88515502:+
LUAD	cis	rs2898681	0.614	rs962416	ENSG00000248375.1	RP11-177B4.1	4.66	4.07e-06	0.000887	0.31	0.21	Optic nerve measurement (cup area);	chr4:52829490	chr4:52720081~52720831:-
LUAD	cis	rs1106529	0.515	rs1766789	ENSG00000226172.2	RP4-712E4.1	4.66	4.07e-06	0.000887	0.29	0.21	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);	chr1:118913229	chr1:119000344~119001392:-
LUAD	cis	rs228614	0.51	rs223311	ENSG00000251288.2	RP11-10L12.2	-4.66	4.07e-06	0.000887	-0.25	-0.21	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888757	chr4:102751401~102752641:+
LUAD	cis	rs1501911	0.566	rs709387	ENSG00000248489.1	CTD-2007H13.3	4.66	4.07e-06	0.000887	0.26	0.21	Lung function (FEV1/FVC);	chr5:98994337	chr5:98929171~98995013:+
LUAD	cis	rs8098244	0.597	rs12958312	ENSG00000264745.1	TTC39C-AS1	-4.66	4.08e-06	0.000888	-0.21	-0.21	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23784372	chr18:23994213~24015339:-
LUAD	cis	rs6687758	0.687	rs17011141	ENSG00000228437.4	RP11-400N13.2	4.66	4.08e-06	0.000888	0.29	0.21	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221939292	chr1:221966341~221984964:+
LUAD	cis	rs17772222	0.917	rs17188046	ENSG00000258789.1	RP11-507K2.3	-4.66	4.08e-06	0.000888	-0.28	-0.21	Coronary artery calcification;	chr14:88624417	chr14:88551597~88552493:+
LUAD	cis	rs7098414	0.53	rs10749572	ENSG00000226659.1	RP11-137H2.4	-4.66	4.08e-06	0.000888	-0.28	-0.21	Post bronchodilator FEV1;	chr10:80376908	chr10:80529597~80535942:-
LUAD	cis	rs9322193	0.923	rs62441284	ENSG00000268592.3	RAET1E-AS1	4.66	4.08e-06	0.000888	0.25	0.21	Lung cancer;	chr6:149751542	chr6:149863494~149919507:+
LUAD	cis	rs2562456	0.833	rs4429400	ENSG00000268081.1	RP11-678G14.2	4.66	4.08e-06	0.000889	0.33	0.21	Pain;	chr19:21338163	chr19:21554640~21569237:-
LUAD	cis	rs36423	0.748	rs36376	ENSG00000266869.1	RP6-114E22.1	-4.66	4.08e-06	0.000889	-0.31	-0.21	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71906084	chr14:71848606~71908430:+
LUAD	cis	rs9322193	1	rs9399693	ENSG00000268592.3	RAET1E-AS1	4.66	4.08e-06	0.000889	0.25	0.21	Lung cancer;	chr6:149612718	chr6:149863494~149919507:+
LUAD	cis	rs9381040	1	rs2093395	ENSG00000161912.16	ADCY10P1	-4.66	4.09e-06	0.00089	-0.2	-0.21	Alzheimer's disease (late onset);	chr6:41187288	chr6:41101022~41140835:+
LUAD	cis	rs13256369	1	rs873064	ENSG00000253893.2	FAM85B	-4.66	4.09e-06	0.00089	-0.29	-0.21	Obesity-related traits;	chr8:8714870	chr8:8167819~8226614:-
LUAD	cis	rs13256369	1	rs873063	ENSG00000253893.2	FAM85B	-4.66	4.09e-06	0.00089	-0.29	-0.21	Obesity-related traits;	chr8:8714937	chr8:8167819~8226614:-
LUAD	cis	rs2243480	1	rs437889	ENSG00000164669.11	INTS4P1	4.66	4.09e-06	0.00089	0.37	0.21	Diabetic kidney disease;	chr7:66044247	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs402418	ENSG00000164669.11	INTS4P1	4.66	4.09e-06	0.00089	0.37	0.21	Diabetic kidney disease;	chr7:66044482	chr7:65141225~65234216:+
LUAD	cis	rs2243480	0.803	rs423187	ENSG00000164669.11	INTS4P1	4.66	4.09e-06	0.00089	0.37	0.21	Diabetic kidney disease;	chr7:66044512	chr7:65141225~65234216:+
LUAD	cis	rs9487094	0.922	rs1321328	ENSG00000260273.1	RP11-425D10.10	4.66	4.09e-06	0.00089	0.29	0.21	Height;	chr6:109655182	chr6:109382795~109383666:+
LUAD	cis	rs17772222	1	rs55722539	ENSG00000258983.2	RP11-507K2.2	4.66	4.09e-06	0.00089	0.26	0.21	Coronary artery calcification;	chr14:88411691	chr14:88499334~88515502:+
LUAD	cis	rs17772222	1	rs11159856	ENSG00000258983.2	RP11-507K2.2	4.66	4.09e-06	0.00089	0.26	0.21	Coronary artery calcification;	chr14:88417585	chr14:88499334~88515502:+
LUAD	cis	rs2657294	0.62	rs4746261	ENSG00000226051.5	ZNF503-AS1	4.66	4.09e-06	0.00089	0.27	0.21	Pneumonia;	chr10:75085874	chr10:75269819~75373500:+
LUAD	cis	rs17826219	0.568	rs59858012	ENSG00000280069.1	CTD-2349P21.3	-4.66	4.09e-06	0.00089	-0.32	-0.21	Body mass index;	chr17:30751564	chr17:30738182~30740275:+
LUAD	cis	rs3096299	0.754	rs2965816	ENSG00000182376.2	RP5-1142A6.8	-4.66	4.09e-06	0.00089	-0.21	-0.21	Multiple myeloma (IgH translocation);	chr16:89447775	chr16:88742767~88745748:+
LUAD	cis	rs853679	1	rs1679732	ENSG00000219392.1	RP1-265C24.5	4.66	4.09e-06	0.000891	0.31	0.21	Depression;	chr6:28253486	chr6:28115628~28116551:+
LUAD	cis	rs9840812	0.645	rs9883916	ENSG00000239213.4	NCK1-AS1	4.66	4.09e-06	0.000891	0.28	0.21	Fibrinogen levels;	chr3:136489946	chr3:136841726~136862054:-
LUAD	cis	rs10266483	0.774	rs7796802	ENSG00000227986.1	TRIM60P18	4.66	4.09e-06	0.000891	0.25	0.21	Response to statin therapy;	chr7:64323744	chr7:64355078~64356199:+
LUAD	cis	rs5758511	0.68	rs56111723	ENSG00000226450.2	CYP2D8P	4.66	4.1e-06	0.000892	0.19	0.21	Birth weight;	chr22:42268877	chr22:42149886~42155001:-
LUAD	cis	rs7181230	1	rs11638521	ENSG00000275636.1	RP11-521C20.5	-4.66	4.1e-06	0.000892	-0.26	-0.21	Dehydroepiandrosterone sulphate levels;	chr15:40068113	chr15:40078892~40079347:+
LUAD	cis	rs2439831	0.867	rs2251844	ENSG00000249839.1	AC011330.5	-4.66	4.1e-06	0.000892	-0.37	-0.21	Lung cancer in ever smokers;	chr15:43544280	chr15:43663654~43684339:-
LUAD	cis	rs10129255	0.826	rs7150693	ENSG00000211974.3	IGHV2-70	4.66	4.1e-06	0.000892	0.22	0.21	Kawasaki disease;	chr14:106705382	chr14:106723574~106724093:-
LUAD	cis	rs997295	0.592	rs2899724	ENSG00000270964.1	RP11-502I4.3	-4.66	4.1e-06	0.000892	-0.22	-0.21	Motion sickness;	chr15:67468470	chr15:67541072~67542604:-
LUAD	cis	rs12908161	0.959	rs1051168	ENSG00000259295.5	CSPG4P12	4.66	4.1e-06	0.000892	0.3	0.21	Schizophrenia;	chr15:84657289	chr15:85191438~85213905:+
LUAD	cis	rs36423	0.748	rs36408	ENSG00000266869.1	RP6-114E22.1	-4.66	4.1e-06	0.000893	-0.31	-0.21	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71890558	chr14:71848606~71908430:+
LUAD	cis	rs7172677	0.768	rs72730585	ENSG00000260269.4	CTD-2323K18.1	4.66	4.1e-06	0.000893	0.28	0.21	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75061565	chr15:75527150~75601205:-
LUAD	cis	rs11763147	1	rs11763147	ENSG00000224316.1	RP11-479O9.2	-4.66	4.1e-06	0.000893	-0.21	-0.21	Corneal structure;	chr7:65861834	chr7:65773620~65802067:+
LUAD	cis	rs11051970	0.527	rs7962680	ENSG00000274964.1	RP11-817I4.1	-4.66	4.1e-06	0.000893	-0.29	-0.21	Response to tocilizumab in rheumatoid arthritis;	chr12:32322377	chr12:32339368~32340724:+
LUAD	cis	rs7772486	0.754	rs9390358	ENSG00000235652.6	RP11-545I5.3	4.66	4.11e-06	0.000894	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145824542	chr6:145799409~145886585:+
LUAD	cis	rs910316	0.967	rs12890371	ENSG00000279594.1	RP11-950C14.10	4.66	4.11e-06	0.000894	0.24	0.21	Height;	chr14:75127136	chr14:75011269~75012851:-
LUAD	cis	rs910316	1	rs12889309	ENSG00000279594.1	RP11-950C14.10	4.66	4.11e-06	0.000894	0.24	0.21	Height;	chr14:75127199	chr14:75011269~75012851:-
LUAD	cis	rs2380205	0.651	rs1886057	ENSG00000232807.2	RP11-536K7.3	4.66	4.11e-06	0.000894	0.21	0.21	Breast cancer;	chr10:5883532	chr10:5934270~5945900:-
LUAD	cis	rs7945705	0.967	rs7943377	ENSG00000254860.4	TMEM9B-AS1	-4.66	4.11e-06	0.000894	-0.24	-0.21	Hemoglobin concentration;	chr11:8827153	chr11:8964675~8977527:+
LUAD	cis	rs736801	0.808	rs72797306	ENSG00000233006.5	AC034220.3	4.66	4.11e-06	0.000894	0.19	0.21	Mosquito bite size;Breast cancer;	chr5:132465058	chr5:132311285~132369916:-
LUAD	cis	rs7119	0.689	rs11630557	ENSG00000259362.2	RP11-307C19.1	-4.66	4.11e-06	0.000895	-0.26	-0.21	Type 2 diabetes;	chr15:77528370	chr15:77525540~77534110:+
LUAD	cis	rs4660214	0.724	rs12117785	ENSG00000228060.1	RP11-69E11.8	4.66	4.11e-06	0.000895	0.19	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39162739	chr1:39565160~39573203:+
LUAD	cis	rs7829975	0.688	rs13270194	ENSG00000173295.6	FAM86B3P	4.66	4.11e-06	0.000895	0.22	0.21	Mood instability;	chr8:8520592	chr8:8228595~8244865:+
LUAD	cis	rs4664293	0.51	rs72961735	ENSG00000226266.5	AC009961.3	4.66	4.11e-06	0.000895	0.29	0.21	Monocyte percentage of white cells;	chr2:159708009	chr2:159670708~159712435:-
LUAD	cis	rs4819052	1	rs733738	ENSG00000215447.6	BX322557.10	4.66	4.11e-06	0.000895	0.26	0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246481	chr21:45288052~45291738:+
LUAD	cis	rs831571	0.915	rs6797912	ENSG00000280620.1	SCAANT1	-4.66	4.11e-06	0.000895	-0.29	-0.21	Type 2 diabetes;	chr3:64072564	chr3:63911518~63911772:-
LUAD	cis	rs950169	0.922	rs12906983	ENSG00000275120.1	RP11-182J1.17	4.66	4.12e-06	0.000896	0.33	0.21	Schizophrenia;	chr15:84262270	chr15:84599434~84606463:-
LUAD	cis	rs404005	0.818	rs433572	ENSG00000227028.5	SLC8A1-AS1	-4.66	4.12e-06	0.000896	-0.28	-0.21	HIV-associated dementia;	chr2:40177699	chr2:39786453~40255209:+
LUAD	cis	rs219780	0.679	rs219787	ENSG00000233818.1	AP000695.4	4.66	4.12e-06	0.000896	0.24	0.21	Kidney stones;	chr21:36457210	chr21:36445731~36532408:+
LUAD	cis	rs42490	0.7	rs410663	ENSG00000251136.7	RP11-37B2.1	4.66	4.13e-06	0.000898	0.22	0.21	Leprosy;	chr8:89859461	chr8:89609409~89757727:-
LUAD	cis	rs2522056	1	rs7730247	ENSG00000233006.5	AC034220.3	-4.66	4.13e-06	0.000898	-0.22	-0.21	Fibrinogen;Lymphocyte counts;	chr5:132445596	chr5:132311285~132369916:-
LUAD	cis	rs9545047	0.584	rs1886494	ENSG00000227354.5	RBM26-AS1	-4.66	4.13e-06	0.000898	-0.22	-0.21	Schizophrenia;	chr13:79403005	chr13:79406309~79424328:+
LUAD	cis	rs1008375	1	rs2315561	ENSG00000249502.1	AC006160.5	-4.66	4.13e-06	0.000898	-0.19	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17678072	chr4:17587467~17614571:-
LUAD	cis	rs17508449	0.71	rs6699022	ENSG00000232450.1	RP4-730K3.3	-4.66	4.13e-06	0.000898	-0.32	-0.21	Leprosy;	chr1:113567013	chr1:113698884~113699631:-
LUAD	cis	rs17508449	0.736	rs79470224	ENSG00000232450.1	RP4-730K3.3	-4.66	4.13e-06	0.000898	-0.32	-0.21	Leprosy;	chr1:113567163	chr1:113698884~113699631:-
LUAD	cis	rs1318937	0.748	rs78988883	ENSG00000224660.1	SH3BP5-AS1	4.66	4.13e-06	0.000899	0.24	0.21	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15236000	chr3:15254184~15264493:+
LUAD	cis	rs7829975	0.774	rs57312668	ENSG00000253893.2	FAM85B	-4.66	4.13e-06	0.000899	-0.26	-0.21	Mood instability;	chr8:8822967	chr8:8167819~8226614:-
LUAD	cis	rs7617773	0.963	rs12493256	ENSG00000228638.1	FCF1P2	4.66	4.13e-06	0.000899	0.23	0.21	Coronary artery disease;	chr3:48135257	chr3:48290793~48291375:-
LUAD	cis	rs860295	0.702	rs2175391	ENSG00000225855.5	RUSC1-AS1	-4.66	4.14e-06	9e-04	-0.14	-0.21	Body mass index;	chr1:155655811	chr1:155316863~155324176:-
LUAD	cis	rs42490	1	rs40544	ENSG00000251136.7	RP11-37B2.1	-4.66	4.14e-06	9e-04	-0.21	-0.21	Leprosy;	chr8:89768867	chr8:89609409~89757727:-
LUAD	cis	rs2522056	1	rs2706339	ENSG00000233006.5	AC034220.3	-4.66	4.14e-06	9e-04	-0.23	-0.21	Fibrinogen;Lymphocyte counts;	chr5:132464413	chr5:132311285~132369916:-
LUAD	cis	rs7189233	0.531	rs4783813	ENSG00000279344.1	RP11-44F14.7	4.66	4.14e-06	9e-04	0.17	0.21	Intelligence (multi-trait analysis);	chr16:53484458	chr16:53478957~53481550:-
LUAD	cis	rs738722	1	rs1033667	ENSG00000272858.1	CTA-292E10.8	4.66	4.14e-06	9e-04	0.26	0.21	Optic cup area;Esophageal cancer and gastric cancer;	chr22:28734312	chr22:28814914~28815662:+
LUAD	cis	rs9322193	0.884	rs7450246	ENSG00000268592.3	RAET1E-AS1	4.66	4.14e-06	9e-04	0.25	0.21	Lung cancer;	chr6:149702517	chr6:149863494~149919507:+
LUAD	cis	rs73242632	1	rs17828496	ENSG00000269949.1	RP11-738E22.3	4.66	4.14e-06	0.000901	0.55	0.21	Congenital heart disease (maternal effect);	chr4:56988847	chr4:56960927~56961373:-
LUAD	cis	rs170183	1	rs170183	ENSG00000233818.1	AP000695.4	4.66	4.14e-06	0.000901	0.19	0.21	Bone mineral density;	chr21:36476036	chr21:36445731~36532408:+
LUAD	cis	rs1062177	0.756	rs2915817	ENSG00000253921.1	CTB-113P19.3	4.66	4.14e-06	0.000901	0.3	0.21	Preschool internalizing problems;	chr5:151735956	chr5:151753992~151767247:+
LUAD	cis	rs914615	0.552	rs11264337	ENSG00000160766.13	GBAP1	-4.66	4.14e-06	0.000901	-0.21	-0.21	Urinary albumin-to-creatinine ratio;	chr1:155165974	chr1:155213821~155227422:-
LUAD	cis	rs914615	0.529	rs11264338	ENSG00000160766.13	GBAP1	-4.66	4.14e-06	0.000901	-0.21	-0.21	Urinary albumin-to-creatinine ratio;	chr1:155166081	chr1:155213821~155227422:-
LUAD	cis	rs4664293	0.647	rs1549385	ENSG00000226266.5	AC009961.3	-4.66	4.15e-06	0.000902	-0.28	-0.21	Monocyte percentage of white cells;	chr2:159582540	chr2:159670708~159712435:-
LUAD	cis	rs2337406	0.81	rs7161739	ENSG00000223648.3	IGHV3-64	4.66	4.15e-06	0.000902	0.26	0.21	Alzheimer's disease (late onset);	chr14:106776118	chr14:106643132~106658258:-
LUAD	cis	rs9467773	0.869	rs742090	ENSG00000124549.13	BTN2A3P	-4.66	4.15e-06	0.000902	-0.19	-0.21	Intelligence (multi-trait analysis);	chr6:26415409	chr6:26421391~26432383:+
LUAD	cis	rs12908161	0.959	rs3748376	ENSG00000259295.5	CSPG4P12	4.66	4.15e-06	0.000902	0.29	0.21	Schizophrenia;	chr15:84785121	chr15:85191438~85213905:+
LUAD	cis	rs7590268	0.697	rs10495900	ENSG00000279873.2	LINC01126	-4.66	4.15e-06	0.000903	-0.2	-0.21	Orofacial clefts;	chr2:43390020	chr2:43227210~43228855:+
LUAD	cis	rs6686842	0.56	rs12408576	ENSG00000235358.1	RP11-399E6.1	-4.66	4.15e-06	0.000903	-0.25	-0.21	Height;	chr1:40998765	chr1:41242373~41284861:+
LUAD	cis	rs2243480	1	rs59794892	ENSG00000164669.11	INTS4P1	4.66	4.15e-06	0.000903	0.37	0.21	Diabetic kidney disease;	chr7:65950886	chr7:65141225~65234216:+
LUAD	cis	rs2742234	0.541	rs871763	ENSG00000273008.1	RP11-351D16.3	4.66	4.15e-06	0.000903	0.24	0.21	Hirschsprung disease;	chr10:43238740	chr10:43136824~43138334:-
LUAD	cis	rs9549328	0.8	rs9549619	ENSG00000267868.1	RP11-120K24.3	4.66	4.16e-06	0.000903	0.25	0.21	Systolic blood pressure;	chr13:112978306	chr13:112964835~112966131:-
LUAD	cis	rs2243480	0.711	rs1626926	ENSG00000164669.11	INTS4P1	4.66	4.16e-06	0.000904	0.36	0.21	Diabetic kidney disease;	chr7:65970805	chr7:65141225~65234216:+
LUAD	cis	rs2732480	0.538	rs2732462	ENSG00000257735.1	RP11-370I10.6	4.66	4.16e-06	0.000904	0.26	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48302601	chr12:48350945~48442411:+
LUAD	cis	rs4664293	0.647	rs10192408	ENSG00000226266.5	AC009961.3	-4.66	4.16e-06	0.000904	-0.28	-0.21	Monocyte percentage of white cells;	chr2:159568083	chr2:159670708~159712435:-
LUAD	cis	rs80285556	0.579	rs11883067	ENSG00000161643.11	SIGLEC16	4.66	4.17e-06	0.000905	0.3	0.21	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50037214	chr19:49969673~49975814:+
LUAD	cis	rs394563	1	rs394563	ENSG00000216906.2	RP11-350J20.9	4.66	4.17e-06	0.000905	0.25	0.21	Dupuytren's disease;	chr6:149475878	chr6:149904243~149906418:+
LUAD	cis	rs7945705	0.806	rs12224436	ENSG00000254860.4	TMEM9B-AS1	-4.66	4.17e-06	0.000905	-0.24	-0.21	Hemoglobin concentration;	chr11:8794278	chr11:8964675~8977527:+
LUAD	cis	rs6957923	0.967	rs4496867	ENSG00000230658.1	KLHL7-AS1	4.66	4.17e-06	0.000906	0.26	0.21	Height;	chr7:23467900	chr7:23101228~23105703:-
LUAD	cis	rs6545883	0.524	rs12992614	ENSG00000271889.1	RP11-493E12.1	-4.66	4.17e-06	0.000906	-0.24	-0.21	Tuberculosis;	chr2:61365941	chr2:61151433~61162105:-
LUAD	cis	rs8031584	0.578	rs1088473	ENSG00000270015.1	RP11-540B6.6	4.66	4.17e-06	0.000906	0.16	0.21	Huntington's disease progression;	chr15:30847095	chr15:30926514~30928407:+
LUAD	cis	rs7945705	0.846	rs4929911	ENSG00000254860.4	TMEM9B-AS1	-4.66	4.17e-06	0.000906	-0.24	-0.21	Hemoglobin concentration;	chr11:8794948	chr11:8964675~8977527:+
LUAD	cis	rs9322193	0.923	rs9505982	ENSG00000268592.3	RAET1E-AS1	4.66	4.17e-06	0.000906	0.25	0.21	Lung cancer;	chr6:149618465	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.923	rs10782310	ENSG00000268592.3	RAET1E-AS1	4.66	4.17e-06	0.000906	0.25	0.21	Lung cancer;	chr6:149622458	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.923	rs10782311	ENSG00000268592.3	RAET1E-AS1	4.66	4.17e-06	0.000906	0.25	0.21	Lung cancer;	chr6:149622592	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.923	rs10747275	ENSG00000268592.3	RAET1E-AS1	4.66	4.17e-06	0.000906	0.25	0.21	Lung cancer;	chr6:149622782	chr6:149863494~149919507:+
LUAD	cis	rs2243480	0.901	rs35823062	ENSG00000232559.3	GS1-124K5.12	4.66	4.17e-06	0.000907	0.36	0.21	Diabetic kidney disease;	chr7:66500834	chr7:66554588~66576923:-
LUAD	cis	rs6802315	0.575	rs57932243	ENSG00000272087.1	RP11-379F4.7	4.66	4.17e-06	0.000907	0.23	0.21	Periodontitis (CDC/AAP);	chr3:158754187	chr3:158693120~158693768:-
LUAD	cis	rs2439831	0.681	rs3742969	ENSG00000249839.1	AC011330.5	-4.66	4.17e-06	0.000907	-0.36	-0.21	Lung cancer in ever smokers;	chr15:43329749	chr15:43663654~43684339:-
LUAD	cis	rs950169	0.649	rs12911612	ENSG00000225151.9	GOLGA2P7	-4.66	4.17e-06	0.000907	-0.3	-0.21	Schizophrenia;	chr15:84022262	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.649	rs12905952	ENSG00000225151.9	GOLGA2P7	-4.66	4.17e-06	0.000907	-0.3	-0.21	Schizophrenia;	chr15:84022509	chr15:84199311~84230136:-
LUAD	cis	rs950169	0.61	rs34529571	ENSG00000225151.9	GOLGA2P7	-4.66	4.17e-06	0.000907	-0.3	-0.21	Schizophrenia;	chr15:84023055	chr15:84199311~84230136:-
LUAD	cis	rs10463554	0.784	rs187424	ENSG00000250682.4	LINC00491	4.66	4.17e-06	0.000907	0.25	0.21	Parkinson's disease;	chr5:103251882	chr5:102609156~102671559:-
LUAD	cis	rs36093844	0.625	rs17817444	ENSG00000279742.1	RP11-700A24.1	-4.66	4.17e-06	0.000907	-0.22	-0.21	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85897069	chr11:85852557~85854943:-
LUAD	cis	rs875971	0.965	rs7794930	ENSG00000232559.3	GS1-124K5.12	-4.66	4.17e-06	0.000907	-0.24	-0.21	Aortic root size;	chr7:66313559	chr7:66554588~66576923:-
LUAD	cis	rs3096299	0.933	rs2965934	ENSG00000182376.2	RP5-1142A6.8	4.66	4.18e-06	0.000907	0.22	0.21	Multiple myeloma (IgH translocation);	chr16:89414821	chr16:88742767~88745748:+
LUAD	cis	rs4664293	0.647	rs7576644	ENSG00000226266.5	AC009961.3	-4.66	4.18e-06	0.000907	-0.28	-0.21	Monocyte percentage of white cells;	chr2:159584947	chr2:159670708~159712435:-
LUAD	cis	rs1008375	0.931	rs3796814	ENSG00000249502.1	AC006160.5	-4.66	4.18e-06	0.000907	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17600410	chr4:17587467~17614571:-
LUAD	cis	rs7208859	0.623	rs56325146	ENSG00000280069.1	CTD-2349P21.3	-4.66	4.18e-06	0.000907	-0.28	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824006	chr17:30738182~30740275:+
LUAD	cis	rs11168351	1	rs11168351	ENSG00000240399.1	RP1-228P16.1	4.66	4.18e-06	0.000908	0.2	0.21	Bipolar disorder and schizophrenia;	chr12:48009982	chr12:48054813~48055591:-
LUAD	cis	rs2380205	0.517	rs12360409	ENSG00000232807.2	RP11-536K7.3	4.66	4.18e-06	0.000908	0.23	0.21	Breast cancer;	chr10:5933835	chr10:5934270~5945900:-
LUAD	cis	rs7615952	0.605	rs11708269	ENSG00000171084.14	FAM86JP	4.66	4.18e-06	0.000909	0.37	0.21	Blood pressure (smoking interaction);	chr3:125613306	chr3:125916620~125930024:+
LUAD	cis	rs4664293	0.647	rs10198053	ENSG00000226266.5	AC009961.3	-4.66	4.18e-06	0.000909	-0.27	-0.21	Monocyte percentage of white cells;	chr2:159605169	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.669	rs10174515	ENSG00000226266.5	AC009961.3	-4.66	4.18e-06	0.000909	-0.27	-0.21	Monocyte percentage of white cells;	chr2:159605524	chr2:159670708~159712435:-
LUAD	cis	rs287982	1	rs112307255	ENSG00000269973.1	RP11-95D17.1	-4.66	4.19e-06	0.000909	-0.25	-0.21	Nonsyndromic cleft lip with cleft palate;	chr2:9842137	chr2:9936360~9939590:+
LUAD	cis	rs516805	0.561	rs2684238	ENSG00000279453.1	RP3-425C14.4	-4.66	4.19e-06	0.000909	-0.28	-0.21	Lymphocyte counts;	chr6:122085799	chr6:122436789~122439223:-
LUAD	cis	rs950169	0.922	rs11631096	ENSG00000275120.1	RP11-182J1.17	4.66	4.19e-06	0.000909	0.32	0.21	Schizophrenia;	chr15:84557698	chr15:84599434~84606463:-
LUAD	cis	rs6421571	0.564	rs11216972	ENSG00000255422.1	AP002954.4	4.66	4.19e-06	0.000909	0.33	0.21	Primary biliary cholangitis;	chr11:118715117	chr11:118704607~118750263:+
LUAD	cis	rs16873450	0.527	rs7807397	ENSG00000234800.2	PCMTD1P3	-4.66	4.19e-06	0.00091	-0.24	-0.21	Verbal memory performance (residualized delayed recall level);	chr7:23758366	chr7:23721311~23721782:-
LUAD	cis	rs7617773	0.963	rs6800730	ENSG00000228638.1	FCF1P2	-4.66	4.19e-06	0.00091	-0.24	-0.21	Coronary artery disease;	chr3:48132720	chr3:48290793~48291375:-
LUAD	cis	rs2243480	1	rs34637256	ENSG00000164669.11	INTS4P1	4.66	4.19e-06	0.00091	0.38	0.21	Diabetic kidney disease;	chr7:65895144	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs35391607	ENSG00000164669.11	INTS4P1	4.66	4.19e-06	0.00091	0.38	0.21	Diabetic kidney disease;	chr7:65895842	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs13220979	ENSG00000164669.11	INTS4P1	4.66	4.19e-06	0.00091	0.38	0.21	Diabetic kidney disease;	chr7:65898217	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs34974928	ENSG00000164669.11	INTS4P1	4.66	4.19e-06	0.00091	0.38	0.21	Diabetic kidney disease;	chr7:65899019	chr7:65141225~65234216:+
LUAD	cis	rs9926296	0.712	rs258330	ENSG00000260259.1	RP11-368I7.4	4.66	4.19e-06	0.00091	0.2	0.21	Vitiligo;	chr16:89663166	chr16:89682620~89686569:-
LUAD	cis	rs2439831	0.717	rs28495368	ENSG00000249839.1	AC011330.5	-4.66	4.19e-06	0.00091	-0.38	-0.21	Lung cancer in ever smokers;	chr15:43603444	chr15:43663654~43684339:-
LUAD	cis	rs853679	0.766	rs9368561	ENSG00000204709.4	LINC01556	4.66	4.19e-06	0.00091	0.36	0.21	Depression;	chr6:28200565	chr6:28943877~28944537:+
LUAD	cis	rs2976388	1	rs2294008	ENSG00000253741.1	CTD-2292P10.4	4.66	4.19e-06	0.000911	0.23	0.21	Urinary tract infection frequency;	chr8:142680513	chr8:142702252~142726973:-
LUAD	cis	rs642803	0.613	rs565427	ENSG00000255557.1	RP11-770G2.2	-4.66	4.2e-06	0.000911	-0.25	-0.21	Urate levels;	chr11:65765354	chr11:65745729~65771585:+
LUAD	cis	rs4664293	0.647	rs1425042	ENSG00000226266.5	AC009961.3	-4.65	4.2e-06	0.000911	-0.28	-0.21	Monocyte percentage of white cells;	chr2:159584004	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.647	rs7562850	ENSG00000226266.5	AC009961.3	-4.65	4.2e-06	0.000911	-0.28	-0.21	Monocyte percentage of white cells;	chr2:159585023	chr2:159670708~159712435:-
LUAD	cis	rs9487094	0.961	rs6911838	ENSG00000260273.1	RP11-425D10.10	4.65	4.2e-06	0.000911	0.27	0.21	Height;	chr6:109478720	chr6:109382795~109383666:+
LUAD	cis	rs2243480	1	rs34703416	ENSG00000226002.1	RP11-460N20.5	-4.65	4.2e-06	0.000911	-0.36	-0.21	Diabetic kidney disease;	chr7:65835655	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs464895	ENSG00000164669.11	INTS4P1	4.65	4.2e-06	0.000912	0.37	0.21	Diabetic kidney disease;	chr7:66062119	chr7:65141225~65234216:+
LUAD	cis	rs2562456	0.793	rs627522	ENSG00000268081.1	RP11-678G14.2	4.65	4.2e-06	0.000912	0.31	0.21	Pain;	chr19:21313002	chr19:21554640~21569237:-
LUAD	cis	rs5758511	0.68	rs56111723	ENSG00000205702.9	CYP2D7	4.65	4.2e-06	0.000912	0.2	0.21	Birth weight;	chr22:42268877	chr22:42140203~42144577:-
LUAD	cis	rs1008375	0.8	rs35463363	ENSG00000249502.1	AC006160.5	-4.65	4.2e-06	0.000913	-0.21	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17611800	chr4:17587467~17614571:-
LUAD	cis	rs4865169	0.811	rs6841086	ENSG00000269949.1	RP11-738E22.3	4.65	4.21e-06	0.000913	0.27	0.21	Breast cancer;	chr4:57037102	chr4:56960927~56961373:-
LUAD	cis	rs2243480	1	rs2462569	ENSG00000226002.1	RP11-460N20.5	4.65	4.21e-06	0.000913	0.34	0.21	Diabetic kidney disease;	chr7:66009859	chr7:65084103~65100232:+
LUAD	cis	rs7617773	0.925	rs7374376	ENSG00000228638.1	FCF1P2	4.65	4.21e-06	0.000913	0.23	0.21	Coronary artery disease;	chr3:48131197	chr3:48290793~48291375:-
LUAD	cis	rs9322193	0.923	rs9800736	ENSG00000268592.3	RAET1E-AS1	4.65	4.21e-06	0.000914	0.25	0.21	Lung cancer;	chr6:149661281	chr6:149863494~149919507:+
LUAD	cis	rs878939	0.625	rs17493485	ENSG00000230224.1	PHBP9	-4.65	4.21e-06	0.000914	-0.2	-0.21	Warfarin maintenance dose;	chr10:99584123	chr10:100248271~100249095:+
LUAD	cis	rs2933343	0.7	rs1680778	ENSG00000231305.3	RP11-723O4.2	4.65	4.21e-06	0.000914	0.22	0.21	IgG glycosylation;	chr3:128895342	chr3:128861313~128871540:-
LUAD	cis	rs42490	0.528	rs7004089	ENSG00000251136.7	RP11-37B2.1	4.65	4.21e-06	0.000914	0.21	0.21	Leprosy;	chr8:89688329	chr8:89609409~89757727:-
LUAD	cis	rs6604026	0.624	rs11800409	ENSG00000223787.2	RP4-593M8.1	4.65	4.21e-06	0.000914	0.28	0.21	Multiple sclerosis;	chr1:92715456	chr1:92580476~92580821:-
LUAD	cis	rs559928	0.606	rs17773078	ENSG00000236935.1	AP003774.1	4.65	4.22e-06	0.000915	0.3	0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64138752	chr11:64325050~64329504:-
LUAD	cis	rs559928	0.606	rs60394481	ENSG00000236935.1	AP003774.1	4.65	4.22e-06	0.000915	0.3	0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64141563	chr11:64325050~64329504:-
LUAD	cis	rs559928	0.556	rs734762	ENSG00000236935.1	AP003774.1	4.65	4.22e-06	0.000915	0.3	0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64144717	chr11:64325050~64329504:-
LUAD	cis	rs559928	0.606	rs12417635	ENSG00000236935.1	AP003774.1	4.65	4.22e-06	0.000915	0.3	0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64145256	chr11:64325050~64329504:-
LUAD	cis	rs6570726	0.791	rs401331	ENSG00000235652.6	RP11-545I5.3	4.65	4.22e-06	0.000915	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145510272	chr6:145799409~145886585:+
LUAD	cis	rs4268898	0.735	rs34125395	ENSG00000223754.1	AC008073.9	-4.65	4.22e-06	0.000916	-0.24	-0.21	Asthma;	chr2:24335373	chr2:24199839~24201698:-
LUAD	cis	rs7191700	0.644	rs12149160	ENSG00000262703.1	RP11-485G7.6	-4.65	4.22e-06	0.000916	-0.18	-0.21	Multiple sclerosis;	chr16:11345446	chr16:11348143~11349321:-
LUAD	cis	rs61270009	0.913	rs357512	ENSG00000247828.6	TMEM161B-AS1	-4.65	4.22e-06	0.000916	-0.24	-0.21	Depressive symptoms;	chr5:88222061	chr5:88268895~88436685:+
LUAD	cis	rs7923609	0.812	rs10822155	ENSG00000232075.1	MRPL35P2	-4.65	4.22e-06	0.000916	-0.25	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63311455	chr10:63634317~63634827:-
LUAD	cis	rs1062177	1	rs72802204	ENSG00000253921.1	CTB-113P19.3	-4.65	4.22e-06	0.000916	-0.31	-0.21	Preschool internalizing problems;	chr5:151803622	chr5:151753992~151767247:+
LUAD	cis	rs6539288	0.933	rs10861673	ENSG00000260329.1	RP11-412D9.4	-4.65	4.22e-06	0.000916	-0.23	-0.21	Total body bone mineral density;	chr12:106906293	chr12:106954029~106955497:-
LUAD	cis	rs2243480	1	rs160639	ENSG00000164669.11	INTS4P1	4.65	4.23e-06	0.000917	0.37	0.21	Diabetic kidney disease;	chr7:66115000	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs313824	ENSG00000164669.11	INTS4P1	4.65	4.23e-06	0.000917	0.37	0.21	Diabetic kidney disease;	chr7:66116220	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs186378	ENSG00000164669.11	INTS4P1	4.65	4.23e-06	0.000917	0.37	0.21	Diabetic kidney disease;	chr7:66117071	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs160637	ENSG00000164669.11	INTS4P1	4.65	4.23e-06	0.000917	0.37	0.21	Diabetic kidney disease;	chr7:66119331	chr7:65141225~65234216:+
LUAD	cis	rs9650657	0.572	rs11250098	ENSG00000255046.1	RP11-297N6.4	4.65	4.23e-06	0.000917	0.26	0.21	Neuroticism;	chr8:10961097	chr8:11797928~11802568:-
LUAD	cis	rs227275	0.554	rs223357	ENSG00000251288.2	RP11-10L12.2	-4.65	4.23e-06	0.000918	-0.25	-0.21	Allergic disease (asthma, hay fever or eczema);	chr4:102851095	chr4:102751401~102752641:+
LUAD	cis	rs12701220	0.817	rs1058727	ENSG00000229043.2	AC091729.9	-4.65	4.23e-06	0.000918	-0.26	-0.21	Bronchopulmonary dysplasia;	chr7:1047459	chr7:1160374~1165267:+
LUAD	cis	rs375066	0.935	rs429027	ENSG00000267058.1	RP11-15A1.3	-4.65	4.23e-06	0.000918	-0.23	-0.21	Breast cancer;	chr19:43891337	chr19:43891804~43901805:-
LUAD	cis	rs1799949	0.931	rs9912203	ENSG00000236383.6	LINC00854	4.65	4.23e-06	0.000918	0.16	0.21	Menopause (age at onset);	chr17:43367777	chr17:43216941~43305976:-
LUAD	cis	rs2898681	0.614	rs28758563	ENSG00000248375.1	RP11-177B4.1	-4.65	4.23e-06	0.000918	-0.33	-0.21	Optic nerve measurement (cup area);	chr4:52811610	chr4:52720081~52720831:-
LUAD	cis	rs2243480	1	rs59794892	ENSG00000229886.1	RP5-1132H15.3	4.65	4.23e-06	0.000918	0.36	0.21	Diabetic kidney disease;	chr7:65950886	chr7:66025126~66031544:-
LUAD	cis	rs2735413	0.599	rs73562710	ENSG00000276007.1	RP11-358L22.3	4.65	4.23e-06	0.000918	0.29	0.21	Systolic blood pressure (alcohol consumption interaction);	chr16:78090709	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.564	rs79006334	ENSG00000276007.1	RP11-358L22.3	4.65	4.23e-06	0.000918	0.29	0.21	Systolic blood pressure (alcohol consumption interaction);	chr16:78091057	chr16:78123243~78124332:+
LUAD	cis	rs2028299	0.879	rs4932263	ENSG00000259677.1	RP11-493E3.1	4.65	4.24e-06	0.000919	0.25	0.21	Type 2 diabetes;	chr15:89896395	chr15:89876540~89877285:+
LUAD	cis	rs2243480	0.711	rs2420172	ENSG00000232559.3	GS1-124K5.12	-4.65	4.24e-06	0.000919	-0.36	-0.21	Diabetic kidney disease;	chr7:66170354	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs2420171	ENSG00000232559.3	GS1-124K5.12	-4.65	4.24e-06	0.000919	-0.36	-0.21	Diabetic kidney disease;	chr7:66172773	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs6974723	ENSG00000232559.3	GS1-124K5.12	-4.65	4.24e-06	0.000919	-0.36	-0.21	Diabetic kidney disease;	chr7:66172952	chr7:66554588~66576923:-
LUAD	cis	rs783540	0.656	rs783524	ENSG00000276710.3	CSPG4P8	4.65	4.24e-06	0.000919	0.21	0.21	Schizophrenia;	chr15:82615393	chr15:82459472~82477258:+
LUAD	cis	rs11157436	0.602	rs2032441	ENSG00000211813.2	TRAV34	4.65	4.24e-06	0.000919	0.24	0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22157682	chr14:22207522~22208129:+
LUAD	cis	rs910316	0.967	rs2024653	ENSG00000279594.1	RP11-950C14.10	4.65	4.24e-06	0.00092	0.24	0.21	Height;	chr14:75128451	chr14:75011269~75012851:-
LUAD	cis	rs202072	0.676	rs202048	ENSG00000272379.1	RP1-257A7.5	4.65	4.24e-06	0.00092	0.36	0.21	HIV-1 viral setpoint;	chr6:13274269	chr6:13290018~13290490:-
LUAD	cis	rs8103033	0.786	rs997104	ENSG00000226025.8	LGALS17A	-4.65	4.24e-06	0.00092	-0.23	-0.21	Obesity-related traits;	chr19:39658690	chr19:39679374~39686373:+
LUAD	cis	rs507080	0.922	rs508640	ENSG00000278376.1	RP11-158I9.8	-4.65	4.24e-06	0.00092	-0.23	-0.21	Serum metabolite levels;	chr11:118693704	chr11:118791254~118793137:+
LUAD	cis	rs507080	0.922	rs471227	ENSG00000278376.1	RP11-158I9.8	-4.65	4.24e-06	0.00092	-0.23	-0.21	Serum metabolite levels;	chr11:118693892	chr11:118791254~118793137:+
LUAD	cis	rs507080	0.922	rs516153	ENSG00000278376.1	RP11-158I9.8	-4.65	4.24e-06	0.00092	-0.23	-0.21	Serum metabolite levels;	chr11:118694053	chr11:118791254~118793137:+
LUAD	cis	rs507080	0.922	rs518028	ENSG00000278376.1	RP11-158I9.8	-4.65	4.24e-06	0.00092	-0.23	-0.21	Serum metabolite levels;	chr11:118694273	chr11:118791254~118793137:+
LUAD	cis	rs507080	0.922	rs519982	ENSG00000278376.1	RP11-158I9.8	-4.65	4.24e-06	0.00092	-0.23	-0.21	Serum metabolite levels;	chr11:118694522	chr11:118791254~118793137:+
LUAD	cis	rs875971	0.66	rs6460308	ENSG00000224316.1	RP11-479O9.2	-4.65	4.24e-06	0.00092	-0.21	-0.21	Aortic root size;	chr7:66619753	chr7:65773620~65802067:+
LUAD	cis	rs2380205	0.651	rs6602312	ENSG00000232807.2	RP11-536K7.3	4.65	4.25e-06	0.00092	0.21	0.21	Breast cancer;	chr10:5884968	chr10:5934270~5945900:-
LUAD	cis	rs10129255	0.913	rs10140943	ENSG00000274576.2	IGHV2-70	4.65	4.25e-06	0.000921	0.19	0.21	Kawasaki disease;	chr14:106767441	chr14:106770577~106771020:-
LUAD	cis	rs73242632	1	rs7673980	ENSG00000269949.1	RP11-738E22.3	4.65	4.25e-06	0.000921	0.47	0.21	Congenital heart disease (maternal effect);	chr4:56942377	chr4:56960927~56961373:-
LUAD	cis	rs2735413	0.563	rs11647117	ENSG00000276007.1	RP11-358L22.3	4.65	4.25e-06	0.000921	0.29	0.21	Systolic blood pressure (alcohol consumption interaction);	chr16:78024165	chr16:78123243~78124332:+
LUAD	cis	rs854462	1	rs854469	ENSG00000274767.1	AC131056.3	-4.65	4.25e-06	0.000921	-0.3	-0.21	Blood protein levels;	chr17:36062001	chr17:36183235~36196471:+
LUAD	cis	rs4664293	0.625	rs35241460	ENSG00000226266.5	AC009961.3	4.65	4.25e-06	0.000921	0.28	0.21	Monocyte percentage of white cells;	chr2:159651689	chr2:159670708~159712435:-
LUAD	cis	rs848490	0.508	rs6975810	ENSG00000214293.7	APTR	4.65	4.25e-06	0.000921	0.23	0.21	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77659701	chr7:77657660~77696265:-
LUAD	cis	rs2919009	0.6	rs55706145	ENSG00000271670.1	RP11-95I16.4	4.65	4.25e-06	0.000922	0.27	0.21	Obesity-related traits;	chr10:120790581	chr10:120879256~120880667:-
LUAD	cis	rs7208859	0.623	rs216439	ENSG00000266490.1	CTD-2349P21.9	4.65	4.25e-06	0.000922	0.32	0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30600866	chr17:30792372~30792833:+
LUAD	cis	rs2732480	0.5	rs1552550	ENSG00000240399.1	RP1-228P16.1	4.65	4.26e-06	0.000923	0.21	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48249568	chr12:48054813~48055591:-
LUAD	cis	rs12908161	1	rs60957376	ENSG00000259295.5	CSPG4P12	4.65	4.26e-06	0.000923	0.29	0.21	Schizophrenia;	chr15:84737561	chr15:85191438~85213905:+
LUAD	cis	rs338389	0.564	rs338393	ENSG00000260657.2	RP11-315D16.4	-4.65	4.26e-06	0.000923	-0.25	-0.21	Survival in rectal cancer;	chr15:67964657	chr15:68267792~68277994:-
LUAD	cis	rs453301	0.571	rs330054	ENSG00000253981.4	ALG1L13P	-4.65	4.27e-06	0.000924	-0.24	-0.21	Joint mobility (Beighton score);	chr8:9230781	chr8:8236003~8244667:-
LUAD	cis	rs6142102	0.961	rs4911392	ENSG00000275784.1	RP5-1125A11.6	-4.65	4.27e-06	0.000925	-0.23	-0.21	Skin pigmentation;	chr20:33982712	chr20:33989480~33991818:-
LUAD	cis	rs6142102	0.961	rs4911393	ENSG00000275784.1	RP5-1125A11.6	-4.65	4.27e-06	0.000925	-0.23	-0.21	Skin pigmentation;	chr20:33983120	chr20:33989480~33991818:-
LUAD	cis	rs113835537	0.877	rs2275998	ENSG00000255517.5	CTD-3074O7.5	-4.65	4.28e-06	0.000927	-0.28	-0.21	Airway imaging phenotypes;	chr11:66559110	chr11:66473490~66480233:-
LUAD	cis	rs74233809	1	rs11191472	ENSG00000213277.3	MARCKSL1P1	4.65	4.28e-06	0.000927	0.36	0.21	Birth weight;	chr10:102947259	chr10:103175554~103176094:+
LUAD	cis	rs651907	0.535	rs13085776	ENSG00000244119.1	PDCL3P4	4.65	4.28e-06	0.000927	0.22	0.21	Colorectal cancer;	chr3:101786663	chr3:101712472~101713191:+
LUAD	cis	rs2522056	0.932	rs1012793	ENSG00000233006.5	AC034220.3	-4.65	4.28e-06	0.000927	-0.22	-0.21	Fibrinogen;Lymphocyte counts;	chr5:132445653	chr5:132311285~132369916:-
LUAD	cis	rs2562456	0.833	rs2359145	ENSG00000268081.1	RP11-678G14.2	4.65	4.28e-06	0.000928	0.34	0.21	Pain;	chr19:21409791	chr19:21554640~21569237:-
LUAD	cis	rs6565180	1	rs8049108	ENSG00000273724.1	RP11-347C12.12	-4.65	4.28e-06	0.000928	-0.22	-0.21	Tonsillectomy;	chr16:30365165	chr16:30336400~30343336:+
LUAD	cis	rs9322193	0.962	rs2151912	ENSG00000268592.3	RAET1E-AS1	4.65	4.28e-06	0.000928	0.26	0.21	Lung cancer;	chr6:149831772	chr6:149863494~149919507:+
LUAD	cis	rs2562456	0.833	rs61035285	ENSG00000268081.1	RP11-678G14.2	4.65	4.28e-06	0.000928	0.34	0.21	Pain;	chr19:21329475	chr19:21554640~21569237:-
LUAD	cis	rs2834288	0.608	rs2017190	ENSG00000237945.6	LINC00649	4.65	4.28e-06	0.000928	0.27	0.21	Gut microbiota (bacterial taxa);	chr21:33938609	chr21:33915534~33977691:+
LUAD	cis	rs4660214	0.666	rs2275188	ENSG00000228060.1	RP11-69E11.8	4.65	4.28e-06	0.000928	0.19	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39283249	chr1:39565160~39573203:+
LUAD	cis	rs62158211	0.691	rs1964463	ENSG00000234997.1	AC016745.3	4.65	4.29e-06	0.000929	0.25	0.21	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113311444	chr2:113424495~113425324:+
LUAD	cis	rs801193	1	rs2659912	ENSG00000224316.1	RP11-479O9.2	4.65	4.29e-06	0.000929	0.21	0.21	Aortic root size;	chr7:66693012	chr7:65773620~65802067:+
LUAD	cis	rs7712401	0.546	rs10044921	ENSG00000263432.2	RN7SL689P	4.65	4.29e-06	0.000929	0.26	0.21	Mean platelet volume;	chr5:122843662	chr5:123022487~123022783:-
LUAD	cis	rs910316	1	rs8003506	ENSG00000279594.1	RP11-950C14.10	-4.65	4.29e-06	0.00093	-0.24	-0.21	Height;	chr14:75119585	chr14:75011269~75012851:-
LUAD	cis	rs875971	0.964	rs6945019	ENSG00000232559.3	GS1-124K5.12	4.65	4.3e-06	0.00093	0.24	0.21	Aortic root size;	chr7:66457471	chr7:66554588~66576923:-
LUAD	cis	rs11157436	0.918	rs3811285	ENSG00000211813.2	TRAV34	4.65	4.3e-06	0.000931	0.25	0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22155322	chr14:22207522~22208129:+
LUAD	cis	rs9584850	0.834	rs9584855	ENSG00000231194.1	FARP1-AS1	-4.65	4.3e-06	0.000931	-0.25	-0.21	Neuroticism;	chr13:98466746	chr13:98435405~98435840:-
LUAD	cis	rs6545883	0.524	rs2463101	ENSG00000271889.1	RP11-493E12.1	-4.65	4.3e-06	0.000931	-0.24	-0.21	Tuberculosis;	chr2:61347287	chr2:61151433~61162105:-
LUAD	cis	rs34779708	0.741	rs34397613	ENSG00000271335.4	RP11-324I22.4	4.65	4.3e-06	0.000931	0.22	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35261385	chr10:35314552~35336401:-
LUAD	cis	rs891378	1	rs2564974	ENSG00000274245.1	RP11-357P18.2	4.65	4.3e-06	0.000931	0.27	0.21	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207310100	chr1:207372559~207373252:+
LUAD	cis	rs12935418	0.733	rs11150329	ENSG00000261061.1	RP11-303E16.2	-4.65	4.3e-06	0.000931	-0.3	-0.21	Mean corpuscular volume;	chr16:80945189	chr16:81030770~81031485:+
LUAD	cis	rs228614	0.51	rs223397	ENSG00000251288.2	RP11-10L12.2	-4.65	4.3e-06	0.000932	-0.25	-0.21	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102821494	chr4:102751401~102752641:+
LUAD	cis	rs2492286	0.518	rs2712412	ENSG00000242551.2	POU5F1P6	-4.65	4.3e-06	0.000932	-0.26	-0.21	Eosinophil counts;	chr3:128647208	chr3:128674735~128677005:-
LUAD	cis	rs9473147	0.543	rs9349417	ENSG00000270761.1	RP11-385F7.1	-4.65	4.3e-06	0.000932	-0.24	-0.21	Platelet distribution width;Mean platelet volume;	chr6:47612921	chr6:47477243~47477572:-
LUAD	cis	rs9369695	0.883	rs9381581	ENSG00000270761.1	RP11-385F7.1	-4.65	4.3e-06	0.000932	-0.24	-0.21	Reticulocyte count;	chr6:47612959	chr6:47477243~47477572:-
LUAD	cis	rs875971	1	rs6945843	ENSG00000232559.3	GS1-124K5.12	-4.65	4.3e-06	0.000932	-0.25	-0.21	Aortic root size;	chr7:66269796	chr7:66554588~66576923:-
LUAD	cis	rs6545883	0.558	rs7587389	ENSG00000271889.1	RP11-493E12.1	-4.65	4.3e-06	0.000932	-0.25	-0.21	Tuberculosis;	chr2:61422656	chr2:61151433~61162105:-
LUAD	cis	rs2732480	0.5	rs11168468	ENSG00000240399.1	RP1-228P16.1	4.65	4.3e-06	0.000932	0.21	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48218682	chr12:48054813~48055591:-
LUAD	cis	rs11064837	0.55	rs7304996	ENSG00000248636.5	RP11-768F21.1	4.65	4.3e-06	0.000932	0.25	0.21	Schizophrenia;	chr12:119656894	chr12:119387987~119668079:-
LUAD	cis	rs8098244	0.617	rs35943794	ENSG00000264745.1	TTC39C-AS1	4.65	4.3e-06	0.000932	0.21	0.21	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23826485	chr18:23994213~24015339:-
LUAD	cis	rs9322193	0.923	rs12174716	ENSG00000268592.3	RAET1E-AS1	4.65	4.31e-06	0.000933	0.25	0.21	Lung cancer;	chr6:149644487	chr6:149863494~149919507:+
LUAD	cis	rs6545883	0.507	rs34668697	ENSG00000271889.1	RP11-493E12.1	-4.65	4.31e-06	0.000933	-0.24	-0.21	Tuberculosis;	chr2:61341214	chr2:61151433~61162105:-
LUAD	cis	rs5758659	0.737	rs10854749	ENSG00000227370.1	RP4-669P10.19	-4.65	4.31e-06	0.000933	-0.19	-0.21	Cognitive function;	chr22:42051337	chr22:42132543~42132998:+
LUAD	cis	rs9322193	0.576	rs7452592	ENSG00000223701.3	RAET1E-AS1	4.65	4.31e-06	0.000933	0.31	0.21	Lung cancer;	chr6:149875445	chr6:149884431~149919508:+
LUAD	cis	rs7727544	0.716	rs7701414	ENSG00000233006.5	AC034220.3	4.65	4.31e-06	0.000933	0.18	0.21	Blood metabolite levels;	chr5:132250265	chr5:132311285~132369916:-
LUAD	cis	rs9473147	0.516	rs9357546	ENSG00000270761.1	RP11-385F7.1	-4.65	4.31e-06	0.000933	-0.24	-0.21	Platelet distribution width;Mean platelet volume;	chr6:47581759	chr6:47477243~47477572:-
LUAD	cis	rs9322193	0.923	rs4870052	ENSG00000268592.3	RAET1E-AS1	4.65	4.31e-06	0.000934	0.26	0.21	Lung cancer;	chr6:149839978	chr6:149863494~149919507:+
LUAD	cis	rs2562456	0.752	rs7258562	ENSG00000268081.1	RP11-678G14.2	4.65	4.31e-06	0.000934	0.33	0.21	Pain;	chr19:21331762	chr19:21554640~21569237:-
LUAD	cis	rs11992162	0.569	rs35283519	ENSG00000227888.4	FAM66A	-4.65	4.31e-06	0.000934	-0.28	-0.21	Monocyte count;	chr8:11974152	chr8:12362019~12388296:+
LUAD	cis	rs2028299	0.879	rs4932262	ENSG00000259677.1	RP11-493E3.1	4.65	4.32e-06	0.000934	0.25	0.21	Type 2 diabetes;	chr15:89896365	chr15:89876540~89877285:+
LUAD	cis	rs875971	1	rs12532998	ENSG00000232559.3	GS1-124K5.12	4.65	4.32e-06	0.000935	0.24	0.21	Aortic root size;	chr7:66502472	chr7:66554588~66576923:-
LUAD	cis	rs12022452	0.822	rs7514623	ENSG00000238287.1	RP11-656D10.3	-4.65	4.32e-06	0.000935	-0.33	-0.21	Age-related hearing impairment (SNP x SNP interaction);	chr1:40559330	chr1:40493157~40508661:-
LUAD	cis	rs7189233	0.531	rs1072910	ENSG00000279344.1	RP11-44F14.7	4.65	4.32e-06	0.000936	0.17	0.21	Intelligence (multi-trait analysis);	chr16:53465687	chr16:53478957~53481550:-
LUAD	cis	rs7189233	0.55	rs4784312	ENSG00000279344.1	RP11-44F14.7	4.65	4.32e-06	0.000936	0.17	0.21	Intelligence (multi-trait analysis);	chr16:53464490	chr16:53478957~53481550:-
LUAD	cis	rs7985	0.725	rs1007476	ENSG00000244625.4	MIATNB	-4.65	4.32e-06	0.000936	-0.22	-0.21	Electroencephalogram traits;	chr22:26660685	chr22:26672767~26780207:+
LUAD	cis	rs2243480	1	rs34703416	ENSG00000229886.1	RP5-1132H15.3	4.65	4.33e-06	0.000936	0.37	0.21	Diabetic kidney disease;	chr7:65835655	chr7:66025126~66031544:-
LUAD	cis	rs559928	1	rs11601872	ENSG00000236935.1	AP003774.1	4.65	4.33e-06	0.000937	0.29	0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64380155	chr11:64325050~64329504:-
LUAD	cis	rs6714710	0.603	rs34974566	ENSG00000230606.9	AC159540.1	-4.65	4.33e-06	0.000937	-0.22	-0.21	Posterior cortical atrophy and Alzheimer's disease;	chr2:97935836	chr2:97416165~97433527:-
LUAD	cis	rs6714710	0.603	rs35255677	ENSG00000230606.9	AC159540.1	-4.65	4.33e-06	0.000937	-0.22	-0.21	Posterior cortical atrophy and Alzheimer's disease;	chr2:97951357	chr2:97416165~97433527:-
LUAD	cis	rs1106529	0.515	rs1547848	ENSG00000226172.2	RP4-712E4.1	4.65	4.33e-06	0.000937	0.29	0.21	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);	chr1:118913572	chr1:119000344~119001392:-
LUAD	cis	rs11051970	0.614	rs2728684	ENSG00000274964.1	RP11-817I4.1	-4.65	4.33e-06	0.000937	-0.24	-0.21	Response to tocilizumab in rheumatoid arthritis;	chr12:32422731	chr12:32339368~32340724:+
LUAD	cis	rs1502844	0.514	rs3105474	ENSG00000250682.4	LINC00491	4.65	4.33e-06	0.000937	0.25	0.21	Schizophrenia;	chr5:102566331	chr5:102609156~102671559:-
LUAD	cis	rs2288884	0.806	rs12460587	ENSG00000269959.1	SPACA6P-AS	-4.65	4.33e-06	0.000937	-0.28	-0.21	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52083666	chr19:51685363~51693456:-
LUAD	cis	rs1799949	0.965	rs7212284	ENSG00000236383.6	LINC00854	-4.65	4.33e-06	0.000937	-0.16	-0.21	Menopause (age at onset);	chr17:43053924	chr17:43216941~43305976:-
LUAD	cis	rs17772222	0.74	rs10143744	ENSG00000258789.1	RP11-507K2.3	-4.65	4.33e-06	0.000937	-0.26	-0.21	Coronary artery calcification;	chr14:88508073	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.74	rs1999177	ENSG00000258789.1	RP11-507K2.3	-4.65	4.33e-06	0.000937	-0.26	-0.21	Coronary artery calcification;	chr14:88508298	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.74	rs1999176	ENSG00000258789.1	RP11-507K2.3	-4.65	4.33e-06	0.000937	-0.26	-0.21	Coronary artery calcification;	chr14:88508371	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.74	rs1864746	ENSG00000258789.1	RP11-507K2.3	-4.65	4.33e-06	0.000937	-0.26	-0.21	Coronary artery calcification;	chr14:88508455	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.74	rs1864747	ENSG00000258789.1	RP11-507K2.3	-4.65	4.33e-06	0.000937	-0.26	-0.21	Coronary artery calcification;	chr14:88508523	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.74	rs7151164	ENSG00000258789.1	RP11-507K2.3	-4.65	4.33e-06	0.000937	-0.26	-0.21	Coronary artery calcification;	chr14:88509329	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.74	rs12433026	ENSG00000258789.1	RP11-507K2.3	-4.65	4.33e-06	0.000937	-0.26	-0.21	Coronary artery calcification;	chr14:88509495	chr14:88551597~88552493:+
LUAD	cis	rs2243480	1	rs313831	ENSG00000164669.11	INTS4P1	4.65	4.33e-06	0.000938	0.37	0.21	Diabetic kidney disease;	chr7:66086239	chr7:65141225~65234216:+
LUAD	cis	rs1008375	0.932	rs6835077	ENSG00000249502.1	AC006160.5	-4.65	4.33e-06	0.000938	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17651662	chr4:17587467~17614571:-
LUAD	cis	rs9467773	0.869	rs1796521	ENSG00000124549.13	BTN2A3P	-4.65	4.33e-06	0.000938	-0.19	-0.21	Intelligence (multi-trait analysis);	chr6:26421164	chr6:26421391~26432383:+
LUAD	cis	rs950169	0.881	rs72750843	ENSG00000275120.1	RP11-182J1.17	4.65	4.33e-06	0.000938	0.32	0.21	Schizophrenia;	chr15:84592552	chr15:84599434~84606463:-
LUAD	cis	rs11250098	0.567	rs4326350	ENSG00000255046.1	RP11-297N6.4	-4.65	4.34e-06	0.000938	-0.25	-0.21	Morning vs. evening chronotype;	chr8:10906145	chr8:11797928~11802568:-
LUAD	cis	rs9545047	0.625	rs9593391	ENSG00000227354.5	RBM26-AS1	-4.65	4.34e-06	0.000938	-0.22	-0.21	Schizophrenia;	chr13:79329168	chr13:79406309~79424328:+
LUAD	cis	rs11671005	0.735	rs34873624	ENSG00000268912.1	CTD-2619J13.17	-4.65	4.34e-06	0.000939	-0.28	-0.21	Mean platelet volume;	chr19:58432035	chr19:58428632~58431148:-
LUAD	cis	rs11671005	0.693	rs34230465	ENSG00000268912.1	CTD-2619J13.17	-4.65	4.34e-06	0.000939	-0.28	-0.21	Mean platelet volume;	chr19:58432209	chr19:58428632~58431148:-
LUAD	cis	rs11671005	0.735	rs3764529	ENSG00000268912.1	CTD-2619J13.17	-4.65	4.34e-06	0.000939	-0.28	-0.21	Mean platelet volume;	chr19:58433722	chr19:58428632~58431148:-
LUAD	cis	rs2304003	1	rs1560594	ENSG00000235192.1	AC009495.2	4.65	4.34e-06	0.000939	0.25	0.21	Social communication problems;	chr2:165843288	chr2:165794851~165810010:+
LUAD	cis	rs4142110	0.628	rs441079	ENSG00000271216.1	LINC01050	-4.65	4.34e-06	0.00094	-0.24	-0.21	Nephrolithiasis;	chr13:42222986	chr13:42810366~42812562:-
LUAD	cis	rs4142110	0.658	rs431307	ENSG00000271216.1	LINC01050	-4.65	4.34e-06	0.00094	-0.24	-0.21	Nephrolithiasis;	chr13:42223201	chr13:42810366~42812562:-
LUAD	cis	rs2303759	0.709	rs10414921	ENSG00000268686.1	AC010524.2	-4.65	4.35e-06	0.00094	-0.31	-0.21	Multiple sclerosis;	chr19:49319790	chr19:49368705~49388081:-
LUAD	cis	rs10129255	0.957	rs11846893	ENSG00000211967.3	IGHV3-53	-4.65	4.35e-06	0.000941	-0.16	-0.21	Kawasaki disease;	chr14:106779068	chr14:106592676~106593347:-
LUAD	cis	rs7665090	1	rs735403	ENSG00000246560.2	RP11-10L12.4	-4.65	4.35e-06	0.000941	-0.25	-0.21	Primary biliary cholangitis;	chr4:102632386	chr4:102828055~102844075:+
LUAD	cis	rs4601821	0.583	rs1893696	ENSG00000270179.1	RP11-159N11.4	-4.65	4.35e-06	0.000941	-0.21	-0.21	Alcoholic chronic pancreatitis;	chr11:113335553	chr11:113368478~113369117:+
LUAD	cis	rs3096299	0.967	rs2911253	ENSG00000182376.2	RP5-1142A6.8	4.65	4.35e-06	0.000942	0.22	0.21	Multiple myeloma (IgH translocation);	chr16:89422179	chr16:88742767~88745748:+
LUAD	cis	rs507080	0.922	rs478371	ENSG00000278376.1	RP11-158I9.8	-4.65	4.35e-06	0.000942	-0.23	-0.21	Serum metabolite levels;	chr11:118694627	chr11:118791254~118793137:+
LUAD	cis	rs17772222	0.917	rs61986669	ENSG00000258983.2	RP11-507K2.2	4.65	4.36e-06	0.000942	0.25	0.21	Coronary artery calcification;	chr14:88727121	chr14:88499334~88515502:+
LUAD	cis	rs7927592	0.513	rs531163	ENSG00000212093.1	AP000807.1	4.65	4.36e-06	0.000942	0.21	0.21	Total body bone mineral density;	chr11:68427028	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.513	rs630225	ENSG00000212093.1	AP000807.1	4.65	4.36e-06	0.000942	0.21	0.21	Total body bone mineral density;	chr11:68427143	chr11:68506083~68506166:-
LUAD	cis	rs11976180	1	rs1919951	ENSG00000204959.4	ARHGEF34P	4.65	4.36e-06	0.000942	0.26	0.21	Obesity-related traits;	chr7:144071798	chr7:144272445~144286966:-
LUAD	cis	rs6840360	1	rs6823421	ENSG00000270265.1	RP11-731D1.4	-4.65	4.36e-06	0.000942	-0.21	-0.21	Intelligence (multi-trait analysis);	chr4:151683567	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.967	rs6823423	ENSG00000270265.1	RP11-731D1.4	-4.65	4.36e-06	0.000942	-0.21	-0.21	Intelligence (multi-trait analysis);	chr4:151683571	chr4:151333775~151353224:-
LUAD	cis	rs6732565	1	rs6732565	ENSG00000235721.1	AC013268.3	4.65	4.36e-06	0.000942	0.23	0.21	Rheumatoid arthritis;	chr2:110850255	chr2:110007675~110010783:+
LUAD	cis	rs9322193	0.923	rs9383812	ENSG00000268592.3	RAET1E-AS1	4.65	4.36e-06	0.000942	0.25	0.21	Lung cancer;	chr6:149712355	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.847	rs9383844	ENSG00000268592.3	RAET1E-AS1	4.65	4.36e-06	0.000942	0.25	0.21	Lung cancer;	chr6:149716268	chr6:149863494~149919507:+
LUAD	cis	rs9545047	0.604	rs9285310	ENSG00000227354.5	RBM26-AS1	-4.65	4.36e-06	0.000943	-0.22	-0.21	Schizophrenia;	chr13:79328340	chr13:79406309~79424328:+
LUAD	cis	rs7182621	0.622	rs12904160	ENSG00000259363.4	CTD-2054N24.2	-4.65	4.36e-06	0.000943	-0.25	-0.21	Colonoscopy-negative controls vs population controls;	chr15:99869471	chr15:99807023~99877148:+
LUAD	cis	rs950169	0.922	rs11639244	ENSG00000275120.1	RP11-182J1.17	4.65	4.36e-06	0.000943	0.33	0.21	Schizophrenia;	chr15:84163898	chr15:84599434~84606463:-
LUAD	cis	rs9545047	0.604	rs314695	ENSG00000227354.5	RBM26-AS1	-4.65	4.36e-06	0.000943	-0.22	-0.21	Schizophrenia;	chr13:79432206	chr13:79406309~79424328:+
LUAD	cis	rs1061377	0.748	rs35904472	ENSG00000249685.1	RP11-360F5.3	4.65	4.36e-06	0.000944	0.25	0.21	Uric acid levels;	chr4:39094901	chr4:39133913~39135608:+
LUAD	cis	rs1061377	0.748	rs10856841	ENSG00000249685.1	RP11-360F5.3	4.65	4.36e-06	0.000944	0.25	0.21	Uric acid levels;	chr4:39095240	chr4:39133913~39135608:+
LUAD	cis	rs1964356	0.524	rs7839585	ENSG00000253893.2	FAM85B	4.65	4.36e-06	0.000944	0.24	0.21	Mean corpuscular volume;	chr8:8996725	chr8:8167819~8226614:-
LUAD	cis	rs41369048	0.669	rs80327434	ENSG00000272823.1	RP11-295M18.6	-4.65	4.36e-06	0.000944	-0.33	-0.21	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220850961	chr1:220828676~220829211:-
LUAD	cis	rs2028299	0.959	rs4932144	ENSG00000259677.1	RP11-493E3.1	4.65	4.37e-06	0.000944	0.26	0.21	Type 2 diabetes;	chr15:89828870	chr15:89876540~89877285:+
LUAD	cis	rs5758511	0.633	rs5758690	ENSG00000205702.9	CYP2D7	4.65	4.37e-06	0.000945	0.2	0.21	Birth weight;	chr22:42272289	chr22:42140203~42144577:-
LUAD	cis	rs6860806	1	rs6860806	ENSG00000233006.5	AC034220.3	-4.65	4.37e-06	0.000945	-0.18	-0.21	Breast cancer;	chr5:132304843	chr5:132311285~132369916:-
LUAD	cis	rs7829975	0.511	rs2976906	ENSG00000173295.6	FAM86B3P	4.65	4.37e-06	0.000945	0.22	0.21	Mood instability;	chr8:8484905	chr8:8228595~8244865:+
LUAD	cis	rs1555322	0.53	rs2425042	ENSG00000126005.14	MMP24-AS1	-4.65	4.37e-06	0.000946	-0.29	-0.21	Attention deficit hyperactivity disorder;	chr20:35278092	chr20:35216462~35278131:-
LUAD	cis	rs1555322	0.53	rs7004	ENSG00000126005.14	MMP24-AS1	-4.65	4.37e-06	0.000946	-0.29	-0.21	Attention deficit hyperactivity disorder;	chr20:35278950	chr20:35216462~35278131:-
LUAD	cis	rs11122895	0.791	rs10864876	ENSG00000236307.2	EEF1E1P1	4.65	4.38e-06	0.000946	0.23	0.21	Allergic sensitization;	chr2:111712414	chr2:111887914~111888741:+
LUAD	cis	rs9473147	0.543	rs4711880	ENSG00000270761.1	RP11-385F7.1	-4.65	4.38e-06	0.000947	-0.24	-0.21	Platelet distribution width;Mean platelet volume;	chr6:47512940	chr6:47477243~47477572:-
LUAD	cis	rs9473147	0.543	rs9473126	ENSG00000270761.1	RP11-385F7.1	-4.65	4.38e-06	0.000947	-0.24	-0.21	Platelet distribution width;Mean platelet volume;	chr6:47514097	chr6:47477243~47477572:-
LUAD	cis	rs9473147	0.543	rs4715025	ENSG00000270761.1	RP11-385F7.1	-4.65	4.38e-06	0.000947	-0.24	-0.21	Platelet distribution width;Mean platelet volume;	chr6:47515917	chr6:47477243~47477572:-
LUAD	cis	rs9473147	0.516	rs7767350	ENSG00000270761.1	RP11-385F7.1	-4.65	4.38e-06	0.000947	-0.24	-0.21	Platelet distribution width;Mean platelet volume;	chr6:47517390	chr6:47477243~47477572:-
LUAD	cis	rs9473147	0.516	rs10948363	ENSG00000270761.1	RP11-385F7.1	-4.65	4.38e-06	0.000947	-0.24	-0.21	Platelet distribution width;Mean platelet volume;	chr6:47520026	chr6:47477243~47477572:-
LUAD	cis	rs7617773	0.963	rs12494304	ENSG00000228638.1	FCF1P2	4.65	4.38e-06	0.000947	0.23	0.21	Coronary artery disease;	chr3:48136539	chr3:48290793~48291375:-
LUAD	cis	rs603446	0.967	rs180346	ENSG00000254851.1	RP11-109L13.1	-4.65	4.38e-06	0.000947	-0.26	-0.21	Triglycerides;	chr11:116741943	chr11:117135528~117138582:+
LUAD	cis	rs6687758	0.687	rs12137323	ENSG00000227925.1	RP11-191N8.2	4.65	4.38e-06	0.000948	0.29	0.21	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221952186	chr1:221827666~221840666:-
LUAD	cis	rs2732480	0.5	rs2450989	ENSG00000240399.1	RP1-228P16.1	-4.65	4.38e-06	0.000948	-0.21	-0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48259625	chr12:48054813~48055591:-
LUAD	cis	rs2115630	1	rs8037423	ENSG00000229212.6	RP11-561C5.4	4.65	4.39e-06	0.000948	0.24	0.21	P wave terminal force;	chr15:84812263	chr15:85205440~85234795:-
LUAD	cis	rs6687758	0.687	rs13375176	ENSG00000200033.1	RNU6-403P	4.65	4.39e-06	0.000948	0.27	0.21	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221926523	chr1:221837334~221837437:-
LUAD	cis	rs11089937	0.667	rs11704024	ENSG00000211638.2	IGLV8-61	-4.65	4.39e-06	0.000949	-0.26	-0.21	Periodontitis (PAL4Q3);	chr22:22151195	chr22:22098700~22099212:+
LUAD	cis	rs6860806	0.661	rs1588263	ENSG00000233006.5	AC034220.3	4.65	4.39e-06	0.000949	0.18	0.21	Breast cancer;	chr5:132241465	chr5:132311285~132369916:-
LUAD	cis	rs2911132	0.564	rs13181579	ENSG00000248734.2	CTD-2260A17.1	4.65	4.39e-06	0.000949	0.22	0.21	Urate levels (BMI interaction);	chr5:96755234	chr5:96784777~96785999:+
LUAD	cis	rs6545883	0.507	rs2442025	ENSG00000271889.1	RP11-493E12.1	-4.65	4.39e-06	0.000949	-0.24	-0.21	Tuberculosis;	chr2:61344310	chr2:61151433~61162105:-
LUAD	cis	rs6545883	0.524	rs2593631	ENSG00000271889.1	RP11-493E12.1	-4.65	4.39e-06	0.000949	-0.24	-0.21	Tuberculosis;	chr2:61345151	chr2:61151433~61162105:-
LUAD	cis	rs6545883	0.542	rs2593628	ENSG00000271889.1	RP11-493E12.1	-4.65	4.39e-06	0.000949	-0.24	-0.21	Tuberculosis;	chr2:61346152	chr2:61151433~61162105:-
LUAD	cis	rs34779708	0.931	rs11010077	ENSG00000271335.4	RP11-324I22.4	-4.65	4.39e-06	0.000949	-0.21	-0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35039160	chr10:35314552~35336401:-
LUAD	cis	rs12030196	0.788	rs2764929	ENSG00000230812.4	LINC01358	4.65	4.39e-06	0.000949	0.21	0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:58956345	chr1:59020387~59044614:+
LUAD	cis	rs2243480	1	rs73150014	ENSG00000226002.1	RP11-460N20.5	-4.65	4.39e-06	0.000949	-0.35	-0.21	Diabetic kidney disease;	chr7:65985932	chr7:65084103~65100232:+
LUAD	cis	rs7119	0.651	rs34829483	ENSG00000259362.2	RP11-307C19.1	-4.65	4.39e-06	0.00095	-0.26	-0.21	Type 2 diabetes;	chr15:77543644	chr15:77525540~77534110:+
LUAD	cis	rs7138803	0.537	rs2603104	ENSG00000257464.1	RP11-161H23.8	-4.65	4.39e-06	0.00095	-0.2	-0.21	Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index;	chr12:49796051	chr12:49442424~49442652:-
LUAD	cis	rs17711722	0.583	rs10085415	ENSG00000234585.5	CCT6P3	-4.64	4.4e-06	0.00095	-0.2	-0.21	Calcium levels;	chr7:65628655	chr7:65038354~65074713:+
LUAD	cis	rs6545883	0.507	rs4411680	ENSG00000271889.1	RP11-493E12.1	-4.64	4.4e-06	0.00095	-0.24	-0.21	Tuberculosis;	chr2:61356970	chr2:61151433~61162105:-
LUAD	cis	rs7829975	0.714	rs59046059	ENSG00000253981.4	ALG1L13P	4.64	4.4e-06	0.00095	0.24	0.21	Mood instability;	chr8:8813226	chr8:8236003~8244667:-
LUAD	cis	rs12939005	1	rs12939005	ENSG00000275710.1	RP11-257O5.4	-4.64	4.4e-06	0.00095	-0.32	-0.21	Large artery stroke;	chr17:54909123	chr17:54964474~54964679:+
LUAD	cis	rs6840360	1	rs4696111	ENSG00000270265.1	RP11-731D1.4	-4.64	4.4e-06	0.000951	-0.21	-0.21	Intelligence (multi-trait analysis);	chr4:151750253	chr4:151333775~151353224:-
LUAD	cis	rs6840360	1	rs7663045	ENSG00000270265.1	RP11-731D1.4	-4.64	4.4e-06	0.000951	-0.21	-0.21	Intelligence (multi-trait analysis);	chr4:151755198	chr4:151333775~151353224:-
LUAD	cis	rs17711722	0.585	rs6942660	ENSG00000237310.1	GS1-124K5.4	4.64	4.4e-06	0.000951	0.22	0.21	Calcium levels;	chr7:65837419	chr7:66493706~66495474:+
LUAD	cis	rs17711722	0.64	rs13237956	ENSG00000237310.1	GS1-124K5.4	4.64	4.4e-06	0.000951	0.22	0.21	Calcium levels;	chr7:65853042	chr7:66493706~66495474:+
LUAD	cis	rs4908760	0.539	rs6690928	ENSG00000232912.4	RP5-1115A15.1	4.64	4.4e-06	0.000951	0.19	0.21	Vitiligo;	chr1:8799432	chr1:8424645~8434838:+
LUAD	cis	rs1008375	1	rs10939738	ENSG00000249502.1	AC006160.5	-4.64	4.4e-06	0.000951	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17602672	chr4:17587467~17614571:-
LUAD	cis	rs1008375	0.932	rs4698626	ENSG00000249502.1	AC006160.5	-4.64	4.4e-06	0.000951	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17604198	chr4:17587467~17614571:-
LUAD	cis	rs1008375	0.932	rs4698627	ENSG00000249502.1	AC006160.5	-4.64	4.4e-06	0.000951	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17604336	chr4:17587467~17614571:-
LUAD	cis	rs7404843	0.925	rs7404803	ENSG00000207425.1	Y_RNA	4.64	4.4e-06	0.000952	0.41	0.21	Testicular germ cell tumor;	chr16:15436597	chr16:14915457~14915556:-
LUAD	cis	rs848490	0.894	rs6465773	ENSG00000214293.7	APTR	4.64	4.41e-06	0.000952	0.26	0.21	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77677384	chr7:77657660~77696265:-
LUAD	cis	rs2657294	0.62	rs7475340	ENSG00000233313.2	HMGA1P5	-4.64	4.41e-06	0.000952	-0.26	-0.21	Pneumonia;	chr10:75079597	chr10:75276376~75276646:-
LUAD	cis	rs2243480	0.803	rs34804747	ENSG00000164669.11	INTS4P1	4.64	4.41e-06	0.000952	0.37	0.21	Diabetic kidney disease;	chr7:65947955	chr7:65141225~65234216:+
LUAD	cis	rs9910055	0.571	rs28897216	ENSG00000267080.4	ASB16-AS1	-4.64	4.41e-06	0.000952	-0.19	-0.21	Total body bone mineral density;	chr17:44163456	chr17:44175973~44186717:-
LUAD	cis	rs9910055	0.614	rs12944572	ENSG00000267080.4	ASB16-AS1	-4.64	4.41e-06	0.000952	-0.19	-0.21	Total body bone mineral density;	chr17:44167873	chr17:44175973~44186717:-
LUAD	cis	rs1555322	0.53	rs8122819	ENSG00000126005.14	MMP24-AS1	-4.64	4.41e-06	0.000953	-0.28	-0.21	Attention deficit hyperactivity disorder;	chr20:35293783	chr20:35216462~35278131:-
LUAD	cis	rs6728642	1	rs11890407	ENSG00000230606.9	AC159540.1	4.64	4.41e-06	0.000953	0.35	0.21	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96955910	chr2:97416165~97433527:-
LUAD	cis	rs6496932	0.503	rs4842882	ENSG00000202081.1	RNU6-1280P	-4.64	4.41e-06	0.000954	-0.27	-0.21	Central corneal thickness;Corneal structure;	chr15:85440952	chr15:85651522~85651628:-
LUAD	cis	rs9450351	0.744	rs76569085	ENSG00000203875.9	SNHG5	-4.64	4.41e-06	0.000954	-0.54	-0.21	Interferon gamma-induced protein 10 levels;	chr6:85971523	chr6:85660950~85678736:-
LUAD	cis	rs2732480	0.577	rs2732479	ENSG00000257735.1	RP11-370I10.6	4.64	4.42e-06	0.000954	0.25	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342477	chr12:48350945~48442411:+
LUAD	cis	rs2732480	0.537	rs1061986	ENSG00000257735.1	RP11-370I10.6	4.64	4.42e-06	0.000954	0.25	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342656	chr12:48350945~48442411:+
LUAD	cis	rs150992	0.504	rs11745405	ENSG00000248489.1	CTD-2007H13.3	-4.64	4.42e-06	0.000954	-0.25	-0.21	Body mass index;	chr5:99047700	chr5:98929171~98995013:+
LUAD	cis	rs6565653	0.901	rs7216510	ENSG00000262580.4	RP11-334C17.5	4.64	4.42e-06	0.000954	0.14	0.21	Ischemic stroke;	chr17:80226111	chr17:80200673~80205949:-
LUAD	cis	rs6565653	0.934	rs7209632	ENSG00000262580.4	RP11-334C17.5	4.64	4.42e-06	0.000954	0.14	0.21	Ischemic stroke;	chr17:80226114	chr17:80200673~80205949:-
LUAD	cis	rs2933343	1	rs789237	ENSG00000231305.3	RP11-723O4.2	4.64	4.42e-06	0.000954	0.25	0.21	IgG glycosylation;	chr3:128918118	chr3:128861313~128871540:-
LUAD	cis	rs516805	0.748	rs197681	ENSG00000279453.1	RP3-425C14.4	-4.64	4.42e-06	0.000955	-0.28	-0.21	Lymphocyte counts;	chr6:122551788	chr6:122436789~122439223:-
LUAD	cis	rs66823261	0.778	rs2906332	ENSG00000272240.1	RP5-855D21.1	4.64	4.42e-06	0.000955	0.23	0.21	Breast cancer (estrogen-receptor negative);Breast cancer;	chr8:244943	chr8:234347~234887:-
LUAD	cis	rs2115630	0.967	rs11073731	ENSG00000229212.6	RP11-561C5.4	4.64	4.42e-06	0.000955	0.24	0.21	P wave terminal force;	chr15:84811882	chr15:85205440~85234795:-
LUAD	cis	rs4683346	1	rs4683342	ENSG00000173811.9	CCDC13-AS1	-4.64	4.42e-06	0.000955	-0.23	-0.21	Granulocyte percentage of myeloid white cells;	chr3:42835941	chr3:42732575~42746768:+
LUAD	cis	rs73173548	0.502	rs4423262	ENSG00000247828.6	TMEM161B-AS1	4.64	4.42e-06	0.000955	0.25	0.21	Macular telangiectasia type 2;	chr5:88438609	chr5:88268895~88436685:+
LUAD	cis	rs9813712	0.597	rs62281648	ENSG00000249846.5	RP11-77P16.4	-4.64	4.42e-06	0.000955	-0.24	-0.21	Response to amphetamines;	chr3:130244794	chr3:130112550~130120579:+
LUAD	cis	rs801193	0.613	rs2016325	ENSG00000237310.1	GS1-124K5.4	-4.64	4.42e-06	0.000955	-0.22	-0.21	Aortic root size;	chr7:66858513	chr7:66493706~66495474:+
LUAD	cis	rs11023332	0.617	rs1879888	ENSG00000251991.1	RNU7-49P	4.64	4.43e-06	0.000956	0.22	0.21	Vitamin D levels;Adiponectin levels;	chr11:14657701	chr11:14478892~14478953:+
LUAD	cis	rs12928939	0.774	rs7192860	ENSG00000260886.1	TAT-AS1	4.64	4.43e-06	0.000956	0.26	0.21	Post bronchodilator FEV1;	chr16:71609719	chr16:71565789~71578187:+
LUAD	cis	rs453301	0.631	rs17700611	ENSG00000173295.6	FAM86B3P	-4.64	4.43e-06	0.000956	-0.22	-0.21	Joint mobility (Beighton score);	chr8:8936144	chr8:8228595~8244865:+
LUAD	cis	rs761746	0.577	rs5994431	ENSG00000236132.1	CTA-440B3.1	4.64	4.43e-06	0.000956	0.28	0.21	Intelligence;	chr22:31814314	chr22:31816379~31817491:-
LUAD	cis	rs2286503	0.966	rs2286507	ENSG00000226329.2	AC005682.6	4.64	4.43e-06	0.000956	0.26	0.21	Fibrinogen;	chr7:22815141	chr7:22863874~22881350:-
LUAD	cis	rs12468226	1	rs12472408	ENSG00000272966.1	RP11-686O6.1	4.64	4.43e-06	0.000956	0.34	0.21	Urate levels;	chr2:202413973	chr2:202336739~202337200:+
LUAD	cis	rs11673344	0.8	rs826323	ENSG00000226686.6	LINC01535	4.64	4.43e-06	0.000956	0.26	0.21	Obesity-related traits;	chr19:37014051	chr19:37251912~37265535:+
LUAD	cis	rs8050896	1	rs8059932	ENSG00000260695.1	RP11-513N24.1	-4.64	4.43e-06	0.000956	-0.39	-0.21	Response to antipsychotic treatment;	chr16:66121373	chr16:65861112~65863784:-
LUAD	cis	rs4834770	0.668	rs10007409	ENSG00000245958.5	RP11-33B1.1	4.64	4.43e-06	0.000956	0.2	0.21	Blood protein levels;	chr4:119221151	chr4:119454791~119552025:+
LUAD	cis	rs13113518	0.729	rs11133377	ENSG00000223305.1	RN7SKP30	4.64	4.43e-06	0.000956	0.25	0.21	Height;	chr4:55413708	chr4:55540502~55540835:-
LUAD	cis	rs6840360	1	rs2007445	ENSG00000270265.1	RP11-731D1.4	-4.64	4.43e-06	0.000956	-0.21	-0.21	Intelligence (multi-trait analysis);	chr4:151679218	chr4:151333775~151353224:-
LUAD	cis	rs6840360	1	rs4696104	ENSG00000270265.1	RP11-731D1.4	-4.64	4.43e-06	0.000956	-0.21	-0.21	Intelligence (multi-trait analysis);	chr4:151679299	chr4:151333775~151353224:-
LUAD	cis	rs6840360	1	rs749982	ENSG00000270265.1	RP11-731D1.4	-4.64	4.43e-06	0.000956	-0.21	-0.21	Intelligence (multi-trait analysis);	chr4:151680201	chr4:151333775~151353224:-
LUAD	cis	rs6840360	1	rs751014	ENSG00000270265.1	RP11-731D1.4	-4.64	4.43e-06	0.000956	-0.21	-0.21	Intelligence (multi-trait analysis);	chr4:151680750	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.967	rs10776524	ENSG00000270265.1	RP11-731D1.4	-4.64	4.43e-06	0.000956	-0.21	-0.21	Intelligence (multi-trait analysis);	chr4:151681433	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.967	rs6832562	ENSG00000270265.1	RP11-731D1.4	-4.64	4.43e-06	0.000956	-0.21	-0.21	Intelligence (multi-trait analysis);	chr4:151681646	chr4:151333775~151353224:-
LUAD	cis	rs2243480	1	rs34703416	ENSG00000164669.11	INTS4P1	4.64	4.43e-06	0.000957	0.38	0.21	Diabetic kidney disease;	chr7:65835655	chr7:65141225~65234216:+
LUAD	cis	rs2243480	0.901	rs57126451	ENSG00000164669.11	INTS4P1	4.64	4.44e-06	0.000958	0.37	0.21	Diabetic kidney disease;	chr7:65951319	chr7:65141225~65234216:+
LUAD	cis	rs783540	0.521	rs28719490	ENSG00000255769.6	GOLGA2P10	-4.64	4.44e-06	0.000958	-0.25	-0.21	Schizophrenia;	chr15:82720688	chr15:82472993~82513950:-
LUAD	cis	rs889398	0.741	rs11075744	ENSG00000226232.7	RP11-419C5.2	-4.64	4.44e-06	0.000958	-0.17	-0.21	Body mass index;	chr16:69875212	chr16:69976388~69996188:-
LUAD	cis	rs1667284	0.58	rs11081706	ENSG00000266521.1	RP11-650P15.1	-4.64	4.44e-06	0.000958	-0.24	-0.21	Problematic alcohol use in trauma-exposed individuals;	chr18:31655508	chr18:31496645~31497195:-
LUAD	cis	rs7945705	0.776	rs2316865	ENSG00000254860.4	TMEM9B-AS1	-4.64	4.44e-06	0.000958	-0.24	-0.21	Hemoglobin concentration;	chr11:8793923	chr11:8964675~8977527:+
LUAD	cis	rs9487094	0.778	rs6914498	ENSG00000260273.1	RP11-425D10.10	4.64	4.44e-06	0.000959	0.29	0.21	Height;	chr6:109613205	chr6:109382795~109383666:+
LUAD	cis	rs1876905	0.539	rs241003	ENSG00000255389.1	C6orf3	-4.64	4.44e-06	0.000959	-0.29	-0.21	Mean corpuscular hemoglobin;	chr6:111274934	chr6:111599875~111602295:+
LUAD	cis	rs8180040	0.691	rs12489211	ENSG00000271161.1	BOLA2P2	4.64	4.44e-06	0.000959	0.2	0.21	Colorectal cancer;	chr3:47179961	chr3:47499841~47500407:+
LUAD	cis	rs9322193	0.923	rs3924871	ENSG00000268592.3	RAET1E-AS1	4.64	4.44e-06	0.000959	0.25	0.21	Lung cancer;	chr6:149662080	chr6:149863494~149919507:+
LUAD	cis	rs35740288	0.857	rs11632034	ENSG00000259407.1	RP11-158M2.3	-4.64	4.44e-06	0.000959	-0.21	-0.21	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85740841	chr15:85744109~85750281:-
LUAD	cis	rs9815354	0.812	rs794890	ENSG00000273328.4	RP11-141M3.6	4.64	4.45e-06	0.00096	0.33	0.21	Pulse pressure;Diastolic blood pressure;	chr3:42020847	chr3:42809414~42908105:+
LUAD	cis	rs10266483	0.739	rs2692104	ENSG00000228653.2	HNRNPCP7	-4.64	4.45e-06	0.00096	-0.25	-0.21	Response to statin therapy;	chr7:64300577	chr7:64500825~64501729:+
LUAD	cis	rs16873450	0.9	rs2193830	ENSG00000234800.2	PCMTD1P3	-4.64	4.45e-06	0.00096	-0.25	-0.21	Verbal memory performance (residualized delayed recall level);	chr7:23797961	chr7:23721311~23721782:-
LUAD	cis	rs3747113	1	rs11703914	ENSG00000128262.7	POM121L9P	-4.64	4.45e-06	0.000961	-0.22	-0.21	Gut microbiome composition (summer);	chr22:24371634	chr22:24251828~24265525:+
LUAD	cis	rs9322193	0.923	rs9767554	ENSG00000268592.3	RAET1E-AS1	4.64	4.45e-06	0.000961	0.25	0.21	Lung cancer;	chr6:149616860	chr6:149863494~149919507:+
LUAD	cis	rs17772222	0.874	rs61984746	ENSG00000258983.2	RP11-507K2.2	4.64	4.45e-06	0.000961	0.25	0.21	Coronary artery calcification;	chr14:88668136	chr14:88499334~88515502:+
LUAD	cis	rs561341	1	rs4795668	ENSG00000265798.5	RP11-271K11.5	4.64	4.46e-06	0.000961	0.32	0.21	Hip circumference adjusted for BMI;	chr17:31917535	chr17:31038575~31059121:-
LUAD	cis	rs561341	1	rs4795669	ENSG00000265798.5	RP11-271K11.5	4.64	4.46e-06	0.000961	0.32	0.21	Hip circumference adjusted for BMI;	chr17:31917682	chr17:31038575~31059121:-
LUAD	cis	rs11157436	0.581	rs17255433	ENSG00000211813.2	TRAV34	4.64	4.46e-06	0.000961	0.24	0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22167051	chr14:22207522~22208129:+
LUAD	cis	rs11157436	0.602	rs17255440	ENSG00000211813.2	TRAV34	4.64	4.46e-06	0.000961	0.24	0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22167297	chr14:22207522~22208129:+
LUAD	cis	rs11976180	0.517	rs6949375	ENSG00000204959.4	ARHGEF34P	4.64	4.46e-06	0.000962	0.32	0.21	Obesity-related traits;	chr7:144076758	chr7:144272445~144286966:-
LUAD	cis	rs42490	0.716	rs40636	ENSG00000251136.7	RP11-37B2.1	-4.64	4.46e-06	0.000962	-0.21	-0.21	Leprosy;	chr8:89809079	chr8:89609409~89757727:-
LUAD	cis	rs12022452	1	rs2184877	ENSG00000238287.1	RP11-656D10.3	-4.64	4.46e-06	0.000962	-0.37	-0.21	Age-related hearing impairment (SNP x SNP interaction);	chr1:40531260	chr1:40493157~40508661:-
LUAD	cis	rs12439619	0.846	rs62013464	ENSG00000276710.3	CSPG4P8	-4.64	4.46e-06	0.000963	-0.23	-0.21	Intelligence (multi-trait analysis);	chr15:82288250	chr15:82459472~82477258:+
LUAD	cis	rs6802315	0.604	rs9881462	ENSG00000272087.1	RP11-379F4.7	4.64	4.47e-06	0.000963	0.23	0.21	Periodontitis (CDC/AAP);	chr3:158763333	chr3:158693120~158693768:-
LUAD	cis	rs6802315	0.575	rs1864508	ENSG00000272087.1	RP11-379F4.7	4.64	4.47e-06	0.000963	0.23	0.21	Periodontitis (CDC/AAP);	chr3:158765024	chr3:158693120~158693768:-
LUAD	cis	rs7181230	1	rs28620926	ENSG00000275636.1	RP11-521C20.5	4.64	4.47e-06	0.000963	0.26	0.21	Dehydroepiandrosterone sulphate levels;	chr15:40064970	chr15:40078892~40079347:+
LUAD	cis	rs6714710	0.58	rs11680018	ENSG00000230606.9	AC159540.1	-4.64	4.47e-06	0.000963	-0.22	-0.21	Posterior cortical atrophy and Alzheimer's disease;	chr2:97863118	chr2:97416165~97433527:-
LUAD	cis	rs9813712	0.597	rs1453255	ENSG00000249846.5	RP11-77P16.4	-4.64	4.47e-06	0.000964	-0.24	-0.21	Response to amphetamines;	chr3:130258815	chr3:130112550~130120579:+
LUAD	cis	rs10090774	0.71	rs13264524	ENSG00000280303.2	ERICD	-4.64	4.47e-06	0.000965	-0.23	-0.21	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140644559	chr8:140636281~140638283:+
LUAD	cis	rs9650657	0.538	rs6984496	ENSG00000255046.1	RP11-297N6.4	4.64	4.47e-06	0.000965	0.25	0.21	Neuroticism;	chr8:10938583	chr8:11797928~11802568:-
LUAD	cis	rs473651	0.935	rs541128	ENSG00000229915.1	AC016999.2	-4.64	4.48e-06	0.000965	-0.28	-0.21	Multiple system atrophy;	chr2:238427808	chr2:238427077~238427729:-
LUAD	cis	rs6088590	0.965	rs6119534	ENSG00000276073.1	RP5-1125A11.7	-4.64	4.48e-06	0.000965	-0.22	-0.21	Coronary artery disease;	chr20:34853454	chr20:33985617~33988989:-
LUAD	cis	rs2765539	0.781	rs6428790	ENSG00000226172.2	RP4-712E4.1	-4.64	4.48e-06	0.000965	-0.28	-0.21	Waist-hip ratio;	chr1:119063374	chr1:119000344~119001392:-
LUAD	cis	rs11157436	0.602	rs928954	ENSG00000211813.2	TRAV34	4.64	4.48e-06	0.000965	0.24	0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166130	chr14:22207522~22208129:+
LUAD	cis	rs227275	0.554	rs223367	ENSG00000251288.2	RP11-10L12.2	-4.64	4.48e-06	0.000965	-0.25	-0.21	Allergic disease (asthma, hay fever or eczema);	chr4:102843836	chr4:102751401~102752641:+
LUAD	cis	rs11673344	0.864	rs2562606	ENSG00000226686.6	LINC01535	4.64	4.48e-06	0.000966	0.26	0.21	Obesity-related traits;	chr19:37029628	chr19:37251912~37265535:+
LUAD	cis	rs12928939	0.815	rs12448022	ENSG00000260886.1	TAT-AS1	4.64	4.48e-06	0.000966	0.26	0.21	Post bronchodilator FEV1;	chr16:71690466	chr16:71565789~71578187:+
LUAD	cis	rs800160	0.777	rs2521288	ENSG00000236264.4	RPL26P30	-4.64	4.48e-06	0.000967	-0.29	-0.21	Bacteremia;	chr11:2321533	chr11:2335132~2335776:-
LUAD	cis	rs763121	0.853	rs5757141	ENSG00000228274.3	RP3-508I15.9	-4.64	4.49e-06	0.000967	-0.21	-0.21	Menopause (age at onset);	chr22:38561478	chr22:38667585~38681820:-
LUAD	cis	rs36093844	0.642	rs10501601	ENSG00000279742.1	RP11-700A24.1	-4.64	4.49e-06	0.000967	-0.21	-0.21	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85898763	chr11:85852557~85854943:-
LUAD	cis	rs11168618	1	rs10875830	ENSG00000240399.1	RP1-228P16.1	4.64	4.49e-06	0.000968	0.2	0.21	Adiponectin levels;	chr12:48543727	chr12:48054813~48055591:-
LUAD	cis	rs17772222	0.63	rs1344747	ENSG00000258789.1	RP11-507K2.3	4.64	4.49e-06	0.000968	0.25	0.21	Coronary artery calcification;	chr14:88548091	chr14:88551597~88552493:+
LUAD	cis	rs9487605	1	rs9487605	ENSG00000272356.1	RP5-1112D6.8	-4.64	4.49e-06	0.000968	-0.19	-0.21	Inflammatory skin disease;	chr6:111261682	chr6:111309203~111313517:+
LUAD	cis	rs7119	0.745	rs12911649	ENSG00000259362.2	RP11-307C19.1	-4.64	4.49e-06	0.000968	-0.26	-0.21	Type 2 diabetes;	chr15:77514785	chr15:77525540~77534110:+
LUAD	cis	rs2337406	0.852	rs12050239	ENSG00000223648.3	IGHV3-64	4.64	4.49e-06	0.000968	0.25	0.21	Alzheimer's disease (late onset);	chr14:106781132	chr14:106643132~106658258:-
LUAD	cis	rs2033711	0.87	rs7259841	ENSG00000268912.1	CTD-2619J13.17	-4.64	4.49e-06	0.000969	-0.22	-0.21	Uric acid clearance;	chr19:58439756	chr19:58428632~58431148:-
LUAD	cis	rs516805	0.748	rs1989254	ENSG00000279453.1	RP3-425C14.4	-4.64	4.49e-06	0.000969	-0.28	-0.21	Lymphocyte counts;	chr6:122556317	chr6:122436789~122439223:-
LUAD	cis	rs858239	0.669	rs12539467	ENSG00000230042.1	AK3P3	-4.64	4.49e-06	0.000969	-0.27	-0.21	Cerebrospinal fluid biomarker levels;	chr7:23076240	chr7:23129178~23129841:+
LUAD	cis	rs7937890	0.572	rs2597202	ENSG00000251991.1	RNU7-49P	4.64	4.49e-06	0.000969	0.23	0.21	Mitochondrial DNA levels;	chr11:14463099	chr11:14478892~14478953:+
LUAD	cis	rs7811142	0.83	rs78256546	ENSG00000078319.8	PMS2P1	-4.64	4.5e-06	0.000969	-0.25	-0.21	Platelet count;	chr7:100355347	chr7:100320992~100341908:-
LUAD	cis	rs7811142	0.83	rs41280971	ENSG00000078319.8	PMS2P1	-4.64	4.5e-06	0.000969	-0.25	-0.21	Platelet count;	chr7:100356834	chr7:100320992~100341908:-
LUAD	cis	rs7811142	0.83	rs3087502	ENSG00000078319.8	PMS2P1	-4.64	4.5e-06	0.000969	-0.25	-0.21	Platelet count;	chr7:100357741	chr7:100320992~100341908:-
LUAD	cis	rs7811142	0.83	rs61735533	ENSG00000078319.8	PMS2P1	-4.64	4.5e-06	0.000969	-0.25	-0.21	Platelet count;	chr7:100358243	chr7:100320992~100341908:-
LUAD	cis	rs7811142	0.83	rs11761426	ENSG00000078319.8	PMS2P1	-4.64	4.5e-06	0.000969	-0.25	-0.21	Platelet count;	chr7:100359270	chr7:100320992~100341908:-
LUAD	cis	rs7811142	0.83	rs77861211	ENSG00000078319.8	PMS2P1	-4.64	4.5e-06	0.000969	-0.25	-0.21	Platelet count;	chr7:100364473	chr7:100320992~100341908:-
LUAD	cis	rs7811142	0.83	rs11769057	ENSG00000078319.8	PMS2P1	-4.64	4.5e-06	0.000969	-0.25	-0.21	Platelet count;	chr7:100367038	chr7:100320992~100341908:-
LUAD	cis	rs891378	0.92	rs2564975	ENSG00000274245.1	RP11-357P18.2	-4.64	4.5e-06	0.000969	-0.27	-0.21	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207310612	chr1:207372559~207373252:+
LUAD	cis	rs8180040	0.593	rs10433549	ENSG00000271161.1	BOLA2P2	-4.64	4.5e-06	0.000969	-0.2	-0.21	Colorectal cancer;	chr3:46989943	chr3:47499841~47500407:+
LUAD	cis	rs2243480	0.708	rs35825036	ENSG00000232559.3	GS1-124K5.12	4.64	4.5e-06	0.000969	0.36	0.21	Diabetic kidney disease;	chr7:66521515	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs13237037	ENSG00000232559.3	GS1-124K5.12	4.64	4.5e-06	0.000969	0.36	0.21	Diabetic kidney disease;	chr7:66532895	chr7:66554588~66576923:-
LUAD	cis	rs2243480	0.901	rs13237344	ENSG00000232559.3	GS1-124K5.12	4.64	4.5e-06	0.000969	0.36	0.21	Diabetic kidney disease;	chr7:66557269	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs1796228	ENSG00000232559.3	GS1-124K5.12	4.64	4.5e-06	0.000969	0.36	0.21	Diabetic kidney disease;	chr7:66568097	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs1267820	ENSG00000232559.3	GS1-124K5.12	4.64	4.5e-06	0.000969	0.36	0.21	Diabetic kidney disease;	chr7:66585308	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs2533288	ENSG00000232559.3	GS1-124K5.12	4.64	4.5e-06	0.000969	0.36	0.21	Diabetic kidney disease;	chr7:66591724	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs2707844	ENSG00000232559.3	GS1-124K5.12	4.64	4.5e-06	0.000969	0.36	0.21	Diabetic kidney disease;	chr7:66594522	chr7:66554588~66576923:-
LUAD	cis	rs2408955	0.561	rs11168365	ENSG00000240399.1	RP1-228P16.1	-4.64	4.5e-06	0.000969	-0.21	-0.21	Glycated hemoglobin levels;	chr12:48027989	chr12:48054813~48055591:-
LUAD	cis	rs7189233	0.571	rs4146344	ENSG00000279344.1	RP11-44F14.7	4.64	4.5e-06	0.000969	0.17	0.21	Intelligence (multi-trait analysis);	chr16:53435050	chr16:53478957~53481550:-
LUAD	cis	rs10266483	0.774	rs642909	ENSG00000227986.1	TRIM60P18	-4.64	4.5e-06	0.00097	-0.26	-0.21	Response to statin therapy;	chr7:64309943	chr7:64355078~64356199:+
LUAD	cis	rs1979679	0.842	rs11049373	ENSG00000278733.1	RP11-425D17.1	4.64	4.5e-06	0.00097	0.26	0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28148881	chr12:28185625~28186190:-
LUAD	cis	rs1979679	0.842	rs2127315	ENSG00000278733.1	RP11-425D17.1	4.64	4.5e-06	0.00097	0.26	0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28156247	chr12:28185625~28186190:-
LUAD	cis	rs6012564	0.749	rs8120015	ENSG00000230758.1	SNAP23P	4.64	4.5e-06	0.000971	0.22	0.21	Anger;	chr20:49128772	chr20:49038357~49038602:-
LUAD	cis	rs72717009	0.825	rs12746613	ENSG00000225217.1	HSPA7	4.64	4.51e-06	0.000971	0.29	0.21	Rheumatoid arthritis;	chr1:161497252	chr1:161606291~161608217:+
LUAD	cis	rs7208859	0.573	rs216442	ENSG00000266490.1	CTD-2349P21.9	4.64	4.51e-06	0.000972	0.31	0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604179	chr17:30792372~30792833:+
LUAD	cis	rs7138803	0.51	rs1075366	ENSG00000257464.1	RP11-161H23.8	-4.64	4.51e-06	0.000972	-0.2	-0.21	Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index;	chr12:49798226	chr12:49442424~49442652:-
LUAD	cis	rs9322193	0.884	rs9688699	ENSG00000268592.3	RAET1E-AS1	4.64	4.51e-06	0.000972	0.26	0.21	Lung cancer;	chr6:149733680	chr6:149863494~149919507:+
LUAD	cis	rs7621025	0.664	rs6439657	ENSG00000239213.4	NCK1-AS1	-4.64	4.51e-06	0.000972	-0.25	-0.21	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136775797	chr3:136841726~136862054:-
LUAD	cis	rs8180040	0.726	rs2061197	ENSG00000271161.1	BOLA2P2	-4.64	4.51e-06	0.000972	-0.2	-0.21	Colorectal cancer;	chr3:46959860	chr3:47499841~47500407:+
LUAD	cis	rs7210086	0.808	rs72849443	ENSG00000263893.2	CTD-3010D24.3	4.64	4.51e-06	0.000973	0.29	0.21	Ulcerative colitis;	chr17:72641298	chr17:72642731~72644490:+
LUAD	cis	rs1790761	0.692	rs10444362	ENSG00000184224.3	C11orf72	4.64	4.52e-06	0.000973	0.23	0.21	Mean corpuscular volume;	chr11:67565619	chr11:67602880~67606706:-
LUAD	cis	rs516805	0.748	rs197682	ENSG00000279453.1	RP3-425C14.4	-4.64	4.52e-06	0.000974	-0.29	-0.21	Lymphocyte counts;	chr6:122551848	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.748	rs197683	ENSG00000279453.1	RP3-425C14.4	-4.64	4.52e-06	0.000974	-0.29	-0.21	Lymphocyte counts;	chr6:122552277	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.748	rs197684	ENSG00000279453.1	RP3-425C14.4	-4.64	4.52e-06	0.000974	-0.29	-0.21	Lymphocyte counts;	chr6:122553697	chr6:122436789~122439223:-
LUAD	cis	rs2115630	0.967	rs12595786	ENSG00000229212.6	RP11-561C5.4	4.64	4.52e-06	0.000974	0.24	0.21	P wave terminal force;	chr15:84793439	chr15:85205440~85234795:-
LUAD	cis	rs638893	0.617	rs4938565	ENSG00000278376.1	RP11-158I9.8	4.64	4.52e-06	0.000974	0.24	0.21	Vitiligo;	chr11:118850289	chr11:118791254~118793137:+
LUAD	cis	rs4664293	0.934	rs1365800	ENSG00000226266.5	AC009961.3	-4.64	4.52e-06	0.000974	-0.3	-0.21	Monocyte percentage of white cells;	chr2:159699112	chr2:159670708~159712435:-
LUAD	cis	rs4908768	0.501	rs4908760	ENSG00000270282.1	RP5-1115A15.2	4.64	4.53e-06	0.000975	0.23	0.21	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8466082	chr1:8512653~8513021:+
LUAD	cis	rs2732480	0.577	rs2450994	ENSG00000257735.1	RP11-370I10.6	4.64	4.53e-06	0.000975	0.25	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48328049	chr12:48350945~48442411:+
LUAD	cis	rs2880765	0.743	rs8028240	ENSG00000259295.5	CSPG4P12	4.64	4.53e-06	0.000975	0.24	0.21	Coronary artery disease;	chr15:85470017	chr15:85191438~85213905:+
LUAD	cis	rs7138803	0.508	rs2290442	ENSG00000257464.1	RP11-161H23.8	-4.64	4.53e-06	0.000975	-0.2	-0.21	Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index;	chr12:49791551	chr12:49442424~49442652:-
LUAD	cis	rs2243480	1	rs34702770	ENSG00000226002.1	RP11-460N20.5	-4.64	4.53e-06	0.000975	-0.36	-0.21	Diabetic kidney disease;	chr7:65879836	chr7:65084103~65100232:+
LUAD	cis	rs516805	0.715	rs197691	ENSG00000279453.1	RP3-425C14.4	-4.64	4.54e-06	0.000977	-0.28	-0.21	Lymphocyte counts;	chr6:122513394	chr6:122436789~122439223:-
LUAD	cis	rs7804306	0.522	rs34395699	ENSG00000233264.2	AC006042.8	4.64	4.54e-06	0.000977	0.3	0.21	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8037257	chr7:7980312~7982228:+
LUAD	cis	rs7804306	0.522	rs34466770	ENSG00000233264.2	AC006042.8	4.64	4.54e-06	0.000977	0.3	0.21	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8037345	chr7:7980312~7982228:+
LUAD	cis	rs7208859	0.51	rs216402	ENSG00000266490.1	CTD-2349P21.9	4.64	4.54e-06	0.000977	0.32	0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30590108	chr17:30792372~30792833:+
LUAD	cis	rs9910055	0.659	rs6503488	ENSG00000267080.4	ASB16-AS1	-4.64	4.54e-06	0.000977	-0.19	-0.21	Total body bone mineral density;	chr17:44168790	chr17:44175973~44186717:-
LUAD	cis	rs7017914	0.652	rs35863913	ENSG00000223220.1	Y_RNA	4.64	4.54e-06	0.000977	0.24	0.21	Bone mineral density;	chr8:70661024	chr8:70780914~70781008:-
LUAD	cis	rs16873450	0.9	rs2390811	ENSG00000234800.2	PCMTD1P3	-4.64	4.54e-06	0.000978	-0.24	-0.21	Verbal memory performance (residualized delayed recall level);	chr7:23757037	chr7:23721311~23721782:-
LUAD	cis	rs507080	0.922	rs12788848	ENSG00000278376.1	RP11-158I9.8	-4.64	4.54e-06	0.000978	-0.22	-0.21	Serum metabolite levels;	chr11:118683079	chr11:118791254~118793137:+
LUAD	cis	rs507080	0.922	rs4474473	ENSG00000278376.1	RP11-158I9.8	-4.64	4.54e-06	0.000978	-0.22	-0.21	Serum metabolite levels;	chr11:118683180	chr11:118791254~118793137:+
LUAD	cis	rs507080	0.922	rs12796373	ENSG00000278376.1	RP11-158I9.8	-4.64	4.54e-06	0.000978	-0.22	-0.21	Serum metabolite levels;	chr11:118684230	chr11:118791254~118793137:+
LUAD	cis	rs8077577	0.747	rs57490980	ENSG00000273018.4	CTD-2303H24.2	-4.64	4.54e-06	0.000978	-0.29	-0.21	Obesity-related traits;	chr17:18257439	chr17:18511221~18551705:-
LUAD	cis	rs6840360	0.567	rs6844259	ENSG00000270265.1	RP11-731D1.4	-4.64	4.55e-06	0.000978	-0.21	-0.21	Intelligence (multi-trait analysis);	chr4:151370032	chr4:151333775~151353224:-
LUAD	cis	rs6840360	1	rs751012	ENSG00000270265.1	RP11-731D1.4	-4.64	4.55e-06	0.000979	-0.21	-0.21	Intelligence (multi-trait analysis);	chr4:151681095	chr4:151333775~151353224:-
LUAD	cis	rs10895987	1	rs12280510	ENSG00000254614.2	AP003068.23	4.64	4.55e-06	0.00098	0.33	0.21	Blood protein levels;	chr11:65147076	chr11:65177606~65181834:-
LUAD	cis	rs10129255	0.957	rs17113284	ENSG00000211974.3	IGHV2-70	-4.64	4.56e-06	0.000981	-0.22	-0.21	Kawasaki disease;	chr14:106684476	chr14:106723574~106724093:-
LUAD	cis	rs7819412	0.668	rs2409721	ENSG00000255046.1	RP11-297N6.4	4.64	4.56e-06	0.000981	0.25	0.21	Triglycerides;	chr8:11180735	chr8:11797928~11802568:-
LUAD	cis	rs1798817	1	rs78756374	ENSG00000189238.5	LINC00943	-4.64	4.56e-06	0.000981	-0.43	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr12:126779642	chr12:126726270~126746252:+
LUAD	cis	rs1798817	1	rs75395591	ENSG00000189238.5	LINC00943	-4.64	4.56e-06	0.000981	-0.43	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr12:126779851	chr12:126726270~126746252:+
LUAD	cis	rs4664293	0.51	rs66537229	ENSG00000226266.5	AC009961.3	4.64	4.56e-06	0.000981	0.29	0.21	Monocyte percentage of white cells;	chr2:159624095	chr2:159670708~159712435:-
LUAD	cis	rs2522056	1	rs62385693	ENSG00000233006.5	AC034220.3	-4.64	4.56e-06	0.000981	-0.22	-0.21	Fibrinogen;Lymphocyte counts;	chr5:132437982	chr5:132311285~132369916:-
LUAD	cis	rs2243480	1	rs67728539	ENSG00000229886.1	RP5-1132H15.3	4.64	4.56e-06	0.000981	0.36	0.21	Diabetic kidney disease;	chr7:65913137	chr7:66025126~66031544:-
LUAD	cis	rs6957923	0.81	rs7779665	ENSG00000230658.1	KLHL7-AS1	4.64	4.56e-06	0.000981	0.25	0.21	Height;	chr7:23481344	chr7:23101228~23105703:-
LUAD	cis	rs17772222	0.74	rs10138002	ENSG00000258789.1	RP11-507K2.3	4.64	4.56e-06	0.000981	0.26	0.21	Coronary artery calcification;	chr14:88510071	chr14:88551597~88552493:+
LUAD	cis	rs73173548	0.502	rs13180798	ENSG00000247828.6	TMEM161B-AS1	4.64	4.56e-06	0.000981	0.25	0.21	Macular telangiectasia type 2;	chr5:88425633	chr5:88268895~88436685:+
LUAD	cis	rs516805	0.748	rs197692	ENSG00000279453.1	RP3-425C14.4	-4.64	4.56e-06	0.000981	-0.28	-0.21	Lymphocyte counts;	chr6:122515260	chr6:122436789~122439223:-
LUAD	cis	rs11673344	0.931	rs73622783	ENSG00000226686.6	LINC01535	4.64	4.56e-06	0.000981	0.26	0.21	Obesity-related traits;	chr19:37165155	chr19:37251912~37265535:+
LUAD	cis	rs57561814	0.51	rs2066992	ENSG00000179428.2	AC073072.5	-4.64	4.56e-06	0.000982	-0.42	-0.21	Tonsillectomy;	chr7:22728630	chr7:22725395~22727620:-
LUAD	cis	rs7714584	1	rs11167526	ENSG00000197083.10	ZNF300P1	4.64	4.56e-06	0.000982	0.47	0.21	Crohn's disease;	chr5:150952919	chr5:150930645~150946289:-
LUAD	cis	rs516805	0.748	rs12211993	ENSG00000279453.1	RP3-425C14.4	4.64	4.56e-06	0.000982	0.28	0.21	Lymphocyte counts;	chr6:122570216	chr6:122436789~122439223:-
LUAD	cis	rs2562456	0.617	rs34203148	ENSG00000268081.1	RP11-678G14.2	4.64	4.56e-06	0.000982	0.32	0.21	Pain;	chr19:21590743	chr19:21554640~21569237:-
LUAD	cis	rs228614	0.51	rs4699033	ENSG00000251288.2	RP11-10L12.2	-4.64	4.57e-06	0.000983	-0.25	-0.21	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102897577	chr4:102751401~102752641:+
LUAD	cis	rs7119	0.623	rs12905318	ENSG00000259362.2	RP11-307C19.1	-4.64	4.57e-06	0.000983	-0.26	-0.21	Type 2 diabetes;	chr15:77553531	chr15:77525540~77534110:+
LUAD	cis	rs7119	0.651	rs12904200	ENSG00000259362.2	RP11-307C19.1	-4.64	4.57e-06	0.000983	-0.26	-0.21	Type 2 diabetes;	chr15:77553560	chr15:77525540~77534110:+
LUAD	cis	rs7119	0.651	rs12904208	ENSG00000259362.2	RP11-307C19.1	-4.64	4.57e-06	0.000983	-0.26	-0.21	Type 2 diabetes;	chr15:77553569	chr15:77525540~77534110:+
LUAD	cis	rs7119	0.651	rs12905044	ENSG00000259362.2	RP11-307C19.1	-4.64	4.57e-06	0.000983	-0.26	-0.21	Type 2 diabetes;	chr15:77553873	chr15:77525540~77534110:+
LUAD	cis	rs2348418	0.715	rs1355471	ENSG00000247934.4	RP11-967K21.1	-4.64	4.57e-06	0.000983	-0.24	-0.21	Lung function (FEV1);Lung function (FVC);	chr12:28568792	chr12:28163298~28190738:-
LUAD	cis	rs916888	0.647	rs199523	ENSG00000261575.2	RP11-259G18.1	-4.64	4.57e-06	0.000983	-0.27	-0.21	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46267037~46268694:+
LUAD	cis	rs2304003	1	rs1560595	ENSG00000235192.1	AC009495.2	-4.64	4.57e-06	0.000983	-0.25	-0.21	Social communication problems;	chr2:165843358	chr2:165794851~165810010:+
LUAD	cis	rs60180747	0.544	rs11630157	ENSG00000261318.1	RP11-653J6.1	4.64	4.57e-06	0.000983	0.27	0.21	Testicular germ cell tumor;	chr15:66261087	chr15:66278498~66293357:-
LUAD	cis	rs17684571	0.872	rs11961342	ENSG00000231441.1	RP11-472M19.2	4.64	4.57e-06	0.000983	0.28	0.21	Schizophrenia;	chr6:56714550	chr6:56844002~56864078:+
LUAD	cis	rs7688540	0.771	rs10005733	ENSG00000211553.1	AC253576.2	-4.64	4.57e-06	0.000984	-0.29	-0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:298212	chr4:136461~136568:+
LUAD	cis	rs7005380	0.581	rs9649949	ENSG00000279347.1	RP11-85I17.2	-4.64	4.57e-06	0.000984	-0.2	-0.21	Interstitial lung disease;	chr8:119901335	chr8:119838736~119840385:-
LUAD	cis	rs916888	0.61	rs199446	ENSG00000261575.2	RP11-259G18.1	-4.64	4.58e-06	0.000984	-0.28	-0.21	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46267037~46268694:+
LUAD	cis	rs916888	0.61	rs199536	ENSG00000261575.2	RP11-259G18.1	-4.64	4.58e-06	0.000984	-0.28	-0.21	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46267037~46268694:+
LUAD	cis	rs41369048	0.669	rs111238725	ENSG00000238078.1	LINC01352	-4.64	4.58e-06	0.000985	-0.31	-0.21	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220860320	chr1:220829255~220832429:+
LUAD	cis	rs2548724	0.588	rs62369341	ENSG00000250682.4	LINC00491	4.64	4.58e-06	0.000985	0.24	0.21	Type 2 diabetes;	chr5:102402034	chr5:102609156~102671559:-
LUAD	cis	rs6604026	0.624	rs11578004	ENSG00000223787.2	RP4-593M8.1	4.64	4.58e-06	0.000985	0.28	0.21	Multiple sclerosis;	chr1:92726707	chr1:92580476~92580821:-
LUAD	cis	rs559928	0.606	rs56311067	ENSG00000236935.1	AP003774.1	4.64	4.58e-06	0.000985	0.3	0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64164135	chr11:64325050~64329504:-
LUAD	cis	rs559928	0.556	rs11607903	ENSG00000236935.1	AP003774.1	4.64	4.58e-06	0.000985	0.3	0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64164668	chr11:64325050~64329504:-
LUAD	cis	rs17772222	0.653	rs1346996	ENSG00000258789.1	RP11-507K2.3	-4.64	4.58e-06	0.000986	-0.26	-0.21	Coronary artery calcification;	chr14:88507174	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.74	rs7160471	ENSG00000258789.1	RP11-507K2.3	-4.64	4.58e-06	0.000986	-0.26	-0.21	Coronary artery calcification;	chr14:88507241	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.74	rs9323830	ENSG00000258789.1	RP11-507K2.3	-4.64	4.58e-06	0.000986	-0.26	-0.21	Coronary artery calcification;	chr14:88507260	chr14:88551597~88552493:+
LUAD	cis	rs151234	0.8	rs231974	ENSG00000259982.1	CDC37P1	-4.64	4.58e-06	0.000986	-0.4	-0.21	Platelet distribution width;	chr16:28529001	chr16:28700294~28701540:-
LUAD	cis	rs7772486	0.905	rs9373486	ENSG00000235652.6	RP11-545I5.3	-4.64	4.58e-06	0.000986	-0.21	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:146124888	chr6:145799409~145886585:+
LUAD	cis	rs516805	0.748	rs647178	ENSG00000279453.1	RP3-425C14.4	-4.64	4.58e-06	0.000986	-0.28	-0.21	Lymphocyte counts;	chr6:122543602	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.667	rs197679	ENSG00000279453.1	RP3-425C14.4	-4.64	4.58e-06	0.000986	-0.28	-0.21	Lymphocyte counts;	chr6:122548188	chr6:122436789~122439223:-
LUAD	cis	rs9322193	0.923	rs12526675	ENSG00000268592.3	RAET1E-AS1	-4.64	4.59e-06	0.000986	-0.26	-0.21	Lung cancer;	chr6:149729540	chr6:149863494~149919507:+
LUAD	cis	rs2948294	0.588	rs4840913	ENSG00000253981.4	ALG1L13P	4.64	4.59e-06	0.000987	0.25	0.21	Red cell distribution width;	chr8:8259384	chr8:8236003~8244667:-
LUAD	cis	rs5758511	0.514	rs5758622	ENSG00000226450.2	CYP2D8P	4.64	4.59e-06	0.000987	0.2	0.21	Birth weight;	chr22:42167927	chr22:42149886~42155001:-
LUAD	cis	rs1065852	0.906	rs5751232	ENSG00000226450.2	CYP2D8P	4.64	4.59e-06	0.000987	0.2	0.21	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42168298	chr22:42149886~42155001:-
LUAD	cis	rs5758511	0.514	rs9607882	ENSG00000226450.2	CYP2D8P	4.64	4.59e-06	0.000987	0.2	0.21	Birth weight;	chr22:42171445	chr22:42149886~42155001:-
LUAD	cis	rs4237845	0.967	rs4553410	ENSG00000257159.1	RP11-58A17.3	4.64	4.59e-06	0.000988	0.25	0.21	Intelligence (multi-trait analysis);	chr12:57907428	chr12:57967058~57968399:+
LUAD	cis	rs17345786	0.861	rs11707689	ENSG00000244119.1	PDCL3P4	4.64	4.59e-06	0.000988	0.23	0.21	Colonoscopy-negative controls vs population controls;	chr3:101367631	chr3:101712472~101713191:+
LUAD	cis	rs17345786	0.906	rs56171035	ENSG00000244119.1	PDCL3P4	4.64	4.59e-06	0.000988	0.23	0.21	Colonoscopy-negative controls vs population controls;	chr3:101392264	chr3:101712472~101713191:+
LUAD	cis	rs9987353	0.519	rs13276350	ENSG00000253893.2	FAM85B	4.64	4.6e-06	0.000988	0.28	0.21	Recombination measurement;	chr8:9205647	chr8:8167819~8226614:-
LUAD	cis	rs1008375	0.8	rs10008598	ENSG00000249502.1	AC006160.5	-4.64	4.6e-06	0.000989	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17605700	chr4:17587467~17614571:-
LUAD	cis	rs950169	0.579	rs62027818	ENSG00000259728.4	LINC00933	4.64	4.6e-06	0.000989	0.33	0.21	Schizophrenia;	chr15:83992393	chr15:84570649~84580175:+
LUAD	cis	rs9652601	0.779	rs11648679	ENSG00000274038.1	RP11-66H6.4	-4.64	4.6e-06	0.000989	-0.25	-0.21	Systemic lupus erythematosus;	chr16:11082127	chr16:11056556~11057034:+
LUAD	cis	rs11168351	0.927	rs10875716	ENSG00000257735.1	RP11-370I10.6	4.63	4.6e-06	0.00099	0.25	0.21	Bipolar disorder and schizophrenia;	chr12:47995240	chr12:48350945~48442411:+
LUAD	cis	rs780096	0.546	rs1528533	ENSG00000234072.1	AC074117.10	-4.63	4.6e-06	0.00099	-0.16	-0.21	Total body bone mineral density;	chr2:27372889	chr2:27356246~27367622:+
LUAD	cis	rs74233809	1	rs10509759	ENSG00000213277.3	MARCKSL1P1	4.63	4.6e-06	0.00099	0.36	0.21	Birth weight;	chr10:102929908	chr10:103175554~103176094:+
LUAD	cis	rs9341808	0.727	rs9352809	ENSG00000233967.5	RP11-250B2.3	4.63	4.61e-06	0.00099	0.2	0.21	Sitting height ratio;	chr6:80289599	chr6:80443344~80465927:+
LUAD	cis	rs394563	0.967	rs420099	ENSG00000216906.2	RP11-350J20.9	4.63	4.61e-06	0.000991	0.25	0.21	Dupuytren's disease;	chr6:149473154	chr6:149904243~149906418:+
LUAD	cis	rs189798	0.807	rs9949	ENSG00000253981.4	ALG1L13P	4.63	4.61e-06	0.000991	0.28	0.21	Myopia (pathological);	chr8:9137002	chr8:8236003~8244667:-
LUAD	cis	rs453301	0.653	rs7016139	ENSG00000253893.2	FAM85B	4.63	4.62e-06	0.000992	0.27	0.21	Joint mobility (Beighton score);	chr8:9037960	chr8:8167819~8226614:-
LUAD	cis	rs2243480	1	rs6460260	ENSG00000232559.3	GS1-124K5.12	-4.63	4.62e-06	0.000992	-0.36	-0.21	Diabetic kidney disease;	chr7:65750468	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs6460261	ENSG00000232559.3	GS1-124K5.12	-4.63	4.62e-06	0.000992	-0.36	-0.21	Diabetic kidney disease;	chr7:65750593	chr7:66554588~66576923:-
LUAD	cis	rs6714710	0.603	rs34373359	ENSG00000230606.9	AC159540.1	-4.63	4.62e-06	0.000992	-0.22	-0.21	Posterior cortical atrophy and Alzheimer's disease;	chr2:97825739	chr2:97416165~97433527:-
LUAD	cis	rs875971	0.54	rs1723268	ENSG00000237310.1	GS1-124K5.4	4.63	4.62e-06	0.000992	0.22	0.21	Aortic root size;	chr7:66008093	chr7:66493706~66495474:+
LUAD	cis	rs74233809	0.901	rs17115100	ENSG00000213277.3	MARCKSL1P1	4.63	4.62e-06	0.000993	0.34	0.21	Birth weight;	chr10:102831636	chr10:103175554~103176094:+
LUAD	cis	rs6604026	0.555	rs1415296	ENSG00000223787.2	RP4-593M8.1	-4.63	4.62e-06	0.000993	-0.28	-0.21	Multiple sclerosis;	chr1:92624919	chr1:92580476~92580821:-
LUAD	cis	rs1431005	0.858	rs77580406	ENSG00000250658.1	RP11-138B4.1	4.63	4.62e-06	0.000993	0.25	0.21	Response to statin therapy;	chr4:187493654	chr4:187304083~187309682:-
LUAD	cis	rs1799949	0.965	rs8067269	ENSG00000236383.6	LINC00854	-4.63	4.62e-06	0.000993	-0.16	-0.21	Menopause (age at onset);	chr17:43083782	chr17:43216941~43305976:-
LUAD	cis	rs875971	0.66	rs2191268	ENSG00000237310.1	GS1-124K5.4	4.63	4.62e-06	0.000993	0.2	0.21	Aortic root size;	chr7:66645237	chr7:66493706~66495474:+
LUAD	cis	rs228614	0.51	rs223362	ENSG00000251288.2	RP11-10L12.2	-4.63	4.62e-06	0.000993	-0.25	-0.21	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102848077	chr4:102751401~102752641:+
LUAD	cis	rs8180040	0.805	rs17410853	ENSG00000271161.1	BOLA2P2	-4.63	4.63e-06	0.000994	-0.2	-0.21	Colorectal cancer;	chr3:47322481	chr3:47499841~47500407:+
LUAD	cis	rs17301013	0.861	rs1894200	ENSG00000227373.4	RP11-160H22.5	-4.63	4.63e-06	0.000994	-0.26	-0.21	Systemic lupus erythematosus;	chr1:174842039	chr1:174115300~174160004:-
LUAD	cis	rs9309473	0.687	rs10165862	ENSG00000163016.8	ALMS1P	4.63	4.63e-06	0.000994	0.23	0.21	Metabolite levels;	chr2:73383615	chr2:73644919~73685576:+
LUAD	cis	rs4927850	0.723	rs7630825	ENSG00000242086.7	LINC00969	4.63	4.63e-06	0.000994	0.18	0.21	Pancreatic cancer;	chr3:196026869	chr3:195658062~195739964:+
LUAD	cis	rs10129255	0.872	rs8015406	ENSG00000211974.3	IGHV2-70	4.63	4.63e-06	0.000994	0.22	0.21	Kawasaki disease;	chr14:106670611	chr14:106723574~106724093:-
LUAD	cis	rs763512	0.504	rs58201617	ENSG00000276054.1	RP11-378E13.3	4.63	4.63e-06	0.000995	0.31	0.21	3-hydroxypropylmercapturic acid levels in smokers;	chr17:37505345	chr17:37386886~37387926:+
LUAD	cis	rs17772222	0.876	rs4375590	ENSG00000258983.2	RP11-507K2.2	4.63	4.63e-06	0.000995	0.26	0.21	Coronary artery calcification;	chr14:88451334	chr14:88499334~88515502:+
LUAD	cis	rs17684571	0.872	rs59247267	ENSG00000231441.1	RP11-472M19.2	4.63	4.63e-06	0.000995	0.28	0.21	Schizophrenia;	chr6:56733965	chr6:56844002~56864078:+
LUAD	cis	rs11157436	0.602	rs1894370	ENSG00000211813.2	TRAV34	4.63	4.63e-06	0.000995	0.24	0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166764	chr14:22207522~22208129:+
LUAD	cis	rs17345786	0.906	rs72940399	ENSG00000244119.1	PDCL3P4	4.63	4.64e-06	0.000996	0.23	0.21	Colonoscopy-negative controls vs population controls;	chr3:101403731	chr3:101712472~101713191:+
LUAD	cis	rs477895	0.713	rs3802933	ENSG00000236935.1	AP003774.1	-4.63	4.64e-06	0.000996	-0.25	-0.21	Mean platelet volume;	chr11:64220630	chr11:64325050~64329504:-
LUAD	cis	rs9322193	0.886	rs9485408	ENSG00000268592.3	RAET1E-AS1	4.63	4.64e-06	0.000996	0.25	0.21	Lung cancer;	chr6:149618888	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.923	rs1080670	ENSG00000268592.3	RAET1E-AS1	4.63	4.64e-06	0.000996	0.25	0.21	Lung cancer;	chr6:149620161	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.884	rs10782312	ENSG00000268592.3	RAET1E-AS1	4.63	4.64e-06	0.000996	0.25	0.21	Lung cancer;	chr6:149622669	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.886	rs9322198	ENSG00000268592.3	RAET1E-AS1	4.63	4.64e-06	0.000996	0.25	0.21	Lung cancer;	chr6:149623772	chr6:149863494~149919507:+
LUAD	cis	rs2243480	0.808	rs12698508	ENSG00000232559.3	GS1-124K5.12	4.63	4.64e-06	0.000996	0.36	0.21	Diabetic kidney disease;	chr7:65946971	chr7:66554588~66576923:-
LUAD	cis	rs5758511	0.68	rs5751243	ENSG00000227370.1	RP4-669P10.19	4.63	4.64e-06	0.000996	0.23	0.21	Birth weight;	chr22:42221171	chr22:42132543~42132998:+
LUAD	cis	rs5758511	0.637	rs5751244	ENSG00000227370.1	RP4-669P10.19	4.63	4.64e-06	0.000996	0.23	0.21	Birth weight;	chr22:42221405	chr22:42132543~42132998:+
LUAD	cis	rs2243480	1	rs35542501	ENSG00000164669.11	INTS4P1	4.63	4.64e-06	0.000997	0.36	0.21	Diabetic kidney disease;	chr7:65966228	chr7:65141225~65234216:+
LUAD	cis	rs2243480	0.708	rs781141	ENSG00000164669.11	INTS4P1	4.63	4.64e-06	0.000997	0.36	0.21	Diabetic kidney disease;	chr7:65973566	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs781142	ENSG00000164669.11	INTS4P1	4.63	4.64e-06	0.000997	0.36	0.21	Diabetic kidney disease;	chr7:65973791	chr7:65141225~65234216:+
LUAD	cis	rs10129255	0.957	rs8014696	ENSG00000211967.3	IGHV3-53	4.63	4.64e-06	0.000997	0.16	0.21	Kawasaki disease;	chr14:106769752	chr14:106592676~106593347:-
LUAD	cis	rs875971	0.638	rs6960778	ENSG00000236529.1	RP13-254B10.1	-4.63	4.64e-06	0.000997	-0.21	-0.21	Aortic root size;	chr7:66606610	chr7:65840212~65840596:+
LUAD	cis	rs2832077	0.527	rs1048546	ENSG00000232855.5	AF131217.1	4.63	4.65e-06	0.000997	0.21	0.21	Cognitive test performance;	chr21:28872555	chr21:28439346~28674848:-
LUAD	cis	rs2548724	0.617	rs7710414	ENSG00000250682.4	LINC00491	4.63	4.65e-06	0.000998	0.24	0.21	Type 2 diabetes;	chr5:102296671	chr5:102609156~102671559:-
LUAD	cis	rs2278702	0.79	rs11858943	ENSG00000259495.2	RP11-210M15.2	-4.63	4.65e-06	0.000999	-0.32	-0.21	Bipolar disorder;	chr15:80388289	chr15:80344853~80403575:-
LUAD	cis	rs2115630	1	rs10220733	ENSG00000229212.6	RP11-561C5.4	4.63	4.65e-06	0.000999	0.24	0.21	P wave terminal force;	chr15:84737633	chr15:85205440~85234795:-
LUAD	cis	rs17685	0.712	rs7794454	ENSG00000280388.1	RP11-229D13.3	4.63	4.65e-06	0.000999	0.19	0.21	Coffee consumption (cups per day);Coffee consumption;	chr7:76146692	chr7:76043977~76045963:-
LUAD	cis	rs1009115	0.551	rs6952620	ENSG00000272328.1	RP4-594A5.1	-4.63	4.65e-06	0.000999	-0.26	-0.21	Post bronchodilator FEV1;	chr7:8372976	chr7:8303741~8341343:+
LUAD	cis	rs7102710	1	rs11607537	ENSG00000254418.1	RP11-21L19.1	4.63	4.66e-06	0.001	0.53	0.21	Glucagon levels in response to oral glucose tolerance test (fasting);	chr11:14202620	chr11:14262846~14273691:-
LUAD	cis	rs6496044	0.568	rs11632326	ENSG00000259295.5	CSPG4P12	4.63	4.66e-06	0.001	0.23	0.21	Interstitial lung disease;	chr15:85536603	chr15:85191438~85213905:+
LUAD	cis	rs853679	1	rs9986596	ENSG00000219392.1	RP1-265C24.5	-4.63	4.66e-06	0.001	-0.32	-0.21	Depression;	chr6:28251883	chr6:28115628~28116551:+
LUAD	cis	rs7017914	0.652	rs13273773	ENSG00000223220.1	Y_RNA	4.63	4.66e-06	0.001	0.24	0.21	Bone mineral density;	chr8:70867012	chr8:70780914~70781008:-
LUAD	cis	rs2243480	0.901	rs57126451	ENSG00000229886.1	RP5-1132H15.3	4.63	4.66e-06	0.001	0.36	0.21	Diabetic kidney disease;	chr7:65951319	chr7:66025126~66031544:-
LUAD	cis	rs9813712	0.571	rs9866568	ENSG00000249846.5	RP11-77P16.4	-4.63	4.66e-06	0.001	-0.24	-0.21	Response to amphetamines;	chr3:130297539	chr3:130112550~130120579:+
LUAD	cis	rs10266483	0.705	rs660228	ENSG00000228653.2	HNRNPCP7	-4.63	4.66e-06	0.001	-0.25	-0.21	Response to statin therapy;	chr7:64295867	chr7:64500825~64501729:+
LUAD	cis	rs2492286	0.569	rs9289331	ENSG00000242551.2	POU5F1P6	-4.63	4.66e-06	0.001	-0.27	-0.21	Eosinophil counts;	chr3:128635173	chr3:128674735~128677005:-
LUAD	cis	rs5758659	0.652	rs133358	ENSG00000182057.4	OGFRP1	4.63	4.67e-06	0.001	0.25	0.21	Cognitive function;	chr22:42046535	chr22:42269753~42275196:+
LUAD	cis	rs5758511	0.68	rs5758684	ENSG00000226450.2	CYP2D8P	4.63	4.67e-06	0.001	0.2	0.21	Birth weight;	chr22:42253503	chr22:42149886~42155001:-
LUAD	cis	rs6957923	0.967	rs11762106	ENSG00000230658.1	KLHL7-AS1	4.63	4.67e-06	0.001	0.25	0.21	Height;	chr7:23454841	chr7:23101228~23105703:-
LUAD	cis	rs6957923	1	rs11772260	ENSG00000230658.1	KLHL7-AS1	4.63	4.67e-06	0.001	0.25	0.21	Height;	chr7:23454881	chr7:23101228~23105703:-
LUAD	cis	rs2074409	0.571	rs67499664	ENSG00000276054.1	RP11-378E13.3	4.63	4.67e-06	0.001	0.31	0.21	Response to angiotensin II receptor blocker therapy;	chr17:37533543	chr17:37386886~37387926:+
LUAD	cis	rs10266483	0.639	rs6952592	ENSG00000228653.2	HNRNPCP7	-4.63	4.67e-06	0.001	-0.25	-0.21	Response to statin therapy;	chr7:64293667	chr7:64500825~64501729:+
LUAD	cis	rs10266483	0.705	rs599522	ENSG00000228653.2	HNRNPCP7	-4.63	4.67e-06	0.001	-0.25	-0.21	Response to statin therapy;	chr7:64298104	chr7:64500825~64501729:+
LUAD	cis	rs2243480	1	rs465359	ENSG00000164669.11	INTS4P1	4.63	4.67e-06	0.001	0.36	0.21	Diabetic kidney disease;	chr7:66093177	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs462853	ENSG00000164669.11	INTS4P1	4.63	4.67e-06	0.001	0.36	0.21	Diabetic kidney disease;	chr7:66093180	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs160644	ENSG00000164669.11	INTS4P1	4.63	4.67e-06	0.001	0.36	0.21	Diabetic kidney disease;	chr7:66093199	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs160642	ENSG00000164669.11	INTS4P1	4.63	4.67e-06	0.001	0.36	0.21	Diabetic kidney disease;	chr7:66093386	chr7:65141225~65234216:+
LUAD	cis	rs2243480	0.614	rs34032527	ENSG00000164669.11	INTS4P1	4.63	4.67e-06	0.001	0.36	0.21	Diabetic kidney disease;	chr7:66100154	chr7:65141225~65234216:+
LUAD	cis	rs6687758	0.687	rs12140498	ENSG00000200033.1	RNU6-403P	4.63	4.67e-06	0.001	0.27	0.21	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221925348	chr1:221837334~221837437:-
LUAD	cis	rs240993	0.715	rs6920798	ENSG00000271789.1	RP5-1112D6.7	4.63	4.67e-06	0.001	0.25	0.21	Inflammatory skin disease;Psoriasis;	chr6:111526074	chr6:111297126~111298510:+
LUAD	cis	rs8072100	0.935	rs8070759	ENSG00000228782.6	CTD-2026D20.3	-4.63	4.67e-06	0.001	-0.21	-0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47561394	chr17:47450568~47492492:-
LUAD	cis	rs6496044	0.526	rs4291869	ENSG00000259416.2	RP11-158M2.5	4.63	4.68e-06	0.001	0.22	0.21	Interstitial lung disease;	chr15:85511292	chr15:85754941~85756237:-
LUAD	cis	rs7324557	0.683	rs7325328	ENSG00000205861.10	C1QTNF9B-AS1	4.63	4.68e-06	0.001	0.27	0.21	Visceral adipose tissue adjusted for BMI;	chr13:23822955	chr13:23888889~23897263:+
LUAD	cis	rs2281636	0.723	rs3740078	ENSG00000233690.1	EBAG9P1	4.63	4.68e-06	0.001	0.21	0.21	Obesity-related traits;	chr10:99685834	chr10:99697407~99697949:-
LUAD	cis	rs6687758	1	rs17442058	ENSG00000200033.1	RNU6-403P	4.63	4.68e-06	0.001	0.29	0.21	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222006808	chr1:221837334~221837437:-
LUAD	cis	rs80028505	0.803	rs7745927	ENSG00000271304.1	DPRXP2	4.63	4.68e-06	0.001	0.39	0.21	Foot ulcer in diabetes and neuropathy;	chr6:36037898	chr6:35989515~35990436:-
LUAD	cis	rs80028505	0.908	rs7745536	ENSG00000271304.1	DPRXP2	4.63	4.68e-06	0.001	0.39	0.21	Foot ulcer in diabetes and neuropathy;	chr6:36037914	chr6:35989515~35990436:-
LUAD	cis	rs80028505	0.908	rs7760578	ENSG00000271304.1	DPRXP2	4.63	4.68e-06	0.001	0.39	0.21	Foot ulcer in diabetes and neuropathy;	chr6:36040286	chr6:35989515~35990436:-
LUAD	cis	rs6728642	0.519	rs7589232	ENSG00000230606.9	AC159540.1	4.63	4.69e-06	0.00101	0.29	0.21	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96900411	chr2:97416165~97433527:-
LUAD	cis	rs875971	1	rs875971	ENSG00000232559.3	GS1-124K5.12	-4.63	4.69e-06	0.00101	-0.24	-0.21	Aortic root size;	chr7:66152608	chr7:66554588~66576923:-
LUAD	cis	rs2548724	0.561	rs953280	ENSG00000250682.4	LINC00491	-4.63	4.69e-06	0.00101	-0.24	-0.21	Type 2 diabetes;	chr5:102508055	chr5:102609156~102671559:-
LUAD	cis	rs228614	0.51	rs223438	ENSG00000251288.2	RP11-10L12.2	4.63	4.69e-06	0.00101	0.25	0.21	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798584	chr4:102751401~102752641:+
LUAD	cis	rs2702164	0.781	rs2673704	ENSG00000240661.1	RP11-174O3.3	4.63	4.69e-06	0.00101	0.25	0.21	Gut microbiome composition (winter);	chr3:120415584	chr3:120349510~120367998:+
LUAD	cis	rs7396835	0.8	rs6589572	ENSG00000280143.1	AP000892.6	4.63	4.69e-06	0.00101	0.31	0.21	Quantitative traits;	chr11:116810847	chr11:117204967~117210292:+
LUAD	cis	rs12908161	1	rs11632465	ENSG00000259295.5	CSPG4P12	4.63	4.69e-06	0.00101	0.29	0.21	Schizophrenia;	chr15:84738814	chr15:85191438~85213905:+
LUAD	cis	rs2732480	0.5	rs7297824	ENSG00000240399.1	RP1-228P16.1	4.63	4.69e-06	0.00101	0.21	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48204867	chr12:48054813~48055591:-
LUAD	cis	rs9910055	0.659	rs7207464	ENSG00000267080.4	ASB16-AS1	-4.63	4.69e-06	0.00101	-0.19	-0.21	Total body bone mineral density;	chr17:44167665	chr17:44175973~44186717:-
LUAD	cis	rs9876781	0.559	rs1841178	ENSG00000229759.1	MRPS18AP1	4.63	4.7e-06	0.00101	0.2	0.21	Longevity;	chr3:48355556	chr3:48256350~48256938:-
LUAD	cis	rs1008375	0.931	rs7672369	ENSG00000249502.1	AC006160.5	-4.63	4.7e-06	0.00101	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17603202	chr4:17587467~17614571:-
LUAD	cis	rs8031584	0.678	rs3122	ENSG00000259845.1	HERC2P10	-4.63	4.7e-06	0.00101	-0.24	-0.21	Huntington's disease progression;	chr15:30878087	chr15:30815271~30844153:+
LUAD	cis	rs11089937	0.929	rs5750624	ENSG00000211638.2	IGLV8-61	-4.63	4.7e-06	0.00101	-0.2	-0.21	Periodontitis (PAL4Q3);	chr22:22165354	chr22:22098700~22099212:+
LUAD	cis	rs1008375	0.966	rs6449330	ENSG00000249502.1	AC006160.5	4.63	4.7e-06	0.00101	0.2	0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17702326	chr4:17587467~17614571:-
LUAD	cis	rs6908034	0.66	rs7746588	ENSG00000228412.5	RP4-625H18.2	4.63	4.71e-06	0.00101	0.36	0.21	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804409	chr6:19802164~19804752:-
LUAD	cis	rs6908034	0.556	rs7750703	ENSG00000228412.5	RP4-625H18.2	4.63	4.71e-06	0.00101	0.36	0.21	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804583	chr6:19802164~19804752:-
LUAD	cis	rs6840360	1	rs6840678	ENSG00000270265.1	RP11-731D1.4	4.63	4.71e-06	0.00101	0.21	0.21	Intelligence (multi-trait analysis);	chr4:151683179	chr4:151333775~151353224:-
LUAD	cis	rs1008375	1	rs1121089	ENSG00000249502.1	AC006160.5	-4.63	4.71e-06	0.00101	-0.19	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17674853	chr4:17587467~17614571:-
LUAD	cis	rs736801	0.78	rs11951091	ENSG00000233006.5	AC034220.3	4.63	4.71e-06	0.00101	0.19	0.21	Mosquito bite size;Breast cancer;	chr5:132450903	chr5:132311285~132369916:-
LUAD	cis	rs2380205	0.682	rs7919785	ENSG00000232807.2	RP11-536K7.3	4.63	4.71e-06	0.00101	0.21	0.21	Breast cancer;	chr10:5884168	chr10:5934270~5945900:-
LUAD	cis	rs914615	0.507	rs4971085	ENSG00000160766.13	GBAP1	-4.63	4.71e-06	0.00101	-0.21	-0.21	Urinary albumin-to-creatinine ratio;	chr1:155165746	chr1:155213821~155227422:-
LUAD	cis	rs2243480	1	rs9769882	ENSG00000232559.3	GS1-124K5.12	-4.63	4.71e-06	0.00101	-0.36	-0.21	Diabetic kidney disease;	chr7:66177938	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs6966322	ENSG00000232559.3	GS1-124K5.12	-4.63	4.71e-06	0.00101	-0.36	-0.21	Diabetic kidney disease;	chr7:66181767	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs4145008	ENSG00000232559.3	GS1-124K5.12	-4.63	4.71e-06	0.00101	-0.36	-0.21	Diabetic kidney disease;	chr7:66182524	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs4718315	ENSG00000232559.3	GS1-124K5.12	-4.63	4.71e-06	0.00101	-0.36	-0.21	Diabetic kidney disease;	chr7:66183554	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs4718316	ENSG00000232559.3	GS1-124K5.12	-4.63	4.71e-06	0.00101	-0.36	-0.21	Diabetic kidney disease;	chr7:66183744	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs1873494	ENSG00000232559.3	GS1-124K5.12	-4.63	4.71e-06	0.00101	-0.36	-0.21	Diabetic kidney disease;	chr7:66184912	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs6959002	ENSG00000232559.3	GS1-124K5.12	-4.63	4.71e-06	0.00101	-0.36	-0.21	Diabetic kidney disease;	chr7:66185509	chr7:66554588~66576923:-
LUAD	cis	rs2252586	0.92	rs73410447	ENSG00000176826.14	FKBP9P1	-4.63	4.72e-06	0.00101	-0.28	-0.21	Glioma;	chr7:54902458	chr7:55681074~55713252:-
LUAD	cis	rs9322193	0.923	rs1934534	ENSG00000268592.3	RAET1E-AS1	4.63	4.72e-06	0.00101	0.25	0.21	Lung cancer;	chr6:149711896	chr6:149863494~149919507:+
LUAD	cis	rs442309	0.687	rs10822057	ENSG00000238280.1	RP11-436D10.3	-4.63	4.72e-06	0.00101	-0.26	-0.21	Vogt-Koyanagi-Harada syndrome;	chr10:62760391	chr10:62793562~62805887:-
LUAD	cis	rs4819052	0.679	rs2255761	ENSG00000223768.1	LINC00205	-4.63	4.72e-06	0.00101	-0.24	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263707	chr21:45293285~45297354:+
LUAD	cis	rs5758511	0.679	rs55867855	ENSG00000226450.2	CYP2D8P	4.63	4.72e-06	0.00101	0.2	0.21	Birth weight;	chr22:42227252	chr22:42149886~42155001:-
LUAD	cis	rs6840360	0.582	rs2709826	ENSG00000270265.1	RP11-731D1.4	-4.63	4.72e-06	0.00101	-0.21	-0.21	Intelligence (multi-trait analysis);	chr4:151410968	chr4:151333775~151353224:-
LUAD	cis	rs878939	0.625	rs17578234	ENSG00000230224.1	PHBP9	-4.63	4.73e-06	0.00101	-0.2	-0.21	Warfarin maintenance dose;	chr10:99583560	chr10:100248271~100249095:+
LUAD	cis	rs2243480	0.615	rs34363376	ENSG00000232559.3	GS1-124K5.12	4.63	4.73e-06	0.00101	0.36	0.21	Diabetic kidney disease;	chr7:66474549	chr7:66554588~66576923:-
LUAD	cis	rs7665090	1	rs4586937	ENSG00000246560.2	RP11-10L12.4	-4.63	4.73e-06	0.00101	-0.25	-0.21	Primary biliary cholangitis;	chr4:102635305	chr4:102828055~102844075:+
LUAD	cis	rs228614	0.51	rs223356	ENSG00000251288.2	RP11-10L12.2	-4.63	4.73e-06	0.00101	-0.25	-0.21	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102852344	chr4:102751401~102752641:+
LUAD	cis	rs559928	0.606	rs11600628	ENSG00000236935.1	AP003774.1	4.63	4.73e-06	0.00101	0.3	0.21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64208555	chr11:64325050~64329504:-
LUAD	cis	rs6700559	0.74	rs10919997	ENSG00000260088.1	RP11-92G12.3	4.63	4.73e-06	0.00101	0.25	0.21	Coronary artery disease;	chr1:200677522	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.74	rs4437908	ENSG00000260088.1	RP11-92G12.3	4.63	4.73e-06	0.00101	0.25	0.21	Coronary artery disease;	chr1:200679311	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.74	rs4072551	ENSG00000260088.1	RP11-92G12.3	4.63	4.73e-06	0.00101	0.25	0.21	Coronary artery disease;	chr1:200679993	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.74	rs4072554	ENSG00000260088.1	RP11-92G12.3	4.63	4.73e-06	0.00101	0.25	0.21	Coronary artery disease;	chr1:200680238	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.74	rs10919999	ENSG00000260088.1	RP11-92G12.3	4.63	4.73e-06	0.00101	0.25	0.21	Coronary artery disease;	chr1:200680631	chr1:200669507~200694250:+
LUAD	cis	rs9473147	0.516	rs9349415	ENSG00000270761.1	RP11-385F7.1	-4.63	4.74e-06	0.00102	-0.24	-0.21	Platelet distribution width;Mean platelet volume;	chr6:47584125	chr6:47477243~47477572:-
LUAD	cis	rs9473147	0.516	rs9349416	ENSG00000270761.1	RP11-385F7.1	-4.63	4.74e-06	0.00102	-0.24	-0.21	Platelet distribution width;Mean platelet volume;	chr6:47584202	chr6:47477243~47477572:-
LUAD	cis	rs9473147	0.516	rs1485780	ENSG00000270761.1	RP11-385F7.1	-4.63	4.74e-06	0.00102	-0.24	-0.21	Platelet distribution width;Mean platelet volume;	chr6:47588894	chr6:47477243~47477572:-
LUAD	cis	rs9473147	0.543	rs9381578	ENSG00000270761.1	RP11-385F7.1	-4.63	4.74e-06	0.00102	-0.24	-0.21	Platelet distribution width;Mean platelet volume;	chr6:47588898	chr6:47477243~47477572:-
LUAD	cis	rs9473147	0.516	rs9381579	ENSG00000270761.1	RP11-385F7.1	-4.63	4.74e-06	0.00102	-0.24	-0.21	Platelet distribution width;Mean platelet volume;	chr6:47588944	chr6:47477243~47477572:-
LUAD	cis	rs9473147	0.516	rs10456570	ENSG00000270761.1	RP11-385F7.1	-4.63	4.74e-06	0.00102	-0.24	-0.21	Platelet distribution width;Mean platelet volume;	chr6:47591715	chr6:47477243~47477572:-
LUAD	cis	rs193541	0.53	rs1466371	ENSG00000263432.2	RN7SL689P	4.63	4.74e-06	0.00102	0.28	0.21	Glucose homeostasis traits;	chr5:122748093	chr5:123022487~123022783:-
LUAD	cis	rs1529102	1	rs2433388	ENSG00000225889.6	AC074289.1	-4.63	4.74e-06	0.00102	-0.2	-0.21	Breast size;	chr2:64266485	chr2:64143239~64252859:+
LUAD	cis	rs1799949	0.931	rs34474989	ENSG00000236383.6	LINC00854	-4.63	4.74e-06	0.00102	-0.16	-0.21	Menopause (age at onset);	chr17:43368042	chr17:43216941~43305976:-
LUAD	cis	rs736801	0.78	rs12521868	ENSG00000233006.5	AC034220.3	-4.63	4.75e-06	0.00102	-0.18	-0.21	Mosquito bite size;Breast cancer;	chr5:132448701	chr5:132311285~132369916:-
LUAD	cis	rs7189233	0.55	rs9938788	ENSG00000279344.1	RP11-44F14.7	4.63	4.75e-06	0.00102	0.17	0.21	Intelligence (multi-trait analysis);	chr16:53447510	chr16:53478957~53481550:-
LUAD	cis	rs2243480	1	rs316322	ENSG00000232559.3	GS1-124K5.12	4.63	4.75e-06	0.00102	0.36	0.21	Diabetic kidney disease;	chr7:66146246	chr7:66554588~66576923:-
LUAD	cis	rs1707322	1	rs1707322	ENSG00000280836.1	AL355480.1	-4.63	4.75e-06	0.00102	-0.26	-0.21	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039475	chr1:45581219~45581321:-
LUAD	cis	rs9928842	0.765	rs4479268	ENSG00000280152.1	RP11-331F4.5	-4.63	4.76e-06	0.00102	-0.23	-0.21	Alcoholic chronic pancreatitis;	chr16:75190835	chr16:75245994~75250077:-
LUAD	cis	rs12122100	0.545	rs1984615	ENSG00000244371.2	PFN1P8	4.63	4.76e-06	0.00102	0.23	0.21	HIV-1 control;	chr1:147034652	chr1:146957117~146957659:-
LUAD	cis	rs2243480	0.803	rs36004293	ENSG00000229886.1	RP5-1132H15.3	4.63	4.76e-06	0.00102	0.36	0.21	Diabetic kidney disease;	chr7:65951525	chr7:66025126~66031544:-
LUAD	cis	rs2243480	0.803	rs35268390	ENSG00000229886.1	RP5-1132H15.3	4.63	4.76e-06	0.00102	0.36	0.21	Diabetic kidney disease;	chr7:65951549	chr7:66025126~66031544:-
LUAD	cis	rs7911264	0.739	rs4933734	ENSG00000236493.2	EIF2S2P3	4.63	4.77e-06	0.00102	0.24	0.21	Inflammatory bowel disease;	chr10:92654810	chr10:92668745~92669743:-
LUAD	cis	rs227275	0.554	rs223314	ENSG00000251288.2	RP11-10L12.2	-4.63	4.77e-06	0.00102	-0.25	-0.21	Allergic disease (asthma, hay fever or eczema);	chr4:102884642	chr4:102751401~102752641:+
LUAD	cis	rs228614	0.51	rs7254	ENSG00000251288.2	RP11-10L12.2	-4.63	4.77e-06	0.00102	-0.25	-0.21	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888488	chr4:102751401~102752641:+
LUAD	cis	rs11722779	0.566	rs6822658	ENSG00000251288.2	RP11-10L12.2	-4.63	4.77e-06	0.00102	-0.25	-0.21	Schizophrenia;	chr4:102891964	chr4:102751401~102752641:+
LUAD	cis	rs228614	0.51	rs6823625	ENSG00000251288.2	RP11-10L12.2	-4.63	4.77e-06	0.00102	-0.25	-0.21	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892437	chr4:102751401~102752641:+
LUAD	cis	rs228614	0.51	rs6846762	ENSG00000251288.2	RP11-10L12.2	-4.63	4.77e-06	0.00102	-0.25	-0.21	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892577	chr4:102751401~102752641:+
LUAD	cis	rs228614	0.51	rs4699032	ENSG00000251288.2	RP11-10L12.2	-4.63	4.77e-06	0.00102	-0.25	-0.21	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892724	chr4:102751401~102752641:+
LUAD	cis	rs228614	0.51	rs6830407	ENSG00000251288.2	RP11-10L12.2	-4.63	4.77e-06	0.00102	-0.25	-0.21	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102895366	chr4:102751401~102752641:+
LUAD	cis	rs6969780	1	rs73071548	ENSG00000233429.8	HOTAIRM1	4.63	4.77e-06	0.00102	0.37	0.21	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27107811	chr7:27095647~27100265:+
LUAD	cis	rs516805	0.561	rs2816094	ENSG00000279453.1	RP3-425C14.4	-4.63	4.77e-06	0.00102	-0.26	-0.21	Lymphocyte counts;	chr6:122077926	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.528	rs2816093	ENSG00000279453.1	RP3-425C14.4	-4.63	4.77e-06	0.00102	-0.26	-0.21	Lymphocyte counts;	chr6:122078123	chr6:122436789~122439223:-
LUAD	cis	rs2235642	0.671	rs2235641	ENSG00000280231.1	LA16c-380F5.3	-4.63	4.78e-06	0.00102	-0.3	-0.21	Coronary artery disease;	chr16:1558176	chr16:1553655~1554130:-
LUAD	cis	rs17772222	0.917	rs8018755	ENSG00000258789.1	RP11-507K2.3	-4.63	4.78e-06	0.00102	-0.28	-0.21	Coronary artery calcification;	chr14:88714249	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.917	rs8018630	ENSG00000258789.1	RP11-507K2.3	-4.63	4.78e-06	0.00102	-0.28	-0.21	Coronary artery calcification;	chr14:88714250	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.917	rs8020072	ENSG00000258789.1	RP11-507K2.3	-4.63	4.78e-06	0.00102	-0.28	-0.21	Coronary artery calcification;	chr14:88714332	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.917	rs12589982	ENSG00000258789.1	RP11-507K2.3	-4.63	4.78e-06	0.00102	-0.28	-0.21	Coronary artery calcification;	chr14:88716861	chr14:88551597~88552493:+
LUAD	cis	rs2823962	0.759	rs2027625	ENSG00000270093.1	AP000473.8	-4.63	4.78e-06	0.00102	-0.21	-0.21	Amyotrophic lateral sclerosis;	chr21:16641872	chr21:16643529~16645065:+
LUAD	cis	rs11155671	0.546	rs1999633	ENSG00000223701.3	RAET1E-AS1	4.63	4.78e-06	0.00102	0.29	0.21	Testicular germ cell tumor;	chr6:149866576	chr6:149884431~149919508:+
LUAD	cis	rs7811142	0.83	rs75636500	ENSG00000078319.8	PMS2P1	-4.63	4.78e-06	0.00102	-0.26	-0.21	Platelet count;	chr7:100350034	chr7:100320992~100341908:-
LUAD	cis	rs4908768	0.52	rs11121224	ENSG00000270282.1	RP5-1115A15.2	4.63	4.78e-06	0.00102	0.23	0.21	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8713456	chr1:8512653~8513021:+
LUAD	cis	rs228614	0.536	rs223484	ENSG00000251288.2	RP11-10L12.2	-4.63	4.79e-06	0.00102	-0.25	-0.21	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102764314	chr4:102751401~102752641:+
LUAD	cis	rs34779708	0.706	rs36027395	ENSG00000271335.4	RP11-324I22.4	4.63	4.79e-06	0.00102	0.22	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35261395	chr10:35314552~35336401:-
LUAD	cis	rs2243480	0.803	rs35480979	ENSG00000226002.1	RP11-460N20.5	-4.63	4.79e-06	0.00103	-0.35	-0.21	Diabetic kidney disease;	chr7:65892097	chr7:65084103~65100232:+
LUAD	cis	rs6840360	1	rs6535810	ENSG00000270265.1	RP11-731D1.4	-4.63	4.79e-06	0.00103	-0.21	-0.21	Intelligence (multi-trait analysis);	chr4:151671801	chr4:151333775~151353224:-
LUAD	cis	rs1008375	1	rs10805358	ENSG00000249502.1	AC006160.5	-4.63	4.79e-06	0.00103	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17650827	chr4:17587467~17614571:-
LUAD	cis	rs7811142	0.83	rs705866	ENSG00000078319.8	PMS2P1	-4.63	4.79e-06	0.00103	-0.26	-0.21	Platelet count;	chr7:100367662	chr7:100320992~100341908:-
LUAD	cis	rs7811142	0.83	rs6965458	ENSG00000078319.8	PMS2P1	-4.63	4.79e-06	0.00103	-0.26	-0.21	Platelet count;	chr7:100375779	chr7:100320992~100341908:-
LUAD	cis	rs13256369	1	rs4840352	ENSG00000253893.2	FAM85B	-4.63	4.8e-06	0.00103	-0.29	-0.21	Obesity-related traits;	chr8:8715998	chr8:8167819~8226614:-
LUAD	cis	rs2765539	0.701	rs10754391	ENSG00000226172.2	RP4-712E4.1	-4.63	4.8e-06	0.00103	-0.26	-0.21	Waist-hip ratio;	chr1:119087081	chr1:119000344~119001392:-
LUAD	cis	rs6750795	0.641	rs10933375	ENSG00000181798.2	LINC00471	4.63	4.8e-06	0.00103	0.26	0.21	Height;	chr2:231502585	chr2:231508426~231514339:-
LUAD	cis	rs6012564	0.927	rs932451	ENSG00000230758.1	SNAP23P	-4.63	4.8e-06	0.00103	-0.22	-0.21	Anger;	chr20:48957061	chr20:49038357~49038602:-
LUAD	cis	rs2380205	0.651	rs12357094	ENSG00000232807.2	RP11-536K7.3	4.63	4.8e-06	0.00103	0.21	0.21	Breast cancer;	chr10:5884340	chr10:5934270~5945900:-
LUAD	cis	rs2976388	0.967	rs2978981	ENSG00000253741.1	CTD-2292P10.4	4.63	4.8e-06	0.00103	0.23	0.21	Urinary tract infection frequency;	chr8:142677719	chr8:142702252~142726973:-
LUAD	cis	rs449789	0.857	rs10806706	ENSG00000235086.1	FNDC1-IT1	4.63	4.8e-06	0.00103	0.28	0.21	Pulse pressure;	chr6:159300913	chr6:159240786~159243329:+
LUAD	cis	rs6840360	0.934	rs6817058	ENSG00000270265.1	RP11-731D1.4	-4.63	4.8e-06	0.00103	-0.21	-0.21	Intelligence (multi-trait analysis);	chr4:151682713	chr4:151333775~151353224:-
LUAD	cis	rs9487094	0.922	rs59056467	ENSG00000260273.1	RP11-425D10.10	4.63	4.81e-06	0.00103	0.28	0.21	Height;	chr6:109446728	chr6:109382795~109383666:+
LUAD	cis	rs9473147	0.571	rs9463335	ENSG00000270761.1	RP11-385F7.1	-4.63	4.81e-06	0.00103	-0.24	-0.21	Platelet distribution width;Mean platelet volume;	chr6:47511400	chr6:47477243~47477572:-
LUAD	cis	rs11673344	0.864	rs703535	ENSG00000226686.6	LINC01535	4.63	4.81e-06	0.00103	0.27	0.21	Obesity-related traits;	chr19:37014838	chr19:37251912~37265535:+
LUAD	cis	rs1008375	0.932	rs4698629	ENSG00000249502.1	AC006160.5	-4.63	4.81e-06	0.00103	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17607261	chr4:17587467~17614571:-
LUAD	cis	rs301901	0.965	rs158803	ENSG00000250155.1	CTD-2353F22.1	-4.63	4.81e-06	0.00103	-0.21	-0.21	Height;	chr5:36911514	chr5:36666214~36725195:-
LUAD	cis	rs875971	1	rs1363055	ENSG00000232559.3	GS1-124K5.12	4.63	4.81e-06	0.00103	0.24	0.21	Aortic root size;	chr7:66478288	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.964	rs9691480	ENSG00000232559.3	GS1-124K5.12	4.63	4.81e-06	0.00103	0.24	0.21	Aortic root size;	chr7:66479319	chr7:66554588~66576923:-
LUAD	cis	rs875971	1	rs7789554	ENSG00000232559.3	GS1-124K5.12	4.63	4.81e-06	0.00103	0.24	0.21	Aortic root size;	chr7:66481051	chr7:66554588~66576923:-
LUAD	cis	rs875971	1	rs4717300	ENSG00000232559.3	GS1-124K5.12	4.63	4.81e-06	0.00103	0.24	0.21	Aortic root size;	chr7:66482393	chr7:66554588~66576923:-
LUAD	cis	rs11673344	0.864	rs7256213	ENSG00000226686.6	LINC01535	4.63	4.81e-06	0.00103	0.26	0.21	Obesity-related traits;	chr19:37020589	chr19:37251912~37265535:+
LUAD	cis	rs11168249	0.819	rs2525051	ENSG00000276691.1	RP5-1057I20.5	4.63	4.81e-06	0.00103	0.18	0.21	Lymphocyte counts;Inflammatory bowel disease;Ulcerative colitis;	chr12:47802156	chr12:47788426~47788971:+
LUAD	cis	rs4835473	0.618	rs7666297	ENSG00000251600.4	RP11-673E1.1	-4.63	4.81e-06	0.00103	-0.26	-0.21	Immature fraction of reticulocytes;	chr4:143999005	chr4:143912331~143982454:+
LUAD	cis	rs4845875	0.6	rs4846039	ENSG00000242349.4	NPPA-AS1	4.63	4.82e-06	0.00103	0.23	0.21	Midregional pro atrial natriuretic peptide levels;	chr1:11776811	chr1:11841017~11848079:+
LUAD	cis	rs4845875	0.6	rs4846040	ENSG00000242349.4	NPPA-AS1	4.63	4.82e-06	0.00103	0.23	0.21	Midregional pro atrial natriuretic peptide levels;	chr1:11776991	chr1:11841017~11848079:+
LUAD	cis	rs4845875	0.6	rs4846041	ENSG00000242349.4	NPPA-AS1	4.63	4.82e-06	0.00103	0.23	0.21	Midregional pro atrial natriuretic peptide levels;	chr1:11776994	chr1:11841017~11848079:+
LUAD	cis	rs4845875	0.6	rs10779765	ENSG00000242349.4	NPPA-AS1	4.63	4.82e-06	0.00103	0.23	0.21	Midregional pro atrial natriuretic peptide levels;	chr1:11777954	chr1:11841017~11848079:+
LUAD	cis	rs4845875	0.563	rs10864540	ENSG00000242349.4	NPPA-AS1	4.63	4.82e-06	0.00103	0.23	0.21	Midregional pro atrial natriuretic peptide levels;	chr1:11778042	chr1:11841017~11848079:+
LUAD	cis	rs4845875	0.6	rs1889293	ENSG00000242349.4	NPPA-AS1	4.63	4.82e-06	0.00103	0.23	0.21	Midregional pro atrial natriuretic peptide levels;	chr1:11780805	chr1:11841017~11848079:+
LUAD	cis	rs914615	0.552	rs4276914	ENSG00000160766.13	GBAP1	-4.63	4.82e-06	0.00103	-0.21	-0.21	Urinary albumin-to-creatinine ratio;	chr1:155169753	chr1:155213821~155227422:-
LUAD	cis	rs914615	0.552	rs4971088	ENSG00000160766.13	GBAP1	-4.63	4.82e-06	0.00103	-0.21	-0.21	Urinary albumin-to-creatinine ratio;	chr1:155170407	chr1:155213821~155227422:-
LUAD	cis	rs914615	0.552	rs4971089	ENSG00000160766.13	GBAP1	-4.63	4.82e-06	0.00103	-0.21	-0.21	Urinary albumin-to-creatinine ratio;	chr1:155170451	chr1:155213821~155227422:-
LUAD	cis	rs151234	0.741	rs151227	ENSG00000259982.1	CDC37P1	-4.63	4.82e-06	0.00103	-0.36	-0.21	Platelet distribution width;	chr16:28538187	chr16:28700294~28701540:-
LUAD	cis	rs4819052	0.851	rs9977178	ENSG00000237664.1	LINC00316	-4.62	4.82e-06	0.00103	-0.24	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244616	chr21:45338590~45341990:-
LUAD	cis	rs2243480	1	rs34815098	ENSG00000229886.1	RP5-1132H15.3	4.62	4.83e-06	0.00103	0.36	0.21	Diabetic kidney disease;	chr7:65827267	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs4548056	ENSG00000229886.1	RP5-1132H15.3	4.62	4.83e-06	0.00103	0.36	0.21	Diabetic kidney disease;	chr7:65833886	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs7456042	ENSG00000229886.1	RP5-1132H15.3	4.62	4.83e-06	0.00103	0.36	0.21	Diabetic kidney disease;	chr7:65834791	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs35735127	ENSG00000229886.1	RP5-1132H15.3	4.62	4.83e-06	0.00103	0.36	0.21	Diabetic kidney disease;	chr7:65835436	chr7:66025126~66031544:-
LUAD	cis	rs2243480	0.901	rs35256305	ENSG00000229886.1	RP5-1132H15.3	4.62	4.83e-06	0.00103	0.36	0.21	Diabetic kidney disease;	chr7:65841418	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs73142121	ENSG00000229886.1	RP5-1132H15.3	4.62	4.83e-06	0.00103	0.36	0.21	Diabetic kidney disease;	chr7:65846219	chr7:66025126~66031544:-
LUAD	cis	rs2243480	0.803	rs34004500	ENSG00000229886.1	RP5-1132H15.3	4.62	4.83e-06	0.00103	0.36	0.21	Diabetic kidney disease;	chr7:65847191	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs35825738	ENSG00000229886.1	RP5-1132H15.3	4.62	4.83e-06	0.00103	0.36	0.21	Diabetic kidney disease;	chr7:65853040	chr7:66025126~66031544:-
LUAD	cis	rs7119	0.717	rs11635567	ENSG00000259362.2	RP11-307C19.1	-4.62	4.83e-06	0.00103	-0.26	-0.21	Type 2 diabetes;	chr15:77527173	chr15:77525540~77534110:+
LUAD	cis	rs2880765	0.743	rs8032488	ENSG00000259295.5	CSPG4P12	4.62	4.83e-06	0.00103	0.24	0.21	Coronary artery disease;	chr15:85469537	chr15:85191438~85213905:+
LUAD	cis	rs2742234	1	rs2742234	ENSG00000273008.1	RP11-351D16.3	4.62	4.84e-06	0.00103	0.22	0.21	Hirschsprung disease;	chr10:43117161	chr10:43136824~43138334:-
LUAD	cis	rs1823874	0.72	rs1993296	ENSG00000182397.13	DNM1P46	-4.62	4.84e-06	0.00103	-0.23	-0.21	IgG glycosylation;	chr15:99823383	chr15:99790156~99806927:-
LUAD	cis	rs3738443	0.599	rs1934986	ENSG00000259865.1	RP11-488L18.10	4.62	4.84e-06	0.00103	0.21	0.21	Alcohol dependence;	chr1:247235696	chr1:247187281~247188526:-
LUAD	cis	rs116175783	0.557	rs16845770	ENSG00000227403.1	AC009299.3	4.62	4.84e-06	0.00103	0.38	0.21	Intelligence (multi-trait analysis);	chr2:161325276	chr2:161244739~161249050:+
LUAD	cis	rs1008375	0.932	rs4698628	ENSG00000249502.1	AC006160.5	-4.62	4.84e-06	0.00104	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17606997	chr4:17587467~17614571:-
LUAD	cis	rs783540	0.592	rs2567632	ENSG00000276710.3	CSPG4P8	4.62	4.84e-06	0.00104	0.21	0.21	Schizophrenia;	chr15:82616053	chr15:82459472~82477258:+
LUAD	cis	rs11673344	0.711	rs112857724	ENSG00000226686.6	LINC01535	4.62	4.84e-06	0.00104	0.26	0.21	Obesity-related traits;	chr19:37030176	chr19:37251912~37265535:+
LUAD	cis	rs4660214	0.666	rs598415	ENSG00000228060.1	RP11-69E11.8	-4.62	4.84e-06	0.00104	-0.18	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39366735	chr1:39565160~39573203:+
LUAD	cis	rs1008375	0.9	rs13144986	ENSG00000249502.1	AC006160.5	4.62	4.85e-06	0.00104	0.2	0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17673396	chr4:17587467~17614571:-
LUAD	cis	rs5758511	0.68	rs58654759	ENSG00000226450.2	CYP2D8P	4.62	4.85e-06	0.00104	0.2	0.21	Birth weight;	chr22:42246570	chr22:42149886~42155001:-
LUAD	cis	rs4601821	0.823	rs4938013	ENSG00000270179.1	RP11-159N11.4	-4.62	4.85e-06	0.00104	-0.22	-0.21	Alcoholic chronic pancreatitis;	chr11:113393748	chr11:113368478~113369117:+
LUAD	cis	rs6012564	1	rs2295028	ENSG00000230758.1	SNAP23P	-4.62	4.85e-06	0.00104	-0.22	-0.21	Anger;	chr20:48966421	chr20:49038357~49038602:-
LUAD	cis	rs507080	0.922	rs546890	ENSG00000278376.1	RP11-158I9.8	-4.62	4.85e-06	0.00104	-0.22	-0.21	Serum metabolite levels;	chr11:118686489	chr11:118791254~118793137:+
LUAD	cis	rs507080	0.883	rs693306	ENSG00000278376.1	RP11-158I9.8	-4.62	4.85e-06	0.00104	-0.22	-0.21	Serum metabolite levels;	chr11:118687624	chr11:118791254~118793137:+
LUAD	cis	rs507080	0.922	rs558907	ENSG00000278376.1	RP11-158I9.8	-4.62	4.85e-06	0.00104	-0.22	-0.21	Serum metabolite levels;	chr11:118687746	chr11:118791254~118793137:+
LUAD	cis	rs507080	0.922	rs561845	ENSG00000278376.1	RP11-158I9.8	-4.62	4.85e-06	0.00104	-0.22	-0.21	Serum metabolite levels;	chr11:118688118	chr11:118791254~118793137:+
LUAD	cis	rs507080	0.922	rs638805	ENSG00000278376.1	RP11-158I9.8	-4.62	4.85e-06	0.00104	-0.22	-0.21	Serum metabolite levels;	chr11:118688180	chr11:118791254~118793137:+
LUAD	cis	rs507080	0.845	rs510408	ENSG00000278376.1	RP11-158I9.8	-4.62	4.85e-06	0.00104	-0.22	-0.21	Serum metabolite levels;	chr11:118688192	chr11:118791254~118793137:+
LUAD	cis	rs507080	0.845	rs509641	ENSG00000278376.1	RP11-158I9.8	-4.62	4.85e-06	0.00104	-0.22	-0.21	Serum metabolite levels;	chr11:118688243	chr11:118791254~118793137:+
LUAD	cis	rs507080	0.883	rs563549	ENSG00000278376.1	RP11-158I9.8	-4.62	4.85e-06	0.00104	-0.22	-0.21	Serum metabolite levels;	chr11:118688244	chr11:118791254~118793137:+
LUAD	cis	rs507080	0.885	rs533144	ENSG00000278376.1	RP11-158I9.8	-4.62	4.85e-06	0.00104	-0.22	-0.21	Serum metabolite levels;	chr11:118688538	chr11:118791254~118793137:+
LUAD	cis	rs507080	0.885	rs4938530	ENSG00000278376.1	RP11-158I9.8	-4.62	4.85e-06	0.00104	-0.22	-0.21	Serum metabolite levels;	chr11:118689861	chr11:118791254~118793137:+
LUAD	cis	rs9322193	0.884	rs9322210	ENSG00000268592.3	RAET1E-AS1	4.62	4.85e-06	0.00104	0.25	0.21	Lung cancer;	chr6:149695440	chr6:149863494~149919507:+
LUAD	cis	rs12439619	0.883	rs62012045	ENSG00000276710.3	CSPG4P8	-4.62	4.85e-06	0.00104	-0.21	-0.21	Intelligence (multi-trait analysis);	chr15:82229366	chr15:82459472~82477258:+
LUAD	cis	rs950169	0.922	rs4338765	ENSG00000275120.1	RP11-182J1.17	4.62	4.85e-06	0.00104	0.32	0.21	Schizophrenia;	chr15:84248084	chr15:84599434~84606463:-
LUAD	cis	rs737008	0.96	rs949429	ENSG00000262703.1	RP11-485G7.6	-4.62	4.85e-06	0.00104	-0.19	-0.21	Obesity-related traits;	chr16:11282172	chr16:11348143~11349321:-
LUAD	cis	rs9303029	0.866	rs72857495	ENSG00000265458.1	RP13-20L14.6	4.62	4.86e-06	0.00104	0.37	0.21	Protein quantitative trait loci;	chr17:82454991	chr17:82454273~82458521:-
LUAD	cis	rs17685	0.753	rs10085567	ENSG00000280388.1	RP11-229D13.3	-4.62	4.86e-06	0.00104	-0.19	-0.21	Coffee consumption (cups per day);Coffee consumption;	chr7:76104888	chr7:76043977~76045963:-
LUAD	cis	rs6700559	0.74	rs11582610	ENSG00000260088.1	RP11-92G12.3	4.62	4.86e-06	0.00104	0.25	0.21	Coronary artery disease;	chr1:200675973	chr1:200669507~200694250:+
LUAD	cis	rs8062405	0.754	rs151179	ENSG00000251417.2	RP11-1348G14.4	-4.62	4.87e-06	0.00104	-0.21	-0.21	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28802743~28817828:+
LUAD	cis	rs875971	0.964	rs1643388	ENSG00000232559.3	GS1-124K5.12	4.62	4.87e-06	0.00104	0.24	0.21	Aortic root size;	chr7:66379575	chr7:66554588~66576923:-
LUAD	cis	rs875971	1	rs778722	ENSG00000232559.3	GS1-124K5.12	4.62	4.87e-06	0.00104	0.24	0.21	Aortic root size;	chr7:66379841	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.964	rs778721	ENSG00000232559.3	GS1-124K5.12	4.62	4.87e-06	0.00104	0.24	0.21	Aortic root size;	chr7:66380410	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.929	rs778712	ENSG00000232559.3	GS1-124K5.12	4.62	4.87e-06	0.00104	0.24	0.21	Aortic root size;	chr7:66384991	chr7:66554588~66576923:-
LUAD	cis	rs875971	1	rs778710	ENSG00000232559.3	GS1-124K5.12	4.62	4.87e-06	0.00104	0.24	0.21	Aortic root size;	chr7:66389847	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.964	rs778708	ENSG00000232559.3	GS1-124K5.12	4.62	4.87e-06	0.00104	0.24	0.21	Aortic root size;	chr7:66391332	chr7:66554588~66576923:-
LUAD	cis	rs875971	1	rs778706	ENSG00000232559.3	GS1-124K5.12	4.62	4.87e-06	0.00104	0.24	0.21	Aortic root size;	chr7:66395437	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.895	rs778700	ENSG00000232559.3	GS1-124K5.12	4.62	4.87e-06	0.00104	0.24	0.21	Aortic root size;	chr7:66401463	chr7:66554588~66576923:-
LUAD	cis	rs875971	1	rs778699	ENSG00000232559.3	GS1-124K5.12	4.62	4.87e-06	0.00104	0.24	0.21	Aortic root size;	chr7:66403303	chr7:66554588~66576923:-
LUAD	cis	rs875971	1	rs778696	ENSG00000232559.3	GS1-124K5.12	4.62	4.87e-06	0.00104	0.24	0.21	Aortic root size;	chr7:66405826	chr7:66554588~66576923:-
LUAD	cis	rs875971	1	rs778694	ENSG00000232559.3	GS1-124K5.12	4.62	4.87e-06	0.00104	0.24	0.21	Aortic root size;	chr7:66406571	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.929	rs778692	ENSG00000232559.3	GS1-124K5.12	4.62	4.87e-06	0.00104	0.24	0.21	Aortic root size;	chr7:66407462	chr7:66554588~66576923:-
LUAD	cis	rs875971	1	rs4718343	ENSG00000232559.3	GS1-124K5.12	4.62	4.87e-06	0.00104	0.24	0.21	Aortic root size;	chr7:66409301	chr7:66554588~66576923:-
LUAD	cis	rs875971	1	rs4718344	ENSG00000232559.3	GS1-124K5.12	4.62	4.87e-06	0.00104	0.24	0.21	Aortic root size;	chr7:66409394	chr7:66554588~66576923:-
LUAD	cis	rs875971	1	rs1968225	ENSG00000232559.3	GS1-124K5.12	4.62	4.87e-06	0.00104	0.24	0.21	Aortic root size;	chr7:66409786	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.737	rs7803424	ENSG00000232559.3	GS1-124K5.12	4.62	4.87e-06	0.00104	0.24	0.21	Aortic root size;	chr7:66415618	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.83	rs7799834	ENSG00000232559.3	GS1-124K5.12	4.62	4.87e-06	0.00104	0.24	0.21	Aortic root size;	chr7:66415707	chr7:66554588~66576923:-
LUAD	cis	rs875971	1	rs6460295	ENSG00000232559.3	GS1-124K5.12	4.62	4.87e-06	0.00104	0.24	0.21	Aortic root size;	chr7:66417741	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.964	rs6978721	ENSG00000232559.3	GS1-124K5.12	4.62	4.87e-06	0.00104	0.24	0.21	Aortic root size;	chr7:66418217	chr7:66554588~66576923:-
LUAD	cis	rs11023332	0.706	rs11023379	ENSG00000251991.1	RNU7-49P	4.62	4.87e-06	0.00104	0.23	0.21	Vitamin D levels;Adiponectin levels;	chr11:14908414	chr11:14478892~14478953:+
LUAD	cis	rs2380205	0.516	rs7919913	ENSG00000232807.2	RP11-536K7.3	4.62	4.87e-06	0.00104	0.22	0.21	Breast cancer;	chr10:5884253	chr10:5934270~5945900:-
LUAD	cis	rs6840360	1	rs4696283	ENSG00000270265.1	RP11-731D1.4	-4.62	4.87e-06	0.00104	-0.21	-0.21	Intelligence (multi-trait analysis);	chr4:151659364	chr4:151333775~151353224:-
LUAD	cis	rs6957923	0.967	rs34677598	ENSG00000230658.1	KLHL7-AS1	4.62	4.88e-06	0.00104	0.25	0.21	Height;	chr7:23460008	chr7:23101228~23105703:-
LUAD	cis	rs9532669	0.926	rs7329302	ENSG00000168852.11	TPTE2P5	-4.62	4.88e-06	0.00104	-0.2	-0.21	Cervical cancer;	chr13:40962396	chr13:40822296~40921749:-
LUAD	cis	rs7138803	0.538	rs4488285	ENSG00000257464.1	RP11-161H23.8	-4.62	4.88e-06	0.00104	-0.21	-0.21	Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index;	chr12:49818613	chr12:49442424~49442652:-
LUAD	cis	rs7138803	0.538	rs11615911	ENSG00000257464.1	RP11-161H23.8	-4.62	4.88e-06	0.00104	-0.21	-0.21	Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index;	chr12:49819137	chr12:49442424~49442652:-
LUAD	cis	rs9467773	0.836	rs1624440	ENSG00000124549.13	BTN2A3P	-4.62	4.88e-06	0.00104	-0.19	-0.21	Intelligence (multi-trait analysis);	chr6:26433101	chr6:26421391~26432383:+
LUAD	cis	rs12681366	0.881	rs12676373	ENSG00000253704.1	RP11-267M23.4	4.62	4.88e-06	0.00104	0.26	0.21	Nonsyndromic cleft lip with cleft palate;	chr8:94349890	chr8:94553722~94569745:+
LUAD	cis	rs7208859	0.562	rs216408	ENSG00000280069.1	CTD-2349P21.3	4.62	4.88e-06	0.00104	0.24	0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30580739	chr17:30738182~30740275:+
LUAD	cis	rs1008375	0.863	rs2058336	ENSG00000249502.1	AC006160.5	-4.62	4.88e-06	0.00104	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17606676	chr4:17587467~17614571:-
LUAD	cis	rs60180747	0.543	rs1871006	ENSG00000261318.1	RP11-653J6.1	4.62	4.89e-06	0.00104	0.27	0.21	Testicular germ cell tumor;	chr15:66255303	chr15:66278498~66293357:-
LUAD	cis	rs60180747	0.544	rs1020927	ENSG00000261318.1	RP11-653J6.1	4.62	4.89e-06	0.00104	0.27	0.21	Testicular germ cell tumor;	chr15:66258920	chr15:66278498~66293357:-
LUAD	cis	rs875971	0.66	rs7807930	ENSG00000224316.1	RP11-479O9.2	-4.62	4.89e-06	0.00104	-0.21	-0.21	Aortic root size;	chr7:66622178	chr7:65773620~65802067:+
LUAD	cis	rs875971	0.66	rs7807944	ENSG00000224316.1	RP11-479O9.2	-4.62	4.89e-06	0.00104	-0.21	-0.21	Aortic root size;	chr7:66622208	chr7:65773620~65802067:+
LUAD	cis	rs1005277	0.579	rs176838	ENSG00000263064.2	RP11-291L22.7	-4.62	4.89e-06	0.00104	-0.22	-0.21	Extrinsic epigenetic age acceleration;	chr10:38082971	chr10:38448689~38448949:+
LUAD	cis	rs9322193	0.884	rs9688794	ENSG00000268592.3	RAET1E-AS1	4.62	4.89e-06	0.00104	0.25	0.21	Lung cancer;	chr6:149632121	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.923	rs9322204	ENSG00000268592.3	RAET1E-AS1	4.62	4.89e-06	0.00104	0.25	0.21	Lung cancer;	chr6:149636047	chr6:149863494~149919507:+
LUAD	cis	rs755249	0.501	rs2484749	ENSG00000182109.6	RP11-69E11.4	-4.62	4.89e-06	0.00104	-0.23	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39293283	chr1:39522280~39546187:-
LUAD	cis	rs848490	0.928	rs62460675	ENSG00000214293.7	APTR	4.62	4.89e-06	0.00104	0.27	0.21	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77678027	chr7:77657660~77696265:-
LUAD	cis	rs7772486	0.641	rs2748489	ENSG00000235652.6	RP11-545I5.3	4.62	4.89e-06	0.00104	0.22	0.21	Lobe attachment (rater-scored or self-reported);	chr6:146010151	chr6:145799409~145886585:+
LUAD	cis	rs453301	0.686	rs2409120	ENSG00000253893.2	FAM85B	4.62	4.89e-06	0.00104	0.26	0.21	Joint mobility (Beighton score);	chr8:9025061	chr8:8167819~8226614:-
LUAD	cis	rs2976388	1	rs2976398	ENSG00000253741.1	CTD-2292P10.4	4.62	4.9e-06	0.00104	0.23	0.21	Urinary tract infection frequency;	chr8:142683461	chr8:142702252~142726973:-
LUAD	cis	rs2243480	1	rs316307	ENSG00000164669.11	INTS4P1	4.62	4.9e-06	0.00104	0.38	0.21	Diabetic kidney disease;	chr7:66105184	chr7:65141225~65234216:+
LUAD	cis	rs12550612	0.83	rs10111172	ENSG00000253616.4	RP11-875O11.3	-4.62	4.9e-06	0.00104	-0.3	-0.21	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23111578	chr8:23071377~23074488:-
LUAD	cis	rs35740288	0.929	rs11073537	ENSG00000259407.1	RP11-158M2.3	-4.62	4.9e-06	0.00105	-0.21	-0.21	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85769450	chr15:85744109~85750281:-
LUAD	cis	rs9309473	0.607	rs10198301	ENSG00000163016.8	ALMS1P	4.62	4.9e-06	0.00105	0.23	0.21	Metabolite levels;	chr2:73354472	chr2:73644919~73685576:+
LUAD	cis	rs2243480	0.803	rs36127118	ENSG00000164669.11	INTS4P1	4.62	4.9e-06	0.00105	0.36	0.21	Diabetic kidney disease;	chr7:66100518	chr7:65141225~65234216:+
LUAD	cis	rs2562456	0.833	rs11666447	ENSG00000268081.1	RP11-678G14.2	4.62	4.9e-06	0.00105	0.34	0.21	Pain;	chr19:21416270	chr19:21554640~21569237:-
LUAD	cis	rs4819052	0.704	rs2297283	ENSG00000215447.6	BX322557.10	-4.62	4.9e-06	0.00105	-0.24	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263675	chr21:45288052~45291738:+
LUAD	cis	rs6570726	0.905	rs442435	ENSG00000235652.6	RP11-545I5.3	4.62	4.91e-06	0.00105	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145494423	chr6:145799409~145886585:+
LUAD	cis	rs7829975	0.744	rs2409092	ENSG00000253893.2	FAM85B	-4.62	4.91e-06	0.00105	-0.26	-0.21	Mood instability;	chr8:8824682	chr8:8167819~8226614:-
LUAD	cis	rs7493	0.76	rs17876092	ENSG00000233942.1	AC004012.1	4.62	4.91e-06	0.00105	0.31	0.21	Yu-Zhi constitution type in type 2 diabetes;	chr7:95424001	chr7:95471835~95473998:+
LUAD	cis	rs12701220	0.52	rs7803208	ENSG00000229043.2	AC091729.9	-4.62	4.91e-06	0.00105	-0.24	-0.21	Bronchopulmonary dysplasia;	chr7:1122448	chr7:1160374~1165267:+
LUAD	cis	rs12554020	0.582	rs79565493	ENSG00000227603.1	RP11-165J3.6	4.62	4.91e-06	0.00105	0.45	0.21	Schizophrenia;	chr9:93634820	chr9:93435332~93437121:-
LUAD	cis	rs12554020	0.582	rs74421510	ENSG00000227603.1	RP11-165J3.6	4.62	4.91e-06	0.00105	0.45	0.21	Schizophrenia;	chr9:93634872	chr9:93435332~93437121:-
LUAD	cis	rs12554020	0.582	rs55783552	ENSG00000227603.1	RP11-165J3.6	4.62	4.91e-06	0.00105	0.45	0.21	Schizophrenia;	chr9:93637205	chr9:93435332~93437121:-
LUAD	cis	rs12554020	0.582	rs80228675	ENSG00000227603.1	RP11-165J3.6	4.62	4.91e-06	0.00105	0.45	0.21	Schizophrenia;	chr9:93637918	chr9:93435332~93437121:-
LUAD	cis	rs12554020	0.582	rs79391190	ENSG00000227603.1	RP11-165J3.6	4.62	4.91e-06	0.00105	0.45	0.21	Schizophrenia;	chr9:93637992	chr9:93435332~93437121:-
LUAD	cis	rs10266483	0.739	rs12671185	ENSG00000227986.1	TRIM60P18	4.62	4.91e-06	0.00105	0.25	0.21	Response to statin therapy;	chr7:64333329	chr7:64355078~64356199:+
LUAD	cis	rs9309473	0.632	rs6546825	ENSG00000163016.8	ALMS1P	4.62	4.91e-06	0.00105	0.23	0.21	Metabolite levels;	chr2:73365125	chr2:73644919~73685576:+
LUAD	cis	rs4664293	0.605	rs6745815	ENSG00000226266.5	AC009961.3	4.62	4.91e-06	0.00105	0.28	0.21	Monocyte percentage of white cells;	chr2:159693558	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.551	rs11898293	ENSG00000226266.5	AC009961.3	4.62	4.91e-06	0.00105	0.28	0.21	Monocyte percentage of white cells;	chr2:159696082	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.605	rs6741498	ENSG00000226266.5	AC009961.3	4.62	4.91e-06	0.00105	0.28	0.21	Monocyte percentage of white cells;	chr2:159698111	chr2:159670708~159712435:-
LUAD	cis	rs6840360	1	rs1366909	ENSG00000270265.1	RP11-731D1.4	-4.62	4.92e-06	0.00105	-0.21	-0.21	Intelligence (multi-trait analysis);	chr4:151667269	chr4:151333775~151353224:-
LUAD	cis	rs12701220	0.817	rs59471534	ENSG00000229043.2	AC091729.9	-4.62	4.92e-06	0.00105	-0.26	-0.21	Bronchopulmonary dysplasia;	chr7:1045588	chr7:1160374~1165267:+
LUAD	cis	rs9425766	0.679	rs4650990	ENSG00000227373.4	RP11-160H22.5	4.62	4.92e-06	0.00105	0.26	0.21	Life satisfaction;	chr1:174289943	chr1:174115300~174160004:-
LUAD	cis	rs2115630	1	rs11073730	ENSG00000229212.6	RP11-561C5.4	4.62	4.92e-06	0.00105	0.24	0.21	P wave terminal force;	chr15:84811365	chr15:85205440~85234795:-
LUAD	cis	rs17772222	0.674	rs112788894	ENSG00000258983.2	RP11-507K2.2	4.62	4.92e-06	0.00105	0.26	0.21	Coronary artery calcification;	chr14:88442850	chr14:88499334~88515502:+
LUAD	cis	rs7945705	0.738	rs11042067	ENSG00000254860.4	TMEM9B-AS1	4.62	4.92e-06	0.00105	0.23	0.21	Hemoglobin concentration;	chr11:8793906	chr11:8964675~8977527:+
LUAD	cis	rs228614	0.51	rs223453	ENSG00000251288.2	RP11-10L12.2	-4.62	4.92e-06	0.00105	-0.25	-0.21	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789895	chr4:102751401~102752641:+
LUAD	cis	rs3096299	0.658	rs4785679	ENSG00000261118.1	RP11-104N10.1	4.62	4.93e-06	0.00105	0.21	0.21	Multiple myeloma (IgH translocation);	chr16:89499705	chr16:89492017~89504460:-
LUAD	cis	rs763567	0.935	rs1234275	ENSG00000271811.1	RP1-79C4.4	-4.62	4.93e-06	0.00105	-0.24	-0.21	Tonsillectomy;	chr1:170627117	chr1:170667381~170669425:+
LUAD	cis	rs34375054	0.573	rs12831151	ENSG00000279233.1	RP11-158L12.4	4.62	4.93e-06	0.00105	0.2	0.21	Post bronchodilator FEV1/FVC ratio;	chr12:125171717	chr12:125138245~125141711:+
LUAD	cis	rs736801	0.74	rs17622378	ENSG00000233006.5	AC034220.3	4.62	4.93e-06	0.00105	0.19	0.21	Mosquito bite size;Breast cancer;	chr5:132442760	chr5:132311285~132369916:-
LUAD	cis	rs9322193	0.923	rs10872644	ENSG00000268592.3	RAET1E-AS1	4.62	4.93e-06	0.00105	0.25	0.21	Lung cancer;	chr6:149741819	chr6:149863494~149919507:+
LUAD	cis	rs1075232	1	rs12439239	ENSG00000215302.7	CTD-3092A11.1	-4.62	4.93e-06	0.00105	-0.46	-0.21	Survival in colorectal cancer (non-distant metastatic);	chr15:31359515	chr15:30470779~30507623:+
LUAD	cis	rs2243480	1	rs12698509	ENSG00000164669.11	INTS4P1	4.62	4.93e-06	0.00105	0.36	0.21	Diabetic kidney disease;	chr7:65953889	chr7:65141225~65234216:+
LUAD	cis	rs4664293	0.625	rs6760931	ENSG00000226266.5	AC009961.3	4.62	4.93e-06	0.00105	0.28	0.21	Monocyte percentage of white cells;	chr2:159702600	chr2:159670708~159712435:-
LUAD	cis	rs2933343	1	rs2933343	ENSG00000231305.3	RP11-723O4.2	4.62	4.93e-06	0.00105	0.25	0.21	IgG glycosylation;	chr3:128939649	chr3:128861313~128871540:-
LUAD	cis	rs7302981	0.9	rs836180	ENSG00000200428.1	Y_RNA	-4.62	4.94e-06	0.00105	-0.26	-0.21	Systolic blood pressure;	chr12:50109486	chr12:50743568~50743684:+
LUAD	cis	rs6570726	0.875	rs368744	ENSG00000235652.6	RP11-545I5.3	4.62	4.94e-06	0.00105	0.21	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145491486	chr6:145799409~145886585:+
LUAD	cis	rs2898681	0.614	rs62338810	ENSG00000248375.1	RP11-177B4.1	-4.62	4.94e-06	0.00105	-0.33	-0.21	Optic nerve measurement (cup area);	chr4:52812340	chr4:52720081~52720831:-
LUAD	cis	rs948562	0.744	rs5020736	ENSG00000280010.1	AP001350.4	4.62	4.95e-06	0.00105	0.28	0.21	Lymphoma;	chr11:58661000	chr11:58627435~58628528:+
LUAD	cis	rs948562	0.627	rs5020737	ENSG00000280010.1	AP001350.4	4.62	4.95e-06	0.00105	0.28	0.21	Lymphoma;	chr11:58661003	chr11:58627435~58628528:+
LUAD	cis	rs7119	0.651	rs35577135	ENSG00000259362.2	RP11-307C19.1	-4.62	4.95e-06	0.00105	-0.26	-0.21	Type 2 diabetes;	chr15:77547732	chr15:77525540~77534110:+
LUAD	cis	rs2243480	1	rs781150	ENSG00000232559.3	GS1-124K5.12	4.62	4.95e-06	0.00106	0.36	0.21	Diabetic kidney disease;	chr7:66015986	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs313798	ENSG00000232559.3	GS1-124K5.12	4.62	4.95e-06	0.00106	0.36	0.21	Diabetic kidney disease;	chr7:66028044	chr7:66554588~66576923:-
LUAD	cis	rs172166	0.637	rs1233708	ENSG00000216901.1	AL022393.7	4.62	4.95e-06	0.00106	0.24	0.21	Cardiac Troponin-T levels;	chr6:28205441	chr6:28176188~28176674:+
LUAD	cis	rs234043	1	rs234043	ENSG00000223387.5	RP11-408H1.3	4.62	4.95e-06	0.00106	0.27	0.21	Renal cell carcinoma;	chr3:172595577	chr3:172560888~172595607:-
LUAD	cis	rs950169	0.84	rs62019457	ENSG00000275120.1	RP11-182J1.17	4.62	4.96e-06	0.00106	0.32	0.21	Schizophrenia;	chr15:84558911	chr15:84599434~84606463:-
LUAD	cis	rs750134	0.892	rs12423307	ENSG00000257221.1	RP11-689B22.2	-4.62	4.96e-06	0.00106	-0.32	-0.21	Low high density lipoprotein cholesterol levels;	chr12:108668905	chr12:108628687~108641318:+
LUAD	cis	rs750134	1	rs12578143	ENSG00000257221.1	RP11-689B22.2	-4.62	4.96e-06	0.00106	-0.32	-0.21	Low high density lipoprotein cholesterol levels;	chr12:108669500	chr12:108628687~108641318:+
LUAD	cis	rs750134	1	rs77103653	ENSG00000257221.1	RP11-689B22.2	-4.62	4.96e-06	0.00106	-0.32	-0.21	Low high density lipoprotein cholesterol levels;	chr12:108671385	chr12:108628687~108641318:+
LUAD	cis	rs750134	1	rs1861638	ENSG00000257221.1	RP11-689B22.2	-4.62	4.96e-06	0.00106	-0.32	-0.21	Low high density lipoprotein cholesterol levels;	chr12:108671681	chr12:108628687~108641318:+
LUAD	cis	rs12745968	0.653	rs11164796	ENSG00000223787.2	RP4-593M8.1	-4.62	4.96e-06	0.00106	-0.24	-0.21	Bipolar disorder and schizophrenia;	chr1:92678523	chr1:92580476~92580821:-
LUAD	cis	rs2548724	0.588	rs62369342	ENSG00000250682.4	LINC00491	4.62	4.96e-06	0.00106	0.24	0.21	Type 2 diabetes;	chr5:102402190	chr5:102609156~102671559:-
LUAD	cis	rs2153535	0.561	rs2181194	ENSG00000230939.1	RP11-314C16.1	-4.62	4.96e-06	0.00106	-0.23	-0.21	Motion sickness;	chr6:8667318	chr6:8784178~8785445:+
LUAD	cis	rs4664293	0.51	rs12469374	ENSG00000226266.5	AC009961.3	4.62	4.96e-06	0.00106	0.29	0.21	Monocyte percentage of white cells;	chr2:159720393	chr2:159670708~159712435:-
LUAD	cis	rs875971	0.965	rs6971509	ENSG00000232559.3	GS1-124K5.12	-4.62	4.96e-06	0.00106	-0.24	-0.21	Aortic root size;	chr7:66249983	chr7:66554588~66576923:-
LUAD	cis	rs1876905	0.68	rs193281	ENSG00000272356.1	RP5-1112D6.8	4.62	4.96e-06	0.00106	0.22	0.21	Mean corpuscular hemoglobin;	chr6:111166487	chr6:111309203~111313517:+
LUAD	cis	rs2243480	0.803	rs35480979	ENSG00000164669.11	INTS4P1	4.62	4.96e-06	0.00106	0.37	0.21	Diabetic kidney disease;	chr7:65892097	chr7:65141225~65234216:+
LUAD	cis	rs6988985	0.818	rs7463212	ENSG00000247317.3	RP11-273G15.2	4.62	4.96e-06	0.00106	0.23	0.21	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142910442	chr8:142981738~143018437:-
LUAD	cis	rs2033711	0.87	rs4801583	ENSG00000268912.1	CTD-2619J13.17	-4.62	4.96e-06	0.00106	-0.22	-0.21	Uric acid clearance;	chr19:58407038	chr19:58428632~58431148:-
LUAD	cis	rs9649213	0.531	rs35216698	ENSG00000272950.1	RP11-307C18.1	4.62	4.96e-06	0.00106	0.26	0.21	Prostate cancer (SNP x SNP interaction);	chr7:98266863	chr7:98322853~98323430:+
LUAD	cis	rs4908768	0.501	rs12030885	ENSG00000270282.1	RP5-1115A15.2	4.62	4.97e-06	0.00106	0.23	0.21	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8721337	chr1:8512653~8513021:+
LUAD	cis	rs6802315	0.604	rs2364927	ENSG00000272087.1	RP11-379F4.7	4.62	4.97e-06	0.00106	0.23	0.21	Periodontitis (CDC/AAP);	chr3:158760066	chr3:158693120~158693768:-
LUAD	cis	rs2742234	0.541	rs7098236	ENSG00000273008.1	RP11-351D16.3	4.62	4.97e-06	0.00106	0.24	0.21	Hirschsprung disease;	chr10:43245060	chr10:43136824~43138334:-
LUAD	cis	rs1864400	0.69	rs7098237	ENSG00000273008.1	RP11-351D16.3	4.62	4.97e-06	0.00106	0.24	0.21	Hirschsprung disease;	chr10:43245065	chr10:43136824~43138334:-
LUAD	cis	rs12745968	0.652	rs7546197	ENSG00000223787.2	RP4-593M8.1	-4.62	4.97e-06	0.00106	-0.26	-0.21	Bipolar disorder and schizophrenia;	chr1:92690382	chr1:92580476~92580821:-
LUAD	cis	rs338389	0.586	rs338402	ENSG00000260657.2	RP11-315D16.4	-4.62	4.97e-06	0.00106	-0.25	-0.21	Survival in rectal cancer;	chr15:67961613	chr15:68267792~68277994:-
LUAD	cis	rs338389	0.586	rs338400	ENSG00000260657.2	RP11-315D16.4	-4.62	4.97e-06	0.00106	-0.25	-0.21	Survival in rectal cancer;	chr15:67961818	chr15:68267792~68277994:-
LUAD	cis	rs9425766	0.679	rs6670617	ENSG00000227373.4	RP11-160H22.5	4.62	4.97e-06	0.00106	0.26	0.21	Life satisfaction;	chr1:174277574	chr1:174115300~174160004:-
LUAD	cis	rs858239	0.698	rs4265084	ENSG00000226816.2	AC005082.12	4.62	4.97e-06	0.00106	0.27	0.21	Cerebrospinal fluid biomarker levels;	chr7:23367621	chr7:23206013~23208045:+
LUAD	cis	rs2732480	0.5	rs1387257	ENSG00000240399.1	RP1-228P16.1	4.62	4.97e-06	0.00106	0.21	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48242883	chr12:48054813~48055591:-
LUAD	cis	rs1075265	0.547	rs6743627	ENSG00000233266.1	HMGB1P31	-4.62	4.97e-06	0.00106	-0.26	-0.21	Chronotype;Morning vs. evening chronotype;	chr2:53687024	chr2:54051334~54051760:+
LUAD	cis	rs13113518	0.841	rs7699867	ENSG00000223305.1	RN7SKP30	4.62	4.97e-06	0.00106	0.24	0.21	Height;	chr4:55483718	chr4:55540502~55540835:-
LUAD	cis	rs1062177	1	rs12518722	ENSG00000253921.1	CTB-113P19.3	-4.62	4.97e-06	0.00106	-0.31	-0.21	Preschool internalizing problems;	chr5:151851899	chr5:151753992~151767247:+
LUAD	cis	rs34779708	0.931	rs2384289	ENSG00000271335.4	RP11-324I22.4	4.62	4.98e-06	0.00106	0.21	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35054597	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.931	rs11010082	ENSG00000271335.4	RP11-324I22.4	4.62	4.98e-06	0.00106	0.21	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35062227	chr10:35314552~35336401:-
LUAD	cis	rs910316	0.875	rs12588099	ENSG00000279594.1	RP11-950C14.10	4.62	4.98e-06	0.00106	0.24	0.21	Height;	chr14:75127759	chr14:75011269~75012851:-
LUAD	cis	rs1499614	0.803	rs1796229	ENSG00000232559.3	GS1-124K5.12	4.62	4.98e-06	0.00106	0.36	0.21	Gout;	chr7:66654674	chr7:66554588~66576923:-
LUAD	cis	rs1499614	0.901	rs3936	ENSG00000232559.3	GS1-124K5.12	4.62	4.98e-06	0.00106	0.36	0.21	Gout;	chr7:66661502	chr7:66554588~66576923:-
LUAD	cis	rs11671005	0.695	rs12972898	ENSG00000268912.1	CTD-2619J13.17	-4.62	4.98e-06	0.00106	-0.29	-0.21	Mean platelet volume;	chr19:58445521	chr19:58428632~58431148:-
LUAD	cis	rs11122895	0.791	rs11122894	ENSG00000236307.2	EEF1E1P1	4.62	4.99e-06	0.00106	0.23	0.21	Allergic sensitization;	chr2:111711540	chr2:111887914~111888741:+
LUAD	cis	rs6671200	0.573	rs3738171	ENSG00000228852.5	RP11-57H12.5	-4.62	4.99e-06	0.00106	-0.26	-0.21	Stearic acid (18:0) levels;	chr1:95234038	chr1:95243167~95278940:-
LUAD	cis	rs2380205	0.651	rs7907053	ENSG00000232807.2	RP11-536K7.3	4.62	4.99e-06	0.00106	0.21	0.21	Breast cancer;	chr10:5884191	chr10:5934270~5945900:-
LUAD	cis	rs891378	1	rs2802233	ENSG00000274245.1	RP11-357P18.2	4.62	4.99e-06	0.00106	0.27	0.21	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207297879	chr1:207372559~207373252:+
LUAD	cis	rs7618915	1	rs59565798	ENSG00000243224.1	RP5-1157M23.2	-4.62	4.99e-06	0.00106	-0.22	-0.21	Bipolar disorder;	chr3:52273153	chr3:52239258~52241097:+
LUAD	cis	rs1008375	0.966	rs6449329	ENSG00000249502.1	AC006160.5	-4.62	4.99e-06	0.00106	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17702054	chr4:17587467~17614571:-
LUAD	cis	rs1008375	0.863	rs7680984	ENSG00000249502.1	AC006160.5	-4.62	4.99e-06	0.00106	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17599261	chr4:17587467~17614571:-
LUAD	cis	rs42490	0.868	rs1605997	ENSG00000251136.7	RP11-37B2.1	4.62	4.99e-06	0.00106	0.21	0.21	Leprosy;	chr8:89655885	chr8:89609409~89757727:-
LUAD	cis	rs1275468	1	rs1275468	ENSG00000257497.2	RP11-585P4.5	-4.62	4.99e-06	0.00106	-0.29	-0.21	Polycystic ovary syndrome;	chr12:75541377	chr12:75483454~75489820:-
LUAD	cis	rs7017914	0.628	rs7830515	ENSG00000223220.1	Y_RNA	4.62	5e-06	0.00106	0.23	0.21	Bone mineral density;	chr8:70657999	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs12674694	ENSG00000223220.1	Y_RNA	4.62	5e-06	0.00106	0.23	0.21	Bone mineral density;	chr8:70658599	chr8:70780914~70781008:-
LUAD	cis	rs9400467	0.528	rs7752361	ENSG00000271789.1	RP5-1112D6.7	-4.62	5e-06	0.00106	-0.22	-0.21	Amino acid levels;Blood metabolite levels;	chr6:111459502	chr6:111297126~111298510:+
LUAD	cis	rs7760535	0.811	rs7764591	ENSG00000271789.1	RP5-1112D6.7	-4.62	5e-06	0.00106	-0.22	-0.21	Metabolic traits;	chr6:111462211	chr6:111297126~111298510:+
LUAD	cis	rs875971	1	rs2077593	ENSG00000232559.3	GS1-124K5.12	4.62	5e-06	0.00106	0.24	0.21	Aortic root size;	chr7:66427543	chr7:66554588~66576923:-
LUAD	cis	rs8177876	0.57	rs11863158	ENSG00000261061.1	RP11-303E16.2	-4.62	5e-06	0.00106	-0.34	-0.21	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81034525	chr16:81030770~81031485:+
LUAD	cis	rs17508449	0.819	rs4839000	ENSG00000232450.1	RP4-730K3.3	-4.62	5e-06	0.00106	-0.35	-0.21	Leprosy;	chr1:113737513	chr1:113698884~113699631:-
LUAD	cis	rs643506	0.874	rs640651	ENSG00000230911.1	PPIHP1	-4.62	5e-06	0.00106	-0.25	-0.21	Breast cancer;	chr11:111858188	chr11:112029858~112030367:-
LUAD	cis	rs6840360	0.87	rs6814554	ENSG00000270265.1	RP11-731D1.4	-4.62	5e-06	0.00106	-0.21	-0.21	Intelligence (multi-trait analysis);	chr4:151533182	chr4:151333775~151353224:-
LUAD	cis	rs8031584	0.678	rs4779496	ENSG00000270015.1	RP11-540B6.6	-4.62	5e-06	0.00107	-0.16	-0.21	Huntington's disease progression;	chr15:30858851	chr15:30926514~30928407:+
LUAD	cis	rs8031584	0.678	rs4779497	ENSG00000270015.1	RP11-540B6.6	-4.62	5e-06	0.00107	-0.16	-0.21	Huntington's disease progression;	chr15:30859162	chr15:30926514~30928407:+
LUAD	cis	rs8031584	0.678	rs8028173	ENSG00000270015.1	RP11-540B6.6	-4.62	5e-06	0.00107	-0.16	-0.21	Huntington's disease progression;	chr15:30863546	chr15:30926514~30928407:+
LUAD	cis	rs8031584	0.706	rs2177670	ENSG00000270015.1	RP11-540B6.6	-4.62	5e-06	0.00107	-0.16	-0.21	Huntington's disease progression;	chr15:30865548	chr15:30926514~30928407:+
LUAD	cis	rs8031584	0.678	rs36047941	ENSG00000270015.1	RP11-540B6.6	-4.62	5e-06	0.00107	-0.16	-0.21	Huntington's disease progression;	chr15:30867032	chr15:30926514~30928407:+
LUAD	cis	rs812925	0.519	rs1186696	ENSG00000271889.1	RP11-493E12.1	4.62	5e-06	0.00107	0.24	0.21	Immature fraction of reticulocytes;	chr2:61433348	chr2:61151433~61162105:-
LUAD	cis	rs7688540	0.76	rs28460123	ENSG00000211553.1	AC253576.2	-4.62	5e-06	0.00107	-0.26	-0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:246419	chr4:136461~136568:+
LUAD	cis	rs4845875	0.6	rs6696752	ENSG00000242349.4	NPPA-AS1	4.62	5.01e-06	0.00107	0.23	0.21	Midregional pro atrial natriuretic peptide levels;	chr1:11775878	chr1:11841017~11848079:+
LUAD	cis	rs6840360	0.901	rs6826799	ENSG00000270265.1	RP11-731D1.4	-4.62	5.01e-06	0.00107	-0.21	-0.21	Intelligence (multi-trait analysis);	chr4:151534548	chr4:151333775~151353224:-
LUAD	cis	rs9303029	1	rs9303029	ENSG00000265458.1	RP13-20L14.6	4.62	5.01e-06	0.00107	0.37	0.21	Protein quantitative trait loci;	chr17:82450939	chr17:82454273~82458521:-
LUAD	cis	rs9473147	0.516	rs9463342	ENSG00000270761.1	RP11-385F7.1	-4.62	5.01e-06	0.00107	-0.24	-0.21	Platelet distribution width;Mean platelet volume;	chr6:47617370	chr6:47477243~47477572:-
LUAD	cis	rs9545047	0.604	rs9601217	ENSG00000227354.5	RBM26-AS1	-4.62	5.01e-06	0.00107	-0.21	-0.21	Schizophrenia;	chr13:79359797	chr13:79406309~79424328:+
LUAD	cis	rs507080	0.961	rs4938523	ENSG00000278376.1	RP11-158I9.8	-4.62	5.01e-06	0.00107	-0.22	-0.21	Serum metabolite levels;	chr11:118678129	chr11:118791254~118793137:+
LUAD	cis	rs9649213	0.574	rs34830366	ENSG00000272950.1	RP11-307C18.1	4.62	5.01e-06	0.00107	0.26	0.21	Prostate cancer (SNP x SNP interaction);	chr7:98270223	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.593	rs34776142	ENSG00000272950.1	RP11-307C18.1	4.62	5.01e-06	0.00107	0.26	0.21	Prostate cancer (SNP x SNP interaction);	chr7:98270561	chr7:98322853~98323430:+
LUAD	cis	rs1501911	0.588	rs709386	ENSG00000248489.1	CTD-2007H13.3	4.62	5.01e-06	0.00107	0.26	0.21	Lung function (FEV1/FVC);	chr5:98994346	chr5:98929171~98995013:+
LUAD	cis	rs736801	0.74	rs12515180	ENSG00000233006.5	AC034220.3	4.62	5.01e-06	0.00107	0.19	0.21	Mosquito bite size;Breast cancer;	chr5:132449992	chr5:132311285~132369916:-
LUAD	cis	rs2243480	1	rs67728539	ENSG00000164669.11	INTS4P1	4.62	5.01e-06	0.00107	0.37	0.21	Diabetic kidney disease;	chr7:65913137	chr7:65141225~65234216:+
LUAD	cis	rs35740288	0.545	rs12916187	ENSG00000259407.1	RP11-158M2.3	-4.62	5.01e-06	0.00107	-0.24	-0.21	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85782893	chr15:85744109~85750281:-
LUAD	cis	rs910316	1	rs12588240	ENSG00000279594.1	RP11-950C14.10	4.62	5.01e-06	0.00107	0.24	0.21	Height;	chr14:75145380	chr14:75011269~75012851:-
LUAD	cis	rs17772222	0.605	rs4899955	ENSG00000258789.1	RP11-507K2.3	4.62	5.02e-06	0.00107	0.25	0.21	Coronary artery calcification;	chr14:88530381	chr14:88551597~88552493:+
LUAD	cis	rs9652601	0.959	rs9746695	ENSG00000274038.1	RP11-66H6.4	4.62	5.02e-06	0.00107	0.26	0.21	Systemic lupus erythematosus;	chr16:11114037	chr16:11056556~11057034:+
LUAD	cis	rs4845875	0.529	rs6680385	ENSG00000242349.4	NPPA-AS1	4.62	5.02e-06	0.00107	0.22	0.21	Midregional pro atrial natriuretic peptide levels;	chr1:11771699	chr1:11841017~11848079:+
LUAD	cis	rs2243480	1	rs1723269	ENSG00000232559.3	GS1-124K5.12	4.62	5.02e-06	0.00107	0.36	0.21	Diabetic kidney disease;	chr7:66007799	chr7:66554588~66576923:-
LUAD	cis	rs11155671	0.53	rs9371542	ENSG00000268592.3	RAET1E-AS1	4.62	5.02e-06	0.00107	0.26	0.21	Testicular germ cell tumor;	chr6:149891949	chr6:149863494~149919507:+
LUAD	cis	rs11155671	0.53	rs9371223	ENSG00000268592.3	RAET1E-AS1	4.62	5.02e-06	0.00107	0.26	0.21	Testicular germ cell tumor;	chr6:149893670	chr6:149863494~149919507:+
LUAD	cis	rs62355900	0.627	rs16886429	ENSG00000271828.1	CTD-2310F14.1	4.62	5.02e-06	0.00107	0.39	0.21	Endometriosis;	chr5:56857265	chr5:56927874~56929573:+
LUAD	cis	rs62355900	0.627	rs62358104	ENSG00000271828.1	CTD-2310F14.1	4.62	5.02e-06	0.00107	0.39	0.21	Endometriosis;	chr5:56863344	chr5:56927874~56929573:+
LUAD	cis	rs2832077	0.943	rs11702320	ENSG00000232855.5	AF131217.1	4.62	5.03e-06	0.00107	0.23	0.21	Cognitive test performance;	chr21:28822929	chr21:28439346~28674848:-
LUAD	cis	rs6604026	0.695	rs11164801	ENSG00000223787.2	RP4-593M8.1	4.62	5.03e-06	0.00107	0.26	0.21	Multiple sclerosis;	chr1:92737621	chr1:92580476~92580821:-
LUAD	cis	rs9545047	0.604	rs9545054	ENSG00000227354.5	RBM26-AS1	4.62	5.03e-06	0.00107	0.21	0.21	Schizophrenia;	chr13:79298833	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.547	rs2876739	ENSG00000227354.5	RBM26-AS1	4.62	5.03e-06	0.00107	0.21	0.21	Schizophrenia;	chr13:79299057	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.567	rs7988331	ENSG00000227354.5	RBM26-AS1	4.62	5.03e-06	0.00107	0.21	0.21	Schizophrenia;	chr13:79299745	chr13:79406309~79424328:+
LUAD	cis	rs1008375	1	rs1121091	ENSG00000249502.1	AC006160.5	-4.62	5.03e-06	0.00107	-0.19	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17674763	chr4:17587467~17614571:-
LUAD	cis	rs1008375	1	rs1121090	ENSG00000249502.1	AC006160.5	-4.62	5.03e-06	0.00107	-0.19	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17674814	chr4:17587467~17614571:-
LUAD	cis	rs1008375	1	rs2315560	ENSG00000249502.1	AC006160.5	-4.62	5.03e-06	0.00107	-0.19	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17675682	chr4:17587467~17614571:-
LUAD	cis	rs1008375	0.966	rs4698642	ENSG00000249502.1	AC006160.5	-4.62	5.03e-06	0.00107	-0.19	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17677551	chr4:17587467~17614571:-
LUAD	cis	rs8180040	0.593	rs12715421	ENSG00000271161.1	BOLA2P2	4.62	5.03e-06	0.00107	0.2	0.21	Colorectal cancer;	chr3:47043369	chr3:47499841~47500407:+
LUAD	cis	rs642803	0.613	rs489574	ENSG00000255557.1	RP11-770G2.2	-4.62	5.04e-06	0.00107	-0.25	-0.21	Urate levels;	chr11:65775268	chr11:65745729~65771585:+
LUAD	cis	rs42490	1	rs431264	ENSG00000251136.7	RP11-37B2.1	-4.62	5.04e-06	0.00107	-0.21	-0.21	Leprosy;	chr8:89765282	chr8:89609409~89757727:-
LUAD	cis	rs7017914	0.652	rs56352991	ENSG00000223220.1	Y_RNA	4.62	5.04e-06	0.00107	0.23	0.21	Bone mineral density;	chr8:70655843	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs6994814	ENSG00000223220.1	Y_RNA	4.62	5.04e-06	0.00107	0.23	0.21	Bone mineral density;	chr8:70656903	chr8:70780914~70781008:-
LUAD	cis	rs891378	0.959	rs77542432	ENSG00000274245.1	RP11-357P18.2	-4.62	5.04e-06	0.00107	-0.27	-0.21	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207301020	chr1:207372559~207373252:+
LUAD	cis	rs875971	1	rs778726	ENSG00000232559.3	GS1-124K5.12	4.62	5.04e-06	0.00107	0.24	0.21	Aortic root size;	chr7:66363744	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.964	rs778723	ENSG00000232559.3	GS1-124K5.12	4.62	5.04e-06	0.00107	0.24	0.21	Aortic root size;	chr7:66364510	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.767	rs1695815	ENSG00000232559.3	GS1-124K5.12	4.62	5.04e-06	0.00107	0.24	0.21	Aortic root size;	chr7:66366357	chr7:66554588~66576923:-
LUAD	cis	rs875971	1	rs778685	ENSG00000232559.3	GS1-124K5.12	4.62	5.04e-06	0.00107	0.24	0.21	Aortic root size;	chr7:66371189	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.929	rs778682	ENSG00000232559.3	GS1-124K5.12	4.62	5.04e-06	0.00107	0.24	0.21	Aortic root size;	chr7:66372947	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.964	rs11765965	ENSG00000232559.3	GS1-124K5.12	4.62	5.04e-06	0.00107	0.24	0.21	Aortic root size;	chr7:66377234	chr7:66554588~66576923:-
LUAD	cis	rs2028299	0.879	rs8034631	ENSG00000259677.1	RP11-493E3.1	4.62	5.04e-06	0.00107	0.24	0.21	Type 2 diabetes;	chr15:89879433	chr15:89876540~89877285:+
LUAD	cis	rs1799949	0.894	rs36062488	ENSG00000236383.6	LINC00854	4.62	5.05e-06	0.00107	0.16	0.21	Menopause (age at onset);	chr17:43185455	chr17:43216941~43305976:-
LUAD	cis	rs4308124	1	rs62160391	ENSG00000227992.1	AC108463.2	-4.62	5.05e-06	0.00107	-0.25	-0.21	Vitiligo;	chr2:111251258	chr2:111203964~111206215:-
LUAD	cis	rs9322193	0.516	rs1999632	ENSG00000223701.3	RAET1E-AS1	4.62	5.05e-06	0.00107	0.3	0.21	Lung cancer;	chr6:149866737	chr6:149884431~149919508:+
LUAD	cis	rs2378497	1	rs5013041	ENSG00000232679.1	RP11-400N13.3	4.62	5.05e-06	0.00107	0.33	0.21	Serum thyroid-stimulating hormone levels;	chr1:221983648	chr1:222041705~222064763:-
LUAD	cis	rs4845875	0.6	rs6699881	ENSG00000242349.4	NPPA-AS1	4.61	5.05e-06	0.00107	0.23	0.21	Midregional pro atrial natriuretic peptide levels;	chr1:11776571	chr1:11841017~11848079:+
LUAD	cis	rs516805	0.528	rs2684247	ENSG00000279453.1	RP3-425C14.4	-4.61	5.05e-06	0.00107	-0.26	-0.21	Lymphocyte counts;	chr6:122076755	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.528	rs7738997	ENSG00000279453.1	RP3-425C14.4	-4.61	5.05e-06	0.00107	-0.26	-0.21	Lymphocyte counts;	chr6:122077264	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.528	rs13203915	ENSG00000279453.1	RP3-425C14.4	-4.61	5.05e-06	0.00107	-0.26	-0.21	Lymphocyte counts;	chr6:122077325	chr6:122436789~122439223:-
LUAD	cis	rs7189233	0.531	rs62048526	ENSG00000279344.1	RP11-44F14.7	4.61	5.05e-06	0.00107	0.17	0.21	Intelligence (multi-trait analysis);	chr16:53478014	chr16:53478957~53481550:-
LUAD	cis	rs2028299	0.959	rs12912009	ENSG00000259677.1	RP11-493E3.1	4.61	5.05e-06	0.00107	0.24	0.21	Type 2 diabetes;	chr15:89885916	chr15:89876540~89877285:+
LUAD	cis	rs11155671	0.53	rs4870080	ENSG00000268592.3	RAET1E-AS1	4.61	5.06e-06	0.00107	0.25	0.21	Testicular germ cell tumor;	chr6:149881508	chr6:149863494~149919507:+
LUAD	cis	rs2522056	0.808	rs2706373	ENSG00000233006.5	AC034220.3	-4.61	5.06e-06	0.00108	-0.23	-0.21	Fibrinogen;Lymphocyte counts;	chr5:132468564	chr5:132311285~132369916:-
LUAD	cis	rs2522056	1	rs2522063	ENSG00000233006.5	AC034220.3	-4.61	5.06e-06	0.00108	-0.23	-0.21	Fibrinogen;Lymphocyte counts;	chr5:132469899	chr5:132311285~132369916:-
LUAD	cis	rs2522056	1	rs2706379	ENSG00000233006.5	AC034220.3	-4.61	5.06e-06	0.00108	-0.23	-0.21	Fibrinogen;Lymphocyte counts;	chr5:132470043	chr5:132311285~132369916:-
LUAD	cis	rs9322193	0.772	rs7738696	ENSG00000268592.3	RAET1E-AS1	4.61	5.06e-06	0.00108	0.26	0.21	Lung cancer;	chr6:149848985	chr6:149863494~149919507:+
LUAD	cis	rs800160	0.668	rs10734191	ENSG00000236264.4	RPL26P30	-4.61	5.06e-06	0.00108	-0.29	-0.21	Bacteremia;	chr11:2319772	chr11:2335132~2335776:-
LUAD	cis	rs4660214	0.666	rs588326	ENSG00000228060.1	RP11-69E11.8	-4.61	5.06e-06	0.00108	-0.19	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39443054	chr1:39565160~39573203:+
LUAD	cis	rs7899628	1	rs7899628	ENSG00000276742.1	RP11-500G22.4	-4.61	5.06e-06	0.00108	-0.26	-0.21	Breast cancer;	chr10:121904429	chr10:121956782~121957098:+
LUAD	cis	rs2733201	1	rs1426658	ENSG00000205771.5	CATSPER2P1	4.61	5.06e-06	0.00108	0.45	0.21	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44046721	chr15:43726918~43747094:-
LUAD	cis	rs2286503	0.752	rs59538378	ENSG00000221740.1	SNORD93	4.61	5.06e-06	0.00108	0.24	0.21	Fibrinogen;	chr7:22837478	chr7:22856613~22856686:+
LUAD	cis	rs7968440	0.808	rs829112	ENSG00000200428.1	Y_RNA	4.61	5.06e-06	0.00108	0.26	0.21	Fibrinogen;	chr12:50813921	chr12:50743568~50743684:+
LUAD	cis	rs8072100	0.713	rs3871595	ENSG00000228782.6	CTD-2026D20.3	4.61	5.07e-06	0.00108	0.22	0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47434022	chr17:47450568~47492492:-
LUAD	cis	rs6545883	0.507	rs59981505	ENSG00000271889.1	RP11-493E12.1	-4.61	5.07e-06	0.00108	-0.24	-0.21	Tuberculosis;	chr2:61353394	chr2:61151433~61162105:-
LUAD	cis	rs875971	1	rs6460296	ENSG00000232559.3	GS1-124K5.12	4.61	5.07e-06	0.00108	0.24	0.21	Aortic root size;	chr7:66430152	chr7:66554588~66576923:-
LUAD	cis	rs875971	1	rs4717292	ENSG00000232559.3	GS1-124K5.12	4.61	5.07e-06	0.00108	0.24	0.21	Aortic root size;	chr7:66430611	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.895	rs4718349	ENSG00000232559.3	GS1-124K5.12	4.61	5.07e-06	0.00108	0.24	0.21	Aortic root size;	chr7:66444024	chr7:66554588~66576923:-
LUAD	cis	rs875971	1	rs2420591	ENSG00000232559.3	GS1-124K5.12	4.61	5.07e-06	0.00108	0.24	0.21	Aortic root size;	chr7:66447394	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.895	rs10755833	ENSG00000232559.3	GS1-124K5.12	4.61	5.07e-06	0.00108	0.24	0.21	Aortic root size;	chr7:66448930	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.964	rs12668936	ENSG00000232559.3	GS1-124K5.12	4.61	5.07e-06	0.00108	0.24	0.21	Aortic root size;	chr7:66449417	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.895	rs1833495	ENSG00000232559.3	GS1-124K5.12	4.61	5.07e-06	0.00108	0.24	0.21	Aortic root size;	chr7:66456608	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.964	rs6945032	ENSG00000232559.3	GS1-124K5.12	4.61	5.07e-06	0.00108	0.24	0.21	Aortic root size;	chr7:66457499	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.929	rs12673810	ENSG00000232559.3	GS1-124K5.12	4.61	5.07e-06	0.00108	0.24	0.21	Aortic root size;	chr7:66458866	chr7:66554588~66576923:-
LUAD	cis	rs875971	1	rs2042133	ENSG00000232559.3	GS1-124K5.12	4.61	5.07e-06	0.00108	0.24	0.21	Aortic root size;	chr7:66466935	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.964	rs2161065	ENSG00000232559.3	GS1-124K5.12	4.61	5.07e-06	0.00108	0.24	0.21	Aortic root size;	chr7:66467918	chr7:66554588~66576923:-
LUAD	cis	rs875971	1	rs6961155	ENSG00000232559.3	GS1-124K5.12	4.61	5.07e-06	0.00108	0.24	0.21	Aortic root size;	chr7:66468308	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.895	rs3857684	ENSG00000232559.3	GS1-124K5.12	4.61	5.07e-06	0.00108	0.24	0.21	Aortic root size;	chr7:66473171	chr7:66554588~66576923:-
LUAD	cis	rs875971	1	rs7789768	ENSG00000232559.3	GS1-124K5.12	4.61	5.07e-06	0.00108	0.24	0.21	Aortic root size;	chr7:66473993	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs12698521	ENSG00000232559.3	GS1-124K5.12	4.61	5.07e-06	0.00108	0.24	0.21	Aortic root size;	chr7:66474502	chr7:66554588~66576923:-
LUAD	cis	rs17772222	0.839	rs2274735	ENSG00000258789.1	RP11-507K2.3	-4.61	5.07e-06	0.00108	-0.25	-0.21	Coronary artery calcification;	chr14:88505414	chr14:88551597~88552493:+
LUAD	cis	rs36423	0.748	rs36415	ENSG00000266869.1	RP6-114E22.1	-4.61	5.07e-06	0.00108	-0.3	-0.21	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71888958	chr14:71848606~71908430:+
LUAD	cis	rs5758511	0.633	rs5758690	ENSG00000226450.2	CYP2D8P	4.61	5.07e-06	0.00108	0.19	0.21	Birth weight;	chr22:42272289	chr22:42149886~42155001:-
LUAD	cis	rs9487094	0.961	rs3778477	ENSG00000260273.1	RP11-425D10.10	4.61	5.07e-06	0.00108	0.28	0.21	Height;	chr6:109454855	chr6:109382795~109383666:+
LUAD	cis	rs7727544	0.716	rs4594848	ENSG00000233006.5	AC034220.3	4.61	5.07e-06	0.00108	0.18	0.21	Blood metabolite levels;	chr5:132250905	chr5:132311285~132369916:-
LUAD	cis	rs2243480	0.803	rs13224048	ENSG00000232559.3	GS1-124K5.12	4.61	5.08e-06	0.00108	0.36	0.21	Diabetic kidney disease;	chr7:66528779	chr7:66554588~66576923:-
LUAD	cis	rs34779708	0.931	rs2505631	ENSG00000271335.4	RP11-324I22.4	-4.61	5.08e-06	0.00108	-0.21	-0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35079457	chr10:35314552~35336401:-
LUAD	cis	rs2378497	0.938	rs2153352	ENSG00000232679.1	RP11-400N13.3	4.61	5.08e-06	0.00108	0.33	0.21	Serum thyroid-stimulating hormone levels;	chr1:221984008	chr1:222041705~222064763:-
LUAD	cis	rs3738443	0.644	rs2799177	ENSG00000259865.1	RP11-488L18.10	-4.61	5.08e-06	0.00108	-0.21	-0.21	Alcohol dependence;	chr1:247235898	chr1:247187281~247188526:-
LUAD	cis	rs375066	0.935	rs397346	ENSG00000267058.1	RP11-15A1.3	-4.61	5.08e-06	0.00108	-0.23	-0.21	Breast cancer;	chr19:43894963	chr19:43891804~43901805:-
LUAD	cis	rs477895	0.713	rs882146	ENSG00000236935.1	AP003774.1	-4.61	5.08e-06	0.00108	-0.26	-0.21	Mean platelet volume;	chr11:64209227	chr11:64325050~64329504:-
LUAD	cis	rs7119	0.717	rs12902912	ENSG00000259362.2	RP11-307C19.1	-4.61	5.09e-06	0.00108	-0.26	-0.21	Type 2 diabetes;	chr15:77516828	chr15:77525540~77534110:+
LUAD	cis	rs950169	0.922	rs67804993	ENSG00000275120.1	RP11-182J1.17	4.61	5.09e-06	0.00108	0.32	0.21	Schizophrenia;	chr15:84560799	chr15:84599434~84606463:-
LUAD	cis	rs4268898	0.76	rs11676939	ENSG00000223754.1	AC008073.9	-4.61	5.09e-06	0.00108	-0.25	-0.21	Asthma;	chr2:24256188	chr2:24199839~24201698:-
LUAD	cis	rs1008375	0.932	rs9884565	ENSG00000249502.1	AC006160.5	-4.61	5.1e-06	0.00108	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17653473	chr4:17587467~17614571:-
LUAD	cis	rs2562456	0.833	rs56179986	ENSG00000268081.1	RP11-678G14.2	4.61	5.11e-06	0.00108	0.33	0.21	Pain;	chr19:21337882	chr19:21554640~21569237:-
LUAD	cis	rs17345786	0.906	rs11708616	ENSG00000244119.1	PDCL3P4	4.61	5.11e-06	0.00108	0.22	0.21	Colonoscopy-negative controls vs population controls;	chr3:101512887	chr3:101712472~101713191:+
LUAD	cis	rs748404	0.63	rs35278805	ENSG00000205771.5	CATSPER2P1	-4.61	5.11e-06	0.00108	-0.31	-0.21	Lung cancer;	chr15:43361124	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.666	rs35160541	ENSG00000205771.5	CATSPER2P1	-4.61	5.11e-06	0.00108	-0.31	-0.21	Lung cancer;	chr15:43365601	chr15:43726918~43747094:-
LUAD	cis	rs9322193	0.923	rs17745062	ENSG00000268592.3	RAET1E-AS1	4.61	5.11e-06	0.00108	0.25	0.21	Lung cancer;	chr6:149721079	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.923	rs62441279	ENSG00000268592.3	RAET1E-AS1	4.61	5.11e-06	0.00108	0.25	0.21	Lung cancer;	chr6:149721194	chr6:149863494~149919507:+
LUAD	cis	rs7772486	0.764	rs7745696	ENSG00000235652.6	RP11-545I5.3	4.61	5.11e-06	0.00108	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145841693	chr6:145799409~145886585:+
LUAD	cis	rs867371	0.717	rs3858954	ENSG00000276710.3	CSPG4P8	-4.61	5.11e-06	0.00108	-0.2	-0.21	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82265693	chr15:82459472~82477258:+
LUAD	cis	rs3096299	0.738	rs9929606	ENSG00000261118.1	RP11-104N10.1	4.61	5.11e-06	0.00109	0.21	0.21	Multiple myeloma (IgH translocation);	chr16:89461129	chr16:89492017~89504460:-
LUAD	cis	rs9860428	0.527	rs9847365	ENSG00000242770.2	RP11-180K7.1	4.61	5.11e-06	0.00109	0.22	0.21	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112835746	chr3:112802478~112812819:+
LUAD	cis	rs2243480	1	rs34815098	ENSG00000226002.1	RP11-460N20.5	-4.61	5.11e-06	0.00109	-0.35	-0.21	Diabetic kidney disease;	chr7:65827267	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs4548056	ENSG00000226002.1	RP11-460N20.5	-4.61	5.11e-06	0.00109	-0.35	-0.21	Diabetic kidney disease;	chr7:65833886	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs7456042	ENSG00000226002.1	RP11-460N20.5	-4.61	5.11e-06	0.00109	-0.35	-0.21	Diabetic kidney disease;	chr7:65834791	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs35735127	ENSG00000226002.1	RP11-460N20.5	-4.61	5.11e-06	0.00109	-0.35	-0.21	Diabetic kidney disease;	chr7:65835436	chr7:65084103~65100232:+
LUAD	cis	rs2243480	0.901	rs35256305	ENSG00000226002.1	RP11-460N20.5	-4.61	5.11e-06	0.00109	-0.35	-0.21	Diabetic kidney disease;	chr7:65841418	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs73142121	ENSG00000226002.1	RP11-460N20.5	-4.61	5.11e-06	0.00109	-0.35	-0.21	Diabetic kidney disease;	chr7:65846219	chr7:65084103~65100232:+
LUAD	cis	rs2243480	0.803	rs34004500	ENSG00000226002.1	RP11-460N20.5	-4.61	5.11e-06	0.00109	-0.35	-0.21	Diabetic kidney disease;	chr7:65847191	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs35825738	ENSG00000226002.1	RP11-460N20.5	-4.61	5.11e-06	0.00109	-0.35	-0.21	Diabetic kidney disease;	chr7:65853040	chr7:65084103~65100232:+
LUAD	cis	rs11157436	0.918	rs12433895	ENSG00000211813.2	TRAV34	4.61	5.11e-06	0.00109	0.25	0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22154577	chr14:22207522~22208129:+
LUAD	cis	rs17264034	0.861	rs55713652	ENSG00000250786.1	SNHG18	4.61	5.12e-06	0.00109	0.3	0.21	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9557010	chr5:9546200~9550609:+
LUAD	cis	rs763121	0.853	rs5757231	ENSG00000225450.1	RP3-508I15.14	4.61	5.12e-06	0.00109	0.2	0.21	Menopause (age at onset);	chr22:38675653	chr22:38739003~38749041:+
LUAD	cis	rs9322193	0.923	rs9689084	ENSG00000268592.3	RAET1E-AS1	4.61	5.12e-06	0.00109	0.25	0.21	Lung cancer;	chr6:149639648	chr6:149863494~149919507:+
LUAD	cis	rs42490	1	rs42490	ENSG00000251136.7	RP11-37B2.1	-4.61	5.12e-06	0.00109	-0.21	-0.21	Leprosy;	chr8:89766285	chr8:89609409~89757727:-
LUAD	cis	rs42490	0.966	rs40377	ENSG00000251136.7	RP11-37B2.1	-4.61	5.12e-06	0.00109	-0.21	-0.21	Leprosy;	chr8:89769725	chr8:89609409~89757727:-
LUAD	cis	rs4664293	0.647	rs10196064	ENSG00000226266.5	AC009961.3	-4.61	5.12e-06	0.00109	-0.27	-0.21	Monocyte percentage of white cells;	chr2:159569454	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.647	rs2162023	ENSG00000226266.5	AC009961.3	-4.61	5.12e-06	0.00109	-0.27	-0.21	Monocyte percentage of white cells;	chr2:159569719	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.647	rs10202352	ENSG00000226266.5	AC009961.3	-4.61	5.12e-06	0.00109	-0.27	-0.21	Monocyte percentage of white cells;	chr2:159571097	chr2:159670708~159712435:-
LUAD	cis	rs6088590	0.748	rs6142206	ENSG00000276073.1	RP5-1125A11.7	-4.61	5.12e-06	0.00109	-0.21	-0.21	Coronary artery disease;	chr20:34624251	chr20:33985617~33988989:-
LUAD	cis	rs477895	0.838	rs2070765	ENSG00000236935.1	AP003774.1	-4.61	5.13e-06	0.00109	-0.25	-0.21	Mean platelet volume;	chr11:64242613	chr11:64325050~64329504:-
LUAD	cis	rs11020821	0.886	rs16912567	ENSG00000255893.1	RP11-685N10.1	-4.61	5.13e-06	0.00109	-0.29	-0.21	Response to angiotensin II receptor blocker therapy;Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94536839	chr11:94472908~94473570:-
LUAD	cis	rs11157436	0.918	rs1983520	ENSG00000211813.2	TRAV34	4.61	5.13e-06	0.00109	0.25	0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22150390	chr14:22207522~22208129:+
LUAD	cis	rs11157436	0.918	rs1983522	ENSG00000211813.2	TRAV34	4.61	5.13e-06	0.00109	0.25	0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22150588	chr14:22207522~22208129:+
LUAD	cis	rs5758659	1	rs134882	ENSG00000227370.1	RP4-669P10.19	-4.61	5.13e-06	0.00109	-0.18	-0.21	Cognitive function;	chr22:42274959	chr22:42132543~42132998:+
LUAD	cis	rs11064837	0.523	rs7979627	ENSG00000248636.5	RP11-768F21.1	4.61	5.13e-06	0.00109	0.25	0.21	Schizophrenia;	chr12:119662399	chr12:119387987~119668079:-
LUAD	cis	rs2239547	0.563	rs4302374	ENSG00000242142.1	SERBP1P3	4.61	5.13e-06	0.00109	0.25	0.21	Schizophrenia;	chr3:52871786	chr3:53064283~53065091:-
LUAD	cis	rs6496044	0.568	rs11636764	ENSG00000259295.5	CSPG4P12	4.61	5.14e-06	0.00109	0.24	0.21	Interstitial lung disease;	chr15:85536520	chr15:85191438~85213905:+
LUAD	cis	rs6539288	0.933	rs2053205	ENSG00000260329.1	RP11-412D9.4	-4.61	5.14e-06	0.00109	-0.22	-0.21	Total body bone mineral density;	chr12:106912489	chr12:106954029~106955497:-
LUAD	cis	rs6539288	0.933	rs759605	ENSG00000260329.1	RP11-412D9.4	-4.61	5.14e-06	0.00109	-0.22	-0.21	Total body bone mineral density;	chr12:106913401	chr12:106954029~106955497:-
LUAD	cis	rs6539288	0.933	rs759604	ENSG00000260329.1	RP11-412D9.4	-4.61	5.14e-06	0.00109	-0.22	-0.21	Total body bone mineral density;	chr12:106913518	chr12:106954029~106955497:-
LUAD	cis	rs6539288	0.899	rs759603	ENSG00000260329.1	RP11-412D9.4	-4.61	5.14e-06	0.00109	-0.22	-0.21	Total body bone mineral density;	chr12:106913613	chr12:106954029~106955497:-
LUAD	cis	rs6539288	0.933	rs2075289	ENSG00000260329.1	RP11-412D9.4	-4.61	5.14e-06	0.00109	-0.22	-0.21	Total body bone mineral density;	chr12:106913860	chr12:106954029~106955497:-
LUAD	cis	rs4664293	0.647	rs4665082	ENSG00000226266.5	AC009961.3	-4.61	5.14e-06	0.00109	-0.27	-0.21	Monocyte percentage of white cells;	chr2:159573455	chr2:159670708~159712435:-
LUAD	cis	rs914187	1	rs914187	ENSG00000226496.2	LINC00323	-4.61	5.14e-06	0.00109	-0.26	-0.21	Body mass index;	chr21:41247822	chr21:41141493~41148133:-
LUAD	cis	rs11673344	0.67	rs505717	ENSG00000226686.6	LINC01535	4.61	5.15e-06	0.00109	0.26	0.21	Obesity-related traits;	chr19:36939414	chr19:37251912~37265535:+
LUAD	cis	rs11673344	0.704	rs544543	ENSG00000226686.6	LINC01535	4.61	5.15e-06	0.00109	0.26	0.21	Obesity-related traits;	chr19:36939921	chr19:37251912~37265535:+
LUAD	cis	rs11673344	0.67	rs568654	ENSG00000226686.6	LINC01535	4.61	5.15e-06	0.00109	0.26	0.21	Obesity-related traits;	chr19:36940285	chr19:37251912~37265535:+
LUAD	cis	rs1008375	0.932	rs6449317	ENSG00000249502.1	AC006160.5	-4.61	5.15e-06	0.00109	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17629630	chr4:17587467~17614571:-
LUAD	cis	rs6558530	0.692	rs6981804	ENSG00000253982.1	CTD-2336O2.1	4.61	5.15e-06	0.00109	0.27	0.21	Systolic blood pressure;	chr8:1752118	chr8:1761990~1764502:-
LUAD	cis	rs9322193	0.884	rs62439836	ENSG00000268592.3	RAET1E-AS1	4.61	5.15e-06	0.00109	0.25	0.21	Lung cancer;	chr6:149669173	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.923	rs4869812	ENSG00000268592.3	RAET1E-AS1	4.61	5.15e-06	0.00109	0.25	0.21	Lung cancer;	chr6:149669447	chr6:149863494~149919507:+
LUAD	cis	rs4664293	0.647	rs1425040	ENSG00000226266.5	AC009961.3	-4.61	5.16e-06	0.00109	-0.27	-0.21	Monocyte percentage of white cells;	chr2:159571912	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.625	rs11693108	ENSG00000226266.5	AC009961.3	-4.61	5.16e-06	0.00109	-0.27	-0.21	Monocyte percentage of white cells;	chr2:159572076	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.647	rs7575924	ENSG00000226266.5	AC009961.3	-4.61	5.16e-06	0.00109	-0.27	-0.21	Monocyte percentage of white cells;	chr2:159573049	chr2:159670708~159712435:-
LUAD	cis	rs34779708	0.931	rs12767414	ENSG00000271335.4	RP11-324I22.4	4.61	5.16e-06	0.00109	0.21	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35101265	chr10:35314552~35336401:-
LUAD	cis	rs1008375	0.932	rs6814465	ENSG00000249502.1	AC006160.5	-4.61	5.16e-06	0.00109	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17657411	chr4:17587467~17614571:-
LUAD	cis	rs1008375	0.932	rs6844593	ENSG00000249502.1	AC006160.5	-4.61	5.16e-06	0.00109	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17657416	chr4:17587467~17614571:-
LUAD	cis	rs227275	0.525	rs9917919	ENSG00000251288.2	RP11-10L12.2	-4.61	5.16e-06	0.00109	-0.25	-0.21	Allergic disease (asthma, hay fever or eczema);	chr4:102918497	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.525	rs3974608	ENSG00000251288.2	RP11-10L12.2	-4.61	5.16e-06	0.00109	-0.25	-0.21	Allergic disease (asthma, hay fever or eczema);	chr4:102925641	chr4:102751401~102752641:+
LUAD	cis	rs17711722	0.522	rs4642526	ENSG00000226002.1	RP11-460N20.5	4.61	5.16e-06	0.00109	0.23	0.21	Calcium levels;	chr7:65751755	chr7:65084103~65100232:+
LUAD	cis	rs9545047	0.604	rs7996652	ENSG00000227354.5	RBM26-AS1	4.61	5.17e-06	0.00109	0.21	0.21	Schizophrenia;	chr13:79341474	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs9565488	ENSG00000227354.5	RBM26-AS1	4.61	5.17e-06	0.00109	0.21	0.21	Schizophrenia;	chr13:79341604	chr13:79406309~79424328:+
LUAD	cis	rs2243480	1	rs316330	ENSG00000232559.3	GS1-124K5.12	4.61	5.17e-06	0.0011	0.36	0.21	Diabetic kidney disease;	chr7:66140385	chr7:66554588~66576923:-
LUAD	cis	rs9322193	0.923	rs1572229	ENSG00000268592.3	RAET1E-AS1	4.61	5.17e-06	0.0011	0.25	0.21	Lung cancer;	chr6:149743841	chr6:149863494~149919507:+
LUAD	cis	rs12908161	1	rs12911736	ENSG00000259295.5	CSPG4P12	4.61	5.17e-06	0.0011	0.29	0.21	Schizophrenia;	chr15:84696777	chr15:85191438~85213905:+
LUAD	cis	rs9425766	0.679	rs4652234	ENSG00000227373.4	RP11-160H22.5	4.61	5.17e-06	0.0011	0.26	0.21	Life satisfaction;	chr1:174181712	chr1:174115300~174160004:-
LUAD	cis	rs6840360	1	rs2278304	ENSG00000270265.1	RP11-731D1.4	4.61	5.17e-06	0.0011	0.21	0.21	Intelligence (multi-trait analysis);	chr4:151672257	chr4:151333775~151353224:-
LUAD	cis	rs1348850	0.831	rs1345139	ENSG00000280374.1	RP11-337N6.3	-4.61	5.17e-06	0.0011	-0.44	-0.21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177585063	chr2:177317715~177318471:-
LUAD	cis	rs2742234	0.59	rs2293020	ENSG00000273008.1	RP11-351D16.3	4.61	5.17e-06	0.0011	0.24	0.21	Hirschsprung disease;	chr10:43197439	chr10:43136824~43138334:-
LUAD	cis	rs561341	0.882	rs28649357	ENSG00000265798.5	RP11-271K11.5	4.61	5.17e-06	0.0011	0.3	0.21	Hip circumference adjusted for BMI;	chr17:32040171	chr17:31038575~31059121:-
LUAD	cis	rs2847297	1	rs2847297	ENSG00000260302.1	RP11-973H7.1	4.61	5.17e-06	0.0011	0.29	0.21	Rheumatoid arthritis;	chr18:12797695	chr18:12774651~12775923:-
LUAD	cis	rs6088590	1	rs6120747	ENSG00000276073.1	RP5-1125A11.7	-4.61	5.17e-06	0.0011	-0.21	-0.21	Coronary artery disease;	chr20:34861966	chr20:33985617~33988989:-
LUAD	cis	rs4834770	0.668	rs6833072	ENSG00000245958.5	RP11-33B1.1	4.61	5.18e-06	0.0011	0.19	0.21	Blood protein levels;	chr4:119212737	chr4:119454791~119552025:+
LUAD	cis	rs875971	0.895	rs12698520	ENSG00000232559.3	GS1-124K5.12	4.61	5.18e-06	0.0011	0.24	0.21	Aortic root size;	chr7:66453720	chr7:66554588~66576923:-
LUAD	cis	rs2522056	1	rs6874639	ENSG00000233006.5	AC034220.3	4.61	5.18e-06	0.0011	0.22	0.21	Fibrinogen;Lymphocyte counts;	chr5:132443024	chr5:132311285~132369916:-
LUAD	cis	rs34779708	0.931	rs10466072	ENSG00000271335.4	RP11-324I22.4	4.61	5.18e-06	0.0011	0.21	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35113828	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.966	rs998658	ENSG00000271335.4	RP11-324I22.4	4.61	5.18e-06	0.0011	0.21	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35119726	chr10:35314552~35336401:-
LUAD	cis	rs10466239	0.667	rs10899792	ENSG00000230555.2	RP11-517P14.2	4.61	5.18e-06	0.0011	0.33	0.21	Telomere length;	chr10:43364722	chr10:43420738~43422100:+
LUAD	cis	rs8031584	0.958	rs7168641	ENSG00000270015.1	RP11-540B6.6	-4.61	5.18e-06	0.0011	-0.15	-0.21	Huntington's disease progression;	chr15:30943249	chr15:30926514~30928407:+
LUAD	cis	rs801193	0.591	rs9986881	ENSG00000237310.1	GS1-124K5.4	4.61	5.19e-06	0.0011	0.22	0.21	Aortic root size;	chr7:66708053	chr7:66493706~66495474:+
LUAD	cis	rs11722779	0.869	rs223323	ENSG00000251288.2	RP11-10L12.2	-4.61	5.19e-06	0.0011	-0.25	-0.21	Schizophrenia;	chr4:102878412	chr4:102751401~102752641:+
LUAD	cis	rs10129255	0.957	rs10141009	ENSG00000274576.2	IGHV2-70	4.61	5.19e-06	0.0011	0.18	0.21	Kawasaki disease;	chr14:106776695	chr14:106770577~106771020:-
LUAD	cis	rs10129255	0.912	rs6576227	ENSG00000274576.2	IGHV2-70	4.61	5.19e-06	0.0011	0.18	0.21	Kawasaki disease;	chr14:106778202	chr14:106770577~106771020:-
LUAD	cis	rs10129255	0.957	rs6576228	ENSG00000274576.2	IGHV2-70	4.61	5.19e-06	0.0011	0.18	0.21	Kawasaki disease;	chr14:106778401	chr14:106770577~106771020:-
LUAD	cis	rs8072100	0.967	rs7221548	ENSG00000228782.6	CTD-2026D20.3	-4.61	5.19e-06	0.0011	-0.21	-0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47505586	chr17:47450568~47492492:-
LUAD	cis	rs11722779	0.838	rs4533776	ENSG00000251288.2	RP11-10L12.2	-4.61	5.19e-06	0.0011	-0.25	-0.21	Schizophrenia;	chr4:102912732	chr4:102751401~102752641:+
LUAD	cis	rs11722779	0.838	rs6821247	ENSG00000251288.2	RP11-10L12.2	-4.61	5.19e-06	0.0011	-0.25	-0.21	Schizophrenia;	chr4:102913483	chr4:102751401~102752641:+
LUAD	cis	rs8072100	0.817	rs11869940	ENSG00000228782.6	CTD-2026D20.3	-4.61	5.19e-06	0.0011	-0.21	-0.21	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47501069	chr17:47450568~47492492:-
LUAD	cis	rs17301013	0.93	rs6425279	ENSG00000227373.4	RP11-160H22.5	-4.61	5.19e-06	0.0011	-0.25	-0.21	Systemic lupus erythematosus;	chr1:174418717	chr1:174115300~174160004:-
LUAD	cis	rs498872	1	rs498872	ENSG00000255422.1	AP002954.4	-4.61	5.19e-06	0.0011	-0.26	-0.21	Glioma;	chr11:118606652	chr11:118704607~118750263:+
LUAD	cis	rs9545047	0.584	rs7995243	ENSG00000227354.5	RBM26-AS1	-4.61	5.19e-06	0.0011	-0.21	-0.21	Schizophrenia;	chr13:79358645	chr13:79406309~79424328:+
LUAD	cis	rs2378497	1	rs2800859	ENSG00000232679.1	RP11-400N13.3	4.61	5.2e-06	0.0011	0.31	0.21	Serum thyroid-stimulating hormone levels;	chr1:222009246	chr1:222041705~222064763:-
LUAD	cis	rs2243480	1	rs35820085	ENSG00000232559.3	GS1-124K5.12	4.61	5.2e-06	0.0011	0.36	0.21	Diabetic kidney disease;	chr7:65977771	chr7:66554588~66576923:-
LUAD	cis	rs7772486	0.79	rs1832362	ENSG00000235652.6	RP11-545I5.3	4.61	5.2e-06	0.0011	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145858819	chr6:145799409~145886585:+
LUAD	cis	rs944990	0.576	rs6479484	ENSG00000227603.1	RP11-165J3.6	4.61	5.2e-06	0.0011	0.23	0.21	Body mass index;	chr9:93454288	chr9:93435332~93437121:-
LUAD	cis	rs16873450	0.527	rs1469000	ENSG00000234800.2	PCMTD1P3	4.61	5.2e-06	0.0011	0.23	0.21	Verbal memory performance (residualized delayed recall level);	chr7:23770986	chr7:23721311~23721782:-
LUAD	cis	rs5758511	0.68	rs5758682	ENSG00000226450.2	CYP2D8P	4.61	5.2e-06	0.0011	0.19	0.21	Birth weight;	chr22:42249196	chr22:42149886~42155001:-
LUAD	cis	rs36423	0.668	rs28347	ENSG00000266869.1	RP6-114E22.1	-4.61	5.2e-06	0.0011	-0.32	-0.21	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71908561	chr14:71848606~71908430:+
LUAD	cis	rs9545047	0.604	rs7981067	ENSG00000227354.5	RBM26-AS1	4.61	5.2e-06	0.0011	0.21	0.21	Schizophrenia;	chr13:79341254	chr13:79406309~79424328:+
LUAD	cis	rs172166	0.637	rs1225592	ENSG00000216901.1	AL022393.7	4.61	5.2e-06	0.0011	0.25	0.21	Cardiac Troponin-T levels;	chr6:28182464	chr6:28176188~28176674:+
LUAD	cis	rs172166	0.637	rs1225595	ENSG00000216901.1	AL022393.7	4.61	5.2e-06	0.0011	0.25	0.21	Cardiac Troponin-T levels;	chr6:28183562	chr6:28176188~28176674:+
LUAD	cis	rs287982	1	rs72780999	ENSG00000269973.1	RP11-95D17.1	-4.61	5.2e-06	0.0011	-0.25	-0.21	Nonsyndromic cleft lip with cleft palate;	chr2:9841841	chr2:9936360~9939590:+
LUAD	cis	rs11157436	0.602	rs17255447	ENSG00000211813.2	TRAV34	-4.61	5.2e-06	0.0011	-0.24	-0.21	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22167459	chr14:22207522~22208129:+
LUAD	cis	rs11159086	1	rs11626856	ENSG00000259005.1	RP3-449M8.6	4.61	5.21e-06	0.0011	0.29	0.21	Advanced glycation end-product levels;	chr14:74469665	chr14:74474007~74474864:-
LUAD	cis	rs4908760	0.539	rs6698830	ENSG00000232912.4	RP5-1115A15.1	4.61	5.21e-06	0.0011	0.19	0.21	Vitiligo;	chr1:8794486	chr1:8424645~8434838:+
LUAD	cis	rs35740288	0.52	rs56183577	ENSG00000259407.1	RP11-158M2.3	-4.61	5.22e-06	0.0011	-0.23	-0.21	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85776475	chr15:85744109~85750281:-
LUAD	cis	rs3002131	0.688	rs3008650	ENSG00000225265.1	TAF1A-AS1	4.61	5.22e-06	0.0011	0.29	0.21	Interleukin-10 levels;	chr1:222589873	chr1:222589825~222593032:+
LUAD	cis	rs2243480	1	rs2961102	ENSG00000226002.1	RP11-460N20.5	-4.61	5.22e-06	0.0011	-0.35	-0.21	Diabetic kidney disease;	chr7:65959671	chr7:65084103~65100232:+
LUAD	cis	rs9652601	0.879	rs8062322	ENSG00000274038.1	RP11-66H6.4	-4.61	5.22e-06	0.0011	-0.25	-0.21	Systemic lupus erythematosus;	chr16:10998462	chr16:11056556~11057034:+
LUAD	cis	rs7172677	0.768	rs12148425	ENSG00000260269.4	CTD-2323K18.1	4.61	5.22e-06	0.00111	0.28	0.21	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75062631	chr15:75527150~75601205:-
LUAD	cis	rs10129255	0.957	rs10150241	ENSG00000274576.2	IGHV2-70	-4.61	5.22e-06	0.00111	-0.18	-0.21	Kawasaki disease;	chr14:106775945	chr14:106770577~106771020:-
LUAD	cis	rs1541160	0.956	rs541655	ENSG00000239494.2	RN7SL333P	-4.61	5.22e-06	0.00111	-0.2	-0.21	Amyotrophic lateral sclerosis;	chr1:169971617	chr1:169859756~169860052:+
LUAD	cis	rs2115630	1	rs1030863	ENSG00000229212.6	RP11-561C5.4	4.61	5.22e-06	0.00111	0.24	0.21	P wave terminal force;	chr15:84739404	chr15:85205440~85234795:-
LUAD	cis	rs875971	0.929	rs34406470	ENSG00000232559.3	GS1-124K5.12	4.61	5.23e-06	0.00111	0.24	0.21	Aortic root size;	chr7:66464969	chr7:66554588~66576923:-
LUAD	cis	rs4865169	0.783	rs7668814	ENSG00000269949.1	RP11-738E22.3	4.61	5.23e-06	0.00111	0.26	0.21	Breast cancer;	chr4:56959024	chr4:56960927~56961373:-
LUAD	cis	rs17772222	0.876	rs12586348	ENSG00000258983.2	RP11-507K2.2	4.61	5.23e-06	0.00111	0.25	0.21	Coronary artery calcification;	chr14:88643523	chr14:88499334~88515502:+
LUAD	cis	rs7811142	0.83	rs11765869	ENSG00000078319.8	PMS2P1	-4.61	5.23e-06	0.00111	-0.26	-0.21	Platelet count;	chr7:100367166	chr7:100320992~100341908:-
LUAD	cis	rs1008375	0.931	rs979823	ENSG00000249502.1	AC006160.5	-4.61	5.23e-06	0.00111	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17698553	chr4:17587467~17614571:-
LUAD	cis	rs11971779	0.711	rs6961204	ENSG00000273391.1	RP11-634H22.1	4.61	5.23e-06	0.00111	0.24	0.21	Diisocyanate-induced asthma;	chr7:139362653	chr7:139359032~139359566:-
LUAD	cis	rs55823223	0.648	rs66584478	ENSG00000267801.1	RP11-552F3.9	4.61	5.23e-06	0.00111	0.23	0.21	Psoriasis;	chr17:75874122	chr17:75876372~75879546:+
LUAD	cis	rs6840360	0.582	rs2709812	ENSG00000270265.1	RP11-731D1.4	4.61	5.23e-06	0.00111	0.21	0.21	Intelligence (multi-trait analysis);	chr4:151414597	chr4:151333775~151353224:-
LUAD	cis	rs219780	0.784	rs219781	ENSG00000233818.1	AP000695.4	4.61	5.23e-06	0.00111	0.23	0.21	Kidney stones;	chr21:36460323	chr21:36445731~36532408:+
LUAD	cis	rs911119	0.955	rs6048930	ENSG00000270001.1	RP11-218C14.8	-4.61	5.24e-06	0.00111	-0.3	-0.21	Chronic kidney disease;	chr20:23611855	chr20:23631826~23632316:-
LUAD	cis	rs219780	0.898	rs219786	ENSG00000233818.1	AP000695.4	4.61	5.24e-06	0.00111	0.26	0.21	Kidney stones;	chr21:36459453	chr21:36445731~36532408:+
LUAD	cis	rs6840360	0.642	rs2724574	ENSG00000270265.1	RP11-731D1.4	4.61	5.24e-06	0.00111	0.21	0.21	Intelligence (multi-trait analysis);	chr4:151460648	chr4:151333775~151353224:-
LUAD	cis	rs62025270	0.688	rs17577869	ENSG00000202081.1	RNU6-1280P	-4.61	5.24e-06	0.00111	-0.3	-0.21	Idiopathic pulmonary fibrosis;	chr15:85771142	chr15:85651522~85651628:-
LUAD	cis	rs950169	0.686	rs12906474	ENSG00000275120.1	RP11-182J1.17	4.61	5.24e-06	0.00111	0.32	0.21	Schizophrenia;	chr15:84566006	chr15:84599434~84606463:-
LUAD	cis	rs950169	0.81	rs2879976	ENSG00000275120.1	RP11-182J1.17	4.61	5.24e-06	0.00111	0.32	0.21	Schizophrenia;	chr15:84566347	chr15:84599434~84606463:-
LUAD	cis	rs7772486	0.79	rs9403750	ENSG00000235652.6	RP11-545I5.3	4.61	5.24e-06	0.00111	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145846626	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.791	rs1509213	ENSG00000235652.6	RP11-545I5.3	-4.61	5.25e-06	0.00111	-0.2	-0.21	Lobe attachment (rater-scored or self-reported);	chr6:145462224	chr6:145799409~145886585:+
LUAD	cis	rs783540	0.681	rs1259178	ENSG00000276710.3	CSPG4P8	4.61	5.25e-06	0.00111	0.21	0.21	Schizophrenia;	chr15:82603127	chr15:82459472~82477258:+
LUAD	cis	rs138341189	1	rs138341189	ENSG00000212093.1	AP000807.1	4.61	5.25e-06	0.00111	0.28	0.21	Monobrow;	chr11:68456954	chr11:68506083~68506166:-
LUAD	cis	rs2243480	1	rs2961102	ENSG00000232559.3	GS1-124K5.12	4.61	5.25e-06	0.00111	0.36	0.21	Diabetic kidney disease;	chr7:65959671	chr7:66554588~66576923:-
LUAD	cis	rs30380	1	rs30187	ENSG00000248734.2	CTD-2260A17.1	4.61	5.25e-06	0.00111	0.21	0.21	Cerebrospinal fluid biomarker levels;	chr5:96788627	chr5:96784777~96785999:+
LUAD	cis	rs9400467	0.528	rs6568680	ENSG00000271789.1	RP5-1112D6.7	-4.61	5.25e-06	0.00111	-0.22	-0.21	Amino acid levels;Blood metabolite levels;	chr6:111454961	chr6:111297126~111298510:+
LUAD	cis	rs338389	0.516	rs17308514	ENSG00000260657.2	RP11-315D16.4	4.61	5.25e-06	0.00111	0.23	0.21	Survival in rectal cancer;	chr15:68020833	chr15:68267792~68277994:-
LUAD	cis	rs301901	0.828	rs4308503	ENSG00000250155.1	CTD-2353F22.1	4.61	5.25e-06	0.00111	0.21	0.21	Height;	chr5:37454091	chr5:36666214~36725195:-
LUAD	cis	rs12900463	0.813	rs187316	ENSG00000259295.5	CSPG4P12	4.61	5.25e-06	0.00111	0.29	0.21	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);	chr15:84862764	chr15:85191438~85213905:+
LUAD	cis	rs9322193	0.923	rs4869750	ENSG00000268592.3	RAET1E-AS1	4.61	5.26e-06	0.00111	0.25	0.21	Lung cancer;	chr6:149855996	chr6:149863494~149919507:+
LUAD	cis	rs116175783	0.557	rs62188136	ENSG00000227403.1	AC009299.3	4.61	5.26e-06	0.00111	0.38	0.21	Intelligence (multi-trait analysis);	chr2:161399439	chr2:161244739~161249050:+
LUAD	cis	rs2562152	0.706	rs216598	ENSG00000226942.2	IL9RP3	-4.61	5.26e-06	0.00111	-0.29	-0.21	Glioblastoma;	chr16:58586	chr16:29336~38321:-
LUAD	cis	rs6545883	0.507	rs62149712	ENSG00000271889.1	RP11-493E12.1	-4.61	5.26e-06	0.00111	-0.24	-0.21	Tuberculosis;	chr2:61374137	chr2:61151433~61162105:-
LUAD	cis	rs338389	0.542	rs12439223	ENSG00000260657.2	RP11-315D16.4	-4.61	5.26e-06	0.00111	-0.24	-0.21	Survival in rectal cancer;	chr15:67949308	chr15:68267792~68277994:-
LUAD	cis	rs2243480	1	rs313809	ENSG00000232559.3	GS1-124K5.12	4.61	5.26e-06	0.00111	0.36	0.21	Diabetic kidney disease;	chr7:66034996	chr7:66554588~66576923:-
LUAD	cis	rs4601821	0.858	rs7945132	ENSG00000270179.1	RP11-159N11.4	-4.61	5.27e-06	0.00111	-0.22	-0.21	Alcoholic chronic pancreatitis;	chr11:113391751	chr11:113368478~113369117:+
LUAD	cis	rs11886999	0.723	rs3852673	ENSG00000237510.6	AC008268.2	-4.61	5.27e-06	0.00111	-0.34	-0.21	Cardiac Troponin-T levels;	chr2:96253904	chr2:95789654~95800166:+
LUAD	cis	rs8180040	0.62	rs11707736	ENSG00000271161.1	BOLA2P2	-4.61	5.27e-06	0.00111	-0.2	-0.21	Colorectal cancer;	chr3:47028014	chr3:47499841~47500407:+
LUAD	cis	rs6539288	0.899	rs7298423	ENSG00000260329.1	RP11-412D9.4	-4.61	5.27e-06	0.00111	-0.22	-0.21	Total body bone mineral density;	chr12:106908202	chr12:106954029~106955497:-
LUAD	cis	rs6539288	0.933	rs1037011	ENSG00000260329.1	RP11-412D9.4	-4.61	5.27e-06	0.00111	-0.22	-0.21	Total body bone mineral density;	chr12:106909000	chr12:106954029~106955497:-
LUAD	cis	rs2212361	0.558	rs12576083	ENSG00000255893.1	RP11-685N10.1	-4.61	5.27e-06	0.00111	-0.29	-0.21	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94537839	chr11:94472908~94473570:-
LUAD	cis	rs34779708	0.966	rs2505639	ENSG00000271335.4	RP11-324I22.4	-4.61	5.27e-06	0.00111	-0.21	-0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35185493	chr10:35314552~35336401:-
LUAD	cis	rs7826238	0.601	rs2976907	ENSG00000173295.6	FAM86B3P	4.61	5.27e-06	0.00111	0.22	0.21	Systolic blood pressure;	chr8:8487658	chr8:8228595~8244865:+
LUAD	cis	rs1075265	0.621	rs2542593	ENSG00000272156.1	RP11-477N3.1	-4.61	5.27e-06	0.00111	-0.25	-0.21	Chronotype;Morning vs. evening chronotype;	chr2:53804299	chr2:54082554~54085066:+
LUAD	cis	rs910316	0.967	rs175432	ENSG00000259138.1	RP11-950C14.7	-4.61	5.27e-06	0.00111	-0.22	-0.21	Height;	chr14:75148543	chr14:75127153~75136930:+
LUAD	cis	rs2933343	0.601	rs1680759	ENSG00000231305.3	RP11-723O4.2	4.61	5.27e-06	0.00112	0.22	0.21	IgG glycosylation;	chr3:128876053	chr3:128861313~128871540:-
LUAD	cis	rs2933343	0.601	rs1680758	ENSG00000231305.3	RP11-723O4.2	4.61	5.27e-06	0.00112	0.22	0.21	IgG glycosylation;	chr3:128876054	chr3:128861313~128871540:-
LUAD	cis	rs2933343	0.649	rs789214	ENSG00000231305.3	RP11-723O4.2	4.61	5.27e-06	0.00112	0.22	0.21	IgG glycosylation;	chr3:128876152	chr3:128861313~128871540:-
LUAD	cis	rs2933343	0.729	rs789224	ENSG00000231305.3	RP11-723O4.2	4.61	5.27e-06	0.00112	0.22	0.21	IgG glycosylation;	chr3:128879388	chr3:128861313~128871540:-
LUAD	cis	rs2933343	0.761	rs789225	ENSG00000231305.3	RP11-723O4.2	4.61	5.27e-06	0.00112	0.22	0.21	IgG glycosylation;	chr3:128881386	chr3:128861313~128871540:-
LUAD	cis	rs7772486	0.641	rs2777485	ENSG00000235652.6	RP11-545I5.3	4.61	5.27e-06	0.00112	0.22	0.21	Lobe attachment (rater-scored or self-reported);	chr6:146013241	chr6:145799409~145886585:+
LUAD	cis	rs736801	0.808	rs72797303	ENSG00000233006.5	AC034220.3	4.61	5.27e-06	0.00112	0.18	0.21	Mosquito bite size;Breast cancer;	chr5:132460471	chr5:132311285~132369916:-
LUAD	cis	rs2243480	1	rs410128	ENSG00000164669.11	INTS4P1	4.61	5.28e-06	0.00112	0.37	0.21	Diabetic kidney disease;	chr7:66138186	chr7:65141225~65234216:+
LUAD	cis	rs2273788	1	rs12554057	ENSG00000204173.9	LRRC37A5P	4.61	5.28e-06	0.00112	0.24	0.21	Monocyte count;	chr9:111582948	chr9:111602831~111631289:-
LUAD	cis	rs7555523	0.887	rs4657476	ENSG00000224358.1	RP11-466F5.8	4.61	5.28e-06	0.00112	0.35	0.21	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165763424	chr1:165768929~165775176:+
LUAD	cis	rs878939	0.625	rs35137159	ENSG00000230224.1	PHBP9	-4.61	5.28e-06	0.00112	-0.2	-0.21	Warfarin maintenance dose;	chr10:99584492	chr10:100248271~100249095:+
LUAD	cis	rs878939	0.625	rs35564340	ENSG00000230224.1	PHBP9	-4.61	5.28e-06	0.00112	-0.2	-0.21	Warfarin maintenance dose;	chr10:99584506	chr10:100248271~100249095:+
LUAD	cis	rs4372836	1	rs55835850	ENSG00000226833.4	AC097724.3	-4.61	5.28e-06	0.00112	-0.24	-0.21	Body mass index;	chr2:28726430	chr2:28708953~28736205:-
LUAD	cis	rs2243480	1	rs11538349	ENSG00000164669.11	INTS4P1	4.61	5.28e-06	0.00112	0.36	0.21	Diabetic kidney disease;	chr7:65956884	chr7:65141225~65234216:+
LUAD	cis	rs17508449	0.819	rs17031795	ENSG00000232450.1	RP4-730K3.3	-4.61	5.28e-06	0.00112	-0.35	-0.21	Leprosy;	chr1:113713206	chr1:113698884~113699631:-
LUAD	cis	rs4841097	0.806	rs6992247	ENSG00000253893.2	FAM85B	-4.61	5.28e-06	0.00112	-0.26	-0.21	Platelet distribution width;	chr8:9090959	chr8:8167819~8226614:-
LUAD	cis	rs6921919	0.673	rs13201681	ENSG00000219392.1	RP1-265C24.5	-4.61	5.29e-06	0.00112	-0.47	-0.21	Autism spectrum disorder or schizophrenia;	chr6:28426903	chr6:28115628~28116551:+
LUAD	cis	rs338389	0.542	rs12914946	ENSG00000260657.2	RP11-315D16.4	-4.6	5.3e-06	0.00112	-0.24	-0.21	Survival in rectal cancer;	chr15:67949990	chr15:68267792~68277994:-
LUAD	cis	rs6539288	0.899	rs2053206	ENSG00000260329.1	RP11-412D9.4	-4.6	5.3e-06	0.00112	-0.22	-0.21	Total body bone mineral density;	chr12:106912401	chr12:106954029~106955497:-
LUAD	cis	rs11168618	0.626	rs11514105	ENSG00000240399.1	RP1-228P16.1	4.6	5.3e-06	0.00112	0.2	0.21	Adiponectin levels;	chr12:48427151	chr12:48054813~48055591:-
LUAD	cis	rs193541	0.617	rs2045628	ENSG00000263432.2	RN7SL689P	4.6	5.3e-06	0.00112	0.28	0.21	Glucose homeostasis traits;	chr5:122759459	chr5:123022487~123022783:-
LUAD	cis	rs6565653	1	rs6565653	ENSG00000262580.4	RP11-334C17.5	4.6	5.3e-06	0.00112	0.14	0.21	Ischemic stroke;	chr17:80227984	chr17:80200673~80205949:-
LUAD	cis	rs12745968	0.653	rs4847301	ENSG00000223787.2	RP4-593M8.1	-4.6	5.31e-06	0.00112	-0.24	-0.21	Bipolar disorder and schizophrenia;	chr1:92735367	chr1:92580476~92580821:-
LUAD	cis	rs12745968	0.595	rs6604014	ENSG00000223787.2	RP4-593M8.1	-4.6	5.31e-06	0.00112	-0.24	-0.21	Bipolar disorder and schizophrenia;	chr1:92750161	chr1:92580476~92580821:-
LUAD	cis	rs12745968	0.561	rs4847306	ENSG00000223787.2	RP4-593M8.1	-4.6	5.31e-06	0.00112	-0.24	-0.21	Bipolar disorder and schizophrenia;	chr1:92751415	chr1:92580476~92580821:-
LUAD	cis	rs12745968	0.59	rs2391195	ENSG00000223787.2	RP4-593M8.1	-4.6	5.31e-06	0.00112	-0.24	-0.21	Bipolar disorder and schizophrenia;	chr1:92753126	chr1:92580476~92580821:-
LUAD	cis	rs12745968	0.59	rs1337107	ENSG00000223787.2	RP4-593M8.1	-4.6	5.31e-06	0.00112	-0.24	-0.21	Bipolar disorder and schizophrenia;	chr1:92753219	chr1:92580476~92580821:-
LUAD	cis	rs7937682	0.881	rs4936678	ENSG00000230911.1	PPIHP1	4.6	5.31e-06	0.00112	0.29	0.21	Primary sclerosing cholangitis;	chr11:111754361	chr11:112029858~112030367:-
LUAD	cis	rs10483853	0.525	rs7158272	ENSG00000258695.2	RP3-414A15.2	4.6	5.31e-06	0.00112	0.29	0.21	Coronary artery calcification;	chr14:73476486	chr14:73522878~73530610:+
LUAD	cis	rs7119038	0.774	rs73005423	ENSG00000255422.1	AP002954.4	4.6	5.31e-06	0.00112	0.32	0.21	Sjögren's syndrome;	chr11:118810370	chr11:118704607~118750263:+
LUAD	cis	rs301901	0.514	rs10073063	ENSG00000250155.1	CTD-2353F22.1	-4.6	5.32e-06	0.00112	-0.23	-0.21	Height;	chr5:37259873	chr5:36666214~36725195:-
LUAD	cis	rs2919009	0.607	rs12265028	ENSG00000271670.1	RP11-95I16.4	4.6	5.32e-06	0.00112	0.26	0.21	Obesity-related traits;	chr10:120959561	chr10:120879256~120880667:-
LUAD	cis	rs11673344	0.864	rs11667146	ENSG00000226686.6	LINC01535	4.6	5.32e-06	0.00112	0.26	0.21	Obesity-related traits;	chr19:37004493	chr19:37251912~37265535:+
LUAD	cis	rs2354432	0.556	rs12568866	ENSG00000226015.2	CCT8P1	4.6	5.32e-06	0.00112	0.38	0.21	Mitochondrial DNA levels;	chr1:147246776	chr1:147203276~147204932:-
LUAD	cis	rs11673344	0.864	rs703530	ENSG00000226686.6	LINC01535	4.6	5.32e-06	0.00112	0.26	0.21	Obesity-related traits;	chr19:37010016	chr19:37251912~37265535:+
LUAD	cis	rs875971	1	rs937495	ENSG00000232559.3	GS1-124K5.12	-4.6	5.32e-06	0.00112	-0.24	-0.21	Aortic root size;	chr7:66314811	chr7:66554588~66576923:-
LUAD	cis	rs2898681	0.519	rs6554057	ENSG00000248375.1	RP11-177B4.1	-4.6	5.33e-06	0.00113	-0.34	-0.21	Optic nerve measurement (cup area);	chr4:52863980	chr4:52720081~52720831:-
LUAD	cis	rs2898681	0.519	rs6848200	ENSG00000248375.1	RP11-177B4.1	-4.6	5.33e-06	0.00113	-0.34	-0.21	Optic nerve measurement (cup area);	chr4:52864014	chr4:52720081~52720831:-
LUAD	cis	rs2898681	0.519	rs73814886	ENSG00000248375.1	RP11-177B4.1	-4.6	5.33e-06	0.00113	-0.34	-0.21	Optic nerve measurement (cup area);	chr4:52867084	chr4:52720081~52720831:-
LUAD	cis	rs1318937	0.588	rs112820857	ENSG00000224660.1	SH3BP5-AS1	4.6	5.33e-06	0.00113	0.24	0.21	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15208493	chr3:15254184~15264493:+
LUAD	cis	rs7520050	0.667	rs11211176	ENSG00000280836.1	AL355480.1	4.6	5.33e-06	0.00113	0.24	0.21	Reticulocyte count;Red blood cell count;	chr1:45757414	chr1:45581219~45581321:-
LUAD	cis	rs6565653	0.967	rs9891253	ENSG00000262580.4	RP11-334C17.5	4.6	5.33e-06	0.00113	0.14	0.21	Ischemic stroke;	chr17:80226377	chr17:80200673~80205949:-
LUAD	cis	rs11064837	0.523	rs7967558	ENSG00000248636.5	RP11-768F21.1	4.6	5.33e-06	0.00113	0.24	0.21	Schizophrenia;	chr12:119659201	chr12:119387987~119668079:-
LUAD	cis	rs2742234	0.955	rs2503841	ENSG00000273008.1	RP11-351D16.3	-4.6	5.33e-06	0.00113	-0.22	-0.21	Hirschsprung disease;	chr10:43180273	chr10:43136824~43138334:-
LUAD	cis	rs17685	0.74	rs2286821	ENSG00000280388.1	RP11-229D13.3	4.6	5.34e-06	0.00113	0.2	0.21	Coffee consumption (cups per day);Coffee consumption;	chr7:75982037	chr7:76043977~76045963:-
LUAD	cis	rs875971	0.619	rs12533585	ENSG00000224316.1	RP11-479O9.2	4.6	5.34e-06	0.00113	0.21	0.21	Aortic root size;	chr7:66519618	chr7:65773620~65802067:+
LUAD	cis	rs875971	0.66	rs12698534	ENSG00000224316.1	RP11-479O9.2	4.6	5.34e-06	0.00113	0.21	0.21	Aortic root size;	chr7:66521858	chr7:65773620~65802067:+
LUAD	cis	rs2836974	0.563	rs6517522	ENSG00000255568.3	BRWD1-AS2	4.6	5.34e-06	0.00113	0.2	0.21	Cognitive function;	chr21:39181919	chr21:39313935~39314962:+
LUAD	cis	rs6957923	0.967	rs35133514	ENSG00000230658.1	KLHL7-AS1	4.6	5.34e-06	0.00113	0.25	0.21	Height;	chr7:23462189	chr7:23101228~23105703:-
LUAD	cis	rs301901	0.828	rs151944	ENSG00000250155.1	CTD-2353F22.1	-4.6	5.34e-06	0.00113	-0.22	-0.21	Height;	chr5:36904297	chr5:36666214~36725195:-
LUAD	cis	rs2243480	1	rs316321	ENSG00000232559.3	GS1-124K5.12	4.6	5.34e-06	0.00113	0.36	0.21	Diabetic kidney disease;	chr7:66146626	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs316318	ENSG00000232559.3	GS1-124K5.12	4.6	5.34e-06	0.00113	0.36	0.21	Diabetic kidney disease;	chr7:66147917	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs316317	ENSG00000232559.3	GS1-124K5.12	4.6	5.34e-06	0.00113	0.36	0.21	Diabetic kidney disease;	chr7:66148650	chr7:66554588~66576923:-
LUAD	cis	rs2732480	0.577	rs2634693	ENSG00000257735.1	RP11-370I10.6	4.6	5.34e-06	0.00113	0.26	0.21	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48312715	chr12:48350945~48442411:+
LUAD	cis	rs1008375	0.931	rs6449328	ENSG00000249502.1	AC006160.5	-4.6	5.34e-06	0.00113	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17698851	chr4:17587467~17614571:-
LUAD	cis	rs1008375	0.966	rs10006317	ENSG00000249502.1	AC006160.5	-4.6	5.34e-06	0.00113	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17700902	chr4:17587467~17614571:-
LUAD	cis	rs17508449	0.732	rs74533448	ENSG00000232450.1	RP4-730K3.3	-4.6	5.34e-06	0.00113	-0.37	-0.21	Leprosy;	chr1:113750266	chr1:113698884~113699631:-
LUAD	cis	rs10129255	0.828	rs10140989	ENSG00000211974.3	IGHV2-70	4.6	5.34e-06	0.00113	0.22	0.21	Kawasaki disease;	chr14:106668657	chr14:106723574~106724093:-
LUAD	cis	rs755249	0.508	rs624971	ENSG00000228060.1	RP11-69E11.8	-4.6	5.34e-06	0.00113	-0.18	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39393275	chr1:39565160~39573203:+
LUAD	cis	rs7309	0.935	rs11884495	ENSG00000227403.1	AC009299.3	-4.6	5.34e-06	0.00113	-0.25	-0.21	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161203458	chr2:161244739~161249050:+
LUAD	cis	rs6088590	1	rs12626122	ENSG00000276073.1	RP5-1125A11.7	-4.6	5.34e-06	0.00113	-0.22	-0.21	Coronary artery disease;	chr20:34837997	chr20:33985617~33988989:-
LUAD	cis	rs1783925	0.549	rs11220082	ENSG00000254671.2	STT3A-AS1	-4.6	5.35e-06	0.00113	-0.23	-0.21	Formal thought disorder in schizophrenia;	chr11:125454069	chr11:125570284~125592568:-
LUAD	cis	rs2243480	1	rs316304	ENSG00000232559.3	GS1-124K5.12	4.6	5.35e-06	0.00113	0.36	0.21	Diabetic kidney disease;	chr7:66151907	chr7:66554588~66576923:-
LUAD	cis	rs6568686	0.553	rs9372301	ENSG00000255389.1	C6orf3	-4.6	5.35e-06	0.00113	-0.27	-0.21	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111582126	chr6:111599875~111602295:+
LUAD	cis	rs6969780	0.915	rs4722657	ENSG00000233429.8	HOTAIRM1	-4.6	5.36e-06	0.00113	-0.31	-0.21	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27118137	chr7:27095647~27100265:+
LUAD	cis	rs4835473	0.897	rs13135627	ENSG00000251600.4	RP11-673E1.1	-4.6	5.36e-06	0.00113	-0.26	-0.21	Immature fraction of reticulocytes;	chr4:143691099	chr4:143912331~143982454:+
LUAD	cis	rs2933343	0.729	rs1680780	ENSG00000261159.1	RP11-723O4.9	4.6	5.36e-06	0.00113	0.23	0.21	IgG glycosylation;	chr3:128893816	chr3:128859716~128860526:-
LUAD	cis	rs1551277	0.916	rs9719534	ENSG00000146666.5	LINC00525	-4.6	5.36e-06	0.00113	-0.23	-0.21	Anxiety disorder;	chr7:47795429	chr7:47761476~47766772:+
LUAD	cis	rs12745968	0.652	rs4565725	ENSG00000223787.2	RP4-593M8.1	-4.6	5.36e-06	0.00113	-0.26	-0.21	Bipolar disorder and schizophrenia;	chr1:92485380	chr1:92580476~92580821:-
LUAD	cis	rs2303759	0.709	rs2278405	ENSG00000268686.1	AC010524.2	4.6	5.36e-06	0.00113	0.31	0.21	Multiple sclerosis;	chr19:49309146	chr19:49368705~49388081:-
LUAD	cis	rs11822910	1	rs2439448	ENSG00000265566.2	RN7SL605P	4.6	5.36e-06	0.00113	0.27	0.21	Platelet distribution width;	chr11:57431738	chr11:57528085~57528365:-
LUAD	cis	rs9322193	0.886	rs9767555	ENSG00000268592.3	RAET1E-AS1	4.6	5.36e-06	0.00113	0.26	0.21	Lung cancer;	chr6:149647022	chr6:149863494~149919507:+
LUAD	cis	rs7927592	0.513	rs689075	ENSG00000212093.1	AP000807.1	4.6	5.36e-06	0.00113	0.21	0.21	Total body bone mineral density;	chr11:68426964	chr11:68506083~68506166:-
LUAD	cis	rs7927592	0.513	rs608343	ENSG00000212093.1	AP000807.1	4.6	5.36e-06	0.00113	0.21	0.21	Total body bone mineral density;	chr11:68429362	chr11:68506083~68506166:-
LUAD	cis	rs67311347	0.549	rs60249586	ENSG00000223797.4	ENTPD3-AS1	4.6	5.36e-06	0.00113	0.21	0.21	Renal cell carcinoma;	chr3:40205168	chr3:40313802~40453329:-
LUAD	cis	rs1401999	1	rs3805108	ENSG00000223882.1	ABCC5-AS1	-4.6	5.36e-06	0.00113	-0.21	-0.21	Anterior chamber depth;	chr3:183973862	chr3:184006338~184011419:+
LUAD	cis	rs55823223	0.564	rs4572466	ENSG00000267801.1	RP11-552F3.9	4.6	5.36e-06	0.00113	0.22	0.21	Psoriasis;	chr17:75850233	chr17:75876372~75879546:+
LUAD	cis	rs227275	0.554	rs223381	ENSG00000251288.2	RP11-10L12.2	-4.6	5.36e-06	0.00113	-0.25	-0.21	Allergic disease (asthma, hay fever or eczema);	chr4:102832578	chr4:102751401~102752641:+
LUAD	cis	rs12439619	0.768	rs28694364	ENSG00000276710.3	CSPG4P8	-4.6	5.37e-06	0.00113	-0.23	-0.21	Intelligence (multi-trait analysis);	chr15:82208119	chr15:82459472~82477258:+
LUAD	cis	rs3096299	0.933	rs2965823	ENSG00000182376.2	RP5-1142A6.8	4.6	5.37e-06	0.00113	0.21	0.21	Multiple myeloma (IgH translocation);	chr16:89388516	chr16:88742767~88745748:+
LUAD	cis	rs2765539	0.701	rs4659148	ENSG00000226172.2	RP4-712E4.1	-4.6	5.38e-06	0.00113	-0.25	-0.21	Waist-hip ratio;	chr1:119104071	chr1:119000344~119001392:-
LUAD	cis	rs9652601	0.959	rs2058531	ENSG00000274038.1	RP11-66H6.4	-4.6	5.38e-06	0.00113	-0.25	-0.21	Systemic lupus erythematosus;	chr16:11078252	chr16:11056556~11057034:+
LUAD	cis	rs7580658	0.711	rs12469035	ENSG00000236682.1	AC068282.3	-4.6	5.38e-06	0.00113	-0.27	-0.21	Protein C levels;	chr2:127227341	chr2:127389130~127400580:+
LUAD	cis	rs708547	0.581	rs10020462	ENSG00000269949.1	RP11-738E22.3	-4.6	5.38e-06	0.00113	-0.29	-0.21	Response to bleomycin (chromatid breaks);	chr4:56959427	chr4:56960927~56961373:-
LUAD	cis	rs6728642	1	rs60608738	ENSG00000230606.9	AC159540.1	4.6	5.38e-06	0.00114	0.34	0.21	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96942348	chr2:97416165~97433527:-
LUAD	cis	rs74233809	0.901	rs1004467	ENSG00000213277.3	MARCKSL1P1	4.6	5.38e-06	0.00114	0.33	0.21	Birth weight;	chr10:102834750	chr10:103175554~103176094:+
LUAD	cis	rs889398	0.741	rs10852461	ENSG00000226232.7	RP11-419C5.2	-4.6	5.38e-06	0.00114	-0.17	-0.21	Body mass index;	chr16:69894943	chr16:69976388~69996188:-
LUAD	cis	rs950169	0.922	rs17531523	ENSG00000229212.6	RP11-561C5.4	-4.6	5.38e-06	0.00114	-0.3	-0.21	Schizophrenia;	chr15:84589218	chr15:85205440~85234795:-
LUAD	cis	rs7309	0.81	rs11684253	ENSG00000227403.1	AC009299.3	-4.6	5.39e-06	0.00114	-0.25	-0.21	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161178025	chr2:161244739~161249050:+
LUAD	cis	rs7309	0.935	rs1921309	ENSG00000227403.1	AC009299.3	-4.6	5.39e-06	0.00114	-0.25	-0.21	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161192464	chr2:161244739~161249050:+
LUAD	cis	rs4819052	0.655	rs2330102	ENSG00000223768.1	LINC00205	-4.6	5.39e-06	0.00114	-0.24	-0.21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45271053	chr21:45293285~45297354:+
LUAD	cis	rs2243480	1	rs1546059	ENSG00000232559.3	GS1-124K5.12	-4.6	5.39e-06	0.00114	-0.35	-0.21	Diabetic kidney disease;	chr7:66189722	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs6958289	ENSG00000232559.3	GS1-124K5.12	-4.6	5.39e-06	0.00114	-0.35	-0.21	Diabetic kidney disease;	chr7:66192124	chr7:66554588~66576923:-
LUAD	cis	rs7923609	0.818	rs10822159	ENSG00000232075.1	MRPL35P2	-4.6	5.39e-06	0.00114	-0.25	-0.21	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63336490	chr10:63634317~63634827:-
LUAD	cis	rs7138803	0.538	rs7313563	ENSG00000257464.1	RP11-161H23.8	-4.6	5.4e-06	0.00114	-0.2	-0.21	Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index;	chr12:49810554	chr12:49442424~49442652:-
LUAD	cis	rs4143844	0.867	rs11637967	ENSG00000259251.2	RP11-643M14.1	4.6	5.4e-06	0.00114	0.35	0.21	Bipolar disorder and schizophrenia;	chr15:61928417	chr15:62060503~62062434:+
LUAD	cis	rs11168618	0.626	rs11609074	ENSG00000240399.1	RP1-228P16.1	4.6	5.4e-06	0.00114	0.2	0.21	Adiponectin levels;	chr12:48425552	chr12:48054813~48055591:-
LUAD	cis	rs11673344	0.864	rs7247589	ENSG00000226686.6	LINC01535	4.6	5.4e-06	0.00114	0.26	0.21	Obesity-related traits;	chr19:37019879	chr19:37251912~37265535:+
LUAD	cis	rs10266483	0.96	rs13221291	ENSG00000227986.1	TRIM60P18	-4.6	5.4e-06	0.00114	-0.23	-0.21	Response to statin therapy;	chr7:64279114	chr7:64355078~64356199:+
LUAD	cis	rs5769707	0.967	rs2051626	ENSG00000235111.1	RP1-29C18.8	-4.6	5.4e-06	0.00114	-0.22	-0.21	Monocyte percentage of white cells;Monocyte count;	chr22:49615325	chr22:49612657~49615716:-
LUAD	cis	rs17301013	0.803	rs2187562	ENSG00000227373.4	RP11-160H22.5	4.6	5.4e-06	0.00114	0.25	0.21	Systemic lupus erythematosus;	chr1:174842513	chr1:174115300~174160004:-
LUAD	cis	rs4660214	0.666	rs950805	ENSG00000228060.1	RP11-69E11.8	4.6	5.41e-06	0.00114	0.19	0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39239786	chr1:39565160~39573203:+
LUAD	cis	rs17345786	0.906	rs55710435	ENSG00000244119.1	PDCL3P4	4.6	5.41e-06	0.00114	0.23	0.21	Colonoscopy-negative controls vs population controls;	chr3:101461486	chr3:101712472~101713191:+
LUAD	cis	rs910316	1	rs175512	ENSG00000279594.1	RP11-950C14.10	-4.6	5.41e-06	0.00114	-0.23	-0.21	Height;	chr14:75056679	chr14:75011269~75012851:-
LUAD	cis	rs4664293	0.51	rs2042781	ENSG00000226266.5	AC009961.3	4.6	5.41e-06	0.00114	0.28	0.21	Monocyte percentage of white cells;	chr2:159789899	chr2:159670708~159712435:-
LUAD	cis	rs1062177	1	rs62394155	ENSG00000253921.1	CTB-113P19.3	-4.6	5.41e-06	0.00114	-0.31	-0.21	Preschool internalizing problems;	chr5:151868508	chr5:151753992~151767247:+
LUAD	cis	rs5769707	0.967	rs763127	ENSG00000235111.1	RP1-29C18.8	-4.6	5.42e-06	0.00114	-0.22	-0.21	Monocyte percentage of white cells;Monocyte count;	chr22:49612430	chr22:49612657~49615716:-
LUAD	cis	rs6759004	1	rs6759004	ENSG00000183308.6	AC005037.3	4.6	5.42e-06	0.00114	0.34	0.21	Triptolide cytotoxicity;	chr2:201139953	chr2:200963263~201009102:+
LUAD	cis	rs2243480	0.808	rs12698508	ENSG00000229886.1	RP5-1132H15.3	4.6	5.42e-06	0.00114	0.36	0.21	Diabetic kidney disease;	chr7:65946971	chr7:66025126~66031544:-
LUAD	cis	rs6750795	0.569	rs1667313	ENSG00000181798.2	LINC00471	-4.6	5.42e-06	0.00114	-0.23	-0.21	Height;	chr2:231543307	chr2:231508426~231514339:-
LUAD	cis	rs17818399	0.502	rs1451152	ENSG00000279254.1	RP11-536C12.1	-4.6	5.42e-06	0.00114	-0.22	-0.21	Height;	chr2:46573011	chr2:46668870~46670778:+
LUAD	cis	rs77688320	0.553	rs6722889	ENSG00000213090.2	AC007256.5	-4.6	5.42e-06	0.00114	-0.24	-0.21	Breast cancer;	chr2:201439359	chr2:201410544~201413308:-
LUAD	cis	rs1499614	1	rs1638731	ENSG00000232559.3	GS1-124K5.12	4.6	5.42e-06	0.00114	0.36	0.21	Gout;	chr7:66679692	chr7:66554588~66576923:-
LUAD	cis	rs1499614	1	rs1882655	ENSG00000232559.3	GS1-124K5.12	-4.6	5.42e-06	0.00114	-0.36	-0.21	Gout;	chr7:66682070	chr7:66554588~66576923:-
LUAD	cis	rs1499614	0.831	rs3800822	ENSG00000232559.3	GS1-124K5.12	-4.6	5.42e-06	0.00114	-0.36	-0.21	Gout;	chr7:66682162	chr7:66554588~66576923:-
LUAD	cis	rs2976388	0.647	rs13272904	ENSG00000253741.1	CTD-2292P10.4	-4.6	5.43e-06	0.00114	-0.24	-0.21	Urinary tract infection frequency;	chr8:142701196	chr8:142702252~142726973:-
LUAD	cis	rs11722779	0.658	rs6533044	ENSG00000251288.2	RP11-10L12.2	-4.6	5.43e-06	0.00114	-0.25	-0.21	Schizophrenia;	chr4:102965261	chr4:102751401~102752641:+
LUAD	cis	rs17684571	0.872	rs3002009	ENSG00000231441.1	RP11-472M19.2	4.6	5.43e-06	0.00115	0.28	0.21	Schizophrenia;	chr6:56757983	chr6:56844002~56864078:+
LUAD	cis	rs227275	0.554	rs223371	ENSG00000251288.2	RP11-10L12.2	-4.6	5.44e-06	0.00115	-0.24	-0.21	Allergic disease (asthma, hay fever or eczema);	chr4:102838032	chr4:102751401~102752641:+
LUAD	cis	rs1502844	0.514	rs3114586	ENSG00000250682.4	LINC00491	4.6	5.44e-06	0.00115	0.25	0.21	Schizophrenia;	chr5:102562698	chr5:102609156~102671559:-
LUAD	cis	rs9545047	0.625	rs1408657	ENSG00000227354.5	RBM26-AS1	4.6	5.44e-06	0.00115	0.21	0.21	Schizophrenia;	chr13:79329315	chr13:79406309~79424328:+
LUAD	cis	rs73242632	0.881	rs73242633	ENSG00000269949.1	RP11-738E22.3	4.6	5.44e-06	0.00115	0.53	0.21	Congenital heart disease (maternal effect);	chr4:57053900	chr4:56960927~56961373:-
LUAD	cis	rs10863681	0.764	rs10495184	ENSG00000228437.4	RP11-400N13.2	4.6	5.44e-06	0.00115	0.26	0.21	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222086335	chr1:221966341~221984964:+
LUAD	cis	rs1062177	1	rs1062177	ENSG00000253921.1	CTB-113P19.3	-4.6	5.45e-06	0.00115	-0.31	-0.21	Preschool internalizing problems;	chr5:151805140	chr5:151753992~151767247:+
LUAD	cis	rs73173548	0.502	rs13165211	ENSG00000247828.6	TMEM161B-AS1	4.6	5.45e-06	0.00115	0.25	0.21	Macular telangiectasia type 2;	chr5:88443772	chr5:88268895~88436685:+
LUAD	cis	rs73173548	0.528	rs68019847	ENSG00000247828.6	TMEM161B-AS1	4.6	5.45e-06	0.00115	0.25	0.21	Macular telangiectasia type 2;	chr5:88446795	chr5:88268895~88436685:+
LUAD	cis	rs7555523	0.887	rs10800155	ENSG00000224358.1	RP11-466F5.8	-4.6	5.45e-06	0.00115	-0.34	-0.21	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165754533	chr1:165768929~165775176:+
LUAD	cis	rs17685	0.702	rs6960598	ENSG00000280388.1	RP11-229D13.3	-4.6	5.45e-06	0.00115	-0.19	-0.21	Coffee consumption (cups per day);Coffee consumption;	chr7:76143673	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.712	rs10235738	ENSG00000280388.1	RP11-229D13.3	-4.6	5.45e-06	0.00115	-0.19	-0.21	Coffee consumption (cups per day);Coffee consumption;	chr7:76144142	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.712	rs6953342	ENSG00000280388.1	RP11-229D13.3	-4.6	5.45e-06	0.00115	-0.19	-0.21	Coffee consumption (cups per day);Coffee consumption;	chr7:76147435	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.712	rs10952842	ENSG00000280388.1	RP11-229D13.3	-4.6	5.45e-06	0.00115	-0.19	-0.21	Coffee consumption (cups per day);Coffee consumption;	chr7:76151095	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.712	rs6464994	ENSG00000280388.1	RP11-229D13.3	-4.6	5.45e-06	0.00115	-0.19	-0.21	Coffee consumption (cups per day);Coffee consumption;	chr7:76155350	chr7:76043977~76045963:-
LUAD	cis	rs910316	1	rs4899546	ENSG00000279594.1	RP11-950C14.10	4.6	5.45e-06	0.00115	0.24	0.21	Height;	chr14:75128243	chr14:75011269~75012851:-
LUAD	cis	rs1005277	0.579	rs2504143	ENSG00000263064.2	RP11-291L22.7	4.6	5.46e-06	0.00115	0.22	0.21	Extrinsic epigenetic age acceleration;	chr10:38094778	chr10:38448689~38448949:+
LUAD	cis	rs10754283	0.967	rs1953821	ENSG00000231613.1	RP5-943J3.1	4.6	5.46e-06	0.00115	0.21	0.21	Amyotrophic lateral sclerosis (sporadic);	chr1:89641539	chr1:89788914~89790492:+
LUAD	cis	rs1874124	0.895	rs2642420	ENSG00000238078.1	LINC01352	4.6	5.46e-06	0.00115	0.28	0.21	Cholesterol, total;	chr1:220804308	chr1:220829255~220832429:+
LUAD	cis	rs3758785	0.623	rs13447720	ENSG00000255893.1	RP11-685N10.1	-4.6	5.46e-06	0.00115	-0.29	-0.21	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94432160	chr11:94472908~94473570:-
LUAD	cis	rs10266483	0.774	rs10239221	ENSG00000227986.1	TRIM60P18	4.6	5.46e-06	0.00115	0.25	0.21	Response to statin therapy;	chr7:64352852	chr7:64355078~64356199:+
LUAD	cis	rs6496932	0.503	rs7176605	ENSG00000202081.1	RNU6-1280P	-4.6	5.46e-06	0.00115	-0.27	-0.21	Central corneal thickness;Corneal structure;	chr15:85443491	chr15:85651522~85651628:-
LUAD	cis	rs516805	0.667	rs197676	ENSG00000279453.1	RP3-425C14.4	-4.6	5.46e-06	0.00115	-0.28	-0.21	Lymphocyte counts;	chr6:122532410	chr6:122436789~122439223:-
LUAD	cis	rs4372836	1	rs7562170	ENSG00000226833.4	AC097724.3	-4.6	5.46e-06	0.00115	-0.24	-0.21	Body mass index;	chr2:28720650	chr2:28708953~28736205:-
LUAD	cis	rs4835473	0.932	rs28668841	ENSG00000251600.4	RP11-673E1.1	-4.6	5.46e-06	0.00115	-0.26	-0.21	Immature fraction of reticulocytes;	chr4:143982530	chr4:143912331~143982454:+
LUAD	cis	rs4143844	0.867	rs35523559	ENSG00000259251.2	RP11-643M14.1	4.6	5.46e-06	0.00115	0.35	0.21	Bipolar disorder and schizophrenia;	chr15:61936571	chr15:62060503~62062434:+
LUAD	cis	rs6570726	0.791	rs422099	ENSG00000235652.6	RP11-545I5.3	4.6	5.46e-06	0.00115	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145485800	chr6:145799409~145886585:+
LUAD	cis	rs9652601	0.748	rs9927527	ENSG00000274038.1	RP11-66H6.4	-4.6	5.47e-06	0.00115	-0.25	-0.21	Systemic lupus erythematosus;	chr16:11118824	chr16:11056556~11057034:+
LUAD	cis	rs7598759	0.617	rs6437017	ENSG00000181798.2	LINC00471	-4.6	5.47e-06	0.00115	-0.23	-0.21	Noise-induced hearing loss;	chr2:231462873	chr2:231508426~231514339:-
LUAD	cis	rs3764021	1	rs7977720	ENSG00000278635.1	CTD-2318O12.1	-4.6	5.47e-06	0.00115	-0.18	-0.21	Type 1 diabetes;	chr12:9713753	chr12:9415641~9416718:+
LUAD	cis	rs4568518	0.616	rs10950691	ENSG00000279048.1	RP11-511H23.2	4.6	5.47e-06	0.00115	0.17	0.21	Measles;	chr7:17966511	chr7:17940503~17942922:+
LUAD	cis	rs228614	0.51	rs223358	ENSG00000251288.2	RP11-10L12.2	-4.6	5.47e-06	0.00115	-0.25	-0.21	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102849637	chr4:102751401~102752641:+
LUAD	cis	rs453301	0.631	rs17700611	ENSG00000253893.2	FAM85B	4.6	5.48e-06	0.00115	0.26	0.21	Joint mobility (Beighton score);	chr8:8936144	chr8:8167819~8226614:-
LUAD	cis	rs11722779	0.935	rs7681629	ENSG00000251288.2	RP11-10L12.2	-4.6	5.48e-06	0.00115	-0.25	-0.21	Schizophrenia;	chr4:102974407	chr4:102751401~102752641:+
LUAD	cis	rs11722779	0.844	rs17033381	ENSG00000251288.2	RP11-10L12.2	-4.6	5.48e-06	0.00115	-0.25	-0.21	Schizophrenia;	chr4:102974952	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.556	rs4699044	ENSG00000251288.2	RP11-10L12.2	-4.6	5.48e-06	0.00115	-0.25	-0.21	Allergic disease (asthma, hay fever or eczema);	chr4:102976939	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.556	rs4699045	ENSG00000251288.2	RP11-10L12.2	-4.6	5.48e-06	0.00115	-0.25	-0.21	Allergic disease (asthma, hay fever or eczema);	chr4:102977009	chr4:102751401~102752641:+
LUAD	cis	rs11159086	1	rs4899516	ENSG00000259005.1	RP3-449M8.6	4.6	5.48e-06	0.00115	0.28	0.21	Advanced glycation end-product levels;	chr14:74492825	chr14:74474007~74474864:-
LUAD	cis	rs4664293	0.647	rs357028	ENSG00000226266.5	AC009961.3	-4.6	5.48e-06	0.00115	-0.27	-0.21	Monocyte percentage of white cells;	chr2:159635331	chr2:159670708~159712435:-
LUAD	cis	rs7119038	0.774	rs73005426	ENSG00000255422.1	AP002954.4	4.6	5.48e-06	0.00115	0.31	0.21	Sjögren's syndrome;	chr11:118810374	chr11:118704607~118750263:+
LUAD	cis	rs17772222	0.917	rs61986664	ENSG00000258983.2	RP11-507K2.2	4.6	5.48e-06	0.00115	0.25	0.21	Coronary artery calcification;	chr14:88711251	chr14:88499334~88515502:+
LUAD	cis	rs1401999	0.966	rs2313212	ENSG00000223882.1	ABCC5-AS1	-4.6	5.48e-06	0.00115	-0.21	-0.21	Anterior chamber depth;	chr3:183983140	chr3:184006338~184011419:+
LUAD	cis	rs7811142	0.83	rs1063945	ENSG00000078319.8	PMS2P1	-4.6	5.49e-06	0.00115	-0.25	-0.21	Platelet count;	chr7:100332824	chr7:100320992~100341908:-
LUAD	cis	rs13113518	0.783	rs7690837	ENSG00000223305.1	RN7SKP30	4.6	5.49e-06	0.00116	0.24	0.21	Height;	chr4:55575856	chr4:55540502~55540835:-
LUAD	cis	rs2933343	0.729	rs1680781	ENSG00000261159.1	RP11-723O4.9	4.6	5.49e-06	0.00116	0.23	0.21	IgG glycosylation;	chr3:128893987	chr3:128859716~128860526:-
LUAD	cis	rs5758511	0.508	rs58099562	ENSG00000205702.9	CYP2D7	4.6	5.49e-06	0.00116	0.21	0.21	Birth weight;	chr22:42057768	chr22:42140203~42144577:-
LUAD	cis	rs1005277	0.522	rs289650	ENSG00000263064.2	RP11-291L22.7	4.6	5.49e-06	0.00116	0.21	0.21	Extrinsic epigenetic age acceleration;	chr10:37686577	chr10:38448689~38448949:+
LUAD	cis	rs55823223	0.648	rs56901103	ENSG00000267801.1	RP11-552F3.9	4.6	5.49e-06	0.00116	0.23	0.21	Psoriasis;	chr17:75869586	chr17:75876372~75879546:+
LUAD	cis	rs12554020	0.582	rs77133953	ENSG00000227603.1	RP11-165J3.6	4.6	5.49e-06	0.00116	0.45	0.21	Schizophrenia;	chr9:93635287	chr9:93435332~93437121:-
LUAD	cis	rs2303759	0.709	rs10422677	ENSG00000268686.1	AC010524.2	-4.6	5.49e-06	0.00116	-0.31	-0.21	Multiple sclerosis;	chr19:49321033	chr19:49368705~49388081:-
LUAD	cis	rs7948661	1	rs2071702	ENSG00000278376.1	RP11-158I9.8	4.6	5.49e-06	0.00116	0.41	0.21	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118503146	chr11:118791254~118793137:+
LUAD	cis	rs9341808	0.727	rs9352809	ENSG00000260645.1	RP11-250B2.5	4.6	5.49e-06	0.00116	0.19	0.21	Sitting height ratio;	chr6:80289599	chr6:80466958~80469080:+
LUAD	cis	rs7061710	0.711	rs17565983	ENSG00000271811.1	RP1-79C4.4	-4.6	5.49e-06	0.00116	-0.32	-0.21	Blood metabolite levels;	chr1:171148793	chr1:170667381~170669425:+
LUAD	cis	rs6565180	0.962	rs6565183	ENSG00000273724.1	RP11-347C12.12	-4.6	5.5e-06	0.00116	-0.22	-0.21	Tonsillectomy;	chr16:30371434	chr16:30336400~30343336:+
LUAD	cis	rs9545047	0.604	rs1007569	ENSG00000227354.5	RBM26-AS1	4.6	5.5e-06	0.00116	0.21	0.21	Schizophrenia;	chr13:79306752	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.584	rs4885626	ENSG00000227354.5	RBM26-AS1	4.6	5.5e-06	0.00116	0.21	0.21	Schizophrenia;	chr13:79309765	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs4885627	ENSG00000227354.5	RBM26-AS1	4.6	5.5e-06	0.00116	0.21	0.21	Schizophrenia;	chr13:79309786	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs4885628	ENSG00000227354.5	RBM26-AS1	4.6	5.5e-06	0.00116	0.21	0.21	Schizophrenia;	chr13:79309830	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.554	rs4885629	ENSG00000227354.5	RBM26-AS1	4.6	5.5e-06	0.00116	0.21	0.21	Schizophrenia;	chr13:79309855	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs1927506	ENSG00000227354.5	RBM26-AS1	4.6	5.5e-06	0.00116	0.21	0.21	Schizophrenia;	chr13:79311350	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs1409019	ENSG00000227354.5	RBM26-AS1	4.6	5.5e-06	0.00116	0.21	0.21	Schizophrenia;	chr13:79312431	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs7317343	ENSG00000227354.5	RBM26-AS1	4.6	5.5e-06	0.00116	0.21	0.21	Schizophrenia;	chr13:79312542	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs6563098	ENSG00000227354.5	RBM26-AS1	4.6	5.5e-06	0.00116	0.21	0.21	Schizophrenia;	chr13:79313102	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.532	rs1748768	ENSG00000227354.5	RBM26-AS1	4.6	5.5e-06	0.00116	0.21	0.21	Schizophrenia;	chr13:79313276	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs1748767	ENSG00000227354.5	RBM26-AS1	4.6	5.5e-06	0.00116	0.21	0.21	Schizophrenia;	chr13:79313381	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.567	rs1409018	ENSG00000227354.5	RBM26-AS1	4.6	5.5e-06	0.00116	0.21	0.21	Schizophrenia;	chr13:79313403	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs1410332	ENSG00000227354.5	RBM26-AS1	4.6	5.5e-06	0.00116	0.21	0.21	Schizophrenia;	chr13:79315171	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs9545065	ENSG00000227354.5	RBM26-AS1	4.6	5.5e-06	0.00116	0.21	0.21	Schizophrenia;	chr13:79317034	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs3818563	ENSG00000227354.5	RBM26-AS1	4.6	5.5e-06	0.00116	0.21	0.21	Schizophrenia;	chr13:79318587	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.625	rs9318621	ENSG00000227354.5	RBM26-AS1	4.6	5.5e-06	0.00116	0.21	0.21	Schizophrenia;	chr13:79325662	chr13:79406309~79424328:+
LUAD	cis	rs62025270	0.632	rs62022920	ENSG00000202081.1	RNU6-1280P	-4.6	5.5e-06	0.00116	-0.3	-0.21	Idiopathic pulmonary fibrosis;	chr15:85680159	chr15:85651522~85651628:-
LUAD	cis	rs9650657	0.571	rs4240673	ENSG00000255046.1	RP11-297N6.4	4.6	5.5e-06	0.00116	0.26	0.21	Neuroticism;	chr8:10930102	chr8:11797928~11802568:-
LUAD	cis	rs516805	0.748	rs72962455	ENSG00000279453.1	RP3-425C14.4	4.6	5.5e-06	0.00116	0.28	0.21	Lymphocyte counts;	chr6:122563378	chr6:122436789~122439223:-
LUAD	cis	rs7688540	0.8	rs61794998	ENSG00000211553.1	AC253576.2	-4.6	5.5e-06	0.00116	-0.26	-0.21	Facial morphology (factor 6, height of vermillion lower lip);	chr4:233148	chr4:136461~136568:+
LUAD	cis	rs755249	0.501	rs1889830	ENSG00000182109.6	RP11-69E11.4	-4.6	5.5e-06	0.00116	-0.23	-0.21	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39264500	chr1:39522280~39546187:-
LUAD	cis	rs1401999	1	rs939336	ENSG00000223882.1	ABCC5-AS1	-4.6	5.51e-06	0.00116	-0.21	-0.21	Anterior chamber depth;	chr3:183967746	chr3:184006338~184011419:+
LUAD	cis	rs1401999	1	rs6800217	ENSG00000223882.1	ABCC5-AS1	-4.6	5.51e-06	0.00116	-0.21	-0.21	Anterior chamber depth;	chr3:183968105	chr3:184006338~184011419:+
LUAD	cis	rs1401999	1	rs869417	ENSG00000223882.1	ABCC5-AS1	-4.6	5.51e-06	0.00116	-0.21	-0.21	Anterior chamber depth;	chr3:183971350	chr3:184006338~184011419:+
LUAD	cis	rs1979679	0.842	rs60025108	ENSG00000278733.1	RP11-425D17.1	4.6	5.51e-06	0.00116	0.26	0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28168238	chr12:28185625~28186190:-
LUAD	cis	rs1979679	0.842	rs7487773	ENSG00000278733.1	RP11-425D17.1	4.6	5.51e-06	0.00116	0.26	0.21	Ossification of the posterior longitudinal ligament of the spine;	chr12:28168418	chr12:28185625~28186190:-
LUAD	cis	rs12908161	0.959	rs17534709	ENSG00000259295.5	CSPG4P12	4.6	5.51e-06	0.00116	0.29	0.21	Schizophrenia;	chr15:84771166	chr15:85191438~85213905:+
LUAD	cis	rs875971	1	rs11971949	ENSG00000232559.3	GS1-124K5.12	-4.6	5.51e-06	0.00116	-0.24	-0.21	Aortic root size;	chr7:66161027	chr7:66554588~66576923:-
LUAD	cis	rs4142995	0.962	rs1917368	ENSG00000279048.1	RP11-511H23.2	-4.6	5.51e-06	0.00116	-0.16	-0.21	HDL cholesterol;HDL cholesterol levels;	chr7:17872129	chr7:17940503~17942922:+
LUAD	cis	rs599083	0.793	rs471966	ENSG00000212093.1	AP000807.1	-4.6	5.51e-06	0.00116	-0.22	-0.21	Bone mineral density (spine);	chr11:68406393	chr11:68506083~68506166:-
LUAD	cis	rs910316	1	rs11159117	ENSG00000279594.1	RP11-950C14.10	4.6	5.51e-06	0.00116	0.24	0.21	Height;	chr14:75118164	chr14:75011269~75012851:-
LUAD	cis	rs8098244	0.603	rs1711460	ENSG00000264745.1	TTC39C-AS1	4.6	5.52e-06	0.00116	0.21	0.21	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23711441	chr18:23994213~24015339:-
LUAD	cis	rs74233809	1	rs12221193	ENSG00000213277.3	MARCKSL1P1	4.6	5.52e-06	0.00116	0.36	0.21	Birth weight;	chr10:102905510	chr10:103175554~103176094:+
LUAD	cis	rs74233809	1	rs77180047	ENSG00000213277.3	MARCKSL1P1	4.6	5.52e-06	0.00116	0.36	0.21	Birth weight;	chr10:102907000	chr10:103175554~103176094:+
LUAD	cis	rs74233809	1	rs12221064	ENSG00000213277.3	MARCKSL1P1	4.6	5.52e-06	0.00116	0.36	0.21	Birth weight;	chr10:102917369	chr10:103175554~103176094:+
LUAD	cis	rs1008375	1	rs10019856	ENSG00000249502.1	AC006160.5	-4.6	5.52e-06	0.00116	-0.2	-0.21	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17614119	chr4:17587467~17614571:-
LUAD	cis	rs7811142	0.779	rs77370288	ENSG00000078319.8	PMS2P1	-4.6	5.52e-06	0.00116	-0.25	-0.21	Platelet count;	chr7:100350274	chr7:100320992~100341908:-
LUAD	cis	rs2337406	0.714	rs2337463	ENSG00000223648.3	IGHV3-64	4.6	5.53e-06	0.00116	0.25	0.21	Alzheimer's disease (late onset);	chr14:106816066	chr14:106643132~106658258:-
LUAD	cis	rs801193	1	rs2659909	ENSG00000236529.1	RP13-254B10.1	4.6	5.53e-06	0.00116	0.21	0.21	Aortic root size;	chr7:66695292	chr7:65840212~65840596:+
LUAD	cis	rs7172677	0.737	rs8027604	ENSG00000260269.4	CTD-2323K18.1	-4.6	5.53e-06	0.00116	-0.26	-0.21	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75155432	chr15:75527150~75601205:-
LUAD	cis	rs7172677	0.737	rs4886668	ENSG00000260269.4	CTD-2323K18.1	-4.6	5.53e-06	0.00116	-0.26	-0.21	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75155693	chr15:75527150~75601205:-
LUAD	cis	rs7811142	0.83	rs6948685	ENSG00000078319.8	PMS2P1	-4.6	5.53e-06	0.00116	-0.25	-0.21	Platelet count;	chr7:100372565	chr7:100320992~100341908:-
LUAD	cis	rs6142102	0.651	rs1015361	ENSG00000275784.1	RP5-1125A11.6	4.6	5.53e-06	0.00116	0.23	0.21	Skin pigmentation;	chr20:34150880	chr20:33989480~33991818:-
LUAD	cis	rs1510272	0.515	rs6807235	ENSG00000243926.1	TIPARP-AS1	-4.6	5.53e-06	0.00116	-0.27	-0.21	Testicular germ cell tumor;	chr3:156623812	chr3:156671862~156674378:-
LUAD	cis	rs7772486	0.79	rs2249147	ENSG00000235652.6	RP11-545I5.3	4.6	5.53e-06	0.00116	0.2	0.21	Lobe attachment (rater-scored or self-reported);	chr6:145863863	chr6:145799409~145886585:+
LUAD	cis	rs9487094	0.922	rs971434	ENSG00000260273.1	RP11-425D10.10	4.6	5.53e-06	0.00116	0.28	0.21	Height;	chr6:109656105	chr6:109382795~109383666:+
LUAD	cis	rs911119	0.955	rs8116859	ENSG00000270001.1	RP11-218C14.8	-4.6	5.53e-06	0.00116	-0.3	-0.21	Chronic kidney disease;	chr20:23610066	chr20:23631826~23632316:-
LUAD	cis	rs17597773	0.527	rs2484699	ENSG00000238078.1	LINC01352	-4.6	5.53e-06	0.00116	-0.22	-0.21	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220910410	chr1:220829255~220832429:+
LUAD	cis	rs7324557	0.683	rs7327303	ENSG00000205861.10	C1QTNF9B-AS1	4.59	5.54e-06	0.00117	0.27	0.21	Visceral adipose tissue adjusted for BMI;	chr13:23823175	chr13:23888889~23897263:+
LUAD	cis	rs7819412	0.775	rs2001329	ENSG00000255046.1	RP11-297N6.4	4.59	5.54e-06	0.00117	0.25	0.21	Triglycerides;	chr8:11129349	chr8:11797928~11802568:-
LUAD	cis	rs7189233	0.531	rs56126229	ENSG00000279344.1	RP11-44F14.7	4.59	5.54e-06	0.00117	0.17	0.21	Intelligence (multi-trait analysis);	chr16:53476775	chr16:53478957~53481550:-
LUAD	cis	rs4568518	0.587	rs4576329	ENSG00000279048.1	RP11-511H23.2	4.59	5.54e-06	0.00117	0.17	0.21	Measles;	chr7:17967529	chr7:17940503~17942922:+
LUAD	cis	rs9341808	0.754	rs3793000	ENSG00000233967.5	RP11-250B2.3	4.59	5.54e-06	0.00117	0.2	0.21	Sitting height ratio;	chr6:80285420	chr6:80443344~80465927:+
LUAD	cis	rs2288884	0.943	rs1433089	ENSG00000269959.1	SPACA6P-AS	-4.59	5.54e-06	0.00117	-0.26	-0.21	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52003732	chr19:51685363~51693456:-
LUAD	cis	rs6957923	0.935	rs67128962	ENSG00000230658.1	KLHL7-AS1	4.59	5.55e-06	0.00117	0.25	0.21	Height;	chr7:23447928	chr7:23101228~23105703:-
LUAD	cis	rs10129255	0.912	rs67410411	ENSG00000211974.3	IGHV2-70	4.59	5.55e-06	0.00117	0.22	0.21	Kawasaki disease;	chr14:106680324	chr14:106723574~106724093:-
LUAD	cis	rs875971	1	rs35149210	ENSG00000232559.3	GS1-124K5.12	4.59	5.55e-06	0.00117	0.24	0.21	Aortic root size;	chr7:66464938	chr7:66554588~66576923:-
LUAD	cis	rs1799949	1	rs8077486	ENSG00000236383.6	LINC00854	-4.59	5.55e-06	0.00117	-0.16	-0.21	Menopause (age at onset);	chr17:43060788	chr17:43216941~43305976:-
LUAD	cis	rs338389	0.9	rs11636268	ENSG00000260657.2	RP11-315D16.4	-4.59	5.55e-06	0.00117	-0.23	-0.21	Survival in rectal cancer;	chr15:67981481	chr15:68267792~68277994:-
LUAD	cis	rs338389	0.542	rs28694418	ENSG00000260657.2	RP11-315D16.4	-4.59	5.55e-06	0.00117	-0.24	-0.21	Survival in rectal cancer;	chr15:67949855	chr15:68267792~68277994:-
LUAD	cis	rs12745968	0.652	rs4294422	ENSG00000223787.2	RP4-593M8.1	4.59	5.56e-06	0.00117	0.25	0.21	Bipolar disorder and schizophrenia;	chr1:92639098	chr1:92580476~92580821:-
LUAD	cis	rs7119	0.717	rs12898370	ENSG00000259362.2	RP11-307C19.1	-4.59	5.56e-06	0.00117	-0.26	-0.21	Type 2 diabetes;	chr15:77516256	chr15:77525540~77534110:+
LUAD	cis	rs8180040	0.726	rs6785790	ENSG00000271161.1	BOLA2P2	4.59	5.56e-06	0.00117	0.19	0.21	Colorectal cancer;	chr3:47105442	chr3:47499841~47500407:+
LUAD	cis	rs860295	0.702	rs3738590	ENSG00000225855.5	RUSC1-AS1	4.59	5.56e-06	0.00117	0.15	0.21	Body mass index;	chr1:155660961	chr1:155316863~155324176:-
LUAD	cis	rs34779708	0.733	rs16935948	ENSG00000271335.4	RP11-324I22.4	4.59	5.56e-06	0.00117	0.22	0.21	Inflammatory bowel disease;Crohn's disease;	chr10:35260820	chr10:35314552~35336401:-
LUAD	cis	rs7208859	0.614	rs73265646	ENSG00000280069.1	CTD-2349P21.3	-4.59	5.56e-06	0.00117	-0.3	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917005	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs58908911	ENSG00000280069.1	CTD-2349P21.3	-4.59	5.56e-06	0.00117	-0.3	-0.21	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917540	chr17:30738182~30740275:+
LUAD	cis	rs35740288	0.862	rs11637444	ENSG00000259407.1	RP11-158M2.3	-4.59	5.56e-06	0.00117	-0.2	-0.21	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85767957	chr15:85744109~85750281:-
LUAD	cis	rs3096299	0.504	rs4785574	ENSG00000261118.1	RP11-104N10.1	4.59	5.57e-06	0.00117	0.21	0.21	Multiple myeloma (IgH translocation);	chr16:89502467	chr16:89492017~89504460:-
LUAD	cis	rs2299587	0.585	rs379167	ENSG00000253671.1	RP11-806O11.1	-4.59	5.57e-06	0.00117	-0.24	-0.21	Economic and political preferences;	chr8:17921415	chr8:17808941~17820868:+
LUAD	cis	rs73173548	0.502	rs34969608	ENSG00000247828.6	TMEM161B-AS1	4.59	5.57e-06	0.00117	0.25	0.21	Macular telangiectasia type 2;	chr5:88448606	chr5:88268895~88436685:+
LUAD	cis	rs73173548	0.502	rs6885165	ENSG00000247828.6	TMEM161B-AS1	4.59	5.57e-06	0.00117	0.25	0.21	Macular telangiectasia type 2;	chr5:88449705	chr5:88268895~88436685:+
LUAD	cis	rs2439831	0.867	rs3213990	ENSG00000249839.1	AC011330.5	-4.59	5.57e-06	0.00117	-0.37	-0.21	Lung cancer in ever smokers;	chr15:43378028	chr15:43663654~43684339:-
LUAD	cis	rs7208859	0.673	rs216424	ENSG00000263603.1	CTD-2349P21.5	-4.59	5.58e-06	0.00117	-0.31	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30616046	chr17:30729469~30731202:+
LUAD	cis	rs12439619	0.846	rs62010071	ENSG00000276710.3	CSPG4P8	-4.59	5.58e-06	0.00117	-0.23	-0.2	Intelligence (multi-trait analysis);	chr15:82289442	chr15:82459472~82477258:+
LUAD	cis	rs34779708	0.966	rs57081218	ENSG00000271335.4	RP11-324I22.4	4.59	5.58e-06	0.00117	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35145680	chr10:35314552~35336401:-
LUAD	cis	rs75422866	0.51	rs74733564	ENSG00000276691.1	RP5-1057I20.5	4.59	5.58e-06	0.00117	0.35	0.2	Pneumonia;	chr12:47724644	chr12:47788426~47788971:+
LUAD	cis	rs75422866	0.51	rs73105814	ENSG00000276691.1	RP5-1057I20.5	4.59	5.58e-06	0.00117	0.35	0.2	Pneumonia;	chr12:47725817	chr12:47788426~47788971:+
LUAD	cis	rs12745968	0.623	rs6680578	ENSG00000223787.2	RP4-593M8.1	-4.59	5.59e-06	0.00117	-0.24	-0.2	Bipolar disorder and schizophrenia;	chr1:92711321	chr1:92580476~92580821:-
LUAD	cis	rs800160	0.72	rs2106604	ENSG00000236264.4	RPL26P30	-4.59	5.59e-06	0.00117	-0.29	-0.2	Bacteremia;	chr11:2319927	chr11:2335132~2335776:-
LUAD	cis	rs6951245	0.706	rs1133116	ENSG00000229043.2	AC091729.9	-4.59	5.59e-06	0.00117	-0.3	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1155579	chr7:1160374~1165267:+
LUAD	cis	rs2300747	0.872	rs12044773	ENSG00000177173.5	NAP1L4P1	-4.59	5.59e-06	0.00117	-0.33	-0.2	Primary biliary cholangitis;Multiple sclerosis;	chr1:116544880	chr1:116532936~116534092:-
LUAD	cis	rs516805	0.528	rs1379094	ENSG00000279453.1	RP3-425C14.4	4.59	5.59e-06	0.00117	0.26	0.2	Lymphocyte counts;	chr6:122098054	chr6:122436789~122439223:-
LUAD	cis	rs8180040	0.701	rs12491473	ENSG00000271161.1	BOLA2P2	-4.59	5.59e-06	0.00117	-0.2	-0.2	Colorectal cancer;	chr3:46948414	chr3:47499841~47500407:+
LUAD	cis	rs8180040	0.726	rs1463393	ENSG00000271161.1	BOLA2P2	-4.59	5.59e-06	0.00117	-0.2	-0.2	Colorectal cancer;	chr3:46953497	chr3:47499841~47500407:+
LUAD	cis	rs1008375	0.897	rs3733577	ENSG00000249502.1	AC006160.5	-4.59	5.59e-06	0.00117	-0.19	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17647610	chr4:17587467~17614571:-
LUAD	cis	rs13113518	0.812	rs11133385	ENSG00000223305.1	RN7SKP30	4.59	5.59e-06	0.00118	0.24	0.2	Height;	chr4:55460485	chr4:55540502~55540835:-
LUAD	cis	rs7493	0.853	rs2299266	ENSG00000233942.1	AC004012.1	4.59	5.6e-06	0.00118	0.3	0.2	Yu-Zhi constitution type in type 2 diabetes;	chr7:95419761	chr7:95471835~95473998:+
LUAD	cis	rs2834288	0.5	rs766425	ENSG00000237945.6	LINC00649	4.59	5.6e-06	0.00118	0.25	0.2	Gut microbiota (bacterial taxa);	chr21:33962264	chr21:33915534~33977691:+
LUAD	cis	rs9322193	0.576	rs7452592	ENSG00000268592.3	RAET1E-AS1	4.59	5.6e-06	0.00118	0.33	0.2	Lung cancer;	chr6:149875445	chr6:149863494~149919507:+
LUAD	cis	rs1005277	0.565	rs2474565	ENSG00000263064.2	RP11-291L22.7	4.59	5.6e-06	0.00118	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38091900	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.579	rs2474567	ENSG00000263064.2	RP11-291L22.7	4.59	5.6e-06	0.00118	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38093564	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.579	rs2472175	ENSG00000263064.2	RP11-291L22.7	4.59	5.6e-06	0.00118	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38093973	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.579	rs2472176	ENSG00000263064.2	RP11-291L22.7	4.59	5.6e-06	0.00118	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38093993	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.579	rs2983343	ENSG00000263064.2	RP11-291L22.7	4.59	5.6e-06	0.00118	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38094404	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.579	rs2474569	ENSG00000263064.2	RP11-291L22.7	4.59	5.6e-06	0.00118	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38094563	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.602	rs2504142	ENSG00000263064.2	RP11-291L22.7	4.59	5.6e-06	0.00118	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38094865	chr10:38448689~38448949:+
LUAD	cis	rs7178375	1	rs11070678	ENSG00000270015.1	RP11-540B6.6	4.59	5.6e-06	0.00118	0.19	0.2	Hypertriglyceridemia;	chr15:30927561	chr15:30926514~30928407:+
LUAD	cis	rs11168351	0.926	rs10875719	ENSG00000240399.1	RP1-228P16.1	4.59	5.6e-06	0.00118	0.2	0.2	Bipolar disorder and schizophrenia;	chr12:48017375	chr12:48054813~48055591:-
LUAD	cis	rs1790761	0.667	rs1254123	ENSG00000184224.3	C11orf72	4.59	5.6e-06	0.00118	0.23	0.2	Mean corpuscular volume;	chr11:67567341	chr11:67602880~67606706:-
LUAD	cis	rs6570726	0.791	rs1509214	ENSG00000235652.6	RP11-545I5.3	-4.59	5.6e-06	0.00118	-0.2	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145463470	chr6:145799409~145886585:+
LUAD	cis	rs6840360	0.571	rs17275598	ENSG00000270265.1	RP11-731D1.4	-4.59	5.6e-06	0.00118	-0.24	-0.2	Intelligence (multi-trait analysis);	chr4:151647326	chr4:151333775~151353224:-
LUAD	cis	rs6545883	0.507	rs12478192	ENSG00000271889.1	RP11-493E12.1	-4.59	5.61e-06	0.00118	-0.24	-0.2	Tuberculosis;	chr2:61364040	chr2:61151433~61162105:-
LUAD	cis	rs6700559	0.703	rs10919993	ENSG00000260088.1	RP11-92G12.3	4.59	5.61e-06	0.00118	0.25	0.2	Coronary artery disease;	chr1:200658184	chr1:200669507~200694250:+
LUAD	cis	rs875971	0.66	rs79009421	ENSG00000224316.1	RP11-479O9.2	-4.59	5.61e-06	0.00118	-0.21	-0.2	Aortic root size;	chr7:66603522	chr7:65773620~65802067:+
LUAD	cis	rs4873772	0.735	rs16928696	ENSG00000253330.1	RP11-697N18.3	-4.59	5.61e-06	0.00118	-0.23	-0.2	Lobe attachment (rater-scored or self-reported);	chr8:47612438	chr8:47511034~47512141:-
LUAD	cis	rs2378497	1	rs2185327	ENSG00000232679.1	RP11-400N13.3	4.59	5.61e-06	0.00118	0.31	0.2	Serum thyroid-stimulating hormone levels;	chr1:222014300	chr1:222041705~222064763:-
LUAD	cis	rs17772222	0.63	rs12437422	ENSG00000258789.1	RP11-507K2.3	4.59	5.61e-06	0.00118	0.24	0.2	Coronary artery calcification;	chr14:88529621	chr14:88551597~88552493:+
LUAD	cis	rs7819412	0.645	rs4841508	ENSG00000255046.1	RP11-297N6.4	4.59	5.61e-06	0.00118	0.25	0.2	Triglycerides;	chr8:11207494	chr8:11797928~11802568:-
LUAD	cis	rs7615952	0.515	rs4267608	ENSG00000171084.14	FAM86JP	4.59	5.61e-06	0.00118	0.28	0.2	Blood pressure (smoking interaction);	chr3:125961657	chr3:125916620~125930024:+
LUAD	cis	rs11976180	1	rs11975942	ENSG00000204959.4	ARHGEF34P	4.59	5.61e-06	0.00118	0.26	0.2	Obesity-related traits;	chr7:144043487	chr7:144272445~144286966:-
LUAD	cis	rs2976388	0.935	rs2978980	ENSG00000253741.1	CTD-2292P10.4	4.59	5.61e-06	0.00118	0.23	0.2	Urinary tract infection frequency;	chr8:142676290	chr8:142702252~142726973:-
LUAD	cis	rs2976388	1	rs2920282	ENSG00000253741.1	CTD-2292P10.4	4.59	5.61e-06	0.00118	0.23	0.2	Urinary tract infection frequency;	chr8:142676345	chr8:142702252~142726973:-
LUAD	cis	rs7727544	0.631	rs13357280	ENSG00000233006.5	AC034220.3	4.59	5.61e-06	0.00118	0.18	0.2	Blood metabolite levels;	chr5:132264494	chr5:132311285~132369916:-
LUAD	cis	rs67311347	0.577	rs1317217	ENSG00000223797.4	ENTPD3-AS1	4.59	5.61e-06	0.00118	0.21	0.2	Renal cell carcinoma;	chr3:40230206	chr3:40313802~40453329:-
LUAD	cis	rs367615	0.591	rs4530812	ENSG00000249476.1	CTD-2587M2.1	-4.59	5.61e-06	0.00118	-0.23	-0.2	Colorectal cancer (SNP x SNP interaction);	chr5:109522886	chr5:109237120~109326369:-
LUAD	cis	rs7119	0.651	rs12904823	ENSG00000259362.2	RP11-307C19.1	-4.59	5.62e-06	0.00118	-0.26	-0.2	Type 2 diabetes;	chr15:77545320	chr15:77525540~77534110:+
LUAD	cis	rs1062177	1	rs12515762	ENSG00000253921.1	CTB-113P19.3	-4.59	5.62e-06	0.00118	-0.31	-0.2	Preschool internalizing problems;	chr5:151830361	chr5:151753992~151767247:+
LUAD	cis	rs2274273	0.905	rs17128183	ENSG00000258413.1	RP11-665C16.6	4.59	5.62e-06	0.00118	0.26	0.2	Protein biomarker;	chr14:55112795	chr14:55262767~55272075:-
LUAD	cis	rs2153535	0.561	rs9505511	ENSG00000230939.1	RP11-314C16.1	-4.59	5.62e-06	0.00118	-0.23	-0.2	Motion sickness;	chr6:8667322	chr6:8784178~8785445:+
LUAD	cis	rs7811142	0.83	rs11771936	ENSG00000078319.8	PMS2P1	-4.59	5.63e-06	0.00118	-0.25	-0.2	Platelet count;	chr7:100345660	chr7:100320992~100341908:-
LUAD	cis	rs9341808	0.754	rs3805885	ENSG00000233967.5	RP11-250B2.3	-4.59	5.63e-06	0.00118	-0.2	-0.2	Sitting height ratio;	chr6:80287034	chr6:80443344~80465927:+
LUAD	cis	rs858239	0.539	rs10247268	ENSG00000230042.1	AK3P3	-4.59	5.63e-06	0.00118	-0.27	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23147560	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.539	rs6461694	ENSG00000230042.1	AK3P3	-4.59	5.63e-06	0.00118	-0.27	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23148160	chr7:23129178~23129841:+
LUAD	cis	rs13434995	0.842	rs62303685	ENSG00000273257.1	RP11-177J6.1	-4.59	5.63e-06	0.00118	-0.33	-0.2	Adiponectin levels;	chr4:55418915	chr4:55387949~55388271:+
LUAD	cis	rs2028299	1	rs12910992	ENSG00000259677.1	RP11-493E3.1	4.59	5.64e-06	0.00118	0.25	0.2	Type 2 diabetes;	chr15:89829233	chr15:89876540~89877285:+
LUAD	cis	rs16928809	1	rs16928809	ENSG00000183562.3	CTC-343N3.1	4.59	5.64e-06	0.00118	0.26	0.2	Bilirubin levels;	chr11:2915722	chr11:2989863~2991344:+
LUAD	cis	rs7098414	0.511	rs7071752	ENSG00000226659.1	RP11-137H2.4	-4.59	5.64e-06	0.00118	-0.27	-0.2	Post bronchodilator FEV1;	chr10:80399783	chr10:80529597~80535942:-
LUAD	cis	rs6545883	0.507	rs12617371	ENSG00000271889.1	RP11-493E12.1	-4.59	5.64e-06	0.00118	-0.24	-0.2	Tuberculosis;	chr2:61341999	chr2:61151433~61162105:-
LUAD	cis	rs2832077	0.527	rs9981922	ENSG00000232855.5	AF131217.1	4.59	5.65e-06	0.00119	0.2	0.2	Cognitive test performance;	chr21:28840396	chr21:28439346~28674848:-
LUAD	cis	rs375066	0.935	rs396874	ENSG00000267058.1	RP11-15A1.3	-4.59	5.65e-06	0.00119	-0.23	-0.2	Breast cancer;	chr19:43893073	chr19:43891804~43901805:-
LUAD	cis	rs2380205	0.517	rs17319759	ENSG00000232807.2	RP11-536K7.3	4.59	5.65e-06	0.00119	0.22	0.2	Breast cancer;	chr10:5920927	chr10:5934270~5945900:-
LUAD	cis	rs4811196	0.748	rs6068008	ENSG00000226144.2	RPS27AP3	-4.59	5.65e-06	0.00119	-0.23	-0.2	Bone mineral density;	chr20:37876382	chr20:37049254~37049707:+
LUAD	cis	rs17406451	0.731	rs6544667	ENSG00000279873.2	LINC01126	4.59	5.66e-06	0.00119	0.17	0.2	Mitochondrial DNA levels;	chr2:43505208	chr2:43227210~43228855:+
LUAD	cis	rs34097030	1	rs34097030	ENSG00000207217.1	SNORA42	-4.59	5.66e-06	0.00119	-0.28	-0.2	Reticulocyte fraction of red cells;	chr7:6014758	chr7:6016877~6017011:+
LUAD	cis	rs891378	1	rs2802234	ENSG00000274245.1	RP11-357P18.2	-4.59	5.66e-06	0.00119	-0.27	-0.2	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207298244	chr1:207372559~207373252:+
LUAD	cis	rs453301	0.597	rs7001187	ENSG00000253981.4	ALG1L13P	-4.59	5.66e-06	0.00119	-0.24	-0.2	Joint mobility (Beighton score);	chr8:8935272	chr8:8236003~8244667:-
LUAD	cis	rs6750795	0.746	rs2916579	ENSG00000181798.2	LINC00471	-4.59	5.67e-06	0.00119	-0.24	-0.2	Height;	chr2:231556448	chr2:231508426~231514339:-
LUAD	cis	rs17772222	0.655	rs1152376	ENSG00000258789.1	RP11-507K2.3	4.59	5.67e-06	0.00119	0.25	0.2	Coronary artery calcification;	chr14:88495121	chr14:88551597~88552493:+
LUAD	cis	rs36423	0.748	rs36401	ENSG00000266869.1	RP6-114E22.1	-4.59	5.67e-06	0.00119	-0.3	-0.2	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71893031	chr14:71848606~71908430:+
LUAD	cis	rs911119	0.818	rs56077567	ENSG00000270001.1	RP11-218C14.8	-4.59	5.67e-06	0.00119	-0.3	-0.2	Chronic kidney disease;	chr20:23610450	chr20:23631826~23632316:-
LUAD	cis	rs2976388	0.935	rs2978979	ENSG00000253741.1	CTD-2292P10.4	4.59	5.67e-06	0.00119	0.23	0.2	Urinary tract infection frequency;	chr8:142675868	chr8:142702252~142726973:-
LUAD	cis	rs4908760	0.827	rs7513420	ENSG00000270282.1	RP5-1115A15.2	4.59	5.68e-06	0.00119	0.22	0.2	Vitiligo;	chr1:8620985	chr1:8512653~8513021:+
LUAD	cis	rs6570726	1	rs373778	ENSG00000235652.6	RP11-545I5.3	4.59	5.68e-06	0.00119	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145552116	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.79	rs9376968	ENSG00000235652.6	RP11-545I5.3	4.59	5.68e-06	0.00119	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145859228	chr6:145799409~145886585:+
LUAD	cis	rs2711721	0.557	rs2522270	ENSG00000274723.1	RP11-618L22.1	4.59	5.68e-06	0.00119	0.27	0.2	Prostate cancer (SNP x SNP interaction);	chr12:47020033	chr12:46970504~46972155:+
LUAD	cis	rs17772222	0.74	rs10138139	ENSG00000258789.1	RP11-507K2.3	-4.59	5.68e-06	0.00119	-0.26	-0.2	Coronary artery calcification;	chr14:88510027	chr14:88551597~88552493:+
LUAD	cis	rs7396835	0.866	rs7927820	ENSG00000280143.1	AP000892.6	4.59	5.68e-06	0.00119	0.31	0.2	Quantitative traits;	chr11:116811440	chr11:117204967~117210292:+
LUAD	cis	rs7829975	0.626	rs332040	ENSG00000233609.3	RP11-62H7.2	4.59	5.68e-06	0.00119	0.17	0.2	Mood instability;	chr8:8872978	chr8:8961200~8979025:+
LUAD	cis	rs75422866	0.51	rs73105812	ENSG00000276691.1	RP5-1057I20.5	4.59	5.68e-06	0.00119	0.35	0.2	Pneumonia;	chr12:47724404	chr12:47788426~47788971:+
LUAD	cis	rs7819412	0.936	rs7814499	ENSG00000255046.1	RP11-297N6.4	4.59	5.69e-06	0.00119	0.25	0.2	Triglycerides;	chr8:11183138	chr8:11797928~11802568:-
LUAD	cis	rs9545047	0.604	rs1853830	ENSG00000227354.5	RBM26-AS1	-4.59	5.69e-06	0.00119	-0.22	-0.2	Schizophrenia;	chr13:79406877	chr13:79406309~79424328:+
LUAD	cis	rs35740288	0.571	rs11631009	ENSG00000259407.1	RP11-158M2.3	-4.59	5.69e-06	0.00119	-0.23	-0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85775422	chr15:85744109~85750281:-
LUAD	cis	rs3096299	0.685	rs4785675	ENSG00000261118.1	RP11-104N10.1	4.59	5.69e-06	0.00119	0.21	0.2	Multiple myeloma (IgH translocation);	chr16:89473566	chr16:89492017~89504460:-
LUAD	cis	rs3096299	0.632	rs4399533	ENSG00000182376.2	RP5-1142A6.8	4.59	5.69e-06	0.00119	0.21	0.2	Multiple myeloma (IgH translocation);	chr16:89472974	chr16:88742767~88745748:+
LUAD	cis	rs4841134	1	rs12542898	ENSG00000233609.3	RP11-62H7.2	-4.59	5.7e-06	0.00119	-0.16	-0.2	Age-related disease endophenotypes;	chr8:9329325	chr8:8961200~8979025:+
LUAD	cis	rs10266483	0.739	rs682662	ENSG00000227986.1	TRIM60P18	-4.59	5.7e-06	0.00119	-0.24	-0.2	Response to statin therapy;	chr7:64306107	chr7:64355078~64356199:+
LUAD	cis	rs2732480	0.557	rs2732454	ENSG00000240399.1	RP1-228P16.1	4.59	5.7e-06	0.00119	0.21	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48325894	chr12:48054813~48055591:-
LUAD	cis	rs6700559	0.654	rs12061556	ENSG00000260088.1	RP11-92G12.3	4.59	5.7e-06	0.00119	0.25	0.2	Coronary artery disease;	chr1:200681111	chr1:200669507~200694250:+
LUAD	cis	rs5758511	0.508	rs28715885	ENSG00000205702.9	CYP2D7	4.59	5.7e-06	0.00119	0.21	0.2	Birth weight;	chr22:42045087	chr22:42140203~42144577:-
LUAD	cis	rs62355900	0.627	rs62355943	ENSG00000271828.1	CTD-2310F14.1	4.59	5.7e-06	0.0012	0.39	0.2	Endometriosis;	chr5:56814472	chr5:56927874~56929573:+
LUAD	cis	rs6570726	1	rs405622	ENSG00000235652.6	RP11-545I5.3	4.59	5.7e-06	0.0012	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145550761	chr6:145799409~145886585:+
LUAD	cis	rs6570726	1	rs455109	ENSG00000235652.6	RP11-545I5.3	4.59	5.7e-06	0.0012	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145551529	chr6:145799409~145886585:+
LUAD	cis	rs9322193	0.847	rs880246	ENSG00000268592.3	RAET1E-AS1	4.59	5.71e-06	0.0012	0.26	0.2	Lung cancer;	chr6:149845972	chr6:149863494~149919507:+
LUAD	cis	rs5758511	0.524	rs738257	ENSG00000226450.2	CYP2D8P	4.59	5.71e-06	0.0012	0.2	0.2	Birth weight;	chr22:42173292	chr22:42149886~42155001:-
LUAD	cis	rs73173548	0.502	rs13163266	ENSG00000247828.6	TMEM161B-AS1	4.59	5.71e-06	0.0012	0.25	0.2	Macular telangiectasia type 2;	chr5:88425703	chr5:88268895~88436685:+
LUAD	cis	rs73173548	0.502	rs13180932	ENSG00000247828.6	TMEM161B-AS1	4.59	5.71e-06	0.0012	0.25	0.2	Macular telangiectasia type 2;	chr5:88425720	chr5:88268895~88436685:+
LUAD	cis	rs3096299	0.967	rs28575874	ENSG00000182376.2	RP5-1142A6.8	4.59	5.71e-06	0.0012	0.21	0.2	Multiple myeloma (IgH translocation);	chr16:89403482	chr16:88742767~88745748:+
LUAD	cis	rs2281603	0.694	rs12385910	ENSG00000259116.1	RP11-973N13.4	-4.59	5.71e-06	0.0012	-0.18	-0.2	Lymphocyte counts;	chr14:64533252	chr14:64514154~64540368:-
LUAD	cis	rs1401999	0.934	rs1132776	ENSG00000223882.1	ABCC5-AS1	-4.59	5.71e-06	0.0012	-0.21	-0.2	Anterior chamber depth;	chr3:183978614	chr3:184006338~184011419:+
LUAD	cis	rs7182621	0.774	rs12101368	ENSG00000259363.4	CTD-2054N24.2	-4.59	5.71e-06	0.0012	-0.25	-0.2	Colonoscopy-negative controls vs population controls;	chr15:99872475	chr15:99807023~99877148:+
LUAD	cis	rs7208859	0.673	rs28588622	ENSG00000280069.1	CTD-2349P21.3	-4.59	5.71e-06	0.0012	-0.29	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30918681	chr17:30738182~30740275:+
LUAD	cis	rs17772222	0.876	rs61986665	ENSG00000258983.2	RP11-507K2.2	4.59	5.71e-06	0.0012	0.25	0.2	Coronary artery calcification;	chr14:88711354	chr14:88499334~88515502:+
LUAD	cis	rs219780	0.948	rs219788	ENSG00000233818.1	AP000695.4	4.59	5.71e-06	0.0012	0.26	0.2	Kidney stones;	chr21:36456864	chr21:36445731~36532408:+
LUAD	cis	rs4568518	0.502	rs4544985	ENSG00000279048.1	RP11-511H23.2	4.59	5.71e-06	0.0012	0.17	0.2	Measles;	chr7:17944184	chr7:17940503~17942922:+
LUAD	cis	rs9400467	0.528	rs6913769	ENSG00000271789.1	RP5-1112D6.7	-4.59	5.72e-06	0.0012	-0.22	-0.2	Amino acid levels;Blood metabolite levels;	chr6:111471694	chr6:111297126~111298510:+
LUAD	cis	rs2408955	0.522	rs4760612	ENSG00000257735.1	RP11-370I10.6	-4.59	5.72e-06	0.0012	-0.24	-0.2	Glycated hemoglobin levels;	chr12:48028073	chr12:48350945~48442411:+
LUAD	cis	rs11992162	0.967	rs10108320	ENSG00000255046.1	RP11-297N6.4	4.59	5.72e-06	0.0012	0.24	0.2	Monocyte count;	chr8:11974754	chr8:11797928~11802568:-
LUAD	cis	rs17772222	0.74	rs7160647	ENSG00000258789.1	RP11-507K2.3	-4.59	5.72e-06	0.0012	-0.26	-0.2	Coronary artery calcification;	chr14:88507340	chr14:88551597~88552493:+
LUAD	cis	rs1707322	0.963	rs34907901	ENSG00000280836.1	AL355480.1	-4.59	5.72e-06	0.0012	-0.27	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45939542	chr1:45581219~45581321:-
LUAD	cis	rs2243480	1	rs34637256	ENSG00000226002.1	RP11-460N20.5	-4.59	5.72e-06	0.0012	-0.35	-0.2	Diabetic kidney disease;	chr7:65895144	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs35391607	ENSG00000226002.1	RP11-460N20.5	-4.59	5.72e-06	0.0012	-0.35	-0.2	Diabetic kidney disease;	chr7:65895842	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs13220979	ENSG00000226002.1	RP11-460N20.5	-4.59	5.72e-06	0.0012	-0.35	-0.2	Diabetic kidney disease;	chr7:65898217	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs34974928	ENSG00000226002.1	RP11-460N20.5	-4.59	5.72e-06	0.0012	-0.35	-0.2	Diabetic kidney disease;	chr7:65899019	chr7:65084103~65100232:+
LUAD	cis	rs2115630	1	rs6496452	ENSG00000229212.6	RP11-561C5.4	4.59	5.72e-06	0.0012	0.24	0.2	P wave terminal force;	chr15:84829414	chr15:85205440~85234795:-
LUAD	cis	rs11673344	0.864	rs55921822	ENSG00000226686.6	LINC01535	4.59	5.72e-06	0.0012	0.26	0.2	Obesity-related traits;	chr19:37005910	chr19:37251912~37265535:+
LUAD	cis	rs2380205	0.682	rs3750657	ENSG00000232807.2	RP11-536K7.3	4.59	5.72e-06	0.0012	0.21	0.2	Breast cancer;	chr10:5884116	chr10:5934270~5945900:-
LUAD	cis	rs7555523	0.887	rs4657471	ENSG00000224358.1	RP11-466F5.8	-4.59	5.73e-06	0.0012	-0.36	-0.2	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165717636	chr1:165768929~165775176:+
LUAD	cis	rs9601248	0.711	rs9530937	ENSG00000227354.5	RBM26-AS1	-4.59	5.73e-06	0.0012	-0.23	-0.2	Major depressive disorder;	chr13:79603701	chr13:79406309~79424328:+
LUAD	cis	rs4664293	0.625	rs6745448	ENSG00000226266.5	AC009961.3	-4.59	5.73e-06	0.0012	-0.27	-0.2	Monocyte percentage of white cells;	chr2:159699087	chr2:159670708~159712435:-
LUAD	cis	rs6539288	0.899	rs7956807	ENSG00000260329.1	RP11-412D9.4	-4.59	5.73e-06	0.0012	-0.22	-0.2	Total body bone mineral density;	chr12:106906748	chr12:106954029~106955497:-
LUAD	cis	rs11673344	0.864	rs1879497	ENSG00000226686.6	LINC01535	4.59	5.73e-06	0.0012	0.27	0.2	Obesity-related traits;	chr19:37141975	chr19:37251912~37265535:+
LUAD	cis	rs41369048	0.669	rs77986094	ENSG00000272823.1	RP11-295M18.6	-4.59	5.73e-06	0.0012	-0.32	-0.2	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220854514	chr1:220828676~220829211:-
LUAD	cis	rs17301013	0.861	rs7538650	ENSG00000227373.4	RP11-160H22.5	-4.59	5.73e-06	0.0012	-0.26	-0.2	Systemic lupus erythematosus;	chr1:174788821	chr1:174115300~174160004:-
LUAD	cis	rs6723226	0.806	rs2710606	ENSG00000276334.1	AL133243.1	4.59	5.73e-06	0.0012	0.24	0.2	Intelligence (multi-trait analysis);	chr2:32586842	chr2:32521927~32523547:+
LUAD	cis	rs9309473	0.607	rs6716776	ENSG00000163016.8	ALMS1P	4.59	5.73e-06	0.0012	0.23	0.2	Metabolite levels;	chr2:73360585	chr2:73644919~73685576:+
LUAD	cis	rs467650	1	rs468238	ENSG00000248489.1	CTD-2007H13.3	4.59	5.73e-06	0.0012	0.21	0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98640401	chr5:98929171~98995013:+
LUAD	cis	rs910316	0.967	rs4899551	ENSG00000259138.1	RP11-950C14.7	-4.59	5.74e-06	0.0012	-0.22	-0.2	Height;	chr14:75193543	chr14:75127153~75136930:+
LUAD	cis	rs442309	0.551	rs10822056	ENSG00000238280.1	RP11-436D10.3	-4.59	5.74e-06	0.0012	-0.25	-0.2	Vogt-Koyanagi-Harada syndrome;	chr10:62754351	chr10:62793562~62805887:-
LUAD	cis	rs7777677	0.925	rs4726544	ENSG00000244273.1	PGBD4P1	-4.59	5.74e-06	0.0012	-0.22	-0.2	Alcoholic chronic pancreatitis;	chr7:142659616	chr7:142722358~142722764:+
LUAD	cis	rs7189233	0.531	rs13337544	ENSG00000279344.1	RP11-44F14.7	4.59	5.74e-06	0.0012	0.17	0.2	Intelligence (multi-trait analysis);	chr16:53485123	chr16:53478957~53481550:-
LUAD	cis	rs9425766	0.679	rs12087441	ENSG00000227373.4	RP11-160H22.5	4.59	5.74e-06	0.0012	0.26	0.2	Life satisfaction;	chr1:174188696	chr1:174115300~174160004:-
LUAD	cis	rs6957923	1	rs10807815	ENSG00000230658.1	KLHL7-AS1	4.59	5.74e-06	0.0012	0.25	0.2	Height;	chr7:23453199	chr7:23101228~23105703:-
LUAD	cis	rs9322193	0.923	rs7769101	ENSG00000268592.3	RAET1E-AS1	4.59	5.74e-06	0.0012	0.26	0.2	Lung cancer;	chr6:149848768	chr6:149863494~149919507:+
LUAD	cis	rs57502260	0.68	rs7104806	ENSG00000212093.1	AP000807.1	4.59	5.74e-06	0.0012	0.28	0.2	Total body bone mineral density (age 45-60);	chr11:68454720	chr11:68506083~68506166:-
LUAD	cis	rs9500256	0.655	rs12209098	ENSG00000266579.1	RP1-71H19.2	4.59	5.74e-06	0.0012	0.27	0.2	Eosinophilic esophagitis (pediatric);	chr6:58014194	chr6:57493855~57497691:+
LUAD	cis	rs9425766	0.679	rs4652237	ENSG00000227373.4	RP11-160H22.5	4.59	5.74e-06	0.0012	0.26	0.2	Life satisfaction;	chr1:174189718	chr1:174115300~174160004:-
LUAD	cis	rs6840360	0.967	rs10028961	ENSG00000270265.1	RP11-731D1.4	-4.59	5.74e-06	0.0012	-0.21	-0.2	Intelligence (multi-trait analysis);	chr4:151747072	chr4:151333775~151353224:-
LUAD	cis	rs1876905	0.539	rs240985	ENSG00000255389.1	C6orf3	-4.59	5.75e-06	0.0012	-0.3	-0.2	Mean corpuscular hemoglobin;	chr6:111263428	chr6:111599875~111602295:+
LUAD	cis	rs791888	0.929	rs2755431	ENSG00000225913.2	RP11-57C13.6	4.59	5.75e-06	0.0012	0.27	0.2	Magnesium levels;	chr10:87655347	chr10:87607985~87659279:+
LUAD	cis	rs910316	1	rs876403	ENSG00000279594.1	RP11-950C14.10	4.59	5.75e-06	0.0012	0.23	0.2	Height;	chr14:75136131	chr14:75011269~75012851:-
LUAD	cis	rs1501911	0.611	rs7712408	ENSG00000248489.1	CTD-2007H13.3	-4.59	5.75e-06	0.0012	-0.25	-0.2	Lung function (FEV1/FVC);	chr5:99020633	chr5:98929171~98995013:+
LUAD	cis	rs6969780	0.915	rs3801320	ENSG00000233429.8	HOTAIRM1	4.59	5.75e-06	0.0012	0.31	0.2	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27124745	chr7:27095647~27100265:+
LUAD	cis	rs6969780	0.915	rs4722659	ENSG00000233429.8	HOTAIRM1	-4.59	5.75e-06	0.0012	-0.31	-0.2	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27127131	chr7:27095647~27100265:+
LUAD	cis	rs9487094	1	rs17070580	ENSG00000260273.1	RP11-425D10.10	-4.59	5.75e-06	0.0012	-0.27	-0.2	Height;	chr6:109417511	chr6:109382795~109383666:+
LUAD	cis	rs17301013	0.897	rs1793291	ENSG00000227373.4	RP11-160H22.5	-4.59	5.76e-06	0.00121	-0.26	-0.2	Systemic lupus erythematosus;	chr1:174822675	chr1:174115300~174160004:-
LUAD	cis	rs2243480	0.831	rs7806717	ENSG00000164669.11	INTS4P1	-4.59	5.76e-06	0.00121	-0.37	-0.2	Diabetic kidney disease;	chr7:65928187	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs34136756	ENSG00000164669.11	INTS4P1	4.59	5.76e-06	0.00121	0.37	0.2	Diabetic kidney disease;	chr7:65916269	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs78803505	ENSG00000164669.11	INTS4P1	4.59	5.76e-06	0.00121	0.37	0.2	Diabetic kidney disease;	chr7:65917585	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs34933526	ENSG00000164669.11	INTS4P1	4.59	5.76e-06	0.00121	0.37	0.2	Diabetic kidney disease;	chr7:65918212	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs34577383	ENSG00000164669.11	INTS4P1	4.59	5.76e-06	0.00121	0.37	0.2	Diabetic kidney disease;	chr7:65920739	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs6949812	ENSG00000164669.11	INTS4P1	4.59	5.76e-06	0.00121	0.37	0.2	Diabetic kidney disease;	chr7:65922114	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs55895244	ENSG00000164669.11	INTS4P1	4.59	5.76e-06	0.00121	0.37	0.2	Diabetic kidney disease;	chr7:65922691	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs6970243	ENSG00000164669.11	INTS4P1	4.59	5.76e-06	0.00121	0.37	0.2	Diabetic kidney disease;	chr7:65923503	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs7794661	ENSG00000164669.11	INTS4P1	4.59	5.76e-06	0.00121	0.37	0.2	Diabetic kidney disease;	chr7:65924743	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs7795242	ENSG00000164669.11	INTS4P1	4.59	5.76e-06	0.00121	0.37	0.2	Diabetic kidney disease;	chr7:65925107	chr7:65141225~65234216:+
LUAD	cis	rs2243480	0.708	rs35310401	ENSG00000164669.11	INTS4P1	4.59	5.76e-06	0.00121	0.37	0.2	Diabetic kidney disease;	chr7:65925372	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs35058610	ENSG00000164669.11	INTS4P1	4.59	5.76e-06	0.00121	0.37	0.2	Diabetic kidney disease;	chr7:65925938	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs2177703	ENSG00000164669.11	INTS4P1	4.59	5.76e-06	0.00121	0.37	0.2	Diabetic kidney disease;	chr7:65926730	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs35432774	ENSG00000164669.11	INTS4P1	4.59	5.76e-06	0.00121	0.37	0.2	Diabetic kidney disease;	chr7:65928032	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs56985706	ENSG00000164669.11	INTS4P1	4.59	5.76e-06	0.00121	0.37	0.2	Diabetic kidney disease;	chr7:65929575	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs60683927	ENSG00000164669.11	INTS4P1	4.59	5.76e-06	0.00121	0.37	0.2	Diabetic kidney disease;	chr7:65929781	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs58062456	ENSG00000164669.11	INTS4P1	4.59	5.76e-06	0.00121	0.37	0.2	Diabetic kidney disease;	chr7:65929865	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs34529418	ENSG00000164669.11	INTS4P1	4.59	5.76e-06	0.00121	0.37	0.2	Diabetic kidney disease;	chr7:65938222	chr7:65141225~65234216:+
LUAD	cis	rs2243480	0.901	rs35087093	ENSG00000164669.11	INTS4P1	4.59	5.76e-06	0.00121	0.37	0.2	Diabetic kidney disease;	chr7:65940221	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs35046236	ENSG00000164669.11	INTS4P1	4.59	5.76e-06	0.00121	0.37	0.2	Diabetic kidney disease;	chr7:65943626	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs36068983	ENSG00000164669.11	INTS4P1	4.59	5.76e-06	0.00121	0.37	0.2	Diabetic kidney disease;	chr7:65944004	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs68189316	ENSG00000164669.11	INTS4P1	4.59	5.76e-06	0.00121	0.37	0.2	Diabetic kidney disease;	chr7:65944182	chr7:65141225~65234216:+
LUAD	cis	rs1008375	0.966	rs3733581	ENSG00000249502.1	AC006160.5	4.59	5.76e-06	0.00121	0.19	0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17693583	chr4:17587467~17614571:-
LUAD	cis	rs8062405	0.824	rs4788083	ENSG00000251417.2	RP11-1348G14.4	-4.59	5.76e-06	0.00121	-0.2	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28802743~28817828:+
LUAD	cis	rs16873450	0.527	rs12700462	ENSG00000234800.2	PCMTD1P3	-4.59	5.76e-06	0.00121	-0.23	-0.2	Verbal memory performance (residualized delayed recall level);	chr7:23753221	chr7:23721311~23721782:-
LUAD	cis	rs14027	0.921	rs3812463	ENSG00000279347.1	RP11-85I17.2	-4.59	5.76e-06	0.00121	-0.18	-0.2	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119839860	chr8:119838736~119840385:-
LUAD	cis	rs6969780	0.524	rs12530948	ENSG00000233429.8	HOTAIRM1	-4.59	5.76e-06	0.00121	-0.3	-0.2	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27161639	chr7:27095647~27100265:+
LUAD	cis	rs6570726	0.935	rs392014	ENSG00000235652.6	RP11-545I5.3	4.59	5.76e-06	0.00121	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145522555	chr6:145799409~145886585:+
LUAD	cis	rs9322193	0.962	rs9688750	ENSG00000268592.3	RAET1E-AS1	4.59	5.77e-06	0.00121	0.25	0.2	Lung cancer;	chr6:149657633	chr6:149863494~149919507:+
LUAD	cis	rs11673344	0.764	rs569371	ENSG00000226686.6	LINC01535	4.59	5.77e-06	0.00121	0.26	0.2	Obesity-related traits;	chr19:36963095	chr19:37251912~37265535:+
LUAD	cis	rs1329650	1	rs1329650	ENSG00000228701.1	TNKS2-AS1	4.59	5.77e-06	0.00121	0.28	0.2	Smoking behavior;	chr10:91588363	chr10:91782839~91798291:-
LUAD	cis	rs4819052	0.679	rs8132135	ENSG00000223768.1	LINC00205	-4.59	5.78e-06	0.00121	-0.24	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45274867	chr21:45293285~45297354:+
LUAD	cis	rs141413113	1	rs141413113	ENSG00000173811.9	CCDC13-AS1	4.59	5.78e-06	0.00121	0.23	0.2	Lymphocyte percentage of white cells;	chr3:42865919	chr3:42732575~42746768:+
LUAD	cis	rs6496044	0.611	rs8026938	ENSG00000259295.5	CSPG4P12	-4.59	5.78e-06	0.00121	-0.24	-0.2	Interstitial lung disease;	chr15:85525887	chr15:85191438~85213905:+
LUAD	cis	rs853679	0.567	rs6905380	ENSG00000216901.1	AL022393.7	4.59	5.78e-06	0.00121	0.26	0.2	Depression;	chr6:28407125	chr6:28176188~28176674:+
LUAD	cis	rs2408955	0.561	rs11168365	ENSG00000257735.1	RP11-370I10.6	-4.59	5.78e-06	0.00121	-0.25	-0.2	Glycated hemoglobin levels;	chr12:48027989	chr12:48350945~48442411:+
LUAD	cis	rs4308124	1	rs57874285	ENSG00000227992.1	AC108463.2	-4.59	5.79e-06	0.00121	-0.25	-0.2	Vitiligo;	chr2:111255095	chr2:111203964~111206215:-
LUAD	cis	rs4308124	1	rs57707030	ENSG00000227992.1	AC108463.2	-4.59	5.79e-06	0.00121	-0.25	-0.2	Vitiligo;	chr2:111255105	chr2:111203964~111206215:-
LUAD	cis	rs2243480	1	rs313831	ENSG00000232559.3	GS1-124K5.12	4.59	5.79e-06	0.00121	0.35	0.2	Diabetic kidney disease;	chr7:66086239	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs465359	ENSG00000232559.3	GS1-124K5.12	4.59	5.79e-06	0.00121	0.35	0.2	Diabetic kidney disease;	chr7:66093177	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs462853	ENSG00000232559.3	GS1-124K5.12	4.59	5.79e-06	0.00121	0.35	0.2	Diabetic kidney disease;	chr7:66093180	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs160644	ENSG00000232559.3	GS1-124K5.12	4.59	5.79e-06	0.00121	0.35	0.2	Diabetic kidney disease;	chr7:66093199	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs160642	ENSG00000232559.3	GS1-124K5.12	4.59	5.79e-06	0.00121	0.35	0.2	Diabetic kidney disease;	chr7:66093386	chr7:66554588~66576923:-
LUAD	cis	rs2243480	0.614	rs34032527	ENSG00000232559.3	GS1-124K5.12	4.59	5.79e-06	0.00121	0.35	0.2	Diabetic kidney disease;	chr7:66100154	chr7:66554588~66576923:-
LUAD	cis	rs150992	0.603	rs326481	ENSG00000248489.1	CTD-2007H13.3	4.59	5.79e-06	0.00121	0.26	0.2	Body mass index;	chr5:98949581	chr5:98929171~98995013:+
LUAD	cis	rs7829975	0.623	rs10087493	ENSG00000253893.2	FAM85B	4.59	5.79e-06	0.00121	0.26	0.2	Mood instability;	chr8:8516047	chr8:8167819~8226614:-
LUAD	cis	rs4061073	1	rs4061073	ENSG00000198711.5	SSBP3-AS1	4.59	5.79e-06	0.00121	0.18	0.2	Body mass index;	chr1:54231070	chr1:54236440~54239063:+
LUAD	cis	rs11023332	0.641	rs4281505	ENSG00000251991.1	RNU7-49P	4.59	5.79e-06	0.00121	0.22	0.2	Vitamin D levels;Adiponectin levels;	chr11:14779114	chr11:14478892~14478953:+
LUAD	cis	rs2243480	0.711	rs2460426	ENSG00000232559.3	GS1-124K5.12	-4.59	5.8e-06	0.00121	-0.36	-0.2	Diabetic kidney disease;	chr7:66158142	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs2465120	ENSG00000232559.3	GS1-124K5.12	4.58	5.8e-06	0.00121	0.36	0.2	Diabetic kidney disease;	chr7:66155987	chr7:66554588~66576923:-
LUAD	cis	rs2243480	0.908	rs2460431	ENSG00000232559.3	GS1-124K5.12	-4.58	5.8e-06	0.00121	-0.36	-0.2	Diabetic kidney disease;	chr7:66157859	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs4718309	ENSG00000232559.3	GS1-124K5.12	-4.58	5.8e-06	0.00121	-0.36	-0.2	Diabetic kidney disease;	chr7:66162777	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs6460274	ENSG00000232559.3	GS1-124K5.12	-4.58	5.8e-06	0.00121	-0.36	-0.2	Diabetic kidney disease;	chr7:66163497	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs7787230	ENSG00000232559.3	GS1-124K5.12	-4.58	5.8e-06	0.00121	-0.36	-0.2	Diabetic kidney disease;	chr7:66164112	chr7:66554588~66576923:-
LUAD	cis	rs7829975	0.593	rs2921051	ENSG00000173295.6	FAM86B3P	4.58	5.8e-06	0.00121	0.21	0.2	Mood instability;	chr8:8462594	chr8:8228595~8244865:+
LUAD	cis	rs780094	0.606	rs6729709	ENSG00000234072.1	AC074117.10	-4.58	5.8e-06	0.00121	-0.16	-0.2	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27360289	chr2:27356246~27367622:+
LUAD	cis	rs780094	0.585	rs7586601	ENSG00000234072.1	AC074117.10	-4.58	5.8e-06	0.00121	-0.16	-0.2	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27361799	chr2:27356246~27367622:+
LUAD	cis	rs10129255	0.957	rs8005468	ENSG00000211974.3	IGHV2-70	4.58	5.8e-06	0.00121	0.21	0.2	Kawasaki disease;	chr14:106686431	chr14:106723574~106724093:-
LUAD	cis	rs875971	0.516	rs6945322	ENSG00000237310.1	GS1-124K5.4	4.58	5.8e-06	0.00121	0.22	0.2	Aortic root size;	chr7:65871069	chr7:66493706~66495474:+
LUAD	cis	rs17711722	0.701	rs55773927	ENSG00000237310.1	GS1-124K5.4	4.58	5.8e-06	0.00121	0.22	0.2	Calcium levels;	chr7:65872915	chr7:66493706~66495474:+
LUAD	cis	rs17711722	0.727	rs35850374	ENSG00000237310.1	GS1-124K5.4	4.58	5.8e-06	0.00121	0.22	0.2	Calcium levels;	chr7:65892789	chr7:66493706~66495474:+
LUAD	cis	rs60180747	0.544	rs11633568	ENSG00000261318.1	RP11-653J6.1	4.58	5.8e-06	0.00121	0.27	0.2	Testicular germ cell tumor;	chr15:66272068	chr15:66278498~66293357:-
LUAD	cis	rs2492286	0.597	rs2712384	ENSG00000242551.2	POU5F1P6	-4.58	5.8e-06	0.00121	-0.27	-0.2	Eosinophil counts;	chr3:128615429	chr3:128674735~128677005:-
LUAD	cis	rs6988985	0.818	rs3802228	ENSG00000247317.3	RP11-273G15.2	-4.58	5.81e-06	0.00121	-0.23	-0.2	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142910802	chr8:142981738~143018437:-
LUAD	cis	rs12900463	0.813	rs306198	ENSG00000259295.5	CSPG4P12	-4.58	5.81e-06	0.00121	-0.28	-0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);	chr15:84862138	chr15:85191438~85213905:+
LUAD	cis	rs910316	0.967	rs4903285	ENSG00000279594.1	RP11-950C14.10	4.58	5.81e-06	0.00122	0.24	0.2	Height;	chr14:75142565	chr14:75011269~75012851:-
LUAD	cis	rs2732480	0.5	rs7315820	ENSG00000240399.1	RP1-228P16.1	4.58	5.81e-06	0.00122	0.2	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48205155	chr12:48054813~48055591:-
LUAD	cis	rs2898681	0.614	rs10032097	ENSG00000248375.1	RP11-177B4.1	-4.58	5.81e-06	0.00122	-0.32	-0.2	Optic nerve measurement (cup area);	chr4:52793409	chr4:52720081~52720831:-
LUAD	cis	rs2735413	0.75	rs60659587	ENSG00000276007.1	RP11-358L22.3	4.58	5.82e-06	0.00122	0.25	0.2	Systolic blood pressure (alcohol consumption interaction);	chr16:78037657	chr16:78123243~78124332:+
LUAD	cis	rs2742234	0.955	rs2075913	ENSG00000273008.1	RP11-351D16.3	-4.58	5.82e-06	0.00122	-0.22	-0.2	Hirschsprung disease;	chr10:43126920	chr10:43136824~43138334:-
LUAD	cis	rs2337406	0.539	rs2583292	ENSG00000211972.2	IGHV3-66	4.58	5.82e-06	0.00122	0.21	0.2	Alzheimer's disease (late onset);	chr14:106649040	chr14:106675017~106675544:-
LUAD	cis	rs853679	0.567	rs13209596	ENSG00000216901.1	AL022393.7	4.58	5.82e-06	0.00122	0.26	0.2	Depression;	chr6:28428413	chr6:28176188~28176674:+
LUAD	cis	rs10266483	0.739	rs2692104	ENSG00000227986.1	TRIM60P18	-4.58	5.82e-06	0.00122	-0.24	-0.2	Response to statin therapy;	chr7:64300577	chr7:64355078~64356199:+
LUAD	cis	rs61542988	0.535	rs10807813	ENSG00000228649.7	AC005682.5	4.58	5.82e-06	0.00122	0.3	0.2	Fibrinogen levels;	chr7:22790342	chr7:22854178~22861579:+
LUAD	cis	rs2212361	0.558	rs72963805	ENSG00000255893.1	RP11-685N10.1	-4.58	5.83e-06	0.00122	-0.28	-0.2	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94535532	chr11:94472908~94473570:-
LUAD	cis	rs10266483	0.774	rs10949894	ENSG00000227986.1	TRIM60P18	4.58	5.83e-06	0.00122	0.25	0.2	Response to statin therapy;	chr7:64340143	chr7:64355078~64356199:+
LUAD	cis	rs10266483	0.774	rs28580000	ENSG00000227986.1	TRIM60P18	4.58	5.83e-06	0.00122	0.25	0.2	Response to statin therapy;	chr7:64341531	chr7:64355078~64356199:+
LUAD	cis	rs10266483	0.656	rs670966	ENSG00000227986.1	TRIM60P18	-4.58	5.83e-06	0.00122	-0.24	-0.2	Response to statin therapy;	chr7:64302521	chr7:64355078~64356199:+
LUAD	cis	rs2235642	0.533	rs9922661	ENSG00000280231.1	LA16c-380F5.3	-4.58	5.83e-06	0.00122	-0.32	-0.2	Coronary artery disease;	chr16:1555162	chr16:1553655~1554130:-
LUAD	cis	rs8014204	0.544	rs2286913	ENSG00000279594.1	RP11-950C14.10	4.58	5.83e-06	0.00122	0.25	0.2	Caffeine consumption;	chr14:74919873	chr14:75011269~75012851:-
LUAD	cis	rs7811142	0.83	rs7792525	ENSG00000078319.8	PMS2P1	-4.58	5.83e-06	0.00122	-0.25	-0.2	Platelet count;	chr7:100374499	chr7:100320992~100341908:-
LUAD	cis	rs2337406	0.587	rs10129888	ENSG00000223648.3	IGHV3-64	4.58	5.83e-06	0.00122	0.24	0.2	Alzheimer's disease (late onset);	chr14:106647421	chr14:106643132~106658258:-
LUAD	cis	rs847577	0.609	rs6465658	ENSG00000272950.1	RP11-307C18.1	4.58	5.83e-06	0.00122	0.25	0.2	Breast cancer;	chr7:98187326	chr7:98322853~98323430:+
LUAD	cis	rs950169	0.922	rs11630760	ENSG00000229212.6	RP11-561C5.4	-4.58	5.83e-06	0.00122	-0.29	-0.2	Schizophrenia;	chr15:84570106	chr15:85205440~85234795:-
LUAD	cis	rs950169	0.887	rs71395453	ENSG00000229212.6	RP11-561C5.4	-4.58	5.83e-06	0.00122	-0.29	-0.2	Schizophrenia;	chr15:84570259	chr15:85205440~85234795:-
LUAD	cis	rs950169	0.922	rs11633075	ENSG00000229212.6	RP11-561C5.4	-4.58	5.83e-06	0.00122	-0.29	-0.2	Schizophrenia;	chr15:84570741	chr15:85205440~85234795:-
LUAD	cis	rs12745968	0.629	rs2145824	ENSG00000223787.2	RP4-593M8.1	-4.58	5.83e-06	0.00122	-0.24	-0.2	Bipolar disorder and schizophrenia;	chr1:92734844	chr1:92580476~92580821:-
LUAD	cis	rs1008375	0.932	rs7697329	ENSG00000249502.1	AC006160.5	-4.58	5.83e-06	0.00122	-0.2	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17656230	chr4:17587467~17614571:-
LUAD	cis	rs6840360	0.935	rs3919716	ENSG00000270265.1	RP11-731D1.4	-4.58	5.84e-06	0.00122	-0.21	-0.2	Intelligence (multi-trait analysis);	chr4:151535235	chr4:151333775~151353224:-
LUAD	cis	rs1401999	1	rs6443924	ENSG00000223882.1	ABCC5-AS1	-4.58	5.84e-06	0.00122	-0.21	-0.2	Anterior chamber depth;	chr3:183961744	chr3:184006338~184011419:+
LUAD	cis	rs7829975	0.626	rs907183	ENSG00000253981.4	ALG1L13P	-4.58	5.84e-06	0.00122	-0.24	-0.2	Mood instability;	chr8:8872251	chr8:8236003~8244667:-
LUAD	cis	rs2028299	0.92	rs4932265	ENSG00000259677.1	RP11-493E3.1	4.58	5.84e-06	0.00122	0.25	0.2	Type 2 diabetes;	chr15:89880061	chr15:89876540~89877285:+
LUAD	cis	rs60180747	0.544	rs11635253	ENSG00000261318.1	RP11-653J6.1	4.58	5.84e-06	0.00122	0.27	0.2	Testicular germ cell tumor;	chr15:66276869	chr15:66278498~66293357:-
LUAD	cis	rs7772486	0.727	rs11155442	ENSG00000235652.6	RP11-545I5.3	4.58	5.84e-06	0.00122	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145819589	chr6:145799409~145886585:+
LUAD	cis	rs30380	1	rs26510	ENSG00000248734.2	CTD-2260A17.1	4.58	5.84e-06	0.00122	0.21	0.2	Cerebrospinal fluid biomarker levels;	chr5:96790207	chr5:96784777~96785999:+
LUAD	cis	rs17826219	0.5	rs28452421	ENSG00000266490.1	CTD-2349P21.9	4.58	5.84e-06	0.00122	0.31	0.2	Body mass index;	chr17:30756962	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.573	rs28779471	ENSG00000266490.1	CTD-2349P21.9	4.58	5.84e-06	0.00122	0.31	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30792372~30792833:+
LUAD	cis	rs17826219	0.5	rs61685770	ENSG00000266490.1	CTD-2349P21.9	4.58	5.84e-06	0.00122	0.31	0.2	Body mass index;	chr17:30758695	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs57486336	ENSG00000266490.1	CTD-2349P21.9	4.58	5.84e-06	0.00122	0.31	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs12103440	ENSG00000266490.1	CTD-2349P21.9	4.58	5.84e-06	0.00122	0.31	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs11657777	ENSG00000266490.1	CTD-2349P21.9	4.58	5.84e-06	0.00122	0.31	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30792372~30792833:+
LUAD	cis	rs878939	0.625	rs1035209	ENSG00000230224.1	PHBP9	-4.58	5.84e-06	0.00122	-0.2	-0.2	Warfarin maintenance dose;	chr10:99585609	chr10:100248271~100249095:+
LUAD	cis	rs4664293	0.528	rs1549386	ENSG00000226266.5	AC009961.3	4.58	5.85e-06	0.00122	0.29	0.2	Monocyte percentage of white cells;	chr2:159558015	chr2:159670708~159712435:-
LUAD	cis	rs8062405	0.824	rs62034319	ENSG00000251417.2	RP11-1348G14.4	-4.58	5.85e-06	0.00122	-0.21	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28802743~28817828:+
LUAD	cis	rs9545047	0.604	rs7336581	ENSG00000227354.5	RBM26-AS1	4.58	5.85e-06	0.00122	0.22	0.2	Schizophrenia;	chr13:79385739	chr13:79406309~79424328:+
LUAD	cis	rs950169	0.881	rs34117475	ENSG00000275120.1	RP11-182J1.17	4.58	5.85e-06	0.00122	0.31	0.2	Schizophrenia;	chr15:84565212	chr15:84599434~84606463:-
LUAD	cis	rs338389	0.867	rs7402193	ENSG00000260657.2	RP11-315D16.4	-4.58	5.85e-06	0.00122	-0.23	-0.2	Survival in rectal cancer;	chr15:67984513	chr15:68267792~68277994:-
LUAD	cis	rs4833407	0.593	rs4833406	ENSG00000251441.2	RTEL1P1	-4.58	5.85e-06	0.00122	-0.25	-0.2	Obesity;	chr4:112383656	chr4:112356135~112359819:+
LUAD	cis	rs4266144	0.592	rs1545854	ENSG00000244515.1	KRT18P34	4.58	5.85e-06	0.00122	0.29	0.2	Coronary artery disease;	chr3:157122349	chr3:157162663~157163932:-
LUAD	cis	rs2243480	1	rs160646	ENSG00000232559.3	GS1-124K5.12	4.58	5.85e-06	0.00122	0.35	0.2	Diabetic kidney disease;	chr7:66091293	chr7:66554588~66576923:-
LUAD	cis	rs9473147	0.503	rs2171086	ENSG00000270761.1	RP11-385F7.1	-4.58	5.85e-06	0.00122	-0.24	-0.2	Platelet distribution width;Mean platelet volume;	chr6:47622368	chr6:47477243~47477572:-
LUAD	cis	rs9473147	0.516	rs7754971	ENSG00000270761.1	RP11-385F7.1	-4.58	5.85e-06	0.00122	-0.24	-0.2	Platelet distribution width;Mean platelet volume;	chr6:47622740	chr6:47477243~47477572:-
LUAD	cis	rs228614	0.51	rs223349	ENSG00000251288.2	RP11-10L12.2	-4.58	5.85e-06	0.00122	-0.25	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102857277	chr4:102751401~102752641:+
LUAD	cis	rs6840360	1	rs10007015	ENSG00000270265.1	RP11-731D1.4	-4.58	5.86e-06	0.00122	-0.21	-0.2	Intelligence (multi-trait analysis);	chr4:151682376	chr4:151333775~151353224:-
LUAD	cis	rs2880765	0.546	rs36098649	ENSG00000259295.5	CSPG4P12	4.58	5.86e-06	0.00122	0.25	0.2	Coronary artery disease;	chr15:85513576	chr15:85191438~85213905:+
LUAD	cis	rs394563	0.934	rs384334	ENSG00000216906.2	RP11-350J20.9	4.58	5.86e-06	0.00122	0.25	0.2	Dupuytren's disease;	chr6:149475036	chr6:149904243~149906418:+
LUAD	cis	rs6840360	0.681	rs9968292	ENSG00000270265.1	RP11-731D1.4	-4.58	5.86e-06	0.00122	-0.21	-0.2	Intelligence (multi-trait analysis);	chr4:151376216	chr4:151333775~151353224:-
LUAD	cis	rs7098414	0.511	rs7898787	ENSG00000226659.1	RP11-137H2.4	-4.58	5.86e-06	0.00123	-0.27	-0.2	Post bronchodilator FEV1;	chr10:80396286	chr10:80529597~80535942:-
LUAD	cis	rs2018683	0.707	rs4719961	ENSG00000228421.2	AC005013.5	4.58	5.86e-06	0.00123	0.23	0.2	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28929896	chr7:28957667~28959345:+
LUAD	cis	rs6714710	0.603	rs2044459	ENSG00000230606.9	AC159540.1	-4.58	5.86e-06	0.00123	-0.22	-0.2	Posterior cortical atrophy and Alzheimer's disease;	chr2:97830541	chr2:97416165~97433527:-
LUAD	cis	rs6714710	0.557	rs17490429	ENSG00000230606.9	AC159540.1	-4.58	5.86e-06	0.00123	-0.22	-0.2	Posterior cortical atrophy and Alzheimer's disease;	chr2:97832561	chr2:97416165~97433527:-
LUAD	cis	rs228614	0.51	rs223400	ENSG00000251288.2	RP11-10L12.2	-4.58	5.86e-06	0.00123	-0.25	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102820439	chr4:102751401~102752641:+
LUAD	cis	rs875971	0.577	rs34888281	ENSG00000236529.1	RP13-254B10.1	-4.58	5.87e-06	0.00123	-0.21	-0.2	Aortic root size;	chr7:66120784	chr7:65840212~65840596:+
LUAD	cis	rs9400467	0.528	rs56827	ENSG00000271789.1	RP5-1112D6.7	-4.58	5.87e-06	0.00123	-0.21	-0.2	Amino acid levels;Blood metabolite levels;	chr6:111302000	chr6:111297126~111298510:+
LUAD	cis	rs2243480	0.901	rs57126451	ENSG00000226002.1	RP11-460N20.5	-4.58	5.87e-06	0.00123	-0.35	-0.2	Diabetic kidney disease;	chr7:65951319	chr7:65084103~65100232:+
LUAD	cis	rs62355901	0.545	rs6895844	ENSG00000271828.1	CTD-2310F14.1	4.58	5.87e-06	0.00123	0.34	0.2	Breast cancer;	chr5:56762113	chr5:56927874~56929573:+
LUAD	cis	rs375066	0.762	rs239943	ENSG00000267058.1	RP11-15A1.3	-4.58	5.88e-06	0.00123	-0.23	-0.2	Breast cancer;	chr19:43870564	chr19:43891804~43901805:-
LUAD	cis	rs2243480	0.708	rs13242216	ENSG00000232559.3	GS1-124K5.12	4.58	5.88e-06	0.00123	0.36	0.2	Diabetic kidney disease;	chr7:66433290	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs67536397	ENSG00000232559.3	GS1-124K5.12	4.58	5.88e-06	0.00123	0.36	0.2	Diabetic kidney disease;	chr7:66482930	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs58669269	ENSG00000232559.3	GS1-124K5.12	4.58	5.88e-06	0.00123	0.36	0.2	Diabetic kidney disease;	chr7:66486966	chr7:66554588~66576923:-
LUAD	cis	rs2243480	0.901	rs34807232	ENSG00000232559.3	GS1-124K5.12	4.58	5.88e-06	0.00123	0.36	0.2	Diabetic kidney disease;	chr7:66500146	chr7:66554588~66576923:-
LUAD	cis	rs61270009	0.955	rs450202	ENSG00000247828.6	TMEM161B-AS1	-4.58	5.88e-06	0.00123	-0.24	-0.2	Depressive symptoms;	chr5:88222635	chr5:88268895~88436685:+
LUAD	cis	rs2288073	0.965	rs13395596	ENSG00000242628.4	AC009228.1	4.58	5.88e-06	0.00123	0.28	0.2	Venous thromboembolism (SNP x SNP interaction);	chr2:24187869	chr2:24214381~24221516:+
LUAD	cis	rs2288073	0.896	rs13404513	ENSG00000242628.4	AC009228.1	4.58	5.88e-06	0.00123	0.28	0.2	Venous thromboembolism (SNP x SNP interaction);	chr2:24187911	chr2:24214381~24221516:+
LUAD	cis	rs10266483	0.739	rs10949900	ENSG00000227986.1	TRIM60P18	4.58	5.88e-06	0.00123	0.25	0.2	Response to statin therapy;	chr7:64351751	chr7:64355078~64356199:+
LUAD	cis	rs10266483	0.774	rs10949901	ENSG00000227986.1	TRIM60P18	4.58	5.88e-06	0.00123	0.25	0.2	Response to statin therapy;	chr7:64352396	chr7:64355078~64356199:+
LUAD	cis	rs228614	0.51	rs223353	ENSG00000251288.2	RP11-10L12.2	-4.58	5.88e-06	0.00123	-0.25	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102854547	chr4:102751401~102752641:+
LUAD	cis	rs228614	0.51	rs223352	ENSG00000251288.2	RP11-10L12.2	-4.58	5.88e-06	0.00123	-0.25	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102855710	chr4:102751401~102752641:+
LUAD	cis	rs6061231	0.74	rs11698650	ENSG00000273619.1	RP5-908M14.9	-4.58	5.88e-06	0.00123	-0.19	-0.2	Colorectal cancer;	chr20:62383318	chr20:62386303~62386970:-
LUAD	cis	rs516805	0.748	rs197693	ENSG00000279453.1	RP3-425C14.4	-4.58	5.88e-06	0.00123	-0.28	-0.2	Lymphocyte counts;	chr6:122521294	chr6:122436789~122439223:-
LUAD	cis	rs453301	0.624	rs2288673	ENSG00000173295.6	FAM86B3P	4.58	5.89e-06	0.00123	0.22	0.2	Joint mobility (Beighton score);	chr8:9002766	chr8:8228595~8244865:+
LUAD	cis	rs2880765	0.743	rs6497194	ENSG00000259295.5	CSPG4P12	4.58	5.89e-06	0.00123	0.23	0.2	Coronary artery disease;	chr15:85470885	chr15:85191438~85213905:+
LUAD	cis	rs10971721	0.554	rs55917897	ENSG00000260947.1	RP11-384P7.7	4.58	5.89e-06	0.00123	0.47	0.2	Body mass index;	chr9:33795952	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.643	rs12378415	ENSG00000260947.1	RP11-384P7.7	4.58	5.89e-06	0.00123	0.47	0.2	Body mass index;	chr9:33797335	chr9:33697459~33700986:+
LUAD	cis	rs2836950	0.527	rs2836958	ENSG00000255568.3	BRWD1-AS2	-4.58	5.89e-06	0.00123	-0.2	-0.2	Menarche (age at onset);	chr21:39251600	chr21:39313935~39314962:+
LUAD	cis	rs896854	0.715	rs12548874	ENSG00000253528.2	RP11-347C18.4	-4.58	5.9e-06	0.00123	-0.2	-0.2	Type 2 diabetes;	chr8:94922936	chr8:94974573~94974853:-
LUAD	cis	rs1008375	0.966	rs2191504	ENSG00000249502.1	AC006160.5	-4.58	5.9e-06	0.00123	-0.19	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17673969	chr4:17587467~17614571:-
LUAD	cis	rs7819412	0.527	rs7821914	ENSG00000255046.1	RP11-297N6.4	4.58	5.9e-06	0.00123	0.25	0.2	Triglycerides;	chr8:10947505	chr8:11797928~11802568:-
LUAD	cis	rs4664293	0.609	rs10167143	ENSG00000226266.5	AC009961.3	-4.58	5.9e-06	0.00123	-0.27	-0.2	Monocyte percentage of white cells;	chr2:159606885	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.669	rs13389096	ENSG00000226266.5	AC009961.3	-4.58	5.9e-06	0.00123	-0.27	-0.2	Monocyte percentage of white cells;	chr2:159611246	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.609	rs12470879	ENSG00000226266.5	AC009961.3	-4.58	5.9e-06	0.00123	-0.27	-0.2	Monocyte percentage of white cells;	chr2:159612116	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.55	rs13388082	ENSG00000226266.5	AC009961.3	-4.58	5.9e-06	0.00123	-0.27	-0.2	Monocyte percentage of white cells;	chr2:159616439	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.582	rs1046496	ENSG00000226266.5	AC009961.3	-4.58	5.9e-06	0.00123	-0.27	-0.2	Monocyte percentage of white cells;	chr2:159616888	chr2:159670708~159712435:-
LUAD	cis	rs6687758	1	rs6695584	ENSG00000200033.1	RNU6-403P	4.58	5.9e-06	0.00123	0.28	0.2	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221988647	chr1:221837334~221837437:-
LUAD	cis	rs6762	0.748	rs1130719	ENSG00000279672.1	CMB9-55F22.1	4.58	5.9e-06	0.00123	0.22	0.2	Mean platelet volume;	chr11:838760	chr11:779617~780755:+
LUAD	cis	rs74233809	1	rs12411886	ENSG00000213277.3	MARCKSL1P1	4.58	5.9e-06	0.00123	0.36	0.2	Birth weight;	chr10:102925542	chr10:103175554~103176094:+
LUAD	cis	rs950169	0.922	rs4586394	ENSG00000275120.1	RP11-182J1.17	-4.58	5.9e-06	0.00123	-0.32	-0.2	Schizophrenia;	chr15:84153633	chr15:84599434~84606463:-
LUAD	cis	rs17711722	0.565	rs73372653	ENSG00000237310.1	GS1-124K5.4	4.58	5.9e-06	0.00123	0.22	0.2	Calcium levels;	chr7:65977808	chr7:66493706~66495474:+
LUAD	cis	rs2033711	0.87	rs1051500	ENSG00000268912.1	CTD-2619J13.17	-4.58	5.91e-06	0.00123	-0.22	-0.2	Uric acid clearance;	chr19:58433035	chr19:58428632~58431148:-
LUAD	cis	rs748404	0.626	rs35992154	ENSG00000205771.5	CATSPER2P1	-4.58	5.91e-06	0.00123	-0.31	-0.2	Lung cancer;	chr15:43345669	chr15:43726918~43747094:-
LUAD	cis	rs6430553	0.964	rs56383182	ENSG00000224043.6	CCNT2-AS1	-4.58	5.91e-06	0.00123	-0.25	-0.2	Blood metabolite levels;	chr2:134850641	chr2:134735464~134918710:-
LUAD	cis	rs6723108	0.534	rs6430546	ENSG00000224043.6	CCNT2-AS1	-4.58	5.91e-06	0.00123	-0.25	-0.2	Type 2 diabetes;	chr2:134851231	chr2:134735464~134918710:-
LUAD	cis	rs6430553	0.964	rs60793693	ENSG00000224043.6	CCNT2-AS1	-4.58	5.91e-06	0.00123	-0.25	-0.2	Blood metabolite levels;	chr2:134852125	chr2:134735464~134918710:-
LUAD	cis	rs10266483	0.739	rs2692099	ENSG00000227986.1	TRIM60P18	-4.58	5.91e-06	0.00123	-0.25	-0.2	Response to statin therapy;	chr7:64307384	chr7:64355078~64356199:+
LUAD	cis	rs17685	0.767	rs10954732	ENSG00000280388.1	RP11-229D13.3	4.58	5.91e-06	0.00123	0.19	0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:75981831	chr7:76043977~76045963:-
LUAD	cis	rs12928939	0.815	rs8049163	ENSG00000260886.1	TAT-AS1	4.58	5.91e-06	0.00123	0.25	0.2	Post bronchodilator FEV1;	chr16:71685450	chr16:71565789~71578187:+
LUAD	cis	rs6957923	1	rs34287907	ENSG00000230658.1	KLHL7-AS1	4.58	5.91e-06	0.00123	0.25	0.2	Height;	chr7:23451065	chr7:23101228~23105703:-
LUAD	cis	rs6061231	1	rs67941642	ENSG00000273619.1	RP5-908M14.9	-4.58	5.91e-06	0.00123	-0.21	-0.2	Colorectal cancer;	chr20:62383052	chr20:62386303~62386970:-
LUAD	cis	rs2028299	0.879	rs3803534	ENSG00000259677.1	RP11-493E3.1	4.58	5.92e-06	0.00124	0.25	0.2	Type 2 diabetes;	chr15:89898638	chr15:89876540~89877285:+
LUAD	cis	rs9545047	0.604	rs9574411	ENSG00000227354.5	RBM26-AS1	-4.58	5.92e-06	0.00124	-0.21	-0.2	Schizophrenia;	chr13:79354342	chr13:79406309~79424328:+
LUAD	cis	rs6840360	0.571	rs11931934	ENSG00000270265.1	RP11-731D1.4	-4.58	5.92e-06	0.00124	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151630930	chr4:151333775~151353224:-
LUAD	cis	rs1008375	0.931	rs6449326	ENSG00000249502.1	AC006160.5	-4.58	5.92e-06	0.00124	-0.2	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17698167	chr4:17587467~17614571:-
LUAD	cis	rs911119	0.955	rs2067488	ENSG00000270001.1	RP11-218C14.8	-4.58	5.92e-06	0.00124	-0.3	-0.2	Chronic kidney disease;	chr20:23613694	chr20:23631826~23632316:-
LUAD	cis	rs911119	0.955	rs1555355	ENSG00000270001.1	RP11-218C14.8	-4.58	5.92e-06	0.00124	-0.3	-0.2	Chronic kidney disease;	chr20:23613943	chr20:23631826~23632316:-
LUAD	cis	rs7811142	0.83	rs11761253	ENSG00000078319.8	PMS2P1	-4.58	5.92e-06	0.00124	-0.25	-0.2	Platelet count;	chr7:100341698	chr7:100320992~100341908:-
LUAD	cis	rs7189233	0.531	rs9932007	ENSG00000279344.1	RP11-44F14.7	4.58	5.92e-06	0.00124	0.17	0.2	Intelligence (multi-trait analysis);	chr16:53422749	chr16:53478957~53481550:-
LUAD	cis	rs2243480	0.706	rs6460257	ENSG00000226002.1	RP11-460N20.5	-4.58	5.93e-06	0.00124	-0.3	-0.2	Diabetic kidney disease;	chr7:65731813	chr7:65084103~65100232:+
LUAD	cis	rs6565180	0.632	rs8050812	ENSG00000183604.13	SMG1P5	-4.58	5.93e-06	0.00124	-0.23	-0.2	Tonsillectomy;	chr16:30374516	chr16:30267553~30335374:-
LUAD	cis	rs2239547	0.603	rs6805298	ENSG00000242142.1	SERBP1P3	-4.58	5.93e-06	0.00124	-0.24	-0.2	Schizophrenia;	chr3:53062536	chr3:53064283~53065091:-
LUAD	cis	rs42490	0.674	rs447989	ENSG00000251136.7	RP11-37B2.1	-4.58	5.93e-06	0.00124	-0.22	-0.2	Leprosy;	chr8:89848575	chr8:89609409~89757727:-
LUAD	cis	rs16873450	0.9	rs79130239	ENSG00000234800.2	PCMTD1P3	4.58	5.93e-06	0.00124	0.24	0.2	Verbal memory performance (residualized delayed recall level);	chr7:23800174	chr7:23721311~23721782:-
LUAD	cis	rs10995356	0.932	rs10822082	ENSG00000238280.1	RP11-436D10.3	4.58	5.93e-06	0.00124	0.26	0.2	Temperament;	chr10:62917547	chr10:62793562~62805887:-
LUAD	cis	rs12439619	0.846	rs62012056	ENSG00000276710.3	CSPG4P8	-4.58	5.93e-06	0.00124	-0.23	-0.2	Intelligence (multi-trait analysis);	chr15:82247278	chr15:82459472~82477258:+
LUAD	cis	rs728616	0.558	rs116434658	ENSG00000225484.5	NUTM2B-AS1	-4.58	5.93e-06	0.00124	-0.34	-0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79994870	chr10:79663088~79826594:-
LUAD	cis	rs9322193	0.607	rs3798763	ENSG00000268592.3	RAET1E-AS1	4.58	5.93e-06	0.00124	0.31	0.2	Lung cancer;	chr6:149889964	chr6:149863494~149919507:+
LUAD	cis	rs172166	0.637	rs1233691	ENSG00000216901.1	AL022393.7	4.58	5.93e-06	0.00124	0.25	0.2	Cardiac Troponin-T levels;	chr6:28186119	chr6:28176188~28176674:+
LUAD	cis	rs3738443	0.577	rs1771936	ENSG00000259865.1	RP11-488L18.10	-4.58	5.93e-06	0.00124	-0.22	-0.2	Alcohol dependence;	chr1:247236534	chr1:247187281~247188526:-
LUAD	cis	rs36423	0.748	rs36375	ENSG00000266869.1	RP6-114E22.1	-4.58	5.94e-06	0.00124	-0.3	-0.2	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71907229	chr14:71848606~71908430:+
LUAD	cis	rs8098244	0.576	rs11082762	ENSG00000264745.1	TTC39C-AS1	4.58	5.95e-06	0.00124	0.21	0.2	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23785889	chr18:23994213~24015339:-
LUAD	cis	rs6762	0.748	rs1130663	ENSG00000279672.1	CMB9-55F22.1	4.58	5.95e-06	0.00124	0.22	0.2	Mean platelet volume;	chr11:837582	chr11:779617~780755:+
LUAD	cis	rs62355900	0.627	rs16886407	ENSG00000271828.1	CTD-2310F14.1	4.58	5.95e-06	0.00124	0.39	0.2	Endometriosis;	chr5:56845540	chr5:56927874~56929573:+
LUAD	cis	rs62355900	0.627	rs16886419	ENSG00000271828.1	CTD-2310F14.1	4.58	5.95e-06	0.00124	0.39	0.2	Endometriosis;	chr5:56847034	chr5:56927874~56929573:+
LUAD	cis	rs62355901	0.545	rs1862621	ENSG00000271828.1	CTD-2310F14.1	4.58	5.95e-06	0.00124	0.39	0.2	Breast cancer;	chr5:56847332	chr5:56927874~56929573:+
LUAD	cis	rs62355900	0.627	rs62358076	ENSG00000271828.1	CTD-2310F14.1	4.58	5.95e-06	0.00124	0.39	0.2	Endometriosis;	chr5:56848189	chr5:56927874~56929573:+
LUAD	cis	rs62355900	0.627	rs16886424	ENSG00000271828.1	CTD-2310F14.1	4.58	5.95e-06	0.00124	0.39	0.2	Endometriosis;	chr5:56850866	chr5:56927874~56929573:+
LUAD	cis	rs950169	0.545	rs4354897	ENSG00000225151.9	GOLGA2P7	-4.58	5.95e-06	0.00124	-0.3	-0.2	Schizophrenia;	chr15:83976219	chr15:84199311~84230136:-
LUAD	cis	rs2243480	1	rs2465120	ENSG00000229886.1	RP5-1132H15.3	4.58	5.95e-06	0.00124	0.36	0.2	Diabetic kidney disease;	chr7:66155987	chr7:66025126~66031544:-
LUAD	cis	rs2243480	0.908	rs2460431	ENSG00000229886.1	RP5-1132H15.3	-4.58	5.95e-06	0.00124	-0.36	-0.2	Diabetic kidney disease;	chr7:66157859	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs4718309	ENSG00000229886.1	RP5-1132H15.3	-4.58	5.95e-06	0.00124	-0.36	-0.2	Diabetic kidney disease;	chr7:66162777	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs6460274	ENSG00000229886.1	RP5-1132H15.3	-4.58	5.95e-06	0.00124	-0.36	-0.2	Diabetic kidney disease;	chr7:66163497	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs7787230	ENSG00000229886.1	RP5-1132H15.3	-4.58	5.95e-06	0.00124	-0.36	-0.2	Diabetic kidney disease;	chr7:66164112	chr7:66025126~66031544:-
LUAD	cis	rs914615	0.552	rs7556304	ENSG00000160766.13	GBAP1	-4.58	5.95e-06	0.00124	-0.21	-0.2	Urinary albumin-to-creatinine ratio;	chr1:155167033	chr1:155213821~155227422:-
LUAD	cis	rs11250098	0.6	rs4240671	ENSG00000255046.1	RP11-297N6.4	-4.58	5.95e-06	0.00124	-0.24	-0.2	Morning vs. evening chronotype;	chr8:10910238	chr8:11797928~11802568:-
LUAD	cis	rs950169	0.922	rs62028133	ENSG00000275120.1	RP11-182J1.17	4.58	5.95e-06	0.00124	0.32	0.2	Schizophrenia;	chr15:84250623	chr15:84599434~84606463:-
LUAD	cis	rs9473147	0.543	rs9296559	ENSG00000270761.1	RP11-385F7.1	-4.58	5.95e-06	0.00124	-0.24	-0.2	Platelet distribution width;Mean platelet volume;	chr6:47484534	chr6:47477243~47477572:-
LUAD	cis	rs9545047	0.604	rs9545068	ENSG00000227354.5	RBM26-AS1	4.58	5.95e-06	0.00124	0.21	0.2	Schizophrenia;	chr13:79324101	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs7322167	ENSG00000227354.5	RBM26-AS1	4.58	5.95e-06	0.00124	0.21	0.2	Schizophrenia;	chr13:79325931	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs9285309	ENSG00000227354.5	RBM26-AS1	4.58	5.95e-06	0.00124	0.21	0.2	Schizophrenia;	chr13:79326707	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.584	rs9545069	ENSG00000227354.5	RBM26-AS1	4.58	5.95e-06	0.00124	0.21	0.2	Schizophrenia;	chr13:79328065	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.647	rs7317416	ENSG00000227354.5	RBM26-AS1	4.58	5.95e-06	0.00124	0.21	0.2	Schizophrenia;	chr13:79328400	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.588	rs1408658	ENSG00000227354.5	RBM26-AS1	4.58	5.95e-06	0.00124	0.21	0.2	Schizophrenia;	chr13:79329294	chr13:79406309~79424328:+
LUAD	cis	rs6142102	0.812	rs6059558	ENSG00000275784.1	RP5-1125A11.6	-4.58	5.95e-06	0.00124	-0.23	-0.2	Skin pigmentation;	chr20:33929024	chr20:33989480~33991818:-
LUAD	cis	rs2288073	1	rs2288073	ENSG00000242628.4	AC009228.1	-4.58	5.96e-06	0.00124	-0.27	-0.2	Venous thromboembolism (SNP x SNP interaction);	chr2:24190429	chr2:24214381~24221516:+
LUAD	cis	rs800160	0.777	rs962902	ENSG00000236264.4	RPL26P30	-4.58	5.96e-06	0.00124	-0.28	-0.2	Bacteremia;	chr11:2330995	chr11:2335132~2335776:-
LUAD	cis	rs2243480	1	rs160646	ENSG00000164669.11	INTS4P1	4.58	5.96e-06	0.00124	0.36	0.2	Diabetic kidney disease;	chr7:66091293	chr7:65141225~65234216:+
LUAD	cis	rs2880765	0.835	rs11856869	ENSG00000259416.2	RP11-158M2.5	4.58	5.96e-06	0.00124	0.21	0.2	Coronary artery disease;	chr15:85485866	chr15:85754941~85756237:-
LUAD	cis	rs2153535	0.609	rs1328864	ENSG00000230939.1	RP11-314C16.1	-4.58	5.96e-06	0.00124	-0.23	-0.2	Motion sickness;	chr6:8656048	chr6:8784178~8785445:+
LUAD	cis	rs11155671	0.53	rs9383940	ENSG00000268592.3	RAET1E-AS1	4.58	5.96e-06	0.00124	0.26	0.2	Testicular germ cell tumor;	chr6:149904923	chr6:149863494~149919507:+
LUAD	cis	rs73607972	0.518	rs7193898	ENSG00000275191.1	RP11-36I17.2	4.58	5.96e-06	0.00124	0.25	0.2	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53551009	chr16:53628256~53628816:-
LUAD	cis	rs7772486	0.641	rs9390370	ENSG00000235652.6	RP11-545I5.3	4.58	5.96e-06	0.00124	0.22	0.2	Lobe attachment (rater-scored or self-reported);	chr6:146036433	chr6:145799409~145886585:+
LUAD	cis	rs1355223	0.902	rs34875830	ENSG00000271369.1	RP11-350D17.3	-4.58	5.96e-06	0.00124	-0.24	-0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34700658	chr11:34709600~34710161:+
LUAD	cis	rs9487094	0.961	rs752262	ENSG00000260273.1	RP11-425D10.10	4.58	5.96e-06	0.00124	0.28	0.2	Height;	chr6:109449796	chr6:109382795~109383666:+
LUAD	cis	rs1009115	0.551	rs2110521	ENSG00000272328.1	RP4-594A5.1	-4.58	5.97e-06	0.00124	-0.26	-0.2	Post bronchodilator FEV1;	chr7:8356090	chr7:8303741~8341343:+
LUAD	cis	rs11157436	0.918	rs12586393	ENSG00000211813.2	TRAV34	4.58	5.97e-06	0.00124	0.25	0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22150815	chr14:22207522~22208129:+
LUAD	cis	rs11157436	0.83	rs61972214	ENSG00000211813.2	TRAV34	4.58	5.97e-06	0.00124	0.25	0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22152416	chr14:22207522~22208129:+
LUAD	cis	rs11051970	0.636	rs2733704	ENSG00000274964.1	RP11-817I4.1	-4.58	5.97e-06	0.00124	-0.2	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr12:32414924	chr12:32339368~32340724:+
LUAD	cis	rs801193	1	rs2420824	ENSG00000224316.1	RP11-479O9.2	-4.58	5.97e-06	0.00125	-0.21	-0.2	Aortic root size;	chr7:66666129	chr7:65773620~65802067:+
LUAD	cis	rs6539288	0.933	rs4964497	ENSG00000260329.1	RP11-412D9.4	-4.58	5.97e-06	0.00125	-0.22	-0.2	Total body bone mineral density;	chr12:106910711	chr12:106954029~106955497:-
LUAD	cis	rs4841134	0.967	rs11778929	ENSG00000233609.3	RP11-62H7.2	-4.58	5.98e-06	0.00125	-0.16	-0.2	Age-related disease endophenotypes;	chr8:9327019	chr8:8961200~8979025:+
LUAD	cis	rs875971	0.638	rs6960778	ENSG00000224316.1	RP11-479O9.2	-4.58	5.98e-06	0.00125	-0.21	-0.2	Aortic root size;	chr7:66606610	chr7:65773620~65802067:+
LUAD	cis	rs2243480	1	rs34702770	ENSG00000164669.11	INTS4P1	4.58	5.98e-06	0.00125	0.37	0.2	Diabetic kidney disease;	chr7:65879836	chr7:65141225~65234216:+
LUAD	cis	rs9900062	0.519	rs2676293	ENSG00000270714.1	MINOS1P2	-4.58	5.98e-06	0.00125	-0.27	-0.2	QT interval;	chr17:64714343	chr17:64747264~64747492:-
LUAD	cis	rs2115630	0.967	rs7171167	ENSG00000225151.9	GOLGA2P7	4.58	5.98e-06	0.00125	0.23	0.2	P wave terminal force;	chr15:84695892	chr15:84199311~84230136:-
LUAD	cis	rs10938353	0.68	rs66691259	ENSG00000273369.1	RP11-700J17.1	4.58	5.98e-06	0.00125	0.27	0.2	Body mass index;	chr4:44705036	chr4:44693946~44694386:-
LUAD	cis	rs7208859	0.573	rs216443	ENSG00000266490.1	CTD-2349P21.9	4.58	5.98e-06	0.00125	0.32	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30792372~30792833:+
LUAD	cis	rs6687758	1	rs12731064	ENSG00000227925.1	RP11-191N8.2	4.58	5.99e-06	0.00125	0.29	0.2	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222016779	chr1:221827666~221840666:-
LUAD	cis	rs9341808	0.754	rs6907729	ENSG00000233967.5	RP11-250B2.3	-4.58	5.99e-06	0.00125	-0.2	-0.2	Sitting height ratio;	chr6:80295205	chr6:80443344~80465927:+
LUAD	cis	rs4308124	1	rs4308124	ENSG00000227992.1	AC108463.2	-4.58	5.99e-06	0.00125	-0.25	-0.2	Vitiligo;	chr2:111252909	chr2:111203964~111206215:-
LUAD	cis	rs228614	0.51	rs65671	ENSG00000251288.2	RP11-10L12.2	-4.58	5.99e-06	0.00125	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102801081	chr4:102751401~102752641:+
LUAD	cis	rs9987353	0.566	rs6998368	ENSG00000253893.2	FAM85B	4.58	5.99e-06	0.00125	0.28	0.2	Recombination measurement;	chr8:9212778	chr8:8167819~8226614:-
LUAD	cis	rs801193	0.967	rs2707841	ENSG00000224316.1	RP11-479O9.2	4.58	5.99e-06	0.00125	0.21	0.2	Aortic root size;	chr7:66692033	chr7:65773620~65802067:+
LUAD	cis	rs67311347	0.577	rs11712626	ENSG00000223797.4	ENTPD3-AS1	4.58	5.99e-06	0.00125	0.21	0.2	Renal cell carcinoma;	chr3:40218436	chr3:40313802~40453329:-
LUAD	cis	rs1005277	0.579	rs2505194	ENSG00000263064.2	RP11-291L22.7	4.58	5.99e-06	0.00125	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38104953	chr10:38448689~38448949:+
LUAD	cis	rs6840360	0.53	rs62327350	ENSG00000270265.1	RP11-731D1.4	-4.58	5.99e-06	0.00125	-0.24	-0.2	Intelligence (multi-trait analysis);	chr4:151720050	chr4:151333775~151353224:-
LUAD	cis	rs62025270	0.576	rs62022947	ENSG00000202081.1	RNU6-1280P	-4.58	5.99e-06	0.00125	-0.3	-0.2	Idiopathic pulmonary fibrosis;	chr15:85728091	chr15:85651522~85651628:-
LUAD	cis	rs7404843	0.778	rs72774864	ENSG00000207425.1	Y_RNA	-4.58	6e-06	0.00125	-0.41	-0.2	Testicular germ cell tumor;	chr16:15418465	chr16:14915457~14915556:-
LUAD	cis	rs2408955	0.515	rs10875742	ENSG00000240399.1	RP1-228P16.1	-4.58	6e-06	0.00125	-0.2	-0.2	Glycated hemoglobin levels;	chr12:48099591	chr12:48054813~48055591:-
LUAD	cis	rs10266483	0.774	rs1404678	ENSG00000227986.1	TRIM60P18	4.58	6e-06	0.00125	0.25	0.2	Response to statin therapy;	chr7:64342138	chr7:64355078~64356199:+
LUAD	cis	rs7208859	0.673	rs7211776	ENSG00000263603.1	CTD-2349P21.5	-4.58	6e-06	0.00125	-0.31	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793178	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs9912122	ENSG00000263603.1	CTD-2349P21.5	-4.58	6e-06	0.00125	-0.31	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813698	chr17:30729469~30731202:+
LUAD	cis	rs11064837	0.523	rs11064873	ENSG00000248636.5	RP11-768F21.1	4.58	6.01e-06	0.00125	0.24	0.2	Schizophrenia;	chr12:119667187	chr12:119387987~119668079:-
LUAD	cis	rs240993	0.516	rs173287	ENSG00000230177.1	RP5-1112D6.4	-4.58	6.01e-06	0.00125	-0.22	-0.2	Inflammatory skin disease;Psoriasis;	chr6:111276236	chr6:111277932~111278742:+
LUAD	cis	rs9860428	0.527	rs2087284	ENSG00000242770.2	RP11-180K7.1	4.58	6.01e-06	0.00125	0.22	0.2	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112842544	chr3:112802478~112812819:+
LUAD	cis	rs867371	0.502	rs1846908	ENSG00000276710.3	CSPG4P8	-4.58	6.02e-06	0.00125	-0.19	-0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82230185	chr15:82459472~82477258:+
LUAD	cis	rs2665103	0.655	rs1501367	ENSG00000276710.3	CSPG4P8	-4.58	6.02e-06	0.00125	-0.19	-0.2	Intelligence (multi-trait analysis);	chr15:82230475	chr15:82459472~82477258:+
LUAD	cis	rs6689263	0.929	rs112322975	ENSG00000117242.7	PINK1-AS	4.58	6.02e-06	0.00125	0.44	0.2	Intelligence (multi-trait analysis);	chr1:20449006	chr1:20642657~20652193:-
LUAD	cis	rs7299940	1	rs7299940	ENSG00000256250.1	RP11-989F5.1	-4.58	6.02e-06	0.00125	-0.23	-0.2	Panic disorder;	chr12:130906209	chr12:130810606~130812438:+
LUAD	cis	rs4819052	1	rs733738	ENSG00000237664.1	LINC00316	4.58	6.02e-06	0.00126	0.26	0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246481	chr21:45338590~45341990:-
LUAD	cis	rs228614	0.51	rs3774987	ENSG00000251288.2	RP11-10L12.2	-4.58	6.02e-06	0.00126	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799709	chr4:102751401~102752641:+
LUAD	cis	rs6102185	0.55	rs6129700	ENSG00000229771.2	RP4-644L1.2	4.58	6.03e-06	0.00126	0.25	0.2	IgG glycosylation;	chr20:40892941	chr20:40696499~40698616:-
LUAD	cis	rs12819124	0.502	rs10875718	ENSG00000257735.1	RP11-370I10.6	4.58	6.03e-06	0.00126	0.25	0.2	Glycated hemoglobin levels;	chr12:48017319	chr12:48350945~48442411:+
LUAD	cis	rs801193	0.66	rs2659914	ENSG00000232559.3	GS1-124K5.12	4.58	6.03e-06	0.00126	0.24	0.2	Aortic root size;	chr7:66691927	chr7:66554588~66576923:-
LUAD	cis	rs11157436	0.918	rs1983518	ENSG00000211813.2	TRAV34	4.58	6.03e-06	0.00126	0.25	0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22149336	chr14:22207522~22208129:+
LUAD	cis	rs7119	0.651	rs12902948	ENSG00000259362.2	RP11-307C19.1	-4.58	6.04e-06	0.00126	-0.26	-0.2	Type 2 diabetes;	chr15:77556912	chr15:77525540~77534110:+
LUAD	cis	rs3795324	0.793	rs16832302	ENSG00000228863.7	RP11-404F10.2	-4.58	6.04e-06	0.00126	-0.24	-0.2	Microalbuminuria;	chr1:160653382	chr1:160670778~160699761:+
LUAD	cis	rs4664293	0.609	rs357033	ENSG00000226266.5	AC009961.3	-4.58	6.04e-06	0.00126	-0.27	-0.2	Monocyte percentage of white cells;	chr2:159637962	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.625	rs6432543	ENSG00000226266.5	AC009961.3	4.58	6.04e-06	0.00126	0.27	0.2	Monocyte percentage of white cells;	chr2:159638820	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.647	rs4665099	ENSG00000226266.5	AC009961.3	4.58	6.04e-06	0.00126	0.27	0.2	Monocyte percentage of white cells;	chr2:159639027	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.647	rs6724151	ENSG00000226266.5	AC009961.3	4.58	6.04e-06	0.00126	0.27	0.2	Monocyte percentage of white cells;	chr2:159642788	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.625	rs34573069	ENSG00000226266.5	AC009961.3	4.58	6.04e-06	0.00126	0.27	0.2	Monocyte percentage of white cells;	chr2:159643561	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.567	rs6711125	ENSG00000226266.5	AC009961.3	4.58	6.04e-06	0.00126	0.27	0.2	Monocyte percentage of white cells;	chr2:159645040	chr2:159670708~159712435:-
LUAD	cis	rs853679	0.882	rs9380069	ENSG00000204709.4	LINC01556	4.58	6.04e-06	0.00126	0.33	0.2	Depression;	chr6:28235522	chr6:28943877~28944537:+
LUAD	cis	rs6714710	0.603	rs17489984	ENSG00000230606.9	AC159540.1	-4.58	6.04e-06	0.00126	-0.22	-0.2	Posterior cortical atrophy and Alzheimer's disease;	chr2:97804901	chr2:97416165~97433527:-
LUAD	cis	rs7811142	1	rs67163493	ENSG00000078319.8	PMS2P1	-4.58	6.04e-06	0.00126	-0.24	-0.2	Platelet count;	chr7:100426215	chr7:100320992~100341908:-
LUAD	cis	rs875971	0.838	rs2173570	ENSG00000232559.3	GS1-124K5.12	-4.58	6.04e-06	0.00126	-0.24	-0.2	Aortic root size;	chr7:66297976	chr7:66554588~66576923:-
LUAD	cis	rs2898681	0.519	rs3811781	ENSG00000248375.1	RP11-177B4.1	-4.58	6.05e-06	0.00126	-0.34	-0.2	Optic nerve measurement (cup area);	chr4:52862999	chr4:52720081~52720831:-
LUAD	cis	rs2919009	0.607	rs17594946	ENSG00000271670.1	RP11-95I16.4	4.58	6.05e-06	0.00126	0.27	0.2	Obesity-related traits;	chr10:120953414	chr10:120879256~120880667:-
LUAD	cis	rs4843747	0.619	rs66508972	ENSG00000205037.2	RP11-863P13.4	4.58	6.05e-06	0.00126	0.3	0.2	Menopause (age at onset);	chr16:88052779	chr16:88088041~88100985:-
LUAD	cis	rs7945705	0.875	rs10769955	ENSG00000254860.4	TMEM9B-AS1	-4.58	6.05e-06	0.00126	-0.24	-0.2	Hemoglobin concentration;	chr11:8763100	chr11:8964675~8977527:+
LUAD	cis	rs9813712	0.597	rs10934931	ENSG00000249846.5	RP11-77P16.4	-4.58	6.06e-06	0.00126	-0.24	-0.2	Response to amphetamines;	chr3:130261365	chr3:130112550~130120579:+
LUAD	cis	rs10129255	0.957	rs10141052	ENSG00000274576.2	IGHV2-70	4.58	6.06e-06	0.00126	0.18	0.2	Kawasaki disease;	chr14:106776528	chr14:106770577~106771020:-
LUAD	cis	rs2522056	1	rs11242113	ENSG00000233006.5	AC034220.3	-4.58	6.06e-06	0.00126	-0.22	-0.2	Fibrinogen;Lymphocyte counts;	chr5:132441542	chr5:132311285~132369916:-
LUAD	cis	rs4664293	0.647	rs4144512	ENSG00000226266.5	AC009961.3	4.58	6.06e-06	0.00126	0.27	0.2	Monocyte percentage of white cells;	chr2:159651008	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.625	rs13006088	ENSG00000226266.5	AC009961.3	4.58	6.06e-06	0.00126	0.27	0.2	Monocyte percentage of white cells;	chr2:159652915	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.605	rs2042774	ENSG00000226266.5	AC009961.3	4.58	6.06e-06	0.00126	0.27	0.2	Monocyte percentage of white cells;	chr2:159653496	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.647	rs2042775	ENSG00000226266.5	AC009961.3	4.58	6.06e-06	0.00126	0.27	0.2	Monocyte percentage of white cells;	chr2:159653581	chr2:159670708~159712435:-
LUAD	cis	rs7829975	0.508	rs1594437	ENSG00000253893.2	FAM85B	-4.58	6.06e-06	0.00126	-0.25	-0.2	Mood instability;	chr8:8968365	chr8:8167819~8226614:-
LUAD	cis	rs712022	1	rs712022	ENSG00000246225.5	RP11-17A1.3	-4.58	6.06e-06	0.00126	-0.25	-0.2	Dialysis-related mortality;	chr11:22821609	chr11:22829380~22945393:+
LUAD	cis	rs4660214	0.666	rs2275186	ENSG00000228060.1	RP11-69E11.8	4.58	6.06e-06	0.00126	0.18	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39300383	chr1:39565160~39573203:+
LUAD	cis	rs643506	0.874	rs1633471	ENSG00000230911.1	PPIHP1	-4.58	6.06e-06	0.00126	-0.25	-0.2	Breast cancer;	chr11:111819607	chr11:112029858~112030367:-
LUAD	cis	rs7119	0.689	rs8040318	ENSG00000259362.2	RP11-307C19.1	-4.58	6.06e-06	0.00126	-0.25	-0.2	Type 2 diabetes;	chr15:77511318	chr15:77525540~77534110:+
LUAD	cis	rs2115630	0.936	rs8033459	ENSG00000225151.9	GOLGA2P7	4.58	6.06e-06	0.00126	0.23	0.2	P wave terminal force;	chr15:84710027	chr15:84199311~84230136:-
LUAD	cis	rs748404	0.666	rs34178146	ENSG00000205771.5	CATSPER2P1	-4.58	6.07e-06	0.00126	-0.31	-0.2	Lung cancer;	chr15:43384406	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.626	rs62021176	ENSG00000205771.5	CATSPER2P1	-4.58	6.07e-06	0.00126	-0.31	-0.2	Lung cancer;	chr15:43388014	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.666	rs16957680	ENSG00000205771.5	CATSPER2P1	-4.58	6.07e-06	0.00126	-0.31	-0.2	Lung cancer;	chr15:43396207	chr15:43726918~43747094:-
LUAD	cis	rs6969780	1	rs6969780	ENSG00000233429.8	HOTAIRM1	4.58	6.07e-06	0.00126	0.36	0.2	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27119517	chr7:27095647~27100265:+
LUAD	cis	rs6969780	1	rs1801085	ENSG00000233429.8	HOTAIRM1	4.58	6.07e-06	0.00126	0.36	0.2	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27128971	chr7:27095647~27100265:+
LUAD	cis	rs9425766	0.679	rs6681618	ENSG00000227373.4	RP11-160H22.5	-4.58	6.07e-06	0.00126	-0.25	-0.2	Life satisfaction;	chr1:174201203	chr1:174115300~174160004:-
LUAD	cis	rs643506	0.874	rs614144	ENSG00000230911.1	PPIHP1	-4.57	6.07e-06	0.00126	-0.25	-0.2	Breast cancer;	chr11:111797895	chr11:112029858~112030367:-
LUAD	cis	rs2790457	0.833	rs1265846	ENSG00000254635.4	WAC-AS1	-4.57	6.07e-06	0.00126	-0.22	-0.2	Multiple myeloma;	chr10:28640168	chr10:28522652~28532743:-
LUAD	cis	rs3808502	0.549	rs11991139	ENSG00000255046.1	RP11-297N6.4	4.57	6.07e-06	0.00126	0.25	0.2	Neuroticism;	chr8:11570886	chr8:11797928~11802568:-
LUAD	cis	rs6840360	0.87	rs1372978	ENSG00000270265.1	RP11-731D1.4	-4.57	6.07e-06	0.00126	-0.21	-0.2	Intelligence (multi-trait analysis);	chr4:151535028	chr4:151333775~151353224:-
LUAD	cis	rs9322193	0.923	rs4870529	ENSG00000268592.3	RAET1E-AS1	4.57	6.08e-06	0.00127	0.25	0.2	Lung cancer;	chr6:149716436	chr6:149863494~149919507:+
LUAD	cis	rs13256369	0.774	rs11777719	ENSG00000253893.2	FAM85B	-4.57	6.08e-06	0.00127	-0.28	-0.2	Obesity-related traits;	chr8:8723528	chr8:8167819~8226614:-
LUAD	cis	rs1355223	0.902	rs1901831	ENSG00000271369.1	RP11-350D17.3	-4.57	6.08e-06	0.00127	-0.24	-0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34703628	chr11:34709600~34710161:+
LUAD	cis	rs1355223	0.902	rs34610590	ENSG00000271369.1	RP11-350D17.3	-4.57	6.08e-06	0.00127	-0.24	-0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34703893	chr11:34709600~34710161:+
LUAD	cis	rs1355223	0.902	rs4465347	ENSG00000271369.1	RP11-350D17.3	-4.57	6.08e-06	0.00127	-0.24	-0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34705786	chr11:34709600~34710161:+
LUAD	cis	rs2933343	0.7	rs789233	ENSG00000231305.3	RP11-723O4.2	4.57	6.08e-06	0.00127	0.22	0.2	IgG glycosylation;	chr3:128884307	chr3:128861313~128871540:-
LUAD	cis	rs911555	0.755	rs8014013	ENSG00000244691.1	RPL10AP1	4.57	6.09e-06	0.00127	0.27	0.2	Intelligence (multi-trait analysis);	chr14:103471035	chr14:103412119~103412761:-
LUAD	cis	rs7829975	0.508	rs1594437	ENSG00000253981.4	ALG1L13P	4.57	6.09e-06	0.00127	0.23	0.2	Mood instability;	chr8:8968365	chr8:8236003~8244667:-
LUAD	cis	rs7580658	0.545	rs13006847	ENSG00000236682.1	AC068282.3	4.57	6.09e-06	0.00127	0.25	0.2	Protein C levels;	chr2:127194687	chr2:127389130~127400580:+
LUAD	cis	rs7829975	0.508	rs1594437	ENSG00000233609.3	RP11-62H7.2	4.57	6.09e-06	0.00127	0.16	0.2	Mood instability;	chr8:8968365	chr8:8961200~8979025:+
LUAD	cis	rs9649213	0.574	rs7794187	ENSG00000272950.1	RP11-307C18.1	4.57	6.09e-06	0.00127	0.26	0.2	Prostate cancer (SNP x SNP interaction);	chr7:98260446	chr7:98322853~98323430:+
LUAD	cis	rs4664293	0.669	rs2042778	ENSG00000226266.5	AC009961.3	4.57	6.09e-06	0.00127	0.27	0.2	Monocyte percentage of white cells;	chr2:159672119	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.625	rs62171654	ENSG00000226266.5	AC009961.3	4.57	6.09e-06	0.00127	0.27	0.2	Monocyte percentage of white cells;	chr2:159675107	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.625	rs11903816	ENSG00000226266.5	AC009961.3	4.57	6.09e-06	0.00127	0.27	0.2	Monocyte percentage of white cells;	chr2:159675347	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.625	rs6738523	ENSG00000226266.5	AC009961.3	4.57	6.09e-06	0.00127	0.27	0.2	Monocyte percentage of white cells;	chr2:159681203	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.585	rs11893106	ENSG00000226266.5	AC009961.3	4.57	6.09e-06	0.00127	0.27	0.2	Monocyte percentage of white cells;	chr2:159684294	chr2:159670708~159712435:-
LUAD	cis	rs5758511	0.633	rs5758689	ENSG00000226450.2	CYP2D8P	4.57	6.1e-06	0.00127	0.19	0.2	Birth weight;	chr22:42268966	chr22:42149886~42155001:-
LUAD	cis	rs9438901	0.614	rs2375278	ENSG00000261349.1	RP3-465N24.5	4.57	6.1e-06	0.00127	0.33	0.2	Red cell distribution width;	chr1:25202547	chr1:25266102~25267136:-
LUAD	cis	rs6921919	0.945	rs16901847	ENSG00000216901.1	AL022393.7	4.57	6.1e-06	0.00127	0.28	0.2	Autism spectrum disorder or schizophrenia;	chr6:28408074	chr6:28176188~28176674:+
LUAD	cis	rs11157436	0.874	rs35951144	ENSG00000211813.2	TRAV34	4.57	6.1e-06	0.00127	0.25	0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22149973	chr14:22207522~22208129:+
LUAD	cis	rs227275	0.554	rs223339	ENSG00000251288.2	RP11-10L12.2	-4.57	6.1e-06	0.00127	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102864700	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.554	rs223333	ENSG00000251288.2	RP11-10L12.2	-4.57	6.1e-06	0.00127	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102868653	chr4:102751401~102752641:+
LUAD	cis	rs228614	0.51	rs223328	ENSG00000251288.2	RP11-10L12.2	-4.57	6.1e-06	0.00127	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873379	chr4:102751401~102752641:+
LUAD	cis	rs228614	0.536	rs223325	ENSG00000251288.2	RP11-10L12.2	-4.57	6.1e-06	0.00127	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102875751	chr4:102751401~102752641:+
LUAD	cis	rs9425766	0.679	rs4650945	ENSG00000227373.4	RP11-160H22.5	-4.57	6.1e-06	0.00127	-0.26	-0.2	Life satisfaction;	chr1:174114966	chr1:174115300~174160004:-
LUAD	cis	rs4664293	0.867	rs13022404	ENSG00000226266.5	AC009961.3	-4.57	6.1e-06	0.00127	-0.29	-0.2	Monocyte percentage of white cells;	chr2:159732981	chr2:159670708~159712435:-
LUAD	cis	rs453301	0.686	rs7814328	ENSG00000173295.6	FAM86B3P	-4.57	6.1e-06	0.00127	-0.23	-0.2	Joint mobility (Beighton score);	chr8:9018719	chr8:8228595~8244865:+
LUAD	cis	rs6908034	0.66	rs7750716	ENSG00000228412.5	RP4-625H18.2	4.57	6.11e-06	0.00127	0.36	0.2	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804608	chr6:19802164~19804752:-
LUAD	cis	rs6604026	0.624	rs12731107	ENSG00000223787.2	RP4-593M8.1	4.57	6.11e-06	0.00127	0.28	0.2	Multiple sclerosis;	chr1:92701772	chr1:92580476~92580821:-
LUAD	cis	rs4654783	1	rs4654783	ENSG00000218510.5	LINC00339	4.57	6.11e-06	0.00127	0.25	0.2	Endometriosis;	chr1:22113027	chr1:22025188~22031223:+
LUAD	cis	rs27434	0.66	rs26493	ENSG00000272109.1	CTD-2260A17.3	-4.57	6.11e-06	0.00127	-0.28	-0.2	Ankylosing spondylitis;	chr5:96819615	chr5:96804353~96806105:+
LUAD	cis	rs4835473	0.9	rs13101531	ENSG00000251600.4	RP11-673E1.1	-4.57	6.11e-06	0.00127	-0.25	-0.2	Immature fraction of reticulocytes;	chr4:143982197	chr4:143912331~143982454:+
LUAD	cis	rs6840258	0.689	rs340639	ENSG00000251411.1	RP11-397E7.4	4.57	6.11e-06	0.00127	0.23	0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87003827	chr4:86913266~86914817:-
LUAD	cis	rs2617170	0.922	rs2086098	ENSG00000245648.1	RP11-277P12.20	4.57	6.12e-06	0.00127	0.26	0.2	Behcet's disease;	chr12:10373949	chr12:10363769~10398506:+
LUAD	cis	rs2337406	0.587	rs10139664	ENSG00000223648.3	IGHV3-64	4.57	6.12e-06	0.00127	0.24	0.2	Alzheimer's disease (late onset);	chr14:106647254	chr14:106643132~106658258:-
LUAD	cis	rs7119	0.689	rs11630926	ENSG00000259362.2	RP11-307C19.1	-4.57	6.12e-06	0.00127	-0.26	-0.2	Type 2 diabetes;	chr15:77527240	chr15:77525540~77534110:+
LUAD	cis	rs7119	0.636	rs34020536	ENSG00000259362.2	RP11-307C19.1	-4.57	6.12e-06	0.00127	-0.26	-0.2	Type 2 diabetes;	chr15:77527244	chr15:77525540~77534110:+
LUAD	cis	rs7119	0.636	rs11635606	ENSG00000259362.2	RP11-307C19.1	-4.57	6.12e-06	0.00127	-0.26	-0.2	Type 2 diabetes;	chr15:77527249	chr15:77525540~77534110:+
LUAD	cis	rs7811142	0.72	rs7795656	ENSG00000078319.8	PMS2P1	-4.57	6.12e-06	0.00127	-0.25	-0.2	Platelet count;	chr7:100352674	chr7:100320992~100341908:-
LUAD	cis	rs12554020	0.786	rs60076242	ENSG00000227603.1	RP11-165J3.6	4.57	6.12e-06	0.00127	0.31	0.2	Schizophrenia;	chr9:93571634	chr9:93435332~93437121:-
LUAD	cis	rs12554020	0.786	rs10429558	ENSG00000227603.1	RP11-165J3.6	4.57	6.12e-06	0.00127	0.31	0.2	Schizophrenia;	chr9:93574508	chr9:93435332~93437121:-
LUAD	cis	rs8050896	1	rs77118944	ENSG00000260695.1	RP11-513N24.1	-4.57	6.12e-06	0.00127	-0.37	-0.2	Response to antipsychotic treatment;	chr16:66123369	chr16:65861112~65863784:-
LUAD	cis	rs9992667	0.91	rs4535339	ENSG00000231160.8	KLF3-AS1	4.57	6.12e-06	0.00127	0.26	0.2	Eosinophil percentage of granulocytes;	chr4:38687607	chr4:38612701~38664883:-
LUAD	cis	rs2933343	0.679	rs789221	ENSG00000231305.3	RP11-723O4.2	4.57	6.12e-06	0.00127	0.22	0.2	IgG glycosylation;	chr3:128872782	chr3:128861313~128871540:-
LUAD	cis	rs11157436	0.602	rs928955	ENSG00000211813.2	TRAV34	4.57	6.13e-06	0.00127	0.24	0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166273	chr14:22207522~22208129:+
LUAD	cis	rs11157436	0.602	rs12587826	ENSG00000211813.2	TRAV34	4.57	6.13e-06	0.00127	0.24	0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166305	chr14:22207522~22208129:+
LUAD	cis	rs11673344	0.734	rs1644638	ENSG00000226686.6	LINC01535	4.57	6.13e-06	0.00127	0.26	0.2	Obesity-related traits;	chr19:36970513	chr19:37251912~37265535:+
LUAD	cis	rs11673344	0.764	rs1644643	ENSG00000226686.6	LINC01535	4.57	6.13e-06	0.00127	0.26	0.2	Obesity-related traits;	chr19:36972269	chr19:37251912~37265535:+
LUAD	cis	rs11673344	0.764	rs1644645	ENSG00000226686.6	LINC01535	4.57	6.13e-06	0.00127	0.26	0.2	Obesity-related traits;	chr19:36972528	chr19:37251912~37265535:+
LUAD	cis	rs2742234	1	rs1864399	ENSG00000273008.1	RP11-351D16.3	-4.57	6.13e-06	0.00127	-0.22	-0.2	Hirschsprung disease;	chr10:43115007	chr10:43136824~43138334:-
LUAD	cis	rs6568686	0.627	rs174387	ENSG00000255389.1	C6orf3	4.57	6.13e-06	0.00127	0.26	0.2	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111593820	chr6:111599875~111602295:+
LUAD	cis	rs4819052	0.565	rs35776291	ENSG00000237664.1	LINC00316	-4.57	6.13e-06	0.00127	-0.24	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45286227	chr21:45338590~45341990:-
LUAD	cis	rs10938353	0.638	rs61549581	ENSG00000273369.1	RP11-700J17.1	4.57	6.13e-06	0.00127	0.28	0.2	Body mass index;	chr4:44692702	chr4:44693946~44694386:-
LUAD	cis	rs11168618	0.81	rs11168595	ENSG00000240399.1	RP1-228P16.1	4.57	6.13e-06	0.00128	0.2	0.2	Adiponectin levels;	chr12:48474428	chr12:48054813~48055591:-
LUAD	cis	rs11168618	0.743	rs12815151	ENSG00000240399.1	RP1-228P16.1	4.57	6.13e-06	0.00128	0.2	0.2	Adiponectin levels;	chr12:48481053	chr12:48054813~48055591:-
LUAD	cis	rs11673344	0.864	rs826322	ENSG00000226686.6	LINC01535	4.57	6.14e-06	0.00128	0.26	0.2	Obesity-related traits;	chr19:37013694	chr19:37251912~37265535:+
LUAD	cis	rs13113518	0.812	rs4865001	ENSG00000223305.1	RN7SKP30	4.57	6.14e-06	0.00128	0.24	0.2	Height;	chr4:55490176	chr4:55540502~55540835:-
LUAD	cis	rs2243480	0.764	rs2460423	ENSG00000232559.3	GS1-124K5.12	4.57	6.14e-06	0.00128	0.35	0.2	Diabetic kidney disease;	chr7:66136229	chr7:66554588~66576923:-
LUAD	cis	rs10266483	0.656	rs670966	ENSG00000228653.2	HNRNPCP7	-4.57	6.14e-06	0.00128	-0.25	-0.2	Response to statin therapy;	chr7:64302521	chr7:64500825~64501729:+
LUAD	cis	rs6687758	1	rs6695584	ENSG00000227925.1	RP11-191N8.2	4.57	6.14e-06	0.00128	0.28	0.2	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221988647	chr1:221827666~221840666:-
LUAD	cis	rs2243480	1	rs313832	ENSG00000232559.3	GS1-124K5.12	4.57	6.15e-06	0.00128	0.35	0.2	Diabetic kidney disease;	chr7:66085904	chr7:66554588~66576923:-
LUAD	cis	rs7580658	0.545	rs67996371	ENSG00000236682.1	AC068282.3	-4.57	6.15e-06	0.00128	-0.26	-0.2	Protein C levels;	chr2:127195841	chr2:127389130~127400580:+
LUAD	cis	rs599083	0.59	rs661988	ENSG00000212093.1	AP000807.1	4.57	6.15e-06	0.00128	0.24	0.2	Bone mineral density (spine);	chr11:68421783	chr11:68506083~68506166:-
LUAD	cis	rs2880765	0.743	rs4551990	ENSG00000259416.2	RP11-158M2.5	4.57	6.16e-06	0.00128	0.21	0.2	Coronary artery disease;	chr15:85472056	chr15:85754941~85756237:-
LUAD	cis	rs2153535	0.585	rs6915130	ENSG00000230939.1	RP11-314C16.1	-4.57	6.16e-06	0.00128	-0.23	-0.2	Motion sickness;	chr6:8661262	chr6:8784178~8785445:+
LUAD	cis	rs4789693	0.873	rs8069111	ENSG00000265458.1	RP13-20L14.6	4.57	6.16e-06	0.00128	0.29	0.2	Glucocorticoid-induced osteonecrosis;	chr17:82437581	chr17:82454273~82458521:-
LUAD	cis	rs262150	0.503	rs11769917	ENSG00000231419.5	LINC00689	-4.57	6.16e-06	0.00128	-0.25	-0.2	Facial morphology (factor 20);	chr7:159024807	chr7:159006522~159030195:+
LUAD	cis	rs712039	0.652	rs34711199	ENSG00000276054.1	RP11-378E13.3	4.57	6.16e-06	0.00128	0.3	0.2	Tuberculosis;	chr17:37497933	chr17:37386886~37387926:+
LUAD	cis	rs3177980	0.673	rs6694855	ENSG00000239494.2	RN7SL333P	-4.57	6.17e-06	0.00128	-0.2	-0.2	Amyotrophic lateral sclerosis;	chr1:169883710	chr1:169859756~169860052:+
LUAD	cis	rs1790761	0.607	rs656652	ENSG00000184224.3	C11orf72	4.57	6.17e-06	0.00128	0.23	0.2	Mean corpuscular volume;	chr11:67576486	chr11:67602880~67606706:-
LUAD	cis	rs1790761	0.632	rs625978	ENSG00000184224.3	C11orf72	4.57	6.17e-06	0.00128	0.23	0.2	Mean corpuscular volume;	chr11:67577193	chr11:67602880~67606706:-
LUAD	cis	rs338389	0.933	rs399113	ENSG00000260657.2	RP11-315D16.4	-4.57	6.17e-06	0.00128	-0.23	-0.2	Survival in rectal cancer;	chr15:67974155	chr15:68267792~68277994:-
LUAD	cis	rs9425766	0.64	rs7512930	ENSG00000227373.4	RP11-160H22.5	4.57	6.17e-06	0.00128	0.26	0.2	Life satisfaction;	chr1:174319464	chr1:174115300~174160004:-
LUAD	cis	rs9425766	0.679	rs7523460	ENSG00000227373.4	RP11-160H22.5	4.57	6.17e-06	0.00128	0.26	0.2	Life satisfaction;	chr1:174319664	chr1:174115300~174160004:-
LUAD	cis	rs9425766	0.679	rs7552830	ENSG00000227373.4	RP11-160H22.5	4.57	6.17e-06	0.00128	0.26	0.2	Life satisfaction;	chr1:174321643	chr1:174115300~174160004:-
LUAD	cis	rs867371	0.762	rs12905578	ENSG00000276710.3	CSPG4P8	4.57	6.17e-06	0.00128	0.2	0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82288923	chr15:82459472~82477258:+
LUAD	cis	rs9545047	0.604	rs9318623	ENSG00000227354.5	RBM26-AS1	-4.57	6.17e-06	0.00128	-0.21	-0.2	Schizophrenia;	chr13:79346913	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.564	rs7998837	ENSG00000227354.5	RBM26-AS1	-4.57	6.17e-06	0.00128	-0.21	-0.2	Schizophrenia;	chr13:79349190	chr13:79406309~79424328:+
LUAD	cis	rs944990	0.557	rs4237221	ENSG00000227603.1	RP11-165J3.6	4.57	6.17e-06	0.00128	0.23	0.2	Body mass index;	chr9:93533821	chr9:93435332~93437121:-
LUAD	cis	rs4819052	0.679	rs2838859	ENSG00000223768.1	LINC00205	-4.57	6.18e-06	0.00128	-0.24	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45264602	chr21:45293285~45297354:+
LUAD	cis	rs228614	0.51	rs223447	ENSG00000251288.2	RP11-10L12.2	-4.57	6.18e-06	0.00128	-0.25	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102792202	chr4:102751401~102752641:+
LUAD	cis	rs984222	0.527	rs2645291	ENSG00000231365.4	RP11-418J17.1	-4.57	6.18e-06	0.00128	-0.24	-0.2	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119029918	chr1:119140396~119275973:+
LUAD	cis	rs34779708	0.733	rs12240638	ENSG00000271335.4	RP11-324I22.4	4.57	6.19e-06	0.00128	0.22	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35253682	chr10:35314552~35336401:-
LUAD	cis	rs847577	0.506	rs7808528	ENSG00000272950.1	RP11-307C18.1	4.57	6.19e-06	0.00129	0.25	0.2	Breast cancer;	chr7:98092113	chr7:98322853~98323430:+
LUAD	cis	rs7061710	0.711	rs17623598	ENSG00000271811.1	RP1-79C4.4	-4.57	6.19e-06	0.00129	-0.31	-0.2	Blood metabolite levels;	chr1:171148766	chr1:170667381~170669425:+
LUAD	cis	rs2243480	0.803	rs36004293	ENSG00000226002.1	RP11-460N20.5	-4.57	6.19e-06	0.00129	-0.35	-0.2	Diabetic kidney disease;	chr7:65951525	chr7:65084103~65100232:+
LUAD	cis	rs2243480	0.803	rs35268390	ENSG00000226002.1	RP11-460N20.5	-4.57	6.19e-06	0.00129	-0.35	-0.2	Diabetic kidney disease;	chr7:65951549	chr7:65084103~65100232:+
LUAD	cis	rs2072438	0.505	rs7034074	ENSG00000226752.6	PSMD5-AS1	-4.57	6.19e-06	0.00129	-0.21	-0.2	Rheumatoid arthritis;	chr9:121160751	chr9:120824828~120854385:+
LUAD	cis	rs3096299	0.685	rs2911244	ENSG00000182376.2	RP5-1142A6.8	4.57	6.2e-06	0.00129	0.21	0.2	Multiple myeloma (IgH translocation);	chr16:89455452	chr16:88742767~88745748:+
LUAD	cis	rs7811142	1	rs11763414	ENSG00000078319.8	PMS2P1	-4.57	6.2e-06	0.00129	-0.24	-0.2	Platelet count;	chr7:100419221	chr7:100320992~100341908:-
LUAD	cis	rs6012564	0.806	rs4810903	ENSG00000230758.1	SNAP23P	-4.57	6.2e-06	0.00129	-0.21	-0.2	Anger;	chr20:48982668	chr20:49038357~49038602:-
LUAD	cis	rs4713118	0.588	rs200994	ENSG00000280107.1	AL022393.9	4.57	6.2e-06	0.00129	0.27	0.2	Parkinson's disease;	chr6:27846035	chr6:28170845~28172521:+
LUAD	cis	rs9425766	0.679	rs7523938	ENSG00000227373.4	RP11-160H22.5	4.57	6.2e-06	0.00129	0.26	0.2	Life satisfaction;	chr1:174327373	chr1:174115300~174160004:-
LUAD	cis	rs9425766	0.64	rs6681780	ENSG00000227373.4	RP11-160H22.5	4.57	6.2e-06	0.00129	0.26	0.2	Life satisfaction;	chr1:174328980	chr1:174115300~174160004:-
LUAD	cis	rs9425766	0.55	rs57366619	ENSG00000227373.4	RP11-160H22.5	4.57	6.2e-06	0.00129	0.26	0.2	Life satisfaction;	chr1:174334929	chr1:174115300~174160004:-
LUAD	cis	rs2548724	0.593	rs1597768	ENSG00000250682.4	LINC00491	4.57	6.2e-06	0.00129	0.24	0.2	Type 2 diabetes;	chr5:102321151	chr5:102609156~102671559:-
LUAD	cis	rs9341808	0.754	rs9352808	ENSG00000260645.1	RP11-250B2.5	4.57	6.2e-06	0.00129	0.19	0.2	Sitting height ratio;	chr6:80287625	chr6:80466958~80469080:+
LUAD	cis	rs17345786	0.906	rs59359251	ENSG00000244119.1	PDCL3P4	4.57	6.2e-06	0.00129	0.23	0.2	Colonoscopy-negative controls vs population controls;	chr3:101427518	chr3:101712472~101713191:+
LUAD	cis	rs6142102	0.961	rs2377957	ENSG00000275784.1	RP5-1125A11.6	-4.57	6.2e-06	0.00129	-0.22	-0.2	Skin pigmentation;	chr20:33966667	chr20:33989480~33991818:-
LUAD	cis	rs10266483	0.739	rs2692099	ENSG00000228653.2	HNRNPCP7	-4.57	6.21e-06	0.00129	-0.25	-0.2	Response to statin therapy;	chr7:64307384	chr7:64500825~64501729:+
LUAD	cis	rs7647973	0.58	rs7652746	ENSG00000225399.4	RP11-3B7.1	-4.57	6.21e-06	0.00129	-0.26	-0.2	Menarche (age at onset);	chr3:49224874	chr3:49260085~49261316:+
LUAD	cis	rs4568518	0.616	rs11766489	ENSG00000279048.1	RP11-511H23.2	4.57	6.21e-06	0.00129	0.17	0.2	Measles;	chr7:17964047	chr7:17940503~17942922:+
LUAD	cis	rs4568518	0.616	rs11766586	ENSG00000279048.1	RP11-511H23.2	4.57	6.21e-06	0.00129	0.17	0.2	Measles;	chr7:17964342	chr7:17940503~17942922:+
LUAD	cis	rs2283792	0.764	rs2298432	ENSG00000224086.5	LL22NC03-86G7.1	-4.57	6.21e-06	0.00129	-0.2	-0.2	Multiple sclerosis;	chr22:21768900	chr22:21938293~21977632:+
LUAD	cis	rs338389	0.934	rs440516	ENSG00000260657.2	RP11-315D16.4	-4.57	6.21e-06	0.00129	-0.23	-0.2	Survival in rectal cancer;	chr15:67973743	chr15:68267792~68277994:-
LUAD	cis	rs4713118	0.614	rs9468209	ENSG00000219392.1	RP1-265C24.5	-4.57	6.21e-06	0.00129	-0.25	-0.2	Parkinson's disease;	chr6:27726642	chr6:28115628~28116551:+
LUAD	cis	rs2243480	1	rs1638734	ENSG00000232559.3	GS1-124K5.12	4.57	6.21e-06	0.00129	0.36	0.2	Diabetic kidney disease;	chr7:66632552	chr7:66554588~66576923:-
LUAD	cis	rs801193	0.935	rs2659916	ENSG00000224316.1	RP11-479O9.2	4.57	6.21e-06	0.00129	0.21	0.2	Aortic root size;	chr7:66686365	chr7:65773620~65802067:+
LUAD	cis	rs801193	1	rs6958520	ENSG00000224316.1	RP11-479O9.2	4.57	6.21e-06	0.00129	0.21	0.2	Aortic root size;	chr7:66686466	chr7:65773620~65802067:+
LUAD	cis	rs801193	0.967	rs2707849	ENSG00000224316.1	RP11-479O9.2	4.57	6.21e-06	0.00129	0.21	0.2	Aortic root size;	chr7:66687725	chr7:65773620~65802067:+
LUAD	cis	rs801193	1	rs7788576	ENSG00000224316.1	RP11-479O9.2	-4.57	6.21e-06	0.00129	-0.21	-0.2	Aortic root size;	chr7:66683315	chr7:65773620~65802067:+
LUAD	cis	rs9341808	0.754	rs9352808	ENSG00000233967.5	RP11-250B2.3	4.57	6.21e-06	0.00129	0.2	0.2	Sitting height ratio;	chr6:80287625	chr6:80443344~80465927:+
LUAD	cis	rs477895	0.713	rs12787852	ENSG00000236935.1	AP003774.1	-4.57	6.22e-06	0.00129	-0.25	-0.2	Mean platelet volume;	chr11:64187176	chr11:64325050~64329504:-
LUAD	cis	rs61542988	0.57	rs10950919	ENSG00000228649.7	AC005682.5	4.57	6.22e-06	0.00129	0.3	0.2	Fibrinogen levels;	chr7:22794202	chr7:22854178~22861579:+
LUAD	cis	rs748404	0.697	rs564946	ENSG00000249839.1	AC011330.5	-4.57	6.22e-06	0.00129	-0.26	-0.2	Lung cancer;	chr15:43264074	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.723	rs565658	ENSG00000249839.1	AC011330.5	-4.57	6.22e-06	0.00129	-0.26	-0.2	Lung cancer;	chr15:43264109	chr15:43663654~43684339:-
LUAD	cis	rs7727544	0.594	rs10479000	ENSG00000233006.5	AC034220.3	4.57	6.22e-06	0.00129	0.18	0.2	Blood metabolite levels;	chr5:132271709	chr5:132311285~132369916:-
LUAD	cis	rs11673344	0.73	rs826314	ENSG00000226686.6	LINC01535	4.57	6.22e-06	0.00129	0.26	0.2	Obesity-related traits;	chr19:36959533	chr19:37251912~37265535:+
LUAD	cis	rs9322193	0.923	rs10782318	ENSG00000268592.3	RAET1E-AS1	4.57	6.22e-06	0.00129	0.26	0.2	Lung cancer;	chr6:149754137	chr6:149863494~149919507:+
LUAD	cis	rs4664293	0.647	rs357022	ENSG00000226266.5	AC009961.3	-4.57	6.23e-06	0.00129	-0.27	-0.2	Monocyte percentage of white cells;	chr2:159632933	chr2:159670708~159712435:-
LUAD	cis	rs7189233	0.55	rs1861350	ENSG00000279344.1	RP11-44F14.7	4.57	6.23e-06	0.00129	0.17	0.2	Intelligence (multi-trait analysis);	chr16:53499430	chr16:53478957~53481550:-
LUAD	cis	rs7772486	0.754	rs9399567	ENSG00000235652.6	RP11-545I5.3	4.57	6.23e-06	0.00129	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145826159	chr6:145799409~145886585:+
LUAD	cis	rs2115630	1	rs2115630	ENSG00000225151.9	GOLGA2P7	4.57	6.24e-06	0.00129	0.23	0.2	P wave terminal force;	chr15:84821285	chr15:84199311~84230136:-
LUAD	cis	rs1355223	0.902	rs1453380	ENSG00000271369.1	RP11-350D17.3	-4.57	6.24e-06	0.00129	-0.24	-0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34682135	chr11:34709600~34710161:+
LUAD	cis	rs524281	0.731	rs78578425	ENSG00000255320.1	RP11-755F10.1	4.57	6.24e-06	0.00129	0.35	0.2	Electroencephalogram traits;	chr11:66042768	chr11:66244840~66246239:-
LUAD	cis	rs1355223	0.902	rs1258464	ENSG00000271369.1	RP11-350D17.3	-4.57	6.25e-06	0.0013	-0.24	-0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34709949	chr11:34709600~34710161:+
LUAD	cis	rs1167827	0.71	rs1167836	ENSG00000205583.12	STAG3L1	4.57	6.25e-06	0.0013	0.24	0.2	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75539580	chr7:75359194~75395383:+
LUAD	cis	rs7182621	0.846	rs12915935	ENSG00000259363.4	CTD-2054N24.2	-4.57	6.25e-06	0.0013	-0.24	-0.2	Colonoscopy-negative controls vs population controls;	chr15:99871875	chr15:99807023~99877148:+
LUAD	cis	rs8180040	0.726	rs7628747	ENSG00000271161.1	BOLA2P2	4.57	6.25e-06	0.0013	0.19	0.2	Colorectal cancer;	chr3:46960500	chr3:47499841~47500407:+
LUAD	cis	rs7819412	0.875	rs6981523	ENSG00000255046.1	RP11-297N6.4	4.57	6.26e-06	0.0013	0.25	0.2	Triglycerides;	chr8:11204283	chr8:11797928~11802568:-
LUAD	cis	rs1062177	1	rs17804178	ENSG00000253921.1	CTB-113P19.3	-4.57	6.26e-06	0.0013	-0.31	-0.2	Preschool internalizing problems;	chr5:151818168	chr5:151753992~151767247:+
LUAD	cis	rs7811142	1	rs60257855	ENSG00000078319.8	PMS2P1	-4.57	6.27e-06	0.0013	-0.24	-0.2	Platelet count;	chr7:100429157	chr7:100320992~100341908:-
LUAD	cis	rs3096299	0.692	rs4785565	ENSG00000182376.2	RP5-1142A6.8	4.57	6.27e-06	0.0013	0.21	0.2	Multiple myeloma (IgH translocation);	chr16:89449351	chr16:88742767~88745748:+
LUAD	cis	rs9649213	0.555	rs6955259	ENSG00000272950.1	RP11-307C18.1	4.57	6.27e-06	0.0013	0.26	0.2	Prostate cancer (SNP x SNP interaction);	chr7:98263044	chr7:98322853~98323430:+
LUAD	cis	rs7302981	0.741	rs8181679	ENSG00000200428.1	Y_RNA	4.57	6.27e-06	0.0013	0.25	0.2	Systolic blood pressure;	chr12:50217237	chr12:50743568~50743684:+
LUAD	cis	rs9400467	0.528	rs10872067	ENSG00000271789.1	RP5-1112D6.7	-4.57	6.27e-06	0.0013	-0.22	-0.2	Amino acid levels;Blood metabolite levels;	chr6:111467188	chr6:111297126~111298510:+
LUAD	cis	rs704795	0.867	rs7566052	ENSG00000234072.1	AC074117.10	-4.57	6.27e-06	0.0013	-0.16	-0.2	Menopause (age at onset);	chr2:27405768	chr2:27356246~27367622:+
LUAD	cis	rs9545047	0.604	rs9565497	ENSG00000227354.5	RBM26-AS1	-4.57	6.27e-06	0.0013	-0.22	-0.2	Schizophrenia;	chr13:79406330	chr13:79406309~79424328:+
LUAD	cis	rs375066	0.935	rs10414702	ENSG00000267058.1	RP11-15A1.3	-4.57	6.27e-06	0.0013	-0.23	-0.2	Breast cancer;	chr19:43876384	chr19:43891804~43901805:-
LUAD	cis	rs375066	0.935	rs10421518	ENSG00000267058.1	RP11-15A1.3	-4.57	6.27e-06	0.0013	-0.23	-0.2	Breast cancer;	chr19:43877134	chr19:43891804~43901805:-
LUAD	cis	rs494562	0.892	rs632163	ENSG00000234155.1	RP11-30P6.6	-4.57	6.28e-06	0.0013	-0.38	-0.2	Metabolic traits;Blood metabolite levels;	chr6:85412344	chr6:85387219~85390186:-
LUAD	cis	rs8031584	0.723	rs11632229	ENSG00000259845.1	HERC2P10	-4.57	6.28e-06	0.0013	-0.23	-0.2	Huntington's disease progression;	chr15:30887331	chr15:30815271~30844153:+
LUAD	cis	rs11089937	0.667	rs10483108	ENSG00000211638.2	IGLV8-61	-4.57	6.29e-06	0.0013	-0.25	-0.2	Periodontitis (PAL4Q3);	chr22:22152664	chr22:22098700~22099212:+
LUAD	cis	rs875971	1	rs2420820	ENSG00000232559.3	GS1-124K5.12	-4.57	6.29e-06	0.0013	-0.24	-0.2	Aortic root size;	chr7:66626920	chr7:66554588~66576923:-
LUAD	cis	rs62025270	0.688	rs10163064	ENSG00000202081.1	RNU6-1280P	-4.57	6.29e-06	0.0013	-0.29	-0.2	Idiopathic pulmonary fibrosis;	chr15:85734289	chr15:85651522~85651628:-
LUAD	cis	rs4865762	0.617	rs251517	ENSG00000247796.2	CTD-2366F13.1	4.57	6.29e-06	0.0013	0.21	0.2	Intraocular pressure;	chr5:53213121	chr5:53109842~53115126:+
LUAD	cis	rs3808502	0.549	rs1382563	ENSG00000255046.1	RP11-297N6.4	-4.57	6.3e-06	0.00131	-0.24	-0.2	Neuroticism;	chr8:11569281	chr8:11797928~11802568:-
LUAD	cis	rs1075232	1	rs72722829	ENSG00000215302.7	CTD-3092A11.1	-4.57	6.3e-06	0.00131	-0.45	-0.2	Survival in colorectal cancer (non-distant metastatic);	chr15:31346911	chr15:30470779~30507623:+
LUAD	cis	rs1075232	1	rs16956707	ENSG00000215302.7	CTD-3092A11.1	-4.57	6.3e-06	0.00131	-0.45	-0.2	Survival in colorectal cancer (non-distant metastatic);	chr15:31349430	chr15:30470779~30507623:+
LUAD	cis	rs338389	0.967	rs338345	ENSG00000260657.2	RP11-315D16.4	-4.57	6.3e-06	0.00131	-0.23	-0.2	Survival in rectal cancer;	chr15:67977758	chr15:68267792~68277994:-
LUAD	cis	rs11157436	0.602	rs11157438	ENSG00000211813.2	TRAV34	4.57	6.3e-06	0.00131	0.23	0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22169147	chr14:22207522~22208129:+
LUAD	cis	rs11168618	0.875	rs11458	ENSG00000240399.1	RP1-228P16.1	4.57	6.3e-06	0.00131	0.2	0.2	Adiponectin levels;	chr12:48494811	chr12:48054813~48055591:-
LUAD	cis	rs6714710	0.603	rs34149969	ENSG00000230606.9	AC159540.1	-4.57	6.3e-06	0.00131	-0.22	-0.2	Posterior cortical atrophy and Alzheimer's disease;	chr2:97725860	chr2:97416165~97433527:-
LUAD	cis	rs867371	0.502	rs2047679	ENSG00000276710.3	CSPG4P8	-4.57	6.31e-06	0.00131	-0.19	-0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82239540	chr15:82459472~82477258:+
LUAD	cis	rs4664293	0.625	rs6722715	ENSG00000226266.5	AC009961.3	4.57	6.31e-06	0.00131	0.27	0.2	Monocyte percentage of white cells;	chr2:159668515	chr2:159670708~159712435:-
LUAD	cis	rs750134	1	rs75258935	ENSG00000257221.1	RP11-689B22.2	-4.57	6.31e-06	0.00131	-0.32	-0.2	Low high density lipoprotein cholesterol levels;	chr12:108659436	chr12:108628687~108641318:+
LUAD	cis	rs750134	1	rs78091339	ENSG00000257221.1	RP11-689B22.2	-4.57	6.31e-06	0.00131	-0.32	-0.2	Low high density lipoprotein cholesterol levels;	chr12:108662916	chr12:108628687~108641318:+
LUAD	cis	rs750134	1	rs78894088	ENSG00000257221.1	RP11-689B22.2	-4.57	6.31e-06	0.00131	-0.32	-0.2	Low high density lipoprotein cholesterol levels;	chr12:108663673	chr12:108628687~108641318:+
LUAD	cis	rs750134	1	rs750133	ENSG00000257221.1	RP11-689B22.2	-4.57	6.31e-06	0.00131	-0.32	-0.2	Low high density lipoprotein cholesterol levels;	chr12:108667009	chr12:108628687~108641318:+
LUAD	cis	rs2439831	0.618	rs8023508	ENSG00000249839.1	AC011330.5	4.57	6.31e-06	0.00131	0.36	0.2	Lung cancer in ever smokers;	chr15:43883905	chr15:43663654~43684339:-
LUAD	cis	rs7829975	1	rs7829975	ENSG00000253981.4	ALG1L13P	-4.57	6.31e-06	0.00131	-0.23	-0.2	Mood instability;	chr8:8690607	chr8:8236003~8244667:-
LUAD	cis	rs6496932	0.503	rs4564526	ENSG00000202081.1	RNU6-1280P	-4.57	6.31e-06	0.00131	-0.27	-0.2	Central corneal thickness;Corneal structure;	chr15:85455914	chr15:85651522~85651628:-
LUAD	cis	rs6001482	0.964	rs5750797	ENSG00000223350.2	IGLV9-49	-4.57	6.31e-06	0.00131	-0.2	-0.2	Diastolic blood pressure;	chr22:22242651	chr22:22343187~22343732:+
LUAD	cis	rs4591358	0.608	rs12693770	ENSG00000223466.1	AC064834.2	4.57	6.32e-06	0.00131	0.29	0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195461422	chr2:195533035~195538681:+
LUAD	cis	rs2115630	0.967	rs11073702	ENSG00000229212.6	RP11-561C5.4	4.57	6.32e-06	0.00131	0.24	0.2	P wave terminal force;	chr15:84766840	chr15:85205440~85234795:-
LUAD	cis	rs7178375	1	rs1474381	ENSG00000270015.1	RP11-540B6.6	4.57	6.32e-06	0.00131	0.18	0.2	Hypertriglyceridemia;	chr15:30922788	chr15:30926514~30928407:+
LUAD	cis	rs17772222	0.682	rs1152377	ENSG00000258789.1	RP11-507K2.3	4.57	6.32e-06	0.00131	0.25	0.2	Coronary artery calcification;	chr14:88496243	chr14:88551597~88552493:+
LUAD	cis	rs2243480	1	rs160633	ENSG00000164669.11	INTS4P1	4.57	6.32e-06	0.00131	0.36	0.2	Diabetic kidney disease;	chr7:66063241	chr7:65141225~65234216:+
LUAD	cis	rs7309	0.935	rs10930013	ENSG00000227403.1	AC009299.3	-4.57	6.32e-06	0.00131	-0.25	-0.2	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161213814	chr2:161244739~161249050:+
LUAD	cis	rs262150	0.501	rs1017034	ENSG00000231419.5	LINC00689	-4.57	6.32e-06	0.00131	-0.25	-0.2	Facial morphology (factor 20);	chr7:159027769	chr7:159006522~159030195:+
LUAD	cis	rs4699052	0.963	rs4699057	ENSG00000246560.2	RP11-10L12.4	-4.57	6.33e-06	0.00131	-0.26	-0.2	Testicular germ cell tumor;	chr4:103249966	chr4:102828055~102844075:+
LUAD	cis	rs17666538	0.71	rs12716640	ENSG00000254207.1	RP11-43A14.1	4.57	6.33e-06	0.00131	0.42	0.2	IgG glycosylation;	chr8:695376	chr8:725188~725877:-
LUAD	cis	rs1005277	0.579	rs2472173	ENSG00000263064.2	RP11-291L22.7	4.57	6.33e-06	0.00131	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38085710	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.579	rs2472174	ENSG00000263064.2	RP11-291L22.7	4.57	6.33e-06	0.00131	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38086454	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.579	rs2474563	ENSG00000263064.2	RP11-291L22.7	4.57	6.33e-06	0.00131	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38087010	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.579	rs9418322	ENSG00000263064.2	RP11-291L22.7	4.57	6.33e-06	0.00131	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38088368	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.579	rs9299760	ENSG00000263064.2	RP11-291L22.7	4.57	6.33e-06	0.00131	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38088992	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.579	rs2023351	ENSG00000263064.2	RP11-291L22.7	4.57	6.33e-06	0.00131	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38089886	chr10:38448689~38448949:+
LUAD	cis	rs5758659	0.652	rs133340	ENSG00000182057.4	OGFRP1	-4.57	6.33e-06	0.00131	-0.24	-0.2	Cognitive function;	chr22:42021683	chr22:42269753~42275196:+
LUAD	cis	rs2115630	1	rs58581703	ENSG00000229212.6	RP11-561C5.4	4.57	6.33e-06	0.00131	0.24	0.2	P wave terminal force;	chr15:84733704	chr15:85205440~85234795:-
LUAD	cis	rs6751744	0.855	rs6432534	ENSG00000226266.5	AC009961.3	-4.57	6.33e-06	0.00131	-0.3	-0.2	Dysphagia;	chr2:159521561	chr2:159670708~159712435:-
LUAD	cis	rs10129255	0.957	rs10150241	ENSG00000211967.3	IGHV3-53	4.57	6.33e-06	0.00131	0.15	0.2	Kawasaki disease;	chr14:106775945	chr14:106592676~106593347:-
LUAD	cis	rs910316	0.934	rs4903278	ENSG00000279594.1	RP11-950C14.10	4.57	6.34e-06	0.00131	0.23	0.2	Height;	chr14:75068316	chr14:75011269~75012851:-
LUAD	cis	rs4604234	0.573	rs11961361	ENSG00000272129.1	RP11-250B2.6	-4.57	6.34e-06	0.00131	-0.46	-0.2	Cancer;	chr6:80294840	chr6:80355424~80356859:+
LUAD	cis	rs4604234	0.541	rs11963917	ENSG00000272129.1	RP11-250B2.6	-4.57	6.34e-06	0.00131	-0.46	-0.2	Cancer;	chr6:80294843	chr6:80355424~80356859:+
LUAD	cis	rs1555322	0.53	rs2425053	ENSG00000126005.14	MMP24-AS1	-4.57	6.35e-06	0.00131	-0.28	-0.2	Attention deficit hyperactivity disorder;	chr20:35294017	chr20:35216462~35278131:-
LUAD	cis	rs6687758	1	rs12121134	ENSG00000227925.1	RP11-191N8.2	4.56	6.35e-06	0.00132	0.29	0.2	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222021538	chr1:221827666~221840666:-
LUAD	cis	rs6687758	1	rs56170536	ENSG00000227925.1	RP11-191N8.2	4.56	6.35e-06	0.00132	0.29	0.2	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222024527	chr1:221827666~221840666:-
LUAD	cis	rs6687758	1	rs66732677	ENSG00000227925.1	RP11-191N8.2	4.56	6.35e-06	0.00132	0.29	0.2	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222026325	chr1:221827666~221840666:-
LUAD	cis	rs867371	0.502	rs3759800	ENSG00000276710.3	CSPG4P8	4.56	6.35e-06	0.00132	0.18	0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82240622	chr15:82459472~82477258:+
LUAD	cis	rs4664293	0.802	rs7563417	ENSG00000226266.5	AC009961.3	-4.56	6.35e-06	0.00132	-0.29	-0.2	Monocyte percentage of white cells;	chr2:159727762	chr2:159670708~159712435:-
LUAD	cis	rs9840812	0.645	rs13068119	ENSG00000239213.4	NCK1-AS1	-4.56	6.35e-06	0.00132	-0.27	-0.2	Fibrinogen levels;	chr3:136487527	chr3:136841726~136862054:-
LUAD	cis	rs6723226	0.65	rs6729952	ENSG00000276334.1	AL133243.1	4.56	6.35e-06	0.00132	0.23	0.2	Intelligence (multi-trait analysis);	chr2:32539855	chr2:32521927~32523547:+
LUAD	cis	rs62355901	0.545	rs58774999	ENSG00000271828.1	CTD-2310F14.1	4.56	6.36e-06	0.00132	0.39	0.2	Breast cancer;	chr5:56798018	chr5:56927874~56929573:+
LUAD	cis	rs62355901	0.545	rs62355938	ENSG00000271828.1	CTD-2310F14.1	4.56	6.36e-06	0.00132	0.39	0.2	Breast cancer;	chr5:56798887	chr5:56927874~56929573:+
LUAD	cis	rs559928	1	rs72924202	ENSG00000236935.1	AP003774.1	4.56	6.36e-06	0.00132	0.29	0.2	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64365756	chr11:64325050~64329504:-
LUAD	cis	rs2354432	0.607	rs55918563	ENSG00000226015.2	CCT8P1	4.56	6.36e-06	0.00132	0.38	0.2	Mitochondrial DNA levels;	chr1:147247319	chr1:147203276~147204932:-
LUAD	cis	rs2354432	0.607	rs7511989	ENSG00000226015.2	CCT8P1	4.56	6.36e-06	0.00132	0.38	0.2	Mitochondrial DNA levels;	chr1:147248504	chr1:147203276~147204932:-
LUAD	cis	rs1790761	0.667	rs4147581	ENSG00000184224.3	C11orf72	4.56	6.36e-06	0.00132	0.23	0.2	Mean corpuscular volume;	chr11:67584114	chr11:67602880~67606706:-
LUAD	cis	rs75920871	0.609	rs1473177	ENSG00000254851.1	RP11-109L13.1	-4.56	6.36e-06	0.00132	-0.44	-0.2	Subjective well-being;	chr11:116888616	chr11:117135528~117138582:+
LUAD	cis	rs17747401	0.778	rs1538311	ENSG00000213731.2	RAB5CP1	4.56	6.36e-06	0.00132	0.22	0.2	Hypospadias;	chr10:74655751	chr10:74423435~74424014:-
LUAD	cis	rs34779708	0.733	rs7083266	ENSG00000271335.4	RP11-324I22.4	4.56	6.36e-06	0.00132	0.22	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35252704	chr10:35314552~35336401:-
LUAD	cis	rs4879677	1	rs10125353	ENSG00000215441.3	CTAGE12P	4.56	6.36e-06	0.00132	0.24	0.2	Gut microbiome composition (summer and winter);	chr9:27677546	chr9:27608382~27610745:-
LUAD	cis	rs12439619	0.81	rs28876157	ENSG00000276710.3	CSPG4P8	-4.56	6.36e-06	0.00132	-0.23	-0.2	Intelligence (multi-trait analysis);	chr15:82216708	chr15:82459472~82477258:+
LUAD	cis	rs1499614	1	rs2659913	ENSG00000232559.3	GS1-124K5.12	4.56	6.36e-06	0.00132	0.36	0.2	Gout;	chr7:66692349	chr7:66554588~66576923:-
LUAD	cis	rs1499614	1	rs2659911	ENSG00000232559.3	GS1-124K5.12	4.56	6.36e-06	0.00132	0.36	0.2	Gout;	chr7:66693433	chr7:66554588~66576923:-
LUAD	cis	rs1499614	1	rs2707838	ENSG00000232559.3	GS1-124K5.12	4.56	6.36e-06	0.00132	0.36	0.2	Gout;	chr7:66694214	chr7:66554588~66576923:-
LUAD	cis	rs1499614	1	rs60326618	ENSG00000232559.3	GS1-124K5.12	4.56	6.36e-06	0.00132	0.36	0.2	Gout;	chr7:66701371	chr7:66554588~66576923:-
LUAD	cis	rs1499614	1	rs2707830	ENSG00000232559.3	GS1-124K5.12	4.56	6.36e-06	0.00132	0.36	0.2	Gout;	chr7:66702658	chr7:66554588~66576923:-
LUAD	cis	rs1499614	1	rs2707828	ENSG00000232559.3	GS1-124K5.12	4.56	6.36e-06	0.00132	0.36	0.2	Gout;	chr7:66706390	chr7:66554588~66576923:-
LUAD	cis	rs1499614	0.803	rs1922723	ENSG00000232559.3	GS1-124K5.12	4.56	6.36e-06	0.00132	0.36	0.2	Gout;	chr7:66710076	chr7:66554588~66576923:-
LUAD	cis	rs1499614	1	rs2659903	ENSG00000232559.3	GS1-124K5.12	4.56	6.36e-06	0.00132	0.36	0.2	Gout;	chr7:66715944	chr7:66554588~66576923:-
LUAD	cis	rs1499614	1	rs2141924	ENSG00000232559.3	GS1-124K5.12	4.56	6.36e-06	0.00132	0.36	0.2	Gout;	chr7:66721259	chr7:66554588~66576923:-
LUAD	cis	rs9425766	0.679	rs7537517	ENSG00000227373.4	RP11-160H22.5	4.56	6.37e-06	0.00132	0.26	0.2	Life satisfaction;	chr1:174207225	chr1:174115300~174160004:-
LUAD	cis	rs867371	0.502	rs28610286	ENSG00000276710.3	CSPG4P8	-4.56	6.37e-06	0.00132	-0.19	-0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82233314	chr15:82459472~82477258:+
LUAD	cis	rs11722779	0.933	rs7695096	ENSG00000251288.2	RP11-10L12.2	-4.56	6.37e-06	0.00132	-0.25	-0.2	Schizophrenia;	chr4:103011399	chr4:102751401~102752641:+
LUAD	cis	rs524281	0.731	rs3829937	ENSG00000255320.1	RP11-755F10.1	4.56	6.37e-06	0.00132	0.34	0.2	Electroencephalogram traits;	chr11:66020195	chr11:66244840~66246239:-
LUAD	cis	rs8077577	0.747	rs35738574	ENSG00000273018.4	CTD-2303H24.2	-4.56	6.37e-06	0.00132	-0.29	-0.2	Obesity-related traits;	chr17:18248110	chr17:18511221~18551705:-
LUAD	cis	rs1005277	0.522	rs1208767	ENSG00000263064.2	RP11-291L22.7	4.56	6.37e-06	0.00132	0.21	0.2	Extrinsic epigenetic age acceleration;	chr10:37753367	chr10:38448689~38448949:+
LUAD	cis	rs1008375	1	rs10939740	ENSG00000249502.1	AC006160.5	-4.56	6.37e-06	0.00132	-0.19	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17615867	chr4:17587467~17614571:-
LUAD	cis	rs11673344	0.832	rs56210764	ENSG00000226686.6	LINC01535	4.56	6.37e-06	0.00132	0.28	0.2	Obesity-related traits;	chr19:37125970	chr19:37251912~37265535:+
LUAD	cis	rs7189233	0.55	rs9927982	ENSG00000279344.1	RP11-44F14.7	4.56	6.38e-06	0.00132	0.17	0.2	Intelligence (multi-trait analysis);	chr16:53440196	chr16:53478957~53481550:-
LUAD	cis	rs2243480	1	rs7804223	ENSG00000232559.3	GS1-124K5.12	-4.56	6.38e-06	0.00132	-0.35	-0.2	Diabetic kidney disease;	chr7:66199572	chr7:66554588~66576923:-
LUAD	cis	rs7189233	0.531	rs17800577	ENSG00000279344.1	RP11-44F14.7	4.56	6.38e-06	0.00132	0.17	0.2	Intelligence (multi-trait analysis);	chr16:53442892	chr16:53478957~53481550:-
LUAD	cis	rs17685	0.753	rs7804598	ENSG00000280388.1	RP11-229D13.3	-4.56	6.38e-06	0.00132	-0.19	-0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76073260	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.712	rs59659102	ENSG00000280388.1	RP11-229D13.3	-4.56	6.38e-06	0.00132	-0.19	-0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76080796	chr7:76043977~76045963:-
LUAD	cis	rs9322193	0.886	rs4870055	ENSG00000268592.3	RAET1E-AS1	4.56	6.38e-06	0.00132	0.25	0.2	Lung cancer;	chr6:149848433	chr6:149863494~149919507:+
LUAD	cis	rs2243480	0.803	rs36127118	ENSG00000232559.3	GS1-124K5.12	4.56	6.39e-06	0.00132	0.35	0.2	Diabetic kidney disease;	chr7:66100518	chr7:66554588~66576923:-
LUAD	cis	rs780096	0.526	rs2010087	ENSG00000234072.1	AC074117.10	-4.56	6.39e-06	0.00132	-0.15	-0.2	Total body bone mineral density;	chr2:27414368	chr2:27356246~27367622:+
LUAD	cis	rs11051970	0.545	rs2728681	ENSG00000274964.1	RP11-817I4.1	-4.56	6.4e-06	0.00132	-0.21	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr12:32430043	chr12:32339368~32340724:+
LUAD	cis	rs6604026	0.624	rs72724587	ENSG00000223787.2	RP4-593M8.1	4.56	6.4e-06	0.00132	0.28	0.2	Multiple sclerosis;	chr1:92707653	chr1:92580476~92580821:-
LUAD	cis	rs2976388	0.632	rs2585139	ENSG00000253741.1	CTD-2292P10.4	-4.56	6.4e-06	0.00132	-0.24	-0.2	Urinary tract infection frequency;	chr8:142726757	chr8:142702252~142726973:-
LUAD	cis	rs2562152	0.744	rs216597	ENSG00000226942.2	IL9RP3	-4.56	6.41e-06	0.00133	-0.29	-0.2	Glioblastoma;	chr16:56777	chr16:29336~38321:-
LUAD	cis	rs2153535	0.585	rs6932720	ENSG00000230939.1	RP11-314C16.1	-4.56	6.41e-06	0.00133	-0.23	-0.2	Motion sickness;	chr6:8644999	chr6:8784178~8785445:+
LUAD	cis	rs1790761	0.658	rs684928	ENSG00000184224.3	C11orf72	4.56	6.41e-06	0.00133	0.23	0.2	Mean corpuscular volume;	chr11:67562271	chr11:67602880~67606706:-
LUAD	cis	rs9341808	0.718	rs9448908	ENSG00000260645.1	RP11-250B2.5	4.56	6.41e-06	0.00133	0.19	0.2	Sitting height ratio;	chr6:80188352	chr6:80466958~80469080:+
LUAD	cis	rs38055	0.881	rs37809	ENSG00000247796.2	CTD-2366F13.1	4.56	6.41e-06	0.00133	0.22	0.2	Acne (severe);	chr5:53277462	chr5:53109842~53115126:+
LUAD	cis	rs36423	0.702	rs36373	ENSG00000266869.1	RP6-114E22.1	-4.56	6.41e-06	0.00133	-0.3	-0.2	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71907901	chr14:71848606~71908430:+
LUAD	cis	rs228614	0.51	rs223446	ENSG00000251288.2	RP11-10L12.2	-4.56	6.42e-06	0.00133	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793025	chr4:102751401~102752641:+
LUAD	cis	rs858239	0.614	rs10229956	ENSG00000226816.2	AC005082.12	-4.56	6.42e-06	0.00133	-0.25	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23363317	chr7:23206013~23208045:+
LUAD	cis	rs2732480	0.5	rs11168464	ENSG00000240399.1	RP1-228P16.1	4.56	6.42e-06	0.00133	0.2	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48208332	chr12:48054813~48055591:-
LUAD	cis	rs2243480	0.901	rs2456483	ENSG00000229886.1	RP5-1132H15.3	4.56	6.43e-06	0.00133	0.35	0.2	Diabetic kidney disease;	chr7:65996588	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs1701750	ENSG00000229886.1	RP5-1132H15.3	4.56	6.43e-06	0.00133	0.35	0.2	Diabetic kidney disease;	chr7:66002158	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs1701758	ENSG00000229886.1	RP5-1132H15.3	4.56	6.43e-06	0.00133	0.35	0.2	Diabetic kidney disease;	chr7:66005214	chr7:66025126~66031544:-
LUAD	cis	rs2243480	0.901	rs1701759	ENSG00000229886.1	RP5-1132H15.3	4.56	6.43e-06	0.00133	0.35	0.2	Diabetic kidney disease;	chr7:66005945	chr7:66025126~66031544:-
LUAD	cis	rs712039	0.652	rs1616371	ENSG00000276054.1	RP11-378E13.3	4.56	6.43e-06	0.00133	0.3	0.2	Tuberculosis;	chr17:37413714	chr17:37386886~37387926:+
LUAD	cis	rs875971	1	rs7801282	ENSG00000232559.3	GS1-124K5.12	-4.56	6.43e-06	0.00133	-0.24	-0.2	Aortic root size;	chr7:66148700	chr7:66554588~66576923:-
LUAD	cis	rs11976180	1	rs2961134	ENSG00000204959.4	ARHGEF34P	4.56	6.43e-06	0.00133	0.25	0.2	Obesity-related traits;	chr7:144073969	chr7:144272445~144286966:-
LUAD	cis	rs561341	0.941	rs8066156	ENSG00000265798.5	RP11-271K11.5	4.56	6.43e-06	0.00133	0.3	0.2	Hip circumference adjusted for BMI;	chr17:32034610	chr17:31038575~31059121:-
LUAD	cis	rs7580658	0.545	rs59318157	ENSG00000236682.1	AC068282.3	-4.56	6.43e-06	0.00133	-0.26	-0.2	Protein C levels;	chr2:127192498	chr2:127389130~127400580:+
LUAD	cis	rs4865762	0.617	rs152977	ENSG00000247796.2	CTD-2366F13.1	4.56	6.43e-06	0.00133	0.21	0.2	Intraocular pressure;	chr5:53209780	chr5:53109842~53115126:+
LUAD	cis	rs73198271	0.813	rs56007835	ENSG00000253893.2	FAM85B	4.56	6.43e-06	0.00133	0.27	0.2	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8752516	chr8:8167819~8226614:-
LUAD	cis	rs2834288	0.5	rs2051189	ENSG00000237945.6	LINC00649	4.56	6.43e-06	0.00133	0.25	0.2	Gut microbiota (bacterial taxa);	chr21:33949712	chr21:33915534~33977691:+
LUAD	cis	rs5758511	0.514	rs2899354	ENSG00000226450.2	CYP2D8P	4.56	6.43e-06	0.00133	0.2	0.2	Birth weight;	chr22:42158403	chr22:42149886~42155001:-
LUAD	cis	rs7172677	1	rs8032261	ENSG00000260269.4	CTD-2323K18.1	-4.56	6.43e-06	0.00133	-0.27	-0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75131671	chr15:75527150~75601205:-
LUAD	cis	rs4061073	1	rs2297026	ENSG00000198711.5	SSBP3-AS1	-4.56	6.44e-06	0.00133	-0.18	-0.2	Body mass index;	chr1:54228541	chr1:54236440~54239063:+
LUAD	cis	rs11673344	0.683	rs11668615	ENSG00000226686.6	LINC01535	4.56	6.44e-06	0.00133	0.28	0.2	Obesity-related traits;	chr19:37063632	chr19:37251912~37265535:+
LUAD	cis	rs11671005	0.735	rs34188294	ENSG00000268912.1	CTD-2619J13.17	-4.56	6.44e-06	0.00133	-0.28	-0.2	Mean platelet volume;	chr19:58408190	chr19:58428632~58431148:-
LUAD	cis	rs3020264	0.962	rs1974946	ENSG00000271743.1	CTD-2541M15.3	-4.56	6.44e-06	0.00133	-0.29	-0.2	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6631266	chr8:6615604~6617198:-
LUAD	cis	rs17684571	0.751	rs11970648	ENSG00000231441.1	RP11-472M19.2	4.56	6.44e-06	0.00133	0.28	0.2	Schizophrenia;	chr6:56762797	chr6:56844002~56864078:+
LUAD	cis	rs910316	0.967	rs4899549	ENSG00000259138.1	RP11-950C14.7	-4.56	6.45e-06	0.00133	-0.22	-0.2	Height;	chr14:75180791	chr14:75127153~75136930:+
LUAD	cis	rs910316	0.967	rs4899550	ENSG00000259138.1	RP11-950C14.7	-4.56	6.45e-06	0.00133	-0.22	-0.2	Height;	chr14:75180963	chr14:75127153~75136930:+
LUAD	cis	rs227275	0.556	rs223449	ENSG00000251288.2	RP11-10L12.2	-4.56	6.45e-06	0.00133	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102791180	chr4:102751401~102752641:+
LUAD	cis	rs9322193	0.923	rs9478291	ENSG00000268592.3	RAET1E-AS1	4.56	6.45e-06	0.00133	0.25	0.2	Lung cancer;	chr6:149729434	chr6:149863494~149919507:+
LUAD	cis	rs854462	1	rs854462	ENSG00000274767.1	AC131056.3	-4.56	6.45e-06	0.00133	-0.3	-0.2	Blood protein levels;	chr17:36058726	chr17:36183235~36196471:+
LUAD	cis	rs1005277	0.54	rs2145487	ENSG00000263064.2	RP11-291L22.7	4.56	6.45e-06	0.00133	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:37721149	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.579	rs2474594	ENSG00000263064.2	RP11-291L22.7	4.56	6.45e-06	0.00133	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38137733	chr10:38448689~38448949:+
LUAD	cis	rs11089937	0.667	rs10483107	ENSG00000211638.2	IGLV8-61	-4.56	6.45e-06	0.00133	-0.25	-0.2	Periodontitis (PAL4Q3);	chr22:22151036	chr22:22098700~22099212:+
LUAD	cis	rs9910055	0.593	rs2905983	ENSG00000267080.4	ASB16-AS1	4.56	6.45e-06	0.00133	0.19	0.2	Total body bone mineral density;	chr17:44135061	chr17:44175973~44186717:-
LUAD	cis	rs11155671	0.53	rs2342769	ENSG00000268592.3	RAET1E-AS1	4.56	6.45e-06	0.00133	0.25	0.2	Testicular germ cell tumor;	chr6:149895371	chr6:149863494~149919507:+
LUAD	cis	rs2243480	1	rs437889	ENSG00000226002.1	RP11-460N20.5	-4.56	6.46e-06	0.00133	-0.34	-0.2	Diabetic kidney disease;	chr7:66044247	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs402418	ENSG00000226002.1	RP11-460N20.5	-4.56	6.46e-06	0.00133	-0.34	-0.2	Diabetic kidney disease;	chr7:66044482	chr7:65084103~65100232:+
LUAD	cis	rs2243480	0.803	rs423187	ENSG00000226002.1	RP11-460N20.5	-4.56	6.46e-06	0.00133	-0.34	-0.2	Diabetic kidney disease;	chr7:66044512	chr7:65084103~65100232:+
LUAD	cis	rs7189233	0.531	rs8046307	ENSG00000279344.1	RP11-44F14.7	4.56	6.46e-06	0.00133	0.17	0.2	Intelligence (multi-trait analysis);	chr16:53484774	chr16:53478957~53481550:-
LUAD	cis	rs11673344	0.764	rs529468	ENSG00000226686.6	LINC01535	4.56	6.46e-06	0.00134	0.26	0.2	Obesity-related traits;	chr19:36955298	chr19:37251912~37265535:+
LUAD	cis	rs11673344	0.764	rs524802	ENSG00000226686.6	LINC01535	4.56	6.46e-06	0.00134	0.26	0.2	Obesity-related traits;	chr19:36956045	chr19:37251912~37265535:+
LUAD	cis	rs338389	0.543	rs449487	ENSG00000260657.2	RP11-315D16.4	-4.56	6.46e-06	0.00134	-0.24	-0.2	Survival in rectal cancer;	chr15:67948410	chr15:68267792~68277994:-
LUAD	cis	rs301901	1	rs300051	ENSG00000250155.1	CTD-2353F22.1	-4.56	6.46e-06	0.00134	-0.21	-0.2	Height;	chr5:37088525	chr5:36666214~36725195:-
LUAD	cis	rs6570726	1	rs441477	ENSG00000235652.6	RP11-545I5.3	4.56	6.46e-06	0.00134	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145527107	chr6:145799409~145886585:+
LUAD	cis	rs736408	0.608	rs2239547	ENSG00000242142.1	SERBP1P3	4.56	6.47e-06	0.00134	0.22	0.2	Bipolar disorder;	chr3:52821213	chr3:53064283~53065091:-
LUAD	cis	rs875971	0.522	rs4502988	ENSG00000237310.1	GS1-124K5.4	4.56	6.47e-06	0.00134	0.22	0.2	Aortic root size;	chr7:65832759	chr7:66493706~66495474:+
LUAD	cis	rs1876905	0.597	rs1150076	ENSG00000255389.1	C6orf3	4.56	6.47e-06	0.00134	0.28	0.2	Mean corpuscular hemoglobin;	chr6:111227227	chr6:111599875~111602295:+
LUAD	cis	rs2439831	1	rs2439841	ENSG00000249839.1	AC011330.5	-4.56	6.48e-06	0.00134	-0.36	-0.2	Lung cancer in ever smokers;	chr15:43442551	chr15:43663654~43684339:-
LUAD	cis	rs847577	0.609	rs11763970	ENSG00000272950.1	RP11-307C18.1	4.56	6.48e-06	0.00134	0.25	0.2	Breast cancer;	chr7:98188009	chr7:98322853~98323430:+
LUAD	cis	rs1499614	1	rs1638731	ENSG00000229886.1	RP5-1132H15.3	4.56	6.48e-06	0.00134	0.36	0.2	Gout;	chr7:66679692	chr7:66025126~66031544:-
LUAD	cis	rs1499614	1	rs1882655	ENSG00000229886.1	RP5-1132H15.3	-4.56	6.48e-06	0.00134	-0.36	-0.2	Gout;	chr7:66682070	chr7:66025126~66031544:-
LUAD	cis	rs1499614	0.831	rs3800822	ENSG00000229886.1	RP5-1132H15.3	-4.56	6.48e-06	0.00134	-0.36	-0.2	Gout;	chr7:66682162	chr7:66025126~66031544:-
LUAD	cis	rs62025270	0.593	rs7166540	ENSG00000202081.1	RNU6-1280P	-4.56	6.48e-06	0.00134	-0.3	-0.2	Idiopathic pulmonary fibrosis;	chr15:85700854	chr15:85651522~85651628:-
LUAD	cis	rs5758659	0.716	rs5758661	ENSG00000227370.1	RP4-669P10.19	-4.56	6.48e-06	0.00134	-0.18	-0.2	Cognitive function;	chr22:42228439	chr22:42132543~42132998:+
LUAD	cis	rs9322193	0.567	rs7747457	ENSG00000268592.3	RAET1E-AS1	4.56	6.48e-06	0.00134	0.25	0.2	Lung cancer;	chr6:149892366	chr6:149863494~149919507:+
LUAD	cis	rs17772222	0.876	rs12587598	ENSG00000258983.2	RP11-507K2.2	4.56	6.49e-06	0.00134	0.24	0.2	Coronary artery calcification;	chr14:88729474	chr14:88499334~88515502:+
LUAD	cis	rs17739794	0.677	rs17739674	ENSG00000254207.1	RP11-43A14.1	4.56	6.49e-06	0.00134	0.23	0.2	Clozapine-induced cytotoxicity;	chr8:851584	chr8:725188~725877:-
LUAD	cis	rs7760535	0.93	rs7742244	ENSG00000266032.1	AL357515.1	4.56	6.49e-06	0.00134	0.27	0.2	Metabolic traits;	chr6:111531459	chr6:110969773~110969872:-
LUAD	cis	rs9545047	0.604	rs9574419	ENSG00000227354.5	RBM26-AS1	-4.56	6.49e-06	0.00134	-0.22	-0.2	Schizophrenia;	chr13:79402337	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs9601226	ENSG00000227354.5	RBM26-AS1	-4.56	6.49e-06	0.00134	-0.22	-0.2	Schizophrenia;	chr13:79403400	chr13:79406309~79424328:+
LUAD	cis	rs57709857	0.957	rs12056642	ENSG00000272092.1	RP11-350N15.5	-4.56	6.49e-06	0.00134	-0.27	-0.2	Autism spectrum disorder or schizophrenia;	chr8:38307554	chr8:38382364~38383461:+
LUAD	cis	rs7555523	0.778	rs4233408	ENSG00000224358.1	RP11-466F5.8	-4.56	6.49e-06	0.00134	-0.33	-0.2	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165743723	chr1:165768929~165775176:+
LUAD	cis	rs801193	1	rs2707856	ENSG00000236529.1	RP13-254B10.1	4.56	6.5e-06	0.00134	0.21	0.2	Aortic root size;	chr7:66746023	chr7:65840212~65840596:+
LUAD	cis	rs2243480	1	rs160634	ENSG00000164669.11	INTS4P1	-4.56	6.5e-06	0.00134	-0.34	-0.2	Diabetic kidney disease;	chr7:66063677	chr7:65141225~65234216:+
LUAD	cis	rs453301	0.624	rs2979265	ENSG00000173295.6	FAM86B3P	4.56	6.5e-06	0.00134	0.22	0.2	Joint mobility (Beighton score);	chr8:9001207	chr8:8228595~8244865:+
LUAD	cis	rs6142102	0.962	rs2206448	ENSG00000275784.1	RP5-1125A11.6	-4.56	6.5e-06	0.00134	-0.22	-0.2	Skin pigmentation;	chr20:34121719	chr20:33989480~33991818:-
LUAD	cis	rs10266483	0.739	rs682662	ENSG00000228653.2	HNRNPCP7	-4.56	6.51e-06	0.00134	-0.24	-0.2	Response to statin therapy;	chr7:64306107	chr7:64500825~64501729:+
LUAD	cis	rs3795324	0.793	rs61295253	ENSG00000228863.7	RP11-404F10.2	-4.56	6.51e-06	0.00134	-0.25	-0.2	Microalbuminuria;	chr1:160649131	chr1:160670778~160699761:+
LUAD	cis	rs67311347	0.713	rs73073505	ENSG00000223797.4	ENTPD3-AS1	4.56	6.51e-06	0.00134	0.22	0.2	Renal cell carcinoma;	chr3:40269202	chr3:40313802~40453329:-
LUAD	cis	rs12745968	0.624	rs1059268	ENSG00000223787.2	RP4-593M8.1	-4.56	6.51e-06	0.00134	-0.24	-0.2	Bipolar disorder and schizophrenia;	chr1:92509687	chr1:92580476~92580821:-
LUAD	cis	rs12745968	0.589	rs1059267	ENSG00000223787.2	RP4-593M8.1	-4.56	6.51e-06	0.00134	-0.24	-0.2	Bipolar disorder and schizophrenia;	chr1:92509705	chr1:92580476~92580821:-
LUAD	cis	rs12439619	0.846	rs62012003	ENSG00000276710.3	CSPG4P8	-4.56	6.51e-06	0.00134	-0.23	-0.2	Intelligence (multi-trait analysis);	chr15:82183236	chr15:82459472~82477258:+
LUAD	cis	rs9467773	1	rs9467783	ENSG00000261353.1	CTA-14H9.5	-4.56	6.51e-06	0.00134	-0.22	-0.2	Intelligence (multi-trait analysis);	chr6:26542666	chr6:26527063~26527404:+
LUAD	cis	rs73173548	0.502	rs10505855	ENSG00000247828.6	TMEM161B-AS1	4.56	6.51e-06	0.00135	0.25	0.2	Macular telangiectasia type 2;	chr5:88440962	chr5:88268895~88436685:+
LUAD	cis	rs73173548	0.502	rs4129235	ENSG00000247828.6	TMEM161B-AS1	4.56	6.51e-06	0.00135	0.25	0.2	Macular telangiectasia type 2;	chr5:88441465	chr5:88268895~88436685:+
LUAD	cis	rs853679	0.546	rs483143	ENSG00000219392.1	RP1-265C24.5	-4.56	6.52e-06	0.00135	-0.4	-0.2	Depression;	chr6:27878966	chr6:28115628~28116551:+
LUAD	cis	rs875971	0.505	rs6955582	ENSG00000224316.1	RP11-479O9.2	4.56	6.52e-06	0.00135	0.2	0.2	Aortic root size;	chr7:65966699	chr7:65773620~65802067:+
LUAD	cis	rs4266290	0.671	rs868763	ENSG00000214846.4	RP11-115L11.1	-4.56	6.52e-06	0.00135	-0.3	-0.2	Parkinson's disease;	chr4:15754282	chr4:15730962~15731627:-
LUAD	cis	rs4568518	0.616	rs17661083	ENSG00000279048.1	RP11-511H23.2	4.56	6.52e-06	0.00135	0.17	0.2	Measles;	chr7:17965230	chr7:17940503~17942922:+
LUAD	cis	rs2836950	0.545	rs11701805	ENSG00000255568.3	BRWD1-AS2	-4.56	6.52e-06	0.00135	-0.2	-0.2	Menarche (age at onset);	chr21:39246757	chr21:39313935~39314962:+
LUAD	cis	rs10266483	0.705	rs1111649	ENSG00000227986.1	TRIM60P18	-4.56	6.52e-06	0.00135	-0.25	-0.2	Response to statin therapy;	chr7:64296435	chr7:64355078~64356199:+
LUAD	cis	rs2880765	0.714	rs6497187	ENSG00000259295.5	CSPG4P12	4.56	6.52e-06	0.00135	0.23	0.2	Coronary artery disease;	chr15:85468119	chr15:85191438~85213905:+
LUAD	cis	rs2880765	0.743	rs6497191	ENSG00000259295.5	CSPG4P12	4.56	6.52e-06	0.00135	0.23	0.2	Coronary artery disease;	chr15:85468270	chr15:85191438~85213905:+
LUAD	cis	rs2880765	0.743	rs6416598	ENSG00000259295.5	CSPG4P12	4.56	6.52e-06	0.00135	0.23	0.2	Coronary artery disease;	chr15:85468617	chr15:85191438~85213905:+
LUAD	cis	rs17684571	0.872	rs34824960	ENSG00000231441.1	RP11-472M19.2	4.56	6.52e-06	0.00135	0.28	0.2	Schizophrenia;	chr6:56722732	chr6:56844002~56864078:+
LUAD	cis	rs9987353	0.519	rs11779181	ENSG00000253893.2	FAM85B	-4.56	6.53e-06	0.00135	-0.27	-0.2	Recombination measurement;	chr8:9205517	chr8:8167819~8226614:-
LUAD	cis	rs9322193	0.607	rs12204653	ENSG00000268592.3	RAET1E-AS1	4.56	6.53e-06	0.00135	0.31	0.2	Lung cancer;	chr6:149891885	chr6:149863494~149919507:+
LUAD	cis	rs11155671	0.53	rs9383577	ENSG00000268592.3	RAET1E-AS1	4.56	6.53e-06	0.00135	0.25	0.2	Testicular germ cell tumor;	chr6:149886059	chr6:149863494~149919507:+
LUAD	cis	rs11155671	0.53	rs9383914	ENSG00000268592.3	RAET1E-AS1	4.56	6.53e-06	0.00135	0.25	0.2	Testicular germ cell tumor;	chr6:149886098	chr6:149863494~149919507:+
LUAD	cis	rs11155671	0.517	rs9397058	ENSG00000268592.3	RAET1E-AS1	4.56	6.53e-06	0.00135	0.25	0.2	Testicular germ cell tumor;	chr6:149886113	chr6:149863494~149919507:+
LUAD	cis	rs2153535	0.585	rs9379237	ENSG00000230939.1	RP11-314C16.1	-4.56	6.53e-06	0.00135	-0.23	-0.2	Motion sickness;	chr6:8654330	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.585	rs7450731	ENSG00000230939.1	RP11-314C16.1	-4.56	6.53e-06	0.00135	-0.23	-0.2	Motion sickness;	chr6:8656501	chr6:8784178~8785445:+
LUAD	cis	rs11673344	0.864	rs8106386	ENSG00000226686.6	LINC01535	-4.56	6.53e-06	0.00135	-0.26	-0.2	Obesity-related traits;	chr19:37012997	chr19:37251912~37265535:+
LUAD	cis	rs7102710	1	rs74588266	ENSG00000254418.1	RP11-21L19.1	4.56	6.53e-06	0.00135	0.53	0.2	Glucagon levels in response to oral glucose tolerance test (fasting);	chr11:14228915	chr11:14262846~14273691:-
LUAD	cis	rs9303029	1	rs72859113	ENSG00000265458.1	RP13-20L14.6	4.56	6.54e-06	0.00135	0.39	0.2	Protein quantitative trait loci;	chr17:82459567	chr17:82454273~82458521:-
LUAD	cis	rs9303029	0.932	rs78720068	ENSG00000265458.1	RP13-20L14.6	4.56	6.54e-06	0.00135	0.39	0.2	Protein quantitative trait loci;	chr17:82459853	chr17:82454273~82458521:-
LUAD	cis	rs9545047	0.567	rs9574420	ENSG00000227354.5	RBM26-AS1	-4.56	6.54e-06	0.00135	-0.22	-0.2	Schizophrenia;	chr13:79404342	chr13:79406309~79424328:+
LUAD	cis	rs4819052	0.851	rs2838842	ENSG00000237664.1	LINC00316	-4.56	6.54e-06	0.00135	-0.24	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249302	chr21:45338590~45341990:-
LUAD	cis	rs9400467	0.528	rs7750792	ENSG00000271789.1	RP5-1112D6.7	-4.56	6.54e-06	0.00135	-0.22	-0.2	Amino acid levels;Blood metabolite levels;	chr6:111462556	chr6:111297126~111298510:+
LUAD	cis	rs17772222	0.56	rs3742681	ENSG00000258789.1	RP11-507K2.3	4.56	6.54e-06	0.00135	0.25	0.2	Coronary artery calcification;	chr14:88554903	chr14:88551597~88552493:+
LUAD	cis	rs2933343	0.649	rs789219	ENSG00000231305.3	RP11-723O4.2	4.56	6.54e-06	0.00135	0.22	0.2	IgG glycosylation;	chr3:128873677	chr3:128861313~128871540:-
LUAD	cis	rs3219474	0.614	rs114562368	ENSG00000280836.1	AL355480.1	-4.56	6.54e-06	0.00135	-0.41	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:45433506	chr1:45581219~45581321:-
LUAD	cis	rs6723108	0.517	rs6729702	ENSG00000224043.6	CCNT2-AS1	-4.56	6.55e-06	0.00135	-0.25	-0.2	Type 2 diabetes;	chr2:134844586	chr2:134735464~134918710:-
LUAD	cis	rs2115630	0.967	rs8028490	ENSG00000229212.6	RP11-561C5.4	4.56	6.55e-06	0.00135	0.24	0.2	P wave terminal force;	chr15:84734657	chr15:85205440~85234795:-
LUAD	cis	rs7727544	0.678	rs7735891	ENSG00000233006.5	AC034220.3	4.56	6.55e-06	0.00135	0.18	0.2	Blood metabolite levels;	chr5:132261312	chr5:132311285~132369916:-
LUAD	cis	rs6435862	0.636	rs717548	ENSG00000229267.2	AC072062.1	4.56	6.55e-06	0.00135	0.24	0.2	Neuroblastoma (high-risk);	chr2:214812181	chr2:214810229~214963274:+
LUAD	cis	rs11168351	0.75	rs11168366	ENSG00000257735.1	RP11-370I10.6	-4.56	6.55e-06	0.00135	-0.25	-0.2	Bipolar disorder and schizophrenia;	chr12:48027990	chr12:48350945~48442411:+
LUAD	cis	rs7937890	0.56	rs2597194	ENSG00000254418.1	RP11-21L19.1	4.56	6.55e-06	0.00135	0.25	0.2	Mitochondrial DNA levels;	chr11:14475723	chr11:14262846~14273691:-
LUAD	cis	rs7937890	0.593	rs2597189	ENSG00000254418.1	RP11-21L19.1	4.56	6.55e-06	0.00135	0.25	0.2	Mitochondrial DNA levels;	chr11:14490514	chr11:14262846~14273691:-
LUAD	cis	rs2243480	1	rs431076	ENSG00000232559.3	GS1-124K5.12	4.56	6.56e-06	0.00135	0.35	0.2	Diabetic kidney disease;	chr7:66135333	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs2257790	ENSG00000232559.3	GS1-124K5.12	4.56	6.56e-06	0.00135	0.35	0.2	Diabetic kidney disease;	chr7:66135463	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs2460422	ENSG00000232559.3	GS1-124K5.12	4.56	6.56e-06	0.00135	0.35	0.2	Diabetic kidney disease;	chr7:66136518	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs316334	ENSG00000232559.3	GS1-124K5.12	4.56	6.56e-06	0.00135	0.35	0.2	Diabetic kidney disease;	chr7:66137139	chr7:66554588~66576923:-
LUAD	cis	rs858239	0.508	rs7805071	ENSG00000230042.1	AK3P3	-4.56	6.56e-06	0.00135	-0.26	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23150593	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.508	rs7805085	ENSG00000230042.1	AK3P3	-4.56	6.56e-06	0.00135	-0.26	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23150624	chr7:23129178~23129841:+
LUAD	cis	rs6570726	0.967	rs365515	ENSG00000235652.6	RP11-545I5.3	-4.56	6.56e-06	0.00135	-0.2	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145481697	chr6:145799409~145886585:+
LUAD	cis	rs7829975	0.681	rs2271342	ENSG00000253981.4	ALG1L13P	4.56	6.56e-06	0.00135	0.23	0.2	Mood instability;	chr8:8786428	chr8:8236003~8244667:-
LUAD	cis	rs9652601	0.779	rs9929994	ENSG00000274038.1	RP11-66H6.4	-4.56	6.56e-06	0.00135	-0.25	-0.2	Systemic lupus erythematosus;	chr16:11084388	chr16:11056556~11057034:+
LUAD	cis	rs7927592	0.513	rs901823	ENSG00000212093.1	AP000807.1	4.56	6.56e-06	0.00135	0.21	0.2	Total body bone mineral density;	chr11:68438110	chr11:68506083~68506166:-
LUAD	cis	rs6840360	1	rs1877187	ENSG00000270265.1	RP11-731D1.4	-4.56	6.56e-06	0.00135	-0.2	-0.2	Intelligence (multi-trait analysis);	chr4:151684469	chr4:151333775~151353224:-
LUAD	cis	rs4664293	0.647	rs918969	ENSG00000226266.5	AC009961.3	4.56	6.57e-06	0.00136	0.27	0.2	Monocyte percentage of white cells;	chr2:159610145	chr2:159670708~159712435:-
LUAD	cis	rs1707322	1	rs785465	ENSG00000280836.1	AL355480.1	-4.56	6.57e-06	0.00136	-0.26	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46056905	chr1:45581219~45581321:-
LUAD	cis	rs2898681	0.519	rs7670068	ENSG00000248375.1	RP11-177B4.1	-4.56	6.57e-06	0.00136	-0.34	-0.2	Optic nerve measurement (cup area);	chr4:52867817	chr4:52720081~52720831:-
LUAD	cis	rs4268898	0.679	rs2551181	ENSG00000242628.4	AC009228.1	-4.56	6.57e-06	0.00136	-0.29	-0.2	Asthma;	chr2:24214679	chr2:24214381~24221516:+
LUAD	cis	rs62355900	0.627	rs72758038	ENSG00000271828.1	CTD-2310F14.1	4.56	6.57e-06	0.00136	0.39	0.2	Endometriosis;	chr5:56814857	chr5:56927874~56929573:+
LUAD	cis	rs7727544	0.606	rs72795121	ENSG00000233006.5	AC034220.3	4.56	6.57e-06	0.00136	0.19	0.2	Blood metabolite levels;	chr5:132302631	chr5:132311285~132369916:-
LUAD	cis	rs6687758	0.687	rs11118902	ENSG00000200033.1	RNU6-403P	4.56	6.58e-06	0.00136	0.27	0.2	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221932275	chr1:221837334~221837437:-
LUAD	cis	rs1864400	0.605	rs12360493	ENSG00000273008.1	RP11-351D16.3	4.56	6.58e-06	0.00136	0.23	0.2	Hirschsprung disease;	chr10:43223165	chr10:43136824~43138334:-
LUAD	cis	rs2243480	1	rs906134	ENSG00000226002.1	RP11-460N20.5	-4.56	6.58e-06	0.00136	-0.35	-0.2	Diabetic kidney disease;	chr7:65979301	chr7:65084103~65100232:+
LUAD	cis	rs875971	0.964	rs778735	ENSG00000232559.3	GS1-124K5.12	4.56	6.58e-06	0.00136	0.24	0.2	Aortic root size;	chr7:66349822	chr7:66554588~66576923:-
LUAD	cis	rs763121	0.853	rs2413545	ENSG00000228274.3	RP3-508I15.9	-4.56	6.58e-06	0.00136	-0.21	-0.2	Menopause (age at onset);	chr22:38696519	chr22:38667585~38681820:-
LUAD	cis	rs11976180	1	rs11976180	ENSG00000204959.4	ARHGEF34P	4.56	6.58e-06	0.00136	0.25	0.2	Obesity-related traits;	chr7:144044487	chr7:144272445~144286966:-
LUAD	cis	rs1008375	0.932	rs6449321	ENSG00000249502.1	AC006160.5	-4.56	6.58e-06	0.00136	-0.19	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17642849	chr4:17587467~17614571:-
LUAD	cis	rs559928	0.606	rs11605856	ENSG00000236935.1	AP003774.1	4.56	6.58e-06	0.00136	0.3	0.2	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64158056	chr11:64325050~64329504:-
LUAD	cis	rs559928	0.606	rs11231710	ENSG00000236935.1	AP003774.1	4.56	6.58e-06	0.00136	0.3	0.2	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64158271	chr11:64325050~64329504:-
LUAD	cis	rs858239	0.601	rs6461702	ENSG00000230042.1	AK3P3	-4.56	6.58e-06	0.00136	-0.27	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23209654	chr7:23129178~23129841:+
LUAD	cis	rs7210086	0.808	rs8073267	ENSG00000263893.2	CTD-3010D24.3	4.56	6.59e-06	0.00136	0.29	0.2	Ulcerative colitis;	chr17:72643375	chr17:72642731~72644490:+
LUAD	cis	rs6723226	0.75	rs1033751	ENSG00000276334.1	AL133243.1	4.56	6.59e-06	0.00136	0.23	0.2	Intelligence (multi-trait analysis);	chr2:32470691	chr2:32521927~32523547:+
LUAD	cis	rs507080	0.885	rs693037	ENSG00000278376.1	RP11-158I9.8	-4.56	6.59e-06	0.00136	-0.22	-0.2	Serum metabolite levels;	chr11:118682617	chr11:118791254~118793137:+
LUAD	cis	rs4845875	0.563	rs11121829	ENSG00000242349.4	NPPA-AS1	4.56	6.59e-06	0.00136	0.22	0.2	Midregional pro atrial natriuretic peptide levels;	chr1:11774708	chr1:11841017~11848079:+
LUAD	cis	rs228614	0.51	rs170565	ENSG00000251288.2	RP11-10L12.2	-4.56	6.59e-06	0.00136	-0.25	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798277	chr4:102751401~102752641:+
LUAD	cis	rs875971	1	rs6957199	ENSG00000232559.3	GS1-124K5.12	4.56	6.6e-06	0.00136	0.24	0.2	Aortic root size;	chr7:66513532	chr7:66554588~66576923:-
LUAD	cis	rs9303029	1	rs60482040	ENSG00000265458.1	RP13-20L14.6	4.56	6.6e-06	0.00136	0.39	0.2	Protein quantitative trait loci;	chr17:82445183	chr17:82454273~82458521:-
LUAD	cis	rs875971	0.706	rs1643374	ENSG00000236529.1	RP13-254B10.1	4.56	6.6e-06	0.00136	0.21	0.2	Aortic root size;	chr7:66407695	chr7:65840212~65840596:+
LUAD	cis	rs3795324	0.793	rs12076119	ENSG00000228863.7	RP11-404F10.2	-4.56	6.6e-06	0.00136	-0.25	-0.2	Microalbuminuria;	chr1:160648558	chr1:160670778~160699761:+
LUAD	cis	rs6723226	0.739	rs2069213	ENSG00000276334.1	AL133243.1	4.56	6.6e-06	0.00136	0.23	0.2	Intelligence (multi-trait analysis);	chr2:32518017	chr2:32521927~32523547:+
LUAD	cis	rs6604026	0.59	rs35612297	ENSG00000223787.2	RP4-593M8.1	4.56	6.6e-06	0.00136	0.28	0.2	Multiple sclerosis;	chr1:92688538	chr1:92580476~92580821:-
LUAD	cis	rs6604026	0.59	rs72724574	ENSG00000223787.2	RP4-593M8.1	4.56	6.6e-06	0.00136	0.28	0.2	Multiple sclerosis;	chr1:92692547	chr1:92580476~92580821:-
LUAD	cis	rs881375	0.502	rs4837811	ENSG00000226752.6	PSMD5-AS1	-4.56	6.6e-06	0.00136	-0.23	-0.2	Rheumatoid arthritis;	chr9:121139316	chr9:120824828~120854385:+
LUAD	cis	rs910316	1	rs10140851	ENSG00000279594.1	RP11-950C14.10	4.56	6.6e-06	0.00136	0.23	0.2	Height;	chr14:75045909	chr14:75011269~75012851:-
LUAD	cis	rs2243480	0.901	rs313808	ENSG00000232559.3	GS1-124K5.12	4.56	6.6e-06	0.00136	0.35	0.2	Diabetic kidney disease;	chr7:66034886	chr7:66554588~66576923:-
LUAD	cis	rs13256369	0.826	rs7846050	ENSG00000253893.2	FAM85B	-4.56	6.61e-06	0.00136	-0.28	-0.2	Obesity-related traits;	chr8:8718159	chr8:8167819~8226614:-
LUAD	cis	rs925255	0.682	rs7590263	ENSG00000270210.1	RP11-373D23.3	4.56	6.62e-06	0.00136	0.23	0.2	Inflammatory bowel disease;Crohn's disease;	chr2:28422935	chr2:28425945~28426719:+
LUAD	cis	rs2115630	1	rs11854313	ENSG00000229212.6	RP11-561C5.4	4.56	6.62e-06	0.00136	0.24	0.2	P wave terminal force;	chr15:84760817	chr15:85205440~85234795:-
LUAD	cis	rs11051970	0.611	rs10844197	ENSG00000274964.1	RP11-817I4.1	-4.56	6.62e-06	0.00136	-0.21	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr12:32408081	chr12:32339368~32340724:+
LUAD	cis	rs929843	1	rs929843	ENSG00000196696.11	PDXDC2P	-4.56	6.62e-06	0.00136	-0.16	-0.2	Menarche (age at onset);	chr16:70011845	chr16:69976297~70065948:-
LUAD	cis	rs227275	0.525	rs10032234	ENSG00000251288.2	RP11-10L12.2	-4.56	6.62e-06	0.00137	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102980538	chr4:102751401~102752641:+
LUAD	cis	rs1979679	0.918	rs1257741	ENSG00000278733.1	RP11-425D17.1	4.56	6.62e-06	0.00137	0.26	0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28381636	chr12:28185625~28186190:-
LUAD	cis	rs11157436	0.918	rs2178788	ENSG00000211813.2	TRAV34	4.56	6.63e-06	0.00137	0.25	0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22150916	chr14:22207522~22208129:+
LUAD	cis	rs1075265	0.547	rs7557799	ENSG00000233266.1	HMGB1P31	-4.56	6.63e-06	0.00137	-0.25	-0.2	Chronotype;Morning vs. evening chronotype;	chr2:53674760	chr2:54051334~54051760:+
LUAD	cis	rs875971	0.965	rs10267430	ENSG00000232559.3	GS1-124K5.12	-4.56	6.64e-06	0.00137	-0.24	-0.2	Aortic root size;	chr7:66278036	chr7:66554588~66576923:-
LUAD	cis	rs17507216	0.518	rs1877240	ENSG00000255769.6	GOLGA2P10	-4.56	6.64e-06	0.00137	-0.28	-0.2	Excessive daytime sleepiness;	chr15:82770126	chr15:82472993~82513950:-
LUAD	cis	rs6840360	1	rs4696284	ENSG00000270265.1	RP11-731D1.4	-4.56	6.64e-06	0.00137	-0.21	-0.2	Intelligence (multi-trait analysis);	chr4:151674684	chr4:151333775~151353224:-
LUAD	cis	rs6840360	1	rs12502055	ENSG00000270265.1	RP11-731D1.4	-4.56	6.64e-06	0.00137	-0.21	-0.2	Intelligence (multi-trait analysis);	chr4:151675516	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.967	rs6841204	ENSG00000270265.1	RP11-731D1.4	-4.56	6.64e-06	0.00137	-0.21	-0.2	Intelligence (multi-trait analysis);	chr4:151677451	chr4:151333775~151353224:-
LUAD	cis	rs6840360	1	rs6818667	ENSG00000270265.1	RP11-731D1.4	-4.56	6.64e-06	0.00137	-0.21	-0.2	Intelligence (multi-trait analysis);	chr4:151677546	chr4:151333775~151353224:-
LUAD	cis	rs227275	0.525	rs28845922	ENSG00000251288.2	RP11-10L12.2	-4.56	6.64e-06	0.00137	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102981959	chr4:102751401~102752641:+
LUAD	cis	rs875971	0.66	rs6460308	ENSG00000236529.1	RP13-254B10.1	-4.56	6.64e-06	0.00137	-0.21	-0.2	Aortic root size;	chr7:66619753	chr7:65840212~65840596:+
LUAD	cis	rs6687758	0.735	rs12032653	ENSG00000200033.1	RNU6-403P	4.56	6.64e-06	0.00137	0.27	0.2	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221975457	chr1:221837334~221837437:-
LUAD	cis	rs6687758	0.679	rs12029332	ENSG00000200033.1	RNU6-403P	4.56	6.64e-06	0.00137	0.27	0.2	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221975480	chr1:221837334~221837437:-
LUAD	cis	rs4819052	0.851	rs8126930	ENSG00000237664.1	LINC00316	-4.56	6.64e-06	0.00137	-0.23	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251800	chr21:45338590~45341990:-
LUAD	cis	rs2187895	0.704	rs1476040	ENSG00000271811.1	RP1-79C4.4	4.56	6.65e-06	0.00137	0.26	0.2	Tonsillectomy;	chr1:170731617	chr1:170667381~170669425:+
LUAD	cis	rs1387259	0.929	rs11168460	ENSG00000240399.1	RP1-228P16.1	4.56	6.65e-06	0.00137	0.2	0.2	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48203582	chr12:48054813~48055591:-
LUAD	cis	rs2439831	0.618	rs8023508	ENSG00000205771.5	CATSPER2P1	4.56	6.65e-06	0.00137	0.35	0.2	Lung cancer in ever smokers;	chr15:43883905	chr15:43726918~43747094:-
LUAD	cis	rs11051970	0.625	rs2728709	ENSG00000274964.1	RP11-817I4.1	-4.55	6.65e-06	0.00137	-0.24	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr12:32414782	chr12:32339368~32340724:+
LUAD	cis	rs2281636	0.723	rs2150916	ENSG00000233690.1	EBAG9P1	4.55	6.65e-06	0.00137	0.21	0.2	Obesity-related traits;	chr10:99692737	chr10:99697407~99697949:-
LUAD	cis	rs2834288	0.5	rs2834305	ENSG00000237945.6	LINC00649	4.55	6.66e-06	0.00137	0.25	0.2	Gut microbiota (bacterial taxa);	chr21:33955321	chr21:33915534~33977691:+
LUAD	cis	rs227275	0.556	rs4455413	ENSG00000251288.2	RP11-10L12.2	-4.55	6.66e-06	0.00137	-0.25	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102971925	chr4:102751401~102752641:+
LUAD	cis	rs8177876	0.554	rs56286107	ENSG00000261061.1	RP11-303E16.2	-4.55	6.66e-06	0.00137	-0.4	-0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81084227	chr16:81030770~81031485:+
LUAD	cis	rs6545883	0.542	rs10177225	ENSG00000271889.1	RP11-493E12.1	-4.55	6.66e-06	0.00137	-0.23	-0.2	Tuberculosis;	chr2:61367363	chr2:61151433~61162105:-
LUAD	cis	rs6142102	0.923	rs6059635	ENSG00000275784.1	RP5-1125A11.6	-4.55	6.66e-06	0.00137	-0.23	-0.2	Skin pigmentation;	chr20:34025687	chr20:33989480~33991818:-
LUAD	cis	rs17508449	0.819	rs78552134	ENSG00000232450.1	RP4-730K3.3	-4.55	6.66e-06	0.00137	-0.36	-0.2	Leprosy;	chr1:113727044	chr1:113698884~113699631:-
LUAD	cis	rs875971	0.66	rs10263935	ENSG00000236529.1	RP13-254B10.1	4.55	6.66e-06	0.00137	0.2	0.2	Aortic root size;	chr7:66631041	chr7:65840212~65840596:+
LUAD	cis	rs4908760	0.731	rs12075458	ENSG00000270282.1	RP5-1115A15.2	4.55	6.66e-06	0.00137	0.23	0.2	Vitiligo;	chr1:8698735	chr1:8512653~8513021:+
LUAD	cis	rs151234	0.8	rs231972	ENSG00000259982.1	CDC37P1	-4.55	6.67e-06	0.00137	-0.39	-0.2	Platelet distribution width;	chr16:28527015	chr16:28700294~28701540:-
LUAD	cis	rs6903823	0.527	rs4713158	ENSG00000219392.1	RP1-265C24.5	-4.55	6.67e-06	0.00137	-0.26	-0.2	Pulmonary function;	chr6:28309994	chr6:28115628~28116551:+
LUAD	cis	rs878939	0.625	rs2193352	ENSG00000230224.1	PHBP9	-4.55	6.67e-06	0.00137	-0.2	-0.2	Warfarin maintenance dose;	chr10:99586852	chr10:100248271~100249095:+
LUAD	cis	rs2243480	0.901	rs2456483	ENSG00000232559.3	GS1-124K5.12	4.55	6.67e-06	0.00137	0.35	0.2	Diabetic kidney disease;	chr7:65996588	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs1701750	ENSG00000232559.3	GS1-124K5.12	4.55	6.67e-06	0.00137	0.35	0.2	Diabetic kidney disease;	chr7:66002158	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs1701758	ENSG00000232559.3	GS1-124K5.12	4.55	6.67e-06	0.00137	0.35	0.2	Diabetic kidney disease;	chr7:66005214	chr7:66554588~66576923:-
LUAD	cis	rs2243480	0.901	rs1701759	ENSG00000232559.3	GS1-124K5.12	4.55	6.67e-06	0.00137	0.35	0.2	Diabetic kidney disease;	chr7:66005945	chr7:66554588~66576923:-
LUAD	cis	rs17508449	0.819	rs4839331	ENSG00000232450.1	RP4-730K3.3	-4.55	6.67e-06	0.00137	-0.33	-0.2	Leprosy;	chr1:113619009	chr1:113698884~113699631:-
LUAD	cis	rs17508449	0.819	rs77892281	ENSG00000232450.1	RP4-730K3.3	-4.55	6.67e-06	0.00137	-0.33	-0.2	Leprosy;	chr1:113620995	chr1:113698884~113699631:-
LUAD	cis	rs5758511	0.68	rs5758688	ENSG00000226450.2	CYP2D8P	4.55	6.67e-06	0.00137	0.19	0.2	Birth weight;	chr22:42266495	chr22:42149886~42155001:-
LUAD	cis	rs1355223	0.902	rs35032224	ENSG00000271369.1	RP11-350D17.3	-4.55	6.67e-06	0.00137	-0.24	-0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34676607	chr11:34709600~34710161:+
LUAD	cis	rs4819052	0.851	rs2838845	ENSG00000237664.1	LINC00316	-4.55	6.68e-06	0.00137	-0.24	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250897	chr21:45338590~45341990:-
LUAD	cis	rs7404843	0.852	rs111259294	ENSG00000207425.1	Y_RNA	-4.55	6.68e-06	0.00137	-0.41	-0.2	Testicular germ cell tumor;	chr16:15418073	chr16:14915457~14915556:-
LUAD	cis	rs858239	0.539	rs4559148	ENSG00000230042.1	AK3P3	-4.55	6.68e-06	0.00137	-0.26	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23146348	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.539	rs4377861	ENSG00000230042.1	AK3P3	-4.55	6.68e-06	0.00137	-0.26	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23146350	chr7:23129178~23129841:+
LUAD	cis	rs62355901	0.599	rs10513090	ENSG00000271828.1	CTD-2310F14.1	-4.55	6.68e-06	0.00138	-0.38	-0.2	Breast cancer;	chr5:56758238	chr5:56927874~56929573:+
LUAD	cis	rs228614	0.514	rs59550147	ENSG00000251288.2	RP11-10L12.2	-4.55	6.68e-06	0.00138	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102914239	chr4:102751401~102752641:+
LUAD	cis	rs9309473	0.607	rs6546826	ENSG00000163016.8	ALMS1P	-4.55	6.68e-06	0.00138	-0.23	-0.2	Metabolite levels;	chr2:73372680	chr2:73644919~73685576:+
LUAD	cis	rs9400467	0.508	rs12211763	ENSG00000271789.1	RP5-1112D6.7	-4.55	6.68e-06	0.00138	-0.22	-0.2	Amino acid levels;Blood metabolite levels;	chr6:111465953	chr6:111297126~111298510:+
LUAD	cis	rs61270009	1	rs61270009	ENSG00000247828.6	TMEM161B-AS1	4.55	6.69e-06	0.00138	0.24	0.2	Depressive symptoms;	chr5:88280322	chr5:88268895~88436685:+
LUAD	cis	rs1499614	1	rs2659913	ENSG00000229886.1	RP5-1132H15.3	4.55	6.69e-06	0.00138	0.35	0.2	Gout;	chr7:66692349	chr7:66025126~66031544:-
LUAD	cis	rs1499614	1	rs2659911	ENSG00000229886.1	RP5-1132H15.3	4.55	6.69e-06	0.00138	0.35	0.2	Gout;	chr7:66693433	chr7:66025126~66031544:-
LUAD	cis	rs1499614	1	rs2707838	ENSG00000229886.1	RP5-1132H15.3	4.55	6.69e-06	0.00138	0.35	0.2	Gout;	chr7:66694214	chr7:66025126~66031544:-
LUAD	cis	rs1499614	1	rs60326618	ENSG00000229886.1	RP5-1132H15.3	4.55	6.69e-06	0.00138	0.35	0.2	Gout;	chr7:66701371	chr7:66025126~66031544:-
LUAD	cis	rs1499614	1	rs2707830	ENSG00000229886.1	RP5-1132H15.3	4.55	6.69e-06	0.00138	0.35	0.2	Gout;	chr7:66702658	chr7:66025126~66031544:-
LUAD	cis	rs1499614	1	rs2707828	ENSG00000229886.1	RP5-1132H15.3	4.55	6.69e-06	0.00138	0.35	0.2	Gout;	chr7:66706390	chr7:66025126~66031544:-
LUAD	cis	rs1499614	0.803	rs1922723	ENSG00000229886.1	RP5-1132H15.3	4.55	6.69e-06	0.00138	0.35	0.2	Gout;	chr7:66710076	chr7:66025126~66031544:-
LUAD	cis	rs1499614	1	rs2659903	ENSG00000229886.1	RP5-1132H15.3	4.55	6.69e-06	0.00138	0.35	0.2	Gout;	chr7:66715944	chr7:66025126~66031544:-
LUAD	cis	rs1499614	1	rs2141924	ENSG00000229886.1	RP5-1132H15.3	4.55	6.69e-06	0.00138	0.35	0.2	Gout;	chr7:66721259	chr7:66025126~66031544:-
LUAD	cis	rs2665103	0.632	rs3902959	ENSG00000276710.3	CSPG4P8	-4.55	6.69e-06	0.00138	-0.19	-0.2	Intelligence (multi-trait analysis);	chr15:82252586	chr15:82459472~82477258:+
LUAD	cis	rs891378	1	rs1652333	ENSG00000274245.1	RP11-357P18.2	4.55	6.69e-06	0.00138	0.26	0.2	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207297115	chr1:207372559~207373252:+
LUAD	cis	rs227275	0.554	rs9307281	ENSG00000251288.2	RP11-10L12.2	-4.55	6.69e-06	0.00138	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102934971	chr4:102751401~102752641:+
LUAD	cis	rs11722779	0.903	rs6533037	ENSG00000251288.2	RP11-10L12.2	-4.55	6.69e-06	0.00138	-0.24	-0.2	Schizophrenia;	chr4:102935865	chr4:102751401~102752641:+
LUAD	cis	rs11722779	0.903	rs4530634	ENSG00000251288.2	RP11-10L12.2	-4.55	6.69e-06	0.00138	-0.24	-0.2	Schizophrenia;	chr4:102937924	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.525	rs7676943	ENSG00000251288.2	RP11-10L12.2	-4.55	6.69e-06	0.00138	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102938135	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.525	rs6419160	ENSG00000251288.2	RP11-10L12.2	-4.55	6.69e-06	0.00138	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102938648	chr4:102751401~102752641:+
LUAD	cis	rs11722779	0.901	rs28674656	ENSG00000251288.2	RP11-10L12.2	-4.55	6.69e-06	0.00138	-0.24	-0.2	Schizophrenia;	chr4:102944396	chr4:102751401~102752641:+
LUAD	cis	rs11722779	0.838	rs3974494	ENSG00000251288.2	RP11-10L12.2	-4.55	6.69e-06	0.00138	-0.24	-0.2	Schizophrenia;	chr4:102945323	chr4:102751401~102752641:+
LUAD	cis	rs11722779	0.873	rs6533041	ENSG00000251288.2	RP11-10L12.2	-4.55	6.69e-06	0.00138	-0.24	-0.2	Schizophrenia;	chr4:102951615	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.525	rs4699037	ENSG00000251288.2	RP11-10L12.2	-4.55	6.69e-06	0.00138	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102957010	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.556	rs3857198	ENSG00000251288.2	RP11-10L12.2	-4.55	6.69e-06	0.00138	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102957720	chr4:102751401~102752641:+
LUAD	cis	rs11722779	0.935	rs3857199	ENSG00000251288.2	RP11-10L12.2	-4.55	6.69e-06	0.00138	-0.24	-0.2	Schizophrenia;	chr4:102957991	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.525	rs4699039	ENSG00000251288.2	RP11-10L12.2	-4.55	6.69e-06	0.00138	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102958354	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.525	rs5028609	ENSG00000251288.2	RP11-10L12.2	-4.55	6.69e-06	0.00138	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102959294	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.525	rs6815540	ENSG00000251288.2	RP11-10L12.2	-4.55	6.69e-06	0.00138	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102959922	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.525	rs4698867	ENSG00000251288.2	RP11-10L12.2	-4.55	6.69e-06	0.00138	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102961049	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.525	rs7663876	ENSG00000251288.2	RP11-10L12.2	-4.55	6.69e-06	0.00138	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102966174	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.556	rs6821173	ENSG00000251288.2	RP11-10L12.2	-4.55	6.69e-06	0.00138	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102966404	chr4:102751401~102752641:+
LUAD	cis	rs73173548	0.502	rs71639111	ENSG00000247828.6	TMEM161B-AS1	4.55	6.69e-06	0.00138	0.25	0.2	Macular telangiectasia type 2;	chr5:88428788	chr5:88268895~88436685:+
LUAD	cis	rs227275	0.525	rs6533050	ENSG00000251288.2	RP11-10L12.2	-4.55	6.69e-06	0.00138	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102979044	chr4:102751401~102752641:+
LUAD	cis	rs11722779	0.935	rs3974481	ENSG00000251288.2	RP11-10L12.2	-4.55	6.69e-06	0.00138	-0.24	-0.2	Schizophrenia;	chr4:102956834	chr4:102751401~102752641:+
LUAD	cis	rs7138803	0.538	rs2720287	ENSG00000257464.1	RP11-161H23.8	-4.55	6.69e-06	0.00138	-0.2	-0.2	Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index;	chr12:49807665	chr12:49442424~49442652:-
LUAD	cis	rs11089937	0.568	rs5756989	ENSG00000211640.3	IGLV6-57	4.55	6.69e-06	0.00138	0.15	0.2	Periodontitis (PAL4Q3);	chr22:22132415	chr22:22195713~22196460:+
LUAD	cis	rs2657294	0.62	rs4746261	ENSG00000233313.2	HMGA1P5	4.55	6.69e-06	0.00138	0.25	0.2	Pneumonia;	chr10:75085874	chr10:75276376~75276646:-
LUAD	cis	rs910316	1	rs4322591	ENSG00000279594.1	RP11-950C14.10	4.55	6.7e-06	0.00138	0.23	0.2	Height;	chr14:75133994	chr14:75011269~75012851:-
LUAD	cis	rs6840360	1	rs6823002	ENSG00000270265.1	RP11-731D1.4	-4.55	6.7e-06	0.00138	-0.21	-0.2	Intelligence (multi-trait analysis);	chr4:151683315	chr4:151333775~151353224:-
LUAD	cis	rs6687758	1	rs12731064	ENSG00000200033.1	RNU6-403P	4.55	6.7e-06	0.00138	0.28	0.2	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222016779	chr1:221837334~221837437:-
LUAD	cis	rs910316	1	rs1047418	ENSG00000279594.1	RP11-950C14.10	4.55	6.7e-06	0.00138	0.23	0.2	Height;	chr14:75139089	chr14:75011269~75012851:-
LUAD	cis	rs7098414	0.511	rs12262228	ENSG00000226659.1	RP11-137H2.4	-4.55	6.7e-06	0.00138	-0.27	-0.2	Post bronchodilator FEV1;	chr10:80400669	chr10:80529597~80535942:-
LUAD	cis	rs7098414	0.511	rs4934134	ENSG00000226659.1	RP11-137H2.4	-4.55	6.7e-06	0.00138	-0.27	-0.2	Post bronchodilator FEV1;	chr10:80400826	chr10:80529597~80535942:-
LUAD	cis	rs7017914	0.582	rs7012796	ENSG00000223220.1	Y_RNA	4.55	6.7e-06	0.00138	0.23	0.2	Bone mineral density;	chr8:70763958	chr8:70780914~70781008:-
LUAD	cis	rs9532669	0.926	rs4942014	ENSG00000239827.7	SUGT1P3	-4.55	6.71e-06	0.00138	-0.23	-0.2	Cervical cancer;	chr13:40966366	chr13:40908159~40921774:-
LUAD	cis	rs875971	1	rs3735148	ENSG00000232559.3	GS1-124K5.12	4.55	6.71e-06	0.00138	0.24	0.2	Aortic root size;	chr7:66506022	chr7:66554588~66576923:-
LUAD	cis	rs11157436	0.602	rs2075493	ENSG00000211813.2	TRAV34	4.55	6.71e-06	0.00138	0.23	0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22163782	chr14:22207522~22208129:+
LUAD	cis	rs2115536	0.935	rs11854390	ENSG00000278600.1	RP11-81A1.6	-4.55	6.71e-06	0.00138	-0.17	-0.2	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79932475	chr15:79920195~79922455:-
LUAD	cis	rs9876781	1	rs9876781	ENSG00000229759.1	MRPS18AP1	4.55	6.72e-06	0.00138	0.19	0.2	Longevity;	chr3:48445934	chr3:48256350~48256938:-
LUAD	cis	rs6957923	0.934	rs4464860	ENSG00000230658.1	KLHL7-AS1	4.55	6.72e-06	0.00138	0.24	0.2	Height;	chr7:23460927	chr7:23101228~23105703:-
LUAD	cis	rs2033711	0.837	rs3764535	ENSG00000268912.1	CTD-2619J13.17	-4.55	6.73e-06	0.00138	-0.22	-0.2	Uric acid clearance;	chr19:58417685	chr19:58428632~58431148:-
LUAD	cis	rs2033711	0.84	rs3764533	ENSG00000268912.1	CTD-2619J13.17	-4.55	6.73e-06	0.00138	-0.22	-0.2	Uric acid clearance;	chr19:58417827	chr19:58428632~58431148:-
LUAD	cis	rs867371	0.896	rs8033831	ENSG00000276710.3	CSPG4P8	-4.55	6.73e-06	0.00138	-0.19	-0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82220953	chr15:82459472~82477258:+
LUAD	cis	rs7119	0.651	rs12904533	ENSG00000259362.2	RP11-307C19.1	-4.55	6.73e-06	0.00138	-0.26	-0.2	Type 2 diabetes;	chr15:77553586	chr15:77525540~77534110:+
LUAD	cis	rs227275	0.556	rs4235407	ENSG00000251288.2	RP11-10L12.2	-4.55	6.73e-06	0.00138	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102897427	chr4:102751401~102752641:+
LUAD	cis	rs7829975	0.846	rs6601724	ENSG00000253893.2	FAM85B	4.55	6.74e-06	0.00139	0.25	0.2	Mood instability;	chr8:8687362	chr8:8167819~8226614:-
LUAD	cis	rs7302981	0.741	rs4459386	ENSG00000200428.1	Y_RNA	4.55	6.74e-06	0.00139	0.25	0.2	Systolic blood pressure;	chr12:50201164	chr12:50743568~50743684:+
LUAD	cis	rs6687758	1	rs17442058	ENSG00000227925.1	RP11-191N8.2	4.55	6.74e-06	0.00139	0.29	0.2	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222006808	chr1:221827666~221840666:-
LUAD	cis	rs62025270	0.632	rs16943251	ENSG00000202081.1	RNU6-1280P	-4.55	6.75e-06	0.00139	-0.29	-0.2	Idiopathic pulmonary fibrosis;	chr15:85692004	chr15:85651522~85651628:-
LUAD	cis	rs453301	0.631	rs11780774	ENSG00000233609.3	RP11-62H7.2	-4.55	6.75e-06	0.00139	-0.17	-0.2	Joint mobility (Beighton score);	chr8:8941601	chr8:8961200~8979025:+
LUAD	cis	rs1667284	0.547	rs1449087	ENSG00000266521.1	RP11-650P15.1	-4.55	6.75e-06	0.00139	-0.24	-0.2	Problematic alcohol use in trauma-exposed individuals;	chr18:31657897	chr18:31496645~31497195:-
LUAD	cis	rs801193	1	rs6975195	ENSG00000224316.1	RP11-479O9.2	-4.55	6.75e-06	0.00139	-0.21	-0.2	Aortic root size;	chr7:66659787	chr7:65773620~65802067:+
LUAD	cis	rs801193	1	rs3857688	ENSG00000224316.1	RP11-479O9.2	-4.55	6.75e-06	0.00139	-0.21	-0.2	Aortic root size;	chr7:66662819	chr7:65773620~65802067:+
LUAD	cis	rs801193	1	rs2286684	ENSG00000224316.1	RP11-479O9.2	-4.55	6.75e-06	0.00139	-0.21	-0.2	Aortic root size;	chr7:66664843	chr7:65773620~65802067:+
LUAD	cis	rs801193	0.935	rs2286683	ENSG00000224316.1	RP11-479O9.2	-4.55	6.75e-06	0.00139	-0.21	-0.2	Aortic root size;	chr7:66664856	chr7:65773620~65802067:+
LUAD	cis	rs801193	1	rs10274773	ENSG00000224316.1	RP11-479O9.2	-4.55	6.75e-06	0.00139	-0.21	-0.2	Aortic root size;	chr7:66668591	chr7:65773620~65802067:+
LUAD	cis	rs7760535	0.656	rs7766190	ENSG00000255389.1	C6orf3	-4.55	6.75e-06	0.00139	-0.2	-0.2	Metabolic traits;	chr6:111583863	chr6:111599875~111602295:+
LUAD	cis	rs755249	0.565	rs7539261	ENSG00000228060.1	RP11-69E11.8	4.55	6.75e-06	0.00139	0.18	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39584831	chr1:39565160~39573203:+
LUAD	cis	rs6012564	1	rs6012564	ENSG00000230758.1	SNAP23P	4.55	6.75e-06	0.00139	0.22	0.2	Anger;	chr20:48925063	chr20:49038357~49038602:-
LUAD	cis	rs9545047	0.604	rs9574416	ENSG00000227354.5	RBM26-AS1	-4.55	6.76e-06	0.00139	-0.22	-0.2	Schizophrenia;	chr13:79388577	chr13:79406309~79424328:+
LUAD	cis	rs1075232	1	rs12437749	ENSG00000215302.7	CTD-3092A11.1	-4.55	6.76e-06	0.00139	-0.44	-0.2	Survival in colorectal cancer (non-distant metastatic);	chr15:31357685	chr15:30470779~30507623:+
LUAD	cis	rs11673344	0.832	rs8104296	ENSG00000226686.6	LINC01535	4.55	6.76e-06	0.00139	0.26	0.2	Obesity-related traits;	chr19:37025634	chr19:37251912~37265535:+
LUAD	cis	rs801193	0.901	rs4273746	ENSG00000236529.1	RP13-254B10.1	-4.55	6.76e-06	0.00139	-0.21	-0.2	Aortic root size;	chr7:66836124	chr7:65840212~65840596:+
LUAD	cis	rs683257	0.636	rs56266921	ENSG00000234147.1	RP3-460G2.2	-4.55	6.76e-06	0.00139	-0.32	-0.2	Facial emotion recognition (angry faces);	chr6:140827339	chr6:140845958~140852924:-
LUAD	cis	rs683257	0.636	rs72988142	ENSG00000234147.1	RP3-460G2.2	-4.55	6.76e-06	0.00139	-0.32	-0.2	Facial emotion recognition (angry faces);	chr6:140827387	chr6:140845958~140852924:-
LUAD	cis	rs683257	0.563	rs9495842	ENSG00000234147.1	RP3-460G2.2	-4.55	6.76e-06	0.00139	-0.32	-0.2	Facial emotion recognition (angry faces);	chr6:140828411	chr6:140845958~140852924:-
LUAD	cis	rs683257	0.636	rs9495843	ENSG00000234147.1	RP3-460G2.2	-4.55	6.76e-06	0.00139	-0.32	-0.2	Facial emotion recognition (angry faces);	chr6:140829354	chr6:140845958~140852924:-
LUAD	cis	rs801193	1	rs2055682	ENSG00000236529.1	RP13-254B10.1	4.55	6.76e-06	0.00139	0.21	0.2	Aortic root size;	chr7:66795302	chr7:65840212~65840596:+
LUAD	cis	rs227275	0.525	rs223332	ENSG00000251288.2	RP11-10L12.2	-4.55	6.76e-06	0.00139	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102869029	chr4:102751401~102752641:+
LUAD	cis	rs228614	0.536	rs223327	ENSG00000251288.2	RP11-10L12.2	-4.55	6.76e-06	0.00139	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873560	chr4:102751401~102752641:+
LUAD	cis	rs228614	0.51	rs223326	ENSG00000251288.2	RP11-10L12.2	-4.55	6.76e-06	0.00139	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873770	chr4:102751401~102752641:+
LUAD	cis	rs2731006	0.591	rs9788178	ENSG00000257114.2	RP11-25I15.3	4.55	6.76e-06	0.00139	0.31	0.2	Panic disorder;	chr12:42811931	chr12:42692216~42717119:+
LUAD	cis	rs2243480	1	rs2420170	ENSG00000232559.3	GS1-124K5.12	-4.55	6.77e-06	0.00139	-0.35	-0.2	Diabetic kidney disease;	chr7:66191066	chr7:66554588~66576923:-
LUAD	cis	rs442309	0.551	rs1509966	ENSG00000238280.1	RP11-436D10.3	-4.55	6.77e-06	0.00139	-0.24	-0.2	Vogt-Koyanagi-Harada syndrome;	chr10:62792847	chr10:62793562~62805887:-
LUAD	cis	rs2243480	1	rs56016656	ENSG00000232559.3	GS1-124K5.12	4.55	6.77e-06	0.00139	0.36	0.2	Diabetic kidney disease;	chr7:65918494	chr7:66554588~66576923:-
LUAD	cis	rs2243480	0.803	rs55700941	ENSG00000232559.3	GS1-124K5.12	4.55	6.77e-06	0.00139	0.36	0.2	Diabetic kidney disease;	chr7:65924813	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs56291018	ENSG00000232559.3	GS1-124K5.12	4.55	6.77e-06	0.00139	0.36	0.2	Diabetic kidney disease;	chr7:65925352	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs36033484	ENSG00000232559.3	GS1-124K5.12	4.55	6.77e-06	0.00139	0.36	0.2	Diabetic kidney disease;	chr7:65925571	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs34193460	ENSG00000232559.3	GS1-124K5.12	4.55	6.77e-06	0.00139	0.36	0.2	Diabetic kidney disease;	chr7:65928123	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs34560516	ENSG00000232559.3	GS1-124K5.12	4.55	6.77e-06	0.00139	0.36	0.2	Diabetic kidney disease;	chr7:65939105	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs57057549	ENSG00000232559.3	GS1-124K5.12	4.55	6.77e-06	0.00139	0.36	0.2	Diabetic kidney disease;	chr7:65940751	chr7:66554588~66576923:-
LUAD	cis	rs10863681	0.764	rs6678715	ENSG00000228437.4	RP11-400N13.2	4.55	6.77e-06	0.00139	0.25	0.2	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222103941	chr1:221966341~221984964:+
LUAD	cis	rs7324557	0.717	rs7318360	ENSG00000205861.10	C1QTNF9B-AS1	-4.55	6.78e-06	0.00139	-0.27	-0.2	Visceral adipose tissue adjusted for BMI;	chr13:23818143	chr13:23888889~23897263:+
LUAD	cis	rs2243480	1	rs13247184	ENSG00000229886.1	RP5-1132H15.3	4.55	6.78e-06	0.00139	0.36	0.2	Diabetic kidney disease;	chr7:65893941	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs35283677	ENSG00000229886.1	RP5-1132H15.3	4.55	6.78e-06	0.00139	0.36	0.2	Diabetic kidney disease;	chr7:65894246	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs35421653	ENSG00000229886.1	RP5-1132H15.3	4.55	6.78e-06	0.00139	0.36	0.2	Diabetic kidney disease;	chr7:65898442	chr7:66025126~66031544:-
LUAD	cis	rs11673344	0.73	rs475026	ENSG00000226686.6	LINC01535	4.55	6.79e-06	0.00139	0.26	0.2	Obesity-related traits;	chr19:36968115	chr19:37251912~37265535:+
LUAD	cis	rs6496044	0.547	rs1564719	ENSG00000259416.2	RP11-158M2.5	4.55	6.79e-06	0.00139	0.21	0.2	Interstitial lung disease;	chr15:85511035	chr15:85754941~85756237:-
LUAD	cis	rs1979679	0.842	rs1118097	ENSG00000278733.1	RP11-425D17.1	4.55	6.79e-06	0.00139	0.25	0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28177156	chr12:28185625~28186190:-
LUAD	cis	rs7937890	0.869	rs2915404	ENSG00000251991.1	RNU7-49P	4.55	6.79e-06	0.00139	0.21	0.2	Mitochondrial DNA levels;	chr11:14383279	chr11:14478892~14478953:+
LUAD	cis	rs6088590	1	rs6120750	ENSG00000276073.1	RP5-1125A11.7	-4.55	6.79e-06	0.00139	-0.21	-0.2	Coronary artery disease;	chr20:34877486	chr20:33985617~33988989:-
LUAD	cis	rs6487679	1	rs7298108	ENSG00000255753.1	RP11-22B23.2	-4.55	6.79e-06	0.0014	-0.24	-0.2	Non-alcoholic fatty liver disease histology (AST);	chr12:9223572	chr12:9314402~9316173:-
LUAD	cis	rs453301	0.657	rs36056437	ENSG00000253981.4	ALG1L13P	-4.55	6.8e-06	0.0014	-0.24	-0.2	Joint mobility (Beighton score);	chr8:8935355	chr8:8236003~8244667:-
LUAD	cis	rs7119	0.717	rs12910951	ENSG00000259362.2	RP11-307C19.1	-4.55	6.8e-06	0.0014	-0.25	-0.2	Type 2 diabetes;	chr15:77514455	chr15:77525540~77534110:+
LUAD	cis	rs7119	0.717	rs12911963	ENSG00000259362.2	RP11-307C19.1	-4.55	6.8e-06	0.0014	-0.25	-0.2	Type 2 diabetes;	chr15:77514833	chr15:77525540~77534110:+
LUAD	cis	rs12474201	0.572	rs7596521	ENSG00000279254.1	RP11-536C12.1	-4.55	6.8e-06	0.0014	-0.24	-0.2	Height;	chr2:46691526	chr2:46668870~46670778:+
LUAD	cis	rs875971	1	rs10257427	ENSG00000232559.3	GS1-124K5.12	-4.55	6.8e-06	0.0014	-0.24	-0.2	Aortic root size;	chr7:66278221	chr7:66554588~66576923:-
LUAD	cis	rs875971	1	rs10215948	ENSG00000232559.3	GS1-124K5.12	-4.55	6.8e-06	0.0014	-0.24	-0.2	Aortic root size;	chr7:66282799	chr7:66554588~66576923:-
LUAD	cis	rs2522056	0.808	rs17771891	ENSG00000233006.5	AC034220.3	4.55	6.8e-06	0.0014	0.23	0.2	Fibrinogen;Lymphocyte counts;	chr5:132408510	chr5:132311285~132369916:-
LUAD	cis	rs2033711	0.87	rs11084545	ENSG00000268912.1	CTD-2619J13.17	-4.55	6.81e-06	0.0014	-0.22	-0.2	Uric acid clearance;	chr19:58440326	chr19:58428632~58431148:-
LUAD	cis	rs875971	1	rs7781698	ENSG00000232559.3	GS1-124K5.12	4.55	6.81e-06	0.0014	0.24	0.2	Aortic root size;	chr7:66431325	chr7:66554588~66576923:-
LUAD	cis	rs6687758	1	rs17442323	ENSG00000227925.1	RP11-191N8.2	4.55	6.81e-06	0.0014	0.29	0.2	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222019622	chr1:221827666~221840666:-
LUAD	cis	rs3096299	0.685	rs4238830	ENSG00000261118.1	RP11-104N10.1	4.55	6.81e-06	0.0014	0.2	0.2	Multiple myeloma (IgH translocation);	chr16:89473833	chr16:89492017~89504460:-
LUAD	cis	rs4964805	0.913	rs7134701	ENSG00000257681.1	RP11-341G23.4	4.55	6.81e-06	0.0014	0.25	0.2	Attention deficit hyperactivity disorder;	chr12:103808913	chr12:103746315~103768858:-
LUAD	cis	rs6860806	0.695	rs11952099	ENSG00000233006.5	AC034220.3	4.55	6.81e-06	0.0014	0.18	0.2	Breast cancer;	chr5:132241079	chr5:132311285~132369916:-
LUAD	cis	rs950169	0.649	rs12911612	ENSG00000259728.4	LINC00933	4.55	6.82e-06	0.0014	0.32	0.2	Schizophrenia;	chr15:84022262	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.649	rs12905952	ENSG00000259728.4	LINC00933	4.55	6.82e-06	0.0014	0.32	0.2	Schizophrenia;	chr15:84022509	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.61	rs34529571	ENSG00000259728.4	LINC00933	4.55	6.82e-06	0.0014	0.32	0.2	Schizophrenia;	chr15:84023055	chr15:84570649~84580175:+
LUAD	cis	rs2252586	0.92	rs55662545	ENSG00000176826.14	FKBP9P1	-4.55	6.82e-06	0.0014	-0.27	-0.2	Glioma;	chr7:54901266	chr7:55681074~55713252:-
LUAD	cis	rs9309473	0.607	rs7574291	ENSG00000163016.8	ALMS1P	4.55	6.82e-06	0.0014	0.23	0.2	Metabolite levels;	chr2:73367813	chr2:73644919~73685576:+
LUAD	cis	rs131777	0.576	rs131758	ENSG00000205559.3	CHKB-AS1	-4.55	6.83e-06	0.0014	-0.23	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50578653	chr22:50583026~50583877:+
LUAD	cis	rs17685	0.725	rs6467993	ENSG00000280388.1	RP11-229D13.3	-4.55	6.83e-06	0.0014	-0.19	-0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76090032	chr7:76043977~76045963:-
LUAD	cis	rs561341	1	rs8069199	ENSG00000265798.5	RP11-271K11.5	4.55	6.83e-06	0.0014	0.3	0.2	Hip circumference adjusted for BMI;	chr17:31954826	chr17:31038575~31059121:-
LUAD	cis	rs561341	0.882	rs111484028	ENSG00000265798.5	RP11-271K11.5	4.55	6.83e-06	0.0014	0.3	0.2	Hip circumference adjusted for BMI;	chr17:31960682	chr17:31038575~31059121:-
LUAD	cis	rs10897473	0.573	rs2701543	ENSG00000236935.1	AP003774.1	4.55	6.83e-06	0.0014	0.21	0.2	Immature fraction of reticulocytes;	chr11:64094651	chr11:64325050~64329504:-
LUAD	cis	rs6860806	0.631	rs6863548	ENSG00000233006.5	AC034220.3	4.55	6.83e-06	0.0014	0.18	0.2	Breast cancer;	chr5:132240227	chr5:132311285~132369916:-
LUAD	cis	rs858239	0.539	rs6975852	ENSG00000230042.1	AK3P3	-4.55	6.84e-06	0.0014	-0.26	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23147035	chr7:23129178~23129841:+
LUAD	cis	rs9425766	0.679	rs9787001	ENSG00000227373.4	RP11-160H22.5	4.55	6.84e-06	0.0014	0.25	0.2	Life satisfaction;	chr1:174222556	chr1:174115300~174160004:-
LUAD	cis	rs228614	0.51	rs50034	ENSG00000251288.2	RP11-10L12.2	-4.55	6.84e-06	0.0014	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102832214	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.556	rs223380	ENSG00000251288.2	RP11-10L12.2	-4.55	6.84e-06	0.0014	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102833343	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.556	rs223379	ENSG00000251288.2	RP11-10L12.2	-4.55	6.84e-06	0.0014	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102833434	chr4:102751401~102752641:+
LUAD	cis	rs228614	0.536	rs223375	ENSG00000251288.2	RP11-10L12.2	-4.55	6.84e-06	0.0014	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102836484	chr4:102751401~102752641:+
LUAD	cis	rs35934224	0.783	rs12106549	ENSG00000232926.1	AC000078.5	4.55	6.84e-06	0.0014	0.21	0.2	Glaucoma (primary open-angle);	chr22:19859464	chr22:19887289~19887970:+
LUAD	cis	rs6957923	0.967	rs11770192	ENSG00000230658.1	KLHL7-AS1	4.55	6.84e-06	0.0014	0.25	0.2	Height;	chr7:23458739	chr7:23101228~23105703:-
LUAD	cis	rs9813712	0.597	rs11711883	ENSG00000249846.5	RP11-77P16.4	-4.55	6.85e-06	0.00141	-0.24	-0.2	Response to amphetamines;	chr3:130241367	chr3:130112550~130120579:+
LUAD	cis	rs9813712	0.574	rs62281647	ENSG00000249846.5	RP11-77P16.4	-4.55	6.85e-06	0.00141	-0.24	-0.2	Response to amphetamines;	chr3:130242670	chr3:130112550~130120579:+
LUAD	cis	rs12908161	1	rs35808647	ENSG00000259295.5	CSPG4P12	4.55	6.85e-06	0.00141	0.29	0.2	Schizophrenia;	chr15:84834210	chr15:85191438~85213905:+
LUAD	cis	rs1805008	0.568	rs118068966	ENSG00000261172.1	RP11-356C4.5	-4.55	6.85e-06	0.00141	-0.48	-0.2	Skin colour saturation;	chr16:90045108	chr16:90110574~90168225:-
LUAD	cis	rs4664293	0.528	rs12466650	ENSG00000226266.5	AC009961.3	4.55	6.85e-06	0.00141	0.28	0.2	Monocyte percentage of white cells;	chr2:159552252	chr2:159670708~159712435:-
LUAD	cis	rs6860806	0.661	rs2136188	ENSG00000233006.5	AC034220.3	-4.55	6.85e-06	0.00141	-0.18	-0.2	Breast cancer;	chr5:132241821	chr5:132311285~132369916:-
LUAD	cis	rs2243480	1	rs313807	ENSG00000232559.3	GS1-124K5.12	4.55	6.85e-06	0.00141	0.35	0.2	Diabetic kidney disease;	chr7:66034494	chr7:66554588~66576923:-
LUAD	cis	rs12935418	0.83	rs7188549	ENSG00000261061.1	RP11-303E16.2	-4.55	6.85e-06	0.00141	-0.26	-0.2	Mean corpuscular volume;	chr16:81016371	chr16:81030770~81031485:+
LUAD	cis	rs2300747	0.932	rs12038673	ENSG00000177173.5	NAP1L4P1	-4.55	6.86e-06	0.00141	-0.33	-0.2	Primary biliary cholangitis;Multiple sclerosis;	chr1:116546014	chr1:116532936~116534092:-
LUAD	cis	rs528808	1	rs528808	ENSG00000279170.1	RP1-199J3.6	4.55	6.86e-06	0.00141	0.32	0.2	Age-related hearing impairment;	chr6:99656413	chr6:99587611~99589898:+
LUAD	cis	rs2439831	0.85	rs16977798	ENSG00000249839.1	AC011330.5	-4.55	6.86e-06	0.00141	-0.41	-0.2	Lung cancer in ever smokers;	chr15:43859750	chr15:43663654~43684339:-
LUAD	cis	rs3750082	0.505	rs7807550	ENSG00000231952.3	DPY19L1P2	4.55	6.86e-06	0.00141	0.31	0.2	Glomerular filtration rate (creatinine);	chr7:32944860	chr7:32812757~32838570:+
LUAD	cis	rs11157436	0.602	rs1894371	ENSG00000211813.2	TRAV34	-4.55	6.86e-06	0.00141	-0.23	-0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166799	chr14:22207522~22208129:+
LUAD	cis	rs9341808	0.754	rs978814	ENSG00000272129.1	RP11-250B2.6	4.55	6.86e-06	0.00141	0.25	0.2	Sitting height ratio;	chr6:80250195	chr6:80355424~80356859:+
LUAD	cis	rs4660214	0.639	rs6699928	ENSG00000228060.1	RP11-69E11.8	4.55	6.87e-06	0.00141	0.18	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39267827	chr1:39565160~39573203:+
LUAD	cis	rs7829975	0.593	rs2979241	ENSG00000173295.6	FAM86B3P	4.55	6.87e-06	0.00141	0.22	0.2	Mood instability;	chr8:8445843	chr8:8228595~8244865:+
LUAD	cis	rs2732480	0.538	rs2468943	ENSG00000257735.1	RP11-370I10.6	-4.55	6.87e-06	0.00141	-0.25	-0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48353466	chr12:48350945~48442411:+
LUAD	cis	rs9545047	0.604	rs9545082	ENSG00000227354.5	RBM26-AS1	4.55	6.87e-06	0.00141	0.21	0.2	Schizophrenia;	chr13:79358994	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs7332913	ENSG00000227354.5	RBM26-AS1	4.55	6.87e-06	0.00141	0.21	0.2	Schizophrenia;	chr13:79359149	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs9545083	ENSG00000227354.5	RBM26-AS1	4.55	6.87e-06	0.00141	0.21	0.2	Schizophrenia;	chr13:79360695	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs7322756	ENSG00000227354.5	RBM26-AS1	4.55	6.87e-06	0.00141	0.21	0.2	Schizophrenia;	chr13:79361120	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs7324006	ENSG00000227354.5	RBM26-AS1	4.55	6.87e-06	0.00141	0.21	0.2	Schizophrenia;	chr13:79361225	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs7322673	ENSG00000227354.5	RBM26-AS1	4.55	6.87e-06	0.00141	0.21	0.2	Schizophrenia;	chr13:79361266	chr13:79406309~79424328:+
LUAD	cis	rs6988985	0.818	rs3802230	ENSG00000247317.3	RP11-273G15.2	-4.55	6.87e-06	0.00141	-0.23	-0.2	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142911448	chr8:142981738~143018437:-
LUAD	cis	rs2243480	1	rs427044	ENSG00000229886.1	RP5-1132H15.3	4.55	6.88e-06	0.00141	0.35	0.2	Diabetic kidney disease;	chr7:66043558	chr7:66025126~66031544:-
LUAD	cis	rs11992162	0.967	rs4841661	ENSG00000255046.1	RP11-297N6.4	-4.55	6.88e-06	0.00141	-0.25	-0.2	Monocyte count;	chr8:11975260	chr8:11797928~11802568:-
LUAD	cis	rs2239547	0.563	rs9839035	ENSG00000242142.1	SERBP1P3	4.55	6.88e-06	0.00141	0.24	0.2	Schizophrenia;	chr3:52875861	chr3:53064283~53065091:-
LUAD	cis	rs2898681	0.614	rs10016904	ENSG00000248375.1	RP11-177B4.1	-4.55	6.88e-06	0.00141	-0.31	-0.2	Optic nerve measurement (cup area);	chr4:52828129	chr4:52720081~52720831:-
LUAD	cis	rs10995356	0.966	rs7915640	ENSG00000238280.1	RP11-436D10.3	-4.55	6.88e-06	0.00141	-0.25	-0.2	Temperament;	chr10:62910533	chr10:62793562~62805887:-
LUAD	cis	rs4908768	0.539	rs1061039	ENSG00000270282.1	RP5-1115A15.2	4.55	6.88e-06	0.00141	0.23	0.2	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8582529	chr1:8512653~8513021:+
LUAD	cis	rs62355900	0.627	rs61243567	ENSG00000271828.1	CTD-2310F14.1	4.55	6.88e-06	0.00141	0.38	0.2	Endometriosis;	chr5:56867986	chr5:56927874~56929573:+
LUAD	cis	rs62355900	0.627	rs16886449	ENSG00000271828.1	CTD-2310F14.1	4.55	6.88e-06	0.00141	0.38	0.2	Endometriosis;	chr5:56880479	chr5:56927874~56929573:+
LUAD	cis	rs62355900	0.627	rs895380	ENSG00000271828.1	CTD-2310F14.1	4.55	6.88e-06	0.00141	0.38	0.2	Endometriosis;	chr5:56881321	chr5:56927874~56929573:+
LUAD	cis	rs62355900	0.627	rs16886463	ENSG00000271828.1	CTD-2310F14.1	4.55	6.88e-06	0.00141	0.38	0.2	Endometriosis;	chr5:56883514	chr5:56927874~56929573:+
LUAD	cis	rs62355900	0.627	rs62358106	ENSG00000271828.1	CTD-2310F14.1	4.55	6.88e-06	0.00141	0.38	0.2	Endometriosis;	chr5:56885542	chr5:56927874~56929573:+
LUAD	cis	rs62355900	0.627	rs3817119	ENSG00000271828.1	CTD-2310F14.1	4.55	6.88e-06	0.00141	0.38	0.2	Endometriosis;	chr5:56887916	chr5:56927874~56929573:+
LUAD	cis	rs4908768	0.539	rs1934138	ENSG00000270282.1	RP5-1115A15.2	4.55	6.88e-06	0.00141	0.22	0.2	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8585757	chr1:8512653~8513021:+
LUAD	cis	rs12468226	0.873	rs1474267	ENSG00000272966.1	RP11-686O6.1	-4.55	6.89e-06	0.00141	-0.35	-0.2	Urate levels;	chr2:202178596	chr2:202336739~202337200:+
LUAD	cis	rs9652601	0.959	rs9888908	ENSG00000274038.1	RP11-66H6.4	-4.55	6.89e-06	0.00141	-0.25	-0.2	Systemic lupus erythematosus;	chr16:11087387	chr16:11056556~11057034:+
LUAD	cis	rs7829975	0.711	rs4841051	ENSG00000173295.6	FAM86B3P	-4.55	6.89e-06	0.00141	-0.21	-0.2	Mood instability;	chr8:8828136	chr8:8228595~8244865:+
LUAD	cis	rs748404	0.666	rs17780417	ENSG00000205771.5	CATSPER2P1	-4.55	6.9e-06	0.00141	-0.31	-0.2	Lung cancer;	chr15:43347264	chr15:43726918~43747094:-
LUAD	cis	rs914615	0.552	rs4421576	ENSG00000160766.13	GBAP1	-4.55	6.9e-06	0.00141	-0.21	-0.2	Urinary albumin-to-creatinine ratio;	chr1:155169734	chr1:155213821~155227422:-
LUAD	cis	rs950169	0.922	rs11630507	ENSG00000275120.1	RP11-182J1.17	4.55	6.9e-06	0.00142	0.31	0.2	Schizophrenia;	chr15:84552494	chr15:84599434~84606463:-
LUAD	cis	rs10246939	0.543	rs11765106	ENSG00000270923.1	TAS2R6P	-4.55	6.91e-06	0.00142	-0.25	-0.2	Bitter taste perception;	chr7:141902676	chr7:141787815~141788640:+
LUAD	cis	rs10246939	0.543	rs7786202	ENSG00000270923.1	TAS2R6P	-4.55	6.91e-06	0.00142	-0.25	-0.2	Bitter taste perception;	chr7:141906099	chr7:141787815~141788640:+
LUAD	cis	rs10246939	0.543	rs7802271	ENSG00000270923.1	TAS2R6P	-4.55	6.91e-06	0.00142	-0.25	-0.2	Bitter taste perception;	chr7:141909624	chr7:141787815~141788640:+
LUAD	cis	rs10246939	0.52	rs7782886	ENSG00000270923.1	TAS2R6P	-4.55	6.91e-06	0.00142	-0.25	-0.2	Bitter taste perception;	chr7:141909958	chr7:141787815~141788640:+
LUAD	cis	rs10246939	0.543	rs994808	ENSG00000270923.1	TAS2R6P	-4.55	6.91e-06	0.00142	-0.25	-0.2	Bitter taste perception;	chr7:141911091	chr7:141787815~141788640:+
LUAD	cis	rs10246939	0.543	rs7808421	ENSG00000270923.1	TAS2R6P	-4.55	6.91e-06	0.00142	-0.25	-0.2	Bitter taste perception;	chr7:141911592	chr7:141787815~141788640:+
LUAD	cis	rs10246939	0.543	rs7789123	ENSG00000270923.1	TAS2R6P	-4.55	6.91e-06	0.00142	-0.25	-0.2	Bitter taste perception;	chr7:141911699	chr7:141787815~141788640:+
LUAD	cis	rs10246939	0.543	rs11767947	ENSG00000270923.1	TAS2R6P	-4.55	6.91e-06	0.00142	-0.25	-0.2	Bitter taste perception;	chr7:141912821	chr7:141787815~141788640:+
LUAD	cis	rs10246939	0.543	rs11769089	ENSG00000270923.1	TAS2R6P	-4.55	6.91e-06	0.00142	-0.25	-0.2	Bitter taste perception;	chr7:141914310	chr7:141787815~141788640:+
LUAD	cis	rs10246939	0.543	rs11765974	ENSG00000270923.1	TAS2R6P	-4.55	6.91e-06	0.00142	-0.25	-0.2	Bitter taste perception;	chr7:141914390	chr7:141787815~141788640:+
LUAD	cis	rs301901	0.828	rs10941337	ENSG00000250155.1	CTD-2353F22.1	4.55	6.91e-06	0.00142	0.21	0.2	Height;	chr5:37474023	chr5:36666214~36725195:-
LUAD	cis	rs41369048	0.669	rs11589654	ENSG00000272823.1	RP11-295M18.6	-4.55	6.91e-06	0.00142	-0.3	-0.2	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220866646	chr1:220828676~220829211:-
LUAD	cis	rs13113518	0.783	rs34534635	ENSG00000223305.1	RN7SKP30	4.55	6.91e-06	0.00142	0.24	0.2	Height;	chr4:55573424	chr4:55540502~55540835:-
LUAD	cis	rs673078	0.66	rs17440336	ENSG00000275409.1	RP11-131L12.4	4.55	6.92e-06	0.00142	0.29	0.2	Glucose homeostasis traits;	chr12:118163305	chr12:118430147~118430699:+
LUAD	cis	rs17685	0.753	rs2302438	ENSG00000280388.1	RP11-229D13.3	-4.55	6.92e-06	0.00142	-0.19	-0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76047747	chr7:76043977~76045963:-
LUAD	cis	rs6565180	0.926	rs12446288	ENSG00000273724.1	RP11-347C12.12	4.55	6.92e-06	0.00142	0.22	0.2	Tonsillectomy;	chr16:30377388	chr16:30336400~30343336:+
LUAD	cis	rs916888	0.647	rs199524	ENSG00000261575.2	RP11-259G18.1	-4.55	6.92e-06	0.00142	-0.27	-0.2	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46267037~46268694:+
LUAD	cis	rs2933343	0.951	rs9871612	ENSG00000261159.1	RP11-723O4.9	4.55	6.93e-06	0.00142	0.25	0.2	IgG glycosylation;	chr3:128851559	chr3:128859716~128860526:-
LUAD	cis	rs853679	0.546	rs13213986	ENSG00000219392.1	RP1-265C24.5	-4.55	6.94e-06	0.00142	-0.46	-0.2	Depression;	chr6:28390232	chr6:28115628~28116551:+
LUAD	cis	rs603446	0.967	rs180361	ENSG00000254851.1	RP11-109L13.1	-4.55	6.94e-06	0.00142	-0.26	-0.2	Triglycerides;	chr11:116727933	chr11:117135528~117138582:+
LUAD	cis	rs11846409	0.587	rs1806881	ENSG00000211972.2	IGHV3-66	-4.55	6.94e-06	0.00142	-0.21	-0.2	Rheumatic heart disease;	chr14:106650770	chr14:106675017~106675544:-
LUAD	cis	rs2153535	0.585	rs6900539	ENSG00000230939.1	RP11-314C16.1	-4.55	6.94e-06	0.00142	-0.23	-0.2	Motion sickness;	chr6:8592054	chr6:8784178~8785445:+
LUAD	cis	rs10463554	0.889	rs246908	ENSG00000250682.4	LINC00491	4.55	6.94e-06	0.00142	0.25	0.2	Parkinson's disease;	chr5:103228476	chr5:102609156~102671559:-
LUAD	cis	rs1113500	0.73	rs1618693	ENSG00000226822.1	RP11-356N1.2	-4.55	6.95e-06	0.00142	-0.23	-0.2	Growth-regulated protein alpha levels;	chr1:108048961	chr1:108071482~108074519:+
LUAD	cis	rs1113500	0.698	rs1781078	ENSG00000226822.1	RP11-356N1.2	-4.55	6.95e-06	0.00142	-0.23	-0.2	Growth-regulated protein alpha levels;	chr1:108049020	chr1:108071482~108074519:+
LUAD	cis	rs36093844	0.66	rs895256	ENSG00000279742.1	RP11-700A24.1	-4.55	6.95e-06	0.00142	-0.3	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85824166	chr11:85852557~85854943:-
LUAD	cis	rs17772222	0.682	rs28482235	ENSG00000258789.1	RP11-507K2.3	-4.55	6.95e-06	0.00142	-0.25	-0.2	Coronary artery calcification;	chr14:88472857	chr14:88551597~88552493:+
LUAD	cis	rs2243480	0.666	rs1880311	ENSG00000164669.11	INTS4P1	-4.55	6.95e-06	0.00142	-0.38	-0.2	Diabetic kidney disease;	chr7:65811765	chr7:65141225~65234216:+
LUAD	cis	rs10246939	0.505	rs12703409	ENSG00000270923.1	TAS2R6P	-4.55	6.96e-06	0.00143	-0.24	-0.2	Bitter taste perception;	chr7:141812058	chr7:141787815~141788640:+
LUAD	cis	rs10895987	0.955	rs7113761	ENSG00000254614.2	AP003068.23	4.54	6.96e-06	0.00143	0.32	0.2	Blood protein levels;	chr11:65159251	chr11:65177606~65181834:-
LUAD	cis	rs6088590	0.965	rs6087639	ENSG00000276073.1	RP5-1125A11.7	-4.54	6.96e-06	0.00143	-0.21	-0.2	Coronary artery disease;	chr20:34856063	chr20:33985617~33988989:-
LUAD	cis	rs73242632	1	rs73242620	ENSG00000269949.1	RP11-738E22.3	4.54	6.97e-06	0.00143	0.48	0.2	Congenital heart disease (maternal effect);	chr4:56948884	chr4:56960927~56961373:-
LUAD	cis	rs17711722	0.653	rs2460421	ENSG00000237310.1	GS1-124K5.4	-4.54	6.97e-06	0.00143	-0.22	-0.2	Calcium levels;	chr7:66026136	chr7:66493706~66495474:+
LUAD	cis	rs11673344	0.832	rs77772684	ENSG00000226686.6	LINC01535	4.54	6.97e-06	0.00143	0.26	0.2	Obesity-related traits;	chr19:37055838	chr19:37251912~37265535:+
LUAD	cis	rs3096299	0.933	rs2965938	ENSG00000182376.2	RP5-1142A6.8	4.54	6.97e-06	0.00143	0.21	0.2	Multiple myeloma (IgH translocation);	chr16:89424928	chr16:88742767~88745748:+
LUAD	cis	rs17807185	0.653	rs9641271	ENSG00000214293.7	APTR	4.54	6.98e-06	0.00143	0.22	0.2	Height;	chr7:77668098	chr7:77657660~77696265:-
LUAD	cis	rs6763848	0.962	rs6795158	ENSG00000214073.2	RPL21P17	-4.54	6.98e-06	0.00143	-0.2	-0.2	Prostate cancer (SNP x SNP interaction);	chr3:1480703	chr3:1905651~1906125:+
LUAD	cis	rs11673344	0.797	rs3745768	ENSG00000226686.6	LINC01535	4.54	6.98e-06	0.00143	0.26	0.2	Obesity-related traits;	chr19:36997907	chr19:37251912~37265535:+
LUAD	cis	rs8077577	0.747	rs11872031	ENSG00000273018.4	CTD-2303H24.2	-4.54	6.98e-06	0.00143	-0.29	-0.2	Obesity-related traits;	chr17:18247500	chr17:18511221~18551705:-
LUAD	cis	rs7772486	0.521	rs9485017	ENSG00000235652.6	RP11-545I5.3	4.54	6.98e-06	0.00143	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145702190	chr6:145799409~145886585:+
LUAD	cis	rs2281603	0.951	rs1453004	ENSG00000259116.1	RP11-973N13.4	-4.54	6.98e-06	0.00143	-0.18	-0.2	Lymphocyte counts;	chr14:64530237	chr14:64514154~64540368:-
LUAD	cis	rs4664293	0.867	rs2059698	ENSG00000226266.5	AC009961.3	4.54	6.98e-06	0.00143	0.29	0.2	Monocyte percentage of white cells;	chr2:159785905	chr2:159670708~159712435:-
LUAD	cis	rs1062177	0.756	rs2964589	ENSG00000253921.1	CTB-113P19.3	4.54	6.99e-06	0.00143	0.3	0.2	Preschool internalizing problems;	chr5:151738628	chr5:151753992~151767247:+
LUAD	cis	rs9309473	0.607	rs2421488	ENSG00000163016.8	ALMS1P	4.54	6.99e-06	0.00143	0.23	0.2	Metabolite levels;	chr2:73363497	chr2:73644919~73685576:+
LUAD	cis	rs7760535	0.93	rs10872069	ENSG00000266032.1	AL357515.1	4.54	6.99e-06	0.00143	0.26	0.2	Metabolic traits;	chr6:111540523	chr6:110969773~110969872:-
LUAD	cis	rs761746	0.577	rs2012150	ENSG00000236132.1	CTA-440B3.1	-4.54	6.99e-06	0.00143	-0.26	-0.2	Intelligence;	chr22:31820153	chr22:31816379~31817491:-
LUAD	cis	rs944990	0.64	rs10821131	ENSG00000227603.1	RP11-165J3.6	4.54	7e-06	0.00143	0.23	0.2	Body mass index;	chr9:93466540	chr9:93435332~93437121:-
LUAD	cis	rs6840360	1	rs10023298	ENSG00000270265.1	RP11-731D1.4	-4.54	7e-06	0.00143	-0.2	-0.2	Intelligence (multi-trait analysis);	chr4:151745616	chr4:151333775~151353224:-
LUAD	cis	rs467650	0.553	rs469946	ENSG00000248489.1	CTD-2007H13.3	4.54	7e-06	0.00143	0.23	0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98653345	chr5:98929171~98995013:+
LUAD	cis	rs34779708	0.733	rs16935945	ENSG00000271335.4	RP11-324I22.4	4.54	7e-06	0.00143	0.22	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35251392	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.733	rs12777960	ENSG00000271335.4	RP11-324I22.4	4.54	7e-06	0.00143	0.22	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35252098	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.733	rs60553075	ENSG00000271335.4	RP11-324I22.4	4.54	7e-06	0.00143	0.22	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35253534	chr10:35314552~35336401:-
LUAD	cis	rs2446066	0.872	rs2002555	ENSG00000257379.1	RP11-793H13.8	4.54	7e-06	0.00143	0.35	0.2	Red blood cell count;	chr12:53423453	chr12:53441741~53467528:+
LUAD	cis	rs2288884	0.634	rs74476955	ENSG00000275055.1	CTC-471J1.11	-4.54	7.01e-06	0.00143	-0.33	-0.2	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51997806	chr19:52049007~52049754:+
LUAD	cis	rs2288884	0.596	rs12459638	ENSG00000275055.1	CTC-471J1.11	-4.54	7.01e-06	0.00143	-0.33	-0.2	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51998549	chr19:52049007~52049754:+
LUAD	cis	rs9322193	0.923	rs9688452	ENSG00000268592.3	RAET1E-AS1	4.54	7.01e-06	0.00144	0.25	0.2	Lung cancer;	chr6:149658764	chr6:149863494~149919507:+
LUAD	cis	rs2243480	1	rs313799	ENSG00000164669.11	INTS4P1	4.54	7.01e-06	0.00144	0.35	0.2	Diabetic kidney disease;	chr7:66029343	chr7:65141225~65234216:+
LUAD	cis	rs7937890	0.81	rs10734224	ENSG00000251991.1	RNU7-49P	4.54	7.01e-06	0.00144	0.21	0.2	Mitochondrial DNA levels;	chr11:14402578	chr11:14478892~14478953:+
LUAD	cis	rs17684571	0.872	rs13213878	ENSG00000231441.1	RP11-472M19.2	4.54	7.01e-06	0.00144	0.28	0.2	Schizophrenia;	chr6:56725043	chr6:56844002~56864078:+
LUAD	cis	rs2790457	0.833	rs1265847	ENSG00000254635.4	WAC-AS1	-4.54	7.01e-06	0.00144	-0.22	-0.2	Multiple myeloma;	chr10:28640757	chr10:28522652~28532743:-
LUAD	cis	rs6565189	0.865	rs4350585	ENSG00000273724.1	RP11-347C12.12	4.54	7.01e-06	0.00144	0.23	0.2	Tonsillectomy;	chr16:30494192	chr16:30336400~30343336:+
LUAD	cis	rs12468226	0.702	rs114634431	ENSG00000272966.1	RP11-686O6.1	4.54	7.02e-06	0.00144	0.34	0.2	Urate levels;	chr2:202142530	chr2:202336739~202337200:+
LUAD	cis	rs7727544	0.716	rs7720230	ENSG00000233006.5	AC034220.3	4.54	7.02e-06	0.00144	0.18	0.2	Blood metabolite levels;	chr5:132256712	chr5:132311285~132369916:-
LUAD	cis	rs11051970	0.545	rs2651374	ENSG00000274964.1	RP11-817I4.1	-4.54	7.02e-06	0.00144	-0.2	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr12:32429924	chr12:32339368~32340724:+
LUAD	cis	rs6840258	0.891	rs151451	ENSG00000251411.1	RP11-397E7.4	-4.54	7.02e-06	0.00144	-0.26	-0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87085215	chr4:86913266~86914817:-
LUAD	cis	rs1009115	0.551	rs7801567	ENSG00000272328.1	RP4-594A5.1	-4.54	7.02e-06	0.00144	-0.26	-0.2	Post bronchodilator FEV1;	chr7:8350988	chr7:8303741~8341343:+
LUAD	cis	rs4268898	0.76	rs55863105	ENSG00000223754.1	AC008073.9	-4.54	7.03e-06	0.00144	-0.24	-0.2	Asthma;	chr2:24347826	chr2:24199839~24201698:-
LUAD	cis	rs6723108	0.517	rs10928520	ENSG00000224043.6	CCNT2-AS1	-4.54	7.03e-06	0.00144	-0.25	-0.2	Type 2 diabetes;	chr2:134846613	chr2:134735464~134918710:-
LUAD	cis	rs801193	1	rs7785213	ENSG00000224316.1	RP11-479O9.2	-4.54	7.03e-06	0.00144	-0.2	-0.2	Aortic root size;	chr7:66673991	chr7:65773620~65802067:+
LUAD	cis	rs11051970	0.659	rs904917	ENSG00000274964.1	RP11-817I4.1	-4.54	7.03e-06	0.00144	-0.24	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr12:32438368	chr12:32339368~32340724:+
LUAD	cis	rs13113518	0.783	rs11133389	ENSG00000223305.1	RN7SKP30	4.54	7.03e-06	0.00144	0.24	0.2	Height;	chr4:55486718	chr4:55540502~55540835:-
LUAD	cis	rs13113518	0.812	rs4864543	ENSG00000223305.1	RN7SKP30	4.54	7.03e-06	0.00144	0.24	0.2	Height;	chr4:55490228	chr4:55540502~55540835:-
LUAD	cis	rs9532669	0.926	rs7799	ENSG00000239827.7	SUGT1P3	-4.54	7.03e-06	0.00144	-0.24	-0.2	Cervical cancer;	chr13:40958916	chr13:40908159~40921774:-
LUAD	cis	rs910316	1	rs10136948	ENSG00000279594.1	RP11-950C14.10	4.54	7.03e-06	0.00144	0.23	0.2	Height;	chr14:75044372	chr14:75011269~75012851:-
LUAD	cis	rs9876781	1	rs9849509	ENSG00000229759.1	MRPS18AP1	4.54	7.03e-06	0.00144	0.19	0.2	Longevity;	chr3:48442021	chr3:48256350~48256938:-
LUAD	cis	rs9876781	1	rs60512868	ENSG00000229759.1	MRPS18AP1	4.54	7.03e-06	0.00144	0.19	0.2	Longevity;	chr3:48442035	chr3:48256350~48256938:-
LUAD	cis	rs9876781	1	rs6442123	ENSG00000229759.1	MRPS18AP1	4.54	7.03e-06	0.00144	0.19	0.2	Longevity;	chr3:48458887	chr3:48256350~48256938:-
LUAD	cis	rs7829975	0.774	rs35039922	ENSG00000253981.4	ALG1L13P	4.54	7.04e-06	0.00144	0.24	0.2	Mood instability;	chr8:8817815	chr8:8236003~8244667:-
LUAD	cis	rs2153535	0.526	rs9505487	ENSG00000230939.1	RP11-314C16.1	-4.54	7.04e-06	0.00144	-0.23	-0.2	Motion sickness;	chr6:8593521	chr6:8784178~8785445:+
LUAD	cis	rs11673344	0.801	rs17707446	ENSG00000226686.6	LINC01535	-4.54	7.04e-06	0.00144	-0.27	-0.2	Obesity-related traits;	chr19:37092140	chr19:37251912~37265535:+
LUAD	cis	rs858239	0.601	rs7805206	ENSG00000226816.2	AC005082.12	4.54	7.05e-06	0.00144	0.25	0.2	Cerebrospinal fluid biomarker levels;	chr7:23120591	chr7:23206013~23208045:+
LUAD	cis	rs6570726	0.791	rs447992	ENSG00000235652.6	RP11-545I5.3	4.54	7.05e-06	0.00144	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145496048	chr6:145799409~145886585:+
LUAD	cis	rs2898681	0.614	rs4864680	ENSG00000248375.1	RP11-177B4.1	-4.54	7.05e-06	0.00144	-0.3	-0.2	Optic nerve measurement (cup area);	chr4:52842254	chr4:52720081~52720831:-
LUAD	cis	rs7044106	0.69	rs10739569	ENSG00000238181.2	AHCYP2	-4.54	7.06e-06	0.00144	-0.25	-0.2	Hip circumference adjusted for BMI;	chr9:120598749	chr9:120720673~120721972:+
LUAD	cis	rs875971	0.522	rs1701760	ENSG00000237310.1	GS1-124K5.4	4.54	7.06e-06	0.00145	0.22	0.2	Aortic root size;	chr7:66008701	chr7:66493706~66495474:+
LUAD	cis	rs62355900	0.627	rs58292679	ENSG00000271828.1	CTD-2310F14.1	4.54	7.06e-06	0.00145	0.38	0.2	Endometriosis;	chr5:56839989	chr5:56927874~56929573:+
LUAD	cis	rs62355900	0.627	rs16886400	ENSG00000271828.1	CTD-2310F14.1	4.54	7.06e-06	0.00145	0.38	0.2	Endometriosis;	chr5:56841605	chr5:56927874~56929573:+
LUAD	cis	rs62355900	0.627	rs61141156	ENSG00000271828.1	CTD-2310F14.1	4.54	7.06e-06	0.00145	0.38	0.2	Endometriosis;	chr5:56842951	chr5:56927874~56929573:+
LUAD	cis	rs62355900	0.627	rs58151318	ENSG00000271828.1	CTD-2310F14.1	4.54	7.06e-06	0.00145	0.38	0.2	Endometriosis;	chr5:56843355	chr5:56927874~56929573:+
LUAD	cis	rs8031584	0.652	rs2691683	ENSG00000270015.1	RP11-540B6.6	4.54	7.06e-06	0.00145	0.16	0.2	Huntington's disease progression;	chr15:30842857	chr15:30926514~30928407:+
LUAD	cis	rs12745968	0.623	rs1886684	ENSG00000223787.2	RP4-593M8.1	-4.54	7.06e-06	0.00145	-0.24	-0.2	Bipolar disorder and schizophrenia;	chr1:92510381	chr1:92580476~92580821:-
LUAD	cis	rs889398	0.683	rs8047682	ENSG00000226232.7	RP11-419C5.2	-4.54	7.07e-06	0.00145	-0.17	-0.2	Body mass index;	chr16:69879543	chr16:69976388~69996188:-
LUAD	cis	rs9322193	0.923	rs11155671	ENSG00000268592.3	RAET1E-AS1	4.54	7.07e-06	0.00145	0.25	0.2	Lung cancer;	chr6:149650996	chr6:149863494~149919507:+
LUAD	cis	rs2562456	0.833	rs7260065	ENSG00000268081.1	RP11-678G14.2	4.54	7.07e-06	0.00145	0.32	0.2	Pain;	chr19:21334175	chr19:21554640~21569237:-
LUAD	cis	rs17685	0.725	rs7795291	ENSG00000280388.1	RP11-229D13.3	-4.54	7.07e-06	0.00145	-0.19	-0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76095888	chr7:76043977~76045963:-
LUAD	cis	rs13256369	0.95	rs13270006	ENSG00000253893.2	FAM85B	-4.54	7.07e-06	0.00145	-0.28	-0.2	Obesity-related traits;	chr8:8716687	chr8:8167819~8226614:-
LUAD	cis	rs11673344	0.832	rs76781063	ENSG00000226686.6	LINC01535	4.54	7.07e-06	0.00145	0.26	0.2	Obesity-related traits;	chr19:37036040	chr19:37251912~37265535:+
LUAD	cis	rs11673344	0.618	rs4420645	ENSG00000226686.6	LINC01535	4.54	7.07e-06	0.00145	0.26	0.2	Obesity-related traits;	chr19:37054086	chr19:37251912~37265535:+
LUAD	cis	rs11673344	0.832	rs2011475	ENSG00000226686.6	LINC01535	4.54	7.07e-06	0.00145	0.26	0.2	Obesity-related traits;	chr19:37054712	chr19:37251912~37265535:+
LUAD	cis	rs17685	0.712	rs10271413	ENSG00000280388.1	RP11-229D13.3	-4.54	7.07e-06	0.00145	-0.19	-0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76125540	chr7:76043977~76045963:-
LUAD	cis	rs7302981	0.9	rs836179	ENSG00000200428.1	Y_RNA	-4.54	7.08e-06	0.00145	-0.25	-0.2	Systolic blood pressure;	chr12:50109299	chr12:50743568~50743684:+
LUAD	cis	rs8072100	0.713	rs2292346	ENSG00000228782.6	CTD-2026D20.3	4.54	7.08e-06	0.00145	0.22	0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378107	chr17:47450568~47492492:-
LUAD	cis	rs8072100	0.666	rs9913014	ENSG00000228782.6	CTD-2026D20.3	4.54	7.08e-06	0.00145	0.22	0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47382823	chr17:47450568~47492492:-
LUAD	cis	rs7829975	0.714	rs11784052	ENSG00000253893.2	FAM85B	-4.54	7.08e-06	0.00145	-0.25	-0.2	Mood instability;	chr8:8814452	chr8:8167819~8226614:-
LUAD	cis	rs2243480	1	rs34970380	ENSG00000226002.1	RP11-460N20.5	-4.54	7.08e-06	0.00145	-0.35	-0.2	Diabetic kidney disease;	chr7:65966506	chr7:65084103~65100232:+
LUAD	cis	rs2243480	0.901	rs73148097	ENSG00000226002.1	RP11-460N20.5	-4.54	7.08e-06	0.00145	-0.35	-0.2	Diabetic kidney disease;	chr7:65966800	chr7:65084103~65100232:+
LUAD	cis	rs9545047	0.604	rs2057573	ENSG00000227354.5	RBM26-AS1	-4.54	7.08e-06	0.00145	-0.21	-0.2	Schizophrenia;	chr13:79357736	chr13:79406309~79424328:+
LUAD	cis	rs301901	0.796	rs11742177	ENSG00000250155.1	CTD-2353F22.1	4.54	7.09e-06	0.00145	0.21	0.2	Height;	chr5:37504063	chr5:36666214~36725195:-
LUAD	cis	rs4789693	0.808	rs12935995	ENSG00000265458.1	RP13-20L14.6	4.54	7.09e-06	0.00145	0.29	0.2	Glucocorticoid-induced osteonecrosis;	chr17:82437007	chr17:82454273~82458521:-
LUAD	cis	rs7829975	0.624	rs7823056	ENSG00000173295.6	FAM86B3P	4.54	7.09e-06	0.00145	0.22	0.2	Mood instability;	chr8:8525195	chr8:8228595~8244865:+
LUAD	cis	rs1707322	1	rs12077974	ENSG00000280836.1	AL355480.1	-4.54	7.09e-06	0.00145	-0.27	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45918469	chr1:45581219~45581321:-
LUAD	cis	rs9876781	0.559	rs7630053	ENSG00000229759.1	MRPS18AP1	4.54	7.1e-06	0.00145	0.2	0.2	Longevity;	chr3:48357096	chr3:48256350~48256938:-
LUAD	cis	rs9876781	0.559	rs11130167	ENSG00000229759.1	MRPS18AP1	4.54	7.1e-06	0.00145	0.2	0.2	Longevity;	chr3:48358570	chr3:48256350~48256938:-
LUAD	cis	rs9876781	0.559	rs13073692	ENSG00000229759.1	MRPS18AP1	4.54	7.1e-06	0.00145	0.2	0.2	Longevity;	chr3:48361812	chr3:48256350~48256938:-
LUAD	cis	rs9876781	0.559	rs7611415	ENSG00000229759.1	MRPS18AP1	4.54	7.1e-06	0.00145	0.2	0.2	Longevity;	chr3:48363659	chr3:48256350~48256938:-
LUAD	cis	rs7829975	0.582	rs448231	ENSG00000253893.2	FAM85B	4.54	7.1e-06	0.00145	0.26	0.2	Mood instability;	chr8:8932549	chr8:8167819~8226614:-
LUAD	cis	rs6840360	0.571	rs11940881	ENSG00000270265.1	RP11-731D1.4	-4.54	7.1e-06	0.00145	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151579898	chr4:151333775~151353224:-
LUAD	cis	rs6714710	0.58	rs11690737	ENSG00000230606.9	AC159540.1	-4.54	7.1e-06	0.00145	-0.21	-0.2	Posterior cortical atrophy and Alzheimer's disease;	chr2:97845490	chr2:97416165~97433527:-
LUAD	cis	rs561341	0.505	rs548298	ENSG00000265798.5	RP11-271K11.5	4.54	7.1e-06	0.00145	0.3	0.2	Hip circumference adjusted for BMI;	chr17:31970475	chr17:31038575~31059121:-
LUAD	cis	rs561341	0.714	rs547473	ENSG00000265798.5	RP11-271K11.5	4.54	7.1e-06	0.00145	0.3	0.2	Hip circumference adjusted for BMI;	chr17:31970541	chr17:31038575~31059121:-
LUAD	cis	rs561341	1	rs546519	ENSG00000265798.5	RP11-271K11.5	4.54	7.1e-06	0.00145	0.3	0.2	Hip circumference adjusted for BMI;	chr17:31970663	chr17:31038575~31059121:-
LUAD	cis	rs35264875	0.808	rs921675	ENSG00000259799.1	RP11-554A11.9	-4.54	7.1e-06	0.00145	-0.26	-0.2	Blond vs. brown hair color;	chr11:69101566	chr11:69155910~69159752:+
LUAD	cis	rs4811196	0.748	rs4811279	ENSG00000226144.2	RPS27AP3	-4.54	7.1e-06	0.00145	-0.23	-0.2	Bone mineral density;	chr20:37887522	chr20:37049254~37049707:+
LUAD	cis	rs875971	0.929	rs10950041	ENSG00000232559.3	GS1-124K5.12	4.54	7.1e-06	0.00145	0.24	0.2	Aortic root size;	chr7:66508888	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.929	rs6970860	ENSG00000232559.3	GS1-124K5.12	4.54	7.1e-06	0.00145	0.24	0.2	Aortic root size;	chr7:66511647	chr7:66554588~66576923:-
LUAD	cis	rs748404	0.697	rs473016	ENSG00000249839.1	AC011330.5	-4.54	7.11e-06	0.00145	-0.26	-0.2	Lung cancer;	chr15:43266625	chr15:43663654~43684339:-
LUAD	cis	rs875971	0.895	rs1974769	ENSG00000232559.3	GS1-124K5.12	4.54	7.11e-06	0.00145	0.24	0.2	Aortic root size;	chr7:66485627	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.895	rs6460300	ENSG00000232559.3	GS1-124K5.12	4.54	7.11e-06	0.00145	0.24	0.2	Aortic root size;	chr7:66487937	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs7803416	ENSG00000232559.3	GS1-124K5.12	4.54	7.11e-06	0.00145	0.24	0.2	Aortic root size;	chr7:66489212	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.862	rs1981799	ENSG00000232559.3	GS1-124K5.12	4.54	7.11e-06	0.00145	0.24	0.2	Aortic root size;	chr7:66490572	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.964	rs2277911	ENSG00000232559.3	GS1-124K5.12	4.54	7.11e-06	0.00145	0.24	0.2	Aortic root size;	chr7:66493638	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.964	rs6978429	ENSG00000232559.3	GS1-124K5.12	4.54	7.11e-06	0.00145	0.24	0.2	Aortic root size;	chr7:66494889	chr7:66554588~66576923:-
LUAD	cis	rs875971	1	rs4718357	ENSG00000232559.3	GS1-124K5.12	4.54	7.11e-06	0.00145	0.24	0.2	Aortic root size;	chr7:66495891	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.929	rs12535036	ENSG00000232559.3	GS1-124K5.12	4.54	7.11e-06	0.00145	0.24	0.2	Aortic root size;	chr7:66499076	chr7:66554588~66576923:-
LUAD	cis	rs875971	1	rs12533997	ENSG00000232559.3	GS1-124K5.12	4.54	7.11e-06	0.00145	0.24	0.2	Aortic root size;	chr7:66500390	chr7:66554588~66576923:-
LUAD	cis	rs875971	1	rs12698523	ENSG00000232559.3	GS1-124K5.12	4.54	7.11e-06	0.00145	0.24	0.2	Aortic root size;	chr7:66503126	chr7:66554588~66576923:-
LUAD	cis	rs875971	1	rs6970030	ENSG00000232559.3	GS1-124K5.12	4.54	7.11e-06	0.00145	0.24	0.2	Aortic root size;	chr7:66503692	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.928	rs6970357	ENSG00000232559.3	GS1-124K5.12	4.54	7.11e-06	0.00145	0.24	0.2	Aortic root size;	chr7:66503891	chr7:66554588~66576923:-
LUAD	cis	rs2933343	0.621	rs883843	ENSG00000231305.3	RP11-723O4.2	-4.54	7.11e-06	0.00145	-0.22	-0.2	IgG glycosylation;	chr3:128848540	chr3:128861313~128871540:-
LUAD	cis	rs4713118	0.513	rs149955	ENSG00000216901.1	AL022393.7	4.54	7.11e-06	0.00145	0.25	0.2	Parkinson's disease;	chr6:28068447	chr6:28176188~28176674:+
LUAD	cis	rs2742234	0.541	rs10793422	ENSG00000273008.1	RP11-351D16.3	4.54	7.11e-06	0.00145	0.24	0.2	Hirschsprung disease;	chr10:43208426	chr10:43136824~43138334:-
LUAD	cis	rs35740288	0.929	rs11556865	ENSG00000259407.1	RP11-158M2.3	-4.54	7.11e-06	0.00145	-0.2	-0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85759949	chr15:85744109~85750281:-
LUAD	cis	rs889398	0.741	rs3790075	ENSG00000226232.7	RP11-419C5.2	-4.54	7.11e-06	0.00145	-0.17	-0.2	Body mass index;	chr16:69873908	chr16:69976388~69996188:-
LUAD	cis	rs889398	0.741	rs7190013	ENSG00000226232.7	RP11-419C5.2	-4.54	7.11e-06	0.00145	-0.17	-0.2	Body mass index;	chr16:69874345	chr16:69976388~69996188:-
LUAD	cis	rs748404	0.723	rs573169	ENSG00000249839.1	AC011330.5	-4.54	7.11e-06	0.00145	-0.26	-0.2	Lung cancer;	chr15:43258383	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.697	rs524547	ENSG00000249839.1	AC011330.5	-4.54	7.11e-06	0.00145	-0.26	-0.2	Lung cancer;	chr15:43258825	chr15:43663654~43684339:-
LUAD	cis	rs9425766	0.679	rs7533430	ENSG00000227373.4	RP11-160H22.5	4.54	7.11e-06	0.00145	0.25	0.2	Life satisfaction;	chr1:174109279	chr1:174115300~174160004:-
LUAD	cis	rs8031584	1	rs35239376	ENSG00000270015.1	RP11-540B6.6	-4.54	7.12e-06	0.00145	-0.16	-0.2	Huntington's disease progression;	chr15:30998335	chr15:30926514~30928407:+
LUAD	cis	rs4811196	0.748	rs910759	ENSG00000226144.2	RPS27AP3	4.54	7.12e-06	0.00145	0.23	0.2	Bone mineral density;	chr20:37870525	chr20:37049254~37049707:+
LUAD	cis	rs4811196	0.748	rs1884502	ENSG00000226144.2	RPS27AP3	4.54	7.12e-06	0.00145	0.23	0.2	Bone mineral density;	chr20:37870836	chr20:37049254~37049707:+
LUAD	cis	rs4811196	0.748	rs910760	ENSG00000226144.2	RPS27AP3	4.54	7.12e-06	0.00145	0.23	0.2	Bone mineral density;	chr20:37871593	chr20:37049254~37049707:+
LUAD	cis	rs9473147	0.543	rs9369716	ENSG00000270761.1	RP11-385F7.1	-4.54	7.12e-06	0.00146	-0.24	-0.2	Platelet distribution width;Mean platelet volume;	chr6:47584444	chr6:47477243~47477572:-
LUAD	cis	rs1551277	0.916	rs2348459	ENSG00000146666.5	LINC00525	4.54	7.12e-06	0.00146	0.23	0.2	Anxiety disorder;	chr7:47795518	chr7:47761476~47766772:+
LUAD	cis	rs9876781	0.53	rs11708617	ENSG00000229759.1	MRPS18AP1	4.54	7.13e-06	0.00146	0.2	0.2	Longevity;	chr3:48354819	chr3:48256350~48256938:-
LUAD	cis	rs12754538	1	rs12754538	ENSG00000232912.4	RP5-1115A15.1	-4.54	7.13e-06	0.00146	-0.21	-0.2	Subjective well-being;	chr1:8413753	chr1:8424645~8434838:+
LUAD	cis	rs3096299	0.685	rs8050512	ENSG00000182376.2	RP5-1142A6.8	4.54	7.13e-06	0.00146	0.21	0.2	Multiple myeloma (IgH translocation);	chr16:89485912	chr16:88742767~88745748:+
LUAD	cis	rs227275	0.527	rs223338	ENSG00000251288.2	RP11-10L12.2	-4.54	7.13e-06	0.00146	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102864959	chr4:102751401~102752641:+
LUAD	cis	rs9322193	0.886	rs4870049	ENSG00000268592.3	RAET1E-AS1	4.54	7.13e-06	0.00146	0.25	0.2	Lung cancer;	chr6:149837058	chr6:149863494~149919507:+
LUAD	cis	rs1113500	0.73	rs1781080	ENSG00000226822.1	RP11-356N1.2	-4.54	7.14e-06	0.00146	-0.22	-0.2	Growth-regulated protein alpha levels;	chr1:108050793	chr1:108071482~108074519:+
LUAD	cis	rs4865169	0.56	rs1277311	ENSG00000269949.1	RP11-738E22.3	4.54	7.14e-06	0.00146	0.26	0.2	Breast cancer;	chr4:57036595	chr4:56960927~56961373:-
LUAD	cis	rs4865169	0.56	rs1277312	ENSG00000269949.1	RP11-738E22.3	4.54	7.14e-06	0.00146	0.26	0.2	Breast cancer;	chr4:57036779	chr4:56960927~56961373:-
LUAD	cis	rs4873772	0.735	rs4873437	ENSG00000253330.1	RP11-697N18.3	-4.54	7.14e-06	0.00146	-0.23	-0.2	Lobe attachment (rater-scored or self-reported);	chr8:47531194	chr8:47511034~47512141:-
LUAD	cis	rs6723108	0.603	rs6733130	ENSG00000224043.6	CCNT2-AS1	-4.54	7.14e-06	0.00146	-0.25	-0.2	Type 2 diabetes;	chr2:134908983	chr2:134735464~134918710:-
LUAD	cis	rs6723108	0.627	rs1374287	ENSG00000224043.6	CCNT2-AS1	-4.54	7.14e-06	0.00146	-0.25	-0.2	Type 2 diabetes;	chr2:134909631	chr2:134735464~134918710:-
LUAD	cis	rs801193	1	rs11773829	ENSG00000224316.1	RP11-479O9.2	-4.54	7.14e-06	0.00146	-0.2	-0.2	Aortic root size;	chr7:66676087	chr7:65773620~65802067:+
LUAD	cis	rs4819052	1	rs2297285	ENSG00000237664.1	LINC00316	4.54	7.14e-06	0.00146	0.27	0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285706	chr21:45338590~45341990:-
LUAD	cis	rs301901	0.796	rs3941788	ENSG00000250155.1	CTD-2353F22.1	4.54	7.15e-06	0.00146	0.21	0.2	Height;	chr5:37498809	chr5:36666214~36725195:-
LUAD	cis	rs984222	0.508	rs2645303	ENSG00000231365.4	RP11-418J17.1	-4.54	7.15e-06	0.00146	-0.24	-0.2	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119012523	chr1:119140396~119275973:+
LUAD	cis	rs1355223	0.902	rs1588353	ENSG00000271369.1	RP11-350D17.3	-4.54	7.15e-06	0.00146	-0.24	-0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34709267	chr11:34709600~34710161:+
LUAD	cis	rs12908161	0.959	rs34342559	ENSG00000259295.5	CSPG4P12	4.54	7.15e-06	0.00146	0.29	0.2	Schizophrenia;	chr15:84788040	chr15:85191438~85213905:+
LUAD	cis	rs12908161	0.959	rs35557864	ENSG00000259295.5	CSPG4P12	4.54	7.15e-06	0.00146	0.29	0.2	Schizophrenia;	chr15:84788398	chr15:85191438~85213905:+
LUAD	cis	rs9545047	0.604	rs2274555	ENSG00000227354.5	RBM26-AS1	-4.54	7.15e-06	0.00146	-0.21	-0.2	Schizophrenia;	chr13:79344188	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs9565491	ENSG00000227354.5	RBM26-AS1	-4.54	7.15e-06	0.00146	-0.21	-0.2	Schizophrenia;	chr13:79346037	chr13:79406309~79424328:+
LUAD	cis	rs12439619	0.846	rs62011975	ENSG00000276710.3	CSPG4P8	-4.54	7.15e-06	0.00146	-0.23	-0.2	Intelligence (multi-trait analysis);	chr15:82159213	chr15:82459472~82477258:+
LUAD	cis	rs801193	0.967	rs3800823	ENSG00000236529.1	RP13-254B10.1	-4.54	7.15e-06	0.00146	-0.21	-0.2	Aortic root size;	chr7:66682123	chr7:65840212~65840596:+
LUAD	cis	rs6539288	0.933	rs10861672	ENSG00000260329.1	RP11-412D9.4	-4.54	7.15e-06	0.00146	-0.22	-0.2	Total body bone mineral density;	chr12:106906222	chr12:106954029~106955497:-
LUAD	cis	rs9322193	0.962	rs9478848	ENSG00000268592.3	RAET1E-AS1	4.54	7.16e-06	0.00146	0.25	0.2	Lung cancer;	chr6:149825080	chr6:149863494~149919507:+
LUAD	cis	rs301901	0.772	rs7735138	ENSG00000250155.1	CTD-2353F22.1	-4.54	7.16e-06	0.00146	-0.22	-0.2	Height;	chr5:37239138	chr5:36666214~36725195:-
LUAD	cis	rs2281636	0.723	rs11190246	ENSG00000233690.1	EBAG9P1	4.54	7.16e-06	0.00146	0.21	0.2	Obesity-related traits;	chr10:99691854	chr10:99697407~99697949:-
LUAD	cis	rs12439619	0.846	rs28470877	ENSG00000276710.3	CSPG4P8	-4.54	7.17e-06	0.00146	-0.23	-0.2	Intelligence (multi-trait analysis);	chr15:82245797	chr15:82459472~82477258:+
LUAD	cis	rs9322193	0.923	rs10782315	ENSG00000268592.3	RAET1E-AS1	4.54	7.17e-06	0.00147	0.25	0.2	Lung cancer;	chr6:149743093	chr6:149863494~149919507:+
LUAD	cis	rs1023500	0.505	rs134886	ENSG00000205702.9	CYP2D7	-4.54	7.18e-06	0.00147	-0.16	-0.2	Schizophrenia;	chr22:42277850	chr22:42140203~42144577:-
LUAD	cis	rs950169	0.8	rs4842847	ENSG00000275120.1	RP11-182J1.17	4.54	7.18e-06	0.00147	0.32	0.2	Schizophrenia;	chr15:84262447	chr15:84599434~84606463:-
LUAD	cis	rs2115630	1	rs4633690	ENSG00000225151.9	GOLGA2P7	4.54	7.18e-06	0.00147	0.23	0.2	P wave terminal force;	chr15:84818729	chr15:84199311~84230136:-
LUAD	cis	rs16873450	0.527	rs12539789	ENSG00000234800.2	PCMTD1P3	4.54	7.18e-06	0.00147	0.23	0.2	Verbal memory performance (residualized delayed recall level);	chr7:23736797	chr7:23721311~23721782:-
LUAD	cis	rs16873450	0.527	rs10234251	ENSG00000234800.2	PCMTD1P3	4.54	7.18e-06	0.00147	0.23	0.2	Verbal memory performance (residualized delayed recall level);	chr7:23741022	chr7:23721311~23721782:-
LUAD	cis	rs6840360	0.615	rs6858483	ENSG00000270265.1	RP11-731D1.4	-4.54	7.18e-06	0.00147	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151544357	chr4:151333775~151353224:-
LUAD	cis	rs10129255	0.701	rs2005643	ENSG00000211974.3	IGHV2-70	4.54	7.18e-06	0.00147	0.21	0.2	Kawasaki disease;	chr14:106676288	chr14:106723574~106724093:-
LUAD	cis	rs4268898	0.76	rs11125535	ENSG00000223754.1	AC008073.9	-4.54	7.18e-06	0.00147	-0.24	-0.2	Asthma;	chr2:24305245	chr2:24199839~24201698:-
LUAD	cis	rs1008375	0.966	rs6832962	ENSG00000249502.1	AC006160.5	-4.54	7.18e-06	0.00147	-0.2	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17650510	chr4:17587467~17614571:-
LUAD	cis	rs228614	0.51	rs223412	ENSG00000251288.2	RP11-10L12.2	-4.54	7.18e-06	0.00147	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102812443	chr4:102751401~102752641:+
LUAD	cis	rs9813712	0.526	rs62281641	ENSG00000228252.7	COL6A4P2	-4.54	7.18e-06	0.00147	-0.19	-0.2	Response to amphetamines;	chr3:130235668	chr3:130212823~130273806:+
LUAD	cis	rs9322193	0.923	rs9689716	ENSG00000268592.3	RAET1E-AS1	4.54	7.19e-06	0.00147	0.25	0.2	Lung cancer;	chr6:149655662	chr6:149863494~149919507:+
LUAD	cis	rs6125961	0.598	rs6067395	ENSG00000224397.4	LINC01272	-4.54	7.19e-06	0.00147	-0.26	-0.2	Granulocyte percentage of myeloid white cells;Monocyte count;	chr20:50297049	chr20:50267486~50279795:+
LUAD	cis	rs7819412	0.715	rs35223712	ENSG00000255046.1	RP11-297N6.4	4.54	7.19e-06	0.00147	0.24	0.2	Triglycerides;	chr8:11186417	chr8:11797928~11802568:-
LUAD	cis	rs7178375	1	rs4779797	ENSG00000270015.1	RP11-540B6.6	-4.54	7.19e-06	0.00147	-0.19	-0.2	Hypertriglyceridemia;	chr15:30916222	chr15:30926514~30928407:+
LUAD	cis	rs1355223	0.902	rs1597962	ENSG00000271369.1	RP11-350D17.3	-4.54	7.19e-06	0.00147	-0.24	-0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34705625	chr11:34709600~34710161:+
LUAD	cis	rs800160	0.777	rs962903	ENSG00000236264.4	RPL26P30	-4.54	7.19e-06	0.00147	-0.28	-0.2	Bacteremia;	chr11:2331111	chr11:2335132~2335776:-
LUAD	cis	rs7773456	0.74	rs6917179	ENSG00000228412.5	RP4-625H18.2	-4.54	7.19e-06	0.00147	-0.26	-0.2	Lupus nephritis in systemic lupus erythematosus;	chr6:19817570	chr6:19802164~19804752:-
LUAD	cis	rs2929278	0.561	rs3099045	ENSG00000166763.7	STRCP1	4.54	7.2e-06	0.00147	0.24	0.2	Schizophrenia;	chr15:43631757	chr15:43699488~43718184:-
LUAD	cis	rs7937890	0.599	rs2597204	ENSG00000251991.1	RNU7-49P	4.54	7.2e-06	0.00147	0.23	0.2	Mitochondrial DNA levels;	chr11:14459471	chr11:14478892~14478953:+
LUAD	cis	rs801193	1	rs10252765	ENSG00000224316.1	RP11-479O9.2	4.54	7.2e-06	0.00147	0.2	0.2	Aortic root size;	chr7:66763745	chr7:65773620~65802067:+
LUAD	cis	rs11673344	0.764	rs826303	ENSG00000226686.6	LINC01535	4.54	7.2e-06	0.00147	0.26	0.2	Obesity-related traits;	chr19:36951549	chr19:37251912~37265535:+
LUAD	cis	rs2348418	0.864	rs7957495	ENSG00000244712.1	RP11-874G11.1	-4.54	7.2e-06	0.00147	-0.24	-0.2	Lung function (FEV1);Lung function (FVC);	chr12:28564522	chr12:28564678~28565141:-
LUAD	cis	rs11673344	0.832	rs11084871	ENSG00000226686.6	LINC01535	4.54	7.2e-06	0.00147	0.26	0.2	Obesity-related traits;	chr19:37042023	chr19:37251912~37265535:+
LUAD	cis	rs12745968	0.653	rs6604013	ENSG00000223787.2	RP4-593M8.1	-4.54	7.2e-06	0.00147	-0.24	-0.2	Bipolar disorder and schizophrenia;	chr1:92726577	chr1:92580476~92580821:-
LUAD	cis	rs11009175	0.929	rs7094668	ENSG00000273038.2	RP11-479G22.8	-4.54	7.2e-06	0.00147	-0.32	-0.2	Depression (quantitative trait);	chr10:33054429	chr10:32887255~32889311:-
LUAD	cis	rs6762	0.748	rs7929032	ENSG00000279672.1	CMB9-55F22.1	4.54	7.2e-06	0.00147	0.22	0.2	Mean platelet volume;	chr11:839078	chr11:779617~780755:+
LUAD	cis	rs6762	0.748	rs7936838	ENSG00000279672.1	CMB9-55F22.1	4.54	7.2e-06	0.00147	0.22	0.2	Mean platelet volume;	chr11:839093	chr11:779617~780755:+
LUAD	cis	rs7119	0.717	rs12902896	ENSG00000259362.2	RP11-307C19.1	4.54	7.2e-06	0.00147	0.25	0.2	Type 2 diabetes;	chr15:77516808	chr15:77525540~77534110:+
LUAD	cis	rs11168187	0.506	rs12812960	ENSG00000280054.1	RP1-197B17.7	4.54	7.2e-06	0.00147	0.28	0.2	Vertical cup-disc ratio;	chr12:47729395	chr12:47728151~47730598:-
LUAD	cis	rs2243480	1	rs1964692	ENSG00000164669.11	INTS4P1	4.54	7.21e-06	0.00147	0.36	0.2	Diabetic kidney disease;	chr7:65989196	chr7:65141225~65234216:+
LUAD	cis	rs7665090	0.905	rs2866410	ENSG00000246560.2	RP11-10L12.4	4.54	7.21e-06	0.00147	0.25	0.2	Primary biliary cholangitis;	chr4:102633178	chr4:102828055~102844075:+
LUAD	cis	rs7665090	0.936	rs2866411	ENSG00000246560.2	RP11-10L12.4	4.54	7.21e-06	0.00147	0.25	0.2	Primary biliary cholangitis;	chr4:102633183	chr4:102828055~102844075:+
LUAD	cis	rs6570726	0.791	rs1935612	ENSG00000235652.6	RP11-545I5.3	4.54	7.21e-06	0.00147	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145584954	chr6:145799409~145886585:+
LUAD	cis	rs477895	0.653	rs2015226	ENSG00000236935.1	AP003774.1	-4.54	7.21e-06	0.00147	-0.25	-0.2	Mean platelet volume;	chr11:64135062	chr11:64325050~64329504:-
LUAD	cis	rs477895	0.653	rs2875749	ENSG00000236935.1	AP003774.1	-4.54	7.21e-06	0.00147	-0.25	-0.2	Mean platelet volume;	chr11:64136406	chr11:64325050~64329504:-
LUAD	cis	rs4811196	0.748	rs4811246	ENSG00000226144.2	RPS27AP3	-4.54	7.21e-06	0.00147	-0.22	-0.2	Bone mineral density;	chr20:37867355	chr20:37049254~37049707:+
LUAD	cis	rs7260598	0.535	rs13343732	ENSG00000269397.1	CTB-92J24.2	-4.54	7.22e-06	0.00147	-0.28	-0.2	Response to taxane treatment (placlitaxel);	chr19:23928479	chr19:23927788~23929287:+
LUAD	cis	rs10938353	0.638	rs11732880	ENSG00000273369.1	RP11-700J17.1	-4.54	7.22e-06	0.00147	-0.26	-0.2	Body mass index;	chr4:44673497	chr4:44693946~44694386:-
LUAD	cis	rs6570726	0.791	rs425999	ENSG00000235652.6	RP11-545I5.3	4.54	7.23e-06	0.00147	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145498234	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.791	rs387376	ENSG00000235652.6	RP11-545I5.3	4.54	7.23e-06	0.00147	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145501429	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.764	rs1912023	ENSG00000235652.6	RP11-545I5.3	4.54	7.23e-06	0.00147	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145503142	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.791	rs9376945	ENSG00000235652.6	RP11-545I5.3	4.54	7.23e-06	0.00147	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145506944	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.755	rs451699	ENSG00000235652.6	RP11-545I5.3	4.54	7.23e-06	0.00147	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145509458	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.791	rs401561	ENSG00000235652.6	RP11-545I5.3	4.54	7.23e-06	0.00147	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145514781	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.791	rs405206	ENSG00000235652.6	RP11-545I5.3	4.54	7.23e-06	0.00147	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145515737	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.791	rs374478	ENSG00000235652.6	RP11-545I5.3	4.54	7.23e-06	0.00147	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145518886	chr6:145799409~145886585:+
LUAD	cis	rs9322193	0.962	rs4380763	ENSG00000268592.3	RAET1E-AS1	4.54	7.23e-06	0.00147	0.25	0.2	Lung cancer;	chr6:149678086	chr6:149863494~149919507:+
LUAD	cis	rs6061231	1	rs6061231	ENSG00000273619.1	RP5-908M14.9	-4.54	7.23e-06	0.00147	-0.21	-0.2	Colorectal cancer;	chr20:62381861	chr20:62386303~62386970:-
LUAD	cis	rs761746	0.577	rs5998136	ENSG00000236132.1	CTA-440B3.1	-4.54	7.23e-06	0.00148	-0.26	-0.2	Intelligence;	chr22:31828687	chr22:31816379~31817491:-
LUAD	cis	rs875971	0.642	rs35526611	ENSG00000224316.1	RP11-479O9.2	-4.54	7.23e-06	0.00148	-0.2	-0.2	Aortic root size;	chr7:66629021	chr7:65773620~65802067:+
LUAD	cis	rs9425766	0.732	rs6658543	ENSG00000227373.4	RP11-160H22.5	4.54	7.24e-06	0.00148	0.25	0.2	Life satisfaction;	chr1:174183338	chr1:174115300~174160004:-
LUAD	cis	rs9545047	0.604	rs3187338	ENSG00000227354.5	RBM26-AS1	4.54	7.24e-06	0.00148	0.21	0.2	Schizophrenia;	chr13:79320601	chr13:79406309~79424328:+
LUAD	cis	rs16873450	0.9	rs7782389	ENSG00000234800.2	PCMTD1P3	4.54	7.25e-06	0.00148	0.24	0.2	Verbal memory performance (residualized delayed recall level);	chr7:23788469	chr7:23721311~23721782:-
LUAD	cis	rs7172677	0.96	rs8026273	ENSG00000260269.4	CTD-2323K18.1	-4.54	7.25e-06	0.00148	-0.27	-0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75121425	chr15:75527150~75601205:-
LUAD	cis	rs1722141	0.633	rs788717	ENSG00000229628.1	AC073115.7	4.54	7.25e-06	0.00148	0.3	0.2	Sitting height ratio;	chr7:45964897	chr7:45990905~46000898:+
LUAD	cis	rs6969780	1	rs73071550	ENSG00000233429.8	HOTAIRM1	4.54	7.26e-06	0.00148	0.35	0.2	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27109480	chr7:27095647~27100265:+
LUAD	cis	rs6969780	1	rs6461985	ENSG00000233429.8	HOTAIRM1	4.54	7.26e-06	0.00148	0.35	0.2	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27111015	chr7:27095647~27100265:+
LUAD	cis	rs516805	0.528	rs2684235	ENSG00000279453.1	RP3-425C14.4	4.54	7.26e-06	0.00148	0.26	0.2	Lymphocyte counts;	chr6:122082083	chr6:122436789~122439223:-
LUAD	cis	rs6570726	0.791	rs6570692	ENSG00000235652.6	RP11-545I5.3	4.54	7.26e-06	0.00148	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145583265	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.791	rs6902410	ENSG00000235652.6	RP11-545I5.3	4.54	7.26e-06	0.00148	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145584125	chr6:145799409~145886585:+
LUAD	cis	rs10875976	0.704	rs11169167	ENSG00000257464.1	RP11-161H23.8	4.54	7.26e-06	0.00148	0.19	0.2	Obesity;	chr12:49823018	chr12:49442424~49442652:-
LUAD	cis	rs4927850	0.521	rs4927679	ENSG00000207650.1	MIR570	-4.54	7.26e-06	0.00148	-0.19	-0.2	Pancreatic cancer;	chr3:195931489	chr3:195699401~195699497:+
LUAD	cis	rs2735413	0.75	rs76833828	ENSG00000276007.1	RP11-358L22.3	4.54	7.26e-06	0.00148	0.25	0.2	Systolic blood pressure (alcohol consumption interaction);	chr16:78037098	chr16:78123243~78124332:+
LUAD	cis	rs227275	0.525	rs13113923	ENSG00000251288.2	RP11-10L12.2	-4.54	7.27e-06	0.00148	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102918936	chr4:102751401~102752641:+
LUAD	cis	rs858239	0.796	rs433395	ENSG00000230042.1	AK3P3	-4.54	7.27e-06	0.00148	-0.25	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23362336	chr7:23129178~23129841:+
LUAD	cis	rs41369048	0.669	rs111238725	ENSG00000272823.1	RP11-295M18.6	-4.54	7.27e-06	0.00148	-0.3	-0.2	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220860320	chr1:220828676~220829211:-
LUAD	cis	rs875971	0.638	rs35986979	ENSG00000224316.1	RP11-479O9.2	-4.54	7.27e-06	0.00148	-0.2	-0.2	Aortic root size;	chr7:66624003	chr7:65773620~65802067:+
LUAD	cis	rs6951245	0.744	rs1133122	ENSG00000229043.2	AC091729.9	-4.54	7.28e-06	0.00148	-0.3	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1152936	chr7:1160374~1165267:+
LUAD	cis	rs11157436	0.918	rs7159024	ENSG00000211813.2	TRAV34	4.54	7.28e-06	0.00148	0.26	0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22228760	chr14:22207522~22208129:+
LUAD	cis	rs12439619	0.846	rs62012004	ENSG00000276710.3	CSPG4P8	-4.54	7.28e-06	0.00148	-0.23	-0.2	Intelligence (multi-trait analysis);	chr15:82183924	chr15:82459472~82477258:+
LUAD	cis	rs11155671	0.53	rs7768626	ENSG00000268592.3	RAET1E-AS1	4.54	7.28e-06	0.00148	0.25	0.2	Testicular germ cell tumor;	chr6:149886826	chr6:149863494~149919507:+
LUAD	cis	rs11155671	0.53	rs7768665	ENSG00000268592.3	RAET1E-AS1	4.54	7.28e-06	0.00148	0.25	0.2	Testicular germ cell tumor;	chr6:149886888	chr6:149863494~149919507:+
LUAD	cis	rs11155671	0.53	rs7758020	ENSG00000268592.3	RAET1E-AS1	4.54	7.28e-06	0.00148	0.25	0.2	Testicular germ cell tumor;	chr6:149886975	chr6:149863494~149919507:+
LUAD	cis	rs7208859	0.623	rs73267858	ENSG00000266490.1	CTD-2349P21.9	4.53	7.28e-06	0.00148	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732719	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs56095789	ENSG00000266490.1	CTD-2349P21.9	4.53	7.28e-06	0.00148	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733152	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs11656844	ENSG00000266490.1	CTD-2349P21.9	4.53	7.28e-06	0.00148	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733579	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs11652533	ENSG00000266490.1	CTD-2349P21.9	4.53	7.28e-06	0.00148	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733583	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs11652631	ENSG00000266490.1	CTD-2349P21.9	4.53	7.28e-06	0.00148	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733748	chr17:30792372~30792833:+
LUAD	cis	rs9487094	0.922	rs10782162	ENSG00000260273.1	RP11-425D10.10	-4.53	7.28e-06	0.00148	-0.28	-0.2	Height;	chr6:109485060	chr6:109382795~109383666:+
LUAD	cis	rs17772222	0.638	rs11159859	ENSG00000258789.1	RP11-507K2.3	-4.53	7.28e-06	0.00148	-0.24	-0.2	Coronary artery calcification;	chr14:88561547	chr14:88551597~88552493:+
LUAD	cis	rs8062405	0.69	rs6498089	ENSG00000251417.2	RP11-1348G14.4	4.53	7.28e-06	0.00148	0.2	0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28617979	chr16:28802743~28817828:+
LUAD	cis	rs7119038	0.509	rs11216956	ENSG00000255422.1	AP002954.4	4.53	7.28e-06	0.00148	0.31	0.2	Sjögren's syndrome;	chr11:118704617	chr11:118704607~118750263:+
LUAD	cis	rs875971	0.522	rs9530	ENSG00000237310.1	GS1-124K5.4	4.53	7.29e-06	0.00149	0.22	0.2	Aortic root size;	chr7:65960907	chr7:66493706~66495474:+
LUAD	cis	rs2243480	1	rs59794892	ENSG00000226002.1	RP11-460N20.5	-4.53	7.29e-06	0.00149	-0.34	-0.2	Diabetic kidney disease;	chr7:65950886	chr7:65084103~65100232:+
LUAD	cis	rs35740288	0.929	rs3858927	ENSG00000259407.1	RP11-158M2.3	-4.53	7.29e-06	0.00149	-0.2	-0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85758385	chr15:85744109~85750281:-
LUAD	cis	rs763121	0.889	rs1043402	ENSG00000228274.3	RP3-508I15.9	-4.53	7.29e-06	0.00149	-0.2	-0.2	Menopause (age at onset);	chr22:38483683	chr22:38667585~38681820:-
LUAD	cis	rs8127691	0.874	rs2838516	ENSG00000237604.1	AP001056.1	4.53	7.29e-06	0.00149	0.24	0.2	Inflammatory bowel disease;	chr21:44192592	chr21:44175489~44176453:+
LUAD	cis	rs2439831	0.85	rs8032649	ENSG00000249839.1	AC011330.5	4.53	7.3e-06	0.00149	0.4	0.2	Lung cancer in ever smokers;	chr15:43842724	chr15:43663654~43684339:-
LUAD	cis	rs11722779	0.844	rs3974602	ENSG00000251288.2	RP11-10L12.2	-4.53	7.3e-06	0.00149	-0.24	-0.2	Schizophrenia;	chr4:102928840	chr4:102751401~102752641:+
LUAD	cis	rs172166	0.637	rs1225597	ENSG00000216901.1	AL022393.7	4.53	7.3e-06	0.00149	0.24	0.2	Cardiac Troponin-T levels;	chr6:28194309	chr6:28176188~28176674:+
LUAD	cis	rs1008375	0.966	rs12503517	ENSG00000249502.1	AC006160.5	-4.53	7.3e-06	0.00149	-0.19	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17697102	chr4:17587467~17614571:-
LUAD	cis	rs42490	0.934	rs218947	ENSG00000251136.7	RP11-37B2.1	4.53	7.3e-06	0.00149	0.21	0.2	Leprosy;	chr8:89705148	chr8:89609409~89757727:-
LUAD	cis	rs4834770	0.668	rs1397610	ENSG00000245958.5	RP11-33B1.1	4.53	7.3e-06	0.00149	0.19	0.2	Blood protein levels;	chr4:119206606	chr4:119454791~119552025:+
LUAD	cis	rs7102710	1	rs7928209	ENSG00000254418.1	RP11-21L19.1	4.53	7.3e-06	0.00149	0.48	0.2	Glucagon levels in response to oral glucose tolerance test (fasting);	chr11:14249818	chr11:14262846~14273691:-
LUAD	cis	rs801193	0.935	rs3800820	ENSG00000224316.1	RP11-479O9.2	-4.53	7.31e-06	0.00149	-0.2	-0.2	Aortic root size;	chr7:66682191	chr7:65773620~65802067:+
LUAD	cis	rs4843747	0.749	rs13333619	ENSG00000205037.2	RP11-863P13.4	4.53	7.31e-06	0.00149	0.29	0.2	Menopause (age at onset);	chr16:88038470	chr16:88088041~88100985:-
LUAD	cis	rs11168351	0.927	rs10875716	ENSG00000240399.1	RP1-228P16.1	4.53	7.31e-06	0.00149	0.21	0.2	Bipolar disorder and schizophrenia;	chr12:47995240	chr12:48054813~48055591:-
LUAD	cis	rs6142102	1	rs12480839	ENSG00000275784.1	RP5-1125A11.6	-4.53	7.31e-06	0.00149	-0.22	-0.2	Skin pigmentation;	chr20:34139624	chr20:33989480~33991818:-
LUAD	cis	rs2288884	1	rs58817690	ENSG00000269959.1	SPACA6P-AS	-4.53	7.31e-06	0.00149	-0.27	-0.2	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52033439	chr19:51685363~51693456:-
LUAD	cis	rs16846053	0.642	rs1979112	ENSG00000227403.1	AC009299.3	4.53	7.32e-06	0.00149	0.34	0.2	Blood osmolality (transformed sodium);	chr2:161801445	chr2:161244739~161249050:+
LUAD	cis	rs7945705	0.875	rs11042059	ENSG00000254860.4	TMEM9B-AS1	-4.53	7.32e-06	0.00149	-0.24	-0.2	Hemoglobin concentration;	chr11:8773533	chr11:8964675~8977527:+
LUAD	cis	rs3770081	1	rs78032828	ENSG00000273080.1	RP11-301O19.1	-4.53	7.32e-06	0.00149	-0.48	-0.2	Facial emotion recognition (sad faces);	chr2:86081909	chr2:86195590~86196049:+
LUAD	cis	rs9322193	0.962	rs7745915	ENSG00000268592.3	RAET1E-AS1	4.53	7.33e-06	0.00149	0.25	0.2	Lung cancer;	chr6:149834111	chr6:149863494~149919507:+
LUAD	cis	rs9400467	0.528	rs459403	ENSG00000271789.1	RP5-1112D6.7	-4.53	7.33e-06	0.00149	-0.21	-0.2	Amino acid levels;Blood metabolite levels;	chr6:111332674	chr6:111297126~111298510:+
LUAD	cis	rs11673344	0.864	rs55792845	ENSG00000226686.6	LINC01535	4.53	7.33e-06	0.00149	0.26	0.2	Obesity-related traits;	chr19:37007783	chr19:37251912~37265535:+
LUAD	cis	rs5758659	0.652	rs133300	ENSG00000182057.4	OGFRP1	4.53	7.33e-06	0.00149	0.24	0.2	Cognitive function;	chr22:41993835	chr22:42269753~42275196:+
LUAD	cis	rs516805	0.748	rs197685	ENSG00000279453.1	RP3-425C14.4	-4.53	7.33e-06	0.00149	-0.28	-0.2	Lymphocyte counts;	chr6:122554622	chr6:122436789~122439223:-
LUAD	cis	rs4835473	0.868	rs1828503	ENSG00000251600.4	RP11-673E1.1	-4.53	7.33e-06	0.00149	-0.26	-0.2	Immature fraction of reticulocytes;	chr4:143993354	chr4:143912331~143982454:+
LUAD	cis	rs2243480	1	rs781150	ENSG00000226002.1	RP11-460N20.5	-4.53	7.34e-06	0.00149	-0.34	-0.2	Diabetic kidney disease;	chr7:66015986	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs313798	ENSG00000226002.1	RP11-460N20.5	-4.53	7.34e-06	0.00149	-0.34	-0.2	Diabetic kidney disease;	chr7:66028044	chr7:65084103~65100232:+
LUAD	cis	rs11722779	0.869	rs223350	ENSG00000251288.2	RP11-10L12.2	-4.53	7.34e-06	0.00149	-0.24	-0.2	Schizophrenia;	chr4:102856899	chr4:102751401~102752641:+
LUAD	cis	rs2274273	0.682	rs1201378	ENSG00000258413.1	RP11-665C16.6	4.53	7.34e-06	0.00149	0.25	0.2	Protein biomarker;	chr14:55026690	chr14:55262767~55272075:-
LUAD	cis	rs62025270	0.576	rs62022925	ENSG00000202081.1	RNU6-1280P	-4.53	7.34e-06	0.00149	-0.29	-0.2	Idiopathic pulmonary fibrosis;	chr15:85692835	chr15:85651522~85651628:-
LUAD	cis	rs858267	0.661	rs7786708	ENSG00000230658.1	KLHL7-AS1	-4.53	7.34e-06	0.00149	-0.44	-0.2	Blood protein levels;	chr7:23075797	chr7:23101228~23105703:-
LUAD	cis	rs7617773	1	rs12496784	ENSG00000228638.1	FCF1P2	4.53	7.34e-06	0.0015	0.23	0.2	Coronary artery disease;	chr3:48144777	chr3:48290793~48291375:-
LUAD	cis	rs6570726	0.791	rs9390336	ENSG00000235652.6	RP11-545I5.3	4.53	7.34e-06	0.0015	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145575687	chr6:145799409~145886585:+
LUAD	cis	rs847577	0.609	rs7791463	ENSG00000272950.1	RP11-307C18.1	4.53	7.34e-06	0.0015	0.25	0.2	Breast cancer;	chr7:98189735	chr7:98322853~98323430:+
LUAD	cis	rs847577	0.609	rs6465657	ENSG00000272950.1	RP11-307C18.1	4.53	7.34e-06	0.0015	0.25	0.2	Breast cancer;	chr7:98187015	chr7:98322853~98323430:+
LUAD	cis	rs11168351	0.889	rs12817104	ENSG00000240399.1	RP1-228P16.1	4.53	7.34e-06	0.0015	0.2	0.2	Bipolar disorder and schizophrenia;	chr12:47988790	chr12:48054813~48055591:-
LUAD	cis	rs847577	0.609	rs6965016	ENSG00000272950.1	RP11-307C18.1	4.53	7.34e-06	0.0015	0.25	0.2	Breast cancer;	chr7:98178570	chr7:98322853~98323430:+
LUAD	cis	rs453301	0.686	rs7017868	ENSG00000173295.6	FAM86B3P	-4.53	7.34e-06	0.0015	-0.23	-0.2	Joint mobility (Beighton score);	chr8:9015783	chr8:8228595~8244865:+
LUAD	cis	rs453301	0.686	rs3895823	ENSG00000173295.6	FAM86B3P	-4.53	7.34e-06	0.0015	-0.23	-0.2	Joint mobility (Beighton score);	chr8:9016136	chr8:8228595~8244865:+
LUAD	cis	rs2243480	1	rs56016656	ENSG00000229886.1	RP5-1132H15.3	4.53	7.35e-06	0.0015	0.36	0.2	Diabetic kidney disease;	chr7:65918494	chr7:66025126~66031544:-
LUAD	cis	rs2243480	0.803	rs55700941	ENSG00000229886.1	RP5-1132H15.3	4.53	7.35e-06	0.0015	0.36	0.2	Diabetic kidney disease;	chr7:65924813	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs56291018	ENSG00000229886.1	RP5-1132H15.3	4.53	7.35e-06	0.0015	0.36	0.2	Diabetic kidney disease;	chr7:65925352	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs36033484	ENSG00000229886.1	RP5-1132H15.3	4.53	7.35e-06	0.0015	0.36	0.2	Diabetic kidney disease;	chr7:65925571	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs34193460	ENSG00000229886.1	RP5-1132H15.3	4.53	7.35e-06	0.0015	0.36	0.2	Diabetic kidney disease;	chr7:65928123	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs34560516	ENSG00000229886.1	RP5-1132H15.3	4.53	7.35e-06	0.0015	0.36	0.2	Diabetic kidney disease;	chr7:65939105	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs57057549	ENSG00000229886.1	RP5-1132H15.3	4.53	7.35e-06	0.0015	0.36	0.2	Diabetic kidney disease;	chr7:65940751	chr7:66025126~66031544:-
LUAD	cis	rs5758659	0.652	rs129857	ENSG00000182057.4	OGFRP1	-4.53	7.35e-06	0.0015	-0.24	-0.2	Cognitive function;	chr22:42003682	chr22:42269753~42275196:+
LUAD	cis	rs13256369	1	rs10103769	ENSG00000253893.2	FAM85B	-4.53	7.35e-06	0.0015	-0.28	-0.2	Obesity-related traits;	chr8:8715526	chr8:8167819~8226614:-
LUAD	cis	rs62355900	0.627	rs1862620	ENSG00000271828.1	CTD-2310F14.1	4.53	7.35e-06	0.0015	0.39	0.2	Endometriosis;	chr5:56802543	chr5:56927874~56929573:+
LUAD	cis	rs853679	0.546	rs34546986	ENSG00000219392.1	RP1-265C24.5	-4.53	7.35e-06	0.0015	-0.46	-0.2	Depression;	chr6:28394532	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.546	rs34871267	ENSG00000219392.1	RP1-265C24.5	-4.53	7.35e-06	0.0015	-0.46	-0.2	Depression;	chr6:28396455	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.546	rs35883476	ENSG00000219392.1	RP1-265C24.5	-4.53	7.35e-06	0.0015	-0.46	-0.2	Depression;	chr6:28400731	chr6:28115628~28116551:+
LUAD	cis	rs4578769	0.531	rs12969559	ENSG00000265943.1	RP11-739L10.1	4.53	7.35e-06	0.0015	0.25	0.2	Eosinophil percentage of white cells;	chr18:22913702	chr18:22699481~22933764:-
LUAD	cis	rs6687821	0.531	rs4656135	ENSG00000267734.1	RP4-604K5.3	-4.53	7.35e-06	0.0015	-0.27	-0.2	Yeast infection;	chr1:87023404	chr1:86932199~86934891:-
LUAD	cis	rs7665090	0.934	rs35112949	ENSG00000246560.2	RP11-10L12.4	4.53	7.36e-06	0.0015	0.25	0.2	Primary biliary cholangitis;	chr4:102638473	chr4:102828055~102844075:+
LUAD	cis	rs7665090	0.87	rs34349956	ENSG00000246560.2	RP11-10L12.4	4.53	7.36e-06	0.0015	0.25	0.2	Primary biliary cholangitis;	chr4:102638476	chr4:102828055~102844075:+
LUAD	cis	rs7829975	0.533	rs1039917	ENSG00000173295.6	FAM86B3P	4.53	7.36e-06	0.0015	0.22	0.2	Mood instability;	chr8:8861340	chr8:8228595~8244865:+
LUAD	cis	rs6687758	1	rs12125368	ENSG00000227925.1	RP11-191N8.2	4.53	7.36e-06	0.0015	0.29	0.2	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222025330	chr1:221827666~221840666:-
LUAD	cis	rs865483	0.895	rs1112173	ENSG00000276054.1	RP11-378E13.3	-4.53	7.36e-06	0.0015	-0.24	-0.2	Monocyte count;	chr17:37399966	chr17:37386886~37387926:+
LUAD	cis	rs2115630	0.905	rs6496401	ENSG00000229212.6	RP11-561C5.4	4.53	7.36e-06	0.0015	0.24	0.2	P wave terminal force;	chr15:84754562	chr15:85205440~85234795:-
LUAD	cis	rs77926410	0.604	rs11053801	ENSG00000245648.1	RP11-277P12.20	-4.53	7.36e-06	0.0015	-0.25	-0.2	Mean corpuscular volume;	chr12:10443518	chr12:10363769~10398506:+
LUAD	cis	rs755249	0.753	rs72663529	ENSG00000228060.1	RP11-69E11.8	-4.53	7.36e-06	0.0015	-0.17	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39557684	chr1:39565160~39573203:+
LUAD	cis	rs7302981	0.967	rs35549836	ENSG00000200428.1	Y_RNA	-4.53	7.36e-06	0.0015	-0.25	-0.2	Systolic blood pressure;	chr12:50159419	chr12:50743568~50743684:+
LUAD	cis	rs7208859	0.725	rs7342938	ENSG00000280069.1	CTD-2349P21.3	-4.53	7.36e-06	0.0015	-0.24	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862812	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.725	rs6505215	ENSG00000280069.1	CTD-2349P21.3	-4.53	7.36e-06	0.0015	-0.24	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862885	chr17:30738182~30740275:+
LUAD	cis	rs2243480	1	rs67728539	ENSG00000226002.1	RP11-460N20.5	-4.53	7.36e-06	0.0015	-0.35	-0.2	Diabetic kidney disease;	chr7:65913137	chr7:65084103~65100232:+
LUAD	cis	rs2742234	0.656	rs1864400	ENSG00000273008.1	RP11-351D16.3	-4.53	7.36e-06	0.0015	-0.23	-0.2	Hirschsprung disease;	chr10:43114918	chr10:43136824~43138334:-
LUAD	cis	rs4811196	0.719	rs6123115	ENSG00000226144.2	RPS27AP3	4.53	7.36e-06	0.0015	0.22	0.2	Bone mineral density;	chr20:37885548	chr20:37049254~37049707:+
LUAD	cis	rs11155671	0.53	rs9383912	ENSG00000268592.3	RAET1E-AS1	4.53	7.36e-06	0.0015	0.25	0.2	Testicular germ cell tumor;	chr6:149885479	chr6:149863494~149919507:+
LUAD	cis	rs6430553	0.964	rs1530556	ENSG00000224043.6	CCNT2-AS1	-4.53	7.36e-06	0.0015	-0.25	-0.2	Blood metabolite levels;	chr2:134842164	chr2:134735464~134918710:-
LUAD	cis	rs755249	0.545	rs12037073	ENSG00000228060.1	RP11-69E11.8	4.53	7.37e-06	0.0015	0.18	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39581225	chr1:39565160~39573203:+
LUAD	cis	rs338389	0.934	rs338404	ENSG00000260657.2	RP11-315D16.4	-4.53	7.37e-06	0.0015	-0.23	-0.2	Survival in rectal cancer;	chr15:67959337	chr15:68267792~68277994:-
LUAD	cis	rs338389	0.934	rs338403	ENSG00000260657.2	RP11-315D16.4	-4.53	7.37e-06	0.0015	-0.23	-0.2	Survival in rectal cancer;	chr15:67959349	chr15:68267792~68277994:-
LUAD	cis	rs60180747	0.544	rs11637318	ENSG00000261318.1	RP11-653J6.1	4.53	7.37e-06	0.0015	0.27	0.2	Testicular germ cell tumor;	chr15:66266317	chr15:66278498~66293357:-
LUAD	cis	rs60180747	0.544	rs11638535	ENSG00000261318.1	RP11-653J6.1	4.53	7.37e-06	0.0015	0.27	0.2	Testicular germ cell tumor;	chr15:66266923	chr15:66278498~66293357:-
LUAD	cis	rs1499614	1	rs2707832	ENSG00000232559.3	GS1-124K5.12	4.53	7.37e-06	0.0015	0.34	0.2	Gout;	chr7:66671562	chr7:66554588~66576923:-
LUAD	cis	rs2299587	0.689	rs1847154	ENSG00000253671.1	RP11-806O11.1	-4.53	7.37e-06	0.0015	-0.23	-0.2	Economic and political preferences;	chr8:17922829	chr8:17808941~17820868:+
LUAD	cis	rs950169	0.922	rs4842940	ENSG00000275120.1	RP11-182J1.17	-4.53	7.38e-06	0.0015	-0.32	-0.2	Schizophrenia;	chr15:84162473	chr15:84599434~84606463:-
LUAD	cis	rs12928939	0.769	rs12445161	ENSG00000260886.1	TAT-AS1	4.53	7.38e-06	0.0015	0.25	0.2	Post bronchodilator FEV1;	chr16:71708025	chr16:71565789~71578187:+
LUAD	cis	rs12928939	0.815	rs34731378	ENSG00000260886.1	TAT-AS1	4.53	7.38e-06	0.0015	0.25	0.2	Post bronchodilator FEV1;	chr16:71711845	chr16:71565789~71578187:+
LUAD	cis	rs17772222	1	rs12589480	ENSG00000258789.1	RP11-507K2.3	-4.53	7.38e-06	0.0015	-0.28	-0.2	Coronary artery calcification;	chr14:88414926	chr14:88551597~88552493:+
LUAD	cis	rs6969780	0.915	rs10085570	ENSG00000233429.8	HOTAIRM1	-4.53	7.38e-06	0.0015	-0.3	-0.2	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27111569	chr7:27095647~27100265:+
LUAD	cis	rs2288884	1	rs11673286	ENSG00000269959.1	SPACA6P-AS	-4.53	7.38e-06	0.0015	-0.27	-0.2	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52037065	chr19:51685363~51693456:-
LUAD	cis	rs11089937	0.597	rs11704434	ENSG00000211640.3	IGLV6-57	4.53	7.39e-06	0.0015	0.16	0.2	Periodontitis (PAL4Q3);	chr22:22131715	chr22:22195713~22196460:+
LUAD	cis	rs228614	0.536	rs223419	ENSG00000251288.2	RP11-10L12.2	-4.53	7.39e-06	0.0015	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102808586	chr4:102751401~102752641:+
LUAD	cis	rs910316	1	rs175442	ENSG00000279594.1	RP11-950C14.10	-4.53	7.39e-06	0.0015	-0.23	-0.2	Height;	chr14:75136861	chr14:75011269~75012851:-
LUAD	cis	rs9545047	0.604	rs7331867	ENSG00000227354.5	RBM26-AS1	-4.53	7.39e-06	0.0015	-0.22	-0.2	Schizophrenia;	chr13:79418791	chr13:79406309~79424328:+
LUAD	cis	rs5758511	0.68	rs5758681	ENSG00000227370.1	RP4-669P10.19	4.53	7.39e-06	0.0015	0.22	0.2	Birth weight;	chr22:42249085	chr22:42132543~42132998:+
LUAD	cis	rs13113518	0.756	rs11939652	ENSG00000223305.1	RN7SKP30	4.53	7.4e-06	0.0015	0.24	0.2	Height;	chr4:55532542	chr4:55540502~55540835:-
LUAD	cis	rs9400467	0.508	rs61269242	ENSG00000271789.1	RP5-1112D6.7	-4.53	7.4e-06	0.0015	-0.22	-0.2	Amino acid levels;Blood metabolite levels;	chr6:111481856	chr6:111297126~111298510:+
LUAD	cis	rs2286503	0.839	rs2240728	ENSG00000226329.2	AC005682.6	4.53	7.4e-06	0.0015	0.26	0.2	Fibrinogen;	chr7:22812880	chr7:22863874~22881350:-
LUAD	cis	rs6496932	0.503	rs2086756	ENSG00000202081.1	RNU6-1280P	-4.53	7.4e-06	0.00151	-0.27	-0.2	Central corneal thickness;Corneal structure;	chr15:85424322	chr15:85651522~85651628:-
LUAD	cis	rs897984	0.542	rs7294	ENSG00000260911.2	RP11-196G11.2	-4.53	7.4e-06	0.00151	-0.18	-0.2	Dementia with Lewy bodies;	chr16:31091000	chr16:31043150~31049868:+
LUAD	cis	rs1008375	0.931	rs2109519	ENSG00000249502.1	AC006160.5	-4.53	7.41e-06	0.00151	-0.19	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17693830	chr4:17587467~17614571:-
LUAD	cis	rs9545047	0.604	rs2876740	ENSG00000227354.5	RBM26-AS1	-4.53	7.41e-06	0.00151	-0.21	-0.2	Schizophrenia;	chr13:79409829	chr13:79406309~79424328:+
LUAD	cis	rs878939	0.625	rs17578367	ENSG00000230224.1	PHBP9	-4.53	7.41e-06	0.00151	-0.19	-0.2	Warfarin maintenance dose;	chr10:99584410	chr10:100248271~100249095:+
LUAD	cis	rs1318937	0.588	rs80123042	ENSG00000224660.1	SH3BP5-AS1	4.53	7.41e-06	0.00151	0.23	0.2	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15241957	chr3:15254184~15264493:+
LUAD	cis	rs11051970	0.679	rs2651366	ENSG00000274964.1	RP11-817I4.1	-4.53	7.41e-06	0.00151	-0.21	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr12:32407497	chr12:32339368~32340724:+
LUAD	cis	rs7829975	0.606	rs6422352	ENSG00000173295.6	FAM86B3P	-4.53	7.41e-06	0.00151	-0.21	-0.2	Mood instability;	chr8:8936683	chr8:8228595~8244865:+
LUAD	cis	rs8072100	0.87	rs10432035	ENSG00000228782.6	CTD-2026D20.3	-4.53	7.41e-06	0.00151	-0.21	-0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47547547	chr17:47450568~47492492:-
LUAD	cis	rs2337406	0.587	rs2516886	ENSG00000223648.3	IGHV3-64	-4.53	7.42e-06	0.00151	-0.23	-0.2	Alzheimer's disease (late onset);	chr14:106649674	chr14:106643132~106658258:-
LUAD	cis	rs2243480	0.901	rs2949697	ENSG00000229886.1	RP5-1132H15.3	4.53	7.42e-06	0.00151	0.35	0.2	Diabetic kidney disease;	chr7:65999249	chr7:66025126~66031544:-
LUAD	cis	rs2522056	0.808	rs7704457	ENSG00000233006.5	AC034220.3	4.53	7.43e-06	0.00151	0.23	0.2	Fibrinogen;Lymphocyte counts;	chr5:132409098	chr5:132311285~132369916:-
LUAD	cis	rs1555322	0.505	rs591590	ENSG00000126005.14	MMP24-AS1	4.53	7.43e-06	0.00151	0.28	0.2	Attention deficit hyperactivity disorder;	chr20:35278225	chr20:35216462~35278131:-
LUAD	cis	rs1355223	0.902	rs1578622	ENSG00000271369.1	RP11-350D17.3	-4.53	7.44e-06	0.00151	-0.24	-0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34704368	chr11:34709600~34710161:+
LUAD	cis	rs6840360	0.967	rs10028410	ENSG00000270265.1	RP11-731D1.4	-4.53	7.44e-06	0.00151	-0.21	-0.2	Intelligence (multi-trait analysis);	chr4:151685421	chr4:151333775~151353224:-
LUAD	cis	rs7829975	0.742	rs1533059	ENSG00000233609.3	RP11-62H7.2	-4.53	7.44e-06	0.00151	-0.17	-0.2	Mood instability;	chr8:8827443	chr8:8961200~8979025:+
LUAD	cis	rs11992162	0.967	rs7461062	ENSG00000255046.1	RP11-297N6.4	-4.53	7.45e-06	0.00151	-0.25	-0.2	Monocyte count;	chr8:11974439	chr8:11797928~11802568:-
LUAD	cis	rs4664293	0.625	rs6713600	ENSG00000226266.5	AC009961.3	4.53	7.45e-06	0.00151	0.27	0.2	Monocyte percentage of white cells;	chr2:159706559	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.625	rs7607394	ENSG00000226266.5	AC009961.3	4.53	7.45e-06	0.00151	0.27	0.2	Monocyte percentage of white cells;	chr2:159707286	chr2:159670708~159712435:-
LUAD	cis	rs801193	0.591	rs2707839	ENSG00000232559.3	GS1-124K5.12	4.53	7.46e-06	0.00152	0.24	0.2	Aortic root size;	chr7:66728097	chr7:66554588~66576923:-
LUAD	cis	rs4268898	0.76	rs7597919	ENSG00000223754.1	AC008073.9	-4.53	7.46e-06	0.00152	-0.24	-0.2	Asthma;	chr2:24340777	chr2:24199839~24201698:-
LUAD	cis	rs603446	0.967	rs180365	ENSG00000254851.1	RP11-109L13.1	-4.53	7.46e-06	0.00152	-0.26	-0.2	Triglycerides;	chr11:116725458	chr11:117135528~117138582:+
LUAD	cis	rs2562456	0.833	rs11666525	ENSG00000268081.1	RP11-678G14.2	4.53	7.46e-06	0.00152	0.33	0.2	Pain;	chr19:21416503	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.793	rs62110424	ENSG00000268081.1	RP11-678G14.2	4.53	7.46e-06	0.00152	0.33	0.2	Pain;	chr19:21416835	chr19:21554640~21569237:-
LUAD	cis	rs848490	0.928	rs55919387	ENSG00000214293.7	APTR	4.53	7.46e-06	0.00152	0.26	0.2	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77686304	chr7:77657660~77696265:-
LUAD	cis	rs1541160	1	rs1330377	ENSG00000239494.2	RN7SL333P	4.53	7.46e-06	0.00152	0.2	0.2	Amyotrophic lateral sclerosis;	chr1:170081461	chr1:169859756~169860052:+
LUAD	cis	rs780096	0.546	rs1104	ENSG00000234072.1	AC074117.10	-4.53	7.46e-06	0.00152	-0.16	-0.2	Total body bone mineral density;	chr2:27377008	chr2:27356246~27367622:+
LUAD	cis	rs13113518	0.513	rs13132085	ENSG00000223305.1	RN7SKP30	-4.53	7.47e-06	0.00152	-0.24	-0.2	Height;	chr4:55593918	chr4:55540502~55540835:-
LUAD	cis	rs7493	0.901	rs13226149	ENSG00000233942.1	AC004012.1	4.53	7.48e-06	0.00152	0.28	0.2	Yu-Zhi constitution type in type 2 diabetes;	chr7:95396288	chr7:95471835~95473998:+
LUAD	cis	rs11992162	0.933	rs10108075	ENSG00000255046.1	RP11-297N6.4	-4.53	7.48e-06	0.00152	-0.25	-0.2	Monocyte count;	chr8:11974570	chr8:11797928~11802568:-
LUAD	cis	rs2243480	0.901	rs2949697	ENSG00000164669.11	INTS4P1	4.53	7.48e-06	0.00152	0.36	0.2	Diabetic kidney disease;	chr7:65999249	chr7:65141225~65234216:+
LUAD	cis	rs9341808	0.718	rs9294171	ENSG00000272129.1	RP11-250B2.6	4.53	7.48e-06	0.00152	0.25	0.2	Sitting height ratio;	chr6:80130098	chr6:80355424~80356859:+
LUAD	cis	rs911555	0.755	rs12432803	ENSG00000244691.1	RPL10AP1	4.53	7.48e-06	0.00152	0.27	0.2	Intelligence (multi-trait analysis);	chr14:103463695	chr14:103412119~103412761:-
LUAD	cis	rs2446066	0.872	rs3741664	ENSG00000257379.1	RP11-793H13.8	4.53	7.48e-06	0.00152	0.34	0.2	Red blood cell count;	chr12:53428886	chr12:53441741~53467528:+
LUAD	cis	rs2933343	0.679	rs789254	ENSG00000231305.3	RP11-723O4.2	4.53	7.49e-06	0.00152	0.22	0.2	IgG glycosylation;	chr3:128855750	chr3:128861313~128871540:-
LUAD	cis	rs7635879	0.702	rs4687494	ENSG00000230102.6	RP11-407B7.1	-4.53	7.49e-06	0.00152	-0.23	-0.2	Breastfeeding duration;	chr3:194010581	chr3:194005259~194070970:-
LUAD	cis	rs57502260	0.651	rs3781586	ENSG00000212093.1	AP000807.1	4.53	7.49e-06	0.00152	0.27	0.2	Total body bone mineral density (age 45-60);	chr11:68431925	chr11:68506083~68506166:-
LUAD	cis	rs950169	0.922	rs4842941	ENSG00000275120.1	RP11-182J1.17	-4.53	7.49e-06	0.00152	-0.32	-0.2	Schizophrenia;	chr15:84162560	chr15:84599434~84606463:-
LUAD	cis	rs950169	0.922	rs12911223	ENSG00000275120.1	RP11-182J1.17	-4.53	7.49e-06	0.00152	-0.32	-0.2	Schizophrenia;	chr15:84162919	chr15:84599434~84606463:-
LUAD	cis	rs6860806	0.661	rs2136187	ENSG00000233006.5	AC034220.3	4.53	7.49e-06	0.00152	0.18	0.2	Breast cancer;	chr5:132242201	chr5:132311285~132369916:-
LUAD	cis	rs4908768	0.539	rs6675443	ENSG00000270282.1	RP5-1115A15.2	4.53	7.49e-06	0.00152	0.22	0.2	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8591523	chr1:8512653~8513021:+
LUAD	cis	rs4664293	0.631	rs13019272	ENSG00000226266.5	AC009961.3	-4.53	7.49e-06	0.00152	-0.28	-0.2	Monocyte percentage of white cells;	chr2:159802352	chr2:159670708~159712435:-
LUAD	cis	rs72717009	0.825	rs7552317	ENSG00000225217.1	HSPA7	-4.53	7.49e-06	0.00152	-0.29	-0.2	Rheumatoid arthritis;	chr1:161509648	chr1:161606291~161608217:+
LUAD	cis	rs16846053	0.534	rs1227926	ENSG00000227403.1	AC009299.3	4.53	7.5e-06	0.00152	0.34	0.2	Blood osmolality (transformed sodium);	chr2:161827383	chr2:161244739~161249050:+
LUAD	cis	rs950169	0.881	rs150965	ENSG00000275120.1	RP11-182J1.17	4.53	7.5e-06	0.00152	0.32	0.2	Schizophrenia;	chr15:84537296	chr15:84599434~84606463:-
LUAD	cis	rs7138803	0.538	rs60062868	ENSG00000257464.1	RP11-161H23.8	-4.53	7.5e-06	0.00152	-0.2	-0.2	Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index;	chr12:49813136	chr12:49442424~49442652:-
LUAD	cis	rs7138803	0.572	rs59766494	ENSG00000257464.1	RP11-161H23.8	-4.53	7.5e-06	0.00152	-0.2	-0.2	Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index;	chr12:49813194	chr12:49442424~49442652:-
LUAD	cis	rs7432375	0.61	rs7621932	ENSG00000239213.4	NCK1-AS1	4.53	7.5e-06	0.00152	0.21	0.2	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136798174	chr3:136841726~136862054:-
LUAD	cis	rs7432375	0.61	rs7633629	ENSG00000239213.4	NCK1-AS1	4.53	7.5e-06	0.00152	0.21	0.2	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136798186	chr3:136841726~136862054:-
LUAD	cis	rs1799949	0.965	rs4793230	ENSG00000236383.6	LINC00854	-4.53	7.5e-06	0.00152	-0.16	-0.2	Menopause (age at onset);	chr17:43350035	chr17:43216941~43305976:-
LUAD	cis	rs1799949	0.965	rs4793234	ENSG00000236383.6	LINC00854	-4.53	7.5e-06	0.00152	-0.16	-0.2	Menopause (age at onset);	chr17:43358815	chr17:43216941~43305976:-
LUAD	cis	rs73173548	0.528	rs12189274	ENSG00000247828.6	TMEM161B-AS1	-4.53	7.5e-06	0.00152	-0.25	-0.2	Macular telangiectasia type 2;	chr5:88468669	chr5:88268895~88436685:+
LUAD	cis	rs911119	0.955	rs61035931	ENSG00000270001.1	RP11-218C14.8	-4.53	7.51e-06	0.00152	-0.29	-0.2	Chronic kidney disease;	chr20:23615077	chr20:23631826~23632316:-
LUAD	cis	rs911119	0.955	rs55897275	ENSG00000270001.1	RP11-218C14.8	-4.53	7.51e-06	0.00152	-0.29	-0.2	Chronic kidney disease;	chr20:23615316	chr20:23631826~23632316:-
LUAD	cis	rs801193	1	rs2659909	ENSG00000224316.1	RP11-479O9.2	4.53	7.51e-06	0.00152	0.2	0.2	Aortic root size;	chr7:66695292	chr7:65773620~65802067:+
LUAD	cis	rs477895	0.653	rs11231701	ENSG00000236935.1	AP003774.1	-4.53	7.51e-06	0.00152	-0.25	-0.2	Mean platelet volume;	chr11:64126230	chr11:64325050~64329504:-
LUAD	cis	rs5769707	0.967	rs9616327	ENSG00000235111.1	RP1-29C18.8	-4.53	7.51e-06	0.00153	-0.22	-0.2	Monocyte percentage of white cells;Monocyte count;	chr22:49617243	chr22:49612657~49615716:-
LUAD	cis	rs2239557	1	rs4903201	ENSG00000259065.1	RP5-1021I20.1	4.53	7.51e-06	0.00153	0.23	0.2	Common traits (Other);	chr14:74192987	chr14:73787360~73803270:+
LUAD	cis	rs2239557	1	rs10140433	ENSG00000259065.1	RP5-1021I20.1	4.53	7.51e-06	0.00153	0.23	0.2	Common traits (Other);	chr14:74193286	chr14:73787360~73803270:+
LUAD	cis	rs2239557	1	rs4903202	ENSG00000259065.1	RP5-1021I20.1	4.53	7.51e-06	0.00153	0.23	0.2	Common traits (Other);	chr14:74193599	chr14:73787360~73803270:+
LUAD	cis	rs2239557	1	rs4903203	ENSG00000259065.1	RP5-1021I20.1	4.53	7.51e-06	0.00153	0.23	0.2	Common traits (Other);	chr14:74193805	chr14:73787360~73803270:+
LUAD	cis	rs338389	0.967	rs338394	ENSG00000260657.2	RP11-315D16.4	-4.53	7.52e-06	0.00153	-0.23	-0.2	Survival in rectal cancer;	chr15:67964602	chr15:68267792~68277994:-
LUAD	cis	rs10771431	0.782	rs10771415	ENSG00000111788.10	RP11-22B23.1	4.53	7.52e-06	0.00153	0.17	0.2	Breast size;	chr12:9205627	chr12:9277235~9313241:+
LUAD	cis	rs8072100	0.713	rs8074451	ENSG00000228782.6	CTD-2026D20.3	4.53	7.52e-06	0.00153	0.22	0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47400207	chr17:47450568~47492492:-
LUAD	cis	rs7811142	0.779	rs111312383	ENSG00000078319.8	PMS2P1	-4.53	7.52e-06	0.00153	-0.25	-0.2	Platelet count;	chr7:100307702	chr7:100320992~100341908:-
LUAD	cis	rs9652601	0.959	rs12925642	ENSG00000274038.1	RP11-66H6.4	-4.53	7.52e-06	0.00153	-0.25	-0.2	Systemic lupus erythematosus;	chr16:11077745	chr16:11056556~11057034:+
LUAD	cis	rs2243480	1	rs4718334	ENSG00000232559.3	GS1-124K5.12	-4.53	7.53e-06	0.00153	-0.35	-0.2	Diabetic kidney disease;	chr7:66324467	chr7:66554588~66576923:-
LUAD	cis	rs7208859	0.673	rs7211776	ENSG00000280069.1	CTD-2349P21.3	-4.53	7.53e-06	0.00153	-0.24	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793178	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs9912122	ENSG00000280069.1	CTD-2349P21.3	-4.53	7.53e-06	0.00153	-0.24	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813698	chr17:30738182~30740275:+
LUAD	cis	rs2378497	0.877	rs12126368	ENSG00000232679.1	RP11-400N13.3	4.53	7.54e-06	0.00153	0.32	0.2	Serum thyroid-stimulating hormone levels;	chr1:222001793	chr1:222041705~222064763:-
LUAD	cis	rs228614	0.51	rs223435	ENSG00000251288.2	RP11-10L12.2	-4.53	7.54e-06	0.00153	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799826	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.556	rs223426	ENSG00000251288.2	RP11-10L12.2	-4.53	7.54e-06	0.00153	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102801330	chr4:102751401~102752641:+
LUAD	cis	rs61542988	0.57	rs62448268	ENSG00000228649.7	AC005682.5	4.53	7.54e-06	0.00153	0.3	0.2	Fibrinogen levels;	chr7:22789845	chr7:22854178~22861579:+
LUAD	cis	rs3177980	0.673	rs73026213	ENSG00000239494.2	RN7SL333P	-4.53	7.54e-06	0.00153	-0.2	-0.2	Amyotrophic lateral sclerosis;	chr1:169881233	chr1:169859756~169860052:+
LUAD	cis	rs11673344	0.796	rs16971886	ENSG00000226686.6	LINC01535	4.53	7.55e-06	0.00153	0.26	0.2	Obesity-related traits;	chr19:36997073	chr19:37251912~37265535:+
LUAD	cis	rs11673344	0.83	rs3745770	ENSG00000226686.6	LINC01535	4.53	7.55e-06	0.00153	0.26	0.2	Obesity-related traits;	chr19:36997663	chr19:37251912~37265535:+
LUAD	cis	rs4925386	0.808	rs1741634	ENSG00000273619.1	RP5-908M14.9	4.53	7.55e-06	0.00153	0.19	0.2	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62350923	chr20:62386303~62386970:-
LUAD	cis	rs77204473	1	rs2044426	ENSG00000254851.1	RP11-109L13.1	4.53	7.55e-06	0.00153	0.48	0.2	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116885467	chr11:117135528~117138582:+
LUAD	cis	rs453301	0.658	rs6986044	ENSG00000253981.4	ALG1L13P	-4.53	7.55e-06	0.00153	-0.25	-0.2	Joint mobility (Beighton score);	chr8:9017276	chr8:8236003~8244667:-
LUAD	cis	rs6714710	0.603	rs6738389	ENSG00000230606.9	AC159540.1	-4.53	7.55e-06	0.00153	-0.21	-0.2	Posterior cortical atrophy and Alzheimer's disease;	chr2:97770268	chr2:97416165~97433527:-
LUAD	cis	rs5758511	0.68	rs34107327	ENSG00000226450.2	CYP2D8P	4.53	7.56e-06	0.00153	0.19	0.2	Birth weight;	chr22:42252347	chr22:42149886~42155001:-
LUAD	cis	rs2599510	0.693	rs2754514	ENSG00000276334.1	AL133243.1	4.53	7.56e-06	0.00153	0.23	0.2	Interleukin-18 levels;	chr2:32563769	chr2:32521927~32523547:+
LUAD	cis	rs5758511	0.68	rs5758667	ENSG00000226450.2	CYP2D8P	4.53	7.56e-06	0.00153	0.19	0.2	Birth weight;	chr22:42237198	chr22:42149886~42155001:-
LUAD	cis	rs6968802	1	rs6968802	ENSG00000233264.2	AC006042.8	4.53	7.56e-06	0.00153	0.29	0.2	Granulocyte percentage of myeloid white cells;	chr7:8016446	chr7:7980312~7982228:+
LUAD	cis	rs1062177	0.756	rs2964591	ENSG00000253921.1	CTB-113P19.3	4.53	7.56e-06	0.00153	0.28	0.2	Preschool internalizing problems;	chr5:151737836	chr5:151753992~151767247:+
LUAD	cis	rs6866614	0.627	rs27437	ENSG00000233006.5	AC034220.3	4.53	7.56e-06	0.00153	0.19	0.2	Perceived unattractiveness to mosquitoes;	chr5:132101268	chr5:132311285~132369916:-
LUAD	cis	rs13113518	0.783	rs6843722	ENSG00000223305.1	RN7SKP30	4.53	7.57e-06	0.00153	0.24	0.2	Height;	chr4:55465165	chr4:55540502~55540835:-
LUAD	cis	rs2933343	0.621	rs728838	ENSG00000231305.3	RP11-723O4.2	4.53	7.57e-06	0.00153	0.21	0.2	IgG glycosylation;	chr3:128870170	chr3:128861313~128871540:-
LUAD	cis	rs878939	0.625	rs7476059	ENSG00000230224.1	PHBP9	-4.53	7.57e-06	0.00153	-0.2	-0.2	Warfarin maintenance dose;	chr10:99587281	chr10:100248271~100249095:+
LUAD	cis	rs62025270	0.632	rs62022924	ENSG00000202081.1	RNU6-1280P	-4.53	7.57e-06	0.00154	-0.29	-0.2	Idiopathic pulmonary fibrosis;	chr15:85692276	chr15:85651522~85651628:-
LUAD	cis	rs9992667	0.91	rs17428945	ENSG00000231160.8	KLF3-AS1	4.53	7.57e-06	0.00154	0.26	0.2	Eosinophil percentage of granulocytes;	chr4:38688124	chr4:38612701~38664883:-
LUAD	cis	rs2832077	0.883	rs11702413	ENSG00000232855.5	AF131217.1	4.53	7.57e-06	0.00154	0.23	0.2	Cognitive test performance;	chr21:28816072	chr21:28439346~28674848:-
LUAD	cis	rs2832077	0.883	rs35672956	ENSG00000232855.5	AF131217.1	4.53	7.57e-06	0.00154	0.23	0.2	Cognitive test performance;	chr21:28816719	chr21:28439346~28674848:-
LUAD	cis	rs2832077	0.943	rs11700746	ENSG00000232855.5	AF131217.1	4.53	7.57e-06	0.00154	0.23	0.2	Cognitive test performance;	chr21:28816884	chr21:28439346~28674848:-
LUAD	cis	rs2832077	0.943	rs2272701	ENSG00000232855.5	AF131217.1	4.53	7.57e-06	0.00154	0.23	0.2	Cognitive test performance;	chr21:28818585	chr21:28439346~28674848:-
LUAD	cis	rs13113518	0.812	rs12500601	ENSG00000223305.1	RN7SKP30	4.53	7.58e-06	0.00154	0.23	0.2	Height;	chr4:55451489	chr4:55540502~55540835:-
LUAD	cis	rs950169	0.519	rs7237	ENSG00000259295.5	CSPG4P12	4.53	7.58e-06	0.00154	0.29	0.2	Schizophrenia;	chr15:84643346	chr15:85191438~85213905:+
LUAD	cis	rs2286503	1	rs2286499	ENSG00000226329.2	AC005682.6	4.53	7.58e-06	0.00154	0.25	0.2	Fibrinogen;	chr7:22817858	chr7:22863874~22881350:-
LUAD	cis	rs2337406	0.587	rs2583291	ENSG00000223648.3	IGHV3-64	-4.53	7.59e-06	0.00154	-0.23	-0.2	Alzheimer's disease (late onset);	chr14:106649293	chr14:106643132~106658258:-
LUAD	cis	rs77688320	0.535	rs10186894	ENSG00000213090.2	AC007256.5	4.53	7.59e-06	0.00154	0.23	0.2	Breast cancer;	chr2:201440909	chr2:201410544~201413308:-
LUAD	cis	rs4666360	1	rs4666359	ENSG00000234378.1	AC098828.2	4.53	7.59e-06	0.00154	0.24	0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);	chr2:20135853	chr2:20063856~20106829:-
LUAD	cis	rs4666360	1	rs4666360	ENSG00000234378.1	AC098828.2	4.53	7.59e-06	0.00154	0.24	0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);	chr2:20135948	chr2:20063856~20106829:-
LUAD	cis	rs7945705	0.782	rs3763918	ENSG00000254860.4	TMEM9B-AS1	-4.53	7.59e-06	0.00154	-0.23	-0.2	Hemoglobin concentration;	chr11:8798136	chr11:8964675~8977527:+
LUAD	cis	rs801193	1	rs2003301	ENSG00000224316.1	RP11-479O9.2	-4.53	7.59e-06	0.00154	-0.2	-0.2	Aortic root size;	chr7:66682669	chr7:65773620~65802067:+
LUAD	cis	rs34779708	0.966	rs1213392	ENSG00000271335.4	RP11-324I22.4	4.53	7.59e-06	0.00154	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35141357	chr10:35314552~35336401:-
LUAD	cis	rs860295	0.702	rs12040100	ENSG00000225855.5	RUSC1-AS1	4.53	7.59e-06	0.00154	0.15	0.2	Body mass index;	chr1:155642056	chr1:155316863~155324176:-
LUAD	cis	rs9400467	0.528	rs445349	ENSG00000230177.1	RP5-1112D6.4	4.53	7.59e-06	0.00154	0.18	0.2	Amino acid levels;Blood metabolite levels;	chr6:111340899	chr6:111277932~111278742:+
LUAD	cis	rs6565653	0.967	rs6565652	ENSG00000262580.4	RP11-334C17.5	4.53	7.59e-06	0.00154	0.14	0.2	Ischemic stroke;	chr17:80227755	chr17:80200673~80205949:-
LUAD	cis	rs9322193	0.923	rs9322196	ENSG00000268592.3	RAET1E-AS1	4.53	7.59e-06	0.00154	0.25	0.2	Lung cancer;	chr6:149619645	chr6:149863494~149919507:+
LUAD	cis	rs7493	1	rs17876123	ENSG00000233942.1	AC004012.1	4.53	7.6e-06	0.00154	0.3	0.2	Yu-Zhi constitution type in type 2 diabetes;	chr7:95415995	chr7:95471835~95473998:+
LUAD	cis	rs7493	1	rs2299265	ENSG00000233942.1	AC004012.1	4.53	7.6e-06	0.00154	0.3	0.2	Yu-Zhi constitution type in type 2 diabetes;	chr7:95419558	chr7:95471835~95473998:+
LUAD	cis	rs7493	1	rs1034809	ENSG00000233942.1	AC004012.1	4.53	7.6e-06	0.00154	0.3	0.2	Yu-Zhi constitution type in type 2 diabetes;	chr7:95422340	chr7:95471835~95473998:+
LUAD	cis	rs7493	1	rs2158806	ENSG00000233942.1	AC004012.1	4.53	7.6e-06	0.00154	0.3	0.2	Yu-Zhi constitution type in type 2 diabetes;	chr7:95422686	chr7:95471835~95473998:+
LUAD	cis	rs6714710	0.603	rs58546246	ENSG00000230606.9	AC159540.1	-4.53	7.6e-06	0.00154	-0.21	-0.2	Posterior cortical atrophy and Alzheimer's disease;	chr2:97905360	chr2:97416165~97433527:-
LUAD	cis	rs2380205	0.517	rs7090411	ENSG00000232807.2	RP11-536K7.3	4.53	7.6e-06	0.00154	0.22	0.2	Breast cancer;	chr10:5920764	chr10:5934270~5945900:-
LUAD	cis	rs17684571	0.748	rs13192478	ENSG00000231441.1	RP11-472M19.2	4.53	7.6e-06	0.00154	0.28	0.2	Schizophrenia;	chr6:56719979	chr6:56844002~56864078:+
LUAD	cis	rs17684571	0.872	rs34703847	ENSG00000231441.1	RP11-472M19.2	4.53	7.6e-06	0.00154	0.28	0.2	Schizophrenia;	chr6:56722130	chr6:56844002~56864078:+
LUAD	cis	rs4908760	0.864	rs1463052	ENSG00000270282.1	RP5-1115A15.2	4.53	7.61e-06	0.00154	0.22	0.2	Vitiligo;	chr1:8641172	chr1:8512653~8513021:+
LUAD	cis	rs4664293	0.836	rs4516379	ENSG00000226266.5	AC009961.3	-4.53	7.61e-06	0.00154	-0.28	-0.2	Monocyte percentage of white cells;	chr2:159808892	chr2:159670708~159712435:-
LUAD	cis	rs35264875	0.808	rs2305498	ENSG00000259799.1	RP11-554A11.9	4.53	7.61e-06	0.00154	0.27	0.2	Blond vs. brown hair color;	chr11:69099446	chr11:69155910~69159752:+
LUAD	cis	rs219780	0.898	rs219785	ENSG00000233818.1	AP000695.4	4.53	7.62e-06	0.00154	0.27	0.2	Kidney stones;	chr21:36459562	chr21:36445731~36532408:+
LUAD	cis	rs7804306	0.522	rs34261596	ENSG00000233264.2	AC006042.8	4.53	7.62e-06	0.00154	0.29	0.2	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8036054	chr7:7980312~7982228:+
LUAD	cis	rs7714584	1	rs11957134	ENSG00000197083.10	ZNF300P1	-4.53	7.62e-06	0.00154	-0.39	-0.2	Crohn's disease;	chr5:150851388	chr5:150930645~150946289:-
LUAD	cis	rs6496932	0.503	rs10520588	ENSG00000202081.1	RNU6-1280P	-4.52	7.63e-06	0.00155	-0.27	-0.2	Central corneal thickness;Corneal structure;	chr15:85419479	chr15:85651522~85651628:-
LUAD	cis	rs8180040	0.729	rs11720439	ENSG00000271161.1	BOLA2P2	-4.52	7.63e-06	0.00155	-0.2	-0.2	Colorectal cancer;	chr3:47305513	chr3:47499841~47500407:+
LUAD	cis	rs11971779	0.838	rs11764161	ENSG00000273391.1	RP11-634H22.1	4.52	7.63e-06	0.00155	0.23	0.2	Diisocyanate-induced asthma;	chr7:139430452	chr7:139359032~139359566:-
LUAD	cis	rs6570726	0.764	rs376257	ENSG00000235652.6	RP11-545I5.3	4.52	7.63e-06	0.00155	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145541813	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.693	rs450921	ENSG00000235652.6	RP11-545I5.3	4.52	7.63e-06	0.00155	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145543124	chr6:145799409~145886585:+
LUAD	cis	rs8180040	0.62	rs6767907	ENSG00000271161.1	BOLA2P2	-4.52	7.63e-06	0.00155	-0.19	-0.2	Colorectal cancer;	chr3:47121171	chr3:47499841~47500407:+
LUAD	cis	rs1401999	1	rs13317532	ENSG00000223882.1	ABCC5-AS1	-4.52	7.63e-06	0.00155	-0.21	-0.2	Anterior chamber depth;	chr3:183923881	chr3:184006338~184011419:+
LUAD	cis	rs10895987	0.955	rs12365171	ENSG00000254614.2	AP003068.23	4.52	7.63e-06	0.00155	0.32	0.2	Blood protein levels;	chr11:65161417	chr11:65177606~65181834:-
LUAD	cis	rs4873772	0.735	rs10958058	ENSG00000253330.1	RP11-697N18.3	-4.52	7.64e-06	0.00155	-0.23	-0.2	Lobe attachment (rater-scored or self-reported);	chr8:47592067	chr8:47511034~47512141:-
LUAD	cis	rs11673344	0.764	rs519551	ENSG00000226686.6	LINC01535	4.52	7.64e-06	0.00155	0.26	0.2	Obesity-related traits;	chr19:36965046	chr19:37251912~37265535:+
LUAD	cis	rs7116495	0.737	rs693648	ENSG00000254682.1	RP11-660L16.2	-4.52	7.64e-06	0.00155	-0.4	-0.2	Severe influenza A (H1N1) infection;	chr11:71859400	chr11:71448674~71452157:+
LUAD	cis	rs9322193	0.923	rs9800871	ENSG00000268592.3	RAET1E-AS1	4.52	7.64e-06	0.00155	0.25	0.2	Lung cancer;	chr6:149644540	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.923	rs9800614	ENSG00000268592.3	RAET1E-AS1	4.52	7.64e-06	0.00155	0.25	0.2	Lung cancer;	chr6:149644604	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.923	rs2342765	ENSG00000268592.3	RAET1E-AS1	4.52	7.64e-06	0.00155	0.25	0.2	Lung cancer;	chr6:149858873	chr6:149863494~149919507:+
LUAD	cis	rs6689263	1	rs112662287	ENSG00000117242.7	PINK1-AS	4.52	7.65e-06	0.00155	0.44	0.2	Intelligence (multi-trait analysis);	chr1:20460331	chr1:20642657~20652193:-
LUAD	cis	rs2243480	1	rs35396113	ENSG00000232559.3	GS1-124K5.12	4.52	7.65e-06	0.00155	0.35	0.2	Diabetic kidney disease;	chr7:66030474	chr7:66554588~66576923:-
LUAD	cis	rs2288073	0.965	rs10173949	ENSG00000242628.4	AC009228.1	4.52	7.65e-06	0.00155	0.27	0.2	Venous thromboembolism (SNP x SNP interaction);	chr2:24187387	chr2:24214381~24221516:+
LUAD	cis	rs11673344	0.764	rs826304	ENSG00000226686.6	LINC01535	4.52	7.65e-06	0.00155	0.26	0.2	Obesity-related traits;	chr19:36952681	chr19:37251912~37265535:+
LUAD	cis	rs228614	0.51	rs223410	ENSG00000251288.2	RP11-10L12.2	-4.52	7.65e-06	0.00155	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102813568	chr4:102751401~102752641:+
LUAD	cis	rs7208859	0.673	rs11652370	ENSG00000263603.1	CTD-2349P21.5	-4.52	7.66e-06	0.00155	-0.3	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770205	chr17:30729469~30731202:+
LUAD	cis	rs6840360	0.615	rs4696266	ENSG00000270265.1	RP11-731D1.4	-4.52	7.66e-06	0.00155	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151542269	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.615	rs55932132	ENSG00000270265.1	RP11-731D1.4	-4.52	7.66e-06	0.00155	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151542745	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.615	rs6836249	ENSG00000270265.1	RP11-731D1.4	-4.52	7.66e-06	0.00155	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151544677	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.615	rs72728179	ENSG00000270265.1	RP11-731D1.4	-4.52	7.66e-06	0.00155	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151556725	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.615	rs1561917	ENSG00000270265.1	RP11-731D1.4	-4.52	7.66e-06	0.00155	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151558081	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.615	rs1561916	ENSG00000270265.1	RP11-731D1.4	-4.52	7.66e-06	0.00155	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151558082	chr4:151333775~151353224:-
LUAD	cis	rs3770081	1	rs12620810	ENSG00000273080.1	RP11-301O19.1	-4.52	7.66e-06	0.00155	-0.47	-0.2	Facial emotion recognition (sad faces);	chr2:86164358	chr2:86195590~86196049:+
LUAD	cis	rs13113518	0.756	rs7658446	ENSG00000223305.1	RN7SKP30	4.52	7.66e-06	0.00155	0.24	0.2	Height;	chr4:55495262	chr4:55540502~55540835:-
LUAD	cis	rs228614	0.536	rs223420	ENSG00000251288.2	RP11-10L12.2	-4.52	7.66e-06	0.00155	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102806853	chr4:102751401~102752641:+
LUAD	cis	rs9813712	0.574	rs35856399	ENSG00000249846.5	RP11-77P16.4	-4.52	7.66e-06	0.00155	-0.24	-0.2	Response to amphetamines;	chr3:130241961	chr3:130112550~130120579:+
LUAD	cis	rs228614	0.534	rs223387	ENSG00000251288.2	RP11-10L12.2	-4.52	7.66e-06	0.00155	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102828359	chr4:102751401~102752641:+
LUAD	cis	rs6142102	0.659	rs6057945	ENSG00000275784.1	RP5-1125A11.6	-4.52	7.66e-06	0.00155	-0.22	-0.2	Skin pigmentation;	chr20:33929374	chr20:33989480~33991818:-
LUAD	cis	rs6570726	0.791	rs9322029	ENSG00000235652.6	RP11-545I5.3	4.52	7.66e-06	0.00155	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145585547	chr6:145799409~145886585:+
LUAD	cis	rs227275	0.554	rs223421	ENSG00000251288.2	RP11-10L12.2	-4.52	7.66e-06	0.00155	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102805861	chr4:102751401~102752641:+
LUAD	cis	rs1334894	1	rs2294807	ENSG00000228559.1	RP3-340B19.3	-4.52	7.67e-06	0.00155	-0.43	-0.2	Coronary artery disease;	chr6:35587333	chr6:35544632~35545669:+
LUAD	cis	rs35740288	0.895	rs3743332	ENSG00000259407.1	RP11-158M2.3	-4.52	7.67e-06	0.00155	-0.2	-0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85760520	chr15:85744109~85750281:-
LUAD	cis	rs35740288	0.929	rs11635081	ENSG00000259407.1	RP11-158M2.3	-4.52	7.67e-06	0.00155	-0.2	-0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85761029	chr15:85744109~85750281:-
LUAD	cis	rs897984	0.806	rs8050588	ENSG00000260911.2	RP11-196G11.2	4.52	7.68e-06	0.00156	0.18	0.2	Dementia with Lewy bodies;	chr16:30926478	chr16:31043150~31049868:+
LUAD	cis	rs6969780	1	rs1548497	ENSG00000233429.8	HOTAIRM1	-4.52	7.68e-06	0.00156	-0.34	-0.2	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27134697	chr7:27095647~27100265:+
LUAD	cis	rs801193	0.66	rs974239	ENSG00000232559.3	GS1-124K5.12	4.52	7.68e-06	0.00156	0.24	0.2	Aortic root size;	chr7:66748504	chr7:66554588~66576923:-
LUAD	cis	rs708547	0.581	rs13121027	ENSG00000269949.1	RP11-738E22.3	-4.52	7.68e-06	0.00156	-0.28	-0.2	Response to bleomycin (chromatid breaks);	chr4:56947203	chr4:56960927~56961373:-
LUAD	cis	rs7119	0.717	rs35284122	ENSG00000259362.2	RP11-307C19.1	-4.52	7.68e-06	0.00156	-0.25	-0.2	Type 2 diabetes;	chr15:77512226	chr15:77525540~77534110:+
LUAD	cis	rs7119	0.717	rs62007350	ENSG00000259362.2	RP11-307C19.1	-4.52	7.68e-06	0.00156	-0.25	-0.2	Type 2 diabetes;	chr15:77512248	chr15:77525540~77534110:+
LUAD	cis	rs7119	0.717	rs12901338	ENSG00000259362.2	RP11-307C19.1	-4.52	7.68e-06	0.00156	-0.25	-0.2	Type 2 diabetes;	chr15:77512558	chr15:77525540~77534110:+
LUAD	cis	rs2239547	0.563	rs6445547	ENSG00000242142.1	SERBP1P3	4.52	7.68e-06	0.00156	0.24	0.2	Schizophrenia;	chr3:52874561	chr3:53064283~53065091:-
LUAD	cis	rs5758511	0.514	rs5751240	ENSG00000227370.1	RP4-669P10.19	4.52	7.69e-06	0.00156	0.23	0.2	Birth weight;	chr22:42199252	chr22:42132543~42132998:+
LUAD	cis	rs801193	1	rs4717310	ENSG00000224316.1	RP11-479O9.2	4.52	7.69e-06	0.00156	0.2	0.2	Aortic root size;	chr7:66696020	chr7:65773620~65802067:+
LUAD	cis	rs17772222	0.655	rs816072	ENSG00000258789.1	RP11-507K2.3	4.52	7.69e-06	0.00156	0.24	0.2	Coronary artery calcification;	chr14:88484335	chr14:88551597~88552493:+
LUAD	cis	rs1979679	0.918	rs2169755	ENSG00000278733.1	RP11-425D17.1	4.52	7.69e-06	0.00156	0.25	0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28338224	chr12:28185625~28186190:-
LUAD	cis	rs524281	0.731	rs10791840	ENSG00000255320.1	RP11-755F10.1	4.52	7.7e-06	0.00156	0.34	0.2	Electroencephalogram traits;	chr11:66035912	chr11:66244840~66246239:-
LUAD	cis	rs755249	0.501	rs4660669	ENSG00000182109.6	RP11-69E11.4	-4.52	7.7e-06	0.00156	-0.22	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39341786	chr1:39522280~39546187:-
LUAD	cis	rs227275	0.525	rs10028116	ENSG00000251288.2	RP11-10L12.2	-4.52	7.7e-06	0.00156	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102931421	chr4:102751401~102752641:+
LUAD	cis	rs2933343	0.951	rs789218	ENSG00000231305.3	RP11-723O4.2	4.52	7.7e-06	0.00156	0.24	0.2	IgG glycosylation;	chr3:128873827	chr3:128861313~128871540:-
LUAD	cis	rs6840360	0.571	rs55808836	ENSG00000270265.1	RP11-731D1.4	-4.52	7.7e-06	0.00156	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151633839	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.571	rs11726892	ENSG00000270265.1	RP11-731D1.4	-4.52	7.7e-06	0.00156	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151633954	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.55	rs7689266	ENSG00000270265.1	RP11-731D1.4	-4.52	7.7e-06	0.00156	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151639896	chr4:151333775~151353224:-
LUAD	cis	rs6570726	0.791	rs7755253	ENSG00000235652.6	RP11-545I5.3	4.52	7.7e-06	0.00156	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145537757	chr6:145799409~145886585:+
LUAD	cis	rs7590268	0.636	rs35590893	ENSG00000279873.2	LINC01126	4.52	7.7e-06	0.00156	0.19	0.2	Orofacial clefts;	chr2:43489794	chr2:43227210~43228855:+
LUAD	cis	rs950169	0.922	rs8037078	ENSG00000275120.1	RP11-182J1.17	-4.52	7.71e-06	0.00156	-0.32	-0.2	Schizophrenia;	chr15:84150119	chr15:84599434~84606463:-
LUAD	cis	rs2310173	0.575	rs719248	ENSG00000281162.1	LINC01127	-4.52	7.71e-06	0.00156	-0.23	-0.2	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:102007413	chr2:101962056~101987167:+
LUAD	cis	rs2243480	0.901	rs2949697	ENSG00000232559.3	GS1-124K5.12	4.52	7.72e-06	0.00156	0.35	0.2	Diabetic kidney disease;	chr7:65999249	chr7:66554588~66576923:-
LUAD	cis	rs1555322	0.53	rs2425043	ENSG00000126005.14	MMP24-AS1	-4.52	7.73e-06	0.00156	-0.28	-0.2	Attention deficit hyperactivity disorder;	chr20:35280899	chr20:35216462~35278131:-
LUAD	cis	rs17685	0.753	rs10245584	ENSG00000280388.1	RP11-229D13.3	-4.52	7.73e-06	0.00156	-0.19	-0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76116548	chr7:76043977~76045963:-
LUAD	cis	rs11051970	0.636	rs2651368	ENSG00000274964.1	RP11-817I4.1	-4.52	7.74e-06	0.00157	-0.2	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr12:32408572	chr12:32339368~32340724:+
LUAD	cis	rs11051970	0.636	rs2733705	ENSG00000274964.1	RP11-817I4.1	-4.52	7.74e-06	0.00157	-0.2	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr12:32408630	chr12:32339368~32340724:+
LUAD	cis	rs11051970	0.636	rs10844198	ENSG00000274964.1	RP11-817I4.1	-4.52	7.74e-06	0.00157	-0.2	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr12:32410545	chr12:32339368~32340724:+
LUAD	cis	rs6570726	0.935	rs400968	ENSG00000235652.6	RP11-545I5.3	4.52	7.74e-06	0.00157	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145498582	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs391820	ENSG00000235652.6	RP11-545I5.3	4.52	7.74e-06	0.00157	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145500148	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.875	rs1883407	ENSG00000235652.6	RP11-545I5.3	4.52	7.74e-06	0.00157	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145502296	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.935	rs367612	ENSG00000235652.6	RP11-545I5.3	4.52	7.74e-06	0.00157	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145507851	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.905	rs375692	ENSG00000235652.6	RP11-545I5.3	4.52	7.74e-06	0.00157	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145519232	chr6:145799409~145886585:+
LUAD	cis	rs7191700	0.578	rs243327	ENSG00000262703.1	RP11-485G7.6	-4.52	7.75e-06	0.00157	-0.18	-0.2	Multiple sclerosis;	chr16:11259447	chr16:11348143~11349321:-
LUAD	cis	rs748404	0.697	rs579651	ENSG00000249839.1	AC011330.5	-4.52	7.75e-06	0.00157	-0.26	-0.2	Lung cancer;	chr15:43266178	chr15:43663654~43684339:-
LUAD	cis	rs875971	0.54	rs736270	ENSG00000224316.1	RP11-479O9.2	4.52	7.75e-06	0.00157	0.2	0.2	Aortic root size;	chr7:65963835	chr7:65773620~65802067:+
LUAD	cis	rs2252586	0.792	rs6945082	ENSG00000176826.14	FKBP9P1	-4.52	7.75e-06	0.00157	-0.27	-0.2	Glioma;	chr7:54890765	chr7:55681074~55713252:-
LUAD	cis	rs9652601	0.92	rs12923098	ENSG00000274038.1	RP11-66H6.4	-4.52	7.75e-06	0.00157	-0.25	-0.2	Systemic lupus erythematosus;	chr16:11083196	chr16:11056556~11057034:+
LUAD	cis	rs911119	0.955	rs17751897	ENSG00000270001.1	RP11-218C14.8	-4.52	7.76e-06	0.00157	-0.29	-0.2	Chronic kidney disease;	chr20:23612077	chr20:23631826~23632316:-
LUAD	cis	rs911119	0.955	rs67997662	ENSG00000270001.1	RP11-218C14.8	-4.52	7.76e-06	0.00157	-0.29	-0.2	Chronic kidney disease;	chr20:23612227	chr20:23631826~23632316:-
LUAD	cis	rs2976388	1	rs2920294	ENSG00000253741.1	CTD-2292P10.4	4.52	7.76e-06	0.00157	0.23	0.2	Urinary tract infection frequency;	chr8:142683908	chr8:142702252~142726973:-
LUAD	cis	rs2976388	1	rs2920293	ENSG00000253741.1	CTD-2292P10.4	4.52	7.76e-06	0.00157	0.23	0.2	Urinary tract infection frequency;	chr8:142683996	chr8:142702252~142726973:-
LUAD	cis	rs2976388	1	rs2920292	ENSG00000253741.1	CTD-2292P10.4	4.52	7.76e-06	0.00157	0.23	0.2	Urinary tract infection frequency;	chr8:142684281	chr8:142702252~142726973:-
LUAD	cis	rs7208859	0.623	rs79607958	ENSG00000266490.1	CTD-2349P21.9	4.52	7.76e-06	0.00157	0.32	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607530	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs75136574	ENSG00000266490.1	CTD-2349P21.9	4.52	7.76e-06	0.00157	0.32	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607531	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs77544470	ENSG00000266490.1	CTD-2349P21.9	4.52	7.76e-06	0.00157	0.32	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607532	chr17:30792372~30792833:+
LUAD	cis	rs2880765	0.677	rs7181410	ENSG00000259295.5	CSPG4P12	-4.52	7.77e-06	0.00157	-0.23	-0.2	Coronary artery disease;	chr15:85463104	chr15:85191438~85213905:+
LUAD	cis	rs7208859	0.623	rs11658022	ENSG00000266490.1	CTD-2349P21.9	4.52	7.77e-06	0.00157	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30792372~30792833:+
LUAD	cis	rs9473147	0.602	rs9296567	ENSG00000270761.1	RP11-385F7.1	-4.52	7.77e-06	0.00157	-0.24	-0.2	Platelet distribution width;Mean platelet volume;	chr6:47585666	chr6:47477243~47477572:-
LUAD	cis	rs9473147	0.571	rs9395285	ENSG00000270761.1	RP11-385F7.1	-4.52	7.77e-06	0.00157	-0.24	-0.2	Platelet distribution width;Mean platelet volume;	chr6:47586441	chr6:47477243~47477572:-
LUAD	cis	rs9322193	0.923	rs10782317	ENSG00000268592.3	RAET1E-AS1	-4.52	7.78e-06	0.00157	-0.24	-0.2	Lung cancer;	chr6:149753911	chr6:149863494~149919507:+
LUAD	cis	rs4713118	0.699	rs573179	ENSG00000280107.1	AL022393.9	-4.52	7.78e-06	0.00157	-0.27	-0.2	Parkinson's disease;	chr6:27881898	chr6:28170845~28172521:+
LUAD	cis	rs227275	0.524	rs223337	ENSG00000251288.2	RP11-10L12.2	-4.52	7.78e-06	0.00157	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102865214	chr4:102751401~102752641:+
LUAD	cis	rs875971	0.66	rs7807930	ENSG00000236529.1	RP13-254B10.1	-4.52	7.78e-06	0.00157	-0.2	-0.2	Aortic root size;	chr7:66622178	chr7:65840212~65840596:+
LUAD	cis	rs875971	0.66	rs7807944	ENSG00000236529.1	RP13-254B10.1	-4.52	7.78e-06	0.00157	-0.2	-0.2	Aortic root size;	chr7:66622208	chr7:65840212~65840596:+
LUAD	cis	rs9425766	0.679	rs6695636	ENSG00000227373.4	RP11-160H22.5	4.52	7.78e-06	0.00157	0.26	0.2	Life satisfaction;	chr1:174303087	chr1:174115300~174160004:-
LUAD	cis	rs45509595	0.841	rs370155	ENSG00000219392.1	RP1-265C24.5	-4.52	7.79e-06	0.00157	-0.38	-0.2	Breast cancer;	chr6:27814253	chr6:28115628~28116551:+
LUAD	cis	rs11051970	0.559	rs56670459	ENSG00000274964.1	RP11-817I4.1	-4.52	7.79e-06	0.00157	-0.28	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr12:32390391	chr12:32339368~32340724:+
LUAD	cis	rs12200782	0.53	rs9379892	ENSG00000241549.7	GUSBP2	4.52	7.79e-06	0.00158	0.28	0.2	Small cell lung carcinoma;	chr6:26582186	chr6:26871484~26956554:-
LUAD	cis	rs7432375	0.61	rs56163507	ENSG00000239213.4	NCK1-AS1	4.52	7.8e-06	0.00158	0.21	0.2	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136797214	chr3:136841726~136862054:-
LUAD	cis	rs35740288	0.929	rs1978391	ENSG00000259407.1	RP11-158M2.3	4.52	7.8e-06	0.00158	0.2	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85768464	chr15:85744109~85750281:-
LUAD	cis	rs6479901	0.947	rs10761781	ENSG00000232075.1	MRPL35P2	4.52	7.81e-06	0.00158	0.28	0.2	Intelligence (multi-trait analysis);	chr10:63524843	chr10:63634317~63634827:-
LUAD	cis	rs1005277	0.579	rs2472178	ENSG00000263064.2	RP11-291L22.7	4.52	7.81e-06	0.00158	0.21	0.2	Extrinsic epigenetic age acceleration;	chr10:38095822	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.579	rs2474572	ENSG00000263064.2	RP11-291L22.7	4.52	7.81e-06	0.00158	0.21	0.2	Extrinsic epigenetic age acceleration;	chr10:38096388	chr10:38448689~38448949:+
LUAD	cis	rs748404	0.697	rs531910	ENSG00000249839.1	AC011330.5	-4.52	7.81e-06	0.00158	-0.26	-0.2	Lung cancer;	chr15:43268409	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.697	rs491804	ENSG00000249839.1	AC011330.5	-4.52	7.81e-06	0.00158	-0.26	-0.2	Lung cancer;	chr15:43268627	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.697	rs492743	ENSG00000249839.1	AC011330.5	-4.52	7.81e-06	0.00158	-0.26	-0.2	Lung cancer;	chr15:43268747	chr15:43663654~43684339:-
LUAD	cis	rs9400467	0.528	rs445349	ENSG00000271789.1	RP5-1112D6.7	4.52	7.81e-06	0.00158	0.21	0.2	Amino acid levels;Blood metabolite levels;	chr6:111340899	chr6:111297126~111298510:+
LUAD	cis	rs10050311	0.685	rs7678571	ENSG00000251411.1	RP11-397E7.4	-4.52	7.82e-06	0.00158	-0.23	-0.2	Insulin-related traits;	chr4:86833560	chr4:86913266~86914817:-
LUAD	cis	rs12754538	0.808	rs2024774	ENSG00000232912.4	RP5-1115A15.1	4.52	7.82e-06	0.00158	0.22	0.2	Subjective well-being;	chr1:8510397	chr1:8424645~8434838:+
LUAD	cis	rs2617170	0.961	rs1841957	ENSG00000245648.1	RP11-277P12.20	4.52	7.82e-06	0.00158	0.24	0.2	Behcet's disease;	chr12:10409426	chr12:10363769~10398506:+
LUAD	cis	rs4143844	1	rs34017665	ENSG00000259251.2	RP11-643M14.1	4.52	7.82e-06	0.00158	0.36	0.2	Bipolar disorder and schizophrenia;	chr15:62027008	chr15:62060503~62062434:+
LUAD	cis	rs2976388	0.935	rs2920285	ENSG00000253741.1	CTD-2292P10.4	4.52	7.82e-06	0.00158	0.23	0.2	Urinary tract infection frequency;	chr8:142674800	chr8:142702252~142726973:-
LUAD	cis	rs2976388	0.935	rs2978978	ENSG00000253741.1	CTD-2292P10.4	4.52	7.82e-06	0.00158	0.23	0.2	Urinary tract infection frequency;	chr8:142675112	chr8:142702252~142726973:-
LUAD	cis	rs2976388	0.935	rs2920284	ENSG00000253741.1	CTD-2292P10.4	4.52	7.82e-06	0.00158	0.23	0.2	Urinary tract infection frequency;	chr8:142675501	chr8:142702252~142726973:-
LUAD	cis	rs2976388	1	rs2920283	ENSG00000253741.1	CTD-2292P10.4	4.52	7.82e-06	0.00158	0.23	0.2	Urinary tract infection frequency;	chr8:142675619	chr8:142702252~142726973:-
LUAD	cis	rs1005277	0.579	rs2474568	ENSG00000263064.2	RP11-291L22.7	4.52	7.82e-06	0.00158	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38094219	chr10:38448689~38448949:+
LUAD	cis	rs2492286	0.569	rs9848287	ENSG00000242551.2	POU5F1P6	-4.52	7.82e-06	0.00158	-0.27	-0.2	Eosinophil counts;	chr3:128628799	chr3:128674735~128677005:-
LUAD	cis	rs2492286	0.569	rs2712383	ENSG00000242551.2	POU5F1P6	-4.52	7.82e-06	0.00158	-0.27	-0.2	Eosinophil counts;	chr3:128629033	chr3:128674735~128677005:-
LUAD	cis	rs227275	0.556	rs223398	ENSG00000251288.2	RP11-10L12.2	-4.52	7.83e-06	0.00158	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102821256	chr4:102751401~102752641:+
LUAD	cis	rs11168351	0.889	rs12817104	ENSG00000257735.1	RP11-370I10.6	4.52	7.83e-06	0.00158	0.25	0.2	Bipolar disorder and schizophrenia;	chr12:47988790	chr12:48350945~48442411:+
LUAD	cis	rs228614	0.51	rs223434	ENSG00000251288.2	RP11-10L12.2	-4.52	7.83e-06	0.00158	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799902	chr4:102751401~102752641:+
LUAD	cis	rs9322193	1	rs9377228	ENSG00000268592.3	RAET1E-AS1	4.52	7.83e-06	0.00158	0.25	0.2	Lung cancer;	chr6:149600862	chr6:149863494~149919507:+
LUAD	cis	rs5758659	0.716	rs86669	ENSG00000182057.4	OGFRP1	4.52	7.83e-06	0.00158	0.24	0.2	Cognitive function;	chr22:42284794	chr22:42269753~42275196:+
LUAD	cis	rs2274273	0.588	rs17128145	ENSG00000258413.1	RP11-665C16.6	4.52	7.83e-06	0.00158	0.26	0.2	Protein biomarker;	chr14:55069688	chr14:55262767~55272075:-
LUAD	cis	rs4968361	0.892	rs68025251	ENSG00000266992.1	DHX40P1	4.52	7.83e-06	0.00158	0.37	0.2	Schizophrenia;	chr17:59442071	chr17:59976009~60002384:-
LUAD	cis	rs6687821	0.531	rs7553360	ENSG00000267734.1	RP4-604K5.3	-4.52	7.84e-06	0.00158	-0.27	-0.2	Yeast infection;	chr1:87069032	chr1:86932199~86934891:-
LUAD	cis	rs7116495	0.737	rs7126838	ENSG00000254682.1	RP11-660L16.2	-4.52	7.84e-06	0.00158	-0.44	-0.2	Severe influenza A (H1N1) infection;	chr11:72115191	chr11:71448674~71452157:+
LUAD	cis	rs7116495	1	rs73543633	ENSG00000254682.1	RP11-660L16.2	-4.52	7.84e-06	0.00158	-0.44	-0.2	Severe influenza A (H1N1) infection;	chr11:72117798	chr11:71448674~71452157:+
LUAD	cis	rs7116495	1	rs12283462	ENSG00000254682.1	RP11-660L16.2	-4.52	7.84e-06	0.00158	-0.44	-0.2	Severe influenza A (H1N1) infection;	chr11:72124360	chr11:71448674~71452157:+
LUAD	cis	rs1816752	0.776	rs7998843	ENSG00000273628.1	RP11-756A22.7	4.52	7.85e-06	0.00158	0.23	0.2	Obesity-related traits;	chr13:24443147	chr13:24933006~24936796:+
LUAD	cis	rs9322193	0.923	rs9322207	ENSG00000268592.3	RAET1E-AS1	4.52	7.85e-06	0.00158	0.25	0.2	Lung cancer;	chr6:149657185	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.923	rs9322208	ENSG00000268592.3	RAET1E-AS1	4.52	7.85e-06	0.00158	0.25	0.2	Lung cancer;	chr6:149658547	chr6:149863494~149919507:+
LUAD	cis	rs35160687	0.644	rs11680025	ENSG00000273080.1	RP11-301O19.1	-4.52	7.85e-06	0.00159	-0.22	-0.2	Night sleep phenotypes;	chr2:86318215	chr2:86195590~86196049:+
LUAD	cis	rs8062405	0.72	rs9926245	ENSG00000251417.2	RP11-1348G14.4	-4.52	7.85e-06	0.00159	-0.2	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28802743~28817828:+
LUAD	cis	rs17818399	0.645	rs35870739	ENSG00000279254.1	RP11-536C12.1	-4.52	7.85e-06	0.00159	-0.25	-0.2	Height;	chr2:46557092	chr2:46668870~46670778:+
LUAD	cis	rs2933343	0.7	rs883602	ENSG00000231305.3	RP11-723O4.2	4.52	7.85e-06	0.00159	0.22	0.2	IgG glycosylation;	chr3:128935109	chr3:128861313~128871540:-
LUAD	cis	rs9425766	0.679	rs7555067	ENSG00000227373.4	RP11-160H22.5	4.52	7.86e-06	0.00159	0.26	0.2	Life satisfaction;	chr1:174297504	chr1:174115300~174160004:-
LUAD	cis	rs875971	0.898	rs6977501	ENSG00000232559.3	GS1-124K5.12	-4.52	7.86e-06	0.00159	-0.24	-0.2	Aortic root size;	chr7:66228355	chr7:66554588~66576923:-
LUAD	cis	rs17772222	1	rs3814855	ENSG00000258983.2	RP11-507K2.2	4.52	7.86e-06	0.00159	0.25	0.2	Coronary artery calcification;	chr14:88467016	chr14:88499334~88515502:+
LUAD	cis	rs2310173	0.575	rs11123902	ENSG00000281162.1	LINC01127	-4.52	7.86e-06	0.00159	-0.23	-0.2	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:101994180	chr2:101962056~101987167:+
LUAD	cis	rs4927850	0.709	rs6783079	ENSG00000242086.7	LINC00969	4.52	7.86e-06	0.00159	0.19	0.2	Pancreatic cancer;	chr3:195925837	chr3:195658062~195739964:+
LUAD	cis	rs4927850	0.709	rs6765762	ENSG00000242086.7	LINC00969	4.52	7.86e-06	0.00159	0.19	0.2	Pancreatic cancer;	chr3:195925980	chr3:195658062~195739964:+
LUAD	cis	rs6723108	0.517	rs6430548	ENSG00000224043.6	CCNT2-AS1	-4.52	7.87e-06	0.00159	-0.25	-0.2	Type 2 diabetes;	chr2:134854869	chr2:134735464~134918710:-
LUAD	cis	rs35740288	0.685	rs12899481	ENSG00000259407.1	RP11-158M2.3	-4.52	7.87e-06	0.00159	-0.2	-0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85765739	chr15:85744109~85750281:-
LUAD	cis	rs13256369	0.865	rs13282523	ENSG00000253893.2	FAM85B	-4.52	7.87e-06	0.00159	-0.27	-0.2	Obesity-related traits;	chr8:8719783	chr8:8167819~8226614:-
LUAD	cis	rs2439831	0.85	rs3825783	ENSG00000249839.1	AC011330.5	-4.52	7.87e-06	0.00159	-0.41	-0.2	Lung cancer in ever smokers;	chr15:43810111	chr15:43663654~43684339:-
LUAD	cis	rs1400816	0.85	rs59414074	ENSG00000228389.1	AC068039.4	-4.52	7.88e-06	0.00159	-0.32	-0.2	Amyotrophic lateral sclerosis (sporadic);	chr2:171678688	chr2:171773482~171775844:+
LUAD	cis	rs6568686	0.577	rs383515	ENSG00000255389.1	C6orf3	4.52	7.88e-06	0.00159	0.27	0.2	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111595465	chr6:111599875~111602295:+
LUAD	cis	rs60180747	0.544	rs11632542	ENSG00000261318.1	RP11-653J6.1	-4.52	7.89e-06	0.00159	-0.26	-0.2	Testicular germ cell tumor;	chr15:66267733	chr15:66278498~66293357:-
LUAD	cis	rs2446066	0.872	rs12368222	ENSG00000257379.1	RP11-793H13.8	4.52	7.89e-06	0.00159	0.34	0.2	Red blood cell count;	chr12:53430960	chr12:53441741~53467528:+
LUAD	cis	rs2446066	0.872	rs7309494	ENSG00000257379.1	RP11-793H13.8	4.52	7.89e-06	0.00159	0.34	0.2	Red blood cell count;	chr12:53432209	chr12:53441741~53467528:+
LUAD	cis	rs2281636	0.6	rs56901709	ENSG00000233690.1	EBAG9P1	4.52	7.89e-06	0.00159	0.21	0.2	Obesity-related traits;	chr10:99639205	chr10:99697407~99697949:-
LUAD	cis	rs925255	0.81	rs1396733	ENSG00000270210.1	RP11-373D23.3	-4.52	7.89e-06	0.00159	-0.24	-0.2	Inflammatory bowel disease;Crohn's disease;	chr2:28419880	chr2:28425945~28426719:+
LUAD	cis	rs2933343	0.679	rs789229	ENSG00000261159.1	RP11-723O4.9	4.52	7.89e-06	0.00159	0.22	0.2	IgG glycosylation;	chr3:128883683	chr3:128859716~128860526:-
LUAD	cis	rs2933343	0.729	rs789230	ENSG00000261159.1	RP11-723O4.9	4.52	7.89e-06	0.00159	0.22	0.2	IgG glycosylation;	chr3:128883715	chr3:128859716~128860526:-
LUAD	cis	rs2933343	0.729	rs6790091	ENSG00000261159.1	RP11-723O4.9	4.52	7.89e-06	0.00159	0.22	0.2	IgG glycosylation;	chr3:128889908	chr3:128859716~128860526:-
LUAD	cis	rs7208859	0.673	rs2470251	ENSG00000263603.1	CTD-2349P21.5	-4.52	7.89e-06	0.00159	-0.3	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30768043	chr17:30729469~30731202:+
LUAD	cis	rs1005277	0.522	rs9417256	ENSG00000263064.2	RP11-291L22.7	4.52	7.89e-06	0.00159	0.21	0.2	Extrinsic epigenetic age acceleration;	chr10:37688062	chr10:38448689~38448949:+
LUAD	cis	rs12999542	0.636	rs17821875	ENSG00000234389.1	AC007278.3	4.52	7.89e-06	0.00159	0.32	0.2	Serum protein levels (sST2);	chr2:102454570	chr2:102438713~102440475:+
LUAD	cis	rs950169	0.84	rs72748702	ENSG00000275120.1	RP11-182J1.17	4.52	7.89e-06	0.00159	0.32	0.2	Schizophrenia;	chr15:84246494	chr15:84599434~84606463:-
LUAD	cis	rs6689263	1	rs74335351	ENSG00000117242.7	PINK1-AS	4.52	7.89e-06	0.00159	0.44	0.2	Intelligence (multi-trait analysis);	chr1:20450528	chr1:20642657~20652193:-
LUAD	cis	rs6754311	0.773	rs309137	ENSG00000226806.1	AC011893.3	4.52	7.89e-06	0.00159	0.25	0.2	Mosquito bite size;	chr2:136008381	chr2:135820191~135823087:+
LUAD	cis	rs853679	0.546	rs493161	ENSG00000219392.1	RP1-265C24.5	-4.52	7.89e-06	0.00159	-0.4	-0.2	Depression;	chr6:27882936	chr6:28115628~28116551:+
LUAD	cis	rs2243480	1	rs12698509	ENSG00000226002.1	RP11-460N20.5	-4.52	7.89e-06	0.00159	-0.34	-0.2	Diabetic kidney disease;	chr7:65953889	chr7:65084103~65100232:+
LUAD	cis	rs1113500	0.814	rs12039712	ENSG00000226822.1	RP11-356N1.2	4.52	7.89e-06	0.00159	0.23	0.2	Growth-regulated protein alpha levels;	chr1:108098577	chr1:108071482~108074519:+
LUAD	cis	rs9987353	0.544	rs2929470	ENSG00000253893.2	FAM85B	4.52	7.9e-06	0.00159	0.26	0.2	Recombination measurement;	chr8:9204980	chr8:8167819~8226614:-
LUAD	cis	rs3096299	0.503	rs9940093	ENSG00000182376.2	RP5-1142A6.8	4.52	7.9e-06	0.00159	0.21	0.2	Multiple myeloma (IgH translocation);	chr16:89492297	chr16:88742767~88745748:+
LUAD	cis	rs4568518	0.557	rs13224298	ENSG00000279048.1	RP11-511H23.2	4.52	7.9e-06	0.00159	0.17	0.2	Measles;	chr7:17962503	chr7:17940503~17942922:+
LUAD	cis	rs2310173	0.575	rs2110563	ENSG00000281162.1	LINC01127	-4.52	7.9e-06	0.00159	-0.23	-0.2	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:102011971	chr2:101962056~101987167:+
LUAD	cis	rs7208859	0.623	rs73271869	ENSG00000263603.1	CTD-2349P21.5	-4.52	7.9e-06	0.00159	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825203	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs73271872	ENSG00000263603.1	CTD-2349P21.5	-4.52	7.9e-06	0.00159	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825210	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs56146117	ENSG00000263603.1	CTD-2349P21.5	-4.52	7.9e-06	0.00159	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826307	chr17:30729469~30731202:+
LUAD	cis	rs17826219	0.568	rs9907834	ENSG00000263603.1	CTD-2349P21.5	-4.52	7.9e-06	0.00159	-0.36	-0.2	Body mass index;	chr17:30826995	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs73271887	ENSG00000263603.1	CTD-2349P21.5	-4.52	7.9e-06	0.00159	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827917	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs9898858	ENSG00000263603.1	CTD-2349P21.5	-4.52	7.9e-06	0.00159	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829193	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs55658077	ENSG00000263603.1	CTD-2349P21.5	-4.52	7.9e-06	0.00159	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829501	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs9899692	ENSG00000263603.1	CTD-2349P21.5	-4.52	7.9e-06	0.00159	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829921	chr17:30729469~30731202:+
LUAD	cis	rs9545047	0.604	rs912639	ENSG00000227354.5	RBM26-AS1	-4.52	7.9e-06	0.00159	-0.21	-0.2	Schizophrenia;	chr13:79409788	chr13:79406309~79424328:+
LUAD	cis	rs683257	0.636	rs72988149	ENSG00000234147.1	RP3-460G2.2	-4.52	7.9e-06	0.00159	-0.32	-0.2	Facial emotion recognition (angry faces);	chr6:140829500	chr6:140845958~140852924:-
LUAD	cis	rs853679	0.599	rs149990	ENSG00000219392.1	RP1-265C24.5	-4.52	7.91e-06	0.0016	-0.35	-0.2	Depression;	chr6:28030480	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.599	rs149943	ENSG00000219392.1	RP1-265C24.5	-4.52	7.91e-06	0.0016	-0.35	-0.2	Depression;	chr6:28034610	chr6:28115628~28116551:+
LUAD	cis	rs9425766	0.679	rs2064149	ENSG00000227373.4	RP11-160H22.5	4.52	7.92e-06	0.0016	0.25	0.2	Life satisfaction;	chr1:174255856	chr1:174115300~174160004:-
LUAD	cis	rs2243480	0.711	rs2460426	ENSG00000229886.1	RP5-1132H15.3	-4.52	7.92e-06	0.0016	-0.35	-0.2	Diabetic kidney disease;	chr7:66158142	chr7:66025126~66031544:-
LUAD	cis	rs6453278	1	rs6453278	ENSG00000250802.5	ZBED3-AS1	4.52	7.92e-06	0.0016	0.23	0.2	Autism;	chr5:77121217	chr5:77086740~77166909:+
LUAD	cis	rs2735413	0.75	rs75500355	ENSG00000276007.1	RP11-358L22.3	4.52	7.93e-06	0.0016	0.24	0.2	Systolic blood pressure (alcohol consumption interaction);	chr16:78041499	chr16:78123243~78124332:+
LUAD	cis	rs6570726	1	rs404229	ENSG00000235652.6	RP11-545I5.3	4.52	7.93e-06	0.0016	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145547064	chr6:145799409~145886585:+
LUAD	cis	rs910316	1	rs11623413	ENSG00000279594.1	RP11-950C14.10	-4.52	7.93e-06	0.0016	-0.23	-0.2	Height;	chr14:75122121	chr14:75011269~75012851:-
LUAD	cis	rs42490	0.625	rs427854	ENSG00000251136.7	RP11-37B2.1	-4.52	7.93e-06	0.0016	-0.22	-0.2	Leprosy;	chr8:89843518	chr8:89609409~89757727:-
LUAD	cis	rs9545047	0.604	rs9574410	ENSG00000227354.5	RBM26-AS1	-4.52	7.93e-06	0.0016	-0.21	-0.2	Schizophrenia;	chr13:79343091	chr13:79406309~79424328:+
LUAD	cis	rs6723108	0.627	rs4954189	ENSG00000224043.6	CCNT2-AS1	-4.52	7.93e-06	0.0016	-0.25	-0.2	Type 2 diabetes;	chr2:134849763	chr2:134735464~134918710:-
LUAD	cis	rs6723108	0.627	rs10432371	ENSG00000224043.6	CCNT2-AS1	-4.52	7.93e-06	0.0016	-0.25	-0.2	Type 2 diabetes;	chr2:134852176	chr2:134735464~134918710:-
LUAD	cis	rs2548724	0.716	rs62371032	ENSG00000250682.4	LINC00491	4.52	7.93e-06	0.0016	0.26	0.2	Type 2 diabetes;	chr5:102477185	chr5:102609156~102671559:-
LUAD	cis	rs2153535	0.585	rs11243268	ENSG00000230939.1	RP11-314C16.1	-4.52	7.93e-06	0.0016	-0.23	-0.2	Motion sickness;	chr6:8662375	chr6:8784178~8785445:+
LUAD	cis	rs1008375	0.966	rs2159582	ENSG00000249502.1	AC006160.5	-4.52	7.94e-06	0.0016	-0.19	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17694032	chr4:17587467~17614571:-
LUAD	cis	rs1729951	0.575	rs35289288	ENSG00000239213.4	NCK1-AS1	4.52	7.94e-06	0.0016	0.22	0.2	Neuroticism;	chr3:136961726	chr3:136841726~136862054:-
LUAD	cis	rs11023332	0.617	rs1451678	ENSG00000251991.1	RNU7-49P	4.52	7.95e-06	0.0016	0.22	0.2	Vitamin D levels;Adiponectin levels;	chr11:14760075	chr11:14478892~14478953:+
LUAD	cis	rs35264875	0.851	rs72930631	ENSG00000259799.1	RP11-554A11.9	4.52	7.95e-06	0.0016	0.27	0.2	Blond vs. brown hair color;	chr11:69100367	chr11:69155910~69159752:+
LUAD	cis	rs453301	0.686	rs3989373	ENSG00000233609.3	RP11-62H7.2	-4.52	7.95e-06	0.0016	-0.16	-0.2	Joint mobility (Beighton score);	chr8:9053798	chr8:8961200~8979025:+
LUAD	cis	rs9876781	1	rs7636044	ENSG00000229759.1	MRPS18AP1	4.52	7.96e-06	0.0016	0.19	0.2	Longevity;	chr3:48443151	chr3:48256350~48256938:-
LUAD	cis	rs9876781	1	rs4490383	ENSG00000229759.1	MRPS18AP1	4.52	7.96e-06	0.0016	0.19	0.2	Longevity;	chr3:48443275	chr3:48256350~48256938:-
LUAD	cis	rs7580658	0.545	rs885275	ENSG00000236682.1	AC068282.3	-4.52	7.96e-06	0.00161	-0.26	-0.2	Protein C levels;	chr2:127193519	chr2:127389130~127400580:+
LUAD	cis	rs801193	1	rs2707836	ENSG00000224316.1	RP11-479O9.2	4.52	7.97e-06	0.00161	0.2	0.2	Aortic root size;	chr7:66695448	chr7:65773620~65802067:+
LUAD	cis	rs801193	0.844	rs7779971	ENSG00000224316.1	RP11-479O9.2	4.52	7.97e-06	0.00161	0.2	0.2	Aortic root size;	chr7:66696803	chr7:65773620~65802067:+
LUAD	cis	rs9322193	0.923	rs9800580	ENSG00000268592.3	RAET1E-AS1	4.52	7.97e-06	0.00161	0.25	0.2	Lung cancer;	chr6:149632845	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.884	rs11155669	ENSG00000268592.3	RAET1E-AS1	4.52	7.97e-06	0.00161	0.25	0.2	Lung cancer;	chr6:149633501	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.887	rs9505824	ENSG00000268592.3	RAET1E-AS1	4.52	7.97e-06	0.00161	0.25	0.2	Lung cancer;	chr6:149633663	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.923	rs9505826	ENSG00000268592.3	RAET1E-AS1	4.52	7.97e-06	0.00161	0.25	0.2	Lung cancer;	chr6:149633912	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.923	rs9766886	ENSG00000268592.3	RAET1E-AS1	4.52	7.97e-06	0.00161	0.25	0.2	Lung cancer;	chr6:149637048	chr6:149863494~149919507:+
LUAD	cis	rs1447352	0.777	rs11020127	ENSG00000279684.1	RP11-755E23.2	-4.52	7.97e-06	0.00161	-0.25	-0.2	Metabolic traits;	chr11:92974394	chr11:93286629~93288903:-
LUAD	cis	rs11779988	0.545	rs397096	ENSG00000253671.1	RP11-806O11.1	4.52	7.97e-06	0.00161	0.24	0.2	Breast cancer;	chr8:17941339	chr8:17808941~17820868:+
LUAD	cis	rs853679	0.567	rs16894091	ENSG00000216901.1	AL022393.7	-4.51	7.97e-06	0.00161	-0.25	-0.2	Depression;	chr6:28422360	chr6:28176188~28176674:+
LUAD	cis	rs10129255	0.956	rs10137268	ENSG00000211974.3	IGHV2-70	4.51	7.98e-06	0.00161	0.22	0.2	Kawasaki disease;	chr14:106697402	chr14:106723574~106724093:-
LUAD	cis	rs6687758	1	rs12121134	ENSG00000200033.1	RNU6-403P	4.51	7.98e-06	0.00161	0.28	0.2	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222021538	chr1:221837334~221837437:-
LUAD	cis	rs6687758	1	rs56170536	ENSG00000200033.1	RNU6-403P	4.51	7.98e-06	0.00161	0.28	0.2	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222024527	chr1:221837334~221837437:-
LUAD	cis	rs6687758	1	rs66732677	ENSG00000200033.1	RNU6-403P	4.51	7.98e-06	0.00161	0.28	0.2	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222026325	chr1:221837334~221837437:-
LUAD	cis	rs7005380	0.581	rs2326432	ENSG00000279347.1	RP11-85I17.2	-4.51	7.98e-06	0.00161	-0.2	-0.2	Interstitial lung disease;	chr8:119920672	chr8:119838736~119840385:-
LUAD	cis	rs17818399	0.749	rs13000560	ENSG00000279254.1	RP11-536C12.1	-4.51	7.98e-06	0.00161	-0.25	-0.2	Height;	chr2:46563858	chr2:46668870~46670778:+
LUAD	cis	rs6723226	0.739	rs2754525	ENSG00000276334.1	AL133243.1	4.51	7.98e-06	0.00161	0.23	0.2	Intelligence (multi-trait analysis);	chr2:32580219	chr2:32521927~32523547:+
LUAD	cis	rs227275	0.554	rs223382	ENSG00000251288.2	RP11-10L12.2	-4.51	7.98e-06	0.00161	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102831145	chr4:102751401~102752641:+
LUAD	cis	rs228614	0.51	rs223377	ENSG00000251288.2	RP11-10L12.2	-4.51	7.98e-06	0.00161	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102834919	chr4:102751401~102752641:+
LUAD	cis	rs228614	0.51	rs223443	ENSG00000251288.2	RP11-10L12.2	-4.51	7.98e-06	0.00161	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793629	chr4:102751401~102752641:+
LUAD	cis	rs7202877	0.706	rs247425	ENSG00000280152.1	RP11-331F4.5	-4.51	7.99e-06	0.00161	-0.24	-0.2	Type 1 diabetes;Type 2 diabetes;	chr16:75426504	chr16:75245994~75250077:-
LUAD	cis	rs950169	0.614	rs765524	ENSG00000225151.9	GOLGA2P7	-4.51	7.99e-06	0.00161	-0.29	-0.2	Schizophrenia;	chr15:84013030	chr15:84199311~84230136:-
LUAD	cis	rs338389	0.933	rs338401	ENSG00000260657.2	RP11-315D16.4	-4.51	7.99e-06	0.00161	-0.23	-0.2	Survival in rectal cancer;	chr15:67961702	chr15:68267792~68277994:-
LUAD	cis	rs42490	0.966	rs39499	ENSG00000251136.7	RP11-37B2.1	-4.51	7.99e-06	0.00161	-0.21	-0.2	Leprosy;	chr8:89758381	chr8:89609409~89757727:-
LUAD	cis	rs7819412	0.715	rs2409727	ENSG00000255046.1	RP11-297N6.4	4.51	7.99e-06	0.00161	0.24	0.2	Triglycerides;	chr8:11185727	chr8:11797928~11802568:-
LUAD	cis	rs7208859	0.623	rs3752019	ENSG00000263603.1	CTD-2349P21.5	-4.51	7.99e-06	0.00161	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824687	chr17:30729469~30731202:+
LUAD	cis	rs4968361	0.892	rs67028302	ENSG00000266992.1	DHX40P1	4.51	8e-06	0.00161	0.37	0.2	Schizophrenia;	chr17:59443342	chr17:59976009~60002384:-
LUAD	cis	rs453301	0.658	rs6986044	ENSG00000173295.6	FAM86B3P	-4.51	8e-06	0.00161	-0.22	-0.2	Joint mobility (Beighton score);	chr8:9017276	chr8:8228595~8244865:+
LUAD	cis	rs6732565	0.75	rs10183338	ENSG00000235721.1	AC013268.3	4.51	8e-06	0.00161	0.23	0.2	Rheumatoid arthritis;	chr2:110853239	chr2:110007675~110010783:+
LUAD	cis	rs4664293	0.737	rs1549579	ENSG00000230783.1	AC009961.2	-4.51	8e-06	0.00161	-0.24	-0.2	Monocyte percentage of white cells;	chr2:159812150	chr2:159689217~159690291:-
LUAD	cis	rs11159086	1	rs12433848	ENSG00000259005.1	RP3-449M8.6	4.51	8.01e-06	0.00161	0.27	0.2	Advanced glycation end-product levels;	chr14:74497570	chr14:74474007~74474864:-
LUAD	cis	rs4845875	0.6	rs11805138	ENSG00000242349.4	NPPA-AS1	4.51	8.01e-06	0.00161	0.22	0.2	Midregional pro atrial natriuretic peptide levels;	chr1:11773102	chr1:11841017~11848079:+
LUAD	cis	rs1876905	0.539	rs240956	ENSG00000255389.1	C6orf3	-4.51	8.01e-06	0.00161	-0.27	-0.2	Mean corpuscular hemoglobin;	chr6:111294848	chr6:111599875~111602295:+
LUAD	cis	rs7493	1	rs3779492	ENSG00000233942.1	AC004012.1	4.51	8.01e-06	0.00161	0.3	0.2	Yu-Zhi constitution type in type 2 diabetes;	chr7:95414871	chr7:95471835~95473998:+
LUAD	cis	rs7493	1	rs17876124	ENSG00000233942.1	AC004012.1	4.51	8.01e-06	0.00161	0.3	0.2	Yu-Zhi constitution type in type 2 diabetes;	chr7:95415946	chr7:95471835~95473998:+
LUAD	cis	rs7493	0.95	rs56265549	ENSG00000233942.1	AC004012.1	4.51	8.01e-06	0.00161	0.3	0.2	Yu-Zhi constitution type in type 2 diabetes;	chr7:95417843	chr7:95471835~95473998:+
LUAD	cis	rs7493	1	rs2040993	ENSG00000233942.1	AC004012.1	4.51	8.01e-06	0.00161	0.3	0.2	Yu-Zhi constitution type in type 2 diabetes;	chr7:95417988	chr7:95471835~95473998:+
LUAD	cis	rs228614	0.51	rs223452	ENSG00000251288.2	RP11-10L12.2	-4.51	8.01e-06	0.00161	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102790277	chr4:102751401~102752641:+
LUAD	cis	rs45509595	0.556	rs34409918	ENSG00000219392.1	RP1-265C24.5	-4.51	8.01e-06	0.00161	-0.43	-0.2	Breast cancer;	chr6:27717569	chr6:28115628~28116551:+
LUAD	cis	rs7746199	0.736	rs34064842	ENSG00000219392.1	RP1-265C24.5	-4.51	8.01e-06	0.00161	-0.43	-0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27720846	chr6:28115628~28116551:+
LUAD	cis	rs7746199	0.736	rs13212318	ENSG00000219392.1	RP1-265C24.5	-4.51	8.01e-06	0.00161	-0.43	-0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27721062	chr6:28115628~28116551:+
LUAD	cis	rs10129255	0.719	rs7156660	ENSG00000211974.3	IGHV2-70	4.51	8.01e-06	0.00161	0.21	0.2	Kawasaki disease;	chr14:106673171	chr14:106723574~106724093:-
LUAD	cis	rs2446066	0.872	rs11170555	ENSG00000257379.1	RP11-793H13.8	4.51	8.01e-06	0.00161	0.34	0.2	Red blood cell count;	chr12:53430359	chr12:53441741~53467528:+
LUAD	cis	rs2446066	0.872	rs17099205	ENSG00000257379.1	RP11-793H13.8	4.51	8.01e-06	0.00161	0.34	0.2	Red blood cell count;	chr12:53430798	chr12:53441741~53467528:+
LUAD	cis	rs228614	0.536	rs223477	ENSG00000251288.2	RP11-10L12.2	-4.51	8.01e-06	0.00161	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769099	chr4:102751401~102752641:+
LUAD	cis	rs467650	1	rs469930	ENSG00000248489.1	CTD-2007H13.3	-4.51	8.02e-06	0.00162	-0.21	-0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98633416	chr5:98929171~98995013:+
LUAD	cis	rs9400467	0.528	rs17539197	ENSG00000271789.1	RP5-1112D6.7	-4.51	8.02e-06	0.00162	-0.21	-0.2	Amino acid levels;Blood metabolite levels;	chr6:111447968	chr6:111297126~111298510:+
LUAD	cis	rs2735413	0.564	rs74864339	ENSG00000276007.1	RP11-358L22.3	4.51	8.03e-06	0.00162	0.27	0.2	Systolic blood pressure (alcohol consumption interaction);	chr16:78061174	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.564	rs74715500	ENSG00000276007.1	RP11-358L22.3	4.51	8.03e-06	0.00162	0.27	0.2	Systolic blood pressure (alcohol consumption interaction);	chr16:78061515	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.564	rs80225322	ENSG00000276007.1	RP11-358L22.3	4.51	8.03e-06	0.00162	0.27	0.2	Systolic blood pressure (alcohol consumption interaction);	chr16:78061856	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.564	rs2344491	ENSG00000276007.1	RP11-358L22.3	4.51	8.03e-06	0.00162	0.27	0.2	Systolic blood pressure (alcohol consumption interaction);	chr16:78062257	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.564	rs2344492	ENSG00000276007.1	RP11-358L22.3	4.51	8.03e-06	0.00162	0.27	0.2	Systolic blood pressure (alcohol consumption interaction);	chr16:78062329	chr16:78123243~78124332:+
LUAD	cis	rs16873450	0.934	rs2193828	ENSG00000234800.2	PCMTD1P3	-4.51	8.03e-06	0.00162	-0.24	-0.2	Verbal memory performance (residualized delayed recall level);	chr7:23767458	chr7:23721311~23721782:-
LUAD	cis	rs7308116	0.645	rs10861833	ENSG00000257951.1	RP11-554D14.4	4.51	8.03e-06	0.00162	0.22	0.2	Pelvic organ prolapse (moderate/severe);	chr12:107902358	chr12:107881242~107883382:+
LUAD	cis	rs780096	0.506	rs2950834	ENSG00000234072.1	AC074117.10	-4.51	8.03e-06	0.00162	-0.16	-0.2	Total body bone mineral density;	chr2:27404499	chr2:27356246~27367622:+
LUAD	cis	rs2998286	0.597	rs1272396	ENSG00000254635.4	WAC-AS1	-4.51	8.03e-06	0.00162	-0.27	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28643416	chr10:28522652~28532743:-
LUAD	cis	rs2998286	0.636	rs2772436	ENSG00000254635.4	WAC-AS1	-4.51	8.03e-06	0.00162	-0.27	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28644655	chr10:28522652~28532743:-
LUAD	cis	rs7432375	0.641	rs835649	ENSG00000239213.4	NCK1-AS1	4.51	8.03e-06	0.00162	0.21	0.2	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136953048	chr3:136841726~136862054:-
LUAD	cis	rs1009115	0.62	rs10256790	ENSG00000272328.1	RP4-594A5.1	-4.51	8.04e-06	0.00162	-0.26	-0.2	Post bronchodilator FEV1;	chr7:8377770	chr7:8303741~8341343:+
LUAD	cis	rs7208859	0.673	rs11651802	ENSG00000263603.1	CTD-2349P21.5	-4.51	8.04e-06	0.00162	-0.37	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832642	chr17:30729469~30731202:+
LUAD	cis	rs17772222	1	rs12589467	ENSG00000258983.2	RP11-507K2.2	4.51	8.04e-06	0.00162	0.24	0.2	Coronary artery calcification;	chr14:88357239	chr14:88499334~88515502:+
LUAD	cis	rs736801	0.808	rs6866614	ENSG00000233006.5	AC034220.3	-4.51	8.04e-06	0.00162	-0.18	-0.2	Mosquito bite size;Breast cancer;	chr5:132451445	chr5:132311285~132369916:-
LUAD	cis	rs7590268	0.606	rs6718648	ENSG00000279873.2	LINC01126	4.51	8.04e-06	0.00162	0.19	0.2	Orofacial clefts;	chr2:43406585	chr2:43227210~43228855:+
LUAD	cis	rs17684571	0.872	rs6926134	ENSG00000231441.1	RP11-472M19.2	4.51	8.04e-06	0.00162	0.28	0.2	Schizophrenia;	chr6:56723974	chr6:56844002~56864078:+
LUAD	cis	rs13256369	0.802	rs12541520	ENSG00000253893.2	FAM85B	-4.51	8.05e-06	0.00162	-0.27	-0.2	Obesity-related traits;	chr8:8706636	chr8:8167819~8226614:-
LUAD	cis	rs228614	0.51	rs223445	ENSG00000251288.2	RP11-10L12.2	-4.51	8.05e-06	0.00162	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793337	chr4:102751401~102752641:+
LUAD	cis	rs228614	0.536	rs223437	ENSG00000251288.2	RP11-10L12.2	-4.51	8.05e-06	0.00162	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798736	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.556	rs7676765	ENSG00000251288.2	RP11-10L12.2	4.51	8.05e-06	0.00162	0.24	0.2	Allergic disease (asthma, hay fever or eczema);	chr4:103016776	chr4:102751401~102752641:+
LUAD	cis	rs910316	1	rs175492	ENSG00000259138.1	RP11-950C14.7	4.51	8.05e-06	0.00162	0.21	0.2	Height;	chr14:75078517	chr14:75127153~75136930:+
LUAD	cis	rs910316	1	rs12879542	ENSG00000279594.1	RP11-950C14.10	4.51	8.05e-06	0.00162	0.23	0.2	Height;	chr14:75040822	chr14:75011269~75012851:-
LUAD	cis	rs4835473	0.868	rs7683365	ENSG00000251600.4	RP11-673E1.1	-4.51	8.05e-06	0.00162	-0.25	-0.2	Immature fraction of reticulocytes;	chr4:143999443	chr4:143912331~143982454:+
LUAD	cis	rs950169	0.887	rs35986397	ENSG00000275120.1	RP11-182J1.17	4.51	8.05e-06	0.00162	0.31	0.2	Schizophrenia;	chr15:84400409	chr15:84599434~84606463:-
LUAD	cis	rs516805	0.528	rs2684230	ENSG00000279453.1	RP3-425C14.4	-4.51	8.06e-06	0.00162	-0.26	-0.2	Lymphocyte counts;	chr6:122078062	chr6:122436789~122439223:-
LUAD	cis	rs4834770	0.668	rs11737086	ENSG00000245958.5	RP11-33B1.1	4.51	8.06e-06	0.00162	0.19	0.2	Blood protein levels;	chr4:119205962	chr4:119454791~119552025:+
LUAD	cis	rs2243480	0.803	rs34804747	ENSG00000226002.1	RP11-460N20.5	-4.51	8.07e-06	0.00162	-0.34	-0.2	Diabetic kidney disease;	chr7:65947955	chr7:65084103~65100232:+
LUAD	cis	rs9341808	0.718	rs10943699	ENSG00000272129.1	RP11-250B2.6	4.51	8.07e-06	0.00162	0.25	0.2	Sitting height ratio;	chr6:80230824	chr6:80355424~80356859:+
LUAD	cis	rs13256369	1	rs13267501	ENSG00000253893.2	FAM85B	-4.51	8.07e-06	0.00162	-0.28	-0.2	Obesity-related traits;	chr8:8716548	chr8:8167819~8226614:-
LUAD	cis	rs8077577	0.671	rs12450760	ENSG00000273018.4	CTD-2303H24.2	-4.51	8.07e-06	0.00162	-0.27	-0.2	Obesity-related traits;	chr17:18350508	chr17:18511221~18551705:-
LUAD	cis	rs9652601	0.879	rs9926367	ENSG00000274038.1	RP11-66H6.4	-4.51	8.07e-06	0.00162	-0.25	-0.2	Systemic lupus erythematosus;	chr16:10999322	chr16:11056556~11057034:+
LUAD	cis	rs75920871	0.688	rs77953246	ENSG00000254851.1	RP11-109L13.1	-4.51	8.08e-06	0.00162	-0.46	-0.2	Subjective well-being;	chr11:116925271	chr11:117135528~117138582:+
LUAD	cis	rs6840360	1	rs6535821	ENSG00000270265.1	RP11-731D1.4	-4.51	8.08e-06	0.00163	-0.21	-0.2	Intelligence (multi-trait analysis);	chr4:151757822	chr4:151333775~151353224:-
LUAD	cis	rs6714710	0.627	rs6748124	ENSG00000230606.9	AC159540.1	-4.51	8.08e-06	0.00163	-0.21	-0.2	Posterior cortical atrophy and Alzheimer's disease;	chr2:97902551	chr2:97416165~97433527:-
LUAD	cis	rs9309473	0.632	rs7599076	ENSG00000163016.8	ALMS1P	4.51	8.08e-06	0.00163	0.23	0.2	Metabolite levels;	chr2:73358391	chr2:73644919~73685576:+
LUAD	cis	rs9309473	0.583	rs11126397	ENSG00000163016.8	ALMS1P	4.51	8.08e-06	0.00163	0.23	0.2	Metabolite levels;	chr2:73361605	chr2:73644919~73685576:+
LUAD	cis	rs2281636	0.798	rs3184991	ENSG00000233690.1	EBAG9P1	-4.51	8.08e-06	0.00163	-0.2	-0.2	Obesity-related traits;	chr10:99755559	chr10:99697407~99697949:-
LUAD	cis	rs1008375	0.932	rs2302394	ENSG00000249502.1	AC006160.5	-4.51	8.08e-06	0.00163	-0.2	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17639565	chr4:17587467~17614571:-
LUAD	cis	rs7636293	0.964	rs10804589	ENSG00000270773.1	RP13-685P2.7	4.51	8.08e-06	0.00163	0.24	0.2	Height;	chr3:129331778	chr3:129345411~129346164:+
LUAD	cis	rs848490	0.546	rs7384722	ENSG00000214293.7	APTR	4.51	8.08e-06	0.00163	0.22	0.2	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77646106	chr7:77657660~77696265:-
LUAD	cis	rs12908161	1	rs36033486	ENSG00000259295.5	CSPG4P12	4.51	8.09e-06	0.00163	0.28	0.2	Schizophrenia;	chr15:84776461	chr15:85191438~85213905:+
LUAD	cis	rs12908161	1	rs12908549	ENSG00000259295.5	CSPG4P12	4.51	8.09e-06	0.00163	0.28	0.2	Schizophrenia;	chr15:84779120	chr15:85191438~85213905:+
LUAD	cis	rs7590268	0.636	rs12988285	ENSG00000279873.2	LINC01126	4.51	8.09e-06	0.00163	0.2	0.2	Orofacial clefts;	chr2:43487967	chr2:43227210~43228855:+
LUAD	cis	rs4879677	1	rs10116400	ENSG00000215441.3	CTAGE12P	-4.51	8.1e-06	0.00163	-0.24	-0.2	Gut microbiome composition (summer and winter);	chr9:27686882	chr9:27608382~27610745:-
LUAD	cis	rs2242116	0.727	rs6442040	ENSG00000271161.1	BOLA2P2	4.51	8.1e-06	0.00163	0.19	0.2	Birth weight;	chr3:46921545	chr3:47499841~47500407:+
LUAD	cis	rs12446632	0.539	rs9941245	ENSG00000261195.1	CTD-2380F24.1	4.51	8.1e-06	0.00163	0.25	0.2	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Menarche (age at onset);Obesity;Childhood body mass index;Waist circumference;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr16:19905573	chr16:19761172~19766099:-
LUAD	cis	rs7580658	0.545	rs12477559	ENSG00000236682.1	AC068282.3	-4.51	8.1e-06	0.00163	-0.25	-0.2	Protein C levels;	chr2:127194221	chr2:127389130~127400580:+
LUAD	cis	rs16873450	0.527	rs11982084	ENSG00000234800.2	PCMTD1P3	4.51	8.1e-06	0.00163	0.23	0.2	Verbal memory performance (residualized delayed recall level);	chr7:23743097	chr7:23721311~23721782:-
LUAD	cis	rs4664293	0.625	rs7590617	ENSG00000226266.5	AC009961.3	4.51	8.1e-06	0.00163	0.27	0.2	Monocyte percentage of white cells;	chr2:159775437	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.625	rs7564585	ENSG00000226266.5	AC009961.3	4.51	8.1e-06	0.00163	0.27	0.2	Monocyte percentage of white cells;	chr2:159775582	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.546	rs7564399	ENSG00000226266.5	AC009961.3	4.51	8.1e-06	0.00163	0.27	0.2	Monocyte percentage of white cells;	chr2:159775608	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.625	rs10460300	ENSG00000226266.5	AC009961.3	4.51	8.1e-06	0.00163	0.27	0.2	Monocyte percentage of white cells;	chr2:159778210	chr2:159670708~159712435:-
LUAD	cis	rs889398	0.741	rs3790076	ENSG00000226232.7	RP11-419C5.2	4.51	8.11e-06	0.00163	0.17	0.2	Body mass index;	chr16:69873542	chr16:69976388~69996188:-
LUAD	cis	rs755249	0.501	rs2455648	ENSG00000182109.6	RP11-69E11.4	4.51	8.11e-06	0.00163	0.23	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39178040	chr1:39522280~39546187:-
LUAD	cis	rs6496932	0.663	rs7496211	ENSG00000259630.2	CTD-2262B20.1	-4.51	8.11e-06	0.00163	-0.26	-0.2	Central corneal thickness;Corneal structure;	chr15:85379358	chr15:85415228~85415633:+
LUAD	cis	rs2749097	0.696	rs1506397	ENSG00000244256.3	RN7SL130P	-4.51	8.11e-06	0.00163	-0.27	-0.2	Alcohol consumption (transferrin glycosylation);	chr1:63679612	chr1:63655743~63656047:+
LUAD	cis	rs9322193	0.962	rs4870048	ENSG00000268592.3	RAET1E-AS1	4.51	8.11e-06	0.00163	0.25	0.2	Lung cancer;	chr6:149834324	chr6:149863494~149919507:+
LUAD	cis	rs853679	0.607	rs13194781	ENSG00000219392.1	RP1-265C24.5	-4.51	8.12e-06	0.00163	-0.43	-0.2	Depression;	chr6:27847861	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.546	rs36116761	ENSG00000219392.1	RP1-265C24.5	-4.51	8.12e-06	0.00163	-0.43	-0.2	Depression;	chr6:27850704	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.546	rs34194357	ENSG00000219392.1	RP1-265C24.5	-4.51	8.12e-06	0.00163	-0.43	-0.2	Depression;	chr6:27850757	chr6:28115628~28116551:+
LUAD	cis	rs6840360	0.967	rs7695162	ENSG00000270265.1	RP11-731D1.4	-4.51	8.12e-06	0.00163	-0.2	-0.2	Intelligence (multi-trait analysis);	chr4:151589389	chr4:151333775~151353224:-
LUAD	cis	rs7208859	0.524	rs11653098	ENSG00000266490.1	CTD-2349P21.9	4.51	8.12e-06	0.00163	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30792372~30792833:+
LUAD	cis	rs11992162	0.569	rs35283519	ENSG00000255046.1	RP11-297N6.4	4.51	8.12e-06	0.00163	0.27	0.2	Monocyte count;	chr8:11974152	chr8:11797928~11802568:-
LUAD	cis	rs2742234	0.541	rs12220534	ENSG00000273008.1	RP11-351D16.3	-4.51	8.12e-06	0.00163	-0.22	-0.2	Hirschsprung disease;	chr10:43238858	chr10:43136824~43138334:-
LUAD	cis	rs3847687	0.901	rs12370258	ENSG00000279128.1	RP11-76C10.4	4.51	8.13e-06	0.00163	0.22	0.2	Longevity;	chr12:131042756	chr12:131022769~131024741:-
LUAD	cis	rs4664293	0.625	rs35481084	ENSG00000226266.5	AC009961.3	4.51	8.13e-06	0.00163	0.27	0.2	Monocyte percentage of white cells;	chr2:159777729	chr2:159670708~159712435:-
LUAD	cis	rs9847710	1	rs6770152	ENSG00000242142.1	SERBP1P3	4.51	8.13e-06	0.00163	0.21	0.2	Ulcerative colitis;	chr3:53066198	chr3:53064283~53065091:-
LUAD	cis	rs950169	0.845	rs4106951	ENSG00000275120.1	RP11-182J1.17	4.51	8.13e-06	0.00164	0.32	0.2	Schizophrenia;	chr15:84164642	chr15:84599434~84606463:-
LUAD	cis	rs2239547	0.563	rs6797399	ENSG00000242142.1	SERBP1P3	4.51	8.13e-06	0.00164	0.24	0.2	Schizophrenia;	chr3:52871901	chr3:53064283~53065091:-
LUAD	cis	rs62025270	0.688	rs62022940	ENSG00000202081.1	RNU6-1280P	-4.51	8.14e-06	0.00164	-0.29	-0.2	Idiopathic pulmonary fibrosis;	chr15:85709289	chr15:85651522~85651628:-
LUAD	cis	rs910316	0.967	rs175451	ENSG00000259138.1	RP11-950C14.7	-4.51	8.14e-06	0.00164	-0.21	-0.2	Height;	chr14:75123026	chr14:75127153~75136930:+
LUAD	cis	rs1387259	0.69	rs1601985	ENSG00000257735.1	RP11-370I10.6	4.51	8.14e-06	0.00164	0.24	0.2	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48368131	chr12:48350945~48442411:+
LUAD	cis	rs4811196	0.748	rs16987016	ENSG00000226144.2	RPS27AP3	4.51	8.14e-06	0.00164	0.22	0.2	Bone mineral density;	chr20:37877639	chr20:37049254~37049707:+
LUAD	cis	rs12935418	0.83	rs7195459	ENSG00000261061.1	RP11-303E16.2	-4.51	8.14e-06	0.00164	-0.26	-0.2	Mean corpuscular volume;	chr16:81016376	chr16:81030770~81031485:+
LUAD	cis	rs2060793	0.519	rs1357332	ENSG00000251991.1	RNU7-49P	4.51	8.15e-06	0.00164	0.21	0.2	Vitamin D levels;	chr11:14618570	chr11:14478892~14478953:+
LUAD	cis	rs2976388	0.647	rs2572898	ENSG00000253741.1	CTD-2292P10.4	-4.51	8.15e-06	0.00164	-0.23	-0.2	Urinary tract infection frequency;	chr8:142700856	chr8:142702252~142726973:-
LUAD	cis	rs2832077	0.527	rs2832116	ENSG00000232855.5	AF131217.1	4.51	8.15e-06	0.00164	0.2	0.2	Cognitive test performance;	chr21:28856046	chr21:28439346~28674848:-
LUAD	cis	rs7811142	0.887	rs111972532	ENSG00000078319.8	PMS2P1	-4.51	8.15e-06	0.00164	-0.24	-0.2	Platelet count;	chr7:100471465	chr7:100320992~100341908:-
LUAD	cis	rs1799949	1	rs4793229	ENSG00000236383.6	LINC00854	4.51	8.15e-06	0.00164	0.16	0.2	Menopause (age at onset);	chr17:43340966	chr17:43216941~43305976:-
LUAD	cis	rs28386778	0.863	rs4968661	ENSG00000240280.5	TCAM1P	-4.51	8.15e-06	0.00164	-0.23	-0.2	Prudent dietary pattern;	chr17:63718946	chr17:63849292~63864379:+
LUAD	cis	rs7829975	0.742	rs7832968	ENSG00000253981.4	ALG1L13P	4.51	8.16e-06	0.00164	0.23	0.2	Mood instability;	chr8:8795379	chr8:8236003~8244667:-
LUAD	cis	rs848490	0.925	rs56215603	ENSG00000214293.7	APTR	4.51	8.16e-06	0.00164	0.26	0.2	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77688865	chr7:77657660~77696265:-
LUAD	cis	rs2933343	0.661	rs2630259	ENSG00000261159.1	RP11-723O4.9	4.51	8.16e-06	0.00164	0.22	0.2	IgG glycosylation;	chr3:128887479	chr3:128859716~128860526:-
LUAD	cis	rs7208859	0.778	rs6505219	ENSG00000263531.1	RP13-753N3.1	4.51	8.16e-06	0.00164	0.33	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30938603	chr17:30863921~30864940:-
LUAD	cis	rs67311347	0.521	rs2887963	ENSG00000223797.4	ENTPD3-AS1	-4.51	8.16e-06	0.00164	-0.21	-0.2	Renal cell carcinoma;	chr3:40201975	chr3:40313802~40453329:-
LUAD	cis	rs9309473	0.607	rs6740173	ENSG00000163016.8	ALMS1P	4.51	8.17e-06	0.00164	0.23	0.2	Metabolite levels;	chr2:73375138	chr2:73644919~73685576:+
LUAD	cis	rs2479106	0.656	rs10117940	ENSG00000236901.4	MIR600HG	4.51	8.17e-06	0.00164	0.14	0.2	Polycystic ovary syndrome;	chr9:123707451	chr9:123109494~123115477:-
LUAD	cis	rs1075265	0.756	rs6751105	ENSG00000272156.1	RP11-477N3.1	-4.51	8.17e-06	0.00164	-0.24	-0.2	Chronotype;Morning vs. evening chronotype;	chr2:54129214	chr2:54082554~54085066:+
LUAD	cis	rs9341808	0.69	rs6930534	ENSG00000260645.1	RP11-250B2.5	4.51	8.17e-06	0.00164	0.19	0.2	Sitting height ratio;	chr6:80186333	chr6:80466958~80469080:+
LUAD	cis	rs9860428	0.527	rs1387024	ENSG00000242770.2	RP11-180K7.1	4.51	8.18e-06	0.00164	0.21	0.2	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112828754	chr3:112802478~112812819:+
LUAD	cis	rs875971	0.638	rs7793569	ENSG00000224316.1	RP11-479O9.2	-4.51	8.19e-06	0.00164	-0.2	-0.2	Aortic root size;	chr7:66651646	chr7:65773620~65802067:+
LUAD	cis	rs11168618	0.967	rs10875831	ENSG00000240399.1	RP1-228P16.1	4.51	8.19e-06	0.00164	0.2	0.2	Adiponectin levels;	chr12:48544597	chr12:48054813~48055591:-
LUAD	cis	rs17711722	0.528	rs73138179	ENSG00000189316.3	RP11-797H7.5	-4.51	8.19e-06	0.00165	-0.22	-0.2	Calcium levels;	chr7:65829495	chr7:64888527~64890100:-
LUAD	cis	rs7560272	0.723	rs1052161	ENSG00000163016.8	ALMS1P	4.51	8.19e-06	0.00165	0.22	0.2	Schizophrenia;	chr2:73601411	chr2:73644919~73685576:+
LUAD	cis	rs2243480	1	rs3885839	ENSG00000229886.1	RP5-1132H15.3	4.51	8.19e-06	0.00165	0.36	0.2	Diabetic kidney disease;	chr7:65825416	chr7:66025126~66031544:-
LUAD	cis	rs2243480	0.901	rs3813708	ENSG00000229886.1	RP5-1132H15.3	4.51	8.19e-06	0.00165	0.36	0.2	Diabetic kidney disease;	chr7:65840645	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs73142122	ENSG00000229886.1	RP5-1132H15.3	4.51	8.19e-06	0.00165	0.36	0.2	Diabetic kidney disease;	chr7:65846311	chr7:66025126~66031544:-
LUAD	cis	rs2243480	0.901	rs73142137	ENSG00000229886.1	RP5-1132H15.3	4.51	8.19e-06	0.00165	0.36	0.2	Diabetic kidney disease;	chr7:65878455	chr7:66025126~66031544:-
LUAD	cis	rs6570726	0.791	rs9403730	ENSG00000235652.6	RP11-545I5.3	4.51	8.2e-06	0.00165	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145586097	chr6:145799409~145886585:+
LUAD	cis	rs6012564	0.927	rs6019570	ENSG00000230758.1	SNAP23P	-4.51	8.2e-06	0.00165	-0.21	-0.2	Anger;	chr20:48983153	chr20:49038357~49038602:-
LUAD	cis	rs2243480	0.901	rs2456483	ENSG00000164669.11	INTS4P1	4.51	8.2e-06	0.00165	0.36	0.2	Diabetic kidney disease;	chr7:65996588	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs1701750	ENSG00000164669.11	INTS4P1	4.51	8.2e-06	0.00165	0.36	0.2	Diabetic kidney disease;	chr7:66002158	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs1701758	ENSG00000164669.11	INTS4P1	4.51	8.2e-06	0.00165	0.36	0.2	Diabetic kidney disease;	chr7:66005214	chr7:65141225~65234216:+
LUAD	cis	rs2243480	0.901	rs1701759	ENSG00000164669.11	INTS4P1	4.51	8.2e-06	0.00165	0.36	0.2	Diabetic kidney disease;	chr7:66005945	chr7:65141225~65234216:+
LUAD	cis	rs301901	0.581	rs292175	ENSG00000250155.1	CTD-2353F22.1	-4.51	8.2e-06	0.00165	-0.22	-0.2	Height;	chr5:36832512	chr5:36666214~36725195:-
LUAD	cis	rs2617170	0.922	rs11838084	ENSG00000245648.1	RP11-277P12.20	-4.51	8.21e-06	0.00165	-0.25	-0.2	Behcet's disease;	chr12:10427704	chr12:10363769~10398506:+
LUAD	cis	rs4142995	0.772	rs2723509	ENSG00000279048.1	RP11-511H23.2	-4.51	8.21e-06	0.00165	-0.16	-0.2	HDL cholesterol;HDL cholesterol levels;	chr7:17777413	chr7:17940503~17942922:+
LUAD	cis	rs10483853	0.579	rs58546337	ENSG00000258695.2	RP3-414A15.2	-4.51	8.22e-06	0.00165	-0.29	-0.2	Coronary artery calcification;	chr14:73483753	chr14:73522878~73530610:+
LUAD	cis	rs7191700	0.601	rs243329	ENSG00000262703.1	RP11-485G7.6	4.51	8.22e-06	0.00165	0.18	0.2	Multiple sclerosis;	chr16:11258456	chr16:11348143~11349321:-
LUAD	cis	rs12446632	0.539	rs2883659	ENSG00000261195.1	CTD-2380F24.1	-4.51	8.22e-06	0.00165	-0.26	-0.2	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Menarche (age at onset);Obesity;Childhood body mass index;Waist circumference;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr16:19899852	chr16:19761172~19766099:-
LUAD	cis	rs12446632	0.539	rs66751349	ENSG00000261195.1	CTD-2380F24.1	-4.51	8.22e-06	0.00165	-0.26	-0.2	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Menarche (age at onset);Obesity;Childhood body mass index;Waist circumference;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr16:19900547	chr16:19761172~19766099:-
LUAD	cis	rs6754311	0.773	rs2322818	ENSG00000226806.1	AC011893.3	4.51	8.22e-06	0.00165	0.25	0.2	Mosquito bite size;	chr2:136018328	chr2:135820191~135823087:+
LUAD	cis	rs62025270	0.632	rs8029034	ENSG00000202081.1	RNU6-1280P	-4.51	8.23e-06	0.00165	-0.31	-0.2	Idiopathic pulmonary fibrosis;	chr15:85582497	chr15:85651522~85651628:-
LUAD	cis	rs13113518	0.812	rs13116035	ENSG00000223305.1	RN7SKP30	4.51	8.23e-06	0.00165	0.23	0.2	Height;	chr4:55561218	chr4:55540502~55540835:-
LUAD	cis	rs4664293	0.647	rs6756502	ENSG00000226266.5	AC009961.3	4.51	8.23e-06	0.00165	0.27	0.2	Monocyte percentage of white cells;	chr2:159698072	chr2:159670708~159712435:-
LUAD	cis	rs853679	1	rs2799079	ENSG00000219392.1	RP1-265C24.5	-4.51	8.23e-06	0.00165	-0.3	-0.2	Depression;	chr6:28267398	chr6:28115628~28116551:+
LUAD	cis	rs9500256	0.967	rs4928431	ENSG00000266579.1	RP1-71H19.2	4.51	8.23e-06	0.00165	0.25	0.2	Eosinophilic esophagitis (pediatric);	chr6:57979980	chr6:57493855~57497691:+
LUAD	cis	rs1334894	1	rs10498734	ENSG00000228559.1	RP3-340B19.3	-4.51	8.24e-06	0.00165	-0.43	-0.2	Coronary artery disease;	chr6:35591996	chr6:35544632~35545669:+
LUAD	cis	rs860295	0.702	rs11264380	ENSG00000225855.5	RUSC1-AS1	4.51	8.24e-06	0.00165	0.14	0.2	Body mass index;	chr1:155550353	chr1:155316863~155324176:-
LUAD	cis	rs228614	0.51	rs223463	ENSG00000251288.2	RP11-10L12.2	-4.51	8.24e-06	0.00165	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780620	chr4:102751401~102752641:+
LUAD	cis	rs7567389	0.568	rs7568070	ENSG00000236682.1	AC068282.3	-4.51	8.24e-06	0.00165	-0.28	-0.2	Self-rated health;	chr2:127195478	chr2:127389130~127400580:+
LUAD	cis	rs4713118	0.662	rs4713120	ENSG00000216901.1	AL022393.7	4.51	8.25e-06	0.00166	0.23	0.2	Parkinson's disease;	chr6:27754056	chr6:28176188~28176674:+
LUAD	cis	rs13113518	0.783	rs12510400	ENSG00000223305.1	RN7SKP30	4.51	8.25e-06	0.00166	0.23	0.2	Height;	chr4:55577294	chr4:55540502~55540835:-
LUAD	cis	rs6700559	0.565	rs11807125	ENSG00000260088.1	RP11-92G12.3	4.51	8.25e-06	0.00166	0.25	0.2	Coronary artery disease;	chr1:200623167	chr1:200669507~200694250:+
LUAD	cis	rs12908161	0.959	rs62019472	ENSG00000259295.5	CSPG4P12	4.51	8.26e-06	0.00166	0.28	0.2	Schizophrenia;	chr15:84788262	chr15:85191438~85213905:+
LUAD	cis	rs910316	1	rs175443	ENSG00000259138.1	RP11-950C14.7	-4.51	8.26e-06	0.00166	-0.21	-0.2	Height;	chr14:75135260	chr14:75127153~75136930:+
LUAD	cis	rs2439831	0.867	rs7170489	ENSG00000249839.1	AC011330.5	-4.51	8.26e-06	0.00166	-0.37	-0.2	Lung cancer in ever smokers;	chr15:43344453	chr15:43663654~43684339:-
LUAD	cis	rs2439831	0.867	rs16957630	ENSG00000249839.1	AC011330.5	-4.51	8.26e-06	0.00166	-0.37	-0.2	Lung cancer in ever smokers;	chr15:43350582	chr15:43663654~43684339:-
LUAD	cis	rs2439831	0.867	rs16957632	ENSG00000249839.1	AC011330.5	-4.51	8.26e-06	0.00166	-0.37	-0.2	Lung cancer in ever smokers;	chr15:43350699	chr15:43663654~43684339:-
LUAD	cis	rs1113500	0.73	rs1781077	ENSG00000226822.1	RP11-356N1.2	-4.51	8.26e-06	0.00166	-0.22	-0.2	Growth-regulated protein alpha levels;	chr1:108046967	chr1:108071482~108074519:+
LUAD	cis	rs561341	1	rs521919	ENSG00000265798.5	RP11-271K11.5	4.51	8.27e-06	0.00166	0.29	0.2	Hip circumference adjusted for BMI;	chr17:31971020	chr17:31038575~31059121:-
LUAD	cis	rs875971	0.964	rs60193905	ENSG00000232559.3	GS1-124K5.12	4.51	8.27e-06	0.00166	0.24	0.2	Aortic root size;	chr7:66506273	chr7:66554588~66576923:-
LUAD	cis	rs7208859	0.573	rs55661352	ENSG00000266490.1	CTD-2349P21.9	4.51	8.28e-06	0.00166	0.31	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30792372~30792833:+
LUAD	cis	rs7191700	0.644	rs918738	ENSG00000262636.1	CTD-3088G3.4	-4.51	8.28e-06	0.00166	-0.24	-0.2	Multiple sclerosis;	chr16:11345822	chr16:11380859~11381118:-
LUAD	cis	rs227275	0.554	rs223399	ENSG00000251288.2	RP11-10L12.2	-4.51	8.28e-06	0.00166	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102820800	chr4:102751401~102752641:+
LUAD	cis	rs7665090	1	rs11727546	ENSG00000246560.2	RP11-10L12.4	4.51	8.28e-06	0.00166	0.24	0.2	Primary biliary cholangitis;	chr4:102636507	chr4:102828055~102844075:+
LUAD	cis	rs7208859	0.673	rs1347360	ENSG00000280069.1	CTD-2349P21.3	-4.51	8.28e-06	0.00166	-0.27	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587514	chr17:30738182~30740275:+
LUAD	cis	rs12908161	1	rs12903134	ENSG00000259295.5	CSPG4P12	4.51	8.29e-06	0.00166	0.28	0.2	Schizophrenia;	chr15:84794468	chr15:85191438~85213905:+
LUAD	cis	rs12908161	1	rs35726233	ENSG00000259295.5	CSPG4P12	4.51	8.29e-06	0.00166	0.28	0.2	Schizophrenia;	chr15:84794569	chr15:85191438~85213905:+
LUAD	cis	rs10214930	0.56	rs42089	ENSG00000235574.1	AC073150.6	4.51	8.29e-06	0.00166	0.23	0.2	Hypospadias;	chr7:27663321	chr7:27491682~27492765:-
LUAD	cis	rs375066	0.967	rs8104290	ENSG00000267058.1	RP11-15A1.3	-4.51	8.29e-06	0.00166	-0.23	-0.2	Breast cancer;	chr19:43863186	chr19:43891804~43901805:-
LUAD	cis	rs17345786	0.861	rs17402964	ENSG00000244119.1	PDCL3P4	4.51	8.29e-06	0.00166	0.23	0.2	Colonoscopy-negative controls vs population controls;	chr3:101349101	chr3:101712472~101713191:+
LUAD	cis	rs12446632	0.511	rs13335015	ENSG00000261195.1	CTD-2380F24.1	-4.51	8.3e-06	0.00166	-0.25	-0.2	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Menarche (age at onset);Obesity;Childhood body mass index;Waist circumference;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr16:19893842	chr16:19761172~19766099:-
LUAD	cis	rs473651	0.904	rs62196716	ENSG00000229915.1	AC016999.2	-4.51	8.3e-06	0.00166	-0.27	-0.2	Multiple system atrophy;	chr2:238448336	chr2:238427077~238427729:-
LUAD	cis	rs2998286	0.862	rs2807738	ENSG00000254635.4	WAC-AS1	-4.51	8.3e-06	0.00167	-0.24	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28496479	chr10:28522652~28532743:-
LUAD	cis	rs228614	0.51	rs223455	ENSG00000251288.2	RP11-10L12.2	-4.51	8.3e-06	0.00167	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789026	chr4:102751401~102752641:+
LUAD	cis	rs738722	1	rs1807609	ENSG00000272858.1	CTA-292E10.8	-4.51	8.31e-06	0.00167	-0.24	-0.2	Optic cup area;Esophageal cancer and gastric cancer;	chr22:28735141	chr22:28814914~28815662:+
LUAD	cis	rs6570726	0.818	rs9390338	ENSG00000235652.6	RP11-545I5.3	4.51	8.31e-06	0.00167	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145587129	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.791	rs6570693	ENSG00000235652.6	RP11-545I5.3	4.51	8.31e-06	0.00167	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145589705	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.791	rs6570694	ENSG00000235652.6	RP11-545I5.3	4.51	8.31e-06	0.00167	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145590068	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.791	rs6570695	ENSG00000235652.6	RP11-545I5.3	4.51	8.31e-06	0.00167	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145590150	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.764	rs9386125	ENSG00000235652.6	RP11-545I5.3	4.51	8.31e-06	0.00167	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145590541	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.791	rs9373466	ENSG00000235652.6	RP11-545I5.3	4.51	8.31e-06	0.00167	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145590880	chr6:145799409~145886585:+
LUAD	cis	rs17772222	1	rs2295135	ENSG00000258983.2	RP11-507K2.2	4.51	8.31e-06	0.00167	0.25	0.2	Coronary artery calcification;	chr14:88427866	chr14:88499334~88515502:+
LUAD	cis	rs801193	0.66	rs1016265	ENSG00000232559.3	GS1-124K5.12	4.51	8.31e-06	0.00167	0.24	0.2	Aortic root size;	chr7:66749580	chr7:66554588~66576923:-
LUAD	cis	rs801193	0.66	rs4610622	ENSG00000232559.3	GS1-124K5.12	4.51	8.31e-06	0.00167	0.24	0.2	Aortic root size;	chr7:66759510	chr7:66554588~66576923:-
LUAD	cis	rs1008375	0.646	rs13103430	ENSG00000249502.1	AC006160.5	4.51	8.31e-06	0.00167	0.2	0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17565732	chr4:17587467~17614571:-
LUAD	cis	rs9322193	0.923	rs9688861	ENSG00000268592.3	RAET1E-AS1	4.51	8.31e-06	0.00167	0.25	0.2	Lung cancer;	chr6:149637924	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.923	rs7740278	ENSG00000268592.3	RAET1E-AS1	4.51	8.31e-06	0.00167	0.25	0.2	Lung cancer;	chr6:149640116	chr6:149863494~149919507:+
LUAD	cis	rs9467773	1	rs9467779	ENSG00000261353.1	CTA-14H9.5	4.51	8.32e-06	0.00167	0.22	0.2	Intelligence (multi-trait analysis);	chr6:26536459	chr6:26527063~26527404:+
LUAD	cis	rs77688320	0.553	rs2243791	ENSG00000213090.2	AC007256.5	-4.51	8.32e-06	0.00167	-0.24	-0.2	Breast cancer;	chr2:201478079	chr2:201410544~201413308:-
LUAD	cis	rs736801	0.836	rs2522052	ENSG00000233006.5	AC034220.3	-4.51	8.32e-06	0.00167	-0.18	-0.2	Mosquito bite size;Breast cancer;	chr5:132462795	chr5:132311285~132369916:-
LUAD	cis	rs736801	0.808	rs2706403	ENSG00000233006.5	AC034220.3	-4.51	8.32e-06	0.00167	-0.18	-0.2	Mosquito bite size;Breast cancer;	chr5:132463320	chr5:132311285~132369916:-
LUAD	cis	rs736801	0.754	rs2706336	ENSG00000233006.5	AC034220.3	-4.51	8.32e-06	0.00167	-0.18	-0.2	Mosquito bite size;Breast cancer;	chr5:132464269	chr5:132311285~132369916:-
LUAD	cis	rs453301	0.571	rs2929456	ENSG00000253981.4	ALG1L13P	-4.51	8.32e-06	0.00167	-0.23	-0.2	Joint mobility (Beighton score);	chr8:9225906	chr8:8236003~8244667:-
LUAD	cis	rs6570726	0.791	rs407887	ENSG00000235652.6	RP11-545I5.3	4.51	8.33e-06	0.00167	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145522623	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.764	rs451108	ENSG00000235652.6	RP11-545I5.3	4.51	8.33e-06	0.00167	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145523173	chr6:145799409~145886585:+
LUAD	cis	rs11168618	0.875	rs11168606	ENSG00000240399.1	RP1-228P16.1	4.51	8.33e-06	0.00167	0.2	0.2	Adiponectin levels;	chr12:48498906	chr12:48054813~48055591:-
LUAD	cis	rs71520386	0.632	rs12535331	ENSG00000228649.7	AC005682.5	4.51	8.33e-06	0.00167	0.27	0.2	Fibrinogen levels;	chr7:22838485	chr7:22854178~22861579:+
LUAD	cis	rs6061231	1	rs13043313	ENSG00000273619.1	RP5-908M14.9	-4.51	8.33e-06	0.00167	-0.21	-0.2	Colorectal cancer;	chr20:62383213	chr20:62386303~62386970:-
LUAD	cis	rs17772222	1	rs74071851	ENSG00000258983.2	RP11-507K2.2	4.51	8.33e-06	0.00167	0.25	0.2	Coronary artery calcification;	chr14:88415858	chr14:88499334~88515502:+
LUAD	cis	rs910316	1	rs3742780	ENSG00000279594.1	RP11-950C14.10	4.51	8.33e-06	0.00167	0.23	0.2	Height;	chr14:75038305	chr14:75011269~75012851:-
LUAD	cis	rs4843747	0.697	rs72818533	ENSG00000205037.2	RP11-863P13.4	4.5	8.34e-06	0.00167	0.29	0.2	Menopause (age at onset);	chr16:88040235	chr16:88088041~88100985:-
LUAD	cis	rs4843747	0.749	rs72818535	ENSG00000205037.2	RP11-863P13.4	4.5	8.34e-06	0.00167	0.29	0.2	Menopause (age at onset);	chr16:88040433	chr16:88088041~88100985:-
LUAD	cis	rs473651	0.904	rs508274	ENSG00000229915.1	AC016999.2	-4.5	8.34e-06	0.00167	-0.27	-0.2	Multiple system atrophy;	chr2:238429082	chr2:238427077~238427729:-
LUAD	cis	rs12701220	0.894	rs34712249	ENSG00000229043.2	AC091729.9	-4.5	8.35e-06	0.00167	-0.27	-0.2	Bronchopulmonary dysplasia;	chr7:996998	chr7:1160374~1165267:+
LUAD	cis	rs2976388	0.507	rs13279795	ENSG00000253741.1	CTD-2292P10.4	-4.5	8.35e-06	0.00167	-0.25	-0.2	Urinary tract infection frequency;	chr8:142757251	chr8:142702252~142726973:-
LUAD	cis	rs2239547	0.522	rs9844736	ENSG00000242142.1	SERBP1P3	-4.5	8.35e-06	0.00167	-0.24	-0.2	Schizophrenia;	chr3:52897955	chr3:53064283~53065091:-
LUAD	cis	rs2880765	0.835	rs7178991	ENSG00000259416.2	RP11-158M2.5	4.5	8.36e-06	0.00167	0.21	0.2	Coronary artery disease;	chr15:85507713	chr15:85754941~85756237:-
LUAD	cis	rs8180040	0.653	rs6808742	ENSG00000271161.1	BOLA2P2	4.5	8.36e-06	0.00167	0.19	0.2	Colorectal cancer;	chr3:47010022	chr3:47499841~47500407:+
LUAD	cis	rs3770081	1	rs3770066	ENSG00000273080.1	RP11-301O19.1	-4.5	8.36e-06	0.00168	-0.44	-0.2	Facial emotion recognition (sad faces);	chr2:86165227	chr2:86195590~86196049:+
LUAD	cis	rs34779708	0.677	rs112355105	ENSG00000271335.4	RP11-324I22.4	4.5	8.36e-06	0.00168	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35261366	chr10:35314552~35336401:-
LUAD	cis	rs227275	0.556	rs11722779	ENSG00000251288.2	RP11-10L12.2	-4.5	8.36e-06	0.00168	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102906331	chr4:102751401~102752641:+
LUAD	cis	rs17772222	0.958	rs60213984	ENSG00000258983.2	RP11-507K2.2	4.5	8.36e-06	0.00168	0.25	0.2	Coronary artery calcification;	chr14:88401473	chr14:88499334~88515502:+
LUAD	cis	rs2303759	0.709	rs7256363	ENSG00000268686.1	AC010524.2	-4.5	8.36e-06	0.00168	-0.3	-0.2	Multiple sclerosis;	chr19:49324547	chr19:49368705~49388081:-
LUAD	cis	rs2303759	0.709	rs8102574	ENSG00000268686.1	AC010524.2	-4.5	8.36e-06	0.00168	-0.3	-0.2	Multiple sclerosis;	chr19:49325640	chr19:49368705~49388081:-
LUAD	cis	rs6840258	0.628	rs9715807	ENSG00000251411.1	RP11-397E7.4	4.5	8.37e-06	0.00168	0.23	0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86991479	chr4:86913266~86914817:-
LUAD	cis	rs910316	1	rs4903275	ENSG00000279594.1	RP11-950C14.10	4.5	8.37e-06	0.00168	0.23	0.2	Height;	chr14:75045806	chr14:75011269~75012851:-
LUAD	cis	rs6969780	1	rs6948297	ENSG00000233429.8	HOTAIRM1	4.5	8.37e-06	0.00168	0.35	0.2	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27109785	chr7:27095647~27100265:+
LUAD	cis	rs7945705	0.818	rs4929916	ENSG00000254860.4	TMEM9B-AS1	-4.5	8.37e-06	0.00168	-0.22	-0.2	Hemoglobin concentration;	chr11:8803449	chr11:8964675~8977527:+
LUAD	cis	rs9649213	0.574	rs34817002	ENSG00000272950.1	RP11-307C18.1	4.5	8.38e-06	0.00168	0.26	0.2	Prostate cancer (SNP x SNP interaction);	chr7:98257739	chr7:98322853~98323430:+
LUAD	cis	rs7172677	0.737	rs11072528	ENSG00000260269.4	CTD-2323K18.1	-4.5	8.38e-06	0.00168	-0.25	-0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75144114	chr15:75527150~75601205:-
LUAD	cis	rs228614	0.543	rs223330	ENSG00000251288.2	RP11-10L12.2	-4.5	8.39e-06	0.00168	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102872502	chr4:102751401~102752641:+
LUAD	cis	rs228614	0.51	rs223329	ENSG00000251288.2	RP11-10L12.2	-4.5	8.39e-06	0.00168	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873031	chr4:102751401~102752641:+
LUAD	cis	rs763121	0.819	rs5757126	ENSG00000228274.3	RP3-508I15.9	-4.5	8.39e-06	0.00168	-0.2	-0.2	Menopause (age at onset);	chr22:38527670	chr22:38667585~38681820:-
LUAD	cis	rs9467773	1	rs1321481	ENSG00000261353.1	CTA-14H9.5	-4.5	8.39e-06	0.00168	-0.22	-0.2	Intelligence (multi-trait analysis);	chr6:26537982	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs4713008	ENSG00000261353.1	CTA-14H9.5	-4.5	8.39e-06	0.00168	-0.22	-0.2	Intelligence (multi-trait analysis);	chr6:26538040	chr6:26527063~26527404:+
LUAD	cis	rs9467773	0.967	rs6932865	ENSG00000261353.1	CTA-14H9.5	-4.5	8.39e-06	0.00168	-0.22	-0.2	Intelligence (multi-trait analysis);	chr6:26539938	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs6933176	ENSG00000261353.1	CTA-14H9.5	-4.5	8.39e-06	0.00168	-0.22	-0.2	Intelligence (multi-trait analysis);	chr6:26539950	chr6:26527063~26527404:+
LUAD	cis	rs4908760	0.827	rs1463053	ENSG00000270282.1	RP5-1115A15.2	4.5	8.39e-06	0.00168	0.21	0.2	Vitiligo;	chr1:8644978	chr1:8512653~8513021:+
LUAD	cis	rs4061073	0.924	rs67060003	ENSG00000198711.5	SSBP3-AS1	-4.5	8.4e-06	0.00168	-0.18	-0.2	Body mass index;	chr1:54232568	chr1:54236440~54239063:+
LUAD	cis	rs9473147	0.516	rs10948367	ENSG00000270761.1	RP11-385F7.1	-4.5	8.4e-06	0.00168	-0.23	-0.2	Platelet distribution width;Mean platelet volume;	chr6:47617879	chr6:47477243~47477572:-
LUAD	cis	rs780096	0.527	rs59644396	ENSG00000234072.1	AC074117.10	-4.5	8.4e-06	0.00168	-0.15	-0.2	Total body bone mineral density;	chr2:27423216	chr2:27356246~27367622:+
LUAD	cis	rs10771431	0.817	rs17202253	ENSG00000111788.10	RP11-22B23.1	4.5	8.4e-06	0.00168	0.17	0.2	Breast size;	chr12:9209254	chr12:9277235~9313241:+
LUAD	cis	rs11155671	0.53	rs2342770	ENSG00000268592.3	RAET1E-AS1	4.5	8.41e-06	0.00168	0.25	0.2	Testicular germ cell tumor;	chr6:149895549	chr6:149863494~149919507:+
LUAD	cis	rs473651	0.935	rs541013	ENSG00000229915.1	AC016999.2	-4.5	8.41e-06	0.00168	-0.27	-0.2	Multiple system atrophy;	chr2:238427851	chr2:238427077~238427729:-
LUAD	cis	rs6964833	1	rs34324835	ENSG00000278416.1	PMS2L2	4.5	8.41e-06	0.00168	0.3	0.2	Menarche (age at onset);	chr7:74717986	chr7:75344015~75359550:-
LUAD	cis	rs6840360	0.547	rs9991859	ENSG00000270265.1	RP11-731D1.4	-4.5	8.42e-06	0.00169	-0.21	-0.2	Intelligence (multi-trait analysis);	chr4:151344420	chr4:151333775~151353224:-
LUAD	cis	rs750134	0.901	rs12579145	ENSG00000257221.1	RP11-689B22.2	-4.5	8.42e-06	0.00169	-0.3	-0.2	Low high density lipoprotein cholesterol levels;	chr12:108848093	chr12:108628687~108641318:+
LUAD	cis	rs28448403	1	rs28448403	ENSG00000255046.1	RP11-297N6.4	4.5	8.42e-06	0.00169	0.26	0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr8:11448055	chr8:11797928~11802568:-
LUAD	cis	rs9400467	0.508	rs456871	ENSG00000271789.1	RP5-1112D6.7	-4.5	8.43e-06	0.00169	-0.21	-0.2	Amino acid levels;Blood metabolite levels;	chr6:111366447	chr6:111297126~111298510:+
LUAD	cis	rs7760535	0.811	rs455732	ENSG00000271789.1	RP5-1112D6.7	-4.5	8.43e-06	0.00169	-0.21	-0.2	Metabolic traits;	chr6:111374065	chr6:111297126~111298510:+
LUAD	cis	rs1799949	0.965	rs4793233	ENSG00000236383.6	LINC00854	-4.5	8.43e-06	0.00169	-0.16	-0.2	Menopause (age at onset);	chr17:43358069	chr17:43216941~43305976:-
LUAD	cis	rs2212361	0.558	rs72980453	ENSG00000255893.1	RP11-685N10.1	-4.5	8.43e-06	0.00169	-0.27	-0.2	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94522923	chr11:94472908~94473570:-
LUAD	cis	rs910316	0.967	rs119076	ENSG00000279594.1	RP11-950C14.10	-4.5	8.43e-06	0.00169	-0.23	-0.2	Height;	chr14:75105716	chr14:75011269~75012851:-
LUAD	cis	rs4664293	0.669	rs1549387	ENSG00000226266.5	AC009961.3	4.5	8.44e-06	0.00169	0.27	0.2	Monocyte percentage of white cells;	chr2:159561029	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.669	rs1863219	ENSG00000226266.5	AC009961.3	4.5	8.44e-06	0.00169	0.27	0.2	Monocyte percentage of white cells;	chr2:159561660	chr2:159670708~159712435:-
LUAD	cis	rs10895987	1	rs10895987	ENSG00000254614.2	AP003068.23	-4.5	8.44e-06	0.00169	-0.31	-0.2	Blood protein levels;	chr11:65137437	chr11:65177606~65181834:-
LUAD	cis	rs7945705	0.791	rs12421789	ENSG00000254860.4	TMEM9B-AS1	4.5	8.44e-06	0.00169	0.23	0.2	Hemoglobin concentration;	chr11:8792409	chr11:8964675~8977527:+
LUAD	cis	rs12073359	1	rs72694946	ENSG00000223945.2	RP11-458I7.1	-4.5	8.45e-06	0.00169	-0.3	-0.2	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150143308	chr1:150053864~150055034:+
LUAD	cis	rs910316	1	rs7147118	ENSG00000279594.1	RP11-950C14.10	4.5	8.45e-06	0.00169	0.23	0.2	Height;	chr14:75143467	chr14:75011269~75012851:-
LUAD	cis	rs7208859	0.614	rs7216394	ENSG00000266490.1	CTD-2349P21.9	-4.5	8.45e-06	0.00169	-0.28	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30498738	chr17:30792372~30792833:+
LUAD	cis	rs2060793	0.519	rs1403247	ENSG00000251991.1	RNU7-49P	-4.5	8.45e-06	0.00169	-0.21	-0.2	Vitamin D levels;	chr11:14611024	chr11:14478892~14478953:+
LUAD	cis	rs9400467	0.528	rs1623806	ENSG00000271789.1	RP5-1112D6.7	-4.5	8.46e-06	0.00169	-0.21	-0.2	Amino acid levels;Blood metabolite levels;	chr6:111343868	chr6:111297126~111298510:+
LUAD	cis	rs9400467	0.528	rs455247	ENSG00000271789.1	RP5-1112D6.7	-4.5	8.46e-06	0.00169	-0.21	-0.2	Amino acid levels;Blood metabolite levels;	chr6:111346596	chr6:111297126~111298510:+
LUAD	cis	rs7760535	0.811	rs464401	ENSG00000271789.1	RP5-1112D6.7	-4.5	8.46e-06	0.00169	-0.21	-0.2	Metabolic traits;	chr6:111347804	chr6:111297126~111298510:+
LUAD	cis	rs9400467	0.509	rs463854	ENSG00000271789.1	RP5-1112D6.7	-4.5	8.46e-06	0.00169	-0.21	-0.2	Amino acid levels;Blood metabolite levels;	chr6:111352004	chr6:111297126~111298510:+
LUAD	cis	rs9400467	0.509	rs463853	ENSG00000271789.1	RP5-1112D6.7	-4.5	8.46e-06	0.00169	-0.21	-0.2	Amino acid levels;Blood metabolite levels;	chr6:111352008	chr6:111297126~111298510:+
LUAD	cis	rs9400467	0.528	rs456569	ENSG00000271789.1	RP5-1112D6.7	-4.5	8.46e-06	0.00169	-0.21	-0.2	Amino acid levels;Blood metabolite levels;	chr6:111353598	chr6:111297126~111298510:+
LUAD	cis	rs9400467	0.528	rs455335	ENSG00000271789.1	RP5-1112D6.7	-4.5	8.46e-06	0.00169	-0.21	-0.2	Amino acid levels;Blood metabolite levels;	chr6:111354313	chr6:111297126~111298510:+
LUAD	cis	rs9341808	0.754	rs1324121	ENSG00000272129.1	RP11-250B2.6	4.5	8.46e-06	0.00169	0.25	0.2	Sitting height ratio;	chr6:80236360	chr6:80355424~80356859:+
LUAD	cis	rs7208859	0.623	rs7217984	ENSG00000266490.1	CTD-2349P21.9	4.5	8.46e-06	0.00169	0.29	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765748	chr17:30792372~30792833:+
LUAD	cis	rs338389	0.967	rs338386	ENSG00000260657.2	RP11-315D16.4	-4.5	8.46e-06	0.00169	-0.23	-0.2	Survival in rectal cancer;	chr15:67969255	chr15:68267792~68277994:-
LUAD	cis	rs11064837	0.523	rs3930004	ENSG00000248636.5	RP11-768F21.1	4.5	8.46e-06	0.00169	0.23	0.2	Schizophrenia;	chr12:119664621	chr12:119387987~119668079:-
LUAD	cis	rs7107174	1	rs1942352	ENSG00000251323.2	RP11-452H21.4	4.5	8.46e-06	0.00169	0.25	0.2	Testicular germ cell tumor;	chr11:78259517	chr11:78423982~78429836:-
LUAD	cis	rs1799949	0.864	rs60309406	ENSG00000236383.6	LINC00854	-4.5	8.46e-06	0.00169	-0.16	-0.2	Menopause (age at onset);	chr17:43358297	chr17:43216941~43305976:-
LUAD	cis	rs2348418	0.767	rs1478332	ENSG00000247934.4	RP11-967K21.1	-4.5	8.46e-06	0.00169	-0.22	-0.2	Lung function (FEV1);Lung function (FVC);	chr12:28255432	chr12:28163298~28190738:-
LUAD	cis	rs73173548	0.502	rs7726289	ENSG00000247828.6	TMEM161B-AS1	4.5	8.46e-06	0.00169	0.25	0.2	Macular telangiectasia type 2;	chr5:88437392	chr5:88268895~88436685:+
LUAD	cis	rs9400467	0.528	rs465795	ENSG00000271789.1	RP5-1112D6.7	-4.5	8.46e-06	0.00169	-0.21	-0.2	Amino acid levels;Blood metabolite levels;	chr6:111355240	chr6:111297126~111298510:+
LUAD	cis	rs9400467	0.528	rs110732	ENSG00000271789.1	RP5-1112D6.7	-4.5	8.46e-06	0.00169	-0.21	-0.2	Amino acid levels;Blood metabolite levels;	chr6:111358666	chr6:111297126~111298510:+
LUAD	cis	rs9400467	0.592	rs462493	ENSG00000271789.1	RP5-1112D6.7	-4.5	8.46e-06	0.00169	-0.21	-0.2	Amino acid levels;Blood metabolite levels;	chr6:111362537	chr6:111297126~111298510:+
LUAD	cis	rs2239557	0.961	rs4903200	ENSG00000259065.1	RP5-1021I20.1	4.5	8.47e-06	0.00169	0.23	0.2	Common traits (Other);	chr14:74192934	chr14:73787360~73803270:+
LUAD	cis	rs1113500	0.73	rs1361829	ENSG00000226822.1	RP11-356N1.2	-4.5	8.47e-06	0.00169	-0.22	-0.2	Growth-regulated protein alpha levels;	chr1:108051273	chr1:108071482~108074519:+
LUAD	cis	rs9400467	0.508	rs12211763	ENSG00000230177.1	RP5-1112D6.4	-4.5	8.47e-06	0.00169	-0.18	-0.2	Amino acid levels;Blood metabolite levels;	chr6:111465953	chr6:111277932~111278742:+
LUAD	cis	rs6723226	0.881	rs10181198	ENSG00000276334.1	AL133243.1	4.5	8.47e-06	0.0017	0.24	0.2	Intelligence (multi-trait analysis);	chr2:32461514	chr2:32521927~32523547:+
LUAD	cis	rs7138803	0.538	rs66721590	ENSG00000257464.1	RP11-161H23.8	-4.5	8.47e-06	0.0017	-0.2	-0.2	Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index;	chr12:49811929	chr12:49442424~49442652:-
LUAD	cis	rs36093844	0.625	rs1445509	ENSG00000279742.1	RP11-700A24.1	-4.5	8.48e-06	0.0017	-0.22	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85891971	chr11:85852557~85854943:-
LUAD	cis	rs10129255	1	rs8010605	ENSG00000211974.3	IGHV2-70	4.5	8.48e-06	0.0017	0.21	0.2	Kawasaki disease;	chr14:106678742	chr14:106723574~106724093:-
LUAD	cis	rs6840360	0.967	rs10049728	ENSG00000270265.1	RP11-731D1.4	-4.5	8.48e-06	0.0017	-0.2	-0.2	Intelligence (multi-trait analysis);	chr4:151750969	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.967	rs7684350	ENSG00000270265.1	RP11-731D1.4	-4.5	8.48e-06	0.0017	-0.2	-0.2	Intelligence (multi-trait analysis);	chr4:151751730	chr4:151333775~151353224:-
LUAD	cis	rs6840360	1	rs7669977	ENSG00000270265.1	RP11-731D1.4	-4.5	8.48e-06	0.0017	-0.2	-0.2	Intelligence (multi-trait analysis);	chr4:151756375	chr4:151333775~151353224:-
LUAD	cis	rs2439831	0.681	rs484029	ENSG00000249839.1	AC011330.5	-4.5	8.48e-06	0.0017	-0.36	-0.2	Lung cancer in ever smokers;	chr15:43327362	chr15:43663654~43684339:-
LUAD	cis	rs62246343	0.541	rs17050396	ENSG00000254485.4	RP11-380O24.1	4.5	8.48e-06	0.0017	0.26	0.2	Fibrinogen levels;	chr3:9492652	chr3:9292588~9363303:-
LUAD	cis	rs228614	0.51	rs223324	ENSG00000251288.2	RP11-10L12.2	-4.5	8.48e-06	0.0017	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102876177	chr4:102751401~102752641:+
LUAD	cis	rs7826238	0.535	rs2979179	ENSG00000253981.4	ALG1L13P	4.5	8.48e-06	0.0017	0.23	0.2	Systolic blood pressure;	chr8:8462519	chr8:8236003~8244667:-
LUAD	cis	rs9545047	0.604	rs9318641	ENSG00000227354.5	RBM26-AS1	-4.5	8.48e-06	0.0017	-0.22	-0.2	Schizophrenia;	chr13:79426545	chr13:79406309~79424328:+
LUAD	cis	rs8072100	0.967	rs62076549	ENSG00000228782.6	CTD-2026D20.3	-4.5	8.49e-06	0.0017	-0.21	-0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47502189	chr17:47450568~47492492:-
LUAD	cis	rs2439831	0.85	rs28513374	ENSG00000249839.1	AC011330.5	-4.5	8.49e-06	0.0017	-0.43	-0.2	Lung cancer in ever smokers;	chr15:43833297	chr15:43663654~43684339:-
LUAD	cis	rs7116495	1	rs17161991	ENSG00000254682.1	RP11-660L16.2	-4.5	8.49e-06	0.0017	-0.44	-0.2	Severe influenza A (H1N1) infection;	chr11:72128914	chr11:71448674~71452157:+
LUAD	cis	rs7116495	0.619	rs7116188	ENSG00000254682.1	RP11-660L16.2	-4.5	8.49e-06	0.0017	-0.44	-0.2	Severe influenza A (H1N1) infection;	chr11:72130707	chr11:71448674~71452157:+
LUAD	cis	rs1008375	0.931	rs6837181	ENSG00000249502.1	AC006160.5	-4.5	8.49e-06	0.0017	-0.19	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17699630	chr4:17587467~17614571:-
LUAD	cis	rs2288884	0.634	rs80309583	ENSG00000275055.1	CTC-471J1.11	-4.5	8.49e-06	0.0017	-0.3	-0.2	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51996949	chr19:52049007~52049754:+
LUAD	cis	rs7208859	0.673	rs79541516	ENSG00000263603.1	CTD-2349P21.5	-4.5	8.49e-06	0.0017	-0.38	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913565	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs9895684	ENSG00000263603.1	CTD-2349P21.5	-4.5	8.49e-06	0.0017	-0.38	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30915582	chr17:30729469~30731202:+
LUAD	cis	rs889398	0.741	rs7192213	ENSG00000226232.7	RP11-419C5.2	-4.5	8.5e-06	0.0017	-0.17	-0.2	Body mass index;	chr16:69892377	chr16:69976388~69996188:-
LUAD	cis	rs708547	0.581	rs781661	ENSG00000269949.1	RP11-738E22.3	-4.5	8.5e-06	0.0017	-0.28	-0.2	Response to bleomycin (chromatid breaks);	chr4:56914141	chr4:56960927~56961373:-
LUAD	cis	rs1783925	0.549	rs12797616	ENSG00000254671.2	STT3A-AS1	-4.5	8.5e-06	0.0017	-0.23	-0.2	Formal thought disorder in schizophrenia;	chr11:125444363	chr11:125570284~125592568:-
LUAD	cis	rs17826219	0.706	rs8075357	ENSG00000280069.1	CTD-2349P21.3	-4.5	8.5e-06	0.0017	-0.27	-0.2	Body mass index;	chr17:30730179	chr17:30738182~30740275:+
LUAD	cis	rs17826219	0.706	rs61643715	ENSG00000280069.1	CTD-2349P21.3	-4.5	8.5e-06	0.0017	-0.27	-0.2	Body mass index;	chr17:30730744	chr17:30738182~30740275:+
LUAD	cis	rs17826219	0.636	rs8080829	ENSG00000280069.1	CTD-2349P21.3	-4.5	8.5e-06	0.0017	-0.27	-0.2	Body mass index;	chr17:30731712	chr17:30738182~30740275:+
LUAD	cis	rs853679	0.882	rs9468300	ENSG00000204709.4	LINC01556	4.5	8.5e-06	0.0017	0.35	0.2	Depression;	chr6:28159062	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.882	rs9380064	ENSG00000204709.4	LINC01556	4.5	8.5e-06	0.0017	0.35	0.2	Depression;	chr6:28175340	chr6:28943877~28944537:+
LUAD	cis	rs17772222	0.917	rs17260408	ENSG00000258789.1	RP11-507K2.3	-4.5	8.51e-06	0.0017	-0.27	-0.2	Coronary artery calcification;	chr14:88715464	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.917	rs8021690	ENSG00000258789.1	RP11-507K2.3	-4.5	8.51e-06	0.0017	-0.27	-0.2	Coronary artery calcification;	chr14:88717806	chr14:88551597~88552493:+
LUAD	cis	rs2115630	1	rs7183401	ENSG00000229212.6	RP11-561C5.4	4.5	8.51e-06	0.0017	0.23	0.2	P wave terminal force;	chr15:84828713	chr15:85205440~85234795:-
LUAD	cis	rs1113500	0.73	rs1343203	ENSG00000226822.1	RP11-356N1.2	4.5	8.51e-06	0.0017	0.23	0.2	Growth-regulated protein alpha levels;	chr1:108048560	chr1:108071482~108074519:+
LUAD	cis	rs301901	0.796	rs1829292	ENSG00000250155.1	CTD-2353F22.1	4.5	8.51e-06	0.0017	0.21	0.2	Height;	chr5:37505544	chr5:36666214~36725195:-
LUAD	cis	rs9322193	0.847	rs62439808	ENSG00000268592.3	RAET1E-AS1	4.5	8.52e-06	0.0017	0.25	0.2	Lung cancer;	chr6:149629690	chr6:149863494~149919507:+
LUAD	cis	rs780096	0.525	rs13388159	ENSG00000234072.1	AC074117.10	-4.5	8.52e-06	0.0017	-0.15	-0.2	Total body bone mineral density;	chr2:27425417	chr2:27356246~27367622:+
LUAD	cis	rs2522056	1	rs2522062	ENSG00000233006.5	AC034220.3	-4.5	8.53e-06	0.0017	-0.23	-0.2	Fibrinogen;Lymphocyte counts;	chr5:132469724	chr5:132311285~132369916:-
LUAD	cis	rs17685	0.753	rs1104879	ENSG00000280388.1	RP11-229D13.3	-4.5	8.53e-06	0.0017	-0.19	-0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76056250	chr7:76043977~76045963:-
LUAD	cis	rs11157436	0.602	rs11157439	ENSG00000211813.2	TRAV34	4.5	8.53e-06	0.0017	0.23	0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22171061	chr14:22207522~22208129:+
LUAD	cis	rs6840360	0.571	rs7692700	ENSG00000270265.1	RP11-731D1.4	-4.5	8.53e-06	0.0017	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151631645	chr4:151333775~151353224:-
LUAD	cis	rs7017914	0.644	rs13251367	ENSG00000223220.1	Y_RNA	4.5	8.53e-06	0.00171	0.24	0.2	Bone mineral density;	chr8:71089696	chr8:70780914~70781008:-
LUAD	cis	rs750134	1	rs10507231	ENSG00000257221.1	RP11-689B22.2	-4.5	8.53e-06	0.00171	-0.29	-0.2	Low high density lipoprotein cholesterol levels;	chr12:108679562	chr12:108628687~108641318:+
LUAD	cis	rs17772222	1	rs17124700	ENSG00000258789.1	RP11-507K2.3	-4.5	8.53e-06	0.00171	-0.28	-0.2	Coronary artery calcification;	chr14:88439285	chr14:88551597~88552493:+
LUAD	cis	rs1005277	0.579	rs2474571	ENSG00000263064.2	RP11-291L22.7	4.5	8.53e-06	0.00171	0.22	0.2	Extrinsic epigenetic age acceleration;	chr10:38095711	chr10:38448689~38448949:+
LUAD	cis	rs8072100	0.869	rs4439799	ENSG00000228782.6	CTD-2026D20.3	4.5	8.54e-06	0.00171	0.21	0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47704233	chr17:47450568~47492492:-
LUAD	cis	rs2898681	0.561	rs58577680	ENSG00000248375.1	RP11-177B4.1	-4.5	8.55e-06	0.00171	-0.33	-0.2	Optic nerve measurement (cup area);	chr4:52868127	chr4:52720081~52720831:-
LUAD	cis	rs7172677	1	rs4886658	ENSG00000260269.4	CTD-2323K18.1	-4.5	8.55e-06	0.00171	-0.27	-0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75122195	chr15:75527150~75601205:-
LUAD	cis	rs1113500	0.787	rs4571989	ENSG00000226822.1	RP11-356N1.2	4.5	8.55e-06	0.00171	0.23	0.2	Growth-regulated protein alpha levels;	chr1:108088722	chr1:108071482~108074519:+
LUAD	cis	rs1113500	0.787	rs12047429	ENSG00000226822.1	RP11-356N1.2	4.5	8.55e-06	0.00171	0.23	0.2	Growth-regulated protein alpha levels;	chr1:108090617	chr1:108071482~108074519:+
LUAD	cis	rs73173548	0.502	rs10505856	ENSG00000247828.6	TMEM161B-AS1	4.5	8.56e-06	0.00171	0.24	0.2	Macular telangiectasia type 2;	chr5:88440636	chr5:88268895~88436685:+
LUAD	cis	rs7819412	0.818	rs11989439	ENSG00000255046.1	RP11-297N6.4	4.5	8.56e-06	0.00171	0.25	0.2	Triglycerides;	chr8:11198088	chr8:11797928~11802568:-
LUAD	cis	rs11671005	0.737	rs11671033	ENSG00000268912.1	CTD-2619J13.17	-4.5	8.56e-06	0.00171	-0.29	-0.2	Mean platelet volume;	chr19:58452302	chr19:58428632~58431148:-
LUAD	cis	rs10090774	0.664	rs28605671	ENSG00000280303.2	ERICD	-4.5	8.56e-06	0.00171	-0.22	-0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140645013	chr8:140636281~140638283:+
LUAD	cis	rs4819052	0.851	rs2236443	ENSG00000237664.1	LINC00316	-4.5	8.56e-06	0.00171	-0.24	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258259	chr21:45338590~45341990:-
LUAD	cis	rs6964587	1	rs4265	ENSG00000188693.7	CYP51A1-AS1	4.5	8.56e-06	0.00171	0.23	0.2	Breast cancer;	chr7:92090294	chr7:92134604~92180725:+
LUAD	cis	rs9309473	0.687	rs6706409	ENSG00000163016.8	ALMS1P	-4.5	8.57e-06	0.00171	-0.22	-0.2	Metabolite levels;	chr2:73379380	chr2:73644919~73685576:+
LUAD	cis	rs7200786	0.669	rs4781027	ENSG00000274038.1	RP11-66H6.4	4.5	8.57e-06	0.00171	0.25	0.2	Systemic lupus erythematosus;Multiple sclerosis;	chr16:10958591	chr16:11056556~11057034:+
LUAD	cis	rs7200786	0.692	rs7404554	ENSG00000274038.1	RP11-66H6.4	4.5	8.57e-06	0.00171	0.25	0.2	Systemic lupus erythematosus;Multiple sclerosis;	chr16:10959067	chr16:11056556~11057034:+
LUAD	cis	rs16923476	1	rs12259862	ENSG00000279029.1	RP11-144I2.1	4.5	8.57e-06	0.00171	0.55	0.2	Obesity (early onset extreme);	chr10:23674742	chr10:24481180~24483034:-
LUAD	cis	rs11089937	0.568	rs5756988	ENSG00000211640.3	IGLV6-57	-4.5	8.57e-06	0.00171	-0.15	-0.2	Periodontitis (PAL4Q3);	chr22:22132397	chr22:22195713~22196460:+
LUAD	cis	rs11023332	0.65	rs2122942	ENSG00000251991.1	RNU7-49P	4.5	8.57e-06	0.00171	0.22	0.2	Vitamin D levels;Adiponectin levels;	chr11:14785829	chr11:14478892~14478953:+
LUAD	cis	rs9633740	0.578	rs11185951	ENSG00000226659.1	RP11-137H2.4	4.5	8.57e-06	0.00171	0.37	0.2	Post bronchodilator FEV1;	chr10:80541780	chr10:80529597~80535942:-
LUAD	cis	rs875971	0.929	rs4122249	ENSG00000232559.3	GS1-124K5.12	4.5	8.57e-06	0.00171	0.24	0.2	Aortic root size;	chr7:66455949	chr7:66554588~66576923:-
LUAD	cis	rs2742234	0.666	rs715106	ENSG00000273008.1	RP11-351D16.3	-4.5	8.58e-06	0.00171	-0.23	-0.2	Hirschsprung disease;	chr10:43121303	chr10:43136824~43138334:-
LUAD	cis	rs34779708	0.733	rs11010146	ENSG00000271335.4	RP11-324I22.4	4.5	8.58e-06	0.00171	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35252633	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.733	rs7086715	ENSG00000271335.4	RP11-324I22.4	4.5	8.58e-06	0.00171	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35252912	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.702	rs7087150	ENSG00000271335.4	RP11-324I22.4	4.5	8.58e-06	0.00171	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35253210	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.733	rs12249814	ENSG00000271335.4	RP11-324I22.4	4.5	8.58e-06	0.00171	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35253829	chr10:35314552~35336401:-
LUAD	cis	rs9860428	0.967	rs9820264	ENSG00000242770.2	RP11-180K7.1	4.5	8.59e-06	0.00171	0.21	0.2	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112869728	chr3:112802478~112812819:+
LUAD	cis	rs9860428	1	rs9825121	ENSG00000242770.2	RP11-180K7.1	4.5	8.59e-06	0.00171	0.21	0.2	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112870357	chr3:112802478~112812819:+
LUAD	cis	rs9650657	0.504	rs2409724	ENSG00000255046.1	RP11-297N6.4	4.5	8.59e-06	0.00172	0.25	0.2	Neuroticism;	chr8:11184133	chr8:11797928~11802568:-
LUAD	cis	rs9341808	0.718	rs2322636	ENSG00000272129.1	RP11-250B2.6	4.5	8.59e-06	0.00172	0.25	0.2	Sitting height ratio;	chr6:80187719	chr6:80355424~80356859:+
LUAD	cis	rs16866061	1	rs11686590	ENSG00000228446.2	AC073052.1	-4.5	8.6e-06	0.00172	-0.22	-0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr2:224469353	chr2:224499387~224500100:-
LUAD	cis	rs16866061	1	rs12470077	ENSG00000228446.2	AC073052.1	-4.5	8.6e-06	0.00172	-0.22	-0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr2:224470254	chr2:224499387~224500100:-
LUAD	cis	rs34779708	0.733	rs7087099	ENSG00000271335.4	RP11-324I22.4	4.5	8.6e-06	0.00172	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35253054	chr10:35314552~35336401:-
LUAD	cis	rs11157436	0.602	rs10872984	ENSG00000211813.2	TRAV34	4.5	8.6e-06	0.00172	0.23	0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22171245	chr14:22207522~22208129:+
LUAD	cis	rs477895	0.713	rs2282490	ENSG00000236935.1	AP003774.1	-4.5	8.6e-06	0.00172	-0.25	-0.2	Mean platelet volume;	chr11:64194680	chr11:64325050~64329504:-
LUAD	cis	rs477895	0.713	rs67546972	ENSG00000236935.1	AP003774.1	-4.5	8.6e-06	0.00172	-0.25	-0.2	Mean platelet volume;	chr11:64194690	chr11:64325050~64329504:-
LUAD	cis	rs477895	0.713	rs11607165	ENSG00000236935.1	AP003774.1	-4.5	8.6e-06	0.00172	-0.25	-0.2	Mean platelet volume;	chr11:64196475	chr11:64325050~64329504:-
LUAD	cis	rs8062405	0.721	rs151181	ENSG00000251417.2	RP11-1348G14.4	-4.5	8.61e-06	0.00172	-0.21	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28802743~28817828:+
LUAD	cis	rs7665090	1	rs735404	ENSG00000246560.2	RP11-10L12.4	4.5	8.61e-06	0.00172	0.24	0.2	Primary biliary cholangitis;	chr4:102632508	chr4:102828055~102844075:+
LUAD	cis	rs2299587	0.543	rs12546204	ENSG00000253671.1	RP11-806O11.1	-4.5	8.61e-06	0.00172	-0.23	-0.2	Economic and political preferences;	chr8:17939362	chr8:17808941~17820868:+
LUAD	cis	rs910316	0.967	rs119076	ENSG00000259138.1	RP11-950C14.7	-4.5	8.61e-06	0.00172	-0.21	-0.2	Height;	chr14:75105716	chr14:75127153~75136930:+
LUAD	cis	rs375066	0.901	rs1978723	ENSG00000267058.1	RP11-15A1.3	4.5	8.61e-06	0.00172	0.23	0.2	Breast cancer;	chr19:43879648	chr19:43891804~43901805:-
LUAD	cis	rs62355901	0.545	rs12654176	ENSG00000271828.1	CTD-2310F14.1	4.5	8.61e-06	0.00172	0.37	0.2	Breast cancer;	chr5:56762660	chr5:56927874~56929573:+
LUAD	cis	rs4908768	0.539	rs922366	ENSG00000270282.1	RP5-1115A15.2	4.5	8.62e-06	0.00172	0.22	0.2	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8593674	chr1:8512653~8513021:+
LUAD	cis	rs7208859	0.673	rs11652370	ENSG00000280069.1	CTD-2349P21.3	-4.5	8.62e-06	0.00172	-0.24	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770205	chr17:30738182~30740275:+
LUAD	cis	rs8072100	0.967	rs4794058	ENSG00000228782.6	CTD-2026D20.3	-4.5	8.62e-06	0.00172	-0.21	-0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47519732	chr17:47450568~47492492:-
LUAD	cis	rs6565180	1	rs11863150	ENSG00000273724.1	RP11-347C12.12	4.5	8.62e-06	0.00172	0.21	0.2	Tonsillectomy;	chr16:30374182	chr16:30336400~30343336:+
LUAD	cis	rs1551277	0.84	rs12702389	ENSG00000146666.5	LINC00525	-4.5	8.62e-06	0.00172	-0.22	-0.2	Anxiety disorder;	chr7:47801267	chr7:47761476~47766772:+
LUAD	cis	rs9925964	0.622	rs8046707	ENSG00000232748.3	RP11-196G11.6	4.5	8.63e-06	0.00172	0.24	0.2	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:30904912	chr16:31056460~31062803:+
LUAD	cis	rs12468226	0.752	rs79058237	ENSG00000272966.1	RP11-686O6.1	4.5	8.63e-06	0.00172	0.34	0.2	Urate levels;	chr2:202140247	chr2:202336739~202337200:+
LUAD	cis	rs8072100	0.727	rs4794052	ENSG00000228782.6	CTD-2026D20.3	4.5	8.63e-06	0.00172	0.21	0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47691870	chr17:47450568~47492492:-
LUAD	cis	rs77688320	0.573	rs2714480	ENSG00000213090.2	AC007256.5	-4.5	8.63e-06	0.00172	-0.23	-0.2	Breast cancer;	chr2:201486286	chr2:201410544~201413308:-
LUAD	cis	rs17772222	0.682	rs2274736	ENSG00000258789.1	RP11-507K2.3	-4.5	8.63e-06	0.00172	-0.25	-0.2	Coronary artery calcification;	chr14:88472308	chr14:88551597~88552493:+
LUAD	cis	rs240993	0.516	rs240981	ENSG00000230177.1	RP5-1112D6.4	-4.5	8.63e-06	0.00172	-0.22	-0.2	Inflammatory skin disease;Psoriasis;	chr6:111289990	chr6:111277932~111278742:+
LUAD	cis	rs9400467	0.528	rs462432	ENSG00000271789.1	RP5-1112D6.7	-4.5	8.63e-06	0.00172	-0.21	-0.2	Amino acid levels;Blood metabolite levels;	chr6:111338552	chr6:111297126~111298510:+
LUAD	cis	rs7760535	0.931	rs466923	ENSG00000271789.1	RP5-1112D6.7	-4.5	8.63e-06	0.00172	-0.21	-0.2	Metabolic traits;	chr6:111341774	chr6:111297126~111298510:+
LUAD	cis	rs2243480	1	rs73150014	ENSG00000232559.3	GS1-124K5.12	4.5	8.63e-06	0.00172	0.35	0.2	Diabetic kidney disease;	chr7:65985932	chr7:66554588~66576923:-
LUAD	cis	rs78773383	0.505	rs10033019	ENSG00000249207.1	RP11-360F5.1	4.5	8.63e-06	0.00172	0.21	0.2	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr4:39390320	chr4:39112677~39126818:-
LUAD	cis	rs755249	0.509	rs710913	ENSG00000228060.1	RP11-69E11.8	4.5	8.63e-06	0.00172	0.17	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39524254	chr1:39565160~39573203:+
LUAD	cis	rs7945705	0.776	rs11042069	ENSG00000254860.4	TMEM9B-AS1	-4.5	8.64e-06	0.00172	-0.24	-0.2	Hemoglobin concentration;	chr11:8795768	chr11:8964675~8977527:+
LUAD	cis	rs944990	0.538	rs10992789	ENSG00000227603.1	RP11-165J3.6	4.5	8.64e-06	0.00172	0.23	0.2	Body mass index;	chr9:93578914	chr9:93435332~93437121:-
LUAD	cis	rs6565180	0.888	rs12447833	ENSG00000273724.1	RP11-347C12.12	4.5	8.64e-06	0.00172	0.22	0.2	Tonsillectomy;	chr16:30378993	chr16:30336400~30343336:+
LUAD	cis	rs62025270	0.688	rs62025297	ENSG00000202081.1	RNU6-1280P	-4.5	8.64e-06	0.00172	-0.29	-0.2	Idiopathic pulmonary fibrosis;	chr15:85773708	chr15:85651522~85651628:-
LUAD	cis	rs62025270	0.688	rs62025298	ENSG00000202081.1	RNU6-1280P	-4.5	8.64e-06	0.00172	-0.29	-0.2	Idiopathic pulmonary fibrosis;	chr15:85773921	chr15:85651522~85651628:-
LUAD	cis	rs3096299	0.685	rs12446145	ENSG00000261118.1	RP11-104N10.1	4.5	8.64e-06	0.00172	0.2	0.2	Multiple myeloma (IgH translocation);	chr16:89476287	chr16:89492017~89504460:-
LUAD	cis	rs2998286	0.723	rs1034087	ENSG00000254635.4	WAC-AS1	-4.5	8.65e-06	0.00173	-0.27	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28643143	chr10:28522652~28532743:-
LUAD	cis	rs910316	0.967	rs175502	ENSG00000279594.1	RP11-950C14.10	-4.5	8.65e-06	0.00173	-0.23	-0.2	Height;	chr14:75066976	chr14:75011269~75012851:-
LUAD	cis	rs12575642	0.66	rs58632573	ENSG00000236935.1	AP003774.1	-4.5	8.65e-06	0.00173	-0.25	-0.2	Attention deficit hyperactivity disorder;	chr11:64128827	chr11:64325050~64329504:-
LUAD	cis	rs477895	0.653	rs11606544	ENSG00000236935.1	AP003774.1	-4.5	8.65e-06	0.00173	-0.25	-0.2	Mean platelet volume;	chr11:64129429	chr11:64325050~64329504:-
LUAD	cis	rs477895	0.653	rs66648159	ENSG00000236935.1	AP003774.1	-4.5	8.65e-06	0.00173	-0.25	-0.2	Mean platelet volume;	chr11:64131957	chr11:64325050~64329504:-
LUAD	cis	rs17772222	0.63	rs12436642	ENSG00000258789.1	RP11-507K2.3	4.5	8.65e-06	0.00173	0.24	0.2	Coronary artery calcification;	chr14:88559032	chr14:88551597~88552493:+
LUAD	cis	rs4873772	0.735	rs923499	ENSG00000253330.1	RP11-697N18.3	-4.5	8.65e-06	0.00173	-0.23	-0.2	Lobe attachment (rater-scored or self-reported);	chr8:47523060	chr8:47511034~47512141:-
LUAD	cis	rs3096299	0.719	rs12934708	ENSG00000261118.1	RP11-104N10.1	4.5	8.66e-06	0.00173	0.2	0.2	Multiple myeloma (IgH translocation);	chr16:89457382	chr16:89492017~89504460:-
LUAD	cis	rs2299587	0.689	rs12546237	ENSG00000253671.1	RP11-806O11.1	-4.5	8.66e-06	0.00173	-0.22	-0.2	Economic and political preferences;	chr8:17939546	chr8:17808941~17820868:+
LUAD	cis	rs11992186	0.505	rs7845203	ENSG00000253893.2	FAM85B	-4.5	8.66e-06	0.00173	-0.24	-0.2	Neuroticism;	chr8:8287918	chr8:8167819~8226614:-
LUAD	cis	rs9341808	0.727	rs9361599	ENSG00000233967.5	RP11-250B2.3	4.5	8.67e-06	0.00173	0.2	0.2	Sitting height ratio;	chr6:80315525	chr6:80443344~80465927:+
LUAD	cis	rs9341808	0.754	rs9352817	ENSG00000233967.5	RP11-250B2.3	4.5	8.67e-06	0.00173	0.2	0.2	Sitting height ratio;	chr6:80316162	chr6:80443344~80465927:+
LUAD	cis	rs2933343	1	rs1680790	ENSG00000231305.3	RP11-723O4.2	4.5	8.67e-06	0.00173	0.24	0.2	IgG glycosylation;	chr3:128907010	chr3:128861313~128871540:-
LUAD	cis	rs2933343	1	rs876755	ENSG00000231305.3	RP11-723O4.2	4.5	8.67e-06	0.00173	0.24	0.2	IgG glycosylation;	chr3:128909090	chr3:128861313~128871540:-
LUAD	cis	rs17301013	0.932	rs12077622	ENSG00000227373.4	RP11-160H22.5	4.5	8.67e-06	0.00173	0.25	0.2	Systemic lupus erythematosus;	chr1:174442507	chr1:174115300~174160004:-
LUAD	cis	rs7636293	1	rs6439169	ENSG00000270773.1	RP13-685P2.7	4.5	8.67e-06	0.00173	0.24	0.2	Height;	chr3:129332792	chr3:129345411~129346164:+
LUAD	cis	rs3096299	0.685	rs4238830	ENSG00000182376.2	RP5-1142A6.8	4.5	8.68e-06	0.00173	0.21	0.2	Multiple myeloma (IgH translocation);	chr16:89473833	chr16:88742767~88745748:+
LUAD	cis	rs3219474	0.505	rs487174	ENSG00000280836.1	AL355480.1	-4.5	8.68e-06	0.00173	-0.38	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:45543864	chr1:45581219~45581321:-
LUAD	cis	rs6687758	1	rs17442323	ENSG00000200033.1	RNU6-403P	4.5	8.68e-06	0.00173	0.28	0.2	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222019622	chr1:221837334~221837437:-
LUAD	cis	rs2562456	0.754	rs112195516	ENSG00000268081.1	RP11-678G14.2	4.5	8.68e-06	0.00173	0.33	0.2	Pain;	chr19:21410849	chr19:21554640~21569237:-
LUAD	cis	rs12073359	1	rs72694953	ENSG00000223945.2	RP11-458I7.1	-4.5	8.68e-06	0.00173	-0.3	-0.2	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150147539	chr1:150053864~150055034:+
LUAD	cis	rs4879677	1	rs10968061	ENSG00000215441.3	CTAGE12P	4.5	8.68e-06	0.00173	0.24	0.2	Gut microbiome composition (summer and winter);	chr9:27688780	chr9:27608382~27610745:-
LUAD	cis	rs1008375	0.966	rs6839660	ENSG00000249502.1	AC006160.5	-4.5	8.69e-06	0.00173	-0.19	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17666364	chr4:17587467~17614571:-
LUAD	cis	rs755249	0.508	rs12023553	ENSG00000228060.1	RP11-69E11.8	4.5	8.69e-06	0.00173	0.18	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39205820	chr1:39565160~39573203:+
LUAD	cis	rs7590268	0.666	rs6746996	ENSG00000279873.2	LINC01126	4.5	8.69e-06	0.00173	0.19	0.2	Orofacial clefts;	chr2:43406689	chr2:43227210~43228855:+
LUAD	cis	rs7590268	0.666	rs9677398	ENSG00000279873.2	LINC01126	4.5	8.69e-06	0.00173	0.19	0.2	Orofacial clefts;	chr2:43406996	chr2:43227210~43228855:+
LUAD	cis	rs800160	0.777	rs11529118	ENSG00000236264.4	RPL26P30	4.5	8.69e-06	0.00173	0.26	0.2	Bacteremia;	chr11:2322636	chr11:2335132~2335776:-
LUAD	cis	rs1864585	0.52	rs17776404	ENSG00000255046.1	RP11-297N6.4	4.5	8.69e-06	0.00173	0.28	0.2	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10815319	chr8:11797928~11802568:-
LUAD	cis	rs2976388	1	rs2920295	ENSG00000253741.1	CTD-2292P10.4	4.5	8.7e-06	0.00173	0.23	0.2	Urinary tract infection frequency;	chr8:142683519	chr8:142702252~142726973:-
LUAD	cis	rs4819052	0.679	rs4819053	ENSG00000237664.1	LINC00316	4.5	8.7e-06	0.00173	0.23	0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291442	chr21:45338590~45341990:-
LUAD	cis	rs9400467	0.528	rs458486	ENSG00000271789.1	RP5-1112D6.7	-4.5	8.7e-06	0.00173	-0.21	-0.2	Amino acid levels;Blood metabolite levels;	chr6:111375649	chr6:111297126~111298510:+
LUAD	cis	rs6102185	0.608	rs6102194	ENSG00000229771.2	RP4-644L1.2	-4.5	8.7e-06	0.00174	-0.24	-0.2	IgG glycosylation;	chr20:40880647	chr20:40696499~40698616:-
LUAD	cis	rs9322193	0.923	rs9767123	ENSG00000268592.3	RAET1E-AS1	4.5	8.7e-06	0.00174	0.24	0.2	Lung cancer;	chr6:149660323	chr6:149863494~149919507:+
LUAD	cis	rs77688320	0.553	rs2714488	ENSG00000213090.2	AC007256.5	-4.5	8.7e-06	0.00174	-0.23	-0.2	Breast cancer;	chr2:201405050	chr2:201410544~201413308:-
LUAD	cis	rs77688320	0.553	rs2249868	ENSG00000213090.2	AC007256.5	-4.5	8.7e-06	0.00174	-0.23	-0.2	Breast cancer;	chr2:201412503	chr2:201410544~201413308:-
LUAD	cis	rs7202877	0.706	rs467780	ENSG00000280152.1	RP11-331F4.5	-4.5	8.7e-06	0.00174	-0.23	-0.2	Type 1 diabetes;Type 2 diabetes;	chr16:75403240	chr16:75245994~75250077:-
LUAD	cis	rs7324557	0.684	rs9510871	ENSG00000205861.10	C1QTNF9B-AS1	-4.5	8.71e-06	0.00174	-0.26	-0.2	Visceral adipose tissue adjusted for BMI;	chr13:23810713	chr13:23888889~23897263:+
LUAD	cis	rs2243480	1	rs422164	ENSG00000232559.3	GS1-124K5.12	4.5	8.71e-06	0.00174	0.35	0.2	Diabetic kidney disease;	chr7:66121618	chr7:66554588~66576923:-
LUAD	cis	rs2243480	0.908	rs1532573	ENSG00000232559.3	GS1-124K5.12	-4.5	8.71e-06	0.00174	-0.35	-0.2	Diabetic kidney disease;	chr7:66333815	chr7:66554588~66576923:-
LUAD	cis	rs6860806	0.661	rs6890009	ENSG00000233006.5	AC034220.3	4.5	8.71e-06	0.00174	0.17	0.2	Breast cancer;	chr5:132244340	chr5:132311285~132369916:-
LUAD	cis	rs6570726	0.791	rs440477	ENSG00000235652.6	RP11-545I5.3	4.5	8.71e-06	0.00174	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145533052	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.791	rs385729	ENSG00000235652.6	RP11-545I5.3	4.5	8.71e-06	0.00174	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145534329	chr6:145799409~145886585:+
LUAD	cis	rs7811142	1	rs66632384	ENSG00000078319.8	PMS2P1	-4.5	8.72e-06	0.00174	-0.24	-0.2	Platelet count;	chr7:100421281	chr7:100320992~100341908:-
LUAD	cis	rs7811142	0.943	rs73403312	ENSG00000078319.8	PMS2P1	-4.5	8.72e-06	0.00174	-0.24	-0.2	Platelet count;	chr7:100426530	chr7:100320992~100341908:-
LUAD	cis	rs858239	0.571	rs6953020	ENSG00000226816.2	AC005082.12	4.5	8.72e-06	0.00174	0.26	0.2	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23206013~23208045:+
LUAD	cis	rs853679	1	rs853685	ENSG00000219392.1	RP1-265C24.5	-4.5	8.72e-06	0.00174	-0.31	-0.2	Depression;	chr6:28321008	chr6:28115628~28116551:+
LUAD	cis	rs12908161	1	rs11637142	ENSG00000259295.5	CSPG4P12	4.5	8.72e-06	0.00174	0.28	0.2	Schizophrenia;	chr15:84752696	chr15:85191438~85213905:+
LUAD	cis	rs12908161	0.92	rs35758837	ENSG00000259295.5	CSPG4P12	4.5	8.73e-06	0.00174	0.28	0.2	Schizophrenia;	chr15:84768151	chr15:85191438~85213905:+
LUAD	cis	rs1729951	0.575	rs12494558	ENSG00000239213.4	NCK1-AS1	4.49	8.73e-06	0.00174	0.22	0.2	Neuroticism;	chr3:136959939	chr3:136841726~136862054:-
LUAD	cis	rs847577	0.587	rs34307903	ENSG00000272950.1	RP11-307C18.1	4.49	8.73e-06	0.00174	0.25	0.2	Breast cancer;	chr7:98099137	chr7:98322853~98323430:+
LUAD	cis	rs34779708	0.966	rs12257770	ENSG00000271335.4	RP11-324I22.4	4.49	8.73e-06	0.00174	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35228306	chr10:35314552~35336401:-
LUAD	cis	rs3814244	0.528	rs61923060	ENSG00000236946.2	HNRNPA1P70	-4.49	8.73e-06	0.00174	-0.18	-0.2	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997341	chr12:68035767~68036853:+
LUAD	cis	rs6723108	0.604	rs6430551	ENSG00000224043.6	CCNT2-AS1	-4.49	8.74e-06	0.00174	-0.25	-0.2	Type 2 diabetes;	chr2:134863986	chr2:134735464~134918710:-
LUAD	cis	rs4664293	0.647	rs7580816	ENSG00000226266.5	AC009961.3	-4.49	8.74e-06	0.00174	-0.27	-0.2	Monocyte percentage of white cells;	chr2:159619370	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.647	rs1966530	ENSG00000226266.5	AC009961.3	-4.49	8.74e-06	0.00174	-0.27	-0.2	Monocyte percentage of white cells;	chr2:159620897	chr2:159670708~159712435:-
LUAD	cis	rs9341808	0.69	rs3805926	ENSG00000272129.1	RP11-250B2.6	4.49	8.74e-06	0.00174	0.25	0.2	Sitting height ratio;	chr6:80169563	chr6:80355424~80356859:+
LUAD	cis	rs4819052	0.851	rs2236446	ENSG00000237664.1	LINC00316	-4.49	8.74e-06	0.00174	-0.24	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259070	chr21:45338590~45341990:-
LUAD	cis	rs2304003	0.95	rs6742727	ENSG00000235192.1	AC009495.2	4.49	8.75e-06	0.00174	0.25	0.2	Social communication problems;	chr2:165836176	chr2:165794851~165810010:+
LUAD	cis	rs6539288	0.933	rs4964498	ENSG00000260329.1	RP11-412D9.4	-4.49	8.75e-06	0.00174	-0.22	-0.2	Total body bone mineral density;	chr12:106912945	chr12:106954029~106955497:-
LUAD	cis	rs9341808	0.718	rs3828754	ENSG00000272129.1	RP11-250B2.6	4.49	8.75e-06	0.00174	0.25	0.2	Sitting height ratio;	chr6:80190923	chr6:80355424~80356859:+
LUAD	cis	rs9341808	0.718	rs10943696	ENSG00000272129.1	RP11-250B2.6	4.49	8.75e-06	0.00174	0.25	0.2	Sitting height ratio;	chr6:80191555	chr6:80355424~80356859:+
LUAD	cis	rs9341808	0.718	rs6910201	ENSG00000272129.1	RP11-250B2.6	4.49	8.75e-06	0.00174	0.25	0.2	Sitting height ratio;	chr6:80195221	chr6:80355424~80356859:+
LUAD	cis	rs9341808	0.69	rs9448909	ENSG00000272129.1	RP11-250B2.6	4.49	8.75e-06	0.00174	0.25	0.2	Sitting height ratio;	chr6:80199314	chr6:80355424~80356859:+
LUAD	cis	rs11886999	0.767	rs72825877	ENSG00000237510.6	AC008268.2	-4.49	8.75e-06	0.00174	-0.33	-0.2	Cardiac Troponin-T levels;	chr2:96255155	chr2:95789654~95800166:+
LUAD	cis	rs7324557	0.717	rs7330646	ENSG00000205861.10	C1QTNF9B-AS1	4.49	8.75e-06	0.00174	0.25	0.2	Visceral adipose tissue adjusted for BMI;	chr13:23828025	chr13:23888889~23897263:+
LUAD	cis	rs4664293	0.669	rs357021	ENSG00000226266.5	AC009961.3	-4.49	8.76e-06	0.00174	-0.27	-0.2	Monocyte percentage of white cells;	chr2:159632572	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.647	rs357030	ENSG00000226266.5	AC009961.3	-4.49	8.76e-06	0.00174	-0.27	-0.2	Monocyte percentage of white cells;	chr2:159636515	chr2:159670708~159712435:-
LUAD	cis	rs1355223	0.902	rs2185700	ENSG00000271369.1	RP11-350D17.3	-4.49	8.76e-06	0.00175	-0.24	-0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34702657	chr11:34709600~34710161:+
LUAD	cis	rs7208859	0.673	rs450585	ENSG00000280069.1	CTD-2349P21.3	-4.49	8.76e-06	0.00175	-0.23	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624021	chr17:30738182~30740275:+
LUAD	cis	rs3096299	0.632	rs4399533	ENSG00000261118.1	RP11-104N10.1	4.49	8.76e-06	0.00175	0.2	0.2	Multiple myeloma (IgH translocation);	chr16:89472974	chr16:89492017~89504460:-
LUAD	cis	rs13113518	0.812	rs6825774	ENSG00000223305.1	RN7SKP30	4.49	8.76e-06	0.00175	0.23	0.2	Height;	chr4:55491150	chr4:55540502~55540835:-
LUAD	cis	rs13113518	0.812	rs3805153	ENSG00000223305.1	RN7SKP30	4.49	8.76e-06	0.00175	0.23	0.2	Height;	chr4:55493557	chr4:55540502~55540835:-
LUAD	cis	rs750134	1	rs1079088	ENSG00000257221.1	RP11-689B22.2	-4.49	8.76e-06	0.00175	-0.31	-0.2	Low high density lipoprotein cholesterol levels;	chr12:108667755	chr12:108628687~108641318:+
LUAD	cis	rs750134	1	rs1861639	ENSG00000257221.1	RP11-689B22.2	-4.49	8.76e-06	0.00175	-0.31	-0.2	Low high density lipoprotein cholesterol levels;	chr12:108668422	chr12:108628687~108641318:+
LUAD	cis	rs750134	1	rs10507230	ENSG00000257221.1	RP11-689B22.2	-4.49	8.76e-06	0.00175	-0.31	-0.2	Low high density lipoprotein cholesterol levels;	chr12:108668645	chr12:108628687~108641318:+
LUAD	cis	rs7172677	1	rs7177528	ENSG00000260269.4	CTD-2323K18.1	-4.49	8.76e-06	0.00175	-0.27	-0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75117253	chr15:75527150~75601205:-
LUAD	cis	rs9322193	0.924	rs9498382	ENSG00000268592.3	RAET1E-AS1	4.49	8.76e-06	0.00175	0.25	0.2	Lung cancer;	chr6:149610982	chr6:149863494~149919507:+
LUAD	cis	rs957448	1	rs12679345	ENSG00000254315.1	RP11-267M23.3	4.49	8.77e-06	0.00175	0.25	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94552305	chr8:94533628~94534391:+
LUAD	cis	rs2033711	0.87	rs11669741	ENSG00000268912.1	CTD-2619J13.17	4.49	8.77e-06	0.00175	0.21	0.2	Uric acid clearance;	chr19:58449114	chr19:58428632~58431148:-
LUAD	cis	rs9322193	0.923	rs4354168	ENSG00000268592.3	RAET1E-AS1	4.49	8.77e-06	0.00175	0.25	0.2	Lung cancer;	chr6:149696642	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.923	rs4455682	ENSG00000268592.3	RAET1E-AS1	4.49	8.77e-06	0.00175	0.25	0.2	Lung cancer;	chr6:149700161	chr6:149863494~149919507:+
LUAD	cis	rs7923837	0.713	rs10882099	ENSG00000236493.2	EIF2S2P3	4.49	8.77e-06	0.00175	0.23	0.2	Multiple sclerosis;Body mass index;	chr10:92700893	chr10:92668745~92669743:-
LUAD	cis	rs7209700	1	rs7209700	ENSG00000228782.6	CTD-2026D20.3	-4.49	8.78e-06	0.00175	-0.21	-0.2	IgG glycosylation;	chr17:47273752	chr17:47450568~47492492:-
LUAD	cis	rs8062405	0.755	rs56209193	ENSG00000261419.1	RP11-57A19.4	-4.49	8.78e-06	0.00175	-0.22	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28659696~28740781:-
LUAD	cis	rs1729951	0.575	rs1654904	ENSG00000239213.4	NCK1-AS1	4.49	8.79e-06	0.00175	0.22	0.2	Neuroticism;	chr3:136962307	chr3:136841726~136862054:-
LUAD	cis	rs9860428	0.76	rs9823692	ENSG00000242770.2	RP11-180K7.1	4.49	8.79e-06	0.00175	0.22	0.2	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112910375	chr3:112802478~112812819:+
LUAD	cis	rs2153535	0.585	rs2208540	ENSG00000230939.1	RP11-314C16.1	-4.49	8.79e-06	0.00175	-0.23	-0.2	Motion sickness;	chr6:8627147	chr6:8784178~8785445:+
LUAD	cis	rs950169	0.614	rs12911536	ENSG00000259728.4	LINC00933	4.49	8.79e-06	0.00175	0.32	0.2	Schizophrenia;	chr15:84004278	chr15:84570649~84580175:+
LUAD	cis	rs11822910	0.911	rs61886978	ENSG00000265566.2	RN7SL605P	4.49	8.79e-06	0.00175	0.26	0.2	Platelet distribution width;	chr11:57427375	chr11:57528085~57528365:-
LUAD	cis	rs11742741	0.905	rs57590048	ENSG00000248874.4	C5orf17	-4.49	8.79e-06	0.00175	-0.25	-0.2	Educational attainment;	chr5:24106579	chr5:23951348~24178263:+
LUAD	cis	rs2281636	0.66	rs11190184	ENSG00000233690.1	EBAG9P1	4.49	8.8e-06	0.00175	0.21	0.2	Obesity-related traits;	chr10:99608442	chr10:99697407~99697949:-
LUAD	cis	rs12073359	1	rs6687454	ENSG00000223945.2	RP11-458I7.1	-4.49	8.8e-06	0.00175	-0.29	-0.2	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150027806	chr1:150053864~150055034:+
LUAD	cis	rs2657294	0.62	rs7475340	ENSG00000226051.5	ZNF503-AS1	-4.49	8.81e-06	0.00175	-0.27	-0.2	Pneumonia;	chr10:75079597	chr10:75269819~75373500:+
LUAD	cis	rs3096299	0.933	rs3096297	ENSG00000182376.2	RP5-1142A6.8	4.49	8.81e-06	0.00175	0.21	0.2	Multiple myeloma (IgH translocation);	chr16:89386747	chr16:88742767~88745748:+
LUAD	cis	rs11673344	0.526	rs2291001	ENSG00000226686.6	LINC01535	4.49	8.81e-06	0.00175	0.25	0.2	Obesity-related traits;	chr19:37594431	chr19:37251912~37265535:+
LUAD	cis	rs6969780	1	rs739734	ENSG00000233429.8	HOTAIRM1	4.49	8.82e-06	0.00176	0.36	0.2	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27119786	chr7:27095647~27100265:+
LUAD	cis	rs6969780	1	rs929249	ENSG00000233429.8	HOTAIRM1	4.49	8.82e-06	0.00176	0.36	0.2	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27127918	chr7:27095647~27100265:+
LUAD	cis	rs6728642	1	rs6728642	ENSG00000230606.9	AC159540.1	4.49	8.82e-06	0.00176	0.33	0.2	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96941334	chr2:97416165~97433527:-
LUAD	cis	rs875971	1	rs55962648	ENSG00000232559.3	GS1-124K5.12	-4.49	8.82e-06	0.00176	-0.23	-0.2	Aortic root size;	chr7:66160764	chr7:66554588~66576923:-
LUAD	cis	rs875971	1	rs2420168	ENSG00000232559.3	GS1-124K5.12	-4.49	8.82e-06	0.00176	-0.23	-0.2	Aortic root size;	chr7:66165644	chr7:66554588~66576923:-
LUAD	cis	rs8077577	0.747	rs3829956	ENSG00000273018.4	CTD-2303H24.2	-4.49	8.82e-06	0.00176	-0.28	-0.2	Obesity-related traits;	chr17:18316521	chr17:18511221~18551705:-
LUAD	cis	rs848490	0.723	rs62462685	ENSG00000214293.7	APTR	4.49	8.82e-06	0.00176	0.25	0.2	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77879316	chr7:77657660~77696265:-
LUAD	cis	rs34375054	0.526	rs4412800	ENSG00000279233.1	RP11-158L12.4	-4.49	8.82e-06	0.00176	-0.17	-0.2	Post bronchodilator FEV1/FVC ratio;	chr12:125190196	chr12:125138245~125141711:+
LUAD	cis	rs1876905	0.68	rs9384787	ENSG00000255389.1	C6orf3	-4.49	8.83e-06	0.00176	-0.24	-0.2	Mean corpuscular hemoglobin;	chr6:111113707	chr6:111599875~111602295:+
LUAD	cis	rs1008375	0.868	rs6816286	ENSG00000249502.1	AC006160.5	-4.49	8.83e-06	0.00176	-0.19	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17696465	chr4:17587467~17614571:-
LUAD	cis	rs2303759	0.709	rs8102658	ENSG00000268686.1	AC010524.2	-4.49	8.83e-06	0.00176	-0.3	-0.2	Multiple sclerosis;	chr19:49325598	chr19:49368705~49388081:-
LUAD	cis	rs2252586	0.792	rs6946428	ENSG00000176826.14	FKBP9P1	-4.49	8.83e-06	0.00176	-0.27	-0.2	Glioma;	chr7:54890916	chr7:55681074~55713252:-
LUAD	cis	rs9513627	0.915	rs7327204	ENSG00000280710.1	RP11-214F16.8	-4.49	8.83e-06	0.00176	-0.34	-0.2	Obesity-related traits;	chr13:99474698	chr13:99498524~99501315:+
LUAD	cis	rs2243480	1	rs313814	ENSG00000232559.3	GS1-124K5.12	4.49	8.84e-06	0.00176	0.35	0.2	Diabetic kidney disease;	chr7:66038306	chr7:66554588~66576923:-
LUAD	cis	rs2337406	0.587	rs2516889	ENSG00000223648.3	IGHV3-64	-4.49	8.84e-06	0.00176	-0.23	-0.2	Alzheimer's disease (late onset);	chr14:106648903	chr14:106643132~106658258:-
LUAD	cis	rs2281636	0.66	rs7072263	ENSG00000233690.1	EBAG9P1	4.49	8.84e-06	0.00176	0.21	0.2	Obesity-related traits;	chr10:99607888	chr10:99697407~99697949:-
LUAD	cis	rs8062405	0.755	rs7186573	ENSG00000261419.1	RP11-57A19.4	-4.49	8.84e-06	0.00176	-0.22	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28659696~28740781:-
LUAD	cis	rs6570726	0.791	rs6914203	ENSG00000235652.6	RP11-545I5.3	4.49	8.84e-06	0.00176	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145578839	chr6:145799409~145886585:+
LUAD	cis	rs950169	0.545	rs4842841	ENSG00000225151.9	GOLGA2P7	-4.49	8.85e-06	0.00176	-0.29	-0.2	Schizophrenia;	chr15:83972373	chr15:84199311~84230136:-
LUAD	cis	rs74233809	0.901	rs4409766	ENSG00000213277.3	MARCKSL1P1	4.49	8.85e-06	0.00176	0.32	0.2	Birth weight;	chr10:102856906	chr10:103175554~103176094:+
LUAD	cis	rs301901	1	rs158791	ENSG00000250155.1	CTD-2353F22.1	4.49	8.85e-06	0.00176	0.21	0.2	Height;	chr5:36948260	chr5:36666214~36725195:-
LUAD	cis	rs7948661	1	rs9332858	ENSG00000278376.1	RP11-158I9.8	4.49	8.85e-06	0.00176	0.38	0.2	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118519367	chr11:118791254~118793137:+
LUAD	cis	rs9545047	0.604	rs9530897	ENSG00000227354.5	RBM26-AS1	4.49	8.85e-06	0.00176	0.21	0.2	Schizophrenia;	chr13:79336420	chr13:79406309~79424328:+
LUAD	cis	rs6012564	1	rs730543	ENSG00000230758.1	SNAP23P	-4.49	8.85e-06	0.00176	-0.21	-0.2	Anger;	chr20:49019178	chr20:49038357~49038602:-
LUAD	cis	rs8014252	0.803	rs2018131	ENSG00000259158.2	ADAM20P1	-4.49	8.85e-06	0.00176	-0.31	-0.2	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70595715	chr14:70468881~70483756:-
LUAD	cis	rs6496932	0.802	rs4843047	ENSG00000218052.5	ADAMTS7P4	4.49	8.85e-06	0.00176	0.23	0.2	Central corneal thickness;Corneal structure;	chr15:85316545	chr15:85255369~85330334:-
LUAD	cis	rs9322193	0.923	rs9322200	ENSG00000268592.3	RAET1E-AS1	4.49	8.85e-06	0.00176	0.25	0.2	Lung cancer;	chr6:149630078	chr6:149863494~149919507:+
LUAD	cis	rs8031584	0.958	rs35256769	ENSG00000270015.1	RP11-540B6.6	-4.49	8.85e-06	0.00176	-0.14	-0.2	Huntington's disease progression;	chr15:30945573	chr15:30926514~30928407:+
LUAD	cis	rs8031584	0.958	rs11629793	ENSG00000270015.1	RP11-540B6.6	-4.49	8.85e-06	0.00176	-0.14	-0.2	Huntington's disease progression;	chr15:30946220	chr15:30926514~30928407:+
LUAD	cis	rs11122895	0.527	rs10186692	ENSG00000236307.2	EEF1E1P1	4.49	8.86e-06	0.00176	0.21	0.2	Allergic sensitization;	chr2:111686719	chr2:111887914~111888741:+
LUAD	cis	rs62025270	0.632	rs62022943	ENSG00000202081.1	RNU6-1280P	-4.49	8.86e-06	0.00176	-0.29	-0.2	Idiopathic pulmonary fibrosis;	chr15:85716239	chr15:85651522~85651628:-
LUAD	cis	rs7200786	0.618	rs7185491	ENSG00000274038.1	RP11-66H6.4	-4.49	8.86e-06	0.00176	-0.24	-0.2	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11040807	chr16:11056556~11057034:+
LUAD	cis	rs2243480	1	rs4718270	ENSG00000232559.3	GS1-124K5.12	4.49	8.86e-06	0.00176	0.35	0.2	Diabetic kidney disease;	chr7:65737415	chr7:66554588~66576923:-
LUAD	cis	rs2243480	0.901	rs2900904	ENSG00000232559.3	GS1-124K5.12	4.49	8.86e-06	0.00176	0.35	0.2	Diabetic kidney disease;	chr7:65739282	chr7:66554588~66576923:-
LUAD	cis	rs6840360	0.967	rs4696105	ENSG00000270265.1	RP11-731D1.4	-4.49	8.86e-06	0.00176	-0.21	-0.2	Intelligence (multi-trait analysis);	chr4:151685550	chr4:151333775~151353224:-
LUAD	cis	rs227275	0.554	rs223425	ENSG00000251288.2	RP11-10L12.2	-4.49	8.86e-06	0.00176	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102802836	chr4:102751401~102752641:+
LUAD	cis	rs6860806	0.661	rs28472559	ENSG00000233006.5	AC034220.3	4.49	8.86e-06	0.00176	0.18	0.2	Breast cancer;	chr5:132245918	chr5:132311285~132369916:-
LUAD	cis	rs2919009	0.709	rs55710400	ENSG00000271670.1	RP11-95I16.4	4.49	8.86e-06	0.00176	0.26	0.2	Obesity-related traits;	chr10:120802676	chr10:120879256~120880667:-
LUAD	cis	rs240993	0.516	rs241006	ENSG00000230177.1	RP5-1112D6.4	-4.49	8.86e-06	0.00176	-0.21	-0.2	Inflammatory skin disease;Psoriasis;	chr6:111279910	chr6:111277932~111278742:+
LUAD	cis	rs897984	0.806	rs1046276	ENSG00000260911.2	RP11-196G11.2	-4.49	8.87e-06	0.00176	-0.19	-0.2	Dementia with Lewy bodies;	chr16:30903305	chr16:31043150~31049868:+
LUAD	cis	rs1008375	0.933	rs4698637	ENSG00000249502.1	AC006160.5	-4.49	8.87e-06	0.00177	-0.19	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17631220	chr4:17587467~17614571:-
LUAD	cis	rs875971	0.54	rs736270	ENSG00000237310.1	GS1-124K5.4	4.49	8.87e-06	0.00177	0.22	0.2	Aortic root size;	chr7:65963835	chr7:66493706~66495474:+
LUAD	cis	rs7819412	0.521	rs2409720	ENSG00000255046.1	RP11-297N6.4	4.49	8.88e-06	0.00177	0.24	0.2	Triglycerides;	chr8:11180394	chr8:11797928~11802568:-
LUAD	cis	rs9341808	0.727	rs10943697	ENSG00000272129.1	RP11-250B2.6	4.49	8.88e-06	0.00177	0.25	0.2	Sitting height ratio;	chr6:80221789	chr6:80355424~80356859:+
LUAD	cis	rs853679	0.546	rs13213152	ENSG00000219392.1	RP1-265C24.5	-4.49	8.88e-06	0.00177	-0.46	-0.2	Depression;	chr6:28381921	chr6:28115628~28116551:+
LUAD	cis	rs6957923	0.934	rs4265095	ENSG00000230658.1	KLHL7-AS1	4.49	8.88e-06	0.00177	0.24	0.2	Height;	chr7:23460605	chr7:23101228~23105703:-
LUAD	cis	rs1387259	0.931	rs1107654	ENSG00000240399.1	RP1-228P16.1	4.49	8.88e-06	0.00177	0.2	0.2	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48287314	chr12:48054813~48055591:-
LUAD	cis	rs17772222	1	rs74071851	ENSG00000258789.1	RP11-507K2.3	-4.49	8.88e-06	0.00177	-0.28	-0.2	Coronary artery calcification;	chr14:88415858	chr14:88551597~88552493:+
LUAD	cis	rs2522056	1	rs2522056	ENSG00000233006.5	AC034220.3	-4.49	8.88e-06	0.00177	-0.22	-0.2	Fibrinogen;Lymphocyte counts;	chr5:132466034	chr5:132311285~132369916:-
LUAD	cis	rs7746199	0.673	rs72845046	ENSG00000219392.1	RP1-265C24.5	-4.49	8.89e-06	0.00177	-0.43	-0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27607489	chr6:28115628~28116551:+
LUAD	cis	rs7432375	0.61	rs4420814	ENSG00000239213.4	NCK1-AS1	4.49	8.89e-06	0.00177	0.21	0.2	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136794440	chr3:136841726~136862054:-
LUAD	cis	rs7189233	0.55	rs3803657	ENSG00000279344.1	RP11-44F14.7	4.49	8.9e-06	0.00177	0.16	0.2	Intelligence (multi-trait analysis);	chr16:53482047	chr16:53478957~53481550:-
LUAD	cis	rs77688320	0.553	rs7582946	ENSG00000213090.2	AC007256.5	4.49	8.9e-06	0.00177	0.23	0.2	Breast cancer;	chr2:201423969	chr2:201410544~201413308:-
LUAD	cis	rs77688320	0.553	rs2540339	ENSG00000213090.2	AC007256.5	-4.49	8.9e-06	0.00177	-0.23	-0.2	Breast cancer;	chr2:201415725	chr2:201410544~201413308:-
LUAD	cis	rs77688320	0.553	rs2540340	ENSG00000213090.2	AC007256.5	-4.49	8.9e-06	0.00177	-0.23	-0.2	Breast cancer;	chr2:201416477	chr2:201410544~201413308:-
LUAD	cis	rs227275	0.556	rs10015289	ENSG00000251288.2	RP11-10L12.2	-4.49	8.9e-06	0.00177	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102984956	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.556	rs6852141	ENSG00000251288.2	RP11-10L12.2	-4.49	8.9e-06	0.00177	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102986439	chr4:102751401~102752641:+
LUAD	cis	rs228614	0.509	rs4455415	ENSG00000251288.2	RP11-10L12.2	-4.49	8.9e-06	0.00177	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102993663	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.525	rs6853193	ENSG00000251288.2	RP11-10L12.2	-4.49	8.9e-06	0.00177	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102994888	chr4:102751401~102752641:+
LUAD	cis	rs8180040	0.701	rs1079276	ENSG00000271161.1	BOLA2P2	4.49	8.9e-06	0.00177	0.19	0.2	Colorectal cancer;	chr3:47004249	chr3:47499841~47500407:+
LUAD	cis	rs1008375	0.932	rs11934968	ENSG00000249502.1	AC006160.5	-4.49	8.9e-06	0.00177	-0.19	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17666143	chr4:17587467~17614571:-
LUAD	cis	rs8091660	0.624	rs1028010	ENSG00000278983.1	RP11-426J5.3	4.49	8.9e-06	0.00177	0.25	0.2	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48559459	chr18:48564795~48568342:+
LUAD	cis	rs8031584	0.678	rs4779790	ENSG00000270015.1	RP11-540B6.6	-4.49	8.9e-06	0.00177	-0.15	-0.2	Huntington's disease progression;	chr15:30872392	chr15:30926514~30928407:+
LUAD	cis	rs36093844	0.904	rs7101889	ENSG00000279742.1	RP11-700A24.1	4.49	8.9e-06	0.00177	0.22	0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85884536	chr11:85852557~85854943:-
LUAD	cis	rs3096299	0.967	rs2965937	ENSG00000182376.2	RP5-1142A6.8	4.49	8.91e-06	0.00177	0.21	0.2	Multiple myeloma (IgH translocation);	chr16:89422371	chr16:88742767~88745748:+
LUAD	cis	rs9400467	0.528	rs6933627	ENSG00000230177.1	RP5-1112D6.4	-4.49	8.91e-06	0.00177	-0.18	-0.2	Amino acid levels;Blood metabolite levels;	chr6:111279606	chr6:111277932~111278742:+
LUAD	cis	rs6687758	1	rs12125368	ENSG00000200033.1	RNU6-403P	4.49	8.91e-06	0.00177	0.28	0.2	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222025330	chr1:221837334~221837437:-
LUAD	cis	rs453301	0.686	rs11785819	ENSG00000173295.6	FAM86B3P	-4.49	8.92e-06	0.00177	-0.22	-0.2	Joint mobility (Beighton score);	chr8:9012868	chr8:8228595~8244865:+
LUAD	cis	rs71520386	0.632	rs9654968	ENSG00000228649.7	AC005682.5	-4.49	8.92e-06	0.00177	-0.27	-0.2	Fibrinogen levels;	chr7:22836697	chr7:22854178~22861579:+
LUAD	cis	rs507080	0.769	rs745663	ENSG00000278376.1	RP11-158I9.8	-4.49	8.92e-06	0.00177	-0.22	-0.2	Serum metabolite levels;	chr11:118658886	chr11:118791254~118793137:+
LUAD	cis	rs4372836	1	rs11690423	ENSG00000226833.4	AC097724.3	-4.49	8.92e-06	0.00177	-0.23	-0.2	Body mass index;	chr2:28728671	chr2:28708953~28736205:-
LUAD	cis	rs4372836	0.964	rs4665432	ENSG00000226833.4	AC097724.3	-4.49	8.92e-06	0.00177	-0.23	-0.2	Body mass index;	chr2:28729160	chr2:28708953~28736205:-
LUAD	cis	rs4372836	1	rs2169751	ENSG00000226833.4	AC097724.3	4.49	8.92e-06	0.00177	0.23	0.2	Body mass index;	chr2:28743892	chr2:28708953~28736205:-
LUAD	cis	rs4372836	0.93	rs7589860	ENSG00000226833.4	AC097724.3	4.49	8.92e-06	0.00177	0.23	0.2	Body mass index;	chr2:28744782	chr2:28708953~28736205:-
LUAD	cis	rs9907295	0.688	rs9754	ENSG00000270977.1	AC015849.16	-4.49	8.93e-06	0.00178	-0.3	-0.2	Fibroblast growth factor basic levels;	chr17:35934827	chr17:35893707~35911023:-
LUAD	cis	rs858239	0.932	rs199355	ENSG00000226816.2	AC005082.12	4.49	8.93e-06	0.00178	0.26	0.2	Cerebrospinal fluid biomarker levels;	chr7:23256914	chr7:23206013~23208045:+
LUAD	cis	rs7580658	0.521	rs7605733	ENSG00000236682.1	AC068282.3	-4.49	8.93e-06	0.00178	-0.26	-0.2	Protein C levels;	chr2:127174211	chr2:127389130~127400580:+
LUAD	cis	rs13113518	0.967	rs4340844	ENSG00000272969.1	RP11-528I4.2	4.49	8.93e-06	0.00178	0.21	0.2	Height;	chr4:55462689	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs1522112	ENSG00000272969.1	RP11-528I4.2	4.49	8.93e-06	0.00178	0.21	0.2	Height;	chr4:55463606	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs4864997	ENSG00000272969.1	RP11-528I4.2	4.49	8.93e-06	0.00178	0.21	0.2	Height;	chr4:55466010	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs960152	ENSG00000272969.1	RP11-528I4.2	4.49	8.93e-06	0.00178	0.21	0.2	Height;	chr4:55467308	chr4:55547112~55547889:+
LUAD	cis	rs13113518	0.967	rs12644948	ENSG00000272969.1	RP11-528I4.2	4.49	8.93e-06	0.00178	0.21	0.2	Height;	chr4:55470266	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs3805151	ENSG00000272969.1	RP11-528I4.2	4.49	8.93e-06	0.00178	0.21	0.2	Height;	chr4:55470874	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs13118237	ENSG00000272969.1	RP11-528I4.2	4.49	8.93e-06	0.00178	0.21	0.2	Height;	chr4:55474259	chr4:55547112~55547889:+
LUAD	cis	rs12554020	0.892	rs7870210	ENSG00000227603.1	RP11-165J3.6	4.49	8.94e-06	0.00178	0.3	0.2	Schizophrenia;	chr9:93569534	chr9:93435332~93437121:-
LUAD	cis	rs12554020	0.892	rs7860098	ENSG00000227603.1	RP11-165J3.6	4.49	8.94e-06	0.00178	0.3	0.2	Schizophrenia;	chr9:93569562	chr9:93435332~93437121:-
LUAD	cis	rs6840360	0.837	rs13137669	ENSG00000270265.1	RP11-731D1.4	-4.49	8.94e-06	0.00178	-0.2	-0.2	Intelligence (multi-trait analysis);	chr4:151789791	chr4:151333775~151353224:-
LUAD	cis	rs9393777	0.92	rs35716472	ENSG00000219392.1	RP1-265C24.5	-4.49	8.94e-06	0.00178	-0.39	-0.2	Intelligence (multi-trait analysis);	chr6:27438828	chr6:28115628~28116551:+
LUAD	cis	rs473651	0.904	rs501333	ENSG00000229915.1	AC016999.2	-4.49	8.94e-06	0.00178	-0.27	-0.2	Multiple system atrophy;	chr2:238427404	chr2:238427077~238427729:-
LUAD	cis	rs875971	0.505	rs6955582	ENSG00000237310.1	GS1-124K5.4	4.49	8.94e-06	0.00178	0.21	0.2	Aortic root size;	chr7:65966699	chr7:66493706~66495474:+
LUAD	cis	rs7772486	0.79	rs2253880	ENSG00000235652.6	RP11-545I5.3	4.49	8.94e-06	0.00178	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145879638	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.79	rs2814879	ENSG00000235652.6	RP11-545I5.3	4.49	8.94e-06	0.00178	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145880607	chr6:145799409~145886585:+
LUAD	cis	rs11846409	0.932	rs28378201	ENSG00000223648.3	IGHV3-64	4.49	8.94e-06	0.00178	0.24	0.2	Rheumatic heart disease;	chr14:106637262	chr14:106643132~106658258:-
LUAD	cis	rs11846409	0.86	rs74091720	ENSG00000223648.3	IGHV3-64	4.49	8.94e-06	0.00178	0.24	0.2	Rheumatic heart disease;	chr14:106638192	chr14:106643132~106658258:-
LUAD	cis	rs6604026	0.624	rs34761380	ENSG00000223787.2	RP4-593M8.1	4.49	8.95e-06	0.00178	0.28	0.2	Multiple sclerosis;	chr1:92731928	chr1:92580476~92580821:-
LUAD	cis	rs6604026	0.59	rs35241270	ENSG00000223787.2	RP4-593M8.1	4.49	8.95e-06	0.00178	0.28	0.2	Multiple sclerosis;	chr1:92739957	chr1:92580476~92580821:-
LUAD	cis	rs6604026	0.624	rs12746893	ENSG00000223787.2	RP4-593M8.1	4.49	8.95e-06	0.00178	0.28	0.2	Multiple sclerosis;	chr1:92745319	chr1:92580476~92580821:-
LUAD	cis	rs6604026	0.624	rs11164803	ENSG00000223787.2	RP4-593M8.1	4.49	8.95e-06	0.00178	0.28	0.2	Multiple sclerosis;	chr1:92746363	chr1:92580476~92580821:-
LUAD	cis	rs853679	0.824	rs34712084	ENSG00000204709.4	LINC01556	4.49	8.95e-06	0.00178	0.34	0.2	Depression;	chr6:28076050	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.824	rs1321505	ENSG00000204709.4	LINC01556	4.49	8.95e-06	0.00178	0.34	0.2	Depression;	chr6:28085045	chr6:28943877~28944537:+
LUAD	cis	rs2243480	1	rs1723269	ENSG00000226002.1	RP11-460N20.5	-4.49	8.95e-06	0.00178	-0.34	-0.2	Diabetic kidney disease;	chr7:66007799	chr7:65084103~65100232:+
LUAD	cis	rs12908161	0.515	rs12907646	ENSG00000259728.4	LINC00933	4.49	8.95e-06	0.00178	0.31	0.2	Schizophrenia;	chr15:84860265	chr15:84570649~84580175:+
LUAD	cis	rs453301	0.598	rs10104303	ENSG00000173295.6	FAM86B3P	4.49	8.95e-06	0.00178	0.21	0.2	Joint mobility (Beighton score);	chr8:8977018	chr8:8228595~8244865:+
LUAD	cis	rs7560272	0.723	rs7566315	ENSG00000163016.8	ALMS1P	4.49	8.95e-06	0.00178	0.21	0.2	Schizophrenia;	chr2:73564681	chr2:73644919~73685576:+
LUAD	cis	rs853679	0.517	rs868987	ENSG00000226314.6	ZNF192P1	4.49	8.96e-06	0.00178	0.27	0.2	Depression;	chr6:28142370	chr6:28161781~28169594:+
LUAD	cis	rs2911132	0.564	rs7356594	ENSG00000248734.2	CTD-2260A17.1	4.49	8.96e-06	0.00178	0.22	0.2	Urate levels (BMI interaction);	chr5:96760485	chr5:96784777~96785999:+
LUAD	cis	rs875971	0.522	rs2949690	ENSG00000237310.1	GS1-124K5.4	-4.49	8.96e-06	0.00178	-0.22	-0.2	Aortic root size;	chr7:66018255	chr7:66493706~66495474:+
LUAD	cis	rs9341808	0.718	rs910266	ENSG00000272129.1	RP11-250B2.6	4.49	8.96e-06	0.00178	0.25	0.2	Sitting height ratio;	chr6:80211453	chr6:80355424~80356859:+
LUAD	cis	rs1790761	0.692	rs614080	ENSG00000184224.3	C11orf72	4.49	8.97e-06	0.00178	0.22	0.2	Mean corpuscular volume;	chr11:67579816	chr11:67602880~67606706:-
LUAD	cis	rs11742741	0.905	rs1428550	ENSG00000248874.4	C5orf17	-4.49	8.97e-06	0.00178	-0.25	-0.2	Educational attainment;	chr5:24107016	chr5:23951348~24178263:+
LUAD	cis	rs62355901	0.505	rs12657396	ENSG00000271828.1	CTD-2310F14.1	4.49	8.97e-06	0.00178	0.38	0.2	Breast cancer;	chr5:56930778	chr5:56927874~56929573:+
LUAD	cis	rs62355901	0.505	rs62356561	ENSG00000271828.1	CTD-2310F14.1	4.49	8.97e-06	0.00178	0.38	0.2	Breast cancer;	chr5:56933826	chr5:56927874~56929573:+
LUAD	cis	rs1551277	0.877	rs12702387	ENSG00000146666.5	LINC00525	-4.49	8.97e-06	0.00178	-0.22	-0.2	Anxiety disorder;	chr7:47798871	chr7:47761476~47766772:+
LUAD	cis	rs1551277	0.877	rs12702388	ENSG00000146666.5	LINC00525	-4.49	8.97e-06	0.00178	-0.22	-0.2	Anxiety disorder;	chr7:47798872	chr7:47761476~47766772:+
LUAD	cis	rs8062405	0.824	rs240702	ENSG00000251417.2	RP11-1348G14.4	-4.49	8.97e-06	0.00178	-0.2	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520032	chr16:28802743~28817828:+
LUAD	cis	rs2299587	0.689	rs2285303	ENSG00000253671.1	RP11-806O11.1	-4.49	8.97e-06	0.00178	-0.22	-0.2	Economic and political preferences;	chr8:17939900	chr8:17808941~17820868:+
LUAD	cis	rs2976388	0.578	rs13263987	ENSG00000253741.1	CTD-2292P10.4	4.49	8.98e-06	0.00178	0.24	0.2	Urinary tract infection frequency;	chr8:142745969	chr8:142702252~142726973:-
LUAD	cis	rs4660214	0.666	rs10888682	ENSG00000228060.1	RP11-69E11.8	4.49	8.98e-06	0.00178	0.18	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39157635	chr1:39565160~39573203:+
LUAD	cis	rs4660214	0.666	rs11205698	ENSG00000228060.1	RP11-69E11.8	4.49	8.98e-06	0.00178	0.18	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39158708	chr1:39565160~39573203:+
LUAD	cis	rs11157436	0.602	rs2331594	ENSG00000211813.2	TRAV34	4.49	8.98e-06	0.00178	0.23	0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22171871	chr14:22207522~22208129:+
LUAD	cis	rs7200786	0.607	rs7184431	ENSG00000274038.1	RP11-66H6.4	-4.49	8.99e-06	0.00178	-0.24	-0.2	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11041529	chr16:11056556~11057034:+
LUAD	cis	rs12478296	0.792	rs57482298	ENSG00000261186.2	RP11-341N2.1	-4.49	8.99e-06	0.00179	-0.36	-0.2	Obesity-related traits;	chr2:242068997	chr2:242087351~242088457:-
LUAD	cis	rs2933343	0.649	rs2638845	ENSG00000231305.3	RP11-723O4.2	4.49	8.99e-06	0.00179	0.21	0.2	IgG glycosylation;	chr3:128868526	chr3:128861313~128871540:-
LUAD	cis	rs7590268	0.666	rs12471207	ENSG00000279873.2	LINC01126	4.49	9e-06	0.00179	0.19	0.2	Orofacial clefts;	chr2:43438859	chr2:43227210~43228855:+
LUAD	cis	rs4819052	0.807	rs1075788	ENSG00000237664.1	LINC00316	-4.49	9e-06	0.00179	-0.24	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246649	chr21:45338590~45341990:-
LUAD	cis	rs2243480	1	rs73142166	ENSG00000229886.1	RP5-1132H15.3	4.49	9e-06	0.00179	0.36	0.2	Diabetic kidney disease;	chr7:65910845	chr7:66025126~66031544:-
LUAD	cis	rs10800713	0.56	rs10919965	ENSG00000260088.1	RP11-92G12.3	-4.49	9e-06	0.00179	-0.32	-0.2	Tandem gait;	chr1:200532134	chr1:200669507~200694250:+
LUAD	cis	rs7772486	0.79	rs6570723	ENSG00000235652.6	RP11-545I5.3	4.49	9e-06	0.00179	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145830094	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.79	rs6570724	ENSG00000235652.6	RP11-545I5.3	4.49	9e-06	0.00179	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145830147	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.79	rs6917135	ENSG00000235652.6	RP11-545I5.3	4.49	9e-06	0.00179	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145831290	chr6:145799409~145886585:+
LUAD	cis	rs7138803	0.538	rs66924167	ENSG00000257464.1	RP11-161H23.8	-4.49	9e-06	0.00179	-0.2	-0.2	Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index;	chr12:49811911	chr12:49442424~49442652:-
LUAD	cis	rs227275	0.555	rs223403	ENSG00000251288.2	RP11-10L12.2	-4.49	9e-06	0.00179	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102817086	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.555	rs223402	ENSG00000251288.2	RP11-10L12.2	-4.49	9e-06	0.00179	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102817198	chr4:102751401~102752641:+
LUAD	cis	rs7172677	0.96	rs1602360	ENSG00000260269.4	CTD-2323K18.1	-4.49	9e-06	0.00179	-0.26	-0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75128420	chr15:75527150~75601205:-
LUAD	cis	rs1729951	0.575	rs16844325	ENSG00000239213.4	NCK1-AS1	4.49	9e-06	0.00179	0.22	0.2	Neuroticism;	chr3:136959319	chr3:136841726~136862054:-
LUAD	cis	rs1729951	0.575	rs16844326	ENSG00000239213.4	NCK1-AS1	4.49	9e-06	0.00179	0.22	0.2	Neuroticism;	chr3:136959543	chr3:136841726~136862054:-
LUAD	cis	rs35740288	0.545	rs11637283	ENSG00000259407.1	RP11-158M2.3	-4.49	9.01e-06	0.00179	-0.23	-0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85772872	chr15:85744109~85750281:-
LUAD	cis	rs800160	0.72	rs11022259	ENSG00000236264.4	RPL26P30	-4.49	9.01e-06	0.00179	-0.28	-0.2	Bacteremia;	chr11:2317026	chr11:2335132~2335776:-
LUAD	cis	rs7829975	0.626	rs332040	ENSG00000173295.6	FAM86B3P	4.49	9.01e-06	0.00179	0.21	0.2	Mood instability;	chr8:8872978	chr8:8228595~8244865:+
LUAD	cis	rs13113518	0.812	rs2035691	ENSG00000223305.1	RN7SKP30	4.49	9.01e-06	0.00179	0.23	0.2	Height;	chr4:55529786	chr4:55540502~55540835:-
LUAD	cis	rs2742234	0.541	rs1254959	ENSG00000273008.1	RP11-351D16.3	4.49	9.01e-06	0.00179	0.23	0.2	Hirschsprung disease;	chr10:43205531	chr10:43136824~43138334:-
LUAD	cis	rs2742234	0.541	rs1254958	ENSG00000273008.1	RP11-351D16.3	4.49	9.01e-06	0.00179	0.23	0.2	Hirschsprung disease;	chr10:43206695	chr10:43136824~43138334:-
LUAD	cis	rs9341808	0.718	rs2322636	ENSG00000260645.1	RP11-250B2.5	4.49	9.02e-06	0.00179	0.19	0.2	Sitting height ratio;	chr6:80187719	chr6:80466958~80469080:+
LUAD	cis	rs2933343	0.729	rs789228	ENSG00000261159.1	RP11-723O4.9	4.49	9.02e-06	0.00179	0.22	0.2	IgG glycosylation;	chr3:128882207	chr3:128859716~128860526:-
LUAD	cis	rs11742741	0.6	rs1428201	ENSG00000248874.4	C5orf17	-4.49	9.02e-06	0.00179	-0.25	-0.2	Educational attainment;	chr5:24141009	chr5:23951348~24178263:+
LUAD	cis	rs477895	0.653	rs11601577	ENSG00000236935.1	AP003774.1	-4.49	9.02e-06	0.00179	-0.24	-0.2	Mean platelet volume;	chr11:64161102	chr11:64325050~64329504:-
LUAD	cis	rs17772222	0.958	rs61579615	ENSG00000258789.1	RP11-507K2.3	-4.49	9.03e-06	0.00179	-0.28	-0.2	Coronary artery calcification;	chr14:88400054	chr14:88551597~88552493:+
LUAD	cis	rs1979679	0.842	rs34043014	ENSG00000278733.1	RP11-425D17.1	4.49	9.03e-06	0.00179	0.25	0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28171359	chr12:28185625~28186190:-
LUAD	cis	rs1979679	0.842	rs10492370	ENSG00000278733.1	RP11-425D17.1	4.49	9.03e-06	0.00179	0.25	0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28171900	chr12:28185625~28186190:-
LUAD	cis	rs4660214	0.666	rs11205696	ENSG00000228060.1	RP11-69E11.8	4.49	9.03e-06	0.00179	0.18	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39155880	chr1:39565160~39573203:+
LUAD	cis	rs4660214	0.666	rs6600290	ENSG00000228060.1	RP11-69E11.8	4.49	9.03e-06	0.00179	0.18	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39157151	chr1:39565160~39573203:+
LUAD	cis	rs8072100	0.967	rs8074149	ENSG00000228782.6	CTD-2026D20.3	-4.49	9.03e-06	0.00179	-0.21	-0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47506009	chr17:47450568~47492492:-
LUAD	cis	rs1062177	0.756	rs2964592	ENSG00000253921.1	CTB-113P19.3	4.49	9.04e-06	0.00179	0.29	0.2	Preschool internalizing problems;	chr5:151736127	chr5:151753992~151767247:+
LUAD	cis	rs227275	0.554	rs223334	ENSG00000251288.2	RP11-10L12.2	4.49	9.04e-06	0.00179	0.24	0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102867054	chr4:102751401~102752641:+
LUAD	cis	rs7911264	0.739	rs10736069	ENSG00000236493.2	EIF2S2P3	4.49	9.04e-06	0.00179	0.23	0.2	Inflammatory bowel disease;	chr10:92635636	chr10:92668745~92669743:-
LUAD	cis	rs7911264	0.739	rs7900689	ENSG00000236493.2	EIF2S2P3	4.49	9.04e-06	0.00179	0.23	0.2	Inflammatory bowel disease;	chr10:92635991	chr10:92668745~92669743:-
LUAD	cis	rs7911264	0.739	rs6583830	ENSG00000236493.2	EIF2S2P3	4.49	9.04e-06	0.00179	0.23	0.2	Inflammatory bowel disease;	chr10:92638361	chr10:92668745~92669743:-
LUAD	cis	rs17684571	0.938	rs4072271	ENSG00000231441.1	RP11-472M19.2	-4.49	9.05e-06	0.0018	-0.25	-0.2	Schizophrenia;	chr6:56707679	chr6:56844002~56864078:+
LUAD	cis	rs7811142	1	rs6975729	ENSG00000078319.8	PMS2P1	-4.49	9.05e-06	0.0018	-0.24	-0.2	Platelet count;	chr7:100430564	chr7:100320992~100341908:-
LUAD	cis	rs7811142	1	rs1073	ENSG00000078319.8	PMS2P1	-4.49	9.05e-06	0.0018	-0.24	-0.2	Platelet count;	chr7:100433989	chr7:100320992~100341908:-
LUAD	cis	rs7811142	0.887	rs4074838	ENSG00000078319.8	PMS2P1	-4.49	9.05e-06	0.0018	-0.24	-0.2	Platelet count;	chr7:100435042	chr7:100320992~100341908:-
LUAD	cis	rs7811142	1	rs11764818	ENSG00000078319.8	PMS2P1	-4.49	9.05e-06	0.0018	-0.24	-0.2	Platelet count;	chr7:100445432	chr7:100320992~100341908:-
LUAD	cis	rs7811142	0.945	rs6955362	ENSG00000078319.8	PMS2P1	-4.49	9.05e-06	0.0018	-0.24	-0.2	Platelet count;	chr7:100458543	chr7:100320992~100341908:-
LUAD	cis	rs7811142	1	rs6975514	ENSG00000078319.8	PMS2P1	-4.49	9.05e-06	0.0018	-0.24	-0.2	Platelet count;	chr7:100458597	chr7:100320992~100341908:-
LUAD	cis	rs7811142	1	rs7811142	ENSG00000078319.8	PMS2P1	-4.49	9.05e-06	0.0018	-0.24	-0.2	Platelet count;	chr7:100467820	chr7:100320992~100341908:-
LUAD	cis	rs6012564	1	rs56131635	ENSG00000230758.1	SNAP23P	4.49	9.05e-06	0.0018	0.21	0.2	Anger;	chr20:49157806	chr20:49038357~49038602:-
LUAD	cis	rs780096	0.546	rs1647284	ENSG00000234072.1	AC074117.10	-4.49	9.05e-06	0.0018	-0.15	-0.2	Total body bone mineral density;	chr2:27385248	chr2:27356246~27367622:+
LUAD	cis	rs704795	0.805	rs1728926	ENSG00000234072.1	AC074117.10	-4.49	9.05e-06	0.0018	-0.15	-0.2	Menopause (age at onset);	chr2:27390070	chr2:27356246~27367622:+
LUAD	cis	rs704795	0.836	rs1647281	ENSG00000234072.1	AC074117.10	-4.49	9.05e-06	0.0018	-0.15	-0.2	Menopause (age at onset);	chr2:27390071	chr2:27356246~27367622:+
LUAD	cis	rs780096	0.526	rs809058	ENSG00000234072.1	AC074117.10	-4.49	9.05e-06	0.0018	-0.15	-0.2	Total body bone mineral density;	chr2:27393923	chr2:27356246~27367622:+
LUAD	cis	rs736801	0.808	rs2706396	ENSG00000233006.5	AC034220.3	-4.49	9.05e-06	0.0018	-0.18	-0.2	Mosquito bite size;Breast cancer;	chr5:132461117	chr5:132311285~132369916:-
LUAD	cis	rs7208859	0.623	rs9906957	ENSG00000263603.1	CTD-2349P21.5	-4.49	9.05e-06	0.0018	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30830737	chr17:30729469~30731202:+
LUAD	cis	rs11157436	0.509	rs12589104	ENSG00000211813.2	TRAV34	4.49	9.06e-06	0.0018	0.23	0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22167754	chr14:22207522~22208129:+
LUAD	cis	rs228614	0.51	rs223415	ENSG00000251288.2	RP11-10L12.2	-4.49	9.06e-06	0.0018	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102811016	chr4:102751401~102752641:+
LUAD	cis	rs1864585	0.52	rs73209918	ENSG00000255046.1	RP11-297N6.4	4.49	9.06e-06	0.0018	0.28	0.2	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10845754	chr8:11797928~11802568:-
LUAD	cis	rs4667682	0.529	rs62181338	ENSG00000234061.1	AC007969.4	-4.49	9.06e-06	0.0018	-0.4	-0.2	Hippocampal atrophy;Body mass index;	chr2:171295700	chr2:171492905~171493095:+
LUAD	cis	rs4601821	0.858	rs4938012	ENSG00000270179.1	RP11-159N11.4	-4.49	9.06e-06	0.0018	-0.21	-0.2	Alcoholic chronic pancreatitis;	chr11:113388932	chr11:113368478~113369117:+
LUAD	cis	rs7665090	1	rs9996834	ENSG00000246560.2	RP11-10L12.4	4.49	9.06e-06	0.0018	0.25	0.2	Primary biliary cholangitis;	chr4:102636372	chr4:102828055~102844075:+
LUAD	cis	rs875971	0.619	rs2302918	ENSG00000236529.1	RP13-254B10.1	4.49	9.06e-06	0.0018	0.21	0.2	Aortic root size;	chr7:66535945	chr7:65840212~65840596:+
LUAD	cis	rs524281	0.731	rs10791838	ENSG00000255320.1	RP11-755F10.1	4.49	9.07e-06	0.0018	0.34	0.2	Electroencephalogram traits;	chr11:66022383	chr11:66244840~66246239:-
LUAD	cis	rs847577	0.609	rs11768309	ENSG00000272950.1	RP11-307C18.1	4.49	9.07e-06	0.0018	0.24	0.2	Breast cancer;	chr7:98144500	chr7:98322853~98323430:+
LUAD	cis	rs11673344	0.864	rs12151313	ENSG00000226686.6	LINC01535	4.49	9.08e-06	0.0018	0.26	0.2	Obesity-related traits;	chr19:37072309	chr19:37251912~37265535:+
LUAD	cis	rs7955901	0.775	rs11178646	ENSG00000258053.1	CTD-2021H9.3	4.49	9.08e-06	0.0018	0.23	0.2	Type 2 diabetes;	chr12:71135116	chr12:71047402~71118247:-
LUAD	cis	rs7138300	0.532	rs12833368	ENSG00000258053.1	CTD-2021H9.3	4.49	9.08e-06	0.0018	0.23	0.2	Type 2 diabetes;	chr12:71135221	chr12:71047402~71118247:-
LUAD	cis	rs7955901	0.775	rs67877703	ENSG00000258053.1	CTD-2021H9.3	4.49	9.08e-06	0.0018	0.23	0.2	Type 2 diabetes;	chr12:71135566	chr12:71047402~71118247:-
LUAD	cis	rs9309473	0.607	rs2421489	ENSG00000163016.8	ALMS1P	4.49	9.08e-06	0.0018	0.23	0.2	Metabolite levels;	chr2:73366320	chr2:73644919~73685576:+
LUAD	cis	rs1113500	0.787	rs10881501	ENSG00000226822.1	RP11-356N1.2	4.49	9.09e-06	0.0018	0.23	0.2	Growth-regulated protein alpha levels;	chr1:108099123	chr1:108071482~108074519:+
LUAD	cis	rs6714710	0.535	rs62158274	ENSG00000230606.9	AC159540.1	-4.49	9.09e-06	0.0018	-0.21	-0.2	Posterior cortical atrophy and Alzheimer's disease;	chr2:98004597	chr2:97416165~97433527:-
LUAD	cis	rs516805	0.528	rs2679708	ENSG00000279453.1	RP3-425C14.4	4.49	9.09e-06	0.0018	0.25	0.2	Lymphocyte counts;	chr6:122079365	chr6:122436789~122439223:-
LUAD	cis	rs7590268	0.666	rs17406625	ENSG00000279873.2	LINC01126	4.49	9.1e-06	0.0018	0.19	0.2	Orofacial clefts;	chr2:43446751	chr2:43227210~43228855:+
LUAD	cis	rs6840360	0.53	rs11946622	ENSG00000270265.1	RP11-731D1.4	-4.49	9.1e-06	0.0018	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151564866	chr4:151333775~151353224:-
LUAD	cis	rs7746199	0.736	rs13210634	ENSG00000219392.1	RP1-265C24.5	-4.49	9.1e-06	0.0018	-0.43	-0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27678713	chr6:28115628~28116551:+
LUAD	cis	rs7746199	0.736	rs13215275	ENSG00000219392.1	RP1-265C24.5	-4.49	9.1e-06	0.0018	-0.43	-0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27679730	chr6:28115628~28116551:+
LUAD	cis	rs7746199	0.736	rs17749927	ENSG00000219392.1	RP1-265C24.5	-4.49	9.1e-06	0.0018	-0.43	-0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27702197	chr6:28115628~28116551:+
LUAD	cis	rs7746199	0.736	rs13192965	ENSG00000219392.1	RP1-265C24.5	-4.49	9.1e-06	0.0018	-0.43	-0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27704046	chr6:28115628~28116551:+
LUAD	cis	rs7819412	1	rs2409722	ENSG00000255046.1	RP11-297N6.4	4.49	9.1e-06	0.0018	0.25	0.2	Triglycerides;	chr8:11182307	chr8:11797928~11802568:-
LUAD	cis	rs73242632	1	rs10023009	ENSG00000269949.1	RP11-738E22.3	4.49	9.1e-06	0.00181	0.52	0.2	Congenital heart disease (maternal effect);	chr4:57018172	chr4:56960927~56961373:-
LUAD	cis	rs7968440	0.933	rs7308872	ENSG00000200428.1	Y_RNA	4.49	9.1e-06	0.00181	0.24	0.2	Fibrinogen;	chr12:50726391	chr12:50743568~50743684:+
LUAD	cis	rs11064837	0.523	rs1978108	ENSG00000248636.5	RP11-768F21.1	4.49	9.1e-06	0.00181	0.23	0.2	Schizophrenia;	chr12:119664448	chr12:119387987~119668079:-
LUAD	cis	rs338389	0.586	rs10851782	ENSG00000260657.2	RP11-315D16.4	-4.49	9.1e-06	0.00181	-0.25	-0.2	Survival in rectal cancer;	chr15:67972711	chr15:68267792~68277994:-
LUAD	cis	rs6539288	0.739	rs1053050	ENSG00000260329.1	RP11-412D9.4	-4.49	9.1e-06	0.00181	-0.22	-0.2	Total body bone mineral density;	chr12:106973446	chr12:106954029~106955497:-
LUAD	cis	rs6570726	0.738	rs6925594	ENSG00000235652.6	RP11-545I5.3	4.49	9.11e-06	0.00181	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145577318	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.791	rs11155432	ENSG00000235652.6	RP11-545I5.3	4.49	9.11e-06	0.00181	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145577625	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.791	rs6913727	ENSG00000235652.6	RP11-545I5.3	4.49	9.11e-06	0.00181	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145578690	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.791	rs10872577	ENSG00000235652.6	RP11-545I5.3	4.49	9.11e-06	0.00181	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145579424	chr6:145799409~145886585:+
LUAD	cis	rs9545047	0.604	rs9545104	ENSG00000227354.5	RBM26-AS1	4.49	9.11e-06	0.00181	0.21	0.2	Schizophrenia;	chr13:79404000	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs9545106	ENSG00000227354.5	RBM26-AS1	4.49	9.11e-06	0.00181	0.21	0.2	Schizophrenia;	chr13:79404130	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs2763810	ENSG00000227354.5	RBM26-AS1	4.49	9.11e-06	0.00181	0.21	0.2	Schizophrenia;	chr13:79405544	chr13:79406309~79424328:+
LUAD	cis	rs6012564	1	rs6125540	ENSG00000230758.1	SNAP23P	4.49	9.11e-06	0.00181	0.21	0.2	Anger;	chr20:49087502	chr20:49038357~49038602:-
LUAD	cis	rs6969780	0.915	rs2107063	ENSG00000233429.8	HOTAIRM1	-4.49	9.11e-06	0.00181	-0.31	-0.2	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27127727	chr7:27095647~27100265:+
LUAD	cis	rs12265836	0.869	rs7101270	ENSG00000271046.1	RP11-138I18.2	4.49	9.11e-06	0.00181	0.23	0.2	Obesity-related traits;	chr10:11670594	chr10:11679675~11680514:+
LUAD	cis	rs227275	0.586	rs223448	ENSG00000251288.2	RP11-10L12.2	-4.49	9.11e-06	0.00181	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102792189	chr4:102751401~102752641:+
LUAD	cis	rs6687758	0.687	rs12123928	ENSG00000227925.1	RP11-191N8.2	4.49	9.12e-06	0.00181	0.27	0.2	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221948533	chr1:221827666~221840666:-
LUAD	cis	rs4489787	1	rs12231229	ENSG00000240399.1	RP1-228P16.1	-4.49	9.12e-06	0.00181	-0.3	-0.2	Prostate cancer (SNP x SNP interaction);	chr12:48416125	chr12:48054813~48055591:-
LUAD	cis	rs4489787	1	rs17122979	ENSG00000240399.1	RP1-228P16.1	-4.49	9.12e-06	0.00181	-0.3	-0.2	Prostate cancer (SNP x SNP interaction);	chr12:48419914	chr12:48054813~48055591:-
LUAD	cis	rs4489787	1	rs4489787	ENSG00000240399.1	RP1-228P16.1	4.49	9.12e-06	0.00181	0.3	0.2	Prostate cancer (SNP x SNP interaction);	chr12:48417317	chr12:48054813~48055591:-
LUAD	cis	rs6840360	1	rs6834095	ENSG00000270265.1	RP11-731D1.4	-4.49	9.12e-06	0.00181	-0.2	-0.2	Intelligence (multi-trait analysis);	chr4:151682126	chr4:151333775~151353224:-
LUAD	cis	rs1799949	0.501	rs2343819	ENSG00000236383.6	LINC00854	-4.49	9.12e-06	0.00181	-0.16	-0.2	Menopause (age at onset);	chr17:43332285	chr17:43216941~43305976:-
LUAD	cis	rs12554020	0.786	rs78547192	ENSG00000227603.1	RP11-165J3.6	4.49	9.13e-06	0.00181	0.4	0.2	Schizophrenia;	chr9:93597221	chr9:93435332~93437121:-
LUAD	cis	rs4819052	0.851	rs1056101	ENSG00000237664.1	LINC00316	-4.48	9.13e-06	0.00181	-0.24	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258787	chr21:45338590~45341990:-
LUAD	cis	rs4873772	0.837	rs55941013	ENSG00000253330.1	RP11-697N18.3	-4.48	9.13e-06	0.00181	-0.23	-0.2	Lobe attachment (rater-scored or self-reported);	chr8:47567514	chr8:47511034~47512141:-
LUAD	cis	rs4835473	0.637	rs13110964	ENSG00000251600.4	RP11-673E1.1	4.48	9.13e-06	0.00181	0.23	0.2	Immature fraction of reticulocytes;	chr4:143765119	chr4:143912331~143982454:+
LUAD	cis	rs3096299	0.642	rs12934829	ENSG00000261118.1	RP11-104N10.1	4.48	9.14e-06	0.00181	0.2	0.2	Multiple myeloma (IgH translocation);	chr16:89456941	chr16:89492017~89504460:-
LUAD	cis	rs2243480	1	rs431318	ENSG00000226002.1	RP11-460N20.5	-4.48	9.14e-06	0.00181	-0.34	-0.2	Diabetic kidney disease;	chr7:66046610	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs313803	ENSG00000226002.1	RP11-460N20.5	-4.48	9.14e-06	0.00181	-0.34	-0.2	Diabetic kidney disease;	chr7:66049744	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs313802	ENSG00000226002.1	RP11-460N20.5	-4.48	9.14e-06	0.00181	-0.34	-0.2	Diabetic kidney disease;	chr7:66051386	chr7:65084103~65100232:+
LUAD	cis	rs2243480	0.803	rs403089	ENSG00000226002.1	RP11-460N20.5	-4.48	9.14e-06	0.00181	-0.34	-0.2	Diabetic kidney disease;	chr7:66052736	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs458291	ENSG00000226002.1	RP11-460N20.5	-4.48	9.14e-06	0.00181	-0.34	-0.2	Diabetic kidney disease;	chr7:66055492	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs466983	ENSG00000226002.1	RP11-460N20.5	-4.48	9.14e-06	0.00181	-0.34	-0.2	Diabetic kidney disease;	chr7:66055509	chr7:65084103~65100232:+
LUAD	cis	rs7119	0.679	rs12902698	ENSG00000259362.2	RP11-307C19.1	-4.48	9.14e-06	0.00181	-0.25	-0.2	Type 2 diabetes;	chr15:77516668	chr15:77525540~77534110:+
LUAD	cis	rs7119	0.717	rs12902852	ENSG00000259362.2	RP11-307C19.1	-4.48	9.14e-06	0.00181	-0.25	-0.2	Type 2 diabetes;	chr15:77516674	chr15:77525540~77534110:+
LUAD	cis	rs10129255	1	rs10137758	ENSG00000211974.3	IGHV2-70	4.48	9.14e-06	0.00181	0.22	0.2	Kawasaki disease;	chr14:106697673	chr14:106723574~106724093:-
LUAD	cis	rs7580658	0.724	rs4662711	ENSG00000236682.1	AC068282.3	-4.48	9.14e-06	0.00181	-0.26	-0.2	Protein C levels;	chr2:127233264	chr2:127389130~127400580:+
LUAD	cis	rs11065706	0.752	rs76858926	ENSG00000278993.1	RP3-424M6.4	4.48	9.14e-06	0.00181	0.25	0.2	Heart rate;	chr12:110296413	chr12:110501614~110503441:+
LUAD	cis	rs6539288	0.865	rs2888893	ENSG00000260329.1	RP11-412D9.4	-4.48	9.14e-06	0.00181	-0.22	-0.2	Total body bone mineral density;	chr12:106944853	chr12:106954029~106955497:-
LUAD	cis	rs9649213	0.593	rs10953255	ENSG00000272950.1	RP11-307C18.1	4.48	9.15e-06	0.00181	0.25	0.2	Prostate cancer (SNP x SNP interaction);	chr7:98293886	chr7:98322853~98323430:+
LUAD	cis	rs11673344	0.864	rs56208574	ENSG00000226686.6	LINC01535	4.48	9.15e-06	0.00181	0.26	0.2	Obesity-related traits;	chr19:37007843	chr19:37251912~37265535:+
LUAD	cis	rs11064837	0.523	rs6490266	ENSG00000248636.5	RP11-768F21.1	4.48	9.15e-06	0.00181	0.24	0.2	Schizophrenia;	chr12:119667935	chr12:119387987~119668079:-
LUAD	cis	rs7208859	0.725	rs9897673	ENSG00000263603.1	CTD-2349P21.5	-4.48	9.15e-06	0.00181	-0.31	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916348	chr17:30729469~30731202:+
LUAD	cis	rs4908760	0.832	rs11121209	ENSG00000270282.1	RP5-1115A15.2	4.48	9.15e-06	0.00181	0.22	0.2	Vitiligo;	chr1:8626803	chr1:8512653~8513021:+
LUAD	cis	rs2288073	0.93	rs7604097	ENSG00000242628.4	AC009228.1	4.48	9.15e-06	0.00181	0.27	0.2	Venous thromboembolism (SNP x SNP interaction);	chr2:24178936	chr2:24214381~24221516:+
LUAD	cis	rs875971	0.597	rs11771318	ENSG00000224316.1	RP11-479O9.2	-4.48	9.16e-06	0.00181	-0.21	-0.2	Aortic root size;	chr7:66597493	chr7:65773620~65802067:+
LUAD	cis	rs950169	0.763	rs35372971	ENSG00000275120.1	RP11-182J1.17	4.48	9.16e-06	0.00181	0.31	0.2	Schizophrenia;	chr15:84387097	chr15:84599434~84606463:-
LUAD	cis	rs4819052	0.851	rs1056099	ENSG00000237664.1	LINC00316	-4.48	9.16e-06	0.00182	-0.24	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258977	chr21:45338590~45341990:-
LUAD	cis	rs9425766	0.679	rs972361	ENSG00000227373.4	RP11-160H22.5	4.48	9.16e-06	0.00182	0.25	0.2	Life satisfaction;	chr1:174228270	chr1:174115300~174160004:-
LUAD	cis	rs9341808	0.683	rs7771449	ENSG00000272129.1	RP11-250B2.6	4.48	9.16e-06	0.00182	0.25	0.2	Sitting height ratio;	chr6:80210260	chr6:80355424~80356859:+
LUAD	cis	rs780096	0.526	rs12476704	ENSG00000234072.1	AC074117.10	-4.48	9.17e-06	0.00182	-0.16	-0.2	Total body bone mineral density;	chr2:27390164	chr2:27356246~27367622:+
LUAD	cis	rs780096	0.526	rs75855890	ENSG00000234072.1	AC074117.10	-4.48	9.17e-06	0.00182	-0.16	-0.2	Total body bone mineral density;	chr2:27402138	chr2:27356246~27367622:+
LUAD	cis	rs2243480	1	rs410128	ENSG00000232559.3	GS1-124K5.12	4.48	9.17e-06	0.00182	0.35	0.2	Diabetic kidney disease;	chr7:66138186	chr7:66554588~66576923:-
LUAD	cis	rs11051970	0.659	rs950082	ENSG00000274964.1	RP11-817I4.1	-4.48	9.17e-06	0.00182	-0.23	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr12:32435480	chr12:32339368~32340724:+
LUAD	cis	rs11051970	0.659	rs950081	ENSG00000274964.1	RP11-817I4.1	-4.48	9.17e-06	0.00182	-0.23	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr12:32435554	chr12:32339368~32340724:+
LUAD	cis	rs477895	0.652	rs72920332	ENSG00000236935.1	AP003774.1	-4.48	9.17e-06	0.00182	-0.25	-0.2	Mean platelet volume;	chr11:64179599	chr11:64325050~64329504:-
LUAD	cis	rs10129255	0.785	rs10150044	ENSG00000274576.2	IGHV2-70	4.48	9.17e-06	0.00182	0.18	0.2	Kawasaki disease;	chr14:106775695	chr14:106770577~106771020:-
LUAD	cis	rs10129255	0.957	rs10137980	ENSG00000274576.2	IGHV2-70	4.48	9.17e-06	0.00182	0.18	0.2	Kawasaki disease;	chr14:106775735	chr14:106770577~106771020:-
LUAD	cis	rs9473147	0.516	rs9349413	ENSG00000270761.1	RP11-385F7.1	-4.48	9.18e-06	0.00182	-0.24	-0.2	Platelet distribution width;Mean platelet volume;	chr6:47543755	chr6:47477243~47477572:-
LUAD	cis	rs2522056	1	rs886286	ENSG00000233006.5	AC034220.3	-4.48	9.18e-06	0.00182	-0.22	-0.2	Fibrinogen;Lymphocyte counts;	chr5:132459905	chr5:132311285~132369916:-
LUAD	cis	rs2522056	1	rs757105	ENSG00000233006.5	AC034220.3	-4.48	9.18e-06	0.00182	-0.22	-0.2	Fibrinogen;Lymphocyte counts;	chr5:132459971	chr5:132311285~132369916:-
LUAD	cis	rs2522056	1	rs2522047	ENSG00000233006.5	AC034220.3	-4.48	9.18e-06	0.00182	-0.22	-0.2	Fibrinogen;Lymphocyte counts;	chr5:132460190	chr5:132311285~132369916:-
LUAD	cis	rs2522056	1	rs2706393	ENSG00000233006.5	AC034220.3	-4.48	9.18e-06	0.00182	-0.22	-0.2	Fibrinogen;Lymphocyte counts;	chr5:132460375	chr5:132311285~132369916:-
LUAD	cis	rs2522056	1	rs2522050	ENSG00000233006.5	AC034220.3	-4.48	9.18e-06	0.00182	-0.22	-0.2	Fibrinogen;Lymphocyte counts;	chr5:132460917	chr5:132311285~132369916:-
LUAD	cis	rs2522056	1	rs2706395	ENSG00000233006.5	AC034220.3	-4.48	9.18e-06	0.00182	-0.22	-0.2	Fibrinogen;Lymphocyte counts;	chr5:132461111	chr5:132311285~132369916:-
LUAD	cis	rs9341808	0.754	rs1015158	ENSG00000272129.1	RP11-250B2.6	4.48	9.18e-06	0.00182	0.24	0.2	Sitting height ratio;	chr6:80236028	chr6:80355424~80356859:+
LUAD	cis	rs783540	0.5	rs7163840	ENSG00000255769.6	GOLGA2P10	4.48	9.18e-06	0.00182	0.24	0.2	Schizophrenia;	chr15:82729551	chr15:82472993~82513950:-
LUAD	cis	rs6951245	0.706	rs28522260	ENSG00000229043.2	AC091729.9	-4.48	9.18e-06	0.00182	-0.3	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1144328	chr7:1160374~1165267:+
LUAD	cis	rs62025270	0.688	rs55738258	ENSG00000202081.1	RNU6-1280P	-4.48	9.18e-06	0.00182	-0.29	-0.2	Idiopathic pulmonary fibrosis;	chr15:85773000	chr15:85651522~85651628:-
LUAD	cis	rs62025270	0.688	rs55957626	ENSG00000202081.1	RNU6-1280P	-4.48	9.18e-06	0.00182	-0.29	-0.2	Idiopathic pulmonary fibrosis;	chr15:85773486	chr15:85651522~85651628:-
LUAD	cis	rs1009115	0.596	rs1158788	ENSG00000272328.1	RP4-594A5.1	-4.48	9.18e-06	0.00182	-0.26	-0.2	Post bronchodilator FEV1;	chr7:8375763	chr7:8303741~8341343:+
LUAD	cis	rs7202877	0.706	rs247423	ENSG00000280152.1	RP11-331F4.5	-4.48	9.18e-06	0.00182	-0.23	-0.2	Type 1 diabetes;Type 2 diabetes;	chr16:75422733	chr16:75245994~75250077:-
LUAD	cis	rs2243480	1	rs313813	ENSG00000229886.1	RP5-1132H15.3	4.48	9.19e-06	0.00182	0.35	0.2	Diabetic kidney disease;	chr7:66038513	chr7:66025126~66031544:-
LUAD	cis	rs9545047	0.604	rs9530900	ENSG00000227354.5	RBM26-AS1	4.48	9.19e-06	0.00182	0.21	0.2	Schizophrenia;	chr13:79355048	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs9530901	ENSG00000227354.5	RBM26-AS1	4.48	9.19e-06	0.00182	0.21	0.2	Schizophrenia;	chr13:79355191	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs4328330	ENSG00000227354.5	RBM26-AS1	4.48	9.19e-06	0.00182	0.21	0.2	Schizophrenia;	chr13:79355503	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.567	rs4497554	ENSG00000227354.5	RBM26-AS1	4.48	9.19e-06	0.00182	0.21	0.2	Schizophrenia;	chr13:79355651	chr13:79406309~79424328:+
LUAD	cis	rs6840360	0.615	rs4696094	ENSG00000270265.1	RP11-731D1.4	-4.48	9.19e-06	0.00182	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151544349	chr4:151333775~151353224:-
LUAD	cis	rs17772222	0.682	rs3783889	ENSG00000258789.1	RP11-507K2.3	-4.48	9.19e-06	0.00182	-0.25	-0.2	Coronary artery calcification;	chr14:88475637	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.637	rs879932	ENSG00000258789.1	RP11-507K2.3	-4.48	9.19e-06	0.00182	-0.25	-0.2	Coronary artery calcification;	chr14:88479247	chr14:88551597~88552493:+
LUAD	cis	rs34779708	0.733	rs3936503	ENSG00000271335.4	RP11-324I22.4	-4.48	9.19e-06	0.00182	-0.21	-0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35260329	chr10:35314552~35336401:-
LUAD	cis	rs36423	0.668	rs36369	ENSG00000266869.1	RP6-114E22.1	-4.48	9.19e-06	0.00182	-0.31	-0.2	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71910726	chr14:71848606~71908430:+
LUAD	cis	rs36423	0.668	rs36368	ENSG00000266869.1	RP6-114E22.1	-4.48	9.19e-06	0.00182	-0.31	-0.2	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71910897	chr14:71848606~71908430:+
LUAD	cis	rs1501911	0.527	rs161934	ENSG00000248489.1	CTD-2007H13.3	-4.48	9.19e-06	0.00182	-0.21	-0.2	Lung function (FEV1/FVC);	chr5:98981283	chr5:98929171~98995013:+
LUAD	cis	rs5769707	0.967	rs739248	ENSG00000235111.1	RP1-29C18.8	-4.48	9.2e-06	0.00182	-0.22	-0.2	Monocyte percentage of white cells;Monocyte count;	chr22:49631557	chr22:49612657~49615716:-
LUAD	cis	rs5769707	0.967	rs9616701	ENSG00000235111.1	RP1-29C18.8	-4.48	9.2e-06	0.00182	-0.22	-0.2	Monocyte percentage of white cells;Monocyte count;	chr22:49631898	chr22:49612657~49615716:-
LUAD	cis	rs11064837	0.523	rs7960723	ENSG00000248636.5	RP11-768F21.1	4.48	9.2e-06	0.00182	0.24	0.2	Schizophrenia;	chr12:119661716	chr12:119387987~119668079:-
LUAD	cis	rs453301	0.605	rs7843024	ENSG00000233609.3	RP11-62H7.2	-4.48	9.2e-06	0.00182	-0.17	-0.2	Joint mobility (Beighton score);	chr8:8942466	chr8:8961200~8979025:+
LUAD	cis	rs228614	0.536	rs223418	ENSG00000251288.2	RP11-10L12.2	-4.48	9.21e-06	0.00182	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102809336	chr4:102751401~102752641:+
LUAD	cis	rs9876781	0.933	rs6442124	ENSG00000229759.1	MRPS18AP1	4.48	9.21e-06	0.00182	0.19	0.2	Longevity;	chr3:48463903	chr3:48256350~48256938:-
LUAD	cis	rs7432375	0.61	rs56695781	ENSG00000239213.4	NCK1-AS1	4.48	9.21e-06	0.00182	0.21	0.2	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136791759	chr3:136841726~136862054:-
LUAD	cis	rs913672	0.609	rs4811019	ENSG00000229222.1	KRT18P4	4.48	9.21e-06	0.00182	0.24	0.2	Monocyte count;	chr20:50281932	chr20:49956745~49958032:+
LUAD	cis	rs467650	0.553	rs469731	ENSG00000248489.1	CTD-2007H13.3	-4.48	9.21e-06	0.00182	-0.22	-0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98651703	chr5:98929171~98995013:+
LUAD	cis	rs1334894	1	rs72913423	ENSG00000228559.1	RP3-340B19.3	-4.48	9.21e-06	0.00182	-0.42	-0.2	Coronary artery disease;	chr6:35607930	chr6:35544632~35545669:+
LUAD	cis	rs4908768	0.52	rs6681362	ENSG00000270282.1	RP5-1115A15.2	4.48	9.22e-06	0.00182	0.22	0.2	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8598468	chr1:8512653~8513021:+
LUAD	cis	rs4908768	0.539	rs1318218	ENSG00000270282.1	RP5-1115A15.2	4.48	9.22e-06	0.00182	0.22	0.2	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8598653	chr1:8512653~8513021:+
LUAD	cis	rs2243480	1	rs1039664	ENSG00000164669.11	INTS4P1	4.48	9.22e-06	0.00182	0.35	0.2	Diabetic kidney disease;	chr7:65984729	chr7:65141225~65234216:+
LUAD	cis	rs13113518	0.812	rs11939580	ENSG00000223305.1	RN7SKP30	4.48	9.22e-06	0.00183	0.23	0.2	Height;	chr4:55517185	chr4:55540502~55540835:-
LUAD	cis	rs559928	0.606	rs1011219	ENSG00000236935.1	AP003774.1	-4.48	9.22e-06	0.00183	-0.27	-0.2	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64205924	chr11:64325050~64329504:-
LUAD	cis	rs6570726	0.764	rs9403726	ENSG00000235652.6	RP11-545I5.3	4.48	9.23e-06	0.00183	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145580550	chr6:145799409~145886585:+
LUAD	cis	rs7119	0.717	rs12916973	ENSG00000259362.2	RP11-307C19.1	4.48	9.23e-06	0.00183	0.25	0.2	Type 2 diabetes;	chr15:77515757	chr15:77525540~77534110:+
LUAD	cis	rs950169	0.734	rs67119537	ENSG00000259570.1	RP11-671M22.4	4.48	9.23e-06	0.00183	0.26	0.2	Schizophrenia;	chr15:84395671	chr15:84394512~84395514:+
LUAD	cis	rs1005277	0.522	rs1208684	ENSG00000263064.2	RP11-291L22.7	4.48	9.23e-06	0.00183	0.21	0.2	Extrinsic epigenetic age acceleration;	chr10:37805008	chr10:38448689~38448949:+
LUAD	cis	rs6570726	0.818	rs412350	ENSG00000235652.6	RP11-545I5.3	4.48	9.23e-06	0.00183	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145531273	chr6:145799409~145886585:+
LUAD	cis	rs801193	1	rs10234018	ENSG00000273142.1	RP11-458F8.4	4.48	9.23e-06	0.00183	0.14	0.2	Aortic root size;	chr7:66681297	chr7:66902857~66906297:+
LUAD	cis	rs2998286	0.906	rs2807742	ENSG00000254635.4	WAC-AS1	-4.48	9.24e-06	0.00183	-0.24	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28492438	chr10:28522652~28532743:-
LUAD	cis	rs9309473	0.687	rs6546827	ENSG00000163016.8	ALMS1P	4.48	9.24e-06	0.00183	0.22	0.2	Metabolite levels;	chr2:73379365	chr2:73644919~73685576:+
LUAD	cis	rs1008375	1	rs10009541	ENSG00000249502.1	AC006160.5	4.48	9.24e-06	0.00183	0.19	0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17680595	chr4:17587467~17614571:-
LUAD	cis	rs477895	0.713	rs11601024	ENSG00000236935.1	AP003774.1	-4.48	9.25e-06	0.00183	-0.25	-0.2	Mean platelet volume;	chr11:64175602	chr11:64325050~64329504:-
LUAD	cis	rs7005380	0.581	rs6469866	ENSG00000279347.1	RP11-85I17.2	-4.48	9.25e-06	0.00183	-0.19	-0.2	Interstitial lung disease;	chr8:119899057	chr8:119838736~119840385:-
LUAD	cis	rs4660214	0.724	rs7554301	ENSG00000228060.1	RP11-69E11.8	4.48	9.26e-06	0.00183	0.18	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39177792	chr1:39565160~39573203:+
LUAD	cis	rs2239557	0.961	rs10133356	ENSG00000259065.1	RP5-1021I20.1	4.48	9.26e-06	0.00183	0.23	0.2	Common traits (Other);	chr14:74181056	chr14:73787360~73803270:+
LUAD	cis	rs2239557	1	rs10144220	ENSG00000259065.1	RP5-1021I20.1	4.48	9.26e-06	0.00183	0.23	0.2	Common traits (Other);	chr14:74181201	chr14:73787360~73803270:+
LUAD	cis	rs2239557	0.961	rs10135858	ENSG00000259065.1	RP5-1021I20.1	4.48	9.26e-06	0.00183	0.23	0.2	Common traits (Other);	chr14:74181259	chr14:73787360~73803270:+
LUAD	cis	rs2933343	0.649	rs728839	ENSG00000231305.3	RP11-723O4.2	4.48	9.26e-06	0.00183	0.21	0.2	IgG glycosylation;	chr3:128870516	chr3:128861313~128871540:-
LUAD	cis	rs7208859	0.614	rs216477	ENSG00000266490.1	CTD-2349P21.9	-4.48	9.26e-06	0.00183	-0.28	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30539726	chr17:30792372~30792833:+
LUAD	cis	rs801193	0.66	rs10950049	ENSG00000232559.3	GS1-124K5.12	4.48	9.26e-06	0.00183	0.23	0.2	Aortic root size;	chr7:66765873	chr7:66554588~66576923:-
LUAD	cis	rs2243480	0.908	rs55876148	ENSG00000229886.1	RP5-1132H15.3	4.48	9.26e-06	0.00183	0.35	0.2	Diabetic kidney disease;	chr7:65914813	chr7:66025126~66031544:-
LUAD	cis	rs4372836	1	rs4372836	ENSG00000226833.4	AC097724.3	4.48	9.27e-06	0.00183	0.23	0.2	Body mass index;	chr2:28751017	chr2:28708953~28736205:-
LUAD	cis	rs1008375	0.966	rs6837664	ENSG00000249502.1	AC006160.5	-4.48	9.27e-06	0.00183	-0.19	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17696212	chr4:17587467~17614571:-
LUAD	cis	rs1008375	0.966	rs10939758	ENSG00000249502.1	AC006160.5	-4.48	9.27e-06	0.00183	-0.19	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17696632	chr4:17587467~17614571:-
LUAD	cis	rs11089937	0.568	rs6001078	ENSG00000211640.3	IGLV6-57	4.48	9.27e-06	0.00183	0.15	0.2	Periodontitis (PAL4Q3);	chr22:22134365	chr22:22195713~22196460:+
LUAD	cis	rs736408	0.561	rs2276815	ENSG00000242142.1	SERBP1P3	4.48	9.28e-06	0.00184	0.22	0.2	Bipolar disorder;	chr3:52819731	chr3:53064283~53065091:-
LUAD	cis	rs801193	1	rs7782320	ENSG00000224316.1	RP11-479O9.2	4.48	9.28e-06	0.00184	0.2	0.2	Aortic root size;	chr7:66712111	chr7:65773620~65802067:+
LUAD	cis	rs6487679	0.526	rs34362	ENSG00000111788.10	RP11-22B23.1	-4.48	9.28e-06	0.00184	-0.18	-0.2	Non-alcoholic fatty liver disease histology (AST);	chr12:9232829	chr12:9277235~9313241:+
LUAD	cis	rs860295	0.665	rs12079134	ENSG00000225855.5	RUSC1-AS1	4.48	9.28e-06	0.00184	0.14	0.2	Body mass index;	chr1:155496993	chr1:155316863~155324176:-
LUAD	cis	rs7119	0.689	rs12916833	ENSG00000259362.2	RP11-307C19.1	-4.48	9.28e-06	0.00184	-0.25	-0.2	Type 2 diabetes;	chr15:77527436	chr15:77525540~77534110:+
LUAD	cis	rs8077577	0.747	rs7215678	ENSG00000273018.4	CTD-2303H24.2	4.48	9.29e-06	0.00184	0.28	0.2	Obesity-related traits;	chr17:18236479	chr17:18511221~18551705:-
LUAD	cis	rs4713118	0.513	rs149954	ENSG00000216901.1	AL022393.7	4.48	9.29e-06	0.00184	0.24	0.2	Parkinson's disease;	chr6:28067468	chr6:28176188~28176674:+
LUAD	cis	rs9659323	0.7	rs2885226	ENSG00000231365.4	RP11-418J17.1	-4.48	9.29e-06	0.00184	-0.23	-0.2	Body mass index;	chr1:119081540	chr1:119140396~119275973:+
LUAD	cis	rs228614	0.51	rs223472	ENSG00000251288.2	RP11-10L12.2	-4.48	9.29e-06	0.00184	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102774327	chr4:102751401~102752641:+
LUAD	cis	rs1876905	0.539	rs240969	ENSG00000255389.1	C6orf3	-4.48	9.29e-06	0.00184	-0.28	-0.2	Mean corpuscular hemoglobin;	chr6:111314605	chr6:111599875~111602295:+
LUAD	cis	rs12440869	0.649	rs4776929	ENSG00000270964.1	RP11-502I4.3	4.48	9.3e-06	0.00184	0.25	0.2	Peak velocity of the mitral A-wave;	chr15:67414796	chr15:67541072~67542604:-
LUAD	cis	rs11722779	0.903	rs6830193	ENSG00000251288.2	RP11-10L12.2	-4.48	9.3e-06	0.00184	-0.24	-0.2	Schizophrenia;	chr4:102955457	chr4:102751401~102752641:+
LUAD	cis	rs11722779	0.935	rs6533046	ENSG00000251288.2	RP11-10L12.2	-4.48	9.3e-06	0.00184	-0.24	-0.2	Schizophrenia;	chr4:102965917	chr4:102751401~102752641:+
LUAD	cis	rs7191700	0.712	rs7187741	ENSG00000262703.1	RP11-485G7.6	-4.48	9.31e-06	0.00184	-0.17	-0.2	Multiple sclerosis;	chr16:11339246	chr16:11348143~11349321:-
LUAD	cis	rs9341808	0.754	rs9294173	ENSG00000233967.5	RP11-250B2.3	4.48	9.31e-06	0.00184	0.2	0.2	Sitting height ratio;	chr6:80281913	chr6:80443344~80465927:+
LUAD	cis	rs1008375	0.932	rs1008894	ENSG00000249502.1	AC006160.5	4.48	9.31e-06	0.00184	0.19	0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17703044	chr4:17587467~17614571:-
LUAD	cis	rs9545047	0.604	rs7987193	ENSG00000227354.5	RBM26-AS1	-4.48	9.32e-06	0.00184	-0.21	-0.2	Schizophrenia;	chr13:79408449	chr13:79406309~79424328:+
LUAD	cis	rs6686842	0.56	rs6672914	ENSG00000235358.1	RP11-399E6.1	-4.48	9.32e-06	0.00184	-0.24	-0.2	Height;	chr1:41201257	chr1:41242373~41284861:+
LUAD	cis	rs11673344	0.73	rs1644641	ENSG00000226686.6	LINC01535	4.48	9.32e-06	0.00184	0.26	0.2	Obesity-related traits;	chr19:36971237	chr19:37251912~37265535:+
LUAD	cis	rs17772222	0.917	rs61983300	ENSG00000258789.1	RP11-507K2.3	-4.48	9.33e-06	0.00184	-0.28	-0.2	Coronary artery calcification;	chr14:88754047	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.876	rs78068036	ENSG00000258789.1	RP11-507K2.3	-4.48	9.33e-06	0.00184	-0.28	-0.2	Coronary artery calcification;	chr14:88754817	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.917	rs11159868	ENSG00000258789.1	RP11-507K2.3	-4.48	9.33e-06	0.00184	-0.28	-0.2	Coronary artery calcification;	chr14:88760528	chr14:88551597~88552493:+
LUAD	cis	rs1478897	0.898	rs2248696	ENSG00000270154.1	RP11-419I17.1	-4.48	9.33e-06	0.00184	-0.23	-0.2	Systemic lupus erythematosus;	chr8:11536294	chr8:12476462~12477122:+
LUAD	cis	rs2348418	0.966	rs7316797	ENSG00000247934.4	RP11-967K21.1	4.48	9.33e-06	0.00184	0.23	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28529776	chr12:28163298~28190738:-
LUAD	cis	rs8180040	0.62	rs6414435	ENSG00000271161.1	BOLA2P2	4.48	9.33e-06	0.00185	0.19	0.2	Colorectal cancer;	chr3:47079650	chr3:47499841~47500407:+
LUAD	cis	rs8062405	0.721	rs151303	ENSG00000251417.2	RP11-1348G14.4	-4.48	9.33e-06	0.00185	-0.21	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28481189	chr16:28802743~28817828:+
LUAD	cis	rs867371	0.762	rs1846910	ENSG00000276710.3	CSPG4P8	-4.48	9.33e-06	0.00185	-0.2	-0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82279439	chr15:82459472~82477258:+
LUAD	cis	rs4908760	0.864	rs1953827	ENSG00000270282.1	RP5-1115A15.2	4.48	9.34e-06	0.00185	0.22	0.2	Vitiligo;	chr1:8619789	chr1:8512653~8513021:+
LUAD	cis	rs12701220	0.894	rs10257744	ENSG00000229043.2	AC091729.9	-4.48	9.34e-06	0.00185	-0.27	-0.2	Bronchopulmonary dysplasia;	chr7:1005976	chr7:1160374~1165267:+
LUAD	cis	rs10771431	0.817	rs10843149	ENSG00000111788.10	RP11-22B23.1	4.48	9.34e-06	0.00185	0.17	0.2	Breast size;	chr12:9209471	chr12:9277235~9313241:+
LUAD	cis	rs228614	0.51	rs150893	ENSG00000251288.2	RP11-10L12.2	4.48	9.34e-06	0.00185	0.24	0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102817075	chr4:102751401~102752641:+
LUAD	cis	rs867371	0.722	rs8033050	ENSG00000276710.3	CSPG4P8	-4.48	9.34e-06	0.00185	-0.2	-0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82269648	chr15:82459472~82477258:+
LUAD	cis	rs7937890	0.598	rs10734225	ENSG00000254418.1	RP11-21L19.1	4.48	9.34e-06	0.00185	0.25	0.2	Mitochondrial DNA levels;	chr11:14421448	chr11:14262846~14273691:-
LUAD	cis	rs6691170	0.632	rs9441981	ENSG00000228437.4	RP11-400N13.2	4.48	9.34e-06	0.00185	0.26	0.2	Colorectal cancer;	chr1:221837846	chr1:221966341~221984964:+
LUAD	cis	rs9400467	0.528	rs7752361	ENSG00000230177.1	RP5-1112D6.4	-4.48	9.34e-06	0.00185	-0.18	-0.2	Amino acid levels;Blood metabolite levels;	chr6:111459502	chr6:111277932~111278742:+
LUAD	cis	rs7760535	0.811	rs7764591	ENSG00000230177.1	RP5-1112D6.4	-4.48	9.34e-06	0.00185	-0.18	-0.2	Metabolic traits;	chr6:111462211	chr6:111277932~111278742:+
LUAD	cis	rs11051970	0.566	rs2651372	ENSG00000274964.1	RP11-817I4.1	-4.48	9.34e-06	0.00185	-0.2	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr12:32430265	chr12:32339368~32340724:+
LUAD	cis	rs11673344	0.8	rs8108214	ENSG00000226686.6	LINC01535	-4.48	9.36e-06	0.00185	-0.25	-0.2	Obesity-related traits;	chr19:37025184	chr19:37251912~37265535:+
LUAD	cis	rs227275	0.556	rs9999303	ENSG00000251288.2	RP11-10L12.2	-4.48	9.36e-06	0.00185	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102986881	chr4:102751401~102752641:+
LUAD	cis	rs910316	0.87	rs7147712	ENSG00000279594.1	RP11-950C14.10	-4.48	9.36e-06	0.00185	-0.23	-0.2	Height;	chr14:75204004	chr14:75011269~75012851:-
LUAD	cis	rs2255336	0.817	rs4764430	ENSG00000245648.1	RP11-277P12.20	4.48	9.36e-06	0.00185	0.31	0.2	Blood protein levels;	chr12:10365209	chr12:10363769~10398506:+
LUAD	cis	rs1008375	0.966	rs7666888	ENSG00000249502.1	AC006160.5	-4.48	9.36e-06	0.00185	-0.19	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17694099	chr4:17587467~17614571:-
LUAD	cis	rs6957923	0.755	rs34979424	ENSG00000230658.1	KLHL7-AS1	4.48	9.36e-06	0.00185	0.24	0.2	Height;	chr7:23480028	chr7:23101228~23105703:-
LUAD	cis	rs7116495	1	rs11235440	ENSG00000254682.1	RP11-660L16.2	-4.48	9.36e-06	0.00185	-0.42	-0.2	Severe influenza A (H1N1) infection;	chr11:72115598	chr11:71448674~71452157:+
LUAD	cis	rs11763147	1	rs11763147	ENSG00000237310.1	GS1-124K5.4	-4.48	9.36e-06	0.00185	-0.21	-0.2	Corneal structure;	chr7:65861834	chr7:66493706~66495474:+
LUAD	cis	rs5758659	1	rs134900	ENSG00000182057.4	OGFRP1	4.48	9.36e-06	0.00185	0.23	0.2	Cognitive function;	chr22:42287337	chr22:42269753~42275196:+
LUAD	cis	rs4819052	0.851	rs35560973	ENSG00000237664.1	LINC00316	-4.48	9.37e-06	0.00185	-0.24	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242658	chr21:45338590~45341990:-
LUAD	cis	rs12754538	0.961	rs12047377	ENSG00000232912.4	RP5-1115A15.1	4.48	9.37e-06	0.00185	0.21	0.2	Subjective well-being;	chr1:8433873	chr1:8424645~8434838:+
LUAD	cis	rs877356	1	rs13167664	ENSG00000250378.1	RP11-119J18.1	-4.48	9.37e-06	0.00185	-0.35	-0.2	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (dichotomous);	chr5:135826778	chr5:135812667~135826582:+
LUAD	cis	rs910316	0.81	rs77939209	ENSG00000259138.1	RP11-950C14.7	-4.48	9.37e-06	0.00185	-0.21	-0.2	Height;	chr14:75203367	chr14:75127153~75136930:+
LUAD	cis	rs780096	0.526	rs4582	ENSG00000234072.1	AC074117.10	-4.48	9.37e-06	0.00185	-0.15	-0.2	Total body bone mineral density;	chr2:27381412	chr2:27356246~27367622:+
LUAD	cis	rs2227564	0.62	rs4746143	ENSG00000271816.1	BMS1P4	4.48	9.38e-06	0.00185	0.19	0.2	Crohn's disease;Inflammatory bowel disease;	chr10:73717540	chr10:73699151~73730487:-
LUAD	cis	rs1799949	0.894	rs71367985	ENSG00000236383.6	LINC00854	-4.48	9.38e-06	0.00185	-0.16	-0.2	Menopause (age at onset);	chr17:43222443	chr17:43216941~43305976:-
LUAD	cis	rs2998286	0.862	rs2153300	ENSG00000254635.4	WAC-AS1	-4.48	9.38e-06	0.00185	-0.26	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28519041	chr10:28522652~28532743:-
LUAD	cis	rs6088590	1	rs6120748	ENSG00000276073.1	RP5-1125A11.7	-4.48	9.38e-06	0.00185	-0.2	-0.2	Coronary artery disease;	chr20:34870481	chr20:33985617~33988989:-
LUAD	cis	rs13113518	0.812	rs13140590	ENSG00000223305.1	RN7SKP30	4.48	9.39e-06	0.00185	0.23	0.2	Height;	chr4:55548666	chr4:55540502~55540835:-
LUAD	cis	rs9425766	0.679	rs6682017	ENSG00000227373.4	RP11-160H22.5	4.48	9.39e-06	0.00186	0.25	0.2	Life satisfaction;	chr1:174097809	chr1:174115300~174160004:-
LUAD	cis	rs7580658	0.75	rs6731176	ENSG00000236682.1	AC068282.3	-4.48	9.4e-06	0.00186	-0.26	-0.2	Protein C levels;	chr2:127313427	chr2:127389130~127400580:+
LUAD	cis	rs10246939	0.543	rs11767119	ENSG00000270923.1	TAS2R6P	-4.48	9.4e-06	0.00186	-0.24	-0.2	Bitter taste perception;	chr7:141912316	chr7:141787815~141788640:+
LUAD	cis	rs2880765	0.835	rs6497206	ENSG00000259416.2	RP11-158M2.5	4.48	9.4e-06	0.00186	0.21	0.2	Coronary artery disease;	chr15:85485994	chr15:85754941~85756237:-
LUAD	cis	rs17772222	0.674	rs112788894	ENSG00000258789.1	RP11-507K2.3	-4.48	9.42e-06	0.00186	-0.28	-0.2	Coronary artery calcification;	chr14:88442850	chr14:88551597~88552493:+
LUAD	cis	rs9860428	0.509	rs6805959	ENSG00000242770.2	RP11-180K7.1	-4.48	9.42e-06	0.00186	-0.23	-0.2	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112871493	chr3:112802478~112812819:+
LUAD	cis	rs2562456	0.833	rs62109223	ENSG00000268081.1	RP11-678G14.2	4.48	9.42e-06	0.00186	0.32	0.2	Pain;	chr19:21349591	chr19:21554640~21569237:-
LUAD	cis	rs202072	0.652	rs202064	ENSG00000272379.1	RP1-257A7.5	-4.48	9.42e-06	0.00186	-0.34	-0.2	HIV-1 viral setpoint;	chr6:13263794	chr6:13290018~13290490:-
LUAD	cis	rs1062177	1	rs973529	ENSG00000253921.1	CTB-113P19.3	-4.48	9.43e-06	0.00186	-0.3	-0.2	Preschool internalizing problems;	chr5:151808597	chr5:151753992~151767247:+
LUAD	cis	rs16846053	0.642	rs13390292	ENSG00000227403.1	AC009299.3	4.48	9.43e-06	0.00186	0.32	0.2	Blood osmolality (transformed sodium);	chr2:161787585	chr2:161244739~161249050:+
LUAD	cis	rs6496932	0.503	rs10220820	ENSG00000202081.1	RNU6-1280P	-4.48	9.43e-06	0.00186	-0.26	-0.2	Central corneal thickness;Corneal structure;	chr15:85441932	chr15:85651522~85651628:-
LUAD	cis	rs4601821	1	rs877138	ENSG00000270179.1	RP11-159N11.4	4.48	9.43e-06	0.00186	0.21	0.2	Alcoholic chronic pancreatitis;	chr11:113385786	chr11:113368478~113369117:+
LUAD	cis	rs7746199	0.736	rs67652222	ENSG00000219392.1	RP1-265C24.5	-4.48	9.43e-06	0.00186	-0.43	-0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27618441	chr6:28115628~28116551:+
LUAD	cis	rs13113518	0.812	rs56055342	ENSG00000223305.1	RN7SKP30	4.48	9.43e-06	0.00186	0.24	0.2	Height;	chr4:55540928	chr4:55540502~55540835:-
LUAD	cis	rs2243480	1	rs781156	ENSG00000164669.11	INTS4P1	4.48	9.44e-06	0.00186	0.35	0.2	Diabetic kidney disease;	chr7:66014154	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs781149	ENSG00000164669.11	INTS4P1	4.48	9.44e-06	0.00186	0.35	0.2	Diabetic kidney disease;	chr7:66016297	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs451396	ENSG00000164669.11	INTS4P1	4.48	9.44e-06	0.00186	0.35	0.2	Diabetic kidney disease;	chr7:66019087	chr7:65141225~65234216:+
LUAD	cis	rs2243480	0.901	rs58207111	ENSG00000164669.11	INTS4P1	4.48	9.44e-06	0.00186	0.35	0.2	Diabetic kidney disease;	chr7:66021736	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs1167613	ENSG00000164669.11	INTS4P1	4.48	9.44e-06	0.00186	0.35	0.2	Diabetic kidney disease;	chr7:66022452	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs1715235	ENSG00000164669.11	INTS4P1	4.48	9.44e-06	0.00186	0.35	0.2	Diabetic kidney disease;	chr7:66023407	chr7:65141225~65234216:+
LUAD	cis	rs7772486	0.79	rs2253764	ENSG00000235652.6	RP11-545I5.3	4.48	9.44e-06	0.00186	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145878745	chr6:145799409~145886585:+
LUAD	cis	rs7829975	0.659	rs4382480	ENSG00000253893.2	FAM85B	-4.48	9.44e-06	0.00186	-0.25	-0.2	Mood instability;	chr8:8863963	chr8:8167819~8226614:-
LUAD	cis	rs853679	0.825	rs8180562	ENSG00000204709.4	LINC01556	4.48	9.44e-06	0.00186	0.34	0.2	Depression;	chr6:28173682	chr6:28943877~28944537:+
LUAD	cis	rs1499614	1	rs2707840	ENSG00000232559.3	GS1-124K5.12	4.48	9.44e-06	0.00186	0.35	0.2	Gout;	chr7:66693028	chr7:66554588~66576923:-
LUAD	cis	rs755249	0.588	rs6665948	ENSG00000228060.1	RP11-69E11.8	4.48	9.45e-06	0.00186	0.18	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39478508	chr1:39565160~39573203:+
LUAD	cis	rs7138803	0.538	rs2603112	ENSG00000257464.1	RP11-161H23.8	-4.48	9.45e-06	0.00187	-0.2	-0.2	Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index;	chr12:49806166	chr12:49442424~49442652:-
LUAD	cis	rs2011013	1	rs12148239	ENSG00000259570.1	RP11-671M22.4	4.48	9.45e-06	0.00187	0.26	0.2	Sitting height ratio;	chr15:83972266	chr15:84394512~84395514:+
LUAD	cis	rs889398	0.616	rs35808754	ENSG00000226232.7	RP11-419C5.2	4.48	9.45e-06	0.00187	0.17	0.2	Body mass index;	chr16:69737807	chr16:69976388~69996188:-
LUAD	cis	rs8180040	0.701	rs62248439	ENSG00000271161.1	BOLA2P2	-4.48	9.45e-06	0.00187	-0.19	-0.2	Colorectal cancer;	chr3:46954958	chr3:47499841~47500407:+
LUAD	cis	rs7208859	0.623	rs9906957	ENSG00000266490.1	CTD-2349P21.9	4.48	9.46e-06	0.00187	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30830737	chr17:30792372~30792833:+
LUAD	cis	rs8180040	0.764	rs62246375	ENSG00000271161.1	BOLA2P2	-4.48	9.46e-06	0.00187	-0.19	-0.2	Colorectal cancer;	chr3:46972974	chr3:47499841~47500407:+
LUAD	cis	rs7763441	0.545	rs9378700	ENSG00000272465.1	RP1-136B1.1	4.48	9.46e-06	0.00187	0.24	0.2	Monobrow;	chr6:2452320	chr6:2437549~2438249:+
LUAD	cis	rs11157436	0.509	rs12589104	ENSG00000211812.1	TRAV26-2	-4.48	9.47e-06	0.00187	-0.21	-0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22167754	chr14:22202583~22203368:+
LUAD	cis	rs227275	0.554	rs150895	ENSG00000251288.2	RP11-10L12.2	-4.48	9.47e-06	0.00187	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102791432	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.554	rs223442	ENSG00000251288.2	RP11-10L12.2	-4.48	9.47e-06	0.00187	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102793960	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.554	rs223441	ENSG00000251288.2	RP11-10L12.2	-4.48	9.47e-06	0.00187	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102794228	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.554	rs223439	ENSG00000251288.2	RP11-10L12.2	-4.48	9.47e-06	0.00187	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102798377	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.554	rs223436	ENSG00000251288.2	RP11-10L12.2	-4.48	9.47e-06	0.00187	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102798749	chr4:102751401~102752641:+
LUAD	cis	rs950169	0.84	rs2896002	ENSG00000275120.1	RP11-182J1.17	4.48	9.47e-06	0.00187	0.31	0.2	Schizophrenia;	chr15:84390423	chr15:84599434~84606463:-
LUAD	cis	rs34375054	0.558	rs12578774	ENSG00000279233.1	RP11-158L12.4	-4.48	9.47e-06	0.00187	-0.17	-0.2	Post bronchodilator FEV1/FVC ratio;	chr12:125197215	chr12:125138245~125141711:+
LUAD	cis	rs12446632	0.511	rs13335003	ENSG00000261195.1	CTD-2380F24.1	-4.48	9.47e-06	0.00187	-0.25	-0.2	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Menarche (age at onset);Obesity;Childhood body mass index;Waist circumference;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr16:19893761	chr16:19761172~19766099:-
LUAD	cis	rs3096299	0.658	rs3934737	ENSG00000261118.1	RP11-104N10.1	4.48	9.47e-06	0.00187	0.2	0.2	Multiple myeloma (IgH translocation);	chr16:89493801	chr16:89492017~89504460:-
LUAD	cis	rs6479891	0.908	rs61853655	ENSG00000232075.1	MRPL35P2	4.48	9.47e-06	0.00187	0.34	0.2	Arthritis (juvenile idiopathic);	chr10:63570645	chr10:63634317~63634827:-
LUAD	cis	rs10971721	0.822	rs11848	ENSG00000260947.1	RP11-384P7.7	4.48	9.48e-06	0.00187	0.41	0.2	Body mass index;	chr9:33921921	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs10971793	ENSG00000260947.1	RP11-384P7.7	4.48	9.48e-06	0.00187	0.41	0.2	Body mass index;	chr9:33922628	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs10971794	ENSG00000260947.1	RP11-384P7.7	4.48	9.48e-06	0.00187	0.41	0.2	Body mass index;	chr9:33924314	chr9:33697459~33700986:+
LUAD	cis	rs9549328	0.67	rs2873372	ENSG00000267868.1	RP11-120K24.3	4.48	9.48e-06	0.00187	0.23	0.2	Systolic blood pressure;	chr13:112959069	chr13:112964835~112966131:-
LUAD	cis	rs9341808	0.727	rs10943697	ENSG00000260645.1	RP11-250B2.5	4.48	9.48e-06	0.00187	0.19	0.2	Sitting height ratio;	chr6:80221789	chr6:80466958~80469080:+
LUAD	cis	rs375066	0.87	rs7258418	ENSG00000267058.1	RP11-15A1.3	-4.48	9.48e-06	0.00187	-0.23	-0.2	Breast cancer;	chr19:43878931	chr19:43891804~43901805:-
LUAD	cis	rs712022	1	rs1019217	ENSG00000246225.5	RP11-17A1.3	4.48	9.49e-06	0.00187	0.24	0.2	Dialysis-related mortality;	chr11:22821076	chr11:22829380~22945393:+
LUAD	cis	rs60180747	0.544	rs11635096	ENSG00000261318.1	RP11-653J6.1	4.48	9.49e-06	0.00187	0.26	0.2	Testicular germ cell tumor;	chr15:66276362	chr15:66278498~66293357:-
LUAD	cis	rs9309473	0.607	rs7586361	ENSG00000163016.8	ALMS1P	4.48	9.49e-06	0.00187	0.23	0.2	Metabolite levels;	chr2:73374478	chr2:73644919~73685576:+
LUAD	cis	rs9341808	0.718	rs7740627	ENSG00000272129.1	RP11-250B2.6	4.48	9.5e-06	0.00187	0.25	0.2	Sitting height ratio;	chr6:80206630	chr6:80355424~80356859:+
LUAD	cis	rs9815354	0.812	rs939561	ENSG00000273328.4	RP11-141M3.6	4.48	9.5e-06	0.00187	0.31	0.2	Pulse pressure;Diastolic blood pressure;	chr3:42015609	chr3:42809414~42908105:+
LUAD	cis	rs4835473	0.9	rs10025455	ENSG00000251600.4	RP11-673E1.1	-4.48	9.5e-06	0.00187	-0.25	-0.2	Immature fraction of reticulocytes;	chr4:143998417	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.722	rs7666296	ENSG00000251600.4	RP11-673E1.1	-4.48	9.5e-06	0.00187	-0.25	-0.2	Immature fraction of reticulocytes;	chr4:143999004	chr4:143912331~143982454:+
LUAD	cis	rs4835473	0.722	rs7662277	ENSG00000251600.4	RP11-673E1.1	-4.48	9.5e-06	0.00187	-0.25	-0.2	Immature fraction of reticulocytes;	chr4:143999485	chr4:143912331~143982454:+
LUAD	cis	rs2834288	0.959	rs2834294	ENSG00000237945.6	LINC00649	-4.48	9.5e-06	0.00187	-0.26	-0.2	Gut microbiota (bacterial taxa);	chr21:33908326	chr21:33915534~33977691:+
LUAD	cis	rs11976180	0.569	rs12703565	ENSG00000273234.1	OR2A13P	-4.48	9.5e-06	0.00187	-0.31	-0.2	Obesity-related traits;	chr7:144057308	chr7:144142009~144142938:+
LUAD	cis	rs6723108	0.627	rs766271	ENSG00000224043.6	CCNT2-AS1	-4.48	9.5e-06	0.00188	-0.25	-0.2	Type 2 diabetes;	chr2:134909561	chr2:134735464~134918710:-
LUAD	cis	rs7107174	1	rs2450128	ENSG00000251323.2	RP11-452H21.4	4.48	9.5e-06	0.00188	0.25	0.2	Testicular germ cell tumor;	chr11:78229029	chr11:78423982~78429836:-
LUAD	cis	rs8031584	0.678	rs8035703	ENSG00000270015.1	RP11-540B6.6	-4.48	9.51e-06	0.00188	-0.15	-0.2	Huntington's disease progression;	chr15:30876269	chr15:30926514~30928407:+
LUAD	cis	rs11971779	0.68	rs73154134	ENSG00000273391.1	RP11-634H22.1	4.48	9.51e-06	0.00188	0.21	0.2	Diisocyanate-induced asthma;	chr7:139355205	chr7:139359032~139359566:-
LUAD	cis	rs9860428	1	rs10934197	ENSG00000242770.2	RP11-180K7.1	4.48	9.51e-06	0.00188	0.21	0.2	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112861621	chr3:112802478~112812819:+
LUAD	cis	rs2243480	1	rs316307	ENSG00000232559.3	GS1-124K5.12	4.48	9.51e-06	0.00188	0.36	0.2	Diabetic kidney disease;	chr7:66105184	chr7:66554588~66576923:-
LUAD	cis	rs4835473	0.6	rs9997101	ENSG00000251600.4	RP11-673E1.1	4.48	9.52e-06	0.00188	0.23	0.2	Immature fraction of reticulocytes;	chr4:143777892	chr4:143912331~143982454:+
LUAD	cis	rs9341808	0.519	rs607130	ENSG00000260645.1	RP11-250B2.5	-4.48	9.52e-06	0.00188	-0.19	-0.2	Sitting height ratio;	chr6:80289516	chr6:80466958~80469080:+
LUAD	cis	rs7829975	0.606	rs891570	ENSG00000173295.6	FAM86B3P	-4.48	9.52e-06	0.00188	-0.21	-0.2	Mood instability;	chr8:8936944	chr8:8228595~8244865:+
LUAD	cis	rs2243480	1	rs437889	ENSG00000232559.3	GS1-124K5.12	4.48	9.52e-06	0.00188	0.34	0.2	Diabetic kidney disease;	chr7:66044247	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs402418	ENSG00000232559.3	GS1-124K5.12	4.48	9.52e-06	0.00188	0.34	0.2	Diabetic kidney disease;	chr7:66044482	chr7:66554588~66576923:-
LUAD	cis	rs2243480	0.803	rs423187	ENSG00000232559.3	GS1-124K5.12	4.48	9.52e-06	0.00188	0.34	0.2	Diabetic kidney disease;	chr7:66044512	chr7:66554588~66576923:-
LUAD	cis	rs4811196	0.748	rs4809877	ENSG00000226144.2	RPS27AP3	4.48	9.52e-06	0.00188	0.22	0.2	Bone mineral density;	chr20:37874999	chr20:37049254~37049707:+
LUAD	cis	rs5769707	0.967	rs5770585	ENSG00000235111.1	RP1-29C18.8	-4.48	9.52e-06	0.00188	-0.21	-0.2	Monocyte percentage of white cells;Monocyte count;	chr22:49614226	chr22:49612657~49615716:-
LUAD	cis	rs338389	0.586	rs338390	ENSG00000260657.2	RP11-315D16.4	-4.48	9.52e-06	0.00188	-0.24	-0.2	Survival in rectal cancer;	chr15:67966876	chr15:68267792~68277994:-
LUAD	cis	rs875971	0.862	rs10256544	ENSG00000232559.3	GS1-124K5.12	4.48	9.53e-06	0.00188	0.24	0.2	Aortic root size;	chr7:66210141	chr7:66554588~66576923:-
LUAD	cis	rs12478296	1	rs12478296	ENSG00000261186.2	RP11-341N2.1	4.48	9.53e-06	0.00188	0.33	0.2	Obesity-related traits;	chr2:242106609	chr2:242087351~242088457:-
LUAD	cis	rs853679	0.546	rs200977	ENSG00000219392.1	RP1-265C24.5	-4.48	9.53e-06	0.00188	-0.4	-0.2	Depression;	chr6:27886523	chr6:28115628~28116551:+
LUAD	cis	rs3096299	0.658	rs12443705	ENSG00000182376.2	RP5-1142A6.8	4.48	9.53e-06	0.00188	0.21	0.2	Multiple myeloma (IgH translocation);	chr16:89480646	chr16:88742767~88745748:+
LUAD	cis	rs9652601	0.779	rs725613	ENSG00000274038.1	RP11-66H6.4	-4.48	9.53e-06	0.00188	-0.24	-0.2	Systemic lupus erythematosus;	chr16:11075826	chr16:11056556~11057034:+
LUAD	cis	rs704795	0.836	rs1083865	ENSG00000234072.1	AC074117.10	-4.48	9.53e-06	0.00188	-0.15	-0.2	Menopause (age at onset);	chr2:27397960	chr2:27356246~27367622:+
LUAD	cis	rs780096	0.546	rs2911712	ENSG00000234072.1	AC074117.10	-4.48	9.53e-06	0.00188	-0.15	-0.2	Total body bone mineral density;	chr2:27404078	chr2:27356246~27367622:+
LUAD	cis	rs11122895	0.509	rs55937046	ENSG00000236307.2	EEF1E1P1	4.48	9.53e-06	0.00188	0.21	0.2	Allergic sensitization;	chr2:111689719	chr2:111887914~111888741:+
LUAD	cis	rs9467773	1	rs10946834	ENSG00000261353.1	CTA-14H9.5	-4.48	9.53e-06	0.00188	-0.22	-0.2	Intelligence (multi-trait analysis);	chr6:26533436	chr6:26527063~26527404:+
LUAD	cis	rs7172677	1	rs2029520	ENSG00000260269.4	CTD-2323K18.1	-4.48	9.53e-06	0.00188	-0.27	-0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75123427	chr15:75527150~75601205:-
LUAD	cis	rs8180040	0.62	rs9845728	ENSG00000271161.1	BOLA2P2	4.48	9.53e-06	0.00188	0.19	0.2	Colorectal cancer;	chr3:47061886	chr3:47499841~47500407:+
LUAD	cis	rs8180040	0.62	rs9844122	ENSG00000271161.1	BOLA2P2	4.48	9.53e-06	0.00188	0.19	0.2	Colorectal cancer;	chr3:47066840	chr3:47499841~47500407:+
LUAD	cis	rs1008375	1	rs2058337	ENSG00000249502.1	AC006160.5	-4.48	9.54e-06	0.00188	-0.18	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17677026	chr4:17587467~17614571:-
LUAD	cis	rs5758511	0.68	rs5758699	ENSG00000227370.1	RP4-669P10.19	4.48	9.54e-06	0.00188	0.22	0.2	Birth weight;	chr22:42292028	chr22:42132543~42132998:+
LUAD	cis	rs755249	0.727	rs12028034	ENSG00000228060.1	RP11-69E11.8	4.48	9.54e-06	0.00188	0.18	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39574035	chr1:39565160~39573203:+
LUAD	cis	rs6723108	0.627	rs6430549	ENSG00000224043.6	CCNT2-AS1	-4.48	9.54e-06	0.00188	-0.25	-0.2	Type 2 diabetes;	chr2:134858776	chr2:134735464~134918710:-
LUAD	cis	rs9287719	1	rs9287719	ENSG00000243819.4	RN7SL832P	4.48	9.54e-06	0.00188	0.21	0.2	Prostate cancer;	chr2:10570604	chr2:10690344~10692099:+
LUAD	cis	rs4664293	0.647	rs1425039	ENSG00000226266.5	AC009961.3	-4.47	9.55e-06	0.00188	-0.26	-0.2	Monocyte percentage of white cells;	chr2:159571612	chr2:159670708~159712435:-
LUAD	cis	rs2562456	0.833	rs62109225	ENSG00000268081.1	RP11-678G14.2	4.47	9.55e-06	0.00188	0.32	0.2	Pain;	chr19:21353861	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.754	rs62109226	ENSG00000268081.1	RP11-678G14.2	4.47	9.55e-06	0.00188	0.32	0.2	Pain;	chr19:21354111	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.754	rs62109227	ENSG00000268081.1	RP11-678G14.2	4.47	9.55e-06	0.00188	0.32	0.2	Pain;	chr19:21354128	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.754	rs62109228	ENSG00000268081.1	RP11-678G14.2	4.47	9.55e-06	0.00188	0.32	0.2	Pain;	chr19:21354129	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.833	rs8102783	ENSG00000268081.1	RP11-678G14.2	4.47	9.55e-06	0.00188	0.32	0.2	Pain;	chr19:21355751	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.833	rs2061916	ENSG00000268081.1	RP11-678G14.2	4.47	9.55e-06	0.00188	0.32	0.2	Pain;	chr19:21358906	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.833	rs4359573	ENSG00000268081.1	RP11-678G14.2	4.47	9.55e-06	0.00188	0.32	0.2	Pain;	chr19:21359494	chr19:21554640~21569237:-
LUAD	cis	rs6700559	0.565	rs12728040	ENSG00000260088.1	RP11-92G12.3	4.47	9.55e-06	0.00188	0.25	0.2	Coronary artery disease;	chr1:200626751	chr1:200669507~200694250:+
LUAD	cis	rs997295	0.554	rs4261477	ENSG00000270964.1	RP11-502I4.3	4.47	9.55e-06	0.00188	0.21	0.2	Motion sickness;	chr15:67781630	chr15:67541072~67542604:-
LUAD	cis	rs150992	0.504	rs7719649	ENSG00000248489.1	CTD-2007H13.3	4.47	9.56e-06	0.00188	0.25	0.2	Body mass index;	chr5:99036711	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.537	rs1604450	ENSG00000248489.1	CTD-2007H13.3	-4.47	9.56e-06	0.00188	-0.25	-0.2	Body mass index;	chr5:99036274	chr5:98929171~98995013:+
LUAD	cis	rs7923609	0.54	rs10733789	ENSG00000232075.1	MRPL35P2	4.47	9.56e-06	0.00188	0.26	0.2	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63188924	chr10:63634317~63634827:-
LUAD	cis	rs3120667	0.79	rs11205001	ENSG00000237975.5	FLG-AS1	4.47	9.56e-06	0.00188	0.32	0.2	Eating disorders;	chr1:152423472	chr1:152168125~152445456:+
LUAD	cis	rs17264034	0.821	rs422309	ENSG00000250786.1	SNHG18	4.47	9.56e-06	0.00189	0.3	0.2	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9544284	chr5:9546200~9550609:+
LUAD	cis	rs5758511	0.68	rs5758651	ENSG00000227370.1	RP4-669P10.19	4.47	9.56e-06	0.00189	0.23	0.2	Birth weight;	chr22:42213142	chr22:42132543~42132998:+
LUAD	cis	rs5758511	0.68	rs5758652	ENSG00000227370.1	RP4-669P10.19	4.47	9.56e-06	0.00189	0.23	0.2	Birth weight;	chr22:42216402	chr22:42132543~42132998:+
LUAD	cis	rs9341808	0.754	rs9361591	ENSG00000272129.1	RP11-250B2.6	4.47	9.57e-06	0.00189	0.24	0.2	Sitting height ratio;	chr6:80243538	chr6:80355424~80356859:+
LUAD	cis	rs1044826	0.879	rs13071857	ENSG00000214280.3	RP11-553K23.2	-4.47	9.57e-06	0.00189	-0.23	-0.2	Obesity-related traits;	chr3:139433311	chr3:139582928~139583593:-
LUAD	cis	rs6723108	0.627	rs1446523	ENSG00000224043.6	CCNT2-AS1	-4.47	9.57e-06	0.00189	-0.25	-0.2	Type 2 diabetes;	chr2:134859051	chr2:134735464~134918710:-
LUAD	cis	rs1876905	0.539	rs240962	ENSG00000255389.1	C6orf3	-4.47	9.57e-06	0.00189	-0.28	-0.2	Mean corpuscular hemoglobin;	chr6:111321243	chr6:111599875~111602295:+
LUAD	cis	rs7005380	0.581	rs12677306	ENSG00000279347.1	RP11-85I17.2	-4.47	9.57e-06	0.00189	-0.19	-0.2	Interstitial lung disease;	chr8:119903842	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.538	rs7461170	ENSG00000279347.1	RP11-85I17.2	-4.47	9.57e-06	0.00189	-0.19	-0.2	Interstitial lung disease;	chr8:119904014	chr8:119838736~119840385:-
LUAD	cis	rs910316	1	rs10138183	ENSG00000279594.1	RP11-950C14.10	4.47	9.57e-06	0.00189	0.23	0.2	Height;	chr14:75148524	chr14:75011269~75012851:-
LUAD	cis	rs453301	0.562	rs1038248	ENSG00000173295.6	FAM86B3P	-4.47	9.57e-06	0.00189	-0.21	-0.2	Joint mobility (Beighton score);	chr8:9183348	chr8:8228595~8244865:+
LUAD	cis	rs16873450	1	rs16873450	ENSG00000234800.2	PCMTD1P3	-4.47	9.58e-06	0.00189	-0.24	-0.2	Verbal memory performance (residualized delayed recall level);	chr7:23767021	chr7:23721311~23721782:-
LUAD	cis	rs9381040	0.674	rs3747742	ENSG00000161912.16	ADCY10P1	-4.47	9.58e-06	0.00189	-0.19	-0.2	Alzheimer's disease (late onset);	chr6:41194780	chr6:41101022~41140835:+
LUAD	cis	rs2243480	1	rs316326	ENSG00000232559.3	GS1-124K5.12	4.47	9.58e-06	0.00189	0.35	0.2	Diabetic kidney disease;	chr7:66144466	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs316325	ENSG00000232559.3	GS1-124K5.12	4.47	9.58e-06	0.00189	0.35	0.2	Diabetic kidney disease;	chr7:66144531	chr7:66554588~66576923:-
LUAD	cis	rs11159086	1	rs11159087	ENSG00000259005.1	RP3-449M8.6	4.47	9.58e-06	0.00189	0.27	0.2	Advanced glycation end-product levels;	chr14:74504671	chr14:74474007~74474864:-
LUAD	cis	rs4660214	0.614	rs11205802	ENSG00000228060.1	RP11-69E11.8	4.47	9.58e-06	0.00189	0.18	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39233442	chr1:39565160~39573203:+
LUAD	cis	rs4660214	0.614	rs10888715	ENSG00000228060.1	RP11-69E11.8	4.47	9.58e-06	0.00189	0.18	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39233572	chr1:39565160~39573203:+
LUAD	cis	rs477895	0.639	rs35858916	ENSG00000236935.1	AP003774.1	-4.47	9.58e-06	0.00189	-0.25	-0.2	Mean platelet volume;	chr11:64183057	chr11:64325050~64329504:-
LUAD	cis	rs202072	0.729	rs202038	ENSG00000272379.1	RP1-257A7.5	-4.47	9.59e-06	0.00189	-0.32	-0.2	HIV-1 viral setpoint;	chr6:13288416	chr6:13290018~13290490:-
LUAD	cis	rs2976388	0.669	rs2976391	ENSG00000253741.1	CTD-2292P10.4	-4.47	9.6e-06	0.00189	-0.23	-0.2	Urinary tract infection frequency;	chr8:142681306	chr8:142702252~142726973:-
LUAD	cis	rs2742234	0.554	rs1254963	ENSG00000273008.1	RP11-351D16.3	4.47	9.6e-06	0.00189	0.23	0.2	Hirschsprung disease;	chr10:43200638	chr10:43136824~43138334:-
LUAD	cis	rs2742234	0.59	rs1254962	ENSG00000273008.1	RP11-351D16.3	4.47	9.6e-06	0.00189	0.23	0.2	Hirschsprung disease;	chr10:43201544	chr10:43136824~43138334:-
LUAD	cis	rs2742234	0.59	rs1254960	ENSG00000273008.1	RP11-351D16.3	4.47	9.6e-06	0.00189	0.23	0.2	Hirschsprung disease;	chr10:43204209	chr10:43136824~43138334:-
LUAD	cis	rs9545047	0.604	rs7327603	ENSG00000227354.5	RBM26-AS1	4.47	9.6e-06	0.00189	0.21	0.2	Schizophrenia;	chr13:79366676	chr13:79406309~79424328:+
LUAD	cis	rs62355900	0.627	rs60985357	ENSG00000271828.1	CTD-2310F14.1	4.47	9.6e-06	0.00189	0.38	0.2	Endometriosis;	chr5:56827875	chr5:56927874~56929573:+
LUAD	cis	rs62355900	0.627	rs16886383	ENSG00000271828.1	CTD-2310F14.1	4.47	9.6e-06	0.00189	0.38	0.2	Endometriosis;	chr5:56829869	chr5:56927874~56929573:+
LUAD	cis	rs62355900	0.627	rs62358073	ENSG00000271828.1	CTD-2310F14.1	4.47	9.6e-06	0.00189	0.38	0.2	Endometriosis;	chr5:56831013	chr5:56927874~56929573:+
LUAD	cis	rs62355900	0.627	rs726501	ENSG00000271828.1	CTD-2310F14.1	4.47	9.6e-06	0.00189	0.38	0.2	Endometriosis;	chr5:56832039	chr5:56927874~56929573:+
LUAD	cis	rs228614	0.509	rs223480	ENSG00000251288.2	RP11-10L12.2	-4.47	9.61e-06	0.00189	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766881	chr4:102751401~102752641:+
LUAD	cis	rs7804306	0.579	rs13245462	ENSG00000233264.2	AC006042.8	4.47	9.61e-06	0.00189	0.29	0.2	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8034978	chr7:7980312~7982228:+
LUAD	cis	rs9532669	0.926	rs7329302	ENSG00000239827.7	SUGT1P3	4.47	9.61e-06	0.00189	0.23	0.2	Cervical cancer;	chr13:40962396	chr13:40908159~40921774:-
LUAD	cis	rs1876905	0.597	rs1215964	ENSG00000255389.1	C6orf3	4.47	9.61e-06	0.00189	0.28	0.2	Mean corpuscular hemoglobin;	chr6:111225666	chr6:111599875~111602295:+
LUAD	cis	rs9309473	0.583	rs6705203	ENSG00000163016.8	ALMS1P	4.47	9.61e-06	0.00189	0.23	0.2	Metabolite levels;	chr2:73347472	chr2:73644919~73685576:+
LUAD	cis	rs66823261	0.741	rs7841786	ENSG00000272240.1	RP5-855D21.1	4.47	9.61e-06	0.00189	0.22	0.2	Breast cancer (estrogen-receptor negative);Breast cancer;	chr8:241746	chr8:234347~234887:-
LUAD	cis	rs755249	0.508	rs586057	ENSG00000228060.1	RP11-69E11.8	-4.47	9.61e-06	0.00189	-0.18	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39393122	chr1:39565160~39573203:+
LUAD	cis	rs801193	0.935	rs11772264	ENSG00000224316.1	RP11-479O9.2	4.47	9.61e-06	0.00189	0.2	0.2	Aortic root size;	chr7:66711400	chr7:65773620~65802067:+
LUAD	cis	rs7772486	0.754	rs9497419	ENSG00000235652.6	RP11-545I5.3	4.47	9.61e-06	0.00189	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145821473	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.754	rs6921073	ENSG00000235652.6	RP11-545I5.3	4.47	9.61e-06	0.00189	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145823241	chr6:145799409~145886585:+
LUAD	cis	rs7826238	0.653	rs2979202	ENSG00000173295.6	FAM86B3P	4.47	9.62e-06	0.00189	0.21	0.2	Systolic blood pressure;	chr8:8486617	chr8:8228595~8244865:+
LUAD	cis	rs1005277	0.579	rs11011461	ENSG00000263064.2	RP11-291L22.7	4.47	9.63e-06	0.0019	0.21	0.2	Extrinsic epigenetic age acceleration;	chr10:38142499	chr10:38448689~38448949:+
LUAD	cis	rs7119038	0.731	rs28409215	ENSG00000255422.1	AP002954.4	4.47	9.63e-06	0.0019	0.31	0.2	Sjögren's syndrome;	chr11:118808595	chr11:118704607~118750263:+
LUAD	cis	rs950169	0.614	rs12903883	ENSG00000259728.4	LINC00933	4.47	9.64e-06	0.0019	0.31	0.2	Schizophrenia;	chr15:84011801	chr15:84570649~84580175:+
LUAD	cis	rs7937890	0.572	rs2597218	ENSG00000254418.1	RP11-21L19.1	4.47	9.64e-06	0.0019	0.25	0.2	Mitochondrial DNA levels;	chr11:14510792	chr11:14262846~14273691:-
LUAD	cis	rs2562152	0.744	rs1045001	ENSG00000226942.2	IL9RP3	4.47	9.64e-06	0.0019	0.27	0.2	Glioblastoma;	chr16:57275	chr16:29336~38321:-
LUAD	cis	rs77688320	0.553	rs2540449	ENSG00000213090.2	AC007256.5	-4.47	9.65e-06	0.0019	-0.23	-0.2	Breast cancer;	chr2:201451036	chr2:201410544~201413308:-
LUAD	cis	rs453301	0.624	rs2979265	ENSG00000253981.4	ALG1L13P	4.47	9.65e-06	0.0019	0.24	0.2	Joint mobility (Beighton score);	chr8:9001207	chr8:8236003~8244667:-
LUAD	cis	rs74233809	1	rs17115213	ENSG00000213277.3	MARCKSL1P1	4.47	9.65e-06	0.0019	0.35	0.2	Birth weight;	chr10:102921386	chr10:103175554~103176094:+
LUAD	cis	rs9467773	1	rs9467782	ENSG00000261353.1	CTA-14H9.5	-4.47	9.65e-06	0.0019	-0.22	-0.2	Intelligence (multi-trait analysis);	chr6:26542545	chr6:26527063~26527404:+
LUAD	cis	rs9467773	0.935	rs9461270	ENSG00000261353.1	CTA-14H9.5	-4.47	9.65e-06	0.0019	-0.22	-0.2	Intelligence (multi-trait analysis);	chr6:26543882	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs1884946	ENSG00000261353.1	CTA-14H9.5	-4.47	9.65e-06	0.0019	-0.22	-0.2	Intelligence (multi-trait analysis);	chr6:26545080	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs4871	ENSG00000261353.1	CTA-14H9.5	-4.47	9.65e-06	0.0019	-0.22	-0.2	Intelligence (multi-trait analysis);	chr6:26545404	chr6:26527063~26527404:+
LUAD	cis	rs12554020	0.786	rs12551314	ENSG00000227603.1	RP11-165J3.6	4.47	9.66e-06	0.0019	0.33	0.2	Schizophrenia;	chr9:93617515	chr9:93435332~93437121:-
LUAD	cis	rs11168351	0.927	rs11168342	ENSG00000257735.1	RP11-370I10.6	4.47	9.67e-06	0.0019	0.24	0.2	Bipolar disorder and schizophrenia;	chr12:47990014	chr12:48350945~48442411:+
LUAD	cis	rs72634501	0.542	rs2134472	ENSG00000228060.1	RP11-69E11.8	4.47	9.67e-06	0.0019	0.18	0.2	HDL cholesterol;	chr1:39137542	chr1:39565160~39573203:+
LUAD	cis	rs228614	0.51	rs223392	ENSG00000251288.2	RP11-10L12.2	-4.47	9.67e-06	0.0019	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102824599	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.554	rs223390	ENSG00000251288.2	RP11-10L12.2	-4.47	9.67e-06	0.0019	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102827640	chr4:102751401~102752641:+
LUAD	cis	rs35740288	0.539	rs4843101	ENSG00000259407.1	RP11-158M2.3	-4.47	9.67e-06	0.0019	-0.23	-0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85796430	chr15:85744109~85750281:-
LUAD	cis	rs9425766	0.679	rs12079063	ENSG00000227373.4	RP11-160H22.5	4.47	9.67e-06	0.0019	0.25	0.2	Life satisfaction;	chr1:174110447	chr1:174115300~174160004:-
LUAD	cis	rs2836754	1	rs2836754	ENSG00000205622.8	AF064858.6	4.47	9.67e-06	0.0019	0.22	0.2	Body mass index;Crohn's disease;	chr21:38919816	chr21:38863676~38956467:-
LUAD	cis	rs9926296	0.744	rs164747	ENSG00000260259.1	RP11-368I7.4	4.47	9.68e-06	0.0019	0.19	0.2	Vitiligo;	chr16:89642272	chr16:89682620~89686569:-
LUAD	cis	rs4819052	0.819	rs13046807	ENSG00000237664.1	LINC00316	-4.47	9.68e-06	0.0019	-0.24	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252371	chr21:45338590~45341990:-
LUAD	cis	rs7208859	0.573	rs73267873	ENSG00000280069.1	CTD-2349P21.3	-4.47	9.68e-06	0.00191	-0.25	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741439	chr17:30738182~30740275:+
LUAD	cis	rs17826219	0.561	rs4085382	ENSG00000280069.1	CTD-2349P21.3	-4.47	9.68e-06	0.00191	-0.25	-0.2	Body mass index;	chr17:30744184	chr17:30738182~30740275:+
LUAD	cis	rs9425766	0.679	rs2860846	ENSG00000227373.4	RP11-160H22.5	4.47	9.68e-06	0.00191	0.25	0.2	Life satisfaction;	chr1:174106786	chr1:174115300~174160004:-
LUAD	cis	rs9425766	0.679	rs2860847	ENSG00000227373.4	RP11-160H22.5	4.47	9.68e-06	0.00191	0.25	0.2	Life satisfaction;	chr1:174106787	chr1:174115300~174160004:-
LUAD	cis	rs9425766	0.679	rs6672986	ENSG00000227373.4	RP11-160H22.5	4.47	9.68e-06	0.00191	0.25	0.2	Life satisfaction;	chr1:174107726	chr1:174115300~174160004:-
LUAD	cis	rs9425766	0.679	rs7526024	ENSG00000227373.4	RP11-160H22.5	4.47	9.68e-06	0.00191	0.25	0.2	Life satisfaction;	chr1:174109722	chr1:174115300~174160004:-
LUAD	cis	rs9425766	0.679	rs12094341	ENSG00000227373.4	RP11-160H22.5	4.47	9.68e-06	0.00191	0.25	0.2	Life satisfaction;	chr1:174110562	chr1:174115300~174160004:-
LUAD	cis	rs896854	0.714	rs572547	ENSG00000253528.2	RP11-347C18.4	-4.47	9.68e-06	0.00191	-0.2	-0.2	Type 2 diabetes;	chr8:94954058	chr8:94974573~94974853:-
LUAD	cis	rs2227564	0.62	rs7098573	ENSG00000271816.1	BMS1P4	4.47	9.69e-06	0.00191	0.19	0.2	Crohn's disease;Inflammatory bowel disease;	chr10:73820256	chr10:73699151~73730487:-
LUAD	cis	rs7829975	0.582	rs448231	ENSG00000173295.6	FAM86B3P	-4.47	9.69e-06	0.00191	-0.21	-0.2	Mood instability;	chr8:8932549	chr8:8228595~8244865:+
LUAD	cis	rs7937890	0.668	rs12361851	ENSG00000254418.1	RP11-21L19.1	-4.47	9.69e-06	0.00191	-0.23	-0.2	Mitochondrial DNA levels;	chr11:14246122	chr11:14262846~14273691:-
LUAD	cis	rs10129255	1	rs10129319	ENSG00000211967.3	IGHV3-53	-4.47	9.69e-06	0.00191	-0.15	-0.2	Kawasaki disease;	chr14:106767996	chr14:106592676~106593347:-
LUAD	cis	rs3758785	0.679	rs13447595	ENSG00000255893.1	RP11-685N10.1	-4.47	9.69e-06	0.00191	-0.28	-0.2	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94489524	chr11:94472908~94473570:-
LUAD	cis	rs2243480	1	rs35820085	ENSG00000226002.1	RP11-460N20.5	-4.47	9.7e-06	0.00191	-0.34	-0.2	Diabetic kidney disease;	chr7:65977771	chr7:65084103~65100232:+
LUAD	cis	rs7945705	0.791	rs4579928	ENSG00000254860.4	TMEM9B-AS1	-4.47	9.7e-06	0.00191	-0.22	-0.2	Hemoglobin concentration;	chr11:8794157	chr11:8964675~8977527:+
LUAD	cis	rs7204230	0.921	rs62047990	ENSG00000261291.1	RP11-295M3.2	4.47	9.7e-06	0.00191	0.26	0.2	Fibrinogen;	chr16:53137752	chr16:53168522~53169450:+
LUAD	cis	rs7208859	0.573	rs79505916	ENSG00000266490.1	CTD-2349P21.9	4.47	9.7e-06	0.00191	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30735308	chr17:30792372~30792833:+
LUAD	cis	rs910316	1	rs10873275	ENSG00000279594.1	RP11-950C14.10	4.47	9.7e-06	0.00191	0.23	0.2	Height;	chr14:75064757	chr14:75011269~75012851:-
LUAD	cis	rs5758511	0.68	rs5758692	ENSG00000226450.2	CYP2D8P	4.47	9.71e-06	0.00191	0.19	0.2	Birth weight;	chr22:42273023	chr22:42149886~42155001:-
LUAD	cis	rs2617170	0.961	rs1841958	ENSG00000245648.1	RP11-277P12.20	4.47	9.71e-06	0.00191	0.25	0.2	Behcet's disease;	chr12:10409490	chr12:10363769~10398506:+
LUAD	cis	rs453301	0.571	rs2929454	ENSG00000253981.4	ALG1L13P	-4.47	9.71e-06	0.00191	-0.23	-0.2	Joint mobility (Beighton score);	chr8:9226344	chr8:8236003~8244667:-
LUAD	cis	rs17772222	0.63	rs8017811	ENSG00000258789.1	RP11-507K2.3	4.47	9.71e-06	0.00191	0.24	0.2	Coronary artery calcification;	chr14:88534559	chr14:88551597~88552493:+
LUAD	cis	rs6479891	0.908	rs11817901	ENSG00000232075.1	MRPL35P2	4.47	9.71e-06	0.00191	0.34	0.2	Arthritis (juvenile idiopathic);	chr10:63580123	chr10:63634317~63634827:-
LUAD	cis	rs10129255	0.957	rs10136781	ENSG00000211967.3	IGHV3-53	-4.47	9.71e-06	0.00191	-0.15	-0.2	Kawasaki disease;	chr14:106780451	chr14:106592676~106593347:-
LUAD	cis	rs10129255	0.957	rs8022165	ENSG00000211967.3	IGHV3-53	-4.47	9.71e-06	0.00191	-0.15	-0.2	Kawasaki disease;	chr14:106781682	chr14:106592676~106593347:-
LUAD	cis	rs10129255	0.917	rs8022493	ENSG00000211967.3	IGHV3-53	-4.47	9.71e-06	0.00191	-0.15	-0.2	Kawasaki disease;	chr14:106781820	chr14:106592676~106593347:-
LUAD	cis	rs1502337	0.561	rs12313391	ENSG00000278993.1	RP3-424M6.4	4.47	9.71e-06	0.00191	0.25	0.2	Body mass index;	chr12:110359925	chr12:110501614~110503441:+
LUAD	cis	rs2898681	0.614	rs11947787	ENSG00000248375.1	RP11-177B4.1	-4.47	9.71e-06	0.00191	-0.29	-0.2	Optic nerve measurement (cup area);	chr4:52839058	chr4:52720081~52720831:-
LUAD	cis	rs9545047	0.604	rs3752994	ENSG00000227354.5	RBM26-AS1	4.47	9.72e-06	0.00191	0.21	0.2	Schizophrenia;	chr13:79345076	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.567	rs4884129	ENSG00000227354.5	RBM26-AS1	4.47	9.72e-06	0.00191	0.21	0.2	Schizophrenia;	chr13:79346448	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.567	rs1410336	ENSG00000227354.5	RBM26-AS1	4.47	9.72e-06	0.00191	0.21	0.2	Schizophrenia;	chr13:79347598	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs9565492	ENSG00000227354.5	RBM26-AS1	4.47	9.72e-06	0.00191	0.21	0.2	Schizophrenia;	chr13:79348554	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs9318625	ENSG00000227354.5	RBM26-AS1	4.47	9.72e-06	0.00191	0.21	0.2	Schizophrenia;	chr13:79351429	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs9530899	ENSG00000227354.5	RBM26-AS1	4.47	9.72e-06	0.00191	0.21	0.2	Schizophrenia;	chr13:79352461	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs7338677	ENSG00000227354.5	RBM26-AS1	4.47	9.72e-06	0.00191	0.21	0.2	Schizophrenia;	chr13:79352580	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs7322744	ENSG00000227354.5	RBM26-AS1	4.47	9.72e-06	0.00191	0.21	0.2	Schizophrenia;	chr13:79354070	chr13:79406309~79424328:+
LUAD	cis	rs911555	0.723	rs12894652	ENSG00000244691.1	RPL10AP1	4.47	9.72e-06	0.00191	0.27	0.2	Intelligence (multi-trait analysis);	chr14:103459687	chr14:103412119~103412761:-
LUAD	cis	rs11722779	0.935	rs11938650	ENSG00000251288.2	RP11-10L12.2	-4.47	9.72e-06	0.00191	-0.24	-0.2	Schizophrenia;	chr4:103021639	chr4:102751401~102752641:+
LUAD	cis	rs1008375	1	rs1006722	ENSG00000249502.1	AC006160.5	4.47	9.73e-06	0.00191	0.19	0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17617090	chr4:17587467~17614571:-
LUAD	cis	rs7119	0.717	rs62007348	ENSG00000259362.2	RP11-307C19.1	-4.47	9.73e-06	0.00191	-0.25	-0.2	Type 2 diabetes;	chr15:77512159	chr15:77525540~77534110:+
LUAD	cis	rs8030379	1	rs11259931	ENSG00000230373.7	GOLGA6L5P	4.47	9.73e-06	0.00191	0.18	0.2	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83911270	chr15:84507885~84516814:-
LUAD	cis	rs6687758	0.945	rs17011182	ENSG00000200033.1	RNU6-403P	4.47	9.73e-06	0.00192	0.27	0.2	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221990985	chr1:221837334~221837437:-
LUAD	cis	rs11673344	0.796	rs9676450	ENSG00000226686.6	LINC01535	4.47	9.73e-06	0.00192	0.26	0.2	Obesity-related traits;	chr19:36998505	chr19:37251912~37265535:+
LUAD	cis	rs10761482	0.566	rs4505011	ENSG00000254271.1	RP11-131N11.4	4.47	9.74e-06	0.00192	0.24	0.2	Schizophrenia;	chr10:60440550	chr10:60734342~60741828:+
LUAD	cis	rs6840360	0.55	rs62327349	ENSG00000270265.1	RP11-731D1.4	-4.47	9.74e-06	0.00192	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151706078	chr4:151333775~151353224:-
LUAD	cis	rs987724	0.778	rs2321295	ENSG00000240875.4	LINC00886	-4.47	9.74e-06	0.00192	-0.22	-0.2	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156944556	chr3:156747346~156817062:-
LUAD	cis	rs9425766	0.679	rs12079062	ENSG00000227373.4	RP11-160H22.5	4.47	9.74e-06	0.00192	0.25	0.2	Life satisfaction;	chr1:174110446	chr1:174115300~174160004:-
LUAD	cis	rs45509595	0.841	rs200485	ENSG00000219392.1	RP1-265C24.5	-4.47	9.75e-06	0.00192	-0.38	-0.2	Breast cancer;	chr6:27807919	chr6:28115628~28116551:+
LUAD	cis	rs13113518	0.812	rs11945371	ENSG00000223305.1	RN7SKP30	4.47	9.75e-06	0.00192	0.23	0.2	Height;	chr4:55409063	chr4:55540502~55540835:-
LUAD	cis	rs6570726	1	rs436066	ENSG00000235652.6	RP11-545I5.3	4.47	9.75e-06	0.00192	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145525991	chr6:145799409~145886585:+
LUAD	cis	rs2711721	0.557	rs2711715	ENSG00000274723.1	RP11-618L22.1	4.47	9.75e-06	0.00192	0.25	0.2	Prostate cancer (SNP x SNP interaction);	chr12:47020031	chr12:46970504~46972155:+
LUAD	cis	rs2735413	0.67	rs11861339	ENSG00000276007.1	RP11-358L22.3	4.47	9.75e-06	0.00192	0.25	0.2	Systolic blood pressure (alcohol consumption interaction);	chr16:78060493	chr16:78123243~78124332:+
LUAD	cis	rs4372836	1	rs7598876	ENSG00000226833.4	AC097724.3	4.47	9.76e-06	0.00192	0.23	0.2	Body mass index;	chr2:28751600	chr2:28708953~28736205:-
LUAD	cis	rs8040855	0.86	rs7172266	ENSG00000259774.1	RP11-182J1.13	-4.47	9.76e-06	0.00192	-0.24	-0.2	Bulimia nervosa;	chr15:85172982	chr15:84422618~84425882:+
LUAD	cis	rs7968440	0.554	rs861204	ENSG00000200428.1	Y_RNA	4.47	9.76e-06	0.00192	0.24	0.2	Fibrinogen;	chr12:50844033	chr12:50743568~50743684:+
LUAD	cis	rs9652601	0.845	rs7184615	ENSG00000274038.1	RP11-66H6.4	-4.47	9.77e-06	0.00192	-0.24	-0.2	Systemic lupus erythematosus;	chr16:11071685	chr16:11056556~11057034:+
LUAD	cis	rs875971	0.651	rs313829	ENSG00000222364.1	RNU6-96P	4.47	9.77e-06	0.00192	0.25	0.2	Aortic root size;	chr7:66087510	chr7:66395191~66395286:+
LUAD	cis	rs8050896	1	rs13332122	ENSG00000260695.1	RP11-513N24.1	-4.47	9.77e-06	0.00192	-0.36	-0.2	Response to antipsychotic treatment;	chr16:66125732	chr16:65861112~65863784:-
LUAD	cis	rs8050896	1	rs13332162	ENSG00000260695.1	RP11-513N24.1	-4.47	9.77e-06	0.00192	-0.36	-0.2	Response to antipsychotic treatment;	chr16:66125795	chr16:65861112~65863784:-
LUAD	cis	rs9341808	0.718	rs1324123	ENSG00000260645.1	RP11-250B2.5	4.47	9.77e-06	0.00192	0.19	0.2	Sitting height ratio;	chr6:80223177	chr6:80466958~80469080:+
LUAD	cis	rs2243480	1	rs778679	ENSG00000232559.3	GS1-124K5.12	4.47	9.77e-06	0.00192	0.35	0.2	Diabetic kidney disease;	chr7:66375924	chr7:66554588~66576923:-
LUAD	cis	rs453301	0.597	rs7001187	ENSG00000173295.6	FAM86B3P	-4.47	9.77e-06	0.00192	-0.22	-0.2	Joint mobility (Beighton score);	chr8:8935272	chr8:8228595~8244865:+
LUAD	cis	rs17772222	0.565	rs845759	ENSG00000258789.1	RP11-507K2.3	4.47	9.78e-06	0.00192	0.25	0.2	Coronary artery calcification;	chr14:88415538	chr14:88551597~88552493:+
LUAD	cis	rs6570726	0.791	rs9373464	ENSG00000235652.6	RP11-545I5.3	4.47	9.78e-06	0.00192	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145586031	chr6:145799409~145886585:+
LUAD	cis	rs228614	0.51	rs223405	ENSG00000251288.2	RP11-10L12.2	-4.47	9.79e-06	0.00192	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102815894	chr4:102751401~102752641:+
LUAD	cis	rs2562456	0.793	rs7259396	ENSG00000268081.1	RP11-678G14.2	4.47	9.79e-06	0.00192	0.32	0.2	Pain;	chr19:21340661	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.678	rs7260140	ENSG00000268081.1	RP11-678G14.2	4.47	9.79e-06	0.00192	0.32	0.2	Pain;	chr19:21340723	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.833	rs11880624	ENSG00000268081.1	RP11-678G14.2	4.47	9.79e-06	0.00192	0.32	0.2	Pain;	chr19:21341028	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.833	rs62107547	ENSG00000268081.1	RP11-678G14.2	4.47	9.79e-06	0.00192	0.32	0.2	Pain;	chr19:21341245	chr19:21554640~21569237:-
LUAD	cis	rs13113518	0.812	rs2035692	ENSG00000223305.1	RN7SKP30	4.47	9.79e-06	0.00192	0.23	0.2	Height;	chr4:55528801	chr4:55540502~55540835:-
LUAD	cis	rs11673344	0.864	rs79927931	ENSG00000226686.6	LINC01535	4.47	9.79e-06	0.00192	0.25	0.2	Obesity-related traits;	chr19:37012241	chr19:37251912~37265535:+
LUAD	cis	rs11673344	0.864	rs11670216	ENSG00000226686.6	LINC01535	4.47	9.79e-06	0.00192	0.25	0.2	Obesity-related traits;	chr19:37012526	chr19:37251912~37265535:+
LUAD	cis	rs11673344	0.864	rs8104919	ENSG00000226686.6	LINC01535	4.47	9.79e-06	0.00192	0.25	0.2	Obesity-related traits;	chr19:37012881	chr19:37251912~37265535:+
LUAD	cis	rs9341808	0.718	rs1324123	ENSG00000272129.1	RP11-250B2.6	4.47	9.79e-06	0.00193	0.25	0.2	Sitting height ratio;	chr6:80223177	chr6:80355424~80356859:+
LUAD	cis	rs55823223	0.564	rs1463485	ENSG00000267801.1	RP11-552F3.9	4.47	9.79e-06	0.00193	0.22	0.2	Psoriasis;	chr17:75855710	chr17:75876372~75879546:+
LUAD	cis	rs4908769	0.659	rs12144098	ENSG00000270282.1	RP5-1115A15.2	4.47	9.8e-06	0.00193	0.22	0.2	Allergy;	chr1:8756114	chr1:8512653~8513021:+
LUAD	cis	rs9650657	0.504	rs10093053	ENSG00000255046.1	RP11-297N6.4	4.47	9.8e-06	0.00193	0.24	0.2	Neuroticism;	chr8:11179678	chr8:11797928~11802568:-
LUAD	cis	rs1729951	0.575	rs361241	ENSG00000239213.4	NCK1-AS1	4.47	9.8e-06	0.00193	0.22	0.2	Neuroticism;	chr3:136980719	chr3:136841726~136862054:-
LUAD	cis	rs7829975	0.684	rs488904	ENSG00000253893.2	FAM85B	4.47	9.8e-06	0.00193	0.24	0.2	Mood instability;	chr8:8730061	chr8:8167819~8226614:-
LUAD	cis	rs2153535	0.585	rs9328498	ENSG00000230939.1	RP11-314C16.1	-4.47	9.8e-06	0.00193	-0.22	-0.2	Motion sickness;	chr6:8623536	chr6:8784178~8785445:+
LUAD	cis	rs9545047	0.567	rs2296287	ENSG00000227354.5	RBM26-AS1	4.47	9.81e-06	0.00193	0.21	0.2	Schizophrenia;	chr13:79407045	chr13:79406309~79424328:+
LUAD	cis	rs1012068	0.96	rs12167583	ENSG00000236132.1	CTA-440B3.1	-4.47	9.81e-06	0.00193	-0.26	-0.2	Chronic hepatitis C infection;	chr22:31873725	chr22:31816379~31817491:-
LUAD	cis	rs13113518	0.776	rs13124436	ENSG00000223305.1	RN7SKP30	4.47	9.81e-06	0.00193	0.23	0.2	Height;	chr4:55502504	chr4:55540502~55540835:-
LUAD	cis	rs11673344	0.526	rs2306201	ENSG00000226686.6	LINC01535	4.47	9.82e-06	0.00193	0.25	0.2	Obesity-related traits;	chr19:37586573	chr19:37251912~37265535:+
LUAD	cis	rs11886999	0.767	rs62153029	ENSG00000237510.6	AC008268.2	-4.47	9.82e-06	0.00193	-0.33	-0.2	Cardiac Troponin-T levels;	chr2:96255255	chr2:95789654~95800166:+
LUAD	cis	rs7665090	1	rs7665090	ENSG00000246560.2	RP11-10L12.4	-4.47	9.82e-06	0.00193	-0.24	-0.2	Primary biliary cholangitis;	chr4:102630446	chr4:102828055~102844075:+
LUAD	cis	rs2395128	0.519	rs10824261	ENSG00000213731.2	RAB5CP1	4.47	9.82e-06	0.00193	0.38	0.2	Ulcerative colitis;Inflammatory bowel disease;	chr10:75061324	chr10:74423435~74424014:-
LUAD	cis	rs2303759	0.709	rs10411679	ENSG00000268686.1	AC010524.2	-4.47	9.82e-06	0.00193	-0.3	-0.2	Multiple sclerosis;	chr19:49323223	chr19:49368705~49388081:-
LUAD	cis	rs950169	0.922	rs62029585	ENSG00000275120.1	RP11-182J1.17	4.47	9.82e-06	0.00193	0.31	0.2	Schizophrenia;	chr15:84397176	chr15:84599434~84606463:-
LUAD	cis	rs11971779	0.715	rs7787398	ENSG00000273391.1	RP11-634H22.1	4.47	9.82e-06	0.00193	0.21	0.2	Diisocyanate-induced asthma;	chr7:139377100	chr7:139359032~139359566:-
LUAD	cis	rs1008375	0.931	rs2315558	ENSG00000249502.1	AC006160.5	-4.47	9.83e-06	0.00193	-0.19	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17672935	chr4:17587467~17614571:-
LUAD	cis	rs1008375	1	rs2215450	ENSG00000249502.1	AC006160.5	-4.47	9.83e-06	0.00193	-0.19	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17673771	chr4:17587467~17614571:-
LUAD	cis	rs2243480	0.901	rs778687	ENSG00000232559.3	GS1-124K5.12	4.47	9.83e-06	0.00193	0.35	0.2	Diabetic kidney disease;	chr7:66370832	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs778704	ENSG00000232559.3	GS1-124K5.12	4.47	9.83e-06	0.00193	0.35	0.2	Diabetic kidney disease;	chr7:66398480	chr7:66554588~66576923:-
LUAD	cis	rs2243480	0.901	rs778693	ENSG00000232559.3	GS1-124K5.12	4.47	9.83e-06	0.00193	0.35	0.2	Diabetic kidney disease;	chr7:66407358	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs778691	ENSG00000232559.3	GS1-124K5.12	4.47	9.83e-06	0.00193	0.35	0.2	Diabetic kidney disease;	chr7:66408105	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs13235972	ENSG00000232559.3	GS1-124K5.12	4.47	9.83e-06	0.00193	0.35	0.2	Diabetic kidney disease;	chr7:66418618	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs34192067	ENSG00000232559.3	GS1-124K5.12	4.47	9.83e-06	0.00193	0.35	0.2	Diabetic kidney disease;	chr7:66422670	chr7:66554588~66576923:-
LUAD	cis	rs7429990	0.932	rs6766641	ENSG00000228638.1	FCF1P2	4.47	9.83e-06	0.00193	0.24	0.2	Educational attainment (years of education);	chr3:48103734	chr3:48290793~48291375:-
LUAD	cis	rs73173548	0.502	rs13185071	ENSG00000247828.6	TMEM161B-AS1	4.47	9.83e-06	0.00193	0.25	0.2	Macular telangiectasia type 2;	chr5:88429895	chr5:88268895~88436685:+
LUAD	cis	rs2243480	1	rs10247526	ENSG00000232559.3	GS1-124K5.12	-4.47	9.83e-06	0.00193	-0.35	-0.2	Diabetic kidney disease;	chr7:66315709	chr7:66554588~66576923:-
LUAD	cis	rs6496932	0.802	rs56306166	ENSG00000218052.5	ADAMTS7P4	4.47	9.84e-06	0.00193	0.23	0.2	Central corneal thickness;Corneal structure;	chr15:85326848	chr15:85255369~85330334:-
LUAD	cis	rs6964587	1	rs6970277	ENSG00000188693.7	CYP51A1-AS1	-4.47	9.84e-06	0.00193	-0.24	-0.2	Breast cancer;	chr7:92051341	chr7:92134604~92180725:+
LUAD	cis	rs7772486	0.727	rs12190966	ENSG00000235652.6	RP11-545I5.3	4.47	9.84e-06	0.00193	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145825684	chr6:145799409~145886585:+
LUAD	cis	rs227275	0.556	rs12508069	ENSG00000251288.2	RP11-10L12.2	-4.47	9.84e-06	0.00193	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102983598	chr4:102751401~102752641:+
LUAD	cis	rs2227564	0.62	rs10740418	ENSG00000271816.1	BMS1P4	4.47	9.84e-06	0.00193	0.19	0.2	Crohn's disease;Inflammatory bowel disease;	chr10:73759564	chr10:73699151~73730487:-
LUAD	cis	rs763121	0.853	rs5757193	ENSG00000228274.3	RP3-508I15.9	4.47	9.84e-06	0.00193	0.2	0.2	Menopause (age at onset);	chr22:38638862	chr22:38667585~38681820:-
LUAD	cis	rs12478296	1	rs57603292	ENSG00000261186.2	RP11-341N2.1	-4.47	9.85e-06	0.00193	-0.36	-0.2	Obesity-related traits;	chr2:242086386	chr2:242087351~242088457:-
LUAD	cis	rs1447352	0.715	rs10765576	ENSG00000279684.1	RP11-755E23.2	-4.47	9.85e-06	0.00193	-0.24	-0.2	Metabolic traits;	chr11:92973778	chr11:93286629~93288903:-
LUAD	cis	rs6723108	0.627	rs2053726	ENSG00000224043.6	CCNT2-AS1	-4.47	9.85e-06	0.00194	-0.25	-0.2	Type 2 diabetes;	chr2:134852584	chr2:134735464~134918710:-
LUAD	cis	rs453301	0.652	rs2043129	ENSG00000253893.2	FAM85B	-4.47	9.85e-06	0.00194	-0.24	-0.2	Joint mobility (Beighton score);	chr8:8967994	chr8:8167819~8226614:-
LUAD	cis	rs4811196	0.748	rs4811240	ENSG00000226144.2	RPS27AP3	4.47	9.86e-06	0.00194	0.22	0.2	Bone mineral density;	chr20:37864674	chr20:37049254~37049707:+
LUAD	cis	rs4811196	0.719	rs4811242	ENSG00000226144.2	RPS27AP3	4.47	9.86e-06	0.00194	0.22	0.2	Bone mineral density;	chr20:37865513	chr20:37049254~37049707:+
LUAD	cis	rs4811196	0.748	rs4811245	ENSG00000226144.2	RPS27AP3	4.47	9.86e-06	0.00194	0.22	0.2	Bone mineral density;	chr20:37866975	chr20:37049254~37049707:+
LUAD	cis	rs1501911	0.566	rs709388	ENSG00000248489.1	CTD-2007H13.3	4.47	9.87e-06	0.00194	0.25	0.2	Lung function (FEV1/FVC);	chr5:98994037	chr5:98929171~98995013:+
LUAD	cis	rs10090774	0.71	rs11166986	ENSG00000280303.2	ERICD	4.47	9.88e-06	0.00194	0.22	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140646056	chr8:140636281~140638283:+
LUAD	cis	rs6700559	0.545	rs12744758	ENSG00000260088.1	RP11-92G12.3	4.47	9.88e-06	0.00194	0.25	0.2	Coronary artery disease;	chr1:200624010	chr1:200669507~200694250:+
LUAD	cis	rs7665090	1	rs4013	ENSG00000246560.2	RP11-10L12.4	4.47	9.88e-06	0.00194	0.24	0.2	Primary biliary cholangitis;	chr4:102631656	chr4:102828055~102844075:+
LUAD	cis	rs7665090	0.967	rs4019	ENSG00000246560.2	RP11-10L12.4	4.47	9.88e-06	0.00194	0.24	0.2	Primary biliary cholangitis;	chr4:102631673	chr4:102828055~102844075:+
LUAD	cis	rs1008375	0.966	rs2098152	ENSG00000249502.1	AC006160.5	-4.47	9.88e-06	0.00194	-0.19	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17682769	chr4:17587467~17614571:-
LUAD	cis	rs1008375	1	rs10805359	ENSG00000249502.1	AC006160.5	-4.47	9.88e-06	0.00194	-0.19	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17683263	chr4:17587467~17614571:-
LUAD	cis	rs9467773	0.967	rs7753565	ENSG00000261353.1	CTA-14H9.5	-4.47	9.89e-06	0.00194	-0.22	-0.2	Intelligence (multi-trait analysis);	chr6:26559784	chr6:26527063~26527404:+
LUAD	cis	rs7665090	0.84	rs7674640	ENSG00000246560.2	RP11-10L12.4	4.47	9.89e-06	0.00194	0.25	0.2	Primary biliary cholangitis;	chr4:102619623	chr4:102828055~102844075:+
LUAD	cis	rs8062405	0.755	rs4149398	ENSG00000251417.2	RP11-1348G14.4	-4.47	9.89e-06	0.00194	-0.2	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597617	chr16:28802743~28817828:+
LUAD	cis	rs9341808	0.727	rs9361599	ENSG00000260645.1	RP11-250B2.5	4.47	9.89e-06	0.00194	0.19	0.2	Sitting height ratio;	chr6:80315525	chr6:80466958~80469080:+
LUAD	cis	rs9341808	0.754	rs9352817	ENSG00000260645.1	RP11-250B2.5	4.47	9.89e-06	0.00194	0.19	0.2	Sitting height ratio;	chr6:80316162	chr6:80466958~80469080:+
LUAD	cis	rs4460629	0.742	rs7368345	ENSG00000160766.13	GBAP1	4.47	9.89e-06	0.00194	0.2	0.2	Serum magnesium levels;	chr1:155107614	chr1:155213821~155227422:-
LUAD	cis	rs227275	0.554	rs223359	ENSG00000251288.2	RP11-10L12.2	-4.47	9.9e-06	0.00194	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102849422	chr4:102751401~102752641:+
LUAD	cis	rs57502260	0.573	rs11228294	ENSG00000212093.1	AP000807.1	4.47	9.9e-06	0.00194	0.23	0.2	Total body bone mineral density (age 45-60);	chr11:68621099	chr11:68506083~68506166:-
LUAD	cis	rs6479891	0.908	rs16918603	ENSG00000232075.1	MRPL35P2	4.47	9.9e-06	0.00194	0.34	0.2	Arthritis (juvenile idiopathic);	chr10:63561712	chr10:63634317~63634827:-
LUAD	cis	rs783540	0.521	rs1259176	ENSG00000276710.3	CSPG4P8	4.47	9.9e-06	0.00194	0.21	0.2	Schizophrenia;	chr15:82602149	chr15:82459472~82477258:+
LUAD	cis	rs950169	0.922	rs12915832	ENSG00000275120.1	RP11-182J1.17	4.47	9.91e-06	0.00194	0.31	0.2	Schizophrenia;	chr15:84568226	chr15:84599434~84606463:-
LUAD	cis	rs7590268	0.697	rs10495901	ENSG00000279873.2	LINC01126	4.47	9.91e-06	0.00195	0.2	0.2	Orofacial clefts;	chr2:43390587	chr2:43227210~43228855:+
LUAD	cis	rs6088590	1	rs11696546	ENSG00000276073.1	RP5-1125A11.7	-4.47	9.91e-06	0.00195	-0.2	-0.2	Coronary artery disease;	chr20:34865196	chr20:33985617~33988989:-
LUAD	cis	rs997295	0.52	rs4776971	ENSG00000270964.1	RP11-502I4.3	4.47	9.92e-06	0.00195	0.21	0.2	Motion sickness;	chr15:67788759	chr15:67541072~67542604:-
LUAD	cis	rs4819052	0.851	rs8134392	ENSG00000237664.1	LINC00316	4.47	9.92e-06	0.00195	0.24	0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243875	chr21:45338590~45341990:-
LUAD	cis	rs13113518	1	rs4864999	ENSG00000272969.1	RP11-528I4.2	4.47	9.92e-06	0.00195	0.21	0.2	Height;	chr4:55476736	chr4:55547112~55547889:+
LUAD	cis	rs13113518	0.966	rs12506788	ENSG00000272969.1	RP11-528I4.2	4.47	9.92e-06	0.00195	0.21	0.2	Height;	chr4:55477426	chr4:55547112~55547889:+
LUAD	cis	rs13113518	0.966	rs10517344	ENSG00000272969.1	RP11-528I4.2	4.47	9.92e-06	0.00195	0.21	0.2	Height;	chr4:55477545	chr4:55547112~55547889:+
LUAD	cis	rs9341808	0.718	rs3828754	ENSG00000260645.1	RP11-250B2.5	4.47	9.92e-06	0.00195	0.19	0.2	Sitting height ratio;	chr6:80190923	chr6:80466958~80469080:+
LUAD	cis	rs9341808	0.718	rs10943696	ENSG00000260645.1	RP11-250B2.5	4.47	9.92e-06	0.00195	0.19	0.2	Sitting height ratio;	chr6:80191555	chr6:80466958~80469080:+
LUAD	cis	rs9341808	0.718	rs6910201	ENSG00000260645.1	RP11-250B2.5	4.47	9.92e-06	0.00195	0.19	0.2	Sitting height ratio;	chr6:80195221	chr6:80466958~80469080:+
LUAD	cis	rs9341808	0.69	rs9448909	ENSG00000260645.1	RP11-250B2.5	4.47	9.92e-06	0.00195	0.19	0.2	Sitting height ratio;	chr6:80199314	chr6:80466958~80469080:+
LUAD	cis	rs1799949	0.965	rs9897425	ENSG00000236383.6	LINC00854	-4.47	9.92e-06	0.00195	-0.16	-0.2	Menopause (age at onset);	chr17:43352811	chr17:43216941~43305976:-
LUAD	cis	rs6964833	0.554	rs112506907	ENSG00000184616.8	AC004166.6	4.47	9.92e-06	0.00195	0.26	0.2	Menarche (age at onset);	chr7:74654407	chr7:74906673~74913256:-
LUAD	cis	rs6570726	0.764	rs9403731	ENSG00000235652.6	RP11-545I5.3	4.47	9.92e-06	0.00195	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145586801	chr6:145799409~145886585:+
LUAD	cis	rs7714584	1	rs12652003	ENSG00000197083.10	ZNF300P1	4.47	9.92e-06	0.00195	0.39	0.2	Crohn's disease;	chr5:150852383	chr5:150930645~150946289:-
LUAD	cis	rs6539288	0.901	rs4964193	ENSG00000260329.1	RP11-412D9.4	-4.47	9.92e-06	0.00195	-0.21	-0.2	Total body bone mineral density;	chr12:106927970	chr12:106954029~106955497:-
LUAD	cis	rs2834288	0.5	rs7277248	ENSG00000237945.6	LINC00649	4.47	9.93e-06	0.00195	0.24	0.2	Gut microbiota (bacterial taxa);	chr21:33957948	chr21:33915534~33977691:+
LUAD	cis	rs6714710	0.603	rs13008968	ENSG00000230606.9	AC159540.1	-4.47	9.93e-06	0.00195	-0.21	-0.2	Posterior cortical atrophy and Alzheimer's disease;	chr2:97819519	chr2:97416165~97433527:-
LUAD	cis	rs6081541	0.689	rs723768	ENSG00000179447.2	RP5-1027G4.3	-4.47	9.94e-06	0.00195	-0.21	-0.2	Psychosis (atypical);	chr20:19234998	chr20:19242302~19284596:-
LUAD	cis	rs7829975	0.606	rs10112585	ENSG00000173295.6	FAM86B3P	-4.47	9.94e-06	0.00195	-0.21	-0.2	Mood instability;	chr8:8937520	chr8:8228595~8244865:+
LUAD	cis	rs228614	0.51	rs223451	ENSG00000251288.2	RP11-10L12.2	-4.47	9.94e-06	0.00195	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791032	chr4:102751401~102752641:+
LUAD	cis	rs228614	0.51	rs223450	ENSG00000251288.2	RP11-10L12.2	-4.47	9.94e-06	0.00195	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791052	chr4:102751401~102752641:+
LUAD	cis	rs11673344	0.764	rs565721	ENSG00000226686.6	LINC01535	4.47	9.94e-06	0.00195	0.25	0.2	Obesity-related traits;	chr19:36964929	chr19:37251912~37265535:+
LUAD	cis	rs7324557	0.683	rs9510868	ENSG00000205861.10	C1QTNF9B-AS1	-4.47	9.95e-06	0.00195	-0.26	-0.2	Visceral adipose tissue adjusted for BMI;	chr13:23809555	chr13:23888889~23897263:+
LUAD	cis	rs2243480	1	rs316313	ENSG00000232559.3	GS1-124K5.12	4.47	9.95e-06	0.00195	0.35	0.2	Diabetic kidney disease;	chr7:66128561	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs316312	ENSG00000232559.3	GS1-124K5.12	4.47	9.95e-06	0.00195	0.35	0.2	Diabetic kidney disease;	chr7:66131504	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs419603	ENSG00000232559.3	GS1-124K5.12	4.47	9.95e-06	0.00195	0.35	0.2	Diabetic kidney disease;	chr7:66132354	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs387676	ENSG00000232559.3	GS1-124K5.12	4.47	9.95e-06	0.00195	0.35	0.2	Diabetic kidney disease;	chr7:66133233	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs13310597	ENSG00000232559.3	GS1-124K5.12	4.47	9.95e-06	0.00195	0.35	0.2	Diabetic kidney disease;	chr7:66133553	chr7:66554588~66576923:-
LUAD	cis	rs7819412	0.521	rs10100660	ENSG00000255046.1	RP11-297N6.4	4.47	9.96e-06	0.00195	0.25	0.2	Triglycerides;	chr8:11181376	chr8:11797928~11802568:-
LUAD	cis	rs6957923	0.967	rs11773741	ENSG00000230658.1	KLHL7-AS1	4.47	9.96e-06	0.00195	0.24	0.2	Height;	chr7:23444613	chr7:23101228~23105703:-
LUAD	cis	rs9341808	0.754	rs6916405	ENSG00000260645.1	RP11-250B2.5	4.47	9.96e-06	0.00195	0.19	0.2	Sitting height ratio;	chr6:80314471	chr6:80466958~80469080:+
LUAD	cis	rs699371	0.507	rs10149538	ENSG00000259005.1	RP3-449M8.6	4.47	9.96e-06	0.00195	0.21	0.2	Height;	chr14:74458694	chr14:74474007~74474864:-
LUAD	cis	rs860295	0.702	rs11264397	ENSG00000225855.5	RUSC1-AS1	4.47	9.96e-06	0.00195	0.14	0.2	Body mass index;	chr1:155641694	chr1:155316863~155324176:-
LUAD	cis	rs8072100	0.713	rs2136750	ENSG00000228782.6	CTD-2026D20.3	4.47	9.96e-06	0.00195	0.21	0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378734	chr17:47450568~47492492:-
LUAD	cis	rs8072100	0.607	rs9894594	ENSG00000228782.6	CTD-2026D20.3	4.47	9.96e-06	0.00195	0.21	0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47384017	chr17:47450568~47492492:-
LUAD	cis	rs4819052	0.851	rs8130285	ENSG00000237664.1	LINC00316	-4.47	9.96e-06	0.00195	-0.24	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251786	chr21:45338590~45341990:-
LUAD	cis	rs453301	0.571	rs2929305	ENSG00000253981.4	ALG1L13P	-4.47	9.97e-06	0.00195	-0.23	-0.2	Joint mobility (Beighton score);	chr8:9227707	chr8:8236003~8244667:-
LUAD	cis	rs11065706	0.747	rs1860561	ENSG00000278993.1	RP3-424M6.4	4.47	9.97e-06	0.00195	0.25	0.2	Heart rate;	chr12:110345436	chr12:110501614~110503441:+
LUAD	cis	rs860295	0.702	rs10908479	ENSG00000225855.5	RUSC1-AS1	4.47	9.97e-06	0.00195	0.14	0.2	Body mass index;	chr1:155673612	chr1:155316863~155324176:-
LUAD	cis	rs10129255	1	rs11621409	ENSG00000211974.3	IGHV2-70	4.47	9.97e-06	0.00195	0.22	0.2	Kawasaki disease;	chr14:106695603	chr14:106723574~106724093:-
LUAD	cis	rs7829975	0.667	rs1877119	ENSG00000253893.2	FAM85B	-4.47	9.98e-06	0.00196	-0.25	-0.2	Mood instability;	chr8:8849687	chr8:8167819~8226614:-
LUAD	cis	rs394563	0.601	rs367133	ENSG00000231760.4	RP11-350J20.5	4.47	9.98e-06	0.00196	0.26	0.2	Dupuytren's disease;	chr6:149476584	chr6:149796151~149826294:-
LUAD	cis	rs10129255	0.957	rs12590799	ENSG00000211967.3	IGHV3-53	-4.47	9.98e-06	0.00196	-0.15	-0.2	Kawasaki disease;	chr14:106779713	chr14:106592676~106593347:-
LUAD	cis	rs7339483	0.85	rs8108185	ENSG00000268058.1	BNIP3P40	-4.47	9.99e-06	0.00196	-0.36	-0.2	Discordance in emotional problems in monozygotic twins;	chr19:24239371	chr19:24098425~24098980:-
LUAD	cis	rs7339483	0.867	rs10406126	ENSG00000268058.1	BNIP3P40	-4.47	9.99e-06	0.00196	-0.36	-0.2	Discordance in emotional problems in monozygotic twins;	chr19:24241263	chr19:24098425~24098980:-
LUAD	cis	rs7339483	1	rs10420480	ENSG00000268058.1	BNIP3P40	-4.47	9.99e-06	0.00196	-0.36	-0.2	Discordance in emotional problems in monozygotic twins;	chr19:24245149	chr19:24098425~24098980:-
LUAD	cis	rs13113518	0.966	rs11133387	ENSG00000272969.1	RP11-528I4.2	4.47	9.99e-06	0.00196	0.21	0.2	Height;	chr4:55475130	chr4:55547112~55547889:+
LUAD	cis	rs6723108	0.627	rs6430545	ENSG00000224043.6	CCNT2-AS1	4.46	9.99e-06	0.00196	0.25	0.2	Type 2 diabetes;	chr2:134845031	chr2:134735464~134918710:-
LUAD	cis	rs9341808	0.718	rs3805922	ENSG00000260645.1	RP11-250B2.5	4.46	9.99e-06	0.00196	0.19	0.2	Sitting height ratio;	chr6:80182272	chr6:80466958~80469080:+
LUAD	cis	rs9341808	0.718	rs3805920	ENSG00000260645.1	RP11-250B2.5	4.46	9.99e-06	0.00196	0.19	0.2	Sitting height ratio;	chr6:80183028	chr6:80466958~80469080:+
LUAD	cis	rs12439619	0.846	rs7496227	ENSG00000276710.3	CSPG4P8	-4.46	1e-05	0.00196	-0.23	-0.2	Intelligence (multi-trait analysis);	chr15:82275241	chr15:82459472~82477258:+
LUAD	cis	rs763121	0.853	rs5757162	ENSG00000228274.3	RP3-508I15.9	-4.46	1e-05	0.00196	-0.2	-0.2	Menopause (age at onset);	chr22:38597365	chr22:38667585~38681820:-
LUAD	cis	rs7208859	0.673	rs1347359	ENSG00000280069.1	CTD-2349P21.3	-4.46	1e-05	0.00196	-0.23	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587511	chr17:30738182~30740275:+
LUAD	cis	rs7923837	0.687	rs2185756	ENSG00000236493.2	EIF2S2P3	4.46	1e-05	0.00196	0.23	0.2	Multiple sclerosis;Body mass index;	chr10:92670740	chr10:92668745~92669743:-
LUAD	cis	rs2933343	0.729	rs789231	ENSG00000261159.1	RP11-723O4.9	4.46	1e-05	0.00196	0.22	0.2	IgG glycosylation;	chr3:128884004	chr3:128859716~128860526:-
LUAD	cis	rs13256369	1	rs10110591	ENSG00000253893.2	FAM85B	4.46	1e-05	0.00196	0.27	0.2	Obesity-related traits;	chr8:8719098	chr8:8167819~8226614:-
LUAD	cis	rs4763879	0.593	rs2080206	ENSG00000278635.1	CTD-2318O12.1	4.46	1e-05	0.00196	0.18	0.2	Type 1 diabetes;	chr12:9715370	chr12:9415641~9416718:+
LUAD	cis	rs2032366	0.583	rs1452594	ENSG00000267279.1	RP11-879F14.2	-4.46	1e-05	0.00196	-0.26	-0.2	Obesity-related traits;	chr18:61590689	chr18:61585746~61606916:-
LUAD	cis	rs13113518	1	rs10462032	ENSG00000272969.1	RP11-528I4.2	4.46	1e-05	0.00196	0.21	0.2	Height;	chr4:55479069	chr4:55547112~55547889:+
LUAD	cis	rs750134	1	rs12581386	ENSG00000257221.1	RP11-689B22.2	4.46	1e-05	0.00196	0.31	0.2	Low high density lipoprotein cholesterol levels;	chr12:108689223	chr12:108628687~108641318:+
LUAD	cis	rs1075265	0.587	rs2949812	ENSG00000272156.1	RP11-477N3.1	-4.46	1e-05	0.00196	-0.24	-0.2	Chronotype;Morning vs. evening chronotype;	chr2:53797190	chr2:54082554~54085066:+
LUAD	cis	rs73173548	0.502	rs12516483	ENSG00000247828.6	TMEM161B-AS1	4.46	1e-05	0.00196	0.24	0.2	Macular telangiectasia type 2;	chr5:88454718	chr5:88268895~88436685:+
LUAD	cis	rs1005277	0.579	rs2505198	ENSG00000263064.2	RP11-291L22.7	4.46	1e-05	0.00196	0.21	0.2	Extrinsic epigenetic age acceleration;	chr10:38104255	chr10:38448689~38448949:+
LUAD	cis	rs5760092	0.572	rs738806	ENSG00000099984.9	GSTT2	-4.46	1e-05	0.00196	-0.28	-0.2	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23980123~23983911:+
LUAD	cis	rs875971	0.522	rs4718285	ENSG00000237310.1	GS1-124K5.4	4.46	1e-05	0.00196	0.21	0.2	Aortic root size;	chr7:65827018	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.522	rs4718286	ENSG00000237310.1	GS1-124K5.4	4.46	1e-05	0.00196	0.21	0.2	Aortic root size;	chr7:65827777	chr7:66493706~66495474:+
LUAD	cis	rs62355900	0.627	rs61663138	ENSG00000271828.1	CTD-2310F14.1	4.46	1e-05	0.00196	0.38	0.2	Endometriosis;	chr5:56899946	chr5:56927874~56929573:+
LUAD	cis	rs2033711	0.902	rs4801589	ENSG00000268912.1	CTD-2619J13.17	-4.46	1e-05	0.00196	-0.21	-0.2	Uric acid clearance;	chr19:58442031	chr19:58428632~58431148:-
LUAD	cis	rs477895	0.653	rs34089806	ENSG00000236935.1	AP003774.1	-4.46	1e-05	0.00196	-0.25	-0.2	Mean platelet volume;	chr11:64120515	chr11:64325050~64329504:-
LUAD	cis	rs60180747	0.544	rs11635867	ENSG00000261318.1	RP11-653J6.1	4.46	1e-05	0.00196	0.26	0.2	Testicular germ cell tumor;	chr15:66278908	chr15:66278498~66293357:-
LUAD	cis	rs7811142	1	rs67315960	ENSG00000078319.8	PMS2P1	-4.46	1e-05	0.00197	-0.24	-0.2	Platelet count;	chr7:100417501	chr7:100320992~100341908:-
LUAD	cis	rs4660214	0.724	rs11205695	ENSG00000228060.1	RP11-69E11.8	4.46	1e-05	0.00197	0.18	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39155285	chr1:39565160~39573203:+
LUAD	cis	rs12468226	1	rs6739198	ENSG00000272966.1	RP11-686O6.1	4.46	1e-05	0.00197	0.31	0.2	Urate levels;	chr2:202492273	chr2:202336739~202337200:+
LUAD	cis	rs72772090	0.71	rs17478897	ENSG00000248734.2	CTD-2260A17.1	-4.46	1e-05	0.00197	-0.32	-0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96726913	chr5:96784777~96785999:+
LUAD	cis	rs13113518	0.812	rs4865003	ENSG00000223305.1	RN7SKP30	4.46	1e-05	0.00197	0.23	0.2	Height;	chr4:55514802	chr4:55540502~55540835:-
LUAD	cis	rs896854	0.738	rs509594	ENSG00000253528.2	RP11-347C18.4	-4.46	1e-05	0.00197	-0.2	-0.2	Type 2 diabetes;	chr8:94954928	chr8:94974573~94974853:-
LUAD	cis	rs17772222	0.917	rs61977053	ENSG00000258983.2	RP11-507K2.2	4.46	1e-05	0.00197	0.25	0.2	Coronary artery calcification;	chr14:88380876	chr14:88499334~88515502:+
LUAD	cis	rs17772222	1	rs61977058	ENSG00000258983.2	RP11-507K2.2	4.46	1e-05	0.00197	0.25	0.2	Coronary artery calcification;	chr14:88415571	chr14:88499334~88515502:+
LUAD	cis	rs708547	0.533	rs3806746	ENSG00000269949.1	RP11-738E22.3	-4.46	1.01e-05	0.00197	-0.28	-0.2	Response to bleomycin (chromatid breaks);	chr4:56907164	chr4:56960927~56961373:-
LUAD	cis	rs1005277	0.579	rs2474595	ENSG00000263064.2	RP11-291L22.7	-4.46	1.01e-05	0.00197	-0.22	-0.2	Extrinsic epigenetic age acceleration;	chr10:38137854	chr10:38448689~38448949:+
LUAD	cis	rs6840360	0.582	rs2709827	ENSG00000270265.1	RP11-731D1.4	-4.46	1.01e-05	0.00197	-0.2	-0.2	Intelligence (multi-trait analysis);	chr4:151410100	chr4:151333775~151353224:-
LUAD	cis	rs11159086	1	rs58384818	ENSG00000259005.1	RP3-449M8.6	4.46	1.01e-05	0.00197	0.27	0.2	Advanced glycation end-product levels;	chr14:74487045	chr14:74474007~74474864:-
LUAD	cis	rs11159086	1	rs17100588	ENSG00000259005.1	RP3-449M8.6	4.46	1.01e-05	0.00197	0.27	0.2	Advanced glycation end-product levels;	chr14:74487624	chr14:74474007~74474864:-
LUAD	cis	rs7131987	0.585	rs2059362	ENSG00000257176.2	RP11-996F15.2	4.46	1.01e-05	0.00197	0.2	0.2	QT interval;	chr12:29243072	chr12:29280418~29317848:-
LUAD	cis	rs2243480	1	rs3885839	ENSG00000226002.1	RP11-460N20.5	-4.46	1.01e-05	0.00197	-0.35	-0.2	Diabetic kidney disease;	chr7:65825416	chr7:65084103~65100232:+
LUAD	cis	rs2243480	0.901	rs3813708	ENSG00000226002.1	RP11-460N20.5	-4.46	1.01e-05	0.00197	-0.35	-0.2	Diabetic kidney disease;	chr7:65840645	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs73142122	ENSG00000226002.1	RP11-460N20.5	-4.46	1.01e-05	0.00197	-0.35	-0.2	Diabetic kidney disease;	chr7:65846311	chr7:65084103~65100232:+
LUAD	cis	rs2243480	0.901	rs73142137	ENSG00000226002.1	RP11-460N20.5	-4.46	1.01e-05	0.00197	-0.35	-0.2	Diabetic kidney disease;	chr7:65878455	chr7:65084103~65100232:+
LUAD	cis	rs950169	0.84	rs4842854	ENSG00000275120.1	RP11-182J1.17	4.46	1.01e-05	0.00197	0.31	0.2	Schizophrenia;	chr15:84387641	chr15:84599434~84606463:-
LUAD	cis	rs35264875	0.851	rs7933746	ENSG00000259799.1	RP11-554A11.9	4.46	1.01e-05	0.00197	0.27	0.2	Blond vs. brown hair color;	chr11:69100254	chr11:69155910~69159752:+
LUAD	cis	rs9907295	0.748	rs2526328	ENSG00000270977.1	AC015849.16	-4.46	1.01e-05	0.00197	-0.3	-0.2	Fibroblast growth factor basic levels;	chr17:35932348	chr17:35893707~35911023:-
LUAD	cis	rs75422866	0.541	rs61918136	ENSG00000280054.1	RP1-197B17.7	4.46	1.01e-05	0.00197	0.45	0.2	Pneumonia;	chr12:47566798	chr12:47728151~47730598:-
LUAD	cis	rs4142995	0.772	rs2691584	ENSG00000279048.1	RP11-511H23.2	-4.46	1.01e-05	0.00197	-0.16	-0.2	HDL cholesterol;HDL cholesterol levels;	chr7:17777193	chr7:17940503~17942922:+
LUAD	cis	rs453301	0.631	rs13250781	ENSG00000173295.6	FAM86B3P	-4.46	1.01e-05	0.00197	-0.21	-0.2	Joint mobility (Beighton score);	chr8:8935833	chr8:8228595~8244865:+
LUAD	cis	rs875971	0.505	rs1723275	ENSG00000237310.1	GS1-124K5.4	-4.46	1.01e-05	0.00197	-0.21	-0.2	Aortic root size;	chr7:66039646	chr7:66493706~66495474:+
LUAD	cis	rs6687821	0.596	rs263493	ENSG00000267734.1	RP4-604K5.3	4.46	1.01e-05	0.00197	0.25	0.2	Yeast infection;	chr1:86755868	chr1:86932199~86934891:-
LUAD	cis	rs1062177	1	rs62377945	ENSG00000253921.1	CTB-113P19.3	-4.46	1.01e-05	0.00197	-0.3	-0.2	Preschool internalizing problems;	chr5:151828443	chr5:151753992~151767247:+
LUAD	cis	rs1502337	0.504	rs3026433	ENSG00000278993.1	RP3-424M6.4	4.46	1.01e-05	0.00197	0.25	0.2	Body mass index;	chr12:110281387	chr12:110501614~110503441:+
LUAD	cis	rs4578769	0.55	rs4517887	ENSG00000265943.1	RP11-739L10.1	-4.46	1.01e-05	0.00198	-0.25	-0.2	Eosinophil percentage of white cells;	chr18:22994715	chr18:22699481~22933764:-
LUAD	cis	rs603446	0.967	rs180350	ENSG00000254851.1	RP11-109L13.1	-4.46	1.01e-05	0.00198	-0.25	-0.2	Triglycerides;	chr11:116739332	chr11:117135528~117138582:+
LUAD	cis	rs28386778	0.863	rs3760252	ENSG00000240280.5	TCAM1P	-4.46	1.01e-05	0.00198	-0.23	-0.2	Prudent dietary pattern;	chr17:63774826	chr17:63849292~63864379:+
LUAD	cis	rs7940646	0.812	rs2052691	ENSG00000246308.1	RP11-685M7.3	-4.46	1.01e-05	0.00198	-0.24	-0.2	Platelet aggregation;	chr11:10642874	chr11:10809297~10822931:+
LUAD	cis	rs6496932	0.663	rs2062238	ENSG00000259630.2	CTD-2262B20.1	-4.46	1.01e-05	0.00198	-0.25	-0.2	Central corneal thickness;Corneal structure;	chr15:85376002	chr15:85415228~85415633:+
LUAD	cis	rs7172677	0.737	rs4886669	ENSG00000260269.4	CTD-2323K18.1	-4.46	1.01e-05	0.00198	-0.26	-0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75155840	chr15:75527150~75601205:-
LUAD	cis	rs160451	1	rs160449	ENSG00000251136.7	RP11-37B2.1	4.46	1.01e-05	0.00198	0.2	0.2	Leprosy;	chr8:89648287	chr8:89609409~89757727:-
LUAD	cis	rs7811142	0.775	rs1636980	ENSG00000078319.8	PMS2P1	4.46	1.01e-05	0.00198	0.24	0.2	Platelet count;	chr7:100341241	chr7:100320992~100341908:-
LUAD	cis	rs11673344	0.864	rs8107192	ENSG00000226686.6	LINC01535	4.46	1.01e-05	0.00198	0.25	0.2	Obesity-related traits;	chr19:37008725	chr19:37251912~37265535:+
LUAD	cis	rs2236295	0.533	rs73279609	ENSG00000238280.1	RP11-436D10.3	-4.46	1.01e-05	0.00198	-0.25	-0.2	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr10:62889873	chr10:62793562~62805887:-
LUAD	cis	rs9400467	0.528	rs7750792	ENSG00000230177.1	RP5-1112D6.4	-4.46	1.01e-05	0.00198	-0.18	-0.2	Amino acid levels;Blood metabolite levels;	chr6:111462556	chr6:111277932~111278742:+
LUAD	cis	rs2562456	0.793	rs3853837	ENSG00000268081.1	RP11-678G14.2	4.46	1.01e-05	0.00198	0.33	0.2	Pain;	chr19:21419172	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.793	rs3853838	ENSG00000268081.1	RP11-678G14.2	4.46	1.01e-05	0.00198	0.33	0.2	Pain;	chr19:21419192	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.833	rs62110426	ENSG00000268081.1	RP11-678G14.2	4.46	1.01e-05	0.00198	0.33	0.2	Pain;	chr19:21420124	chr19:21554640~21569237:-
LUAD	cis	rs17685	0.753	rs6951943	ENSG00000280388.1	RP11-229D13.3	-4.46	1.01e-05	0.00198	-0.19	-0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76143134	chr7:76043977~76045963:-
LUAD	cis	rs6687758	0.687	rs7520544	ENSG00000227925.1	RP11-191N8.2	4.46	1.01e-05	0.00198	0.27	0.2	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221943856	chr1:221827666~221840666:-
LUAD	cis	rs7430456	1	rs7430456	ENSG00000225790.1	RP11-2L8.1	4.46	1.01e-05	0.00198	0.23	0.2	Breast cancer;	chr3:177768082	chr3:177934823~177937662:+
LUAD	cis	rs801193	0.636	rs10233806	ENSG00000232559.3	GS1-124K5.12	-4.46	1.01e-05	0.00198	-0.23	-0.2	Aortic root size;	chr7:66653261	chr7:66554588~66576923:-
LUAD	cis	rs9467773	0.869	rs9295689	ENSG00000124549.13	BTN2A3P	4.46	1.01e-05	0.00198	0.19	0.2	Intelligence (multi-trait analysis);	chr6:26455583	chr6:26421391~26432383:+
LUAD	cis	rs9400467	0.528	rs7451051	ENSG00000271789.1	RP5-1112D6.7	-4.46	1.01e-05	0.00198	-0.21	-0.2	Amino acid levels;Blood metabolite levels;	chr6:111423615	chr6:111297126~111298510:+
LUAD	cis	rs10129255	1	rs10141557	ENSG00000274576.2	IGHV2-70	4.46	1.01e-05	0.00198	0.18	0.2	Kawasaki disease;	chr14:106767990	chr14:106770577~106771020:-
LUAD	cis	rs73173548	0.502	rs34394411	ENSG00000247828.6	TMEM161B-AS1	4.46	1.01e-05	0.00198	0.25	0.2	Macular telangiectasia type 2;	chr5:88436903	chr5:88268895~88436685:+
LUAD	cis	rs6723108	0.627	rs4954187	ENSG00000224043.6	CCNT2-AS1	-4.46	1.01e-05	0.00198	-0.25	-0.2	Type 2 diabetes;	chr2:134842848	chr2:134735464~134918710:-
LUAD	cis	rs12030196	0.536	rs2716130	ENSG00000230812.4	LINC01358	4.46	1.02e-05	0.00199	0.18	0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:59021456	chr1:59020387~59044614:+
LUAD	cis	rs763121	0.853	rs5750621	ENSG00000228274.3	RP3-508I15.9	-4.46	1.02e-05	0.00199	-0.2	-0.2	Menopause (age at onset);	chr22:38560161	chr22:38667585~38681820:-
LUAD	cis	rs763121	0.744	rs5757140	ENSG00000228274.3	RP3-508I15.9	-4.46	1.02e-05	0.00199	-0.2	-0.2	Menopause (age at onset);	chr22:38561008	chr22:38667585~38681820:-
LUAD	cis	rs1355223	0.902	rs7102625	ENSG00000271369.1	RP11-350D17.3	4.46	1.02e-05	0.00199	0.23	0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34718170	chr11:34709600~34710161:+
LUAD	cis	rs11846409	0.932	rs60659763	ENSG00000223648.3	IGHV3-64	4.46	1.02e-05	0.00199	0.23	0.2	Rheumatic heart disease;	chr14:106634172	chr14:106643132~106658258:-
LUAD	cis	rs11846409	0.932	rs57080270	ENSG00000223648.3	IGHV3-64	4.46	1.02e-05	0.00199	0.23	0.2	Rheumatic heart disease;	chr14:106634215	chr14:106643132~106658258:-
LUAD	cis	rs11846409	0.932	rs60917084	ENSG00000223648.3	IGHV3-64	4.46	1.02e-05	0.00199	0.23	0.2	Rheumatic heart disease;	chr14:106634621	chr14:106643132~106658258:-
LUAD	cis	rs2299587	0.585	rs2299590	ENSG00000253671.1	RP11-806O11.1	-4.46	1.02e-05	0.00199	-0.23	-0.2	Economic and political preferences;	chr8:17944683	chr8:17808941~17820868:+
LUAD	cis	rs1113500	0.814	rs893983	ENSG00000226822.1	RP11-356N1.2	-4.46	1.02e-05	0.00199	-0.22	-0.2	Growth-regulated protein alpha levels;	chr1:108087716	chr1:108071482~108074519:+
LUAD	cis	rs9659323	0.7	rs10923746	ENSG00000231365.4	RP11-418J17.1	-4.46	1.02e-05	0.00199	-0.23	-0.2	Body mass index;	chr1:119073655	chr1:119140396~119275973:+
LUAD	cis	rs4908769	0.624	rs1763839	ENSG00000232912.4	RP5-1115A15.1	4.46	1.02e-05	0.00199	0.18	0.2	Allergy;	chr1:8413276	chr1:8424645~8434838:+
LUAD	cis	rs7945705	0.791	rs10769958	ENSG00000254860.4	TMEM9B-AS1	4.46	1.02e-05	0.00199	0.22	0.2	Hemoglobin concentration;	chr11:8793568	chr11:8964675~8977527:+
LUAD	cis	rs4664293	0.625	rs11899419	ENSG00000226266.5	AC009961.3	4.46	1.02e-05	0.00199	0.27	0.2	Monocyte percentage of white cells;	chr2:159688858	chr2:159670708~159712435:-
LUAD	cis	rs7208859	0.725	rs7210904	ENSG00000280069.1	CTD-2349P21.3	-4.46	1.02e-05	0.00199	-0.24	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843187	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.725	rs9915802	ENSG00000280069.1	CTD-2349P21.3	-4.46	1.02e-05	0.00199	-0.24	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846040	chr17:30738182~30740275:+
LUAD	cis	rs13113518	1	rs4864548	ENSG00000272969.1	RP11-528I4.2	-4.46	1.02e-05	0.00199	-0.21	-0.2	Height;	chr4:55547636	chr4:55547112~55547889:+
LUAD	cis	rs6714710	0.603	rs35505530	ENSG00000230606.9	AC159540.1	-4.46	1.02e-05	0.00199	-0.21	-0.2	Posterior cortical atrophy and Alzheimer's disease;	chr2:97890447	chr2:97416165~97433527:-
LUAD	cis	rs11714574	0.557	rs6787467	ENSG00000273493.1	RP11-80H18.4	-4.46	1.02e-05	0.00199	-0.23	-0.2	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);	chr3:58392161	chr3:58329965~58330118:+
LUAD	cis	rs2537594	0.56	rs2723521	ENSG00000279048.1	RP11-511H23.2	-4.46	1.02e-05	0.00199	-0.17	-0.2	Mean corpuscular hemoglobin;	chr7:17774027	chr7:17940503~17942922:+
LUAD	cis	rs1005277	0.505	rs10827835	ENSG00000263064.2	RP11-291L22.7	-4.46	1.02e-05	0.00199	-0.21	-0.2	Extrinsic epigenetic age acceleration;	chr10:37861781	chr10:38448689~38448949:+
LUAD	cis	rs9910055	0.708	rs2631298	ENSG00000267080.4	ASB16-AS1	-4.46	1.02e-05	0.00199	-0.18	-0.2	Total body bone mineral density;	chr17:44142464	chr17:44175973~44186717:-
LUAD	cis	rs28530618	0.564	rs4911248	ENSG00000198547.7	C20orf203	4.46	1.02e-05	0.00199	0.22	0.2	Birth weight;	chr20:32626432	chr20:32631652~32673941:-
LUAD	cis	rs3096299	0.685	rs4785675	ENSG00000182376.2	RP5-1142A6.8	4.46	1.02e-05	0.00199	0.21	0.2	Multiple myeloma (IgH translocation);	chr16:89473566	chr16:88742767~88745748:+
LUAD	cis	rs3758785	0.679	rs11819857	ENSG00000255893.1	RP11-685N10.1	-4.46	1.02e-05	0.00199	-0.29	-0.2	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94495070	chr11:94472908~94473570:-
LUAD	cis	rs679515	1	rs679515	ENSG00000274245.1	RP11-357P18.2	-4.46	1.02e-05	0.00199	-0.33	-0.2	Alzheimer's disease in APOE e4+ carriers;	chr1:207577223	chr1:207372559~207373252:+
LUAD	cis	rs9400467	0.528	rs9689727	ENSG00000271789.1	RP5-1112D6.7	-4.46	1.02e-05	0.00199	-0.21	-0.2	Amino acid levels;Blood metabolite levels;	chr6:111475360	chr6:111297126~111298510:+
LUAD	cis	rs9400467	0.528	rs12214380	ENSG00000271789.1	RP5-1112D6.7	-4.46	1.02e-05	0.00199	-0.21	-0.2	Amino acid levels;Blood metabolite levels;	chr6:111475734	chr6:111297126~111298510:+
LUAD	cis	rs1401999	1	rs4148575	ENSG00000223882.1	ABCC5-AS1	-4.46	1.02e-05	0.00199	-0.2	-0.2	Anterior chamber depth;	chr3:183984487	chr3:184006338~184011419:+
LUAD	cis	rs2439831	1	rs471229	ENSG00000249839.1	AC011330.5	-4.46	1.02e-05	0.002	-0.36	-0.2	Lung cancer in ever smokers;	chr15:43441796	chr15:43663654~43684339:-
LUAD	cis	rs4664293	0.647	rs1863686	ENSG00000226266.5	AC009961.3	-4.46	1.02e-05	0.002	-0.27	-0.2	Monocyte percentage of white cells;	chr2:159647538	chr2:159670708~159712435:-
LUAD	cis	rs227275	0.525	rs17215211	ENSG00000251288.2	RP11-10L12.2	-4.46	1.02e-05	0.002	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:103025961	chr4:102751401~102752641:+
LUAD	cis	rs5758511	0.633	rs5751258	ENSG00000226450.2	CYP2D8P	4.46	1.02e-05	0.002	0.19	0.2	Birth weight;	chr22:42267865	chr22:42149886~42155001:-
LUAD	cis	rs950169	0.881	rs4842852	ENSG00000275120.1	RP11-182J1.17	4.46	1.02e-05	0.002	0.31	0.2	Schizophrenia;	chr15:84387263	chr15:84599434~84606463:-
LUAD	cis	rs950169	0.84	rs4842853	ENSG00000275120.1	RP11-182J1.17	4.46	1.02e-05	0.002	0.31	0.2	Schizophrenia;	chr15:84387606	chr15:84599434~84606463:-
LUAD	cis	rs950169	0.922	rs4842946	ENSG00000275120.1	RP11-182J1.17	4.46	1.02e-05	0.002	0.31	0.2	Schizophrenia;	chr15:84387633	chr15:84599434~84606463:-
LUAD	cis	rs950169	0.887	rs3860265	ENSG00000275120.1	RP11-182J1.17	4.46	1.02e-05	0.002	0.31	0.2	Schizophrenia;	chr15:84390487	chr15:84599434~84606463:-
LUAD	cis	rs1387259	0.723	rs2732488	ENSG00000257735.1	RP11-370I10.6	4.46	1.02e-05	0.002	0.24	0.2	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48377661	chr12:48350945~48442411:+
LUAD	cis	rs1387259	0.758	rs2634670	ENSG00000257735.1	RP11-370I10.6	4.46	1.02e-05	0.002	0.24	0.2	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48378094	chr12:48350945~48442411:+
LUAD	cis	rs9341808	0.718	rs3805922	ENSG00000272129.1	RP11-250B2.6	4.46	1.02e-05	0.002	0.24	0.2	Sitting height ratio;	chr6:80182272	chr6:80355424~80356859:+
LUAD	cis	rs9341808	0.718	rs3805920	ENSG00000272129.1	RP11-250B2.6	4.46	1.02e-05	0.002	0.24	0.2	Sitting height ratio;	chr6:80183028	chr6:80355424~80356859:+
LUAD	cis	rs473651	0.935	rs472357	ENSG00000229915.1	AC016999.2	4.46	1.02e-05	0.002	0.26	0.2	Multiple system atrophy;	chr2:238446813	chr2:238427077~238427729:-
LUAD	cis	rs516805	0.528	rs2679709	ENSG00000279453.1	RP3-425C14.4	-4.46	1.02e-05	0.002	-0.26	-0.2	Lymphocyte counts;	chr6:122080783	chr6:122436789~122439223:-
LUAD	cis	rs2380205	0.651	rs1512694	ENSG00000232807.2	RP11-536K7.3	4.46	1.02e-05	0.002	0.2	0.2	Breast cancer;	chr10:5874808	chr10:5934270~5945900:-
LUAD	cis	rs7811142	0.779	rs28680963	ENSG00000078319.8	PMS2P1	-4.46	1.02e-05	0.002	-0.25	-0.2	Platelet count;	chr7:100307852	chr7:100320992~100341908:-
LUAD	cis	rs13113518	0.812	rs2412648	ENSG00000223305.1	RN7SKP30	4.46	1.02e-05	0.002	0.23	0.2	Height;	chr4:55454900	chr4:55540502~55540835:-
LUAD	cis	rs13113518	0.812	rs12512737	ENSG00000223305.1	RN7SKP30	4.46	1.02e-05	0.002	0.23	0.2	Height;	chr4:55454938	chr4:55540502~55540835:-
LUAD	cis	rs13113518	0.812	rs13125984	ENSG00000223305.1	RN7SKP30	4.46	1.02e-05	0.002	0.23	0.2	Height;	chr4:55455102	chr4:55540502~55540835:-
LUAD	cis	rs875971	0.628	rs6974355	ENSG00000236529.1	RP13-254B10.1	4.46	1.02e-05	0.002	0.21	0.2	Aortic root size;	chr7:66376994	chr7:65840212~65840596:+
LUAD	cis	rs2243480	1	rs781157	ENSG00000164669.11	INTS4P1	4.46	1.02e-05	0.002	0.35	0.2	Diabetic kidney disease;	chr7:66013324	chr7:65141225~65234216:+
LUAD	cis	rs17685	0.753	rs4732595	ENSG00000280388.1	RP11-229D13.3	-4.46	1.02e-05	0.002	-0.19	-0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76125821	chr7:76043977~76045963:-
LUAD	cis	rs6860806	0.695	rs6867282	ENSG00000233006.5	AC034220.3	4.46	1.02e-05	0.002	0.18	0.2	Breast cancer;	chr5:132247427	chr5:132311285~132369916:-
LUAD	cis	rs3770081	1	rs2303339	ENSG00000273080.1	RP11-301O19.1	4.46	1.02e-05	0.002	0.48	0.2	Facial emotion recognition (sad faces);	chr2:86119057	chr2:86195590~86196049:+
LUAD	cis	rs7208859	0.573	rs55661352	ENSG00000280069.1	CTD-2349P21.3	-4.46	1.02e-05	0.002	-0.28	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30738182~30740275:+
LUAD	cis	rs1005277	0.522	rs1208681	ENSG00000263064.2	RP11-291L22.7	4.46	1.02e-05	0.002	0.21	0.2	Extrinsic epigenetic age acceleration;	chr10:37804047	chr10:38448689~38448949:+
LUAD	cis	rs17826219	0.568	rs11658027	ENSG00000280069.1	CTD-2349P21.3	4.46	1.02e-05	0.002	0.27	0.2	Body mass index;	chr17:30767864	chr17:30738182~30740275:+
LUAD	cis	rs72772090	0.708	rs17082200	ENSG00000248734.2	CTD-2260A17.1	-4.46	1.02e-05	0.002	-0.28	-0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96712900	chr5:96784777~96785999:+
LUAD	cis	rs4568518	0.616	rs4721675	ENSG00000279048.1	RP11-511H23.2	4.46	1.02e-05	0.002	0.16	0.2	Measles;	chr7:17965079	chr7:17940503~17942922:+
LUAD	cis	rs2439831	1	rs7173487	ENSG00000249839.1	AC011330.5	-4.46	1.02e-05	0.002	-0.39	-0.2	Lung cancer in ever smokers;	chr15:43458041	chr15:43663654~43684339:-
LUAD	cis	rs860295	0.557	rs348196	ENSG00000225855.5	RUSC1-AS1	4.46	1.02e-05	0.002	0.14	0.2	Body mass index;	chr1:155697170	chr1:155316863~155324176:-
LUAD	cis	rs11673344	0.563	rs4805199	ENSG00000276846.1	CTD-3220F14.3	4.46	1.03e-05	0.002	0.22	0.2	Obesity-related traits;	chr19:37115527	chr19:37314868~37315620:-
LUAD	cis	rs4811196	0.748	rs909769	ENSG00000226144.2	RPS27AP3	4.46	1.03e-05	0.002	0.22	0.2	Bone mineral density;	chr20:37868026	chr20:37049254~37049707:+
LUAD	cis	rs2933343	1	rs1683776	ENSG00000231305.3	RP11-723O4.2	4.46	1.03e-05	0.002	0.24	0.2	IgG glycosylation;	chr3:128903917	chr3:128861313~128871540:-
LUAD	cis	rs2933343	1	rs2630252	ENSG00000231305.3	RP11-723O4.2	4.46	1.03e-05	0.002	0.24	0.2	IgG glycosylation;	chr3:128905929	chr3:128861313~128871540:-
LUAD	cis	rs853679	1	rs853676	ENSG00000219392.1	RP1-265C24.5	-4.46	1.03e-05	0.002	-0.32	-0.2	Depression;	chr6:28331910	chr6:28115628~28116551:+
LUAD	cis	rs11722779	0.844	rs10003326	ENSG00000251288.2	RP11-10L12.2	-4.46	1.03e-05	0.002	-0.24	-0.2	Schizophrenia;	chr4:102948193	chr4:102751401~102752641:+
LUAD	cis	rs55823223	0.752	rs34974290	ENSG00000267801.1	RP11-552F3.9	4.46	1.03e-05	0.002	0.23	0.2	Psoriasis;	chr17:75892273	chr17:75876372~75879546:+
LUAD	cis	rs6754311	0.773	rs680428	ENSG00000226806.1	AC011893.3	-4.46	1.03e-05	0.00201	-0.25	-0.2	Mosquito bite size;	chr2:135873187	chr2:135820191~135823087:+
LUAD	cis	rs6754311	0.773	rs188680	ENSG00000226806.1	AC011893.3	-4.46	1.03e-05	0.00201	-0.25	-0.2	Mosquito bite size;	chr2:135873419	chr2:135820191~135823087:+
LUAD	cis	rs6754311	0.773	rs309130	ENSG00000226806.1	AC011893.3	-4.46	1.03e-05	0.00201	-0.25	-0.2	Mosquito bite size;	chr2:135873461	chr2:135820191~135823087:+
LUAD	cis	rs12745968	0.652	rs11164601	ENSG00000223787.2	RP4-593M8.1	-4.46	1.03e-05	0.00201	-0.25	-0.2	Bipolar disorder and schizophrenia;	chr1:92479950	chr1:92580476~92580821:-
LUAD	cis	rs227275	0.525	rs223462	ENSG00000251288.2	RP11-10L12.2	-4.46	1.03e-05	0.00201	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102780661	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.531	rs223460	ENSG00000251288.2	RP11-10L12.2	-4.46	1.03e-05	0.00201	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102782903	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.588	rs223458	ENSG00000251288.2	RP11-10L12.2	-4.46	1.03e-05	0.00201	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102788414	chr4:102751401~102752641:+
LUAD	cis	rs9813712	0.595	rs12490957	ENSG00000249846.5	RP11-77P16.4	4.46	1.03e-05	0.00201	0.23	0.2	Response to amphetamines;	chr3:130287851	chr3:130112550~130120579:+
LUAD	cis	rs330048	0.51	rs11784654	ENSG00000253893.2	FAM85B	4.46	1.03e-05	0.00201	0.25	0.2	Systemic lupus erythematosus;	chr8:9112101	chr8:8167819~8226614:-
LUAD	cis	rs228614	0.51	rs223459	ENSG00000251288.2	RP11-10L12.2	-4.46	1.03e-05	0.00201	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102788229	chr4:102751401~102752641:+
LUAD	cis	rs1876905	0.539	rs240969	ENSG00000230177.1	RP5-1112D6.4	4.46	1.03e-05	0.00201	0.25	0.2	Mean corpuscular hemoglobin;	chr6:111314605	chr6:111277932~111278742:+
LUAD	cis	rs860295	0.702	rs12039893	ENSG00000225855.5	RUSC1-AS1	4.46	1.03e-05	0.00201	0.14	0.2	Body mass index;	chr1:155645024	chr1:155316863~155324176:-
LUAD	cis	rs7493	1	rs7493	ENSG00000233942.1	AC004012.1	-4.46	1.03e-05	0.00201	-0.28	-0.2	Yu-Zhi constitution type in type 2 diabetes;	chr7:95405463	chr7:95471835~95473998:+
LUAD	cis	rs7208859	0.623	rs73271869	ENSG00000266490.1	CTD-2349P21.9	4.46	1.03e-05	0.00201	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825203	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs73271872	ENSG00000266490.1	CTD-2349P21.9	4.46	1.03e-05	0.00201	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825210	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs56146117	ENSG00000266490.1	CTD-2349P21.9	4.46	1.03e-05	0.00201	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826307	chr17:30792372~30792833:+
LUAD	cis	rs17826219	0.568	rs9907834	ENSG00000266490.1	CTD-2349P21.9	4.46	1.03e-05	0.00201	0.3	0.2	Body mass index;	chr17:30826995	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs73271887	ENSG00000266490.1	CTD-2349P21.9	4.46	1.03e-05	0.00201	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827917	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs9898858	ENSG00000266490.1	CTD-2349P21.9	4.46	1.03e-05	0.00201	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829193	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs55658077	ENSG00000266490.1	CTD-2349P21.9	4.46	1.03e-05	0.00201	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829501	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs9899692	ENSG00000266490.1	CTD-2349P21.9	4.46	1.03e-05	0.00201	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829921	chr17:30792372~30792833:+
LUAD	cis	rs1008375	0.966	rs6449325	ENSG00000249502.1	AC006160.5	4.46	1.03e-05	0.00201	0.2	0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17697886	chr4:17587467~17614571:-
LUAD	cis	rs1005277	0.579	rs176880	ENSG00000263064.2	RP11-291L22.7	-4.46	1.03e-05	0.00201	-0.21	-0.2	Extrinsic epigenetic age acceleration;	chr10:38112489	chr10:38448689~38448949:+
LUAD	cis	rs7665090	1	rs7664828	ENSG00000246560.2	RP11-10L12.4	4.46	1.03e-05	0.00201	0.24	0.2	Primary biliary cholangitis;	chr4:102630219	chr4:102828055~102844075:+
LUAD	cis	rs7665090	0.967	rs7690123	ENSG00000246560.2	RP11-10L12.4	4.46	1.03e-05	0.00201	0.24	0.2	Primary biliary cholangitis;	chr4:102630602	chr4:102828055~102844075:+
LUAD	cis	rs7665090	1	rs7665659	ENSG00000246560.2	RP11-10L12.4	4.46	1.03e-05	0.00201	0.24	0.2	Primary biliary cholangitis;	chr4:102630661	chr4:102828055~102844075:+
LUAD	cis	rs7665090	1	rs7665854	ENSG00000246560.2	RP11-10L12.4	4.46	1.03e-05	0.00201	0.24	0.2	Primary biliary cholangitis;	chr4:102630752	chr4:102828055~102844075:+
LUAD	cis	rs7665090	0.846	rs7690700	ENSG00000246560.2	RP11-10L12.4	4.46	1.03e-05	0.00201	0.24	0.2	Primary biliary cholangitis;	chr4:102630911	chr4:102828055~102844075:+
LUAD	cis	rs7665090	1	rs12644381	ENSG00000246560.2	RP11-10L12.4	4.46	1.03e-05	0.00201	0.24	0.2	Primary biliary cholangitis;	chr4:102631273	chr4:102828055~102844075:+
LUAD	cis	rs7665090	1	rs1054037	ENSG00000246560.2	RP11-10L12.4	4.46	1.03e-05	0.00201	0.24	0.2	Primary biliary cholangitis;	chr4:102631552	chr4:102828055~102844075:+
LUAD	cis	rs17772222	1	rs7145588	ENSG00000258983.2	RP11-507K2.2	4.46	1.03e-05	0.00201	0.24	0.2	Coronary artery calcification;	chr14:88360452	chr14:88499334~88515502:+
LUAD	cis	rs17772222	1	rs61977049	ENSG00000258983.2	RP11-507K2.2	4.46	1.03e-05	0.00201	0.24	0.2	Coronary artery calcification;	chr14:88360656	chr14:88499334~88515502:+
LUAD	cis	rs17772222	1	rs12587386	ENSG00000258983.2	RP11-507K2.2	4.46	1.03e-05	0.00201	0.24	0.2	Coronary artery calcification;	chr14:88361420	chr14:88499334~88515502:+
LUAD	cis	rs6453278	0.961	rs6453277	ENSG00000250802.5	ZBED3-AS1	4.46	1.03e-05	0.00201	0.23	0.2	Autism;	chr5:77121056	chr5:77086740~77166909:+
LUAD	cis	rs6723108	0.627	rs6706537	ENSG00000224043.6	CCNT2-AS1	-4.46	1.03e-05	0.00202	-0.25	-0.2	Type 2 diabetes;	chr2:134861412	chr2:134735464~134918710:-
LUAD	cis	rs6570726	0.791	rs418701	ENSG00000235652.6	RP11-545I5.3	4.46	1.03e-05	0.00202	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145568856	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.791	rs1280275	ENSG00000235652.6	RP11-545I5.3	4.46	1.03e-05	0.00202	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145571266	chr6:145799409~145886585:+
LUAD	cis	rs11920354	0.642	rs9812878	ENSG00000271161.1	BOLA2P2	4.46	1.03e-05	0.00202	0.19	0.2	Sum neutrophil eosinophil counts;Granulocyte count;	chr3:47141297	chr3:47499841~47500407:+
LUAD	cis	rs6840360	0.582	rs4696259	ENSG00000270265.1	RP11-731D1.4	-4.46	1.03e-05	0.00202	-0.2	-0.2	Intelligence (multi-trait analysis);	chr4:151389636	chr4:151333775~151353224:-
LUAD	cis	rs13256369	1	rs7004438	ENSG00000253893.2	FAM85B	-4.46	1.03e-05	0.00202	-0.28	-0.2	Obesity-related traits;	chr8:8716869	chr8:8167819~8226614:-
LUAD	cis	rs6095360	0.649	rs34832487	ENSG00000222365.1	SNORD12B	-4.46	1.03e-05	0.00202	-0.23	-0.2	Intelligence (multi-trait analysis);	chr20:48930575	chr20:49280319~49280409:+
LUAD	cis	rs17711722	0.565	rs4275112	ENSG00000237310.1	GS1-124K5.4	-4.46	1.03e-05	0.00202	-0.21	-0.2	Calcium levels;	chr7:65733651	chr7:66493706~66495474:+
LUAD	cis	rs453301	0.686	rs7017868	ENSG00000253981.4	ALG1L13P	-4.46	1.03e-05	0.00202	-0.24	-0.2	Joint mobility (Beighton score);	chr8:9015783	chr8:8236003~8244667:-
LUAD	cis	rs453301	0.686	rs3895823	ENSG00000253981.4	ALG1L13P	-4.46	1.03e-05	0.00202	-0.24	-0.2	Joint mobility (Beighton score);	chr8:9016136	chr8:8236003~8244667:-
LUAD	cis	rs30380	1	rs27710	ENSG00000248734.2	CTD-2260A17.1	-4.46	1.03e-05	0.00202	-0.2	-0.2	Cerebrospinal fluid biomarker levels;	chr5:96790494	chr5:96784777~96785999:+
LUAD	cis	rs11673344	0.526	rs17244769	ENSG00000226686.6	LINC01535	4.46	1.03e-05	0.00202	0.24	0.2	Obesity-related traits;	chr19:37562031	chr19:37251912~37265535:+
LUAD	cis	rs17508449	0.732	rs74610368	ENSG00000232450.1	RP4-730K3.3	-4.46	1.03e-05	0.00202	-0.35	-0.2	Leprosy;	chr1:113742681	chr1:113698884~113699631:-
LUAD	cis	rs4072980	0.545	rs10890285	ENSG00000212541.1	RNU6-510P	4.46	1.03e-05	0.00202	0.26	0.2	Coronary artery disease;	chr1:37987904	chr1:37991462~37991569:+
LUAD	cis	rs77688320	0.553	rs2080322	ENSG00000213090.2	AC007256.5	-4.46	1.04e-05	0.00202	-0.23	-0.2	Breast cancer;	chr2:201514317	chr2:201410544~201413308:-
LUAD	cis	rs12478296	1	rs11899408	ENSG00000261186.2	RP11-341N2.1	-4.46	1.04e-05	0.00202	-0.32	-0.2	Obesity-related traits;	chr2:242072479	chr2:242087351~242088457:-
LUAD	cis	rs6565189	0.865	rs4500746	ENSG00000273724.1	RP11-347C12.12	4.46	1.04e-05	0.00202	0.23	0.2	Tonsillectomy;	chr16:30493023	chr16:30336400~30343336:+
LUAD	cis	rs13113518	0.812	rs11932712	ENSG00000223305.1	RN7SKP30	4.46	1.04e-05	0.00202	0.23	0.2	Height;	chr4:55436423	chr4:55540502~55540835:-
LUAD	cis	rs13113518	0.812	rs12501746	ENSG00000223305.1	RN7SKP30	4.46	1.04e-05	0.00202	0.23	0.2	Height;	chr4:55437438	chr4:55540502~55540835:-
LUAD	cis	rs13160562	0.527	rs27525	ENSG00000272109.1	CTD-2260A17.3	-4.46	1.04e-05	0.00202	-0.21	-0.2	Alcohol dependence;	chr5:96766255	chr5:96804353~96806105:+
LUAD	cis	rs4372836	1	rs4549034	ENSG00000226833.4	AC097724.3	4.46	1.04e-05	0.00202	0.23	0.2	Body mass index;	chr2:28749713	chr2:28708953~28736205:-
LUAD	cis	rs4372836	1	rs11688129	ENSG00000226833.4	AC097724.3	-4.46	1.04e-05	0.00202	-0.23	-0.2	Body mass index;	chr2:28729715	chr2:28708953~28736205:-
LUAD	cis	rs7172677	1	rs1021382	ENSG00000260269.4	CTD-2323K18.1	-4.46	1.04e-05	0.00202	-0.27	-0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75125057	chr15:75527150~75601205:-
LUAD	cis	rs36423	0.748	rs36377	ENSG00000266869.1	RP6-114E22.1	-4.46	1.04e-05	0.00202	-0.29	-0.2	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71905994	chr14:71848606~71908430:+
LUAD	cis	rs6539288	0.901	rs7974499	ENSG00000260329.1	RP11-412D9.4	-4.46	1.04e-05	0.00202	-0.21	-0.2	Total body bone mineral density;	chr12:106947607	chr12:106954029~106955497:-
LUAD	cis	rs6539288	0.901	rs4964505	ENSG00000260329.1	RP11-412D9.4	-4.46	1.04e-05	0.00202	-0.21	-0.2	Total body bone mineral density;	chr12:106948062	chr12:106954029~106955497:-
LUAD	cis	rs442309	0.551	rs7083045	ENSG00000238280.1	RP11-436D10.3	-4.46	1.04e-05	0.00202	-0.24	-0.2	Vogt-Koyanagi-Harada syndrome;	chr10:62780204	chr10:62793562~62805887:-
LUAD	cis	rs748404	0.697	rs471122	ENSG00000249839.1	AC011330.5	4.46	1.04e-05	0.00202	0.25	0.2	Lung cancer;	chr15:43266376	chr15:43663654~43684339:-
LUAD	cis	rs3096299	0.719	rs2965818	ENSG00000182376.2	RP5-1142A6.8	4.46	1.04e-05	0.00202	0.21	0.2	Multiple myeloma (IgH translocation);	chr16:89444086	chr16:88742767~88745748:+
LUAD	cis	rs11009175	0.929	rs7078479	ENSG00000273038.2	RP11-479G22.8	-4.46	1.04e-05	0.00202	-0.32	-0.2	Depression (quantitative trait);	chr10:33056273	chr10:32887255~32889311:-
LUAD	cis	rs9652601	0.959	rs12919083	ENSG00000274038.1	RP11-66H6.4	4.46	1.04e-05	0.00202	0.25	0.2	Systemic lupus erythematosus;	chr16:11095073	chr16:11056556~11057034:+
LUAD	cis	rs2153535	0.585	rs4959494	ENSG00000230939.1	RP11-314C16.1	-4.46	1.04e-05	0.00202	-0.22	-0.2	Motion sickness;	chr6:8640935	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.585	rs4959495	ENSG00000230939.1	RP11-314C16.1	-4.46	1.04e-05	0.00202	-0.22	-0.2	Motion sickness;	chr6:8641186	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.585	rs11243264	ENSG00000230939.1	RP11-314C16.1	-4.46	1.04e-05	0.00202	-0.22	-0.2	Motion sickness;	chr6:8642912	chr6:8784178~8785445:+
LUAD	cis	rs6762	0.719	rs28620453	ENSG00000279672.1	CMB9-55F22.1	4.46	1.04e-05	0.00202	0.21	0.2	Mean platelet volume;	chr11:836971	chr11:779617~780755:+
LUAD	cis	rs9341808	0.754	rs10806185	ENSG00000272129.1	RP11-250B2.6	4.46	1.04e-05	0.00202	0.24	0.2	Sitting height ratio;	chr6:80244794	chr6:80355424~80356859:+
LUAD	cis	rs2486288	0.656	rs11632920	ENSG00000259479.5	SORD2P	-4.46	1.04e-05	0.00202	-0.24	-0.2	Glomerular filtration rate;	chr15:45259066	chr15:44826371~44884694:-
LUAD	cis	rs17772222	0.958	rs60213984	ENSG00000258789.1	RP11-507K2.3	-4.46	1.04e-05	0.00202	-0.27	-0.2	Coronary artery calcification;	chr14:88401473	chr14:88551597~88552493:+
LUAD	cis	rs847577	0.63	rs2132276	ENSG00000272950.1	RP11-307C18.1	4.46	1.04e-05	0.00203	0.25	0.2	Breast cancer;	chr7:98197028	chr7:98322853~98323430:+
LUAD	cis	rs17345786	0.906	rs72946021	ENSG00000244119.1	PDCL3P4	4.46	1.04e-05	0.00203	0.22	0.2	Colonoscopy-negative controls vs population controls;	chr3:101531164	chr3:101712472~101713191:+
LUAD	cis	rs7208859	0.623	rs73269913	ENSG00000266490.1	CTD-2349P21.9	4.46	1.04e-05	0.00203	0.29	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765165	chr17:30792372~30792833:+
LUAD	cis	rs1150668	0.83	rs2531831	ENSG00000219392.1	RP1-265C24.5	-4.46	1.04e-05	0.00203	-0.24	-0.2	Pubertal anthropometrics;	chr6:28420988	chr6:28115628~28116551:+
LUAD	cis	rs4683346	0.859	rs2099022	ENSG00000173811.9	CCDC13-AS1	-4.46	1.04e-05	0.00203	-0.22	-0.2	Granulocyte percentage of myeloid white cells;	chr3:42850556	chr3:42732575~42746768:+
LUAD	cis	rs4666002	0.564	rs13030345	ENSG00000223522.1	AC093690.1	-4.46	1.04e-05	0.00203	-0.24	-0.2	Phospholipid levels (plasma);	chr2:27780307	chr2:28307691~28310459:-
LUAD	cis	rs4835473	0.637	rs1020497	ENSG00000251600.4	RP11-673E1.1	4.46	1.04e-05	0.00203	0.23	0.2	Immature fraction of reticulocytes;	chr4:143741029	chr4:143912331~143982454:+
LUAD	cis	rs2288884	0.541	rs7508746	ENSG00000275055.1	CTC-471J1.11	-4.46	1.04e-05	0.00203	-0.32	-0.2	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51990246	chr19:52049007~52049754:+
LUAD	cis	rs11250098	0.548	rs7843470	ENSG00000255046.1	RP11-297N6.4	4.46	1.04e-05	0.00203	0.25	0.2	Morning vs. evening chronotype;	chr8:10926982	chr8:11797928~11802568:-
LUAD	cis	rs2153535	0.585	rs7763881	ENSG00000230939.1	RP11-314C16.1	4.46	1.04e-05	0.00203	0.22	0.2	Motion sickness;	chr6:8653014	chr6:8784178~8785445:+
LUAD	cis	rs4835473	0.637	rs9993457	ENSG00000251600.4	RP11-673E1.1	4.46	1.04e-05	0.00203	0.23	0.2	Immature fraction of reticulocytes;	chr4:143752364	chr4:143912331~143982454:+
LUAD	cis	rs17301013	0.965	rs7548540	ENSG00000227373.4	RP11-160H22.5	4.46	1.04e-05	0.00203	0.25	0.2	Systemic lupus erythematosus;	chr1:174411672	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.965	rs2179214	ENSG00000227373.4	RP11-160H22.5	4.46	1.04e-05	0.00203	0.25	0.2	Systemic lupus erythematosus;	chr1:174413954	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.93	rs7523263	ENSG00000227373.4	RP11-160H22.5	4.46	1.04e-05	0.00203	0.25	0.2	Systemic lupus erythematosus;	chr1:174414542	chr1:174115300~174160004:-
LUAD	cis	rs6142102	1	rs2143230	ENSG00000275784.1	RP5-1125A11.6	-4.46	1.04e-05	0.00203	-0.22	-0.2	Skin pigmentation;	chr20:34136539	chr20:33989480~33991818:-
LUAD	cis	rs338389	0.967	rs338395	ENSG00000260657.2	RP11-315D16.4	4.46	1.04e-05	0.00203	0.22	0.2	Survival in rectal cancer;	chr15:67962938	chr15:68267792~68277994:-
LUAD	cis	rs2976388	0.533	rs12543368	ENSG00000253741.1	CTD-2292P10.4	4.46	1.04e-05	0.00203	0.24	0.2	Urinary tract infection frequency;	chr8:142738032	chr8:142702252~142726973:-
LUAD	cis	rs6964587	0.967	rs4626516	ENSG00000188693.7	CYP51A1-AS1	-4.46	1.04e-05	0.00203	-0.24	-0.2	Breast cancer;	chr7:92177839	chr7:92134604~92180725:+
LUAD	cis	rs847577	0.609	rs11765552	ENSG00000272950.1	RP11-307C18.1	4.46	1.04e-05	0.00203	0.25	0.2	Breast cancer;	chr7:98192803	chr7:98322853~98323430:+
LUAD	cis	rs847577	0.63	rs3801294	ENSG00000272950.1	RP11-307C18.1	4.46	1.04e-05	0.00203	0.25	0.2	Breast cancer;	chr7:98192898	chr7:98322853~98323430:+
LUAD	cis	rs847577	0.63	rs11764933	ENSG00000272950.1	RP11-307C18.1	4.46	1.04e-05	0.00203	0.25	0.2	Breast cancer;	chr7:98195876	chr7:98322853~98323430:+
LUAD	cis	rs9425766	0.523	rs6668959	ENSG00000227373.4	RP11-160H22.5	4.46	1.04e-05	0.00203	0.25	0.2	Life satisfaction;	chr1:174088488	chr1:174115300~174160004:-
LUAD	cis	rs9425766	0.665	rs7553788	ENSG00000227373.4	RP11-160H22.5	4.46	1.04e-05	0.00203	0.25	0.2	Life satisfaction;	chr1:174093773	chr1:174115300~174160004:-
LUAD	cis	rs227275	0.556	rs3886723	ENSG00000251288.2	RP11-10L12.2	-4.46	1.04e-05	0.00204	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102983013	chr4:102751401~102752641:+
LUAD	cis	rs228614	0.517	rs3886722	ENSG00000251288.2	RP11-10L12.2	-4.46	1.04e-05	0.00204	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102983084	chr4:102751401~102752641:+
LUAD	cis	rs9341808	0.754	rs9343973	ENSG00000260645.1	RP11-250B2.5	4.45	1.04e-05	0.00204	0.19	0.2	Sitting height ratio;	chr6:80203499	chr6:80466958~80469080:+
LUAD	cis	rs62025270	0.632	rs13379832	ENSG00000202081.1	RNU6-1280P	-4.45	1.04e-05	0.00204	-0.3	-0.2	Idiopathic pulmonary fibrosis;	chr15:85572669	chr15:85651522~85651628:-
LUAD	cis	rs3743772	0.5	rs28804772	ENSG00000279722.1	RP11-44F14.6	4.45	1.05e-05	0.00204	0.27	0.2	Depressive symptoms (SSRI exposure interaction);	chr16:53411252	chr16:53487607~53489943:-
LUAD	cis	rs227275	0.554	rs223424	ENSG00000251288.2	RP11-10L12.2	-4.45	1.05e-05	0.00204	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102804177	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.524	rs223423	ENSG00000251288.2	RP11-10L12.2	-4.45	1.05e-05	0.00204	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102804737	chr4:102751401~102752641:+
LUAD	cis	rs9545047	0.625	rs9545109	ENSG00000227354.5	RBM26-AS1	4.45	1.05e-05	0.00204	0.21	0.2	Schizophrenia;	chr13:79413480	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.518	rs7328494	ENSG00000227354.5	RBM26-AS1	4.45	1.05e-05	0.00204	0.21	0.2	Schizophrenia;	chr13:79414673	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs2147568	ENSG00000227354.5	RBM26-AS1	4.45	1.05e-05	0.00204	0.21	0.2	Schizophrenia;	chr13:79417091	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs9530917	ENSG00000227354.5	RBM26-AS1	4.45	1.05e-05	0.00204	0.21	0.2	Schizophrenia;	chr13:79417719	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs7990321	ENSG00000227354.5	RBM26-AS1	4.45	1.05e-05	0.00204	0.21	0.2	Schizophrenia;	chr13:79418066	chr13:79406309~79424328:+
LUAD	cis	rs8180040	0.8	rs11921117	ENSG00000271161.1	BOLA2P2	-4.45	1.05e-05	0.00204	-0.19	-0.2	Colorectal cancer;	chr3:47252510	chr3:47499841~47500407:+
LUAD	cis	rs1387259	0.929	rs2634666	ENSG00000240399.1	RP1-228P16.1	4.45	1.05e-05	0.00204	0.2	0.2	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48269887	chr12:48054813~48055591:-
LUAD	cis	rs1008375	0.932	rs2302391	ENSG00000249502.1	AC006160.5	-4.45	1.05e-05	0.00204	-0.19	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17658614	chr4:17587467~17614571:-
LUAD	cis	rs227275	0.525	rs11737544	ENSG00000251288.2	RP11-10L12.2	-4.45	1.05e-05	0.00204	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102983877	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.525	rs7685399	ENSG00000251288.2	RP11-10L12.2	-4.45	1.05e-05	0.00204	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102991926	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.525	rs3974485	ENSG00000251288.2	RP11-10L12.2	-4.45	1.05e-05	0.00204	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102993283	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.525	rs2866417	ENSG00000251288.2	RP11-10L12.2	-4.45	1.05e-05	0.00204	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102993481	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.525	rs7688940	ENSG00000251288.2	RP11-10L12.2	-4.45	1.05e-05	0.00204	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102994153	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.525	rs1383733	ENSG00000251288.2	RP11-10L12.2	-4.45	1.05e-05	0.00204	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102995297	chr4:102751401~102752641:+
LUAD	cis	rs737008	0.96	rs11640295	ENSG00000262703.1	RP11-485G7.6	4.45	1.05e-05	0.00204	0.19	0.2	Obesity-related traits;	chr16:11296871	chr16:11348143~11349321:-
LUAD	cis	rs2243480	1	rs1723267	ENSG00000164669.11	INTS4P1	4.45	1.05e-05	0.00204	0.35	0.2	Diabetic kidney disease;	chr7:66008327	chr7:65141225~65234216:+
LUAD	cis	rs13113518	0.902	rs12642716	ENSG00000272969.1	RP11-528I4.2	4.45	1.05e-05	0.00204	0.21	0.2	Height;	chr4:55479996	chr4:55547112~55547889:+
LUAD	cis	rs9322193	0.962	rs2275046	ENSG00000268592.3	RAET1E-AS1	4.45	1.05e-05	0.00204	0.25	0.2	Lung cancer;	chr6:149835865	chr6:149863494~149919507:+
LUAD	cis	rs6012564	0.793	rs6125552	ENSG00000230758.1	SNAP23P	4.45	1.05e-05	0.00204	0.21	0.2	Anger;	chr20:49107788	chr20:49038357~49038602:-
LUAD	cis	rs6012564	1	rs6066968	ENSG00000230758.1	SNAP23P	4.45	1.05e-05	0.00204	0.21	0.2	Anger;	chr20:49110804	chr20:49038357~49038602:-
LUAD	cis	rs889398	0.741	rs6499270	ENSG00000226232.7	RP11-419C5.2	4.45	1.05e-05	0.00205	0.17	0.2	Body mass index;	chr16:69883837	chr16:69976388~69996188:-
LUAD	cis	rs7086627	0.515	rs2125040	ENSG00000226659.1	RP11-137H2.4	-4.45	1.05e-05	0.00205	-0.26	-0.2	Post bronchodilator FEV1;	chr10:80448666	chr10:80529597~80535942:-
LUAD	cis	rs7086627	0.515	rs7088877	ENSG00000226659.1	RP11-137H2.4	-4.45	1.05e-05	0.00205	-0.26	-0.2	Post bronchodilator FEV1;	chr10:80449104	chr10:80529597~80535942:-
LUAD	cis	rs6061231	0.755	rs11699160	ENSG00000273619.1	RP5-908M14.9	-4.45	1.05e-05	0.00205	-0.19	-0.2	Colorectal cancer;	chr20:62383595	chr20:62386303~62386970:-
LUAD	cis	rs6142102	0.59	rs6059691	ENSG00000275784.1	RP5-1125A11.6	4.45	1.05e-05	0.00205	0.23	0.2	Skin pigmentation;	chr20:34149161	chr20:33989480~33991818:-
LUAD	cis	rs13113518	0.756	rs12510275	ENSG00000223305.1	RN7SKP30	4.45	1.05e-05	0.00205	0.23	0.2	Height;	chr4:55516548	chr4:55540502~55540835:-
LUAD	cis	rs13113518	0.812	rs12510327	ENSG00000223305.1	RN7SKP30	4.45	1.05e-05	0.00205	0.23	0.2	Height;	chr4:55516744	chr4:55540502~55540835:-
LUAD	cis	rs1823874	0.72	rs2003037	ENSG00000182397.13	DNM1P46	-4.45	1.05e-05	0.00205	-0.22	-0.2	IgG glycosylation;	chr15:99821757	chr15:99790156~99806927:-
LUAD	cis	rs2227564	0.7	rs12413039	ENSG00000271816.1	BMS1P4	-4.45	1.05e-05	0.00205	-0.21	-0.2	Crohn's disease;Inflammatory bowel disease;	chr10:73765001	chr10:73699151~73730487:-
LUAD	cis	rs6860806	0.603	rs112300250	ENSG00000233006.5	AC034220.3	4.45	1.05e-05	0.00205	0.18	0.2	Breast cancer;	chr5:132247599	chr5:132311285~132369916:-
LUAD	cis	rs2998286	0.678	rs1755205	ENSG00000254635.4	WAC-AS1	-4.45	1.05e-05	0.00205	-0.27	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28644828	chr10:28522652~28532743:-
LUAD	cis	rs7572733	0.935	rs6434942	ENSG00000222017.1	AC011997.1	4.45	1.05e-05	0.00205	0.25	0.2	Dermatomyositis;	chr2:197891964	chr2:197693106~197774823:+
LUAD	cis	rs9322193	0.923	rs9688517	ENSG00000268592.3	RAET1E-AS1	4.45	1.05e-05	0.00205	0.24	0.2	Lung cancer;	chr6:149740655	chr6:149863494~149919507:+
LUAD	cis	rs2834288	0.5	rs4817602	ENSG00000237945.6	LINC00649	4.45	1.06e-05	0.00205	0.24	0.2	Gut microbiota (bacterial taxa);	chr21:33952354	chr21:33915534~33977691:+
LUAD	cis	rs9400467	0.528	rs56827	ENSG00000230177.1	RP5-1112D6.4	-4.45	1.06e-05	0.00205	-0.17	-0.2	Amino acid levels;Blood metabolite levels;	chr6:111302000	chr6:111277932~111278742:+
LUAD	cis	rs160451	0.966	rs218886	ENSG00000251136.7	RP11-37B2.1	-4.45	1.06e-05	0.00206	-0.2	-0.2	Leprosy;	chr8:89678365	chr8:89609409~89757727:-
LUAD	cis	rs160451	0.933	rs218889	ENSG00000251136.7	RP11-37B2.1	-4.45	1.06e-05	0.00206	-0.2	-0.2	Leprosy;	chr8:89679935	chr8:89609409~89757727:-
LUAD	cis	rs860295	0.702	rs11264366	ENSG00000225855.5	RUSC1-AS1	4.45	1.06e-05	0.00206	0.14	0.2	Body mass index;	chr1:155365620	chr1:155316863~155324176:-
LUAD	cis	rs13113518	0.812	rs6830409	ENSG00000223305.1	RN7SKP30	4.45	1.06e-05	0.00206	0.23	0.2	Height;	chr4:55522229	chr4:55540502~55540835:-
LUAD	cis	rs7208859	0.623	rs3752019	ENSG00000266490.1	CTD-2349P21.9	4.45	1.06e-05	0.00206	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824687	chr17:30792372~30792833:+
LUAD	cis	rs9322193	0.923	rs9479494	ENSG00000268592.3	RAET1E-AS1	4.45	1.06e-05	0.00206	0.24	0.2	Lung cancer;	chr6:149739108	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.923	rs9800806	ENSG00000268592.3	RAET1E-AS1	4.45	1.06e-05	0.00206	0.24	0.2	Lung cancer;	chr6:149740350	chr6:149863494~149919507:+
LUAD	cis	rs13256369	0.802	rs11249884	ENSG00000253893.2	FAM85B	4.45	1.06e-05	0.00206	0.27	0.2	Obesity-related traits;	chr8:8704042	chr8:8167819~8226614:-
LUAD	cis	rs62355900	0.627	rs59715006	ENSG00000271828.1	CTD-2310F14.1	4.45	1.06e-05	0.00206	0.38	0.2	Endometriosis;	chr5:56899820	chr5:56927874~56929573:+
LUAD	cis	rs957448	1	rs7829886	ENSG00000254315.1	RP11-267M23.3	4.45	1.06e-05	0.00206	0.25	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94485160	chr8:94533628~94534391:+
LUAD	cis	rs227275	0.525	rs6533052	ENSG00000251288.2	RP11-10L12.2	-4.45	1.06e-05	0.00206	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102990624	chr4:102751401~102752641:+
LUAD	cis	rs17711722	0.503	rs453835	ENSG00000237310.1	GS1-124K5.4	-4.45	1.06e-05	0.00206	-0.21	-0.2	Calcium levels;	chr7:66046172	chr7:66493706~66495474:+
LUAD	cis	rs6487679	0.526	rs7972426	ENSG00000111788.10	RP11-22B23.1	4.45	1.06e-05	0.00206	0.18	0.2	Non-alcoholic fatty liver disease histology (AST);	chr12:9228658	chr12:9277235~9313241:+
LUAD	cis	rs875971	0.522	rs1917563	ENSG00000237310.1	GS1-124K5.4	-4.45	1.06e-05	0.00206	-0.21	-0.2	Aortic root size;	chr7:65950660	chr7:66493706~66495474:+
LUAD	cis	rs1614887	1	rs1614887	ENSG00000124549.13	BTN2A3P	4.45	1.06e-05	0.00206	0.18	0.2	Lobe attachment (rater-scored or self-reported);Intelligence (multi-trait analysis);	chr6:26392793	chr6:26421391~26432383:+
LUAD	cis	rs891378	1	rs2017760	ENSG00000274245.1	RP11-357P18.2	-4.45	1.06e-05	0.00206	-0.26	-0.2	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207282076	chr1:207372559~207373252:+
LUAD	cis	rs858239	0.601	rs11984129	ENSG00000226816.2	AC005082.12	4.45	1.06e-05	0.00206	0.26	0.2	Cerebrospinal fluid biomarker levels;	chr7:23113058	chr7:23206013~23208045:+
LUAD	cis	rs881375	0.501	rs10156413	ENSG00000226752.6	PSMD5-AS1	-4.45	1.06e-05	0.00206	-0.22	-0.2	Rheumatoid arthritis;	chr9:121105504	chr9:120824828~120854385:+
LUAD	cis	rs7829975	0.806	rs2428	ENSG00000173295.6	FAM86B3P	4.45	1.06e-05	0.00206	0.2	0.2	Mood instability;	chr8:8783635	chr8:8228595~8244865:+
LUAD	cis	rs2115630	0.967	rs11073731	ENSG00000225151.9	GOLGA2P7	4.45	1.06e-05	0.00206	0.22	0.2	P wave terminal force;	chr15:84811882	chr15:84199311~84230136:-
LUAD	cis	rs1165668	0.785	rs1165681	ENSG00000214198.6	RP11-642P15.1	-4.45	1.06e-05	0.00206	-0.21	-0.2	Coronary heart disease (SNP X SNP interaction);	chr12:103931333	chr12:103843749~103930211:-
LUAD	cis	rs2243480	1	rs13247184	ENSG00000226002.1	RP11-460N20.5	-4.45	1.06e-05	0.00206	-0.34	-0.2	Diabetic kidney disease;	chr7:65893941	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs35283677	ENSG00000226002.1	RP11-460N20.5	-4.45	1.06e-05	0.00206	-0.34	-0.2	Diabetic kidney disease;	chr7:65894246	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs35421653	ENSG00000226002.1	RP11-460N20.5	-4.45	1.06e-05	0.00206	-0.34	-0.2	Diabetic kidney disease;	chr7:65898442	chr7:65084103~65100232:+
LUAD	cis	rs17772222	0.958	rs61579615	ENSG00000258983.2	RP11-507K2.2	4.45	1.06e-05	0.00206	0.25	0.2	Coronary artery calcification;	chr14:88400054	chr14:88499334~88515502:+
LUAD	cis	rs12554020	0.681	rs76725109	ENSG00000227603.1	RP11-165J3.6	4.45	1.06e-05	0.00206	0.43	0.2	Schizophrenia;	chr9:93639802	chr9:93435332~93437121:-
LUAD	cis	rs73186030	0.764	rs9834317	ENSG00000272758.4	RP11-299J3.8	4.45	1.06e-05	0.00206	0.26	0.2	Serum parathyroid hormone levels;	chr3:122370512	chr3:122416207~122443180:+
LUAD	cis	rs2115630	1	rs8037423	ENSG00000225151.9	GOLGA2P7	4.45	1.06e-05	0.00206	0.22	0.2	P wave terminal force;	chr15:84812263	chr15:84199311~84230136:-
LUAD	cis	rs1499614	1	rs2707832	ENSG00000229886.1	RP5-1132H15.3	4.45	1.06e-05	0.00206	0.34	0.2	Gout;	chr7:66671562	chr7:66025126~66031544:-
LUAD	cis	rs1478897	0.898	rs2248700	ENSG00000270154.1	RP11-419I17.1	-4.45	1.06e-05	0.00206	-0.23	-0.2	Systemic lupus erythematosus;	chr8:11536236	chr8:12476462~12477122:+
LUAD	cis	rs4578769	0.513	rs2034933	ENSG00000265943.1	RP11-739L10.1	4.45	1.06e-05	0.00206	0.25	0.2	Eosinophil percentage of white cells;	chr18:22918788	chr18:22699481~22933764:-
LUAD	cis	rs2708977	0.698	rs772160	ENSG00000237510.6	AC008268.2	-4.45	1.06e-05	0.00206	-0.28	-0.2	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96373928	chr2:95789654~95800166:+
LUAD	cis	rs2337406	0.866	rs4280141	ENSG00000223648.3	IGHV3-64	-4.45	1.06e-05	0.00206	-0.23	-0.2	Alzheimer's disease (late onset);	chr14:106780476	chr14:106643132~106658258:-
LUAD	cis	rs2337406	0.866	rs4280141	ENSG00000211972.2	IGHV3-66	-4.45	1.06e-05	0.00206	-0.21	-0.2	Alzheimer's disease (late onset);	chr14:106780476	chr14:106675017~106675544:-
LUAD	cis	rs4660214	0.614	rs1537815	ENSG00000228060.1	RP11-69E11.8	4.45	1.06e-05	0.00206	0.18	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39278946	chr1:39565160~39573203:+
LUAD	cis	rs7178424	0.87	rs12898423	ENSG00000259251.2	RP11-643M14.1	4.45	1.06e-05	0.00207	0.21	0.2	Height;	chr15:61959252	chr15:62060503~62062434:+
LUAD	cis	rs1555322	0.53	rs6058224	ENSG00000261582.1	RP4-614O4.11	-4.45	1.06e-05	0.00207	-0.25	-0.2	Attention deficit hyperactivity disorder;	chr20:35293971	chr20:35267885~35280043:-
LUAD	cis	rs1799949	1	rs11651341	ENSG00000236383.6	LINC00854	-4.45	1.06e-05	0.00207	-0.16	-0.2	Menopause (age at onset);	chr17:43350693	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs34572725	ENSG00000236383.6	LINC00854	-4.45	1.06e-05	0.00207	-0.16	-0.2	Menopause (age at onset);	chr17:43351298	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs4534897	ENSG00000236383.6	LINC00854	-4.45	1.06e-05	0.00207	-0.16	-0.2	Menopause (age at onset);	chr17:43354440	chr17:43216941~43305976:-
LUAD	cis	rs2731006	0.591	rs7962735	ENSG00000257114.2	RP11-25I15.3	4.45	1.06e-05	0.00207	0.3	0.2	Panic disorder;	chr12:42814269	chr12:42692216~42717119:+
LUAD	cis	rs6860806	0.661	rs4705929	ENSG00000233006.5	AC034220.3	4.45	1.06e-05	0.00207	0.18	0.2	Breast cancer;	chr5:132248485	chr5:132311285~132369916:-
LUAD	cis	rs77688320	0.573	rs2080327	ENSG00000213090.2	AC007256.5	-4.45	1.06e-05	0.00207	-0.23	-0.2	Breast cancer;	chr2:201461495	chr2:201410544~201413308:-
LUAD	cis	rs6714710	0.603	rs6746768	ENSG00000230606.9	AC159540.1	-4.45	1.06e-05	0.00207	-0.21	-0.2	Posterior cortical atrophy and Alzheimer's disease;	chr2:97850184	chr2:97416165~97433527:-
LUAD	cis	rs6714710	0.603	rs6757357	ENSG00000230606.9	AC159540.1	-4.45	1.06e-05	0.00207	-0.21	-0.2	Posterior cortical atrophy and Alzheimer's disease;	chr2:97875287	chr2:97416165~97433527:-
LUAD	cis	rs6714710	0.58	rs55886305	ENSG00000230606.9	AC159540.1	-4.45	1.06e-05	0.00207	-0.21	-0.2	Posterior cortical atrophy and Alzheimer's disease;	chr2:97879198	chr2:97416165~97433527:-
LUAD	cis	rs6714710	0.603	rs13023980	ENSG00000230606.9	AC159540.1	-4.45	1.06e-05	0.00207	-0.21	-0.2	Posterior cortical atrophy and Alzheimer's disease;	chr2:97886524	chr2:97416165~97433527:-
LUAD	cis	rs7824557	0.507	rs7010590	ENSG00000255046.1	RP11-297N6.4	-4.45	1.06e-05	0.00207	-0.24	-0.2	Retinal vascular caliber;	chr8:11205373	chr8:11797928~11802568:-
LUAD	cis	rs4819052	0.679	rs2838860	ENSG00000215447.6	BX322557.10	-4.45	1.06e-05	0.00207	-0.23	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45264989	chr21:45288052~45291738:+
LUAD	cis	rs4908760	0.539	rs7513880	ENSG00000270282.1	RP5-1115A15.2	4.45	1.06e-05	0.00207	0.22	0.2	Vitiligo;	chr1:8779241	chr1:8512653~8513021:+
LUAD	cis	rs4841134	1	rs35918648	ENSG00000233609.3	RP11-62H7.2	-4.45	1.06e-05	0.00207	-0.16	-0.2	Age-related disease endophenotypes;	chr8:9328614	chr8:8961200~8979025:+
LUAD	cis	rs227275	0.556	rs6815526	ENSG00000251288.2	RP11-10L12.2	-4.45	1.06e-05	0.00207	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102899729	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.556	rs6824070	ENSG00000251288.2	RP11-10L12.2	-4.45	1.06e-05	0.00207	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102901676	chr4:102751401~102752641:+
LUAD	cis	rs11722779	0.935	rs6856176	ENSG00000251288.2	RP11-10L12.2	-4.45	1.06e-05	0.00207	-0.24	-0.2	Schizophrenia;	chr4:102902574	chr4:102751401~102752641:+
LUAD	cis	rs6840258	0.891	rs75921854	ENSG00000251411.1	RP11-397E7.4	-4.45	1.07e-05	0.00207	-0.25	-0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87110944	chr4:86913266~86914817:-
LUAD	cis	rs2702164	0.781	rs1259297	ENSG00000240661.1	RP11-174O3.3	-4.45	1.07e-05	0.00207	-0.24	-0.2	Gut microbiome composition (winter);	chr3:120422362	chr3:120349510~120367998:+
LUAD	cis	rs9652601	0.748	rs8064154	ENSG00000274038.1	RP11-66H6.4	-4.45	1.07e-05	0.00207	-0.25	-0.2	Systemic lupus erythematosus;	chr16:11125562	chr16:11056556~11057034:+
LUAD	cis	rs889398	0.715	rs13330951	ENSG00000226232.7	RP11-419C5.2	-4.45	1.07e-05	0.00207	-0.17	-0.2	Body mass index;	chr16:69529939	chr16:69976388~69996188:-
LUAD	cis	rs2153535	0.553	rs6932565	ENSG00000230939.1	RP11-314C16.1	-4.45	1.07e-05	0.00207	-0.22	-0.2	Motion sickness;	chr6:8644926	chr6:8784178~8785445:+
LUAD	cis	rs2735413	0.56	rs73562716	ENSG00000276007.1	RP11-358L22.3	4.45	1.07e-05	0.00207	0.23	0.2	Systolic blood pressure (alcohol consumption interaction);	chr16:78092518	chr16:78123243~78124332:+
LUAD	cis	rs858239	0.601	rs6969733	ENSG00000226816.2	AC005082.12	4.45	1.07e-05	0.00208	0.26	0.2	Cerebrospinal fluid biomarker levels;	chr7:23128758	chr7:23206013~23208045:+
LUAD	cis	rs6095360	1	rs3092427	ENSG00000222365.1	SNORD12B	-4.45	1.07e-05	0.00208	-0.21	-0.2	Intelligence (multi-trait analysis);	chr20:49158244	chr20:49280319~49280409:+
LUAD	cis	rs11064837	0.523	rs7310266	ENSG00000248636.5	RP11-768F21.1	4.45	1.07e-05	0.00208	0.23	0.2	Schizophrenia;	chr12:119660604	chr12:119387987~119668079:-
LUAD	cis	rs16846053	0.642	rs13399126	ENSG00000227403.1	AC009299.3	4.45	1.07e-05	0.00208	0.32	0.2	Blood osmolality (transformed sodium);	chr2:161777799	chr2:161244739~161249050:+
LUAD	cis	rs16846053	0.642	rs10469686	ENSG00000227403.1	AC009299.3	4.45	1.07e-05	0.00208	0.32	0.2	Blood osmolality (transformed sodium);	chr2:161779321	chr2:161244739~161249050:+
LUAD	cis	rs9545047	0.625	rs9565489	ENSG00000227354.5	RBM26-AS1	4.45	1.07e-05	0.00208	0.21	0.2	Schizophrenia;	chr13:79342106	chr13:79406309~79424328:+
LUAD	cis	rs9907295	0.688	rs4795101	ENSG00000270977.1	AC015849.16	-4.45	1.07e-05	0.00208	-0.3	-0.2	Fibroblast growth factor basic levels;	chr17:35932989	chr17:35893707~35911023:-
LUAD	cis	rs6964833	0.873	rs4717905	ENSG00000184616.8	AC004166.6	4.45	1.07e-05	0.00208	0.3	0.2	Menarche (age at onset);	chr7:74668903	chr7:74906673~74913256:-
LUAD	cis	rs4925386	1	rs2151512	ENSG00000273619.1	RP5-908M14.9	4.45	1.07e-05	0.00208	0.18	0.2	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62338439	chr20:62386303~62386970:-
LUAD	cis	rs227275	0.554	rs223404	ENSG00000251288.2	RP11-10L12.2	-4.45	1.07e-05	0.00208	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102816951	chr4:102751401~102752641:+
LUAD	cis	rs2243480	1	rs313820	ENSG00000232559.3	GS1-124K5.12	4.45	1.07e-05	0.00208	0.35	0.2	Diabetic kidney disease;	chr7:66109479	chr7:66554588~66576923:-
LUAD	cis	rs12478296	1	rs4973685	ENSG00000261186.2	RP11-341N2.1	-4.45	1.07e-05	0.00208	-0.36	-0.2	Obesity-related traits;	chr2:242076938	chr2:242087351~242088457:-
LUAD	cis	rs9341808	0.754	rs3793000	ENSG00000260645.1	RP11-250B2.5	4.45	1.07e-05	0.00208	0.19	0.2	Sitting height ratio;	chr6:80285420	chr6:80466958~80469080:+
LUAD	cis	rs2153535	0.585	rs1328867	ENSG00000230939.1	RP11-314C16.1	-4.45	1.07e-05	0.00208	-0.22	-0.2	Motion sickness;	chr6:8652454	chr6:8784178~8785445:+
LUAD	cis	rs5769707	0.967	rs1018812	ENSG00000235111.1	RP1-29C18.8	-4.45	1.07e-05	0.00208	-0.22	-0.2	Monocyte percentage of white cells;Monocyte count;	chr22:49616425	chr22:49612657~49615716:-
LUAD	cis	rs7746199	0.736	rs13212093	ENSG00000219392.1	RP1-265C24.5	-4.45	1.07e-05	0.00208	-0.43	-0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27638937	chr6:28115628~28116551:+
LUAD	cis	rs7746199	0.736	rs34038546	ENSG00000219392.1	RP1-265C24.5	-4.45	1.07e-05	0.00208	-0.43	-0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27639881	chr6:28115628~28116551:+
LUAD	cis	rs141342723	1	rs141342723	ENSG00000219392.1	RP1-265C24.5	-4.45	1.07e-05	0.00208	-0.43	-0.2	Autism spectrum disorder or schizophrenia;	chr6:27654305	chr6:28115628~28116551:+
LUAD	cis	rs7746199	0.736	rs34543938	ENSG00000219392.1	RP1-265C24.5	-4.45	1.07e-05	0.00208	-0.43	-0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27656861	chr6:28115628~28116551:+
LUAD	cis	rs7746199	0.736	rs56405707	ENSG00000219392.1	RP1-265C24.5	-4.45	1.07e-05	0.00208	-0.43	-0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27672467	chr6:28115628~28116551:+
LUAD	cis	rs6714710	0.58	rs13032265	ENSG00000230606.9	AC159540.1	-4.45	1.07e-05	0.00208	-0.21	-0.2	Posterior cortical atrophy and Alzheimer's disease;	chr2:97793102	chr2:97416165~97433527:-
LUAD	cis	rs11742741	0.905	rs1428194	ENSG00000248874.4	C5orf17	-4.45	1.07e-05	0.00208	-0.25	-0.2	Educational attainment;	chr5:24112220	chr5:23951348~24178263:+
LUAD	cis	rs561341	0.714	rs474455	ENSG00000265798.5	RP11-271K11.5	4.45	1.07e-05	0.00208	0.3	0.2	Hip circumference adjusted for BMI;	chr17:31985446	chr17:31038575~31059121:-
LUAD	cis	rs6496932	0.802	rs12442399	ENSG00000218052.5	ADAMTS7P4	4.45	1.07e-05	0.00208	0.23	0.2	Central corneal thickness;Corneal structure;	chr15:85311619	chr15:85255369~85330334:-
LUAD	cis	rs6496932	0.802	rs8038403	ENSG00000218052.5	ADAMTS7P4	4.45	1.07e-05	0.00208	0.23	0.2	Central corneal thickness;Corneal structure;	chr15:85313364	chr15:85255369~85330334:-
LUAD	cis	rs6496932	0.802	rs2063442	ENSG00000218052.5	ADAMTS7P4	4.45	1.07e-05	0.00208	0.23	0.2	Central corneal thickness;Corneal structure;	chr15:85314813	chr15:85255369~85330334:-
LUAD	cis	rs9341808	0.754	rs3812126	ENSG00000260645.1	RP11-250B2.5	-4.45	1.07e-05	0.00208	-0.18	-0.2	Sitting height ratio;	chr6:80242984	chr6:80466958~80469080:+
LUAD	cis	rs8098244	0.603	rs4800507	ENSG00000264745.1	TTC39C-AS1	4.45	1.07e-05	0.00208	0.21	0.2	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23726168	chr18:23994213~24015339:-
LUAD	cis	rs858239	0.73	rs10255155	ENSG00000226816.2	AC005082.12	-4.45	1.07e-05	0.00208	-0.26	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23362528	chr7:23206013~23208045:+
LUAD	cis	rs17772222	0.876	rs58655091	ENSG00000258789.1	RP11-507K2.3	-4.45	1.07e-05	0.00208	-0.27	-0.2	Coronary artery calcification;	chr14:88748567	chr14:88551597~88552493:+
LUAD	cis	rs1005277	0.505	rs7099777	ENSG00000263064.2	RP11-291L22.7	-4.45	1.07e-05	0.00208	-0.21	-0.2	Extrinsic epigenetic age acceleration;	chr10:37894641	chr10:38448689~38448949:+
LUAD	cis	rs9894429	0.966	rs6565605	ENSG00000263853.1	AC139530.1	-4.45	1.07e-05	0.00208	-0.2	-0.2	Eye color traits;	chr17:81622333	chr17:81676001~81676086:+
LUAD	cis	rs13315649	0.562	rs6797317	ENSG00000242551.2	POU5F1P6	-4.45	1.07e-05	0.00208	-0.24	-0.2	Sum eosinophil basophil counts;	chr3:128684381	chr3:128674735~128677005:-
LUAD	cis	rs9788333	0.792	rs34479949	ENSG00000224429.6	LINC00539	-4.45	1.07e-05	0.00208	-0.18	-0.2	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr13:21321435	chr13:21303515~21348721:-
LUAD	cis	rs227275	0.524	rs150894	ENSG00000251288.2	RP11-10L12.2	-4.45	1.07e-05	0.00208	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102811541	chr4:102751401~102752641:+
LUAD	cis	rs11168618	1	rs11168621	ENSG00000240399.1	RP1-228P16.1	4.45	1.07e-05	0.00208	0.19	0.2	Adiponectin levels;	chr12:48545188	chr12:48054813~48055591:-
LUAD	cis	rs7590268	0.549	rs34706823	ENSG00000279873.2	LINC01126	4.45	1.07e-05	0.00208	0.21	0.2	Orofacial clefts;	chr2:43613764	chr2:43227210~43228855:+
LUAD	cis	rs240993	0.516	rs369594	ENSG00000230177.1	RP5-1112D6.4	-4.45	1.07e-05	0.00209	-0.22	-0.2	Inflammatory skin disease;Psoriasis;	chr6:111303197	chr6:111277932~111278742:+
LUAD	cis	rs9341808	0.718	rs9352803	ENSG00000272129.1	RP11-250B2.6	4.45	1.07e-05	0.00209	0.24	0.2	Sitting height ratio;	chr6:80154950	chr6:80355424~80356859:+
LUAD	cis	rs9341808	0.655	rs9350846	ENSG00000272129.1	RP11-250B2.6	4.45	1.07e-05	0.00209	0.24	0.2	Sitting height ratio;	chr6:80155764	chr6:80355424~80356859:+
LUAD	cis	rs1876905	0.539	rs240958	ENSG00000230177.1	RP5-1112D6.4	4.45	1.07e-05	0.00209	0.24	0.2	Mean corpuscular hemoglobin;	chr6:111298449	chr6:111277932~111278742:+
LUAD	cis	rs2492286	0.597	rs7647337	ENSG00000242551.2	POU5F1P6	-4.45	1.07e-05	0.00209	-0.26	-0.2	Eosinophil counts;	chr3:128628353	chr3:128674735~128677005:-
LUAD	cis	rs862034	0.531	rs11159084	ENSG00000270000.1	RP3-449M8.9	4.45	1.07e-05	0.00209	0.22	0.2	Height;	chr14:74458441	chr14:74471930~74472360:-
LUAD	cis	rs4819052	0.851	rs34101026	ENSG00000237664.1	LINC00316	-4.45	1.07e-05	0.00209	-0.24	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242285	chr21:45338590~45341990:-
LUAD	cis	rs4819052	0.851	rs13052312	ENSG00000237664.1	LINC00316	-4.45	1.07e-05	0.00209	-0.24	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242444	chr21:45338590~45341990:-
LUAD	cis	rs4819052	0.851	rs2838828	ENSG00000237664.1	LINC00316	-4.45	1.07e-05	0.00209	-0.24	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243508	chr21:45338590~45341990:-
LUAD	cis	rs4819052	0.851	rs13049337	ENSG00000237664.1	LINC00316	-4.45	1.07e-05	0.00209	-0.24	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243545	chr21:45338590~45341990:-
LUAD	cis	rs2274273	0.745	rs56262555	ENSG00000258413.1	RP11-665C16.6	-4.45	1.07e-05	0.00209	-0.26	-0.2	Protein biomarker;	chr14:55095244	chr14:55262767~55272075:-
LUAD	cis	rs13113518	0.783	rs13111128	ENSG00000223305.1	RN7SKP30	4.45	1.07e-05	0.00209	0.23	0.2	Height;	chr4:55578154	chr4:55540502~55540835:-
LUAD	cis	rs11159086	1	rs4899514	ENSG00000259005.1	RP3-449M8.6	-4.45	1.08e-05	0.00209	-0.26	-0.2	Advanced glycation end-product levels;	chr14:74473467	chr14:74474007~74474864:-
LUAD	cis	rs1008375	0.966	rs758483	ENSG00000249502.1	AC006160.5	4.45	1.08e-05	0.00209	0.19	0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17701991	chr4:17587467~17614571:-
LUAD	cis	rs3096299	0.719	rs2353581	ENSG00000261118.1	RP11-104N10.1	4.45	1.08e-05	0.00209	0.2	0.2	Multiple myeloma (IgH translocation);	chr16:89452500	chr16:89492017~89504460:-
LUAD	cis	rs2274273	0.84	rs2009291	ENSG00000259318.1	RP11-454L9.2	-4.45	1.08e-05	0.00209	-0.17	-0.2	Protein biomarker;	chr14:55371512	chr14:55394940~55395233:-
LUAD	cis	rs453301	0.631	rs7843789	ENSG00000253893.2	FAM85B	4.45	1.08e-05	0.00209	0.25	0.2	Joint mobility (Beighton score);	chr8:8943051	chr8:8167819~8226614:-
LUAD	cis	rs17772222	1	rs2295135	ENSG00000258789.1	RP11-507K2.3	-4.45	1.08e-05	0.00209	-0.27	-0.2	Coronary artery calcification;	chr14:88427866	chr14:88551597~88552493:+
LUAD	cis	rs11673344	0.542	rs826325	ENSG00000276846.1	CTD-3220F14.3	4.45	1.08e-05	0.00209	0.22	0.2	Obesity-related traits;	chr19:37003580	chr19:37314868~37315620:-
LUAD	cis	rs9876781	1	rs922075	ENSG00000229759.1	MRPS18AP1	-4.45	1.08e-05	0.00209	-0.19	-0.2	Longevity;	chr3:48447994	chr3:48256350~48256938:-
LUAD	cis	rs9876781	1	rs2045554	ENSG00000229759.1	MRPS18AP1	-4.45	1.08e-05	0.00209	-0.19	-0.2	Longevity;	chr3:48453142	chr3:48256350~48256938:-
LUAD	cis	rs9545047	0.625	rs7319320	ENSG00000227354.5	RBM26-AS1	4.45	1.08e-05	0.00209	0.21	0.2	Schizophrenia;	chr13:79343072	chr13:79406309~79424328:+
LUAD	cis	rs9341808	0.754	rs9341810	ENSG00000272129.1	RP11-250B2.6	4.45	1.08e-05	0.00209	0.24	0.2	Sitting height ratio;	chr6:80265121	chr6:80355424~80356859:+
LUAD	cis	rs9341808	0.7	rs12215236	ENSG00000272129.1	RP11-250B2.6	4.45	1.08e-05	0.00209	0.24	0.2	Sitting height ratio;	chr6:80265341	chr6:80355424~80356859:+
LUAD	cis	rs6570726	0.791	rs448939	ENSG00000235652.6	RP11-545I5.3	4.45	1.08e-05	0.0021	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145487184	chr6:145799409~145886585:+
LUAD	cis	rs7208859	0.623	rs59447372	ENSG00000266490.1	CTD-2349P21.9	4.45	1.08e-05	0.0021	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30730567	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs8079891	ENSG00000266490.1	CTD-2349P21.9	4.45	1.08e-05	0.0021	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30731845	chr17:30792372~30792833:+
LUAD	cis	rs228614	0.536	rs150897	ENSG00000251288.2	RP11-10L12.2	-4.45	1.08e-05	0.0021	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769309	chr4:102751401~102752641:+
LUAD	cis	rs228614	0.536	rs223475	ENSG00000251288.2	RP11-10L12.2	-4.45	1.08e-05	0.0021	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771986	chr4:102751401~102752641:+
LUAD	cis	rs228614	0.536	rs223474	ENSG00000251288.2	RP11-10L12.2	-4.45	1.08e-05	0.0021	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102772007	chr4:102751401~102752641:+
LUAD	cis	rs7829975	0.682	rs7013471	ENSG00000173295.6	FAM86B3P	-4.45	1.08e-05	0.0021	-0.2	-0.2	Mood instability;	chr8:8829815	chr8:8228595~8244865:+
LUAD	cis	rs77688320	0.553	rs12473387	ENSG00000213090.2	AC007256.5	4.45	1.08e-05	0.0021	0.23	0.2	Breast cancer;	chr2:201415778	chr2:201410544~201413308:-
LUAD	cis	rs77688320	0.553	rs4507084	ENSG00000213090.2	AC007256.5	4.45	1.08e-05	0.0021	0.23	0.2	Breast cancer;	chr2:201420377	chr2:201410544~201413308:-
LUAD	cis	rs453301	0.631	rs28572014	ENSG00000173295.6	FAM86B3P	-4.45	1.08e-05	0.0021	-0.21	-0.2	Joint mobility (Beighton score);	chr8:8936097	chr8:8228595~8244865:+
LUAD	cis	rs12908161	1	rs56864281	ENSG00000259295.5	CSPG4P12	4.45	1.08e-05	0.0021	0.28	0.2	Schizophrenia;	chr15:84814418	chr15:85191438~85213905:+
LUAD	cis	rs8062405	0.755	rs4788073	ENSG00000261419.1	RP11-57A19.4	-4.45	1.08e-05	0.0021	-0.22	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28659696~28740781:-
LUAD	cis	rs5758511	0.68	rs5758657	ENSG00000227370.1	RP4-669P10.19	4.45	1.08e-05	0.0021	0.22	0.2	Birth weight;	chr22:42222663	chr22:42132543~42132998:+
LUAD	cis	rs5758511	0.68	rs1033459	ENSG00000227370.1	RP4-669P10.19	4.45	1.08e-05	0.0021	0.22	0.2	Birth weight;	chr22:42223061	chr22:42132543~42132998:+
LUAD	cis	rs1198430	0.925	rs2811975	ENSG00000232482.2	RP4-654C18.1	-4.45	1.08e-05	0.0021	-0.35	-0.2	Total cholesterol levels;	chr1:23474588	chr1:23410832~23412146:+
LUAD	cis	rs6430553	0.929	rs6758113	ENSG00000224043.6	CCNT2-AS1	-4.45	1.08e-05	0.0021	-0.24	-0.2	Blood metabolite levels;	chr2:134851677	chr2:134735464~134918710:-
LUAD	cis	rs2243480	1	rs1723270	ENSG00000226002.1	RP11-460N20.5	-4.45	1.08e-05	0.0021	-0.34	-0.2	Diabetic kidney disease;	chr7:66004843	chr7:65084103~65100232:+
LUAD	cis	rs227275	0.527	rs12500379	ENSG00000251288.2	RP11-10L12.2	-4.45	1.08e-05	0.0021	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102983665	chr4:102751401~102752641:+
LUAD	cis	rs9425766	0.679	rs6667267	ENSG00000227373.4	RP11-160H22.5	4.45	1.08e-05	0.0021	0.25	0.2	Life satisfaction;	chr1:174243623	chr1:174115300~174160004:-
LUAD	cis	rs1864585	0.52	rs9650659	ENSG00000255046.1	RP11-297N6.4	4.45	1.08e-05	0.0021	0.28	0.2	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10810255	chr8:11797928~11802568:-
LUAD	cis	rs2243480	1	rs316332	ENSG00000232559.3	GS1-124K5.12	4.45	1.08e-05	0.0021	0.34	0.2	Diabetic kidney disease;	chr7:66139312	chr7:66554588~66576923:-
LUAD	cis	rs9601248	0.756	rs928640	ENSG00000227354.5	RBM26-AS1	-4.45	1.08e-05	0.0021	-0.22	-0.2	Major depressive disorder;	chr13:79603348	chr13:79406309~79424328:+
LUAD	cis	rs7208859	0.573	rs8070182	ENSG00000266490.1	CTD-2349P21.9	4.45	1.08e-05	0.0021	0.28	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30792372~30792833:+
LUAD	cis	rs8072100	0.782	rs62074054	ENSG00000228782.6	CTD-2026D20.3	4.45	1.08e-05	0.0021	0.21	0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47694450	chr17:47450568~47492492:-
LUAD	cis	rs5758659	0.714	rs133376	ENSG00000182057.4	OGFRP1	4.45	1.08e-05	0.0021	0.24	0.2	Cognitive function;	chr22:42070901	chr22:42269753~42275196:+
LUAD	cis	rs875971	0.66	rs801193	ENSG00000224316.1	RP11-479O9.2	-4.45	1.08e-05	0.0021	-0.2	-0.2	Aortic root size;	chr7:66565625	chr7:65773620~65802067:+
LUAD	cis	rs7324557	0.717	rs6490826	ENSG00000205861.10	C1QTNF9B-AS1	-4.45	1.08e-05	0.0021	-0.27	-0.2	Visceral adipose tissue adjusted for BMI;	chr13:23804999	chr13:23888889~23897263:+
LUAD	cis	rs3096299	0.748	rs2965822	ENSG00000182376.2	RP5-1142A6.8	4.45	1.08e-05	0.0021	0.21	0.2	Multiple myeloma (IgH translocation);	chr16:89378269	chr16:88742767~88745748:+
LUAD	cis	rs6496932	0.802	rs12441698	ENSG00000218052.5	ADAMTS7P4	4.45	1.08e-05	0.0021	0.23	0.2	Central corneal thickness;Corneal structure;	chr15:85310470	chr15:85255369~85330334:-
LUAD	cis	rs16846053	0.642	rs2389533	ENSG00000227403.1	AC009299.3	4.45	1.08e-05	0.00211	0.32	0.2	Blood osmolality (transformed sodium);	chr2:161783216	chr2:161244739~161249050:+
LUAD	cis	rs6012564	1	rs17632	ENSG00000230758.1	SNAP23P	4.45	1.09e-05	0.00211	0.21	0.2	Anger;	chr20:49096526	chr20:49038357~49038602:-
LUAD	cis	rs2834288	0.5	rs7280837	ENSG00000237945.6	LINC00649	4.45	1.09e-05	0.00211	0.24	0.2	Gut microbiota (bacterial taxa);	chr21:33951533	chr21:33915534~33977691:+
LUAD	cis	rs7727544	0.582	rs2301579	ENSG00000233006.5	AC034220.3	4.45	1.09e-05	0.00211	0.18	0.2	Blood metabolite levels;	chr5:132217647	chr5:132311285~132369916:-
LUAD	cis	rs801193	0.613	rs2659900	ENSG00000232559.3	GS1-124K5.12	4.45	1.09e-05	0.00211	0.23	0.2	Aortic root size;	chr7:66719456	chr7:66554588~66576923:-
LUAD	cis	rs6964587	1	rs6960867	ENSG00000188693.7	CYP51A1-AS1	-4.45	1.09e-05	0.00211	-0.24	-0.2	Breast cancer;	chr7:92083384	chr7:92134604~92180725:+
LUAD	cis	rs6061231	0.837	rs6121558	ENSG00000273619.1	RP5-908M14.9	-4.45	1.09e-05	0.00211	-0.21	-0.2	Colorectal cancer;	chr20:62386309	chr20:62386303~62386970:-
LUAD	cis	rs2348418	0.801	rs7298379	ENSG00000247934.4	RP11-967K21.1	4.45	1.09e-05	0.00211	0.23	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28270541	chr12:28163298~28190738:-
LUAD	cis	rs2880765	0.677	rs7181410	ENSG00000259416.2	RP11-158M2.5	-4.45	1.09e-05	0.00211	-0.2	-0.2	Coronary artery disease;	chr15:85463104	chr15:85754941~85756237:-
LUAD	cis	rs13113518	0.812	rs12649507	ENSG00000223305.1	RN7SKP30	-4.45	1.09e-05	0.00211	-0.23	-0.2	Height;	chr4:55514317	chr4:55540502~55540835:-
LUAD	cis	rs227275	0.554	rs223422	ENSG00000251288.2	RP11-10L12.2	-4.45	1.09e-05	0.00211	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102805616	chr4:102751401~102752641:+
LUAD	cis	rs6479891	1	rs4745729	ENSG00000232075.1	MRPL35P2	4.45	1.09e-05	0.00211	0.33	0.2	Arthritis (juvenile idiopathic);	chr10:63517323	chr10:63634317~63634827:-
LUAD	cis	rs6479891	1	rs12416349	ENSG00000232075.1	MRPL35P2	4.45	1.09e-05	0.00211	0.33	0.2	Arthritis (juvenile idiopathic);	chr10:63517783	chr10:63634317~63634827:-
LUAD	cis	rs4713118	0.513	rs9368547	ENSG00000216901.1	AL022393.7	4.45	1.09e-05	0.00211	0.24	0.2	Parkinson's disease;	chr6:28060289	chr6:28176188~28176674:+
LUAD	cis	rs13113518	0.783	rs6843997	ENSG00000223305.1	RN7SKP30	4.45	1.09e-05	0.00211	0.23	0.2	Height;	chr4:55508982	chr4:55540502~55540835:-
LUAD	cis	rs7590268	0.577	rs71420056	ENSG00000279873.2	LINC01126	4.45	1.09e-05	0.00211	0.2	0.2	Orofacial clefts;	chr2:43575363	chr2:43227210~43228855:+
LUAD	cis	rs4372836	1	rs72782294	ENSG00000226833.4	AC097724.3	-4.45	1.09e-05	0.00211	-0.23	-0.2	Body mass index;	chr2:28730524	chr2:28708953~28736205:-
LUAD	cis	rs4372836	1	rs6710959	ENSG00000226833.4	AC097724.3	4.45	1.09e-05	0.00211	0.23	0.2	Body mass index;	chr2:28735737	chr2:28708953~28736205:-
LUAD	cis	rs4372836	1	rs4640348	ENSG00000226833.4	AC097724.3	4.45	1.09e-05	0.00211	0.23	0.2	Body mass index;	chr2:28742613	chr2:28708953~28736205:-
LUAD	cis	rs11089937	0.597	rs5756991	ENSG00000211640.3	IGLV6-57	4.45	1.09e-05	0.00212	0.15	0.2	Periodontitis (PAL4Q3);	chr22:22132541	chr22:22195713~22196460:+
LUAD	cis	rs11089937	0.54	rs5756992	ENSG00000211640.3	IGLV6-57	4.45	1.09e-05	0.00212	0.15	0.2	Periodontitis (PAL4Q3);	chr22:22132636	chr22:22195713~22196460:+
LUAD	cis	rs11089937	0.597	rs9622919	ENSG00000211640.3	IGLV6-57	4.45	1.09e-05	0.00212	0.15	0.2	Periodontitis (PAL4Q3);	chr22:22132863	chr22:22195713~22196460:+
LUAD	cis	rs11089937	0.597	rs9619793	ENSG00000211640.3	IGLV6-57	4.45	1.09e-05	0.00212	0.15	0.2	Periodontitis (PAL4Q3);	chr22:22132952	chr22:22195713~22196460:+
LUAD	cis	rs35491132	1	rs35491132	ENSG00000219392.1	RP1-265C24.5	-4.45	1.09e-05	0.00212	-0.42	-0.2	Urinary tract infection frequency;	chr6:27559449	chr6:28115628~28116551:+
LUAD	cis	rs2212361	0.558	rs56365771	ENSG00000255893.1	RP11-685N10.1	-4.45	1.09e-05	0.00212	-0.27	-0.2	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94529586	chr11:94472908~94473570:-
LUAD	cis	rs2274273	0.686	rs28631821	ENSG00000259318.1	RP11-454L9.2	4.45	1.09e-05	0.00212	0.17	0.2	Protein biomarker;	chr14:55379269	chr14:55394940~55395233:-
LUAD	cis	rs2274273	0.87	rs946059	ENSG00000259318.1	RP11-454L9.2	4.45	1.09e-05	0.00212	0.17	0.2	Protein biomarker;	chr14:55380748	chr14:55394940~55395233:-
LUAD	cis	rs9910055	0.529	rs425038	ENSG00000267080.4	ASB16-AS1	4.45	1.09e-05	0.00212	0.18	0.2	Total body bone mineral density;	chr17:44104660	chr17:44175973~44186717:-
LUAD	cis	rs7339483	0.718	rs73015232	ENSG00000268058.1	BNIP3P40	-4.45	1.09e-05	0.00212	-0.36	-0.2	Discordance in emotional problems in monozygotic twins;	chr19:24250467	chr19:24098425~24098980:-
LUAD	cis	rs34779708	0.801	rs12255409	ENSG00000271335.4	RP11-324I22.4	4.44	1.09e-05	0.00212	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35246497	chr10:35314552~35336401:-
LUAD	cis	rs4811196	0.748	rs4809881	ENSG00000226144.2	RPS27AP3	4.44	1.09e-05	0.00212	0.22	0.2	Bone mineral density;	chr20:37880261	chr20:37049254~37049707:+
LUAD	cis	rs12073359	1	rs1382573	ENSG00000223945.2	RP11-458I7.1	-4.44	1.09e-05	0.00212	-0.3	-0.2	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150160129	chr1:150053864~150055034:+
LUAD	cis	rs2115630	1	rs11073730	ENSG00000225151.9	GOLGA2P7	4.44	1.09e-05	0.00212	0.22	0.2	P wave terminal force;	chr15:84811365	chr15:84199311~84230136:-
LUAD	cis	rs1005277	0.505	rs719569	ENSG00000263064.2	RP11-291L22.7	-4.44	1.09e-05	0.00212	-0.21	-0.2	Extrinsic epigenetic age acceleration;	chr10:37865487	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.522	rs200943	ENSG00000263064.2	RP11-291L22.7	4.44	1.09e-05	0.00212	0.21	0.2	Extrinsic epigenetic age acceleration;	chr10:37859802	chr10:38448689~38448949:+
LUAD	cis	rs6723108	0.517	rs1530555	ENSG00000224043.6	CCNT2-AS1	-4.44	1.09e-05	0.00212	-0.25	-0.2	Type 2 diabetes;	chr2:134842169	chr2:134735464~134918710:-
LUAD	cis	rs9473147	0.543	rs9349407	ENSG00000270761.1	RP11-385F7.1	-4.44	1.09e-05	0.00212	-0.22	-0.2	Platelet distribution width;Mean platelet volume;	chr6:47485642	chr6:47477243~47477572:-
LUAD	cis	rs4660214	0.568	rs6692769	ENSG00000228060.1	RP11-69E11.8	4.44	1.09e-05	0.00212	0.18	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39217503	chr1:39565160~39573203:+
LUAD	cis	rs8072100	0.905	rs11651766	ENSG00000228782.6	CTD-2026D20.3	4.44	1.09e-05	0.00212	0.21	0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47497565	chr17:47450568~47492492:-
LUAD	cis	rs8072100	0.905	rs9901869	ENSG00000228782.6	CTD-2026D20.3	4.44	1.09e-05	0.00212	0.21	0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47497840	chr17:47450568~47492492:-
LUAD	cis	rs7811142	0.72	rs112622797	ENSG00000078319.8	PMS2P1	-4.44	1.09e-05	0.00212	-0.25	-0.2	Platelet count;	chr7:100319793	chr7:100320992~100341908:-
LUAD	cis	rs853679	0.882	rs9393908	ENSG00000204709.4	LINC01556	4.44	1.09e-05	0.00212	0.34	0.2	Depression;	chr6:28223052	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.882	rs9366717	ENSG00000204709.4	LINC01556	4.44	1.09e-05	0.00212	0.34	0.2	Depression;	chr6:28223279	chr6:28943877~28944537:+
LUAD	cis	rs7665090	0.936	rs2866412	ENSG00000246560.2	RP11-10L12.4	4.44	1.1e-05	0.00212	0.24	0.2	Primary biliary cholangitis;	chr4:102633193	chr4:102828055~102844075:+
LUAD	cis	rs9341808	0.69	rs2322634	ENSG00000272129.1	RP11-250B2.6	4.44	1.1e-05	0.00212	0.24	0.2	Sitting height ratio;	chr6:80164297	chr6:80355424~80356859:+
LUAD	cis	rs6012564	0.826	rs2869715	ENSG00000230758.1	SNAP23P	4.44	1.1e-05	0.00212	0.21	0.2	Anger;	chr20:49143463	chr20:49038357~49038602:-
LUAD	cis	rs6012564	0.793	rs6066979	ENSG00000230758.1	SNAP23P	4.44	1.1e-05	0.00212	0.21	0.2	Anger;	chr20:49144319	chr20:49038357~49038602:-
LUAD	cis	rs6012564	0.762	rs6066980	ENSG00000230758.1	SNAP23P	4.44	1.1e-05	0.00212	0.21	0.2	Anger;	chr20:49144320	chr20:49038357~49038602:-
LUAD	cis	rs801193	0.761	rs2659888	ENSG00000224316.1	RP11-479O9.2	4.44	1.1e-05	0.00212	0.2	0.2	Aortic root size;	chr7:66765184	chr7:65773620~65802067:+
LUAD	cis	rs7086627	0.515	rs11202959	ENSG00000226659.1	RP11-137H2.4	-4.44	1.1e-05	0.00213	-0.26	-0.2	Post bronchodilator FEV1;	chr10:80449916	chr10:80529597~80535942:-
LUAD	cis	rs7086627	0.515	rs11202960	ENSG00000226659.1	RP11-137H2.4	-4.44	1.1e-05	0.00213	-0.26	-0.2	Post bronchodilator FEV1;	chr10:80450051	chr10:80529597~80535942:-
LUAD	cis	rs7086627	0.515	rs10887894	ENSG00000226659.1	RP11-137H2.4	-4.44	1.1e-05	0.00213	-0.26	-0.2	Post bronchodilator FEV1;	chr10:80450196	chr10:80529597~80535942:-
LUAD	cis	rs7086627	0.515	rs10887895	ENSG00000226659.1	RP11-137H2.4	-4.44	1.1e-05	0.00213	-0.26	-0.2	Post bronchodilator FEV1;	chr10:80450255	chr10:80529597~80535942:-
LUAD	cis	rs453301	0.658	rs3855900	ENSG00000233609.3	RP11-62H7.2	-4.44	1.1e-05	0.00213	-0.16	-0.2	Joint mobility (Beighton score);	chr8:9044411	chr8:8961200~8979025:+
LUAD	cis	rs3096299	0.685	rs4329923	ENSG00000182376.2	RP5-1142A6.8	4.44	1.1e-05	0.00213	0.21	0.2	Multiple myeloma (IgH translocation);	chr16:89493770	chr16:88742767~88745748:+
LUAD	cis	rs6570726	0.764	rs366673	ENSG00000235652.6	RP11-545I5.3	4.44	1.1e-05	0.00213	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145493492	chr6:145799409~145886585:+
LUAD	cis	rs9545047	0.532	rs9545079	ENSG00000227354.5	RBM26-AS1	4.44	1.1e-05	0.00213	0.21	0.2	Schizophrenia;	chr13:79346044	chr13:79406309~79424328:+
LUAD	cis	rs2976388	1	rs2572910	ENSG00000253741.1	CTD-2292P10.4	4.44	1.1e-05	0.00213	0.22	0.2	Urinary tract infection frequency;	chr8:142688717	chr8:142702252~142726973:-
LUAD	cis	rs2281603	0.951	rs11158544	ENSG00000259116.1	RP11-973N13.4	-4.44	1.1e-05	0.00213	-0.18	-0.2	Lymphocyte counts;	chr14:64529769	chr14:64514154~64540368:-
LUAD	cis	rs2281603	0.951	rs12588886	ENSG00000259116.1	RP11-973N13.4	-4.44	1.1e-05	0.00213	-0.18	-0.2	Lymphocyte counts;	chr14:64530226	chr14:64514154~64540368:-
LUAD	cis	rs2281603	0.857	rs3783722	ENSG00000259116.1	RP11-973N13.4	-4.44	1.1e-05	0.00213	-0.18	-0.2	Lymphocyte counts;	chr14:64531248	chr14:64514154~64540368:-
LUAD	cis	rs7005380	0.581	rs12679478	ENSG00000279347.1	RP11-85I17.2	-4.44	1.1e-05	0.00213	-0.19	-0.2	Interstitial lung disease;	chr8:119903994	chr8:119838736~119840385:-
LUAD	cis	rs7208859	0.673	rs2470251	ENSG00000280069.1	CTD-2349P21.3	-4.44	1.1e-05	0.00213	-0.23	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30768043	chr17:30738182~30740275:+
LUAD	cis	rs1979679	0.918	rs11049562	ENSG00000278733.1	RP11-425D17.1	4.44	1.1e-05	0.00213	0.25	0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28375576	chr12:28185625~28186190:-
LUAD	cis	rs34779708	0.733	rs61449529	ENSG00000271335.4	RP11-324I22.4	4.44	1.1e-05	0.00213	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35254986	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.733	rs59287215	ENSG00000271335.4	RP11-324I22.4	4.44	1.1e-05	0.00213	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35255066	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.702	rs35969476	ENSG00000271335.4	RP11-324I22.4	4.44	1.1e-05	0.00213	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35255390	chr10:35314552~35336401:-
LUAD	cis	rs11157436	0.581	rs17255433	ENSG00000211812.1	TRAV26-2	-4.44	1.1e-05	0.00213	-0.2	-0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22167051	chr14:22202583~22203368:+
LUAD	cis	rs11157436	0.602	rs17255440	ENSG00000211812.1	TRAV26-2	-4.44	1.1e-05	0.00213	-0.2	-0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22167297	chr14:22202583~22203368:+
LUAD	cis	rs911555	0.755	rs8014013	ENSG00000259775.1	RP11-45P15.4	4.44	1.1e-05	0.00213	0.26	0.2	Intelligence (multi-trait analysis);	chr14:103471035	chr14:103331674~103332367:-
LUAD	cis	rs1008375	1	rs11947857	ENSG00000249502.1	AC006160.5	4.44	1.1e-05	0.00213	0.19	0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17689424	chr4:17587467~17614571:-
LUAD	cis	rs17772222	0.92	rs61975260	ENSG00000258983.2	RP11-507K2.2	4.44	1.1e-05	0.00213	0.25	0.2	Coronary artery calcification;	chr14:88429597	chr14:88499334~88515502:+
LUAD	cis	rs7189233	0.531	rs3929	ENSG00000279344.1	RP11-44F14.7	-4.44	1.1e-05	0.00213	-0.16	-0.2	Intelligence (multi-trait analysis);	chr16:53490396	chr16:53478957~53481550:-
LUAD	cis	rs667920	0.575	rs9861150	ENSG00000239213.4	NCK1-AS1	4.44	1.1e-05	0.00213	0.27	0.2	Coronary artery disease;	chr3:136464478	chr3:136841726~136862054:-
LUAD	cis	rs8177876	0.822	rs4889231	ENSG00000261061.1	RP11-303E16.2	4.44	1.1e-05	0.00213	0.3	0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080110	chr16:81030770~81031485:+
LUAD	cis	rs4664293	0.967	rs13397722	ENSG00000226266.5	AC009961.3	-4.44	1.1e-05	0.00213	-0.28	-0.2	Monocyte percentage of white cells;	chr2:159659140	chr2:159670708~159712435:-
LUAD	cis	rs4819052	0.851	rs1056100	ENSG00000237664.1	LINC00316	-4.44	1.1e-05	0.00213	-0.23	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258796	chr21:45338590~45341990:-
LUAD	cis	rs12664251	0.809	rs6931074	ENSG00000253194.1	RP11-351A11.1	4.44	1.1e-05	0.00213	0.26	0.2	Schizophrenia;	chr6:119020840	chr6:118934785~119031541:+
LUAD	cis	rs9649213	0.574	rs7789440	ENSG00000272950.1	RP11-307C18.1	4.44	1.1e-05	0.00213	0.26	0.2	Prostate cancer (SNP x SNP interaction);	chr7:98259486	chr7:98322853~98323430:+
LUAD	cis	rs910316	0.967	rs4899545	ENSG00000279594.1	RP11-950C14.10	4.44	1.1e-05	0.00213	0.23	0.2	Height;	chr14:75101435	chr14:75011269~75012851:-
LUAD	cis	rs9815354	0.761	rs1851149	ENSG00000273328.4	RP11-141M3.6	4.44	1.1e-05	0.00213	0.32	0.2	Pulse pressure;Diastolic blood pressure;	chr3:41980216	chr3:42809414~42908105:+
LUAD	cis	rs9815354	0.857	rs794902	ENSG00000273328.4	RP11-141M3.6	4.44	1.1e-05	0.00213	0.32	0.2	Pulse pressure;Diastolic blood pressure;	chr3:41984447	chr3:42809414~42908105:+
LUAD	cis	rs8062405	0.755	rs12447461	ENSG00000261419.1	RP11-57A19.4	-4.44	1.1e-05	0.00213	-0.22	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28659696~28740781:-
LUAD	cis	rs9545047	0.604	rs2182873	ENSG00000227354.5	RBM26-AS1	4.44	1.1e-05	0.00213	0.21	0.2	Schizophrenia;	chr13:79356846	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs2025913	ENSG00000227354.5	RBM26-AS1	4.44	1.1e-05	0.00213	0.21	0.2	Schizophrenia;	chr13:79357315	chr13:79406309~79424328:+
LUAD	cis	rs6012564	1	rs2426109	ENSG00000230758.1	SNAP23P	-4.44	1.1e-05	0.00213	-0.21	-0.2	Anger;	chr20:49046090	chr20:49038357~49038602:-
LUAD	cis	rs2304003	1	rs10754968	ENSG00000235192.1	AC009495.2	4.44	1.1e-05	0.00213	0.24	0.2	Social communication problems;	chr2:165845956	chr2:165794851~165810010:+
LUAD	cis	rs2243480	1	rs1964692	ENSG00000232559.3	GS1-124K5.12	4.44	1.1e-05	0.00213	0.34	0.2	Diabetic kidney disease;	chr7:65989196	chr7:66554588~66576923:-
LUAD	cis	rs9910055	0.639	rs227583	ENSG00000267080.4	ASB16-AS1	-4.44	1.1e-05	0.00213	-0.18	-0.2	Total body bone mineral density;	chr17:44154330	chr17:44175973~44186717:-
LUAD	cis	rs9910055	0.659	rs2246287	ENSG00000267080.4	ASB16-AS1	-4.44	1.1e-05	0.00213	-0.18	-0.2	Total body bone mineral density;	chr17:44155074	chr17:44175973~44186717:-
LUAD	cis	rs9860428	0.527	rs6766388	ENSG00000242770.2	RP11-180K7.1	4.44	1.1e-05	0.00213	0.21	0.2	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112845954	chr3:112802478~112812819:+
LUAD	cis	rs9860428	0.527	rs4682440	ENSG00000242770.2	RP11-180K7.1	4.44	1.1e-05	0.00213	0.21	0.2	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112846226	chr3:112802478~112812819:+
LUAD	cis	rs449789	0.857	rs543547	ENSG00000235086.1	FNDC1-IT1	-4.44	1.1e-05	0.00213	-0.28	-0.2	Pulse pressure;	chr6:159281319	chr6:159240786~159243329:+
LUAD	cis	rs449789	0.857	rs625687	ENSG00000235086.1	FNDC1-IT1	-4.44	1.1e-05	0.00213	-0.28	-0.2	Pulse pressure;	chr6:159282262	chr6:159240786~159243329:+
LUAD	cis	rs449789	0.857	rs625284	ENSG00000235086.1	FNDC1-IT1	-4.44	1.1e-05	0.00213	-0.28	-0.2	Pulse pressure;	chr6:159282341	chr6:159240786~159243329:+
LUAD	cis	rs449789	0.857	rs575681	ENSG00000235086.1	FNDC1-IT1	-4.44	1.1e-05	0.00213	-0.28	-0.2	Pulse pressure;	chr6:159282502	chr6:159240786~159243329:+
LUAD	cis	rs449789	0.857	rs9346784	ENSG00000235086.1	FNDC1-IT1	-4.44	1.1e-05	0.00213	-0.28	-0.2	Pulse pressure;	chr6:159282725	chr6:159240786~159243329:+
LUAD	cis	rs449789	0.681	rs12529478	ENSG00000235086.1	FNDC1-IT1	-4.44	1.1e-05	0.00213	-0.28	-0.2	Pulse pressure;	chr6:159283690	chr6:159240786~159243329:+
LUAD	cis	rs449789	0.711	rs7765794	ENSG00000235086.1	FNDC1-IT1	-4.44	1.1e-05	0.00213	-0.28	-0.2	Pulse pressure;	chr6:159283893	chr6:159240786~159243329:+
LUAD	cis	rs449789	0.857	rs592212	ENSG00000235086.1	FNDC1-IT1	-4.44	1.1e-05	0.00213	-0.28	-0.2	Pulse pressure;	chr6:159290051	chr6:159240786~159243329:+
LUAD	cis	rs449789	0.857	rs2451988	ENSG00000235086.1	FNDC1-IT1	-4.44	1.1e-05	0.00213	-0.28	-0.2	Pulse pressure;	chr6:159293358	chr6:159240786~159243329:+
LUAD	cis	rs9309473	0.607	rs1851546	ENSG00000163016.8	ALMS1P	4.44	1.1e-05	0.00213	0.22	0.2	Metabolite levels;	chr2:73363999	chr2:73644919~73685576:+
LUAD	cis	rs6751744	0.513	rs10173538	ENSG00000230783.1	AC009961.2	-4.44	1.1e-05	0.00213	-0.25	-0.2	Dysphagia;	chr2:159712765	chr2:159689217~159690291:-
LUAD	cis	rs1005277	0.522	rs11011343	ENSG00000263064.2	RP11-291L22.7	4.44	1.1e-05	0.00214	0.21	0.2	Extrinsic epigenetic age acceleration;	chr10:37713770	chr10:38448689~38448949:+
LUAD	cis	rs987724	0.519	rs12492968	ENSG00000240875.4	LINC00886	-4.44	1.1e-05	0.00214	-0.21	-0.2	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156824048	chr3:156747346~156817062:-
LUAD	cis	rs7621025	0.599	rs13063987	ENSG00000239213.4	NCK1-AS1	-4.44	1.1e-05	0.00214	-0.25	-0.2	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136726555	chr3:136841726~136862054:-
LUAD	cis	rs28386778	0.897	rs2727333	ENSG00000240280.5	TCAM1P	-4.44	1.1e-05	0.00214	-0.23	-0.2	Prudent dietary pattern;	chr17:63798663	chr17:63849292~63864379:+
LUAD	cis	rs6565180	0.791	rs4247355	ENSG00000273724.1	RP11-347C12.12	4.44	1.1e-05	0.00214	0.21	0.2	Tonsillectomy;	chr16:30380778	chr16:30336400~30343336:+
LUAD	cis	rs910316	1	rs7156328	ENSG00000279594.1	RP11-950C14.10	4.44	1.1e-05	0.00214	0.23	0.2	Height;	chr14:75066238	chr14:75011269~75012851:-
LUAD	cis	rs4819052	0.679	rs2236450	ENSG00000237664.1	LINC00316	-4.44	1.1e-05	0.00214	-0.23	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45282638	chr21:45338590~45341990:-
LUAD	cis	rs6840360	1	rs6535819	ENSG00000270265.1	RP11-731D1.4	-4.44	1.1e-05	0.00214	-0.2	-0.2	Intelligence (multi-trait analysis);	chr4:151730351	chr4:151333775~151353224:-
LUAD	cis	rs4664293	0.605	rs12474082	ENSG00000226266.5	AC009961.3	4.44	1.11e-05	0.00214	0.26	0.2	Monocyte percentage of white cells;	chr2:159657403	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.585	rs1991372	ENSG00000226266.5	AC009961.3	4.44	1.11e-05	0.00214	0.26	0.2	Monocyte percentage of white cells;	chr2:159659556	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.546	rs1991373	ENSG00000226266.5	AC009961.3	4.44	1.11e-05	0.00214	0.26	0.2	Monocyte percentage of white cells;	chr2:159659714	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.625	rs6707985	ENSG00000226266.5	AC009961.3	4.44	1.11e-05	0.00214	0.26	0.2	Monocyte percentage of white cells;	chr2:159659877	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.625	rs62171641	ENSG00000226266.5	AC009961.3	4.44	1.11e-05	0.00214	0.26	0.2	Monocyte percentage of white cells;	chr2:159659994	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.585	rs35293435	ENSG00000226266.5	AC009961.3	4.44	1.11e-05	0.00214	0.26	0.2	Monocyte percentage of white cells;	chr2:159662396	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.625	rs62171646	ENSG00000226266.5	AC009961.3	4.44	1.11e-05	0.00214	0.26	0.2	Monocyte percentage of white cells;	chr2:159662563	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.625	rs4664295	ENSG00000226266.5	AC009961.3	4.44	1.11e-05	0.00214	0.26	0.2	Monocyte percentage of white cells;	chr2:159663807	chr2:159670708~159712435:-
LUAD	cis	rs1729951	0.575	rs1682333	ENSG00000239213.4	NCK1-AS1	4.44	1.11e-05	0.00214	0.22	0.2	Neuroticism;	chr3:136969776	chr3:136841726~136862054:-
LUAD	cis	rs7208859	0.623	rs8075163	ENSG00000266490.1	CTD-2349P21.9	4.44	1.11e-05	0.00214	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30792372~30792833:+
LUAD	cis	rs17826219	0.706	rs8075107	ENSG00000266490.1	CTD-2349P21.9	4.44	1.11e-05	0.00214	0.3	0.2	Body mass index;	chr17:30779631	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs7223209	ENSG00000266490.1	CTD-2349P21.9	4.44	1.11e-05	0.00214	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs7223404	ENSG00000266490.1	CTD-2349P21.9	4.44	1.11e-05	0.00214	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs9916725	ENSG00000266490.1	CTD-2349P21.9	4.44	1.11e-05	0.00214	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs9916727	ENSG00000266490.1	CTD-2349P21.9	4.44	1.11e-05	0.00214	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs73269945	ENSG00000266490.1	CTD-2349P21.9	4.44	1.11e-05	0.00214	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs9897728	ENSG00000266490.1	CTD-2349P21.9	4.44	1.11e-05	0.00214	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs1054400	ENSG00000266490.1	CTD-2349P21.9	4.44	1.11e-05	0.00214	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs1054397	ENSG00000266490.1	CTD-2349P21.9	4.44	1.11e-05	0.00214	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs9890558	ENSG00000266490.1	CTD-2349P21.9	4.44	1.11e-05	0.00214	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs3752020	ENSG00000266490.1	CTD-2349P21.9	4.44	1.11e-05	0.00214	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs9890855	ENSG00000266490.1	CTD-2349P21.9	4.44	1.11e-05	0.00214	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs9893422	ENSG00000266490.1	CTD-2349P21.9	4.44	1.11e-05	0.00214	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs9891166	ENSG00000266490.1	CTD-2349P21.9	4.44	1.11e-05	0.00214	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs73269974	ENSG00000266490.1	CTD-2349P21.9	4.44	1.11e-05	0.00214	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs34756112	ENSG00000266490.1	CTD-2349P21.9	4.44	1.11e-05	0.00214	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.573	rs60724269	ENSG00000266490.1	CTD-2349P21.9	4.44	1.11e-05	0.00214	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs76633166	ENSG00000266490.1	CTD-2349P21.9	4.44	1.11e-05	0.00214	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs1061346	ENSG00000266490.1	CTD-2349P21.9	4.44	1.11e-05	0.00214	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs1061343	ENSG00000266490.1	CTD-2349P21.9	4.44	1.11e-05	0.00214	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs73269988	ENSG00000266490.1	CTD-2349P21.9	4.44	1.11e-05	0.00214	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs9899525	ENSG00000266490.1	CTD-2349P21.9	4.44	1.11e-05	0.00214	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs9911784	ENSG00000266490.1	CTD-2349P21.9	4.44	1.11e-05	0.00214	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs9911997	ENSG00000266490.1	CTD-2349P21.9	4.44	1.11e-05	0.00214	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs9890862	ENSG00000266490.1	CTD-2349P21.9	4.44	1.11e-05	0.00214	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs78071511	ENSG00000266490.1	CTD-2349P21.9	4.44	1.11e-05	0.00214	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs2035494	ENSG00000266490.1	CTD-2349P21.9	4.44	1.11e-05	0.00214	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs9915566	ENSG00000266490.1	CTD-2349P21.9	4.44	1.11e-05	0.00214	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.573	rs8064686	ENSG00000266490.1	CTD-2349P21.9	4.44	1.11e-05	0.00214	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs11657369	ENSG00000266490.1	CTD-2349P21.9	4.44	1.11e-05	0.00214	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs8075341	ENSG00000266490.1	CTD-2349P21.9	4.44	1.11e-05	0.00214	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs73271842	ENSG00000266490.1	CTD-2349P21.9	4.44	1.11e-05	0.00214	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.524	rs28760584	ENSG00000266490.1	CTD-2349P21.9	4.44	1.11e-05	0.00214	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs7212991	ENSG00000266490.1	CTD-2349P21.9	4.44	1.11e-05	0.00214	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs28627615	ENSG00000266490.1	CTD-2349P21.9	4.44	1.11e-05	0.00214	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30792372~30792833:+
LUAD	cis	rs9876781	1	rs6442119	ENSG00000229759.1	MRPS18AP1	4.44	1.11e-05	0.00214	0.19	0.2	Longevity;	chr3:48398713	chr3:48256350~48256938:-
LUAD	cis	rs2239557	0.961	rs11159061	ENSG00000259065.1	RP5-1021I20.1	-4.44	1.11e-05	0.00214	-0.23	-0.2	Common traits (Other);	chr14:74089560	chr14:73787360~73803270:+
LUAD	cis	rs2239557	1	rs17096228	ENSG00000259065.1	RP5-1021I20.1	-4.44	1.11e-05	0.00214	-0.23	-0.2	Common traits (Other);	chr14:74091966	chr14:73787360~73803270:+
LUAD	cis	rs5758511	0.68	rs5758699	ENSG00000226450.2	CYP2D8P	4.44	1.11e-05	0.00214	0.19	0.2	Birth weight;	chr22:42292028	chr22:42149886~42155001:-
LUAD	cis	rs7746199	0.736	rs13209332	ENSG00000219392.1	RP1-265C24.5	-4.44	1.11e-05	0.00214	-0.42	-0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27552973	chr6:28115628~28116551:+
LUAD	cis	rs7746199	0.736	rs34965299	ENSG00000219392.1	RP1-265C24.5	-4.44	1.11e-05	0.00214	-0.42	-0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27554077	chr6:28115628~28116551:+
LUAD	cis	rs3219474	0.502	rs41343546	ENSG00000280836.1	AL355480.1	-4.44	1.11e-05	0.00214	-0.39	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:45442591	chr1:45581219~45581321:-
LUAD	cis	rs2115630	1	rs2879828	ENSG00000225151.9	GOLGA2P7	4.44	1.11e-05	0.00214	0.22	0.2	P wave terminal force;	chr15:84818746	chr15:84199311~84230136:-
LUAD	cis	rs10129255	0.957	rs2007467	ENSG00000274576.2	IGHV2-70	-4.44	1.11e-05	0.00214	-0.18	-0.2	Kawasaki disease;	chr14:106771605	chr14:106770577~106771020:-
LUAD	cis	rs227275	0.525	rs3974604	ENSG00000251288.2	RP11-10L12.2	-4.44	1.11e-05	0.00214	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102928601	chr4:102751401~102752641:+
LUAD	cis	rs643506	0.874	rs10789849	ENSG00000230911.1	PPIHP1	-4.44	1.11e-05	0.00214	-0.24	-0.2	Breast cancer;	chr11:111845347	chr11:112029858~112030367:-
LUAD	cis	rs6840360	0.571	rs17360385	ENSG00000270265.1	RP11-731D1.4	-4.44	1.11e-05	0.00214	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151666818	chr4:151333775~151353224:-
LUAD	cis	rs6754311	0.773	rs666407	ENSG00000226806.1	AC011893.3	4.44	1.11e-05	0.00214	0.25	0.2	Mosquito bite size;	chr2:135882663	chr2:135820191~135823087:+
LUAD	cis	rs8396	1	rs4690909	ENSG00000271817.2	U3	-4.44	1.11e-05	0.00215	-0.23	-0.2	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158707999	chr4:158700691~158700909:+
LUAD	cis	rs2933343	1	rs876756	ENSG00000231305.3	RP11-723O4.2	4.44	1.11e-05	0.00215	0.24	0.2	IgG glycosylation;	chr3:128908780	chr3:128861313~128871540:-
LUAD	cis	rs227275	0.525	rs4596243	ENSG00000251288.2	RP11-10L12.2	-4.44	1.11e-05	0.00215	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102964411	chr4:102751401~102752641:+
LUAD	cis	rs5758511	0.68	rs1033460	ENSG00000227370.1	RP4-669P10.19	4.44	1.11e-05	0.00215	0.22	0.2	Birth weight;	chr22:42223302	chr22:42132543~42132998:+
LUAD	cis	rs7665090	0.967	rs6533022	ENSG00000246560.2	RP11-10L12.4	4.44	1.11e-05	0.00215	0.24	0.2	Primary biliary cholangitis;	chr4:102637794	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.554	rs149576	ENSG00000251288.2	RP11-10L12.2	-4.44	1.11e-05	0.00215	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102811411	chr4:102751401~102752641:+
LUAD	cis	rs7829975	0.688	rs6995407	ENSG00000173295.6	FAM86B3P	4.44	1.11e-05	0.00215	0.21	0.2	Mood instability;	chr8:8527137	chr8:8228595~8244865:+
LUAD	cis	rs61542988	0.57	rs7781074	ENSG00000228649.7	AC005682.5	-4.44	1.11e-05	0.00215	-0.29	-0.2	Fibrinogen levels;	chr7:22786741	chr7:22854178~22861579:+
LUAD	cis	rs75920871	0.66	rs12271161	ENSG00000254851.1	RP11-109L13.1	4.44	1.11e-05	0.00215	0.29	0.2	Subjective well-being;	chr11:117109195	chr11:117135528~117138582:+
LUAD	cis	rs7923837	0.687	rs11187139	ENSG00000236493.2	EIF2S2P3	4.44	1.11e-05	0.00215	0.23	0.2	Multiple sclerosis;Body mass index;	chr10:92706670	chr10:92668745~92669743:-
LUAD	cis	rs62246343	0.605	rs17050395	ENSG00000254485.4	RP11-380O24.1	4.44	1.11e-05	0.00215	0.25	0.2	Fibrinogen levels;	chr3:9492290	chr3:9292588~9363303:-
LUAD	cis	rs2933343	0.859	rs789245	ENSG00000231305.3	RP11-723O4.2	4.44	1.11e-05	0.00215	0.24	0.2	IgG glycosylation;	chr3:128864737	chr3:128861313~128871540:-
LUAD	cis	rs375066	0.934	rs2191564	ENSG00000267058.1	RP11-15A1.3	-4.44	1.11e-05	0.00215	-0.22	-0.2	Breast cancer;	chr19:43863459	chr19:43891804~43901805:-
LUAD	cis	rs375066	0.935	rs11673020	ENSG00000267058.1	RP11-15A1.3	-4.44	1.11e-05	0.00215	-0.22	-0.2	Breast cancer;	chr19:43870479	chr19:43891804~43901805:-
LUAD	cis	rs17826219	0.714	rs11650821	ENSG00000266490.1	CTD-2349P21.9	4.44	1.11e-05	0.00215	0.3	0.2	Body mass index;	chr17:30641132	chr17:30792372~30792833:+
LUAD	cis	rs13434995	0.796	rs2412664	ENSG00000273257.1	RP11-177J6.1	4.44	1.11e-05	0.00215	0.32	0.2	Adiponectin levels;	chr4:55591220	chr4:55387949~55388271:+
LUAD	cis	rs8062405	0.823	rs7202948	ENSG00000261419.1	RP11-57A19.4	-4.44	1.11e-05	0.00215	-0.22	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28659696~28740781:-
LUAD	cis	rs6012564	1	rs11696870	ENSG00000230758.1	SNAP23P	4.44	1.11e-05	0.00215	0.21	0.2	Anger;	chr20:49109070	chr20:49038357~49038602:-
LUAD	cis	rs6012564	0.963	rs6063355	ENSG00000230758.1	SNAP23P	4.44	1.11e-05	0.00215	0.21	0.2	Anger;	chr20:49109592	chr20:49038357~49038602:-
LUAD	cis	rs11742741	0.87	rs62350773	ENSG00000248874.4	C5orf17	-4.44	1.11e-05	0.00215	-0.25	-0.2	Educational attainment;	chr5:24098745	chr5:23951348~24178263:+
LUAD	cis	rs73242632	1	rs11935933	ENSG00000269949.1	RP11-738E22.3	4.44	1.11e-05	0.00215	0.54	0.2	Congenital heart disease (maternal effect);	chr4:56937040	chr4:56960927~56961373:-
LUAD	cis	rs73242632	1	rs73242619	ENSG00000269949.1	RP11-738E22.3	4.44	1.11e-05	0.00215	0.54	0.2	Congenital heart disease (maternal effect);	chr4:56944191	chr4:56960927~56961373:-
LUAD	cis	rs4568518	0.616	rs13223642	ENSG00000279048.1	RP11-511H23.2	4.44	1.11e-05	0.00215	0.16	0.2	Measles;	chr7:17965352	chr7:17940503~17942922:+
LUAD	cis	rs9652601	0.779	rs7203793	ENSG00000274038.1	RP11-66H6.4	-4.44	1.11e-05	0.00215	-0.24	-0.2	Systemic lupus erythematosus;	chr16:11088277	chr16:11056556~11057034:+
LUAD	cis	rs11157436	0.602	rs928954	ENSG00000211812.1	TRAV26-2	-4.44	1.12e-05	0.00216	-0.2	-0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166130	chr14:22202583~22203368:+
LUAD	cis	rs4664293	0.585	rs34385495	ENSG00000226266.5	AC009961.3	4.44	1.12e-05	0.00216	0.26	0.2	Monocyte percentage of white cells;	chr2:159656372	chr2:159670708~159712435:-
LUAD	cis	rs34375054	0.624	rs7132026	ENSG00000279233.1	RP11-158L12.4	-4.44	1.12e-05	0.00216	-0.18	-0.2	Post bronchodilator FEV1/FVC ratio;	chr12:125193550	chr12:125138245~125141711:+
LUAD	cis	rs1005277	0.54	rs4934907	ENSG00000263064.2	RP11-291L22.7	4.44	1.12e-05	0.00216	0.21	0.2	Extrinsic epigenetic age acceleration;	chr10:37726302	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.54	rs11011351	ENSG00000263064.2	RP11-291L22.7	4.44	1.12e-05	0.00216	0.21	0.2	Extrinsic epigenetic age acceleration;	chr10:37741597	chr10:38448689~38448949:+
LUAD	cis	rs7819412	0.805	rs4333549	ENSG00000255046.1	RP11-297N6.4	4.44	1.12e-05	0.00216	0.25	0.2	Triglycerides;	chr8:11122051	chr8:11797928~11802568:-
LUAD	cis	rs9907295	0.688	rs4796138	ENSG00000270977.1	AC015849.16	-4.44	1.12e-05	0.00216	-0.3	-0.2	Fibroblast growth factor basic levels;	chr17:35932791	chr17:35893707~35911023:-
LUAD	cis	rs2153535	0.585	rs6934905	ENSG00000230939.1	RP11-314C16.1	-4.44	1.12e-05	0.00216	-0.22	-0.2	Motion sickness;	chr6:8661326	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.618	rs11243267	ENSG00000230939.1	RP11-314C16.1	-4.44	1.12e-05	0.00216	-0.22	-0.2	Motion sickness;	chr6:8662287	chr6:8784178~8785445:+
LUAD	cis	rs712022	1	rs10766969	ENSG00000246225.5	RP11-17A1.3	-4.44	1.12e-05	0.00216	-0.24	-0.2	Dialysis-related mortality;	chr11:22828406	chr11:22829380~22945393:+
LUAD	cis	rs1876905	0.539	rs240987	ENSG00000255389.1	C6orf3	4.44	1.12e-05	0.00216	0.27	0.2	Mean corpuscular hemoglobin;	chr6:111268552	chr6:111599875~111602295:+
LUAD	cis	rs1008375	0.933	rs7689101	ENSG00000249502.1	AC006160.5	-4.44	1.12e-05	0.00216	-0.19	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17692411	chr4:17587467~17614571:-
LUAD	cis	rs1008375	0.933	rs10939757	ENSG00000249502.1	AC006160.5	-4.44	1.12e-05	0.00216	-0.19	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17692502	chr4:17587467~17614571:-
LUAD	cis	rs1008375	1	rs4698651	ENSG00000249502.1	AC006160.5	-4.44	1.12e-05	0.00216	-0.19	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17692600	chr4:17587467~17614571:-
LUAD	cis	rs9287719	0.967	rs12464817	ENSG00000243819.4	RN7SL832P	4.44	1.12e-05	0.00216	0.21	0.2	Prostate cancer;	chr2:10567086	chr2:10690344~10692099:+
LUAD	cis	rs2229637	1	rs2229637	ENSG00000224796.1	RPL32P1	4.44	1.12e-05	0.00216	0.19	0.2	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr6:33675781	chr6:33079451~33079860:+
LUAD	cis	rs13113518	0.812	rs4507426	ENSG00000223305.1	RN7SKP30	4.44	1.12e-05	0.00216	0.23	0.2	Height;	chr4:55529387	chr4:55540502~55540835:-
LUAD	cis	rs2880765	0.743	rs11630410	ENSG00000259416.2	RP11-158M2.5	4.44	1.12e-05	0.00216	0.2	0.2	Coronary artery disease;	chr15:85461510	chr15:85754941~85756237:-
LUAD	cis	rs2880765	0.71	rs11630457	ENSG00000259416.2	RP11-158M2.5	4.44	1.12e-05	0.00216	0.2	0.2	Coronary artery disease;	chr15:85461570	chr15:85754941~85756237:-
LUAD	cis	rs736408	0.608	rs35004449	ENSG00000242142.1	SERBP1P3	4.44	1.12e-05	0.00216	0.22	0.2	Bipolar disorder;	chr3:52818881	chr3:53064283~53065091:-
LUAD	cis	rs8072100	0.57	rs9905073	ENSG00000228782.6	CTD-2026D20.3	4.44	1.12e-05	0.00216	0.21	0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47390930	chr17:47450568~47492492:-
LUAD	cis	rs7727544	0.647	rs6898270	ENSG00000233006.5	AC034220.3	4.44	1.12e-05	0.00216	0.18	0.2	Blood metabolite levels;	chr5:132085497	chr5:132311285~132369916:-
LUAD	cis	rs454217	0.714	rs395142	ENSG00000277851.1	RP11-756G20.1	-4.44	1.12e-05	0.00217	-0.2	-0.2	Smoking quantity;	chr12:92341860	chr12:92247756~92363832:-
LUAD	cis	rs7208859	0.623	rs216434	ENSG00000266490.1	CTD-2349P21.9	4.44	1.12e-05	0.00217	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595317	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs216436	ENSG00000266490.1	CTD-2349P21.9	4.44	1.12e-05	0.00217	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595882	chr17:30792372~30792833:+
LUAD	cis	rs7176527	0.579	rs366717	ENSG00000229212.6	RP11-561C5.4	4.44	1.12e-05	0.00217	0.27	0.2	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84544848	chr15:85205440~85234795:-
LUAD	cis	rs7208859	0.623	rs56018041	ENSG00000280069.1	CTD-2349P21.3	-4.44	1.12e-05	0.00217	-0.27	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732967	chr17:30738182~30740275:+
LUAD	cis	rs4372836	1	rs4666119	ENSG00000226833.4	AC097724.3	4.44	1.12e-05	0.00217	0.23	0.2	Body mass index;	chr2:28752824	chr2:28708953~28736205:-
LUAD	cis	rs910316	1	rs12435391	ENSG00000279594.1	RP11-950C14.10	4.44	1.12e-05	0.00217	0.23	0.2	Height;	chr14:75135034	chr14:75011269~75012851:-
LUAD	cis	rs736408	0.5	rs2878762	ENSG00000242142.1	SERBP1P3	4.44	1.12e-05	0.00217	0.22	0.2	Bipolar disorder;	chr3:52884986	chr3:53064283~53065091:-
LUAD	cis	rs7172677	1	rs4886422	ENSG00000260269.4	CTD-2323K18.1	-4.44	1.12e-05	0.00217	-0.26	-0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75134382	chr15:75527150~75601205:-
LUAD	cis	rs2742234	0.541	rs1317214	ENSG00000273008.1	RP11-351D16.3	4.44	1.12e-05	0.00217	0.23	0.2	Hirschsprung disease;	chr10:43238083	chr10:43136824~43138334:-
LUAD	cis	rs957448	1	rs60655325	ENSG00000254315.1	RP11-267M23.3	4.44	1.12e-05	0.00217	0.25	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94552606	chr8:94533628~94534391:+
LUAD	cis	rs17685	0.753	rs869804	ENSG00000280388.1	RP11-229D13.3	-4.44	1.12e-05	0.00217	-0.19	-0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76059636	chr7:76043977~76045963:-
LUAD	cis	rs36093844	0.848	rs1564550	ENSG00000279742.1	RP11-700A24.1	-4.44	1.12e-05	0.00217	-0.23	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85824318	chr11:85852557~85854943:-
LUAD	cis	rs8062405	0.755	rs17640009	ENSG00000261419.1	RP11-57A19.4	-4.44	1.13e-05	0.00217	-0.22	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28659696~28740781:-
LUAD	cis	rs9287719	0.967	rs4669593	ENSG00000243819.4	RN7SL832P	4.44	1.13e-05	0.00217	0.21	0.2	Prostate cancer;	chr2:10561782	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs3814388	ENSG00000243819.4	RN7SL832P	4.44	1.13e-05	0.00217	0.21	0.2	Prostate cancer;	chr2:10561973	chr2:10690344~10692099:+
LUAD	cis	rs11722779	0.787	rs6533040	ENSG00000251288.2	RP11-10L12.2	-4.44	1.13e-05	0.00217	-0.24	-0.2	Schizophrenia;	chr4:102951421	chr4:102751401~102752641:+
LUAD	cis	rs2348418	0.864	rs2175464	ENSG00000244712.1	RP11-874G11.1	-4.44	1.13e-05	0.00217	-0.23	-0.2	Lung function (FEV1);Lung function (FVC);	chr12:28564178	chr12:28564678~28565141:-
LUAD	cis	rs3096299	0.685	rs4785571	ENSG00000261118.1	RP11-104N10.1	4.44	1.13e-05	0.00218	0.2	0.2	Multiple myeloma (IgH translocation);	chr16:89498761	chr16:89492017~89504460:-
LUAD	cis	rs7302981	0.967	rs2178173	ENSG00000200428.1	Y_RNA	4.44	1.13e-05	0.00218	0.25	0.2	Systolic blood pressure;	chr12:50124146	chr12:50743568~50743684:+
LUAD	cis	rs7302981	0.967	rs7297421	ENSG00000200428.1	Y_RNA	4.44	1.13e-05	0.00218	0.25	0.2	Systolic blood pressure;	chr12:50125143	chr12:50743568~50743684:+
LUAD	cis	rs11157436	0.602	rs12588757	ENSG00000211813.2	TRAV34	4.44	1.13e-05	0.00218	0.23	0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22172100	chr14:22207522~22208129:+
LUAD	cis	rs8072100	0.666	rs6503804	ENSG00000228782.6	CTD-2026D20.3	4.44	1.13e-05	0.00218	0.21	0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47695081	chr17:47450568~47492492:-
LUAD	cis	rs9309473	0.528	rs10191517	ENSG00000163016.8	ALMS1P	4.44	1.13e-05	0.00218	0.23	0.2	Metabolite levels;	chr2:73331275	chr2:73644919~73685576:+
LUAD	cis	rs780096	0.546	rs2293571	ENSG00000234072.1	AC074117.10	-4.44	1.13e-05	0.00218	-0.15	-0.2	Total body bone mineral density;	chr2:27506613	chr2:27356246~27367622:+
LUAD	cis	rs6496044	0.568	rs3743321	ENSG00000259295.5	CSPG4P12	4.44	1.13e-05	0.00218	0.23	0.2	Interstitial lung disease;	chr15:85521737	chr15:85191438~85213905:+
LUAD	cis	rs2014572	0.51	rs8111661	ENSG00000268379.1	CTC-360J11.4	-4.44	1.13e-05	0.00218	-0.23	-0.2	Hyperactive-impulsive symptoms;	chr19:57240958	chr19:57175233~57177921:+
LUAD	cis	rs4819052	0.788	rs9978857	ENSG00000237664.1	LINC00316	-4.44	1.13e-05	0.00218	-0.24	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285240	chr21:45338590~45341990:-
LUAD	cis	rs2227564	0.533	rs3870402	ENSG00000271816.1	BMS1P4	4.44	1.13e-05	0.00218	0.19	0.2	Crohn's disease;Inflammatory bowel disease;	chr10:73714029	chr10:73699151~73730487:-
LUAD	cis	rs2548724	0.738	rs1982418	ENSG00000250682.4	LINC00491	4.44	1.13e-05	0.00218	0.24	0.2	Type 2 diabetes;	chr5:102302677	chr5:102609156~102671559:-
LUAD	cis	rs7688540	0.8	rs10028482	ENSG00000211553.1	AC253576.2	-4.44	1.13e-05	0.00218	-0.25	-0.2	Facial morphology (factor 6, height of vermillion lower lip);	chr4:254036	chr4:136461~136568:+
LUAD	cis	rs867371	0.656	rs2665103	ENSG00000278603.1	RP13-608F4.5	-4.44	1.13e-05	0.00218	-0.22	-0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82140374	chr15:82472203~82472426:+
LUAD	cis	rs12073359	1	rs72694945	ENSG00000223945.2	RP11-458I7.1	-4.44	1.13e-05	0.00218	-0.3	-0.2	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150141312	chr1:150053864~150055034:+
LUAD	cis	rs12073359	0.954	rs72694951	ENSG00000223945.2	RP11-458I7.1	-4.44	1.13e-05	0.00218	-0.3	-0.2	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150146987	chr1:150053864~150055034:+
LUAD	cis	rs12439619	0.846	rs62012059	ENSG00000276710.3	CSPG4P8	-4.44	1.13e-05	0.00218	-0.22	-0.2	Intelligence (multi-trait analysis);	chr15:82251669	chr15:82459472~82477258:+
LUAD	cis	rs801193	0.636	rs2659895	ENSG00000232559.3	GS1-124K5.12	4.44	1.13e-05	0.00218	0.23	0.2	Aortic root size;	chr7:66731484	chr7:66554588~66576923:-
LUAD	cis	rs75422866	0.51	rs73104197	ENSG00000276691.1	RP5-1057I20.5	4.44	1.13e-05	0.00218	0.34	0.2	Pneumonia;	chr12:47717273	chr12:47788426~47788971:+
LUAD	cis	rs10971721	0.822	rs72727335	ENSG00000260947.1	RP11-384P7.7	4.44	1.13e-05	0.00218	0.4	0.2	Body mass index;	chr9:33931720	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs72727336	ENSG00000260947.1	RP11-384P7.7	4.44	1.13e-05	0.00218	0.4	0.2	Body mass index;	chr9:33931795	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs10971802	ENSG00000260947.1	RP11-384P7.7	4.44	1.13e-05	0.00218	0.4	0.2	Body mass index;	chr9:33933284	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs10971803	ENSG00000260947.1	RP11-384P7.7	4.44	1.13e-05	0.00218	0.4	0.2	Body mass index;	chr9:33933289	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs41314578	ENSG00000260947.1	RP11-384P7.7	4.44	1.13e-05	0.00218	0.4	0.2	Body mass index;	chr9:33933943	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs56274755	ENSG00000260947.1	RP11-384P7.7	4.44	1.13e-05	0.00218	0.4	0.2	Body mass index;	chr9:33934273	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs118115128	ENSG00000260947.1	RP11-384P7.7	4.44	1.13e-05	0.00218	0.4	0.2	Body mass index;	chr9:33935451	chr9:33697459~33700986:+
LUAD	cis	rs2018683	0.707	rs10279870	ENSG00000228421.2	AC005013.5	4.44	1.13e-05	0.00218	0.22	0.2	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28929318	chr7:28957667~28959345:+
LUAD	cis	rs7086627	0.515	rs11202963	ENSG00000226659.1	RP11-137H2.4	-4.44	1.13e-05	0.00218	-0.26	-0.2	Post bronchodilator FEV1;	chr10:80450636	chr10:80529597~80535942:-
LUAD	cis	rs7086627	0.515	rs10887901	ENSG00000226659.1	RP11-137H2.4	-4.44	1.13e-05	0.00218	-0.26	-0.2	Post bronchodilator FEV1;	chr10:80450825	chr10:80529597~80535942:-
LUAD	cis	rs957448	1	rs72674861	ENSG00000253175.1	RP11-267M23.6	4.44	1.13e-05	0.00218	0.24	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94550051	chr8:94565036~94565715:+
LUAD	cis	rs2408955	0.504	rs11168441	ENSG00000257735.1	RP11-370I10.6	4.44	1.13e-05	0.00218	0.24	0.2	Glycated hemoglobin levels;	chr12:48182271	chr12:48350945~48442411:+
LUAD	cis	rs7404843	0.852	rs111259294	ENSG00000263335.1	AF001548.5	4.44	1.13e-05	0.00218	0.43	0.2	Testicular germ cell tumor;	chr16:15418073	chr16:15726674~15732993:+
LUAD	cis	rs1334894	0.892	rs72911394	ENSG00000228559.1	RP3-340B19.3	-4.44	1.13e-05	0.00218	-0.42	-0.2	Coronary artery disease;	chr6:35557387	chr6:35544632~35545669:+
LUAD	cis	rs5758511	0.634	rs1001587	ENSG00000226450.2	CYP2D8P	4.44	1.13e-05	0.00218	0.19	0.2	Birth weight;	chr22:42274105	chr22:42149886~42155001:-
LUAD	cis	rs9425766	0.655	rs2145376	ENSG00000227373.4	RP11-160H22.5	4.44	1.13e-05	0.00218	0.25	0.2	Life satisfaction;	chr1:174098911	chr1:174115300~174160004:-
LUAD	cis	rs9425766	0.679	rs6663794	ENSG00000227373.4	RP11-160H22.5	4.44	1.13e-05	0.00218	0.25	0.2	Life satisfaction;	chr1:174099791	chr1:174115300~174160004:-
LUAD	cis	rs780096	0.545	rs6716894	ENSG00000234072.1	AC074117.10	-4.44	1.13e-05	0.00218	-0.15	-0.2	Total body bone mineral density;	chr2:27360406	chr2:27356246~27367622:+
LUAD	cis	rs2980439	0.525	rs1850511	ENSG00000253981.4	ALG1L13P	4.44	1.13e-05	0.00219	0.23	0.2	Neuroticism;	chr8:8312807	chr8:8236003~8244667:-
LUAD	cis	rs9425766	0.64	rs6658769	ENSG00000227373.4	RP11-160H22.5	4.44	1.13e-05	0.00219	0.25	0.2	Life satisfaction;	chr1:174100843	chr1:174115300~174160004:-
LUAD	cis	rs950169	0.922	rs17531523	ENSG00000275120.1	RP11-182J1.17	4.44	1.13e-05	0.00219	0.31	0.2	Schizophrenia;	chr15:84589218	chr15:84599434~84606463:-
LUAD	cis	rs3743772	0.5	rs11866060	ENSG00000279722.1	RP11-44F14.6	4.44	1.13e-05	0.00219	0.28	0.2	Depressive symptoms (SSRI exposure interaction);	chr16:53394937	chr16:53487607~53489943:-
LUAD	cis	rs17685	0.796	rs3757594	ENSG00000280388.1	RP11-229D13.3	4.44	1.13e-05	0.00219	0.18	0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76049326	chr7:76043977~76045963:-
LUAD	cis	rs1355223	0.902	rs1361645	ENSG00000271369.1	RP11-350D17.3	-4.44	1.13e-05	0.00219	-0.23	-0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34724838	chr11:34709600~34710161:+
LUAD	cis	rs7617773	0.963	rs6766754	ENSG00000228638.1	FCF1P2	4.44	1.13e-05	0.00219	0.22	0.2	Coronary artery disease;	chr3:48141099	chr3:48290793~48291375:-
LUAD	cis	rs7617773	0.832	rs6775114	ENSG00000228638.1	FCF1P2	4.44	1.13e-05	0.00219	0.22	0.2	Coronary artery disease;	chr3:48141130	chr3:48290793~48291375:-
LUAD	cis	rs4819052	0.679	rs28623526	ENSG00000223768.1	LINC00205	-4.44	1.13e-05	0.00219	-0.23	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45292409	chr21:45293285~45297354:+
LUAD	cis	rs9425766	0.64	rs10912734	ENSG00000227373.4	RP11-160H22.5	4.44	1.13e-05	0.00219	0.25	0.2	Life satisfaction;	chr1:174141977	chr1:174115300~174160004:-
LUAD	cis	rs338389	0.9	rs11636279	ENSG00000260657.2	RP11-315D16.4	-4.44	1.13e-05	0.00219	-0.23	-0.2	Survival in rectal cancer;	chr15:67981537	chr15:68267792~68277994:-
LUAD	cis	rs338389	0.9	rs8029628	ENSG00000260657.2	RP11-315D16.4	-4.44	1.13e-05	0.00219	-0.23	-0.2	Survival in rectal cancer;	chr15:67982217	chr15:68267792~68277994:-
LUAD	cis	rs7619708	1	rs7619708	ENSG00000207650.1	MIR570	-4.44	1.13e-05	0.00219	-0.24	-0.2	Red cell distribution width;	chr3:196083316	chr3:195699401~195699497:+
LUAD	cis	rs2255336	0.817	rs7310643	ENSG00000245648.1	RP11-277P12.20	4.44	1.13e-05	0.00219	0.31	0.2	Blood protein levels;	chr12:10365501	chr12:10363769~10398506:+
LUAD	cis	rs17597773	0.527	rs1537806	ENSG00000238078.1	LINC01352	-4.44	1.13e-05	0.00219	-0.22	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220910880	chr1:220829255~220832429:+
LUAD	cis	rs11089937	0.512	rs6001073	ENSG00000211640.3	IGLV6-57	4.44	1.14e-05	0.00219	0.15	0.2	Periodontitis (PAL4Q3);	chr22:22133650	chr22:22195713~22196460:+
LUAD	cis	rs7714584	0.793	rs12653039	ENSG00000197083.10	ZNF300P1	4.44	1.14e-05	0.00219	0.4	0.2	Crohn's disease;	chr5:150873069	chr5:150930645~150946289:-
LUAD	cis	rs4835473	0.637	rs11932061	ENSG00000251600.4	RP11-673E1.1	4.44	1.14e-05	0.00219	0.23	0.2	Immature fraction of reticulocytes;	chr4:143768124	chr4:143912331~143982454:+
LUAD	cis	rs728616	0.51	rs12416084	ENSG00000225484.5	NUTM2B-AS1	-4.44	1.14e-05	0.00219	-0.33	-0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79989459	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.51	rs34817075	ENSG00000225484.5	NUTM2B-AS1	-4.44	1.14e-05	0.00219	-0.33	-0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79989984	chr10:79663088~79826594:-
LUAD	cis	rs1387259	0.929	rs2956703	ENSG00000240399.1	RP1-228P16.1	4.44	1.14e-05	0.00219	0.2	0.2	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48276511	chr12:48054813~48055591:-
LUAD	cis	rs950169	0.649	rs12901010	ENSG00000259728.4	LINC00933	4.44	1.14e-05	0.00219	0.32	0.2	Schizophrenia;	chr15:84030282	chr15:84570649~84580175:+
LUAD	cis	rs950169	0.69	rs12901166	ENSG00000259728.4	LINC00933	4.44	1.14e-05	0.00219	0.32	0.2	Schizophrenia;	chr15:84030361	chr15:84570649~84580175:+
LUAD	cis	rs240993	0.809	rs11153277	ENSG00000271789.1	RP5-1112D6.7	-4.44	1.14e-05	0.00219	-0.23	-0.2	Inflammatory skin disease;Psoriasis;	chr6:111259358	chr6:111297126~111298510:+
LUAD	cis	rs853679	1	rs1936365	ENSG00000219392.1	RP1-265C24.5	4.44	1.14e-05	0.00219	0.3	0.2	Depression;	chr6:28300675	chr6:28115628~28116551:+
LUAD	cis	rs712022	0.837	rs2159668	ENSG00000246225.5	RP11-17A1.3	4.44	1.14e-05	0.00219	0.24	0.2	Dialysis-related mortality;	chr11:22817914	chr11:22829380~22945393:+
LUAD	cis	rs950169	0.887	rs220333	ENSG00000275120.1	RP11-182J1.17	4.44	1.14e-05	0.00219	0.31	0.2	Schizophrenia;	chr15:84547902	chr15:84599434~84606463:-
LUAD	cis	rs7208859	0.623	rs609063	ENSG00000266490.1	CTD-2349P21.9	4.44	1.14e-05	0.00219	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs383436	ENSG00000266490.1	CTD-2349P21.9	4.44	1.14e-05	0.00219	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30632161	chr17:30792372~30792833:+
LUAD	cis	rs2439831	0.681	rs526450	ENSG00000249839.1	AC011330.5	-4.44	1.14e-05	0.00219	-0.34	-0.2	Lung cancer in ever smokers;	chr15:43307127	chr15:43663654~43684339:-
LUAD	cis	rs2243480	0.901	rs12530490	ENSG00000232559.3	GS1-124K5.12	-4.44	1.14e-05	0.00219	-0.35	-0.2	Diabetic kidney disease;	chr7:66226660	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs7778911	ENSG00000232559.3	GS1-124K5.12	-4.44	1.14e-05	0.00219	-0.35	-0.2	Diabetic kidney disease;	chr7:66229519	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs1979823	ENSG00000232559.3	GS1-124K5.12	-4.44	1.14e-05	0.00219	-0.35	-0.2	Diabetic kidney disease;	chr7:66239626	chr7:66554588~66576923:-
LUAD	cis	rs17711722	0.523	rs313812	ENSG00000237310.1	GS1-124K5.4	-4.44	1.14e-05	0.00219	-0.21	-0.2	Calcium levels;	chr7:66040056	chr7:66493706~66495474:+
LUAD	cis	rs453301	0.605	rs7843024	ENSG00000253893.2	FAM85B	4.44	1.14e-05	0.00219	0.25	0.2	Joint mobility (Beighton score);	chr8:8942466	chr8:8167819~8226614:-
LUAD	cis	rs2153535	0.56	rs9405406	ENSG00000230939.1	RP11-314C16.1	-4.44	1.14e-05	0.00219	-0.22	-0.2	Motion sickness;	chr6:8654625	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.585	rs1998364	ENSG00000230939.1	RP11-314C16.1	-4.44	1.14e-05	0.00219	-0.22	-0.2	Motion sickness;	chr6:8657091	chr6:8784178~8785445:+
LUAD	cis	rs453301	0.686	rs11785819	ENSG00000253981.4	ALG1L13P	-4.44	1.14e-05	0.00219	-0.24	-0.2	Joint mobility (Beighton score);	chr8:9012868	chr8:8236003~8244667:-
LUAD	cis	rs2255336	0.873	rs10743888	ENSG00000245648.1	RP11-277P12.20	4.44	1.14e-05	0.0022	0.31	0.2	Blood protein levels;	chr12:10368255	chr12:10363769~10398506:+
LUAD	cis	rs35740288	0.929	rs11630585	ENSG00000259407.1	RP11-158M2.3	-4.44	1.14e-05	0.0022	-0.2	-0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85762773	chr15:85744109~85750281:-
LUAD	cis	rs35740288	0.929	rs11636821	ENSG00000259407.1	RP11-158M2.3	-4.44	1.14e-05	0.0022	-0.2	-0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85762774	chr15:85744109~85750281:-
LUAD	cis	rs35740288	0.929	rs11630684	ENSG00000259407.1	RP11-158M2.3	-4.44	1.14e-05	0.0022	-0.2	-0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85763025	chr15:85744109~85750281:-
LUAD	cis	rs227275	0.554	rs223395	ENSG00000251288.2	RP11-10L12.2	-4.44	1.14e-05	0.0022	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102823801	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.554	rs223388	ENSG00000251288.2	RP11-10L12.2	-4.44	1.14e-05	0.0022	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102828287	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.554	rs223386	ENSG00000251288.2	RP11-10L12.2	-4.44	1.14e-05	0.0022	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102829111	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.554	rs223385	ENSG00000251288.2	RP11-10L12.2	-4.44	1.14e-05	0.0022	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102829159	chr4:102751401~102752641:+
LUAD	cis	rs11722779	0.873	rs223384	ENSG00000251288.2	RP11-10L12.2	-4.44	1.14e-05	0.0022	-0.24	-0.2	Schizophrenia;	chr4:102829976	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.554	rs223383	ENSG00000251288.2	RP11-10L12.2	-4.44	1.14e-05	0.0022	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102830094	chr4:102751401~102752641:+
LUAD	cis	rs7107174	0.681	rs4340079	ENSG00000251323.2	RP11-452H21.4	4.44	1.14e-05	0.0022	0.25	0.2	Testicular germ cell tumor;	chr11:78296874	chr11:78423982~78429836:-
LUAD	cis	rs2880765	0.743	rs7168345	ENSG00000259416.2	RP11-158M2.5	-4.44	1.14e-05	0.0022	-0.21	-0.2	Coronary artery disease;	chr15:85470370	chr15:85754941~85756237:-
LUAD	cis	rs712022	1	rs10833825	ENSG00000246225.5	RP11-17A1.3	-4.44	1.14e-05	0.0022	-0.25	-0.2	Dialysis-related mortality;	chr11:22829207	chr11:22829380~22945393:+
LUAD	cis	rs8031584	0.678	rs3122	ENSG00000270015.1	RP11-540B6.6	4.44	1.14e-05	0.0022	0.15	0.2	Huntington's disease progression;	chr15:30878087	chr15:30926514~30928407:+
LUAD	cis	rs7200786	0.715	rs8050144	ENSG00000274038.1	RP11-66H6.4	-4.44	1.14e-05	0.0022	-0.24	-0.2	Systemic lupus erythematosus;Multiple sclerosis;	chr16:10996230	chr16:11056556~11057034:+
LUAD	cis	rs4873772	0.735	rs2130412	ENSG00000253330.1	RP11-697N18.3	-4.44	1.14e-05	0.0022	-0.22	-0.2	Lobe attachment (rater-scored or self-reported);	chr8:47527279	chr8:47511034~47512141:-
LUAD	cis	rs11159086	1	rs8006909	ENSG00000259005.1	RP3-449M8.6	4.44	1.14e-05	0.0022	0.27	0.2	Advanced glycation end-product levels;	chr14:74478085	chr14:74474007~74474864:-
LUAD	cis	rs11159086	1	rs8006958	ENSG00000259005.1	RP3-449M8.6	4.44	1.14e-05	0.0022	0.27	0.2	Advanced glycation end-product levels;	chr14:74478148	chr14:74474007~74474864:-
LUAD	cis	rs9910055	0.659	rs227584	ENSG00000267080.4	ASB16-AS1	-4.44	1.14e-05	0.0022	-0.18	-0.2	Total body bone mineral density;	chr17:44148179	chr17:44175973~44186717:-
LUAD	cis	rs8180040	0.8	rs7632501	ENSG00000271161.1	BOLA2P2	-4.44	1.14e-05	0.0022	-0.19	-0.2	Colorectal cancer;	chr3:47226816	chr3:47499841~47500407:+
LUAD	cis	rs8180040	0.8	rs62248905	ENSG00000271161.1	BOLA2P2	-4.44	1.14e-05	0.0022	-0.19	-0.2	Colorectal cancer;	chr3:47232592	chr3:47499841~47500407:+
LUAD	cis	rs8180040	0.8	rs56250009	ENSG00000271161.1	BOLA2P2	-4.44	1.14e-05	0.0022	-0.19	-0.2	Colorectal cancer;	chr3:47238007	chr3:47499841~47500407:+
LUAD	cis	rs8180040	0.8	rs2088135	ENSG00000271161.1	BOLA2P2	-4.44	1.14e-05	0.0022	-0.19	-0.2	Colorectal cancer;	chr3:47238528	chr3:47499841~47500407:+
LUAD	cis	rs8180040	0.8	rs6768221	ENSG00000271161.1	BOLA2P2	-4.44	1.14e-05	0.0022	-0.19	-0.2	Colorectal cancer;	chr3:47255409	chr3:47499841~47500407:+
LUAD	cis	rs8180040	0.8	rs11130126	ENSG00000271161.1	BOLA2P2	-4.44	1.14e-05	0.0022	-0.19	-0.2	Colorectal cancer;	chr3:47265404	chr3:47499841~47500407:+
LUAD	cis	rs8180040	0.767	rs11920853	ENSG00000271161.1	BOLA2P2	-4.44	1.14e-05	0.0022	-0.19	-0.2	Colorectal cancer;	chr3:47266693	chr3:47499841~47500407:+
LUAD	cis	rs7044106	0.655	rs1359329	ENSG00000238181.2	AHCYP2	-4.44	1.14e-05	0.0022	-0.31	-0.2	Hip circumference adjusted for BMI;	chr9:120608707	chr9:120720673~120721972:+
LUAD	cis	rs202072	0.585	rs536208	ENSG00000272379.1	RP1-257A7.5	4.44	1.14e-05	0.0022	0.33	0.2	HIV-1 viral setpoint;	chr6:13256715	chr6:13290018~13290490:-
LUAD	cis	rs10129255	0.912	rs8009135	ENSG00000274576.2	IGHV2-70	4.43	1.14e-05	0.0022	0.17	0.2	Kawasaki disease;	chr14:106777528	chr14:106770577~106771020:-
LUAD	cis	rs2243480	1	rs1039664	ENSG00000229886.1	RP5-1132H15.3	4.43	1.14e-05	0.0022	0.33	0.2	Diabetic kidney disease;	chr7:65984729	chr7:66025126~66031544:-
LUAD	cis	rs9341808	0.754	rs3805925	ENSG00000272129.1	RP11-250B2.6	4.43	1.14e-05	0.0022	0.24	0.2	Sitting height ratio;	chr6:80174116	chr6:80355424~80356859:+
LUAD	cis	rs2562456	0.833	rs62110367	ENSG00000268081.1	RP11-678G14.2	4.43	1.14e-05	0.0022	0.32	0.2	Pain;	chr19:21365829	chr19:21554640~21569237:-
LUAD	cis	rs2980439	0.557	rs2976876	ENSG00000253981.4	ALG1L13P	4.43	1.14e-05	0.0022	0.23	0.2	Neuroticism;	chr8:8461340	chr8:8236003~8244667:-
LUAD	cis	rs1009115	0.551	rs10269724	ENSG00000272328.1	RP4-594A5.1	-4.43	1.14e-05	0.0022	-0.26	-0.2	Post bronchodilator FEV1;	chr7:8358696	chr7:8303741~8341343:+
LUAD	cis	rs6714710	0.603	rs17489454	ENSG00000230606.9	AC159540.1	-4.43	1.14e-05	0.0022	-0.21	-0.2	Posterior cortical atrophy and Alzheimer's disease;	chr2:97790887	chr2:97416165~97433527:-
LUAD	cis	rs2235642	0.507	rs2235645	ENSG00000280231.1	LA16c-380F5.3	-4.43	1.14e-05	0.0022	-0.31	-0.2	Coronary artery disease;	chr16:1547923	chr16:1553655~1554130:-
LUAD	cis	rs9400467	0.528	rs455726	ENSG00000271789.1	RP5-1112D6.7	-4.43	1.14e-05	0.0022	-0.21	-0.2	Amino acid levels;Blood metabolite levels;	chr6:111378165	chr6:111297126~111298510:+
LUAD	cis	rs800160	0.844	rs2937373	ENSG00000236264.4	RPL26P30	-4.43	1.14e-05	0.0022	-0.27	-0.2	Bacteremia;	chr11:2337391	chr11:2335132~2335776:-
LUAD	cis	rs1008375	1	rs10939746	ENSG00000249502.1	AC006160.5	4.43	1.14e-05	0.0022	0.19	0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17683328	chr4:17587467~17614571:-
LUAD	cis	rs9649213	0.593	rs35983874	ENSG00000272950.1	RP11-307C18.1	4.43	1.14e-05	0.0022	0.25	0.2	Prostate cancer (SNP x SNP interaction);	chr7:98287149	chr7:98322853~98323430:+
LUAD	cis	rs9652601	0.959	rs9652582	ENSG00000274038.1	RP11-66H6.4	-4.43	1.14e-05	0.0022	-0.24	-0.2	Systemic lupus erythematosus;	chr16:11080707	chr16:11056556~11057034:+
LUAD	cis	rs2446066	0.872	rs12368491	ENSG00000257379.1	RP11-793H13.8	4.43	1.15e-05	0.00221	0.32	0.2	Red blood cell count;	chr12:53389175	chr12:53441741~53467528:+
LUAD	cis	rs2304003	1	rs2060167	ENSG00000235192.1	AC009495.2	4.43	1.15e-05	0.00221	0.23	0.2	Social communication problems;	chr2:165832832	chr2:165794851~165810010:+
LUAD	cis	rs9815354	0.812	rs13084436	ENSG00000273328.4	RP11-141M3.6	4.43	1.15e-05	0.00221	0.32	0.2	Pulse pressure;Diastolic blood pressure;	chr3:41976045	chr3:42809414~42908105:+
LUAD	cis	rs1062177	1	rs2915887	ENSG00000253921.1	CTB-113P19.3	-4.43	1.15e-05	0.00221	-0.3	-0.2	Preschool internalizing problems;	chr5:151825943	chr5:151753992~151767247:+
LUAD	cis	rs17685	0.736	rs4732594	ENSG00000280388.1	RP11-229D13.3	-4.43	1.15e-05	0.00221	-0.19	-0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76123955	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.671	rs60303271	ENSG00000280388.1	RP11-229D13.3	-4.43	1.15e-05	0.00221	-0.19	-0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76130690	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.735	rs11763339	ENSG00000280388.1	RP11-229D13.3	-4.43	1.15e-05	0.00221	-0.19	-0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76132223	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.775	rs11761172	ENSG00000280388.1	RP11-229D13.3	-4.43	1.15e-05	0.00221	-0.19	-0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76132229	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.753	rs11764129	ENSG00000280388.1	RP11-229D13.3	-4.43	1.15e-05	0.00221	-0.19	-0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76132572	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.712	rs28506984	ENSG00000280388.1	RP11-229D13.3	-4.43	1.15e-05	0.00221	-0.19	-0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76134166	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.623	rs7782808	ENSG00000280388.1	RP11-229D13.3	-4.43	1.15e-05	0.00221	-0.19	-0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76139327	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.753	rs6953665	ENSG00000280388.1	RP11-229D13.3	-4.43	1.15e-05	0.00221	-0.19	-0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76139731	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.712	rs7778735	ENSG00000280388.1	RP11-229D13.3	-4.43	1.15e-05	0.00221	-0.19	-0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76140919	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.712	rs10275521	ENSG00000280388.1	RP11-229D13.3	-4.43	1.15e-05	0.00221	-0.19	-0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76141654	chr7:76043977~76045963:-
LUAD	cis	rs6991838	0.593	rs7011464	ENSG00000200714.1	Y_RNA	-4.43	1.15e-05	0.00221	-0.25	-0.2	Intelligence (multi-trait analysis);	chr8:65723052	chr8:65592731~65592820:+
LUAD	cis	rs2731006	0.543	rs11181693	ENSG00000257114.2	RP11-25I15.3	4.43	1.15e-05	0.00221	0.3	0.2	Panic disorder;	chr12:42813605	chr12:42692216~42717119:+
LUAD	cis	rs957448	0.698	rs116348949	ENSG00000253704.1	RP11-267M23.4	4.43	1.15e-05	0.00221	0.24	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94557488	chr8:94553722~94569745:+
LUAD	cis	rs131777	0.508	rs140518	ENSG00000260613.1	RP3-522J7.6	4.43	1.15e-05	0.00221	0.23	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50560753	chr22:49832616~49837786:-
LUAD	cis	rs11089937	0.597	rs6001072	ENSG00000211640.3	IGLV6-57	4.43	1.15e-05	0.00221	0.15	0.2	Periodontitis (PAL4Q3);	chr22:22133629	chr22:22195713~22196460:+
LUAD	cis	rs7646881	0.504	rs4264773	ENSG00000240207.5	RP11-379F4.4	-4.43	1.15e-05	0.00221	-0.22	-0.2	Tetralogy of Fallot;	chr3:158745436	chr3:158732263~158784070:+
LUAD	cis	rs780096	0.565	rs10169261	ENSG00000234072.1	AC074117.10	-4.43	1.15e-05	0.00221	-0.15	-0.2	Total body bone mineral density;	chr2:27504447	chr2:27356246~27367622:+
LUAD	cis	rs2919009	0.766	rs56102659	ENSG00000271670.1	RP11-95I16.4	4.43	1.15e-05	0.00221	0.25	0.2	Obesity-related traits;	chr10:120786205	chr10:120879256~120880667:-
LUAD	cis	rs11168618	0.74	rs4523733	ENSG00000240399.1	RP1-228P16.1	-4.43	1.15e-05	0.00221	-0.19	-0.2	Adiponectin levels;	chr12:48533731	chr12:48054813~48055591:-
LUAD	cis	rs42490	1	rs454441	ENSG00000251136.7	RP11-37B2.1	-4.43	1.15e-05	0.00221	-0.2	-0.2	Leprosy;	chr8:89750842	chr8:89609409~89757727:-
LUAD	cis	rs1499614	1	rs2707840	ENSG00000229886.1	RP5-1132H15.3	4.43	1.15e-05	0.00221	0.34	0.2	Gout;	chr7:66693028	chr7:66025126~66031544:-
LUAD	cis	rs8077577	0.747	rs11867895	ENSG00000273018.4	CTD-2303H24.2	-4.43	1.15e-05	0.00221	-0.28	-0.2	Obesity-related traits;	chr17:18243407	chr17:18511221~18551705:-
LUAD	cis	rs77688320	0.529	rs2540438	ENSG00000213090.2	AC007256.5	-4.43	1.15e-05	0.00222	-0.23	-0.2	Breast cancer;	chr2:201485833	chr2:201410544~201413308:-
LUAD	cis	rs9650657	0.504	rs6601565	ENSG00000255046.1	RP11-297N6.4	4.43	1.15e-05	0.00222	0.25	0.2	Neuroticism;	chr8:11174719	chr8:11797928~11802568:-
LUAD	cis	rs1979679	0.918	rs78500430	ENSG00000278733.1	RP11-425D17.1	4.43	1.15e-05	0.00222	0.25	0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28369828	chr12:28185625~28186190:-
LUAD	cis	rs4865762	0.595	rs27323	ENSG00000247796.2	CTD-2366F13.1	-4.43	1.15e-05	0.00222	-0.2	-0.2	Intraocular pressure;	chr5:53256409	chr5:53109842~53115126:+
LUAD	cis	rs1167827	0.805	rs809439	ENSG00000223705.8	NSUN5P1	-4.43	1.15e-05	0.00222	-0.14	-0.2	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75531992	chr7:75410322~75416787:+
LUAD	cis	rs4873772	0.738	rs62539116	ENSG00000253330.1	RP11-697N18.3	-4.43	1.15e-05	0.00222	-0.23	-0.2	Lobe attachment (rater-scored or self-reported);	chr8:47585965	chr8:47511034~47512141:-
LUAD	cis	rs11242704	0.632	rs57995235	ENSG00000272279.1	RP11-157J24.2	-4.43	1.15e-05	0.00222	-0.3	-0.2	Response to hepatitis C treatment;	chr6:1530716	chr6:1528364~1528911:-
LUAD	cis	rs561341	0.941	rs550213	ENSG00000265798.5	RP11-271K11.5	4.43	1.15e-05	0.00222	0.3	0.2	Hip circumference adjusted for BMI;	chr17:31990499	chr17:31038575~31059121:-
LUAD	cis	rs561341	1	rs530715	ENSG00000265798.5	RP11-271K11.5	4.43	1.15e-05	0.00222	0.3	0.2	Hip circumference adjusted for BMI;	chr17:31993525	chr17:31038575~31059121:-
LUAD	cis	rs10971721	0.822	rs72727332	ENSG00000260947.1	RP11-384P7.7	4.43	1.15e-05	0.00222	0.4	0.2	Body mass index;	chr9:33929479	chr9:33697459~33700986:+
LUAD	cis	rs736408	0.608	rs4687657	ENSG00000242142.1	SERBP1P3	4.43	1.15e-05	0.00222	0.22	0.2	Bipolar disorder;	chr3:52818522	chr3:53064283~53065091:-
LUAD	cis	rs9341808	0.718	rs9448908	ENSG00000272129.1	RP11-250B2.6	4.43	1.15e-05	0.00222	0.24	0.2	Sitting height ratio;	chr6:80188352	chr6:80355424~80356859:+
LUAD	cis	rs338389	0.967	rs338392	ENSG00000260657.2	RP11-315D16.4	-4.43	1.15e-05	0.00222	-0.23	-0.2	Survival in rectal cancer;	chr15:67965073	chr15:68267792~68277994:-
LUAD	cis	rs11220082	0.602	rs10893383	ENSG00000254671.2	STT3A-AS1	-4.43	1.16e-05	0.00222	-0.22	-0.2	Schizophrenia;	chr11:125466237	chr11:125570284~125592568:-
LUAD	cis	rs2243480	1	rs778729	ENSG00000232559.3	GS1-124K5.12	4.43	1.16e-05	0.00222	0.34	0.2	Diabetic kidney disease;	chr7:66359432	chr7:66554588~66576923:-
LUAD	cis	rs7208859	0.623	rs60890550	ENSG00000266490.1	CTD-2349P21.9	4.43	1.16e-05	0.00222	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30703843	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs11653955	ENSG00000266490.1	CTD-2349P21.9	4.43	1.16e-05	0.00222	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30706274	chr17:30792372~30792833:+
LUAD	cis	rs1062177	0.547	rs2915818	ENSG00000213433.5	RPLP1P6	4.43	1.16e-05	0.00222	0.24	0.2	Preschool internalizing problems;	chr5:151735729	chr5:151765859~151766378:-
LUAD	cis	rs1555322	0.53	rs6060341	ENSG00000279253.1	RP4-614O4.13	4.43	1.16e-05	0.00222	0.25	0.2	Attention deficit hyperactivity disorder;	chr20:35275830	chr20:35262727~35264187:-
LUAD	cis	rs1167827	0.68	rs1167800	ENSG00000205583.12	STAG3L1	4.43	1.16e-05	0.00222	0.23	0.2	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75546898	chr7:75359194~75395383:+
LUAD	cis	rs8072100	0.701	rs6503807	ENSG00000228782.6	CTD-2026D20.3	4.43	1.16e-05	0.00223	0.21	0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47695566	chr17:47450568~47492492:-
LUAD	cis	rs1061377	0.621	rs11096974	ENSG00000249685.1	RP11-360F5.3	4.43	1.16e-05	0.00223	0.24	0.2	Uric acid levels;	chr4:39062039	chr4:39133913~39135608:+
LUAD	cis	rs4819052	1	rs9306123	ENSG00000223768.1	LINC00205	-4.43	1.16e-05	0.00223	-0.26	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45290007	chr21:45293285~45297354:+
LUAD	cis	rs4938573	0.526	rs11216973	ENSG00000255422.1	AP002954.4	4.43	1.16e-05	0.00223	0.32	0.2	Follicular lymphoma;	chr11:118716292	chr11:118704607~118750263:+
LUAD	cis	rs11089937	0.54	rs9622920	ENSG00000211640.3	IGLV6-57	-4.43	1.16e-05	0.00223	-0.15	-0.2	Periodontitis (PAL4Q3);	chr22:22133024	chr22:22195713~22196460:+
LUAD	cis	rs16846053	0.642	rs10193728	ENSG00000227403.1	AC009299.3	4.43	1.16e-05	0.00223	0.32	0.2	Blood osmolality (transformed sodium);	chr2:161772833	chr2:161244739~161249050:+
LUAD	cis	rs8072100	0.701	rs4794053	ENSG00000228782.6	CTD-2026D20.3	4.43	1.16e-05	0.00223	0.21	0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47692185	chr17:47450568~47492492:-
LUAD	cis	rs6012564	1	rs11696396	ENSG00000230758.1	SNAP23P	4.43	1.16e-05	0.00223	0.21	0.2	Anger;	chr20:49136482	chr20:49038357~49038602:-
LUAD	cis	rs6012564	1	rs6066977	ENSG00000230758.1	SNAP23P	4.43	1.16e-05	0.00223	0.21	0.2	Anger;	chr20:49138538	chr20:49038357~49038602:-
LUAD	cis	rs6012564	1	rs6066978	ENSG00000230758.1	SNAP23P	4.43	1.16e-05	0.00223	0.21	0.2	Anger;	chr20:49139205	chr20:49038357~49038602:-
LUAD	cis	rs6012564	1	rs6066982	ENSG00000230758.1	SNAP23P	4.43	1.16e-05	0.00223	0.21	0.2	Anger;	chr20:49147021	chr20:49038357~49038602:-
LUAD	cis	rs6012564	1	rs7272164	ENSG00000230758.1	SNAP23P	4.43	1.16e-05	0.00223	0.21	0.2	Anger;	chr20:49149660	chr20:49038357~49038602:-
LUAD	cis	rs1008375	1	rs11722037	ENSG00000249502.1	AC006160.5	-4.43	1.16e-05	0.00223	-0.19	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17682188	chr4:17587467~17614571:-
LUAD	cis	rs7086627	0.515	rs10887905	ENSG00000226659.1	RP11-137H2.4	-4.43	1.16e-05	0.00223	-0.26	-0.2	Post bronchodilator FEV1;	chr10:80451099	chr10:80529597~80535942:-
LUAD	cis	rs7086627	0.515	rs7077373	ENSG00000226659.1	RP11-137H2.4	-4.43	1.16e-05	0.00223	-0.26	-0.2	Post bronchodilator FEV1;	chr10:80451859	chr10:80529597~80535942:-
LUAD	cis	rs7086627	0.515	rs12245180	ENSG00000226659.1	RP11-137H2.4	-4.43	1.16e-05	0.00223	-0.26	-0.2	Post bronchodilator FEV1;	chr10:80452141	chr10:80529597~80535942:-
LUAD	cis	rs172166	0.694	rs203876	ENSG00000216901.1	AL022393.7	4.43	1.16e-05	0.00223	0.24	0.2	Cardiac Troponin-T levels;	chr6:28078895	chr6:28176188~28176674:+
LUAD	cis	rs172166	0.694	rs203877	ENSG00000216901.1	AL022393.7	4.43	1.16e-05	0.00223	0.24	0.2	Cardiac Troponin-T levels;	chr6:28080846	chr6:28176188~28176674:+
LUAD	cis	rs7138803	0.588	rs2720301	ENSG00000257464.1	RP11-161H23.8	-4.43	1.16e-05	0.00223	-0.2	-0.2	Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index;	chr12:49786667	chr12:49442424~49442652:-
LUAD	cis	rs8180040	0.62	rs11720139	ENSG00000271161.1	BOLA2P2	-4.43	1.16e-05	0.00223	-0.19	-0.2	Colorectal cancer;	chr3:46995266	chr3:47499841~47500407:+
LUAD	cis	rs2243480	1	rs709607	ENSG00000226002.1	RP11-460N20.5	4.43	1.16e-05	0.00223	0.32	0.2	Diabetic kidney disease;	chr7:65984554	chr7:65084103~65100232:+
LUAD	cis	rs8062405	0.755	rs111693583	ENSG00000261419.1	RP11-57A19.4	-4.43	1.16e-05	0.00223	-0.22	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28659696~28740781:-
LUAD	cis	rs17772222	0.917	rs1956406	ENSG00000258789.1	RP11-507K2.3	-4.43	1.16e-05	0.00223	-0.27	-0.2	Coronary artery calcification;	chr14:88749711	chr14:88551597~88552493:+
LUAD	cis	rs7746199	0.736	rs13195636	ENSG00000219392.1	RP1-265C24.5	-4.43	1.16e-05	0.00223	-0.42	-0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27541714	chr6:28115628~28116551:+
LUAD	cis	rs6500602	0.963	rs7201012	ENSG00000280063.1	RP11-295D4.3	4.43	1.16e-05	0.00223	0.13	0.2	Schizophrenia;	chr16:4430681	chr16:4346694~4348648:-
LUAD	cis	rs1346081	1	rs6819515	ENSG00000250075.4	RP11-584P21.2	-4.43	1.16e-05	0.00223	-0.22	-0.2	Intelligence (multi-trait analysis);	chr4:67192304	chr4:67417305~67468251:-
LUAD	cis	rs7493	0.95	rs11981299	ENSG00000233942.1	AC004012.1	4.43	1.16e-05	0.00223	0.29	0.2	Yu-Zhi constitution type in type 2 diabetes;	chr7:95400389	chr7:95471835~95473998:+
LUAD	cis	rs12682352	0.602	rs635594	ENSG00000253893.2	FAM85B	4.43	1.16e-05	0.00224	0.26	0.2	Neuroticism;	chr8:8755877	chr8:8167819~8226614:-
LUAD	cis	rs10129255	0.83	rs61997609	ENSG00000211974.3	IGHV2-70	4.43	1.16e-05	0.00224	0.21	0.2	Kawasaki disease;	chr14:106692376	chr14:106723574~106724093:-
LUAD	cis	rs865483	0.861	rs72828246	ENSG00000276054.1	RP11-378E13.3	-4.43	1.16e-05	0.00224	-0.24	-0.2	Monocyte count;	chr17:37406385	chr17:37386886~37387926:+
LUAD	cis	rs394563	0.601	rs376269	ENSG00000231760.4	RP11-350J20.5	4.43	1.16e-05	0.00224	0.26	0.2	Dupuytren's disease;	chr6:149474018	chr6:149796151~149826294:-
LUAD	cis	rs6142102	1	rs4911410	ENSG00000275784.1	RP5-1125A11.6	-4.43	1.16e-05	0.00224	-0.22	-0.2	Skin pigmentation;	chr20:34123168	chr20:33989480~33991818:-
LUAD	cis	rs4664293	0.867	rs2114626	ENSG00000226266.5	AC009961.3	4.43	1.16e-05	0.00224	0.27	0.2	Monocyte percentage of white cells;	chr2:159783459	chr2:159670708~159712435:-
LUAD	cis	rs9487094	0.961	rs12209691	ENSG00000260273.1	RP11-425D10.10	4.43	1.16e-05	0.00224	0.27	0.2	Height;	chr6:109465229	chr6:109382795~109383666:+
LUAD	cis	rs10129255	0.833	rs7156689	ENSG00000211955.2	IGHV3-33	-4.43	1.16e-05	0.00224	-0.16	-0.2	Kawasaki disease;	chr14:106816039	chr14:106359793~106360324:-
LUAD	cis	rs4811196	0.748	rs909770	ENSG00000226144.2	RPS27AP3	4.43	1.16e-05	0.00224	0.22	0.2	Bone mineral density;	chr20:37867890	chr20:37049254~37049707:+
LUAD	cis	rs17685	0.753	rs10476	ENSG00000280388.1	RP11-229D13.3	4.43	1.16e-05	0.00224	0.18	0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76067102	chr7:76043977~76045963:-
LUAD	cis	rs4268898	0.735	rs12469585	ENSG00000223754.1	AC008073.9	-4.43	1.16e-05	0.00224	-0.24	-0.2	Asthma;	chr2:24266185	chr2:24199839~24201698:-
LUAD	cis	rs1008375	0.966	rs4515155	ENSG00000249502.1	AC006160.5	-4.43	1.16e-05	0.00224	-0.19	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17694854	chr4:17587467~17614571:-
LUAD	cis	rs1008375	0.966	rs6832414	ENSG00000249502.1	AC006160.5	-4.43	1.16e-05	0.00224	-0.19	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17695243	chr4:17587467~17614571:-
LUAD	cis	rs1008375	0.932	rs6857678	ENSG00000249502.1	AC006160.5	-4.43	1.16e-05	0.00224	-0.19	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17695341	chr4:17587467~17614571:-
LUAD	cis	rs1008375	0.966	rs11722132	ENSG00000249502.1	AC006160.5	-4.43	1.16e-05	0.00224	-0.19	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17695594	chr4:17587467~17614571:-
LUAD	cis	rs1008375	0.966	rs6832387	ENSG00000249502.1	AC006160.5	-4.43	1.16e-05	0.00224	-0.19	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17695923	chr4:17587467~17614571:-
LUAD	cis	rs9815354	1	rs9856633	ENSG00000273328.4	RP11-141M3.6	-4.43	1.16e-05	0.00224	-0.29	-0.2	Pulse pressure;Diastolic blood pressure;	chr3:41972358	chr3:42809414~42908105:+
LUAD	cis	rs7590268	0.577	rs7604544	ENSG00000279873.2	LINC01126	4.43	1.16e-05	0.00224	0.19	0.2	Orofacial clefts;	chr2:43396347	chr2:43227210~43228855:+
LUAD	cis	rs4489787	1	rs2705126	ENSG00000240399.1	RP1-228P16.1	4.43	1.16e-05	0.00224	0.29	0.2	Prostate cancer (SNP x SNP interaction);	chr12:48488779	chr12:48054813~48055591:-
LUAD	cis	rs60180747	0.544	rs12908529	ENSG00000261318.1	RP11-653J6.1	4.43	1.17e-05	0.00224	0.26	0.2	Testicular germ cell tumor;	chr15:66279630	chr15:66278498~66293357:-
LUAD	cis	rs9341808	0.718	rs10080237	ENSG00000272129.1	RP11-250B2.6	4.43	1.17e-05	0.00224	0.24	0.2	Sitting height ratio;	chr6:80144753	chr6:80355424~80356859:+
LUAD	cis	rs4819052	0.807	rs4819047	ENSG00000237664.1	LINC00316	-4.43	1.17e-05	0.00224	-0.24	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245224	chr21:45338590~45341990:-
LUAD	cis	rs780096	0.526	rs7594812	ENSG00000234072.1	AC074117.10	-4.43	1.17e-05	0.00224	-0.15	-0.2	Total body bone mineral density;	chr2:27388602	chr2:27356246~27367622:+
LUAD	cis	rs2933343	0.621	rs789242	ENSG00000231305.3	RP11-723O4.2	4.43	1.17e-05	0.00224	0.21	0.2	IgG glycosylation;	chr3:128866864	chr3:128861313~128871540:-
LUAD	cis	rs10246939	0.511	rs62475469	ENSG00000270923.1	TAS2R6P	-4.43	1.17e-05	0.00224	-0.22	-0.2	Bitter taste perception;	chr7:141864846	chr7:141787815~141788640:+
LUAD	cis	rs7119038	0.818	rs2077579	ENSG00000255422.1	AP002954.4	4.43	1.17e-05	0.00224	0.31	0.2	Sjögren's syndrome;	chr11:118748338	chr11:118704607~118750263:+
LUAD	cis	rs875971	1	rs6460292	ENSG00000232559.3	GS1-124K5.12	-4.43	1.17e-05	0.00224	-0.23	-0.2	Aortic root size;	chr7:66345088	chr7:66554588~66576923:-
LUAD	cis	rs2898681	0.519	rs76606067	ENSG00000248375.1	RP11-177B4.1	-4.43	1.17e-05	0.00224	-0.33	-0.2	Optic nerve measurement (cup area);	chr4:52862054	chr4:52720081~52720831:-
LUAD	cis	rs2898681	0.521	rs115874483	ENSG00000248375.1	RP11-177B4.1	-4.43	1.17e-05	0.00224	-0.33	-0.2	Optic nerve measurement (cup area);	chr4:52862105	chr4:52720081~52720831:-
LUAD	cis	rs4660214	0.59	rs11205885	ENSG00000228060.1	RP11-69E11.8	4.43	1.17e-05	0.00224	0.18	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39306633	chr1:39565160~39573203:+
LUAD	cis	rs4660214	0.666	rs3116398	ENSG00000228060.1	RP11-69E11.8	4.43	1.17e-05	0.00224	0.18	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39314130	chr1:39565160~39573203:+
LUAD	cis	rs7172677	0.737	rs11855234	ENSG00000260269.4	CTD-2323K18.1	-4.43	1.17e-05	0.00224	-0.25	-0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75154493	chr15:75527150~75601205:-
LUAD	cis	rs227275	0.556	rs11731885	ENSG00000251288.2	RP11-10L12.2	-4.43	1.17e-05	0.00224	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:103010913	chr4:102751401~102752641:+
LUAD	cis	rs1355223	0.902	rs865070	ENSG00000271369.1	RP11-350D17.3	-4.43	1.17e-05	0.00224	-0.23	-0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34720950	chr11:34709600~34710161:+
LUAD	cis	rs2880765	0.835	rs6496027	ENSG00000259416.2	RP11-158M2.5	4.43	1.17e-05	0.00224	0.21	0.2	Coronary artery disease;	chr15:85506757	chr15:85754941~85756237:-
LUAD	cis	rs17596685	1	rs2148073	ENSG00000271216.1	LINC01050	-4.43	1.17e-05	0.00224	-0.28	-0.2	C-reactive protein levels;	chr13:42589663	chr13:42810366~42812562:-
LUAD	cis	rs524281	0.731	rs10791841	ENSG00000255320.1	RP11-755F10.1	4.43	1.17e-05	0.00224	0.33	0.2	Electroencephalogram traits;	chr11:66041116	chr11:66244840~66246239:-
LUAD	cis	rs7493	0.755	rs17883791	ENSG00000233942.1	AC004012.1	4.43	1.17e-05	0.00225	0.28	0.2	Yu-Zhi constitution type in type 2 diabetes;	chr7:95370126	chr7:95471835~95473998:+
LUAD	cis	rs34779708	0.801	rs12246600	ENSG00000271335.4	RP11-324I22.4	4.43	1.17e-05	0.00225	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35249193	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.801	rs12098720	ENSG00000271335.4	RP11-324I22.4	4.43	1.17e-05	0.00225	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35249755	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.801	rs34592588	ENSG00000271335.4	RP11-324I22.4	4.43	1.17e-05	0.00225	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35251206	chr10:35314552~35336401:-
LUAD	cis	rs7178424	0.711	rs7166891	ENSG00000259251.2	RP11-643M14.1	4.43	1.17e-05	0.00225	0.2	0.2	Height;	chr15:61947105	chr15:62060503~62062434:+
LUAD	cis	rs801193	1	rs1553609	ENSG00000224316.1	RP11-479O9.2	4.43	1.17e-05	0.00225	0.2	0.2	Aortic root size;	chr7:66732152	chr7:65773620~65802067:+
LUAD	cis	rs3096299	0.719	rs2965817	ENSG00000261118.1	RP11-104N10.1	4.43	1.17e-05	0.00225	0.2	0.2	Multiple myeloma (IgH translocation);	chr16:89446826	chr16:89492017~89504460:-
LUAD	cis	rs28386778	0.83	rs2597636	ENSG00000240280.5	TCAM1P	-4.43	1.17e-05	0.00225	-0.23	-0.2	Prudent dietary pattern;	chr17:63798650	chr17:63849292~63864379:+
LUAD	cis	rs1005277	0.579	rs2474584	ENSG00000263064.2	RP11-291L22.7	4.43	1.17e-05	0.00225	0.21	0.2	Extrinsic epigenetic age acceleration;	chr10:38127461	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.579	rs1548255	ENSG00000263064.2	RP11-291L22.7	4.43	1.17e-05	0.00225	0.21	0.2	Extrinsic epigenetic age acceleration;	chr10:38128265	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.579	rs2474586	ENSG00000263064.2	RP11-291L22.7	4.43	1.17e-05	0.00225	0.21	0.2	Extrinsic epigenetic age acceleration;	chr10:38129954	chr10:38448689~38448949:+
LUAD	cis	rs950169	0.887	rs12903946	ENSG00000275120.1	RP11-182J1.17	4.43	1.17e-05	0.00225	0.31	0.2	Schizophrenia;	chr15:84399732	chr15:84599434~84606463:-
LUAD	cis	rs950169	0.887	rs62029593	ENSG00000275120.1	RP11-182J1.17	4.43	1.17e-05	0.00225	0.31	0.2	Schizophrenia;	chr15:84400482	chr15:84599434~84606463:-
LUAD	cis	rs950169	0.81	rs62029594	ENSG00000275120.1	RP11-182J1.17	4.43	1.17e-05	0.00225	0.31	0.2	Schizophrenia;	chr15:84400554	chr15:84599434~84606463:-
LUAD	cis	rs950169	0.881	rs62029596	ENSG00000275120.1	RP11-182J1.17	4.43	1.17e-05	0.00225	0.31	0.2	Schizophrenia;	chr15:84400736	chr15:84599434~84606463:-
LUAD	cis	rs950169	0.881	rs4081123	ENSG00000275120.1	RP11-182J1.17	4.43	1.17e-05	0.00225	0.31	0.2	Schizophrenia;	chr15:84401537	chr15:84599434~84606463:-
LUAD	cis	rs950169	0.881	rs62029599	ENSG00000275120.1	RP11-182J1.17	4.43	1.17e-05	0.00225	0.31	0.2	Schizophrenia;	chr15:84401867	chr15:84599434~84606463:-
LUAD	cis	rs950169	0.8	rs4099846	ENSG00000275120.1	RP11-182J1.17	4.43	1.17e-05	0.00225	0.31	0.2	Schizophrenia;	chr15:84402196	chr15:84599434~84606463:-
LUAD	cis	rs453301	0.631	rs7843789	ENSG00000233609.3	RP11-62H7.2	-4.43	1.17e-05	0.00225	-0.16	-0.2	Joint mobility (Beighton score);	chr8:8943051	chr8:8961200~8979025:+
LUAD	cis	rs2060793	0.659	rs1839834	ENSG00000251991.1	RNU7-49P	4.43	1.17e-05	0.00225	0.22	0.2	Vitamin D levels;	chr11:14807914	chr11:14478892~14478953:+
LUAD	cis	rs2810114	0.76	rs2810105	ENSG00000269927.1	RP6-91H8.3	-4.43	1.17e-05	0.00225	-0.26	-0.2	Alcohol dependence;	chr14:70957934	chr14:71141125~71143253:-
LUAD	cis	rs801193	0.935	rs2659899	ENSG00000224316.1	RP11-479O9.2	4.43	1.17e-05	0.00225	0.2	0.2	Aortic root size;	chr7:66721734	chr7:65773620~65802067:+
LUAD	cis	rs801193	1	rs62466794	ENSG00000224316.1	RP11-479O9.2	4.43	1.17e-05	0.00225	0.2	0.2	Aortic root size;	chr7:66726592	chr7:65773620~65802067:+
LUAD	cis	rs5758659	0.716	rs2143138	ENSG00000227370.1	RP4-669P10.19	-4.43	1.17e-05	0.00226	-0.18	-0.2	Cognitive function;	chr22:42222334	chr22:42132543~42132998:+
LUAD	cis	rs875971	0.66	rs1860470	ENSG00000224316.1	RP11-479O9.2	-4.43	1.18e-05	0.00226	-0.2	-0.2	Aortic root size;	chr7:66638707	chr7:65773620~65802067:+
LUAD	cis	rs116175783	0.557	rs62194490	ENSG00000227403.1	AC009299.3	4.43	1.18e-05	0.00226	0.36	0.2	Intelligence (multi-trait analysis);	chr2:161344287	chr2:161244739~161249050:+
LUAD	cis	rs7324557	0.717	rs9510869	ENSG00000205861.10	C1QTNF9B-AS1	-4.43	1.18e-05	0.00226	-0.26	-0.2	Visceral adipose tissue adjusted for BMI;	chr13:23809990	chr13:23888889~23897263:+
LUAD	cis	rs7324557	0.717	rs9510870	ENSG00000205861.10	C1QTNF9B-AS1	-4.43	1.18e-05	0.00226	-0.26	-0.2	Visceral adipose tissue adjusted for BMI;	chr13:23810346	chr13:23888889~23897263:+
LUAD	cis	rs7172677	0.737	rs8025412	ENSG00000260269.4	CTD-2323K18.1	-4.43	1.18e-05	0.00226	-0.25	-0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75151692	chr15:75527150~75601205:-
LUAD	cis	rs7107174	1	rs7939352	ENSG00000251323.2	RP11-452H21.4	4.43	1.18e-05	0.00226	0.24	0.2	Testicular germ cell tumor;	chr11:78292105	chr11:78423982~78429836:-
LUAD	cis	rs10266483	0.705	rs660228	ENSG00000227986.1	TRIM60P18	-4.43	1.18e-05	0.00226	-0.24	-0.2	Response to statin therapy;	chr7:64295867	chr7:64355078~64356199:+
LUAD	cis	rs7208859	0.623	rs9912283	ENSG00000266490.1	CTD-2349P21.9	4.43	1.18e-05	0.00226	0.29	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30792372~30792833:+
LUAD	cis	rs60180747	0.544	rs12913465	ENSG00000261318.1	RP11-653J6.1	4.43	1.18e-05	0.00226	0.26	0.2	Testicular germ cell tumor;	chr15:66280896	chr15:66278498~66293357:-
LUAD	cis	rs1106529	0.515	rs10923697	ENSG00000226172.2	RP4-712E4.1	4.43	1.18e-05	0.00226	0.3	0.2	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);	chr1:118913367	chr1:119000344~119001392:-
LUAD	cis	rs750134	0.901	rs78181570	ENSG00000257221.1	RP11-689B22.2	-4.43	1.18e-05	0.00226	-0.29	-0.2	Low high density lipoprotein cholesterol levels;	chr12:108684139	chr12:108628687~108641318:+
LUAD	cis	rs5769707	1	rs5769707	ENSG00000235111.1	RP1-29C18.8	-4.43	1.18e-05	0.00226	-0.21	-0.2	Monocyte percentage of white cells;Monocyte count;	chr22:49619754	chr22:49612657~49615716:-
LUAD	cis	rs2243480	1	rs781157	ENSG00000229886.1	RP5-1132H15.3	4.43	1.18e-05	0.00226	0.34	0.2	Diabetic kidney disease;	chr7:66013324	chr7:66025126~66031544:-
LUAD	cis	rs11673344	0.764	rs474017	ENSG00000226686.6	LINC01535	4.43	1.18e-05	0.00226	0.25	0.2	Obesity-related traits;	chr19:36963217	chr19:37251912~37265535:+
LUAD	cis	rs16866061	1	rs11688397	ENSG00000228446.2	AC073052.1	-4.43	1.18e-05	0.00226	-0.21	-0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr2:224528456	chr2:224499387~224500100:-
LUAD	cis	rs6723108	0.517	rs6430543	ENSG00000224043.6	CCNT2-AS1	4.43	1.18e-05	0.00226	0.24	0.2	Type 2 diabetes;	chr2:134844839	chr2:134735464~134918710:-
LUAD	cis	rs7590268	0.666	rs7570751	ENSG00000279873.2	LINC01126	4.43	1.18e-05	0.00226	0.19	0.2	Orofacial clefts;	chr2:43408367	chr2:43227210~43228855:+
LUAD	cis	rs7590268	0.606	rs6544657	ENSG00000279873.2	LINC01126	4.43	1.18e-05	0.00226	0.19	0.2	Orofacial clefts;	chr2:43408440	chr2:43227210~43228855:+
LUAD	cis	rs7178375	0.607	rs12903674	ENSG00000259845.1	HERC2P10	4.43	1.18e-05	0.00226	0.37	0.2	Hypertriglyceridemia;	chr15:30902349	chr15:30815271~30844153:+
LUAD	cis	rs2057178	0.929	rs61889172	ENSG00000183242.10	WT1-AS	4.43	1.18e-05	0.00226	0.3	0.2	Tuberculosis;	chr11:32315541	chr11:32435518~32458769:+
LUAD	cis	rs2057178	0.929	rs61889173	ENSG00000183242.10	WT1-AS	4.43	1.18e-05	0.00226	0.3	0.2	Tuberculosis;	chr11:32316700	chr11:32435518~32458769:+
LUAD	cis	rs189798	1	rs189798	ENSG00000253893.2	FAM85B	4.43	1.18e-05	0.00227	0.26	0.2	Myopia (pathological);	chr8:9133067	chr8:8167819~8226614:-
LUAD	cis	rs477895	0.653	rs11602181	ENSG00000236935.1	AP003774.1	-4.43	1.18e-05	0.00227	-0.23	-0.2	Mean platelet volume;	chr11:64129119	chr11:64325050~64329504:-
LUAD	cis	rs12073359	0.954	rs72694956	ENSG00000223945.2	RP11-458I7.1	-4.43	1.18e-05	0.00227	-0.3	-0.2	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150162023	chr1:150053864~150055034:+
LUAD	cis	rs4578769	0.531	rs9951973	ENSG00000265943.1	RP11-739L10.1	-4.43	1.18e-05	0.00227	-0.25	-0.2	Eosinophil percentage of white cells;	chr18:22974353	chr18:22699481~22933764:-
LUAD	cis	rs55823223	0.503	rs9906971	ENSG00000267801.1	RP11-552F3.9	4.43	1.18e-05	0.00227	0.21	0.2	Psoriasis;	chr17:75852396	chr17:75876372~75879546:+
LUAD	cis	rs55823223	0.564	rs9894009	ENSG00000267801.1	RP11-552F3.9	4.43	1.18e-05	0.00227	0.21	0.2	Psoriasis;	chr17:75854333	chr17:75876372~75879546:+
LUAD	cis	rs9467773	1	rs2393670	ENSG00000261353.1	CTA-14H9.5	-4.43	1.18e-05	0.00227	-0.22	-0.2	Intelligence (multi-trait analysis);	chr6:26535313	chr6:26527063~26527404:+
LUAD	cis	rs8050896	1	rs6499063	ENSG00000260695.1	RP11-513N24.1	-4.43	1.18e-05	0.00227	-0.36	-0.2	Response to antipsychotic treatment;	chr16:66127232	chr16:65861112~65863784:-
LUAD	cis	rs16869652	0.748	rs59248104	ENSG00000224557.6	HLA-DPB2	4.43	1.18e-05	0.00227	0.34	0.2	Schizophrenia;	chr6:33877432	chr6:33112451~33129084:+
LUAD	cis	rs1912483	0.545	rs35161461	ENSG00000228782.6	CTD-2026D20.3	4.43	1.18e-05	0.00227	0.23	0.2	Coronary artery disease;	chr17:47324391	chr17:47450568~47492492:-
LUAD	cis	rs2115630	1	rs55646601	ENSG00000225151.9	GOLGA2P7	4.43	1.18e-05	0.00227	0.22	0.2	P wave terminal force;	chr15:84780337	chr15:84199311~84230136:-
LUAD	cis	rs8072100	0.701	rs8075566	ENSG00000228782.6	CTD-2026D20.3	4.43	1.18e-05	0.00227	0.21	0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47693671	chr17:47450568~47492492:-
LUAD	cis	rs9341808	0.718	rs2143887	ENSG00000272129.1	RP11-250B2.6	4.43	1.18e-05	0.00227	0.24	0.2	Sitting height ratio;	chr6:80207570	chr6:80355424~80356859:+
LUAD	cis	rs2236295	0.533	rs10995356	ENSG00000238280.1	RP11-436D10.3	-4.43	1.18e-05	0.00227	-0.24	-0.2	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr10:62896153	chr10:62793562~62805887:-
LUAD	cis	rs72717009	0.756	rs10494359	ENSG00000225217.1	HSPA7	-4.43	1.19e-05	0.00227	-0.28	-0.2	Rheumatoid arthritis;	chr1:161494086	chr1:161606291~161608217:+
LUAD	cis	rs73173548	0.528	rs6872276	ENSG00000247828.6	TMEM161B-AS1	4.43	1.19e-05	0.00227	0.25	0.2	Macular telangiectasia type 2;	chr5:88473903	chr5:88268895~88436685:+
LUAD	cis	rs73173548	0.502	rs74429030	ENSG00000247828.6	TMEM161B-AS1	4.43	1.19e-05	0.00227	0.25	0.2	Macular telangiectasia type 2;	chr5:88474689	chr5:88268895~88436685:+
LUAD	cis	rs6723108	0.627	rs6430550	ENSG00000224043.6	CCNT2-AS1	-4.43	1.19e-05	0.00228	-0.25	-0.2	Type 2 diabetes;	chr2:134858815	chr2:134735464~134918710:-
LUAD	cis	rs74233809	0.901	rs3824755	ENSG00000213277.3	MARCKSL1P1	4.43	1.19e-05	0.00228	0.32	0.2	Birth weight;	chr10:102836092	chr10:103175554~103176094:+
LUAD	cis	rs4873772	0.735	rs4608108	ENSG00000253330.1	RP11-697N18.3	-4.43	1.19e-05	0.00228	-0.22	-0.2	Lobe attachment (rater-scored or self-reported);	chr8:47602961	chr8:47511034~47512141:-
LUAD	cis	rs11722779	0.935	rs7676736	ENSG00000251288.2	RP11-10L12.2	-4.43	1.19e-05	0.00228	-0.24	-0.2	Schizophrenia;	chr4:103016729	chr4:102751401~102752641:+
LUAD	cis	rs11722779	0.935	rs3857200	ENSG00000251288.2	RP11-10L12.2	-4.43	1.19e-05	0.00228	-0.24	-0.2	Schizophrenia;	chr4:103001864	chr4:102751401~102752641:+
LUAD	cis	rs957448	1	rs28817653	ENSG00000254315.1	RP11-267M23.3	4.43	1.19e-05	0.00228	0.25	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94557822	chr8:94533628~94534391:+
LUAD	cis	rs11722779	0.692	rs223414	ENSG00000251288.2	RP11-10L12.2	-4.43	1.19e-05	0.00228	-0.24	-0.2	Schizophrenia;	chr4:102811688	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.525	rs28445579	ENSG00000251288.2	RP11-10L12.2	-4.43	1.19e-05	0.00228	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:103016438	chr4:102751401~102752641:+
LUAD	cis	rs801193	1	rs2659906	ENSG00000224316.1	RP11-479O9.2	4.43	1.19e-05	0.00228	0.2	0.2	Aortic root size;	chr7:66700323	chr7:65773620~65802067:+
LUAD	cis	rs227275	0.525	rs13150426	ENSG00000251288.2	RP11-10L12.2	-4.43	1.19e-05	0.00228	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:103013743	chr4:102751401~102752641:+
LUAD	cis	rs6964587	1	rs2299232	ENSG00000188693.7	CYP51A1-AS1	-4.43	1.19e-05	0.00228	-0.23	-0.2	Breast cancer;	chr7:91997385	chr7:92134604~92180725:+
LUAD	cis	rs5758511	0.689	rs5758691	ENSG00000226450.2	CYP2D8P	4.43	1.19e-05	0.00228	0.18	0.2	Birth weight;	chr22:42272498	chr22:42149886~42155001:-
LUAD	cis	rs5758511	0.68	rs1001586	ENSG00000226450.2	CYP2D8P	4.43	1.19e-05	0.00228	0.18	0.2	Birth weight;	chr22:42274287	chr22:42149886~42155001:-
LUAD	cis	rs6714710	0.58	rs35564270	ENSG00000230606.9	AC159540.1	-4.43	1.19e-05	0.00228	-0.21	-0.2	Posterior cortical atrophy and Alzheimer's disease;	chr2:97985702	chr2:97416165~97433527:-
LUAD	cis	rs17711722	0.565	rs4717276	ENSG00000189316.3	RP11-797H7.5	-4.43	1.19e-05	0.00228	-0.21	-0.2	Calcium levels;	chr7:65829754	chr7:64888527~64890100:-
LUAD	cis	rs950169	0.724	rs11632668	ENSG00000275120.1	RP11-182J1.17	4.43	1.19e-05	0.00228	0.31	0.2	Schizophrenia;	chr15:84393989	chr15:84599434~84606463:-
LUAD	cis	rs7208859	0.623	rs122898	ENSG00000280069.1	CTD-2349P21.3	4.43	1.19e-05	0.00228	0.27	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30738182~30740275:+
LUAD	cis	rs2243480	1	rs464895	ENSG00000226002.1	RP11-460N20.5	-4.43	1.19e-05	0.00228	-0.34	-0.2	Diabetic kidney disease;	chr7:66062119	chr7:65084103~65100232:+
LUAD	cis	rs897984	0.646	rs9938088	ENSG00000232748.3	RP11-196G11.6	-4.43	1.19e-05	0.00228	-0.25	-0.2	Dementia with Lewy bodies;	chr16:30818683	chr16:31056460~31062803:+
LUAD	cis	rs7829975	0.533	rs13274028	ENSG00000253981.4	ALG1L13P	4.43	1.19e-05	0.00228	0.23	0.2	Mood instability;	chr8:8871683	chr8:8236003~8244667:-
LUAD	cis	rs7208859	0.623	rs9912440	ENSG00000266490.1	CTD-2349P21.9	4.43	1.19e-05	0.00228	0.29	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30821754	chr17:30792372~30792833:+
LUAD	cis	rs853679	0.556	rs34706883	ENSG00000219392.1	RP1-265C24.5	-4.43	1.19e-05	0.00228	-0.42	-0.2	Depression;	chr6:27837477	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.546	rs35819751	ENSG00000219392.1	RP1-265C24.5	-4.43	1.19e-05	0.00228	-0.42	-0.2	Depression;	chr6:27842791	chr6:28115628~28116551:+
LUAD	cis	rs750134	0.901	rs78866567	ENSG00000257221.1	RP11-689B22.2	-4.43	1.19e-05	0.00228	-0.28	-0.2	Low high density lipoprotein cholesterol levels;	chr12:108786339	chr12:108628687~108641318:+
LUAD	cis	rs783540	0.632	rs17356528	ENSG00000276710.3	CSPG4P8	4.43	1.19e-05	0.00228	0.2	0.2	Schizophrenia;	chr15:82636799	chr15:82459472~82477258:+
LUAD	cis	rs875971	1	rs6958271	ENSG00000232559.3	GS1-124K5.12	4.43	1.19e-05	0.00229	0.23	0.2	Aortic root size;	chr7:66514344	chr7:66554588~66576923:-
LUAD	cis	rs875971	1	rs6958277	ENSG00000232559.3	GS1-124K5.12	4.43	1.19e-05	0.00229	0.23	0.2	Aortic root size;	chr7:66514362	chr7:66554588~66576923:-
LUAD	cis	rs453301	0.631	rs11780774	ENSG00000253893.2	FAM85B	4.43	1.19e-05	0.00229	0.25	0.2	Joint mobility (Beighton score);	chr8:8941601	chr8:8167819~8226614:-
LUAD	cis	rs6012564	0.783	rs6125575	ENSG00000230758.1	SNAP23P	4.43	1.19e-05	0.00229	0.21	0.2	Anger;	chr20:49159159	chr20:49038357~49038602:-
LUAD	cis	rs6012564	0.928	rs8118105	ENSG00000230758.1	SNAP23P	4.43	1.19e-05	0.00229	0.21	0.2	Anger;	chr20:49182127	chr20:49038357~49038602:-
LUAD	cis	rs8062405	0.755	rs62034358	ENSG00000261419.1	RP11-57A19.4	-4.43	1.19e-05	0.00229	-0.22	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28659696~28740781:-
LUAD	cis	rs8062405	0.755	rs12445823	ENSG00000261419.1	RP11-57A19.4	-4.43	1.19e-05	0.00229	-0.22	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28659696~28740781:-
LUAD	cis	rs4237845	0.844	rs7306124	ENSG00000257159.1	RP11-58A17.3	4.43	1.19e-05	0.00229	0.24	0.2	Intelligence (multi-trait analysis);	chr12:57909566	chr12:57967058~57968399:+
LUAD	cis	rs12091564	1	rs12091564	ENSG00000233396.6	RP11-458D21.1	4.43	1.19e-05	0.00229	0.47	0.2	Coronary heart disease (SNP X SNP interaction);	chr1:146039391	chr1:146052566~146061948:+
LUAD	cis	rs3770081	1	rs2241435	ENSG00000273080.1	RP11-301O19.1	-4.43	1.19e-05	0.00229	-0.46	-0.2	Facial emotion recognition (sad faces);	chr2:86133793	chr2:86195590~86196049:+
LUAD	cis	rs4968361	0.892	rs4968363	ENSG00000266992.1	DHX40P1	4.43	1.19e-05	0.00229	0.36	0.2	Schizophrenia;	chr17:59433712	chr17:59976009~60002384:-
LUAD	cis	rs643506	0.817	rs623491	ENSG00000230911.1	PPIHP1	-4.43	1.19e-05	0.00229	-0.24	-0.2	Breast cancer;	chr11:111830546	chr11:112029858~112030367:-
LUAD	cis	rs7208859	0.673	rs56846352	ENSG00000280069.1	CTD-2349P21.3	-4.43	1.19e-05	0.00229	-0.23	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792170	chr17:30738182~30740275:+
LUAD	cis	rs4699052	1	rs7661702	ENSG00000246560.2	RP11-10L12.4	4.42	1.19e-05	0.00229	0.25	0.2	Testicular germ cell tumor;	chr4:103218972	chr4:102828055~102844075:+
LUAD	cis	rs8024893	0.764	rs7182545	ENSG00000270055.1	CTD-3092A11.2	-4.42	1.19e-05	0.00229	-0.27	-0.2	Red cell distribution width;	chr15:31239638	chr15:30487963~30490313:+
LUAD	cis	rs7208859	0.623	rs11651857	ENSG00000266490.1	CTD-2349P21.9	4.42	1.2e-05	0.00229	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30599344	chr17:30792372~30792833:+
LUAD	cis	rs2929278	0.589	rs11638972	ENSG00000166763.7	STRCP1	-4.42	1.2e-05	0.00229	-0.23	-0.2	Schizophrenia;	chr15:43782493	chr15:43699488~43718184:-
LUAD	cis	rs10938353	0.638	rs6813425	ENSG00000273369.1	RP11-700J17.1	4.42	1.2e-05	0.00229	0.27	0.2	Body mass index;	chr4:44659503	chr4:44693946~44694386:-
LUAD	cis	rs10938353	0.68	rs72624165	ENSG00000273369.1	RP11-700J17.1	4.42	1.2e-05	0.00229	0.27	0.2	Body mass index;	chr4:44662457	chr4:44693946~44694386:-
LUAD	cis	rs3096299	0.719	rs2911265	ENSG00000182376.2	RP5-1142A6.8	4.42	1.2e-05	0.00229	0.21	0.2	Multiple myeloma (IgH translocation);	chr16:89444920	chr16:88742767~88745748:+
LUAD	cis	rs889398	0.741	rs6499269	ENSG00000226232.7	RP11-419C5.2	-4.42	1.2e-05	0.00229	-0.17	-0.2	Body mass index;	chr16:69875015	chr16:69976388~69996188:-
LUAD	cis	rs6565180	0.962	rs6565182	ENSG00000273724.1	RP11-347C12.12	-4.42	1.2e-05	0.00229	-0.22	-0.2	Tonsillectomy;	chr16:30363060	chr16:30336400~30343336:+
LUAD	cis	rs2731006	0.64	rs2056196	ENSG00000257114.2	RP11-25I15.3	4.42	1.2e-05	0.00229	0.29	0.2	Panic disorder;	chr12:42809340	chr12:42692216~42717119:+
LUAD	cis	rs5758511	0.68	rs1107554	ENSG00000226450.2	CYP2D8P	4.42	1.2e-05	0.00229	0.18	0.2	Birth weight;	chr22:42271588	chr22:42149886~42155001:-
LUAD	cis	rs2153535	0.585	rs9379236	ENSG00000230939.1	RP11-314C16.1	-4.42	1.2e-05	0.00229	-0.22	-0.2	Motion sickness;	chr6:8651792	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.56	rs1328866	ENSG00000230939.1	RP11-314C16.1	-4.42	1.2e-05	0.00229	-0.22	-0.2	Motion sickness;	chr6:8653283	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.585	rs1328865	ENSG00000230939.1	RP11-314C16.1	-4.42	1.2e-05	0.00229	-0.22	-0.2	Motion sickness;	chr6:8653454	chr6:8784178~8785445:+
LUAD	cis	rs17772222	0.917	rs17260380	ENSG00000258789.1	RP11-507K2.3	-4.42	1.2e-05	0.00229	-0.27	-0.2	Coronary artery calcification;	chr14:88682142	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.917	rs58984912	ENSG00000258789.1	RP11-507K2.3	-4.42	1.2e-05	0.00229	-0.27	-0.2	Coronary artery calcification;	chr14:88698172	chr14:88551597~88552493:+
LUAD	cis	rs73173548	0.557	rs71580759	ENSG00000247828.6	TMEM161B-AS1	4.42	1.2e-05	0.0023	0.25	0.2	Macular telangiectasia type 2;	chr5:88474306	chr5:88268895~88436685:+
LUAD	cis	rs6840258	0.76	rs340650	ENSG00000251411.1	RP11-397E7.4	4.42	1.2e-05	0.0023	0.23	0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87017533	chr4:86913266~86914817:-
LUAD	cis	rs6691170	0.632	rs7519761	ENSG00000228437.4	RP11-400N13.2	4.42	1.2e-05	0.0023	0.25	0.2	Colorectal cancer;	chr1:221838958	chr1:221966341~221984964:+
LUAD	cis	rs1979679	0.842	rs981494	ENSG00000278733.1	RP11-425D17.1	-4.42	1.2e-05	0.0023	-0.25	-0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28172916	chr12:28185625~28186190:-
LUAD	cis	rs7122539	0.734	rs2513658	ENSG00000213409.4	RP11-658F2.3	4.42	1.2e-05	0.0023	0.24	0.2	HIV-1 susceptibility;	chr11:66860778	chr11:66761575~66762399:-
LUAD	cis	rs240993	0.809	rs11153277	ENSG00000272356.1	RP5-1112D6.8	-4.42	1.2e-05	0.0023	-0.18	-0.2	Inflammatory skin disease;Psoriasis;	chr6:111259358	chr6:111309203~111313517:+
LUAD	cis	rs6840360	0.571	rs12648420	ENSG00000270265.1	RP11-731D1.4	-4.42	1.2e-05	0.0023	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151622282	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.571	rs72730104	ENSG00000270265.1	RP11-731D1.4	-4.42	1.2e-05	0.0023	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151622705	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.571	rs62327272	ENSG00000270265.1	RP11-731D1.4	-4.42	1.2e-05	0.0023	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151623938	chr4:151333775~151353224:-
LUAD	cis	rs7107174	1	rs2511185	ENSG00000251323.2	RP11-452H21.4	4.42	1.2e-05	0.0023	0.24	0.2	Testicular germ cell tumor;	chr11:78271450	chr11:78423982~78429836:-
LUAD	cis	rs2281636	0.723	rs1128642	ENSG00000233690.1	EBAG9P1	4.42	1.2e-05	0.0023	0.2	0.2	Obesity-related traits;	chr10:99711938	chr10:99697407~99697949:-
LUAD	cis	rs12962334	0.568	rs2034932	ENSG00000265943.1	RP11-739L10.1	4.42	1.2e-05	0.0023	0.25	0.2	Breast cancer;	chr18:22918727	chr18:22699481~22933764:-
LUAD	cis	rs4660214	0.694	rs16866216	ENSG00000228060.1	RP11-69E11.8	4.42	1.2e-05	0.0023	0.18	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39208916	chr1:39565160~39573203:+
LUAD	cis	rs17711722	0.523	rs365896	ENSG00000237310.1	GS1-124K5.4	-4.42	1.2e-05	0.0023	-0.21	-0.2	Calcium levels;	chr7:66045710	chr7:66493706~66495474:+
LUAD	cis	rs8180040	0.62	rs6768722	ENSG00000271161.1	BOLA2P2	4.42	1.2e-05	0.0023	0.19	0.2	Colorectal cancer;	chr3:47037622	chr3:47499841~47500407:+
LUAD	cis	rs8180040	0.62	rs7373821	ENSG00000271161.1	BOLA2P2	4.42	1.2e-05	0.0023	0.19	0.2	Colorectal cancer;	chr3:47038637	chr3:47499841~47500407:+
LUAD	cis	rs8180040	0.62	rs11715121	ENSG00000271161.1	BOLA2P2	-4.42	1.2e-05	0.0023	-0.19	-0.2	Colorectal cancer;	chr3:47031131	chr3:47499841~47500407:+
LUAD	cis	rs8180040	0.62	rs11709660	ENSG00000271161.1	BOLA2P2	-4.42	1.2e-05	0.0023	-0.19	-0.2	Colorectal cancer;	chr3:47033437	chr3:47499841~47500407:+
LUAD	cis	rs12073359	0.955	rs72694965	ENSG00000223945.2	RP11-458I7.1	-4.42	1.2e-05	0.0023	-0.3	-0.2	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150186473	chr1:150053864~150055034:+
LUAD	cis	rs1008375	0.8	rs62296338	ENSG00000249502.1	AC006160.5	-4.42	1.2e-05	0.0023	-0.19	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17611802	chr4:17587467~17614571:-
LUAD	cis	rs453301	0.686	rs28482034	ENSG00000173295.6	FAM86B3P	-4.42	1.2e-05	0.0023	-0.22	-0.2	Joint mobility (Beighton score);	chr8:9012154	chr8:8228595~8244865:+
LUAD	cis	rs1799949	1	rs2271573	ENSG00000236383.6	LINC00854	-4.42	1.2e-05	0.0023	-0.16	-0.2	Menopause (age at onset);	chr17:43175604	chr17:43216941~43305976:-
LUAD	cis	rs11168618	1	rs12815544	ENSG00000240399.1	RP1-228P16.1	4.42	1.2e-05	0.0023	0.2	0.2	Adiponectin levels;	chr12:48555825	chr12:48054813~48055591:-
LUAD	cis	rs2274273	0.87	rs3783650	ENSG00000259318.1	RP11-454L9.2	4.42	1.2e-05	0.0023	0.17	0.2	Protein biomarker;	chr14:55382254	chr14:55394940~55395233:-
LUAD	cis	rs7208859	0.623	rs170051	ENSG00000266490.1	CTD-2349P21.9	4.42	1.2e-05	0.0023	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587135	chr17:30792372~30792833:+
LUAD	cis	rs875971	0.66	rs3764903	ENSG00000224316.1	RP11-479O9.2	-4.42	1.2e-05	0.0023	-0.2	-0.2	Aortic root size;	chr7:66633495	chr7:65773620~65802067:+
LUAD	cis	rs889398	0.741	rs4146819	ENSG00000226232.7	RP11-419C5.2	-4.42	1.2e-05	0.0023	-0.17	-0.2	Body mass index;	chr16:69889660	chr16:69976388~69996188:-
LUAD	cis	rs889398	0.741	rs7193038	ENSG00000226232.7	RP11-419C5.2	-4.42	1.2e-05	0.0023	-0.17	-0.2	Body mass index;	chr16:69892231	chr16:69976388~69996188:-
LUAD	cis	rs9860428	0.808	rs10804506	ENSG00000242770.2	RP11-180K7.1	4.42	1.2e-05	0.0023	0.22	0.2	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112875850	chr3:112802478~112812819:+
LUAD	cis	rs2115630	0.641	rs11073613	ENSG00000225151.9	GOLGA2P7	4.42	1.2e-05	0.0023	0.23	0.2	P wave terminal force;	chr15:84642662	chr15:84199311~84230136:-
LUAD	cis	rs2735413	0.564	rs7201557	ENSG00000276007.1	RP11-358L22.3	4.42	1.2e-05	0.0023	0.27	0.2	Systolic blood pressure (alcohol consumption interaction);	chr16:78076162	chr16:78123243~78124332:+
LUAD	cis	rs12754538	0.961	rs12095124	ENSG00000232912.4	RP5-1115A15.1	4.42	1.2e-05	0.0023	0.21	0.2	Subjective well-being;	chr1:8421972	chr1:8424645~8434838:+
LUAD	cis	rs42490	0.899	rs1397308	ENSG00000251136.7	RP11-37B2.1	4.42	1.2e-05	0.0023	0.2	0.2	Leprosy;	chr8:89628493	chr8:89609409~89757727:-
LUAD	cis	rs6751744	0.824	rs10205689	ENSG00000226266.5	AC009961.3	-4.42	1.2e-05	0.00231	-0.29	-0.2	Dysphagia;	chr2:159507158	chr2:159670708~159712435:-
LUAD	cis	rs13113518	1	rs13152173	ENSG00000272969.1	RP11-528I4.2	4.42	1.2e-05	0.00231	0.21	0.2	Height;	chr4:55534788	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs13141049	ENSG00000272969.1	RP11-528I4.2	4.42	1.2e-05	0.00231	0.21	0.2	Height;	chr4:55535489	chr4:55547112~55547889:+
LUAD	cis	rs13113518	0.967	rs12507722	ENSG00000272969.1	RP11-528I4.2	4.42	1.2e-05	0.00231	0.21	0.2	Height;	chr4:55536421	chr4:55547112~55547889:+
LUAD	cis	rs13113518	0.967	rs7696832	ENSG00000272969.1	RP11-528I4.2	4.42	1.2e-05	0.00231	0.21	0.2	Height;	chr4:55537080	chr4:55547112~55547889:+
LUAD	cis	rs10875976	0.647	rs4391887	ENSG00000257464.1	RP11-161H23.8	-4.42	1.2e-05	0.00231	-0.19	-0.2	Obesity;	chr12:49831467	chr12:49442424~49442652:-
LUAD	cis	rs7200786	0.546	rs7201415	ENSG00000274038.1	RP11-66H6.4	-4.42	1.2e-05	0.00231	-0.26	-0.2	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11127428	chr16:11056556~11057034:+
LUAD	cis	rs858239	0.867	rs10250602	ENSG00000226816.2	AC005082.12	4.42	1.21e-05	0.00231	0.27	0.2	Cerebrospinal fluid biomarker levels;	chr7:23264082	chr7:23206013~23208045:+
LUAD	cis	rs13113518	0.812	rs13107810	ENSG00000272969.1	RP11-528I4.2	4.42	1.21e-05	0.00231	0.21	0.2	Height;	chr4:55542243	chr4:55547112~55547889:+
LUAD	cis	rs801193	1	rs1553610	ENSG00000224316.1	RP11-479O9.2	4.42	1.21e-05	0.00231	0.2	0.2	Aortic root size;	chr7:66732246	chr7:65773620~65802067:+
LUAD	cis	rs6095360	0.727	rs71351953	ENSG00000222365.1	SNORD12B	-4.42	1.21e-05	0.00231	-0.23	-0.2	Intelligence (multi-trait analysis);	chr20:48958210	chr20:49280319~49280409:+
LUAD	cis	rs34779708	0.931	rs11010067	ENSG00000271335.4	RP11-324I22.4	-4.42	1.21e-05	0.00231	-0.2	-0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35006503	chr10:35314552~35336401:-
LUAD	cis	rs80028505	0.908	rs76703794	ENSG00000271304.1	DPRXP2	4.42	1.21e-05	0.00231	0.38	0.2	Foot ulcer in diabetes and neuropathy;	chr6:36083422	chr6:35989515~35990436:-
LUAD	cis	rs80028505	0.908	rs76171341	ENSG00000271304.1	DPRXP2	4.42	1.21e-05	0.00231	0.38	0.2	Foot ulcer in diabetes and neuropathy;	chr6:36083423	chr6:35989515~35990436:-
LUAD	cis	rs13113518	0.934	rs11133397	ENSG00000272969.1	RP11-528I4.2	4.42	1.21e-05	0.00231	0.21	0.2	Height;	chr4:55534166	chr4:55547112~55547889:+
LUAD	cis	rs13113518	0.934	rs11133398	ENSG00000272969.1	RP11-528I4.2	4.42	1.21e-05	0.00231	0.21	0.2	Height;	chr4:55534180	chr4:55547112~55547889:+
LUAD	cis	rs293748	0.891	rs56261529	ENSG00000250155.1	CTD-2353F22.1	-4.42	1.21e-05	0.00231	-0.26	-0.2	Obesity-related traits;	chr5:37018714	chr5:36666214~36725195:-
LUAD	cis	rs8177876	0.584	rs2602404	ENSG00000261061.1	RP11-303E16.2	4.42	1.21e-05	0.00231	0.27	0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81056042	chr16:81030770~81031485:+
LUAD	cis	rs9467773	1	rs28558133	ENSG00000261353.1	CTA-14H9.5	-4.42	1.21e-05	0.00231	-0.22	-0.2	Intelligence (multi-trait analysis);	chr6:26531205	chr6:26527063~26527404:+
LUAD	cis	rs227275	0.554	rs223457	ENSG00000251288.2	RP11-10L12.2	-4.42	1.21e-05	0.00231	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102788506	chr4:102751401~102752641:+
LUAD	cis	rs17772222	0.917	rs17188207	ENSG00000258789.1	RP11-507K2.3	-4.42	1.21e-05	0.00231	-0.27	-0.2	Coronary artery calcification;	chr14:88699579	chr14:88551597~88552493:+
LUAD	cis	rs11673344	0.864	rs8108727	ENSG00000226686.6	LINC01535	4.42	1.21e-05	0.00231	0.25	0.2	Obesity-related traits;	chr19:37090622	chr19:37251912~37265535:+
LUAD	cis	rs750134	1	rs12581716	ENSG00000257221.1	RP11-689B22.2	-4.42	1.21e-05	0.00231	-0.31	-0.2	Low high density lipoprotein cholesterol levels;	chr12:108642825	chr12:108628687~108641318:+
LUAD	cis	rs4664293	0.625	rs7595852	ENSG00000226266.5	AC009961.3	4.42	1.21e-05	0.00231	0.27	0.2	Monocyte percentage of white cells;	chr2:159683656	chr2:159670708~159712435:-
LUAD	cis	rs2274273	0.87	rs10144345	ENSG00000259318.1	RP11-454L9.2	4.42	1.21e-05	0.00231	0.17	0.2	Protein biomarker;	chr14:55381019	chr14:55394940~55395233:-
LUAD	cis	rs11009175	0.929	rs10430572	ENSG00000273038.2	RP11-479G22.8	-4.42	1.21e-05	0.00231	-0.32	-0.2	Depression (quantitative trait);	chr10:33051471	chr10:32887255~32889311:-
LUAD	cis	rs9840812	0.61	rs34967300	ENSG00000239213.4	NCK1-AS1	-4.42	1.21e-05	0.00231	-0.27	-0.2	Fibrinogen levels;	chr3:136549976	chr3:136841726~136862054:-
LUAD	cis	rs763121	0.813	rs4821807	ENSG00000228274.3	RP3-508I15.9	-4.42	1.21e-05	0.00231	-0.19	-0.2	Menopause (age at onset);	chr22:38669577	chr22:38667585~38681820:-
LUAD	cis	rs7116495	0.737	rs7102192	ENSG00000254682.1	RP11-660L16.2	4.42	1.21e-05	0.00231	0.43	0.2	Severe influenza A (H1N1) infection;	chr11:71937123	chr11:71448674~71452157:+
LUAD	cis	rs858239	0.669	rs6461687	ENSG00000226816.2	AC005082.12	4.42	1.21e-05	0.00232	0.25	0.2	Cerebrospinal fluid biomarker levels;	chr7:23076961	chr7:23206013~23208045:+
LUAD	cis	rs7189233	0.592	rs2024449	ENSG00000279344.1	RP11-44F14.7	4.42	1.21e-05	0.00232	0.16	0.2	Intelligence (multi-trait analysis);	chr16:53460705	chr16:53478957~53481550:-
LUAD	cis	rs2274273	0.713	rs56725788	ENSG00000258413.1	RP11-665C16.6	-4.42	1.21e-05	0.00232	-0.25	-0.2	Protein biomarker;	chr14:55073383	chr14:55262767~55272075:-
LUAD	cis	rs2274273	0.743	rs13379159	ENSG00000258413.1	RP11-665C16.6	-4.42	1.21e-05	0.00232	-0.25	-0.2	Protein biomarker;	chr14:55074083	chr14:55262767~55272075:-
LUAD	cis	rs2274273	0.774	rs9323278	ENSG00000258413.1	RP11-665C16.6	-4.42	1.21e-05	0.00232	-0.25	-0.2	Protein biomarker;	chr14:55074856	chr14:55262767~55272075:-
LUAD	cis	rs9467773	1	rs9393731	ENSG00000261353.1	CTA-14H9.5	-4.42	1.21e-05	0.00232	-0.22	-0.2	Intelligence (multi-trait analysis);	chr6:26529146	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs11756120	ENSG00000261353.1	CTA-14H9.5	-4.42	1.21e-05	0.00232	-0.22	-0.2	Intelligence (multi-trait analysis);	chr6:26529580	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs9393732	ENSG00000261353.1	CTA-14H9.5	-4.42	1.21e-05	0.00232	-0.22	-0.2	Intelligence (multi-trait analysis);	chr6:26530670	chr6:26527063~26527404:+
LUAD	cis	rs9467773	0.967	rs9358954	ENSG00000261353.1	CTA-14H9.5	-4.42	1.21e-05	0.00232	-0.22	-0.2	Intelligence (multi-trait analysis);	chr6:26530950	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs1321480	ENSG00000261353.1	CTA-14H9.5	-4.42	1.21e-05	0.00232	-0.22	-0.2	Intelligence (multi-trait analysis);	chr6:26532514	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs10946835	ENSG00000261353.1	CTA-14H9.5	-4.42	1.21e-05	0.00232	-0.22	-0.2	Intelligence (multi-trait analysis);	chr6:26533529	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs9467778	ENSG00000261353.1	CTA-14H9.5	-4.42	1.21e-05	0.00232	-0.22	-0.2	Intelligence (multi-trait analysis);	chr6:26534515	chr6:26527063~26527404:+
LUAD	cis	rs202072	0.729	rs202040	ENSG00000272379.1	RP1-257A7.5	4.42	1.21e-05	0.00232	0.33	0.2	HIV-1 viral setpoint;	chr6:13288303	chr6:13290018~13290490:-
LUAD	cis	rs1881744	0.588	rs78808618	ENSG00000280054.1	RP1-197B17.7	4.42	1.21e-05	0.00232	0.44	0.2	Metabolite levels (HVA/5-HIAA ratio);	chr12:47567624	chr12:47728151~47730598:-
LUAD	cis	rs7005380	0.581	rs13265513	ENSG00000279347.1	RP11-85I17.2	4.42	1.21e-05	0.00232	0.18	0.2	Interstitial lung disease;	chr8:119907686	chr8:119838736~119840385:-
LUAD	cis	rs1876905	0.539	rs190246	ENSG00000255389.1	C6orf3	-4.42	1.21e-05	0.00232	-0.28	-0.2	Mean corpuscular hemoglobin;	chr6:111277043	chr6:111599875~111602295:+
LUAD	cis	rs77688320	0.553	rs2244438	ENSG00000213090.2	AC007256.5	-4.42	1.21e-05	0.00232	-0.23	-0.2	Breast cancer;	chr2:201387816	chr2:201410544~201413308:-
LUAD	cis	rs7811142	1	rs11773661	ENSG00000078319.8	PMS2P1	-4.42	1.21e-05	0.00232	-0.23	-0.2	Platelet count;	chr7:100475446	chr7:100320992~100341908:-
LUAD	cis	rs7811142	0.943	rs66958101	ENSG00000078319.8	PMS2P1	-4.42	1.21e-05	0.00232	-0.23	-0.2	Platelet count;	chr7:100476397	chr7:100320992~100341908:-
LUAD	cis	rs7646881	0.504	rs61080878	ENSG00000240207.5	RP11-379F4.4	-4.42	1.21e-05	0.00232	-0.22	-0.2	Tetralogy of Fallot;	chr3:158745108	chr3:158732263~158784070:+
LUAD	cis	rs6012564	1	rs911411	ENSG00000230758.1	SNAP23P	4.42	1.21e-05	0.00232	0.21	0.2	Anger;	chr20:49101894	chr20:49038357~49038602:-
LUAD	cis	rs6012564	1	rs6063352	ENSG00000230758.1	SNAP23P	4.42	1.21e-05	0.00232	0.21	0.2	Anger;	chr20:49102057	chr20:49038357~49038602:-
LUAD	cis	rs2548724	0.661	rs7716398	ENSG00000250682.4	LINC00491	4.42	1.21e-05	0.00232	0.25	0.2	Type 2 diabetes;	chr5:102468541	chr5:102609156~102671559:-
LUAD	cis	rs957448	1	rs1055797	ENSG00000254315.1	RP11-267M23.3	4.42	1.21e-05	0.00232	0.25	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94511005	chr8:94533628~94534391:+
LUAD	cis	rs11157436	0.602	rs1894370	ENSG00000211812.1	TRAV26-2	-4.42	1.21e-05	0.00232	-0.2	-0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166764	chr14:22202583~22203368:+
LUAD	cis	rs11157436	0.56	rs988997	ENSG00000211812.1	TRAV26-2	-4.42	1.21e-05	0.00232	-0.19	-0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22225937	chr14:22202583~22203368:+
LUAD	cis	rs11157436	0.56	rs2242543	ENSG00000211812.1	TRAV26-2	-4.42	1.21e-05	0.00232	-0.19	-0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22226436	chr14:22202583~22203368:+
LUAD	cis	rs801193	1	rs62466793	ENSG00000224316.1	RP11-479O9.2	4.42	1.21e-05	0.00232	0.2	0.2	Aortic root size;	chr7:66726530	chr7:65773620~65802067:+
LUAD	cis	rs10090774	0.71	rs13266116	ENSG00000280303.2	ERICD	-4.42	1.21e-05	0.00232	-0.22	-0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140646656	chr8:140636281~140638283:+
LUAD	cis	rs2562456	0.833	rs62110416	ENSG00000268081.1	RP11-678G14.2	4.42	1.21e-05	0.00232	0.32	0.2	Pain;	chr19:21401924	chr19:21554640~21569237:-
LUAD	cis	rs2933343	0.7	rs6787833	ENSG00000231305.3	RP11-723O4.2	4.42	1.21e-05	0.00232	0.21	0.2	IgG glycosylation;	chr3:128937341	chr3:128861313~128871540:-
LUAD	cis	rs12900463	0.752	rs12904777	ENSG00000259295.5	CSPG4P12	4.42	1.21e-05	0.00232	0.25	0.2	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);	chr15:84872514	chr15:85191438~85213905:+
LUAD	cis	rs34779708	0.733	rs4007271	ENSG00000271335.4	RP11-324I22.4	4.42	1.21e-05	0.00232	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35257683	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.702	rs4007272	ENSG00000271335.4	RP11-324I22.4	4.42	1.21e-05	0.00232	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35257931	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.733	rs4934740	ENSG00000271335.4	RP11-324I22.4	4.42	1.21e-05	0.00232	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35258213	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.702	rs4244995	ENSG00000271335.4	RP11-324I22.4	4.42	1.21e-05	0.00232	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35258247	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.733	rs4244997	ENSG00000271335.4	RP11-324I22.4	4.42	1.21e-05	0.00232	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35258326	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.733	rs4298846	ENSG00000271335.4	RP11-324I22.4	4.42	1.21e-05	0.00232	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35258452	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.733	rs4391768	ENSG00000271335.4	RP11-324I22.4	4.42	1.21e-05	0.00232	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35258667	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.733	rs7914468	ENSG00000271335.4	RP11-324I22.4	4.42	1.21e-05	0.00232	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35259143	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.733	rs7914560	ENSG00000271335.4	RP11-324I22.4	4.42	1.21e-05	0.00232	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35259171	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.733	rs4444023	ENSG00000271335.4	RP11-324I22.4	4.42	1.21e-05	0.00232	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35259426	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.733	rs12243593	ENSG00000271335.4	RP11-324I22.4	4.42	1.21e-05	0.00232	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35260117	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.733	rs3936502	ENSG00000271335.4	RP11-324I22.4	4.42	1.21e-05	0.00232	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35260290	chr10:35314552~35336401:-
LUAD	cis	rs17772222	0.917	rs61977053	ENSG00000258789.1	RP11-507K2.3	-4.42	1.21e-05	0.00232	-0.27	-0.2	Coronary artery calcification;	chr14:88380876	chr14:88551597~88552493:+
LUAD	cis	rs17772222	1	rs61977058	ENSG00000258789.1	RP11-507K2.3	-4.42	1.21e-05	0.00232	-0.27	-0.2	Coronary artery calcification;	chr14:88415571	chr14:88551597~88552493:+
LUAD	cis	rs2243480	1	rs34136756	ENSG00000226002.1	RP11-460N20.5	-4.42	1.21e-05	0.00232	-0.34	-0.2	Diabetic kidney disease;	chr7:65916269	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs78803505	ENSG00000226002.1	RP11-460N20.5	-4.42	1.21e-05	0.00232	-0.34	-0.2	Diabetic kidney disease;	chr7:65917585	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs34933526	ENSG00000226002.1	RP11-460N20.5	-4.42	1.21e-05	0.00232	-0.34	-0.2	Diabetic kidney disease;	chr7:65918212	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs34577383	ENSG00000226002.1	RP11-460N20.5	-4.42	1.21e-05	0.00232	-0.34	-0.2	Diabetic kidney disease;	chr7:65920739	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs6949812	ENSG00000226002.1	RP11-460N20.5	-4.42	1.21e-05	0.00232	-0.34	-0.2	Diabetic kidney disease;	chr7:65922114	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs55895244	ENSG00000226002.1	RP11-460N20.5	-4.42	1.21e-05	0.00232	-0.34	-0.2	Diabetic kidney disease;	chr7:65922691	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs6970243	ENSG00000226002.1	RP11-460N20.5	-4.42	1.21e-05	0.00232	-0.34	-0.2	Diabetic kidney disease;	chr7:65923503	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs7794661	ENSG00000226002.1	RP11-460N20.5	-4.42	1.21e-05	0.00232	-0.34	-0.2	Diabetic kidney disease;	chr7:65924743	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs7795242	ENSG00000226002.1	RP11-460N20.5	-4.42	1.21e-05	0.00232	-0.34	-0.2	Diabetic kidney disease;	chr7:65925107	chr7:65084103~65100232:+
LUAD	cis	rs2243480	0.708	rs35310401	ENSG00000226002.1	RP11-460N20.5	-4.42	1.21e-05	0.00232	-0.34	-0.2	Diabetic kidney disease;	chr7:65925372	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs35058610	ENSG00000226002.1	RP11-460N20.5	-4.42	1.21e-05	0.00232	-0.34	-0.2	Diabetic kidney disease;	chr7:65925938	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs2177703	ENSG00000226002.1	RP11-460N20.5	-4.42	1.21e-05	0.00232	-0.34	-0.2	Diabetic kidney disease;	chr7:65926730	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs35432774	ENSG00000226002.1	RP11-460N20.5	-4.42	1.21e-05	0.00232	-0.34	-0.2	Diabetic kidney disease;	chr7:65928032	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs56985706	ENSG00000226002.1	RP11-460N20.5	-4.42	1.21e-05	0.00232	-0.34	-0.2	Diabetic kidney disease;	chr7:65929575	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs60683927	ENSG00000226002.1	RP11-460N20.5	-4.42	1.21e-05	0.00232	-0.34	-0.2	Diabetic kidney disease;	chr7:65929781	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs58062456	ENSG00000226002.1	RP11-460N20.5	-4.42	1.21e-05	0.00232	-0.34	-0.2	Diabetic kidney disease;	chr7:65929865	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs34529418	ENSG00000226002.1	RP11-460N20.5	-4.42	1.21e-05	0.00232	-0.34	-0.2	Diabetic kidney disease;	chr7:65938222	chr7:65084103~65100232:+
LUAD	cis	rs2243480	0.901	rs35087093	ENSG00000226002.1	RP11-460N20.5	-4.42	1.21e-05	0.00232	-0.34	-0.2	Diabetic kidney disease;	chr7:65940221	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs35046236	ENSG00000226002.1	RP11-460N20.5	-4.42	1.21e-05	0.00232	-0.34	-0.2	Diabetic kidney disease;	chr7:65943626	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs36068983	ENSG00000226002.1	RP11-460N20.5	-4.42	1.21e-05	0.00232	-0.34	-0.2	Diabetic kidney disease;	chr7:65944004	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs68189316	ENSG00000226002.1	RP11-460N20.5	-4.42	1.21e-05	0.00232	-0.34	-0.2	Diabetic kidney disease;	chr7:65944182	chr7:65084103~65100232:+
LUAD	cis	rs2243480	0.831	rs7806717	ENSG00000226002.1	RP11-460N20.5	4.42	1.21e-05	0.00232	0.34	0.2	Diabetic kidney disease;	chr7:65928187	chr7:65084103~65100232:+
LUAD	cis	rs8030379	1	rs10906982	ENSG00000230373.7	GOLGA6L5P	-4.42	1.21e-05	0.00232	-0.18	-0.2	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83899406	chr15:84507885~84516814:-
LUAD	cis	rs11673344	0.864	rs2562587	ENSG00000226686.6	LINC01535	4.42	1.21e-05	0.00232	0.25	0.2	Obesity-related traits;	chr19:37019357	chr19:37251912~37265535:+
LUAD	cis	rs4819052	1	rs2297286	ENSG00000223768.1	LINC00205	-4.42	1.21e-05	0.00232	-0.26	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45287982	chr21:45293285~45297354:+
LUAD	cis	rs4811196	0.748	rs4811244	ENSG00000226144.2	RPS27AP3	4.42	1.22e-05	0.00232	0.22	0.2	Bone mineral density;	chr20:37866952	chr20:37049254~37049707:+
LUAD	cis	rs1005277	0.54	rs1814077	ENSG00000263064.2	RP11-291L22.7	4.42	1.22e-05	0.00232	0.21	0.2	Extrinsic epigenetic age acceleration;	chr10:37703090	chr10:38448689~38448949:+
LUAD	cis	rs957448	1	rs16916881	ENSG00000254315.1	RP11-267M23.3	4.42	1.22e-05	0.00232	0.25	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94554042	chr8:94533628~94534391:+
LUAD	cis	rs1062177	1	rs2964612	ENSG00000253921.1	CTB-113P19.3	-4.42	1.22e-05	0.00232	-0.3	-0.2	Preschool internalizing problems;	chr5:151819189	chr5:151753992~151767247:+
LUAD	cis	rs2446066	0.872	rs11170532	ENSG00000257379.1	RP11-793H13.8	4.42	1.22e-05	0.00232	0.32	0.2	Red blood cell count;	chr12:53394551	chr12:53441741~53467528:+
LUAD	cis	rs6723108	0.517	rs1530557	ENSG00000224043.6	CCNT2-AS1	4.42	1.22e-05	0.00232	0.24	0.2	Type 2 diabetes;	chr2:134849309	chr2:134735464~134918710:-
LUAD	cis	rs7636293	1	rs10934882	ENSG00000270773.1	RP13-685P2.7	4.42	1.22e-05	0.00232	0.24	0.2	Height;	chr3:129325163	chr3:129345411~129346164:+
LUAD	cis	rs897984	0.683	rs12926237	ENSG00000260911.2	RP11-196G11.2	-4.42	1.22e-05	0.00232	-0.18	-0.2	Dementia with Lewy bodies;	chr16:30826275	chr16:31043150~31049868:+
LUAD	cis	rs957448	1	rs60655325	ENSG00000253175.1	RP11-267M23.6	4.42	1.22e-05	0.00232	0.24	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94552606	chr8:94565036~94565715:+
LUAD	cis	rs7665090	1	rs2866409	ENSG00000246560.2	RP11-10L12.4	4.42	1.22e-05	0.00232	0.24	0.2	Primary biliary cholangitis;	chr4:102633104	chr4:102828055~102844075:+
LUAD	cis	rs13113518	1	rs11724094	ENSG00000272969.1	RP11-528I4.2	4.42	1.22e-05	0.00233	0.21	0.2	Height;	chr4:55501479	chr4:55547112~55547889:+
LUAD	cis	rs858239	0.67	rs3807452	ENSG00000226816.2	AC005082.12	-4.42	1.22e-05	0.00233	-0.24	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23206013~23208045:+
LUAD	cis	rs2243480	1	rs316304	ENSG00000229886.1	RP5-1132H15.3	4.42	1.22e-05	0.00233	0.34	0.2	Diabetic kidney disease;	chr7:66151907	chr7:66025126~66031544:-
LUAD	cis	rs9341808	0.718	rs2874829	ENSG00000272129.1	RP11-250B2.6	4.42	1.22e-05	0.00233	0.24	0.2	Sitting height ratio;	chr6:80146380	chr6:80355424~80356859:+
LUAD	cis	rs11089937	0.597	rs9619794	ENSG00000211640.3	IGLV6-57	4.42	1.22e-05	0.00233	0.15	0.2	Periodontitis (PAL4Q3);	chr22:22132999	chr22:22195713~22196460:+
LUAD	cis	rs77688320	0.517	rs10497868	ENSG00000213090.2	AC007256.5	-4.42	1.22e-05	0.00233	-0.22	-0.2	Breast cancer;	chr2:201439317	chr2:201410544~201413308:-
LUAD	cis	rs2060793	0.741	rs1542291	ENSG00000251991.1	RNU7-49P	4.42	1.22e-05	0.00233	0.22	0.2	Vitamin D levels;	chr11:14784720	chr11:14478892~14478953:+
LUAD	cis	rs950169	0.512	rs4374136	ENSG00000225151.9	GOLGA2P7	-4.42	1.22e-05	0.00233	-0.28	-0.2	Schizophrenia;	chr15:83976255	chr15:84199311~84230136:-
LUAD	cis	rs8073060	0.544	rs225274	ENSG00000267592.1	CTC-507E2.2	-4.42	1.22e-05	0.00233	-0.28	-0.2	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35644202	chr17:35596904~35597128:-
LUAD	cis	rs2011013	0.957	rs17370601	ENSG00000259570.1	RP11-671M22.4	-4.42	1.22e-05	0.00233	-0.26	-0.2	Sitting height ratio;	chr15:83948494	chr15:84394512~84395514:+
LUAD	cis	rs9303029	1	rs72859125	ENSG00000265458.1	RP13-20L14.6	4.42	1.22e-05	0.00233	0.36	0.2	Protein quantitative trait loci;	chr17:82470099	chr17:82454273~82458521:-
LUAD	cis	rs911119	0.908	rs8114619	ENSG00000270001.1	RP11-218C14.8	-4.42	1.22e-05	0.00233	-0.29	-0.2	Chronic kidney disease;	chr20:23621176	chr20:23631826~23632316:-
LUAD	cis	rs4865762	0.617	rs251512	ENSG00000247796.2	CTD-2366F13.1	4.42	1.22e-05	0.00233	0.2	0.2	Intraocular pressure;	chr5:53204209	chr5:53109842~53115126:+
LUAD	cis	rs896854	0.738	rs481887	ENSG00000253528.2	RP11-347C18.4	-4.42	1.22e-05	0.00233	-0.2	-0.2	Type 2 diabetes;	chr8:94955610	chr8:94974573~94974853:-
LUAD	cis	rs467650	1	rs467650	ENSG00000248489.1	CTD-2007H13.3	4.42	1.22e-05	0.00233	0.21	0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98633749	chr5:98929171~98995013:+
LUAD	cis	rs950169	0.922	rs11630760	ENSG00000275120.1	RP11-182J1.17	4.42	1.22e-05	0.00233	0.31	0.2	Schizophrenia;	chr15:84570106	chr15:84599434~84606463:-
LUAD	cis	rs950169	0.887	rs71395453	ENSG00000275120.1	RP11-182J1.17	4.42	1.22e-05	0.00233	0.31	0.2	Schizophrenia;	chr15:84570259	chr15:84599434~84606463:-
LUAD	cis	rs950169	0.922	rs11633075	ENSG00000275120.1	RP11-182J1.17	4.42	1.22e-05	0.00233	0.31	0.2	Schizophrenia;	chr15:84570741	chr15:84599434~84606463:-
LUAD	cis	rs394563	0.602	rs409111	ENSG00000216906.2	RP11-350J20.9	4.42	1.22e-05	0.00234	0.24	0.2	Dupuytren's disease;	chr6:149445724	chr6:149904243~149906418:+
LUAD	cis	rs1167827	0.68	rs1167800	ENSG00000223705.8	NSUN5P1	4.42	1.22e-05	0.00234	0.14	0.2	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75546898	chr7:75410322~75416787:+
LUAD	cis	rs9425766	0.679	rs12563301	ENSG00000227373.4	RP11-160H22.5	4.42	1.22e-05	0.00234	0.25	0.2	Life satisfaction;	chr1:174090924	chr1:174115300~174160004:-
LUAD	cis	rs889398	0.74	rs56096139	ENSG00000226232.7	RP11-419C5.2	4.42	1.22e-05	0.00234	0.16	0.2	Body mass index;	chr16:69529509	chr16:69976388~69996188:-
LUAD	cis	rs6723108	0.517	rs3739029	ENSG00000224043.6	CCNT2-AS1	-4.42	1.22e-05	0.00234	-0.24	-0.2	Type 2 diabetes;	chr2:134841837	chr2:134735464~134918710:-
LUAD	cis	rs8062405	0.824	rs153106	ENSG00000251417.2	RP11-1348G14.4	-4.42	1.22e-05	0.00234	-0.2	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28802743~28817828:+
LUAD	cis	rs62025270	0.576	rs55639123	ENSG00000202081.1	RNU6-1280P	-4.42	1.22e-05	0.00234	-0.3	-0.2	Idiopathic pulmonary fibrosis;	chr15:85617037	chr15:85651522~85651628:-
LUAD	cis	rs17772222	0.74	rs10150986	ENSG00000258789.1	RP11-507K2.3	-4.42	1.22e-05	0.00234	-0.25	-0.2	Coronary artery calcification;	chr14:88517326	chr14:88551597~88552493:+
LUAD	cis	rs780096	0.505	rs12475426	ENSG00000234072.1	AC074117.10	-4.42	1.23e-05	0.00234	-0.15	-0.2	Total body bone mineral density;	chr2:27376265	chr2:27356246~27367622:+
LUAD	cis	rs17345786	1	rs3804775	ENSG00000244119.1	PDCL3P4	4.42	1.23e-05	0.00234	0.21	0.2	Colonoscopy-negative controls vs population controls;	chr3:101587663	chr3:101712472~101713191:+
LUAD	cis	rs228614	0.51	rs223470	ENSG00000251288.2	RP11-10L12.2	-4.42	1.23e-05	0.00234	-0.24	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102778004	chr4:102751401~102752641:+
LUAD	cis	rs1864585	0.52	rs17720365	ENSG00000255046.1	RP11-297N6.4	-4.42	1.23e-05	0.00234	-0.27	-0.2	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10821989	chr8:11797928~11802568:-
LUAD	cis	rs6840360	0.573	rs11099806	ENSG00000270265.1	RP11-731D1.4	-4.42	1.23e-05	0.00234	-0.2	-0.2	Intelligence (multi-trait analysis);	chr4:151347964	chr4:151333775~151353224:-
LUAD	cis	rs2439831	0.867	rs2245715	ENSG00000249839.1	AC011330.5	-4.42	1.23e-05	0.00234	-0.35	-0.2	Lung cancer in ever smokers;	chr15:43525854	chr15:43663654~43684339:-
LUAD	cis	rs8396	1	rs8396	ENSG00000271817.2	U3	-4.42	1.23e-05	0.00234	-0.23	-0.2	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158709665	chr4:158700691~158700909:+
LUAD	cis	rs227275	0.554	rs223485	ENSG00000251288.2	RP11-10L12.2	-4.42	1.23e-05	0.00234	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102764018	chr4:102751401~102752641:+
LUAD	cis	rs2522056	1	rs2706383	ENSG00000233006.5	AC034220.3	-4.42	1.23e-05	0.00234	-0.22	-0.2	Fibrinogen;Lymphocyte counts;	chr5:132456710	chr5:132311285~132369916:-
LUAD	cis	rs2018683	0.677	rs55718000	ENSG00000228421.2	AC005013.5	4.42	1.23e-05	0.00234	0.22	0.2	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28936008	chr7:28957667~28959345:+
LUAD	cis	rs7665090	1	rs2866413	ENSG00000246560.2	RP11-10L12.4	4.42	1.23e-05	0.00234	0.24	0.2	Primary biliary cholangitis;	chr4:102635920	chr4:102828055~102844075:+
LUAD	cis	rs7665090	1	rs4547797	ENSG00000246560.2	RP11-10L12.4	4.42	1.23e-05	0.00234	0.24	0.2	Primary biliary cholangitis;	chr4:102636035	chr4:102828055~102844075:+
LUAD	cis	rs7665090	1	rs2866414	ENSG00000246560.2	RP11-10L12.4	4.42	1.23e-05	0.00234	0.24	0.2	Primary biliary cholangitis;	chr4:102636062	chr4:102828055~102844075:+
LUAD	cis	rs7665090	1	rs2903283	ENSG00000246560.2	RP11-10L12.4	4.42	1.23e-05	0.00234	0.24	0.2	Primary biliary cholangitis;	chr4:102636596	chr4:102828055~102844075:+
LUAD	cis	rs75422866	0.51	rs73105803	ENSG00000276691.1	RP5-1057I20.5	4.42	1.23e-05	0.00234	0.33	0.2	Pneumonia;	chr12:47722135	chr12:47788426~47788971:+
LUAD	cis	rs193541	0.632	rs6878609	ENSG00000263432.2	RN7SL689P	4.42	1.23e-05	0.00234	0.27	0.2	Glucose homeostasis traits;	chr5:122759854	chr5:123022487~123022783:-
LUAD	cis	rs1864585	0.52	rs17721089	ENSG00000255046.1	RP11-297N6.4	4.42	1.23e-05	0.00235	0.28	0.2	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10847928	chr8:11797928~11802568:-
LUAD	cis	rs17597773	0.674	rs2378425	ENSG00000272823.1	RP11-295M18.6	-4.42	1.23e-05	0.00235	-0.26	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220842716	chr1:220828676~220829211:-
LUAD	cis	rs2708977	0.665	rs1081717	ENSG00000237510.6	AC008268.2	-4.42	1.23e-05	0.00235	-0.28	-0.2	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96312579	chr2:95789654~95800166:+
LUAD	cis	rs8040855	0.965	rs1961276	ENSG00000259774.1	RP11-182J1.13	4.42	1.23e-05	0.00235	0.23	0.2	Bulimia nervosa;	chr15:85170986	chr15:84422618~84425882:+
LUAD	cis	rs2153535	0.585	rs7750891	ENSG00000230939.1	RP11-314C16.1	-4.42	1.23e-05	0.00235	-0.22	-0.2	Motion sickness;	chr6:8624613	chr6:8784178~8785445:+
LUAD	cis	rs7829975	0.774	rs35039922	ENSG00000173295.6	FAM86B3P	4.42	1.23e-05	0.00235	0.21	0.2	Mood instability;	chr8:8817815	chr8:8228595~8244865:+
LUAD	cis	rs9400467	0.528	rs465796	ENSG00000230177.1	RP5-1112D6.4	-4.42	1.23e-05	0.00235	-0.17	-0.2	Amino acid levels;Blood metabolite levels;	chr6:111298522	chr6:111277932~111278742:+
LUAD	cis	rs17685	0.816	rs11763076	ENSG00000280388.1	RP11-229D13.3	-4.42	1.23e-05	0.00235	-0.18	-0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76136645	chr7:76043977~76045963:-
LUAD	cis	rs7202877	0.706	rs42472	ENSG00000280152.1	RP11-331F4.5	-4.42	1.23e-05	0.00235	-0.23	-0.2	Type 1 diabetes;Type 2 diabetes;	chr16:75439422	chr16:75245994~75250077:-
LUAD	cis	rs10938353	0.773	rs73191016	ENSG00000273369.1	RP11-700J17.1	4.42	1.23e-05	0.00235	0.29	0.2	Body mass index;	chr4:44613093	chr4:44693946~44694386:-
LUAD	cis	rs1008375	0.932	rs4235390	ENSG00000249502.1	AC006160.5	-4.42	1.23e-05	0.00235	-0.19	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17694755	chr4:17587467~17614571:-
LUAD	cis	rs1008375	0.966	rs4235391	ENSG00000249502.1	AC006160.5	-4.42	1.23e-05	0.00235	-0.19	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17694786	chr4:17587467~17614571:-
LUAD	cis	rs9341808	0.69	rs9343970	ENSG00000272129.1	RP11-250B2.6	4.42	1.23e-05	0.00235	0.24	0.2	Sitting height ratio;	chr6:80171572	chr6:80355424~80356859:+
LUAD	cis	rs2243480	0.908	rs55876148	ENSG00000232559.3	GS1-124K5.12	4.42	1.23e-05	0.00235	0.35	0.2	Diabetic kidney disease;	chr7:65914813	chr7:66554588~66576923:-
LUAD	cis	rs7746199	0.736	rs34105070	ENSG00000219392.1	RP1-265C24.5	-4.42	1.23e-05	0.00235	-0.42	-0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27593026	chr6:28115628~28116551:+
LUAD	cis	rs6964587	0.732	rs12539523	ENSG00000188693.7	CYP51A1-AS1	-4.42	1.23e-05	0.00235	-0.24	-0.2	Breast cancer;	chr7:92081522	chr7:92134604~92180725:+
LUAD	cis	rs1876905	0.62	rs354530	ENSG00000230177.1	RP5-1112D6.4	-4.42	1.23e-05	0.00236	-0.23	-0.2	Mean corpuscular hemoglobin;	chr6:111183286	chr6:111277932~111278742:+
LUAD	cis	rs5758659	0.652	rs6519301	ENSG00000182057.4	OGFRP1	4.42	1.23e-05	0.00236	0.24	0.2	Cognitive function;	chr22:41989963	chr22:42269753~42275196:+
LUAD	cis	rs11638352	0.661	rs2615281	ENSG00000205771.5	CATSPER2P1	-4.42	1.23e-05	0.00236	-0.43	-0.2	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44158391	chr15:43726918~43747094:-
LUAD	cis	rs9341808	0.718	rs9448898	ENSG00000272129.1	RP11-250B2.6	4.42	1.23e-05	0.00236	0.24	0.2	Sitting height ratio;	chr6:80135624	chr6:80355424~80356859:+
LUAD	cis	rs6603134	0.502	rs10405582	ENSG00000267939.1	CTD-2325M2.1	-4.42	1.24e-05	0.00236	-0.23	-0.2	Blood protein levels;	chr19:8038654	chr19:8008729~8016025:+
LUAD	cis	rs6603134	0.502	rs10405588	ENSG00000267939.1	CTD-2325M2.1	-4.42	1.24e-05	0.00236	-0.23	-0.2	Blood protein levels;	chr19:8038663	chr19:8008729~8016025:+
LUAD	cis	rs6603134	0.502	rs10406511	ENSG00000267939.1	CTD-2325M2.1	-4.42	1.24e-05	0.00236	-0.23	-0.2	Blood protein levels;	chr19:8039061	chr19:8008729~8016025:+
LUAD	cis	rs2682471	1	rs2682471	ENSG00000245648.1	RP11-277P12.20	-4.42	1.24e-05	0.00236	-0.24	-0.2	Macrophage inflammatory protein 1a levels;	chr12:10446748	chr12:10363769~10398506:+
LUAD	cis	rs5758659	0.653	rs133383	ENSG00000182057.4	OGFRP1	4.42	1.24e-05	0.00236	0.23	0.2	Cognitive function;	chr22:42077599	chr22:42269753~42275196:+
LUAD	cis	rs227275	0.525	rs1080081	ENSG00000251288.2	RP11-10L12.2	-4.42	1.24e-05	0.00236	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:103029268	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.525	rs4699049	ENSG00000251288.2	RP11-10L12.2	-4.42	1.24e-05	0.00236	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:103030467	chr4:102751401~102752641:+
LUAD	cis	rs6840360	0.55	rs4696288	ENSG00000270265.1	RP11-731D1.4	-4.42	1.24e-05	0.00236	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151699998	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.55	rs4696289	ENSG00000270265.1	RP11-731D1.4	-4.42	1.24e-05	0.00236	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151700085	chr4:151333775~151353224:-
LUAD	cis	rs6723108	0.559	rs1942051	ENSG00000224043.6	CCNT2-AS1	-4.42	1.24e-05	0.00236	-0.25	-0.2	Type 2 diabetes;	chr2:134846120	chr2:134735464~134918710:-
LUAD	cis	rs6723108	0.627	rs10928519	ENSG00000224043.6	CCNT2-AS1	-4.42	1.24e-05	0.00236	-0.25	-0.2	Type 2 diabetes;	chr2:134846389	chr2:134735464~134918710:-
LUAD	cis	rs2348418	0.733	rs4931078	ENSG00000247934.4	RP11-967K21.1	-4.42	1.24e-05	0.00236	-0.23	-0.2	Lung function (FEV1);Lung function (FVC);	chr12:28215067	chr12:28163298~28190738:-
LUAD	cis	rs394563	0.602	rs409099	ENSG00000216906.2	RP11-350J20.9	4.42	1.24e-05	0.00236	0.24	0.2	Dupuytren's disease;	chr6:149445727	chr6:149904243~149906418:+
LUAD	cis	rs9907295	0.584	rs2280787	ENSG00000270977.1	AC015849.16	-4.42	1.24e-05	0.00236	-0.3	-0.2	Fibroblast growth factor basic levels;	chr17:35930046	chr17:35893707~35911023:-
LUAD	cis	rs7714584	1	rs73282209	ENSG00000197083.10	ZNF300P1	4.42	1.24e-05	0.00236	0.4	0.2	Crohn's disease;	chr5:150795397	chr5:150930645~150946289:-
LUAD	cis	rs7665090	1	rs4579121	ENSG00000246560.2	RP11-10L12.4	4.42	1.24e-05	0.00236	0.24	0.2	Primary biliary cholangitis;	chr4:102637012	chr4:102828055~102844075:+
LUAD	cis	rs7665090	1	rs6810869	ENSG00000246560.2	RP11-10L12.4	4.42	1.24e-05	0.00236	0.24	0.2	Primary biliary cholangitis;	chr4:102637357	chr4:102828055~102844075:+
LUAD	cis	rs7665090	0.934	rs6533020	ENSG00000246560.2	RP11-10L12.4	4.42	1.24e-05	0.00236	0.24	0.2	Primary biliary cholangitis;	chr4:102637648	chr4:102828055~102844075:+
LUAD	cis	rs7665090	0.934	rs6533021	ENSG00000246560.2	RP11-10L12.4	4.42	1.24e-05	0.00236	0.24	0.2	Primary biliary cholangitis;	chr4:102637696	chr4:102828055~102844075:+
LUAD	cis	rs2243480	1	rs1404147	ENSG00000164669.11	INTS4P1	4.42	1.24e-05	0.00236	0.32	0.2	Diabetic kidney disease;	chr7:65799537	chr7:65141225~65234216:+
LUAD	cis	rs875971	0.522	rs709604	ENSG00000237310.1	GS1-124K5.4	-4.42	1.24e-05	0.00236	-0.21	-0.2	Aortic root size;	chr7:66032447	chr7:66493706~66495474:+
LUAD	cis	rs7923837	0.687	rs10882102	ENSG00000236493.2	EIF2S2P3	4.42	1.24e-05	0.00236	0.22	0.2	Multiple sclerosis;Body mass index;	chr10:92706738	chr10:92668745~92669743:-
LUAD	cis	rs34286592	1	rs3976455	ENSG00000214725.6	CDIPT-AS1	-4.42	1.24e-05	0.00236	-0.31	-0.2	Multiple sclerosis;	chr16:29850126	chr16:29863593~29868053:+
LUAD	cis	rs6754311	0.628	rs309811	ENSG00000226806.1	AC011893.3	-4.42	1.24e-05	0.00237	-0.25	-0.2	Mosquito bite size;	chr2:135868032	chr2:135820191~135823087:+
LUAD	cis	rs10761482	0.532	rs1938533	ENSG00000254271.1	RP11-131N11.4	4.42	1.24e-05	0.00237	0.24	0.2	Schizophrenia;	chr10:60474351	chr10:60734342~60741828:+
LUAD	cis	rs338389	0.516	rs4777016	ENSG00000260657.2	RP11-315D16.4	-4.42	1.24e-05	0.00237	-0.22	-0.2	Survival in rectal cancer;	chr15:68022581	chr15:68267792~68277994:-
LUAD	cis	rs11168618	0.846	rs11168599	ENSG00000240399.1	RP1-228P16.1	4.42	1.24e-05	0.00237	0.19	0.2	Adiponectin levels;	chr12:48486168	chr12:48054813~48055591:-
LUAD	cis	rs10819861	0.55	rs4743558	ENSG00000175611.10	LINC00476	4.42	1.24e-05	0.00237	0.21	0.2	Electrocardiographic traits;	chr9:96122862	chr9:95759231~95875977:-
LUAD	cis	rs7097610	1	rs7097610	ENSG00000226659.1	RP11-137H2.4	4.42	1.24e-05	0.00237	0.34	0.2	Post bronchodilator FEV1;	chr10:80544406	chr10:80529597~80535942:-
LUAD	cis	rs9341808	0.727	rs1324120	ENSG00000272129.1	RP11-250B2.6	4.42	1.24e-05	0.00237	0.24	0.2	Sitting height ratio;	chr6:80266408	chr6:80355424~80356859:+
LUAD	cis	rs7968440	0.933	rs4768885	ENSG00000200428.1	Y_RNA	4.42	1.24e-05	0.00237	0.24	0.2	Fibrinogen;	chr12:50527989	chr12:50743568~50743684:+
LUAD	cis	rs7968440	0.902	rs4768886	ENSG00000200428.1	Y_RNA	4.42	1.24e-05	0.00237	0.24	0.2	Fibrinogen;	chr12:50528196	chr12:50743568~50743684:+
LUAD	cis	rs860295	0.702	rs34124416	ENSG00000225855.5	RUSC1-AS1	4.42	1.24e-05	0.00237	0.14	0.2	Body mass index;	chr1:155608258	chr1:155316863~155324176:-
LUAD	cis	rs8062405	0.723	rs113208333	ENSG00000261419.1	RP11-57A19.4	-4.42	1.24e-05	0.00237	-0.22	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28594839	chr16:28659696~28740781:-
LUAD	cis	rs8062405	0.691	rs743590	ENSG00000261419.1	RP11-57A19.4	-4.42	1.24e-05	0.00237	-0.22	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28596909	chr16:28659696~28740781:-
LUAD	cis	rs13113518	0.783	rs12508367	ENSG00000223305.1	RN7SKP30	4.42	1.24e-05	0.00237	0.23	0.2	Height;	chr4:55509442	chr4:55540502~55540835:-
LUAD	cis	rs13113518	0.812	rs2272073	ENSG00000223305.1	RN7SKP30	4.42	1.24e-05	0.00237	0.23	0.2	Height;	chr4:55510177	chr4:55540502~55540835:-
LUAD	cis	rs42490	0.51	rs13278061	ENSG00000251136.7	RP11-37B2.1	-4.42	1.24e-05	0.00237	-0.2	-0.2	Leprosy;	chr8:89686032	chr8:89609409~89757727:-
LUAD	cis	rs11512640	0.655	rs77468344	ENSG00000254671.2	STT3A-AS1	4.42	1.24e-05	0.00237	0.44	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125586910	chr11:125570284~125592568:-
LUAD	cis	rs6603134	0.502	rs6603133	ENSG00000267939.1	CTD-2325M2.1	-4.42	1.24e-05	0.00237	-0.23	-0.2	Blood protein levels;	chr19:8038352	chr19:8008729~8016025:+
LUAD	cis	rs1005277	0.541	rs2472177	ENSG00000263064.2	RP11-291L22.7	4.42	1.24e-05	0.00237	0.21	0.2	Extrinsic epigenetic age acceleration;	chr10:38095087	chr10:38448689~38448949:+
LUAD	cis	rs13434995	0.842	rs62309759	ENSG00000249700.7	SRD5A3-AS1	-4.42	1.24e-05	0.00237	-0.29	-0.2	Adiponectin levels;	chr4:55557826	chr4:55363971~55395847:-
LUAD	cis	rs853679	1	rs1778508	ENSG00000219392.1	RP1-265C24.5	4.42	1.25e-05	0.00237	0.29	0.2	Depression;	chr6:28262103	chr6:28115628~28116551:+
LUAD	cis	rs897984	0.644	rs73524556	ENSG00000232748.3	RP11-196G11.6	-4.42	1.25e-05	0.00237	-0.24	-0.2	Dementia with Lewy bodies;	chr16:30811841	chr16:31056460~31062803:+
LUAD	cis	rs2976388	1	rs2585179	ENSG00000253741.1	CTD-2292P10.4	4.42	1.25e-05	0.00237	0.22	0.2	Urinary tract infection frequency;	chr8:142692775	chr8:142702252~142726973:-
LUAD	cis	rs4660214	0.666	rs6704246	ENSG00000228060.1	RP11-69E11.8	4.42	1.25e-05	0.00237	0.18	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39343612	chr1:39565160~39573203:+
LUAD	cis	rs8180040	0.553	rs7620997	ENSG00000271161.1	BOLA2P2	-4.42	1.25e-05	0.00238	-0.19	-0.2	Colorectal cancer;	chr3:47172632	chr3:47499841~47500407:+
LUAD	cis	rs5758511	0.68	rs739147	ENSG00000226450.2	CYP2D8P	4.42	1.25e-05	0.00238	0.18	0.2	Birth weight;	chr22:42275060	chr22:42149886~42155001:-
LUAD	cis	rs763121	0.853	rs5750630	ENSG00000228274.3	RP3-508I15.9	-4.42	1.25e-05	0.00238	-0.2	-0.2	Menopause (age at onset);	chr22:38589813	chr22:38667585~38681820:-
LUAD	cis	rs11089937	0.597	rs5757005	ENSG00000211640.3	IGLV6-57	4.42	1.25e-05	0.00238	0.15	0.2	Periodontitis (PAL4Q3);	chr22:22134775	chr22:22195713~22196460:+
LUAD	cis	rs1348850	0.567	rs3770005	ENSG00000213963.5	AC074286.1	4.42	1.25e-05	0.00238	0.24	0.2	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177664146	chr2:177283508~177392691:-
LUAD	cis	rs4811196	0.748	rs4809878	ENSG00000226144.2	RPS27AP3	-4.42	1.25e-05	0.00238	-0.21	-0.2	Bone mineral density;	chr20:37878219	chr20:37049254~37049707:+
LUAD	cis	rs11671005	0.735	rs12977592	ENSG00000268912.1	CTD-2619J13.17	-4.41	1.25e-05	0.00238	-0.25	-0.2	Mean platelet volume;	chr19:58449689	chr19:58428632~58431148:-
LUAD	cis	rs853679	0.607	rs13190888	ENSG00000219392.1	RP1-265C24.5	-4.41	1.25e-05	0.00238	-0.43	-0.2	Depression;	chr6:28318208	chr6:28115628~28116551:+
LUAD	cis	rs8072100	0.701	rs8078309	ENSG00000228782.6	CTD-2026D20.3	4.41	1.25e-05	0.00238	0.21	0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47696706	chr17:47450568~47492492:-
LUAD	cis	rs6012564	1	rs2252259	ENSG00000230758.1	SNAP23P	-4.41	1.25e-05	0.00238	-0.21	-0.2	Anger;	chr20:49046286	chr20:49038357~49038602:-
LUAD	cis	rs6012564	0.964	rs2064853	ENSG00000230758.1	SNAP23P	-4.41	1.25e-05	0.00238	-0.21	-0.2	Anger;	chr20:49058639	chr20:49038357~49038602:-
LUAD	cis	rs8062405	0.573	rs11645306	ENSG00000261419.1	RP11-57A19.4	4.41	1.25e-05	0.00238	0.23	0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28972615	chr16:28659696~28740781:-
LUAD	cis	rs9400467	0.528	rs6933627	ENSG00000271789.1	RP5-1112D6.7	-4.41	1.25e-05	0.00238	-0.21	-0.2	Amino acid levels;Blood metabolite levels;	chr6:111279606	chr6:111297126~111298510:+
LUAD	cis	rs9815354	0.857	rs794894	ENSG00000273328.4	RP11-141M3.6	4.41	1.25e-05	0.00238	0.32	0.2	Pulse pressure;Diastolic blood pressure;	chr3:41990991	chr3:42809414~42908105:+
LUAD	cis	rs77688320	0.553	rs2540330	ENSG00000213090.2	AC007256.5	-4.41	1.25e-05	0.00238	-0.23	-0.2	Breast cancer;	chr2:201388133	chr2:201410544~201413308:-
LUAD	cis	rs77688320	0.553	rs2540331	ENSG00000213090.2	AC007256.5	-4.41	1.25e-05	0.00238	-0.23	-0.2	Breast cancer;	chr2:201388150	chr2:201410544~201413308:-
LUAD	cis	rs17772222	1	rs3814855	ENSG00000258789.1	RP11-507K2.3	-4.41	1.25e-05	0.00238	-0.27	-0.2	Coronary artery calcification;	chr14:88467016	chr14:88551597~88552493:+
LUAD	cis	rs2032366	0.591	rs7241479	ENSG00000266920.1	ACTBP9	4.41	1.25e-05	0.00238	0.21	0.2	Obesity-related traits;	chr18:61631923	chr18:62442028~62443126:+
LUAD	cis	rs2032366	0.654	rs7227661	ENSG00000266920.1	ACTBP9	4.41	1.25e-05	0.00238	0.21	0.2	Obesity-related traits;	chr18:61632275	chr18:62442028~62443126:+
LUAD	cis	rs7202877	0.61	rs468079	ENSG00000280152.1	RP11-331F4.5	-4.41	1.25e-05	0.00238	-0.23	-0.2	Type 1 diabetes;Type 2 diabetes;	chr16:75394576	chr16:75245994~75250077:-
LUAD	cis	rs2286503	1	rs1029740	ENSG00000226329.2	AC005682.6	4.41	1.25e-05	0.00238	0.25	0.2	Fibrinogen;	chr7:22833967	chr7:22863874~22881350:-
LUAD	cis	rs4819052	0.807	rs7283915	ENSG00000237664.1	LINC00316	-4.41	1.25e-05	0.00238	-0.24	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251373	chr21:45338590~45341990:-
LUAD	cis	rs7829975	0.617	rs4841072	ENSG00000173295.6	FAM86B3P	-4.41	1.25e-05	0.00238	-0.21	-0.2	Mood instability;	chr8:8933743	chr8:8228595~8244865:+
LUAD	cis	rs1729951	0.575	rs2163896	ENSG00000239213.4	NCK1-AS1	4.41	1.25e-05	0.00238	0.22	0.2	Neuroticism;	chr3:136972335	chr3:136841726~136862054:-
LUAD	cis	rs1729951	0.575	rs1682357	ENSG00000239213.4	NCK1-AS1	4.41	1.25e-05	0.00238	0.22	0.2	Neuroticism;	chr3:136973167	chr3:136841726~136862054:-
LUAD	cis	rs1729951	0.575	rs1682356	ENSG00000239213.4	NCK1-AS1	4.41	1.25e-05	0.00238	0.22	0.2	Neuroticism;	chr3:136973195	chr3:136841726~136862054:-
LUAD	cis	rs1729951	0.575	rs1654923	ENSG00000239213.4	NCK1-AS1	4.41	1.25e-05	0.00238	0.22	0.2	Neuroticism;	chr3:136973778	chr3:136841726~136862054:-
LUAD	cis	rs1729951	0.575	rs10935214	ENSG00000239213.4	NCK1-AS1	4.41	1.25e-05	0.00238	0.22	0.2	Neuroticism;	chr3:136974643	chr3:136841726~136862054:-
LUAD	cis	rs1729951	0.545	rs1097288	ENSG00000239213.4	NCK1-AS1	4.41	1.25e-05	0.00238	0.22	0.2	Neuroticism;	chr3:136974879	chr3:136841726~136862054:-
LUAD	cis	rs847577	0.63	rs6969384	ENSG00000272950.1	RP11-307C18.1	4.41	1.25e-05	0.00238	0.24	0.2	Breast cancer;	chr7:98103530	chr7:98322853~98323430:+
LUAD	cis	rs7208859	0.673	rs999797	ENSG00000280069.1	CTD-2349P21.3	-4.41	1.25e-05	0.00239	-0.28	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832311	chr17:30738182~30740275:+
LUAD	cis	rs7432375	0.61	rs6793936	ENSG00000239213.4	NCK1-AS1	4.41	1.25e-05	0.00239	0.21	0.2	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136790951	chr3:136841726~136862054:-
LUAD	cis	rs467650	0.963	rs154197	ENSG00000248489.1	CTD-2007H13.3	4.41	1.25e-05	0.00239	0.21	0.2	Venous thromboembolism (SNP x SNP interaction);	chr5:98642639	chr5:98929171~98995013:+
LUAD	cis	rs8180040	0.587	rs62246398	ENSG00000271161.1	BOLA2P2	-4.41	1.25e-05	0.00239	-0.19	-0.2	Colorectal cancer;	chr3:47024713	chr3:47499841~47500407:+
LUAD	cis	rs2239557	1	rs2239557	ENSG00000259065.1	RP5-1021I20.1	-4.41	1.25e-05	0.00239	-0.23	-0.2	Common traits (Other);	chr14:74085267	chr14:73787360~73803270:+
LUAD	cis	rs12986445	0.843	rs11688006	ENSG00000218682.1	AC010150.1	4.41	1.25e-05	0.00239	0.25	0.2	Multiple myeloma;Multiple myeloma and monoclonal gammopathy;	chr2:25761151	chr2:25856461~25856966:-
LUAD	cis	rs4142110	0.628	rs347386	ENSG00000271216.1	LINC01050	-4.41	1.25e-05	0.00239	-0.23	-0.2	Nephrolithiasis;	chr13:42221985	chr13:42810366~42812562:-
LUAD	cis	rs4142110	0.628	rs347388	ENSG00000271216.1	LINC01050	-4.41	1.25e-05	0.00239	-0.23	-0.2	Nephrolithiasis;	chr13:42222823	chr13:42810366~42812562:-
LUAD	cis	rs853679	0.607	rs67101035	ENSG00000219392.1	RP1-265C24.5	-4.41	1.25e-05	0.00239	-0.42	-0.2	Depression;	chr6:27831109	chr6:28115628~28116551:+
LUAD	cis	rs67340775	0.748	rs13212651	ENSG00000219392.1	RP1-265C24.5	-4.41	1.25e-05	0.00239	-0.42	-0.2	Lung cancer in ever smokers;	chr6:27839207	chr6:28115628~28116551:+
LUAD	cis	rs6957923	0.714	rs11766660	ENSG00000230658.1	KLHL7-AS1	4.41	1.25e-05	0.00239	0.24	0.2	Height;	chr7:23484606	chr7:23101228~23105703:-
LUAD	cis	rs3096299	0.685	rs12446145	ENSG00000182376.2	RP5-1142A6.8	4.41	1.25e-05	0.00239	0.2	0.2	Multiple myeloma (IgH translocation);	chr16:89476287	chr16:88742767~88745748:+
LUAD	cis	rs72615157	0.645	rs11771660	ENSG00000078319.8	PMS2P1	-4.41	1.26e-05	0.00239	-0.23	-0.2	Lung function (FEV1/FVC);	chr7:100253646	chr7:100320992~100341908:-
LUAD	cis	rs911119	0.908	rs8121147	ENSG00000270001.1	RP11-218C14.8	-4.41	1.26e-05	0.00239	-0.29	-0.2	Chronic kidney disease;	chr20:23621071	chr20:23631826~23632316:-
LUAD	cis	rs911119	0.955	rs6048945	ENSG00000270001.1	RP11-218C14.8	-4.41	1.26e-05	0.00239	-0.29	-0.2	Chronic kidney disease;	chr20:23621591	chr20:23631826~23632316:-
LUAD	cis	rs911119	0.955	rs6048946	ENSG00000270001.1	RP11-218C14.8	-4.41	1.26e-05	0.00239	-0.29	-0.2	Chronic kidney disease;	chr20:23621670	chr20:23631826~23632316:-
LUAD	cis	rs9322193	0.923	rs9767309	ENSG00000268592.3	RAET1E-AS1	4.41	1.26e-05	0.00239	0.24	0.2	Lung cancer;	chr6:149716807	chr6:149863494~149919507:+
LUAD	cis	rs2976388	0.692	rs2978983	ENSG00000253741.1	CTD-2292P10.4	-4.41	1.26e-05	0.00239	-0.23	-0.2	Urinary tract infection frequency;	chr8:142684424	chr8:142702252~142726973:-
LUAD	cis	rs910316	0.967	rs175451	ENSG00000279594.1	RP11-950C14.10	-4.41	1.26e-05	0.00239	-0.22	-0.2	Height;	chr14:75123026	chr14:75011269~75012851:-
LUAD	cis	rs4937333	0.584	rs10893871	ENSG00000254703.2	SENCR	4.41	1.26e-05	0.00239	0.22	0.2	Plateletcrit;Platelet count;	chr11:128455612	chr11:128691672~128696023:-
LUAD	cis	rs17685	0.753	rs4732542	ENSG00000280388.1	RP11-229D13.3	-4.41	1.26e-05	0.00239	-0.18	-0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76033885	chr7:76043977~76045963:-
LUAD	cis	rs7210086	0.606	rs72849437	ENSG00000263893.2	CTD-3010D24.3	4.41	1.26e-05	0.00239	0.31	0.2	Ulcerative colitis;	chr17:72634985	chr17:72642731~72644490:+
LUAD	cis	rs910316	0.935	rs3742771	ENSG00000279594.1	RP11-950C14.10	4.41	1.26e-05	0.00239	0.23	0.2	Height;	chr14:75132944	chr14:75011269~75012851:-
LUAD	cis	rs17508449	0.819	rs6678422	ENSG00000232450.1	RP4-730K3.3	-4.41	1.26e-05	0.0024	-0.33	-0.2	Leprosy;	chr1:113662078	chr1:113698884~113699631:-
LUAD	cis	rs9925964	0.591	rs11649653	ENSG00000232748.3	RP11-196G11.6	4.41	1.26e-05	0.0024	0.23	0.2	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:30907166	chr16:31056460~31062803:+
LUAD	cis	rs2242116	0.833	rs6442038	ENSG00000271161.1	BOLA2P2	4.41	1.26e-05	0.0024	0.2	0.2	Birth weight;	chr3:46919252	chr3:47499841~47500407:+
LUAD	cis	rs9341808	0.754	rs9343973	ENSG00000272129.1	RP11-250B2.6	4.41	1.26e-05	0.0024	0.24	0.2	Sitting height ratio;	chr6:80203499	chr6:80355424~80356859:+
LUAD	cis	rs801193	0.66	rs2659897	ENSG00000232559.3	GS1-124K5.12	-4.41	1.26e-05	0.0024	-0.23	-0.2	Aortic root size;	chr7:66722728	chr7:66554588~66576923:-
LUAD	cis	rs858239	0.539	rs2103281	ENSG00000230042.1	AK3P3	-4.41	1.26e-05	0.0024	-0.25	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23154612	chr7:23129178~23129841:+
LUAD	cis	rs10129255	0.957	rs1024349	ENSG00000211974.3	IGHV2-70	4.41	1.26e-05	0.0024	0.21	0.2	Kawasaki disease;	chr14:106689997	chr14:106723574~106724093:-
LUAD	cis	rs791888	1	rs2147288	ENSG00000225913.2	RP11-57C13.6	4.41	1.26e-05	0.0024	0.25	0.2	Magnesium levels;	chr10:87656125	chr10:87607985~87659279:+
LUAD	cis	rs8072100	0.837	rs62074055	ENSG00000228782.6	CTD-2026D20.3	4.41	1.26e-05	0.0024	0.21	0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47694567	chr17:47450568~47492492:-
LUAD	cis	rs34375054	0.624	rs12826658	ENSG00000279233.1	RP11-158L12.4	4.41	1.26e-05	0.0024	0.18	0.2	Post bronchodilator FEV1/FVC ratio;	chr12:125195691	chr12:125138245~125141711:+
LUAD	cis	rs4873772	0.704	rs4536257	ENSG00000253330.1	RP11-697N18.3	-4.41	1.26e-05	0.0024	-0.22	-0.2	Lobe attachment (rater-scored or self-reported);	chr8:47508977	chr8:47511034~47512141:-
LUAD	cis	rs6142102	0.847	rs4911413	ENSG00000275784.1	RP5-1125A11.6	-4.41	1.26e-05	0.0024	-0.22	-0.2	Skin pigmentation;	chr20:34133969	chr20:33989480~33991818:-
LUAD	cis	rs7208859	0.623	rs7214570	ENSG00000266490.1	CTD-2349P21.9	4.41	1.26e-05	0.0024	0.29	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30820146	chr17:30792372~30792833:+
LUAD	cis	rs6723108	0.604	rs1893396	ENSG00000224043.6	CCNT2-AS1	-4.41	1.26e-05	0.0024	-0.24	-0.2	Type 2 diabetes;	chr2:134841439	chr2:134735464~134918710:-
LUAD	cis	rs6723108	0.603	rs3739030	ENSG00000224043.6	CCNT2-AS1	-4.41	1.26e-05	0.0024	-0.24	-0.2	Type 2 diabetes;	chr2:134841811	chr2:134735464~134918710:-
LUAD	cis	rs6496932	0.755	rs56909106	ENSG00000218052.5	ADAMTS7P4	4.41	1.26e-05	0.0024	0.22	0.2	Central corneal thickness;Corneal structure;	chr15:85320817	chr15:85255369~85330334:-
LUAD	cis	rs10463554	0.963	rs13340364	ENSG00000250682.4	LINC00491	4.41	1.26e-05	0.0024	0.24	0.2	Parkinson's disease;	chr5:103003406	chr5:102609156~102671559:-
LUAD	cis	rs6102185	0.647	rs4142346	ENSG00000229771.2	RP4-644L1.2	4.41	1.26e-05	0.0024	0.24	0.2	IgG glycosylation;	chr20:40885225	chr20:40696499~40698616:-
LUAD	cis	rs2243480	1	rs160639	ENSG00000232559.3	GS1-124K5.12	4.41	1.26e-05	0.0024	0.34	0.2	Diabetic kidney disease;	chr7:66115000	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs313824	ENSG00000232559.3	GS1-124K5.12	4.41	1.26e-05	0.0024	0.34	0.2	Diabetic kidney disease;	chr7:66116220	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs186378	ENSG00000232559.3	GS1-124K5.12	4.41	1.26e-05	0.0024	0.34	0.2	Diabetic kidney disease;	chr7:66117071	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs160637	ENSG00000232559.3	GS1-124K5.12	4.41	1.26e-05	0.0024	0.34	0.2	Diabetic kidney disease;	chr7:66119331	chr7:66554588~66576923:-
LUAD	cis	rs516805	0.961	rs573709	ENSG00000279114.1	RP3-425C14.5	4.41	1.26e-05	0.0024	0.21	0.2	Lymphocyte counts;	chr6:122457673	chr6:122471923~122484161:+
LUAD	cis	rs858239	0.676	rs3807459	ENSG00000226816.2	AC005082.12	4.41	1.26e-05	0.0024	0.26	0.2	Cerebrospinal fluid biomarker levels;	chr7:23350132	chr7:23206013~23208045:+
LUAD	cis	rs34375054	0.624	rs12832525	ENSG00000279233.1	RP11-158L12.4	4.41	1.26e-05	0.0024	0.18	0.2	Post bronchodilator FEV1/FVC ratio;	chr12:125195820	chr12:125138245~125141711:+
LUAD	cis	rs4819052	0.918	rs34886433	ENSG00000215447.6	BX322557.10	-4.41	1.26e-05	0.00241	-0.26	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260623	chr21:45288052~45291738:+
LUAD	cis	rs5758511	0.68	rs5758667	ENSG00000227370.1	RP4-669P10.19	4.41	1.26e-05	0.00241	0.22	0.2	Birth weight;	chr22:42237198	chr22:42132543~42132998:+
LUAD	cis	rs911555	0.504	rs4906340	ENSG00000258851.1	RP11-894P9.2	4.41	1.26e-05	0.00241	0.24	0.2	Intelligence (multi-trait analysis);	chr14:103610308	chr14:103553421~103561877:+
LUAD	cis	rs1431005	0.963	rs72725286	ENSG00000250658.1	RP11-138B4.1	4.41	1.27e-05	0.00241	0.24	0.2	Response to statin therapy;	chr4:187475655	chr4:187304083~187309682:-
LUAD	cis	rs73186030	0.764	rs56236741	ENSG00000272758.4	RP11-299J3.8	4.41	1.27e-05	0.00241	0.26	0.2	Serum parathyroid hormone levels;	chr3:122379136	chr3:122416207~122443180:+
LUAD	cis	rs17772222	0.701	rs845757	ENSG00000258789.1	RP11-507K2.3	4.41	1.27e-05	0.00241	0.24	0.2	Coronary artery calcification;	chr14:88455372	chr14:88551597~88552493:+
LUAD	cis	rs2467099	0.735	rs55793071	ENSG00000267801.1	RP11-552F3.9	4.41	1.27e-05	0.00241	0.24	0.2	Systolic blood pressure;	chr17:75913867	chr17:75876372~75879546:+
LUAD	cis	rs9652601	0.779	rs12708716	ENSG00000274038.1	RP11-66H6.4	4.41	1.27e-05	0.00241	0.24	0.2	Systemic lupus erythematosus;	chr16:11086016	chr16:11056556~11057034:+
LUAD	cis	rs4819052	0.851	rs2838836	ENSG00000237664.1	LINC00316	-4.41	1.27e-05	0.00241	-0.24	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245960	chr21:45338590~45341990:-
LUAD	cis	rs7208859	0.524	rs8065744	ENSG00000266490.1	CTD-2349P21.9	4.41	1.27e-05	0.00241	0.29	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30772431	chr17:30792372~30792833:+
LUAD	cis	rs17826219	0.706	rs8071236	ENSG00000266490.1	CTD-2349P21.9	4.41	1.27e-05	0.00241	0.29	0.2	Body mass index;	chr17:30772984	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs56163556	ENSG00000266490.1	CTD-2349P21.9	4.41	1.27e-05	0.00241	0.29	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774850	chr17:30792372~30792833:+
LUAD	cis	rs8062405	0.723	rs762633	ENSG00000261419.1	RP11-57A19.4	-4.41	1.27e-05	0.00241	-0.22	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597020	chr16:28659696~28740781:-
LUAD	cis	rs3764021	1	rs3764021	ENSG00000256582.1	RP11-75L1.1	4.41	1.27e-05	0.00241	0.21	0.2	Type 1 diabetes;	chr12:9681032	chr12:9704077~9709350:+
LUAD	cis	rs17772222	0.876	rs4375590	ENSG00000258789.1	RP11-507K2.3	-4.41	1.27e-05	0.00241	-0.27	-0.2	Coronary artery calcification;	chr14:88451334	chr14:88551597~88552493:+
LUAD	cis	rs2976388	0.578	rs3758081	ENSG00000253741.1	CTD-2292P10.4	4.41	1.27e-05	0.00241	0.24	0.2	Urinary tract infection frequency;	chr8:142742955	chr8:142702252~142726973:-
LUAD	cis	rs301901	0.556	rs13176996	ENSG00000250155.1	CTD-2353F22.1	-4.41	1.27e-05	0.00241	-0.23	-0.2	Height;	chr5:37178659	chr5:36666214~36725195:-
LUAD	cis	rs6840360	0.541	rs4696251	ENSG00000270265.1	RP11-731D1.4	-4.41	1.27e-05	0.00241	-0.2	-0.2	Intelligence (multi-trait analysis);	chr4:151345174	chr4:151333775~151353224:-
LUAD	cis	rs944990	0.538	rs10761234	ENSG00000227603.1	RP11-165J3.6	4.41	1.27e-05	0.00241	0.22	0.2	Body mass index;	chr9:93545230	chr9:93435332~93437121:-
LUAD	cis	rs7760535	0.811	rs1002475	ENSG00000271789.1	RP5-1112D6.7	-4.41	1.27e-05	0.00241	-0.21	-0.2	Metabolic traits;	chr6:111388386	chr6:111297126~111298510:+
LUAD	cis	rs9400467	0.528	rs11153288	ENSG00000271789.1	RP5-1112D6.7	-4.41	1.27e-05	0.00241	-0.21	-0.2	Amino acid levels;Blood metabolite levels;	chr6:111394035	chr6:111297126~111298510:+
LUAD	cis	rs9400467	0.528	rs11153290	ENSG00000271789.1	RP5-1112D6.7	-4.41	1.27e-05	0.00241	-0.21	-0.2	Amino acid levels;Blood metabolite levels;	chr6:111396929	chr6:111297126~111298510:+
LUAD	cis	rs9400467	0.528	rs11153291	ENSG00000271789.1	RP5-1112D6.7	-4.41	1.27e-05	0.00241	-0.21	-0.2	Amino acid levels;Blood metabolite levels;	chr6:111398927	chr6:111297126~111298510:+
LUAD	cis	rs9400467	0.528	rs11153292	ENSG00000271789.1	RP5-1112D6.7	-4.41	1.27e-05	0.00241	-0.21	-0.2	Amino acid levels;Blood metabolite levels;	chr6:111401176	chr6:111297126~111298510:+
LUAD	cis	rs9400467	0.528	rs12190634	ENSG00000271789.1	RP5-1112D6.7	-4.41	1.27e-05	0.00241	-0.21	-0.2	Amino acid levels;Blood metabolite levels;	chr6:111403957	chr6:111297126~111298510:+
LUAD	cis	rs9400467	0.508	rs11153293	ENSG00000271789.1	RP5-1112D6.7	-4.41	1.27e-05	0.00241	-0.21	-0.2	Amino acid levels;Blood metabolite levels;	chr6:111404696	chr6:111297126~111298510:+
LUAD	cis	rs9400467	0.508	rs11756643	ENSG00000271789.1	RP5-1112D6.7	-4.41	1.27e-05	0.00241	-0.21	-0.2	Amino acid levels;Blood metabolite levels;	chr6:111404943	chr6:111297126~111298510:+
LUAD	cis	rs9400467	0.508	rs11153294	ENSG00000271789.1	RP5-1112D6.7	-4.41	1.27e-05	0.00241	-0.21	-0.2	Amino acid levels;Blood metabolite levels;	chr6:111409043	chr6:111297126~111298510:+
LUAD	cis	rs6142102	0.961	rs8119937	ENSG00000275784.1	RP5-1125A11.6	-4.41	1.27e-05	0.00241	-0.21	-0.2	Skin pigmentation;	chr20:34057745	chr20:33989480~33991818:-
LUAD	cis	rs858239	0.669	rs6461688	ENSG00000226816.2	AC005082.12	4.41	1.27e-05	0.00241	0.25	0.2	Cerebrospinal fluid biomarker levels;	chr7:23076996	chr7:23206013~23208045:+
LUAD	cis	rs2333021	0.78	rs28619241	ENSG00000259015.1	RP11-109N23.6	4.41	1.27e-05	0.00241	0.18	0.2	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72972902	chr14:72960595~72961993:+
LUAD	cis	rs2333021	0.78	rs12931	ENSG00000259015.1	RP11-109N23.6	4.41	1.27e-05	0.00241	0.18	0.2	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72974156	chr14:72960595~72961993:+
LUAD	cis	rs7555523	0.779	rs6662839	ENSG00000224358.1	RP11-466F5.8	-4.41	1.27e-05	0.00241	-0.34	-0.2	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165753409	chr1:165768929~165775176:+
LUAD	cis	rs150992	0.504	rs7719562	ENSG00000248489.1	CTD-2007H13.3	-4.41	1.27e-05	0.00242	-0.25	-0.2	Body mass index;	chr5:99029419	chr5:98929171~98995013:+
LUAD	cis	rs150992	0.504	rs4583911	ENSG00000248489.1	CTD-2007H13.3	-4.41	1.27e-05	0.00242	-0.25	-0.2	Body mass index;	chr5:99031401	chr5:98929171~98995013:+
LUAD	cis	rs860295	0.702	rs12043132	ENSG00000225855.5	RUSC1-AS1	4.41	1.27e-05	0.00242	0.13	0.2	Body mass index;	chr1:155592576	chr1:155316863~155324176:-
LUAD	cis	rs3812049	0.737	rs1993878	ENSG00000245937.6	LINC01184	4.41	1.27e-05	0.00242	0.29	0.2	Lymphocyte counts;Red cell distribution width;	chr5:128141279	chr5:127940426~128083172:-
LUAD	cis	rs9341808	0.718	rs7740627	ENSG00000260645.1	RP11-250B2.5	4.41	1.27e-05	0.00242	0.19	0.2	Sitting height ratio;	chr6:80206630	chr6:80466958~80469080:+
LUAD	cis	rs2212361	0.558	rs16924610	ENSG00000255893.1	RP11-685N10.1	-4.41	1.27e-05	0.00242	-0.27	-0.2	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94531490	chr11:94472908~94473570:-
LUAD	cis	rs2212361	0.558	rs72980480	ENSG00000255893.1	RP11-685N10.1	-4.41	1.27e-05	0.00242	-0.27	-0.2	Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction);	chr11:94532852	chr11:94472908~94473570:-
LUAD	cis	rs4873772	0.735	rs6989917	ENSG00000253330.1	RP11-697N18.3	-4.41	1.27e-05	0.00242	-0.22	-0.2	Lobe attachment (rater-scored or self-reported);	chr8:47614197	chr8:47511034~47512141:-
LUAD	cis	rs9652601	0.919	rs12924729	ENSG00000274038.1	RP11-66H6.4	-4.41	1.27e-05	0.00242	-0.24	-0.2	Systemic lupus erythematosus;	chr16:11093926	chr16:11056556~11057034:+
LUAD	cis	rs875971	0.666	rs13242072	ENSG00000224316.1	RP11-479O9.2	-4.41	1.27e-05	0.00242	-0.2	-0.2	Aortic root size;	chr7:66301001	chr7:65773620~65802067:+
LUAD	cis	rs896854	0.738	rs2515226	ENSG00000253528.2	RP11-347C18.4	-4.41	1.27e-05	0.00242	-0.2	-0.2	Type 2 diabetes;	chr8:94953515	chr8:94974573~94974853:-
LUAD	cis	rs7005380	0.581	rs13265734	ENSG00000279347.1	RP11-85I17.2	-4.41	1.27e-05	0.00242	-0.19	-0.2	Interstitial lung disease;	chr8:119907708	chr8:119838736~119840385:-
LUAD	cis	rs1799949	0.859	rs11657004	ENSG00000236383.6	LINC00854	-4.41	1.27e-05	0.00242	-0.16	-0.2	Menopause (age at onset);	chr17:43365383	chr17:43216941~43305976:-
LUAD	cis	rs1729951	0.575	rs361243	ENSG00000239213.4	NCK1-AS1	4.41	1.27e-05	0.00242	0.21	0.2	Neuroticism;	chr3:136978944	chr3:136841726~136862054:-
LUAD	cis	rs1729951	0.575	rs361242	ENSG00000239213.4	NCK1-AS1	4.41	1.27e-05	0.00242	0.21	0.2	Neuroticism;	chr3:136979488	chr3:136841726~136862054:-
LUAD	cis	rs6832769	1	rs473005	ENSG00000272969.1	RP11-528I4.2	4.41	1.27e-05	0.00242	0.21	0.2	Personality dimensions;	chr4:55421958	chr4:55547112~55547889:+
LUAD	cis	rs9341808	0.718	rs2322630	ENSG00000260645.1	RP11-250B2.5	4.41	1.27e-05	0.00242	0.19	0.2	Sitting height ratio;	chr6:80131316	chr6:80466958~80469080:+
LUAD	cis	rs1334894	0.892	rs12527303	ENSG00000228559.1	RP3-340B19.3	-4.41	1.27e-05	0.00242	-0.41	-0.2	Coronary artery disease;	chr6:35519957	chr6:35544632~35545669:+
LUAD	cis	rs1864585	0.52	rs73208766	ENSG00000255046.1	RP11-297N6.4	4.41	1.27e-05	0.00242	0.28	0.2	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10807027	chr8:11797928~11802568:-
LUAD	cis	rs1864585	0.52	rs714370	ENSG00000255046.1	RP11-297N6.4	4.41	1.27e-05	0.00242	0.28	0.2	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10808337	chr8:11797928~11802568:-
LUAD	cis	rs240993	0.812	rs6937734	ENSG00000230177.1	RP5-1112D6.4	4.41	1.27e-05	0.00242	0.2	0.2	Inflammatory skin disease;Psoriasis;	chr6:111415439	chr6:111277932~111278742:+
LUAD	cis	rs2742234	0.614	rs3026750	ENSG00000273008.1	RP11-351D16.3	-4.41	1.27e-05	0.00242	-0.21	-0.2	Hirschsprung disease;	chr10:43112308	chr10:43136824~43138334:-
LUAD	cis	rs13113518	0.812	rs4864996	ENSG00000223305.1	RN7SKP30	4.41	1.28e-05	0.00242	0.23	0.2	Height;	chr4:55452921	chr4:55540502~55540835:-
LUAD	cis	rs9381040	1	rs9381040	ENSG00000161912.16	ADCY10P1	4.41	1.28e-05	0.00242	0.19	0.2	Alzheimer's disease (late onset);	chr6:41186912	chr6:41101022~41140835:+
LUAD	cis	rs1005277	0.577	rs4934906	ENSG00000263064.2	RP11-291L22.7	4.41	1.28e-05	0.00242	0.21	0.2	Extrinsic epigenetic age acceleration;	chr10:37726100	chr10:38448689~38448949:+
LUAD	cis	rs7086627	0.515	rs10887896	ENSG00000226659.1	RP11-137H2.4	-4.41	1.28e-05	0.00242	-0.26	-0.2	Post bronchodilator FEV1;	chr10:80450388	chr10:80529597~80535942:-
LUAD	cis	rs7086627	0.515	rs10887899	ENSG00000226659.1	RP11-137H2.4	-4.41	1.28e-05	0.00242	-0.26	-0.2	Post bronchodilator FEV1;	chr10:80450458	chr10:80529597~80535942:-
LUAD	cis	rs6487679	1	rs6487679	ENSG00000255753.1	RP11-22B23.2	4.41	1.28e-05	0.00242	0.25	0.2	Non-alcoholic fatty liver disease histology (AST);	chr12:9218736	chr12:9314402~9316173:-
LUAD	cis	rs2919009	0.607	rs2303951	ENSG00000271670.1	RP11-95I16.4	4.41	1.28e-05	0.00242	0.26	0.2	Obesity-related traits;	chr10:120954568	chr10:120879256~120880667:-
LUAD	cis	rs7208859	0.623	rs3794796	ENSG00000266490.1	CTD-2349P21.9	4.41	1.28e-05	0.00243	0.29	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30792372~30792833:+
LUAD	cis	rs17772222	0.545	rs1758846	ENSG00000258789.1	RP11-507K2.3	4.41	1.28e-05	0.00243	0.24	0.2	Coronary artery calcification;	chr14:88449288	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.675	rs845769	ENSG00000258789.1	RP11-507K2.3	4.41	1.28e-05	0.00243	0.24	0.2	Coronary artery calcification;	chr14:88461455	chr14:88551597~88552493:+
LUAD	cis	rs7829975	0.508	rs1594437	ENSG00000173295.6	FAM86B3P	4.41	1.28e-05	0.00243	0.2	0.2	Mood instability;	chr8:8968365	chr8:8228595~8244865:+
LUAD	cis	rs12478296	1	rs7603984	ENSG00000261186.2	RP11-341N2.1	-4.41	1.28e-05	0.00243	-0.36	-0.2	Obesity-related traits;	chr2:242105143	chr2:242087351~242088457:-
LUAD	cis	rs7200786	0.528	rs8050875	ENSG00000274038.1	RP11-66H6.4	-4.41	1.28e-05	0.00243	-0.25	-0.2	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11129680	chr16:11056556~11057034:+
LUAD	cis	rs8177876	0.749	rs2970076	ENSG00000261061.1	RP11-303E16.2	-4.41	1.28e-05	0.00243	-0.27	-0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81056211	chr16:81030770~81031485:+
LUAD	cis	rs848490	0.925	rs56111978	ENSG00000214293.7	APTR	4.41	1.28e-05	0.00243	0.26	0.2	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77755031	chr7:77657660~77696265:-
LUAD	cis	rs4268898	0.722	rs11680491	ENSG00000223754.1	AC008073.9	-4.41	1.28e-05	0.00243	-0.24	-0.2	Asthma;	chr2:24193423	chr2:24199839~24201698:-
LUAD	cis	rs6421571	0.564	rs11216972	ENSG00000255239.1	AP002954.6	-4.41	1.28e-05	0.00243	-0.3	-0.2	Primary biliary cholangitis;	chr11:118715117	chr11:118688039~118690600:-
LUAD	cis	rs13014235	0.667	rs2540328	ENSG00000213090.2	AC007256.5	-4.41	1.28e-05	0.00243	-0.23	-0.2	Basal cell carcinoma;	chr2:201384337	chr2:201410544~201413308:-
LUAD	cis	rs77688320	0.509	rs2714487	ENSG00000213090.2	AC007256.5	-4.41	1.28e-05	0.00243	-0.23	-0.2	Breast cancer;	chr2:201384837	chr2:201410544~201413308:-
LUAD	cis	rs10761482	0.564	rs10733765	ENSG00000254271.1	RP11-131N11.4	4.41	1.28e-05	0.00243	0.23	0.2	Schizophrenia;	chr10:60477641	chr10:60734342~60741828:+
LUAD	cis	rs13113518	1	rs4864547	ENSG00000272969.1	RP11-528I4.2	4.41	1.28e-05	0.00243	0.21	0.2	Height;	chr4:55538228	chr4:55547112~55547889:+
LUAD	cis	rs2548724	0.617	rs2167585	ENSG00000250682.4	LINC00491	4.41	1.28e-05	0.00243	0.24	0.2	Type 2 diabetes;	chr5:102378598	chr5:102609156~102671559:-
LUAD	cis	rs1008375	0.9	rs3822235	ENSG00000249502.1	AC006160.5	4.41	1.28e-05	0.00243	0.19	0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17693293	chr4:17587467~17614571:-
LUAD	cis	rs13113518	0.812	rs13140173	ENSG00000223305.1	RN7SKP30	4.41	1.28e-05	0.00243	0.23	0.2	Height;	chr4:55527164	chr4:55540502~55540835:-
LUAD	cis	rs35828350	1	rs35828350	ENSG00000259295.5	CSPG4P12	4.41	1.28e-05	0.00243	0.28	0.2	Autism spectrum disorder or schizophrenia;	chr15:84812610	chr15:85191438~85213905:+
LUAD	cis	rs858239	0.601	rs4440529	ENSG00000226816.2	AC005082.12	4.41	1.28e-05	0.00243	0.26	0.2	Cerebrospinal fluid biomarker levels;	chr7:23129132	chr7:23206013~23208045:+
LUAD	cis	rs6964587	1	rs11982047	ENSG00000188693.7	CYP51A1-AS1	-4.41	1.28e-05	0.00243	-0.24	-0.2	Breast cancer;	chr7:92075960	chr7:92134604~92180725:+
LUAD	cis	rs910316	1	rs10142865	ENSG00000279594.1	RP11-950C14.10	4.41	1.28e-05	0.00243	0.23	0.2	Height;	chr14:75088921	chr14:75011269~75012851:-
LUAD	cis	rs910316	1	rs10142626	ENSG00000279594.1	RP11-950C14.10	4.41	1.28e-05	0.00243	0.23	0.2	Height;	chr14:75088933	chr14:75011269~75012851:-
LUAD	cis	rs2732480	0.5	rs7966829	ENSG00000240399.1	RP1-228P16.1	4.41	1.28e-05	0.00243	0.2	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48221820	chr12:48054813~48055591:-
LUAD	cis	rs2834288	0.5	rs2834304	ENSG00000237945.6	LINC00649	4.41	1.28e-05	0.00243	0.24	0.2	Gut microbiota (bacterial taxa);	chr21:33949550	chr21:33915534~33977691:+
LUAD	cis	rs2115630	1	rs11854291	ENSG00000225151.9	GOLGA2P7	4.41	1.28e-05	0.00243	0.22	0.2	P wave terminal force;	chr15:84820477	chr15:84199311~84230136:-
LUAD	cis	rs4819052	0.851	rs2838856	ENSG00000237664.1	LINC00316	-4.41	1.28e-05	0.00244	-0.23	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260851	chr21:45338590~45341990:-
LUAD	cis	rs2243480	1	rs160655	ENSG00000164669.11	INTS4P1	4.41	1.28e-05	0.00244	0.34	0.2	Diabetic kidney disease;	chr7:66068227	chr7:65141225~65234216:+
LUAD	cis	rs3761847	0.508	rs4837813	ENSG00000226752.6	PSMD5-AS1	-4.41	1.28e-05	0.00244	-0.21	-0.2	Rheumatoid arthritis;	chr9:121172185	chr9:120824828~120854385:+
LUAD	cis	rs8030379	1	rs11259936	ENSG00000230373.7	GOLGA6L5P	4.41	1.28e-05	0.00244	0.18	0.2	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83911830	chr15:84507885~84516814:-
LUAD	cis	rs1355223	0.867	rs7943363	ENSG00000271369.1	RP11-350D17.3	-4.41	1.28e-05	0.00244	-0.23	-0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34669587	chr11:34709600~34710161:+
LUAD	cis	rs875971	0.867	rs1002053	ENSG00000232559.3	GS1-124K5.12	-4.41	1.28e-05	0.00244	-0.23	-0.2	Aortic root size;	chr7:66333558	chr7:66554588~66576923:-
LUAD	cis	rs13113518	0.812	rs13107810	ENSG00000223305.1	RN7SKP30	4.41	1.28e-05	0.00244	0.23	0.2	Height;	chr4:55542243	chr4:55540502~55540835:-
LUAD	cis	rs847577	0.588	rs6946915	ENSG00000272950.1	RP11-307C18.1	4.41	1.28e-05	0.00244	0.24	0.2	Breast cancer;	chr7:98082028	chr7:98322853~98323430:+
LUAD	cis	rs2242116	0.796	rs4587	ENSG00000271161.1	BOLA2P2	4.41	1.28e-05	0.00244	0.19	0.2	Birth weight;	chr3:46922012	chr3:47499841~47500407:+
LUAD	cis	rs853679	0.76	rs9357067	ENSG00000204709.4	LINC01556	4.41	1.28e-05	0.00244	0.28	0.2	Depression;	chr6:28242515	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.76	rs967005	ENSG00000204709.4	LINC01556	4.41	1.28e-05	0.00244	0.28	0.2	Depression;	chr6:28242910	chr6:28943877~28944537:+
LUAD	cis	rs2243480	1	rs781157	ENSG00000232559.3	GS1-124K5.12	4.41	1.28e-05	0.00244	0.34	0.2	Diabetic kidney disease;	chr7:66013324	chr7:66554588~66576923:-
LUAD	cis	rs34779708	0.643	rs4275563	ENSG00000271335.4	RP11-324I22.4	4.41	1.29e-05	0.00244	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35256358	chr10:35314552~35336401:-
LUAD	cis	rs1322639	0.614	rs6925188	ENSG00000261039.2	RP11-417E7.2	-4.41	1.29e-05	0.00244	-0.32	-0.2	Pulse pressure;	chr6:169163242	chr6:169175304~169182740:-
LUAD	cis	rs950169	0.922	rs11638445	ENSG00000229212.6	RP11-561C5.4	-4.41	1.29e-05	0.00244	-0.28	-0.2	Schizophrenia;	chr15:84594463	chr15:85205440~85234795:-
LUAD	cis	rs4908768	0.539	rs11121204	ENSG00000270282.1	RP5-1115A15.2	-4.41	1.29e-05	0.00244	-0.22	-0.2	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8594246	chr1:8512653~8513021:+
LUAD	cis	rs8180040	0.62	rs9875235	ENSG00000271161.1	BOLA2P2	4.41	1.29e-05	0.00244	0.19	0.2	Colorectal cancer;	chr3:47042131	chr3:47499841~47500407:+
LUAD	cis	rs7665090	1	rs735405	ENSG00000246560.2	RP11-10L12.4	4.41	1.29e-05	0.00244	0.24	0.2	Primary biliary cholangitis;	chr4:102632759	chr4:102828055~102844075:+
LUAD	cis	rs8062405	0.755	rs55792032	ENSG00000261419.1	RP11-57A19.4	-4.41	1.29e-05	0.00244	-0.21	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28659696~28740781:-
LUAD	cis	rs17345786	0.861	rs11711808	ENSG00000244119.1	PDCL3P4	4.41	1.29e-05	0.00244	0.22	0.2	Colonoscopy-negative controls vs population controls;	chr3:101516257	chr3:101712472~101713191:+
LUAD	cis	rs950169	0.92	rs12915390	ENSG00000275120.1	RP11-182J1.17	4.41	1.29e-05	0.00244	0.31	0.2	Schizophrenia;	chr15:84123317	chr15:84599434~84606463:-
LUAD	cis	rs11122895	0.509	rs10174353	ENSG00000236307.2	EEF1E1P1	4.41	1.29e-05	0.00244	0.21	0.2	Allergic sensitization;	chr2:111690311	chr2:111887914~111888741:+
LUAD	cis	rs1023500	0.573	rs133377	ENSG00000205702.9	CYP2D7	4.41	1.29e-05	0.00244	0.16	0.2	Schizophrenia;	chr22:42070946	chr22:42140203~42144577:-
LUAD	cis	rs4819052	0.851	rs2838850	ENSG00000237664.1	LINC00316	-4.41	1.29e-05	0.00244	-0.23	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251530	chr21:45338590~45341990:-
LUAD	cis	rs6687758	1	rs17011200	ENSG00000227925.1	RP11-191N8.2	4.41	1.29e-05	0.00244	0.27	0.2	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222018163	chr1:221827666~221840666:-
LUAD	cis	rs7191700	0.578	rs243324	ENSG00000262703.1	RP11-485G7.6	4.41	1.29e-05	0.00244	0.18	0.2	Multiple sclerosis;	chr16:11261113	chr16:11348143~11349321:-
LUAD	cis	rs4908760	0.539	rs10864367	ENSG00000270282.1	RP5-1115A15.2	4.41	1.29e-05	0.00245	0.21	0.2	Vitiligo;	chr1:8787321	chr1:8512653~8513021:+
LUAD	cis	rs1334894	0.892	rs72913412	ENSG00000228559.1	RP3-340B19.3	-4.41	1.29e-05	0.00245	-0.41	-0.2	Coronary artery disease;	chr6:35568877	chr6:35544632~35545669:+
LUAD	cis	rs7208859	0.623	rs28556733	ENSG00000280069.1	CTD-2349P21.3	-4.41	1.29e-05	0.00245	-0.27	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30756927	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs28433704	ENSG00000280069.1	CTD-2349P21.3	-4.41	1.29e-05	0.00245	-0.27	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757267	chr17:30738182~30740275:+
LUAD	cis	rs17826219	0.706	rs55764512	ENSG00000280069.1	CTD-2349P21.3	-4.41	1.29e-05	0.00245	-0.27	-0.2	Body mass index;	chr17:30758740	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs12103508	ENSG00000280069.1	CTD-2349P21.3	-4.41	1.29e-05	0.00245	-0.27	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759763	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.524	rs11653605	ENSG00000280069.1	CTD-2349P21.3	-4.41	1.29e-05	0.00245	-0.27	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30738182~30740275:+
LUAD	cis	rs7829975	0.593	rs2921061	ENSG00000173295.6	FAM86B3P	4.41	1.29e-05	0.00245	0.21	0.2	Mood instability;	chr8:8460105	chr8:8228595~8244865:+
LUAD	cis	rs477895	0.713	rs11600867	ENSG00000236935.1	AP003774.1	-4.41	1.29e-05	0.00245	-0.24	-0.2	Mean platelet volume;	chr11:64204580	chr11:64325050~64329504:-
LUAD	cis	rs9487605	1	rs9487605	ENSG00000271789.1	RP5-1112D6.7	-4.41	1.29e-05	0.00245	-0.23	-0.2	Inflammatory skin disease;	chr6:111261682	chr6:111297126~111298510:+
LUAD	cis	rs9545047	0.604	rs2765078	ENSG00000227354.5	RBM26-AS1	4.41	1.29e-05	0.00245	0.21	0.2	Schizophrenia;	chr13:79420604	chr13:79406309~79424328:+
LUAD	cis	rs7119	0.604	rs2667781	ENSG00000259362.2	RP11-307C19.1	4.41	1.29e-05	0.00245	0.25	0.2	Type 2 diabetes;	chr15:77566277	chr15:77525540~77534110:+
LUAD	cis	rs11168618	0.692	rs4760707	ENSG00000240399.1	RP1-228P16.1	4.41	1.29e-05	0.00245	0.19	0.2	Adiponectin levels;	chr12:48454857	chr12:48054813~48055591:-
LUAD	cis	rs6479891	0.908	rs4746201	ENSG00000232075.1	MRPL35P2	4.41	1.29e-05	0.00245	0.33	0.2	Arthritis (juvenile idiopathic);	chr10:63562621	chr10:63634317~63634827:-
LUAD	cis	rs227275	0.556	rs6842179	ENSG00000251288.2	RP11-10L12.2	-4.41	1.29e-05	0.00245	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:103018363	chr4:102751401~102752641:+
LUAD	cis	rs9330264	0.508	rs7364869	ENSG00000160766.13	GBAP1	-4.41	1.29e-05	0.00245	-0.2	-0.2	1,5-anhydroglucitol levels;	chr1:155114712	chr1:155213821~155227422:-
LUAD	cis	rs875971	0.862	rs6944374	ENSG00000232559.3	GS1-124K5.12	-4.41	1.29e-05	0.00245	-0.23	-0.2	Aortic root size;	chr7:66221942	chr7:66554588~66576923:-
LUAD	cis	rs2467099	0.786	rs1463486	ENSG00000267801.1	RP11-552F3.9	4.41	1.29e-05	0.00245	0.23	0.2	Systolic blood pressure;	chr17:75947861	chr17:75876372~75879546:+
LUAD	cis	rs7107174	0.892	rs2090095	ENSG00000251323.2	RP11-452H21.4	4.41	1.29e-05	0.00245	0.23	0.2	Testicular germ cell tumor;	chr11:78322974	chr11:78423982~78429836:-
LUAD	cis	rs13113518	0.812	rs6849474	ENSG00000223305.1	RN7SKP30	4.41	1.29e-05	0.00245	0.23	0.2	Height;	chr4:55452295	chr4:55540502~55540835:-
LUAD	cis	rs2243480	1	rs1964692	ENSG00000229886.1	RP5-1132H15.3	4.41	1.29e-05	0.00245	0.34	0.2	Diabetic kidney disease;	chr7:65989196	chr7:66025126~66031544:-
LUAD	cis	rs2153535	0.585	rs7753781	ENSG00000230939.1	RP11-314C16.1	-4.41	1.29e-05	0.00245	-0.22	-0.2	Motion sickness;	chr6:8637268	chr6:8784178~8785445:+
LUAD	cis	rs1023500	0.505	rs134889	ENSG00000205702.9	CYP2D7	4.41	1.29e-05	0.00245	0.16	0.2	Schizophrenia;	chr22:42278344	chr22:42140203~42144577:-
LUAD	cis	rs7945705	0.846	rs905290	ENSG00000254860.4	TMEM9B-AS1	-4.41	1.29e-05	0.00245	-0.23	-0.2	Hemoglobin concentration;	chr11:8732182	chr11:8964675~8977527:+
LUAD	cis	rs4843747	0.641	rs11117353	ENSG00000205037.2	RP11-863P13.4	4.41	1.29e-05	0.00245	0.28	0.2	Menopause (age at onset);	chr16:88057289	chr16:88088041~88100985:-
LUAD	cis	rs853679	0.517	rs4713146	ENSG00000226314.6	ZNF192P1	-4.41	1.29e-05	0.00245	-0.27	-0.2	Depression;	chr6:28143758	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs9393894	ENSG00000226314.6	ZNF192P1	-4.41	1.29e-05	0.00245	-0.27	-0.2	Depression;	chr6:28144784	chr6:28161781~28169594:+
LUAD	cis	rs4578769	0.55	rs9949333	ENSG00000265943.1	RP11-739L10.1	4.41	1.29e-05	0.00245	0.25	0.2	Eosinophil percentage of white cells;	chr18:22815080	chr18:22699481~22933764:-
LUAD	cis	rs877356	0.831	rs2288833	ENSG00000250378.1	RP11-119J18.1	-4.41	1.29e-05	0.00245	-0.38	-0.2	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (dichotomous);	chr5:135834982	chr5:135812667~135826582:+
LUAD	cis	rs6957923	0.818	rs7810773	ENSG00000230658.1	KLHL7-AS1	4.41	1.29e-05	0.00245	0.23	0.2	Height;	chr7:23480485	chr7:23101228~23105703:-
LUAD	cis	rs8062405	0.789	rs1968752	ENSG00000251417.2	RP11-1348G14.4	-4.41	1.29e-05	0.00245	-0.19	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620264	chr16:28802743~28817828:+
LUAD	cis	rs7829975	0.684	rs474892	ENSG00000253893.2	FAM85B	4.41	1.29e-05	0.00245	0.25	0.2	Mood instability;	chr8:8739221	chr8:8167819~8226614:-
LUAD	cis	rs7208859	0.573	rs79505916	ENSG00000280069.1	CTD-2349P21.3	-4.41	1.3e-05	0.00246	-0.27	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30735308	chr17:30738182~30740275:+
LUAD	cis	rs748404	0.666	rs12911569	ENSG00000205771.5	CATSPER2P1	-4.41	1.3e-05	0.00246	-0.3	-0.2	Lung cancer;	chr15:43305099	chr15:43726918~43747094:-
LUAD	cis	rs7138803	0.51	rs2603107	ENSG00000257464.1	RP11-161H23.8	-4.41	1.3e-05	0.00246	-0.19	-0.2	Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index;	chr12:49790091	chr12:49442424~49442652:-
LUAD	cis	rs394563	0.967	rs444784	ENSG00000216906.2	RP11-350J20.9	4.41	1.3e-05	0.00246	0.24	0.2	Dupuytren's disease;	chr6:149477230	chr6:149904243~149906418:+
LUAD	cis	rs4835473	0.637	rs2323201	ENSG00000251600.4	RP11-673E1.1	4.41	1.3e-05	0.00246	0.23	0.2	Immature fraction of reticulocytes;	chr4:143765629	chr4:143912331~143982454:+
LUAD	cis	rs7590268	0.636	rs3764769	ENSG00000279873.2	LINC01126	4.41	1.3e-05	0.00246	0.19	0.2	Orofacial clefts;	chr2:43505819	chr2:43227210~43228855:+
LUAD	cis	rs7811142	0.887	rs35111986	ENSG00000078319.8	PMS2P1	-4.41	1.3e-05	0.00246	-0.24	-0.2	Platelet count;	chr7:100402651	chr7:100320992~100341908:-
LUAD	cis	rs4843747	0.749	rs12102841	ENSG00000205037.2	RP11-863P13.4	-4.41	1.3e-05	0.00246	-0.28	-0.2	Menopause (age at onset);	chr16:88038968	chr16:88088041~88100985:-
LUAD	cis	rs16958445	1	rs16958445	ENSG00000247240.6	UBL7-AS1	4.41	1.3e-05	0.00246	0.4	0.2	Exfoliation glaucoma or exfoliation syndrome;	chr15:73884216	chr15:74461265~74481302:+
LUAD	cis	rs6687758	0.945	rs12033415	ENSG00000200033.1	RNU6-403P	4.41	1.3e-05	0.00246	0.27	0.2	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221981726	chr1:221837334~221837437:-
LUAD	cis	rs7665090	1	rs13112557	ENSG00000246560.2	RP11-10L12.4	4.41	1.3e-05	0.00246	0.24	0.2	Primary biliary cholangitis;	chr4:102631096	chr4:102828055~102844075:+
LUAD	cis	rs763121	0.819	rs4560233	ENSG00000228274.3	RP3-508I15.9	-4.41	1.3e-05	0.00246	-0.19	-0.2	Menopause (age at onset);	chr22:38586437	chr22:38667585~38681820:-
LUAD	cis	rs651907	0.513	rs34963630	ENSG00000244119.1	PDCL3P4	4.41	1.3e-05	0.00246	0.2	0.2	Colorectal cancer;	chr3:101785973	chr3:101712472~101713191:+
LUAD	cis	rs9545047	0.604	rs1748762	ENSG00000227354.5	RBM26-AS1	4.41	1.3e-05	0.00246	0.21	0.2	Schizophrenia;	chr13:79407914	chr13:79406309~79424328:+
LUAD	cis	rs293748	0.891	rs292180	ENSG00000250155.1	CTD-2353F22.1	-4.41	1.3e-05	0.00246	-0.26	-0.2	Obesity-related traits;	chr5:36950157	chr5:36666214~36725195:-
LUAD	cis	rs7811142	1	rs74460138	ENSG00000078319.8	PMS2P1	-4.41	1.3e-05	0.00246	-0.23	-0.2	Platelet count;	chr7:100429716	chr7:100320992~100341908:-
LUAD	cis	rs7811142	1	rs4989959	ENSG00000078319.8	PMS2P1	-4.41	1.3e-05	0.00246	-0.23	-0.2	Platelet count;	chr7:100434665	chr7:100320992~100341908:-
LUAD	cis	rs2742234	0.541	rs10793427	ENSG00000273008.1	RP11-351D16.3	4.41	1.3e-05	0.00246	0.22	0.2	Hirschsprung disease;	chr10:43251995	chr10:43136824~43138334:-
LUAD	cis	rs77688320	0.553	rs2080320	ENSG00000213090.2	AC007256.5	4.41	1.3e-05	0.00246	0.23	0.2	Breast cancer;	chr2:201514450	chr2:201410544~201413308:-
LUAD	cis	rs6964587	0.967	rs34040612	ENSG00000188693.7	CYP51A1-AS1	-4.41	1.3e-05	0.00246	-0.24	-0.2	Breast cancer;	chr7:92169602	chr7:92134604~92180725:+
LUAD	cis	rs10971721	0.822	rs72727340	ENSG00000260947.1	RP11-384P7.7	4.41	1.3e-05	0.00246	0.4	0.2	Body mass index;	chr9:33936736	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs72727341	ENSG00000260947.1	RP11-384P7.7	4.41	1.3e-05	0.00246	0.4	0.2	Body mass index;	chr9:33936878	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs72727342	ENSG00000260947.1	RP11-384P7.7	4.41	1.3e-05	0.00246	0.4	0.2	Body mass index;	chr9:33938084	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs117733169	ENSG00000260947.1	RP11-384P7.7	4.41	1.3e-05	0.00246	0.4	0.2	Body mass index;	chr9:33938101	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs72727344	ENSG00000260947.1	RP11-384P7.7	4.41	1.3e-05	0.00246	0.4	0.2	Body mass index;	chr9:33939122	chr9:33697459~33700986:+
LUAD	cis	rs2243480	1	rs781156	ENSG00000232559.3	GS1-124K5.12	4.41	1.3e-05	0.00246	0.34	0.2	Diabetic kidney disease;	chr7:66014154	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs781149	ENSG00000232559.3	GS1-124K5.12	4.41	1.3e-05	0.00246	0.34	0.2	Diabetic kidney disease;	chr7:66016297	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs451396	ENSG00000232559.3	GS1-124K5.12	4.41	1.3e-05	0.00246	0.34	0.2	Diabetic kidney disease;	chr7:66019087	chr7:66554588~66576923:-
LUAD	cis	rs2243480	0.901	rs58207111	ENSG00000232559.3	GS1-124K5.12	4.41	1.3e-05	0.00246	0.34	0.2	Diabetic kidney disease;	chr7:66021736	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs1167613	ENSG00000232559.3	GS1-124K5.12	4.41	1.3e-05	0.00246	0.34	0.2	Diabetic kidney disease;	chr7:66022452	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs1715235	ENSG00000232559.3	GS1-124K5.12	4.41	1.3e-05	0.00246	0.34	0.2	Diabetic kidney disease;	chr7:66023407	chr7:66554588~66576923:-
LUAD	cis	rs9545047	0.604	rs1748761	ENSG00000227354.5	RBM26-AS1	4.41	1.3e-05	0.00246	0.21	0.2	Schizophrenia;	chr13:79407491	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs2763809	ENSG00000227354.5	RBM26-AS1	4.41	1.3e-05	0.00246	0.21	0.2	Schizophrenia;	chr13:79407544	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs1748763	ENSG00000227354.5	RBM26-AS1	4.41	1.3e-05	0.00246	0.21	0.2	Schizophrenia;	chr13:79407965	chr13:79406309~79424328:+
LUAD	cis	rs10463554	0.927	rs34795	ENSG00000250682.4	LINC00491	4.41	1.3e-05	0.00246	0.24	0.2	Parkinson's disease;	chr5:103088716	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.927	rs34796	ENSG00000250682.4	LINC00491	4.41	1.3e-05	0.00246	0.24	0.2	Parkinson's disease;	chr5:103088725	chr5:102609156~102671559:-
LUAD	cis	rs1009115	0.551	rs10242578	ENSG00000272328.1	RP4-594A5.1	-4.41	1.3e-05	0.00246	-0.25	-0.2	Post bronchodilator FEV1;	chr7:8369641	chr7:8303741~8341343:+
LUAD	cis	rs8062405	0.698	rs7188071	ENSG00000261419.1	RP11-57A19.4	4.41	1.3e-05	0.00247	0.22	0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28906323	chr16:28659696~28740781:-
LUAD	cis	rs2562456	0.754	rs58338799	ENSG00000268081.1	RP11-678G14.2	4.41	1.3e-05	0.00247	0.31	0.2	Pain;	chr19:21339009	chr19:21554640~21569237:-
LUAD	cis	rs8030379	1	rs11259933	ENSG00000230373.7	GOLGA6L5P	-4.41	1.3e-05	0.00247	-0.18	-0.2	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83911404	chr15:84507885~84516814:-
LUAD	cis	rs6558530	0.692	rs7818406	ENSG00000253982.1	CTD-2336O2.1	4.41	1.3e-05	0.00247	0.26	0.2	Systolic blood pressure;	chr8:1753084	chr8:1761990~1764502:-
LUAD	cis	rs7086627	0.515	rs7078254	ENSG00000226659.1	RP11-137H2.4	-4.41	1.3e-05	0.00247	-0.26	-0.2	Post bronchodilator FEV1;	chr10:80452437	chr10:80529597~80535942:-
LUAD	cis	rs7202877	0.706	rs40217	ENSG00000280152.1	RP11-331F4.5	-4.41	1.3e-05	0.00247	-0.24	-0.2	Type 1 diabetes;Type 2 diabetes;	chr16:75446168	chr16:75245994~75250077:-
LUAD	cis	rs6570726	0.967	rs9497316	ENSG00000235652.6	RP11-545I5.3	-4.41	1.3e-05	0.00247	-0.2	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145471251	chr6:145799409~145886585:+
LUAD	cis	rs4873772	0.703	rs2130413	ENSG00000253330.1	RP11-697N18.3	-4.41	1.3e-05	0.00247	-0.22	-0.2	Lobe attachment (rater-scored or self-reported);	chr8:47569536	chr8:47511034~47512141:-
LUAD	cis	rs6714710	0.603	rs55776387	ENSG00000230606.9	AC159540.1	-4.41	1.3e-05	0.00247	-0.21	-0.2	Posterior cortical atrophy and Alzheimer's disease;	chr2:97788571	chr2:97416165~97433527:-
LUAD	cis	rs8180040	0.8	rs11920354	ENSG00000271161.1	BOLA2P2	-4.41	1.3e-05	0.00247	-0.19	-0.2	Colorectal cancer;	chr3:47220756	chr3:47499841~47500407:+
LUAD	cis	rs651907	0.535	rs34263427	ENSG00000244119.1	PDCL3P4	4.41	1.3e-05	0.00247	0.2	0.2	Colorectal cancer;	chr3:101788961	chr3:101712472~101713191:+
LUAD	cis	rs865483	0.764	rs113593735	ENSG00000276054.1	RP11-378E13.3	-4.41	1.3e-05	0.00247	-0.24	-0.2	Monocyte count;	chr17:37398591	chr17:37386886~37387926:+
LUAD	cis	rs2522056	0.935	rs757104	ENSG00000233006.5	AC034220.3	-4.41	1.3e-05	0.00247	-0.22	-0.2	Fibrinogen;Lymphocyte counts;	chr5:132459537	chr5:132311285~132369916:-
LUAD	cis	rs34421088	0.576	rs2736369	ENSG00000255046.1	RP11-297N6.4	4.41	1.3e-05	0.00247	0.25	0.2	Neuroticism;	chr8:11243889	chr8:11797928~11802568:-
LUAD	cis	rs4819052	0.788	rs13049700	ENSG00000237664.1	LINC00316	-4.41	1.3e-05	0.00247	-0.24	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45281994	chr21:45338590~45341990:-
LUAD	cis	rs453301	0.686	rs28482034	ENSG00000253981.4	ALG1L13P	-4.41	1.3e-05	0.00247	-0.24	-0.2	Joint mobility (Beighton score);	chr8:9012154	chr8:8236003~8244667:-
LUAD	cis	rs9309473	0.583	rs6546822	ENSG00000163016.8	ALMS1P	4.4	1.31e-05	0.00247	0.22	0.2	Metabolite levels;	chr2:73347970	chr2:73644919~73685576:+
LUAD	cis	rs2976388	0.578	rs3736010	ENSG00000253741.1	CTD-2292P10.4	4.4	1.31e-05	0.00247	0.24	0.2	Urinary tract infection frequency;	chr8:142736085	chr8:142702252~142726973:-
LUAD	cis	rs763121	0.889	rs1043402	ENSG00000225450.1	RP3-508I15.14	-4.4	1.31e-05	0.00247	-0.2	-0.2	Menopause (age at onset);	chr22:38483683	chr22:38739003~38749041:+
LUAD	cis	rs62025270	0.632	rs7181796	ENSG00000259416.2	RP11-158M2.5	-4.4	1.31e-05	0.00247	-0.27	-0.2	Idiopathic pulmonary fibrosis;	chr15:85689778	chr15:85754941~85756237:-
LUAD	cis	rs8072100	0.576	rs7216112	ENSG00000228782.6	CTD-2026D20.3	-4.4	1.31e-05	0.00247	-0.22	-0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47328979	chr17:47450568~47492492:-
LUAD	cis	rs71636778	0.509	rs6659176	ENSG00000260063.1	RP5-968P14.2	-4.4	1.31e-05	0.00247	-0.37	-0.2	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26913429	chr1:26692132~26694131:-
LUAD	cis	rs526231	0.543	rs34804	ENSG00000250682.4	LINC00491	4.4	1.31e-05	0.00247	0.26	0.2	Primary biliary cholangitis;	chr5:103092535	chr5:102609156~102671559:-
LUAD	cis	rs2348418	0.864	rs11049716	ENSG00000244712.1	RP11-874G11.1	4.4	1.31e-05	0.00247	0.23	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28564713	chr12:28564678~28565141:-
LUAD	cis	rs2348418	0.864	rs7136843	ENSG00000244712.1	RP11-874G11.1	4.4	1.31e-05	0.00247	0.23	0.2	Lung function (FEV1);Lung function (FVC);	chr12:28564875	chr12:28564678~28565141:-
LUAD	cis	rs9322193	0.504	rs7771014	ENSG00000268592.3	RAET1E-AS1	4.4	1.31e-05	0.00248	0.24	0.2	Lung cancer;	chr6:149884310	chr6:149863494~149919507:+
LUAD	cis	rs1729951	0.575	rs361244	ENSG00000239213.4	NCK1-AS1	4.4	1.31e-05	0.00248	0.21	0.2	Neuroticism;	chr3:136978664	chr3:136841726~136862054:-
LUAD	cis	rs7918232	0.574	rs10458708	ENSG00000262412.1	RP11-85G18.6	4.4	1.31e-05	0.00248	0.25	0.2	Breast cancer;	chr10:27166676	chr10:27243130~27250804:+
LUAD	cis	rs1805008	0.561	rs8046635	ENSG00000261172.1	RP11-356C4.5	-4.4	1.31e-05	0.00248	-0.3	-0.2	Skin colour saturation;	chr16:90057085	chr16:90110574~90168225:-
LUAD	cis	rs454217	0.846	rs428699	ENSG00000277851.1	RP11-756G20.1	4.4	1.31e-05	0.00248	0.2	0.2	Smoking quantity;	chr12:92334822	chr12:92247756~92363832:-
LUAD	cis	rs7324557	0.717	rs9507164	ENSG00000205861.10	C1QTNF9B-AS1	-4.4	1.31e-05	0.00248	-0.26	-0.2	Visceral adipose tissue adjusted for BMI;	chr13:23806400	chr13:23888889~23897263:+
LUAD	cis	rs4908768	0.501	rs11121212	ENSG00000270282.1	RP5-1115A15.2	4.4	1.31e-05	0.00248	0.21	0.2	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8665934	chr1:8512653~8513021:+
LUAD	cis	rs11009175	0.929	rs11009198	ENSG00000273038.2	RP11-479G22.8	-4.4	1.31e-05	0.00248	-0.32	-0.2	Depression (quantitative trait);	chr10:33053379	chr10:32887255~32889311:-
LUAD	cis	rs11009175	0.929	rs11009200	ENSG00000273038.2	RP11-479G22.8	-4.4	1.31e-05	0.00248	-0.32	-0.2	Depression (quantitative trait);	chr10:33053456	chr10:32887255~32889311:-
LUAD	cis	rs4489787	0.892	rs4448729	ENSG00000240399.1	RP1-228P16.1	-4.4	1.31e-05	0.00248	-0.3	-0.2	Prostate cancer (SNP x SNP interaction);	chr12:48428545	chr12:48054813~48055591:-
LUAD	cis	rs7191700	0.674	rs12597893	ENSG00000262703.1	RP11-485G7.6	4.4	1.31e-05	0.00248	0.18	0.2	Multiple sclerosis;	chr16:11332474	chr16:11348143~11349321:-
LUAD	cis	rs7208859	0.615	rs216462	ENSG00000266490.1	CTD-2349P21.9	-4.4	1.31e-05	0.00248	-0.3	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30568879	chr17:30792372~30792833:+
LUAD	cis	rs2446066	0.872	rs10876449	ENSG00000257379.1	RP11-793H13.8	4.4	1.31e-05	0.00248	0.32	0.2	Red blood cell count;	chr12:53385991	chr12:53441741~53467528:+
LUAD	cis	rs2446066	0.872	rs11170525	ENSG00000257379.1	RP11-793H13.8	4.4	1.31e-05	0.00248	0.32	0.2	Red blood cell count;	chr12:53388844	chr12:53441741~53467528:+
LUAD	cis	rs2446066	0.818	rs7315782	ENSG00000257379.1	RP11-793H13.8	4.4	1.31e-05	0.00248	0.32	0.2	Red blood cell count;	chr12:53391129	chr12:53441741~53467528:+
LUAD	cis	rs2554380	0.628	rs11853983	ENSG00000230373.7	GOLGA6L5P	4.4	1.31e-05	0.00248	0.2	0.2	Height;	chr15:83794058	chr15:84507885~84516814:-
LUAD	cis	rs801193	1	rs2707845	ENSG00000224316.1	RP11-479O9.2	4.4	1.31e-05	0.00248	0.2	0.2	Aortic root size;	chr7:66733811	chr7:65773620~65802067:+
LUAD	cis	rs2810114	0.916	rs2810099	ENSG00000269927.1	RP6-91H8.3	-4.4	1.31e-05	0.00248	-0.26	-0.2	Alcohol dependence;	chr14:70965704	chr14:71141125~71143253:-
LUAD	cis	rs72615157	0.628	rs7801070	ENSG00000078319.8	PMS2P1	-4.4	1.31e-05	0.00249	-0.23	-0.2	Lung function (FEV1/FVC);	chr7:100249524	chr7:100320992~100341908:-
LUAD	cis	rs1979679	0.918	rs7977429	ENSG00000278733.1	RP11-425D17.1	4.4	1.31e-05	0.00249	0.25	0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28370376	chr12:28185625~28186190:-
LUAD	cis	rs4819052	0.851	rs9974891	ENSG00000237664.1	LINC00316	-4.4	1.31e-05	0.00249	-0.23	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260852	chr21:45338590~45341990:-
LUAD	cis	rs16846053	0.642	rs13420505	ENSG00000227403.1	AC009299.3	4.4	1.31e-05	0.00249	0.32	0.2	Blood osmolality (transformed sodium);	chr2:161776433	chr2:161244739~161249050:+
LUAD	cis	rs12200782	0.53	rs6929908	ENSG00000241549.7	GUSBP2	4.4	1.31e-05	0.00249	0.27	0.2	Small cell lung carcinoma;	chr6:26555061	chr6:26871484~26956554:-
LUAD	cis	rs3096299	0.933	rs2965824	ENSG00000182376.2	RP5-1142A6.8	4.4	1.32e-05	0.00249	0.2	0.2	Multiple myeloma (IgH translocation);	chr16:89388898	chr16:88742767~88745748:+
LUAD	cis	rs911119	0.955	rs7270413	ENSG00000270001.1	RP11-218C14.8	-4.4	1.32e-05	0.00249	-0.29	-0.2	Chronic kidney disease;	chr20:23613184	chr20:23631826~23632316:-
LUAD	cis	rs2911132	0.564	rs28580505	ENSG00000248734.2	CTD-2260A17.1	4.4	1.32e-05	0.00249	0.21	0.2	Urate levels (BMI interaction);	chr5:96765516	chr5:96784777~96785999:+
LUAD	cis	rs957448	1	rs28817653	ENSG00000253175.1	RP11-267M23.6	4.4	1.32e-05	0.00249	0.24	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94557822	chr8:94565036~94565715:+
LUAD	cis	rs7590268	0.666	rs12473294	ENSG00000279873.2	LINC01126	4.4	1.32e-05	0.00249	0.19	0.2	Orofacial clefts;	chr2:43410335	chr2:43227210~43228855:+
LUAD	cis	rs62355900	0.627	rs62355941	ENSG00000271828.1	CTD-2310F14.1	4.4	1.32e-05	0.00249	0.38	0.2	Endometriosis;	chr5:56807871	chr5:56927874~56929573:+
LUAD	cis	rs2243480	1	rs431318	ENSG00000232559.3	GS1-124K5.12	4.4	1.32e-05	0.00249	0.34	0.2	Diabetic kidney disease;	chr7:66046610	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs313803	ENSG00000232559.3	GS1-124K5.12	4.4	1.32e-05	0.00249	0.34	0.2	Diabetic kidney disease;	chr7:66049744	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs313802	ENSG00000232559.3	GS1-124K5.12	4.4	1.32e-05	0.00249	0.34	0.2	Diabetic kidney disease;	chr7:66051386	chr7:66554588~66576923:-
LUAD	cis	rs2243480	0.803	rs403089	ENSG00000232559.3	GS1-124K5.12	4.4	1.32e-05	0.00249	0.34	0.2	Diabetic kidney disease;	chr7:66052736	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs458291	ENSG00000232559.3	GS1-124K5.12	4.4	1.32e-05	0.00249	0.34	0.2	Diabetic kidney disease;	chr7:66055492	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs466983	ENSG00000232559.3	GS1-124K5.12	4.4	1.32e-05	0.00249	0.34	0.2	Diabetic kidney disease;	chr7:66055509	chr7:66554588~66576923:-
LUAD	cis	rs6687758	1	rs12135286	ENSG00000227925.1	RP11-191N8.2	4.4	1.32e-05	0.00249	0.28	0.2	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222045419	chr1:221827666~221840666:-
LUAD	cis	rs2227564	0.62	rs11000785	ENSG00000271816.1	BMS1P4	4.4	1.32e-05	0.00249	0.18	0.2	Crohn's disease;Inflammatory bowel disease;	chr10:73816205	chr10:73699151~73730487:-
LUAD	cis	rs2115630	0.967	rs10438428	ENSG00000225151.9	GOLGA2P7	4.4	1.32e-05	0.00249	0.22	0.2	P wave terminal force;	chr15:84787514	chr15:84199311~84230136:-
LUAD	cis	rs2243480	1	rs1723267	ENSG00000232559.3	GS1-124K5.12	4.4	1.32e-05	0.00249	0.34	0.2	Diabetic kidney disease;	chr7:66008327	chr7:66554588~66576923:-
LUAD	cis	rs13113518	0.783	rs2171618	ENSG00000223305.1	RN7SKP30	4.4	1.32e-05	0.00249	0.23	0.2	Height;	chr4:55564241	chr4:55540502~55540835:-
LUAD	cis	rs8180040	0.62	rs2305635	ENSG00000271161.1	BOLA2P2	-4.4	1.32e-05	0.00249	-0.19	-0.2	Colorectal cancer;	chr3:47002132	chr3:47499841~47500407:+
LUAD	cis	rs1551277	0.916	rs965143	ENSG00000146666.5	LINC00525	-4.4	1.32e-05	0.0025	-0.22	-0.2	Anxiety disorder;	chr7:47797519	chr7:47761476~47766772:+
LUAD	cis	rs1551277	0.916	rs965144	ENSG00000146666.5	LINC00525	-4.4	1.32e-05	0.0025	-0.22	-0.2	Anxiety disorder;	chr7:47797526	chr7:47761476~47766772:+
LUAD	cis	rs6714710	0.603	rs11690687	ENSG00000230606.9	AC159540.1	-4.4	1.32e-05	0.0025	-0.21	-0.2	Posterior cortical atrophy and Alzheimer's disease;	chr2:97845358	chr2:97416165~97433527:-
LUAD	cis	rs453301	0.652	rs2043129	ENSG00000253981.4	ALG1L13P	4.4	1.32e-05	0.0025	0.22	0.2	Joint mobility (Beighton score);	chr8:8967994	chr8:8236003~8244667:-
LUAD	cis	rs2790457	0.76	rs1265834	ENSG00000254635.4	WAC-AS1	4.4	1.32e-05	0.0025	0.21	0.2	Multiple myeloma;	chr10:28652932	chr10:28522652~28532743:-
LUAD	cis	rs6687821	0.684	rs10873802	ENSG00000267734.1	RP4-604K5.3	-4.4	1.32e-05	0.0025	-0.23	-0.2	Yeast infection;	chr1:86820751	chr1:86932199~86934891:-
LUAD	cis	rs9341808	0.718	rs2322631	ENSG00000272129.1	RP11-250B2.6	4.4	1.32e-05	0.0025	0.24	0.2	Sitting height ratio;	chr6:80134239	chr6:80355424~80356859:+
LUAD	cis	rs6496044	0.547	rs7173125	ENSG00000259416.2	RP11-158M2.5	-4.4	1.32e-05	0.0025	-0.21	-0.2	Interstitial lung disease;	chr15:85512214	chr15:85754941~85756237:-
LUAD	cis	rs1729951	0.546	rs361246	ENSG00000239213.4	NCK1-AS1	4.4	1.32e-05	0.0025	0.21	0.2	Neuroticism;	chr3:136976825	chr3:136841726~136862054:-
LUAD	cis	rs4604732	1	rs4604732	ENSG00000227135.1	GCSAML-AS1	4.4	1.32e-05	0.0025	0.28	0.2	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247460570	chr1:247524679~247526752:-
LUAD	cis	rs7189233	0.531	rs6499617	ENSG00000279344.1	RP11-44F14.7	4.4	1.32e-05	0.0025	0.16	0.2	Intelligence (multi-trait analysis);	chr16:53433810	chr16:53478957~53481550:-
LUAD	cis	rs151227923	1	rs151227923	ENSG00000273117.1	AC144652.1	4.4	1.32e-05	0.0025	0.21	0.2	Stem cell growth factor beta levels;	chr7:155314854	chr7:155295918~155297541:-
LUAD	cis	rs140365914	1	rs140365914	ENSG00000273117.1	AC144652.1	4.4	1.32e-05	0.0025	0.21	0.2	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr7:155314860	chr7:155295918~155297541:-
LUAD	cis	rs9341808	0.718	rs2143887	ENSG00000260645.1	RP11-250B2.5	4.4	1.32e-05	0.0025	0.19	0.2	Sitting height ratio;	chr6:80207570	chr6:80466958~80469080:+
LUAD	cis	rs4925386	1	rs1889201	ENSG00000273619.1	RP5-908M14.9	4.4	1.32e-05	0.0025	0.18	0.2	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62348019	chr20:62386303~62386970:-
LUAD	cis	rs7819412	0.775	rs4841489	ENSG00000255046.1	RP11-297N6.4	4.4	1.32e-05	0.0025	0.24	0.2	Triglycerides;	chr8:11079301	chr8:11797928~11802568:-
LUAD	cis	rs7819412	0.775	rs4841490	ENSG00000255046.1	RP11-297N6.4	4.4	1.32e-05	0.0025	0.24	0.2	Triglycerides;	chr8:11079381	chr8:11797928~11802568:-
LUAD	cis	rs957448	1	rs12680965	ENSG00000254315.1	RP11-267M23.3	4.4	1.32e-05	0.0025	0.25	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94554069	chr8:94533628~94534391:+
LUAD	cis	rs4819052	0.634	rs8128636	ENSG00000223768.1	LINC00205	-4.4	1.32e-05	0.0025	-0.23	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270718	chr21:45293285~45297354:+
LUAD	cis	rs7172677	1	rs7172205	ENSG00000260269.4	CTD-2323K18.1	-4.4	1.32e-05	0.0025	-0.26	-0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75131994	chr15:75527150~75601205:-
LUAD	cis	rs8030379	0.967	rs10520573	ENSG00000230373.7	GOLGA6L5P	-4.4	1.32e-05	0.0025	-0.18	-0.2	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83922823	chr15:84507885~84516814:-
LUAD	cis	rs2439831	0.717	rs10518820	ENSG00000249839.1	AC011330.5	-4.4	1.32e-05	0.0025	-0.41	-0.2	Lung cancer in ever smokers;	chr15:43596778	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.666	rs10518812	ENSG00000205771.5	CATSPER2P1	4.4	1.33e-05	0.00251	0.29	0.2	Lung cancer;	chr15:43360739	chr15:43726918~43747094:-
LUAD	cis	rs911555	0.723	rs56227024	ENSG00000244691.1	RPL10AP1	4.4	1.33e-05	0.00251	0.26	0.2	Intelligence (multi-trait analysis);	chr14:103395369	chr14:103412119~103412761:-
LUAD	cis	rs16944613	0.588	rs8042497	ENSG00000259212.1	CTD-3065B20.2	4.4	1.33e-05	0.00251	0.33	0.2	Colorectal cancer;	chr15:90567099	chr15:90595840~90596447:-
LUAD	cis	rs4819052	0.632	rs4819050	ENSG00000223768.1	LINC00205	-4.4	1.33e-05	0.00251	-0.23	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273028	chr21:45293285~45297354:+
LUAD	cis	rs11677416	0.601	rs12469600	ENSG00000236307.2	EEF1E1P1	-4.4	1.33e-05	0.00251	-0.26	-0.2	Response to antipsychotic treatment in schizophrenia (working memory);	chr2:112814780	chr2:111887914~111888741:+
LUAD	cis	rs4713118	0.614	rs9468209	ENSG00000216901.1	AL022393.7	4.4	1.33e-05	0.00251	0.22	0.2	Parkinson's disease;	chr6:27726642	chr6:28176188~28176674:+
LUAD	cis	rs7302981	0.809	rs66768395	ENSG00000272368.2	RP4-605O3.4	4.4	1.33e-05	0.00251	0.23	0.2	Systolic blood pressure;	chr12:50174482	chr12:50112197~50165618:+
LUAD	cis	rs7302981	0.809	rs1044370	ENSG00000272368.2	RP4-605O3.4	4.4	1.33e-05	0.00251	0.23	0.2	Systolic blood pressure;	chr12:50176827	chr12:50112197~50165618:+
LUAD	cis	rs2032366	0.63	rs1377172	ENSG00000266920.1	ACTBP9	4.4	1.33e-05	0.00251	0.21	0.2	Obesity-related traits;	chr18:61629148	chr18:62442028~62443126:+
LUAD	cis	rs2032366	0.63	rs12457579	ENSG00000266920.1	ACTBP9	4.4	1.33e-05	0.00251	0.21	0.2	Obesity-related traits;	chr18:61629575	chr18:62442028~62443126:+
LUAD	cis	rs875971	0.66	rs1860470	ENSG00000236529.1	RP13-254B10.1	-4.4	1.33e-05	0.00251	-0.2	-0.2	Aortic root size;	chr7:66638707	chr7:65840212~65840596:+
LUAD	cis	rs13113518	0.783	rs1586555	ENSG00000223305.1	RN7SKP30	4.4	1.33e-05	0.00251	0.23	0.2	Height;	chr4:55587104	chr4:55540502~55540835:-
LUAD	cis	rs12478296	0.901	rs7603560	ENSG00000261186.2	RP11-341N2.1	-4.4	1.33e-05	0.00251	-0.36	-0.2	Obesity-related traits;	chr2:242101105	chr2:242087351~242088457:-
LUAD	cis	rs11673344	0.582	rs114437741	ENSG00000226686.6	LINC01535	4.4	1.33e-05	0.00251	0.25	0.2	Obesity-related traits;	chr19:36955379	chr19:37251912~37265535:+
LUAD	cis	rs6088590	1	rs11698977	ENSG00000276073.1	RP5-1125A11.7	-4.4	1.33e-05	0.00251	-0.2	-0.2	Coronary artery disease;	chr20:34861888	chr20:33985617~33988989:-
LUAD	cis	rs7172677	1	rs2029519	ENSG00000260269.4	CTD-2323K18.1	-4.4	1.33e-05	0.00251	-0.26	-0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75123621	chr15:75527150~75601205:-
LUAD	cis	rs1355223	0.837	rs11600402	ENSG00000271369.1	RP11-350D17.3	-4.4	1.33e-05	0.00251	-0.23	-0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34670204	chr11:34709600~34710161:+
LUAD	cis	rs7208859	0.623	rs7208441	ENSG00000280069.1	CTD-2349P21.3	-4.4	1.33e-05	0.00251	-0.27	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30738182~30740275:+
LUAD	cis	rs4879677	1	rs10812642	ENSG00000215441.3	CTAGE12P	-4.4	1.33e-05	0.00251	-0.24	-0.2	Gut microbiome composition (summer and winter);	chr9:27684906	chr9:27608382~27610745:-
LUAD	cis	rs4879677	0.881	rs10968058	ENSG00000215441.3	CTAGE12P	-4.4	1.33e-05	0.00251	-0.24	-0.2	Gut microbiome composition (summer and winter);	chr9:27685336	chr9:27608382~27610745:-
LUAD	cis	rs2735413	0.563	rs2072663	ENSG00000276007.1	RP11-358L22.3	4.4	1.33e-05	0.00251	0.27	0.2	Systolic blood pressure (alcohol consumption interaction);	chr16:78030836	chr16:78123243~78124332:+
LUAD	cis	rs1005277	0.541	rs2263163	ENSG00000263064.2	RP11-291L22.7	4.4	1.33e-05	0.00251	0.21	0.2	Extrinsic epigenetic age acceleration;	chr10:38100959	chr10:38448689~38448949:+
LUAD	cis	rs2834288	0.5	rs881231	ENSG00000237945.6	LINC00649	4.4	1.33e-05	0.00251	0.24	0.2	Gut microbiota (bacterial taxa);	chr21:33950526	chr21:33915534~33977691:+
LUAD	cis	rs2823962	0.759	rs8133801	ENSG00000270093.1	AP000473.8	-4.4	1.33e-05	0.00251	-0.21	-0.2	Amyotrophic lateral sclerosis;	chr21:16647963	chr21:16643529~16645065:+
LUAD	cis	rs13113518	0.783	rs6843722	ENSG00000272969.1	RP11-528I4.2	4.4	1.33e-05	0.00251	0.21	0.2	Height;	chr4:55465165	chr4:55547112~55547889:+
LUAD	cis	rs12439619	0.921	rs4778672	ENSG00000276710.3	CSPG4P8	4.4	1.33e-05	0.00251	0.2	0.2	Intelligence (multi-trait analysis);	chr15:82245013	chr15:82459472~82477258:+
LUAD	cis	rs7208859	0.614	rs4794874	ENSG00000266490.1	CTD-2349P21.9	-4.4	1.33e-05	0.00251	-0.27	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30514300	chr17:30792372~30792833:+
LUAD	cis	rs6951245	0.882	rs10252404	ENSG00000199023.2	MIR339	-4.4	1.33e-05	0.00251	-0.35	-0.2	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1169971	chr7:1022935~1023045:-
LUAD	cis	rs4268898	0.722	rs35520052	ENSG00000223754.1	AC008073.9	-4.4	1.33e-05	0.00251	-0.23	-0.2	Asthma;	chr2:24192408	chr2:24199839~24201698:-
LUAD	cis	rs750134	0.786	rs56067627	ENSG00000257221.1	RP11-689B22.2	-4.4	1.33e-05	0.00252	-0.31	-0.2	Low high density lipoprotein cholesterol levels;	chr12:108639503	chr12:108628687~108641318:+
LUAD	cis	rs6012564	1	rs3092720	ENSG00000230758.1	SNAP23P	-4.4	1.33e-05	0.00252	-0.21	-0.2	Anger;	chr20:49023929	chr20:49038357~49038602:-
LUAD	cis	rs6012564	1	rs755587	ENSG00000230758.1	SNAP23P	4.4	1.33e-05	0.00252	0.21	0.2	Anger;	chr20:49104420	chr20:49038357~49038602:-
LUAD	cis	rs17772222	0.917	rs12431548	ENSG00000258789.1	RP11-507K2.3	-4.4	1.33e-05	0.00252	-0.27	-0.2	Coronary artery calcification;	chr14:88635826	chr14:88551597~88552493:+
LUAD	cis	rs8018967	1	rs8018967	ENSG00000258695.2	RP3-414A15.2	-4.4	1.33e-05	0.00252	-0.22	-0.2	Blood metabolite ratios;	chr14:73510230	chr14:73522878~73530610:+
LUAD	cis	rs11874381	0.965	rs34798017	ENSG00000266696.1	RP11-30L3.2	-4.4	1.33e-05	0.00252	-0.22	-0.2	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);	chr18:49684684	chr18:49205912~49208781:+
LUAD	cis	rs6088580	0.634	rs4277599	ENSG00000276073.1	RP5-1125A11.7	4.4	1.33e-05	0.00252	0.19	0.2	Glomerular filtration rate (creatinine);	chr20:34421099	chr20:33985617~33988989:-
LUAD	cis	rs7302981	0.667	rs1362984	ENSG00000272368.2	RP4-605O3.4	-4.4	1.33e-05	0.00252	-0.22	-0.2	Systolic blood pressure;	chr12:50206201	chr12:50112197~50165618:+
LUAD	cis	rs11089937	0.667	rs9622981	ENSG00000211638.2	IGLV8-61	-4.4	1.33e-05	0.00252	-0.24	-0.2	Periodontitis (PAL4Q3);	chr22:22150100	chr22:22098700~22099212:+
LUAD	cis	rs780096	0.546	rs12473776	ENSG00000234072.1	AC074117.10	-4.4	1.33e-05	0.00252	-0.15	-0.2	Total body bone mineral density;	chr2:27413607	chr2:27356246~27367622:+
LUAD	cis	rs780096	0.506	rs1728922	ENSG00000234072.1	AC074117.10	-4.4	1.33e-05	0.00252	-0.15	-0.2	Total body bone mineral density;	chr2:27421597	chr2:27356246~27367622:+
LUAD	cis	rs2243480	1	rs73142162	ENSG00000229886.1	RP5-1132H15.3	4.4	1.33e-05	0.00252	0.35	0.2	Diabetic kidney disease;	chr7:65909309	chr7:66025126~66031544:-
LUAD	cis	rs9341808	0.739	rs4706831	ENSG00000260645.1	RP11-250B2.5	4.4	1.33e-05	0.00252	0.18	0.2	Sitting height ratio;	chr6:80297982	chr6:80466958~80469080:+
LUAD	cis	rs2976388	0.578	rs34956412	ENSG00000253741.1	CTD-2292P10.4	4.4	1.33e-05	0.00252	0.23	0.2	Urinary tract infection frequency;	chr8:142740610	chr8:142702252~142726973:-
LUAD	cis	rs2976388	0.556	rs4736321	ENSG00000253741.1	CTD-2292P10.4	4.4	1.33e-05	0.00252	0.23	0.2	Urinary tract infection frequency;	chr8:142740776	chr8:142702252~142726973:-
LUAD	cis	rs9487094	0.744	rs11964533	ENSG00000260273.1	RP11-425D10.10	4.4	1.33e-05	0.00252	0.28	0.2	Height;	chr6:109737797	chr6:109382795~109383666:+
LUAD	cis	rs11018904	0.636	rs61903695	ENSG00000280367.1	RP11-121L10.2	4.4	1.33e-05	0.00252	0.24	0.2	Intelligence (multi-trait analysis);	chr11:90189249	chr11:90223153~90226538:+
LUAD	cis	rs12073359	0.955	rs2319280	ENSG00000223945.2	RP11-458I7.1	4.4	1.33e-05	0.00252	0.29	0.2	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150042041	chr1:150053864~150055034:+
LUAD	cis	rs7746199	0.673	rs72847313	ENSG00000219392.1	RP1-265C24.5	-4.4	1.33e-05	0.00252	-0.41	-0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762303	chr6:28115628~28116551:+
LUAD	cis	rs7746199	0.611	rs17750747	ENSG00000219392.1	RP1-265C24.5	-4.4	1.33e-05	0.00252	-0.41	-0.2	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762555	chr6:28115628~28116551:+
LUAD	cis	rs4667682	0.529	rs62181339	ENSG00000234061.1	AC007969.4	-4.4	1.34e-05	0.00252	-0.39	-0.2	Hippocampal atrophy;Body mass index;	chr2:171296235	chr2:171492905~171493095:+
LUAD	cis	rs4667682	0.529	rs62181340	ENSG00000234061.1	AC007969.4	-4.4	1.34e-05	0.00252	-0.39	-0.2	Hippocampal atrophy;Body mass index;	chr2:171306484	chr2:171492905~171493095:+
LUAD	cis	rs4667682	0.646	rs2356706	ENSG00000234061.1	AC007969.4	-4.4	1.34e-05	0.00252	-0.39	-0.2	Hippocampal atrophy;Body mass index;	chr2:171307024	chr2:171492905~171493095:+
LUAD	cis	rs4667682	0.529	rs77060433	ENSG00000234061.1	AC007969.4	-4.4	1.34e-05	0.00252	-0.39	-0.2	Hippocampal atrophy;Body mass index;	chr2:171309290	chr2:171492905~171493095:+
LUAD	cis	rs4683346	1	rs4683346	ENSG00000173811.9	CCDC13-AS1	-4.4	1.34e-05	0.00252	-0.21	-0.2	Granulocyte percentage of myeloid white cells;	chr3:42851469	chr3:42732575~42746768:+
LUAD	cis	rs2018683	0.707	rs1874974	ENSG00000228421.2	AC005013.5	4.4	1.34e-05	0.00252	0.22	0.2	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28928030	chr7:28957667~28959345:+
LUAD	cis	rs5758511	0.68	rs739146	ENSG00000227370.1	RP4-669P10.19	4.4	1.34e-05	0.00252	0.22	0.2	Birth weight;	chr22:42264408	chr22:42132543~42132998:+
LUAD	cis	rs9907295	0.688	rs2526327	ENSG00000270977.1	AC015849.16	4.4	1.34e-05	0.00252	0.28	0.2	Fibroblast growth factor basic levels;	chr17:35929902	chr17:35893707~35911023:-
LUAD	cis	rs853679	0.76	rs9393910	ENSG00000204709.4	LINC01556	4.4	1.34e-05	0.00252	0.28	0.2	Depression;	chr6:28240414	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.76	rs9368563	ENSG00000204709.4	LINC01556	4.4	1.34e-05	0.00252	0.28	0.2	Depression;	chr6:28240780	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.76	rs9295768	ENSG00000204709.4	LINC01556	4.4	1.34e-05	0.00252	0.28	0.2	Depression;	chr6:28241324	chr6:28943877~28944537:+
LUAD	cis	rs853679	0.699	rs9468318	ENSG00000204709.4	LINC01556	4.4	1.34e-05	0.00252	0.28	0.2	Depression;	chr6:28241753	chr6:28943877~28944537:+
LUAD	cis	rs7017914	0.503	rs2639935	ENSG00000223220.1	Y_RNA	4.4	1.34e-05	0.00252	0.23	0.2	Bone mineral density;	chr8:70954045	chr8:70780914~70781008:-
LUAD	cis	rs172166	0.694	rs1770131	ENSG00000216901.1	AL022393.7	4.4	1.34e-05	0.00252	0.24	0.2	Cardiac Troponin-T levels;	chr6:28118635	chr6:28176188~28176674:+
LUAD	cis	rs4908768	0.539	rs6666191	ENSG00000270282.1	RP5-1115A15.2	4.4	1.34e-05	0.00253	0.22	0.2	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8598383	chr1:8512653~8513021:+
LUAD	cis	rs6565180	1	rs11646130	ENSG00000273724.1	RP11-347C12.12	-4.4	1.34e-05	0.00253	-0.22	-0.2	Tonsillectomy;	chr16:30365638	chr16:30336400~30343336:+
LUAD	cis	rs860295	0.665	rs11264393	ENSG00000225855.5	RUSC1-AS1	4.4	1.34e-05	0.00253	0.14	0.2	Body mass index;	chr1:155604680	chr1:155316863~155324176:-
LUAD	cis	rs9487094	0.645	rs34533653	ENSG00000260273.1	RP11-425D10.10	4.4	1.34e-05	0.00253	0.31	0.2	Height;	chr6:109479488	chr6:109382795~109383666:+
LUAD	cis	rs8062405	0.754	rs62034323	ENSG00000251417.2	RP11-1348G14.4	-4.4	1.34e-05	0.00253	-0.2	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28802743~28817828:+
LUAD	cis	rs8062405	0.824	rs62034324	ENSG00000251417.2	RP11-1348G14.4	-4.4	1.34e-05	0.00253	-0.2	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28802743~28817828:+
LUAD	cis	rs6714710	0.603	rs2044458	ENSG00000230606.9	AC159540.1	-4.4	1.34e-05	0.00253	-0.21	-0.2	Posterior cortical atrophy and Alzheimer's disease;	chr2:97761049	chr2:97416165~97433527:-
LUAD	cis	rs6714710	0.603	rs11680321	ENSG00000230606.9	AC159540.1	-4.4	1.34e-05	0.00253	-0.21	-0.2	Posterior cortical atrophy and Alzheimer's disease;	chr2:97762804	chr2:97416165~97433527:-
LUAD	cis	rs9926296	0.744	rs164748	ENSG00000260259.1	RP11-368I7.4	4.4	1.34e-05	0.00253	0.19	0.2	Vitiligo;	chr16:89641884	chr16:89682620~89686569:-
LUAD	cis	rs1075265	0.587	rs2949811	ENSG00000272156.1	RP11-477N3.1	-4.4	1.34e-05	0.00253	-0.24	-0.2	Chronotype;Morning vs. evening chronotype;	chr2:53797028	chr2:54082554~54085066:+
LUAD	cis	rs12928939	0.637	rs8046629	ENSG00000260886.1	TAT-AS1	4.4	1.34e-05	0.00253	0.25	0.2	Post bronchodilator FEV1;	chr16:71609213	chr16:71565789~71578187:+
LUAD	cis	rs10050311	0.746	rs969734	ENSG00000251411.1	RP11-397E7.4	-4.4	1.34e-05	0.00253	-0.27	-0.2	Insulin-related traits;	chr4:86744231	chr4:86913266~86914817:-
LUAD	cis	rs6095360	0.727	rs7274612	ENSG00000222365.1	SNORD12B	4.4	1.34e-05	0.00253	0.22	0.2	Intelligence (multi-trait analysis);	chr20:49086284	chr20:49280319~49280409:+
LUAD	cis	rs10129255	0.957	rs8009073	ENSG00000211967.3	IGHV3-53	-4.4	1.34e-05	0.00253	-0.15	-0.2	Kawasaki disease;	chr14:106777278	chr14:106592676~106593347:-
LUAD	cis	rs2735413	0.564	rs8051817	ENSG00000276007.1	RP11-358L22.3	4.4	1.34e-05	0.00253	0.28	0.2	Systolic blood pressure (alcohol consumption interaction);	chr16:78087357	chr16:78123243~78124332:+
LUAD	cis	rs5758659	0.652	rs4822084	ENSG00000182057.4	OGFRP1	-4.4	1.34e-05	0.00253	-0.24	-0.2	Cognitive function;	chr22:42039864	chr22:42269753~42275196:+
LUAD	cis	rs1008375	1	rs7688682	ENSG00000249502.1	AC006160.5	4.4	1.34e-05	0.00253	0.19	0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17692171	chr4:17587467~17614571:-
LUAD	cis	rs3785309	0.519	rs72763698	ENSG00000268836.1	LA16c-OS12.2	-4.4	1.34e-05	0.00253	-0.34	-0.2	Immature fraction of reticulocytes;	chr16:214794	chr16:185748~186294:-
LUAD	cis	rs2732480	0.538	rs2468943	ENSG00000240399.1	RP1-228P16.1	-4.4	1.34e-05	0.00254	-0.2	-0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48353466	chr12:48054813~48055591:-
LUAD	cis	rs61270009	0.955	rs13172095	ENSG00000247828.6	TMEM161B-AS1	-4.4	1.34e-05	0.00254	-0.22	-0.2	Depressive symptoms;	chr5:88295130	chr5:88268895~88436685:+
LUAD	cis	rs4819052	0.851	rs10470246	ENSG00000237664.1	LINC00316	-4.4	1.34e-05	0.00254	-0.24	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239102	chr21:45338590~45341990:-
LUAD	cis	rs4819052	0.851	rs10470247	ENSG00000237664.1	LINC00316	-4.4	1.34e-05	0.00254	-0.24	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239103	chr21:45338590~45341990:-
LUAD	cis	rs4819052	0.851	rs4819043	ENSG00000237664.1	LINC00316	-4.4	1.34e-05	0.00254	-0.24	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240163	chr21:45338590~45341990:-
LUAD	cis	rs4819052	0.851	rs4819044	ENSG00000237664.1	LINC00316	-4.4	1.34e-05	0.00254	-0.24	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240203	chr21:45338590~45341990:-
LUAD	cis	rs9393777	0.841	rs34332556	ENSG00000219392.1	RP1-265C24.5	-4.4	1.34e-05	0.00254	-0.39	-0.2	Intelligence (multi-trait analysis);	chr6:27389635	chr6:28115628~28116551:+
LUAD	cis	rs9545047	0.604	rs3742117	ENSG00000227354.5	RBM26-AS1	4.4	1.35e-05	0.00254	0.21	0.2	Schizophrenia;	chr13:79342498	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.647	rs3742118	ENSG00000227354.5	RBM26-AS1	4.4	1.35e-05	0.00254	0.21	0.2	Schizophrenia;	chr13:79342838	chr13:79406309~79424328:+
LUAD	cis	rs10761482	0.566	rs10159663	ENSG00000254271.1	RP11-131N11.4	-4.4	1.35e-05	0.00254	-0.23	-0.2	Schizophrenia;	chr10:60448659	chr10:60734342~60741828:+
LUAD	cis	rs6001482	0.778	rs1012819	ENSG00000253818.1	IGLV1-41	-4.4	1.35e-05	0.00254	-0.21	-0.2	Diastolic blood pressure;	chr22:22238997	chr22:22404207~22404721:+
LUAD	cis	rs10078	1	rs10078	ENSG00000221990.4	EXOC3-AS1	4.4	1.35e-05	0.00254	0.21	0.2	Fat distribution (HIV);	chr5:437987	chr5:441498~443160:-
LUAD	cis	rs2018683	0.707	rs2057957	ENSG00000228421.2	AC005013.5	-4.4	1.35e-05	0.00254	-0.22	-0.2	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28935009	chr7:28957667~28959345:+
LUAD	cis	rs812925	0.519	rs2463099	ENSG00000271889.1	RP11-493E12.1	-4.4	1.35e-05	0.00254	-0.23	-0.2	Immature fraction of reticulocytes;	chr2:61391176	chr2:61151433~61162105:-
LUAD	cis	rs13256369	0.76	rs7816171	ENSG00000253893.2	FAM85B	-4.4	1.35e-05	0.00254	-0.27	-0.2	Obesity-related traits;	chr8:8718325	chr8:8167819~8226614:-
LUAD	cis	rs13256369	0.76	rs7839473	ENSG00000253893.2	FAM85B	-4.4	1.35e-05	0.00254	-0.27	-0.2	Obesity-related traits;	chr8:8718326	chr8:8167819~8226614:-
LUAD	cis	rs6061231	0.505	rs13037253	ENSG00000273619.1	RP5-908M14.9	-4.4	1.35e-05	0.00254	-0.21	-0.2	Colorectal cancer;	chr20:62353668	chr20:62386303~62386970:-
LUAD	cis	rs1008375	1	rs10939756	ENSG00000249502.1	AC006160.5	-4.4	1.35e-05	0.00254	-0.19	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17692244	chr4:17587467~17614571:-
LUAD	cis	rs728616	0.867	rs3088308	ENSG00000225484.5	NUTM2B-AS1	-4.4	1.35e-05	0.00254	-0.5	-0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79938112	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.867	rs17879726	ENSG00000225484.5	NUTM2B-AS1	-4.4	1.35e-05	0.00254	-0.5	-0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79938967	chr10:79663088~79826594:-
LUAD	cis	rs7078012	0.504	rs10400059	ENSG00000225484.5	NUTM2B-AS1	-4.4	1.35e-05	0.00254	-0.47	-0.2	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79920782	chr10:79663088~79826594:-
LUAD	cis	rs1799949	0.501	rs35399157	ENSG00000236383.6	LINC00854	-4.4	1.35e-05	0.00254	-0.16	-0.2	Menopause (age at onset);	chr17:43334234	chr17:43216941~43305976:-
LUAD	cis	rs1799949	0.602	rs4600503	ENSG00000236383.6	LINC00854	-4.4	1.35e-05	0.00254	-0.16	-0.2	Menopause (age at onset);	chr17:43336956	chr17:43216941~43305976:-
LUAD	cis	rs453301	0.652	rs2043129	ENSG00000173295.6	FAM86B3P	4.4	1.35e-05	0.00254	0.2	0.2	Joint mobility (Beighton score);	chr8:8967994	chr8:8228595~8244865:+
LUAD	cis	rs6570726	0.791	rs414297	ENSG00000235652.6	RP11-545I5.3	4.4	1.35e-05	0.00254	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145566420	chr6:145799409~145886585:+
LUAD	cis	rs7208859	0.673	rs8077116	ENSG00000266490.1	CTD-2349P21.9	4.4	1.35e-05	0.00254	0.29	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30792372~30792833:+
LUAD	cis	rs10466239	0.57	rs4627023	ENSG00000230555.2	RP11-517P14.2	4.4	1.35e-05	0.00254	0.36	0.2	Telomere length;	chr10:43370437	chr10:43420738~43422100:+
LUAD	cis	rs8077577	0.708	rs4450455	ENSG00000273018.4	CTD-2303H24.2	4.4	1.35e-05	0.00254	0.28	0.2	Obesity-related traits;	chr17:18237133	chr17:18511221~18551705:-
LUAD	cis	rs4908760	0.759	rs6577514	ENSG00000270282.1	RP5-1115A15.2	4.4	1.35e-05	0.00254	0.21	0.2	Vitiligo;	chr1:8652684	chr1:8512653~8513021:+
LUAD	cis	rs73173548	0.502	rs76393802	ENSG00000247828.6	TMEM161B-AS1	4.4	1.35e-05	0.00254	0.24	0.2	Macular telangiectasia type 2;	chr5:88455311	chr5:88268895~88436685:+
LUAD	cis	rs750134	0.636	rs11838115	ENSG00000257221.1	RP11-689B22.2	-4.4	1.35e-05	0.00255	-0.23	-0.2	Low high density lipoprotein cholesterol levels;	chr12:108820060	chr12:108628687~108641318:+
LUAD	cis	rs172166	0.694	rs188105	ENSG00000216901.1	AL022393.7	4.4	1.35e-05	0.00255	0.24	0.2	Cardiac Troponin-T levels;	chr6:28103615	chr6:28176188~28176674:+
LUAD	cis	rs11673344	0.526	rs8101610	ENSG00000226686.6	LINC01535	-4.4	1.35e-05	0.00255	-0.24	-0.2	Obesity-related traits;	chr19:37566604	chr19:37251912~37265535:+
LUAD	cis	rs172166	0.694	rs203893	ENSG00000216901.1	AL022393.7	4.4	1.35e-05	0.00255	0.24	0.2	Cardiac Troponin-T levels;	chr6:28094288	chr6:28176188~28176674:+
LUAD	cis	rs7119038	0.818	rs10892287	ENSG00000255422.1	AP002954.4	-4.4	1.35e-05	0.00255	-0.31	-0.2	Sjögren's syndrome;	chr11:118772290	chr11:118704607~118750263:+
LUAD	cis	rs9341808	0.718	rs2322630	ENSG00000272129.1	RP11-250B2.6	4.4	1.35e-05	0.00255	0.24	0.2	Sitting height ratio;	chr6:80131316	chr6:80355424~80356859:+
LUAD	cis	rs11089937	0.963	rs5757098	ENSG00000211638.2	IGLV8-61	4.4	1.35e-05	0.00255	0.2	0.2	Periodontitis (PAL4Q3);	chr22:22154322	chr22:22098700~22099212:+
LUAD	cis	rs8072100	0.713	rs9807106	ENSG00000228782.6	CTD-2026D20.3	4.4	1.35e-05	0.00255	0.21	0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47379736	chr17:47450568~47492492:-
LUAD	cis	rs34034104	1	rs34034104	ENSG00000223313.1	RNU6-516P	4.4	1.35e-05	0.00255	0.29	0.2	Itch intensity from mosquito bite;Itch intensity from mosquito bite adjusted by bite size;	chr15:40432834	chr15:40529570~40529673:+
LUAD	cis	rs6928977	0.5	rs6925161	ENSG00000231028.7	LINC00271	-4.4	1.35e-05	0.00255	-0.23	-0.2	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135615496	chr6:135497801~135716055:+
LUAD	cis	rs1499614	0.803	rs1796229	ENSG00000229886.1	RP5-1132H15.3	4.4	1.35e-05	0.00255	0.34	0.2	Gout;	chr7:66654674	chr7:66025126~66031544:-
LUAD	cis	rs1499614	0.901	rs3936	ENSG00000229886.1	RP5-1132H15.3	4.4	1.35e-05	0.00255	0.34	0.2	Gout;	chr7:66661502	chr7:66025126~66031544:-
LUAD	cis	rs11157436	0.602	rs4982569	ENSG00000211813.2	TRAV34	4.4	1.35e-05	0.00255	0.22	0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22169716	chr14:22207522~22208129:+
LUAD	cis	rs7927592	0.513	rs556442	ENSG00000212093.1	AP000807.1	-4.4	1.35e-05	0.00255	-0.21	-0.2	Total body bone mineral density;	chr11:68425222	chr11:68506083~68506166:-
LUAD	cis	rs8031584	1	rs1474380	ENSG00000270015.1	RP11-540B6.6	-4.4	1.35e-05	0.00255	-0.14	-0.2	Huntington's disease progression;	chr15:30977032	chr15:30926514~30928407:+
LUAD	cis	rs763121	0.853	rs5750622	ENSG00000228274.3	RP3-508I15.9	-4.4	1.35e-05	0.00255	-0.2	-0.2	Menopause (age at onset);	chr22:38560459	chr22:38667585~38681820:-
LUAD	cis	rs9860428	0.525	rs4682441	ENSG00000242770.2	RP11-180K7.1	4.4	1.35e-05	0.00255	0.21	0.2	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112846326	chr3:112802478~112812819:+
LUAD	cis	rs9532580	0.62	rs2755210	ENSG00000229456.1	RLIMP1	4.4	1.35e-05	0.00255	0.22	0.2	Mean corpuscular hemoglobin;	chr13:40567145	chr13:40618738~40621348:+
LUAD	cis	rs9487094	0.567	rs13198879	ENSG00000260273.1	RP11-425D10.10	4.4	1.35e-05	0.00255	0.28	0.2	Height;	chr6:109769861	chr6:109382795~109383666:+
LUAD	cis	rs957448	0.687	rs10104041	ENSG00000253704.1	RP11-267M23.4	4.4	1.35e-05	0.00255	0.23	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94559374	chr8:94553722~94569745:+
LUAD	cis	rs2243480	1	rs316321	ENSG00000229886.1	RP5-1132H15.3	4.4	1.35e-05	0.00255	0.34	0.2	Diabetic kidney disease;	chr7:66146626	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs316318	ENSG00000229886.1	RP5-1132H15.3	4.4	1.35e-05	0.00255	0.34	0.2	Diabetic kidney disease;	chr7:66147917	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs316317	ENSG00000229886.1	RP5-1132H15.3	4.4	1.35e-05	0.00255	0.34	0.2	Diabetic kidney disease;	chr7:66148650	chr7:66025126~66031544:-
LUAD	cis	rs7985	0.901	rs736690	ENSG00000244625.4	MIATNB	4.4	1.35e-05	0.00255	0.21	0.2	Electroencephalogram traits;	chr22:26678805	chr22:26672767~26780207:+
LUAD	cis	rs9907295	0.688	rs4796135	ENSG00000270977.1	AC015849.16	-4.4	1.36e-05	0.00256	-0.29	-0.2	Fibroblast growth factor basic levels;	chr17:35924236	chr17:35893707~35911023:-
LUAD	cis	rs9907295	0.688	rs4796136	ENSG00000270977.1	AC015849.16	-4.4	1.36e-05	0.00256	-0.29	-0.2	Fibroblast growth factor basic levels;	chr17:35924397	chr17:35893707~35911023:-
LUAD	cis	rs9907295	0.688	rs4796137	ENSG00000270977.1	AC015849.16	-4.4	1.36e-05	0.00256	-0.29	-0.2	Fibroblast growth factor basic levels;	chr17:35924448	chr17:35893707~35911023:-
LUAD	cis	rs9341808	0.791	rs1324122	ENSG00000272129.1	RP11-250B2.6	4.4	1.36e-05	0.00256	0.24	0.2	Sitting height ratio;	chr6:80236344	chr6:80355424~80356859:+
LUAD	cis	rs2274273	0.623	rs1187881	ENSG00000258413.1	RP11-665C16.6	4.4	1.36e-05	0.00256	0.25	0.2	Protein biomarker;	chr14:55022479	chr14:55262767~55272075:-
LUAD	cis	rs13113518	1	rs34648901	ENSG00000272969.1	RP11-528I4.2	4.4	1.36e-05	0.00256	0.2	0.2	Height;	chr4:55541259	chr4:55547112~55547889:+
LUAD	cis	rs875971	0.66	rs3764903	ENSG00000236529.1	RP13-254B10.1	-4.4	1.36e-05	0.00256	-0.2	-0.2	Aortic root size;	chr7:66633495	chr7:65840212~65840596:+
LUAD	cis	rs1275468	0.518	rs1552040	ENSG00000257497.2	RP11-585P4.5	-4.4	1.36e-05	0.00256	-0.29	-0.2	Polycystic ovary syndrome;	chr12:75528437	chr12:75483454~75489820:-
LUAD	cis	rs4374383	0.884	rs1996325	ENSG00000207383.1	Y_RNA	4.4	1.36e-05	0.00256	0.24	0.2	Hepatitis C induced liver fibrosis;	chr2:111984498	chr2:112579484~112579584:-
LUAD	cis	rs3743772	0.5	rs28671196	ENSG00000279722.1	RP11-44F14.6	4.4	1.36e-05	0.00256	0.27	0.2	Depressive symptoms (SSRI exposure interaction);	chr16:53404024	chr16:53487607~53489943:-
LUAD	cis	rs6088590	0.931	rs12625149	ENSG00000276073.1	RP5-1125A11.7	4.4	1.36e-05	0.00256	0.21	0.2	Coronary artery disease;	chr20:34838009	chr20:33985617~33988989:-
LUAD	cis	rs4879677	0.959	rs10812643	ENSG00000215441.3	CTAGE12P	-4.4	1.36e-05	0.00256	-0.24	-0.2	Gut microbiome composition (summer and winter);	chr9:27690092	chr9:27608382~27610745:-
LUAD	cis	rs193541	0.621	rs898391	ENSG00000263432.2	RN7SL689P	4.4	1.36e-05	0.00256	0.27	0.2	Glucose homeostasis traits;	chr5:122746471	chr5:123022487~123022783:-
LUAD	cis	rs7204230	0.921	rs62049817	ENSG00000261291.1	RP11-295M3.2	4.4	1.36e-05	0.00256	0.25	0.2	Fibrinogen;	chr16:53336109	chr16:53168522~53169450:+
LUAD	cis	rs12554020	0.681	rs78792144	ENSG00000227603.1	RP11-165J3.6	4.4	1.36e-05	0.00256	0.39	0.2	Schizophrenia;	chr9:93583725	chr9:93435332~93437121:-
LUAD	cis	rs7727544	0.507	rs9791170	ENSG00000263597.1	MIR3936	4.4	1.36e-05	0.00256	0.2	0.2	Blood metabolite levels;	chr5:132233934	chr5:132365490~132365599:-
LUAD	cis	rs6964587	0.967	rs58673519	ENSG00000188693.7	CYP51A1-AS1	-4.4	1.36e-05	0.00256	-0.23	-0.2	Breast cancer;	chr7:92194573	chr7:92134604~92180725:+
LUAD	cis	rs2904524	1	rs7309116	ENSG00000257815.4	RP11-611E13.2	-4.4	1.36e-05	0.00256	-0.27	-0.2	Amyotrophic lateral sclerosis (age of onset);	chr12:70341314	chr12:69904033~70243360:-
LUAD	cis	rs34375054	0.558	rs67041765	ENSG00000279233.1	RP11-158L12.4	4.4	1.36e-05	0.00256	0.17	0.2	Post bronchodilator FEV1/FVC ratio;	chr12:125188367	chr12:125138245~125141711:+
LUAD	cis	rs11673344	0.502	rs17304703	ENSG00000226686.6	LINC01535	4.4	1.36e-05	0.00256	0.24	0.2	Obesity-related traits;	chr19:37582646	chr19:37251912~37265535:+
LUAD	cis	rs7432375	0.609	rs835637	ENSG00000239213.4	NCK1-AS1	4.4	1.36e-05	0.00256	0.2	0.2	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136954315	chr3:136841726~136862054:-
LUAD	cis	rs8031584	0.918	rs34095794	ENSG00000270015.1	RP11-540B6.6	-4.4	1.36e-05	0.00256	-0.14	-0.2	Huntington's disease progression;	chr15:30977488	chr15:30926514~30928407:+
LUAD	cis	rs11157436	0.602	rs11157437	ENSG00000211813.2	TRAV34	4.4	1.36e-05	0.00256	0.23	0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22169058	chr14:22207522~22208129:+
LUAD	cis	rs16873450	0.934	rs12531019	ENSG00000234800.2	PCMTD1P3	4.4	1.36e-05	0.00256	0.23	0.2	Verbal memory performance (residualized delayed recall level);	chr7:23766983	chr7:23721311~23721782:-
LUAD	cis	rs16873450	0.934	rs12536120	ENSG00000234800.2	PCMTD1P3	4.4	1.36e-05	0.00256	0.23	0.2	Verbal memory performance (residualized delayed recall level);	chr7:23767035	chr7:23721311~23721782:-
LUAD	cis	rs4908760	0.864	rs6701331	ENSG00000270282.1	RP5-1115A15.2	4.4	1.36e-05	0.00256	0.21	0.2	Vitiligo;	chr1:8610147	chr1:8512653~8513021:+
LUAD	cis	rs6570726	0.791	rs379040	ENSG00000235652.6	RP11-545I5.3	4.4	1.36e-05	0.00256	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145567899	chr6:145799409~145886585:+
LUAD	cis	rs4819052	0.851	rs2236444	ENSG00000237664.1	LINC00316	-4.4	1.36e-05	0.00256	-0.24	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258311	chr21:45338590~45341990:-
LUAD	cis	rs875971	0.505	rs2462573	ENSG00000237310.1	GS1-124K5.4	-4.4	1.36e-05	0.00257	-0.21	-0.2	Aortic root size;	chr7:66042405	chr7:66493706~66495474:+
LUAD	cis	rs1008375	1	rs10939747	ENSG00000249502.1	AC006160.5	-4.4	1.36e-05	0.00257	-0.19	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17689543	chr4:17587467~17614571:-
LUAD	cis	rs1008375	1	rs10939748	ENSG00000249502.1	AC006160.5	-4.4	1.36e-05	0.00257	-0.19	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17689607	chr4:17587467~17614571:-
LUAD	cis	rs2243480	1	rs73142166	ENSG00000226002.1	RP11-460N20.5	-4.4	1.36e-05	0.00257	-0.34	-0.2	Diabetic kidney disease;	chr7:65910845	chr7:65084103~65100232:+
LUAD	cis	rs17772222	0.63	rs816069	ENSG00000258789.1	RP11-507K2.3	4.4	1.36e-05	0.00257	0.23	0.2	Coronary artery calcification;	chr14:88500992	chr14:88551597~88552493:+
LUAD	cis	rs5758659	0.729	rs134866	ENSG00000227370.1	RP4-669P10.19	-4.4	1.36e-05	0.00257	-0.17	-0.2	Cognitive function;	chr22:42254657	chr22:42132543~42132998:+
LUAD	cis	rs2286503	1	rs1029740	ENSG00000221740.1	SNORD93	4.4	1.36e-05	0.00257	0.22	0.2	Fibrinogen;	chr7:22833967	chr7:22856613~22856686:+
LUAD	cis	rs4705952	1	rs4705952	ENSG00000233006.5	AC034220.3	-4.4	1.36e-05	0.00257	-0.2	-0.2	C-reactive protein levels;	chr5:132503926	chr5:132311285~132369916:-
LUAD	cis	rs10266483	0.639	rs6952592	ENSG00000227986.1	TRIM60P18	-4.4	1.36e-05	0.00257	-0.24	-0.2	Response to statin therapy;	chr7:64293667	chr7:64355078~64356199:+
LUAD	cis	rs10266483	0.705	rs599522	ENSG00000227986.1	TRIM60P18	-4.4	1.36e-05	0.00257	-0.24	-0.2	Response to statin therapy;	chr7:64298104	chr7:64355078~64356199:+
LUAD	cis	rs6496932	0.802	rs12439958	ENSG00000218052.5	ADAMTS7P4	4.4	1.36e-05	0.00257	0.22	0.2	Central corneal thickness;Corneal structure;	chr15:85310499	chr15:85255369~85330334:-
LUAD	cis	rs473651	0.935	rs474478	ENSG00000229915.1	AC016999.2	-4.4	1.36e-05	0.00257	-0.26	-0.2	Multiple system atrophy;	chr2:238426832	chr2:238427077~238427729:-
LUAD	cis	rs17301013	0.932	rs6664864	ENSG00000227373.4	RP11-160H22.5	4.39	1.36e-05	0.00257	0.25	0.2	Systemic lupus erythematosus;	chr1:174622912	chr1:174115300~174160004:-
LUAD	cis	rs12285276	0.576	rs2593756	ENSG00000205106.4	DKFZp779M0652	4.39	1.36e-05	0.00257	0.23	0.2	Visceral fat;	chr11:45746850	chr11:45771432~45772358:+
LUAD	cis	rs149291347	1	rs149291347	ENSG00000279453.1	RP3-425C14.4	-4.39	1.36e-05	0.00257	-0.2	-0.2	Plateletcrit;	chr6:122457804	chr6:122436789~122439223:-
LUAD	cis	rs910316	1	rs175492	ENSG00000279594.1	RP11-950C14.10	4.39	1.36e-05	0.00257	0.22	0.2	Height;	chr14:75078517	chr14:75011269~75012851:-
LUAD	cis	rs4660214	0.724	rs2484751	ENSG00000182109.6	RP11-69E11.4	-4.39	1.36e-05	0.00257	-0.22	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39282867	chr1:39522280~39546187:-
LUAD	cis	rs6802315	0.604	rs2115941	ENSG00000272087.1	RP11-379F4.7	4.39	1.37e-05	0.00257	0.22	0.2	Periodontitis (CDC/AAP);	chr3:158781906	chr3:158693120~158693768:-
LUAD	cis	rs4578769	0.569	rs9962620	ENSG00000265943.1	RP11-739L10.1	4.39	1.37e-05	0.00257	0.25	0.2	Eosinophil percentage of white cells;	chr18:22815811	chr18:22699481~22933764:-
LUAD	cis	rs4578769	0.569	rs4800433	ENSG00000265943.1	RP11-739L10.1	4.39	1.37e-05	0.00257	0.25	0.2	Eosinophil percentage of white cells;	chr18:22816691	chr18:22699481~22933764:-
LUAD	cis	rs4578769	0.569	rs11082155	ENSG00000265943.1	RP11-739L10.1	4.39	1.37e-05	0.00257	0.25	0.2	Eosinophil percentage of white cells;	chr18:22824527	chr18:22699481~22933764:-
LUAD	cis	rs4578769	0.569	rs4289091	ENSG00000265943.1	RP11-739L10.1	4.39	1.37e-05	0.00257	0.25	0.2	Eosinophil percentage of white cells;	chr18:22825856	chr18:22699481~22933764:-
LUAD	cis	rs4578769	0.569	rs12956367	ENSG00000265943.1	RP11-739L10.1	4.39	1.37e-05	0.00257	0.25	0.2	Eosinophil percentage of white cells;	chr18:22833742	chr18:22699481~22933764:-
LUAD	cis	rs2732480	0.5	rs2450986	ENSG00000240399.1	RP1-228P16.1	4.39	1.37e-05	0.00257	0.2	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48267905	chr12:48054813~48055591:-
LUAD	cis	rs7302981	0.934	rs7279	ENSG00000200428.1	Y_RNA	4.39	1.37e-05	0.00257	0.24	0.2	Systolic blood pressure;	chr12:50130164	chr12:50743568~50743684:+
LUAD	cis	rs4819052	0.819	rs34818688	ENSG00000237664.1	LINC00316	-4.39	1.37e-05	0.00257	-0.24	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252501	chr21:45338590~45341990:-
LUAD	cis	rs1499614	1	rs1267818	ENSG00000229886.1	RP5-1132H15.3	4.39	1.37e-05	0.00257	0.34	0.2	Gout;	chr7:66642037	chr7:66025126~66031544:-
LUAD	cis	rs6840360	0.55	rs4696269	ENSG00000270265.1	RP11-731D1.4	-4.39	1.37e-05	0.00257	-0.22	-0.2	Intelligence (multi-trait analysis);	chr4:151560552	chr4:151333775~151353224:-
LUAD	cis	rs3096299	0.658	rs12443705	ENSG00000261118.1	RP11-104N10.1	4.39	1.37e-05	0.00257	0.2	0.2	Multiple myeloma (IgH translocation);	chr16:89480646	chr16:89492017~89504460:-
LUAD	cis	rs2976388	0.566	rs4736373	ENSG00000253741.1	CTD-2292P10.4	4.39	1.37e-05	0.00257	0.23	0.2	Urinary tract infection frequency;	chr8:142710939	chr8:142702252~142726973:-
LUAD	cis	rs9435732	0.778	rs3738815	ENSG00000235241.1	RP11-108M9.5	4.39	1.37e-05	0.00258	0.26	0.2	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:16988207	chr1:16889095~16889602:+
LUAD	cis	rs8091660	0.624	rs907546	ENSG00000278983.1	RP11-426J5.3	4.39	1.37e-05	0.00258	0.24	0.2	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48549919	chr18:48564795~48568342:+
LUAD	cis	rs35740288	0.77	rs17635450	ENSG00000259407.1	RP11-158M2.3	4.39	1.37e-05	0.00258	0.2	0.2	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85655818	chr15:85744109~85750281:-
LUAD	cis	rs1979679	0.918	rs1586868	ENSG00000278733.1	RP11-425D17.1	4.39	1.37e-05	0.00258	0.25	0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28368176	chr12:28185625~28186190:-
LUAD	cis	rs1979679	0.918	rs1586867	ENSG00000278733.1	RP11-425D17.1	4.39	1.37e-05	0.00258	0.25	0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28368345	chr12:28185625~28186190:-
LUAD	cis	rs454510	0.857	rs838990	ENSG00000226172.2	RP4-712E4.1	-4.39	1.37e-05	0.00258	-0.23	-0.2	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;	chr1:119650629	chr1:119000344~119001392:-
LUAD	cis	rs7138803	0.51	rs2954129	ENSG00000257464.1	RP11-161H23.8	-4.39	1.37e-05	0.00258	-0.19	-0.2	Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index;	chr12:49789578	chr12:49442424~49442652:-
LUAD	cis	rs4819052	0.565	rs35776291	ENSG00000215447.6	BX322557.10	-4.39	1.37e-05	0.00258	-0.23	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45286227	chr21:45288052~45291738:+
LUAD	cis	rs910316	0.935	rs175076	ENSG00000279594.1	RP11-950C14.10	-4.39	1.37e-05	0.00258	-0.22	-0.2	Height;	chr14:75038783	chr14:75011269~75012851:-
LUAD	cis	rs957448	1	rs72674866	ENSG00000254315.1	RP11-267M23.3	4.39	1.37e-05	0.00258	0.25	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94564619	chr8:94533628~94534391:+
LUAD	cis	rs957448	1	rs55897841	ENSG00000254315.1	RP11-267M23.3	4.39	1.37e-05	0.00258	0.25	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94565042	chr8:94533628~94534391:+
LUAD	cis	rs957448	0.948	rs72674867	ENSG00000254315.1	RP11-267M23.3	4.39	1.37e-05	0.00258	0.25	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94565973	chr8:94533628~94534391:+
LUAD	cis	rs16866061	1	rs4674916	ENSG00000228446.2	AC073052.1	-4.39	1.37e-05	0.00258	-0.21	-0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr2:224500918	chr2:224499387~224500100:-
LUAD	cis	rs750134	1	rs76482184	ENSG00000257221.1	RP11-689B22.2	-4.39	1.37e-05	0.00258	-0.3	-0.2	Low high density lipoprotein cholesterol levels;	chr12:108691072	chr12:108628687~108641318:+
LUAD	cis	rs7208859	0.573	rs11654035	ENSG00000280069.1	CTD-2349P21.3	-4.39	1.37e-05	0.00258	-0.27	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30738182~30740275:+
LUAD	cis	rs12188164	0.62	rs56070387	ENSG00000221990.4	EXOC3-AS1	4.39	1.37e-05	0.00258	0.21	0.2	Cystic fibrosis severity;	chr5:482416	chr5:441498~443160:-
LUAD	cis	rs17301013	0.932	rs1653632	ENSG00000227373.4	RP11-160H22.5	-4.39	1.37e-05	0.00258	-0.24	-0.2	Systemic lupus erythematosus;	chr1:174786459	chr1:174115300~174160004:-
LUAD	cis	rs2243480	1	rs781156	ENSG00000229886.1	RP5-1132H15.3	4.39	1.37e-05	0.00258	0.34	0.2	Diabetic kidney disease;	chr7:66014154	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs781149	ENSG00000229886.1	RP5-1132H15.3	4.39	1.37e-05	0.00258	0.34	0.2	Diabetic kidney disease;	chr7:66016297	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs451396	ENSG00000229886.1	RP5-1132H15.3	4.39	1.37e-05	0.00258	0.34	0.2	Diabetic kidney disease;	chr7:66019087	chr7:66025126~66031544:-
LUAD	cis	rs2243480	0.901	rs58207111	ENSG00000229886.1	RP5-1132H15.3	4.39	1.37e-05	0.00258	0.34	0.2	Diabetic kidney disease;	chr7:66021736	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs1167613	ENSG00000229886.1	RP5-1132H15.3	4.39	1.37e-05	0.00258	0.34	0.2	Diabetic kidney disease;	chr7:66022452	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs1715235	ENSG00000229886.1	RP5-1132H15.3	4.39	1.37e-05	0.00258	0.34	0.2	Diabetic kidney disease;	chr7:66023407	chr7:66025126~66031544:-
LUAD	cis	rs7911264	0.739	rs7914814	ENSG00000236493.2	EIF2S2P3	4.39	1.37e-05	0.00258	0.23	0.2	Inflammatory bowel disease;	chr10:92623193	chr10:92668745~92669743:-
LUAD	cis	rs6570726	0.846	rs372904	ENSG00000235652.6	RP11-545I5.3	4.39	1.37e-05	0.00258	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145566289	chr6:145799409~145886585:+
LUAD	cis	rs7208859	0.623	rs73269916	ENSG00000266490.1	CTD-2349P21.9	4.39	1.37e-05	0.00258	0.28	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30769308	chr17:30792372~30792833:+
LUAD	cis	rs6714710	0.603	rs4311104	ENSG00000230606.9	AC159540.1	-4.39	1.37e-05	0.00258	-0.21	-0.2	Posterior cortical atrophy and Alzheimer's disease;	chr2:97808339	chr2:97416165~97433527:-
LUAD	cis	rs6714710	0.603	rs2278700	ENSG00000230606.9	AC159540.1	-4.39	1.37e-05	0.00258	-0.21	-0.2	Posterior cortical atrophy and Alzheimer's disease;	chr2:97810919	chr2:97416165~97433527:-
LUAD	cis	rs6714710	0.603	rs12104810	ENSG00000230606.9	AC159540.1	-4.39	1.37e-05	0.00258	-0.21	-0.2	Posterior cortical atrophy and Alzheimer's disease;	chr2:97827195	chr2:97416165~97433527:-
LUAD	cis	rs62355901	0.505	rs12655082	ENSG00000271828.1	CTD-2310F14.1	4.39	1.37e-05	0.00258	0.37	0.2	Breast cancer;	chr5:56930384	chr5:56927874~56929573:+
LUAD	cis	rs9341808	0.69	rs6930534	ENSG00000272129.1	RP11-250B2.6	4.39	1.37e-05	0.00258	0.24	0.2	Sitting height ratio;	chr6:80186333	chr6:80355424~80356859:+
LUAD	cis	rs2153535	0.585	rs11243265	ENSG00000230939.1	RP11-314C16.1	-4.39	1.37e-05	0.00258	-0.22	-0.2	Motion sickness;	chr6:8642925	chr6:8784178~8785445:+
LUAD	cis	rs9341808	0.718	rs9448899	ENSG00000272129.1	RP11-250B2.6	4.39	1.37e-05	0.00258	0.24	0.2	Sitting height ratio;	chr6:80136147	chr6:80355424~80356859:+
LUAD	cis	rs7829975	0.684	rs546603	ENSG00000253893.2	FAM85B	4.39	1.37e-05	0.00258	0.24	0.2	Mood instability;	chr8:8738328	chr8:8167819~8226614:-
LUAD	cis	rs4908769	0.624	rs1763838	ENSG00000232912.4	RP5-1115A15.1	4.39	1.37e-05	0.00258	0.18	0.2	Allergy;	chr1:8413271	chr1:8424645~8434838:+
LUAD	cis	rs7590268	0.666	rs6544655	ENSG00000279873.2	LINC01126	4.39	1.37e-05	0.00258	0.19	0.2	Orofacial clefts;	chr2:43407937	chr2:43227210~43228855:+
LUAD	cis	rs1729951	0.575	rs1654925	ENSG00000239213.4	NCK1-AS1	-4.39	1.37e-05	0.00258	-0.21	-0.2	Neuroticism;	chr3:136971549	chr3:136841726~136862054:-
LUAD	cis	rs2227564	0.62	rs3812637	ENSG00000271816.1	BMS1P4	4.39	1.37e-05	0.00258	0.19	0.2	Crohn's disease;Inflammatory bowel disease;	chr10:73809088	chr10:73699151~73730487:-
LUAD	cis	rs2227564	0.62	rs12783161	ENSG00000271816.1	BMS1P4	4.39	1.37e-05	0.00258	0.19	0.2	Crohn's disease;Inflammatory bowel disease;	chr10:73812443	chr10:73699151~73730487:-
LUAD	cis	rs6421571	0.565	rs10892263	ENSG00000255422.1	AP002954.4	4.39	1.37e-05	0.00259	0.31	0.2	Primary biliary cholangitis;	chr11:118716610	chr11:118704607~118750263:+
LUAD	cis	rs2354432	0.607	rs9661159	ENSG00000226015.2	CCT8P1	4.39	1.37e-05	0.00259	0.39	0.2	Mitochondrial DNA levels;	chr1:147286246	chr1:147203276~147204932:-
LUAD	cis	rs2548724	0.755	rs56218837	ENSG00000250682.4	LINC00491	4.39	1.37e-05	0.00259	0.25	0.2	Type 2 diabetes;	chr5:102464083	chr5:102609156~102671559:-
LUAD	cis	rs17772222	0.917	rs61984737	ENSG00000258789.1	RP11-507K2.3	-4.39	1.37e-05	0.00259	-0.27	-0.2	Coronary artery calcification;	chr14:88637028	chr14:88551597~88552493:+
LUAD	cis	rs858239	0.863	rs274054	ENSG00000230042.1	AK3P3	-4.39	1.37e-05	0.00259	-0.25	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23350848	chr7:23129178~23129841:+
LUAD	cis	rs71520386	0.607	rs4308627	ENSG00000228649.7	AC005682.5	-4.39	1.38e-05	0.00259	-0.27	-0.2	Fibrinogen levels;	chr7:22840285	chr7:22854178~22861579:+
LUAD	cis	rs72634501	0.517	rs7522362	ENSG00000228060.1	RP11-69E11.8	4.39	1.38e-05	0.00259	0.18	0.2	HDL cholesterol;	chr1:39139419	chr1:39565160~39573203:+
LUAD	cis	rs1799949	0.965	rs1842147	ENSG00000236383.6	LINC00854	-4.39	1.38e-05	0.00259	-0.16	-0.2	Menopause (age at onset);	chr17:43357824	chr17:43216941~43305976:-
LUAD	cis	rs4819052	0.766	rs4819035	ENSG00000215447.6	BX322557.10	-4.39	1.38e-05	0.00259	-0.26	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45225800	chr21:45288052~45291738:+
LUAD	cis	rs7172677	1	rs4243032	ENSG00000260269.4	CTD-2323K18.1	-4.39	1.38e-05	0.00259	-0.26	-0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75134543	chr15:75527150~75601205:-
LUAD	cis	rs473651	0.967	rs483042	ENSG00000229915.1	AC016999.2	-4.39	1.38e-05	0.00259	-0.26	-0.2	Multiple system atrophy;	chr2:238426679	chr2:238427077~238427729:-
LUAD	cis	rs72802342	0.541	rs185052	ENSG00000280152.1	RP11-331F4.5	-4.39	1.38e-05	0.00259	-0.23	-0.2	Advanced age-related macular degeneration;	chr16:75433165	chr16:75245994~75250077:-
LUAD	cis	rs11512640	1	rs11220136	ENSG00000254671.2	STT3A-AS1	4.39	1.38e-05	0.00259	0.43	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125582185	chr11:125570284~125592568:-
LUAD	cis	rs293748	0.891	rs6861906	ENSG00000250155.1	CTD-2353F22.1	-4.39	1.38e-05	0.00259	-0.24	-0.2	Obesity-related traits;	chr5:37075834	chr5:36666214~36725195:-
LUAD	cis	rs62025270	0.632	rs80036674	ENSG00000202081.1	RNU6-1280P	-4.39	1.38e-05	0.00259	-0.29	-0.2	Idiopathic pulmonary fibrosis;	chr15:85571217	chr15:85651522~85651628:-
LUAD	cis	rs6604026	0.59	rs12743005	ENSG00000223787.2	RP4-593M8.1	4.39	1.38e-05	0.00259	0.27	0.2	Multiple sclerosis;	chr1:92727181	chr1:92580476~92580821:-
LUAD	cis	rs13256369	0.95	rs13255655	ENSG00000253893.2	FAM85B	-4.39	1.38e-05	0.0026	-0.28	-0.2	Obesity-related traits;	chr8:8720226	chr8:8167819~8226614:-
LUAD	cis	rs750134	1	rs17040870	ENSG00000257221.1	RP11-689B22.2	-4.39	1.38e-05	0.0026	-0.3	-0.2	Low high density lipoprotein cholesterol levels;	chr12:108691634	chr12:108628687~108641318:+
LUAD	cis	rs4879677	1	rs4879706	ENSG00000215441.3	CTAGE12P	-4.39	1.38e-05	0.0026	-0.24	-0.2	Gut microbiome composition (summer and winter);	chr9:27685777	chr9:27608382~27610745:-
LUAD	cis	rs7829975	0.517	rs12542733	ENSG00000233609.3	RP11-62H7.2	-4.39	1.38e-05	0.0026	-0.16	-0.2	Mood instability;	chr8:8967348	chr8:8961200~8979025:+
LUAD	cis	rs67981189	0.546	rs2810075	ENSG00000269927.1	RP6-91H8.3	-4.39	1.38e-05	0.0026	-0.27	-0.2	Schizophrenia;	chr14:70908363	chr14:71141125~71143253:-
LUAD	cis	rs1008375	1	rs2872959	ENSG00000249502.1	AC006160.5	4.39	1.38e-05	0.0026	0.19	0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17675540	chr4:17587467~17614571:-
LUAD	cis	rs1008375	1	rs7661631	ENSG00000249502.1	AC006160.5	4.39	1.38e-05	0.0026	0.19	0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17678128	chr4:17587467~17614571:-
LUAD	cis	rs4660214	0.666	rs596062	ENSG00000228060.1	RP11-69E11.8	-4.39	1.38e-05	0.0026	-0.18	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39360333	chr1:39565160~39573203:+
LUAD	cis	rs6558530	0.692	rs10105317	ENSG00000253982.1	CTD-2336O2.1	4.39	1.38e-05	0.0026	0.26	0.2	Systolic blood pressure;	chr8:1753266	chr8:1761990~1764502:-
LUAD	cis	rs11051970	0.545	rs2651375	ENSG00000274964.1	RP11-817I4.1	4.39	1.38e-05	0.0026	0.2	0.2	Response to tocilizumab in rheumatoid arthritis;	chr12:32429718	chr12:32339368~32340724:+
LUAD	cis	rs6840360	0.55	rs11723438	ENSG00000270265.1	RP11-731D1.4	4.39	1.38e-05	0.0026	0.22	0.2	Intelligence (multi-trait analysis);	chr4:151610649	chr4:151333775~151353224:-
LUAD	cis	rs2274273	0.87	rs4597235	ENSG00000259318.1	RP11-454L9.2	4.39	1.38e-05	0.0026	0.17	0.2	Protein biomarker;	chr14:55385269	chr14:55394940~55395233:-
LUAD	cis	rs6723108	0.627	rs4954191	ENSG00000224043.6	CCNT2-AS1	-4.39	1.38e-05	0.0026	-0.24	-0.2	Type 2 diabetes;	chr2:134854878	chr2:134735464~134918710:-
LUAD	cis	rs77688320	0.535	rs2540441	ENSG00000213090.2	AC007256.5	-4.39	1.38e-05	0.0026	-0.23	-0.2	Breast cancer;	chr2:201481946	chr2:201410544~201413308:-
LUAD	cis	rs77688320	0.553	rs2540432	ENSG00000213090.2	AC007256.5	-4.39	1.38e-05	0.0026	-0.23	-0.2	Breast cancer;	chr2:201500171	chr2:201410544~201413308:-
LUAD	cis	rs77688320	0.553	rs2908763	ENSG00000213090.2	AC007256.5	-4.39	1.38e-05	0.0026	-0.23	-0.2	Breast cancer;	chr2:201503860	chr2:201410544~201413308:-
LUAD	cis	rs77688320	0.535	rs60148247	ENSG00000213090.2	AC007256.5	-4.39	1.38e-05	0.0026	-0.23	-0.2	Breast cancer;	chr2:201513770	chr2:201410544~201413308:-
LUAD	cis	rs77688320	0.553	rs2080324	ENSG00000213090.2	AC007256.5	-4.39	1.38e-05	0.0026	-0.23	-0.2	Breast cancer;	chr2:201514089	chr2:201410544~201413308:-
LUAD	cis	rs77688320	0.553	rs2080323	ENSG00000213090.2	AC007256.5	-4.39	1.38e-05	0.0026	-0.23	-0.2	Breast cancer;	chr2:201514126	chr2:201410544~201413308:-
LUAD	cis	rs13113518	1	rs55699500	ENSG00000272969.1	RP11-528I4.2	4.39	1.38e-05	0.0026	0.21	0.2	Height;	chr4:55540912	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs56362210	ENSG00000272969.1	RP11-528I4.2	4.39	1.38e-05	0.0026	0.21	0.2	Height;	chr4:55540972	chr4:55547112~55547889:+
LUAD	cis	rs8180040	0.783	rs11710121	ENSG00000271161.1	BOLA2P2	-4.39	1.39e-05	0.00261	-0.19	-0.2	Colorectal cancer;	chr3:47310011	chr3:47499841~47500407:+
LUAD	cis	rs7829975	0.567	rs6601273	ENSG00000173295.6	FAM86B3P	-4.39	1.39e-05	0.00261	-0.21	-0.2	Mood instability;	chr8:8939009	chr8:8228595~8244865:+
LUAD	cis	rs12478296	1	rs55777943	ENSG00000261186.2	RP11-341N2.1	-4.39	1.39e-05	0.00261	-0.36	-0.2	Obesity-related traits;	chr2:242098535	chr2:242087351~242088457:-
LUAD	cis	rs2243480	1	rs316322	ENSG00000229886.1	RP5-1132H15.3	4.39	1.39e-05	0.00261	0.34	0.2	Diabetic kidney disease;	chr7:66146246	chr7:66025126~66031544:-
LUAD	cis	rs227275	0.525	rs10029073	ENSG00000251288.2	RP11-10L12.2	-4.39	1.39e-05	0.00261	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:103006991	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.525	rs724446	ENSG00000251288.2	RP11-10L12.2	-4.39	1.39e-05	0.00261	-0.24	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:103010206	chr4:102751401~102752641:+
LUAD	cis	rs4873772	0.837	rs56092229	ENSG00000253330.1	RP11-697N18.3	-4.39	1.39e-05	0.00261	-0.22	-0.2	Lobe attachment (rater-scored or self-reported);	chr8:47562955	chr8:47511034~47512141:-
LUAD	cis	rs4873772	0.837	rs2129618	ENSG00000253330.1	RP11-697N18.3	-4.39	1.39e-05	0.00261	-0.22	-0.2	Lobe attachment (rater-scored or self-reported);	chr8:47643557	chr8:47511034~47512141:-
LUAD	cis	rs875971	0.505	rs1167386	ENSG00000237310.1	GS1-124K5.4	-4.39	1.39e-05	0.00261	-0.21	-0.2	Aortic root size;	chr7:66048109	chr7:66493706~66495474:+
LUAD	cis	rs875971	0.505	rs1167385	ENSG00000237310.1	GS1-124K5.4	-4.39	1.39e-05	0.00261	-0.21	-0.2	Aortic root size;	chr7:66048321	chr7:66493706~66495474:+
LUAD	cis	rs11157436	0.56	rs2031071	ENSG00000211813.2	TRAV34	4.39	1.39e-05	0.00261	0.22	0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22157547	chr14:22207522~22208129:+
LUAD	cis	rs957448	0.904	rs56302978	ENSG00000254315.1	RP11-267M23.3	4.39	1.39e-05	0.00261	0.25	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94505883	chr8:94533628~94534391:+
LUAD	cis	rs8054556	0.692	rs4788199	ENSG00000214725.6	CDIPT-AS1	-4.39	1.39e-05	0.00261	-0.23	-0.2	Autism spectrum disorder or schizophrenia;	chr16:29959536	chr16:29863593~29868053:+
LUAD	cis	rs5758659	0.714	rs5751220	ENSG00000182057.4	OGFRP1	-4.39	1.39e-05	0.00261	-0.23	-0.2	Cognitive function;	chr22:42120201	chr22:42269753~42275196:+
LUAD	cis	rs2439831	0.85	rs7181039	ENSG00000249839.1	AC011330.5	-4.39	1.39e-05	0.00261	-0.43	-0.2	Lung cancer in ever smokers;	chr15:43886914	chr15:43663654~43684339:-
LUAD	cis	rs9376098	0.763	rs7746481	ENSG00000232876.1	CTA-212D2.2	-4.39	1.39e-05	0.00261	-0.24	-0.2	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135162673	chr6:135055033~135060550:+
LUAD	cis	rs6860806	0.631	rs4705931	ENSG00000233006.5	AC034220.3	4.39	1.39e-05	0.00261	0.18	0.2	Breast cancer;	chr5:132252652	chr5:132311285~132369916:-
LUAD	cis	rs3096299	0.667	rs2965947	ENSG00000182376.2	RP5-1142A6.8	4.39	1.39e-05	0.00261	0.2	0.2	Multiple myeloma (IgH translocation);	chr16:89452262	chr16:88742767~88745748:+
LUAD	cis	rs801193	0.967	rs2707853	ENSG00000224316.1	RP11-479O9.2	4.39	1.39e-05	0.00261	0.2	0.2	Aortic root size;	chr7:66749023	chr7:65773620~65802067:+
LUAD	cis	rs801193	1	rs2659889	ENSG00000224316.1	RP11-479O9.2	4.39	1.39e-05	0.00261	0.2	0.2	Aortic root size;	chr7:66752125	chr7:65773620~65802067:+
LUAD	cis	rs7665090	1	rs7677509	ENSG00000246560.2	RP11-10L12.4	4.39	1.39e-05	0.00261	0.24	0.2	Primary biliary cholangitis;	chr4:102628849	chr4:102828055~102844075:+
LUAD	cis	rs7665090	0.967	rs7699231	ENSG00000246560.2	RP11-10L12.4	4.39	1.39e-05	0.00261	0.24	0.2	Primary biliary cholangitis;	chr4:102628918	chr4:102828055~102844075:+
LUAD	cis	rs7665090	1	rs7699678	ENSG00000246560.2	RP11-10L12.4	4.39	1.39e-05	0.00261	0.24	0.2	Primary biliary cholangitis;	chr4:102628939	chr4:102828055~102844075:+
LUAD	cis	rs7665090	1	rs11724614	ENSG00000246560.2	RP11-10L12.4	4.39	1.39e-05	0.00261	0.24	0.2	Primary biliary cholangitis;	chr4:102629091	chr4:102828055~102844075:+
LUAD	cis	rs4705952	0.832	rs17690122	ENSG00000233006.5	AC034220.3	-4.39	1.39e-05	0.00261	-0.23	-0.2	C-reactive protein levels;	chr5:132532143	chr5:132311285~132369916:-
LUAD	cis	rs11159086	1	rs17100451	ENSG00000259005.1	RP3-449M8.6	4.39	1.39e-05	0.00261	0.27	0.2	Advanced glycation end-product levels;	chr14:74476210	chr14:74474007~74474864:-
LUAD	cis	rs73219805	0.536	rs73217710	ENSG00000228451.3	SDAD1P1	-4.39	1.39e-05	0.00261	-0.48	-0.2	Schizophrenia;	chr8:26340717	chr8:26379259~26382953:-
LUAD	cis	rs950169	0.92	rs34672825	ENSG00000275120.1	RP11-182J1.17	4.39	1.39e-05	0.00262	0.32	0.2	Schizophrenia;	chr15:84034718	chr15:84599434~84606463:-
LUAD	cis	rs2274273	0.87	rs3825616	ENSG00000259318.1	RP11-454L9.2	4.39	1.39e-05	0.00262	0.17	0.2	Protein biomarker;	chr14:55386570	chr14:55394940~55395233:-
LUAD	cis	rs227275	0.525	rs11097796	ENSG00000251288.2	RP11-10L12.2	-4.39	1.39e-05	0.00262	-0.23	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:103002401	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.525	rs11097797	ENSG00000251288.2	RP11-10L12.2	-4.39	1.39e-05	0.00262	-0.23	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:103002507	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.525	rs13117110	ENSG00000251288.2	RP11-10L12.2	-4.39	1.39e-05	0.00262	-0.23	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:103003981	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.525	rs13144033	ENSG00000251288.2	RP11-10L12.2	-4.39	1.39e-05	0.00262	-0.23	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:103004032	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.525	rs4699046	ENSG00000251288.2	RP11-10L12.2	-4.39	1.39e-05	0.00262	-0.23	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:103004514	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.525	rs4699047	ENSG00000251288.2	RP11-10L12.2	-4.39	1.39e-05	0.00262	-0.23	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:103005385	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.525	rs28778380	ENSG00000251288.2	RP11-10L12.2	-4.39	1.39e-05	0.00262	-0.23	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:103006416	chr4:102751401~102752641:+
LUAD	cis	rs34375054	0.624	rs73233307	ENSG00000279233.1	RP11-158L12.4	4.39	1.39e-05	0.00262	0.18	0.2	Post bronchodilator FEV1/FVC ratio;	chr12:125191327	chr12:125138245~125141711:+
LUAD	cis	rs34375054	0.624	rs12580033	ENSG00000279233.1	RP11-158L12.4	4.39	1.39e-05	0.00262	0.18	0.2	Post bronchodilator FEV1/FVC ratio;	chr12:125191537	chr12:125138245~125141711:+
LUAD	cis	rs4664293	0.867	rs13432	ENSG00000226266.5	AC009961.3	-4.39	1.39e-05	0.00262	-0.28	-0.2	Monocyte percentage of white cells;	chr2:159769216	chr2:159670708~159712435:-
LUAD	cis	rs9341808	0.65	rs6909546	ENSG00000272129.1	RP11-250B2.6	4.39	1.39e-05	0.00262	0.24	0.2	Sitting height ratio;	chr6:80160206	chr6:80355424~80356859:+
LUAD	cis	rs17772222	0.876	rs12436982	ENSG00000258789.1	RP11-507K2.3	-4.39	1.39e-05	0.00262	-0.27	-0.2	Coronary artery calcification;	chr14:88689862	chr14:88551597~88552493:+
LUAD	cis	rs6121246	0.559	rs6087771	ENSG00000230613.1	HM13-AS1	4.39	1.39e-05	0.00262	0.24	0.2	Mean corpuscular hemoglobin;	chr20:31718921	chr20:31567707~31573263:-
LUAD	cis	rs17772222	0.682	rs2297129	ENSG00000258789.1	RP11-507K2.3	-4.39	1.39e-05	0.00262	-0.24	-0.2	Coronary artery calcification;	chr14:88469581	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.682	rs61542857	ENSG00000258789.1	RP11-507K2.3	-4.39	1.39e-05	0.00262	-0.24	-0.2	Coronary artery calcification;	chr14:88470358	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.637	rs7161660	ENSG00000258789.1	RP11-507K2.3	-4.39	1.39e-05	0.00262	-0.24	-0.2	Coronary artery calcification;	chr14:88471832	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.682	rs7141363	ENSG00000258789.1	RP11-507K2.3	-4.39	1.39e-05	0.00262	-0.24	-0.2	Coronary artery calcification;	chr14:88471879	chr14:88551597~88552493:+
LUAD	cis	rs1008375	0.931	rs6831211	ENSG00000249502.1	AC006160.5	-4.39	1.39e-05	0.00262	-0.19	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17695386	chr4:17587467~17614571:-
LUAD	cis	rs860295	0.702	rs10796945	ENSG00000225855.5	RUSC1-AS1	4.39	1.39e-05	0.00262	0.13	0.2	Body mass index;	chr1:155457897	chr1:155316863~155324176:-
LUAD	cis	rs11220082	0.666	rs35203305	ENSG00000254671.2	STT3A-AS1	-4.39	1.4e-05	0.00262	-0.22	-0.2	Schizophrenia;	chr11:125468987	chr11:125570284~125592568:-
LUAD	cis	rs2243480	0.901	rs57126451	ENSG00000232559.3	GS1-124K5.12	4.39	1.4e-05	0.00262	0.34	0.2	Diabetic kidney disease;	chr7:65951319	chr7:66554588~66576923:-
LUAD	cis	rs6840360	0.642	rs2709825	ENSG00000270265.1	RP11-731D1.4	-4.39	1.4e-05	0.00263	-0.2	-0.2	Intelligence (multi-trait analysis);	chr4:151444411	chr4:151333775~151353224:-
LUAD	cis	rs73193808	0.901	rs8134232	ENSG00000215533.7	LINC00189	-4.39	1.4e-05	0.00263	-0.27	-0.2	Coronary artery disease;	chr21:29199348	chr21:29193480~29288205:+
LUAD	cis	rs9341808	0.683	rs7771449	ENSG00000260645.1	RP11-250B2.5	4.39	1.4e-05	0.00263	0.19	0.2	Sitting height ratio;	chr6:80210260	chr6:80466958~80469080:+
LUAD	cis	rs12908161	0.959	rs11637728	ENSG00000259295.5	CSPG4P12	4.39	1.4e-05	0.00263	0.28	0.2	Schizophrenia;	chr15:84660161	chr15:85191438~85213905:+
LUAD	cis	rs6095360	0.7	rs67777906	ENSG00000222365.1	SNORD12B	-4.39	1.4e-05	0.00263	-0.23	-0.2	Intelligence (multi-trait analysis);	chr20:48940592	chr20:49280319~49280409:+
LUAD	cis	rs4971059	0.654	rs4971052	ENSG00000160766.13	GBAP1	-4.39	1.4e-05	0.00263	-0.2	-0.2	Breast cancer;	chr1:155153542	chr1:155213821~155227422:-
LUAD	cis	rs1167827	0.68	rs1167796	ENSG00000165178.9	NCF1C	-4.39	1.4e-05	0.00263	-0.17	-0.2	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75156639~75172044:-
LUAD	cis	rs9649213	0.593	rs6949718	ENSG00000272950.1	RP11-307C18.1	4.39	1.4e-05	0.00263	0.25	0.2	Prostate cancer (SNP x SNP interaction);	chr7:98295171	chr7:98322853~98323430:+
LUAD	cis	rs62355901	0.653	rs16886206	ENSG00000271828.1	CTD-2310F14.1	4.39	1.4e-05	0.00263	0.39	0.2	Breast cancer;	chr5:56742321	chr5:56927874~56929573:+
LUAD	cis	rs10129255	0.957	rs12589190	ENSG00000211967.3	IGHV3-53	-4.39	1.4e-05	0.00263	-0.15	-0.2	Kawasaki disease;	chr14:106783079	chr14:106592676~106593347:-
LUAD	cis	rs10129255	0.957	rs7493713	ENSG00000211967.3	IGHV3-53	-4.39	1.4e-05	0.00263	-0.15	-0.2	Kawasaki disease;	chr14:106783685	chr14:106592676~106593347:-
LUAD	cis	rs10129255	0.912	rs35468694	ENSG00000211967.3	IGHV3-53	-4.39	1.4e-05	0.00263	-0.15	-0.2	Kawasaki disease;	chr14:106784199	chr14:106592676~106593347:-
LUAD	cis	rs10129255	0.957	rs8019272	ENSG00000211967.3	IGHV3-53	-4.39	1.4e-05	0.00263	-0.15	-0.2	Kawasaki disease;	chr14:106784709	chr14:106592676~106593347:-
LUAD	cis	rs9910055	0.659	rs227580	ENSG00000267080.4	ASB16-AS1	4.39	1.4e-05	0.00263	0.18	0.2	Total body bone mineral density;	chr17:44145700	chr17:44175973~44186717:-
LUAD	cis	rs3785309	0.519	rs72763696	ENSG00000268836.1	LA16c-OS12.2	-4.39	1.4e-05	0.00264	-0.34	-0.2	Immature fraction of reticulocytes;	chr16:212801	chr16:185748~186294:-
LUAD	cis	rs780096	0.526	rs13391837	ENSG00000234072.1	AC074117.10	-4.39	1.4e-05	0.00264	-0.15	-0.2	Total body bone mineral density;	chr2:27426508	chr2:27356246~27367622:+
LUAD	cis	rs10510102	0.516	rs10437506	ENSG00000276742.1	RP11-500G22.4	4.39	1.41e-05	0.00264	0.33	0.2	Breast cancer;	chr10:121984011	chr10:121956782~121957098:+
LUAD	cis	rs910316	1	rs4903289	ENSG00000279594.1	RP11-950C14.10	-4.39	1.41e-05	0.00264	-0.22	-0.2	Height;	chr14:75157285	chr14:75011269~75012851:-
LUAD	cis	rs13113518	0.812	rs7667741	ENSG00000223305.1	RN7SKP30	4.39	1.41e-05	0.00264	0.23	0.2	Height;	chr4:55544621	chr4:55540502~55540835:-
LUAD	cis	rs17772222	0.74	rs10150311	ENSG00000258983.2	RP11-507K2.2	4.39	1.41e-05	0.00264	0.22	0.2	Coronary artery calcification;	chr14:88510128	chr14:88499334~88515502:+
LUAD	cis	rs897984	0.683	rs9932572	ENSG00000260911.2	RP11-196G11.2	4.39	1.41e-05	0.00264	0.18	0.2	Dementia with Lewy bodies;	chr16:30830321	chr16:31043150~31049868:+
LUAD	cis	rs891378	1	rs1572275	ENSG00000274245.1	RP11-357P18.2	4.39	1.41e-05	0.00264	0.25	0.2	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207305635	chr1:207372559~207373252:+
LUAD	cis	rs8098244	0.683	rs10853591	ENSG00000264745.1	TTC39C-AS1	4.39	1.41e-05	0.00264	0.2	0.2	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23845888	chr18:23994213~24015339:-
LUAD	cis	rs2028299	0.92	rs12594774	ENSG00000259677.1	RP11-493E3.1	4.39	1.41e-05	0.00264	0.24	0.2	Type 2 diabetes;	chr15:89863652	chr15:89876540~89877285:+
LUAD	cis	rs5758659	0.729	rs134866	ENSG00000182057.4	OGFRP1	4.39	1.41e-05	0.00264	0.23	0.2	Cognitive function;	chr22:42254657	chr22:42269753~42275196:+
LUAD	cis	rs11155671	0.53	rs6935829	ENSG00000268592.3	RAET1E-AS1	4.39	1.41e-05	0.00264	0.25	0.2	Testicular germ cell tumor;	chr6:149896675	chr6:149863494~149919507:+
LUAD	cis	rs6957923	0.846	rs12700443	ENSG00000230658.1	KLHL7-AS1	4.39	1.41e-05	0.00264	0.23	0.2	Height;	chr7:23475249	chr7:23101228~23105703:-
LUAD	cis	rs2998286	0.637	rs332113	ENSG00000254635.4	WAC-AS1	-4.39	1.41e-05	0.00264	-0.26	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28634806	chr10:28522652~28532743:-
LUAD	cis	rs2562456	0.876	rs4638726	ENSG00000268081.1	RP11-678G14.2	4.39	1.41e-05	0.00264	0.31	0.2	Pain;	chr19:21409710	chr19:21554640~21569237:-
LUAD	cis	rs1008375	1	rs60178264	ENSG00000249502.1	AC006160.5	-4.39	1.41e-05	0.00264	-0.18	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17683685	chr4:17587467~17614571:-
LUAD	cis	rs1008375	1	rs28497813	ENSG00000249502.1	AC006160.5	-4.39	1.41e-05	0.00264	-0.18	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17683880	chr4:17587467~17614571:-
LUAD	cis	rs1008375	1	rs28480159	ENSG00000249502.1	AC006160.5	-4.39	1.41e-05	0.00264	-0.18	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17684084	chr4:17587467~17614571:-
LUAD	cis	rs4908760	0.864	rs6674832	ENSG00000270282.1	RP5-1115A15.2	4.39	1.41e-05	0.00264	0.21	0.2	Vitiligo;	chr1:8631820	chr1:8512653~8513021:+
LUAD	cis	rs73219805	0.536	rs3200031	ENSG00000228451.3	SDAD1P1	-4.39	1.41e-05	0.00264	-0.5	-0.2	Schizophrenia;	chr8:26369968	chr8:26379259~26382953:-
LUAD	cis	rs73219805	0.536	rs1048527	ENSG00000228451.3	SDAD1P1	-4.39	1.41e-05	0.00264	-0.5	-0.2	Schizophrenia;	chr8:26372177	chr8:26379259~26382953:-
LUAD	cis	rs9341808	0.618	rs6916507	ENSG00000272129.1	RP11-250B2.6	4.39	1.41e-05	0.00264	0.24	0.2	Sitting height ratio;	chr6:80152548	chr6:80355424~80356859:+
LUAD	cis	rs2018683	0.677	rs12540529	ENSG00000228421.2	AC005013.5	4.39	1.41e-05	0.00264	0.22	0.2	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28929767	chr7:28957667~28959345:+
LUAD	cis	rs7017914	0.622	rs10957534	ENSG00000223220.1	Y_RNA	4.39	1.41e-05	0.00265	0.23	0.2	Bone mineral density;	chr8:71096068	chr8:70780914~70781008:-
LUAD	cis	rs875971	1	rs709595	ENSG00000232559.3	GS1-124K5.12	4.39	1.41e-05	0.00265	0.23	0.2	Aortic root size;	chr7:66352346	chr7:66554588~66576923:-
LUAD	cis	rs875971	1	rs811880	ENSG00000232559.3	GS1-124K5.12	4.39	1.41e-05	0.00265	0.23	0.2	Aortic root size;	chr7:66353659	chr7:66554588~66576923:-
LUAD	cis	rs8030379	0.967	rs8036748	ENSG00000230373.7	GOLGA6L5P	-4.39	1.41e-05	0.00265	-0.18	-0.2	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83903084	chr15:84507885~84516814:-
LUAD	cis	rs60180747	0.544	rs9920422	ENSG00000261318.1	RP11-653J6.1	4.39	1.41e-05	0.00265	0.26	0.2	Testicular germ cell tumor;	chr15:66283212	chr15:66278498~66293357:-
LUAD	cis	rs4819052	0.851	rs2838834	ENSG00000237664.1	LINC00316	-4.39	1.41e-05	0.00265	-0.24	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245293	chr21:45338590~45341990:-
LUAD	cis	rs338389	0.542	rs338342	ENSG00000260657.2	RP11-315D16.4	4.39	1.41e-05	0.00265	0.24	0.2	Survival in rectal cancer;	chr15:67979714	chr15:68267792~68277994:-
LUAD	cis	rs7826238	0.601	rs2979206	ENSG00000173295.6	FAM86B3P	4.39	1.41e-05	0.00265	0.2	0.2	Systolic blood pressure;	chr8:8488071	chr8:8228595~8244865:+
LUAD	cis	rs6714710	0.603	rs11691494	ENSG00000230606.9	AC159540.1	-4.39	1.41e-05	0.00265	-0.21	-0.2	Posterior cortical atrophy and Alzheimer's disease;	chr2:97803263	chr2:97416165~97433527:-
LUAD	cis	rs6714710	0.603	rs11684749	ENSG00000230606.9	AC159540.1	-4.39	1.41e-05	0.00265	-0.21	-0.2	Posterior cortical atrophy and Alzheimer's disease;	chr2:97803679	chr2:97416165~97433527:-
LUAD	cis	rs6714710	0.58	rs17489915	ENSG00000230606.9	AC159540.1	-4.39	1.41e-05	0.00265	-0.21	-0.2	Posterior cortical atrophy and Alzheimer's disease;	chr2:97803968	chr2:97416165~97433527:-
LUAD	cis	rs4660214	0.666	rs2275187	ENSG00000228060.1	RP11-69E11.8	4.39	1.41e-05	0.00265	0.18	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39297570	chr1:39565160~39573203:+
LUAD	cis	rs11673344	0.864	rs7256876	ENSG00000226686.6	LINC01535	4.39	1.41e-05	0.00265	0.25	0.2	Obesity-related traits;	chr19:37088570	chr19:37251912~37265535:+
LUAD	cis	rs2243480	1	rs4718269	ENSG00000232559.3	GS1-124K5.12	-4.39	1.41e-05	0.00265	-0.34	-0.2	Diabetic kidney disease;	chr7:65735810	chr7:66554588~66576923:-
LUAD	cis	rs9309473	0.583	rs6713196	ENSG00000163016.8	ALMS1P	4.39	1.41e-05	0.00265	0.22	0.2	Metabolite levels;	chr2:73349277	chr2:73644919~73685576:+
LUAD	cis	rs858239	0.863	rs274058	ENSG00000230042.1	AK3P3	-4.39	1.41e-05	0.00265	-0.25	-0.2	Cerebrospinal fluid biomarker levels;	chr7:23351890	chr7:23129178~23129841:+
LUAD	cis	rs911119	0.818	rs12625182	ENSG00000270001.1	RP11-218C14.8	-4.39	1.41e-05	0.00265	-0.28	-0.2	Chronic kidney disease;	chr20:23623386	chr20:23631826~23632316:-
LUAD	cis	rs911119	0.955	rs8121283	ENSG00000270001.1	RP11-218C14.8	-4.39	1.41e-05	0.00265	-0.28	-0.2	Chronic kidney disease;	chr20:23624365	chr20:23631826~23632316:-
LUAD	cis	rs911119	0.955	rs8115417	ENSG00000270001.1	RP11-218C14.8	-4.39	1.41e-05	0.00265	-0.28	-0.2	Chronic kidney disease;	chr20:23624586	chr20:23631826~23632316:-
LUAD	cis	rs911119	0.955	rs8121405	ENSG00000270001.1	RP11-218C14.8	-4.39	1.41e-05	0.00265	-0.28	-0.2	Chronic kidney disease;	chr20:23624589	chr20:23631826~23632316:-
LUAD	cis	rs911119	0.955	rs8115423	ENSG00000270001.1	RP11-218C14.8	-4.39	1.41e-05	0.00265	-0.28	-0.2	Chronic kidney disease;	chr20:23624616	chr20:23631826~23632316:-
LUAD	cis	rs6142102	0.961	rs761235	ENSG00000275784.1	RP5-1125A11.6	-4.39	1.41e-05	0.00265	-0.22	-0.2	Skin pigmentation;	chr20:33946602	chr20:33989480~33991818:-
LUAD	cis	rs910316	1	rs13099	ENSG00000279594.1	RP11-950C14.10	-4.39	1.41e-05	0.00265	-0.22	-0.2	Height;	chr14:75132452	chr14:75011269~75012851:-
LUAD	cis	rs293748	0.771	rs35135658	ENSG00000250155.1	CTD-2353F22.1	-4.39	1.41e-05	0.00265	-0.26	-0.2	Obesity-related traits;	chr5:36786777	chr5:36666214~36725195:-
LUAD	cis	rs293748	0.771	rs58952013	ENSG00000250155.1	CTD-2353F22.1	-4.39	1.41e-05	0.00265	-0.26	-0.2	Obesity-related traits;	chr5:36787362	chr5:36666214~36725195:-
LUAD	cis	rs10510102	0.516	rs74461504	ENSG00000276742.1	RP11-500G22.4	4.39	1.41e-05	0.00265	0.33	0.2	Breast cancer;	chr10:121986077	chr10:121956782~121957098:+
LUAD	cis	rs1005277	0.579	rs2472181	ENSG00000263064.2	RP11-291L22.7	4.39	1.41e-05	0.00265	0.21	0.2	Extrinsic epigenetic age acceleration;	chr10:38097836	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.579	rs2474574	ENSG00000263064.2	RP11-291L22.7	4.39	1.41e-05	0.00265	0.21	0.2	Extrinsic epigenetic age acceleration;	chr10:38098367	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.579	rs2504140	ENSG00000263064.2	RP11-291L22.7	4.39	1.41e-05	0.00265	0.21	0.2	Extrinsic epigenetic age acceleration;	chr10:38098651	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.579	rs2474575	ENSG00000263064.2	RP11-291L22.7	4.39	1.41e-05	0.00265	0.21	0.2	Extrinsic epigenetic age acceleration;	chr10:38098973	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.579	rs2472182	ENSG00000263064.2	RP11-291L22.7	4.39	1.41e-05	0.00265	0.21	0.2	Extrinsic epigenetic age acceleration;	chr10:38099937	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.579	rs2021649	ENSG00000263064.2	RP11-291L22.7	4.39	1.41e-05	0.00265	0.21	0.2	Extrinsic epigenetic age acceleration;	chr10:38103194	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.579	rs2472183	ENSG00000263064.2	RP11-291L22.7	4.39	1.41e-05	0.00265	0.21	0.2	Extrinsic epigenetic age acceleration;	chr10:38103567	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.579	rs2505197	ENSG00000263064.2	RP11-291L22.7	4.39	1.41e-05	0.00265	0.21	0.2	Extrinsic epigenetic age acceleration;	chr10:38104382	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.579	rs2505196	ENSG00000263064.2	RP11-291L22.7	4.39	1.41e-05	0.00265	0.21	0.2	Extrinsic epigenetic age acceleration;	chr10:38104635	chr10:38448689~38448949:+
LUAD	cis	rs7204230	1	rs3743771	ENSG00000261291.1	RP11-295M3.2	4.39	1.42e-05	0.00266	0.25	0.2	Fibrinogen;	chr16:53324527	chr16:53168522~53169450:+
LUAD	cis	rs1113500	0.787	rs10881502	ENSG00000226822.1	RP11-356N1.2	-4.39	1.42e-05	0.00266	-0.22	-0.2	Growth-regulated protein alpha levels;	chr1:108099197	chr1:108071482~108074519:+
LUAD	cis	rs2933343	0.909	rs1683817	ENSG00000231305.3	RP11-723O4.2	4.39	1.42e-05	0.00266	0.24	0.2	IgG glycosylation;	chr3:128932693	chr3:128861313~128871540:-
LUAD	cis	rs473651	0.935	rs482775	ENSG00000229915.1	AC016999.2	-4.39	1.42e-05	0.00266	-0.26	-0.2	Multiple system atrophy;	chr2:238426762	chr2:238427077~238427729:-
LUAD	cis	rs4819052	0.851	rs2838848	ENSG00000237664.1	LINC00316	-4.39	1.42e-05	0.00266	-0.24	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251102	chr21:45338590~45341990:-
LUAD	cis	rs4819052	0.851	rs2838849	ENSG00000237664.1	LINC00316	-4.39	1.42e-05	0.00266	-0.24	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251112	chr21:45338590~45341990:-
LUAD	cis	rs6012564	1	rs2426106	ENSG00000230758.1	SNAP23P	-4.39	1.42e-05	0.00266	-0.21	-0.2	Anger;	chr20:49022927	chr20:49038357~49038602:-
LUAD	cis	rs6012564	1	rs3091866	ENSG00000230758.1	SNAP23P	-4.39	1.42e-05	0.00266	-0.21	-0.2	Anger;	chr20:49031816	chr20:49038357~49038602:-
LUAD	cis	rs7005380	0.581	rs7007672	ENSG00000279347.1	RP11-85I17.2	-4.39	1.42e-05	0.00266	-0.19	-0.2	Interstitial lung disease;	chr8:119906981	chr8:119838736~119840385:-
LUAD	cis	rs8014204	0.604	rs11159109	ENSG00000279594.1	RP11-950C14.10	4.39	1.42e-05	0.00266	0.24	0.2	Caffeine consumption;	chr14:74922371	chr14:75011269~75012851:-
LUAD	cis	rs950169	0.65	rs12902052	ENSG00000275120.1	RP11-182J1.17	4.39	1.42e-05	0.00266	0.31	0.2	Schizophrenia;	chr15:84582607	chr15:84599434~84606463:-
LUAD	cis	rs6465657	0.903	rs11767962	ENSG00000272950.1	RP11-307C18.1	4.39	1.42e-05	0.00266	0.24	0.2	Prostate cancer;Prostate cancer (SNP x SNP interaction);	chr7:98149264	chr7:98322853~98323430:+
LUAD	cis	rs8031584	0.918	rs61997139	ENSG00000270015.1	RP11-540B6.6	-4.39	1.42e-05	0.00266	-0.14	-0.2	Huntington's disease progression;	chr15:30981399	chr15:30926514~30928407:+
LUAD	cis	rs9393777	0.92	rs34071253	ENSG00000219392.1	RP1-265C24.5	-4.39	1.42e-05	0.00266	-0.38	-0.2	Intelligence (multi-trait analysis);	chr6:27424023	chr6:28115628~28116551:+
LUAD	cis	rs6496932	0.802	rs10163187	ENSG00000218052.5	ADAMTS7P4	4.39	1.42e-05	0.00266	0.22	0.2	Central corneal thickness;Corneal structure;	chr15:85327287	chr15:85255369~85330334:-
LUAD	cis	rs7760535	0.794	rs3851225	ENSG00000230177.1	RP5-1112D6.4	-4.39	1.42e-05	0.00266	-0.17	-0.2	Metabolic traits;	chr6:111503929	chr6:111277932~111278742:+
LUAD	cis	rs7665090	1	rs5026472	ENSG00000246560.2	RP11-10L12.4	4.39	1.42e-05	0.00266	0.24	0.2	Primary biliary cholangitis;	chr4:102633616	chr4:102828055~102844075:+
LUAD	cis	rs17772222	0.917	rs8006652	ENSG00000258789.1	RP11-507K2.3	-4.39	1.42e-05	0.00266	-0.27	-0.2	Coronary artery calcification;	chr14:88631290	chr14:88551597~88552493:+
LUAD	cis	rs950169	0.579	rs62027818	ENSG00000225151.9	GOLGA2P7	-4.39	1.42e-05	0.00266	-0.29	-0.2	Schizophrenia;	chr15:83992393	chr15:84199311~84230136:-
LUAD	cis	rs2243480	0.803	rs36004293	ENSG00000232559.3	GS1-124K5.12	4.39	1.42e-05	0.00266	0.34	0.2	Diabetic kidney disease;	chr7:65951525	chr7:66554588~66576923:-
LUAD	cis	rs2243480	0.803	rs35268390	ENSG00000232559.3	GS1-124K5.12	4.39	1.42e-05	0.00266	0.34	0.2	Diabetic kidney disease;	chr7:65951549	chr7:66554588~66576923:-
LUAD	cis	rs6496932	0.802	rs6497006	ENSG00000218052.5	ADAMTS7P4	4.39	1.42e-05	0.00266	0.22	0.2	Central corneal thickness;Corneal structure;	chr15:85330306	chr15:85255369~85330334:-
LUAD	cis	rs8062405	0.655	rs7184597	ENSG00000261419.1	RP11-57A19.4	4.39	1.42e-05	0.00266	0.22	0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28659696~28740781:-
LUAD	cis	rs228614	0.51	rs223468	ENSG00000251288.2	RP11-10L12.2	-4.39	1.42e-05	0.00266	-0.23	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102779265	chr4:102751401~102752641:+
LUAD	cis	rs228614	0.51	rs223465	ENSG00000251288.2	RP11-10L12.2	-4.39	1.42e-05	0.00266	-0.23	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780174	chr4:102751401~102752641:+
LUAD	cis	rs228614	0.51	rs223464	ENSG00000251288.2	RP11-10L12.2	-4.39	1.42e-05	0.00266	-0.23	-0.2	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780603	chr4:102751401~102752641:+
LUAD	cis	rs3096299	0.692	rs4785565	ENSG00000261118.1	RP11-104N10.1	4.39	1.42e-05	0.00266	0.2	0.2	Multiple myeloma (IgH translocation);	chr16:89449351	chr16:89492017~89504460:-
LUAD	cis	rs4819052	0.788	rs2236449	ENSG00000237664.1	LINC00316	-4.39	1.42e-05	0.00267	-0.24	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45282591	chr21:45338590~45341990:-
LUAD	cis	rs2243480	1	rs59794892	ENSG00000232559.3	GS1-124K5.12	4.39	1.42e-05	0.00267	0.34	0.2	Diabetic kidney disease;	chr7:65950886	chr7:66554588~66576923:-
LUAD	cis	rs4908760	0.73	rs10779704	ENSG00000270282.1	RP5-1115A15.2	4.39	1.42e-05	0.00267	0.21	0.2	Vitiligo;	chr1:8633478	chr1:8512653~8513021:+
LUAD	cis	rs561341	1	rs7214017	ENSG00000265798.5	RP11-271K11.5	4.39	1.42e-05	0.00267	0.29	0.2	Hip circumference adjusted for BMI;	chr17:32005201	chr17:31038575~31059121:-
LUAD	cis	rs9322193	0.923	rs9505823	ENSG00000268592.3	RAET1E-AS1	4.39	1.42e-05	0.00267	0.24	0.2	Lung cancer;	chr6:149628899	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.923	rs9689599	ENSG00000268592.3	RAET1E-AS1	4.39	1.42e-05	0.00267	0.24	0.2	Lung cancer;	chr6:149631973	chr6:149863494~149919507:+
LUAD	cis	rs1609391	0.567	rs835633	ENSG00000239213.4	NCK1-AS1	4.39	1.42e-05	0.00267	0.21	0.2	Neuroticism;	chr3:136957654	chr3:136841726~136862054:-
LUAD	cis	rs726288	1	rs12243433	ENSG00000225484.5	NUTM2B-AS1	-4.39	1.42e-05	0.00267	-0.46	-0.2	Rheumatoid arthritis;	chr10:79973021	chr10:79663088~79826594:-
LUAD	cis	rs726288	1	rs12264259	ENSG00000225484.5	NUTM2B-AS1	-4.39	1.42e-05	0.00267	-0.46	-0.2	Rheumatoid arthritis;	chr10:79973032	chr10:79663088~79826594:-
LUAD	cis	rs726288	1	rs12245535	ENSG00000225484.5	NUTM2B-AS1	-4.39	1.42e-05	0.00267	-0.46	-0.2	Rheumatoid arthritis;	chr10:79973248	chr10:79663088~79826594:-
LUAD	cis	rs7923837	0.687	rs10882101	ENSG00000236493.2	EIF2S2P3	4.39	1.42e-05	0.00267	0.22	0.2	Multiple sclerosis;Body mass index;	chr10:92702670	chr10:92668745~92669743:-
LUAD	cis	rs12468226	0.752	rs116078354	ENSG00000272966.1	RP11-686O6.1	4.39	1.42e-05	0.00267	0.32	0.2	Urate levels;	chr2:202136356	chr2:202336739~202337200:+
LUAD	cis	rs2562456	0.876	rs2359144	ENSG00000268081.1	RP11-678G14.2	4.39	1.42e-05	0.00267	0.31	0.2	Pain;	chr19:21407834	chr19:21554640~21569237:-
LUAD	cis	rs1501911	0.611	rs2221268	ENSG00000248489.1	CTD-2007H13.3	-4.39	1.43e-05	0.00267	-0.24	-0.2	Lung function (FEV1/FVC);	chr5:99021711	chr5:98929171~98995013:+
LUAD	cis	rs453301	0.686	rs7814328	ENSG00000253981.4	ALG1L13P	-4.39	1.43e-05	0.00267	-0.24	-0.2	Joint mobility (Beighton score);	chr8:9018719	chr8:8236003~8244667:-
LUAD	cis	rs750134	0.892	rs75642916	ENSG00000257221.1	RP11-689B22.2	-4.39	1.43e-05	0.00267	-0.3	-0.2	Low high density lipoprotein cholesterol levels;	chr12:108705847	chr12:108628687~108641318:+
LUAD	cis	rs750134	1	rs10507233	ENSG00000257221.1	RP11-689B22.2	-4.39	1.43e-05	0.00267	-0.3	-0.2	Low high density lipoprotein cholesterol levels;	chr12:108709908	chr12:108628687~108641318:+
LUAD	cis	rs750134	1	rs78457084	ENSG00000257221.1	RP11-689B22.2	-4.39	1.43e-05	0.00267	-0.3	-0.2	Low high density lipoprotein cholesterol levels;	chr12:108713024	chr12:108628687~108641318:+
LUAD	cis	rs9341808	0.718	rs910266	ENSG00000260645.1	RP11-250B2.5	4.38	1.43e-05	0.00267	0.19	0.2	Sitting height ratio;	chr6:80211453	chr6:80466958~80469080:+
LUAD	cis	rs8062405	0.573	rs7187575	ENSG00000261419.1	RP11-57A19.4	4.38	1.43e-05	0.00267	0.23	0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28978780	chr16:28659696~28740781:-
LUAD	cis	rs36423	1	rs36423	ENSG00000266869.1	RP6-114E22.1	-4.38	1.43e-05	0.00267	-0.32	-0.2	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71886485	chr14:71848606~71908430:+
LUAD	cis	rs875971	0.66	rs801193	ENSG00000236529.1	RP13-254B10.1	-4.38	1.43e-05	0.00267	-0.2	-0.2	Aortic root size;	chr7:66565625	chr7:65840212~65840596:+
LUAD	cis	rs41411047	0.826	rs73155079	ENSG00000271711.1	RP11-392O18.2	4.38	1.43e-05	0.00267	0.37	0.2	Myocardial infarction;	chr3:149858673	chr3:150611262~150611877:-
LUAD	cis	rs394563	0.69	rs237009	ENSG00000216906.2	RP11-350J20.9	4.38	1.43e-05	0.00267	0.24	0.2	Dupuytren's disease;	chr6:149438416	chr6:149904243~149906418:+
LUAD	cis	rs860295	0.702	rs34620961	ENSG00000225855.5	RUSC1-AS1	4.38	1.43e-05	0.00267	0.14	0.2	Body mass index;	chr1:155680036	chr1:155316863~155324176:-
LUAD	cis	rs750134	0.901	rs1362614	ENSG00000257221.1	RP11-689B22.2	-4.38	1.43e-05	0.00268	-0.29	-0.2	Low high density lipoprotein cholesterol levels;	chr12:108670182	chr12:108628687~108641318:+
LUAD	cis	rs1499614	1	rs1267817	ENSG00000229886.1	RP5-1132H15.3	4.38	1.43e-05	0.00268	0.34	0.2	Gout;	chr7:66645053	chr7:66025126~66031544:-
LUAD	cis	rs2731006	0.591	rs7976690	ENSG00000257114.2	RP11-25I15.3	4.38	1.43e-05	0.00268	0.3	0.2	Panic disorder;	chr12:42814392	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.591	rs7962980	ENSG00000257114.2	RP11-25I15.3	4.38	1.43e-05	0.00268	0.3	0.2	Panic disorder;	chr12:42814441	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.591	rs11181694	ENSG00000257114.2	RP11-25I15.3	4.38	1.43e-05	0.00268	0.3	0.2	Panic disorder;	chr12:42814797	chr12:42692216~42717119:+
LUAD	cis	rs763121	0.889	rs2267390	ENSG00000228274.3	RP3-508I15.9	-4.38	1.43e-05	0.00268	-0.19	-0.2	Menopause (age at onset);	chr22:38493652	chr22:38667585~38681820:-
LUAD	cis	rs6687758	0.945	rs12033415	ENSG00000227925.1	RP11-191N8.2	4.38	1.43e-05	0.00268	0.27	0.2	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221981726	chr1:221827666~221840666:-
LUAD	cis	rs17685	0.712	rs60721456	ENSG00000280388.1	RP11-229D13.3	-4.38	1.43e-05	0.00268	-0.19	-0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76114502	chr7:76043977~76045963:-
LUAD	cis	rs7219021	0.743	rs575556	ENSG00000234494.6	SP2-AS1	4.38	1.43e-05	0.00268	0.23	0.2	Schizophrenia or bipolar disorder;	chr17:48780125	chr17:47897330~47941410:-
LUAD	cis	rs4554975	0.902	rs4491335	ENSG00000274723.1	RP11-618L22.1	-4.38	1.43e-05	0.00268	-0.23	-0.2	Metabolite levels (small molecules and protein measures);	chr12:46809717	chr12:46970504~46972155:+
LUAD	cis	rs7590268	0.666	rs12104876	ENSG00000279873.2	LINC01126	4.38	1.43e-05	0.00268	0.19	0.2	Orofacial clefts;	chr2:43400239	chr2:43227210~43228855:+
LUAD	cis	rs6095360	0.933	rs348267	ENSG00000222365.1	SNORD12B	-4.38	1.43e-05	0.00268	-0.2	-0.2	Intelligence (multi-trait analysis);	chr20:49159384	chr20:49280319~49280409:+
LUAD	cis	rs17772222	1	rs17124700	ENSG00000258983.2	RP11-507K2.2	4.38	1.43e-05	0.00268	0.24	0.2	Coronary artery calcification;	chr14:88439285	chr14:88499334~88515502:+
LUAD	cis	rs12073359	1	rs72692857	ENSG00000223945.2	RP11-458I7.1	-4.38	1.43e-05	0.00268	-0.29	-0.2	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150029674	chr1:150053864~150055034:+
LUAD	cis	rs12073359	0.954	rs28366567	ENSG00000223945.2	RP11-458I7.1	-4.38	1.43e-05	0.00268	-0.29	-0.2	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150032389	chr1:150053864~150055034:+
LUAD	cis	rs1729951	0.546	rs12054219	ENSG00000239213.4	NCK1-AS1	4.38	1.43e-05	0.00268	0.21	0.2	Neuroticism;	chr3:136958630	chr3:136841726~136862054:-
LUAD	cis	rs17406451	0.759	rs6544651	ENSG00000279873.2	LINC01126	4.38	1.43e-05	0.00268	0.17	0.2	Mitochondrial DNA levels;	chr2:43396656	chr2:43227210~43228855:+
LUAD	cis	rs7208859	0.623	rs11658022	ENSG00000280069.1	CTD-2349P21.3	-4.38	1.43e-05	0.00268	-0.27	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30738182~30740275:+
LUAD	cis	rs338389	0.521	rs338381	ENSG00000260657.2	RP11-315D16.4	-4.38	1.43e-05	0.00268	-0.24	-0.2	Survival in rectal cancer;	chr15:67951850	chr15:68267792~68277994:-
LUAD	cis	rs4819052	0.851	rs2838839	ENSG00000237664.1	LINC00316	4.38	1.43e-05	0.00268	0.24	0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45247943	chr21:45338590~45341990:-
LUAD	cis	rs2880765	0.835	rs4843063	ENSG00000259416.2	RP11-158M2.5	4.38	1.43e-05	0.00268	0.2	0.2	Coronary artery disease;	chr15:85505517	chr15:85754941~85756237:-
LUAD	cis	rs12478296	0.685	rs35577962	ENSG00000261186.2	RP11-341N2.1	-4.38	1.43e-05	0.00268	-0.33	-0.2	Obesity-related traits;	chr2:242051424	chr2:242087351~242088457:-
LUAD	cis	rs6570726	0.791	rs7765687	ENSG00000235652.6	RP11-545I5.3	4.38	1.43e-05	0.00268	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145593964	chr6:145799409~145886585:+
LUAD	cis	rs13113518	1	rs1047354	ENSG00000272969.1	RP11-528I4.2	4.38	1.43e-05	0.00268	0.2	0.2	Height;	chr4:55429416	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs1056547	ENSG00000272969.1	RP11-528I4.2	4.38	1.43e-05	0.00268	0.2	0.2	Height;	chr4:55430596	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs1056545	ENSG00000272969.1	RP11-528I4.2	4.38	1.43e-05	0.00268	0.2	0.2	Height;	chr4:55430730	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs5863	ENSG00000272969.1	RP11-528I4.2	4.38	1.43e-05	0.00268	0.2	0.2	Height;	chr4:55430740	chr4:55547112~55547889:+
LUAD	cis	rs13113518	0.966	rs6828570	ENSG00000272969.1	RP11-528I4.2	4.38	1.43e-05	0.00268	0.2	0.2	Height;	chr4:55431595	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs3749474	ENSG00000272969.1	RP11-528I4.2	4.38	1.43e-05	0.00268	0.2	0.2	Height;	chr4:55434518	chr4:55547112~55547889:+
LUAD	cis	rs9322193	0.923	rs9689723	ENSG00000268592.3	RAET1E-AS1	4.38	1.43e-05	0.00268	0.24	0.2	Lung cancer;	chr6:149655935	chr6:149863494~149919507:+
LUAD	cis	rs4879677	1	rs7859172	ENSG00000215441.3	CTAGE12P	-4.38	1.43e-05	0.00268	-0.25	-0.2	Gut microbiome composition (summer and winter);	chr9:27659388	chr9:27608382~27610745:-
LUAD	cis	rs910316	1	rs175436	ENSG00000279594.1	RP11-950C14.10	-4.38	1.43e-05	0.00268	-0.22	-0.2	Height;	chr14:75141980	chr14:75011269~75012851:-
LUAD	cis	rs6957923	0.935	rs10950943	ENSG00000230658.1	KLHL7-AS1	4.38	1.43e-05	0.00269	0.24	0.2	Height;	chr7:23450611	chr7:23101228~23105703:-
LUAD	cis	rs11168618	0.703	rs4760721	ENSG00000240399.1	RP1-228P16.1	4.38	1.44e-05	0.00269	0.19	0.2	Adiponectin levels;	chr12:48531941	chr12:48054813~48055591:-
LUAD	cis	rs11168618	0.74	rs4760723	ENSG00000240399.1	RP1-228P16.1	4.38	1.44e-05	0.00269	0.19	0.2	Adiponectin levels;	chr12:48532079	chr12:48054813~48055591:-
LUAD	cis	rs10771431	0.81	rs10771418	ENSG00000111788.10	RP11-22B23.1	4.38	1.44e-05	0.00269	0.17	0.2	Breast size;	chr12:9206399	chr12:9277235~9313241:+
LUAD	cis	rs6687821	1	rs6687821	ENSG00000267734.1	RP4-604K5.3	-4.38	1.44e-05	0.00269	-0.24	-0.2	Yeast infection;	chr1:86741033	chr1:86932199~86934891:-
LUAD	cis	rs6676180	0.514	rs868675	ENSG00000231365.4	RP11-418J17.1	-4.38	1.44e-05	0.00269	-0.23	-0.2	Monobrow;	chr1:119230973	chr1:119140396~119275973:+
LUAD	cis	rs12468226	0.574	rs4675271	ENSG00000272966.1	RP11-686O6.1	-4.38	1.44e-05	0.00269	-0.29	-0.2	Urate levels;	chr2:202170967	chr2:202336739~202337200:+
LUAD	cis	rs1008375	1	rs13106338	ENSG00000249502.1	AC006160.5	4.38	1.44e-05	0.00269	0.19	0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17675248	chr4:17587467~17614571:-
LUAD	cis	rs2243480	1	rs1723267	ENSG00000229886.1	RP5-1132H15.3	4.38	1.44e-05	0.00269	0.33	0.2	Diabetic kidney disease;	chr7:66008327	chr7:66025126~66031544:-
LUAD	cis	rs7208859	0.673	rs17826219	ENSG00000263603.1	CTD-2349P21.5	-4.38	1.44e-05	0.00269	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834827	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs61223749	ENSG00000263603.1	CTD-2349P21.5	-4.38	1.44e-05	0.00269	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30836729	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs3764420	ENSG00000263603.1	CTD-2349P21.5	-4.38	1.44e-05	0.00269	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837136	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs3764421	ENSG00000263603.1	CTD-2349P21.5	-4.38	1.44e-05	0.00269	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30840635	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs11651858	ENSG00000263603.1	CTD-2349P21.5	-4.38	1.44e-05	0.00269	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843700	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs36056619	ENSG00000263603.1	CTD-2349P21.5	-4.38	1.44e-05	0.00269	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30845266	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs9909497	ENSG00000263603.1	CTD-2349P21.5	-4.38	1.44e-05	0.00269	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846210	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs11080135	ENSG00000263603.1	CTD-2349P21.5	-4.38	1.44e-05	0.00269	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30849463	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs9894876	ENSG00000263603.1	CTD-2349P21.5	-4.38	1.44e-05	0.00269	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855002	chr17:30729469~30731202:+
LUAD	cis	rs7493	0.853	rs17166879	ENSG00000233942.1	AC004012.1	4.38	1.44e-05	0.00269	0.29	0.2	Yu-Zhi constitution type in type 2 diabetes;	chr7:95424103	chr7:95471835~95473998:+
LUAD	cis	rs2284219	0.565	rs2284217	ENSG00000196295.10	AC005154.6	-4.38	1.44e-05	0.00269	-0.15	-0.2	Type 2 diabetes;	chr7:30673992	chr7:30516309~30594809:-
LUAD	cis	rs860295	0.702	rs12047756	ENSG00000225855.5	RUSC1-AS1	4.38	1.44e-05	0.00269	0.14	0.2	Body mass index;	chr1:155655153	chr1:155316863~155324176:-
LUAD	cis	rs28386778	0.897	rs2584635	ENSG00000240280.5	TCAM1P	-4.38	1.44e-05	0.00269	-0.23	-0.2	Prudent dietary pattern;	chr17:63788574	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.897	rs9915552	ENSG00000240280.5	TCAM1P	-4.38	1.44e-05	0.00269	-0.23	-0.2	Prudent dietary pattern;	chr17:63791735	chr17:63849292~63864379:+
LUAD	cis	rs16873450	0.527	rs10950958	ENSG00000234800.2	PCMTD1P3	4.38	1.44e-05	0.0027	0.22	0.2	Verbal memory performance (residualized delayed recall level);	chr7:23748650	chr7:23721311~23721782:-
LUAD	cis	rs6012564	1	rs6063353	ENSG00000230758.1	SNAP23P	4.38	1.44e-05	0.0027	0.21	0.2	Anger;	chr20:49103273	chr20:49038357~49038602:-
LUAD	cis	rs6012564	1	rs6063354	ENSG00000230758.1	SNAP23P	4.38	1.44e-05	0.0027	0.21	0.2	Anger;	chr20:49103412	chr20:49038357~49038602:-
LUAD	cis	rs7208859	0.673	rs11657270	ENSG00000266490.1	CTD-2349P21.9	4.38	1.44e-05	0.0027	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887369	chr17:30792372~30792833:+
LUAD	cis	rs4934494	0.911	rs7098233	ENSG00000240996.1	RP11-80H5.7	4.38	1.44e-05	0.0027	0.26	0.2	Red blood cell count;	chr10:89663111	chr10:89694295~89697928:-
LUAD	cis	rs9341808	0.718	rs3812121	ENSG00000272129.1	RP11-250B2.6	4.38	1.44e-05	0.0027	0.24	0.2	Sitting height ratio;	chr6:80259010	chr6:80355424~80356859:+
LUAD	cis	rs116095464	1	rs62331560	ENSG00000277812.1	AC021087.1	4.38	1.44e-05	0.0027	0.56	0.2	Breast cancer;	chr5:346670	chr5:262769~262881:+
LUAD	cis	rs4660214	0.666	rs636083	ENSG00000228060.1	RP11-69E11.8	-4.38	1.44e-05	0.0027	-0.18	-0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39356009	chr1:39565160~39573203:+
LUAD	cis	rs11065706	0.699	rs3026482	ENSG00000278993.1	RP3-424M6.4	4.38	1.44e-05	0.0027	0.25	0.2	Heart rate;	chr12:110342735	chr12:110501614~110503441:+
LUAD	cis	rs6570726	1	rs444564	ENSG00000235652.6	RP11-545I5.3	4.38	1.44e-05	0.0027	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145538659	chr6:145799409~145886585:+
LUAD	cis	rs2880765	0.743	rs8039049	ENSG00000259416.2	RP11-158M2.5	4.38	1.44e-05	0.0027	0.2	0.2	Coronary artery disease;	chr15:85464398	chr15:85754941~85756237:-
LUAD	cis	rs2880765	0.743	rs8039631	ENSG00000259416.2	RP11-158M2.5	4.38	1.44e-05	0.0027	0.2	0.2	Coronary artery disease;	chr15:85464700	chr15:85754941~85756237:-
LUAD	cis	rs2880765	0.743	rs12906308	ENSG00000259416.2	RP11-158M2.5	-4.38	1.44e-05	0.0027	-0.2	-0.2	Coronary artery disease;	chr15:85464828	chr15:85754941~85756237:-
LUAD	cis	rs8180040	0.62	rs17784127	ENSG00000271161.1	BOLA2P2	-4.38	1.44e-05	0.0027	-0.19	-0.2	Colorectal cancer;	chr3:47020210	chr3:47499841~47500407:+
LUAD	cis	rs151234	0.741	rs10521145	ENSG00000259982.1	CDC37P1	4.38	1.44e-05	0.0027	0.34	0.2	Platelet distribution width;	chr16:28585563	chr16:28700294~28701540:-
LUAD	cis	rs9788333	0.962	rs12584792	ENSG00000224429.6	LINC00539	-4.38	1.45e-05	0.0027	-0.19	-0.2	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr13:21313069	chr13:21303515~21348721:-
LUAD	cis	rs7829975	0.711	rs4481596	ENSG00000173295.6	FAM86B3P	4.38	1.45e-05	0.0027	0.2	0.2	Mood instability;	chr8:8846820	chr8:8228595~8244865:+
LUAD	cis	rs7136702	1	rs7136702	ENSG00000272368.2	RP4-605O3.4	4.38	1.45e-05	0.0027	0.22	0.2	Colorectal cancer (SNP x SNP interaction);	chr12:50486433	chr12:50112197~50165618:+
LUAD	cis	rs12291225	0.585	rs34171876	ENSG00000251991.1	RNU7-49P	4.38	1.45e-05	0.00271	0.22	0.2	Sense of smell;	chr11:14332411	chr11:14478892~14478953:+
LUAD	cis	rs2354432	0.556	rs11239964	ENSG00000226015.2	CCT8P1	4.38	1.45e-05	0.00271	0.39	0.2	Mitochondrial DNA levels;	chr1:147282229	chr1:147203276~147204932:-
LUAD	cis	rs7985	0.901	rs6005133	ENSG00000244625.4	MIATNB	4.38	1.45e-05	0.00271	0.2	0.2	Electroencephalogram traits;	chr22:26681021	chr22:26672767~26780207:+
LUAD	cis	rs9303029	1	rs9891900	ENSG00000265458.1	RP13-20L14.6	4.38	1.45e-05	0.00271	0.37	0.2	Protein quantitative trait loci;	chr17:82466510	chr17:82454273~82458521:-
LUAD	cis	rs11065706	0.699	rs11065612	ENSG00000278993.1	RP3-424M6.4	4.38	1.45e-05	0.00271	0.24	0.2	Heart rate;	chr12:110270728	chr12:110501614~110503441:+
LUAD	cis	rs7204230	0.96	rs2892439	ENSG00000261291.1	RP11-295M3.2	4.38	1.45e-05	0.00271	0.25	0.2	Fibrinogen;	chr16:53341152	chr16:53168522~53169450:+
LUAD	cis	rs1979679	0.918	rs2348234	ENSG00000278733.1	RP11-425D17.1	4.38	1.45e-05	0.00271	0.25	0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28354126	chr12:28185625~28186190:-
LUAD	cis	rs875971	0.638	rs35986979	ENSG00000236529.1	RP13-254B10.1	-4.38	1.45e-05	0.00271	-0.2	-0.2	Aortic root size;	chr7:66624003	chr7:65840212~65840596:+
LUAD	cis	rs9910055	0.636	rs7089	ENSG00000267080.4	ASB16-AS1	-4.38	1.45e-05	0.00271	-0.18	-0.2	Total body bone mineral density;	chr17:44191649	chr17:44175973~44186717:-
LUAD	cis	rs9910055	0.639	rs11656871	ENSG00000267080.4	ASB16-AS1	-4.38	1.45e-05	0.00271	-0.18	-0.2	Total body bone mineral density;	chr17:44191773	chr17:44175973~44186717:-
LUAD	cis	rs13113518	0.812	rs12500456	ENSG00000223305.1	RN7SKP30	4.38	1.45e-05	0.00271	0.23	0.2	Height;	chr4:55561053	chr4:55540502~55540835:-
LUAD	cis	rs7119038	0.774	rs2004781	ENSG00000255422.1	AP002954.4	4.38	1.45e-05	0.00271	0.31	0.2	Sjögren's syndrome;	chr11:118748544	chr11:118704607~118750263:+
LUAD	cis	rs7119038	0.818	rs3889239	ENSG00000255422.1	AP002954.4	4.38	1.45e-05	0.00271	0.31	0.2	Sjögren's syndrome;	chr11:118749251	chr11:118704607~118750263:+
LUAD	cis	rs7430456	0.837	rs7651130	ENSG00000225790.1	RP11-2L8.1	-4.38	1.45e-05	0.00271	-0.23	-0.2	Breast cancer;	chr3:177719720	chr3:177934823~177937662:+
LUAD	cis	rs2408955	0.542	rs7975632	ENSG00000257735.1	RP11-370I10.6	4.38	1.45e-05	0.00271	0.24	0.2	Glycated hemoglobin levels;	chr12:48049265	chr12:48350945~48442411:+
LUAD	cis	rs812925	0.537	rs10208769	ENSG00000271889.1	RP11-493E12.1	-4.38	1.45e-05	0.00271	-0.23	-0.2	Immature fraction of reticulocytes;	chr2:61378479	chr2:61151433~61162105:-
LUAD	cis	rs9487094	0.922	rs68042406	ENSG00000260273.1	RP11-425D10.10	4.38	1.45e-05	0.00272	0.27	0.2	Height;	chr6:109482392	chr6:109382795~109383666:+
LUAD	cis	rs6723226	0.767	rs10172308	ENSG00000276334.1	AL133243.1	-4.38	1.45e-05	0.00272	-0.23	-0.2	Intelligence (multi-trait analysis);	chr2:32330691	chr2:32521927~32523547:+
LUAD	cis	rs7493	0.755	rs62467350	ENSG00000233942.1	AC004012.1	4.38	1.45e-05	0.00272	0.28	0.2	Yu-Zhi constitution type in type 2 diabetes;	chr7:95340802	chr7:95471835~95473998:+
LUAD	cis	rs7493	0.755	rs17886036	ENSG00000233942.1	AC004012.1	4.38	1.45e-05	0.00272	0.28	0.2	Yu-Zhi constitution type in type 2 diabetes;	chr7:95358415	chr7:95471835~95473998:+
LUAD	cis	rs9545047	0.604	rs9318640	ENSG00000227354.5	RBM26-AS1	-4.38	1.45e-05	0.00272	-0.21	-0.2	Schizophrenia;	chr13:79426527	chr13:79406309~79424328:+
LUAD	cis	rs2243480	1	rs6964530	ENSG00000232559.3	GS1-124K5.12	-4.38	1.45e-05	0.00272	-0.34	-0.2	Diabetic kidney disease;	chr7:66253864	chr7:66554588~66576923:-
LUAD	cis	rs858239	0.601	rs6461702	ENSG00000226816.2	AC005082.12	4.38	1.45e-05	0.00272	0.27	0.2	Cerebrospinal fluid biomarker levels;	chr7:23209654	chr7:23206013~23208045:+
LUAD	cis	rs7208859	0.673	rs9889968	ENSG00000263603.1	CTD-2349P21.5	-4.38	1.45e-05	0.00272	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30893110	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs61348930	ENSG00000263603.1	CTD-2349P21.5	-4.38	1.45e-05	0.00272	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30894745	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.614	rs28758251	ENSG00000263603.1	CTD-2349P21.5	-4.38	1.45e-05	0.00272	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896294	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs9899943	ENSG00000263603.1	CTD-2349P21.5	-4.38	1.45e-05	0.00272	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896907	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs11080138	ENSG00000263603.1	CTD-2349P21.5	-4.38	1.45e-05	0.00272	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30897524	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs73265612	ENSG00000263603.1	CTD-2349P21.5	-4.38	1.45e-05	0.00272	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30898965	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs2433	ENSG00000263603.1	CTD-2349P21.5	-4.38	1.45e-05	0.00272	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30899210	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs11658435	ENSG00000263603.1	CTD-2349P21.5	-4.38	1.45e-05	0.00272	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30901543	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs73265624	ENSG00000263603.1	CTD-2349P21.5	-4.38	1.45e-05	0.00272	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905048	chr17:30729469~30731202:+
LUAD	cis	rs6545883	0.542	rs7584500	ENSG00000271889.1	RP11-493E12.1	4.38	1.45e-05	0.00272	0.23	0.2	Tuberculosis;	chr2:61464980	chr2:61151433~61162105:-
LUAD	cis	rs6964587	0.869	rs11769726	ENSG00000188693.7	CYP51A1-AS1	4.38	1.46e-05	0.00272	0.24	0.2	Breast cancer;	chr7:91855917	chr7:92134604~92180725:+
LUAD	cis	rs6964587	0.839	rs10236107	ENSG00000188693.7	CYP51A1-AS1	4.38	1.46e-05	0.00272	0.24	0.2	Breast cancer;	chr7:91856147	chr7:92134604~92180725:+
LUAD	cis	rs172166	0.611	rs203882	ENSG00000216901.1	AL022393.7	4.38	1.46e-05	0.00272	0.24	0.2	Cardiac Troponin-T levels;	chr6:28110724	chr6:28176188~28176674:+
LUAD	cis	rs62355901	0.545	rs72756091	ENSG00000271828.1	CTD-2310F14.1	4.38	1.46e-05	0.00272	0.39	0.2	Breast cancer;	chr5:56765903	chr5:56927874~56929573:+
LUAD	cis	rs7493	1	rs2299264	ENSG00000233942.1	AC004012.1	4.38	1.46e-05	0.00272	0.29	0.2	Yu-Zhi constitution type in type 2 diabetes;	chr7:95417396	chr7:95471835~95473998:+
LUAD	cis	rs2732480	0.557	rs2732454	ENSG00000257735.1	RP11-370I10.6	4.38	1.46e-05	0.00272	0.24	0.2	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48325894	chr12:48350945~48442411:+
LUAD	cis	rs957448	0.948	rs11992893	ENSG00000254315.1	RP11-267M23.3	4.38	1.46e-05	0.00272	0.25	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94508473	chr8:94533628~94534391:+
LUAD	cis	rs957448	1	rs12678305	ENSG00000254315.1	RP11-267M23.3	4.38	1.46e-05	0.00272	0.25	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94508911	chr8:94533628~94534391:+
LUAD	cis	rs957448	1	rs1048029	ENSG00000254315.1	RP11-267M23.3	4.38	1.46e-05	0.00272	0.25	0.2	Nonsyndromic cleft lip with cleft palate;	chr8:94510149	chr8:94533628~94534391:+
LUAD	cis	rs2548724	0.617	rs7728630	ENSG00000250682.4	LINC00491	4.38	1.46e-05	0.00272	0.24	0.2	Type 2 diabetes;	chr5:102389775	chr5:102609156~102671559:-
LUAD	cis	rs17772222	0.682	rs28371093	ENSG00000258789.1	RP11-507K2.3	-4.38	1.46e-05	0.00272	-0.24	-0.2	Coronary artery calcification;	chr14:88486112	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.655	rs10150594	ENSG00000258789.1	RP11-507K2.3	-4.38	1.46e-05	0.00272	-0.24	-0.2	Coronary artery calcification;	chr14:88489613	chr14:88551597~88552493:+
LUAD	cis	rs11722779	0.81	rs223417	ENSG00000251288.2	RP11-10L12.2	-4.38	1.46e-05	0.00272	-0.23	-0.2	Schizophrenia;	chr4:102810568	chr4:102751401~102752641:+
LUAD	cis	rs11722779	0.805	rs223416	ENSG00000251288.2	RP11-10L12.2	-4.38	1.46e-05	0.00272	-0.23	-0.2	Schizophrenia;	chr4:102810580	chr4:102751401~102752641:+
LUAD	cis	rs3018712	0.59	rs2156464	ENSG00000212093.1	AP000807.1	-4.38	1.46e-05	0.00272	-0.27	-0.2	Total body bone mineral density;	chr11:68659776	chr11:68506083~68506166:-
LUAD	cis	rs9652601	0.748	rs12924112	ENSG00000274038.1	RP11-66H6.4	-4.38	1.46e-05	0.00273	-0.24	-0.2	Systemic lupus erythematosus;	chr16:11125863	chr16:11056556~11057034:+
LUAD	cis	rs651907	0.535	rs35810977	ENSG00000244119.1	PDCL3P4	4.38	1.46e-05	0.00273	0.2	0.2	Colorectal cancer;	chr3:101812536	chr3:101712472~101713191:+
LUAD	cis	rs2243480	0.803	rs160649	ENSG00000164669.11	INTS4P1	4.38	1.46e-05	0.00273	0.34	0.2	Diabetic kidney disease;	chr7:66078212	chr7:65141225~65234216:+
LUAD	cis	rs2243480	1	rs160648	ENSG00000164669.11	INTS4P1	4.38	1.46e-05	0.00273	0.34	0.2	Diabetic kidney disease;	chr7:66078397	chr7:65141225~65234216:+
LUAD	cis	rs2562456	0.833	rs4334427	ENSG00000268081.1	RP11-678G14.2	4.38	1.46e-05	0.00273	0.31	0.2	Pain;	chr19:21338090	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.833	rs4644962	ENSG00000268081.1	RP11-678G14.2	4.38	1.46e-05	0.00273	0.31	0.2	Pain;	chr19:21338125	chr19:21554640~21569237:-
LUAD	cis	rs2467099	1	rs2467099	ENSG00000267801.1	RP11-552F3.9	4.38	1.46e-05	0.00273	0.23	0.2	Systolic blood pressure;	chr17:75952964	chr17:75876372~75879546:+
LUAD	cis	rs875971	0.66	rs10229345	ENSG00000236529.1	RP13-254B10.1	4.38	1.46e-05	0.00273	0.2	0.2	Aortic root size;	chr7:66517181	chr7:65840212~65840596:+
LUAD	cis	rs2933343	0.621	rs6764682	ENSG00000231305.3	RP11-723O4.2	-4.38	1.46e-05	0.00273	-0.21	-0.2	IgG glycosylation;	chr3:128849540	chr3:128861313~128871540:-
LUAD	cis	rs7665090	0.87	rs227361	ENSG00000251288.2	RP11-10L12.2	-4.38	1.46e-05	0.00273	-0.23	-0.2	Primary biliary cholangitis;	chr4:102665820	chr4:102751401~102752641:+
LUAD	cis	rs860818	1	rs858253	ENSG00000226816.2	AC005082.12	4.38	1.46e-05	0.00273	0.52	0.2	Initial pursuit acceleration;	chr7:23178101	chr7:23206013~23208045:+
LUAD	cis	rs860818	1	rs858252	ENSG00000226816.2	AC005082.12	4.38	1.46e-05	0.00273	0.52	0.2	Initial pursuit acceleration;	chr7:23178253	chr7:23206013~23208045:+
LUAD	cis	rs860818	1	rs858250	ENSG00000226816.2	AC005082.12	4.38	1.46e-05	0.00273	0.52	0.2	Initial pursuit acceleration;	chr7:23178941	chr7:23206013~23208045:+
LUAD	cis	rs7804306	0.522	rs2882015	ENSG00000233264.2	AC006042.8	4.38	1.46e-05	0.00273	0.28	0.2	Granulocyte count;Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;	chr7:8029247	chr7:7980312~7982228:+
LUAD	cis	rs36093844	0.625	rs1445510	ENSG00000279742.1	RP11-700A24.1	-4.38	1.46e-05	0.00273	-0.21	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85891930	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.625	rs1445508	ENSG00000279742.1	RP11-700A24.1	-4.38	1.46e-05	0.00273	-0.21	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85892077	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.625	rs17744745	ENSG00000279742.1	RP11-700A24.1	-4.38	1.46e-05	0.00273	-0.21	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85892360	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.625	rs12286210	ENSG00000279742.1	RP11-700A24.1	-4.38	1.46e-05	0.00273	-0.21	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85893598	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.625	rs11234465	ENSG00000279742.1	RP11-700A24.1	-4.38	1.46e-05	0.00273	-0.21	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85894291	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.625	rs12274739	ENSG00000279742.1	RP11-700A24.1	-4.38	1.46e-05	0.00273	-0.21	-0.2	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85894299	chr11:85852557~85854943:-
LUAD	cis	rs6496932	0.663	rs7183764	ENSG00000218052.5	ADAMTS7P4	-4.38	1.46e-05	0.00273	-0.22	-0.2	Central corneal thickness;Corneal structure;	chr15:85359820	chr15:85255369~85330334:-
LUAD	cis	rs6496932	0.663	rs4842878	ENSG00000218052.5	ADAMTS7P4	-4.38	1.46e-05	0.00273	-0.22	-0.2	Central corneal thickness;Corneal structure;	chr15:85361001	chr15:85255369~85330334:-
LUAD	cis	rs7829975	0.591	rs12677543	ENSG00000253981.4	ALG1L13P	4.38	1.46e-05	0.00273	0.23	0.2	Mood instability;	chr8:8786764	chr8:8236003~8244667:-
LUAD	cis	rs16866061	1	rs11681451	ENSG00000228446.2	AC073052.1	-4.38	1.46e-05	0.00273	-0.21	-0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr2:224469387	chr2:224499387~224500100:-
LUAD	cis	rs10463554	0.853	rs246907	ENSG00000250682.4	LINC00491	4.38	1.46e-05	0.00273	0.24	0.2	Parkinson's disease;	chr5:103230577	chr5:102609156~102671559:-
LUAD	cis	rs13113518	1	rs3762837	ENSG00000272969.1	RP11-528I4.2	4.38	1.46e-05	0.00273	0.2	0.2	Height;	chr4:55511198	chr4:55547112~55547889:+
LUAD	cis	rs5758659	0.714	rs7245	ENSG00000182057.4	OGFRP1	-4.38	1.46e-05	0.00273	-0.24	-0.2	Cognitive function;	chr22:42085845	chr22:42269753~42275196:+
LUAD	cis	rs42490	1	rs13252013	ENSG00000251136.7	RP11-37B2.1	-4.38	1.46e-05	0.00273	-0.2	-0.2	Leprosy;	chr8:89746881	chr8:89609409~89757727:-
LUAD	cis	rs42490	1	rs13279023	ENSG00000251136.7	RP11-37B2.1	-4.38	1.46e-05	0.00273	-0.2	-0.2	Leprosy;	chr8:89748816	chr8:89609409~89757727:-
LUAD	cis	rs9381040	1	rs2093396	ENSG00000161912.16	ADCY10P1	4.38	1.46e-05	0.00273	0.19	0.2	Alzheimer's disease (late onset);	chr6:41187262	chr6:41101022~41140835:+
LUAD	cis	rs2548724	0.645	rs2600824	ENSG00000250682.4	LINC00491	-4.38	1.46e-05	0.00273	-0.24	-0.2	Type 2 diabetes;	chr5:102291707	chr5:102609156~102671559:-
LUAD	cis	rs643506	0.817	rs610437	ENSG00000230911.1	PPIHP1	-4.38	1.46e-05	0.00273	-0.24	-0.2	Breast cancer;	chr11:111825716	chr11:112029858~112030367:-
LUAD	cis	rs911555	0.755	rs2756122	ENSG00000244691.1	RPL10AP1	-4.38	1.46e-05	0.00273	-0.23	-0.2	Intelligence (multi-trait analysis);	chr14:103516696	chr14:103412119~103412761:-
LUAD	cis	rs62025270	0.688	rs76902341	ENSG00000202081.1	RNU6-1280P	-4.38	1.46e-05	0.00273	-0.28	-0.2	Idiopathic pulmonary fibrosis;	chr15:85737059	chr15:85651522~85651628:-
LUAD	cis	rs2243480	0.803	rs160649	ENSG00000229886.1	RP5-1132H15.3	4.38	1.46e-05	0.00273	0.33	0.2	Diabetic kidney disease;	chr7:66078212	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs160648	ENSG00000229886.1	RP5-1132H15.3	4.38	1.46e-05	0.00273	0.33	0.2	Diabetic kidney disease;	chr7:66078397	chr7:66025126~66031544:-
LUAD	cis	rs12073359	0.955	rs72694960	ENSG00000223945.2	RP11-458I7.1	-4.38	1.47e-05	0.00274	-0.31	-0.2	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150174687	chr1:150053864~150055034:+
LUAD	cis	rs28386778	0.897	rs2727320	ENSG00000240280.5	TCAM1P	-4.38	1.47e-05	0.00274	-0.23	-0.2	Prudent dietary pattern;	chr17:63787965	chr17:63849292~63864379:+
LUAD	cis	rs7208859	0.573	rs11654035	ENSG00000266490.1	CTD-2349P21.9	4.38	1.47e-05	0.00274	0.29	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30792372~30792833:+
LUAD	cis	rs2823962	0.759	rs2823931	ENSG00000270093.1	AP000473.8	-4.38	1.47e-05	0.00274	-0.2	-0.2	Amyotrophic lateral sclerosis;	chr21:16642730	chr21:16643529~16645065:+
LUAD	cis	rs62025270	0.632	rs62023935	ENSG00000202081.1	RNU6-1280P	-4.38	1.47e-05	0.00274	-0.29	-0.2	Idiopathic pulmonary fibrosis;	chr15:85605604	chr15:85651522~85651628:-
LUAD	cis	rs10463554	0.927	rs34799	ENSG00000250682.4	LINC00491	4.38	1.47e-05	0.00274	0.24	0.2	Parkinson's disease;	chr5:103090498	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.927	rs34800	ENSG00000250682.4	LINC00491	4.38	1.47e-05	0.00274	0.24	0.2	Parkinson's disease;	chr5:103090799	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.927	rs34802	ENSG00000250682.4	LINC00491	4.38	1.47e-05	0.00274	0.24	0.2	Parkinson's disease;	chr5:103091301	chr5:102609156~102671559:-
LUAD	cis	rs526231	0.508	rs34805	ENSG00000250682.4	LINC00491	4.38	1.47e-05	0.00274	0.24	0.2	Primary biliary cholangitis;	chr5:103092608	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.927	rs34810	ENSG00000250682.4	LINC00491	4.38	1.47e-05	0.00274	0.24	0.2	Parkinson's disease;	chr5:103095045	chr5:102609156~102671559:-
LUAD	cis	rs7590268	0.666	rs17406472	ENSG00000279873.2	LINC01126	4.38	1.47e-05	0.00274	0.19	0.2	Orofacial clefts;	chr2:43406707	chr2:43227210~43228855:+
LUAD	cis	rs7129556	0.69	rs648601	ENSG00000241782.1	RP11-91P24.1	4.38	1.47e-05	0.00274	0.27	0.2	Weight loss (gastric bypass surgery);	chr11:77875864	chr11:77868722~77869195:-
LUAD	cis	rs7202877	0.706	rs247437	ENSG00000280152.1	RP11-331F4.5	-4.38	1.47e-05	0.00274	-0.22	-0.2	Type 1 diabetes;Type 2 diabetes;	chr16:75397377	chr16:75245994~75250077:-
LUAD	cis	rs2239547	0.607	rs9836178	ENSG00000242142.1	SERBP1P3	-4.38	1.47e-05	0.00274	-0.24	-0.2	Schizophrenia;	chr3:52891387	chr3:53064283~53065091:-
LUAD	cis	rs6840360	1	rs2007218	ENSG00000270265.1	RP11-731D1.4	4.38	1.47e-05	0.00274	0.2	0.2	Intelligence (multi-trait analysis);	chr4:151722820	chr4:151333775~151353224:-
LUAD	cis	rs490608	0.608	rs11264360	ENSG00000225855.5	RUSC1-AS1	4.38	1.47e-05	0.00274	0.14	0.2	Inflammatory bowel disease;	chr1:155314795	chr1:155316863~155324176:-
LUAD	cis	rs11512640	1	rs12363935	ENSG00000254671.2	STT3A-AS1	4.38	1.47e-05	0.00274	0.43	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125558406	chr11:125570284~125592568:-
LUAD	cis	rs28386778	0.863	rs2597633	ENSG00000240280.5	TCAM1P	-4.38	1.47e-05	0.00274	-0.23	-0.2	Prudent dietary pattern;	chr17:63795511	chr17:63849292~63864379:+
LUAD	cis	rs4819052	0.679	rs28623526	ENSG00000215447.6	BX322557.10	-4.38	1.47e-05	0.00274	-0.23	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45292409	chr21:45288052~45291738:+
LUAD	cis	rs4660214	0.666	rs1984143	ENSG00000228060.1	RP11-69E11.8	4.38	1.47e-05	0.00274	0.18	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39290645	chr1:39565160~39573203:+
LUAD	cis	rs4819052	1	rs2297285	ENSG00000223768.1	LINC00205	4.38	1.47e-05	0.00274	0.26	0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285706	chr21:45293285~45297354:+
LUAD	cis	rs2288884	0.943	rs11671792	ENSG00000269959.1	SPACA6P-AS	-4.38	1.47e-05	0.00274	-0.26	-0.2	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52078430	chr19:51685363~51693456:-
LUAD	cis	rs9860428	0.679	rs1392785	ENSG00000242770.2	RP11-180K7.1	-4.38	1.47e-05	0.00274	-0.2	-0.2	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112970690	chr3:112802478~112812819:+
LUAD	cis	rs1499614	0.901	rs2178742	ENSG00000229886.1	RP5-1132H15.3	4.38	1.47e-05	0.00274	0.35	0.2	Gout;	chr7:66732812	chr7:66025126~66031544:-
LUAD	cis	rs2153535	0.536	rs1328876	ENSG00000230939.1	RP11-314C16.1	-4.38	1.47e-05	0.00275	-0.22	-0.2	Motion sickness;	chr6:8620940	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.585	rs1328875	ENSG00000230939.1	RP11-314C16.1	-4.38	1.47e-05	0.00275	-0.22	-0.2	Motion sickness;	chr6:8620946	chr6:8784178~8785445:+
LUAD	cis	rs7119038	0.818	rs2155433	ENSG00000255422.1	AP002954.4	4.38	1.47e-05	0.00275	0.3	0.2	Sjögren's syndrome;	chr11:118742212	chr11:118704607~118750263:+
LUAD	cis	rs1005277	0.579	rs2474608	ENSG00000263064.2	RP11-291L22.7	4.38	1.47e-05	0.00275	0.21	0.2	Extrinsic epigenetic age acceleration;	chr10:38168181	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.603	rs1998062	ENSG00000263064.2	RP11-291L22.7	4.38	1.47e-05	0.00275	0.21	0.2	Extrinsic epigenetic age acceleration;	chr10:38168724	chr10:38448689~38448949:+
LUAD	cis	rs2018683	0.683	rs12538606	ENSG00000228421.2	AC005013.5	4.38	1.47e-05	0.00275	0.22	0.2	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28929791	chr7:28957667~28959345:+
LUAD	cis	rs3808502	0.526	rs11985709	ENSG00000255046.1	RP11-297N6.4	4.38	1.47e-05	0.00275	0.24	0.2	Neuroticism;	chr8:11565574	chr8:11797928~11802568:-
LUAD	cis	rs2243480	1	rs427044	ENSG00000232559.3	GS1-124K5.12	4.38	1.47e-05	0.00275	0.34	0.2	Diabetic kidney disease;	chr7:66043558	chr7:66554588~66576923:-
LUAD	cis	rs2274273	0.682	rs1187876	ENSG00000258413.1	RP11-665C16.6	4.38	1.47e-05	0.00275	0.24	0.2	Protein biomarker;	chr14:55028481	chr14:55262767~55272075:-
LUAD	cis	rs2018683	0.707	rs2391718	ENSG00000228421.2	AC005013.5	4.38	1.47e-05	0.00275	0.22	0.2	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28935371	chr7:28957667~28959345:+
LUAD	cis	rs11051970	0.559	rs113700251	ENSG00000274964.1	RP11-817I4.1	-4.38	1.47e-05	0.00275	-0.26	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr12:32409337	chr12:32339368~32340724:+
LUAD	cis	rs889398	0.835	rs12925429	ENSG00000226232.7	RP11-419C5.2	4.38	1.47e-05	0.00275	0.17	0.2	Body mass index;	chr16:69767636	chr16:69976388~69996188:-
LUAD	cis	rs7208859	0.673	rs73277967	ENSG00000263603.1	CTD-2349P21.5	-4.38	1.47e-05	0.00275	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30857148	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs60020217	ENSG00000263603.1	CTD-2349P21.5	-4.38	1.47e-05	0.00275	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30858036	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.573	rs73277974	ENSG00000263603.1	CTD-2349P21.5	-4.38	1.47e-05	0.00275	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862851	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs73277978	ENSG00000263603.1	CTD-2349P21.5	-4.38	1.47e-05	0.00275	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864431	chr17:30729469~30731202:+
LUAD	cis	rs17826219	0.706	rs9905827	ENSG00000263603.1	CTD-2349P21.5	-4.38	1.47e-05	0.00275	-0.36	-0.2	Body mass index;	chr17:30865150	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs11657391	ENSG00000263603.1	CTD-2349P21.5	-4.38	1.47e-05	0.00275	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30867269	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs58089675	ENSG00000263603.1	CTD-2349P21.5	-4.38	1.47e-05	0.00275	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869746	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs73263755	ENSG00000263603.1	CTD-2349P21.5	-4.38	1.47e-05	0.00275	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30871954	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs9899349	ENSG00000263603.1	CTD-2349P21.5	-4.38	1.47e-05	0.00275	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30873104	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs11652358	ENSG00000263603.1	CTD-2349P21.5	-4.38	1.47e-05	0.00275	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30878462	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs11656845	ENSG00000263603.1	CTD-2349P21.5	-4.38	1.47e-05	0.00275	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30879146	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs9891179	ENSG00000263603.1	CTD-2349P21.5	-4.38	1.47e-05	0.00275	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881142	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs9891413	ENSG00000263603.1	CTD-2349P21.5	-4.38	1.47e-05	0.00275	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881191	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs73263776	ENSG00000263603.1	CTD-2349P21.5	-4.38	1.47e-05	0.00275	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30884313	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs11650271	ENSG00000263603.1	CTD-2349P21.5	-4.38	1.47e-05	0.00275	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30886925	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs73263785	ENSG00000263603.1	CTD-2349P21.5	-4.38	1.47e-05	0.00275	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887790	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs55904046	ENSG00000263603.1	CTD-2349P21.5	-4.38	1.47e-05	0.00275	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888373	chr17:30729469~30731202:+
LUAD	cis	rs704795	0.775	rs4665975	ENSG00000234072.1	AC074117.10	-4.38	1.47e-05	0.00275	-0.15	-0.2	Menopause (age at onset);	chr2:27403150	chr2:27356246~27367622:+
LUAD	cis	rs1167827	0.805	rs809439	ENSG00000205583.12	STAG3L1	-4.38	1.47e-05	0.00275	-0.23	-0.2	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75531992	chr7:75359194~75395383:+
LUAD	cis	rs6095360	0.727	rs11906450	ENSG00000222365.1	SNORD12B	-4.38	1.48e-05	0.00275	-0.22	-0.2	Intelligence (multi-trait analysis);	chr20:48938545	chr20:49280319~49280409:+
LUAD	cis	rs7204230	1	rs8063660	ENSG00000261291.1	RP11-295M3.2	4.38	1.48e-05	0.00275	0.25	0.2	Fibrinogen;	chr16:53319247	chr16:53168522~53169450:+
LUAD	cis	rs2153535	0.585	rs7739573	ENSG00000230939.1	RP11-314C16.1	4.38	1.48e-05	0.00275	0.22	0.2	Motion sickness;	chr6:8659671	chr6:8784178~8785445:+
LUAD	cis	rs9860428	0.844	rs9288964	ENSG00000242770.2	RP11-180K7.1	4.38	1.48e-05	0.00275	0.22	0.2	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112874676	chr3:112802478~112812819:+
LUAD	cis	rs16866061	1	rs1568750	ENSG00000228446.2	AC073052.1	-4.38	1.48e-05	0.00275	-0.21	-0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr2:224477880	chr2:224499387~224500100:-
LUAD	cis	rs950169	0.922	rs2033284	ENSG00000275120.1	RP11-182J1.17	4.38	1.48e-05	0.00275	0.31	0.2	Schizophrenia;	chr15:84391575	chr15:84599434~84606463:-
LUAD	cis	rs1502337	0.532	rs10744765	ENSG00000278993.1	RP3-424M6.4	4.38	1.48e-05	0.00275	0.24	0.2	Body mass index;	chr12:110445991	chr12:110501614~110503441:+
LUAD	cis	rs16873450	0.903	rs12700464	ENSG00000234800.2	PCMTD1P3	4.38	1.48e-05	0.00275	0.23	0.2	Verbal memory performance (residualized delayed recall level);	chr7:23766910	chr7:23721311~23721782:-
LUAD	cis	rs9876781	0.874	rs56298324	ENSG00000229759.1	MRPS18AP1	-4.38	1.48e-05	0.00275	-0.19	-0.2	Longevity;	chr3:48393626	chr3:48256350~48256938:-
LUAD	cis	rs6686842	0.536	rs12123384	ENSG00000235358.1	RP11-399E6.1	-4.38	1.48e-05	0.00275	-0.23	-0.2	Height;	chr1:41239346	chr1:41242373~41284861:+
LUAD	cis	rs4819052	0.655	rs2330103	ENSG00000215447.6	BX322557.10	-4.38	1.48e-05	0.00276	-0.23	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45274599	chr21:45288052~45291738:+
LUAD	cis	rs2470135	1	rs2470135	ENSG00000166763.7	STRCP1	4.38	1.48e-05	0.00276	0.23	0.2	Diastolic blood pressure;	chr15:43703591	chr15:43699488~43718184:-
LUAD	cis	rs11168351	1	rs11168351	ENSG00000257735.1	RP11-370I10.6	4.38	1.48e-05	0.00276	0.23	0.2	Bipolar disorder and schizophrenia;	chr12:48009982	chr12:48350945~48442411:+
LUAD	cis	rs17685	0.753	rs6951808	ENSG00000280388.1	RP11-229D13.3	-4.38	1.48e-05	0.00276	-0.18	-0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76143095	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.753	rs10952840	ENSG00000280388.1	RP11-229D13.3	-4.38	1.48e-05	0.00276	-0.18	-0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76143560	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.672	rs10952841	ENSG00000280388.1	RP11-229D13.3	-4.38	1.48e-05	0.00276	-0.18	-0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76149308	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.753	rs2108274	ENSG00000280388.1	RP11-229D13.3	-4.38	1.48e-05	0.00276	-0.18	-0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76152318	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.753	rs1806885	ENSG00000280388.1	RP11-229D13.3	-4.38	1.48e-05	0.00276	-0.18	-0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76156294	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.753	rs1859791	ENSG00000280388.1	RP11-229D13.3	-4.38	1.48e-05	0.00276	-0.18	-0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76156725	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.753	rs6464999	ENSG00000280388.1	RP11-229D13.3	-4.38	1.48e-05	0.00276	-0.18	-0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76157997	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.753	rs6465000	ENSG00000280388.1	RP11-229D13.3	-4.38	1.48e-05	0.00276	-0.18	-0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76158099	chr7:76043977~76045963:-
LUAD	cis	rs1979679	0.842	rs7139154	ENSG00000278733.1	RP11-425D17.1	4.38	1.48e-05	0.00276	0.24	0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28181603	chr12:28185625~28186190:-
LUAD	cis	rs1979679	0.842	rs11049411	ENSG00000278733.1	RP11-425D17.1	4.38	1.48e-05	0.00276	0.24	0.2	Ossification of the posterior longitudinal ligament of the spine;	chr12:28184723	chr12:28185625~28186190:-
LUAD	cis	rs750134	0.636	rs6539455	ENSG00000257221.1	RP11-689B22.2	-4.38	1.48e-05	0.00276	-0.23	-0.2	Low high density lipoprotein cholesterol levels;	chr12:108826127	chr12:108628687~108641318:+
LUAD	cis	rs2243480	0.803	rs34804747	ENSG00000232559.3	GS1-124K5.12	4.38	1.48e-05	0.00276	0.34	0.2	Diabetic kidney disease;	chr7:65947955	chr7:66554588~66576923:-
LUAD	cis	rs7107174	1	rs1385600	ENSG00000251323.2	RP11-452H21.4	-4.38	1.48e-05	0.00276	-0.24	-0.2	Testicular germ cell tumor;	chr11:78225120	chr11:78423982~78429836:-
LUAD	cis	rs2348418	0.831	rs7296538	ENSG00000244712.1	RP11-874G11.1	-4.38	1.48e-05	0.00276	-0.23	-0.2	Lung function (FEV1);Lung function (FVC);	chr12:28558850	chr12:28564678~28565141:-
LUAD	cis	rs6701713	1	rs2093761	ENSG00000274245.1	RP11-357P18.2	-4.38	1.48e-05	0.00276	-0.31	-0.2	Alzheimer's disease (late onset);	chr1:207613197	chr1:207372559~207373252:+
LUAD	cis	rs683250	0.567	rs482938	ENSG00000246067.6	RAB30-AS1	4.38	1.48e-05	0.00276	0.22	0.2	Subcortical brain region volumes;	chr11:83292997	chr11:83072066~83106719:+
LUAD	cis	rs2153535	0.585	rs1328873	ENSG00000230939.1	RP11-314C16.1	-4.38	1.48e-05	0.00276	-0.22	-0.2	Motion sickness;	chr6:8621171	chr6:8784178~8785445:+
LUAD	cis	rs12986445	0.738	rs7581255	ENSG00000218682.1	AC010150.1	4.38	1.48e-05	0.00276	0.25	0.2	Multiple myeloma;Multiple myeloma and monoclonal gammopathy;	chr2:25825673	chr2:25856461~25856966:-
LUAD	cis	rs5758659	0.714	rs6002626	ENSG00000182057.4	OGFRP1	-4.38	1.48e-05	0.00276	-0.23	-0.2	Cognitive function;	chr22:42121985	chr22:42269753~42275196:+
LUAD	cis	rs2243480	0.808	rs12698508	ENSG00000226002.1	RP11-460N20.5	-4.38	1.48e-05	0.00276	-0.33	-0.2	Diabetic kidney disease;	chr7:65946971	chr7:65084103~65100232:+
LUAD	cis	rs1061377	0.585	rs3733271	ENSG00000249685.1	RP11-360F5.3	4.38	1.48e-05	0.00276	0.24	0.2	Uric acid levels;	chr4:39047948	chr4:39133913~39135608:+
LUAD	cis	rs2880765	0.835	rs4360874	ENSG00000259416.2	RP11-158M2.5	4.38	1.48e-05	0.00276	0.2	0.2	Coronary artery disease;	chr15:85497589	chr15:85754941~85756237:-
LUAD	cis	rs11122895	0.509	rs6708131	ENSG00000236307.2	EEF1E1P1	4.38	1.48e-05	0.00276	0.21	0.2	Allergic sensitization;	chr2:111688082	chr2:111887914~111888741:+
LUAD	cis	rs73173548	0.502	rs4601863	ENSG00000247828.6	TMEM161B-AS1	4.38	1.48e-05	0.00276	0.24	0.2	Macular telangiectasia type 2;	chr5:88433804	chr5:88268895~88436685:+
LUAD	cis	rs4578769	0.569	rs12605806	ENSG00000265943.1	RP11-739L10.1	4.38	1.48e-05	0.00276	0.25	0.2	Eosinophil percentage of white cells;	chr18:22882093	chr18:22699481~22933764:-
LUAD	cis	rs10419113	0.641	rs12611312	ENSG00000270804.1	CTD-2583A14.11	-4.38	1.48e-05	0.00276	-0.18	-0.2	Pediatric bone mineral density (spine);	chr19:57764436	chr19:57867885~57868834:+
LUAD	cis	rs7204230	1	rs7188463	ENSG00000261291.1	RP11-295M3.2	-4.38	1.48e-05	0.00276	-0.24	-0.2	Fibrinogen;	chr16:53293129	chr16:53168522~53169450:+
LUAD	cis	rs2274273	0.623	rs1187877	ENSG00000258413.1	RP11-665C16.6	4.38	1.48e-05	0.00276	0.25	0.2	Protein biomarker;	chr14:55028443	chr14:55262767~55272075:-
LUAD	cis	rs7324557	0.717	rs729137	ENSG00000205861.10	C1QTNF9B-AS1	-4.38	1.48e-05	0.00276	-0.26	-0.2	Visceral adipose tissue adjusted for BMI;	chr13:23821523	chr13:23888889~23897263:+
LUAD	cis	rs950169	0.8	rs34302901	ENSG00000275120.1	RP11-182J1.17	4.38	1.48e-05	0.00277	0.3	0.2	Schizophrenia;	chr15:84567712	chr15:84599434~84606463:-
LUAD	cis	rs4819052	1	rs2297284	ENSG00000223768.1	LINC00205	-4.38	1.48e-05	0.00277	-0.25	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285430	chr21:45293285~45297354:+
LUAD	cis	rs7493	0.853	rs6973380	ENSG00000233942.1	AC004012.1	4.38	1.49e-05	0.00277	0.29	0.2	Yu-Zhi constitution type in type 2 diabetes;	chr7:95414211	chr7:95471835~95473998:+
LUAD	cis	rs4578769	0.569	rs12326874	ENSG00000265943.1	RP11-739L10.1	4.38	1.49e-05	0.00277	0.24	0.2	Eosinophil percentage of white cells;	chr18:22926670	chr18:22699481~22933764:-
LUAD	cis	rs6570726	0.967	rs441364	ENSG00000235652.6	RP11-545I5.3	4.38	1.49e-05	0.00277	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145532526	chr6:145799409~145886585:+
LUAD	cis	rs6714710	0.58	rs57804205	ENSG00000230606.9	AC159540.1	-4.38	1.49e-05	0.00277	-0.21	-0.2	Posterior cortical atrophy and Alzheimer's disease;	chr2:97838009	chr2:97416165~97433527:-
LUAD	cis	rs6714710	0.58	rs57681139	ENSG00000230606.9	AC159540.1	-4.38	1.49e-05	0.00277	-0.21	-0.2	Posterior cortical atrophy and Alzheimer's disease;	chr2:97838010	chr2:97416165~97433527:-
LUAD	cis	rs6714710	0.58	rs1838797	ENSG00000230606.9	AC159540.1	-4.38	1.49e-05	0.00277	-0.21	-0.2	Posterior cortical atrophy and Alzheimer's disease;	chr2:97838109	chr2:97416165~97433527:-
LUAD	cis	rs6714710	0.603	rs78006955	ENSG00000230606.9	AC159540.1	-4.38	1.49e-05	0.00277	-0.21	-0.2	Posterior cortical atrophy and Alzheimer's disease;	chr2:97839047	chr2:97416165~97433527:-
LUAD	cis	rs12214131	0.5	rs7739539	ENSG00000219088.1	RP3-359N14.1	4.38	1.49e-05	0.00277	0.2	0.2	Male-pattern baldness;	chr6:105745090	chr6:105666326~105667998:+
LUAD	cis	rs12073359	0.955	rs72694959	ENSG00000223945.2	RP11-458I7.1	-4.38	1.49e-05	0.00277	-0.3	-0.2	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150165955	chr1:150053864~150055034:+
LUAD	cis	rs453301	0.571	rs2929305	ENSG00000173295.6	FAM86B3P	-4.38	1.49e-05	0.00277	-0.21	-0.2	Joint mobility (Beighton score);	chr8:9227707	chr8:8228595~8244865:+
LUAD	cis	rs10938353	0.68	rs66829609	ENSG00000273369.1	RP11-700J17.1	4.38	1.49e-05	0.00277	0.25	0.2	Body mass index;	chr4:44769814	chr4:44693946~44694386:-
LUAD	cis	rs7302981	0.934	rs7532	ENSG00000200428.1	Y_RNA	4.38	1.49e-05	0.00277	0.24	0.2	Systolic blood pressure;	chr12:50130181	chr12:50743568~50743684:+
LUAD	cis	rs7493	0.853	rs11770901	ENSG00000233942.1	AC004012.1	4.38	1.49e-05	0.00277	0.29	0.2	Yu-Zhi constitution type in type 2 diabetes;	chr7:95425168	chr7:95471835~95473998:+
LUAD	cis	rs561341	0.714	rs473535	ENSG00000265798.5	RP11-271K11.5	4.38	1.49e-05	0.00277	0.31	0.2	Hip circumference adjusted for BMI;	chr17:31985346	chr17:31038575~31059121:-
LUAD	cis	rs7590268	0.577	rs6715054	ENSG00000279873.2	LINC01126	4.38	1.49e-05	0.00277	0.19	0.2	Orofacial clefts;	chr2:43396893	chr2:43227210~43228855:+
LUAD	cis	rs7590268	0.636	rs33979934	ENSG00000279873.2	LINC01126	4.38	1.49e-05	0.00277	0.19	0.2	Orofacial clefts;	chr2:43398045	chr2:43227210~43228855:+
LUAD	cis	rs27434	0.605	rs39840	ENSG00000272109.1	CTD-2260A17.3	-4.38	1.49e-05	0.00277	-0.27	-0.2	Ankylosing spondylitis;	chr5:96784350	chr5:96804353~96806105:+
LUAD	cis	rs17685	0.753	rs1574107	ENSG00000280388.1	RP11-229D13.3	-4.38	1.49e-05	0.00277	-0.18	-0.2	Coffee consumption (cups per day);Coffee consumption;	chr7:76055729	chr7:76043977~76045963:-
LUAD	cis	rs4908768	0.539	rs6670508	ENSG00000270282.1	RP5-1115A15.2	4.38	1.49e-05	0.00277	0.22	0.2	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8587858	chr1:8512653~8513021:+
LUAD	cis	rs1334894	0.901	rs6906096	ENSG00000228559.1	RP3-340B19.3	-4.38	1.49e-05	0.00277	-0.41	-0.2	Coronary artery disease;	chr6:35532877	chr6:35544632~35545669:+
LUAD	cis	rs6754311	0.773	rs4988226	ENSG00000226806.1	AC011893.3	-4.37	1.49e-05	0.00277	-0.24	-0.2	Mosquito bite size;	chr2:135853028	chr2:135820191~135823087:+
LUAD	cis	rs6754311	0.773	rs309178	ENSG00000226806.1	AC011893.3	-4.37	1.49e-05	0.00277	-0.24	-0.2	Mosquito bite size;	chr2:135854054	chr2:135820191~135823087:+
LUAD	cis	rs6754311	0.773	rs309179	ENSG00000226806.1	AC011893.3	-4.37	1.49e-05	0.00277	-0.24	-0.2	Mosquito bite size;	chr2:135856210	chr2:135820191~135823087:+
LUAD	cis	rs6754311	0.678	rs309181	ENSG00000226806.1	AC011893.3	-4.37	1.49e-05	0.00277	-0.24	-0.2	Mosquito bite size;	chr2:135857243	chr2:135820191~135823087:+
LUAD	cis	rs113835537	0.935	rs79496339	ENSG00000255517.5	CTD-3074O7.5	-4.37	1.49e-05	0.00278	-0.29	-0.2	Airway imaging phenotypes;	chr11:66700298	chr11:66473490~66480233:-
LUAD	cis	rs3785309	0.519	rs111739409	ENSG00000268836.1	LA16c-OS12.2	-4.37	1.49e-05	0.00278	-0.35	-0.2	Immature fraction of reticulocytes;	chr16:233956	chr16:185748~186294:-
LUAD	cis	rs6754311	0.773	rs309176	ENSG00000226806.1	AC011893.3	-4.37	1.49e-05	0.00278	-0.24	-0.2	Mosquito bite size;	chr2:135864646	chr2:135820191~135823087:+
LUAD	cis	rs9309473	0.607	rs10196402	ENSG00000163016.8	ALMS1P	4.37	1.49e-05	0.00278	0.22	0.2	Metabolite levels;	chr2:73344953	chr2:73644919~73685576:+
LUAD	cis	rs7107174	1	rs2512549	ENSG00000251323.2	RP11-452H21.4	-4.37	1.49e-05	0.00278	-0.24	-0.2	Testicular germ cell tumor;	chr11:78229117	chr11:78423982~78429836:-
LUAD	cis	rs8062405	0.688	rs3924376	ENSG00000261419.1	RP11-57A19.4	4.37	1.49e-05	0.00278	0.23	0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28659696~28740781:-
LUAD	cis	rs6421571	0.565	rs10892263	ENSG00000255239.1	AP002954.6	-4.37	1.49e-05	0.00278	-0.3	-0.2	Primary biliary cholangitis;	chr11:118716610	chr11:118688039~118690600:-
LUAD	cis	rs868036	0.56	rs12443086	ENSG00000270964.1	RP11-502I4.3	4.37	1.49e-05	0.00278	0.2	0.2	Restless legs syndrome;	chr15:67788116	chr15:67541072~67542604:-
LUAD	cis	rs6840360	0.571	rs718801	ENSG00000270265.1	RP11-731D1.4	-4.37	1.49e-05	0.00278	-0.22	-0.2	Intelligence (multi-trait analysis);	chr4:151628095	chr4:151333775~151353224:-
LUAD	cis	rs10510102	0.623	rs10159856	ENSG00000276742.1	RP11-500G22.4	4.37	1.49e-05	0.00278	0.33	0.2	Breast cancer;	chr10:121988292	chr10:121956782~121957098:+
LUAD	cis	rs57502260	0.573	rs11228295	ENSG00000212093.1	AP000807.1	4.37	1.49e-05	0.00278	0.22	0.2	Total body bone mineral density (age 45-60);	chr11:68621120	chr11:68506083~68506166:-
LUAD	cis	rs4819052	0.851	rs2838840	ENSG00000237664.1	LINC00316	-4.37	1.49e-05	0.00278	-0.24	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45248579	chr21:45338590~45341990:-
LUAD	cis	rs6860806	0.661	rs334902	ENSG00000233006.5	AC034220.3	4.37	1.49e-05	0.00278	0.17	0.2	Breast cancer;	chr5:132250866	chr5:132311285~132369916:-
LUAD	cis	rs853679	0.607	rs13199772	ENSG00000219392.1	RP1-265C24.5	-4.37	1.5e-05	0.00278	-0.42	-0.2	Depression;	chr6:27866307	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.607	rs13199906	ENSG00000219392.1	RP1-265C24.5	-4.37	1.5e-05	0.00278	-0.42	-0.2	Depression;	chr6:27866361	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.607	rs17763089	ENSG00000219392.1	RP1-265C24.5	-4.37	1.5e-05	0.00278	-0.42	-0.2	Depression;	chr6:27867440	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.546	rs17695758	ENSG00000219392.1	RP1-265C24.5	-4.37	1.5e-05	0.00278	-0.42	-0.2	Depression;	chr6:27869405	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.607	rs34950484	ENSG00000219392.1	RP1-265C24.5	-4.37	1.5e-05	0.00278	-0.43	-0.2	Depression;	chr6:28310911	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.607	rs34661125	ENSG00000219392.1	RP1-265C24.5	-4.37	1.5e-05	0.00278	-0.43	-0.2	Depression;	chr6:28314117	chr6:28115628~28116551:+
LUAD	cis	rs6840360	0.642	rs7658169	ENSG00000270265.1	RP11-731D1.4	-4.37	1.5e-05	0.00278	-0.2	-0.2	Intelligence (multi-trait analysis);	chr4:151432262	chr4:151333775~151353224:-
LUAD	cis	rs6714710	0.603	rs2305143	ENSG00000230606.9	AC159540.1	-4.37	1.5e-05	0.00278	-0.21	-0.2	Posterior cortical atrophy and Alzheimer's disease;	chr2:97797318	chr2:97416165~97433527:-
LUAD	cis	rs6570726	0.791	rs398408	ENSG00000235652.6	RP11-545I5.3	4.37	1.5e-05	0.00279	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145479884	chr6:145799409~145886585:+
LUAD	cis	rs9910055	0.659	rs2251165	ENSG00000267080.4	ASB16-AS1	-4.37	1.5e-05	0.00279	-0.18	-0.2	Total body bone mineral density;	chr17:44157380	chr17:44175973~44186717:-
LUAD	cis	rs7665090	0.967	rs5026469	ENSG00000246560.2	RP11-10L12.4	4.37	1.5e-05	0.00279	0.24	0.2	Primary biliary cholangitis;	chr4:102633556	chr4:102828055~102844075:+
LUAD	cis	rs7665090	0.967	rs5026470	ENSG00000246560.2	RP11-10L12.4	4.37	1.5e-05	0.00279	0.24	0.2	Primary biliary cholangitis;	chr4:102633565	chr4:102828055~102844075:+
LUAD	cis	rs7665090	0.967	rs5026471	ENSG00000246560.2	RP11-10L12.4	4.37	1.5e-05	0.00279	0.24	0.2	Primary biliary cholangitis;	chr4:102633576	chr4:102828055~102844075:+
LUAD	cis	rs7688540	0.8	rs2353599	ENSG00000211553.1	AC253576.2	-4.37	1.5e-05	0.00279	-0.25	-0.2	Facial morphology (factor 6, height of vermillion lower lip);	chr4:286637	chr4:136461~136568:+
LUAD	cis	rs7208859	0.573	rs7223803	ENSG00000266490.1	CTD-2349P21.9	4.37	1.5e-05	0.00279	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750175	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs55814012	ENSG00000266490.1	CTD-2349P21.9	4.37	1.5e-05	0.00279	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750679	chr17:30792372~30792833:+
LUAD	cis	rs17826219	0.5	rs2449749	ENSG00000266490.1	CTD-2349P21.9	4.37	1.5e-05	0.00279	0.3	0.2	Body mass index;	chr17:30751280	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs9894709	ENSG00000266490.1	CTD-2349P21.9	4.37	1.5e-05	0.00279	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751436	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs9896603	ENSG00000266490.1	CTD-2349P21.9	4.37	1.5e-05	0.00279	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751494	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs8080882	ENSG00000266490.1	CTD-2349P21.9	4.37	1.5e-05	0.00279	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30754128	chr17:30792372~30792833:+
LUAD	cis	rs1005277	0.579	rs932538	ENSG00000263064.2	RP11-291L22.7	4.37	1.5e-05	0.00279	0.21	0.2	Extrinsic epigenetic age acceleration;	chr10:38092386	chr10:38448689~38448949:+
LUAD	cis	rs6840258	0.723	rs443459	ENSG00000251411.1	RP11-397E7.4	-4.37	1.5e-05	0.00279	-0.22	-0.2	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87054903	chr4:86913266~86914817:-
LUAD	cis	rs10510102	0.516	rs10219133	ENSG00000276742.1	RP11-500G22.4	4.37	1.5e-05	0.00279	0.34	0.2	Breast cancer;	chr10:121987898	chr10:121956782~121957098:+
LUAD	cis	rs11250098	0.541	rs6997839	ENSG00000255046.1	RP11-297N6.4	4.37	1.5e-05	0.00279	0.24	0.2	Morning vs. evening chronotype;	chr8:10908518	chr8:11797928~11802568:-
LUAD	cis	rs7430456	0.674	rs9814974	ENSG00000228221.4	LINC00578	4.37	1.5e-05	0.00279	0.25	0.2	Breast cancer;	chr3:177774073	chr3:177441921~177752305:+
LUAD	cis	rs1707322	0.638	rs1416706	ENSG00000234329.1	RP11-767N6.2	-4.37	1.5e-05	0.00279	-0.2	-0.2	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46137172	chr1:45651039~45651826:-
LUAD	cis	rs494459	0.536	rs10790267	ENSG00000278376.1	RP11-158I9.8	-4.37	1.5e-05	0.00279	-0.21	-0.2	Height;	chr11:118856460	chr11:118791254~118793137:+
LUAD	cis	rs494459	0.536	rs11217067	ENSG00000278376.1	RP11-158I9.8	-4.37	1.5e-05	0.00279	-0.21	-0.2	Height;	chr11:118856623	chr11:118791254~118793137:+
LUAD	cis	rs2510897	0.675	rs4936442	ENSG00000278376.1	RP11-158I9.8	-4.37	1.5e-05	0.00279	-0.21	-0.2	Height;	chr11:118857611	chr11:118791254~118793137:+
LUAD	cis	rs860295	0.557	rs10796944	ENSG00000225855.5	RUSC1-AS1	4.37	1.5e-05	0.00279	0.15	0.2	Body mass index;	chr1:155446537	chr1:155316863~155324176:-
LUAD	cis	rs2976388	0.578	rs13254358	ENSG00000253741.1	CTD-2292P10.4	4.37	1.5e-05	0.00279	0.23	0.2	Urinary tract infection frequency;	chr8:142742458	chr8:142702252~142726973:-
LUAD	cis	rs67981189	0.529	rs2810096	ENSG00000269927.1	RP6-91H8.3	-4.37	1.5e-05	0.00279	-0.26	-0.2	Schizophrenia;	chr14:70968583	chr14:71141125~71143253:-
LUAD	cis	rs4639966	0.569	rs603486	ENSG00000278376.1	RP11-158I9.8	-4.37	1.5e-05	0.00279	-0.2	-0.2	Systemic lupus erythematosus;	chr11:118716638	chr11:118791254~118793137:+
LUAD	cis	rs2976388	0.669	rs1836633	ENSG00000253741.1	CTD-2292P10.4	-4.37	1.5e-05	0.00279	-0.23	-0.2	Urinary tract infection frequency;	chr8:142693174	chr8:142702252~142726973:-
LUAD	cis	rs172166	0.694	rs1631552	ENSG00000216901.1	AL022393.7	4.37	1.5e-05	0.00279	0.24	0.2	Cardiac Troponin-T levels;	chr6:28121921	chr6:28176188~28176674:+
LUAD	cis	rs4907240	0.658	rs4907319	ENSG00000237510.6	AC008268.2	-4.37	1.5e-05	0.00279	-0.27	-0.2	Event-related brain oscillations;	chr2:96472788	chr2:95789654~95800166:+
LUAD	cis	rs2378497	0.564	rs115883774	ENSG00000200033.1	RNU6-403P	4.37	1.5e-05	0.00279	0.22	0.2	Serum thyroid-stimulating hormone levels;	chr1:221986970	chr1:221837334~221837437:-
LUAD	cis	rs7208859	0.573	rs8070182	ENSG00000280069.1	CTD-2349P21.3	-4.37	1.5e-05	0.00279	-0.26	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30738182~30740275:+
LUAD	cis	rs7976269	0.609	rs7310276	ENSG00000257176.2	RP11-996F15.2	4.37	1.5e-05	0.0028	0.21	0.2	Male-pattern baldness;	chr12:29054128	chr12:29280418~29317848:-
LUAD	cis	rs10938353	0.68	rs12645110	ENSG00000273369.1	RP11-700J17.1	4.37	1.5e-05	0.0028	0.27	0.2	Body mass index;	chr4:44667706	chr4:44693946~44694386:-
LUAD	cis	rs4664293	0.902	rs13391919	ENSG00000230783.1	AC009961.2	-4.37	1.5e-05	0.0028	-0.24	-0.2	Monocyte percentage of white cells;	chr2:159703649	chr2:159689217~159690291:-
LUAD	cis	rs2823962	0.759	rs4485639	ENSG00000270093.1	AP000473.8	-4.37	1.5e-05	0.0028	-0.2	-0.2	Amyotrophic lateral sclerosis;	chr21:16645671	chr21:16643529~16645065:+
LUAD	cis	rs2823962	0.727	rs1116415	ENSG00000270093.1	AP000473.8	-4.37	1.5e-05	0.0028	-0.2	-0.2	Amyotrophic lateral sclerosis;	chr21:16646505	chr21:16643529~16645065:+
LUAD	cis	rs1005277	0.522	rs7090858	ENSG00000263064.2	RP11-291L22.7	-4.37	1.5e-05	0.0028	-0.21	-0.2	Extrinsic epigenetic age acceleration;	chr10:37714742	chr10:38448689~38448949:+
LUAD	cis	rs9322193	0.923	rs4870267	ENSG00000268592.3	RAET1E-AS1	4.37	1.5e-05	0.0028	0.24	0.2	Lung cancer;	chr6:149671572	chr6:149863494~149919507:+
LUAD	cis	rs2933343	0.729	rs1683816	ENSG00000261159.1	RP11-723O4.9	-4.37	1.5e-05	0.0028	-0.22	-0.2	IgG glycosylation;	chr3:128932352	chr3:128859716~128860526:-
LUAD	cis	rs2242116	0.76	rs4682845	ENSG00000271161.1	BOLA2P2	4.37	1.5e-05	0.0028	0.19	0.2	Birth weight;	chr3:46913914	chr3:47499841~47500407:+
LUAD	cis	rs5758511	0.68	rs58654759	ENSG00000227370.1	RP4-669P10.19	4.37	1.5e-05	0.0028	0.22	0.2	Birth weight;	chr22:42246570	chr22:42132543~42132998:+
LUAD	cis	rs13113518	1	rs6822740	ENSG00000272969.1	RP11-528I4.2	4.37	1.5e-05	0.0028	0.2	0.2	Height;	chr4:55518922	chr4:55547112~55547889:+
LUAD	cis	rs7688540	0.74	rs28784663	ENSG00000211553.1	AC253576.2	-4.37	1.51e-05	0.0028	-0.25	-0.2	Facial morphology (factor 6, height of vermillion lower lip);	chr4:293257	chr4:136461~136568:+
LUAD	cis	rs7189233	0.55	rs4783811	ENSG00000279344.1	RP11-44F14.7	4.37	1.51e-05	0.0028	0.16	0.2	Intelligence (multi-trait analysis);	chr16:53449464	chr16:53478957~53481550:-
LUAD	cis	rs1401999	0.966	rs2292998	ENSG00000223882.1	ABCC5-AS1	-4.37	1.51e-05	0.0028	-0.2	-0.2	Anterior chamber depth;	chr3:183946045	chr3:184006338~184011419:+
LUAD	cis	rs240993	0.516	rs181294	ENSG00000230177.1	RP5-1112D6.4	-4.37	1.51e-05	0.0028	-0.22	-0.2	Inflammatory skin disease;Psoriasis;	chr6:111298999	chr6:111277932~111278742:+
LUAD	cis	rs73193808	0.901	rs8132759	ENSG00000215533.7	LINC00189	-4.37	1.51e-05	0.0028	-0.28	-0.2	Coronary artery disease;	chr21:29218630	chr21:29193480~29288205:+
LUAD	cis	rs950169	0.922	rs12912934	ENSG00000275120.1	RP11-182J1.17	4.37	1.51e-05	0.0028	0.3	0.2	Schizophrenia;	chr15:84571216	chr15:84599434~84606463:-
LUAD	cis	rs2243480	0.901	rs778730	ENSG00000229886.1	RP5-1132H15.3	4.37	1.51e-05	0.0028	0.34	0.2	Diabetic kidney disease;	chr7:66358338	chr7:66025126~66031544:-
LUAD	cis	rs4713118	0.513	rs183244	ENSG00000216901.1	AL022393.7	4.37	1.51e-05	0.0028	0.23	0.2	Parkinson's disease;	chr6:28064060	chr6:28176188~28176674:+
LUAD	cis	rs950169	0.614	rs765524	ENSG00000259728.4	LINC00933	4.37	1.51e-05	0.0028	0.3	0.2	Schizophrenia;	chr15:84013030	chr15:84570649~84580175:+
LUAD	cis	rs454217	0.846	rs381966	ENSG00000277851.1	RP11-756G20.1	4.37	1.51e-05	0.0028	0.2	0.2	Smoking quantity;	chr12:92335913	chr12:92247756~92363832:-
LUAD	cis	rs2562456	0.833	rs2650776	ENSG00000268081.1	RP11-678G14.2	4.37	1.51e-05	0.0028	0.32	0.2	Pain;	chr19:21430595	chr19:21554640~21569237:-
LUAD	cis	rs875971	0.642	rs35526611	ENSG00000236529.1	RP13-254B10.1	-4.37	1.51e-05	0.0028	-0.2	-0.2	Aortic root size;	chr7:66629021	chr7:65840212~65840596:+
LUAD	cis	rs2929278	0.617	rs3087657	ENSG00000166763.7	STRCP1	4.37	1.51e-05	0.00281	0.22	0.2	Schizophrenia;	chr15:43771661	chr15:43699488~43718184:-
LUAD	cis	rs2562456	0.834	rs13346641	ENSG00000268081.1	RP11-678G14.2	4.37	1.51e-05	0.00281	0.31	0.2	Pain;	chr19:21409481	chr19:21554640~21569237:-
LUAD	cis	rs1005277	0.505	rs200936	ENSG00000273019.1	RP11-508N22.13	-4.37	1.51e-05	0.00281	-0.22	-0.2	Extrinsic epigenetic age acceleration;	chr10:37846007	chr10:38149968~38150293:+
LUAD	cis	rs1005277	0.505	rs200937	ENSG00000273019.1	RP11-508N22.13	-4.37	1.51e-05	0.00281	-0.22	-0.2	Extrinsic epigenetic age acceleration;	chr10:37846844	chr10:38149968~38150293:+
LUAD	cis	rs4072980	0.545	rs12120737	ENSG00000212541.1	RNU6-510P	-4.37	1.51e-05	0.00281	-0.25	-0.2	Coronary artery disease;	chr1:37956872	chr1:37991462~37991569:+
LUAD	cis	rs11089937	0.539	rs6001075	ENSG00000211640.3	IGLV6-57	4.37	1.51e-05	0.00281	0.15	0.2	Periodontitis (PAL4Q3);	chr22:22133765	chr22:22195713~22196460:+
LUAD	cis	rs11089937	0.597	rs6001076	ENSG00000211640.3	IGLV6-57	4.37	1.51e-05	0.00281	0.15	0.2	Periodontitis (PAL4Q3);	chr22:22133873	chr22:22195713~22196460:+
LUAD	cis	rs11089937	0.597	rs5995560	ENSG00000211640.3	IGLV6-57	4.37	1.51e-05	0.00281	0.15	0.2	Periodontitis (PAL4Q3);	chr22:22133989	chr22:22195713~22196460:+
LUAD	cis	rs848490	0.962	rs62462680	ENSG00000214293.7	APTR	4.37	1.51e-05	0.00281	0.27	0.2	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77859117	chr7:77657660~77696265:-
LUAD	cis	rs14027	0.883	rs16893025	ENSG00000279347.1	RP11-85I17.2	-4.37	1.51e-05	0.00281	-0.17	-0.2	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119701440	chr8:119838736~119840385:-
LUAD	cis	rs801193	1	rs2707854	ENSG00000224316.1	RP11-479O9.2	4.37	1.51e-05	0.00281	0.2	0.2	Aortic root size;	chr7:66747610	chr7:65773620~65802067:+
LUAD	cis	rs651907	0.535	rs11717638	ENSG00000244119.1	PDCL3P4	4.37	1.51e-05	0.00281	0.2	0.2	Colorectal cancer;	chr3:101786624	chr3:101712472~101713191:+
LUAD	cis	rs7727544	0.507	rs11741341	ENSG00000263597.1	MIR3936	4.37	1.51e-05	0.00281	0.2	0.2	Blood metabolite levels;	chr5:132234525	chr5:132365490~132365599:-
LUAD	cis	rs1964356	0.967	rs2953802	ENSG00000253981.4	ALG1L13P	4.37	1.51e-05	0.00281	0.24	0.2	Mean corpuscular volume;	chr8:8994371	chr8:8236003~8244667:-
LUAD	cis	rs12122100	0.913	rs35811591	ENSG00000244371.2	PFN1P8	4.37	1.51e-05	0.00281	0.25	0.2	HIV-1 control;	chr1:147043678	chr1:146957117~146957659:-
LUAD	cis	rs34792	0.525	rs12708795	ENSG00000275910.1	RP11-680G24.6	-4.37	1.51e-05	0.00281	-0.19	-0.2	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15533861	chr16:15015828~15016390:-
LUAD	cis	rs6840360	0.642	rs11729923	ENSG00000270265.1	RP11-731D1.4	-4.37	1.52e-05	0.00281	-0.2	-0.2	Intelligence (multi-trait analysis);	chr4:151470884	chr4:151333775~151353224:-
LUAD	cis	rs1729951	0.546	rs12054218	ENSG00000239213.4	NCK1-AS1	4.37	1.52e-05	0.00282	0.21	0.2	Neuroticism;	chr3:136958654	chr3:136841726~136862054:-
LUAD	cis	rs1729951	0.546	rs12054408	ENSG00000239213.4	NCK1-AS1	4.37	1.52e-05	0.00282	0.21	0.2	Neuroticism;	chr3:136958803	chr3:136841726~136862054:-
LUAD	cis	rs858239	0.899	rs2268745	ENSG00000226816.2	AC005082.12	4.37	1.52e-05	0.00282	0.27	0.2	Cerebrospinal fluid biomarker levels;	chr7:23277981	chr7:23206013~23208045:+
LUAD	cis	rs2281603	0.951	rs73267743	ENSG00000259116.1	RP11-973N13.4	-4.37	1.52e-05	0.00282	-0.18	-0.2	Lymphocyte counts;	chr14:64511424	chr14:64514154~64540368:-
LUAD	cis	rs2281603	0.951	rs73267744	ENSG00000259116.1	RP11-973N13.4	-4.37	1.52e-05	0.00282	-0.18	-0.2	Lymphocyte counts;	chr14:64511461	chr14:64514154~64540368:-
LUAD	cis	rs2281603	0.951	rs61985707	ENSG00000259116.1	RP11-973N13.4	-4.37	1.52e-05	0.00282	-0.18	-0.2	Lymphocyte counts;	chr14:64512846	chr14:64514154~64540368:-
LUAD	cis	rs6570726	1	rs951143	ENSG00000235652.6	RP11-545I5.3	4.37	1.52e-05	0.00282	0.2	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145611440	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.967	rs373704	ENSG00000235652.6	RP11-545I5.3	4.37	1.52e-05	0.00282	0.19	0.2	Lobe attachment (rater-scored or self-reported);	chr6:145539482	chr6:145799409~145886585:+
LUAD	cis	rs9910055	0.529	rs2523161	ENSG00000267080.4	ASB16-AS1	4.37	1.52e-05	0.00282	0.18	0.2	Total body bone mineral density;	chr17:44102037	chr17:44175973~44186717:-
LUAD	cis	rs9910055	0.54	rs609292	ENSG00000267080.4	ASB16-AS1	4.37	1.52e-05	0.00282	0.18	0.2	Total body bone mineral density;	chr17:44103068	chr17:44175973~44186717:-
LUAD	cis	rs2911132	0.621	rs28432918	ENSG00000248734.2	CTD-2260A17.1	4.37	1.52e-05	0.00282	0.21	0.2	Urate levels (BMI interaction);	chr5:96765522	chr5:96784777~96785999:+
LUAD	cis	rs7208859	0.673	rs2269915	ENSG00000263603.1	CTD-2349P21.5	-4.37	1.52e-05	0.00282	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906326	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs2269916	ENSG00000263603.1	CTD-2349P21.5	-4.37	1.52e-05	0.00282	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906745	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs11649765	ENSG00000263603.1	CTD-2349P21.5	-4.37	1.52e-05	0.00282	-0.36	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906870	chr17:30729469~30731202:+
LUAD	cis	rs8072100	0.713	rs4968318	ENSG00000228782.6	CTD-2026D20.3	4.37	1.52e-05	0.00282	0.21	0.2	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47374528	chr17:47450568~47492492:-
LUAD	cis	rs2243480	1	rs383402	ENSG00000164669.11	INTS4P1	-4.37	1.52e-05	0.00282	-0.34	-0.2	Diabetic kidney disease;	chr7:66121666	chr7:65141225~65234216:+
LUAD	cis	rs862034	0.509	rs7149930	ENSG00000270000.1	RP3-449M8.9	4.37	1.52e-05	0.00282	0.22	0.2	Height;	chr14:74487356	chr14:74471930~74472360:-
LUAD	cis	rs73173548	0.502	rs4129236	ENSG00000247828.6	TMEM161B-AS1	4.37	1.52e-05	0.00282	0.24	0.2	Macular telangiectasia type 2;	chr5:88441542	chr5:88268895~88436685:+
LUAD	cis	rs73173548	0.502	rs36077166	ENSG00000247828.6	TMEM161B-AS1	4.37	1.52e-05	0.00282	0.24	0.2	Macular telangiectasia type 2;	chr5:88441770	chr5:88268895~88436685:+
LUAD	cis	rs6723108	0.627	rs4954197	ENSG00000224043.6	CCNT2-AS1	-4.37	1.52e-05	0.00282	-0.24	-0.2	Type 2 diabetes;	chr2:134904674	chr2:134735464~134918710:-
LUAD	cis	rs6723108	0.627	rs766270	ENSG00000224043.6	CCNT2-AS1	-4.37	1.52e-05	0.00282	-0.24	-0.2	Type 2 diabetes;	chr2:134909356	chr2:134735464~134918710:-
LUAD	cis	rs73193808	1	rs73193819	ENSG00000215533.7	LINC00189	-4.37	1.52e-05	0.00282	-0.28	-0.2	Coronary artery disease;	chr21:29172336	chr21:29193480~29288205:+
LUAD	cis	rs73193808	1	rs73193820	ENSG00000215533.7	LINC00189	-4.37	1.52e-05	0.00282	-0.28	-0.2	Coronary artery disease;	chr21:29172348	chr21:29193480~29288205:+
LUAD	cis	rs12446554	0.509	rs56108048	ENSG00000261195.1	CTD-2380F24.1	-4.37	1.52e-05	0.00282	-0.27	-0.2	Obesity;	chr16:19698457	chr16:19761172~19766099:-
LUAD	cis	rs4554975	0.689	rs2465208	ENSG00000274723.1	RP11-618L22.1	4.37	1.52e-05	0.00282	0.23	0.2	Metabolite levels (small molecules and protein measures);	chr12:46876759	chr12:46970504~46972155:+
LUAD	cis	rs4374383	0.884	rs10188640	ENSG00000207383.1	Y_RNA	-4.37	1.52e-05	0.00282	-0.24	-0.2	Hepatitis C induced liver fibrosis;	chr2:111983520	chr2:112579484~112579584:-
LUAD	cis	rs4374383	0.884	rs10188642	ENSG00000207383.1	Y_RNA	-4.37	1.52e-05	0.00282	-0.24	-0.2	Hepatitis C induced liver fibrosis;	chr2:111983522	chr2:112579484~112579584:-
LUAD	cis	rs6479891	0.908	rs12412946	ENSG00000232075.1	MRPL35P2	4.37	1.52e-05	0.00282	0.33	0.2	Arthritis (juvenile idiopathic);	chr10:63529792	chr10:63634317~63634827:-
LUAD	cis	rs6479891	1	rs59035163	ENSG00000232075.1	MRPL35P2	4.37	1.52e-05	0.00282	0.33	0.2	Arthritis (juvenile idiopathic);	chr10:63532283	chr10:63634317~63634827:-
LUAD	cis	rs62355901	0.599	rs12657013	ENSG00000271828.1	CTD-2310F14.1	4.37	1.52e-05	0.00283	0.39	0.2	Breast cancer;	chr5:56739441	chr5:56927874~56929573:+
LUAD	cis	rs867371	0.929	rs1045508	ENSG00000276710.3	CSPG4P8	4.37	1.52e-05	0.00283	0.18	0.2	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82157565	chr15:82459472~82477258:+
LUAD	cis	rs9545047	0.519	rs8001281	ENSG00000227354.5	RBM26-AS1	4.37	1.52e-05	0.00283	0.21	0.2	Schizophrenia;	chr13:79410707	chr13:79406309~79424328:+
LUAD	cis	rs8177876	0.749	rs2549896	ENSG00000261061.1	RP11-303E16.2	4.37	1.52e-05	0.00283	0.27	0.2	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81054334	chr16:81030770~81031485:+
LUAD	cis	rs2348418	0.8	rs6487667	ENSG00000247934.4	RP11-967K21.1	-4.37	1.52e-05	0.00283	-0.22	-0.2	Lung function (FEV1);Lung function (FVC);	chr12:28195643	chr12:28163298~28190738:-
LUAD	cis	rs453301	0.686	rs6601280	ENSG00000253893.2	FAM85B	-4.37	1.52e-05	0.00283	-0.26	-0.2	Joint mobility (Beighton score);	chr8:9051726	chr8:8167819~8226614:-
LUAD	cis	rs11673344	0.864	rs7259513	ENSG00000226686.6	LINC01535	4.37	1.52e-05	0.00283	0.25	0.2	Obesity-related traits;	chr19:37085802	chr19:37251912~37265535:+
LUAD	cis	rs6496932	0.635	rs12900455	ENSG00000218052.5	ADAMTS7P4	-4.37	1.52e-05	0.00283	-0.22	-0.2	Central corneal thickness;Corneal structure;	chr15:85362345	chr15:85255369~85330334:-
LUAD	cis	rs7660883	0.897	rs342452	ENSG00000251411.1	RP11-397E7.4	-4.37	1.52e-05	0.00283	-0.21	-0.2	HDL cholesterol levels;	chr4:87097256	chr4:86913266~86914817:-
LUAD	cis	rs2346177	0.777	rs7587138	ENSG00000279254.1	RP11-536C12.1	4.37	1.52e-05	0.00283	0.2	0.2	HDL cholesterol;	chr2:46429950	chr2:46668870~46670778:+
LUAD	cis	rs17772222	1	rs55722539	ENSG00000258789.1	RP11-507K2.3	-4.37	1.53e-05	0.00283	-0.27	-0.2	Coronary artery calcification;	chr14:88411691	chr14:88551597~88552493:+
LUAD	cis	rs17772222	1	rs11159856	ENSG00000258789.1	RP11-507K2.3	-4.37	1.53e-05	0.00283	-0.27	-0.2	Coronary artery calcification;	chr14:88417585	chr14:88551597~88552493:+
LUAD	cis	rs6012564	0.89	rs6066976	ENSG00000230758.1	SNAP23P	4.37	1.53e-05	0.00283	0.21	0.2	Anger;	chr20:49134464	chr20:49038357~49038602:-
LUAD	cis	rs6012564	1	rs6063361	ENSG00000230758.1	SNAP23P	4.37	1.53e-05	0.00283	0.21	0.2	Anger;	chr20:49141426	chr20:49038357~49038602:-
LUAD	cis	rs2227564	0.62	rs11000787	ENSG00000271816.1	BMS1P4	4.37	1.53e-05	0.00283	0.19	0.2	Crohn's disease;Inflammatory bowel disease;	chr10:73824625	chr10:73699151~73730487:-
LUAD	cis	rs4819052	0.679	rs2838859	ENSG00000237664.1	LINC00316	-4.37	1.53e-05	0.00283	-0.23	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45264602	chr21:45338590~45341990:-
LUAD	cis	rs4908768	0.52	rs7520025	ENSG00000270282.1	RP5-1115A15.2	4.37	1.53e-05	0.00283	0.21	0.2	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8638218	chr1:8512653~8513021:+
LUAD	cis	rs812925	0.537	rs2463097	ENSG00000271889.1	RP11-493E12.1	-4.37	1.53e-05	0.00283	-0.23	-0.2	Immature fraction of reticulocytes;	chr2:61387166	chr2:61151433~61162105:-
LUAD	cis	rs6723108	0.603	rs62168891	ENSG00000224043.6	CCNT2-AS1	-4.37	1.53e-05	0.00283	-0.25	-0.2	Type 2 diabetes;	chr2:134914617	chr2:134735464~134918710:-
LUAD	cis	rs28386778	0.897	rs968719	ENSG00000240280.5	TCAM1P	-4.37	1.53e-05	0.00283	-0.23	-0.2	Prudent dietary pattern;	chr17:63830911	chr17:63849292~63864379:+
LUAD	cis	rs227275	0.525	rs223461	ENSG00000251288.2	RP11-10L12.2	-4.37	1.53e-05	0.00283	-0.23	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102782372	chr4:102751401~102752641:+
LUAD	cis	rs911555	0.755	rs12436729	ENSG00000244691.1	RPL10AP1	4.37	1.53e-05	0.00283	0.26	0.2	Intelligence (multi-trait analysis);	chr14:103463552	chr14:103412119~103412761:-
LUAD	cis	rs6840360	0.573	rs11099807	ENSG00000270265.1	RP11-731D1.4	-4.37	1.53e-05	0.00283	-0.2	-0.2	Intelligence (multi-trait analysis);	chr4:151348076	chr4:151333775~151353224:-
LUAD	cis	rs11220082	0.666	rs7103665	ENSG00000254671.2	STT3A-AS1	-4.37	1.53e-05	0.00283	-0.22	-0.2	Schizophrenia;	chr11:125472998	chr11:125570284~125592568:-
LUAD	cis	rs11220082	0.644	rs61917855	ENSG00000254671.2	STT3A-AS1	-4.37	1.53e-05	0.00283	-0.22	-0.2	Schizophrenia;	chr11:125473652	chr11:125570284~125592568:-
LUAD	cis	rs6723108	0.517	rs6430552	ENSG00000224043.6	CCNT2-AS1	-4.37	1.53e-05	0.00284	-0.24	-0.2	Type 2 diabetes;	chr2:134865238	chr2:134735464~134918710:-
LUAD	cis	rs9601248	0.756	rs2146592	ENSG00000227676.3	LINC01068	-4.37	1.53e-05	0.00284	-0.24	-0.2	Major depressive disorder;	chr13:79606146	chr13:79566727~79571436:+
LUAD	cis	rs6496044	0.568	rs2880764	ENSG00000259295.5	CSPG4P12	4.37	1.53e-05	0.00284	0.23	0.2	Interstitial lung disease;	chr15:85513177	chr15:85191438~85213905:+
LUAD	cis	rs5758659	0.652	rs133303	ENSG00000182057.4	OGFRP1	4.37	1.53e-05	0.00284	0.24	0.2	Cognitive function;	chr22:41999238	chr22:42269753~42275196:+
LUAD	cis	rs1729951	0.546	rs835634	ENSG00000239213.4	NCK1-AS1	4.37	1.53e-05	0.00284	0.21	0.2	Neuroticism;	chr3:136957461	chr3:136841726~136862054:-
LUAD	cis	rs780096	0.526	rs13472	ENSG00000234072.1	AC074117.10	-4.37	1.53e-05	0.00284	-0.15	-0.2	Total body bone mineral density;	chr2:27377372	chr2:27356246~27367622:+
LUAD	cis	rs10751647	0.804	rs3809112	ENSG00000251661.3	RP11-326C3.11	-4.37	1.53e-05	0.00284	-0.23	-0.2	Monocyte count;	chr11:307036	chr11:318640~325631:+
LUAD	cis	rs7061710	0.711	rs3817765	ENSG00000271811.1	RP1-79C4.4	-4.37	1.53e-05	0.00284	-0.29	-0.2	Blood metabolite levels;	chr1:171149956	chr1:170667381~170669425:+
LUAD	cis	rs1005277	0.505	rs200935	ENSG00000273019.1	RP11-508N22.13	-4.37	1.53e-05	0.00284	-0.22	-0.2	Extrinsic epigenetic age acceleration;	chr10:37843882	chr10:38149968~38150293:+
LUAD	cis	rs2395128	0.586	rs10762650	ENSG00000213731.2	RAB5CP1	4.37	1.53e-05	0.00284	0.37	0.2	Ulcerative colitis;Inflammatory bowel disease;	chr10:75058862	chr10:74423435~74424014:-
LUAD	cis	rs6496932	0.663	rs8040940	ENSG00000218052.5	ADAMTS7P4	-4.37	1.53e-05	0.00284	-0.22	-0.2	Central corneal thickness;Corneal structure;	chr15:85361817	chr15:85255369~85330334:-
LUAD	cis	rs1864585	0.52	rs73208782	ENSG00000255046.1	RP11-297N6.4	4.37	1.53e-05	0.00284	0.28	0.2	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10820045	chr8:11797928~11802568:-
LUAD	cis	rs2562456	0.833	rs62110428	ENSG00000268081.1	RP11-678G14.2	4.37	1.53e-05	0.00284	0.32	0.2	Pain;	chr19:21430854	chr19:21554640~21569237:-
LUAD	cis	rs4604732	0.642	rs4489599	ENSG00000227135.1	GCSAML-AS1	4.37	1.53e-05	0.00284	0.27	0.2	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247471911	chr1:247524679~247526752:-
LUAD	cis	rs7138803	0.51	rs10783320	ENSG00000257464.1	RP11-161H23.8	-4.37	1.53e-05	0.00284	-0.19	-0.2	Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index;	chr12:49786145	chr12:49442424~49442652:-
LUAD	cis	rs2348418	0.765	rs12368743	ENSG00000247934.4	RP11-967K21.1	-4.37	1.53e-05	0.00284	-0.22	-0.2	Lung function (FEV1);Lung function (FVC);	chr12:28192409	chr12:28163298~28190738:-
LUAD	cis	rs812925	0.519	rs10199672	ENSG00000271889.1	RP11-493E12.1	-4.37	1.53e-05	0.00284	-0.23	-0.2	Immature fraction of reticulocytes;	chr2:61400499	chr2:61151433~61162105:-
LUAD	cis	rs699371	0.548	rs2058126	ENSG00000270000.1	RP3-449M8.9	4.37	1.53e-05	0.00284	0.21	0.2	Height;	chr14:74432576	chr14:74471930~74472360:-
LUAD	cis	rs490592	0.568	rs693603	ENSG00000278768.1	BACE1-AS	4.37	1.53e-05	0.00284	0.24	0.2	Brain structure;	chr11:116425526	chr11:117290874~117293571:+
LUAD	cis	rs800160	1	rs800153	ENSG00000236264.4	RPL26P30	-4.37	1.53e-05	0.00284	-0.27	-0.2	Bacteremia;	chr11:2352285	chr11:2335132~2335776:-
LUAD	cis	rs2243480	1	rs160633	ENSG00000226002.1	RP11-460N20.5	-4.37	1.53e-05	0.00285	-0.33	-0.2	Diabetic kidney disease;	chr7:66063241	chr7:65084103~65100232:+
LUAD	cis	rs2562456	0.833	rs56187954	ENSG00000268081.1	RP11-678G14.2	4.37	1.53e-05	0.00285	0.31	0.2	Pain;	chr19:21345258	chr19:21554640~21569237:-
LUAD	cis	rs4879677	1	rs10812638	ENSG00000215441.3	CTAGE12P	-4.37	1.53e-05	0.00285	-0.24	-0.2	Gut microbiome composition (summer and winter);	chr9:27668808	chr9:27608382~27610745:-
LUAD	cis	rs6840360	0.571	rs7664663	ENSG00000270265.1	RP11-731D1.4	-4.37	1.53e-05	0.00285	-0.22	-0.2	Intelligence (multi-trait analysis);	chr4:151586862	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.571	rs4696271	ENSG00000270265.1	RP11-731D1.4	-4.37	1.53e-05	0.00285	-0.22	-0.2	Intelligence (multi-trait analysis);	chr4:151587966	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.571	rs1978955	ENSG00000270265.1	RP11-731D1.4	-4.37	1.53e-05	0.00285	-0.22	-0.2	Intelligence (multi-trait analysis);	chr4:151588357	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.571	rs1473305	ENSG00000270265.1	RP11-731D1.4	-4.37	1.53e-05	0.00285	-0.22	-0.2	Intelligence (multi-trait analysis);	chr4:151590569	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.571	rs62329101	ENSG00000270265.1	RP11-731D1.4	-4.37	1.53e-05	0.00285	-0.22	-0.2	Intelligence (multi-trait analysis);	chr4:151591087	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.571	rs4696100	ENSG00000270265.1	RP11-731D1.4	-4.37	1.53e-05	0.00285	-0.22	-0.2	Intelligence (multi-trait analysis);	chr4:151593090	chr4:151333775~151353224:-
LUAD	cis	rs651907	0.535	rs34743741	ENSG00000244119.1	PDCL3P4	4.37	1.53e-05	0.00285	0.2	0.2	Colorectal cancer;	chr3:101813604	chr3:101712472~101713191:+
LUAD	cis	rs2731006	0.591	rs11181692	ENSG00000257114.2	RP11-25I15.3	4.37	1.53e-05	0.00285	0.3	0.2	Panic disorder;	chr12:42812202	chr12:42692216~42717119:+
LUAD	cis	rs2242116	0.793	rs9855938	ENSG00000271161.1	BOLA2P2	4.37	1.53e-05	0.00285	0.19	0.2	Birth weight;	chr3:46915808	chr3:47499841~47500407:+
LUAD	cis	rs12358692	0.669	rs7068614	ENSG00000271046.1	RP11-138I18.2	-4.37	1.54e-05	0.00285	-0.21	-0.2	Alzheimer's disease;	chr10:11679478	chr10:11679675~11680514:+
LUAD	cis	rs11009175	0.929	rs72786108	ENSG00000273038.2	RP11-479G22.8	-4.37	1.54e-05	0.00285	-0.32	-0.2	Depression (quantitative trait);	chr10:33059085	chr10:32887255~32889311:-
LUAD	cis	rs6687758	1	rs12140604	ENSG00000200033.1	RNU6-403P	4.37	1.54e-05	0.00285	0.26	0.2	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221985808	chr1:221837334~221837437:-
LUAD	cis	rs1075265	0.563	rs2542588	ENSG00000272156.1	RP11-477N3.1	4.37	1.54e-05	0.00285	0.23	0.2	Chronotype;Morning vs. evening chronotype;	chr2:53791787	chr2:54082554~54085066:+
LUAD	cis	rs6565180	0.926	rs4787643	ENSG00000273724.1	RP11-347C12.12	4.37	1.54e-05	0.00285	0.21	0.2	Tonsillectomy;	chr16:30382339	chr16:30336400~30343336:+
LUAD	cis	rs6565180	0.926	rs4788409	ENSG00000273724.1	RP11-347C12.12	4.37	1.54e-05	0.00285	0.21	0.2	Tonsillectomy;	chr16:30382450	chr16:30336400~30343336:+
LUAD	cis	rs4819052	0.851	rs28442024	ENSG00000237664.1	LINC00316	-4.37	1.54e-05	0.00285	-0.23	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254560	chr21:45338590~45341990:-
LUAD	cis	rs4908768	0.539	rs7537982	ENSG00000270282.1	RP5-1115A15.2	4.37	1.54e-05	0.00285	0.22	0.2	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8583948	chr1:8512653~8513021:+
LUAD	cis	rs875971	1	rs3981131	ENSG00000232559.3	GS1-124K5.12	4.37	1.54e-05	0.00285	0.23	0.2	Aortic root size;	chr7:66486690	chr7:66554588~66576923:-
LUAD	cis	rs73173548	0.528	rs80083342	ENSG00000247828.6	TMEM161B-AS1	4.37	1.54e-05	0.00285	0.24	0.2	Macular telangiectasia type 2;	chr5:88476921	chr5:88268895~88436685:+
LUAD	cis	rs2548724	0.617	rs62372237	ENSG00000250682.4	LINC00491	4.37	1.54e-05	0.00285	0.23	0.2	Type 2 diabetes;	chr5:102332390	chr5:102609156~102671559:-
LUAD	cis	rs2548724	0.648	rs12655961	ENSG00000250682.4	LINC00491	4.37	1.54e-05	0.00285	0.23	0.2	Type 2 diabetes;	chr5:102333311	chr5:102609156~102671559:-
LUAD	cis	rs2548724	0.648	rs12654151	ENSG00000250682.4	LINC00491	4.37	1.54e-05	0.00285	0.23	0.2	Type 2 diabetes;	chr5:102333505	chr5:102609156~102671559:-
LUAD	cis	rs2548724	0.617	rs7714927	ENSG00000250682.4	LINC00491	4.37	1.54e-05	0.00285	0.23	0.2	Type 2 diabetes;	chr5:102341173	chr5:102609156~102671559:-
LUAD	cis	rs16866061	0.962	rs72972361	ENSG00000228446.2	AC073052.1	-4.37	1.54e-05	0.00285	-0.21	-0.2	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr2:224476833	chr2:224499387~224500100:-
LUAD	cis	rs3750965	0.881	rs61057353	ENSG00000260895.1	RP11-554A11.7	4.37	1.54e-05	0.00285	0.24	0.2	Hair color;	chr11:69049582	chr11:69103493~69109094:+
LUAD	cis	rs9545047	0.604	rs1028770	ENSG00000227354.5	RBM26-AS1	-4.37	1.54e-05	0.00285	-0.21	-0.2	Schizophrenia;	chr13:79297346	chr13:79406309~79424328:+
LUAD	cis	rs820077	0.8	rs13216424	ENSG00000232909.1	RP3-510O8.4	-4.37	1.54e-05	0.00285	-0.27	-0.2	Systemic lupus erythematosus;	chr6:35086408	chr6:35733867~35736947:-
LUAD	cis	rs2115630	0.967	rs8027779	ENSG00000225151.9	GOLGA2P7	4.37	1.54e-05	0.00285	0.22	0.2	P wave terminal force;	chr15:84712154	chr15:84199311~84230136:-
LUAD	cis	rs8062405	0.723	rs35175818	ENSG00000261419.1	RP11-57A19.4	-4.37	1.54e-05	0.00285	-0.22	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597425	chr16:28659696~28740781:-
LUAD	cis	rs10761482	0.531	rs10740029	ENSG00000254271.1	RP11-131N11.4	4.37	1.54e-05	0.00285	0.23	0.2	Schizophrenia;	chr10:60479144	chr10:60734342~60741828:+
LUAD	cis	rs2018683	0.745	rs917217	ENSG00000228421.2	AC005013.5	-4.37	1.54e-05	0.00285	-0.21	-0.2	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28935408	chr7:28957667~28959345:+
LUAD	cis	rs7208859	0.623	rs60890550	ENSG00000280069.1	CTD-2349P21.3	-4.37	1.54e-05	0.00285	-0.28	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30703843	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs11653955	ENSG00000280069.1	CTD-2349P21.3	-4.37	1.54e-05	0.00285	-0.28	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30706274	chr17:30738182~30740275:+
LUAD	cis	rs9815354	1	rs1716984	ENSG00000273328.4	RP11-141M3.6	4.37	1.54e-05	0.00286	0.29	0.2	Pulse pressure;Diastolic blood pressure;	chr3:41924040	chr3:42809414~42908105:+
LUAD	cis	rs11779988	0.545	rs208764	ENSG00000253671.1	RP11-806O11.1	-4.37	1.54e-05	0.00286	-0.24	-0.2	Breast cancer;	chr8:17948761	chr8:17808941~17820868:+
LUAD	cis	rs227275	0.525	rs7672319	ENSG00000251288.2	RP11-10L12.2	-4.37	1.54e-05	0.00286	-0.23	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102990002	chr4:102751401~102752641:+
LUAD	cis	rs227275	0.525	rs6533051	ENSG00000251288.2	RP11-10L12.2	-4.37	1.54e-05	0.00286	-0.23	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102990065	chr4:102751401~102752641:+
LUAD	cis	rs13160562	0.522	rs26502	ENSG00000272109.1	CTD-2260A17.3	-4.37	1.54e-05	0.00286	-0.2	-0.2	Alcohol dependence;	chr5:96764254	chr5:96804353~96806105:+
LUAD	cis	rs13160562	0.509	rs26501	ENSG00000272109.1	CTD-2260A17.3	-4.37	1.54e-05	0.00286	-0.2	-0.2	Alcohol dependence;	chr5:96765060	chr5:96804353~96806105:+
LUAD	cis	rs2524005	1	rs2524005	ENSG00000272236.1	XXbac-BPG170G13.32	-4.37	1.54e-05	0.00286	-0.27	-0.2	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29751965~29752207:-
LUAD	cis	rs13434995	0.842	rs55869433	ENSG00000249700.7	SRD5A3-AS1	-4.37	1.54e-05	0.00286	-0.29	-0.2	Adiponectin levels;	chr4:55544770	chr4:55363971~55395847:-
LUAD	cis	rs2708977	0.545	rs772177	ENSG00000237510.6	AC008268.2	-4.37	1.54e-05	0.00286	-0.28	-0.2	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96294733	chr2:95789654~95800166:+
LUAD	cis	rs136161	1	rs136161	ENSG00000268818.2	CITF22-62D4.1	-4.37	1.54e-05	0.00286	-0.21	-0.2	Diabetic kidney disease;	chr22:36261386	chr22:35626988~35635134:-
LUAD	cis	rs7762018	0.621	rs3823465	ENSG00000231690.2	LINC00574	-4.37	1.54e-05	0.00286	-0.31	-0.2	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169668084	chr6:169790321~169802873:+
LUAD	cis	rs950169	0.922	rs12910334	ENSG00000275120.1	RP11-182J1.17	4.37	1.54e-05	0.00286	0.31	0.2	Schizophrenia;	chr15:84403620	chr15:84599434~84606463:-
LUAD	cis	rs4908760	0.539	rs6698830	ENSG00000270282.1	RP5-1115A15.2	4.37	1.54e-05	0.00286	0.21	0.2	Vitiligo;	chr1:8794486	chr1:8512653~8513021:+
LUAD	cis	rs3026445	0.519	rs75013764	ENSG00000278993.1	RP3-424M6.4	4.37	1.54e-05	0.00286	0.24	0.2	QT interval;	chr12:110290196	chr12:110501614~110503441:+
LUAD	cis	rs8014252	0.803	rs12588723	ENSG00000259158.2	ADAM20P1	4.37	1.54e-05	0.00286	0.35	0.2	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70518234	chr14:70468881~70483756:-
LUAD	cis	rs853679	0.527	rs9468333	ENSG00000219392.1	RP1-265C24.5	-4.37	1.54e-05	0.00286	-0.25	-0.2	Depression;	chr6:28303421	chr6:28115628~28116551:+
LUAD	cis	rs6957923	0.846	rs6967145	ENSG00000230658.1	KLHL7-AS1	4.37	1.54e-05	0.00286	0.23	0.2	Height;	chr7:23477849	chr7:23101228~23105703:-
LUAD	cis	rs73173548	0.502	rs10942532	ENSG00000247828.6	TMEM161B-AS1	4.37	1.54e-05	0.00286	0.24	0.2	Macular telangiectasia type 2;	chr5:88462015	chr5:88268895~88436685:+
LUAD	cis	rs6142102	0.651	rs6119463	ENSG00000275784.1	RP5-1125A11.6	4.37	1.54e-05	0.00286	0.23	0.2	Skin pigmentation;	chr20:34149412	chr20:33989480~33991818:-
LUAD	cis	rs801193	1	rs2707850	ENSG00000224316.1	RP11-479O9.2	4.37	1.54e-05	0.00286	0.2	0.2	Aortic root size;	chr7:66738883	chr7:65773620~65802067:+
LUAD	cis	rs801193	0.967	rs1110414	ENSG00000224316.1	RP11-479O9.2	4.37	1.54e-05	0.00286	0.2	0.2	Aortic root size;	chr7:66740595	chr7:65773620~65802067:+
LUAD	cis	rs801193	1	rs7783924	ENSG00000224316.1	RP11-479O9.2	4.37	1.54e-05	0.00286	0.2	0.2	Aortic root size;	chr7:66744070	chr7:65773620~65802067:+
LUAD	cis	rs801193	1	rs7789184	ENSG00000224316.1	RP11-479O9.2	4.37	1.54e-05	0.00286	0.2	0.2	Aortic root size;	chr7:66745208	chr7:65773620~65802067:+
LUAD	cis	rs9341808	0.718	rs4437429	ENSG00000272129.1	RP11-250B2.6	4.37	1.55e-05	0.00286	0.24	0.2	Sitting height ratio;	chr6:80118875	chr6:80355424~80356859:+
LUAD	cis	rs853679	0.546	rs36092177	ENSG00000219392.1	RP1-265C24.5	-4.37	1.55e-05	0.00286	-0.44	-0.2	Depression;	chr6:28390030	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.546	rs2232429	ENSG00000219392.1	RP1-265C24.5	-4.37	1.55e-05	0.00286	-0.44	-0.2	Depression;	chr6:28391855	chr6:28115628~28116551:+
LUAD	cis	rs853679	1	rs853679	ENSG00000219392.1	RP1-265C24.5	-4.37	1.55e-05	0.00286	-0.3	-0.2	Depression;	chr6:28329086	chr6:28115628~28116551:+
LUAD	cis	rs853679	1	rs853678	ENSG00000219392.1	RP1-265C24.5	-4.37	1.55e-05	0.00286	-0.3	-0.2	Depression;	chr6:28329536	chr6:28115628~28116551:+
LUAD	cis	rs6964833	0.786	rs35633336	ENSG00000278416.1	PMS2L2	4.37	1.55e-05	0.00286	0.27	0.2	Menarche (age at onset);	chr7:74643961	chr7:75344015~75359550:-
LUAD	cis	rs6964833	0.935	rs35735900	ENSG00000278416.1	PMS2L2	4.37	1.55e-05	0.00286	0.27	0.2	Menarche (age at onset);	chr7:74651887	chr7:75344015~75359550:-
LUAD	cis	rs41411047	0.826	rs73155089	ENSG00000271711.1	RP11-392O18.2	4.37	1.55e-05	0.00287	0.38	0.2	Myocardial infarction;	chr3:149870421	chr3:150611262~150611877:-
LUAD	cis	rs910316	1	rs7303	ENSG00000279594.1	RP11-950C14.10	4.37	1.55e-05	0.00287	0.22	0.2	Height;	chr14:75053362	chr14:75011269~75012851:-
LUAD	cis	rs910316	1	rs10143132	ENSG00000279594.1	RP11-950C14.10	4.37	1.55e-05	0.00287	0.22	0.2	Height;	chr14:75059147	chr14:75011269~75012851:-
LUAD	cis	rs17772222	0.63	rs7146241	ENSG00000258789.1	RP11-507K2.3	4.37	1.55e-05	0.00287	0.24	0.2	Coronary artery calcification;	chr14:88551622	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.63	rs930181	ENSG00000258789.1	RP11-507K2.3	4.37	1.55e-05	0.00287	0.24	0.2	Coronary artery calcification;	chr14:88552364	chr14:88551597~88552493:+
LUAD	cis	rs6840360	0.642	rs7698816	ENSG00000270265.1	RP11-731D1.4	-4.37	1.55e-05	0.00287	-0.2	-0.2	Intelligence (multi-trait analysis);	chr4:151431820	chr4:151333775~151353224:-
LUAD	cis	rs561341	0.941	rs2470236	ENSG00000265798.5	RP11-271K11.5	4.37	1.55e-05	0.00287	0.29	0.2	Hip circumference adjusted for BMI;	chr17:31977921	chr17:31038575~31059121:-
LUAD	cis	rs561341	0.941	rs501773	ENSG00000265798.5	RP11-271K11.5	4.37	1.55e-05	0.00287	0.29	0.2	Hip circumference adjusted for BMI;	chr17:31987416	chr17:31038575~31059121:-
LUAD	cis	rs7189233	0.531	rs11859538	ENSG00000279344.1	RP11-44F14.7	4.37	1.55e-05	0.00287	0.16	0.2	Intelligence (multi-trait analysis);	chr16:53463133	chr16:53478957~53481550:-
LUAD	cis	rs2239557	0.961	rs8003212	ENSG00000259065.1	RP5-1021I20.1	4.37	1.55e-05	0.00287	0.23	0.2	Common traits (Other);	chr14:74158260	chr14:73787360~73803270:+
LUAD	cis	rs7189233	0.513	rs2908797	ENSG00000279344.1	RP11-44F14.7	4.37	1.55e-05	0.00287	0.16	0.2	Intelligence (multi-trait analysis);	chr16:53395261	chr16:53478957~53481550:-
LUAD	cis	rs75422866	0.51	rs73105818	ENSG00000276691.1	RP5-1057I20.5	4.37	1.55e-05	0.00287	0.33	0.2	Pneumonia;	chr12:47726538	chr12:47788426~47788971:+
LUAD	cis	rs4819052	0.62	rs421619	ENSG00000215447.6	BX322557.10	-4.37	1.55e-05	0.00287	-0.26	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45126200	chr21:45288052~45291738:+
LUAD	cis	rs7665090	1	rs1077358	ENSG00000246560.2	RP11-10L12.4	4.37	1.55e-05	0.00287	0.24	0.2	Primary biliary cholangitis;	chr4:102632769	chr4:102828055~102844075:+
LUAD	cis	rs4971059	0.617	rs10908458	ENSG00000160766.13	GBAP1	-4.37	1.55e-05	0.00287	-0.2	-0.2	Breast cancer;	chr1:155154472	chr1:155213821~155227422:-
LUAD	cis	rs17772222	0.917	rs12434935	ENSG00000258789.1	RP11-507K2.3	-4.37	1.55e-05	0.00287	-0.27	-0.2	Coronary artery calcification;	chr14:88645449	chr14:88551597~88552493:+
LUAD	cis	rs2281603	0.951	rs12385918	ENSG00000259116.1	RP11-973N13.4	-4.37	1.55e-05	0.00287	-0.18	-0.2	Lymphocyte counts;	chr14:64533227	chr14:64514154~64540368:-
LUAD	cis	rs7208859	0.623	rs3794796	ENSG00000280069.1	CTD-2349P21.3	-4.37	1.55e-05	0.00287	-0.27	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30738182~30740275:+
LUAD	cis	rs600231	0.706	rs1111934	ENSG00000245532.5	NEAT1	4.37	1.55e-05	0.00287	0.16	0.2	Bone mineral density;	chr11:65561921	chr11:65422774~65445540:+
LUAD	cis	rs6840360	0.642	rs2709838	ENSG00000270265.1	RP11-731D1.4	-4.37	1.55e-05	0.00287	-0.2	-0.2	Intelligence (multi-trait analysis);	chr4:151450212	chr4:151333775~151353224:-
LUAD	cis	rs7772486	0.713	rs2328704	ENSG00000235652.6	RP11-545I5.3	-4.37	1.55e-05	0.00287	-0.2	-0.2	Lobe attachment (rater-scored or self-reported);	chr6:145699358	chr6:145799409~145886585:+
LUAD	cis	rs13113518	0.966	rs1474271	ENSG00000272969.1	RP11-528I4.2	4.37	1.55e-05	0.00287	0.2	0.2	Height;	chr4:55435912	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs11937487	ENSG00000272969.1	RP11-528I4.2	4.37	1.55e-05	0.00287	0.2	0.2	Height;	chr4:55436576	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs3805146	ENSG00000272969.1	RP11-528I4.2	4.37	1.55e-05	0.00287	0.2	0.2	Height;	chr4:55436985	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs11133378	ENSG00000272969.1	RP11-528I4.2	4.37	1.55e-05	0.00287	0.2	0.2	Height;	chr4:55439472	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs11942279	ENSG00000272969.1	RP11-528I4.2	4.37	1.55e-05	0.00287	0.2	0.2	Height;	chr4:55439652	chr4:55547112~55547889:+
LUAD	cis	rs62025270	0.632	rs7177107	ENSG00000202081.1	RNU6-1280P	-4.37	1.55e-05	0.00287	-0.3	-0.2	Idiopathic pulmonary fibrosis;	chr15:85580133	chr15:85651522~85651628:-
LUAD	cis	rs9393777	0.92	rs35120058	ENSG00000219392.1	RP1-265C24.5	-4.37	1.55e-05	0.00287	-0.38	-0.2	Intelligence (multi-trait analysis);	chr6:27390387	chr6:28115628~28116551:+
LUAD	cis	rs2976388	0.556	rs10956985	ENSG00000253741.1	CTD-2292P10.4	4.37	1.55e-05	0.00287	0.23	0.2	Urinary tract infection frequency;	chr8:142737332	chr8:142702252~142726973:-
LUAD	cis	rs7985	0.901	rs5761679	ENSG00000244625.4	MIATNB	4.37	1.55e-05	0.00288	0.2	0.2	Electroencephalogram traits;	chr22:26681268	chr22:26672767~26780207:+
LUAD	cis	rs4699052	0.928	rs2169511	ENSG00000246560.2	RP11-10L12.4	4.37	1.55e-05	0.00288	0.25	0.2	Testicular germ cell tumor;	chr4:103271423	chr4:102828055~102844075:+
LUAD	cis	rs4699052	0.963	rs6849319	ENSG00000246560.2	RP11-10L12.4	4.37	1.55e-05	0.00288	0.25	0.2	Testicular germ cell tumor;	chr4:103271585	chr4:102828055~102844075:+
LUAD	cis	rs17784882	0.524	rs7433300	ENSG00000271161.1	BOLA2P2	4.37	1.55e-05	0.00288	0.19	0.2	QT interval;	chr3:47079150	chr3:47499841~47500407:+
LUAD	cis	rs62025270	0.688	rs7164373	ENSG00000202081.1	RNU6-1280P	-4.37	1.55e-05	0.00288	-0.28	-0.2	Idiopathic pulmonary fibrosis;	chr15:85722432	chr15:85651522~85651628:-
LUAD	cis	rs41369048	0.669	rs11586003	ENSG00000272823.1	RP11-295M18.6	-4.37	1.55e-05	0.00288	-0.3	-0.2	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220866816	chr1:220828676~220829211:-
LUAD	cis	rs889398	0.771	rs1566453	ENSG00000226232.7	RP11-419C5.2	-4.37	1.55e-05	0.00288	-0.17	-0.2	Body mass index;	chr16:69865884	chr16:69976388~69996188:-
LUAD	cis	rs7189233	0.531	rs1072911	ENSG00000279344.1	RP11-44F14.7	4.37	1.56e-05	0.00288	0.16	0.2	Intelligence (multi-trait analysis);	chr16:53465813	chr16:53478957~53481550:-
LUAD	cis	rs12579720	0.631	rs7975918	ENSG00000255910.1	RP11-405A12.2	4.37	1.56e-05	0.00288	0.24	0.2	Diastolic blood pressure;	chr12:20084689	chr12:19775451~20009937:+
LUAD	cis	rs7116495	0.529	rs575871	ENSG00000254682.1	RP11-660L16.2	4.37	1.56e-05	0.00288	0.49	0.2	Severe influenza A (H1N1) infection;	chr11:72067776	chr11:71448674~71452157:+
LUAD	cis	rs9322193	0.923	rs9968911	ENSG00000268592.3	RAET1E-AS1	4.37	1.56e-05	0.00288	0.24	0.2	Lung cancer;	chr6:149657419	chr6:149863494~149919507:+
LUAD	cis	rs7665090	1	rs1054029	ENSG00000246560.2	RP11-10L12.4	4.37	1.56e-05	0.00288	0.24	0.2	Primary biliary cholangitis;	chr4:102631896	chr4:102828055~102844075:+
LUAD	cis	rs7665090	1	rs3194585	ENSG00000246560.2	RP11-10L12.4	4.37	1.56e-05	0.00288	0.24	0.2	Primary biliary cholangitis;	chr4:102631933	chr4:102828055~102844075:+
LUAD	cis	rs227275	0.556	rs28367331	ENSG00000251288.2	RP11-10L12.2	-4.37	1.56e-05	0.00288	-0.23	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102900734	chr4:102751401~102752641:+
LUAD	cis	rs10463554	0.892	rs66759661	ENSG00000250682.4	LINC00491	4.37	1.56e-05	0.00288	0.24	0.2	Parkinson's disease;	chr5:102925894	chr5:102609156~102671559:-
LUAD	cis	rs453301	0.571	rs330048	ENSG00000253981.4	ALG1L13P	-4.37	1.56e-05	0.00288	-0.23	-0.2	Joint mobility (Beighton score);	chr8:9229768	chr8:8236003~8244667:-
LUAD	cis	rs889398	0.771	rs11075732	ENSG00000226232.7	RP11-419C5.2	4.37	1.56e-05	0.00288	0.17	0.2	Body mass index;	chr16:69732135	chr16:69976388~69996188:-
LUAD	cis	rs11168618	0.904	rs7136845	ENSG00000240399.1	RP1-228P16.1	4.37	1.56e-05	0.00288	0.19	0.2	Adiponectin levels;	chr12:48513246	chr12:48054813~48055591:-
LUAD	cis	rs34779708	0.649	rs34421369	ENSG00000271335.4	RP11-324I22.4	4.36	1.56e-05	0.00288	0.21	0.2	Inflammatory bowel disease;Crohn's disease;	chr10:35261347	chr10:35314552~35336401:-
LUAD	cis	rs801193	1	rs3800812	ENSG00000224316.1	RP11-479O9.2	4.36	1.56e-05	0.00288	0.2	0.2	Aortic root size;	chr7:66758474	chr7:65773620~65802067:+
LUAD	cis	rs801193	1	rs4279493	ENSG00000224316.1	RP11-479O9.2	4.36	1.56e-05	0.00288	0.2	0.2	Aortic root size;	chr7:66761633	chr7:65773620~65802067:+
LUAD	cis	rs131777	0.575	rs131760	ENSG00000273272.1	CTA-384D8.34	4.36	1.56e-05	0.00288	0.23	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50573507	chr22:50542650~50543011:+
LUAD	cis	rs9900062	0.56	rs11656678	ENSG00000270714.1	MINOS1P2	-4.36	1.56e-05	0.00288	-0.25	-0.2	QT interval;	chr17:64685387	chr17:64747264~64747492:-
LUAD	cis	rs8127691	0.935	rs2838519	ENSG00000237604.1	AP001056.1	4.36	1.56e-05	0.00289	0.22	0.2	Inflammatory bowel disease;	chr21:44195140	chr21:44175489~44176453:+
LUAD	cis	rs7493	0.901	rs2237586	ENSG00000233942.1	AC004012.1	4.36	1.56e-05	0.00289	0.29	0.2	Yu-Zhi constitution type in type 2 diabetes;	chr7:95421740	chr7:95471835~95473998:+
LUAD	cis	rs28386778	0.897	rs2665844	ENSG00000240280.5	TCAM1P	-4.36	1.56e-05	0.00289	-0.23	-0.2	Prudent dietary pattern;	chr17:63797095	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.83	rs2597637	ENSG00000240280.5	TCAM1P	-4.36	1.56e-05	0.00289	-0.23	-0.2	Prudent dietary pattern;	chr17:63797706	chr17:63849292~63864379:+
LUAD	cis	rs2880765	0.835	rs11074276	ENSG00000259416.2	RP11-158M2.5	4.36	1.56e-05	0.00289	0.2	0.2	Coronary artery disease;	chr15:85487132	chr15:85754941~85756237:-
LUAD	cis	rs6565180	0.962	rs11642676	ENSG00000273724.1	RP11-347C12.12	-4.36	1.56e-05	0.00289	-0.21	-0.2	Tonsillectomy;	chr16:30360334	chr16:30336400~30343336:+
LUAD	cis	rs9341808	0.667	rs3828753	ENSG00000260645.1	RP11-250B2.5	4.36	1.56e-05	0.00289	0.18	0.2	Sitting height ratio;	chr6:80203029	chr6:80466958~80469080:+
LUAD	cis	rs911119	0.908	rs6048949	ENSG00000270001.1	RP11-218C14.8	-4.36	1.56e-05	0.00289	-0.28	-0.2	Chronic kidney disease;	chr20:23622562	chr20:23631826~23632316:-
LUAD	cis	rs911119	0.908	rs6048950	ENSG00000270001.1	RP11-218C14.8	-4.36	1.56e-05	0.00289	-0.28	-0.2	Chronic kidney disease;	chr20:23622615	chr20:23631826~23632316:-
LUAD	cis	rs911119	0.955	rs7265178	ENSG00000270001.1	RP11-218C14.8	-4.36	1.56e-05	0.00289	-0.28	-0.2	Chronic kidney disease;	chr20:23622745	chr20:23631826~23632316:-
LUAD	cis	rs41411047	0.702	rs73155073	ENSG00000271711.1	RP11-392O18.2	4.36	1.56e-05	0.00289	0.38	0.2	Myocardial infarction;	chr3:149849160	chr3:150611262~150611877:-
LUAD	cis	rs41411047	0.826	rs73155075	ENSG00000271711.1	RP11-392O18.2	4.36	1.56e-05	0.00289	0.38	0.2	Myocardial infarction;	chr3:149850695	chr3:150611262~150611877:-
LUAD	cis	rs6840360	0.571	rs11932059	ENSG00000270265.1	RP11-731D1.4	-4.36	1.56e-05	0.00289	-0.22	-0.2	Intelligence (multi-trait analysis);	chr4:151603344	chr4:151333775~151353224:-
LUAD	cis	rs7555523	0.887	rs6696454	ENSG00000224358.1	RP11-466F5.8	-4.36	1.56e-05	0.00289	-0.34	-0.2	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165738686	chr1:165768929~165775176:+
LUAD	cis	rs7555523	0.943	rs4537525	ENSG00000224358.1	RP11-466F5.8	-4.36	1.56e-05	0.00289	-0.34	-0.2	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165741852	chr1:165768929~165775176:+
LUAD	cis	rs7555523	0.887	rs4269750	ENSG00000224358.1	RP11-466F5.8	-4.36	1.56e-05	0.00289	-0.34	-0.2	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165742273	chr1:165768929~165775176:+
LUAD	cis	rs17772222	0.682	rs10132554	ENSG00000258789.1	RP11-507K2.3	-4.36	1.56e-05	0.00289	-0.25	-0.2	Coronary artery calcification;	chr14:88473090	chr14:88551597~88552493:+
LUAD	cis	rs6840360	0.571	rs62327274	ENSG00000270265.1	RP11-731D1.4	-4.36	1.56e-05	0.00289	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151626860	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.571	rs62327275	ENSG00000270265.1	RP11-731D1.4	-4.36	1.56e-05	0.00289	-0.23	-0.2	Intelligence (multi-trait analysis);	chr4:151627086	chr4:151333775~151353224:-
LUAD	cis	rs8040855	0.825	rs3964197	ENSG00000259774.1	RP11-182J1.13	4.36	1.56e-05	0.00289	0.24	0.2	Bulimia nervosa;	chr15:85178681	chr15:84422618~84425882:+
LUAD	cis	rs11714574	0.557	rs58279771	ENSG00000273493.1	RP11-80H18.4	-4.36	1.56e-05	0.00289	-0.23	-0.2	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);	chr3:58343535	chr3:58329965~58330118:+
LUAD	cis	rs6496932	0.635	rs4356428	ENSG00000259630.2	CTD-2262B20.1	-4.36	1.56e-05	0.00289	-0.25	-0.2	Central corneal thickness;Corneal structure;	chr15:85386349	chr15:85415228~85415633:+
LUAD	cis	rs7555523	0.779	rs2790049	ENSG00000224358.1	RP11-466F5.8	-4.36	1.56e-05	0.00289	-0.33	-0.2	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165774286	chr1:165768929~165775176:+
LUAD	cis	rs1008375	0.966	rs4235392	ENSG00000249502.1	AC006160.5	-4.36	1.56e-05	0.00289	-0.19	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17694799	chr4:17587467~17614571:-
LUAD	cis	rs16873450	0.9	rs10231702	ENSG00000234800.2	PCMTD1P3	4.36	1.56e-05	0.00289	0.23	0.2	Verbal memory performance (residualized delayed recall level);	chr7:23757922	chr7:23721311~23721782:-
LUAD	cis	rs11673344	0.931	rs1234251	ENSG00000267309.1	CTD-2630F21.1	-4.36	1.56e-05	0.00289	-0.25	-0.2	Obesity-related traits;	chr19:37180354	chr19:36489649~36491040:+
LUAD	cis	rs7208859	0.623	rs7219361	ENSG00000266490.1	CTD-2349P21.9	4.36	1.56e-05	0.00289	0.3	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30792372~30792833:+
LUAD	cis	rs6549438	0.524	rs4677087	ENSG00000241163.6	LINC00877	-4.36	1.57e-05	0.0029	-0.19	-0.2	Migraine - clinic-based;	chr3:72109292	chr3:72035300~72279503:-
LUAD	cis	rs453301	0.624	rs2288671	ENSG00000173295.6	FAM86B3P	4.36	1.57e-05	0.0029	0.21	0.2	Joint mobility (Beighton score);	chr8:9003384	chr8:8228595~8244865:+
LUAD	cis	rs2227564	0.62	rs11000765	ENSG00000271816.1	BMS1P4	4.36	1.57e-05	0.0029	0.19	0.2	Crohn's disease;Inflammatory bowel disease;	chr10:73752694	chr10:73699151~73730487:-
LUAD	cis	rs7208859	0.623	rs59447372	ENSG00000280069.1	CTD-2349P21.3	-4.36	1.57e-05	0.0029	-0.27	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30730567	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs8079891	ENSG00000280069.1	CTD-2349P21.3	-4.36	1.57e-05	0.0029	-0.27	-0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30731845	chr17:30738182~30740275:+
LUAD	cis	rs4660214	0.666	rs12025847	ENSG00000228060.1	RP11-69E11.8	4.36	1.57e-05	0.0029	0.18	0.2	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39300977	chr1:39565160~39573203:+
LUAD	cis	rs6095360	1	rs2426139	ENSG00000222365.1	SNORD12B	-4.36	1.57e-05	0.0029	-0.2	-0.2	Intelligence (multi-trait analysis);	chr20:49163568	chr20:49280319~49280409:+
LUAD	cis	rs28386778	0.897	rs2665831	ENSG00000240280.5	TCAM1P	-4.36	1.57e-05	0.0029	-0.23	-0.2	Prudent dietary pattern;	chr17:63835032	chr17:63849292~63864379:+
LUAD	cis	rs1167827	1	rs1167827	ENSG00000205583.12	STAG3L1	4.36	1.57e-05	0.0029	0.22	0.2	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75359194~75395383:+
LUAD	cis	rs10463554	0.824	rs427430	ENSG00000250682.4	LINC00491	4.36	1.57e-05	0.0029	0.24	0.2	Parkinson's disease;	chr5:103096320	chr5:102609156~102671559:-
LUAD	cis	rs2032366	0.591	rs9783921	ENSG00000266920.1	ACTBP9	-4.36	1.57e-05	0.0029	-0.2	-0.2	Obesity-related traits;	chr18:61635219	chr18:62442028~62443126:+
LUAD	cis	rs6539288	0.933	rs10746070	ENSG00000260329.1	RP11-412D9.4	-4.36	1.57e-05	0.0029	-0.21	-0.2	Total body bone mineral density;	chr12:106910681	chr12:106954029~106955497:-
LUAD	cis	rs6964587	1	rs12536529	ENSG00000188693.7	CYP51A1-AS1	4.36	1.57e-05	0.0029	0.23	0.2	Breast cancer;	chr7:92054772	chr7:92134604~92180725:+
LUAD	cis	rs6840360	0.573	rs4696249	ENSG00000270265.1	RP11-731D1.4	-4.36	1.57e-05	0.0029	-0.2	-0.2	Intelligence (multi-trait analysis);	chr4:151343495	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.573	rs10024721	ENSG00000270265.1	RP11-731D1.4	-4.36	1.57e-05	0.0029	-0.2	-0.2	Intelligence (multi-trait analysis);	chr4:151344179	chr4:151333775~151353224:-
LUAD	cis	rs2243480	1	rs958550	ENSG00000229886.1	RP5-1132H15.3	-4.36	1.57e-05	0.0029	-0.31	-0.2	Diabetic kidney disease;	chr7:66170692	chr7:66025126~66031544:-
LUAD	cis	rs27434	0.66	rs42398	ENSG00000272109.1	CTD-2260A17.3	-4.36	1.57e-05	0.0029	-0.26	-0.2	Ankylosing spondylitis;	chr5:96784751	chr5:96804353~96806105:+
LUAD	cis	rs2548724	0.513	rs1452058	ENSG00000250682.4	LINC00491	4.36	1.57e-05	0.0029	0.24	0.2	Type 2 diabetes;	chr5:102307199	chr5:102609156~102671559:-
LUAD	cis	rs2998286	0.723	rs332151	ENSG00000254635.4	WAC-AS1	-4.36	1.57e-05	0.0029	-0.25	-0.2	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28585331	chr10:28522652~28532743:-
LUAD	cis	rs1008375	0.966	rs28750296	ENSG00000249502.1	AC006160.5	-4.36	1.57e-05	0.0029	-0.18	-0.2	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17684203	chr4:17587467~17614571:-
LUAD	cis	rs4819052	0.851	rs4819049	ENSG00000237664.1	LINC00316	-4.36	1.57e-05	0.0029	-0.23	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253171	chr21:45338590~45341990:-
LUAD	cis	rs6754311	0.689	rs192822	ENSG00000226806.1	AC011893.3	4.36	1.57e-05	0.0029	0.24	0.2	Mosquito bite size;	chr2:135924704	chr2:135820191~135823087:+
LUAD	cis	rs11157436	0.602	rs928955	ENSG00000211812.1	TRAV26-2	-4.36	1.57e-05	0.0029	-0.2	-0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166273	chr14:22202583~22203368:+
LUAD	cis	rs11157436	0.602	rs12587826	ENSG00000211812.1	TRAV26-2	-4.36	1.57e-05	0.0029	-0.2	-0.2	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166305	chr14:22202583~22203368:+
LUAD	cis	rs34792	0.554	rs12919246	ENSG00000275910.1	RP11-680G24.6	-4.36	1.57e-05	0.0029	-0.19	-0.2	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15533103	chr16:15015828~15016390:-
LUAD	cis	rs10971721	0.822	rs10971788	ENSG00000260947.1	RP11-384P7.7	4.36	1.57e-05	0.00291	0.4	0.2	Body mass index;	chr9:33915087	chr9:33697459~33700986:+
LUAD	cis	rs9652601	0.959	rs2041670	ENSG00000274038.1	RP11-66H6.4	-4.36	1.57e-05	0.00291	-0.24	-0.2	Systemic lupus erythematosus;	chr16:11080795	chr16:11056556~11057034:+
LUAD	cis	rs7208859	0.524	rs59923796	ENSG00000266490.1	CTD-2349P21.9	4.36	1.57e-05	0.00291	0.29	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737901	chr17:30792372~30792833:+
LUAD	cis	rs17826219	0.5	rs57005940	ENSG00000266490.1	CTD-2349P21.9	4.36	1.57e-05	0.00291	0.29	0.2	Body mass index;	chr17:30739311	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.573	rs73267872	ENSG00000266490.1	CTD-2349P21.9	4.36	1.57e-05	0.00291	0.29	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30740189	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs56812022	ENSG00000266490.1	CTD-2349P21.9	4.36	1.57e-05	0.00291	0.29	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741715	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.524	rs57670615	ENSG00000266490.1	CTD-2349P21.9	4.36	1.57e-05	0.00291	0.29	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30742480	chr17:30792372~30792833:+
LUAD	cis	rs17826219	0.5	rs2874724	ENSG00000266490.1	CTD-2349P21.9	4.36	1.57e-05	0.00291	0.29	0.2	Body mass index;	chr17:30745415	chr17:30792372~30792833:+
LUAD	cis	rs17826219	0.568	rs9898097	ENSG00000266490.1	CTD-2349P21.9	4.36	1.57e-05	0.00291	0.29	0.2	Body mass index;	chr17:30745654	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs9911490	ENSG00000266490.1	CTD-2349P21.9	4.36	1.57e-05	0.00291	0.29	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30745995	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs7503542	ENSG00000266490.1	CTD-2349P21.9	4.36	1.57e-05	0.00291	0.29	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746812	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.573	rs11656278	ENSG00000266490.1	CTD-2349P21.9	4.36	1.57e-05	0.00291	0.29	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748170	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs6505207	ENSG00000266490.1	CTD-2349P21.9	4.36	1.57e-05	0.00291	0.29	0.2	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749553	chr17:30792372~30792833:+
LUAD	cis	rs6687758	0.735	rs12032653	ENSG00000227925.1	RP11-191N8.2	4.36	1.57e-05	0.00291	0.26	0.2	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221975457	chr1:221827666~221840666:-
LUAD	cis	rs6687758	0.679	rs12029332	ENSG00000227925.1	RP11-191N8.2	4.36	1.57e-05	0.00291	0.26	0.2	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221975480	chr1:221827666~221840666:-
LUAD	cis	rs1799949	1	rs35956818	ENSG00000236383.6	LINC00854	-4.36	1.57e-05	0.00291	-0.16	-0.2	Menopause (age at onset);	chr17:43345617	chr17:43216941~43305976:-
LUAD	cis	rs831571	1	rs831571	ENSG00000280620.1	SCAANT1	-4.36	1.57e-05	0.00291	-0.26	-0.2	Type 2 diabetes;	chr3:64062621	chr3:63911518~63911772:-
LUAD	cis	rs8062405	0.754	rs149299	ENSG00000251417.2	RP11-1348G14.4	-4.36	1.57e-05	0.00291	-0.2	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28473820	chr16:28802743~28817828:+
LUAD	cis	rs12468226	0.752	rs77319662	ENSG00000272966.1	RP11-686O6.1	4.36	1.58e-05	0.00291	0.32	0.2	Urate levels;	chr2:202126928	chr2:202336739~202337200:+
LUAD	cis	rs4268898	0.76	rs4665675	ENSG00000223754.1	AC008073.9	4.36	1.58e-05	0.00291	0.23	0.2	Asthma;	chr2:24245263	chr2:24199839~24201698:-
LUAD	cis	rs62025270	0.593	rs62022926	ENSG00000202081.1	RNU6-1280P	-4.36	1.58e-05	0.00291	-0.29	-0.2	Idiopathic pulmonary fibrosis;	chr15:85696261	chr15:85651522~85651628:-
LUAD	cis	rs7819412	0.775	rs6601564	ENSG00000255046.1	RP11-297N6.4	4.36	1.58e-05	0.00291	0.25	0.2	Triglycerides;	chr8:11124541	chr8:11797928~11802568:-
LUAD	cis	rs763121	0.853	rs6519119	ENSG00000228274.3	RP3-508I15.9	-4.36	1.58e-05	0.00291	-0.19	-0.2	Menopause (age at onset);	chr22:38593002	chr22:38667585~38681820:-
LUAD	cis	rs763121	0.853	rs9622833	ENSG00000228274.3	RP3-508I15.9	-4.36	1.58e-05	0.00291	-0.19	-0.2	Menopause (age at onset);	chr22:38604392	chr22:38667585~38681820:-
LUAD	cis	rs763121	0.853	rs8140617	ENSG00000228274.3	RP3-508I15.9	4.36	1.58e-05	0.00291	0.19	0.2	Menopause (age at onset);	chr22:38574434	chr22:38667585~38681820:-
LUAD	cis	rs17772222	0.727	rs3179969	ENSG00000258789.1	RP11-507K2.3	-4.36	1.58e-05	0.00291	-0.24	-0.2	Coronary artery calcification;	chr14:88396185	chr14:88551597~88552493:+
LUAD	cis	rs11051970	0.659	rs1809913	ENSG00000274964.1	RP11-817I4.1	-4.36	1.58e-05	0.00291	-0.23	-0.2	Response to tocilizumab in rheumatoid arthritis;	chr12:32438692	chr12:32339368~32340724:+
LUAD	cis	rs1040	0.727	rs7382431	ENSG00000261039.2	RP11-417E7.2	-4.36	1.58e-05	0.00291	-0.25	-0.2	Joint mobility (Beighton score);	chr6:169221734	chr6:169175304~169182740:-
LUAD	cis	rs812925	0.502	rs778150	ENSG00000271889.1	RP11-493E12.1	-4.36	1.58e-05	0.00291	-0.23	-0.2	Immature fraction of reticulocytes;	chr2:61381237	chr2:61151433~61162105:-
LUAD	cis	rs6088590	0.707	rs67159833	ENSG00000276073.1	RP5-1125A11.7	-4.36	1.58e-05	0.00291	-0.21	-0.2	Coronary artery disease;	chr20:34900276	chr20:33985617~33988989:-
LUAD	cis	rs7107174	1	rs10899485	ENSG00000251323.2	RP11-452H21.4	-4.36	1.58e-05	0.00292	-0.23	-0.2	Testicular germ cell tumor;	chr11:78361337	chr11:78423982~78429836:-
LUAD	cis	rs12745968	0.653	rs11164810	ENSG00000223787.2	RP4-593M8.1	-4.36	1.58e-05	0.00292	-0.24	-0.2	Bipolar disorder and schizophrenia;	chr1:92779423	chr1:92580476~92580821:-
LUAD	cis	rs853679	0.599	rs156743	ENSG00000219392.1	RP1-265C24.5	-4.36	1.58e-05	0.00292	-0.35	-0.2	Depression;	chr6:27999311	chr6:28115628~28116551:+
LUAD	cis	rs13113518	0.812	rs7667741	ENSG00000272969.1	RP11-528I4.2	4.36	1.58e-05	0.00292	0.21	0.2	Height;	chr4:55544621	chr4:55547112~55547889:+
LUAD	cis	rs262150	0.501	rs2730206	ENSG00000231419.5	LINC00689	-4.36	1.58e-05	0.00292	-0.24	-0.2	Facial morphology (factor 20);	chr7:159022482	chr7:159006522~159030195:+
LUAD	cis	rs763121	0.849	rs12004	ENSG00000225450.1	RP3-508I15.14	-4.36	1.58e-05	0.00292	-0.2	-0.2	Menopause (age at onset);	chr22:38481456	chr22:38739003~38749041:+
LUAD	cis	rs9487094	0.567	rs11964864	ENSG00000260273.1	RP11-425D10.10	4.36	1.58e-05	0.00292	0.28	0.2	Height;	chr6:109773423	chr6:109382795~109383666:+
LUAD	cis	rs13113518	0.812	rs56055342	ENSG00000272969.1	RP11-528I4.2	4.36	1.58e-05	0.00292	0.21	0.2	Height;	chr4:55540928	chr4:55547112~55547889:+
LUAD	cis	rs227275	0.554	rs223467	ENSG00000251288.2	RP11-10L12.2	-4.36	1.58e-05	0.00292	-0.23	-0.2	Allergic disease (asthma, hay fever or eczema);	chr4:102779721	chr4:102751401~102752641:+
LUAD	cis	rs11722779	0.903	rs13130741	ENSG00000251288.2	RP11-10L12.2	-4.36	1.58e-05	0.00292	-0.24	-0.2	Schizophrenia;	chr4:103035799	chr4:102751401~102752641:+
LUAD	cis	rs875971	1	rs6956179	ENSG00000232559.3	GS1-124K5.12	-4.36	1.58e-05	0.00292	-0.23	-0.2	Aortic root size;	chr7:66341672	chr7:66554588~66576923:-
LUAD	cis	rs9309473	0.5	rs6546862	ENSG00000163016.8	ALMS1P	-4.36	1.58e-05	0.00292	-0.21	-0.2	Metabolite levels;	chr2:73633221	chr2:73644919~73685576:+
LUAD	cis	rs10419113	0.522	rs10422444	ENSG00000269867.1	CTD-2583A14.8	-4.36	1.58e-05	0.00292	-0.17	-0.2	Pediatric bone mineral density (spine);	chr19:57767061	chr19:57867038~57868172:-
LUAD	cis	rs6012564	1	rs3818262	ENSG00000230758.1	SNAP23P	4.36	1.58e-05	0.00292	0.21	0.2	Anger;	chr20:49125019	chr20:49038357~49038602:-
LUAD	cis	rs17772222	0.917	rs17124652	ENSG00000258789.1	RP11-507K2.3	-4.36	1.58e-05	0.00292	-0.27	-0.2	Coronary artery calcification;	chr14:88424384	chr14:88551597~88552493:+
LUAD	cis	rs8062405	0.69	rs4787458	ENSG00000251417.2	RP11-1348G14.4	-4.36	1.58e-05	0.00293	-0.2	-0.2	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28519966	chr16:28802743~28817828:+
LUAD	cis	rs7493	0.853	rs35686517	ENSG00000233942.1	AC004012.1	4.36	1.58e-05	0.00293	0.29	0.2	Yu-Zhi constitution type in type 2 diabetes;	chr7:95423299	chr7:95471835~95473998:+
LUAD	cis	rs1275468	0.954	rs6582292	ENSG00000257497.2	RP11-585P4.5	4.36	1.58e-05	0.00293	0.26	0.2	Polycystic ovary syndrome;	chr12:75539175	chr12:75483454~75489820:-
LUAD	cis	rs4819052	0.959	rs8130866	ENSG00000215447.6	BX322557.10	-4.36	1.58e-05	0.00293	-0.24	-0.2	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252197	chr21:45288052~45291738:+
LUAD	cis	rs1355223	0.902	rs1258470	ENSG00000271369.1	RP11-350D17.3	4.36	1.59e-05	0.00293	0.23	0.2	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34707718	chr11:34709600~34710161:+
LUAD	cis	rs62025270	0.632	rs17637411	ENSG00000202081.1	RNU6-1280P	-4.36	1.59e-05	0.00293	-0.28	-0.2	Idiopathic pulmonary fibrosis;	chr15:85703216	chr15:85651522~85651628:-
LUAD	cis	rs62025270	0.58	rs62022938	ENSG00000202081.1	RNU6-1280P	-4.36	1.59e-05	0.00293	-0.28	-0.2	Idiopathic pulmonary fibrosis;	chr15:85704764	chr15:85651522~85651628:-
LUAD	cis	rs17772222	0.837	rs57118463	ENSG00000258789.1	RP11-507K2.3	-4.36	1.59e-05	0.00293	-0.27	-0.2	Coronary artery calcification;	chr14:88665822	chr14:88551597~88552493:+
LUAD	cis	rs780094	0.585	rs3739095	ENSG00000234072.1	AC074117.10	-4.36	1.59e-05	0.00293	-0.15	-0.2	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27333854	chr2:27356246~27367622:+
LUAD	cis	rs77688320	0.553	rs10804114	ENSG00000213090.2	AC007256.5	4.36	1.59e-05	0.00293	0.22	0.2	Breast cancer;	chr2:201402139	chr2:201410544~201413308:-
LUAD	cis	rs4934494	0.911	rs34486602	ENSG00000240996.1	RP11-80H5.7	-4.36	1.59e-05	0.00293	-0.25	-0.2	Red blood cell count;	chr10:89655895	chr10:89694295~89697928:-
LUAD	cis	rs2880765	0.835	rs7169429	ENSG00000259416.2	RP11-158M2.5	4.36	1.59e-05	0.00293	0.2	0.2	Coronary artery disease;	chr15:85493417	chr15:85754941~85756237:-
LUAD	cis	rs12701220	0.803	rs12701432	ENSG00000229043.2	AC091729.9	-4.36	1.59e-05	0.00293	-0.26	-0.2	Bronchopulmonary dysplasia;	chr7:1012817	chr7:1160374~1165267:+
LUAD	cis	rs11673344	0.931	rs73622783	ENSG00000267309.1	CTD-2630F21.1	-4.36	1.59e-05	0.00293	-0.25	-0.2	Obesity-related traits;	chr19:37165155	chr19:36489649~36491040:+
LUAD	cis	rs28735056	0.903	rs56185453	ENSG00000261126.6	RP11-795F19.1	-4.36	1.59e-05	0.00293	-0.2	-0.2	Schizophrenia;	chr18:79878297	chr18:80046900~80095482:+
LUAD	cis	rs6012564	0.963	rs6063359	ENSG00000230758.1	SNAP23P	4.36	1.59e-05	0.00293	0.21	0.2	Anger;	chr20:49128547	chr20:49038357~49038602:-
LUAD	cis	rs1864585	0.52	rs57348261	ENSG00000255046.1	RP11-297N6.4	4.36	1.59e-05	0.00293	0.28	0.2	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10811579	chr8:11797928~11802568:-
LUAD	cis	rs262150	0.522	rs2527182	ENSG00000231419.5	LINC00689	-4.36	1.59e-05	0.00293	-0.24	-0.2	Facial morphology (factor 20);	chr7:159021121	chr7:159006522~159030195:+
LUAD	cis	rs7107174	1	rs2256051	ENSG00000251323.2	RP11-452H21.4	4.36	1.59e-05	0.00293	0.25	0.19	Testicular germ cell tumor;	chr11:78209411	chr11:78423982~78429836:-
LUAD	cis	rs17772222	0.582	rs1288122	ENSG00000258789.1	RP11-507K2.3	4.36	1.59e-05	0.00293	0.24	0.19	Coronary artery calcification;	chr14:88472736	chr14:88551597~88552493:+
LUAD	cis	rs62025270	0.632	rs78572940	ENSG00000202081.1	RNU6-1280P	-4.36	1.59e-05	0.00293	-0.29	-0.19	Idiopathic pulmonary fibrosis;	chr15:85696539	chr15:85651522~85651628:-
LUAD	cis	rs1355223	0.872	rs1258466	ENSG00000271369.1	RP11-350D17.3	-4.36	1.59e-05	0.00293	-0.23	-0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34708519	chr11:34709600~34710161:+
LUAD	cis	rs4819052	0.851	rs13050359	ENSG00000237664.1	LINC00316	-4.36	1.59e-05	0.00293	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252756	chr21:45338590~45341990:-
LUAD	cis	rs4819052	0.851	rs13052344	ENSG00000237664.1	LINC00316	-4.36	1.59e-05	0.00293	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256186	chr21:45338590~45341990:-
LUAD	cis	rs4819052	0.808	rs11909411	ENSG00000237664.1	LINC00316	-4.36	1.59e-05	0.00293	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256641	chr21:45338590~45341990:-
LUAD	cis	rs4819052	0.851	rs28676615	ENSG00000237664.1	LINC00316	-4.36	1.59e-05	0.00293	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256661	chr21:45338590~45341990:-
LUAD	cis	rs4819052	0.851	rs28501512	ENSG00000237664.1	LINC00316	-4.36	1.59e-05	0.00293	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256787	chr21:45338590~45341990:-
LUAD	cis	rs219780	0.687	rs219790	ENSG00000230479.1	AP000695.6	4.36	1.59e-05	0.00294	0.22	0.19	Kidney stones;	chr21:36456564	chr21:36430360~36481070:+
LUAD	cis	rs1005277	0.579	rs1985707	ENSG00000263064.2	RP11-291L22.7	4.36	1.59e-05	0.00294	0.21	0.19	Extrinsic epigenetic age acceleration;	chr10:38145170	chr10:38448689~38448949:+
LUAD	cis	rs9309473	0.607	rs7560272	ENSG00000163016.8	ALMS1P	4.36	1.59e-05	0.00294	0.22	0.19	Metabolite levels;	chr2:73334357	chr2:73644919~73685576:+
LUAD	cis	rs11976180	0.517	rs6949375	ENSG00000273234.1	OR2A13P	-4.36	1.59e-05	0.00294	-0.31	-0.19	Obesity-related traits;	chr7:144076758	chr7:144142009~144142938:+
LUAD	cis	rs73173548	0.502	rs34743961	ENSG00000247828.6	TMEM161B-AS1	4.36	1.59e-05	0.00294	0.24	0.19	Macular telangiectasia type 2;	chr5:88435952	chr5:88268895~88436685:+
LUAD	cis	rs7178424	0.905	rs7177173	ENSG00000259251.2	RP11-643M14.1	4.36	1.59e-05	0.00294	0.2	0.19	Height;	chr15:61944605	chr15:62060503~62062434:+
LUAD	cis	rs10208649	0.611	rs75340524	ENSG00000272156.1	RP11-477N3.1	4.36	1.59e-05	0.00294	0.38	0.19	Body mass index;	chr2:54068793	chr2:54082554~54085066:+
LUAD	cis	rs7107174	0.901	rs2511159	ENSG00000251323.2	RP11-452H21.4	-4.36	1.59e-05	0.00294	-0.24	-0.19	Testicular germ cell tumor;	chr11:78263147	chr11:78423982~78429836:-
LUAD	cis	rs11685299	1	rs11685299	ENSG00000228446.2	AC073052.1	-4.36	1.59e-05	0.00294	-0.21	-0.19	Schizophrenia;	chr2:224526579	chr2:224499387~224500100:-
LUAD	cis	rs6964833	1	rs4717906	ENSG00000278416.1	PMS2L2	4.36	1.59e-05	0.00294	0.27	0.19	Menarche (age at onset);	chr7:74671923	chr7:75344015~75359550:-
LUAD	cis	rs2153535	0.585	rs9393047	ENSG00000230939.1	RP11-314C16.1	-4.36	1.59e-05	0.00294	-0.22	-0.19	Motion sickness;	chr6:8622373	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.585	rs9505495	ENSG00000230939.1	RP11-314C16.1	-4.36	1.59e-05	0.00294	-0.22	-0.19	Motion sickness;	chr6:8622963	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.585	rs9328499	ENSG00000230939.1	RP11-314C16.1	-4.36	1.59e-05	0.00294	-0.22	-0.19	Motion sickness;	chr6:8623546	chr6:8784178~8785445:+
LUAD	cis	rs62025270	0.688	rs7182210	ENSG00000202081.1	RNU6-1280P	-4.36	1.59e-05	0.00294	-0.28	-0.19	Idiopathic pulmonary fibrosis;	chr15:85722551	chr15:85651522~85651628:-
LUAD	cis	rs2446066	0.872	rs57676448	ENSG00000257379.1	RP11-793H13.8	4.36	1.59e-05	0.00294	0.32	0.19	Red blood cell count;	chr12:53401003	chr12:53441741~53467528:+
LUAD	cis	rs172166	0.652	rs476167	ENSG00000216901.1	AL022393.7	4.36	1.59e-05	0.00294	0.24	0.19	Cardiac Troponin-T levels;	chr6:28098110	chr6:28176188~28176674:+
LUAD	cis	rs172166	0.694	rs203892	ENSG00000216901.1	AL022393.7	4.36	1.59e-05	0.00294	0.24	0.19	Cardiac Troponin-T levels;	chr6:28099418	chr6:28176188~28176674:+
LUAD	cis	rs8133949	0.638	rs871545	ENSG00000237232.6	ZNF295-AS1	4.36	1.59e-05	0.00294	0.28	0.19	Hand grip strength;	chr21:41993542	chr21:42009194~42024924:+
LUAD	cis	rs1864585	0.52	rs73208789	ENSG00000255046.1	RP11-297N6.4	4.36	1.59e-05	0.00294	0.28	0.19	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10821677	chr8:11797928~11802568:-
LUAD	cis	rs7819412	0.806	rs10113808	ENSG00000255046.1	RP11-297N6.4	4.36	1.59e-05	0.00294	0.24	0.19	Triglycerides;	chr8:11069382	chr8:11797928~11802568:-
LUAD	cis	rs6479901	0.947	rs9971294	ENSG00000232075.1	MRPL35P2	-4.36	1.59e-05	0.00294	-0.27	-0.19	Intelligence (multi-trait analysis);	chr10:63503108	chr10:63634317~63634827:-
LUAD	cis	rs5742933	0.857	rs2289226	ENSG00000253559.1	OSGEPL1-AS1	-4.36	1.6e-05	0.00294	-0.23	-0.19	Ferritin levels;	chr2:189661479	chr2:189762704~189765556:+
LUAD	cis	rs1062177	1	rs12654573	ENSG00000253921.1	CTB-113P19.3	-4.36	1.6e-05	0.00294	-0.29	-0.19	Preschool internalizing problems;	chr5:151827912	chr5:151753992~151767247:+
LUAD	cis	rs8040855	0.965	rs4843027	ENSG00000259774.1	RP11-182J1.13	-4.36	1.6e-05	0.00294	-0.23	-0.19	Bulimia nervosa;	chr15:85171892	chr15:84422618~84425882:+
LUAD	cis	rs7204230	1	rs12598049	ENSG00000261291.1	RP11-295M3.2	-4.36	1.6e-05	0.00294	-0.23	-0.19	Fibrinogen;	chr16:53282942	chr16:53168522~53169450:+
LUAD	cis	rs17345786	0.906	rs58835747	ENSG00000244119.1	PDCL3P4	4.36	1.6e-05	0.00294	0.22	0.19	Colonoscopy-negative controls vs population controls;	chr3:101524790	chr3:101712472~101713191:+
LUAD	cis	rs9341808	0.754	rs9294173	ENSG00000260645.1	RP11-250B2.5	4.36	1.6e-05	0.00295	0.18	0.19	Sitting height ratio;	chr6:80281913	chr6:80466958~80469080:+
LUAD	cis	rs6568686	0.73	rs4526232	ENSG00000255389.1	C6orf3	-4.36	1.6e-05	0.00295	-0.27	-0.19	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111535842	chr6:111599875~111602295:+
LUAD	cis	rs17772222	0.874	rs78077739	ENSG00000258789.1	RP11-507K2.3	-4.36	1.6e-05	0.00295	-0.27	-0.19	Coronary artery calcification;	chr14:88741176	chr14:88551597~88552493:+
LUAD	cis	rs9545047	0.604	rs9601227	ENSG00000227354.5	RBM26-AS1	-4.36	1.6e-05	0.00295	-0.21	-0.19	Schizophrenia;	chr13:79420805	chr13:79406309~79424328:+
LUAD	cis	rs2288884	0.945	rs78336183	ENSG00000269959.1	SPACA6P-AS	-4.36	1.6e-05	0.00295	-0.24	-0.19	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52058230	chr19:51685363~51693456:-
LUAD	cis	rs7826238	0.524	rs2921055	ENSG00000253981.4	ALG1L13P	4.36	1.6e-05	0.00295	0.23	0.19	Systolic blood pressure;	chr8:8461832	chr8:8236003~8244667:-
LUAD	cis	rs2153535	0.585	rs4960448	ENSG00000230939.1	RP11-314C16.1	-4.36	1.6e-05	0.00295	-0.22	-0.19	Motion sickness;	chr6:8624438	chr6:8784178~8785445:+
LUAD	cis	rs262150	0.567	rs2527177	ENSG00000231419.5	LINC00689	-4.36	1.6e-05	0.00295	-0.24	-0.19	Facial morphology (factor 20);	chr7:159012046	chr7:159006522~159030195:+
LUAD	cis	rs11168618	0.567	rs7314569	ENSG00000240399.1	RP1-228P16.1	4.36	1.6e-05	0.00295	0.19	0.19	Adiponectin levels;	chr12:48423198	chr12:48054813~48055591:-
LUAD	cis	rs7493	0.755	rs17166859	ENSG00000233942.1	AC004012.1	4.36	1.6e-05	0.00295	0.28	0.19	Yu-Zhi constitution type in type 2 diabetes;	chr7:95366207	chr7:95471835~95473998:+
LUAD	cis	rs6479891	0.818	rs59215788	ENSG00000232075.1	MRPL35P2	4.36	1.6e-05	0.00295	0.32	0.19	Arthritis (juvenile idiopathic);	chr10:63474074	chr10:63634317~63634827:-
LUAD	cis	rs6479891	1	rs59246603	ENSG00000232075.1	MRPL35P2	4.36	1.6e-05	0.00295	0.32	0.19	Arthritis (juvenile idiopathic);	chr10:63474182	chr10:63634317~63634827:-
LUAD	cis	rs6479891	1	rs4746138	ENSG00000232075.1	MRPL35P2	4.36	1.6e-05	0.00295	0.32	0.19	Arthritis (juvenile idiopathic);	chr10:63481981	chr10:63634317~63634827:-
LUAD	cis	rs6751744	0.924	rs13386318	ENSG00000230783.1	AC009961.2	-4.36	1.6e-05	0.00295	-0.26	-0.19	Dysphagia;	chr2:159541846	chr2:159689217~159690291:-
LUAD	cis	rs4879677	1	rs72712238	ENSG00000215441.3	CTAGE12P	-4.36	1.6e-05	0.00295	-0.23	-0.19	Gut microbiome composition (summer and winter);	chr9:27675371	chr9:27608382~27610745:-
LUAD	cis	rs11168351	0.927	rs7971880	ENSG00000257735.1	RP11-370I10.6	4.36	1.6e-05	0.00295	0.24	0.19	Bipolar disorder and schizophrenia;	chr12:47997272	chr12:48350945~48442411:+
LUAD	cis	rs1334894	1	rs113244441	ENSG00000228559.1	RP3-340B19.3	-4.36	1.6e-05	0.00295	-0.41	-0.19	Coronary artery disease;	chr6:35560913	chr6:35544632~35545669:+
LUAD	cis	rs1334894	1	rs72913405	ENSG00000228559.1	RP3-340B19.3	-4.36	1.6e-05	0.00295	-0.41	-0.19	Coronary artery disease;	chr6:35562285	chr6:35544632~35545669:+
LUAD	cis	rs1334894	0.792	rs56318292	ENSG00000228559.1	RP3-340B19.3	-4.36	1.6e-05	0.00295	-0.41	-0.19	Coronary artery disease;	chr6:35563386	chr6:35544632~35545669:+
LUAD	cis	rs2933343	0.621	rs789241	ENSG00000231305.3	RP11-723O4.2	4.36	1.6e-05	0.00295	0.21	0.19	IgG glycosylation;	chr3:128866909	chr3:128861313~128871540:-
LUAD	cis	rs473651	0.904	rs472247	ENSG00000229915.1	AC016999.2	-4.36	1.6e-05	0.00295	-0.25	-0.19	Multiple system atrophy;	chr2:238453932	chr2:238427077~238427729:-
LUAD	cis	rs4934494	1	rs4934494	ENSG00000240996.1	RP11-80H5.7	-4.36	1.6e-05	0.00295	-0.26	-0.19	Red blood cell count;	chr10:89687662	chr10:89694295~89697928:-
LUAD	cis	rs783540	0.5	rs7178459	ENSG00000255769.6	GOLGA2P10	-4.36	1.6e-05	0.00295	-0.23	-0.19	Schizophrenia;	chr15:82729632	chr15:82472993~82513950:-
LUAD	cis	rs755249	0.501	rs2484133	ENSG00000182109.6	RP11-69E11.4	4.36	1.6e-05	0.00295	0.22	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39188322	chr1:39522280~39546187:-
LUAD	cis	rs9876781	0.53	rs35516531	ENSG00000229759.1	MRPS18AP1	4.36	1.6e-05	0.00295	0.19	0.19	Longevity;	chr3:48364275	chr3:48256350~48256938:-
LUAD	cis	rs2243480	0.908	rs4718273	ENSG00000229886.1	RP5-1132H15.3	-4.36	1.6e-05	0.00295	-0.34	-0.19	Diabetic kidney disease;	chr7:65751112	chr7:66025126~66031544:-
LUAD	cis	rs4601821	0.635	rs11214579	ENSG00000270179.1	RP11-159N11.4	4.36	1.6e-05	0.00295	0.2	0.19	Alcoholic chronic pancreatitis;	chr11:113337464	chr11:113368478~113369117:+
LUAD	cis	rs17406451	0.704	rs7563949	ENSG00000279873.2	LINC01126	4.36	1.6e-05	0.00296	0.17	0.19	Mitochondrial DNA levels;	chr2:43498082	chr2:43227210~43228855:+
LUAD	cis	rs2243480	1	rs4718333	ENSG00000232559.3	GS1-124K5.12	-4.36	1.6e-05	0.00296	-0.34	-0.19	Diabetic kidney disease;	chr7:66307771	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs7792391	ENSG00000232559.3	GS1-124K5.12	-4.36	1.6e-05	0.00296	-0.34	-0.19	Diabetic kidney disease;	chr7:66308442	chr7:66554588~66576923:-
LUAD	cis	rs9303029	1	rs12450240	ENSG00000265458.1	RP13-20L14.6	4.36	1.6e-05	0.00296	0.35	0.19	Protein quantitative trait loci;	chr17:82465836	chr17:82454273~82458521:-
LUAD	cis	rs9649213	0.593	rs13246942	ENSG00000272950.1	RP11-307C18.1	4.36	1.6e-05	0.00296	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98285709	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.593	rs6968144	ENSG00000272950.1	RP11-307C18.1	4.36	1.6e-05	0.00296	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98286385	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.574	rs62479853	ENSG00000272950.1	RP11-307C18.1	4.36	1.6e-05	0.00296	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98287846	chr7:98322853~98323430:+
LUAD	cis	rs7945705	0.846	rs11042055	ENSG00000254860.4	TMEM9B-AS1	-4.36	1.6e-05	0.00296	-0.23	-0.19	Hemoglobin concentration;	chr11:8735309	chr11:8964675~8977527:+
LUAD	cis	rs9341808	0.538	rs620147	ENSG00000260645.1	RP11-250B2.5	-4.36	1.61e-05	0.00296	-0.19	-0.19	Sitting height ratio;	chr6:80282373	chr6:80466958~80469080:+
LUAD	cis	rs3096299	0.838	rs4785561	ENSG00000261574.1	RP1-168P16.2	4.36	1.61e-05	0.00296	0.2	0.19	Multiple myeloma (IgH translocation);	chr16:89362644	chr16:89392375~89412564:-
LUAD	cis	rs4578769	0.569	rs4800438	ENSG00000265943.1	RP11-739L10.1	4.36	1.61e-05	0.00296	0.24	0.19	Eosinophil percentage of white cells;	chr18:22920482	chr18:22699481~22933764:-
LUAD	cis	rs1005277	0.579	rs2505240	ENSG00000263064.2	RP11-291L22.7	4.36	1.61e-05	0.00296	0.21	0.19	Extrinsic epigenetic age acceleration;	chr10:38153491	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.579	rs2505241	ENSG00000263064.2	RP11-291L22.7	4.36	1.61e-05	0.00296	0.21	0.19	Extrinsic epigenetic age acceleration;	chr10:38153493	chr10:38448689~38448949:+
LUAD	cis	rs7017914	0.677	rs7012577	ENSG00000223220.1	Y_RNA	4.36	1.61e-05	0.00296	0.22	0.19	Bone mineral density;	chr8:70559809	chr8:70780914~70781008:-
LUAD	cis	rs6687821	0.749	rs263457	ENSG00000267734.1	RP4-604K5.3	4.36	1.61e-05	0.00296	0.23	0.19	Yeast infection;	chr1:86775307	chr1:86932199~86934891:-
LUAD	cis	rs12908161	1	rs35960805	ENSG00000259295.5	CSPG4P12	4.36	1.61e-05	0.00296	0.27	0.19	Schizophrenia;	chr15:84800749	chr15:85191438~85213905:+
LUAD	cis	rs12908161	1	rs12912388	ENSG00000259295.5	CSPG4P12	4.36	1.61e-05	0.00296	0.27	0.19	Schizophrenia;	chr15:84801319	chr15:85191438~85213905:+
LUAD	cis	rs9650657	0.513	rs4841459	ENSG00000255046.1	RP11-297N6.4	4.36	1.61e-05	0.00296	0.24	0.19	Neuroticism;	chr8:10924932	chr8:11797928~11802568:-
LUAD	cis	rs453301	0.522	rs1964356	ENSG00000253981.4	ALG1L13P	4.36	1.61e-05	0.00296	0.24	0.19	Joint mobility (Beighton score);	chr8:8995760	chr8:8236003~8244667:-
LUAD	cis	rs9309473	0.579	rs6728128	ENSG00000163016.8	ALMS1P	4.36	1.61e-05	0.00296	0.22	0.19	Metabolite levels;	chr2:73368854	chr2:73644919~73685576:+
LUAD	cis	rs9309473	0.607	rs7567343	ENSG00000163016.8	ALMS1P	4.36	1.61e-05	0.00296	0.22	0.19	Metabolite levels;	chr2:73369477	chr2:73644919~73685576:+
LUAD	cis	rs2548724	0.755	rs62371010	ENSG00000250682.4	LINC00491	4.36	1.61e-05	0.00296	0.25	0.19	Type 2 diabetes;	chr5:102460569	chr5:102609156~102671559:-
LUAD	cis	rs7937682	1	rs10789843	ENSG00000230911.1	PPIHP1	4.36	1.61e-05	0.00297	0.27	0.19	Primary sclerosing cholangitis;	chr11:111705434	chr11:112029858~112030367:-
LUAD	cis	rs6832769	0.922	rs501679	ENSG00000272969.1	RP11-528I4.2	4.36	1.61e-05	0.00297	0.2	0.19	Personality dimensions;	chr4:55371160	chr4:55547112~55547889:+
LUAD	cis	rs2243480	1	rs6958420	ENSG00000232559.3	GS1-124K5.12	-4.36	1.61e-05	0.00297	-0.34	-0.19	Diabetic kidney disease;	chr7:66286184	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs1392104	ENSG00000232559.3	GS1-124K5.12	-4.36	1.61e-05	0.00297	-0.34	-0.19	Diabetic kidney disease;	chr7:66294120	chr7:66554588~66576923:-
LUAD	cis	rs7119038	0.818	rs11217042	ENSG00000255422.1	AP002954.4	4.36	1.61e-05	0.00297	0.29	0.19	Sjögren's syndrome;	chr11:118811819	chr11:118704607~118750263:+
LUAD	cis	rs7119038	0.818	rs17122453	ENSG00000255422.1	AP002954.4	4.36	1.61e-05	0.00297	0.29	0.19	Sjögren's syndrome;	chr11:118812855	chr11:118704607~118750263:+
LUAD	cis	rs67981189	0.529	rs2526850	ENSG00000269927.1	RP6-91H8.3	-4.36	1.61e-05	0.00297	-0.26	-0.19	Schizophrenia;	chr14:70950532	chr14:71141125~71143253:-
LUAD	cis	rs875971	0.508	rs10242423	ENSG00000236529.1	RP13-254B10.1	-4.36	1.61e-05	0.00297	-0.19	-0.19	Aortic root size;	chr7:66594188	chr7:65840212~65840596:+
LUAD	cis	rs17685	0.753	rs869806	ENSG00000280388.1	RP11-229D13.3	-4.36	1.61e-05	0.00297	-0.18	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76059305	chr7:76043977~76045963:-
LUAD	cis	rs80028505	0.908	rs58583792	ENSG00000271304.1	DPRXP2	4.36	1.61e-05	0.00297	0.36	0.19	Foot ulcer in diabetes and neuropathy;	chr6:36032925	chr6:35989515~35990436:-
LUAD	cis	rs4968361	0.892	rs11653976	ENSG00000266992.1	DHX40P1	-4.36	1.61e-05	0.00297	-0.34	-0.19	Schizophrenia;	chr17:59439633	chr17:59976009~60002384:-
LUAD	cis	rs5758511	0.68	rs34107327	ENSG00000227370.1	RP4-669P10.19	4.36	1.61e-05	0.00297	0.22	0.19	Birth weight;	chr22:42252347	chr22:42132543~42132998:+
LUAD	cis	rs2243480	0.831	rs57294491	ENSG00000232559.3	GS1-124K5.12	-4.36	1.61e-05	0.00297	-0.34	-0.19	Diabetic kidney disease;	chr7:66219914	chr7:66554588~66576923:-
LUAD	cis	rs227275	0.525	rs4698874	ENSG00000251288.2	RP11-10L12.2	-4.36	1.61e-05	0.00297	-0.23	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:103009354	chr4:102751401~102752641:+
LUAD	cis	rs12986445	0.793	rs1515948	ENSG00000218682.1	AC010150.1	4.36	1.61e-05	0.00297	0.24	0.19	Multiple myeloma;Multiple myeloma and monoclonal gammopathy;	chr2:25874738	chr2:25856461~25856966:-
LUAD	cis	rs603446	0.935	rs180372	ENSG00000254851.1	RP11-109L13.1	-4.36	1.61e-05	0.00297	-0.24	-0.19	Triglycerides;	chr11:116721218	chr11:117135528~117138582:+
LUAD	cis	rs6687758	0.645	rs949618	ENSG00000200033.1	RNU6-403P	4.36	1.61e-05	0.00297	0.25	0.19	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221940598	chr1:221837334~221837437:-
LUAD	cis	rs2274273	0.87	rs10149420	ENSG00000259318.1	RP11-454L9.2	4.36	1.61e-05	0.00297	0.17	0.19	Protein biomarker;	chr14:55387539	chr14:55394940~55395233:-
LUAD	cis	rs4568518	0.74	rs12699927	ENSG00000279048.1	RP11-511H23.2	4.36	1.61e-05	0.00297	0.16	0.19	Measles;	chr7:17972129	chr7:17940503~17942922:+
LUAD	cis	rs8098244	0.603	rs1711457	ENSG00000264745.1	TTC39C-AS1	4.36	1.61e-05	0.00297	0.21	0.19	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23699494	chr18:23994213~24015339:-
LUAD	cis	rs8098244	0.603	rs1788813	ENSG00000264745.1	TTC39C-AS1	4.36	1.61e-05	0.00297	0.21	0.19	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23701204	chr18:23994213~24015339:-
LUAD	cis	rs11157436	0.602	rs1894369	ENSG00000211813.2	TRAV34	-4.36	1.61e-05	0.00297	-0.22	-0.19	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166597	chr14:22207522~22208129:+
LUAD	cis	rs853679	0.517	rs1904841	ENSG00000226314.6	ZNF192P1	-4.36	1.62e-05	0.00297	-0.26	-0.19	Depression;	chr6:28140307	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs1904840	ENSG00000226314.6	ZNF192P1	-4.36	1.62e-05	0.00297	-0.26	-0.19	Depression;	chr6:28140454	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs9368555	ENSG00000226314.6	ZNF192P1	-4.36	1.62e-05	0.00297	-0.26	-0.19	Depression;	chr6:28141189	chr6:28161781~28169594:+
LUAD	cis	rs2274273	0.84	rs943590	ENSG00000258413.1	RP11-665C16.6	-4.36	1.62e-05	0.00297	-0.25	-0.19	Protein biomarker;	chr14:55271878	chr14:55262767~55272075:-
LUAD	cis	rs1167827	0.68	rs1167796	ENSG00000205583.12	STAG3L1	-4.36	1.62e-05	0.00298	-0.23	-0.19	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75359194~75395383:+
LUAD	cis	rs6840360	0.571	rs72728182	ENSG00000270265.1	RP11-731D1.4	-4.36	1.62e-05	0.00298	-0.22	-0.19	Intelligence (multi-trait analysis);	chr4:151565875	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.571	rs4696098	ENSG00000270265.1	RP11-731D1.4	-4.36	1.62e-05	0.00298	-0.22	-0.19	Intelligence (multi-trait analysis);	chr4:151567901	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.55	rs6816471	ENSG00000270265.1	RP11-731D1.4	-4.36	1.62e-05	0.00298	-0.22	-0.19	Intelligence (multi-trait analysis);	chr4:151573717	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.55	rs7683134	ENSG00000270265.1	RP11-731D1.4	-4.36	1.62e-05	0.00298	-0.22	-0.19	Intelligence (multi-trait analysis);	chr4:151582210	chr4:151333775~151353224:-
LUAD	cis	rs950169	0.579	rs12912716	ENSG00000259570.1	RP11-671M22.4	4.36	1.62e-05	0.00298	0.29	0.19	Schizophrenia;	chr15:83995511	chr15:84394512~84395514:+
LUAD	cis	rs4266144	1	rs4266144	ENSG00000244515.1	KRT18P34	-4.36	1.62e-05	0.00298	-0.25	-0.19	Coronary artery disease;	chr3:157134803	chr3:157162663~157163932:-
LUAD	cis	rs7221109	0.961	rs757411	ENSG00000278834.1	RP11-458J1.1	4.36	1.62e-05	0.00298	0.22	0.19	Type 1 diabetes;	chr17:40618898	chr17:40648300~40649718:+
LUAD	cis	rs7221109	0.961	rs9911533	ENSG00000278834.1	RP11-458J1.1	4.36	1.62e-05	0.00298	0.22	0.19	Type 1 diabetes;	chr17:40619224	chr17:40648300~40649718:+
LUAD	cis	rs3814244	0.569	rs2051993	ENSG00000236946.2	HNRNPA1P70	-4.36	1.62e-05	0.00298	-0.17	-0.19	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019898	chr12:68035767~68036853:+
LUAD	cis	rs11703808	1	rs11703808	ENSG00000236132.1	CTA-440B3.1	4.36	1.62e-05	0.00298	0.23	0.19	Intelligence;	chr22:31628994	chr22:31816379~31817491:-
LUAD	cis	rs1005277	0.557	rs176887	ENSG00000263064.2	RP11-291L22.7	4.36	1.62e-05	0.00298	0.21	0.19	Extrinsic epigenetic age acceleration;	chr10:38117166	chr10:38448689~38448949:+
LUAD	cis	rs3743772	0.5	rs2388117	ENSG00000279722.1	RP11-44F14.6	4.36	1.62e-05	0.00298	0.27	0.19	Depressive symptoms (SSRI exposure interaction);	chr16:53413692	chr16:53487607~53489943:-
LUAD	cis	rs9652601	0.959	rs9931397	ENSG00000274038.1	RP11-66H6.4	-4.36	1.62e-05	0.00298	-0.24	-0.19	Systemic lupus erythematosus;	chr16:11083537	chr16:11056556~11057034:+
LUAD	cis	rs9652601	0.959	rs12708715	ENSG00000274038.1	RP11-66H6.4	-4.36	1.62e-05	0.00298	-0.24	-0.19	Systemic lupus erythematosus;	chr16:11083967	chr16:11056556~11057034:+
LUAD	cis	rs9309473	0.528	rs2091022	ENSG00000163016.8	ALMS1P	4.36	1.62e-05	0.00298	0.23	0.19	Metabolite levels;	chr2:73337442	chr2:73644919~73685576:+
LUAD	cis	rs2492301	0.54	rs10796907	ENSG00000233621.1	LINC01137	-4.36	1.62e-05	0.00298	-0.19	-0.19	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr1:37434572	chr1:37454879~37474411:-
LUAD	cis	rs7208859	0.623	rs55811708	ENSG00000266490.1	CTD-2349P21.9	4.36	1.62e-05	0.00298	0.29	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30792372~30792833:+
LUAD	cis	rs763121	0.853	rs4821812	ENSG00000225450.1	RP3-508I15.14	-4.36	1.62e-05	0.00298	-0.19	-0.19	Menopause (age at onset);	chr22:38679230	chr22:38739003~38749041:+
LUAD	cis	rs763121	0.853	rs9607566	ENSG00000225450.1	RP3-508I15.14	-4.36	1.62e-05	0.00298	-0.19	-0.19	Menopause (age at onset);	chr22:38679429	chr22:38739003~38749041:+
LUAD	cis	rs1005277	0.505	rs10827835	ENSG00000273019.1	RP11-508N22.13	4.36	1.62e-05	0.00298	0.22	0.19	Extrinsic epigenetic age acceleration;	chr10:37861781	chr10:38149968~38150293:+
LUAD	cis	rs5758659	0.714	rs6002607	ENSG00000182057.4	OGFRP1	-4.36	1.62e-05	0.00298	-0.23	-0.19	Cognitive function;	chr22:42100502	chr22:42269753~42275196:+
LUAD	cis	rs2823962	0.759	rs2823929	ENSG00000270093.1	AP000473.8	4.36	1.62e-05	0.00298	0.2	0.19	Amyotrophic lateral sclerosis;	chr21:16641907	chr21:16643529~16645065:+
LUAD	cis	rs5751168	0.527	rs2236730	ENSG00000211654.2	IGLV5-37	4.36	1.62e-05	0.00298	0.25	0.19	Prostate cancer (SNP x SNP interaction);	chr22:22488793	chr22:22427540~22428035:+
LUAD	cis	rs4713118	0.513	rs2294480	ENSG00000216901.1	AL022393.7	4.36	1.62e-05	0.00298	0.23	0.19	Parkinson's disease;	chr6:27616182	chr6:28176188~28176674:+
LUAD	cis	rs2998286	0.862	rs2807740	ENSG00000254635.4	WAC-AS1	-4.36	1.62e-05	0.00298	-0.24	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28495554	chr10:28522652~28532743:-
LUAD	cis	rs9652601	0.779	rs7186106	ENSG00000274038.1	RP11-66H6.4	-4.36	1.62e-05	0.00299	-0.24	-0.19	Systemic lupus erythematosus;	chr16:11116974	chr16:11056556~11057034:+
LUAD	cis	rs7955901	0.746	rs4142883	ENSG00000258053.1	CTD-2021H9.3	4.36	1.62e-05	0.00299	0.23	0.19	Type 2 diabetes;	chr12:71130802	chr12:71047402~71118247:-
LUAD	cis	rs7955901	0.746	rs3844208	ENSG00000258053.1	CTD-2021H9.3	4.36	1.62e-05	0.00299	0.23	0.19	Type 2 diabetes;	chr12:71131157	chr12:71047402~71118247:-
LUAD	cis	rs7955901	0.775	rs3844209	ENSG00000258053.1	CTD-2021H9.3	4.36	1.62e-05	0.00299	0.23	0.19	Type 2 diabetes;	chr12:71131351	chr12:71047402~71118247:-
LUAD	cis	rs7955901	0.746	rs3896814	ENSG00000258053.1	CTD-2021H9.3	4.36	1.62e-05	0.00299	0.23	0.19	Type 2 diabetes;	chr12:71131490	chr12:71047402~71118247:-
LUAD	cis	rs7955901	0.775	rs3851613	ENSG00000258053.1	CTD-2021H9.3	4.36	1.62e-05	0.00299	0.23	0.19	Type 2 diabetes;	chr12:71131943	chr12:71047402~71118247:-
LUAD	cis	rs7955901	0.746	rs3851614	ENSG00000258053.1	CTD-2021H9.3	4.36	1.62e-05	0.00299	0.23	0.19	Type 2 diabetes;	chr12:71132167	chr12:71047402~71118247:-
LUAD	cis	rs7955901	0.746	rs3851615	ENSG00000258053.1	CTD-2021H9.3	4.36	1.62e-05	0.00299	0.23	0.19	Type 2 diabetes;	chr12:71132284	chr12:71047402~71118247:-
LUAD	cis	rs7955901	0.775	rs2270589	ENSG00000258053.1	CTD-2021H9.3	4.36	1.62e-05	0.00299	0.23	0.19	Type 2 diabetes;	chr12:71132507	chr12:71047402~71118247:-
LUAD	cis	rs7955901	0.775	rs2270588	ENSG00000258053.1	CTD-2021H9.3	4.36	1.62e-05	0.00299	0.23	0.19	Type 2 diabetes;	chr12:71132634	chr12:71047402~71118247:-
LUAD	cis	rs7955901	0.775	rs3816942	ENSG00000258053.1	CTD-2021H9.3	4.36	1.62e-05	0.00299	0.23	0.19	Type 2 diabetes;	chr12:71132929	chr12:71047402~71118247:-
LUAD	cis	rs7955901	0.805	rs3851617	ENSG00000258053.1	CTD-2021H9.3	4.36	1.62e-05	0.00299	0.23	0.19	Type 2 diabetes;	chr12:71133430	chr12:71047402~71118247:-
LUAD	cis	rs7955901	0.775	rs10784895	ENSG00000258053.1	CTD-2021H9.3	4.36	1.62e-05	0.00299	0.23	0.19	Type 2 diabetes;	chr12:71134005	chr12:71047402~71118247:-
LUAD	cis	rs7893279	0.505	rs12766105	ENSG00000225527.1	RP11-383B4.4	4.36	1.62e-05	0.00299	0.28	0.19	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18584296	chr10:18531849~18533336:-
LUAD	cis	rs160451	0.966	rs160423	ENSG00000251136.7	RP11-37B2.1	4.36	1.62e-05	0.00299	0.2	0.19	Leprosy;	chr8:89658395	chr8:89609409~89757727:-
LUAD	cis	rs238295	0.766	rs6085197	ENSG00000230563.2	RP5-828H9.1	4.36	1.62e-05	0.00299	0.25	0.19	Occipital cortical area (total cortical area interaction);	chr20:5530364	chr20:5471207~5475182:+
LUAD	cis	rs2348418	0.701	rs6487670	ENSG00000247934.4	RP11-967K21.1	-4.36	1.62e-05	0.00299	-0.22	-0.19	Lung function (FEV1);Lung function (FVC);	chr12:28210856	chr12:28163298~28190738:-
LUAD	cis	rs5758511	0.679	rs55867855	ENSG00000227370.1	RP4-669P10.19	4.36	1.62e-05	0.00299	0.22	0.19	Birth weight;	chr22:42227252	chr22:42132543~42132998:+
LUAD	cis	rs11512640	1	rs11220129	ENSG00000254671.2	STT3A-AS1	4.36	1.62e-05	0.00299	0.42	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125564929	chr11:125570284~125592568:-
LUAD	cis	rs4683346	0.584	rs339731	ENSG00000173811.9	CCDC13-AS1	-4.36	1.62e-05	0.00299	-0.23	-0.19	Granulocyte percentage of myeloid white cells;	chr3:42725867	chr3:42732575~42746768:+
LUAD	cis	rs858239	0.6	rs10233039	ENSG00000226816.2	AC005082.12	4.36	1.62e-05	0.00299	0.25	0.19	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23206013~23208045:+
LUAD	cis	rs7772486	0.658	rs9403737	ENSG00000235652.6	RP11-545I5.3	4.36	1.62e-05	0.00299	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145641057	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.754	rs4896832	ENSG00000235652.6	RP11-545I5.3	4.36	1.62e-05	0.00299	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145643015	chr6:145799409~145886585:+
LUAD	cis	rs7727544	0.625	rs4705916	ENSG00000233006.5	AC034220.3	4.36	1.62e-05	0.00299	0.18	0.19	Blood metabolite levels;	chr5:132071800	chr5:132311285~132369916:-
LUAD	cis	rs11168618	0.74	rs11168617	ENSG00000240399.1	RP1-228P16.1	4.36	1.62e-05	0.00299	0.19	0.19	Adiponectin levels;	chr12:48534925	chr12:48054813~48055591:-
LUAD	cis	rs11168618	0.703	rs11495272	ENSG00000240399.1	RP1-228P16.1	4.36	1.62e-05	0.00299	0.19	0.19	Adiponectin levels;	chr12:48535043	chr12:48054813~48055591:-
LUAD	cis	rs8072100	0.666	rs9913503	ENSG00000228782.6	CTD-2026D20.3	4.36	1.62e-05	0.00299	0.21	0.19	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47698964	chr17:47450568~47492492:-
LUAD	cis	rs1005277	0.557	rs1854563	ENSG00000263064.2	RP11-291L22.7	4.36	1.62e-05	0.00299	0.21	0.19	Extrinsic epigenetic age acceleration;	chr10:38146033	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.579	rs2505237	ENSG00000263064.2	RP11-291L22.7	4.36	1.62e-05	0.00299	0.21	0.19	Extrinsic epigenetic age acceleration;	chr10:38149970	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.579	rs2474599	ENSG00000263064.2	RP11-291L22.7	4.36	1.62e-05	0.00299	0.21	0.19	Extrinsic epigenetic age acceleration;	chr10:38150011	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.54	rs2224248	ENSG00000263064.2	RP11-291L22.7	4.36	1.62e-05	0.00299	0.21	0.19	Extrinsic epigenetic age acceleration;	chr10:38162958	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.505	rs200939	ENSG00000273019.1	RP11-508N22.13	-4.36	1.62e-05	0.00299	-0.22	-0.19	Extrinsic epigenetic age acceleration;	chr10:37850555	chr10:38149968~38150293:+
LUAD	cis	rs7578361	0.959	rs10204282	ENSG00000231969.1	AC144449.1	4.36	1.62e-05	0.00299	0.28	0.19	Acute lymphoblastic leukemia (childhood);	chr2:149564944	chr2:149587196~149848233:+
LUAD	cis	rs4908760	0.827	rs10864360	ENSG00000270282.1	RP5-1115A15.2	4.36	1.62e-05	0.00299	0.21	0.19	Vitiligo;	chr1:8664463	chr1:8512653~8513021:+
LUAD	cis	rs1979679	0.76	rs16932640	ENSG00000278733.1	RP11-425D17.1	4.36	1.63e-05	0.00299	0.25	0.19	Ossification of the posterior longitudinal ligament of the spine;	chr12:28142034	chr12:28185625~28186190:-
LUAD	cis	rs2243480	1	rs160655	ENSG00000229886.1	RP5-1132H15.3	4.36	1.63e-05	0.00299	0.33	0.19	Diabetic kidney disease;	chr7:66068227	chr7:66025126~66031544:-
LUAD	cis	rs7119	0.717	rs8042307	ENSG00000259362.2	RP11-307C19.1	-4.36	1.63e-05	0.00299	-0.24	-0.19	Type 2 diabetes;	chr15:77511671	chr15:77525540~77534110:+
LUAD	cis	rs11907546	1	rs11907546	ENSG00000275784.1	RP5-1125A11.6	-4.36	1.63e-05	0.00299	-0.21	-0.19	Cancer (pleiotropy);Cancer;	chr20:34131991	chr20:33989480~33991818:-
LUAD	cis	rs72634501	0.517	rs10788925	ENSG00000228060.1	RP11-69E11.8	4.36	1.63e-05	0.00299	0.18	0.19	HDL cholesterol;	chr1:39128430	chr1:39565160~39573203:+
LUAD	cis	rs4819052	0.851	rs7275870	ENSG00000237664.1	LINC00316	-4.35	1.63e-05	0.00299	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251299	chr21:45338590~45341990:-
LUAD	cis	rs4819052	0.851	rs7275874	ENSG00000237664.1	LINC00316	-4.35	1.63e-05	0.00299	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251308	chr21:45338590~45341990:-
LUAD	cis	rs812925	0.519	rs2694638	ENSG00000271889.1	RP11-493E12.1	-4.35	1.63e-05	0.003	-0.23	-0.19	Immature fraction of reticulocytes;	chr2:61408228	chr2:61151433~61162105:-
LUAD	cis	rs10938353	0.68	rs17654223	ENSG00000273369.1	RP11-700J17.1	4.35	1.63e-05	0.003	0.25	0.19	Body mass index;	chr4:44741551	chr4:44693946~44694386:-
LUAD	cis	rs7937890	0.684	rs12799007	ENSG00000251991.1	RNU7-49P	4.35	1.63e-05	0.003	0.2	0.19	Mitochondrial DNA levels;	chr11:14404938	chr11:14478892~14478953:+
LUAD	cis	rs8180040	0.966	rs12636851	ENSG00000271161.1	BOLA2P2	4.35	1.63e-05	0.003	0.19	0.19	Colorectal cancer;	chr3:47422077	chr3:47499841~47500407:+
LUAD	cis	rs2898681	0.614	rs58260946	ENSG00000248375.1	RP11-177B4.1	-4.35	1.63e-05	0.003	-0.29	-0.19	Optic nerve measurement (cup area);	chr4:52809253	chr4:52720081~52720831:-
LUAD	cis	rs812925	0.537	rs778153	ENSG00000271889.1	RP11-493E12.1	-4.35	1.63e-05	0.003	-0.23	-0.19	Immature fraction of reticulocytes;	chr2:61381517	chr2:61151433~61162105:-
LUAD	cis	rs2243480	1	rs1499613	ENSG00000232559.3	GS1-124K5.12	-4.35	1.63e-05	0.003	-0.34	-0.19	Diabetic kidney disease;	chr7:66265873	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs1553174	ENSG00000232559.3	GS1-124K5.12	-4.35	1.63e-05	0.003	-0.34	-0.19	Diabetic kidney disease;	chr7:66266207	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs10950032	ENSG00000232559.3	GS1-124K5.12	-4.35	1.63e-05	0.003	-0.34	-0.19	Diabetic kidney disease;	chr7:66273604	chr7:66554588~66576923:-
LUAD	cis	rs6714710	0.535	rs3192177	ENSG00000230606.9	AC159540.1	-4.35	1.63e-05	0.003	-0.21	-0.19	Posterior cortical atrophy and Alzheimer's disease;	chr2:97738048	chr2:97416165~97433527:-
LUAD	cis	rs9341808	0.718	rs9448893	ENSG00000272129.1	RP11-250B2.6	4.35	1.63e-05	0.003	0.24	0.19	Sitting height ratio;	chr6:80127522	chr6:80355424~80356859:+
LUAD	cis	rs7324557	0.717	rs9318064	ENSG00000205861.10	C1QTNF9B-AS1	-4.35	1.63e-05	0.003	-0.26	-0.19	Visceral adipose tissue adjusted for BMI;	chr13:23822010	chr13:23888889~23897263:+
LUAD	cis	rs853679	1	rs853694	ENSG00000219392.1	RP1-265C24.5	-4.35	1.63e-05	0.003	-0.31	-0.19	Depression;	chr6:28311323	chr6:28115628~28116551:+
LUAD	cis	rs2354432	0.556	rs11239965	ENSG00000226015.2	CCT8P1	4.35	1.63e-05	0.003	0.38	0.19	Mitochondrial DNA levels;	chr1:147282234	chr1:147203276~147204932:-
LUAD	cis	rs812925	0.537	rs778146	ENSG00000271889.1	RP11-493E12.1	-4.35	1.63e-05	0.003	-0.23	-0.19	Immature fraction of reticulocytes;	chr2:61379340	chr2:61151433~61162105:-
LUAD	cis	rs7923837	0.616	rs12778642	ENSG00000236493.2	EIF2S2P3	4.35	1.63e-05	0.003	0.22	0.19	Multiple sclerosis;Body mass index;	chr10:92704550	chr10:92668745~92669743:-
LUAD	cis	rs7555523	0.83	rs6660601	ENSG00000224358.1	RP11-466F5.8	-4.35	1.63e-05	0.00301	-0.34	-0.19	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165726618	chr1:165768929~165775176:+
LUAD	cis	rs6479901	0.947	rs10761764	ENSG00000232075.1	MRPL35P2	-4.35	1.63e-05	0.00301	-0.27	-0.19	Intelligence (multi-trait analysis);	chr10:63429143	chr10:63634317~63634827:-
LUAD	cis	rs6479901	0.846	rs7917169	ENSG00000232075.1	MRPL35P2	-4.35	1.63e-05	0.00301	-0.27	-0.19	Intelligence (multi-trait analysis);	chr10:63433181	chr10:63634317~63634827:-
LUAD	cis	rs6479901	0.895	rs10822172	ENSG00000232075.1	MRPL35P2	-4.35	1.63e-05	0.00301	-0.27	-0.19	Intelligence (multi-trait analysis);	chr10:63455478	chr10:63634317~63634827:-
LUAD	cis	rs8098244	0.516	rs1711451	ENSG00000264745.1	TTC39C-AS1	4.35	1.64e-05	0.00301	0.21	0.19	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23690470	chr18:23994213~24015339:-
LUAD	cis	rs5769707	0.967	rs2071904	ENSG00000235111.1	RP1-29C18.8	-4.35	1.64e-05	0.00301	-0.21	-0.19	Monocyte percentage of white cells;Monocyte count;	chr22:49640829	chr22:49612657~49615716:-
LUAD	cis	rs160451	0.966	rs160447	ENSG00000251136.7	RP11-37B2.1	4.35	1.64e-05	0.00301	0.21	0.19	Leprosy;	chr8:89647432	chr8:89609409~89757727:-
LUAD	cis	rs950169	0.922	rs62021167	ENSG00000275120.1	RP11-182J1.17	4.35	1.64e-05	0.00301	0.31	0.19	Schizophrenia;	chr15:84574820	chr15:84599434~84606463:-
LUAD	cis	rs34783982	0.919	rs4534818	ENSG00000261441.1	RP11-217B1.2	-4.35	1.64e-05	0.00301	-0.25	-0.19	Squamous cell lung carcinoma;	chr15:88958997	chr15:89335053~89336161:+
LUAD	cis	rs853679	0.546	rs2232426	ENSG00000219392.1	RP1-265C24.5	-4.35	1.64e-05	0.00301	-0.44	-0.19	Depression;	chr6:28392882	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.546	rs2232423	ENSG00000219392.1	RP1-265C24.5	-4.35	1.64e-05	0.00301	-0.44	-0.19	Depression;	chr6:28398374	chr6:28115628~28116551:+
LUAD	cis	rs3096299	0.802	rs3102336	ENSG00000182376.2	RP5-1142A6.8	4.35	1.64e-05	0.00301	0.2	0.19	Multiple myeloma (IgH translocation);	chr16:89375598	chr16:88742767~88745748:+
LUAD	cis	rs1005277	0.541	rs2505193	ENSG00000263064.2	RP11-291L22.7	4.35	1.64e-05	0.00301	0.21	0.19	Extrinsic epigenetic age acceleration;	chr10:38105710	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.579	rs2474580	ENSG00000263064.2	RP11-291L22.7	4.35	1.64e-05	0.00301	0.21	0.19	Extrinsic epigenetic age acceleration;	chr10:38109785	chr10:38448689~38448949:+
LUAD	cis	rs7590268	0.549	rs34156621	ENSG00000279873.2	LINC01126	4.35	1.64e-05	0.00301	0.2	0.19	Orofacial clefts;	chr2:43613099	chr2:43227210~43228855:+
LUAD	cis	rs477895	0.653	rs7939784	ENSG00000236935.1	AP003774.1	-4.35	1.64e-05	0.00301	-0.24	-0.19	Mean platelet volume;	chr11:64142681	chr11:64325050~64329504:-
LUAD	cis	rs5758511	0.596	rs55644935	ENSG00000205702.9	CYP2D7	4.35	1.64e-05	0.00301	0.19	0.19	Birth weight;	chr22:42270063	chr22:42140203~42144577:-
LUAD	cis	rs750134	1	rs55721100	ENSG00000257221.1	RP11-689B22.2	-4.35	1.64e-05	0.00301	-0.29	-0.19	Low high density lipoprotein cholesterol levels;	chr12:108728878	chr12:108628687~108641318:+
LUAD	cis	rs1008375	1	rs11727312	ENSG00000249502.1	AC006160.5	-4.35	1.64e-05	0.00301	-0.18	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17667562	chr4:17587467~17614571:-
LUAD	cis	rs2735413	0.564	rs1882595	ENSG00000276007.1	RP11-358L22.3	4.35	1.64e-05	0.00301	0.26	0.19	Systolic blood pressure (alcohol consumption interaction);	chr16:78066787	chr16:78123243~78124332:+
LUAD	cis	rs10266483	0.661	rs608769	ENSG00000227986.1	TRIM60P18	-4.35	1.64e-05	0.00302	-0.24	-0.19	Response to statin therapy;	chr7:64292783	chr7:64355078~64356199:+
LUAD	cis	rs1008375	0.618	rs13129002	ENSG00000249502.1	AC006160.5	-4.35	1.64e-05	0.00302	-0.19	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17565890	chr4:17587467~17614571:-
LUAD	cis	rs2227564	0.597	rs2271271	ENSG00000271816.1	BMS1P4	4.35	1.64e-05	0.00302	0.18	0.19	Crohn's disease;Inflammatory bowel disease;	chr10:73799109	chr10:73699151~73730487:-
LUAD	cis	rs763121	0.889	rs2267390	ENSG00000225450.1	RP3-508I15.14	-4.35	1.64e-05	0.00302	-0.19	-0.19	Menopause (age at onset);	chr22:38493652	chr22:38739003~38749041:+
LUAD	cis	rs13113518	0.902	rs11133386	ENSG00000272969.1	RP11-528I4.2	4.35	1.64e-05	0.00302	0.2	0.19	Height;	chr4:55461320	chr4:55547112~55547889:+
LUAD	cis	rs13113518	0.812	rs11945371	ENSG00000272969.1	RP11-528I4.2	4.35	1.64e-05	0.00302	0.21	0.19	Height;	chr4:55409063	chr4:55547112~55547889:+
LUAD	cis	rs5769707	0.935	rs5770594	ENSG00000235111.1	RP1-29C18.8	-4.35	1.64e-05	0.00302	-0.21	-0.19	Monocyte percentage of white cells;Monocyte count;	chr22:49624849	chr22:49612657~49615716:-
LUAD	cis	rs5769707	0.967	rs4524218	ENSG00000235111.1	RP1-29C18.8	-4.35	1.64e-05	0.00302	-0.21	-0.19	Monocyte percentage of white cells;Monocyte count;	chr22:49624991	chr22:49612657~49615716:-
LUAD	cis	rs2834288	0.5	rs881230	ENSG00000237945.6	LINC00649	4.35	1.64e-05	0.00302	0.24	0.19	Gut microbiota (bacterial taxa);	chr21:33950521	chr21:33915534~33977691:+
LUAD	cis	rs6957923	0.901	rs34113317	ENSG00000230658.1	KLHL7-AS1	4.35	1.64e-05	0.00302	0.24	0.19	Height;	chr7:23446300	chr7:23101228~23105703:-
LUAD	cis	rs4578769	0.569	rs8094359	ENSG00000265943.1	RP11-739L10.1	4.35	1.64e-05	0.00302	0.24	0.19	Eosinophil percentage of white cells;	chr18:22907743	chr18:22699481~22933764:-
LUAD	cis	rs4578769	0.55	rs8092358	ENSG00000265943.1	RP11-739L10.1	4.35	1.64e-05	0.00302	0.24	0.19	Eosinophil percentage of white cells;	chr18:22911835	chr18:22699481~22933764:-
LUAD	cis	rs4578769	0.569	rs1379805	ENSG00000265943.1	RP11-739L10.1	4.35	1.64e-05	0.00302	0.24	0.19	Eosinophil percentage of white cells;	chr18:22914589	chr18:22699481~22933764:-
LUAD	cis	rs4578769	0.569	rs1031652	ENSG00000265943.1	RP11-739L10.1	4.35	1.64e-05	0.00302	0.24	0.19	Eosinophil percentage of white cells;	chr18:22916035	chr18:22699481~22933764:-
LUAD	cis	rs10971721	0.822	rs10971817	ENSG00000260947.1	RP11-384P7.7	4.35	1.64e-05	0.00302	0.4	0.19	Body mass index;	chr9:33951886	chr9:33697459~33700986:+
LUAD	cis	rs17772222	1	rs12589480	ENSG00000258983.2	RP11-507K2.2	4.35	1.64e-05	0.00302	0.24	0.19	Coronary artery calcification;	chr14:88414926	chr14:88499334~88515502:+
LUAD	cis	rs3096299	0.685	rs4785571	ENSG00000182376.2	RP5-1142A6.8	4.35	1.64e-05	0.00302	0.2	0.19	Multiple myeloma (IgH translocation);	chr16:89498761	chr16:88742767~88745748:+
LUAD	cis	rs1864585	0.52	rs73209921	ENSG00000255046.1	RP11-297N6.4	4.35	1.64e-05	0.00302	0.28	0.19	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10850214	chr8:11797928~11802568:-
LUAD	cis	rs61542988	1	rs61542988	ENSG00000228649.7	AC005682.5	4.35	1.64e-05	0.00302	0.26	0.19	Fibrinogen levels;	chr7:22842672	chr7:22854178~22861579:+
LUAD	cis	rs875971	0.965	rs9969301	ENSG00000232559.3	GS1-124K5.12	-4.35	1.64e-05	0.00302	-0.23	-0.19	Aortic root size;	chr7:66316668	chr7:66554588~66576923:-
LUAD	cis	rs950169	1	rs11638297	ENSG00000275120.1	RP11-182J1.17	4.35	1.64e-05	0.00302	0.3	0.19	Schizophrenia;	chr15:84113665	chr15:84599434~84606463:-
LUAD	cis	rs3743772	0.5	rs28415605	ENSG00000279722.1	RP11-44F14.6	4.35	1.64e-05	0.00302	0.27	0.19	Depressive symptoms (SSRI exposure interaction);	chr16:53415274	chr16:53487607~53489943:-
LUAD	cis	rs3743772	0.5	rs2160290	ENSG00000279722.1	RP11-44F14.6	4.35	1.64e-05	0.00302	0.27	0.19	Depressive symptoms (SSRI exposure interaction);	chr16:53415763	chr16:53487607~53489943:-
LUAD	cis	rs57502260	0.764	rs7105218	ENSG00000212093.1	AP000807.1	4.35	1.64e-05	0.00302	0.25	0.19	Total body bone mineral density (age 45-60);	chr11:68454993	chr11:68506083~68506166:-
LUAD	cis	rs1667284	0.555	rs1551006	ENSG00000266521.1	RP11-650P15.1	4.35	1.65e-05	0.00302	0.22	0.19	Problematic alcohol use in trauma-exposed individuals;	chr18:31653282	chr18:31496645~31497195:-
LUAD	cis	rs34779708	0.931	rs10508815	ENSG00000271335.4	RP11-324I22.4	4.35	1.65e-05	0.00302	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35043693	chr10:35314552~35336401:-
LUAD	cis	rs7204230	1	rs62049816	ENSG00000261291.1	RP11-295M3.2	4.35	1.65e-05	0.00302	0.24	0.19	Fibrinogen;	chr16:53336072	chr16:53168522~53169450:+
LUAD	cis	rs11822910	0.911	rs11828218	ENSG00000265566.2	RN7SL605P	4.35	1.65e-05	0.00302	0.25	0.19	Platelet distribution width;	chr11:57428750	chr11:57528085~57528365:-
LUAD	cis	rs655601	0.643	rs112702671	ENSG00000280161.1	CTC-205M6.1	4.35	1.65e-05	0.00303	0.45	0.19	Quantitative traits;	chr5:180793930	chr5:180810401~180811384:+
LUAD	cis	rs453301	0.658	rs6983877	ENSG00000233609.3	RP11-62H7.2	-4.35	1.65e-05	0.00303	-0.16	-0.19	Joint mobility (Beighton score);	chr8:9047129	chr8:8961200~8979025:+
LUAD	cis	rs10129255	0.833	rs61997797	ENSG00000211955.2	IGHV3-33	-4.35	1.65e-05	0.00303	-0.15	-0.19	Kawasaki disease;	chr14:106815190	chr14:106359793~106360324:-
LUAD	cis	rs3770081	1	rs2303340	ENSG00000273080.1	RP11-301O19.1	-4.35	1.65e-05	0.00303	-0.43	-0.19	Facial emotion recognition (sad faces);	chr2:86106070	chr2:86195590~86196049:+
LUAD	cis	rs7119038	0.818	rs1048024	ENSG00000255422.1	AP002954.4	4.35	1.65e-05	0.00303	0.31	0.19	Sjögren's syndrome;	chr11:118748067	chr11:118704607~118750263:+
LUAD	cis	rs10129255	0.957	rs10136560	ENSG00000211967.3	IGHV3-53	-4.35	1.65e-05	0.00303	-0.15	-0.19	Kawasaki disease;	chr14:106787630	chr14:106592676~106593347:-
LUAD	cis	rs2933343	0.729	rs1683780	ENSG00000261159.1	RP11-723O4.9	4.35	1.65e-05	0.00303	0.22	0.19	IgG glycosylation;	chr3:128921396	chr3:128859716~128860526:-
LUAD	cis	rs6088590	1	rs6119535	ENSG00000276073.1	RP5-1125A11.7	-4.35	1.65e-05	0.00303	-0.2	-0.19	Coronary artery disease;	chr20:34854335	chr20:33985617~33988989:-
LUAD	cis	rs6860806	0.632	rs4330455	ENSG00000233006.5	AC034220.3	4.35	1.65e-05	0.00303	0.17	0.19	Breast cancer;	chr5:132250656	chr5:132311285~132369916:-
LUAD	cis	rs6012564	1	rs2024959	ENSG00000230758.1	SNAP23P	4.35	1.65e-05	0.00303	0.2	0.19	Anger;	chr20:49078854	chr20:49038357~49038602:-
LUAD	cis	rs2274273	0.684	rs2340921	ENSG00000258413.1	RP11-665C16.6	-4.35	1.65e-05	0.00303	-0.26	-0.19	Protein biomarker;	chr14:55096987	chr14:55262767~55272075:-
LUAD	cis	rs11220082	0.542	rs11220079	ENSG00000254671.2	STT3A-AS1	-4.35	1.65e-05	0.00304	-0.23	-0.19	Schizophrenia;	chr11:125450033	chr11:125570284~125592568:-
LUAD	cis	rs848490	0.962	rs17807802	ENSG00000214293.7	APTR	-4.35	1.65e-05	0.00304	-0.24	-0.19	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77840169	chr7:77657660~77696265:-
LUAD	cis	rs394563	0.601	rs439495	ENSG00000231760.4	RP11-350J20.5	-4.35	1.65e-05	0.00304	-0.26	-0.19	Dupuytren's disease;	chr6:149472088	chr6:149796151~149826294:-
LUAD	cis	rs6840360	1	rs10019048	ENSG00000270265.1	RP11-731D1.4	-4.35	1.66e-05	0.00304	-0.2	-0.19	Intelligence (multi-trait analysis);	chr4:151682463	chr4:151333775~151353224:-
LUAD	cis	rs8062405	0.792	rs12446550	ENSG00000251417.2	RP11-1348G14.4	-4.35	1.66e-05	0.00304	-0.2	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28802743~28817828:+
LUAD	cis	rs6754311	0.689	rs191079	ENSG00000226806.1	AC011893.3	4.35	1.66e-05	0.00304	0.24	0.19	Mosquito bite size;	chr2:135876201	chr2:135820191~135823087:+
LUAD	cis	rs256438	0.93	rs2438635	ENSG00000251050.1	RP11-168A11.4	-4.35	1.66e-05	0.00304	-0.21	-0.19	Serum thyroid-stimulating hormone levels;	chr5:80095582	chr5:80019609~80019920:+
LUAD	cis	rs4578769	0.569	rs12960915	ENSG00000265943.1	RP11-739L10.1	4.35	1.66e-05	0.00304	0.24	0.19	Eosinophil percentage of white cells;	chr18:22924013	chr18:22699481~22933764:-
LUAD	cis	rs875971	0.964	rs55748098	ENSG00000232559.3	GS1-124K5.12	-4.35	1.66e-05	0.00304	-0.23	-0.19	Aortic root size;	chr7:66298631	chr7:66554588~66576923:-
LUAD	cis	rs13256369	1	rs13271966	ENSG00000253893.2	FAM85B	-4.35	1.66e-05	0.00304	-0.27	-0.19	Obesity-related traits;	chr8:8717962	chr8:8167819~8226614:-
LUAD	cis	rs853679	0.527	rs853683	ENSG00000219392.1	RP1-265C24.5	-4.35	1.66e-05	0.00304	-0.24	-0.19	Depression;	chr6:28327262	chr6:28115628~28116551:+
LUAD	cis	rs5769707	0.681	rs4824068	ENSG00000235111.1	RP1-29C18.8	-4.35	1.66e-05	0.00304	-0.24	-0.19	Monocyte percentage of white cells;Monocyte count;	chr22:49631153	chr22:49612657~49615716:-
LUAD	cis	rs957448	1	rs16916881	ENSG00000253175.1	RP11-267M23.6	4.35	1.66e-05	0.00304	0.23	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94554042	chr8:94565036~94565715:+
LUAD	cis	rs2153535	0.585	rs2224480	ENSG00000230939.1	RP11-314C16.1	-4.35	1.66e-05	0.00304	-0.22	-0.19	Motion sickness;	chr6:8647646	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.585	rs7770688	ENSG00000230939.1	RP11-314C16.1	-4.35	1.66e-05	0.00304	-0.22	-0.19	Motion sickness;	chr6:8648663	chr6:8784178~8785445:+
LUAD	cis	rs7208859	0.573	rs4055105	ENSG00000266490.1	CTD-2349P21.9	4.35	1.66e-05	0.00304	0.29	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775532	chr17:30792372~30792833:+
LUAD	cis	rs4819052	0.679	rs2236450	ENSG00000223768.1	LINC00205	-4.35	1.66e-05	0.00304	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45282638	chr21:45293285~45297354:+
LUAD	cis	rs449789	0.857	rs10455775	ENSG00000235086.1	FNDC1-IT1	-4.35	1.66e-05	0.00305	-0.28	-0.19	Pulse pressure;	chr6:159302689	chr6:159240786~159243329:+
LUAD	cis	rs2273156	0.57	rs7156322	ENSG00000226677.3	IGBP1P1	-4.35	1.66e-05	0.00305	-0.31	-0.19	Immunoglobulin light chain (AL) amyloidosis;	chr14:35075124	chr14:34939324~34940332:+
LUAD	cis	rs5758511	0.508	rs2854827	ENSG00000205702.9	CYP2D7	4.35	1.66e-05	0.00305	0.19	0.19	Birth weight;	chr22:42065914	chr22:42140203~42144577:-
LUAD	cis	rs6142102	0.651	rs6059692	ENSG00000275784.1	RP5-1125A11.6	4.35	1.66e-05	0.00305	0.23	0.19	Skin pigmentation;	chr20:34158397	chr20:33989480~33991818:-
LUAD	cis	rs13256369	1	rs4840351	ENSG00000253893.2	FAM85B	-4.35	1.66e-05	0.00305	-0.27	-0.19	Obesity-related traits;	chr8:8715638	chr8:8167819~8226614:-
LUAD	cis	rs2980436	1	rs2980436	ENSG00000254340.1	RP11-10A14.3	-4.35	1.66e-05	0.00305	-0.24	-0.19	Schizophrenia;	chr8:8234503	chr8:9141424~9145435:+
LUAD	cis	rs7208859	0.614	rs216474	ENSG00000266490.1	CTD-2349P21.9	-4.35	1.66e-05	0.00305	-0.28	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30538073	chr17:30792372~30792833:+
LUAD	cis	rs193541	0.53	rs2125857	ENSG00000263432.2	RN7SL689P	4.35	1.66e-05	0.00305	0.26	0.19	Glucose homeostasis traits;	chr5:122747461	chr5:123022487~123022783:-
LUAD	cis	rs6969780	0.524	rs875898	ENSG00000233429.8	HOTAIRM1	-4.35	1.66e-05	0.00305	-0.27	-0.19	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27161286	chr7:27095647~27100265:+
LUAD	cis	rs3758785	0.623	rs75164831	ENSG00000255893.1	RP11-685N10.1	-4.35	1.66e-05	0.00305	-0.28	-0.19	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94410667	chr11:94472908~94473570:-
LUAD	cis	rs3758785	0.562	rs79850307	ENSG00000255893.1	RP11-685N10.1	-4.35	1.66e-05	0.00305	-0.28	-0.19	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94411859	chr11:94472908~94473570:-
LUAD	cis	rs2243480	1	rs316329	ENSG00000232559.3	GS1-124K5.12	4.35	1.66e-05	0.00305	0.34	0.19	Diabetic kidney disease;	chr7:66143429	chr7:66554588~66576923:-
LUAD	cis	rs4873772	0.735	rs1872840	ENSG00000253330.1	RP11-697N18.3	-4.35	1.66e-05	0.00305	-0.22	-0.19	Lobe attachment (rater-scored or self-reported);	chr8:47719868	chr8:47511034~47512141:-
LUAD	cis	rs2281636	0.625	rs7075305	ENSG00000233690.1	EBAG9P1	-4.35	1.66e-05	0.00305	-0.2	-0.19	Obesity-related traits;	chr10:99604767	chr10:99697407~99697949:-
LUAD	cis	rs1334894	1	rs72913417	ENSG00000228559.1	RP3-340B19.3	-4.35	1.66e-05	0.00305	-0.42	-0.19	Coronary artery disease;	chr6:35579089	chr6:35544632~35545669:+
LUAD	cis	rs10266483	0.774	rs10253630	ENSG00000227986.1	TRIM60P18	4.35	1.67e-05	0.00305	0.24	0.19	Response to statin therapy;	chr7:64366962	chr7:64355078~64356199:+
LUAD	cis	rs62025270	0.632	rs56153788	ENSG00000202081.1	RNU6-1280P	-4.35	1.67e-05	0.00305	-0.29	-0.19	Idiopathic pulmonary fibrosis;	chr15:85627761	chr15:85651522~85651628:-
LUAD	cis	rs11220082	0.666	rs12223186	ENSG00000254671.2	STT3A-AS1	-4.35	1.67e-05	0.00306	-0.22	-0.19	Schizophrenia;	chr11:125461743	chr11:125570284~125592568:-
LUAD	cis	rs9601248	0.756	rs928640	ENSG00000227676.3	LINC01068	-4.35	1.67e-05	0.00306	-0.24	-0.19	Major depressive disorder;	chr13:79603348	chr13:79566727~79571436:+
LUAD	cis	rs34779708	0.733	rs12254018	ENSG00000271335.4	RP11-324I22.4	4.35	1.67e-05	0.00306	0.21	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35261713	chr10:35314552~35336401:-
LUAD	cis	rs6942407	0.592	rs886318	ENSG00000224046.1	AC005076.5	-4.35	1.67e-05	0.00306	-0.24	-0.19	Food allergy;	chr7:87117184	chr7:87151423~87152420:-
LUAD	cis	rs17772222	0.917	rs4635267	ENSG00000258789.1	RP11-507K2.3	-4.35	1.67e-05	0.00306	-0.26	-0.19	Coronary artery calcification;	chr14:88621922	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.876	rs56144430	ENSG00000258789.1	RP11-507K2.3	-4.35	1.67e-05	0.00306	-0.26	-0.19	Coronary artery calcification;	chr14:88622013	chr14:88551597~88552493:+
LUAD	cis	rs227275	0.554	rs223409	ENSG00000251288.2	RP11-10L12.2	-4.35	1.67e-05	0.00306	-0.23	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102815023	chr4:102751401~102752641:+
LUAD	cis	rs4761702	0.527	rs12824664	ENSG00000257252.4	RP11-486A14.2	-4.35	1.67e-05	0.00306	-0.25	-0.19	Immature fraction of reticulocytes;	chr12:93343125	chr12:93317135~93377736:-
LUAD	cis	rs11250098	0.541	rs6997997	ENSG00000255046.1	RP11-297N6.4	4.35	1.67e-05	0.00306	0.24	0.19	Morning vs. evening chronotype;	chr8:10908572	chr8:11797928~11802568:-
LUAD	cis	rs957448	0.948	rs1470153	ENSG00000254315.1	RP11-267M23.3	4.35	1.67e-05	0.00307	0.25	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94514587	chr8:94533628~94534391:+
LUAD	cis	rs9309473	0.519	rs2421545	ENSG00000163016.8	ALMS1P	-4.35	1.67e-05	0.00307	-0.21	-0.19	Metabolite levels;	chr2:73412348	chr2:73644919~73685576:+
LUAD	cis	rs9900062	0.586	rs35018407	ENSG00000270714.1	MINOS1P2	-4.35	1.67e-05	0.00307	-0.25	-0.19	QT interval;	chr17:64694063	chr17:64747264~64747492:-
LUAD	cis	rs4554975	0.514	rs1986584	ENSG00000274723.1	RP11-618L22.1	-4.35	1.67e-05	0.00307	-0.23	-0.19	Metabolite levels (small molecules and protein measures);	chr12:46909419	chr12:46970504~46972155:+
LUAD	cis	rs11157436	0.602	rs1894369	ENSG00000211812.1	TRAV26-2	4.35	1.67e-05	0.00307	0.2	0.19	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166597	chr14:22202583~22203368:+
LUAD	cis	rs6012564	1	rs2426112	ENSG00000230758.1	SNAP23P	-4.35	1.67e-05	0.00307	-0.2	-0.19	Anger;	chr20:49073602	chr20:49038357~49038602:-
LUAD	cis	rs6012564	1	rs2426113	ENSG00000230758.1	SNAP23P	-4.35	1.67e-05	0.00307	-0.2	-0.19	Anger;	chr20:49073652	chr20:49038357~49038602:-
LUAD	cis	rs6012564	1	rs3092411	ENSG00000230758.1	SNAP23P	-4.35	1.67e-05	0.00307	-0.2	-0.19	Anger;	chr20:49074054	chr20:49038357~49038602:-
LUAD	cis	rs6012564	0.929	rs2426114	ENSG00000230758.1	SNAP23P	-4.35	1.67e-05	0.00307	-0.2	-0.19	Anger;	chr20:49075855	chr20:49038357~49038602:-
LUAD	cis	rs17122278	0.858	rs11216899	ENSG00000243431.1	RPL5P30	-4.35	1.67e-05	0.00307	-0.24	-0.19	Total cholesterol levels;	chr11:118563706	chr11:118560690~118561580:+
LUAD	cis	rs1106529	0.515	rs1779454	ENSG00000226172.2	RP4-712E4.1	-4.35	1.67e-05	0.00307	-0.27	-0.19	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);	chr1:118915494	chr1:119000344~119001392:-
LUAD	cis	rs6479901	0.947	rs10995540	ENSG00000232075.1	MRPL35P2	-4.35	1.67e-05	0.00307	-0.27	-0.19	Intelligence (multi-trait analysis);	chr10:63460170	chr10:63634317~63634827:-
LUAD	cis	rs6479901	0.947	rs10159609	ENSG00000232075.1	MRPL35P2	-4.35	1.67e-05	0.00307	-0.27	-0.19	Intelligence (multi-trait analysis);	chr10:63461168	chr10:63634317~63634827:-
LUAD	cis	rs6479901	0.947	rs10995541	ENSG00000232075.1	MRPL35P2	-4.35	1.67e-05	0.00307	-0.27	-0.19	Intelligence (multi-trait analysis);	chr10:63473575	chr10:63634317~63634827:-
LUAD	cis	rs17406451	0.743	rs6722806	ENSG00000279873.2	LINC01126	4.35	1.68e-05	0.00307	0.17	0.19	Mitochondrial DNA levels;	chr2:43400576	chr2:43227210~43228855:+
LUAD	cis	rs11886999	0.812	rs59664047	ENSG00000237510.6	AC008268.2	-4.35	1.68e-05	0.00307	-0.32	-0.19	Cardiac Troponin-T levels;	chr2:96203553	chr2:95789654~95800166:+
LUAD	cis	rs9400467	0.528	rs10872067	ENSG00000230177.1	RP5-1112D6.4	-4.35	1.68e-05	0.00307	-0.17	-0.19	Amino acid levels;Blood metabolite levels;	chr6:111467188	chr6:111277932~111278742:+
LUAD	cis	rs34779708	0.733	rs7081597	ENSG00000271335.4	RP11-324I22.4	4.35	1.68e-05	0.00307	0.21	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35257403	chr10:35314552~35336401:-
LUAD	cis	rs227275	0.525	rs4623004	ENSG00000251288.2	RP11-10L12.2	-4.35	1.68e-05	0.00307	-0.23	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:103000141	chr4:102751401~102752641:+
LUAD	cis	rs160451	0.934	rs160422	ENSG00000251136.7	RP11-37B2.1	4.35	1.68e-05	0.00307	0.2	0.19	Leprosy;	chr8:89657610	chr8:89609409~89757727:-
LUAD	cis	rs8072100	0.701	rs2013383	ENSG00000228782.6	CTD-2026D20.3	4.35	1.68e-05	0.00307	0.21	0.19	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47713757	chr17:47450568~47492492:-
LUAD	cis	rs116175783	0.557	rs7349280	ENSG00000227403.1	AC009299.3	4.35	1.68e-05	0.00307	0.36	0.19	Intelligence (multi-trait analysis);	chr2:161354120	chr2:161244739~161249050:+
LUAD	cis	rs75422866	0.558	rs73104190	ENSG00000276691.1	RP5-1057I20.5	4.35	1.68e-05	0.00307	0.33	0.19	Pneumonia;	chr12:47716040	chr12:47788426~47788971:+
LUAD	cis	rs160451	0.934	rs160453	ENSG00000251136.7	RP11-37B2.1	4.35	1.68e-05	0.00308	0.2	0.19	Leprosy;	chr8:89652326	chr8:89609409~89757727:-
LUAD	cis	rs1023500	0.505	rs134885	ENSG00000205702.9	CYP2D7	4.35	1.68e-05	0.00308	0.16	0.19	Schizophrenia;	chr22:42277805	chr22:42140203~42144577:-
LUAD	cis	rs394563	0.967	rs369643	ENSG00000216906.2	RP11-350J20.9	4.35	1.68e-05	0.00308	0.24	0.19	Dupuytren's disease;	chr6:149478662	chr6:149904243~149906418:+
LUAD	cis	rs950169	0.959	rs12902070	ENSG00000275120.1	RP11-182J1.17	4.35	1.68e-05	0.00308	0.31	0.19	Schizophrenia;	chr15:84124806	chr15:84599434~84606463:-
LUAD	cis	rs7208859	0.623	rs73269923	ENSG00000266490.1	CTD-2349P21.9	4.35	1.68e-05	0.00308	0.29	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30792372~30792833:+
LUAD	cis	rs2304003	0.948	rs1432270	ENSG00000235192.1	AC009495.2	4.35	1.68e-05	0.00308	0.24	0.19	Social communication problems;	chr2:165847910	chr2:165794851~165810010:+
LUAD	cis	rs3096299	0.503	rs9940093	ENSG00000261118.1	RP11-104N10.1	4.35	1.68e-05	0.00308	0.2	0.19	Multiple myeloma (IgH translocation);	chr16:89492297	chr16:89492017~89504460:-
LUAD	cis	rs181553	0.504	rs7237062	ENSG00000266696.1	RP11-30L3.2	4.35	1.68e-05	0.00308	0.26	0.19	Hip circumference adjusted for BMI;	chr18:49200883	chr18:49205912~49208781:+
LUAD	cis	rs1005277	0.579	rs2505257	ENSG00000263064.2	RP11-291L22.7	4.35	1.68e-05	0.00308	0.21	0.19	Extrinsic epigenetic age acceleration;	chr10:38083736	chr10:38448689~38448949:+
LUAD	cis	rs6496932	0.755	rs6497021	ENSG00000218052.5	ADAMTS7P4	-4.35	1.68e-05	0.00308	-0.22	-0.19	Central corneal thickness;Corneal structure;	chr15:85353036	chr15:85255369~85330334:-
LUAD	cis	rs62025270	0.632	rs1807309	ENSG00000202081.1	RNU6-1280P	-4.35	1.68e-05	0.00308	-0.29	-0.19	Idiopathic pulmonary fibrosis;	chr15:85668526	chr15:85651522~85651628:-
LUAD	cis	rs73198271	0.603	rs546606	ENSG00000253893.2	FAM85B	4.35	1.68e-05	0.00308	0.25	0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8738333	chr8:8167819~8226614:-
LUAD	cis	rs6754311	0.731	rs7569057	ENSG00000226806.1	AC011893.3	4.35	1.68e-05	0.00308	0.24	0.19	Mosquito bite size;	chr2:135826388	chr2:135820191~135823087:+
LUAD	cis	rs8077577	0.671	rs9910090	ENSG00000273018.4	CTD-2303H24.2	-4.35	1.68e-05	0.00308	-0.26	-0.19	Obesity-related traits;	chr17:18347085	chr17:18511221~18551705:-
LUAD	cis	rs34792	0.554	rs28393495	ENSG00000275910.1	RP11-680G24.6	-4.35	1.68e-05	0.00308	-0.19	-0.19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15516406	chr16:15015828~15016390:-
LUAD	cis	rs853679	0.546	rs35353359	ENSG00000219392.1	RP1-265C24.5	-4.35	1.68e-05	0.00308	-0.43	-0.19	Depression;	chr6:28356601	chr6:28115628~28116551:+
LUAD	cis	rs11089937	0.568	rs35626600	ENSG00000211640.3	IGLV6-57	4.35	1.68e-05	0.00309	0.15	0.19	Periodontitis (PAL4Q3);	chr22:22130811	chr22:22195713~22196460:+
LUAD	cis	rs11089937	0.539	rs34228957	ENSG00000211640.3	IGLV6-57	4.35	1.68e-05	0.00309	0.15	0.19	Periodontitis (PAL4Q3);	chr22:22130838	chr22:22195713~22196460:+
LUAD	cis	rs11089937	0.512	rs13054756	ENSG00000211640.3	IGLV6-57	4.35	1.68e-05	0.00309	0.15	0.19	Periodontitis (PAL4Q3);	chr22:22130948	chr22:22195713~22196460:+
LUAD	cis	rs11089937	0.597	rs4821768	ENSG00000211640.3	IGLV6-57	4.35	1.68e-05	0.00309	0.15	0.19	Periodontitis (PAL4Q3);	chr22:22131047	chr22:22195713~22196460:+
LUAD	cis	rs17772222	0.917	rs17260415	ENSG00000258983.2	RP11-507K2.2	4.35	1.68e-05	0.00309	0.24	0.19	Coronary artery calcification;	chr14:88745629	chr14:88499334~88515502:+
LUAD	cis	rs2638953	0.886	rs7973241	ENSG00000278733.1	RP11-425D17.1	-4.35	1.69e-05	0.00309	-0.23	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28207583	chr12:28185625~28186190:-
LUAD	cis	rs860295	0.702	rs11264375	ENSG00000225855.5	RUSC1-AS1	-4.35	1.69e-05	0.00309	-0.13	-0.19	Body mass index;	chr1:155454274	chr1:155316863~155324176:-
LUAD	cis	rs9341808	0.727	rs4706834	ENSG00000260645.1	RP11-250B2.5	4.35	1.69e-05	0.00309	0.18	0.19	Sitting height ratio;	chr6:80302888	chr6:80466958~80469080:+
LUAD	cis	rs2274273	0.87	rs8023197	ENSG00000259318.1	RP11-454L9.2	4.35	1.69e-05	0.00309	0.17	0.19	Protein biomarker;	chr14:55300677	chr14:55394940~55395233:-
LUAD	cis	rs4578769	0.55	rs7237400	ENSG00000265943.1	RP11-739L10.1	4.35	1.69e-05	0.00309	0.24	0.19	Eosinophil percentage of white cells;	chr18:22986533	chr18:22699481~22933764:-
LUAD	cis	rs3808502	0.525	rs9650661	ENSG00000255046.1	RP11-297N6.4	4.35	1.69e-05	0.00309	0.23	0.19	Neuroticism;	chr8:11569624	chr8:11797928~11802568:-
LUAD	cis	rs16866061	0.962	rs3845840	ENSG00000228446.2	AC073052.1	-4.35	1.69e-05	0.00309	-0.21	-0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr2:224494383	chr2:224499387~224500100:-
LUAD	cis	rs16866061	1	rs72972378	ENSG00000228446.2	AC073052.1	-4.35	1.69e-05	0.00309	-0.21	-0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr2:224507845	chr2:224499387~224500100:-
LUAD	cis	rs2921036	0.529	rs2979192	ENSG00000253981.4	ALG1L13P	4.35	1.69e-05	0.00309	0.23	0.19	Neuroticism;	chr8:8480637	chr8:8236003~8244667:-
LUAD	cis	rs854462	1	rs1102934	ENSG00000274767.1	AC131056.3	-4.35	1.69e-05	0.00309	-0.28	-0.19	Blood protein levels;	chr17:36062554	chr17:36183235~36196471:+
LUAD	cis	rs6088590	0.61	rs6120663	ENSG00000275784.1	RP5-1125A11.6	4.35	1.69e-05	0.00309	0.21	0.19	Coronary artery disease;	chr20:34494101	chr20:33989480~33991818:-
LUAD	cis	rs6714710	0.603	rs11678591	ENSG00000230606.9	AC159540.1	-4.35	1.69e-05	0.0031	-0.21	-0.19	Posterior cortical atrophy and Alzheimer's disease;	chr2:97924538	chr2:97416165~97433527:-
LUAD	cis	rs6714710	0.603	rs10432626	ENSG00000230606.9	AC159540.1	-4.35	1.69e-05	0.0031	-0.21	-0.19	Posterior cortical atrophy and Alzheimer's disease;	chr2:97944690	chr2:97416165~97433527:-
LUAD	cis	rs6714710	0.603	rs1875699	ENSG00000230606.9	AC159540.1	-4.35	1.69e-05	0.0031	-0.21	-0.19	Posterior cortical atrophy and Alzheimer's disease;	chr2:97964261	chr2:97416165~97433527:-
LUAD	cis	rs4266144	0.563	rs61124401	ENSG00000244515.1	KRT18P34	-4.35	1.69e-05	0.0031	-0.28	-0.19	Coronary artery disease;	chr3:157123130	chr3:157162663~157163932:-
LUAD	cis	rs4763879	0.502	rs11052552	ENSG00000278635.1	CTD-2318O12.1	-4.35	1.69e-05	0.0031	-0.17	-0.19	Type 1 diabetes;	chr12:9703362	chr12:9415641~9416718:+
LUAD	cis	rs7061710	0.711	rs7887142	ENSG00000271811.1	RP1-79C4.4	4.35	1.69e-05	0.0031	0.29	0.19	Blood metabolite levels;	chr1:171152282	chr1:170667381~170669425:+
LUAD	cis	rs897200	0.775	rs2168168	ENSG00000280083.1	RP11-317J9.1	4.35	1.69e-05	0.0031	0.26	0.19	Behcet's disease;	chr2:191157702	chr2:191154118~191156070:-
LUAD	cis	rs1061377	0.513	rs2566163	ENSG00000249685.1	RP11-360F5.3	4.35	1.69e-05	0.0031	0.29	0.19	Uric acid levels;	chr4:39128345	chr4:39133913~39135608:+
LUAD	cis	rs1552244	0.882	rs3846168	ENSG00000180385.7	EMC3-AS1	4.35	1.69e-05	0.0031	0.22	0.19	Alzheimer's disease;	chr3:9955241	chr3:9986893~10006990:+
LUAD	cis	rs11673344	0.504	rs7245882	ENSG00000276846.1	CTD-3220F14.3	-4.35	1.69e-05	0.0031	-0.21	-0.19	Obesity-related traits;	chr19:37089513	chr19:37314868~37315620:-
LUAD	cis	rs5758511	0.68	rs5758682	ENSG00000227370.1	RP4-669P10.19	4.35	1.69e-05	0.0031	0.22	0.19	Birth weight;	chr22:42249196	chr22:42132543~42132998:+
LUAD	cis	rs11168618	0.904	rs7137866	ENSG00000240399.1	RP1-228P16.1	4.35	1.69e-05	0.0031	0.19	0.19	Adiponectin levels;	chr12:48529019	chr12:48054813~48055591:-
LUAD	cis	rs2153535	0.585	rs9406183	ENSG00000230939.1	RP11-314C16.1	4.35	1.69e-05	0.0031	0.22	0.19	Motion sickness;	chr6:8639538	chr6:8784178~8785445:+
LUAD	cis	rs7324557	0.717	rs9510876	ENSG00000205861.10	C1QTNF9B-AS1	-4.35	1.7e-05	0.0031	-0.26	-0.19	Visceral adipose tissue adjusted for BMI;	chr13:23822149	chr13:23888889~23897263:+
LUAD	cis	rs8062405	0.824	rs62034326	ENSG00000251417.2	RP11-1348G14.4	-4.35	1.7e-05	0.0031	-0.2	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28802743~28817828:+
LUAD	cis	rs8062405	0.824	rs4788084	ENSG00000251417.2	RP11-1348G14.4	-4.35	1.7e-05	0.0031	-0.2	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28802743~28817828:+
LUAD	cis	rs8098244	0.706	rs720064	ENSG00000264745.1	TTC39C-AS1	4.35	1.7e-05	0.0031	0.2	0.19	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23890360	chr18:23994213~24015339:-
LUAD	cis	rs9400467	0.528	rs459403	ENSG00000230177.1	RP5-1112D6.4	-4.35	1.7e-05	0.0031	-0.17	-0.19	Amino acid levels;Blood metabolite levels;	chr6:111332674	chr6:111277932~111278742:+
LUAD	cis	rs6142102	0.961	rs4911408	ENSG00000275784.1	RP5-1125A11.6	-4.35	1.7e-05	0.00311	-0.22	-0.19	Skin pigmentation;	chr20:34112760	chr20:33989480~33991818:-
LUAD	cis	rs189798	0.807	rs330909	ENSG00000253981.4	ALG1L13P	4.35	1.7e-05	0.00311	0.25	0.19	Myopia (pathological);	chr8:9137877	chr8:8236003~8244667:-
LUAD	cis	rs812925	0.519	rs1186706	ENSG00000271889.1	RP11-493E12.1	4.35	1.7e-05	0.00311	0.23	0.19	Immature fraction of reticulocytes;	chr2:61446259	chr2:61151433~61162105:-
LUAD	cis	rs858239	0.509	rs57611130	ENSG00000226816.2	AC005082.12	4.35	1.7e-05	0.00311	0.26	0.19	Cerebrospinal fluid biomarker levels;	chr7:23144933	chr7:23206013~23208045:+
LUAD	cis	rs13113518	0.934	rs3805155	ENSG00000272969.1	RP11-528I4.2	4.35	1.7e-05	0.00311	0.2	0.19	Height;	chr4:55497842	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs7686261	ENSG00000272969.1	RP11-528I4.2	4.35	1.7e-05	0.00311	0.2	0.19	Height;	chr4:55500224	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs11729220	ENSG00000272969.1	RP11-528I4.2	4.35	1.7e-05	0.00311	0.2	0.19	Height;	chr4:55501629	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs11133390	ENSG00000272969.1	RP11-528I4.2	4.35	1.7e-05	0.00311	0.2	0.19	Height;	chr4:55501726	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs11133391	ENSG00000272969.1	RP11-528I4.2	4.35	1.7e-05	0.00311	0.2	0.19	Height;	chr4:55501788	chr4:55547112~55547889:+
LUAD	cis	rs13113518	0.966	rs13133484	ENSG00000272969.1	RP11-528I4.2	4.35	1.7e-05	0.00311	0.2	0.19	Height;	chr4:55504176	chr4:55547112~55547889:+
LUAD	cis	rs13113518	0.934	rs13127906	ENSG00000272969.1	RP11-528I4.2	4.35	1.7e-05	0.00311	0.2	0.19	Height;	chr4:55504201	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs6849433	ENSG00000272969.1	RP11-528I4.2	4.35	1.7e-05	0.00311	0.2	0.19	Height;	chr4:55506498	chr4:55547112~55547889:+
LUAD	cis	rs6964833	1	rs36044436	ENSG00000278416.1	PMS2L2	4.35	1.7e-05	0.00311	0.28	0.19	Menarche (age at onset);	chr7:74675495	chr7:75344015~75359550:-
LUAD	cis	rs12073359	0.955	rs78676616	ENSG00000223945.2	RP11-458I7.1	-4.35	1.7e-05	0.00311	-0.29	-0.19	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150171103	chr1:150053864~150055034:+
LUAD	cis	rs910316	1	rs10146482	ENSG00000279594.1	RP11-950C14.10	4.35	1.7e-05	0.00311	0.22	0.19	Height;	chr14:75107384	chr14:75011269~75012851:-
LUAD	cis	rs62025270	0.747	rs12324721	ENSG00000202081.1	RNU6-1280P	-4.35	1.7e-05	0.00311	-0.28	-0.19	Idiopathic pulmonary fibrosis;	chr15:85767741	chr15:85651522~85651628:-
LUAD	cis	rs36093844	0.575	rs12286312	ENSG00000279742.1	RP11-700A24.1	-4.35	1.7e-05	0.00311	-0.21	-0.19	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85893781	chr11:85852557~85854943:-
LUAD	cis	rs4819052	0.851	rs2330011	ENSG00000237664.1	LINC00316	-4.34	1.7e-05	0.00311	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238583	chr21:45338590~45341990:-
LUAD	cis	rs897984	0.683	rs72799316	ENSG00000260911.2	RP11-196G11.2	4.34	1.7e-05	0.00311	0.17	0.19	Dementia with Lewy bodies;	chr16:30815884	chr16:31043150~31049868:+
LUAD	cis	rs1864585	0.52	rs73208775	ENSG00000255046.1	RP11-297N6.4	4.34	1.7e-05	0.00311	0.28	0.19	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10810771	chr8:11797928~11802568:-
LUAD	cis	rs7208859	0.673	rs3816780	ENSG00000280069.1	CTD-2349P21.3	-4.34	1.7e-05	0.00311	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834340	chr17:30738182~30740275:+
LUAD	cis	rs8141529	0.732	rs5762788	ENSG00000272858.1	CTA-292E10.8	-4.34	1.7e-05	0.00311	-0.22	-0.19	Lymphocyte counts;	chr22:28778782	chr22:28814914~28815662:+
LUAD	cis	rs55823223	0.564	rs936391	ENSG00000267801.1	RP11-552F3.9	-4.34	1.7e-05	0.00312	-0.21	-0.19	Psoriasis;	chr17:75851718	chr17:75876372~75879546:+
LUAD	cis	rs9652601	0.881	rs11860603	ENSG00000274038.1	RP11-66H6.4	-4.34	1.7e-05	0.00312	-0.24	-0.19	Systemic lupus erythematosus;	chr16:11071160	chr16:11056556~11057034:+
LUAD	cis	rs9652601	0.959	rs11865121	ENSG00000274038.1	RP11-66H6.4	-4.34	1.7e-05	0.00312	-0.24	-0.19	Systemic lupus erythematosus;	chr16:11072831	chr16:11056556~11057034:+
LUAD	cis	rs9652601	0.959	rs7198621	ENSG00000274038.1	RP11-66H6.4	-4.34	1.7e-05	0.00312	-0.24	-0.19	Systemic lupus erythematosus;	chr16:11073601	chr16:11056556~11057034:+
LUAD	cis	rs728616	0.51	rs61860860	ENSG00000225484.5	NUTM2B-AS1	-4.34	1.7e-05	0.00312	-0.34	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79998816	chr10:79663088~79826594:-
LUAD	cis	rs1799949	0.501	rs9675035	ENSG00000236383.6	LINC00854	-4.34	1.7e-05	0.00312	-0.16	-0.19	Menopause (age at onset);	chr17:43337648	chr17:43216941~43305976:-
LUAD	cis	rs4873772	0.837	rs2129617	ENSG00000253330.1	RP11-697N18.3	-4.34	1.7e-05	0.00312	-0.22	-0.19	Lobe attachment (rater-scored or self-reported);	chr8:47643268	chr8:47511034~47512141:-
LUAD	cis	rs240993	0.516	rs241004	ENSG00000230177.1	RP5-1112D6.4	-4.34	1.7e-05	0.00312	-0.21	-0.19	Inflammatory skin disease;Psoriasis;	chr6:111275341	chr6:111277932~111278742:+
LUAD	cis	rs12439619	0.774	rs2867649	ENSG00000276710.3	CSPG4P8	-4.34	1.71e-05	0.00312	-0.22	-0.19	Intelligence (multi-trait analysis);	chr15:82262331	chr15:82459472~82477258:+
LUAD	cis	rs1964356	0.967	rs17701675	ENSG00000253981.4	ALG1L13P	-4.34	1.71e-05	0.00312	-0.23	-0.19	Mean corpuscular volume;	chr8:8993123	chr8:8236003~8244667:-
LUAD	cis	rs7945705	0.875	rs10769947	ENSG00000254860.4	TMEM9B-AS1	-4.34	1.71e-05	0.00312	-0.22	-0.19	Hemoglobin concentration;	chr11:8736567	chr11:8964675~8977527:+
LUAD	cis	rs7893279	0.505	rs11815228	ENSG00000225527.1	RP11-383B4.4	4.34	1.71e-05	0.00312	0.28	0.19	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18590899	chr10:18531849~18533336:-
LUAD	cis	rs2492286	0.597	rs2811487	ENSG00000242551.2	POU5F1P6	-4.34	1.71e-05	0.00312	-0.26	-0.19	Eosinophil counts;	chr3:128613036	chr3:128674735~128677005:-
LUAD	cis	rs228614	0.51	rs223378	ENSG00000251288.2	RP11-10L12.2	-4.34	1.71e-05	0.00312	-0.23	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102833488	chr4:102751401~102752641:+
LUAD	cis	rs115344852	0.557	rs2859351	ENSG00000216901.1	AL022393.7	4.34	1.71e-05	0.00312	0.27	0.19	Epithelial ovarian cancer;	chr6:28488418	chr6:28176188~28176674:+
LUAD	cis	rs7061710	0.871	rs7879557	ENSG00000271811.1	RP1-79C4.4	4.34	1.71e-05	0.00312	0.27	0.19	Blood metabolite levels;	chr1:171148202	chr1:170667381~170669425:+
LUAD	cis	rs6700559	0.716	rs12140579	ENSG00000260088.1	RP11-92G12.3	4.34	1.71e-05	0.00312	0.24	0.19	Coronary artery disease;	chr1:200655368	chr1:200669507~200694250:+
LUAD	cis	rs17406451	0.788	rs6751139	ENSG00000279873.2	LINC01126	4.34	1.71e-05	0.00312	0.17	0.19	Mitochondrial DNA levels;	chr2:43400224	chr2:43227210~43228855:+
LUAD	cis	rs6496932	1	rs35796484	ENSG00000202081.1	RNU6-1280P	4.34	1.71e-05	0.00312	0.27	0.19	Central corneal thickness;Corneal structure;	chr15:85282019	chr15:85651522~85651628:-
LUAD	cis	rs889398	0.802	rs12925700	ENSG00000226232.7	RP11-419C5.2	4.34	1.71e-05	0.00312	0.17	0.19	Body mass index;	chr16:69759560	chr16:69976388~69996188:-
LUAD	cis	rs957448	1	rs2381882	ENSG00000254315.1	RP11-267M23.3	4.34	1.71e-05	0.00312	0.25	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94535496	chr8:94533628~94534391:+
LUAD	cis	rs10938353	0.68	rs73191059	ENSG00000273369.1	RP11-700J17.1	4.34	1.71e-05	0.00313	0.27	0.19	Body mass index;	chr4:44629998	chr4:44693946~44694386:-
LUAD	cis	rs1551277	0.916	rs11760871	ENSG00000146666.5	LINC00525	-4.34	1.71e-05	0.00313	-0.22	-0.19	Anxiety disorder;	chr7:47798385	chr7:47761476~47766772:+
LUAD	cis	rs1008375	0.966	rs11737844	ENSG00000249502.1	AC006160.5	-4.34	1.71e-05	0.00313	-0.18	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17695798	chr4:17587467~17614571:-
LUAD	cis	rs2439831	0.571	rs689883	ENSG00000249839.1	AC011330.5	-4.34	1.71e-05	0.00313	-0.35	-0.19	Lung cancer in ever smokers;	chr15:43520398	chr15:43663654~43684339:-
LUAD	cis	rs911555	0.755	rs4906329	ENSG00000244691.1	RPL10AP1	4.34	1.71e-05	0.00313	0.26	0.19	Intelligence (multi-trait analysis);	chr14:103476332	chr14:103412119~103412761:-
LUAD	cis	rs1334894	0.901	rs12526404	ENSG00000228559.1	RP3-340B19.3	-4.34	1.71e-05	0.00313	-0.4	-0.19	Coronary artery disease;	chr6:35533171	chr6:35544632~35545669:+
LUAD	cis	rs6012564	1	rs6063360	ENSG00000230758.1	SNAP23P	4.34	1.71e-05	0.00313	0.21	0.19	Anger;	chr20:49131838	chr20:49038357~49038602:-
LUAD	cis	rs2880765	0.714	rs6497187	ENSG00000259416.2	RP11-158M2.5	4.34	1.71e-05	0.00313	0.2	0.19	Coronary artery disease;	chr15:85468119	chr15:85754941~85756237:-
LUAD	cis	rs2880765	0.743	rs6497191	ENSG00000259416.2	RP11-158M2.5	4.34	1.71e-05	0.00313	0.2	0.19	Coronary artery disease;	chr15:85468270	chr15:85754941~85756237:-
LUAD	cis	rs2880765	0.743	rs6416598	ENSG00000259416.2	RP11-158M2.5	4.34	1.71e-05	0.00313	0.2	0.19	Coronary artery disease;	chr15:85468617	chr15:85754941~85756237:-
LUAD	cis	rs9341808	0.718	rs11962614	ENSG00000272129.1	RP11-250B2.6	4.34	1.71e-05	0.00313	0.24	0.19	Sitting height ratio;	chr6:80113589	chr6:80355424~80356859:+
LUAD	cis	rs9341808	0.718	rs12208016	ENSG00000272129.1	RP11-250B2.6	4.34	1.71e-05	0.00313	0.24	0.19	Sitting height ratio;	chr6:80113846	chr6:80355424~80356859:+
LUAD	cis	rs9341808	0.718	rs9448886	ENSG00000272129.1	RP11-250B2.6	4.34	1.71e-05	0.00313	0.24	0.19	Sitting height ratio;	chr6:80116184	chr6:80355424~80356859:+
LUAD	cis	rs9341808	0.683	rs9359409	ENSG00000272129.1	RP11-250B2.6	4.34	1.71e-05	0.00313	0.24	0.19	Sitting height ratio;	chr6:80117180	chr6:80355424~80356859:+
LUAD	cis	rs6762	0.719	rs28655651	ENSG00000279672.1	CMB9-55F22.1	4.34	1.71e-05	0.00313	0.21	0.19	Mean platelet volume;	chr11:837121	chr11:779617~780755:+
LUAD	cis	rs755249	0.727	rs16826349	ENSG00000228060.1	RP11-69E11.8	-4.34	1.71e-05	0.00313	-0.17	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39573264	chr1:39565160~39573203:+
LUAD	cis	rs7204230	1	rs62048047	ENSG00000261291.1	RP11-295M3.2	4.34	1.71e-05	0.00313	0.24	0.19	Fibrinogen;	chr16:53195637	chr16:53168522~53169450:+
LUAD	cis	rs7760535	0.831	rs62420437	ENSG00000271789.1	RP5-1112D6.7	-4.34	1.71e-05	0.00313	-0.21	-0.19	Metabolic traits;	chr6:111427577	chr6:111297126~111298510:+
LUAD	cis	rs9860428	1	rs9814893	ENSG00000242770.2	RP11-180K7.1	4.34	1.71e-05	0.00313	0.2	0.19	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112868645	chr3:112802478~112812819:+
LUAD	cis	rs950169	0.881	rs34591918	ENSG00000275120.1	RP11-182J1.17	4.34	1.71e-05	0.00313	0.3	0.19	Schizophrenia;	chr15:84396135	chr15:84599434~84606463:-
LUAD	cis	rs897200	0.775	rs13030488	ENSG00000280083.1	RP11-317J9.1	4.34	1.71e-05	0.00313	0.26	0.19	Behcet's disease;	chr2:191155321	chr2:191154118~191156070:-
LUAD	cis	rs5758511	0.68	rs5758684	ENSG00000227370.1	RP4-669P10.19	4.34	1.71e-05	0.00313	0.22	0.19	Birth weight;	chr22:42253503	chr22:42132543~42132998:+
LUAD	cis	rs7893279	0.505	rs2171922	ENSG00000225527.1	RP11-383B4.4	4.34	1.71e-05	0.00313	0.28	0.19	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18646977	chr10:18531849~18533336:-
LUAD	cis	rs7580658	0.724	rs6712213	ENSG00000236682.1	AC068282.3	-4.34	1.71e-05	0.00313	-0.25	-0.19	Protein C levels;	chr2:127240654	chr2:127389130~127400580:+
LUAD	cis	rs12579720	0.679	rs10841446	ENSG00000255910.1	RP11-405A12.2	4.34	1.71e-05	0.00313	0.24	0.19	Diastolic blood pressure;	chr12:20085269	chr12:19775451~20009937:+
LUAD	cis	rs2823962	0.759	rs8134854	ENSG00000270093.1	AP000473.8	-4.34	1.71e-05	0.00313	-0.2	-0.19	Amyotrophic lateral sclerosis;	chr21:16643723	chr21:16643529~16645065:+
LUAD	cis	rs6964587	0.967	rs34574955	ENSG00000188693.7	CYP51A1-AS1	-4.34	1.72e-05	0.00313	-0.23	-0.19	Breast cancer;	chr7:92218236	chr7:92134604~92180725:+
LUAD	cis	rs8072100	0.64	rs3851808	ENSG00000228782.6	CTD-2026D20.3	4.34	1.72e-05	0.00314	0.21	0.19	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47347778	chr17:47450568~47492492:-
LUAD	cis	rs8030379	1	rs11259937	ENSG00000230373.7	GOLGA6L5P	-4.34	1.72e-05	0.00314	-0.18	-0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83919081	chr15:84507885~84516814:-
LUAD	cis	rs8030379	1	rs11637866	ENSG00000230373.7	GOLGA6L5P	-4.34	1.72e-05	0.00314	-0.18	-0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83919206	chr15:84507885~84516814:-
LUAD	cis	rs8030379	1	rs2135880	ENSG00000230373.7	GOLGA6L5P	-4.34	1.72e-05	0.00314	-0.18	-0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83920861	chr15:84507885~84516814:-
LUAD	cis	rs8030379	1	rs1526080	ENSG00000230373.7	GOLGA6L5P	-4.34	1.72e-05	0.00314	-0.18	-0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83921168	chr15:84507885~84516814:-
LUAD	cis	rs8030379	1	rs1852264	ENSG00000230373.7	GOLGA6L5P	-4.34	1.72e-05	0.00314	-0.18	-0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83921188	chr15:84507885~84516814:-
LUAD	cis	rs8030379	1	rs1526081	ENSG00000230373.7	GOLGA6L5P	-4.34	1.72e-05	0.00314	-0.18	-0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83921314	chr15:84507885~84516814:-
LUAD	cis	rs8030379	1	rs8030379	ENSG00000230373.7	GOLGA6L5P	-4.34	1.72e-05	0.00314	-0.18	-0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83922158	chr15:84507885~84516814:-
LUAD	cis	rs55823223	0.564	rs58363746	ENSG00000267801.1	RP11-552F3.9	4.34	1.72e-05	0.00314	0.21	0.19	Psoriasis;	chr17:75854738	chr17:75876372~75879546:+
LUAD	cis	rs172166	0.611	rs203883	ENSG00000216901.1	AL022393.7	4.34	1.72e-05	0.00314	0.24	0.19	Cardiac Troponin-T levels;	chr6:28110578	chr6:28176188~28176674:+
LUAD	cis	rs524281	0.731	rs3814744	ENSG00000255320.1	RP11-755F10.1	4.34	1.72e-05	0.00314	0.32	0.19	Electroencephalogram traits;	chr11:66042292	chr11:66244840~66246239:-
LUAD	cis	rs524281	0.648	rs4565902	ENSG00000255320.1	RP11-755F10.1	4.34	1.72e-05	0.00314	0.32	0.19	Electroencephalogram traits;	chr11:66042574	chr11:66244840~66246239:-
LUAD	cis	rs6840258	0.76	rs340637	ENSG00000251411.1	RP11-397E7.4	4.34	1.72e-05	0.00314	0.22	0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87008040	chr4:86913266~86914817:-
LUAD	cis	rs6840258	0.723	rs340633	ENSG00000251411.1	RP11-397E7.4	4.34	1.72e-05	0.00314	0.22	0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87010746	chr4:86913266~86914817:-
LUAD	cis	rs13113518	0.812	rs2048564	ENSG00000223305.1	RN7SKP30	4.34	1.72e-05	0.00314	0.23	0.19	Height;	chr4:55407965	chr4:55540502~55540835:-
LUAD	cis	rs3814244	0.528	rs10878723	ENSG00000236946.2	HNRNPA1P70	-4.34	1.72e-05	0.00314	-0.17	-0.19	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005493	chr12:68035767~68036853:+
LUAD	cis	rs262150	0.659	rs2730275	ENSG00000231419.5	LINC00689	-4.34	1.72e-05	0.00314	-0.24	-0.19	Facial morphology (factor 20);	chr7:159000706	chr7:159006522~159030195:+
LUAD	cis	rs6661961	0.714	rs6695950	ENSG00000237975.5	FLG-AS1	-4.34	1.72e-05	0.00314	-0.26	-0.19	Atopic dermatitis;	chr1:152440211	chr1:152168125~152445456:+
LUAD	cis	rs9649213	0.593	rs6970990	ENSG00000272950.1	RP11-307C18.1	4.34	1.72e-05	0.00314	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98296070	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.555	rs34695842	ENSG00000272950.1	RP11-307C18.1	4.34	1.72e-05	0.00314	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98301750	chr7:98322853~98323430:+
LUAD	cis	rs7772486	0.712	rs1292335	ENSG00000235652.6	RP11-545I5.3	4.34	1.72e-05	0.00315	0.2	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145646741	chr6:145799409~145886585:+
LUAD	cis	rs11168618	0.715	rs35367885	ENSG00000240399.1	RP1-228P16.1	4.34	1.72e-05	0.00315	0.19	0.19	Adiponectin levels;	chr12:48525877	chr12:48054813~48055591:-
LUAD	cis	rs7937890	0.706	rs7115393	ENSG00000254418.1	RP11-21L19.1	-4.34	1.72e-05	0.00315	-0.22	-0.19	Mitochondrial DNA levels;	chr11:14246832	chr11:14262846~14273691:-
LUAD	cis	rs34792	0.525	rs12708795	ENSG00000207425.1	Y_RNA	-4.34	1.72e-05	0.00315	-0.24	-0.19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15533861	chr16:14915457~14915556:-
LUAD	cis	rs8180040	0.967	rs807935	ENSG00000271161.1	BOLA2P2	4.34	1.72e-05	0.00315	0.18	0.19	Colorectal cancer;	chr3:47280179	chr3:47499841~47500407:+
LUAD	cis	rs8180040	1	rs811115	ENSG00000271161.1	BOLA2P2	4.34	1.72e-05	0.00315	0.18	0.19	Colorectal cancer;	chr3:47280643	chr3:47499841~47500407:+
LUAD	cis	rs8180040	1	rs807936	ENSG00000271161.1	BOLA2P2	4.34	1.72e-05	0.00315	0.18	0.19	Colorectal cancer;	chr3:47281006	chr3:47499841~47500407:+
LUAD	cis	rs8180040	1	rs1638676	ENSG00000271161.1	BOLA2P2	4.34	1.72e-05	0.00315	0.18	0.19	Colorectal cancer;	chr3:47286161	chr3:47499841~47500407:+
LUAD	cis	rs8180040	0.845	rs295441	ENSG00000271161.1	BOLA2P2	4.34	1.72e-05	0.00315	0.18	0.19	Colorectal cancer;	chr3:47291805	chr3:47499841~47500407:+
LUAD	cis	rs17772222	1	rs56987357	ENSG00000258983.2	RP11-507K2.2	4.34	1.72e-05	0.00315	0.23	0.19	Coronary artery calcification;	chr14:88358019	chr14:88499334~88515502:+
LUAD	cis	rs8059260	0.541	rs12927046	ENSG00000274038.1	RP11-66H6.4	-4.34	1.72e-05	0.00315	-0.45	-0.19	Alcohol consumption over the past year;	chr16:11148334	chr16:11056556~11057034:+
LUAD	cis	rs7204230	1	rs11075782	ENSG00000261291.1	RP11-295M3.2	4.34	1.72e-05	0.00315	0.24	0.19	Fibrinogen;	chr16:53198047	chr16:53168522~53169450:+
LUAD	cis	rs7811142	0.83	rs7341507	ENSG00000078319.8	PMS2P1	-4.34	1.72e-05	0.00315	-0.24	-0.19	Platelet count;	chr7:100353692	chr7:100320992~100341908:-
LUAD	cis	rs7819412	0.775	rs11773990	ENSG00000255046.1	RP11-297N6.4	4.34	1.72e-05	0.00315	0.24	0.19	Triglycerides;	chr8:11077572	chr8:11797928~11802568:-
LUAD	cis	rs7324557	0.651	rs9510875	ENSG00000205861.10	C1QTNF9B-AS1	-4.34	1.72e-05	0.00315	-0.26	-0.19	Visceral adipose tissue adjusted for BMI;	chr13:23820351	chr13:23888889~23897263:+
LUAD	cis	rs4879677	1	rs620232	ENSG00000215441.3	CTAGE12P	4.34	1.72e-05	0.00315	0.24	0.19	Gut microbiome composition (summer and winter);	chr9:27656448	chr9:27608382~27610745:-
LUAD	cis	rs7762018	0.891	rs4716343	ENSG00000231690.2	LINC00574	-4.34	1.73e-05	0.00315	-0.37	-0.19	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169743721	chr6:169790321~169802873:+
LUAD	cis	rs7762018	0.891	rs3088346	ENSG00000231690.2	LINC00574	-4.34	1.73e-05	0.00315	-0.37	-0.19	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169749697	chr6:169790321~169802873:+
LUAD	cis	rs8062405	0.755	rs4149398	ENSG00000261419.1	RP11-57A19.4	-4.34	1.73e-05	0.00315	-0.21	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597617	chr16:28659696~28740781:-
LUAD	cis	rs4879677	1	rs10757677	ENSG00000215441.3	CTAGE12P	-4.34	1.73e-05	0.00315	-0.24	-0.19	Gut microbiome composition (summer and winter);	chr9:27684534	chr9:27608382~27610745:-
LUAD	cis	rs7555523	0.887	rs10918274	ENSG00000224358.1	RP11-466F5.8	-4.34	1.73e-05	0.00315	-0.34	-0.19	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165745179	chr1:165768929~165775176:+
LUAD	cis	rs150992	0.504	rs6878136	ENSG00000248489.1	CTD-2007H13.3	-4.34	1.73e-05	0.00316	-0.24	-0.19	Body mass index;	chr5:99022487	chr5:98929171~98995013:+
LUAD	cis	rs4143844	1	rs4143844	ENSG00000259251.2	RP11-643M14.1	-4.34	1.73e-05	0.00316	-0.33	-0.19	Bipolar disorder and schizophrenia;	chr15:62020641	chr15:62060503~62062434:+
LUAD	cis	rs4699052	0.963	rs4698890	ENSG00000246560.2	RP11-10L12.4	4.34	1.73e-05	0.00316	0.25	0.19	Testicular germ cell tumor;	chr4:103260721	chr4:102828055~102844075:+
LUAD	cis	rs6496667	0.586	rs7162687	ENSG00000214433.4	GOLGA2P8	-4.34	1.73e-05	0.00316	-0.25	-0.19	Rheumatoid arthritis;	chr15:90346091	chr15:90291962~90295683:+
LUAD	cis	rs2933343	0.7	rs789238	ENSG00000231305.3	RP11-723O4.2	4.34	1.73e-05	0.00316	0.21	0.19	IgG glycosylation;	chr3:128917872	chr3:128861313~128871540:-
LUAD	cis	rs17685	0.712	rs1637049	ENSG00000280388.1	RP11-229D13.3	-4.34	1.73e-05	0.00316	-0.18	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76100657	chr7:76043977~76045963:-
LUAD	cis	rs801193	0.967	rs34356500	ENSG00000224316.1	RP11-479O9.2	4.34	1.73e-05	0.00316	0.2	0.19	Aortic root size;	chr7:66771620	chr7:65773620~65802067:+
LUAD	cis	rs1023500	0.573	rs4822088	ENSG00000205702.9	CYP2D7	4.34	1.73e-05	0.00316	0.16	0.19	Schizophrenia;	chr22:42074585	chr22:42140203~42144577:-
LUAD	cis	rs910316	1	rs3742773	ENSG00000279594.1	RP11-950C14.10	4.34	1.73e-05	0.00316	0.22	0.19	Height;	chr14:75112940	chr14:75011269~75012851:-
LUAD	cis	rs8030379	1	rs8024418	ENSG00000230373.7	GOLGA6L5P	-4.34	1.73e-05	0.00316	-0.18	-0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83917556	chr15:84507885~84516814:-
LUAD	cis	rs8030379	1	rs8042970	ENSG00000230373.7	GOLGA6L5P	-4.34	1.73e-05	0.00316	-0.18	-0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83917616	chr15:84507885~84516814:-
LUAD	cis	rs8030379	1	rs8024628	ENSG00000230373.7	GOLGA6L5P	-4.34	1.73e-05	0.00316	-0.18	-0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83917711	chr15:84507885~84516814:-
LUAD	cis	rs8030379	1	rs8029016	ENSG00000230373.7	GOLGA6L5P	-4.34	1.73e-05	0.00316	-0.18	-0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83917712	chr15:84507885~84516814:-
LUAD	cis	rs6471393	0.895	rs4255106	ENSG00000253848.1	RP11-10N23.5	4.34	1.73e-05	0.00316	0.24	0.19	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93766367	chr8:93741193~93744534:+
LUAD	cis	rs1387259	0.859	rs2054905	ENSG00000240399.1	RP1-228P16.1	4.34	1.73e-05	0.00316	0.2	0.19	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48294168	chr12:48054813~48055591:-
LUAD	cis	rs4971059	0.654	rs4971078	ENSG00000160766.13	GBAP1	-4.34	1.73e-05	0.00316	-0.2	-0.19	Breast cancer;	chr1:155156547	chr1:155213821~155227422:-
LUAD	cis	rs8062405	0.789	rs240704	ENSG00000251417.2	RP11-1348G14.4	-4.34	1.73e-05	0.00316	-0.2	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28518628	chr16:28802743~28817828:+
LUAD	cis	rs7200786	0.654	rs12447132	ENSG00000274038.1	RP11-66H6.4	4.34	1.73e-05	0.00316	0.24	0.19	Systemic lupus erythematosus;Multiple sclerosis;	chr16:10992559	chr16:11056556~11057034:+
LUAD	cis	rs2880765	0.835	rs730372	ENSG00000259416.2	RP11-158M2.5	-4.34	1.73e-05	0.00316	-0.2	-0.19	Coronary artery disease;	chr15:85494962	chr15:85754941~85756237:-
LUAD	cis	rs12908161	0.959	rs12906348	ENSG00000259295.5	CSPG4P12	4.34	1.73e-05	0.00316	0.27	0.19	Schizophrenia;	chr15:84786190	chr15:85191438~85213905:+
LUAD	cis	rs7122539	0.734	rs4930391	ENSG00000213409.4	RP11-658F2.3	4.34	1.73e-05	0.00316	0.23	0.19	HIV-1 susceptibility;	chr11:66877783	chr11:66761575~66762399:-
LUAD	cis	rs910316	1	rs12589376	ENSG00000279594.1	RP11-950C14.10	4.34	1.73e-05	0.00316	0.22	0.19	Height;	chr14:75094449	chr14:75011269~75012851:-
LUAD	cis	rs910316	0.967	rs1071989	ENSG00000279594.1	RP11-950C14.10	4.34	1.73e-05	0.00316	0.22	0.19	Height;	chr14:75097956	chr14:75011269~75012851:-
LUAD	cis	rs910316	1	rs9805979	ENSG00000279594.1	RP11-950C14.10	4.34	1.73e-05	0.00316	0.22	0.19	Height;	chr14:75099506	chr14:75011269~75012851:-
LUAD	cis	rs262150	0.714	rs2657397	ENSG00000231419.5	LINC00689	-4.34	1.73e-05	0.00316	-0.23	-0.19	Facial morphology (factor 20);	chr7:158992404	chr7:159006522~159030195:+
LUAD	cis	rs9322193	0.884	rs9689702	ENSG00000268592.3	RAET1E-AS1	4.34	1.73e-05	0.00316	0.24	0.19	Lung cancer;	chr6:149740720	chr6:149863494~149919507:+
LUAD	cis	rs6728642	0.708	rs56807297	ENSG00000230606.9	AC159540.1	4.34	1.74e-05	0.00317	0.32	0.19	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97195603	chr2:97416165~97433527:-
LUAD	cis	rs17406451	0.731	rs7605661	ENSG00000279873.2	LINC01126	4.34	1.74e-05	0.00317	0.17	0.19	Mitochondrial DNA levels;	chr2:43397939	chr2:43227210~43228855:+
LUAD	cis	rs6142102	1	rs4911414	ENSG00000275784.1	RP5-1125A11.6	-4.34	1.74e-05	0.00317	-0.22	-0.19	Skin pigmentation;	chr20:34141638	chr20:33989480~33991818:-
LUAD	cis	rs454217	0.846	rs337663	ENSG00000277851.1	RP11-756G20.1	-4.34	1.74e-05	0.00317	-0.2	-0.19	Smoking quantity;	chr12:92311428	chr12:92247756~92363832:-
LUAD	cis	rs4908768	0.52	rs6695867	ENSG00000270282.1	RP5-1115A15.2	4.34	1.74e-05	0.00317	0.21	0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8670720	chr1:8512653~8513021:+
LUAD	cis	rs748404	0.697	rs574065	ENSG00000249839.1	AC011330.5	4.34	1.74e-05	0.00317	0.24	0.19	Lung cancer;	chr15:43258457	chr15:43663654~43684339:-
LUAD	cis	rs9815354	1	rs1612124	ENSG00000273328.4	RP11-141M3.6	4.34	1.74e-05	0.00317	0.29	0.19	Pulse pressure;Diastolic blood pressure;	chr3:41926401	chr3:42809414~42908105:+
LUAD	cis	rs9815354	1	rs1716644	ENSG00000273328.4	RP11-141M3.6	4.34	1.74e-05	0.00317	0.29	0.19	Pulse pressure;Diastolic blood pressure;	chr3:41926536	chr3:42809414~42908105:+
LUAD	cis	rs9815354	1	rs1716987	ENSG00000273328.4	RP11-141M3.6	4.34	1.74e-05	0.00317	0.29	0.19	Pulse pressure;Diastolic blood pressure;	chr3:41929024	chr3:42809414~42908105:+
LUAD	cis	rs9815354	1	rs1716993	ENSG00000273328.4	RP11-141M3.6	4.34	1.74e-05	0.00317	0.29	0.19	Pulse pressure;Diastolic blood pressure;	chr3:41933064	chr3:42809414~42908105:+
LUAD	cis	rs9815354	0.868	rs1716653	ENSG00000273328.4	RP11-141M3.6	4.34	1.74e-05	0.00317	0.29	0.19	Pulse pressure;Diastolic blood pressure;	chr3:41934106	chr3:42809414~42908105:+
LUAD	cis	rs9815354	1	rs3934103	ENSG00000273328.4	RP11-141M3.6	4.34	1.74e-05	0.00317	0.29	0.19	Pulse pressure;Diastolic blood pressure;	chr3:41935722	chr3:42809414~42908105:+
LUAD	cis	rs17508449	0.819	rs17359468	ENSG00000232450.1	RP4-730K3.3	-4.34	1.74e-05	0.00317	-0.34	-0.19	Leprosy;	chr1:113700084	chr1:113698884~113699631:-
LUAD	cis	rs9322193	0.923	rs56397000	ENSG00000268592.3	RAET1E-AS1	4.34	1.74e-05	0.00317	0.24	0.19	Lung cancer;	chr6:149739347	chr6:149863494~149919507:+
LUAD	cis	rs750134	0.786	rs78063826	ENSG00000257221.1	RP11-689B22.2	-4.34	1.74e-05	0.00317	-0.3	-0.19	Low high density lipoprotein cholesterol levels;	chr12:108638656	chr12:108628687~108641318:+
LUAD	cis	rs11874381	0.931	rs7236198	ENSG00000266696.1	RP11-30L3.2	-4.34	1.74e-05	0.00317	-0.21	-0.19	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);	chr18:49690074	chr18:49205912~49208781:+
LUAD	cis	rs11874381	0.93	rs62101784	ENSG00000266696.1	RP11-30L3.2	-4.34	1.74e-05	0.00317	-0.21	-0.19	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);	chr18:49690514	chr18:49205912~49208781:+
LUAD	cis	rs8062405	0.723	rs4788077	ENSG00000251417.2	RP11-1348G14.4	-4.34	1.74e-05	0.00317	-0.2	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28802743~28817828:+
LUAD	cis	rs8062405	0.755	rs2077031	ENSG00000261419.1	RP11-57A19.4	-4.34	1.74e-05	0.00317	-0.21	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28591847	chr16:28659696~28740781:-
LUAD	cis	rs1799949	0.93	rs4584865	ENSG00000236383.6	LINC00854	-4.34	1.74e-05	0.00317	-0.16	-0.19	Menopause (age at onset);	chr17:43347551	chr17:43216941~43305976:-
LUAD	cis	rs4372836	0.897	rs6707130	ENSG00000226833.4	AC097724.3	4.34	1.74e-05	0.00317	0.22	0.19	Body mass index;	chr2:28750410	chr2:28708953~28736205:-
LUAD	cis	rs9425766	0.628	rs6425274	ENSG00000227373.4	RP11-160H22.5	4.34	1.74e-05	0.00317	0.24	0.19	Life satisfaction;	chr1:174144270	chr1:174115300~174160004:-
LUAD	cis	rs9425766	0.566	rs6696076	ENSG00000227373.4	RP11-160H22.5	4.34	1.74e-05	0.00317	0.24	0.19	Life satisfaction;	chr1:174149900	chr1:174115300~174160004:-
LUAD	cis	rs77688320	0.517	rs2270315	ENSG00000213090.2	AC007256.5	4.34	1.74e-05	0.00317	0.22	0.19	Breast cancer;	chr2:201452542	chr2:201410544~201413308:-
LUAD	cis	rs77688320	0.517	rs2287054	ENSG00000213090.2	AC007256.5	4.34	1.74e-05	0.00317	0.22	0.19	Breast cancer;	chr2:201454315	chr2:201410544~201413308:-
LUAD	cis	rs77688320	0.5	rs10931948	ENSG00000213090.2	AC007256.5	4.34	1.74e-05	0.00317	0.22	0.19	Breast cancer;	chr2:201459199	chr2:201410544~201413308:-
LUAD	cis	rs7302981	0.967	rs35998534	ENSG00000200428.1	Y_RNA	-4.34	1.74e-05	0.00317	-0.24	-0.19	Systolic blood pressure;	chr12:50162999	chr12:50743568~50743684:+
LUAD	cis	rs853679	0.517	rs4711164	ENSG00000226314.6	ZNF192P1	-4.34	1.74e-05	0.00317	-0.26	-0.19	Depression;	chr6:28147378	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs4711165	ENSG00000226314.6	ZNF192P1	-4.34	1.74e-05	0.00317	-0.26	-0.19	Depression;	chr6:28147406	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs4713148	ENSG00000226314.6	ZNF192P1	-4.34	1.74e-05	0.00317	-0.26	-0.19	Depression;	chr6:28148143	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs9348794	ENSG00000226314.6	ZNF192P1	-4.34	1.74e-05	0.00317	-0.26	-0.19	Depression;	chr6:28149979	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs9468297	ENSG00000226314.6	ZNF192P1	-4.34	1.74e-05	0.00317	-0.26	-0.19	Depression;	chr6:28151096	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs9295758	ENSG00000226314.6	ZNF192P1	-4.34	1.74e-05	0.00317	-0.26	-0.19	Depression;	chr6:28152885	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs17774663	ENSG00000226314.6	ZNF192P1	-4.34	1.74e-05	0.00317	-0.26	-0.19	Depression;	chr6:28153120	chr6:28161781~28169594:+
LUAD	cis	rs6840360	1	rs10049991	ENSG00000270265.1	RP11-731D1.4	-4.34	1.74e-05	0.00317	-0.2	-0.19	Intelligence (multi-trait analysis);	chr4:151743011	chr4:151333775~151353224:-
LUAD	cis	rs801193	0.742	rs9969300	ENSG00000273142.1	RP11-458F8.4	4.34	1.74e-05	0.00318	0.14	0.19	Aortic root size;	chr7:66316659	chr7:66902857~66906297:+
LUAD	cis	rs6012564	0.964	rs73266241	ENSG00000230758.1	SNAP23P	4.34	1.74e-05	0.00318	0.21	0.19	Anger;	chr20:49043748	chr20:49038357~49038602:-
LUAD	cis	rs4667682	0.529	rs17285541	ENSG00000234061.1	AC007969.4	-4.34	1.74e-05	0.00318	-0.38	-0.19	Hippocampal atrophy;Body mass index;	chr2:171362887	chr2:171492905~171493095:+
LUAD	cis	rs6496932	0.865	rs10520600	ENSG00000202081.1	RNU6-1280P	4.34	1.74e-05	0.00318	0.29	0.19	Central corneal thickness;Corneal structure;	chr15:85365171	chr15:85651522~85651628:-
LUAD	cis	rs8030379	1	rs4842924	ENSG00000230373.7	GOLGA6L5P	4.34	1.74e-05	0.00318	0.18	0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83918855	chr15:84507885~84516814:-
LUAD	cis	rs17772222	0.701	rs1627444	ENSG00000258789.1	RP11-507K2.3	4.34	1.74e-05	0.00318	0.24	0.19	Coronary artery calcification;	chr14:88413784	chr14:88551597~88552493:+
LUAD	cis	rs160451	0.933	rs218888	ENSG00000251136.7	RP11-37B2.1	-4.34	1.74e-05	0.00318	-0.2	-0.19	Leprosy;	chr8:89679693	chr8:89609409~89757727:-
LUAD	cis	rs2731006	0.543	rs908666	ENSG00000257114.2	RP11-25I15.3	4.34	1.74e-05	0.00318	0.29	0.19	Panic disorder;	chr12:42815567	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.591	rs11181697	ENSG00000257114.2	RP11-25I15.3	4.34	1.74e-05	0.00318	0.29	0.19	Panic disorder;	chr12:42816666	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.591	rs10880365	ENSG00000257114.2	RP11-25I15.3	4.34	1.74e-05	0.00318	0.29	0.19	Panic disorder;	chr12:42816805	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.591	rs10880366	ENSG00000257114.2	RP11-25I15.3	4.34	1.74e-05	0.00318	0.29	0.19	Panic disorder;	chr12:42816935	chr12:42692216~42717119:+
LUAD	cis	rs473651	0.935	rs540636	ENSG00000229915.1	AC016999.2	-4.34	1.74e-05	0.00318	-0.26	-0.19	Multiple system atrophy;	chr2:238449700	chr2:238427077~238427729:-
LUAD	cis	rs9425766	0.54	rs2294492	ENSG00000227373.4	RP11-160H22.5	4.34	1.74e-05	0.00318	0.24	0.19	Life satisfaction;	chr1:174157884	chr1:174115300~174160004:-
LUAD	cis	rs2243480	0.522	rs73150635	ENSG00000232559.3	GS1-124K5.12	4.34	1.74e-05	0.00318	0.4	0.19	Diabetic kidney disease;	chr7:66507503	chr7:66554588~66576923:-
LUAD	cis	rs12579720	0.859	rs10770611	ENSG00000255910.1	RP11-405A12.2	4.34	1.74e-05	0.00318	0.25	0.19	Diastolic blood pressure;	chr12:20056442	chr12:19775451~20009937:+
LUAD	cis	rs7829975	0.742	rs12547493	ENSG00000233609.3	RP11-62H7.2	-4.34	1.74e-05	0.00318	-0.16	-0.19	Mood instability;	chr8:8804024	chr8:8961200~8979025:+
LUAD	cis	rs780096	0.546	rs6547626	ENSG00000234072.1	AC074117.10	-4.34	1.74e-05	0.00318	-0.15	-0.19	Total body bone mineral density;	chr2:27423903	chr2:27356246~27367622:+
LUAD	cis	rs73242632	0.867	rs4596307	ENSG00000269949.1	RP11-738E22.3	4.34	1.74e-05	0.00318	0.52	0.19	Congenital heart disease (maternal effect);	chr4:57066008	chr4:56960927~56961373:-
LUAD	cis	rs14027	1	rs14027	ENSG00000279347.1	RP11-85I17.2	-4.34	1.75e-05	0.00318	-0.17	-0.19	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119834349	chr8:119838736~119840385:-
LUAD	cis	rs2337406	0.866	rs4773949	ENSG00000223648.3	IGHV3-64	-4.34	1.75e-05	0.00318	-0.22	-0.19	Alzheimer's disease (late onset);	chr14:106808070	chr14:106643132~106658258:-
LUAD	cis	rs2548724	0.509	rs1580038	ENSG00000250682.4	LINC00491	4.34	1.75e-05	0.00318	0.23	0.19	Type 2 diabetes;	chr5:102382180	chr5:102609156~102671559:-
LUAD	cis	rs6539288	0.901	rs11113143	ENSG00000260329.1	RP11-412D9.4	-4.34	1.75e-05	0.00318	-0.21	-0.19	Total body bone mineral density;	chr12:106910081	chr12:106954029~106955497:-
LUAD	cis	rs34792	0.554	rs12919246	ENSG00000207425.1	Y_RNA	-4.34	1.75e-05	0.00318	-0.24	-0.19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15533103	chr16:14915457~14915556:-
LUAD	cis	rs10971721	0.822	rs10971791	ENSG00000260947.1	RP11-384P7.7	4.34	1.75e-05	0.00318	0.4	0.19	Body mass index;	chr9:33920912	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs10971792	ENSG00000260947.1	RP11-384P7.7	4.34	1.75e-05	0.00318	0.4	0.19	Body mass index;	chr9:33920955	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs72727329	ENSG00000260947.1	RP11-384P7.7	4.34	1.75e-05	0.00318	0.4	0.19	Body mass index;	chr9:33921666	chr9:33697459~33700986:+
LUAD	cis	rs9926296	0.715	rs2115401	ENSG00000260259.1	RP11-368I7.4	-4.34	1.75e-05	0.00318	-0.18	-0.19	Vitiligo;	chr16:89674201	chr16:89682620~89686569:-
LUAD	cis	rs987710	0.568	rs5757077	ENSG00000211639.2	IGLV4-60	-4.34	1.75e-05	0.00318	-0.27	-0.19	Iron status biomarkers;Iron deficiency;	chr22:22145518	chr22:22162199~22162681:+
LUAD	cis	rs4937333	0.584	rs4937331	ENSG00000254703.2	SENCR	-4.34	1.75e-05	0.00318	-0.21	-0.19	Plateletcrit;Platelet count;	chr11:128455833	chr11:128691672~128696023:-
LUAD	cis	rs853679	0.607	rs56075693	ENSG00000219392.1	RP1-265C24.5	-4.34	1.75e-05	0.00319	-0.43	-0.19	Depression;	chr6:28322551	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.607	rs34218844	ENSG00000219392.1	RP1-265C24.5	-4.34	1.75e-05	0.00319	-0.43	-0.19	Depression;	chr6:28322870	chr6:28115628~28116551:+
LUAD	cis	rs9322193	0.923	rs4242279	ENSG00000268592.3	RAET1E-AS1	4.34	1.75e-05	0.00319	0.24	0.19	Lung cancer;	chr6:149839815	chr6:149863494~149919507:+
LUAD	cis	rs42490	0.546	rs160437	ENSG00000251136.7	RP11-37B2.1	4.34	1.75e-05	0.00319	0.2	0.19	Leprosy;	chr8:89669656	chr8:89609409~89757727:-
LUAD	cis	rs17301013	0.932	rs6425280	ENSG00000227373.4	RP11-160H22.5	4.34	1.75e-05	0.00319	0.24	0.19	Systemic lupus erythematosus;	chr1:174422186	chr1:174115300~174160004:-
LUAD	cis	rs10266483	0.774	rs4718067	ENSG00000227986.1	TRIM60P18	-4.34	1.75e-05	0.00319	-0.24	-0.19	Response to statin therapy;	chr7:64356018	chr7:64355078~64356199:+
LUAD	cis	rs2880765	0.835	rs4526974	ENSG00000259416.2	RP11-158M2.5	4.34	1.75e-05	0.00319	0.2	0.19	Coronary artery disease;	chr15:85481053	chr15:85754941~85756237:-
LUAD	cis	rs72772090	1	rs56116814	ENSG00000248734.2	CTD-2260A17.1	-4.34	1.75e-05	0.00319	-0.28	-0.19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96713010	chr5:96784777~96785999:+
LUAD	cis	rs17772222	0.682	rs4904452	ENSG00000258789.1	RP11-507K2.3	4.34	1.75e-05	0.00319	0.23	0.19	Coronary artery calcification;	chr14:88517329	chr14:88551597~88552493:+
LUAD	cis	rs699371	0.525	rs7140692	ENSG00000270000.1	RP3-449M8.9	4.34	1.75e-05	0.00319	0.21	0.19	Height;	chr14:74434484	chr14:74471930~74472360:-
LUAD	cis	rs6570726	1	rs1935617	ENSG00000235652.6	RP11-545I5.3	4.34	1.75e-05	0.00319	0.2	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145622190	chr6:145799409~145886585:+
LUAD	cis	rs4664293	0.967	rs1006192	ENSG00000230783.1	AC009961.2	-4.34	1.75e-05	0.00319	-0.24	-0.19	Monocyte percentage of white cells;	chr2:159711078	chr2:159689217~159690291:-
LUAD	cis	rs9287719	0.967	rs7570118	ENSG00000243819.4	RN7SL832P	4.34	1.75e-05	0.00319	0.21	0.19	Prostate cancer;	chr2:10577881	chr2:10690344~10692099:+
LUAD	cis	rs10129255	1	rs4612959	ENSG00000211967.3	IGHV3-53	-4.34	1.75e-05	0.00319	-0.15	-0.19	Kawasaki disease;	chr14:106767055	chr14:106592676~106593347:-
LUAD	cis	rs7200786	0.546	rs11642542	ENSG00000274038.1	RP11-66H6.4	-4.34	1.75e-05	0.00319	-0.25	-0.19	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11118197	chr16:11056556~11057034:+
LUAD	cis	rs8098244	0.603	rs2337186	ENSG00000264745.1	TTC39C-AS1	4.34	1.75e-05	0.00319	0.2	0.19	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23732088	chr18:23994213~24015339:-
LUAD	cis	rs10129255	0.957	rs8009638	ENSG00000274576.2	IGHV2-70	4.34	1.75e-05	0.00319	0.17	0.19	Kawasaki disease;	chr14:106777570	chr14:106770577~106771020:-
LUAD	cis	rs8062405	0.824	rs28698667	ENSG00000251417.2	RP11-1348G14.4	-4.34	1.75e-05	0.00319	-0.2	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28802743~28817828:+
LUAD	cis	rs1005277	0.579	rs2504148	ENSG00000263064.2	RP11-291L22.7	4.34	1.75e-05	0.00319	0.21	0.19	Extrinsic epigenetic age acceleration;	chr10:38111860	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.579	rs176886	ENSG00000263064.2	RP11-291L22.7	4.34	1.75e-05	0.00319	0.21	0.19	Extrinsic epigenetic age acceleration;	chr10:38115046	chr10:38448689~38448949:+
LUAD	cis	rs11051970	0.592	rs7132235	ENSG00000274964.1	RP11-817I4.1	-4.34	1.75e-05	0.00319	-0.26	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr12:32383369	chr12:32339368~32340724:+
LUAD	cis	rs6860806	0.661	rs2171247	ENSG00000233006.5	AC034220.3	4.34	1.75e-05	0.00319	0.17	0.19	Breast cancer;	chr5:132244541	chr5:132311285~132369916:-
LUAD	cis	rs595244	1	rs591519	ENSG00000259705.1	RP11-227D13.1	4.34	1.75e-05	0.00319	0.39	0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48602003	chr15:48645951~48652016:+
LUAD	cis	rs10863681	0.664	rs10863680	ENSG00000227925.1	RP11-191N8.2	-4.34	1.75e-05	0.0032	-0.24	-0.19	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222071538	chr1:221827666~221840666:-
LUAD	cis	rs4683346	0.616	rs3846063	ENSG00000173811.9	CCDC13-AS1	4.34	1.75e-05	0.0032	0.22	0.19	Granulocyte percentage of myeloid white cells;	chr3:42762336	chr3:42732575~42746768:+
LUAD	cis	rs3808502	0.503	rs34190028	ENSG00000255046.1	RP11-297N6.4	4.34	1.75e-05	0.0032	0.24	0.19	Neuroticism;	chr8:11559641	chr8:11797928~11802568:-
LUAD	cis	rs6012564	1	rs2426116	ENSG00000230758.1	SNAP23P	-4.34	1.75e-05	0.0032	-0.2	-0.19	Anger;	chr20:49076510	chr20:49038357~49038602:-
LUAD	cis	rs6802315	0.604	rs4680467	ENSG00000272087.1	RP11-379F4.7	4.34	1.75e-05	0.0032	0.21	0.19	Periodontitis (CDC/AAP);	chr3:158782988	chr3:158693120~158693768:-
LUAD	cis	rs7119	0.634	rs2682922	ENSG00000259362.2	RP11-307C19.1	4.34	1.75e-05	0.0032	0.24	0.19	Type 2 diabetes;	chr15:77572664	chr15:77525540~77534110:+
LUAD	cis	rs12701220	0.947	rs1007765	ENSG00000229043.2	AC091729.9	-4.34	1.76e-05	0.0032	-0.27	-0.19	Bronchopulmonary dysplasia;	chr7:993169	chr7:1160374~1165267:+
LUAD	cis	rs13113518	1	rs7660980	ENSG00000272969.1	RP11-528I4.2	-4.34	1.76e-05	0.0032	-0.2	-0.19	Height;	chr4:55542948	chr4:55547112~55547889:+
LUAD	cis	rs4819052	0.851	rs2838843	ENSG00000237664.1	LINC00316	-4.34	1.76e-05	0.0032	-0.24	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249369	chr21:45338590~45341990:-
LUAD	cis	rs36093844	0.642	rs7934759	ENSG00000279742.1	RP11-700A24.1	-4.34	1.76e-05	0.0032	-0.2	-0.19	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85902826	chr11:85852557~85854943:-
LUAD	cis	rs2790457	0.771	rs2800737	ENSG00000254635.4	WAC-AS1	-4.34	1.76e-05	0.0032	-0.2	-0.19	Multiple myeloma;	chr10:28654143	chr10:28522652~28532743:-
LUAD	cis	rs2289583	0.544	rs6495132	ENSG00000261813.2	RP11-151H2.3	4.34	1.76e-05	0.0032	0.21	0.19	Systemic lupus erythematosus;	chr15:74962981	chr15:74976240~74976573:-
LUAD	cis	rs4568518	0.74	rs11543650	ENSG00000279048.1	RP11-511H23.2	4.34	1.76e-05	0.0032	0.16	0.19	Measles;	chr7:17970257	chr7:17940503~17942922:+
LUAD	cis	rs73242632	0.881	rs7654665	ENSG00000269949.1	RP11-738E22.3	4.34	1.76e-05	0.0032	0.49	0.19	Congenital heart disease (maternal effect);	chr4:57057608	chr4:56960927~56961373:-
LUAD	cis	rs8072100	0.575	rs1221385	ENSG00000228782.6	CTD-2026D20.3	4.34	1.76e-05	0.0032	0.21	0.19	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47450208	chr17:47450568~47492492:-
LUAD	cis	rs17772222	0.682	rs8017689	ENSG00000258789.1	RP11-507K2.3	-4.34	1.76e-05	0.00321	-0.24	-0.19	Coronary artery calcification;	chr14:88483442	chr14:88551597~88552493:+
LUAD	cis	rs9500256	0.655	rs12191043	ENSG00000266579.1	RP1-71H19.2	-4.34	1.76e-05	0.00321	-0.26	-0.19	Eosinophilic esophagitis (pediatric);	chr6:58020205	chr6:57493855~57497691:+
LUAD	cis	rs6754311	0.773	rs1435576	ENSG00000226806.1	AC011893.3	4.34	1.76e-05	0.00321	0.24	0.19	Mosquito bite size;	chr2:135884312	chr2:135820191~135823087:+
LUAD	cis	rs910316	1	rs4903281	ENSG00000279594.1	RP11-950C14.10	4.34	1.76e-05	0.00321	0.22	0.19	Height;	chr14:75087658	chr14:75011269~75012851:-
LUAD	cis	rs73186030	0.764	rs6438725	ENSG00000272758.4	RP11-299J3.8	4.34	1.76e-05	0.00321	0.26	0.19	Serum parathyroid hormone levels;	chr3:122369259	chr3:122416207~122443180:+
LUAD	cis	rs73186030	0.764	rs9881201	ENSG00000272758.4	RP11-299J3.8	4.34	1.76e-05	0.00321	0.26	0.19	Serum parathyroid hormone levels;	chr3:122375838	chr3:122416207~122443180:+
LUAD	cis	rs1355223	0.902	rs11603774	ENSG00000271369.1	RP11-350D17.3	-4.34	1.76e-05	0.00321	-0.23	-0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34711344	chr11:34709600~34710161:+
LUAD	cis	rs1799955	0.935	rs7337784	ENSG00000215515.2	IFIT1P1	-4.34	1.76e-05	0.00321	-0.28	-0.19	LDL cholesterol levels;	chr13:32383835	chr13:32384660~32386108:+
LUAD	cis	rs2236295	0.513	rs2393934	ENSG00000238280.1	RP11-436D10.3	-4.34	1.76e-05	0.00321	-0.24	-0.19	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr10:62885433	chr10:62793562~62805887:-
LUAD	cis	rs13113518	1	rs13133579	ENSG00000272969.1	RP11-528I4.2	4.34	1.76e-05	0.00321	0.2	0.19	Height;	chr4:55459921	chr4:55547112~55547889:+
LUAD	cis	rs6603134	0.502	rs10406540	ENSG00000267939.1	CTD-2325M2.1	-4.34	1.76e-05	0.00321	-0.23	-0.19	Blood protein levels;	chr19:8039113	chr19:8008729~8016025:+
LUAD	cis	rs987710	0.568	rs2213160	ENSG00000211639.2	IGLV4-60	-4.34	1.76e-05	0.00321	-0.27	-0.19	Iron status biomarkers;Iron deficiency;	chr22:22142704	chr22:22162199~22162681:+
LUAD	cis	rs2153535	0.561	rs9405404	ENSG00000230939.1	RP11-314C16.1	-4.34	1.76e-05	0.00321	-0.22	-0.19	Motion sickness;	chr6:8646583	chr6:8784178~8785445:+
LUAD	cis	rs17301013	0.932	rs6664764	ENSG00000227373.4	RP11-160H22.5	4.34	1.76e-05	0.00321	0.24	0.19	Systemic lupus erythematosus;	chr1:174443402	chr1:174115300~174160004:-
LUAD	cis	rs9341808	0.69	rs3805926	ENSG00000260645.1	RP11-250B2.5	4.34	1.76e-05	0.00321	0.18	0.19	Sitting height ratio;	chr6:80169563	chr6:80466958~80469080:+
LUAD	cis	rs8062405	0.723	rs62031562	ENSG00000261419.1	RP11-57A19.4	-4.34	1.76e-05	0.00321	-0.22	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28598008	chr16:28659696~28740781:-
LUAD	cis	rs42490	0.506	rs160429	ENSG00000251136.7	RP11-37B2.1	4.34	1.76e-05	0.00321	0.2	0.19	Leprosy;	chr8:89661255	chr8:89609409~89757727:-
LUAD	cis	rs202072	0.729	rs202030	ENSG00000272379.1	RP1-257A7.5	4.34	1.76e-05	0.00321	0.33	0.19	HIV-1 viral setpoint;	chr6:13291920	chr6:13290018~13290490:-
LUAD	cis	rs11779988	0.545	rs436506	ENSG00000253671.1	RP11-806O11.1	4.34	1.77e-05	0.00321	0.24	0.19	Breast cancer;	chr8:17940734	chr8:17808941~17820868:+
LUAD	cis	rs9322193	0.607	rs4869755	ENSG00000268592.3	RAET1E-AS1	4.34	1.77e-05	0.00321	0.29	0.19	Lung cancer;	chr6:149886347	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.639	rs4869756	ENSG00000268592.3	RAET1E-AS1	4.34	1.77e-05	0.00321	0.29	0.19	Lung cancer;	chr6:149886360	chr6:149863494~149919507:+
LUAD	cis	rs7196129	0.966	rs12598978	ENSG00000183604.13	SMG1P5	4.34	1.77e-05	0.00322	0.2	0.19	Monocyte count;	chr16:30471219	chr16:30267553~30335374:-
LUAD	cis	rs780094	0.564	rs4665978	ENSG00000234072.1	AC074117.10	-4.34	1.77e-05	0.00322	-0.15	-0.19	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27425859	chr2:27356246~27367622:+
LUAD	cis	rs11512640	1	rs11220120	ENSG00000254671.2	STT3A-AS1	4.34	1.77e-05	0.00322	0.43	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125529894	chr11:125570284~125592568:-
LUAD	cis	rs34792	0.554	rs4597346	ENSG00000275910.1	RP11-680G24.6	-4.34	1.77e-05	0.00322	-0.19	-0.19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15529889	chr16:15015828~15016390:-
LUAD	cis	rs4819052	0.655	rs2330102	ENSG00000237664.1	LINC00316	-4.34	1.77e-05	0.00322	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45271053	chr21:45338590~45341990:-
LUAD	cis	rs7616559	0.512	rs9818874	ENSG00000240875.4	LINC00886	-4.34	1.77e-05	0.00322	-0.21	-0.19	Carotid artery intima media thickness (sex interaction);	chr3:157012352	chr3:156747346~156817062:-
LUAD	cis	rs9400467	0.528	rs458486	ENSG00000230177.1	RP5-1112D6.4	-4.34	1.77e-05	0.00322	-0.17	-0.19	Amino acid levels;Blood metabolite levels;	chr6:111375649	chr6:111277932~111278742:+
LUAD	cis	rs5769707	0.846	rs5770610	ENSG00000235111.1	RP1-29C18.8	-4.34	1.77e-05	0.00322	-0.21	-0.19	Monocyte percentage of white cells;Monocyte count;	chr22:49643249	chr22:49612657~49615716:-
LUAD	cis	rs3770081	1	rs17584578	ENSG00000273080.1	RP11-301O19.1	4.34	1.77e-05	0.00322	0.43	0.19	Facial emotion recognition (sad faces);	chr2:86080501	chr2:86195590~86196049:+
LUAD	cis	rs6686842	0.56	rs60351276	ENSG00000235358.1	RP11-399E6.1	-4.34	1.77e-05	0.00322	-0.23	-0.19	Height;	chr1:41202879	chr1:41242373~41284861:+
LUAD	cis	rs865483	0.895	rs878520	ENSG00000276054.1	RP11-378E13.3	-4.34	1.77e-05	0.00322	-0.23	-0.19	Monocyte count;	chr17:37402018	chr17:37386886~37387926:+
LUAD	cis	rs7061710	0.673	rs2272799	ENSG00000271811.1	RP1-79C4.4	-4.34	1.77e-05	0.00322	-0.29	-0.19	Blood metabolite levels;	chr1:171149909	chr1:170667381~170669425:+
LUAD	cis	rs7061710	0.664	rs7885569	ENSG00000271811.1	RP1-79C4.4	-4.34	1.77e-05	0.00322	-0.29	-0.19	Blood metabolite levels;	chr1:171150025	chr1:170667381~170669425:+
LUAD	cis	rs34783982	0.881	rs34031857	ENSG00000261441.1	RP11-217B1.2	-4.34	1.77e-05	0.00322	-0.26	-0.19	Squamous cell lung carcinoma;	chr15:88957329	chr15:89335053~89336161:+
LUAD	cis	rs7819412	0.74	rs11250119	ENSG00000255046.1	RP11-297N6.4	4.34	1.77e-05	0.00322	0.22	0.19	Triglycerides;	chr8:11179525	chr8:11797928~11802568:-
LUAD	cis	rs6723108	0.603	rs12469411	ENSG00000224043.6	CCNT2-AS1	-4.34	1.77e-05	0.00323	-0.24	-0.19	Type 2 diabetes;	chr2:134906986	chr2:134735464~134918710:-
LUAD	cis	rs755249	0.727	rs2242500	ENSG00000228060.1	RP11-69E11.8	-4.34	1.77e-05	0.00323	-0.17	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572230	chr1:39565160~39573203:+
LUAD	cis	rs7204230	1	rs11859353	ENSG00000261291.1	RP11-295M3.2	4.34	1.77e-05	0.00323	0.24	0.19	Fibrinogen;	chr16:53333699	chr16:53168522~53169450:+
LUAD	cis	rs210138	1	rs210138	ENSG00000197251.3	LINC00336	-4.34	1.77e-05	0.00323	-0.3	-0.19	Testicular germ cell tumor;	chr6:33574761	chr6:33586106~33593338:-
LUAD	cis	rs1707322	0.613	rs1473840	ENSG00000234329.1	RP11-767N6.2	-4.34	1.77e-05	0.00323	-0.2	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46135525	chr1:45651039~45651826:-
LUAD	cis	rs8062405	0.754	rs3859172	ENSG00000261419.1	RP11-57A19.4	-4.34	1.77e-05	0.00323	-0.21	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28659696~28740781:-
LUAD	cis	rs4460629	0.712	rs11264313	ENSG00000160766.13	GBAP1	-4.34	1.77e-05	0.00323	-0.2	-0.19	Serum magnesium levels;	chr1:155104029	chr1:155213821~155227422:-
LUAD	cis	rs17685	0.784	rs1637043	ENSG00000280388.1	RP11-229D13.3	-4.34	1.77e-05	0.00323	-0.18	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76069781	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.753	rs1639617	ENSG00000280388.1	RP11-229D13.3	-4.34	1.77e-05	0.00323	-0.18	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76072410	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.672	rs1639618	ENSG00000280388.1	RP11-229D13.3	-4.34	1.77e-05	0.00323	-0.18	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76072669	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.753	rs1637044	ENSG00000280388.1	RP11-229D13.3	-4.34	1.77e-05	0.00323	-0.18	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76074426	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.712	rs1639620	ENSG00000280388.1	RP11-229D13.3	-4.34	1.77e-05	0.00323	-0.18	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76074772	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.753	rs11982200	ENSG00000280388.1	RP11-229D13.3	-4.34	1.77e-05	0.00323	-0.18	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76085565	chr7:76043977~76045963:-
LUAD	cis	rs2562456	0.833	rs55920089	ENSG00000268081.1	RP11-678G14.2	4.34	1.78e-05	0.00323	0.31	0.19	Pain;	chr19:21337891	chr19:21554640~21569237:-
LUAD	cis	rs7201929	0.959	rs35725751	ENSG00000251417.2	RP11-1348G14.4	4.34	1.78e-05	0.00323	0.24	0.19	QT interval;	chr16:28834263	chr16:28802743~28817828:+
LUAD	cis	rs13113518	1	rs13146987	ENSG00000272969.1	RP11-528I4.2	4.33	1.78e-05	0.00323	0.2	0.19	Height;	chr4:55491628	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs7677085	ENSG00000272969.1	RP11-528I4.2	4.33	1.78e-05	0.00323	0.2	0.19	Height;	chr4:55495801	chr4:55547112~55547889:+
LUAD	cis	rs13113518	0.966	rs12510681	ENSG00000272969.1	RP11-528I4.2	4.33	1.78e-05	0.00323	0.2	0.19	Height;	chr4:55496737	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs12500162	ENSG00000272969.1	RP11-528I4.2	4.33	1.78e-05	0.00323	0.2	0.19	Height;	chr4:55496933	chr4:55547112~55547889:+
LUAD	cis	rs763567	0.935	rs2988392	ENSG00000271811.1	RP1-79C4.4	4.33	1.78e-05	0.00323	0.23	0.19	Tonsillectomy;	chr1:170647214	chr1:170667381~170669425:+
LUAD	cis	rs11874381	0.965	rs62101775	ENSG00000266696.1	RP11-30L3.2	-4.33	1.78e-05	0.00323	-0.21	-0.19	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);	chr18:49683693	chr18:49205912~49208781:+
LUAD	cis	rs651907	0.535	rs17412601	ENSG00000244119.1	PDCL3P4	4.33	1.78e-05	0.00323	0.19	0.19	Colorectal cancer;	chr3:101780431	chr3:101712472~101713191:+
LUAD	cis	rs848490	0.926	rs17807580	ENSG00000214293.7	APTR	4.33	1.78e-05	0.00324	0.26	0.19	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77829461	chr7:77657660~77696265:-
LUAD	cis	rs2998286	1	rs2998286	ENSG00000254635.4	WAC-AS1	-4.33	1.78e-05	0.00324	-0.23	-0.19	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28491444	chr10:28522652~28532743:-
LUAD	cis	rs56114371	0.777	rs200481	ENSG00000219392.1	RP1-265C24.5	-4.33	1.78e-05	0.00324	-0.34	-0.19	Breast cancer;	chr6:27806054	chr6:28115628~28116551:+
LUAD	cis	rs2735413	0.563	rs17776016	ENSG00000276007.1	RP11-358L22.3	-4.33	1.78e-05	0.00324	-0.27	-0.19	Systolic blood pressure (alcohol consumption interaction);	chr16:78013920	chr16:78123243~78124332:+
LUAD	cis	rs3743772	0.5	rs62048485	ENSG00000279722.1	RP11-44F14.6	4.33	1.78e-05	0.00324	0.27	0.19	Depressive symptoms (SSRI exposure interaction);	chr16:53414065	chr16:53487607~53489943:-
LUAD	cis	rs750134	0.818	rs55873675	ENSG00000257221.1	RP11-689B22.2	-4.33	1.78e-05	0.00324	-0.28	-0.19	Low high density lipoprotein cholesterol levels;	chr12:108640389	chr12:108628687~108641318:+
LUAD	cis	rs8180040	0.62	rs56217494	ENSG00000271161.1	BOLA2P2	-4.33	1.78e-05	0.00324	-0.19	-0.19	Colorectal cancer;	chr3:47006962	chr3:47499841~47500407:+
LUAD	cis	rs10971721	0.822	rs10971773	ENSG00000260947.1	RP11-384P7.7	4.33	1.78e-05	0.00324	0.4	0.19	Body mass index;	chr9:33898781	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs10971774	ENSG00000260947.1	RP11-384P7.7	4.33	1.78e-05	0.00324	0.4	0.19	Body mass index;	chr9:33900111	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs72727318	ENSG00000260947.1	RP11-384P7.7	4.33	1.78e-05	0.00324	0.4	0.19	Body mass index;	chr9:33901802	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.731	rs10971782	ENSG00000260947.1	RP11-384P7.7	4.33	1.78e-05	0.00324	0.4	0.19	Body mass index;	chr9:33909466	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.908	rs10971787	ENSG00000260947.1	RP11-384P7.7	4.33	1.78e-05	0.00324	0.4	0.19	Body mass index;	chr9:33914414	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs72727327	ENSG00000260947.1	RP11-384P7.7	4.33	1.78e-05	0.00324	0.4	0.19	Body mass index;	chr9:33918818	chr9:33697459~33700986:+
LUAD	cis	rs4908768	0.52	rs4908507	ENSG00000270282.1	RP5-1115A15.2	4.33	1.78e-05	0.00324	0.21	0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8678878	chr1:8512653~8513021:+
LUAD	cis	rs17685	0.697	rs28689051	ENSG00000280388.1	RP11-229D13.3	-4.33	1.78e-05	0.00324	-0.18	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76134306	chr7:76043977~76045963:-
LUAD	cis	rs858239	0.67	rs3807452	ENSG00000230042.1	AK3P3	4.33	1.78e-05	0.00324	0.23	0.19	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23129178~23129841:+
LUAD	cis	rs1061377	0.585	rs12648581	ENSG00000249685.1	RP11-360F5.3	4.33	1.79e-05	0.00325	0.23	0.19	Uric acid levels;	chr4:39054024	chr4:39133913~39135608:+
LUAD	cis	rs2880765	0.835	rs7174323	ENSG00000259416.2	RP11-158M2.5	4.33	1.79e-05	0.00325	0.2	0.19	Coronary artery disease;	chr15:85506488	chr15:85754941~85756237:-
LUAD	cis	rs737008	0.96	rs34764020	ENSG00000262703.1	RP11-485G7.6	-4.33	1.79e-05	0.00325	-0.18	-0.19	Obesity-related traits;	chr16:11284502	chr16:11348143~11349321:-
LUAD	cis	rs681343	1	rs516316	ENSG00000232871.7	SEC1P	4.33	1.79e-05	0.00325	0.21	0.19	Primary sclerosing cholangitis;Childhood ear infection;Lung adenocarcinoma;	chr19:48702888	chr19:48638071~48682245:+
LUAD	cis	rs1355223	0.902	rs704744	ENSG00000271369.1	RP11-350D17.3	-4.33	1.79e-05	0.00325	-0.23	-0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34715014	chr11:34709600~34710161:+
LUAD	cis	rs1355223	0.902	rs836466	ENSG00000271369.1	RP11-350D17.3	-4.33	1.79e-05	0.00325	-0.23	-0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34715819	chr11:34709600~34710161:+
LUAD	cis	rs1061377	0.748	rs4974933	ENSG00000249685.1	RP11-360F5.3	4.33	1.79e-05	0.00325	0.23	0.19	Uric acid levels;	chr4:39105636	chr4:39133913~39135608:+
LUAD	cis	rs7172677	0.731	rs1108059	ENSG00000260269.4	CTD-2323K18.1	4.33	1.79e-05	0.00325	0.26	0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75046549	chr15:75527150~75601205:-
LUAD	cis	rs6723108	0.604	rs2322251	ENSG00000224043.6	CCNT2-AS1	-4.33	1.79e-05	0.00325	-0.24	-0.19	Type 2 diabetes;	chr2:134913732	chr2:134735464~134918710:-
LUAD	cis	rs6686842	0.56	rs6672508	ENSG00000235358.1	RP11-399E6.1	4.33	1.79e-05	0.00325	0.23	0.19	Height;	chr1:41200899	chr1:41242373~41284861:+
LUAD	cis	rs11673344	0.504	rs10402907	ENSG00000276846.1	CTD-3220F14.3	4.33	1.79e-05	0.00325	0.21	0.19	Obesity-related traits;	chr19:37112874	chr19:37314868~37315620:-
LUAD	cis	rs853679	0.517	rs9393893	ENSG00000226314.6	ZNF192P1	-4.33	1.79e-05	0.00325	-0.26	-0.19	Depression;	chr6:28141484	chr6:28161781~28169594:+
LUAD	cis	rs6095360	1	rs348276	ENSG00000222365.1	SNORD12B	-4.33	1.79e-05	0.00325	-0.2	-0.19	Intelligence (multi-trait analysis);	chr20:49169653	chr20:49280319~49280409:+
LUAD	cis	rs706293	0.512	rs258221	ENSG00000261360.1	CTD-2165H16.4	-4.33	1.79e-05	0.00325	-0.18	-0.19	Urate levels (BMI interaction);	chr5:14799652	chr5:14661808~14664604:-
LUAD	cis	rs7107174	1	rs7119933	ENSG00000251323.2	RP11-452H21.4	4.33	1.79e-05	0.00325	0.23	0.19	Testicular germ cell tumor;	chr11:78338704	chr11:78423982~78429836:-
LUAD	cis	rs860295	0.557	rs12035524	ENSG00000225855.5	RUSC1-AS1	4.33	1.79e-05	0.00325	0.14	0.19	Body mass index;	chr1:155697311	chr1:155316863~155324176:-
LUAD	cis	rs7893279	0.505	rs7919487	ENSG00000225527.1	RP11-383B4.4	4.33	1.79e-05	0.00325	0.28	0.19	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18579870	chr10:18531849~18533336:-
LUAD	cis	rs6723108	0.627	rs62168872	ENSG00000224043.6	CCNT2-AS1	-4.33	1.79e-05	0.00325	-0.24	-0.19	Type 2 diabetes;	chr2:134904177	chr2:134735464~134918710:-
LUAD	cis	rs6723108	0.627	rs4954196	ENSG00000224043.6	CCNT2-AS1	-4.33	1.79e-05	0.00325	-0.24	-0.19	Type 2 diabetes;	chr2:134904446	chr2:134735464~134918710:-
LUAD	cis	rs6723108	0.592	rs10928523	ENSG00000224043.6	CCNT2-AS1	-4.33	1.79e-05	0.00325	-0.24	-0.19	Type 2 diabetes;	chr2:134907891	chr2:134735464~134918710:-
LUAD	cis	rs6723108	0.627	rs1374288	ENSG00000224043.6	CCNT2-AS1	-4.33	1.79e-05	0.00325	-0.24	-0.19	Type 2 diabetes;	chr2:134909483	chr2:134735464~134918710:-
LUAD	cis	rs11673344	0.667	rs504549	ENSG00000226686.6	LINC01535	4.33	1.79e-05	0.00325	0.25	0.19	Obesity-related traits;	chr19:36946299	chr19:37251912~37265535:+
LUAD	cis	rs7727544	0.507	rs10051679	ENSG00000263597.1	MIR3936	4.33	1.79e-05	0.00325	0.2	0.19	Blood metabolite levels;	chr5:132235238	chr5:132365490~132365599:-
LUAD	cis	rs4811196	0.692	rs753215	ENSG00000226144.2	RPS27AP3	4.33	1.79e-05	0.00326	0.22	0.19	Bone mineral density;	chr20:37869643	chr20:37049254~37049707:+
LUAD	cis	rs9309473	0.519	rs12991161	ENSG00000163016.8	ALMS1P	-4.33	1.79e-05	0.00326	-0.21	-0.19	Metabolite levels;	chr2:73644244	chr2:73644919~73685576:+
LUAD	cis	rs1401999	1	rs6443926	ENSG00000223882.1	ABCC5-AS1	-4.33	1.79e-05	0.00326	-0.2	-0.19	Anterior chamber depth;	chr3:183988842	chr3:184006338~184011419:+
LUAD	cis	rs62025270	0.632	rs7163838	ENSG00000202081.1	RNU6-1280P	-4.33	1.79e-05	0.00326	-0.29	-0.19	Idiopathic pulmonary fibrosis;	chr15:85664390	chr15:85651522~85651628:-
LUAD	cis	rs1005277	0.54	rs2474598	ENSG00000263064.2	RP11-291L22.7	-4.33	1.79e-05	0.00326	-0.21	-0.19	Extrinsic epigenetic age acceleration;	chr10:38141368	chr10:38448689~38448949:+
LUAD	cis	rs9815354	0.762	rs794899	ENSG00000273328.4	RP11-141M3.6	4.33	1.79e-05	0.00326	0.31	0.19	Pulse pressure;Diastolic blood pressure;	chr3:41987230	chr3:42809414~42908105:+
LUAD	cis	rs6840360	0.571	rs62327269	ENSG00000270265.1	RP11-731D1.4	-4.33	1.79e-05	0.00326	-0.22	-0.19	Intelligence (multi-trait analysis);	chr4:151606821	chr4:151333775~151353224:-
LUAD	cis	rs13113518	0.966	rs7677952	ENSG00000272969.1	RP11-528I4.2	4.33	1.79e-05	0.00326	0.2	0.19	Height;	chr4:55425312	chr4:55547112~55547889:+
LUAD	cis	rs860295	0.702	rs11264381	ENSG00000225855.5	RUSC1-AS1	-4.33	1.8e-05	0.00326	-0.14	-0.19	Body mass index;	chr1:155552781	chr1:155316863~155324176:-
LUAD	cis	rs4819052	0.885	rs9980676	ENSG00000237664.1	LINC00316	-4.33	1.8e-05	0.00326	-0.24	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245515	chr21:45338590~45341990:-
LUAD	cis	rs8014252	0.803	rs77359887	ENSG00000259158.2	ADAM20P1	-4.33	1.8e-05	0.00326	-0.36	-0.19	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70532521	chr14:70468881~70483756:-
LUAD	cis	rs897984	0.683	rs12447534	ENSG00000232748.3	RP11-196G11.6	4.33	1.8e-05	0.00326	0.24	0.19	Dementia with Lewy bodies;	chr16:30792936	chr16:31056460~31062803:+
LUAD	cis	rs1005277	0.505	rs7917943	ENSG00000263064.2	RP11-291L22.7	-4.33	1.8e-05	0.00327	-0.2	-0.19	Extrinsic epigenetic age acceleration;	chr10:37906883	chr10:38448689~38448949:+
LUAD	cis	rs9467773	1	rs12526680	ENSG00000261353.1	CTA-14H9.5	-4.33	1.8e-05	0.00327	-0.22	-0.19	Intelligence (multi-trait analysis);	chr6:26550726	chr6:26527063~26527404:+
LUAD	cis	rs17486696	0.51	rs10009649	ENSG00000248771.4	LINC01207	4.33	1.8e-05	0.00327	0.4	0.19	Positive affect;	chr4:164761828	chr4:164754064~164803795:+
LUAD	cis	rs7911264	0.703	rs7894183	ENSG00000236493.2	EIF2S2P3	4.33	1.8e-05	0.00327	0.22	0.19	Inflammatory bowel disease;	chr10:92622283	chr10:92668745~92669743:-
LUAD	cis	rs7911264	0.739	rs7071905	ENSG00000236493.2	EIF2S2P3	4.33	1.8e-05	0.00327	0.22	0.19	Inflammatory bowel disease;	chr10:92626365	chr10:92668745~92669743:-
LUAD	cis	rs7911264	0.739	rs10882094	ENSG00000236493.2	EIF2S2P3	4.33	1.8e-05	0.00327	0.22	0.19	Inflammatory bowel disease;	chr10:92627919	chr10:92668745~92669743:-
LUAD	cis	rs6933660	0.676	rs3757316	ENSG00000219395.2	HSPA8P15	4.33	1.8e-05	0.00327	0.2	0.19	Menarche (age at onset);	chr6:151453204	chr6:151411259~151413945:-
LUAD	cis	rs57677839	1	rs57677839	ENSG00000184669.7	OR7E14P	-4.33	1.8e-05	0.00327	-0.27	-0.19	Coronary artery disease;	chr11:17006642	chr11:17013998~17053024:+
LUAD	cis	rs2731006	0.591	rs11181695	ENSG00000257114.2	RP11-25I15.3	-4.33	1.8e-05	0.00327	-0.29	-0.19	Panic disorder;	chr12:42815306	chr12:42692216~42717119:+
LUAD	cis	rs4460629	0.742	rs11264314	ENSG00000160766.13	GBAP1	-4.33	1.8e-05	0.00327	-0.19	-0.19	Serum magnesium levels;	chr1:155105947	chr1:155213821~155227422:-
LUAD	cis	rs910316	1	rs175426	ENSG00000279594.1	RP11-950C14.10	-4.33	1.8e-05	0.00327	-0.22	-0.19	Height;	chr14:75157431	chr14:75011269~75012851:-
LUAD	cis	rs7580658	0.614	rs7585198	ENSG00000236682.1	AC068282.3	4.33	1.8e-05	0.00327	0.25	0.19	Protein C levels;	chr2:127205059	chr2:127389130~127400580:+
LUAD	cis	rs6751744	0.855	rs933794	ENSG00000226266.5	AC009961.3	-4.33	1.8e-05	0.00327	-0.29	-0.19	Dysphagia;	chr2:159524380	chr2:159670708~159712435:-
LUAD	cis	rs8141529	0.732	rs2269577	ENSG00000272858.1	CTA-292E10.8	-4.33	1.8e-05	0.00328	-0.22	-0.19	Lymphocyte counts;	chr22:28800769	chr22:28814914~28815662:+
LUAD	cis	rs9928842	0.882	rs4737	ENSG00000280152.1	RP11-331F4.5	-4.33	1.8e-05	0.00328	-0.2	-0.19	Alcoholic chronic pancreatitis;	chr16:75204205	chr16:75245994~75250077:-
LUAD	cis	rs10510102	0.516	rs61071865	ENSG00000276742.1	RP11-500G22.4	4.33	1.8e-05	0.00328	0.33	0.19	Breast cancer;	chr10:121986236	chr10:121956782~121957098:+
LUAD	cis	rs10510102	0.516	rs10159759	ENSG00000276742.1	RP11-500G22.4	4.33	1.8e-05	0.00328	0.33	0.19	Breast cancer;	chr10:121986533	chr10:121956782~121957098:+
LUAD	cis	rs10510102	0.516	rs10159589	ENSG00000276742.1	RP11-500G22.4	4.33	1.8e-05	0.00328	0.33	0.19	Breast cancer;	chr10:121986659	chr10:121956782~121957098:+
LUAD	cis	rs3020736	0.5	rs8143153	ENSG00000205702.9	CYP2D7	-4.33	1.8e-05	0.00328	-0.16	-0.19	Autism spectrum disorder or schizophrenia;	chr22:42119633	chr22:42140203~42144577:-
LUAD	cis	rs2243480	0.711	rs1626926	ENSG00000232559.3	GS1-124K5.12	4.33	1.8e-05	0.00328	0.33	0.19	Diabetic kidney disease;	chr7:65970805	chr7:66554588~66576923:-
LUAD	cis	rs12530	0.715	rs5749416	ENSG00000230736.2	RP1-149A16.3	4.33	1.8e-05	0.00328	0.22	0.19	IgG glycosylation;	chr22:32381136	chr22:32376664~32384343:+
LUAD	cis	rs9341808	0.714	rs4256394	ENSG00000260645.1	RP11-250B2.5	4.33	1.81e-05	0.00328	0.18	0.19	Sitting height ratio;	chr6:80172425	chr6:80466958~80469080:+
LUAD	cis	rs7086627	0.515	rs4933390	ENSG00000226659.1	RP11-137H2.4	-4.33	1.81e-05	0.00328	-0.26	-0.19	Post bronchodilator FEV1;	chr10:80453325	chr10:80529597~80535942:-
LUAD	cis	rs6430553	0.964	rs10496731	ENSG00000224043.6	CCNT2-AS1	-4.33	1.81e-05	0.00328	-0.24	-0.19	Blood metabolite levels;	chr2:134840058	chr2:134735464~134918710:-
LUAD	cis	rs699371	0.545	rs7569	ENSG00000270000.1	RP3-449M8.9	4.33	1.81e-05	0.00328	0.22	0.19	Height;	chr14:74500060	chr14:74471930~74472360:-
LUAD	cis	rs34779708	0.931	rs4934711	ENSG00000271335.4	RP11-324I22.4	4.33	1.81e-05	0.00328	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35071382	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.931	rs13376871	ENSG00000271335.4	RP11-324I22.4	4.33	1.81e-05	0.00328	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35080128	chr10:35314552~35336401:-
LUAD	cis	rs6142102	0.961	rs4911411	ENSG00000275784.1	RP5-1125A11.6	-4.33	1.81e-05	0.00328	-0.21	-0.19	Skin pigmentation;	chr20:34128036	chr20:33989480~33991818:-
LUAD	cis	rs2115630	1	rs58581703	ENSG00000259728.4	LINC00933	-4.33	1.81e-05	0.00328	-0.23	-0.19	P wave terminal force;	chr15:84733704	chr15:84570649~84580175:+
LUAD	cis	rs17772222	0.682	rs28711639	ENSG00000258789.1	RP11-507K2.3	-4.33	1.81e-05	0.00328	-0.24	-0.19	Coronary artery calcification;	chr14:88482277	chr14:88551597~88552493:+
LUAD	cis	rs13256369	1	rs13282915	ENSG00000253893.2	FAM85B	-4.33	1.81e-05	0.00328	-0.27	-0.19	Obesity-related traits;	chr8:8713381	chr8:8167819~8226614:-
LUAD	cis	rs750134	1	rs1344513	ENSG00000257221.1	RP11-689B22.2	-4.33	1.81e-05	0.00328	-0.3	-0.19	Low high density lipoprotein cholesterol levels;	chr12:108696805	chr12:108628687~108641318:+
LUAD	cis	rs750134	1	rs55756843	ENSG00000257221.1	RP11-689B22.2	-4.33	1.81e-05	0.00328	-0.3	-0.19	Low high density lipoprotein cholesterol levels;	chr12:108699020	chr12:108628687~108641318:+
LUAD	cis	rs7138803	0.511	rs10875972	ENSG00000257464.1	RP11-161H23.8	-4.33	1.81e-05	0.00328	-0.2	-0.19	Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index;	chr12:49816752	chr12:49442424~49442652:-
LUAD	cis	rs2980439	0.525	rs2945238	ENSG00000253981.4	ALG1L13P	4.33	1.81e-05	0.00328	0.22	0.19	Neuroticism;	chr8:8312614	chr8:8236003~8244667:-
LUAD	cis	rs7616559	0.512	rs35354535	ENSG00000240875.4	LINC00886	-4.33	1.81e-05	0.00328	-0.21	-0.19	Carotid artery intima media thickness (sex interaction);	chr3:157014591	chr3:156747346~156817062:-
LUAD	cis	rs2098713	0.544	rs2056870	ENSG00000250155.1	CTD-2353F22.1	-4.33	1.81e-05	0.00328	-0.23	-0.19	Telomere length;	chr5:37424947	chr5:36666214~36725195:-
LUAD	cis	rs62355901	0.545	rs16886256	ENSG00000271828.1	CTD-2310F14.1	-4.33	1.81e-05	0.00329	-0.32	-0.19	Breast cancer;	chr5:56765737	chr5:56927874~56929573:+
LUAD	cis	rs1876905	0.68	rs354528	ENSG00000230177.1	RP5-1112D6.4	-4.33	1.81e-05	0.00329	-0.22	-0.19	Mean corpuscular hemoglobin;	chr6:111184068	chr6:111277932~111278742:+
LUAD	cis	rs1876905	0.62	rs354525	ENSG00000230177.1	RP5-1112D6.4	-4.33	1.81e-05	0.00329	-0.22	-0.19	Mean corpuscular hemoglobin;	chr6:111186193	chr6:111277932~111278742:+
LUAD	cis	rs2548724	0.561	rs12658397	ENSG00000250682.4	LINC00491	4.33	1.81e-05	0.00329	0.23	0.19	Type 2 diabetes;	chr5:102415949	chr5:102609156~102671559:-
LUAD	cis	rs2548724	0.561	rs6596486	ENSG00000250682.4	LINC00491	4.33	1.81e-05	0.00329	0.23	0.19	Type 2 diabetes;	chr5:102420358	chr5:102609156~102671559:-
LUAD	cis	rs10761482	0.601	rs7922622	ENSG00000254271.1	RP11-131N11.4	-4.33	1.81e-05	0.00329	-0.23	-0.19	Schizophrenia;	chr10:60447765	chr10:60734342~60741828:+
LUAD	cis	rs8048589	0.603	rs2457193	ENSG00000175604.2	RP11-276H1.3	-4.33	1.81e-05	0.00329	-0.25	-0.19	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12084940	chr16:12086746~12090302:-
LUAD	cis	rs750134	1	rs750134	ENSG00000257221.1	RP11-689B22.2	-4.33	1.81e-05	0.00329	-0.28	-0.19	Low high density lipoprotein cholesterol levels;	chr12:108667330	chr12:108628687~108641318:+
LUAD	cis	rs8062405	0.698	rs8046545	ENSG00000261419.1	RP11-57A19.4	4.33	1.81e-05	0.00329	0.23	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28903896	chr16:28659696~28740781:-
LUAD	cis	rs8062405	0.698	rs10499	ENSG00000261419.1	RP11-57A19.4	4.33	1.81e-05	0.00329	0.23	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28904206	chr16:28659696~28740781:-
LUAD	cis	rs28386778	0.897	rs2854214	ENSG00000240280.5	TCAM1P	4.33	1.81e-05	0.00329	0.22	0.19	Prudent dietary pattern;	chr17:63868089	chr17:63849292~63864379:+
LUAD	cis	rs17345786	0.798	rs9817043	ENSG00000244119.1	PDCL3P4	4.33	1.81e-05	0.00329	0.19	0.19	Colonoscopy-negative controls vs population controls;	chr3:101563008	chr3:101712472~101713191:+
LUAD	cis	rs516805	0.528	rs2816088	ENSG00000279453.1	RP3-425C14.4	-4.33	1.81e-05	0.00329	-0.25	-0.19	Lymphocyte counts;	chr6:122081706	chr6:122436789~122439223:-
LUAD	cis	rs896854	0.738	rs1713669	ENSG00000253528.2	RP11-347C18.4	4.33	1.81e-05	0.00329	0.19	0.19	Type 2 diabetes;	chr8:94946409	chr8:94974573~94974853:-
LUAD	cis	rs7324557	0.717	rs7139473	ENSG00000205861.10	C1QTNF9B-AS1	-4.33	1.82e-05	0.00329	-0.26	-0.19	Visceral adipose tissue adjusted for BMI;	chr13:23824083	chr13:23888889~23897263:+
LUAD	cis	rs1881744	0.588	rs78808618	ENSG00000257433.4	RP1-197B17.3	4.33	1.82e-05	0.00329	0.41	0.19	Metabolite levels (HVA/5-HIAA ratio);	chr12:47567624	chr12:47706085~47742294:+
LUAD	cis	rs9322193	0.923	rs4870050	ENSG00000268592.3	RAET1E-AS1	4.33	1.82e-05	0.00329	0.24	0.19	Lung cancer;	chr6:149838917	chr6:149863494~149919507:+
LUAD	cis	rs36093844	0.526	rs17817402	ENSG00000279742.1	RP11-700A24.1	-4.33	1.82e-05	0.00329	-0.21	-0.19	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85892783	chr11:85852557~85854943:-
LUAD	cis	rs4879677	1	rs7858681	ENSG00000215441.3	CTAGE12P	-4.33	1.82e-05	0.0033	-0.24	-0.19	Gut microbiome composition (summer and winter);	chr9:27659161	chr9:27608382~27610745:-
LUAD	cis	rs7665090	1	rs2866406	ENSG00000246560.2	RP11-10L12.4	4.33	1.82e-05	0.0033	0.24	0.19	Primary biliary cholangitis;	chr4:102632862	chr4:102828055~102844075:+
LUAD	cis	rs1154275	0.666	rs1154278	ENSG00000242770.2	RP11-180K7.1	-4.33	1.82e-05	0.0033	-0.2	-0.19	Takotsubo syndrome;	chr3:112767890	chr3:112802478~112812819:+
LUAD	cis	rs7302981	0.967	rs7972842	ENSG00000200428.1	Y_RNA	4.33	1.82e-05	0.0033	0.24	0.19	Systolic blood pressure;	chr12:50122540	chr12:50743568~50743684:+
LUAD	cis	rs35740288	0.787	rs2291048	ENSG00000259407.1	RP11-158M2.3	4.33	1.82e-05	0.0033	0.19	0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85682427	chr15:85744109~85750281:-
LUAD	cis	rs12935418	0.83	rs12928638	ENSG00000261061.1	RP11-303E16.2	-4.33	1.82e-05	0.0033	-0.27	-0.19	Mean corpuscular volume;	chr16:81016195	chr16:81030770~81031485:+
LUAD	cis	rs293748	0.771	rs12656269	ENSG00000250155.1	CTD-2353F22.1	4.33	1.82e-05	0.0033	0.25	0.19	Obesity-related traits;	chr5:36787776	chr5:36666214~36725195:-
LUAD	cis	rs17807624	1	rs17807624	ENSG00000255046.1	RP11-297N6.4	4.33	1.82e-05	0.0033	0.24	0.19	Systemic lupus erythematosus;	chr8:11605506	chr8:11797928~11802568:-
LUAD	cis	rs2554380	0.542	rs7164141	ENSG00000230373.7	GOLGA6L5P	4.33	1.82e-05	0.0033	0.22	0.19	Height;	chr15:83824253	chr15:84507885~84516814:-
LUAD	cis	rs1113500	0.787	rs473704	ENSG00000226822.1	RP11-356N1.2	-4.33	1.82e-05	0.0033	-0.22	-0.19	Growth-regulated protein alpha levels;	chr1:108094688	chr1:108071482~108074519:+
LUAD	cis	rs4879677	1	rs2150022	ENSG00000215441.3	CTAGE12P	-4.33	1.82e-05	0.0033	-0.23	-0.19	Gut microbiome composition (summer and winter);	chr9:27688031	chr9:27608382~27610745:-
LUAD	cis	rs9322193	0.962	rs7752089	ENSG00000268592.3	RAET1E-AS1	4.33	1.82e-05	0.0033	0.24	0.19	Lung cancer;	chr6:149839298	chr6:149863494~149919507:+
LUAD	cis	rs812925	0.519	rs2922089	ENSG00000271889.1	RP11-493E12.1	-4.33	1.82e-05	0.00331	-0.23	-0.19	Immature fraction of reticulocytes;	chr2:61397994	chr2:61151433~61162105:-
LUAD	cis	rs812925	0.519	rs2694627	ENSG00000271889.1	RP11-493E12.1	-4.33	1.82e-05	0.00331	-0.23	-0.19	Immature fraction of reticulocytes;	chr2:61398371	chr2:61151433~61162105:-
LUAD	cis	rs7172677	1	rs4886659	ENSG00000260269.4	CTD-2323K18.1	-4.33	1.82e-05	0.00331	-0.26	-0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75122419	chr15:75527150~75601205:-
LUAD	cis	rs7119038	0.629	rs10892272	ENSG00000255239.1	AP002954.6	-4.33	1.82e-05	0.00331	-0.27	-0.19	Sjögren's syndrome;	chr11:118731998	chr11:118688039~118690600:-
LUAD	cis	rs9393777	0.92	rs13195040	ENSG00000219392.1	RP1-265C24.5	4.33	1.82e-05	0.00331	0.37	0.19	Intelligence (multi-trait analysis);	chr6:27446145	chr6:28115628~28116551:+
LUAD	cis	rs2348418	0.832	rs4931080	ENSG00000247934.4	RP11-967K21.1	4.33	1.83e-05	0.00331	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28433843	chr12:28163298~28190738:-
LUAD	cis	rs10197140	0.925	rs10204997	ENSG00000235721.1	AC013268.3	-4.33	1.83e-05	0.00331	-0.21	-0.19	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110865211	chr2:110007675~110010783:+
LUAD	cis	rs7172677	0.538	rs1806795	ENSG00000260269.4	CTD-2323K18.1	-4.33	1.83e-05	0.00331	-0.26	-0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75130403	chr15:75527150~75601205:-
LUAD	cis	rs7172677	1	rs1806794	ENSG00000260269.4	CTD-2323K18.1	-4.33	1.83e-05	0.00331	-0.26	-0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75130599	chr15:75527150~75601205:-
LUAD	cis	rs755249	0.501	rs621807	ENSG00000182109.6	RP11-69E11.4	4.33	1.83e-05	0.00331	0.21	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39376771	chr1:39522280~39546187:-
LUAD	cis	rs394563	0.625	rs384306	ENSG00000231760.4	RP11-350J20.5	4.33	1.83e-05	0.00331	0.25	0.19	Dupuytren's disease;	chr6:149475004	chr6:149796151~149826294:-
LUAD	cis	rs2243480	1	rs313814	ENSG00000229886.1	RP5-1132H15.3	4.33	1.83e-05	0.00331	0.34	0.19	Diabetic kidney disease;	chr7:66038306	chr7:66025126~66031544:-
LUAD	cis	rs7189233	0.531	rs8045674	ENSG00000279344.1	RP11-44F14.7	4.33	1.83e-05	0.00331	0.16	0.19	Intelligence (multi-trait analysis);	chr16:53476024	chr16:53478957~53481550:-
LUAD	cis	rs4664293	0.967	rs7597482	ENSG00000230783.1	AC009961.2	-4.33	1.83e-05	0.00332	-0.24	-0.19	Monocyte percentage of white cells;	chr2:159690580	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.967	rs7597488	ENSG00000230783.1	AC009961.2	-4.33	1.83e-05	0.00332	-0.24	-0.19	Monocyte percentage of white cells;	chr2:159690585	chr2:159689217~159690291:-
LUAD	cis	rs453301	0.658	rs12114954	ENSG00000233609.3	RP11-62H7.2	-4.33	1.83e-05	0.00332	-0.16	-0.19	Joint mobility (Beighton score);	chr8:9047352	chr8:8961200~8979025:+
LUAD	cis	rs41411047	0.826	rs73155077	ENSG00000271711.1	RP11-392O18.2	4.33	1.83e-05	0.00332	0.37	0.19	Myocardial infarction;	chr3:149857824	chr3:150611262~150611877:-
LUAD	cis	rs41411047	0.826	rs73155082	ENSG00000271711.1	RP11-392O18.2	4.33	1.83e-05	0.00332	0.37	0.19	Myocardial infarction;	chr3:149861319	chr3:150611262~150611877:-
LUAD	cis	rs41411047	0.826	rs73155084	ENSG00000271711.1	RP11-392O18.2	4.33	1.83e-05	0.00332	0.37	0.19	Myocardial infarction;	chr3:149864575	chr3:150611262~150611877:-
LUAD	cis	rs41411047	0.826	rs73155086	ENSG00000271711.1	RP11-392O18.2	4.33	1.83e-05	0.00332	0.37	0.19	Myocardial infarction;	chr3:149866875	chr3:150611262~150611877:-
LUAD	cis	rs3096299	0.685	rs3803682	ENSG00000182376.2	RP5-1142A6.8	4.33	1.83e-05	0.00332	0.2	0.19	Multiple myeloma (IgH translocation);	chr16:89478228	chr16:88742767~88745748:+
LUAD	cis	rs2243480	1	rs35542501	ENSG00000232559.3	GS1-124K5.12	4.33	1.83e-05	0.00332	0.33	0.19	Diabetic kidney disease;	chr7:65966228	chr7:66554588~66576923:-
LUAD	cis	rs2243480	0.708	rs781141	ENSG00000232559.3	GS1-124K5.12	4.33	1.83e-05	0.00332	0.33	0.19	Diabetic kidney disease;	chr7:65973566	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs781142	ENSG00000232559.3	GS1-124K5.12	4.33	1.83e-05	0.00332	0.33	0.19	Diabetic kidney disease;	chr7:65973791	chr7:66554588~66576923:-
LUAD	cis	rs737008	0.922	rs11074957	ENSG00000262703.1	RP11-485G7.6	-4.33	1.83e-05	0.00332	-0.18	-0.19	Obesity-related traits;	chr16:11284294	chr16:11348143~11349321:-
LUAD	cis	rs2281603	0.951	rs60908674	ENSG00000259116.1	RP11-973N13.4	-4.33	1.83e-05	0.00332	-0.18	-0.19	Lymphocyte counts;	chr14:64514181	chr14:64514154~64540368:-
LUAD	cis	rs2281603	0.904	rs59440409	ENSG00000259116.1	RP11-973N13.4	-4.33	1.83e-05	0.00332	-0.18	-0.19	Lymphocyte counts;	chr14:64514249	chr14:64514154~64540368:-
LUAD	cis	rs1023500	0.551	rs2859438	ENSG00000205702.9	CYP2D7	4.33	1.83e-05	0.00332	0.16	0.19	Schizophrenia;	chr22:42070976	chr22:42140203~42144577:-
LUAD	cis	rs9303029	0.932	rs12450192	ENSG00000265458.1	RP13-20L14.6	4.33	1.83e-05	0.00332	0.36	0.19	Protein quantitative trait loci;	chr17:82450102	chr17:82454273~82458521:-
LUAD	cis	rs7616559	0.512	rs2046270	ENSG00000240875.4	LINC00886	-4.33	1.83e-05	0.00332	-0.21	-0.19	Carotid artery intima media thickness (sex interaction);	chr3:157012975	chr3:156747346~156817062:-
LUAD	cis	rs9788333	0.888	rs35880230	ENSG00000224429.6	LINC00539	-4.33	1.83e-05	0.00332	-0.19	-0.19	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr13:21311833	chr13:21303515~21348721:-
LUAD	cis	rs9788333	0.962	rs61951450	ENSG00000224429.6	LINC00539	-4.33	1.83e-05	0.00332	-0.19	-0.19	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr13:21312215	chr13:21303515~21348721:-
LUAD	cis	rs8098244	0.516	rs2960586	ENSG00000264745.1	TTC39C-AS1	4.33	1.83e-05	0.00332	0.2	0.19	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23690207	chr18:23994213~24015339:-
LUAD	cis	rs2243480	1	rs2462569	ENSG00000164669.11	INTS4P1	-4.33	1.83e-05	0.00332	-0.33	-0.19	Diabetic kidney disease;	chr7:66009859	chr7:65141225~65234216:+
LUAD	cis	rs10863681	0.664	rs10863680	ENSG00000228437.4	RP11-400N13.2	-4.33	1.84e-05	0.00333	-0.25	-0.19	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222071538	chr1:221966341~221984964:+
LUAD	cis	rs1799949	1	rs11649954	ENSG00000236383.6	LINC00854	-4.33	1.84e-05	0.00333	-0.16	-0.19	Menopause (age at onset);	chr17:43342667	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs1824889	ENSG00000236383.6	LINC00854	-4.33	1.84e-05	0.00333	-0.16	-0.19	Menopause (age at onset);	chr17:43344508	chr17:43216941~43305976:-
LUAD	cis	rs1023500	0.596	rs133369	ENSG00000205702.9	CYP2D7	4.33	1.84e-05	0.00333	0.16	0.19	Schizophrenia;	chr22:42067810	chr22:42140203~42144577:-
LUAD	cis	rs227275	0.556	rs724447	ENSG00000251288.2	RP11-10L12.2	4.33	1.84e-05	0.00333	0.23	0.19	Allergic disease (asthma, hay fever or eczema);	chr4:103010149	chr4:102751401~102752641:+
LUAD	cis	rs1005277	0.54	rs1987431	ENSG00000263064.2	RP11-291L22.7	4.33	1.84e-05	0.00333	0.2	0.19	Extrinsic epigenetic age acceleration;	chr10:37699959	chr10:38448689~38448949:+
LUAD	cis	rs116175783	0.557	rs62188123	ENSG00000227403.1	AC009299.3	4.33	1.84e-05	0.00333	0.36	0.19	Intelligence (multi-trait analysis);	chr2:161385335	chr2:161244739~161249050:+
LUAD	cis	rs62355901	0.653	rs62355882	ENSG00000271828.1	CTD-2310F14.1	4.33	1.84e-05	0.00333	0.38	0.19	Breast cancer;	chr5:56749283	chr5:56927874~56929573:+
LUAD	cis	rs3743772	0.5	rs35346613	ENSG00000279722.1	RP11-44F14.6	4.33	1.84e-05	0.00333	0.27	0.19	Depressive symptoms (SSRI exposure interaction);	chr16:53408246	chr16:53487607~53489943:-
LUAD	cis	rs812925	0.519	rs967968	ENSG00000271889.1	RP11-493E12.1	-4.33	1.84e-05	0.00334	-0.23	-0.19	Immature fraction of reticulocytes;	chr2:61428921	chr2:61151433~61162105:-
LUAD	cis	rs262150	0.842	rs2657398	ENSG00000231419.5	LINC00689	-4.33	1.84e-05	0.00334	-0.23	-0.19	Facial morphology (factor 20);	chr7:158992220	chr7:159006522~159030195:+
LUAD	cis	rs755249	0.501	rs2490945	ENSG00000182109.6	RP11-69E11.4	4.33	1.84e-05	0.00334	0.21	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39371672	chr1:39522280~39546187:-
LUAD	cis	rs6496932	0.563	rs2344083	ENSG00000259416.2	RP11-158M2.5	4.33	1.84e-05	0.00334	0.21	0.19	Central corneal thickness;Corneal structure;	chr15:85354201	chr15:85754941~85756237:-
LUAD	cis	rs910316	0.967	rs8013444	ENSG00000279594.1	RP11-950C14.10	-4.33	1.84e-05	0.00334	-0.22	-0.19	Height;	chr14:75195278	chr14:75011269~75012851:-
LUAD	cis	rs7746199	0.736	rs13202291	ENSG00000219392.1	RP1-265C24.5	-4.33	1.84e-05	0.00334	-0.4	-0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731078	chr6:28115628~28116551:+
LUAD	cis	rs7746199	0.736	rs17750424	ENSG00000219392.1	RP1-265C24.5	-4.33	1.84e-05	0.00334	-0.4	-0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27733343	chr6:28115628~28116551:+
LUAD	cis	rs7746199	0.736	rs13193542	ENSG00000219392.1	RP1-265C24.5	-4.33	1.84e-05	0.00334	-0.4	-0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734646	chr6:28115628~28116551:+
LUAD	cis	rs7746199	0.736	rs13193480	ENSG00000219392.1	RP1-265C24.5	-4.33	1.84e-05	0.00334	-0.4	-0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734782	chr6:28115628~28116551:+
LUAD	cis	rs10218795	1	rs10218795	ENSG00000233396.6	RP11-458D21.1	-4.33	1.84e-05	0.00334	-0.47	-0.19	Coronary heart disease (SNP X SNP interaction);	chr1:146018957	chr1:146052566~146061948:+
LUAD	cis	rs7429990	0.901	rs9825114	ENSG00000228638.1	FCF1P2	4.33	1.84e-05	0.00334	0.23	0.19	Educational attainment (years of education);	chr3:48096592	chr3:48290793~48291375:-
LUAD	cis	rs2236295	0.533	rs931977	ENSG00000238280.1	RP11-436D10.3	4.33	1.84e-05	0.00334	0.24	0.19	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr10:62898218	chr10:62793562~62805887:-
LUAD	cis	rs1799949	0.794	rs116409325	ENSG00000236383.6	LINC00854	-4.33	1.85e-05	0.00334	-0.16	-0.19	Menopause (age at onset);	chr17:43368092	chr17:43216941~43305976:-
LUAD	cis	rs1334894	0.892	rs11545925	ENSG00000228559.1	RP3-340B19.3	-4.33	1.85e-05	0.00334	-0.4	-0.19	Coronary artery disease;	chr6:35574749	chr6:35544632~35545669:+
LUAD	cis	rs7560272	0.564	rs4852939	ENSG00000163016.8	ALMS1P	4.33	1.85e-05	0.00334	0.21	0.19	Schizophrenia;	chr2:73629642	chr2:73644919~73685576:+
LUAD	cis	rs1005277	0.579	rs2008449	ENSG00000263064.2	RP11-291L22.7	-4.33	1.85e-05	0.00334	-0.2	-0.19	Extrinsic epigenetic age acceleration;	chr10:38125276	chr10:38448689~38448949:+
LUAD	cis	rs5758659	0.623	rs133328	ENSG00000182057.4	OGFRP1	4.33	1.85e-05	0.00334	0.23	0.19	Cognitive function;	chr22:42012075	chr22:42269753~42275196:+
LUAD	cis	rs80028505	0.908	rs16884906	ENSG00000271304.1	DPRXP2	4.33	1.85e-05	0.00334	0.37	0.19	Foot ulcer in diabetes and neuropathy;	chr6:36102922	chr6:35989515~35990436:-
LUAD	cis	rs8062405	0.723	rs12445744	ENSG00000261419.1	RP11-57A19.4	-4.33	1.85e-05	0.00334	-0.21	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28659696~28740781:-
LUAD	cis	rs997295	0.554	rs7180312	ENSG00000270964.1	RP11-502I4.3	4.33	1.85e-05	0.00335	0.2	0.19	Motion sickness;	chr15:67812918	chr15:67541072~67542604:-
LUAD	cis	rs6940638	0.688	rs9295730	ENSG00000219392.1	RP1-265C24.5	-4.33	1.85e-05	0.00335	-0.24	-0.19	Intelligence (multi-trait analysis);	chr6:27161027	chr6:28115628~28116551:+
LUAD	cis	rs8077577	0.747	rs7405677	ENSG00000273018.4	CTD-2303H24.2	4.33	1.85e-05	0.00335	0.28	0.19	Obesity-related traits;	chr17:18227922	chr17:18511221~18551705:-
LUAD	cis	rs1876905	0.68	rs1215848	ENSG00000230177.1	RP5-1112D6.4	-4.33	1.85e-05	0.00335	-0.22	-0.19	Mean corpuscular hemoglobin;	chr6:111204333	chr6:111277932~111278742:+
LUAD	cis	rs1876905	0.68	rs402940	ENSG00000230177.1	RP5-1112D6.4	-4.33	1.85e-05	0.00335	-0.22	-0.19	Mean corpuscular hemoglobin;	chr6:111206785	chr6:111277932~111278742:+
LUAD	cis	rs1234598	1	rs1234598	ENSG00000230177.1	RP5-1112D6.4	-4.33	1.85e-05	0.00335	-0.22	-0.19	Mean corpuscular volume;	chr6:111208250	chr6:111277932~111278742:+
LUAD	cis	rs1876905	0.68	rs354543	ENSG00000230177.1	RP5-1112D6.4	-4.33	1.85e-05	0.00335	-0.22	-0.19	Mean corpuscular hemoglobin;	chr6:111209050	chr6:111277932~111278742:+
LUAD	cis	rs7819412	0.775	rs34094119	ENSG00000255046.1	RP11-297N6.4	4.33	1.85e-05	0.00335	0.24	0.19	Triglycerides;	chr8:11078388	chr8:11797928~11802568:-
LUAD	cis	rs1008375	0.872	rs2315552	ENSG00000249502.1	AC006160.5	-4.33	1.85e-05	0.00335	-0.19	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17625671	chr4:17587467~17614571:-
LUAD	cis	rs454217	0.846	rs418571	ENSG00000277851.1	RP11-756G20.1	4.33	1.85e-05	0.00335	0.2	0.19	Smoking quantity;	chr12:92330380	chr12:92247756~92363832:-
LUAD	cis	rs454217	0.846	rs1661024	ENSG00000277851.1	RP11-756G20.1	4.33	1.85e-05	0.00335	0.2	0.19	Smoking quantity;	chr12:92330771	chr12:92247756~92363832:-
LUAD	cis	rs80028505	0.908	rs6457878	ENSG00000271304.1	DPRXP2	4.33	1.85e-05	0.00335	0.37	0.19	Foot ulcer in diabetes and neuropathy;	chr6:36108503	chr6:35989515~35990436:-
LUAD	cis	rs80028505	0.908	rs3804451	ENSG00000271304.1	DPRXP2	4.33	1.85e-05	0.00335	0.37	0.19	Foot ulcer in diabetes and neuropathy;	chr6:36110184	chr6:35989515~35990436:-
LUAD	cis	rs4843747	0.671	rs28671027	ENSG00000205037.2	RP11-863P13.4	4.33	1.85e-05	0.00335	0.27	0.19	Menopause (age at onset);	chr16:88082717	chr16:88088041~88100985:-
LUAD	cis	rs1799955	0.935	rs11571787	ENSG00000215515.2	IFIT1P1	-4.33	1.85e-05	0.00335	-0.27	-0.19	LDL cholesterol levels;	chr13:32384329	chr13:32384660~32386108:+
LUAD	cis	rs1799955	0.935	rs9567639	ENSG00000215515.2	IFIT1P1	-4.33	1.85e-05	0.00335	-0.27	-0.19	LDL cholesterol levels;	chr13:32384512	chr13:32384660~32386108:+
LUAD	cis	rs34779708	0.966	rs17591857	ENSG00000271335.4	RP11-324I22.4	-4.33	1.85e-05	0.00335	-0.2	-0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35210115	chr10:35314552~35336401:-
LUAD	cis	rs4819052	0.851	rs2838833	ENSG00000237664.1	LINC00316	-4.33	1.85e-05	0.00335	-0.24	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245245	chr21:45338590~45341990:-
LUAD	cis	rs997295	0.554	rs28568344	ENSG00000270964.1	RP11-502I4.3	4.33	1.85e-05	0.00335	0.2	0.19	Motion sickness;	chr15:67804189	chr15:67541072~67542604:-
LUAD	cis	rs7200786	0.546	rs1861198	ENSG00000274038.1	RP11-66H6.4	-4.33	1.85e-05	0.00335	-0.25	-0.19	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11117726	chr16:11056556~11057034:+
LUAD	cis	rs7829975	0.714	rs11784052	ENSG00000233609.3	RP11-62H7.2	4.33	1.85e-05	0.00335	0.16	0.19	Mood instability;	chr8:8814452	chr8:8961200~8979025:+
LUAD	cis	rs4143844	0.867	rs2303405	ENSG00000259251.2	RP11-643M14.1	-4.33	1.85e-05	0.00335	-0.34	-0.19	Bipolar disorder and schizophrenia;	chr15:61961592	chr15:62060503~62062434:+
LUAD	cis	rs6840360	0.573	rs7692939	ENSG00000270265.1	RP11-731D1.4	-4.33	1.85e-05	0.00335	-0.2	-0.19	Intelligence (multi-trait analysis);	chr4:151337303	chr4:151333775~151353224:-
LUAD	cis	rs7826238	0.502	rs10503377	ENSG00000173295.6	FAM86B3P	4.33	1.85e-05	0.00335	0.23	0.19	Systolic blood pressure;	chr8:8520912	chr8:8228595~8244865:+
LUAD	cis	rs7119038	0.818	rs73003215	ENSG00000255422.1	AP002954.4	4.33	1.85e-05	0.00336	0.29	0.19	Sjögren's syndrome;	chr11:118778803	chr11:118704607~118750263:+
LUAD	cis	rs881375	0.501	rs10739591	ENSG00000226752.6	PSMD5-AS1	-4.33	1.86e-05	0.00336	-0.22	-0.19	Rheumatoid arthritis;	chr9:121123450	chr9:120824828~120854385:+
LUAD	cis	rs9393777	0.92	rs41269265	ENSG00000219392.1	RP1-265C24.5	-4.33	1.86e-05	0.00336	-0.38	-0.19	Intelligence (multi-trait analysis);	chr6:27457570	chr6:28115628~28116551:+
LUAD	cis	rs4819052	1	rs2838847	ENSG00000215447.6	BX322557.10	-4.32	1.86e-05	0.00336	-0.24	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251043	chr21:45288052~45291738:+
LUAD	cis	rs11220082	0.627	rs34912904	ENSG00000254671.2	STT3A-AS1	-4.32	1.86e-05	0.00336	-0.22	-0.19	Schizophrenia;	chr11:125475460	chr11:125570284~125592568:-
LUAD	cis	rs6142102	0.778	rs4911374	ENSG00000275784.1	RP5-1125A11.6	-4.32	1.86e-05	0.00336	-0.22	-0.19	Skin pigmentation;	chr20:33928195	chr20:33989480~33991818:-
LUAD	cis	rs2243480	0.666	rs1880311	ENSG00000229886.1	RP5-1132H15.3	-4.32	1.86e-05	0.00336	-0.35	-0.19	Diabetic kidney disease;	chr7:65811765	chr7:66025126~66031544:-
LUAD	cis	rs75422866	0.541	rs61918136	ENSG00000257433.4	RP1-197B17.3	4.32	1.86e-05	0.00336	0.41	0.19	Pneumonia;	chr12:47566798	chr12:47706085~47742294:+
LUAD	cis	rs1113500	0.636	rs3853493	ENSG00000226822.1	RP11-356N1.2	4.32	1.86e-05	0.00336	0.22	0.19	Growth-regulated protein alpha levels;	chr1:108094571	chr1:108071482~108074519:+
LUAD	cis	rs2243480	1	rs937108	ENSG00000229886.1	RP5-1132H15.3	4.32	1.86e-05	0.00336	0.33	0.19	Diabetic kidney disease;	chr7:65963465	chr7:66025126~66031544:-
LUAD	cis	rs651907	0.535	rs13084113	ENSG00000244119.1	PDCL3P4	4.32	1.86e-05	0.00336	0.2	0.19	Colorectal cancer;	chr3:101815195	chr3:101712472~101713191:+
LUAD	cis	rs6012564	1	rs3091529	ENSG00000230758.1	SNAP23P	-4.32	1.86e-05	0.00336	-0.21	-0.19	Anger;	chr20:49030531	chr20:49038357~49038602:-
LUAD	cis	rs6012564	1	rs1022687	ENSG00000230758.1	SNAP23P	-4.32	1.86e-05	0.00336	-0.21	-0.19	Anger;	chr20:49032317	chr20:49038357~49038602:-
LUAD	cis	rs6012564	0.964	rs3092302	ENSG00000230758.1	SNAP23P	-4.32	1.86e-05	0.00336	-0.21	-0.19	Anger;	chr20:49037721	chr20:49038357~49038602:-
LUAD	cis	rs11157436	0.602	rs2331594	ENSG00000211812.1	TRAV26-2	-4.32	1.86e-05	0.00336	-0.2	-0.19	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22171871	chr14:22202583~22203368:+
LUAD	cis	rs703842	1	rs6581155	ENSG00000270039.1	RP11-571M6.17	-4.32	1.86e-05	0.00336	-0.23	-0.19	Multiple sclerosis;	chr12:57784379	chr12:57803838~57804415:+
LUAD	cis	rs561341	0.941	rs2428338	ENSG00000265798.5	RP11-271K11.5	4.32	1.86e-05	0.00337	0.29	0.19	Hip circumference adjusted for BMI;	chr17:31972610	chr17:31038575~31059121:-
LUAD	cis	rs561341	0.882	rs563539	ENSG00000265798.5	RP11-271K11.5	4.32	1.86e-05	0.00337	0.29	0.19	Hip circumference adjusted for BMI;	chr17:31980939	chr17:31038575~31059121:-
LUAD	cis	rs6570726	0.967	rs373527	ENSG00000235652.6	RP11-545I5.3	4.32	1.86e-05	0.00337	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145480725	chr6:145799409~145886585:+
LUAD	cis	rs11157436	0.602	rs1894371	ENSG00000211812.1	TRAV26-2	4.32	1.86e-05	0.00337	0.2	0.19	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22166799	chr14:22202583~22203368:+
LUAD	cis	rs911119	0.913	rs6036465	ENSG00000270001.1	RP11-218C14.8	-4.32	1.86e-05	0.00337	-0.28	-0.19	Chronic kidney disease;	chr20:23607366	chr20:23631826~23632316:-
LUAD	cis	rs4908760	0.566	rs7532459	ENSG00000270282.1	RP5-1115A15.2	4.32	1.86e-05	0.00337	0.21	0.19	Vitiligo;	chr1:8617714	chr1:8512653~8513021:+
LUAD	cis	rs12025262	0.546	rs10754539	ENSG00000259865.1	RP11-488L18.10	4.32	1.86e-05	0.00337	0.16	0.19	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr1:247202128	chr1:247187281~247188526:-
LUAD	cis	rs9400467	0.509	rs11153287	ENSG00000271789.1	RP5-1112D6.7	-4.32	1.86e-05	0.00337	-0.2	-0.19	Amino acid levels;Blood metabolite levels;	chr6:111383334	chr6:111297126~111298510:+
LUAD	cis	rs877356	1	rs17169180	ENSG00000250378.1	RP11-119J18.1	-4.32	1.86e-05	0.00337	-0.34	-0.19	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (dichotomous);	chr5:135825366	chr5:135812667~135826582:+
LUAD	cis	rs4819052	0.679	rs8132135	ENSG00000237664.1	LINC00316	-4.32	1.86e-05	0.00337	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45274867	chr21:45338590~45341990:-
LUAD	cis	rs151234	0.676	rs508022	ENSG00000259982.1	CDC37P1	-4.32	1.86e-05	0.00337	-0.35	-0.19	Platelet distribution width;	chr16:28562642	chr16:28700294~28701540:-
LUAD	cis	rs151234	0.676	rs554206	ENSG00000259982.1	CDC37P1	-4.32	1.86e-05	0.00337	-0.35	-0.19	Platelet distribution width;	chr16:28565048	chr16:28700294~28701540:-
LUAD	cis	rs4795519	0.744	rs35353742	ENSG00000266313.1	RP11-173M1.4	4.32	1.87e-05	0.00337	0.25	0.19	Chronic myeloid leukemia;	chr17:27193286	chr17:27333256~27348491:+
LUAD	cis	rs4795519	0.778	rs61166727	ENSG00000266313.1	RP11-173M1.4	4.32	1.87e-05	0.00337	0.25	0.19	Chronic myeloid leukemia;	chr17:27196729	chr17:27333256~27348491:+
LUAD	cis	rs4795519	0.736	rs12450961	ENSG00000266313.1	RP11-173M1.4	4.32	1.87e-05	0.00337	0.25	0.19	Chronic myeloid leukemia;	chr17:27197758	chr17:27333256~27348491:+
LUAD	cis	rs2115630	0.967	rs11073702	ENSG00000225151.9	GOLGA2P7	4.32	1.87e-05	0.00337	0.22	0.19	P wave terminal force;	chr15:84766840	chr15:84199311~84230136:-
LUAD	cis	rs7665090	1	rs6821119	ENSG00000246560.2	RP11-10L12.4	4.32	1.87e-05	0.00337	0.24	0.19	Primary biliary cholangitis;	chr4:102634076	chr4:102828055~102844075:+
LUAD	cis	rs7665090	0.934	rs6844332	ENSG00000246560.2	RP11-10L12.4	4.32	1.87e-05	0.00337	0.24	0.19	Primary biliary cholangitis;	chr4:102634095	chr4:102828055~102844075:+
LUAD	cis	rs7665090	0.967	rs6821133	ENSG00000246560.2	RP11-10L12.4	4.32	1.87e-05	0.00337	0.24	0.19	Primary biliary cholangitis;	chr4:102634096	chr4:102828055~102844075:+
LUAD	cis	rs2243480	0.901	rs778730	ENSG00000232559.3	GS1-124K5.12	4.32	1.87e-05	0.00337	0.34	0.19	Diabetic kidney disease;	chr7:66358338	chr7:66554588~66576923:-
LUAD	cis	rs848490	0.962	rs11765656	ENSG00000214293.7	APTR	4.32	1.87e-05	0.00337	0.26	0.19	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77827673	chr7:77657660~77696265:-
LUAD	cis	rs7208859	0.562	rs8078897	ENSG00000266490.1	CTD-2349P21.9	4.32	1.87e-05	0.00338	0.28	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs9914499	ENSG00000266490.1	CTD-2349P21.9	4.32	1.87e-05	0.00338	0.28	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs12006	ENSG00000266490.1	CTD-2349P21.9	4.32	1.87e-05	0.00338	0.28	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs3752021	ENSG00000266490.1	CTD-2349P21.9	4.32	1.87e-05	0.00338	0.28	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs1061342	ENSG00000266490.1	CTD-2349P21.9	4.32	1.87e-05	0.00338	0.28	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs55938328	ENSG00000266490.1	CTD-2349P21.9	4.32	1.87e-05	0.00338	0.28	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs55961983	ENSG00000266490.1	CTD-2349P21.9	4.32	1.87e-05	0.00338	0.28	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30792372~30792833:+
LUAD	cis	rs17826219	0.568	rs7213925	ENSG00000266490.1	CTD-2349P21.9	4.32	1.87e-05	0.00338	0.28	0.19	Body mass index;	chr17:30794616	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs11658945	ENSG00000266490.1	CTD-2349P21.9	4.32	1.87e-05	0.00338	0.28	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs11657990	ENSG00000266490.1	CTD-2349P21.9	4.32	1.87e-05	0.00338	0.28	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs11650982	ENSG00000266490.1	CTD-2349P21.9	4.32	1.87e-05	0.00338	0.28	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs9915546	ENSG00000266490.1	CTD-2349P21.9	4.32	1.87e-05	0.00338	0.28	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs9895815	ENSG00000266490.1	CTD-2349P21.9	4.32	1.87e-05	0.00338	0.28	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30792372~30792833:+
LUAD	cis	rs17826219	0.706	rs73271850	ENSG00000266490.1	CTD-2349P21.9	4.32	1.87e-05	0.00338	0.28	0.19	Body mass index;	chr17:30815122	chr17:30792372~30792833:+
LUAD	cis	rs17826219	0.636	rs79565452	ENSG00000266490.1	CTD-2349P21.9	4.32	1.87e-05	0.00338	0.28	0.19	Body mass index;	chr17:30815823	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs7208088	ENSG00000266490.1	CTD-2349P21.9	4.32	1.87e-05	0.00338	0.28	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30792372~30792833:+
LUAD	cis	rs75422866	0.541	rs61918136	ENSG00000274902.1	RP1-197B17.4	4.32	1.87e-05	0.00338	0.43	0.19	Pneumonia;	chr12:47566798	chr12:47731908~47732351:+
LUAD	cis	rs2288073	0.965	rs10192600	ENSG00000242628.4	AC009228.1	4.32	1.87e-05	0.00338	0.26	0.19	Venous thromboembolism (SNP x SNP interaction);	chr2:24173811	chr2:24214381~24221516:+
LUAD	cis	rs16944613	0.588	rs10852136	ENSG00000259212.1	CTD-3065B20.2	4.32	1.87e-05	0.00338	0.31	0.19	Colorectal cancer;	chr15:90596566	chr15:90595840~90596447:-
LUAD	cis	rs6840360	0.642	rs7677131	ENSG00000270265.1	RP11-731D1.4	-4.32	1.87e-05	0.00338	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151431863	chr4:151333775~151353224:-
LUAD	cis	rs6556937	0.736	rs1421911	ENSG00000272109.1	CTD-2260A17.3	4.32	1.87e-05	0.00338	0.27	0.19	Blood protein levels;	chr5:96665243	chr5:96804353~96806105:+
LUAD	cis	rs6012564	0.963	rs6125551	ENSG00000230758.1	SNAP23P	-4.32	1.87e-05	0.00338	-0.2	-0.19	Anger;	chr20:49103849	chr20:49038357~49038602:-
LUAD	cis	rs9341808	0.718	rs9352806	ENSG00000272129.1	RP11-250B2.6	4.32	1.87e-05	0.00338	0.23	0.19	Sitting height ratio;	chr6:80270340	chr6:80355424~80356859:+
LUAD	cis	rs651907	0.557	rs34947019	ENSG00000244119.1	PDCL3P4	4.32	1.87e-05	0.00338	0.2	0.19	Colorectal cancer;	chr3:101813391	chr3:101712472~101713191:+
LUAD	cis	rs2731006	0.64	rs2056192	ENSG00000257114.2	RP11-25I15.3	4.32	1.87e-05	0.00338	0.29	0.19	Panic disorder;	chr12:42808192	chr12:42692216~42717119:+
LUAD	cis	rs2153535	0.585	rs9379226	ENSG00000230939.1	RP11-314C16.1	-4.32	1.87e-05	0.00338	-0.22	-0.19	Motion sickness;	chr6:8584232	chr6:8784178~8785445:+
LUAD	cis	rs28386778	0.863	rs7221573	ENSG00000240280.5	TCAM1P	-4.32	1.87e-05	0.00338	-0.22	-0.19	Prudent dietary pattern;	chr17:63782030	chr17:63849292~63864379:+
LUAD	cis	rs11168618	0.875	rs7972785	ENSG00000240399.1	RP1-228P16.1	4.32	1.87e-05	0.00338	0.19	0.19	Adiponectin levels;	chr12:48483273	chr12:48054813~48055591:-
LUAD	cis	rs34792	0.554	rs4597346	ENSG00000207425.1	Y_RNA	-4.32	1.87e-05	0.00338	-0.24	-0.19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15529889	chr16:14915457~14915556:-
LUAD	cis	rs4819052	0.851	rs3673	ENSG00000237664.1	LINC00316	-4.32	1.87e-05	0.00338	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261860	chr21:45338590~45341990:-
LUAD	cis	rs9649213	0.593	rs3801255	ENSG00000272950.1	RP11-307C18.1	4.32	1.87e-05	0.00338	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98371617	chr7:98322853~98323430:+
LUAD	cis	rs3018712	0.532	rs2513289	ENSG00000212093.1	AP000807.1	-4.32	1.87e-05	0.00338	-0.25	-0.19	Total body bone mineral density;	chr11:68652187	chr11:68506083~68506166:-
LUAD	cis	rs2933343	0.7	rs789240	ENSG00000231305.3	RP11-723O4.2	4.32	1.87e-05	0.00338	0.21	0.19	IgG glycosylation;	chr3:128911792	chr3:128861313~128871540:-
LUAD	cis	rs3814244	0.528	rs11177002	ENSG00000236946.2	HNRNPA1P70	-4.32	1.87e-05	0.00339	-0.17	-0.19	Itch intensity from mosquito bite adjusted by bite size;	chr12:68003377	chr12:68035767~68036853:+
LUAD	cis	rs80028505	0.808	rs73729685	ENSG00000271304.1	DPRXP2	4.32	1.87e-05	0.00339	0.36	0.19	Foot ulcer in diabetes and neuropathy;	chr6:36043296	chr6:35989515~35990436:-
LUAD	cis	rs80028505	0.908	rs7759175	ENSG00000271304.1	DPRXP2	4.32	1.87e-05	0.00339	0.36	0.19	Foot ulcer in diabetes and neuropathy;	chr6:36045247	chr6:35989515~35990436:-
LUAD	cis	rs80028505	0.71	rs6934216	ENSG00000271304.1	DPRXP2	4.32	1.87e-05	0.00339	0.36	0.19	Foot ulcer in diabetes and neuropathy;	chr6:36059856	chr6:35989515~35990436:-
LUAD	cis	rs80028505	0.731	rs61364424	ENSG00000271304.1	DPRXP2	4.32	1.87e-05	0.00339	0.36	0.19	Foot ulcer in diabetes and neuropathy;	chr6:36064129	chr6:35989515~35990436:-
LUAD	cis	rs4268898	0.722	rs7563958	ENSG00000223754.1	AC008073.9	-4.32	1.87e-05	0.00339	-0.23	-0.19	Asthma;	chr2:24199512	chr2:24199839~24201698:-
LUAD	cis	rs3096299	0.582	rs12935119	ENSG00000261118.1	RP11-104N10.1	4.32	1.88e-05	0.00339	0.2	0.19	Multiple myeloma (IgH translocation);	chr16:89476466	chr16:89492017~89504460:-
LUAD	cis	rs3018712	0.532	rs28551086	ENSG00000212093.1	AP000807.1	4.32	1.88e-05	0.00339	0.27	0.19	Total body bone mineral density;	chr11:68633271	chr11:68506083~68506166:-
LUAD	cis	rs911555	0.755	rs2756132	ENSG00000244691.1	RPL10AP1	4.32	1.88e-05	0.00339	0.26	0.19	Intelligence (multi-trait analysis);	chr14:103501483	chr14:103412119~103412761:-
LUAD	cis	rs6723108	0.627	rs55865348	ENSG00000224043.6	CCNT2-AS1	-4.32	1.88e-05	0.00339	-0.24	-0.19	Type 2 diabetes;	chr2:134892235	chr2:134735464~134918710:-
LUAD	cis	rs6964587	1	rs28927678	ENSG00000188693.7	CYP51A1-AS1	-4.32	1.88e-05	0.00339	-0.23	-0.19	Breast cancer;	chr7:92086348	chr7:92134604~92180725:+
LUAD	cis	rs897984	0.537	rs8045637	ENSG00000260911.2	RP11-196G11.2	4.32	1.88e-05	0.00339	0.17	0.19	Dementia with Lewy bodies;	chr16:30807341	chr16:31043150~31049868:+
LUAD	cis	rs453301	0.686	rs11785634	ENSG00000233609.3	RP11-62H7.2	-4.32	1.88e-05	0.00339	-0.16	-0.19	Joint mobility (Beighton score);	chr8:9035087	chr8:8961200~8979025:+
LUAD	cis	rs4819052	0.851	rs2838829	ENSG00000237664.1	LINC00316	-4.32	1.88e-05	0.00339	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244125	chr21:45338590~45341990:-
LUAD	cis	rs11009175	0.929	rs11009199	ENSG00000273038.2	RP11-479G22.8	-4.32	1.88e-05	0.00339	-0.31	-0.19	Depression (quantitative trait);	chr10:33053400	chr10:32887255~32889311:-
LUAD	cis	rs8077577	0.671	rs4925177	ENSG00000273018.4	CTD-2303H24.2	-4.32	1.88e-05	0.00339	-0.26	-0.19	Obesity-related traits;	chr17:18349554	chr17:18511221~18551705:-
LUAD	cis	rs8077577	0.671	rs4925178	ENSG00000273018.4	CTD-2303H24.2	-4.32	1.88e-05	0.00339	-0.26	-0.19	Obesity-related traits;	chr17:18349597	chr17:18511221~18551705:-
LUAD	cis	rs7772486	0.686	rs857883	ENSG00000235652.6	RP11-545I5.3	-4.32	1.88e-05	0.00339	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145648078	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.686	rs857882	ENSG00000235652.6	RP11-545I5.3	-4.32	1.88e-05	0.00339	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145648580	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.686	rs857877	ENSG00000235652.6	RP11-545I5.3	-4.32	1.88e-05	0.00339	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145655094	chr6:145799409~145886585:+
LUAD	cis	rs2060793	0.519	rs7931291	ENSG00000251991.1	RNU7-49P	-4.32	1.88e-05	0.00339	-0.2	-0.19	Vitamin D levels;	chr11:14622880	chr11:14478892~14478953:+
LUAD	cis	rs12468226	1	rs7565875	ENSG00000272966.1	RP11-686O6.1	4.32	1.88e-05	0.00339	0.3	0.19	Urate levels;	chr2:202516412	chr2:202336739~202337200:+
LUAD	cis	rs6081541	0.622	rs6035257	ENSG00000179447.2	RP5-1027G4.3	4.32	1.88e-05	0.00339	0.21	0.19	Psychosis (atypical);	chr20:19224067	chr20:19242302~19284596:-
LUAD	cis	rs6081541	0.622	rs6035259	ENSG00000179447.2	RP5-1027G4.3	4.32	1.88e-05	0.00339	0.21	0.19	Psychosis (atypical);	chr20:19225349	chr20:19242302~19284596:-
LUAD	cis	rs11009175	0.512	rs6481832	ENSG00000273038.2	RP11-479G22.8	-4.32	1.88e-05	0.00339	-0.23	-0.19	Depression (quantitative trait);	chr10:33092853	chr10:32887255~32889311:-
LUAD	cis	rs2348418	0.864	rs7314984	ENSG00000244712.1	RP11-874G11.1	4.32	1.88e-05	0.00339	0.23	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28557936	chr12:28564678~28565141:-
LUAD	cis	rs17685	0.712	rs4552844	ENSG00000280388.1	RP11-229D13.3	-4.32	1.88e-05	0.0034	-0.18	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76088777	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.712	rs4732578	ENSG00000280388.1	RP11-229D13.3	-4.32	1.88e-05	0.0034	-0.18	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76092214	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.587	rs1623759	ENSG00000280388.1	RP11-229D13.3	-4.32	1.88e-05	0.0034	-0.18	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76095361	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.625	rs1639630	ENSG00000280388.1	RP11-229D13.3	-4.32	1.88e-05	0.0034	-0.18	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76101181	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.753	rs1637051	ENSG00000280388.1	RP11-229D13.3	-4.32	1.88e-05	0.0034	-0.18	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76101341	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.753	rs4573217	ENSG00000280388.1	RP11-229D13.3	-4.32	1.88e-05	0.0034	-0.18	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76104628	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.784	rs1613890	ENSG00000280388.1	RP11-229D13.3	-4.32	1.88e-05	0.0034	-0.18	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76105719	chr7:76043977~76045963:-
LUAD	cis	rs12188164	0.965	rs41282625	ENSG00000225138.6	CTD-2228K2.7	4.32	1.88e-05	0.0034	0.19	0.19	Cystic fibrosis severity;	chr5:475511	chr5:473236~480884:+
LUAD	cis	rs453301	0.686	rs2409120	ENSG00000233609.3	RP11-62H7.2	-4.32	1.88e-05	0.0034	-0.16	-0.19	Joint mobility (Beighton score);	chr8:9025061	chr8:8961200~8979025:+
LUAD	cis	rs2281603	0.951	rs12586212	ENSG00000259116.1	RP11-973N13.4	-4.32	1.88e-05	0.0034	-0.18	-0.19	Lymphocyte counts;	chr14:64513329	chr14:64514154~64540368:-
LUAD	cis	rs2281603	0.951	rs61615397	ENSG00000259116.1	RP11-973N13.4	-4.32	1.88e-05	0.0034	-0.18	-0.19	Lymphocyte counts;	chr14:64514346	chr14:64514154~64540368:-
LUAD	cis	rs2281603	0.951	rs10133243	ENSG00000259116.1	RP11-973N13.4	-4.32	1.88e-05	0.0034	-0.18	-0.19	Lymphocyte counts;	chr14:64514807	chr14:64514154~64540368:-
LUAD	cis	rs2281603	0.951	rs12589947	ENSG00000259116.1	RP11-973N13.4	-4.32	1.88e-05	0.0034	-0.18	-0.19	Lymphocyte counts;	chr14:64515453	chr14:64514154~64540368:-
LUAD	cis	rs2281603	0.951	rs3783724	ENSG00000259116.1	RP11-973N13.4	-4.32	1.88e-05	0.0034	-0.18	-0.19	Lymphocyte counts;	chr14:64516759	chr14:64514154~64540368:-
LUAD	cis	rs2281603	0.951	rs3783723	ENSG00000259116.1	RP11-973N13.4	-4.32	1.88e-05	0.0034	-0.18	-0.19	Lymphocyte counts;	chr14:64516821	chr14:64514154~64540368:-
LUAD	cis	rs2281603	0.951	rs12587136	ENSG00000259116.1	RP11-973N13.4	-4.32	1.88e-05	0.0034	-0.18	-0.19	Lymphocyte counts;	chr14:64518570	chr14:64514154~64540368:-
LUAD	cis	rs2281603	0.951	rs58893738	ENSG00000259116.1	RP11-973N13.4	-4.32	1.88e-05	0.0034	-0.18	-0.19	Lymphocyte counts;	chr14:64519093	chr14:64514154~64540368:-
LUAD	cis	rs2281603	0.951	rs28626711	ENSG00000259116.1	RP11-973N13.4	-4.32	1.88e-05	0.0034	-0.18	-0.19	Lymphocyte counts;	chr14:64521561	chr14:64514154~64540368:-
LUAD	cis	rs2281603	0.951	rs10133411	ENSG00000259116.1	RP11-973N13.4	-4.32	1.88e-05	0.0034	-0.18	-0.19	Lymphocyte counts;	chr14:64522206	chr14:64514154~64540368:-
LUAD	cis	rs2281603	0.951	rs17101896	ENSG00000259116.1	RP11-973N13.4	-4.32	1.88e-05	0.0034	-0.18	-0.19	Lymphocyte counts;	chr14:64526205	chr14:64514154~64540368:-
LUAD	cis	rs2281603	0.951	rs59512674	ENSG00000259116.1	RP11-973N13.4	-4.32	1.88e-05	0.0034	-0.18	-0.19	Lymphocyte counts;	chr14:64526295	chr14:64514154~64540368:-
LUAD	cis	rs2281603	0.951	rs61985711	ENSG00000259116.1	RP11-973N13.4	-4.32	1.88e-05	0.0034	-0.18	-0.19	Lymphocyte counts;	chr14:64526540	chr14:64514154~64540368:-
LUAD	cis	rs2281603	0.951	rs10142835	ENSG00000259116.1	RP11-973N13.4	-4.32	1.88e-05	0.0034	-0.18	-0.19	Lymphocyte counts;	chr14:64526733	chr14:64514154~64540368:-
LUAD	cis	rs2281603	0.951	rs10143170	ENSG00000259116.1	RP11-973N13.4	-4.32	1.88e-05	0.0034	-0.18	-0.19	Lymphocyte counts;	chr14:64527045	chr14:64514154~64540368:-
LUAD	cis	rs2281603	0.951	rs10138256	ENSG00000259116.1	RP11-973N13.4	-4.32	1.88e-05	0.0034	-0.18	-0.19	Lymphocyte counts;	chr14:64528494	chr14:64514154~64540368:-
LUAD	cis	rs2281603	0.951	rs10149286	ENSG00000259116.1	RP11-973N13.4	-4.32	1.88e-05	0.0034	-0.18	-0.19	Lymphocyte counts;	chr14:64528518	chr14:64514154~64540368:-
LUAD	cis	rs2281603	0.951	rs1453009	ENSG00000259116.1	RP11-973N13.4	-4.32	1.88e-05	0.0034	-0.18	-0.19	Lymphocyte counts;	chr14:64528976	chr14:64514154~64540368:-
LUAD	cis	rs2243480	0.764	rs2460423	ENSG00000229886.1	RP5-1132H15.3	4.32	1.88e-05	0.0034	0.33	0.19	Diabetic kidney disease;	chr7:66136229	chr7:66025126~66031544:-
LUAD	cis	rs4578769	0.569	rs9967326	ENSG00000265943.1	RP11-739L10.1	4.32	1.88e-05	0.0034	0.24	0.19	Eosinophil percentage of white cells;	chr18:22916787	chr18:22699481~22933764:-
LUAD	cis	rs4578769	0.569	rs9946660	ENSG00000265943.1	RP11-739L10.1	4.32	1.88e-05	0.0034	0.24	0.19	Eosinophil percentage of white cells;	chr18:22917007	chr18:22699481~22933764:-
LUAD	cis	rs4578769	0.55	rs721578	ENSG00000265943.1	RP11-739L10.1	4.32	1.88e-05	0.0034	0.24	0.19	Eosinophil percentage of white cells;	chr18:22922719	chr18:22699481~22933764:-
LUAD	cis	rs4578769	0.569	rs7229422	ENSG00000265943.1	RP11-739L10.1	4.32	1.88e-05	0.0034	0.24	0.19	Eosinophil percentage of white cells;	chr18:22923157	chr18:22699481~22933764:-
LUAD	cis	rs4578769	0.589	rs9964726	ENSG00000265943.1	RP11-739L10.1	4.32	1.88e-05	0.0034	0.24	0.19	Eosinophil percentage of white cells;	chr18:22925516	chr18:22699481~22933764:-
LUAD	cis	rs4578769	0.569	rs9958831	ENSG00000265943.1	RP11-739L10.1	4.32	1.88e-05	0.0034	0.24	0.19	Eosinophil percentage of white cells;	chr18:22926050	chr18:22699481~22933764:-
LUAD	cis	rs4578769	0.569	rs11659166	ENSG00000265943.1	RP11-739L10.1	4.32	1.88e-05	0.0034	0.24	0.19	Eosinophil percentage of white cells;	chr18:22926143	chr18:22699481~22933764:-
LUAD	cis	rs4908768	0.539	rs1809332	ENSG00000270282.1	RP5-1115A15.2	4.32	1.88e-05	0.0034	0.21	0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8596375	chr1:8512653~8513021:+
LUAD	cis	rs6687758	1	rs12135286	ENSG00000200033.1	RNU6-403P	4.32	1.88e-05	0.0034	0.27	0.19	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222045419	chr1:221837334~221837437:-
LUAD	cis	rs6549438	0.504	rs7634042	ENSG00000241163.6	LINC00877	-4.32	1.88e-05	0.0034	-0.19	-0.19	Migraine - clinic-based;	chr3:72118931	chr3:72035300~72279503:-
LUAD	cis	rs11779988	0.545	rs404186	ENSG00000253671.1	RP11-806O11.1	-4.32	1.88e-05	0.0034	-0.24	-0.19	Breast cancer;	chr8:17937987	chr8:17808941~17820868:+
LUAD	cis	rs35762459	1	rs35762459	ENSG00000254860.4	TMEM9B-AS1	4.32	1.88e-05	0.0034	0.23	0.19	Immature fraction of reticulocytes;	chr11:8823106	chr11:8964675~8977527:+
LUAD	cis	rs7119038	0.818	rs10892280	ENSG00000255422.1	AP002954.4	4.32	1.88e-05	0.0034	0.31	0.19	Sjögren's syndrome;	chr11:118741108	chr11:118704607~118750263:+
LUAD	cis	rs4819052	0.851	rs2838864	ENSG00000237664.1	LINC00316	4.32	1.88e-05	0.0034	0.24	0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291559	chr21:45338590~45341990:-
LUAD	cis	rs8177876	0.749	rs11537	ENSG00000261061.1	RP11-303E16.2	-4.32	1.88e-05	0.0034	-0.31	-0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81046894	chr16:81030770~81031485:+
LUAD	cis	rs891378	1	rs2914937	ENSG00000274245.1	RP11-357P18.2	-4.32	1.88e-05	0.0034	-0.25	-0.19	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207315423	chr1:207372559~207373252:+
LUAD	cis	rs1876905	0.539	rs241003	ENSG00000230177.1	RP5-1112D6.4	4.32	1.88e-05	0.0034	0.24	0.19	Mean corpuscular hemoglobin;	chr6:111274934	chr6:111277932~111278742:+
LUAD	cis	rs9506514	0.509	rs9509279	ENSG00000222726.1	RNU2-7P	4.32	1.88e-05	0.0034	0.24	0.19	Coronary artery calcification;	chr13:20559580	chr13:20612161~20612338:+
LUAD	cis	rs34375054	0.624	rs7295689	ENSG00000279233.1	RP11-158L12.4	4.32	1.89e-05	0.0034	0.17	0.19	Post bronchodilator FEV1/FVC ratio;	chr12:125196376	chr12:125138245~125141711:+
LUAD	cis	rs7061710	0.711	rs2272797	ENSG00000271811.1	RP1-79C4.4	-4.32	1.89e-05	0.0034	-0.29	-0.19	Blood metabolite levels;	chr1:171149701	chr1:170667381~170669425:+
LUAD	cis	rs7100689	0.524	rs7902460	ENSG00000226659.1	RP11-137H2.4	-4.32	1.89e-05	0.00341	-0.26	-0.19	Post bronchodilator FEV1;	chr10:80439507	chr10:80529597~80535942:-
LUAD	cis	rs1005277	0.505	rs200935	ENSG00000263064.2	RP11-291L22.7	4.32	1.89e-05	0.00341	0.2	0.19	Extrinsic epigenetic age acceleration;	chr10:37843882	chr10:38448689~38448949:+
LUAD	cis	rs9500256	1	rs9500256	ENSG00000266579.1	RP1-71H19.2	-4.32	1.89e-05	0.00341	-0.24	-0.19	Eosinophilic esophagitis (pediatric);	chr6:57982677	chr6:57493855~57497691:+
LUAD	cis	rs62025270	0.688	rs62022941	ENSG00000202081.1	RNU6-1280P	-4.32	1.89e-05	0.00341	-0.28	-0.19	Idiopathic pulmonary fibrosis;	chr15:85712824	chr15:85651522~85651628:-
LUAD	cis	rs4819052	0.851	rs28616694	ENSG00000237664.1	LINC00316	-4.32	1.89e-05	0.00341	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254871	chr21:45338590~45341990:-
LUAD	cis	rs6471393	0.929	rs7016930	ENSG00000253848.1	RP11-10N23.5	4.32	1.89e-05	0.00341	0.24	0.19	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93743185	chr8:93741193~93744534:+
LUAD	cis	rs6471393	0.929	rs7017036	ENSG00000253848.1	RP11-10N23.5	4.32	1.89e-05	0.00341	0.24	0.19	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93743216	chr8:93741193~93744534:+
LUAD	cis	rs2446066	0.872	rs7300593	ENSG00000257379.1	RP11-793H13.8	4.32	1.89e-05	0.00341	0.32	0.19	Red blood cell count;	chr12:53396666	chr12:53441741~53467528:+
LUAD	cis	rs3814244	0.528	rs12582272	ENSG00000236946.2	HNRNPA1P70	-4.32	1.89e-05	0.00341	-0.17	-0.19	Itch intensity from mosquito bite adjusted by bite size;	chr12:68006298	chr12:68035767~68036853:+
LUAD	cis	rs6840360	0.642	rs7678823	ENSG00000270265.1	RP11-731D1.4	-4.32	1.89e-05	0.00341	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151435967	chr4:151333775~151353224:-
LUAD	cis	rs6687758	0.732	rs72740077	ENSG00000227925.1	RP11-191N8.2	4.32	1.89e-05	0.00341	0.26	0.19	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221940827	chr1:221827666~221840666:-
LUAD	cis	rs75920871	0.61	rs74341458	ENSG00000254851.1	RP11-109L13.1	-4.32	1.89e-05	0.00341	-0.42	-0.19	Subjective well-being;	chr11:116880833	chr11:117135528~117138582:+
LUAD	cis	rs12701220	0.894	rs10263252	ENSG00000229043.2	AC091729.9	-4.32	1.89e-05	0.00342	-0.25	-0.19	Bronchopulmonary dysplasia;	chr7:1010313	chr7:1160374~1165267:+
LUAD	cis	rs4819052	0.851	rs1999333	ENSG00000237664.1	LINC00316	-4.32	1.89e-05	0.00342	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250486	chr21:45338590~45341990:-
LUAD	cis	rs2243480	1	rs73142162	ENSG00000226002.1	RP11-460N20.5	-4.32	1.89e-05	0.00342	-0.34	-0.19	Diabetic kidney disease;	chr7:65909309	chr7:65084103~65100232:+
LUAD	cis	rs17711722	1	rs17711722	ENSG00000237310.1	GS1-124K5.4	-4.32	1.89e-05	0.00342	-0.21	-0.19	Calcium levels;	chr7:65806210	chr7:66493706~66495474:+
LUAD	cis	rs17711722	0.675	rs6947132	ENSG00000237310.1	GS1-124K5.4	-4.32	1.89e-05	0.00342	-0.21	-0.19	Calcium levels;	chr7:65808508	chr7:66493706~66495474:+
LUAD	cis	rs17772222	1	rs79579293	ENSG00000258983.2	RP11-507K2.2	4.32	1.89e-05	0.00342	0.23	0.19	Coronary artery calcification;	chr14:88355724	chr14:88499334~88515502:+
LUAD	cis	rs17772222	0.917	rs77382318	ENSG00000258983.2	RP11-507K2.2	4.32	1.89e-05	0.00342	0.23	0.19	Coronary artery calcification;	chr14:88355785	chr14:88499334~88515502:+
LUAD	cis	rs1707322	0.638	rs1707302	ENSG00000234329.1	RP11-767N6.2	-4.32	1.89e-05	0.00342	-0.19	-0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46135245	chr1:45651039~45651826:-
LUAD	cis	rs8072100	0.688	rs8079142	ENSG00000228782.6	CTD-2026D20.3	4.32	1.89e-05	0.00342	0.21	0.19	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47364683	chr17:47450568~47492492:-
LUAD	cis	rs8072100	0.688	rs8075843	ENSG00000228782.6	CTD-2026D20.3	4.32	1.89e-05	0.00342	0.21	0.19	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47364997	chr17:47450568~47492492:-
LUAD	cis	rs2467099	0.732	rs2168855	ENSG00000267801.1	RP11-552F3.9	4.32	1.89e-05	0.00342	0.23	0.19	Systolic blood pressure;	chr17:75947269	chr17:75876372~75879546:+
LUAD	cis	rs6840360	0.642	rs2724578	ENSG00000270265.1	RP11-731D1.4	-4.32	1.89e-05	0.00342	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151446152	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.574	rs2709844	ENSG00000270265.1	RP11-731D1.4	-4.32	1.89e-05	0.00342	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151447060	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.642	rs7657670	ENSG00000270265.1	RP11-731D1.4	-4.32	1.9e-05	0.00342	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151432223	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.642	rs2709828	ENSG00000270265.1	RP11-731D1.4	-4.32	1.9e-05	0.00342	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151434116	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.642	rs2724551	ENSG00000270265.1	RP11-731D1.4	-4.32	1.9e-05	0.00342	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151434231	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.667	rs2709829	ENSG00000270265.1	RP11-731D1.4	-4.32	1.9e-05	0.00342	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151434238	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.606	rs2709813	ENSG00000270265.1	RP11-731D1.4	-4.32	1.9e-05	0.00342	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151436292	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.606	rs2724550	ENSG00000270265.1	RP11-731D1.4	-4.32	1.9e-05	0.00342	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151437834	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.642	rs2709815	ENSG00000270265.1	RP11-731D1.4	-4.32	1.9e-05	0.00342	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151442620	chr4:151333775~151353224:-
LUAD	cis	rs1355223	0.768	rs11032806	ENSG00000271369.1	RP11-350D17.3	-4.32	1.9e-05	0.00342	-0.23	-0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34670758	chr11:34709600~34710161:+
LUAD	cis	rs7580658	0.724	rs12623948	ENSG00000236682.1	AC068282.3	-4.32	1.9e-05	0.00342	-0.25	-0.19	Protein C levels;	chr2:127243766	chr2:127389130~127400580:+
LUAD	cis	rs791888	0.858	rs2180968	ENSG00000225913.2	RP11-57C13.6	-4.32	1.9e-05	0.00342	-0.25	-0.19	Magnesium levels;	chr10:87658973	chr10:87607985~87659279:+
LUAD	cis	rs3758785	0.737	rs79512686	ENSG00000255893.1	RP11-685N10.1	-4.32	1.9e-05	0.00342	-0.27	-0.19	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94398331	chr11:94472908~94473570:-
LUAD	cis	rs10971721	0.822	rs10971739	ENSG00000260947.1	RP11-384P7.7	4.32	1.9e-05	0.00342	0.38	0.19	Body mass index;	chr9:33855467	chr9:33697459~33700986:+
LUAD	cis	rs17685	0.753	rs3757593	ENSG00000280388.1	RP11-229D13.3	4.32	1.9e-05	0.00342	0.18	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76049417	chr7:76043977~76045963:-
LUAD	cis	rs9487094	0.961	rs3807005	ENSG00000260273.1	RP11-425D10.10	4.32	1.9e-05	0.00342	0.26	0.19	Height;	chr6:109469907	chr6:109382795~109383666:+
LUAD	cis	rs62025270	0.688	rs12148571	ENSG00000202081.1	RNU6-1280P	-4.32	1.9e-05	0.00343	-0.29	-0.19	Idiopathic pulmonary fibrosis;	chr15:85724162	chr15:85651522~85651628:-
LUAD	cis	rs9341808	0.718	rs12203867	ENSG00000272129.1	RP11-250B2.6	4.32	1.9e-05	0.00343	0.24	0.19	Sitting height ratio;	chr6:80111116	chr6:80355424~80356859:+
LUAD	cis	rs4938573	0.526	rs11216973	ENSG00000255239.1	AP002954.6	-4.32	1.9e-05	0.00343	-0.3	-0.19	Follicular lymphoma;	chr11:118716292	chr11:118688039~118690600:-
LUAD	cis	rs2933343	0.621	rs789249	ENSG00000231305.3	RP11-723O4.2	4.32	1.9e-05	0.00343	0.21	0.19	IgG glycosylation;	chr3:128859610	chr3:128861313~128871540:-
LUAD	cis	rs4819052	0.851	rs9974628	ENSG00000237664.1	LINC00316	-4.32	1.9e-05	0.00343	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252732	chr21:45338590~45341990:-
LUAD	cis	rs6951245	0.744	rs10275401	ENSG00000229043.2	AC091729.9	-4.32	1.9e-05	0.00343	-0.29	-0.19	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1174307	chr7:1160374~1165267:+
LUAD	cis	rs6570726	0.967	rs9403706	ENSG00000235652.6	RP11-545I5.3	-4.32	1.9e-05	0.00343	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145474051	chr6:145799409~145886585:+
LUAD	cis	rs7208859	0.573	rs7222803	ENSG00000280069.1	CTD-2349P21.3	-4.32	1.9e-05	0.00343	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30738182~30740275:+
LUAD	cis	rs4795519	0.744	rs67532205	ENSG00000266313.1	RP11-173M1.4	4.32	1.9e-05	0.00343	0.25	0.19	Chronic myeloid leukemia;	chr17:27159966	chr17:27333256~27348491:+
LUAD	cis	rs4795519	0.778	rs57555285	ENSG00000266313.1	RP11-173M1.4	4.32	1.9e-05	0.00343	0.25	0.19	Chronic myeloid leukemia;	chr17:27163823	chr17:27333256~27348491:+
LUAD	cis	rs4795519	0.778	rs4795501	ENSG00000266313.1	RP11-173M1.4	4.32	1.9e-05	0.00343	0.25	0.19	Chronic myeloid leukemia;	chr17:27174837	chr17:27333256~27348491:+
LUAD	cis	rs4795519	0.778	rs1479361	ENSG00000266313.1	RP11-173M1.4	4.32	1.9e-05	0.00343	0.25	0.19	Chronic myeloid leukemia;	chr17:27180715	chr17:27333256~27348491:+
LUAD	cis	rs7015630	0.738	rs7013987	ENSG00000251136.7	RP11-37B2.1	-4.32	1.9e-05	0.00343	-0.24	-0.19	Inflammatory bowel disease;Crohn's disease;	chr8:89860755	chr8:89609409~89757727:-
LUAD	cis	rs7131987	0.565	rs10743652	ENSG00000257176.2	RP11-996F15.2	4.32	1.9e-05	0.00343	0.2	0.19	QT interval;	chr12:29255074	chr12:29280418~29317848:-
LUAD	cis	rs2243480	1	rs4149468	ENSG00000232559.3	GS1-124K5.12	4.32	1.9e-05	0.00343	0.33	0.19	Diabetic kidney disease;	chr7:66360703	chr7:66554588~66576923:-
LUAD	cis	rs10197140	0.925	rs10164695	ENSG00000235721.1	AC013268.3	-4.32	1.9e-05	0.00343	-0.21	-0.19	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110868114	chr2:110007675~110010783:+
LUAD	cis	rs10197140	0.925	rs880507	ENSG00000235721.1	AC013268.3	-4.32	1.9e-05	0.00343	-0.21	-0.19	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110869546	chr2:110007675~110010783:+
LUAD	cis	rs73198271	0.71	rs11779565	ENSG00000233609.3	RP11-62H7.2	-4.32	1.9e-05	0.00343	-0.16	-0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8822510	chr8:8961200~8979025:+
LUAD	cis	rs2115630	0.905	rs1975277	ENSG00000225151.9	GOLGA2P7	4.32	1.91e-05	0.00343	0.22	0.19	P wave terminal force;	chr15:84786327	chr15:84199311~84230136:-
LUAD	cis	rs17772222	1	rs17772222	ENSG00000258789.1	RP11-507K2.3	4.32	1.91e-05	0.00344	0.27	0.19	Coronary artery calcification;	chr14:88360138	chr14:88551597~88552493:+
LUAD	cis	rs6061231	0.561	rs67072353	ENSG00000273619.1	RP5-908M14.9	-4.32	1.91e-05	0.00344	-0.24	-0.19	Colorectal cancer;	chr20:62365646	chr20:62386303~62386970:-
LUAD	cis	rs6860806	0.631	rs7736284	ENSG00000233006.5	AC034220.3	4.32	1.91e-05	0.00344	0.17	0.19	Breast cancer;	chr5:132252458	chr5:132311285~132369916:-
LUAD	cis	rs62025270	0.688	rs17638180	ENSG00000202081.1	RNU6-1280P	-4.32	1.91e-05	0.00344	-0.27	-0.19	Idiopathic pulmonary fibrosis;	chr15:85735164	chr15:85651522~85651628:-
LUAD	cis	rs62229266	0.626	rs2835268	ENSG00000214914.3	RPL23AP3	4.32	1.91e-05	0.00344	0.23	0.19	Mitral valve prolapse;	chr21:36076838	chr21:36016079~36016546:-
LUAD	cis	rs6496044	0.568	rs6496049	ENSG00000259295.5	CSPG4P12	4.32	1.91e-05	0.00344	0.22	0.19	Interstitial lung disease;	chr15:85525974	chr15:85191438~85213905:+
LUAD	cis	rs7927592	0.513	rs653056	ENSG00000212093.1	AP000807.1	4.32	1.91e-05	0.00344	0.2	0.19	Total body bone mineral density;	chr11:68436157	chr11:68506083~68506166:-
LUAD	cis	rs5758659	0.714	rs133373	ENSG00000182057.4	OGFRP1	4.32	1.91e-05	0.00344	0.23	0.19	Cognitive function;	chr22:42069784	chr22:42269753~42275196:+
LUAD	cis	rs17772222	1	rs1955599	ENSG00000258983.2	RP11-507K2.2	4.32	1.91e-05	0.00344	0.23	0.19	Coronary artery calcification;	chr14:88358788	chr14:88499334~88515502:+
LUAD	cis	rs17772222	1	rs1955600	ENSG00000258983.2	RP11-507K2.2	4.32	1.91e-05	0.00344	0.23	0.19	Coronary artery calcification;	chr14:88359040	chr14:88499334~88515502:+
LUAD	cis	rs62025270	0.632	rs10520594	ENSG00000202081.1	RNU6-1280P	4.32	1.91e-05	0.00344	0.29	0.19	Idiopathic pulmonary fibrosis;	chr15:85585410	chr15:85651522~85651628:-
LUAD	cis	rs9400467	0.528	rs1623806	ENSG00000230177.1	RP5-1112D6.4	-4.32	1.91e-05	0.00344	-0.17	-0.19	Amino acid levels;Blood metabolite levels;	chr6:111343868	chr6:111277932~111278742:+
LUAD	cis	rs9400467	0.528	rs455247	ENSG00000230177.1	RP5-1112D6.4	-4.32	1.91e-05	0.00344	-0.17	-0.19	Amino acid levels;Blood metabolite levels;	chr6:111346596	chr6:111277932~111278742:+
LUAD	cis	rs7760535	0.811	rs464401	ENSG00000230177.1	RP5-1112D6.4	-4.32	1.91e-05	0.00344	-0.17	-0.19	Metabolic traits;	chr6:111347804	chr6:111277932~111278742:+
LUAD	cis	rs9400467	0.509	rs463854	ENSG00000230177.1	RP5-1112D6.4	-4.32	1.91e-05	0.00344	-0.17	-0.19	Amino acid levels;Blood metabolite levels;	chr6:111352004	chr6:111277932~111278742:+
LUAD	cis	rs9400467	0.509	rs463853	ENSG00000230177.1	RP5-1112D6.4	-4.32	1.91e-05	0.00344	-0.17	-0.19	Amino acid levels;Blood metabolite levels;	chr6:111352008	chr6:111277932~111278742:+
LUAD	cis	rs9400467	0.528	rs456569	ENSG00000230177.1	RP5-1112D6.4	-4.32	1.91e-05	0.00344	-0.17	-0.19	Amino acid levels;Blood metabolite levels;	chr6:111353598	chr6:111277932~111278742:+
LUAD	cis	rs9400467	0.528	rs455335	ENSG00000230177.1	RP5-1112D6.4	-4.32	1.91e-05	0.00344	-0.17	-0.19	Amino acid levels;Blood metabolite levels;	chr6:111354313	chr6:111277932~111278742:+
LUAD	cis	rs11168351	0.927	rs7971880	ENSG00000240399.1	RP1-228P16.1	4.32	1.91e-05	0.00344	0.19	0.19	Bipolar disorder and schizophrenia;	chr12:47997272	chr12:48054813~48055591:-
LUAD	cis	rs2281558	0.837	rs67676850	ENSG00000125804.12	FAM182A	-4.32	1.91e-05	0.00344	-0.27	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25388781	chr20:26054655~26086917:+
LUAD	cis	rs911555	0.755	rs1116095	ENSG00000244691.1	RPL10AP1	4.32	1.91e-05	0.00344	0.26	0.19	Intelligence (multi-trait analysis);	chr14:103465542	chr14:103412119~103412761:-
LUAD	cis	rs911555	0.755	rs8010247	ENSG00000244691.1	RPL10AP1	4.32	1.91e-05	0.00344	0.26	0.19	Intelligence (multi-trait analysis);	chr14:103467219	chr14:103412119~103412761:-
LUAD	cis	rs1876905	0.569	rs354523	ENSG00000230177.1	RP5-1112D6.4	-4.32	1.91e-05	0.00344	-0.22	-0.19	Mean corpuscular hemoglobin;	chr6:111188122	chr6:111277932~111278742:+
LUAD	cis	rs6957923	1	rs6957923	ENSG00000230658.1	KLHL7-AS1	4.32	1.91e-05	0.00344	0.23	0.19	Height;	chr7:23443066	chr7:23101228~23105703:-
LUAD	cis	rs17122278	1	rs11216896	ENSG00000243431.1	RPL5P30	4.32	1.91e-05	0.00344	0.24	0.19	Total cholesterol levels;	chr11:118559333	chr11:118560690~118561580:+
LUAD	cis	rs950169	0.96	rs35159785	ENSG00000275120.1	RP11-182J1.17	4.32	1.91e-05	0.00344	0.31	0.19	Schizophrenia;	chr15:84135262	chr15:84599434~84606463:-
LUAD	cis	rs66486766	1	rs66486766	ENSG00000275120.1	RP11-182J1.17	4.32	1.91e-05	0.00344	0.31	0.19	Bipolar disorder lithium response (categorical) or schizophrenia;	chr15:84137308	chr15:84599434~84606463:-
LUAD	cis	rs8030379	1	rs2401176	ENSG00000230373.7	GOLGA6L5P	-4.32	1.91e-05	0.00344	-0.18	-0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83909612	chr15:84507885~84516814:-
LUAD	cis	rs6964587	1	rs13231820	ENSG00000188693.7	CYP51A1-AS1	-4.32	1.91e-05	0.00344	-0.23	-0.19	Breast cancer;	chr7:92034215	chr7:92134604~92180725:+
LUAD	cis	rs516805	0.528	rs2606658	ENSG00000279453.1	RP3-425C14.4	-4.32	1.91e-05	0.00344	-0.26	-0.19	Lymphocyte counts;	chr6:122082742	chr6:122436789~122439223:-
LUAD	cis	rs7208859	0.673	rs216440	ENSG00000280069.1	CTD-2349P21.3	-4.32	1.91e-05	0.00344	-0.23	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30601291	chr17:30738182~30740275:+
LUAD	cis	rs62355901	0.599	rs62355899	ENSG00000271828.1	CTD-2310F14.1	4.32	1.91e-05	0.00344	0.38	0.19	Breast cancer;	chr5:56754638	chr5:56927874~56929573:+
LUAD	cis	rs17685	0.633	rs3801471	ENSG00000280388.1	RP11-229D13.3	-4.32	1.91e-05	0.00344	-0.18	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76066870	chr7:76043977~76045963:-
LUAD	cis	rs5758511	0.68	rs1107553	ENSG00000227370.1	RP4-669P10.19	4.32	1.91e-05	0.00344	0.21	0.19	Birth weight;	chr22:42271467	chr22:42132543~42132998:+
LUAD	cis	rs6496932	0.635	rs11632761	ENSG00000259630.2	CTD-2262B20.1	-4.32	1.91e-05	0.00344	-0.24	-0.19	Central corneal thickness;Corneal structure;	chr15:85387562	chr15:85415228~85415633:+
LUAD	cis	rs6496932	0.635	rs67659163	ENSG00000259630.2	CTD-2262B20.1	-4.32	1.91e-05	0.00344	-0.24	-0.19	Central corneal thickness;Corneal structure;	chr15:85387673	chr15:85415228~85415633:+
LUAD	cis	rs9876781	0.559	rs7610524	ENSG00000229759.1	MRPS18AP1	4.32	1.91e-05	0.00344	0.19	0.19	Longevity;	chr3:48353882	chr3:48256350~48256938:-
LUAD	cis	rs13256369	0.95	rs13248096	ENSG00000253893.2	FAM85B	-4.32	1.91e-05	0.00344	-0.26	-0.19	Obesity-related traits;	chr8:8719966	chr8:8167819~8226614:-
LUAD	cis	rs7138803	0.51	rs7313400	ENSG00000257464.1	RP11-161H23.8	-4.32	1.91e-05	0.00344	-0.19	-0.19	Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index;	chr12:49810306	chr12:49442424~49442652:-
LUAD	cis	rs3096299	0.632	rs8051537	ENSG00000182376.2	RP5-1142A6.8	4.32	1.91e-05	0.00344	0.2	0.19	Multiple myeloma (IgH translocation);	chr16:89477976	chr16:88742767~88745748:+
LUAD	cis	rs2288073	0.965	rs10173173	ENSG00000242628.4	AC009228.1	-4.32	1.91e-05	0.00344	-0.26	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr2:24192592	chr2:24214381~24221516:+
LUAD	cis	rs1501911	0.545	rs4703345	ENSG00000248489.1	CTD-2007H13.3	-4.32	1.91e-05	0.00344	-0.24	-0.19	Lung function (FEV1/FVC);	chr5:99016679	chr5:98929171~98995013:+
LUAD	cis	rs7665090	0.875	rs6813322	ENSG00000246560.2	RP11-10L12.4	4.32	1.91e-05	0.00345	0.24	0.19	Primary biliary cholangitis;	chr4:102634462	chr4:102828055~102844075:+
LUAD	cis	rs2348418	0.801	rs7298379	ENSG00000244712.1	RP11-874G11.1	4.32	1.91e-05	0.00345	0.23	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28270541	chr12:28564678~28565141:-
LUAD	cis	rs4664293	0.718	rs4477859	ENSG00000230783.1	AC009961.2	4.32	1.91e-05	0.00345	0.23	0.19	Monocyte percentage of white cells;	chr2:159738616	chr2:159689217~159690291:-
LUAD	cis	rs477895	0.653	rs34113693	ENSG00000236935.1	AP003774.1	-4.32	1.91e-05	0.00345	-0.24	-0.19	Mean platelet volume;	chr11:64132651	chr11:64325050~64329504:-
LUAD	cis	rs910316	0.967	rs175498	ENSG00000279594.1	RP11-950C14.10	-4.32	1.92e-05	0.00345	-0.22	-0.19	Height;	chr14:75069666	chr14:75011269~75012851:-
LUAD	cis	rs6840360	0.642	rs2709834	ENSG00000270265.1	RP11-731D1.4	-4.32	1.92e-05	0.00345	-0.2	-0.19	Intelligence (multi-trait analysis);	chr4:151454272	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.642	rs6845648	ENSG00000270265.1	RP11-731D1.4	-4.32	1.92e-05	0.00345	-0.2	-0.19	Intelligence (multi-trait analysis);	chr4:151454898	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.642	rs2724571	ENSG00000270265.1	RP11-731D1.4	-4.32	1.92e-05	0.00345	-0.2	-0.19	Intelligence (multi-trait analysis);	chr4:151455643	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.642	rs2709833	ENSG00000270265.1	RP11-731D1.4	-4.32	1.92e-05	0.00345	-0.2	-0.19	Intelligence (multi-trait analysis);	chr4:151456470	chr4:151333775~151353224:-
LUAD	cis	rs2243480	1	rs1499614	ENSG00000232559.3	GS1-124K5.12	4.32	1.92e-05	0.00345	0.33	0.19	Diabetic kidney disease;	chr7:66265811	chr7:66554588~66576923:-
LUAD	cis	rs6840360	0.573	rs4696080	ENSG00000270265.1	RP11-731D1.4	-4.32	1.92e-05	0.00345	-0.2	-0.19	Intelligence (multi-trait analysis);	chr4:151355313	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.571	rs2165789	ENSG00000270265.1	RP11-731D1.4	-4.32	1.92e-05	0.00345	-0.22	-0.19	Intelligence (multi-trait analysis);	chr4:151588978	chr4:151333775~151353224:-
LUAD	cis	rs3814244	0.569	rs11177008	ENSG00000236946.2	HNRNPA1P70	-4.32	1.92e-05	0.00346	-0.17	-0.19	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021024	chr12:68035767~68036853:+
LUAD	cis	rs12701220	0.857	rs1057558	ENSG00000229043.2	AC091729.9	-4.32	1.92e-05	0.00346	-0.25	-0.19	Bronchopulmonary dysplasia;	chr7:1022730	chr7:1160374~1165267:+
LUAD	cis	rs2011013	0.912	rs3748369	ENSG00000259570.1	RP11-671M22.4	-4.32	1.92e-05	0.00346	-0.26	-0.19	Sitting height ratio;	chr15:83923610	chr15:84394512~84395514:+
LUAD	cis	rs9400467	0.528	rs456865	ENSG00000230177.1	RP5-1112D6.4	-4.32	1.92e-05	0.00346	-0.17	-0.19	Amino acid levels;Blood metabolite levels;	chr6:111311725	chr6:111277932~111278742:+
LUAD	cis	rs11216126	1	rs34637368	ENSG00000280143.1	AP000892.6	-4.32	1.92e-05	0.00346	-0.36	-0.19	HDL cholesterol;	chr11:116748889	chr11:117204967~117210292:+
LUAD	cis	rs1008375	0.897	rs67455495	ENSG00000249502.1	AC006160.5	4.32	1.92e-05	0.00346	0.19	0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17663615	chr4:17587467~17614571:-
LUAD	cis	rs1008375	0.932	rs6845288	ENSG00000249502.1	AC006160.5	4.32	1.92e-05	0.00346	0.19	0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17663875	chr4:17587467~17614571:-
LUAD	cis	rs8030379	1	rs6603004	ENSG00000230373.7	GOLGA6L5P	4.32	1.92e-05	0.00346	0.18	0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83899752	chr15:84507885~84516814:-
LUAD	cis	rs4639966	0.589	rs480958	ENSG00000255239.1	AP002954.6	4.32	1.92e-05	0.00346	0.23	0.19	Systemic lupus erythematosus;	chr11:118707281	chr11:118688039~118690600:-
LUAD	cis	rs7665090	0.87	rs228616	ENSG00000251288.2	RP11-10L12.2	4.32	1.92e-05	0.00346	0.23	0.19	Primary biliary cholangitis;	chr4:102658534	chr4:102751401~102752641:+
LUAD	cis	rs2898681	1	rs2898681	ENSG00000248375.1	RP11-177B4.1	-4.32	1.92e-05	0.00346	-0.29	-0.19	Optic nerve measurement (cup area);	chr4:52890833	chr4:52720081~52720831:-
LUAD	cis	rs11122895	0.509	rs3860380	ENSG00000236307.2	EEF1E1P1	-4.32	1.92e-05	0.00346	-0.2	-0.19	Allergic sensitization;	chr2:111693810	chr2:111887914~111888741:+
LUAD	cis	rs7714584	1	rs1000113	ENSG00000197083.10	ZNF300P1	4.32	1.92e-05	0.00346	0.35	0.19	Crohn's disease;	chr5:150860514	chr5:150930645~150946289:-
LUAD	cis	rs2243480	1	rs10807701	ENSG00000232559.3	GS1-124K5.12	-4.32	1.92e-05	0.00346	-0.34	-0.19	Diabetic kidney disease;	chr7:66259699	chr7:66554588~66576923:-
LUAD	cis	rs6714710	0.58	rs6711101	ENSG00000230606.9	AC159540.1	-4.32	1.92e-05	0.00346	-0.2	-0.19	Posterior cortical atrophy and Alzheimer's disease;	chr2:97763350	chr2:97416165~97433527:-
LUAD	cis	rs2243480	1	rs73142166	ENSG00000232559.3	GS1-124K5.12	4.32	1.92e-05	0.00346	0.34	0.19	Diabetic kidney disease;	chr7:65910845	chr7:66554588~66576923:-
LUAD	cis	rs17685	0.753	rs2868203	ENSG00000280388.1	RP11-229D13.3	4.32	1.92e-05	0.00346	0.18	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76050708	chr7:76043977~76045963:-
LUAD	cis	rs13113518	0.513	rs13147861	ENSG00000223305.1	RN7SKP30	4.32	1.92e-05	0.00347	0.23	0.19	Height;	chr4:55611014	chr4:55540502~55540835:-
LUAD	cis	rs80028505	0.908	rs7745082	ENSG00000271304.1	DPRXP2	4.32	1.92e-05	0.00347	0.37	0.19	Foot ulcer in diabetes and neuropathy;	chr6:36097845	chr6:35989515~35990436:-
LUAD	cis	rs2880765	0.743	rs16940052	ENSG00000259416.2	RP11-158M2.5	4.32	1.93e-05	0.00347	0.2	0.19	Coronary artery disease;	chr15:85463443	chr15:85754941~85756237:-
LUAD	cis	rs9400467	0.528	rs465795	ENSG00000230177.1	RP5-1112D6.4	-4.32	1.93e-05	0.00347	-0.17	-0.19	Amino acid levels;Blood metabolite levels;	chr6:111355240	chr6:111277932~111278742:+
LUAD	cis	rs9400467	0.528	rs110732	ENSG00000230177.1	RP5-1112D6.4	-4.32	1.93e-05	0.00347	-0.17	-0.19	Amino acid levels;Blood metabolite levels;	chr6:111358666	chr6:111277932~111278742:+
LUAD	cis	rs9400467	0.592	rs462493	ENSG00000230177.1	RP5-1112D6.4	-4.32	1.93e-05	0.00347	-0.17	-0.19	Amino acid levels;Blood metabolite levels;	chr6:111362537	chr6:111277932~111278742:+
LUAD	cis	rs2243480	1	rs313799	ENSG00000232559.3	GS1-124K5.12	4.32	1.93e-05	0.00347	0.33	0.19	Diabetic kidney disease;	chr7:66029343	chr7:66554588~66576923:-
LUAD	cis	rs4947019	1	rs12206574	ENSG00000260273.1	RP11-425D10.10	4.32	1.93e-05	0.00347	0.4	0.19	Hematological parameters;	chr6:109746570	chr6:109382795~109383666:+
LUAD	cis	rs477895	0.653	rs11603212	ENSG00000236935.1	AP003774.1	4.32	1.93e-05	0.00347	0.23	0.19	Mean platelet volume;	chr11:64160338	chr11:64325050~64329504:-
LUAD	cis	rs10463554	0.927	rs468844	ENSG00000250682.4	LINC00491	4.32	1.93e-05	0.00347	0.24	0.19	Parkinson's disease;	chr5:103087872	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.927	rs469094	ENSG00000250682.4	LINC00491	4.32	1.93e-05	0.00347	0.24	0.19	Parkinson's disease;	chr5:103087875	chr5:102609156~102671559:-
LUAD	cis	rs4819052	0.851	rs2877019	ENSG00000237664.1	LINC00316	-4.32	1.93e-05	0.00347	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238732	chr21:45338590~45341990:-
LUAD	cis	rs507080	0.922	rs654792	ENSG00000278376.1	RP11-158I9.8	4.32	1.93e-05	0.00347	0.21	0.19	Serum metabolite levels;	chr11:118682287	chr11:118791254~118793137:+
LUAD	cis	rs911119	0.913	rs13038990	ENSG00000270001.1	RP11-218C14.8	-4.32	1.93e-05	0.00347	-0.28	-0.19	Chronic kidney disease;	chr20:23608416	chr20:23631826~23632316:-
LUAD	cis	rs77972916	0.561	rs13411629	ENSG00000234936.1	AC010883.5	4.32	1.93e-05	0.00347	0.25	0.19	Granulocyte percentage of myeloid white cells;	chr2:43339851	chr2:43229573~43233394:+
LUAD	cis	rs11089937	0.637	rs988200	ENSG00000211640.3	IGLV6-57	4.32	1.93e-05	0.00347	0.15	0.19	Periodontitis (PAL4Q3);	chr22:22154715	chr22:22195713~22196460:+
LUAD	cis	rs12444979	0.517	rs720176	ENSG00000261195.1	CTD-2380F24.1	-4.32	1.93e-05	0.00347	-0.26	-0.19	Body mass index;	chr16:19710193	chr16:19761172~19766099:-
LUAD	cis	rs6832769	0.961	rs13152650	ENSG00000272969.1	RP11-528I4.2	4.32	1.93e-05	0.00347	0.2	0.19	Personality dimensions;	chr4:55491691	chr4:55547112~55547889:+
LUAD	cis	rs6686842	0.513	rs11579483	ENSG00000235358.1	RP11-399E6.1	-4.32	1.93e-05	0.00347	-0.23	-0.19	Height;	chr1:41014192	chr1:41242373~41284861:+
LUAD	cis	rs853679	0.55	rs1225598	ENSG00000226314.6	ZNF192P1	-4.32	1.93e-05	0.00347	-0.25	-0.19	Depression;	chr6:28193021	chr6:28161781~28169594:+
LUAD	cis	rs2273156	0.57	rs28365850	ENSG00000226677.3	IGBP1P1	-4.32	1.93e-05	0.00347	-0.31	-0.19	Immunoglobulin light chain (AL) amyloidosis;	chr14:35122110	chr14:34939324~34940332:+
LUAD	cis	rs6723226	0.75	rs762019	ENSG00000276334.1	AL133243.1	4.32	1.93e-05	0.00348	0.22	0.19	Intelligence (multi-trait analysis);	chr2:32463533	chr2:32521927~32523547:+
LUAD	cis	rs910316	0.967	rs7146523	ENSG00000279594.1	RP11-950C14.10	-4.32	1.93e-05	0.00348	-0.22	-0.19	Height;	chr14:75193177	chr14:75011269~75012851:-
LUAD	cis	rs10129255	0.719	rs7156660	ENSG00000211967.3	IGHV3-53	-4.32	1.93e-05	0.00348	-0.15	-0.19	Kawasaki disease;	chr14:106673171	chr14:106592676~106593347:-
LUAD	cis	rs262150	0.574	rs2730273	ENSG00000231419.5	LINC00689	-4.32	1.93e-05	0.00348	-0.24	-0.19	Facial morphology (factor 20);	chr7:159005063	chr7:159006522~159030195:+
LUAD	cis	rs7208859	0.623	rs55724095	ENSG00000266490.1	CTD-2349P21.9	4.32	1.93e-05	0.00348	0.28	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826040	chr17:30792372~30792833:+
LUAD	cis	rs17826219	0.568	rs9903854	ENSG00000266490.1	CTD-2349P21.9	4.32	1.93e-05	0.00348	0.28	0.19	Body mass index;	chr17:30826980	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs80355557	ENSG00000266490.1	CTD-2349P21.9	4.32	1.93e-05	0.00348	0.28	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827403	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs9911173	ENSG00000266490.1	CTD-2349P21.9	4.32	1.93e-05	0.00348	0.28	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827732	chr17:30792372~30792833:+
LUAD	cis	rs2732480	0.577	rs2634693	ENSG00000240399.1	RP1-228P16.1	4.32	1.93e-05	0.00348	0.2	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48312715	chr12:48054813~48055591:-
LUAD	cis	rs17685	0.753	rs1637045	ENSG00000280388.1	RP11-229D13.3	-4.32	1.93e-05	0.00348	-0.18	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76074577	chr7:76043977~76045963:-
LUAD	cis	rs442309	0.812	rs224135	ENSG00000238280.1	RP11-436D10.3	-4.32	1.93e-05	0.00348	-0.24	-0.19	Vogt-Koyanagi-Harada syndrome;	chr10:62707042	chr10:62793562~62805887:-
LUAD	cis	rs944990	0.538	rs966789	ENSG00000227603.1	RP11-165J3.6	4.32	1.93e-05	0.00348	0.22	0.19	Body mass index;	chr9:93556861	chr9:93435332~93437121:-
LUAD	cis	rs860295	0.557	rs10796941	ENSG00000225855.5	RUSC1-AS1	4.32	1.94e-05	0.00348	0.14	0.19	Body mass index;	chr1:155314470	chr1:155316863~155324176:-
LUAD	cis	rs860295	0.58	rs10908463	ENSG00000225855.5	RUSC1-AS1	4.32	1.94e-05	0.00348	0.14	0.19	Body mass index;	chr1:155316467	chr1:155316863~155324176:-
LUAD	cis	rs6142102	0.778	rs6059555	ENSG00000275784.1	RP5-1125A11.6	-4.32	1.94e-05	0.00348	-0.22	-0.19	Skin pigmentation;	chr20:33926518	chr20:33989480~33991818:-
LUAD	cis	rs957448	1	rs2381882	ENSG00000253175.1	RP11-267M23.6	4.32	1.94e-05	0.00348	0.24	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94535496	chr8:94565036~94565715:+
LUAD	cis	rs7829975	0.711	rs4481596	ENSG00000253981.4	ALG1L13P	4.31	1.94e-05	0.00349	0.22	0.19	Mood instability;	chr8:8846820	chr8:8236003~8244667:-
LUAD	cis	rs17122278	1	rs55857590	ENSG00000243431.1	RPL5P30	4.31	1.94e-05	0.00349	0.24	0.19	Total cholesterol levels;	chr11:118554348	chr11:118560690~118561580:+
LUAD	cis	rs4819052	0.679	rs28623526	ENSG00000237664.1	LINC00316	-4.31	1.94e-05	0.00349	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45292409	chr21:45338590~45341990:-
LUAD	cis	rs9303029	1	rs9911854	ENSG00000265458.1	RP13-20L14.6	4.31	1.94e-05	0.00349	0.35	0.19	Protein quantitative trait loci;	chr17:82450472	chr17:82454273~82458521:-
LUAD	cis	rs7665090	0.967	rs13106304	ENSG00000246560.2	RP11-10L12.4	4.31	1.94e-05	0.00349	0.24	0.19	Primary biliary cholangitis;	chr4:102633818	chr4:102828055~102844075:+
LUAD	cis	rs4819052	0.851	rs12626188	ENSG00000237664.1	LINC00316	-4.31	1.94e-05	0.00349	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249343	chr21:45338590~45341990:-
LUAD	cis	rs7208859	0.524	rs73263982	ENSG00000280069.1	CTD-2349P21.3	-4.31	1.94e-05	0.00349	-0.23	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593606	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs216433	ENSG00000280069.1	CTD-2349P21.3	-4.31	1.94e-05	0.00349	-0.23	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30594842	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs216435	ENSG00000280069.1	CTD-2349P21.3	-4.31	1.94e-05	0.00349	-0.23	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595719	chr17:30738182~30740275:+
LUAD	cis	rs2439831	0.867	rs12443102	ENSG00000249839.1	AC011330.5	-4.31	1.94e-05	0.00349	-0.36	-0.19	Lung cancer in ever smokers;	chr15:43639905	chr15:43663654~43684339:-
LUAD	cis	rs9815354	1	rs7617397	ENSG00000273328.4	RP11-141M3.6	4.31	1.94e-05	0.00349	0.28	0.19	Pulse pressure;Diastolic blood pressure;	chr3:41917545	chr3:42809414~42908105:+
LUAD	cis	rs9815354	1	rs1716661	ENSG00000273328.4	RP11-141M3.6	4.31	1.94e-05	0.00349	0.28	0.19	Pulse pressure;Diastolic blood pressure;	chr3:41921326	chr3:42809414~42908105:+
LUAD	cis	rs9815354	0.83	rs1716983	ENSG00000273328.4	RP11-141M3.6	4.31	1.94e-05	0.00349	0.28	0.19	Pulse pressure;Diastolic blood pressure;	chr3:41922636	chr3:42809414~42908105:+
LUAD	cis	rs9815354	1	rs1615243	ENSG00000273328.4	RP11-141M3.6	4.31	1.94e-05	0.00349	0.28	0.19	Pulse pressure;Diastolic blood pressure;	chr3:41923742	chr3:42809414~42908105:+
LUAD	cis	rs9815354	1	rs1716642	ENSG00000273328.4	RP11-141M3.6	4.31	1.94e-05	0.00349	0.28	0.19	Pulse pressure;Diastolic blood pressure;	chr3:41924373	chr3:42809414~42908105:+
LUAD	cis	rs9815354	1	rs1716651	ENSG00000273328.4	RP11-141M3.6	4.31	1.94e-05	0.00349	0.28	0.19	Pulse pressure;Diastolic blood pressure;	chr3:41933607	chr3:42809414~42908105:+
LUAD	cis	rs9815354	1	rs939558	ENSG00000273328.4	RP11-141M3.6	4.31	1.94e-05	0.00349	0.28	0.19	Pulse pressure;Diastolic blood pressure;	chr3:41934548	chr3:42809414~42908105:+
LUAD	cis	rs9815354	1	rs1717011	ENSG00000273328.4	RP11-141M3.6	4.31	1.94e-05	0.00349	0.28	0.19	Pulse pressure;Diastolic blood pressure;	chr3:41938707	chr3:42809414~42908105:+
LUAD	cis	rs6568686	0.527	rs174407	ENSG00000255389.1	C6orf3	4.31	1.94e-05	0.00349	0.25	0.19	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111610484	chr6:111599875~111602295:+
LUAD	cis	rs860295	0.702	rs4971095	ENSG00000225855.5	RUSC1-AS1	-4.31	1.94e-05	0.00349	-0.13	-0.19	Body mass index;	chr1:155636433	chr1:155316863~155324176:-
LUAD	cis	rs6840360	0.55	rs6853955	ENSG00000270265.1	RP11-731D1.4	-4.31	1.94e-05	0.0035	-0.22	-0.19	Intelligence (multi-trait analysis);	chr4:151589654	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.571	rs17275577	ENSG00000270265.1	RP11-731D1.4	-4.31	1.94e-05	0.0035	-0.22	-0.19	Intelligence (multi-trait analysis);	chr4:151598747	chr4:151333775~151353224:-
LUAD	cis	rs7200786	0.527	rs7200146	ENSG00000274038.1	RP11-66H6.4	-4.31	1.94e-05	0.0035	-0.25	-0.19	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11119592	chr16:11056556~11057034:+
LUAD	cis	rs2880765	0.835	rs4514633	ENSG00000259416.2	RP11-158M2.5	4.31	1.94e-05	0.0035	0.2	0.19	Coronary artery disease;	chr15:85497786	chr15:85754941~85756237:-
LUAD	cis	rs800160	1	rs1088984	ENSG00000236264.4	RPL26P30	-4.31	1.94e-05	0.0035	-0.26	-0.19	Bacteremia;	chr11:2356351	chr11:2335132~2335776:-
LUAD	cis	rs4819052	0.851	rs2838837	ENSG00000237664.1	LINC00316	-4.31	1.95e-05	0.0035	-0.24	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246073	chr21:45338590~45341990:-
LUAD	cis	rs7208859	0.562	rs8078897	ENSG00000280069.1	CTD-2349P21.3	-4.31	1.95e-05	0.0035	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs9914499	ENSG00000280069.1	CTD-2349P21.3	-4.31	1.95e-05	0.0035	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs12006	ENSG00000280069.1	CTD-2349P21.3	-4.31	1.95e-05	0.0035	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs3752021	ENSG00000280069.1	CTD-2349P21.3	-4.31	1.95e-05	0.0035	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs1061342	ENSG00000280069.1	CTD-2349P21.3	-4.31	1.95e-05	0.0035	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs55938328	ENSG00000280069.1	CTD-2349P21.3	-4.31	1.95e-05	0.0035	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs55961983	ENSG00000280069.1	CTD-2349P21.3	-4.31	1.95e-05	0.0035	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30738182~30740275:+
LUAD	cis	rs17826219	0.568	rs7213925	ENSG00000280069.1	CTD-2349P21.3	-4.31	1.95e-05	0.0035	-0.26	-0.19	Body mass index;	chr17:30794616	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs11658945	ENSG00000280069.1	CTD-2349P21.3	-4.31	1.95e-05	0.0035	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs11657990	ENSG00000280069.1	CTD-2349P21.3	-4.31	1.95e-05	0.0035	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs11650982	ENSG00000280069.1	CTD-2349P21.3	-4.31	1.95e-05	0.0035	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs9915546	ENSG00000280069.1	CTD-2349P21.3	-4.31	1.95e-05	0.0035	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs9895815	ENSG00000280069.1	CTD-2349P21.3	-4.31	1.95e-05	0.0035	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30738182~30740275:+
LUAD	cis	rs17826219	0.706	rs73271850	ENSG00000280069.1	CTD-2349P21.3	-4.31	1.95e-05	0.0035	-0.26	-0.19	Body mass index;	chr17:30815122	chr17:30738182~30740275:+
LUAD	cis	rs17826219	0.636	rs79565452	ENSG00000280069.1	CTD-2349P21.3	-4.31	1.95e-05	0.0035	-0.26	-0.19	Body mass index;	chr17:30815823	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs7208088	ENSG00000280069.1	CTD-2349P21.3	-4.31	1.95e-05	0.0035	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30738182~30740275:+
LUAD	cis	rs2299587	0.585	rs208751	ENSG00000253671.1	RP11-806O11.1	-4.31	1.95e-05	0.0035	-0.22	-0.19	Economic and political preferences;	chr8:17918581	chr8:17808941~17820868:+
LUAD	cis	rs2299587	0.585	rs208750	ENSG00000253671.1	RP11-806O11.1	-4.31	1.95e-05	0.0035	-0.22	-0.19	Economic and political preferences;	chr8:17918710	chr8:17808941~17820868:+
LUAD	cis	rs755249	0.753	rs72663529	ENSG00000237624.1	OXCT2P1	4.31	1.95e-05	0.0035	0.25	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39557684	chr1:39514956~39516490:+
LUAD	cis	rs4819052	0.851	rs2255766	ENSG00000237664.1	LINC00316	-4.31	1.95e-05	0.0035	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263862	chr21:45338590~45341990:-
LUAD	cis	rs801193	1	rs2659915	ENSG00000224316.1	RP11-479O9.2	4.31	1.95e-05	0.0035	0.2	0.19	Aortic root size;	chr7:66688114	chr7:65773620~65802067:+
LUAD	cis	rs4578769	0.589	rs12606787	ENSG00000265943.1	RP11-739L10.1	4.31	1.95e-05	0.0035	0.24	0.19	Eosinophil percentage of white cells;	chr18:22830392	chr18:22699481~22933764:-
LUAD	cis	rs12439619	0.846	rs28697264	ENSG00000276710.3	CSPG4P8	-4.31	1.95e-05	0.0035	-0.21	-0.19	Intelligence (multi-trait analysis);	chr15:82265559	chr15:82459472~82477258:+
LUAD	cis	rs1979679	0.837	rs2881860	ENSG00000278733.1	RP11-425D17.1	4.31	1.95e-05	0.0035	0.25	0.19	Ossification of the posterior longitudinal ligament of the spine;	chr12:28363268	chr12:28185625~28186190:-
LUAD	cis	rs800160	1	rs1088993	ENSG00000236264.4	RPL26P30	-4.31	1.95e-05	0.0035	-0.26	-0.19	Bacteremia;	chr11:2361401	chr11:2335132~2335776:-
LUAD	cis	rs4819052	0.679	rs2255761	ENSG00000237664.1	LINC00316	-4.31	1.95e-05	0.0035	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263707	chr21:45338590~45341990:-
LUAD	cis	rs2731006	0.64	rs991703	ENSG00000257114.2	RP11-25I15.3	-4.31	1.95e-05	0.0035	-0.29	-0.19	Panic disorder;	chr12:42801910	chr12:42692216~42717119:+
LUAD	cis	rs17807185	0.653	rs7802732	ENSG00000214293.7	APTR	4.31	1.95e-05	0.0035	0.21	0.19	Height;	chr7:77658613	chr7:77657660~77696265:-
LUAD	cis	rs9876781	1	rs9838618	ENSG00000229759.1	MRPS18AP1	4.31	1.95e-05	0.0035	0.19	0.19	Longevity;	chr3:48445949	chr3:48256350~48256938:-
LUAD	cis	rs62025270	0.632	rs55981798	ENSG00000202081.1	RNU6-1280P	-4.31	1.95e-05	0.0035	-0.29	-0.19	Idiopathic pulmonary fibrosis;	chr15:85600869	chr15:85651522~85651628:-
LUAD	cis	rs62025270	0.576	rs17633959	ENSG00000202081.1	RNU6-1280P	-4.31	1.95e-05	0.0035	-0.29	-0.19	Idiopathic pulmonary fibrosis;	chr15:85600950	chr15:85651522~85651628:-
LUAD	cis	rs910316	0.967	rs175505	ENSG00000279594.1	RP11-950C14.10	-4.31	1.95e-05	0.0035	-0.22	-0.19	Height;	chr14:75062916	chr14:75011269~75012851:-
LUAD	cis	rs2136690	0.51	rs10454220	ENSG00000243926.1	TIPARP-AS1	4.31	1.95e-05	0.0035	0.2	0.19	Breast cancer;	chr3:156649966	chr3:156671862~156674378:-
LUAD	cis	rs9400467	0.508	rs456871	ENSG00000230177.1	RP5-1112D6.4	-4.31	1.95e-05	0.0035	-0.17	-0.19	Amino acid levels;Blood metabolite levels;	chr6:111366447	chr6:111277932~111278742:+
LUAD	cis	rs7760535	0.811	rs455732	ENSG00000230177.1	RP5-1112D6.4	-4.31	1.95e-05	0.0035	-0.17	-0.19	Metabolic traits;	chr6:111374065	chr6:111277932~111278742:+
LUAD	cis	rs17345786	0.861	rs74768235	ENSG00000244119.1	PDCL3P4	4.31	1.95e-05	0.0035	0.22	0.19	Colonoscopy-negative controls vs population controls;	chr3:101423977	chr3:101712472~101713191:+
LUAD	cis	rs77688320	0.535	rs6435084	ENSG00000213090.2	AC007256.5	4.31	1.95e-05	0.0035	0.22	0.19	Breast cancer;	chr2:201461274	chr2:201410544~201413308:-
LUAD	cis	rs73173548	0.502	rs34634636	ENSG00000247828.6	TMEM161B-AS1	4.31	1.95e-05	0.0035	0.24	0.19	Macular telangiectasia type 2;	chr5:88435989	chr5:88268895~88436685:+
LUAD	cis	rs6686842	0.536	rs12128359	ENSG00000235358.1	RP11-399E6.1	-4.31	1.95e-05	0.0035	-0.23	-0.19	Height;	chr1:41243240	chr1:41242373~41284861:+
LUAD	cis	rs6686842	0.536	rs59911668	ENSG00000235358.1	RP11-399E6.1	-4.31	1.95e-05	0.0035	-0.23	-0.19	Height;	chr1:41243803	chr1:41242373~41284861:+
LUAD	cis	rs6686842	0.536	rs61774707	ENSG00000235358.1	RP11-399E6.1	-4.31	1.95e-05	0.0035	-0.23	-0.19	Height;	chr1:41247552	chr1:41242373~41284861:+
LUAD	cis	rs77688320	0.553	rs1558637	ENSG00000213090.2	AC007256.5	-4.31	1.95e-05	0.0035	-0.22	-0.19	Breast cancer;	chr2:201398651	chr2:201410544~201413308:-
LUAD	cis	rs9876781	0.967	rs1870444	ENSG00000229759.1	MRPS18AP1	4.31	1.95e-05	0.0035	0.18	0.19	Longevity;	chr3:48445369	chr3:48256350~48256938:-
LUAD	cis	rs957448	1	rs957447	ENSG00000254315.1	RP11-267M23.3	4.31	1.95e-05	0.0035	0.25	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94528995	chr8:94533628~94534391:+
LUAD	cis	rs957448	1	rs72674852	ENSG00000254315.1	RP11-267M23.3	4.31	1.95e-05	0.0035	0.25	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94536523	chr8:94533628~94534391:+
LUAD	cis	rs7189233	0.531	rs7203132	ENSG00000279344.1	RP11-44F14.7	-4.31	1.95e-05	0.0035	-0.16	-0.19	Intelligence (multi-trait analysis);	chr16:53395863	chr16:53478957~53481550:-
LUAD	cis	rs7580658	0.75	rs4497825	ENSG00000236682.1	AC068282.3	-4.31	1.95e-05	0.00351	-0.25	-0.19	Protein C levels;	chr2:127303477	chr2:127389130~127400580:+
LUAD	cis	rs4873772	0.837	rs62539144	ENSG00000253330.1	RP11-697N18.3	-4.31	1.95e-05	0.00351	-0.22	-0.19	Lobe attachment (rater-scored or self-reported);	chr8:47650686	chr8:47511034~47512141:-
LUAD	cis	rs7911264	0.739	rs10882091	ENSG00000236493.2	EIF2S2P3	4.31	1.95e-05	0.00351	0.22	0.19	Inflammatory bowel disease;	chr10:92614620	chr10:92668745~92669743:-
LUAD	cis	rs11886999	0.812	rs62153022	ENSG00000237510.6	AC008268.2	-4.31	1.95e-05	0.00351	-0.32	-0.19	Cardiac Troponin-T levels;	chr2:96222426	chr2:95789654~95800166:+
LUAD	cis	rs11886999	0.762	rs72825864	ENSG00000237510.6	AC008268.2	-4.31	1.95e-05	0.00351	-0.32	-0.19	Cardiac Troponin-T levels;	chr2:96222870	chr2:95789654~95800166:+
LUAD	cis	rs7204230	1	rs62049814	ENSG00000261291.1	RP11-295M3.2	4.31	1.95e-05	0.00351	0.24	0.19	Fibrinogen;	chr16:53333541	chr16:53168522~53169450:+
LUAD	cis	rs1538970	0.504	rs3790585	ENSG00000234329.1	RP11-767N6.2	4.31	1.95e-05	0.00351	0.27	0.19	Platelet count;	chr1:45557684	chr1:45651039~45651826:-
LUAD	cis	rs71520386	0.607	rs11767419	ENSG00000228649.7	AC005682.5	-4.31	1.95e-05	0.00351	-0.27	-0.19	Fibrinogen levels;	chr7:22839364	chr7:22854178~22861579:+
LUAD	cis	rs858239	0.601	rs764533	ENSG00000226816.2	AC005082.12	4.31	1.95e-05	0.00351	0.25	0.19	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23206013~23208045:+
LUAD	cis	rs950169	0.614	rs12903883	ENSG00000225151.9	GOLGA2P7	-4.31	1.95e-05	0.00351	-0.28	-0.19	Schizophrenia;	chr15:84011801	chr15:84199311~84230136:-
LUAD	cis	rs2980439	0.557	rs2921056	ENSG00000253981.4	ALG1L13P	4.31	1.96e-05	0.00351	0.22	0.19	Neuroticism;	chr8:8461672	chr8:8236003~8244667:-
LUAD	cis	rs9341808	0.718	rs9343971	ENSG00000272129.1	RP11-250B2.6	4.31	1.96e-05	0.00351	0.24	0.19	Sitting height ratio;	chr6:80172339	chr6:80355424~80356859:+
LUAD	cis	rs2348418	0.864	rs11049580	ENSG00000247934.4	RP11-967K21.1	4.31	1.96e-05	0.00351	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28414696	chr12:28163298~28190738:-
LUAD	cis	rs2735413	0.564	rs4324138	ENSG00000276007.1	RP11-358L22.3	4.31	1.96e-05	0.00351	0.25	0.19	Systolic blood pressure (alcohol consumption interaction);	chr16:78067475	chr16:78123243~78124332:+
LUAD	cis	rs7829975	0.755	rs3789849	ENSG00000253893.2	FAM85B	-4.31	1.96e-05	0.00352	-0.25	-0.19	Mood instability;	chr8:8829544	chr8:8167819~8226614:-
LUAD	cis	rs2880765	0.805	rs11858817	ENSG00000259416.2	RP11-158M2.5	4.31	1.96e-05	0.00352	0.2	0.19	Coronary artery disease;	chr15:85488029	chr15:85754941~85756237:-
LUAD	cis	rs2880765	0.835	rs28874135	ENSG00000259416.2	RP11-158M2.5	4.31	1.96e-05	0.00352	0.2	0.19	Coronary artery disease;	chr15:85488272	chr15:85754941~85756237:-
LUAD	cis	rs2880765	0.835	rs11633604	ENSG00000259416.2	RP11-158M2.5	4.31	1.96e-05	0.00352	0.2	0.19	Coronary artery disease;	chr15:85488348	chr15:85754941~85756237:-
LUAD	cis	rs2880765	0.835	rs7164106	ENSG00000259416.2	RP11-158M2.5	4.31	1.96e-05	0.00352	0.2	0.19	Coronary artery disease;	chr15:85489359	chr15:85754941~85756237:-
LUAD	cis	rs2880765	0.835	rs1872074	ENSG00000259416.2	RP11-158M2.5	4.31	1.96e-05	0.00352	0.2	0.19	Coronary artery disease;	chr15:85489953	chr15:85754941~85756237:-
LUAD	cis	rs2880765	0.835	rs4842884	ENSG00000259416.2	RP11-158M2.5	4.31	1.96e-05	0.00352	0.2	0.19	Coronary artery disease;	chr15:85491943	chr15:85754941~85756237:-
LUAD	cis	rs7200786	0.583	rs7185202	ENSG00000274038.1	RP11-66H6.4	-4.31	1.96e-05	0.00352	-0.23	-0.19	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11041207	chr16:11056556~11057034:+
LUAD	cis	rs34779708	0.931	rs2384275	ENSG00000271335.4	RP11-324I22.4	4.31	1.96e-05	0.00352	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35008214	chr10:35314552~35336401:-
LUAD	cis	rs9649213	0.593	rs13246725	ENSG00000272950.1	RP11-307C18.1	4.31	1.96e-05	0.00352	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98285586	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.593	rs11766808	ENSG00000272950.1	RP11-307C18.1	4.31	1.96e-05	0.00352	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98286064	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.593	rs35941058	ENSG00000272950.1	RP11-307C18.1	4.31	1.96e-05	0.00352	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98288847	chr7:98322853~98323430:+
LUAD	cis	rs5769707	0.554	rs10854876	ENSG00000235111.1	RP1-29C18.8	-4.31	1.96e-05	0.00352	-0.24	-0.19	Monocyte percentage of white cells;Monocyte count;	chr22:49616922	chr22:49612657~49615716:-
LUAD	cis	rs12554020	0.579	rs79056932	ENSG00000227603.1	RP11-165J3.6	4.31	1.96e-05	0.00352	0.38	0.19	Schizophrenia;	chr9:93585431	chr9:93435332~93437121:-
LUAD	cis	rs7688540	0.8	rs1578898	ENSG00000211553.1	AC253576.2	-4.31	1.96e-05	0.00352	-0.24	-0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:235130	chr4:136461~136568:+
LUAD	cis	rs6840360	0.667	rs2709832	ENSG00000270265.1	RP11-731D1.4	-4.31	1.96e-05	0.00352	-0.2	-0.19	Intelligence (multi-trait analysis);	chr4:151458242	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.642	rs2709816	ENSG00000270265.1	RP11-731D1.4	-4.31	1.96e-05	0.00352	-0.2	-0.19	Intelligence (multi-trait analysis);	chr4:151459117	chr4:151333775~151353224:-
LUAD	cis	rs561341	0.769	rs12941700	ENSG00000265798.5	RP11-271K11.5	-4.31	1.96e-05	0.00352	-0.32	-0.19	Hip circumference adjusted for BMI;	chr17:31858003	chr17:31038575~31059121:-
LUAD	cis	rs2115630	1	rs6496441	ENSG00000225151.9	GOLGA2P7	4.31	1.96e-05	0.00352	0.21	0.19	P wave terminal force;	chr15:84820117	chr15:84199311~84230136:-
LUAD	cis	rs4713118	0.513	rs149950	ENSG00000216901.1	AL022393.7	4.31	1.96e-05	0.00352	0.23	0.19	Parkinson's disease;	chr6:28065261	chr6:28176188~28176674:+
LUAD	cis	rs4713118	0.513	rs149951	ENSG00000216901.1	AL022393.7	4.31	1.96e-05	0.00352	0.23	0.19	Parkinson's disease;	chr6:28065309	chr6:28176188~28176674:+
LUAD	cis	rs6686842	0.56	rs7534059	ENSG00000235358.1	RP11-399E6.1	-4.31	1.96e-05	0.00352	-0.23	-0.19	Height;	chr1:41015223	chr1:41242373~41284861:+
LUAD	cis	rs4873772	0.735	rs11784823	ENSG00000253330.1	RP11-697N18.3	4.31	1.96e-05	0.00352	0.22	0.19	Lobe attachment (rater-scored or self-reported);	chr8:47498758	chr8:47511034~47512141:-
LUAD	cis	rs710913	0.966	rs3738676	ENSG00000228060.1	RP11-69E11.8	-4.31	1.96e-05	0.00352	-0.17	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39525916	chr1:39565160~39573203:+
LUAD	cis	rs12745968	0.652	rs1359490	ENSG00000223787.2	RP4-593M8.1	4.31	1.96e-05	0.00352	0.24	0.19	Bipolar disorder and schizophrenia;	chr1:92488298	chr1:92580476~92580821:-
LUAD	cis	rs2911132	0.506	rs1862609	ENSG00000248734.2	CTD-2260A17.1	4.31	1.96e-05	0.00352	0.21	0.19	Urate levels (BMI interaction);	chr5:96750986	chr5:96784777~96785999:+
LUAD	cis	rs9322193	0.847	rs12234128	ENSG00000268592.3	RAET1E-AS1	4.31	1.96e-05	0.00352	0.24	0.19	Lung cancer;	chr6:149627553	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.923	rs57012784	ENSG00000268592.3	RAET1E-AS1	4.31	1.96e-05	0.00352	0.24	0.19	Lung cancer;	chr6:149627691	chr6:149863494~149919507:+
LUAD	cis	rs6570726	0.791	rs6900040	ENSG00000235652.6	RP11-545I5.3	4.31	1.96e-05	0.00352	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145571998	chr6:145799409~145886585:+
LUAD	cis	rs4578769	0.531	rs4616385	ENSG00000265943.1	RP11-739L10.1	4.31	1.96e-05	0.00352	0.24	0.19	Eosinophil percentage of white cells;	chr18:22895327	chr18:22699481~22933764:-
LUAD	cis	rs1401999	1	rs1402003	ENSG00000223882.1	ABCC5-AS1	-4.31	1.96e-05	0.00352	-0.2	-0.19	Anterior chamber depth;	chr3:183925091	chr3:184006338~184011419:+
LUAD	cis	rs11242704	0.632	rs4959568	ENSG00000272279.1	RP11-157J24.2	-4.31	1.96e-05	0.00353	-0.28	-0.19	Response to hepatitis C treatment;	chr6:1530194	chr6:1528364~1528911:-
LUAD	cis	rs12999542	0.636	rs62151904	ENSG00000234389.1	AC007278.3	4.31	1.96e-05	0.00353	0.31	0.19	Serum protein levels (sST2);	chr2:102474247	chr2:102438713~102440475:+
LUAD	cis	rs1876905	0.569	rs354542	ENSG00000230177.1	RP5-1112D6.4	-4.31	1.96e-05	0.00353	-0.22	-0.19	Mean corpuscular hemoglobin;	chr6:111193483	chr6:111277932~111278742:+
LUAD	cis	rs1876905	0.68	rs1216020	ENSG00000230177.1	RP5-1112D6.4	-4.31	1.96e-05	0.00353	-0.22	-0.19	Mean corpuscular hemoglobin;	chr6:111194004	chr6:111277932~111278742:+
LUAD	cis	rs1876905	0.569	rs354541	ENSG00000230177.1	RP5-1112D6.4	-4.31	1.96e-05	0.00353	-0.22	-0.19	Mean corpuscular hemoglobin;	chr6:111195262	chr6:111277932~111278742:+
LUAD	cis	rs1876905	0.68	rs354537	ENSG00000230177.1	RP5-1112D6.4	-4.31	1.96e-05	0.00353	-0.22	-0.19	Mean corpuscular hemoglobin;	chr6:111197097	chr6:111277932~111278742:+
LUAD	cis	rs1876905	0.68	rs354536	ENSG00000230177.1	RP5-1112D6.4	-4.31	1.96e-05	0.00353	-0.22	-0.19	Mean corpuscular hemoglobin;	chr6:111197808	chr6:111277932~111278742:+
LUAD	cis	rs1876905	0.68	rs557028	ENSG00000230177.1	RP5-1112D6.4	-4.31	1.96e-05	0.00353	-0.22	-0.19	Mean corpuscular hemoglobin;	chr6:111201606	chr6:111277932~111278742:+
LUAD	cis	rs800160	1	rs800142	ENSG00000236264.4	RPL26P30	-4.31	1.96e-05	0.00353	-0.27	-0.19	Bacteremia;	chr11:2363841	chr11:2335132~2335776:-
LUAD	cis	rs10129255	0.957	rs2007467	ENSG00000211967.3	IGHV3-53	4.31	1.96e-05	0.00353	0.15	0.19	Kawasaki disease;	chr14:106771605	chr14:106592676~106593347:-
LUAD	cis	rs7178424	0.905	rs8027751	ENSG00000259251.2	RP11-643M14.1	4.31	1.96e-05	0.00353	0.2	0.19	Height;	chr15:61955521	chr15:62060503~62062434:+
LUAD	cis	rs12073359	0.908	rs72694964	ENSG00000223945.2	RP11-458I7.1	-4.31	1.97e-05	0.00353	-0.29	-0.19	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150177071	chr1:150053864~150055034:+
LUAD	cis	rs9649213	0.593	rs6969731	ENSG00000272950.1	RP11-307C18.1	4.31	1.97e-05	0.00353	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98295259	chr7:98322853~98323430:+
LUAD	cis	rs853679	0.546	rs35017208	ENSG00000219392.1	RP1-265C24.5	-4.31	1.97e-05	0.00353	-0.43	-0.19	Depression;	chr6:28377505	chr6:28115628~28116551:+
LUAD	cis	rs848490	1	rs11767651	ENSG00000214293.7	APTR	4.31	1.97e-05	0.00353	0.26	0.19	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77761063	chr7:77657660~77696265:-
LUAD	cis	rs9303029	1	rs3751913	ENSG00000265458.1	RP13-20L14.6	4.31	1.97e-05	0.00353	0.35	0.19	Protein quantitative trait loci;	chr17:82447676	chr17:82454273~82458521:-
LUAD	cis	rs7098414	0.511	rs10788603	ENSG00000226659.1	RP11-137H2.4	-4.31	1.97e-05	0.00353	-0.26	-0.19	Post bronchodilator FEV1;	chr10:80388381	chr10:80529597~80535942:-
LUAD	cis	rs8030379	1	rs11633301	ENSG00000230373.7	GOLGA6L5P	4.31	1.97e-05	0.00353	0.18	0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83916286	chr15:84507885~84516814:-
LUAD	cis	rs6487679	1	rs1017302	ENSG00000255753.1	RP11-22B23.2	4.31	1.97e-05	0.00353	0.25	0.19	Non-alcoholic fatty liver disease histology (AST);	chr12:9214806	chr12:9314402~9316173:-
LUAD	cis	rs6487679	1	rs10734765	ENSG00000255753.1	RP11-22B23.2	4.31	1.97e-05	0.00353	0.25	0.19	Non-alcoholic fatty liver disease histology (AST);	chr12:9216789	chr12:9314402~9316173:-
LUAD	cis	rs7131987	0.565	rs7137141	ENSG00000257176.2	RP11-996F15.2	4.31	1.97e-05	0.00353	0.2	0.19	QT interval;	chr12:29272168	chr12:29280418~29317848:-
LUAD	cis	rs1005277	0.522	rs289647	ENSG00000273019.1	RP11-508N22.13	-4.31	1.97e-05	0.00353	-0.22	-0.19	Extrinsic epigenetic age acceleration;	chr10:37679350	chr10:38149968~38150293:+
LUAD	cis	rs2976388	1	rs2717562	ENSG00000253741.1	CTD-2292P10.4	4.31	1.97e-05	0.00353	0.22	0.19	Urinary tract infection frequency;	chr8:142695250	chr8:142702252~142726973:-
LUAD	cis	rs3743772	0.5	rs4784308	ENSG00000279722.1	RP11-44F14.6	4.31	1.97e-05	0.00353	0.27	0.19	Depressive symptoms (SSRI exposure interaction);	chr16:53406387	chr16:53487607~53489943:-
LUAD	cis	rs9543976	1	rs2031236	ENSG00000261105.4	LMO7-AS1	-4.31	1.97e-05	0.00353	-0.31	-0.19	Diabetic retinopathy;	chr13:75595641	chr13:75604700~75635994:-
LUAD	cis	rs2354432	0.607	rs68080346	ENSG00000226015.2	CCT8P1	4.31	1.97e-05	0.00353	0.38	0.19	Mitochondrial DNA levels;	chr1:147236836	chr1:147203276~147204932:-
LUAD	cis	rs2354432	0.556	rs1932979	ENSG00000226015.2	CCT8P1	4.31	1.97e-05	0.00353	0.38	0.19	Mitochondrial DNA levels;	chr1:147237263	chr1:147203276~147204932:-
LUAD	cis	rs853679	0.517	rs3757187	ENSG00000226314.6	ZNF192P1	-4.31	1.97e-05	0.00353	-0.26	-0.19	Depression;	chr6:28139876	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs3757185	ENSG00000226314.6	ZNF192P1	-4.31	1.97e-05	0.00353	-0.26	-0.19	Depression;	chr6:28139998	chr6:28161781~28169594:+
LUAD	cis	rs4578769	0.524	rs9956919	ENSG00000265943.1	RP11-739L10.1	4.31	1.97e-05	0.00353	0.24	0.19	Eosinophil percentage of white cells;	chr18:22896538	chr18:22699481~22933764:-
LUAD	cis	rs6940638	0.688	rs7744759	ENSG00000219392.1	RP1-265C24.5	-4.31	1.97e-05	0.00353	-0.24	-0.19	Intelligence (multi-trait analysis);	chr6:27152047	chr6:28115628~28116551:+
LUAD	cis	rs6754311	0.731	rs7579771	ENSG00000226806.1	AC011893.3	4.31	1.97e-05	0.00354	0.24	0.19	Mosquito bite size;	chr2:135822690	chr2:135820191~135823087:+
LUAD	cis	rs3742264	1	rs9534305	ENSG00000235903.6	CPB2-AS1	-4.31	1.97e-05	0.00354	-0.24	-0.19	Blood protein levels;	chr13:46068021	chr13:46052806~46113332:+
LUAD	cis	rs8014252	0.803	rs60120955	ENSG00000259158.2	ADAM20P1	-4.31	1.97e-05	0.00354	-0.34	-0.19	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70595016	chr14:70468881~70483756:-
LUAD	cis	rs8014252	0.803	rs17113651	ENSG00000259158.2	ADAM20P1	-4.31	1.97e-05	0.00354	-0.34	-0.19	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70595119	chr14:70468881~70483756:-
LUAD	cis	rs1447352	0.87	rs3781638	ENSG00000279684.1	RP11-755E23.2	-4.31	1.97e-05	0.00354	-0.24	-0.19	Metabolic traits;	chr11:92980341	chr11:93286629~93288903:-
LUAD	cis	rs9601248	0.756	rs9601251	ENSG00000227676.3	LINC01068	-4.31	1.97e-05	0.00354	-0.23	-0.19	Major depressive disorder;	chr13:79615582	chr13:79566727~79571436:+
LUAD	cis	rs6570726	0.791	rs6923074	ENSG00000235652.6	RP11-545I5.3	4.31	1.97e-05	0.00354	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145572196	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.755	rs2092296	ENSG00000235652.6	RP11-545I5.3	4.31	1.97e-05	0.00354	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145572548	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.755	rs2092297	ENSG00000235652.6	RP11-545I5.3	4.31	1.97e-05	0.00354	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145572629	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.755	rs2103633	ENSG00000235652.6	RP11-545I5.3	4.31	1.97e-05	0.00354	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145572885	chr6:145799409~145886585:+
LUAD	cis	rs4819052	0.851	rs2877018	ENSG00000237664.1	LINC00316	-4.31	1.97e-05	0.00354	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238391	chr21:45338590~45341990:-
LUAD	cis	rs4819052	0.851	rs2330012	ENSG00000237664.1	LINC00316	-4.31	1.97e-05	0.00354	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238677	chr21:45338590~45341990:-
LUAD	cis	rs4819052	0.851	rs2877020	ENSG00000237664.1	LINC00316	-4.31	1.97e-05	0.00354	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238827	chr21:45338590~45341990:-
LUAD	cis	rs4819052	0.851	rs10470245	ENSG00000237664.1	LINC00316	-4.31	1.97e-05	0.00354	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238997	chr21:45338590~45341990:-
LUAD	cis	rs4819052	0.851	rs10470258	ENSG00000237664.1	LINC00316	-4.31	1.97e-05	0.00354	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239074	chr21:45338590~45341990:-
LUAD	cis	rs4819052	0.851	rs4819038	ENSG00000237664.1	LINC00316	-4.31	1.97e-05	0.00354	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239478	chr21:45338590~45341990:-
LUAD	cis	rs4819052	0.851	rs4819039	ENSG00000237664.1	LINC00316	-4.31	1.97e-05	0.00354	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239543	chr21:45338590~45341990:-
LUAD	cis	rs4819052	0.851	rs4818768	ENSG00000237664.1	LINC00316	-4.31	1.97e-05	0.00354	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239903	chr21:45338590~45341990:-
LUAD	cis	rs4819052	0.851	rs4819042	ENSG00000237664.1	LINC00316	-4.31	1.97e-05	0.00354	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240157	chr21:45338590~45341990:-
LUAD	cis	rs4819052	0.8	rs4819045	ENSG00000237664.1	LINC00316	-4.31	1.97e-05	0.00354	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240223	chr21:45338590~45341990:-
LUAD	cis	rs4819052	0.851	rs13048789	ENSG00000237664.1	LINC00316	-4.31	1.97e-05	0.00354	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240799	chr21:45338590~45341990:-
LUAD	cis	rs4819052	0.851	rs13047598	ENSG00000237664.1	LINC00316	-4.31	1.97e-05	0.00354	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240862	chr21:45338590~45341990:-
LUAD	cis	rs62025270	0.688	rs7179917	ENSG00000202081.1	RNU6-1280P	-4.31	1.97e-05	0.00354	-0.28	-0.19	Idiopathic pulmonary fibrosis;	chr15:85722413	chr15:85651522~85651628:-
LUAD	cis	rs9322193	0.607	rs12527391	ENSG00000268592.3	RAET1E-AS1	4.31	1.97e-05	0.00354	0.29	0.19	Lung cancer;	chr6:149882156	chr6:149863494~149919507:+
LUAD	cis	rs4763879	0.865	rs4763839	ENSG00000278635.1	CTD-2318O12.1	4.31	1.97e-05	0.00354	0.18	0.19	Type 1 diabetes;	chr12:9730104	chr12:9415641~9416718:+
LUAD	cis	rs62445005	1	rs62445005	ENSG00000228668.1	TRGV5P	4.31	1.98e-05	0.00354	0.24	0.19	Shingles;	chr7:38346957	chr7:38345030~38345499:-
LUAD	cis	rs5758511	0.68	rs17002902	ENSG00000227370.1	RP4-669P10.19	4.31	1.98e-05	0.00354	0.22	0.19	Birth weight;	chr22:42229503	chr22:42132543~42132998:+
LUAD	cis	rs5758511	0.68	rs5758662	ENSG00000227370.1	RP4-669P10.19	4.31	1.98e-05	0.00354	0.22	0.19	Birth weight;	chr22:42232082	chr22:42132543~42132998:+
LUAD	cis	rs13113518	0.966	rs13108409	ENSG00000272969.1	RP11-528I4.2	4.31	1.98e-05	0.00354	0.2	0.19	Height;	chr4:55520278	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs11726198	ENSG00000272969.1	RP11-528I4.2	4.31	1.98e-05	0.00354	0.2	0.19	Height;	chr4:55523835	chr4:55547112~55547889:+
LUAD	cis	rs13113518	0.966	rs11133396	ENSG00000272969.1	RP11-528I4.2	4.31	1.98e-05	0.00354	0.2	0.19	Height;	chr4:55524246	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs7675109	ENSG00000272969.1	RP11-528I4.2	4.31	1.98e-05	0.00354	0.2	0.19	Height;	chr4:55525589	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs4865005	ENSG00000272969.1	RP11-528I4.2	4.31	1.98e-05	0.00354	0.2	0.19	Height;	chr4:55525781	chr4:55547112~55547889:+
LUAD	cis	rs889398	0.835	rs62050037	ENSG00000226232.7	RP11-419C5.2	4.31	1.98e-05	0.00354	0.17	0.19	Body mass index;	chr16:69750767	chr16:69976388~69996188:-
LUAD	cis	rs1799949	0.965	rs11080034	ENSG00000236383.6	LINC00854	-4.31	1.98e-05	0.00354	-0.15	-0.19	Menopause (age at onset);	chr17:43365646	chr17:43216941~43305976:-
LUAD	cis	rs7665090	1	rs5026476	ENSG00000246560.2	RP11-10L12.4	4.31	1.98e-05	0.00355	0.24	0.19	Primary biliary cholangitis;	chr4:102633753	chr4:102828055~102844075:+
LUAD	cis	rs7665090	0.967	rs13106325	ENSG00000246560.2	RP11-10L12.4	4.31	1.98e-05	0.00355	0.24	0.19	Primary biliary cholangitis;	chr4:102633835	chr4:102828055~102844075:+
LUAD	cis	rs7665090	0.967	rs6812747	ENSG00000246560.2	RP11-10L12.4	4.31	1.98e-05	0.00355	0.24	0.19	Primary biliary cholangitis;	chr4:102634260	chr4:102828055~102844075:+
LUAD	cis	rs7665090	1	rs6839064	ENSG00000246560.2	RP11-10L12.4	4.31	1.98e-05	0.00355	0.24	0.19	Primary biliary cholangitis;	chr4:102634519	chr4:102828055~102844075:+
LUAD	cis	rs7665090	1	rs2272695	ENSG00000246560.2	RP11-10L12.4	4.31	1.98e-05	0.00355	0.24	0.19	Primary biliary cholangitis;	chr4:102634646	chr4:102828055~102844075:+
LUAD	cis	rs7665090	1	rs2272696	ENSG00000246560.2	RP11-10L12.4	4.31	1.98e-05	0.00355	0.24	0.19	Primary biliary cholangitis;	chr4:102634664	chr4:102828055~102844075:+
LUAD	cis	rs7665090	1	rs2272697	ENSG00000246560.2	RP11-10L12.4	4.31	1.98e-05	0.00355	0.24	0.19	Primary biliary cholangitis;	chr4:102634835	chr4:102828055~102844075:+
LUAD	cis	rs3750965	0.92	rs4930644	ENSG00000260895.1	RP11-554A11.7	4.31	1.98e-05	0.00355	0.23	0.19	Hair color;	chr11:69051629	chr11:69103493~69109094:+
LUAD	cis	rs8098244	0.603	rs3017550	ENSG00000264745.1	TTC39C-AS1	4.31	1.98e-05	0.00355	0.2	0.19	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23696510	chr18:23994213~24015339:-
LUAD	cis	rs6081541	0.689	rs6081546	ENSG00000179447.2	RP5-1027G4.3	-4.31	1.98e-05	0.00355	-0.21	-0.19	Psychosis (atypical);	chr20:19240785	chr20:19242302~19284596:-
LUAD	cis	rs8072100	0.807	rs4561509	ENSG00000228782.6	CTD-2026D20.3	4.31	1.98e-05	0.00355	0.21	0.19	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47704433	chr17:47450568~47492492:-
LUAD	cis	rs9400467	0.528	rs462432	ENSG00000230177.1	RP5-1112D6.4	-4.31	1.98e-05	0.00355	-0.17	-0.19	Amino acid levels;Blood metabolite levels;	chr6:111338552	chr6:111277932~111278742:+
LUAD	cis	rs7760535	0.931	rs466923	ENSG00000230177.1	RP5-1112D6.4	-4.31	1.98e-05	0.00355	-0.17	-0.19	Metabolic traits;	chr6:111341774	chr6:111277932~111278742:+
LUAD	cis	rs7824557	0.547	rs2409749	ENSG00000255046.1	RP11-297N6.4	4.31	1.98e-05	0.00355	0.24	0.19	Retinal vascular caliber;	chr8:11221440	chr8:11797928~11802568:-
LUAD	cis	rs1555322	0.53	rs6058224	ENSG00000279253.1	RP4-614O4.13	-4.31	1.98e-05	0.00355	-0.23	-0.19	Attention deficit hyperactivity disorder;	chr20:35293971	chr20:35262727~35264187:-
LUAD	cis	rs7107174	1	rs10793295	ENSG00000251323.2	RP11-452H21.4	-4.31	1.98e-05	0.00355	-0.23	-0.19	Testicular germ cell tumor;	chr11:78285475	chr11:78423982~78429836:-
LUAD	cis	rs28386778	0.83	rs67905415	ENSG00000240280.5	TCAM1P	-4.31	1.98e-05	0.00355	-0.22	-0.19	Prudent dietary pattern;	chr17:63763876	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.797	rs4968664	ENSG00000240280.5	TCAM1P	-4.31	1.98e-05	0.00355	-0.22	-0.19	Prudent dietary pattern;	chr17:63774006	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.897	rs9913323	ENSG00000240280.5	TCAM1P	-4.31	1.98e-05	0.00355	-0.22	-0.19	Prudent dietary pattern;	chr17:63774125	chr17:63849292~63864379:+
LUAD	cis	rs897984	0.683	rs8046001	ENSG00000260911.2	RP11-196G11.2	4.31	1.98e-05	0.00355	0.17	0.19	Dementia with Lewy bodies;	chr16:30822000	chr16:31043150~31049868:+
LUAD	cis	rs17826219	0.706	rs28469200	ENSG00000266490.1	CTD-2349P21.9	4.31	1.98e-05	0.00355	0.28	0.19	Body mass index;	chr17:30806554	chr17:30792372~30792833:+
LUAD	cis	rs6723108	0.627	rs3814358	ENSG00000224043.6	CCNT2-AS1	-4.31	1.98e-05	0.00355	-0.24	-0.19	Type 2 diabetes;	chr2:134866438	chr2:134735464~134918710:-
LUAD	cis	rs6565180	0.962	rs35480350	ENSG00000273724.1	RP11-347C12.12	-4.31	1.98e-05	0.00355	-0.21	-0.19	Tonsillectomy;	chr16:30354718	chr16:30336400~30343336:+
LUAD	cis	rs9287719	0.967	rs6748036	ENSG00000243819.4	RN7SL832P	4.31	1.98e-05	0.00355	0.2	0.19	Prostate cancer;	chr2:10577363	chr2:10690344~10692099:+
LUAD	cis	rs6714710	0.603	rs7583868	ENSG00000230606.9	AC159540.1	-4.31	1.98e-05	0.00355	-0.2	-0.19	Posterior cortical atrophy and Alzheimer's disease;	chr2:97971909	chr2:97416165~97433527:-
LUAD	cis	rs858239	0.669	rs1006709	ENSG00000230042.1	AK3P3	-4.31	1.98e-05	0.00355	-0.24	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23100480	chr7:23129178~23129841:+
LUAD	cis	rs6832769	0.89	rs1980273	ENSG00000272969.1	RP11-528I4.2	4.31	1.98e-05	0.00355	0.2	0.19	Personality dimensions;	chr4:55501234	chr4:55547112~55547889:+
LUAD	cis	rs1008375	1	rs6449323	ENSG00000249502.1	AC006160.5	-4.31	1.98e-05	0.00356	-0.18	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17682293	chr4:17587467~17614571:-
LUAD	cis	rs7811142	1	rs76913697	ENSG00000078319.8	PMS2P1	-4.31	1.98e-05	0.00356	-0.23	-0.19	Platelet count;	chr7:100405149	chr7:100320992~100341908:-
LUAD	cis	rs67981189	0.501	rs3829954	ENSG00000269927.1	RP6-91H8.3	4.31	1.98e-05	0.00356	0.26	0.19	Schizophrenia;	chr14:70988823	chr14:71141125~71143253:-
LUAD	cis	rs9545047	0.604	rs2477395	ENSG00000227354.5	RBM26-AS1	-4.31	1.98e-05	0.00356	-0.2	-0.19	Schizophrenia;	chr13:79427679	chr13:79406309~79424328:+
LUAD	cis	rs957448	1	rs1992370	ENSG00000254315.1	RP11-267M23.3	4.31	1.98e-05	0.00356	0.25	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94546466	chr8:94533628~94534391:+
LUAD	cis	rs28386778	0.897	rs9906247	ENSG00000240280.5	TCAM1P	-4.31	1.99e-05	0.00356	-0.22	-0.19	Prudent dietary pattern;	chr17:63779954	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.897	rs7221853	ENSG00000240280.5	TCAM1P	-4.31	1.99e-05	0.00356	-0.22	-0.19	Prudent dietary pattern;	chr17:63782476	chr17:63849292~63864379:+
LUAD	cis	rs13113518	0.812	rs11932712	ENSG00000272969.1	RP11-528I4.2	4.31	1.99e-05	0.00356	0.21	0.19	Height;	chr4:55436423	chr4:55547112~55547889:+
LUAD	cis	rs13113518	0.812	rs12501746	ENSG00000272969.1	RP11-528I4.2	4.31	1.99e-05	0.00356	0.21	0.19	Height;	chr4:55437438	chr4:55547112~55547889:+
LUAD	cis	rs2354432	0.607	rs11579626	ENSG00000226015.2	CCT8P1	4.31	1.99e-05	0.00356	0.38	0.19	Mitochondrial DNA levels;	chr1:147270300	chr1:147203276~147204932:-
LUAD	cis	rs2354432	0.607	rs6685775	ENSG00000226015.2	CCT8P1	4.31	1.99e-05	0.00356	0.38	0.19	Mitochondrial DNA levels;	chr1:147272633	chr1:147203276~147204932:-
LUAD	cis	rs2354432	0.607	rs6694347	ENSG00000226015.2	CCT8P1	4.31	1.99e-05	0.00356	0.38	0.19	Mitochondrial DNA levels;	chr1:147279467	chr1:147203276~147204932:-
LUAD	cis	rs699371	0.525	rs7156302	ENSG00000270000.1	RP3-449M8.9	4.31	1.99e-05	0.00356	0.21	0.19	Height;	chr14:74428260	chr14:74471930~74472360:-
LUAD	cis	rs9649213	0.593	rs7778015	ENSG00000272950.1	RP11-307C18.1	4.31	1.99e-05	0.00356	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98290958	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.593	rs1132971	ENSG00000272950.1	RP11-307C18.1	4.31	1.99e-05	0.00356	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98292221	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.593	rs6465664	ENSG00000272950.1	RP11-307C18.1	4.31	1.99e-05	0.00356	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98292522	chr7:98322853~98323430:+
LUAD	cis	rs1876905	0.539	rs240985	ENSG00000230177.1	RP5-1112D6.4	4.31	1.99e-05	0.00356	0.25	0.19	Mean corpuscular hemoglobin;	chr6:111263428	chr6:111277932~111278742:+
LUAD	cis	rs875971	0.558	rs4433015	ENSG00000236529.1	RP13-254B10.1	-4.31	1.99e-05	0.00356	-0.2	-0.19	Aortic root size;	chr7:66174736	chr7:65840212~65840596:+
LUAD	cis	rs2028299	0.92	rs11638138	ENSG00000259677.1	RP11-493E3.1	-4.31	1.99e-05	0.00356	-0.22	-0.19	Type 2 diabetes;	chr15:89885523	chr15:89876540~89877285:+
LUAD	cis	rs6479891	1	rs16918575	ENSG00000232075.1	MRPL35P2	-4.31	1.99e-05	0.00356	-0.33	-0.19	Arthritis (juvenile idiopathic);	chr10:63541565	chr10:63634317~63634827:-
LUAD	cis	rs4879677	1	rs10757674	ENSG00000215441.3	CTAGE12P	4.31	1.99e-05	0.00356	0.23	0.19	Gut microbiome composition (summer and winter);	chr9:27671312	chr9:27608382~27610745:-
LUAD	cis	rs2880765	0.835	rs7161880	ENSG00000259416.2	RP11-158M2.5	4.31	1.99e-05	0.00356	0.2	0.19	Coronary artery disease;	chr15:85475515	chr15:85754941~85756237:-
LUAD	cis	rs12681366	0.96	rs2930961	ENSG00000253704.1	RP11-267M23.4	4.31	1.99e-05	0.00356	0.23	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94431578	chr8:94553722~94569745:+
LUAD	cis	rs3096299	0.685	rs3803681	ENSG00000182376.2	RP5-1142A6.8	4.31	1.99e-05	0.00356	0.2	0.19	Multiple myeloma (IgH translocation);	chr16:89478348	chr16:88742767~88745748:+
LUAD	cis	rs11673344	0.526	rs17244713	ENSG00000226686.6	LINC01535	4.31	1.99e-05	0.00356	0.23	0.19	Obesity-related traits;	chr19:37559938	chr19:37251912~37265535:+
LUAD	cis	rs11673344	0.526	rs8111790	ENSG00000226686.6	LINC01535	4.31	1.99e-05	0.00356	0.23	0.19	Obesity-related traits;	chr19:37565861	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.943	rs6508711	ENSG00000226686.6	LINC01535	-4.31	1.99e-05	0.00356	-0.29	-0.19	Coronary artery calcification;	chr19:37324232	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.882	rs6508716	ENSG00000226686.6	LINC01535	-4.31	1.99e-05	0.00356	-0.29	-0.19	Coronary artery calcification;	chr19:37328108	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.882	rs13345148	ENSG00000226686.6	LINC01535	-4.31	1.99e-05	0.00356	-0.29	-0.19	Coronary artery calcification;	chr19:37328729	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.943	rs7257672	ENSG00000226686.6	LINC01535	-4.31	1.99e-05	0.00356	-0.29	-0.19	Coronary artery calcification;	chr19:37332957	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.891	rs7257495	ENSG00000226686.6	LINC01535	-4.31	1.99e-05	0.00356	-0.29	-0.19	Coronary artery calcification;	chr19:37332974	chr19:37251912~37265535:+
LUAD	cis	rs4795519	0.778	rs11080096	ENSG00000266313.1	RP11-173M1.4	4.31	1.99e-05	0.00356	0.25	0.19	Chronic myeloid leukemia;	chr17:27165974	chr17:27333256~27348491:+
LUAD	cis	rs2243480	1	rs313813	ENSG00000232559.3	GS1-124K5.12	4.31	1.99e-05	0.00356	0.34	0.19	Diabetic kidney disease;	chr7:66038513	chr7:66554588~66576923:-
LUAD	cis	rs1502337	0.532	rs10160981	ENSG00000278993.1	RP3-424M6.4	-4.31	1.99e-05	0.00356	-0.24	-0.19	Body mass index;	chr12:110466270	chr12:110501614~110503441:+
LUAD	cis	rs1502337	0.561	rs7958683	ENSG00000278993.1	RP3-424M6.4	-4.31	1.99e-05	0.00356	-0.24	-0.19	Body mass index;	chr12:110468064	chr12:110501614~110503441:+
LUAD	cis	rs800160	0.844	rs1088992	ENSG00000236264.4	RPL26P30	-4.31	1.99e-05	0.00356	-0.26	-0.19	Bacteremia;	chr11:2361287	chr11:2335132~2335776:-
LUAD	cis	rs7172677	0.696	rs56262544	ENSG00000260269.4	CTD-2323K18.1	4.31	1.99e-05	0.00357	0.27	0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75087130	chr15:75527150~75601205:-
LUAD	cis	rs4664293	0.967	rs12611922	ENSG00000230783.1	AC009961.2	-4.31	1.99e-05	0.00357	-0.24	-0.19	Monocyte percentage of white cells;	chr2:159606238	chr2:159689217~159690291:-
LUAD	cis	rs6754311	0.773	rs309180	ENSG00000226806.1	AC011893.3	4.31	1.99e-05	0.00357	0.24	0.19	Mosquito bite size;	chr2:135856685	chr2:135820191~135823087:+
LUAD	cis	rs1005277	0.505	rs200936	ENSG00000263064.2	RP11-291L22.7	4.31	1.99e-05	0.00357	0.2	0.19	Extrinsic epigenetic age acceleration;	chr10:37846007	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.505	rs200937	ENSG00000263064.2	RP11-291L22.7	4.31	1.99e-05	0.00357	0.2	0.19	Extrinsic epigenetic age acceleration;	chr10:37846844	chr10:38448689~38448949:+
LUAD	cis	rs7200786	0.546	rs6498161	ENSG00000274038.1	RP11-66H6.4	-4.31	1.99e-05	0.00357	-0.25	-0.19	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11118682	chr16:11056556~11057034:+
LUAD	cis	rs847577	0.63	rs13221758	ENSG00000272950.1	RP11-307C18.1	4.31	1.99e-05	0.00357	0.24	0.19	Breast cancer;	chr7:98090494	chr7:98322853~98323430:+
LUAD	cis	rs301901	0.54	rs12657783	ENSG00000250155.1	CTD-2353F22.1	4.31	1.99e-05	0.00357	0.21	0.19	Height;	chr5:37397119	chr5:36666214~36725195:-
LUAD	cis	rs1334894	1	rs72911397	ENSG00000228559.1	RP3-340B19.3	-4.31	1.99e-05	0.00357	-0.4	-0.19	Coronary artery disease;	chr6:35558044	chr6:35544632~35545669:+
LUAD	cis	rs7829975	0.508	rs4841006	ENSG00000253981.4	ALG1L13P	-4.31	2e-05	0.00357	-0.22	-0.19	Mood instability;	chr8:8643964	chr8:8236003~8244667:-
LUAD	cis	rs2904524	1	rs17107933	ENSG00000257815.4	RP11-611E13.2	4.31	2e-05	0.00357	0.28	0.19	Amyotrophic lateral sclerosis (age of onset);	chr12:70283707	chr12:69904033~70243360:-
LUAD	cis	rs17345786	1	rs3804778	ENSG00000244119.1	PDCL3P4	4.31	2e-05	0.00357	0.22	0.19	Colonoscopy-negative controls vs population controls;	chr3:101575728	chr3:101712472~101713191:+
LUAD	cis	rs7107174	1	rs2510041	ENSG00000251323.2	RP11-452H21.4	4.31	2e-05	0.00357	0.24	0.19	Testicular germ cell tumor;	chr11:78234238	chr11:78423982~78429836:-
LUAD	cis	rs9545047	0.511	rs1624537	ENSG00000227354.5	RBM26-AS1	4.31	2e-05	0.00357	0.2	0.19	Schizophrenia;	chr13:79411686	chr13:79406309~79424328:+
LUAD	cis	rs17301013	0.932	rs6425281	ENSG00000227373.4	RP11-160H22.5	4.31	2e-05	0.00358	0.24	0.19	Systemic lupus erythematosus;	chr1:174449784	chr1:174115300~174160004:-
LUAD	cis	rs7560272	0.723	rs2421548	ENSG00000163016.8	ALMS1P	-4.31	2e-05	0.00358	-0.21	-0.19	Schizophrenia;	chr2:73414112	chr2:73644919~73685576:+
LUAD	cis	rs7560272	0.723	rs12995433	ENSG00000163016.8	ALMS1P	-4.31	2e-05	0.00358	-0.21	-0.19	Schizophrenia;	chr2:73414198	chr2:73644919~73685576:+
LUAD	cis	rs7560272	0.723	rs4852927	ENSG00000163016.8	ALMS1P	-4.31	2e-05	0.00358	-0.21	-0.19	Schizophrenia;	chr2:73414429	chr2:73644919~73685576:+
LUAD	cis	rs812925	0.502	rs2053750	ENSG00000271889.1	RP11-493E12.1	-4.31	2e-05	0.00358	-0.23	-0.19	Immature fraction of reticulocytes;	chr2:61429138	chr2:61151433~61162105:-
LUAD	cis	rs875971	0.545	rs316306	ENSG00000222364.1	RNU6-96P	4.31	2e-05	0.00358	0.25	0.19	Aortic root size;	chr7:66153687	chr7:66395191~66395286:+
LUAD	cis	rs17685	0.671	rs10274404	ENSG00000280388.1	RP11-229D13.3	-4.31	2e-05	0.00358	-0.18	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76077316	chr7:76043977~76045963:-
LUAD	cis	rs858239	0.536	rs6961109	ENSG00000226816.2	AC005082.12	4.31	2e-05	0.00358	0.26	0.19	Cerebrospinal fluid biomarker levels;	chr7:23212794	chr7:23206013~23208045:+
LUAD	cis	rs9990333	0.562	rs12632706	ENSG00000231464.1	AC024937.4	4.31	2e-05	0.00358	0.21	0.19	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196088723	chr3:195996738~195998233:+
LUAD	cis	rs77633900	0.803	rs8042255	ENSG00000196274.5	Metazoa_SRP	-4.31	2e-05	0.00358	-0.25	-0.19	Glioma;Non-glioblastoma glioma;	chr15:76279269	chr15:76230048~76230390:-
LUAD	cis	rs2243480	1	rs11538349	ENSG00000229886.1	RP5-1132H15.3	4.31	2e-05	0.00358	0.33	0.19	Diabetic kidney disease;	chr7:65956884	chr7:66025126~66031544:-
LUAD	cis	rs1799949	0.55	rs2343818	ENSG00000236383.6	LINC00854	-4.31	2e-05	0.00358	-0.16	-0.19	Menopause (age at onset);	chr17:43332406	chr17:43216941~43305976:-
LUAD	cis	rs62025270	0.632	rs62022942	ENSG00000202081.1	RNU6-1280P	-4.31	2e-05	0.00358	-0.28	-0.19	Idiopathic pulmonary fibrosis;	chr15:85715337	chr15:85651522~85651628:-
LUAD	cis	rs889398	0.771	rs3790080	ENSG00000226232.7	RP11-419C5.2	-4.31	2e-05	0.00358	-0.17	-0.19	Body mass index;	chr16:69868236	chr16:69976388~69996188:-
LUAD	cis	rs4666360	1	rs6725416	ENSG00000234378.1	AC098828.2	4.31	2e-05	0.00358	0.23	0.19	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);	chr2:20137012	chr2:20063856~20106829:-
LUAD	cis	rs2288073	1	rs6708328	ENSG00000242628.4	AC009228.1	4.31	2e-05	0.00358	0.26	0.19	Venous thromboembolism (SNP x SNP interaction);	chr2:24189544	chr2:24214381~24221516:+
LUAD	cis	rs911119	0.913	rs6048929	ENSG00000270001.1	RP11-218C14.8	-4.31	2e-05	0.00358	-0.28	-0.19	Chronic kidney disease;	chr20:23608218	chr20:23631826~23632316:-
LUAD	cis	rs13113518	1	rs11133388	ENSG00000223305.1	RN7SKP30	-4.31	2e-05	0.00358	-0.21	-0.19	Height;	chr4:55477866	chr4:55540502~55540835:-
LUAD	cis	rs738722	0.514	rs695567	ENSG00000272858.1	CTA-292E10.8	-4.31	2e-05	0.00359	-0.21	-0.19	Optic cup area;Esophageal cancer and gastric cancer;	chr22:28493747	chr22:28814914~28815662:+
LUAD	cis	rs6496932	0.802	rs67928464	ENSG00000218052.5	ADAMTS7P4	4.31	2e-05	0.00359	0.22	0.19	Central corneal thickness;Corneal structure;	chr15:85338535	chr15:85255369~85330334:-
LUAD	cis	rs1798817	1	rs78756145	ENSG00000189238.5	LINC00943	-4.31	2e-05	0.00359	-0.36	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr12:126782928	chr12:126726270~126746252:+
LUAD	cis	rs1876905	0.68	rs373526	ENSG00000230177.1	RP5-1112D6.4	4.31	2e-05	0.00359	0.22	0.19	Mean corpuscular hemoglobin;	chr6:111190261	chr6:111277932~111278742:+
LUAD	cis	rs4819052	0.724	rs9753962	ENSG00000237664.1	LINC00316	-4.31	2.01e-05	0.00359	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241469	chr21:45338590~45341990:-
LUAD	cis	rs4819052	0.724	rs9753987	ENSG00000237664.1	LINC00316	-4.31	2.01e-05	0.00359	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241474	chr21:45338590~45341990:-
LUAD	cis	rs4819052	0.851	rs9753963	ENSG00000237664.1	LINC00316	-4.31	2.01e-05	0.00359	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241522	chr21:45338590~45341990:-
LUAD	cis	rs950027	0.787	rs2433616	ENSG00000259479.5	SORD2P	4.31	2.01e-05	0.00359	0.23	0.19	Response to fenofibrate (adiponectin levels);	chr15:45436401	chr15:44826371~44884694:-
LUAD	cis	rs7208859	0.623	rs9898084	ENSG00000280069.1	CTD-2349P21.3	-4.31	2.01e-05	0.00359	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30738182~30740275:+
LUAD	cis	rs6840258	0.843	rs3755985	ENSG00000251411.1	RP11-397E7.4	-4.31	2.01e-05	0.00359	-0.25	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87103586	chr4:86913266~86914817:-
LUAD	cis	rs561341	0.714	rs75861674	ENSG00000265798.5	RP11-271K11.5	4.31	2.01e-05	0.00359	0.29	0.19	Hip circumference adjusted for BMI;	chr17:31977298	chr17:31038575~31059121:-
LUAD	cis	rs7404843	0.925	rs12600043	ENSG00000183458.12	RP11-958N24.1	4.31	2.01e-05	0.00359	0.24	0.19	Testicular germ cell tumor;	chr16:15446095	chr16:14911551~14935708:+
LUAD	cis	rs28386778	0.897	rs2584608	ENSG00000240280.5	TCAM1P	-4.31	2.01e-05	0.00359	-0.22	-0.19	Prudent dietary pattern;	chr17:63859350	chr17:63849292~63864379:+
LUAD	cis	rs9545047	0.604	rs2265382	ENSG00000227354.5	RBM26-AS1	-4.31	2.01e-05	0.00359	-0.2	-0.19	Schizophrenia;	chr13:79426196	chr13:79406309~79424328:+
LUAD	cis	rs7646881	0.504	rs67305172	ENSG00000240207.5	RP11-379F4.4	-4.31	2.01e-05	0.00359	-0.22	-0.19	Tetralogy of Fallot;	chr3:158746485	chr3:158732263~158784070:+
LUAD	cis	rs9739640	1	rs9739640	ENSG00000257379.1	RP11-793H13.8	4.31	2.01e-05	0.00359	0.32	0.19	Reticulocyte count;	chr12:53389390	chr12:53441741~53467528:+
LUAD	cis	rs2446066	0.872	rs7955418	ENSG00000257379.1	RP11-793H13.8	4.31	2.01e-05	0.00359	0.32	0.19	Red blood cell count;	chr12:53397846	chr12:53441741~53467528:+
LUAD	cis	rs910316	1	rs12897094	ENSG00000279594.1	RP11-950C14.10	4.31	2.01e-05	0.00359	0.22	0.19	Height;	chr14:75112713	chr14:75011269~75012851:-
LUAD	cis	rs910316	1	rs12590452	ENSG00000279594.1	RP11-950C14.10	4.31	2.01e-05	0.0036	0.22	0.19	Height;	chr14:75082053	chr14:75011269~75012851:-
LUAD	cis	rs910316	1	rs1043674	ENSG00000279594.1	RP11-950C14.10	4.31	2.01e-05	0.0036	0.22	0.19	Height;	chr14:75082667	chr14:75011269~75012851:-
LUAD	cis	rs910316	0.967	rs2010678	ENSG00000279594.1	RP11-950C14.10	4.31	2.01e-05	0.0036	0.22	0.19	Height;	chr14:75100475	chr14:75011269~75012851:-
LUAD	cis	rs2115630	0.967	rs8028490	ENSG00000225151.9	GOLGA2P7	4.31	2.01e-05	0.0036	0.22	0.19	P wave terminal force;	chr15:84734657	chr15:84199311~84230136:-
LUAD	cis	rs2243480	0.711	rs1626926	ENSG00000229886.1	RP5-1132H15.3	4.31	2.01e-05	0.0036	0.33	0.19	Diabetic kidney disease;	chr7:65970805	chr7:66025126~66031544:-
LUAD	cis	rs4268898	0.717	rs3731626	ENSG00000242628.4	AC009228.1	4.31	2.01e-05	0.0036	0.27	0.19	Asthma;	chr2:24204995	chr2:24214381~24221516:+
LUAD	cis	rs7665090	1	rs12498722	ENSG00000246560.2	RP11-10L12.4	4.31	2.01e-05	0.0036	0.24	0.19	Primary biliary cholangitis;	chr4:102633365	chr4:102828055~102844075:+
LUAD	cis	rs7107174	1	rs2510037	ENSG00000251323.2	RP11-452H21.4	4.31	2.01e-05	0.0036	0.24	0.19	Testicular germ cell tumor;	chr11:78255053	chr11:78423982~78429836:-
LUAD	cis	rs6714710	0.603	rs34502870	ENSG00000230606.9	AC159540.1	-4.31	2.01e-05	0.0036	-0.2	-0.19	Posterior cortical atrophy and Alzheimer's disease;	chr2:97789466	chr2:97416165~97433527:-
LUAD	cis	rs651907	0.535	rs4342086	ENSG00000244119.1	PDCL3P4	4.31	2.01e-05	0.0036	0.2	0.19	Colorectal cancer;	chr3:101784921	chr3:101712472~101713191:+
LUAD	cis	rs4811196	0.719	rs4809868	ENSG00000226144.2	RPS27AP3	4.31	2.01e-05	0.0036	0.21	0.19	Bone mineral density;	chr20:37861496	chr20:37049254~37049707:+
LUAD	cis	rs801193	0.967	rs2420827	ENSG00000224316.1	RP11-479O9.2	-4.31	2.01e-05	0.0036	-0.2	-0.19	Aortic root size;	chr7:66682114	chr7:65773620~65802067:+
LUAD	cis	rs11673344	0.503	rs1667370	ENSG00000276846.1	CTD-3220F14.3	4.31	2.01e-05	0.0036	0.21	0.19	Obesity-related traits;	chr19:36999318	chr19:37314868~37315620:-
LUAD	cis	rs858239	1	rs199351	ENSG00000230042.1	AK3P3	-4.31	2.01e-05	0.0036	-0.24	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23260430	chr7:23129178~23129841:+
LUAD	cis	rs4819052	0.851	rs9754134	ENSG00000237664.1	LINC00316	-4.31	2.02e-05	0.0036	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241836	chr21:45338590~45341990:-
LUAD	cis	rs35740288	0.77	rs11633893	ENSG00000259407.1	RP11-158M2.3	4.31	2.02e-05	0.0036	0.19	0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85605207	chr15:85744109~85750281:-
LUAD	cis	rs7098414	0.511	rs10887826	ENSG00000226659.1	RP11-137H2.4	-4.31	2.02e-05	0.00361	-0.26	-0.19	Post bronchodilator FEV1;	chr10:80391624	chr10:80529597~80535942:-
LUAD	cis	rs4908769	0.66	rs159961	ENSG00000232912.4	RP5-1115A15.1	4.31	2.02e-05	0.00361	0.18	0.19	Allergy;	chr1:8424168	chr1:8424645~8434838:+
LUAD	cis	rs5015933	0.788	rs3896096	ENSG00000232630.1	PRPS1P2	-4.31	2.02e-05	0.00361	-0.18	-0.19	Body mass index;	chr9:125265566	chr9:125150653~125151589:+
LUAD	cis	rs7598759	0.527	rs4973417	ENSG00000223198.1	RNU2-22P	-4.31	2.02e-05	0.00361	-0.22	-0.19	Noise-induced hearing loss;	chr2:231484925	chr2:231501990~231502201:-
LUAD	cis	rs2933343	0.63	rs75824035	ENSG00000261159.1	RP11-723O4.9	4.31	2.02e-05	0.00361	0.21	0.19	IgG glycosylation;	chr3:128934142	chr3:128859716~128860526:-
LUAD	cis	rs738722	0.514	rs737622	ENSG00000272858.1	CTA-292E10.8	-4.31	2.02e-05	0.00361	-0.21	-0.19	Optic cup area;Esophageal cancer and gastric cancer;	chr22:28481727	chr22:28814914~28815662:+
LUAD	cis	rs6570726	0.791	rs9373463	ENSG00000235652.6	RP11-545I5.3	4.31	2.02e-05	0.00361	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145573626	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.764	rs9322028	ENSG00000235652.6	RP11-545I5.3	4.31	2.02e-05	0.00361	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145574661	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.791	rs12205752	ENSG00000235652.6	RP11-545I5.3	4.31	2.02e-05	0.00361	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145574982	chr6:145799409~145886585:+
LUAD	cis	rs2018683	0.707	rs1021690	ENSG00000228421.2	AC005013.5	4.31	2.02e-05	0.00361	0.21	0.19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28934871	chr7:28957667~28959345:+
LUAD	cis	rs2018683	0.707	rs1021691	ENSG00000228421.2	AC005013.5	4.31	2.02e-05	0.00361	0.21	0.19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28934879	chr7:28957667~28959345:+
LUAD	cis	rs42490	1	rs40246	ENSG00000251136.7	RP11-37B2.1	-4.31	2.02e-05	0.00361	-0.2	-0.19	Leprosy;	chr8:89752944	chr8:89609409~89757727:-
LUAD	cis	rs7324557	0.684	rs9507165	ENSG00000205861.10	C1QTNF9B-AS1	-4.31	2.02e-05	0.00361	-0.26	-0.19	Visceral adipose tissue adjusted for BMI;	chr13:23810291	chr13:23888889~23897263:+
LUAD	cis	rs9860428	0.844	rs16860225	ENSG00000242770.2	RP11-180K7.1	-4.31	2.02e-05	0.00361	-0.2	-0.19	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112904882	chr3:112802478~112812819:+
LUAD	cis	rs2880765	0.835	rs12324277	ENSG00000259416.2	RP11-158M2.5	4.31	2.02e-05	0.00361	0.2	0.19	Coronary artery disease;	chr15:85498504	chr15:85754941~85756237:-
LUAD	cis	rs6840360	0.571	rs11939356	ENSG00000270265.1	RP11-731D1.4	-4.31	2.02e-05	0.00361	-0.22	-0.19	Intelligence (multi-trait analysis);	chr4:151584082	chr4:151333775~151353224:-
LUAD	cis	rs10463554	0.963	rs17154959	ENSG00000250682.4	LINC00491	4.31	2.02e-05	0.00361	0.24	0.19	Parkinson's disease;	chr5:103020587	chr5:102609156~102671559:-
LUAD	cis	rs4664293	0.967	rs9646765	ENSG00000230783.1	AC009961.2	-4.31	2.02e-05	0.00362	-0.24	-0.19	Monocyte percentage of white cells;	chr2:159709137	chr2:159689217~159690291:-
LUAD	cis	rs34779708	0.832	rs6481946	ENSG00000271335.4	RP11-324I22.4	4.31	2.02e-05	0.00362	0.21	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35240186	chr10:35314552~35336401:-
LUAD	cis	rs13113518	0.812	rs1522114	ENSG00000272969.1	RP11-528I4.2	4.3	2.03e-05	0.00362	0.21	0.19	Height;	chr4:55489895	chr4:55547112~55547889:+
LUAD	cis	rs9926296	0.744	rs154656	ENSG00000260259.1	RP11-368I7.4	4.3	2.03e-05	0.00362	0.19	0.19	Vitiligo;	chr16:89641595	chr16:89682620~89686569:-
LUAD	cis	rs7665090	1	rs5026473	ENSG00000246560.2	RP11-10L12.4	4.3	2.03e-05	0.00362	0.24	0.19	Primary biliary cholangitis;	chr4:102633636	chr4:102828055~102844075:+
LUAD	cis	rs5758659	0.652	rs133301	ENSG00000182057.4	OGFRP1	4.3	2.03e-05	0.00362	0.23	0.19	Cognitive function;	chr22:41994089	chr22:42269753~42275196:+
LUAD	cis	rs8030379	1	rs2401173	ENSG00000230373.7	GOLGA6L5P	-4.3	2.03e-05	0.00362	-0.18	-0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83908218	chr15:84507885~84516814:-
LUAD	cis	rs2348418	0.639	rs10459087	ENSG00000247934.4	RP11-967K21.1	4.3	2.03e-05	0.00362	0.21	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28115904	chr12:28163298~28190738:-
LUAD	cis	rs7829975	0.606	rs7819827	ENSG00000173295.6	FAM86B3P	-4.3	2.03e-05	0.00362	-0.2	-0.19	Mood instability;	chr8:8939545	chr8:8228595~8244865:+
LUAD	cis	rs7829975	0.573	rs7842359	ENSG00000173295.6	FAM86B3P	-4.3	2.03e-05	0.00362	-0.2	-0.19	Mood instability;	chr8:8939568	chr8:8228595~8244865:+
LUAD	cis	rs7927592	0.513	rs7950129	ENSG00000212093.1	AP000807.1	4.3	2.03e-05	0.00362	0.2	0.19	Total body bone mineral density;	chr11:68435435	chr11:68506083~68506166:-
LUAD	cis	rs6687758	1	rs12140604	ENSG00000227925.1	RP11-191N8.2	4.3	2.03e-05	0.00362	0.26	0.19	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221985808	chr1:221827666~221840666:-
LUAD	cis	rs853679	0.527	rs1997660	ENSG00000219392.1	RP1-265C24.5	-4.3	2.03e-05	0.00362	-0.24	-0.19	Depression;	chr6:28301886	chr6:28115628~28116551:+
LUAD	cis	rs13434995	0.891	rs62309728	ENSG00000249700.7	SRD5A3-AS1	-4.3	2.03e-05	0.00362	-0.28	-0.19	Adiponectin levels;	chr4:55530648	chr4:55363971~55395847:-
LUAD	cis	rs10027350	0.857	rs3796793	ENSG00000281501.1	SEPSECS-AS1	4.3	2.03e-05	0.00362	0.24	0.19	Childhood ear infection;	chr4:25142945	chr4:25160641~25201440:+
LUAD	cis	rs7955901	0.904	rs7138300	ENSG00000258053.1	CTD-2021H9.3	-4.3	2.03e-05	0.00362	-0.23	-0.19	Type 2 diabetes;	chr12:71045809	chr12:71047402~71118247:-
LUAD	cis	rs28386778	0.897	rs2137144	ENSG00000240280.5	TCAM1P	-4.3	2.03e-05	0.00362	-0.22	-0.19	Prudent dietary pattern;	chr17:63728247	chr17:63849292~63864379:+
LUAD	cis	rs7746199	0.736	rs58616630	ENSG00000219392.1	RP1-265C24.5	-4.3	2.03e-05	0.00362	-0.41	-0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27506936	chr6:28115628~28116551:+
LUAD	cis	rs9959145	0.543	rs11664013	ENSG00000267199.1	RP11-861E21.2	-4.3	2.03e-05	0.00362	-0.2	-0.19	Immune response to smallpox vaccine (IL-6);	chr18:12582789	chr18:12438890~12448205:+
LUAD	cis	rs12188164	0.965	rs41282625	ENSG00000221990.4	EXOC3-AS1	4.3	2.03e-05	0.00362	0.19	0.19	Cystic fibrosis severity;	chr5:475511	chr5:441498~443160:-
LUAD	cis	rs17826219	0.636	rs4055314	ENSG00000266490.1	CTD-2349P21.9	4.3	2.03e-05	0.00362	0.29	0.19	Body mass index;	chr17:30752751	chr17:30792372~30792833:+
LUAD	cis	rs7636293	0.647	rs13095008	ENSG00000270773.1	RP13-685P2.7	4.3	2.03e-05	0.00362	0.28	0.19	Height;	chr3:129326057	chr3:129345411~129346164:+
LUAD	cis	rs7636293	0.592	rs6801264	ENSG00000270773.1	RP13-685P2.7	4.3	2.03e-05	0.00362	0.28	0.19	Height;	chr3:129326435	chr3:129345411~129346164:+
LUAD	cis	rs170183	0.679	rs9636632	ENSG00000233818.1	AP000695.4	-4.3	2.03e-05	0.00363	-0.18	-0.19	Bone mineral density;	chr21:36483462	chr21:36445731~36532408:+
LUAD	cis	rs7665090	1	rs10027437	ENSG00000246560.2	RP11-10L12.4	4.3	2.03e-05	0.00363	0.23	0.19	Primary biliary cholangitis;	chr4:102636094	chr4:102828055~102844075:+
LUAD	cis	rs2562456	0.839	rs2562411	ENSG00000268081.1	RP11-678G14.2	4.3	2.03e-05	0.00363	0.31	0.19	Pain;	chr19:21419181	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.876	rs2562413	ENSG00000268081.1	RP11-678G14.2	4.3	2.03e-05	0.00363	0.31	0.19	Pain;	chr19:21420084	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.916	rs1967182	ENSG00000268081.1	RP11-678G14.2	4.3	2.03e-05	0.00363	0.31	0.19	Pain;	chr19:21420337	chr19:21554640~21569237:-
LUAD	cis	rs116095464	0.558	rs28558836	ENSG00000248925.1	CTD-2083E4.6	4.3	2.03e-05	0.00363	0.33	0.19	Breast cancer;	chr5:285633	chr5:269858~271516:-
LUAD	cis	rs950169	0.579	rs881983	ENSG00000225151.9	GOLGA2P7	-4.3	2.03e-05	0.00363	-0.28	-0.19	Schizophrenia;	chr15:83978556	chr15:84199311~84230136:-
LUAD	cis	rs2057178	0.929	rs61889183	ENSG00000183242.10	WT1-AS	4.3	2.03e-05	0.00363	0.3	0.19	Tuberculosis;	chr11:32335825	chr11:32435518~32458769:+
LUAD	cis	rs477895	0.713	rs35095324	ENSG00000236935.1	AP003774.1	-4.3	2.03e-05	0.00363	-0.24	-0.19	Mean platelet volume;	chr11:64180940	chr11:64325050~64329504:-
LUAD	cis	rs7107174	0.792	rs2888465	ENSG00000251323.2	RP11-452H21.4	4.3	2.03e-05	0.00363	0.26	0.19	Testicular germ cell tumor;	chr11:78234761	chr11:78423982~78429836:-
LUAD	cis	rs4879677	1	rs10757676	ENSG00000215441.3	CTAGE12P	-4.3	2.03e-05	0.00363	-0.23	-0.19	Gut microbiome composition (summer and winter);	chr9:27680309	chr9:27608382~27610745:-
LUAD	cis	rs858239	0.899	rs28635122	ENSG00000226816.2	AC005082.12	4.3	2.03e-05	0.00363	0.26	0.19	Cerebrospinal fluid biomarker levels;	chr7:23270562	chr7:23206013~23208045:+
LUAD	cis	rs858239	0.899	rs7794684	ENSG00000226816.2	AC005082.12	4.3	2.03e-05	0.00363	0.26	0.19	Cerebrospinal fluid biomarker levels;	chr7:23271186	chr7:23206013~23208045:+
LUAD	cis	rs6754311	0.731	rs2236783	ENSG00000226806.1	AC011893.3	-4.3	2.03e-05	0.00363	-0.24	-0.19	Mosquito bite size;	chr2:135836588	chr2:135820191~135823087:+
LUAD	cis	rs8050896	0.51	rs78631370	ENSG00000260695.1	RP11-513N24.1	-4.3	2.03e-05	0.00363	-0.32	-0.19	Response to antipsychotic treatment;	chr16:66131817	chr16:65861112~65863784:-
LUAD	cis	rs6565180	0.963	rs4787642	ENSG00000273724.1	RP11-347C12.12	-4.3	2.03e-05	0.00363	-0.21	-0.19	Tonsillectomy;	chr16:30348087	chr16:30336400~30343336:+
LUAD	cis	rs7204230	0.96	rs12596696	ENSG00000261291.1	RP11-295M3.2	4.3	2.03e-05	0.00363	0.24	0.19	Fibrinogen;	chr16:53334858	chr16:53168522~53169450:+
LUAD	cis	rs7172677	0.737	rs7163083	ENSG00000260269.4	CTD-2323K18.1	-4.3	2.04e-05	0.00363	-0.25	-0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75149996	chr15:75527150~75601205:-
LUAD	cis	rs36093844	0.642	rs7108491	ENSG00000279742.1	RP11-700A24.1	-4.3	2.04e-05	0.00364	-0.2	-0.19	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85901796	chr11:85852557~85854943:-
LUAD	cis	rs262150	0.659	rs2527236	ENSG00000231419.5	LINC00689	-4.3	2.04e-05	0.00364	-0.23	-0.19	Facial morphology (factor 20);	chr7:159003953	chr7:159006522~159030195:+
LUAD	cis	rs9487094	0.885	rs11153214	ENSG00000260273.1	RP11-425D10.10	4.3	2.04e-05	0.00364	0.28	0.19	Height;	chr6:109694120	chr6:109382795~109383666:+
LUAD	cis	rs4873772	0.837	rs11778548	ENSG00000253330.1	RP11-697N18.3	-4.3	2.04e-05	0.00364	-0.22	-0.19	Lobe attachment (rater-scored or self-reported);	chr8:47717645	chr8:47511034~47512141:-
LUAD	cis	rs13113518	0.812	rs13116035	ENSG00000272969.1	RP11-528I4.2	4.3	2.04e-05	0.00364	0.21	0.19	Height;	chr4:55561218	chr4:55547112~55547889:+
LUAD	cis	rs875971	1	rs9986696	ENSG00000232559.3	GS1-124K5.12	-4.3	2.04e-05	0.00364	-0.23	-0.19	Aortic root size;	chr7:66239589	chr7:66554588~66576923:-
LUAD	cis	rs80028505	0.908	rs7764494	ENSG00000271304.1	DPRXP2	4.3	2.04e-05	0.00364	0.36	0.19	Foot ulcer in diabetes and neuropathy;	chr6:36113563	chr6:35989515~35990436:-
LUAD	cis	rs2243480	1	rs431076	ENSG00000229886.1	RP5-1132H15.3	4.3	2.04e-05	0.00364	0.33	0.19	Diabetic kidney disease;	chr7:66135333	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs2257790	ENSG00000229886.1	RP5-1132H15.3	4.3	2.04e-05	0.00364	0.33	0.19	Diabetic kidney disease;	chr7:66135463	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs2460422	ENSG00000229886.1	RP5-1132H15.3	4.3	2.04e-05	0.00364	0.33	0.19	Diabetic kidney disease;	chr7:66136518	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs316334	ENSG00000229886.1	RP5-1132H15.3	4.3	2.04e-05	0.00364	0.33	0.19	Diabetic kidney disease;	chr7:66137139	chr7:66025126~66031544:-
LUAD	cis	rs9545047	0.604	rs2477397	ENSG00000227354.5	RBM26-AS1	-4.3	2.04e-05	0.00364	-0.2	-0.19	Schizophrenia;	chr13:79428211	chr13:79406309~79424328:+
LUAD	cis	rs17881320	0.51	rs6503699	ENSG00000108785.7	HSD17B1P1	-4.3	2.04e-05	0.00364	-0.33	-0.19	Atopic dermatitis;	chr17:42402243	chr17:42546764~42548706:+
LUAD	cis	rs858239	0.6	rs10235786	ENSG00000226816.2	AC005082.12	4.3	2.04e-05	0.00364	0.25	0.19	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23206013~23208045:+
LUAD	cis	rs12446632	0.539	rs28588186	ENSG00000261195.1	CTD-2380F24.1	-4.3	2.04e-05	0.00364	-0.24	-0.19	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Menarche (age at onset);Obesity;Childhood body mass index;Waist circumference;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr16:19898991	chr16:19761172~19766099:-
LUAD	cis	rs11009175	0.725	rs1832926	ENSG00000273038.2	RP11-479G22.8	-4.3	2.04e-05	0.00364	-0.27	-0.19	Depression (quantitative trait);	chr10:33014676	chr10:32887255~32889311:-
LUAD	cis	rs4934494	0.911	rs7081788	ENSG00000240996.1	RP11-80H5.7	-4.3	2.04e-05	0.00364	-0.25	-0.19	Red blood cell count;	chr10:89648999	chr10:89694295~89697928:-
LUAD	cis	rs11168618	0.87	rs7302209	ENSG00000240399.1	RP1-228P16.1	4.3	2.04e-05	0.00364	0.19	0.19	Adiponectin levels;	chr12:48501601	chr12:48054813~48055591:-
LUAD	cis	rs9393777	0.777	rs56114371	ENSG00000219392.1	RP1-265C24.5	-4.3	2.04e-05	0.00365	-0.41	-0.19	Intelligence (multi-trait analysis);	chr6:27307055	chr6:28115628~28116551:+
LUAD	cis	rs7615952	1	rs7615952	ENSG00000241288.6	RP11-379B18.5	4.3	2.04e-05	0.00365	0.24	0.19	Blood pressure (smoking interaction);	chr3:125930560	chr3:125827238~125916384:-
LUAD	cis	rs791888	1	rs791882	ENSG00000225913.2	RP11-57C13.6	4.3	2.04e-05	0.00365	0.25	0.19	Magnesium levels;	chr10:87648501	chr10:87607985~87659279:+
LUAD	cis	rs3808502	0.526	rs1042701	ENSG00000255046.1	RP11-297N6.4	4.3	2.04e-05	0.00365	0.23	0.19	Neuroticism;	chr8:11564536	chr8:11797928~11802568:-
LUAD	cis	rs3808502	0.526	rs7843987	ENSG00000255046.1	RP11-297N6.4	4.3	2.04e-05	0.00365	0.23	0.19	Neuroticism;	chr8:11564621	chr8:11797928~11802568:-
LUAD	cis	rs3808502	0.526	rs7822958	ENSG00000255046.1	RP11-297N6.4	4.3	2.04e-05	0.00365	0.23	0.19	Neuroticism;	chr8:11564933	chr8:11797928~11802568:-
LUAD	cis	rs3808502	0.526	rs7823100	ENSG00000255046.1	RP11-297N6.4	4.3	2.04e-05	0.00365	0.23	0.19	Neuroticism;	chr8:11564982	chr8:11797928~11802568:-
LUAD	cis	rs3808502	0.526	rs7823101	ENSG00000255046.1	RP11-297N6.4	4.3	2.04e-05	0.00365	0.23	0.19	Neuroticism;	chr8:11564983	chr8:11797928~11802568:-
LUAD	cis	rs4879677	1	rs10812633	ENSG00000215441.3	CTAGE12P	-4.3	2.04e-05	0.00365	-0.24	-0.19	Gut microbiome composition (summer and winter);	chr9:27656975	chr9:27608382~27610745:-
LUAD	cis	rs454217	0.846	rs413415	ENSG00000277851.1	RP11-756G20.1	4.3	2.04e-05	0.00365	0.2	0.19	Smoking quantity;	chr12:92327115	chr12:92247756~92363832:-
LUAD	cis	rs561341	1	rs1557731	ENSG00000265798.5	RP11-271K11.5	4.3	2.05e-05	0.00365	0.28	0.19	Hip circumference adjusted for BMI;	chr17:31994548	chr17:31038575~31059121:-
LUAD	cis	rs561341	1	rs537166	ENSG00000265798.5	RP11-271K11.5	4.3	2.05e-05	0.00365	0.28	0.19	Hip circumference adjusted for BMI;	chr17:31999808	chr17:31038575~31059121:-
LUAD	cis	rs8054556	0.74	rs12716974	ENSG00000183604.13	SMG1P5	-4.3	2.05e-05	0.00365	-0.19	-0.19	Autism spectrum disorder or schizophrenia;	chr16:29933511	chr16:30267553~30335374:-
LUAD	cis	rs763121	0.853	rs6519119	ENSG00000225450.1	RP3-508I15.14	-4.3	2.05e-05	0.00365	-0.19	-0.19	Menopause (age at onset);	chr22:38593002	chr22:38739003~38749041:+
LUAD	cis	rs763121	0.853	rs9622833	ENSG00000225450.1	RP3-508I15.14	-4.3	2.05e-05	0.00365	-0.19	-0.19	Menopause (age at onset);	chr22:38604392	chr22:38739003~38749041:+
LUAD	cis	rs2911132	0.506	rs10037212	ENSG00000248734.2	CTD-2260A17.1	-4.3	2.05e-05	0.00365	-0.2	-0.19	Urate levels (BMI interaction);	chr5:96749072	chr5:96784777~96785999:+
LUAD	cis	rs11673344	0.542	rs826328	ENSG00000276846.1	CTD-3220F14.3	4.3	2.05e-05	0.00365	0.21	0.19	Obesity-related traits;	chr19:37004479	chr19:37314868~37315620:-
LUAD	cis	rs17772222	0.675	rs1099698	ENSG00000258789.1	RP11-507K2.3	4.3	2.05e-05	0.00366	0.24	0.19	Coronary artery calcification;	chr14:88414904	chr14:88551597~88552493:+
LUAD	cis	rs2273156	0.57	rs941653	ENSG00000226677.3	IGBP1P1	-4.3	2.05e-05	0.00366	-0.3	-0.19	Immunoglobulin light chain (AL) amyloidosis;	chr14:35123332	chr14:34939324~34940332:+
LUAD	cis	rs2731006	0.591	rs7976494	ENSG00000257114.2	RP11-25I15.3	4.3	2.05e-05	0.00366	0.29	0.19	Panic disorder;	chr12:42814285	chr12:42692216~42717119:+
LUAD	cis	rs9516	1	rs9516	ENSG00000213333.3	NPM1P50	4.3	2.05e-05	0.00366	0.2	0.19	Facial morphology (factor 15, philtrum width);	chr11:74455233	chr11:75079265~75080131:-
LUAD	cis	rs12534093	0.522	rs11768826	ENSG00000234286.1	AC006026.13	-4.3	2.05e-05	0.00366	-0.25	-0.19	Infant length;Height;	chr7:23534595	chr7:23680195~23680786:-
LUAD	cis	rs4374383	0.923	rs4848923	ENSG00000207383.1	Y_RNA	-4.3	2.05e-05	0.00366	-0.23	-0.19	Hepatitis C induced liver fibrosis;	chr2:111984874	chr2:112579484~112579584:-
LUAD	cis	rs2279440	0.759	rs17050392	ENSG00000206573.7	THUMPD3-AS1	-4.3	2.05e-05	0.00366	-0.19	-0.19	Glucose homeostasis traits;	chr3:9481610	chr3:9349689~9398579:-
LUAD	cis	rs3096299	0.685	rs4329923	ENSG00000261118.1	RP11-104N10.1	4.3	2.05e-05	0.00366	0.2	0.19	Multiple myeloma (IgH translocation);	chr16:89493770	chr16:89492017~89504460:-
LUAD	cis	rs8141529	0.719	rs2097461	ENSG00000272858.1	CTA-292E10.8	-4.3	2.05e-05	0.00366	-0.22	-0.19	Lymphocyte counts;	chr22:28795891	chr22:28814914~28815662:+
LUAD	cis	rs2933343	1	rs1680795	ENSG00000231305.3	RP11-723O4.2	4.3	2.05e-05	0.00366	0.23	0.19	IgG glycosylation;	chr3:128901545	chr3:128861313~128871540:-
LUAD	cis	rs7615952	0.8	rs12489350	ENSG00000241288.6	RP11-379B18.5	-4.3	2.05e-05	0.00366	-0.25	-0.19	Blood pressure (smoking interaction);	chr3:125925273	chr3:125827238~125916384:-
LUAD	cis	rs910316	0.967	rs175479	ENSG00000279594.1	RP11-950C14.10	-4.3	2.05e-05	0.00366	-0.22	-0.19	Height;	chr14:75095168	chr14:75011269~75012851:-
LUAD	cis	rs4268898	0.76	rs11676939	ENSG00000242628.4	AC009228.1	-4.3	2.05e-05	0.00367	-0.24	-0.19	Asthma;	chr2:24256188	chr2:24214381~24221516:+
LUAD	cis	rs34792	0.554	rs28393495	ENSG00000207425.1	Y_RNA	-4.3	2.05e-05	0.00367	-0.24	-0.19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15516406	chr16:14915457~14915556:-
LUAD	cis	rs9876781	0.967	rs7618883	ENSG00000229759.1	MRPS18AP1	4.3	2.06e-05	0.00367	0.18	0.19	Longevity;	chr3:48457056	chr3:48256350~48256938:-
LUAD	cis	rs1729951	0.575	rs10935213	ENSG00000239213.4	NCK1-AS1	4.3	2.06e-05	0.00367	0.21	0.19	Neuroticism;	chr3:136974617	chr3:136841726~136862054:-
LUAD	cis	rs11673344	0.598	rs826326	ENSG00000276846.1	CTD-3220F14.3	4.3	2.06e-05	0.00367	0.21	0.19	Obesity-related traits;	chr19:37003863	chr19:37314868~37315620:-
LUAD	cis	rs2933343	0.7	rs1683779	ENSG00000231305.3	RP11-723O4.2	4.3	2.06e-05	0.00367	0.21	0.19	IgG glycosylation;	chr3:128923205	chr3:128861313~128871540:-
LUAD	cis	rs897984	0.806	rs8050588	ENSG00000232748.3	RP11-196G11.6	-4.3	2.06e-05	0.00367	-0.24	-0.19	Dementia with Lewy bodies;	chr16:30926478	chr16:31056460~31062803:+
LUAD	cis	rs755249	0.565	rs9729677	ENSG00000228060.1	RP11-69E11.8	4.3	2.06e-05	0.00367	0.17	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39587137	chr1:39565160~39573203:+
LUAD	cis	rs9549367	0.577	rs3024718	ENSG00000269125.1	RP11-98F14.11	4.3	2.06e-05	0.00367	0.26	0.19	Platelet distribution width;	chr13:113159539	chr13:113165002~113165183:-
LUAD	cis	rs847577	0.609	rs705308	ENSG00000272950.1	RP11-307C18.1	-4.3	2.06e-05	0.00367	-0.24	-0.19	Breast cancer;	chr7:98066051	chr7:98322853~98323430:+
LUAD	cis	rs9400467	0.508	rs61269242	ENSG00000230177.1	RP5-1112D6.4	-4.3	2.06e-05	0.00367	-0.17	-0.19	Amino acid levels;Blood metabolite levels;	chr6:111481856	chr6:111277932~111278742:+
LUAD	cis	rs2803122	0.501	rs10811140	ENSG00000273226.1	RP11-513M16.8	-4.3	2.06e-05	0.00367	-0.25	-0.19	Pulse pressure;	chr9:19230401	chr9:19375451~19375996:+
LUAD	cis	rs11250098	0.503	rs13270870	ENSG00000255046.1	RP11-297N6.4	4.3	2.06e-05	0.00367	0.23	0.19	Morning vs. evening chronotype;	chr8:10913272	chr8:11797928~11802568:-
LUAD	cis	rs2153535	0.585	rs58117210	ENSG00000230939.1	RP11-314C16.1	-4.3	2.06e-05	0.00367	-0.21	-0.19	Motion sickness;	chr6:8603881	chr6:8784178~8785445:+
LUAD	cis	rs2522056	1	rs2405528	ENSG00000233006.5	AC034220.3	-4.3	2.06e-05	0.00367	-0.21	-0.19	Fibrinogen;Lymphocyte counts;	chr5:132458606	chr5:132311285~132369916:-
LUAD	cis	rs7247513	0.639	rs12984441	ENSG00000230310.1	CTD-2192J16.11	-4.3	2.06e-05	0.00367	-0.22	-0.19	Bipolar disorder;	chr19:12649473	chr19:12552597~12553644:+
LUAD	cis	rs219780	0.898	rs219789	ENSG00000233818.1	AP000695.4	4.3	2.06e-05	0.00367	0.25	0.19	Kidney stones;	chr21:36456742	chr21:36445731~36532408:+
LUAD	cis	rs957448	1	rs12680965	ENSG00000253175.1	RP11-267M23.6	4.3	2.06e-05	0.00367	0.23	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94554069	chr8:94565036~94565715:+
LUAD	cis	rs957448	1	rs72674861	ENSG00000254315.1	RP11-267M23.3	4.3	2.06e-05	0.00367	0.25	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94550051	chr8:94533628~94534391:+
LUAD	cis	rs7107174	0.892	rs7115850	ENSG00000251323.2	RP11-452H21.4	4.3	2.06e-05	0.00368	0.23	0.19	Testicular germ cell tumor;	chr11:78334025	chr11:78423982~78429836:-
LUAD	cis	rs10129255	0.957	rs6576233	ENSG00000211967.3	IGHV3-53	-4.3	2.06e-05	0.00368	-0.15	-0.19	Kawasaki disease;	chr14:106787239	chr14:106592676~106593347:-
LUAD	cis	rs4873772	0.653	rs7014443	ENSG00000253330.1	RP11-697N18.3	-4.3	2.06e-05	0.00368	-0.22	-0.19	Lobe attachment (rater-scored or self-reported);	chr8:47684382	chr8:47511034~47512141:-
LUAD	cis	rs6012564	0.893	rs6012579	ENSG00000230758.1	SNAP23P	-4.3	2.06e-05	0.00368	-0.2	-0.19	Anger;	chr20:49006883	chr20:49038357~49038602:-
LUAD	cis	rs17122278	1	rs10892243	ENSG00000243431.1	RPL5P30	4.3	2.06e-05	0.00368	0.24	0.19	Total cholesterol levels;	chr11:118571131	chr11:118560690~118561580:+
LUAD	cis	rs4873772	0.735	rs4873395	ENSG00000253330.1	RP11-697N18.3	4.3	2.06e-05	0.00368	0.21	0.19	Lobe attachment (rater-scored or self-reported);	chr8:47594066	chr8:47511034~47512141:-
LUAD	cis	rs889398	0.741	rs6499268	ENSG00000226232.7	RP11-419C5.2	-4.3	2.06e-05	0.00368	-0.17	-0.19	Body mass index;	chr16:69872626	chr16:69976388~69996188:-
LUAD	cis	rs67478160	0.643	rs2887282	ENSG00000272533.1	SNORA28	4.3	2.06e-05	0.00368	0.19	0.19	Schizophrenia;	chr14:103814397	chr14:103337849~103337974:+
LUAD	cis	rs780096	0.506	rs2288155	ENSG00000234072.1	AC074117.10	-4.3	2.06e-05	0.00368	-0.15	-0.19	Total body bone mineral density;	chr2:27491659	chr2:27356246~27367622:+
LUAD	cis	rs2243480	1	rs4718270	ENSG00000226002.1	RP11-460N20.5	-4.3	2.06e-05	0.00368	-0.33	-0.19	Diabetic kidney disease;	chr7:65737415	chr7:65084103~65100232:+
LUAD	cis	rs2243480	0.901	rs2900904	ENSG00000226002.1	RP11-460N20.5	-4.3	2.06e-05	0.00368	-0.33	-0.19	Diabetic kidney disease;	chr7:65739282	chr7:65084103~65100232:+
LUAD	cis	rs6840360	0.571	rs62327271	ENSG00000270265.1	RP11-731D1.4	-4.3	2.07e-05	0.00368	-0.22	-0.19	Intelligence (multi-trait analysis);	chr4:151614764	chr4:151333775~151353224:-
LUAD	cis	rs2810114	0.916	rs2526851	ENSG00000269927.1	RP6-91H8.3	-4.3	2.07e-05	0.00368	-0.26	-0.19	Alcohol dependence;	chr14:70949563	chr14:71141125~71143253:-
LUAD	cis	rs7208859	0.623	rs73267858	ENSG00000280069.1	CTD-2349P21.3	-4.3	2.07e-05	0.00369	-0.27	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732719	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs56095789	ENSG00000280069.1	CTD-2349P21.3	-4.3	2.07e-05	0.00369	-0.27	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733152	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs11656844	ENSG00000280069.1	CTD-2349P21.3	-4.3	2.07e-05	0.00369	-0.27	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733579	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs11652533	ENSG00000280069.1	CTD-2349P21.3	-4.3	2.07e-05	0.00369	-0.27	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733583	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs11652631	ENSG00000280069.1	CTD-2349P21.3	-4.3	2.07e-05	0.00369	-0.27	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733748	chr17:30738182~30740275:+
LUAD	cis	rs4667682	0.529	rs62181336	ENSG00000234061.1	AC007969.4	-4.3	2.07e-05	0.00369	-0.38	-0.19	Hippocampal atrophy;Body mass index;	chr2:171291871	chr2:171492905~171493095:+
LUAD	cis	rs7086627	0.515	rs11202957	ENSG00000226659.1	RP11-137H2.4	-4.3	2.07e-05	0.00369	-0.26	-0.19	Post bronchodilator FEV1;	chr10:80449836	chr10:80529597~80535942:-
LUAD	cis	rs4819052	1	rs2297284	ENSG00000237664.1	LINC00316	-4.3	2.07e-05	0.00369	-0.25	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285430	chr21:45338590~45341990:-
LUAD	cis	rs4666360	1	rs4666361	ENSG00000234378.1	AC098828.2	4.3	2.07e-05	0.00369	0.23	0.19	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);	chr2:20136454	chr2:20063856~20106829:-
LUAD	cis	rs11673344	0.526	rs17303902	ENSG00000226686.6	LINC01535	4.3	2.07e-05	0.00369	0.23	0.19	Obesity-related traits;	chr19:37551912	chr19:37251912~37265535:+
LUAD	cis	rs11673344	0.526	rs55754546	ENSG00000226686.6	LINC01535	4.3	2.07e-05	0.00369	0.23	0.19	Obesity-related traits;	chr19:37552860	chr19:37251912~37265535:+
LUAD	cis	rs5762752	0.555	rs695388	ENSG00000272858.1	CTA-292E10.8	-4.3	2.07e-05	0.00369	-0.2	-0.19	Optic disc area;	chr22:28437514	chr22:28814914~28815662:+
LUAD	cis	rs831571	0.774	rs40610	ENSG00000280620.1	SCAANT1	4.3	2.07e-05	0.00369	0.24	0.19	Type 2 diabetes;	chr3:64023832	chr3:63911518~63911772:-
LUAD	cis	rs9649213	0.593	rs6465662	ENSG00000272950.1	RP11-307C18.1	4.3	2.07e-05	0.00369	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98288489	chr7:98322853~98323430:+
LUAD	cis	rs11673344	0.504	rs4806407	ENSG00000276846.1	CTD-3220F14.3	-4.3	2.07e-05	0.00369	-0.21	-0.19	Obesity-related traits;	chr19:37097849	chr19:37314868~37315620:-
LUAD	cis	rs11122895	0.716	rs3860383	ENSG00000236307.2	EEF1E1P1	4.3	2.07e-05	0.00369	0.22	0.19	Allergic sensitization;	chr2:111715291	chr2:111887914~111888741:+
LUAD	cis	rs113835537	0.935	rs76228630	ENSG00000255517.5	CTD-3074O7.5	-4.3	2.07e-05	0.00369	-0.29	-0.19	Airway imaging phenotypes;	chr11:66691205	chr11:66473490~66480233:-
LUAD	cis	rs1075265	0.575	rs2692531	ENSG00000272156.1	RP11-477N3.1	-4.3	2.07e-05	0.00369	-0.23	-0.19	Chronotype;Morning vs. evening chronotype;	chr2:53776640	chr2:54082554~54085066:+
LUAD	cis	rs4819052	0.851	rs13047104	ENSG00000237664.1	LINC00316	-4.3	2.07e-05	0.00369	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253647	chr21:45338590~45341990:-
LUAD	cis	rs4819052	0.885	rs28576202	ENSG00000237664.1	LINC00316	-4.3	2.07e-05	0.00369	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254769	chr21:45338590~45341990:-
LUAD	cis	rs4819052	0.851	rs35871601	ENSG00000237664.1	LINC00316	-4.3	2.07e-05	0.00369	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45255299	chr21:45338590~45341990:-
LUAD	cis	rs4819052	0.851	rs28622522	ENSG00000237664.1	LINC00316	-4.3	2.07e-05	0.00369	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256684	chr21:45338590~45341990:-
LUAD	cis	rs1023500	0.505	rs134899	ENSG00000273366.1	CTA-989H11.1	-4.3	2.07e-05	0.00369	-0.22	-0.19	Schizophrenia;	chr22:42287024	chr22:42278188~42278846:+
LUAD	cis	rs9900062	0.546	rs2676289	ENSG00000270714.1	MINOS1P2	4.3	2.07e-05	0.0037	0.25	0.19	QT interval;	chr17:64709620	chr17:64747264~64747492:-
LUAD	cis	rs62355900	0.636	rs62355907	ENSG00000271828.1	CTD-2310F14.1	4.3	2.07e-05	0.0037	0.38	0.19	Endometriosis;	chr5:56775503	chr5:56927874~56929573:+
LUAD	cis	rs1401999	1	rs6767013	ENSG00000223882.1	ABCC5-AS1	-4.3	2.08e-05	0.0037	-0.2	-0.19	Anterior chamber depth;	chr3:183962314	chr3:184006338~184011419:+
LUAD	cis	rs62481355	0.68	rs11563620	ENSG00000224138.1	AC000123.4	4.3	2.08e-05	0.0037	0.19	0.19	Type 2 diabetes;	chr7:127419182	chr7:127350128~127351523:+
LUAD	cis	rs2243480	1	rs160643	ENSG00000164669.11	INTS4P1	4.3	2.08e-05	0.0037	0.32	0.19	Diabetic kidney disease;	chr7:66093235	chr7:65141225~65234216:+
LUAD	cis	rs858239	0.67	rs6967526	ENSG00000230042.1	AK3P3	-4.3	2.08e-05	0.0037	-0.24	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23129178~23129841:+
LUAD	cis	rs36093844	0.748	rs1596740	ENSG00000279742.1	RP11-700A24.1	-4.3	2.08e-05	0.0037	-0.22	-0.19	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85879387	chr11:85852557~85854943:-
LUAD	cis	rs72717009	0.825	rs867624	ENSG00000225217.1	HSPA7	-4.3	2.08e-05	0.0037	-0.27	-0.19	Rheumatoid arthritis;	chr1:161498047	chr1:161606291~161608217:+
LUAD	cis	rs4660456	0.556	rs823674	ENSG00000237899.1	RP4-739H11.3	-4.3	2.08e-05	0.0037	-0.21	-0.19	Platelet count;	chr1:40774799	chr1:40669089~40687588:-
LUAD	cis	rs17189298	0.934	rs12466015	ENSG00000231013.1	AC013275.2	4.3	2.08e-05	0.0037	0.2	0.19	Cerebrospinal T-tau levels;	chr2:119113784	chr2:119476448~119487346:+
LUAD	cis	rs7196129	0.966	rs11150589	ENSG00000183604.13	SMG1P5	4.3	2.08e-05	0.0037	0.2	0.19	Monocyte count;	chr16:30471173	chr16:30267553~30335374:-
LUAD	cis	rs12716977	1	rs12716977	ENSG00000183604.13	SMG1P5	4.3	2.08e-05	0.0037	0.2	0.19	Lymphocyte percentage of white cells;Lymphocyte counts;	chr16:30471482	chr16:30267553~30335374:-
LUAD	cis	rs7061710	0.711	rs17640463	ENSG00000271811.1	RP1-79C4.4	-4.3	2.08e-05	0.0037	-0.29	-0.19	Blood metabolite levels;	chr1:171151508	chr1:170667381~170669425:+
LUAD	cis	rs877819	0.583	rs1993985	ENSG00000228403.1	RP11-563N6.6	-4.3	2.08e-05	0.0037	-0.2	-0.19	Systemic lupus erythematosus;	chr10:48850986	chr10:48878022~48878649:+
LUAD	cis	rs4459386	0.509	rs10876020	ENSG00000272368.2	RP4-605O3.4	4.3	2.08e-05	0.0037	0.23	0.19	Schizophrenia;	chr12:50342482	chr12:50112197~50165618:+
LUAD	cis	rs7665090	0.87	rs228613	ENSG00000251288.2	RP11-10L12.2	4.3	2.08e-05	0.0037	0.23	0.19	Primary biliary cholangitis;	chr4:102656308	chr4:102751401~102752641:+
LUAD	cis	rs1881744	0.588	rs78808618	ENSG00000274902.1	RP1-197B17.4	4.3	2.08e-05	0.0037	0.43	0.19	Metabolite levels (HVA/5-HIAA ratio);	chr12:47567624	chr12:47731908~47732351:+
LUAD	cis	rs957448	1	rs72674843	ENSG00000253175.1	RP11-267M23.6	4.3	2.08e-05	0.0037	0.23	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94520772	chr8:94565036~94565715:+
LUAD	cis	rs2011013	0.957	rs61378395	ENSG00000259570.1	RP11-671M22.4	-4.3	2.08e-05	0.00371	-0.25	-0.19	Sitting height ratio;	chr15:83939182	chr15:84394512~84395514:+
LUAD	cis	rs17685	0.753	rs13240404	ENSG00000280388.1	RP11-229D13.3	4.3	2.08e-05	0.00371	0.18	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76046401	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.697	rs2302437	ENSG00000280388.1	RP11-229D13.3	4.3	2.08e-05	0.00371	0.18	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76047698	chr7:76043977~76045963:-
LUAD	cis	rs703842	1	rs10431505	ENSG00000270039.1	RP11-571M6.17	-4.3	2.08e-05	0.00371	-0.23	-0.19	Multiple sclerosis;	chr12:57784806	chr12:57803838~57804415:+
LUAD	cis	rs703842	1	rs11172344	ENSG00000270039.1	RP11-571M6.17	-4.3	2.08e-05	0.00371	-0.23	-0.19	Multiple sclerosis;	chr12:57799665	chr12:57803838~57804415:+
LUAD	cis	rs703842	1	rs10783847	ENSG00000270039.1	RP11-571M6.17	-4.3	2.08e-05	0.00371	-0.23	-0.19	Multiple sclerosis;	chr12:57802664	chr12:57803838~57804415:+
LUAD	cis	rs703842	1	rs10783848	ENSG00000270039.1	RP11-571M6.17	-4.3	2.08e-05	0.00371	-0.23	-0.19	Multiple sclerosis;	chr12:57802745	chr12:57803838~57804415:+
LUAD	cis	rs853679	0.607	rs56189111	ENSG00000219392.1	RP1-265C24.5	-4.3	2.08e-05	0.00371	-0.43	-0.19	Depression;	chr6:28304196	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.607	rs35072899	ENSG00000219392.1	RP1-265C24.5	-4.3	2.08e-05	0.00371	-0.43	-0.19	Depression;	chr6:28313764	chr6:28115628~28116551:+
LUAD	cis	rs7208859	0.673	rs8077116	ENSG00000280069.1	CTD-2349P21.3	-4.3	2.08e-05	0.00371	-0.27	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30738182~30740275:+
LUAD	cis	rs4811196	0.692	rs8121628	ENSG00000226144.2	RPS27AP3	4.3	2.09e-05	0.00371	0.21	0.19	Bone mineral density;	chr20:37886268	chr20:37049254~37049707:+
LUAD	cis	rs6661961	0.714	rs986903	ENSG00000237975.5	FLG-AS1	-4.3	2.09e-05	0.00371	-0.26	-0.19	Atopic dermatitis;	chr1:152438093	chr1:152168125~152445456:+
LUAD	cis	rs5758659	0.652	rs133347	ENSG00000182057.4	OGFRP1	4.3	2.09e-05	0.00371	0.23	0.19	Cognitive function;	chr22:42027641	chr22:42269753~42275196:+
LUAD	cis	rs6568686	0.786	rs6911772	ENSG00000255389.1	C6orf3	-4.3	2.09e-05	0.00371	-0.27	-0.19	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111536435	chr6:111599875~111602295:+
LUAD	cis	rs35740288	0.822	rs4843092	ENSG00000259407.1	RP11-158M2.3	-4.3	2.09e-05	0.00371	-0.19	-0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85689949	chr15:85744109~85750281:-
LUAD	cis	rs4819052	0.679	rs2255761	ENSG00000215447.6	BX322557.10	-4.3	2.09e-05	0.00372	-0.22	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263707	chr21:45288052~45291738:+
LUAD	cis	rs6012564	1	rs6122763	ENSG00000230758.1	SNAP23P	-4.3	2.09e-05	0.00372	-0.2	-0.19	Anger;	chr20:49181116	chr20:49038357~49038602:-
LUAD	cis	rs804280	0.564	rs4639	ENSG00000255046.1	RP11-297N6.4	-4.3	2.09e-05	0.00372	-0.23	-0.19	Myopia (pathological);	chr8:11787242	chr8:11797928~11802568:-
LUAD	cis	rs7208859	0.623	rs73269923	ENSG00000280069.1	CTD-2349P21.3	-4.3	2.09e-05	0.00372	-0.27	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30738182~30740275:+
LUAD	cis	rs7893279	0.543	rs7093454	ENSG00000225527.1	RP11-383B4.4	4.3	2.09e-05	0.00372	0.28	0.19	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18597751	chr10:18531849~18533336:-
LUAD	cis	rs6479901	0.947	rs12573212	ENSG00000232075.1	MRPL35P2	-4.3	2.09e-05	0.00372	-0.26	-0.19	Intelligence (multi-trait analysis);	chr10:63458665	chr10:63634317~63634827:-
LUAD	cis	rs17772222	1	rs60310240	ENSG00000258983.2	RP11-507K2.2	4.3	2.09e-05	0.00372	0.23	0.19	Coronary artery calcification;	chr14:88356365	chr14:88499334~88515502:+
LUAD	cis	rs7580658	0.724	rs6712446	ENSG00000236682.1	AC068282.3	-4.3	2.09e-05	0.00372	-0.25	-0.19	Protein C levels;	chr2:127240823	chr2:127389130~127400580:+
LUAD	cis	rs7580658	0.724	rs6712551	ENSG00000236682.1	AC068282.3	-4.3	2.09e-05	0.00372	-0.25	-0.19	Protein C levels;	chr2:127240909	chr2:127389130~127400580:+
LUAD	cis	rs9649213	0.593	rs6970801	ENSG00000272950.1	RP11-307C18.1	4.3	2.09e-05	0.00372	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98295928	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.593	rs12704982	ENSG00000272950.1	RP11-307C18.1	4.3	2.09e-05	0.00372	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98296741	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.593	rs34129434	ENSG00000272950.1	RP11-307C18.1	4.3	2.09e-05	0.00372	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98297152	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.593	rs12704983	ENSG00000272950.1	RP11-307C18.1	4.3	2.09e-05	0.00372	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98297733	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.593	rs7781916	ENSG00000272950.1	RP11-307C18.1	4.3	2.09e-05	0.00372	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98300426	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.593	rs736753	ENSG00000272950.1	RP11-307C18.1	4.3	2.09e-05	0.00372	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98302177	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.593	rs736754	ENSG00000272950.1	RP11-307C18.1	4.3	2.09e-05	0.00372	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98302247	chr7:98322853~98323430:+
LUAD	cis	rs9987353	0.544	rs2929469	ENSG00000253893.2	FAM85B	-4.3	2.09e-05	0.00372	-0.25	-0.19	Recombination measurement;	chr8:9205146	chr8:8167819~8226614:-
LUAD	cis	rs2153535	0.585	rs9405400	ENSG00000230939.1	RP11-314C16.1	-4.3	2.09e-05	0.00372	-0.21	-0.19	Motion sickness;	chr6:8606895	chr6:8784178~8785445:+
LUAD	cis	rs80028505	0.908	rs7760405	ENSG00000271304.1	DPRXP2	4.3	2.09e-05	0.00372	0.36	0.19	Foot ulcer in diabetes and neuropathy;	chr6:36106054	chr6:35989515~35990436:-
LUAD	cis	rs2562456	0.833	rs2562416	ENSG00000268081.1	RP11-678G14.2	4.3	2.09e-05	0.00372	0.32	0.19	Pain;	chr19:21430609	chr19:21554640~21569237:-
LUAD	cis	rs889398	0.769	rs12927052	ENSG00000226232.7	RP11-419C5.2	4.3	2.09e-05	0.00372	0.16	0.19	Body mass index;	chr16:69823140	chr16:69976388~69996188:-
LUAD	cis	rs4713118	0.699	rs200969	ENSG00000280107.1	AL022393.9	-4.3	2.09e-05	0.00372	-0.25	-0.19	Parkinson's disease;	chr6:27891675	chr6:28170845~28172521:+
LUAD	cis	rs6686842	0.56	rs61781833	ENSG00000235358.1	RP11-399E6.1	-4.3	2.09e-05	0.00373	-0.23	-0.19	Height;	chr1:41175418	chr1:41242373~41284861:+
LUAD	cis	rs6686842	0.56	rs74069080	ENSG00000235358.1	RP11-399E6.1	-4.3	2.09e-05	0.00373	-0.23	-0.19	Height;	chr1:41185358	chr1:41242373~41284861:+
LUAD	cis	rs6686842	0.56	rs11209659	ENSG00000235358.1	RP11-399E6.1	-4.3	2.09e-05	0.00373	-0.23	-0.19	Height;	chr1:41194607	chr1:41242373~41284861:+
LUAD	cis	rs748404	1	rs12909095	ENSG00000205771.5	CATSPER2P1	-4.3	2.09e-05	0.00373	-0.27	-0.19	Lung cancer;	chr15:43265944	chr15:43726918~43747094:-
LUAD	cis	rs780096	0.506	rs8395	ENSG00000234072.1	AC074117.10	-4.3	2.09e-05	0.00373	-0.15	-0.19	Total body bone mineral density;	chr2:27492340	chr2:27356246~27367622:+
LUAD	cis	rs4372836	1	rs4666118	ENSG00000226833.4	AC097724.3	4.3	2.1e-05	0.00373	0.22	0.19	Body mass index;	chr2:28728832	chr2:28708953~28736205:-
LUAD	cis	rs1005277	0.505	rs7069702	ENSG00000263064.2	RP11-291L22.7	-4.3	2.1e-05	0.00373	-0.2	-0.19	Extrinsic epigenetic age acceleration;	chr10:37958431	chr10:38448689~38448949:+
LUAD	cis	rs2731006	0.543	rs11181696	ENSG00000257114.2	RP11-25I15.3	4.3	2.1e-05	0.00373	0.29	0.19	Panic disorder;	chr12:42815339	chr12:42692216~42717119:+
LUAD	cis	rs875971	1	rs6963646	ENSG00000232559.3	GS1-124K5.12	-4.3	2.1e-05	0.00373	-0.22	-0.19	Aortic root size;	chr7:66220780	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.965	rs28682868	ENSG00000232559.3	GS1-124K5.12	-4.3	2.1e-05	0.00373	-0.22	-0.19	Aortic root size;	chr7:66224822	chr7:66554588~66576923:-
LUAD	cis	rs7555523	1	rs7555523	ENSG00000224358.1	RP11-466F5.8	-4.3	2.1e-05	0.00373	-0.33	-0.19	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165749742	chr1:165768929~165775176:+
LUAD	cis	rs3808502	0.516	rs6983727	ENSG00000255046.1	RP11-297N6.4	-4.3	2.1e-05	0.00373	-0.24	-0.19	Neuroticism;	chr8:11558303	chr8:11797928~11802568:-
LUAD	cis	rs4374383	0.884	rs11676037	ENSG00000207383.1	Y_RNA	-4.3	2.1e-05	0.00373	-0.23	-0.19	Hepatitis C induced liver fibrosis;	chr2:111985808	chr2:112579484~112579584:-
LUAD	cis	rs4795519	0.778	rs2313511	ENSG00000266313.1	RP11-173M1.4	4.3	2.1e-05	0.00373	0.24	0.19	Chronic myeloid leukemia;	chr17:27155141	chr17:27333256~27348491:+
LUAD	cis	rs4795519	0.744	rs57236752	ENSG00000266313.1	RP11-173M1.4	4.3	2.1e-05	0.00373	0.24	0.19	Chronic myeloid leukemia;	chr17:27155382	chr17:27333256~27348491:+
LUAD	cis	rs4795519	0.744	rs12449745	ENSG00000266313.1	RP11-173M1.4	4.3	2.1e-05	0.00373	0.24	0.19	Chronic myeloid leukemia;	chr17:27190136	chr17:27333256~27348491:+
LUAD	cis	rs4568518	0.71	rs12699929	ENSG00000279048.1	RP11-511H23.2	4.3	2.1e-05	0.00373	0.16	0.19	Measles;	chr7:17972634	chr7:17940503~17942922:+
LUAD	cis	rs4568518	0.71	rs12699930	ENSG00000279048.1	RP11-511H23.2	4.3	2.1e-05	0.00373	0.16	0.19	Measles;	chr7:17972635	chr7:17940503~17942922:+
LUAD	cis	rs7590268	0.609	rs17335134	ENSG00000279873.2	LINC01126	4.3	2.1e-05	0.00373	0.19	0.19	Orofacial clefts;	chr2:43526767	chr2:43227210~43228855:+
LUAD	cis	rs6957923	0.967	rs10950944	ENSG00000230658.1	KLHL7-AS1	4.3	2.1e-05	0.00373	0.23	0.19	Height;	chr7:23451447	chr7:23101228~23105703:-
LUAD	cis	rs35740288	0.787	rs11637768	ENSG00000259407.1	RP11-158M2.3	-4.3	2.1e-05	0.00373	-0.19	-0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85680179	chr15:85744109~85750281:-
LUAD	cis	rs858239	0.601	rs6948469	ENSG00000226816.2	AC005082.12	4.3	2.1e-05	0.00373	0.25	0.19	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23206013~23208045:+
LUAD	cis	rs7945705	0.846	rs4929912	ENSG00000254860.4	TMEM9B-AS1	4.3	2.1e-05	0.00373	0.22	0.19	Hemoglobin concentration;	chr11:8795148	chr11:8964675~8977527:+
LUAD	cis	rs6860806	0.661	rs3763112	ENSG00000233006.5	AC034220.3	4.3	2.1e-05	0.00374	0.17	0.19	Breast cancer;	chr5:132250787	chr5:132311285~132369916:-
LUAD	cis	rs6964833	0.935	rs34630792	ENSG00000278416.1	PMS2L2	4.3	2.1e-05	0.00374	0.27	0.19	Menarche (age at onset);	chr7:74646869	chr7:75344015~75359550:-
LUAD	cis	rs12935418	0.672	rs9925780	ENSG00000261061.1	RP11-303E16.2	-4.3	2.1e-05	0.00374	-0.22	-0.19	Mean corpuscular volume;	chr16:81011571	chr16:81030770~81031485:+
LUAD	cis	rs28386778	0.897	rs3744293	ENSG00000240280.5	TCAM1P	-4.3	2.1e-05	0.00374	-0.22	-0.19	Prudent dietary pattern;	chr17:63764428	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.897	rs6504184	ENSG00000240280.5	TCAM1P	-4.3	2.1e-05	0.00374	-0.22	-0.19	Prudent dietary pattern;	chr17:63765048	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.897	rs8081454	ENSG00000240280.5	TCAM1P	-4.3	2.1e-05	0.00374	-0.22	-0.19	Prudent dietary pattern;	chr17:63765286	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.863	rs58269663	ENSG00000240280.5	TCAM1P	-4.3	2.1e-05	0.00374	-0.22	-0.19	Prudent dietary pattern;	chr17:63765770	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.897	rs8067102	ENSG00000240280.5	TCAM1P	-4.3	2.1e-05	0.00374	-0.22	-0.19	Prudent dietary pattern;	chr17:63771419	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.897	rs6504185	ENSG00000240280.5	TCAM1P	-4.3	2.1e-05	0.00374	-0.22	-0.19	Prudent dietary pattern;	chr17:63771432	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.897	rs8077013	ENSG00000240280.5	TCAM1P	-4.3	2.1e-05	0.00374	-0.22	-0.19	Prudent dietary pattern;	chr17:63773032	chr17:63849292~63864379:+
LUAD	cis	rs9649213	0.593	rs34534766	ENSG00000272950.1	RP11-307C18.1	4.3	2.1e-05	0.00374	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98291559	chr7:98322853~98323430:+
LUAD	cis	rs7204230	0.961	rs7197925	ENSG00000261291.1	RP11-295M3.2	4.3	2.1e-05	0.00374	0.24	0.19	Fibrinogen;	chr16:53330567	chr16:53168522~53169450:+
LUAD	cis	rs2346177	0.58	rs7565770	ENSG00000279254.1	RP11-536C12.1	-4.3	2.1e-05	0.00374	-0.2	-0.19	HDL cholesterol;	chr2:46456544	chr2:46668870~46670778:+
LUAD	cis	rs262150	0.788	rs2657408	ENSG00000231419.5	LINC00689	-4.3	2.1e-05	0.00374	-0.23	-0.19	Facial morphology (factor 20);	chr7:158989584	chr7:159006522~159030195:+
LUAD	cis	rs897984	0.683	rs12926237	ENSG00000232748.3	RP11-196G11.6	4.3	2.1e-05	0.00374	0.24	0.19	Dementia with Lewy bodies;	chr16:30826275	chr16:31056460~31062803:+
LUAD	cis	rs2880765	0.835	rs4536419	ENSG00000259416.2	RP11-158M2.5	4.3	2.1e-05	0.00374	0.2	0.19	Coronary artery disease;	chr15:85496240	chr15:85754941~85756237:-
LUAD	cis	rs8030379	1	rs11259932	ENSG00000230373.7	GOLGA6L5P	-4.3	2.1e-05	0.00374	-0.18	-0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83911305	chr15:84507885~84516814:-
LUAD	cis	rs8030379	1	rs11259934	ENSG00000230373.7	GOLGA6L5P	-4.3	2.1e-05	0.00374	-0.18	-0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83911419	chr15:84507885~84516814:-
LUAD	cis	rs8030379	1	rs11259935	ENSG00000230373.7	GOLGA6L5P	-4.3	2.1e-05	0.00374	-0.18	-0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83911675	chr15:84507885~84516814:-
LUAD	cis	rs8030379	1	rs12914857	ENSG00000230373.7	GOLGA6L5P	-4.3	2.1e-05	0.00374	-0.18	-0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83912414	chr15:84507885~84516814:-
LUAD	cis	rs8030379	1	rs2055712	ENSG00000230373.7	GOLGA6L5P	-4.3	2.1e-05	0.00374	-0.18	-0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83912853	chr15:84507885~84516814:-
LUAD	cis	rs8030379	1	rs2061999	ENSG00000230373.7	GOLGA6L5P	-4.3	2.1e-05	0.00374	-0.18	-0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83913988	chr15:84507885~84516814:-
LUAD	cis	rs8030379	1	rs3934135	ENSG00000230373.7	GOLGA6L5P	-4.3	2.1e-05	0.00374	-0.18	-0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83915047	chr15:84507885~84516814:-
LUAD	cis	rs8030379	1	rs2030838	ENSG00000230373.7	GOLGA6L5P	-4.3	2.1e-05	0.00374	-0.18	-0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83915058	chr15:84507885~84516814:-
LUAD	cis	rs8030379	1	rs2030840	ENSG00000230373.7	GOLGA6L5P	-4.3	2.1e-05	0.00374	-0.18	-0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83915382	chr15:84507885~84516814:-
LUAD	cis	rs8030379	1	rs1880730	ENSG00000230373.7	GOLGA6L5P	-4.3	2.1e-05	0.00374	-0.18	-0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83915432	chr15:84507885~84516814:-
LUAD	cis	rs7955901	0.775	rs3844207	ENSG00000258053.1	CTD-2021H9.3	4.3	2.1e-05	0.00374	0.23	0.19	Type 2 diabetes;	chr12:71131078	chr12:71047402~71118247:-
LUAD	cis	rs858239	0.6	rs6461692	ENSG00000226816.2	AC005082.12	4.3	2.11e-05	0.00374	0.25	0.19	Cerebrospinal fluid biomarker levels;	chr7:23100076	chr7:23206013~23208045:+
LUAD	cis	rs28386778	0.897	rs2597634	ENSG00000240280.5	TCAM1P	-4.3	2.11e-05	0.00374	-0.22	-0.19	Prudent dietary pattern;	chr17:63800784	chr17:63849292~63864379:+
LUAD	cis	rs2018683	0.711	rs2158788	ENSG00000228421.2	AC005013.5	4.3	2.11e-05	0.00374	0.21	0.19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28932341	chr7:28957667~28959345:+
LUAD	cis	rs2898681	0.874	rs6839084	ENSG00000248375.1	RP11-177B4.1	-4.3	2.11e-05	0.00374	-0.28	-0.19	Optic nerve measurement (cup area);	chr4:52891160	chr4:52720081~52720831:-
LUAD	cis	rs80028505	0.908	rs73730440	ENSG00000271304.1	DPRXP2	4.3	2.11e-05	0.00375	0.36	0.19	Foot ulcer in diabetes and neuropathy;	chr6:36069449	chr6:35989515~35990436:-
LUAD	cis	rs80028505	0.908	rs56362075	ENSG00000271304.1	DPRXP2	4.3	2.11e-05	0.00375	0.36	0.19	Foot ulcer in diabetes and neuropathy;	chr6:36073360	chr6:35989515~35990436:-
LUAD	cis	rs80028505	0.908	rs3730366	ENSG00000271304.1	DPRXP2	4.3	2.11e-05	0.00375	0.36	0.19	Foot ulcer in diabetes and neuropathy;	chr6:36076448	chr6:35989515~35990436:-
LUAD	cis	rs80028505	0.908	rs6910685	ENSG00000271304.1	DPRXP2	4.3	2.11e-05	0.00375	0.36	0.19	Foot ulcer in diabetes and neuropathy;	chr6:36080640	chr6:35989515~35990436:-
LUAD	cis	rs80028505	0.908	rs73409842	ENSG00000271304.1	DPRXP2	4.3	2.11e-05	0.00375	0.36	0.19	Foot ulcer in diabetes and neuropathy;	chr6:36083636	chr6:35989515~35990436:-
LUAD	cis	rs80028505	0.908	rs6908622	ENSG00000271304.1	DPRXP2	4.3	2.11e-05	0.00375	0.36	0.19	Foot ulcer in diabetes and neuropathy;	chr6:36085370	chr6:35989515~35990436:-
LUAD	cis	rs2274273	0.905	rs28429419	ENSG00000259318.1	RP11-454L9.2	4.3	2.11e-05	0.00375	0.17	0.19	Protein biomarker;	chr14:55108075	chr14:55394940~55395233:-
LUAD	cis	rs2439831	1	rs527921	ENSG00000249839.1	AC011330.5	4.3	2.11e-05	0.00375	0.35	0.19	Lung cancer in ever smokers;	chr15:43478218	chr15:43663654~43684339:-
LUAD	cis	rs2243480	1	rs34136756	ENSG00000232559.3	GS1-124K5.12	4.3	2.11e-05	0.00375	0.34	0.19	Diabetic kidney disease;	chr7:65916269	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs78803505	ENSG00000232559.3	GS1-124K5.12	4.3	2.11e-05	0.00375	0.34	0.19	Diabetic kidney disease;	chr7:65917585	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs34933526	ENSG00000232559.3	GS1-124K5.12	4.3	2.11e-05	0.00375	0.34	0.19	Diabetic kidney disease;	chr7:65918212	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs34577383	ENSG00000232559.3	GS1-124K5.12	4.3	2.11e-05	0.00375	0.34	0.19	Diabetic kidney disease;	chr7:65920739	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs6949812	ENSG00000232559.3	GS1-124K5.12	4.3	2.11e-05	0.00375	0.34	0.19	Diabetic kidney disease;	chr7:65922114	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs55895244	ENSG00000232559.3	GS1-124K5.12	4.3	2.11e-05	0.00375	0.34	0.19	Diabetic kidney disease;	chr7:65922691	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs6970243	ENSG00000232559.3	GS1-124K5.12	4.3	2.11e-05	0.00375	0.34	0.19	Diabetic kidney disease;	chr7:65923503	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs7794661	ENSG00000232559.3	GS1-124K5.12	4.3	2.11e-05	0.00375	0.34	0.19	Diabetic kidney disease;	chr7:65924743	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs7795242	ENSG00000232559.3	GS1-124K5.12	4.3	2.11e-05	0.00375	0.34	0.19	Diabetic kidney disease;	chr7:65925107	chr7:66554588~66576923:-
LUAD	cis	rs2243480	0.708	rs35310401	ENSG00000232559.3	GS1-124K5.12	4.3	2.11e-05	0.00375	0.34	0.19	Diabetic kidney disease;	chr7:65925372	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs35058610	ENSG00000232559.3	GS1-124K5.12	4.3	2.11e-05	0.00375	0.34	0.19	Diabetic kidney disease;	chr7:65925938	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs2177703	ENSG00000232559.3	GS1-124K5.12	4.3	2.11e-05	0.00375	0.34	0.19	Diabetic kidney disease;	chr7:65926730	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs35432774	ENSG00000232559.3	GS1-124K5.12	4.3	2.11e-05	0.00375	0.34	0.19	Diabetic kidney disease;	chr7:65928032	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs56985706	ENSG00000232559.3	GS1-124K5.12	4.3	2.11e-05	0.00375	0.34	0.19	Diabetic kidney disease;	chr7:65929575	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs60683927	ENSG00000232559.3	GS1-124K5.12	4.3	2.11e-05	0.00375	0.34	0.19	Diabetic kidney disease;	chr7:65929781	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs58062456	ENSG00000232559.3	GS1-124K5.12	4.3	2.11e-05	0.00375	0.34	0.19	Diabetic kidney disease;	chr7:65929865	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs34529418	ENSG00000232559.3	GS1-124K5.12	4.3	2.11e-05	0.00375	0.34	0.19	Diabetic kidney disease;	chr7:65938222	chr7:66554588~66576923:-
LUAD	cis	rs2243480	0.901	rs35087093	ENSG00000232559.3	GS1-124K5.12	4.3	2.11e-05	0.00375	0.34	0.19	Diabetic kidney disease;	chr7:65940221	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs35046236	ENSG00000232559.3	GS1-124K5.12	4.3	2.11e-05	0.00375	0.34	0.19	Diabetic kidney disease;	chr7:65943626	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs36068983	ENSG00000232559.3	GS1-124K5.12	4.3	2.11e-05	0.00375	0.34	0.19	Diabetic kidney disease;	chr7:65944004	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs68189316	ENSG00000232559.3	GS1-124K5.12	4.3	2.11e-05	0.00375	0.34	0.19	Diabetic kidney disease;	chr7:65944182	chr7:66554588~66576923:-
LUAD	cis	rs2243480	0.831	rs7806717	ENSG00000232559.3	GS1-124K5.12	-4.3	2.11e-05	0.00375	-0.34	-0.19	Diabetic kidney disease;	chr7:65928187	chr7:66554588~66576923:-
LUAD	cis	rs28510890	0.785	rs11074079	ENSG00000260337.3	RP11-386M24.6	4.3	2.11e-05	0.00375	0.24	0.19	Lung cancer in ever smokers;	chr15:92581719	chr15:92592574~92596462:-
LUAD	cis	rs28386778	0.863	rs3760254	ENSG00000240280.5	TCAM1P	-4.3	2.11e-05	0.00375	-0.22	-0.19	Prudent dietary pattern;	chr17:63774391	chr17:63849292~63864379:+
LUAD	cis	rs7937890	0.684	rs12799007	ENSG00000254418.1	RP11-21L19.1	4.3	2.11e-05	0.00375	0.22	0.19	Mitochondrial DNA levels;	chr11:14404938	chr11:14262846~14273691:-
LUAD	cis	rs11512640	1	rs11220138	ENSG00000254671.2	STT3A-AS1	4.3	2.11e-05	0.00375	0.43	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125585927	chr11:125570284~125592568:-
LUAD	cis	rs13113518	1	rs939823	ENSG00000272969.1	RP11-528I4.2	4.3	2.11e-05	0.00375	0.2	0.19	Height;	chr4:55487368	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs6838882	ENSG00000272969.1	RP11-528I4.2	4.3	2.11e-05	0.00375	0.2	0.19	Height;	chr4:55489310	chr4:55547112~55547889:+
LUAD	cis	rs6701713	0.879	rs4562624	ENSG00000274245.1	RP11-357P18.2	-4.3	2.11e-05	0.00375	-0.32	-0.19	Alzheimer's disease (late onset);	chr1:207512620	chr1:207372559~207373252:+
LUAD	cis	rs9425766	0.679	rs12085290	ENSG00000227373.4	RP11-160H22.5	-4.3	2.11e-05	0.00375	-0.24	-0.19	Life satisfaction;	chr1:174124699	chr1:174115300~174160004:-
LUAD	cis	rs860295	0.702	rs3851912	ENSG00000225855.5	RUSC1-AS1	4.3	2.11e-05	0.00375	0.14	0.19	Body mass index;	chr1:155616653	chr1:155316863~155324176:-
LUAD	cis	rs2243480	1	rs35542501	ENSG00000229886.1	RP5-1132H15.3	4.3	2.11e-05	0.00375	0.33	0.19	Diabetic kidney disease;	chr7:65966228	chr7:66025126~66031544:-
LUAD	cis	rs2243480	0.708	rs781141	ENSG00000229886.1	RP5-1132H15.3	4.3	2.11e-05	0.00375	0.33	0.19	Diabetic kidney disease;	chr7:65973566	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs781142	ENSG00000229886.1	RP5-1132H15.3	4.3	2.11e-05	0.00375	0.33	0.19	Diabetic kidney disease;	chr7:65973791	chr7:66025126~66031544:-
LUAD	cis	rs7215564	0.908	rs77750710	ENSG00000232083.3	RPL31P7	4.3	2.11e-05	0.00375	0.34	0.19	Myopia (pathological);	chr17:80743317	chr17:80602549~80602926:-
LUAD	cis	rs8180040	0.522	rs749512	ENSG00000271161.1	BOLA2P2	-4.3	2.11e-05	0.00375	-0.19	-0.19	Colorectal cancer;	chr3:46994410	chr3:47499841~47500407:+
LUAD	cis	rs8054556	0.74	rs12444978	ENSG00000183604.13	SMG1P5	-4.3	2.11e-05	0.00375	-0.19	-0.19	Autism spectrum disorder or schizophrenia;	chr16:29913101	chr16:30267553~30335374:-
LUAD	cis	rs9649213	0.593	rs6945554	ENSG00000272950.1	RP11-307C18.1	4.3	2.11e-05	0.00375	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98343634	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.537	rs6971825	ENSG00000272950.1	RP11-307C18.1	4.3	2.11e-05	0.00375	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98350236	chr7:98322853~98323430:+
LUAD	cis	rs10863681	0.52	rs10863689	ENSG00000228437.4	RP11-400N13.2	-4.3	2.11e-05	0.00375	-0.24	-0.19	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222109143	chr1:221966341~221984964:+
LUAD	cis	rs7616559	0.512	rs1600978	ENSG00000240875.4	LINC00886	-4.3	2.11e-05	0.00375	-0.21	-0.19	Carotid artery intima media thickness (sex interaction);	chr3:157017010	chr3:156747346~156817062:-
LUAD	cis	rs6142102	1	rs4911409	ENSG00000275784.1	RP5-1125A11.6	-4.3	2.11e-05	0.00375	-0.21	-0.19	Skin pigmentation;	chr20:34122904	chr20:33989480~33991818:-
LUAD	cis	rs860295	0.702	rs12067371	ENSG00000225855.5	RUSC1-AS1	4.3	2.11e-05	0.00376	0.13	0.19	Body mass index;	chr1:155467878	chr1:155316863~155324176:-
LUAD	cis	rs950169	0.579	rs12913054	ENSG00000259570.1	RP11-671M22.4	4.3	2.11e-05	0.00376	0.29	0.19	Schizophrenia;	chr15:83995704	chr15:84394512~84395514:+
LUAD	cis	rs11779988	0.545	rs208763	ENSG00000253671.1	RP11-806O11.1	-4.3	2.11e-05	0.00376	-0.23	-0.19	Breast cancer;	chr8:17948973	chr8:17808941~17820868:+
LUAD	cis	rs11779988	0.545	rs208762	ENSG00000253671.1	RP11-806O11.1	-4.3	2.11e-05	0.00376	-0.23	-0.19	Breast cancer;	chr8:17949225	chr8:17808941~17820868:+
LUAD	cis	rs4819052	0.765	rs2838852	ENSG00000237664.1	LINC00316	-4.3	2.11e-05	0.00376	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45257122	chr21:45338590~45341990:-
LUAD	cis	rs7189233	0.531	rs1362429	ENSG00000279344.1	RP11-44F14.7	4.3	2.11e-05	0.00376	0.16	0.19	Intelligence (multi-trait analysis);	chr16:53445172	chr16:53478957~53481550:-
LUAD	cis	rs473651	0.935	rs508483	ENSG00000229915.1	AC016999.2	-4.29	2.11e-05	0.00376	-0.25	-0.19	Multiple system atrophy;	chr2:238431068	chr2:238427077~238427729:-
LUAD	cis	rs13113518	1	rs12501636	ENSG00000272969.1	RP11-528I4.2	4.29	2.12e-05	0.00376	0.2	0.19	Height;	chr4:55482317	chr4:55547112~55547889:+
LUAD	cis	rs6964587	0.869	rs6975243	ENSG00000188693.7	CYP51A1-AS1	4.29	2.12e-05	0.00376	0.23	0.19	Breast cancer;	chr7:91885358	chr7:92134604~92180725:+
LUAD	cis	rs10463554	0.892	rs6872442	ENSG00000250682.4	LINC00491	4.29	2.12e-05	0.00376	0.23	0.19	Parkinson's disease;	chr5:102930818	chr5:102609156~102671559:-
LUAD	cis	rs62432291	0.867	rs294907	ENSG00000235086.1	FNDC1-IT1	-4.29	2.12e-05	0.00376	-0.45	-0.19	Joint mobility (Beighton score);	chr6:159249244	chr6:159240786~159243329:+
LUAD	cis	rs7119038	0.818	rs56758835	ENSG00000255422.1	AP002954.4	4.29	2.12e-05	0.00376	0.31	0.19	Sjögren's syndrome;	chr11:118744631	chr11:118704607~118750263:+
LUAD	cis	rs453301	0.598	rs1025395	ENSG00000173295.6	FAM86B3P	4.29	2.12e-05	0.00376	0.2	0.19	Joint mobility (Beighton score);	chr8:8979093	chr8:8228595~8244865:+
LUAD	cis	rs3808502	0.549	rs4841564	ENSG00000255046.1	RP11-297N6.4	4.29	2.12e-05	0.00376	0.23	0.19	Neuroticism;	chr8:11568300	chr8:11797928~11802568:-
LUAD	cis	rs2153535	0.585	rs9392233	ENSG00000230939.1	RP11-314C16.1	-4.29	2.12e-05	0.00376	-0.22	-0.19	Motion sickness;	chr6:8645042	chr6:8784178~8785445:+
LUAD	cis	rs7191700	0.583	rs243314	ENSG00000262703.1	RP11-485G7.6	4.29	2.12e-05	0.00376	0.17	0.19	Multiple sclerosis;	chr16:11291247	chr16:11348143~11349321:-
LUAD	cis	rs7208859	0.524	rs60114476	ENSG00000266490.1	CTD-2349P21.9	4.29	2.12e-05	0.00376	0.28	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770649	chr17:30792372~30792833:+
LUAD	cis	rs17826219	0.636	rs2449770	ENSG00000266490.1	CTD-2349P21.9	4.29	2.12e-05	0.00376	0.28	0.19	Body mass index;	chr17:30774046	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.524	rs59913838	ENSG00000266490.1	CTD-2349P21.9	4.29	2.12e-05	0.00376	0.28	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774545	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs8067338	ENSG00000266490.1	CTD-2349P21.9	4.29	2.12e-05	0.00376	0.28	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775327	chr17:30792372~30792833:+
LUAD	cis	rs9649213	0.593	rs6969234	ENSG00000272950.1	RP11-307C18.1	4.29	2.12e-05	0.00376	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98358674	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.593	rs3801256	ENSG00000272950.1	RP11-307C18.1	4.29	2.12e-05	0.00376	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98362783	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.593	rs2240349	ENSG00000272950.1	RP11-307C18.1	4.29	2.12e-05	0.00376	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98355351	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.593	rs6944262	ENSG00000272950.1	RP11-307C18.1	4.29	2.12e-05	0.00376	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98356103	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.593	rs13307593	ENSG00000272950.1	RP11-307C18.1	4.29	2.12e-05	0.00376	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98356834	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.593	rs1468340	ENSG00000272950.1	RP11-307C18.1	4.29	2.12e-05	0.00376	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98358364	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.593	rs13246843	ENSG00000272950.1	RP11-307C18.1	4.29	2.12e-05	0.00376	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98373349	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.593	rs6961438	ENSG00000272950.1	RP11-307C18.1	4.29	2.12e-05	0.00376	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98376537	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.593	rs7787858	ENSG00000272950.1	RP11-307C18.1	4.29	2.12e-05	0.00376	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98380602	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.593	rs3801254	ENSG00000272950.1	RP11-307C18.1	4.29	2.12e-05	0.00376	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98381499	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.593	rs55825602	ENSG00000272950.1	RP11-307C18.1	4.29	2.12e-05	0.00376	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98383727	chr7:98322853~98323430:+
LUAD	cis	rs57502260	1	rs57502260	ENSG00000212093.1	AP000807.1	4.29	2.12e-05	0.00377	0.25	0.19	Total body bone mineral density (age 45-60);	chr11:68453437	chr11:68506083~68506166:-
LUAD	cis	rs13113518	0.966	rs12501327	ENSG00000272969.1	RP11-528I4.2	4.29	2.12e-05	0.00377	0.2	0.19	Height;	chr4:55507248	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs11133392	ENSG00000272969.1	RP11-528I4.2	4.29	2.12e-05	0.00377	0.2	0.19	Height;	chr4:55507729	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs6838305	ENSG00000272969.1	RP11-528I4.2	4.29	2.12e-05	0.00377	0.2	0.19	Height;	chr4:55508587	chr4:55547112~55547889:+
LUAD	cis	rs13113518	0.902	rs12503578	ENSG00000272969.1	RP11-528I4.2	4.29	2.12e-05	0.00377	0.2	0.19	Height;	chr4:55509367	chr4:55547112~55547889:+
LUAD	cis	rs13113518	0.966	rs3828480	ENSG00000272969.1	RP11-528I4.2	4.29	2.12e-05	0.00377	0.2	0.19	Height;	chr4:55510352	chr4:55547112~55547889:+
LUAD	cis	rs11886999	0.812	rs62153014	ENSG00000237510.6	AC008268.2	-4.29	2.12e-05	0.00377	-0.32	-0.19	Cardiac Troponin-T levels;	chr2:96200079	chr2:95789654~95800166:+
LUAD	cis	rs848490	0.928	rs73138424	ENSG00000214293.7	APTR	4.29	2.12e-05	0.00377	0.26	0.19	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77858999	chr7:77657660~77696265:-
LUAD	cis	rs6840258	0.76	rs340638	ENSG00000251411.1	RP11-397E7.4	4.29	2.12e-05	0.00377	0.22	0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87007052	chr4:86913266~86914817:-
LUAD	cis	rs17685	0.672	rs1639623	ENSG00000280388.1	RP11-229D13.3	-4.29	2.12e-05	0.00377	-0.18	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76078633	chr7:76043977~76045963:-
LUAD	cis	rs8072100	0.544	rs7214993	ENSG00000228782.6	CTD-2026D20.3	4.29	2.12e-05	0.00377	0.2	0.19	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47309431	chr17:47450568~47492492:-
LUAD	cis	rs2711721	0.56	rs739707	ENSG00000274723.1	RP11-618L22.1	-4.29	2.13e-05	0.00377	-0.24	-0.19	Prostate cancer (SNP x SNP interaction);	chr12:47019283	chr12:46970504~46972155:+
LUAD	cis	rs36093844	0.642	rs7949837	ENSG00000279742.1	RP11-700A24.1	-4.29	2.13e-05	0.00377	-0.2	-0.19	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85902749	chr11:85852557~85854943:-
LUAD	cis	rs11051970	0.918	rs12229856	ENSG00000274964.1	RP11-817I4.1	-4.29	2.13e-05	0.00377	-0.22	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr12:32378286	chr12:32339368~32340724:+
LUAD	cis	rs1005277	0.579	rs2505248	ENSG00000263064.2	RP11-291L22.7	4.29	2.13e-05	0.00378	0.21	0.19	Extrinsic epigenetic age acceleration;	chr10:38170169	chr10:38448689~38448949:+
LUAD	cis	rs4591358	0.608	rs13003168	ENSG00000223466.1	AC064834.2	-4.29	2.13e-05	0.00378	-0.29	-0.19	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195496394	chr2:195533035~195538681:+
LUAD	cis	rs7811142	1	rs2406255	ENSG00000078319.8	PMS2P1	-4.29	2.13e-05	0.00378	-0.23	-0.19	Platelet count;	chr7:100456067	chr7:100320992~100341908:-
LUAD	cis	rs3096299	0.658	rs34590044	ENSG00000182376.2	RP5-1142A6.8	4.29	2.13e-05	0.00378	0.2	0.19	Multiple myeloma (IgH translocation);	chr16:89476749	chr16:88742767~88745748:+
LUAD	cis	rs17122278	1	rs112430997	ENSG00000243431.1	RPL5P30	4.29	2.13e-05	0.00378	0.24	0.19	Total cholesterol levels;	chr11:118558975	chr11:118560690~118561580:+
LUAD	cis	rs150992	0.568	rs34498	ENSG00000248489.1	CTD-2007H13.3	4.29	2.13e-05	0.00378	0.24	0.19	Body mass index;	chr5:98960690	chr5:98929171~98995013:+
LUAD	cis	rs780096	0.526	rs3845687	ENSG00000234072.1	AC074117.10	-4.29	2.13e-05	0.00378	-0.15	-0.19	Total body bone mineral density;	chr2:27467032	chr2:27356246~27367622:+
LUAD	cis	rs3794924	1	rs34350106	ENSG00000266521.1	RP11-650P15.1	4.29	2.13e-05	0.00378	0.36	0.19	Survival in colon cancer;	chr18:31462496	chr18:31496645~31497195:-
LUAD	cis	rs9303029	1	rs72859120	ENSG00000265458.1	RP13-20L14.6	4.29	2.13e-05	0.00378	0.37	0.19	Protein quantitative trait loci;	chr17:82463234	chr17:82454273~82458521:-
LUAD	cis	rs7204230	1	rs12596466	ENSG00000261291.1	RP11-295M3.2	4.29	2.13e-05	0.00378	0.25	0.19	Fibrinogen;	chr16:53308948	chr16:53168522~53169450:+
LUAD	cis	rs2735413	0.564	rs7193020	ENSG00000276007.1	RP11-358L22.3	4.29	2.13e-05	0.00379	0.26	0.19	Systolic blood pressure (alcohol consumption interaction);	chr16:78072543	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.564	rs73578752	ENSG00000276007.1	RP11-358L22.3	4.29	2.13e-05	0.00379	0.26	0.19	Systolic blood pressure (alcohol consumption interaction);	chr16:78073657	chr16:78123243~78124332:+
LUAD	cis	rs7107174	1	rs2511177	ENSG00000251323.2	RP11-452H21.4	4.29	2.13e-05	0.00379	0.24	0.19	Testicular germ cell tumor;	chr11:78211914	chr11:78423982~78429836:-
LUAD	cis	rs7829975	0.711	rs4481596	ENSG00000253893.2	FAM85B	-4.29	2.13e-05	0.00379	-0.23	-0.19	Mood instability;	chr8:8846820	chr8:8167819~8226614:-
LUAD	cis	rs34779708	0.966	rs11010129	ENSG00000271335.4	RP11-324I22.4	4.29	2.13e-05	0.00379	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35221894	chr10:35314552~35336401:-
LUAD	cis	rs11250098	0.574	rs4240672	ENSG00000255046.1	RP11-297N6.4	4.29	2.13e-05	0.00379	0.23	0.19	Morning vs. evening chronotype;	chr8:10910407	chr8:11797928~11802568:-
LUAD	cis	rs957448	1	rs72674843	ENSG00000254315.1	RP11-267M23.3	4.29	2.13e-05	0.00379	0.24	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94520772	chr8:94533628~94534391:+
LUAD	cis	rs4713118	0.615	rs9295747	ENSG00000280107.1	AL022393.9	4.29	2.13e-05	0.00379	0.22	0.19	Parkinson's disease;	chr6:27769214	chr6:28170845~28172521:+
LUAD	cis	rs3026445	0.519	rs3026444	ENSG00000278993.1	RP3-424M6.4	4.29	2.14e-05	0.00379	0.24	0.19	QT interval;	chr12:110284827	chr12:110501614~110503441:+
LUAD	cis	rs17189298	0.678	rs4849756	ENSG00000231013.1	AC013275.2	4.29	2.14e-05	0.00379	0.2	0.19	Cerebrospinal T-tau levels;	chr2:119116810	chr2:119476448~119487346:+
LUAD	cis	rs875971	0.545	rs316324	ENSG00000222364.1	RNU6-96P	4.29	2.14e-05	0.00379	0.24	0.19	Aortic root size;	chr7:66145627	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.545	rs316323	ENSG00000222364.1	RNU6-96P	4.29	2.14e-05	0.00379	0.24	0.19	Aortic root size;	chr7:66146002	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.545	rs316316	ENSG00000222364.1	RNU6-96P	4.29	2.14e-05	0.00379	0.24	0.19	Aortic root size;	chr7:66149270	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.545	rs316305	ENSG00000222364.1	RNU6-96P	4.29	2.14e-05	0.00379	0.24	0.19	Aortic root size;	chr7:66152984	chr7:66395191~66395286:+
LUAD	cis	rs1167827	1	rs1167827	ENSG00000165178.9	NCF1C	4.29	2.14e-05	0.00379	0.16	0.19	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75156639~75172044:-
LUAD	cis	rs6570726	0.967	rs7772286	ENSG00000235652.6	RP11-545I5.3	-4.29	2.14e-05	0.00379	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145609287	chr6:145799409~145886585:+
LUAD	cis	rs4845570	0.92	rs11810571	ENSG00000203288.3	RP11-98D18.9	4.29	2.14e-05	0.00379	0.27	0.19	Coronary artery disease;	chr1:151789832	chr1:151790804~151794402:+
LUAD	cis	rs7216064	0.655	rs8078543	ENSG00000265055.1	AC145343.2	-4.29	2.14e-05	0.00379	-0.18	-0.19	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68041135	chr17:68096046~68101474:-
LUAD	cis	rs4843747	0.671	rs8062855	ENSG00000205037.2	RP11-863P13.4	4.29	2.14e-05	0.00379	0.27	0.19	Menopause (age at onset);	chr16:88073335	chr16:88088041~88100985:-
LUAD	cis	rs7208859	0.623	rs7217984	ENSG00000280069.1	CTD-2349P21.3	-4.29	2.14e-05	0.00379	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765748	chr17:30738182~30740275:+
LUAD	cis	rs6430553	0.894	rs6730306	ENSG00000224043.6	CCNT2-AS1	-4.29	2.14e-05	0.0038	-0.23	-0.19	Blood metabolite levels;	chr2:134851597	chr2:134735464~134918710:-
LUAD	cis	rs13113518	1	rs13108499	ENSG00000272969.1	RP11-528I4.2	4.29	2.14e-05	0.0038	0.2	0.19	Height;	chr4:55526514	chr4:55547112~55547889:+
LUAD	cis	rs6840360	0.642	rs2724580	ENSG00000270265.1	RP11-731D1.4	-4.29	2.14e-05	0.0038	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151451353	chr4:151333775~151353224:-
LUAD	cis	rs10761482	0.6	rs1572843	ENSG00000254271.1	RP11-131N11.4	4.29	2.14e-05	0.0038	0.23	0.19	Schizophrenia;	chr10:60467222	chr10:60734342~60741828:+
LUAD	cis	rs6687758	0.687	rs17011146	ENSG00000200033.1	RNU6-403P	4.29	2.14e-05	0.0038	0.25	0.19	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221940306	chr1:221837334~221837437:-
LUAD	cis	rs9860428	0.815	rs10511313	ENSG00000242770.2	RP11-180K7.1	4.29	2.14e-05	0.0038	0.21	0.19	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112890642	chr3:112802478~112812819:+
LUAD	cis	rs28386778	0.863	rs11649912	ENSG00000240280.5	TCAM1P	-4.29	2.14e-05	0.0038	-0.22	-0.19	Prudent dietary pattern;	chr17:63720155	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.897	rs4968597	ENSG00000240280.5	TCAM1P	-4.29	2.14e-05	0.0038	-0.22	-0.19	Prudent dietary pattern;	chr17:63728387	chr17:63849292~63864379:+
LUAD	cis	rs115344852	0.575	rs2531820	ENSG00000216901.1	AL022393.7	4.29	2.14e-05	0.0038	0.27	0.19	Epithelial ovarian cancer;	chr6:28488942	chr6:28176188~28176674:+
LUAD	cis	rs748404	1	rs12911132	ENSG00000205771.5	CATSPER2P1	-4.29	2.14e-05	0.0038	-0.27	-0.19	Lung cancer;	chr15:43268238	chr15:43726918~43747094:-
LUAD	cis	rs189798	0.807	rs330912	ENSG00000173295.6	FAM86B3P	4.29	2.14e-05	0.0038	0.24	0.19	Myopia (pathological);	chr8:9138784	chr8:8228595~8244865:+
LUAD	cis	rs7772486	0.743	rs62433835	ENSG00000235652.6	RP11-545I5.3	-4.29	2.14e-05	0.0038	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145711552	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.743	rs2092262	ENSG00000235652.6	RP11-545I5.3	-4.29	2.14e-05	0.0038	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145715969	chr6:145799409~145886585:+
LUAD	cis	rs11673344	0.542	rs826331	ENSG00000276846.1	CTD-3220F14.3	4.29	2.14e-05	0.0038	0.21	0.19	Obesity-related traits;	chr19:37007360	chr19:37314868~37315620:-
LUAD	cis	rs5758659	0.652	rs133322	ENSG00000182057.4	OGFRP1	4.29	2.14e-05	0.0038	0.23	0.19	Cognitive function;	chr22:42009655	chr22:42269753~42275196:+
LUAD	cis	rs7208859	0.673	rs73263981	ENSG00000280069.1	CTD-2349P21.3	-4.29	2.14e-05	0.0038	-0.23	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593484	chr17:30738182~30740275:+
LUAD	cis	rs12898179	0.53	rs3818242	ENSG00000258561.1	RP11-72M17.1	4.29	2.14e-05	0.0038	0.28	0.19	Glomerular filtration rate in chronic kidney disease;	chr14:67503471	chr14:66212810~66509394:-
LUAD	cis	rs2880765	0.835	rs12708553	ENSG00000259416.2	RP11-158M2.5	-4.29	2.15e-05	0.00381	-0.2	-0.19	Coronary artery disease;	chr15:85503602	chr15:85754941~85756237:-
LUAD	cis	rs1005277	0.522	rs289649	ENSG00000263064.2	RP11-291L22.7	4.29	2.15e-05	0.00381	0.2	0.19	Extrinsic epigenetic age acceleration;	chr10:37686456	chr10:38448689~38448949:+
LUAD	cis	rs1502337	0.516	rs9652060	ENSG00000278993.1	RP3-424M6.4	-4.29	2.15e-05	0.00381	-0.24	-0.19	Body mass index;	chr12:110471012	chr12:110501614~110503441:+
LUAD	cis	rs4819052	0.851	rs7276103	ENSG00000237664.1	LINC00316	-4.29	2.15e-05	0.00381	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246163	chr21:45338590~45341990:-
LUAD	cis	rs6686842	0.536	rs12121121	ENSG00000235358.1	RP11-399E6.1	-4.29	2.15e-05	0.00381	-0.23	-0.19	Height;	chr1:41218784	chr1:41242373~41284861:+
LUAD	cis	rs12468226	0.689	rs17651413	ENSG00000272966.1	RP11-686O6.1	4.29	2.15e-05	0.00381	0.32	0.19	Urate levels;	chr2:202104086	chr2:202336739~202337200:+
LUAD	cis	rs712022	1	rs11026804	ENSG00000246225.5	RP11-17A1.3	4.29	2.15e-05	0.00381	0.23	0.19	Dialysis-related mortality;	chr11:22820036	chr11:22829380~22945393:+
LUAD	cis	rs8014252	0.803	rs74062769	ENSG00000259158.2	ADAM20P1	-4.29	2.15e-05	0.00381	-0.34	-0.19	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70603859	chr14:70468881~70483756:-
LUAD	cis	rs4713118	0.869	rs6922574	ENSG00000280107.1	AL022393.9	-4.29	2.15e-05	0.00381	-0.25	-0.19	Parkinson's disease;	chr6:27725224	chr6:28170845~28172521:+
LUAD	cis	rs1876905	0.539	rs240958	ENSG00000255389.1	C6orf3	-4.29	2.15e-05	0.00381	-0.27	-0.19	Mean corpuscular hemoglobin;	chr6:111298449	chr6:111599875~111602295:+
LUAD	cis	rs913672	0.637	rs12625213	ENSG00000229222.1	KRT18P4	-4.29	2.15e-05	0.00381	-0.24	-0.19	Monocyte count;	chr20:50278382	chr20:49956745~49958032:+
LUAD	cis	rs7119038	0.731	rs10892283	ENSG00000255422.1	AP002954.4	4.29	2.15e-05	0.00381	0.3	0.19	Sjögren's syndrome;	chr11:118766272	chr11:118704607~118750263:+
LUAD	cis	rs7119038	0.774	rs11217020	ENSG00000255422.1	AP002954.4	4.29	2.15e-05	0.00381	0.3	0.19	Sjögren's syndrome;	chr11:118768644	chr11:118704607~118750263:+
LUAD	cis	rs7119038	0.818	rs10892286	ENSG00000255422.1	AP002954.4	4.29	2.15e-05	0.00381	0.3	0.19	Sjögren's syndrome;	chr11:118771376	chr11:118704607~118750263:+
LUAD	cis	rs897984	0.806	rs1046276	ENSG00000232748.3	RP11-196G11.6	4.29	2.15e-05	0.00381	0.25	0.19	Dementia with Lewy bodies;	chr16:30903305	chr16:31056460~31062803:+
LUAD	cis	rs62025270	0.649	rs12148610	ENSG00000202081.1	RNU6-1280P	-4.29	2.15e-05	0.00381	-0.28	-0.19	Idiopathic pulmonary fibrosis;	chr15:85702697	chr15:85651522~85651628:-
LUAD	cis	rs2243480	0.666	rs1880311	ENSG00000226002.1	RP11-460N20.5	4.29	2.15e-05	0.00381	0.34	0.19	Diabetic kidney disease;	chr7:65811765	chr7:65084103~65100232:+
LUAD	cis	rs8030379	1	rs2401175	ENSG00000230373.7	GOLGA6L5P	4.29	2.15e-05	0.00381	0.18	0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83909465	chr15:84507885~84516814:-
LUAD	cis	rs13113518	1	rs6858803	ENSG00000272969.1	RP11-528I4.2	4.29	2.15e-05	0.00381	0.2	0.19	Height;	chr4:55484534	chr4:55547112~55547889:+
LUAD	cis	rs4372836	0.893	rs745645	ENSG00000226833.4	AC097724.3	-4.29	2.15e-05	0.00381	-0.23	-0.19	Body mass index;	chr2:28708705	chr2:28708953~28736205:-
LUAD	cis	rs66823261	0.741	rs7841786	ENSG00000223508.5	RPL23AP53	4.29	2.15e-05	0.00381	0.3	0.19	Breast cancer (estrogen-receptor negative);Breast cancer;	chr8:241746	chr8:213186~232231:-
LUAD	cis	rs2735413	0.563	rs72800915	ENSG00000276007.1	RP11-358L22.3	4.29	2.15e-05	0.00381	0.28	0.19	Systolic blood pressure (alcohol consumption interaction);	chr16:78021880	chr16:78123243~78124332:+
LUAD	cis	rs3761847	0.5	rs7037673	ENSG00000226752.6	PSMD5-AS1	-4.29	2.15e-05	0.00382	-0.21	-0.19	Rheumatoid arthritis;	chr9:120978206	chr9:120824828~120854385:+
LUAD	cis	rs62025270	0.632	rs62022915	ENSG00000202081.1	RNU6-1280P	-4.29	2.15e-05	0.00382	-0.29	-0.19	Idiopathic pulmonary fibrosis;	chr15:85670365	chr15:85651522~85651628:-
LUAD	cis	rs17406451	0.659	rs13396727	ENSG00000279873.2	LINC01126	4.29	2.15e-05	0.00382	0.16	0.19	Mitochondrial DNA levels;	chr2:43497505	chr2:43227210~43228855:+
LUAD	cis	rs17122278	1	rs11552421	ENSG00000243431.1	RPL5P30	4.29	2.15e-05	0.00382	0.24	0.19	Total cholesterol levels;	chr11:118559804	chr11:118560690~118561580:+
LUAD	cis	rs7208859	0.673	rs79541516	ENSG00000266490.1	CTD-2349P21.9	4.29	2.15e-05	0.00382	0.31	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913565	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs9895684	ENSG00000266490.1	CTD-2349P21.9	4.29	2.15e-05	0.00382	0.31	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30915582	chr17:30792372~30792833:+
LUAD	cis	rs1005277	0.579	rs2474587	ENSG00000263064.2	RP11-291L22.7	4.29	2.15e-05	0.00382	0.21	0.19	Extrinsic epigenetic age acceleration;	chr10:38131738	chr10:38448689~38448949:+
LUAD	cis	rs1005277	0.579	rs2474588	ENSG00000263064.2	RP11-291L22.7	4.29	2.15e-05	0.00382	0.21	0.19	Extrinsic epigenetic age acceleration;	chr10:38131942	chr10:38448689~38448949:+
LUAD	cis	rs9649213	0.593	rs12728	ENSG00000272950.1	RP11-307C18.1	4.29	2.16e-05	0.00382	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98293539	chr7:98322853~98323430:+
LUAD	cis	rs9549260	0.709	rs12585870	ENSG00000229456.1	RLIMP1	4.29	2.16e-05	0.00382	0.21	0.19	Red blood cell count;	chr13:40625350	chr13:40618738~40621348:+
LUAD	cis	rs7204230	0.96	rs62048016	ENSG00000261291.1	RP11-295M3.2	4.29	2.16e-05	0.00382	0.25	0.19	Fibrinogen;	chr16:53154481	chr16:53168522~53169450:+
LUAD	cis	rs4474465	0.92	rs7941889	ENSG00000251323.2	RP11-452H21.4	4.29	2.16e-05	0.00382	0.24	0.19	Alzheimer's disease (survival time);	chr11:78443355	chr11:78423982~78429836:-
LUAD	cis	rs11009175	0.512	rs7898994	ENSG00000273038.2	RP11-479G22.8	-4.29	2.16e-05	0.00382	-0.22	-0.19	Depression (quantitative trait);	chr10:33092724	chr10:32887255~32889311:-
LUAD	cis	rs7172677	1	rs7178784	ENSG00000260269.4	CTD-2323K18.1	-4.29	2.16e-05	0.00382	-0.26	-0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75133103	chr15:75527150~75601205:-
LUAD	cis	rs7247513	0.93	rs35275129	ENSG00000230310.1	CTD-2192J16.11	-4.29	2.16e-05	0.00382	-0.21	-0.19	Bipolar disorder;	chr19:12605679	chr19:12552597~12553644:+
LUAD	cis	rs7247513	0.897	rs12979146	ENSG00000230310.1	CTD-2192J16.11	-4.29	2.16e-05	0.00382	-0.21	-0.19	Bipolar disorder;	chr19:12607090	chr19:12552597~12553644:+
LUAD	cis	rs910316	0.967	rs8007539	ENSG00000279594.1	RP11-950C14.10	-4.29	2.16e-05	0.00382	-0.22	-0.19	Height;	chr14:75198250	chr14:75011269~75012851:-
LUAD	cis	rs6496932	0.755	rs12905673	ENSG00000218052.5	ADAMTS7P4	-4.29	2.16e-05	0.00382	-0.22	-0.19	Central corneal thickness;Corneal structure;	chr15:85346540	chr15:85255369~85330334:-
LUAD	cis	rs2880765	0.835	rs7180923	ENSG00000259416.2	RP11-158M2.5	4.29	2.16e-05	0.00382	0.2	0.19	Coronary artery disease;	chr15:85507659	chr15:85754941~85756237:-
LUAD	cis	rs6964833	0.872	rs4717903	ENSG00000278416.1	PMS2L2	4.29	2.16e-05	0.00382	0.27	0.19	Menarche (age at onset);	chr7:74653827	chr7:75344015~75359550:-
LUAD	cis	rs2348418	0.831	rs7299042	ENSG00000247934.4	RP11-967K21.1	4.29	2.16e-05	0.00382	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28571750	chr12:28163298~28190738:-
LUAD	cis	rs7017914	0.667	rs6990397	ENSG00000223220.1	Y_RNA	4.29	2.16e-05	0.00383	0.23	0.19	Bone mineral density;	chr8:71099537	chr8:70780914~70781008:-
LUAD	cis	rs858239	0.899	rs2268747	ENSG00000226816.2	AC005082.12	4.29	2.16e-05	0.00383	0.26	0.19	Cerebrospinal fluid biomarker levels;	chr7:23273843	chr7:23206013~23208045:+
LUAD	cis	rs6840360	0.642	rs2709819	ENSG00000270265.1	RP11-731D1.4	-4.29	2.16e-05	0.00383	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151462680	chr4:151333775~151353224:-
LUAD	cis	rs11671005	0.779	rs35631681	ENSG00000268912.1	CTD-2619J13.17	-4.29	2.16e-05	0.00383	-0.28	-0.19	Mean platelet volume;	chr19:58488473	chr19:58428632~58431148:-
LUAD	cis	rs10463554	0.963	rs3776857	ENSG00000250682.4	LINC00491	4.29	2.16e-05	0.00383	0.23	0.19	Parkinson's disease;	chr5:103022456	chr5:102609156~102671559:-
LUAD	cis	rs4699052	0.963	rs11943325	ENSG00000246560.2	RP11-10L12.4	4.29	2.16e-05	0.00383	0.25	0.19	Testicular germ cell tumor;	chr4:103257236	chr4:102828055~102844075:+
LUAD	cis	rs7138803	0.538	rs11611168	ENSG00000257464.1	RP11-161H23.8	-4.29	2.16e-05	0.00383	-0.2	-0.19	Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index;	chr12:49809383	chr12:49442424~49442652:-
LUAD	cis	rs12701220	0.689	rs12701824	ENSG00000229043.2	AC091729.9	-4.29	2.16e-05	0.00383	-0.27	-0.19	Bronchopulmonary dysplasia;	chr7:1062728	chr7:1160374~1165267:+
LUAD	cis	rs11122895	0.716	rs3952774	ENSG00000236307.2	EEF1E1P1	4.29	2.16e-05	0.00383	0.22	0.19	Allergic sensitization;	chr2:111711830	chr2:111887914~111888741:+
LUAD	cis	rs780096	0.506	rs72819512	ENSG00000234072.1	AC074117.10	-4.29	2.16e-05	0.00383	-0.15	-0.19	Total body bone mineral density;	chr2:27391582	chr2:27356246~27367622:+
LUAD	cis	rs2731006	0.64	rs2678141	ENSG00000257114.2	RP11-25I15.3	4.29	2.17e-05	0.00384	0.28	0.19	Panic disorder;	chr12:42807005	chr12:42692216~42717119:+
LUAD	cis	rs7204230	1	rs11075783	ENSG00000261291.1	RP11-295M3.2	4.29	2.17e-05	0.00384	0.24	0.19	Fibrinogen;	chr16:53198229	chr16:53168522~53169450:+
LUAD	cis	rs9847710	0.933	rs1529544	ENSG00000242142.1	SERBP1P3	-4.29	2.17e-05	0.00384	-0.21	-0.19	Ulcerative colitis;	chr3:53005439	chr3:53064283~53065091:-
LUAD	cis	rs17122278	1	rs2277292	ENSG00000243431.1	RPL5P30	4.29	2.17e-05	0.00384	0.23	0.19	Total cholesterol levels;	chr11:118554704	chr11:118560690~118561580:+
LUAD	cis	rs848490	0.928	rs62462681	ENSG00000214293.7	APTR	4.29	2.17e-05	0.00384	0.25	0.19	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77863702	chr7:77657660~77696265:-
LUAD	cis	rs7955901	0.775	rs3914135	ENSG00000258053.1	CTD-2021H9.3	4.29	2.17e-05	0.00384	0.22	0.19	Type 2 diabetes;	chr12:71130511	chr12:71047402~71118247:-
LUAD	cis	rs7955901	0.746	rs3851612	ENSG00000258053.1	CTD-2021H9.3	4.29	2.17e-05	0.00384	0.22	0.19	Type 2 diabetes;	chr12:71131030	chr12:71047402~71118247:-
LUAD	cis	rs9659323	0.706	rs1409160	ENSG00000231365.4	RP11-418J17.1	-4.29	2.17e-05	0.00384	-0.22	-0.19	Body mass index;	chr1:119041231	chr1:119140396~119275973:+
LUAD	cis	rs2153535	0.585	rs1885203	ENSG00000230939.1	RP11-314C16.1	-4.29	2.17e-05	0.00384	-0.21	-0.19	Motion sickness;	chr6:8633646	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.537	rs9379232	ENSG00000230939.1	RP11-314C16.1	-4.29	2.17e-05	0.00384	-0.21	-0.19	Motion sickness;	chr6:8634176	chr6:8784178~8785445:+
LUAD	cis	rs1799949	0.965	rs6503726	ENSG00000236383.6	LINC00854	-4.29	2.17e-05	0.00384	-0.15	-0.19	Menopause (age at onset);	chr17:43132725	chr17:43216941~43305976:-
LUAD	cis	rs2446066	0.872	rs10876452	ENSG00000257379.1	RP11-793H13.8	4.29	2.17e-05	0.00384	0.31	0.19	Red blood cell count;	chr12:53420474	chr12:53441741~53467528:+
LUAD	cis	rs2273156	0.57	rs2010648	ENSG00000226677.3	IGBP1P1	-4.29	2.17e-05	0.00384	-0.29	-0.19	Immunoglobulin light chain (AL) amyloidosis;	chr14:35135686	chr14:34939324~34940332:+
LUAD	cis	rs4819052	1	rs13047688	ENSG00000215447.6	BX322557.10	-4.29	2.17e-05	0.00384	-0.24	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249375	chr21:45288052~45291738:+
LUAD	cis	rs860818	1	rs858287	ENSG00000226816.2	AC005082.12	4.29	2.17e-05	0.00384	0.5	0.19	Initial pursuit acceleration;	chr7:23209594	chr7:23206013~23208045:+
LUAD	cis	rs1816752	0.716	rs9553289	ENSG00000273628.1	RP11-756A22.7	-4.29	2.17e-05	0.00385	-0.22	-0.19	Obesity-related traits;	chr13:24400640	chr13:24933006~24936796:+
LUAD	cis	rs11673344	0.563	rs55825113	ENSG00000276846.1	CTD-3220F14.3	4.29	2.17e-05	0.00385	0.22	0.19	Obesity-related traits;	chr19:37191523	chr19:37314868~37315620:-
LUAD	cis	rs9860428	0.787	rs11713508	ENSG00000242770.2	RP11-180K7.1	4.29	2.17e-05	0.00385	0.21	0.19	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112865339	chr3:112802478~112812819:+
LUAD	cis	rs1478897	0.898	rs2248932	ENSG00000270154.1	RP11-419I17.1	-4.29	2.17e-05	0.00385	-0.22	-0.19	Systemic lupus erythematosus;	chr8:11534141	chr8:12476462~12477122:+
LUAD	cis	rs4879677	1	rs12237360	ENSG00000215441.3	CTAGE12P	-4.29	2.18e-05	0.00385	-0.24	-0.19	Gut microbiome composition (summer and winter);	chr9:27660200	chr9:27608382~27610745:-
LUAD	cis	rs950169	0.84	rs12905223	ENSG00000275120.1	RP11-182J1.17	4.29	2.18e-05	0.00385	0.3	0.19	Schizophrenia;	chr15:84571037	chr15:84599434~84606463:-
LUAD	cis	rs6754311	0.731	rs309160	ENSG00000226806.1	AC011893.3	4.29	2.18e-05	0.00386	0.24	0.19	Mosquito bite size;	chr2:135927658	chr2:135820191~135823087:+
LUAD	cis	rs7208859	0.623	rs28556733	ENSG00000266490.1	CTD-2349P21.9	4.29	2.18e-05	0.00386	0.28	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30756927	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs28433704	ENSG00000266490.1	CTD-2349P21.9	4.29	2.18e-05	0.00386	0.28	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757267	chr17:30792372~30792833:+
LUAD	cis	rs17826219	0.706	rs55764512	ENSG00000266490.1	CTD-2349P21.9	4.29	2.18e-05	0.00386	0.28	0.19	Body mass index;	chr17:30758740	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs12103508	ENSG00000266490.1	CTD-2349P21.9	4.29	2.18e-05	0.00386	0.28	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759763	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.524	rs11653605	ENSG00000266490.1	CTD-2349P21.9	4.29	2.18e-05	0.00386	0.28	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30792372~30792833:+
LUAD	cis	rs750134	1	rs17040915	ENSG00000257221.1	RP11-689B22.2	-4.29	2.18e-05	0.00386	-0.29	-0.19	Low high density lipoprotein cholesterol levels;	chr12:108722068	chr12:108628687~108641318:+
LUAD	cis	rs750134	1	rs11114040	ENSG00000257221.1	RP11-689B22.2	-4.29	2.18e-05	0.00386	-0.29	-0.19	Low high density lipoprotein cholesterol levels;	chr12:108727983	chr12:108628687~108641318:+
LUAD	cis	rs1910358	0.879	rs6863146	ENSG00000248874.4	C5orf17	-4.29	2.18e-05	0.00386	-0.29	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr5:23929060	chr5:23951348~24178263:+
LUAD	cis	rs4699052	0.963	rs2061646	ENSG00000246560.2	RP11-10L12.4	4.29	2.18e-05	0.00386	0.25	0.19	Testicular germ cell tumor;	chr4:103262737	chr4:102828055~102844075:+
LUAD	cis	rs950169	0.649	rs12911612	ENSG00000259570.1	RP11-671M22.4	4.29	2.18e-05	0.00386	0.28	0.19	Schizophrenia;	chr15:84022262	chr15:84394512~84395514:+
LUAD	cis	rs950169	0.649	rs12905952	ENSG00000259570.1	RP11-671M22.4	4.29	2.18e-05	0.00386	0.28	0.19	Schizophrenia;	chr15:84022509	chr15:84394512~84395514:+
LUAD	cis	rs950169	0.61	rs34529571	ENSG00000259570.1	RP11-671M22.4	4.29	2.18e-05	0.00386	0.28	0.19	Schizophrenia;	chr15:84023055	chr15:84394512~84395514:+
LUAD	cis	rs41308713	0.606	rs77984335	ENSG00000196756.10	SNHG17	-4.29	2.18e-05	0.00386	-0.38	-0.19	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr20:38444643	chr20:38420588~38435353:-
LUAD	cis	rs7555523	0.887	rs2790053	ENSG00000224358.1	RP11-466F5.8	-4.29	2.18e-05	0.00386	-0.32	-0.19	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165768467	chr1:165768929~165775176:+
LUAD	cis	rs7555523	0.778	rs2790052	ENSG00000224358.1	RP11-466F5.8	-4.29	2.18e-05	0.00386	-0.32	-0.19	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165769226	chr1:165768929~165775176:+
LUAD	cis	rs748404	0.666	rs7176923	ENSG00000205771.5	CATSPER2P1	-4.29	2.18e-05	0.00386	-0.29	-0.19	Lung cancer;	chr15:43317679	chr15:43726918~43747094:-
LUAD	cis	rs7172677	1	rs11072525	ENSG00000260269.4	CTD-2323K18.1	-4.29	2.18e-05	0.00386	-0.25	-0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75126769	chr15:75527150~75601205:-
LUAD	cis	rs42490	0.635	rs418634	ENSG00000251136.7	RP11-37B2.1	-4.29	2.18e-05	0.00386	-0.2	-0.19	Leprosy;	chr8:89847469	chr8:89609409~89757727:-
LUAD	cis	rs848490	1	rs56364559	ENSG00000214293.7	APTR	4.29	2.18e-05	0.00386	0.26	0.19	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77851244	chr7:77657660~77696265:-
LUAD	cis	rs67981189	0.542	rs17109053	ENSG00000269927.1	RP6-91H8.3	4.29	2.18e-05	0.00386	0.26	0.19	Schizophrenia;	chr14:71142981	chr14:71141125~71143253:-
LUAD	cis	rs1015362	0.869	rs6088411	ENSG00000275784.1	RP5-1125A11.6	4.29	2.18e-05	0.00386	0.22	0.19	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:34152101	chr20:33989480~33991818:-
LUAD	cis	rs853679	0.517	rs36078605	ENSG00000226314.6	ZNF192P1	-4.29	2.18e-05	0.00386	-0.25	-0.19	Depression;	chr6:28110254	chr6:28161781~28169594:+
LUAD	cis	rs7819412	0.775	rs4545055	ENSG00000255046.1	RP11-297N6.4	4.29	2.18e-05	0.00386	0.24	0.19	Triglycerides;	chr8:11077856	chr8:11797928~11802568:-
LUAD	cis	rs7819412	0.775	rs2898257	ENSG00000255046.1	RP11-297N6.4	4.29	2.18e-05	0.00386	0.24	0.19	Triglycerides;	chr8:11077858	chr8:11797928~11802568:-
LUAD	cis	rs9549260	0.564	rs7998724	ENSG00000229456.1	RLIMP1	4.29	2.18e-05	0.00386	0.21	0.19	Red blood cell count;	chr13:40750657	chr13:40618738~40621348:+
LUAD	cis	rs6964587	1	rs6953515	ENSG00000188693.7	CYP51A1-AS1	-4.29	2.18e-05	0.00387	-0.23	-0.19	Breast cancer;	chr7:92029306	chr7:92134604~92180725:+
LUAD	cis	rs10129255	0.957	rs8009464	ENSG00000274576.2	IGHV2-70	4.29	2.19e-05	0.00387	0.17	0.19	Kawasaki disease;	chr14:106777611	chr14:106770577~106771020:-
LUAD	cis	rs57221529	0.713	rs12521091	ENSG00000248925.1	CTD-2083E4.6	4.29	2.19e-05	0.00387	0.29	0.19	Lung disease severity in cystic fibrosis;	chr5:590595	chr5:269858~271516:-
LUAD	cis	rs5758511	0.68	rs5758698	ENSG00000226450.2	CYP2D8P	4.29	2.19e-05	0.00387	0.18	0.19	Birth weight;	chr22:42288812	chr22:42149886~42155001:-
LUAD	cis	rs4664293	1	rs6745766	ENSG00000230783.1	AC009961.2	-4.29	2.19e-05	0.00387	-0.23	-0.19	Monocyte percentage of white cells;	chr2:159598284	chr2:159689217~159690291:-
LUAD	cis	rs4554975	0.689	rs4374015	ENSG00000274723.1	RP11-618L22.1	-4.29	2.19e-05	0.00387	-0.23	-0.19	Metabolite levels (small molecules and protein measures);	chr12:46832877	chr12:46970504~46972155:+
LUAD	cis	rs4554975	0.689	rs4495962	ENSG00000274723.1	RP11-618L22.1	-4.29	2.19e-05	0.00387	-0.23	-0.19	Metabolite levels (small molecules and protein measures);	chr12:46832903	chr12:46970504~46972155:+
LUAD	cis	rs4554975	0.689	rs11183625	ENSG00000274723.1	RP11-618L22.1	-4.29	2.19e-05	0.00387	-0.23	-0.19	Metabolite levels (small molecules and protein measures);	chr12:46833239	chr12:46970504~46972155:+
LUAD	cis	rs11886999	0.812	rs57476471	ENSG00000237510.6	AC008268.2	-4.29	2.19e-05	0.00387	-0.31	-0.19	Cardiac Troponin-T levels;	chr2:96236582	chr2:95789654~95800166:+
LUAD	cis	rs7560272	0.723	rs7609249	ENSG00000163016.8	ALMS1P	4.29	2.19e-05	0.00387	0.21	0.19	Schizophrenia;	chr2:73586693	chr2:73644919~73685576:+
LUAD	cis	rs7560272	0.723	rs6743576	ENSG00000163016.8	ALMS1P	4.29	2.19e-05	0.00387	0.21	0.19	Schizophrenia;	chr2:73587206	chr2:73644919~73685576:+
LUAD	cis	rs1008375	1	rs13119927	ENSG00000249502.1	AC006160.5	4.29	2.19e-05	0.00387	0.18	0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17690017	chr4:17587467~17614571:-
LUAD	cis	rs8014252	1	rs78647552	ENSG00000274818.1	RP1-292L20.3	4.29	2.19e-05	0.00387	0.31	0.19	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70466715	chr14:70906657~70907111:-
LUAD	cis	rs17772222	0.958	rs59136503	ENSG00000258789.1	RP11-507K2.3	-4.29	2.19e-05	0.00387	-0.27	-0.19	Coronary artery calcification;	chr14:88501921	chr14:88551597~88552493:+
LUAD	cis	rs28386778	0.897	rs7210443	ENSG00000240280.5	TCAM1P	-4.29	2.19e-05	0.00387	-0.22	-0.19	Prudent dietary pattern;	chr17:63708014	chr17:63849292~63864379:+
LUAD	cis	rs8077577	0.708	rs4925151	ENSG00000273018.4	CTD-2303H24.2	4.29	2.19e-05	0.00388	0.28	0.19	Obesity-related traits;	chr17:18226818	chr17:18511221~18551705:-
LUAD	cis	rs8077577	0.708	rs7211573	ENSG00000273018.4	CTD-2303H24.2	4.29	2.19e-05	0.00388	0.28	0.19	Obesity-related traits;	chr17:18228299	chr17:18511221~18551705:-
LUAD	cis	rs2243480	0.803	rs13224048	ENSG00000229886.1	RP5-1132H15.3	4.29	2.19e-05	0.00388	0.34	0.19	Diabetic kidney disease;	chr7:66528779	chr7:66025126~66031544:-
LUAD	cis	rs11673344	0.523	rs10420330	ENSG00000276846.1	CTD-3220F14.3	4.29	2.19e-05	0.00388	0.21	0.19	Obesity-related traits;	chr19:37111269	chr19:37314868~37315620:-
LUAD	cis	rs12122100	0.742	rs12122092	ENSG00000244371.2	PFN1P8	4.29	2.19e-05	0.00388	0.23	0.19	HIV-1 control;	chr1:147037318	chr1:146957117~146957659:-
LUAD	cis	rs2153535	0.561	rs9406184	ENSG00000230939.1	RP11-314C16.1	-4.29	2.19e-05	0.00388	-0.21	-0.19	Motion sickness;	chr6:8642681	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.585	rs11243263	ENSG00000230939.1	RP11-314C16.1	-4.29	2.19e-05	0.00388	-0.21	-0.19	Motion sickness;	chr6:8642880	chr6:8784178~8785445:+
LUAD	cis	rs8072100	0.738	rs9915222	ENSG00000228782.6	CTD-2026D20.3	4.29	2.19e-05	0.00388	0.21	0.19	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47371249	chr17:47450568~47492492:-
LUAD	cis	rs17345786	0.511	rs13061565	ENSG00000244119.1	PDCL3P4	4.29	2.19e-05	0.00388	0.19	0.19	Colonoscopy-negative controls vs population controls;	chr3:101673426	chr3:101712472~101713191:+
LUAD	cis	rs651907	0.557	rs7651404	ENSG00000244119.1	PDCL3P4	4.29	2.19e-05	0.00388	0.19	0.19	Colorectal cancer;	chr3:101674450	chr3:101712472~101713191:+
LUAD	cis	rs6095360	0.7	rs67623477	ENSG00000222365.1	SNORD12B	-4.29	2.19e-05	0.00388	-0.22	-0.19	Intelligence (multi-trait analysis);	chr20:49052640	chr20:49280319~49280409:+
LUAD	cis	rs301901	0.897	rs12657771	ENSG00000250155.1	CTD-2353F22.1	-4.29	2.19e-05	0.00388	-0.2	-0.19	Height;	chr5:36787860	chr5:36666214~36725195:-
LUAD	cis	rs9646944	0.501	rs7586983	ENSG00000234389.1	AC007278.3	4.29	2.19e-05	0.00388	0.22	0.19	Blood protein levels;	chr2:102411606	chr2:102438713~102440475:+
LUAD	cis	rs1552244	0.882	rs13064570	ENSG00000180385.7	EMC3-AS1	4.29	2.2e-05	0.00388	0.22	0.19	Alzheimer's disease;	chr3:9955861	chr3:9986893~10006990:+
LUAD	cis	rs62025270	0.848	rs2554	ENSG00000202081.1	RNU6-1280P	-4.29	2.2e-05	0.00388	-0.27	-0.19	Idiopathic pulmonary fibrosis;	chr15:85759412	chr15:85651522~85651628:-
LUAD	cis	rs12754538	0.961	rs11121181	ENSG00000232912.4	RP5-1115A15.1	4.29	2.2e-05	0.00388	0.2	0.19	Subjective well-being;	chr1:8416946	chr1:8424645~8434838:+
LUAD	cis	rs1876905	0.597	rs354546	ENSG00000255389.1	C6orf3	4.29	2.2e-05	0.00388	0.27	0.19	Mean corpuscular hemoglobin;	chr6:111211927	chr6:111599875~111602295:+
LUAD	cis	rs11838725	1	rs11838725	ENSG00000239827.7	SUGT1P3	-4.29	2.2e-05	0.00388	-0.22	-0.19	CSF tryptophan concentration in tuberculous meningitis;	chr13:41096949	chr13:40908159~40921774:-
LUAD	cis	rs4664293	0.903	rs10185155	ENSG00000230783.1	AC009961.2	-4.29	2.2e-05	0.00388	-0.25	-0.19	Monocyte percentage of white cells;	chr2:159696717	chr2:159689217~159690291:-
LUAD	cis	rs10090774	0.71	rs10283368	ENSG00000280303.2	ERICD	4.29	2.2e-05	0.00388	0.21	0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140669718	chr8:140636281~140638283:+
LUAD	cis	rs442309	0.846	rs224145	ENSG00000238280.1	RP11-436D10.3	-4.29	2.2e-05	0.00388	-0.23	-0.19	Vogt-Koyanagi-Harada syndrome;	chr10:62718695	chr10:62793562~62805887:-
LUAD	cis	rs2834288	0.535	rs13049489	ENSG00000237945.6	LINC00649	4.29	2.2e-05	0.00389	0.25	0.19	Gut microbiota (bacterial taxa);	chr21:33961054	chr21:33915534~33977691:+
LUAD	cis	rs1555322	0.53	rs2425042	ENSG00000279253.1	RP4-614O4.13	-4.29	2.2e-05	0.00389	-0.24	-0.19	Attention deficit hyperactivity disorder;	chr20:35278092	chr20:35262727~35264187:-
LUAD	cis	rs1555322	0.53	rs7004	ENSG00000279253.1	RP4-614O4.13	-4.29	2.2e-05	0.00389	-0.24	-0.19	Attention deficit hyperactivity disorder;	chr20:35278950	chr20:35262727~35264187:-
LUAD	cis	rs17122278	1	rs11216904	ENSG00000243431.1	RPL5P30	4.29	2.2e-05	0.00389	0.24	0.19	Total cholesterol levels;	chr11:118570148	chr11:118560690~118561580:+
LUAD	cis	rs9649213	0.537	rs6465663	ENSG00000272950.1	RP11-307C18.1	4.29	2.2e-05	0.00389	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98289571	chr7:98322853~98323430:+
LUAD	cis	rs2836754	1	rs11701004	ENSG00000205622.8	AF064858.6	-4.29	2.2e-05	0.00389	-0.21	-0.19	Body mass index;Crohn's disease;	chr21:38920178	chr21:38863676~38956467:-
LUAD	cis	rs526231	0.547	rs72783895	ENSG00000250682.4	LINC00491	4.29	2.2e-05	0.00389	0.24	0.19	Primary biliary cholangitis;	chr5:102951792	chr5:102609156~102671559:-
LUAD	cis	rs2243480	1	rs313799	ENSG00000229886.1	RP5-1132H15.3	4.29	2.2e-05	0.00389	0.33	0.19	Diabetic kidney disease;	chr7:66029343	chr7:66025126~66031544:-
LUAD	cis	rs17685	0.753	rs4728550	ENSG00000280388.1	RP11-229D13.3	4.29	2.2e-05	0.00389	0.18	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76041670	chr7:76043977~76045963:-
LUAD	cis	rs34779708	0.931	rs12240347	ENSG00000271335.4	RP11-324I22.4	4.29	2.2e-05	0.00389	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35070547	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.931	rs4934533	ENSG00000271335.4	RP11-324I22.4	4.29	2.2e-05	0.00389	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35070691	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.931	rs12248333	ENSG00000271335.4	RP11-324I22.4	4.29	2.2e-05	0.00389	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35074049	chr10:35314552~35336401:-
LUAD	cis	rs2243480	1	rs160652	ENSG00000226002.1	RP11-460N20.5	-4.29	2.2e-05	0.00389	-0.32	-0.19	Diabetic kidney disease;	chr7:66073444	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs6964245	ENSG00000232559.3	GS1-124K5.12	-4.29	2.2e-05	0.00389	-0.33	-0.19	Diabetic kidney disease;	chr7:66253730	chr7:66554588~66576923:-
LUAD	cis	rs11122895	0.716	rs11679110	ENSG00000236307.2	EEF1E1P1	4.29	2.2e-05	0.00389	0.21	0.19	Allergic sensitization;	chr2:111710778	chr2:111887914~111888741:+
LUAD	cis	rs256438	0.93	rs2438639	ENSG00000251050.1	RP11-168A11.4	-4.29	2.2e-05	0.00389	-0.21	-0.19	Serum thyroid-stimulating hormone levels;	chr5:80094151	chr5:80019609~80019920:+
LUAD	cis	rs2274273	0.837	rs11625968	ENSG00000258413.1	RP11-665C16.6	-4.29	2.2e-05	0.00389	-0.25	-0.19	Protein biomarker;	chr14:55334286	chr14:55262767~55272075:-
LUAD	cis	rs7098414	0.511	rs10749592	ENSG00000226659.1	RP11-137H2.4	-4.29	2.2e-05	0.0039	-0.26	-0.19	Post bronchodilator FEV1;	chr10:80391135	chr10:80529597~80535942:-
LUAD	cis	rs1979679	0.801	rs7977538	ENSG00000278733.1	RP11-425D17.1	4.29	2.2e-05	0.0039	0.24	0.19	Ossification of the posterior longitudinal ligament of the spine;	chr12:28143503	chr12:28185625~28186190:-
LUAD	cis	rs1979679	0.801	rs1965280	ENSG00000278733.1	RP11-425D17.1	4.29	2.2e-05	0.0039	0.24	0.19	Ossification of the posterior longitudinal ligament of the spine;	chr12:28143639	chr12:28185625~28186190:-
LUAD	cis	rs28386778	0.897	rs2036911	ENSG00000240280.5	TCAM1P	-4.29	2.2e-05	0.0039	-0.22	-0.19	Prudent dietary pattern;	chr17:63717479	chr17:63849292~63864379:+
LUAD	cis	rs6763848	0.923	rs9310450	ENSG00000214073.2	RPL21P17	-4.29	2.21e-05	0.0039	-0.2	-0.19	Prostate cancer (SNP x SNP interaction);	chr3:1473959	chr3:1905651~1906125:+
LUAD	cis	rs910316	1	rs7145159	ENSG00000279594.1	RP11-950C14.10	4.29	2.21e-05	0.0039	0.22	0.19	Height;	chr14:75116565	chr14:75011269~75012851:-
LUAD	cis	rs9649213	0.593	rs6975156	ENSG00000272950.1	RP11-307C18.1	4.29	2.21e-05	0.0039	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98296222	chr7:98322853~98323430:+
LUAD	cis	rs17772222	0.917	rs1998670	ENSG00000258789.1	RP11-507K2.3	-4.29	2.21e-05	0.0039	-0.27	-0.19	Coronary artery calcification;	chr14:88504581	chr14:88551597~88552493:+
LUAD	cis	rs2836754	1	rs11701117	ENSG00000205622.8	AF064858.6	-4.29	2.21e-05	0.0039	-0.21	-0.19	Body mass index;Crohn's disease;	chr21:38920588	chr21:38863676~38956467:-
LUAD	cis	rs8031584	0.697	rs8036176	ENSG00000270015.1	RP11-540B6.6	-4.29	2.21e-05	0.0039	-0.15	-0.19	Huntington's disease progression;	chr15:30883066	chr15:30926514~30928407:+
LUAD	cis	rs3020736	0.5	rs4147638	ENSG00000205702.9	CYP2D7	-4.29	2.21e-05	0.0039	-0.16	-0.19	Autism spectrum disorder or schizophrenia;	chr22:42091896	chr22:42140203~42144577:-
LUAD	cis	rs7172677	0.768	rs2304901	ENSG00000260269.4	CTD-2323K18.1	4.29	2.21e-05	0.0039	0.26	0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75048381	chr15:75527150~75601205:-
LUAD	cis	rs2337406	0.866	rs8003852	ENSG00000223648.3	IGHV3-64	4.29	2.21e-05	0.0039	0.23	0.19	Alzheimer's disease (late onset);	chr14:106776648	chr14:106643132~106658258:-
LUAD	cis	rs2337406	0.866	rs988131	ENSG00000223648.3	IGHV3-64	4.29	2.21e-05	0.0039	0.23	0.19	Alzheimer's disease (late onset);	chr14:106776833	chr14:106643132~106658258:-
LUAD	cis	rs2337406	0.866	rs8005518	ENSG00000223648.3	IGHV3-64	4.29	2.21e-05	0.0039	0.23	0.19	Alzheimer's disease (late onset);	chr14:106777009	chr14:106643132~106658258:-
LUAD	cis	rs2337406	0.866	rs57684263	ENSG00000223648.3	IGHV3-64	4.29	2.21e-05	0.0039	0.23	0.19	Alzheimer's disease (late onset);	chr14:106777263	chr14:106643132~106658258:-
LUAD	cis	rs2337406	0.866	rs7152809	ENSG00000223648.3	IGHV3-64	4.29	2.21e-05	0.0039	0.23	0.19	Alzheimer's disease (late onset);	chr14:106778385	chr14:106643132~106658258:-
LUAD	cis	rs2337406	0.866	rs7152832	ENSG00000223648.3	IGHV3-64	4.29	2.21e-05	0.0039	0.23	0.19	Alzheimer's disease (late onset);	chr14:106778427	chr14:106643132~106658258:-
LUAD	cis	rs2337406	0.5	rs7152934	ENSG00000223648.3	IGHV3-64	4.29	2.21e-05	0.0039	0.23	0.19	Alzheimer's disease (late onset);	chr14:106778702	chr14:106643132~106658258:-
LUAD	cis	rs2337406	0.789	rs12050392	ENSG00000223648.3	IGHV3-64	4.29	2.21e-05	0.0039	0.23	0.19	Alzheimer's disease (late onset);	chr14:106779073	chr14:106643132~106658258:-
LUAD	cis	rs2337406	0.866	rs74092505	ENSG00000223648.3	IGHV3-64	4.29	2.21e-05	0.0039	0.23	0.19	Alzheimer's disease (late onset);	chr14:106779163	chr14:106643132~106658258:-
LUAD	cis	rs2337406	0.789	rs74092507	ENSG00000223648.3	IGHV3-64	4.29	2.21e-05	0.0039	0.23	0.19	Alzheimer's disease (late onset);	chr14:106779174	chr14:106643132~106658258:-
LUAD	cis	rs2337406	0.866	rs74092511	ENSG00000223648.3	IGHV3-64	4.29	2.21e-05	0.0039	0.23	0.19	Alzheimer's disease (late onset);	chr14:106779234	chr14:106643132~106658258:-
LUAD	cis	rs4964805	0.913	rs12229276	ENSG00000257681.1	RP11-341G23.4	-4.29	2.21e-05	0.0039	-0.23	-0.19	Attention deficit hyperactivity disorder;	chr12:103810993	chr12:103746315~103768858:-
LUAD	cis	rs7107174	1	rs11237456	ENSG00000251323.2	RP11-452H21.4	4.29	2.21e-05	0.0039	0.23	0.19	Testicular germ cell tumor;	chr11:78329734	chr11:78423982~78429836:-
LUAD	cis	rs12554020	0.792	rs11975	ENSG00000227603.1	RP11-165J3.6	4.29	2.21e-05	0.0039	0.29	0.19	Schizophrenia;	chr9:93565409	chr9:93435332~93437121:-
LUAD	cis	rs2153535	0.585	rs6597343	ENSG00000230939.1	RP11-314C16.1	-4.29	2.21e-05	0.0039	-0.22	-0.19	Motion sickness;	chr6:8620270	chr6:8784178~8785445:+
LUAD	cis	rs13205254	0.618	rs17533587	ENSG00000260273.1	RP11-425D10.10	4.28	2.21e-05	0.0039	0.38	0.19	Lung cancer in ever smokers;	chr6:109333284	chr6:109382795~109383666:+
LUAD	cis	rs11168618	0.846	rs7958521	ENSG00000240399.1	RP1-228P16.1	4.28	2.21e-05	0.0039	0.19	0.19	Adiponectin levels;	chr12:48483617	chr12:48054813~48055591:-
LUAD	cis	rs1864585	0.52	rs7845731	ENSG00000255046.1	RP11-297N6.4	4.28	2.21e-05	0.0039	0.28	0.19	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10817949	chr8:11797928~11802568:-
LUAD	cis	rs910316	0.967	rs4899551	ENSG00000279594.1	RP11-950C14.10	-4.28	2.21e-05	0.0039	-0.22	-0.19	Height;	chr14:75193543	chr14:75011269~75012851:-
LUAD	cis	rs2243480	1	rs6460260	ENSG00000229886.1	RP5-1132H15.3	-4.28	2.21e-05	0.0039	-0.34	-0.19	Diabetic kidney disease;	chr7:65750468	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs6460261	ENSG00000229886.1	RP5-1132H15.3	-4.28	2.21e-05	0.0039	-0.34	-0.19	Diabetic kidney disease;	chr7:65750593	chr7:66025126~66031544:-
LUAD	cis	rs17596685	1	rs4356365	ENSG00000271216.1	LINC01050	4.28	2.21e-05	0.00391	0.28	0.19	C-reactive protein levels;	chr13:42590035	chr13:42810366~42812562:-
LUAD	cis	rs6687758	1	rs12125383	ENSG00000227925.1	RP11-191N8.2	4.28	2.21e-05	0.00391	0.27	0.19	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221995092	chr1:221827666~221840666:-
LUAD	cis	rs17711722	0.522	rs6957759	ENSG00000189316.3	RP11-797H7.5	-4.28	2.21e-05	0.00391	-0.21	-0.19	Calcium levels;	chr7:65806798	chr7:64888527~64890100:-
LUAD	cis	rs8098244	0.58	rs1620152	ENSG00000264745.1	TTC39C-AS1	4.28	2.21e-05	0.00391	0.2	0.19	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23678335	chr18:23994213~24015339:-
LUAD	cis	rs11886999	0.812	rs72825856	ENSG00000237510.6	AC008268.2	-4.28	2.21e-05	0.00391	-0.32	-0.19	Cardiac Troponin-T levels;	chr2:96190389	chr2:95789654~95800166:+
LUAD	cis	rs193541	0.53	rs6595405	ENSG00000263432.2	RN7SL689P	4.28	2.21e-05	0.00391	0.26	0.19	Glucose homeostasis traits;	chr5:122749050	chr5:123022487~123022783:-
LUAD	cis	rs7208859	0.573	rs7214313	ENSG00000266490.1	CTD-2349P21.9	4.28	2.21e-05	0.00391	0.28	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811578	chr17:30792372~30792833:+
LUAD	cis	rs6686842	0.56	rs11209361	ENSG00000235358.1	RP11-399E6.1	-4.28	2.21e-05	0.00391	-0.23	-0.19	Height;	chr1:41018279	chr1:41242373~41284861:+
LUAD	cis	rs2274273	0.712	rs6572999	ENSG00000258413.1	RP11-665C16.6	-4.28	2.21e-05	0.00391	-0.24	-0.19	Protein biomarker;	chr14:55060656	chr14:55262767~55272075:-
LUAD	cis	rs2274273	0.712	rs1002054	ENSG00000258413.1	RP11-665C16.6	-4.28	2.21e-05	0.00391	-0.24	-0.19	Protein biomarker;	chr14:55062195	chr14:55262767~55272075:-
LUAD	cis	rs2243480	0.831	rs57294491	ENSG00000229886.1	RP5-1132H15.3	-4.28	2.22e-05	0.00391	-0.34	-0.19	Diabetic kidney disease;	chr7:66219914	chr7:66025126~66031544:-
LUAD	cis	rs4843747	0.671	rs72818540	ENSG00000205037.2	RP11-863P13.4	4.28	2.22e-05	0.00391	0.27	0.19	Menopause (age at onset);	chr16:88045382	chr16:88088041~88100985:-
LUAD	cis	rs10129255	0.957	rs12590735	ENSG00000274576.2	IGHV2-70	4.28	2.22e-05	0.00392	0.17	0.19	Kawasaki disease;	chr14:106779660	chr14:106770577~106771020:-
LUAD	cis	rs17711722	0.522	rs62469933	ENSG00000189316.3	RP11-797H7.5	-4.28	2.22e-05	0.00392	-0.21	-0.19	Calcium levels;	chr7:65800652	chr7:64888527~64890100:-
LUAD	cis	rs27434	0.66	rs27043	ENSG00000272109.1	CTD-2260A17.3	4.28	2.22e-05	0.00392	0.26	0.19	Ankylosing spondylitis;	chr5:96781596	chr5:96804353~96806105:+
LUAD	cis	rs6964587	0.869	rs7810391	ENSG00000188693.7	CYP51A1-AS1	4.28	2.22e-05	0.00392	0.23	0.19	Breast cancer;	chr7:91890913	chr7:92134604~92180725:+
LUAD	cis	rs6964587	0.869	rs7778667	ENSG00000188693.7	CYP51A1-AS1	4.28	2.22e-05	0.00392	0.23	0.19	Breast cancer;	chr7:91891502	chr7:92134604~92180725:+
LUAD	cis	rs1555322	0.53	rs8122819	ENSG00000279253.1	RP4-614O4.13	-4.28	2.22e-05	0.00392	-0.24	-0.19	Attention deficit hyperactivity disorder;	chr20:35293783	chr20:35262727~35264187:-
LUAD	cis	rs2154319	0.609	rs13374676	ENSG00000235358.1	RP11-399E6.1	-4.28	2.22e-05	0.00392	-0.23	-0.19	Height;	chr1:41275223	chr1:41242373~41284861:+
LUAD	cis	rs9341808	0.754	rs6916405	ENSG00000233967.5	RP11-250B2.3	4.28	2.22e-05	0.00392	0.19	0.19	Sitting height ratio;	chr6:80314471	chr6:80443344~80465927:+
LUAD	cis	rs6686842	0.536	rs17358157	ENSG00000235358.1	RP11-399E6.1	-4.28	2.22e-05	0.00392	-0.23	-0.19	Height;	chr1:41233850	chr1:41242373~41284861:+
LUAD	cis	rs2933343	0.7	rs789239	ENSG00000231305.3	RP11-723O4.2	4.28	2.22e-05	0.00392	0.21	0.19	IgG glycosylation;	chr3:128914965	chr3:128861313~128871540:-
LUAD	cis	rs7208859	0.573	rs8078182	ENSG00000263603.1	CTD-2349P21.5	-4.28	2.22e-05	0.00392	-0.29	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822646	chr17:30729469~30731202:+
LUAD	cis	rs651907	0.557	rs3806653	ENSG00000244119.1	PDCL3P4	4.28	2.22e-05	0.00392	0.19	0.19	Colorectal cancer;	chr3:101678128	chr3:101712472~101713191:+
LUAD	cis	rs651907	0.557	rs1056579	ENSG00000244119.1	PDCL3P4	4.28	2.22e-05	0.00392	0.19	0.19	Colorectal cancer;	chr3:101679033	chr3:101712472~101713191:+
LUAD	cis	rs8141529	0.732	rs5762815	ENSG00000272858.1	CTA-292E10.8	-4.28	2.22e-05	0.00392	-0.22	-0.19	Lymphocyte counts;	chr22:28809088	chr22:28814914~28815662:+
LUAD	cis	rs1008375	0.966	rs10489036	ENSG00000249502.1	AC006160.5	-4.28	2.22e-05	0.00392	-0.18	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17696064	chr4:17587467~17614571:-
LUAD	cis	rs11971779	0.793	rs4732366	ENSG00000273391.1	RP11-634H22.1	4.28	2.22e-05	0.00392	0.21	0.19	Diisocyanate-induced asthma;	chr7:139343099	chr7:139359032~139359566:-
LUAD	cis	rs2933343	0.729	rs1680794	ENSG00000231305.3	RP11-723O4.2	4.28	2.22e-05	0.00392	0.21	0.19	IgG glycosylation;	chr3:128901547	chr3:128861313~128871540:-
LUAD	cis	rs2933343	0.7	rs1683777	ENSG00000231305.3	RP11-723O4.2	4.28	2.22e-05	0.00392	0.21	0.19	IgG glycosylation;	chr3:128906037	chr3:128861313~128871540:-
LUAD	cis	rs2933343	0.7	rs1680788	ENSG00000231305.3	RP11-723O4.2	4.28	2.22e-05	0.00392	0.21	0.19	IgG glycosylation;	chr3:128906475	chr3:128861313~128871540:-
LUAD	cis	rs7551222	0.752	rs4252718	ENSG00000240219.1	RP11-430C7.5	-4.28	2.22e-05	0.00392	-0.2	-0.19	Schizophrenia;	chr1:204543067	chr1:204626775~204629712:+
LUAD	cis	rs8177876	0.658	rs11150337	ENSG00000261061.1	RP11-303E16.2	-4.28	2.22e-05	0.00392	-0.31	-0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81035712	chr16:81030770~81031485:+
LUAD	cis	rs712022	0.967	rs11026800	ENSG00000246225.5	RP11-17A1.3	-4.28	2.22e-05	0.00392	-0.24	-0.19	Dialysis-related mortality;	chr11:22810859	chr11:22829380~22945393:+
LUAD	cis	rs2243480	1	rs12698509	ENSG00000229886.1	RP5-1132H15.3	4.28	2.23e-05	0.00393	0.33	0.19	Diabetic kidney disease;	chr7:65953889	chr7:66025126~66031544:-
LUAD	cis	rs7829975	0.572	rs28446104	ENSG00000173295.6	FAM86B3P	-4.28	2.23e-05	0.00393	-0.2	-0.19	Mood instability;	chr8:8938391	chr8:8228595~8244865:+
LUAD	cis	rs7429990	0.895	rs35790549	ENSG00000228638.1	FCF1P2	-4.28	2.23e-05	0.00393	-0.26	-0.19	Educational attainment (years of education);	chr3:48029998	chr3:48290793~48291375:-
LUAD	cis	rs6095360	1	rs1538482	ENSG00000222365.1	SNORD12B	-4.28	2.23e-05	0.00393	-0.2	-0.19	Intelligence (multi-trait analysis);	chr20:49088959	chr20:49280319~49280409:+
LUAD	cis	rs1062177	0.694	rs2915816	ENSG00000253921.1	CTB-113P19.3	4.28	2.23e-05	0.00393	0.27	0.19	Preschool internalizing problems;	chr5:151736296	chr5:151753992~151767247:+
LUAD	cis	rs867371	0.929	rs7173852	ENSG00000276710.3	CSPG4P8	-4.28	2.23e-05	0.00393	-0.18	-0.19	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82169512	chr15:82459472~82477258:+
LUAD	cis	rs35740288	0.787	rs2291047	ENSG00000259407.1	RP11-158M2.3	-4.28	2.23e-05	0.00393	-0.19	-0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85682574	chr15:85744109~85750281:-
LUAD	cis	rs7208859	0.623	rs73269913	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.23e-05	0.00393	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765165	chr17:30738182~30740275:+
LUAD	cis	rs603446	0.967	rs3741300	ENSG00000254851.1	RP11-109L13.1	-4.28	2.23e-05	0.00393	-0.24	-0.19	Triglycerides;	chr11:116760974	chr11:117135528~117138582:+
LUAD	cis	rs4664293	0.667	rs6432562	ENSG00000226266.5	AC009961.3	-4.28	2.23e-05	0.00393	-0.26	-0.19	Monocyte percentage of white cells;	chr2:159791495	chr2:159670708~159712435:-
LUAD	cis	rs4819052	1	rs13053002	ENSG00000215447.6	BX322557.10	-4.28	2.23e-05	0.00394	-0.24	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45257939	chr21:45288052~45291738:+
LUAD	cis	rs9393777	0.777	rs35984974	ENSG00000219392.1	RP1-265C24.5	-4.28	2.23e-05	0.00394	-0.35	-0.19	Intelligence (multi-trait analysis);	chr6:27442643	chr6:28115628~28116551:+
LUAD	cis	rs7660883	0.897	rs3775214	ENSG00000251411.1	RP11-397E7.4	4.28	2.23e-05	0.00394	0.21	0.19	HDL cholesterol levels;	chr4:87102147	chr4:86913266~86914817:-
LUAD	cis	rs4295623	0.553	rs34962960	ENSG00000255046.1	RP11-297N6.4	4.28	2.23e-05	0.00394	0.24	0.19	Morning vs. evening chronotype;	chr8:11737088	chr8:11797928~11802568:-
LUAD	cis	rs4237845	0.68	rs10877033	ENSG00000245651.2	RP11-620J15.2	4.28	2.23e-05	0.00394	0.19	0.19	Intelligence (multi-trait analysis);	chr12:57889948	chr12:57869835~57896482:-
LUAD	cis	rs728616	0.867	rs17883671	ENSG00000225484.5	NUTM2B-AS1	-4.28	2.23e-05	0.00394	-0.48	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79935437	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.867	rs17885031	ENSG00000225484.5	NUTM2B-AS1	-4.28	2.23e-05	0.00394	-0.48	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79936335	chr10:79663088~79826594:-
LUAD	cis	rs853679	0.517	rs4713141	ENSG00000226314.6	ZNF192P1	-4.28	2.23e-05	0.00394	-0.25	-0.19	Depression;	chr6:28133900	chr6:28161781~28169594:+
LUAD	cis	rs62355901	0.545	rs12657172	ENSG00000271828.1	CTD-2310F14.1	4.28	2.23e-05	0.00394	0.39	0.19	Breast cancer;	chr5:56768280	chr5:56927874~56929573:+
LUAD	cis	rs11673344	0.526	rs17305823	ENSG00000226686.6	LINC01535	-4.28	2.23e-05	0.00394	-0.23	-0.19	Obesity-related traits;	chr19:37644145	chr19:37251912~37265535:+
LUAD	cis	rs10895987	1	rs72932837	ENSG00000254614.2	AP003068.23	4.28	2.23e-05	0.00394	0.31	0.19	Blood protein levels;	chr11:65109268	chr11:65177606~65181834:-
LUAD	cis	rs9309473	0.5	rs12996463	ENSG00000163016.8	ALMS1P	-4.28	2.23e-05	0.00394	-0.21	-0.19	Metabolite levels;	chr2:73428368	chr2:73644919~73685576:+
LUAD	cis	rs73198271	0.603	rs557892	ENSG00000253893.2	FAM85B	4.28	2.23e-05	0.00394	0.24	0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8738538	chr8:8167819~8226614:-
LUAD	cis	rs2243480	1	rs56016656	ENSG00000226002.1	RP11-460N20.5	-4.28	2.23e-05	0.00394	-0.33	-0.19	Diabetic kidney disease;	chr7:65918494	chr7:65084103~65100232:+
LUAD	cis	rs2243480	0.803	rs55700941	ENSG00000226002.1	RP11-460N20.5	-4.28	2.23e-05	0.00394	-0.33	-0.19	Diabetic kidney disease;	chr7:65924813	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs56291018	ENSG00000226002.1	RP11-460N20.5	-4.28	2.23e-05	0.00394	-0.33	-0.19	Diabetic kidney disease;	chr7:65925352	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs36033484	ENSG00000226002.1	RP11-460N20.5	-4.28	2.23e-05	0.00394	-0.33	-0.19	Diabetic kidney disease;	chr7:65925571	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs34193460	ENSG00000226002.1	RP11-460N20.5	-4.28	2.23e-05	0.00394	-0.33	-0.19	Diabetic kidney disease;	chr7:65928123	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs34560516	ENSG00000226002.1	RP11-460N20.5	-4.28	2.23e-05	0.00394	-0.33	-0.19	Diabetic kidney disease;	chr7:65939105	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs57057549	ENSG00000226002.1	RP11-460N20.5	-4.28	2.23e-05	0.00394	-0.33	-0.19	Diabetic kidney disease;	chr7:65940751	chr7:65084103~65100232:+
LUAD	cis	rs10463554	0.892	rs13340345	ENSG00000250682.4	LINC00491	4.28	2.23e-05	0.00394	0.23	0.19	Parkinson's disease;	chr5:103003518	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.963	rs3776860	ENSG00000250682.4	LINC00491	4.28	2.23e-05	0.00394	0.23	0.19	Parkinson's disease;	chr5:103014266	chr5:102609156~102671559:-
LUAD	cis	rs6840360	0.615	rs2120098	ENSG00000270265.1	RP11-731D1.4	-4.28	2.23e-05	0.00394	-0.21	-0.19	Intelligence (multi-trait analysis);	chr4:151536028	chr4:151333775~151353224:-
LUAD	cis	rs11723261	0.664	rs4627799	ENSG00000211553.1	AC253576.2	-4.28	2.24e-05	0.00394	-0.27	-0.19	Immune response to smallpox vaccine (IL-6);	chr4:138608	chr4:136461~136568:+
LUAD	cis	rs7172677	0.737	rs6495153	ENSG00000260269.4	CTD-2323K18.1	-4.28	2.24e-05	0.00394	-0.25	-0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75144669	chr15:75527150~75601205:-
LUAD	cis	rs4660214	0.666	rs11205739	ENSG00000228060.1	RP11-69E11.8	4.28	2.24e-05	0.00394	0.17	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39190729	chr1:39565160~39573203:+
LUAD	cis	rs957448	0.948	rs1470153	ENSG00000253175.1	RP11-267M23.6	4.28	2.24e-05	0.00394	0.23	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94514587	chr8:94565036~94565715:+
LUAD	cis	rs3808502	0.525	rs13280813	ENSG00000255046.1	RP11-297N6.4	4.28	2.24e-05	0.00394	0.23	0.19	Neuroticism;	chr8:11567596	chr8:11797928~11802568:-
LUAD	cis	rs2348418	0.864	rs2203088	ENSG00000244712.1	RP11-874G11.1	4.28	2.24e-05	0.00395	0.23	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28556767	chr12:28564678~28565141:-
LUAD	cis	rs6479891	1	rs12411988	ENSG00000232075.1	MRPL35P2	-4.28	2.24e-05	0.00395	-0.33	-0.19	Arthritis (juvenile idiopathic);	chr10:63555637	chr10:63634317~63634827:-
LUAD	cis	rs9467773	1	rs9986382	ENSG00000261353.1	CTA-14H9.5	-4.28	2.24e-05	0.00395	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26550391	chr6:26527063~26527404:+
LUAD	cis	rs2446066	0.872	rs10876451	ENSG00000257379.1	RP11-793H13.8	4.28	2.24e-05	0.00395	0.32	0.19	Red blood cell count;	chr12:53419640	chr12:53441741~53467528:+
LUAD	cis	rs4843747	0.671	rs4072871	ENSG00000205037.2	RP11-863P13.4	4.28	2.24e-05	0.00395	0.27	0.19	Menopause (age at onset);	chr16:88073008	chr16:88088041~88100985:-
LUAD	cis	rs910316	0.967	rs4903292	ENSG00000259138.1	RP11-950C14.7	4.28	2.24e-05	0.00395	0.2	0.19	Height;	chr14:75189542	chr14:75127153~75136930:+
LUAD	cis	rs7772486	0.79	rs7742333	ENSG00000235652.6	RP11-545I5.3	-4.28	2.24e-05	0.00396	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145837893	chr6:145799409~145886585:+
LUAD	cis	rs2153535	0.56	rs7748421	ENSG00000230939.1	RP11-314C16.1	-4.28	2.25e-05	0.00396	-0.21	-0.19	Motion sickness;	chr6:8636271	chr6:8784178~8785445:+
LUAD	cis	rs2115630	1	rs58581703	ENSG00000225151.9	GOLGA2P7	4.28	2.25e-05	0.00396	0.22	0.19	P wave terminal force;	chr15:84733704	chr15:84199311~84230136:-
LUAD	cis	rs2060793	0.539	rs962025	ENSG00000251991.1	RNU7-49P	4.28	2.25e-05	0.00396	0.2	0.19	Vitamin D levels;	chr11:14618744	chr11:14478892~14478953:+
LUAD	cis	rs6785206	0.614	rs2712430	ENSG00000242551.2	POU5F1P6	-4.28	2.25e-05	0.00396	-0.36	-0.19	Lymphocyte percentage of white cells;	chr3:128618595	chr3:128674735~128677005:-
LUAD	cis	rs6785206	0.803	rs2712380	ENSG00000242551.2	POU5F1P6	-4.28	2.25e-05	0.00396	-0.36	-0.19	Lymphocyte percentage of white cells;	chr3:128619818	chr3:128674735~128677005:-
LUAD	cis	rs17189298	0.902	rs4085873	ENSG00000231013.1	AC013275.2	4.28	2.25e-05	0.00396	0.2	0.19	Cerebrospinal T-tau levels;	chr2:119115121	chr2:119476448~119487346:+
LUAD	cis	rs2243480	0.908	rs4718273	ENSG00000226002.1	RP11-460N20.5	4.28	2.25e-05	0.00396	0.33	0.19	Diabetic kidney disease;	chr7:65751112	chr7:65084103~65100232:+
LUAD	cis	rs7208859	0.524	rs11653098	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.25e-05	0.00396	-0.27	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30738182~30740275:+
LUAD	cis	rs4372836	1	rs6547872	ENSG00000226833.4	AC097724.3	4.28	2.25e-05	0.00396	0.22	0.19	Body mass index;	chr2:28755208	chr2:28708953~28736205:-
LUAD	cis	rs791888	0.965	rs791873	ENSG00000225913.2	RP11-57C13.6	4.28	2.25e-05	0.00396	0.24	0.19	Magnesium levels;	chr10:87645801	chr10:87607985~87659279:+
LUAD	cis	rs791888	0.965	rs791875	ENSG00000225913.2	RP11-57C13.6	4.28	2.25e-05	0.00396	0.24	0.19	Magnesium levels;	chr10:87646331	chr10:87607985~87659279:+
LUAD	cis	rs42490	0.664	rs389848	ENSG00000251136.7	RP11-37B2.1	-4.28	2.25e-05	0.00396	-0.2	-0.19	Leprosy;	chr8:89784739	chr8:89609409~89757727:-
LUAD	cis	rs4971059	0.617	rs12025371	ENSG00000160766.13	GBAP1	-4.28	2.25e-05	0.00396	-0.2	-0.19	Breast cancer;	chr1:155146851	chr1:155213821~155227422:-
LUAD	cis	rs6687758	1	rs17011200	ENSG00000200033.1	RNU6-403P	4.28	2.25e-05	0.00396	0.26	0.19	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222018163	chr1:221837334~221837437:-
LUAD	cis	rs9545047	0.625	rs7338170	ENSG00000227354.5	RBM26-AS1	-4.28	2.25e-05	0.00396	-0.2	-0.19	Schizophrenia;	chr13:79286030	chr13:79406309~79424328:+
LUAD	cis	rs2348418	0.832	rs1032391	ENSG00000247934.4	RP11-967K21.1	4.28	2.25e-05	0.00396	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28383775	chr12:28163298~28190738:-
LUAD	cis	rs7829975	0.509	rs7838674	ENSG00000173295.6	FAM86B3P	-4.28	2.25e-05	0.00396	-0.2	-0.19	Mood instability;	chr8:8939563	chr8:8228595~8244865:+
LUAD	cis	rs2243480	1	rs160652	ENSG00000232559.3	GS1-124K5.12	4.28	2.25e-05	0.00396	0.33	0.19	Diabetic kidney disease;	chr7:66073444	chr7:66554588~66576923:-
LUAD	cis	rs2302464	1	rs6828144	ENSG00000214846.4	RP11-115L11.1	4.28	2.25e-05	0.00396	0.52	0.19	Cerebrospinal fluid biomarker levels;	chr4:15725766	chr4:15730962~15731627:-
LUAD	cis	rs755249	0.565	rs4660846	ENSG00000228060.1	RP11-69E11.8	4.28	2.25e-05	0.00397	0.17	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39583839	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.565	rs7539279	ENSG00000228060.1	RP11-69E11.8	4.28	2.25e-05	0.00397	0.17	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39584896	chr1:39565160~39573203:+
LUAD	cis	rs6964587	0.869	rs6979024	ENSG00000188693.7	CYP51A1-AS1	4.28	2.25e-05	0.00397	0.23	0.19	Breast cancer;	chr7:91852198	chr7:92134604~92180725:+
LUAD	cis	rs4372836	1	rs34409160	ENSG00000226833.4	AC097724.3	-4.28	2.25e-05	0.00397	-0.23	-0.19	Body mass index;	chr2:28720999	chr2:28708953~28736205:-
LUAD	cis	rs11155671	0.53	rs7758033	ENSG00000268592.3	RAET1E-AS1	4.28	2.25e-05	0.00397	0.24	0.19	Testicular germ cell tumor;	chr6:149886999	chr6:149863494~149919507:+
LUAD	cis	rs9633740	0.578	rs7084416	ENSG00000226659.1	RP11-137H2.4	4.28	2.25e-05	0.00397	0.33	0.19	Post bronchodilator FEV1;	chr10:80544541	chr10:80529597~80535942:-
LUAD	cis	rs11220082	0.666	rs12789687	ENSG00000254671.2	STT3A-AS1	-4.28	2.25e-05	0.00397	-0.22	-0.19	Schizophrenia;	chr11:125461254	chr11:125570284~125592568:-
LUAD	cis	rs9467773	1	rs6456734	ENSG00000261353.1	CTA-14H9.5	-4.28	2.25e-05	0.00397	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26566737	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs1535277	ENSG00000261353.1	CTA-14H9.5	-4.28	2.25e-05	0.00397	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26567574	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs1884948	ENSG00000261353.1	CTA-14H9.5	-4.28	2.25e-05	0.00397	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26567760	chr6:26527063~26527404:+
LUAD	cis	rs6479901	0.947	rs10740123	ENSG00000232075.1	MRPL35P2	-4.28	2.26e-05	0.00397	-0.26	-0.19	Intelligence (multi-trait analysis);	chr10:63404755	chr10:63634317~63634827:-
LUAD	cis	rs6479901	0.947	rs10995530	ENSG00000232075.1	MRPL35P2	-4.28	2.26e-05	0.00397	-0.26	-0.19	Intelligence (multi-trait analysis);	chr10:63419654	chr10:63634317~63634827:-
LUAD	cis	rs6479901	0.841	rs72837019	ENSG00000232075.1	MRPL35P2	-4.28	2.26e-05	0.00397	-0.26	-0.19	Intelligence (multi-trait analysis);	chr10:63427258	chr10:63634317~63634827:-
LUAD	cis	rs6479901	0.947	rs10761767	ENSG00000232075.1	MRPL35P2	-4.28	2.26e-05	0.00397	-0.26	-0.19	Intelligence (multi-trait analysis);	chr10:63432671	chr10:63634317~63634827:-
LUAD	cis	rs6479901	0.947	rs10761768	ENSG00000232075.1	MRPL35P2	-4.28	2.26e-05	0.00397	-0.26	-0.19	Intelligence (multi-trait analysis);	chr10:63434369	chr10:63634317~63634827:-
LUAD	cis	rs34779708	0.733	rs7070778	ENSG00000271335.4	RP11-324I22.4	4.28	2.26e-05	0.00397	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35252760	chr10:35314552~35336401:-
LUAD	cis	rs80028505	0.908	rs56059109	ENSG00000271304.1	DPRXP2	4.28	2.26e-05	0.00398	0.36	0.19	Foot ulcer in diabetes and neuropathy;	chr6:36057530	chr6:35989515~35990436:-
LUAD	cis	rs5850	0.602	rs1005786	ENSG00000226816.2	AC005082.12	4.28	2.26e-05	0.00398	0.24	0.19	Blood protein levels;	chr7:23106218	chr7:23206013~23208045:+
LUAD	cis	rs1850744	0.702	rs13136217	ENSG00000163612.10	FAM86KP	-4.28	2.26e-05	0.00398	-0.52	-0.19	Economic and political preferences;	chr4:9720668	chr4:9153296~9165451:+
LUAD	cis	rs1850744	0.609	rs2037315	ENSG00000163612.10	FAM86KP	-4.28	2.26e-05	0.00398	-0.52	-0.19	Economic and political preferences;	chr4:9720784	chr4:9153296~9165451:+
LUAD	cis	rs1850744	0.536	rs2037313	ENSG00000163612.10	FAM86KP	-4.28	2.26e-05	0.00398	-0.52	-0.19	Economic and political preferences;	chr4:9723087	chr4:9153296~9165451:+
LUAD	cis	rs67981189	0.529	rs17108808	ENSG00000269927.1	RP6-91H8.3	4.28	2.26e-05	0.00398	0.25	0.19	Schizophrenia;	chr14:70974835	chr14:71141125~71143253:-
LUAD	cis	rs7760535	0.826	rs10872068	ENSG00000230177.1	RP5-1112D6.4	4.28	2.26e-05	0.00398	0.17	0.19	Metabolic traits;	chr6:111528657	chr6:111277932~111278742:+
LUAD	cis	rs948562	0.657	rs11229574	ENSG00000280010.1	AP001350.4	4.28	2.26e-05	0.00398	0.27	0.19	Lymphoma;	chr11:58667837	chr11:58627435~58628528:+
LUAD	cis	rs7324557	0.717	rs9553071	ENSG00000205861.10	C1QTNF9B-AS1	-4.28	2.26e-05	0.00398	-0.26	-0.19	Visceral adipose tissue adjusted for BMI;	chr13:23807240	chr13:23888889~23897263:+
LUAD	cis	rs7189233	0.531	rs1131220	ENSG00000279344.1	RP11-44F14.7	4.28	2.26e-05	0.00398	0.16	0.19	Intelligence (multi-trait analysis);	chr16:53470022	chr16:53478957~53481550:-
LUAD	cis	rs7189233	0.513	rs10748	ENSG00000279344.1	RP11-44F14.7	4.28	2.26e-05	0.00398	0.16	0.19	Intelligence (multi-trait analysis);	chr16:53470809	chr16:53478957~53481550:-
LUAD	cis	rs9545047	0.604	rs9565483	ENSG00000227354.5	RBM26-AS1	-4.28	2.26e-05	0.00399	-0.2	-0.19	Schizophrenia;	chr13:79294001	chr13:79406309~79424328:+
LUAD	cis	rs17406451	0.704	rs2172169	ENSG00000279873.2	LINC01126	4.28	2.26e-05	0.00399	0.16	0.19	Mitochondrial DNA levels;	chr2:43530726	chr2:43227210~43228855:+
LUAD	cis	rs57502260	0.834	rs3736228	ENSG00000212093.1	AP000807.1	-4.28	2.26e-05	0.00399	-0.25	-0.19	Total body bone mineral density (age 45-60);	chr11:68433827	chr11:68506083~68506166:-
LUAD	cis	rs2548724	0.617	rs62369307	ENSG00000250682.4	LINC00491	4.28	2.26e-05	0.00399	0.23	0.19	Type 2 diabetes;	chr5:102380755	chr5:102609156~102671559:-
LUAD	cis	rs12534093	0.562	rs6461714	ENSG00000234286.1	AC006026.13	-4.28	2.27e-05	0.00399	-0.25	-0.19	Infant length;Height;	chr7:23536633	chr7:23680195~23680786:-
LUAD	cis	rs6921919	0.562	rs13198809	ENSG00000219392.1	RP1-265C24.5	-4.28	2.27e-05	0.00399	-0.43	-0.19	Autism spectrum disorder or schizophrenia;	chr6:28355925	chr6:28115628~28116551:+
LUAD	cis	rs3096299	0.719	rs2965945	ENSG00000182376.2	RP5-1142A6.8	4.28	2.27e-05	0.00399	0.2	0.19	Multiple myeloma (IgH translocation);	chr16:89447609	chr16:88742767~88745748:+
LUAD	cis	rs6066835	0.702	rs2073073	ENSG00000230758.1	SNAP23P	-4.28	2.27e-05	0.00399	-0.4	-0.19	Multiple myeloma;	chr20:48652999	chr20:49038357~49038602:-
LUAD	cis	rs210138	1	rs210137	ENSG00000197251.3	LINC00336	4.28	2.27e-05	0.00399	0.32	0.19	Testicular germ cell tumor;	chr6:33574701	chr6:33586106~33593338:-
LUAD	cis	rs2243480	0.711	rs2420172	ENSG00000229886.1	RP5-1132H15.3	-4.28	2.27e-05	0.00399	-0.33	-0.19	Diabetic kidney disease;	chr7:66170354	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs2420171	ENSG00000229886.1	RP5-1132H15.3	-4.28	2.27e-05	0.00399	-0.33	-0.19	Diabetic kidney disease;	chr7:66172773	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs6974723	ENSG00000229886.1	RP5-1132H15.3	-4.28	2.27e-05	0.00399	-0.33	-0.19	Diabetic kidney disease;	chr7:66172952	chr7:66025126~66031544:-
LUAD	cis	rs7208859	0.573	rs7222803	ENSG00000266490.1	CTD-2349P21.9	4.28	2.27e-05	0.00399	0.28	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30792372~30792833:+
LUAD	cis	rs262150	0.644	rs2730228	ENSG00000231419.5	LINC00689	-4.28	2.27e-05	0.00399	-0.23	-0.19	Facial morphology (factor 20);	chr7:158996670	chr7:159006522~159030195:+
LUAD	cis	rs2348418	0.864	rs7312339	ENSG00000244712.1	RP11-874G11.1	4.28	2.27e-05	0.00399	0.23	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28558751	chr12:28564678~28565141:-
LUAD	cis	rs6142102	0.812	rs6059554	ENSG00000275784.1	RP5-1125A11.6	-4.28	2.27e-05	0.00399	-0.21	-0.19	Skin pigmentation;	chr20:33926286	chr20:33989480~33991818:-
LUAD	cis	rs7189233	0.513	rs8044091	ENSG00000279344.1	RP11-44F14.7	4.28	2.27e-05	0.00399	0.16	0.19	Intelligence (multi-trait analysis);	chr16:53487086	chr16:53478957~53481550:-
LUAD	cis	rs950169	0.579	rs12912716	ENSG00000225151.9	GOLGA2P7	-4.28	2.27e-05	0.00399	-0.28	-0.19	Schizophrenia;	chr15:83995511	chr15:84199311~84230136:-
LUAD	cis	rs6088590	0.55	rs12624640	ENSG00000275784.1	RP5-1125A11.6	-4.28	2.27e-05	0.00399	-0.21	-0.19	Coronary artery disease;	chr20:34364319	chr20:33989480~33991818:-
LUAD	cis	rs1876905	0.597	rs354546	ENSG00000230177.1	RP5-1112D6.4	-4.28	2.27e-05	0.00399	-0.24	-0.19	Mean corpuscular hemoglobin;	chr6:111211927	chr6:111277932~111278742:+
LUAD	cis	rs67981189	0.501	rs2810104	ENSG00000269927.1	RP6-91H8.3	4.28	2.27e-05	0.00399	0.25	0.19	Schizophrenia;	chr14:70958096	chr14:71141125~71143253:-
LUAD	cis	rs7615952	0.546	rs2979307	ENSG00000243429.1	OR7E29P	-4.28	2.27e-05	0.00399	-0.26	-0.19	Blood pressure (smoking interaction);	chr3:125590730	chr3:125712139~125713045:+
LUAD	cis	rs12122100	0.526	rs12122534	ENSG00000227242.3	NBPF13P	4.28	2.27e-05	0.004	0.22	0.19	HIV-1 control;	chr1:147032846	chr1:147021320~147124525:-
LUAD	cis	rs7829975	0.744	rs2409092	ENSG00000233609.3	RP11-62H7.2	4.28	2.27e-05	0.004	0.16	0.19	Mood instability;	chr8:8824682	chr8:8961200~8979025:+
LUAD	cis	rs28386778	0.734	rs7210724	ENSG00000240280.5	TCAM1P	-4.28	2.27e-05	0.004	-0.22	-0.19	Prudent dietary pattern;	chr17:63721838	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.897	rs1470697	ENSG00000240280.5	TCAM1P	-4.28	2.27e-05	0.004	-0.22	-0.19	Prudent dietary pattern;	chr17:63722480	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.897	rs57108948	ENSG00000240280.5	TCAM1P	-4.28	2.27e-05	0.004	-0.22	-0.19	Prudent dietary pattern;	chr17:63725018	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.897	rs7501614	ENSG00000240280.5	TCAM1P	-4.28	2.27e-05	0.004	-0.22	-0.19	Prudent dietary pattern;	chr17:63725252	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.897	rs10221279	ENSG00000240280.5	TCAM1P	-4.28	2.27e-05	0.004	-0.22	-0.19	Prudent dietary pattern;	chr17:63728778	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.687	rs59596917	ENSG00000240280.5	TCAM1P	-4.28	2.27e-05	0.004	-0.22	-0.19	Prudent dietary pattern;	chr17:63728904	chr17:63849292~63864379:+
LUAD	cis	rs13113518	0.783	rs1586555	ENSG00000272969.1	RP11-528I4.2	4.28	2.27e-05	0.004	0.21	0.19	Height;	chr4:55587104	chr4:55547112~55547889:+
LUAD	cis	rs853679	0.607	rs13211507	ENSG00000219392.1	RP1-265C24.5	-4.28	2.27e-05	0.004	-0.41	-0.19	Depression;	chr6:28289600	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.607	rs34691223	ENSG00000219392.1	RP1-265C24.5	-4.28	2.27e-05	0.004	-0.41	-0.19	Depression;	chr6:28290431	chr6:28115628~28116551:+
LUAD	cis	rs7772486	0.754	rs10872580	ENSG00000235652.6	RP11-545I5.3	-4.28	2.27e-05	0.004	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145819145	chr6:145799409~145886585:+
LUAD	cis	rs17685	0.753	rs8200	ENSG00000280388.1	RP11-229D13.3	4.28	2.27e-05	0.004	0.18	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76067288	chr7:76043977~76045963:-
LUAD	cis	rs12188164	0.582	rs80273890	ENSG00000221990.4	EXOC3-AS1	4.28	2.27e-05	0.004	0.2	0.19	Cystic fibrosis severity;	chr5:482942	chr5:441498~443160:-
LUAD	cis	rs7665090	1	rs2866407	ENSG00000246560.2	RP11-10L12.4	4.28	2.27e-05	0.004	0.23	0.19	Primary biliary cholangitis;	chr4:102632951	chr4:102828055~102844075:+
LUAD	cis	rs7665090	1	rs2866408	ENSG00000246560.2	RP11-10L12.4	4.28	2.27e-05	0.004	0.23	0.19	Primary biliary cholangitis;	chr4:102632956	chr4:102828055~102844075:+
LUAD	cis	rs9894429	1	rs7222241	ENSG00000263853.1	AC139530.1	-4.28	2.27e-05	0.004	-0.19	-0.19	Eye color traits;	chr17:81607688	chr17:81676001~81676086:+
LUAD	cis	rs2153535	0.585	rs9393053	ENSG00000230939.1	RP11-314C16.1	-4.28	2.28e-05	0.004	-0.21	-0.19	Motion sickness;	chr6:8644947	chr6:8784178~8785445:+
LUAD	cis	rs10129255	0.957	rs61997760	ENSG00000274576.2	IGHV2-70	4.28	2.28e-05	0.004	0.17	0.19	Kawasaki disease;	chr14:106716993	chr14:106770577~106771020:-
LUAD	cis	rs2243480	1	rs1039664	ENSG00000232559.3	GS1-124K5.12	4.28	2.28e-05	0.00401	0.32	0.19	Diabetic kidney disease;	chr7:65984729	chr7:66554588~66576923:-
LUAD	cis	rs8014252	0.614	rs60251828	ENSG00000259158.2	ADAM20P1	-4.28	2.28e-05	0.00401	-0.34	-0.19	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70594734	chr14:70468881~70483756:-
LUAD	cis	rs8014252	0.803	rs17108264	ENSG00000259158.2	ADAM20P1	-4.28	2.28e-05	0.00401	-0.34	-0.19	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70599767	chr14:70468881~70483756:-
LUAD	cis	rs8014252	0.803	rs57598551	ENSG00000259158.2	ADAM20P1	-4.28	2.28e-05	0.00401	-0.34	-0.19	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70601684	chr14:70468881~70483756:-
LUAD	cis	rs7555523	0.887	rs4657477	ENSG00000224358.1	RP11-466F5.8	-4.28	2.28e-05	0.00401	-0.32	-0.19	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165766938	chr1:165768929~165775176:+
LUAD	cis	rs8062405	0.755	rs4787455	ENSG00000261419.1	RP11-57A19.4	-4.28	2.28e-05	0.00401	-0.21	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28659696~28740781:-
LUAD	cis	rs2243480	1	rs313807	ENSG00000229886.1	RP5-1132H15.3	4.28	2.28e-05	0.00401	0.33	0.19	Diabetic kidney disease;	chr7:66034494	chr7:66025126~66031544:-
LUAD	cis	rs7208859	0.673	rs9907197	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.28e-05	0.00401	-0.23	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30691245	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs9915963	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.28e-05	0.00401	-0.23	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30692625	chr17:30738182~30740275:+
LUAD	cis	rs62246343	0.63	rs11542009	ENSG00000254485.4	RP11-380O24.1	4.28	2.28e-05	0.00401	0.36	0.19	Fibrinogen levels;	chr3:9475685	chr3:9292588~9363303:-
LUAD	cis	rs3814244	0.528	rs17104682	ENSG00000236946.2	HNRNPA1P70	4.28	2.28e-05	0.00401	0.17	0.19	Itch intensity from mosquito bite adjusted by bite size;	chr12:68033256	chr12:68035767~68036853:+
LUAD	cis	rs7208859	0.623	rs8075163	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.28e-05	0.00401	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30738182~30740275:+
LUAD	cis	rs17826219	0.706	rs8075107	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.28e-05	0.00401	-0.26	-0.19	Body mass index;	chr17:30779631	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs7223209	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.28e-05	0.00401	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs7223404	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.28e-05	0.00401	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs9916725	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.28e-05	0.00401	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs9916727	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.28e-05	0.00401	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs73269945	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.28e-05	0.00401	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs9897728	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.28e-05	0.00401	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs1054400	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.28e-05	0.00401	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs1054397	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.28e-05	0.00401	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs9890558	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.28e-05	0.00401	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs3752020	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.28e-05	0.00401	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs9890855	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.28e-05	0.00401	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs9893422	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.28e-05	0.00401	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs9891166	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.28e-05	0.00401	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs73269974	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.28e-05	0.00401	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs34756112	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.28e-05	0.00401	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.573	rs60724269	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.28e-05	0.00401	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs76633166	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.28e-05	0.00401	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs1061346	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.28e-05	0.00401	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs1061343	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.28e-05	0.00401	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs73269988	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.28e-05	0.00401	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs9899525	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.28e-05	0.00401	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs9911784	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.28e-05	0.00401	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs9911997	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.28e-05	0.00401	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs9890862	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.28e-05	0.00401	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs78071511	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.28e-05	0.00401	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs2035494	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.28e-05	0.00401	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs9915566	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.28e-05	0.00401	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.573	rs8064686	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.28e-05	0.00401	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs11657369	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.28e-05	0.00401	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs8075341	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.28e-05	0.00401	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs73271842	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.28e-05	0.00401	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.524	rs28760584	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.28e-05	0.00401	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs7212991	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.28e-05	0.00401	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs28627615	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.28e-05	0.00401	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30738182~30740275:+
LUAD	cis	rs7119038	0.818	rs10892288	ENSG00000255422.1	AP002954.4	4.28	2.28e-05	0.00401	0.3	0.19	Sjögren's syndrome;	chr11:118773985	chr11:118704607~118750263:+
LUAD	cis	rs7119038	0.818	rs10892289	ENSG00000255422.1	AP002954.4	4.28	2.28e-05	0.00401	0.3	0.19	Sjögren's syndrome;	chr11:118775294	chr11:118704607~118750263:+
LUAD	cis	rs7172677	0.711	rs8027552	ENSG00000260269.4	CTD-2323K18.1	-4.28	2.28e-05	0.00401	-0.25	-0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75147052	chr15:75527150~75601205:-
LUAD	cis	rs453301	0.624	rs2979265	ENSG00000253893.2	FAM85B	-4.28	2.28e-05	0.00401	-0.25	-0.19	Joint mobility (Beighton score);	chr8:9001207	chr8:8167819~8226614:-
LUAD	cis	rs9341808	0.754	rs6918172	ENSG00000260645.1	RP11-250B2.5	4.28	2.28e-05	0.00401	0.18	0.19	Sitting height ratio;	chr6:80309525	chr6:80466958~80469080:+
LUAD	cis	rs1075265	0.73	rs805391	ENSG00000233266.1	HMGB1P31	-4.28	2.28e-05	0.00401	-0.24	-0.19	Chronotype;Morning vs. evening chronotype;	chr2:53877181	chr2:54051334~54051760:+
LUAD	cis	rs17345786	0.511	rs1138818	ENSG00000244119.1	PDCL3P4	4.28	2.28e-05	0.00401	0.19	0.19	Colonoscopy-negative controls vs population controls;	chr3:101680739	chr3:101712472~101713191:+
LUAD	cis	rs8113308	0.81	rs17695737	ENSG00000269235.1	ZNF350-AS1	4.28	2.28e-05	0.00401	0.36	0.19	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51942283	chr19:51949134~51981367:+
LUAD	cis	rs7746199	0.673	rs35501037	ENSG00000219392.1	RP1-265C24.5	-4.28	2.28e-05	0.00401	-0.4	-0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27771787	chr6:28115628~28116551:+
LUAD	cis	rs2348418	0.864	rs2137071	ENSG00000244712.1	RP11-874G11.1	4.28	2.28e-05	0.00401	0.23	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28563797	chr12:28564678~28565141:-
LUAD	cis	rs1334894	0.901	rs7768598	ENSG00000228559.1	RP3-340B19.3	4.28	2.28e-05	0.00402	0.38	0.19	Coronary artery disease;	chr6:35552874	chr6:35544632~35545669:+
LUAD	cis	rs6452524	0.618	rs6452501	ENSG00000281327.1	LINC01338	4.28	2.29e-05	0.00402	0.2	0.19	Hypertension (SNP x SNP interaction);	chr5:83068681	chr5:82850864~82859836:-
LUAD	cis	rs7204230	1	rs12596346	ENSG00000261291.1	RP11-295M3.2	4.28	2.29e-05	0.00402	0.25	0.19	Fibrinogen;	chr16:53220264	chr16:53168522~53169450:+
LUAD	cis	rs699371	0.525	rs1156021	ENSG00000270000.1	RP3-449M8.9	4.28	2.29e-05	0.00402	0.21	0.19	Height;	chr14:74432889	chr14:74471930~74472360:-
LUAD	cis	rs12554020	0.582	rs2001609	ENSG00000227603.1	RP11-165J3.6	4.28	2.29e-05	0.00402	0.37	0.19	Schizophrenia;	chr9:93633081	chr9:93435332~93437121:-
LUAD	cis	rs7829975	0.606	rs11776838	ENSG00000173295.6	FAM86B3P	-4.28	2.29e-05	0.00402	-0.2	-0.19	Mood instability;	chr8:8937291	chr8:8228595~8244865:+
LUAD	cis	rs12579720	0.909	rs4344568	ENSG00000255910.1	RP11-405A12.2	4.28	2.29e-05	0.00402	0.24	0.19	Diastolic blood pressure;	chr12:20050493	chr12:19775451~20009937:+
LUAD	cis	rs2348418	0.831	rs2348416	ENSG00000247934.4	RP11-967K21.1	4.28	2.29e-05	0.00402	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28556283	chr12:28163298~28190738:-
LUAD	cis	rs28386778	0.897	rs2584640	ENSG00000240280.5	TCAM1P	-4.28	2.29e-05	0.00402	-0.22	-0.19	Prudent dietary pattern;	chr17:63786128	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.897	rs2584639	ENSG00000240280.5	TCAM1P	-4.28	2.29e-05	0.00402	-0.22	-0.19	Prudent dietary pattern;	chr17:63786372	chr17:63849292~63864379:+
LUAD	cis	rs2274273	0.712	rs17832311	ENSG00000258413.1	RP11-665C16.6	-4.28	2.29e-05	0.00402	-0.24	-0.19	Protein biomarker;	chr14:55067748	chr14:55262767~55272075:-
LUAD	cis	rs10129255	0.957	rs6576233	ENSG00000274576.2	IGHV2-70	4.28	2.29e-05	0.00403	0.17	0.19	Kawasaki disease;	chr14:106787239	chr14:106770577~106771020:-
LUAD	cis	rs7396835	0.866	rs6589571	ENSG00000280143.1	AP000892.6	4.28	2.29e-05	0.00403	0.3	0.19	Quantitative traits;	chr11:116809702	chr11:117204967~117210292:+
LUAD	cis	rs7208859	0.623	rs79607958	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.29e-05	0.00403	-0.28	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607530	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs75136574	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.29e-05	0.00403	-0.28	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607531	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs77544470	ENSG00000280069.1	CTD-2349P21.3	-4.28	2.29e-05	0.00403	-0.28	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607532	chr17:30738182~30740275:+
LUAD	cis	rs1401999	1	rs10937158	ENSG00000223882.1	ABCC5-AS1	-4.28	2.29e-05	0.00403	-0.2	-0.19	Anterior chamber depth;	chr3:183990651	chr3:184006338~184011419:+
LUAD	cis	rs28386778	0.897	rs7207005	ENSG00000240280.5	TCAM1P	-4.28	2.29e-05	0.00403	-0.22	-0.19	Prudent dietary pattern;	chr17:63782995	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.897	rs896064	ENSG00000240280.5	TCAM1P	-4.28	2.29e-05	0.00403	-0.22	-0.19	Prudent dietary pattern;	chr17:63783572	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.83	rs2665841	ENSG00000240280.5	TCAM1P	-4.28	2.29e-05	0.00403	-0.22	-0.19	Prudent dietary pattern;	chr17:63783859	chr17:63849292~63864379:+
LUAD	cis	rs1876905	0.597	rs191631	ENSG00000255389.1	C6orf3	4.28	2.29e-05	0.00403	0.27	0.19	Mean corpuscular hemoglobin;	chr6:111226862	chr6:111599875~111602295:+
LUAD	cis	rs4664293	0.967	rs10803758	ENSG00000230783.1	AC009961.2	-4.28	2.29e-05	0.00403	-0.23	-0.19	Monocyte percentage of white cells;	chr2:159691708	chr2:159689217~159690291:-
LUAD	cis	rs2028299	0.92	rs1866476	ENSG00000259677.1	RP11-493E3.1	4.28	2.3e-05	0.00403	0.23	0.19	Type 2 diabetes;	chr15:89885311	chr15:89876540~89877285:+
LUAD	cis	rs11723261	0.621	rs6599307	ENSG00000211553.1	AC253576.2	-4.28	2.3e-05	0.00403	-0.26	-0.19	Immune response to smallpox vaccine (IL-6);	chr4:149993	chr4:136461~136568:+
LUAD	cis	rs848490	0.851	rs11761228	ENSG00000214293.7	APTR	4.28	2.3e-05	0.00403	0.25	0.19	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77833181	chr7:77657660~77696265:-
LUAD	cis	rs8064024	0.676	rs56919624	ENSG00000267077.1	RP11-127I20.5	4.28	2.3e-05	0.00404	0.23	0.19	Cancer;	chr16:4827592	chr16:4795265~4796532:-
LUAD	cis	rs2337406	0.587	rs10150642	ENSG00000223648.3	IGHV3-64	-4.28	2.3e-05	0.00404	-0.22	-0.19	Alzheimer's disease (late onset);	chr14:106647269	chr14:106643132~106658258:-
LUAD	cis	rs8062405	0.723	rs35175818	ENSG00000251417.2	RP11-1348G14.4	-4.28	2.3e-05	0.00404	-0.2	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597425	chr16:28802743~28817828:+
LUAD	cis	rs6840360	0.642	rs2709817	ENSG00000270265.1	RP11-731D1.4	-4.28	2.3e-05	0.00404	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151460898	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.642	rs2709818	ENSG00000270265.1	RP11-731D1.4	-4.28	2.3e-05	0.00404	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151461482	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.642	rs2709820	ENSG00000270265.1	RP11-731D1.4	-4.28	2.3e-05	0.00404	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151462887	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.642	rs7682770	ENSG00000270265.1	RP11-731D1.4	-4.28	2.3e-05	0.00404	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151469261	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.667	rs9994482	ENSG00000270265.1	RP11-731D1.4	-4.28	2.3e-05	0.00404	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151470078	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.642	rs7676059	ENSG00000270265.1	RP11-731D1.4	-4.28	2.3e-05	0.00404	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151472115	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.642	rs7657747	ENSG00000270265.1	RP11-731D1.4	-4.28	2.3e-05	0.00404	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151473102	chr4:151333775~151353224:-
LUAD	cis	rs9467773	1	rs6456733	ENSG00000261353.1	CTA-14H9.5	-4.28	2.3e-05	0.00404	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26566576	chr6:26527063~26527404:+
LUAD	cis	rs16944613	0.636	rs6416552	ENSG00000259212.1	CTD-3065B20.2	4.28	2.3e-05	0.00404	0.31	0.19	Colorectal cancer;	chr15:90588879	chr15:90595840~90596447:-
LUAD	cis	rs6095360	0.727	rs6095391	ENSG00000222365.1	SNORD12B	-4.28	2.3e-05	0.00404	-0.22	-0.19	Intelligence (multi-trait analysis);	chr20:49002298	chr20:49280319~49280409:+
LUAD	cis	rs3096299	0.685	rs12935112	ENSG00000261118.1	RP11-104N10.1	-4.28	2.3e-05	0.00404	-0.19	-0.19	Multiple myeloma (IgH translocation);	chr16:89476450	chr16:89492017~89504460:-
LUAD	cis	rs763121	0.853	rs5757196	ENSG00000228274.3	RP3-508I15.9	-4.28	2.3e-05	0.00404	-0.19	-0.19	Menopause (age at onset);	chr22:38643850	chr22:38667585~38681820:-
LUAD	cis	rs763121	0.785	rs5757199	ENSG00000228274.3	RP3-508I15.9	-4.28	2.3e-05	0.00404	-0.19	-0.19	Menopause (age at onset);	chr22:38644612	chr22:38667585~38681820:-
LUAD	cis	rs763121	0.853	rs7289577	ENSG00000228274.3	RP3-508I15.9	-4.28	2.3e-05	0.00404	-0.19	-0.19	Menopause (age at onset);	chr22:38646209	chr22:38667585~38681820:-
LUAD	cis	rs763121	0.853	rs5757200	ENSG00000228274.3	RP3-508I15.9	-4.28	2.3e-05	0.00404	-0.19	-0.19	Menopause (age at onset);	chr22:38647486	chr22:38667585~38681820:-
LUAD	cis	rs763121	0.853	rs5757203	ENSG00000228274.3	RP3-508I15.9	-4.28	2.3e-05	0.00404	-0.19	-0.19	Menopause (age at onset);	chr22:38648147	chr22:38667585~38681820:-
LUAD	cis	rs763121	0.853	rs2205802	ENSG00000228274.3	RP3-508I15.9	-4.28	2.3e-05	0.00404	-0.19	-0.19	Menopause (age at onset);	chr22:38650322	chr22:38667585~38681820:-
LUAD	cis	rs763121	0.853	rs5757204	ENSG00000228274.3	RP3-508I15.9	-4.28	2.3e-05	0.00404	-0.19	-0.19	Menopause (age at onset);	chr22:38650695	chr22:38667585~38681820:-
LUAD	cis	rs763121	0.853	rs8138996	ENSG00000228274.3	RP3-508I15.9	-4.28	2.3e-05	0.00404	-0.19	-0.19	Menopause (age at onset);	chr22:38651430	chr22:38667585~38681820:-
LUAD	cis	rs763121	0.853	rs6001182	ENSG00000228274.3	RP3-508I15.9	-4.28	2.3e-05	0.00404	-0.19	-0.19	Menopause (age at onset);	chr22:38651438	chr22:38667585~38681820:-
LUAD	cis	rs11122895	0.716	rs7580929	ENSG00000236307.2	EEF1E1P1	4.28	2.3e-05	0.00404	0.21	0.19	Allergic sensitization;	chr2:111713904	chr2:111887914~111888741:+
LUAD	cis	rs2337406	0.866	rs988130	ENSG00000223648.3	IGHV3-64	4.28	2.3e-05	0.00404	0.23	0.19	Alzheimer's disease (late onset);	chr14:106777154	chr14:106643132~106658258:-
LUAD	cis	rs4237845	0.537	rs4237844	ENSG00000245651.2	RP11-620J15.2	-4.28	2.3e-05	0.00404	-0.2	-0.19	Intelligence (multi-trait analysis);	chr12:57874204	chr12:57869835~57896482:-
LUAD	cis	rs6785206	0.892	rs2712429	ENSG00000242551.2	POU5F1P6	-4.28	2.3e-05	0.00404	-0.36	-0.19	Lymphocyte percentage of white cells;	chr3:128617378	chr3:128674735~128677005:-
LUAD	cis	rs1005277	0.505	rs10827836	ENSG00000273019.1	RP11-508N22.13	4.28	2.3e-05	0.00404	0.21	0.19	Extrinsic epigenetic age acceleration;	chr10:37926513	chr10:38149968~38150293:+
LUAD	cis	rs1008375	0.966	rs11947836	ENSG00000249502.1	AC006160.5	4.28	2.3e-05	0.00405	0.18	0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17695564	chr4:17587467~17614571:-
LUAD	cis	rs2933343	0.729	rs6767104	ENSG00000261159.1	RP11-723O4.9	-4.28	2.3e-05	0.00405	-0.21	-0.19	IgG glycosylation;	chr3:128929274	chr3:128859716~128860526:-
LUAD	cis	rs17122278	1	rs7929887	ENSG00000243431.1	RPL5P30	4.28	2.3e-05	0.00405	0.24	0.19	Total cholesterol levels;	chr11:118558076	chr11:118560690~118561580:+
LUAD	cis	rs2243480	1	rs160655	ENSG00000226002.1	RP11-460N20.5	-4.28	2.3e-05	0.00405	-0.31	-0.19	Diabetic kidney disease;	chr7:66068227	chr7:65084103~65100232:+
LUAD	cis	rs72634501	0.568	rs590214	ENSG00000182109.6	RP11-69E11.4	4.28	2.31e-05	0.00405	0.21	0.19	HDL cholesterol;	chr1:39146821	chr1:39522280~39546187:-
LUAD	cis	rs6687758	0.687	rs17011141	ENSG00000200033.1	RNU6-403P	4.28	2.31e-05	0.00405	0.25	0.19	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221939292	chr1:221837334~221837437:-
LUAD	cis	rs6142102	0.961	rs6059587	ENSG00000275784.1	RP5-1125A11.6	-4.27	2.31e-05	0.00405	-0.21	-0.19	Skin pigmentation;	chr20:33955120	chr20:33989480~33991818:-
LUAD	cis	rs5769707	0.616	rs135869	ENSG00000235111.1	RP1-29C18.8	-4.27	2.31e-05	0.00405	-0.24	-0.19	Monocyte percentage of white cells;Monocyte count;	chr22:49614718	chr22:49612657~49615716:-
LUAD	cis	rs1876905	0.539	rs240956	ENSG00000230177.1	RP5-1112D6.4	4.27	2.31e-05	0.00405	0.23	0.19	Mean corpuscular hemoglobin;	chr6:111294848	chr6:111277932~111278742:+
LUAD	cis	rs6840360	0.642	rs4696089	ENSG00000270265.1	RP11-731D1.4	-4.27	2.31e-05	0.00405	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151474581	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.642	rs11932398	ENSG00000270265.1	RP11-731D1.4	-4.27	2.31e-05	0.00405	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151476402	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.642	rs4263379	ENSG00000270265.1	RP11-731D1.4	-4.27	2.31e-05	0.00405	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151477979	chr4:151333775~151353224:-
LUAD	cis	rs6964587	0.967	rs12531966	ENSG00000188693.7	CYP51A1-AS1	-4.27	2.31e-05	0.00405	-0.23	-0.19	Breast cancer;	chr7:92136526	chr7:92134604~92180725:+
LUAD	cis	rs1005277	0.505	rs1208689	ENSG00000263064.2	RP11-291L22.7	4.27	2.31e-05	0.00405	0.2	0.19	Extrinsic epigenetic age acceleration;	chr10:37808847	chr10:38448689~38448949:+
LUAD	cis	rs3177980	0.559	rs12089057	ENSG00000239494.2	RN7SL333P	-4.27	2.31e-05	0.00405	-0.19	-0.19	Amyotrophic lateral sclerosis;	chr1:169876615	chr1:169859756~169860052:+
LUAD	cis	rs9649213	0.593	rs7795176	ENSG00000272950.1	RP11-307C18.1	4.27	2.31e-05	0.00405	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98348975	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.593	rs62478200	ENSG00000272950.1	RP11-307C18.1	4.27	2.31e-05	0.00405	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98350733	chr7:98322853~98323430:+
LUAD	cis	rs2304003	1	rs4667844	ENSG00000235192.1	AC009495.2	4.27	2.31e-05	0.00405	0.23	0.19	Social communication problems;	chr2:165844614	chr2:165794851~165810010:+
LUAD	cis	rs2711721	0.56	rs2711716	ENSG00000274723.1	RP11-618L22.1	4.27	2.31e-05	0.00405	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr12:46980238	chr12:46970504~46972155:+
LUAD	cis	rs9649213	0.555	rs67132564	ENSG00000272950.1	RP11-307C18.1	4.27	2.31e-05	0.00405	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98385588	chr7:98322853~98323430:+
LUAD	cis	rs7005380	0.561	rs7818471	ENSG00000279347.1	RP11-85I17.2	-4.27	2.31e-05	0.00405	-0.16	-0.19	Interstitial lung disease;	chr8:119897596	chr8:119838736~119840385:-
LUAD	cis	rs28386778	0.897	rs1982400	ENSG00000240280.5	TCAM1P	-4.27	2.31e-05	0.00405	-0.22	-0.19	Prudent dietary pattern;	chr17:63716458	chr17:63849292~63864379:+
LUAD	cis	rs891378	1	rs1507761	ENSG00000274245.1	RP11-357P18.2	4.27	2.31e-05	0.00405	0.25	0.19	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207336454	chr1:207372559~207373252:+
LUAD	cis	rs7017914	0.667	rs13277069	ENSG00000223220.1	Y_RNA	4.27	2.31e-05	0.00406	0.23	0.19	Bone mineral density;	chr8:71097296	chr8:70780914~70781008:-
LUAD	cis	rs28386778	0.897	rs6504176	ENSG00000240280.5	TCAM1P	-4.27	2.31e-05	0.00406	-0.22	-0.19	Prudent dietary pattern;	chr17:63734560	chr17:63849292~63864379:+
LUAD	cis	rs11157436	0.602	rs11157439	ENSG00000211812.1	TRAV26-2	-4.27	2.31e-05	0.00406	-0.19	-0.19	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22171061	chr14:22202583~22203368:+
LUAD	cis	rs28735056	0.508	rs67651675	ENSG00000261126.6	RP11-795F19.1	-4.27	2.31e-05	0.00406	-0.19	-0.19	Schizophrenia;	chr18:79913562	chr18:80046900~80095482:+
LUAD	cis	rs28386778	0.897	rs8073515	ENSG00000240280.5	TCAM1P	-4.27	2.31e-05	0.00406	-0.22	-0.19	Prudent dietary pattern;	chr17:63717968	chr17:63849292~63864379:+
LUAD	cis	rs6539288	0.901	rs2041894	ENSG00000260329.1	RP11-412D9.4	-4.27	2.31e-05	0.00406	-0.21	-0.19	Total body bone mineral density;	chr12:106956389	chr12:106954029~106955497:-
LUAD	cis	rs293748	0.771	rs13184774	ENSG00000250155.1	CTD-2353F22.1	-4.27	2.31e-05	0.00406	-0.26	-0.19	Obesity-related traits;	chr5:36803578	chr5:36666214~36725195:-
LUAD	cis	rs293748	0.713	rs292162	ENSG00000250155.1	CTD-2353F22.1	-4.27	2.31e-05	0.00406	-0.26	-0.19	Obesity-related traits;	chr5:36803778	chr5:36666214~36725195:-
LUAD	cis	rs293748	0.771	rs292166	ENSG00000250155.1	CTD-2353F22.1	-4.27	2.31e-05	0.00406	-0.26	-0.19	Obesity-related traits;	chr5:36805367	chr5:36666214~36725195:-
LUAD	cis	rs3770081	1	rs17027011	ENSG00000273080.1	RP11-301O19.1	-4.27	2.31e-05	0.00406	-0.42	-0.19	Facial emotion recognition (sad faces);	chr2:86179433	chr2:86195590~86196049:+
LUAD	cis	rs6687758	1	rs66666316	ENSG00000227925.1	RP11-191N8.2	4.27	2.31e-05	0.00406	0.28	0.19	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222018592	chr1:221827666~221840666:-
LUAD	cis	rs9649213	0.593	rs1859482	ENSG00000272950.1	RP11-307C18.1	4.27	2.31e-05	0.00406	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98354462	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.593	rs13246868	ENSG00000272950.1	RP11-307C18.1	4.27	2.31e-05	0.00406	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98357141	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.593	rs12672092	ENSG00000272950.1	RP11-307C18.1	4.27	2.31e-05	0.00406	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98357245	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.593	rs7776638	ENSG00000272950.1	RP11-307C18.1	4.27	2.31e-05	0.00406	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98364194	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.574	rs36099592	ENSG00000272950.1	RP11-307C18.1	4.27	2.31e-05	0.00406	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98373019	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.502	rs6465680	ENSG00000272950.1	RP11-307C18.1	4.27	2.31e-05	0.00406	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98376466	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.593	rs3779194	ENSG00000272950.1	RP11-307C18.1	4.27	2.31e-05	0.00406	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98380965	chr7:98322853~98323430:+
LUAD	cis	rs4372836	0.964	rs2045884	ENSG00000226833.4	AC097724.3	4.27	2.31e-05	0.00406	0.23	0.19	Body mass index;	chr2:28741489	chr2:28708953~28736205:-
LUAD	cis	rs911555	0.662	rs4906322	ENSG00000244691.1	RPL10AP1	4.27	2.31e-05	0.00406	0.26	0.19	Intelligence (multi-trait analysis);	chr14:103412695	chr14:103412119~103412761:-
LUAD	cis	rs800160	1	rs800156	ENSG00000236264.4	RPL26P30	-4.27	2.31e-05	0.00406	-0.26	-0.19	Bacteremia;	chr11:2355206	chr11:2335132~2335776:-
LUAD	cis	rs2348418	0.864	rs7977817	ENSG00000244712.1	RP11-874G11.1	4.27	2.31e-05	0.00406	0.23	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28562549	chr12:28564678~28565141:-
LUAD	cis	rs2348418	0.831	rs7977525	ENSG00000244712.1	RP11-874G11.1	4.27	2.31e-05	0.00406	0.23	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28562584	chr12:28564678~28565141:-
LUAD	cis	rs2348418	0.864	rs7977850	ENSG00000244712.1	RP11-874G11.1	4.27	2.31e-05	0.00406	0.23	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28562715	chr12:28564678~28565141:-
LUAD	cis	rs2348418	0.864	rs7978086	ENSG00000244712.1	RP11-874G11.1	4.27	2.31e-05	0.00406	0.23	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28562761	chr12:28564678~28565141:-
LUAD	cis	rs2348418	0.864	rs11609924	ENSG00000244712.1	RP11-874G11.1	4.27	2.31e-05	0.00406	0.23	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28563197	chr12:28564678~28565141:-
LUAD	cis	rs2348418	0.864	rs7968563	ENSG00000244712.1	RP11-874G11.1	4.27	2.31e-05	0.00406	0.23	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28563844	chr12:28564678~28565141:-
LUAD	cis	rs2348418	0.864	rs2137072	ENSG00000244712.1	RP11-874G11.1	4.27	2.31e-05	0.00406	0.23	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28563872	chr12:28564678~28565141:-
LUAD	cis	rs726288	1	rs11200985	ENSG00000225484.5	NUTM2B-AS1	4.27	2.31e-05	0.00406	0.44	0.19	Rheumatoid arthritis;	chr10:79972897	chr10:79663088~79826594:-
LUAD	cis	rs911555	0.723	rs6575982	ENSG00000244691.1	RPL10AP1	4.27	2.31e-05	0.00406	0.25	0.19	Intelligence (multi-trait analysis);	chr14:103396344	chr14:103412119~103412761:-
LUAD	cis	rs4660214	0.666	rs7538300	ENSG00000228060.1	RP11-69E11.8	4.27	2.32e-05	0.00406	0.17	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39187092	chr1:39565160~39573203:+
LUAD	cis	rs6012564	0.964	rs6125577	ENSG00000230758.1	SNAP23P	4.27	2.32e-05	0.00406	0.2	0.19	Anger;	chr20:49166558	chr20:49038357~49038602:-
LUAD	cis	rs57502260	0.704	rs41478448	ENSG00000212093.1	AP000807.1	4.27	2.32e-05	0.00406	0.25	0.19	Total body bone mineral density (age 45-60);	chr11:68414153	chr11:68506083~68506166:-
LUAD	cis	rs2337406	0.866	rs4773949	ENSG00000211972.2	IGHV3-66	-4.27	2.32e-05	0.00406	-0.19	-0.19	Alzheimer's disease (late onset);	chr14:106808070	chr14:106675017~106675544:-
LUAD	cis	rs11122895	0.716	rs11122898	ENSG00000236307.2	EEF1E1P1	4.27	2.32e-05	0.00406	0.21	0.19	Allergic sensitization;	chr2:111716597	chr2:111887914~111888741:+
LUAD	cis	rs7968440	1	rs10747586	ENSG00000200428.1	Y_RNA	4.27	2.32e-05	0.00406	0.24	0.19	Fibrinogen;	chr12:50589782	chr12:50743568~50743684:+
LUAD	cis	rs17772222	0.74	rs7143642	ENSG00000258983.2	RP11-507K2.2	4.27	2.32e-05	0.00406	0.22	0.19	Coronary artery calcification;	chr14:88507616	chr14:88499334~88515502:+
LUAD	cis	rs9649213	0.613	rs6961129	ENSG00000272950.1	RP11-307C18.1	4.27	2.32e-05	0.00406	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98346230	chr7:98322853~98323430:+
LUAD	cis	rs9545047	0.604	rs2265381	ENSG00000227354.5	RBM26-AS1	-4.27	2.32e-05	0.00406	-0.2	-0.19	Schizophrenia;	chr13:79425903	chr13:79406309~79424328:+
LUAD	cis	rs7005380	0.525	rs7000068	ENSG00000279347.1	RP11-85I17.2	-4.27	2.32e-05	0.00406	-0.18	-0.19	Interstitial lung disease;	chr8:119910723	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.538	rs7000488	ENSG00000279347.1	RP11-85I17.2	-4.27	2.32e-05	0.00406	-0.18	-0.19	Interstitial lung disease;	chr8:119911059	chr8:119838736~119840385:-
LUAD	cis	rs9652601	0.959	rs12928537	ENSG00000274038.1	RP11-66H6.4	-4.27	2.32e-05	0.00407	-0.24	-0.19	Systemic lupus erythematosus;	chr16:11097543	chr16:11056556~11057034:+
LUAD	cis	rs62025270	0.631	rs55968154	ENSG00000202081.1	RNU6-1280P	-4.27	2.32e-05	0.00407	-0.28	-0.19	Idiopathic pulmonary fibrosis;	chr15:85725399	chr15:85651522~85651628:-
LUAD	cis	rs62025270	0.688	rs55851385	ENSG00000202081.1	RNU6-1280P	-4.27	2.32e-05	0.00407	-0.28	-0.19	Idiopathic pulmonary fibrosis;	chr15:85725400	chr15:85651522~85651628:-
LUAD	cis	rs10971721	0.822	rs10971807	ENSG00000260947.1	RP11-384P7.7	4.27	2.32e-05	0.00407	0.39	0.19	Body mass index;	chr9:33939557	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs72727345	ENSG00000260947.1	RP11-384P7.7	4.27	2.32e-05	0.00407	0.39	0.19	Body mass index;	chr9:33940200	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs72727346	ENSG00000260947.1	RP11-384P7.7	4.27	2.32e-05	0.00407	0.39	0.19	Body mass index;	chr9:33940420	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs72727350	ENSG00000260947.1	RP11-384P7.7	4.27	2.32e-05	0.00407	0.39	0.19	Body mass index;	chr9:33944732	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs72727351	ENSG00000260947.1	RP11-384P7.7	4.27	2.32e-05	0.00407	0.39	0.19	Body mass index;	chr9:33950434	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs72727353	ENSG00000260947.1	RP11-384P7.7	4.27	2.32e-05	0.00407	0.39	0.19	Body mass index;	chr9:33950824	chr9:33697459~33700986:+
LUAD	cis	rs1075265	0.73	rs6713088	ENSG00000272156.1	RP11-477N3.1	-4.27	2.32e-05	0.00407	-0.23	-0.19	Chronotype;Morning vs. evening chronotype;	chr2:54118332	chr2:54082554~54085066:+
LUAD	cis	rs10129255	0.957	rs10142859	ENSG00000274576.2	IGHV2-70	4.27	2.32e-05	0.00407	0.17	0.19	Kawasaki disease;	chr14:106782238	chr14:106770577~106771020:-
LUAD	cis	rs853679	0.517	rs9393891	ENSG00000226314.6	ZNF192P1	-4.27	2.32e-05	0.00407	-0.25	-0.19	Depression;	chr6:28111382	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs9468286	ENSG00000226314.6	ZNF192P1	-4.27	2.32e-05	0.00407	-0.25	-0.19	Depression;	chr6:28111650	chr6:28161781~28169594:+
LUAD	cis	rs12073359	0.908	rs11589801	ENSG00000223945.2	RP11-458I7.1	-4.27	2.32e-05	0.00407	-0.29	-0.19	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150168635	chr1:150053864~150055034:+
LUAD	cis	rs9341808	0.754	rs10733162	ENSG00000260645.1	RP11-250B2.5	4.27	2.32e-05	0.00407	0.18	0.19	Sitting height ratio;	chr6:80313672	chr6:80466958~80469080:+
LUAD	cis	rs9400467	0.528	rs6568680	ENSG00000230177.1	RP5-1112D6.4	-4.27	2.32e-05	0.00407	-0.17	-0.19	Amino acid levels;Blood metabolite levels;	chr6:111454961	chr6:111277932~111278742:+
LUAD	cis	rs4811196	0.692	rs4811237	ENSG00000226144.2	RPS27AP3	4.27	2.32e-05	0.00407	0.21	0.19	Bone mineral density;	chr20:37861497	chr20:37049254~37049707:+
LUAD	cis	rs6751744	0.514	rs12386214	ENSG00000230783.1	AC009961.2	-4.27	2.32e-05	0.00407	-0.23	-0.19	Dysphagia;	chr2:159675012	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.932	rs4665104	ENSG00000230783.1	AC009961.2	-4.27	2.32e-05	0.00407	-0.23	-0.19	Monocyte percentage of white cells;	chr2:159675847	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.967	rs7595639	ENSG00000230783.1	AC009961.2	-4.27	2.32e-05	0.00407	-0.23	-0.19	Monocyte percentage of white cells;	chr2:159676533	chr2:159689217~159690291:-
LUAD	cis	rs651907	0.514	rs11706494	ENSG00000244119.1	PDCL3P4	4.27	2.32e-05	0.00407	0.19	0.19	Colorectal cancer;	chr3:101790631	chr3:101712472~101713191:+
LUAD	cis	rs651907	0.535	rs34063583	ENSG00000244119.1	PDCL3P4	4.27	2.32e-05	0.00407	0.19	0.19	Colorectal cancer;	chr3:101791104	chr3:101712472~101713191:+
LUAD	cis	rs8077577	0.708	rs59366579	ENSG00000273018.4	CTD-2303H24.2	-4.27	2.32e-05	0.00407	-0.26	-0.19	Obesity-related traits;	chr17:18258430	chr17:18511221~18551705:-
LUAD	cis	rs9860428	0.844	rs9826834	ENSG00000242770.2	RP11-180K7.1	4.27	2.32e-05	0.00407	0.21	0.19	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112858340	chr3:112802478~112812819:+
LUAD	cis	rs9860428	0.844	rs6781547	ENSG00000242770.2	RP11-180K7.1	4.27	2.32e-05	0.00407	0.21	0.19	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112864167	chr3:112802478~112812819:+
LUAD	cis	rs2348418	0.83	rs4930821	ENSG00000247934.4	RP11-967K21.1	4.27	2.32e-05	0.00407	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28410948	chr12:28163298~28190738:-
LUAD	cis	rs7743045	0.548	rs2357023	ENSG00000253194.1	RP11-351A11.1	-4.27	2.32e-05	0.00407	-0.23	-0.19	Mean platelet volume;	chr6:119023364	chr6:118934785~119031541:+
LUAD	cis	rs172166	0.769	rs149965	ENSG00000216901.1	AL022393.7	4.27	2.32e-05	0.00407	0.23	0.19	Cardiac Troponin-T levels;	chr6:28050911	chr6:28176188~28176674:+
LUAD	cis	rs17685	0.753	rs1639609	ENSG00000280388.1	RP11-229D13.3	-4.27	2.32e-05	0.00408	-0.18	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76054263	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.753	rs1104878	ENSG00000280388.1	RP11-229D13.3	-4.27	2.32e-05	0.00408	-0.18	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76056275	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.712	rs869805	ENSG00000280388.1	RP11-229D13.3	-4.27	2.32e-05	0.00408	-0.18	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76059278	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.753	rs1637037	ENSG00000280388.1	RP11-229D13.3	-4.27	2.32e-05	0.00408	-0.18	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76063609	chr7:76043977~76045963:-
LUAD	cis	rs728616	0.681	rs11815284	ENSG00000234382.2	RP11-40F6.1	-4.27	2.32e-05	0.00408	-0.32	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80263386	chr10:80233664~80245367:+
LUAD	cis	rs950169	0.734	rs67119537	ENSG00000275120.1	RP11-182J1.17	4.27	2.32e-05	0.00408	0.28	0.19	Schizophrenia;	chr15:84395671	chr15:84599434~84606463:-
LUAD	cis	rs4763879	0.54	rs741200	ENSG00000278635.1	CTD-2318O12.1	4.27	2.32e-05	0.00408	0.17	0.19	Type 1 diabetes;	chr12:9717819	chr12:9415641~9416718:+
LUAD	cis	rs875971	0.508	rs6947808	ENSG00000236529.1	RP13-254B10.1	-4.27	2.32e-05	0.00408	-0.19	-0.19	Aortic root size;	chr7:66580095	chr7:65840212~65840596:+
LUAD	cis	rs1106529	0.515	rs1779428	ENSG00000226172.2	RP4-712E4.1	4.27	2.32e-05	0.00408	0.26	0.19	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);	chr1:118917306	chr1:119000344~119001392:-
LUAD	cis	rs1106529	0.515	rs1779429	ENSG00000226172.2	RP4-712E4.1	4.27	2.32e-05	0.00408	0.26	0.19	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);	chr1:118917858	chr1:119000344~119001392:-
LUAD	cis	rs6687758	0.687	rs12140529	ENSG00000227925.1	RP11-191N8.2	4.27	2.33e-05	0.00408	0.26	0.19	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221925411	chr1:221827666~221840666:-
LUAD	cis	rs703842	0.963	rs923829	ENSG00000270039.1	RP11-571M6.17	-4.27	2.33e-05	0.00408	-0.23	-0.19	Multiple sclerosis;	chr12:57780523	chr12:57803838~57804415:+
LUAD	cis	rs9601248	0.756	rs7997134	ENSG00000227676.3	LINC01068	-4.27	2.33e-05	0.00408	-0.24	-0.19	Major depressive disorder;	chr13:79619594	chr13:79566727~79571436:+
LUAD	cis	rs13113518	0.966	rs7668429	ENSG00000272969.1	RP11-528I4.2	4.27	2.33e-05	0.00408	0.2	0.19	Height;	chr4:55531811	chr4:55547112~55547889:+
LUAD	cis	rs28386778	0.897	rs2584601	ENSG00000240280.5	TCAM1P	-4.27	2.33e-05	0.00408	-0.22	-0.19	Prudent dietary pattern;	chr17:63863617	chr17:63849292~63864379:+
LUAD	cis	rs2028299	0.879	rs7163629	ENSG00000259677.1	RP11-493E3.1	4.27	2.33e-05	0.00408	0.23	0.19	Type 2 diabetes;	chr15:89873508	chr15:89876540~89877285:+
LUAD	cis	rs13113518	1	rs13116194	ENSG00000272969.1	RP11-528I4.2	4.27	2.33e-05	0.00408	0.2	0.19	Height;	chr4:55531150	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs13117836	ENSG00000272969.1	RP11-528I4.2	4.27	2.33e-05	0.00408	0.2	0.19	Height;	chr4:55531218	chr4:55547112~55547889:+
LUAD	cis	rs2288884	1	rs2043298	ENSG00000269959.1	SPACA6P-AS	4.27	2.33e-05	0.00408	0.24	0.19	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52069814	chr19:51685363~51693456:-
LUAD	cis	rs6686842	0.536	rs10493093	ENSG00000235358.1	RP11-399E6.1	-4.27	2.33e-05	0.00408	-0.22	-0.19	Height;	chr1:41236514	chr1:41242373~41284861:+
LUAD	cis	rs7102710	1	rs61883843	ENSG00000254418.1	RP11-21L19.1	4.27	2.33e-05	0.00408	0.45	0.19	Glucagon levels in response to oral glucose tolerance test (fasting);	chr11:14239172	chr11:14262846~14273691:-
LUAD	cis	rs8098244	0.708	rs1131521	ENSG00000264745.1	TTC39C-AS1	-4.27	2.33e-05	0.00408	-0.24	-0.19	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23933804	chr18:23994213~24015339:-
LUAD	cis	rs1008375	0.932	rs10029173	ENSG00000249502.1	AC006160.5	4.27	2.33e-05	0.00408	0.18	0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17657975	chr4:17587467~17614571:-
LUAD	cis	rs7204230	0.774	rs12596226	ENSG00000261291.1	RP11-295M3.2	4.27	2.33e-05	0.00408	0.24	0.19	Fibrinogen;	chr16:53334867	chr16:53168522~53169450:+
LUAD	cis	rs6061231	0.571	rs482010	ENSG00000273619.1	RP5-908M14.9	4.27	2.33e-05	0.00408	0.18	0.19	Colorectal cancer;	chr20:62352495	chr20:62386303~62386970:-
LUAD	cis	rs7772486	0.79	rs2254283	ENSG00000235652.6	RP11-545I5.3	4.27	2.33e-05	0.00408	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145883153	chr6:145799409~145886585:+
LUAD	cis	rs1799949	1	rs4793231	ENSG00000236383.6	LINC00854	-4.27	2.33e-05	0.00408	-0.15	-0.19	Menopause (age at onset);	chr17:43350101	chr17:43216941~43305976:-
LUAD	cis	rs1799955	0.935	rs7337574	ENSG00000215515.2	IFIT1P1	-4.27	2.33e-05	0.00409	-0.27	-0.19	LDL cholesterol levels;	chr13:32383682	chr13:32384660~32386108:+
LUAD	cis	rs34779708	0.931	rs2001893	ENSG00000271335.4	RP11-324I22.4	4.27	2.33e-05	0.00409	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35011695	chr10:35314552~35336401:-
LUAD	cis	rs6687758	1	rs6687758	ENSG00000200033.1	RNU6-403P	4.27	2.33e-05	0.00409	0.26	0.19	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221991606	chr1:221837334~221837437:-
LUAD	cis	rs6687758	0.945	rs17011182	ENSG00000227925.1	RP11-191N8.2	4.27	2.33e-05	0.00409	0.26	0.19	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221990985	chr1:221827666~221840666:-
LUAD	cis	rs17783634	0.509	rs11775489	ENSG00000255046.1	RP11-297N6.4	4.27	2.33e-05	0.00409	0.23	0.19	Subjective well-being;	chr8:11179334	chr8:11797928~11802568:-
LUAD	cis	rs4819052	0.851	rs2236445	ENSG00000237664.1	LINC00316	-4.27	2.33e-05	0.00409	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258538	chr21:45338590~45341990:-
LUAD	cis	rs1555322	0.505	rs639763	ENSG00000279253.1	RP4-614O4.13	-4.27	2.34e-05	0.00409	-0.24	-0.19	Attention deficit hyperactivity disorder;	chr20:35274101	chr20:35262727~35264187:-
LUAD	cis	rs9400467	0.528	rs6913769	ENSG00000230177.1	RP5-1112D6.4	-4.27	2.34e-05	0.00409	-0.17	-0.19	Amino acid levels;Blood metabolite levels;	chr6:111471694	chr6:111277932~111278742:+
LUAD	cis	rs2836950	0.545	rs2836956	ENSG00000232608.1	TIMM9P2	-4.27	2.34e-05	0.0041	-0.21	-0.19	Menarche (age at onset);	chr21:39251092	chr21:39216624~39217506:+
LUAD	cis	rs11673344	0.504	rs8109501	ENSG00000276846.1	CTD-3220F14.3	4.27	2.34e-05	0.0041	0.21	0.19	Obesity-related traits;	chr19:37102194	chr19:37314868~37315620:-
LUAD	cis	rs6751744	0.889	rs12692553	ENSG00000230783.1	AC009961.2	-4.27	2.34e-05	0.0041	-0.26	-0.19	Dysphagia;	chr2:159534337	chr2:159689217~159690291:-
LUAD	cis	rs10461617	0.531	rs2662033	ENSG00000271828.1	CTD-2310F14.1	4.27	2.34e-05	0.0041	0.27	0.19	Type 2 diabetes;	chr5:56917583	chr5:56927874~56929573:+
LUAD	cis	rs6142102	0.961	rs973409	ENSG00000275784.1	RP5-1125A11.6	-4.27	2.34e-05	0.0041	-0.21	-0.19	Skin pigmentation;	chr20:33948558	chr20:33989480~33991818:-
LUAD	cis	rs858239	0.899	rs5850	ENSG00000226816.2	AC005082.12	4.27	2.34e-05	0.0041	0.26	0.19	Cerebrospinal fluid biomarker levels;	chr7:23274928	chr7:23206013~23208045:+
LUAD	cis	rs11886999	0.812	rs12618133	ENSG00000237510.6	AC008268.2	-4.27	2.34e-05	0.0041	-0.31	-0.19	Cardiac Troponin-T levels;	chr2:96226396	chr2:95789654~95800166:+
LUAD	cis	rs2243480	0.908	rs55876148	ENSG00000226002.1	RP11-460N20.5	-4.27	2.34e-05	0.0041	-0.33	-0.19	Diabetic kidney disease;	chr7:65914813	chr7:65084103~65100232:+
LUAD	cis	rs10129255	0.957	rs2013423	ENSG00000211974.3	IGHV2-70	4.27	2.34e-05	0.0041	0.2	0.19	Kawasaki disease;	chr14:106690675	chr14:106723574~106724093:-
LUAD	cis	rs8072100	0.576	rs12948299	ENSG00000228782.6	CTD-2026D20.3	4.27	2.34e-05	0.0041	0.22	0.19	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47325691	chr17:47450568~47492492:-
LUAD	cis	rs11707813	0.593	rs28738855	ENSG00000226360.5	RPL10AP6	-4.27	2.34e-05	0.0041	-0.2	-0.19	Lip morphology;	chr3:61224796	chr3:61742455~61743106:-
LUAD	cis	rs4873772	0.802	rs4873619	ENSG00000253330.1	RP11-697N18.3	-4.27	2.34e-05	0.0041	-0.21	-0.19	Lobe attachment (rater-scored or self-reported);	chr8:47718125	chr8:47511034~47512141:-
LUAD	cis	rs7208859	0.673	rs73277967	ENSG00000266490.1	CTD-2349P21.9	4.27	2.34e-05	0.0041	0.3	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30857148	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs60020217	ENSG00000266490.1	CTD-2349P21.9	4.27	2.34e-05	0.0041	0.3	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30858036	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.573	rs73277974	ENSG00000266490.1	CTD-2349P21.9	4.27	2.34e-05	0.0041	0.3	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862851	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs73277978	ENSG00000266490.1	CTD-2349P21.9	4.27	2.34e-05	0.0041	0.3	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864431	chr17:30792372~30792833:+
LUAD	cis	rs17826219	0.706	rs9905827	ENSG00000266490.1	CTD-2349P21.9	4.27	2.34e-05	0.0041	0.3	0.19	Body mass index;	chr17:30865150	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs11657391	ENSG00000266490.1	CTD-2349P21.9	4.27	2.34e-05	0.0041	0.3	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30867269	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs58089675	ENSG00000266490.1	CTD-2349P21.9	4.27	2.34e-05	0.0041	0.3	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869746	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs73263755	ENSG00000266490.1	CTD-2349P21.9	4.27	2.34e-05	0.0041	0.3	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30871954	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs9899349	ENSG00000266490.1	CTD-2349P21.9	4.27	2.34e-05	0.0041	0.3	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30873104	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs11652358	ENSG00000266490.1	CTD-2349P21.9	4.27	2.34e-05	0.0041	0.3	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30878462	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs11656845	ENSG00000266490.1	CTD-2349P21.9	4.27	2.34e-05	0.0041	0.3	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30879146	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs9891179	ENSG00000266490.1	CTD-2349P21.9	4.27	2.34e-05	0.0041	0.3	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881142	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs9891413	ENSG00000266490.1	CTD-2349P21.9	4.27	2.34e-05	0.0041	0.3	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881191	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs73263776	ENSG00000266490.1	CTD-2349P21.9	4.27	2.34e-05	0.0041	0.3	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30884313	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs11650271	ENSG00000266490.1	CTD-2349P21.9	4.27	2.34e-05	0.0041	0.3	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30886925	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs73263785	ENSG00000266490.1	CTD-2349P21.9	4.27	2.34e-05	0.0041	0.3	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887790	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs55904046	ENSG00000266490.1	CTD-2349P21.9	4.27	2.34e-05	0.0041	0.3	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888373	chr17:30792372~30792833:+
LUAD	cis	rs858239	0.665	rs858305	ENSG00000226816.2	AC005082.12	-4.27	2.35e-05	0.00411	-0.24	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23206013~23208045:+
LUAD	cis	rs1023500	0.573	rs2269524	ENSG00000205702.9	CYP2D7	-4.27	2.35e-05	0.00411	-0.16	-0.19	Schizophrenia;	chr22:42079699	chr22:42140203~42144577:-
LUAD	cis	rs1023500	0.573	rs6002592	ENSG00000205702.9	CYP2D7	-4.27	2.35e-05	0.00411	-0.16	-0.19	Schizophrenia;	chr22:42080750	chr22:42140203~42144577:-
LUAD	cis	rs7107174	1	rs10793309	ENSG00000251323.2	RP11-452H21.4	4.27	2.35e-05	0.00411	0.23	0.19	Testicular germ cell tumor;	chr11:78382753	chr11:78423982~78429836:-
LUAD	cis	rs12474201	0.63	rs897529	ENSG00000279254.1	RP11-536C12.1	-4.27	2.35e-05	0.00411	-0.2	-0.19	Height;	chr2:46721036	chr2:46668870~46670778:+
LUAD	cis	rs2354432	0.505	rs72691009	ENSG00000226015.2	CCT8P1	4.27	2.35e-05	0.00411	0.38	0.19	Mitochondrial DNA levels;	chr1:147236749	chr1:147203276~147204932:-
LUAD	cis	rs1355223	0.872	rs12785367	ENSG00000271369.1	RP11-350D17.3	-4.27	2.35e-05	0.00411	-0.23	-0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34693722	chr11:34709600~34710161:+
LUAD	cis	rs1355223	0.902	rs11819839	ENSG00000271369.1	RP11-350D17.3	-4.27	2.35e-05	0.00411	-0.23	-0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34694231	chr11:34709600~34710161:+
LUAD	cis	rs2274273	0.743	rs7161656	ENSG00000258413.1	RP11-665C16.6	-4.27	2.35e-05	0.00411	-0.24	-0.19	Protein biomarker;	chr14:55057812	chr14:55262767~55272075:-
LUAD	cis	rs2976388	0.566	rs2585141	ENSG00000253741.1	CTD-2292P10.4	4.27	2.35e-05	0.00411	0.22	0.19	Urinary tract infection frequency;	chr8:142724925	chr8:142702252~142726973:-
LUAD	cis	rs73108077	1	rs12479885	ENSG00000281376.1	ABALON	-4.27	2.35e-05	0.00412	-0.33	-0.19	Red blood cell density in sickle cell anemia;	chr20:31398024	chr20:31721507~31723409:+
LUAD	cis	rs2243480	0.666	rs1880311	ENSG00000232559.3	GS1-124K5.12	-4.27	2.35e-05	0.00412	-0.35	-0.19	Diabetic kidney disease;	chr7:65811765	chr7:66554588~66576923:-
LUAD	cis	rs9921338	0.54	rs2868409	ENSG00000263080.1	RP11-485G7.5	4.27	2.35e-05	0.00412	0.23	0.19	Vein graft stenosis in coronary artery bypass grafting;	chr16:11323512	chr16:11341809~11345211:-
LUAD	cis	rs2898681	0.561	rs2200225	ENSG00000248375.1	RP11-177B4.1	-4.27	2.35e-05	0.00412	-0.31	-0.19	Optic nerve measurement (cup area);	chr4:52872244	chr4:52720081~52720831:-
LUAD	cis	rs4795519	0.961	rs12450669	ENSG00000266313.1	RP11-173M1.4	4.27	2.35e-05	0.00412	0.23	0.19	Chronic myeloid leukemia;	chr17:27190294	chr17:27333256~27348491:+
LUAD	cis	rs7119038	0.818	rs11217032	ENSG00000255422.1	AP002954.4	4.27	2.35e-05	0.00412	0.3	0.19	Sjögren's syndrome;	chr11:118798896	chr11:118704607~118750263:+
LUAD	cis	rs5758659	0.7	rs739294	ENSG00000182057.4	OGFRP1	4.27	2.35e-05	0.00412	0.24	0.19	Cognitive function;	chr22:41985722	chr22:42269753~42275196:+
LUAD	cis	rs858239	1	rs858239	ENSG00000230042.1	AK3P3	-4.27	2.35e-05	0.00412	-0.24	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23246696	chr7:23129178~23129841:+
LUAD	cis	rs4578769	0.55	rs11082182	ENSG00000265943.1	RP11-739L10.1	4.27	2.35e-05	0.00412	0.24	0.19	Eosinophil percentage of white cells;	chr18:22872136	chr18:22699481~22933764:-
LUAD	cis	rs4578769	0.531	rs11082183	ENSG00000265943.1	RP11-739L10.1	4.27	2.35e-05	0.00412	0.24	0.19	Eosinophil percentage of white cells;	chr18:22872137	chr18:22699481~22933764:-
LUAD	cis	rs11051970	0.636	rs325421	ENSG00000274964.1	RP11-817I4.1	-4.27	2.35e-05	0.00412	-0.2	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr12:32418661	chr12:32339368~32340724:+
LUAD	cis	rs1864585	0.552	rs17776497	ENSG00000255046.1	RP11-297N6.4	4.27	2.35e-05	0.00412	0.27	0.19	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10817652	chr8:11797928~11802568:-
LUAD	cis	rs2033711	0.783	rs11671113	ENSG00000268912.1	CTD-2619J13.17	-4.27	2.35e-05	0.00412	-0.2	-0.19	Uric acid clearance;	chr19:58446720	chr19:58428632~58431148:-
LUAD	cis	rs957448	1	rs16916874	ENSG00000254315.1	RP11-267M23.3	4.27	2.36e-05	0.00412	0.24	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94537749	chr8:94533628~94534391:+
LUAD	cis	rs17826219	0.706	rs609472	ENSG00000280069.1	CTD-2349P21.3	-4.27	2.36e-05	0.00412	-0.22	-0.19	Body mass index;	chr17:30624409	chr17:30738182~30740275:+
LUAD	cis	rs6840360	0.571	rs875667	ENSG00000270265.1	RP11-731D1.4	-4.27	2.36e-05	0.00412	-0.22	-0.19	Intelligence (multi-trait analysis);	chr4:151604325	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.571	rs4696102	ENSG00000270265.1	RP11-731D1.4	-4.27	2.36e-05	0.00412	-0.22	-0.19	Intelligence (multi-trait analysis);	chr4:151608506	chr4:151333775~151353224:-
LUAD	cis	rs9393777	0.841	rs13191474	ENSG00000219392.1	RP1-265C24.5	-4.27	2.36e-05	0.00412	-0.37	-0.19	Intelligence (multi-trait analysis);	chr6:27445566	chr6:28115628~28116551:+
LUAD	cis	rs875971	0.545	rs4441996	ENSG00000222364.1	RNU6-96P	4.27	2.36e-05	0.00412	0.24	0.19	Aortic root size;	chr7:66123233	chr7:66395191~66395286:+
LUAD	cis	rs7829975	0.582	rs6983150	ENSG00000173295.6	FAM86B3P	-4.27	2.36e-05	0.00413	-0.2	-0.19	Mood instability;	chr8:8934916	chr8:8228595~8244865:+
LUAD	cis	rs526231	0.644	rs35797	ENSG00000175749.11	EIF3KP1	-4.27	2.36e-05	0.00413	-0.23	-0.19	Primary biliary cholangitis;	chr5:103278626	chr5:103032376~103033031:+
LUAD	cis	rs2732480	0.577	rs2732448	ENSG00000240399.1	RP1-228P16.1	4.27	2.36e-05	0.00413	0.19	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48336817	chr12:48054813~48055591:-
LUAD	cis	rs7246657	0.943	rs10415024	ENSG00000226686.6	LINC01535	-4.27	2.36e-05	0.00413	-0.29	-0.19	Coronary artery calcification;	chr19:37323822	chr19:37251912~37265535:+
LUAD	cis	rs5769707	0.609	rs2071890	ENSG00000235111.1	RP1-29C18.8	-4.27	2.36e-05	0.00413	-0.23	-0.19	Monocyte percentage of white cells;Monocyte count;	chr22:49607643	chr22:49612657~49615716:-
LUAD	cis	rs12579720	0.868	rs2417823	ENSG00000255910.1	RP11-405A12.2	4.27	2.36e-05	0.00413	0.24	0.19	Diastolic blood pressure;	chr12:20035157	chr12:19775451~20009937:+
LUAD	cis	rs12579720	0.909	rs10770609	ENSG00000255910.1	RP11-405A12.2	4.27	2.36e-05	0.00413	0.24	0.19	Diastolic blood pressure;	chr12:20036687	chr12:19775451~20009937:+
LUAD	cis	rs12579720	0.909	rs2417821	ENSG00000255910.1	RP11-405A12.2	4.27	2.36e-05	0.00413	0.24	0.19	Diastolic blood pressure;	chr12:20037334	chr12:19775451~20009937:+
LUAD	cis	rs12579720	0.909	rs2417820	ENSG00000255910.1	RP11-405A12.2	4.27	2.36e-05	0.00413	0.24	0.19	Diastolic blood pressure;	chr12:20037540	chr12:19775451~20009937:+
LUAD	cis	rs12579720	0.909	rs4306343	ENSG00000255910.1	RP11-405A12.2	4.27	2.36e-05	0.00413	0.24	0.19	Diastolic blood pressure;	chr12:20037696	chr12:19775451~20009937:+
LUAD	cis	rs12579720	0.868	rs4529947	ENSG00000255910.1	RP11-405A12.2	4.27	2.36e-05	0.00413	0.24	0.19	Diastolic blood pressure;	chr12:20038142	chr12:19775451~20009937:+
LUAD	cis	rs12579720	0.909	rs2417817	ENSG00000255910.1	RP11-405A12.2	4.27	2.36e-05	0.00413	0.24	0.19	Diastolic blood pressure;	chr12:20038727	chr12:19775451~20009937:+
LUAD	cis	rs12579720	0.909	rs4409914	ENSG00000255910.1	RP11-405A12.2	4.27	2.36e-05	0.00413	0.24	0.19	Diastolic blood pressure;	chr12:20038966	chr12:19775451~20009937:+
LUAD	cis	rs4873772	0.837	rs4489323	ENSG00000253330.1	RP11-697N18.3	-4.27	2.36e-05	0.00413	-0.21	-0.19	Lobe attachment (rater-scored or self-reported);	chr8:47679430	chr8:47511034~47512141:-
LUAD	cis	rs6479891	1	rs9415705	ENSG00000232075.1	MRPL35P2	4.27	2.36e-05	0.00413	0.29	0.19	Arthritis (juvenile idiopathic);	chr10:63401790	chr10:63634317~63634827:-
LUAD	cis	rs5769707	0.605	rs6009791	ENSG00000235111.1	RP1-29C18.8	-4.27	2.36e-05	0.00413	-0.23	-0.19	Monocyte percentage of white cells;Monocyte count;	chr22:49631617	chr22:49612657~49615716:-
LUAD	cis	rs5769707	0.667	rs4824069	ENSG00000235111.1	RP1-29C18.8	-4.27	2.36e-05	0.00413	-0.23	-0.19	Monocyte percentage of white cells;Monocyte count;	chr22:49636677	chr22:49612657~49615716:-
LUAD	cis	rs2976388	0.692	rs1435453	ENSG00000253741.1	CTD-2292P10.4	-4.27	2.36e-05	0.00413	-0.22	-0.19	Urinary tract infection frequency;	chr8:142699357	chr8:142702252~142726973:-
LUAD	cis	rs11009175	0.547	rs10763910	ENSG00000273038.2	RP11-479G22.8	-4.27	2.36e-05	0.00413	-0.23	-0.19	Depression (quantitative trait);	chr10:33107061	chr10:32887255~32889311:-
LUAD	cis	rs5758659	0.652	rs133336	ENSG00000182057.4	OGFRP1	4.27	2.36e-05	0.00413	0.23	0.19	Cognitive function;	chr22:42020299	chr22:42269753~42275196:+
LUAD	cis	rs7923837	0.687	rs1977833	ENSG00000236493.2	EIF2S2P3	4.27	2.36e-05	0.00413	0.22	0.19	Multiple sclerosis;Body mass index;	chr10:92704188	chr10:92668745~92669743:-
LUAD	cis	rs11195128	1	rs11195128	ENSG00000270589.1	RP11-348N5.7	4.27	2.36e-05	0.00413	0.15	0.19	Crohn's disease;Inflammatory bowel disease;	chr10:110426390	chr10:110910596~110912244:+
LUAD	cis	rs6496044	0.963	rs7165300	ENSG00000259407.1	RP11-158M2.3	-4.27	2.36e-05	0.00413	-0.18	-0.19	Interstitial lung disease;	chr15:85526838	chr15:85744109~85750281:-
LUAD	cis	rs9400467	0.528	rs4276544	ENSG00000271789.1	RP5-1112D6.7	-4.27	2.36e-05	0.00413	-0.2	-0.19	Amino acid levels;Blood metabolite levels;	chr6:111438496	chr6:111297126~111298510:+
LUAD	cis	rs338389	0.542	rs7494835	ENSG00000260657.2	RP11-315D16.4	-4.27	2.36e-05	0.00413	-0.23	-0.19	Survival in rectal cancer;	chr15:68001993	chr15:68267792~68277994:-
LUAD	cis	rs9467773	0.62	rs2451738	ENSG00000241549.7	GUSBP2	-4.27	2.36e-05	0.00413	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26618231	chr6:26871484~26956554:-
LUAD	cis	rs6714710	0.603	rs11692010	ENSG00000230606.9	AC159540.1	-4.27	2.36e-05	0.00414	-0.2	-0.19	Posterior cortical atrophy and Alzheimer's disease;	chr2:97780838	chr2:97416165~97433527:-
LUAD	cis	rs6928977	0.5	rs6570022	ENSG00000231028.7	LINC00271	-4.27	2.37e-05	0.00414	-0.23	-0.19	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135627683	chr6:135497801~135716055:+
LUAD	cis	rs6964833	0.872	rs4717903	ENSG00000184616.8	AC004166.6	4.27	2.37e-05	0.00414	0.28	0.19	Menarche (age at onset);	chr7:74653827	chr7:74906673~74913256:-
LUAD	cis	rs7824557	0.564	rs2736288	ENSG00000255046.1	RP11-297N6.4	4.27	2.37e-05	0.00414	0.23	0.19	Retinal vascular caliber;	chr8:11370591	chr8:11797928~11802568:-
LUAD	cis	rs13256369	1	rs12547721	ENSG00000253893.2	FAM85B	-4.27	2.37e-05	0.00414	-0.26	-0.19	Obesity-related traits;	chr8:8713161	chr8:8167819~8226614:-
LUAD	cis	rs1167827	0.805	rs809439	ENSG00000165178.9	NCF1C	-4.27	2.37e-05	0.00414	-0.16	-0.19	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75531992	chr7:75156639~75172044:-
LUAD	cis	rs523522	0.962	rs2393590	ENSG00000278344.1	RP11-18C24.8	4.27	2.37e-05	0.00414	0.26	0.19	High light scatter reticulocyte count;	chr12:120476097	chr12:120500735~120501090:-
LUAD	cis	rs7772486	0.743	rs9390344	ENSG00000235652.6	RP11-545I5.3	-4.27	2.37e-05	0.00414	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145691619	chr6:145799409~145886585:+
LUAD	cis	rs2841233	0.558	rs10145270	ENSG00000258701.1	LINC00638	4.27	2.37e-05	0.00414	0.23	0.19	IgG glycosylation;	chr14:104883554	chr14:104821201~104823718:+
LUAD	cis	rs3177980	0.673	rs35296671	ENSG00000239494.2	RN7SL333P	-4.27	2.37e-05	0.00414	-0.19	-0.19	Amyotrophic lateral sclerosis;	chr1:169789148	chr1:169859756~169860052:+
LUAD	cis	rs7098414	0.511	rs7899513	ENSG00000226659.1	RP11-137H2.4	-4.27	2.37e-05	0.00414	-0.25	-0.19	Post bronchodilator FEV1;	chr10:80390803	chr10:80529597~80535942:-
LUAD	cis	rs7098414	0.511	rs7899545	ENSG00000226659.1	RP11-137H2.4	-4.27	2.37e-05	0.00414	-0.25	-0.19	Post bronchodilator FEV1;	chr10:80390879	chr10:80529597~80535942:-
LUAD	cis	rs7208859	0.623	rs9912283	ENSG00000280069.1	CTD-2349P21.3	-4.27	2.37e-05	0.00414	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30738182~30740275:+
LUAD	cis	rs987710	0.537	rs2213148	ENSG00000211639.2	IGLV4-60	-4.27	2.37e-05	0.00414	-0.27	-0.19	Iron status biomarkers;Iron deficiency;	chr22:22166359	chr22:22162199~22162681:+
LUAD	cis	rs4666002	0.636	rs13023194	ENSG00000223522.1	AC093690.1	4.27	2.37e-05	0.00414	0.24	0.19	Phospholipid levels (plasma);	chr2:27744393	chr2:28307691~28310459:-
LUAD	cis	rs7746199	0.736	rs17693963	ENSG00000219392.1	RP1-265C24.5	-4.27	2.37e-05	0.00414	-0.39	-0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27742386	chr6:28115628~28116551:+
LUAD	cis	rs2442825	0.508	rs2648545	ENSG00000206573.7	THUMPD3-AS1	-4.27	2.37e-05	0.00414	-0.15	-0.19	Cerebrospinal fluid clusterin levels;	chr3:9347539	chr3:9349689~9398579:-
LUAD	cis	rs11089937	0.929	rs2236727	ENSG00000211638.2	IGLV8-61	-4.27	2.37e-05	0.00415	-0.19	-0.19	Periodontitis (PAL4Q3);	chr22:22156654	chr22:22098700~22099212:+
LUAD	cis	rs2836974	0.563	rs997147	ENSG00000232608.1	TIMM9P2	4.27	2.37e-05	0.00415	0.23	0.19	Cognitive function;	chr21:39323399	chr21:39216624~39217506:+
LUAD	cis	rs9910055	0.529	rs228748	ENSG00000267080.4	ASB16-AS1	4.27	2.37e-05	0.00415	0.18	0.19	Total body bone mineral density;	chr17:44097022	chr17:44175973~44186717:-
LUAD	cis	rs6840360	0.571	rs11729136	ENSG00000270265.1	RP11-731D1.4	-4.27	2.37e-05	0.00415	-0.22	-0.19	Intelligence (multi-trait analysis);	chr4:151608075	chr4:151333775~151353224:-
LUAD	cis	rs2018683	0.834	rs2012754	ENSG00000228421.2	AC005013.5	4.27	2.37e-05	0.00415	0.21	0.19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28986641	chr7:28957667~28959345:+
LUAD	cis	rs4819052	0.634	rs8128636	ENSG00000237664.1	LINC00316	-4.27	2.37e-05	0.00415	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270718	chr21:45338590~45341990:-
LUAD	cis	rs17486696	0.655	rs62352418	ENSG00000248771.4	LINC01207	4.27	2.37e-05	0.00415	0.41	0.19	Positive affect;	chr4:164759536	chr4:164754064~164803795:+
LUAD	cis	rs5758659	1	rs134882	ENSG00000273366.1	CTA-989H11.1	-4.27	2.37e-05	0.00415	-0.22	-0.19	Cognitive function;	chr22:42274959	chr22:42278188~42278846:+
LUAD	cis	rs7216064	0.7	rs4791295	ENSG00000265055.1	AC145343.2	4.27	2.37e-05	0.00415	0.19	0.19	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68001201	chr17:68096046~68101474:-
LUAD	cis	rs1552244	0.882	rs13063098	ENSG00000180385.7	EMC3-AS1	4.27	2.37e-05	0.00415	0.23	0.19	Alzheimer's disease;	chr3:9968235	chr3:9986893~10006990:+
LUAD	cis	rs9516	0.966	rs2887135	ENSG00000213333.3	NPM1P50	-4.27	2.37e-05	0.00415	-0.2	-0.19	Facial morphology (factor 15, philtrum width);	chr11:74452810	chr11:75079265~75080131:-
LUAD	cis	rs11779988	0.545	rs448882	ENSG00000253671.1	RP11-806O11.1	-4.27	2.38e-05	0.00415	-0.24	-0.19	Breast cancer;	chr8:17936530	chr8:17808941~17820868:+
LUAD	cis	rs7760535	0.757	rs10456875	ENSG00000271789.1	RP5-1112D6.7	-4.27	2.38e-05	0.00415	-0.2	-0.19	Metabolic traits;	chr6:111428522	chr6:111297126~111298510:+
LUAD	cis	rs7824557	0.564	rs2572399	ENSG00000255046.1	RP11-297N6.4	4.27	2.38e-05	0.00415	0.24	0.19	Retinal vascular caliber;	chr8:11377011	chr8:11797928~11802568:-
LUAD	cis	rs7119038	0.818	rs56043232	ENSG00000255422.1	AP002954.4	4.27	2.38e-05	0.00416	0.3	0.19	Sjögren's syndrome;	chr11:118777664	chr11:118704607~118750263:+
LUAD	cis	rs763121	0.853	rs5750626	ENSG00000228274.3	RP3-508I15.9	-4.27	2.38e-05	0.00416	-0.2	-0.19	Menopause (age at onset);	chr22:38581885	chr22:38667585~38681820:-
LUAD	cis	rs1876905	0.68	rs354527	ENSG00000230177.1	RP5-1112D6.4	-4.27	2.38e-05	0.00416	-0.24	-0.19	Mean corpuscular hemoglobin;	chr6:111217390	chr6:111277932~111278742:+
LUAD	cis	rs9649213	0.555	rs6968193	ENSG00000272950.1	RP11-307C18.1	4.27	2.38e-05	0.00416	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98286590	chr7:98322853~98323430:+
LUAD	cis	rs2153535	0.585	rs9505505	ENSG00000230939.1	RP11-314C16.1	-4.27	2.38e-05	0.00416	-0.21	-0.19	Motion sickness;	chr6:8640246	chr6:8784178~8785445:+
LUAD	cis	rs7204230	1	rs12598505	ENSG00000261291.1	RP11-295M3.2	4.27	2.38e-05	0.00416	0.24	0.19	Fibrinogen;	chr16:53312907	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs62049810	ENSG00000261291.1	RP11-295M3.2	4.27	2.38e-05	0.00416	0.24	0.19	Fibrinogen;	chr16:53314245	chr16:53168522~53169450:+
LUAD	cis	rs73193808	0.851	rs11911017	ENSG00000215533.7	LINC00189	-4.27	2.38e-05	0.00416	-0.26	-0.19	Coronary artery disease;	chr21:29195620	chr21:29193480~29288205:+
LUAD	cis	rs13113518	0.783	rs2171618	ENSG00000272969.1	RP11-528I4.2	4.27	2.38e-05	0.00416	0.21	0.19	Height;	chr4:55564241	chr4:55547112~55547889:+
LUAD	cis	rs1113500	0.787	rs11185266	ENSG00000226822.1	RP11-356N1.2	4.27	2.38e-05	0.00416	0.22	0.19	Growth-regulated protein alpha levels;	chr1:108100042	chr1:108071482~108074519:+
LUAD	cis	rs11051970	0.704	rs2733694	ENSG00000274964.1	RP11-817I4.1	-4.27	2.38e-05	0.00416	-0.2	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr12:32402296	chr12:32339368~32340724:+
LUAD	cis	rs6570726	0.967	rs413880	ENSG00000235652.6	RP11-545I5.3	4.27	2.38e-05	0.00416	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145483686	chr6:145799409~145886585:+
LUAD	cis	rs2823962	0.759	rs2823933	ENSG00000270093.1	AP000473.8	-4.27	2.38e-05	0.00416	-0.2	-0.19	Amyotrophic lateral sclerosis;	chr21:16650099	chr21:16643529~16645065:+
LUAD	cis	rs62025270	0.632	rs6496109	ENSG00000202081.1	RNU6-1280P	-4.27	2.38e-05	0.00416	-0.29	-0.19	Idiopathic pulmonary fibrosis;	chr15:85588777	chr15:85651522~85651628:-
LUAD	cis	rs4713118	0.699	rs200978	ENSG00000280107.1	AL022393.9	-4.27	2.38e-05	0.00416	-0.25	-0.19	Parkinson's disease;	chr6:27885390	chr6:28170845~28172521:+
LUAD	cis	rs11155671	0.53	rs7763849	ENSG00000268592.3	RAET1E-AS1	4.27	2.38e-05	0.00416	0.23	0.19	Testicular germ cell tumor;	chr6:149885244	chr6:149863494~149919507:+
LUAD	cis	rs172166	0.694	rs536704	ENSG00000216901.1	AL022393.7	4.27	2.38e-05	0.00416	0.23	0.19	Cardiac Troponin-T levels;	chr6:28124825	chr6:28176188~28176674:+
LUAD	cis	rs55692468	0.52	rs62180799	ENSG00000213197.3	AC012066.1	4.27	2.38e-05	0.00416	0.22	0.19	Intraocular pressure;	chr2:152445594	chr2:152389937~152390630:+
LUAD	cis	rs7107174	1	rs9651768	ENSG00000251323.2	RP11-452H21.4	4.27	2.38e-05	0.00417	0.23	0.19	Testicular germ cell tumor;	chr11:78284974	chr11:78423982~78429836:-
LUAD	cis	rs847577	0.588	rs12666406	ENSG00000272950.1	RP11-307C18.1	4.27	2.38e-05	0.00417	0.24	0.19	Breast cancer;	chr7:98161679	chr7:98322853~98323430:+
LUAD	cis	rs13113518	0.812	rs4507426	ENSG00000272969.1	RP11-528I4.2	4.27	2.38e-05	0.00417	0.21	0.19	Height;	chr4:55529387	chr4:55547112~55547889:+
LUAD	cis	rs2243480	1	rs11538349	ENSG00000232559.3	GS1-124K5.12	4.27	2.38e-05	0.00417	0.33	0.19	Diabetic kidney disease;	chr7:65956884	chr7:66554588~66576923:-
LUAD	cis	rs10129255	0.957	rs56134540	ENSG00000211974.3	IGHV2-70	4.27	2.39e-05	0.00417	0.2	0.19	Kawasaki disease;	chr14:106691290	chr14:106723574~106724093:-
LUAD	cis	rs12073359	1	rs72694926	ENSG00000223945.2	RP11-458I7.1	-4.27	2.39e-05	0.00417	-0.29	-0.19	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150107999	chr1:150053864~150055034:+
LUAD	cis	rs12073359	1	rs72694928	ENSG00000223945.2	RP11-458I7.1	-4.27	2.39e-05	0.00417	-0.29	-0.19	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150109454	chr1:150053864~150055034:+
LUAD	cis	rs12073359	0.954	rs113082139	ENSG00000223945.2	RP11-458I7.1	-4.27	2.39e-05	0.00417	-0.29	-0.19	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150117796	chr1:150053864~150055034:+
LUAD	cis	rs12073359	1	rs72694933	ENSG00000223945.2	RP11-458I7.1	-4.27	2.39e-05	0.00417	-0.29	-0.19	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150122414	chr1:150053864~150055034:+
LUAD	cis	rs12073359	1	rs55840680	ENSG00000223945.2	RP11-458I7.1	-4.27	2.39e-05	0.00417	-0.29	-0.19	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150125477	chr1:150053864~150055034:+
LUAD	cis	rs12073359	1	rs72694936	ENSG00000223945.2	RP11-458I7.1	-4.27	2.39e-05	0.00417	-0.29	-0.19	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150125986	chr1:150053864~150055034:+
LUAD	cis	rs911555	0.574	rs34251103	ENSG00000244691.1	RPL10AP1	4.27	2.39e-05	0.00417	0.25	0.19	Intelligence (multi-trait analysis);	chr14:103393726	chr14:103412119~103412761:-
LUAD	cis	rs8048589	1	rs12596549	ENSG00000175604.2	RP11-276H1.3	-4.27	2.39e-05	0.00417	-0.26	-0.19	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12089643	chr16:12086746~12090302:-
LUAD	cis	rs256438	0.896	rs34655435	ENSG00000251050.1	RP11-168A11.4	-4.27	2.39e-05	0.00417	-0.21	-0.19	Serum thyroid-stimulating hormone levels;	chr5:80095187	chr5:80019609~80019920:+
LUAD	cis	rs2732480	0.538	rs1387259	ENSG00000257763.1	OR5BK1P	-4.27	2.39e-05	0.00417	-0.21	-0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309739	chr12:48355792~48356614:-
LUAD	cis	rs780096	0.587	rs1049817	ENSG00000234072.1	AC074117.10	-4.27	2.39e-05	0.00417	-0.15	-0.19	Total body bone mineral density;	chr2:27328100	chr2:27356246~27367622:+
LUAD	cis	rs6088590	1	rs2236270	ENSG00000276073.1	RP5-1125A11.7	-4.27	2.39e-05	0.00417	-0.2	-0.19	Coronary artery disease;	chr20:34935352	chr20:33985617~33988989:-
LUAD	cis	rs453301	0.624	rs6987558	ENSG00000253981.4	ALG1L13P	4.27	2.39e-05	0.00417	0.23	0.19	Joint mobility (Beighton score);	chr8:9005011	chr8:8236003~8244667:-
LUAD	cis	rs2153535	0.585	rs9378564	ENSG00000230939.1	RP11-314C16.1	-4.27	2.39e-05	0.00418	-0.21	-0.19	Motion sickness;	chr6:8639694	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.585	rs9379233	ENSG00000230939.1	RP11-314C16.1	-4.27	2.39e-05	0.00418	-0.21	-0.19	Motion sickness;	chr6:8639729	chr6:8784178~8785445:+
LUAD	cis	rs2243480	0.708	rs35825036	ENSG00000229886.1	RP5-1132H15.3	4.27	2.39e-05	0.00418	0.33	0.19	Diabetic kidney disease;	chr7:66521515	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs13237037	ENSG00000229886.1	RP5-1132H15.3	4.27	2.39e-05	0.00418	0.33	0.19	Diabetic kidney disease;	chr7:66532895	chr7:66025126~66031544:-
LUAD	cis	rs2243480	0.901	rs13237344	ENSG00000229886.1	RP5-1132H15.3	4.27	2.39e-05	0.00418	0.33	0.19	Diabetic kidney disease;	chr7:66557269	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs1796228	ENSG00000229886.1	RP5-1132H15.3	4.27	2.39e-05	0.00418	0.33	0.19	Diabetic kidney disease;	chr7:66568097	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs1267820	ENSG00000229886.1	RP5-1132H15.3	4.27	2.39e-05	0.00418	0.33	0.19	Diabetic kidney disease;	chr7:66585308	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs2533288	ENSG00000229886.1	RP5-1132H15.3	4.27	2.39e-05	0.00418	0.33	0.19	Diabetic kidney disease;	chr7:66591724	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs2707844	ENSG00000229886.1	RP5-1132H15.3	4.27	2.39e-05	0.00418	0.33	0.19	Diabetic kidney disease;	chr7:66594522	chr7:66025126~66031544:-
LUAD	cis	rs4811196	0.748	rs6013310	ENSG00000226144.2	RPS27AP3	4.27	2.39e-05	0.00418	0.21	0.19	Bone mineral density;	chr20:37873898	chr20:37049254~37049707:+
LUAD	cis	rs394563	0.967	rs438852	ENSG00000216906.2	RP11-350J20.9	-4.27	2.39e-05	0.00418	-0.23	-0.19	Dupuytren's disease;	chr6:149473397	chr6:149904243~149906418:+
LUAD	cis	rs8030379	1	rs2030839	ENSG00000230373.7	GOLGA6L5P	-4.27	2.39e-05	0.00418	-0.17	-0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83915207	chr15:84507885~84516814:-
LUAD	cis	rs73173548	0.528	rs34857793	ENSG00000247828.6	TMEM161B-AS1	4.27	2.39e-05	0.00418	0.24	0.19	Macular telangiectasia type 2;	chr5:88467749	chr5:88268895~88436685:+
LUAD	cis	rs7760535	0.826	rs3777905	ENSG00000271789.1	RP5-1112D6.7	-4.27	2.39e-05	0.00418	-0.2	-0.19	Metabolic traits;	chr6:111549385	chr6:111297126~111298510:+
LUAD	cis	rs454217	0.74	rs373627	ENSG00000277851.1	RP11-756G20.1	4.27	2.39e-05	0.00418	0.19	0.19	Smoking quantity;	chr12:92325837	chr12:92247756~92363832:-
LUAD	cis	rs28386778	0.83	rs2665798	ENSG00000240280.5	TCAM1P	-4.27	2.39e-05	0.00418	-0.22	-0.19	Prudent dietary pattern;	chr17:63844037	chr17:63849292~63864379:+
LUAD	cis	rs7806994	1	rs7806994	ENSG00000226278.1	PSPHP1	-4.27	2.39e-05	0.00418	-0.29	-0.19	PR interval in Tripanosoma cruzi seropositivity;	chr7:56071812	chr7:55764797~55773288:+
LUAD	cis	rs7204230	0.961	rs7203402	ENSG00000261291.1	RP11-295M3.2	4.27	2.39e-05	0.00418	0.24	0.19	Fibrinogen;	chr16:53307406	chr16:53168522~53169450:+
LUAD	cis	rs12908161	1	rs35630683	ENSG00000259295.5	CSPG4P12	4.27	2.39e-05	0.00418	0.26	0.19	Schizophrenia;	chr15:84806000	chr15:85191438~85213905:+
LUAD	cis	rs595244	1	rs1036476	ENSG00000259705.1	RP11-227D13.1	4.27	2.39e-05	0.00418	0.38	0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48622578	chr15:48645951~48652016:+
LUAD	cis	rs17826219	0.5	rs28452421	ENSG00000280069.1	CTD-2349P21.3	-4.27	2.39e-05	0.00418	-0.26	-0.19	Body mass index;	chr17:30756962	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.573	rs28779471	ENSG00000280069.1	CTD-2349P21.3	-4.27	2.39e-05	0.00418	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30738182~30740275:+
LUAD	cis	rs17826219	0.5	rs61685770	ENSG00000280069.1	CTD-2349P21.3	-4.27	2.39e-05	0.00418	-0.26	-0.19	Body mass index;	chr17:30758695	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs57486336	ENSG00000280069.1	CTD-2349P21.3	-4.27	2.39e-05	0.00418	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs12103440	ENSG00000280069.1	CTD-2349P21.3	-4.27	2.39e-05	0.00418	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs11657777	ENSG00000280069.1	CTD-2349P21.3	-4.27	2.39e-05	0.00418	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30738182~30740275:+
LUAD	cis	rs2732480	0.5	rs2450986	ENSG00000257763.1	OR5BK1P	4.27	2.39e-05	0.00418	0.2	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48267905	chr12:48355792~48356614:-
LUAD	cis	rs516805	0.683	rs502071	ENSG00000279453.1	RP3-425C14.4	-4.27	2.4e-05	0.00418	-0.26	-0.19	Lymphocyte counts;	chr6:122417917	chr6:122436789~122439223:-
LUAD	cis	rs12073837	0.5	rs2807845	ENSG00000238078.1	LINC01352	-4.27	2.4e-05	0.00418	-0.21	-0.19	F-cell distribution;	chr1:220822945	chr1:220829255~220832429:+
LUAD	cis	rs8062405	0.789	rs28676837	ENSG00000251417.2	RP11-1348G14.4	4.27	2.4e-05	0.00418	0.19	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28615742	chr16:28802743~28817828:+
LUAD	cis	rs950169	0.84	rs62029595	ENSG00000275120.1	RP11-182J1.17	4.27	2.4e-05	0.00418	0.3	0.19	Schizophrenia;	chr15:84400603	chr15:84599434~84606463:-
LUAD	cis	rs62355901	0.545	rs2113084	ENSG00000271828.1	CTD-2310F14.1	4.27	2.4e-05	0.00418	0.38	0.19	Breast cancer;	chr5:56737844	chr5:56927874~56929573:+
LUAD	cis	rs12908161	1	rs56864281	ENSG00000254414.1	RP11-182J1.1	4.27	2.4e-05	0.00418	0.24	0.19	Schizophrenia;	chr15:84814418	chr15:84631898~84633987:-
LUAD	cis	rs910316	1	rs175443	ENSG00000279594.1	RP11-950C14.10	-4.27	2.4e-05	0.00418	-0.22	-0.19	Height;	chr14:75135260	chr14:75011269~75012851:-
LUAD	cis	rs1040	0.69	rs9393165	ENSG00000261039.2	RP11-417E7.2	-4.27	2.4e-05	0.00419	-0.25	-0.19	Joint mobility (Beighton score);	chr6:169220152	chr6:169175304~169182740:-
LUAD	cis	rs7937682	0.961	rs17113227	ENSG00000230911.1	PPIHP1	-4.27	2.4e-05	0.00419	-0.26	-0.19	Primary sclerosing cholangitis;	chr11:111749767	chr11:112029858~112030367:-
LUAD	cis	rs11168618	0.846	rs11168592	ENSG00000240399.1	RP1-228P16.1	4.27	2.4e-05	0.00419	0.19	0.19	Adiponectin levels;	chr12:48471296	chr12:48054813~48055591:-
LUAD	cis	rs35740288	0.822	rs17636864	ENSG00000259407.1	RP11-158M2.3	-4.27	2.4e-05	0.00419	-0.19	-0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85691358	chr15:85744109~85750281:-
LUAD	cis	rs11065706	0.747	rs111298771	ENSG00000278993.1	RP3-424M6.4	4.27	2.4e-05	0.00419	0.24	0.19	Heart rate;	chr12:110405608	chr12:110501614~110503441:+
LUAD	cis	rs2702164	0.781	rs1259295	ENSG00000240661.1	RP11-174O3.3	4.27	2.4e-05	0.00419	0.23	0.19	Gut microbiome composition (winter);	chr3:120421884	chr3:120349510~120367998:+
LUAD	cis	rs4908769	0.66	rs301797	ENSG00000232912.4	RP5-1115A15.1	4.27	2.4e-05	0.00419	0.18	0.19	Allergy;	chr1:8427263	chr1:8424645~8434838:+
LUAD	cis	rs2976388	0.556	rs4736300	ENSG00000253741.1	CTD-2292P10.4	4.27	2.4e-05	0.00419	0.22	0.19	Urinary tract infection frequency;	chr8:142747851	chr8:142702252~142726973:-
LUAD	cis	rs1876905	0.597	rs354538	ENSG00000230177.1	RP5-1112D6.4	-4.27	2.4e-05	0.00419	-0.23	-0.19	Mean corpuscular hemoglobin;	chr6:111196863	chr6:111277932~111278742:+
LUAD	cis	rs4795519	0.71	rs1600325	ENSG00000266313.1	RP11-173M1.4	4.27	2.4e-05	0.00419	0.24	0.19	Chronic myeloid leukemia;	chr17:27160113	chr17:27333256~27348491:+
LUAD	cis	rs12908161	0.959	rs17598603	ENSG00000259295.5	CSPG4P12	-4.27	2.4e-05	0.00419	-0.26	-0.19	Schizophrenia;	chr15:84656980	chr15:85191438~85213905:+
LUAD	cis	rs1790761	0.692	rs1148883	ENSG00000184224.3	C11orf72	4.27	2.4e-05	0.00419	0.22	0.19	Mean corpuscular volume;	chr11:67537215	chr11:67602880~67606706:-
LUAD	cis	rs73198271	0.74	rs10105920	ENSG00000253893.2	FAM85B	-4.27	2.4e-05	0.00419	-0.25	-0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791227	chr8:8167819~8226614:-
LUAD	cis	rs11886999	0.812	rs72825865	ENSG00000237510.6	AC008268.2	-4.27	2.4e-05	0.00419	-0.31	-0.19	Cardiac Troponin-T levels;	chr2:96224162	chr2:95789654~95800166:+
LUAD	cis	rs9815354	0.812	rs704964	ENSG00000273328.4	RP11-141M3.6	4.27	2.4e-05	0.00419	0.3	0.19	Pulse pressure;Diastolic blood pressure;	chr3:42012407	chr3:42809414~42908105:+
LUAD	cis	rs8098244	0.706	rs1154227	ENSG00000264745.1	TTC39C-AS1	-4.27	2.4e-05	0.0042	-0.2	-0.19	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23901376	chr18:23994213~24015339:-
LUAD	cis	rs3096299	0.933	rs2965939	ENSG00000182376.2	RP5-1142A6.8	4.27	2.4e-05	0.0042	0.2	0.19	Multiple myeloma (IgH translocation);	chr16:89426635	chr16:88742767~88745748:+
LUAD	cis	rs737008	0.922	rs2550475	ENSG00000262703.1	RP11-485G7.6	4.27	2.41e-05	0.0042	0.18	0.19	Obesity-related traits;	chr16:11278129	chr16:11348143~11349321:-
LUAD	cis	rs2976388	0.507	rs7813604	ENSG00000253741.1	CTD-2292P10.4	-4.27	2.41e-05	0.0042	-0.23	-0.19	Urinary tract infection frequency;	chr8:142756644	chr8:142702252~142726973:-
LUAD	cis	rs6496044	0.568	rs12708554	ENSG00000259295.5	CSPG4P12	4.27	2.41e-05	0.0042	0.22	0.19	Interstitial lung disease;	chr15:85531066	chr15:85191438~85213905:+
LUAD	cis	rs7829975	0.774	rs35431455	ENSG00000233609.3	RP11-62H7.2	4.27	2.41e-05	0.0042	0.16	0.19	Mood instability;	chr8:8816226	chr8:8961200~8979025:+
LUAD	cis	rs7204230	0.921	rs12597502	ENSG00000261291.1	RP11-295M3.2	4.27	2.41e-05	0.0042	0.24	0.19	Fibrinogen;	chr16:53136157	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs8057569	ENSG00000261291.1	RP11-295M3.2	4.27	2.41e-05	0.0042	0.24	0.19	Fibrinogen;	chr16:53139321	chr16:53168522~53169450:+
LUAD	cis	rs7204230	0.846	rs62047991	ENSG00000261291.1	RP11-295M3.2	4.27	2.41e-05	0.0042	0.24	0.19	Fibrinogen;	chr16:53140359	chr16:53168522~53169450:+
LUAD	cis	rs1005277	0.505	rs10827836	ENSG00000263064.2	RP11-291L22.7	-4.27	2.41e-05	0.0042	-0.2	-0.19	Extrinsic epigenetic age acceleration;	chr10:37926513	chr10:38448689~38448949:+
LUAD	cis	rs2153535	0.585	rs9393056	ENSG00000230939.1	RP11-314C16.1	-4.26	2.41e-05	0.0042	-0.22	-0.19	Motion sickness;	chr6:8667641	chr6:8784178~8785445:+
LUAD	cis	rs7590268	0.606	rs11124933	ENSG00000279873.2	LINC01126	4.26	2.41e-05	0.0042	0.18	0.19	Orofacial clefts;	chr2:43424544	chr2:43227210~43228855:+
LUAD	cis	rs4811196	0.719	rs760846	ENSG00000226144.2	RPS27AP3	4.26	2.41e-05	0.0042	0.21	0.19	Bone mineral density;	chr20:37861125	chr20:37049254~37049707:+
LUAD	cis	rs800160	0.925	rs2097686	ENSG00000236264.4	RPL26P30	-4.26	2.41e-05	0.00421	-0.25	-0.19	Bacteremia;	chr11:2362171	chr11:2335132~2335776:-
LUAD	cis	rs4660214	0.666	rs597311	ENSG00000228060.1	RP11-69E11.8	-4.26	2.41e-05	0.00421	-0.17	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39355254	chr1:39565160~39573203:+
LUAD	cis	rs4660214	0.615	rs597708	ENSG00000228060.1	RP11-69E11.8	-4.26	2.41e-05	0.00421	-0.17	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39355291	chr1:39565160~39573203:+
LUAD	cis	rs4660214	0.666	rs636156	ENSG00000228060.1	RP11-69E11.8	-4.26	2.41e-05	0.00421	-0.17	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39356065	chr1:39565160~39573203:+
LUAD	cis	rs9487094	1	rs10872032	ENSG00000260273.1	RP11-425D10.10	4.26	2.41e-05	0.00421	0.24	0.19	Height;	chr6:109355573	chr6:109382795~109383666:+
LUAD	cis	rs17406451	0.704	rs6717153	ENSG00000279873.2	LINC01126	4.26	2.41e-05	0.00421	0.16	0.19	Mitochondrial DNA levels;	chr2:43536390	chr2:43227210~43228855:+
LUAD	cis	rs56114371	0.777	rs200482	ENSG00000219392.1	RP1-265C24.5	-4.26	2.41e-05	0.00421	-0.35	-0.19	Breast cancer;	chr6:27806126	chr6:28115628~28116551:+
LUAD	cis	rs2346160	1	rs6937935	ENSG00000231720.1	RP11-568A7.3	-4.26	2.41e-05	0.00421	-0.19	-0.19	Parental extreme longevity (95 years and older);	chr6:167256735	chr6:167237508~167240480:-
LUAD	cis	rs28714278	0.857	rs35602605	ENSG00000248508.5	SRP14-AS1	-4.26	2.41e-05	0.00421	-0.23	-0.19	Mean corpuscular hemoglobin;	chr15:40016658	chr15:40039311~40067290:+
LUAD	cis	rs4795519	1	rs1479364	ENSG00000266313.1	RP11-173M1.4	4.26	2.41e-05	0.00421	0.23	0.19	Chronic myeloid leukemia;	chr17:27214941	chr17:27333256~27348491:+
LUAD	cis	rs2274273	0.712	rs7144652	ENSG00000258413.1	RP11-665C16.6	-4.26	2.41e-05	0.00421	-0.24	-0.19	Protein biomarker;	chr14:55071000	chr14:55262767~55272075:-
LUAD	cis	rs28386778	0.897	rs2584617	ENSG00000240280.5	TCAM1P	-4.26	2.42e-05	0.00421	-0.22	-0.19	Prudent dietary pattern;	chr17:63847938	chr17:63849292~63864379:+
LUAD	cis	rs7178424	0.729	rs12909947	ENSG00000259251.2	RP11-643M14.1	4.26	2.42e-05	0.00421	0.19	0.19	Height;	chr15:61956353	chr15:62060503~62062434:+
LUAD	cis	rs1799949	0.536	rs4793227	ENSG00000236383.6	LINC00854	-4.26	2.42e-05	0.00422	-0.15	-0.19	Menopause (age at onset);	chr17:43334882	chr17:43216941~43305976:-
LUAD	cis	rs11089937	0.54	rs2329931	ENSG00000211640.3	IGLV6-57	4.26	2.42e-05	0.00422	0.14	0.19	Periodontitis (PAL4Q3);	chr22:22131994	chr22:22195713~22196460:+
LUAD	cis	rs11089937	0.568	rs2876996	ENSG00000211640.3	IGLV6-57	4.26	2.42e-05	0.00422	0.14	0.19	Periodontitis (PAL4Q3);	chr22:22132006	chr22:22195713~22196460:+
LUAD	cis	rs11051970	0.679	rs2931554	ENSG00000274964.1	RP11-817I4.1	-4.26	2.42e-05	0.00422	-0.19	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr12:32403228	chr12:32339368~32340724:+
LUAD	cis	rs2057178	0.929	rs11031714	ENSG00000183242.10	WT1-AS	4.26	2.42e-05	0.00422	0.29	0.19	Tuberculosis;	chr11:32320477	chr11:32435518~32458769:+
LUAD	cis	rs73242632	1	rs2227902	ENSG00000269949.1	RP11-738E22.3	4.26	2.42e-05	0.00422	0.46	0.19	Congenital heart disease (maternal effect);	chr4:56930934	chr4:56960927~56961373:-
LUAD	cis	rs73242632	1	rs73242618	ENSG00000269949.1	RP11-738E22.3	4.26	2.42e-05	0.00422	0.46	0.19	Congenital heart disease (maternal effect);	chr4:56943383	chr4:56960927~56961373:-
LUAD	cis	rs1864585	0.52	rs7817252	ENSG00000255046.1	RP11-297N6.4	4.26	2.42e-05	0.00422	0.27	0.19	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10828422	chr8:11797928~11802568:-
LUAD	cis	rs1864585	0.52	rs12375394	ENSG00000255046.1	RP11-297N6.4	4.26	2.42e-05	0.00422	0.27	0.19	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10831702	chr8:11797928~11802568:-
LUAD	cis	rs12073359	1	rs112521467	ENSG00000223945.2	RP11-458I7.1	-4.26	2.42e-05	0.00422	-0.29	-0.19	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150101194	chr1:150053864~150055034:+
LUAD	cis	rs12073359	1	rs112245786	ENSG00000223945.2	RP11-458I7.1	-4.26	2.42e-05	0.00422	-0.29	-0.19	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150102532	chr1:150053864~150055034:+
LUAD	cis	rs12073359	1	rs112814713	ENSG00000223945.2	RP11-458I7.1	-4.26	2.42e-05	0.00422	-0.29	-0.19	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150102647	chr1:150053864~150055034:+
LUAD	cis	rs12073359	1	rs72694914	ENSG00000223945.2	RP11-458I7.1	-4.26	2.42e-05	0.00422	-0.29	-0.19	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150102833	chr1:150053864~150055034:+
LUAD	cis	rs12073359	1	rs72694915	ENSG00000223945.2	RP11-458I7.1	-4.26	2.42e-05	0.00422	-0.29	-0.19	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150102876	chr1:150053864~150055034:+
LUAD	cis	rs12073359	1	rs72694923	ENSG00000223945.2	RP11-458I7.1	-4.26	2.42e-05	0.00422	-0.29	-0.19	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150105152	chr1:150053864~150055034:+
LUAD	cis	rs240993	0.502	rs240966	ENSG00000230177.1	RP5-1112D6.4	-4.26	2.42e-05	0.00422	-0.2	-0.19	Inflammatory skin disease;Psoriasis;	chr6:111323462	chr6:111277932~111278742:+
LUAD	cis	rs2288073	0.965	rs6545335	ENSG00000242628.4	AC009228.1	4.26	2.42e-05	0.00422	0.26	0.19	Venous thromboembolism (SNP x SNP interaction);	chr2:24199142	chr2:24214381~24221516:+
LUAD	cis	rs2288073	0.965	rs6545338	ENSG00000242628.4	AC009228.1	4.26	2.42e-05	0.00422	0.26	0.19	Venous thromboembolism (SNP x SNP interaction);	chr2:24199287	chr2:24214381~24221516:+
LUAD	cis	rs2288073	0.965	rs6545340	ENSG00000242628.4	AC009228.1	4.26	2.42e-05	0.00422	0.26	0.19	Venous thromboembolism (SNP x SNP interaction);	chr2:24199400	chr2:24214381~24221516:+
LUAD	cis	rs6687758	1	rs66666316	ENSG00000200033.1	RNU6-403P	4.26	2.42e-05	0.00422	0.27	0.19	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222018592	chr1:221837334~221837437:-
LUAD	cis	rs8040855	0.627	rs12900012	ENSG00000259774.1	RP11-182J1.13	4.26	2.42e-05	0.00422	0.24	0.19	Bulimia nervosa;	chr15:85046955	chr15:84422618~84425882:+
LUAD	cis	rs8040855	0.627	rs72757059	ENSG00000259774.1	RP11-182J1.13	4.26	2.42e-05	0.00422	0.24	0.19	Bulimia nervosa;	chr15:85059918	chr15:84422618~84425882:+
LUAD	cis	rs8040855	0.627	rs11634975	ENSG00000259774.1	RP11-182J1.13	4.26	2.42e-05	0.00422	0.24	0.19	Bulimia nervosa;	chr15:85063247	chr15:84422618~84425882:+
LUAD	cis	rs7189233	0.531	rs9931702	ENSG00000279344.1	RP11-44F14.7	4.26	2.42e-05	0.00422	0.16	0.19	Intelligence (multi-trait analysis);	chr16:53492639	chr16:53478957~53481550:-
LUAD	cis	rs3814244	0.528	rs7306466	ENSG00000236946.2	HNRNPA1P70	-4.26	2.42e-05	0.00422	-0.16	-0.19	Itch intensity from mosquito bite adjusted by bite size;	chr12:68014942	chr12:68035767~68036853:+
LUAD	cis	rs4664293	0.967	rs35975814	ENSG00000230783.1	AC009961.2	-4.26	2.42e-05	0.00422	-0.24	-0.19	Monocyte percentage of white cells;	chr2:159691280	chr2:159689217~159690291:-
LUAD	cis	rs7560272	0.723	rs780391	ENSG00000163016.8	ALMS1P	-4.26	2.42e-05	0.00423	-0.2	-0.19	Schizophrenia;	chr2:73476777	chr2:73644919~73685576:+
LUAD	cis	rs11009175	0.725	rs11009183	ENSG00000273038.2	RP11-479G22.8	-4.26	2.42e-05	0.00423	-0.26	-0.19	Depression (quantitative trait);	chr10:33017381	chr10:32887255~32889311:-
LUAD	cis	rs7202877	0.706	rs247443	ENSG00000280152.1	RP11-331F4.5	-4.26	2.42e-05	0.00423	-0.23	-0.19	Type 1 diabetes;Type 2 diabetes;	chr16:75431175	chr16:75245994~75250077:-
LUAD	cis	rs6687758	1	rs12125383	ENSG00000200033.1	RNU6-403P	4.26	2.42e-05	0.00423	0.27	0.19	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221995092	chr1:221837334~221837437:-
LUAD	cis	rs847577	0.609	rs17435590	ENSG00000272950.1	RP11-307C18.1	4.26	2.42e-05	0.00423	0.24	0.19	Breast cancer;	chr7:98154749	chr7:98322853~98323430:+
LUAD	cis	rs847577	0.609	rs34320230	ENSG00000272950.1	RP11-307C18.1	4.26	2.42e-05	0.00423	0.24	0.19	Breast cancer;	chr7:98156188	chr7:98322853~98323430:+
LUAD	cis	rs7208859	0.623	rs8068645	ENSG00000266490.1	CTD-2349P21.9	4.26	2.42e-05	0.00423	0.28	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777324	chr17:30792372~30792833:+
LUAD	cis	rs1864585	0.52	rs10503409	ENSG00000255046.1	RP11-297N6.4	-4.26	2.43e-05	0.00423	-0.27	-0.19	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10812144	chr8:11797928~11802568:-
LUAD	cis	rs11089937	0.597	rs4821774	ENSG00000211640.3	IGLV6-57	4.26	2.43e-05	0.00423	0.14	0.19	Periodontitis (PAL4Q3);	chr22:22131536	chr22:22195713~22196460:+
LUAD	cis	rs28386778	0.897	rs2044125	ENSG00000240280.5	TCAM1P	4.26	2.43e-05	0.00423	0.22	0.19	Prudent dietary pattern;	chr17:63785824	chr17:63849292~63864379:+
LUAD	cis	rs848490	0.962	rs11772392	ENSG00000214293.7	APTR	4.26	2.43e-05	0.00423	0.26	0.19	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77834526	chr7:77657660~77696265:-
LUAD	cis	rs6750795	0.502	rs11685196	ENSG00000223198.1	RNU2-22P	-4.26	2.43e-05	0.00423	-0.22	-0.19	Height;	chr2:231516587	chr2:231501990~231502201:-
LUAD	cis	rs9549260	0.739	rs7330614	ENSG00000229456.1	RLIMP1	4.26	2.43e-05	0.00423	0.21	0.19	Red blood cell count;	chr13:40625284	chr13:40618738~40621348:+
LUAD	cis	rs41411047	0.826	rs112285435	ENSG00000271711.1	RP11-392O18.2	4.26	2.43e-05	0.00423	0.37	0.19	Myocardial infarction;	chr3:149829153	chr3:150611262~150611877:-
LUAD	cis	rs2657294	0.796	rs2804534	ENSG00000226051.5	ZNF503-AS1	4.26	2.43e-05	0.00423	0.25	0.19	Pneumonia;	chr10:75208023	chr10:75269819~75373500:+
LUAD	cis	rs6940638	0.688	rs9461335	ENSG00000219392.1	RP1-265C24.5	-4.26	2.43e-05	0.00423	-0.24	-0.19	Intelligence (multi-trait analysis);	chr6:27170750	chr6:28115628~28116551:+
LUAD	cis	rs2446066	0.872	rs114075368	ENSG00000257379.1	RP11-793H13.8	4.26	2.43e-05	0.00423	0.31	0.19	Red blood cell count;	chr12:53407960	chr12:53441741~53467528:+
LUAD	cis	rs875971	0.66	rs1860468	ENSG00000236529.1	RP13-254B10.1	-4.26	2.43e-05	0.00423	-0.2	-0.19	Aortic root size;	chr7:66642265	chr7:65840212~65840596:+
LUAD	cis	rs2281636	0.754	rs7087826	ENSG00000233690.1	EBAG9P1	4.26	2.43e-05	0.00423	0.19	0.19	Obesity-related traits;	chr10:99604588	chr10:99697407~99697949:-
LUAD	cis	rs301901	0.965	rs13180309	ENSG00000250155.1	CTD-2353F22.1	-4.26	2.43e-05	0.00423	-0.2	-0.19	Height;	chr5:36789899	chr5:36666214~36725195:-
LUAD	cis	rs6964587	0.967	rs13233496	ENSG00000188693.7	CYP51A1-AS1	-4.26	2.43e-05	0.00424	-0.23	-0.19	Breast cancer;	chr7:92183721	chr7:92134604~92180725:+
LUAD	cis	rs2153535	0.585	rs4960449	ENSG00000230939.1	RP11-314C16.1	-4.26	2.43e-05	0.00424	-0.21	-0.19	Motion sickness;	chr6:8625762	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.585	rs9393048	ENSG00000230939.1	RP11-314C16.1	-4.26	2.43e-05	0.00424	-0.21	-0.19	Motion sickness;	chr6:8626321	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.585	rs7766729	ENSG00000230939.1	RP11-314C16.1	-4.26	2.43e-05	0.00424	-0.21	-0.19	Motion sickness;	chr6:8627408	chr6:8784178~8785445:+
LUAD	cis	rs7811142	1	rs11761725	ENSG00000078319.8	PMS2P1	-4.26	2.43e-05	0.00424	-0.23	-0.19	Platelet count;	chr7:100442192	chr7:100320992~100341908:-
LUAD	cis	rs4374383	0.962	rs11683819	ENSG00000207383.1	Y_RNA	4.26	2.43e-05	0.00424	0.23	0.19	Hepatitis C induced liver fibrosis;	chr2:112020864	chr2:112579484~112579584:-
LUAD	cis	rs801193	1	rs17566701	ENSG00000224316.1	RP11-479O9.2	4.26	2.43e-05	0.00424	0.2	0.19	Aortic root size;	chr7:66728196	chr7:65773620~65802067:+
LUAD	cis	rs11886999	0.812	rs7579709	ENSG00000237510.6	AC008268.2	-4.26	2.43e-05	0.00424	-0.31	-0.19	Cardiac Troponin-T levels;	chr2:96215858	chr2:95789654~95800166:+
LUAD	cis	rs11886999	0.723	rs62153020	ENSG00000237510.6	AC008268.2	-4.26	2.43e-05	0.00424	-0.31	-0.19	Cardiac Troponin-T levels;	chr2:96216390	chr2:95789654~95800166:+
LUAD	cis	rs210138	1	rs210144	ENSG00000197251.3	LINC00336	4.26	2.43e-05	0.00424	0.31	0.19	Testicular germ cell tumor;	chr6:33579653	chr6:33586106~33593338:-
LUAD	cis	rs9532669	0.926	rs9562254	ENSG00000239827.7	SUGT1P3	4.26	2.43e-05	0.00424	0.22	0.19	Cervical cancer;	chr13:40960902	chr13:40908159~40921774:-
LUAD	cis	rs6840258	0.831	rs3775226	ENSG00000251411.1	RP11-397E7.4	-4.26	2.43e-05	0.00424	-0.25	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87068313	chr4:86913266~86914817:-
LUAD	cis	rs6840258	0.831	rs3736668	ENSG00000251411.1	RP11-397E7.4	-4.26	2.43e-05	0.00424	-0.25	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87071058	chr4:86913266~86914817:-
LUAD	cis	rs9341808	0.718	rs35447745	ENSG00000272129.1	RP11-250B2.6	4.26	2.43e-05	0.00424	0.23	0.19	Sitting height ratio;	chr6:80107031	chr6:80355424~80356859:+
LUAD	cis	rs9341808	0.718	rs9352801	ENSG00000272129.1	RP11-250B2.6	4.26	2.43e-05	0.00424	0.23	0.19	Sitting height ratio;	chr6:80107751	chr6:80355424~80356859:+
LUAD	cis	rs9309473	0.519	rs4852951	ENSG00000163016.8	ALMS1P	-4.26	2.44e-05	0.00424	-0.21	-0.19	Metabolite levels;	chr2:73642669	chr2:73644919~73685576:+
LUAD	cis	rs4819052	0.851	rs2838857	ENSG00000237664.1	LINC00316	-4.26	2.44e-05	0.00425	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261085	chr21:45338590~45341990:-
LUAD	cis	rs12682352	0.652	rs1567398	ENSG00000173295.6	FAM86B3P	-4.26	2.44e-05	0.00425	-0.2	-0.19	Neuroticism;	chr8:8869294	chr8:8228595~8244865:+
LUAD	cis	rs1979679	0.766	rs11049365	ENSG00000278733.1	RP11-425D17.1	4.26	2.44e-05	0.00425	0.24	0.19	Ossification of the posterior longitudinal ligament of the spine;	chr12:28138401	chr12:28185625~28186190:-
LUAD	cis	rs7208859	0.623	rs73269916	ENSG00000280069.1	CTD-2349P21.3	-4.26	2.44e-05	0.00425	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30769308	chr17:30738182~30740275:+
LUAD	cis	rs12534093	0.562	rs6461715	ENSG00000234286.1	AC006026.13	-4.26	2.44e-05	0.00425	-0.25	-0.19	Infant length;Height;	chr7:23539496	chr7:23680195~23680786:-
LUAD	cis	rs6430553	0.861	rs12463645	ENSG00000224043.6	CCNT2-AS1	-4.26	2.44e-05	0.00425	-0.23	-0.19	Blood metabolite levels;	chr2:134916800	chr2:134735464~134918710:-
LUAD	cis	rs10090774	0.71	rs13275969	ENSG00000280303.2	ERICD	-4.26	2.44e-05	0.00425	-0.21	-0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140663317	chr8:140636281~140638283:+
LUAD	cis	rs12073359	1	rs12063329	ENSG00000223945.2	RP11-458I7.1	-4.26	2.44e-05	0.00425	-0.28	-0.19	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150030478	chr1:150053864~150055034:+
LUAD	cis	rs9649213	0.537	rs35997266	ENSG00000272950.1	RP11-307C18.1	4.26	2.44e-05	0.00425	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98336254	chr7:98322853~98323430:+
LUAD	cis	rs2439831	0.867	rs2447196	ENSG00000249839.1	AC011330.5	4.26	2.44e-05	0.00425	0.34	0.19	Lung cancer in ever smokers;	chr15:43601620	chr15:43663654~43684339:-
LUAD	cis	rs4873772	0.808	rs6987043	ENSG00000253330.1	RP11-697N18.3	-4.26	2.44e-05	0.00425	-0.21	-0.19	Lobe attachment (rater-scored or self-reported);	chr8:47679023	chr8:47511034~47512141:-
LUAD	cis	rs10863681	0.664	rs11118934	ENSG00000228437.4	RP11-400N13.2	4.26	2.44e-05	0.00425	0.24	0.19	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222070113	chr1:221966341~221984964:+
LUAD	cis	rs10863681	0.713	rs12134885	ENSG00000228437.4	RP11-400N13.2	4.26	2.44e-05	0.00425	0.24	0.19	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222071038	chr1:221966341~221984964:+
LUAD	cis	rs136161	1	rs713753	ENSG00000268818.2	CITF22-62D4.1	4.26	2.44e-05	0.00425	0.21	0.19	Diabetic kidney disease;	chr22:36262488	chr22:35626988~35635134:-
LUAD	cis	rs2929278	0.561	rs2927071	ENSG00000166763.7	STRCP1	4.26	2.44e-05	0.00425	0.23	0.19	Schizophrenia;	chr15:43626883	chr15:43699488~43718184:-
LUAD	cis	rs5758659	0.652	rs133349	ENSG00000182057.4	OGFRP1	4.26	2.44e-05	0.00425	0.23	0.19	Cognitive function;	chr22:42032723	chr22:42269753~42275196:+
LUAD	cis	rs763121	0.849	rs12004	ENSG00000228274.3	RP3-508I15.9	-4.26	2.44e-05	0.00425	-0.19	-0.19	Menopause (age at onset);	chr22:38481456	chr22:38667585~38681820:-
LUAD	cis	rs681343	1	rs681343	ENSG00000232871.7	SEC1P	4.26	2.44e-05	0.00425	0.21	0.19	Primary sclerosing cholangitis;Childhood ear infection;Lung adenocarcinoma;	chr19:48703205	chr19:48638071~48682245:+
LUAD	cis	rs791888	0.965	rs791876	ENSG00000225913.2	RP11-57C13.6	4.26	2.44e-05	0.00425	0.24	0.19	Magnesium levels;	chr10:87646770	chr10:87607985~87659279:+
LUAD	cis	rs2115630	0.818	rs7176522	ENSG00000229212.6	RP11-561C5.4	4.26	2.44e-05	0.00425	0.23	0.19	P wave terminal force;	chr15:84672152	chr15:85205440~85234795:-
LUAD	cis	rs473651	0.935	rs483166	ENSG00000229915.1	AC016999.2	4.26	2.44e-05	0.00425	0.25	0.19	Multiple system atrophy;	chr2:238438000	chr2:238427077~238427729:-
LUAD	cis	rs7196129	0.932	rs11574938	ENSG00000183604.13	SMG1P5	4.26	2.44e-05	0.00425	0.2	0.19	Monocyte count;	chr16:30474072	chr16:30267553~30335374:-
LUAD	cis	rs7772486	0.681	rs9390343	ENSG00000235652.6	RP11-545I5.3	-4.26	2.44e-05	0.00425	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145689391	chr6:145799409~145886585:+
LUAD	cis	rs4865762	0.595	rs251505	ENSG00000247796.2	CTD-2366F13.1	4.26	2.44e-05	0.00425	0.19	0.19	Intraocular pressure;	chr5:53248259	chr5:53109842~53115126:+
LUAD	cis	rs6706648	0.55	rs13034649	ENSG00000234624.2	AC016894.1	-4.26	2.44e-05	0.00426	-0.22	-0.19	F-cell distribution;	chr2:60445120	chr2:61416887~61417197:-
LUAD	cis	rs1329650	1	rs4933206	ENSG00000228701.1	TNKS2-AS1	-4.26	2.44e-05	0.00426	-0.26	-0.19	Smoking behavior;	chr10:91578843	chr10:91782839~91798291:-
LUAD	cis	rs7829975	0.572	rs28730413	ENSG00000173295.6	FAM86B3P	-4.26	2.44e-05	0.00426	-0.2	-0.19	Mood instability;	chr8:8937937	chr8:8228595~8244865:+
LUAD	cis	rs2239547	0.618	rs1573815	ENSG00000242142.1	SERBP1P3	-4.26	2.44e-05	0.00426	-0.22	-0.19	Schizophrenia;	chr3:52836116	chr3:53064283~53065091:-
LUAD	cis	rs394563	0.601	rs391875	ENSG00000231760.4	RP11-350J20.5	4.26	2.45e-05	0.00426	0.25	0.19	Dupuytren's disease;	chr6:149474000	chr6:149796151~149826294:-
LUAD	cis	rs4664293	0.934	rs1365800	ENSG00000230783.1	AC009961.2	-4.26	2.45e-05	0.00426	-0.24	-0.19	Monocyte percentage of white cells;	chr2:159699112	chr2:159689217~159690291:-
LUAD	cis	rs473651	0.935	rs578510	ENSG00000229915.1	AC016999.2	-4.26	2.45e-05	0.00426	-0.25	-0.19	Multiple system atrophy;	chr2:238434499	chr2:238427077~238427729:-
LUAD	cis	rs2412475	0.705	rs12899662	ENSG00000248508.5	SRP14-AS1	-4.26	2.45e-05	0.00426	-0.23	-0.19	Obesity-related traits;	chr15:40068909	chr15:40039311~40067290:+
LUAD	cis	rs6822297	1	rs6822297	ENSG00000240005.4	RP11-293A21.1	-4.26	2.45e-05	0.00426	-0.23	-0.19	Obesity-related traits;	chr4:26999373	chr4:26859806~26860599:-
LUAD	cis	rs7208859	0.673	rs78799101	ENSG00000280069.1	CTD-2349P21.3	-4.26	2.45e-05	0.00426	-0.27	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888142	chr17:30738182~30740275:+
LUAD	cis	rs7829975	0.582	rs6982832	ENSG00000173295.6	FAM86B3P	-4.26	2.45e-05	0.00426	-0.2	-0.19	Mood instability;	chr8:8934707	chr8:8228595~8244865:+
LUAD	cis	rs7829975	0.774	rs11775523	ENSG00000233609.3	RP11-62H7.2	4.26	2.45e-05	0.00426	0.16	0.19	Mood instability;	chr8:8821666	chr8:8961200~8979025:+
LUAD	cis	rs7829975	0.774	rs1039915	ENSG00000233609.3	RP11-62H7.2	4.26	2.45e-05	0.00426	0.16	0.19	Mood instability;	chr8:8822104	chr8:8961200~8979025:+
LUAD	cis	rs2749097	0.545	rs7541882	ENSG00000244256.3	RN7SL130P	-4.26	2.45e-05	0.00426	-0.25	-0.19	Alcohol consumption (transferrin glycosylation);	chr1:63655898	chr1:63655743~63656047:+
LUAD	cis	rs6570726	1	rs374464	ENSG00000235652.6	RP11-545I5.3	4.26	2.45e-05	0.00426	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145525543	chr6:145799409~145886585:+
LUAD	cis	rs6570726	1	rs450076	ENSG00000235652.6	RP11-545I5.3	4.26	2.45e-05	0.00426	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145526519	chr6:145799409~145886585:+
LUAD	cis	rs12073837	0.5	rs2807845	ENSG00000272823.1	RP11-295M18.6	-4.26	2.45e-05	0.00426	-0.21	-0.19	F-cell distribution;	chr1:220822945	chr1:220828676~220829211:-
LUAD	cis	rs8030379	1	rs922664	ENSG00000230373.7	GOLGA6L5P	-4.26	2.45e-05	0.00426	-0.18	-0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83900803	chr15:84507885~84516814:-
LUAD	cis	rs9341808	0.718	rs9294171	ENSG00000260645.1	RP11-250B2.5	4.26	2.45e-05	0.00426	0.18	0.19	Sitting height ratio;	chr6:80130098	chr6:80466958~80469080:+
LUAD	cis	rs6686842	0.56	rs213751	ENSG00000235358.1	RP11-399E6.1	-4.26	2.45e-05	0.00426	-0.22	-0.19	Height;	chr1:41144214	chr1:41242373~41284861:+
LUAD	cis	rs228614	0.509	rs223481	ENSG00000251288.2	RP11-10L12.2	-4.26	2.45e-05	0.00426	-0.23	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766860	chr4:102751401~102752641:+
LUAD	cis	rs6964587	0.967	rs34344935	ENSG00000188693.7	CYP51A1-AS1	-4.26	2.45e-05	0.00426	-0.23	-0.19	Breast cancer;	chr7:92206122	chr7:92134604~92180725:+
LUAD	cis	rs7119038	0.818	rs11217033	ENSG00000255422.1	AP002954.4	4.26	2.45e-05	0.00426	0.3	0.19	Sjögren's syndrome;	chr11:118802997	chr11:118704607~118750263:+
LUAD	cis	rs11217036	1	rs11217036	ENSG00000255422.1	AP002954.4	4.26	2.45e-05	0.00426	0.3	0.19	Allergy;	chr11:118805063	chr11:118704607~118750263:+
LUAD	cis	rs7119038	0.774	rs11217038	ENSG00000255422.1	AP002954.4	4.26	2.45e-05	0.00426	0.3	0.19	Sjögren's syndrome;	chr11:118806646	chr11:118704607~118750263:+
LUAD	cis	rs6964587	1	rs55745934	ENSG00000188693.7	CYP51A1-AS1	-4.26	2.45e-05	0.00427	-0.23	-0.19	Breast cancer;	chr7:92041684	chr7:92134604~92180725:+
LUAD	cis	rs67981189	0.579	rs2240533	ENSG00000269927.1	RP6-91H8.3	4.26	2.45e-05	0.00427	0.25	0.19	Schizophrenia;	chr14:71074309	chr14:71141125~71143253:-
LUAD	cis	rs11512640	0.655	rs80057612	ENSG00000254671.2	STT3A-AS1	4.26	2.45e-05	0.00427	0.42	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125542949	chr11:125570284~125592568:-
LUAD	cis	rs6570726	0.902	rs4895678	ENSG00000235652.6	RP11-545I5.3	4.26	2.45e-05	0.00427	0.2	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145614374	chr6:145799409~145886585:+
LUAD	cis	rs9309473	0.583	rs6718864	ENSG00000163016.8	ALMS1P	4.26	2.45e-05	0.00427	0.22	0.19	Metabolite levels;	chr2:73347463	chr2:73644919~73685576:+
LUAD	cis	rs28386778	0.897	rs1043127	ENSG00000240280.5	TCAM1P	-4.26	2.45e-05	0.00427	-0.22	-0.19	Prudent dietary pattern;	chr17:63713850	chr17:63849292~63864379:+
LUAD	cis	rs8062405	0.755	rs7193402	ENSG00000261419.1	RP11-57A19.4	-4.26	2.45e-05	0.00427	-0.21	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28659696~28740781:-
LUAD	cis	rs7819412	0.805	rs2409710	ENSG00000255046.1	RP11-297N6.4	4.26	2.45e-05	0.00427	0.24	0.19	Triglycerides;	chr8:11122311	chr8:11797928~11802568:-
LUAD	cis	rs61989804	0.536	rs1123493	ENSG00000258613.1	RPL21P7	4.26	2.45e-05	0.00427	0.38	0.19	Midgestational circulating levels of PCBs (fetal genetic effect);	chr14:65200828	chr14:65266638~65267690:-
LUAD	cis	rs2834288	1	rs2834288	ENSG00000237945.6	LINC00649	4.26	2.46e-05	0.00427	0.24	0.19	Gut microbiota (bacterial taxa);	chr21:33892093	chr21:33915534~33977691:+
LUAD	cis	rs12073359	1	rs72694954	ENSG00000223945.2	RP11-458I7.1	-4.26	2.46e-05	0.00427	-0.29	-0.19	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150151572	chr1:150053864~150055034:+
LUAD	cis	rs4578769	0.55	rs4635434	ENSG00000265943.1	RP11-739L10.1	-4.26	2.46e-05	0.00427	-0.24	-0.19	Eosinophil percentage of white cells;	chr18:22996032	chr18:22699481~22933764:-
LUAD	cis	rs4578769	0.55	rs4471804	ENSG00000265943.1	RP11-739L10.1	-4.26	2.46e-05	0.00427	-0.24	-0.19	Eosinophil percentage of white cells;	chr18:22996218	chr18:22699481~22933764:-
LUAD	cis	rs2243480	1	rs73142162	ENSG00000232559.3	GS1-124K5.12	4.26	2.46e-05	0.00428	0.34	0.19	Diabetic kidney disease;	chr7:65909309	chr7:66554588~66576923:-
LUAD	cis	rs9532580	0.656	rs2721068	ENSG00000229456.1	RLIMP1	4.26	2.46e-05	0.00428	0.22	0.19	Mean corpuscular hemoglobin;	chr13:40565575	chr13:40618738~40621348:+
LUAD	cis	rs10129255	0.957	rs10132367	ENSG00000211974.3	IGHV2-70	4.26	2.46e-05	0.00428	0.2	0.19	Kawasaki disease;	chr14:106690981	chr14:106723574~106724093:-
LUAD	cis	rs2060793	0.741	rs2060794	ENSG00000251991.1	RNU7-49P	4.26	2.46e-05	0.00428	0.21	0.19	Vitamin D levels;	chr11:14791437	chr11:14478892~14478953:+
LUAD	cis	rs2060793	0.741	rs3740823	ENSG00000251991.1	RNU7-49P	4.26	2.46e-05	0.00428	0.21	0.19	Vitamin D levels;	chr11:14804158	chr11:14478892~14478953:+
LUAD	cis	rs763121	0.853	rs2413547	ENSG00000225450.1	RP3-508I15.14	-4.26	2.46e-05	0.00428	-0.19	-0.19	Menopause (age at onset);	chr22:38711333	chr22:38739003~38749041:+
LUAD	cis	rs35740288	0.822	rs2306225	ENSG00000259407.1	RP11-158M2.3	-4.26	2.46e-05	0.00428	-0.19	-0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85684721	chr15:85744109~85750281:-
LUAD	cis	rs35740288	0.822	rs11638720	ENSG00000259407.1	RP11-158M2.3	-4.26	2.46e-05	0.00428	-0.19	-0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85686042	chr15:85744109~85750281:-
LUAD	cis	rs35740288	0.822	rs1961601	ENSG00000259407.1	RP11-158M2.3	-4.26	2.46e-05	0.00428	-0.19	-0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85686375	chr15:85744109~85750281:-
LUAD	cis	rs35740288	0.822	rs2016517	ENSG00000259407.1	RP11-158M2.3	-4.26	2.46e-05	0.00428	-0.19	-0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85686387	chr15:85744109~85750281:-
LUAD	cis	rs35740288	0.787	rs727379	ENSG00000259407.1	RP11-158M2.3	-4.26	2.46e-05	0.00428	-0.19	-0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85686659	chr15:85744109~85750281:-
LUAD	cis	rs11089937	0.597	rs4821773	ENSG00000211640.3	IGLV6-57	4.26	2.46e-05	0.00428	0.14	0.19	Periodontitis (PAL4Q3);	chr22:22131434	chr22:22195713~22196460:+
LUAD	cis	rs1008375	1	rs62295634	ENSG00000249502.1	AC006160.5	-4.26	2.46e-05	0.00428	-0.18	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17683723	chr4:17587467~17614571:-
LUAD	cis	rs9815354	0.812	rs794897	ENSG00000273328.4	RP11-141M3.6	4.26	2.46e-05	0.00428	0.3	0.19	Pulse pressure;Diastolic blood pressure;	chr3:41990373	chr3:42809414~42908105:+
LUAD	cis	rs9815354	0.761	rs794896	ENSG00000273328.4	RP11-141M3.6	4.26	2.46e-05	0.00428	0.3	0.19	Pulse pressure;Diastolic blood pressure;	chr3:41990410	chr3:42809414~42908105:+
LUAD	cis	rs848490	0.962	rs1045463	ENSG00000214293.7	APTR	4.26	2.46e-05	0.00428	0.26	0.19	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77793835	chr7:77657660~77696265:-
LUAD	cis	rs910316	0.839	rs35977276	ENSG00000279594.1	RP11-950C14.10	-4.26	2.46e-05	0.00428	-0.22	-0.19	Height;	chr14:75170656	chr14:75011269~75012851:-
LUAD	cis	rs7829975	0.54	rs2976909	ENSG00000233609.3	RP11-62H7.2	-4.26	2.46e-05	0.00428	-0.15	-0.19	Mood instability;	chr8:8489180	chr8:8961200~8979025:+
LUAD	cis	rs2274273	0.661	rs2147964	ENSG00000258413.1	RP11-665C16.6	-4.26	2.46e-05	0.00428	-0.25	-0.19	Protein biomarker;	chr14:55097677	chr14:55262767~55272075:-
LUAD	cis	rs4811196	0.748	rs1474623	ENSG00000226144.2	RPS27AP3	4.26	2.46e-05	0.00428	0.21	0.19	Bone mineral density;	chr20:37860509	chr20:37049254~37049707:+
LUAD	cis	rs911555	0.723	rs4906324	ENSG00000244691.1	RPL10AP1	4.26	2.46e-05	0.00428	0.25	0.19	Intelligence (multi-trait analysis);	chr14:103456762	chr14:103412119~103412761:-
LUAD	cis	rs911555	0.723	rs2273701	ENSG00000244691.1	RPL10AP1	4.26	2.46e-05	0.00428	0.25	0.19	Intelligence (multi-trait analysis);	chr14:103456888	chr14:103412119~103412761:-
LUAD	cis	rs12030196	0.788	rs10889125	ENSG00000230812.4	LINC01358	4.26	2.46e-05	0.00428	0.19	0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:58951444	chr1:59020387~59044614:+
LUAD	cis	rs453301	0.686	rs7814328	ENSG00000253893.2	FAM85B	4.26	2.46e-05	0.00428	0.25	0.19	Joint mobility (Beighton score);	chr8:9018719	chr8:8167819~8226614:-
LUAD	cis	rs6095360	1	rs1569750	ENSG00000222365.1	SNORD12B	-4.26	2.46e-05	0.00428	-0.2	-0.19	Intelligence (multi-trait analysis);	chr20:48986704	chr20:49280319~49280409:+
LUAD	cis	rs944990	0.618	rs7023577	ENSG00000227603.1	RP11-165J3.6	4.26	2.46e-05	0.00428	0.21	0.19	Body mass index;	chr9:93574711	chr9:93435332~93437121:-
LUAD	cis	rs28386778	0.897	rs894413	ENSG00000240280.5	TCAM1P	-4.26	2.46e-05	0.00428	-0.22	-0.19	Prudent dietary pattern;	chr17:63838987	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.863	rs894414	ENSG00000240280.5	TCAM1P	-4.26	2.46e-05	0.00428	-0.22	-0.19	Prudent dietary pattern;	chr17:63839024	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.863	rs8076760	ENSG00000240280.5	TCAM1P	-4.26	2.46e-05	0.00428	-0.22	-0.19	Prudent dietary pattern;	chr17:63843137	chr17:63849292~63864379:+
LUAD	cis	rs5758511	0.68	rs5758698	ENSG00000227370.1	RP4-669P10.19	4.26	2.46e-05	0.00428	0.21	0.19	Birth weight;	chr22:42288812	chr22:42132543~42132998:+
LUAD	cis	rs2657294	0.895	rs2395137	ENSG00000233313.2	HMGA1P5	-4.26	2.46e-05	0.00428	-0.24	-0.19	Pneumonia;	chr10:75088235	chr10:75276376~75276646:-
LUAD	cis	rs10266483	0.774	rs1404679	ENSG00000227986.1	TRIM60P18	4.26	2.46e-05	0.00429	0.23	0.19	Response to statin therapy;	chr7:64358254	chr7:64355078~64356199:+
LUAD	cis	rs7208859	0.673	rs17826219	ENSG00000266490.1	CTD-2349P21.9	4.26	2.46e-05	0.00429	0.3	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834827	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs61223749	ENSG00000266490.1	CTD-2349P21.9	4.26	2.46e-05	0.00429	0.3	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30836729	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs3764420	ENSG00000266490.1	CTD-2349P21.9	4.26	2.46e-05	0.00429	0.3	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837136	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs3764421	ENSG00000266490.1	CTD-2349P21.9	4.26	2.46e-05	0.00429	0.3	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30840635	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs11651858	ENSG00000266490.1	CTD-2349P21.9	4.26	2.46e-05	0.00429	0.3	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843700	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs36056619	ENSG00000266490.1	CTD-2349P21.9	4.26	2.46e-05	0.00429	0.3	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30845266	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs9909497	ENSG00000266490.1	CTD-2349P21.9	4.26	2.46e-05	0.00429	0.3	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846210	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs11080135	ENSG00000266490.1	CTD-2349P21.9	4.26	2.46e-05	0.00429	0.3	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30849463	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs9894876	ENSG00000266490.1	CTD-2349P21.9	4.26	2.46e-05	0.00429	0.3	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855002	chr17:30792372~30792833:+
LUAD	cis	rs1729951	0.575	rs361245	ENSG00000239213.4	NCK1-AS1	4.26	2.47e-05	0.00429	0.21	0.19	Neuroticism;	chr3:136976864	chr3:136841726~136862054:-
LUAD	cis	rs7772486	0.682	rs1337840	ENSG00000235652.6	RP11-545I5.3	-4.26	2.47e-05	0.00429	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145721422	chr6:145799409~145886585:+
LUAD	cis	rs2562456	0.876	rs10424079	ENSG00000268081.1	RP11-678G14.2	4.26	2.47e-05	0.00429	0.3	0.19	Pain;	chr19:21406377	chr19:21554640~21569237:-
LUAD	cis	rs7208859	0.623	rs8082537	ENSG00000280069.1	CTD-2349P21.3	-4.26	2.47e-05	0.00429	-0.24	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30688914	chr17:30738182~30740275:+
LUAD	cis	rs6563842	0.528	rs56340348	ENSG00000229456.1	RLIMP1	4.26	2.47e-05	0.00429	0.2	0.19	Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr13:40722235	chr13:40618738~40621348:+
LUAD	cis	rs6432852	0.516	rs2304002	ENSG00000232411.1	AC009495.3	4.26	2.47e-05	0.00429	0.19	0.19	Diabetic kidney disease;	chr2:165857585	chr2:165833048~165839098:-
LUAD	cis	rs9400467	0.528	rs455726	ENSG00000230177.1	RP5-1112D6.4	-4.26	2.47e-05	0.00429	-0.17	-0.19	Amino acid levels;Blood metabolite levels;	chr6:111378165	chr6:111277932~111278742:+
LUAD	cis	rs1993293	0.569	rs62042315	ENSG00000182397.13	DNM1P46	-4.26	2.47e-05	0.00429	-0.29	-0.19	Coronary artery calcification;	chr15:99751724	chr15:99790156~99806927:-
LUAD	cis	rs11673344	0.504	rs7252940	ENSG00000276846.1	CTD-3220F14.3	4.26	2.47e-05	0.00429	0.21	0.19	Obesity-related traits;	chr19:37138589	chr19:37314868~37315620:-
LUAD	cis	rs2288073	0.965	rs10199334	ENSG00000242628.4	AC009228.1	4.26	2.47e-05	0.00429	0.26	0.19	Venous thromboembolism (SNP x SNP interaction);	chr2:24169749	chr2:24214381~24221516:+
LUAD	cis	rs4811196	0.748	rs4811232	ENSG00000226144.2	RPS27AP3	4.26	2.47e-05	0.00429	0.21	0.19	Bone mineral density;	chr20:37857805	chr20:37049254~37049707:+
LUAD	cis	rs4971059	0.654	rs4971076	ENSG00000160766.13	GBAP1	-4.26	2.47e-05	0.0043	-0.19	-0.19	Breast cancer;	chr1:155152296	chr1:155213821~155227422:-
LUAD	cis	rs2274273	0.774	rs17128440	ENSG00000258413.1	RP11-665C16.6	-4.26	2.47e-05	0.0043	-0.24	-0.19	Protein biomarker;	chr14:55395194	chr14:55262767~55272075:-
LUAD	cis	rs227275	0.554	rs223454	ENSG00000251288.2	RP11-10L12.2	-4.26	2.47e-05	0.0043	-0.22	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102789773	chr4:102751401~102752641:+
LUAD	cis	rs10090774	0.71	rs11780289	ENSG00000280303.2	ERICD	-4.26	2.47e-05	0.0043	-0.21	-0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140679315	chr8:140636281~140638283:+
LUAD	cis	rs6951245	1	rs2363286	ENSG00000199023.2	MIR339	-4.26	2.47e-05	0.0043	-0.32	-0.19	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1051989	chr7:1022935~1023045:-
LUAD	cis	rs2115630	1	rs56074163	ENSG00000225151.9	GOLGA2P7	4.26	2.47e-05	0.0043	0.21	0.19	P wave terminal force;	chr15:84808101	chr15:84199311~84230136:-
LUAD	cis	rs748404	0.706	rs35975365	ENSG00000249839.1	AC011330.5	-4.26	2.47e-05	0.0043	-0.32	-0.19	Lung cancer;	chr15:43379347	chr15:43663654~43684339:-
LUAD	cis	rs8014252	0.803	rs17108274	ENSG00000259158.2	ADAM20P1	-4.26	2.47e-05	0.0043	-0.34	-0.19	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70603684	chr14:70468881~70483756:-
LUAD	cis	rs17772222	0.74	rs11845147	ENSG00000258983.2	RP11-507K2.2	4.26	2.47e-05	0.0043	0.22	0.19	Coronary artery calcification;	chr14:88502804	chr14:88499334~88515502:+
LUAD	cis	rs4666360	1	rs4233757	ENSG00000234378.1	AC098828.2	4.26	2.48e-05	0.0043	0.23	0.19	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);	chr2:20136316	chr2:20063856~20106829:-
LUAD	cis	rs4713118	0.869	rs9348775	ENSG00000280107.1	AL022393.9	-4.26	2.48e-05	0.0043	-0.24	-0.19	Parkinson's disease;	chr6:27727550	chr6:28170845~28172521:+
LUAD	cis	rs2147959	0.941	rs4653960	ENSG00000269934.1	RP5-1139B12.3	-4.26	2.48e-05	0.0043	-0.24	-0.19	Adult asthma;	chr1:228444018	chr1:228274584~228276066:-
LUAD	cis	rs6728642	0.561	rs62152901	ENSG00000230606.9	AC159540.1	4.26	2.48e-05	0.0043	0.28	0.19	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96899161	chr2:97416165~97433527:-
LUAD	cis	rs9467773	1	rs9461271	ENSG00000261353.1	CTA-14H9.5	-4.26	2.48e-05	0.0043	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26554740	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs9467787	ENSG00000261353.1	CTA-14H9.5	-4.26	2.48e-05	0.0043	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26556541	chr6:26527063~26527404:+
LUAD	cis	rs2243480	1	rs778729	ENSG00000229886.1	RP5-1132H15.3	4.26	2.48e-05	0.0043	0.33	0.19	Diabetic kidney disease;	chr7:66359432	chr7:66025126~66031544:-
LUAD	cis	rs2154319	0.609	rs78715416	ENSG00000235358.1	RP11-399E6.1	-4.26	2.48e-05	0.00431	-0.23	-0.19	Height;	chr1:41272417	chr1:41242373~41284861:+
LUAD	cis	rs3814244	0.528	rs7962511	ENSG00000236946.2	HNRNPA1P70	-4.26	2.48e-05	0.00431	-0.17	-0.19	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002854	chr12:68035767~68036853:+
LUAD	cis	rs2153535	0.585	rs1328870	ENSG00000230939.1	RP11-314C16.1	-4.26	2.48e-05	0.00431	-0.21	-0.19	Motion sickness;	chr6:8637803	chr6:8784178~8785445:+
LUAD	cis	rs4795519	1	rs4795519	ENSG00000266313.1	RP11-173M1.4	4.26	2.48e-05	0.00431	0.23	0.19	Chronic myeloid leukemia;	chr17:27214252	chr17:27333256~27348491:+
LUAD	cis	rs2274273	0.688	rs6573001	ENSG00000258413.1	RP11-665C16.6	-4.26	2.48e-05	0.00431	-0.25	-0.19	Protein biomarker;	chr14:55089784	chr14:55262767~55272075:-
LUAD	cis	rs17428076	0.556	rs12692976	ENSG00000228389.1	AC068039.4	4.26	2.48e-05	0.00431	0.2	0.19	Myopia;	chr2:171827893	chr2:171773482~171775844:+
LUAD	cis	rs9970334	0.596	rs709209	ENSG00000226944.1	RP1-120G22.11	4.26	2.48e-05	0.00431	0.21	0.19	Resting heart rate;	chr1:6218354	chr1:6204840~6205780:-
LUAD	cis	rs4964805	0.913	rs11111795	ENSG00000257681.1	RP11-341G23.4	4.26	2.48e-05	0.00431	0.23	0.19	Attention deficit hyperactivity disorder;	chr12:103811052	chr12:103746315~103768858:-
LUAD	cis	rs7404843	0.925	rs7404803	ENSG00000263335.1	AF001548.5	-4.26	2.48e-05	0.00431	-0.4	-0.19	Testicular germ cell tumor;	chr16:15436597	chr16:15726674~15732993:+
LUAD	cis	rs6496932	0.865	rs4842874	ENSG00000202081.1	RNU6-1280P	4.26	2.48e-05	0.00431	0.28	0.19	Central corneal thickness;Corneal structure;	chr15:85323464	chr15:85651522~85651628:-
LUAD	cis	rs6496932	0.865	rs4843049	ENSG00000202081.1	RNU6-1280P	4.26	2.48e-05	0.00431	0.28	0.19	Central corneal thickness;Corneal structure;	chr15:85331141	chr15:85651522~85651628:-
LUAD	cis	rs6840258	0.689	rs6811587	ENSG00000251411.1	RP11-397E7.4	4.26	2.48e-05	0.00431	0.22	0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87000653	chr4:86913266~86914817:-
LUAD	cis	rs853679	0.538	rs13199081	ENSG00000219392.1	RP1-265C24.5	-4.26	2.48e-05	0.00432	-0.25	-0.19	Depression;	chr6:28364057	chr6:28115628~28116551:+
LUAD	cis	rs7688540	0.8	rs28531997	ENSG00000211553.1	AC253576.2	-4.26	2.49e-05	0.00432	-0.24	-0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:248998	chr4:136461~136568:+
LUAD	cis	rs10463554	0.926	rs3776858	ENSG00000250682.4	LINC00491	4.26	2.49e-05	0.00432	0.23	0.19	Parkinson's disease;	chr5:103021790	chr5:102609156~102671559:-
LUAD	cis	rs2243480	1	rs6460260	ENSG00000226002.1	RP11-460N20.5	4.26	2.49e-05	0.00432	0.33	0.19	Diabetic kidney disease;	chr7:65750468	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs6460261	ENSG00000226002.1	RP11-460N20.5	4.26	2.49e-05	0.00432	0.33	0.19	Diabetic kidney disease;	chr7:65750593	chr7:65084103~65100232:+
LUAD	cis	rs12073359	1	rs11577346	ENSG00000223945.2	RP11-458I7.1	-4.26	2.49e-05	0.00432	-0.29	-0.19	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150094433	chr1:150053864~150055034:+
LUAD	cis	rs7178424	0.742	rs963024	ENSG00000259251.2	RP11-643M14.1	4.26	2.49e-05	0.00432	0.19	0.19	Height;	chr15:61919251	chr15:62060503~62062434:+
LUAD	cis	rs763121	0.651	rs738249	ENSG00000228274.3	RP3-508I15.9	-4.26	2.49e-05	0.00432	-0.19	-0.19	Menopause (age at onset);	chr22:38641974	chr22:38667585~38681820:-
LUAD	cis	rs9840812	0.683	rs8045	ENSG00000239213.4	NCK1-AS1	-4.26	2.49e-05	0.00432	-0.26	-0.19	Fibrinogen levels;	chr3:136336617	chr3:136841726~136862054:-
LUAD	cis	rs2657294	0.965	rs7088974	ENSG00000233313.2	HMGA1P5	-4.26	2.49e-05	0.00433	-0.24	-0.19	Pneumonia;	chr10:75131338	chr10:75276376~75276646:-
LUAD	cis	rs7760535	0.826	rs10872068	ENSG00000271789.1	RP5-1112D6.7	4.26	2.49e-05	0.00433	0.2	0.19	Metabolic traits;	chr6:111528657	chr6:111297126~111298510:+
LUAD	cis	rs16944613	0.528	rs6416554	ENSG00000259212.1	CTD-3065B20.2	4.26	2.49e-05	0.00433	0.3	0.19	Colorectal cancer;	chr15:90595058	chr15:90595840~90596447:-
LUAD	cis	rs7204230	1	rs17302113	ENSG00000261291.1	RP11-295M3.2	4.26	2.49e-05	0.00433	0.24	0.19	Fibrinogen;	chr16:53138241	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs8057285	ENSG00000261291.1	RP11-295M3.2	4.26	2.49e-05	0.00433	0.24	0.19	Fibrinogen;	chr16:53149968	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs62048018	ENSG00000261291.1	RP11-295M3.2	4.26	2.49e-05	0.00433	0.24	0.19	Fibrinogen;	chr16:53158519	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs62048020	ENSG00000261291.1	RP11-295M3.2	4.26	2.49e-05	0.00433	0.24	0.19	Fibrinogen;	chr16:53161035	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs12599521	ENSG00000261291.1	RP11-295M3.2	4.26	2.49e-05	0.00433	0.24	0.19	Fibrinogen;	chr16:53161352	chr16:53168522~53169450:+
LUAD	cis	rs2348418	0.831	rs1581074	ENSG00000247934.4	RP11-967K21.1	4.26	2.49e-05	0.00433	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28571031	chr12:28163298~28190738:-
LUAD	cis	rs7107174	1	rs2292572	ENSG00000251323.2	RP11-452H21.4	4.26	2.49e-05	0.00433	0.23	0.19	Testicular germ cell tumor;	chr11:78341818	chr11:78423982~78429836:-
LUAD	cis	rs73186030	0.764	rs2332179	ENSG00000272758.4	RP11-299J3.8	4.26	2.49e-05	0.00433	0.25	0.19	Serum parathyroid hormone levels;	chr3:122360583	chr3:122416207~122443180:+
LUAD	cis	rs8180040	0.835	rs6780013	ENSG00000271161.1	BOLA2P2	-4.26	2.49e-05	0.00433	-0.18	-0.19	Colorectal cancer;	chr3:47410628	chr3:47499841~47500407:+
LUAD	cis	rs2274273	0.967	rs8009670	ENSG00000259318.1	RP11-454L9.2	4.26	2.49e-05	0.00433	0.17	0.19	Protein biomarker;	chr14:55116759	chr14:55394940~55395233:-
LUAD	cis	rs6832769	0.89	rs564762	ENSG00000272969.1	RP11-528I4.2	4.26	2.5e-05	0.00434	0.2	0.19	Personality dimensions;	chr4:55418464	chr4:55547112~55547889:+
LUAD	cis	rs1894292	1	rs1894292	ENSG00000221639.1	SNORA3	-4.26	2.5e-05	0.00434	-0.19	-0.19	Prostate cancer;	chr4:73483441	chr4:73263960~73264084:+
LUAD	cis	rs6479891	1	rs4746195	ENSG00000232075.1	MRPL35P2	4.26	2.5e-05	0.00434	0.32	0.19	Arthritis (juvenile idiopathic);	chr10:63547893	chr10:63634317~63634827:-
LUAD	cis	rs7819412	0.807	rs10105315	ENSG00000255046.1	RP11-297N6.4	4.26	2.5e-05	0.00434	0.24	0.19	Triglycerides;	chr8:11074693	chr8:11797928~11802568:-
LUAD	cis	rs8030379	1	rs10906983	ENSG00000230373.7	GOLGA6L5P	-4.26	2.5e-05	0.00434	-0.18	-0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83900431	chr15:84507885~84516814:-
LUAD	cis	rs2252586	0.916	rs6593195	ENSG00000176826.14	FKBP9P1	4.26	2.5e-05	0.00434	0.25	0.19	Glioma;	chr7:54896701	chr7:55681074~55713252:-
LUAD	cis	rs67981189	0.529	rs61990380	ENSG00000269927.1	RP6-91H8.3	4.26	2.5e-05	0.00434	0.25	0.19	Schizophrenia;	chr14:71005229	chr14:71141125~71143253:-
LUAD	cis	rs9803723	0.826	rs12737245	ENSG00000261349.1	RP3-465N24.5	-4.26	2.5e-05	0.00434	-0.22	-0.19	Male-pattern baldness;	chr1:25137010	chr1:25266102~25267136:-
LUAD	cis	rs3026445	0.519	rs11065209	ENSG00000278993.1	RP3-424M6.4	4.26	2.5e-05	0.00434	0.24	0.19	QT interval;	chr12:110156465	chr12:110501614~110503441:+
LUAD	cis	rs62025270	0.688	rs17575870	ENSG00000202081.1	RNU6-1280P	-4.26	2.5e-05	0.00434	-0.28	-0.19	Idiopathic pulmonary fibrosis;	chr15:85713926	chr15:85651522~85651628:-
LUAD	cis	rs2661868	0.51	rs11584036	ENSG00000232912.4	RP5-1115A15.1	-4.26	2.5e-05	0.00434	-0.2	-0.19	Life satisfaction;	chr1:8327403	chr1:8424645~8434838:+
LUAD	cis	rs1005277	0.505	rs13503	ENSG00000263064.2	RP11-291L22.7	-4.26	2.5e-05	0.00435	-0.2	-0.19	Extrinsic epigenetic age acceleration;	chr10:37950915	chr10:38448689~38448949:+
LUAD	cis	rs4840086	1	rs2894891	ENSG00000219755.1	RP1-199J3.5	4.26	2.5e-05	0.00435	0.24	0.19	Menarche (age at onset);	chr6:99762031	chr6:99575712~99576456:+
LUAD	cis	rs7636293	0.565	rs6763292	ENSG00000270773.1	RP13-685P2.7	4.26	2.5e-05	0.00435	0.28	0.19	Height;	chr3:129325862	chr3:129345411~129346164:+
LUAD	cis	rs4934494	0.768	rs34993776	ENSG00000240996.1	RP11-80H5.7	-4.26	2.5e-05	0.00435	-0.28	-0.19	Red blood cell count;	chr10:89681932	chr10:89694295~89697928:-
LUAD	cis	rs7061710	0.711	rs2272800	ENSG00000271811.1	RP1-79C4.4	4.26	2.51e-05	0.00435	0.28	0.19	Blood metabolite levels;	chr1:171149920	chr1:170667381~170669425:+
LUAD	cis	rs11051970	0.679	rs2651377	ENSG00000274964.1	RP11-817I4.1	-4.26	2.51e-05	0.00435	-0.19	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr12:32403985	chr12:32339368~32340724:+
LUAD	cis	rs4819052	0.851	rs2838831	ENSG00000237664.1	LINC00316	-4.26	2.51e-05	0.00435	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244860	chr21:45338590~45341990:-
LUAD	cis	rs7005380	0.538	rs6469875	ENSG00000279347.1	RP11-85I17.2	-4.26	2.51e-05	0.00435	-0.18	-0.19	Interstitial lung disease;	chr8:119914393	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.538	rs2056305	ENSG00000279347.1	RP11-85I17.2	-4.26	2.51e-05	0.00435	-0.18	-0.19	Interstitial lung disease;	chr8:119916865	chr8:119838736~119840385:-
LUAD	cis	rs889398	0.771	rs4985448	ENSG00000226232.7	RP11-419C5.2	-4.26	2.51e-05	0.00435	-0.16	-0.19	Body mass index;	chr16:69865492	chr16:69976388~69996188:-
LUAD	cis	rs889398	0.771	rs1566454	ENSG00000226232.7	RP11-419C5.2	-4.26	2.51e-05	0.00435	-0.16	-0.19	Body mass index;	chr16:69866180	chr16:69976388~69996188:-
LUAD	cis	rs889398	0.651	rs1566455	ENSG00000226232.7	RP11-419C5.2	-4.26	2.51e-05	0.00435	-0.16	-0.19	Body mass index;	chr16:69866261	chr16:69976388~69996188:-
LUAD	cis	rs6686842	0.56	rs2802549	ENSG00000235358.1	RP11-399E6.1	4.26	2.51e-05	0.00435	0.23	0.19	Height;	chr1:41034874	chr1:41242373~41284861:+
LUAD	cis	rs1799949	0.965	rs9646418	ENSG00000236383.6	LINC00854	-4.26	2.51e-05	0.00435	-0.15	-0.19	Menopause (age at onset);	chr17:43348533	chr17:43216941~43305976:-
LUAD	cis	rs442309	0.875	rs224056	ENSG00000238280.1	RP11-436D10.3	-4.26	2.51e-05	0.00435	-0.22	-0.19	Vogt-Koyanagi-Harada syndrome;	chr10:62737240	chr10:62793562~62805887:-
LUAD	cis	rs2243480	1	rs4718317	ENSG00000229886.1	RP5-1132H15.3	-4.26	2.51e-05	0.00435	-0.32	-0.19	Diabetic kidney disease;	chr7:66183914	chr7:66025126~66031544:-
LUAD	cis	rs4763879	0.593	rs7960328	ENSG00000278635.1	CTD-2318O12.1	4.26	2.51e-05	0.00435	0.17	0.19	Type 1 diabetes;	chr12:9699584	chr12:9415641~9416718:+
LUAD	cis	rs12073359	0.955	rs72694962	ENSG00000223945.2	RP11-458I7.1	-4.26	2.51e-05	0.00435	-0.28	-0.19	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150175740	chr1:150053864~150055034:+
LUAD	cis	rs7208859	0.623	rs8067035	ENSG00000266490.1	CTD-2349P21.9	4.26	2.51e-05	0.00436	0.28	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775170	chr17:30792372~30792833:+
LUAD	cis	rs11707813	0.593	rs9850978	ENSG00000226360.5	RPL10AP6	-4.26	2.51e-05	0.00436	-0.21	-0.19	Lip morphology;	chr3:61201600	chr3:61742455~61743106:-
LUAD	cis	rs2711721	0.56	rs2522268	ENSG00000274723.1	RP11-618L22.1	4.26	2.51e-05	0.00436	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr12:47015123	chr12:46970504~46972155:+
LUAD	cis	rs2153535	0.585	rs9405403	ENSG00000230939.1	RP11-314C16.1	-4.26	2.51e-05	0.00436	-0.21	-0.19	Motion sickness;	chr6:8636061	chr6:8784178~8785445:+
LUAD	cis	rs2243480	1	rs9769882	ENSG00000229886.1	RP5-1132H15.3	-4.25	2.52e-05	0.00436	-0.33	-0.19	Diabetic kidney disease;	chr7:66177938	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs6966322	ENSG00000229886.1	RP5-1132H15.3	-4.25	2.52e-05	0.00436	-0.33	-0.19	Diabetic kidney disease;	chr7:66181767	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs4145008	ENSG00000229886.1	RP5-1132H15.3	-4.25	2.52e-05	0.00436	-0.33	-0.19	Diabetic kidney disease;	chr7:66182524	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs4718315	ENSG00000229886.1	RP5-1132H15.3	-4.25	2.52e-05	0.00436	-0.33	-0.19	Diabetic kidney disease;	chr7:66183554	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs4718316	ENSG00000229886.1	RP5-1132H15.3	-4.25	2.52e-05	0.00436	-0.33	-0.19	Diabetic kidney disease;	chr7:66183744	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs1873494	ENSG00000229886.1	RP5-1132H15.3	-4.25	2.52e-05	0.00436	-0.33	-0.19	Diabetic kidney disease;	chr7:66184912	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs6959002	ENSG00000229886.1	RP5-1132H15.3	-4.25	2.52e-05	0.00436	-0.33	-0.19	Diabetic kidney disease;	chr7:66185509	chr7:66025126~66031544:-
LUAD	cis	rs3808502	0.574	rs4841559	ENSG00000255046.1	RP11-297N6.4	4.25	2.52e-05	0.00436	0.23	0.19	Neuroticism;	chr8:11559376	chr8:11797928~11802568:-
LUAD	cis	rs7129556	0.645	rs598071	ENSG00000241782.1	RP11-91P24.1	4.25	2.52e-05	0.00437	0.27	0.19	Weight loss (gastric bypass surgery);	chr11:77849606	chr11:77868722~77869195:-
LUAD	cis	rs7923837	0.616	rs12219514	ENSG00000236493.2	EIF2S2P3	4.25	2.52e-05	0.00437	0.21	0.19	Multiple sclerosis;Body mass index;	chr10:92706682	chr10:92668745~92669743:-
LUAD	cis	rs5769707	0.837	rs5769709	ENSG00000235111.1	RP1-29C18.8	-4.25	2.52e-05	0.00437	-0.21	-0.19	Monocyte percentage of white cells;Monocyte count;	chr22:49628109	chr22:49612657~49615716:-
LUAD	cis	rs11992162	0.967	rs11250185	ENSG00000255046.1	RP11-297N6.4	-4.25	2.52e-05	0.00437	-0.23	-0.19	Monocyte count;	chr8:11975614	chr8:11797928~11802568:-
LUAD	cis	rs11992162	1	rs12334769	ENSG00000255046.1	RP11-297N6.4	-4.25	2.52e-05	0.00437	-0.23	-0.19	Monocyte count;	chr8:11975652	chr8:11797928~11802568:-
LUAD	cis	rs2354432	0.607	rs7537483	ENSG00000226015.2	CCT8P1	-4.25	2.52e-05	0.00437	-0.38	-0.19	Mitochondrial DNA levels;	chr1:147238228	chr1:147203276~147204932:-
LUAD	cis	rs8177876	0.822	rs10514514	ENSG00000261061.1	RP11-303E16.2	-4.25	2.52e-05	0.00437	-0.31	-0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081668	chr16:81030770~81031485:+
LUAD	cis	rs34792	0.688	rs153783	ENSG00000207425.1	Y_RNA	4.25	2.52e-05	0.00437	0.24	0.19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15508509	chr16:14915457~14915556:-
LUAD	cis	rs7204230	1	rs11075899	ENSG00000261291.1	RP11-295M3.2	4.25	2.52e-05	0.00437	0.24	0.19	Fibrinogen;	chr16:53289384	chr16:53168522~53169450:+
LUAD	cis	rs80028505	1	rs16883989	ENSG00000271304.1	DPRXP2	4.25	2.52e-05	0.00437	0.36	0.19	Foot ulcer in diabetes and neuropathy;	chr6:36043181	chr6:35989515~35990436:-
LUAD	cis	rs80028505	0.908	rs6930333	ENSG00000271304.1	DPRXP2	4.25	2.52e-05	0.00437	0.36	0.19	Foot ulcer in diabetes and neuropathy;	chr6:36046811	chr6:35989515~35990436:-
LUAD	cis	rs80028505	0.908	rs6921999	ENSG00000271304.1	DPRXP2	4.25	2.52e-05	0.00437	0.36	0.19	Foot ulcer in diabetes and neuropathy;	chr6:36052151	chr6:35989515~35990436:-
LUAD	cis	rs80028505	0.908	rs73407870	ENSG00000271304.1	DPRXP2	4.25	2.52e-05	0.00437	0.36	0.19	Foot ulcer in diabetes and neuropathy;	chr6:36060470	chr6:35989515~35990436:-
LUAD	cis	rs80028505	0.908	rs73407871	ENSG00000271304.1	DPRXP2	4.25	2.52e-05	0.00437	0.36	0.19	Foot ulcer in diabetes and neuropathy;	chr6:36060866	chr6:35989515~35990436:-
LUAD	cis	rs80028505	0.908	rs60100837	ENSG00000271304.1	DPRXP2	4.25	2.52e-05	0.00437	0.36	0.19	Foot ulcer in diabetes and neuropathy;	chr6:36064311	chr6:35989515~35990436:-
LUAD	cis	rs17685	0.753	rs1637039	ENSG00000280388.1	RP11-229D13.3	-4.25	2.52e-05	0.00437	-0.18	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76063691	chr7:76043977~76045963:-
LUAD	cis	rs860818	1	rs858286	ENSG00000226816.2	AC005082.12	4.25	2.52e-05	0.00437	0.5	0.19	Initial pursuit acceleration;	chr7:23209844	chr7:23206013~23208045:+
LUAD	cis	rs80028505	0.908	rs7771484	ENSG00000271304.1	DPRXP2	-4.25	2.52e-05	0.00437	-0.33	-0.19	Foot ulcer in diabetes and neuropathy;	chr6:36095214	chr6:35989515~35990436:-
LUAD	cis	rs8030379	1	rs2401179	ENSG00000230373.7	GOLGA6L5P	-4.25	2.52e-05	0.00437	-0.18	-0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83910196	chr15:84507885~84516814:-
LUAD	cis	rs8030379	1	rs2401180	ENSG00000230373.7	GOLGA6L5P	-4.25	2.52e-05	0.00437	-0.18	-0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83910434	chr15:84507885~84516814:-
LUAD	cis	rs2348418	0.767	rs7972954	ENSG00000244712.1	RP11-874G11.1	4.25	2.52e-05	0.00437	0.23	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28260273	chr12:28564678~28565141:-
LUAD	cis	rs6095360	0.727	rs35971376	ENSG00000222365.1	SNORD12B	-4.25	2.52e-05	0.00437	-0.22	-0.19	Intelligence (multi-trait analysis);	chr20:49105171	chr20:49280319~49280409:+
LUAD	cis	rs9467773	0.967	rs6941022	ENSG00000261353.1	CTA-14H9.5	-4.25	2.52e-05	0.00437	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26553303	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs2224380	ENSG00000261353.1	CTA-14H9.5	-4.25	2.52e-05	0.00437	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26553715	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs6930120	ENSG00000261353.1	CTA-14H9.5	-4.25	2.52e-05	0.00437	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26555256	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs10484442	ENSG00000261353.1	CTA-14H9.5	-4.25	2.52e-05	0.00437	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26555651	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs767471	ENSG00000261353.1	CTA-14H9.5	-4.25	2.52e-05	0.00437	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26557626	chr6:26527063~26527404:+
LUAD	cis	rs831571	0.774	rs254858	ENSG00000280620.1	SCAANT1	-4.25	2.52e-05	0.00437	-0.25	-0.19	Type 2 diabetes;	chr3:64070579	chr3:63911518~63911772:-
LUAD	cis	rs16944613	0.588	rs12438183	ENSG00000259212.1	CTD-3065B20.2	4.25	2.52e-05	0.00438	0.3	0.19	Colorectal cancer;	chr15:90596012	chr15:90595840~90596447:-
LUAD	cis	rs4761702	0.551	rs11106987	ENSG00000257252.4	RP11-486A14.2	-4.25	2.53e-05	0.00438	-0.24	-0.19	Immature fraction of reticulocytes;	chr12:93339760	chr12:93317135~93377736:-
LUAD	cis	rs8133949	0.638	rs2839429	ENSG00000237232.6	ZNF295-AS1	4.25	2.53e-05	0.00438	0.27	0.19	Hand grip strength;	chr21:41982063	chr21:42009194~42024924:+
LUAD	cis	rs4968361	1	rs4968361	ENSG00000266992.1	DHX40P1	4.25	2.53e-05	0.00438	0.35	0.19	Schizophrenia;	chr17:59425467	chr17:59976009~60002384:-
LUAD	cis	rs853679	1	rs735765	ENSG00000219392.1	RP1-265C24.5	-4.25	2.53e-05	0.00438	-0.32	-0.19	Depression;	chr6:28202519	chr6:28115628~28116551:+
LUAD	cis	rs1431005	0.892	rs72725289	ENSG00000250658.1	RP11-138B4.1	4.25	2.53e-05	0.00438	0.23	0.19	Response to statin therapy;	chr4:187477579	chr4:187304083~187309682:-
LUAD	cis	rs6832769	0.961	rs11939815	ENSG00000272969.1	RP11-528I4.2	4.25	2.53e-05	0.00438	0.2	0.19	Personality dimensions;	chr4:55492116	chr4:55547112~55547889:+
LUAD	cis	rs6832769	0.826	rs58894703	ENSG00000272969.1	RP11-528I4.2	4.25	2.53e-05	0.00438	0.2	0.19	Personality dimensions;	chr4:55492371	chr4:55547112~55547889:+
LUAD	cis	rs9649213	0.555	rs6956686	ENSG00000272950.1	RP11-307C18.1	4.25	2.53e-05	0.00438	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98368633	chr7:98322853~98323430:+
LUAD	cis	rs4664293	1	rs13014418	ENSG00000230783.1	AC009961.2	-4.25	2.53e-05	0.00438	-0.24	-0.19	Monocyte percentage of white cells;	chr2:159627174	chr2:159689217~159690291:-
LUAD	cis	rs853679	0.607	rs34878803	ENSG00000219392.1	RP1-265C24.5	-4.25	2.53e-05	0.00438	-0.41	-0.19	Depression;	chr6:28282402	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.607	rs34396849	ENSG00000219392.1	RP1-265C24.5	-4.25	2.53e-05	0.00438	-0.41	-0.19	Depression;	chr6:28283178	chr6:28115628~28116551:+
LUAD	cis	rs28386778	0.799	rs2727322	ENSG00000240280.5	TCAM1P	-4.25	2.53e-05	0.00438	-0.22	-0.19	Prudent dietary pattern;	chr17:63844346	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.897	rs2727323	ENSG00000240280.5	TCAM1P	-4.25	2.53e-05	0.00438	-0.22	-0.19	Prudent dietary pattern;	chr17:63844639	chr17:63849292~63864379:+
LUAD	cis	rs2243480	0.901	rs313808	ENSG00000229886.1	RP5-1132H15.3	4.25	2.53e-05	0.00438	0.33	0.19	Diabetic kidney disease;	chr7:66034886	chr7:66025126~66031544:-
LUAD	cis	rs7208859	0.673	rs999796	ENSG00000280069.1	CTD-2349P21.3	-4.25	2.53e-05	0.00438	-0.23	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832386	chr17:30738182~30740275:+
LUAD	cis	rs11168618	0.74	rs11495433	ENSG00000240399.1	RP1-228P16.1	4.25	2.53e-05	0.00438	0.18	0.19	Adiponectin levels;	chr12:48535289	chr12:48054813~48055591:-
LUAD	cis	rs12478296	0.685	rs67829386	ENSG00000261186.2	RP11-341N2.1	-4.25	2.53e-05	0.00438	-0.32	-0.19	Obesity-related traits;	chr2:242050125	chr2:242087351~242088457:-
LUAD	cis	rs62355901	0.551	rs72756073	ENSG00000271828.1	CTD-2310F14.1	4.25	2.53e-05	0.00438	0.37	0.19	Breast cancer;	chr5:56732554	chr5:56927874~56929573:+
LUAD	cis	rs62355901	0.551	rs61103728	ENSG00000271828.1	CTD-2310F14.1	4.25	2.53e-05	0.00438	0.37	0.19	Breast cancer;	chr5:56733066	chr5:56927874~56929573:+
LUAD	cis	rs6840258	0.76	rs10032244	ENSG00000251411.1	RP11-397E7.4	-4.25	2.53e-05	0.00439	-0.22	-0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86996779	chr4:86913266~86914817:-
LUAD	cis	rs911555	0.755	rs975892	ENSG00000244691.1	RPL10AP1	-4.25	2.53e-05	0.00439	-0.25	-0.19	Intelligence (multi-trait analysis);	chr14:103417012	chr14:103412119~103412761:-
LUAD	cis	rs6687758	0.687	rs12140498	ENSG00000227925.1	RP11-191N8.2	4.25	2.53e-05	0.00439	0.25	0.19	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221925348	chr1:221827666~221840666:-
LUAD	cis	rs2554380	0.943	rs2033071	ENSG00000259570.1	RP11-671M22.4	4.25	2.53e-05	0.00439	0.28	0.19	Height;	chr15:83696682	chr15:84394512~84395514:+
LUAD	cis	rs10971721	0.584	rs56145814	ENSG00000260947.1	RP11-384P7.7	4.25	2.53e-05	0.00439	0.38	0.19	Body mass index;	chr9:34088953	chr9:33697459~33700986:+
LUAD	cis	rs7665090	0.87	rs228614	ENSG00000251288.2	RP11-10L12.2	4.25	2.53e-05	0.00439	0.23	0.19	Primary biliary cholangitis;	chr4:102657480	chr4:102751401~102752641:+
LUAD	cis	rs2337406	0.81	rs7161739	ENSG00000280411.1	IGHV1-69-2	-4.25	2.53e-05	0.00439	-0.18	-0.19	Alzheimer's disease (late onset);	chr14:106776118	chr14:106762092~106762588:-
LUAD	cis	rs4699052	0.507	rs7662107	ENSG00000246560.2	RP11-10L12.4	4.25	2.54e-05	0.00439	0.27	0.19	Testicular germ cell tumor;	chr4:103337239	chr4:102828055~102844075:+
LUAD	cis	rs6754311	0.731	rs309168	ENSG00000226806.1	AC011893.3	4.25	2.54e-05	0.00439	0.23	0.19	Mosquito bite size;	chr2:135912728	chr2:135820191~135823087:+
LUAD	cis	rs889398	0.802	rs12598642	ENSG00000226232.7	RP11-419C5.2	4.25	2.54e-05	0.00439	0.16	0.19	Body mass index;	chr16:69814869	chr16:69976388~69996188:-
LUAD	cis	rs4460629	0.742	rs7365544	ENSG00000160766.13	GBAP1	-4.25	2.54e-05	0.00439	-0.19	-0.19	Serum magnesium levels;	chr1:155096272	chr1:155213821~155227422:-
LUAD	cis	rs4460629	0.804	rs56112907	ENSG00000160766.13	GBAP1	-4.25	2.54e-05	0.00439	-0.19	-0.19	Serum magnesium levels;	chr1:155098386	chr1:155213821~155227422:-
LUAD	cis	rs1062177	0.756	rs2915826	ENSG00000253921.1	CTB-113P19.3	4.25	2.54e-05	0.00439	0.28	0.19	Preschool internalizing problems;	chr5:151740402	chr5:151753992~151767247:+
LUAD	cis	rs1062177	0.756	rs2964587	ENSG00000253921.1	CTB-113P19.3	4.25	2.54e-05	0.00439	0.28	0.19	Preschool internalizing problems;	chr5:151740411	chr5:151753992~151767247:+
LUAD	cis	rs42490	0.789	rs416324	ENSG00000251136.7	RP11-37B2.1	4.25	2.54e-05	0.00439	0.19	0.19	Leprosy;	chr8:89803007	chr8:89609409~89757727:-
LUAD	cis	rs7339483	1	rs10410193	ENSG00000268058.1	BNIP3P40	-4.25	2.54e-05	0.00439	-0.34	-0.19	Discordance in emotional problems in monozygotic twins;	chr19:24219116	chr19:24098425~24098980:-
LUAD	cis	rs2904524	1	rs4761189	ENSG00000257815.4	RP11-611E13.2	-4.25	2.54e-05	0.00439	-0.26	-0.19	Amyotrophic lateral sclerosis (age of onset);	chr12:70247078	chr12:69904033~70243360:-
LUAD	cis	rs2836974	0.965	rs34578707	ENSG00000232608.1	TIMM9P2	-4.25	2.54e-05	0.0044	-0.23	-0.19	Cognitive function;	chr21:39303241	chr21:39216624~39217506:+
LUAD	cis	rs3742264	1	rs9316181	ENSG00000235903.6	CPB2-AS1	-4.25	2.54e-05	0.0044	-0.24	-0.19	Blood protein levels;	chr13:46071605	chr13:46052806~46113332:+
LUAD	cis	rs3742264	0.961	rs9534308	ENSG00000235903.6	CPB2-AS1	-4.25	2.54e-05	0.0044	-0.24	-0.19	Blood protein levels;	chr13:46071726	chr13:46052806~46113332:+
LUAD	cis	rs2657294	0.895	rs2002023	ENSG00000233313.2	HMGA1P5	-4.25	2.54e-05	0.0044	-0.24	-0.19	Pneumonia;	chr10:75088766	chr10:75276376~75276646:-
LUAD	cis	rs9649213	0.593	rs13232181	ENSG00000272950.1	RP11-307C18.1	4.25	2.54e-05	0.0044	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98306359	chr7:98322853~98323430:+
LUAD	cis	rs2032366	0.606	rs9783923	ENSG00000266920.1	ACTBP9	4.25	2.54e-05	0.0044	0.2	0.19	Obesity-related traits;	chr18:61635518	chr18:62442028~62443126:+
LUAD	cis	rs2548724	0.561	rs10463981	ENSG00000250682.4	LINC00491	4.25	2.54e-05	0.0044	0.22	0.19	Type 2 diabetes;	chr5:102451358	chr5:102609156~102671559:-
LUAD	cis	rs889398	0.771	rs12927431	ENSG00000226232.7	RP11-419C5.2	4.25	2.54e-05	0.0044	0.16	0.19	Body mass index;	chr16:69823144	chr16:69976388~69996188:-
LUAD	cis	rs4763879	0.634	rs61915472	ENSG00000278635.1	CTD-2318O12.1	4.25	2.54e-05	0.0044	0.17	0.19	Type 1 diabetes;	chr12:9700995	chr12:9415641~9416718:+
LUAD	cis	rs240993	0.595	rs3777911	ENSG00000230177.1	RP5-1112D6.4	4.25	2.54e-05	0.0044	0.19	0.19	Inflammatory skin disease;Psoriasis;	chr6:111581277	chr6:111277932~111278742:+
LUAD	cis	rs9500256	0.934	rs1343391	ENSG00000266579.1	RP1-71H19.2	-4.25	2.54e-05	0.0044	-0.23	-0.19	Eosinophilic esophagitis (pediatric);	chr6:58017876	chr6:57493855~57497691:+
LUAD	cis	rs683257	0.636	rs58922657	ENSG00000234147.1	RP3-460G2.2	-4.25	2.54e-05	0.0044	-0.3	-0.19	Facial emotion recognition (angry faces);	chr6:140831739	chr6:140845958~140852924:-
LUAD	cis	rs858239	0.541	rs4624924	ENSG00000226816.2	AC005082.12	4.25	2.54e-05	0.0044	0.25	0.19	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23206013~23208045:+
LUAD	cis	rs7208859	0.673	rs9889968	ENSG00000266490.1	CTD-2349P21.9	4.25	2.54e-05	0.0044	0.3	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30893110	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs61348930	ENSG00000266490.1	CTD-2349P21.9	4.25	2.54e-05	0.0044	0.3	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30894745	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.614	rs28758251	ENSG00000266490.1	CTD-2349P21.9	4.25	2.54e-05	0.0044	0.3	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896294	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs9899943	ENSG00000266490.1	CTD-2349P21.9	4.25	2.54e-05	0.0044	0.3	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896907	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs11080138	ENSG00000266490.1	CTD-2349P21.9	4.25	2.54e-05	0.0044	0.3	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30897524	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs73265612	ENSG00000266490.1	CTD-2349P21.9	4.25	2.54e-05	0.0044	0.3	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30898965	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs2433	ENSG00000266490.1	CTD-2349P21.9	4.25	2.54e-05	0.0044	0.3	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30899210	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs11658435	ENSG00000266490.1	CTD-2349P21.9	4.25	2.54e-05	0.0044	0.3	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30901543	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs73265624	ENSG00000266490.1	CTD-2349P21.9	4.25	2.54e-05	0.0044	0.3	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905048	chr17:30792372~30792833:+
LUAD	cis	rs9649213	0.574	rs7790229	ENSG00000272950.1	RP11-307C18.1	4.25	2.54e-05	0.0044	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98290026	chr7:98322853~98323430:+
LUAD	cis	rs6568686	0.627	rs174381	ENSG00000255389.1	C6orf3	4.25	2.55e-05	0.00441	0.24	0.19	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111592276	chr6:111599875~111602295:+
LUAD	cis	rs2243480	0.908	rs1532573	ENSG00000229886.1	RP5-1132H15.3	-4.25	2.55e-05	0.00441	-0.33	-0.19	Diabetic kidney disease;	chr7:66333815	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs422164	ENSG00000229886.1	RP5-1132H15.3	4.25	2.55e-05	0.00441	0.33	0.19	Diabetic kidney disease;	chr7:66121618	chr7:66025126~66031544:-
LUAD	cis	rs4664293	0.967	rs13020365	ENSG00000230783.1	AC009961.2	-4.25	2.55e-05	0.00441	-0.24	-0.19	Monocyte percentage of white cells;	chr2:159619893	chr2:159689217~159690291:-
LUAD	cis	rs3096299	0.685	rs4785676	ENSG00000261118.1	RP11-104N10.1	4.25	2.55e-05	0.00441	0.19	0.19	Multiple myeloma (IgH translocation);	chr16:89487216	chr16:89492017~89504460:-
LUAD	cis	rs4705952	0.832	rs72797338	ENSG00000233006.5	AC034220.3	-4.25	2.55e-05	0.00441	-0.22	-0.19	C-reactive protein levels;	chr5:132530716	chr5:132311285~132369916:-
LUAD	cis	rs1350171	0.92	rs7944919	ENSG00000255471.1	RP11-736K20.5	-4.25	2.55e-05	0.00441	-0.34	-0.19	Hepatocellular carcinoma in hepatitis B infection;	chr11:86931573	chr11:86892214~86925037:-
LUAD	cis	rs11168618	0.74	rs4237859	ENSG00000240399.1	RP1-228P16.1	4.25	2.55e-05	0.00441	0.18	0.19	Adiponectin levels;	chr12:48530892	chr12:48054813~48055591:-
LUAD	cis	rs6568686	0.527	rs174406	ENSG00000255389.1	C6orf3	4.25	2.55e-05	0.00441	0.25	0.19	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111610125	chr6:111599875~111602295:+
LUAD	cis	rs4819052	0.851	rs8133045	ENSG00000237664.1	LINC00316	-4.25	2.55e-05	0.00441	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238222	chr21:45338590~45341990:-
LUAD	cis	rs801193	0.773	rs801207	ENSG00000236529.1	RP13-254B10.1	-4.25	2.55e-05	0.00442	-0.19	-0.19	Aortic root size;	chr7:66555603	chr7:65840212~65840596:+
LUAD	cis	rs11822910	0.737	rs2729389	ENSG00000265566.2	RN7SL605P	-4.25	2.55e-05	0.00442	-0.24	-0.19	Platelet distribution width;	chr11:57444173	chr11:57528085~57528365:-
LUAD	cis	rs2243480	1	rs13247184	ENSG00000232559.3	GS1-124K5.12	4.25	2.55e-05	0.00442	0.34	0.19	Diabetic kidney disease;	chr7:65893941	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs35283677	ENSG00000232559.3	GS1-124K5.12	4.25	2.55e-05	0.00442	0.34	0.19	Diabetic kidney disease;	chr7:65894246	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs35421653	ENSG00000232559.3	GS1-124K5.12	4.25	2.55e-05	0.00442	0.34	0.19	Diabetic kidney disease;	chr7:65898442	chr7:66554588~66576923:-
LUAD	cis	rs1876905	0.539	rs190246	ENSG00000230177.1	RP5-1112D6.4	4.25	2.55e-05	0.00442	0.24	0.19	Mean corpuscular hemoglobin;	chr6:111277043	chr6:111277932~111278742:+
LUAD	cis	rs7119	0.651	rs12902898	ENSG00000259362.2	RP11-307C19.1	-4.25	2.56e-05	0.00442	-0.24	-0.19	Type 2 diabetes;	chr15:77556849	chr15:77525540~77534110:+
LUAD	cis	rs11644601	1	rs11644601	ENSG00000207425.1	Y_RNA	4.25	2.56e-05	0.00442	0.25	0.19	Metabolite levels (lipid measures);	chr16:15078261	chr16:14915457~14915556:-
LUAD	cis	rs6763848	0.923	rs12638386	ENSG00000214073.2	RPL21P17	-4.25	2.56e-05	0.00442	-0.19	-0.19	Prostate cancer (SNP x SNP interaction);	chr3:1477300	chr3:1905651~1906125:+
LUAD	cis	rs7824557	0.547	rs4512344	ENSG00000255046.1	RP11-297N6.4	4.25	2.56e-05	0.00442	0.24	0.19	Retinal vascular caliber;	chr8:11221272	chr8:11797928~11802568:-
LUAD	cis	rs7773456	0.74	rs4140625	ENSG00000228412.5	RP4-625H18.2	-4.25	2.56e-05	0.00442	-0.24	-0.19	Lupus nephritis in systemic lupus erythematosus;	chr6:19818109	chr6:19802164~19804752:-
LUAD	cis	rs7061710	0.711	rs55855977	ENSG00000271811.1	RP1-79C4.4	-4.25	2.56e-05	0.00442	-0.29	-0.19	Blood metabolite levels;	chr1:171151822	chr1:170667381~170669425:+
LUAD	cis	rs7061710	0.711	rs7889839	ENSG00000271811.1	RP1-79C4.4	-4.25	2.56e-05	0.00442	-0.29	-0.19	Blood metabolite levels;	chr1:171152034	chr1:170667381~170669425:+
LUAD	cis	rs11009175	0.547	rs12256121	ENSG00000273038.2	RP11-479G22.8	-4.25	2.56e-05	0.00443	-0.23	-0.19	Depression (quantitative trait);	chr10:33106677	chr10:32887255~32889311:-
LUAD	cis	rs7208859	0.524	rs73988172	ENSG00000266490.1	CTD-2349P21.9	4.25	2.56e-05	0.00443	0.28	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30792372~30792833:+
LUAD	cis	rs6686842	0.56	rs3738368	ENSG00000235358.1	RP11-399E6.1	-4.25	2.56e-05	0.00443	-0.23	-0.19	Height;	chr1:41020230	chr1:41242373~41284861:+
LUAD	cis	rs7911264	0.739	rs10786050	ENSG00000236493.2	EIF2S2P3	4.25	2.56e-05	0.00443	0.22	0.19	Inflammatory bowel disease;	chr10:92607473	chr10:92668745~92669743:-
LUAD	cis	rs1005277	0.505	rs200910	ENSG00000273019.1	RP11-508N22.13	-4.25	2.56e-05	0.00443	-0.21	-0.19	Extrinsic epigenetic age acceleration;	chr10:37819248	chr10:38149968~38150293:+
LUAD	cis	rs9650657	0.538	rs11250093	ENSG00000255046.1	RP11-297N6.4	-4.25	2.56e-05	0.00443	-0.25	-0.19	Neuroticism;	chr8:10941318	chr8:11797928~11802568:-
LUAD	cis	rs13113518	0.812	rs11133385	ENSG00000272969.1	RP11-528I4.2	4.25	2.56e-05	0.00443	0.2	0.19	Height;	chr4:55460485	chr4:55547112~55547889:+
LUAD	cis	rs9341808	0.628	rs2490245	ENSG00000260645.1	RP11-250B2.5	4.25	2.56e-05	0.00443	0.18	0.19	Sitting height ratio;	chr6:80182710	chr6:80466958~80469080:+
LUAD	cis	rs17685	0.593	rs56265719	ENSG00000280388.1	RP11-229D13.3	-4.25	2.56e-05	0.00443	-0.18	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76166951	chr7:76043977~76045963:-
LUAD	cis	rs4908768	0.539	rs11121205	ENSG00000270282.1	RP5-1115A15.2	4.25	2.56e-05	0.00443	0.21	0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8598026	chr1:8512653~8513021:+
LUAD	cis	rs7302981	0.667	rs1362984	ENSG00000200428.1	Y_RNA	4.25	2.56e-05	0.00443	0.23	0.19	Systolic blood pressure;	chr12:50206201	chr12:50743568~50743684:+
LUAD	cis	rs28386778	0.897	rs9912557	ENSG00000240280.5	TCAM1P	-4.25	2.56e-05	0.00443	-0.22	-0.19	Prudent dietary pattern;	chr17:63707603	chr17:63849292~63864379:+
LUAD	cis	rs4578769	0.569	rs12957183	ENSG00000265943.1	RP11-739L10.1	4.25	2.56e-05	0.00443	0.24	0.19	Eosinophil percentage of white cells;	chr18:22927124	chr18:22699481~22933764:-
LUAD	cis	rs4578769	0.569	rs9948922	ENSG00000265943.1	RP11-739L10.1	4.25	2.56e-05	0.00443	0.24	0.19	Eosinophil percentage of white cells;	chr18:22930198	chr18:22699481~22933764:-
LUAD	cis	rs5758511	0.689	rs17002947	ENSG00000205702.9	CYP2D7	-4.25	2.56e-05	0.00443	-0.19	-0.19	Birth weight;	chr22:42292526	chr22:42140203~42144577:-
LUAD	cis	rs1355223	0.902	rs2226113	ENSG00000271369.1	RP11-350D17.3	-4.25	2.57e-05	0.00444	-0.22	-0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34724742	chr11:34709600~34710161:+
LUAD	cis	rs4819052	0.851	rs35064782	ENSG00000237664.1	LINC00316	-4.25	2.57e-05	0.00444	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254445	chr21:45338590~45341990:-
LUAD	cis	rs7665090	0.936	rs5026474	ENSG00000246560.2	RP11-10L12.4	4.25	2.57e-05	0.00444	0.23	0.19	Primary biliary cholangitis;	chr4:102633653	chr4:102828055~102844075:+
LUAD	cis	rs957448	1	rs2381885	ENSG00000254315.1	RP11-267M23.3	4.25	2.57e-05	0.00444	0.24	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94499974	chr8:94533628~94534391:+
LUAD	cis	rs875971	0.545	rs2460427	ENSG00000222364.1	RNU6-96P	4.25	2.57e-05	0.00444	0.24	0.19	Aortic root size;	chr7:66154218	chr7:66395191~66395286:+
LUAD	cis	rs4819052	0.851	rs1999334	ENSG00000237664.1	LINC00316	-4.25	2.57e-05	0.00444	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250542	chr21:45338590~45341990:-
LUAD	cis	rs7760535	0.826	rs7753887	ENSG00000271789.1	RP5-1112D6.7	-4.25	2.57e-05	0.00444	-0.2	-0.19	Metabolic traits;	chr6:111533904	chr6:111297126~111298510:+
LUAD	cis	rs763121	0.813	rs4821807	ENSG00000225450.1	RP3-508I15.14	-4.25	2.57e-05	0.00444	-0.19	-0.19	Menopause (age at onset);	chr22:38669577	chr22:38739003~38749041:+
LUAD	cis	rs853679	0.517	rs9380056	ENSG00000226314.6	ZNF192P1	-4.25	2.57e-05	0.00444	-0.25	-0.19	Depression;	chr6:28136698	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs9380057	ENSG00000226314.6	ZNF192P1	-4.25	2.57e-05	0.00444	-0.25	-0.19	Depression;	chr6:28136856	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs6941992	ENSG00000226314.6	ZNF192P1	-4.25	2.57e-05	0.00444	-0.25	-0.19	Depression;	chr6:28138363	chr6:28161781~28169594:+
LUAD	cis	rs4713118	0.516	rs4713142	ENSG00000226314.6	ZNF192P1	-4.25	2.57e-05	0.00444	-0.25	-0.19	Parkinson's disease;	chr6:28138569	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs4713143	ENSG00000226314.6	ZNF192P1	-4.25	2.57e-05	0.00444	-0.25	-0.19	Depression;	chr6:28138981	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs4713144	ENSG00000226314.6	ZNF192P1	-4.25	2.57e-05	0.00444	-0.25	-0.19	Depression;	chr6:28139012	chr6:28161781~28169594:+
LUAD	cis	rs10875976	0.875	rs1031477	ENSG00000257464.1	RP11-161H23.8	-4.25	2.57e-05	0.00444	-0.18	-0.19	Obesity;	chr12:49824861	chr12:49442424~49442652:-
LUAD	cis	rs7618501	0.519	rs3774749	ENSG00000234667.1	ACTBP13	4.25	2.57e-05	0.00445	0.21	0.19	Intelligence (multi-trait analysis);	chr3:50169794	chr3:49873347~49877980:-
LUAD	cis	rs12908161	1	rs17600551	ENSG00000259295.5	CSPG4P12	4.25	2.57e-05	0.00445	0.26	0.19	Schizophrenia;	chr15:84776027	chr15:85191438~85213905:+
LUAD	cis	rs12908161	1	rs62019469	ENSG00000259295.5	CSPG4P12	4.25	2.57e-05	0.00445	0.26	0.19	Schizophrenia;	chr15:84777989	chr15:85191438~85213905:+
LUAD	cis	rs7819412	0.54	rs2409725	ENSG00000255046.1	RP11-297N6.4	4.25	2.57e-05	0.00445	0.23	0.19	Triglycerides;	chr8:11184152	chr8:11797928~11802568:-
LUAD	cis	rs2154319	0.666	rs3856251	ENSG00000235358.1	RP11-399E6.1	-4.25	2.57e-05	0.00445	-0.22	-0.19	Height;	chr1:41250375	chr1:41242373~41284861:+
LUAD	cis	rs3020736	0.5	rs6002616	ENSG00000205702.9	CYP2D7	-4.25	2.57e-05	0.00445	-0.16	-0.19	Autism spectrum disorder or schizophrenia;	chr22:42108675	chr22:42140203~42144577:-
LUAD	cis	rs3020736	0.5	rs7364293	ENSG00000205702.9	CYP2D7	-4.25	2.57e-05	0.00445	-0.16	-0.19	Autism spectrum disorder or schizophrenia;	chr22:42110366	chr22:42140203~42144577:-
LUAD	cis	rs763121	0.853	rs9610993	ENSG00000228274.3	RP3-508I15.9	-4.25	2.58e-05	0.00445	-0.19	-0.19	Menopause (age at onset);	chr22:38646813	chr22:38667585~38681820:-
LUAD	cis	rs2929278	0.546	rs686666	ENSG00000166763.7	STRCP1	4.25	2.58e-05	0.00445	0.22	0.19	Schizophrenia;	chr15:43869352	chr15:43699488~43718184:-
LUAD	cis	rs4374383	0.884	rs7579906	ENSG00000207383.1	Y_RNA	-4.25	2.58e-05	0.00445	-0.23	-0.19	Hepatitis C induced liver fibrosis;	chr2:111965789	chr2:112579484~112579584:-
LUAD	cis	rs987710	0.568	rs738885	ENSG00000211639.2	IGLV4-60	-4.25	2.58e-05	0.00445	-0.27	-0.19	Iron status biomarkers;Iron deficiency;	chr22:22162633	chr22:22162199~22162681:+
LUAD	cis	rs2749097	0.696	rs12129559	ENSG00000244256.3	RN7SL130P	-4.25	2.58e-05	0.00445	-0.26	-0.19	Alcohol consumption (transferrin glycosylation);	chr1:63680890	chr1:63655743~63656047:+
LUAD	cis	rs6012564	0.826	rs34778847	ENSG00000230758.1	SNAP23P	4.25	2.58e-05	0.00445	0.2	0.19	Anger;	chr20:49121421	chr20:49038357~49038602:-
LUAD	cis	rs13113518	1	rs13136282	ENSG00000272969.1	RP11-528I4.2	4.25	2.58e-05	0.00445	0.2	0.19	Height;	chr4:55551845	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs11934897	ENSG00000272969.1	RP11-528I4.2	4.25	2.58e-05	0.00445	0.2	0.19	Height;	chr4:55553396	chr4:55547112~55547889:+
LUAD	cis	rs13113518	0.934	rs11932293	ENSG00000272969.1	RP11-528I4.2	4.25	2.58e-05	0.00445	0.2	0.19	Height;	chr4:55554025	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs4865011	ENSG00000272969.1	RP11-528I4.2	4.25	2.58e-05	0.00445	0.2	0.19	Height;	chr4:55554456	chr4:55547112~55547889:+
LUAD	cis	rs763121	0.819	rs5757126	ENSG00000225450.1	RP3-508I15.14	-4.25	2.58e-05	0.00445	-0.19	-0.19	Menopause (age at onset);	chr22:38527670	chr22:38739003~38749041:+
LUAD	cis	rs897984	0.683	rs13337900	ENSG00000232748.3	RP11-196G11.6	-4.25	2.58e-05	0.00445	-0.23	-0.19	Dementia with Lewy bodies;	chr16:30811088	chr16:31056460~31062803:+
LUAD	cis	rs7246657	0.943	rs10415358	ENSG00000226686.6	LINC01535	-4.25	2.58e-05	0.00446	-0.29	-0.19	Coronary artery calcification;	chr19:37317961	chr19:37251912~37265535:+
LUAD	cis	rs394563	0.601	rs432582	ENSG00000231760.4	RP11-350J20.5	4.25	2.58e-05	0.00446	0.25	0.19	Dupuytren's disease;	chr6:149473007	chr6:149796151~149826294:-
LUAD	cis	rs4925386	0.681	rs2427296	ENSG00000273619.1	RP5-908M14.9	-4.25	2.58e-05	0.00446	-0.2	-0.19	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62352419	chr20:62386303~62386970:-
LUAD	cis	rs8073060	0.544	rs17550716	ENSG00000267592.1	CTC-507E2.2	-4.25	2.58e-05	0.00446	-0.27	-0.19	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35566189	chr17:35596904~35597128:-
LUAD	cis	rs6430553	0.964	rs62168869	ENSG00000224043.6	CCNT2-AS1	-4.25	2.58e-05	0.00446	-0.23	-0.19	Blood metabolite levels;	chr2:134889209	chr2:134735464~134918710:-
LUAD	cis	rs11722779	0.844	rs223345	ENSG00000251288.2	RP11-10L12.2	-4.25	2.58e-05	0.00446	-0.23	-0.19	Schizophrenia;	chr4:102859366	chr4:102751401~102752641:+
LUAD	cis	rs11722779	0.873	rs223344	ENSG00000251288.2	RP11-10L12.2	-4.25	2.58e-05	0.00446	-0.23	-0.19	Schizophrenia;	chr4:102859765	chr4:102751401~102752641:+
LUAD	cis	rs6723108	0.627	rs10928522	ENSG00000224043.6	CCNT2-AS1	-4.25	2.58e-05	0.00446	-0.24	-0.19	Type 2 diabetes;	chr2:134875292	chr2:134735464~134918710:-
LUAD	cis	rs2657294	0.796	rs7082123	ENSG00000233313.2	HMGA1P5	-4.25	2.58e-05	0.00446	-0.24	-0.19	Pneumonia;	chr10:75091101	chr10:75276376~75276646:-
LUAD	cis	rs2836950	0.772	rs62222988	ENSG00000255568.3	BRWD1-AS2	-4.25	2.58e-05	0.00446	-0.19	-0.19	Menarche (age at onset);	chr21:39197582	chr21:39313935~39314962:+
LUAD	cis	rs2255336	0.578	rs7980379	ENSG00000245648.1	RP11-277P12.20	4.25	2.58e-05	0.00446	0.29	0.19	Blood protein levels;	chr12:10367591	chr12:10363769~10398506:+
LUAD	cis	rs5758659	0.652	rs5758553	ENSG00000182057.4	OGFRP1	4.25	2.58e-05	0.00446	0.23	0.19	Cognitive function;	chr22:42035425	chr22:42269753~42275196:+
LUAD	cis	rs763121	0.853	rs2064088	ENSG00000228274.3	RP3-508I15.9	-4.25	2.58e-05	0.00446	-0.19	-0.19	Menopause (age at onset);	chr22:38657377	chr22:38667585~38681820:-
LUAD	cis	rs763121	0.853	rs5757213	ENSG00000228274.3	RP3-508I15.9	-4.25	2.58e-05	0.00446	-0.19	-0.19	Menopause (age at onset);	chr22:38657883	chr22:38667585~38681820:-
LUAD	cis	rs944990	0.538	rs10115234	ENSG00000227603.1	RP11-165J3.6	-4.25	2.58e-05	0.00446	-0.21	-0.19	Body mass index;	chr9:93538990	chr9:93435332~93437121:-
LUAD	cis	rs7208859	0.623	rs122898	ENSG00000266490.1	CTD-2349P21.9	-4.25	2.58e-05	0.00446	-0.28	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30792372~30792833:+
LUAD	cis	rs897984	0.646	rs9938088	ENSG00000260911.2	RP11-196G11.2	4.25	2.58e-05	0.00446	0.17	0.19	Dementia with Lewy bodies;	chr16:30818683	chr16:31043150~31049868:+
LUAD	cis	rs6964587	0.869	rs7793946	ENSG00000188693.7	CYP51A1-AS1	4.25	2.59e-05	0.00447	0.23	0.19	Breast cancer;	chr7:91891314	chr7:92134604~92180725:+
LUAD	cis	rs1005277	0.505	rs7917943	ENSG00000273019.1	RP11-508N22.13	4.25	2.59e-05	0.00447	0.21	0.19	Extrinsic epigenetic age acceleration;	chr10:37906883	chr10:38149968~38150293:+
LUAD	cis	rs11168618	0.967	rs11168619	ENSG00000240399.1	RP1-228P16.1	4.25	2.59e-05	0.00447	0.19	0.19	Adiponectin levels;	chr12:48539822	chr12:48054813~48055591:-
LUAD	cis	rs7493	0.755	rs116306774	ENSG00000233942.1	AC004012.1	4.25	2.59e-05	0.00447	0.28	0.19	Yu-Zhi constitution type in type 2 diabetes;	chr7:95387664	chr7:95471835~95473998:+
LUAD	cis	rs7493	0.755	rs17166861	ENSG00000233942.1	AC004012.1	4.25	2.59e-05	0.00447	0.28	0.19	Yu-Zhi constitution type in type 2 diabetes;	chr7:95391290	chr7:95471835~95473998:+
LUAD	cis	rs7493	0.755	rs740264	ENSG00000233942.1	AC004012.1	4.25	2.59e-05	0.00447	0.28	0.19	Yu-Zhi constitution type in type 2 diabetes;	chr7:95392491	chr7:95471835~95473998:+
LUAD	cis	rs2154319	0.609	rs3899207	ENSG00000235358.1	RP11-399E6.1	-4.25	2.59e-05	0.00447	-0.22	-0.19	Height;	chr1:41256005	chr1:41242373~41284861:+
LUAD	cis	rs7107174	1	rs1893448	ENSG00000251323.2	RP11-452H21.4	4.25	2.59e-05	0.00447	0.23	0.19	Testicular germ cell tumor;	chr11:78258134	chr11:78423982~78429836:-
LUAD	cis	rs7107174	1	rs2512535	ENSG00000251323.2	RP11-452H21.4	4.25	2.59e-05	0.00447	0.23	0.19	Testicular germ cell tumor;	chr11:78260422	chr11:78423982~78429836:-
LUAD	cis	rs4268898	0.735	rs12469585	ENSG00000242628.4	AC009228.1	-4.25	2.59e-05	0.00447	-0.24	-0.19	Asthma;	chr2:24266185	chr2:24214381~24221516:+
LUAD	cis	rs712022	1	rs10833824	ENSG00000246225.5	RP11-17A1.3	-4.25	2.59e-05	0.00447	-0.23	-0.19	Dialysis-related mortality;	chr11:22825939	chr11:22829380~22945393:+
LUAD	cis	rs7172677	0.737	rs7179426	ENSG00000260269.4	CTD-2323K18.1	-4.25	2.59e-05	0.00447	-0.24	-0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75149147	chr15:75527150~75601205:-
LUAD	cis	rs7204230	1	rs1894903	ENSG00000261291.1	RP11-295M3.2	4.25	2.59e-05	0.00447	0.23	0.19	Fibrinogen;	chr16:53291779	chr16:53168522~53169450:+
LUAD	cis	rs7172677	0.737	rs6495155	ENSG00000260269.4	CTD-2323K18.1	-4.25	2.59e-05	0.00447	-0.24	-0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75144970	chr15:75527150~75601205:-
LUAD	cis	rs7172677	0.737	rs7178005	ENSG00000260269.4	CTD-2323K18.1	-4.25	2.59e-05	0.00447	-0.24	-0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75145079	chr15:75527150~75601205:-
LUAD	cis	rs7172677	0.737	rs12442392	ENSG00000260269.4	CTD-2323K18.1	-4.25	2.59e-05	0.00447	-0.24	-0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75145137	chr15:75527150~75601205:-
LUAD	cis	rs7172677	0.737	rs12914536	ENSG00000260269.4	CTD-2323K18.1	-4.25	2.59e-05	0.00447	-0.24	-0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75145374	chr15:75527150~75601205:-
LUAD	cis	rs9309473	0.519	rs2178154	ENSG00000163016.8	ALMS1P	-4.25	2.59e-05	0.00447	-0.2	-0.19	Metabolite levels;	chr2:73434610	chr2:73644919~73685576:+
LUAD	cis	rs3177980	0.608	rs10919250	ENSG00000239494.2	RN7SL333P	-4.25	2.59e-05	0.00447	-0.19	-0.19	Amyotrophic lateral sclerosis;	chr1:169815422	chr1:169859756~169860052:+
LUAD	cis	rs7119	0.717	rs12898656	ENSG00000259362.2	RP11-307C19.1	4.25	2.59e-05	0.00448	0.24	0.19	Type 2 diabetes;	chr15:77515653	chr15:77525540~77534110:+
LUAD	cis	rs3096299	0.809	rs2911264	ENSG00000182376.2	RP5-1142A6.8	4.25	2.59e-05	0.00448	0.2	0.19	Multiple myeloma (IgH translocation);	chr16:89432864	chr16:88742767~88745748:+
LUAD	cis	rs8072100	0.713	rs4968257	ENSG00000228782.6	CTD-2026D20.3	4.25	2.59e-05	0.00448	0.21	0.19	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47353168	chr17:47450568~47492492:-
LUAD	cis	rs8072100	0.651	rs1912484	ENSG00000228782.6	CTD-2026D20.3	4.25	2.59e-05	0.00448	0.21	0.19	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47366298	chr17:47450568~47492492:-
LUAD	cis	rs73198271	0.74	rs1039910	ENSG00000253893.2	FAM85B	4.25	2.59e-05	0.00448	0.25	0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790556	chr8:8167819~8226614:-
LUAD	cis	rs6686842	0.56	rs10889885	ENSG00000235358.1	RP11-399E6.1	-4.25	2.59e-05	0.00448	-0.22	-0.19	Height;	chr1:41199081	chr1:41242373~41284861:+
LUAD	cis	rs910316	1	rs7142235	ENSG00000279594.1	RP11-950C14.10	4.25	2.59e-05	0.00448	0.22	0.19	Height;	chr14:75093260	chr14:75011269~75012851:-
LUAD	cis	rs783540	0.5	rs1313494	ENSG00000276710.3	CSPG4P8	4.25	2.6e-05	0.00448	0.2	0.19	Schizophrenia;	chr15:82605530	chr15:82459472~82477258:+
LUAD	cis	rs4664293	0.967	rs3940435	ENSG00000230783.1	AC009961.2	-4.25	2.6e-05	0.00448	-0.23	-0.19	Monocyte percentage of white cells;	chr2:159638272	chr2:159689217~159690291:-
LUAD	cis	rs7216064	0.531	rs62084683	ENSG00000265055.1	AC145343.2	-4.25	2.6e-05	0.00448	-0.18	-0.19	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68035609	chr17:68096046~68101474:-
LUAD	cis	rs4372836	0.93	rs4233727	ENSG00000226833.4	AC097724.3	4.25	2.6e-05	0.00448	0.22	0.19	Body mass index;	chr2:28754378	chr2:28708953~28736205:-
LUAD	cis	rs17772222	0.917	rs12587200	ENSG00000258789.1	RP11-507K2.3	-4.25	2.6e-05	0.00448	-0.26	-0.19	Coronary artery calcification;	chr14:88632060	chr14:88551597~88552493:+
LUAD	cis	rs1729407	0.786	rs5096	ENSG00000280143.1	AP000892.6	4.25	2.6e-05	0.00449	0.21	0.19	Apolipoprotein A-IV levels;	chr11:116822379	chr11:117204967~117210292:+
LUAD	cis	rs4925386	0.808	rs1760073	ENSG00000273619.1	RP5-908M14.9	4.25	2.6e-05	0.00449	0.18	0.19	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62351050	chr20:62386303~62386970:-
LUAD	cis	rs2880765	0.835	rs11638498	ENSG00000259416.2	RP11-158M2.5	4.25	2.6e-05	0.00449	0.19	0.19	Coronary artery disease;	chr15:85479787	chr15:85754941~85756237:-
LUAD	cis	rs62355901	0.599	rs12656399	ENSG00000271828.1	CTD-2310F14.1	4.25	2.6e-05	0.00449	0.37	0.19	Breast cancer;	chr5:56731016	chr5:56927874~56929573:+
LUAD	cis	rs755249	0.517	rs66880209	ENSG00000182109.6	RP11-69E11.4	4.25	2.6e-05	0.00449	0.26	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39254140	chr1:39522280~39546187:-
LUAD	cis	rs2060793	0.741	rs10734227	ENSG00000251991.1	RNU7-49P	4.25	2.6e-05	0.00449	0.21	0.19	Vitamin D levels;	chr11:14767471	chr11:14478892~14478953:+
LUAD	cis	rs6012564	1	rs3092374	ENSG00000230758.1	SNAP23P	-4.25	2.6e-05	0.00449	-0.2	-0.19	Anger;	chr20:49047407	chr20:49038357~49038602:-
LUAD	cis	rs9467773	0.62	rs2494696	ENSG00000241549.7	GUSBP2	4.25	2.6e-05	0.00449	0.21	0.19	Intelligence (multi-trait analysis);	chr6:26620666	chr6:26871484~26956554:-
LUAD	cis	rs2749097	0.877	rs7519583	ENSG00000244256.3	RN7SL130P	-4.25	2.6e-05	0.00449	-0.25	-0.19	Alcohol consumption (transferrin glycosylation);	chr1:63656013	chr1:63655743~63656047:+
LUAD	cis	rs4489787	1	rs2731073	ENSG00000240399.1	RP1-228P16.1	4.25	2.6e-05	0.00449	0.31	0.19	Prostate cancer (SNP x SNP interaction);	chr12:48525773	chr12:48054813~48055591:-
LUAD	cis	rs7208859	0.524	rs77498725	ENSG00000266490.1	CTD-2349P21.9	4.25	2.6e-05	0.00449	0.29	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30736968	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.573	rs73267865	ENSG00000266490.1	CTD-2349P21.9	4.25	2.6e-05	0.00449	0.29	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737186	chr17:30792372~30792833:+
LUAD	cis	rs651907	0.535	rs12633089	ENSG00000244119.1	PDCL3P4	4.25	2.6e-05	0.00449	0.19	0.19	Colorectal cancer;	chr3:101809919	chr3:101712472~101713191:+
LUAD	cis	rs28386778	0.897	rs2028567	ENSG00000240280.5	TCAM1P	-4.25	2.6e-05	0.00449	-0.22	-0.19	Prudent dietary pattern;	chr17:63837966	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.897	rs6504187	ENSG00000240280.5	TCAM1P	-4.25	2.6e-05	0.00449	-0.22	-0.19	Prudent dietary pattern;	chr17:63839739	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.897	rs2859619	ENSG00000240280.5	TCAM1P	-4.25	2.6e-05	0.00449	-0.22	-0.19	Prudent dietary pattern;	chr17:63840326	chr17:63849292~63864379:+
LUAD	cis	rs2153535	0.585	rs9393050	ENSG00000230939.1	RP11-314C16.1	-4.25	2.6e-05	0.00449	-0.21	-0.19	Motion sickness;	chr6:8635219	chr6:8784178~8785445:+
LUAD	cis	rs7189233	0.531	rs1978337	ENSG00000279344.1	RP11-44F14.7	4.25	2.6e-05	0.00449	0.16	0.19	Intelligence (multi-trait analysis);	chr16:53425833	chr16:53478957~53481550:-
LUAD	cis	rs9633740	1	rs10749609	ENSG00000226659.1	RP11-137H2.4	-4.25	2.61e-05	0.0045	-0.3	-0.19	Post bronchodilator FEV1;	chr10:80489996	chr10:80529597~80535942:-
LUAD	cis	rs6840360	0.693	rs28622593	ENSG00000270265.1	RP11-731D1.4	-4.25	2.61e-05	0.0045	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151452928	chr4:151333775~151353224:-
LUAD	cis	rs4841134	0.679	rs958374	ENSG00000233609.3	RP11-62H7.2	4.25	2.61e-05	0.0045	0.15	0.19	Age-related disease endophenotypes;	chr8:9340151	chr8:8961200~8979025:+
LUAD	cis	rs7637701	0.967	rs12638253	ENSG00000240875.4	LINC00886	4.25	2.61e-05	0.0045	0.21	0.19	Breast cancer;	chr3:156908302	chr3:156747346~156817062:-
LUAD	cis	rs34779708	0.766	rs35308730	ENSG00000271335.4	RP11-324I22.4	4.25	2.61e-05	0.0045	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35260868	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.736	rs34195979	ENSG00000271335.4	RP11-324I22.4	4.25	2.61e-05	0.0045	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35260889	chr10:35314552~35336401:-
LUAD	cis	rs2286492	0.655	rs117841439	ENSG00000226329.2	AC005682.6	-4.25	2.61e-05	0.0045	-0.36	-0.19	Bipolar disorder;	chr7:22870922	chr7:22863874~22881350:-
LUAD	cis	rs8050896	1	rs8051838	ENSG00000260695.1	RP11-513N24.1	-4.25	2.61e-05	0.0045	-0.34	-0.19	Response to antipsychotic treatment;	chr16:66125137	chr16:65861112~65863784:-
LUAD	cis	rs7937682	1	rs7937682	ENSG00000230911.1	PPIHP1	-4.25	2.61e-05	0.0045	-0.26	-0.19	Primary sclerosing cholangitis;	chr11:111709215	chr11:112029858~112030367:-
LUAD	cis	rs6519955	0.897	rs4073601	ENSG00000231711.2	LINC00899	4.25	2.61e-05	0.0045	0.17	0.19	Dupuytren's disease;	chr22:46038806	chr22:46039907~46044853:-
LUAD	cis	rs6840360	0.642	rs1899550	ENSG00000270265.1	RP11-731D1.4	-4.25	2.61e-05	0.0045	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151486084	chr4:151333775~151353224:-
LUAD	cis	rs651907	0.535	rs11716558	ENSG00000244119.1	PDCL3P4	4.25	2.61e-05	0.0045	0.19	0.19	Colorectal cancer;	chr3:101809637	chr3:101712472~101713191:+
LUAD	cis	rs1401999	1	rs939337	ENSG00000223882.1	ABCC5-AS1	-4.25	2.61e-05	0.0045	-0.2	-0.19	Anterior chamber depth;	chr3:183983359	chr3:184006338~184011419:+
LUAD	cis	rs17264034	0.821	rs460234	ENSG00000250786.1	SNHG18	4.25	2.61e-05	0.00451	0.28	0.19	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9543022	chr5:9546200~9550609:+
LUAD	cis	rs8072100	0.72	rs4794057	ENSG00000228782.6	CTD-2026D20.3	4.25	2.61e-05	0.00451	0.2	0.19	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47709086	chr17:47450568~47492492:-
LUAD	cis	rs17406451	0.759	rs6544658	ENSG00000279873.2	LINC01126	4.25	2.61e-05	0.00451	0.16	0.19	Mitochondrial DNA levels;	chr2:43424978	chr2:43227210~43228855:+
LUAD	cis	rs7189233	0.531	rs8061398	ENSG00000279344.1	RP11-44F14.7	4.25	2.61e-05	0.00451	0.16	0.19	Intelligence (multi-trait analysis);	chr16:53420239	chr16:53478957~53481550:-
LUAD	cis	rs2354432	0.607	rs6683243	ENSG00000226015.2	CCT8P1	4.25	2.62e-05	0.00451	0.38	0.19	Mitochondrial DNA levels;	chr1:147261765	chr1:147203276~147204932:-
LUAD	cis	rs780096	0.526	rs704795	ENSG00000234072.1	AC074117.10	-4.25	2.62e-05	0.00451	-0.15	-0.19	Total body bone mineral density;	chr2:27493627	chr2:27356246~27367622:+
LUAD	cis	rs8180040	0.966	rs13072802	ENSG00000271161.1	BOLA2P2	4.25	2.62e-05	0.00451	0.18	0.19	Colorectal cancer;	chr3:47304925	chr3:47499841~47500407:+
LUAD	cis	rs7189233	0.531	rs8043918	ENSG00000279344.1	RP11-44F14.7	4.25	2.62e-05	0.00451	0.16	0.19	Intelligence (multi-trait analysis);	chr16:53479121	chr16:53478957~53481550:-
LUAD	cis	rs6500602	0.789	rs2404546	ENSG00000280063.1	RP11-295D4.3	4.25	2.62e-05	0.00451	0.12	0.19	Schizophrenia;	chr16:4429733	chr16:4346694~4348648:-
LUAD	cis	rs9467773	0.62	rs1490488	ENSG00000241549.7	GUSBP2	4.25	2.62e-05	0.00451	0.21	0.19	Intelligence (multi-trait analysis);	chr6:26614580	chr6:26871484~26956554:-
LUAD	cis	rs9467773	0.62	rs2494692	ENSG00000241549.7	GUSBP2	4.25	2.62e-05	0.00451	0.21	0.19	Intelligence (multi-trait analysis);	chr6:26614995	chr6:26871484~26956554:-
LUAD	cis	rs9341808	0.718	rs4437429	ENSG00000260645.1	RP11-250B2.5	4.25	2.62e-05	0.00451	0.18	0.19	Sitting height ratio;	chr6:80118875	chr6:80466958~80469080:+
LUAD	cis	rs800160	0.925	rs800154	ENSG00000236264.4	RPL26P30	-4.25	2.62e-05	0.00451	-0.25	-0.19	Bacteremia;	chr11:2352556	chr11:2335132~2335776:-
LUAD	cis	rs9341808	0.718	rs35447745	ENSG00000260645.1	RP11-250B2.5	4.25	2.62e-05	0.00451	0.18	0.19	Sitting height ratio;	chr6:80107031	chr6:80466958~80469080:+
LUAD	cis	rs9341808	0.718	rs9352801	ENSG00000260645.1	RP11-250B2.5	4.25	2.62e-05	0.00451	0.18	0.19	Sitting height ratio;	chr6:80107751	chr6:80466958~80469080:+
LUAD	cis	rs2348418	0.832	rs4930822	ENSG00000247934.4	RP11-967K21.1	4.25	2.62e-05	0.00451	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28421789	chr12:28163298~28190738:-
LUAD	cis	rs2348418	0.832	rs4930823	ENSG00000247934.4	RP11-967K21.1	4.25	2.62e-05	0.00451	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28421892	chr12:28163298~28190738:-
LUAD	cis	rs1355223	0.902	rs1258468	ENSG00000271369.1	RP11-350D17.3	-4.25	2.62e-05	0.00452	-0.22	-0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34708184	chr11:34709600~34710161:+
LUAD	cis	rs2179367	0.959	rs4897125	ENSG00000216906.2	RP11-350J20.9	4.25	2.62e-05	0.00452	0.23	0.19	Dupuytren's disease;	chr6:149445072	chr6:149904243~149906418:+
LUAD	cis	rs10078	0.898	rs2241598	ENSG00000221990.4	EXOC3-AS1	-4.25	2.62e-05	0.00452	-0.2	-0.19	Fat distribution (HIV);	chr5:438449	chr5:441498~443160:-
LUAD	cis	rs9341808	0.739	rs4706831	ENSG00000233967.5	RP11-250B2.3	4.25	2.62e-05	0.00452	0.19	0.19	Sitting height ratio;	chr6:80297982	chr6:80443344~80465927:+
LUAD	cis	rs7172677	0.961	rs12102035	ENSG00000260269.4	CTD-2323K18.1	-4.25	2.62e-05	0.00452	-0.25	-0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75126530	chr15:75527150~75601205:-
LUAD	cis	rs2348418	0.864	rs6487687	ENSG00000244712.1	RP11-874G11.1	4.24	2.62e-05	0.00452	0.23	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28558230	chr12:28564678~28565141:-
LUAD	cis	rs1008375	0.902	rs7654332	ENSG00000249502.1	AC006160.5	-4.24	2.63e-05	0.00452	-0.18	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17690155	chr4:17587467~17614571:-
LUAD	cis	rs1008375	1	rs7654345	ENSG00000249502.1	AC006160.5	-4.24	2.63e-05	0.00452	-0.18	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17690173	chr4:17587467~17614571:-
LUAD	cis	rs1008375	1	rs10939749	ENSG00000249502.1	AC006160.5	-4.24	2.63e-05	0.00452	-0.18	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17690696	chr4:17587467~17614571:-
LUAD	cis	rs1008375	1	rs10939750	ENSG00000249502.1	AC006160.5	-4.24	2.63e-05	0.00452	-0.18	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17690799	chr4:17587467~17614571:-
LUAD	cis	rs1008375	1	rs4698648	ENSG00000249502.1	AC006160.5	-4.24	2.63e-05	0.00452	-0.18	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17691092	chr4:17587467~17614571:-
LUAD	cis	rs1008375	1	rs4698649	ENSG00000249502.1	AC006160.5	-4.24	2.63e-05	0.00452	-0.18	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17691159	chr4:17587467~17614571:-
LUAD	cis	rs1008375	0.932	rs4698650	ENSG00000249502.1	AC006160.5	-4.24	2.63e-05	0.00452	-0.18	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17691255	chr4:17587467~17614571:-
LUAD	cis	rs1008375	0.966	rs10939755	ENSG00000249502.1	AC006160.5	-4.24	2.63e-05	0.00452	-0.18	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17692132	chr4:17587467~17614571:-
LUAD	cis	rs442309	0.875	rs224055	ENSG00000238280.1	RP11-436D10.3	-4.24	2.63e-05	0.00453	-0.22	-0.19	Vogt-Koyanagi-Harada syndrome;	chr10:62737110	chr10:62793562~62805887:-
LUAD	cis	rs6840360	0.868	rs6823462	ENSG00000270265.1	RP11-731D1.4	-4.24	2.63e-05	0.00453	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151787588	chr4:151333775~151353224:-
LUAD	cis	rs12122100	0.689	rs12129419	ENSG00000244371.2	PFN1P8	4.24	2.63e-05	0.00453	0.24	0.19	HIV-1 control;	chr1:147075155	chr1:146957117~146957659:-
LUAD	cis	rs4591358	0.527	rs16836742	ENSG00000223466.1	AC064834.2	4.24	2.63e-05	0.00453	0.22	0.19	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195512919	chr2:195533035~195538681:+
LUAD	cis	rs2281603	0.951	rs1982440	ENSG00000259116.1	RP11-973N13.4	-4.24	2.63e-05	0.00453	-0.17	-0.19	Lymphocyte counts;	chr14:64494049	chr14:64514154~64540368:-
LUAD	cis	rs910316	0.81	rs77939209	ENSG00000279594.1	RP11-950C14.10	-4.24	2.63e-05	0.00453	-0.22	-0.19	Height;	chr14:75203367	chr14:75011269~75012851:-
LUAD	cis	rs5758659	0.512	rs4822072	ENSG00000182057.4	OGFRP1	4.24	2.63e-05	0.00453	0.23	0.19	Cognitive function;	chr22:41964829	chr22:42269753~42275196:+
LUAD	cis	rs80028505	0.908	rs16884628	ENSG00000271304.1	DPRXP2	4.24	2.63e-05	0.00453	0.35	0.19	Foot ulcer in diabetes and neuropathy;	chr6:36090191	chr6:35989515~35990436:-
LUAD	cis	rs6840360	0.642	rs7680013	ENSG00000270265.1	RP11-731D1.4	-4.24	2.63e-05	0.00453	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151488325	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.642	rs7680236	ENSG00000270265.1	RP11-731D1.4	-4.24	2.63e-05	0.00453	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151488449	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.642	rs4696092	ENSG00000270265.1	RP11-731D1.4	-4.24	2.63e-05	0.00453	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151491451	chr4:151333775~151353224:-
LUAD	cis	rs750134	1	rs12427083	ENSG00000257221.1	RP11-689B22.2	-4.24	2.63e-05	0.00453	-0.28	-0.19	Low high density lipoprotein cholesterol levels;	chr12:108719465	chr12:108628687~108641318:+
LUAD	cis	rs910316	0.763	rs175057	ENSG00000259138.1	RP11-950C14.7	-4.24	2.63e-05	0.00454	-0.2	-0.19	Height;	chr14:75022929	chr14:75127153~75136930:+
LUAD	cis	rs6496932	0.77	rs4843040	ENSG00000218052.5	ADAMTS7P4	4.24	2.63e-05	0.00454	0.21	0.19	Central corneal thickness;Corneal structure;	chr15:85295405	chr15:85255369~85330334:-
LUAD	cis	rs35740288	0.787	rs2008916	ENSG00000259407.1	RP11-158M2.3	-4.24	2.63e-05	0.00454	-0.19	-0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85677959	chr15:85744109~85750281:-
LUAD	cis	rs7208859	0.623	rs56018041	ENSG00000266490.1	CTD-2349P21.9	4.24	2.64e-05	0.00454	0.28	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732967	chr17:30792372~30792833:+
LUAD	cis	rs7142881	0.508	rs1954441	ENSG00000250365.5	CTD-2213F21.2	4.24	2.64e-05	0.00454	0.21	0.19	Response to iloperidone treatment (QT prolongation);	chr14:31649507	chr14:31420286~31452883:+
LUAD	cis	rs1799949	0.965	rs7223952	ENSG00000236383.6	LINC00854	-4.24	2.64e-05	0.00454	-0.15	-0.19	Menopause (age at onset);	chr17:43042868	chr17:43216941~43305976:-
LUAD	cis	rs9900062	1	rs11871616	ENSG00000270714.1	MINOS1P2	-4.24	2.64e-05	0.00454	-0.26	-0.19	QT interval;	chr17:64741484	chr17:64747264~64747492:-
LUAD	cis	rs17660992	0.928	rs12460840	ENSG00000273837.1	LLNLR-470E3.1	-4.24	2.64e-05	0.00454	-0.2	-0.19	Blood protein levels;	chr19:51662141	chr19:51639478~51639931:-
LUAD	cis	rs2242116	0.727	rs4683298	ENSG00000271161.1	BOLA2P2	4.24	2.64e-05	0.00454	0.18	0.19	Birth weight;	chr3:46924897	chr3:47499841~47500407:+
LUAD	cis	rs477895	0.629	rs7130030	ENSG00000236935.1	AP003774.1	-4.24	2.64e-05	0.00454	-0.23	-0.19	Mean platelet volume;	chr11:64166261	chr11:64325050~64329504:-
LUAD	cis	rs9341808	0.718	rs9343971	ENSG00000260645.1	RP11-250B2.5	4.24	2.64e-05	0.00454	0.18	0.19	Sitting height ratio;	chr6:80172339	chr6:80466958~80469080:+
LUAD	cis	rs2274273	0.624	rs67795323	ENSG00000258413.1	RP11-665C16.6	-4.24	2.64e-05	0.00455	-0.26	-0.19	Protein biomarker;	chr14:55331115	chr14:55262767~55272075:-
LUAD	cis	rs2274273	0.624	rs8005450	ENSG00000258413.1	RP11-665C16.6	-4.24	2.64e-05	0.00455	-0.26	-0.19	Protein biomarker;	chr14:55332447	chr14:55262767~55272075:-
LUAD	cis	rs2018683	0.707	rs1021689	ENSG00000228421.2	AC005013.5	4.24	2.64e-05	0.00455	0.21	0.19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28934606	chr7:28957667~28959345:+
LUAD	cis	rs987710	0.568	rs4821790	ENSG00000211639.2	IGLV4-60	-4.24	2.64e-05	0.00455	-0.27	-0.19	Iron status biomarkers;Iron deficiency;	chr22:22156977	chr22:22162199~22162681:+
LUAD	cis	rs987710	0.568	rs987708	ENSG00000211639.2	IGLV4-60	-4.24	2.64e-05	0.00455	-0.27	-0.19	Iron status biomarkers;Iron deficiency;	chr22:22157688	chr22:22162199~22162681:+
LUAD	cis	rs4908760	0.516	rs11121232	ENSG00000270282.1	RP5-1115A15.2	4.24	2.64e-05	0.00455	0.21	0.19	Vitiligo;	chr1:8790650	chr1:8512653~8513021:+
LUAD	cis	rs67981189	0.519	rs2526879	ENSG00000269927.1	RP6-91H8.3	-4.24	2.64e-05	0.00455	-0.26	-0.19	Schizophrenia;	chr14:70910501	chr14:71141125~71143253:-
LUAD	cis	rs7208859	0.673	rs9889755	ENSG00000263603.1	CTD-2349P21.5	4.24	2.64e-05	0.00455	0.3	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30907487	chr17:30729469~30731202:+
LUAD	cis	rs62355901	0.545	rs56008823	ENSG00000271828.1	CTD-2310F14.1	4.24	2.64e-05	0.00455	0.38	0.19	Breast cancer;	chr5:56772187	chr5:56927874~56929573:+
LUAD	cis	rs13434995	0.842	rs3792603	ENSG00000249700.7	SRD5A3-AS1	-4.24	2.64e-05	0.00455	-0.28	-0.19	Adiponectin levels;	chr4:55435891	chr4:55363971~55395847:-
LUAD	cis	rs13434995	0.755	rs62303690	ENSG00000249700.7	SRD5A3-AS1	-4.24	2.64e-05	0.00455	-0.28	-0.19	Adiponectin levels;	chr4:55439838	chr4:55363971~55395847:-
LUAD	cis	rs4795519	1	rs11871551	ENSG00000266313.1	RP11-173M1.4	4.24	2.64e-05	0.00455	0.23	0.19	Chronic myeloid leukemia;	chr17:27153970	chr17:27333256~27348491:+
LUAD	cis	rs67981189	0.529	rs2526858	ENSG00000269927.1	RP6-91H8.3	-4.24	2.64e-05	0.00455	-0.25	-0.19	Schizophrenia;	chr14:70945623	chr14:71141125~71143253:-
LUAD	cis	rs67981189	0.529	rs2526857	ENSG00000269927.1	RP6-91H8.3	-4.24	2.64e-05	0.00455	-0.25	-0.19	Schizophrenia;	chr14:70945909	chr14:71141125~71143253:-
LUAD	cis	rs16944613	0.588	rs6496698	ENSG00000259212.1	CTD-3065B20.2	4.24	2.64e-05	0.00455	0.3	0.19	Colorectal cancer;	chr15:90592326	chr15:90595840~90596447:-
LUAD	cis	rs2153535	0.553	rs2984099	ENSG00000230939.1	RP11-314C16.1	-4.24	2.65e-05	0.00455	-0.21	-0.19	Motion sickness;	chr6:8637041	chr6:8784178~8785445:+
LUAD	cis	rs11773103	0.708	rs802026	ENSG00000224046.1	AC005076.5	4.24	2.65e-05	0.00455	0.31	0.19	Bipolar disorder or major depressive disorder (combined);	chr7:87359723	chr7:87151423~87152420:-
LUAD	cis	rs4819052	0.632	rs4819050	ENSG00000215447.6	BX322557.10	-4.24	2.65e-05	0.00455	-0.22	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273028	chr21:45288052~45291738:+
LUAD	cis	rs34779708	0.931	rs6481935	ENSG00000271335.4	RP11-324I22.4	4.24	2.65e-05	0.00455	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35054031	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.931	rs12242882	ENSG00000271335.4	RP11-324I22.4	4.24	2.65e-05	0.00455	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35058932	chr10:35314552~35336401:-
LUAD	cis	rs55670112	0.739	rs17367096	ENSG00000271797.1	CTC-428G20.6	-4.24	2.65e-05	0.00455	-0.2	-0.19	Epilepsy;	chr5:114797577	chr5:115262505~115263448:+
LUAD	cis	rs7178424	0.742	rs7170293	ENSG00000259251.2	RP11-643M14.1	4.24	2.65e-05	0.00455	0.19	0.19	Height;	chr15:61944174	chr15:62060503~62062434:+
LUAD	cis	rs4568518	0.74	rs11535159	ENSG00000279048.1	RP11-511H23.2	4.24	2.65e-05	0.00456	0.16	0.19	Measles;	chr7:17970686	chr7:17940503~17942922:+
LUAD	cis	rs6832769	1	rs3805157	ENSG00000272969.1	RP11-528I4.2	4.24	2.65e-05	0.00456	0.2	0.19	Personality dimensions;	chr4:55497936	chr4:55547112~55547889:+
LUAD	cis	rs6832769	1	rs2177129	ENSG00000272969.1	RP11-528I4.2	4.24	2.65e-05	0.00456	0.2	0.19	Personality dimensions;	chr4:55499247	chr4:55547112~55547889:+
LUAD	cis	rs17772222	0.917	rs61986669	ENSG00000258789.1	RP11-507K2.3	-4.24	2.65e-05	0.00456	-0.26	-0.19	Coronary artery calcification;	chr14:88727121	chr14:88551597~88552493:+
LUAD	cis	rs4971059	0.654	rs7364524	ENSG00000160766.13	GBAP1	-4.24	2.65e-05	0.00456	-0.19	-0.19	Breast cancer;	chr1:155149446	chr1:155213821~155227422:-
LUAD	cis	rs5769707	0.605	rs9616702	ENSG00000235111.1	RP1-29C18.8	-4.24	2.65e-05	0.00456	-0.23	-0.19	Monocyte percentage of white cells;Monocyte count;	chr22:49632290	chr22:49612657~49615716:-
LUAD	cis	rs2153535	0.585	rs9393052	ENSG00000230939.1	RP11-314C16.1	-4.24	2.65e-05	0.00456	-0.21	-0.19	Motion sickness;	chr6:8644832	chr6:8784178~8785445:+
LUAD	cis	rs950169	0.734	rs67119537	ENSG00000259295.5	CSPG4P12	4.24	2.65e-05	0.00456	0.26	0.19	Schizophrenia;	chr15:84395671	chr15:85191438~85213905:+
LUAD	cis	rs6121246	0.609	rs2377317	ENSG00000230613.1	HM13-AS1	-4.24	2.65e-05	0.00456	-0.23	-0.19	Mean corpuscular hemoglobin;	chr20:31814699	chr20:31567707~31573263:-
LUAD	cis	rs10129255	0.957	rs10142918	ENSG00000211967.3	IGHV3-53	-4.24	2.65e-05	0.00456	-0.15	-0.19	Kawasaki disease;	chr14:106782206	chr14:106592676~106593347:-
LUAD	cis	rs9876781	1	rs9881491	ENSG00000229759.1	MRPS18AP1	4.24	2.65e-05	0.00456	0.18	0.19	Longevity;	chr3:48446507	chr3:48256350~48256938:-
LUAD	cis	rs9649213	0.574	rs12873	ENSG00000272950.1	RP11-307C18.1	4.24	2.65e-05	0.00456	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98293461	chr7:98322853~98323430:+
LUAD	cis	rs293748	0.771	rs34920909	ENSG00000250155.1	CTD-2353F22.1	-4.24	2.65e-05	0.00457	-0.26	-0.19	Obesity-related traits;	chr5:36792614	chr5:36666214~36725195:-
LUAD	cis	rs293748	0.771	rs59889951	ENSG00000250155.1	CTD-2353F22.1	-4.24	2.65e-05	0.00457	-0.26	-0.19	Obesity-related traits;	chr5:36793150	chr5:36666214~36725195:-
LUAD	cis	rs800160	1	rs1088985	ENSG00000236264.4	RPL26P30	-4.24	2.65e-05	0.00457	-0.26	-0.19	Bacteremia;	chr11:2356622	chr11:2335132~2335776:-
LUAD	cis	rs4843747	0.671	rs8053377	ENSG00000205037.2	RP11-863P13.4	4.24	2.65e-05	0.00457	0.27	0.19	Menopause (age at onset);	chr16:88072859	chr16:88088041~88100985:-
LUAD	cis	rs3020736	0.5	rs6002603	ENSG00000205702.9	CYP2D7	-4.24	2.65e-05	0.00457	-0.16	-0.19	Autism spectrum disorder or schizophrenia;	chr22:42096358	chr22:42140203~42144577:-
LUAD	cis	rs9860428	0.509	rs62263730	ENSG00000242770.2	RP11-180K7.1	-4.24	2.65e-05	0.00457	-0.22	-0.19	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112859161	chr3:112802478~112812819:+
LUAD	cis	rs28386778	0.897	rs2156903	ENSG00000240280.5	TCAM1P	-4.24	2.65e-05	0.00457	-0.22	-0.19	Prudent dietary pattern;	chr17:63859819	chr17:63849292~63864379:+
LUAD	cis	rs9487094	0.961	rs12192847	ENSG00000260273.1	RP11-425D10.10	4.24	2.66e-05	0.00457	0.26	0.19	Height;	chr6:109480428	chr6:109382795~109383666:+
LUAD	cis	rs2028299	0.92	rs2118847	ENSG00000259677.1	RP11-493E3.1	4.24	2.66e-05	0.00457	0.23	0.19	Type 2 diabetes;	chr15:89865615	chr15:89876540~89877285:+
LUAD	cis	rs5758511	0.634	rs1001587	ENSG00000227370.1	RP4-669P10.19	4.24	2.66e-05	0.00457	0.21	0.19	Birth weight;	chr22:42274105	chr22:42132543~42132998:+
LUAD	cis	rs454217	0.715	rs400708	ENSG00000277851.1	RP11-756G20.1	4.24	2.66e-05	0.00457	0.19	0.19	Smoking quantity;	chr12:92320502	chr12:92247756~92363832:-
LUAD	cis	rs8062405	0.723	rs62031562	ENSG00000251417.2	RP11-1348G14.4	-4.24	2.66e-05	0.00457	-0.2	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28598008	chr16:28802743~28817828:+
LUAD	cis	rs2836974	0.932	rs2836955	ENSG00000232608.1	TIMM9P2	-4.24	2.66e-05	0.00457	-0.24	-0.19	Cognitive function;	chr21:39247961	chr21:39216624~39217506:+
LUAD	cis	rs4554975	0.869	rs10881002	ENSG00000274723.1	RP11-618L22.1	-4.24	2.66e-05	0.00457	-0.22	-0.19	Metabolite levels (small molecules and protein measures);	chr12:46813270	chr12:46970504~46972155:+
LUAD	cis	rs2921036	0.529	rs2979192	ENSG00000173295.6	FAM86B3P	4.24	2.66e-05	0.00457	0.2	0.19	Neuroticism;	chr8:8480637	chr8:8228595~8244865:+
LUAD	cis	rs2115630	1	rs6496452	ENSG00000225151.9	GOLGA2P7	4.24	2.66e-05	0.00457	0.22	0.19	P wave terminal force;	chr15:84829414	chr15:84199311~84230136:-
LUAD	cis	rs7119038	0.818	rs11826521	ENSG00000255422.1	AP002954.4	4.24	2.66e-05	0.00457	0.3	0.19	Sjögren's syndrome;	chr11:118739840	chr11:118704607~118750263:+
LUAD	cis	rs11886999	0.812	rs72825868	ENSG00000237510.6	AC008268.2	-4.24	2.66e-05	0.00458	-0.31	-0.19	Cardiac Troponin-T levels;	chr2:96231921	chr2:95789654~95800166:+
LUAD	cis	rs9309473	0.583	rs6709853	ENSG00000163016.8	ALMS1P	4.24	2.66e-05	0.00458	0.21	0.19	Metabolite levels;	chr2:73348937	chr2:73644919~73685576:+
LUAD	cis	rs6496044	0.568	rs12899946	ENSG00000259295.5	CSPG4P12	4.24	2.66e-05	0.00458	0.22	0.19	Interstitial lung disease;	chr15:85522851	chr15:85191438~85213905:+
LUAD	cis	rs6496044	0.568	rs12898783	ENSG00000259295.5	CSPG4P12	4.24	2.66e-05	0.00458	0.22	0.19	Interstitial lung disease;	chr15:85522869	chr15:85191438~85213905:+
LUAD	cis	rs2467099	0.679	rs59867239	ENSG00000267801.1	RP11-552F3.9	4.24	2.66e-05	0.00458	0.22	0.19	Systolic blood pressure;	chr17:75935706	chr17:75876372~75879546:+
LUAD	cis	rs2467099	0.679	rs2608882	ENSG00000267801.1	RP11-552F3.9	4.24	2.66e-05	0.00458	0.22	0.19	Systolic blood pressure;	chr17:75938049	chr17:75876372~75879546:+
LUAD	cis	rs6964833	0.935	rs34762099	ENSG00000278416.1	PMS2L2	4.24	2.66e-05	0.00458	0.26	0.19	Menarche (age at onset);	chr7:74636378	chr7:75344015~75359550:-
LUAD	cis	rs2274273	0.84	rs11547116	ENSG00000258413.1	RP11-665C16.6	-4.24	2.66e-05	0.00458	-0.24	-0.19	Protein biomarker;	chr14:55271447	chr14:55262767~55272075:-
LUAD	cis	rs4843747	0.636	rs4075597	ENSG00000205037.2	RP11-863P13.4	4.24	2.66e-05	0.00458	0.27	0.19	Menopause (age at onset);	chr16:88073984	chr16:88088041~88100985:-
LUAD	cis	rs2732480	0.538	rs1387260	ENSG00000257763.1	OR5BK1P	4.24	2.66e-05	0.00458	0.21	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309308	chr12:48355792~48356614:-
LUAD	cis	rs1355223	0.902	rs1539251	ENSG00000271369.1	RP11-350D17.3	-4.24	2.66e-05	0.00458	-0.22	-0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34721225	chr11:34709600~34710161:+
LUAD	cis	rs1355223	0.902	rs1539250	ENSG00000271369.1	RP11-350D17.3	-4.24	2.66e-05	0.00458	-0.22	-0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34721228	chr11:34709600~34710161:+
LUAD	cis	rs1355223	0.902	rs836462	ENSG00000271369.1	RP11-350D17.3	-4.24	2.66e-05	0.00458	-0.22	-0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34721716	chr11:34709600~34710161:+
LUAD	cis	rs1355223	0.902	rs1773908	ENSG00000271369.1	RP11-350D17.3	-4.24	2.66e-05	0.00458	-0.22	-0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34721833	chr11:34709600~34710161:+
LUAD	cis	rs1355223	0.902	rs860712	ENSG00000271369.1	RP11-350D17.3	-4.24	2.66e-05	0.00458	-0.22	-0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34721947	chr11:34709600~34710161:+
LUAD	cis	rs6840360	0.642	rs2709831	ENSG00000270265.1	RP11-731D1.4	-4.24	2.66e-05	0.00458	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151458499	chr4:151333775~151353224:-
LUAD	cis	rs12534093	0.562	rs66797912	ENSG00000234286.1	AC006026.13	-4.24	2.66e-05	0.00458	-0.25	-0.19	Infant length;Height;	chr7:23537569	chr7:23680195~23680786:-
LUAD	cis	rs2239557	1	rs75824542	ENSG00000259065.1	RP5-1021I20.1	-4.24	2.66e-05	0.00458	-0.22	-0.19	Common traits (Other);	chr14:74056344	chr14:73787360~73803270:+
LUAD	cis	rs2239557	1	rs2072293	ENSG00000259065.1	RP5-1021I20.1	-4.24	2.66e-05	0.00458	-0.22	-0.19	Common traits (Other);	chr14:74071182	chr14:73787360~73803270:+
LUAD	cis	rs7204230	1	rs62049763	ENSG00000261291.1	RP11-295M3.2	4.24	2.66e-05	0.00458	0.24	0.19	Fibrinogen;	chr16:53219807	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs62049766	ENSG00000261291.1	RP11-295M3.2	4.24	2.66e-05	0.00458	0.24	0.19	Fibrinogen;	chr16:53229442	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs62049769	ENSG00000261291.1	RP11-295M3.2	4.24	2.66e-05	0.00458	0.24	0.19	Fibrinogen;	chr16:53236840	chr16:53168522~53169450:+
LUAD	cis	rs6750795	0.765	rs6742387	ENSG00000223198.1	RNU2-22P	-4.24	2.66e-05	0.00458	-0.22	-0.19	Height;	chr2:231490121	chr2:231501990~231502201:-
LUAD	cis	rs12073359	1	rs72692862	ENSG00000223945.2	RP11-458I7.1	-4.24	2.66e-05	0.00458	-0.28	-0.19	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150037246	chr1:150053864~150055034:+
LUAD	cis	rs10129255	0.5	rs9324092	ENSG00000253209.1	IGHV3-65	-4.24	2.67e-05	0.00458	-0.15	-0.19	Kawasaki disease;	chr14:106683806	chr14:106666092~106666532:-
LUAD	cis	rs2014572	1	rs2014572	ENSG00000268379.1	CTC-360J11.4	4.24	2.67e-05	0.00458	0.22	0.19	Hyperactive-impulsive symptoms;	chr19:57248650	chr19:57175233~57177921:+
LUAD	cis	rs1707322	0.613	rs1473840	ENSG00000280836.1	AL355480.1	4.24	2.67e-05	0.00458	0.24	0.19	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46135525	chr1:45581219~45581321:-
LUAD	cis	rs9475752	0.793	rs78299307	ENSG00000231441.1	RP11-472M19.2	4.24	2.67e-05	0.00459	0.31	0.19	Menarche (age at onset);	chr6:56885151	chr6:56844002~56864078:+
LUAD	cis	rs9475752	0.793	rs34232358	ENSG00000231441.1	RP11-472M19.2	4.24	2.67e-05	0.00459	0.31	0.19	Menarche (age at onset);	chr6:56886012	chr6:56844002~56864078:+
LUAD	cis	rs9475752	0.793	rs34714091	ENSG00000231441.1	RP11-472M19.2	4.24	2.67e-05	0.00459	0.31	0.19	Menarche (age at onset);	chr6:56887633	chr6:56844002~56864078:+
LUAD	cis	rs7208859	0.614	rs216412	ENSG00000263531.1	RP13-753N3.1	-4.24	2.67e-05	0.00459	-0.32	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576376	chr17:30863921~30864940:-
LUAD	cis	rs2732480	0.557	rs2634682	ENSG00000240399.1	RP1-228P16.1	4.24	2.67e-05	0.00459	0.19	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339160	chr12:48054813~48055591:-
LUAD	cis	rs2880765	0.835	rs6497202	ENSG00000259416.2	RP11-158M2.5	4.24	2.67e-05	0.00459	0.19	0.19	Coronary artery disease;	chr15:85478144	chr15:85754941~85756237:-
LUAD	cis	rs4578769	0.55	rs4474794	ENSG00000265943.1	RP11-739L10.1	4.24	2.67e-05	0.00459	0.24	0.19	Eosinophil percentage of white cells;	chr18:22987010	chr18:22699481~22933764:-
LUAD	cis	rs10971721	0.584	rs12375716	ENSG00000260947.1	RP11-384P7.7	4.24	2.67e-05	0.00459	0.38	0.19	Body mass index;	chr9:34100034	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.584	rs12379730	ENSG00000260947.1	RP11-384P7.7	4.24	2.67e-05	0.00459	0.38	0.19	Body mass index;	chr9:34100072	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.584	rs55672700	ENSG00000260947.1	RP11-384P7.7	4.24	2.67e-05	0.00459	0.38	0.19	Body mass index;	chr9:34102723	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.584	rs1378	ENSG00000260947.1	RP11-384P7.7	4.24	2.67e-05	0.00459	0.38	0.19	Body mass index;	chr9:34107506	chr9:33697459~33700986:+
LUAD	cis	rs11992162	0.636	rs4841645	ENSG00000255046.1	RP11-297N6.4	4.24	2.67e-05	0.00459	0.23	0.19	Monocyte count;	chr8:11941175	chr8:11797928~11802568:-
LUAD	cis	rs755249	0.588	rs2275767	ENSG00000228060.1	RP11-69E11.8	4.24	2.67e-05	0.00459	0.16	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39479625	chr1:39565160~39573203:+
LUAD	cis	rs4568518	0.74	rs12699924	ENSG00000279048.1	RP11-511H23.2	4.24	2.67e-05	0.00459	0.16	0.19	Measles;	chr7:17970768	chr7:17940503~17942922:+
LUAD	cis	rs6832769	1	rs6819660	ENSG00000272969.1	RP11-528I4.2	4.24	2.67e-05	0.00459	0.2	0.19	Personality dimensions;	chr4:55508410	chr4:55547112~55547889:+
LUAD	cis	rs5758511	0.524	rs738257	ENSG00000227370.1	RP4-669P10.19	4.24	2.67e-05	0.00459	0.22	0.19	Birth weight;	chr22:42173292	chr22:42132543~42132998:+
LUAD	cis	rs7772486	0.79	rs2243665	ENSG00000235652.6	RP11-545I5.3	4.24	2.67e-05	0.00459	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145886984	chr6:145799409~145886585:+
LUAD	cis	rs9467773	0.967	rs1056347	ENSG00000261353.1	CTA-14H9.5	-4.24	2.67e-05	0.00459	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26527296	chr6:26527063~26527404:+
LUAD	cis	rs7129556	0.69	rs12285765	ENSG00000241782.1	RP11-91P24.1	4.24	2.67e-05	0.00459	0.27	0.19	Weight loss (gastric bypass surgery);	chr11:77857989	chr11:77868722~77869195:-
LUAD	cis	rs7824557	0.564	rs2043508	ENSG00000255046.1	RP11-297N6.4	4.24	2.67e-05	0.0046	0.23	0.19	Retinal vascular caliber;	chr8:11369897	chr8:11797928~11802568:-
LUAD	cis	rs4604732	0.603	rs10802512	ENSG00000227135.1	GCSAML-AS1	-4.24	2.67e-05	0.0046	-0.27	-0.19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247470428	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.603	rs10802513	ENSG00000227135.1	GCSAML-AS1	-4.24	2.67e-05	0.0046	-0.27	-0.19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247470617	chr1:247524679~247526752:-
LUAD	cis	rs853679	0.517	rs1947862	ENSG00000226314.6	ZNF192P1	-4.24	2.68e-05	0.0046	-0.25	-0.19	Depression;	chr6:28137418	chr6:28161781~28169594:+
LUAD	cis	rs4840086	0.967	rs4240582	ENSG00000219755.1	RP1-199J3.5	4.24	2.68e-05	0.0046	0.23	0.19	Menarche (age at onset);	chr6:99753713	chr6:99575712~99576456:+
LUAD	cis	rs4840086	0.967	rs4240583	ENSG00000219755.1	RP1-199J3.5	4.24	2.68e-05	0.0046	0.23	0.19	Menarche (age at onset);	chr6:99753719	chr6:99575712~99576456:+
LUAD	cis	rs4132509	0.566	rs1578275	ENSG00000236031.1	RP11-269F20.1	-4.24	2.68e-05	0.0046	-0.29	-0.19	RR interval (heart rate);	chr1:243517140	chr1:243545532~243548329:+
LUAD	cis	rs8031584	0.736	rs11635775	ENSG00000259845.1	HERC2P10	4.24	2.68e-05	0.0046	0.23	0.19	Huntington's disease progression;	chr15:30868437	chr15:30815271~30844153:+
LUAD	cis	rs11779988	0.545	rs411531	ENSG00000253671.1	RP11-806O11.1	-4.24	2.68e-05	0.0046	-0.24	-0.19	Breast cancer;	chr8:17938425	chr8:17808941~17820868:+
LUAD	cis	rs42490	0.51	rs7003919	ENSG00000251136.7	RP11-37B2.1	4.24	2.68e-05	0.0046	0.19	0.19	Leprosy;	chr8:89688185	chr8:89609409~89757727:-
LUAD	cis	rs1729951	0.546	rs835632	ENSG00000239213.4	NCK1-AS1	4.24	2.68e-05	0.0046	0.21	0.19	Neuroticism;	chr3:136957683	chr3:136841726~136862054:-
LUAD	cis	rs5015933	0.815	rs13297440	ENSG00000232630.1	PRPS1P2	-4.24	2.68e-05	0.0046	-0.18	-0.19	Body mass index;	chr9:125324921	chr9:125150653~125151589:+
LUAD	cis	rs911186	0.786	rs13211901	ENSG00000219392.1	RP1-265C24.5	-4.24	2.68e-05	0.0046	-0.28	-0.19	Autism spectrum disorder or schizophrenia;	chr6:27219833	chr6:28115628~28116551:+
LUAD	cis	rs7829975	0.806	rs2428	ENSG00000253981.4	ALG1L13P	4.24	2.68e-05	0.0046	0.21	0.19	Mood instability;	chr8:8783635	chr8:8236003~8244667:-
LUAD	cis	rs13113518	0.776	rs13124436	ENSG00000272969.1	RP11-528I4.2	4.24	2.68e-05	0.0046	0.2	0.19	Height;	chr4:55502504	chr4:55547112~55547889:+
LUAD	cis	rs801193	0.967	rs3800823	ENSG00000224316.1	RP11-479O9.2	-4.24	2.68e-05	0.0046	-0.19	-0.19	Aortic root size;	chr7:66682123	chr7:65773620~65802067:+
LUAD	cis	rs7762018	0.891	rs73242950	ENSG00000231690.2	LINC00574	-4.24	2.68e-05	0.0046	-0.36	-0.19	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169744641	chr6:169790321~169802873:+
LUAD	cis	rs7762018	0.891	rs7764839	ENSG00000231690.2	LINC00574	-4.24	2.68e-05	0.0046	-0.36	-0.19	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169746255	chr6:169790321~169802873:+
LUAD	cis	rs7762018	0.891	rs12529402	ENSG00000231690.2	LINC00574	-4.24	2.68e-05	0.0046	-0.36	-0.19	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169747579	chr6:169790321~169802873:+
LUAD	cis	rs7762018	0.655	rs2184194	ENSG00000231690.2	LINC00574	-4.24	2.68e-05	0.0046	-0.36	-0.19	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169748298	chr6:169790321~169802873:+
LUAD	cis	rs7762018	0.655	rs2184195	ENSG00000231690.2	LINC00574	-4.24	2.68e-05	0.0046	-0.36	-0.19	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169748301	chr6:169790321~169802873:+
LUAD	cis	rs7762018	0.891	rs1981069	ENSG00000231690.2	LINC00574	-4.24	2.68e-05	0.0046	-0.36	-0.19	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169748741	chr6:169790321~169802873:+
LUAD	cis	rs7590268	0.848	rs6544656	ENSG00000279873.2	LINC01126	4.24	2.68e-05	0.0046	0.18	0.19	Orofacial clefts;	chr2:43408004	chr2:43227210~43228855:+
LUAD	cis	rs28714278	0.857	rs12164905	ENSG00000248508.5	SRP14-AS1	4.24	2.68e-05	0.0046	0.22	0.19	Mean corpuscular hemoglobin;	chr15:40008490	chr15:40039311~40067290:+
LUAD	cis	rs28386778	0.897	rs7212196	ENSG00000240280.5	TCAM1P	-4.24	2.68e-05	0.0046	-0.22	-0.19	Prudent dietary pattern;	chr17:63757621	chr17:63849292~63864379:+
LUAD	cis	rs516805	0.748	rs11968579	ENSG00000279453.1	RP3-425C14.4	4.24	2.68e-05	0.00461	0.26	0.19	Lymphocyte counts;	chr6:122575950	chr6:122436789~122439223:-
LUAD	cis	rs17345786	0.861	rs79181492	ENSG00000244119.1	PDCL3P4	4.24	2.68e-05	0.00461	0.22	0.19	Colonoscopy-negative controls vs population controls;	chr3:101497177	chr3:101712472~101713191:+
LUAD	cis	rs2898681	0.65	rs6840325	ENSG00000248375.1	RP11-177B4.1	-4.24	2.68e-05	0.00461	-0.28	-0.19	Optic nerve measurement (cup area);	chr4:52809382	chr4:52720081~52720831:-
LUAD	cis	rs875971	0.545	rs221986	ENSG00000222364.1	RNU6-96P	4.24	2.68e-05	0.00461	0.25	0.19	Aortic root size;	chr7:66105323	chr7:66395191~66395286:+
LUAD	cis	rs847577	0.63	rs6967926	ENSG00000272950.1	RP11-307C18.1	4.24	2.68e-05	0.00461	0.23	0.19	Breast cancer;	chr7:98085776	chr7:98322853~98323430:+
LUAD	cis	rs7061710	0.826	rs7889807	ENSG00000271811.1	RP1-79C4.4	-4.24	2.68e-05	0.00461	-0.27	-0.19	Blood metabolite levels;	chr1:171148358	chr1:170667381~170669425:+
LUAD	cis	rs4474465	0.831	rs10899510	ENSG00000251323.2	RP11-452H21.4	4.24	2.68e-05	0.00461	0.25	0.19	Alzheimer's disease (survival time);	chr11:78459795	chr11:78423982~78429836:-
LUAD	cis	rs12935418	0.887	rs3743503	ENSG00000261838.4	RP11-303E16.6	4.24	2.69e-05	0.00461	0.37	0.19	Mean corpuscular volume;	chr16:81022836	chr16:81069854~81076598:+
LUAD	cis	rs4713118	0.513	rs149962	ENSG00000216901.1	AL022393.7	4.24	2.69e-05	0.00461	0.23	0.19	Parkinson's disease;	chr6:28048140	chr6:28176188~28176674:+
LUAD	cis	rs11886999	0.812	rs4371393	ENSG00000237510.6	AC008268.2	-4.24	2.69e-05	0.00461	-0.31	-0.19	Cardiac Troponin-T levels;	chr2:96237622	chr2:95789654~95800166:+
LUAD	cis	rs9341808	0.754	rs3805925	ENSG00000260645.1	RP11-250B2.5	4.24	2.69e-05	0.00461	0.18	0.19	Sitting height ratio;	chr6:80174116	chr6:80466958~80469080:+
LUAD	cis	rs10463554	0.892	rs72783889	ENSG00000250682.4	LINC00491	4.24	2.69e-05	0.00462	0.23	0.19	Parkinson's disease;	chr5:102938835	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.892	rs72783890	ENSG00000250682.4	LINC00491	4.24	2.69e-05	0.00462	0.23	0.19	Parkinson's disease;	chr5:102938836	chr5:102609156~102671559:-
LUAD	cis	rs2273788	1	rs2273788	ENSG00000204173.9	LRRC37A5P	4.24	2.69e-05	0.00462	0.25	0.19	Monocyte count;	chr9:111586337	chr9:111602831~111631289:-
LUAD	cis	rs1355223	0.902	rs1773910	ENSG00000271369.1	RP11-350D17.3	-4.24	2.69e-05	0.00462	-0.22	-0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34719706	chr11:34709600~34710161:+
LUAD	cis	rs2880765	0.835	rs2170736	ENSG00000259416.2	RP11-158M2.5	4.24	2.69e-05	0.00462	0.2	0.19	Coronary artery disease;	chr15:85500167	chr15:85754941~85756237:-
LUAD	cis	rs2880765	0.835	rs2170735	ENSG00000259416.2	RP11-158M2.5	4.24	2.69e-05	0.00462	0.2	0.19	Coronary artery disease;	chr15:85500254	chr15:85754941~85756237:-
LUAD	cis	rs2880765	0.835	rs4340287	ENSG00000259416.2	RP11-158M2.5	4.24	2.69e-05	0.00462	0.2	0.19	Coronary artery disease;	chr15:85500506	chr15:85754941~85756237:-
LUAD	cis	rs17826219	0.636	rs12946563	ENSG00000266490.1	CTD-2349P21.9	4.24	2.69e-05	0.00462	0.28	0.19	Body mass index;	chr17:30776148	chr17:30792372~30792833:+
LUAD	cis	rs7927592	0.546	rs638076	ENSG00000212093.1	AP000807.1	4.24	2.69e-05	0.00462	0.2	0.19	Total body bone mineral density;	chr11:68435112	chr11:68506083~68506166:-
LUAD	cis	rs28386778	0.897	rs2727326	ENSG00000240280.5	TCAM1P	-4.24	2.69e-05	0.00462	-0.22	-0.19	Prudent dietary pattern;	chr17:63845656	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.897	rs2727328	ENSG00000240280.5	TCAM1P	-4.24	2.69e-05	0.00462	-0.22	-0.19	Prudent dietary pattern;	chr17:63846204	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.897	rs2665796	ENSG00000240280.5	TCAM1P	-4.24	2.69e-05	0.00462	-0.22	-0.19	Prudent dietary pattern;	chr17:63846356	chr17:63849292~63864379:+
LUAD	cis	rs12579720	0.909	rs2417822	ENSG00000255910.1	RP11-405A12.2	4.24	2.69e-05	0.00462	0.24	0.19	Diastolic blood pressure;	chr12:20035209	chr12:19775451~20009937:+
LUAD	cis	rs4819052	0.851	rs1999335	ENSG00000237664.1	LINC00316	-4.24	2.69e-05	0.00462	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250698	chr21:45338590~45341990:-
LUAD	cis	rs4819052	0.851	rs2838844	ENSG00000237664.1	LINC00316	-4.24	2.69e-05	0.00462	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250818	chr21:45338590~45341990:-
LUAD	cis	rs875971	0.66	rs1860468	ENSG00000224316.1	RP11-479O9.2	-4.24	2.69e-05	0.00462	-0.19	-0.19	Aortic root size;	chr7:66642265	chr7:65773620~65802067:+
LUAD	cis	rs7119038	0.818	rs10892293	ENSG00000255239.1	AP002954.6	-4.24	2.69e-05	0.00462	-0.28	-0.19	Sjögren's syndrome;	chr11:118794866	chr11:118688039~118690600:-
LUAD	cis	rs1864585	0.52	rs73208785	ENSG00000255046.1	RP11-297N6.4	4.24	2.69e-05	0.00462	0.27	0.19	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10820610	chr8:11797928~11802568:-
LUAD	cis	rs1008375	0.932	rs13134570	ENSG00000249502.1	AC006160.5	4.24	2.69e-05	0.00462	0.18	0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17691240	chr4:17587467~17614571:-
LUAD	cis	rs6570726	0.905	rs377143	ENSG00000235652.6	RP11-545I5.3	4.24	2.69e-05	0.00462	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145513084	chr6:145799409~145886585:+
LUAD	cis	rs7819412	0.521	rs10110684	ENSG00000255046.1	RP11-297N6.4	4.24	2.69e-05	0.00462	0.23	0.19	Triglycerides;	chr8:11181650	chr8:11797928~11802568:-
LUAD	cis	rs4578769	0.55	rs9945620	ENSG00000265943.1	RP11-739L10.1	4.24	2.69e-05	0.00462	0.24	0.19	Eosinophil percentage of white cells;	chr18:22997367	chr18:22699481~22933764:-
LUAD	cis	rs4578769	0.55	rs2305886	ENSG00000265943.1	RP11-739L10.1	4.24	2.69e-05	0.00462	0.24	0.19	Eosinophil percentage of white cells;	chr18:22997493	chr18:22699481~22933764:-
LUAD	cis	rs7551222	0.752	rs4951393	ENSG00000240219.1	RP11-430C7.5	-4.24	2.69e-05	0.00462	-0.19	-0.19	Schizophrenia;	chr1:204520429	chr1:204626775~204629712:+
LUAD	cis	rs848490	0.926	rs73138439	ENSG00000214293.7	APTR	4.24	2.69e-05	0.00462	0.26	0.19	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77887027	chr7:77657660~77696265:-
LUAD	cis	rs28386778	0.897	rs2854221	ENSG00000240280.5	TCAM1P	-4.24	2.69e-05	0.00462	-0.22	-0.19	Prudent dietary pattern;	chr17:63864085	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.897	rs2584642	ENSG00000240280.5	TCAM1P	-4.24	2.69e-05	0.00462	-0.22	-0.19	Prudent dietary pattern;	chr17:63865067	chr17:63849292~63864379:+
LUAD	cis	rs712022	1	rs2286809	ENSG00000246225.5	RP11-17A1.3	4.24	2.69e-05	0.00462	0.23	0.19	Dialysis-related mortality;	chr11:22829909	chr11:22829380~22945393:+
LUAD	cis	rs240993	0.595	rs3777912	ENSG00000230177.1	RP5-1112D6.4	4.24	2.69e-05	0.00462	0.19	0.19	Inflammatory skin disease;Psoriasis;	chr6:111581473	chr6:111277932~111278742:+
LUAD	cis	rs7746199	0.736	rs35037868	ENSG00000219392.1	RP1-265C24.5	-4.24	2.69e-05	0.00462	-0.42	-0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27791336	chr6:28115628~28116551:+
LUAD	cis	rs13113518	0.756	rs11939652	ENSG00000272969.1	RP11-528I4.2	4.24	2.69e-05	0.00462	0.2	0.19	Height;	chr4:55532542	chr4:55547112~55547889:+
LUAD	cis	rs17508449	0.819	rs77042378	ENSG00000232450.1	RP4-730K3.3	-4.24	2.69e-05	0.00463	-0.31	-0.19	Leprosy;	chr1:113666479	chr1:113698884~113699631:-
LUAD	cis	rs9400467	0.528	rs9689727	ENSG00000230177.1	RP5-1112D6.4	-4.24	2.69e-05	0.00463	-0.17	-0.19	Amino acid levels;Blood metabolite levels;	chr6:111475360	chr6:111277932~111278742:+
LUAD	cis	rs9400467	0.528	rs12214380	ENSG00000230177.1	RP5-1112D6.4	-4.24	2.69e-05	0.00463	-0.17	-0.19	Amino acid levels;Blood metabolite levels;	chr6:111475734	chr6:111277932~111278742:+
LUAD	cis	rs910316	0.967	rs4384542	ENSG00000279594.1	RP11-950C14.10	-4.24	2.69e-05	0.00463	-0.22	-0.19	Height;	chr14:75191310	chr14:75011269~75012851:-
LUAD	cis	rs950169	0.614	rs12903883	ENSG00000259570.1	RP11-671M22.4	4.24	2.7e-05	0.00463	0.28	0.19	Schizophrenia;	chr15:84011801	chr15:84394512~84395514:+
LUAD	cis	rs13256369	1	rs4841017	ENSG00000253893.2	FAM85B	-4.24	2.7e-05	0.00463	-0.26	-0.19	Obesity-related traits;	chr8:8719583	chr8:8167819~8226614:-
LUAD	cis	rs5769707	0.872	rs5770604	ENSG00000235111.1	RP1-29C18.8	-4.24	2.7e-05	0.00463	-0.21	-0.19	Monocyte percentage of white cells;Monocyte count;	chr22:49637024	chr22:49612657~49615716:-
LUAD	cis	rs6531209	0.817	rs2881879	ENSG00000234378.1	AC098828.2	4.24	2.7e-05	0.00463	0.24	0.19	Amyotrophic lateral sclerosis (sporadic);	chr2:20136087	chr2:20063856~20106829:-
LUAD	cis	rs5762752	0.509	rs5752746	ENSG00000272858.1	CTA-292E10.8	-4.24	2.7e-05	0.00463	-0.2	-0.19	Optic disc area;	chr22:28450592	chr22:28814914~28815662:+
LUAD	cis	rs7176527	1	rs3762169	ENSG00000259570.1	RP11-671M22.4	-4.24	2.7e-05	0.00463	-0.27	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84598728	chr15:84394512~84395514:+
LUAD	cis	rs763121	0.853	rs2413546	ENSG00000228274.3	RP3-508I15.9	-4.24	2.7e-05	0.00463	-0.19	-0.19	Menopause (age at onset);	chr22:38710996	chr22:38667585~38681820:-
LUAD	cis	rs7923837	0.656	rs6583826	ENSG00000236493.2	EIF2S2P3	4.24	2.7e-05	0.00463	0.21	0.19	Multiple sclerosis;Body mass index;	chr10:92588073	chr10:92668745~92669743:-
LUAD	cis	rs4819052	0.851	rs8127834	ENSG00000215447.6	BX322557.10	-4.24	2.7e-05	0.00463	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45276194	chr21:45288052~45291738:+
LUAD	cis	rs8141529	0.719	rs5762825	ENSG00000272858.1	CTA-292E10.8	-4.24	2.7e-05	0.00463	-0.21	-0.19	Lymphocyte counts;	chr22:28827654	chr22:28814914~28815662:+
LUAD	cis	rs8141529	0.764	rs5752809	ENSG00000272858.1	CTA-292E10.8	-4.24	2.7e-05	0.00463	-0.21	-0.19	Lymphocyte counts;	chr22:28829512	chr22:28814914~28815662:+
LUAD	cis	rs8141529	0.764	rs5752812	ENSG00000272858.1	CTA-292E10.8	-4.24	2.7e-05	0.00463	-0.21	-0.19	Lymphocyte counts;	chr22:28829615	chr22:28814914~28815662:+
LUAD	cis	rs11673344	0.526	rs57654288	ENSG00000226686.6	LINC01535	4.24	2.7e-05	0.00463	0.23	0.19	Obesity-related traits;	chr19:37587870	chr19:37251912~37265535:+
LUAD	cis	rs3742264	1	rs8181800	ENSG00000235903.6	CPB2-AS1	-4.24	2.7e-05	0.00463	-0.24	-0.19	Blood protein levels;	chr13:46076559	chr13:46052806~46113332:+
LUAD	cis	rs73198271	0.694	rs73201840	ENSG00000253893.2	FAM85B	4.24	2.7e-05	0.00464	0.25	0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789557	chr8:8167819~8226614:-
LUAD	cis	rs73198271	0.694	rs113694763	ENSG00000253893.2	FAM85B	4.24	2.7e-05	0.00464	0.25	0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789566	chr8:8167819~8226614:-
LUAD	cis	rs73198271	0.694	rs115037021	ENSG00000253893.2	FAM85B	4.24	2.7e-05	0.00464	0.25	0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789570	chr8:8167819~8226614:-
LUAD	cis	rs73198271	0.694	rs114184516	ENSG00000253893.2	FAM85B	4.24	2.7e-05	0.00464	0.25	0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789572	chr8:8167819~8226614:-
LUAD	cis	rs9649213	0.593	rs6465677	ENSG00000272950.1	RP11-307C18.1	4.24	2.7e-05	0.00464	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98374240	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.593	rs6465678	ENSG00000272950.1	RP11-307C18.1	4.24	2.7e-05	0.00464	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98374745	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.574	rs6961790	ENSG00000272950.1	RP11-307C18.1	4.24	2.7e-05	0.00464	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98378681	chr7:98322853~98323430:+
LUAD	cis	rs9840812	0.639	rs610860	ENSG00000239213.4	NCK1-AS1	4.24	2.7e-05	0.00464	0.27	0.19	Fibrinogen levels;	chr3:136333974	chr3:136841726~136862054:-
LUAD	cis	rs453301	0.571	rs2929452	ENSG00000253981.4	ALG1L13P	-4.24	2.7e-05	0.00464	-0.22	-0.19	Joint mobility (Beighton score);	chr8:9226955	chr8:8236003~8244667:-
LUAD	cis	rs9649213	0.574	rs3801257	ENSG00000272950.1	RP11-307C18.1	4.24	2.7e-05	0.00464	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98362480	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.593	rs7803372	ENSG00000272950.1	RP11-307C18.1	4.24	2.7e-05	0.00464	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98362945	chr7:98322853~98323430:+
LUAD	cis	rs4372836	1	rs11127188	ENSG00000226833.4	AC097724.3	4.24	2.7e-05	0.00464	0.22	0.19	Body mass index;	chr2:28749986	chr2:28708953~28736205:-
LUAD	cis	rs12446632	0.941	rs11640942	ENSG00000261195.1	CTD-2380F24.1	-4.24	2.7e-05	0.00464	-0.28	-0.19	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Menarche (age at onset);Obesity;Childhood body mass index;Waist circumference;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr16:19908624	chr16:19761172~19766099:-
LUAD	cis	rs11089937	0.597	rs9619812	ENSG00000211640.3	IGLV6-57	4.24	2.7e-05	0.00464	0.14	0.19	Periodontitis (PAL4Q3);	chr22:22163945	chr22:22195713~22196460:+
LUAD	cis	rs11673344	0.504	rs11666786	ENSG00000276846.1	CTD-3220F14.3	4.24	2.7e-05	0.00464	0.21	0.19	Obesity-related traits;	chr19:37133947	chr19:37314868~37315620:-
LUAD	cis	rs4601821	1	rs4601821	ENSG00000270179.1	RP11-159N11.4	-4.24	2.7e-05	0.00464	-0.2	-0.19	Alcoholic chronic pancreatitis;	chr11:113379624	chr11:113368478~113369117:+
LUAD	cis	rs11089937	0.597	rs4821770	ENSG00000211640.3	IGLV6-57	4.24	2.7e-05	0.00464	0.14	0.19	Periodontitis (PAL4Q3);	chr22:22131281	chr22:22195713~22196460:+
LUAD	cis	rs11089937	0.568	rs4821771	ENSG00000211640.3	IGLV6-57	4.24	2.7e-05	0.00464	0.14	0.19	Periodontitis (PAL4Q3);	chr22:22131287	chr22:22195713~22196460:+
LUAD	cis	rs17301013	0.932	rs1653627	ENSG00000227373.4	RP11-160H22.5	-4.24	2.7e-05	0.00464	-0.24	-0.19	Systemic lupus erythematosus;	chr1:174771879	chr1:174115300~174160004:-
LUAD	cis	rs2154319	0.559	rs183334	ENSG00000235358.1	RP11-399E6.1	4.24	2.7e-05	0.00464	0.22	0.19	Height;	chr1:41146431	chr1:41242373~41284861:+
LUAD	cis	rs2880765	0.805	rs34598679	ENSG00000259416.2	RP11-158M2.5	4.24	2.7e-05	0.00464	0.2	0.19	Coronary artery disease;	chr15:85498974	chr15:85754941~85756237:-
LUAD	cis	rs2880765	0.835	rs4344688	ENSG00000259416.2	RP11-158M2.5	4.24	2.7e-05	0.00464	0.2	0.19	Coronary artery disease;	chr15:85499776	chr15:85754941~85756237:-
LUAD	cis	rs2880765	0.835	rs4280192	ENSG00000259416.2	RP11-158M2.5	4.24	2.7e-05	0.00464	0.2	0.19	Coronary artery disease;	chr15:85499789	chr15:85754941~85756237:-
LUAD	cis	rs2880765	0.835	rs7162502	ENSG00000259416.2	RP11-158M2.5	4.24	2.7e-05	0.00464	0.2	0.19	Coronary artery disease;	chr15:85501242	chr15:85754941~85756237:-
LUAD	cis	rs2880765	0.835	rs7169632	ENSG00000259416.2	RP11-158M2.5	4.24	2.7e-05	0.00464	0.2	0.19	Coronary artery disease;	chr15:85501436	chr15:85754941~85756237:-
LUAD	cis	rs2880765	0.835	rs7163958	ENSG00000259416.2	RP11-158M2.5	4.24	2.7e-05	0.00464	0.2	0.19	Coronary artery disease;	chr15:85501984	chr15:85754941~85756237:-
LUAD	cis	rs2880765	0.835	rs12910373	ENSG00000259416.2	RP11-158M2.5	4.24	2.7e-05	0.00464	0.2	0.19	Coronary artery disease;	chr15:85503571	chr15:85754941~85756237:-
LUAD	cis	rs8180040	0.903	rs11710013	ENSG00000271161.1	BOLA2P2	4.24	2.71e-05	0.00464	0.18	0.19	Colorectal cancer;	chr3:47255431	chr3:47499841~47500407:+
LUAD	cis	rs1876905	0.68	rs354540	ENSG00000230177.1	RP5-1112D6.4	-4.24	2.71e-05	0.00464	-0.22	-0.19	Mean corpuscular hemoglobin;	chr6:111195827	chr6:111277932~111278742:+
LUAD	cis	rs7107174	1	rs2511166	ENSG00000251323.2	RP11-452H21.4	4.24	2.71e-05	0.00464	0.24	0.19	Testicular germ cell tumor;	chr11:78253285	chr11:78423982~78429836:-
LUAD	cis	rs1431005	1	rs72723291	ENSG00000250658.1	RP11-138B4.1	4.24	2.71e-05	0.00464	0.24	0.19	Response to statin therapy;	chr4:187425714	chr4:187304083~187309682:-
LUAD	cis	rs7119038	0.818	rs7942535	ENSG00000255422.1	AP002954.4	-4.24	2.71e-05	0.00464	-0.28	-0.19	Sjögren's syndrome;	chr11:118810755	chr11:118704607~118750263:+
LUAD	cis	rs2243480	1	rs2243480	ENSG00000232559.3	GS1-124K5.12	4.24	2.71e-05	0.00465	0.33	0.19	Diabetic kidney disease;	chr7:66134209	chr7:66554588~66576923:-
LUAD	cis	rs6840360	0.642	rs2709842	ENSG00000270265.1	RP11-731D1.4	4.24	2.71e-05	0.00465	0.19	0.19	Intelligence (multi-trait analysis);	chr4:151449485	chr4:151333775~151353224:-
LUAD	cis	rs6668534	1	rs6668534	ENSG00000225217.1	HSPA7	-4.24	2.71e-05	0.00465	-0.2	-0.19	Blood protein levels;	chr1:161702205	chr1:161606291~161608217:+
LUAD	cis	rs57502260	0.704	rs2306862	ENSG00000212093.1	AP000807.1	4.24	2.71e-05	0.00465	0.25	0.19	Total body bone mineral density (age 45-60);	chr11:68410042	chr11:68506083~68506166:-
LUAD	cis	rs7005380	0.581	rs28546392	ENSG00000279347.1	RP11-85I17.2	4.24	2.71e-05	0.00465	0.18	0.19	Interstitial lung disease;	chr8:119919067	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.538	rs1879149	ENSG00000279347.1	RP11-85I17.2	4.24	2.71e-05	0.00465	0.18	0.19	Interstitial lung disease;	chr8:119919585	chr8:119838736~119840385:-
LUAD	cis	rs651907	0.557	rs13081846	ENSG00000244119.1	PDCL3P4	4.24	2.71e-05	0.00465	0.19	0.19	Colorectal cancer;	chr3:101664477	chr3:101712472~101713191:+
LUAD	cis	rs651907	0.557	rs11711079	ENSG00000244119.1	PDCL3P4	4.24	2.71e-05	0.00465	0.19	0.19	Colorectal cancer;	chr3:101668074	chr3:101712472~101713191:+
LUAD	cis	rs3096299	0.642	rs12934829	ENSG00000182376.2	RP5-1142A6.8	4.24	2.71e-05	0.00465	0.2	0.19	Multiple myeloma (IgH translocation);	chr16:89456941	chr16:88742767~88745748:+
LUAD	cis	rs62355901	0.505	rs62356567	ENSG00000271828.1	CTD-2310F14.1	4.24	2.71e-05	0.00465	0.4	0.19	Breast cancer;	chr5:56953442	chr5:56927874~56929573:+
LUAD	cis	rs1729407	0.786	rs5100	ENSG00000280143.1	AP000892.6	4.24	2.71e-05	0.00465	0.21	0.19	Apolipoprotein A-IV levels;	chr11:116821978	chr11:117204967~117210292:+
LUAD	cis	rs4705952	0.832	rs763595	ENSG00000233006.5	AC034220.3	-4.24	2.71e-05	0.00465	-0.22	-0.19	C-reactive protein levels;	chr5:132527552	chr5:132311285~132369916:-
LUAD	cis	rs7746199	0.736	rs10484399	ENSG00000219392.1	RP1-265C24.5	-4.24	2.71e-05	0.00466	-0.39	-0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27566749	chr6:28115628~28116551:+
LUAD	cis	rs41369048	1	rs2738751	ENSG00000238078.1	LINC01352	-4.24	2.71e-05	0.00466	-0.29	-0.19	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220878371	chr1:220829255~220832429:+
LUAD	cis	rs2823962	1	rs2823963	ENSG00000270093.1	AP000473.8	-4.24	2.71e-05	0.00466	-0.2	-0.19	Amyotrophic lateral sclerosis;	chr21:16674054	chr21:16643529~16645065:+
LUAD	cis	rs4713118	0.525	rs9357042	ENSG00000219392.1	RP1-265C24.5	-4.24	2.71e-05	0.00466	-0.23	-0.19	Parkinson's disease;	chr6:27615016	chr6:28115628~28116551:+
LUAD	cis	rs11779988	0.545	rs208753	ENSG00000253671.1	RP11-806O11.1	-4.24	2.72e-05	0.00466	-0.23	-0.19	Breast cancer;	chr8:17957406	chr8:17808941~17820868:+
LUAD	cis	rs2243480	0.522	rs778717	ENSG00000230295.1	RP11-458F8.2	-4.24	2.72e-05	0.00466	-0.27	-0.19	Diabetic kidney disease;	chr7:66383164	chr7:66880708~66882981:+
LUAD	cis	rs7561273	0.609	rs2339945	ENSG00000242628.4	AC009228.1	4.24	2.72e-05	0.00466	0.24	0.19	Quantitative traits;	chr2:24125226	chr2:24214381~24221516:+
LUAD	cis	rs7561273	0.586	rs13418279	ENSG00000242628.4	AC009228.1	4.24	2.72e-05	0.00466	0.24	0.19	Quantitative traits;	chr2:24126348	chr2:24214381~24221516:+
LUAD	cis	rs11051970	0.592	rs12227991	ENSG00000274964.1	RP11-817I4.1	-4.24	2.72e-05	0.00466	-0.25	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr12:32387111	chr12:32339368~32340724:+
LUAD	cis	rs11051970	0.559	rs11051973	ENSG00000274964.1	RP11-817I4.1	-4.24	2.72e-05	0.00466	-0.25	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr12:32388978	chr12:32339368~32340724:+
LUAD	cis	rs10129255	0.957	rs10142918	ENSG00000274576.2	IGHV2-70	4.24	2.72e-05	0.00466	0.17	0.19	Kawasaki disease;	chr14:106782206	chr14:106770577~106771020:-
LUAD	cis	rs12986445	0.843	rs10209507	ENSG00000218682.1	AC010150.1	4.24	2.72e-05	0.00466	0.24	0.19	Multiple myeloma;Multiple myeloma and monoclonal gammopathy;	chr2:25781549	chr2:25856461~25856966:-
LUAD	cis	rs17826219	0.561	rs562840	ENSG00000280069.1	CTD-2349P21.3	-4.24	2.72e-05	0.00466	-0.22	-0.19	Body mass index;	chr17:30622372	chr17:30738182~30740275:+
LUAD	cis	rs13256369	1	rs10095733	ENSG00000253893.2	FAM85B	-4.24	2.72e-05	0.00466	-0.26	-0.19	Obesity-related traits;	chr8:8717136	chr8:8167819~8226614:-
LUAD	cis	rs9652601	0.959	rs9934969	ENSG00000274038.1	RP11-66H6.4	-4.24	2.72e-05	0.00466	-0.23	-0.19	Systemic lupus erythematosus;	chr16:11072145	chr16:11056556~11057034:+
LUAD	cis	rs6558530	0.692	rs12335115	ENSG00000253982.1	CTD-2336O2.1	4.24	2.72e-05	0.00466	0.25	0.19	Systolic blood pressure;	chr8:1751686	chr8:1761990~1764502:-
LUAD	cis	rs12754538	0.922	rs902356	ENSG00000232912.4	RP5-1115A15.1	4.24	2.72e-05	0.00466	0.2	0.19	Subjective well-being;	chr1:8372593	chr1:8424645~8434838:+
LUAD	cis	rs11089937	0.553	rs35336247	ENSG00000211640.3	IGLV6-57	4.24	2.72e-05	0.00466	0.14	0.19	Periodontitis (PAL4Q3);	chr22:22131593	chr22:22195713~22196460:+
LUAD	cis	rs11089937	0.553	rs34088081	ENSG00000211640.3	IGLV6-57	4.24	2.72e-05	0.00466	0.14	0.19	Periodontitis (PAL4Q3);	chr22:22131601	chr22:22195713~22196460:+
LUAD	cis	rs2933343	0.621	rs4927921	ENSG00000231305.3	RP11-723O4.2	-4.24	2.72e-05	0.00466	-0.2	-0.19	IgG glycosylation;	chr3:128850025	chr3:128861313~128871540:-
LUAD	cis	rs737008	0.5	rs7189239	ENSG00000262636.1	CTD-3088G3.4	4.24	2.72e-05	0.00466	0.23	0.19	Obesity-related traits;	chr16:11308658	chr16:11380859~11381118:-
LUAD	cis	rs17596685	1	rs8002449	ENSG00000271216.1	LINC01050	4.24	2.72e-05	0.00466	0.28	0.19	C-reactive protein levels;	chr13:42590405	chr13:42810366~42812562:-
LUAD	cis	rs9532669	0.926	rs7799	ENSG00000168852.11	TPTE2P5	4.24	2.72e-05	0.00466	0.19	0.19	Cervical cancer;	chr13:40958916	chr13:40822296~40921749:-
LUAD	cis	rs1544167	0.955	rs35595181	ENSG00000237927.1	RP3-393E18.2	-4.24	2.72e-05	0.00466	-0.29	-0.19	Lipoprotein (a) - cholesterol levels;	chr6:159380881	chr6:159586955~159589169:-
LUAD	cis	rs10419113	0.641	rs12610315	ENSG00000270804.1	CTD-2583A14.11	4.24	2.72e-05	0.00466	0.17	0.19	Pediatric bone mineral density (spine);	chr19:57765288	chr19:57867885~57868834:+
LUAD	cis	rs11220082	0.666	rs2241514	ENSG00000254671.2	STT3A-AS1	-4.24	2.72e-05	0.00467	-0.22	-0.19	Schizophrenia;	chr11:125456130	chr11:125570284~125592568:-
LUAD	cis	rs2300747	0.932	rs12044852	ENSG00000177173.5	NAP1L4P1	-4.24	2.72e-05	0.00467	-0.31	-0.19	Primary biliary cholangitis;Multiple sclerosis;	chr1:116545157	chr1:116532936~116534092:-
LUAD	cis	rs7829975	0.742	rs882462	ENSG00000233609.3	RP11-62H7.2	4.24	2.72e-05	0.00467	0.16	0.19	Mood instability;	chr8:8821020	chr8:8961200~8979025:+
LUAD	cis	rs12935418	0.832	rs79957369	ENSG00000261838.4	RP11-303E16.6	4.24	2.72e-05	0.00467	0.37	0.19	Mean corpuscular volume;	chr16:81025654	chr16:81069854~81076598:+
LUAD	cis	rs642803	0.551	rs1308020	ENSG00000254510.1	RP11-867G23.10	-4.24	2.72e-05	0.00467	-0.23	-0.19	Urate levels;	chr11:65730087	chr11:66409158~66417137:+
LUAD	cis	rs11673344	0.542	rs1667380	ENSG00000276846.1	CTD-3220F14.3	4.24	2.72e-05	0.00467	0.21	0.19	Obesity-related traits;	chr19:37001848	chr19:37314868~37315620:-
LUAD	cis	rs9925964	0.687	rs12917722	ENSG00000232748.3	RP11-196G11.6	4.24	2.72e-05	0.00467	0.23	0.19	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:30937076	chr16:31056460~31062803:+
LUAD	cis	rs6479891	1	rs7087279	ENSG00000232075.1	MRPL35P2	-4.24	2.72e-05	0.00467	-0.31	-0.19	Arthritis (juvenile idiopathic);	chr10:63532176	chr10:63634317~63634827:-
LUAD	cis	rs41369048	0.925	rs2738756	ENSG00000238078.1	LINC01352	-4.24	2.72e-05	0.00467	-0.29	-0.19	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220884717	chr1:220829255~220832429:+
LUAD	cis	rs7098414	0.511	rs10887828	ENSG00000226659.1	RP11-137H2.4	-4.24	2.72e-05	0.00467	-0.25	-0.19	Post bronchodilator FEV1;	chr10:80391714	chr10:80529597~80535942:-
LUAD	cis	rs7098414	0.511	rs4934126	ENSG00000226659.1	RP11-137H2.4	-4.24	2.72e-05	0.00467	-0.25	-0.19	Post bronchodilator FEV1;	chr10:80391842	chr10:80529597~80535942:-
LUAD	cis	rs7098414	0.511	rs7916349	ENSG00000226659.1	RP11-137H2.4	-4.24	2.72e-05	0.00467	-0.25	-0.19	Post bronchodilator FEV1;	chr10:80392882	chr10:80529597~80535942:-
LUAD	cis	rs7086627	0.515	rs7907969	ENSG00000226659.1	RP11-137H2.4	-4.24	2.72e-05	0.00467	-0.25	-0.19	Post bronchodilator FEV1;	chr10:80393249	chr10:80529597~80535942:-
LUAD	cis	rs944990	0.557	rs6479493	ENSG00000227603.1	RP11-165J3.6	-4.24	2.72e-05	0.00467	-0.21	-0.19	Body mass index;	chr9:93536690	chr9:93435332~93437121:-
LUAD	cis	rs4578769	0.569	rs1597239	ENSG00000265943.1	RP11-739L10.1	4.24	2.73e-05	0.00467	0.24	0.19	Eosinophil percentage of white cells;	chr18:22805673	chr18:22699481~22933764:-
LUAD	cis	rs7107174	1	rs1017908	ENSG00000251323.2	RP11-452H21.4	4.24	2.73e-05	0.00467	0.26	0.19	Testicular germ cell tumor;	chr11:78237049	chr11:78423982~78429836:-
LUAD	cis	rs9341808	0.718	rs9343978	ENSG00000272129.1	RP11-250B2.6	4.24	2.73e-05	0.00467	0.23	0.19	Sitting height ratio;	chr6:80262261	chr6:80355424~80356859:+
LUAD	cis	rs9467773	0.873	rs9295698	ENSG00000261353.1	CTA-14H9.5	-4.24	2.73e-05	0.00467	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26565871	chr6:26527063~26527404:+
LUAD	cis	rs228614	0.509	rs223482	ENSG00000251288.2	RP11-10L12.2	-4.24	2.73e-05	0.00467	-0.23	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766051	chr4:102751401~102752641:+
LUAD	cis	rs228614	0.536	rs223478	ENSG00000251288.2	RP11-10L12.2	-4.24	2.73e-05	0.00467	-0.23	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102768648	chr4:102751401~102752641:+
LUAD	cis	rs228614	0.536	rs150898	ENSG00000251288.2	RP11-10L12.2	-4.24	2.73e-05	0.00467	-0.23	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769234	chr4:102751401~102752641:+
LUAD	cis	rs228614	0.509	rs223476	ENSG00000251288.2	RP11-10L12.2	-4.24	2.73e-05	0.00467	-0.23	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771000	chr4:102751401~102752641:+
LUAD	cis	rs228614	0.509	rs150896	ENSG00000251288.2	RP11-10L12.2	-4.24	2.73e-05	0.00467	-0.23	-0.19	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771186	chr4:102751401~102752641:+
LUAD	cis	rs2288884	1	rs12609219	ENSG00000269959.1	SPACA6P-AS	-4.24	2.73e-05	0.00467	-0.26	-0.19	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52077743	chr19:51685363~51693456:-
LUAD	cis	rs160451	1	rs160446	ENSG00000251136.7	RP11-37B2.1	4.24	2.73e-05	0.00467	0.19	0.19	Leprosy;	chr8:89647035	chr8:89609409~89757727:-
LUAD	cis	rs7119038	0.774	rs10892290	ENSG00000255422.1	AP002954.4	4.24	2.73e-05	0.00468	0.3	0.19	Sjögren's syndrome;	chr11:118782794	chr11:118704607~118750263:+
LUAD	cis	rs17826219	0.561	rs11655876	ENSG00000280069.1	CTD-2349P21.3	-4.24	2.73e-05	0.00468	-0.23	-0.19	Body mass index;	chr17:30690132	chr17:30738182~30740275:+
LUAD	cis	rs2980439	0.525	rs2980508	ENSG00000253981.4	ALG1L13P	4.24	2.73e-05	0.00468	0.21	0.19	Neuroticism;	chr8:8314210	chr8:8236003~8244667:-
LUAD	cis	rs7204230	1	rs2042028	ENSG00000261291.1	RP11-295M3.2	-4.24	2.73e-05	0.00468	-0.24	-0.19	Fibrinogen;	chr16:53162364	chr16:53168522~53169450:+
LUAD	cis	rs11673344	0.518	rs73033134	ENSG00000226686.6	LINC01535	4.24	2.73e-05	0.00468	0.23	0.19	Obesity-related traits;	chr19:37596046	chr19:37251912~37265535:+
LUAD	cis	rs2310173	0.612	rs3819369	ENSG00000281162.1	LINC01127	-4.24	2.73e-05	0.00468	-0.21	-0.19	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:102016120	chr2:101962056~101987167:+
LUAD	cis	rs7204230	1	rs12599823	ENSG00000261291.1	RP11-295M3.2	4.24	2.73e-05	0.00468	0.23	0.19	Fibrinogen;	chr16:53315316	chr16:53168522~53169450:+
LUAD	cis	rs42490	0.738	rs39509	ENSG00000251136.7	RP11-37B2.1	-4.24	2.73e-05	0.00468	-0.2	-0.19	Leprosy;	chr8:89791937	chr8:89609409~89757727:-
LUAD	cis	rs10761482	0.601	rs1954117	ENSG00000254271.1	RP11-131N11.4	4.24	2.73e-05	0.00468	0.23	0.19	Schizophrenia;	chr10:60450830	chr10:60734342~60741828:+
LUAD	cis	rs10761482	0.639	rs2067612	ENSG00000254271.1	RP11-131N11.4	4.24	2.73e-05	0.00468	0.23	0.19	Schizophrenia;	chr10:60452576	chr10:60734342~60741828:+
LUAD	cis	rs7824557	0.564	rs11782430	ENSG00000255046.1	RP11-297N6.4	4.24	2.73e-05	0.00468	0.24	0.19	Retinal vascular caliber;	chr8:11368562	chr8:11797928~11802568:-
LUAD	cis	rs17772222	0.638	rs11629164	ENSG00000258789.1	RP11-507K2.3	4.24	2.73e-05	0.00468	0.23	0.19	Coronary artery calcification;	chr14:88564740	chr14:88551597~88552493:+
LUAD	cis	rs11157436	0.602	rs12588757	ENSG00000211812.1	TRAV26-2	-4.24	2.73e-05	0.00468	-0.19	-0.19	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22172100	chr14:22202583~22203368:+
LUAD	cis	rs6840360	0.571	rs6833814	ENSG00000270265.1	RP11-731D1.4	-4.24	2.73e-05	0.00468	-0.22	-0.19	Intelligence (multi-trait analysis);	chr4:151618527	chr4:151333775~151353224:-
LUAD	cis	rs9487094	1	rs36035949	ENSG00000260273.1	RP11-425D10.10	4.24	2.74e-05	0.00468	0.25	0.19	Height;	chr6:109415411	chr6:109382795~109383666:+
LUAD	cis	rs2243480	1	rs160633	ENSG00000232559.3	GS1-124K5.12	4.24	2.74e-05	0.00468	0.33	0.19	Diabetic kidney disease;	chr7:66063241	chr7:66554588~66576923:-
LUAD	cis	rs9813712	0.574	rs11718032	ENSG00000228252.7	COL6A4P2	4.24	2.74e-05	0.00468	0.18	0.19	Response to amphetamines;	chr3:130257749	chr3:130212823~130273806:+
LUAD	cis	rs2274273	0.805	rs7159808	ENSG00000259318.1	RP11-454L9.2	4.24	2.74e-05	0.00468	0.17	0.19	Protein biomarker;	chr14:55157609	chr14:55394940~55395233:-
LUAD	cis	rs848490	0.962	rs55759218	ENSG00000214293.7	APTR	4.24	2.74e-05	0.00469	0.26	0.19	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77824040	chr7:77657660~77696265:-
LUAD	cis	rs11089937	0.559	rs2330014	ENSG00000211640.3	IGLV6-57	4.24	2.74e-05	0.00469	0.13	0.19	Periodontitis (PAL4Q3);	chr22:22166155	chr22:22195713~22196460:+
LUAD	cis	rs131777	0.708	rs131749	ENSG00000273272.1	CTA-384D8.34	-4.24	2.74e-05	0.00469	-0.22	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586195	chr22:50542650~50543011:+
LUAD	cis	rs80028505	0.908	rs73730437	ENSG00000271304.1	DPRXP2	4.24	2.74e-05	0.00469	0.35	0.19	Foot ulcer in diabetes and neuropathy;	chr6:36068735	chr6:35989515~35990436:-
LUAD	cis	rs80028505	0.908	rs7775290	ENSG00000271304.1	DPRXP2	4.24	2.74e-05	0.00469	0.35	0.19	Foot ulcer in diabetes and neuropathy;	chr6:36069132	chr6:35989515~35990436:-
LUAD	cis	rs9303029	0.932	rs9905527	ENSG00000265458.1	RP13-20L14.6	4.24	2.74e-05	0.00469	0.35	0.19	Protein quantitative trait loci;	chr17:82482049	chr17:82454273~82458521:-
LUAD	cis	rs2836754	1	rs7279866	ENSG00000205622.8	AF064858.6	-4.24	2.74e-05	0.00469	-0.21	-0.19	Body mass index;Crohn's disease;	chr21:38920998	chr21:38863676~38956467:-
LUAD	cis	rs2836754	1	rs7278605	ENSG00000205622.8	AF064858.6	-4.24	2.74e-05	0.00469	-0.21	-0.19	Body mass index;Crohn's disease;	chr21:38921022	chr21:38863676~38956467:-
LUAD	cis	rs6095360	0.727	rs8119476	ENSG00000222365.1	SNORD12B	-4.24	2.74e-05	0.00469	-0.22	-0.19	Intelligence (multi-trait analysis);	chr20:49073599	chr20:49280319~49280409:+
LUAD	cis	rs11051970	0.636	rs1128591	ENSG00000274964.1	RP11-817I4.1	-4.24	2.74e-05	0.00469	-0.2	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr12:32416417	chr12:32339368~32340724:+
LUAD	cis	rs11051970	0.636	rs1045751	ENSG00000274964.1	RP11-817I4.1	-4.24	2.74e-05	0.00469	-0.2	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr12:32416562	chr12:32339368~32340724:+
LUAD	cis	rs17685	0.712	rs11770149	ENSG00000280388.1	RP11-229D13.3	-4.24	2.74e-05	0.00469	-0.18	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76162326	chr7:76043977~76045963:-
LUAD	cis	rs2735413	0.564	rs73580867	ENSG00000276007.1	RP11-358L22.3	4.24	2.74e-05	0.00469	0.27	0.19	Systolic blood pressure (alcohol consumption interaction);	chr16:78087056	chr16:78123243~78124332:+
LUAD	cis	rs9341808	0.718	rs9361584	ENSG00000260645.1	RP11-250B2.5	4.24	2.74e-05	0.00469	0.18	0.19	Sitting height ratio;	chr6:80110229	chr6:80466958~80469080:+
LUAD	cis	rs9341808	0.718	rs9359408	ENSG00000260645.1	RP11-250B2.5	4.24	2.74e-05	0.00469	0.18	0.19	Sitting height ratio;	chr6:80110415	chr6:80466958~80469080:+
LUAD	cis	rs9341808	0.718	rs9443734	ENSG00000260645.1	RP11-250B2.5	4.24	2.74e-05	0.00469	0.18	0.19	Sitting height ratio;	chr6:80110576	chr6:80466958~80469080:+
LUAD	cis	rs9341808	0.718	rs9443735	ENSG00000260645.1	RP11-250B2.5	4.24	2.74e-05	0.00469	0.18	0.19	Sitting height ratio;	chr6:80110757	chr6:80466958~80469080:+
LUAD	cis	rs4554975	0.689	rs11183630	ENSG00000274723.1	RP11-618L22.1	-4.24	2.74e-05	0.00469	-0.22	-0.19	Metabolite levels (small molecules and protein measures);	chr12:46843286	chr12:46970504~46972155:+
LUAD	cis	rs5769707	0.681	rs2319346	ENSG00000235111.1	RP1-29C18.8	-4.24	2.74e-05	0.00469	-0.23	-0.19	Monocyte percentage of white cells;Monocyte count;	chr22:49635992	chr22:49612657~49615716:-
LUAD	cis	rs854462	0.852	rs854636	ENSG00000274767.1	AC131056.3	4.23	2.74e-05	0.00469	0.24	0.19	Blood protein levels;	chr17:36045781	chr17:36183235~36196471:+
LUAD	cis	rs17685	0.753	rs4398845	ENSG00000280388.1	RP11-229D13.3	-4.23	2.74e-05	0.00469	-0.18	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76087463	chr7:76043977~76045963:-
LUAD	cis	rs28386778	0.897	rs2236737	ENSG00000240280.5	TCAM1P	-4.23	2.74e-05	0.00469	-0.22	-0.19	Prudent dietary pattern;	chr17:63860740	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.897	rs2236736	ENSG00000240280.5	TCAM1P	-4.23	2.74e-05	0.00469	-0.22	-0.19	Prudent dietary pattern;	chr17:63860888	chr17:63849292~63864379:+
LUAD	cis	rs848490	0.926	rs62460744	ENSG00000214293.7	APTR	4.23	2.74e-05	0.00469	0.25	0.19	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77819363	chr7:77657660~77696265:-
LUAD	cis	rs4268898	0.717	rs2543662	ENSG00000242628.4	AC009228.1	-4.23	2.74e-05	0.00469	-0.26	-0.19	Asthma;	chr2:24220402	chr2:24214381~24221516:+
LUAD	cis	rs6840360	0.642	rs10857260	ENSG00000270265.1	RP11-731D1.4	-4.23	2.74e-05	0.00469	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151502904	chr4:151333775~151353224:-
LUAD	cis	rs8031584	0.918	rs3817498	ENSG00000259845.1	HERC2P10	4.23	2.74e-05	0.0047	0.22	0.19	Huntington's disease progression;	chr15:30976578	chr15:30815271~30844153:+
LUAD	cis	rs7404843	0.789	rs222907	ENSG00000183458.12	RP11-958N24.1	4.23	2.74e-05	0.0047	0.2	0.19	Testicular germ cell tumor;	chr16:15404950	chr16:14911551~14935708:+
LUAD	cis	rs6723108	0.517	rs7580655	ENSG00000224043.6	CCNT2-AS1	-4.23	2.74e-05	0.0047	-0.23	-0.19	Type 2 diabetes;	chr2:134869605	chr2:134735464~134918710:-
LUAD	cis	rs1005277	0.505	rs200939	ENSG00000263064.2	RP11-291L22.7	4.23	2.75e-05	0.0047	0.2	0.19	Extrinsic epigenetic age acceleration;	chr10:37850555	chr10:38448689~38448949:+
LUAD	cis	rs12216545	0.765	rs1851434	ENSG00000177590.7	GIMAP3P	4.23	2.75e-05	0.0047	0.19	0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150532365	chr7:150746893~150747728:-
LUAD	cis	rs8040855	0.627	rs4843019	ENSG00000259774.1	RP11-182J1.13	-4.23	2.75e-05	0.0047	-0.24	-0.19	Bulimia nervosa;	chr15:85101228	chr15:84422618~84425882:+
LUAD	cis	rs71537559	1	rs71537559	ENSG00000219392.1	RP1-265C24.5	-4.23	2.75e-05	0.0047	-0.38	-0.19	Squamous cell lung carcinoma;	chr6:27342000	chr6:28115628~28116551:+
LUAD	cis	rs262150	0.851	rs2527224	ENSG00000231419.5	LINC00689	-4.23	2.75e-05	0.0047	-0.23	-0.19	Facial morphology (factor 20);	chr7:158976507	chr7:159006522~159030195:+
LUAD	cis	rs1008375	0.932	rs13109475	ENSG00000249502.1	AC006160.5	4.23	2.75e-05	0.0047	0.18	0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17675942	chr4:17587467~17614571:-
LUAD	cis	rs2274273	0.87	rs7160523	ENSG00000259318.1	RP11-454L9.2	4.23	2.75e-05	0.0047	0.16	0.19	Protein biomarker;	chr14:55127842	chr14:55394940~55395233:-
LUAD	cis	rs6570726	1	rs1935615	ENSG00000235652.6	RP11-545I5.3	4.23	2.75e-05	0.0047	0.2	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145599981	chr6:145799409~145886585:+
LUAD	cis	rs62025270	0.688	rs62022939	ENSG00000202081.1	RNU6-1280P	-4.23	2.75e-05	0.0047	-0.28	-0.19	Idiopathic pulmonary fibrosis;	chr15:85707651	chr15:85651522~85651628:-
LUAD	cis	rs6496932	0.663	rs4843051	ENSG00000218052.5	ADAMTS7P4	-4.23	2.75e-05	0.0047	-0.22	-0.19	Central corneal thickness;Corneal structure;	chr15:85360907	chr15:85255369~85330334:-
LUAD	cis	rs2735413	0.564	rs73578755	ENSG00000276007.1	RP11-358L22.3	4.23	2.75e-05	0.0047	0.26	0.19	Systolic blood pressure (alcohol consumption interaction);	chr16:78074912	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.564	rs73580814	ENSG00000276007.1	RP11-358L22.3	4.23	2.75e-05	0.0047	0.26	0.19	Systolic blood pressure (alcohol consumption interaction);	chr16:78075002	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.564	rs73580821	ENSG00000276007.1	RP11-358L22.3	4.23	2.75e-05	0.0047	0.26	0.19	Systolic blood pressure (alcohol consumption interaction);	chr16:78076407	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.564	rs73580826	ENSG00000276007.1	RP11-358L22.3	4.23	2.75e-05	0.0047	0.26	0.19	Systolic blood pressure (alcohol consumption interaction);	chr16:78076992	chr16:78123243~78124332:+
LUAD	cis	rs11992186	0.505	rs7845203	ENSG00000173295.6	FAM86B3P	4.23	2.75e-05	0.0047	0.19	0.19	Neuroticism;	chr8:8287918	chr8:8228595~8244865:+
LUAD	cis	rs9309473	0.519	rs2421667	ENSG00000163016.8	ALMS1P	-4.23	2.75e-05	0.0047	-0.2	-0.19	Metabolite levels;	chr2:73605332	chr2:73644919~73685576:+
LUAD	cis	rs62025270	0.632	rs74025655	ENSG00000202081.1	RNU6-1280P	-4.23	2.75e-05	0.0047	-0.27	-0.19	Idiopathic pulmonary fibrosis;	chr15:85674319	chr15:85651522~85651628:-
LUAD	cis	rs453301	0.571	rs2929456	ENSG00000173295.6	FAM86B3P	-4.23	2.75e-05	0.0047	-0.2	-0.19	Joint mobility (Beighton score);	chr8:9225906	chr8:8228595~8244865:+
LUAD	cis	rs2732480	0.5	rs2732461	ENSG00000240399.1	RP1-228P16.1	4.23	2.75e-05	0.00471	0.19	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48299019	chr12:48054813~48055591:-
LUAD	cis	rs1979679	0.673	rs12229872	ENSG00000278733.1	RP11-425D17.1	4.23	2.75e-05	0.00471	0.24	0.19	Ossification of the posterior longitudinal ligament of the spine;	chr12:28137845	chr12:28185625~28186190:-
LUAD	cis	rs8098244	0.756	rs1154229	ENSG00000264745.1	TTC39C-AS1	-4.23	2.75e-05	0.00471	-0.2	-0.19	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23902252	chr18:23994213~24015339:-
LUAD	cis	rs28386778	0.829	rs1877317	ENSG00000240280.5	TCAM1P	-4.23	2.75e-05	0.00471	-0.22	-0.19	Prudent dietary pattern;	chr17:63699119	chr17:63849292~63864379:+
LUAD	cis	rs7560272	0.695	rs780393	ENSG00000163016.8	ALMS1P	-4.23	2.76e-05	0.00472	-0.2	-0.19	Schizophrenia;	chr2:73474542	chr2:73644919~73685576:+
LUAD	cis	rs13113518	0.812	rs2035692	ENSG00000272969.1	RP11-528I4.2	4.23	2.76e-05	0.00472	0.2	0.19	Height;	chr4:55528801	chr4:55547112~55547889:+
LUAD	cis	rs3018712	0.582	rs2513278	ENSG00000212093.1	AP000807.1	-4.23	2.76e-05	0.00472	-0.26	-0.19	Total body bone mineral density;	chr11:68661905	chr11:68506083~68506166:-
LUAD	cis	rs6061231	0.518	rs639836	ENSG00000273619.1	RP5-908M14.9	4.23	2.76e-05	0.00472	0.18	0.19	Colorectal cancer;	chr20:62351167	chr20:62386303~62386970:-
LUAD	cis	rs4554975	0.545	rs11183661	ENSG00000274723.1	RP11-618L22.1	-4.23	2.76e-05	0.00472	-0.22	-0.19	Metabolite levels (small molecules and protein measures);	chr12:46937241	chr12:46970504~46972155:+
LUAD	cis	rs6840360	0.837	rs13146981	ENSG00000270265.1	RP11-731D1.4	4.23	2.76e-05	0.00472	0.19	0.19	Intelligence (multi-trait analysis);	chr4:151799551	chr4:151333775~151353224:-
LUAD	cis	rs8062405	0.824	rs7191618	ENSG00000261419.1	RP11-57A19.4	-4.23	2.76e-05	0.00472	-0.21	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28659696~28740781:-
LUAD	cis	rs2562456	0.526	rs950504	ENSG00000268081.1	RP11-678G14.2	4.23	2.76e-05	0.00472	0.27	0.19	Pain;	chr19:21601193	chr19:21554640~21569237:-
LUAD	cis	rs4554975	0.689	rs10881004	ENSG00000274723.1	RP11-618L22.1	-4.23	2.76e-05	0.00472	-0.22	-0.19	Metabolite levels (small molecules and protein measures);	chr12:46842788	chr12:46970504~46972155:+
LUAD	cis	rs2337406	0.852	rs12050239	ENSG00000280411.1	IGHV1-69-2	-4.23	2.76e-05	0.00473	-0.17	-0.19	Alzheimer's disease (late onset);	chr14:106781132	chr14:106762092~106762588:-
LUAD	cis	rs2115630	0.967	rs12595786	ENSG00000225151.9	GOLGA2P7	4.23	2.76e-05	0.00473	0.21	0.19	P wave terminal force;	chr15:84793439	chr15:84199311~84230136:-
LUAD	cis	rs1008375	0.932	rs7677212	ENSG00000249502.1	AC006160.5	4.23	2.76e-05	0.00473	0.18	0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17674309	chr4:17587467~17614571:-
LUAD	cis	rs4843747	0.671	rs28679286	ENSG00000205037.2	RP11-863P13.4	4.23	2.76e-05	0.00473	0.27	0.19	Menopause (age at onset);	chr16:88072701	chr16:88088041~88100985:-
LUAD	cis	rs2284219	0.565	rs2284217	ENSG00000226874.1	AC005154.8	-4.23	2.76e-05	0.00473	-0.2	-0.19	Type 2 diabetes;	chr7:30673992	chr7:30544053~30544431:+
LUAD	cis	rs2153535	0.585	rs9328500	ENSG00000230939.1	RP11-314C16.1	4.23	2.76e-05	0.00473	0.21	0.19	Motion sickness;	chr6:8658838	chr6:8784178~8785445:+
LUAD	cis	rs6568686	0.786	rs6910340	ENSG00000255389.1	C6orf3	-4.23	2.76e-05	0.00473	-0.26	-0.19	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111541861	chr6:111599875~111602295:+
LUAD	cis	rs8180040	0.966	rs807932	ENSG00000271161.1	BOLA2P2	4.23	2.76e-05	0.00473	0.18	0.19	Colorectal cancer;	chr3:47312751	chr3:47499841~47500407:+
LUAD	cis	rs8180040	1	rs295428	ENSG00000271161.1	BOLA2P2	4.23	2.76e-05	0.00473	0.18	0.19	Colorectal cancer;	chr3:47317772	chr3:47499841~47500407:+
LUAD	cis	rs11157436	0.602	rs2032441	ENSG00000211812.1	TRAV26-2	-4.23	2.76e-05	0.00473	-0.19	-0.19	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22157682	chr14:22202583~22203368:+
LUAD	cis	rs6496932	0.909	rs74024818	ENSG00000202081.1	RNU6-1280P	4.23	2.76e-05	0.00473	0.28	0.19	Central corneal thickness;Corneal structure;	chr15:85339299	chr15:85651522~85651628:-
LUAD	cis	rs17772222	0.917	rs17188228	ENSG00000258789.1	RP11-507K2.3	-4.23	2.77e-05	0.00473	-0.26	-0.19	Coronary artery calcification;	chr14:88738921	chr14:88551597~88552493:+
LUAD	cis	rs6687821	0.774	rs11161891	ENSG00000261737.1	RP4-612B15.3	-4.23	2.77e-05	0.00473	-0.31	-0.19	Yeast infection;	chr1:86791615	chr1:86703502~86704462:-
LUAD	cis	rs62355901	0.505	rs56984944	ENSG00000271828.1	CTD-2310F14.1	4.23	2.77e-05	0.00473	0.39	0.19	Breast cancer;	chr5:56927671	chr5:56927874~56929573:+
LUAD	cis	rs2638953	0.924	rs7957382	ENSG00000278733.1	RP11-425D17.1	4.23	2.77e-05	0.00473	0.22	0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28203643	chr12:28185625~28186190:-
LUAD	cis	rs6071166	0.967	rs6027419	ENSG00000224635.1	RP4-564F22.5	-4.23	2.77e-05	0.00473	-0.21	-0.19	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38703562	chr20:38406011~38416797:-
LUAD	cis	rs13113518	0.812	rs12500456	ENSG00000272969.1	RP11-528I4.2	4.23	2.77e-05	0.00473	0.2	0.19	Height;	chr4:55561053	chr4:55547112~55547889:+
LUAD	cis	rs7129556	0.69	rs947841	ENSG00000241782.1	RP11-91P24.1	4.23	2.77e-05	0.00473	0.26	0.19	Weight loss (gastric bypass surgery);	chr11:77881863	chr11:77868722~77869195:-
LUAD	cis	rs8180040	0.62	rs749511	ENSG00000271161.1	BOLA2P2	-4.23	2.77e-05	0.00473	-0.18	-0.19	Colorectal cancer;	chr3:46994245	chr3:47499841~47500407:+
LUAD	cis	rs1555322	0.53	rs2275275	ENSG00000126005.14	MMP24-AS1	-4.23	2.77e-05	0.00473	-0.26	-0.19	Attention deficit hyperactivity disorder;	chr20:35284508	chr20:35216462~35278131:-
LUAD	cis	rs2274273	0.905	rs8007944	ENSG00000259318.1	RP11-454L9.2	4.23	2.77e-05	0.00473	0.17	0.19	Protein biomarker;	chr14:55110098	chr14:55394940~55395233:-
LUAD	cis	rs7208859	0.673	rs11651802	ENSG00000266490.1	CTD-2349P21.9	4.23	2.77e-05	0.00474	0.3	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832642	chr17:30792372~30792833:+
LUAD	cis	rs748404	0.666	rs16957715	ENSG00000249839.1	AC011330.5	-4.23	2.77e-05	0.00474	-0.29	-0.19	Lung cancer;	chr15:43416539	chr15:43663654~43684339:-
LUAD	cis	rs800160	0.925	rs1088989	ENSG00000236264.4	RPL26P30	-4.23	2.77e-05	0.00474	-0.25	-0.19	Bacteremia;	chr11:2359825	chr11:2335132~2335776:-
LUAD	cis	rs1798817	1	rs116761727	ENSG00000189238.5	LINC00943	-4.23	2.77e-05	0.00474	-0.39	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr12:126775703	chr12:126726270~126746252:+
LUAD	cis	rs7762018	0.891	rs7740218	ENSG00000231690.2	LINC00574	-4.23	2.77e-05	0.00474	-0.36	-0.19	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169741456	chr6:169790321~169802873:+
LUAD	cis	rs9400467	0.528	rs11153280	ENSG00000230177.1	RP5-1112D6.4	-4.23	2.77e-05	0.00474	-0.16	-0.19	Amino acid levels;Blood metabolite levels;	chr6:111268090	chr6:111277932~111278742:+
LUAD	cis	rs853679	0.506	rs1150711	ENSG00000219392.1	RP1-265C24.5	-4.23	2.77e-05	0.00474	-0.24	-0.19	Depression;	chr6:28240757	chr6:28115628~28116551:+
LUAD	cis	rs8133949	0.638	rs2839432	ENSG00000237232.6	ZNF295-AS1	-4.23	2.77e-05	0.00474	-0.28	-0.19	Hand grip strength;	chr21:41989963	chr21:42009194~42024924:+
LUAD	cis	rs10863681	0.738	rs12140558	ENSG00000238042.4	RP11-815M8.1	4.23	2.77e-05	0.00474	0.22	0.19	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222100978	chr1:221880981~221978523:-
LUAD	cis	rs848490	0.963	rs17385959	ENSG00000214293.7	APTR	4.23	2.77e-05	0.00474	0.24	0.19	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77750439	chr7:77657660~77696265:-
LUAD	cis	rs2898290	0.54	rs35005793	ENSG00000255046.1	RP11-297N6.4	-4.23	2.77e-05	0.00474	-0.24	-0.19	Systolic blood pressure;	chr8:11592963	chr8:11797928~11802568:-
LUAD	cis	rs1401999	1	rs1402002	ENSG00000223882.1	ABCC5-AS1	-4.23	2.77e-05	0.00474	-0.19	-0.19	Anterior chamber depth;	chr3:183925006	chr3:184006338~184011419:+
LUAD	cis	rs2243480	0.908	rs313822	ENSG00000232559.3	GS1-124K5.12	4.23	2.77e-05	0.00474	0.33	0.19	Diabetic kidney disease;	chr7:66108952	chr7:66554588~66576923:-
LUAD	cis	rs9341808	0.591	rs7741013	ENSG00000260645.1	RP11-250B2.5	4.23	2.77e-05	0.00474	0.18	0.19	Sitting height ratio;	chr6:80206613	chr6:80466958~80469080:+
LUAD	cis	rs2732480	1	rs2732480	ENSG00000240399.1	RP1-228P16.1	-4.23	2.78e-05	0.00475	-0.18	-0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342520	chr12:48054813~48055591:-
LUAD	cis	rs2492286	0.597	rs2712372	ENSG00000242551.2	POU5F1P6	-4.23	2.78e-05	0.00475	-0.26	-0.19	Eosinophil counts;	chr3:128604994	chr3:128674735~128677005:-
LUAD	cis	rs11220082	0.666	rs12224788	ENSG00000254671.2	STT3A-AS1	-4.23	2.78e-05	0.00475	-0.21	-0.19	Schizophrenia;	chr11:125459165	chr11:125570284~125592568:-
LUAD	cis	rs11846409	0.587	rs1806881	ENSG00000223648.3	IGHV3-64	-4.23	2.78e-05	0.00475	-0.23	-0.19	Rheumatic heart disease;	chr14:106650770	chr14:106643132~106658258:-
LUAD	cis	rs763121	0.853	rs7289855	ENSG00000225450.1	RP3-508I15.14	-4.23	2.78e-05	0.00475	-0.19	-0.19	Menopause (age at onset);	chr22:38646216	chr22:38739003~38749041:+
LUAD	cis	rs6687758	0.687	rs13375176	ENSG00000227925.1	RP11-191N8.2	4.23	2.78e-05	0.00475	0.25	0.19	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221926523	chr1:221827666~221840666:-
LUAD	cis	rs513088	0.681	rs565418	ENSG00000225171.2	DUTP6	4.23	2.78e-05	0.00475	0.25	0.19	Schizophrenia;	chr1:166679839	chr1:166868748~166869209:+
LUAD	cis	rs791888	0.929	rs791887	ENSG00000225913.2	RP11-57C13.6	4.23	2.78e-05	0.00475	0.24	0.19	Magnesium levels;	chr10:87651797	chr10:87607985~87659279:+
LUAD	cis	rs6840360	0.607	rs2724547	ENSG00000270265.1	RP11-731D1.4	-4.23	2.78e-05	0.00475	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151444424	chr4:151333775~151353224:-
LUAD	cis	rs2919009	0.607	rs12257287	ENSG00000271670.1	RP11-95I16.4	4.23	2.78e-05	0.00476	0.25	0.19	Obesity-related traits;	chr10:120950653	chr10:120879256~120880667:-
LUAD	cis	rs7208859	0.673	rs11656462	ENSG00000280069.1	CTD-2349P21.3	-4.23	2.78e-05	0.00476	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30833682	chr17:30738182~30740275:+
LUAD	cis	rs2018683	0.707	rs917218	ENSG00000228421.2	AC005013.5	4.23	2.79e-05	0.00476	0.21	0.19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28935505	chr7:28957667~28959345:+
LUAD	cis	rs6714710	0.535	rs13033383	ENSG00000230606.9	AC159540.1	-4.23	2.79e-05	0.00476	-0.2	-0.19	Posterior cortical atrophy and Alzheimer's disease;	chr2:97723050	chr2:97416165~97433527:-
LUAD	cis	rs1008375	0.9	rs10019460	ENSG00000249502.1	AC006160.5	4.23	2.79e-05	0.00476	0.19	0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17684714	chr4:17587467~17614571:-
LUAD	cis	rs73198271	0.74	rs1039911	ENSG00000253893.2	FAM85B	4.23	2.79e-05	0.00476	0.25	0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790696	chr8:8167819~8226614:-
LUAD	cis	rs11886999	0.812	rs997548	ENSG00000237510.6	AC008268.2	-4.23	2.79e-05	0.00476	-0.31	-0.19	Cardiac Troponin-T levels;	chr2:96193176	chr2:95789654~95800166:+
LUAD	cis	rs1005277	0.505	rs200910	ENSG00000263064.2	RP11-291L22.7	4.23	2.79e-05	0.00476	0.2	0.19	Extrinsic epigenetic age acceleration;	chr10:37819248	chr10:38448689~38448949:+
LUAD	cis	rs2354432	0.607	rs57078845	ENSG00000226015.2	CCT8P1	4.23	2.79e-05	0.00476	0.37	0.19	Mitochondrial DNA levels;	chr1:147250567	chr1:147203276~147204932:-
LUAD	cis	rs6871536	1	rs12187537	ENSG00000233006.5	AC034220.3	-4.23	2.79e-05	0.00476	-0.21	-0.19	Asthma (childhood onset);	chr5:132604212	chr5:132311285~132369916:-
LUAD	cis	rs910316	0.967	rs175432	ENSG00000279594.1	RP11-950C14.10	-4.23	2.79e-05	0.00476	-0.22	-0.19	Height;	chr14:75148543	chr14:75011269~75012851:-
LUAD	cis	rs13113518	0.812	rs2035691	ENSG00000272969.1	RP11-528I4.2	4.23	2.79e-05	0.00476	0.2	0.19	Height;	chr4:55529786	chr4:55547112~55547889:+
LUAD	cis	rs17428076	0.514	rs3821095	ENSG00000228389.1	AC068039.4	4.23	2.79e-05	0.00476	0.2	0.19	Myopia;	chr2:171827496	chr2:171773482~171775844:+
LUAD	cis	rs9926296	0.744	rs154657	ENSG00000260259.1	RP11-368I7.4	-4.23	2.79e-05	0.00476	-0.18	-0.19	Vitiligo;	chr16:89641688	chr16:89682620~89686569:-
LUAD	cis	rs2836974	0.931	rs2735306	ENSG00000232608.1	TIMM9P2	4.23	2.79e-05	0.00476	0.23	0.19	Cognitive function;	chr21:39341208	chr21:39216624~39217506:+
LUAD	cis	rs801193	0.742	rs9969300	ENSG00000224316.1	RP11-479O9.2	-4.23	2.79e-05	0.00476	-0.19	-0.19	Aortic root size;	chr7:66316659	chr7:65773620~65802067:+
LUAD	cis	rs801193	0.569	rs10950050	ENSG00000273448.1	RP11-166O4.6	4.23	2.79e-05	0.00477	0.17	0.19	Aortic root size;	chr7:66774601	chr7:67333047~67334383:+
LUAD	cis	rs853679	0.517	rs6932109	ENSG00000226314.6	ZNF192P1	4.23	2.79e-05	0.00477	0.25	0.19	Depression;	chr6:28110525	chr6:28161781~28169594:+
LUAD	cis	rs10129255	0.913	rs28861466	ENSG00000274576.2	IGHV2-70	4.23	2.79e-05	0.00477	0.17	0.19	Kawasaki disease;	chr14:106718572	chr14:106770577~106771020:-
LUAD	cis	rs755249	0.51	rs1184716	ENSG00000228060.1	RP11-69E11.8	-4.23	2.79e-05	0.00477	-0.17	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39380817	chr1:39565160~39573203:+
LUAD	cis	rs2274273	0.935	rs8004787	ENSG00000259318.1	RP11-454L9.2	4.23	2.79e-05	0.00477	0.17	0.19	Protein biomarker;	chr14:55140648	chr14:55394940~55395233:-
LUAD	cis	rs6570726	1	rs6570699	ENSG00000235652.6	RP11-545I5.3	4.23	2.79e-05	0.00477	0.2	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145599596	chr6:145799409~145886585:+
LUAD	cis	rs8030379	1	rs7496814	ENSG00000230373.7	GOLGA6L5P	-4.23	2.79e-05	0.00477	-0.17	-0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83916207	chr15:84507885~84516814:-
LUAD	cis	rs9400467	0.508	rs1676863	ENSG00000230177.1	RP5-1112D6.4	-4.23	2.79e-05	0.00477	-0.17	-0.19	Amino acid levels;Blood metabolite levels;	chr6:111320387	chr6:111277932~111278742:+
LUAD	cis	rs4374383	0.884	rs1516628	ENSG00000207383.1	Y_RNA	-4.23	2.79e-05	0.00477	-0.23	-0.19	Hepatitis C induced liver fibrosis;	chr2:111986223	chr2:112579484~112579584:-
LUAD	cis	rs4374383	0.847	rs1554215	ENSG00000207383.1	Y_RNA	-4.23	2.79e-05	0.00477	-0.23	-0.19	Hepatitis C induced liver fibrosis;	chr2:111986521	chr2:112579484~112579584:-
LUAD	cis	rs4374383	0.884	rs1996326	ENSG00000207383.1	Y_RNA	-4.23	2.79e-05	0.00477	-0.23	-0.19	Hepatitis C induced liver fibrosis;	chr2:111986936	chr2:112579484~112579584:-
LUAD	cis	rs4374383	0.847	rs1996327	ENSG00000207383.1	Y_RNA	-4.23	2.79e-05	0.00477	-0.23	-0.19	Hepatitis C induced liver fibrosis;	chr2:111987150	chr2:112579484~112579584:-
LUAD	cis	rs293748	0.771	rs12659960	ENSG00000250155.1	CTD-2353F22.1	-4.23	2.79e-05	0.00477	-0.25	-0.19	Obesity-related traits;	chr5:36787913	chr5:36666214~36725195:-
LUAD	cis	rs293748	0.771	rs12659981	ENSG00000250155.1	CTD-2353F22.1	-4.23	2.79e-05	0.00477	-0.25	-0.19	Obesity-related traits;	chr5:36787996	chr5:36666214~36725195:-
LUAD	cis	rs293748	0.771	rs12659983	ENSG00000250155.1	CTD-2353F22.1	-4.23	2.79e-05	0.00477	-0.25	-0.19	Obesity-related traits;	chr5:36788002	chr5:36666214~36725195:-
LUAD	cis	rs7688540	0.8	rs10023604	ENSG00000211553.1	AC253576.2	-4.23	2.79e-05	0.00477	-0.24	-0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:287249	chr4:136461~136568:+
LUAD	cis	rs7665090	0.603	rs17033015	ENSG00000246560.2	RP11-10L12.4	4.23	2.79e-05	0.00477	0.25	0.19	Primary biliary cholangitis;	chr4:102625147	chr4:102828055~102844075:+
LUAD	cis	rs7189233	0.531	rs9302648	ENSG00000279344.1	RP11-44F14.7	4.23	2.79e-05	0.00477	0.16	0.19	Intelligence (multi-trait analysis);	chr16:53493869	chr16:53478957~53481550:-
LUAD	cis	rs516842	0.826	rs73490370	ENSG00000234835.1	PHBP13	-4.23	2.79e-05	0.00477	-0.42	-0.19	Lobe attachment (rater-scored or self-reported);	chr13:34974300	chr13:35251070~35251829:+
LUAD	cis	rs4460629	0.68	rs10796938	ENSG00000160766.13	GBAP1	-4.23	2.79e-05	0.00477	-0.19	-0.19	Serum magnesium levels;	chr1:155099579	chr1:155213821~155227422:-
LUAD	cis	rs9309473	0.519	rs6746971	ENSG00000163016.8	ALMS1P	4.23	2.79e-05	0.00477	0.2	0.19	Metabolite levels;	chr2:73442334	chr2:73644919~73685576:+
LUAD	cis	rs911555	0.755	rs6575988	ENSG00000259775.1	RP11-45P15.4	4.23	2.79e-05	0.00477	0.24	0.19	Intelligence (multi-trait analysis);	chr14:103434490	chr14:103331674~103332367:-
LUAD	cis	rs8048589	1	rs11648816	ENSG00000175604.2	RP11-276H1.3	-4.23	2.8e-05	0.00477	-0.26	-0.19	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12090250	chr16:12086746~12090302:-
LUAD	cis	rs800160	1	rs800158	ENSG00000236264.4	RPL26P30	4.23	2.8e-05	0.00477	0.26	0.19	Bacteremia;	chr11:2357217	chr11:2335132~2335776:-
LUAD	cis	rs17826219	0.706	rs2322197	ENSG00000266490.1	CTD-2349P21.9	4.23	2.8e-05	0.00477	0.28	0.19	Body mass index;	chr17:30778787	chr17:30792372~30792833:+
LUAD	cis	rs6479891	1	rs12412012	ENSG00000232075.1	MRPL35P2	4.23	2.8e-05	0.00478	0.32	0.19	Arthritis (juvenile idiopathic);	chr10:63556003	chr10:63634317~63634827:-
LUAD	cis	rs6479891	1	rs61579729	ENSG00000232075.1	MRPL35P2	4.23	2.8e-05	0.00478	0.32	0.19	Arthritis (juvenile idiopathic);	chr10:63559553	chr10:63634317~63634827:-
LUAD	cis	rs6479891	1	rs16918599	ENSG00000232075.1	MRPL35P2	4.23	2.8e-05	0.00478	0.32	0.19	Arthritis (juvenile idiopathic);	chr10:63560319	chr10:63634317~63634827:-
LUAD	cis	rs1012068	0.961	rs5994441	ENSG00000236132.1	CTA-440B3.1	-4.23	2.8e-05	0.00478	-0.24	-0.19	Chronic hepatitis C infection;	chr22:31870560	chr22:31816379~31817491:-
LUAD	cis	rs853679	0.546	rs35016036	ENSG00000219392.1	RP1-265C24.5	-4.23	2.8e-05	0.00478	-0.43	-0.19	Depression;	chr6:28347103	chr6:28115628~28116551:+
LUAD	cis	rs7107174	1	rs4134379	ENSG00000251323.2	RP11-452H21.4	4.23	2.8e-05	0.00478	0.23	0.19	Testicular germ cell tumor;	chr11:78281542	chr11:78423982~78429836:-
LUAD	cis	rs477895	0.653	rs72918475	ENSG00000236935.1	AP003774.1	-4.23	2.8e-05	0.00478	-0.24	-0.19	Mean platelet volume;	chr11:64111172	chr11:64325050~64329504:-
LUAD	cis	rs763121	0.853	rs2072795	ENSG00000228274.3	RP3-508I15.9	4.23	2.8e-05	0.00478	0.19	0.19	Menopause (age at onset);	chr22:38668204	chr22:38667585~38681820:-
LUAD	cis	rs301901	0.965	rs1466862	ENSG00000250155.1	CTD-2353F22.1	-4.23	2.8e-05	0.00478	-0.2	-0.19	Height;	chr5:36791710	chr5:36666214~36725195:-
LUAD	cis	rs651907	0.535	rs34161138	ENSG00000244119.1	PDCL3P4	4.23	2.8e-05	0.00478	0.19	0.19	Colorectal cancer;	chr3:101791544	chr3:101712472~101713191:+
LUAD	cis	rs651907	0.535	rs11714444	ENSG00000244119.1	PDCL3P4	4.23	2.8e-05	0.00478	0.19	0.19	Colorectal cancer;	chr3:101794838	chr3:101712472~101713191:+
LUAD	cis	rs651907	0.535	rs12631513	ENSG00000244119.1	PDCL3P4	4.23	2.8e-05	0.00478	0.19	0.19	Colorectal cancer;	chr3:101798632	chr3:101712472~101713191:+
LUAD	cis	rs651907	0.535	rs13094911	ENSG00000244119.1	PDCL3P4	4.23	2.8e-05	0.00478	0.19	0.19	Colorectal cancer;	chr3:101800177	chr3:101712472~101713191:+
LUAD	cis	rs651907	0.535	rs11712309	ENSG00000244119.1	PDCL3P4	4.23	2.8e-05	0.00478	0.19	0.19	Colorectal cancer;	chr3:101800253	chr3:101712472~101713191:+
LUAD	cis	rs651907	0.535	rs13094753	ENSG00000244119.1	PDCL3P4	4.23	2.8e-05	0.00478	0.19	0.19	Colorectal cancer;	chr3:101806238	chr3:101712472~101713191:+
LUAD	cis	rs13434995	0.787	rs62303724	ENSG00000249700.7	SRD5A3-AS1	-4.23	2.8e-05	0.00478	-0.28	-0.19	Adiponectin levels;	chr4:55485114	chr4:55363971~55395847:-
LUAD	cis	rs13434995	0.842	rs62305269	ENSG00000249700.7	SRD5A3-AS1	-4.23	2.8e-05	0.00478	-0.28	-0.19	Adiponectin levels;	chr4:55507237	chr4:55363971~55395847:-
LUAD	cis	rs13434995	0.842	rs73236149	ENSG00000249700.7	SRD5A3-AS1	-4.23	2.8e-05	0.00478	-0.28	-0.19	Adiponectin levels;	chr4:55507307	chr4:55363971~55395847:-
LUAD	cis	rs13113518	1	rs3805148	ENSG00000272969.1	RP11-528I4.2	4.23	2.8e-05	0.00478	0.2	0.19	Height;	chr4:55440643	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs11133380	ENSG00000272969.1	RP11-528I4.2	4.23	2.8e-05	0.00478	0.2	0.19	Height;	chr4:55441110	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs12510110	ENSG00000272969.1	RP11-528I4.2	4.23	2.8e-05	0.00478	0.2	0.19	Height;	chr4:55441567	chr4:55547112~55547889:+
LUAD	cis	rs13113518	0.966	rs12510990	ENSG00000272969.1	RP11-528I4.2	4.23	2.8e-05	0.00478	0.2	0.19	Height;	chr4:55441907	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs3805149	ENSG00000272969.1	RP11-528I4.2	4.23	2.8e-05	0.00478	0.2	0.19	Height;	chr4:55442184	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs11945370	ENSG00000272969.1	RP11-528I4.2	4.23	2.8e-05	0.00478	0.2	0.19	Height;	chr4:55442875	chr4:55547112~55547889:+
LUAD	cis	rs13113518	0.966	rs12647677	ENSG00000272969.1	RP11-528I4.2	4.23	2.8e-05	0.00478	0.2	0.19	Height;	chr4:55444253	chr4:55547112~55547889:+
LUAD	cis	rs375066	0.935	rs396973	ENSG00000267058.1	RP11-15A1.3	4.23	2.8e-05	0.00478	0.21	0.19	Breast cancer;	chr19:43895154	chr19:43891804~43901805:-
LUAD	cis	rs4591358	0.68	rs4277541	ENSG00000223466.1	AC064834.2	-4.23	2.8e-05	0.00478	-0.25	-0.19	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195449705	chr2:195533035~195538681:+
LUAD	cis	rs189798	0.807	rs330912	ENSG00000253981.4	ALG1L13P	4.23	2.8e-05	0.00479	0.25	0.19	Myopia (pathological);	chr8:9138784	chr8:8236003~8244667:-
LUAD	cis	rs910316	1	rs12889472	ENSG00000279594.1	RP11-950C14.10	4.23	2.8e-05	0.00479	0.22	0.19	Height;	chr14:75077276	chr14:75011269~75012851:-
LUAD	cis	rs4819052	1	rs4819052	ENSG00000237664.1	LINC00316	-4.23	2.8e-05	0.00479	-0.24	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45279862	chr21:45338590~45341990:-
LUAD	cis	rs763121	0.853	rs5757211	ENSG00000228274.3	RP3-508I15.9	-4.23	2.8e-05	0.00479	-0.19	-0.19	Menopause (age at onset);	chr22:38655700	chr22:38667585~38681820:-
LUAD	cis	rs6539247	0.527	rs10778456	ENSG00000257890.1	RP11-114F10.2	-4.23	2.81e-05	0.00479	-0.21	-0.19	Attention function in attention deficit hyperactive disorder;	chr12:106054524	chr12:106050961~106058254:-
LUAD	cis	rs2242116	0.727	rs10865943	ENSG00000271161.1	BOLA2P2	4.23	2.81e-05	0.00479	0.18	0.19	Birth weight;	chr3:46928480	chr3:47499841~47500407:+
LUAD	cis	rs7107174	0.711	rs66583694	ENSG00000251323.2	RP11-452H21.4	4.23	2.81e-05	0.00479	0.22	0.19	Testicular germ cell tumor;	chr11:78326727	chr11:78423982~78429836:-
LUAD	cis	rs4873772	0.772	rs62539150	ENSG00000253330.1	RP11-697N18.3	-4.23	2.81e-05	0.00479	-0.21	-0.19	Lobe attachment (rater-scored or self-reported);	chr8:47698420	chr8:47511034~47512141:-
LUAD	cis	rs8030379	0.967	rs11857009	ENSG00000230373.7	GOLGA6L5P	-4.23	2.81e-05	0.00479	-0.18	-0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83898661	chr15:84507885~84516814:-
LUAD	cis	rs8030379	1	rs2046120	ENSG00000230373.7	GOLGA6L5P	-4.23	2.81e-05	0.00479	-0.18	-0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83899010	chr15:84507885~84516814:-
LUAD	cis	rs2702164	0.781	rs2700260	ENSG00000240661.1	RP11-174O3.3	4.23	2.81e-05	0.00479	0.23	0.19	Gut microbiome composition (winter);	chr3:120423317	chr3:120349510~120367998:+
LUAD	cis	rs8062405	0.755	rs56272201	ENSG00000251417.2	RP11-1348G14.4	-4.23	2.81e-05	0.00479	-0.2	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28802743~28817828:+
LUAD	cis	rs8062405	0.755	rs62034355	ENSG00000251417.2	RP11-1348G14.4	-4.23	2.81e-05	0.00479	-0.2	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28802743~28817828:+
LUAD	cis	rs9601248	0.627	rs2146593	ENSG00000227676.3	LINC01068	4.23	2.81e-05	0.00479	0.24	0.19	Major depressive disorder;	chr13:79605977	chr13:79566727~79571436:+
LUAD	cis	rs77688320	1	rs2540334	ENSG00000213090.2	AC007256.5	-4.23	2.81e-05	0.0048	-0.28	-0.19	Breast cancer;	chr2:201406624	chr2:201410544~201413308:-
LUAD	cis	rs6840360	0.571	rs4696099	ENSG00000270265.1	RP11-731D1.4	-4.23	2.81e-05	0.0048	-0.22	-0.19	Intelligence (multi-trait analysis);	chr4:151580799	chr4:151333775~151353224:-
LUAD	cis	rs160451	1	rs160424	ENSG00000251136.7	RP11-37B2.1	4.23	2.81e-05	0.0048	0.19	0.19	Leprosy;	chr8:89658452	chr8:89609409~89757727:-
LUAD	cis	rs11773103	0.708	rs802028	ENSG00000224046.1	AC005076.5	4.23	2.81e-05	0.0048	0.31	0.19	Bipolar disorder or major depressive disorder (combined);	chr7:87362359	chr7:87151423~87152420:-
LUAD	cis	rs7968440	0.736	rs10783388	ENSG00000200428.1	Y_RNA	-4.23	2.81e-05	0.0048	-0.23	-0.19	Fibrinogen;	chr12:50787916	chr12:50743568~50743684:+
LUAD	cis	rs4660214	0.666	rs2490946	ENSG00000228060.1	RP11-69E11.8	-4.23	2.81e-05	0.0048	-0.17	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39371955	chr1:39565160~39573203:+
LUAD	cis	rs8048589	1	rs11642386	ENSG00000175604.2	RP11-276H1.3	-4.23	2.81e-05	0.0048	-0.26	-0.19	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12090207	chr16:12086746~12090302:-
LUAD	cis	rs7811142	1	rs7794485	ENSG00000078319.8	PMS2P1	-4.23	2.81e-05	0.0048	-0.23	-0.19	Platelet count;	chr7:100471313	chr7:100320992~100341908:-
LUAD	cis	rs13113518	1	rs13115828	ENSG00000272969.1	RP11-528I4.2	4.23	2.81e-05	0.0048	0.2	0.19	Height;	chr4:55551447	chr4:55547112~55547889:+
LUAD	cis	rs9341808	0.538	rs623048	ENSG00000260645.1	RP11-250B2.5	-4.23	2.82e-05	0.0048	-0.18	-0.19	Sitting height ratio;	chr6:80272199	chr6:80466958~80469080:+
LUAD	cis	rs77688320	0.517	rs12991600	ENSG00000213090.2	AC007256.5	4.23	2.82e-05	0.00481	0.21	0.19	Breast cancer;	chr2:201472513	chr2:201410544~201413308:-
LUAD	cis	rs6964587	1	rs1859114	ENSG00000188693.7	CYP51A1-AS1	-4.23	2.82e-05	0.00481	-0.22	-0.19	Breast cancer;	chr7:92053534	chr7:92134604~92180725:+
LUAD	cis	rs595982	0.501	rs112370206	ENSG00000235191.1	NUCB1-AS1	4.23	2.82e-05	0.00481	0.21	0.19	Red cell distribution width;	chr19:48893366	chr19:48910930~48918891:-
LUAD	cis	rs1401999	1	rs6443927	ENSG00000223882.1	ABCC5-AS1	-4.23	2.82e-05	0.00481	-0.2	-0.19	Anterior chamber depth;	chr3:184001076	chr3:184006338~184011419:+
LUAD	cis	rs8062405	0.573	rs8045689	ENSG00000261419.1	RP11-57A19.4	4.23	2.82e-05	0.00481	0.22	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28976948	chr16:28659696~28740781:-
LUAD	cis	rs7204230	1	rs8051655	ENSG00000261291.1	RP11-295M3.2	4.23	2.82e-05	0.00481	0.24	0.19	Fibrinogen;	chr16:53261824	chr16:53168522~53169450:+
LUAD	cis	rs11673344	0.504	rs2595555	ENSG00000276846.1	CTD-3220F14.3	4.23	2.82e-05	0.00481	0.21	0.19	Obesity-related traits;	chr19:37000219	chr19:37314868~37315620:-
LUAD	cis	rs11673344	0.504	rs1667377	ENSG00000276846.1	CTD-3220F14.3	4.23	2.82e-05	0.00481	0.21	0.19	Obesity-related traits;	chr19:37000966	chr19:37314868~37315620:-
LUAD	cis	rs11673344	0.523	rs1667379	ENSG00000276846.1	CTD-3220F14.3	4.23	2.82e-05	0.00481	0.21	0.19	Obesity-related traits;	chr19:37001192	chr19:37314868~37315620:-
LUAD	cis	rs712022	0.935	rs2286810	ENSG00000246225.5	RP11-17A1.3	4.23	2.82e-05	0.00481	0.23	0.19	Dialysis-related mortality;	chr11:22829863	chr11:22829380~22945393:+
LUAD	cis	rs6496932	0.503	rs11074205	ENSG00000202081.1	RNU6-1280P	-4.23	2.82e-05	0.00481	-0.25	-0.19	Central corneal thickness;Corneal structure;	chr15:85401381	chr15:85651522~85651628:-
LUAD	cis	rs2749097	0.609	rs2269235	ENSG00000244256.3	RN7SL130P	-4.23	2.82e-05	0.00481	-0.25	-0.19	Alcohol consumption (transferrin glycosylation);	chr1:63653244	chr1:63655743~63656047:+
LUAD	cis	rs2749097	0.609	rs2269234	ENSG00000244256.3	RN7SL130P	-4.23	2.82e-05	0.00481	-0.25	-0.19	Alcohol consumption (transferrin glycosylation);	chr1:63653305	chr1:63655743~63656047:+
LUAD	cis	rs1979679	0.879	rs55996833	ENSG00000278733.1	RP11-425D17.1	4.23	2.82e-05	0.00482	0.25	0.19	Ossification of the posterior longitudinal ligament of the spine;	chr12:28313303	chr12:28185625~28186190:-
LUAD	cis	rs2274273	0.84	rs66486619	ENSG00000258413.1	RP11-665C16.6	-4.23	2.82e-05	0.00482	-0.24	-0.19	Protein biomarker;	chr14:55402837	chr14:55262767~55272075:-
LUAD	cis	rs600231	0.706	rs10896016	ENSG00000245532.5	NEAT1	-4.23	2.82e-05	0.00482	-0.15	-0.19	Bone mineral density;	chr11:65568234	chr11:65422774~65445540:+
LUAD	cis	rs2115630	0.967	rs28595395	ENSG00000225151.9	GOLGA2P7	4.23	2.82e-05	0.00482	0.22	0.19	P wave terminal force;	chr15:84791721	chr15:84199311~84230136:-
LUAD	cis	rs2014572	0.967	rs8112572	ENSG00000268379.1	CTC-360J11.4	4.23	2.82e-05	0.00482	0.22	0.19	Hyperactive-impulsive symptoms;	chr19:57248244	chr19:57175233~57177921:+
LUAD	cis	rs7204230	1	rs1109646	ENSG00000261291.1	RP11-295M3.2	4.23	2.82e-05	0.00482	0.23	0.19	Fibrinogen;	chr16:53316927	chr16:53168522~53169450:+
LUAD	cis	rs5758511	0.68	rs1107554	ENSG00000227370.1	RP4-669P10.19	4.23	2.83e-05	0.00482	0.21	0.19	Birth weight;	chr22:42271588	chr22:42132543~42132998:+
LUAD	cis	rs34792	0.554	rs12708796	ENSG00000275910.1	RP11-680G24.6	-4.23	2.83e-05	0.00482	-0.19	-0.19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15535980	chr16:15015828~15016390:-
LUAD	cis	rs603446	0.935	rs180376	ENSG00000254851.1	RP11-109L13.1	-4.23	2.83e-05	0.00482	-0.23	-0.19	Triglycerides;	chr11:116719323	chr11:117135528~117138582:+
LUAD	cis	rs7208859	0.573	rs56031503	ENSG00000266490.1	CTD-2349P21.9	4.23	2.83e-05	0.00482	0.28	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30792372~30792833:+
LUAD	cis	rs11992162	0.636	rs11250182	ENSG00000255046.1	RP11-297N6.4	4.23	2.83e-05	0.00482	0.23	0.19	Monocyte count;	chr8:11950067	chr8:11797928~11802568:-
LUAD	cis	rs67981189	0.529	rs8181986	ENSG00000269927.1	RP6-91H8.3	4.23	2.83e-05	0.00482	0.25	0.19	Schizophrenia;	chr14:71115527	chr14:71141125~71143253:-
LUAD	cis	rs4667682	0.529	rs17284660	ENSG00000234061.1	AC007969.4	-4.23	2.83e-05	0.00483	-0.37	-0.19	Hippocampal atrophy;Body mass index;	chr2:171287254	chr2:171492905~171493095:+
LUAD	cis	rs2467099	0.786	rs1135889	ENSG00000267801.1	RP11-552F3.9	4.23	2.83e-05	0.00483	0.22	0.19	Systolic blood pressure;	chr17:75930040	chr17:75876372~75879546:+
LUAD	cis	rs13256369	1	rs13256369	ENSG00000253893.2	FAM85B	-4.23	2.83e-05	0.00483	-0.26	-0.19	Obesity-related traits;	chr8:8719869	chr8:8167819~8226614:-
LUAD	cis	rs12446632	0.539	rs16969339	ENSG00000261195.1	CTD-2380F24.1	-4.23	2.83e-05	0.00483	-0.25	-0.19	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Menarche (age at onset);Obesity;Childhood body mass index;Waist circumference;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr16:19903462	chr16:19761172~19766099:-
LUAD	cis	rs11051970	0.636	rs325424	ENSG00000274964.1	RP11-817I4.1	-4.23	2.83e-05	0.00483	-0.2	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr12:32417259	chr12:32339368~32340724:+
LUAD	cis	rs2288073	0.965	rs72789923	ENSG00000242628.4	AC009228.1	4.23	2.83e-05	0.00483	0.26	0.19	Venous thromboembolism (SNP x SNP interaction);	chr2:24171635	chr2:24214381~24221516:+
LUAD	cis	rs4843747	0.671	rs72818576	ENSG00000205037.2	RP11-863P13.4	4.23	2.83e-05	0.00483	0.26	0.19	Menopause (age at onset);	chr16:88077413	chr16:88088041~88100985:-
LUAD	cis	rs2280018	0.526	rs2966129	ENSG00000183458.12	RP11-958N24.1	4.23	2.83e-05	0.00483	0.15	0.19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059070	chr16:14911551~14935708:+
LUAD	cis	rs13287066	0.692	rs2184255	ENSG00000227603.1	RP11-165J3.6	-4.23	2.83e-05	0.00483	-0.21	-0.19	Intelligence (multi-trait analysis);	chr9:93413921	chr9:93435332~93437121:-
LUAD	cis	rs2348418	0.966	rs11049698	ENSG00000247934.4	RP11-967K21.1	4.23	2.83e-05	0.00483	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28535354	chr12:28163298~28190738:-
LUAD	cis	rs35740288	0.731	rs12913556	ENSG00000259407.1	RP11-158M2.3	-4.23	2.83e-05	0.00483	-0.19	-0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85558965	chr15:85744109~85750281:-
LUAD	cis	rs17711722	0.565	rs4275112	ENSG00000189316.3	RP11-797H7.5	4.23	2.83e-05	0.00483	0.2	0.19	Calcium levels;	chr7:65733651	chr7:64888527~64890100:-
LUAD	cis	rs6479891	0.915	rs10761744	ENSG00000232075.1	MRPL35P2	-4.23	2.83e-05	0.00483	-0.3	-0.19	Arthritis (juvenile idiopathic);	chr10:63341266	chr10:63634317~63634827:-
LUAD	cis	rs2227564	0.62	rs3911887	ENSG00000271816.1	BMS1P4	4.23	2.83e-05	0.00483	0.18	0.19	Crohn's disease;Inflammatory bowel disease;	chr10:73788268	chr10:73699151~73730487:-
LUAD	cis	rs17596685	1	rs4941433	ENSG00000271216.1	LINC01050	-4.23	2.84e-05	0.00483	-0.26	-0.19	C-reactive protein levels;	chr13:42584999	chr13:42810366~42812562:-
LUAD	cis	rs867371	0.826	rs2047678	ENSG00000255769.6	GOLGA2P10	-4.23	2.84e-05	0.00483	-0.21	-0.19	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82205857	chr15:82472993~82513950:-
LUAD	cis	rs1864585	0.52	rs12155811	ENSG00000255046.1	RP11-297N6.4	4.23	2.84e-05	0.00483	0.27	0.19	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10816003	chr8:11797928~11802568:-
LUAD	cis	rs763121	0.752	rs6001190	ENSG00000225450.1	RP3-508I15.14	-4.23	2.84e-05	0.00484	-0.19	-0.19	Menopause (age at onset);	chr22:38677806	chr22:38739003~38749041:+
LUAD	cis	rs17767294	0.612	rs12332927	ENSG00000219392.1	RP1-265C24.5	-4.23	2.84e-05	0.00484	-0.35	-0.19	Parkinson's disease;	chr6:27987337	chr6:28115628~28116551:+
LUAD	cis	rs5762752	0.555	rs134527	ENSG00000272858.1	CTA-292E10.8	4.23	2.84e-05	0.00484	0.2	0.19	Optic disc area;	chr22:28380003	chr22:28814914~28815662:+
LUAD	cis	rs13113518	0.812	rs6825774	ENSG00000272969.1	RP11-528I4.2	4.23	2.84e-05	0.00484	0.2	0.19	Height;	chr4:55491150	chr4:55547112~55547889:+
LUAD	cis	rs13113518	0.812	rs3805153	ENSG00000272969.1	RP11-528I4.2	4.23	2.84e-05	0.00484	0.2	0.19	Height;	chr4:55493557	chr4:55547112~55547889:+
LUAD	cis	rs7660883	0.866	rs1674999	ENSG00000251411.1	RP11-397E7.4	-4.23	2.84e-05	0.00484	-0.2	-0.19	HDL cholesterol levels;	chr4:87106498	chr4:86913266~86914817:-
LUAD	cis	rs7760535	0.794	rs12529158	ENSG00000230177.1	RP5-1112D6.4	4.23	2.84e-05	0.00484	0.17	0.19	Metabolic traits;	chr6:111501244	chr6:111277932~111278742:+
LUAD	cis	rs1334894	1	rs72913427	ENSG00000228559.1	RP3-340B19.3	-4.23	2.84e-05	0.00484	-0.39	-0.19	Coronary artery disease;	chr6:35614026	chr6:35544632~35545669:+
LUAD	cis	rs5758659	0.652	rs1063392	ENSG00000182057.4	OGFRP1	-4.23	2.84e-05	0.00484	-0.23	-0.19	Cognitive function;	chr22:42058946	chr22:42269753~42275196:+
LUAD	cis	rs4795519	0.71	rs11651630	ENSG00000266313.1	RP11-173M1.4	4.23	2.84e-05	0.00484	0.24	0.19	Chronic myeloid leukemia;	chr17:27151655	chr17:27333256~27348491:+
LUAD	cis	rs4840086	0.967	rs4840084	ENSG00000219755.1	RP1-199J3.5	4.23	2.84e-05	0.00484	0.24	0.19	Menarche (age at onset);	chr6:99755093	chr6:99575712~99576456:+
LUAD	cis	rs4840086	1	rs13215012	ENSG00000219755.1	RP1-199J3.5	4.23	2.84e-05	0.00484	0.24	0.19	Menarche (age at onset);	chr6:99755281	chr6:99575712~99576456:+
LUAD	cis	rs4840086	0.967	rs11969653	ENSG00000219755.1	RP1-199J3.5	4.23	2.84e-05	0.00484	0.24	0.19	Menarche (age at onset);	chr6:99755334	chr6:99575712~99576456:+
LUAD	cis	rs7061710	0.711	rs17566256	ENSG00000271811.1	RP1-79C4.4	-4.23	2.84e-05	0.00484	-0.28	-0.19	Blood metabolite levels;	chr1:171150731	chr1:170667381~170669425:+
LUAD	cis	rs7061710	0.711	rs58374074	ENSG00000271811.1	RP1-79C4.4	-4.23	2.84e-05	0.00484	-0.28	-0.19	Blood metabolite levels;	chr1:171150810	chr1:170667381~170669425:+
LUAD	cis	rs7061710	0.673	rs58044560	ENSG00000271811.1	RP1-79C4.4	-4.23	2.84e-05	0.00484	-0.28	-0.19	Blood metabolite levels;	chr1:171150845	chr1:170667381~170669425:+
LUAD	cis	rs7061710	0.673	rs58509777	ENSG00000271811.1	RP1-79C4.4	-4.23	2.84e-05	0.00484	-0.28	-0.19	Blood metabolite levels;	chr1:171150851	chr1:170667381~170669425:+
LUAD	cis	rs7324557	1	rs7324557	ENSG00000205861.10	C1QTNF9B-AS1	4.23	2.84e-05	0.00484	0.25	0.19	Visceral adipose tissue adjusted for BMI;	chr13:23722723	chr13:23888889~23897263:+
LUAD	cis	rs8180040	0.903	rs13094438	ENSG00000271161.1	BOLA2P2	4.23	2.84e-05	0.00484	0.18	0.19	Colorectal cancer;	chr3:47236395	chr3:47499841~47500407:+
LUAD	cis	rs28386778	0.897	rs2727327	ENSG00000240280.5	TCAM1P	-4.23	2.84e-05	0.00484	-0.22	-0.19	Prudent dietary pattern;	chr17:63846062	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.831	rs2584618	ENSG00000240280.5	TCAM1P	-4.23	2.84e-05	0.00484	-0.22	-0.19	Prudent dietary pattern;	chr17:63846251	chr17:63849292~63864379:+
LUAD	cis	rs3794924	0.866	rs1466379	ENSG00000266521.1	RP11-650P15.1	4.23	2.84e-05	0.00484	0.31	0.19	Survival in colon cancer;	chr18:31476502	chr18:31496645~31497195:-
LUAD	cis	rs34792	0.688	rs153785	ENSG00000207425.1	Y_RNA	4.23	2.84e-05	0.00484	0.23	0.19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15499435	chr16:14915457~14915556:-
LUAD	cis	rs2749097	0.609	rs12027168	ENSG00000244256.3	RN7SL130P	-4.23	2.84e-05	0.00485	-0.25	-0.19	Alcohol consumption (transferrin glycosylation);	chr1:63654942	chr1:63655743~63656047:+
LUAD	cis	rs7429990	0.965	rs7642590	ENSG00000228638.1	FCF1P2	4.23	2.84e-05	0.00485	0.23	0.19	Educational attainment (years of education);	chr3:48058260	chr3:48290793~48291375:-
LUAD	cis	rs7772486	0.79	rs2254257	ENSG00000235652.6	RP11-545I5.3	4.23	2.84e-05	0.00485	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145882588	chr6:145799409~145886585:+
LUAD	cis	rs10938353	0.68	rs2173108	ENSG00000273369.1	RP11-700J17.1	4.23	2.85e-05	0.00485	0.25	0.19	Body mass index;	chr4:44838785	chr4:44693946~44694386:-
LUAD	cis	rs8040855	0.931	rs11855471	ENSG00000259774.1	RP11-182J1.13	-4.23	2.85e-05	0.00485	-0.22	-0.19	Bulimia nervosa;	chr15:85175976	chr15:84422618~84425882:+
LUAD	cis	rs4925386	0.84	rs6143024	ENSG00000273619.1	RP5-908M14.9	-4.23	2.85e-05	0.00485	-0.19	-0.19	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62339173	chr20:62386303~62386970:-
LUAD	cis	rs467650	0.782	rs719246	ENSG00000248489.1	CTD-2007H13.3	-4.23	2.85e-05	0.00485	-0.2	-0.19	Venous thromboembolism (SNP x SNP interaction);	chr5:98722220	chr5:98929171~98995013:+
LUAD	cis	rs9309473	0.5	rs12472502	ENSG00000163016.8	ALMS1P	-4.23	2.85e-05	0.00485	-0.2	-0.19	Metabolite levels;	chr2:73632057	chr2:73644919~73685576:+
LUAD	cis	rs950169	0.579	rs62027818	ENSG00000259570.1	RP11-671M22.4	4.23	2.85e-05	0.00485	0.28	0.19	Schizophrenia;	chr15:83992393	chr15:84394512~84395514:+
LUAD	cis	rs1876905	0.539	rs240962	ENSG00000230177.1	RP5-1112D6.4	4.23	2.85e-05	0.00485	0.23	0.19	Mean corpuscular hemoglobin;	chr6:111321243	chr6:111277932~111278742:+
LUAD	cis	rs13113518	1	rs4864994	ENSG00000272969.1	RP11-528I4.2	4.23	2.85e-05	0.00485	0.2	0.19	Height;	chr4:55451955	chr4:55547112~55547889:+
LUAD	cis	rs2014572	0.967	rs8111977	ENSG00000268379.1	CTC-360J11.4	4.23	2.85e-05	0.00485	0.22	0.19	Hyperactive-impulsive symptoms;	chr19:57247790	chr19:57175233~57177921:+
LUAD	cis	rs800160	1	rs1088990	ENSG00000236264.4	RPL26P30	-4.23	2.85e-05	0.00485	-0.25	-0.19	Bacteremia;	chr11:2360541	chr11:2335132~2335776:-
LUAD	cis	rs1346081	1	rs7677442	ENSG00000250075.4	RP11-584P21.2	-4.23	2.85e-05	0.00485	-0.21	-0.19	Intelligence (multi-trait analysis);	chr4:67191331	chr4:67417305~67468251:-
LUAD	cis	rs2732480	0.5	rs2932093	ENSG00000257763.1	OR5BK1P	4.23	2.85e-05	0.00486	0.2	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48254488	chr12:48355792~48356614:-
LUAD	cis	rs4568518	0.74	rs10429191	ENSG00000279048.1	RP11-511H23.2	4.23	2.85e-05	0.00486	0.16	0.19	Measles;	chr7:17969474	chr7:17940503~17942922:+
LUAD	cis	rs4568518	0.74	rs10428925	ENSG00000279048.1	RP11-511H23.2	4.23	2.85e-05	0.00486	0.16	0.19	Measles;	chr7:17969582	chr7:17940503~17942922:+
LUAD	cis	rs4819052	0.851	rs4819046	ENSG00000237664.1	LINC00316	-4.23	2.85e-05	0.00486	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245040	chr21:45338590~45341990:-
LUAD	cis	rs3096299	0.679	rs3102338	ENSG00000182376.2	RP5-1142A6.8	4.23	2.85e-05	0.00486	0.2	0.19	Multiple myeloma (IgH translocation);	chr16:89375842	chr16:88742767~88745748:+
LUAD	cis	rs62246343	0.63	rs3774063	ENSG00000254485.4	RP11-380O24.1	4.23	2.85e-05	0.00486	0.36	0.19	Fibrinogen levels;	chr3:9470052	chr3:9292588~9363303:-
LUAD	cis	rs2562456	0.833	rs62109229	ENSG00000268081.1	RP11-678G14.2	4.23	2.85e-05	0.00486	0.29	0.19	Pain;	chr19:21354380	chr19:21554640~21569237:-
LUAD	cis	rs1876905	0.597	rs354526	ENSG00000255389.1	C6orf3	4.23	2.85e-05	0.00486	0.26	0.19	Mean corpuscular hemoglobin;	chr6:111216278	chr6:111599875~111602295:+
LUAD	cis	rs2823962	0.759	rs12626360	ENSG00000270093.1	AP000473.8	-4.23	2.85e-05	0.00486	-0.2	-0.19	Amyotrophic lateral sclerosis;	chr21:16643858	chr21:16643529~16645065:+
LUAD	cis	rs2823962	0.759	rs12627532	ENSG00000270093.1	AP000473.8	-4.23	2.85e-05	0.00486	-0.2	-0.19	Amyotrophic lateral sclerosis;	chr21:16643871	chr21:16643529~16645065:+
LUAD	cis	rs9545047	0.604	rs1856997	ENSG00000227354.5	RBM26-AS1	4.23	2.85e-05	0.00486	0.21	0.19	Schizophrenia;	chr13:79287487	chr13:79406309~79424328:+
LUAD	cis	rs750134	0.901	rs12423131	ENSG00000257221.1	RP11-689B22.2	4.23	2.86e-05	0.00486	0.27	0.19	Low high density lipoprotein cholesterol levels;	chr12:108863470	chr12:108628687~108641318:+
LUAD	cis	rs477895	0.653	rs3824854	ENSG00000236935.1	AP003774.1	-4.23	2.86e-05	0.00486	-0.24	-0.19	Mean platelet volume;	chr11:64117833	chr11:64325050~64329504:-
LUAD	cis	rs9928842	0.823	rs12918452	ENSG00000280152.1	RP11-331F4.5	4.23	2.86e-05	0.00486	0.21	0.19	Alcoholic chronic pancreatitis;	chr16:75201536	chr16:75245994~75250077:-
LUAD	cis	rs8040855	0.52	rs67613323	ENSG00000259774.1	RP11-182J1.13	4.23	2.86e-05	0.00486	0.26	0.19	Bulimia nervosa;	chr15:84986541	chr15:84422618~84425882:+
LUAD	cis	rs8040855	0.52	rs11629962	ENSG00000259774.1	RP11-182J1.13	4.23	2.86e-05	0.00486	0.26	0.19	Bulimia nervosa;	chr15:84986797	chr15:84422618~84425882:+
LUAD	cis	rs2898681	0.874	rs59649036	ENSG00000248375.1	RP11-177B4.1	-4.23	2.86e-05	0.00486	-0.27	-0.19	Optic nerve measurement (cup area);	chr4:52875008	chr4:52720081~52720831:-
LUAD	cis	rs17264034	1	rs17263917	ENSG00000250786.1	SNHG18	4.23	2.86e-05	0.00487	0.31	0.19	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9552226	chr5:9546200~9550609:+
LUAD	cis	rs7181230	0.845	rs4923852	ENSG00000275636.1	RP11-521C20.5	-4.23	2.86e-05	0.00487	-0.23	-0.19	Dehydroepiandrosterone sulphate levels;	chr15:40085664	chr15:40078892~40079347:+
LUAD	cis	rs231513	0.906	rs11657681	ENSG00000267595.1	RP11-242D8.2	-4.23	2.86e-05	0.00487	-0.25	-0.19	Cognitive function;	chr17:43927995	chr17:43168170~43168249:-
LUAD	cis	rs231513	0.906	rs11653808	ENSG00000267595.1	RP11-242D8.2	-4.23	2.86e-05	0.00487	-0.25	-0.19	Cognitive function;	chr17:43927998	chr17:43168170~43168249:-
LUAD	cis	rs12214131	0.5	rs12662198	ENSG00000219088.1	RP3-359N14.1	-4.23	2.86e-05	0.00487	-0.2	-0.19	Male-pattern baldness;	chr6:105747135	chr6:105666326~105667998:+
LUAD	cis	rs7772486	0.686	rs1292334	ENSG00000235652.6	RP11-545I5.3	4.23	2.86e-05	0.00487	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145647152	chr6:145799409~145886585:+
LUAD	cis	rs4908768	0.539	rs2100888	ENSG00000270282.1	RP5-1115A15.2	4.23	2.86e-05	0.00487	0.21	0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8599223	chr1:8512653~8513021:+
LUAD	cis	rs17772222	0.876	rs12586348	ENSG00000258789.1	RP11-507K2.3	-4.22	2.86e-05	0.00487	-0.26	-0.19	Coronary artery calcification;	chr14:88643523	chr14:88551597~88552493:+
LUAD	cis	rs4374383	0.884	rs10207820	ENSG00000207383.1	Y_RNA	-4.22	2.86e-05	0.00487	-0.22	-0.19	Hepatitis C induced liver fibrosis;	chr2:111941773	chr2:112579484~112579584:-
LUAD	cis	rs2136690	0.51	rs10428096	ENSG00000243926.1	TIPARP-AS1	4.22	2.86e-05	0.00487	0.2	0.19	Breast cancer;	chr3:156653088	chr3:156671862~156674378:-
LUAD	cis	rs58785573	0.624	rs337605	ENSG00000231160.8	KLF3-AS1	-4.22	2.86e-05	0.00487	-0.18	-0.19	Lymphocyte percentage of white cells;	chr4:38646132	chr4:38612701~38664883:-
LUAD	cis	rs6921919	0.583	rs9468355	ENSG00000219392.1	RP1-265C24.5	-4.22	2.86e-05	0.00488	-0.24	-0.19	Autism spectrum disorder or schizophrenia;	chr6:28374100	chr6:28115628~28116551:+
LUAD	cis	rs4374383	0.715	rs2871922	ENSG00000207383.1	Y_RNA	-4.22	2.86e-05	0.00488	-0.23	-0.19	Hepatitis C induced liver fibrosis;	chr2:111961854	chr2:112579484~112579584:-
LUAD	cis	rs4374383	0.884	rs1996322	ENSG00000207383.1	Y_RNA	-4.22	2.86e-05	0.00488	-0.23	-0.19	Hepatitis C induced liver fibrosis;	chr2:111982669	chr2:112579484~112579584:-
LUAD	cis	rs4374383	0.884	rs1996323	ENSG00000207383.1	Y_RNA	-4.22	2.86e-05	0.00488	-0.23	-0.19	Hepatitis C induced liver fibrosis;	chr2:111982796	chr2:112579484~112579584:-
LUAD	cis	rs5758659	0.504	rs133367	ENSG00000273366.1	CTA-989H11.1	4.22	2.86e-05	0.00488	0.21	0.19	Cognitive function;	chr22:42067362	chr22:42278188~42278846:+
LUAD	cis	rs11064837	0.504	rs7973772	ENSG00000248636.5	RP11-768F21.1	-4.22	2.86e-05	0.00488	-0.21	-0.19	Schizophrenia;	chr12:119648932	chr12:119387987~119668079:-
LUAD	cis	rs11051970	0.661	rs188979	ENSG00000274964.1	RP11-817I4.1	-4.22	2.87e-05	0.00488	-0.2	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr12:32416750	chr12:32339368~32340724:+
LUAD	cis	rs638893	0.673	rs538645	ENSG00000255422.1	AP002954.4	4.22	2.87e-05	0.00488	0.26	0.19	Vitiligo;	chr11:118840360	chr11:118704607~118750263:+
LUAD	cis	rs10129255	0.957	rs10142859	ENSG00000211967.3	IGHV3-53	-4.22	2.87e-05	0.00488	-0.15	-0.19	Kawasaki disease;	chr14:106782238	chr14:106592676~106593347:-
LUAD	cis	rs9287719	0.967	rs4470306	ENSG00000243819.4	RN7SL832P	4.22	2.87e-05	0.00488	0.2	0.19	Prostate cancer;	chr2:10603872	chr2:10690344~10692099:+
LUAD	cis	rs2243480	1	rs3885839	ENSG00000232559.3	GS1-124K5.12	4.22	2.87e-05	0.00488	0.34	0.19	Diabetic kidney disease;	chr7:65825416	chr7:66554588~66576923:-
LUAD	cis	rs2243480	0.901	rs3813708	ENSG00000232559.3	GS1-124K5.12	4.22	2.87e-05	0.00488	0.34	0.19	Diabetic kidney disease;	chr7:65840645	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs73142122	ENSG00000232559.3	GS1-124K5.12	4.22	2.87e-05	0.00488	0.34	0.19	Diabetic kidney disease;	chr7:65846311	chr7:66554588~66576923:-
LUAD	cis	rs2243480	0.901	rs73142137	ENSG00000232559.3	GS1-124K5.12	4.22	2.87e-05	0.00488	0.34	0.19	Diabetic kidney disease;	chr7:65878455	chr7:66554588~66576923:-
LUAD	cis	rs7204230	1	rs62049771	ENSG00000261291.1	RP11-295M3.2	4.22	2.87e-05	0.00488	0.24	0.19	Fibrinogen;	chr16:53241825	chr16:53168522~53169450:+
LUAD	cis	rs8177876	0.584	rs2549899	ENSG00000261061.1	RP11-303E16.2	4.22	2.87e-05	0.00488	0.26	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81055267	chr16:81030770~81031485:+
LUAD	cis	rs7061710	0.711	rs57147275	ENSG00000271811.1	RP1-79C4.4	-4.22	2.87e-05	0.00488	-0.28	-0.19	Blood metabolite levels;	chr1:171151137	chr1:170667381~170669425:+
LUAD	cis	rs11886999	0.723	rs72825854	ENSG00000237510.6	AC008268.2	-4.22	2.87e-05	0.00488	-0.31	-0.19	Cardiac Troponin-T levels;	chr2:96189312	chr2:95789654~95800166:+
LUAD	cis	rs9549260	0.755	rs9532571	ENSG00000229456.1	RLIMP1	4.22	2.87e-05	0.00489	0.2	0.19	Red blood cell count;	chr13:40644533	chr13:40618738~40621348:+
LUAD	cis	rs10504390	0.524	rs16932315	ENSG00000200714.1	Y_RNA	-4.22	2.87e-05	0.00489	-0.43	-0.19	IgG glycosylation;	chr8:65727855	chr8:65592731~65592820:+
LUAD	cis	rs240993	0.595	rs1040383	ENSG00000230177.1	RP5-1112D6.4	4.22	2.87e-05	0.00489	0.19	0.19	Inflammatory skin disease;Psoriasis;	chr6:111580985	chr6:111277932~111278742:+
LUAD	cis	rs12073359	1	rs72692893	ENSG00000223945.2	RP11-458I7.1	-4.22	2.87e-05	0.00489	-0.28	-0.19	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150075047	chr1:150053864~150055034:+
LUAD	cis	rs12073359	1	rs72692898	ENSG00000223945.2	RP11-458I7.1	-4.22	2.87e-05	0.00489	-0.28	-0.19	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150077904	chr1:150053864~150055034:+
LUAD	cis	rs12073359	0.954	rs72692899	ENSG00000223945.2	RP11-458I7.1	-4.22	2.87e-05	0.00489	-0.28	-0.19	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150077980	chr1:150053864~150055034:+
LUAD	cis	rs12073359	1	rs72692900	ENSG00000223945.2	RP11-458I7.1	-4.22	2.87e-05	0.00489	-0.28	-0.19	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150078190	chr1:150053864~150055034:+
LUAD	cis	rs7208859	0.623	rs7208441	ENSG00000266490.1	CTD-2349P21.9	4.22	2.87e-05	0.00489	0.28	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30792372~30792833:+
LUAD	cis	rs2018683	0.707	rs4722877	ENSG00000228421.2	AC005013.5	4.22	2.87e-05	0.00489	0.21	0.19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28933289	chr7:28957667~28959345:+
LUAD	cis	rs2018683	0.707	rs4722878	ENSG00000228421.2	AC005013.5	4.22	2.87e-05	0.00489	0.21	0.19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28933414	chr7:28957667~28959345:+
LUAD	cis	rs11168618	0.904	rs4359253	ENSG00000240399.1	RP1-228P16.1	4.22	2.87e-05	0.00489	0.19	0.19	Adiponectin levels;	chr12:48533925	chr12:48054813~48055591:-
LUAD	cis	rs17406451	0.819	rs6747202	ENSG00000279873.2	LINC01126	-4.22	2.87e-05	0.00489	-0.16	-0.19	Mitochondrial DNA levels;	chr2:43420428	chr2:43227210~43228855:+
LUAD	cis	rs4819052	0.851	rs2838857	ENSG00000223768.1	LINC00205	-4.22	2.88e-05	0.00489	-0.22	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261085	chr21:45293285~45297354:+
LUAD	cis	rs7119038	0.818	rs57494551	ENSG00000255422.1	AP002954.4	4.22	2.88e-05	0.0049	0.3	0.19	Sjögren's syndrome;	chr11:118790689	chr11:118704607~118750263:+
LUAD	cis	rs4795519	1	rs35773175	ENSG00000266313.1	RP11-173M1.4	4.22	2.88e-05	0.0049	0.23	0.19	Chronic myeloid leukemia;	chr17:27194820	chr17:27333256~27348491:+
LUAD	cis	rs8062405	0.755	rs4788074	ENSG00000251417.2	RP11-1348G14.4	4.22	2.88e-05	0.0049	0.19	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28802743~28817828:+
LUAD	cis	rs858239	0.6	rs2072368	ENSG00000226816.2	AC005082.12	4.22	2.88e-05	0.0049	0.25	0.19	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23206013~23208045:+
LUAD	cis	rs1401999	1	rs939338	ENSG00000223882.1	ABCC5-AS1	4.22	2.88e-05	0.0049	0.2	0.19	Anterior chamber depth;	chr3:183986280	chr3:184006338~184011419:+
LUAD	cis	rs262150	0.819	rs6956589	ENSG00000231419.5	LINC00689	-4.22	2.88e-05	0.0049	-0.22	-0.19	Facial morphology (factor 20);	chr7:158976610	chr7:159006522~159030195:+
LUAD	cis	rs11673344	0.503	rs703531	ENSG00000276846.1	CTD-3220F14.3	4.22	2.88e-05	0.0049	0.21	0.19	Obesity-related traits;	chr19:37010050	chr19:37314868~37315620:-
LUAD	cis	rs780094	0.544	rs2303370	ENSG00000234072.1	AC074117.10	-4.22	2.88e-05	0.0049	-0.15	-0.19	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27428508	chr2:27356246~27367622:+
LUAD	cis	rs17685	0.753	rs11972240	ENSG00000280388.1	RP11-229D13.3	-4.22	2.88e-05	0.0049	-0.18	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76064761	chr7:76043977~76045963:-
LUAD	cis	rs7493	0.806	rs17876090	ENSG00000233942.1	AC004012.1	4.22	2.88e-05	0.0049	0.28	0.19	Yu-Zhi constitution type in type 2 diabetes;	chr7:95424092	chr7:95471835~95473998:+
LUAD	cis	rs2274273	0.774	rs17128440	ENSG00000259318.1	RP11-454L9.2	4.22	2.88e-05	0.00491	0.16	0.19	Protein biomarker;	chr14:55395194	chr14:55394940~55395233:-
LUAD	cis	rs9649213	0.593	rs36017146	ENSG00000272950.1	RP11-307C18.1	4.22	2.88e-05	0.00491	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98345305	chr7:98322853~98323430:+
LUAD	cis	rs8062405	0.72	rs9926245	ENSG00000261419.1	RP11-57A19.4	-4.22	2.88e-05	0.00491	-0.2	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28659696~28740781:-
LUAD	cis	rs11673344	0.526	rs17305193	ENSG00000226686.6	LINC01535	4.22	2.88e-05	0.00491	0.23	0.19	Obesity-related traits;	chr19:37598764	chr19:37251912~37265535:+
LUAD	cis	rs911555	0.692	rs7145753	ENSG00000244691.1	RPL10AP1	4.22	2.89e-05	0.00491	0.25	0.19	Intelligence (multi-trait analysis);	chr14:103399763	chr14:103412119~103412761:-
LUAD	cis	rs7590268	0.577	rs11124943	ENSG00000279873.2	LINC01126	4.22	2.89e-05	0.00491	0.19	0.19	Orofacial clefts;	chr2:43605427	chr2:43227210~43228855:+
LUAD	cis	rs8141529	0.764	rs5762824	ENSG00000272858.1	CTA-292E10.8	-4.22	2.89e-05	0.00491	-0.21	-0.19	Lymphocyte counts;	chr22:28826942	chr22:28814914~28815662:+
LUAD	cis	rs8141529	0.764	rs5752807	ENSG00000272858.1	CTA-292E10.8	-4.22	2.89e-05	0.00491	-0.21	-0.19	Lymphocyte counts;	chr22:28827181	chr22:28814914~28815662:+
LUAD	cis	rs5758659	0.652	rs133326	ENSG00000182057.4	OGFRP1	4.22	2.89e-05	0.00491	0.22	0.19	Cognitive function;	chr22:42010881	chr22:42269753~42275196:+
LUAD	cis	rs9549260	0.709	rs9549240	ENSG00000229456.1	RLIMP1	4.22	2.89e-05	0.00491	0.2	0.19	Red blood cell count;	chr13:40612507	chr13:40618738~40621348:+
LUAD	cis	rs4664293	0.967	rs13032135	ENSG00000230783.1	AC009961.2	-4.22	2.89e-05	0.00491	-0.23	-0.19	Monocyte percentage of white cells;	chr2:159675588	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.934	rs4380179	ENSG00000230783.1	AC009961.2	-4.22	2.89e-05	0.00491	-0.23	-0.19	Monocyte percentage of white cells;	chr2:159685064	chr2:159689217~159690291:-
LUAD	cis	rs10504390	0.656	rs17395851	ENSG00000200714.1	Y_RNA	-4.22	2.89e-05	0.00491	-0.48	-0.19	IgG glycosylation;	chr8:65722436	chr8:65592731~65592820:+
LUAD	cis	rs10504390	0.656	rs17395878	ENSG00000200714.1	Y_RNA	-4.22	2.89e-05	0.00491	-0.48	-0.19	IgG glycosylation;	chr8:65723872	chr8:65592731~65592820:+
LUAD	cis	rs10504390	0.656	rs76277884	ENSG00000200714.1	Y_RNA	-4.22	2.89e-05	0.00491	-0.48	-0.19	IgG glycosylation;	chr8:65726325	chr8:65592731~65592820:+
LUAD	cis	rs10504390	0.656	rs17395920	ENSG00000200714.1	Y_RNA	-4.22	2.89e-05	0.00491	-0.48	-0.19	IgG glycosylation;	chr8:65727498	chr8:65592731~65592820:+
LUAD	cis	rs7911264	0.739	rs6583827	ENSG00000236493.2	EIF2S2P3	4.22	2.89e-05	0.00491	0.22	0.19	Inflammatory bowel disease;	chr10:92598266	chr10:92668745~92669743:-
LUAD	cis	rs7911264	0.739	rs7096101	ENSG00000236493.2	EIF2S2P3	4.22	2.89e-05	0.00491	0.22	0.19	Inflammatory bowel disease;	chr10:92603171	chr10:92668745~92669743:-
LUAD	cis	rs595982	0.546	rs12461075	ENSG00000235191.1	NUCB1-AS1	4.22	2.89e-05	0.00491	0.21	0.19	Red cell distribution width;	chr19:48896564	chr19:48910930~48918891:-
LUAD	cis	rs2243480	1	rs709607	ENSG00000232559.3	GS1-124K5.12	-4.22	2.89e-05	0.00491	-0.32	-0.19	Diabetic kidney disease;	chr7:65984554	chr7:66554588~66576923:-
LUAD	cis	rs7178424	0.711	rs11635569	ENSG00000259251.2	RP11-643M14.1	-4.22	2.89e-05	0.00491	-0.19	-0.19	Height;	chr15:61921398	chr15:62060503~62062434:+
LUAD	cis	rs9532580	0.62	rs2701859	ENSG00000229456.1	RLIMP1	4.22	2.89e-05	0.00491	0.22	0.19	Mean corpuscular hemoglobin;	chr13:40567095	chr13:40618738~40621348:+
LUAD	cis	rs875971	0.508	rs10253883	ENSG00000236529.1	RP13-254B10.1	-4.22	2.89e-05	0.00492	-0.19	-0.19	Aortic root size;	chr7:66596151	chr7:65840212~65840596:+
LUAD	cis	rs763121	0.853	rs5757208	ENSG00000228274.3	RP3-508I15.9	-4.22	2.89e-05	0.00492	-0.19	-0.19	Menopause (age at onset);	chr22:38653225	chr22:38667585~38681820:-
LUAD	cis	rs763121	0.853	rs6001184	ENSG00000228274.3	RP3-508I15.9	-4.22	2.89e-05	0.00492	-0.19	-0.19	Menopause (age at onset);	chr22:38656111	chr22:38667585~38681820:-
LUAD	cis	rs763121	0.853	rs6001185	ENSG00000228274.3	RP3-508I15.9	-4.22	2.89e-05	0.00492	-0.19	-0.19	Menopause (age at onset);	chr22:38656150	chr22:38667585~38681820:-
LUAD	cis	rs6940638	0.688	rs9379960	ENSG00000219392.1	RP1-265C24.5	-4.22	2.89e-05	0.00492	-0.24	-0.19	Intelligence (multi-trait analysis);	chr6:27153546	chr6:28115628~28116551:+
LUAD	cis	rs9322193	0.516	rs1999632	ENSG00000268592.3	RAET1E-AS1	4.22	2.89e-05	0.00492	0.29	0.19	Lung cancer;	chr6:149866737	chr6:149863494~149919507:+
LUAD	cis	rs4374383	0.884	rs13385764	ENSG00000207383.1	Y_RNA	-4.22	2.89e-05	0.00492	-0.23	-0.19	Hepatitis C induced liver fibrosis;	chr2:111989314	chr2:112579484~112579584:-
LUAD	cis	rs12922040	1	rs2075516	ENSG00000279866.1	CTB-193M12.4	-4.22	2.89e-05	0.00492	-0.19	-0.19	Serum uric acid levels in response to allopurinol in gout;	chr16:15775668	chr16:15704410~15705984:+
LUAD	cis	rs4554975	0.838	rs11183620	ENSG00000274723.1	RP11-618L22.1	-4.22	2.89e-05	0.00492	-0.22	-0.19	Metabolite levels (small molecules and protein measures);	chr12:46818587	chr12:46970504~46972155:+
LUAD	cis	rs4784934	0.655	rs12932631	ENSG00000260186.4	RP11-481J2.2	4.22	2.89e-05	0.00492	0.22	0.19	QT interval;	chr16:58435506	chr16:58421326~58462470:+
LUAD	cis	rs4784934	0.655	rs12927589	ENSG00000260186.4	RP11-481J2.2	4.22	2.89e-05	0.00492	0.22	0.19	QT interval;	chr16:58435775	chr16:58421326~58462470:+
LUAD	cis	rs4784934	0.655	rs4577076	ENSG00000260186.4	RP11-481J2.2	4.22	2.89e-05	0.00492	0.22	0.19	QT interval;	chr16:58435933	chr16:58421326~58462470:+
LUAD	cis	rs7551222	0.634	rs11801289	ENSG00000240219.1	RP11-430C7.5	4.22	2.89e-05	0.00492	0.2	0.19	Schizophrenia;	chr1:204559841	chr1:204626775~204629712:+
LUAD	cis	rs12468226	1	rs13426118	ENSG00000272966.1	RP11-686O6.1	4.22	2.89e-05	0.00492	0.27	0.19	Urate levels;	chr2:202390762	chr2:202336739~202337200:+
LUAD	cis	rs853679	0.517	rs4713145	ENSG00000226314.6	ZNF192P1	-4.22	2.9e-05	0.00492	-0.25	-0.19	Depression;	chr6:28139049	chr6:28161781~28169594:+
LUAD	cis	rs516805	0.52	rs474440	ENSG00000279453.1	RP3-425C14.4	-4.22	2.9e-05	0.00492	-0.2	-0.19	Lymphocyte counts;	chr6:122457954	chr6:122436789~122439223:-
LUAD	cis	rs11168618	0.904	rs7978948	ENSG00000240399.1	RP1-228P16.1	4.22	2.9e-05	0.00492	0.19	0.19	Adiponectin levels;	chr12:48536240	chr12:48054813~48055591:-
LUAD	cis	rs11168618	0.904	rs12366459	ENSG00000240399.1	RP1-228P16.1	4.22	2.9e-05	0.00492	0.19	0.19	Adiponectin levels;	chr12:48537117	chr12:48054813~48055591:-
LUAD	cis	rs17772222	0.874	rs61984746	ENSG00000258789.1	RP11-507K2.3	-4.22	2.9e-05	0.00493	-0.26	-0.19	Coronary artery calcification;	chr14:88668136	chr14:88551597~88552493:+
LUAD	cis	rs516805	0.52	rs4945703	ENSG00000279453.1	RP3-425C14.4	-4.22	2.9e-05	0.00493	-0.2	-0.19	Lymphocyte counts;	chr6:122460520	chr6:122436789~122439223:-
LUAD	cis	rs9788333	0.762	rs4441120	ENSG00000224429.6	LINC00539	-4.22	2.9e-05	0.00493	-0.17	-0.19	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr13:21312724	chr13:21303515~21348721:-
LUAD	cis	rs11168618	0.686	rs11168574	ENSG00000240399.1	RP1-228P16.1	4.22	2.9e-05	0.00493	0.18	0.19	Adiponectin levels;	chr12:48445186	chr12:48054813~48055591:-
LUAD	cis	rs11168618	0.81	rs35338015	ENSG00000240399.1	RP1-228P16.1	4.22	2.9e-05	0.00493	0.18	0.19	Adiponectin levels;	chr12:48445618	chr12:48054813~48055591:-
LUAD	cis	rs11168618	0.81	rs6580671	ENSG00000240399.1	RP1-228P16.1	4.22	2.9e-05	0.00493	0.18	0.19	Adiponectin levels;	chr12:48447274	chr12:48054813~48055591:-
LUAD	cis	rs11168618	0.846	rs11168577	ENSG00000240399.1	RP1-228P16.1	4.22	2.9e-05	0.00493	0.18	0.19	Adiponectin levels;	chr12:48448809	chr12:48054813~48055591:-
LUAD	cis	rs2823962	0.697	rs9984100	ENSG00000270093.1	AP000473.8	-4.22	2.9e-05	0.00493	-0.2	-0.19	Amyotrophic lateral sclerosis;	chr21:16644167	chr21:16643529~16645065:+
LUAD	cis	rs2823962	0.759	rs9984105	ENSG00000270093.1	AP000473.8	-4.22	2.9e-05	0.00493	-0.2	-0.19	Amyotrophic lateral sclerosis;	chr21:16644176	chr21:16643529~16645065:+
LUAD	cis	rs875971	0.666	rs13242072	ENSG00000236529.1	RP13-254B10.1	-4.22	2.9e-05	0.00493	-0.19	-0.19	Aortic root size;	chr7:66301001	chr7:65840212~65840596:+
LUAD	cis	rs4819052	1	rs9306123	ENSG00000237664.1	LINC00316	-4.22	2.9e-05	0.00493	-0.25	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45290007	chr21:45338590~45341990:-
LUAD	cis	rs12073359	1	rs11591200	ENSG00000223945.2	RP11-458I7.1	4.22	2.9e-05	0.00493	0.27	0.19	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150161365	chr1:150053864~150055034:+
LUAD	cis	rs9341808	0.667	rs3805919	ENSG00000260645.1	RP11-250B2.5	4.22	2.9e-05	0.00493	0.18	0.19	Sitting height ratio;	chr6:80197092	chr6:80466958~80469080:+
LUAD	cis	rs720064	0.537	rs2676106	ENSG00000264745.1	TTC39C-AS1	4.22	2.9e-05	0.00493	0.2	0.19	Strep throat;	chr18:23685075	chr18:23994213~24015339:-
LUAD	cis	rs1334894	1	rs1334894	ENSG00000228559.1	RP3-340B19.3	-4.22	2.9e-05	0.00493	-0.4	-0.19	Coronary artery disease;	chr6:35647353	chr6:35544632~35545669:+
LUAD	cis	rs763567	0.817	rs598993	ENSG00000271811.1	RP1-79C4.4	4.22	2.9e-05	0.00493	0.22	0.19	Tonsillectomy;	chr1:170634981	chr1:170667381~170669425:+
LUAD	cis	rs763567	0.935	rs541557	ENSG00000271811.1	RP1-79C4.4	4.22	2.9e-05	0.00493	0.22	0.19	Tonsillectomy;	chr1:170635797	chr1:170667381~170669425:+
LUAD	cis	rs6496044	0.568	rs1982742	ENSG00000259295.5	CSPG4P12	4.22	2.9e-05	0.00493	0.22	0.19	Interstitial lung disease;	chr15:85525519	chr15:85191438~85213905:+
LUAD	cis	rs6496044	0.568	rs1982743	ENSG00000259295.5	CSPG4P12	4.22	2.9e-05	0.00493	0.22	0.19	Interstitial lung disease;	chr15:85525528	chr15:85191438~85213905:+
LUAD	cis	rs2446066	0.872	rs7133236	ENSG00000257379.1	RP11-793H13.8	4.22	2.9e-05	0.00493	0.31	0.19	Red blood cell count;	chr12:53397201	chr12:53441741~53467528:+
LUAD	cis	rs2446066	0.872	rs74090765	ENSG00000257379.1	RP11-793H13.8	4.22	2.9e-05	0.00493	0.31	0.19	Red blood cell count;	chr12:53399130	chr12:53441741~53467528:+
LUAD	cis	rs214785	0.932	rs214760	ENSG00000234684.5	SDCBP2-AS1	4.22	2.9e-05	0.00493	0.23	0.19	Basal cell carcinoma;	chr20:2295330	chr20:1325405~1378734:+
LUAD	cis	rs865483	0.861	rs56186148	ENSG00000276054.1	RP11-378E13.3	-4.22	2.9e-05	0.00493	-0.22	-0.19	Monocyte count;	chr17:37408740	chr17:37386886~37387926:+
LUAD	cis	rs860818	1	rs858243	ENSG00000226816.2	AC005082.12	4.22	2.9e-05	0.00494	0.49	0.19	Initial pursuit acceleration;	chr7:23184738	chr7:23206013~23208045:+
LUAD	cis	rs6479891	1	rs4469774	ENSG00000232075.1	MRPL35P2	4.22	2.9e-05	0.00494	0.32	0.19	Arthritis (juvenile idiopathic);	chr10:63550017	chr10:63634317~63634827:-
LUAD	cis	rs7561273	0.609	rs3795953	ENSG00000242628.4	AC009228.1	4.22	2.91e-05	0.00494	0.24	0.19	Quantitative traits;	chr2:24122837	chr2:24214381~24221516:+
LUAD	cis	rs7208859	0.623	rs55724095	ENSG00000263603.1	CTD-2349P21.5	-4.22	2.91e-05	0.00494	-0.33	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826040	chr17:30729469~30731202:+
LUAD	cis	rs17826219	0.568	rs9903854	ENSG00000263603.1	CTD-2349P21.5	-4.22	2.91e-05	0.00494	-0.33	-0.19	Body mass index;	chr17:30826980	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs80355557	ENSG00000263603.1	CTD-2349P21.5	-4.22	2.91e-05	0.00494	-0.33	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827403	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs9911173	ENSG00000263603.1	CTD-2349P21.5	-4.22	2.91e-05	0.00494	-0.33	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827732	chr17:30729469~30731202:+
LUAD	cis	rs1075265	0.54	rs2542587	ENSG00000272156.1	RP11-477N3.1	-4.22	2.91e-05	0.00494	-0.23	-0.19	Chronotype;Morning vs. evening chronotype;	chr2:53788839	chr2:54082554~54085066:+
LUAD	cis	rs1075265	0.563	rs2692537	ENSG00000272156.1	RP11-477N3.1	-4.22	2.91e-05	0.00494	-0.23	-0.19	Chronotype;Morning vs. evening chronotype;	chr2:53788840	chr2:54082554~54085066:+
LUAD	cis	rs4295623	0.585	rs13259242	ENSG00000255046.1	RP11-297N6.4	4.22	2.91e-05	0.00494	0.23	0.19	Morning vs. evening chronotype;	chr8:11735524	chr8:11797928~11802568:-
LUAD	cis	rs7116495	1	rs1939242	ENSG00000254682.1	RP11-660L16.2	4.22	2.91e-05	0.00494	0.4	0.19	Severe influenza A (H1N1) infection;	chr11:72042536	chr11:71448674~71452157:+
LUAD	cis	rs61542988	0.797	rs4329182	ENSG00000226329.2	AC005682.6	4.22	2.91e-05	0.00494	0.28	0.19	Fibrinogen levels;	chr7:22843002	chr7:22863874~22881350:-
LUAD	cis	rs858239	0.601	rs11982002	ENSG00000226816.2	AC005082.12	4.22	2.91e-05	0.00494	0.25	0.19	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23206013~23208045:+
LUAD	cis	rs9487094	0.567	rs13196280	ENSG00000260273.1	RP11-425D10.10	4.22	2.91e-05	0.00494	0.28	0.19	Height;	chr6:109764163	chr6:109382795~109383666:+
LUAD	cis	rs4374383	0.772	rs66477683	ENSG00000207383.1	Y_RNA	-4.22	2.91e-05	0.00494	-0.23	-0.19	Hepatitis C induced liver fibrosis;	chr2:111976120	chr2:112579484~112579584:-
LUAD	cis	rs4374383	0.884	rs68087924	ENSG00000207383.1	Y_RNA	-4.22	2.91e-05	0.00494	-0.23	-0.19	Hepatitis C induced liver fibrosis;	chr2:111976140	chr2:112579484~112579584:-
LUAD	cis	rs4374383	0.812	rs66486378	ENSG00000207383.1	Y_RNA	-4.22	2.91e-05	0.00494	-0.23	-0.19	Hepatitis C induced liver fibrosis;	chr2:111976403	chr2:112579484~112579584:-
LUAD	cis	rs4374383	0.884	rs1607059	ENSG00000207383.1	Y_RNA	-4.22	2.91e-05	0.00494	-0.23	-0.19	Hepatitis C induced liver fibrosis;	chr2:111976935	chr2:112579484~112579584:-
LUAD	cis	rs4374383	0.884	rs10199083	ENSG00000207383.1	Y_RNA	-4.22	2.91e-05	0.00494	-0.23	-0.19	Hepatitis C induced liver fibrosis;	chr2:111979065	chr2:112579484~112579584:-
LUAD	cis	rs4374383	0.884	rs10166564	ENSG00000207383.1	Y_RNA	-4.22	2.91e-05	0.00494	-0.23	-0.19	Hepatitis C induced liver fibrosis;	chr2:111979146	chr2:112579484~112579584:-
LUAD	cis	rs4374383	0.884	rs10199616	ENSG00000207383.1	Y_RNA	-4.22	2.91e-05	0.00494	-0.23	-0.19	Hepatitis C induced liver fibrosis;	chr2:111979608	chr2:112579484~112579584:-
LUAD	cis	rs4374383	0.847	rs10177803	ENSG00000207383.1	Y_RNA	-4.22	2.91e-05	0.00494	-0.23	-0.19	Hepatitis C induced liver fibrosis;	chr2:111979715	chr2:112579484~112579584:-
LUAD	cis	rs4374383	0.811	rs6725192	ENSG00000207383.1	Y_RNA	-4.22	2.91e-05	0.00494	-0.23	-0.19	Hepatitis C induced liver fibrosis;	chr2:111980985	chr2:112579484~112579584:-
LUAD	cis	rs4374383	0.884	rs10171174	ENSG00000207383.1	Y_RNA	-4.22	2.91e-05	0.00494	-0.23	-0.19	Hepatitis C induced liver fibrosis;	chr2:111981485	chr2:112579484~112579584:-
LUAD	cis	rs2657294	0.965	rs7079694	ENSG00000226051.5	ZNF503-AS1	-4.22	2.91e-05	0.00494	-0.25	-0.19	Pneumonia;	chr10:75136804	chr10:75269819~75373500:+
LUAD	cis	rs10197140	0.857	rs1533296	ENSG00000235721.1	AC013268.3	-4.22	2.91e-05	0.00495	-0.21	-0.19	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110893926	chr2:110007675~110010783:+
LUAD	cis	rs2439831	1	rs2601014	ENSG00000249839.1	AC011330.5	-4.22	2.91e-05	0.00495	-0.35	-0.19	Lung cancer in ever smokers;	chr15:43463815	chr15:43663654~43684339:-
LUAD	cis	rs2348418	0.832	rs12303069	ENSG00000244712.1	RP11-874G11.1	4.22	2.91e-05	0.00495	0.23	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28294319	chr12:28564678~28565141:-
LUAD	cis	rs755249	0.701	rs1180342	ENSG00000228060.1	RP11-69E11.8	4.22	2.91e-05	0.00495	0.16	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39527206	chr1:39565160~39573203:+
LUAD	cis	rs9467773	0.62	rs2451737	ENSG00000241549.7	GUSBP2	4.22	2.91e-05	0.00495	0.21	0.19	Intelligence (multi-trait analysis);	chr6:26618813	chr6:26871484~26956554:-
LUAD	cis	rs9467773	0.596	rs2494693	ENSG00000241549.7	GUSBP2	4.22	2.91e-05	0.00495	0.21	0.19	Intelligence (multi-trait analysis);	chr6:26618998	chr6:26871484~26956554:-
LUAD	cis	rs9467773	0.62	rs2494694	ENSG00000241549.7	GUSBP2	4.22	2.91e-05	0.00495	0.21	0.19	Intelligence (multi-trait analysis);	chr6:26619100	chr6:26871484~26956554:-
LUAD	cis	rs11886999	0.812	rs12617019	ENSG00000237510.6	AC008268.2	-4.22	2.91e-05	0.00495	-0.31	-0.19	Cardiac Troponin-T levels;	chr2:96239830	chr2:95789654~95800166:+
LUAD	cis	rs7404843	0.789	rs222907	ENSG00000207425.1	Y_RNA	-4.22	2.91e-05	0.00495	-0.32	-0.19	Testicular germ cell tumor;	chr16:15404950	chr16:14915457~14915556:-
LUAD	cis	rs8050896	1	rs7191834	ENSG00000260695.1	RP11-513N24.1	-4.22	2.91e-05	0.00495	-0.33	-0.19	Response to antipsychotic treatment;	chr16:66124668	chr16:65861112~65863784:-
LUAD	cis	rs8050896	1	rs10048071	ENSG00000260695.1	RP11-513N24.1	-4.22	2.91e-05	0.00495	-0.33	-0.19	Response to antipsychotic treatment;	chr16:66124694	chr16:65861112~65863784:-
LUAD	cis	rs7208859	0.524	rs60114476	ENSG00000280069.1	CTD-2349P21.3	-4.22	2.91e-05	0.00495	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770649	chr17:30738182~30740275:+
LUAD	cis	rs17826219	0.636	rs2449770	ENSG00000280069.1	CTD-2349P21.3	-4.22	2.91e-05	0.00495	-0.26	-0.19	Body mass index;	chr17:30774046	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.524	rs59913838	ENSG00000280069.1	CTD-2349P21.3	-4.22	2.91e-05	0.00495	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774545	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs8067338	ENSG00000280069.1	CTD-2349P21.3	-4.22	2.91e-05	0.00495	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775327	chr17:30738182~30740275:+
LUAD	cis	rs5758511	0.68	rs5758692	ENSG00000227370.1	RP4-669P10.19	4.22	2.91e-05	0.00495	0.21	0.19	Birth weight;	chr22:42273023	chr22:42132543~42132998:+
LUAD	cis	rs2286503	0.646	rs17147344	ENSG00000226329.2	AC005682.6	4.22	2.91e-05	0.00495	0.28	0.19	Fibrinogen;	chr7:22841237	chr7:22863874~22881350:-
LUAD	cis	rs262150	0.851	rs2730249	ENSG00000231419.5	LINC00689	4.22	2.92e-05	0.00495	0.22	0.19	Facial morphology (factor 20);	chr7:158974937	chr7:159006522~159030195:+
LUAD	cis	rs1008375	0.932	rs11941874	ENSG00000249502.1	AC006160.5	4.22	2.92e-05	0.00495	0.18	0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17664793	chr4:17587467~17614571:-
LUAD	cis	rs2274273	0.624	rs7152390	ENSG00000258413.1	RP11-665C16.6	-4.22	2.92e-05	0.00495	-0.26	-0.19	Protein biomarker;	chr14:55344983	chr14:55262767~55272075:-
LUAD	cis	rs2274273	0.588	rs9919923	ENSG00000258413.1	RP11-665C16.6	-4.22	2.92e-05	0.00495	-0.26	-0.19	Protein biomarker;	chr14:55347181	chr14:55262767~55272075:-
LUAD	cis	rs2274273	0.588	rs9919932	ENSG00000258413.1	RP11-665C16.6	-4.22	2.92e-05	0.00495	-0.26	-0.19	Protein biomarker;	chr14:55347362	chr14:55262767~55272075:-
LUAD	cis	rs3096299	0.728	rs1011749	ENSG00000182376.2	RP5-1142A6.8	4.22	2.92e-05	0.00495	0.2	0.19	Multiple myeloma (IgH translocation);	chr16:89444461	chr16:88742767~88745748:+
LUAD	cis	rs17685	0.725	rs7807647	ENSG00000280388.1	RP11-229D13.3	4.22	2.92e-05	0.00495	0.18	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:75999351	chr7:76043977~76045963:-
LUAD	cis	rs4925386	0.681	rs2427295	ENSG00000273619.1	RP5-908M14.9	-4.22	2.92e-05	0.00495	-0.2	-0.19	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62352375	chr20:62386303~62386970:-
LUAD	cis	rs4705952	0.832	rs2548989	ENSG00000233006.5	AC034220.3	-4.22	2.92e-05	0.00495	-0.22	-0.19	C-reactive protein levels;	chr5:132524013	chr5:132311285~132369916:-
LUAD	cis	rs2765539	0.701	rs12068932	ENSG00000226172.2	RP4-712E4.1	-4.22	2.92e-05	0.00496	-0.24	-0.19	Waist-hip ratio;	chr1:119113057	chr1:119000344~119001392:-
LUAD	cis	rs17301013	0.932	rs1793297	ENSG00000227373.4	RP11-160H22.5	-4.22	2.92e-05	0.00496	-0.24	-0.19	Systemic lupus erythematosus;	chr1:174784411	chr1:174115300~174160004:-
LUAD	cis	rs7204230	1	rs2388013	ENSG00000261291.1	RP11-295M3.2	4.22	2.92e-05	0.00496	0.23	0.19	Fibrinogen;	chr16:53193469	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs12599389	ENSG00000261291.1	RP11-295M3.2	4.22	2.92e-05	0.00496	0.23	0.19	Fibrinogen;	chr16:53196746	chr16:53168522~53169450:+
LUAD	cis	rs11157436	0.602	rs10872984	ENSG00000211812.1	TRAV26-2	-4.22	2.92e-05	0.00496	-0.19	-0.19	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22171245	chr14:22202583~22203368:+
LUAD	cis	rs8098244	0.683	rs1941524	ENSG00000264745.1	TTC39C-AS1	-4.22	2.92e-05	0.00496	-0.19	-0.19	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23865299	chr18:23994213~24015339:-
LUAD	cis	rs2836974	0.644	rs2836981	ENSG00000232608.1	TIMM9P2	4.22	2.92e-05	0.00496	0.22	0.19	Cognitive function;	chr21:39316439	chr21:39216624~39217506:+
LUAD	cis	rs6840360	0.571	rs718800	ENSG00000270265.1	RP11-731D1.4	4.22	2.92e-05	0.00496	0.22	0.19	Intelligence (multi-trait analysis);	chr4:151628155	chr4:151333775~151353224:-
LUAD	cis	rs6671200	0.607	rs3767313	ENSG00000228852.5	RP11-57H12.5	-4.22	2.92e-05	0.00496	-0.23	-0.19	Stearic acid (18:0) levels;	chr1:95247241	chr1:95243167~95278940:-
LUAD	cis	rs80028505	0.908	rs73407868	ENSG00000271304.1	DPRXP2	4.22	2.92e-05	0.00496	0.35	0.19	Foot ulcer in diabetes and neuropathy;	chr6:36054534	chr6:35989515~35990436:-
LUAD	cis	rs80028505	0.908	rs3730327	ENSG00000271304.1	DPRXP2	4.22	2.92e-05	0.00496	0.35	0.19	Foot ulcer in diabetes and neuropathy;	chr6:36059365	chr6:35989515~35990436:-
LUAD	cis	rs80028505	1	rs73407876	ENSG00000271304.1	DPRXP2	4.22	2.92e-05	0.00496	0.35	0.19	Foot ulcer in diabetes and neuropathy;	chr6:36066143	chr6:35989515~35990436:-
LUAD	cis	rs2274273	0.745	rs8005399	ENSG00000258413.1	RP11-665C16.6	-4.22	2.92e-05	0.00496	-0.24	-0.19	Protein biomarker;	chr14:55076127	chr14:55262767~55272075:-
LUAD	cis	rs4374383	0.884	rs11123073	ENSG00000207383.1	Y_RNA	-4.22	2.93e-05	0.00497	-0.23	-0.19	Hepatitis C induced liver fibrosis;	chr2:111990076	chr2:112579484~112579584:-
LUAD	cis	rs4374383	0.884	rs7564225	ENSG00000207383.1	Y_RNA	-4.22	2.93e-05	0.00497	-0.23	-0.19	Hepatitis C induced liver fibrosis;	chr2:111990555	chr2:112579484~112579584:-
LUAD	cis	rs4374383	0.884	rs10186291	ENSG00000207383.1	Y_RNA	-4.22	2.93e-05	0.00497	-0.23	-0.19	Hepatitis C induced liver fibrosis;	chr2:111990937	chr2:112579484~112579584:-
LUAD	cis	rs4374383	0.884	rs10189399	ENSG00000207383.1	Y_RNA	-4.22	2.93e-05	0.00497	-0.23	-0.19	Hepatitis C induced liver fibrosis;	chr2:111991387	chr2:112579484~112579584:-
LUAD	cis	rs4374383	0.884	rs7571009	ENSG00000207383.1	Y_RNA	-4.22	2.93e-05	0.00497	-0.23	-0.19	Hepatitis C induced liver fibrosis;	chr2:111991934	chr2:112579484~112579584:-
LUAD	cis	rs4374383	0.884	rs7571120	ENSG00000207383.1	Y_RNA	-4.22	2.93e-05	0.00497	-0.23	-0.19	Hepatitis C induced liver fibrosis;	chr2:111992017	chr2:112579484~112579584:-
LUAD	cis	rs4374383	0.884	rs7588459	ENSG00000207383.1	Y_RNA	-4.22	2.93e-05	0.00497	-0.23	-0.19	Hepatitis C induced liver fibrosis;	chr2:111992966	chr2:112579484~112579584:-
LUAD	cis	rs4845570	1	rs4845579	ENSG00000203288.3	RP11-98D18.9	-4.22	2.93e-05	0.00497	-0.26	-0.19	Coronary artery disease;	chr1:151797662	chr1:151790804~151794402:+
LUAD	cis	rs9649213	0.593	rs6465682	ENSG00000272950.1	RP11-307C18.1	4.22	2.93e-05	0.00497	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98387105	chr7:98322853~98323430:+
LUAD	cis	rs7688540	0.76	rs7687833	ENSG00000211553.1	AC253576.2	-4.22	2.93e-05	0.00497	-0.24	-0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:243531	chr4:136461~136568:+
LUAD	cis	rs7204230	1	rs11865438	ENSG00000261291.1	RP11-295M3.2	4.22	2.93e-05	0.00497	0.23	0.19	Fibrinogen;	chr16:53296216	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs11865886	ENSG00000261291.1	RP11-295M3.2	4.22	2.93e-05	0.00497	0.23	0.19	Fibrinogen;	chr16:53297679	chr16:53168522~53169450:+
LUAD	cis	rs853679	0.723	rs9366718	ENSG00000204709.4	LINC01556	4.22	2.93e-05	0.00497	0.27	0.19	Depression;	chr6:28237724	chr6:28943877~28944537:+
LUAD	cis	rs1387259	0.929	rs2634666	ENSG00000257763.1	OR5BK1P	4.22	2.93e-05	0.00497	0.2	0.19	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48269887	chr12:48355792~48356614:-
LUAD	cis	rs9860428	0.774	rs13324496	ENSG00000242770.2	RP11-180K7.1	4.22	2.93e-05	0.00497	0.21	0.19	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112883013	chr3:112802478~112812819:+
LUAD	cis	rs4691139	0.658	rs4691142	ENSG00000248632.1	RP11-366M4.11	4.22	2.93e-05	0.00497	0.22	0.19	Ovarian cancer in BRCA1 mutation carriers;	chr4:165005634	chr4:164968587~164970002:-
LUAD	cis	rs2929278	0.617	rs663214	ENSG00000166763.7	STRCP1	-4.22	2.93e-05	0.00497	-0.22	-0.19	Schizophrenia;	chr15:43821584	chr15:43699488~43718184:-
LUAD	cis	rs812925	0.537	rs2593620	ENSG00000271889.1	RP11-493E12.1	-4.22	2.93e-05	0.00497	-0.22	-0.19	Immature fraction of reticulocytes;	chr2:61386126	chr2:61151433~61162105:-
LUAD	cis	rs800160	1	rs1088988	ENSG00000236264.4	RPL26P30	-4.22	2.93e-05	0.00497	-0.25	-0.19	Bacteremia;	chr11:2359240	chr11:2335132~2335776:-
LUAD	cis	rs1075265	0.518	rs13414393	ENSG00000233266.1	HMGB1P31	4.22	2.93e-05	0.00497	0.25	0.19	Chronotype;Morning vs. evening chronotype;	chr2:54048025	chr2:54051334~54051760:+
LUAD	cis	rs7829975	0.564	rs2921057	ENSG00000173295.6	FAM86B3P	4.22	2.93e-05	0.00498	0.2	0.19	Mood instability;	chr8:8461157	chr8:8228595~8244865:+
LUAD	cis	rs7204230	1	rs7191003	ENSG00000261291.1	RP11-295M3.2	4.22	2.93e-05	0.00498	0.24	0.19	Fibrinogen;	chr16:53169722	chr16:53168522~53169450:+
LUAD	cis	rs116095464	0.558	rs6555058	ENSG00000248925.1	CTD-2083E4.6	-4.22	2.93e-05	0.00498	-0.32	-0.19	Breast cancer;	chr5:226261	chr5:269858~271516:-
LUAD	cis	rs6723226	0.732	rs6747560	ENSG00000276334.1	AL133243.1	4.22	2.93e-05	0.00498	0.22	0.19	Intelligence (multi-trait analysis);	chr2:32559699	chr2:32521927~32523547:+
LUAD	cis	rs1799949	0.526	rs4352088	ENSG00000236383.6	LINC00854	-4.22	2.93e-05	0.00498	-0.15	-0.19	Menopause (age at onset);	chr17:43337311	chr17:43216941~43305976:-
LUAD	cis	rs853679	0.513	rs9468296	ENSG00000226314.6	ZNF192P1	-4.22	2.93e-05	0.00498	-0.25	-0.19	Depression;	chr6:28145952	chr6:28161781~28169594:+
LUAD	cis	rs365302	1	rs369160	ENSG00000235086.1	FNDC1-IT1	4.22	2.93e-05	0.00498	0.26	0.19	Coronary heart disease;	chr6:159217547	chr6:159240786~159243329:+
LUAD	cis	rs7107174	0.892	rs12281104	ENSG00000251323.2	RP11-452H21.4	4.22	2.94e-05	0.00498	0.23	0.19	Testicular germ cell tumor;	chr11:78335894	chr11:78423982~78429836:-
LUAD	cis	rs3020736	0.5	rs6002605	ENSG00000205702.9	CYP2D7	-4.22	2.94e-05	0.00498	-0.16	-0.19	Autism spectrum disorder or schizophrenia;	chr22:42098331	chr22:42140203~42144577:-
LUAD	cis	rs2153535	0.585	rs9379234	ENSG00000230939.1	RP11-314C16.1	-4.22	2.94e-05	0.00498	-0.21	-0.19	Motion sickness;	chr6:8643520	chr6:8784178~8785445:+
LUAD	cis	rs2018683	0.707	rs7799357	ENSG00000228421.2	AC005013.5	4.22	2.94e-05	0.00498	0.21	0.19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28930501	chr7:28957667~28959345:+
LUAD	cis	rs2562456	0.833	rs62110429	ENSG00000268081.1	RP11-678G14.2	4.22	2.94e-05	0.00498	0.31	0.19	Pain;	chr19:21430984	chr19:21554640~21569237:-
LUAD	cis	rs1401999	0.966	rs4148585	ENSG00000223882.1	ABCC5-AS1	-4.22	2.94e-05	0.00498	-0.2	-0.19	Anterior chamber depth;	chr3:183952854	chr3:184006338~184011419:+
LUAD	cis	rs12898179	0.53	rs11622608	ENSG00000258561.1	RP11-72M17.1	4.22	2.94e-05	0.00498	0.29	0.19	Glomerular filtration rate in chronic kidney disease;	chr14:67502833	chr14:66212810~66509394:-
LUAD	cis	rs4268898	0.582	rs1559472	ENSG00000242628.4	AC009228.1	-4.22	2.94e-05	0.00498	-0.24	-0.19	Asthma;	chr2:24232961	chr2:24214381~24221516:+
LUAD	cis	rs853679	0.546	rs35744819	ENSG00000219392.1	RP1-265C24.5	-4.22	2.94e-05	0.00498	-0.42	-0.19	Depression;	chr6:28350554	chr6:28115628~28116551:+
LUAD	cis	rs1401999	1	rs7620350	ENSG00000223882.1	ABCC5-AS1	-4.22	2.94e-05	0.00498	-0.19	-0.19	Anterior chamber depth;	chr3:183992265	chr3:184006338~184011419:+
LUAD	cis	rs7189233	0.531	rs9921587	ENSG00000279344.1	RP11-44F14.7	4.22	2.94e-05	0.00498	0.16	0.19	Intelligence (multi-trait analysis);	chr16:53441738	chr16:53478957~53481550:-
LUAD	cis	rs3743162	0.553	rs12915656	ENSG00000259295.5	CSPG4P12	4.22	2.94e-05	0.00498	0.28	0.19	Alzheimer's disease (age of onset);	chr15:84872349	chr15:85191438~85213905:+
LUAD	cis	rs11051970	0.513	rs4931013	ENSG00000274964.1	RP11-817I4.1	-4.22	2.94e-05	0.00499	-0.25	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr12:32407788	chr12:32339368~32340724:+
LUAD	cis	rs11051970	0.546	rs11051989	ENSG00000274964.1	RP11-817I4.1	-4.22	2.94e-05	0.00499	-0.25	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr12:32407956	chr12:32339368~32340724:+
LUAD	cis	rs7339483	0.85	rs3903525	ENSG00000268058.1	BNIP3P40	-4.22	2.94e-05	0.00499	-0.34	-0.19	Discordance in emotional problems in monozygotic twins;	chr19:24195194	chr19:24098425~24098980:-
LUAD	cis	rs34421088	0.576	rs2572432	ENSG00000255046.1	RP11-297N6.4	4.22	2.94e-05	0.00499	0.24	0.19	Neuroticism;	chr8:11244214	chr8:11797928~11802568:-
LUAD	cis	rs7005380	0.581	rs869340	ENSG00000279347.1	RP11-85I17.2	4.22	2.94e-05	0.00499	0.18	0.19	Interstitial lung disease;	chr8:119920372	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.581	rs869341	ENSG00000279347.1	RP11-85I17.2	4.22	2.94e-05	0.00499	0.18	0.19	Interstitial lung disease;	chr8:119920565	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.581	rs9987297	ENSG00000279347.1	RP11-85I17.2	4.22	2.94e-05	0.00499	0.18	0.19	Interstitial lung disease;	chr8:119921449	chr8:119838736~119840385:-
LUAD	cis	rs13113518	1	rs4865013	ENSG00000272969.1	RP11-528I4.2	4.22	2.94e-05	0.00499	0.2	0.19	Height;	chr4:55559957	chr4:55547112~55547889:+
LUAD	cis	rs67311347	0.544	rs7652439	ENSG00000223797.4	ENTPD3-AS1	4.22	2.94e-05	0.00499	0.2	0.19	Renal cell carcinoma;	chr3:40308457	chr3:40313802~40453329:-
LUAD	cis	rs4865762	0.595	rs254504	ENSG00000247796.2	CTD-2366F13.1	4.22	2.94e-05	0.00499	0.19	0.19	Intraocular pressure;	chr5:53194539	chr5:53109842~53115126:+
LUAD	cis	rs6964587	0.934	rs1544377	ENSG00000188693.7	CYP51A1-AS1	-4.22	2.94e-05	0.00499	-0.22	-0.19	Breast cancer;	chr7:92058037	chr7:92134604~92180725:+
LUAD	cis	rs6964587	1	rs6969536	ENSG00000188693.7	CYP51A1-AS1	-4.22	2.94e-05	0.00499	-0.22	-0.19	Breast cancer;	chr7:92060037	chr7:92134604~92180725:+
LUAD	cis	rs6964587	1	rs6951972	ENSG00000188693.7	CYP51A1-AS1	-4.22	2.94e-05	0.00499	-0.22	-0.19	Breast cancer;	chr7:92060132	chr7:92134604~92180725:+
LUAD	cis	rs6964587	1	rs6969981	ENSG00000188693.7	CYP51A1-AS1	-4.22	2.94e-05	0.00499	-0.22	-0.19	Breast cancer;	chr7:92060147	chr7:92134604~92180725:+
LUAD	cis	rs6964587	1	rs56072181	ENSG00000188693.7	CYP51A1-AS1	-4.22	2.94e-05	0.00499	-0.22	-0.19	Breast cancer;	chr7:92061143	chr7:92134604~92180725:+
LUAD	cis	rs6964587	1	rs10236397	ENSG00000188693.7	CYP51A1-AS1	-4.22	2.94e-05	0.00499	-0.22	-0.19	Breast cancer;	chr7:92062287	chr7:92134604~92180725:+
LUAD	cis	rs6964587	1	rs11981461	ENSG00000188693.7	CYP51A1-AS1	-4.22	2.94e-05	0.00499	-0.22	-0.19	Breast cancer;	chr7:92063348	chr7:92134604~92180725:+
LUAD	cis	rs6964587	0.934	rs73226382	ENSG00000188693.7	CYP51A1-AS1	-4.22	2.94e-05	0.00499	-0.22	-0.19	Breast cancer;	chr7:92063446	chr7:92134604~92180725:+
LUAD	cis	rs6964587	1	rs6465347	ENSG00000188693.7	CYP51A1-AS1	-4.22	2.94e-05	0.00499	-0.22	-0.19	Breast cancer;	chr7:92064523	chr7:92134604~92180725:+
LUAD	cis	rs6964587	0.967	rs10248102	ENSG00000188693.7	CYP51A1-AS1	-4.22	2.94e-05	0.00499	-0.22	-0.19	Breast cancer;	chr7:92070465	chr7:92134604~92180725:+
LUAD	cis	rs6964587	1	rs10270598	ENSG00000188693.7	CYP51A1-AS1	-4.22	2.94e-05	0.00499	-0.22	-0.19	Breast cancer;	chr7:92071513	chr7:92134604~92180725:+
LUAD	cis	rs6964587	1	rs7800582	ENSG00000188693.7	CYP51A1-AS1	-4.22	2.94e-05	0.00499	-0.22	-0.19	Breast cancer;	chr7:92072032	chr7:92134604~92180725:+
LUAD	cis	rs6964587	1	rs10243241	ENSG00000188693.7	CYP51A1-AS1	-4.22	2.94e-05	0.00499	-0.22	-0.19	Breast cancer;	chr7:92076382	chr7:92134604~92180725:+
LUAD	cis	rs6964587	0.869	rs10242792	ENSG00000188693.7	CYP51A1-AS1	-4.22	2.94e-05	0.00499	-0.23	-0.19	Breast cancer;	chr7:91862789	chr7:92134604~92180725:+
LUAD	cis	rs6754311	0.731	rs745500	ENSG00000226806.1	AC011893.3	-4.22	2.94e-05	0.00499	-0.23	-0.19	Mosquito bite size;	chr2:135825622	chr2:135820191~135823087:+
LUAD	cis	rs4811196	0.748	rs2880987	ENSG00000226144.2	RPS27AP3	4.22	2.94e-05	0.00499	0.21	0.19	Bone mineral density;	chr20:37858607	chr20:37049254~37049707:+
LUAD	cis	rs62246343	0.63	rs60771966	ENSG00000254485.4	RP11-380O24.1	4.22	2.94e-05	0.00499	0.35	0.19	Fibrinogen levels;	chr3:9465573	chr3:9292588~9363303:-
LUAD	cis	rs62246343	0.63	rs59302296	ENSG00000254485.4	RP11-380O24.1	4.22	2.94e-05	0.00499	0.35	0.19	Fibrinogen levels;	chr3:9465630	chr3:9292588~9363303:-
LUAD	cis	rs7976269	0.609	rs7979788	ENSG00000257176.2	RP11-996F15.2	-4.22	2.94e-05	0.00499	-0.2	-0.19	Male-pattern baldness;	chr12:29064827	chr12:29280418~29317848:-
LUAD	cis	rs2834288	0.653	rs4817600	ENSG00000237945.6	LINC00649	4.22	2.95e-05	0.00499	0.26	0.19	Gut microbiota (bacterial taxa);	chr21:33925224	chr21:33915534~33977691:+
LUAD	cis	rs4908769	0.627	rs301798	ENSG00000232912.4	RP5-1115A15.1	4.22	2.95e-05	0.005	0.18	0.19	Allergy;	chr1:8428505	chr1:8424645~8434838:+
LUAD	cis	rs11673344	0.504	rs4254428	ENSG00000276846.1	CTD-3220F14.3	4.22	2.95e-05	0.005	0.2	0.19	Obesity-related traits;	chr19:37093748	chr19:37314868~37315620:-
LUAD	cis	rs11673344	0.504	rs11084874	ENSG00000276846.1	CTD-3220F14.3	4.22	2.95e-05	0.005	0.2	0.19	Obesity-related traits;	chr19:37096667	chr19:37314868~37315620:-
LUAD	cis	rs7098414	0.511	rs7907575	ENSG00000226659.1	RP11-137H2.4	-4.22	2.95e-05	0.005	-0.25	-0.19	Post bronchodilator FEV1;	chr10:80392919	chr10:80529597~80535942:-
LUAD	cis	rs9860428	0.844	rs9838295	ENSG00000242770.2	RP11-180K7.1	4.22	2.95e-05	0.005	0.21	0.19	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112909438	chr3:112802478~112812819:+
LUAD	cis	rs4374383	0.884	rs870762	ENSG00000207383.1	Y_RNA	-4.22	2.95e-05	0.005	-0.23	-0.19	Hepatitis C induced liver fibrosis;	chr2:111987850	chr2:112579484~112579584:-
LUAD	cis	rs1075265	0.508	rs12621225	ENSG00000233266.1	HMGB1P31	4.22	2.95e-05	0.005	0.25	0.19	Chronotype;Morning vs. evening chronotype;	chr2:53710040	chr2:54051334~54051760:+
LUAD	cis	rs6964833	0.935	rs34762099	ENSG00000184616.8	AC004166.6	4.22	2.95e-05	0.005	0.27	0.19	Menarche (age at onset);	chr7:74636378	chr7:74906673~74913256:-
LUAD	cis	rs2548724	0.561	rs1584713	ENSG00000250682.4	LINC00491	4.22	2.95e-05	0.005	0.22	0.19	Type 2 diabetes;	chr5:102431585	chr5:102609156~102671559:-
LUAD	cis	rs42490	0.653	rs40453	ENSG00000251136.7	RP11-37B2.1	-4.22	2.95e-05	0.005	-0.19	-0.19	Leprosy;	chr8:89789817	chr8:89609409~89757727:-
LUAD	cis	rs42490	0.752	rs400411	ENSG00000251136.7	RP11-37B2.1	-4.22	2.95e-05	0.005	-0.19	-0.19	Leprosy;	chr8:89789871	chr8:89609409~89757727:-
LUAD	cis	rs2243480	1	rs937108	ENSG00000232559.3	GS1-124K5.12	4.22	2.95e-05	0.005	0.32	0.19	Diabetic kidney disease;	chr7:65963465	chr7:66554588~66576923:-
LUAD	cis	rs7098414	0.53	rs4146515	ENSG00000226659.1	RP11-137H2.4	-4.22	2.95e-05	0.00501	-0.25	-0.19	Post bronchodilator FEV1;	chr10:80356846	chr10:80529597~80535942:-
LUAD	cis	rs6539288	0.901	rs4964506	ENSG00000260329.1	RP11-412D9.4	-4.22	2.95e-05	0.00501	-0.2	-0.19	Total body bone mineral density;	chr12:106953307	chr12:106954029~106955497:-
LUAD	cis	rs9500256	0.966	rs1322446	ENSG00000266579.1	RP1-71H19.2	-4.22	2.95e-05	0.00501	-0.23	-0.19	Eosinophilic esophagitis (pediatric);	chr6:57985672	chr6:57493855~57497691:+
LUAD	cis	rs116175783	0.557	rs72877940	ENSG00000227403.1	AC009299.3	4.22	2.96e-05	0.00501	0.35	0.19	Intelligence (multi-trait analysis);	chr2:161403965	chr2:161244739~161249050:+
LUAD	cis	rs699371	0.525	rs10138386	ENSG00000270000.1	RP3-449M8.9	4.22	2.96e-05	0.00501	0.21	0.19	Height;	chr14:74434183	chr14:74471930~74472360:-
LUAD	cis	rs2742234	0.759	rs12241923	ENSG00000273008.1	RP11-351D16.3	4.22	2.96e-05	0.00501	0.2	0.19	Hirschsprung disease;	chr10:43217599	chr10:43136824~43138334:-
LUAD	cis	rs10129255	1	rs10129407	ENSG00000211967.3	IGHV3-53	-4.22	2.96e-05	0.00501	-0.15	-0.19	Kawasaki disease;	chr14:106767956	chr14:106592676~106593347:-
LUAD	cis	rs9860428	0.787	rs12489734	ENSG00000242770.2	RP11-180K7.1	4.22	2.96e-05	0.00501	0.21	0.19	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112847644	chr3:112802478~112812819:+
LUAD	cis	rs847577	0.609	rs17435847	ENSG00000272950.1	RP11-307C18.1	4.22	2.96e-05	0.00501	0.23	0.19	Breast cancer;	chr7:98163508	chr7:98322853~98323430:+
LUAD	cis	rs877356	1	rs877356	ENSG00000250378.1	RP11-119J18.1	-4.22	2.96e-05	0.00501	-0.34	-0.19	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (dichotomous);	chr5:135825729	chr5:135812667~135826582:+
LUAD	cis	rs8077577	0.708	rs9913139	ENSG00000273018.4	CTD-2303H24.2	-4.22	2.96e-05	0.00501	-0.26	-0.19	Obesity-related traits;	chr17:18250501	chr17:18511221~18551705:-
LUAD	cis	rs1334894	1	rs12527893	ENSG00000228559.1	RP3-340B19.3	-4.22	2.96e-05	0.00502	-0.39	-0.19	Coronary artery disease;	chr6:35617322	chr6:35544632~35545669:+
LUAD	cis	rs6714710	0.603	rs35424768	ENSG00000230606.9	AC159540.1	-4.22	2.96e-05	0.00502	-0.2	-0.19	Posterior cortical atrophy and Alzheimer's disease;	chr2:97779190	chr2:97416165~97433527:-
LUAD	cis	rs6714710	0.603	rs13020776	ENSG00000230606.9	AC159540.1	-4.22	2.96e-05	0.00502	-0.2	-0.19	Posterior cortical atrophy and Alzheimer's disease;	chr2:97786290	chr2:97416165~97433527:-
LUAD	cis	rs987710	0.568	rs5757008	ENSG00000211639.2	IGLV4-60	-4.22	2.96e-05	0.00502	-0.26	-0.19	Iron status biomarkers;Iron deficiency;	chr22:22135171	chr22:22162199~22162681:+
LUAD	cis	rs2562456	0.833	rs7258099	ENSG00000268081.1	RP11-678G14.2	4.22	2.96e-05	0.00502	0.29	0.19	Pain;	chr19:21352941	chr19:21554640~21569237:-
LUAD	cis	rs6802315	1	rs6802315	ENSG00000272087.1	RP11-379F4.7	4.22	2.96e-05	0.00502	0.2	0.19	Periodontitis (CDC/AAP);	chr3:158796571	chr3:158693120~158693768:-
LUAD	cis	rs6840360	0.571	rs7678080	ENSG00000270265.1	RP11-731D1.4	-4.22	2.96e-05	0.00502	-0.21	-0.19	Intelligence (multi-trait analysis);	chr4:151636198	chr4:151333775~151353224:-
LUAD	cis	rs1799949	0.965	rs799916	ENSG00000236383.6	LINC00854	4.22	2.96e-05	0.00502	0.14	0.19	Menopause (age at onset);	chr17:43091173	chr17:43216941~43305976:-
LUAD	cis	rs8048589	1	rs9925009	ENSG00000175604.2	RP11-276H1.3	-4.22	2.96e-05	0.00502	-0.26	-0.19	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12092495	chr16:12086746~12090302:-
LUAD	cis	rs12999542	0.706	rs11465623	ENSG00000234389.1	AC007278.3	4.22	2.96e-05	0.00502	0.3	0.19	Serum protein levels (sST2);	chr2:102376579	chr2:102438713~102440475:+
LUAD	cis	rs6125597	0.967	rs1079661	ENSG00000230758.1	SNAP23P	4.22	2.97e-05	0.00503	0.2	0.19	Intelligence (multi-trait analysis);	chr20:49234077	chr20:49038357~49038602:-
LUAD	cis	rs7829975	0.617	rs4841072	ENSG00000233609.3	RP11-62H7.2	-4.22	2.97e-05	0.00503	-0.15	-0.19	Mood instability;	chr8:8933743	chr8:8961200~8979025:+
LUAD	cis	rs9803723	0.826	rs12736320	ENSG00000261349.1	RP3-465N24.5	-4.22	2.97e-05	0.00503	-0.21	-0.19	Male-pattern baldness;	chr1:25137145	chr1:25266102~25267136:-
LUAD	cis	rs11673344	0.504	rs4806409	ENSG00000276846.1	CTD-3220F14.3	4.22	2.97e-05	0.00503	0.2	0.19	Obesity-related traits;	chr19:37097923	chr19:37314868~37315620:-
LUAD	cis	rs9467773	0.595	rs2451736	ENSG00000241549.7	GUSBP2	4.22	2.97e-05	0.00503	0.21	0.19	Intelligence (multi-trait analysis);	chr6:26620316	chr6:26871484~26956554:-
LUAD	cis	rs9309473	0.519	rs2421670	ENSG00000163016.8	ALMS1P	-4.22	2.97e-05	0.00503	-0.2	-0.19	Metabolite levels;	chr2:73659534	chr2:73644919~73685576:+
LUAD	cis	rs4460629	0.742	rs11581730	ENSG00000160766.13	GBAP1	-4.22	2.97e-05	0.00503	-0.19	-0.19	Serum magnesium levels;	chr1:155109682	chr1:155213821~155227422:-
LUAD	cis	rs4460629	0.742	rs7548955	ENSG00000160766.13	GBAP1	-4.22	2.97e-05	0.00503	-0.19	-0.19	Serum magnesium levels;	chr1:155109822	chr1:155213821~155227422:-
LUAD	cis	rs9309473	0.607	rs12478346	ENSG00000163016.8	ALMS1P	4.22	2.97e-05	0.00503	0.21	0.19	Metabolite levels;	chr2:73357232	chr2:73644919~73685576:+
LUAD	cis	rs36093844	0.698	rs1445498	ENSG00000279742.1	RP11-700A24.1	-4.22	2.97e-05	0.00503	-0.26	-0.19	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85815647	chr11:85852557~85854943:-
LUAD	cis	rs4840086	1	rs34085222	ENSG00000219755.1	RP1-199J3.5	4.22	2.97e-05	0.00503	0.23	0.19	Menarche (age at onset);	chr6:99758601	chr6:99575712~99576456:+
LUAD	cis	rs2823962	0.759	rs2027624	ENSG00000270093.1	AP000473.8	-4.22	2.97e-05	0.00503	-0.19	-0.19	Amyotrophic lateral sclerosis;	chr21:16641601	chr21:16643529~16645065:+
LUAD	cis	rs6479891	1	rs61853589	ENSG00000232075.1	MRPL35P2	4.22	2.97e-05	0.00503	0.31	0.19	Arthritis (juvenile idiopathic);	chr10:63427351	chr10:63634317~63634827:-
LUAD	cis	rs6479891	1	rs9414803	ENSG00000232075.1	MRPL35P2	4.22	2.97e-05	0.00503	0.31	0.19	Arthritis (juvenile idiopathic);	chr10:63428309	chr10:63634317~63634827:-
LUAD	cis	rs6479891	1	rs9415707	ENSG00000232075.1	MRPL35P2	4.22	2.97e-05	0.00503	0.31	0.19	Arthritis (juvenile idiopathic);	chr10:63428530	chr10:63634317~63634827:-
LUAD	cis	rs6479891	1	rs12413029	ENSG00000232075.1	MRPL35P2	4.22	2.97e-05	0.00503	0.31	0.19	Arthritis (juvenile idiopathic);	chr10:63429366	chr10:63634317~63634827:-
LUAD	cis	rs6479891	1	rs9415708	ENSG00000232075.1	MRPL35P2	4.22	2.97e-05	0.00503	0.31	0.19	Arthritis (juvenile idiopathic);	chr10:63430282	chr10:63634317~63634827:-
LUAD	cis	rs6479891	1	rs12784772	ENSG00000232075.1	MRPL35P2	4.22	2.97e-05	0.00503	0.31	0.19	Arthritis (juvenile idiopathic);	chr10:63435695	chr10:63634317~63634827:-
LUAD	cis	rs6479891	1	rs77494594	ENSG00000232075.1	MRPL35P2	4.22	2.97e-05	0.00503	0.31	0.19	Arthritis (juvenile idiopathic);	chr10:63437549	chr10:63634317~63634827:-
LUAD	cis	rs17685	0.712	rs1859792	ENSG00000280388.1	RP11-229D13.3	-4.22	2.97e-05	0.00503	-0.18	-0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76159946	chr7:76043977~76045963:-
LUAD	cis	rs8072100	0.688	rs7221224	ENSG00000228782.6	CTD-2026D20.3	-4.22	2.97e-05	0.00503	-0.21	-0.19	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47341695	chr17:47450568~47492492:-
LUAD	cis	rs12534093	0.562	rs6461716	ENSG00000234286.1	AC006026.13	-4.22	2.97e-05	0.00503	-0.25	-0.19	Infant length;Height;	chr7:23540935	chr7:23680195~23680786:-
LUAD	cis	rs6496932	0.503	rs7170085	ENSG00000202081.1	RNU6-1280P	-4.22	2.97e-05	0.00503	-0.26	-0.19	Central corneal thickness;Corneal structure;	chr15:85403879	chr15:85651522~85651628:-
LUAD	cis	rs9303029	1	rs2291394	ENSG00000265458.1	RP13-20L14.6	4.22	2.97e-05	0.00503	0.35	0.19	Protein quantitative trait loci;	chr17:82446018	chr17:82454273~82458521:-
LUAD	cis	rs35740288	0.822	rs17637142	ENSG00000259407.1	RP11-158M2.3	-4.22	2.97e-05	0.00503	-0.19	-0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85697272	chr15:85744109~85750281:-
LUAD	cis	rs1864585	0.619	rs73209922	ENSG00000255046.1	RP11-297N6.4	4.22	2.97e-05	0.00504	0.27	0.19	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10850999	chr8:11797928~11802568:-
LUAD	cis	rs17711722	0.565	rs4717276	ENSG00000237310.1	GS1-124K5.4	4.22	2.97e-05	0.00504	0.2	0.19	Calcium levels;	chr7:65829754	chr7:66493706~66495474:+
LUAD	cis	rs4840086	0.935	rs9403057	ENSG00000219755.1	RP1-199J3.5	4.22	2.97e-05	0.00504	0.23	0.19	Menarche (age at onset);	chr6:99756625	chr6:99575712~99576456:+
LUAD	cis	rs4938330	0.723	rs7931398	ENSG00000254851.1	RP11-109L13.1	4.22	2.98e-05	0.00504	0.27	0.19	Blood protein levels;	chr11:117008960	chr11:117135528~117138582:+
LUAD	cis	rs6763848	0.923	rs12631577	ENSG00000214073.2	RPL21P17	-4.22	2.98e-05	0.00504	-0.19	-0.19	Prostate cancer (SNP x SNP interaction);	chr3:1477353	chr3:1905651~1906125:+
LUAD	cis	rs910316	0.967	rs11159116	ENSG00000279594.1	RP11-950C14.10	4.22	2.98e-05	0.00504	0.22	0.19	Height;	chr14:75083881	chr14:75011269~75012851:-
LUAD	cis	rs6061231	0.597	rs624313	ENSG00000273619.1	RP5-908M14.9	4.22	2.98e-05	0.00504	0.18	0.19	Colorectal cancer;	chr20:62352356	chr20:62386303~62386970:-
LUAD	cis	rs6496667	0.514	rs62019353	ENSG00000214433.4	GOLGA2P8	4.22	2.98e-05	0.00504	0.27	0.19	Rheumatoid arthritis;	chr15:90390451	chr15:90291962~90295683:+
LUAD	cis	rs42490	0.752	rs411279	ENSG00000251136.7	RP11-37B2.1	-4.22	2.98e-05	0.00504	-0.19	-0.19	Leprosy;	chr8:89795929	chr8:89609409~89757727:-
LUAD	cis	rs13068223	1	rs13095806	ENSG00000243926.1	TIPARP-AS1	-4.22	2.98e-05	0.00504	-0.2	-0.19	Age-related hearing impairment (SNP x SNP interaction);	chr3:156738271	chr3:156671862~156674378:-
LUAD	cis	rs2273156	0.57	rs114200987	ENSG00000226677.3	IGBP1P1	-4.22	2.98e-05	0.00505	-0.3	-0.19	Immunoglobulin light chain (AL) amyloidosis;	chr14:35117710	chr14:34939324~34940332:+
LUAD	cis	rs3096299	0.503	rs9925045	ENSG00000261118.1	RP11-104N10.1	4.22	2.98e-05	0.00505	0.19	0.19	Multiple myeloma (IgH translocation);	chr16:89490068	chr16:89492017~89504460:-
LUAD	cis	rs750134	0.901	rs11114068	ENSG00000257221.1	RP11-689B22.2	-4.22	2.98e-05	0.00505	-0.27	-0.19	Low high density lipoprotein cholesterol levels;	chr12:108844183	chr12:108628687~108641318:+
LUAD	cis	rs4713118	0.516	rs7739216	ENSG00000226314.6	ZNF192P1	-4.22	2.98e-05	0.00505	-0.25	-0.19	Parkinson's disease;	chr6:28112168	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs35512245	ENSG00000226314.6	ZNF192P1	-4.22	2.98e-05	0.00505	-0.25	-0.19	Depression;	chr6:28112175	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs9380055	ENSG00000226314.6	ZNF192P1	-4.22	2.98e-05	0.00505	-0.25	-0.19	Depression;	chr6:28113851	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs9368553	ENSG00000226314.6	ZNF192P1	-4.22	2.98e-05	0.00505	-0.25	-0.19	Depression;	chr6:28114487	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs9368554	ENSG00000226314.6	ZNF192P1	-4.22	2.98e-05	0.00505	-0.25	-0.19	Depression;	chr6:28114933	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs4713137	ENSG00000226314.6	ZNF192P1	-4.22	2.98e-05	0.00505	-0.25	-0.19	Depression;	chr6:28115743	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs9348793	ENSG00000226314.6	ZNF192P1	-4.22	2.98e-05	0.00505	-0.25	-0.19	Depression;	chr6:28116411	chr6:28161781~28169594:+
LUAD	cis	rs4713118	0.586	rs6905516	ENSG00000226314.6	ZNF192P1	-4.22	2.98e-05	0.00505	-0.25	-0.19	Parkinson's disease;	chr6:28118700	chr6:28161781~28169594:+
LUAD	cis	rs4713118	0.586	rs6905522	ENSG00000226314.6	ZNF192P1	-4.22	2.98e-05	0.00505	-0.25	-0.19	Parkinson's disease;	chr6:28118701	chr6:28161781~28169594:+
LUAD	cis	rs4713118	0.586	rs9468290	ENSG00000226314.6	ZNF192P1	-4.22	2.98e-05	0.00505	-0.25	-0.19	Parkinson's disease;	chr6:28119896	chr6:28161781~28169594:+
LUAD	cis	rs4934494	0.813	rs34928397	ENSG00000240996.1	RP11-80H5.7	-4.22	2.98e-05	0.00505	-0.28	-0.19	Red blood cell count;	chr10:89766842	chr10:89694295~89697928:-
LUAD	cis	rs6723108	0.627	rs1446524	ENSG00000224043.6	CCNT2-AS1	-4.22	2.98e-05	0.00505	-0.23	-0.19	Type 2 diabetes;	chr2:134873761	chr2:134735464~134918710:-
LUAD	cis	rs9467773	0.62	rs2451732	ENSG00000241549.7	GUSBP2	-4.22	2.98e-05	0.00505	-0.2	-0.19	Intelligence (multi-trait analysis);	chr6:26622676	chr6:26871484~26956554:-
LUAD	cis	rs10938353	0.731	rs17600700	ENSG00000273369.1	RP11-700J17.1	4.21	2.98e-05	0.00505	0.28	0.19	Body mass index;	chr4:44613435	chr4:44693946~44694386:-
LUAD	cis	rs293748	0.771	rs34701667	ENSG00000250155.1	CTD-2353F22.1	-4.21	2.99e-05	0.00505	-0.25	-0.19	Obesity-related traits;	chr5:36799375	chr5:36666214~36725195:-
LUAD	cis	rs875971	0.571	rs160647	ENSG00000222364.1	RNU6-96P	4.21	2.99e-05	0.00505	0.25	0.19	Aortic root size;	chr7:66089365	chr7:66395191~66395286:+
LUAD	cis	rs9840812	0.725	rs696517	ENSG00000239213.4	NCK1-AS1	4.21	2.99e-05	0.00505	0.26	0.19	Fibrinogen levels;	chr3:136348813	chr3:136841726~136862054:-
LUAD	cis	rs6723108	0.517	rs6711390	ENSG00000224043.6	CCNT2-AS1	-4.21	2.99e-05	0.00506	-0.23	-0.19	Type 2 diabetes;	chr2:134871869	chr2:134735464~134918710:-
LUAD	cis	rs2346177	0.605	rs7598712	ENSG00000279254.1	RP11-536C12.1	-4.21	2.99e-05	0.00506	-0.19	-0.19	HDL cholesterol;	chr2:46433313	chr2:46668870~46670778:+
LUAD	cis	rs9543976	1	rs73223984	ENSG00000261105.4	LMO7-AS1	-4.21	2.99e-05	0.00506	-0.34	-0.19	Diabetic retinopathy;	chr13:75607005	chr13:75604700~75635994:-
LUAD	cis	rs9815354	0.857	rs6796078	ENSG00000273328.4	RP11-141M3.6	4.21	2.99e-05	0.00506	0.3	0.19	Pulse pressure;Diastolic blood pressure;	chr3:41976328	chr3:42809414~42908105:+
LUAD	cis	rs9921338	0.923	rs7186455	ENSG00000263080.1	RP11-485G7.5	4.21	2.99e-05	0.00506	0.25	0.19	Vein graft stenosis in coronary artery bypass grafting;	chr16:11333891	chr16:11341809~11345211:-
LUAD	cis	rs28386778	0.897	rs2584610	ENSG00000240280.5	TCAM1P	-4.21	2.99e-05	0.00506	-0.22	-0.19	Prudent dietary pattern;	chr17:63857423	chr17:63849292~63864379:+
LUAD	cis	rs7937890	0.572	rs2597202	ENSG00000254418.1	RP11-21L19.1	4.21	2.99e-05	0.00506	0.24	0.19	Mitochondrial DNA levels;	chr11:14463099	chr11:14262846~14273691:-
LUAD	cis	rs972578	0.561	rs2072883	ENSG00000230319.1	AL022476.2	4.21	2.99e-05	0.00506	0.21	0.19	Mean platelet volume;	chr22:43039662	chr22:43038585~43052366:+
LUAD	cis	rs10885396	0.967	rs7094463	ENSG00000233547.1	RP11-57H14.2	4.21	2.99e-05	0.00506	0.19	0.19	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr10:112952224	chr10:112950646~112951875:-
LUAD	cis	rs10090774	0.71	rs10103745	ENSG00000280303.2	ERICD	-4.21	2.99e-05	0.00507	-0.21	-0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140680544	chr8:140636281~140638283:+
LUAD	cis	rs10761482	0.601	rs10733764	ENSG00000254271.1	RP11-131N11.4	4.21	2.99e-05	0.00507	0.23	0.19	Schizophrenia;	chr10:60450587	chr10:60734342~60741828:+
LUAD	cis	rs7204230	1	rs72797684	ENSG00000261291.1	RP11-295M3.2	4.21	2.99e-05	0.00507	0.24	0.19	Fibrinogen;	chr16:53183940	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs11859591	ENSG00000261291.1	RP11-295M3.2	-4.21	2.99e-05	0.00507	-0.24	-0.19	Fibrinogen;	chr16:53185507	chr16:53168522~53169450:+
LUAD	cis	rs6471393	0.929	rs4464937	ENSG00000253848.1	RP11-10N23.5	4.21	2.99e-05	0.00507	0.23	0.19	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93744689	chr8:93741193~93744534:+
LUAD	cis	rs848490	1	rs62460740	ENSG00000214293.7	APTR	4.21	3e-05	0.00507	0.25	0.19	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77780122	chr7:77657660~77696265:-
LUAD	cis	rs116175783	0.557	rs3769963	ENSG00000227403.1	AC009299.3	4.21	3e-05	0.00507	0.35	0.19	Intelligence (multi-trait analysis);	chr2:161350999	chr2:161244739~161249050:+
LUAD	cis	rs3742264	1	rs9562633	ENSG00000235903.6	CPB2-AS1	-4.21	3e-05	0.00507	-0.24	-0.19	Blood protein levels;	chr13:46068624	chr13:46052806~46113332:+
LUAD	cis	rs3742264	1	rs9567610	ENSG00000235903.6	CPB2-AS1	-4.21	3e-05	0.00507	-0.24	-0.19	Blood protein levels;	chr13:46068632	chr13:46052806~46113332:+
LUAD	cis	rs3742264	1	rs9562636	ENSG00000235903.6	CPB2-AS1	-4.21	3e-05	0.00507	-0.24	-0.19	Blood protein levels;	chr13:46068889	chr13:46052806~46113332:+
LUAD	cis	rs3742264	1	rs7990092	ENSG00000235903.6	CPB2-AS1	-4.21	3e-05	0.00507	-0.24	-0.19	Blood protein levels;	chr13:46069154	chr13:46052806~46113332:+
LUAD	cis	rs3742264	1	rs7988836	ENSG00000235903.6	CPB2-AS1	-4.21	3e-05	0.00507	-0.24	-0.19	Blood protein levels;	chr13:46069238	chr13:46052806~46113332:+
LUAD	cis	rs3742264	1	rs7993537	ENSG00000235903.6	CPB2-AS1	-4.21	3e-05	0.00507	-0.24	-0.19	Blood protein levels;	chr13:46069426	chr13:46052806~46113332:+
LUAD	cis	rs3742264	1	rs7993567	ENSG00000235903.6	CPB2-AS1	-4.21	3e-05	0.00507	-0.24	-0.19	Blood protein levels;	chr13:46069471	chr13:46052806~46113332:+
LUAD	cis	rs3742264	1	rs7995615	ENSG00000235903.6	CPB2-AS1	-4.21	3e-05	0.00507	-0.24	-0.19	Blood protein levels;	chr13:46069673	chr13:46052806~46113332:+
LUAD	cis	rs6832769	0.922	rs9993675	ENSG00000272969.1	RP11-528I4.2	4.21	3e-05	0.00507	0.2	0.19	Personality dimensions;	chr4:55377355	chr4:55547112~55547889:+
LUAD	cis	rs7204230	0.81	rs7196485	ENSG00000261291.1	RP11-295M3.2	4.21	3e-05	0.00507	0.24	0.19	Fibrinogen;	chr16:53170065	chr16:53168522~53169450:+
LUAD	cis	rs7208859	0.673	rs999797	ENSG00000263603.1	CTD-2349P21.5	-4.21	3e-05	0.00507	-0.34	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832311	chr17:30729469~30731202:+
LUAD	cis	rs4819052	0.765	rs2838854	ENSG00000237664.1	LINC00316	-4.21	3e-05	0.00507	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260449	chr21:45338590~45341990:-
LUAD	cis	rs957448	1	rs10956915	ENSG00000254315.1	RP11-267M23.3	4.21	3e-05	0.00507	0.24	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94502362	chr8:94533628~94534391:+
LUAD	cis	rs4843747	0.519	rs12599755	ENSG00000205037.2	RP11-863P13.4	4.21	3e-05	0.00507	0.27	0.19	Menopause (age at onset);	chr16:88073400	chr16:88088041~88100985:-
LUAD	cis	rs6785206	0.892	rs6793907	ENSG00000242551.2	POU5F1P6	4.21	3e-05	0.00507	0.36	0.19	Lymphocyte percentage of white cells;	chr3:128672783	chr3:128674735~128677005:-
LUAD	cis	rs763121	0.853	rs5750664	ENSG00000225450.1	RP3-508I15.14	-4.21	3e-05	0.00507	-0.19	-0.19	Menopause (age at onset);	chr22:38676764	chr22:38739003~38749041:+
LUAD	cis	rs763121	0.626	rs5757236	ENSG00000225450.1	RP3-508I15.14	-4.21	3e-05	0.00507	-0.19	-0.19	Menopause (age at onset);	chr22:38677819	chr22:38739003~38749041:+
LUAD	cis	rs763121	0.853	rs6001191	ENSG00000225450.1	RP3-508I15.14	-4.21	3e-05	0.00507	-0.19	-0.19	Menopause (age at onset);	chr22:38678447	chr22:38739003~38749041:+
LUAD	cis	rs10197140	0.857	rs12329344	ENSG00000235721.1	AC013268.3	-4.21	3e-05	0.00508	-0.21	-0.19	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110892255	chr2:110007675~110010783:+
LUAD	cis	rs11157436	0.602	rs4982569	ENSG00000211812.1	TRAV26-2	-4.21	3e-05	0.00508	-0.19	-0.19	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22169716	chr14:22202583~22203368:+
LUAD	cis	rs7061710	0.711	rs55639094	ENSG00000271811.1	RP1-79C4.4	-4.21	3e-05	0.00508	-0.29	-0.19	Blood metabolite levels;	chr1:171149238	chr1:170667381~170669425:+
LUAD	cis	rs28386778	0.897	rs2584615	ENSG00000240280.5	TCAM1P	-4.21	3e-05	0.00508	-0.22	-0.19	Prudent dietary pattern;	chr17:63850414	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.865	rs2727276	ENSG00000240280.5	TCAM1P	-4.21	3e-05	0.00508	-0.22	-0.19	Prudent dietary pattern;	chr17:63852349	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.863	rs2727355	ENSG00000240280.5	TCAM1P	-4.21	3e-05	0.00508	-0.22	-0.19	Prudent dietary pattern;	chr17:63854430	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.799	rs2584612	ENSG00000240280.5	TCAM1P	-4.21	3e-05	0.00508	-0.22	-0.19	Prudent dietary pattern;	chr17:63854844	chr17:63849292~63864379:+
LUAD	cis	rs950880	1	rs13019081	ENSG00000234389.1	AC007278.3	4.21	3e-05	0.00508	0.18	0.19	Serum protein levels (sST2);	chr2:102334362	chr2:102438713~102440475:+
LUAD	cis	rs11051970	0.592	rs11052002	ENSG00000274964.1	RP11-817I4.1	-4.21	3e-05	0.00508	-0.25	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr12:32437920	chr12:32339368~32340724:+
LUAD	cis	rs7204230	0.961	rs17394050	ENSG00000261291.1	RP11-295M3.2	4.21	3e-05	0.00508	0.23	0.19	Fibrinogen;	chr16:53201509	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs62048048	ENSG00000261291.1	RP11-295M3.2	4.21	3e-05	0.00508	0.23	0.19	Fibrinogen;	chr16:53201992	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs67384393	ENSG00000261291.1	RP11-295M3.2	4.21	3e-05	0.00508	0.23	0.19	Fibrinogen;	chr16:53202243	chr16:53168522~53169450:+
LUAD	cis	rs454217	0.846	rs427600	ENSG00000277851.1	RP11-756G20.1	4.21	3e-05	0.00508	0.19	0.19	Smoking quantity;	chr12:92326886	chr12:92247756~92363832:-
LUAD	cis	rs454217	0.818	rs1661031	ENSG00000277851.1	RP11-756G20.1	4.21	3e-05	0.00508	0.19	0.19	Smoking quantity;	chr12:92328010	chr12:92247756~92363832:-
LUAD	cis	rs2823962	0.759	rs2211987	ENSG00000270093.1	AP000473.8	-4.21	3.01e-05	0.00508	-0.2	-0.19	Amyotrophic lateral sclerosis;	chr21:16644337	chr21:16643529~16645065:+
LUAD	cis	rs2823962	0.759	rs2211988	ENSG00000270093.1	AP000473.8	-4.21	3.01e-05	0.00508	-0.2	-0.19	Amyotrophic lateral sclerosis;	chr21:16644441	chr21:16643529~16645065:+
LUAD	cis	rs2823962	0.759	rs2211990	ENSG00000270093.1	AP000473.8	-4.21	3.01e-05	0.00508	-0.2	-0.19	Amyotrophic lateral sclerosis;	chr21:16644646	chr21:16643529~16645065:+
LUAD	cis	rs2823962	0.687	rs2154727	ENSG00000270093.1	AP000473.8	-4.21	3.01e-05	0.00508	-0.2	-0.19	Amyotrophic lateral sclerosis;	chr21:16645447	chr21:16643529~16645065:+
LUAD	cis	rs9341808	0.935	rs1535825	ENSG00000260645.1	RP11-250B2.5	-4.21	3.01e-05	0.00509	-0.17	-0.19	Sitting height ratio;	chr6:80228869	chr6:80466958~80469080:+
LUAD	cis	rs7429990	0.932	rs7630685	ENSG00000228638.1	FCF1P2	4.21	3.01e-05	0.00509	0.23	0.19	Educational attainment (years of education);	chr3:48089680	chr3:48290793~48291375:-
LUAD	cis	rs2933343	0.649	rs1683786	ENSG00000231305.3	RP11-723O4.2	4.21	3.01e-05	0.00509	0.2	0.19	IgG glycosylation;	chr3:128908109	chr3:128861313~128871540:-
LUAD	cis	rs2933343	0.7	rs876754	ENSG00000231305.3	RP11-723O4.2	4.21	3.01e-05	0.00509	0.2	0.19	IgG glycosylation;	chr3:128908910	chr3:128861313~128871540:-
LUAD	cis	rs13113518	1	rs4864993	ENSG00000272969.1	RP11-528I4.2	4.21	3.01e-05	0.00509	0.2	0.19	Height;	chr4:55450662	chr4:55547112~55547889:+
LUAD	cis	rs34783982	0.764	rs12440803	ENSG00000261441.1	RP11-217B1.2	4.21	3.01e-05	0.00509	0.26	0.19	Squamous cell lung carcinoma;	chr15:88953869	chr15:89335053~89336161:+
LUAD	cis	rs9322193	0.886	rs9718079	ENSG00000268592.3	RAET1E-AS1	4.21	3.01e-05	0.00509	0.23	0.19	Lung cancer;	chr6:149645947	chr6:149863494~149919507:+
LUAD	cis	rs1126510	0.565	rs75660000	ENSG00000269637.1	RPL12P41	-4.21	3.01e-05	0.00509	-0.25	-0.19	Ulcerative colitis;	chr19:46615970	chr19:46219423~46219920:+
LUAD	cis	rs62246343	0.605	rs9842540	ENSG00000206573.7	THUMPD3-AS1	-4.21	3.01e-05	0.00509	-0.18	-0.19	Fibrinogen levels;	chr3:9399389	chr3:9349689~9398579:-
LUAD	cis	rs9393777	0.92	rs67859638	ENSG00000219392.1	RP1-265C24.5	-4.21	3.01e-05	0.00509	-0.42	-0.19	Intelligence (multi-trait analysis);	chr6:27390199	chr6:28115628~28116551:+
LUAD	cis	rs2154319	0.609	rs11589478	ENSG00000235358.1	RP11-399E6.1	-4.21	3.01e-05	0.00509	-0.23	-0.19	Height;	chr1:41270555	chr1:41242373~41284861:+
LUAD	cis	rs7760535	0.763	rs10457240	ENSG00000230177.1	RP5-1112D6.4	-4.21	3.01e-05	0.00509	-0.17	-0.19	Metabolic traits;	chr6:111527671	chr6:111277932~111278742:+
LUAD	cis	rs4819052	1	rs13052356	ENSG00000215447.6	BX322557.10	-4.21	3.01e-05	0.0051	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243673	chr21:45288052~45291738:+
LUAD	cis	rs4819052	1	rs28628220	ENSG00000215447.6	BX322557.10	-4.21	3.01e-05	0.0051	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243826	chr21:45288052~45291738:+
LUAD	cis	rs6496932	1	rs11638110	ENSG00000202081.1	RNU6-1280P	4.21	3.01e-05	0.0051	0.28	0.19	Central corneal thickness;Corneal structure;	chr15:85279653	chr15:85651522~85651628:-
LUAD	cis	rs2348418	0.864	rs7960369	ENSG00000244712.1	RP11-874G11.1	4.21	3.01e-05	0.0051	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28561569	chr12:28564678~28565141:-
LUAD	cis	rs848490	0.889	rs62462688	ENSG00000214293.7	APTR	4.21	3.01e-05	0.0051	0.25	0.19	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77886105	chr7:77657660~77696265:-
LUAD	cis	rs6988985	0.618	rs62525983	ENSG00000247317.3	RP11-273G15.2	-4.21	3.01e-05	0.0051	-0.22	-0.19	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142907570	chr8:142981738~143018437:-
LUAD	cis	rs7829975	0.774	rs57312668	ENSG00000233609.3	RP11-62H7.2	4.21	3.02e-05	0.0051	0.16	0.19	Mood instability;	chr8:8822967	chr8:8961200~8979025:+
LUAD	cis	rs11673344	0.526	rs55909413	ENSG00000226686.6	LINC01535	4.21	3.02e-05	0.0051	0.23	0.19	Obesity-related traits;	chr19:37578663	chr19:37251912~37265535:+
LUAD	cis	rs11673344	0.526	rs55865869	ENSG00000226686.6	LINC01535	4.21	3.02e-05	0.0051	0.23	0.19	Obesity-related traits;	chr19:37578683	chr19:37251912~37265535:+
LUAD	cis	rs11673344	0.526	rs73033122	ENSG00000226686.6	LINC01535	4.21	3.02e-05	0.0051	0.23	0.19	Obesity-related traits;	chr19:37586006	chr19:37251912~37265535:+
LUAD	cis	rs1864585	0.52	rs73208781	ENSG00000255046.1	RP11-297N6.4	4.21	3.02e-05	0.0051	0.27	0.19	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10819988	chr8:11797928~11802568:-
LUAD	cis	rs9341808	0.754	rs3805907	ENSG00000272129.1	RP11-250B2.6	-4.21	3.02e-05	0.0051	-0.22	-0.19	Sitting height ratio;	chr6:80263948	chr6:80355424~80356859:+
LUAD	cis	rs2243480	1	rs2462569	ENSG00000232559.3	GS1-124K5.12	-4.21	3.02e-05	0.0051	-0.31	-0.19	Diabetic kidney disease;	chr7:66009859	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs1546059	ENSG00000229886.1	RP5-1132H15.3	-4.21	3.02e-05	0.0051	-0.32	-0.19	Diabetic kidney disease;	chr7:66189722	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs6958289	ENSG00000229886.1	RP5-1132H15.3	-4.21	3.02e-05	0.0051	-0.32	-0.19	Diabetic kidney disease;	chr7:66192124	chr7:66025126~66031544:-
LUAD	cis	rs7760535	0.811	rs1002475	ENSG00000230177.1	RP5-1112D6.4	-4.21	3.02e-05	0.0051	-0.17	-0.19	Metabolic traits;	chr6:111388386	chr6:111277932~111278742:+
LUAD	cis	rs9400467	0.528	rs11153288	ENSG00000230177.1	RP5-1112D6.4	-4.21	3.02e-05	0.0051	-0.17	-0.19	Amino acid levels;Blood metabolite levels;	chr6:111394035	chr6:111277932~111278742:+
LUAD	cis	rs9400467	0.528	rs11153290	ENSG00000230177.1	RP5-1112D6.4	-4.21	3.02e-05	0.0051	-0.17	-0.19	Amino acid levels;Blood metabolite levels;	chr6:111396929	chr6:111277932~111278742:+
LUAD	cis	rs9400467	0.528	rs11153291	ENSG00000230177.1	RP5-1112D6.4	-4.21	3.02e-05	0.0051	-0.17	-0.19	Amino acid levels;Blood metabolite levels;	chr6:111398927	chr6:111277932~111278742:+
LUAD	cis	rs9400467	0.528	rs11153292	ENSG00000230177.1	RP5-1112D6.4	-4.21	3.02e-05	0.0051	-0.17	-0.19	Amino acid levels;Blood metabolite levels;	chr6:111401176	chr6:111277932~111278742:+
LUAD	cis	rs9400467	0.528	rs12190634	ENSG00000230177.1	RP5-1112D6.4	-4.21	3.02e-05	0.0051	-0.17	-0.19	Amino acid levels;Blood metabolite levels;	chr6:111403957	chr6:111277932~111278742:+
LUAD	cis	rs9400467	0.508	rs11153293	ENSG00000230177.1	RP5-1112D6.4	-4.21	3.02e-05	0.0051	-0.17	-0.19	Amino acid levels;Blood metabolite levels;	chr6:111404696	chr6:111277932~111278742:+
LUAD	cis	rs9400467	0.508	rs11756643	ENSG00000230177.1	RP5-1112D6.4	-4.21	3.02e-05	0.0051	-0.17	-0.19	Amino acid levels;Blood metabolite levels;	chr6:111404943	chr6:111277932~111278742:+
LUAD	cis	rs9400467	0.508	rs11153294	ENSG00000230177.1	RP5-1112D6.4	-4.21	3.02e-05	0.0051	-0.17	-0.19	Amino acid levels;Blood metabolite levels;	chr6:111409043	chr6:111277932~111278742:+
LUAD	cis	rs2823962	0.759	rs2823932	ENSG00000270093.1	AP000473.8	-4.21	3.02e-05	0.0051	-0.2	-0.19	Amyotrophic lateral sclerosis;	chr21:16647784	chr21:16643529~16645065:+
LUAD	cis	rs1023500	0.505	rs134887	ENSG00000205702.9	CYP2D7	4.21	3.02e-05	0.0051	0.15	0.19	Schizophrenia;	chr22:42278233	chr22:42140203~42144577:-
LUAD	cis	rs13113518	1	rs4864546	ENSG00000272969.1	RP11-528I4.2	4.21	3.02e-05	0.00511	0.19	0.19	Height;	chr4:55537960	chr4:55547112~55547889:+
LUAD	cis	rs8030379	1	rs11259928	ENSG00000230373.7	GOLGA6L5P	-4.21	3.02e-05	0.00511	-0.17	-0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83899343	chr15:84507885~84516814:-
LUAD	cis	rs7893279	0.505	rs4748497	ENSG00000225527.1	RP11-383B4.4	4.21	3.02e-05	0.00511	0.27	0.19	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18618105	chr10:18531849~18533336:-
LUAD	cis	rs17406451	0.759	rs12989996	ENSG00000279873.2	LINC01126	4.21	3.02e-05	0.00511	0.16	0.19	Mitochondrial DNA levels;	chr2:43425030	chr2:43227210~43228855:+
LUAD	cis	rs1075265	0.836	rs11687324	ENSG00000272156.1	RP11-477N3.1	-4.21	3.02e-05	0.00511	-0.23	-0.19	Chronotype;Morning vs. evening chronotype;	chr2:54046589	chr2:54082554~54085066:+
LUAD	cis	rs1008375	1	rs7436403	ENSG00000249502.1	AC006160.5	4.21	3.02e-05	0.00511	0.18	0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17691062	chr4:17587467~17614571:-
LUAD	cis	rs755249	0.583	rs61779328	ENSG00000228060.1	RP11-69E11.8	-4.21	3.03e-05	0.00511	-0.21	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39487795	chr1:39565160~39573203:+
LUAD	cis	rs58106596	0.517	rs17271845	ENSG00000237641.1	RP11-690I21.1	-4.21	3.03e-05	0.00511	-0.18	-0.19	Lymphocyte counts;White blood cell count;	chr2:231788463	chr2:231789481~231789887:-
LUAD	cis	rs4578769	0.569	rs12958551	ENSG00000265943.1	RP11-739L10.1	4.21	3.03e-05	0.00511	0.24	0.19	Eosinophil percentage of white cells;	chr18:22897885	chr18:22699481~22933764:-
LUAD	cis	rs7819412	0.521	rs4451268	ENSG00000255046.1	RP11-297N6.4	4.21	3.03e-05	0.00511	0.22	0.19	Triglycerides;	chr8:11177350	chr8:11797928~11802568:-
LUAD	cis	rs13113518	1	rs13132420	ENSG00000272969.1	RP11-528I4.2	-4.21	3.03e-05	0.00511	-0.19	-0.19	Height;	chr4:55526646	chr4:55547112~55547889:+
LUAD	cis	rs9646944	0.501	rs2293223	ENSG00000234389.1	AC007278.3	4.21	3.03e-05	0.00511	0.21	0.19	Blood protein levels;	chr2:102419008	chr2:102438713~102440475:+
LUAD	cis	rs80028505	0.908	rs60909394	ENSG00000271304.1	DPRXP2	4.21	3.03e-05	0.00512	0.35	0.19	Foot ulcer in diabetes and neuropathy;	chr6:36087155	chr6:35989515~35990436:-
LUAD	cis	rs1979679	0.879	rs980920	ENSG00000278733.1	RP11-425D17.1	4.21	3.03e-05	0.00512	0.25	0.19	Ossification of the posterior longitudinal ligament of the spine;	chr12:28316178	chr12:28185625~28186190:-
LUAD	cis	rs9549367	0.588	rs9549360	ENSG00000269125.1	RP11-98F14.11	-4.21	3.03e-05	0.00512	-0.29	-0.19	Platelet distribution width;	chr13:113238718	chr13:113165002~113165183:-
LUAD	cis	rs2018683	0.739	rs10233884	ENSG00000228421.2	AC005013.5	4.21	3.03e-05	0.00512	0.21	0.19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28932690	chr7:28957667~28959345:+
LUAD	cis	rs4664293	0.867	rs6720304	ENSG00000226266.5	AC009961.3	-4.21	3.03e-05	0.00512	-0.27	-0.19	Monocyte percentage of white cells;	chr2:159787321	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs3764968	ENSG00000226266.5	AC009961.3	-4.21	3.03e-05	0.00512	-0.27	-0.19	Monocyte percentage of white cells;	chr2:159790579	chr2:159670708~159712435:-
LUAD	cis	rs4664293	0.867	rs6740910	ENSG00000226266.5	AC009961.3	-4.21	3.03e-05	0.00512	-0.27	-0.19	Monocyte percentage of white cells;	chr2:159792709	chr2:159670708~159712435:-
LUAD	cis	rs4934494	0.911	rs6586213	ENSG00000240996.1	RP11-80H5.7	-4.21	3.03e-05	0.00512	-0.25	-0.19	Red blood cell count;	chr10:89656327	chr10:89694295~89697928:-
LUAD	cis	rs3120667	0.79	rs12049036	ENSG00000237975.5	FLG-AS1	4.21	3.03e-05	0.00512	0.31	0.19	Eating disorders;	chr1:152417364	chr1:152168125~152445456:+
LUAD	cis	rs4843747	0.636	rs11117358	ENSG00000205037.2	RP11-863P13.4	4.21	3.03e-05	0.00512	0.27	0.19	Menopause (age at onset);	chr16:88071447	chr16:88088041~88100985:-
LUAD	cis	rs728616	0.867	rs41302709	ENSG00000225484.5	NUTM2B-AS1	-4.21	3.03e-05	0.00512	-0.39	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80047522	chr10:79663088~79826594:-
LUAD	cis	rs6964587	0.967	rs10231350	ENSG00000188693.7	CYP51A1-AS1	-4.21	3.03e-05	0.00512	-0.22	-0.19	Breast cancer;	chr7:92179185	chr7:92134604~92180725:+
LUAD	cis	rs10129255	0.5	rs2105989	ENSG00000253209.1	IGHV3-65	4.21	3.03e-05	0.00512	0.15	0.19	Kawasaki disease;	chr14:106682199	chr14:106666092~106666532:-
LUAD	cis	rs2281636	0.66	rs61871318	ENSG00000233690.1	EBAG9P1	4.21	3.03e-05	0.00512	0.19	0.19	Obesity-related traits;	chr10:99606784	chr10:99697407~99697949:-
LUAD	cis	rs2976388	0.507	rs13259549	ENSG00000253741.1	CTD-2292P10.4	-4.21	3.03e-05	0.00512	-0.23	-0.19	Urinary tract infection frequency;	chr8:142757101	chr8:142702252~142726973:-
LUAD	cis	rs950169	0.92	rs11637666	ENSG00000275120.1	RP11-182J1.17	4.21	3.03e-05	0.00513	0.31	0.19	Schizophrenia;	chr15:84035122	chr15:84599434~84606463:-
LUAD	cis	rs853679	0.517	rs17711344	ENSG00000280107.1	AL022393.9	4.21	3.03e-05	0.00513	0.25	0.19	Depression;	chr6:28109824	chr6:28170845~28172521:+
LUAD	cis	rs2735413	0.563	rs8046446	ENSG00000276007.1	RP11-358L22.3	4.21	3.04e-05	0.00513	0.26	0.19	Systolic blood pressure (alcohol consumption interaction);	chr16:78015689	chr16:78123243~78124332:+
LUAD	cis	rs6539288	0.901	rs4964507	ENSG00000260329.1	RP11-412D9.4	-4.21	3.04e-05	0.00513	-0.2	-0.19	Total body bone mineral density;	chr12:106954979	chr12:106954029~106955497:-
LUAD	cis	rs6539288	0.835	rs2041893	ENSG00000260329.1	RP11-412D9.4	-4.21	3.04e-05	0.00513	-0.2	-0.19	Total body bone mineral density;	chr12:106956598	chr12:106954029~106955497:-
LUAD	cis	rs2243480	0.901	rs778687	ENSG00000229886.1	RP5-1132H15.3	4.21	3.04e-05	0.00513	0.32	0.19	Diabetic kidney disease;	chr7:66370832	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs778704	ENSG00000229886.1	RP5-1132H15.3	4.21	3.04e-05	0.00513	0.32	0.19	Diabetic kidney disease;	chr7:66398480	chr7:66025126~66031544:-
LUAD	cis	rs2243480	0.901	rs778693	ENSG00000229886.1	RP5-1132H15.3	4.21	3.04e-05	0.00513	0.32	0.19	Diabetic kidney disease;	chr7:66407358	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs778691	ENSG00000229886.1	RP5-1132H15.3	4.21	3.04e-05	0.00513	0.32	0.19	Diabetic kidney disease;	chr7:66408105	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs13235972	ENSG00000229886.1	RP5-1132H15.3	4.21	3.04e-05	0.00513	0.32	0.19	Diabetic kidney disease;	chr7:66418618	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs34192067	ENSG00000229886.1	RP5-1132H15.3	4.21	3.04e-05	0.00513	0.32	0.19	Diabetic kidney disease;	chr7:66422670	chr7:66025126~66031544:-
LUAD	cis	rs755249	0.501	rs661316	ENSG00000182109.6	RP11-69E11.4	4.21	3.04e-05	0.00513	0.21	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39165625	chr1:39522280~39546187:-
LUAD	cis	rs6558530	0.615	rs12674711	ENSG00000253982.1	CTD-2336O2.1	4.21	3.04e-05	0.00513	0.25	0.19	Systolic blood pressure;	chr8:1751442	chr8:1761990~1764502:-
LUAD	cis	rs12908161	0.683	rs12903256	ENSG00000259295.5	CSPG4P12	4.21	3.04e-05	0.00513	0.24	0.19	Schizophrenia;	chr15:84764910	chr15:85191438~85213905:+
LUAD	cis	rs9467773	0.62	rs2101581	ENSG00000241549.7	GUSBP2	4.21	3.04e-05	0.00513	0.21	0.19	Intelligence (multi-trait analysis);	chr6:26622541	chr6:26871484~26956554:-
LUAD	cis	rs6840360	0.571	rs7685697	ENSG00000270265.1	RP11-731D1.4	-4.21	3.04e-05	0.00513	-0.21	-0.19	Intelligence (multi-trait analysis);	chr4:151637697	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.593	rs10022023	ENSG00000270265.1	RP11-731D1.4	-4.21	3.04e-05	0.00513	-0.21	-0.19	Intelligence (multi-trait analysis);	chr4:151639579	chr4:151333775~151353224:-
LUAD	cis	rs7940646	0.812	rs11042906	ENSG00000246308.1	RP11-685M7.3	4.21	3.04e-05	0.00513	0.23	0.19	Platelet aggregation;	chr11:10643688	chr11:10809297~10822931:+
LUAD	cis	rs34783982	0.881	rs12437678	ENSG00000261441.1	RP11-217B1.2	-4.21	3.04e-05	0.00513	-0.25	-0.19	Squamous cell lung carcinoma;	chr15:88953853	chr15:89335053~89336161:+
LUAD	cis	rs911555	0.755	rs35233301	ENSG00000244691.1	RPL10AP1	4.21	3.04e-05	0.00513	0.25	0.19	Intelligence (multi-trait analysis);	chr14:103418954	chr14:103412119~103412761:-
LUAD	cis	rs6754311	0.731	rs12988076	ENSG00000226806.1	AC011893.3	-4.21	3.04e-05	0.00513	-0.23	-0.19	Mosquito bite size;	chr2:135812278	chr2:135820191~135823087:+
LUAD	cis	rs6754311	0.731	rs6719488	ENSG00000226806.1	AC011893.3	-4.21	3.04e-05	0.00513	-0.23	-0.19	Mosquito bite size;	chr2:135817629	chr2:135820191~135823087:+
LUAD	cis	rs6754311	0.731	rs892715	ENSG00000226806.1	AC011893.3	-4.21	3.04e-05	0.00513	-0.23	-0.19	Mosquito bite size;	chr2:135819007	chr2:135820191~135823087:+
LUAD	cis	rs6754311	0.731	rs2164210	ENSG00000226806.1	AC011893.3	-4.21	3.04e-05	0.00513	-0.23	-0.19	Mosquito bite size;	chr2:135822717	chr2:135820191~135823087:+
LUAD	cis	rs9341808	0.718	rs9361584	ENSG00000272129.1	RP11-250B2.6	4.21	3.04e-05	0.00513	0.23	0.19	Sitting height ratio;	chr6:80110229	chr6:80355424~80356859:+
LUAD	cis	rs9341808	0.718	rs9359408	ENSG00000272129.1	RP11-250B2.6	4.21	3.04e-05	0.00513	0.23	0.19	Sitting height ratio;	chr6:80110415	chr6:80355424~80356859:+
LUAD	cis	rs9341808	0.718	rs9443734	ENSG00000272129.1	RP11-250B2.6	4.21	3.04e-05	0.00513	0.23	0.19	Sitting height ratio;	chr6:80110576	chr6:80355424~80356859:+
LUAD	cis	rs9341808	0.718	rs9443735	ENSG00000272129.1	RP11-250B2.6	4.21	3.04e-05	0.00513	0.23	0.19	Sitting height ratio;	chr6:80110757	chr6:80355424~80356859:+
LUAD	cis	rs75920871	0.688	rs77320801	ENSG00000254851.1	RP11-109L13.1	-4.21	3.04e-05	0.00513	-0.41	-0.19	Subjective well-being;	chr11:116965633	chr11:117135528~117138582:+
LUAD	cis	rs4374383	0.884	rs1996328	ENSG00000207383.1	Y_RNA	-4.21	3.04e-05	0.00513	-0.23	-0.19	Hepatitis C induced liver fibrosis;	chr2:111923164	chr2:112579484~112579584:-
LUAD	cis	rs4374383	0.884	rs4468823	ENSG00000207383.1	Y_RNA	-4.21	3.04e-05	0.00513	-0.23	-0.19	Hepatitis C induced liver fibrosis;	chr2:111926794	chr2:112579484~112579584:-
LUAD	cis	rs2227564	0.62	rs4746148	ENSG00000271816.1	BMS1P4	4.21	3.04e-05	0.00513	0.18	0.19	Crohn's disease;Inflammatory bowel disease;	chr10:73774730	chr10:73699151~73730487:-
LUAD	cis	rs755249	0.565	rs722357	ENSG00000228060.1	RP11-69E11.8	4.21	3.04e-05	0.00513	0.16	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39479096	chr1:39565160~39573203:+
LUAD	cis	rs11009175	0.547	rs10827196	ENSG00000273038.2	RP11-479G22.8	-4.21	3.04e-05	0.00513	-0.23	-0.19	Depression (quantitative trait);	chr10:33105729	chr10:32887255~32889311:-
LUAD	cis	rs72615157	0.613	rs56089143	ENSG00000078319.8	PMS2P1	-4.21	3.04e-05	0.00514	-0.22	-0.19	Lung function (FEV1/FVC);	chr7:100222221	chr7:100320992~100341908:-
LUAD	cis	rs2018683	0.707	rs4722875	ENSG00000228421.2	AC005013.5	4.21	3.04e-05	0.00514	0.21	0.19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28930015	chr7:28957667~28959345:+
LUAD	cis	rs1551277	0.84	rs12702390	ENSG00000146666.5	LINC00525	-4.21	3.04e-05	0.00514	-0.21	-0.19	Anxiety disorder;	chr7:47801461	chr7:47761476~47766772:+
LUAD	cis	rs2492286	0.529	rs11918394	ENSG00000242551.2	POU5F1P6	-4.21	3.04e-05	0.00514	-0.26	-0.19	Eosinophil counts;	chr3:128649868	chr3:128674735~128677005:-
LUAD	cis	rs9341808	0.718	rs11962614	ENSG00000260645.1	RP11-250B2.5	4.21	3.04e-05	0.00514	0.18	0.19	Sitting height ratio;	chr6:80113589	chr6:80466958~80469080:+
LUAD	cis	rs9341808	0.718	rs12208016	ENSG00000260645.1	RP11-250B2.5	4.21	3.04e-05	0.00514	0.18	0.19	Sitting height ratio;	chr6:80113846	chr6:80466958~80469080:+
LUAD	cis	rs9341808	0.718	rs9448886	ENSG00000260645.1	RP11-250B2.5	4.21	3.04e-05	0.00514	0.18	0.19	Sitting height ratio;	chr6:80116184	chr6:80466958~80469080:+
LUAD	cis	rs9341808	0.683	rs9359409	ENSG00000260645.1	RP11-250B2.5	4.21	3.04e-05	0.00514	0.18	0.19	Sitting height ratio;	chr6:80117180	chr6:80466958~80469080:+
LUAD	cis	rs812925	0.537	rs10865324	ENSG00000271889.1	RP11-493E12.1	-4.21	3.05e-05	0.00514	-0.22	-0.19	Immature fraction of reticulocytes;	chr2:61394172	chr2:61151433~61162105:-
LUAD	cis	rs7246657	0.598	rs10417545	ENSG00000267309.1	CTD-2630F21.1	4.21	3.05e-05	0.00514	0.32	0.19	Coronary artery calcification;	chr19:37163361	chr19:36489649~36491040:+
LUAD	cis	rs7660883	0.866	rs342456	ENSG00000251411.1	RP11-397E7.4	-4.21	3.05e-05	0.00514	-0.2	-0.19	HDL cholesterol levels;	chr4:87102718	chr4:86913266~86914817:-
LUAD	cis	rs2439831	0.557	rs13329084	ENSG00000205771.5	CATSPER2P1	4.21	3.05e-05	0.00514	0.42	0.19	Lung cancer in ever smokers;	chr15:43858865	chr15:43726918~43747094:-
LUAD	cis	rs6969780	1	rs6973182	ENSG00000233429.8	HOTAIRM1	4.21	3.05e-05	0.00514	0.33	0.19	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27132702	chr7:27095647~27100265:+
LUAD	cis	rs116095464	0.558	rs7703803	ENSG00000248925.1	CTD-2083E4.6	4.21	3.05e-05	0.00515	0.33	0.19	Breast cancer;	chr5:292196	chr5:269858~271516:-
LUAD	cis	rs2836974	0.583	rs9981884	ENSG00000232608.1	TIMM9P2	-4.21	3.05e-05	0.00515	-0.21	-0.19	Cognitive function;	chr21:39213707	chr21:39216624~39217506:+
LUAD	cis	rs763121	0.853	rs4820345	ENSG00000228274.3	RP3-508I15.9	-4.21	3.05e-05	0.00515	-0.19	-0.19	Menopause (age at onset);	chr22:38695146	chr22:38667585~38681820:-
LUAD	cis	rs17772222	0.74	rs10138309	ENSG00000258983.2	RP11-507K2.2	4.21	3.05e-05	0.00515	0.22	0.19	Coronary artery calcification;	chr14:88510352	chr14:88499334~88515502:+
LUAD	cis	rs334353	0.529	rs7034716	ENSG00000255145.2	STX17-AS1	4.21	3.05e-05	0.00515	0.21	0.19	Age-related macular degeneration;	chr9:99096100	chr9:99886322~99906601:-
LUAD	cis	rs4660214	0.666	rs61783383	ENSG00000228060.1	RP11-69E11.8	4.21	3.05e-05	0.00515	0.17	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39341346	chr1:39565160~39573203:+
LUAD	cis	rs7819412	0.54	rs2409726	ENSG00000255046.1	RP11-297N6.4	4.21	3.05e-05	0.00515	0.23	0.19	Triglycerides;	chr8:11185629	chr8:11797928~11802568:-
LUAD	cis	rs4578769	0.531	rs9957103	ENSG00000265943.1	RP11-739L10.1	4.21	3.05e-05	0.00515	0.24	0.19	Eosinophil percentage of white cells;	chr18:22870172	chr18:22699481~22933764:-
LUAD	cis	rs2348418	0.864	rs6487689	ENSG00000244712.1	RP11-874G11.1	4.21	3.05e-05	0.00515	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28560101	chr12:28564678~28565141:-
LUAD	cis	rs4819052	0.851	rs4819041	ENSG00000237664.1	LINC00316	-4.21	3.06e-05	0.00516	-0.22	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240040	chr21:45338590~45341990:-
LUAD	cis	rs453301	0.522	rs2929309	ENSG00000253981.4	ALG1L13P	-4.21	3.06e-05	0.00516	-0.22	-0.19	Joint mobility (Beighton score);	chr8:9226261	chr8:8236003~8244667:-
LUAD	cis	rs780096	0.526	rs3845686	ENSG00000234072.1	AC074117.10	-4.21	3.06e-05	0.00516	-0.15	-0.19	Total body bone mineral density;	chr2:27432580	chr2:27356246~27367622:+
LUAD	cis	rs2929278	0.617	rs12908467	ENSG00000166763.7	STRCP1	-4.21	3.06e-05	0.00516	-0.23	-0.19	Schizophrenia;	chr15:43755232	chr15:43699488~43718184:-
LUAD	cis	rs1044826	1	rs3772878	ENSG00000214280.3	RP11-553K23.2	-4.21	3.06e-05	0.00516	-0.22	-0.19	Obesity-related traits;	chr3:139468533	chr3:139582928~139583593:-
LUAD	cis	rs2243480	1	rs1723270	ENSG00000229886.1	RP5-1132H15.3	4.21	3.06e-05	0.00516	0.33	0.19	Diabetic kidney disease;	chr7:66004843	chr7:66025126~66031544:-
LUAD	cis	rs16866061	0.962	rs16825685	ENSG00000228446.2	AC073052.1	-4.21	3.06e-05	0.00516	-0.2	-0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr2:224569539	chr2:224499387~224500100:-
LUAD	cis	rs891378	1	rs1858001	ENSG00000274245.1	RP11-357P18.2	4.21	3.06e-05	0.00516	0.24	0.19	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207314659	chr1:207372559~207373252:+
LUAD	cis	rs2836974	0.627	rs8127986	ENSG00000232608.1	TIMM9P2	4.21	3.06e-05	0.00516	0.22	0.19	Cognitive function;	chr21:39315285	chr21:39216624~39217506:+
LUAD	cis	rs1008375	0.966	rs4235389	ENSG00000249502.1	AC006160.5	-4.21	3.06e-05	0.00516	-0.18	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17694657	chr4:17587467~17614571:-
LUAD	cis	rs160451	0.966	rs160450	ENSG00000251136.7	RP11-37B2.1	4.21	3.06e-05	0.00516	0.19	0.19	Leprosy;	chr8:89650354	chr8:89609409~89757727:-
LUAD	cis	rs160451	1	rs160451	ENSG00000251136.7	RP11-37B2.1	4.21	3.06e-05	0.00516	0.19	0.19	Leprosy;	chr8:89650713	chr8:89609409~89757727:-
LUAD	cis	rs36093844	0.799	rs12291381	ENSG00000279742.1	RP11-700A24.1	-4.21	3.06e-05	0.00516	-0.22	-0.19	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85889067	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.799	rs12271536	ENSG00000279742.1	RP11-700A24.1	-4.21	3.06e-05	0.00516	-0.22	-0.19	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85889792	chr11:85852557~85854943:-
LUAD	cis	rs12291225	0.546	rs12795545	ENSG00000251991.1	RNU7-49P	4.21	3.06e-05	0.00517	0.21	0.19	Sense of smell;	chr11:14334018	chr11:14478892~14478953:+
LUAD	cis	rs6832769	1	rs576779	ENSG00000272969.1	RP11-528I4.2	4.21	3.06e-05	0.00517	0.19	0.19	Personality dimensions;	chr4:55408140	chr4:55547112~55547889:+
LUAD	cis	rs6832769	0.961	rs480479	ENSG00000272969.1	RP11-528I4.2	4.21	3.06e-05	0.00517	0.19	0.19	Personality dimensions;	chr4:55408163	chr4:55547112~55547889:+
LUAD	cis	rs4843747	0.671	rs13334603	ENSG00000205037.2	RP11-863P13.4	4.21	3.07e-05	0.00517	0.27	0.19	Menopause (age at onset);	chr16:88082410	chr16:88088041~88100985:-
LUAD	cis	rs2154319	0.559	rs213746	ENSG00000235358.1	RP11-399E6.1	4.21	3.07e-05	0.00517	0.22	0.19	Height;	chr1:41163143	chr1:41242373~41284861:+
LUAD	cis	rs6686842	0.56	rs61781830	ENSG00000235358.1	RP11-399E6.1	-4.21	3.07e-05	0.00517	-0.22	-0.19	Height;	chr1:41167695	chr1:41242373~41284861:+
LUAD	cis	rs6686842	0.56	rs12127030	ENSG00000235358.1	RP11-399E6.1	-4.21	3.07e-05	0.00517	-0.22	-0.19	Height;	chr1:41172726	chr1:41242373~41284861:+
LUAD	cis	rs7208859	0.673	rs11651802	ENSG00000280069.1	CTD-2349P21.3	-4.21	3.07e-05	0.00517	-0.27	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832642	chr17:30738182~30740275:+
LUAD	cis	rs10938353	0.678	rs60018658	ENSG00000273369.1	RP11-700J17.1	4.21	3.07e-05	0.00517	0.25	0.19	Body mass index;	chr4:44800149	chr4:44693946~44694386:-
LUAD	cis	rs3742264	1	rs9534311	ENSG00000235903.6	CPB2-AS1	-4.21	3.07e-05	0.00517	-0.24	-0.19	Blood protein levels;	chr13:46075986	chr13:46052806~46113332:+
LUAD	cis	rs3742264	1	rs9534313	ENSG00000235903.6	CPB2-AS1	-4.21	3.07e-05	0.00517	-0.24	-0.19	Blood protein levels;	chr13:46076411	chr13:46052806~46113332:+
LUAD	cis	rs3742264	1	rs17844052	ENSG00000235903.6	CPB2-AS1	-4.21	3.07e-05	0.00517	-0.24	-0.19	Blood protein levels;	chr13:46076653	chr13:46052806~46113332:+
LUAD	cis	rs3742264	0.922	rs4942473	ENSG00000235903.6	CPB2-AS1	-4.21	3.07e-05	0.00517	-0.24	-0.19	Blood protein levels;	chr13:46077173	chr13:46052806~46113332:+
LUAD	cis	rs3742264	0.961	rs4942474	ENSG00000235903.6	CPB2-AS1	-4.21	3.07e-05	0.00517	-0.24	-0.19	Blood protein levels;	chr13:46077209	chr13:46052806~46113332:+
LUAD	cis	rs3742264	0.922	rs4942475	ENSG00000235903.6	CPB2-AS1	-4.21	3.07e-05	0.00517	-0.24	-0.19	Blood protein levels;	chr13:46077386	chr13:46052806~46113332:+
LUAD	cis	rs2243480	1	rs10247526	ENSG00000229886.1	RP5-1132H15.3	-4.21	3.07e-05	0.00517	-0.32	-0.19	Diabetic kidney disease;	chr7:66315709	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs316313	ENSG00000229886.1	RP5-1132H15.3	4.21	3.07e-05	0.00517	0.32	0.19	Diabetic kidney disease;	chr7:66128561	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs316312	ENSG00000229886.1	RP5-1132H15.3	4.21	3.07e-05	0.00517	0.32	0.19	Diabetic kidney disease;	chr7:66131504	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs419603	ENSG00000229886.1	RP5-1132H15.3	4.21	3.07e-05	0.00517	0.32	0.19	Diabetic kidney disease;	chr7:66132354	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs387676	ENSG00000229886.1	RP5-1132H15.3	4.21	3.07e-05	0.00517	0.32	0.19	Diabetic kidney disease;	chr7:66133233	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs13310597	ENSG00000229886.1	RP5-1132H15.3	4.21	3.07e-05	0.00517	0.32	0.19	Diabetic kidney disease;	chr7:66133553	chr7:66025126~66031544:-
LUAD	cis	rs2273156	0.57	rs75889859	ENSG00000226677.3	IGBP1P1	-4.21	3.07e-05	0.00518	-0.29	-0.19	Immunoglobulin light chain (AL) amyloidosis;	chr14:35069848	chr14:34939324~34940332:+
LUAD	cis	rs79403677	1	rs79403677	ENSG00000226677.3	IGBP1P1	-4.21	3.07e-05	0.00518	-0.29	-0.19	Bipolar disorder lithium response (continuous) or schizophrenia;	chr14:35069925	chr14:34939324~34940332:+
LUAD	cis	rs858239	0.601	rs6971002	ENSG00000226816.2	AC005082.12	4.21	3.07e-05	0.00518	0.25	0.19	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23206013~23208045:+
LUAD	cis	rs11673344	0.504	rs12984458	ENSG00000276846.1	CTD-3220F14.3	-4.21	3.07e-05	0.00518	-0.2	-0.19	Obesity-related traits;	chr19:37138189	chr19:37314868~37315620:-
LUAD	cis	rs780096	0.587	rs6743819	ENSG00000234072.1	AC074117.10	-4.21	3.07e-05	0.00518	-0.15	-0.19	Total body bone mineral density;	chr2:27344540	chr2:27356246~27367622:+
LUAD	cis	rs9341808	0.667	rs2490244	ENSG00000260645.1	RP11-250B2.5	4.21	3.07e-05	0.00518	0.18	0.19	Sitting height ratio;	chr6:80181395	chr6:80466958~80469080:+
LUAD	cis	rs10463554	0.857	rs3776873	ENSG00000250682.4	LINC00491	4.21	3.07e-05	0.00518	0.23	0.19	Parkinson's disease;	chr5:102946768	chr5:102609156~102671559:-
LUAD	cis	rs2976388	0.566	rs2585146	ENSG00000253741.1	CTD-2292P10.4	-4.21	3.07e-05	0.00518	-0.22	-0.19	Urinary tract infection frequency;	chr8:142717223	chr8:142702252~142726973:-
LUAD	cis	rs2154319	0.887	rs7531344	ENSG00000235358.1	RP11-399E6.1	4.21	3.07e-05	0.00518	0.26	0.19	Height;	chr1:41041759	chr1:41242373~41284861:+
LUAD	cis	rs6128907	0.8	rs6129020	ENSG00000224635.1	RP4-564F22.5	-4.21	3.07e-05	0.00518	-0.32	-0.19	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38786294	chr20:38406011~38416797:-
LUAD	cis	rs6723108	0.627	rs7593370	ENSG00000224043.6	CCNT2-AS1	4.21	3.07e-05	0.00518	0.23	0.19	Type 2 diabetes;	chr2:134865947	chr2:134735464~134918710:-
LUAD	cis	rs6840360	0.571	rs11944139	ENSG00000270265.1	RP11-731D1.4	-4.21	3.08e-05	0.00518	-0.22	-0.19	Intelligence (multi-trait analysis);	chr4:151584139	chr4:151333775~151353224:-
LUAD	cis	rs1401999	1	rs1401999	ENSG00000223882.1	ABCC5-AS1	-4.21	3.08e-05	0.00518	-0.2	-0.19	Anterior chamber depth;	chr3:183960554	chr3:184006338~184011419:+
LUAD	cis	rs858239	0.636	rs28706766	ENSG00000230042.1	AK3P3	-4.21	3.08e-05	0.00518	-0.23	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23130215	chr7:23129178~23129841:+
LUAD	cis	rs801193	1	rs13239306	ENSG00000224316.1	RP11-479O9.2	-4.21	3.08e-05	0.00519	-0.19	-0.19	Aortic root size;	chr7:66671030	chr7:65773620~65802067:+
LUAD	cis	rs9910055	0.659	rs8079310	ENSG00000267080.4	ASB16-AS1	-4.21	3.08e-05	0.00519	-0.17	-0.19	Total body bone mineral density;	chr17:44192923	chr17:44175973~44186717:-
LUAD	cis	rs8077577	0.671	rs9909104	ENSG00000273018.4	CTD-2303H24.2	-4.21	3.08e-05	0.00519	-0.25	-0.19	Obesity-related traits;	chr17:18344707	chr17:18511221~18551705:-
LUAD	cis	rs780096	0.546	rs4665976	ENSG00000234072.1	AC074117.10	-4.21	3.08e-05	0.00519	-0.15	-0.19	Total body bone mineral density;	chr2:27417458	chr2:27356246~27367622:+
LUAD	cis	rs780096	0.526	rs2911713	ENSG00000234072.1	AC074117.10	-4.21	3.08e-05	0.00519	-0.15	-0.19	Total body bone mineral density;	chr2:27418113	chr2:27356246~27367622:+
LUAD	cis	rs4879677	0.92	rs3861018	ENSG00000215441.3	CTAGE12P	-4.21	3.08e-05	0.00519	-0.23	-0.19	Gut microbiome composition (summer and winter);	chr9:27654018	chr9:27608382~27610745:-
LUAD	cis	rs12073359	0.955	rs11584354	ENSG00000223945.2	RP11-458I7.1	-4.21	3.08e-05	0.00519	-0.28	-0.19	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150066990	chr1:150053864~150055034:+
LUAD	cis	rs4819052	0.851	rs2838865	ENSG00000237664.1	LINC00316	-4.21	3.08e-05	0.00519	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45292384	chr21:45338590~45341990:-
LUAD	cis	rs2836974	0.966	rs2836977	ENSG00000232608.1	TIMM9P2	-4.21	3.08e-05	0.00519	-0.22	-0.19	Cognitive function;	chr21:39294140	chr21:39216624~39217506:+
LUAD	cis	rs8014252	0.803	rs59233924	ENSG00000259158.2	ADAM20P1	-4.21	3.08e-05	0.00519	-0.33	-0.19	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70583943	chr14:70468881~70483756:-
LUAD	cis	rs2278034	0.502	rs3747672	ENSG00000231464.1	AC024937.4	4.21	3.08e-05	0.00519	0.21	0.19	Bronchopulmonary dysplasia;	chr3:195885163	chr3:195996738~195998233:+
LUAD	cis	rs28530618	0.87	rs6057610	ENSG00000175730.8	BAK1P1	4.21	3.08e-05	0.0052	0.23	0.19	Birth weight;	chr20:32653587	chr20:32690180~32690815:-
LUAD	cis	rs1387259	0.931	rs1107654	ENSG00000257763.1	OR5BK1P	4.21	3.08e-05	0.0052	0.2	0.19	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48287314	chr12:48355792~48356614:-
LUAD	cis	rs3120667	0.79	rs3753444	ENSG00000237975.5	FLG-AS1	4.21	3.08e-05	0.0052	0.31	0.19	Eating disorders;	chr1:152415391	chr1:152168125~152445456:+
LUAD	cis	rs9341808	0.718	rs9352806	ENSG00000260645.1	RP11-250B2.5	4.21	3.08e-05	0.0052	0.18	0.19	Sitting height ratio;	chr6:80270340	chr6:80466958~80469080:+
LUAD	cis	rs240993	0.595	rs3777910	ENSG00000230177.1	RP5-1112D6.4	4.21	3.08e-05	0.0052	0.19	0.19	Inflammatory skin disease;Psoriasis;	chr6:111581248	chr6:111277932~111278742:+
LUAD	cis	rs13113518	0.902	rs3805150	ENSG00000272969.1	RP11-528I4.2	4.21	3.09e-05	0.0052	0.2	0.19	Height;	chr4:55446869	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs4864990	ENSG00000272969.1	RP11-528I4.2	4.21	3.09e-05	0.0052	0.2	0.19	Height;	chr4:55447523	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs11133381	ENSG00000272969.1	RP11-528I4.2	4.21	3.09e-05	0.0052	0.2	0.19	Height;	chr4:55450812	chr4:55547112~55547889:+
LUAD	cis	rs8030379	1	rs7162129	ENSG00000230373.7	GOLGA6L5P	-4.21	3.09e-05	0.0052	-0.17	-0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83897692	chr15:84507885~84516814:-
LUAD	cis	rs6071166	0.903	rs6071174	ENSG00000224635.1	RP4-564F22.5	4.21	3.09e-05	0.0052	0.2	0.19	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38707898	chr20:38406011~38416797:-
LUAD	cis	rs4664293	1	rs6753181	ENSG00000230783.1	AC009961.2	-4.21	3.09e-05	0.0052	-0.23	-0.19	Monocyte percentage of white cells;	chr2:159635927	chr2:159689217~159690291:-
LUAD	cis	rs11168618	0.74	rs7307588	ENSG00000240399.1	RP1-228P16.1	4.21	3.09e-05	0.0052	0.18	0.19	Adiponectin levels;	chr12:48529449	chr12:48054813~48055591:-
LUAD	cis	rs712022	0.872	rs12419860	ENSG00000246225.5	RP11-17A1.3	4.21	3.09e-05	0.00521	0.23	0.19	Dialysis-related mortality;	chr11:22824515	chr11:22829380~22945393:+
LUAD	cis	rs6754311	0.731	rs748841	ENSG00000226806.1	AC011893.3	-4.21	3.09e-05	0.00521	-0.23	-0.19	Mosquito bite size;	chr2:135800587	chr2:135820191~135823087:+
LUAD	cis	rs6964587	0.647	rs38801	ENSG00000188693.7	CYP51A1-AS1	4.21	3.09e-05	0.00521	0.23	0.19	Breast cancer;	chr7:92417013	chr7:92134604~92180725:+
LUAD	cis	rs9921222	0.585	rs7195617	ENSG00000236829.8	Z97634.3	-4.21	3.09e-05	0.00521	-0.22	-0.19	Bone mineral density (spine);Bone mineral density;	chr16:326781	chr16:382097~392960:+
LUAD	cis	rs11168618	0.904	rs12371700	ENSG00000240399.1	RP1-228P16.1	-4.21	3.09e-05	0.00521	-0.18	-0.19	Adiponectin levels;	chr12:48525430	chr12:48054813~48055591:-
LUAD	cis	rs950169	0.614	rs12911536	ENSG00000225151.9	GOLGA2P7	-4.21	3.09e-05	0.00521	-0.28	-0.19	Schizophrenia;	chr15:84004278	chr15:84199311~84230136:-
LUAD	cis	rs2446066	0.872	rs34148420	ENSG00000257379.1	RP11-793H13.8	4.21	3.09e-05	0.00521	0.31	0.19	Red blood cell count;	chr12:53405024	chr12:53441741~53467528:+
LUAD	cis	rs228769	0.543	rs170634	ENSG00000267080.4	ASB16-AS1	4.21	3.09e-05	0.00521	0.18	0.19	Bone mineral density (hip);Bone mineral density (spine);	chr17:44098453	chr17:44175973~44186717:-
LUAD	cis	rs1401999	1	rs4148571	ENSG00000223882.1	ABCC5-AS1	-4.21	3.09e-05	0.00521	-0.2	-0.19	Anterior chamber depth;	chr3:184002788	chr3:184006338~184011419:+
LUAD	cis	rs6012564	1	rs3092039	ENSG00000230758.1	SNAP23P	-4.21	3.09e-05	0.00521	-0.2	-0.19	Anger;	chr20:49062233	chr20:49038357~49038602:-
LUAD	cis	rs708547	0.581	rs6554400	ENSG00000269949.1	RP11-738E22.3	-4.21	3.09e-05	0.00521	-0.26	-0.19	Response to bleomycin (chromatid breaks);	chr4:56939140	chr4:56960927~56961373:-
LUAD	cis	rs2657294	0.796	rs1259501	ENSG00000233313.2	HMGA1P5	-4.21	3.09e-05	0.00521	-0.24	-0.19	Pneumonia;	chr10:75230427	chr10:75276376~75276646:-
LUAD	cis	rs2239557	1	rs7153587	ENSG00000259065.1	RP5-1021I20.1	-4.21	3.09e-05	0.00521	-0.22	-0.19	Common traits (Other);	chr14:74042957	chr14:73787360~73803270:+
LUAD	cis	rs2732480	0.5	rs12829841	ENSG00000257763.1	OR5BK1P	4.21	3.09e-05	0.00521	0.2	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48234956	chr12:48355792~48356614:-
LUAD	cis	rs2732480	0.523	rs34286639	ENSG00000257763.1	OR5BK1P	4.21	3.09e-05	0.00521	0.2	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48235261	chr12:48355792~48356614:-
LUAD	cis	rs1387259	0.929	rs11168484	ENSG00000257763.1	OR5BK1P	4.21	3.09e-05	0.00521	0.2	0.19	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48239806	chr12:48355792~48356614:-
LUAD	cis	rs9649213	0.593	rs7796611	ENSG00000272950.1	RP11-307C18.1	4.21	3.1e-05	0.00521	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98278911	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.574	rs13238610	ENSG00000272950.1	RP11-307C18.1	4.21	3.1e-05	0.00521	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98279965	chr7:98322853~98323430:+
LUAD	cis	rs7107174	0.892	rs10899490	ENSG00000251323.2	RP11-452H21.4	4.21	3.1e-05	0.00521	0.23	0.19	Testicular germ cell tumor;	chr11:78394833	chr11:78423982~78429836:-
LUAD	cis	rs28386778	0.897	rs2727290	ENSG00000240280.5	TCAM1P	-4.21	3.1e-05	0.00521	-0.22	-0.19	Prudent dietary pattern;	chr17:63817368	chr17:63849292~63864379:+
LUAD	cis	rs9649213	0.555	rs12667634	ENSG00000272950.1	RP11-307C18.1	4.21	3.1e-05	0.00521	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98336130	chr7:98322853~98323430:+
LUAD	cis	rs9788333	0.695	rs12871086	ENSG00000224429.6	LINC00539	-4.21	3.1e-05	0.00522	-0.17	-0.19	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr13:21316085	chr13:21303515~21348721:-
LUAD	cis	rs34779708	0.897	rs7900480	ENSG00000271335.4	RP11-324I22.4	-4.21	3.1e-05	0.00522	-0.19	-0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35049771	chr10:35314552~35336401:-
LUAD	cis	rs8046148	0.774	rs4396535	ENSG00000279356.1	RP11-429P3.8	-4.21	3.1e-05	0.00522	-0.2	-0.19	Testicular germ cell tumor;	chr16:50117376	chr16:50072862~50074986:+
LUAD	cis	rs4819052	0.84	rs914217	ENSG00000223768.1	LINC00205	-4.21	3.1e-05	0.00522	-0.24	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278384	chr21:45293285~45297354:+
LUAD	cis	rs877356	0.831	rs34134222	ENSG00000250378.1	RP11-119J18.1	-4.21	3.1e-05	0.00522	-0.36	-0.19	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (dichotomous);	chr5:135830466	chr5:135812667~135826582:+
LUAD	cis	rs1502337	0.532	rs6606689	ENSG00000278993.1	RP3-424M6.4	-4.21	3.1e-05	0.00522	-0.23	-0.19	Body mass index;	chr12:110537870	chr12:110501614~110503441:+
LUAD	cis	rs11673344	0.504	rs6510591	ENSG00000276846.1	CTD-3220F14.3	4.21	3.1e-05	0.00522	0.21	0.19	Obesity-related traits;	chr19:37133186	chr19:37314868~37315620:-
LUAD	cis	rs801193	0.844	rs2244022	ENSG00000236529.1	RP13-254B10.1	4.21	3.1e-05	0.00522	0.19	0.19	Aortic root size;	chr7:66737443	chr7:65840212~65840596:+
LUAD	cis	rs42490	0.664	rs372981	ENSG00000251136.7	RP11-37B2.1	-4.21	3.1e-05	0.00522	-0.19	-0.19	Leprosy;	chr8:89784740	chr8:89609409~89757727:-
LUAD	cis	rs8062405	0.722	rs3785354	ENSG00000251417.2	RP11-1348G14.4	-4.21	3.1e-05	0.00522	-0.19	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28802743~28817828:+
LUAD	cis	rs2617170	0.754	rs12824474	ENSG00000245648.1	RP11-277P12.20	-4.21	3.1e-05	0.00522	-0.23	-0.19	Behcet's disease;	chr12:10450326	chr12:10363769~10398506:+
LUAD	cis	rs9341808	0.618	rs6916507	ENSG00000260645.1	RP11-250B2.5	4.21	3.1e-05	0.00522	0.18	0.19	Sitting height ratio;	chr6:80152548	chr6:80466958~80469080:+
LUAD	cis	rs11673344	0.504	rs6510592	ENSG00000276846.1	CTD-3220F14.3	4.21	3.1e-05	0.00522	0.21	0.19	Obesity-related traits;	chr19:37133430	chr19:37314868~37315620:-
LUAD	cis	rs7598759	0.548	rs1823328	ENSG00000223198.1	RNU2-22P	-4.21	3.1e-05	0.00522	-0.21	-0.19	Noise-induced hearing loss;	chr2:231490473	chr2:231501990~231502201:-
LUAD	cis	rs7598759	0.548	rs11693738	ENSG00000223198.1	RNU2-22P	-4.21	3.1e-05	0.00522	-0.21	-0.19	Noise-induced hearing loss;	chr2:231495773	chr2:231501990~231502201:-
LUAD	cis	rs7598759	0.548	rs11686485	ENSG00000223198.1	RNU2-22P	-4.21	3.1e-05	0.00522	-0.21	-0.19	Noise-induced hearing loss;	chr2:231495986	chr2:231501990~231502201:-
LUAD	cis	rs7560272	0.723	rs1320374	ENSG00000163016.8	ALMS1P	-4.21	3.1e-05	0.00522	-0.2	-0.19	Schizophrenia;	chr2:73601183	chr2:73644919~73685576:+
LUAD	cis	rs8098244	0.683	rs4334381	ENSG00000264745.1	TTC39C-AS1	4.21	3.1e-05	0.00522	0.2	0.19	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23852485	chr18:23994213~24015339:-
LUAD	cis	rs8098244	0.683	rs4488534	ENSG00000264745.1	TTC39C-AS1	4.21	3.1e-05	0.00522	0.2	0.19	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23852486	chr18:23994213~24015339:-
LUAD	cis	rs28386778	0.863	rs6504178	ENSG00000240280.5	TCAM1P	4.21	3.1e-05	0.00522	0.22	0.19	Prudent dietary pattern;	chr17:63735373	chr17:63849292~63864379:+
LUAD	cis	rs7512552	0.839	rs12046446	ENSG00000275557.1	RP11-353N4.6	4.21	3.1e-05	0.00522	0.21	0.19	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150488379	chr1:149607765~149612402:+
LUAD	cis	rs9876781	1	rs6776700	ENSG00000229759.1	MRPS18AP1	4.21	3.1e-05	0.00522	0.18	0.19	Longevity;	chr3:48455358	chr3:48256350~48256938:-
LUAD	cis	rs910316	0.967	rs35446981	ENSG00000279594.1	RP11-950C14.10	-4.21	3.1e-05	0.00523	-0.21	-0.19	Height;	chr14:75170648	chr14:75011269~75012851:-
LUAD	cis	rs116095464	0.558	rs55664502	ENSG00000248925.1	CTD-2083E4.6	4.21	3.1e-05	0.00523	0.32	0.19	Breast cancer;	chr5:270370	chr5:269858~271516:-
LUAD	cis	rs116095464	0.51	rs7723883	ENSG00000248925.1	CTD-2083E4.6	4.21	3.1e-05	0.00523	0.32	0.19	Breast cancer;	chr5:270683	chr5:269858~271516:-
LUAD	cis	rs11671005	0.693	rs11666928	ENSG00000268543.1	CTD-2619J13.16	-4.21	3.11e-05	0.00523	-0.27	-0.19	Mean platelet volume;	chr19:58402864	chr19:58418560~58419310:+
LUAD	cis	rs2933343	0.7	rs2624910	ENSG00000231305.3	RP11-723O4.2	4.21	3.11e-05	0.00523	0.2	0.19	IgG glycosylation;	chr3:128931432	chr3:128861313~128871540:-
LUAD	cis	rs6494488	0.5	rs72742982	ENSG00000239465.1	RP11-330L19.2	4.21	3.11e-05	0.00523	0.39	0.19	Coronary artery disease;	chr15:64684856	chr15:64631109~64631914:-
LUAD	cis	rs73186030	0.687	rs16833080	ENSG00000272758.4	RP11-299J3.8	-4.21	3.11e-05	0.00523	-0.25	-0.19	Serum parathyroid hormone levels;	chr3:122382060	chr3:122416207~122443180:+
LUAD	cis	rs4819052	1	rs13053002	ENSG00000237664.1	LINC00316	-4.21	3.11e-05	0.00523	-0.24	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45257939	chr21:45338590~45341990:-
LUAD	cis	rs7590268	0.577	rs13011594	ENSG00000279873.2	LINC01126	4.21	3.11e-05	0.00523	0.19	0.19	Orofacial clefts;	chr2:43609877	chr2:43227210~43228855:+
LUAD	cis	rs8028182	0.583	rs9944207	ENSG00000260269.4	CTD-2323K18.1	-4.21	3.11e-05	0.00523	-0.26	-0.19	Sudden cardiac arrest;	chr15:75620548	chr15:75527150~75601205:-
LUAD	cis	rs703842	0.616	rs4760332	ENSG00000245651.2	RP11-620J15.2	-4.21	3.11e-05	0.00524	-0.2	-0.19	Multiple sclerosis;	chr12:57828889	chr12:57869835~57896482:-
LUAD	cis	rs910316	0.967	rs10246	ENSG00000279594.1	RP11-950C14.10	4.21	3.11e-05	0.00524	0.22	0.19	Height;	chr14:75077767	chr14:75011269~75012851:-
LUAD	cis	rs12908161	0.853	rs11633788	ENSG00000259295.5	CSPG4P12	4.21	3.11e-05	0.00524	0.24	0.19	Schizophrenia;	chr15:84761911	chr15:85191438~85213905:+
LUAD	cis	rs2117029	1	rs11168827	ENSG00000269514.1	RP11-370I10.12	-4.21	3.11e-05	0.00524	-0.16	-0.19	Intelligence (multi-trait analysis);	chr12:49025894	chr12:48198387~48202031:+
LUAD	cis	rs7637701	0.713	rs9818780	ENSG00000240875.4	LINC00886	-4.21	3.11e-05	0.00524	-0.2	-0.19	Breast cancer;	chr3:156774969	chr3:156747346~156817062:-
LUAD	cis	rs7637701	0.713	rs9878566	ENSG00000240875.4	LINC00886	-4.21	3.11e-05	0.00524	-0.2	-0.19	Breast cancer;	chr3:156775424	chr3:156747346~156817062:-
LUAD	cis	rs3020736	0.5	rs6002597	ENSG00000205702.9	CYP2D7	-4.2	3.11e-05	0.00524	-0.15	-0.19	Autism spectrum disorder or schizophrenia;	chr22:42092156	chr22:42140203~42144577:-
LUAD	cis	rs1061377	0.608	rs35168672	ENSG00000249685.1	RP11-360F5.3	4.2	3.12e-05	0.00524	0.23	0.19	Uric acid levels;	chr4:39078902	chr4:39133913~39135608:+
LUAD	cis	rs3743162	0.553	rs12900463	ENSG00000259295.5	CSPG4P12	4.2	3.12e-05	0.00524	0.28	0.19	Alzheimer's disease (age of onset);	chr15:84872155	chr15:85191438~85213905:+
LUAD	cis	rs6471393	0.964	rs3813853	ENSG00000253848.1	RP11-10N23.5	4.2	3.12e-05	0.00524	0.23	0.19	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93740526	chr8:93741193~93744534:+
LUAD	cis	rs160451	1	rs160448	ENSG00000251136.7	RP11-37B2.1	4.2	3.12e-05	0.00524	0.19	0.19	Leprosy;	chr8:89647622	chr8:89609409~89757727:-
LUAD	cis	rs7210086	0.768	rs72849444	ENSG00000263893.2	CTD-3010D24.3	4.2	3.12e-05	0.00525	0.26	0.19	Ulcerative colitis;	chr17:72641666	chr17:72642731~72644490:+
LUAD	cis	rs35740288	0.77	rs11634177	ENSG00000259407.1	RP11-158M2.3	4.2	3.12e-05	0.00525	0.19	0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85605159	chr15:85744109~85750281:-
LUAD	cis	rs5769707	0.837	rs5770599	ENSG00000235111.1	RP1-29C18.8	-4.2	3.12e-05	0.00525	-0.21	-0.19	Monocyte percentage of white cells;Monocyte count;	chr22:49626333	chr22:49612657~49615716:-
LUAD	cis	rs2836974	0.644	rs1882779	ENSG00000232608.1	TIMM9P2	4.2	3.12e-05	0.00525	0.22	0.19	Cognitive function;	chr21:39319012	chr21:39216624~39217506:+
LUAD	cis	rs7615952	0.515	rs7630575	ENSG00000241288.6	RP11-379B18.5	-4.2	3.12e-05	0.00525	-0.23	-0.19	Blood pressure (smoking interaction);	chr3:125963487	chr3:125827238~125916384:-
LUAD	cis	rs2976388	0.525	rs2016749	ENSG00000253741.1	CTD-2292P10.4	4.2	3.12e-05	0.00525	0.23	0.19	Urinary tract infection frequency;	chr8:142754700	chr8:142702252~142726973:-
LUAD	cis	rs11157436	0.602	rs17255447	ENSG00000211812.1	TRAV26-2	4.2	3.12e-05	0.00525	0.19	0.19	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22167459	chr14:22202583~22203368:+
LUAD	cis	rs10197140	0.857	rs2341897	ENSG00000235721.1	AC013268.3	-4.2	3.12e-05	0.00526	-0.21	-0.19	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110899289	chr2:110007675~110010783:+
LUAD	cis	rs910316	1	rs175425	ENSG00000279594.1	RP11-950C14.10	-4.2	3.12e-05	0.00526	-0.21	-0.19	Height;	chr14:75159428	chr14:75011269~75012851:-
LUAD	cis	rs910316	0.935	rs175422	ENSG00000279594.1	RP11-950C14.10	-4.2	3.12e-05	0.00526	-0.21	-0.19	Height;	chr14:75160616	chr14:75011269~75012851:-
LUAD	cis	rs16866061	1	rs10933068	ENSG00000228446.2	AC073052.1	-4.2	3.12e-05	0.00526	-0.2	-0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr2:224553643	chr2:224499387~224500100:-
LUAD	cis	rs34783982	0.881	rs4627315	ENSG00000261441.1	RP11-217B1.2	-4.2	3.13e-05	0.00526	-0.25	-0.19	Squamous cell lung carcinoma;	chr15:88959162	chr15:89335053~89336161:+
LUAD	cis	rs13201294	1	rs13201294	ENSG00000219392.1	RP1-265C24.5	-4.2	3.13e-05	0.00526	-0.36	-0.19	Squamous cell lung carcinoma;	chr6:27588362	chr6:28115628~28116551:+
LUAD	cis	rs7665090	0.875	rs6813687	ENSG00000246560.2	RP11-10L12.4	4.2	3.13e-05	0.00526	0.23	0.19	Primary biliary cholangitis;	chr4:102634455	chr4:102828055~102844075:+
LUAD	cis	rs240993	0.595	rs4947127	ENSG00000230177.1	RP5-1112D6.4	4.2	3.13e-05	0.00526	0.19	0.19	Inflammatory skin disease;Psoriasis;	chr6:111581595	chr6:111277932~111278742:+
LUAD	cis	rs1419980	0.673	rs12146828	ENSG00000235602.5	POU5F1P3	4.2	3.13e-05	0.00527	0.2	0.19	HDL cholesterol levels;	chr12:7586745	chr12:8133772~8134849:-
LUAD	cis	rs1431005	0.892	rs72725288	ENSG00000250658.1	RP11-138B4.1	4.2	3.13e-05	0.00527	0.22	0.19	Response to statin therapy;	chr4:187477411	chr4:187304083~187309682:-
LUAD	cis	rs6933660	0.745	rs9371517	ENSG00000219395.2	HSPA8P15	-4.2	3.13e-05	0.00527	-0.18	-0.19	Menarche (age at onset);	chr6:151418675	chr6:151411259~151413945:-
LUAD	cis	rs9926296	0.605	rs1800287	ENSG00000260259.1	RP11-368I7.4	-4.2	3.13e-05	0.00527	-0.19	-0.19	Vitiligo;	chr16:89792117	chr16:89682620~89686569:-
LUAD	cis	rs950169	1	rs79318564	ENSG00000275120.1	RP11-182J1.17	4.2	3.13e-05	0.00527	0.3	0.19	Schizophrenia;	chr15:84117398	chr15:84599434~84606463:-
LUAD	cis	rs3742264	0.848	rs9567615	ENSG00000235903.6	CPB2-AS1	-4.2	3.13e-05	0.00527	-0.24	-0.19	Blood protein levels;	chr13:46076945	chr13:46052806~46113332:+
LUAD	cis	rs3742264	0.848	rs9567616	ENSG00000235903.6	CPB2-AS1	-4.2	3.13e-05	0.00527	-0.24	-0.19	Blood protein levels;	chr13:46076956	chr13:46052806~46113332:+
LUAD	cis	rs3742264	0.848	rs9567617	ENSG00000235903.6	CPB2-AS1	-4.2	3.13e-05	0.00527	-0.24	-0.19	Blood protein levels;	chr13:46076973	chr13:46052806~46113332:+
LUAD	cis	rs151234	0.612	rs11641853	ENSG00000259982.1	CDC37P1	-4.2	3.13e-05	0.00527	-0.35	-0.19	Platelet distribution width;	chr16:28578398	chr16:28700294~28701540:-
LUAD	cis	rs8014204	0.604	rs2159906	ENSG00000279594.1	RP11-950C14.10	4.2	3.14e-05	0.00527	0.23	0.19	Caffeine consumption;	chr14:74924209	chr14:75011269~75012851:-
LUAD	cis	rs80028505	1	rs6936327	ENSG00000271304.1	DPRXP2	4.2	3.14e-05	0.00527	0.35	0.19	Foot ulcer in diabetes and neuropathy;	chr6:36102098	chr6:35989515~35990436:-
LUAD	cis	rs80028505	0.908	rs16884857	ENSG00000271304.1	DPRXP2	4.2	3.14e-05	0.00527	0.35	0.19	Foot ulcer in diabetes and neuropathy;	chr6:36102450	chr6:35989515~35990436:-
LUAD	cis	rs1555322	0.53	rs2425047	ENSG00000279253.1	RP4-614O4.13	4.2	3.14e-05	0.00527	0.23	0.19	Attention deficit hyperactivity disorder;	chr20:35283872	chr20:35262727~35264187:-
LUAD	cis	rs17772222	0.701	rs376698	ENSG00000258789.1	RP11-507K2.3	4.2	3.14e-05	0.00527	0.23	0.19	Coronary artery calcification;	chr14:88391886	chr14:88551597~88552493:+
LUAD	cis	rs2354432	0.556	rs12568866	ENSG00000237188.3	RP11-337C18.8	4.2	3.14e-05	0.00528	0.33	0.19	Mitochondrial DNA levels;	chr1:147246776	chr1:147172771~147211568:+
LUAD	cis	rs2153535	0.518	rs913571	ENSG00000230939.1	RP11-314C16.1	-4.2	3.14e-05	0.00528	-0.22	-0.19	Motion sickness;	chr6:8591095	chr6:8784178~8785445:+
LUAD	cis	rs9341808	0.617	rs9294170	ENSG00000272129.1	RP11-250B2.6	4.2	3.14e-05	0.00528	0.23	0.19	Sitting height ratio;	chr6:80104363	chr6:80355424~80356859:+
LUAD	cis	rs5758511	0.689	rs5758691	ENSG00000227370.1	RP4-669P10.19	4.2	3.14e-05	0.00528	0.21	0.19	Birth weight;	chr22:42272498	chr22:42132543~42132998:+
LUAD	cis	rs5758511	0.68	rs1001586	ENSG00000227370.1	RP4-669P10.19	4.2	3.14e-05	0.00528	0.21	0.19	Birth weight;	chr22:42274287	chr22:42132543~42132998:+
LUAD	cis	rs4879677	0.959	rs10968039	ENSG00000215441.3	CTAGE12P	-4.2	3.14e-05	0.00528	-0.23	-0.19	Gut microbiome composition (summer and winter);	chr9:27670118	chr9:27608382~27610745:-
LUAD	cis	rs4879677	1	rs10968041	ENSG00000215441.3	CTAGE12P	-4.2	3.14e-05	0.00528	-0.23	-0.19	Gut microbiome composition (summer and winter);	chr9:27670205	chr9:27608382~27610745:-
LUAD	cis	rs4664293	0.967	rs12999124	ENSG00000230783.1	AC009961.2	-4.2	3.14e-05	0.00528	-0.23	-0.19	Monocyte percentage of white cells;	chr2:159674817	chr2:159689217~159690291:-
LUAD	cis	rs3096299	0.679	rs3102338	ENSG00000261574.1	RP1-168P16.2	4.2	3.14e-05	0.00528	0.21	0.19	Multiple myeloma (IgH translocation);	chr16:89375842	chr16:89392375~89412564:-
LUAD	cis	rs9646944	0.501	rs12712144	ENSG00000234389.1	AC007278.3	4.2	3.14e-05	0.00528	0.22	0.19	Blood protein levels;	chr2:102379140	chr2:102438713~102440475:+
LUAD	cis	rs9646944	0.501	rs3213733	ENSG00000234389.1	AC007278.3	4.2	3.14e-05	0.00528	0.22	0.19	Blood protein levels;	chr2:102381424	chr2:102438713~102440475:+
LUAD	cis	rs9646944	0.501	rs3771161	ENSG00000234389.1	AC007278.3	4.2	3.14e-05	0.00528	0.22	0.19	Blood protein levels;	chr2:102387501	chr2:102438713~102440475:+
LUAD	cis	rs2898681	0.614	rs6839900	ENSG00000248375.1	RP11-177B4.1	-4.2	3.14e-05	0.00528	-0.28	-0.19	Optic nerve measurement (cup area);	chr4:52809167	chr4:52720081~52720831:-
LUAD	cis	rs2274273	0.624	rs10141396	ENSG00000258413.1	RP11-665C16.6	-4.2	3.14e-05	0.00528	-0.26	-0.19	Protein biomarker;	chr14:55350207	chr14:55262767~55272075:-
LUAD	cis	rs11089937	0.568	rs12160318	ENSG00000211640.3	IGLV6-57	4.2	3.14e-05	0.00528	0.14	0.19	Periodontitis (PAL4Q3);	chr22:22131627	chr22:22195713~22196460:+
LUAD	cis	rs11089937	0.568	rs12159174	ENSG00000211640.3	IGLV6-57	4.2	3.14e-05	0.00528	0.14	0.19	Periodontitis (PAL4Q3);	chr22:22131639	chr22:22195713~22196460:+
LUAD	cis	rs11089937	0.568	rs11089919	ENSG00000211640.3	IGLV6-57	4.2	3.14e-05	0.00528	0.14	0.19	Periodontitis (PAL4Q3);	chr22:22131648	chr22:22195713~22196460:+
LUAD	cis	rs7202877	0.706	rs4887813	ENSG00000280152.1	RP11-331F4.5	4.2	3.14e-05	0.00528	0.22	0.19	Type 1 diabetes;Type 2 diabetes;	chr16:75278596	chr16:75245994~75250077:-
LUAD	cis	rs11673344	0.504	rs8099987	ENSG00000276846.1	CTD-3220F14.3	4.2	3.14e-05	0.00529	0.21	0.19	Obesity-related traits;	chr19:37132570	chr19:37314868~37315620:-
LUAD	cis	rs11673344	0.504	rs8110796	ENSG00000276846.1	CTD-3220F14.3	4.2	3.14e-05	0.00529	0.21	0.19	Obesity-related traits;	chr19:37132682	chr19:37314868~37315620:-
LUAD	cis	rs11673344	0.504	rs8111285	ENSG00000276846.1	CTD-3220F14.3	4.2	3.14e-05	0.00529	0.21	0.19	Obesity-related traits;	chr19:37132747	chr19:37314868~37315620:-
LUAD	cis	rs4499344	0.556	rs259231	ENSG00000201388.1	SNORA68	4.2	3.14e-05	0.00529	0.22	0.19	Mean platelet volume;	chr19:32638161	chr19:32608337~32608469:-
LUAD	cis	rs7772486	0.743	rs9376955	ENSG00000235652.6	RP11-545I5.3	4.2	3.15e-05	0.00529	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145628268	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.805	rs4896831	ENSG00000235652.6	RP11-545I5.3	4.2	3.15e-05	0.00529	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145638345	chr6:145799409~145886585:+
LUAD	cis	rs4374383	0.884	rs11683421	ENSG00000207383.1	Y_RNA	4.2	3.15e-05	0.00529	0.23	0.19	Hepatitis C induced liver fibrosis;	chr2:111995653	chr2:112579484~112579584:-
LUAD	cis	rs8030379	1	rs1564472	ENSG00000230373.7	GOLGA6L5P	-4.2	3.15e-05	0.00529	-0.18	-0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83901041	chr15:84507885~84516814:-
LUAD	cis	rs4601821	0.635	rs2303380	ENSG00000270179.1	RP11-159N11.4	-4.2	3.15e-05	0.00529	-0.19	-0.19	Alcoholic chronic pancreatitis;	chr11:113329987	chr11:113368478~113369117:+
LUAD	cis	rs11051970	0.679	rs2733696	ENSG00000274964.1	RP11-817I4.1	-4.2	3.15e-05	0.00529	-0.19	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr12:32401701	chr12:32339368~32340724:+
LUAD	cis	rs11051970	0.704	rs7312698	ENSG00000274964.1	RP11-817I4.1	-4.2	3.15e-05	0.00529	-0.19	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr12:32401761	chr12:32339368~32340724:+
LUAD	cis	rs7976269	0.609	rs2196482	ENSG00000257176.2	RP11-996F15.2	-4.2	3.15e-05	0.00529	-0.2	-0.19	Male-pattern baldness;	chr12:29052559	chr12:29280418~29317848:-
LUAD	cis	rs7976269	0.609	rs2217906	ENSG00000257176.2	RP11-996F15.2	-4.2	3.15e-05	0.00529	-0.2	-0.19	Male-pattern baldness;	chr12:29052626	chr12:29280418~29317848:-
LUAD	cis	rs9500256	0.967	rs1012500	ENSG00000266579.1	RP1-71H19.2	-4.2	3.15e-05	0.00529	-0.23	-0.19	Eosinophilic esophagitis (pediatric);	chr6:57978391	chr6:57493855~57497691:+
LUAD	cis	rs12935418	0.672	rs78895138	ENSG00000261061.1	RP11-303E16.2	-4.2	3.15e-05	0.00529	-0.22	-0.19	Mean corpuscular volume;	chr16:81014820	chr16:81030770~81031485:+
LUAD	cis	rs11195128	1	rs10884966	ENSG00000270589.1	RP11-348N5.7	-4.2	3.15e-05	0.00529	-0.16	-0.19	Crohn's disease;Inflammatory bowel disease;	chr10:110425838	chr10:110910596~110912244:+
LUAD	cis	rs6686842	0.536	rs61774688	ENSG00000235358.1	RP11-399E6.1	-4.2	3.15e-05	0.00529	-0.22	-0.19	Height;	chr1:41212213	chr1:41242373~41284861:+
LUAD	cis	rs8098244	0.737	rs1258148	ENSG00000264745.1	TTC39C-AS1	-4.2	3.15e-05	0.0053	-0.24	-0.19	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23940216	chr18:23994213~24015339:-
LUAD	cis	rs7119038	0.818	rs10892287	ENSG00000255239.1	AP002954.6	4.2	3.15e-05	0.0053	0.28	0.19	Sjögren's syndrome;	chr11:118772290	chr11:118688039~118690600:-
LUAD	cis	rs6840360	0.571	rs12650655	ENSG00000270265.1	RP11-731D1.4	-4.2	3.15e-05	0.0053	-0.21	-0.19	Intelligence (multi-trait analysis);	chr4:151634923	chr4:151333775~151353224:-
LUAD	cis	rs853679	0.607	rs13207345	ENSG00000219392.1	RP1-265C24.5	-4.2	3.15e-05	0.0053	-0.41	-0.19	Depression;	chr6:28297795	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.607	rs72854513	ENSG00000219392.1	RP1-265C24.5	-4.2	3.15e-05	0.0053	-0.41	-0.19	Depression;	chr6:28298177	chr6:28115628~28116551:+
LUAD	cis	rs2933343	0.7	rs1683787	ENSG00000231305.3	RP11-723O4.2	-4.2	3.15e-05	0.0053	-0.2	-0.19	IgG glycosylation;	chr3:128908178	chr3:128861313~128871540:-
LUAD	cis	rs3096299	0.503	rs9925045	ENSG00000182376.2	RP5-1142A6.8	4.2	3.15e-05	0.0053	0.19	0.19	Multiple myeloma (IgH translocation);	chr16:89490068	chr16:88742767~88745748:+
LUAD	cis	rs6928977	0.5	rs719885	ENSG00000231028.7	LINC00271	-4.2	3.15e-05	0.0053	-0.22	-0.19	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135618217	chr6:135497801~135716055:+
LUAD	cis	rs853679	0.542	rs9393892	ENSG00000226314.6	ZNF192P1	-4.2	3.15e-05	0.0053	-0.25	-0.19	Depression;	chr6:28113616	chr6:28161781~28169594:+
LUAD	cis	rs2115630	1	rs10220733	ENSG00000225151.9	GOLGA2P7	4.2	3.15e-05	0.0053	0.21	0.19	P wave terminal force;	chr15:84737633	chr15:84199311~84230136:-
LUAD	cis	rs12712133	0.552	rs10469856	ENSG00000234389.1	AC007278.3	4.2	3.16e-05	0.0053	0.18	0.19	Primary biliary cholangitis;	chr2:102272369	chr2:102438713~102440475:+
LUAD	cis	rs763121	0.853	rs5750622	ENSG00000225450.1	RP3-508I15.14	-4.2	3.16e-05	0.0053	-0.19	-0.19	Menopause (age at onset);	chr22:38560459	chr22:38739003~38749041:+
LUAD	cis	rs860818	1	rs1626853	ENSG00000226816.2	AC005082.12	4.2	3.16e-05	0.0053	0.48	0.19	Initial pursuit acceleration;	chr7:23195723	chr7:23206013~23208045:+
LUAD	cis	rs860818	1	rs1637216	ENSG00000226816.2	AC005082.12	4.2	3.16e-05	0.0053	0.48	0.19	Initial pursuit acceleration;	chr7:23196510	chr7:23206013~23208045:+
LUAD	cis	rs860818	1	rs858238	ENSG00000226816.2	AC005082.12	4.2	3.16e-05	0.0053	0.48	0.19	Initial pursuit acceleration;	chr7:23199514	chr7:23206013~23208045:+
LUAD	cis	rs9341808	0.53	rs3805877	ENSG00000260645.1	RP11-250B2.5	4.2	3.16e-05	0.0053	0.18	0.19	Sitting height ratio;	chr6:80321812	chr6:80466958~80469080:+
LUAD	cis	rs11051970	0.879	rs10844201	ENSG00000274964.1	RP11-817I4.1	-4.2	3.16e-05	0.0053	-0.2	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr12:32422095	chr12:32339368~32340724:+
LUAD	cis	rs6095360	1	rs2426125	ENSG00000222365.1	SNORD12B	-4.2	3.16e-05	0.0053	-0.19	-0.19	Intelligence (multi-trait analysis);	chr20:49084445	chr20:49280319~49280409:+
LUAD	cis	rs7208859	0.623	rs55811708	ENSG00000280069.1	CTD-2349P21.3	-4.2	3.16e-05	0.0053	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30738182~30740275:+
LUAD	cis	rs17122278	1	rs11216900	ENSG00000243431.1	RPL5P30	4.2	3.16e-05	0.0053	0.24	0.19	Total cholesterol levels;	chr11:118565364	chr11:118560690~118561580:+
LUAD	cis	rs910316	0.967	rs4903293	ENSG00000279594.1	RP11-950C14.10	-4.2	3.16e-05	0.0053	-0.21	-0.19	Height;	chr14:75189865	chr14:75011269~75012851:-
LUAD	cis	rs7178375	0.678	rs34678577	ENSG00000270015.1	RP11-540B6.6	4.2	3.16e-05	0.00531	0.18	0.19	Hypertriglyceridemia;	chr15:30885262	chr15:30926514~30928407:+
LUAD	cis	rs651907	0.557	rs7651721	ENSG00000244119.1	PDCL3P4	4.2	3.16e-05	0.00531	0.19	0.19	Colorectal cancer;	chr3:101674739	chr3:101712472~101713191:+
LUAD	cis	rs9341808	0.727	rs4706834	ENSG00000233967.5	RP11-250B2.3	4.2	3.16e-05	0.00531	0.19	0.19	Sitting height ratio;	chr6:80302888	chr6:80443344~80465927:+
LUAD	cis	rs17685	0.753	rs2302435	ENSG00000280388.1	RP11-229D13.3	4.2	3.16e-05	0.00531	0.18	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76047669	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.725	rs2302436	ENSG00000280388.1	RP11-229D13.3	4.2	3.16e-05	0.00531	0.18	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76047670	chr7:76043977~76045963:-
LUAD	cis	rs681343	1	rs492602	ENSG00000232871.7	SEC1P	4.2	3.16e-05	0.00531	0.21	0.19	Primary sclerosing cholangitis;Childhood ear infection;Lung adenocarcinoma;	chr19:48703160	chr19:48638071~48682245:+
LUAD	cis	rs1334894	0.901	rs12528458	ENSG00000228559.1	RP3-340B19.3	-4.2	3.16e-05	0.00531	-0.38	-0.19	Coronary artery disease;	chr6:35537534	chr6:35544632~35545669:+
LUAD	cis	rs13160562	0.527	rs152479	ENSG00000272109.1	CTD-2260A17.3	-4.2	3.16e-05	0.00531	-0.19	-0.19	Alcohol dependence;	chr5:96769339	chr5:96804353~96806105:+
LUAD	cis	rs13160562	0.527	rs25863	ENSG00000272109.1	CTD-2260A17.3	-4.2	3.16e-05	0.00531	-0.19	-0.19	Alcohol dependence;	chr5:96770222	chr5:96804353~96806105:+
LUAD	cis	rs2274273	0.84	rs7144737	ENSG00000258413.1	RP11-665C16.6	-4.2	3.16e-05	0.00531	-0.24	-0.19	Protein biomarker;	chr14:55356228	chr14:55262767~55272075:-
LUAD	cis	rs2153535	0.764	rs12190361	ENSG00000230939.1	RP11-314C16.1	4.2	3.16e-05	0.00531	0.21	0.19	Motion sickness;	chr6:8377079	chr6:8784178~8785445:+
LUAD	cis	rs6785206	0.772	rs6439134	ENSG00000242551.2	POU5F1P6	-4.2	3.16e-05	0.00531	-0.35	-0.19	Lymphocyte percentage of white cells;	chr3:128604661	chr3:128674735~128677005:-
LUAD	cis	rs987710	0.521	rs5757066	ENSG00000211639.2	IGLV4-60	-4.2	3.16e-05	0.00531	-0.26	-0.19	Iron status biomarkers;Iron deficiency;	chr22:22144406	chr22:22162199~22162681:+
LUAD	cis	rs3808502	0.526	rs36048422	ENSG00000255046.1	RP11-297N6.4	4.2	3.16e-05	0.00531	0.23	0.19	Neuroticism;	chr8:11559635	chr8:11797928~11802568:-
LUAD	cis	rs3808502	0.526	rs11783065	ENSG00000255046.1	RP11-297N6.4	4.2	3.16e-05	0.00531	0.23	0.19	Neuroticism;	chr8:11559748	chr8:11797928~11802568:-
LUAD	cis	rs7551222	0.752	rs11240758	ENSG00000240219.1	RP11-430C7.5	4.2	3.16e-05	0.00531	0.2	0.19	Schizophrenia;	chr1:204559523	chr1:204626775~204629712:+
LUAD	cis	rs9341808	0.53	rs3805876	ENSG00000260645.1	RP11-250B2.5	4.2	3.17e-05	0.00531	0.18	0.19	Sitting height ratio;	chr6:80321822	chr6:80466958~80469080:+
LUAD	cis	rs848490	0.928	rs62462679	ENSG00000214293.7	APTR	4.2	3.17e-05	0.00532	0.25	0.19	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77856423	chr7:77657660~77696265:-
LUAD	cis	rs4879677	1	rs10757673	ENSG00000215441.3	CTAGE12P	-4.2	3.17e-05	0.00532	-0.23	-0.19	Gut microbiome composition (summer and winter);	chr9:27670815	chr9:27608382~27610745:-
LUAD	cis	rs9341808	0.65	rs6909546	ENSG00000260645.1	RP11-250B2.5	4.2	3.17e-05	0.00532	0.18	0.19	Sitting height ratio;	chr6:80160206	chr6:80466958~80469080:+
LUAD	cis	rs6500602	0.767	rs8060219	ENSG00000280063.1	RP11-295D4.3	4.2	3.17e-05	0.00532	0.12	0.19	Schizophrenia;	chr16:4430157	chr16:4346694~4348648:-
LUAD	cis	rs13113518	0.934	rs11935823	ENSG00000272969.1	RP11-528I4.2	4.2	3.17e-05	0.00532	0.2	0.19	Height;	chr4:55589624	chr4:55547112~55547889:+
LUAD	cis	rs17772222	0.655	rs7160717	ENSG00000258789.1	RP11-507K2.3	-4.2	3.17e-05	0.00532	-0.23	-0.19	Coronary artery calcification;	chr14:88498232	chr14:88551597~88552493:+
LUAD	cis	rs6840258	0.723	rs340642	ENSG00000251411.1	RP11-397E7.4	4.2	3.17e-05	0.00532	0.22	0.19	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87028261	chr4:86913266~86914817:-
LUAD	cis	rs10090774	0.71	rs13278258	ENSG00000280303.2	ERICD	-4.2	3.17e-05	0.00533	-0.21	-0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140675675	chr8:140636281~140638283:+
LUAD	cis	rs11089937	0.568	rs12160317	ENSG00000211640.3	IGLV6-57	4.2	3.17e-05	0.00533	0.14	0.19	Periodontitis (PAL4Q3);	chr22:22131619	chr22:22195713~22196460:+
LUAD	cis	rs2446066	0.872	rs11170549	ENSG00000257379.1	RP11-793H13.8	4.2	3.17e-05	0.00533	0.31	0.19	Red blood cell count;	chr12:53420596	chr12:53441741~53467528:+
LUAD	cis	rs2354432	0.607	rs12402309	ENSG00000226015.2	CCT8P1	4.2	3.17e-05	0.00533	0.34	0.19	Mitochondrial DNA levels;	chr1:147250328	chr1:147203276~147204932:-
LUAD	cis	rs7590268	0.606	rs12991732	ENSG00000279873.2	LINC01126	4.2	3.17e-05	0.00533	0.18	0.19	Orofacial clefts;	chr2:43418672	chr2:43227210~43228855:+
LUAD	cis	rs6121246	0.909	rs6088962	ENSG00000230613.1	HM13-AS1	4.2	3.17e-05	0.00533	0.29	0.19	Mean corpuscular hemoglobin;	chr20:31680381	chr20:31567707~31573263:-
LUAD	cis	rs1502337	0.532	rs6606687	ENSG00000278993.1	RP3-424M6.4	-4.2	3.17e-05	0.00533	-0.23	-0.19	Body mass index;	chr12:110501616	chr12:110501614~110503441:+
LUAD	cis	rs8177876	0.822	rs7206814	ENSG00000261061.1	RP11-303E16.2	4.2	3.18e-05	0.00533	0.28	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074086	chr16:81030770~81031485:+
LUAD	cis	rs516842	0.655	rs73487665	ENSG00000234835.1	PHBP13	-4.2	3.18e-05	0.00533	-0.42	-0.19	Lobe attachment (rater-scored or self-reported);	chr13:35017506	chr13:35251070~35251829:+
LUAD	cis	rs6071166	0.935	rs1358899	ENSG00000224635.1	RP4-564F22.5	-4.2	3.18e-05	0.00533	-0.21	-0.19	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38701050	chr20:38406011~38416797:-
LUAD	cis	rs9649213	0.593	rs6973775	ENSG00000272950.1	RP11-307C18.1	4.2	3.18e-05	0.00533	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98375373	chr7:98322853~98323430:+
LUAD	cis	rs7324557	0.717	rs9510866	ENSG00000205861.10	C1QTNF9B-AS1	-4.2	3.18e-05	0.00533	-0.25	-0.19	Visceral adipose tissue adjusted for BMI;	chr13:23806708	chr13:23888889~23897263:+
LUAD	cis	rs4713118	0.662	rs4713120	ENSG00000219392.1	RP1-265C24.5	-4.2	3.18e-05	0.00534	-0.23	-0.19	Parkinson's disease;	chr6:27754056	chr6:28115628~28116551:+
LUAD	cis	rs9926296	0.744	rs164746	ENSG00000260259.1	RP11-368I7.4	4.2	3.18e-05	0.00534	0.19	0.19	Vitiligo;	chr16:89642611	chr16:89682620~89686569:-
LUAD	cis	rs473651	0.935	rs477041	ENSG00000229915.1	AC016999.2	4.2	3.18e-05	0.00534	0.25	0.19	Multiple system atrophy;	chr2:238447354	chr2:238427077~238427729:-
LUAD	cis	rs1387259	0.79	rs2732445	ENSG00000257763.1	OR5BK1P	4.2	3.18e-05	0.00534	0.2	0.19	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48251750	chr12:48355792~48356614:-
LUAD	cis	rs11723261	0.582	rs4582104	ENSG00000211553.1	AC253576.2	-4.2	3.18e-05	0.00534	-0.26	-0.19	Immune response to smallpox vaccine (IL-6);	chr4:143160	chr4:136461~136568:+
LUAD	cis	rs467650	0.927	rs154207	ENSG00000248489.1	CTD-2007H13.3	4.2	3.19e-05	0.00534	0.2	0.19	Venous thromboembolism (SNP x SNP interaction);	chr5:98627686	chr5:98929171~98995013:+
LUAD	cis	rs7119038	0.818	rs10892294	ENSG00000255239.1	AP002954.6	4.2	3.19e-05	0.00535	0.27	0.19	Sjögren's syndrome;	chr11:118796648	chr11:118688039~118690600:-
LUAD	cis	rs473651	0.935	rs35080527	ENSG00000229915.1	AC016999.2	-4.2	3.19e-05	0.00535	-0.25	-0.19	Multiple system atrophy;	chr2:238442746	chr2:238427077~238427729:-
LUAD	cis	rs911555	0.692	rs7146215	ENSG00000244691.1	RPL10AP1	4.2	3.19e-05	0.00535	0.25	0.19	Intelligence (multi-trait analysis);	chr14:103449571	chr14:103412119~103412761:-
LUAD	cis	rs4879677	0.959	rs4878536	ENSG00000215441.3	CTAGE12P	-4.2	3.19e-05	0.00535	-0.23	-0.19	Gut microbiome composition (summer and winter);	chr9:27682259	chr9:27608382~27610745:-
LUAD	cis	rs2562456	0.833	rs11667361	ENSG00000268081.1	RP11-678G14.2	4.2	3.19e-05	0.00535	0.29	0.19	Pain;	chr19:21356580	chr19:21554640~21569237:-
LUAD	cis	rs6496932	0.865	rs4842879	ENSG00000202081.1	RNU6-1280P	4.2	3.19e-05	0.00535	0.28	0.19	Central corneal thickness;Corneal structure;	chr15:85381657	chr15:85651522~85651628:-
LUAD	cis	rs853679	0.607	rs13208096	ENSG00000219392.1	RP1-265C24.5	-4.2	3.19e-05	0.00535	-0.42	-0.19	Depression;	chr6:28257533	chr6:28115628~28116551:+
LUAD	cis	rs7119038	0.818	rs76704408	ENSG00000255422.1	AP002954.4	4.2	3.19e-05	0.00535	0.28	0.19	Sjögren's syndrome;	chr11:118812618	chr11:118704607~118750263:+
LUAD	cis	rs9287719	0.967	rs4284804	ENSG00000243819.4	RN7SL832P	4.2	3.19e-05	0.00535	0.2	0.19	Prostate cancer;	chr2:10581998	chr2:10690344~10692099:+
LUAD	cis	rs2348418	0.966	rs11049695	ENSG00000247934.4	RP11-967K21.1	4.2	3.19e-05	0.00535	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28527934	chr12:28163298~28190738:-
LUAD	cis	rs2274273	0.905	rs8007944	ENSG00000258413.1	RP11-665C16.6	-4.2	3.19e-05	0.00536	-0.24	-0.19	Protein biomarker;	chr14:55110098	chr14:55262767~55272075:-
LUAD	cis	rs6840360	0.615	rs4696097	ENSG00000270265.1	RP11-731D1.4	4.2	3.19e-05	0.00536	0.21	0.19	Intelligence (multi-trait analysis);	chr4:151558613	chr4:151333775~151353224:-
LUAD	cis	rs603446	0.967	rs180370	ENSG00000254851.1	RP11-109L13.1	-4.2	3.19e-05	0.00536	-0.24	-0.19	Triglycerides;	chr11:116721649	chr11:117135528~117138582:+
LUAD	cis	rs13113518	1	rs4864995	ENSG00000272969.1	RP11-528I4.2	4.2	3.19e-05	0.00536	0.2	0.19	Height;	chr4:55452853	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs12651640	ENSG00000272969.1	RP11-528I4.2	4.2	3.19e-05	0.00536	0.2	0.19	Height;	chr4:55454154	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs1554483	ENSG00000272969.1	RP11-528I4.2	4.2	3.19e-05	0.00536	0.2	0.19	Height;	chr4:55455650	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs1464490	ENSG00000272969.1	RP11-528I4.2	4.2	3.19e-05	0.00536	0.2	0.19	Height;	chr4:55456620	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs10517346	ENSG00000272969.1	RP11-528I4.2	4.2	3.19e-05	0.00536	0.2	0.19	Height;	chr4:55457027	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs11133384	ENSG00000272969.1	RP11-528I4.2	4.2	3.19e-05	0.00536	0.2	0.19	Height;	chr4:55457086	chr4:55547112~55547889:+
LUAD	cis	rs262150	0.659	rs2657340	ENSG00000231419.5	LINC00689	4.2	3.19e-05	0.00536	0.23	0.19	Facial morphology (factor 20);	chr7:159004277	chr7:159006522~159030195:+
LUAD	cis	rs1005277	0.522	rs1208684	ENSG00000273019.1	RP11-508N22.13	-4.2	3.2e-05	0.00536	-0.21	-0.19	Extrinsic epigenetic age acceleration;	chr10:37805008	chr10:38149968~38150293:+
LUAD	cis	rs7772486	0.79	rs2250387	ENSG00000235652.6	RP11-545I5.3	4.2	3.2e-05	0.00536	0.19	0.19	Lobe attachment (rater-scored or self-reported);	chr6:145884097	chr6:145799409~145886585:+
LUAD	cis	rs7615952	0.8	rs11915699	ENSG00000241288.6	RP11-379B18.5	-4.2	3.2e-05	0.00536	-0.25	-0.19	Blood pressure (smoking interaction);	chr3:125913841	chr3:125827238~125916384:-
LUAD	cis	rs9649213	0.593	rs3801263	ENSG00000272950.1	RP11-307C18.1	4.2	3.2e-05	0.00536	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98335704	chr7:98322853~98323430:+
LUAD	cis	rs7665090	0.87	rs228615	ENSG00000251288.2	RP11-10L12.2	4.2	3.2e-05	0.00536	0.23	0.19	Primary biliary cholangitis;	chr4:102658303	chr4:102751401~102752641:+
LUAD	cis	rs6142102	0.886	rs6059583	ENSG00000275784.1	RP5-1125A11.6	-4.2	3.2e-05	0.00536	-0.21	-0.19	Skin pigmentation;	chr20:33944308	chr20:33989480~33991818:-
LUAD	cis	rs2395128	0.586	rs56124122	ENSG00000213731.2	RAB5CP1	4.2	3.2e-05	0.00536	0.38	0.19	Ulcerative colitis;Inflammatory bowel disease;	chr10:75059102	chr10:74423435~74424014:-
LUAD	cis	rs4908769	0.66	rs172531	ENSG00000232912.4	RP5-1115A15.1	-4.2	3.2e-05	0.00537	-0.17	-0.19	Allergy;	chr1:8435530	chr1:8424645~8434838:+
LUAD	cis	rs2243480	1	rs464895	ENSG00000232559.3	GS1-124K5.12	4.2	3.2e-05	0.00537	0.33	0.19	Diabetic kidney disease;	chr7:66062119	chr7:66554588~66576923:-
LUAD	cis	rs875971	0.789	rs28815324	ENSG00000222364.1	RNU6-96P	4.2	3.2e-05	0.00537	0.25	0.19	Aortic root size;	chr7:66100789	chr7:66395191~66395286:+
LUAD	cis	rs9910816	0.806	rs9900954	ENSG00000267659.4	LINC01482	4.2	3.2e-05	0.00537	0.22	0.19	Bipolar disorder (inflammation and infection response interaction);	chr17:68349156	chr17:68591796~68763882:+
LUAD	cis	rs394563	0.601	rs382720	ENSG00000231760.4	RP11-350J20.5	-4.2	3.21e-05	0.00537	-0.24	-0.19	Dupuytren's disease;	chr6:149474125	chr6:149796151~149826294:-
LUAD	cis	rs189798	0.807	rs330905	ENSG00000253893.2	FAM85B	-4.2	3.21e-05	0.00537	-0.26	-0.19	Myopia (pathological);	chr8:9136041	chr8:8167819~8226614:-
LUAD	cis	rs17685	0.712	rs7785025	ENSG00000280388.1	RP11-229D13.3	4.2	3.21e-05	0.00537	0.18	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:75998783	chr7:76043977~76045963:-
LUAD	cis	rs8072100	0.805	rs67919208	ENSG00000228782.6	CTD-2026D20.3	4.2	3.21e-05	0.00537	0.19	0.19	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47694507	chr17:47450568~47492492:-
LUAD	cis	rs889398	0.802	rs9940315	ENSG00000226232.7	RP11-419C5.2	-4.2	3.21e-05	0.00538	-0.16	-0.19	Body mass index;	chr16:69842261	chr16:69976388~69996188:-
LUAD	cis	rs7119038	0.774	rs874621	ENSG00000255422.1	AP002954.4	4.2	3.21e-05	0.00538	0.3	0.19	Sjögren's syndrome;	chr11:118784936	chr11:118704607~118750263:+
LUAD	cis	rs891378	0.958	rs1354942	ENSG00000274245.1	RP11-357P18.2	4.2	3.21e-05	0.00538	0.24	0.19	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207335147	chr1:207372559~207373252:+
LUAD	cis	rs9341808	0.754	rs3805885	ENSG00000260645.1	RP11-250B2.5	-4.2	3.21e-05	0.00538	-0.17	-0.19	Sitting height ratio;	chr6:80287034	chr6:80466958~80469080:+
LUAD	cis	rs7760535	0.831	rs62420437	ENSG00000230177.1	RP5-1112D6.4	-4.2	3.21e-05	0.00538	-0.17	-0.19	Metabolic traits;	chr6:111427577	chr6:111277932~111278742:+
LUAD	cis	rs16866061	1	rs72974263	ENSG00000228446.2	AC073052.1	-4.2	3.21e-05	0.00538	-0.2	-0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr2:224582654	chr2:224499387~224500100:-
LUAD	cis	rs4664293	1	rs10432413	ENSG00000230783.1	AC009961.2	-4.2	3.21e-05	0.00538	-0.24	-0.19	Monocyte percentage of white cells;	chr2:159639243	chr2:159689217~159690291:-
LUAD	cis	rs910316	1	rs12589815	ENSG00000279594.1	RP11-950C14.10	4.2	3.21e-05	0.00538	0.22	0.19	Height;	chr14:75077398	chr14:75011269~75012851:-
LUAD	cis	rs939960	0.69	rs1403220	ENSG00000279536.1	RP11-445N20.2	4.2	3.21e-05	0.00539	0.25	0.19	Neutrophil percentage of white cells;	chr7:150666612	chr7:149881477~149882105:+
LUAD	cis	rs2153535	0.585	rs1983603	ENSG00000230939.1	RP11-314C16.1	-4.2	3.21e-05	0.00539	-0.21	-0.19	Motion sickness;	chr6:8580747	chr6:8784178~8785445:+
LUAD	cis	rs7819412	0.838	rs3021494	ENSG00000255046.1	RP11-297N6.4	4.2	3.21e-05	0.00539	0.24	0.19	Triglycerides;	chr8:11126024	chr8:11797928~11802568:-
LUAD	cis	rs1552244	0.882	rs56332224	ENSG00000180385.7	EMC3-AS1	4.2	3.22e-05	0.00539	0.22	0.19	Alzheimer's disease;	chr3:9995637	chr3:9986893~10006990:+
LUAD	cis	rs10129255	0.913	rs28861466	ENSG00000211967.3	IGHV3-53	-4.2	3.22e-05	0.00539	-0.15	-0.19	Kawasaki disease;	chr14:106718572	chr14:106592676~106593347:-
LUAD	cis	rs6671200	0.573	rs3820345	ENSG00000228852.5	RP11-57H12.5	-4.2	3.22e-05	0.00539	-0.22	-0.19	Stearic acid (18:0) levels;	chr1:95247619	chr1:95243167~95278940:-
LUAD	cis	rs6671200	0.688	rs4950024	ENSG00000228852.5	RP11-57H12.5	-4.2	3.22e-05	0.00539	-0.22	-0.19	Stearic acid (18:0) levels;	chr1:95247943	chr1:95243167~95278940:-
LUAD	cis	rs2115630	0.936	rs11073663	ENSG00000225151.9	GOLGA2P7	4.2	3.22e-05	0.00539	0.21	0.19	P wave terminal force;	chr15:84717037	chr15:84199311~84230136:-
LUAD	cis	rs77688320	0.553	rs2540430	ENSG00000213090.2	AC007256.5	-4.2	3.22e-05	0.00539	-0.22	-0.19	Breast cancer;	chr2:201503791	chr2:201410544~201413308:-
LUAD	cis	rs12541335	0.639	rs11135995	ENSG00000254064.1	CTD-2530N21.4	-4.2	3.22e-05	0.00539	-0.19	-0.19	Hypertriglyceridemia;	chr8:22342635	chr8:22254576~22275162:-
LUAD	cis	rs2274273	0.905	rs2147961	ENSG00000259318.1	RP11-454L9.2	4.2	3.22e-05	0.00539	0.16	0.19	Protein biomarker;	chr14:55118663	chr14:55394940~55395233:-
LUAD	cis	rs7811142	1	rs73161759	ENSG00000078319.8	PMS2P1	-4.2	3.22e-05	0.00539	-0.22	-0.19	Platelet count;	chr7:100412371	chr7:100320992~100341908:-
LUAD	cis	rs8040855	0.627	rs11637512	ENSG00000259774.1	RP11-182J1.13	4.2	3.22e-05	0.00539	0.24	0.19	Bulimia nervosa;	chr15:85105528	chr15:84422618~84425882:+
LUAD	cis	rs8040855	0.627	rs17541051	ENSG00000259774.1	RP11-182J1.13	4.2	3.22e-05	0.00539	0.24	0.19	Bulimia nervosa;	chr15:85106122	chr15:84422618~84425882:+
LUAD	cis	rs8040855	0.627	rs35668291	ENSG00000259774.1	RP11-182J1.13	4.2	3.22e-05	0.00539	0.24	0.19	Bulimia nervosa;	chr15:85109582	chr15:84422618~84425882:+
LUAD	cis	rs2304003	1	rs9973895	ENSG00000235192.1	AC009495.2	4.2	3.22e-05	0.0054	0.23	0.19	Social communication problems;	chr2:165860936	chr2:165794851~165810010:+
LUAD	cis	rs6471393	0.929	rs4734251	ENSG00000253848.1	RP11-10N23.5	4.2	3.22e-05	0.0054	0.23	0.19	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93744195	chr8:93741193~93744534:+
LUAD	cis	rs6471393	0.929	rs4734252	ENSG00000253848.1	RP11-10N23.5	4.2	3.22e-05	0.0054	0.23	0.19	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93744286	chr8:93741193~93744534:+
LUAD	cis	rs7824557	0.564	rs2572400	ENSG00000255046.1	RP11-297N6.4	4.2	3.22e-05	0.0054	0.23	0.19	Retinal vascular caliber;	chr8:11376858	chr8:11797928~11802568:-
LUAD	cis	rs4372836	1	rs6707848	ENSG00000226833.4	AC097724.3	4.2	3.22e-05	0.0054	0.22	0.19	Body mass index;	chr2:28765217	chr2:28708953~28736205:-
LUAD	cis	rs2075677	0.506	rs2273101	ENSG00000222365.1	SNORD12B	-4.2	3.22e-05	0.0054	-0.22	-0.19	Subjective well-being;	chr20:48921796	chr20:49280319~49280409:+
LUAD	cis	rs7208859	0.623	rs11657662	ENSG00000266490.1	CTD-2349P21.9	-4.2	3.22e-05	0.0054	-0.28	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30792372~30792833:+
LUAD	cis	rs2652822	0.504	rs2134263	ENSG00000259498.1	RP11-244F12.3	4.2	3.23e-05	0.0054	0.22	0.19	Metabolic traits;	chr15:63073195	chr15:63046034~63049387:-
LUAD	cis	rs9467773	1	rs6940053	ENSG00000261353.1	CTA-14H9.5	-4.2	3.23e-05	0.0054	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26561894	chr6:26527063~26527404:+
LUAD	cis	rs17345786	0.906	rs12638137	ENSG00000244119.1	PDCL3P4	4.2	3.23e-05	0.0054	0.22	0.19	Colonoscopy-negative controls vs population controls;	chr3:101432120	chr3:101712472~101713191:+
LUAD	cis	rs5758659	0.904	rs134877	ENSG00000273366.1	CTA-989H11.1	-4.2	3.23e-05	0.0054	-0.21	-0.19	Cognitive function;	chr22:42266365	chr22:42278188~42278846:+
LUAD	cis	rs4819052	0.851	rs2838858	ENSG00000215447.6	BX322557.10	-4.2	3.23e-05	0.0054	-0.22	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261178	chr21:45288052~45291738:+
LUAD	cis	rs1113500	0.805	rs11185244	ENSG00000226822.1	RP11-356N1.2	4.2	3.23e-05	0.0054	0.21	0.19	Growth-regulated protein alpha levels;	chr1:108058525	chr1:108071482~108074519:+
LUAD	cis	rs1113500	0.814	rs1592282	ENSG00000226822.1	RP11-356N1.2	4.2	3.23e-05	0.0054	0.21	0.19	Growth-regulated protein alpha levels;	chr1:108058743	chr1:108071482~108074519:+
LUAD	cis	rs35740288	0.731	rs11634651	ENSG00000259407.1	RP11-158M2.3	-4.2	3.23e-05	0.0054	-0.18	-0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85550695	chr15:85744109~85750281:-
LUAD	cis	rs957448	1	rs12679345	ENSG00000253175.1	RP11-267M23.6	4.2	3.23e-05	0.00541	0.22	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94552305	chr8:94565036~94565715:+
LUAD	cis	rs9341808	0.754	rs10733162	ENSG00000233967.5	RP11-250B2.3	4.2	3.23e-05	0.00541	0.19	0.19	Sitting height ratio;	chr6:80313672	chr6:80443344~80465927:+
LUAD	cis	rs7404843	0.778	rs72774864	ENSG00000183458.12	RP11-958N24.1	4.2	3.23e-05	0.00541	0.24	0.19	Testicular germ cell tumor;	chr16:15418465	chr16:14911551~14935708:+
LUAD	cis	rs4448343	1	rs16909919	ENSG00000271155.1	RP11-435O5.5	4.2	3.23e-05	0.00541	0.24	0.19	Height;	chr9:95503498	chr9:95506235~95507636:+
LUAD	cis	rs7102710	1	rs11604253	ENSG00000254418.1	RP11-21L19.1	4.2	3.23e-05	0.00541	0.5	0.19	Glucagon levels in response to oral glucose tolerance test (fasting);	chr11:14213295	chr11:14262846~14273691:-
LUAD	cis	rs7102710	1	rs79892940	ENSG00000254418.1	RP11-21L19.1	4.2	3.23e-05	0.00541	0.5	0.19	Glucagon levels in response to oral glucose tolerance test (fasting);	chr11:14221340	chr11:14262846~14273691:-
LUAD	cis	rs862034	0.509	rs12586772	ENSG00000270000.1	RP3-449M8.9	4.2	3.23e-05	0.00541	0.21	0.19	Height;	chr14:74465938	chr14:74471930~74472360:-
LUAD	cis	rs2115630	1	rs11854313	ENSG00000225151.9	GOLGA2P7	4.2	3.23e-05	0.00541	0.21	0.19	P wave terminal force;	chr15:84760817	chr15:84199311~84230136:-
LUAD	cis	rs34792	0.688	rs13339072	ENSG00000207425.1	Y_RNA	-4.2	3.23e-05	0.00541	-0.23	-0.19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15504090	chr16:14915457~14915556:-
LUAD	cis	rs5758659	0.819	rs134871	ENSG00000227370.1	RP4-669P10.19	-4.2	3.23e-05	0.00541	-0.17	-0.19	Cognitive function;	chr22:42256710	chr22:42132543~42132998:+
LUAD	cis	rs801193	1	rs10234018	ENSG00000236529.1	RP13-254B10.1	-4.2	3.23e-05	0.00541	-0.19	-0.19	Aortic root size;	chr7:66681297	chr7:65840212~65840596:+
LUAD	cis	rs1714507	0.533	rs2731118	ENSG00000272087.1	RP11-379F4.7	-4.2	3.23e-05	0.00541	-0.2	-0.19	Subjective well-being;	chr3:158589942	chr3:158693120~158693768:-
LUAD	cis	rs1714507	0.533	rs2573179	ENSG00000272087.1	RP11-379F4.7	-4.2	3.23e-05	0.00541	-0.2	-0.19	Subjective well-being;	chr3:158590018	chr3:158693120~158693768:-
LUAD	cis	rs860295	0.702	rs10908470	ENSG00000225855.5	RUSC1-AS1	4.2	3.23e-05	0.00541	0.13	0.19	Body mass index;	chr1:155557222	chr1:155316863~155324176:-
LUAD	cis	rs6951245	0.744	rs1133122	ENSG00000199023.2	MIR339	-4.2	3.24e-05	0.00542	-0.32	-0.19	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1152936	chr7:1022935~1023045:-
LUAD	cis	rs2412819	0.599	rs2470120	ENSG00000166763.7	STRCP1	4.2	3.24e-05	0.00542	0.23	0.19	Lung cancer;	chr15:43636872	chr15:43699488~43718184:-
LUAD	cis	rs73193808	0.851	rs8129987	ENSG00000215533.7	LINC00189	-4.2	3.24e-05	0.00542	-0.26	-0.19	Coronary artery disease;	chr21:29236076	chr21:29193480~29288205:+
LUAD	cis	rs227275	0.554	rs223466	ENSG00000251288.2	RP11-10L12.2	-4.2	3.24e-05	0.00542	-0.22	-0.19	Allergic disease (asthma, hay fever or eczema);	chr4:102780039	chr4:102751401~102752641:+
LUAD	cis	rs7746199	0.736	rs13202295	ENSG00000219392.1	RP1-265C24.5	-4.2	3.24e-05	0.00542	-0.41	-0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731058	chr6:28115628~28116551:+
LUAD	cis	rs6723108	0.517	rs12473839	ENSG00000224043.6	CCNT2-AS1	-4.2	3.24e-05	0.00542	-0.23	-0.19	Type 2 diabetes;	chr2:134880474	chr2:134735464~134918710:-
LUAD	cis	rs7107174	1	rs2510050	ENSG00000251323.2	RP11-452H21.4	4.2	3.24e-05	0.00542	0.24	0.19	Testicular germ cell tumor;	chr11:78271518	chr11:78423982~78429836:-
LUAD	cis	rs7107174	1	rs2512544	ENSG00000251323.2	RP11-452H21.4	4.2	3.24e-05	0.00542	0.24	0.19	Testicular germ cell tumor;	chr11:78275325	chr11:78423982~78429836:-
LUAD	cis	rs10208649	0.611	rs61740458	ENSG00000272156.1	RP11-477N3.1	4.2	3.24e-05	0.00542	0.36	0.19	Body mass index;	chr2:54065503	chr2:54082554~54085066:+
LUAD	cis	rs2033711	0.84	rs4801590	ENSG00000268912.1	CTD-2619J13.17	-4.2	3.24e-05	0.00542	-0.2	-0.19	Uric acid clearance;	chr19:58450446	chr19:58428632~58431148:-
LUAD	cis	rs11089937	0.512	rs34963809	ENSG00000211640.3	IGLV6-57	4.2	3.24e-05	0.00542	0.14	0.19	Periodontitis (PAL4Q3);	chr22:22130737	chr22:22195713~22196460:+
LUAD	cis	rs17826219	0.706	rs57698184	ENSG00000280069.1	CTD-2349P21.3	-4.2	3.24e-05	0.00542	-0.26	-0.19	Body mass index;	chr17:30737900	chr17:30738182~30740275:+
LUAD	cis	rs17826219	0.706	rs9893922	ENSG00000280069.1	CTD-2349P21.3	-4.2	3.24e-05	0.00542	-0.26	-0.19	Body mass index;	chr17:30741407	chr17:30738182~30740275:+
LUAD	cis	rs17826219	0.5	rs9891256	ENSG00000280069.1	CTD-2349P21.3	-4.2	3.24e-05	0.00542	-0.26	-0.19	Body mass index;	chr17:30745674	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs7503335	ENSG00000280069.1	CTD-2349P21.3	-4.2	3.24e-05	0.00542	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30738182~30740275:+
LUAD	cis	rs2832077	0.527	rs11088095	ENSG00000232855.5	AF131217.1	4.2	3.24e-05	0.00542	0.19	0.19	Cognitive test performance;	chr21:28850866	chr21:28439346~28674848:-
LUAD	cis	rs2832077	0.527	rs9980449	ENSG00000232855.5	AF131217.1	4.2	3.24e-05	0.00542	0.19	0.19	Cognitive test performance;	chr21:28852567	chr21:28439346~28674848:-
LUAD	cis	rs2832077	0.527	rs59730679	ENSG00000232855.5	AF131217.1	4.2	3.24e-05	0.00542	0.19	0.19	Cognitive test performance;	chr21:28853922	chr21:28439346~28674848:-
LUAD	cis	rs28386778	0.863	rs2584637	ENSG00000240280.5	TCAM1P	-4.2	3.24e-05	0.00542	-0.22	-0.19	Prudent dietary pattern;	chr17:63865592	chr17:63849292~63864379:+
LUAD	cis	rs11673344	0.504	rs4239587	ENSG00000276846.1	CTD-3220F14.3	4.2	3.24e-05	0.00542	0.21	0.19	Obesity-related traits;	chr19:37136211	chr19:37314868~37315620:-
LUAD	cis	rs11673344	0.504	rs4805202	ENSG00000276846.1	CTD-3220F14.3	4.2	3.24e-05	0.00542	0.21	0.19	Obesity-related traits;	chr19:37136499	chr19:37314868~37315620:-
LUAD	cis	rs11673344	0.504	rs4805203	ENSG00000276846.1	CTD-3220F14.3	4.2	3.24e-05	0.00542	0.21	0.19	Obesity-related traits;	chr19:37136586	chr19:37314868~37315620:-
LUAD	cis	rs9309473	0.607	rs7567017	ENSG00000163016.8	ALMS1P	4.2	3.24e-05	0.00542	0.21	0.19	Metabolite levels;	chr2:73369142	chr2:73644919~73685576:+
LUAD	cis	rs6763848	1	rs6763848	ENSG00000214073.2	RPL21P17	4.2	3.24e-05	0.00542	0.19	0.19	Prostate cancer (SNP x SNP interaction);	chr3:1470903	chr3:1905651~1906125:+
LUAD	cis	rs11051970	0.592	rs73086040	ENSG00000274964.1	RP11-817I4.1	-4.2	3.24e-05	0.00542	-0.25	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr12:32414501	chr12:32339368~32340724:+
LUAD	cis	rs13113518	1	rs7662966	ENSG00000272969.1	RP11-528I4.2	4.2	3.24e-05	0.00542	0.2	0.19	Height;	chr4:55548261	chr4:55547112~55547889:+
LUAD	cis	rs10463554	0.963	rs26262	ENSG00000250682.4	LINC00491	4.2	3.24e-05	0.00542	0.23	0.19	Parkinson's disease;	chr5:103209462	chr5:102609156~102671559:-
LUAD	cis	rs595244	1	rs2455925	ENSG00000259705.1	RP11-227D13.1	4.2	3.24e-05	0.00542	0.38	0.19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48601452	chr15:48645951~48652016:+
LUAD	cis	rs2548724	0.773	rs261098	ENSG00000250682.4	LINC00491	-4.2	3.24e-05	0.00542	-0.25	-0.19	Type 2 diabetes;	chr5:102258642	chr5:102609156~102671559:-
LUAD	cis	rs2243480	1	rs410128	ENSG00000229886.1	RP5-1132H15.3	4.2	3.24e-05	0.00542	0.33	0.19	Diabetic kidney disease;	chr7:66138186	chr7:66025126~66031544:-
LUAD	cis	rs867371	0.82	rs7164362	ENSG00000255769.6	GOLGA2P10	-4.2	3.24e-05	0.00543	-0.21	-0.19	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82194401	chr15:82472993~82513950:-
LUAD	cis	rs9803723	0.648	rs6673342	ENSG00000261349.1	RP3-465N24.5	-4.2	3.24e-05	0.00543	-0.22	-0.19	Male-pattern baldness;	chr1:25134587	chr1:25266102~25267136:-
LUAD	cis	rs453301	0.653	rs7005133	ENSG00000233609.3	RP11-62H7.2	4.2	3.24e-05	0.00543	0.15	0.19	Joint mobility (Beighton score);	chr8:9043712	chr8:8961200~8979025:+
LUAD	cis	rs17406451	0.819	rs6739313	ENSG00000279873.2	LINC01126	4.2	3.24e-05	0.00543	0.16	0.19	Mitochondrial DNA levels;	chr2:43418536	chr2:43227210~43228855:+
LUAD	cis	rs8062405	0.69	rs7187604	ENSG00000261419.1	RP11-57A19.4	-4.2	3.24e-05	0.00543	-0.21	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28659696~28740781:-
LUAD	cis	rs2836974	0.865	rs34778912	ENSG00000232608.1	TIMM9P2	-4.2	3.24e-05	0.00543	-0.22	-0.19	Cognitive function;	chr21:39295111	chr21:39216624~39217506:+
LUAD	cis	rs2836974	0.865	rs7282624	ENSG00000232608.1	TIMM9P2	-4.2	3.24e-05	0.00543	-0.22	-0.19	Cognitive function;	chr21:39295114	chr21:39216624~39217506:+
LUAD	cis	rs950169	0.579	rs11633088	ENSG00000259570.1	RP11-671M22.4	-4.2	3.24e-05	0.00543	-0.27	-0.19	Schizophrenia;	chr15:84003429	chr15:84394512~84395514:+
LUAD	cis	rs133885	1	rs133889	ENSG00000272977.1	CTA-390C10.10	-4.2	3.24e-05	0.00543	-0.2	-0.19	Mathematical ability in children with dyslexia;	chr22:25764138	chr22:25476218~25479971:+
LUAD	cis	rs858239	0.509	rs6962213	ENSG00000226816.2	AC005082.12	4.2	3.25e-05	0.00543	0.25	0.19	Cerebrospinal fluid biomarker levels;	chr7:23148490	chr7:23206013~23208045:+
LUAD	cis	rs1023500	0.505	rs134891	ENSG00000205702.9	CYP2D7	4.2	3.25e-05	0.00543	0.15	0.19	Schizophrenia;	chr22:42279876	chr22:42140203~42144577:-
LUAD	cis	rs12468226	0.808	rs73992849	ENSG00000272966.1	RP11-686O6.1	4.2	3.25e-05	0.00543	0.31	0.19	Urate levels;	chr2:202152444	chr2:202336739~202337200:+
LUAD	cis	rs1334894	1	rs55922240	ENSG00000228559.1	RP3-340B19.3	-4.2	3.25e-05	0.00543	-0.39	-0.19	Coronary artery disease;	chr6:35640319	chr6:35544632~35545669:+
LUAD	cis	rs1334894	1	rs7756437	ENSG00000228559.1	RP3-340B19.3	-4.2	3.25e-05	0.00543	-0.39	-0.19	Coronary artery disease;	chr6:35642037	chr6:35544632~35545669:+
LUAD	cis	rs1334894	1	rs12527329	ENSG00000228559.1	RP3-340B19.3	-4.2	3.25e-05	0.00543	-0.39	-0.19	Coronary artery disease;	chr6:35642974	chr6:35544632~35545669:+
LUAD	cis	rs800160	1	rs708152	ENSG00000236264.4	RPL26P30	-4.2	3.25e-05	0.00543	-0.26	-0.19	Bacteremia;	chr11:2363118	chr11:2335132~2335776:-
LUAD	cis	rs77688320	0.535	rs11680694	ENSG00000213090.2	AC007256.5	4.2	3.25e-05	0.00544	0.21	0.19	Breast cancer;	chr2:201393498	chr2:201410544~201413308:-
LUAD	cis	rs4474465	1	rs4945277	ENSG00000251323.2	RP11-452H21.4	4.19	3.25e-05	0.00544	0.24	0.19	Alzheimer's disease (survival time);	chr11:78455921	chr11:78423982~78429836:-
LUAD	cis	rs2898681	0.581	rs730246	ENSG00000248375.1	RP11-177B4.1	-4.19	3.25e-05	0.00544	-0.28	-0.19	Optic nerve measurement (cup area);	chr4:52814552	chr4:52720081~52720831:-
LUAD	cis	rs2732480	0.5	rs2450989	ENSG00000257763.1	OR5BK1P	-4.19	3.25e-05	0.00544	-0.2	-0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48259625	chr12:48355792~48356614:-
LUAD	cis	rs761746	0.739	rs131225	ENSG00000236132.1	CTA-440B3.1	-4.19	3.25e-05	0.00544	-0.27	-0.19	Intelligence;	chr22:31717863	chr22:31816379~31817491:-
LUAD	cis	rs2243480	1	rs1638734	ENSG00000229886.1	RP5-1132H15.3	4.19	3.25e-05	0.00544	0.33	0.19	Diabetic kidney disease;	chr7:66632552	chr7:66025126~66031544:-
LUAD	cis	rs910316	1	rs2098297	ENSG00000279594.1	RP11-950C14.10	-4.19	3.25e-05	0.00544	-0.22	-0.19	Height;	chr14:75152415	chr14:75011269~75012851:-
LUAD	cis	rs71520386	0.861	rs35841035	ENSG00000228649.7	AC005682.5	-4.19	3.25e-05	0.00544	-0.3	-0.19	Fibrinogen levels;	chr7:22822987	chr7:22854178~22861579:+
LUAD	cis	rs4925386	0.802	rs6142735	ENSG00000273619.1	RP5-908M14.9	-4.19	3.26e-05	0.00544	-0.19	-0.19	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62343031	chr20:62386303~62386970:-
LUAD	cis	rs9815354	0.857	rs7634985	ENSG00000273328.4	RP11-141M3.6	4.19	3.26e-05	0.00545	0.3	0.19	Pulse pressure;Diastolic blood pressure;	chr3:41978073	chr3:42809414~42908105:+
LUAD	cis	rs11722779	0.815	rs223347	ENSG00000251288.2	RP11-10L12.2	-4.19	3.26e-05	0.00545	-0.23	-0.19	Schizophrenia;	chr4:102858815	chr4:102751401~102752641:+
LUAD	cis	rs11722779	0.873	rs223346	ENSG00000251288.2	RP11-10L12.2	-4.19	3.26e-05	0.00545	-0.23	-0.19	Schizophrenia;	chr4:102859339	chr4:102751401~102752641:+
LUAD	cis	rs7617773	0.784	rs11715799	ENSG00000199476.1	Y_RNA	-4.19	3.26e-05	0.00545	-0.25	-0.19	Coronary artery disease;	chr3:48213730	chr3:48288587~48288694:+
LUAD	cis	rs3096299	0.503	rs4785677	ENSG00000182376.2	RP5-1142A6.8	4.19	3.26e-05	0.00546	0.2	0.19	Multiple myeloma (IgH translocation);	chr16:89488693	chr16:88742767~88745748:+
LUAD	cis	rs2014572	1	rs3746231	ENSG00000268379.1	CTC-360J11.4	4.19	3.26e-05	0.00546	0.22	0.19	Hyperactive-impulsive symptoms;	chr19:57248689	chr19:57175233~57177921:+
LUAD	cis	rs17772222	0.74	rs61975278	ENSG00000258983.2	RP11-507K2.2	4.19	3.26e-05	0.00546	0.22	0.19	Coronary artery calcification;	chr14:88511223	chr14:88499334~88515502:+
LUAD	cis	rs858239	0.536	rs6956974	ENSG00000226816.2	AC005082.12	-4.19	3.26e-05	0.00546	-0.24	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23212699	chr7:23206013~23208045:+
LUAD	cis	rs2243480	0.803	rs160649	ENSG00000232559.3	GS1-124K5.12	4.19	3.26e-05	0.00546	0.32	0.19	Diabetic kidney disease;	chr7:66078212	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs160648	ENSG00000232559.3	GS1-124K5.12	4.19	3.26e-05	0.00546	0.32	0.19	Diabetic kidney disease;	chr7:66078397	chr7:66554588~66576923:-
LUAD	cis	rs763121	0.853	rs5757232	ENSG00000225450.1	RP3-508I15.14	-4.19	3.27e-05	0.00546	-0.19	-0.19	Menopause (age at onset);	chr22:38675672	chr22:38739003~38749041:+
LUAD	cis	rs763121	0.853	rs9306329	ENSG00000225450.1	RP3-508I15.14	-4.19	3.27e-05	0.00546	-0.19	-0.19	Menopause (age at onset);	chr22:38676449	chr22:38739003~38749041:+
LUAD	cis	rs763121	0.853	rs5750662	ENSG00000225450.1	RP3-508I15.14	-4.19	3.27e-05	0.00546	-0.19	-0.19	Menopause (age at onset);	chr22:38676467	chr22:38739003~38749041:+
LUAD	cis	rs34792	0.678	rs153787	ENSG00000207425.1	Y_RNA	4.19	3.27e-05	0.00546	0.23	0.19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15499916	chr16:14915457~14915556:-
LUAD	cis	rs4925386	0.759	rs2427293	ENSG00000273619.1	RP5-908M14.9	4.19	3.27e-05	0.00546	0.2	0.19	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62350803	chr20:62386303~62386970:-
LUAD	cis	rs7100689	0.542	rs10887869	ENSG00000226659.1	RP11-137H2.4	-4.19	3.27e-05	0.00547	-0.25	-0.19	Post bronchodilator FEV1;	chr10:80434933	chr10:80529597~80535942:-
LUAD	cis	rs42490	0.625	rs425312	ENSG00000251136.7	RP11-37B2.1	-4.19	3.27e-05	0.00547	-0.2	-0.19	Leprosy;	chr8:89834127	chr8:89609409~89757727:-
LUAD	cis	rs9815354	0.951	rs1717028	ENSG00000273328.4	RP11-141M3.6	-4.19	3.27e-05	0.00547	-0.27	-0.19	Pulse pressure;Diastolic blood pressure;	chr3:41861472	chr3:42809414~42908105:+
LUAD	cis	rs9815354	0.951	rs1716674	ENSG00000273328.4	RP11-141M3.6	-4.19	3.27e-05	0.00547	-0.27	-0.19	Pulse pressure;Diastolic blood pressure;	chr3:41861480	chr3:42809414~42908105:+
LUAD	cis	rs9815354	1	rs1716676	ENSG00000273328.4	RP11-141M3.6	-4.19	3.27e-05	0.00547	-0.27	-0.19	Pulse pressure;Diastolic blood pressure;	chr3:41861716	chr3:42809414~42908105:+
LUAD	cis	rs77688320	0.535	rs7561048	ENSG00000213090.2	AC007256.5	4.19	3.27e-05	0.00547	0.21	0.19	Breast cancer;	chr2:201388316	chr2:201410544~201413308:-
LUAD	cis	rs9341808	0.69	rs9343970	ENSG00000260645.1	RP11-250B2.5	4.19	3.27e-05	0.00547	0.18	0.19	Sitting height ratio;	chr6:80171572	chr6:80466958~80469080:+
LUAD	cis	rs2976388	0.566	rs13250661	ENSG00000253741.1	CTD-2292P10.4	4.19	3.28e-05	0.00547	0.22	0.19	Urinary tract infection frequency;	chr8:142722716	chr8:142702252~142726973:-
LUAD	cis	rs9813712	0.596	rs2587988	ENSG00000253540.4	FAM86HP	-4.19	3.28e-05	0.00548	-0.19	-0.19	Response to amphetamines;	chr3:130201415	chr3:130099092~130111472:-
LUAD	cis	rs7762018	0.891	rs3749882	ENSG00000231690.2	LINC00574	-4.19	3.28e-05	0.00548	-0.35	-0.19	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169751670	chr6:169790321~169802873:+
LUAD	cis	rs36093844	0.642	rs17148585	ENSG00000279742.1	RP11-700A24.1	4.19	3.28e-05	0.00548	0.19	0.19	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85909780	chr11:85852557~85854943:-
LUAD	cis	rs2348418	0.966	rs7136139	ENSG00000247934.4	RP11-967K21.1	4.19	3.28e-05	0.00548	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28531087	chr12:28163298~28190738:-
LUAD	cis	rs2348418	0.966	rs4144964	ENSG00000247934.4	RP11-967K21.1	4.19	3.28e-05	0.00548	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28531249	chr12:28163298~28190738:-
LUAD	cis	rs2274273	0.745	rs748017	ENSG00000258413.1	RP11-665C16.6	-4.19	3.28e-05	0.00548	-0.24	-0.19	Protein biomarker;	chr14:55075582	chr14:55262767~55272075:-
LUAD	cis	rs4908769	0.66	rs302714	ENSG00000232912.4	RP5-1115A15.1	4.19	3.28e-05	0.00548	0.18	0.19	Allergy;	chr1:8426071	chr1:8424645~8434838:+
LUAD	cis	rs6539288	0.739	rs4964511	ENSG00000260329.1	RP11-412D9.4	-4.19	3.28e-05	0.00548	-0.21	-0.19	Total body bone mineral density;	chr12:106966468	chr12:106954029~106955497:-
LUAD	cis	rs763512	0.532	rs3110626	ENSG00000276054.1	RP11-378E13.3	-4.19	3.28e-05	0.00548	-0.28	-0.19	3-hydroxypropylmercapturic acid levels in smokers;	chr17:37536300	chr17:37386886~37387926:+
LUAD	cis	rs651907	0.557	rs13069443	ENSG00000244119.1	PDCL3P4	4.19	3.28e-05	0.00548	0.19	0.19	Colorectal cancer;	chr3:101654461	chr3:101712472~101713191:+
LUAD	cis	rs7107174	1	rs58235466	ENSG00000251323.2	RP11-452H21.4	4.19	3.28e-05	0.00549	0.23	0.19	Testicular germ cell tumor;	chr11:78319840	chr11:78423982~78429836:-
LUAD	cis	rs812925	0.826	rs2694633	ENSG00000271889.1	RP11-493E12.1	-4.19	3.28e-05	0.00549	-0.24	-0.19	Immature fraction of reticulocytes;	chr2:61313507	chr2:61151433~61162105:-
LUAD	cis	rs13113518	0.756	rs7658446	ENSG00000272969.1	RP11-528I4.2	4.19	3.28e-05	0.00549	0.2	0.19	Height;	chr4:55495262	chr4:55547112~55547889:+
LUAD	cis	rs7107174	1	rs1893447	ENSG00000251323.2	RP11-452H21.4	4.19	3.28e-05	0.00549	0.23	0.19	Testicular germ cell tumor;	chr11:78262136	chr11:78423982~78429836:-
LUAD	cis	rs6832769	0.696	rs7660054	ENSG00000272969.1	RP11-528I4.2	4.19	3.28e-05	0.00549	0.2	0.19	Personality dimensions;	chr4:55402340	chr4:55547112~55547889:+
LUAD	cis	rs7061710	0.711	rs17623833	ENSG00000271811.1	RP1-79C4.4	-4.19	3.29e-05	0.00549	-0.28	-0.19	Blood metabolite levels;	chr1:171150573	chr1:170667381~170669425:+
LUAD	cis	rs17406451	0.788	rs12712886	ENSG00000279873.2	LINC01126	4.19	3.29e-05	0.00549	0.16	0.19	Mitochondrial DNA levels;	chr2:43472277	chr2:43227210~43228855:+
LUAD	cis	rs9309473	0.5	rs6757996	ENSG00000163016.8	ALMS1P	4.19	3.29e-05	0.00549	0.2	0.19	Metabolite levels;	chr2:73545124	chr2:73644919~73685576:+
LUAD	cis	rs12439619	0.508	rs8042665	ENSG00000259429.4	UBE2Q2P2	-4.19	3.29e-05	0.00549	-0.16	-0.19	Intelligence (multi-trait analysis);	chr15:82189008	chr15:82355142~82420075:+
LUAD	cis	rs11051970	0.592	rs11051985	ENSG00000274964.1	RP11-817I4.1	-4.19	3.29e-05	0.00549	-0.24	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr12:32402156	chr12:32339368~32340724:+
LUAD	cis	rs11051970	0.559	rs11051986	ENSG00000274964.1	RP11-817I4.1	-4.19	3.29e-05	0.00549	-0.24	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr12:32402339	chr12:32339368~32340724:+
LUAD	cis	rs11051970	0.592	rs11051987	ENSG00000274964.1	RP11-817I4.1	-4.19	3.29e-05	0.00549	-0.24	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr12:32402472	chr12:32339368~32340724:+
LUAD	cis	rs6142102	0.812	rs6059574	ENSG00000275784.1	RP5-1125A11.6	4.19	3.29e-05	0.00549	0.2	0.19	Skin pigmentation;	chr20:33935366	chr20:33989480~33991818:-
LUAD	cis	rs13113518	0.783	rs12508367	ENSG00000272969.1	RP11-528I4.2	4.19	3.29e-05	0.00549	0.2	0.19	Height;	chr4:55509442	chr4:55547112~55547889:+
LUAD	cis	rs13113518	0.812	rs2272073	ENSG00000272969.1	RP11-528I4.2	4.19	3.29e-05	0.00549	0.2	0.19	Height;	chr4:55510177	chr4:55547112~55547889:+
LUAD	cis	rs262150	0.567	rs2040897	ENSG00000231419.5	LINC00689	-4.19	3.29e-05	0.00549	-0.23	-0.19	Facial morphology (factor 20);	chr7:159011157	chr7:159006522~159030195:+
LUAD	cis	rs651907	0.557	rs3094295	ENSG00000244119.1	PDCL3P4	4.19	3.29e-05	0.00549	0.19	0.19	Colorectal cancer;	chr3:101683151	chr3:101712472~101713191:+
LUAD	cis	rs8014252	0.803	rs58092588	ENSG00000259158.2	ADAM20P1	-4.19	3.29e-05	0.00549	-0.33	-0.19	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70561961	chr14:70468881~70483756:-
LUAD	cis	rs3742264	1	rs2404964	ENSG00000235903.6	CPB2-AS1	-4.19	3.29e-05	0.0055	-0.23	-0.19	Blood protein levels;	chr13:46070739	chr13:46052806~46113332:+
LUAD	cis	rs11064837	0.511	rs278154	ENSG00000248636.5	RP11-768F21.1	4.19	3.29e-05	0.0055	0.23	0.19	Schizophrenia;	chr12:119683245	chr12:119387987~119668079:-
LUAD	cis	rs12754538	0.922	rs12045438	ENSG00000232912.4	RP5-1115A15.1	4.19	3.29e-05	0.0055	0.2	0.19	Subjective well-being;	chr1:8425844	chr1:8424645~8434838:+
LUAD	cis	rs7811142	1	rs67471932	ENSG00000078319.8	PMS2P1	-4.19	3.29e-05	0.0055	-0.22	-0.19	Platelet count;	chr7:100412362	chr7:100320992~100341908:-
LUAD	cis	rs16866061	1	rs17480230	ENSG00000228446.2	AC073052.1	-4.19	3.29e-05	0.0055	-0.2	-0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr2:224535147	chr2:224499387~224500100:-
LUAD	cis	rs651907	0.535	rs11707250	ENSG00000244119.1	PDCL3P4	-4.19	3.29e-05	0.0055	-0.19	-0.19	Colorectal cancer;	chr3:101790527	chr3:101712472~101713191:+
LUAD	cis	rs7005380	0.581	rs2017310	ENSG00000279347.1	RP11-85I17.2	4.19	3.29e-05	0.0055	0.18	0.19	Interstitial lung disease;	chr8:119921101	chr8:119838736~119840385:-
LUAD	cis	rs12073359	0.955	rs112287706	ENSG00000223945.2	RP11-458I7.1	-4.19	3.29e-05	0.0055	-0.28	-0.19	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150074061	chr1:150053864~150055034:+
LUAD	cis	rs2153535	0.585	rs9406185	ENSG00000230939.1	RP11-314C16.1	-4.19	3.29e-05	0.0055	-0.21	-0.19	Motion sickness;	chr6:8644491	chr6:8784178~8785445:+
LUAD	cis	rs9500256	0.655	rs12210275	ENSG00000272316.1	XXbac-BPGBPG55C20.2	4.19	3.29e-05	0.0055	0.16	0.19	Eosinophilic esophagitis (pediatric);	chr6:58005481	chr6:57908560~57913911:-
LUAD	cis	rs2154319	0.609	rs61774718	ENSG00000235358.1	RP11-399E6.1	-4.19	3.29e-05	0.0055	-0.22	-0.19	Height;	chr1:41274060	chr1:41242373~41284861:+
LUAD	cis	rs2732480	0.577	rs2732457	ENSG00000257763.1	OR5BK1P	-4.19	3.3e-05	0.0055	-0.2	-0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48364596	chr12:48355792~48356614:-
LUAD	cis	rs73242632	0.867	rs35680048	ENSG00000269949.1	RP11-738E22.3	4.19	3.3e-05	0.0055	0.5	0.19	Congenital heart disease (maternal effect);	chr4:57066033	chr4:56960927~56961373:-
LUAD	cis	rs10737909	1	rs10737909	ENSG00000278480.1	RP5-903E17.2	4.19	3.3e-05	0.00551	0.21	0.19	Migraine;	chr1:15222140	chr1:15226373~15227549:+
LUAD	cis	rs4374383	0.884	rs7604639	ENSG00000207383.1	Y_RNA	-4.19	3.3e-05	0.00551	-0.23	-0.19	Hepatitis C induced liver fibrosis;	chr2:111994351	chr2:112579484~112579584:-
LUAD	cis	rs2832077	0.527	rs2142375	ENSG00000232855.5	AF131217.1	4.19	3.3e-05	0.00551	0.19	0.19	Cognitive test performance;	chr21:28851420	chr21:28439346~28674848:-
LUAD	cis	rs780096	0.526	rs11126999	ENSG00000234072.1	AC074117.10	-4.19	3.3e-05	0.00551	-0.15	-0.19	Total body bone mineral density;	chr2:27447440	chr2:27356246~27367622:+
LUAD	cis	rs9309473	0.5	rs4286298	ENSG00000163016.8	ALMS1P	-4.19	3.3e-05	0.00551	-0.2	-0.19	Metabolite levels;	chr2:73654981	chr2:73644919~73685576:+
LUAD	cis	rs8048589	1	rs8048589	ENSG00000175604.2	RP11-276H1.3	-4.19	3.3e-05	0.00551	-0.25	-0.19	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12091953	chr16:12086746~12090302:-
LUAD	cis	rs8031584	0.678	rs798086	ENSG00000259845.1	HERC2P10	-4.19	3.3e-05	0.00551	-0.23	-0.19	Huntington's disease progression;	chr15:30837008	chr15:30815271~30844153:+
LUAD	cis	rs2348418	0.864	rs1949978	ENSG00000247934.4	RP11-967K21.1	4.19	3.3e-05	0.00551	0.21	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28443951	chr12:28163298~28190738:-
LUAD	cis	rs28386778	0.897	rs2854213	ENSG00000240280.5	TCAM1P	-4.19	3.3e-05	0.00551	-0.22	-0.19	Prudent dietary pattern;	chr17:63868271	chr17:63849292~63864379:+
LUAD	cis	rs7100689	0.542	rs7096715	ENSG00000226659.1	RP11-137H2.4	-4.19	3.3e-05	0.00551	-0.25	-0.19	Post bronchodilator FEV1;	chr10:80436193	chr10:80529597~80535942:-
LUAD	cis	rs957448	0.687	rs10104041	ENSG00000254315.1	RP11-267M23.3	4.19	3.3e-05	0.00551	0.22	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94559374	chr8:94533628~94534391:+
LUAD	cis	rs3096299	0.679	rs3096322	ENSG00000182376.2	RP5-1142A6.8	-4.19	3.3e-05	0.00552	-0.19	-0.19	Multiple myeloma (IgH translocation);	chr16:89374715	chr16:88742767~88745748:+
LUAD	cis	rs17826219	0.636	rs7221463	ENSG00000280069.1	CTD-2349P21.3	-4.19	3.3e-05	0.00552	-0.26	-0.19	Body mass index;	chr17:30753533	chr17:30738182~30740275:+
LUAD	cis	rs338389	0.542	rs8036189	ENSG00000260657.2	RP11-315D16.4	-4.19	3.3e-05	0.00552	-0.23	-0.19	Survival in rectal cancer;	chr15:68000614	chr15:68267792~68277994:-
LUAD	cis	rs712046	0.568	rs854645	ENSG00000267547.1	RP11-686D22.4	-4.19	3.3e-05	0.00552	-0.2	-0.19	Pulmonary function;	chr17:36037728	chr17:35403837~35404373:-
LUAD	cis	rs7172677	0.695	rs8029756	ENSG00000260269.4	CTD-2323K18.1	-4.19	3.3e-05	0.00552	-0.24	-0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75143449	chr15:75527150~75601205:-
LUAD	cis	rs7172677	0.737	rs8029760	ENSG00000260269.4	CTD-2323K18.1	-4.19	3.3e-05	0.00552	-0.24	-0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75143499	chr15:75527150~75601205:-
LUAD	cis	rs2933343	0.679	rs1091938	ENSG00000261159.1	RP11-723O4.9	4.19	3.3e-05	0.00552	0.21	0.19	IgG glycosylation;	chr3:128918182	chr3:128859716~128860526:-
LUAD	cis	rs375066	0.762	rs10424336	ENSG00000267058.1	RP11-15A1.3	-4.19	3.3e-05	0.00552	-0.21	-0.19	Breast cancer;	chr19:43887948	chr19:43891804~43901805:-
LUAD	cis	rs7621025	0.586	rs34553037	ENSG00000239213.4	NCK1-AS1	-4.19	3.31e-05	0.00552	-0.25	-0.19	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136660571	chr3:136841726~136862054:-
LUAD	cis	rs13113518	0.812	rs6830409	ENSG00000272969.1	RP11-528I4.2	4.19	3.31e-05	0.00552	0.2	0.19	Height;	chr4:55522229	chr4:55547112~55547889:+
LUAD	cis	rs7172677	1	rs72730601	ENSG00000260269.4	CTD-2323K18.1	4.19	3.31e-05	0.00552	0.25	0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75129379	chr15:75527150~75601205:-
LUAD	cis	rs910316	1	rs12589876	ENSG00000279594.1	RP11-950C14.10	4.19	3.31e-05	0.00552	0.22	0.19	Height;	chr14:75077486	chr14:75011269~75012851:-
LUAD	cis	rs8050896	1	rs8060523	ENSG00000260695.1	RP11-513N24.1	-4.19	3.31e-05	0.00552	-0.32	-0.19	Response to antipsychotic treatment;	chr16:66121178	chr16:65861112~65863784:-
LUAD	cis	rs9907295	0.688	rs2735475	ENSG00000270977.1	AC015849.16	-4.19	3.31e-05	0.00552	-0.27	-0.19	Fibroblast growth factor basic levels;	chr17:35931003	chr17:35893707~35911023:-
LUAD	cis	rs77688320	0.573	rs59674665	ENSG00000213090.2	AC007256.5	-4.19	3.31e-05	0.00552	-0.22	-0.19	Breast cancer;	chr2:201514881	chr2:201410544~201413308:-
LUAD	cis	rs2880765	0.566	rs12911430	ENSG00000259630.2	CTD-2262B20.1	-4.19	3.31e-05	0.00552	-0.22	-0.19	Coronary artery disease;	chr15:85468033	chr15:85415228~85415633:+
LUAD	cis	rs812925	0.537	rs10196146	ENSG00000271889.1	RP11-493E12.1	-4.19	3.31e-05	0.00552	-0.22	-0.19	Immature fraction of reticulocytes;	chr2:61378244	chr2:61151433~61162105:-
LUAD	cis	rs42490	0.7	rs40250	ENSG00000251136.7	RP11-37B2.1	-4.19	3.31e-05	0.00552	-0.2	-0.19	Leprosy;	chr8:89828779	chr8:89609409~89757727:-
LUAD	cis	rs42490	0.7	rs419890	ENSG00000251136.7	RP11-37B2.1	-4.19	3.31e-05	0.00552	-0.2	-0.19	Leprosy;	chr8:89829012	chr8:89609409~89757727:-
LUAD	cis	rs11233413	1	rs4944425	ENSG00000246067.6	RAB30-AS1	4.19	3.31e-05	0.00552	0.19	0.19	Economic and political preferences (feminism/equality);	chr11:83065819	chr11:83072066~83106719:+
LUAD	cis	rs13113518	0.783	rs11133389	ENSG00000272969.1	RP11-528I4.2	4.19	3.31e-05	0.00553	0.2	0.19	Height;	chr4:55486718	chr4:55547112~55547889:+
LUAD	cis	rs13113518	0.812	rs4864543	ENSG00000272969.1	RP11-528I4.2	4.19	3.31e-05	0.00553	0.2	0.19	Height;	chr4:55490228	chr4:55547112~55547889:+
LUAD	cis	rs4795519	0.922	rs34289884	ENSG00000266313.1	RP11-173M1.4	4.19	3.31e-05	0.00553	0.23	0.19	Chronic myeloid leukemia;	chr17:27196073	chr17:27333256~27348491:+
LUAD	cis	rs4795519	1	rs34480832	ENSG00000266313.1	RP11-173M1.4	4.19	3.31e-05	0.00553	0.23	0.19	Chronic myeloid leukemia;	chr17:27196884	chr17:27333256~27348491:+
LUAD	cis	rs4795519	1	rs8073802	ENSG00000266313.1	RP11-173M1.4	4.19	3.31e-05	0.00553	0.23	0.19	Chronic myeloid leukemia;	chr17:27202481	chr17:27333256~27348491:+
LUAD	cis	rs7178424	0.774	rs7172145	ENSG00000259251.2	RP11-643M14.1	4.19	3.31e-05	0.00553	0.19	0.19	Height;	chr15:61947498	chr15:62060503~62062434:+
LUAD	cis	rs763121	0.853	rs5757231	ENSG00000228274.3	RP3-508I15.9	4.19	3.31e-05	0.00553	0.18	0.19	Menopause (age at onset);	chr22:38675653	chr22:38667585~38681820:-
LUAD	cis	rs6750795	0.746	rs1667301	ENSG00000181798.2	LINC00471	-4.19	3.31e-05	0.00553	-0.22	-0.19	Height;	chr2:231559006	chr2:231508426~231514339:-
LUAD	cis	rs4664293	0.934	rs7604482	ENSG00000230783.1	AC009961.2	-4.19	3.31e-05	0.00553	-0.23	-0.19	Monocyte percentage of white cells;	chr2:159657315	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.967	rs10176436	ENSG00000230783.1	AC009961.2	-4.19	3.31e-05	0.00553	-0.23	-0.19	Monocyte percentage of white cells;	chr2:159658883	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.967	rs7559127	ENSG00000230783.1	AC009961.2	-4.19	3.31e-05	0.00553	-0.23	-0.19	Monocyte percentage of white cells;	chr2:159659424	chr2:159689217~159690291:-
LUAD	cis	rs131777	0.577	rs5770928	ENSG00000273272.1	CTA-384D8.34	4.19	3.31e-05	0.00553	0.22	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50590662	chr22:50542650~50543011:+
LUAD	cis	rs6142102	0.527	rs1015362	ENSG00000275784.1	RP5-1125A11.6	4.19	3.32e-05	0.00553	0.22	0.19	Skin pigmentation;	chr20:34150806	chr20:33989480~33991818:-
LUAD	cis	rs9649213	0.593	rs7807555	ENSG00000272950.1	RP11-307C18.1	4.19	3.32e-05	0.00553	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98328205	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.593	rs7807455	ENSG00000272950.1	RP11-307C18.1	4.19	3.32e-05	0.00553	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98328310	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.593	rs6465667	ENSG00000272950.1	RP11-307C18.1	4.19	3.32e-05	0.00553	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98328573	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.593	rs6949214	ENSG00000272950.1	RP11-307C18.1	4.19	3.32e-05	0.00553	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98330921	chr7:98322853~98323430:+
LUAD	cis	rs1355223	0.966	rs11602318	ENSG00000271369.1	RP11-350D17.3	4.19	3.32e-05	0.00553	0.22	0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34745436	chr11:34709600~34710161:+
LUAD	cis	rs5022636	0.533	rs1752387	ENSG00000232671.4	RP11-126K1.2	-4.19	3.32e-05	0.00553	-0.23	-0.19	Gut microbiota (functional units);	chr1:151341903	chr1:151280024~151281929:-
LUAD	cis	rs8141529	0.732	rs3788409	ENSG00000272858.1	CTA-292E10.8	-4.19	3.32e-05	0.00553	-0.21	-0.19	Lymphocyte counts;	chr22:28802163	chr22:28814914~28815662:+
LUAD	cis	rs9467773	1	rs10214634	ENSG00000261353.1	CTA-14H9.5	-4.19	3.32e-05	0.00554	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26564354	chr6:26527063~26527404:+
LUAD	cis	rs10129255	0.701	rs2005643	ENSG00000211967.3	IGHV3-53	-4.19	3.32e-05	0.00554	-0.14	-0.19	Kawasaki disease;	chr14:106676288	chr14:106592676~106593347:-
LUAD	cis	rs8114671	0.967	rs2093058	ENSG00000269202.1	RP4-614O4.12	4.19	3.32e-05	0.00554	0.18	0.19	Height;	chr20:35203478	chr20:35201747~35203288:-
LUAD	cis	rs6071166	0.935	rs6015693	ENSG00000224635.1	RP4-564F22.5	-4.19	3.32e-05	0.00554	-0.21	-0.19	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38702166	chr20:38406011~38416797:-
LUAD	cis	rs6840360	1	rs6840360	ENSG00000270265.1	RP11-731D1.4	-4.19	3.32e-05	0.00554	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151682879	chr4:151333775~151353224:-
LUAD	cis	rs9467773	1	rs6940188	ENSG00000261353.1	CTA-14H9.5	-4.19	3.32e-05	0.00554	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26561801	chr6:26527063~26527404:+
LUAD	cis	rs3742264	0.961	rs9534309	ENSG00000235903.6	CPB2-AS1	-4.19	3.32e-05	0.00554	-0.24	-0.19	Blood protein levels;	chr13:46073402	chr13:46052806~46113332:+
LUAD	cis	rs3742264	1	rs3742264	ENSG00000235903.6	CPB2-AS1	-4.19	3.32e-05	0.00554	-0.24	-0.19	Blood protein levels;	chr13:46073959	chr13:46052806~46113332:+
LUAD	cis	rs3742264	0.961	rs1326400	ENSG00000235903.6	CPB2-AS1	-4.19	3.32e-05	0.00554	-0.24	-0.19	Blood protein levels;	chr13:46074388	chr13:46052806~46113332:+
LUAD	cis	rs3742264	1	rs1326399	ENSG00000235903.6	CPB2-AS1	-4.19	3.32e-05	0.00554	-0.24	-0.19	Blood protein levels;	chr13:46074472	chr13:46052806~46113332:+
LUAD	cis	rs4819052	0.655	rs2330102	ENSG00000215447.6	BX322557.10	-4.19	3.32e-05	0.00554	-0.22	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45271053	chr21:45288052~45291738:+
LUAD	cis	rs12073359	0.954	rs12061565	ENSG00000223945.2	RP11-458I7.1	-4.19	3.32e-05	0.00554	-0.27	-0.19	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150039388	chr1:150053864~150055034:+
LUAD	cis	rs7172677	0.768	rs34180494	ENSG00000260269.4	CTD-2323K18.1	4.19	3.32e-05	0.00554	0.26	0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75077671	chr15:75527150~75601205:-
LUAD	cis	rs7893279	0.505	rs11812341	ENSG00000225527.1	RP11-383B4.4	4.19	3.32e-05	0.00554	0.28	0.19	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18607994	chr10:18531849~18533336:-
LUAD	cis	rs944990	0.557	rs10821155	ENSG00000227603.1	RP11-165J3.6	4.19	3.32e-05	0.00554	0.21	0.19	Body mass index;	chr9:93541996	chr9:93435332~93437121:-
LUAD	cis	rs4578769	0.55	rs9953702	ENSG00000265943.1	RP11-739L10.1	4.19	3.33e-05	0.00555	0.24	0.19	Eosinophil percentage of white cells;	chr18:22971001	chr18:22699481~22933764:-
LUAD	cis	rs4578769	0.569	rs9951157	ENSG00000265943.1	RP11-739L10.1	4.19	3.33e-05	0.00555	0.24	0.19	Eosinophil percentage of white cells;	chr18:22974173	chr18:22699481~22933764:-
LUAD	cis	rs4934494	0.768	rs72818784	ENSG00000240996.1	RP11-80H5.7	-4.19	3.33e-05	0.00555	-0.28	-0.19	Red blood cell count;	chr10:89789657	chr10:89694295~89697928:-
LUAD	cis	rs8098244	0.603	rs1788787	ENSG00000264745.1	TTC39C-AS1	4.19	3.33e-05	0.00555	0.2	0.19	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23694775	chr18:23994213~24015339:-
LUAD	cis	rs6951245	0.882	rs10252404	ENSG00000229043.2	AC091729.9	-4.19	3.33e-05	0.00555	-0.29	-0.19	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1169971	chr7:1160374~1165267:+
LUAD	cis	rs2221433	0.889	rs1394564	ENSG00000260310.1	RP11-27M24.2	4.19	3.33e-05	0.00555	0.21	0.19	Eating disorders;	chr16:10583324	chr16:10576499~10578183:-
LUAD	cis	rs11971779	0.793	rs11764426	ENSG00000273391.1	RP11-634H22.1	4.19	3.33e-05	0.00555	0.2	0.19	Diisocyanate-induced asthma;	chr7:139339304	chr7:139359032~139359566:-
LUAD	cis	rs2904524	1	rs1983437	ENSG00000257815.4	RP11-611E13.2	-4.19	3.33e-05	0.00555	-0.25	-0.19	Amyotrophic lateral sclerosis (age of onset);	chr12:70329989	chr12:69904033~70243360:-
LUAD	cis	rs2904524	1	rs2272180	ENSG00000257815.4	RP11-611E13.2	-4.19	3.33e-05	0.00555	-0.25	-0.19	Amyotrophic lateral sclerosis (age of onset);	chr12:70330227	chr12:69904033~70243360:-
LUAD	cis	rs2823962	0.759	rs4485640	ENSG00000270093.1	AP000473.8	-4.19	3.33e-05	0.00555	-0.2	-0.19	Amyotrophic lateral sclerosis;	chr21:16645943	chr21:16643529~16645065:+
LUAD	cis	rs7208859	0.673	rs11654331	ENSG00000280069.1	CTD-2349P21.3	-4.19	3.33e-05	0.00555	-0.25	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837999	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs73277964	ENSG00000280069.1	CTD-2349P21.3	-4.19	3.33e-05	0.00555	-0.25	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30852183	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs11652409	ENSG00000280069.1	CTD-2349P21.3	-4.19	3.33e-05	0.00555	-0.25	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855689	chr17:30738182~30740275:+
LUAD	cis	rs9876781	1	rs2242150	ENSG00000229759.1	MRPS18AP1	-4.19	3.33e-05	0.00556	-0.18	-0.19	Longevity;	chr3:48464565	chr3:48256350~48256938:-
LUAD	cis	rs9487094	0.922	rs10872034	ENSG00000260273.1	RP11-425D10.10	4.19	3.34e-05	0.00556	0.26	0.19	Height;	chr6:109486036	chr6:109382795~109383666:+
LUAD	cis	rs77633900	0.803	rs2456063	ENSG00000196274.5	Metazoa_SRP	4.19	3.34e-05	0.00556	0.24	0.19	Glioma;Non-glioblastoma glioma;	chr15:76303208	chr15:76230048~76230390:-
LUAD	cis	rs8031584	0.958	rs34909055	ENSG00000270015.1	RP11-540B6.6	-4.19	3.34e-05	0.00557	-0.13	-0.19	Huntington's disease progression;	chr15:30991967	chr15:30926514~30928407:+
LUAD	cis	rs763567	0.845	rs539045	ENSG00000271811.1	RP1-79C4.4	4.19	3.34e-05	0.00557	0.22	0.19	Tonsillectomy;	chr1:170638940	chr1:170667381~170669425:+
LUAD	cis	rs2711721	0.535	rs1989911	ENSG00000274723.1	RP11-618L22.1	4.19	3.34e-05	0.00557	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr12:47008126	chr12:46970504~46972155:+
LUAD	cis	rs2735413	0.918	rs4888731	ENSG00000276007.1	RP11-358L22.3	-4.19	3.34e-05	0.00557	-0.19	-0.19	Systolic blood pressure (alcohol consumption interaction);	chr16:78046521	chr16:78123243~78124332:+
LUAD	cis	rs3096299	0.728	rs1011749	ENSG00000261118.1	RP11-104N10.1	4.19	3.34e-05	0.00557	0.19	0.19	Multiple myeloma (IgH translocation);	chr16:89444461	chr16:89492017~89504460:-
LUAD	cis	rs7512552	0.839	rs6662108	ENSG00000275557.1	RP11-353N4.6	4.19	3.34e-05	0.00557	0.21	0.19	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150448065	chr1:149607765~149612402:+
LUAD	cis	rs8177876	0.731	rs4889227	ENSG00000261061.1	RP11-303E16.2	4.19	3.34e-05	0.00557	0.28	0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81075576	chr16:81030770~81031485:+
LUAD	cis	rs2836754	1	rs2836751	ENSG00000205622.8	AF064858.6	-4.19	3.34e-05	0.00557	-0.2	-0.19	Body mass index;Crohn's disease;	chr21:38919035	chr21:38863676~38956467:-
LUAD	cis	rs11250098	0.503	rs7821826	ENSG00000255046.1	RP11-297N6.4	4.19	3.34e-05	0.00557	0.23	0.19	Morning vs. evening chronotype;	chr8:10911929	chr8:11797928~11802568:-
LUAD	cis	rs6121246	0.559	rs6058468	ENSG00000230613.1	HM13-AS1	4.19	3.34e-05	0.00557	0.23	0.19	Mean corpuscular hemoglobin;	chr20:31818645	chr20:31567707~31573263:-
LUAD	cis	rs6957923	0.934	rs7808836	ENSG00000230658.1	KLHL7-AS1	4.19	3.34e-05	0.00557	0.23	0.19	Height;	chr7:23434706	chr7:23101228~23105703:-
LUAD	cis	rs7176527	0.519	rs12148368	ENSG00000259570.1	RP11-671M22.4	-4.19	3.34e-05	0.00557	-0.24	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84563274	chr15:84394512~84395514:+
LUAD	cis	rs10197140	0.925	rs62159472	ENSG00000235721.1	AC013268.3	-4.19	3.34e-05	0.00557	-0.21	-0.19	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110877011	chr2:110007675~110010783:+
LUAD	cis	rs4865762	0.595	rs454858	ENSG00000247796.2	CTD-2366F13.1	4.19	3.35e-05	0.00558	0.19	0.19	Intraocular pressure;	chr5:53247761	chr5:53109842~53115126:+
LUAD	cis	rs651907	0.557	rs56291106	ENSG00000244119.1	PDCL3P4	4.19	3.35e-05	0.00558	0.19	0.19	Colorectal cancer;	chr3:101658630	chr3:101712472~101713191:+
LUAD	cis	rs6687758	0.687	rs11118902	ENSG00000227925.1	RP11-191N8.2	4.19	3.35e-05	0.00558	0.26	0.19	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221932275	chr1:221827666~221840666:-
LUAD	cis	rs523522	0.962	rs4766969	ENSG00000278344.1	RP11-18C24.8	4.19	3.35e-05	0.00558	0.25	0.19	High light scatter reticulocyte count;	chr12:120550435	chr12:120500735~120501090:-
LUAD	cis	rs6500602	0.893	rs4786489	ENSG00000280063.1	RP11-295D4.3	4.19	3.35e-05	0.00558	0.12	0.19	Schizophrenia;	chr16:4435526	chr16:4346694~4348648:-
LUAD	cis	rs7204230	1	rs62048051	ENSG00000261291.1	RP11-295M3.2	4.19	3.35e-05	0.00558	0.24	0.19	Fibrinogen;	chr16:53205249	chr16:53168522~53169450:+
LUAD	cis	rs13631	0.894	rs7856589	ENSG00000268996.3	MAN1B1-AS1	-4.19	3.35e-05	0.00558	-0.22	-0.19	Cerebrospinal fluid biomarker levels;	chr9:137109469	chr9:137084946~137086817:-
LUAD	cis	rs160451	1	rs160441	ENSG00000251136.7	RP11-37B2.1	4.19	3.35e-05	0.00558	0.19	0.19	Leprosy;	chr8:89644760	chr8:89609409~89757727:-
LUAD	cis	rs2154319	0.609	rs2275931	ENSG00000235358.1	RP11-399E6.1	-4.19	3.35e-05	0.00558	-0.22	-0.19	Height;	chr1:41264479	chr1:41242373~41284861:+
LUAD	cis	rs4664293	0.967	rs1346325	ENSG00000230783.1	AC009961.2	-4.19	3.35e-05	0.00558	-0.23	-0.19	Monocyte percentage of white cells;	chr2:159685995	chr2:159689217~159690291:-
LUAD	cis	rs862034	0.509	rs2190876	ENSG00000270000.1	RP3-449M8.9	4.19	3.35e-05	0.00558	0.21	0.19	Height;	chr14:74465565	chr14:74471930~74472360:-
LUAD	cis	rs75920871	0.764	rs80259223	ENSG00000254851.1	RP11-109L13.1	-4.19	3.35e-05	0.00558	-0.41	-0.19	Subjective well-being;	chr11:117053602	chr11:117135528~117138582:+
LUAD	cis	rs2645424	1	rs2645424	ENSG00000255046.1	RP11-297N6.4	-4.19	3.35e-05	0.00559	-0.23	-0.19	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11826954	chr8:11797928~11802568:-
LUAD	cis	rs412658	0.504	rs369128	ENSG00000269345.1	VN1R85P	4.19	3.36e-05	0.00559	0.22	0.19	Telomere length;	chr19:21925064	chr19:22174766~22175191:-
LUAD	cis	rs2243480	1	rs316331	ENSG00000232559.3	GS1-124K5.12	-4.19	3.36e-05	0.00559	-0.33	-0.19	Diabetic kidney disease;	chr7:66139635	chr7:66554588~66576923:-
LUAD	cis	rs4683346	0.581	rs339684	ENSG00000173811.9	CCDC13-AS1	-4.19	3.36e-05	0.00559	-0.2	-0.19	Granulocyte percentage of myeloid white cells;	chr3:42742143	chr3:42732575~42746768:+
LUAD	cis	rs2562456	0.833	rs4321312	ENSG00000268081.1	RP11-678G14.2	4.19	3.36e-05	0.0056	0.3	0.19	Pain;	chr19:21336614	chr19:21554640~21569237:-
LUAD	cis	rs9951698	0.703	rs8088313	ENSG00000267480.1	RP11-703I16.1	-4.19	3.36e-05	0.0056	-0.23	-0.19	Intelligence (multi-trait analysis);	chr18:12977207	chr18:12031178~12032181:-
LUAD	cis	rs3742264	1	rs9534310	ENSG00000235903.6	CPB2-AS1	-4.19	3.36e-05	0.0056	-0.24	-0.19	Blood protein levels;	chr13:46074840	chr13:46052806~46113332:+
LUAD	cis	rs6751744	1	rs6751744	ENSG00000230783.1	AC009961.2	-4.19	3.36e-05	0.0056	-0.25	-0.19	Dysphagia;	chr2:159550974	chr2:159689217~159690291:-
LUAD	cis	rs1334894	1	rs747411	ENSG00000228559.1	RP3-340B19.3	-4.19	3.36e-05	0.0056	-0.39	-0.19	Coronary artery disease;	chr6:35618596	chr6:35544632~35545669:+
LUAD	cis	rs8030379	1	rs1480823	ENSG00000230373.7	GOLGA6L5P	-4.19	3.36e-05	0.0056	-0.17	-0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83916994	chr15:84507885~84516814:-
LUAD	cis	rs6531209	0.817	rs34277789	ENSG00000234378.1	AC098828.2	4.19	3.36e-05	0.0056	0.23	0.19	Amyotrophic lateral sclerosis (sporadic);	chr2:20139718	chr2:20063856~20106829:-
LUAD	cis	rs1113500	0.73	rs1777457	ENSG00000226822.1	RP11-356N1.2	-4.19	3.36e-05	0.0056	-0.21	-0.19	Growth-regulated protein alpha levels;	chr1:108045573	chr1:108071482~108074519:+
LUAD	cis	rs12122100	0.913	rs61838896	ENSG00000244371.2	PFN1P8	4.19	3.37e-05	0.0056	0.24	0.19	HIV-1 control;	chr1:147041583	chr1:146957117~146957659:-
LUAD	cis	rs4713118	0.513	rs149959	ENSG00000216901.1	AL022393.7	4.19	3.37e-05	0.0056	0.22	0.19	Parkinson's disease;	chr6:28046076	chr6:28176188~28176674:+
LUAD	cis	rs3764400	0.517	rs7224461	ENSG00000278765.1	RP5-890E16.5	-4.19	3.37e-05	0.0056	-0.34	-0.19	Body mass index;	chr17:48126068	chr17:48066704~48067293:-
LUAD	cis	rs7200786	0.508	rs8060411	ENSG00000274038.1	RP11-66H6.4	-4.19	3.37e-05	0.00561	-0.24	-0.19	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11123250	chr16:11056556~11057034:+
LUAD	cis	rs7204230	1	rs62049768	ENSG00000261291.1	RP11-295M3.2	4.19	3.37e-05	0.00561	0.24	0.19	Fibrinogen;	chr16:53234511	chr16:53168522~53169450:+
LUAD	cis	rs13113518	0.966	rs13144598	ENSG00000272969.1	RP11-528I4.2	4.19	3.37e-05	0.00561	0.2	0.19	Height;	chr4:55570311	chr4:55547112~55547889:+
LUAD	cis	rs7493	0.755	rs2375001	ENSG00000233942.1	AC004012.1	4.19	3.37e-05	0.00561	0.27	0.19	Yu-Zhi constitution type in type 2 diabetes;	chr7:95335328	chr7:95471835~95473998:+
LUAD	cis	rs7746199	0.736	rs34573979	ENSG00000219392.1	RP1-265C24.5	-4.19	3.37e-05	0.00561	-0.39	-0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27512747	chr6:28115628~28116551:+
LUAD	cis	rs9341808	0.718	rs12203867	ENSG00000260645.1	RP11-250B2.5	4.19	3.37e-05	0.00561	0.18	0.19	Sitting height ratio;	chr6:80111116	chr6:80466958~80469080:+
LUAD	cis	rs12928939	1	rs12928939	ENSG00000260886.1	TAT-AS1	4.19	3.37e-05	0.00561	0.25	0.19	Post bronchodilator FEV1;	chr16:71766142	chr16:71565789~71578187:+
LUAD	cis	rs4795519	0.922	rs2313740	ENSG00000266313.1	RP11-173M1.4	4.19	3.37e-05	0.00561	0.23	0.19	Chronic myeloid leukemia;	chr17:27179832	chr17:27333256~27348491:+
LUAD	cis	rs4691139	0.658	rs6839773	ENSG00000248632.1	RP11-366M4.11	4.19	3.37e-05	0.00561	0.23	0.19	Ovarian cancer in BRCA1 mutation carriers;	chr4:165004694	chr4:164968587~164970002:-
LUAD	cis	rs4691139	0.658	rs4691141	ENSG00000248632.1	RP11-366M4.11	4.19	3.37e-05	0.00561	0.23	0.19	Ovarian cancer in BRCA1 mutation carriers;	chr4:165005070	chr4:164968587~164970002:-
LUAD	cis	rs703842	0.616	rs870392	ENSG00000245651.2	RP11-620J15.2	4.19	3.37e-05	0.00561	0.2	0.19	Multiple sclerosis;	chr12:57825390	chr12:57869835~57896482:-
LUAD	cis	rs6471393	0.964	rs7001808	ENSG00000253848.1	RP11-10N23.5	4.19	3.37e-05	0.00561	0.23	0.19	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93725043	chr8:93741193~93744534:+
LUAD	cis	rs7204230	1	rs17302609	ENSG00000261291.1	RP11-295M3.2	4.19	3.37e-05	0.00561	0.24	0.19	Fibrinogen;	chr16:53168612	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs62048028	ENSG00000261291.1	RP11-295M3.2	4.19	3.37e-05	0.00561	0.24	0.19	Fibrinogen;	chr16:53176198	chr16:53168522~53169450:+
LUAD	cis	rs4713118	0.628	rs12179134	ENSG00000219392.1	RP1-265C24.5	-4.19	3.37e-05	0.00561	-0.28	-0.19	Parkinson's disease;	chr6:27707690	chr6:28115628~28116551:+
LUAD	cis	rs7646881	0.544	rs7638518	ENSG00000240207.5	RP11-379F4.4	4.19	3.37e-05	0.00562	0.24	0.19	Tetralogy of Fallot;	chr3:158568953	chr3:158732263~158784070:+
LUAD	cis	rs1387259	0.859	rs2054905	ENSG00000257763.1	OR5BK1P	4.19	3.37e-05	0.00562	0.2	0.19	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48294168	chr12:48355792~48356614:-
LUAD	cis	rs7772486	0.688	rs1884364	ENSG00000235652.6	RP11-545I5.3	4.19	3.37e-05	0.00562	0.2	0.19	Lobe attachment (rater-scored or self-reported);	chr6:146016681	chr6:145799409~145886585:+
LUAD	cis	rs2933343	0.621	rs4927921	ENSG00000261159.1	RP11-723O4.9	-4.19	3.38e-05	0.00562	-0.2	-0.19	IgG glycosylation;	chr3:128850025	chr3:128859716~128860526:-
LUAD	cis	rs11051970	0.659	rs73088096	ENSG00000274964.1	RP11-817I4.1	-4.19	3.38e-05	0.00562	-0.24	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr12:32431469	chr12:32339368~32340724:+
LUAD	cis	rs67478160	0.643	rs11624184	ENSG00000272533.1	SNORA28	4.19	3.38e-05	0.00562	0.2	0.19	Schizophrenia;	chr14:103774661	chr14:103337849~103337974:+
LUAD	cis	rs7107174	1	rs10501426	ENSG00000251323.2	RP11-452H21.4	4.19	3.38e-05	0.00562	0.22	0.19	Testicular germ cell tumor;	chr11:78346076	chr11:78423982~78429836:-
LUAD	cis	rs651907	0.535	rs17347156	ENSG00000244119.1	PDCL3P4	4.19	3.38e-05	0.00562	0.19	0.19	Colorectal cancer;	chr3:101785830	chr3:101712472~101713191:+
LUAD	cis	rs801193	0.844	rs732465	ENSG00000236529.1	RP13-254B10.1	4.19	3.38e-05	0.00562	0.19	0.19	Aortic root size;	chr7:66533463	chr7:65840212~65840596:+
LUAD	cis	rs11673344	0.504	rs35579954	ENSG00000276846.1	CTD-3220F14.3	4.19	3.38e-05	0.00562	0.21	0.19	Obesity-related traits;	chr19:37139308	chr19:37314868~37315620:-
LUAD	cis	rs2115630	1	rs7183401	ENSG00000225151.9	GOLGA2P7	4.19	3.38e-05	0.00562	0.21	0.19	P wave terminal force;	chr15:84828713	chr15:84199311~84230136:-
LUAD	cis	rs6832769	1	rs7673908	ENSG00000272969.1	RP11-528I4.2	-4.19	3.38e-05	0.00562	-0.19	-0.19	Personality dimensions;	chr4:55528652	chr4:55547112~55547889:+
LUAD	cis	rs4795519	1	rs4795504	ENSG00000266313.1	RP11-173M1.4	4.19	3.38e-05	0.00562	0.23	0.19	Chronic myeloid leukemia;	chr17:27182792	chr17:27333256~27348491:+
LUAD	cis	rs6479901	0.894	rs10761747	ENSG00000232075.1	MRPL35P2	4.19	3.38e-05	0.00563	0.25	0.19	Intelligence (multi-trait analysis);	chr10:63348396	chr10:63634317~63634827:-
LUAD	cis	rs2880765	0.743	rs6497194	ENSG00000259416.2	RP11-158M2.5	4.19	3.38e-05	0.00563	0.19	0.19	Coronary artery disease;	chr15:85470885	chr15:85754941~85756237:-
LUAD	cis	rs523522	0.962	rs12371550	ENSG00000278344.1	RP11-18C24.8	4.19	3.38e-05	0.00563	0.25	0.19	High light scatter reticulocyte count;	chr12:120549840	chr12:120500735~120501090:-
LUAD	cis	rs12817211	0.536	rs3184122	ENSG00000272368.2	RP4-605O3.4	-4.19	3.38e-05	0.00563	-0.23	-0.19	Colorectal or endometrial cancer;	chr12:50176344	chr12:50112197~50165618:+
LUAD	cis	rs7840202	1	rs10481100	ENSG00000253328.2	SUMO2P19	-4.19	3.38e-05	0.00563	-0.21	-0.19	Rate of cognitive decline in mild cognitive impairment (time interaction);Gestational age at birth in labor-initiated deliveries (child effect);	chr8:102343899	chr8:102242040~102242619:-
LUAD	cis	rs9543976	1	rs9573592	ENSG00000261105.4	LMO7-AS1	-4.19	3.38e-05	0.00563	-0.33	-0.19	Diabetic retinopathy;	chr13:75623707	chr13:75604700~75635994:-
LUAD	cis	rs2898681	0.77	rs10032190	ENSG00000248375.1	RP11-177B4.1	-4.19	3.38e-05	0.00563	-0.27	-0.19	Optic nerve measurement (cup area);	chr4:52868773	chr4:52720081~52720831:-
LUAD	cis	rs2227564	0.597	rs12256103	ENSG00000271816.1	BMS1P4	4.19	3.38e-05	0.00563	0.18	0.19	Crohn's disease;Inflammatory bowel disease;	chr10:73785493	chr10:73699151~73730487:-
LUAD	cis	rs1167827	1	rs1167827	ENSG00000223705.8	NSUN5P1	4.19	3.38e-05	0.00563	0.13	0.19	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75410322~75416787:+
LUAD	cis	rs783540	0.656	rs783538	ENSG00000255769.6	GOLGA2P10	4.19	3.38e-05	0.00563	0.21	0.19	Schizophrenia;	chr15:82584394	chr15:82472993~82513950:-
LUAD	cis	rs27524	0.734	rs27037	ENSG00000272109.1	CTD-2260A17.3	-4.19	3.39e-05	0.00563	-0.21	-0.19	Hodgkin's lymphoma;Psoriasis;	chr5:96758990	chr5:96804353~96806105:+
LUAD	cis	rs6969780	0.915	rs12666919	ENSG00000233429.8	HOTAIRM1	-4.19	3.39e-05	0.00563	-0.3	-0.19	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27149879	chr7:27095647~27100265:+
LUAD	cis	rs17264034	0.861	rs55891419	ENSG00000250786.1	SNHG18	4.19	3.39e-05	0.00563	0.31	0.19	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9553468	chr5:9546200~9550609:+
LUAD	cis	rs2154319	0.666	rs11209765	ENSG00000235358.1	RP11-399E6.1	-4.19	3.39e-05	0.00564	-0.23	-0.19	Height;	chr1:41262424	chr1:41242373~41284861:+
LUAD	cis	rs910316	0.726	rs12882664	ENSG00000259138.1	RP11-950C14.7	4.19	3.39e-05	0.00564	0.2	0.19	Height;	chr14:74980075	chr14:75127153~75136930:+
LUAD	cis	rs3096299	1	rs3096299	ENSG00000182376.2	RP5-1142A6.8	4.19	3.39e-05	0.00564	0.2	0.19	Multiple myeloma (IgH translocation);	chr16:89382255	chr16:88742767~88745748:+
LUAD	cis	rs780096	0.506	rs1647285	ENSG00000234072.1	AC074117.10	-4.18	3.39e-05	0.00564	-0.15	-0.19	Total body bone mineral density;	chr2:27491644	chr2:27356246~27367622:+
LUAD	cis	rs780096	0.506	rs1647286	ENSG00000234072.1	AC074117.10	-4.18	3.39e-05	0.00564	-0.15	-0.19	Total body bone mineral density;	chr2:27491650	chr2:27356246~27367622:+
LUAD	cis	rs2919009	0.766	rs56259440	ENSG00000271670.1	RP11-95I16.4	4.18	3.39e-05	0.00564	0.24	0.19	Obesity-related traits;	chr10:120809566	chr10:120879256~120880667:-
LUAD	cis	rs7829975	0.659	rs4382480	ENSG00000233609.3	RP11-62H7.2	4.18	3.39e-05	0.00564	0.15	0.19	Mood instability;	chr8:8863963	chr8:8961200~8979025:+
LUAD	cis	rs9860428	0.787	rs9815002	ENSG00000242770.2	RP11-180K7.1	4.18	3.39e-05	0.00564	0.21	0.19	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112903419	chr3:112802478~112812819:+
LUAD	cis	rs7131987	0.527	rs7308534	ENSG00000257176.2	RP11-996F15.2	4.18	3.39e-05	0.00565	0.19	0.19	QT interval;	chr12:29300269	chr12:29280418~29317848:-
LUAD	cis	rs7107174	1	rs10899489	ENSG00000251323.2	RP11-452H21.4	4.18	3.39e-05	0.00565	0.23	0.19	Testicular germ cell tumor;	chr11:78384327	chr11:78423982~78429836:-
LUAD	cis	rs6071166	0.935	rs6071146	ENSG00000224635.1	RP4-564F22.5	4.18	3.4e-05	0.00565	0.21	0.19	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38699962	chr20:38406011~38416797:-
LUAD	cis	rs848490	0.889	rs6955503	ENSG00000214293.7	APTR	4.18	3.4e-05	0.00565	0.24	0.19	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77597924	chr7:77657660~77696265:-
LUAD	cis	rs2898681	0.837	rs2017237	ENSG00000248375.1	RP11-177B4.1	-4.18	3.4e-05	0.00565	-0.27	-0.19	Optic nerve measurement (cup area);	chr4:52882348	chr4:52720081~52720831:-
LUAD	cis	rs301901	0.965	rs13158310	ENSG00000250155.1	CTD-2353F22.1	4.18	3.4e-05	0.00565	0.19	0.19	Height;	chr5:36789552	chr5:36666214~36725195:-
LUAD	cis	rs17596685	1	rs1038434	ENSG00000271216.1	LINC01050	-4.18	3.4e-05	0.00565	-0.26	-0.19	C-reactive protein levels;	chr13:42593197	chr13:42810366~42812562:-
LUAD	cis	rs6558530	0.626	rs6558524	ENSG00000253982.1	CTD-2336O2.1	4.18	3.4e-05	0.00565	0.24	0.19	Systolic blood pressure;	chr8:1754346	chr8:1761990~1764502:-
LUAD	cis	rs6558530	0.692	rs6558525	ENSG00000253982.1	CTD-2336O2.1	4.18	3.4e-05	0.00565	0.24	0.19	Systolic blood pressure;	chr8:1754357	chr8:1761990~1764502:-
LUAD	cis	rs2836974	0.644	rs4818017	ENSG00000232608.1	TIMM9P2	4.18	3.4e-05	0.00566	0.22	0.19	Cognitive function;	chr21:39318635	chr21:39216624~39217506:+
LUAD	cis	rs6840360	0.582	rs11733820	ENSG00000270265.1	RP11-731D1.4	-4.18	3.4e-05	0.00566	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151394987	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.582	rs4473638	ENSG00000270265.1	RP11-731D1.4	-4.18	3.4e-05	0.00566	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151400994	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.548	rs4254751	ENSG00000270265.1	RP11-731D1.4	-4.18	3.4e-05	0.00566	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151401419	chr4:151333775~151353224:-
LUAD	cis	rs897984	0.644	rs73524556	ENSG00000260911.2	RP11-196G11.2	4.18	3.4e-05	0.00566	0.17	0.19	Dementia with Lewy bodies;	chr16:30811841	chr16:31043150~31049868:+
LUAD	cis	rs17772222	0.74	rs11159857	ENSG00000258983.2	RP11-507K2.2	4.18	3.4e-05	0.00566	0.22	0.19	Coronary artery calcification;	chr14:88510796	chr14:88499334~88515502:+
LUAD	cis	rs17772222	0.74	rs4390529	ENSG00000258983.2	RP11-507K2.2	4.18	3.4e-05	0.00566	0.22	0.19	Coronary artery calcification;	chr14:88510853	chr14:88499334~88515502:+
LUAD	cis	rs17772222	0.771	rs4516145	ENSG00000258983.2	RP11-507K2.2	4.18	3.4e-05	0.00566	0.22	0.19	Coronary artery calcification;	chr14:88510953	chr14:88499334~88515502:+
LUAD	cis	rs17772222	0.74	rs4594187	ENSG00000258983.2	RP11-507K2.2	4.18	3.4e-05	0.00566	0.22	0.19	Coronary artery calcification;	chr14:88511071	chr14:88499334~88515502:+
LUAD	cis	rs17772222	0.74	rs4514599	ENSG00000258983.2	RP11-507K2.2	4.18	3.4e-05	0.00566	0.22	0.19	Coronary artery calcification;	chr14:88511083	chr14:88499334~88515502:+
LUAD	cis	rs17772222	0.74	rs73317739	ENSG00000258983.2	RP11-507K2.2	4.18	3.4e-05	0.00566	0.22	0.19	Coronary artery calcification;	chr14:88511400	chr14:88499334~88515502:+
LUAD	cis	rs5758511	0.633	rs5758690	ENSG00000227370.1	RP4-669P10.19	4.18	3.4e-05	0.00566	0.21	0.19	Birth weight;	chr22:42272289	chr22:42132543~42132998:+
LUAD	cis	rs728616	0.867	rs117139504	ENSG00000225484.5	NUTM2B-AS1	-4.18	3.41e-05	0.00566	-0.48	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79974451	chr10:79663088~79826594:-
LUAD	cis	rs6964587	1	rs11971885	ENSG00000188693.7	CYP51A1-AS1	-4.18	3.41e-05	0.00566	-0.22	-0.19	Breast cancer;	chr7:92045493	chr7:92134604~92180725:+
LUAD	cis	rs7617773	0.676	rs13060020	ENSG00000199476.1	Y_RNA	-4.18	3.41e-05	0.00566	-0.25	-0.19	Coronary artery disease;	chr3:48331156	chr3:48288587~48288694:+
LUAD	cis	rs889398	0.677	rs68161338	ENSG00000226232.7	RP11-419C5.2	4.18	3.41e-05	0.00566	0.16	0.19	Body mass index;	chr16:69789875	chr16:69976388~69996188:-
LUAD	cis	rs7746199	0.736	rs72845070	ENSG00000219392.1	RP1-265C24.5	-4.18	3.41e-05	0.00567	-0.42	-0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27700521	chr6:28115628~28116551:+
LUAD	cis	rs6688613	0.685	rs2235184	ENSG00000225171.2	DUTP6	4.18	3.41e-05	0.00567	0.23	0.19	Refractive astigmatism;	chr1:166901291	chr1:166868748~166869209:+
LUAD	cis	rs6430553	0.929	rs6714498	ENSG00000224043.6	CCNT2-AS1	4.18	3.41e-05	0.00567	0.23	0.19	Blood metabolite levels;	chr2:134893196	chr2:134735464~134918710:-
LUAD	cis	rs240993	0.516	rs240968	ENSG00000271789.1	RP5-1112D6.7	-4.18	3.41e-05	0.00567	-0.25	-0.19	Inflammatory skin disease;Psoriasis;	chr6:111311517	chr6:111297126~111298510:+
LUAD	cis	rs2823962	0.759	rs1129247	ENSG00000270093.1	AP000473.8	-4.18	3.41e-05	0.00567	-0.2	-0.19	Amyotrophic lateral sclerosis;	chr21:16646128	chr21:16643529~16645065:+
LUAD	cis	rs11233413	0.957	rs1943341	ENSG00000246067.6	RAB30-AS1	4.18	3.41e-05	0.00567	0.19	0.19	Economic and political preferences (feminism/equality);	chr11:83055784	chr11:83072066~83106719:+
LUAD	cis	rs477895	0.653	rs12797120	ENSG00000236935.1	AP003774.1	-4.18	3.41e-05	0.00567	-0.23	-0.19	Mean platelet volume;	chr11:64139347	chr11:64325050~64329504:-
LUAD	cis	rs477895	0.653	rs7102327	ENSG00000236935.1	AP003774.1	-4.18	3.41e-05	0.00567	-0.23	-0.19	Mean platelet volume;	chr11:64141248	chr11:64325050~64329504:-
LUAD	cis	rs36093844	0.625	rs10501599	ENSG00000279742.1	RP11-700A24.1	-4.18	3.41e-05	0.00567	-0.2	-0.19	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85898312	chr11:85852557~85854943:-
LUAD	cis	rs763121	0.853	rs9610986	ENSG00000228274.3	RP3-508I15.9	-4.18	3.41e-05	0.00567	-0.18	-0.19	Menopause (age at onset);	chr22:38629272	chr22:38667585~38681820:-
LUAD	cis	rs8030379	1	rs8041056	ENSG00000230373.7	GOLGA6L5P	-4.18	3.41e-05	0.00567	-0.17	-0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83896065	chr15:84507885~84516814:-
LUAD	cis	rs9925964	0.748	rs11640961	ENSG00000232748.3	RP11-196G11.6	4.18	3.41e-05	0.00567	0.22	0.19	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:30968497	chr16:31056460~31062803:+
LUAD	cis	rs7974517	1	rs7974517	ENSG00000272368.2	RP4-605O3.4	-4.18	3.41e-05	0.00567	-0.21	-0.19	Male-pattern baldness;	chr12:50751299	chr12:50112197~50165618:+
LUAD	cis	rs9876781	1	rs13091785	ENSG00000229759.1	MRPS18AP1	4.18	3.41e-05	0.00567	0.18	0.19	Longevity;	chr3:48452692	chr3:48256350~48256938:-
LUAD	cis	rs2273156	0.57	rs57075379	ENSG00000226677.3	IGBP1P1	-4.18	3.41e-05	0.00568	-0.3	-0.19	Immunoglobulin light chain (AL) amyloidosis;	chr14:35108595	chr14:34939324~34940332:+
LUAD	cis	rs2273156	0.57	rs79436302	ENSG00000226677.3	IGBP1P1	-4.18	3.41e-05	0.00568	-0.3	-0.19	Immunoglobulin light chain (AL) amyloidosis;	chr14:35109591	chr14:34939324~34940332:+
LUAD	cis	rs2273156	0.57	rs79199019	ENSG00000226677.3	IGBP1P1	-4.18	3.41e-05	0.00568	-0.3	-0.19	Immunoglobulin light chain (AL) amyloidosis;	chr14:35111919	chr14:34939324~34940332:+
LUAD	cis	rs2274273	0.875	rs2075602	ENSG00000259318.1	RP11-454L9.2	4.18	3.41e-05	0.00568	0.16	0.19	Protein biomarker;	chr14:55143056	chr14:55394940~55395233:-
LUAD	cis	rs2790457	0.795	rs7903703	ENSG00000254635.4	WAC-AS1	-4.18	3.41e-05	0.00568	-0.21	-0.19	Multiple myeloma;	chr10:28646220	chr10:28522652~28532743:-
LUAD	cis	rs28386778	0.897	rs2727295	ENSG00000240280.5	TCAM1P	-4.18	3.42e-05	0.00568	-0.21	-0.19	Prudent dietary pattern;	chr17:63810333	chr17:63849292~63864379:+
LUAD	cis	rs2274273	0.905	rs2075601	ENSG00000259318.1	RP11-454L9.2	4.18	3.42e-05	0.00568	0.16	0.19	Protein biomarker;	chr14:55142516	chr14:55394940~55395233:-
LUAD	cis	rs4705952	0.832	rs2706390	ENSG00000233006.5	AC034220.3	-4.18	3.42e-05	0.00568	-0.22	-0.19	C-reactive protein levels;	chr5:132506588	chr5:132311285~132369916:-
LUAD	cis	rs11707813	0.593	rs9856186	ENSG00000226360.5	RPL10AP6	-4.18	3.42e-05	0.00568	-0.2	-0.19	Lip morphology;	chr3:61204559	chr3:61742455~61743106:-
LUAD	cis	rs5758511	0.514	rs2899354	ENSG00000227370.1	RP4-669P10.19	4.18	3.42e-05	0.00569	0.21	0.19	Birth weight;	chr22:42158403	chr22:42132543~42132998:+
LUAD	cis	rs4819052	0.851	rs4819040	ENSG00000237664.1	LINC00316	-4.18	3.42e-05	0.00569	-0.22	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239847	chr21:45338590~45341990:-
LUAD	cis	rs7208859	0.573	rs4055105	ENSG00000280069.1	CTD-2349P21.3	-4.18	3.42e-05	0.00569	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775532	chr17:30738182~30740275:+
LUAD	cis	rs1502844	0.539	rs6872759	ENSG00000250682.4	LINC00491	4.18	3.42e-05	0.00569	0.23	0.19	Schizophrenia;	chr5:102536149	chr5:102609156~102671559:-
LUAD	cis	rs34779708	0.966	rs12260130	ENSG00000271335.4	RP11-324I22.4	4.18	3.42e-05	0.00569	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35178743	chr10:35314552~35336401:-
LUAD	cis	rs911186	0.786	rs3800307	ENSG00000219392.1	RP1-265C24.5	-4.18	3.42e-05	0.00569	-0.27	-0.19	Autism spectrum disorder or schizophrenia;	chr6:27218013	chr6:28115628~28116551:+
LUAD	cis	rs11168618	0.765	rs7301368	ENSG00000240399.1	RP1-228P16.1	4.18	3.42e-05	0.00569	0.18	0.19	Adiponectin levels;	chr12:48533009	chr12:48054813~48055591:-
LUAD	cis	rs2243480	1	rs1404147	ENSG00000229886.1	RP5-1132H15.3	4.18	3.42e-05	0.00569	0.3	0.19	Diabetic kidney disease;	chr7:65799537	chr7:66025126~66031544:-
LUAD	cis	rs6832769	0.961	rs7660808	ENSG00000272969.1	RP11-528I4.2	-4.18	3.42e-05	0.00569	-0.19	-0.19	Personality dimensions;	chr4:55590505	chr4:55547112~55547889:+
LUAD	cis	rs9894429	1	rs12948099	ENSG00000263853.1	AC139530.1	-4.18	3.42e-05	0.00569	-0.18	-0.19	Eye color traits;	chr17:81633773	chr17:81676001~81676086:+
LUAD	cis	rs4873772	0.837	rs12678110	ENSG00000253330.1	RP11-697N18.3	-4.18	3.42e-05	0.00569	-0.21	-0.19	Lobe attachment (rater-scored or self-reported);	chr8:47649528	chr8:47511034~47512141:-
LUAD	cis	rs763121	0.853	rs2294296	ENSG00000228274.3	RP3-508I15.9	-4.18	3.43e-05	0.00569	-0.19	-0.19	Menopause (age at onset);	chr22:38657044	chr22:38667585~38681820:-
LUAD	cis	rs6142102	0.961	rs8123521	ENSG00000275784.1	RP5-1125A11.6	-4.18	3.43e-05	0.00569	-0.21	-0.19	Skin pigmentation;	chr20:34081079	chr20:33989480~33991818:-
LUAD	cis	rs10463554	0.963	rs62362546	ENSG00000250682.4	LINC00491	4.18	3.43e-05	0.00569	0.23	0.19	Parkinson's disease;	chr5:103015615	chr5:102609156~102671559:-
LUAD	cis	rs4819052	0.851	rs8127834	ENSG00000237664.1	LINC00316	-4.18	3.43e-05	0.0057	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45276194	chr21:45338590~45341990:-
LUAD	cis	rs6754311	0.681	rs4954493	ENSG00000226806.1	AC011893.3	-4.18	3.43e-05	0.0057	-0.23	-0.19	Mosquito bite size;	chr2:135852405	chr2:135820191~135823087:+
LUAD	cis	rs9925964	0.933	rs749671	ENSG00000232748.3	RP11-196G11.6	4.18	3.43e-05	0.0057	0.23	0.19	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31077026	chr16:31056460~31062803:+
LUAD	cis	rs34421088	0.56	rs2248699	ENSG00000255046.1	RP11-297N6.4	4.18	3.43e-05	0.0057	0.23	0.19	Neuroticism;	chr8:11536255	chr8:11797928~11802568:-
LUAD	cis	rs12712133	0.552	rs1115281	ENSG00000234389.1	AC007278.3	-4.18	3.43e-05	0.0057	-0.18	-0.19	Primary biliary cholangitis;	chr2:102274647	chr2:102438713~102440475:+
LUAD	cis	rs7742369	0.586	rs6918981	ENSG00000276404.1	MIR6835	-4.18	3.43e-05	0.0057	-0.22	-0.19	Birth weight;Height;	chr6:34270737	chr6:34240673~34240736:+
LUAD	cis	rs875971	0.543	rs801191	ENSG00000236529.1	RP13-254B10.1	-4.18	3.43e-05	0.0057	-0.19	-0.19	Aortic root size;	chr7:66567968	chr7:65840212~65840596:+
LUAD	cis	rs847577	0.609	rs6977321	ENSG00000272950.1	RP11-307C18.1	4.18	3.43e-05	0.0057	0.23	0.19	Breast cancer;	chr7:98145547	chr7:98322853~98323430:+
LUAD	cis	rs1790761	0.505	rs7103713	ENSG00000184224.3	C11orf72	-4.18	3.43e-05	0.0057	-0.21	-0.19	Mean corpuscular volume;	chr11:67570771	chr11:67602880~67606706:-
LUAD	cis	rs6479891	1	rs72837056	ENSG00000232075.1	MRPL35P2	4.18	3.43e-05	0.0057	0.31	0.19	Arthritis (juvenile idiopathic);	chr10:63500718	chr10:63634317~63634827:-
LUAD	cis	rs6479891	0.818	rs11815969	ENSG00000232075.1	MRPL35P2	4.18	3.43e-05	0.0057	0.31	0.19	Arthritis (juvenile idiopathic);	chr10:63506095	chr10:63634317~63634827:-
LUAD	cis	rs3096299	0.802	rs3102336	ENSG00000261574.1	RP1-168P16.2	4.18	3.43e-05	0.0057	0.21	0.19	Multiple myeloma (IgH translocation);	chr16:89375598	chr16:89392375~89412564:-
LUAD	cis	rs365302	0.951	rs413102	ENSG00000235086.1	FNDC1-IT1	4.18	3.43e-05	0.0057	0.25	0.19	Coronary heart disease;	chr6:159223855	chr6:159240786~159243329:+
LUAD	cis	rs7208859	0.524	rs8065744	ENSG00000280069.1	CTD-2349P21.3	-4.18	3.44e-05	0.00571	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30772431	chr17:30738182~30740275:+
LUAD	cis	rs17826219	0.706	rs8071236	ENSG00000280069.1	CTD-2349P21.3	-4.18	3.44e-05	0.00571	-0.26	-0.19	Body mass index;	chr17:30772984	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs56163556	ENSG00000280069.1	CTD-2349P21.3	-4.18	3.44e-05	0.00571	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774850	chr17:30738182~30740275:+
LUAD	cis	rs4819052	0.851	rs875621	ENSG00000237664.1	LINC00316	-4.18	3.44e-05	0.00571	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45262380	chr21:45338590~45341990:-
LUAD	cis	rs2638953	0.849	rs11049388	ENSG00000278733.1	RP11-425D17.1	-4.18	3.44e-05	0.00571	-0.23	-0.19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28169054	chr12:28185625~28186190:-
LUAD	cis	rs4843747	0.636	rs11864872	ENSG00000205037.2	RP11-863P13.4	4.18	3.44e-05	0.00571	0.26	0.19	Menopause (age at onset);	chr16:88072360	chr16:88088041~88100985:-
LUAD	cis	rs4843747	0.605	rs28399183	ENSG00000205037.2	RP11-863P13.4	4.18	3.44e-05	0.00571	0.26	0.19	Menopause (age at onset);	chr16:88073671	chr16:88088041~88100985:-
LUAD	cis	rs4843747	0.605	rs4072779	ENSG00000205037.2	RP11-863P13.4	4.18	3.44e-05	0.00571	0.26	0.19	Menopause (age at onset);	chr16:88073684	chr16:88088041~88100985:-
LUAD	cis	rs9860428	0.808	rs9869058	ENSG00000242770.2	RP11-180K7.1	4.18	3.44e-05	0.00571	0.21	0.19	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112899522	chr3:112802478~112812819:+
LUAD	cis	rs17275866	0.894	rs7671722	ENSG00000251584.1	RP11-440I14.3	-4.18	3.44e-05	0.00571	-0.24	-0.19	Chin dimples;	chr4:174147178	chr4:174536640~174540784:+
LUAD	cis	rs4295623	0.504	rs11250160	ENSG00000255046.1	RP11-297N6.4	4.18	3.44e-05	0.00571	0.23	0.19	Morning vs. evening chronotype;	chr8:11735208	chr8:11797928~11802568:-
LUAD	cis	rs1799949	1	rs9646417	ENSG00000236383.6	LINC00854	-4.18	3.44e-05	0.00571	-0.15	-0.19	Menopause (age at onset);	chr17:43346885	chr17:43216941~43305976:-
LUAD	cis	rs1799949	1	rs1545764	ENSG00000236383.6	LINC00854	-4.18	3.44e-05	0.00571	-0.15	-0.19	Menopause (age at onset);	chr17:43347197	chr17:43216941~43305976:-
LUAD	cis	rs71636778	0.722	rs116491347	ENSG00000260063.1	RP5-968P14.2	-4.18	3.44e-05	0.00571	-0.24	-0.19	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26846193	chr1:26692132~26694131:-
LUAD	cis	rs4601821	0.823	rs10891546	ENSG00000270179.1	RP11-159N11.4	4.18	3.44e-05	0.00571	0.19	0.19	Alcoholic chronic pancreatitis;	chr11:113394570	chr11:113368478~113369117:+
LUAD	cis	rs10197140	0.925	rs4849203	ENSG00000235721.1	AC013268.3	4.18	3.44e-05	0.00571	0.21	0.19	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110900433	chr2:110007675~110010783:+
LUAD	cis	rs10504390	0.524	rs80229839	ENSG00000200714.1	Y_RNA	-4.18	3.44e-05	0.00571	-0.43	-0.19	IgG glycosylation;	chr8:65761471	chr8:65592731~65592820:+
LUAD	cis	rs7216064	0.684	rs7406031	ENSG00000265055.1	AC145343.2	-4.18	3.44e-05	0.00571	-0.17	-0.19	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68025637	chr17:68096046~68101474:-
LUAD	cis	rs11079160	0.715	rs11654125	ENSG00000263096.1	RP11-515O17.2	-4.18	3.44e-05	0.00571	-0.24	-0.19	Urate levels in obese individuals;	chr17:55279944	chr17:55271504~55273653:-
LUAD	cis	rs2179367	0.959	rs4895789	ENSG00000216906.2	RP11-350J20.9	4.18	3.44e-05	0.00571	0.23	0.19	Dupuytren's disease;	chr6:149443518	chr6:149904243~149906418:+
LUAD	cis	rs4795519	0.961	rs8073300	ENSG00000266313.1	RP11-173M1.4	4.18	3.44e-05	0.00571	0.23	0.19	Chronic myeloid leukemia;	chr17:27156394	chr17:27333256~27348491:+
LUAD	cis	rs2274273	0.905	rs4652	ENSG00000259318.1	RP11-454L9.2	4.18	3.44e-05	0.00572	0.16	0.19	Protein biomarker;	chr14:55138318	chr14:55394940~55395233:-
LUAD	cis	rs1008375	0.843	rs59112113	ENSG00000249502.1	AC006160.5	-4.18	3.44e-05	0.00572	-0.18	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17683713	chr4:17587467~17614571:-
LUAD	cis	rs7189233	0.531	rs1074182	ENSG00000279344.1	RP11-44F14.7	4.18	3.44e-05	0.00572	0.16	0.19	Intelligence (multi-trait analysis);	chr16:53437445	chr16:53478957~53481550:-
LUAD	cis	rs12935418	0.672	rs6564814	ENSG00000261061.1	RP11-303E16.2	-4.18	3.45e-05	0.00572	-0.2	-0.19	Mean corpuscular volume;	chr16:81016567	chr16:81030770~81031485:+
LUAD	cis	rs4667682	0.529	rs2080602	ENSG00000234061.1	AC007969.4	-4.18	3.45e-05	0.00572	-0.37	-0.19	Hippocampal atrophy;Body mass index;	chr2:171283358	chr2:171492905~171493095:+
LUAD	cis	rs1005277	0.505	rs7099777	ENSG00000273019.1	RP11-508N22.13	4.18	3.45e-05	0.00573	0.21	0.19	Extrinsic epigenetic age acceleration;	chr10:37894641	chr10:38149968~38150293:+
LUAD	cis	rs7430456	0.674	rs13079337	ENSG00000228221.4	LINC00578	4.18	3.45e-05	0.00573	0.23	0.19	Breast cancer;	chr3:177776996	chr3:177441921~177752305:+
LUAD	cis	rs9393777	0.92	rs72839445	ENSG00000219392.1	RP1-265C24.5	-4.18	3.45e-05	0.00573	-0.4	-0.19	Intelligence (multi-trait analysis);	chr6:27281907	chr6:28115628~28116551:+
LUAD	cis	rs7246657	0.943	rs4802766	ENSG00000226686.6	LINC01535	-4.18	3.45e-05	0.00573	-0.28	-0.19	Coronary artery calcification;	chr19:37491031	chr19:37251912~37265535:+
LUAD	cis	rs1322639	0.614	rs6900200	ENSG00000261039.2	RP11-417E7.2	-4.18	3.45e-05	0.00573	-0.31	-0.19	Pulse pressure;	chr6:169166078	chr6:169175304~169182740:-
LUAD	cis	rs6723108	0.627	rs2053727	ENSG00000224043.6	CCNT2-AS1	-4.18	3.45e-05	0.00573	-0.23	-0.19	Type 2 diabetes;	chr2:134885728	chr2:134735464~134918710:-
LUAD	cis	rs8062405	0.755	rs4788074	ENSG00000261419.1	RP11-57A19.4	4.18	3.45e-05	0.00573	0.2	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28659696~28740781:-
LUAD	cis	rs11157436	0.602	rs11157437	ENSG00000211812.1	TRAV26-2	-4.18	3.45e-05	0.00573	-0.19	-0.19	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22169058	chr14:22202583~22203368:+
LUAD	cis	rs4554975	0.689	rs2263487	ENSG00000274723.1	RP11-618L22.1	4.18	3.45e-05	0.00573	0.22	0.19	Metabolite levels (small molecules and protein measures);	chr12:46857044	chr12:46970504~46972155:+
LUAD	cis	rs4554975	0.689	rs2465211	ENSG00000274723.1	RP11-618L22.1	4.18	3.45e-05	0.00573	0.22	0.19	Metabolite levels (small molecules and protein measures);	chr12:46859159	chr12:46970504~46972155:+
LUAD	cis	rs4554975	0.626	rs2465210	ENSG00000274723.1	RP11-618L22.1	4.18	3.45e-05	0.00573	0.22	0.19	Metabolite levels (small molecules and protein measures);	chr12:46862765	chr12:46970504~46972155:+
LUAD	cis	rs17685	0.753	rs2286830	ENSG00000280388.1	RP11-229D13.3	4.18	3.45e-05	0.00573	0.17	0.19	Coffee consumption (cups per day);Coffee consumption;	chr7:76064645	chr7:76043977~76045963:-
LUAD	cis	rs4873772	0.735	rs4873565	ENSG00000253330.1	RP11-697N18.3	-4.18	3.45e-05	0.00573	-0.21	-0.19	Lobe attachment (rater-scored or self-reported);	chr8:47689290	chr8:47511034~47512141:-
LUAD	cis	rs35740288	0.597	rs12900830	ENSG00000259407.1	RP11-158M2.3	-4.18	3.46e-05	0.00573	-0.21	-0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85782923	chr15:85744109~85750281:-
LUAD	cis	rs8030379	1	rs6603003	ENSG00000230373.7	GOLGA6L5P	-4.18	3.46e-05	0.00573	-0.17	-0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83896850	chr15:84507885~84516814:-
LUAD	cis	rs853679	0.542	rs6934769	ENSG00000226314.6	ZNF192P1	-4.18	3.46e-05	0.00573	-0.25	-0.19	Depression;	chr6:28123153	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs17711801	ENSG00000226314.6	ZNF192P1	-4.18	3.46e-05	0.00573	-0.25	-0.19	Depression;	chr6:28124529	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs6922063	ENSG00000226314.6	ZNF192P1	-4.18	3.46e-05	0.00573	-0.25	-0.19	Depression;	chr6:28126588	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs2275508	ENSG00000226314.6	ZNF192P1	-4.18	3.46e-05	0.00573	-0.25	-0.19	Depression;	chr6:28126953	chr6:28161781~28169594:+
LUAD	cis	rs4713118	0.527	rs9461433	ENSG00000226314.6	ZNF192P1	-4.18	3.46e-05	0.00573	-0.25	-0.19	Parkinson's disease;	chr6:28127394	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs9468292	ENSG00000226314.6	ZNF192P1	-4.18	3.46e-05	0.00573	-0.25	-0.19	Depression;	chr6:28127577	chr6:28161781~28169594:+
LUAD	cis	rs453301	0.652	rs2043129	ENSG00000233609.3	RP11-62H7.2	4.18	3.46e-05	0.00573	0.15	0.19	Joint mobility (Beighton score);	chr8:8967994	chr8:8961200~8979025:+
LUAD	cis	rs860818	1	rs858233	ENSG00000226816.2	AC005082.12	4.18	3.46e-05	0.00573	0.48	0.19	Initial pursuit acceleration;	chr7:23201914	chr7:23206013~23208045:+
LUAD	cis	rs11673344	0.542	rs826324	ENSG00000276846.1	CTD-3220F14.3	4.18	3.46e-05	0.00573	0.21	0.19	Obesity-related traits;	chr19:37014343	chr19:37314868~37315620:-
LUAD	cis	rs35160687	0.545	rs1863050	ENSG00000273080.1	RP11-301O19.1	-4.18	3.46e-05	0.00574	-0.22	-0.19	Night sleep phenotypes;	chr2:86331253	chr2:86195590~86196049:+
LUAD	cis	rs7976269	0.609	rs10843300	ENSG00000257176.2	RP11-996F15.2	-4.18	3.46e-05	0.00574	-0.2	-0.19	Male-pattern baldness;	chr12:29060934	chr12:29280418~29317848:-
LUAD	cis	rs12935418	0.616	rs874053	ENSG00000261061.1	RP11-303E16.2	-4.18	3.46e-05	0.00574	-0.2	-0.19	Mean corpuscular volume;	chr16:80972210	chr16:81030770~81031485:+
LUAD	cis	rs6840360	0.608	rs2724556	ENSG00000270265.1	RP11-731D1.4	-4.18	3.46e-05	0.00574	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151420565	chr4:151333775~151353224:-
LUAD	cis	rs1790761	0.692	rs611663	ENSG00000184224.3	C11orf72	4.18	3.46e-05	0.00574	0.21	0.19	Mean corpuscular volume;	chr11:67544750	chr11:67602880~67606706:-
LUAD	cis	rs45509595	0.841	rs17751184	ENSG00000219392.1	RP1-265C24.5	-4.18	3.46e-05	0.00574	-0.4	-0.19	Breast cancer;	chr6:27807250	chr6:28115628~28116551:+
LUAD	cis	rs35740288	0.731	rs35085180	ENSG00000259407.1	RP11-158M2.3	-4.18	3.46e-05	0.00574	-0.18	-0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85559381	chr15:85744109~85750281:-
LUAD	cis	rs35740288	0.77	rs75039806	ENSG00000259407.1	RP11-158M2.3	-4.18	3.46e-05	0.00574	-0.18	-0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85561813	chr15:85744109~85750281:-
LUAD	cis	rs728616	0.867	rs61860400	ENSG00000225484.5	NUTM2B-AS1	-4.18	3.46e-05	0.00574	-0.48	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79963671	chr10:79663088~79826594:-
LUAD	cis	rs755249	0.565	rs12138051	ENSG00000228060.1	RP11-69E11.8	4.18	3.46e-05	0.00574	0.16	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39482552	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.564	rs6691194	ENSG00000228060.1	RP11-69E11.8	4.18	3.46e-05	0.00574	0.16	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39483069	chr1:39565160~39573203:+
LUAD	cis	rs11250098	0.574	rs4554431	ENSG00000255046.1	RP11-297N6.4	4.18	3.46e-05	0.00574	0.23	0.19	Morning vs. evening chronotype;	chr8:10914128	chr8:11797928~11802568:-
LUAD	cis	rs10197140	0.85	rs1513825	ENSG00000235721.1	AC013268.3	-4.18	3.46e-05	0.00574	-0.21	-0.19	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110899737	chr2:110007675~110010783:+
LUAD	cis	rs2823962	0.759	rs2823930	ENSG00000270093.1	AP000473.8	-4.18	3.46e-05	0.00574	-0.19	-0.19	Amyotrophic lateral sclerosis;	chr21:16641950	chr21:16643529~16645065:+
LUAD	cis	rs38055	0.752	rs372044	ENSG00000247796.2	CTD-2366F13.1	-4.18	3.46e-05	0.00574	-0.2	-0.19	Acne (severe);	chr5:53313889	chr5:53109842~53115126:+
LUAD	cis	rs2243480	1	rs12698509	ENSG00000232559.3	GS1-124K5.12	4.18	3.46e-05	0.00574	0.32	0.19	Diabetic kidney disease;	chr7:65953889	chr7:66554588~66576923:-
LUAD	cis	rs516805	0.52	rs12662883	ENSG00000279453.1	RP3-425C14.4	-4.18	3.46e-05	0.00574	-0.19	-0.19	Lymphocyte counts;	chr6:122471463	chr6:122436789~122439223:-
LUAD	cis	rs9987353	0.566	rs34491841	ENSG00000253893.2	FAM85B	4.18	3.46e-05	0.00574	0.25	0.19	Recombination measurement;	chr8:9208000	chr8:8167819~8226614:-
LUAD	cis	rs34783982	0.881	rs34286613	ENSG00000261441.1	RP11-217B1.2	-4.18	3.46e-05	0.00575	-0.24	-0.19	Squamous cell lung carcinoma;	chr15:88953052	chr15:89335053~89336161:+
LUAD	cis	rs2288884	1	rs17835749	ENSG00000269959.1	SPACA6P-AS	-4.18	3.46e-05	0.00575	-0.26	-0.19	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52075442	chr19:51685363~51693456:-
LUAD	cis	rs4819052	0.918	rs2330013	ENSG00000215447.6	BX322557.10	-4.18	3.47e-05	0.00575	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238747	chr21:45288052~45291738:+
LUAD	cis	rs8073060	0.505	rs225270	ENSG00000267592.1	CTC-507E2.2	4.18	3.47e-05	0.00575	0.27	0.19	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35641852	chr17:35596904~35597128:-
LUAD	cis	rs11242704	0.962	rs12200039	ENSG00000272279.1	RP11-157J24.2	-4.18	3.47e-05	0.00575	-0.27	-0.19	Response to hepatitis C treatment;	chr6:1536150	chr6:1528364~1528911:-
LUAD	cis	rs9646944	0.501	rs11687768	ENSG00000234389.1	AC007278.3	4.18	3.47e-05	0.00575	0.21	0.19	Blood protein levels;	chr2:102409278	chr2:102438713~102440475:+
LUAD	cis	rs3020264	0.74	rs2515563	ENSG00000271743.1	CTD-2541M15.3	-4.18	3.47e-05	0.00575	-0.26	-0.19	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr8:6637329	chr8:6615604~6617198:-
LUAD	cis	rs2153535	0.585	rs7765238	ENSG00000230939.1	RP11-314C16.1	4.18	3.47e-05	0.00575	0.21	0.19	Motion sickness;	chr6:8632560	chr6:8784178~8785445:+
LUAD	cis	rs875971	0.545	rs73136346	ENSG00000222364.1	RNU6-96P	4.18	3.47e-05	0.00575	0.25	0.19	Aortic root size;	chr7:66101095	chr7:66395191~66395286:+
LUAD	cis	rs2732480	0.5	rs2932093	ENSG00000240399.1	RP1-228P16.1	4.18	3.47e-05	0.00576	0.19	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48254488	chr12:48054813~48055591:-
LUAD	cis	rs853679	0.607	rs67340775	ENSG00000219392.1	RP1-265C24.5	-4.18	3.47e-05	0.00576	-0.41	-0.19	Depression;	chr6:28336607	chr6:28115628~28116551:+
LUAD	cis	rs4578769	0.569	rs12966840	ENSG00000265943.1	RP11-739L10.1	-4.18	3.47e-05	0.00576	-0.23	-0.19	Eosinophil percentage of white cells;	chr18:22856911	chr18:22699481~22933764:-
LUAD	cis	rs9467773	1	rs9467773	ENSG00000261353.1	CTA-14H9.5	-4.18	3.47e-05	0.00576	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26498198	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs6926629	ENSG00000261353.1	CTA-14H9.5	-4.18	3.47e-05	0.00576	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26499675	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs6903973	ENSG00000261353.1	CTA-14H9.5	-4.18	3.47e-05	0.00576	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26499714	chr6:26527063~26527404:+
LUAD	cis	rs4699052	0.963	rs11097801	ENSG00000246560.2	RP11-10L12.4	4.18	3.47e-05	0.00576	0.24	0.19	Testicular germ cell tumor;	chr4:103229166	chr4:102828055~102844075:+
LUAD	cis	rs4699052	0.963	rs56144793	ENSG00000246560.2	RP11-10L12.4	4.18	3.47e-05	0.00576	0.24	0.19	Testicular germ cell tumor;	chr4:103229496	chr4:102828055~102844075:+
LUAD	cis	rs6754311	0.593	rs10186843	ENSG00000226806.1	AC011893.3	-4.18	3.47e-05	0.00576	-0.23	-0.19	Mosquito bite size;	chr2:135829388	chr2:135820191~135823087:+
LUAD	cis	rs755249	0.727	rs2242500	ENSG00000237624.1	OXCT2P1	4.18	3.47e-05	0.00576	0.24	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572230	chr1:39514956~39516490:+
LUAD	cis	rs9400467	0.528	rs7451051	ENSG00000230177.1	RP5-1112D6.4	-4.18	3.47e-05	0.00576	-0.17	-0.19	Amino acid levels;Blood metabolite levels;	chr6:111423615	chr6:111277932~111278742:+
LUAD	cis	rs9894429	0.816	rs9747093	ENSG00000263853.1	AC139530.1	-4.18	3.47e-05	0.00576	-0.18	-0.19	Eye color traits;	chr17:81617254	chr17:81676001~81676086:+
LUAD	cis	rs7189233	0.531	rs8056349	ENSG00000279344.1	RP11-44F14.7	4.18	3.47e-05	0.00576	0.16	0.19	Intelligence (multi-trait analysis);	chr16:53434114	chr16:53478957~53481550:-
LUAD	cis	rs11240074	0.516	rs2353996	ENSG00000244371.2	PFN1P8	-4.18	3.48e-05	0.00576	-0.3	-0.19	Type 2 diabetes;	chr1:147454762	chr1:146957117~146957659:-
LUAD	cis	rs9467773	1	rs2255070	ENSG00000261353.1	CTA-14H9.5	-4.18	3.48e-05	0.00576	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26501549	chr6:26527063~26527404:+
LUAD	cis	rs13113518	1	rs13132420	ENSG00000223305.1	RN7SKP30	-4.18	3.48e-05	0.00576	-0.21	-0.19	Height;	chr4:55526646	chr4:55540502~55540835:-
LUAD	cis	rs9652601	0.959	rs7200940	ENSG00000274038.1	RP11-66H6.4	4.18	3.48e-05	0.00576	0.23	0.19	Systemic lupus erythematosus;	chr16:11070710	chr16:11056556~11057034:+
LUAD	cis	rs143626010	1	rs143626010	ENSG00000261419.1	RP11-57A19.4	-4.18	3.48e-05	0.00576	-0.2	-0.19	Mosquito bite size;	chr16:28528081	chr16:28659696~28740781:-
LUAD	cis	rs6728302	0.557	rs73001973	ENSG00000244280.1	ECEL1P2	4.18	3.48e-05	0.00577	0.44	0.19	Height;	chr2:232376865	chr2:232385750~232387457:-
LUAD	cis	rs910316	0.591	rs7157158	ENSG00000259138.1	RP11-950C14.7	4.18	3.48e-05	0.00577	0.2	0.19	Height;	chr14:74990535	chr14:75127153~75136930:+
LUAD	cis	rs7138803	0.561	rs11836282	ENSG00000257464.1	RP11-161H23.8	4.18	3.48e-05	0.00577	0.2	0.19	Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index;	chr12:49783541	chr12:49442424~49442652:-
LUAD	cis	rs80028505	1	rs16884694	ENSG00000271304.1	DPRXP2	4.18	3.48e-05	0.00577	0.34	0.19	Foot ulcer in diabetes and neuropathy;	chr6:36095385	chr6:35989515~35990436:-
LUAD	cis	rs13113518	1	rs13114841	ENSG00000272969.1	RP11-528I4.2	4.18	3.48e-05	0.00577	0.19	0.19	Height;	chr4:55485974	chr4:55547112~55547889:+
LUAD	cis	rs28386778	0.897	rs2665832	ENSG00000240280.5	TCAM1P	-4.18	3.48e-05	0.00577	-0.22	-0.19	Prudent dietary pattern;	chr17:63834901	chr17:63849292~63864379:+
LUAD	cis	rs9467773	0.844	rs2393669	ENSG00000261353.1	CTA-14H9.5	-4.18	3.48e-05	0.00577	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26503645	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs9461259	ENSG00000261353.1	CTA-14H9.5	-4.18	3.48e-05	0.00577	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26504607	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs9467774	ENSG00000261353.1	CTA-14H9.5	-4.18	3.48e-05	0.00577	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26504808	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs3736781	ENSG00000261353.1	CTA-14H9.5	-4.18	3.48e-05	0.00577	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26505134	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs3736782	ENSG00000261353.1	CTA-14H9.5	-4.18	3.48e-05	0.00577	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26505175	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs2208331	ENSG00000261353.1	CTA-14H9.5	-4.18	3.48e-05	0.00577	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26507091	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs9393728	ENSG00000261353.1	CTA-14H9.5	-4.18	3.48e-05	0.00577	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26509102	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs1056667	ENSG00000261353.1	CTA-14H9.5	-4.18	3.48e-05	0.00577	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26510336	chr6:26527063~26527404:+
LUAD	cis	rs17122278	1	rs2277293	ENSG00000243431.1	RPL5P30	4.18	3.48e-05	0.00577	0.23	0.19	Total cholesterol levels;	chr11:118552153	chr11:118560690~118561580:+
LUAD	cis	rs11250097	0.535	rs11250086	ENSG00000255046.1	RP11-297N6.4	4.18	3.48e-05	0.00577	0.23	0.19	Neuroticism;	chr8:10912273	chr8:11797928~11802568:-
LUAD	cis	rs77688320	0.553	rs3795966	ENSG00000213090.2	AC007256.5	4.18	3.48e-05	0.00577	0.21	0.19	Breast cancer;	chr2:201380521	chr2:201410544~201413308:-
LUAD	cis	rs77688320	0.517	rs12623282	ENSG00000213090.2	AC007256.5	4.18	3.48e-05	0.00577	0.21	0.19	Breast cancer;	chr2:201382734	chr2:201410544~201413308:-
LUAD	cis	rs77688320	0.535	rs7579853	ENSG00000213090.2	AC007256.5	4.18	3.48e-05	0.00577	0.21	0.19	Breast cancer;	chr2:201384256	chr2:201410544~201413308:-
LUAD	cis	rs3096299	0.967	rs2965935	ENSG00000182376.2	RP5-1142A6.8	-4.18	3.48e-05	0.00577	-0.19	-0.19	Multiple myeloma (IgH translocation);	chr16:89414866	chr16:88742767~88745748:+
LUAD	cis	rs2346177	0.58	rs1530628	ENSG00000279254.1	RP11-536C12.1	-4.18	3.48e-05	0.00577	-0.19	-0.19	HDL cholesterol;	chr2:46443802	chr2:46668870~46670778:+
LUAD	cis	rs348196	0.672	rs670876	ENSG00000225855.5	RUSC1-AS1	4.18	3.48e-05	0.00577	0.13	0.19	Breast cancer;	chr1:155701887	chr1:155316863~155324176:-
LUAD	cis	rs116095464	1	rs2721025	ENSG00000277812.1	AC021087.1	4.18	3.48e-05	0.00577	0.51	0.19	Breast cancer;	chr5:347329	chr5:262769~262881:+
LUAD	cis	rs16869652	0.748	rs59248104	ENSG00000224796.1	RPL32P1	-4.18	3.48e-05	0.00577	-0.23	-0.19	Schizophrenia;	chr6:33877432	chr6:33079451~33079860:+
LUAD	cis	rs1401999	1	rs6805913	ENSG00000223882.1	ABCC5-AS1	-4.18	3.49e-05	0.00578	-0.2	-0.19	Anterior chamber depth;	chr3:183945136	chr3:184006338~184011419:+
LUAD	cis	rs2898681	0.581	rs730247	ENSG00000248375.1	RP11-177B4.1	-4.18	3.49e-05	0.00578	-0.28	-0.19	Optic nerve measurement (cup area);	chr4:52814529	chr4:52720081~52720831:-
LUAD	cis	rs11157436	0.56	rs988997	ENSG00000211813.2	TRAV34	4.18	3.49e-05	0.00578	0.21	0.19	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22225937	chr14:22207522~22208129:+
LUAD	cis	rs11157436	0.56	rs2242543	ENSG00000211813.2	TRAV34	4.18	3.49e-05	0.00578	0.21	0.19	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22226436	chr14:22207522~22208129:+
LUAD	cis	rs1876905	0.597	rs354526	ENSG00000230177.1	RP5-1112D6.4	-4.18	3.49e-05	0.00578	-0.23	-0.19	Mean corpuscular hemoglobin;	chr6:111216278	chr6:111277932~111278742:+
LUAD	cis	rs10971721	0.822	rs12376145	ENSG00000260947.1	RP11-384P7.7	4.18	3.49e-05	0.00578	0.39	0.19	Body mass index;	chr9:34050408	chr9:33697459~33700986:+
LUAD	cis	rs11853189	1	rs2867933	ENSG00000259562.2	RP11-762H8.2	-4.18	3.49e-05	0.00578	-0.19	-0.19	Red cell distribution width;	chr15:78282445	chr15:78290527~78291221:-
LUAD	cis	rs2836974	0.965	rs8134733	ENSG00000232608.1	TIMM9P2	-4.18	3.49e-05	0.00578	-0.23	-0.19	Cognitive function;	chr21:39311533	chr21:39216624~39217506:+
LUAD	cis	rs2929278	0.589	rs2411284	ENSG00000166763.7	STRCP1	-4.18	3.49e-05	0.00578	-0.22	-0.19	Schizophrenia;	chr15:43746701	chr15:43699488~43718184:-
LUAD	cis	rs1061377	0.513	rs2712000	ENSG00000249685.1	RP11-360F5.3	4.18	3.49e-05	0.00579	0.26	0.19	Uric acid levels;	chr4:39135462	chr4:39133913~39135608:+
LUAD	cis	rs4561483	0.645	rs2192645	ENSG00000261216.1	RP11-166B2.5	-4.18	3.49e-05	0.00579	-0.18	-0.19	Testicular germ cell tumor;	chr16:11834162	chr16:11908208~11908916:+
LUAD	cis	rs2427308	0.607	rs1741635	ENSG00000273619.1	RP5-908M14.9	4.18	3.49e-05	0.00579	0.21	0.19	Colorectal cancer;	chr20:62363141	chr20:62386303~62386970:-
LUAD	cis	rs5769707	0.681	rs2071902	ENSG00000235111.1	RP1-29C18.8	-4.18	3.49e-05	0.00579	-0.23	-0.19	Monocyte percentage of white cells;Monocyte count;	chr22:49640890	chr22:49612657~49615716:-
LUAD	cis	rs13434995	0.588	rs114571142	ENSG00000273257.1	RP11-177J6.1	-4.18	3.5e-05	0.00579	-0.24	-0.19	Adiponectin levels;	chr4:55412991	chr4:55387949~55388271:+
LUAD	cis	rs11673344	0.704	rs484001	ENSG00000267309.1	CTD-2630F21.1	-4.18	3.5e-05	0.00579	-0.23	-0.19	Obesity-related traits;	chr19:36931320	chr19:36489649~36491040:+
LUAD	cis	rs6832769	1	rs1522110	ENSG00000272969.1	RP11-528I4.2	4.18	3.5e-05	0.00579	0.19	0.19	Personality dimensions;	chr4:55514116	chr4:55547112~55547889:+
LUAD	cis	rs1005277	0.522	rs200943	ENSG00000273019.1	RP11-508N22.13	-4.18	3.5e-05	0.00579	-0.21	-0.19	Extrinsic epigenetic age acceleration;	chr10:37859802	chr10:38149968~38150293:+
LUAD	cis	rs1005277	0.505	rs719569	ENSG00000273019.1	RP11-508N22.13	4.18	3.5e-05	0.00579	0.21	0.19	Extrinsic epigenetic age acceleration;	chr10:37865487	chr10:38149968~38150293:+
LUAD	cis	rs13113518	0.902	rs12505266	ENSG00000272969.1	RP11-528I4.2	4.18	3.5e-05	0.00579	0.19	0.19	Height;	chr4:55546002	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs56154935	ENSG00000272969.1	RP11-528I4.2	4.18	3.5e-05	0.00579	0.19	0.19	Height;	chr4:55546378	chr4:55547112~55547889:+
LUAD	cis	rs6479891	0.915	rs2616628	ENSG00000232075.1	MRPL35P2	4.18	3.5e-05	0.00579	0.31	0.19	Arthritis (juvenile idiopathic);	chr10:63460197	chr10:63634317~63634827:-
LUAD	cis	rs6479891	1	rs2393980	ENSG00000232075.1	MRPL35P2	4.18	3.5e-05	0.00579	0.31	0.19	Arthritis (juvenile idiopathic);	chr10:63464750	chr10:63634317~63634827:-
LUAD	cis	rs6479891	1	rs12414159	ENSG00000232075.1	MRPL35P2	4.18	3.5e-05	0.00579	0.31	0.19	Arthritis (juvenile idiopathic);	chr10:63479017	chr10:63634317~63634827:-
LUAD	cis	rs6479891	1	rs10995543	ENSG00000232075.1	MRPL35P2	4.18	3.5e-05	0.00579	0.31	0.19	Arthritis (juvenile idiopathic);	chr10:63479787	chr10:63634317~63634827:-
LUAD	cis	rs17837474	0.656	rs17273	ENSG00000276953.1	TRBV12-4	4.18	3.5e-05	0.00579	0.23	0.19	Cancer;	chr7:142407435	chr7:142563740~142564245:+
LUAD	cis	rs853679	0.607	rs67998226	ENSG00000219392.1	RP1-265C24.5	-4.18	3.5e-05	0.0058	-0.4	-0.19	Depression;	chr6:28270281	chr6:28115628~28116551:+
LUAD	cis	rs1334894	1	rs72921231	ENSG00000228559.1	RP3-340B19.3	-4.18	3.5e-05	0.0058	-0.39	-0.19	Coronary artery disease;	chr6:35621860	chr6:35544632~35545669:+
LUAD	cis	rs1334894	1	rs7754668	ENSG00000228559.1	RP3-340B19.3	-4.18	3.5e-05	0.0058	-0.39	-0.19	Coronary artery disease;	chr6:35622315	chr6:35544632~35545669:+
LUAD	cis	rs1520333	0.602	rs967426	ENSG00000254352.1	RP11-578O24.2	4.18	3.5e-05	0.0058	0.21	0.19	Multiple sclerosis;	chr8:78585664	chr8:78723796~78724136:-
LUAD	cis	rs6763848	0.962	rs17039921	ENSG00000214073.2	RPL21P17	-4.18	3.5e-05	0.0058	-0.19	-0.19	Prostate cancer (SNP x SNP interaction);	chr3:1476380	chr3:1905651~1906125:+
LUAD	cis	rs10090774	0.687	rs13268978	ENSG00000280303.2	ERICD	-4.18	3.5e-05	0.0058	-0.2	-0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140669286	chr8:140636281~140638283:+
LUAD	cis	rs4713118	0.866	rs2179094	ENSG00000280107.1	AL022393.9	-4.18	3.5e-05	0.0058	-0.24	-0.19	Parkinson's disease;	chr6:27774046	chr6:28170845~28172521:+
LUAD	cis	rs2333021	0.78	rs12887074	ENSG00000259015.1	RP11-109N23.6	4.18	3.5e-05	0.0058	0.18	0.19	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72981132	chr14:72960595~72961993:+
LUAD	cis	rs1964356	0.967	rs17701675	ENSG00000253893.2	FAM85B	4.18	3.5e-05	0.0058	0.24	0.19	Mean corpuscular volume;	chr8:8993123	chr8:8167819~8226614:-
LUAD	cis	rs4964805	0.865	rs3935416	ENSG00000257681.1	RP11-341G23.4	4.18	3.5e-05	0.0058	0.22	0.19	Attention deficit hyperactivity disorder;	chr12:103813177	chr12:103746315~103768858:-
LUAD	cis	rs7829975	0.774	rs13259216	ENSG00000233609.3	RP11-62H7.2	4.18	3.5e-05	0.0058	0.15	0.19	Mood instability;	chr8:8816091	chr8:8961200~8979025:+
LUAD	cis	rs858239	0.601	rs10278700	ENSG00000226816.2	AC005082.12	4.18	3.5e-05	0.0058	0.24	0.19	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23206013~23208045:+
LUAD	cis	rs858239	0.601	rs10263110	ENSG00000226816.2	AC005082.12	4.18	3.5e-05	0.0058	0.24	0.19	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23206013~23208045:+
LUAD	cis	rs7247513	0.964	rs12104149	ENSG00000230310.1	CTD-2192J16.11	-4.18	3.5e-05	0.0058	-0.21	-0.19	Bipolar disorder;	chr19:12610274	chr19:12552597~12553644:+
LUAD	cis	rs9860428	0.815	rs11720045	ENSG00000242770.2	RP11-180K7.1	4.18	3.5e-05	0.0058	0.21	0.19	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112906315	chr3:112802478~112812819:+
LUAD	cis	rs9860428	0.844	rs9813901	ENSG00000242770.2	RP11-180K7.1	4.18	3.5e-05	0.0058	0.21	0.19	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112908718	chr3:112802478~112812819:+
LUAD	cis	rs10129255	0.957	rs11847726	ENSG00000211967.3	IGHV3-53	-4.18	3.51e-05	0.0058	-0.15	-0.19	Kawasaki disease;	chr14:106779116	chr14:106592676~106593347:-
LUAD	cis	rs8062405	0.69	rs762634	ENSG00000251417.2	RP11-1348G14.4	-4.18	3.51e-05	0.0058	-0.19	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28802743~28817828:+
LUAD	cis	rs5758511	0.68	rs739147	ENSG00000227370.1	RP4-669P10.19	4.18	3.51e-05	0.0058	0.21	0.19	Birth weight;	chr22:42275060	chr22:42132543~42132998:+
LUAD	cis	rs4713118	0.513	rs156738	ENSG00000216901.1	AL022393.7	4.18	3.51e-05	0.00581	0.22	0.19	Parkinson's disease;	chr6:28046247	chr6:28176188~28176674:+
LUAD	cis	rs10129255	0.789	rs61997796	ENSG00000211955.2	IGHV3-33	-4.18	3.51e-05	0.00581	-0.15	-0.19	Kawasaki disease;	chr14:106813798	chr14:106359793~106360324:-
LUAD	cis	rs7302981	0.899	rs1862043	ENSG00000200428.1	Y_RNA	4.18	3.51e-05	0.00581	0.23	0.19	Systolic blood pressure;	chr12:50182533	chr12:50743568~50743684:+
LUAD	cis	rs7208859	0.623	rs7219712	ENSG00000280069.1	CTD-2349P21.3	-4.18	3.51e-05	0.00581	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753552	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.573	rs8078656	ENSG00000280069.1	CTD-2349P21.3	-4.18	3.51e-05	0.00581	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753953	chr17:30738182~30740275:+
LUAD	cis	rs6732426	0.524	rs10166054	ENSG00000279873.2	LINC01126	4.18	3.51e-05	0.00581	0.16	0.19	Hair morphology;	chr2:43391901	chr2:43227210~43228855:+
LUAD	cis	rs34779708	0.966	rs4934539	ENSG00000271335.4	RP11-324I22.4	4.18	3.51e-05	0.00581	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35183271	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.966	rs1478463	ENSG00000271335.4	RP11-324I22.4	4.18	3.51e-05	0.00581	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35184107	chr10:35314552~35336401:-
LUAD	cis	rs11051970	0.918	rs6488050	ENSG00000274964.1	RP11-817I4.1	-4.18	3.51e-05	0.00581	-0.22	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr12:32379565	chr12:32339368~32340724:+
LUAD	cis	rs58106596	0.517	rs56272010	ENSG00000237641.1	RP11-690I21.1	-4.18	3.51e-05	0.00581	-0.18	-0.19	Lymphocyte counts;White blood cell count;	chr2:231800253	chr2:231789481~231789887:-
LUAD	cis	rs6832769	1	rs13102385	ENSG00000272969.1	RP11-528I4.2	4.18	3.51e-05	0.00581	0.19	0.19	Personality dimensions;	chr4:55479088	chr4:55547112~55547889:+
LUAD	cis	rs6832769	0.961	rs11947623	ENSG00000272969.1	RP11-528I4.2	4.18	3.51e-05	0.00581	0.19	0.19	Personality dimensions;	chr4:55483023	chr4:55547112~55547889:+
LUAD	cis	rs858239	0.899	rs858271	ENSG00000230042.1	AK3P3	-4.18	3.51e-05	0.00581	-0.23	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23238664	chr7:23129178~23129841:+
LUAD	cis	rs9341808	0.628	rs9294172	ENSG00000260645.1	RP11-250B2.5	4.18	3.51e-05	0.00581	0.18	0.19	Sitting height ratio;	chr6:80208844	chr6:80466958~80469080:+
LUAD	cis	rs6964587	1	rs36021614	ENSG00000188693.7	CYP51A1-AS1	-4.18	3.51e-05	0.00582	-0.22	-0.19	Breast cancer;	chr7:92088176	chr7:92134604~92180725:+
LUAD	cis	rs4372836	1	rs2276547	ENSG00000226833.4	AC097724.3	4.18	3.52e-05	0.00582	0.22	0.19	Body mass index;	chr2:28752241	chr2:28708953~28736205:-
LUAD	cis	rs853679	0.556	rs45509595	ENSG00000219392.1	RP1-265C24.5	-4.18	3.52e-05	0.00582	-0.42	-0.19	Depression;	chr6:27873148	chr6:28115628~28116551:+
LUAD	cis	rs1478897	0.575	rs12679960	ENSG00000255046.1	RP11-297N6.4	-4.18	3.52e-05	0.00582	-0.25	-0.19	Systemic lupus erythematosus;	chr8:11573481	chr8:11797928~11802568:-
LUAD	cis	rs17301013	0.932	rs6425282	ENSG00000227373.4	RP11-160H22.5	4.18	3.52e-05	0.00582	0.23	0.19	Systemic lupus erythematosus;	chr1:174493387	chr1:174115300~174160004:-
LUAD	cis	rs2153535	0.585	rs9502734	ENSG00000230939.1	RP11-314C16.1	-4.18	3.52e-05	0.00583	-0.21	-0.19	Motion sickness;	chr6:8631618	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.56	rs7750064	ENSG00000230939.1	RP11-314C16.1	-4.18	3.52e-05	0.00583	-0.21	-0.19	Motion sickness;	chr6:8632012	chr6:8784178~8785445:+
LUAD	cis	rs42490	0.635	rs42186	ENSG00000251136.7	RP11-37B2.1	-4.18	3.52e-05	0.00583	-0.2	-0.19	Leprosy;	chr8:89827257	chr8:89609409~89757727:-
LUAD	cis	rs2562456	0.834	rs2650848	ENSG00000268081.1	RP11-678G14.2	4.18	3.52e-05	0.00583	0.3	0.19	Pain;	chr19:21403835	chr19:21554640~21569237:-
LUAD	cis	rs4578769	0.569	rs1448769	ENSG00000265943.1	RP11-739L10.1	4.18	3.52e-05	0.00583	0.23	0.19	Eosinophil percentage of white cells;	chr18:22838322	chr18:22699481~22933764:-
LUAD	cis	rs9467773	0.838	rs3734540	ENSG00000124549.13	BTN2A3P	4.18	3.52e-05	0.00583	0.17	0.19	Intelligence (multi-trait analysis);	chr6:26463093	chr6:26421391~26432383:+
LUAD	cis	rs2880765	0.835	rs4360875	ENSG00000259416.2	RP11-158M2.5	4.18	3.52e-05	0.00583	0.19	0.19	Coronary artery disease;	chr15:85497163	chr15:85754941~85756237:-
LUAD	cis	rs17772222	0.682	rs2401751	ENSG00000258789.1	RP11-507K2.3	4.18	3.52e-05	0.00583	0.23	0.19	Coronary artery calcification;	chr14:88480278	chr14:88551597~88552493:+
LUAD	cis	rs4819052	0.679	rs2838860	ENSG00000237664.1	LINC00316	-4.18	3.52e-05	0.00583	-0.22	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45264989	chr21:45338590~45341990:-
LUAD	cis	rs1876905	0.539	rs241003	ENSG00000272356.1	RP5-1112D6.8	4.18	3.53e-05	0.00583	0.22	0.19	Mean corpuscular hemoglobin;	chr6:111274934	chr6:111309203~111313517:+
LUAD	cis	rs2348418	0.733	rs11049508	ENSG00000244712.1	RP11-874G11.1	4.18	3.53e-05	0.00583	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28289633	chr12:28564678~28565141:-
LUAD	cis	rs8030379	0.967	rs6603001	ENSG00000230373.7	GOLGA6L5P	-4.18	3.53e-05	0.00583	-0.17	-0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83896516	chr15:84507885~84516814:-
LUAD	cis	rs7590268	0.577	rs2172168	ENSG00000279873.2	LINC01126	4.18	3.53e-05	0.00583	0.2	0.19	Orofacial clefts;	chr2:43607549	chr2:43227210~43228855:+
LUAD	cis	rs12962334	0.518	rs4800141	ENSG00000265943.1	RP11-739L10.1	4.18	3.53e-05	0.00583	0.23	0.19	Breast cancer;	chr18:22984312	chr18:22699481~22933764:-
LUAD	cis	rs2115630	0.967	rs8028490	ENSG00000259728.4	LINC00933	-4.18	3.53e-05	0.00583	-0.23	-0.19	P wave terminal force;	chr15:84734657	chr15:84570649~84580175:+
LUAD	cis	rs338389	0.516	rs11855801	ENSG00000260657.2	RP11-315D16.4	4.18	3.53e-05	0.00584	0.21	0.19	Survival in rectal cancer;	chr15:68020994	chr15:68267792~68277994:-
LUAD	cis	rs7107174	1	rs2512550	ENSG00000251323.2	RP11-452H21.4	4.18	3.53e-05	0.00584	0.24	0.19	Testicular germ cell tumor;	chr11:78232802	chr11:78423982~78429836:-
LUAD	cis	rs1383484	1	rs4357909	ENSG00000259728.4	LINC00933	4.18	3.53e-05	0.00584	0.24	0.19	Height;	chr15:83846823	chr15:84570649~84580175:+
LUAD	cis	rs2732480	0.557	rs2732441	ENSG00000240399.1	RP1-228P16.1	4.18	3.53e-05	0.00584	0.19	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48329541	chr12:48054813~48055591:-
LUAD	cis	rs7204230	0.96	rs8053198	ENSG00000261291.1	RP11-295M3.2	4.18	3.53e-05	0.00584	0.23	0.19	Fibrinogen;	chr16:53309688	chr16:53168522~53169450:+
LUAD	cis	rs12579720	0.909	rs3752728	ENSG00000255910.1	RP11-405A12.2	4.18	3.53e-05	0.00584	0.23	0.19	Diastolic blood pressure;	chr12:20040038	chr12:19775451~20009937:+
LUAD	cis	rs9921338	0.961	rs8043692	ENSG00000263080.1	RP11-485G7.5	4.18	3.53e-05	0.00584	0.25	0.19	Vein graft stenosis in coronary artery bypass grafting;	chr16:11333100	chr16:11341809~11345211:-
LUAD	cis	rs9921338	0.923	rs6498181	ENSG00000263080.1	RP11-485G7.5	4.18	3.53e-05	0.00584	0.25	0.19	Vein graft stenosis in coronary artery bypass grafting;	chr16:11333336	chr16:11341809~11345211:-
LUAD	cis	rs17301013	0.932	rs2072760	ENSG00000227373.4	RP11-160H22.5	4.18	3.53e-05	0.00584	0.23	0.19	Systemic lupus erythematosus;	chr1:174510186	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.932	rs10912797	ENSG00000227373.4	RP11-160H22.5	4.18	3.53e-05	0.00584	0.23	0.19	Systemic lupus erythematosus;	chr1:174511225	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.932	rs6668053	ENSG00000227373.4	RP11-160H22.5	4.18	3.53e-05	0.00584	0.23	0.19	Systemic lupus erythematosus;	chr1:174515139	chr1:174115300~174160004:-
LUAD	cis	rs9549260	0.564	rs4245402	ENSG00000229456.1	RLIMP1	4.18	3.53e-05	0.00584	0.2	0.19	Red blood cell count;	chr13:40713404	chr13:40618738~40621348:+
LUAD	cis	rs6568686	0.627	rs174377	ENSG00000255389.1	C6orf3	4.18	3.53e-05	0.00584	0.24	0.19	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111587443	chr6:111599875~111602295:+
LUAD	cis	rs7208859	0.673	rs9896095	ENSG00000280069.1	CTD-2349P21.3	-4.18	3.53e-05	0.00584	-0.25	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30860479	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.573	rs58920731	ENSG00000280069.1	CTD-2349P21.3	-4.18	3.53e-05	0.00584	-0.25	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864728	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs73277984	ENSG00000280069.1	CTD-2349P21.3	-4.18	3.53e-05	0.00584	-0.25	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869115	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs73277986	ENSG00000280069.1	CTD-2349P21.3	-4.18	3.53e-05	0.00584	-0.25	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869179	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs12103588	ENSG00000280069.1	CTD-2349P21.3	-4.18	3.53e-05	0.00584	-0.25	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30870442	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs4131618	ENSG00000280069.1	CTD-2349P21.3	-4.18	3.53e-05	0.00584	-0.25	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30877783	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs11658344	ENSG00000280069.1	CTD-2349P21.3	-4.18	3.53e-05	0.00584	-0.25	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30880727	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs9900144	ENSG00000280069.1	CTD-2349P21.3	-4.18	3.53e-05	0.00584	-0.25	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881371	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.573	rs11656121	ENSG00000280069.1	CTD-2349P21.3	-4.18	3.53e-05	0.00584	-0.25	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887025	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs11650973	ENSG00000280069.1	CTD-2349P21.3	-4.18	3.53e-05	0.00584	-0.25	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887027	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs56085216	ENSG00000280069.1	CTD-2349P21.3	-4.18	3.53e-05	0.00584	-0.25	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30890216	chr17:30738182~30740275:+
LUAD	cis	rs7189233	0.55	rs17193176	ENSG00000279344.1	RP11-44F14.7	4.18	3.53e-05	0.00584	0.15	0.19	Intelligence (multi-trait analysis);	chr16:53484316	chr16:53478957~53481550:-
LUAD	cis	rs2836950	0.545	rs2836959	ENSG00000232608.1	TIMM9P2	4.18	3.54e-05	0.00585	0.21	0.19	Menarche (age at onset);	chr21:39251742	chr21:39216624~39217506:+
LUAD	cis	rs2765539	0.74	rs12045196	ENSG00000226172.2	RP4-712E4.1	-4.18	3.54e-05	0.00585	-0.25	-0.19	Waist-hip ratio;	chr1:119077020	chr1:119000344~119001392:-
LUAD	cis	rs651907	0.557	rs11925001	ENSG00000244119.1	PDCL3P4	4.18	3.54e-05	0.00585	0.19	0.19	Colorectal cancer;	chr3:101655122	chr3:101712472~101713191:+
LUAD	cis	rs651907	0.557	rs34624546	ENSG00000244119.1	PDCL3P4	4.18	3.54e-05	0.00585	0.19	0.19	Colorectal cancer;	chr3:101655382	chr3:101712472~101713191:+
LUAD	cis	rs13068223	1	rs9868587	ENSG00000243926.1	TIPARP-AS1	4.18	3.54e-05	0.00585	0.19	0.19	Age-related hearing impairment (SNP x SNP interaction);	chr3:156743800	chr3:156671862~156674378:-
LUAD	cis	rs4474465	1	rs966456	ENSG00000251323.2	RP11-452H21.4	4.18	3.54e-05	0.00585	0.24	0.19	Alzheimer's disease (survival time);	chr11:78457557	chr11:78423982~78429836:-
LUAD	cis	rs2548724	0.716	rs6884141	ENSG00000250682.4	LINC00491	4.17	3.54e-05	0.00585	0.26	0.19	Type 2 diabetes;	chr5:102480400	chr5:102609156~102671559:-
LUAD	cis	rs4664293	0.967	rs4665103	ENSG00000230783.1	AC009961.2	-4.17	3.54e-05	0.00585	-0.24	-0.19	Monocyte percentage of white cells;	chr2:159675801	chr2:159689217~159690291:-
LUAD	cis	rs911555	0.723	rs4906320	ENSG00000244691.1	RPL10AP1	4.17	3.54e-05	0.00585	0.25	0.19	Intelligence (multi-trait analysis);	chr14:103410588	chr14:103412119~103412761:-
LUAD	cis	rs9840812	0.817	rs61789561	ENSG00000239213.4	NCK1-AS1	-4.17	3.54e-05	0.00585	-0.27	-0.19	Fibrinogen levels;	chr3:136198785	chr3:136841726~136862054:-
LUAD	cis	rs7208859	0.673	rs11657270	ENSG00000280069.1	CTD-2349P21.3	-4.17	3.54e-05	0.00585	-0.27	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887369	chr17:30738182~30740275:+
LUAD	cis	rs516805	0.52	rs508012	ENSG00000279453.1	RP3-425C14.4	-4.17	3.54e-05	0.00585	-0.2	-0.19	Lymphocyte counts;	chr6:122442594	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.501	rs535954	ENSG00000279453.1	RP3-425C14.4	-4.17	3.54e-05	0.00585	-0.2	-0.19	Lymphocyte counts;	chr6:122442622	chr6:122436789~122439223:-
LUAD	cis	rs2354432	0.556	rs7525622	ENSG00000226015.2	CCT8P1	4.17	3.54e-05	0.00585	0.35	0.19	Mitochondrial DNA levels;	chr1:147302425	chr1:147203276~147204932:-
LUAD	cis	rs2732480	0.577	rs2634691	ENSG00000240399.1	RP1-228P16.1	4.17	3.54e-05	0.00585	0.19	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48314476	chr12:48054813~48055591:-
LUAD	cis	rs4374383	0.847	rs13394651	ENSG00000207383.1	Y_RNA	4.17	3.54e-05	0.00586	0.23	0.19	Hepatitis C induced liver fibrosis;	chr2:111987537	chr2:112579484~112579584:-
LUAD	cis	rs1350171	0.764	rs4631906	ENSG00000255471.1	RP11-736K20.5	-4.17	3.55e-05	0.00586	-0.32	-0.19	Hepatocellular carcinoma in hepatitis B infection;	chr11:86939240	chr11:86892214~86925037:-
LUAD	cis	rs75920871	0.609	rs11216180	ENSG00000254851.1	RP11-109L13.1	-4.17	3.55e-05	0.00586	-0.4	-0.19	Subjective well-being;	chr11:116902662	chr11:117135528~117138582:+
LUAD	cis	rs35828350	1	rs35828350	ENSG00000254414.1	RP11-182J1.1	4.17	3.55e-05	0.00586	0.24	0.19	Autism spectrum disorder or schizophrenia;	chr15:84812610	chr15:84631898~84633987:-
LUAD	cis	rs7107174	0.892	rs2510031	ENSG00000251323.2	RP11-452H21.4	4.17	3.55e-05	0.00587	0.23	0.19	Testicular germ cell tumor;	chr11:78258910	chr11:78423982~78429836:-
LUAD	cis	rs34779708	0.771	rs3867218	ENSG00000271335.4	RP11-324I22.4	4.17	3.55e-05	0.00587	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35238615	chr10:35314552~35336401:-
LUAD	cis	rs8141529	0.732	rs5752798	ENSG00000272858.1	CTA-292E10.8	-4.17	3.55e-05	0.00587	-0.21	-0.19	Lymphocyte counts;	chr22:28785880	chr22:28814914~28815662:+
LUAD	cis	rs1714507	0.533	rs1435642	ENSG00000272087.1	RP11-379F4.7	-4.17	3.55e-05	0.00587	-0.2	-0.19	Subjective well-being;	chr3:158582432	chr3:158693120~158693768:-
LUAD	cis	rs4811196	0.778	rs4811284	ENSG00000226144.2	RPS27AP3	4.17	3.55e-05	0.00587	0.21	0.19	Bone mineral density;	chr20:37892154	chr20:37049254~37049707:+
LUAD	cis	rs17301013	0.932	rs727279	ENSG00000227373.4	RP11-160H22.5	4.17	3.55e-05	0.00587	0.23	0.19	Systemic lupus erythematosus;	chr1:174496026	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.794	rs6425283	ENSG00000227373.4	RP11-160H22.5	4.17	3.55e-05	0.00587	0.23	0.19	Systemic lupus erythematosus;	chr1:174499853	chr1:174115300~174160004:-
LUAD	cis	rs6940638	0.688	rs1028308	ENSG00000219392.1	RP1-265C24.5	-4.17	3.55e-05	0.00587	-0.24	-0.19	Intelligence (multi-trait analysis);	chr6:27161978	chr6:28115628~28116551:+
LUAD	cis	rs35740288	0.77	rs11635711	ENSG00000259407.1	RP11-158M2.3	-4.17	3.55e-05	0.00587	-0.18	-0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85583255	chr15:85744109~85750281:-
LUAD	cis	rs763121	0.853	rs2235230	ENSG00000228274.3	RP3-508I15.9	4.17	3.55e-05	0.00587	0.19	0.19	Menopause (age at onset);	chr22:38728462	chr22:38667585~38681820:-
LUAD	cis	rs12449964	0.515	rs9899364	ENSG00000223979.2	SMCR2	4.17	3.55e-05	0.00587	0.22	0.19	Coronary artery disease or ischemic stroke;	chr17:17663798	chr17:17674026~17677688:-
LUAD	cis	rs6568686	0.527	rs174408	ENSG00000255389.1	C6orf3	4.17	3.55e-05	0.00587	0.25	0.19	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111611146	chr6:111599875~111602295:+
LUAD	cis	rs6568686	0.527	rs174409	ENSG00000255389.1	C6orf3	4.17	3.55e-05	0.00587	0.25	0.19	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111611181	chr6:111599875~111602295:+
LUAD	cis	rs7937890	0.874	rs6486191	ENSG00000251991.1	RNU7-49P	4.17	3.55e-05	0.00587	0.19	0.19	Mitochondrial DNA levels;	chr11:14382193	chr11:14478892~14478953:+
LUAD	cis	rs4699052	1	rs4699055	ENSG00000246560.2	RP11-10L12.4	4.17	3.55e-05	0.00587	0.24	0.19	Testicular germ cell tumor;	chr4:103233343	chr4:102828055~102844075:+
LUAD	cis	rs523522	0.962	rs12814055	ENSG00000278344.1	RP11-18C24.8	4.17	3.56e-05	0.00588	0.25	0.19	High light scatter reticulocyte count;	chr12:120549588	chr12:120500735~120501090:-
LUAD	cis	rs4706831	0.647	rs9350847	ENSG00000260645.1	RP11-250B2.5	4.17	3.56e-05	0.00588	0.18	0.19	Joint mobility (Beighton score);	chr6:80179300	chr6:80466958~80469080:+
LUAD	cis	rs1431005	0.964	rs978629	ENSG00000250658.1	RP11-138B4.1	4.17	3.56e-05	0.00588	0.23	0.19	Response to statin therapy;	chr4:187426241	chr4:187304083~187309682:-
LUAD	cis	rs453301	0.686	rs7017868	ENSG00000253893.2	FAM85B	4.17	3.56e-05	0.00588	0.25	0.19	Joint mobility (Beighton score);	chr8:9015783	chr8:8167819~8226614:-
LUAD	cis	rs453301	0.686	rs3895823	ENSG00000253893.2	FAM85B	4.17	3.56e-05	0.00588	0.25	0.19	Joint mobility (Beighton score);	chr8:9016136	chr8:8167819~8226614:-
LUAD	cis	rs6471393	0.929	rs62525162	ENSG00000253848.1	RP11-10N23.5	4.17	3.56e-05	0.00588	0.23	0.19	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93749654	chr8:93741193~93744534:+
LUAD	cis	rs6471393	0.929	rs62525163	ENSG00000253848.1	RP11-10N23.5	4.17	3.56e-05	0.00588	0.23	0.19	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93749824	chr8:93741193~93744534:+
LUAD	cis	rs651907	0.535	rs61396602	ENSG00000244119.1	PDCL3P4	4.17	3.56e-05	0.00588	0.19	0.19	Colorectal cancer;	chr3:101790202	chr3:101712472~101713191:+
LUAD	cis	rs71636778	0.631	rs60314236	ENSG00000260063.1	RP5-968P14.2	-4.17	3.56e-05	0.00588	-0.25	-0.19	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26828675	chr1:26692132~26694131:-
LUAD	cis	rs3743162	1	rs12917429	ENSG00000225151.9	GOLGA2P7	4.17	3.56e-05	0.00588	0.28	0.19	Alzheimer's disease (age of onset);	chr15:84881866	chr15:84199311~84230136:-
LUAD	cis	rs2765539	0.74	rs10047100	ENSG00000226172.2	RP4-712E4.1	-4.17	3.56e-05	0.00589	-0.25	-0.19	Waist-hip ratio;	chr1:119077734	chr1:119000344~119001392:-
LUAD	cis	rs151234	0.676	rs231970	ENSG00000259982.1	CDC37P1	-4.17	3.57e-05	0.00589	-0.34	-0.19	Platelet distribution width;	chr16:28555683	chr16:28700294~28701540:-
LUAD	cis	rs897984	0.683	rs13337900	ENSG00000260911.2	RP11-196G11.2	4.17	3.57e-05	0.00589	0.17	0.19	Dementia with Lewy bodies;	chr16:30811088	chr16:31043150~31049868:+
LUAD	cis	rs13160562	0.527	rs27581	ENSG00000272109.1	CTD-2260A17.3	-4.17	3.57e-05	0.00589	-0.19	-0.19	Alcohol dependence;	chr5:96772070	chr5:96804353~96806105:+
LUAD	cis	rs7246657	0.943	rs9917081	ENSG00000226686.6	LINC01535	-4.17	3.57e-05	0.00589	-0.29	-0.19	Coronary artery calcification;	chr19:37385714	chr19:37251912~37265535:+
LUAD	cis	rs3096299	0.719	rs12934708	ENSG00000182376.2	RP5-1142A6.8	4.17	3.57e-05	0.00589	0.19	0.19	Multiple myeloma (IgH translocation);	chr16:89457382	chr16:88742767~88745748:+
LUAD	cis	rs9309473	1	rs7576245	ENSG00000230002.2	ALMS1-IT1	4.17	3.57e-05	0.00589	0.23	0.19	Metabolite levels;	chr2:73602551	chr2:73456764~73459484:+
LUAD	cis	rs3742264	1	rs9562635	ENSG00000235903.6	CPB2-AS1	-4.17	3.57e-05	0.00589	-0.24	-0.19	Blood protein levels;	chr13:46068857	chr13:46052806~46113332:+
LUAD	cis	rs7119038	0.629	rs11217000	ENSG00000255422.1	AP002954.4	4.17	3.57e-05	0.00589	0.29	0.19	Sjögren's syndrome;	chr11:118734275	chr11:118704607~118750263:+
LUAD	cis	rs2243480	1	rs1796220	ENSG00000229886.1	RP5-1132H15.3	4.17	3.57e-05	0.00589	0.33	0.19	Diabetic kidney disease;	chr7:66597113	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs2707831	ENSG00000229886.1	RP5-1132H15.3	4.17	3.57e-05	0.00589	0.33	0.19	Diabetic kidney disease;	chr7:66597524	chr7:66025126~66031544:-
LUAD	cis	rs2242116	0.796	rs2290546	ENSG00000271161.1	BOLA2P2	4.17	3.57e-05	0.00589	0.18	0.19	Birth weight;	chr3:46923707	chr3:47499841~47500407:+
LUAD	cis	rs2242116	0.761	rs6780601	ENSG00000271161.1	BOLA2P2	4.17	3.57e-05	0.00589	0.18	0.19	Birth weight;	chr3:46924366	chr3:47499841~47500407:+
LUAD	cis	rs7976269	0.609	rs7135891	ENSG00000257176.2	RP11-996F15.2	-4.17	3.57e-05	0.0059	-0.2	-0.19	Male-pattern baldness;	chr12:29053944	chr12:29280418~29317848:-
LUAD	cis	rs6671200	0.541	rs7555339	ENSG00000228852.5	RP11-57H12.5	-4.17	3.57e-05	0.0059	-0.22	-0.19	Stearic acid (18:0) levels;	chr1:95226023	chr1:95243167~95278940:-
LUAD	cis	rs9500256	0.903	rs726783	ENSG00000266579.1	RP1-71H19.2	-4.17	3.57e-05	0.0059	-0.23	-0.19	Eosinophilic esophagitis (pediatric);	chr6:58006583	chr6:57493855~57497691:+
LUAD	cis	rs7826238	0.502	rs10503377	ENSG00000253981.4	ALG1L13P	4.17	3.57e-05	0.0059	0.25	0.19	Systolic blood pressure;	chr8:8520912	chr8:8236003~8244667:-
LUAD	cis	rs2281558	0.55	rs68007865	ENSG00000125804.12	FAM182A	-4.17	3.57e-05	0.0059	-0.33	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25249342	chr20:26054655~26086917:+
LUAD	cis	rs4664293	0.625	rs4665102	ENSG00000226266.5	AC009961.3	4.17	3.57e-05	0.0059	0.25	0.19	Monocyte percentage of white cells;	chr2:159666076	chr2:159670708~159712435:-
LUAD	cis	rs7086627	0.515	rs4934189	ENSG00000226659.1	RP11-137H2.4	-4.17	3.57e-05	0.0059	-0.25	-0.19	Post bronchodilator FEV1;	chr10:80455036	chr10:80529597~80535942:-
LUAD	cis	rs6964587	0.74	rs2020360	ENSG00000188693.7	CYP51A1-AS1	-4.17	3.57e-05	0.0059	-0.22	-0.19	Breast cancer;	chr7:91810192	chr7:92134604~92180725:+
LUAD	cis	rs1008375	0.646	rs13145480	ENSG00000249502.1	AC006160.5	4.17	3.57e-05	0.0059	0.19	0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17563520	chr4:17587467~17614571:-
LUAD	cis	rs1555322	0.53	rs2275275	ENSG00000279253.1	RP4-614O4.13	-4.17	3.57e-05	0.0059	-0.23	-0.19	Attention deficit hyperactivity disorder;	chr20:35284508	chr20:35262727~35264187:-
LUAD	cis	rs2880765	0.566	rs11630381	ENSG00000259630.2	CTD-2262B20.1	-4.17	3.57e-05	0.0059	-0.22	-0.19	Coronary artery disease;	chr15:85469272	chr15:85415228~85415633:+
LUAD	cis	rs7615952	0.736	rs9866347	ENSG00000241288.6	RP11-379B18.5	-4.17	3.58e-05	0.0059	-0.3	-0.19	Blood pressure (smoking interaction);	chr3:125951082	chr3:125827238~125916384:-
LUAD	cis	rs6663390	0.51	rs2267896	ENSG00000203709.8	C1orf132	-4.17	3.58e-05	0.0059	-0.26	-0.19	Facial morphology (factor 18);	chr1:207907627	chr1:207801518~207869150:-
LUAD	cis	rs58785573	1	rs58785573	ENSG00000231160.8	KLF3-AS1	-4.17	3.58e-05	0.0059	-0.18	-0.19	Lymphocyte percentage of white cells;	chr4:38652152	chr4:38612701~38664883:-
LUAD	cis	rs948562	0.681	rs11229573	ENSG00000280010.1	AP001350.4	-4.17	3.58e-05	0.00591	-0.25	-0.19	Lymphoma;	chr11:58667095	chr11:58627435~58628528:+
LUAD	cis	rs853679	0.546	rs13195291	ENSG00000219392.1	RP1-265C24.5	-4.17	3.58e-05	0.00591	-0.42	-0.19	Depression;	chr6:28201463	chr6:28115628~28116551:+
LUAD	cis	rs4578769	0.55	rs4800435	ENSG00000265943.1	RP11-739L10.1	4.17	3.58e-05	0.00591	0.23	0.19	Eosinophil percentage of white cells;	chr18:22862923	chr18:22699481~22933764:-
LUAD	cis	rs6479891	1	rs11818194	ENSG00000232075.1	MRPL35P2	4.17	3.58e-05	0.00591	0.3	0.19	Arthritis (juvenile idiopathic);	chr10:63420692	chr10:63634317~63634827:-
LUAD	cis	rs17596685	1	rs346591	ENSG00000271216.1	LINC01050	-4.17	3.58e-05	0.00591	-0.27	-0.19	C-reactive protein levels;	chr13:42593338	chr13:42810366~42812562:-
LUAD	cis	rs7617773	0.746	rs6796343	ENSG00000199476.1	Y_RNA	-4.17	3.58e-05	0.00591	-0.25	-0.19	Coronary artery disease;	chr3:48240531	chr3:48288587~48288694:+
LUAD	cis	rs11886999	0.723	rs62153018	ENSG00000237510.6	AC008268.2	-4.17	3.58e-05	0.00591	-0.3	-0.19	Cardiac Troponin-T levels;	chr2:96210717	chr2:95789654~95800166:+
LUAD	cis	rs9393777	0.92	rs13207689	ENSG00000219392.1	RP1-265C24.5	-4.17	3.58e-05	0.00591	-0.4	-0.19	Intelligence (multi-trait analysis);	chr6:27401925	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.517	rs1947863	ENSG00000226314.6	ZNF192P1	-4.17	3.58e-05	0.00591	-0.25	-0.19	Depression;	chr6:28131566	chr6:28161781~28169594:+
LUAD	cis	rs394563	0.69	rs237010	ENSG00000216906.2	RP11-350J20.9	4.17	3.58e-05	0.00591	0.22	0.19	Dupuytren's disease;	chr6:149437614	chr6:149904243~149906418:+
LUAD	cis	rs4767841	1	rs4766947	ENSG00000248636.5	RP11-768F21.1	-4.17	3.58e-05	0.00591	-0.22	-0.19	Urgency urinary incontinence;	chr12:119723596	chr12:119387987~119668079:-
LUAD	cis	rs748404	0.55	rs12912505	ENSG00000249839.1	AC011330.5	-4.17	3.58e-05	0.00591	-0.3	-0.19	Lung cancer;	chr15:43525206	chr15:43663654~43684339:-
LUAD	cis	rs2243480	1	rs316331	ENSG00000229886.1	RP5-1132H15.3	-4.17	3.58e-05	0.00591	-0.33	-0.19	Diabetic kidney disease;	chr7:66139635	chr7:66025126~66031544:-
LUAD	cis	rs1322639	0.614	rs6940913	ENSG00000261039.2	RP11-417E7.2	-4.17	3.58e-05	0.00591	-0.3	-0.19	Pulse pressure;	chr6:169163571	chr6:169175304~169182740:-
LUAD	cis	rs6840360	0.509	rs62327273	ENSG00000270265.1	RP11-731D1.4	-4.17	3.58e-05	0.00591	-0.22	-0.19	Intelligence (multi-trait analysis);	chr4:151626442	chr4:151333775~151353224:-
LUAD	cis	rs4268898	0.76	rs11125535	ENSG00000242628.4	AC009228.1	-4.17	3.58e-05	0.00591	-0.24	-0.19	Asthma;	chr2:24305245	chr2:24214381~24221516:+
LUAD	cis	rs791888	0.767	rs2255684	ENSG00000225913.2	RP11-57C13.6	4.17	3.58e-05	0.00591	0.24	0.19	Magnesium levels;	chr10:87660214	chr10:87607985~87659279:+
LUAD	cis	rs62246343	0.63	rs62246320	ENSG00000254485.4	RP11-380O24.1	4.17	3.58e-05	0.00591	0.35	0.19	Fibrinogen levels;	chr3:9470291	chr3:9292588~9363303:-
LUAD	cis	rs7637701	0.713	rs9867857	ENSG00000240875.4	LINC00886	-4.17	3.58e-05	0.00591	-0.2	-0.19	Breast cancer;	chr3:156773371	chr3:156747346~156817062:-
LUAD	cis	rs1387259	0.839	rs7487682	ENSG00000257763.1	OR5BK1P	-4.17	3.58e-05	0.00592	-0.19	-0.19	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48185882	chr12:48355792~48356614:-
LUAD	cis	rs11673344	0.504	rs6510593	ENSG00000276846.1	CTD-3220F14.3	4.17	3.58e-05	0.00592	0.21	0.19	Obesity-related traits;	chr19:37143153	chr19:37314868~37315620:-
LUAD	cis	rs10971721	0.822	rs117703548	ENSG00000260947.1	RP11-384P7.7	4.17	3.59e-05	0.00592	0.39	0.19	Body mass index;	chr9:34041199	chr9:33697459~33700986:+
LUAD	cis	rs116175783	0.557	rs16845829	ENSG00000227403.1	AC009299.3	4.17	3.59e-05	0.00592	0.35	0.19	Intelligence (multi-trait analysis);	chr2:161399960	chr2:161244739~161249050:+
LUAD	cis	rs875971	0.545	rs313828	ENSG00000222364.1	RNU6-96P	4.17	3.59e-05	0.00592	0.25	0.19	Aortic root size;	chr7:66087627	chr7:66395191~66395286:+
LUAD	cis	rs4699052	0.928	rs2126473	ENSG00000246560.2	RP11-10L12.4	4.17	3.59e-05	0.00592	0.24	0.19	Testicular germ cell tumor;	chr4:103220376	chr4:102828055~102844075:+
LUAD	cis	rs4699052	0.963	rs6816055	ENSG00000246560.2	RP11-10L12.4	4.17	3.59e-05	0.00592	0.24	0.19	Testicular germ cell tumor;	chr4:103222003	chr4:102828055~102844075:+
LUAD	cis	rs2732480	0.577	rs2732466	ENSG00000240399.1	RP1-228P16.1	4.17	3.59e-05	0.00592	0.19	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48338676	chr12:48054813~48055591:-
LUAD	cis	rs728616	0.867	rs12414096	ENSG00000225484.5	NUTM2B-AS1	-4.17	3.59e-05	0.00592	-0.48	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79953873	chr10:79663088~79826594:-
LUAD	cis	rs3213958	0.574	rs17210963	ENSG00000249274.1	PDLIM1P4	-4.17	3.59e-05	0.00592	-0.29	-0.19	Blood protein levels;	chr3:98778815	chr3:98782188~98783193:+
LUAD	cis	rs11064837	0.504	rs746297	ENSG00000248636.5	RP11-768F21.1	4.17	3.59e-05	0.00592	0.21	0.19	Schizophrenia;	chr12:119604996	chr12:119387987~119668079:-
LUAD	cis	rs7107174	1	rs7941617	ENSG00000251323.2	RP11-452H21.4	4.17	3.59e-05	0.00592	0.23	0.19	Testicular germ cell tumor;	chr11:78310100	chr11:78423982~78429836:-
LUAD	cis	rs11673344	0.504	rs7259332	ENSG00000276846.1	CTD-3220F14.3	4.17	3.59e-05	0.00593	0.21	0.19	Obesity-related traits;	chr19:37143389	chr19:37314868~37315620:-
LUAD	cis	rs56104184	0.578	rs7254608	ENSG00000235191.1	NUCB1-AS1	4.17	3.59e-05	0.00593	0.21	0.19	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr19:48892517	chr19:48910930~48918891:-
LUAD	cis	rs8031584	0.918	rs3817498	ENSG00000270015.1	RP11-540B6.6	-4.17	3.59e-05	0.00593	-0.13	-0.19	Huntington's disease progression;	chr15:30976578	chr15:30926514~30928407:+
LUAD	cis	rs7760535	0.656	rs1883136	ENSG00000255389.1	C6orf3	-4.17	3.59e-05	0.00593	-0.19	-0.19	Metabolic traits;	chr6:111585820	chr6:111599875~111602295:+
LUAD	cis	rs12188164	0.931	rs115554641	ENSG00000225138.6	CTD-2228K2.7	4.17	3.6e-05	0.00593	0.19	0.19	Cystic fibrosis severity;	chr5:443121	chr5:473236~480884:+
LUAD	cis	rs12188164	0.965	rs11739543	ENSG00000225138.6	CTD-2228K2.7	4.17	3.6e-05	0.00593	0.19	0.19	Cystic fibrosis severity;	chr5:443561	chr5:473236~480884:+
LUAD	cis	rs12188164	0.965	rs72717430	ENSG00000225138.6	CTD-2228K2.7	4.17	3.6e-05	0.00593	0.19	0.19	Cystic fibrosis severity;	chr5:444387	chr5:473236~480884:+
LUAD	cis	rs10197140	0.885	rs880506	ENSG00000235721.1	AC013268.3	-4.17	3.6e-05	0.00593	-0.21	-0.19	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110869723	chr2:110007675~110010783:+
LUAD	cis	rs10197140	0.925	rs10171765	ENSG00000235721.1	AC013268.3	-4.17	3.6e-05	0.00593	-0.21	-0.19	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110870411	chr2:110007675~110010783:+
LUAD	cis	rs12701220	0.894	rs12701348	ENSG00000229043.2	AC091729.9	-4.17	3.6e-05	0.00593	-0.25	-0.19	Bronchopulmonary dysplasia;	chr7:999821	chr7:1160374~1165267:+
LUAD	cis	rs950169	1	rs1911155	ENSG00000275120.1	RP11-182J1.17	4.17	3.6e-05	0.00593	0.3	0.19	Schizophrenia;	chr15:84118883	chr15:84599434~84606463:-
LUAD	cis	rs16944613	0.541	rs7494949	ENSG00000259212.1	CTD-3065B20.2	4.17	3.6e-05	0.00593	0.3	0.19	Colorectal cancer;	chr15:90547162	chr15:90595840~90596447:-
LUAD	cis	rs2380205	0.504	rs591878	ENSG00000232807.2	RP11-536K7.3	4.17	3.6e-05	0.00593	0.19	0.19	Breast cancer;	chr10:5893474	chr10:5934270~5945900:-
LUAD	cis	rs16886181	0.512	rs12652988	ENSG00000271828.1	CTD-2310F14.1	4.17	3.6e-05	0.00593	0.41	0.19	Breast cancer (early onset);	chr5:56739539	chr5:56927874~56929573:+
LUAD	cis	rs5758511	0.514	rs5758626	ENSG00000227370.1	RP4-669P10.19	4.17	3.6e-05	0.00593	0.21	0.19	Birth weight;	chr22:42176357	chr22:42132543~42132998:+
LUAD	cis	rs1065852	0.861	rs5758627	ENSG00000227370.1	RP4-669P10.19	4.17	3.6e-05	0.00593	0.21	0.19	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42176541	chr22:42132543~42132998:+
LUAD	cis	rs4601821	0.823	rs17115439	ENSG00000270179.1	RP11-159N11.4	-4.17	3.6e-05	0.00594	-0.19	-0.19	Alcoholic chronic pancreatitis;	chr11:113393550	chr11:113368478~113369117:+
LUAD	cis	rs595982	0.546	rs9941490	ENSG00000235191.1	NUCB1-AS1	4.17	3.6e-05	0.00594	0.21	0.19	Red cell distribution width;	chr19:48893480	chr19:48910930~48918891:-
LUAD	cis	rs7208859	0.524	rs8069400	ENSG00000266490.1	CTD-2349P21.9	4.17	3.6e-05	0.00594	0.29	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748949	chr17:30792372~30792833:+
LUAD	cis	rs71636778	0.584	rs36042864	ENSG00000260063.1	RP5-968P14.2	-4.17	3.6e-05	0.00594	-0.25	-0.19	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26820453	chr1:26692132~26694131:-
LUAD	cis	rs34779708	0.966	rs4934540	ENSG00000271335.4	RP11-324I22.4	4.17	3.6e-05	0.00594	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35185771	chr10:35314552~35336401:-
LUAD	cis	rs1790761	0.692	rs10896179	ENSG00000184224.3	C11orf72	4.17	3.6e-05	0.00594	0.21	0.19	Mean corpuscular volume;	chr11:67549457	chr11:67602880~67606706:-
LUAD	cis	rs7578361	0.959	rs4667337	ENSG00000231969.1	AC144449.1	4.17	3.6e-05	0.00594	0.27	0.19	Acute lymphoblastic leukemia (childhood);	chr2:149594314	chr2:149587196~149848233:+
LUAD	cis	rs8062405	0.755	rs62034350	ENSG00000261419.1	RP11-57A19.4	-4.17	3.6e-05	0.00594	-0.2	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28659696~28740781:-
LUAD	cis	rs7617773	0.78	rs11720026	ENSG00000199476.1	Y_RNA	-4.17	3.6e-05	0.00594	-0.25	-0.19	Coronary artery disease;	chr3:48336431	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.743	rs11715876	ENSG00000199476.1	Y_RNA	-4.17	3.6e-05	0.00594	-0.25	-0.19	Coronary artery disease;	chr3:48336432	chr3:48288587~48288694:+
LUAD	cis	rs763121	0.752	rs6001190	ENSG00000228274.3	RP3-508I15.9	-4.17	3.6e-05	0.00594	-0.19	-0.19	Menopause (age at onset);	chr22:38677806	chr22:38667585~38681820:-
LUAD	cis	rs853679	0.517	rs17711344	ENSG00000226314.6	ZNF192P1	4.17	3.6e-05	0.00594	0.25	0.19	Depression;	chr6:28109824	chr6:28161781~28169594:+
LUAD	cis	rs2348418	0.767	rs7972954	ENSG00000247934.4	RP11-967K21.1	4.17	3.61e-05	0.00595	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28260273	chr12:28163298~28190738:-
LUAD	cis	rs13113518	1	rs4864542	ENSG00000272969.1	RP11-528I4.2	-4.17	3.61e-05	0.00595	-0.19	-0.19	Height;	chr4:55487920	chr4:55547112~55547889:+
LUAD	cis	rs11742741	0.87	rs1428207	ENSG00000248874.4	C5orf17	-4.17	3.61e-05	0.00595	-0.23	-0.19	Educational attainment;	chr5:24094910	chr5:23951348~24178263:+
LUAD	cis	rs467650	0.817	rs17730306	ENSG00000248489.1	CTD-2007H13.3	4.17	3.61e-05	0.00595	0.2	0.19	Venous thromboembolism (SNP x SNP interaction);	chr5:98721327	chr5:98929171~98995013:+
LUAD	cis	rs7116495	1	rs562469	ENSG00000254682.1	RP11-660L16.2	-4.17	3.61e-05	0.00595	-0.38	-0.19	Severe influenza A (H1N1) infection;	chr11:71858797	chr11:71448674~71452157:+
LUAD	cis	rs9649213	0.593	rs6967457	ENSG00000272950.1	RP11-307C18.1	4.17	3.61e-05	0.00595	0.23	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98282909	chr7:98322853~98323430:+
LUAD	cis	rs950880	0.961	rs13020553	ENSG00000234389.1	AC007278.3	-4.17	3.61e-05	0.00595	-0.18	-0.19	Serum protein levels (sST2);	chr2:102315366	chr2:102438713~102440475:+
LUAD	cis	rs4811196	0.748	rs2235456	ENSG00000226144.2	RPS27AP3	4.17	3.61e-05	0.00595	0.21	0.19	Bone mineral density;	chr20:37856864	chr20:37049254~37049707:+
LUAD	cis	rs4803480	0.572	rs17710743	ENSG00000270164.1	LINC01480	4.17	3.61e-05	0.00595	0.3	0.19	Schizophrenia;	chr19:41569079	chr19:41535183~41536904:+
LUAD	cis	rs2273156	0.57	rs77477310	ENSG00000226677.3	IGBP1P1	-4.17	3.61e-05	0.00595	-0.29	-0.19	Immunoglobulin light chain (AL) amyloidosis;	chr14:35146587	chr14:34939324~34940332:+
LUAD	cis	rs681343	1	rs516246	ENSG00000232871.7	SEC1P	4.17	3.61e-05	0.00595	0.2	0.19	Primary sclerosing cholangitis;Childhood ear infection;Lung adenocarcinoma;	chr19:48702915	chr19:48638071~48682245:+
LUAD	cis	rs4664293	1	rs10204535	ENSG00000230783.1	AC009961.2	-4.17	3.61e-05	0.00595	-0.23	-0.19	Monocyte percentage of white cells;	chr2:159607181	chr2:159689217~159690291:-
LUAD	cis	rs4819052	0.851	rs1056099	ENSG00000223768.1	LINC00205	-4.17	3.61e-05	0.00595	-0.22	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258977	chr21:45293285~45297354:+
LUAD	cis	rs34779708	0.966	rs7077242	ENSG00000271335.4	RP11-324I22.4	-4.17	3.61e-05	0.00595	-0.2	-0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35193037	chr10:35314552~35336401:-
LUAD	cis	rs34792	0.688	rs153783	ENSG00000275910.1	RP11-680G24.6	4.17	3.61e-05	0.00595	0.19	0.19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15508509	chr16:15015828~15016390:-
LUAD	cis	rs301901	0.581	rs158409	ENSG00000250155.1	CTD-2353F22.1	-4.17	3.61e-05	0.00595	-0.2	-0.19	Height;	chr5:36848456	chr5:36666214~36725195:-
LUAD	cis	rs1864585	0.616	rs117478948	ENSG00000255046.1	RP11-297N6.4	4.17	3.61e-05	0.00595	0.26	0.19	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10807314	chr8:11797928~11802568:-
LUAD	cis	rs2243480	1	rs316330	ENSG00000229886.1	RP5-1132H15.3	4.17	3.61e-05	0.00595	0.33	0.19	Diabetic kidney disease;	chr7:66140385	chr7:66025126~66031544:-
LUAD	cis	rs6840360	0.642	rs11099815	ENSG00000270265.1	RP11-731D1.4	-4.17	3.61e-05	0.00595	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151422736	chr4:151333775~151353224:-
LUAD	cis	rs2348418	0.864	rs1343859	ENSG00000244712.1	RP11-874G11.1	4.17	3.61e-05	0.00595	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28559537	chr12:28564678~28565141:-
LUAD	cis	rs12712133	0.514	rs10188022	ENSG00000234389.1	AC007278.3	-4.17	3.61e-05	0.00596	-0.18	-0.19	Primary biliary cholangitis;	chr2:102258406	chr2:102438713~102440475:+
LUAD	cis	rs1113500	0.73	rs1777456	ENSG00000226822.1	RP11-356N1.2	-4.17	3.61e-05	0.00596	-0.21	-0.19	Growth-regulated protein alpha levels;	chr1:108045850	chr1:108071482~108074519:+
LUAD	cis	rs2378497	1	rs996854	ENSG00000232679.1	RP11-400N13.3	4.17	3.61e-05	0.00596	0.27	0.19	Serum thyroid-stimulating hormone levels;	chr1:222027569	chr1:222041705~222064763:-
LUAD	cis	rs10971721	0.822	rs72729341	ENSG00000260947.1	RP11-384P7.7	4.17	3.61e-05	0.00596	0.39	0.19	Body mass index;	chr9:34031693	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs72729344	ENSG00000260947.1	RP11-384P7.7	4.17	3.61e-05	0.00596	0.39	0.19	Body mass index;	chr9:34034032	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs10971866	ENSG00000260947.1	RP11-384P7.7	4.17	3.61e-05	0.00596	0.39	0.19	Body mass index;	chr9:34043163	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs10971867	ENSG00000260947.1	RP11-384P7.7	4.17	3.61e-05	0.00596	0.39	0.19	Body mass index;	chr9:34046758	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs72729361	ENSG00000260947.1	RP11-384P7.7	4.17	3.61e-05	0.00596	0.39	0.19	Body mass index;	chr9:34047525	chr9:33697459~33700986:+
LUAD	cis	rs34783982	0.881	rs36116028	ENSG00000261441.1	RP11-217B1.2	-4.17	3.61e-05	0.00596	-0.25	-0.19	Squamous cell lung carcinoma;	chr15:88957398	chr15:89335053~89336161:+
LUAD	cis	rs7129556	0.69	rs588217	ENSG00000241782.1	RP11-91P24.1	-4.17	3.61e-05	0.00596	-0.25	-0.19	Weight loss (gastric bypass surgery);	chr11:77872330	chr11:77868722~77869195:-
LUAD	cis	rs2735413	0.958	rs2735401	ENSG00000276007.1	RP11-358L22.3	4.17	3.61e-05	0.00596	0.19	0.19	Systolic blood pressure (alcohol consumption interaction);	chr16:78023206	chr16:78123243~78124332:+
LUAD	cis	rs61542988	0.532	rs10240168	ENSG00000226816.2	AC005082.12	-4.17	3.62e-05	0.00596	-0.26	-0.19	Fibrinogen levels;	chr7:22779715	chr7:23206013~23208045:+
LUAD	cis	rs9287719	0.81	rs7601748	ENSG00000243819.4	RN7SL832P	4.17	3.62e-05	0.00596	0.2	0.19	Prostate cancer;	chr2:10645320	chr2:10690344~10692099:+
LUAD	cis	rs6479891	0.818	rs2393976	ENSG00000232075.1	MRPL35P2	4.17	3.62e-05	0.00596	0.31	0.19	Arthritis (juvenile idiopathic);	chr10:63493679	chr10:63634317~63634827:-
LUAD	cis	rs12935418	1	rs12935418	ENSG00000261061.1	RP11-303E16.2	-4.17	3.62e-05	0.00596	-0.27	-0.19	Mean corpuscular volume;	chr16:81036403	chr16:81030770~81031485:+
LUAD	cis	rs848490	0.962	rs62460738	ENSG00000214293.7	APTR	4.17	3.62e-05	0.00596	0.25	0.19	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77774943	chr7:77657660~77696265:-
LUAD	cis	rs2274273	0.805	rs8012156	ENSG00000258413.1	RP11-665C16.6	-4.17	3.62e-05	0.00596	-0.24	-0.19	Protein biomarker;	chr14:55085782	chr14:55262767~55272075:-
LUAD	cis	rs7061710	0.673	rs57519348	ENSG00000271811.1	RP1-79C4.4	-4.17	3.62e-05	0.00596	-0.28	-0.19	Blood metabolite levels;	chr1:171150960	chr1:170667381~170669425:+
LUAD	cis	rs7061710	0.711	rs57678907	ENSG00000271811.1	RP1-79C4.4	-4.17	3.62e-05	0.00596	-0.28	-0.19	Blood metabolite levels;	chr1:171150963	chr1:170667381~170669425:+
LUAD	cis	rs7246657	0.943	rs7259968	ENSG00000226686.6	LINC01535	-4.17	3.62e-05	0.00596	-0.28	-0.19	Coronary artery calcification;	chr19:37320952	chr19:37251912~37265535:+
LUAD	cis	rs3096299	0.679	rs3096322	ENSG00000261574.1	RP1-168P16.2	-4.17	3.62e-05	0.00597	-0.21	-0.19	Multiple myeloma (IgH translocation);	chr16:89374715	chr16:89392375~89412564:-
LUAD	cis	rs473651	1	rs473651	ENSG00000229915.1	AC016999.2	-4.17	3.62e-05	0.00597	-0.25	-0.19	Multiple system atrophy;	chr2:238426760	chr2:238427077~238427729:-
LUAD	cis	rs7512552	0.839	rs6703652	ENSG00000275557.1	RP11-353N4.6	4.17	3.62e-05	0.00597	0.21	0.19	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150493477	chr1:149607765~149612402:+
LUAD	cis	rs6763848	0.923	rs12631070	ENSG00000214073.2	RPL21P17	-4.17	3.62e-05	0.00597	-0.19	-0.19	Prostate cancer (SNP x SNP interaction);	chr3:1477231	chr3:1905651~1906125:+
LUAD	cis	rs8062405	0.755	rs56272201	ENSG00000261419.1	RP11-57A19.4	-4.17	3.62e-05	0.00597	-0.21	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28659696~28740781:-
LUAD	cis	rs8062405	0.755	rs62034355	ENSG00000261419.1	RP11-57A19.4	-4.17	3.62e-05	0.00597	-0.21	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28659696~28740781:-
LUAD	cis	rs2060793	0.712	rs10832290	ENSG00000251991.1	RNU7-49P	4.17	3.62e-05	0.00597	0.2	0.19	Vitamin D levels;	chr11:14650684	chr11:14478892~14478953:+
LUAD	cis	rs2060793	0.774	rs1403249	ENSG00000251991.1	RNU7-49P	4.17	3.62e-05	0.00597	0.2	0.19	Vitamin D levels;	chr11:14651438	chr11:14478892~14478953:+
LUAD	cis	rs7590268	0.55	rs55735499	ENSG00000279873.2	LINC01126	4.17	3.62e-05	0.00597	0.19	0.19	Orofacial clefts;	chr2:43593062	chr2:43227210~43228855:+
LUAD	cis	rs454217	0.74	rs430709	ENSG00000277851.1	RP11-756G20.1	4.17	3.62e-05	0.00597	0.19	0.19	Smoking quantity;	chr12:92325836	chr12:92247756~92363832:-
LUAD	cis	rs7688540	0.76	rs12506250	ENSG00000211553.1	AC253576.2	-4.17	3.62e-05	0.00597	-0.24	-0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:233593	chr4:136461~136568:+
LUAD	cis	rs7005380	0.581	rs9987165	ENSG00000279347.1	RP11-85I17.2	4.17	3.62e-05	0.00597	0.18	0.19	Interstitial lung disease;	chr8:119921633	chr8:119838736~119840385:-
LUAD	cis	rs2274273	0.868	rs6573007	ENSG00000259318.1	RP11-454L9.2	4.17	3.62e-05	0.00597	0.16	0.19	Protein biomarker;	chr14:55159220	chr14:55394940~55395233:-
LUAD	cis	rs6568686	0.627	rs403667	ENSG00000255389.1	C6orf3	4.17	3.63e-05	0.00597	0.24	0.19	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111589401	chr6:111599875~111602295:+
LUAD	cis	rs651907	0.535	rs35799195	ENSG00000244119.1	PDCL3P4	4.17	3.63e-05	0.00597	0.19	0.19	Colorectal cancer;	chr3:101803083	chr3:101712472~101713191:+
LUAD	cis	rs2898681	0.581	rs10003908	ENSG00000248375.1	RP11-177B4.1	-4.17	3.63e-05	0.00598	-0.28	-0.19	Optic nerve measurement (cup area);	chr4:52814922	chr4:52720081~52720831:-
LUAD	cis	rs9860428	0.844	rs7609699	ENSG00000242770.2	RP11-180K7.1	4.17	3.63e-05	0.00598	0.21	0.19	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112902758	chr3:112802478~112812819:+
LUAD	cis	rs712039	1	rs712039	ENSG00000276054.1	RP11-378E13.3	4.17	3.63e-05	0.00598	0.25	0.19	Tuberculosis;	chr17:37490447	chr17:37386886~37387926:+
LUAD	cis	rs5758659	0.714	rs5758578	ENSG00000182057.4	OGFRP1	-4.17	3.63e-05	0.00598	-0.22	-0.19	Cognitive function;	chr22:42094288	chr22:42269753~42275196:+
LUAD	cis	rs8014252	0.803	rs74062743	ENSG00000259158.2	ADAM20P1	-4.17	3.63e-05	0.00598	-0.33	-0.19	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70556694	chr14:70468881~70483756:-
LUAD	cis	rs8014252	0.803	rs74062746	ENSG00000259158.2	ADAM20P1	-4.17	3.63e-05	0.00598	-0.33	-0.19	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70558227	chr14:70468881~70483756:-
LUAD	cis	rs8014252	0.708	rs74062750	ENSG00000259158.2	ADAM20P1	-4.17	3.63e-05	0.00598	-0.33	-0.19	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70559335	chr14:70468881~70483756:-
LUAD	cis	rs10935480	0.577	rs10804683	ENSG00000249274.1	PDLIM1P4	-4.17	3.63e-05	0.00598	-0.2	-0.19	Blood protein levels;	chr3:98661882	chr3:98782188~98783193:+
LUAD	cis	rs8046148	0.789	rs11865001	ENSG00000279356.1	RP11-429P3.8	-4.17	3.63e-05	0.00598	-0.19	-0.19	Testicular germ cell tumor;	chr16:50116636	chr16:50072862~50074986:+
LUAD	cis	rs4372836	0.964	rs11683296	ENSG00000226833.4	AC097724.3	-4.17	3.63e-05	0.00598	-0.22	-0.19	Body mass index;	chr2:28702538	chr2:28708953~28736205:-
LUAD	cis	rs9400467	0.528	rs1989574	ENSG00000271789.1	RP5-1112D6.7	-4.17	3.63e-05	0.00598	-0.2	-0.19	Amino acid levels;Blood metabolite levels;	chr6:111407330	chr6:111297126~111298510:+
LUAD	cis	rs4908760	0.539	rs6690928	ENSG00000270282.1	RP5-1115A15.2	4.17	3.63e-05	0.00598	0.2	0.19	Vitiligo;	chr1:8799432	chr1:8512653~8513021:+
LUAD	cis	rs780094	0.544	rs780108	ENSG00000234072.1	AC074117.10	-4.17	3.63e-05	0.00598	-0.15	-0.19	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27462090	chr2:27356246~27367622:+
LUAD	cis	rs9322193	0.607	rs6925151	ENSG00000268592.3	RAET1E-AS1	4.17	3.63e-05	0.00598	0.26	0.19	Lung cancer;	chr6:149889587	chr6:149863494~149919507:+
LUAD	cis	rs10971721	0.822	rs72727362	ENSG00000260947.1	RP11-384P7.7	4.17	3.63e-05	0.00598	0.39	0.19	Body mass index;	chr9:33957324	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs72727367	ENSG00000260947.1	RP11-384P7.7	4.17	3.63e-05	0.00598	0.39	0.19	Body mass index;	chr9:33965180	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs72727369	ENSG00000260947.1	RP11-384P7.7	4.17	3.63e-05	0.00598	0.39	0.19	Body mass index;	chr9:33965777	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs10971826	ENSG00000260947.1	RP11-384P7.7	4.17	3.63e-05	0.00598	0.39	0.19	Body mass index;	chr9:33972035	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs10971827	ENSG00000260947.1	RP11-384P7.7	4.17	3.63e-05	0.00598	0.39	0.19	Body mass index;	chr9:33972469	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs10971828	ENSG00000260947.1	RP11-384P7.7	4.17	3.63e-05	0.00598	0.39	0.19	Body mass index;	chr9:33973417	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs72727378	ENSG00000260947.1	RP11-384P7.7	4.17	3.63e-05	0.00598	0.39	0.19	Body mass index;	chr9:33975792	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs72727389	ENSG00000260947.1	RP11-384P7.7	4.17	3.63e-05	0.00598	0.39	0.19	Body mass index;	chr9:33987030	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs72727399	ENSG00000260947.1	RP11-384P7.7	4.17	3.63e-05	0.00598	0.39	0.19	Body mass index;	chr9:33997271	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.686	rs10971839	ENSG00000260947.1	RP11-384P7.7	4.17	3.63e-05	0.00598	0.39	0.19	Body mass index;	chr9:33998410	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs72729305	ENSG00000260947.1	RP11-384P7.7	4.17	3.63e-05	0.00598	0.39	0.19	Body mass index;	chr9:34000293	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs72729316	ENSG00000260947.1	RP11-384P7.7	4.17	3.63e-05	0.00598	0.39	0.19	Body mass index;	chr9:34008175	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs10971845	ENSG00000260947.1	RP11-384P7.7	4.17	3.63e-05	0.00598	0.39	0.19	Body mass index;	chr9:34009879	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs10971847	ENSG00000260947.1	RP11-384P7.7	4.17	3.63e-05	0.00598	0.39	0.19	Body mass index;	chr9:34011460	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs10971848	ENSG00000260947.1	RP11-384P7.7	4.17	3.63e-05	0.00598	0.39	0.19	Body mass index;	chr9:34012504	chr9:33697459~33700986:+
LUAD	cis	rs7560272	0.669	rs7598660	ENSG00000163016.8	ALMS1P	4.17	3.63e-05	0.00599	0.2	0.19	Schizophrenia;	chr2:73513298	chr2:73644919~73685576:+
LUAD	cis	rs1044826	1	rs3821544	ENSG00000214280.3	RP11-553K23.2	-4.17	3.64e-05	0.00599	-0.22	-0.19	Obesity-related traits;	chr3:139471346	chr3:139582928~139583593:-
LUAD	cis	rs77972916	0.561	rs4372955	ENSG00000234936.1	AC010883.5	4.17	3.64e-05	0.00599	0.24	0.19	Granulocyte percentage of myeloid white cells;	chr2:43339007	chr2:43229573~43233394:+
LUAD	cis	rs8028182	0.636	rs11634863	ENSG00000260269.4	CTD-2323K18.1	-4.17	3.64e-05	0.00599	-0.26	-0.19	Sudden cardiac arrest;	chr15:75474331	chr15:75527150~75601205:-
LUAD	cis	rs7204230	1	rs17303177	ENSG00000261291.1	RP11-295M3.2	4.17	3.64e-05	0.00599	0.24	0.19	Fibrinogen;	chr16:53243266	chr16:53168522~53169450:+
LUAD	cis	rs6723108	0.603	rs3814355	ENSG00000224043.6	CCNT2-AS1	-4.17	3.64e-05	0.00599	-0.23	-0.19	Type 2 diabetes;	chr2:134953946	chr2:134735464~134918710:-
LUAD	cis	rs7772486	0.743	rs111332144	ENSG00000235652.6	RP11-545I5.3	-4.17	3.64e-05	0.00599	-0.19	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145735545	chr6:145799409~145886585:+
LUAD	cis	rs763567	0.935	rs639652	ENSG00000271811.1	RP1-79C4.4	4.17	3.64e-05	0.00599	0.22	0.19	Tonsillectomy;	chr1:170643732	chr1:170667381~170669425:+
LUAD	cis	rs763121	0.853	rs5750669	ENSG00000228274.3	RP3-508I15.9	-4.17	3.64e-05	0.00599	-0.19	-0.19	Menopause (age at onset);	chr22:38684633	chr22:38667585~38681820:-
LUAD	cis	rs6723108	0.603	rs10187990	ENSG00000224043.6	CCNT2-AS1	-4.17	3.64e-05	0.006	-0.23	-0.19	Type 2 diabetes;	chr2:134939987	chr2:134735464~134918710:-
LUAD	cis	rs6674176	0.696	rs4448553	ENSG00000237950.1	RP11-7O11.3	4.17	3.64e-05	0.006	0.24	0.19	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43945917	chr1:43944370~43946551:-
LUAD	cis	rs62034325	0.697	rs710410	ENSG00000251417.2	RP11-1348G14.4	-4.17	3.64e-05	0.006	-0.19	-0.19	Body mass index;	chr16:28592021	chr16:28802743~28817828:+
LUAD	cis	rs9393777	0.844	rs28360634	ENSG00000219392.1	RP1-265C24.5	-4.17	3.64e-05	0.006	-0.37	-0.19	Intelligence (multi-trait analysis);	chr6:27365112	chr6:28115628~28116551:+
LUAD	cis	rs7302981	0.967	rs12815871	ENSG00000200428.1	Y_RNA	-4.17	3.64e-05	0.006	-0.23	-0.19	Systolic blood pressure;	chr12:50157165	chr12:50743568~50743684:+
LUAD	cis	rs62034325	0.697	rs710410	ENSG00000261419.1	RP11-57A19.4	-4.17	3.64e-05	0.006	-0.21	-0.19	Body mass index;	chr16:28592021	chr16:28659696~28740781:-
LUAD	cis	rs17772222	0.958	rs60878614	ENSG00000258789.1	RP11-507K2.3	-4.17	3.65e-05	0.006	-0.26	-0.19	Coronary artery calcification;	chr14:88513871	chr14:88551597~88552493:+
LUAD	cis	rs11722779	0.775	rs223341	ENSG00000251288.2	RP11-10L12.2	-4.17	3.65e-05	0.006	-0.22	-0.19	Schizophrenia;	chr4:102862343	chr4:102751401~102752641:+
LUAD	cis	rs7204230	1	rs1133262	ENSG00000261291.1	RP11-295M3.2	4.17	3.65e-05	0.006	0.23	0.19	Fibrinogen;	chr16:53298278	chr16:53168522~53169450:+
LUAD	cis	rs2337406	0.587	rs916547	ENSG00000223648.3	IGHV3-64	4.17	3.65e-05	0.006	0.23	0.19	Alzheimer's disease (late onset);	chr14:106646735	chr14:106643132~106658258:-
LUAD	cis	rs1008375	0.806	rs13139898	ENSG00000249502.1	AC006160.5	4.17	3.65e-05	0.00601	0.18	0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17705305	chr4:17587467~17614571:-
LUAD	cis	rs12073837	0.5	rs11118610	ENSG00000272823.1	RP11-295M18.6	-4.17	3.65e-05	0.00601	-0.21	-0.19	F-cell distribution;	chr1:220816744	chr1:220828676~220829211:-
LUAD	cis	rs4664293	0.967	rs2357526	ENSG00000230783.1	AC009961.2	4.17	3.65e-05	0.00601	0.23	0.19	Monocyte percentage of white cells;	chr2:159668085	chr2:159689217~159690291:-
LUAD	cis	rs262150	0.544	rs2428780	ENSG00000231419.5	LINC00689	-4.17	3.65e-05	0.00601	-0.23	-0.19	Facial morphology (factor 20);	chr7:159019780	chr7:159006522~159030195:+
LUAD	cis	rs910316	0.935	rs11159119	ENSG00000279594.1	RP11-950C14.10	-4.17	3.65e-05	0.00601	-0.21	-0.19	Height;	chr14:75170264	chr14:75011269~75012851:-
LUAD	cis	rs9815354	1	rs2128834	ENSG00000273328.4	RP11-141M3.6	-4.17	3.65e-05	0.00601	-0.27	-0.19	Pulse pressure;Diastolic blood pressure;	chr3:41821153	chr3:42809414~42908105:+
LUAD	cis	rs3540	0.804	rs3743418	ENSG00000214433.4	GOLGA2P8	4.17	3.65e-05	0.00601	0.27	0.19	Lymphocyte counts;Allergic disease (asthma, hay fever or eczema);	chr15:90391099	chr15:90291962~90295683:+
LUAD	cis	rs2280018	0.526	rs2966128	ENSG00000183458.12	RP11-958N24.1	-4.17	3.65e-05	0.00601	-0.15	-0.19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059532	chr16:14911551~14935708:+
LUAD	cis	rs2288073	0.965	rs10469924	ENSG00000242628.4	AC009228.1	4.17	3.65e-05	0.00601	0.25	0.19	Venous thromboembolism (SNP x SNP interaction);	chr2:24193361	chr2:24214381~24221516:+
LUAD	cis	rs10971721	0.822	rs72729357	ENSG00000260947.1	RP11-384P7.7	4.17	3.65e-05	0.00601	0.39	0.19	Body mass index;	chr9:34041170	chr9:33697459~33700986:+
LUAD	cis	rs6964587	0.933	rs13230837	ENSG00000188693.7	CYP51A1-AS1	-4.17	3.65e-05	0.00601	-0.22	-0.19	Breast cancer;	chr7:92149703	chr7:92134604~92180725:+
LUAD	cis	rs7017914	0.605	rs13267098	ENSG00000223220.1	Y_RNA	4.17	3.66e-05	0.00602	0.22	0.19	Bone mineral density;	chr8:70899651	chr8:70780914~70781008:-
LUAD	cis	rs7159888	0.727	rs11847263	ENSG00000258960.1	CTD-2014B16.2	4.17	3.66e-05	0.00602	0.2	0.19	IgG glycosylation;N-glycan levels;	chr14:65308977	chr14:65900932~65901451:-
LUAD	cis	rs4374383	0.884	rs6541971	ENSG00000207383.1	Y_RNA	-4.17	3.66e-05	0.00602	-0.22	-0.19	Hepatitis C induced liver fibrosis;	chr2:111964913	chr2:112579484~112579584:-
LUAD	cis	rs1401999	1	rs6802849	ENSG00000223882.1	ABCC5-AS1	-4.17	3.66e-05	0.00602	-0.2	-0.19	Anterior chamber depth;	chr3:183981155	chr3:184006338~184011419:+
LUAD	cis	rs1401999	0.714	rs7646621	ENSG00000223882.1	ABCC5-AS1	4.17	3.66e-05	0.00602	0.19	0.19	Anterior chamber depth;	chr3:183923077	chr3:184006338~184011419:+
LUAD	cis	rs67079557	1	rs67079557	ENSG00000260269.4	CTD-2323K18.1	-4.17	3.66e-05	0.00602	-0.26	-0.19	Breast cancer;	chr15:75637966	chr15:75527150~75601205:-
LUAD	cis	rs3742264	0.961	rs11620308	ENSG00000235903.6	CPB2-AS1	-4.17	3.66e-05	0.00602	-0.24	-0.19	Blood protein levels;	chr13:46075588	chr13:46052806~46113332:+
LUAD	cis	rs189798	0.807	rs12785	ENSG00000173295.6	FAM86B3P	4.17	3.66e-05	0.00602	0.22	0.19	Myopia (pathological);	chr8:9137426	chr8:8228595~8244865:+
LUAD	cis	rs11122895	0.716	rs11122899	ENSG00000236307.2	EEF1E1P1	4.17	3.66e-05	0.00603	0.21	0.19	Allergic sensitization;	chr2:111716993	chr2:111887914~111888741:+
LUAD	cis	rs2354432	0.607	rs3820130	ENSG00000226015.2	CCT8P1	4.17	3.66e-05	0.00603	0.33	0.19	Mitochondrial DNA levels;	chr1:147252348	chr1:147203276~147204932:-
LUAD	cis	rs12701220	0.59	rs1881124	ENSG00000229043.2	AC091729.9	-4.17	3.66e-05	0.00603	-0.27	-0.19	Bronchopulmonary dysplasia;	chr7:1057130	chr7:1160374~1165267:+
LUAD	cis	rs4843747	0.671	rs4075998	ENSG00000205037.2	RP11-863P13.4	4.17	3.66e-05	0.00603	0.26	0.19	Menopause (age at onset);	chr16:88073170	chr16:88088041~88100985:-
LUAD	cis	rs1876905	0.539	rs240985	ENSG00000272356.1	RP5-1112D6.8	4.17	3.66e-05	0.00603	0.22	0.19	Mean corpuscular hemoglobin;	chr6:111263428	chr6:111309203~111313517:+
LUAD	cis	rs2911132	0.564	rs28580505	ENSG00000272109.1	CTD-2260A17.3	-4.17	3.66e-05	0.00603	-0.21	-0.19	Urate levels (BMI interaction);	chr5:96765516	chr5:96804353~96806105:+
LUAD	cis	rs728616	0.558	rs55803802	ENSG00000225484.5	NUTM2B-AS1	-4.17	3.67e-05	0.00603	-0.31	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79992908	chr10:79663088~79826594:-
LUAD	cis	rs6142102	0.961	rs6088360	ENSG00000275784.1	RP5-1125A11.6	-4.17	3.67e-05	0.00603	-0.21	-0.19	Skin pigmentation;	chr20:33969383	chr20:33989480~33991818:-
LUAD	cis	rs4908760	0.669	rs4908506	ENSG00000270282.1	RP5-1115A15.2	4.17	3.67e-05	0.00603	0.2	0.19	Vitiligo;	chr1:8668919	chr1:8512653~8513021:+
LUAD	cis	rs6452524	0.648	rs27364	ENSG00000281327.1	LINC01338	4.17	3.67e-05	0.00603	0.2	0.19	Hypertension (SNP x SNP interaction);	chr5:83052137	chr5:82850864~82859836:-
LUAD	cis	rs763121	0.853	rs8140617	ENSG00000225450.1	RP3-508I15.14	4.17	3.67e-05	0.00603	0.19	0.19	Menopause (age at onset);	chr22:38574434	chr22:38739003~38749041:+
LUAD	cis	rs763121	0.853	rs5757187	ENSG00000228274.3	RP3-508I15.9	4.17	3.67e-05	0.00603	0.18	0.19	Menopause (age at onset);	chr22:38625517	chr22:38667585~38681820:-
LUAD	cis	rs7617773	0.78	rs13082158	ENSG00000199476.1	Y_RNA	-4.17	3.67e-05	0.00604	-0.25	-0.19	Coronary artery disease;	chr3:48330980	chr3:48288587~48288694:+
LUAD	cis	rs4908769	0.66	rs301801	ENSG00000232912.4	RP5-1115A15.1	4.17	3.67e-05	0.00604	0.17	0.19	Allergy;	chr1:8435885	chr1:8424645~8434838:+
LUAD	cis	rs2288884	0.943	rs12611112	ENSG00000269959.1	SPACA6P-AS	-4.17	3.67e-05	0.00604	-0.25	-0.19	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52071686	chr19:51685363~51693456:-
LUAD	cis	rs13113518	0.966	rs4864544	ENSG00000272969.1	RP11-528I4.2	4.17	3.67e-05	0.00604	0.19	0.19	Height;	chr4:55515292	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs6847529	ENSG00000272969.1	RP11-528I4.2	4.17	3.67e-05	0.00604	0.19	0.19	Height;	chr4:55518776	chr4:55547112~55547889:+
LUAD	cis	rs34779708	0.966	rs4934736	ENSG00000271335.4	RP11-324I22.4	4.17	3.67e-05	0.00604	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35207940	chr10:35314552~35336401:-
LUAD	cis	rs2548724	0.645	rs841922	ENSG00000250682.4	LINC00491	-4.17	3.67e-05	0.00604	-0.23	-0.19	Type 2 diabetes;	chr5:102294992	chr5:102609156~102671559:-
LUAD	cis	rs780096	0.546	rs1260320	ENSG00000234072.1	AC074117.10	4.17	3.67e-05	0.00604	0.14	0.19	Total body bone mineral density;	chr2:27499549	chr2:27356246~27367622:+
LUAD	cis	rs74233809	0.748	rs10786736	ENSG00000213277.3	MARCKSL1P1	4.17	3.67e-05	0.00604	0.3	0.19	Birth weight;	chr10:103089359	chr10:103175554~103176094:+
LUAD	cis	rs2337406	0.714	rs115401799	ENSG00000280411.1	IGHV1-69-2	-4.17	3.67e-05	0.00604	-0.19	-0.19	Alzheimer's disease (late onset);	chr14:106813739	chr14:106762092~106762588:-
LUAD	cis	rs8014252	0.803	rs10483830	ENSG00000259158.2	ADAM20P1	-4.17	3.67e-05	0.00604	-0.33	-0.19	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70587761	chr14:70468881~70483756:-
LUAD	cis	rs865483	0.895	rs72828253	ENSG00000276054.1	RP11-378E13.3	-4.17	3.67e-05	0.00604	-0.22	-0.19	Monocyte count;	chr17:37423316	chr17:37386886~37387926:+
LUAD	cis	rs865483	0.895	rs7501983	ENSG00000276054.1	RP11-378E13.3	-4.17	3.67e-05	0.00604	-0.22	-0.19	Monocyte count;	chr17:37423712	chr17:37386886~37387926:+
LUAD	cis	rs2880765	0.835	rs7168860	ENSG00000259416.2	RP11-158M2.5	4.17	3.68e-05	0.00605	0.19	0.19	Coronary artery disease;	chr15:85493799	chr15:85754941~85756237:-
LUAD	cis	rs913672	0.727	rs6125966	ENSG00000229222.1	KRT18P4	-4.17	3.68e-05	0.00605	-0.22	-0.19	Monocyte count;	chr20:50282119	chr20:49956745~49958032:+
LUAD	cis	rs910316	1	rs910316	ENSG00000279594.1	RP11-950C14.10	4.17	3.68e-05	0.00605	0.21	0.19	Height;	chr14:75159339	chr14:75011269~75012851:-
LUAD	cis	rs910316	0.874	rs61980828	ENSG00000279594.1	RP11-950C14.10	-4.17	3.68e-05	0.00605	-0.21	-0.19	Height;	chr14:75163675	chr14:75011269~75012851:-
LUAD	cis	rs10971721	0.818	rs10971708	ENSG00000260947.1	RP11-384P7.7	4.17	3.68e-05	0.00605	0.41	0.19	Body mass index;	chr9:33803273	chr9:33697459~33700986:+
LUAD	cis	rs4908769	0.66	rs159962	ENSG00000232912.4	RP5-1115A15.1	4.17	3.68e-05	0.00605	0.18	0.19	Allergy;	chr1:8430923	chr1:8424645~8434838:+
LUAD	cis	rs911555	0.755	rs10144051	ENSG00000259775.1	RP11-45P15.4	-4.17	3.68e-05	0.00605	-0.24	-0.19	Intelligence (multi-trait analysis);	chr14:103419594	chr14:103331674~103332367:-
LUAD	cis	rs4660214	0.666	rs2256614	ENSG00000228060.1	RP11-69E11.8	-4.17	3.68e-05	0.00606	-0.17	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39359046	chr1:39565160~39573203:+
LUAD	cis	rs3742264	1	rs4942471	ENSG00000235903.6	CPB2-AS1	-4.17	3.68e-05	0.00606	-0.23	-0.19	Blood protein levels;	chr13:46070358	chr13:46052806~46113332:+
LUAD	cis	rs11064837	0.525	rs739422	ENSG00000248636.5	RP11-768F21.1	4.17	3.68e-05	0.00606	0.22	0.19	Schizophrenia;	chr12:119604701	chr12:119387987~119668079:-
LUAD	cis	rs77688320	0.535	rs11691118	ENSG00000213090.2	AC007256.5	4.17	3.68e-05	0.00606	0.21	0.19	Breast cancer;	chr2:201405121	chr2:201410544~201413308:-
LUAD	cis	rs131777	0.532	rs131747	ENSG00000272940.1	CTA-384D8.33	4.17	3.68e-05	0.00606	0.22	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586645	chr22:50597152~50597599:+
LUAD	cis	rs2115630	1	rs1030863	ENSG00000225151.9	GOLGA2P7	4.17	3.68e-05	0.00606	0.21	0.19	P wave terminal force;	chr15:84739404	chr15:84199311~84230136:-
LUAD	cis	rs35740288	0.77	rs17570529	ENSG00000259407.1	RP11-158M2.3	-4.17	3.69e-05	0.00606	-0.18	-0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85582376	chr15:85744109~85750281:-
LUAD	cis	rs28386778	0.799	rs2665836	ENSG00000240280.5	TCAM1P	-4.17	3.69e-05	0.00606	-0.21	-0.19	Prudent dietary pattern;	chr17:63820775	chr17:63849292~63864379:+
LUAD	cis	rs6991838	0.593	rs953593	ENSG00000200714.1	Y_RNA	-4.17	3.69e-05	0.00606	-0.24	-0.19	Intelligence (multi-trait analysis);	chr8:65719737	chr8:65592731~65592820:+
LUAD	cis	rs2274273	0.682	rs7141975	ENSG00000258413.1	RP11-665C16.6	-4.17	3.69e-05	0.00606	-0.24	-0.19	Protein biomarker;	chr14:55075498	chr14:55262767~55272075:-
LUAD	cis	rs13434995	0.842	rs9790448	ENSG00000273257.1	RP11-177J6.1	-4.17	3.69e-05	0.00606	-0.29	-0.19	Adiponectin levels;	chr4:55592918	chr4:55387949~55388271:+
LUAD	cis	rs6479891	1	rs16918567	ENSG00000232075.1	MRPL35P2	4.17	3.69e-05	0.00606	0.32	0.19	Arthritis (juvenile idiopathic);	chr10:63534910	chr10:63634317~63634827:-
LUAD	cis	rs6479891	1	rs16918573	ENSG00000232075.1	MRPL35P2	4.17	3.69e-05	0.00606	0.32	0.19	Arthritis (juvenile idiopathic);	chr10:63541045	chr10:63634317~63634827:-
LUAD	cis	rs6479891	1	rs12414796	ENSG00000232075.1	MRPL35P2	4.17	3.69e-05	0.00606	0.32	0.19	Arthritis (juvenile idiopathic);	chr10:63543327	chr10:63634317~63634827:-
LUAD	cis	rs6479891	0.908	rs61853639	ENSG00000232075.1	MRPL35P2	4.17	3.69e-05	0.00606	0.32	0.19	Arthritis (juvenile idiopathic);	chr10:63545353	chr10:63634317~63634827:-
LUAD	cis	rs9847710	0.967	rs2564934	ENSG00000242142.1	SERBP1P3	4.17	3.69e-05	0.00606	0.2	0.19	Ulcerative colitis;	chr3:52990564	chr3:53064283~53065091:-
LUAD	cis	rs9309473	0.539	rs7574268	ENSG00000163016.8	ALMS1P	-4.17	3.69e-05	0.00606	-0.2	-0.19	Metabolite levels;	chr2:73677745	chr2:73644919~73685576:+
LUAD	cis	rs5758511	0.573	rs1569451	ENSG00000227370.1	RP4-669P10.19	-4.17	3.69e-05	0.00606	-0.18	-0.19	Birth weight;	chr22:41836287	chr22:42132543~42132998:+
LUAD	cis	rs6832769	0.961	rs13128582	ENSG00000272969.1	RP11-528I4.2	4.17	3.69e-05	0.00607	0.19	0.19	Personality dimensions;	chr4:55462777	chr4:55547112~55547889:+
LUAD	cis	rs6832769	0.925	rs6817267	ENSG00000272969.1	RP11-528I4.2	4.17	3.69e-05	0.00607	0.19	0.19	Personality dimensions;	chr4:55472374	chr4:55547112~55547889:+
LUAD	cis	rs6832769	1	rs11931061	ENSG00000272969.1	RP11-528I4.2	4.17	3.69e-05	0.00607	0.19	0.19	Personality dimensions;	chr4:55472626	chr4:55547112~55547889:+
LUAD	cis	rs6832769	1	rs7668147	ENSG00000272969.1	RP11-528I4.2	4.17	3.69e-05	0.00607	0.19	0.19	Personality dimensions;	chr4:55473217	chr4:55547112~55547889:+
LUAD	cis	rs6832769	0.961	rs11947476	ENSG00000272969.1	RP11-528I4.2	4.17	3.69e-05	0.00607	0.19	0.19	Personality dimensions;	chr4:55473584	chr4:55547112~55547889:+
LUAD	cis	rs453301	0.598	rs10104303	ENSG00000253981.4	ALG1L13P	4.17	3.69e-05	0.00607	0.22	0.19	Joint mobility (Beighton score);	chr8:8977018	chr8:8236003~8244667:-
LUAD	cis	rs6840360	0.642	rs1596290	ENSG00000270265.1	RP11-731D1.4	-4.17	3.69e-05	0.00607	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151489388	chr4:151333775~151353224:-
LUAD	cis	rs4474465	1	rs7943815	ENSG00000251323.2	RP11-452H21.4	4.17	3.69e-05	0.00607	0.23	0.19	Alzheimer's disease (survival time);	chr11:78462114	chr11:78423982~78429836:-
LUAD	cis	rs4474465	1	rs11237511	ENSG00000251323.2	RP11-452H21.4	4.17	3.69e-05	0.00607	0.23	0.19	Alzheimer's disease (survival time);	chr11:78462560	chr11:78423982~78429836:-
LUAD	cis	rs5769707	0.642	rs4824070	ENSG00000235111.1	RP1-29C18.8	-4.17	3.69e-05	0.00607	-0.23	-0.19	Monocyte percentage of white cells;Monocyte count;	chr22:49637873	chr22:49612657~49615716:-
LUAD	cis	rs71520386	0.898	rs12536091	ENSG00000228649.7	AC005682.5	-4.17	3.69e-05	0.00607	-0.29	-0.19	Fibrinogen levels;	chr7:22788581	chr7:22854178~22861579:+
LUAD	cis	rs12908161	1	rs17601029	ENSG00000259295.5	CSPG4P12	4.17	3.69e-05	0.00607	0.26	0.19	Schizophrenia;	chr15:84804478	chr15:85191438~85213905:+
LUAD	cis	rs9860428	0.844	rs2895401	ENSG00000242770.2	RP11-180K7.1	4.16	3.69e-05	0.00607	0.2	0.19	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112867783	chr3:112802478~112812819:+
LUAD	cis	rs9860428	0.844	rs57371910	ENSG00000242770.2	RP11-180K7.1	4.16	3.69e-05	0.00607	0.2	0.19	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112869960	chr3:112802478~112812819:+
LUAD	cis	rs1322639	0.614	rs9455889	ENSG00000261039.2	RP11-417E7.2	-4.16	3.69e-05	0.00607	-0.31	-0.19	Pulse pressure;	chr6:169165992	chr6:169175304~169182740:-
LUAD	cis	rs2243480	0.901	rs35823062	ENSG00000229886.1	RP5-1132H15.3	4.16	3.69e-05	0.00607	0.32	0.19	Diabetic kidney disease;	chr7:66500834	chr7:66025126~66031544:-
LUAD	cis	rs2688608	1	rs2675680	ENSG00000271816.1	BMS1P4	4.16	3.7e-05	0.00607	0.15	0.19	Inflammatory bowel disease;	chr10:73899106	chr10:73699151~73730487:-
LUAD	cis	rs17345786	0.798	rs4257518	ENSG00000244119.1	PDCL3P4	-4.16	3.7e-05	0.00607	-0.18	-0.19	Colonoscopy-negative controls vs population controls;	chr3:101562865	chr3:101712472~101713191:+
LUAD	cis	rs6714710	0.603	rs11123974	ENSG00000230606.9	AC159540.1	-4.16	3.7e-05	0.00608	-0.2	-0.19	Posterior cortical atrophy and Alzheimer's disease;	chr2:97989519	chr2:97416165~97433527:-
LUAD	cis	rs6785206	0.772	rs2811493	ENSG00000242551.2	POU5F1P6	-4.16	3.7e-05	0.00608	-0.37	-0.19	Lymphocyte percentage of white cells;	chr3:128638456	chr3:128674735~128677005:-
LUAD	cis	rs1876905	0.539	rs62420362	ENSG00000255389.1	C6orf3	4.16	3.7e-05	0.00608	0.26	0.19	Mean corpuscular hemoglobin;	chr6:111224167	chr6:111599875~111602295:+
LUAD	cis	rs10419113	0.522	rs2158013	ENSG00000269867.1	CTD-2583A14.8	4.16	3.7e-05	0.00608	0.17	0.19	Pediatric bone mineral density (spine);	chr19:57779860	chr19:57867038~57868172:-
LUAD	cis	rs8054556	0.647	rs4787488	ENSG00000214725.6	CDIPT-AS1	4.16	3.7e-05	0.00608	0.21	0.19	Autism spectrum disorder or schizophrenia;	chr16:29984482	chr16:29863593~29868053:+
LUAD	cis	rs4763879	0.634	rs2098298	ENSG00000256582.1	RP11-75L1.1	-4.16	3.7e-05	0.00608	-0.19	-0.19	Type 1 diabetes;	chr12:9707473	chr12:9704077~9709350:+
LUAD	cis	rs35740288	0.822	rs11630179	ENSG00000259407.1	RP11-158M2.3	-4.16	3.71e-05	0.00609	-0.19	-0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85739703	chr15:85744109~85750281:-
LUAD	cis	rs4474465	1	rs873311	ENSG00000251323.2	RP11-452H21.4	4.16	3.71e-05	0.00609	0.25	0.19	Alzheimer's disease (survival time);	chr11:78434840	chr11:78423982~78429836:-
LUAD	cis	rs3772130	0.603	rs35489993	ENSG00000243544.3	RN7SL172P	4.16	3.71e-05	0.00609	0.2	0.19	Cognitive performance;	chr3:121693029	chr3:121653994~121654296:-
LUAD	cis	rs4843747	0.671	rs74729706	ENSG00000205037.2	RP11-863P13.4	4.16	3.71e-05	0.00609	0.27	0.19	Menopause (age at onset);	chr16:88070553	chr16:88088041~88100985:-
LUAD	cis	rs11841001	0.556	rs1470273	ENSG00000261105.4	LMO7-AS1	-4.16	3.71e-05	0.00609	-0.3	-0.19	Corneal astigmatism;	chr13:75768241	chr13:75604700~75635994:-
LUAD	cis	rs7202877	0.611	rs7187263	ENSG00000280152.1	RP11-331F4.5	4.16	3.71e-05	0.00609	0.21	0.19	Type 1 diabetes;Type 2 diabetes;	chr16:75275080	chr16:75245994~75250077:-
LUAD	cis	rs848490	0.962	rs11764879	ENSG00000214293.7	APTR	4.16	3.71e-05	0.00609	0.25	0.19	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77703950	chr7:77657660~77696265:-
LUAD	cis	rs6479891	1	rs72837025	ENSG00000232075.1	MRPL35P2	4.16	3.71e-05	0.00609	0.3	0.19	Arthritis (juvenile idiopathic);	chr10:63434731	chr10:63634317~63634827:-
LUAD	cis	rs1154275	0.666	rs1154276	ENSG00000242770.2	RP11-180K7.1	-4.16	3.71e-05	0.00609	-0.19	-0.19	Takotsubo syndrome;	chr3:112766633	chr3:112802478~112812819:+
LUAD	cis	rs7086627	0.515	rs10887900	ENSG00000226659.1	RP11-137H2.4	-4.16	3.71e-05	0.00609	-0.25	-0.19	Post bronchodilator FEV1;	chr10:80450509	chr10:80529597~80535942:-
LUAD	cis	rs2439831	0.702	rs16977724	ENSG00000249839.1	AC011330.5	-4.16	3.71e-05	0.00609	-0.42	-0.19	Lung cancer in ever smokers;	chr15:43859101	chr15:43663654~43684339:-
LUAD	cis	rs2735413	0.632	rs11864652	ENSG00000276007.1	RP11-358L22.3	4.16	3.71e-05	0.00609	0.22	0.19	Systolic blood pressure (alcohol consumption interaction);	chr16:78060111	chr16:78123243~78124332:+
LUAD	cis	rs7727544	0.508	rs10900804	ENSG00000233006.5	AC034220.3	4.16	3.71e-05	0.0061	0.17	0.19	Blood metabolite levels;	chr5:132066152	chr5:132311285~132369916:-
LUAD	cis	rs8062405	0.824	rs7191618	ENSG00000251417.2	RP11-1348G14.4	-4.16	3.71e-05	0.0061	-0.19	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28802743~28817828:+
LUAD	cis	rs600231	0.508	rs17146964	ENSG00000245532.5	NEAT1	-4.16	3.71e-05	0.0061	-0.17	-0.19	Bone mineral density;	chr11:65481674	chr11:65422774~65445540:+
LUAD	cis	rs7976269	0.609	rs4931142	ENSG00000257176.2	RP11-996F15.2	-4.16	3.71e-05	0.0061	-0.2	-0.19	Male-pattern baldness;	chr12:29057877	chr12:29280418~29317848:-
LUAD	cis	rs7976269	0.609	rs2117993	ENSG00000257176.2	RP11-996F15.2	-4.16	3.71e-05	0.0061	-0.2	-0.19	Male-pattern baldness;	chr12:29060041	chr12:29280418~29317848:-
LUAD	cis	rs2154319	1	rs57707706	ENSG00000235358.1	RP11-399E6.1	-4.16	3.71e-05	0.0061	-0.26	-0.19	Height;	chr1:41276483	chr1:41242373~41284861:+
LUAD	cis	rs1008375	0.932	rs10009933	ENSG00000249502.1	AC006160.5	-4.16	3.71e-05	0.0061	-0.18	-0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17668484	chr4:17587467~17614571:-
LUAD	cis	rs699371	0.55	rs11851117	ENSG00000259005.1	RP3-449M8.6	4.16	3.72e-05	0.0061	0.2	0.19	Height;	chr14:74454856	chr14:74474007~74474864:-
LUAD	cis	rs2880765	0.835	rs900573	ENSG00000259416.2	RP11-158M2.5	-4.16	3.72e-05	0.0061	-0.19	-0.19	Coronary artery disease;	chr15:85494762	chr15:85754941~85756237:-
LUAD	cis	rs6969780	1	rs6976129	ENSG00000233429.8	HOTAIRM1	4.16	3.72e-05	0.0061	0.34	0.19	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27138127	chr7:27095647~27100265:+
LUAD	cis	rs889398	0.802	rs12921407	ENSG00000226232.7	RP11-419C5.2	4.16	3.72e-05	0.0061	0.16	0.19	Body mass index;	chr16:69827030	chr16:69976388~69996188:-
LUAD	cis	rs7107174	0.681	rs11237443	ENSG00000251323.2	RP11-452H21.4	4.16	3.72e-05	0.0061	0.24	0.19	Testicular germ cell tumor;	chr11:78294043	chr11:78423982~78429836:-
LUAD	cis	rs2933343	0.672	rs1872545	ENSG00000231305.3	RP11-723O4.2	4.16	3.72e-05	0.0061	0.2	0.19	IgG glycosylation;	chr3:128926196	chr3:128861313~128871540:-
LUAD	cis	rs3120667	0.79	rs726864	ENSG00000237975.5	FLG-AS1	4.16	3.72e-05	0.00611	0.3	0.19	Eating disorders;	chr1:152427817	chr1:152168125~152445456:+
LUAD	cis	rs6723226	0.638	rs6543657	ENSG00000276334.1	AL133243.1	4.16	3.72e-05	0.00611	0.21	0.19	Intelligence (multi-trait analysis);	chr2:32480017	chr2:32521927~32523547:+
LUAD	cis	rs7208859	0.725	rs9910051	ENSG00000280069.1	CTD-2349P21.3	-4.16	3.72e-05	0.00611	-0.22	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834184	chr17:30738182~30740275:+
LUAD	cis	rs2243480	0.803	rs160649	ENSG00000226002.1	RP11-460N20.5	-4.16	3.72e-05	0.00611	-0.31	-0.19	Diabetic kidney disease;	chr7:66078212	chr7:65084103~65100232:+
LUAD	cis	rs2243480	1	rs160648	ENSG00000226002.1	RP11-460N20.5	-4.16	3.72e-05	0.00611	-0.31	-0.19	Diabetic kidney disease;	chr7:66078397	chr7:65084103~65100232:+
LUAD	cis	rs7560272	0.723	rs6722867	ENSG00000163016.8	ALMS1P	4.16	3.72e-05	0.00611	0.2	0.19	Schizophrenia;	chr2:73589158	chr2:73644919~73685576:+
LUAD	cis	rs2153535	0.518	rs9393054	ENSG00000230939.1	RP11-314C16.1	-4.16	3.72e-05	0.00611	-0.22	-0.19	Motion sickness;	chr6:8647209	chr6:8784178~8785445:+
LUAD	cis	rs4568518	0.71	rs6955337	ENSG00000279048.1	RP11-511H23.2	-4.16	3.72e-05	0.00611	-0.16	-0.19	Measles;	chr7:17974951	chr7:17940503~17942922:+
LUAD	cis	rs67981189	0.529	rs61990387	ENSG00000269927.1	RP6-91H8.3	4.16	3.72e-05	0.00611	0.25	0.19	Schizophrenia;	chr14:71024850	chr14:71141125~71143253:-
LUAD	cis	rs4840086	0.905	rs4840082	ENSG00000219755.1	RP1-199J3.5	4.16	3.72e-05	0.00611	0.23	0.19	Menarche (age at onset);	chr6:99752021	chr6:99575712~99576456:+
LUAD	cis	rs6964587	1	rs12537846	ENSG00000188693.7	CYP51A1-AS1	4.16	3.72e-05	0.00611	0.22	0.19	Breast cancer;	chr7:92092267	chr7:92134604~92180725:+
LUAD	cis	rs11673344	0.542	rs2562585	ENSG00000276846.1	CTD-3220F14.3	4.16	3.72e-05	0.00611	0.21	0.19	Obesity-related traits;	chr19:37018321	chr19:37314868~37315620:-
LUAD	cis	rs7590268	0.697	rs6738365	ENSG00000279873.2	LINC01126	4.16	3.72e-05	0.00611	0.18	0.19	Orofacial clefts;	chr2:43458598	chr2:43227210~43228855:+
LUAD	cis	rs683250	0.598	rs1943748	ENSG00000246067.6	RAB30-AS1	4.16	3.72e-05	0.00611	0.2	0.19	Subcortical brain region volumes;	chr11:83410879	chr11:83072066~83106719:+
LUAD	cis	rs4908760	0.827	rs11121210	ENSG00000270282.1	RP5-1115A15.2	4.16	3.72e-05	0.00611	0.2	0.19	Vitiligo;	chr1:8648470	chr1:8512653~8513021:+
LUAD	cis	rs6452524	0.561	rs4331874	ENSG00000281327.1	LINC01338	4.16	3.73e-05	0.00612	0.2	0.19	Hypertension (SNP x SNP interaction);	chr5:83068253	chr5:82850864~82859836:-
LUAD	cis	rs17772222	1	rs7145588	ENSG00000258789.1	RP11-507K2.3	-4.16	3.73e-05	0.00612	-0.25	-0.19	Coronary artery calcification;	chr14:88360452	chr14:88551597~88552493:+
LUAD	cis	rs17772222	1	rs61977049	ENSG00000258789.1	RP11-507K2.3	-4.16	3.73e-05	0.00612	-0.25	-0.19	Coronary artery calcification;	chr14:88360656	chr14:88551597~88552493:+
LUAD	cis	rs17772222	1	rs12587386	ENSG00000258789.1	RP11-507K2.3	-4.16	3.73e-05	0.00612	-0.25	-0.19	Coronary artery calcification;	chr14:88361420	chr14:88551597~88552493:+
LUAD	cis	rs6142102	0.886	rs4911147	ENSG00000275784.1	RP5-1125A11.6	-4.16	3.73e-05	0.00612	-0.21	-0.19	Skin pigmentation;	chr20:34079801	chr20:33989480~33991818:-
LUAD	cis	rs4819052	0.851	rs2236446	ENSG00000223768.1	LINC00205	-4.16	3.73e-05	0.00612	-0.22	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259070	chr21:45293285~45297354:+
LUAD	cis	rs4819052	0.851	rs7279182	ENSG00000237664.1	LINC00316	-4.16	3.73e-05	0.00612	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236197	chr21:45338590~45341990:-
LUAD	cis	rs8141529	0.764	rs8137969	ENSG00000272858.1	CTA-292E10.8	-4.16	3.73e-05	0.00612	-0.21	-0.19	Lymphocyte counts;	chr22:28832496	chr22:28814914~28815662:+
LUAD	cis	rs9532669	0.926	rs9525418	ENSG00000239827.7	SUGT1P3	4.16	3.73e-05	0.00612	0.22	0.19	Cervical cancer;	chr13:40879081	chr13:40908159~40921774:-
LUAD	cis	rs9341808	0.727	rs1324120	ENSG00000260645.1	RP11-250B2.5	4.16	3.73e-05	0.00612	0.17	0.19	Sitting height ratio;	chr6:80266408	chr6:80466958~80469080:+
LUAD	cis	rs2836974	0.932	rs2836953	ENSG00000232608.1	TIMM9P2	-4.16	3.73e-05	0.00612	-0.22	-0.19	Cognitive function;	chr21:39245557	chr21:39216624~39217506:+
LUAD	cis	rs4554975	0.714	rs2465213	ENSG00000274723.1	RP11-618L22.1	4.16	3.73e-05	0.00613	0.22	0.19	Metabolite levels (small molecules and protein measures);	chr12:46857179	chr12:46970504~46972155:+
LUAD	cis	rs4683346	0.523	rs12491179	ENSG00000173811.9	CCDC13-AS1	-4.16	3.73e-05	0.00613	-0.22	-0.19	Granulocyte percentage of myeloid white cells;	chr3:42732470	chr3:42732575~42746768:+
LUAD	cis	rs6496932	0.503	rs8037726	ENSG00000202081.1	RNU6-1280P	-4.16	3.73e-05	0.00613	-0.25	-0.19	Central corneal thickness;Corneal structure;	chr15:85408154	chr15:85651522~85651628:-
LUAD	cis	rs6964587	1	rs733957	ENSG00000188693.7	CYP51A1-AS1	-4.16	3.73e-05	0.00613	-0.22	-0.19	Breast cancer;	chr7:92077883	chr7:92134604~92180725:+
LUAD	cis	rs17301013	0.932	rs11804941	ENSG00000227373.4	RP11-160H22.5	-4.16	3.74e-05	0.00613	-0.23	-0.19	Systemic lupus erythematosus;	chr1:174624074	chr1:174115300~174160004:-
LUAD	cis	rs5015933	0.778	rs12238669	ENSG00000232630.1	PRPS1P2	-4.16	3.74e-05	0.00613	-0.18	-0.19	Body mass index;	chr9:125249124	chr9:125150653~125151589:+
LUAD	cis	rs6981523	0.5	rs4412337	ENSG00000255046.1	RP11-297N6.4	-4.16	3.74e-05	0.00613	-0.23	-0.19	Neuroticism;	chr8:11214511	chr8:11797928~11802568:-
LUAD	cis	rs8031584	0.918	rs11639169	ENSG00000259845.1	HERC2P10	4.16	3.74e-05	0.00613	0.22	0.19	Huntington's disease progression;	chr15:30963235	chr15:30815271~30844153:+
LUAD	cis	rs8040855	0.627	rs11632658	ENSG00000259774.1	RP11-182J1.13	-4.16	3.74e-05	0.00613	-0.24	-0.19	Bulimia nervosa;	chr15:85062982	chr15:84422618~84425882:+
LUAD	cis	rs6435862	0.593	rs34732883	ENSG00000229267.2	AC072062.1	4.16	3.74e-05	0.00614	0.22	0.19	Neuroblastoma (high-risk);	chr2:214809647	chr2:214810229~214963274:+
LUAD	cis	rs7208859	0.673	rs11650305	ENSG00000280069.1	CTD-2349P21.3	-4.16	3.74e-05	0.00614	-0.25	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902343	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs11654914	ENSG00000280069.1	CTD-2349P21.3	-4.16	3.74e-05	0.00614	-0.25	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902406	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs9914271	ENSG00000280069.1	CTD-2349P21.3	-4.16	3.74e-05	0.00614	-0.25	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905607	chr17:30738182~30740275:+
LUAD	cis	rs10419113	0.641	rs61333077	ENSG00000270804.1	CTD-2583A14.11	4.16	3.74e-05	0.00614	0.17	0.19	Pediatric bone mineral density (spine);	chr19:57766589	chr19:57867885~57868834:+
LUAD	cis	rs2911132	0.621	rs28432918	ENSG00000272109.1	CTD-2260A17.3	-4.16	3.74e-05	0.00614	-0.21	-0.19	Urate levels (BMI interaction);	chr5:96765522	chr5:96804353~96806105:+
LUAD	cis	rs240993	0.548	rs1040382	ENSG00000230177.1	RP5-1112D6.4	4.16	3.74e-05	0.00614	0.18	0.19	Inflammatory skin disease;Psoriasis;	chr6:111580876	chr6:111277932~111278742:+
LUAD	cis	rs34779708	0.897	rs9665538	ENSG00000271335.4	RP11-324I22.4	4.16	3.74e-05	0.00614	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35172110	chr10:35314552~35336401:-
LUAD	cis	rs6495122	0.501	rs7167261	ENSG00000260269.4	CTD-2323K18.1	4.16	3.74e-05	0.00614	0.23	0.19	Diastolic blood pressure;Coffee consumption;Caffeine consumption;	chr15:75051466	chr15:75527150~75601205:-
LUAD	cis	rs5758511	0.514	rs5758622	ENSG00000227370.1	RP4-669P10.19	4.16	3.74e-05	0.00614	0.21	0.19	Birth weight;	chr22:42167927	chr22:42132543~42132998:+
LUAD	cis	rs1065852	0.906	rs5751232	ENSG00000227370.1	RP4-669P10.19	4.16	3.74e-05	0.00614	0.21	0.19	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42168298	chr22:42132543~42132998:+
LUAD	cis	rs5758511	0.514	rs9607882	ENSG00000227370.1	RP4-669P10.19	4.16	3.74e-05	0.00614	0.21	0.19	Birth weight;	chr22:42171445	chr22:42132543~42132998:+
LUAD	cis	rs453301	0.686	rs13252797	ENSG00000253893.2	FAM85B	-4.16	3.75e-05	0.00614	-0.25	-0.19	Joint mobility (Beighton score);	chr8:9003920	chr8:8167819~8226614:-
LUAD	cis	rs6832769	0.961	rs1011095	ENSG00000272969.1	RP11-528I4.2	4.16	3.75e-05	0.00614	0.19	0.19	Personality dimensions;	chr4:55398774	chr4:55547112~55547889:+
LUAD	cis	rs7131987	0.565	rs10843365	ENSG00000257176.2	RP11-996F15.2	4.16	3.75e-05	0.00615	0.19	0.19	QT interval;	chr12:29252691	chr12:29280418~29317848:-
LUAD	cis	rs7615952	0.932	rs11922218	ENSG00000241288.6	RP11-379B18.5	-4.16	3.75e-05	0.00615	-0.24	-0.19	Blood pressure (smoking interaction);	chr3:125912446	chr3:125827238~125916384:-
LUAD	cis	rs7615952	0.866	rs11922276	ENSG00000241288.6	RP11-379B18.5	-4.16	3.75e-05	0.00615	-0.24	-0.19	Blood pressure (smoking interaction);	chr3:125912483	chr3:125827238~125916384:-
LUAD	cis	rs4840086	0.967	rs4840083	ENSG00000219755.1	RP1-199J3.5	4.16	3.75e-05	0.00615	0.23	0.19	Menarche (age at onset);	chr6:99752323	chr6:99575712~99576456:+
LUAD	cis	rs6142102	0.607	rs6088408	ENSG00000275784.1	RP5-1125A11.6	4.16	3.75e-05	0.00615	0.23	0.19	Skin pigmentation;	chr20:34146800	chr20:33989480~33991818:-
LUAD	cis	rs17406451	0.819	rs12477432	ENSG00000279873.2	LINC01126	-4.16	3.75e-05	0.00615	-0.16	-0.19	Mitochondrial DNA levels;	chr2:43419029	chr2:43227210~43228855:+
LUAD	cis	rs2115630	0.905	rs6496401	ENSG00000225151.9	GOLGA2P7	4.16	3.75e-05	0.00615	0.21	0.19	P wave terminal force;	chr15:84754562	chr15:84199311~84230136:-
LUAD	cis	rs17826219	0.636	rs12946563	ENSG00000280069.1	CTD-2349P21.3	-4.16	3.75e-05	0.00615	-0.25	-0.19	Body mass index;	chr17:30776148	chr17:30738182~30740275:+
LUAD	cis	rs6479891	0.908	rs2616631	ENSG00000232075.1	MRPL35P2	4.16	3.75e-05	0.00615	0.3	0.19	Arthritis (juvenile idiopathic);	chr10:63448154	chr10:63634317~63634827:-
LUAD	cis	rs6479891	0.73	rs16918600	ENSG00000232075.1	MRPL35P2	4.16	3.75e-05	0.00615	0.32	0.19	Arthritis (juvenile idiopathic);	chr10:63560690	chr10:63634317~63634827:-
LUAD	cis	rs6479891	0.915	rs11812934	ENSG00000232075.1	MRPL35P2	4.16	3.75e-05	0.00615	0.32	0.19	Arthritis (juvenile idiopathic);	chr10:63560970	chr10:63634317~63634827:-
LUAD	cis	rs6479891	0.915	rs16918601	ENSG00000232075.1	MRPL35P2	4.16	3.75e-05	0.00615	0.32	0.19	Arthritis (juvenile idiopathic);	chr10:63561291	chr10:63634317~63634827:-
LUAD	cis	rs3096299	0.781	rs2965819	ENSG00000182376.2	RP5-1142A6.8	-4.16	3.75e-05	0.00615	-0.19	-0.19	Multiple myeloma (IgH translocation);	chr16:89434622	chr16:88742767~88745748:+
LUAD	cis	rs2348418	0.832	rs12303069	ENSG00000247934.4	RP11-967K21.1	4.16	3.75e-05	0.00615	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28294319	chr12:28163298~28190738:-
LUAD	cis	rs6495122	0.501	rs7163636	ENSG00000260269.4	CTD-2323K18.1	-4.16	3.75e-05	0.00615	-0.23	-0.19	Diastolic blood pressure;Coffee consumption;Caffeine consumption;	chr15:75054419	chr15:75527150~75601205:-
LUAD	cis	rs2243480	1	rs4718334	ENSG00000229886.1	RP5-1132H15.3	-4.16	3.75e-05	0.00615	-0.32	-0.19	Diabetic kidney disease;	chr7:66324467	chr7:66025126~66031544:-
LUAD	cis	rs8181477	0.764	rs11014484	ENSG00000225527.1	RP11-383B4.4	4.16	3.75e-05	0.00615	0.21	0.19	Obesity-related traits;	chr10:18490395	chr10:18531849~18533336:-
LUAD	cis	rs7688540	0.8	rs9328737	ENSG00000211553.1	AC253576.2	-4.16	3.75e-05	0.00615	-0.24	-0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:252176	chr4:136461~136568:+
LUAD	cis	rs7829975	0.742	rs1533058	ENSG00000233609.3	RP11-62H7.2	4.16	3.75e-05	0.00615	0.15	0.19	Mood instability;	chr8:8827680	chr8:8961200~8979025:+
LUAD	cis	rs4664293	0.899	rs7588710	ENSG00000230783.1	AC009961.2	-4.16	3.75e-05	0.00615	-0.24	-0.19	Monocyte percentage of white cells;	chr2:159673011	chr2:159689217~159690291:-
LUAD	cis	rs875971	0.558	rs4433015	ENSG00000273142.1	RP11-458F8.4	4.16	3.75e-05	0.00616	0.13	0.19	Aortic root size;	chr7:66174736	chr7:66902857~66906297:+
LUAD	cis	rs858239	0.601	rs1558313	ENSG00000226816.2	AC005082.12	4.16	3.75e-05	0.00616	0.24	0.19	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23206013~23208045:+
LUAD	cis	rs858239	0.601	rs6962526	ENSG00000226816.2	AC005082.12	4.16	3.75e-05	0.00616	0.24	0.19	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23206013~23208045:+
LUAD	cis	rs858239	0.539	rs6971673	ENSG00000226816.2	AC005082.12	4.16	3.75e-05	0.00616	0.24	0.19	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23206013~23208045:+
LUAD	cis	rs4441609	0.816	rs4678914	ENSG00000234073.1	AC011816.1	-4.16	3.76e-05	0.00616	-0.21	-0.19	Interleukin-1-receptor antagonist levels;	chr3:36906926	chr3:36880184~36880729:-
LUAD	cis	rs8133949	0.953	rs7278166	ENSG00000237232.6	ZNF295-AS1	4.16	3.76e-05	0.00616	0.24	0.19	Hand grip strength;	chr21:42007431	chr21:42009194~42024924:+
LUAD	cis	rs858239	0.511	rs10256996	ENSG00000230042.1	AK3P3	4.16	3.76e-05	0.00616	0.23	0.19	Cerebrospinal fluid biomarker levels;	chr7:23105676	chr7:23129178~23129841:+
LUAD	cis	rs6964587	1	rs2097739	ENSG00000188693.7	CYP51A1-AS1	-4.16	3.76e-05	0.00616	-0.22	-0.19	Breast cancer;	chr7:92082152	chr7:92134604~92180725:+
LUAD	cis	rs12579720	0.587	rs11044996	ENSG00000255910.1	RP11-405A12.2	4.16	3.76e-05	0.00616	0.25	0.19	Diastolic blood pressure;	chr12:20027650	chr12:19775451~20009937:+
LUAD	cis	rs12579720	0.541	rs7139226	ENSG00000255910.1	RP11-405A12.2	4.16	3.76e-05	0.00616	0.25	0.19	Diastolic blood pressure;	chr12:20027815	chr12:19775451~20009937:+
LUAD	cis	rs12579720	0.587	rs7139244	ENSG00000255910.1	RP11-405A12.2	4.16	3.76e-05	0.00616	0.25	0.19	Diastolic blood pressure;	chr12:20027864	chr12:19775451~20009937:+
LUAD	cis	rs8073060	0.505	rs225276	ENSG00000267592.1	CTC-507E2.2	4.16	3.76e-05	0.00616	0.27	0.19	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35646015	chr17:35596904~35597128:-
LUAD	cis	rs8073060	0.614	rs225279	ENSG00000267592.1	CTC-507E2.2	4.16	3.76e-05	0.00616	0.27	0.19	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35647195	chr17:35596904~35597128:-
LUAD	cis	rs8073060	0.586	rs225280	ENSG00000267592.1	CTC-507E2.2	4.16	3.76e-05	0.00616	0.27	0.19	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35649277	chr17:35596904~35597128:-
LUAD	cis	rs9341808	0.718	rs9352803	ENSG00000260645.1	RP11-250B2.5	4.16	3.76e-05	0.00616	0.18	0.19	Sitting height ratio;	chr6:80154950	chr6:80466958~80469080:+
LUAD	cis	rs9341808	0.655	rs9350846	ENSG00000260645.1	RP11-250B2.5	4.16	3.76e-05	0.00616	0.18	0.19	Sitting height ratio;	chr6:80155764	chr6:80466958~80469080:+
LUAD	cis	rs2235642	0.826	rs8053605	ENSG00000280231.1	LA16c-380F5.3	-4.16	3.76e-05	0.00616	-0.25	-0.19	Coronary artery disease;	chr16:1544157	chr16:1553655~1554130:-
LUAD	cis	rs4819052	0.679	rs8132135	ENSG00000215447.6	BX322557.10	-4.16	3.76e-05	0.00616	-0.22	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45274867	chr21:45288052~45291738:+
LUAD	cis	rs301901	1	rs6899155	ENSG00000250155.1	CTD-2353F22.1	-4.16	3.76e-05	0.00616	-0.19	-0.19	Height;	chr5:36786357	chr5:36666214~36725195:-
LUAD	cis	rs6840360	0.582	rs11732918	ENSG00000270265.1	RP11-731D1.4	-4.16	3.76e-05	0.00617	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151397893	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.557	rs4696261	ENSG00000270265.1	RP11-731D1.4	-4.16	3.76e-05	0.00617	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151401507	chr4:151333775~151353224:-
LUAD	cis	rs853679	0.607	rs35030260	ENSG00000219392.1	RP1-265C24.5	-4.16	3.76e-05	0.00617	-0.42	-0.19	Depression;	chr6:28337731	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.607	rs13217619	ENSG00000219392.1	RP1-265C24.5	-4.16	3.76e-05	0.00617	-0.42	-0.19	Depression;	chr6:28338894	chr6:28115628~28116551:+
LUAD	cis	rs8062405	0.723	rs762633	ENSG00000251417.2	RP11-1348G14.4	-4.16	3.76e-05	0.00617	-0.19	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597020	chr16:28802743~28817828:+
LUAD	cis	rs10971721	0.822	rs10971850	ENSG00000260947.1	RP11-384P7.7	4.16	3.76e-05	0.00617	0.39	0.19	Body mass index;	chr9:34013910	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.731	rs10814061	ENSG00000260947.1	RP11-384P7.7	4.16	3.76e-05	0.00617	0.39	0.19	Body mass index;	chr9:34014032	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs12380173	ENSG00000260947.1	RP11-384P7.7	4.16	3.76e-05	0.00617	0.39	0.19	Body mass index;	chr9:34018500	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs12377970	ENSG00000260947.1	RP11-384P7.7	4.16	3.76e-05	0.00617	0.39	0.19	Body mass index;	chr9:34021269	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.908	rs72729329	ENSG00000260947.1	RP11-384P7.7	4.16	3.76e-05	0.00617	0.39	0.19	Body mass index;	chr9:34022884	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.908	rs10971858	ENSG00000260947.1	RP11-384P7.7	4.16	3.76e-05	0.00617	0.39	0.19	Body mass index;	chr9:34023693	chr9:33697459~33700986:+
LUAD	cis	rs9341808	0.667	rs1408292	ENSG00000260645.1	RP11-250B2.5	4.16	3.77e-05	0.00617	0.18	0.19	Sitting height ratio;	chr6:80174189	chr6:80466958~80469080:+
LUAD	cis	rs875971	0.52	rs160645	ENSG00000222364.1	RNU6-96P	4.16	3.77e-05	0.00617	0.25	0.19	Aortic root size;	chr7:66091320	chr7:66395191~66395286:+
LUAD	cis	rs36423	0.557	rs36457	ENSG00000266869.1	RP6-114E22.1	-4.16	3.77e-05	0.00617	-0.25	-0.19	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71864157	chr14:71848606~71908430:+
LUAD	cis	rs10463554	0.892	rs1837256	ENSG00000250682.4	LINC00491	4.16	3.77e-05	0.00617	0.23	0.19	Parkinson's disease;	chr5:102968852	chr5:102609156~102671559:-
LUAD	cis	rs7598759	0.527	rs12987949	ENSG00000223198.1	RNU2-22P	-4.16	3.77e-05	0.00617	-0.21	-0.19	Noise-induced hearing loss;	chr2:231502800	chr2:231501990~231502201:-
LUAD	cis	rs4667682	0.583	rs1035249	ENSG00000234061.1	AC007969.4	-4.16	3.77e-05	0.00617	-0.4	-0.19	Hippocampal atrophy;Body mass index;	chr2:171282655	chr2:171492905~171493095:+
LUAD	cis	rs6964587	0.708	rs38800	ENSG00000188693.7	CYP51A1-AS1	4.16	3.77e-05	0.00617	0.23	0.19	Breast cancer;	chr7:92416877	chr7:92134604~92180725:+
LUAD	cis	rs780096	0.546	rs1060525	ENSG00000234072.1	AC074117.10	-4.16	3.77e-05	0.00617	-0.14	-0.19	Total body bone mineral density;	chr2:27412715	chr2:27356246~27367622:+
LUAD	cis	rs9393777	0.92	rs34953377	ENSG00000219392.1	RP1-265C24.5	-4.16	3.77e-05	0.00618	-0.36	-0.19	Intelligence (multi-trait analysis);	chr6:27413881	chr6:28115628~28116551:+
LUAD	cis	rs1502337	0.532	rs6606684	ENSG00000278993.1	RP3-424M6.4	-4.16	3.77e-05	0.00618	-0.23	-0.19	Body mass index;	chr12:110362361	chr12:110501614~110503441:+
LUAD	cis	rs7129556	0.69	rs695046	ENSG00000241782.1	RP11-91P24.1	4.16	3.77e-05	0.00618	0.26	0.19	Weight loss (gastric bypass surgery);	chr11:77883308	chr11:77868722~77869195:-
LUAD	cis	rs4819052	1	rs2297286	ENSG00000237664.1	LINC00316	-4.16	3.77e-05	0.00618	-0.24	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45287982	chr21:45338590~45341990:-
LUAD	cis	rs2836974	0.966	rs7283420	ENSG00000232608.1	TIMM9P2	-4.16	3.77e-05	0.00618	-0.22	-0.19	Cognitive function;	chr21:39294939	chr21:39216624~39217506:+
LUAD	cis	rs2018683	0.677	rs12531456	ENSG00000228421.2	AC005013.5	4.16	3.77e-05	0.00618	0.21	0.19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28930994	chr7:28957667~28959345:+
LUAD	cis	rs2018683	0.707	rs2391717	ENSG00000228421.2	AC005013.5	4.16	3.77e-05	0.00618	0.21	0.19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28931545	chr7:28957667~28959345:+
LUAD	cis	rs2018683	0.707	rs917215	ENSG00000228421.2	AC005013.5	4.16	3.77e-05	0.00618	0.21	0.19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28931750	chr7:28957667~28959345:+
LUAD	cis	rs6688613	0.685	rs10800276	ENSG00000225171.2	DUTP6	4.16	3.77e-05	0.00618	0.22	0.19	Refractive astigmatism;	chr1:166889704	chr1:166868748~166869209:+
LUAD	cis	rs9309473	0.519	rs1083922	ENSG00000163016.8	ALMS1P	-4.16	3.77e-05	0.00618	-0.2	-0.19	Metabolite levels;	chr2:73476876	chr2:73644919~73685576:+
LUAD	cis	rs7204230	0.924	rs8058093	ENSG00000261291.1	RP11-295M3.2	4.16	3.78e-05	0.00618	0.23	0.19	Fibrinogen;	chr16:53309961	chr16:53168522~53169450:+
LUAD	cis	rs17826219	0.706	rs8075357	ENSG00000266490.1	CTD-2349P21.9	4.16	3.78e-05	0.00619	0.27	0.19	Body mass index;	chr17:30730179	chr17:30792372~30792833:+
LUAD	cis	rs17826219	0.706	rs61643715	ENSG00000266490.1	CTD-2349P21.9	4.16	3.78e-05	0.00619	0.27	0.19	Body mass index;	chr17:30730744	chr17:30792372~30792833:+
LUAD	cis	rs17826219	0.636	rs8080829	ENSG00000266490.1	CTD-2349P21.9	4.16	3.78e-05	0.00619	0.27	0.19	Body mass index;	chr17:30731712	chr17:30792372~30792833:+
LUAD	cis	rs9649213	0.593	rs6955647	ENSG00000272950.1	RP11-307C18.1	4.16	3.78e-05	0.00619	0.23	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98375250	chr7:98322853~98323430:+
LUAD	cis	rs7214842	0.772	rs7219473	ENSG00000225751.2	AC087501.1	-4.16	3.78e-05	0.00619	-0.22	-0.19	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;	chr17:9446859	chr17:9452197~9470014:+
LUAD	cis	rs780096	0.587	rs10205219	ENSG00000234072.1	AC074117.10	-4.16	3.78e-05	0.00619	-0.14	-0.19	Total body bone mineral density;	chr2:27345698	chr2:27356246~27367622:+
LUAD	cis	rs6931421	1	rs6931421	ENSG00000272129.1	RP11-250B2.6	4.16	3.78e-05	0.00619	0.24	0.19	Sitting height ratio;	chr6:80170421	chr6:80355424~80356859:+
LUAD	cis	rs2278034	0.578	rs881753	ENSG00000231464.1	AC024937.4	-4.16	3.78e-05	0.00619	-0.2	-0.19	Bronchopulmonary dysplasia;	chr3:195879899	chr3:195996738~195998233:+
LUAD	cis	rs2836974	1	rs28360661	ENSG00000232608.1	TIMM9P2	-4.16	3.78e-05	0.00619	-0.23	-0.19	Cognitive function;	chr21:39310046	chr21:39216624~39217506:+
LUAD	cis	rs8062405	0.755	rs4787457	ENSG00000261419.1	RP11-57A19.4	-4.16	3.78e-05	0.00619	-0.2	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28659696~28740781:-
LUAD	cis	rs9549260	0.755	rs9566553	ENSG00000229456.1	RLIMP1	4.16	3.78e-05	0.00619	0.2	0.19	Red blood cell count;	chr13:40600094	chr13:40618738~40621348:+
LUAD	cis	rs116139393	0.517	rs77141752	ENSG00000187953.9	PMS2CL	-4.16	3.78e-05	0.00619	-0.29	-0.19	Alzheimer's disease (APOE e4 interaction);	chr7:6685844	chr7:6710128~6753862:+
LUAD	cis	rs13113518	0.966	rs11942472	ENSG00000272969.1	RP11-528I4.2	4.16	3.78e-05	0.0062	0.19	0.19	Height;	chr4:55574959	chr4:55547112~55547889:+
LUAD	cis	rs189798	0.807	rs330909	ENSG00000173295.6	FAM86B3P	4.16	3.78e-05	0.0062	0.22	0.19	Myopia (pathological);	chr8:9137877	chr8:8228595~8244865:+
LUAD	cis	rs4795519	1	rs2127283	ENSG00000266313.1	RP11-173M1.4	4.16	3.78e-05	0.0062	0.23	0.19	Chronic myeloid leukemia;	chr17:27155854	chr17:27333256~27348491:+
LUAD	cis	rs4795519	1	rs952000	ENSG00000266313.1	RP11-173M1.4	4.16	3.78e-05	0.0062	0.23	0.19	Chronic myeloid leukemia;	chr17:27157815	chr17:27333256~27348491:+
LUAD	cis	rs4795519	1	rs8070395	ENSG00000266313.1	RP11-173M1.4	4.16	3.78e-05	0.0062	0.23	0.19	Chronic myeloid leukemia;	chr17:27159288	chr17:27333256~27348491:+
LUAD	cis	rs4795519	1	rs8082531	ENSG00000266313.1	RP11-173M1.4	4.16	3.78e-05	0.0062	0.23	0.19	Chronic myeloid leukemia;	chr17:27164342	chr17:27333256~27348491:+
LUAD	cis	rs4795519	1	rs1600326	ENSG00000266313.1	RP11-173M1.4	4.16	3.78e-05	0.0062	0.23	0.19	Chronic myeloid leukemia;	chr17:27164515	chr17:27333256~27348491:+
LUAD	cis	rs4795519	0.922	rs11080095	ENSG00000266313.1	RP11-173M1.4	4.16	3.78e-05	0.0062	0.23	0.19	Chronic myeloid leukemia;	chr17:27165926	chr17:27333256~27348491:+
LUAD	cis	rs4795519	1	rs1824903	ENSG00000266313.1	RP11-173M1.4	4.16	3.78e-05	0.0062	0.23	0.19	Chronic myeloid leukemia;	chr17:27171271	chr17:27333256~27348491:+
LUAD	cis	rs4795519	0.961	rs12451637	ENSG00000266313.1	RP11-173M1.4	4.16	3.78e-05	0.0062	0.23	0.19	Chronic myeloid leukemia;	chr17:27173155	chr17:27333256~27348491:+
LUAD	cis	rs4795519	1	rs4794851	ENSG00000266313.1	RP11-173M1.4	4.16	3.78e-05	0.0062	0.23	0.19	Chronic myeloid leukemia;	chr17:27174918	chr17:27333256~27348491:+
LUAD	cis	rs4795519	1	rs28836895	ENSG00000266313.1	RP11-173M1.4	4.16	3.78e-05	0.0062	0.23	0.19	Chronic myeloid leukemia;	chr17:27175075	chr17:27333256~27348491:+
LUAD	cis	rs4795519	1	rs34058557	ENSG00000266313.1	RP11-173M1.4	4.16	3.78e-05	0.0062	0.23	0.19	Chronic myeloid leukemia;	chr17:27175295	chr17:27333256~27348491:+
LUAD	cis	rs4795519	0.961	rs2313739	ENSG00000266313.1	RP11-173M1.4	4.16	3.78e-05	0.0062	0.23	0.19	Chronic myeloid leukemia;	chr17:27180034	chr17:27333256~27348491:+
LUAD	cis	rs4795519	1	rs1479362	ENSG00000266313.1	RP11-173M1.4	4.16	3.78e-05	0.0062	0.23	0.19	Chronic myeloid leukemia;	chr17:27180737	chr17:27333256~27348491:+
LUAD	cis	rs4795519	0.922	rs12451205	ENSG00000266313.1	RP11-173M1.4	4.16	3.78e-05	0.0062	0.23	0.19	Chronic myeloid leukemia;	chr17:27190130	chr17:27333256~27348491:+
LUAD	cis	rs4795519	0.922	rs12452048	ENSG00000266313.1	RP11-173M1.4	4.16	3.78e-05	0.0062	0.23	0.19	Chronic myeloid leukemia;	chr17:27191905	chr17:27333256~27348491:+
LUAD	cis	rs712022	1	rs6483880	ENSG00000246225.5	RP11-17A1.3	4.16	3.78e-05	0.0062	0.23	0.19	Dialysis-related mortality;	chr11:22831194	chr11:22829380~22945393:+
LUAD	cis	rs6121246	0.559	rs6060857	ENSG00000230613.1	HM13-AS1	4.16	3.78e-05	0.0062	0.23	0.19	Mean corpuscular hemoglobin;	chr20:31712419	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.559	rs1484994	ENSG00000230613.1	HM13-AS1	4.16	3.78e-05	0.0062	0.23	0.19	Mean corpuscular hemoglobin;	chr20:31718172	chr20:31567707~31573263:-
LUAD	cis	rs6964587	1	rs7781066	ENSG00000188693.7	CYP51A1-AS1	-4.16	3.79e-05	0.0062	-0.22	-0.19	Breast cancer;	chr7:92062632	chr7:92134604~92180725:+
LUAD	cis	rs4713118	0.955	rs9468201	ENSG00000280107.1	AL022393.9	-4.16	3.79e-05	0.0062	-0.24	-0.19	Parkinson's disease;	chr6:27719256	chr6:28170845~28172521:+
LUAD	cis	rs238295	0.766	rs6139759	ENSG00000230563.2	RP5-828H9.1	-4.16	3.79e-05	0.0062	-0.23	-0.19	Occipital cortical area (total cortical area interaction);	chr20:5531096	chr20:5471207~5475182:+
LUAD	cis	rs853679	0.55	rs1237875	ENSG00000226314.6	ZNF192P1	4.16	3.79e-05	0.0062	0.24	0.19	Depression;	chr6:28205232	chr6:28161781~28169594:+
LUAD	cis	rs11168618	1	rs3961921	ENSG00000240399.1	RP1-228P16.1	4.16	3.79e-05	0.0062	0.19	0.19	Adiponectin levels;	chr12:48549716	chr12:48054813~48055591:-
LUAD	cis	rs17772222	0.696	rs28666030	ENSG00000258983.2	RP11-507K2.2	4.16	3.79e-05	0.0062	0.22	0.19	Coronary artery calcification;	chr14:88511463	chr14:88499334~88515502:+
LUAD	cis	rs17772222	0.74	rs28493481	ENSG00000258983.2	RP11-507K2.2	4.16	3.79e-05	0.0062	0.22	0.19	Coronary artery calcification;	chr14:88511491	chr14:88499334~88515502:+
LUAD	cis	rs865483	0.965	rs853199	ENSG00000276054.1	RP11-378E13.3	4.16	3.79e-05	0.0062	0.23	0.19	Monocyte count;	chr17:37490119	chr17:37386886~37387926:+
LUAD	cis	rs865483	0.86	rs862490	ENSG00000276054.1	RP11-378E13.3	4.16	3.79e-05	0.0062	0.23	0.19	Monocyte count;	chr17:37490169	chr17:37386886~37387926:+
LUAD	cis	rs910316	1	rs4899544	ENSG00000279594.1	RP11-950C14.10	4.16	3.79e-05	0.0062	0.21	0.19	Height;	chr14:75079853	chr14:75011269~75012851:-
LUAD	cis	rs910316	1	rs4903279	ENSG00000279594.1	RP11-950C14.10	4.16	3.79e-05	0.0062	0.21	0.19	Height;	chr14:75079880	chr14:75011269~75012851:-
LUAD	cis	rs516805	0.52	rs553889	ENSG00000279453.1	RP3-425C14.4	-4.16	3.79e-05	0.0062	-0.2	-0.19	Lymphocyte counts;	chr6:122407734	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.52	rs535316	ENSG00000279453.1	RP3-425C14.4	-4.16	3.79e-05	0.0062	-0.2	-0.19	Lymphocyte counts;	chr6:122410673	chr6:122436789~122439223:-
LUAD	cis	rs7617480	0.519	rs6790914	ENSG00000225399.4	RP11-3B7.1	4.16	3.79e-05	0.0062	0.25	0.19	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49168885	chr3:49260085~49261316:+
LUAD	cis	rs6754311	0.731	rs10207652	ENSG00000226806.1	AC011893.3	-4.16	3.79e-05	0.0062	-0.23	-0.19	Mosquito bite size;	chr2:135830908	chr2:135820191~135823087:+
LUAD	cis	rs9341808	0.718	rs9448893	ENSG00000260645.1	RP11-250B2.5	4.16	3.79e-05	0.0062	0.18	0.19	Sitting height ratio;	chr6:80127522	chr6:80466958~80469080:+
LUAD	cis	rs9543976	1	rs73223968	ENSG00000261105.4	LMO7-AS1	-4.16	3.79e-05	0.0062	-0.31	-0.19	Diabetic retinopathy;	chr13:75567585	chr13:75604700~75635994:-
LUAD	cis	rs6723108	0.603	rs1374289	ENSG00000224043.6	CCNT2-AS1	4.16	3.79e-05	0.00621	0.23	0.19	Type 2 diabetes;	chr2:134936809	chr2:134735464~134918710:-
LUAD	cis	rs4843747	0.671	rs72818577	ENSG00000205037.2	RP11-863P13.4	4.16	3.79e-05	0.00621	0.26	0.19	Menopause (age at onset);	chr16:88077575	chr16:88088041~88100985:-
LUAD	cis	rs11874381	1	rs11875097	ENSG00000266696.1	RP11-30L3.2	-4.16	3.79e-05	0.00621	-0.2	-0.19	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);	chr18:49688468	chr18:49205912~49208781:+
LUAD	cis	rs987710	0.568	rs5757039	ENSG00000211639.2	IGLV4-60	-4.16	3.8e-05	0.00621	-0.26	-0.19	Iron status biomarkers;Iron deficiency;	chr22:22140234	chr22:22162199~22162681:+
LUAD	cis	rs13113518	0.783	rs6843997	ENSG00000272969.1	RP11-528I4.2	4.16	3.8e-05	0.00621	0.2	0.19	Height;	chr4:55508982	chr4:55547112~55547889:+
LUAD	cis	rs9309473	0.607	rs6720094	ENSG00000163016.8	ALMS1P	4.16	3.8e-05	0.00621	0.21	0.19	Metabolite levels;	chr2:73360948	chr2:73644919~73685576:+
LUAD	cis	rs2274273	0.84	rs7153110	ENSG00000258413.1	RP11-665C16.6	-4.16	3.8e-05	0.00621	-0.24	-0.19	Protein biomarker;	chr14:55353910	chr14:55262767~55272075:-
LUAD	cis	rs4908768	0.539	rs4480384	ENSG00000270282.1	RP5-1115A15.2	4.16	3.8e-05	0.00621	0.2	0.19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8599655	chr1:8512653~8513021:+
LUAD	cis	rs860295	0.58	rs10908461	ENSG00000225855.5	RUSC1-AS1	4.16	3.8e-05	0.00621	0.13	0.19	Body mass index;	chr1:155305936	chr1:155316863~155324176:-
LUAD	cis	rs6025590	1	rs6025590	ENSG00000124097.7	HMGB1P1	-4.16	3.8e-05	0.00622	-0.22	-0.19	Obesity-related traits;	chr20:57495449	chr20:57488392~57489027:-
LUAD	cis	rs755249	0.727	rs16826349	ENSG00000237624.1	OXCT2P1	4.16	3.8e-05	0.00622	0.24	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39573264	chr1:39514956~39516490:+
LUAD	cis	rs2898681	0.581	rs28618986	ENSG00000248375.1	RP11-177B4.1	-4.16	3.8e-05	0.00622	-0.28	-0.19	Optic nerve measurement (cup area);	chr4:52811735	chr4:52720081~52720831:-
LUAD	cis	rs2898681	0.581	rs731073	ENSG00000248375.1	RP11-177B4.1	-4.16	3.8e-05	0.00622	-0.28	-0.19	Optic nerve measurement (cup area);	chr4:52813923	chr4:52720081~52720831:-
LUAD	cis	rs6496932	0.663	rs12915663	ENSG00000218052.5	ADAMTS7P4	-4.16	3.8e-05	0.00622	-0.21	-0.19	Central corneal thickness;Corneal structure;	chr15:85362249	chr15:85255369~85330334:-
LUAD	cis	rs9894429	0.869	rs9748184	ENSG00000263853.1	AC139530.1	-4.16	3.8e-05	0.00622	-0.18	-0.19	Eye color traits;	chr17:81629254	chr17:81676001~81676086:+
LUAD	cis	rs9894429	1	rs9894429	ENSG00000263853.1	AC139530.1	-4.16	3.8e-05	0.00622	-0.18	-0.19	Eye color traits;	chr17:81629785	chr17:81676001~81676086:+
LUAD	cis	rs9894429	1	rs7406003	ENSG00000263853.1	AC139530.1	-4.16	3.8e-05	0.00622	-0.18	-0.19	Eye color traits;	chr17:81630571	chr17:81676001~81676086:+
LUAD	cis	rs812925	0.555	rs12616433	ENSG00000271889.1	RP11-493E12.1	4.16	3.8e-05	0.00622	0.22	0.19	Immature fraction of reticulocytes;	chr2:61469353	chr2:61151433~61162105:-
LUAD	cis	rs4460629	0.742	rs6427158	ENSG00000160766.13	GBAP1	-4.16	3.8e-05	0.00622	-0.19	-0.19	Serum magnesium levels;	chr1:155102427	chr1:155213821~155227422:-
LUAD	cis	rs8177876	0.749	rs11865207	ENSG00000261061.1	RP11-303E16.2	-4.16	3.8e-05	0.00622	-0.26	-0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81056055	chr16:81030770~81031485:+
LUAD	cis	rs1387259	0.929	rs2956703	ENSG00000257763.1	OR5BK1P	4.16	3.8e-05	0.00622	0.2	0.19	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48276511	chr12:48355792~48356614:-
LUAD	cis	rs9516	1	rs10898990	ENSG00000213333.3	NPM1P50	4.16	3.8e-05	0.00622	0.2	0.19	Facial morphology (factor 15, philtrum width);	chr11:74454121	chr11:75079265~75080131:-
LUAD	cis	rs9516	1	rs10898991	ENSG00000213333.3	NPM1P50	4.16	3.8e-05	0.00622	0.2	0.19	Facial morphology (factor 15, philtrum width);	chr11:74454148	chr11:75079265~75080131:-
LUAD	cis	rs7429990	0.813	rs7637622	ENSG00000228638.1	FCF1P2	4.16	3.8e-05	0.00622	0.22	0.19	Educational attainment (years of education);	chr3:48051561	chr3:48290793~48291375:-
LUAD	cis	rs7429990	0.965	rs7627645	ENSG00000228638.1	FCF1P2	4.16	3.8e-05	0.00622	0.22	0.19	Educational attainment (years of education);	chr3:48051643	chr3:48290793~48291375:-
LUAD	cis	rs72772090	0.908	rs72772091	ENSG00000248734.2	CTD-2260A17.1	-4.16	3.8e-05	0.00622	-0.27	-0.19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96704418	chr5:96784777~96785999:+
LUAD	cis	rs3742264	0.885	rs4942476	ENSG00000235903.6	CPB2-AS1	-4.16	3.8e-05	0.00622	-0.24	-0.19	Blood protein levels;	chr13:46077491	chr13:46052806~46113332:+
LUAD	cis	rs848490	0.963	rs73136294	ENSG00000214293.7	APTR	4.16	3.8e-05	0.00622	0.25	0.19	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77777171	chr7:77657660~77696265:-
LUAD	cis	rs848490	1	rs62460739	ENSG00000214293.7	APTR	4.16	3.8e-05	0.00622	0.25	0.19	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77777430	chr7:77657660~77696265:-
LUAD	cis	rs7172677	0.732	rs1867147	ENSG00000260269.4	CTD-2323K18.1	4.16	3.81e-05	0.00622	0.26	0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75071016	chr15:75527150~75601205:-
LUAD	cis	rs4819052	0.851	rs58644915	ENSG00000237664.1	LINC00316	-4.16	3.81e-05	0.00622	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249997	chr21:45338590~45341990:-
LUAD	cis	rs12999542	0.706	rs11465711	ENSG00000234389.1	AC007278.3	4.16	3.81e-05	0.00622	0.3	0.19	Serum protein levels (sST2);	chr2:102443632	chr2:102438713~102440475:+
LUAD	cis	rs17301013	0.932	rs1754355	ENSG00000227373.4	RP11-160H22.5	-4.16	3.81e-05	0.00623	-0.23	-0.19	Systemic lupus erythematosus;	chr1:174807407	chr1:174115300~174160004:-
LUAD	cis	rs7806994	1	rs7806994	ENSG00000273720.1	RP11-613E4.4	-4.16	3.81e-05	0.00623	-0.29	-0.19	PR interval in Tripanosoma cruzi seropositivity;	chr7:56071812	chr7:55743073~55743457:+
LUAD	cis	rs7557067	0.525	rs11126598	ENSG00000233005.1	AC067959.1	4.16	3.81e-05	0.00623	0.21	0.19	Triglycerides;	chr2:21017492	chr2:21221175~21970959:+
LUAD	cis	rs7204230	1	rs8051675	ENSG00000261291.1	RP11-295M3.2	4.16	3.81e-05	0.00623	0.23	0.19	Fibrinogen;	chr16:53338677	chr16:53168522~53169450:+
LUAD	cis	rs7208859	0.623	rs8068645	ENSG00000280069.1	CTD-2349P21.3	-4.16	3.81e-05	0.00623	-0.25	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777324	chr17:30738182~30740275:+
LUAD	cis	rs7246657	0.943	rs10405325	ENSG00000226686.6	LINC01535	-4.16	3.81e-05	0.00623	-0.29	-0.19	Coronary artery calcification;	chr19:37392575	chr19:37251912~37265535:+
LUAD	cis	rs2836974	0.931	rs13047663	ENSG00000232608.1	TIMM9P2	-4.16	3.81e-05	0.00623	-0.23	-0.19	Cognitive function;	chr21:39336892	chr21:39216624~39217506:+
LUAD	cis	rs12073359	1	rs56212907	ENSG00000223945.2	RP11-458I7.1	-4.16	3.81e-05	0.00624	-0.28	-0.19	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150086719	chr1:150053864~150055034:+
LUAD	cis	rs2929278	0.588	rs1975364	ENSG00000166763.7	STRCP1	4.16	3.81e-05	0.00624	0.22	0.19	Schizophrenia;	chr15:43857991	chr15:43699488~43718184:-
LUAD	cis	rs9973361	0.513	rs13421971	ENSG00000232411.1	AC009495.3	-4.16	3.81e-05	0.00624	-0.21	-0.19	Total body bone mineral density;	chr2:165855094	chr2:165833048~165839098:-
LUAD	cis	rs8014252	0.803	rs61388426	ENSG00000259158.2	ADAM20P1	-4.16	3.82e-05	0.00624	-0.33	-0.19	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70578285	chr14:70468881~70483756:-
LUAD	cis	rs8014252	0.803	rs56328037	ENSG00000259158.2	ADAM20P1	-4.16	3.82e-05	0.00624	-0.33	-0.19	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70578624	chr14:70468881~70483756:-
LUAD	cis	rs8014252	0.803	rs45523543	ENSG00000259158.2	ADAM20P1	-4.16	3.82e-05	0.00624	-0.33	-0.19	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70584371	chr14:70468881~70483756:-
LUAD	cis	rs8014252	0.803	rs56922268	ENSG00000259158.2	ADAM20P1	-4.16	3.82e-05	0.00624	-0.33	-0.19	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70585454	chr14:70468881~70483756:-
LUAD	cis	rs8014252	0.803	rs17108246	ENSG00000259158.2	ADAM20P1	-4.16	3.82e-05	0.00624	-0.33	-0.19	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70588275	chr14:70468881~70483756:-
LUAD	cis	rs2735413	0.564	rs8059851	ENSG00000276007.1	RP11-358L22.3	4.16	3.82e-05	0.00624	0.26	0.19	Systolic blood pressure (alcohol consumption interaction);	chr16:78084435	chr16:78123243~78124332:+
LUAD	cis	rs16940212	0.618	rs16940170	ENSG00000242747.1	RP11-30K9.1	4.16	3.82e-05	0.00624	0.27	0.19	HDL cholesterol;HDL cholesterol levels;	chr15:58392083	chr15:58869659~58870134:+
LUAD	cis	rs2657294	0.861	rs6480769	ENSG00000233313.2	HMGA1P5	-4.16	3.82e-05	0.00624	-0.24	-0.19	Pneumonia;	chr10:75091745	chr10:75276376~75276646:-
LUAD	cis	rs259282	0.851	rs174083	ENSG00000201388.1	SNORA68	4.16	3.82e-05	0.00624	0.19	0.19	Schizophrenia;	chr19:32650274	chr19:32608337~32608469:-
LUAD	cis	rs7204230	1	rs8046380	ENSG00000261291.1	RP11-295M3.2	4.16	3.82e-05	0.00624	0.23	0.19	Fibrinogen;	chr16:53195329	chr16:53168522~53169450:+
LUAD	cis	rs6661961	0.714	rs1923499	ENSG00000237975.5	FLG-AS1	-4.16	3.82e-05	0.00624	-0.26	-0.19	Atopic dermatitis;	chr1:152440699	chr1:152168125~152445456:+
LUAD	cis	rs11157436	0.602	rs11157438	ENSG00000211812.1	TRAV26-2	-4.16	3.82e-05	0.00624	-0.19	-0.19	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22169147	chr14:22202583~22203368:+
LUAD	cis	rs950880	1	rs950880	ENSG00000234389.1	AC007278.3	-4.16	3.82e-05	0.00624	-0.18	-0.19	Serum protein levels (sST2);	chr2:102316102	chr2:102438713~102440475:+
LUAD	cis	rs6142102	1	rs6059681	ENSG00000275784.1	RP5-1125A11.6	-4.16	3.82e-05	0.00624	-0.21	-0.19	Skin pigmentation;	chr20:34135535	chr20:33989480~33991818:-
LUAD	cis	rs6964587	0.869	rs405	ENSG00000188693.7	CYP51A1-AS1	4.16	3.82e-05	0.00624	0.22	0.19	Breast cancer;	chr7:91917013	chr7:92134604~92180725:+
LUAD	cis	rs4132509	0.515	rs76243949	ENSG00000236031.1	RP11-269F20.1	4.16	3.82e-05	0.00625	0.3	0.19	RR interval (heart rate);	chr1:243510792	chr1:243545532~243548329:+
LUAD	cis	rs12030196	0.788	rs2716122	ENSG00000230812.4	LINC01358	4.16	3.82e-05	0.00625	0.19	0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr1:58964673	chr1:59020387~59044614:+
LUAD	cis	rs442309	0.846	rs224130	ENSG00000238280.1	RP11-436D10.3	-4.16	3.82e-05	0.00625	-0.23	-0.19	Vogt-Koyanagi-Harada syndrome;	chr10:62705211	chr10:62793562~62805887:-
LUAD	cis	rs6471393	0.929	rs58575315	ENSG00000253848.1	RP11-10N23.5	4.16	3.82e-05	0.00625	0.23	0.19	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93749495	chr8:93741193~93744534:+
LUAD	cis	rs6471393	0.929	rs62525164	ENSG00000253848.1	RP11-10N23.5	4.16	3.82e-05	0.00625	0.23	0.19	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93750084	chr8:93741193~93744534:+
LUAD	cis	rs34761973	0.569	rs7223411	ENSG00000272911.1	RP11-74E22.6	4.16	3.82e-05	0.00625	0.27	0.19	Depressive symptoms (multi-trait analysis);Subjective well-being (multi-trait analysis);Neuroticism (multi-trait analysis);	chr17:2673883	chr17:2688473~2688960:+
LUAD	cis	rs7404843	0.925	rs12600043	ENSG00000207425.1	Y_RNA	-4.16	3.82e-05	0.00625	-0.38	-0.19	Testicular germ cell tumor;	chr16:15446095	chr16:14915457~14915556:-
LUAD	cis	rs13113518	0.812	rs4865001	ENSG00000272969.1	RP11-528I4.2	4.16	3.82e-05	0.00625	0.2	0.19	Height;	chr4:55490176	chr4:55547112~55547889:+
LUAD	cis	rs1864585	0.52	rs73208769	ENSG00000255046.1	RP11-297N6.4	4.16	3.83e-05	0.00625	0.26	0.19	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10808474	chr8:11797928~11802568:-
LUAD	cis	rs877819	0.583	rs2620880	ENSG00000228403.1	RP11-563N6.6	4.16	3.83e-05	0.00625	0.19	0.19	Systemic lupus erythematosus;	chr10:48877383	chr10:48878022~48878649:+
LUAD	cis	rs4460629	0.742	rs11264312	ENSG00000160766.13	GBAP1	-4.16	3.83e-05	0.00625	-0.19	-0.19	Serum magnesium levels;	chr1:155103412	chr1:155213821~155227422:-
LUAD	cis	rs4460629	0.742	rs4625273	ENSG00000160766.13	GBAP1	-4.16	3.83e-05	0.00625	-0.19	-0.19	Serum magnesium levels;	chr1:155103567	chr1:155213821~155227422:-
LUAD	cis	rs4460629	0.742	rs7366355	ENSG00000160766.13	GBAP1	-4.16	3.83e-05	0.00625	-0.19	-0.19	Serum magnesium levels;	chr1:155104258	chr1:155213821~155227422:-
LUAD	cis	rs763121	0.819	rs5757237	ENSG00000228274.3	RP3-508I15.9	-4.16	3.83e-05	0.00625	-0.19	-0.19	Menopause (age at onset);	chr22:38677830	chr22:38667585~38681820:-
LUAD	cis	rs763121	0.853	rs11704021	ENSG00000228274.3	RP3-508I15.9	-4.16	3.83e-05	0.00625	-0.19	-0.19	Menopause (age at onset);	chr22:38678711	chr22:38667585~38681820:-
LUAD	cis	rs4683346	0.616	rs3843369	ENSG00000173811.9	CCDC13-AS1	-4.16	3.83e-05	0.00625	-0.21	-0.19	Granulocyte percentage of myeloid white cells;	chr3:42765556	chr3:42732575~42746768:+
LUAD	cis	rs13113518	1	rs4865007	ENSG00000272969.1	RP11-528I4.2	-4.16	3.83e-05	0.00625	-0.19	-0.19	Height;	chr4:55537550	chr4:55547112~55547889:+
LUAD	cis	rs1864585	0.52	rs73208790	ENSG00000255046.1	RP11-297N6.4	4.16	3.83e-05	0.00625	0.26	0.19	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10822515	chr8:11797928~11802568:-
LUAD	cis	rs1864585	0.52	rs73208791	ENSG00000255046.1	RP11-297N6.4	4.16	3.83e-05	0.00625	0.26	0.19	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10822828	chr8:11797928~11802568:-
LUAD	cis	rs1864585	0.505	rs73208792	ENSG00000255046.1	RP11-297N6.4	4.16	3.83e-05	0.00625	0.26	0.19	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10822961	chr8:11797928~11802568:-
LUAD	cis	rs1864585	0.52	rs73208793	ENSG00000255046.1	RP11-297N6.4	4.16	3.83e-05	0.00625	0.26	0.19	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10823275	chr8:11797928~11802568:-
LUAD	cis	rs4474465	1	rs7929712	ENSG00000251323.2	RP11-452H21.4	4.16	3.83e-05	0.00625	0.24	0.19	Alzheimer's disease (survival time);	chr11:78447496	chr11:78423982~78429836:-
LUAD	cis	rs10129255	0.957	rs61997760	ENSG00000211967.3	IGHV3-53	-4.16	3.83e-05	0.00626	-0.15	-0.19	Kawasaki disease;	chr14:106716993	chr14:106592676~106593347:-
LUAD	cis	rs11009175	0.547	rs970654	ENSG00000273038.2	RP11-479G22.8	4.16	3.83e-05	0.00626	0.25	0.19	Depression (quantitative trait);	chr10:33110806	chr10:32887255~32889311:-
LUAD	cis	rs4819052	1	rs3746980	ENSG00000223768.1	LINC00205	-4.16	3.83e-05	0.00626	-0.25	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291665	chr21:45293285~45297354:+
LUAD	cis	rs240993	0.715	rs7742724	ENSG00000271789.1	RP5-1112D6.7	4.16	3.83e-05	0.00626	0.22	0.19	Inflammatory skin disease;Psoriasis;	chr6:111517816	chr6:111297126~111298510:+
LUAD	cis	rs62246343	0.572	rs62246311	ENSG00000254485.4	RP11-380O24.1	4.16	3.83e-05	0.00626	0.35	0.19	Fibrinogen levels;	chr3:9456459	chr3:9292588~9363303:-
LUAD	cis	rs62246343	0.572	rs111979419	ENSG00000254485.4	RP11-380O24.1	4.16	3.83e-05	0.00626	0.35	0.19	Fibrinogen levels;	chr3:9457372	chr3:9292588~9363303:-
LUAD	cis	rs7893279	0.505	rs7904949	ENSG00000225527.1	RP11-383B4.4	4.16	3.84e-05	0.00627	0.27	0.19	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18624533	chr10:18531849~18533336:-
LUAD	cis	rs7893279	0.505	rs4468242	ENSG00000225527.1	RP11-383B4.4	4.16	3.84e-05	0.00627	0.27	0.19	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18633730	chr10:18531849~18533336:-
LUAD	cis	rs62355901	0.599	rs751990	ENSG00000271828.1	CTD-2310F14.1	4.16	3.84e-05	0.00627	0.36	0.19	Breast cancer;	chr5:56743292	chr5:56927874~56929573:+
LUAD	cis	rs1714507	0.515	rs2731112	ENSG00000272087.1	RP11-379F4.7	4.16	3.84e-05	0.00627	0.2	0.19	Subjective well-being;	chr3:158572439	chr3:158693120~158693768:-
LUAD	cis	rs17711722	0.522	rs4642526	ENSG00000237310.1	GS1-124K5.4	4.16	3.84e-05	0.00627	0.2	0.19	Calcium levels;	chr7:65751755	chr7:66493706~66495474:+
LUAD	cis	rs651907	0.535	rs2290859	ENSG00000244119.1	PDCL3P4	4.16	3.84e-05	0.00627	0.19	0.19	Colorectal cancer;	chr3:101806781	chr3:101712472~101713191:+
LUAD	cis	rs9309473	0.583	rs11899517	ENSG00000163016.8	ALMS1P	4.16	3.84e-05	0.00627	0.21	0.19	Metabolite levels;	chr2:73346133	chr2:73644919~73685576:+
LUAD	cis	rs727479	0.962	rs2414097	ENSG00000259306.2	RP11-108K3.2	-4.16	3.84e-05	0.00627	-0.2	-0.19	Estradiol levels;	chr15:51237638	chr15:51315841~51321996:+
LUAD	cis	rs2243480	1	rs778679	ENSG00000229886.1	RP5-1132H15.3	4.16	3.84e-05	0.00627	0.32	0.19	Diabetic kidney disease;	chr7:66375924	chr7:66025126~66031544:-
LUAD	cis	rs9649213	0.593	rs62478177	ENSG00000272950.1	RP11-307C18.1	4.16	3.84e-05	0.00627	0.23	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98335299	chr7:98322853~98323430:+
LUAD	cis	rs897984	0.542	rs73530203	ENSG00000232748.3	RP11-196G11.6	-4.16	3.84e-05	0.00627	-0.24	-0.19	Dementia with Lewy bodies;	chr16:31088538	chr16:31056460~31062803:+
LUAD	cis	rs5751168	0.564	rs5758473	ENSG00000211654.2	IGLV5-37	4.16	3.84e-05	0.00627	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr22:22486819	chr22:22427540~22428035:+
LUAD	cis	rs4811196	0.748	rs2038389	ENSG00000226144.2	RPS27AP3	4.16	3.84e-05	0.00627	0.21	0.19	Bone mineral density;	chr20:37892254	chr20:37049254~37049707:+
LUAD	cis	rs7674212	0.541	rs2720460	ENSG00000251288.2	RP11-10L12.2	4.16	3.84e-05	0.00627	0.23	0.19	Type 2 diabetes;	chr4:103133529	chr4:102751401~102752641:+
LUAD	cis	rs193541	0.501	rs3943379	ENSG00000263432.2	RN7SL689P	4.16	3.84e-05	0.00627	0.27	0.19	Glucose homeostasis traits;	chr5:122720442	chr5:123022487~123022783:-
LUAD	cis	rs193541	0.502	rs2061511	ENSG00000263432.2	RN7SL689P	4.16	3.84e-05	0.00627	0.27	0.19	Glucose homeostasis traits;	chr5:122721032	chr5:123022487~123022783:-
LUAD	cis	rs7107174	1	rs10899481	ENSG00000251323.2	RP11-452H21.4	-4.16	3.84e-05	0.00627	-0.23	-0.19	Testicular germ cell tumor;	chr11:78347675	chr11:78423982~78429836:-
LUAD	cis	rs12754538	0.85	rs17385519	ENSG00000232912.4	RP5-1115A15.1	4.16	3.84e-05	0.00627	0.2	0.19	Subjective well-being;	chr1:8467460	chr1:8424645~8434838:+
LUAD	cis	rs2562456	0.833	rs17680605	ENSG00000268081.1	RP11-678G14.2	4.16	3.84e-05	0.00628	0.31	0.19	Pain;	chr19:21379646	chr19:21554640~21569237:-
LUAD	cis	rs4660214	0.671	rs16826012	ENSG00000228060.1	RP11-69E11.8	4.16	3.85e-05	0.00628	0.2	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39253847	chr1:39565160~39573203:+
LUAD	cis	rs4763879	0.594	rs12427310	ENSG00000256582.1	RP11-75L1.1	-4.16	3.85e-05	0.00628	-0.19	-0.19	Type 1 diabetes;	chr12:9707539	chr12:9704077~9709350:+
LUAD	cis	rs2836754	1	rs7279422	ENSG00000205622.8	AF064858.6	-4.16	3.85e-05	0.00628	-0.2	-0.19	Body mass index;Crohn's disease;	chr21:38920776	chr21:38863676~38956467:-
LUAD	cis	rs2836754	1	rs2836755	ENSG00000205622.8	AF064858.6	-4.16	3.85e-05	0.00628	-0.2	-0.19	Body mass index;Crohn's disease;	chr21:38920780	chr21:38863676~38956467:-
LUAD	cis	rs2836754	1	rs2836756	ENSG00000205622.8	AF064858.6	-4.16	3.85e-05	0.00628	-0.2	-0.19	Body mass index;Crohn's disease;	chr21:38921157	chr21:38863676~38956467:-
LUAD	cis	rs2836754	1	rs7279192	ENSG00000205622.8	AF064858.6	-4.16	3.85e-05	0.00628	-0.2	-0.19	Body mass index;Crohn's disease;	chr21:38921160	chr21:38863676~38956467:-
LUAD	cis	rs4474465	1	rs11237495	ENSG00000251323.2	RP11-452H21.4	4.16	3.85e-05	0.00628	0.24	0.19	Alzheimer's disease (survival time);	chr11:78444044	chr11:78423982~78429836:-
LUAD	cis	rs2354432	0.556	rs885305	ENSG00000226015.2	CCT8P1	4.16	3.85e-05	0.00628	0.34	0.19	Mitochondrial DNA levels;	chr1:147314360	chr1:147203276~147204932:-
LUAD	cis	rs957448	0.698	rs116348949	ENSG00000254315.1	RP11-267M23.3	4.16	3.85e-05	0.00628	0.22	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94557488	chr8:94533628~94534391:+
LUAD	cis	rs3096299	0.685	rs12935112	ENSG00000182376.2	RP5-1142A6.8	-4.16	3.85e-05	0.00628	-0.19	-0.19	Multiple myeloma (IgH translocation);	chr16:89476450	chr16:88742767~88745748:+
LUAD	cis	rs763512	0.532	rs3094499	ENSG00000276054.1	RP11-378E13.3	4.16	3.85e-05	0.00628	0.28	0.19	3-hydroxypropylmercapturic acid levels in smokers;	chr17:37531234	chr17:37386886~37387926:+
LUAD	cis	rs9649213	0.574	rs6979373	ENSG00000272950.1	RP11-307C18.1	4.16	3.85e-05	0.00628	0.23	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98332532	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.574	rs34717219	ENSG00000272950.1	RP11-307C18.1	4.16	3.85e-05	0.00628	0.23	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98332959	chr7:98322853~98323430:+
LUAD	cis	rs34779708	0.733	rs3853672	ENSG00000271335.4	RP11-324I22.4	4.16	3.85e-05	0.00629	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35260678	chr10:35314552~35336401:-
LUAD	cis	rs62025270	0.747	rs17639314	ENSG00000202081.1	RNU6-1280P	-4.15	3.85e-05	0.00629	-0.27	-0.19	Idiopathic pulmonary fibrosis;	chr15:85766678	chr15:85651522~85651628:-
LUAD	cis	rs9549260	0.564	rs6563845	ENSG00000229456.1	RLIMP1	4.15	3.85e-05	0.00629	0.2	0.19	Red blood cell count;	chr13:40744771	chr13:40618738~40621348:+
LUAD	cis	rs4578769	0.531	rs12964304	ENSG00000265943.1	RP11-739L10.1	4.15	3.85e-05	0.00629	0.23	0.19	Eosinophil percentage of white cells;	chr18:22928641	chr18:22699481~22933764:-
LUAD	cis	rs4578769	0.531	rs12968784	ENSG00000265943.1	RP11-739L10.1	4.15	3.85e-05	0.00629	0.23	0.19	Eosinophil percentage of white cells;	chr18:22928645	chr18:22699481~22933764:-
LUAD	cis	rs2274273	0.588	rs7145727	ENSG00000259318.1	RP11-454L9.2	4.15	3.85e-05	0.00629	0.16	0.19	Protein biomarker;	chr14:55380855	chr14:55394940~55395233:-
LUAD	cis	rs4578769	0.569	rs4800431	ENSG00000265943.1	RP11-739L10.1	4.15	3.85e-05	0.00629	0.23	0.19	Eosinophil percentage of white cells;	chr18:22803499	chr18:22699481~22933764:-
LUAD	cis	rs4554975	0.689	rs7298017	ENSG00000274723.1	RP11-618L22.1	-4.15	3.85e-05	0.00629	-0.22	-0.19	Metabolite levels (small molecules and protein measures);	chr12:46863261	chr12:46970504~46972155:+
LUAD	cis	rs2880765	0.545	rs11631739	ENSG00000259630.2	CTD-2262B20.1	-4.15	3.86e-05	0.00629	-0.22	-0.19	Coronary artery disease;	chr15:85469347	chr15:85415228~85415633:+
LUAD	cis	rs4568518	0.74	rs12699925	ENSG00000279048.1	RP11-511H23.2	4.15	3.86e-05	0.00629	0.16	0.19	Measles;	chr7:17971039	chr7:17940503~17942922:+
LUAD	cis	rs8048589	0.948	rs71385189	ENSG00000175604.2	RP11-276H1.3	-4.15	3.86e-05	0.0063	-0.25	-0.19	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12088322	chr16:12086746~12090302:-
LUAD	cis	rs8058578	0.832	rs7500719	ENSG00000232748.3	RP11-196G11.6	-4.15	3.86e-05	0.0063	-0.24	-0.19	Multiple myeloma;	chr16:30829556	chr16:31056460~31062803:+
LUAD	cis	rs34779708	0.966	rs17500582	ENSG00000271335.4	RP11-324I22.4	4.15	3.86e-05	0.0063	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35209860	chr10:35314552~35336401:-
LUAD	cis	rs2834288	0.613	rs2040113	ENSG00000237945.6	LINC00649	4.15	3.86e-05	0.0063	0.23	0.19	Gut microbiota (bacterial taxa);	chr21:33908879	chr21:33915534~33977691:+
LUAD	cis	rs12122100	0.955	rs12141289	ENSG00000244371.2	PFN1P8	4.15	3.86e-05	0.0063	0.23	0.19	HIV-1 control;	chr1:147037912	chr1:146957117~146957659:-
LUAD	cis	rs4266144	0.632	rs56268334	ENSG00000244515.1	KRT18P34	-4.15	3.86e-05	0.0063	-0.29	-0.19	Coronary artery disease;	chr3:157130235	chr3:157162663~157163932:-
LUAD	cis	rs10971721	0.731	rs10971857	ENSG00000260947.1	RP11-384P7.7	4.15	3.86e-05	0.0063	0.39	0.19	Body mass index;	chr9:34021621	chr9:33697459~33700986:+
LUAD	cis	rs11051970	0.559	rs73086036	ENSG00000274964.1	RP11-817I4.1	-4.15	3.86e-05	0.0063	-0.24	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr12:32411651	chr12:32339368~32340724:+
LUAD	cis	rs11051970	0.559	rs11051992	ENSG00000274964.1	RP11-817I4.1	-4.15	3.86e-05	0.0063	-0.24	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr12:32411733	chr12:32339368~32340724:+
LUAD	cis	rs12681366	1	rs12681366	ENSG00000253704.1	RP11-267M23.4	4.15	3.86e-05	0.0063	0.22	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94389037	chr8:94553722~94569745:+
LUAD	cis	rs2749097	0.542	rs1701521	ENSG00000244256.3	RN7SL130P	-4.15	3.87e-05	0.00631	-0.22	-0.19	Alcohol consumption (transferrin glycosylation);	chr1:63676124	chr1:63655743~63656047:+
LUAD	cis	rs2919009	0.607	rs12250320	ENSG00000271670.1	RP11-95I16.4	4.15	3.87e-05	0.00631	0.24	0.19	Obesity-related traits;	chr10:120959795	chr10:120879256~120880667:-
LUAD	cis	rs853679	0.527	rs853693	ENSG00000219392.1	RP1-265C24.5	-4.15	3.87e-05	0.00631	-0.24	-0.19	Depression;	chr6:28314871	chr6:28115628~28116551:+
LUAD	cis	rs442309	0.875	rs224065	ENSG00000238280.1	RP11-436D10.3	-4.15	3.87e-05	0.00631	-0.22	-0.19	Vogt-Koyanagi-Harada syndrome;	chr10:62745688	chr10:62793562~62805887:-
LUAD	cis	rs6763848	0.962	rs6792755	ENSG00000214073.2	RPL21P17	4.15	3.87e-05	0.00632	0.18	0.19	Prostate cancer (SNP x SNP interaction);	chr3:1474776	chr3:1905651~1906125:+
LUAD	cis	rs453301	0.507	rs2929306	ENSG00000173295.6	FAM86B3P	-4.15	3.87e-05	0.00632	-0.2	-0.19	Joint mobility (Beighton score);	chr8:9227399	chr8:8228595~8244865:+
LUAD	cis	rs7208859	0.623	rs7214570	ENSG00000280069.1	CTD-2349P21.3	-4.15	3.87e-05	0.00632	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30820146	chr17:30738182~30740275:+
LUAD	cis	rs11009175	0.512	rs1923265	ENSG00000273038.2	RP11-479G22.8	-4.15	3.87e-05	0.00632	-0.21	-0.19	Depression (quantitative trait);	chr10:33089926	chr10:32887255~32889311:-
LUAD	cis	rs10510102	0.516	rs78586895	ENSG00000276742.1	RP11-500G22.4	4.15	3.87e-05	0.00632	0.31	0.19	Breast cancer;	chr10:121977081	chr10:121956782~121957098:+
LUAD	cis	rs7005380	0.62	rs13249122	ENSG00000279347.1	RP11-85I17.2	-4.15	3.87e-05	0.00632	-0.15	-0.19	Interstitial lung disease;	chr8:119893679	chr8:119838736~119840385:-
LUAD	cis	rs10917151	1	rs10917151	ENSG00000228397.1	RP1-224A6.3	-4.15	3.87e-05	0.00632	-0.33	-0.19	Endometriosis;	chr1:22096228	chr1:22023994~22024968:-
LUAD	cis	rs7617773	0.743	rs11716371	ENSG00000199476.1	Y_RNA	-4.15	3.87e-05	0.00632	-0.25	-0.19	Coronary artery disease;	chr3:48321260	chr3:48288587~48288694:+
LUAD	cis	rs17264034	1	rs17264034	ENSG00000250786.1	SNHG18	-4.15	3.88e-05	0.00632	-0.28	-0.19	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9557490	chr5:9546200~9550609:+
LUAD	cis	rs858239	0.601	rs987257	ENSG00000226816.2	AC005082.12	4.15	3.88e-05	0.00632	0.24	0.19	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23206013~23208045:+
LUAD	cis	rs4819052	0.851	rs2838857	ENSG00000215447.6	BX322557.10	-4.15	3.88e-05	0.00632	-0.22	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261085	chr21:45288052~45291738:+
LUAD	cis	rs7829975	0.714	rs11777085	ENSG00000233609.3	RP11-62H7.2	4.15	3.88e-05	0.00632	0.15	0.19	Mood instability;	chr8:8814919	chr8:8961200~8979025:+
LUAD	cis	rs2243480	1	rs34703416	ENSG00000232559.3	GS1-124K5.12	4.15	3.88e-05	0.00633	0.33	0.19	Diabetic kidney disease;	chr7:65835655	chr7:66554588~66576923:-
LUAD	cis	rs256438	0.93	rs2434285	ENSG00000251050.1	RP11-168A11.4	-4.15	3.88e-05	0.00633	-0.2	-0.19	Serum thyroid-stimulating hormone levels;	chr5:80095580	chr5:80019609~80019920:+
LUAD	cis	rs9649213	0.574	rs7791321	ENSG00000272950.1	RP11-307C18.1	4.15	3.88e-05	0.00633	0.23	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98314813	chr7:98322853~98323430:+
LUAD	cis	rs910316	0.763	rs12588981	ENSG00000259138.1	RP11-950C14.7	4.15	3.88e-05	0.00633	0.2	0.19	Height;	chr14:74993858	chr14:75127153~75136930:+
LUAD	cis	rs9467773	0.967	rs9295694	ENSG00000261353.1	CTA-14H9.5	-4.15	3.88e-05	0.00633	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26512766	chr6:26527063~26527404:+
LUAD	cis	rs9467773	0.967	rs9467775	ENSG00000261353.1	CTA-14H9.5	-4.15	3.88e-05	0.00633	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26513207	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs9393729	ENSG00000261353.1	CTA-14H9.5	-4.15	3.88e-05	0.00633	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26513938	chr6:26527063~26527404:+
LUAD	cis	rs7246657	0.882	rs10412043	ENSG00000226686.6	LINC01535	-4.15	3.88e-05	0.00633	-0.28	-0.19	Coronary artery calcification;	chr19:37335724	chr19:37251912~37265535:+
LUAD	cis	rs7616559	0.512	rs1482866	ENSG00000240875.4	LINC00886	-4.15	3.88e-05	0.00633	-0.2	-0.19	Carotid artery intima media thickness (sex interaction);	chr3:156998952	chr3:156747346~156817062:-
LUAD	cis	rs4795519	1	rs8081623	ENSG00000266313.1	RP11-173M1.4	4.15	3.88e-05	0.00633	0.23	0.19	Chronic myeloid leukemia;	chr17:27189579	chr17:27333256~27348491:+
LUAD	cis	rs11105298	0.891	rs11105318	ENSG00000258302.2	RP11-981P6.1	4.15	3.88e-05	0.00633	0.24	0.19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89532881	chr12:89561129~89594878:+
LUAD	cis	rs1552244	0.882	rs36006511	ENSG00000180385.7	EMC3-AS1	4.15	3.88e-05	0.00633	0.22	0.19	Alzheimer's disease;	chr3:10012507	chr3:9986893~10006990:+
LUAD	cis	rs1322639	0.614	rs7768154	ENSG00000261039.2	RP11-417E7.2	-4.15	3.88e-05	0.00633	-0.31	-0.19	Pulse pressure;	chr6:169165375	chr6:169175304~169182740:-
LUAD	cis	rs4879677	0.959	rs10968049	ENSG00000215441.3	CTAGE12P	-4.15	3.88e-05	0.00633	-0.23	-0.19	Gut microbiome composition (summer and winter);	chr9:27676933	chr9:27608382~27610745:-
LUAD	cis	rs4879677	1	rs10968051	ENSG00000215441.3	CTAGE12P	-4.15	3.88e-05	0.00633	-0.23	-0.19	Gut microbiome composition (summer and winter);	chr9:27677646	chr9:27608382~27610745:-
LUAD	cis	rs911555	0.504	rs4906340	ENSG00000269940.1	RP11-73M18.7	-4.15	3.88e-05	0.00633	-0.2	-0.19	Intelligence (multi-trait analysis);	chr14:103610308	chr14:103694560~103695170:+
LUAD	cis	rs911555	0.504	rs8006526	ENSG00000258851.1	RP11-894P9.2	-4.15	3.88e-05	0.00633	-0.22	-0.19	Intelligence (multi-trait analysis);	chr14:103608678	chr14:103553421~103561877:+
LUAD	cis	rs11009175	0.547	rs12241316	ENSG00000273038.2	RP11-479G22.8	-4.15	3.89e-05	0.00634	-0.23	-0.19	Depression (quantitative trait);	chr10:33106452	chr10:32887255~32889311:-
LUAD	cis	rs6751744	0.513	rs6738215	ENSG00000230783.1	AC009961.2	-4.15	3.89e-05	0.00634	-0.22	-0.19	Dysphagia;	chr2:159596794	chr2:159689217~159690291:-
LUAD	cis	rs9860428	0.844	rs7639603	ENSG00000242770.2	RP11-180K7.1	4.15	3.89e-05	0.00634	0.2	0.19	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112887289	chr3:112802478~112812819:+
LUAD	cis	rs9860428	0.844	rs9853006	ENSG00000242770.2	RP11-180K7.1	4.15	3.89e-05	0.00634	0.2	0.19	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112887488	chr3:112802478~112812819:+
LUAD	cis	rs13113518	0.812	rs13140173	ENSG00000272969.1	RP11-528I4.2	4.15	3.89e-05	0.00634	0.2	0.19	Height;	chr4:55527164	chr4:55547112~55547889:+
LUAD	cis	rs5015933	0.815	rs13294021	ENSG00000232630.1	PRPS1P2	-4.15	3.89e-05	0.00634	-0.17	-0.19	Body mass index;	chr9:125306109	chr9:125150653~125151589:+
LUAD	cis	rs889398	0.802	rs12919094	ENSG00000226232.7	RP11-419C5.2	4.15	3.89e-05	0.00634	0.16	0.19	Body mass index;	chr16:69809454	chr16:69976388~69996188:-
LUAD	cis	rs7937682	1	rs4936661	ENSG00000230911.1	PPIHP1	4.15	3.89e-05	0.00634	0.26	0.19	Primary sclerosing cholangitis;	chr11:111716771	chr11:112029858~112030367:-
LUAD	cis	rs240993	0.516	rs240981	ENSG00000271789.1	RP5-1112D6.7	-4.15	3.89e-05	0.00634	-0.24	-0.19	Inflammatory skin disease;Psoriasis;	chr6:111289990	chr6:111297126~111298510:+
LUAD	cis	rs12935418	0.672	rs9938541	ENSG00000261061.1	RP11-303E16.2	-4.15	3.89e-05	0.00634	-0.21	-0.19	Mean corpuscular volume;	chr16:81011623	chr16:81030770~81031485:+
LUAD	cis	rs950169	1	rs11638394	ENSG00000275120.1	RP11-182J1.17	4.15	3.89e-05	0.00635	0.29	0.19	Schizophrenia;	chr15:84110176	chr15:84599434~84606463:-
LUAD	cis	rs703842	1	rs10747783	ENSG00000270039.1	RP11-571M6.17	-4.15	3.89e-05	0.00635	-0.22	-0.19	Multiple sclerosis;	chr12:57782831	chr12:57803838~57804415:+
LUAD	cis	rs703842	0.964	rs10431552	ENSG00000270039.1	RP11-571M6.17	-4.15	3.89e-05	0.00635	-0.22	-0.19	Multiple sclerosis;	chr12:57784365	chr12:57803838~57804415:+
LUAD	cis	rs9467773	0.967	rs6456732	ENSG00000261353.1	CTA-14H9.5	-4.15	3.89e-05	0.00635	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26514217	chr6:26527063~26527404:+
LUAD	cis	rs2880765	0.835	rs4843062	ENSG00000259416.2	RP11-158M2.5	4.15	3.9e-05	0.00635	0.19	0.19	Coronary artery disease;	chr15:85496906	chr15:85754941~85756237:-
LUAD	cis	rs17772222	0.74	rs61975276	ENSG00000258983.2	RP11-507K2.2	4.15	3.9e-05	0.00635	0.22	0.19	Coronary artery calcification;	chr14:88511193	chr14:88499334~88515502:+
LUAD	cis	rs17772222	0.74	rs61975277	ENSG00000258983.2	RP11-507K2.2	4.15	3.9e-05	0.00635	0.22	0.19	Coronary artery calcification;	chr14:88511202	chr14:88499334~88515502:+
LUAD	cis	rs17772222	0.74	rs61984675	ENSG00000258983.2	RP11-507K2.2	4.15	3.9e-05	0.00635	0.22	0.19	Coronary artery calcification;	chr14:88511236	chr14:88499334~88515502:+
LUAD	cis	rs526231	0.578	rs42860	ENSG00000250682.4	LINC00491	4.15	3.9e-05	0.00635	0.23	0.19	Primary biliary cholangitis;	chr5:103092414	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.927	rs34806	ENSG00000250682.4	LINC00491	4.15	3.9e-05	0.00635	0.23	0.19	Parkinson's disease;	chr5:103092733	chr5:102609156~102671559:-
LUAD	cis	rs1555322	0.53	rs2425043	ENSG00000279253.1	RP4-614O4.13	-4.15	3.9e-05	0.00635	-0.23	-0.19	Attention deficit hyperactivity disorder;	chr20:35280899	chr20:35262727~35264187:-
LUAD	cis	rs2980439	0.556	rs2921059	ENSG00000253981.4	ALG1L13P	4.15	3.9e-05	0.00635	0.22	0.19	Neuroticism;	chr8:8460377	chr8:8236003~8244667:-
LUAD	cis	rs9393777	0.778	rs66841633	ENSG00000219392.1	RP1-265C24.5	-4.15	3.9e-05	0.00636	-0.36	-0.19	Intelligence (multi-trait analysis);	chr6:27414607	chr6:28115628~28116551:+
LUAD	cis	rs950169	0.579	rs12913054	ENSG00000225151.9	GOLGA2P7	-4.15	3.9e-05	0.00636	-0.27	-0.19	Schizophrenia;	chr15:83995704	chr15:84199311~84230136:-
LUAD	cis	rs394563	0.775	rs399673	ENSG00000216906.2	RP11-350J20.9	4.15	3.9e-05	0.00636	0.23	0.19	Dupuytren's disease;	chr6:149462085	chr6:149904243~149906418:+
LUAD	cis	rs4374383	0.884	rs10173553	ENSG00000207383.1	Y_RNA	-4.15	3.9e-05	0.00636	-0.22	-0.19	Hepatitis C induced liver fibrosis;	chr2:111996306	chr2:112579484~112579584:-
LUAD	cis	rs6931421	0.8	rs12662365	ENSG00000272129.1	RP11-250B2.6	4.15	3.9e-05	0.00636	0.25	0.19	Sitting height ratio;	chr6:80195672	chr6:80355424~80356859:+
LUAD	cis	rs12073359	1	rs1339495	ENSG00000223945.2	RP11-458I7.1	4.15	3.9e-05	0.00636	0.25	0.19	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150029275	chr1:150053864~150055034:+
LUAD	cis	rs875971	0.66	rs10263935	ENSG00000224316.1	RP11-479O9.2	4.15	3.9e-05	0.00636	0.19	0.19	Aortic root size;	chr7:66631041	chr7:65773620~65802067:+
LUAD	cis	rs7208859	0.673	rs9911989	ENSG00000280069.1	CTD-2349P21.3	4.15	3.91e-05	0.00636	0.26	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30738182~30740275:+
LUAD	cis	rs11168618	0.776	rs7955785	ENSG00000240399.1	RP1-228P16.1	4.15	3.91e-05	0.00636	0.18	0.19	Adiponectin levels;	chr12:48468755	chr12:48054813~48055591:-
LUAD	cis	rs7829975	0.742	rs1533059	ENSG00000253893.2	FAM85B	4.15	3.91e-05	0.00636	0.23	0.19	Mood instability;	chr8:8827443	chr8:8167819~8226614:-
LUAD	cis	rs5015933	0.815	rs3962622	ENSG00000232630.1	PRPS1P2	-4.15	3.91e-05	0.00637	-0.18	-0.19	Body mass index;	chr9:125259218	chr9:125150653~125151589:+
LUAD	cis	rs780096	0.545	rs2280737	ENSG00000234072.1	AC074117.10	-4.15	3.91e-05	0.00637	-0.14	-0.19	Total body bone mineral density;	chr2:27366943	chr2:27356246~27367622:+
LUAD	cis	rs2836974	0.644	rs2410123	ENSG00000232608.1	TIMM9P2	4.15	3.91e-05	0.00637	0.22	0.19	Cognitive function;	chr21:39328167	chr21:39216624~39217506:+
LUAD	cis	rs854765	0.647	rs6826	ENSG00000223979.2	SMCR2	-4.15	3.91e-05	0.00637	-0.22	-0.19	Total body bone mineral density;	chr17:18107826	chr17:17674026~17677688:-
LUAD	cis	rs2274273	0.522	rs2251366	ENSG00000258413.1	RP11-665C16.6	-4.15	3.91e-05	0.00637	-0.23	-0.19	Protein biomarker;	chr14:55051438	chr14:55262767~55272075:-
LUAD	cis	rs2153535	0.518	rs9502728	ENSG00000230939.1	RP11-314C16.1	-4.15	3.91e-05	0.00637	-0.22	-0.19	Motion sickness;	chr6:8602710	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.518	rs6912560	ENSG00000230939.1	RP11-314C16.1	-4.15	3.91e-05	0.00637	-0.22	-0.19	Motion sickness;	chr6:8563878	chr6:8784178~8785445:+
LUAD	cis	rs5758659	1	rs134902	ENSG00000182057.4	OGFRP1	4.15	3.91e-05	0.00637	0.21	0.19	Cognitive function;	chr22:42287991	chr22:42269753~42275196:+
LUAD	cis	rs7760535	0.763	rs10457240	ENSG00000271789.1	RP5-1112D6.7	-4.15	3.91e-05	0.00637	-0.2	-0.19	Metabolic traits;	chr6:111527671	chr6:111297126~111298510:+
LUAD	cis	rs9646944	0.501	rs9807934	ENSG00000234389.1	AC007278.3	4.15	3.91e-05	0.00637	0.21	0.19	Blood protein levels;	chr2:102423722	chr2:102438713~102440475:+
LUAD	cis	rs6964587	1	rs6968870	ENSG00000188693.7	CYP51A1-AS1	-4.15	3.91e-05	0.00637	-0.22	-0.19	Breast cancer;	chr7:92031797	chr7:92134604~92180725:+
LUAD	cis	rs11250098	0.583	rs66724331	ENSG00000255310.2	AF131215.2	-4.15	3.91e-05	0.00638	-0.19	-0.19	Morning vs. evening chronotype;	chr8:10931835	chr8:11107788~11109726:-
LUAD	cis	rs4713118	0.523	rs2179096	ENSG00000219392.1	RP1-265C24.5	-4.15	3.91e-05	0.00638	-0.23	-0.19	Parkinson's disease;	chr6:27698141	chr6:28115628~28116551:+
LUAD	cis	rs7772486	0.686	rs857880	ENSG00000235652.6	RP11-545I5.3	-4.15	3.91e-05	0.00638	-0.18	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145649979	chr6:145799409~145886585:+
LUAD	cis	rs4819052	0.679	rs2838859	ENSG00000215447.6	BX322557.10	-4.15	3.91e-05	0.00638	-0.21	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45264602	chr21:45288052~45291738:+
LUAD	cis	rs910316	0.934	rs8006587	ENSG00000259138.1	RP11-950C14.7	4.15	3.91e-05	0.00638	0.2	0.19	Height;	chr14:75198236	chr14:75127153~75136930:+
LUAD	cis	rs12073359	0.865	rs72692886	ENSG00000223945.2	RP11-458I7.1	-4.15	3.92e-05	0.00638	-0.28	-0.19	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150060225	chr1:150053864~150055034:+
LUAD	cis	rs11742741	0.806	rs62350768	ENSG00000248874.4	C5orf17	-4.15	3.92e-05	0.00638	-0.23	-0.19	Educational attainment;	chr5:24060208	chr5:23951348~24178263:+
LUAD	cis	rs6479891	1	rs2616630	ENSG00000232075.1	MRPL35P2	4.15	3.92e-05	0.00638	0.3	0.19	Arthritis (juvenile idiopathic);	chr10:63453579	chr10:63634317~63634827:-
LUAD	cis	rs6479891	1	rs2616629	ENSG00000232075.1	MRPL35P2	4.15	3.92e-05	0.00638	0.3	0.19	Arthritis (juvenile idiopathic);	chr10:63454056	chr10:63634317~63634827:-
LUAD	cis	rs6840360	0.901	rs4696293	ENSG00000270265.1	RP11-731D1.4	4.15	3.92e-05	0.00638	0.19	0.19	Intelligence (multi-trait analysis);	chr4:151786228	chr4:151333775~151353224:-
LUAD	cis	rs11846409	0.932	rs61233250	ENSG00000223648.3	IGHV3-64	4.15	3.92e-05	0.00638	0.22	0.19	Rheumatic heart disease;	chr14:106634072	chr14:106643132~106658258:-
LUAD	cis	rs2098713	0.534	rs10941338	ENSG00000250155.1	CTD-2353F22.1	4.15	3.92e-05	0.00638	0.21	0.19	Telomere length;	chr5:37488313	chr5:36666214~36725195:-
LUAD	cis	rs2098713	0.534	rs12522043	ENSG00000250155.1	CTD-2353F22.1	4.15	3.92e-05	0.00638	0.21	0.19	Telomere length;	chr5:37488317	chr5:36666214~36725195:-
LUAD	cis	rs11168618	0.846	rs7974213	ENSG00000240399.1	RP1-228P16.1	-4.15	3.92e-05	0.00638	-0.18	-0.19	Adiponectin levels;	chr12:48487709	chr12:48054813~48055591:-
LUAD	cis	rs8062405	0.69	rs762634	ENSG00000261419.1	RP11-57A19.4	-4.15	3.92e-05	0.00638	-0.21	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28659696~28740781:-
LUAD	cis	rs2018683	0.649	rs12536605	ENSG00000228421.2	AC005013.5	4.15	3.92e-05	0.00638	0.21	0.19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28930883	chr7:28957667~28959345:+
LUAD	cis	rs516805	0.715	rs11154087	ENSG00000279453.1	RP3-425C14.4	4.15	3.92e-05	0.00638	0.26	0.19	Lymphocyte counts;	chr6:122575484	chr6:122436789~122439223:-
LUAD	cis	rs755249	0.546	rs7533743	ENSG00000228060.1	RP11-69E11.8	4.15	3.92e-05	0.00639	0.16	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39491497	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.565	rs7555699	ENSG00000228060.1	RP11-69E11.8	4.15	3.92e-05	0.00639	0.16	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39491629	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.565	rs1809697	ENSG00000228060.1	RP11-69E11.8	4.15	3.92e-05	0.00639	0.16	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39493413	chr1:39565160~39573203:+
LUAD	cis	rs9549260	0.564	rs4943808	ENSG00000229456.1	RLIMP1	4.15	3.92e-05	0.00639	0.2	0.19	Red blood cell count;	chr13:40719814	chr13:40618738~40621348:+
LUAD	cis	rs9549260	0.564	rs4941989	ENSG00000229456.1	RLIMP1	4.15	3.92e-05	0.00639	0.2	0.19	Red blood cell count;	chr13:40725551	chr13:40618738~40621348:+
LUAD	cis	rs9549260	0.564	rs4941990	ENSG00000229456.1	RLIMP1	4.15	3.92e-05	0.00639	0.2	0.19	Red blood cell count;	chr13:40725721	chr13:40618738~40621348:+
LUAD	cis	rs12935418	0.672	rs11150334	ENSG00000261061.1	RP11-303E16.2	-4.15	3.92e-05	0.00639	-0.2	-0.19	Mean corpuscular volume;	chr16:81008937	chr16:81030770~81031485:+
LUAD	cis	rs5758659	0.935	rs134879	ENSG00000273366.1	CTA-989H11.1	-4.15	3.92e-05	0.00639	-0.21	-0.19	Cognitive function;	chr22:42268195	chr22:42278188~42278846:+
LUAD	cis	rs2348418	0.864	rs7304540	ENSG00000244712.1	RP11-874G11.1	4.15	3.92e-05	0.00639	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28560489	chr12:28564678~28565141:-
LUAD	cis	rs9309473	0.519	rs13027816	ENSG00000163016.8	ALMS1P	-4.15	3.92e-05	0.00639	-0.2	-0.19	Metabolite levels;	chr2:73670564	chr2:73644919~73685576:+
LUAD	cis	rs2348418	0.831	rs10843173	ENSG00000247934.4	RP11-967K21.1	4.15	3.92e-05	0.00639	0.21	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28453092	chr12:28163298~28190738:-
LUAD	cis	rs2348418	0.864	rs10843174	ENSG00000247934.4	RP11-967K21.1	4.15	3.92e-05	0.00639	0.21	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28453135	chr12:28163298~28190738:-
LUAD	cis	rs2348418	0.864	rs7299039	ENSG00000247934.4	RP11-967K21.1	4.15	3.92e-05	0.00639	0.21	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28454083	chr12:28163298~28190738:-
LUAD	cis	rs5742933	0.711	rs12693551	ENSG00000253559.1	OSGEPL1-AS1	4.15	3.92e-05	0.00639	0.22	0.19	Ferritin levels;	chr2:189664505	chr2:189762704~189765556:+
LUAD	cis	rs6686842	0.536	rs11209720	ENSG00000235358.1	RP11-399E6.1	-4.15	3.92e-05	0.00639	-0.22	-0.19	Height;	chr1:41224745	chr1:41242373~41284861:+
LUAD	cis	rs6686842	0.536	rs11209721	ENSG00000235358.1	RP11-399E6.1	-4.15	3.92e-05	0.00639	-0.22	-0.19	Height;	chr1:41224972	chr1:41242373~41284861:+
LUAD	cis	rs6969780	0.915	rs3807597	ENSG00000233429.8	HOTAIRM1	-4.15	3.93e-05	0.00639	-0.31	-0.19	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27149576	chr7:27095647~27100265:+
LUAD	cis	rs9649213	0.593	rs6465673	ENSG00000272950.1	RP11-307C18.1	4.15	3.93e-05	0.00639	0.23	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98339575	chr7:98322853~98323430:+
LUAD	cis	rs17772222	0.63	rs7141608	ENSG00000258789.1	RP11-507K2.3	4.15	3.93e-05	0.00639	0.22	0.19	Coronary artery calcification;	chr14:88514045	chr14:88551597~88552493:+
LUAD	cis	rs2492286	0.518	rs2811506	ENSG00000242551.2	POU5F1P6	-4.15	3.93e-05	0.0064	-0.24	-0.19	Eosinophil counts;	chr3:128610801	chr3:128674735~128677005:-
LUAD	cis	rs4474465	0.92	rs908002	ENSG00000251323.2	RP11-452H21.4	4.15	3.93e-05	0.0064	0.23	0.19	Alzheimer's disease (survival time);	chr11:78433707	chr11:78423982~78429836:-
LUAD	cis	rs950169	0.922	rs4842939	ENSG00000275120.1	RP11-182J1.17	-4.15	3.93e-05	0.0064	-0.27	-0.19	Schizophrenia;	chr15:84159214	chr15:84599434~84606463:-
LUAD	cis	rs75920871	0.688	rs76972960	ENSG00000254851.1	RP11-109L13.1	-4.15	3.93e-05	0.0064	-0.41	-0.19	Subjective well-being;	chr11:117045962	chr11:117135528~117138582:+
LUAD	cis	rs7937890	0.599	rs2597204	ENSG00000254418.1	RP11-21L19.1	4.15	3.93e-05	0.0064	0.23	0.19	Mitochondrial DNA levels;	chr11:14459471	chr11:14262846~14273691:-
LUAD	cis	rs8177876	0.642	rs10514513	ENSG00000261061.1	RP11-303E16.2	-4.15	3.93e-05	0.0064	-0.3	-0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080578	chr16:81030770~81031485:+
LUAD	cis	rs17772222	0.958	rs1123421	ENSG00000258789.1	RP11-507K2.3	-4.15	3.93e-05	0.0064	-0.25	-0.19	Coronary artery calcification;	chr14:88524651	chr14:88551597~88552493:+
LUAD	cis	rs7555523	0.887	rs2251768	ENSG00000224358.1	RP11-466F5.8	-4.15	3.93e-05	0.0064	-0.31	-0.19	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165769074	chr1:165768929~165775176:+
LUAD	cis	rs9467773	1	rs4713006	ENSG00000261353.1	CTA-14H9.5	-4.15	3.93e-05	0.00641	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26519644	chr6:26527063~26527404:+
LUAD	cis	rs9467773	0.967	rs6924865	ENSG00000261353.1	CTA-14H9.5	-4.15	3.93e-05	0.00641	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26521125	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs6925703	ENSG00000261353.1	CTA-14H9.5	-4.15	3.93e-05	0.00641	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26521361	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs6910899	ENSG00000261353.1	CTA-14H9.5	-4.15	3.93e-05	0.00641	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26524111	chr6:26527063~26527404:+
LUAD	cis	rs9467773	0.967	rs9461267	ENSG00000261353.1	CTA-14H9.5	-4.15	3.93e-05	0.00641	-0.21	-0.19	Intelligence (multi-trait analysis);	chr6:26525227	chr6:26527063~26527404:+
LUAD	cis	rs780096	0.506	rs2303369	ENSG00000234072.1	AC074117.10	-4.15	3.94e-05	0.00641	-0.14	-0.19	Total body bone mineral density;	chr2:27492549	chr2:27356246~27367622:+
LUAD	cis	rs727479	0.962	rs12592697	ENSG00000259306.2	RP11-108K3.2	-4.15	3.94e-05	0.00641	-0.2	-0.19	Estradiol levels;	chr15:51232976	chr15:51315841~51321996:+
LUAD	cis	rs13113518	1	rs13122619	ENSG00000272969.1	RP11-528I4.2	4.15	3.94e-05	0.00641	0.19	0.19	Height;	chr4:55479339	chr4:55547112~55547889:+
LUAD	cis	rs13256369	1	rs7820159	ENSG00000253893.2	FAM85B	-4.15	3.94e-05	0.00641	-0.26	-0.19	Obesity-related traits;	chr8:8718705	chr8:8167819~8226614:-
LUAD	cis	rs13256369	1	rs7843488	ENSG00000253893.2	FAM85B	-4.15	3.94e-05	0.00641	-0.26	-0.19	Obesity-related traits;	chr8:8718707	chr8:8167819~8226614:-
LUAD	cis	rs950169	0.512	rs4374136	ENSG00000259570.1	RP11-671M22.4	4.15	3.94e-05	0.00641	0.26	0.19	Schizophrenia;	chr15:83976255	chr15:84394512~84395514:+
LUAD	cis	rs7246657	0.507	rs8107654	ENSG00000267309.1	CTD-2630F21.1	4.15	3.94e-05	0.00641	0.31	0.19	Coronary artery calcification;	chr19:36962632	chr19:36489649~36491040:+
LUAD	cis	rs9500256	0.655	rs12208465	ENSG00000272316.1	XXbac-BPGBPG55C20.2	4.15	3.94e-05	0.00641	0.16	0.19	Eosinophilic esophagitis (pediatric);	chr6:58004603	chr6:57908560~57913911:-
LUAD	cis	rs4713118	0.955	rs9468204	ENSG00000280107.1	AL022393.9	-4.15	3.94e-05	0.00641	-0.24	-0.19	Parkinson's disease;	chr6:27721030	chr6:28170845~28172521:+
LUAD	cis	rs73198271	0.74	rs10094270	ENSG00000253893.2	FAM85B	4.15	3.94e-05	0.00641	0.24	0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789123	chr8:8167819~8226614:-
LUAD	cis	rs73198271	0.74	rs28521727	ENSG00000253893.2	FAM85B	4.15	3.94e-05	0.00641	0.24	0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789707	chr8:8167819~8226614:-
LUAD	cis	rs73198271	0.74	rs28402110	ENSG00000253893.2	FAM85B	4.15	3.94e-05	0.00641	0.24	0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789739	chr8:8167819~8226614:-
LUAD	cis	rs73198271	0.74	rs10098636	ENSG00000253893.2	FAM85B	4.15	3.94e-05	0.00641	0.24	0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789814	chr8:8167819~8226614:-
LUAD	cis	rs73198271	0.74	rs10112989	ENSG00000253893.2	FAM85B	4.15	3.94e-05	0.00641	0.24	0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789824	chr8:8167819~8226614:-
LUAD	cis	rs73198271	0.74	rs10113326	ENSG00000253893.2	FAM85B	4.15	3.94e-05	0.00641	0.24	0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790120	chr8:8167819~8226614:-
LUAD	cis	rs6832769	0.922	rs6825994	ENSG00000272969.1	RP11-528I4.2	-4.15	3.94e-05	0.00641	-0.19	-0.19	Personality dimensions;	chr4:55524244	chr4:55547112~55547889:+
LUAD	cis	rs2243480	1	rs316332	ENSG00000229886.1	RP5-1132H15.3	4.15	3.94e-05	0.00641	0.32	0.19	Diabetic kidney disease;	chr7:66139312	chr7:66025126~66031544:-
LUAD	cis	rs13256369	1	rs10098234	ENSG00000253893.2	FAM85B	-4.15	3.94e-05	0.00641	-0.25	-0.19	Obesity-related traits;	chr8:8719182	chr8:8167819~8226614:-
LUAD	cis	rs7208859	0.673	rs2269915	ENSG00000266490.1	CTD-2349P21.9	4.15	3.94e-05	0.00641	0.29	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906326	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs2269916	ENSG00000266490.1	CTD-2349P21.9	4.15	3.94e-05	0.00641	0.29	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906745	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs11649765	ENSG00000266490.1	CTD-2349P21.9	4.15	3.94e-05	0.00641	0.29	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906870	chr17:30792372~30792833:+
LUAD	cis	rs6686842	0.56	rs213738	ENSG00000235358.1	RP11-399E6.1	4.15	3.94e-05	0.00641	0.22	0.19	Height;	chr1:41156676	chr1:41242373~41284861:+
LUAD	cis	rs12188164	0.965	rs77101200	ENSG00000225138.6	CTD-2228K2.7	4.15	3.94e-05	0.00641	0.18	0.19	Cystic fibrosis severity;	chr5:442944	chr5:473236~480884:+
LUAD	cis	rs6142102	0.961	rs4911146	ENSG00000275784.1	RP5-1125A11.6	-4.15	3.94e-05	0.00642	-0.21	-0.19	Skin pigmentation;	chr20:34052241	chr20:33989480~33991818:-
LUAD	cis	rs17691394	0.525	rs112919097	ENSG00000224138.1	AC000123.4	4.15	3.94e-05	0.00642	0.23	0.19	Carotid atherosclerosis in HIV infection;	chr7:126537799	chr7:127350128~127351523:+
LUAD	cis	rs73242632	0.881	rs55734441	ENSG00000269949.1	RP11-738E22.3	4.15	3.94e-05	0.00642	0.45	0.19	Congenital heart disease (maternal effect);	chr4:56967551	chr4:56960927~56961373:-
LUAD	cis	rs6142102	0.961	rs4911407	ENSG00000275784.1	RP5-1125A11.6	-4.15	3.94e-05	0.00642	-0.21	-0.19	Skin pigmentation;	chr20:34095759	chr20:33989480~33991818:-
LUAD	cis	rs7119038	0.818	rs715412	ENSG00000255422.1	AP002954.4	4.15	3.95e-05	0.00642	0.29	0.19	Sjögren's syndrome;	chr11:118813901	chr11:118704607~118750263:+
LUAD	cis	rs2348418	0.864	rs7304776	ENSG00000244712.1	RP11-874G11.1	4.15	3.95e-05	0.00642	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28560634	chr12:28564678~28565141:-
LUAD	cis	rs2348418	0.864	rs11049714	ENSG00000244712.1	RP11-874G11.1	4.15	3.95e-05	0.00642	0.22	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28561162	chr12:28564678~28565141:-
LUAD	cis	rs957448	0.904	rs56302978	ENSG00000253175.1	RP11-267M23.6	4.15	3.95e-05	0.00642	0.23	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94505883	chr8:94565036~94565715:+
LUAD	cis	rs8141529	0.644	rs5752795	ENSG00000272858.1	CTA-292E10.8	-4.15	3.95e-05	0.00642	-0.21	-0.19	Lymphocyte counts;	chr22:28782832	chr22:28814914~28815662:+
LUAD	cis	rs8141529	0.732	rs2347447	ENSG00000272858.1	CTA-292E10.8	-4.15	3.95e-05	0.00642	-0.21	-0.19	Lymphocyte counts;	chr22:28783751	chr22:28814914~28815662:+
LUAD	cis	rs6787172	0.811	rs9865460	ENSG00000272087.1	RP11-379F4.7	4.15	3.95e-05	0.00642	0.2	0.19	Subjective well-being;	chr3:158494230	chr3:158693120~158693768:-
LUAD	cis	rs453301	0.571	rs2929454	ENSG00000173295.6	FAM86B3P	-4.15	3.95e-05	0.00642	-0.2	-0.19	Joint mobility (Beighton score);	chr8:9226344	chr8:8228595~8244865:+
LUAD	cis	rs5015933	0.778	rs35843221	ENSG00000232630.1	PRPS1P2	-4.15	3.95e-05	0.00642	-0.17	-0.19	Body mass index;	chr9:125251569	chr9:125150653~125151589:+
LUAD	cis	rs9788333	0.707	rs12584557	ENSG00000224429.6	LINC00539	-4.15	3.95e-05	0.00642	-0.17	-0.19	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr13:21312032	chr13:21303515~21348721:-
LUAD	cis	rs189798	0.807	rs12785	ENSG00000253981.4	ALG1L13P	4.15	3.95e-05	0.00643	0.24	0.19	Myopia (pathological);	chr8:9137426	chr8:8236003~8244667:-
LUAD	cis	rs12986445	0.843	rs11894773	ENSG00000218682.1	AC010150.1	-4.15	3.95e-05	0.00643	-0.23	-0.19	Multiple myeloma;Multiple myeloma and monoclonal gammopathy;	chr2:25852344	chr2:25856461~25856966:-
LUAD	cis	rs4474465	0.831	rs7121299	ENSG00000251323.2	RP11-452H21.4	4.15	3.95e-05	0.00643	0.23	0.19	Alzheimer's disease (survival time);	chr11:78478087	chr11:78423982~78429836:-
LUAD	cis	rs9309473	0.539	rs6732440	ENSG00000163016.8	ALMS1P	-4.15	3.95e-05	0.00643	-0.2	-0.19	Metabolite levels;	chr2:73599972	chr2:73644919~73685576:+
LUAD	cis	rs812925	0.659	rs2167565	ENSG00000271889.1	RP11-493E12.1	-4.15	3.95e-05	0.00643	-0.23	-0.19	Immature fraction of reticulocytes;	chr2:61249323	chr2:61151433~61162105:-
LUAD	cis	rs2735413	0.563	rs11640933	ENSG00000276007.1	RP11-358L22.3	4.15	3.96e-05	0.00644	0.26	0.19	Systolic blood pressure (alcohol consumption interaction);	chr16:78031710	chr16:78123243~78124332:+
LUAD	cis	rs5758659	1	rs134869	ENSG00000273366.1	CTA-989H11.1	-4.15	3.96e-05	0.00644	-0.21	-0.19	Cognitive function;	chr22:42256068	chr22:42278188~42278846:+
LUAD	cis	rs6723108	0.627	rs2197579	ENSG00000224043.6	CCNT2-AS1	-4.15	3.96e-05	0.00644	-0.23	-0.19	Type 2 diabetes;	chr2:134887408	chr2:134735464~134918710:-
LUAD	cis	rs2060793	0.741	rs7119073	ENSG00000251991.1	RNU7-49P	4.15	3.96e-05	0.00644	0.2	0.19	Vitamin D levels;	chr11:14669416	chr11:14478892~14478953:+
LUAD	cis	rs73607972	0.575	rs12926468	ENSG00000275191.1	RP11-36I17.2	-4.15	3.96e-05	0.00644	-0.23	-0.19	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53555488	chr16:53628256~53628816:-
LUAD	cis	rs7208859	0.623	rs8081299	ENSG00000280069.1	CTD-2349P21.3	-4.15	3.96e-05	0.00644	-0.25	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777278	chr17:30738182~30740275:+
LUAD	cis	rs453301	0.686	rs28482034	ENSG00000233609.3	RP11-62H7.2	-4.15	3.96e-05	0.00644	-0.16	-0.19	Joint mobility (Beighton score);	chr8:9012154	chr8:8961200~8979025:+
LUAD	cis	rs9649213	0.593	rs1468341	ENSG00000272950.1	RP11-307C18.1	4.15	3.96e-05	0.00644	0.24	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98358384	chr7:98322853~98323430:+
LUAD	cis	rs944990	0.538	rs10992788	ENSG00000227603.1	RP11-165J3.6	4.15	3.96e-05	0.00644	0.21	0.19	Body mass index;	chr9:93571377	chr9:93435332~93437121:-
LUAD	cis	rs442309	0.875	rs224066	ENSG00000238280.1	RP11-436D10.3	-4.15	3.96e-05	0.00644	-0.22	-0.19	Vogt-Koyanagi-Harada syndrome;	chr10:62746419	chr10:62793562~62805887:-
LUAD	cis	rs910316	0.934	rs7141705	ENSG00000279594.1	RP11-950C14.10	-4.15	3.96e-05	0.00644	-0.21	-0.19	Height;	chr14:75188649	chr14:75011269~75012851:-
LUAD	cis	rs9925964	0.869	rs749670	ENSG00000232748.3	RP11-196G11.6	4.15	3.96e-05	0.00644	0.23	0.19	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31077304	chr16:31056460~31062803:+
LUAD	cis	rs7493	0.755	rs13228784	ENSG00000233942.1	AC004012.1	4.15	3.96e-05	0.00644	0.26	0.19	Yu-Zhi constitution type in type 2 diabetes;	chr7:95331513	chr7:95471835~95473998:+
LUAD	cis	rs2288073	0.965	rs13387930	ENSG00000242628.4	AC009228.1	4.15	3.96e-05	0.00644	0.25	0.19	Venous thromboembolism (SNP x SNP interaction);	chr2:24191531	chr2:24214381~24221516:+
LUAD	cis	rs7819412	0.54	rs11777355	ENSG00000255046.1	RP11-297N6.4	4.15	3.96e-05	0.00645	0.22	0.19	Triglycerides;	chr8:11187180	chr8:11797928~11802568:-
LUAD	cis	rs7208859	0.614	rs9914534	ENSG00000280069.1	CTD-2349P21.3	-4.15	3.96e-05	0.00645	-0.25	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30875646	chr17:30738182~30740275:+
LUAD	cis	rs11707813	0.593	rs62267453	ENSG00000226360.5	RPL10AP6	-4.15	3.96e-05	0.00645	-0.2	-0.19	Lip morphology;	chr3:61204177	chr3:61742455~61743106:-
LUAD	cis	rs11707813	0.544	rs9815151	ENSG00000226360.5	RPL10AP6	-4.15	3.96e-05	0.00645	-0.2	-0.19	Lip morphology;	chr3:61219678	chr3:61742455~61743106:-
LUAD	cis	rs2836974	0.583	rs9981884	ENSG00000255568.3	BRWD1-AS2	4.15	3.97e-05	0.00645	0.18	0.19	Cognitive function;	chr21:39213707	chr21:39313935~39314962:+
LUAD	cis	rs2274273	0.773	rs8012380	ENSG00000258413.1	RP11-665C16.6	-4.15	3.97e-05	0.00645	-0.24	-0.19	Protein biomarker;	chr14:55268292	chr14:55262767~55272075:-
LUAD	cis	rs30380	0.734	rs27044	ENSG00000272109.1	CTD-2260A17.3	-4.15	3.97e-05	0.00645	-0.21	-0.19	Cerebrospinal fluid biomarker levels;	chr5:96783148	chr5:96804353~96806105:+
LUAD	cis	rs30380	0.69	rs27432	ENSG00000272109.1	CTD-2260A17.3	-4.15	3.97e-05	0.00645	-0.21	-0.19	Cerebrospinal fluid biomarker levels;	chr5:96783569	chr5:96804353~96806105:+
LUAD	cis	rs10463554	0.853	rs257309	ENSG00000250682.4	LINC00491	4.15	3.97e-05	0.00646	0.22	0.19	Parkinson's disease;	chr5:103082900	chr5:102609156~102671559:-
LUAD	cis	rs1005277	0.54	rs4934907	ENSG00000273019.1	RP11-508N22.13	-4.15	3.97e-05	0.00646	-0.21	-0.19	Extrinsic epigenetic age acceleration;	chr10:37726302	chr10:38149968~38150293:+
LUAD	cis	rs1005277	0.54	rs11011351	ENSG00000273019.1	RP11-508N22.13	-4.15	3.97e-05	0.00646	-0.21	-0.19	Extrinsic epigenetic age acceleration;	chr10:37741597	chr10:38149968~38150293:+
LUAD	cis	rs858239	0.539	rs6461695	ENSG00000230042.1	AK3P3	-4.15	3.97e-05	0.00646	-0.24	-0.19	Cerebrospinal fluid biomarker levels;	chr7:23158165	chr7:23129178~23129841:+
LUAD	cis	rs13113518	0.812	rs6849474	ENSG00000272969.1	RP11-528I4.2	4.15	3.97e-05	0.00646	0.2	0.19	Height;	chr4:55452295	chr4:55547112~55547889:+
LUAD	cis	rs712022	0.967	rs10766971	ENSG00000246225.5	RP11-17A1.3	-4.15	3.97e-05	0.00646	-0.22	-0.19	Dialysis-related mortality;	chr11:22832005	chr11:22829380~22945393:+
LUAD	cis	rs1799949	0.965	rs34633610	ENSG00000236383.6	LINC00854	-4.15	3.97e-05	0.00646	-0.15	-0.19	Menopause (age at onset);	chr17:43342017	chr17:43216941~43305976:-
LUAD	cis	rs1799949	0.965	rs11654051	ENSG00000236383.6	LINC00854	-4.15	3.97e-05	0.00646	-0.15	-0.19	Menopause (age at onset);	chr17:43342288	chr17:43216941~43305976:-
LUAD	cis	rs1799949	0.93	rs56729776	ENSG00000236383.6	LINC00854	-4.15	3.97e-05	0.00646	-0.15	-0.19	Menopause (age at onset);	chr17:43344763	chr17:43216941~43305976:-
LUAD	cis	rs62244186	0.566	rs3762636	ENSG00000233509.2	ZNF197-AS1	4.15	3.97e-05	0.00646	0.2	0.19	Depressive symptoms;	chr3:44813071	chr3:44617128~44624797:-
LUAD	cis	rs2548724	0.645	rs62372171	ENSG00000250682.4	LINC00491	4.15	3.97e-05	0.00646	0.22	0.19	Type 2 diabetes;	chr5:102298873	chr5:102609156~102671559:-
LUAD	cis	rs1552244	0.882	rs6443279	ENSG00000180385.7	EMC3-AS1	4.15	3.98e-05	0.00646	0.22	0.19	Alzheimer's disease;	chr3:10011915	chr3:9986893~10006990:+
LUAD	cis	rs17767294	1	rs17767294	ENSG00000280107.1	AL022393.9	-4.15	3.98e-05	0.00646	-0.4	-0.19	Parkinson's disease;	chr6:28086420	chr6:28170845~28172521:+
LUAD	cis	rs12444979	0.517	rs75594829	ENSG00000261195.1	CTD-2380F24.1	-4.15	3.98e-05	0.00646	-0.25	-0.19	Body mass index;	chr16:19783001	chr16:19761172~19766099:-
LUAD	cis	rs12446554	0.528	rs117650757	ENSG00000261195.1	CTD-2380F24.1	-4.15	3.98e-05	0.00646	-0.25	-0.19	Obesity;	chr16:19783003	chr16:19761172~19766099:-
LUAD	cis	rs9341808	0.556	rs1474791	ENSG00000260645.1	RP11-250B2.5	4.15	3.98e-05	0.00647	0.18	0.19	Sitting height ratio;	chr6:80323380	chr6:80466958~80469080:+
LUAD	cis	rs6751744	0.513	rs7563368	ENSG00000230783.1	AC009961.2	4.15	3.98e-05	0.00647	0.22	0.19	Dysphagia;	chr2:159600564	chr2:159689217~159690291:-
LUAD	cis	rs1864585	0.52	rs73208773	ENSG00000255046.1	RP11-297N6.4	4.15	3.98e-05	0.00647	0.26	0.19	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10809281	chr8:11797928~11802568:-
LUAD	cis	rs1431005	1	rs12650667	ENSG00000250658.1	RP11-138B4.1	4.15	3.98e-05	0.00647	0.23	0.19	Response to statin therapy;	chr4:187424873	chr4:187304083~187309682:-
LUAD	cis	rs17772222	0.958	rs1816372	ENSG00000258789.1	RP11-507K2.3	-4.15	3.98e-05	0.00647	-0.26	-0.19	Coronary artery calcification;	chr14:88507033	chr14:88551597~88552493:+
LUAD	cis	rs10771431	0.597	rs10843144	ENSG00000111788.10	RP11-22B23.1	4.15	3.98e-05	0.00647	0.16	0.19	Breast size;	chr12:9204981	chr12:9277235~9313241:+
LUAD	cis	rs13113518	0.812	rs4864996	ENSG00000272969.1	RP11-528I4.2	4.15	3.98e-05	0.00647	0.2	0.19	Height;	chr4:55452921	chr4:55547112~55547889:+
LUAD	cis	rs2929278	0.617	rs4617832	ENSG00000166763.7	STRCP1	-4.15	3.98e-05	0.00647	-0.22	-0.19	Schizophrenia;	chr15:43738381	chr15:43699488~43718184:-
LUAD	cis	rs651907	0.535	rs11919389	ENSG00000244119.1	PDCL3P4	4.15	3.98e-05	0.00647	0.18	0.19	Colorectal cancer;	chr3:101705614	chr3:101712472~101713191:+
LUAD	cis	rs651907	0.514	rs55654108	ENSG00000244119.1	PDCL3P4	4.15	3.98e-05	0.00647	0.18	0.19	Colorectal cancer;	chr3:101706859	chr3:101712472~101713191:+
LUAD	cis	rs8106542	0.906	rs2288904	ENSG00000267100.1	ILF3-AS1	4.15	3.98e-05	0.00647	0.22	0.19	Platelet distribution width;	chr19:10631494	chr19:10651862~10653844:-
LUAD	cis	rs7005380	0.58	rs13263296	ENSG00000279347.1	RP11-85I17.2	-4.15	3.98e-05	0.00647	-0.16	-0.19	Interstitial lung disease;	chr8:119874305	chr8:119838736~119840385:-
LUAD	cis	rs6860806	0.661	rs6871350	ENSG00000233006.5	AC034220.3	4.15	3.98e-05	0.00647	0.17	0.19	Breast cancer;	chr5:132244527	chr5:132311285~132369916:-
LUAD	cis	rs1401999	1	rs4148579	ENSG00000223882.1	ABCC5-AS1	-4.15	3.98e-05	0.00647	-0.19	-0.19	Anterior chamber depth;	chr3:183967461	chr3:184006338~184011419:+
LUAD	cis	rs6125597	0.967	rs6067025	ENSG00000230758.1	SNAP23P	4.15	3.98e-05	0.00647	0.19	0.19	Intelligence (multi-trait analysis);	chr20:49237483	chr20:49038357~49038602:-
LUAD	cis	rs2348418	0.864	rs2137073	ENSG00000244712.1	RP11-874G11.1	-4.15	3.98e-05	0.00647	-0.22	-0.19	Lung function (FEV1);Lung function (FVC);	chr12:28564151	chr12:28564678~28565141:-
LUAD	cis	rs2354432	0.607	rs59606861	ENSG00000226015.2	CCT8P1	4.15	3.98e-05	0.00647	0.34	0.19	Mitochondrial DNA levels;	chr1:147289796	chr1:147203276~147204932:-
LUAD	cis	rs9896933	0.732	rs590886	ENSG00000262663.1	RP11-497H17.1	-4.15	3.98e-05	0.00647	-0.21	-0.19	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr17:82809474	chr17:82918282~82918785:+
LUAD	cis	rs4374383	0.884	rs7592909	ENSG00000207383.1	Y_RNA	-4.15	3.98e-05	0.00647	-0.22	-0.19	Hepatitis C induced liver fibrosis;	chr2:111994565	chr2:112579484~112579584:-
LUAD	cis	rs875971	0.545	rs313830	ENSG00000222364.1	RNU6-96P	4.15	3.99e-05	0.00648	0.25	0.19	Aortic root size;	chr7:66086944	chr7:66395191~66395286:+
LUAD	cis	rs7119	0.604	rs1055691	ENSG00000259362.2	RP11-307C19.1	4.15	3.99e-05	0.00648	0.23	0.19	Type 2 diabetes;	chr15:77572283	chr15:77525540~77534110:+
LUAD	cis	rs853679	0.55	rs1150689	ENSG00000226314.6	ZNF192P1	-4.15	3.99e-05	0.00648	-0.24	-0.19	Depression;	chr6:28197321	chr6:28161781~28169594:+
LUAD	cis	rs763121	0.853	rs4821811	ENSG00000225450.1	RP3-508I15.14	-4.15	3.99e-05	0.00648	-0.18	-0.19	Menopause (age at onset);	chr22:38679140	chr22:38739003~38749041:+
LUAD	cis	rs763121	0.853	rs3827357	ENSG00000225450.1	RP3-508I15.14	-4.15	3.99e-05	0.00648	-0.18	-0.19	Menopause (age at onset);	chr22:38683408	chr22:38739003~38749041:+
LUAD	cis	rs2154319	0.609	rs12131741	ENSG00000235358.1	RP11-399E6.1	-4.15	3.99e-05	0.00648	-0.22	-0.19	Height;	chr1:41249191	chr1:41242373~41284861:+
LUAD	cis	rs2154319	0.609	rs12139276	ENSG00000235358.1	RP11-399E6.1	-4.15	3.99e-05	0.00648	-0.22	-0.19	Height;	chr1:41249201	chr1:41242373~41284861:+
LUAD	cis	rs12073359	1	rs12074281	ENSG00000223945.2	RP11-458I7.1	-4.15	3.99e-05	0.00648	-0.27	-0.19	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150053395	chr1:150053864~150055034:+
LUAD	cis	rs12073359	1	rs7540847	ENSG00000223945.2	RP11-458I7.1	-4.15	3.99e-05	0.00648	-0.27	-0.19	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150054837	chr1:150053864~150055034:+
LUAD	cis	rs2147959	0.882	rs4653551	ENSG00000269934.1	RP5-1139B12.3	4.15	3.99e-05	0.00648	0.24	0.19	Adult asthma;	chr1:228440212	chr1:228274584~228276066:-
LUAD	cis	rs7840202	0.961	rs10283189	ENSG00000253328.2	SUMO2P19	-4.15	3.99e-05	0.00648	-0.21	-0.19	Rate of cognitive decline in mild cognitive impairment (time interaction);Gestational age at birth in labor-initiated deliveries (child effect);	chr8:102352501	chr8:102242040~102242619:-
LUAD	cis	rs750134	0.901	rs17040872	ENSG00000257221.1	RP11-689B22.2	-4.15	3.99e-05	0.00648	-0.27	-0.19	Low high density lipoprotein cholesterol levels;	chr12:108693217	chr12:108628687~108641318:+
LUAD	cis	rs854765	0.724	rs62072049	ENSG00000223979.2	SMCR2	-4.15	3.99e-05	0.00648	-0.21	-0.19	Total body bone mineral density;	chr17:18003206	chr17:17674026~17677688:-
LUAD	cis	rs3018712	0.532	rs2513294	ENSG00000212093.1	AP000807.1	-4.15	3.99e-05	0.00648	-0.24	-0.19	Total body bone mineral density;	chr11:68653726	chr11:68506083~68506166:-
LUAD	cis	rs7937682	1	rs11608122	ENSG00000230911.1	PPIHP1	4.15	3.99e-05	0.00649	0.25	0.19	Primary sclerosing cholangitis;	chr11:111664381	chr11:112029858~112030367:-
LUAD	cis	rs2243480	1	rs316326	ENSG00000229886.1	RP5-1132H15.3	4.15	3.99e-05	0.00649	0.32	0.19	Diabetic kidney disease;	chr7:66144466	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs316325	ENSG00000229886.1	RP5-1132H15.3	4.15	3.99e-05	0.00649	0.32	0.19	Diabetic kidney disease;	chr7:66144531	chr7:66025126~66031544:-
LUAD	cis	rs8113308	0.81	rs17695737	ENSG00000269483.1	AC006272.1	4.15	3.99e-05	0.00649	0.31	0.19	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51942283	chr19:51839924~51843324:-
LUAD	cis	rs1334894	0.792	rs9688674	ENSG00000228559.1	RP3-340B19.3	-4.15	3.99e-05	0.00649	-0.43	-0.19	Coronary artery disease;	chr6:35510027	chr6:35544632~35545669:+
LUAD	cis	rs1816752	0.905	rs3818938	ENSG00000273628.1	RP11-756A22.7	4.15	3.99e-05	0.00649	0.22	0.19	Obesity-related traits;	chr13:24454945	chr13:24933006~24936796:+
LUAD	cis	rs6496044	0.568	rs11855789	ENSG00000259295.5	CSPG4P12	4.15	3.99e-05	0.00649	0.21	0.19	Interstitial lung disease;	chr15:85523172	chr15:85191438~85213905:+
LUAD	cis	rs737008	1	rs737008	ENSG00000262703.1	RP11-485G7.6	-4.15	3.99e-05	0.00649	-0.18	-0.19	Obesity-related traits;	chr16:11281009	chr16:11348143~11349321:-
LUAD	cis	rs55670112	0.77	rs1382784	ENSG00000271797.1	CTC-428G20.6	-4.15	3.99e-05	0.00649	-0.2	-0.19	Epilepsy;	chr5:114795168	chr5:115262505~115263448:+
LUAD	cis	rs8062405	0.69	rs62034351	ENSG00000251417.2	RP11-1348G14.4	-4.15	4e-05	0.00649	-0.19	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28802743~28817828:+
LUAD	cis	rs7714584	1	rs9324660	ENSG00000197083.10	ZNF300P1	4.15	4e-05	0.00649	0.35	0.19	Crohn's disease;	chr5:150877492	chr5:150930645~150946289:-
LUAD	cis	rs9951698	0.66	rs12955780	ENSG00000267480.1	RP11-703I16.1	-4.15	4e-05	0.00649	-0.23	-0.19	Intelligence (multi-trait analysis);	chr18:12982761	chr18:12031178~12032181:-
LUAD	cis	rs755249	0.567	rs61779275	ENSG00000182109.6	RP11-69E11.4	4.15	4e-05	0.00649	0.23	0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39354638	chr1:39522280~39546187:-
LUAD	cis	rs12188164	0.965	rs56146525	ENSG00000225138.6	CTD-2228K2.7	4.15	4e-05	0.0065	0.18	0.19	Cystic fibrosis severity;	chr5:442456	chr5:473236~480884:+
LUAD	cis	rs10971721	0.822	rs10971838	ENSG00000260947.1	RP11-384P7.7	4.15	4e-05	0.0065	0.39	0.19	Body mass index;	chr9:33997948	chr9:33697459~33700986:+
LUAD	cis	rs9595908	0.746	rs12427832	ENSG00000281026.1	N4BP2L2-IT2	4.15	4e-05	0.0065	0.11	0.19	Body mass index;	chr13:32644896	chr13:32504506~32509395:-
LUAD	cis	rs9341808	0.591	rs6454147	ENSG00000260645.1	RP11-250B2.5	4.15	4e-05	0.0065	0.18	0.19	Sitting height ratio;	chr6:80206611	chr6:80466958~80469080:+
LUAD	cis	rs9341808	0.754	rs9341811	ENSG00000260645.1	RP11-250B2.5	4.15	4e-05	0.0065	0.17	0.19	Sitting height ratio;	chr6:80272984	chr6:80466958~80469080:+
LUAD	cis	rs10762651	0.522	rs11001275	ENSG00000213731.2	RAB5CP1	4.15	4e-05	0.0065	0.34	0.19	Anxiety disorder;	chr10:75065875	chr10:74423435~74424014:-
LUAD	cis	rs2274273	0.682	rs7151224	ENSG00000258413.1	RP11-665C16.6	-4.15	4e-05	0.0065	-0.23	-0.19	Protein biomarker;	chr14:55050544	chr14:55262767~55272075:-
LUAD	cis	rs7160336	0.641	rs4899503	ENSG00000259065.1	RP5-1021I20.1	4.15	4e-05	0.0065	0.21	0.19	Blood protein levels;	chr14:74217234	chr14:73787360~73803270:+
LUAD	cis	rs6071166	0.683	rs6027333	ENSG00000224635.1	RP4-564F22.5	-4.15	4.01e-05	0.0065	-0.21	-0.19	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38694620	chr20:38406011~38416797:-
LUAD	cis	rs6071166	0.683	rs1830609	ENSG00000224635.1	RP4-564F22.5	-4.15	4.01e-05	0.0065	-0.21	-0.19	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38696382	chr20:38406011~38416797:-
LUAD	cis	rs2348418	0.966	rs11049694	ENSG00000247934.4	RP11-967K21.1	4.15	4.01e-05	0.00651	0.21	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28527925	chr12:28163298~28190738:-
LUAD	cis	rs6840360	0.692	rs4479686	ENSG00000270265.1	RP11-731D1.4	-4.15	4.01e-05	0.00651	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151478172	chr4:151333775~151353224:-
LUAD	cis	rs200986	1	rs200986	ENSG00000280107.1	AL022393.9	-4.15	4.01e-05	0.00651	-0.23	-0.19	Autism spectrum disorder or schizophrenia;	chr6:27856988	chr6:28170845~28172521:+
LUAD	cis	rs910316	1	rs3742778	ENSG00000279594.1	RP11-950C14.10	-4.15	4.01e-05	0.00651	-0.21	-0.19	Height;	chr14:75071514	chr14:75011269~75012851:-
LUAD	cis	rs7191700	0.673	rs12325495	ENSG00000262703.1	RP11-485G7.6	4.15	4.01e-05	0.00651	0.17	0.19	Multiple sclerosis;	chr16:11324471	chr16:11348143~11349321:-
LUAD	cis	rs780096	0.526	rs72819536	ENSG00000234072.1	AC074117.10	-4.15	4.01e-05	0.00651	-0.14	-0.19	Total body bone mineral density;	chr2:27459983	chr2:27356246~27367622:+
LUAD	cis	rs780096	0.526	rs11127013	ENSG00000234072.1	AC074117.10	-4.15	4.01e-05	0.00651	-0.14	-0.19	Total body bone mineral density;	chr2:27470106	chr2:27356246~27367622:+
LUAD	cis	rs7119	0.634	rs2667782	ENSG00000259362.2	RP11-307C19.1	4.15	4.01e-05	0.00651	0.23	0.19	Type 2 diabetes;	chr15:77569954	chr15:77525540~77534110:+
LUAD	cis	rs7119	0.604	rs2667783	ENSG00000259362.2	RP11-307C19.1	4.15	4.01e-05	0.00651	0.23	0.19	Type 2 diabetes;	chr15:77570187	chr15:77525540~77534110:+
LUAD	cis	rs7119	0.604	rs2458035	ENSG00000259362.2	RP11-307C19.1	4.15	4.01e-05	0.00651	0.23	0.19	Type 2 diabetes;	chr15:77570464	chr15:77525540~77534110:+
LUAD	cis	rs12073359	0.908	rs7521783	ENSG00000223945.2	RP11-458I7.1	-4.15	4.01e-05	0.00651	-0.27	-0.19	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150170994	chr1:150053864~150055034:+
LUAD	cis	rs8073060	0.586	rs2428464	ENSG00000267592.1	CTC-507E2.2	4.15	4.01e-05	0.00651	0.27	0.19	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35694975	chr17:35596904~35597128:-
LUAD	cis	rs17772222	0.917	rs58550317	ENSG00000258789.1	RP11-507K2.3	-4.15	4.01e-05	0.00651	-0.26	-0.19	Coronary artery calcification;	chr14:88775243	chr14:88551597~88552493:+
LUAD	cis	rs9467773	1	rs9357010	ENSG00000261353.1	CTA-14H9.5	-4.15	4.01e-05	0.00651	-0.2	-0.19	Intelligence (multi-trait analysis);	chr6:26527717	chr6:26527063~26527404:+
LUAD	cis	rs3742264	1	rs9316180	ENSG00000235903.6	CPB2-AS1	4.15	4.01e-05	0.00651	0.23	0.19	Blood protein levels;	chr13:46067550	chr13:46052806~46113332:+
LUAD	cis	rs73242632	1	rs12511480	ENSG00000269949.1	RP11-738E22.3	-4.15	4.01e-05	0.00651	-0.44	-0.19	Congenital heart disease (maternal effect);	chr4:56881977	chr4:56960927~56961373:-
LUAD	cis	rs6723108	0.517	rs6430553	ENSG00000224043.6	CCNT2-AS1	-4.15	4.01e-05	0.00651	-0.23	-0.19	Type 2 diabetes;	chr2:134873830	chr2:134735464~134918710:-
LUAD	cis	rs73198271	0.583	rs11781985	ENSG00000253893.2	FAM85B	-4.15	4.01e-05	0.00651	-0.25	-0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8732273	chr8:8167819~8226614:-
LUAD	cis	rs7204230	1	rs7189240	ENSG00000261291.1	RP11-295M3.2	4.15	4.01e-05	0.00651	0.23	0.19	Fibrinogen;	chr16:53230026	chr16:53168522~53169450:+
LUAD	cis	rs860295	0.639	rs10908469	ENSG00000225855.5	RUSC1-AS1	4.15	4.01e-05	0.00651	0.13	0.19	Body mass index;	chr1:155498941	chr1:155316863~155324176:-
LUAD	cis	rs2657294	0.965	rs7088974	ENSG00000226051.5	ZNF503-AS1	-4.15	4.01e-05	0.00652	-0.25	-0.19	Pneumonia;	chr10:75131338	chr10:75269819~75373500:+
LUAD	cis	rs6496932	0.865	rs4842879	ENSG00000259630.2	CTD-2262B20.1	4.15	4.01e-05	0.00652	0.27	0.19	Central corneal thickness;Corneal structure;	chr15:85381657	chr15:85415228~85415633:+
LUAD	cis	rs2273156	0.57	rs2143950	ENSG00000226677.3	IGBP1P1	-4.15	4.01e-05	0.00652	-0.29	-0.19	Immunoglobulin light chain (AL) amyloidosis;	chr14:35103151	chr14:34939324~34940332:+
LUAD	cis	rs2735413	0.632	rs111694993	ENSG00000276007.1	RP11-358L22.3	4.15	4.01e-05	0.00652	0.23	0.19	Systolic blood pressure (alcohol consumption interaction);	chr16:78060414	chr16:78123243~78124332:+
LUAD	cis	rs11122895	0.716	rs7605443	ENSG00000236307.2	EEF1E1P1	-4.15	4.01e-05	0.00652	-0.21	-0.19	Allergic sensitization;	chr2:111716295	chr2:111887914~111888741:+
LUAD	cis	rs35522438	1	rs35522438	ENSG00000188693.7	CYP51A1-AS1	-4.15	4.01e-05	0.00652	-0.22	-0.19	Breast cancer;	chr7:92243558	chr7:92134604~92180725:+
LUAD	cis	rs6121246	0.909	rs7354225	ENSG00000230613.1	HM13-AS1	4.15	4.01e-05	0.00652	0.29	0.19	Mean corpuscular hemoglobin;	chr20:31709078	chr20:31567707~31573263:-
LUAD	cis	rs11051970	0.553	rs325419	ENSG00000274964.1	RP11-817I4.1	-4.15	4.02e-05	0.00652	-0.19	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr12:32419526	chr12:32339368~32340724:+
LUAD	cis	rs11051970	0.594	rs325418	ENSG00000274964.1	RP11-817I4.1	-4.15	4.02e-05	0.00652	-0.19	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr12:32419583	chr12:32339368~32340724:+
LUAD	cis	rs6558530	0.666	rs6558526	ENSG00000253982.1	CTD-2336O2.1	4.14	4.02e-05	0.00652	0.24	0.19	Systolic blood pressure;	chr8:1754406	chr8:1761990~1764502:-
LUAD	cis	rs2354432	0.607	rs59689207	ENSG00000226015.2	CCT8P1	4.14	4.02e-05	0.00652	0.34	0.19	Mitochondrial DNA levels;	chr1:147250829	chr1:147203276~147204932:-
LUAD	cis	rs897984	0.806	rs8052245	ENSG00000232748.3	RP11-196G11.6	4.14	4.02e-05	0.00652	0.23	0.19	Dementia with Lewy bodies;	chr16:30905109	chr16:31056460~31062803:+
LUAD	cis	rs6088580	0.66	rs6087592	ENSG00000276073.1	RP5-1125A11.7	-4.14	4.02e-05	0.00652	-0.18	-0.19	Glomerular filtration rate (creatinine);	chr20:34526698	chr20:33985617~33988989:-
LUAD	cis	rs6568686	0.577	rs174391	ENSG00000255389.1	C6orf3	4.14	4.02e-05	0.00652	0.25	0.19	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111596745	chr6:111599875~111602295:+
LUAD	cis	rs11673344	0.536	rs62108291	ENSG00000226686.6	LINC01535	4.14	4.02e-05	0.00652	0.22	0.19	Obesity-related traits;	chr19:37659457	chr19:37251912~37265535:+
LUAD	cis	rs1154275	0.524	rs7616900	ENSG00000242770.2	RP11-180K7.1	4.14	4.02e-05	0.00652	0.19	0.19	Takotsubo syndrome;	chr3:112783067	chr3:112802478~112812819:+
LUAD	cis	rs6910061	1	rs36067344	ENSG00000247925.2	RP3-510L9.1	-4.14	4.02e-05	0.00653	-0.26	-0.19	Diabetic kidney disease;	chr6:11094531	chr6:11173452~11259099:+
LUAD	cis	rs10829156	0.699	rs10764584	ENSG00000240291.1	RP11-499P20.2	-4.14	4.02e-05	0.00653	-0.17	-0.19	Sudden cardiac arrest;	chr10:18546396	chr10:18513115~18545651:-
LUAD	cis	rs2274273	0.624	rs66551709	ENSG00000258413.1	RP11-665C16.6	-4.14	4.02e-05	0.00653	-0.25	-0.19	Protein biomarker;	chr14:55324304	chr14:55262767~55272075:-
LUAD	cis	rs3177980	0.554	rs11576078	ENSG00000239494.2	RN7SL333P	-4.14	4.02e-05	0.00653	-0.18	-0.19	Amyotrophic lateral sclerosis;	chr1:169812968	chr1:169859756~169860052:+
LUAD	cis	rs4843747	0.518	rs4072777	ENSG00000205037.2	RP11-863P13.4	4.14	4.02e-05	0.00653	0.26	0.19	Menopause (age at onset);	chr16:88073424	chr16:88088041~88100985:-
LUAD	cis	rs957448	0.948	rs11992893	ENSG00000253175.1	RP11-267M23.6	4.14	4.02e-05	0.00653	0.23	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94508473	chr8:94565036~94565715:+
LUAD	cis	rs957448	1	rs12678305	ENSG00000253175.1	RP11-267M23.6	4.14	4.02e-05	0.00653	0.23	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94508911	chr8:94565036~94565715:+
LUAD	cis	rs957448	1	rs1048029	ENSG00000253175.1	RP11-267M23.6	4.14	4.02e-05	0.00653	0.23	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94510149	chr8:94565036~94565715:+
LUAD	cis	rs7870753	0.578	rs10990768	ENSG00000188801.9	ZNF322P1	4.14	4.03e-05	0.00653	0.32	0.19	Height;	chr9:96373241	chr9:97198303~97199511:-
LUAD	cis	rs17772222	0.917	rs61984708	ENSG00000258789.1	RP11-507K2.3	-4.14	4.03e-05	0.00653	-0.26	-0.19	Coronary artery calcification;	chr14:88565523	chr14:88551597~88552493:+
LUAD	cis	rs11667325	1	rs4802867	ENSG00000268316.1	AC006272.2	-4.14	4.03e-05	0.00653	-0.19	-0.19	Neutrophil percentage of granulocytes;	chr19:51796632	chr19:51839771~51840945:-
LUAD	cis	rs7824557	0.545	rs34482136	ENSG00000255046.1	RP11-297N6.4	4.14	4.03e-05	0.00653	0.23	0.19	Retinal vascular caliber;	chr8:11370376	chr8:11797928~11802568:-
LUAD	cis	rs12986445	0.793	rs6747116	ENSG00000218682.1	AC010150.1	4.14	4.03e-05	0.00654	0.23	0.19	Multiple myeloma;Multiple myeloma and monoclonal gammopathy;	chr2:25746860	chr2:25856461~25856966:-
LUAD	cis	rs301901	0.965	rs13170811	ENSG00000250155.1	CTD-2353F22.1	-4.14	4.03e-05	0.00654	-0.19	-0.19	Height;	chr5:36795628	chr5:36666214~36725195:-
LUAD	cis	rs7555523	0.887	rs12691499	ENSG00000224358.1	RP11-466F5.8	-4.14	4.03e-05	0.00654	-0.32	-0.19	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165718428	chr1:165768929~165775176:+
LUAD	cis	rs7555523	0.83	rs12691500	ENSG00000224358.1	RP11-466F5.8	-4.14	4.03e-05	0.00654	-0.32	-0.19	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165718524	chr1:165768929~165775176:+
LUAD	cis	rs112029703	1	rs112029703	ENSG00000214293.7	APTR	4.14	4.03e-05	0.00654	0.25	0.19	Glomerular filtration rate (creatinine);	chr7:77609361	chr7:77657660~77696265:-
LUAD	cis	rs11242704	0.632	rs2816292	ENSG00000272279.1	RP11-157J24.2	-4.14	4.03e-05	0.00654	-0.27	-0.19	Response to hepatitis C treatment;	chr6:1537983	chr6:1528364~1528911:-
LUAD	cis	rs4938303	0.549	rs11216096	ENSG00000254851.1	RP11-109L13.1	4.14	4.03e-05	0.00654	0.25	0.19	Triglycerides;	chr11:116691864	chr11:117135528~117138582:+
LUAD	cis	rs2274273	0.653	rs1209087	ENSG00000258413.1	RP11-665C16.6	4.14	4.03e-05	0.00654	0.23	0.19	Protein biomarker;	chr14:55026502	chr14:55262767~55272075:-
LUAD	cis	rs73607972	0.66	rs9923447	ENSG00000275191.1	RP11-36I17.2	-4.14	4.03e-05	0.00654	-0.24	-0.19	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53609191	chr16:53628256~53628816:-
LUAD	cis	rs8049040	0.609	rs9940485	ENSG00000260886.1	TAT-AS1	4.14	4.04e-05	0.00655	0.22	0.19	Blood protein levels;	chr16:71452202	chr16:71565789~71578187:+
LUAD	cis	rs6969780	0.915	rs7341470	ENSG00000233429.8	HOTAIRM1	-4.14	4.04e-05	0.00655	-0.29	-0.19	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27145223	chr7:27095647~27100265:+
LUAD	cis	rs9287719	0.935	rs10803723	ENSG00000243819.4	RN7SL832P	4.14	4.04e-05	0.00655	0.2	0.19	Prostate cancer;	chr2:10582751	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.935	rs6751075	ENSG00000243819.4	RN7SL832P	4.14	4.04e-05	0.00655	0.2	0.19	Prostate cancer;	chr2:10583420	chr2:10690344~10692099:+
LUAD	cis	rs9309473	0.519	rs12618600	ENSG00000163016.8	ALMS1P	-4.14	4.04e-05	0.00655	-0.2	-0.19	Metabolite levels;	chr2:73663555	chr2:73644919~73685576:+
LUAD	cis	rs853679	0.517	rs6932109	ENSG00000280107.1	AL022393.9	4.14	4.04e-05	0.00655	0.24	0.19	Depression;	chr6:28110525	chr6:28170845~28172521:+
LUAD	cis	rs1979679	0.918	rs11049529	ENSG00000278733.1	RP11-425D17.1	4.14	4.04e-05	0.00655	0.24	0.19	Ossification of the posterior longitudinal ligament of the spine;	chr12:28318571	chr12:28185625~28186190:-
LUAD	cis	rs13113518	0.812	rs13140590	ENSG00000272969.1	RP11-528I4.2	4.14	4.04e-05	0.00655	0.2	0.19	Height;	chr4:55548666	chr4:55547112~55547889:+
LUAD	cis	rs467650	0.782	rs56264044	ENSG00000248489.1	CTD-2007H13.3	4.14	4.04e-05	0.00655	0.2	0.19	Venous thromboembolism (SNP x SNP interaction);	chr5:98724439	chr5:98929171~98995013:+
LUAD	cis	rs8062405	0.755	rs1074631	ENSG00000261419.1	RP11-57A19.4	4.14	4.04e-05	0.00656	0.2	0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28659696~28740781:-
LUAD	cis	rs8180040	0.874	rs11130123	ENSG00000271161.1	BOLA2P2	4.14	4.04e-05	0.00656	0.18	0.19	Colorectal cancer;	chr3:47244422	chr3:47499841~47500407:+
LUAD	cis	rs2836974	0.897	rs7280375	ENSG00000232608.1	TIMM9P2	4.14	4.04e-05	0.00656	0.22	0.19	Cognitive function;	chr21:39180482	chr21:39216624~39217506:+
LUAD	cis	rs9649213	0.613	rs7777415	ENSG00000272950.1	RP11-307C18.1	4.14	4.04e-05	0.00656	0.23	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98329902	chr7:98322853~98323430:+
LUAD	cis	rs7893279	0.505	rs7923480	ENSG00000225527.1	RP11-383B4.4	4.14	4.04e-05	0.00656	0.27	0.19	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18616736	chr10:18531849~18533336:-
LUAD	cis	rs2337406	0.641	rs10133227	ENSG00000211974.3	IGHV2-70	4.14	4.04e-05	0.00656	0.24	0.19	Alzheimer's disease (late onset);	chr14:106814260	chr14:106723574~106724093:-
LUAD	cis	rs442309	0.846	rs224133	ENSG00000238280.1	RP11-436D10.3	-4.14	4.04e-05	0.00656	-0.23	-0.19	Vogt-Koyanagi-Harada syndrome;	chr10:62706743	chr10:62793562~62805887:-
LUAD	cis	rs442309	0.819	rs224134	ENSG00000238280.1	RP11-436D10.3	-4.14	4.04e-05	0.00656	-0.23	-0.19	Vogt-Koyanagi-Harada syndrome;	chr10:62706867	chr10:62793562~62805887:-
LUAD	cis	rs2060793	0.741	rs10741653	ENSG00000251991.1	RNU7-49P	4.14	4.04e-05	0.00656	0.2	0.19	Vitamin D levels;	chr11:14683294	chr11:14478892~14478953:+
LUAD	cis	rs1154275	0.524	rs4682426	ENSG00000242770.2	RP11-180K7.1	-4.14	4.04e-05	0.00656	-0.19	-0.19	Takotsubo syndrome;	chr3:112782510	chr3:112802478~112812819:+
LUAD	cis	rs10463554	0.927	rs34811	ENSG00000250682.4	LINC00491	4.14	4.05e-05	0.00656	0.23	0.19	Parkinson's disease;	chr5:103096117	chr5:102609156~102671559:-
LUAD	cis	rs1979679	0.842	rs10459091	ENSG00000278733.1	RP11-425D17.1	4.14	4.05e-05	0.00656	0.23	0.19	Ossification of the posterior longitudinal ligament of the spine;	chr12:28188383	chr12:28185625~28186190:-
LUAD	cis	rs35740288	0.822	rs2241268	ENSG00000259407.1	RP11-158M2.3	-4.14	4.05e-05	0.00656	-0.19	-0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85735078	chr15:85744109~85750281:-
LUAD	cis	rs6479891	1	rs61853635	ENSG00000232075.1	MRPL35P2	4.14	4.05e-05	0.00656	0.3	0.19	Arthritis (juvenile idiopathic);	chr10:63516750	chr10:63634317~63634827:-
LUAD	cis	rs9532580	0.619	rs2755211	ENSG00000229456.1	RLIMP1	4.14	4.05e-05	0.00656	0.21	0.19	Mean corpuscular hemoglobin;	chr13:40568086	chr13:40618738~40621348:+
LUAD	cis	rs7760535	0.757	rs10456875	ENSG00000230177.1	RP5-1112D6.4	-4.14	4.05e-05	0.00656	-0.17	-0.19	Metabolic traits;	chr6:111428522	chr6:111277932~111278742:+
LUAD	cis	rs7551222	0.75	rs898387	ENSG00000236779.1	RP11-430C7.2	4.14	4.05e-05	0.00656	0.24	0.19	Schizophrenia;	chr1:204610245	chr1:204528845~204529692:-
LUAD	cis	rs8028182	0.636	rs11636031	ENSG00000260269.4	CTD-2323K18.1	-4.14	4.05e-05	0.00656	-0.26	-0.19	Sudden cardiac arrest;	chr15:75523417	chr15:75527150~75601205:-
LUAD	cis	rs11168618	0.846	rs11168586	ENSG00000240399.1	RP1-228P16.1	4.14	4.05e-05	0.00657	0.18	0.19	Adiponectin levels;	chr12:48460229	chr12:48054813~48055591:-
LUAD	cis	rs3753275	0.568	rs10864359	ENSG00000232912.4	RP5-1115A15.1	4.14	4.05e-05	0.00657	0.21	0.19	Educational attainment;	chr1:8638551	chr1:8424645~8434838:+
LUAD	cis	rs4938303	0.549	rs12785990	ENSG00000254851.1	RP11-109L13.1	4.14	4.05e-05	0.00657	0.25	0.19	Triglycerides;	chr11:116692990	chr11:117135528~117138582:+
LUAD	cis	rs6736093	0.736	rs10864895	ENSG00000207383.1	Y_RNA	-4.14	4.05e-05	0.00657	-0.23	-0.19	Coronary artery disease;	chr2:112006817	chr2:112579484~112579584:-
LUAD	cis	rs7760535	0.763	rs10457241	ENSG00000230177.1	RP5-1112D6.4	-4.14	4.05e-05	0.00657	-0.17	-0.19	Metabolic traits;	chr6:111527831	chr6:111277932~111278742:+
LUAD	cis	rs1348850	0.958	rs11689550	ENSG00000213963.5	AC074286.1	4.14	4.05e-05	0.00657	0.22	0.19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177591570	chr2:177283508~177392691:-
LUAD	cis	rs4144027	0.935	rs8008020	ENSG00000258914.1	CTD-2134A5.3	4.14	4.05e-05	0.00657	0.22	0.19	Blood metabolite levels;	chr14:103889546	chr14:103875055~103877478:+
LUAD	cis	rs13113518	0.783	rs7690837	ENSG00000272969.1	RP11-528I4.2	4.14	4.05e-05	0.00657	0.2	0.19	Height;	chr4:55575856	chr4:55547112~55547889:+
LUAD	cis	rs1714507	0.533	rs2731122	ENSG00000272087.1	RP11-379F4.7	4.14	4.05e-05	0.00657	0.2	0.19	Subjective well-being;	chr3:158577491	chr3:158693120~158693768:-
LUAD	cis	rs1714507	0.533	rs2731120	ENSG00000272087.1	RP11-379F4.7	-4.14	4.05e-05	0.00657	-0.2	-0.19	Subjective well-being;	chr3:158579844	chr3:158693120~158693768:-
LUAD	cis	rs1322639	0.614	rs6900964	ENSG00000261039.2	RP11-417E7.2	-4.14	4.06e-05	0.00658	-0.31	-0.19	Pulse pressure;	chr6:169166668	chr6:169175304~169182740:-
LUAD	cis	rs8014252	0.518	rs58919501	ENSG00000259158.2	ADAM20P1	-4.14	4.06e-05	0.00658	-0.29	-0.19	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70602305	chr14:70468881~70483756:-
LUAD	cis	rs889398	0.742	rs12446197	ENSG00000226232.7	RP11-419C5.2	4.14	4.06e-05	0.00658	0.16	0.19	Body mass index;	chr16:69820966	chr16:69976388~69996188:-
LUAD	cis	rs7829975	0.688	rs7817376	ENSG00000233609.3	RP11-62H7.2	-4.14	4.06e-05	0.00658	-0.15	-0.19	Mood instability;	chr8:8523020	chr8:8961200~8979025:+
LUAD	cis	rs1552244	0.882	rs13066757	ENSG00000180385.7	EMC3-AS1	4.14	4.06e-05	0.00658	0.22	0.19	Alzheimer's disease;	chr3:10003346	chr3:9986893~10006990:+
LUAD	cis	rs4664293	0.836	rs4665118	ENSG00000226266.5	AC009961.3	-4.14	4.06e-05	0.00658	-0.25	-0.19	Monocyte percentage of white cells;	chr2:159802938	chr2:159670708~159712435:-
LUAD	cis	rs1864585	0.552	rs73208794	ENSG00000255046.1	RP11-297N6.4	4.14	4.06e-05	0.00658	0.26	0.19	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10823738	chr8:11797928~11802568:-
LUAD	cis	rs2227564	0.574	rs3849969	ENSG00000271816.1	BMS1P4	-4.14	4.06e-05	0.00658	-0.18	-0.19	Crohn's disease;Inflammatory bowel disease;	chr10:73766241	chr10:73699151~73730487:-
LUAD	cis	rs4664293	0.967	rs10202187	ENSG00000230783.1	AC009961.2	-4.14	4.06e-05	0.00658	-0.24	-0.19	Monocyte percentage of white cells;	chr2:159571135	chr2:159689217~159690291:-
LUAD	cis	rs10090774	0.735	rs9324530	ENSG00000280303.2	ERICD	-4.14	4.06e-05	0.00658	-0.21	-0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140660808	chr8:140636281~140638283:+
LUAD	cis	rs911555	0.723	rs7144010	ENSG00000244691.1	RPL10AP1	4.14	4.06e-05	0.00659	0.25	0.19	Intelligence (multi-trait analysis);	chr14:103403532	chr14:103412119~103412761:-
LUAD	cis	rs2380205	0.62	rs12777477	ENSG00000232807.2	RP11-536K7.3	4.14	4.06e-05	0.00659	0.2	0.19	Breast cancer;	chr10:5870180	chr10:5934270~5945900:-
LUAD	cis	rs2836974	0.932	rs8129416	ENSG00000232608.1	TIMM9P2	-4.14	4.07e-05	0.00659	-0.22	-0.19	Cognitive function;	chr21:39245219	chr21:39216624~39217506:+
LUAD	cis	rs2836974	0.644	rs2836982	ENSG00000232608.1	TIMM9P2	4.14	4.07e-05	0.00659	0.22	0.19	Cognitive function;	chr21:39317245	chr21:39216624~39217506:+
LUAD	cis	rs256438	0.93	rs2434284	ENSG00000251050.1	RP11-168A11.4	-4.14	4.07e-05	0.00659	-0.2	-0.19	Serum thyroid-stimulating hormone levels;	chr5:80095391	chr5:80019609~80019920:+
LUAD	cis	rs7204230	1	rs8055523	ENSG00000261291.1	RP11-295M3.2	4.14	4.07e-05	0.00659	0.23	0.19	Fibrinogen;	chr16:53139242	chr16:53168522~53169450:+
LUAD	cis	rs10875976	0.625	rs7133995	ENSG00000257464.1	RP11-161H23.8	-4.14	4.07e-05	0.00659	-0.18	-0.19	Obesity;	chr12:49859732	chr12:49442424~49442652:-
LUAD	cis	rs72827839	0.696	rs77244957	ENSG00000228782.6	CTD-2026D20.3	4.14	4.07e-05	0.00659	0.3	0.19	Ease of getting up in the morning;	chr17:48248215	chr17:47450568~47492492:-
LUAD	cis	rs7208859	0.673	rs75142521	ENSG00000280069.1	CTD-2349P21.3	-4.14	4.07e-05	0.00659	-0.26	-0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913519	chr17:30738182~30740275:+
LUAD	cis	rs202072	0.729	rs8541	ENSG00000272379.1	RP1-257A7.5	4.14	4.07e-05	0.00659	0.31	0.19	HIV-1 viral setpoint;	chr6:13290006	chr6:13290018~13290490:-
LUAD	cis	rs7116495	1	rs58991229	ENSG00000254682.1	RP11-660L16.2	-4.14	4.07e-05	0.0066	-0.41	-0.19	Severe influenza A (H1N1) infection;	chr11:72128832	chr11:71448674~71452157:+
LUAD	cis	rs9646944	0.501	rs3771158	ENSG00000234389.1	AC007278.3	4.14	4.07e-05	0.0066	0.21	0.19	Blood protein levels;	chr2:102393434	chr2:102438713~102440475:+
LUAD	cis	rs77972916	0.519	rs13411327	ENSG00000234936.1	AC010883.5	4.14	4.07e-05	0.0066	0.25	0.19	Granulocyte percentage of myeloid white cells;	chr2:43288344	chr2:43229573~43233394:+
LUAD	cis	rs1979679	0.918	rs11049513	ENSG00000278733.1	RP11-425D17.1	4.14	4.07e-05	0.0066	0.24	0.19	Ossification of the posterior longitudinal ligament of the spine;	chr12:28297218	chr12:28185625~28186190:-
LUAD	cis	rs62481355	0.68	rs2106177	ENSG00000224138.1	AC000123.4	4.14	4.07e-05	0.0066	0.18	0.19	Type 2 diabetes;	chr7:127432641	chr7:127350128~127351523:+
LUAD	cis	rs77688320	0.5	rs7603584	ENSG00000213090.2	AC007256.5	4.14	4.07e-05	0.0066	0.21	0.19	Breast cancer;	chr2:201440422	chr2:201410544~201413308:-
LUAD	cis	rs116139393	0.517	rs13230987	ENSG00000187953.9	PMS2CL	-4.14	4.08e-05	0.0066	-0.29	-0.19	Alzheimer's disease (APOE e4 interaction);	chr7:6686689	chr7:6710128~6753862:+
LUAD	cis	rs6479901	0.894	rs10740124	ENSG00000232075.1	MRPL35P2	-4.14	4.08e-05	0.00661	-0.25	-0.19	Intelligence (multi-trait analysis);	chr10:63426034	chr10:63634317~63634827:-
LUAD	cis	rs140505938	1	rs140505938	ENSG00000223945.2	RP11-458I7.1	-4.14	4.08e-05	0.00661	-0.28	-0.19	Schizophrenia;	chr1:150059494	chr1:150053864~150055034:+
LUAD	cis	rs7829975	0.777	rs560544	ENSG00000173295.6	FAM86B3P	-4.14	4.08e-05	0.00661	-0.2	-0.19	Mood instability;	chr8:8779919	chr8:8228595~8244865:+
LUAD	cis	rs6723226	0.75	rs3769597	ENSG00000276334.1	AL133243.1	4.14	4.08e-05	0.00661	0.21	0.19	Intelligence (multi-trait analysis);	chr2:32466332	chr2:32521927~32523547:+
LUAD	cis	rs9532669	0.926	rs9532691	ENSG00000168852.11	TPTE2P5	-4.14	4.08e-05	0.00662	-0.18	-0.19	Cervical cancer;	chr13:40969358	chr13:40822296~40921749:-
LUAD	cis	rs7204230	0.88	rs1421067	ENSG00000261291.1	RP11-295M3.2	4.14	4.08e-05	0.00662	0.23	0.19	Fibrinogen;	chr16:53138731	chr16:53168522~53169450:+
LUAD	cis	rs7772486	0.79	rs9403756	ENSG00000235652.6	RP11-545I5.3	-4.14	4.09e-05	0.00662	-0.18	-0.19	Lobe attachment (rater-scored or self-reported);	chr6:145936625	chr6:145799409~145886585:+
LUAD	cis	rs12935418	0.672	rs9921914	ENSG00000261061.1	RP11-303E16.2	-4.14	4.09e-05	0.00662	-0.2	-0.19	Mean corpuscular volume;	chr16:81022506	chr16:81030770~81031485:+
LUAD	cis	rs12935418	0.672	rs3826048	ENSG00000261061.1	RP11-303E16.2	-4.14	4.09e-05	0.00662	-0.2	-0.19	Mean corpuscular volume;	chr16:81023230	chr16:81030770~81031485:+
LUAD	cis	rs4819052	0.851	rs2838865	ENSG00000215447.6	BX322557.10	-4.14	4.09e-05	0.00662	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45292384	chr21:45288052~45291738:+
LUAD	cis	rs1061377	0.585	rs1367296	ENSG00000249685.1	RP11-360F5.3	4.14	4.09e-05	0.00662	0.22	0.19	Uric acid levels;	chr4:39066895	chr4:39133913~39135608:+
LUAD	cis	rs2834288	0.5	rs766423	ENSG00000237945.6	LINC00649	4.14	4.09e-05	0.00662	0.24	0.19	Gut microbiota (bacterial taxa);	chr21:33962711	chr21:33915534~33977691:+
LUAD	cis	rs897984	0.542	rs35713203	ENSG00000232748.3	RP11-196G11.6	-4.14	4.09e-05	0.00663	-0.23	-0.19	Dementia with Lewy bodies;	chr16:31079086	chr16:31056460~31062803:+
LUAD	cis	rs6832769	0.961	rs28713343	ENSG00000272969.1	RP11-528I4.2	-4.14	4.09e-05	0.00663	-0.19	-0.19	Personality dimensions;	chr4:55590924	chr4:55547112~55547889:+
LUAD	cis	rs6832769	0.925	rs2899037	ENSG00000272969.1	RP11-528I4.2	-4.14	4.09e-05	0.00663	-0.19	-0.19	Personality dimensions;	chr4:55591180	chr4:55547112~55547889:+
LUAD	cis	rs6687758	1	rs6687758	ENSG00000227925.1	RP11-191N8.2	4.14	4.09e-05	0.00663	0.26	0.19	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221991606	chr1:221827666~221840666:-
LUAD	cis	rs2657294	0.965	rs7079694	ENSG00000233313.2	HMGA1P5	-4.14	4.09e-05	0.00663	-0.23	-0.19	Pneumonia;	chr10:75136804	chr10:75276376~75276646:-
LUAD	cis	rs6671200	0.607	rs6671408	ENSG00000228852.5	RP11-57H12.5	-4.14	4.09e-05	0.00663	-0.22	-0.19	Stearic acid (18:0) levels;	chr1:95231535	chr1:95243167~95278940:-
LUAD	cis	rs6671200	0.573	rs6666528	ENSG00000228852.5	RP11-57H12.5	-4.14	4.09e-05	0.00663	-0.22	-0.19	Stearic acid (18:0) levels;	chr1:95231934	chr1:95243167~95278940:-
LUAD	cis	rs17301013	0.932	rs1754349	ENSG00000227373.4	RP11-160H22.5	-4.14	4.09e-05	0.00663	-0.23	-0.19	Systemic lupus erythematosus;	chr1:174837663	chr1:174115300~174160004:-
LUAD	cis	rs9649213	0.593	rs6465675	ENSG00000272950.1	RP11-307C18.1	-4.14	4.1e-05	0.00663	-0.23	-0.19	Prostate cancer (SNP x SNP interaction);	chr7:98352791	chr7:98322853~98323430:+
LUAD	cis	rs728616	0.867	rs12412226	ENSG00000225484.5	NUTM2B-AS1	-4.14	4.1e-05	0.00663	-0.47	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79975532	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.867	rs4387301	ENSG00000225484.5	NUTM2B-AS1	-4.14	4.1e-05	0.00663	-0.47	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79976643	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.764	rs117833443	ENSG00000225484.5	NUTM2B-AS1	-4.14	4.1e-05	0.00663	-0.47	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79978380	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.867	rs116994688	ENSG00000225484.5	NUTM2B-AS1	-4.14	4.1e-05	0.00663	-0.47	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79978381	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.867	rs61860420	ENSG00000225484.5	NUTM2B-AS1	-4.14	4.1e-05	0.00663	-0.47	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79979623	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.867	rs75447386	ENSG00000225484.5	NUTM2B-AS1	-4.14	4.1e-05	0.00663	-0.47	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79979891	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.867	rs4520539	ENSG00000225484.5	NUTM2B-AS1	-4.14	4.1e-05	0.00663	-0.47	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79980773	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.867	rs61860421	ENSG00000225484.5	NUTM2B-AS1	-4.14	4.1e-05	0.00663	-0.47	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79983643	chr10:79663088~79826594:-
LUAD	cis	rs7560272	0.564	rs10496190	ENSG00000163016.8	ALMS1P	-4.14	4.1e-05	0.00664	-0.19	-0.19	Schizophrenia;	chr2:73411695	chr2:73644919~73685576:+
LUAD	cis	rs10463554	0.856	rs26260	ENSG00000250682.4	LINC00491	4.14	4.1e-05	0.00664	0.22	0.19	Parkinson's disease;	chr5:103211493	chr5:102609156~102671559:-
LUAD	cis	rs442309	0.846	rs224131	ENSG00000238280.1	RP11-436D10.3	-4.14	4.1e-05	0.00664	-0.23	-0.19	Vogt-Koyanagi-Harada syndrome;	chr10:62705334	chr10:62793562~62805887:-
LUAD	cis	rs7617773	0.71	rs36064160	ENSG00000199476.1	Y_RNA	-4.14	4.1e-05	0.00664	-0.25	-0.19	Coronary artery disease;	chr3:48201611	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.817	rs34728236	ENSG00000199476.1	Y_RNA	-4.14	4.1e-05	0.00664	-0.25	-0.19	Coronary artery disease;	chr3:48217618	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.817	rs79310258	ENSG00000199476.1	Y_RNA	-4.14	4.1e-05	0.00664	-0.25	-0.19	Coronary artery disease;	chr3:48218177	chr3:48288587~48288694:+
LUAD	cis	rs801193	1	rs10234018	ENSG00000222364.1	RNU6-96P	4.14	4.1e-05	0.00664	0.21	0.19	Aortic root size;	chr7:66681297	chr7:66395191~66395286:+
LUAD	cis	rs865483	0.86	rs853220	ENSG00000276054.1	RP11-378E13.3	4.14	4.1e-05	0.00664	0.22	0.19	Monocyte count;	chr17:37427567	chr17:37386886~37387926:+
LUAD	cis	rs28386778	0.897	rs2665833	ENSG00000240280.5	TCAM1P	-4.14	4.1e-05	0.00664	-0.21	-0.19	Prudent dietary pattern;	chr17:63829486	chr17:63849292~63864379:+
LUAD	cis	rs5758511	0.633	rs5758689	ENSG00000227370.1	RP4-669P10.19	4.14	4.1e-05	0.00664	0.21	0.19	Birth weight;	chr22:42268966	chr22:42132543~42132998:+
LUAD	cis	rs4699052	0.963	rs2085978	ENSG00000246560.2	RP11-10L12.4	4.14	4.1e-05	0.00664	0.23	0.19	Testicular germ cell tumor;	chr4:103272457	chr4:102828055~102844075:+
LUAD	cis	rs7829975	0.564	rs2921060	ENSG00000173295.6	FAM86B3P	-4.14	4.1e-05	0.00664	-0.2	-0.19	Mood instability;	chr8:8460307	chr8:8228595~8244865:+
LUAD	cis	rs865483	0.895	rs2522965	ENSG00000276054.1	RP11-378E13.3	4.14	4.1e-05	0.00664	0.22	0.19	Monocyte count;	chr17:37456216	chr17:37386886~37387926:+
LUAD	cis	rs865483	0.895	rs2680718	ENSG00000276054.1	RP11-378E13.3	4.14	4.1e-05	0.00664	0.22	0.19	Monocyte count;	chr17:37456349	chr17:37386886~37387926:+
LUAD	cis	rs865483	0.895	rs4795200	ENSG00000276054.1	RP11-378E13.3	4.14	4.1e-05	0.00664	0.22	0.19	Monocyte count;	chr17:37457003	chr17:37386886~37387926:+
LUAD	cis	rs7005380	0.58	rs10110216	ENSG00000279347.1	RP11-85I17.2	-4.14	4.11e-05	0.00665	-0.15	-0.19	Interstitial lung disease;	chr8:119875307	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.58	rs10110223	ENSG00000279347.1	RP11-85I17.2	-4.14	4.11e-05	0.00665	-0.15	-0.19	Interstitial lung disease;	chr8:119875326	chr8:119838736~119840385:-
LUAD	cis	rs6121246	0.512	rs45443696	ENSG00000230613.1	HM13-AS1	4.14	4.11e-05	0.00665	0.23	0.19	Mean corpuscular hemoglobin;	chr20:31723593	chr20:31567707~31573263:-
LUAD	cis	rs7590268	0.636	rs17334980	ENSG00000279873.2	LINC01126	-4.14	4.11e-05	0.00665	-0.18	-0.19	Orofacial clefts;	chr2:43491454	chr2:43227210~43228855:+
LUAD	cis	rs8098244	0.58	rs1711452	ENSG00000264745.1	TTC39C-AS1	4.14	4.11e-05	0.00665	0.2	0.19	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23692607	chr18:23994213~24015339:-
LUAD	cis	rs9649213	0.593	rs35535338	ENSG00000272950.1	RP11-307C18.1	4.14	4.11e-05	0.00665	0.23	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98333007	chr7:98322853~98323430:+
LUAD	cis	rs854765	0.619	rs1101727	ENSG00000223979.2	SMCR2	-4.14	4.11e-05	0.00665	-0.22	-0.19	Total body bone mineral density;	chr17:18112834	chr17:17674026~17677688:-
LUAD	cis	rs11157436	0.602	rs2075493	ENSG00000211812.1	TRAV26-2	-4.14	4.11e-05	0.00665	-0.19	-0.19	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22163782	chr14:22202583~22203368:+
LUAD	cis	rs17406451	0.788	rs72790935	ENSG00000279873.2	LINC01126	4.14	4.11e-05	0.00665	0.16	0.19	Mitochondrial DNA levels;	chr2:43463896	chr2:43227210~43228855:+
LUAD	cis	rs2086824	0.538	rs4785673	ENSG00000261118.1	RP11-104N10.1	4.14	4.11e-05	0.00665	0.19	0.19	Multiple myeloma (IgH translocation);	chr16:89470137	chr16:89492017~89504460:-
LUAD	cis	rs1044826	1	rs9835241	ENSG00000214280.3	RP11-553K23.2	-4.14	4.11e-05	0.00665	-0.22	-0.19	Obesity-related traits;	chr3:139515713	chr3:139582928~139583593:-
LUAD	cis	rs2836974	0.931	rs2776307	ENSG00000232608.1	TIMM9P2	4.14	4.11e-05	0.00665	0.22	0.19	Cognitive function;	chr21:39341907	chr21:39216624~39217506:+
LUAD	cis	rs6754311	0.773	rs632632	ENSG00000226806.1	AC011893.3	4.14	4.11e-05	0.00665	0.23	0.19	Mosquito bite size;	chr2:135880646	chr2:135820191~135823087:+
LUAD	cis	rs12579720	0.868	rs2417824	ENSG00000255910.1	RP11-405A12.2	4.14	4.11e-05	0.00665	0.23	0.19	Diastolic blood pressure;	chr12:20034994	chr12:19775451~20009937:+
LUAD	cis	rs3096299	0.559	rs9931073	ENSG00000182376.2	RP5-1142A6.8	4.14	4.11e-05	0.00665	0.19	0.19	Multiple myeloma (IgH translocation);	chr16:89502105	chr16:88742767~88745748:+
LUAD	cis	rs1023500	0.573	rs133381	ENSG00000205702.9	CYP2D7	4.14	4.11e-05	0.00665	0.15	0.19	Schizophrenia;	chr22:42074604	chr22:42140203~42144577:-
LUAD	cis	rs12188164	0.9	rs72717425	ENSG00000225138.6	CTD-2228K2.7	4.14	4.11e-05	0.00666	0.18	0.19	Cystic fibrosis severity;	chr5:438694	chr5:473236~480884:+
LUAD	cis	rs8062405	0.755	rs62034325	ENSG00000251417.2	RP11-1348G14.4	-4.14	4.11e-05	0.00666	-0.19	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28802743~28817828:+
LUAD	cis	rs9341808	0.667	rs3805913	ENSG00000260645.1	RP11-250B2.5	4.14	4.11e-05	0.00666	0.17	0.19	Sitting height ratio;	chr6:80217605	chr6:80466958~80469080:+
LUAD	cis	rs2933343	0.729	rs813732	ENSG00000261159.1	RP11-723O4.9	4.14	4.11e-05	0.00666	0.21	0.19	IgG glycosylation;	chr3:128900514	chr3:128859716~128860526:-
LUAD	cis	rs8028182	0.636	rs4886715	ENSG00000260269.4	CTD-2323K18.1	-4.14	4.11e-05	0.00666	-0.26	-0.19	Sudden cardiac arrest;	chr15:75539108	chr15:75527150~75601205:-
LUAD	cis	rs7107174	0.748	rs11237458	ENSG00000251323.2	RP11-452H21.4	4.14	4.12e-05	0.00666	0.22	0.19	Testicular germ cell tumor;	chr11:78339803	chr11:78423982~78429836:-
LUAD	cis	rs219780	0.821	rs219777	ENSG00000230479.1	AP000695.6	4.14	4.12e-05	0.00666	0.22	0.19	Kidney stones;	chr21:36462423	chr21:36430360~36481070:+
LUAD	cis	rs4072980	0.545	rs7519947	ENSG00000212541.1	RNU6-510P	4.14	4.12e-05	0.00666	0.25	0.19	Coronary artery disease;	chr1:37982053	chr1:37991462~37991569:+
LUAD	cis	rs6840360	0.967	rs4383600	ENSG00000270265.1	RP11-731D1.4	-4.14	4.12e-05	0.00666	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151773231	chr4:151333775~151353224:-
LUAD	cis	rs240993	0.516	rs414763	ENSG00000271789.1	RP5-1112D6.7	-4.14	4.12e-05	0.00666	-0.27	-0.19	Inflammatory skin disease;Psoriasis;	chr6:111324561	chr6:111297126~111298510:+
LUAD	cis	rs8073060	0.586	rs225264	ENSG00000267592.1	CTC-507E2.2	4.14	4.12e-05	0.00666	0.27	0.19	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35634316	chr17:35596904~35597128:-
LUAD	cis	rs8073060	0.586	rs225265	ENSG00000267592.1	CTC-507E2.2	4.14	4.12e-05	0.00666	0.27	0.19	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35634953	chr17:35596904~35597128:-
LUAD	cis	rs2840044	0.554	rs225267	ENSG00000267592.1	CTC-507E2.2	4.14	4.12e-05	0.00666	0.27	0.19	Response to radiotherapy in cancer (late toxicity);	chr17:35637209	chr17:35596904~35597128:-
LUAD	cis	rs8073060	0.544	rs225268	ENSG00000267592.1	CTC-507E2.2	4.14	4.12e-05	0.00666	0.27	0.19	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35639205	chr17:35596904~35597128:-
LUAD	cis	rs11121022	0.965	rs11121021	ENSG00000269925.1	RP3-467L1.6	-4.14	4.12e-05	0.00666	-0.18	-0.19	Morning vs. evening chronotype;	chr1:7775639	chr1:7776383~7776775:+
LUAD	cis	rs12073359	1	rs11584091	ENSG00000223945.2	RP11-458I7.1	-4.14	4.12e-05	0.00667	-0.28	-0.19	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150129018	chr1:150053864~150055034:+
LUAD	cis	rs9341808	0.6	rs590641	ENSG00000260645.1	RP11-250B2.5	4.14	4.12e-05	0.00667	0.17	0.19	Sitting height ratio;	chr6:80256766	chr6:80466958~80469080:+
LUAD	cis	rs80028505	1	rs61212706	ENSG00000271304.1	DPRXP2	4.14	4.12e-05	0.00667	0.34	0.19	Foot ulcer in diabetes and neuropathy;	chr6:36071654	chr6:35989515~35990436:-
LUAD	cis	rs7107174	1	rs4945274	ENSG00000251323.2	RP11-452H21.4	4.14	4.12e-05	0.00667	0.22	0.19	Testicular germ cell tumor;	chr11:78398214	chr11:78423982~78429836:-
LUAD	cis	rs11992162	0.636	rs4841644	ENSG00000255046.1	RP11-297N6.4	-4.14	4.12e-05	0.00667	-0.23	-0.19	Monocyte count;	chr8:11940924	chr8:11797928~11802568:-
LUAD	cis	rs3020736	0.5	rs5996111	ENSG00000205702.9	CYP2D7	-4.14	4.12e-05	0.00667	-0.15	-0.19	Autism spectrum disorder or schizophrenia;	chr22:42097898	chr22:42140203~42144577:-
LUAD	cis	rs17172185	1	rs17172185	ENSG00000229497.1	AC005189.6	4.14	4.13e-05	0.00667	0.35	0.19	Esophageal adenocarcinoma;	chr7:43247240	chr7:43767290~43767599:+
LUAD	cis	rs7829975	0.514	rs2979151	ENSG00000173295.6	FAM86B3P	-4.14	4.13e-05	0.00667	-0.2	-0.19	Mood instability;	chr8:8400509	chr8:8228595~8244865:+
LUAD	cis	rs6142102	0.961	rs4911405	ENSG00000275784.1	RP5-1125A11.6	-4.14	4.13e-05	0.00668	-0.21	-0.19	Skin pigmentation;	chr20:34087161	chr20:33989480~33991818:-
LUAD	cis	rs6840360	0.642	rs6843639	ENSG00000270265.1	RP11-731D1.4	-4.14	4.13e-05	0.00668	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151494863	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.642	rs28666858	ENSG00000270265.1	RP11-731D1.4	-4.14	4.13e-05	0.00668	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151495230	chr4:151333775~151353224:-
LUAD	cis	rs4819052	0.851	rs1056101	ENSG00000215447.6	BX322557.10	-4.14	4.13e-05	0.00668	-0.22	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258787	chr21:45288052~45291738:+
LUAD	cis	rs42490	0.51	rs218917	ENSG00000251136.7	RP11-37B2.1	-4.14	4.13e-05	0.00668	-0.19	-0.19	Leprosy;	chr8:89688902	chr8:89609409~89757727:-
LUAD	cis	rs3742264	1	rs1409434	ENSG00000235903.6	CPB2-AS1	-4.14	4.13e-05	0.00668	-0.23	-0.19	Blood protein levels;	chr13:46072309	chr13:46052806~46113332:+
LUAD	cis	rs11155671	0.53	rs9371544	ENSG00000268592.3	RAET1E-AS1	4.14	4.13e-05	0.00668	0.23	0.19	Testicular germ cell tumor;	chr6:149896224	chr6:149863494~149919507:+
LUAD	cis	rs8073060	0.586	rs2523114	ENSG00000267592.1	CTC-507E2.2	4.14	4.13e-05	0.00668	0.27	0.19	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35696743	chr17:35596904~35597128:-
LUAD	cis	rs8014252	0.803	rs74938470	ENSG00000259158.2	ADAM20P1	-4.14	4.13e-05	0.00668	-0.33	-0.19	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70573305	chr14:70468881~70483756:-
LUAD	cis	rs77633900	0.803	rs2469573	ENSG00000196274.5	Metazoa_SRP	4.14	4.13e-05	0.00668	0.24	0.19	Glioma;Non-glioblastoma glioma;	chr15:76308708	chr15:76230048~76230390:-
LUAD	cis	rs13113518	0.702	rs78829811	ENSG00000272969.1	RP11-528I4.2	4.14	4.13e-05	0.00668	0.2	0.19	Height;	chr4:55558258	chr4:55547112~55547889:+
LUAD	cis	rs13113518	0.702	rs75801206	ENSG00000272969.1	RP11-528I4.2	4.14	4.13e-05	0.00668	0.2	0.19	Height;	chr4:55558259	chr4:55547112~55547889:+
LUAD	cis	rs13113518	0.702	rs34658078	ENSG00000272969.1	RP11-528I4.2	4.14	4.13e-05	0.00668	0.2	0.19	Height;	chr4:55558261	chr4:55547112~55547889:+
LUAD	cis	rs4683346	0.616	rs35584330	ENSG00000173811.9	CCDC13-AS1	-4.14	4.13e-05	0.00669	-0.21	-0.19	Granulocyte percentage of myeloid white cells;	chr3:42769748	chr3:42732575~42746768:+
LUAD	cis	rs7246657	0.943	rs10404602	ENSG00000226686.6	LINC01535	-4.14	4.14e-05	0.00669	-0.29	-0.19	Coronary artery calcification;	chr19:37334731	chr19:37251912~37265535:+
LUAD	cis	rs73242632	1	rs73242621	ENSG00000269949.1	RP11-738E22.3	4.14	4.14e-05	0.00669	0.46	0.19	Congenital heart disease (maternal effect);	chr4:56951915	chr4:56960927~56961373:-
LUAD	cis	rs73242632	1	rs73242622	ENSG00000269949.1	RP11-738E22.3	4.14	4.14e-05	0.00669	0.46	0.19	Congenital heart disease (maternal effect);	chr4:56952398	chr4:56960927~56961373:-
LUAD	cis	rs2657294	0.726	rs4746275	ENSG00000233313.2	HMGA1P5	-4.14	4.14e-05	0.00669	-0.23	-0.19	Pneumonia;	chr10:75214940	chr10:75276376~75276646:-
LUAD	cis	rs9910055	0.529	rs228766	ENSG00000267080.4	ASB16-AS1	4.14	4.14e-05	0.00669	0.18	0.19	Total body bone mineral density;	chr17:44109445	chr17:44175973~44186717:-
LUAD	cis	rs1729407	0.741	rs1263177	ENSG00000280143.1	AP000892.6	4.14	4.14e-05	0.00669	0.21	0.19	Apolipoprotein A-IV levels;	chr11:116819996	chr11:117204967~117210292:+
LUAD	cis	rs17772222	0.63	rs2778936	ENSG00000258789.1	RP11-507K2.3	4.14	4.14e-05	0.0067	0.22	0.19	Coronary artery calcification;	chr14:88505959	chr14:88551597~88552493:+
LUAD	cis	rs17596685	1	rs346592	ENSG00000271216.1	LINC01050	-4.14	4.14e-05	0.0067	-0.27	-0.19	C-reactive protein levels;	chr13:42593377	chr13:42810366~42812562:-
LUAD	cis	rs897984	0.609	rs72800847	ENSG00000232748.3	RP11-196G11.6	-4.14	4.14e-05	0.0067	-0.24	-0.19	Dementia with Lewy bodies;	chr16:31011318	chr16:31056460~31062803:+
LUAD	cis	rs4713118	0.824	rs9468223	ENSG00000280107.1	AL022393.9	-4.14	4.15e-05	0.0067	-0.24	-0.19	Parkinson's disease;	chr6:27772887	chr6:28170845~28172521:+
LUAD	cis	rs4474465	0.915	rs12277503	ENSG00000251323.2	RP11-452H21.4	4.14	4.15e-05	0.0067	0.23	0.19	Alzheimer's disease (survival time);	chr11:78429327	chr11:78423982~78429836:-
LUAD	cis	rs9487094	0.614	rs13191444	ENSG00000260273.1	RP11-425D10.10	4.14	4.15e-05	0.0067	0.28	0.19	Height;	chr6:109762861	chr6:109382795~109383666:+
LUAD	cis	rs4833407	0.513	rs62316106	ENSG00000251441.2	RTEL1P1	-4.14	4.15e-05	0.0067	-0.22	-0.19	Obesity;	chr4:112381585	chr4:112356135~112359819:+
LUAD	cis	rs6871536	1	rs2706338	ENSG00000233006.5	AC034220.3	4.14	4.15e-05	0.00671	0.2	0.19	Asthma (childhood onset);	chr5:132560157	chr5:132311285~132369916:-
LUAD	cis	rs4925386	0.765	rs6142737	ENSG00000273619.1	RP5-908M14.9	-4.14	4.15e-05	0.00671	-0.19	-0.19	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62344744	chr20:62386303~62386970:-
LUAD	cis	rs950169	1	rs12903820	ENSG00000275120.1	RP11-182J1.17	4.14	4.15e-05	0.00671	0.29	0.19	Schizophrenia;	chr15:84055068	chr15:84599434~84606463:-
LUAD	cis	rs7246657	0.943	rs10404920	ENSG00000226686.6	LINC01535	-4.14	4.15e-05	0.00671	-0.29	-0.19	Coronary artery calcification;	chr19:37390654	chr19:37251912~37265535:+
LUAD	cis	rs1355223	0.867	rs7944030	ENSG00000271369.1	RP11-350D17.3	-4.14	4.15e-05	0.00671	-0.22	-0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34670191	chr11:34709600~34710161:+
LUAD	cis	rs17784882	0.521	rs11713693	ENSG00000271161.1	BOLA2P2	-4.14	4.15e-05	0.00671	-0.18	-0.19	QT interval;	chr3:47033416	chr3:47499841~47500407:+
LUAD	cis	rs800160	1	rs800157	ENSG00000236264.4	RPL26P30	-4.14	4.15e-05	0.00671	-0.25	-0.19	Bacteremia;	chr11:2355372	chr11:2335132~2335776:-
LUAD	cis	rs800160	0.748	rs2521242	ENSG00000236264.4	RPL26P30	-4.14	4.15e-05	0.00671	-0.25	-0.19	Bacteremia;	chr11:2355410	chr11:2335132~2335776:-
LUAD	cis	rs4879677	1	rs10812637	ENSG00000215441.3	CTAGE12P	-4.14	4.15e-05	0.00671	-0.23	-0.19	Gut microbiome composition (summer and winter);	chr9:27664832	chr9:27608382~27610745:-
LUAD	cis	rs6732565	0.932	rs11123201	ENSG00000235721.1	AC013268.3	-4.14	4.15e-05	0.00671	-0.21	-0.19	Rheumatoid arthritis;	chr2:110843901	chr2:110007675~110010783:+
LUAD	cis	rs9652601	0.677	rs35732840	ENSG00000274038.1	RP11-66H6.4	-4.14	4.15e-05	0.00671	-0.23	-0.19	Systemic lupus erythematosus;	chr16:11134498	chr16:11056556~11057034:+
LUAD	cis	rs875971	0.545	rs17138149	ENSG00000224316.1	RP11-479O9.2	4.14	4.15e-05	0.00671	0.21	0.19	Aortic root size;	chr7:66228193	chr7:65773620~65802067:+
LUAD	cis	rs2834288	0.536	rs762356	ENSG00000237945.6	LINC00649	4.14	4.15e-05	0.00671	0.24	0.19	Gut microbiota (bacterial taxa);	chr21:33964582	chr21:33915534~33977691:+
LUAD	cis	rs728616	0.867	rs61860417	ENSG00000225484.5	NUTM2B-AS1	-4.14	4.15e-05	0.00671	-0.44	-0.19	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79974971	chr10:79663088~79826594:-
LUAD	cis	rs7688540	0.8	rs6837796	ENSG00000211553.1	AC253576.2	-4.14	4.15e-05	0.00671	-0.23	-0.19	Facial morphology (factor 6, height of vermillion lower lip);	chr4:278733	chr4:136461~136568:+
LUAD	cis	rs7976269	0.559	rs10771477	ENSG00000257176.2	RP11-996F15.2	-4.14	4.15e-05	0.00671	-0.2	-0.19	Male-pattern baldness;	chr12:29074137	chr12:29280418~29317848:-
LUAD	cis	rs7976269	0.559	rs10843307	ENSG00000257176.2	RP11-996F15.2	-4.14	4.15e-05	0.00671	-0.2	-0.19	Male-pattern baldness;	chr12:29074710	chr12:29280418~29317848:-
LUAD	cis	rs12712133	0.552	rs10200945	ENSG00000234389.1	AC007278.3	-4.14	4.15e-05	0.00671	-0.18	-0.19	Primary biliary cholangitis;	chr2:102268297	chr2:102438713~102440475:+
LUAD	cis	rs1008375	0.966	rs12503540	ENSG00000249502.1	AC006160.5	4.14	4.16e-05	0.00672	0.18	0.19	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17697158	chr4:17587467~17614571:-
LUAD	cis	rs911119	0.955	rs1011226	ENSG00000270001.1	RP11-218C14.8	4.14	4.16e-05	0.00672	0.27	0.19	Chronic kidney disease;	chr20:23625196	chr20:23631826~23632316:-
LUAD	cis	rs6500602	0.929	rs9926114	ENSG00000280063.1	RP11-295D4.3	4.14	4.16e-05	0.00672	0.12	0.19	Schizophrenia;	chr16:4428321	chr16:4346694~4348648:-
LUAD	cis	rs1334894	0.901	rs1977655	ENSG00000228559.1	RP3-340B19.3	-4.14	4.16e-05	0.00672	-0.37	-0.19	Coronary artery disease;	chr6:35553925	chr6:35544632~35545669:+
LUAD	cis	rs9287719	0.967	rs4669596	ENSG00000243819.4	RN7SL832P	4.14	4.16e-05	0.00672	0.2	0.19	Prostate cancer;	chr2:10580446	chr2:10690344~10692099:+
LUAD	cis	rs950169	1	rs35658069	ENSG00000275120.1	RP11-182J1.17	4.14	4.16e-05	0.00672	0.29	0.19	Schizophrenia;	chr15:84111394	chr15:84599434~84606463:-
LUAD	cis	rs7537765	0.696	rs2075538	ENSG00000242349.4	NPPA-AS1	-4.14	4.16e-05	0.00672	-0.34	-0.19	QRS complex (12-leadsum);	chr1:11836545	chr1:11841017~11848079:+
LUAD	cis	rs34779708	0.966	rs17591781	ENSG00000271335.4	RP11-324I22.4	4.14	4.16e-05	0.00672	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35209610	chr10:35314552~35336401:-
LUAD	cis	rs5758511	0.596	rs55644935	ENSG00000227370.1	RP4-669P10.19	4.14	4.16e-05	0.00672	0.2	0.19	Birth weight;	chr22:42270063	chr22:42132543~42132998:+
LUAD	cis	rs2548724	0.741	rs62369308	ENSG00000250682.4	LINC00491	4.14	4.16e-05	0.00672	0.25	0.19	Type 2 diabetes;	chr5:102382690	chr5:102609156~102671559:-
LUAD	cis	rs28735056	0.587	rs8093548	ENSG00000261126.6	RP11-795F19.1	-4.14	4.16e-05	0.00672	-0.19	-0.19	Schizophrenia;	chr18:79876451	chr18:80046900~80095482:+
LUAD	cis	rs6071166	0.873	rs6027459	ENSG00000224635.1	RP4-564F22.5	-4.14	4.16e-05	0.00673	-0.2	-0.19	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38708932	chr20:38406011~38416797:-
LUAD	cis	rs6964587	1	rs10234290	ENSG00000188693.7	CYP51A1-AS1	-4.14	4.16e-05	0.00673	-0.22	-0.19	Breast cancer;	chr7:92087637	chr7:92134604~92180725:+
LUAD	cis	rs4578769	0.55	rs12966925	ENSG00000265943.1	RP11-739L10.1	4.14	4.17e-05	0.00673	0.24	0.19	Eosinophil percentage of white cells;	chr18:22953734	chr18:22699481~22933764:-
LUAD	cis	rs6964833	1	rs4717907	ENSG00000278416.1	PMS2L2	4.14	4.17e-05	0.00673	0.25	0.19	Menarche (age at onset);	chr7:74672169	chr7:75344015~75359550:-
LUAD	cis	rs73193808	1	rs2832232	ENSG00000215533.7	LINC00189	-4.14	4.17e-05	0.00673	-0.27	-0.19	Coronary artery disease;	chr21:29168238	chr21:29193480~29288205:+
LUAD	cis	rs12539814	1	rs12666210	ENSG00000244198.4	RP4-545C24.1	-4.14	4.17e-05	0.00673	-0.31	-0.19	Diastolic blood pressure;	chr7:144435635	chr7:144194858~144280547:+
LUAD	cis	rs7138803	0.51	rs1470909	ENSG00000257464.1	RP11-161H23.8	4.14	4.17e-05	0.00673	0.18	0.19	Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index;	chr12:49790183	chr12:49442424~49442652:-
LUAD	cis	rs17154702	0.524	rs2664041	ENSG00000253893.2	FAM85B	4.14	4.17e-05	0.00674	0.23	0.19	Neurocognitive impairment in HIV-1 infection (continuous);	chr8:8735634	chr8:8167819~8226614:-
LUAD	cis	rs73198271	0.632	rs570396	ENSG00000253893.2	FAM85B	4.14	4.17e-05	0.00674	0.23	0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8736142	chr8:8167819~8226614:-
LUAD	cis	rs73198271	0.603	rs571130	ENSG00000253893.2	FAM85B	4.14	4.17e-05	0.00674	0.23	0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8736181	chr8:8167819~8226614:-
LUAD	cis	rs6565180	1	rs12930787	ENSG00000273724.1	RP11-347C12.12	-4.14	4.17e-05	0.00674	-0.2	-0.19	Tonsillectomy;	chr16:30369982	chr16:30336400~30343336:+
LUAD	cis	rs1499614	0.522	rs13247442	ENSG00000230295.1	RP11-458F8.2	-4.14	4.17e-05	0.00674	-0.26	-0.19	Gout;	chr7:66723871	chr7:66880708~66882981:+
LUAD	cis	rs7107174	1	rs11237480	ENSG00000251323.2	RP11-452H21.4	4.14	4.17e-05	0.00674	0.23	0.19	Testicular germ cell tumor;	chr11:78399339	chr11:78423982~78429836:-
LUAD	cis	rs6479891	1	rs6479891	ENSG00000232075.1	MRPL35P2	4.14	4.17e-05	0.00674	0.31	0.19	Arthritis (juvenile idiopathic);	chr10:63246696	chr10:63634317~63634827:-
LUAD	cis	rs10938353	0.68	rs1491313	ENSG00000273369.1	RP11-700J17.1	4.14	4.17e-05	0.00674	0.24	0.19	Body mass index;	chr4:44783372	chr4:44693946~44694386:-
LUAD	cis	rs957448	1	rs16916874	ENSG00000253175.1	RP11-267M23.6	4.14	4.17e-05	0.00674	0.23	0.19	Nonsyndromic cleft lip with cleft palate;	chr8:94537749	chr8:94565036~94565715:+
LUAD	cis	rs12754538	0.85	rs12040962	ENSG00000232912.4	RP5-1115A15.1	4.14	4.18e-05	0.00674	0.19	0.19	Subjective well-being;	chr1:8476841	chr1:8424645~8434838:+
LUAD	cis	rs2836974	0.666	rs11910705	ENSG00000232608.1	TIMM9P2	4.14	4.18e-05	0.00674	0.22	0.19	Cognitive function;	chr21:39313678	chr21:39216624~39217506:+
LUAD	cis	rs2836974	0.931	rs12151994	ENSG00000232608.1	TIMM9P2	-4.14	4.18e-05	0.00674	-0.22	-0.19	Cognitive function;	chr21:39318471	chr21:39216624~39217506:+
LUAD	cis	rs2836974	0.966	rs7283516	ENSG00000232608.1	TIMM9P2	-4.14	4.18e-05	0.00674	-0.22	-0.19	Cognitive function;	chr21:39318611	chr21:39216624~39217506:+
LUAD	cis	rs7976269	0.609	rs2117994	ENSG00000257176.2	RP11-996F15.2	-4.14	4.18e-05	0.00674	-0.2	-0.19	Male-pattern baldness;	chr12:29054666	chr12:29280418~29317848:-
LUAD	cis	rs7976269	0.583	rs6487753	ENSG00000257176.2	RP11-996F15.2	-4.14	4.18e-05	0.00674	-0.2	-0.19	Male-pattern baldness;	chr12:29056103	chr12:29280418~29317848:-
LUAD	cis	rs7976269	0.583	rs6487754	ENSG00000257176.2	RP11-996F15.2	-4.14	4.18e-05	0.00674	-0.2	-0.19	Male-pattern baldness;	chr12:29056104	chr12:29280418~29317848:-
LUAD	cis	rs7976269	0.609	rs6487755	ENSG00000257176.2	RP11-996F15.2	-4.14	4.18e-05	0.00674	-0.2	-0.19	Male-pattern baldness;	chr12:29056156	chr12:29280418~29317848:-
LUAD	cis	rs6964587	0.934	rs7811328	ENSG00000188693.7	CYP51A1-AS1	-4.14	4.18e-05	0.00675	-0.21	-0.19	Breast cancer;	chr7:92091617	chr7:92134604~92180725:+
LUAD	cis	rs9925964	0.748	rs4889603	ENSG00000232748.3	RP11-196G11.6	-4.14	4.18e-05	0.00675	-0.22	-0.19	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:30970904	chr16:31056460~31062803:+
LUAD	cis	rs151234	0.741	rs151230	ENSG00000259982.1	CDC37P1	-4.14	4.18e-05	0.00675	-0.34	-0.19	Platelet distribution width;	chr16:28571894	chr16:28700294~28701540:-
LUAD	cis	rs2251260	0.629	rs1088672	ENSG00000250548.5	RP11-47I22.2	4.14	4.18e-05	0.00675	0.25	0.19	Yeast infection;	chr14:61537581	chr14:61556313~61570653:-
LUAD	cis	rs28386778	0.897	rs1062788	ENSG00000240280.5	TCAM1P	-4.14	4.18e-05	0.00675	-0.21	-0.19	Prudent dietary pattern;	chr17:63818767	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.897	rs1062790	ENSG00000240280.5	TCAM1P	-4.14	4.18e-05	0.00675	-0.21	-0.19	Prudent dietary pattern;	chr17:63819095	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.897	rs894408	ENSG00000240280.5	TCAM1P	-4.14	4.18e-05	0.00675	-0.21	-0.19	Prudent dietary pattern;	chr17:63819454	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.863	rs2727288	ENSG00000240280.5	TCAM1P	-4.14	4.18e-05	0.00675	-0.21	-0.19	Prudent dietary pattern;	chr17:63823837	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.897	rs894407	ENSG00000240280.5	TCAM1P	-4.14	4.18e-05	0.00675	-0.21	-0.19	Prudent dietary pattern;	chr17:63824281	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.897	rs894406	ENSG00000240280.5	TCAM1P	-4.14	4.18e-05	0.00675	-0.21	-0.19	Prudent dietary pattern;	chr17:63824297	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.897	rs716880	ENSG00000240280.5	TCAM1P	-4.14	4.18e-05	0.00675	-0.21	-0.19	Prudent dietary pattern;	chr17:63825462	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.897	rs2584626	ENSG00000240280.5	TCAM1P	-4.14	4.18e-05	0.00675	-0.21	-0.19	Prudent dietary pattern;	chr17:63825819	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.897	rs2584624	ENSG00000240280.5	TCAM1P	-4.14	4.18e-05	0.00675	-0.21	-0.19	Prudent dietary pattern;	chr17:63827186	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.863	rs2665834	ENSG00000240280.5	TCAM1P	-4.14	4.18e-05	0.00675	-0.21	-0.19	Prudent dietary pattern;	chr17:63827364	chr17:63849292~63864379:+
LUAD	cis	rs10463554	0.892	rs3776874	ENSG00000250682.4	LINC00491	4.14	4.18e-05	0.00675	0.22	0.19	Parkinson's disease;	chr5:102946613	chr5:102609156~102671559:-
LUAD	cis	rs9500256	0.683	rs10458024	ENSG00000272316.1	XXbac-BPGBPG55C20.2	4.14	4.18e-05	0.00675	0.16	0.19	Eosinophilic esophagitis (pediatric);	chr6:57997811	chr6:57908560~57913911:-
LUAD	cis	rs8014252	0.803	rs12586441	ENSG00000259158.2	ADAM20P1	-4.14	4.18e-05	0.00675	-0.34	-0.19	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70521345	chr14:70468881~70483756:-
LUAD	cis	rs910316	1	rs7156105	ENSG00000279594.1	RP11-950C14.10	4.14	4.18e-05	0.00675	0.21	0.19	Height;	chr14:75075251	chr14:75011269~75012851:-
LUAD	cis	rs4664293	1	rs4665083	ENSG00000230783.1	AC009961.2	4.14	4.18e-05	0.00675	0.22	0.19	Monocyte percentage of white cells;	chr2:159573616	chr2:159689217~159690291:-
LUAD	cis	rs11009175	0.547	rs12241473	ENSG00000273038.2	RP11-479G22.8	-4.14	4.18e-05	0.00675	-0.23	-0.19	Depression (quantitative trait);	chr10:33106737	chr10:32887255~32889311:-
LUAD	cis	rs12188164	0.965	rs1056465	ENSG00000225138.6	CTD-2228K2.7	4.14	4.18e-05	0.00675	0.18	0.19	Cystic fibrosis severity;	chr5:442323	chr5:473236~480884:+
LUAD	cis	rs2243480	1	rs4718269	ENSG00000226002.1	RP11-460N20.5	4.14	4.18e-05	0.00676	0.32	0.19	Diabetic kidney disease;	chr7:65735810	chr7:65084103~65100232:+
LUAD	cis	rs6142102	0.961	rs6059649	ENSG00000275784.1	RP5-1125A11.6	-4.14	4.19e-05	0.00676	-0.21	-0.19	Skin pigmentation;	chr20:34056071	chr20:33989480~33991818:-
LUAD	cis	rs6142102	0.961	rs6059651	ENSG00000275784.1	RP5-1125A11.6	-4.14	4.19e-05	0.00676	-0.21	-0.19	Skin pigmentation;	chr20:34057246	chr20:33989480~33991818:-
LUAD	cis	rs6142102	0.961	rs909884	ENSG00000275784.1	RP5-1125A11.6	-4.14	4.19e-05	0.00676	-0.21	-0.19	Skin pigmentation;	chr20:34058257	chr20:33989480~33991818:-
LUAD	cis	rs6142102	0.961	rs2268088	ENSG00000275784.1	RP5-1125A11.6	-4.14	4.19e-05	0.00676	-0.21	-0.19	Skin pigmentation;	chr20:34061258	chr20:33989480~33991818:-
LUAD	cis	rs6142102	0.961	rs2284388	ENSG00000275784.1	RP5-1125A11.6	-4.14	4.19e-05	0.00676	-0.21	-0.19	Skin pigmentation;	chr20:34067935	chr20:33989480~33991818:-
LUAD	cis	rs34779708	0.9	rs73262807	ENSG00000271335.4	RP11-324I22.4	4.14	4.19e-05	0.00676	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35207458	chr10:35314552~35336401:-
LUAD	cis	rs9287719	0.967	rs10929682	ENSG00000243819.4	RN7SL832P	4.14	4.19e-05	0.00676	0.2	0.19	Prostate cancer;	chr2:10592063	chr2:10690344~10692099:+
LUAD	cis	rs17711722	0.51	rs11767457	ENSG00000237310.1	GS1-124K5.4	4.14	4.19e-05	0.00676	0.2	0.19	Calcium levels;	chr7:65825628	chr7:66493706~66495474:+
LUAD	cis	rs9487094	0.961	rs12190920	ENSG00000260273.1	RP11-425D10.10	4.14	4.19e-05	0.00676	0.26	0.19	Height;	chr6:109479396	chr6:109382795~109383666:+
LUAD	cis	rs4374383	0.847	rs2230515	ENSG00000207383.1	Y_RNA	-4.14	4.19e-05	0.00676	-0.22	-0.19	Hepatitis C induced liver fibrosis;	chr2:111997424	chr2:112579484~112579584:-
LUAD	cis	rs34779708	0.966	rs4934737	ENSG00000271335.4	RP11-324I22.4	4.14	4.19e-05	0.00676	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35223871	chr10:35314552~35336401:-
LUAD	cis	rs219780	1	rs219780	ENSG00000233818.1	AP000695.4	4.13	4.19e-05	0.00676	0.25	0.19	Kidney stones;	chr21:36461009	chr21:36445731~36532408:+
LUAD	cis	rs7561273	0.586	rs7589717	ENSG00000242628.4	AC009228.1	4.13	4.19e-05	0.00676	0.23	0.19	Quantitative traits;	chr2:24134593	chr2:24214381~24221516:+
LUAD	cis	rs7561273	0.586	rs7580772	ENSG00000242628.4	AC009228.1	4.13	4.19e-05	0.00676	0.23	0.19	Quantitative traits;	chr2:24134787	chr2:24214381~24221516:+
LUAD	cis	rs10090774	0.71	rs13249806	ENSG00000280303.2	ERICD	-4.13	4.19e-05	0.00676	-0.21	-0.19	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140675407	chr8:140636281~140638283:+
LUAD	cis	rs9649213	0.593	rs3801264	ENSG00000272950.1	RP11-307C18.1	4.13	4.19e-05	0.00676	0.23	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98321308	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.593	rs1468338	ENSG00000272950.1	RP11-307C18.1	4.13	4.19e-05	0.00676	0.23	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98321806	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.593	rs2158553	ENSG00000272950.1	RP11-307C18.1	4.13	4.19e-05	0.00676	0.23	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98321819	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.593	rs10808107	ENSG00000272950.1	RP11-307C18.1	4.13	4.19e-05	0.00676	0.23	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98322359	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.613	rs10953256	ENSG00000272950.1	RP11-307C18.1	4.13	4.19e-05	0.00676	0.23	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98322574	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.613	rs2286074	ENSG00000272950.1	RP11-307C18.1	4.13	4.19e-05	0.00676	0.23	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98322699	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.593	rs7789380	ENSG00000272950.1	RP11-307C18.1	4.13	4.19e-05	0.00676	0.23	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98326868	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.593	rs6948540	ENSG00000272950.1	RP11-307C18.1	4.13	4.19e-05	0.00676	0.23	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98330754	chr7:98322853~98323430:+
LUAD	cis	rs858239	0.601	rs10255228	ENSG00000226816.2	AC005082.12	4.13	4.19e-05	0.00676	0.24	0.19	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23206013~23208045:+
LUAD	cis	rs4811196	0.748	rs4811238	ENSG00000226144.2	RPS27AP3	4.13	4.19e-05	0.00677	0.2	0.19	Bone mineral density;	chr20:37863280	chr20:37049254~37049707:+
LUAD	cis	rs6754311	0.731	rs13404551	ENSG00000226806.1	AC011893.3	4.13	4.19e-05	0.00677	0.23	0.19	Mosquito bite size;	chr2:135964425	chr2:135820191~135823087:+
LUAD	cis	rs1912483	0.505	rs11079772	ENSG00000228782.6	CTD-2026D20.3	-4.13	4.19e-05	0.00677	-0.2	-0.19	Coronary artery disease;	chr17:47316373	chr17:47450568~47492492:-
LUAD	cis	rs877356	0.588	rs721834	ENSG00000250378.1	RP11-119J18.1	-4.13	4.19e-05	0.00677	-0.36	-0.19	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (dichotomous);	chr5:135824519	chr5:135812667~135826582:+
LUAD	cis	rs2732480	0.967	rs2732469	ENSG00000240399.1	RP1-228P16.1	4.13	4.19e-05	0.00677	0.18	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48319149	chr12:48054813~48055591:-
LUAD	cis	rs8062405	0.754	rs3859172	ENSG00000251417.2	RP11-1348G14.4	-4.13	4.2e-05	0.00677	-0.19	-0.19	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28802743~28817828:+
LUAD	cis	rs7204230	1	rs11859517	ENSG00000261291.1	RP11-295M3.2	4.13	4.2e-05	0.00677	0.23	0.19	Fibrinogen;	chr16:53147335	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs67499551	ENSG00000261291.1	RP11-295M3.2	4.13	4.2e-05	0.00677	0.23	0.19	Fibrinogen;	chr16:53149693	chr16:53168522~53169450:+
LUAD	cis	rs7204230	0.96	rs8055410	ENSG00000261291.1	RP11-295M3.2	4.13	4.2e-05	0.00677	0.23	0.19	Fibrinogen;	chr16:53149924	chr16:53168522~53169450:+
LUAD	cis	rs7204230	0.96	rs12149129	ENSG00000261291.1	RP11-295M3.2	4.13	4.2e-05	0.00677	0.23	0.19	Fibrinogen;	chr16:53154102	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs12597487	ENSG00000261291.1	RP11-295M3.2	4.13	4.2e-05	0.00677	0.23	0.19	Fibrinogen;	chr16:53157558	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs62048022	ENSG00000261291.1	RP11-295M3.2	4.13	4.2e-05	0.00677	0.23	0.19	Fibrinogen;	chr16:53163547	chr16:53168522~53169450:+
LUAD	cis	rs8028182	0.636	rs11636199	ENSG00000260269.4	CTD-2323K18.1	-4.13	4.2e-05	0.00677	-0.25	-0.19	Sudden cardiac arrest;	chr15:75532996	chr15:75527150~75601205:-
LUAD	cis	rs5758511	0.508	rs2854827	ENSG00000226450.2	CYP2D8P	4.13	4.2e-05	0.00677	0.17	0.19	Birth weight;	chr22:42065914	chr22:42149886~42155001:-
LUAD	cis	rs7208859	0.614	rs73265646	ENSG00000266490.1	CTD-2349P21.9	4.13	4.2e-05	0.00677	0.29	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917005	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs58908911	ENSG00000266490.1	CTD-2349P21.9	4.13	4.2e-05	0.00677	0.29	0.19	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917540	chr17:30792372~30792833:+
LUAD	cis	rs13434995	0.842	rs62303685	ENSG00000249700.7	SRD5A3-AS1	-4.13	4.2e-05	0.00677	-0.27	-0.19	Adiponectin levels;	chr4:55418915	chr4:55363971~55395847:-
LUAD	cis	rs2548724	0.704	rs62372211	ENSG00000250682.4	LINC00491	4.13	4.2e-05	0.00677	0.22	0.19	Type 2 diabetes;	chr5:102301073	chr5:102609156~102671559:-
LUAD	cis	rs7617773	0.817	rs17647717	ENSG00000199476.1	Y_RNA	-4.13	4.2e-05	0.00677	-0.25	-0.19	Coronary artery disease;	chr3:48263966	chr3:48288587~48288694:+
LUAD	cis	rs780096	0.526	rs1647267	ENSG00000234072.1	AC074117.10	-4.13	4.2e-05	0.00677	-0.14	-0.19	Total body bone mineral density;	chr2:27428187	chr2:27356246~27367622:+
LUAD	cis	rs780096	0.526	rs10182937	ENSG00000234072.1	AC074117.10	-4.13	4.2e-05	0.00677	-0.14	-0.19	Total body bone mineral density;	chr2:27428826	chr2:27356246~27367622:+
LUAD	cis	rs780096	0.526	rs704791	ENSG00000234072.1	AC074117.10	-4.13	4.2e-05	0.00677	-0.14	-0.19	Total body bone mineral density;	chr2:27434300	chr2:27356246~27367622:+
LUAD	cis	rs780096	0.526	rs780102	ENSG00000234072.1	AC074117.10	-4.13	4.2e-05	0.00677	-0.14	-0.19	Total body bone mineral density;	chr2:27436624	chr2:27356246~27367622:+
LUAD	cis	rs780096	0.526	rs1260341	ENSG00000234072.1	AC074117.10	-4.13	4.2e-05	0.00677	-0.14	-0.19	Total body bone mineral density;	chr2:27440348	chr2:27356246~27367622:+
LUAD	cis	rs780096	0.526	rs1260342	ENSG00000234072.1	AC074117.10	-4.13	4.2e-05	0.00677	-0.14	-0.19	Total body bone mineral density;	chr2:27440549	chr2:27356246~27367622:+
LUAD	cis	rs780096	0.526	rs780112	ENSG00000234072.1	AC074117.10	-4.13	4.2e-05	0.00677	-0.14	-0.19	Total body bone mineral density;	chr2:27442494	chr2:27356246~27367622:+
LUAD	cis	rs780096	0.526	rs4803	ENSG00000234072.1	AC074117.10	-4.13	4.2e-05	0.00677	-0.14	-0.19	Total body bone mineral density;	chr2:27444430	chr2:27356246~27367622:+
LUAD	cis	rs6964587	0.755	rs13229505	ENSG00000188693.7	CYP51A1-AS1	-4.13	4.2e-05	0.00677	-0.22	-0.19	Breast cancer;	chr7:91815365	chr7:92134604~92180725:+
LUAD	cis	rs4819052	1	rs2838830	ENSG00000215447.6	BX322557.10	-4.13	4.2e-05	0.00678	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244312	chr21:45288052~45291738:+
LUAD	cis	rs2836974	0.644	rs11088472	ENSG00000232608.1	TIMM9P2	4.13	4.2e-05	0.00678	0.22	0.19	Cognitive function;	chr21:39327450	chr21:39216624~39217506:+
LUAD	cis	rs10208649	0.656	rs60191560	ENSG00000272156.1	RP11-477N3.1	4.13	4.2e-05	0.00678	0.37	0.19	Body mass index;	chr2:54058661	chr2:54082554~54085066:+
LUAD	cis	rs12073359	1	rs11587963	ENSG00000223945.2	RP11-458I7.1	-4.13	4.2e-05	0.00678	-0.28	-0.19	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150134393	chr1:150053864~150055034:+
LUAD	cis	rs12073359	1	rs56369603	ENSG00000223945.2	RP11-458I7.1	-4.13	4.2e-05	0.00678	-0.28	-0.19	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150134673	chr1:150053864~150055034:+
LUAD	cis	rs12073359	0.955	rs72694942	ENSG00000223945.2	RP11-458I7.1	-4.13	4.2e-05	0.00678	-0.28	-0.19	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150138317	chr1:150053864~150055034:+
LUAD	cis	rs12073359	1	rs72694944	ENSG00000223945.2	RP11-458I7.1	-4.13	4.2e-05	0.00678	-0.28	-0.19	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150140312	chr1:150053864~150055034:+
LUAD	cis	rs6479891	1	rs2466128	ENSG00000232075.1	MRPL35P2	4.13	4.2e-05	0.00678	0.3	0.19	Arthritis (juvenile idiopathic);	chr10:63448561	chr10:63634317~63634827:-
LUAD	cis	rs6479891	1	rs2719815	ENSG00000232075.1	MRPL35P2	4.13	4.2e-05	0.00678	0.3	0.19	Arthritis (juvenile idiopathic);	chr10:63450534	chr10:63634317~63634827:-
LUAD	cis	rs9649213	0.593	rs7458551	ENSG00000272950.1	RP11-307C18.1	4.13	4.2e-05	0.00678	0.23	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98322855	chr7:98322853~98323430:+
LUAD	cis	rs4474465	1	rs12277701	ENSG00000251323.2	RP11-452H21.4	4.13	4.2e-05	0.00678	0.23	0.19	Alzheimer's disease (survival time);	chr11:78429680	chr11:78423982~78429836:-
LUAD	cis	rs748404	1	rs66651343	ENSG00000205771.5	CATSPER2P1	-4.13	4.2e-05	0.00678	-0.27	-0.19	Lung cancer;	chr15:43265806	chr15:43726918~43747094:-
LUAD	cis	rs2014572	0.967	rs10412975	ENSG00000268379.1	CTC-360J11.4	4.13	4.21e-05	0.00678	0.22	0.19	Hyperactive-impulsive symptoms;	chr19:57259186	chr19:57175233~57177921:+
LUAD	cis	rs12216545	0.765	rs2373816	ENSG00000177590.7	GIMAP3P	-4.13	4.21e-05	0.00678	-0.19	-0.19	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150574041	chr7:150746893~150747728:-
LUAD	cis	rs5758659	0.904	rs5758653	ENSG00000273366.1	CTA-989H11.1	-4.13	4.21e-05	0.00678	-0.21	-0.19	Cognitive function;	chr22:42217479	chr22:42278188~42278846:+
LUAD	cis	rs34792	0.554	rs12708796	ENSG00000207425.1	Y_RNA	-4.13	4.21e-05	0.00678	-0.23	-0.19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15535980	chr16:14915457~14915556:-
LUAD	cis	rs911555	0.755	rs55742283	ENSG00000244691.1	RPL10AP1	4.13	4.21e-05	0.00678	0.25	0.19	Intelligence (multi-trait analysis);	chr14:103476628	chr14:103412119~103412761:-
LUAD	cis	rs28386778	0.897	rs2727287	ENSG00000240280.5	TCAM1P	-4.13	4.21e-05	0.00678	-0.21	-0.19	Prudent dietary pattern;	chr17:63827368	chr17:63849292~63864379:+
LUAD	cis	rs7727544	0.582	rs10052046	ENSG00000233006.5	AC034220.3	4.13	4.21e-05	0.00678	0.17	0.19	Blood metabolite levels;	chr5:132208773	chr5:132311285~132369916:-
LUAD	cis	rs8030379	1	rs4842923	ENSG00000230373.7	GOLGA6L5P	-4.13	4.21e-05	0.00678	-0.17	-0.19	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83913152	chr15:84507885~84516814:-
LUAD	cis	rs9549260	0.755	rs4941987	ENSG00000229456.1	RLIMP1	4.13	4.21e-05	0.00679	0.2	0.19	Red blood cell count;	chr13:40621855	chr13:40618738~40621348:+
LUAD	cis	rs9549260	0.683	rs4941988	ENSG00000229456.1	RLIMP1	4.13	4.21e-05	0.00679	0.2	0.19	Red blood cell count;	chr13:40621869	chr13:40618738~40621348:+
LUAD	cis	rs9549260	0.64	rs4943796	ENSG00000229456.1	RLIMP1	4.13	4.21e-05	0.00679	0.2	0.19	Red blood cell count;	chr13:40621879	chr13:40618738~40621348:+
LUAD	cis	rs62025270	0.688	rs79083718	ENSG00000202081.1	RNU6-1280P	-4.13	4.21e-05	0.00679	-0.27	-0.19	Idiopathic pulmonary fibrosis;	chr15:85720298	chr15:85651522~85651628:-
LUAD	cis	rs6840360	0.642	rs12647555	ENSG00000270265.1	RP11-731D1.4	-4.13	4.21e-05	0.00679	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151479946	chr4:151333775~151353224:-
LUAD	cis	rs5758659	0.569	rs133294	ENSG00000182057.4	OGFRP1	4.13	4.21e-05	0.00679	0.22	0.19	Cognitive function;	chr22:41986801	chr22:42269753~42275196:+
LUAD	cis	rs7829975	0.902	rs485107	ENSG00000253981.4	ALG1L13P	-4.13	4.21e-05	0.00679	-0.22	-0.19	Mood instability;	chr8:8723898	chr8:8236003~8244667:-
LUAD	cis	rs11673344	0.504	rs1667378	ENSG00000276846.1	CTD-3220F14.3	4.13	4.21e-05	0.00679	0.2	0.19	Obesity-related traits;	chr19:37001171	chr19:37314868~37315620:-
LUAD	cis	rs6964587	0.967	rs12535601	ENSG00000188693.7	CYP51A1-AS1	-4.13	4.21e-05	0.00679	-0.22	-0.19	Breast cancer;	chr7:92089032	chr7:92134604~92180725:+
LUAD	cis	rs4660214	0.666	rs1180383	ENSG00000228060.1	RP11-69E11.8	-4.13	4.21e-05	0.00679	-0.17	-0.19	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39380595	chr1:39565160~39573203:+
LUAD	cis	rs7512552	0.839	rs3820544	ENSG00000275557.1	RP11-353N4.6	4.13	4.21e-05	0.00679	0.21	0.19	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150485400	chr1:149607765~149612402:+
LUAD	cis	rs62025270	0.632	rs62022915	ENSG00000259416.2	RP11-158M2.5	-4.13	4.21e-05	0.00679	-0.25	-0.19	Idiopathic pulmonary fibrosis;	chr15:85670365	chr15:85754941~85756237:-
LUAD	cis	rs2243480	1	rs316315	ENSG00000232559.3	GS1-124K5.12	-4.13	4.21e-05	0.00679	-0.28	-0.19	Diabetic kidney disease;	chr7:66126218	chr7:66554588~66576923:-
LUAD	cis	rs4723738	0.729	rs10226230	ENSG00000227191.5	TRGC2	4.13	4.21e-05	0.00679	0.2	0.19	Treatment response for severe sepsis;	chr7:38229691	chr7:38239580~38368091:-
LUAD	cis	rs7660883	0.897	rs342437	ENSG00000251411.1	RP11-397E7.4	-4.13	4.22e-05	0.0068	-0.2	-0.19	HDL cholesterol levels;	chr4:87119757	chr4:86913266~86914817:-
LUAD	cis	rs2446066	0.872	rs11170550	ENSG00000257379.1	RP11-793H13.8	4.13	4.22e-05	0.0068	0.31	0.19	Red blood cell count;	chr12:53420930	chr12:53441741~53467528:+
LUAD	cis	rs240993	0.516	rs414763	ENSG00000230177.1	RP5-1112D6.4	-4.13	4.22e-05	0.0068	-0.23	-0.19	Inflammatory skin disease;Psoriasis;	chr6:111324561	chr6:111277932~111278742:+
LUAD	cis	rs6840360	0.573	rs6810430	ENSG00000270265.1	RP11-731D1.4	-4.13	4.22e-05	0.0068	-0.19	-0.19	Intelligence (multi-trait analysis);	chr4:151338607	chr4:151333775~151353224:-
LUAD	cis	rs143626010	1	rs143626010	ENSG00000251417.2	RP11-1348G14.4	-4.13	4.22e-05	0.0068	-0.19	-0.19	Mosquito bite size;	chr16:28528081	chr16:28802743~28817828:+
LUAD	cis	rs2273156	0.517	rs77803033	ENSG00000226677.3	IGBP1P1	-4.13	4.22e-05	0.0068	-0.29	-0.19	Immunoglobulin light chain (AL) amyloidosis;	chr14:35042646	chr14:34939324~34940332:+
LUAD	cis	rs2273156	0.517	rs8007274	ENSG00000226677.3	IGBP1P1	-4.13	4.22e-05	0.0068	-0.29	-0.19	Immunoglobulin light chain (AL) amyloidosis;	chr14:35043012	chr14:34939324~34940332:+
LUAD	cis	rs2273156	0.706	rs8009093	ENSG00000226677.3	IGBP1P1	-4.13	4.22e-05	0.0068	-0.29	-0.19	Immunoglobulin light chain (AL) amyloidosis;	chr14:35043497	chr14:34939324~34940332:+
LUAD	cis	rs2273156	0.57	rs1028449	ENSG00000226677.3	IGBP1P1	-4.13	4.22e-05	0.0068	-0.29	-0.19	Immunoglobulin light chain (AL) amyloidosis;	chr14:35043789	chr14:34939324~34940332:+
LUAD	cis	rs2273156	0.57	rs60693825	ENSG00000226677.3	IGBP1P1	-4.13	4.22e-05	0.0068	-0.29	-0.19	Immunoglobulin light chain (AL) amyloidosis;	chr14:35045250	chr14:34939324~34940332:+
LUAD	cis	rs7201929	1	rs11644151	ENSG00000251417.2	RP11-1348G14.4	4.13	4.22e-05	0.0068	0.22	0.19	QT interval;	chr16:28884339	chr16:28802743~28817828:+
LUAD	cis	rs2439831	0.85	rs544122	ENSG00000249839.1	AC011330.5	-4.13	4.22e-05	0.0068	-0.34	-0.19	Lung cancer in ever smokers;	chr15:43483534	chr15:43663654~43684339:-
LUAD	cis	rs3018712	0.532	rs948861	ENSG00000212093.1	AP000807.1	-4.13	4.22e-05	0.0068	-0.24	-0.19	Total body bone mineral density;	chr11:68653154	chr11:68506083~68506166:-
LUAD	cis	rs3018712	0.532	rs948863	ENSG00000212093.1	AP000807.1	-4.13	4.22e-05	0.0068	-0.24	-0.19	Total body bone mineral density;	chr11:68653506	chr11:68506083~68506166:-
LUAD	cis	rs11673344	0.504	rs2385374	ENSG00000276846.1	CTD-3220F14.3	4.13	4.22e-05	0.0068	0.2	0.19	Obesity-related traits;	chr19:37092115	chr19:37314868~37315620:-
LUAD	cis	rs911555	0.723	rs7149767	ENSG00000244691.1	RPL10AP1	4.13	4.22e-05	0.0068	0.25	0.19	Intelligence (multi-trait analysis);	chr14:103397208	chr14:103412119~103412761:-
LUAD	cis	rs2143950	0.831	rs12589079	ENSG00000226677.3	IGBP1P1	-4.13	4.22e-05	0.0068	-0.29	-0.19	Atopic dermatitis;	chr14:35073287	chr14:34939324~34940332:+
LUAD	cis	rs4460629	0.65	rs11264319	ENSG00000160766.13	GBAP1	-4.13	4.22e-05	0.0068	-0.19	-0.19	Serum magnesium levels;	chr1:155111466	chr1:155213821~155227422:-
LUAD	cis	rs35740288	0.77	rs62023931	ENSG00000259407.1	RP11-158M2.3	-4.13	4.22e-05	0.00681	-0.18	-0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85589521	chr15:85744109~85750281:-
LUAD	cis	rs35740288	0.77	rs1382534	ENSG00000259407.1	RP11-158M2.3	-4.13	4.22e-05	0.00681	-0.18	-0.19	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85598939	chr15:85744109~85750281:-
LUAD	cis	rs599083	0.569	rs685095	ENSG00000212093.1	AP000807.1	-4.13	4.22e-05	0.00681	-0.2	-0.19	Bone mineral density (spine);	chr11:68402908	chr11:68506083~68506166:-
LUAD	cis	rs10863681	0.664	rs10863680	ENSG00000238042.4	RP11-815M8.1	-4.13	4.22e-05	0.00681	-0.22	-0.19	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222071538	chr1:221880981~221978523:-
LUAD	cis	rs6430553	0.821	rs12477502	ENSG00000224043.6	CCNT2-AS1	-4.13	4.23e-05	0.00681	-0.23	-0.19	Blood metabolite levels;	chr2:134871682	chr2:134735464~134918710:-
LUAD	cis	rs561341	0.824	rs1978115	ENSG00000265798.5	RP11-271K11.5	4.13	4.23e-05	0.00681	0.28	0.19	Hip circumference adjusted for BMI;	chr17:31893757	chr17:31038575~31059121:-
LUAD	cis	rs6604026	0.624	rs34202284	ENSG00000223787.2	RP4-593M8.1	-4.13	4.23e-05	0.00681	-0.25	-0.19	Multiple sclerosis;	chr1:92694445	chr1:92580476~92580821:-
LUAD	cis	rs2749097	0.735	rs12127151	ENSG00000244256.3	RN7SL130P	-4.13	4.23e-05	0.00681	-0.25	-0.19	Alcohol consumption (transferrin glycosylation);	chr1:63684028	chr1:63655743~63656047:+
LUAD	cis	rs711830	0.576	rs1348807	ENSG00000272729.1	RP11-387A1.5	4.13	4.23e-05	0.00681	0.2	0.19	Serous invasive ovarian cancer;Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;High-grade serous ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;	chr2:176141029	chr2:176164164~176165716:-
LUAD	cis	rs7746199	0.736	rs35848276	ENSG00000219392.1	RP1-265C24.5	-4.13	4.23e-05	0.00681	-0.4	-0.19	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27553317	chr6:28115628~28116551:+
LUAD	cis	rs12478296	1	rs56323081	ENSG00000261186.2	RP11-341N2.1	-4.13	4.23e-05	0.00681	-0.33	-0.19	Obesity-related traits;	chr2:242098656	chr2:242087351~242088457:-
LUAD	cis	rs11051970	1	rs1872829	ENSG00000274964.1	RP11-817I4.1	-4.13	4.23e-05	0.00681	-0.2	-0.19	Response to tocilizumab in rheumatoid arthritis;	chr12:32382166	chr12:32339368~32340724:+
LUAD	cis	rs763121	0.853	rs3788544	ENSG00000228274.3	RP3-508I15.9	-4.13	4.23e-05	0.00681	-0.19	-0.19	Menopause (age at onset);	chr22:38668961	chr22:38667585~38681820:-
LUAD	cis	rs7116495	1	rs642573	ENSG00000254682.1	RP11-660L16.2	4.13	4.23e-05	0.00681	0.41	0.19	Severe influenza A (H1N1) infection;	chr11:72069808	chr11:71448674~71452157:+
LUAD	cis	rs17772222	1	rs17698817	ENSG00000258983.2	RP11-507K2.2	4.13	4.23e-05	0.00682	0.22	0.19	Coronary artery calcification;	chr14:88356632	chr14:88499334~88515502:+
LUAD	cis	rs28386778	0.897	rs7222189	ENSG00000240280.5	TCAM1P	-4.13	4.23e-05	0.00682	-0.21	-0.19	Prudent dietary pattern;	chr17:63759012	chr17:63849292~63864379:+
LUAD	cis	rs9815354	1	rs6783001	ENSG00000273328.4	RP11-141M3.6	-4.13	4.23e-05	0.00682	-0.27	-0.19	Pulse pressure;Diastolic blood pressure;	chr3:41820740	chr3:42809414~42908105:+
LUAD	cis	rs9815354	0.953	rs6795797	ENSG00000273328.4	RP11-141M3.6	-4.13	4.23e-05	0.00682	-0.27	-0.19	Pulse pressure;Diastolic blood pressure;	chr3:41820758	chr3:42809414~42908105:+
LUAD	cis	rs36093844	0.799	rs74440131	ENSG00000279742.1	RP11-700A24.1	-4.13	4.23e-05	0.00682	-0.21	-0.19	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85887906	chr11:85852557~85854943:-
LUAD	cis	rs6472235	0.586	rs62507386	ENSG00000200714.1	Y_RNA	-4.13	4.23e-05	0.00682	-0.25	-0.19	Plateletcrit;Myopia (pathological);	chr8:66012724	chr8:65592731~65592820:+
LUAD	cis	rs8177876	0.749	rs12927828	ENSG00000261061.1	RP11-303E16.2	-4.13	4.23e-05	0.00682	-0.26	-0.19	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81057019	chr16:81030770~81031485:+
LUAD	cis	rs7636293	0.551	rs9858960	ENSG00000270773.1	RP13-685P2.7	4.13	4.23e-05	0.00682	0.27	0.19	Height;	chr3:129324182	chr3:129345411~129346164:+
LUAD	cis	rs28386778	0.863	rs2251164	ENSG00000240280.5	TCAM1P	-4.13	4.23e-05	0.00682	-0.21	-0.19	Prudent dietary pattern;	chr17:63806760	chr17:63849292~63864379:+
LUAD	cis	rs7674212	0.51	rs6856593	ENSG00000246560.2	RP11-10L12.4	4.13	4.23e-05	0.00682	0.23	0.19	Type 2 diabetes;	chr4:103256542	chr4:102828055~102844075:+
LUAD	cis	rs2562456	0.833	rs11670815	ENSG00000268081.1	RP11-678G14.2	4.13	4.24e-05	0.00682	0.29	0.19	Pain;	chr19:21356515	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.833	rs11666540	ENSG00000268081.1	RP11-678G14.2	4.13	4.24e-05	0.00682	0.29	0.19	Pain;	chr19:21356550	chr19:21554640~21569237:-
LUAD	cis	rs10463554	0.927	rs55641526	ENSG00000250682.4	LINC00491	4.13	4.24e-05	0.00682	0.22	0.19	Parkinson's disease;	chr5:102915301	chr5:102609156~102671559:-
LUAD	cis	rs6687821	0.605	rs166413	ENSG00000267734.1	RP4-604K5.3	4.13	4.24e-05	0.00682	0.22	0.19	Yeast infection;	chr1:86775503	chr1:86932199~86934891:-
LUAD	cis	rs7131987	0.565	rs766445	ENSG00000257176.2	RP11-996F15.2	4.13	4.24e-05	0.00683	0.19	0.19	QT interval;	chr12:29260560	chr12:29280418~29317848:-
LUAD	cis	rs10899021	0.512	rs10219168	ENSG00000279353.1	RP11-864N7.4	-4.13	4.24e-05	0.00683	-0.26	-0.19	Response to metformin (IC50);	chr11:74663408	chr11:74698231~74699658:-
LUAD	cis	rs13113518	1	rs4864549	ENSG00000272969.1	RP11-528I4.2	4.13	4.24e-05	0.00683	0.19	0.19	Height;	chr4:55554380	chr4:55547112~55547889:+
LUAD	cis	rs13113518	0.812	rs2048564	ENSG00000272969.1	RP11-528I4.2	4.13	4.24e-05	0.00683	0.2	0.19	Height;	chr4:55407965	chr4:55547112~55547889:+
LUAD	cis	rs6142102	1	rs4911412	ENSG00000275784.1	RP5-1125A11.6	-4.13	4.24e-05	0.00683	-0.21	-0.19	Skin pigmentation;	chr20:34128629	chr20:33989480~33991818:-
LUAD	cis	rs860818	1	rs858249	ENSG00000226816.2	AC005082.12	-4.13	4.24e-05	0.00683	-0.47	-0.19	Initial pursuit acceleration;	chr7:23181020	chr7:23206013~23208045:+
LUAD	cis	rs9847710	0.967	rs2244552	ENSG00000242142.1	SERBP1P3	4.13	4.24e-05	0.00683	0.2	0.19	Ulcerative colitis;	chr3:53021506	chr3:53064283~53065091:-
LUAD	cis	rs12935418	1	rs2602431	ENSG00000261061.1	RP11-303E16.2	4.13	4.24e-05	0.00683	0.23	0.19	Mean corpuscular volume;	chr16:81037092	chr16:81030770~81031485:+
LUAD	cis	rs4819052	1	rs9984901	ENSG00000215447.6	BX322557.10	-4.13	4.24e-05	0.00683	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244037	chr21:45288052~45291738:+
LUAD	cis	rs11742741	0.64	rs62349717	ENSG00000248874.4	C5orf17	-4.13	4.24e-05	0.00683	-0.23	-0.19	Educational attainment;	chr5:24045234	chr5:23951348~24178263:+
LUAD	cis	rs516805	0.501	rs564611	ENSG00000279453.1	RP3-425C14.4	-4.13	4.24e-05	0.00683	-0.19	-0.19	Lymphocyte counts;	chr6:122418178	chr6:122436789~122439223:-
LUAD	cis	rs6142102	0.961	rs4911144	ENSG00000275784.1	RP5-1125A11.6	-4.13	4.24e-05	0.00683	-0.21	-0.19	Skin pigmentation;	chr20:34026565	chr20:33989480~33991818:-
LUAD	cis	rs2735413	0.564	rs11863846	ENSG00000276007.1	RP11-358L22.3	4.13	4.24e-05	0.00683	0.26	0.19	Systolic blood pressure (alcohol consumption interaction);	chr16:78085660	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.564	rs7192226	ENSG00000276007.1	RP11-358L22.3	4.13	4.24e-05	0.00683	0.26	0.19	Systolic blood pressure (alcohol consumption interaction);	chr16:78086363	chr16:78123243~78124332:+
LUAD	cis	rs2274273	0.564	rs3783649	ENSG00000258413.1	RP11-665C16.6	-4.13	4.24e-05	0.00683	-0.25	-0.19	Protein biomarker;	chr14:55367692	chr14:55262767~55272075:-
LUAD	cis	rs12999542	0.706	rs11465689	ENSG00000234389.1	AC007278.3	4.13	4.24e-05	0.00683	0.3	0.19	Serum protein levels (sST2);	chr2:102423707	chr2:102438713~102440475:+
LUAD	cis	rs1864585	0.52	rs17776622	ENSG00000255046.1	RP11-297N6.4	4.13	4.24e-05	0.00683	0.26	0.19	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10818987	chr8:11797928~11802568:-
LUAD	cis	rs1355223	0.902	rs12800220	ENSG00000271369.1	RP11-350D17.3	-4.13	4.24e-05	0.00683	-0.22	-0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34680070	chr11:34709600~34710161:+
LUAD	cis	rs5758511	0.508	rs58099562	ENSG00000226450.2	CYP2D8P	4.13	4.25e-05	0.00684	0.18	0.19	Birth weight;	chr22:42057768	chr22:42149886~42155001:-
LUAD	cis	rs301901	0.581	rs292174	ENSG00000250155.1	CTD-2353F22.1	-4.13	4.25e-05	0.00684	-0.2	-0.19	Height;	chr5:36832039	chr5:36666214~36725195:-
LUAD	cis	rs7727544	0.582	rs3792894	ENSG00000233006.5	AC034220.3	4.13	4.25e-05	0.00684	0.16	0.19	Blood metabolite levels;	chr5:132211578	chr5:132311285~132369916:-
LUAD	cis	rs3096299	0.658	rs34590044	ENSG00000261118.1	RP11-104N10.1	4.13	4.25e-05	0.00684	0.19	0.19	Multiple myeloma (IgH translocation);	chr16:89476749	chr16:89492017~89504460:-
LUAD	cis	rs3177980	0.673	rs17603022	ENSG00000239494.2	RN7SL333P	-4.13	4.25e-05	0.00684	-0.18	-0.19	Amyotrophic lateral sclerosis;	chr1:169869137	chr1:169859756~169860052:+
LUAD	cis	rs11841001	0.556	rs12859043	ENSG00000261105.4	LMO7-AS1	-4.13	4.25e-05	0.00684	-0.3	-0.19	Corneal astigmatism;	chr13:75769362	chr13:75604700~75635994:-
LUAD	cis	rs1329650	1	rs10881926	ENSG00000228701.1	TNKS2-AS1	-4.13	4.25e-05	0.00685	-0.25	-0.19	Smoking behavior;	chr10:91584497	chr10:91782839~91798291:-
LUAD	cis	rs8012947	1	rs7153897	ENSG00000279636.2	LINC00216	-4.13	4.25e-05	0.00685	-0.2	-0.19	Alcohol consumption in current drinkers;	chr14:58295479	chr14:58288033~58289158:+
LUAD	cis	rs4713118	0.539	rs200951	ENSG00000280107.1	AL022393.9	-4.13	4.25e-05	0.00685	-0.23	-0.19	Parkinson's disease;	chr6:27868152	chr6:28170845~28172521:+
LUAD	cis	rs6661961	0.714	rs12749879	ENSG00000237975.5	FLG-AS1	-4.13	4.25e-05	0.00685	-0.25	-0.19	Atopic dermatitis;	chr1:152475515	chr1:152168125~152445456:+
LUAD	cis	rs4819052	0.765	rs2838827	ENSG00000237664.1	LINC00316	-4.13	4.26e-05	0.00685	-0.23	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236231	chr21:45338590~45341990:-
LUAD	cis	rs12478296	0.792	rs6738361	ENSG00000261186.2	RP11-341N2.1	-4.13	4.26e-05	0.00685	-0.32	-0.19	Obesity-related traits;	chr2:242072106	chr2:242087351~242088457:-
LUAD	cis	rs2235642	0.928	rs2076435	ENSG00000280231.1	LA16c-380F5.3	-4.13	4.26e-05	0.00685	-0.25	-0.19	Coronary artery disease;	chr16:1557573	chr16:1553655~1554130:-
LUAD	cis	rs4664293	0.667	rs6432562	ENSG00000224152.1	AC009506.1	-4.13	4.26e-05	0.00685	-0.19	-0.19	Monocyte percentage of white cells;	chr2:159791495	chr2:159615296~159617082:+
LUAD	cis	rs1876905	0.539	rs457497	ENSG00000230177.1	RP5-1112D6.4	4.13	4.26e-05	0.00686	0.23	0.19	Mean corpuscular hemoglobin;	chr6:111301346	chr6:111277932~111278742:+
LUAD	cis	rs12898179	0.53	rs11626910	ENSG00000258561.1	RP11-72M17.1	4.13	4.26e-05	0.00686	0.28	0.19	Glomerular filtration rate in chronic kidney disease;	chr14:67503044	chr14:66212810~66509394:-
LUAD	cis	rs7762018	0.943	rs7772889	ENSG00000231690.2	LINC00574	-4.13	4.26e-05	0.00686	-0.35	-0.19	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169742362	chr6:169790321~169802873:+
LUAD	cis	rs17772222	0.958	rs76559451	ENSG00000258789.1	RP11-507K2.3	-4.13	4.26e-05	0.00686	-0.25	-0.19	Coronary artery calcification;	chr14:88523193	chr14:88551597~88552493:+
LUAD	cis	rs7202877	0.706	rs1074961	ENSG00000280152.1	RP11-331F4.5	4.13	4.26e-05	0.00686	0.21	0.19	Type 1 diabetes;Type 2 diabetes;	chr16:75355586	chr16:75245994~75250077:-
LUAD	cis	rs17772222	0.876	rs61983303	ENSG00000258789.1	RP11-507K2.3	-4.13	4.26e-05	0.00686	-0.26	-0.19	Coronary artery calcification;	chr14:88764459	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.917	rs2224333	ENSG00000258789.1	RP11-507K2.3	-4.13	4.26e-05	0.00686	-0.26	-0.19	Coronary artery calcification;	chr14:88768748	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.917	rs12590826	ENSG00000258789.1	RP11-507K2.3	-4.13	4.26e-05	0.00686	-0.26	-0.19	Coronary artery calcification;	chr14:88769357	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.917	rs57889459	ENSG00000258789.1	RP11-507K2.3	-4.13	4.26e-05	0.00686	-0.26	-0.19	Coronary artery calcification;	chr14:88770820	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.917	rs61982733	ENSG00000258789.1	RP11-507K2.3	-4.13	4.26e-05	0.00686	-0.26	-0.19	Coronary artery calcification;	chr14:88776244	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.917	rs2145120	ENSG00000258789.1	RP11-507K2.3	-4.13	4.26e-05	0.00686	-0.26	-0.19	Coronary artery calcification;	chr14:88777699	chr14:88551597~88552493:+
LUAD	cis	rs2460905	1	rs2460898	ENSG00000251468.2	RP11-369K16.1	-4.13	4.26e-05	0.00686	-0.45	-0.19	Post-traumatic stress disorder;	chr8:12972435	chr8:12958387~12962200:+
LUAD	cis	rs1876905	0.68	rs187130	ENSG00000230177.1	RP5-1112D6.4	-4.13	4.26e-05	0.00686	-0.21	-0.19	Mean corpuscular hemoglobin;	chr6:111188360	chr6:111277932~111278742:+
LUAD	cis	rs2014572	0.933	rs8107516	ENSG00000268379.1	CTC-360J11.4	4.13	4.26e-05	0.00686	0.22	0.19	Hyperactive-impulsive symptoms;	chr19:57247077	chr19:57175233~57177921:+
LUAD	cis	rs62355900	0.627	rs72758096	ENSG00000271828.1	CTD-2310F14.1	4.13	4.27e-05	0.00686	0.34	0.19	Endometriosis;	chr5:56870367	chr5:56927874~56929573:+
LUAD	cis	rs62355900	0.627	rs3736430	ENSG00000271828.1	CTD-2310F14.1	4.13	4.27e-05	0.00686	0.34	0.19	Endometriosis;	chr5:56884653	chr5:56927874~56929573:+
LUAD	cis	rs7429990	0.932	rs6442101	ENSG00000228638.1	FCF1P2	4.13	4.27e-05	0.00686	0.22	0.19	Educational attainment (years of education);	chr3:48089403	chr3:48290793~48291375:-
LUAD	cis	rs9876781	1	rs13076076	ENSG00000229759.1	MRPS18AP1	4.13	4.27e-05	0.00687	0.18	0.19	Longevity;	chr3:48437629	chr3:48256350~48256938:-
LUAD	cis	rs910316	0.967	rs11159121	ENSG00000279594.1	RP11-950C14.10	-4.13	4.27e-05	0.00687	-0.21	-0.19	Height;	chr14:75199326	chr14:75011269~75012851:-
LUAD	cis	rs13014235	0.592	rs55860809	ENSG00000213090.2	AC007256.5	4.13	4.27e-05	0.00687	0.21	0.19	Basal cell carcinoma;	chr2:201394347	chr2:201410544~201413308:-
LUAD	cis	rs2836974	0.831	rs2836921	ENSG00000232608.1	TIMM9P2	-4.13	4.27e-05	0.00687	-0.23	-0.19	Cognitive function;	chr21:39144144	chr21:39216624~39217506:+
LUAD	cis	rs9400467	0.528	rs4276544	ENSG00000230177.1	RP5-1112D6.4	-4.13	4.27e-05	0.00687	-0.16	-0.19	Amino acid levels;Blood metabolite levels;	chr6:111438496	chr6:111277932~111278742:+
LUAD	cis	rs780096	0.506	rs780100	ENSG00000234072.1	AC074117.10	-4.13	4.27e-05	0.00687	-0.14	-0.19	Total body bone mineral density;	chr2:27429286	chr2:27356246~27367622:+
LUAD	cis	rs11673344	0.543	rs8108429	ENSG00000276846.1	CTD-3220F14.3	4.13	4.27e-05	0.00687	0.21	0.19	Obesity-related traits;	chr19:37145874	chr19:37314868~37315620:-
LUAD	cis	rs8073060	0.561	rs225260	ENSG00000267592.1	CTC-507E2.2	4.13	4.27e-05	0.00687	0.27	0.19	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35631403	chr17:35596904~35597128:-
LUAD	cis	rs17507216	0.628	rs17158396	ENSG00000255769.6	GOLGA2P10	-4.13	4.27e-05	0.00687	-0.22	-0.19	Excessive daytime sleepiness;	chr15:82615688	chr15:82472993~82513950:-
LUAD	cis	rs860295	0.841	rs7556102	ENSG00000160766.13	GBAP1	4.13	4.27e-05	0.00687	0.2	0.19	Body mass index;	chr1:155398412	chr1:155213821~155227422:-
LUAD	cis	rs9649213	0.574	rs3801251	ENSG00000272950.1	RP11-307C18.1	4.13	4.27e-05	0.00687	0.23	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98398306	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.593	rs3779193	ENSG00000272950.1	RP11-307C18.1	4.13	4.27e-05	0.00687	0.23	0.19	Prostate cancer (SNP x SNP interaction);	chr7:98399154	chr7:98322853~98323430:+
LUAD	cis	rs6088580	0.634	rs6059905	ENSG00000276073.1	RP5-1125A11.7	-4.13	4.27e-05	0.00687	-0.18	-0.19	Glomerular filtration rate (creatinine);	chr20:34539142	chr20:33985617~33988989:-
LUAD	cis	rs1387259	0.79	rs2732445	ENSG00000240399.1	RP1-228P16.1	4.13	4.27e-05	0.00687	0.19	0.19	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48251750	chr12:48054813~48055591:-
LUAD	cis	rs67981189	0.529	rs61990379	ENSG00000269927.1	RP6-91H8.3	4.13	4.27e-05	0.00688	0.24	0.19	Schizophrenia;	chr14:71000353	chr14:71141125~71143253:-
LUAD	cis	rs7635879	0.693	rs4687496	ENSG00000230102.6	RP11-407B7.1	4.13	4.28e-05	0.00688	0.22	0.19	Breastfeeding duration;	chr3:194011436	chr3:194005259~194070970:-
LUAD	cis	rs8073060	0.544	rs1080352	ENSG00000267592.1	CTC-507E2.2	4.13	4.28e-05	0.00688	0.27	0.19	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35675343	chr17:35596904~35597128:-
LUAD	cis	rs911555	0.692	rs7140647	ENSG00000244691.1	RPL10AP1	4.13	4.28e-05	0.00688	0.24	0.19	Intelligence (multi-trait analysis);	chr14:103427128	chr14:103412119~103412761:-
LUAD	cis	rs2732480	0.577	rs2634680	ENSG00000240399.1	RP1-228P16.1	4.13	4.28e-05	0.00688	0.19	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48340781	chr12:48054813~48055591:-
LUAD	cis	rs2732480	0.577	rs2634678	ENSG00000240399.1	RP1-228P16.1	4.13	4.28e-05	0.00688	0.19	0.19	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48341755	chr12:48054813~48055591:-
LUAD	cis	rs7590268	0.895	rs10445925	ENSG00000279873.2	LINC01126	-4.13	4.28e-05	0.00689	-0.18	-0.19	Orofacial clefts;	chr2:43443005	chr2:43227210~43228855:+
LUAD	cis	rs6496932	1	rs28374025	ENSG00000259630.2	CTD-2262B20.1	4.13	4.28e-05	0.00689	0.25	0.19	Central corneal thickness;Corneal structure;	chr15:85284107	chr15:85415228~85415633:+
LUAD	cis	rs6496932	1	rs12917495	ENSG00000259630.2	CTD-2262B20.1	4.13	4.28e-05	0.00689	0.25	0.19	Central corneal thickness;Corneal structure;	chr15:85286330	chr15:85415228~85415633:+
LUAD	cis	rs2348418	0.832	rs11049559	ENSG00000247934.4	RP11-967K21.1	4.13	4.28e-05	0.00689	0.21	0.19	Lung function (FEV1);Lung function (FVC);	chr12:28372264	chr12:28163298~28190738:-
LUAD	cis	rs7204230	1	rs10852504	ENSG00000261291.1	RP11-295M3.2	-4.13	4.28e-05	0.00689	-0.24	-0.19	Fibrinogen;	chr16:53289837	chr16:53168522~53169450:+
LUAD	cis	rs763121	0.853	rs3747172	ENSG00000225450.1	RP3-508I15.14	-4.13	4.28e-05	0.00689	-0.18	-0.19	Menopause (age at onset);	chr22:38671519	chr22:38739003~38749041:+
LUAD	cis	rs763121	0.853	rs5750659	ENSG00000225450.1	RP3-508I15.14	-4.13	4.28e-05	0.00689	-0.18	-0.19	Menopause (age at onset);	chr22:38672784	chr22:38739003~38749041:+
LUAD	cis	rs763121	0.819	rs3747173	ENSG00000225450.1	RP3-508I15.14	-4.13	4.28e-05	0.00689	-0.18	-0.19	Menopause (age at onset);	chr22:38673040	chr22:38739003~38749041:+
LUAD	cis	rs763121	0.853	rs3747174	ENSG00000225450.1	RP3-508I15.14	-4.13	4.28e-05	0.00689	-0.18	-0.19	Menopause (age at onset);	chr22:38673176	chr22:38739003~38749041:+
LUAD	cis	rs763121	0.853	rs5757226	ENSG00000225450.1	RP3-508I15.14	-4.13	4.28e-05	0.00689	-0.18	-0.19	Menopause (age at onset);	chr22:38674545	chr22:38739003~38749041:+
LUAD	cis	rs1322639	0.614	rs6937001	ENSG00000261039.2	RP11-417E7.2	4.13	4.28e-05	0.00689	0.29	0.19	Pulse pressure;	chr6:169164991	chr6:169175304~169182740:-
LUAD	cis	rs1044826	1	rs9834607	ENSG00000214280.3	RP11-553K23.2	-4.13	4.29e-05	0.00689	-0.22	-0.19	Obesity-related traits;	chr3:139515342	chr3:139582928~139583593:-
LUAD	cis	rs77204473	0.793	rs11216206	ENSG00000280143.1	AP000892.6	-4.13	4.29e-05	0.00689	-0.35	-0.19	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116972709	chr11:117204967~117210292:+
LUAD	cis	rs2898290	0.54	rs12677146	ENSG00000255046.1	RP11-297N6.4	4.13	4.29e-05	0.00689	0.23	0.19	Systolic blood pressure;	chr8:11593228	chr8:11797928~11802568:-
LUAD	cis	rs34779708	0.931	rs11010125	ENSG00000271335.4	RP11-324I22.4	4.13	4.29e-05	0.00689	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35214025	chr10:35314552~35336401:-
LUAD	cis	rs4819052	0.851	rs2838856	ENSG00000223768.1	LINC00205	-4.13	4.29e-05	0.0069	-0.22	-0.19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260851	chr21:45293285~45297354:+
LUAD	cis	rs11250098	0.51	rs4840525	ENSG00000255046.1	RP11-297N6.4	4.13	4.29e-05	0.0069	0.23	0.19	Morning vs. evening chronotype;	chr8:10908125	chr8:11797928~11802568:-
LUAD	cis	rs9876781	1	rs11130171	ENSG00000229759.1	MRPS18AP1	4.13	4.29e-05	0.0069	0.18	0.19	Longevity;	chr3:48421052	chr3:48256350~48256938:-
LUAD	cis	rs860295	0.702	rs12025532	ENSG00000225855.5	RUSC1-AS1	4.13	4.29e-05	0.0069	0.13	0.19	Body mass index;	chr1:155399511	chr1:155316863~155324176:-
LUAD	cis	rs6754311	0.731	rs4954490	ENSG00000226806.1	AC011893.3	-4.13	4.29e-05	0.0069	-0.23	-0.19	Mosquito bite size;	chr2:135850661	chr2:135820191~135823087:+
LUAD	cis	rs12122100	0.837	rs12142004	ENSG00000244371.2	PFN1P8	4.13	4.29e-05	0.0069	0.23	0.19	HIV-1 control;	chr1:147035122	chr1:146957117~146957659:-
LUAD	cis	rs2243480	1	rs73150014	ENSG00000229886.1	RP5-1132H15.3	4.13	4.3e-05	0.00691	0.32	0.19	Diabetic kidney disease;	chr7:65985932	chr7:66025126~66031544:-
LUAD	cis	rs34779708	0.931	rs2148482	ENSG00000271335.4	RP11-324I22.4	4.13	4.3e-05	0.00691	0.2	0.19	Inflammatory bowel disease;Crohn's disease;	chr10:35059982	chr10:35314552~35336401:-
LUAD	cis	rs6988985	0.678	rs28491316	ENSG00000247317.3	RP11-273G15.2	-4.13	4.3e-05	0.00691	-0.22	-0.19	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142911245	chr8:142981738~143018437:-
LUAD	cis	rs4699052	1	rs4699052	ENSG00000246560.2	RP11-10L12.4	4.13	4.3e-05	0.00691	0.23	0.19	Testicular germ cell tumor;	chr4:103216633	chr4:102828055~102844075:+
LUAD	cis	rs6964587	0.967	rs7781221	ENSG00000188693.7	CYP51A1-AS1	-4.13	4.3e-05	0.00691	-0.22	-0.19	Breast cancer;	chr7:92035331	chr7:92134604~92180725:+
LUAD	cis	rs6964587	1	rs2285333	ENSG00000188693.7	CYP51A1-AS1	-4.13	4.3e-05	0.00691	-0.22	-0.19	Breast cancer;	chr7:92038378	chr7:92134604~92180725:+
LUAD	cis	rs848490	0.889	rs6966257	ENSG00000214293.7	APTR	4.13	4.3e-05	0.00691	0.24	0.19	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77656151	chr7:77657660~77696265:-
LUAD	cis	rs848490	0.889	rs56198418	ENSG00000214293.7	APTR	4.13	4.3e-05	0.00691	0.24	0.19	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77659141	chr7:77657660~77696265:-
LUAD	cis	rs9860428	0.844	rs9878597	ENSG00000242770.2	RP11-180K7.1	4.13	4.3e-05	0.00691	0.2	0.19	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112866101	chr3:112802478~112812819:+
LUAD	cis	rs4474465	1	rs10899505	ENSG00000251323.2	RP11-452H21.4	4.13	4.3e-05	0.00691	0.23	0.19	Alzheimer's disease (survival time);	chr11:78454297	chr11:78423982~78429836:-
LUAD	cis	rs73193808	0.802	rs7281059	ENSG00000215533.7	LINC00189	-4.13	4.3e-05	0.00691	-0.27	-0.19	Coronary artery disease;	chr21:29216947	chr21:29193480~29288205:+
LUAD	cis	rs11089937	0.597	rs5757007	ENSG00000211640.3	IGLV6-57	4.13	4.3e-05	0.00691	0.14	0.19	Periodontitis (PAL4Q3);	chr22:22135167	chr22:22195713~22196460:+
LUAD	cis	rs8077577	0.747	rs2290505	ENSG00000273018.4	CTD-2303H24.2	4.13	4.3e-05	0.00691	0.27	0.19	Obesity-related traits;	chr17:18233827	chr17:18511221~18551705:-
LUAD	cis	rs720064	0.562	rs1711450	ENSG00000264745.1	TTC39C-AS1	4.13	4.3e-05	0.00691	0.2	0.18	Strep throat;	chr18:23688236	chr18:23994213~24015339:-
LUAD	cis	rs17807624	0.964	rs13249843	ENSG00000255046.1	RP11-297N6.4	-4.13	4.3e-05	0.00692	-0.24	-0.18	Systemic lupus erythematosus;	chr8:11601509	chr8:11797928~11802568:-
LUAD	cis	rs651907	0.535	rs34648996	ENSG00000244119.1	PDCL3P4	4.13	4.3e-05	0.00692	0.19	0.18	Colorectal cancer;	chr3:101792358	chr3:101712472~101713191:+
LUAD	cis	rs11089937	0.626	rs10483106	ENSG00000211639.2	IGLV4-60	4.13	4.3e-05	0.00692	0.25	0.18	Periodontitis (PAL4Q3);	chr22:22149240	chr22:22162199~22162681:+
LUAD	cis	rs848490	0.851	rs62462686	ENSG00000214293.7	APTR	4.13	4.31e-05	0.00692	0.25	0.18	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77879330	chr7:77657660~77696265:-
LUAD	cis	rs3096299	0.503	rs4785677	ENSG00000261118.1	RP11-104N10.1	4.13	4.31e-05	0.00692	0.19	0.18	Multiple myeloma (IgH translocation);	chr16:89488693	chr16:89492017~89504460:-
LUAD	cis	rs858239	0.601	rs2141307	ENSG00000226816.2	AC005082.12	4.13	4.31e-05	0.00692	0.25	0.18	Cerebrospinal fluid biomarker levels;	chr7:23151805	chr7:23206013~23208045:+
LUAD	cis	rs9876781	1	rs6442118	ENSG00000229759.1	MRPS18AP1	4.13	4.31e-05	0.00692	0.18	0.18	Longevity;	chr3:48398582	chr3:48256350~48256938:-
LUAD	cis	rs1334894	0.892	rs76032009	ENSG00000228559.1	RP3-340B19.3	-4.13	4.31e-05	0.00692	-0.42	-0.18	Coronary artery disease;	chr6:35510722	chr6:35544632~35545669:+
LUAD	cis	rs3764021	0.933	rs2268146	ENSG00000256582.1	RP11-75L1.1	4.13	4.31e-05	0.00692	0.19	0.18	Type 1 diabetes;	chr12:9716675	chr12:9704077~9709350:+
LUAD	cis	rs11779988	0.545	rs409217	ENSG00000253671.1	RP11-806O11.1	-4.13	4.31e-05	0.00693	-0.22	-0.18	Breast cancer;	chr8:17959088	chr8:17808941~17820868:+
LUAD	cis	rs5758511	0.68	rs5751243	ENSG00000233903.2	Z83851.4	4.13	4.31e-05	0.00693	0.27	0.18	Birth weight;	chr22:42221171	chr22:42276355~42277052:+
LUAD	cis	rs5758511	0.637	rs5751244	ENSG00000233903.2	Z83851.4	4.13	4.31e-05	0.00693	0.27	0.18	Birth weight;	chr22:42221405	chr22:42276355~42277052:+
LUAD	cis	rs4713118	0.513	rs149958	ENSG00000216901.1	AL022393.7	4.13	4.31e-05	0.00693	0.22	0.18	Parkinson's disease;	chr6:28045839	chr6:28176188~28176674:+
LUAD	cis	rs77633900	0.803	rs2469212	ENSG00000196274.5	Metazoa_SRP	4.13	4.31e-05	0.00693	0.24	0.18	Glioma;Non-glioblastoma glioma;	chr15:76308734	chr15:76230048~76230390:-
LUAD	cis	rs2929278	0.561	rs62018952	ENSG00000166763.7	STRCP1	-4.13	4.32e-05	0.00693	-0.22	-0.18	Schizophrenia;	chr15:43788539	chr15:43699488~43718184:-
LUAD	cis	rs2274273	0.901	rs10140801	ENSG00000259318.1	RP11-454L9.2	4.13	4.32e-05	0.00693	0.16	0.18	Protein biomarker;	chr14:55263686	chr14:55394940~55395233:-
LUAD	cis	rs6723226	0.804	rs17428810	ENSG00000276334.1	AL133243.1	-4.13	4.32e-05	0.00693	-0.23	-0.18	Intelligence (multi-trait analysis);	chr2:32510976	chr2:32521927~32523547:+
LUAD	cis	rs875971	0.502	rs2946580	ENSG00000222364.1	RNU6-96P	4.13	4.32e-05	0.00694	0.25	0.18	Aortic root size;	chr7:66066855	chr7:66395191~66395286:+
LUAD	cis	rs9513627	0.573	rs4771336	ENSG00000280710.1	RP11-214F16.8	4.13	4.32e-05	0.00694	0.26	0.18	Obesity-related traits;	chr13:99558356	chr13:99498524~99501315:+
LUAD	cis	rs4664293	0.967	rs13000070	ENSG00000230783.1	AC009961.2	-4.13	4.32e-05	0.00694	-0.24	-0.18	Monocyte percentage of white cells;	chr2:159669263	chr2:159689217~159690291:-
LUAD	cis	rs2243480	1	rs958550	ENSG00000232559.3	GS1-124K5.12	-4.13	4.32e-05	0.00694	-0.29	-0.18	Diabetic kidney disease;	chr7:66170692	chr7:66554588~66576923:-
LUAD	cis	rs7429990	0.965	rs4858810	ENSG00000228638.1	FCF1P2	4.13	4.32e-05	0.00694	0.23	0.18	Educational attainment (years of education);	chr3:48002247	chr3:48290793~48291375:-
LUAD	cis	rs9876781	1	rs9883927	ENSG00000229759.1	MRPS18AP1	4.13	4.32e-05	0.00694	0.18	0.18	Longevity;	chr3:48422302	chr3:48256350~48256938:-
LUAD	cis	rs9876781	1	rs9817615	ENSG00000229759.1	MRPS18AP1	4.13	4.32e-05	0.00694	0.18	0.18	Longevity;	chr3:48429347	chr3:48256350~48256938:-
LUAD	cis	rs9876781	1	rs2290822	ENSG00000229759.1	MRPS18AP1	4.13	4.32e-05	0.00694	0.18	0.18	Longevity;	chr3:48431794	chr3:48256350~48256938:-
LUAD	cis	rs1864585	0.52	rs56122299	ENSG00000255046.1	RP11-297N6.4	4.13	4.32e-05	0.00694	0.26	0.18	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10805263	chr8:11797928~11802568:-
LUAD	cis	rs28588043	0.555	rs16863926	ENSG00000271811.1	RP1-79C4.4	-4.13	4.32e-05	0.00694	-0.26	-0.18	Number of children (6+ vs. 0 or 1);	chr1:170990167	chr1:170667381~170669425:+
LUAD	cis	rs11220082	0.627	rs35102191	ENSG00000254671.2	STT3A-AS1	-4.13	4.32e-05	0.00695	-0.21	-0.18	Schizophrenia;	chr11:125455250	chr11:125570284~125592568:-
LUAD	cis	rs858239	0.601	rs7805206	ENSG00000230042.1	AK3P3	-4.13	4.33e-05	0.00695	-0.22	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23120591	chr7:23129178~23129841:+
LUAD	cis	rs73198271	0.74	rs10092600	ENSG00000253893.2	FAM85B	4.13	4.33e-05	0.00695	0.24	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791513	chr8:8167819~8226614:-
LUAD	cis	rs73198271	0.74	rs10105690	ENSG00000253893.2	FAM85B	4.13	4.33e-05	0.00695	0.24	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791722	chr8:8167819~8226614:-
LUAD	cis	rs950169	1	rs950169	ENSG00000275120.1	RP11-182J1.17	4.13	4.33e-05	0.00695	0.29	0.18	Schizophrenia;	chr15:84037709	chr15:84599434~84606463:-
LUAD	cis	rs7189233	0.531	rs4281707	ENSG00000279344.1	RP11-44F14.7	4.13	4.33e-05	0.00695	0.15	0.18	Intelligence (multi-trait analysis);	chr16:53468034	chr16:53478957~53481550:-
LUAD	cis	rs7551222	0.752	rs4951398	ENSG00000240219.1	RP11-430C7.5	4.13	4.33e-05	0.00695	0.19	0.18	Schizophrenia;	chr1:204562748	chr1:204626775~204629712:+
LUAD	cis	rs6964587	1	rs2282972	ENSG00000188693.7	CYP51A1-AS1	-4.13	4.33e-05	0.00695	-0.22	-0.18	Breast cancer;	chr7:92037055	chr7:92134604~92180725:+
LUAD	cis	rs9309473	0.5	rs2421668	ENSG00000163016.8	ALMS1P	-4.13	4.33e-05	0.00695	-0.2	-0.18	Metabolite levels;	chr2:73657969	chr2:73644919~73685576:+
LUAD	cis	rs877819	0.583	rs2663029	ENSG00000228403.1	RP11-563N6.6	4.13	4.33e-05	0.00695	0.19	0.18	Systemic lupus erythematosus;	chr10:48878956	chr10:48878022~48878649:+
LUAD	cis	rs9649213	0.593	rs12704989	ENSG00000272950.1	RP11-307C18.1	4.13	4.33e-05	0.00695	0.23	0.18	Prostate cancer (SNP x SNP interaction);	chr7:98400126	chr7:98322853~98323430:+
LUAD	cis	rs4713118	0.869	rs7776351	ENSG00000280107.1	AL022393.9	4.13	4.33e-05	0.00696	0.24	0.18	Parkinson's disease;	chr6:27758952	chr6:28170845~28172521:+
LUAD	cis	rs7302981	0.967	rs6580729	ENSG00000200428.1	Y_RNA	-4.13	4.33e-05	0.00696	-0.23	-0.18	Systolic blood pressure;	chr12:50153255	chr12:50743568~50743684:+
LUAD	cis	rs7098414	0.511	rs10466236	ENSG00000226659.1	RP11-137H2.4	4.13	4.33e-05	0.00696	0.25	0.18	Post bronchodilator FEV1;	chr10:80389961	chr10:80529597~80535942:-
LUAD	cis	rs6969780	0.915	rs12666926	ENSG00000233429.8	HOTAIRM1	-4.13	4.33e-05	0.00696	-0.3	-0.18	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27149942	chr7:27095647~27100265:+
LUAD	cis	rs7208859	0.623	rs8081299	ENSG00000266490.1	CTD-2349P21.9	4.13	4.33e-05	0.00696	0.27	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777278	chr17:30792372~30792833:+
LUAD	cis	rs2974760	0.606	rs6600143	ENSG00000226942.2	IL9RP3	4.13	4.33e-05	0.00696	0.23	0.18	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr16:151390	chr16:29336~38321:-
LUAD	cis	rs7208859	0.673	rs9913782	ENSG00000280069.1	CTD-2349P21.3	-4.13	4.34e-05	0.00696	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910366	chr17:30738182~30740275:+
LUAD	cis	rs7829975	0.902	rs777707	ENSG00000253981.4	ALG1L13P	4.13	4.34e-05	0.00696	0.21	0.18	Mood instability;	chr8:8726834	chr8:8236003~8244667:-
LUAD	cis	rs2836974	0.899	rs34433511	ENSG00000232608.1	TIMM9P2	-4.13	4.34e-05	0.00696	-0.22	-0.18	Cognitive function;	chr21:39246957	chr21:39216624~39217506:+
LUAD	cis	rs7246657	0.891	rs7253114	ENSG00000226686.6	LINC01535	-4.13	4.34e-05	0.00696	-0.27	-0.18	Coronary artery calcification;	chr19:37497823	chr19:37251912~37265535:+
LUAD	cis	rs11089937	0.626	rs737840	ENSG00000211640.3	IGLV6-57	4.13	4.34e-05	0.00696	0.14	0.18	Periodontitis (PAL4Q3);	chr22:22162743	chr22:22195713~22196460:+
LUAD	cis	rs8030379	1	rs4842838	ENSG00000230373.7	GOLGA6L5P	4.13	4.34e-05	0.00696	0.17	0.18	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83913372	chr15:84507885~84516814:-
LUAD	cis	rs2153535	0.518	rs9379225	ENSG00000230939.1	RP11-314C16.1	-4.13	4.34e-05	0.00696	-0.22	-0.18	Motion sickness;	chr6:8566027	chr6:8784178~8785445:+
LUAD	cis	rs12291225	0.679	rs1043237	ENSG00000251991.1	RNU7-49P	4.13	4.34e-05	0.00697	0.21	0.18	Sense of smell;	chr11:14267507	chr11:14478892~14478953:+
LUAD	cis	rs6496667	0.565	rs7162107	ENSG00000214433.4	GOLGA2P8	4.13	4.34e-05	0.00697	0.24	0.18	Rheumatoid arthritis;	chr15:90345814	chr15:90291962~90295683:+
LUAD	cis	rs8062405	0.755	rs4788076	ENSG00000261419.1	RP11-57A19.4	-4.13	4.34e-05	0.00697	-0.2	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28659696~28740781:-
LUAD	cis	rs728616	0.867	rs41298231	ENSG00000225484.5	NUTM2B-AS1	-4.13	4.34e-05	0.00697	-0.47	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79922705	chr10:79663088~79826594:-
LUAD	cis	rs6564219	1	rs6564219	ENSG00000261476.1	RP11-77K12.3	-4.13	4.34e-05	0.00697	-0.25	-0.18	Alcoholic chronic pancreatitis;	chr16:75188108	chr16:75458252~75460017:-
LUAD	cis	rs367615	0.523	rs4330503	ENSG00000249476.1	CTD-2587M2.1	4.13	4.35e-05	0.00697	0.2	0.18	Colorectal cancer (SNP x SNP interaction);	chr5:109519112	chr5:109237120~109326369:-
LUAD	cis	rs9633740	1	rs7922621	ENSG00000226659.1	RP11-137H2.4	-4.13	4.35e-05	0.00697	-0.3	-0.18	Post bronchodilator FEV1;	chr10:80491788	chr10:80529597~80535942:-
LUAD	cis	rs2657294	0.895	rs4746262	ENSG00000233313.2	HMGA1P5	-4.13	4.35e-05	0.00698	-0.23	-0.18	Pneumonia;	chr10:75093631	chr10:75276376~75276646:-
LUAD	cis	rs9813712	0.585	rs16824839	ENSG00000228252.7	COL6A4P2	-4.13	4.35e-05	0.00698	-0.21	-0.18	Response to amphetamines;	chr3:130220886	chr3:130212823~130273806:+
LUAD	cis	rs6840360	0.571	rs11723395	ENSG00000270265.1	RP11-731D1.4	-4.13	4.35e-05	0.00698	-0.21	-0.18	Intelligence (multi-trait analysis);	chr4:151603039	chr4:151333775~151353224:-
LUAD	cis	rs2836974	0.602	rs2037925	ENSG00000232608.1	TIMM9P2	4.13	4.35e-05	0.00698	0.22	0.18	Cognitive function;	chr21:39328005	chr21:39216624~39217506:+
LUAD	cis	rs7985	1	rs5761672	ENSG00000244625.4	MIATNB	4.13	4.35e-05	0.00698	0.19	0.18	Electroencephalogram traits;	chr22:26673476	chr22:26672767~26780207:+
LUAD	cis	rs67981189	0.57	rs67188216	ENSG00000269927.1	RP6-91H8.3	4.13	4.35e-05	0.00698	0.24	0.18	Schizophrenia;	chr14:71042607	chr14:71141125~71143253:-
LUAD	cis	rs67981189	0.529	rs8014273	ENSG00000269927.1	RP6-91H8.3	4.13	4.35e-05	0.00698	0.24	0.18	Schizophrenia;	chr14:71043113	chr14:71141125~71143253:-
LUAD	cis	rs67981189	0.529	rs8010063	ENSG00000269927.1	RP6-91H8.3	4.13	4.35e-05	0.00698	0.24	0.18	Schizophrenia;	chr14:71043408	chr14:71141125~71143253:-
LUAD	cis	rs10466239	1	rs10466239	ENSG00000230555.2	RP11-517P14.2	4.13	4.35e-05	0.00698	0.36	0.18	Telomere length;	chr10:43354379	chr10:43420738~43422100:+
LUAD	cis	rs7551222	0.721	rs4252717	ENSG00000240219.1	RP11-430C7.5	4.13	4.35e-05	0.00698	0.2	0.18	Schizophrenia;	chr1:204542972	chr1:204626775~204629712:+
LUAD	cis	rs1555322	0.53	rs2425053	ENSG00000279253.1	RP4-614O4.13	-4.13	4.35e-05	0.00698	-0.23	-0.18	Attention deficit hyperactivity disorder;	chr20:35294017	chr20:35262727~35264187:-
LUAD	cis	rs1015362	0.54	rs2378026	ENSG00000275784.1	RP5-1125A11.6	-4.13	4.35e-05	0.00699	-0.25	-0.18	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33921845	chr20:33989480~33991818:-
LUAD	cis	rs8073060	0.504	rs225271	ENSG00000267592.1	CTC-507E2.2	4.13	4.35e-05	0.00699	0.27	0.18	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35642817	chr17:35596904~35597128:-
LUAD	cis	rs9649213	0.593	rs10953257	ENSG00000272950.1	RP11-307C18.1	-4.13	4.35e-05	0.00699	-0.23	-0.18	Prostate cancer (SNP x SNP interaction);	chr7:98331352	chr7:98322853~98323430:+
LUAD	cis	rs2378497	0.564	rs115883774	ENSG00000238042.4	RP11-815M8.1	4.13	4.36e-05	0.00699	0.21	0.18	Serum thyroid-stimulating hormone levels;	chr1:221986970	chr1:221880981~221978523:-
LUAD	cis	rs2243480	0.708	rs13242216	ENSG00000229886.1	RP5-1132H15.3	4.13	4.36e-05	0.00699	0.32	0.18	Diabetic kidney disease;	chr7:66433290	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs67536397	ENSG00000229886.1	RP5-1132H15.3	4.13	4.36e-05	0.00699	0.32	0.18	Diabetic kidney disease;	chr7:66482930	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs58669269	ENSG00000229886.1	RP5-1132H15.3	4.13	4.36e-05	0.00699	0.32	0.18	Diabetic kidney disease;	chr7:66486966	chr7:66025126~66031544:-
LUAD	cis	rs2243480	0.901	rs34807232	ENSG00000229886.1	RP5-1132H15.3	4.13	4.36e-05	0.00699	0.32	0.18	Diabetic kidney disease;	chr7:66500146	chr7:66025126~66031544:-
LUAD	cis	rs10510102	0.608	rs4077606	ENSG00000226864.1	ATE1-AS1	-4.13	4.36e-05	0.00699	-0.27	-0.18	Breast cancer;	chr10:121849907	chr10:121928312~121951965:+
LUAD	cis	rs262150	0.574	rs2730272	ENSG00000231419.5	LINC00689	-4.13	4.36e-05	0.00699	-0.23	-0.18	Facial morphology (factor 20);	chr7:159005931	chr7:159006522~159030195:+
LUAD	cis	rs2243480	1	rs2462569	ENSG00000229886.1	RP5-1132H15.3	-4.13	4.36e-05	0.007	-0.31	-0.18	Diabetic kidney disease;	chr7:66009859	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs316307	ENSG00000229886.1	RP5-1132H15.3	4.13	4.36e-05	0.007	0.33	0.18	Diabetic kidney disease;	chr7:66105184	chr7:66025126~66031544:-
LUAD	cis	rs6568686	0.627	rs174374	ENSG00000255389.1	C6orf3	4.13	4.36e-05	0.007	0.23	0.18	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111584852	chr6:111599875~111602295:+
LUAD	cis	rs116139393	0.517	rs17789570	ENSG00000187953.9	PMS2CL	-4.13	4.36e-05	0.007	-0.29	-0.18	Alzheimer's disease (APOE e4 interaction);	chr7:6684713	chr7:6710128~6753862:+
LUAD	cis	rs11240074	0.516	rs116565328	ENSG00000244371.2	PFN1P8	-4.13	4.36e-05	0.007	-0.31	-0.18	Type 2 diabetes;	chr1:147478408	chr1:146957117~146957659:-
LUAD	cis	rs1876905	0.597	rs1215964	ENSG00000230177.1	RP5-1112D6.4	-4.13	4.36e-05	0.007	-0.23	-0.18	Mean corpuscular hemoglobin;	chr6:111225666	chr6:111277932~111278742:+
LUAD	cis	rs7107174	1	rs12277648	ENSG00000251323.2	RP11-452H21.4	4.13	4.37e-05	0.007	0.22	0.18	Testicular germ cell tumor;	chr11:78343290	chr11:78423982~78429836:-
LUAD	cis	rs10463554	0.892	rs34816	ENSG00000250682.4	LINC00491	4.13	4.37e-05	0.007	0.23	0.18	Parkinson's disease;	chr5:103098941	chr5:102609156~102671559:-
LUAD	cis	rs7394190	1	rs10824026	ENSG00000271848.1	RP11-464F9.21	-4.13	4.37e-05	0.007	-0.24	-0.18	Incident atrial fibrillation;	chr10:73661450	chr10:73654039~73674719:+
LUAD	cis	rs804280	0.662	rs11250164	ENSG00000227888.4	FAM66A	-4.13	4.37e-05	0.00701	-0.25	-0.18	Myopia (pathological);	chr8:11753177	chr8:12362019~12388296:+
LUAD	cis	rs4843747	0.708	rs11866437	ENSG00000205037.2	RP11-863P13.4	-4.13	4.37e-05	0.00701	-0.25	-0.18	Menopause (age at onset);	chr16:88038673	chr16:88088041~88100985:-
LUAD	cis	rs293748	0.771	rs35899185	ENSG00000250155.1	CTD-2353F22.1	-4.12	4.37e-05	0.00701	-0.25	-0.18	Obesity-related traits;	chr5:36795884	chr5:36666214~36725195:-
LUAD	cis	rs9341808	0.718	rs2322631	ENSG00000260645.1	RP11-250B2.5	4.12	4.37e-05	0.00701	0.17	0.18	Sitting height ratio;	chr6:80134239	chr6:80466958~80469080:+
LUAD	cis	rs7208859	0.673	rs17826219	ENSG00000280069.1	CTD-2349P21.3	-4.12	4.37e-05	0.00701	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834827	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs61223749	ENSG00000280069.1	CTD-2349P21.3	-4.12	4.37e-05	0.00701	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30836729	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs3764420	ENSG00000280069.1	CTD-2349P21.3	-4.12	4.37e-05	0.00701	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837136	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs3764421	ENSG00000280069.1	CTD-2349P21.3	-4.12	4.37e-05	0.00701	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30840635	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs11651858	ENSG00000280069.1	CTD-2349P21.3	-4.12	4.37e-05	0.00701	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843700	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs36056619	ENSG00000280069.1	CTD-2349P21.3	-4.12	4.37e-05	0.00701	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30845266	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs9909497	ENSG00000280069.1	CTD-2349P21.3	-4.12	4.37e-05	0.00701	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846210	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs11080135	ENSG00000280069.1	CTD-2349P21.3	-4.12	4.37e-05	0.00701	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30849463	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs9894876	ENSG00000280069.1	CTD-2349P21.3	-4.12	4.37e-05	0.00701	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855002	chr17:30738182~30740275:+
LUAD	cis	rs7201929	1	rs7499878	ENSG00000251417.2	RP11-1348G14.4	4.12	4.37e-05	0.00701	0.22	0.18	QT interval;	chr16:28857143	chr16:28802743~28817828:+
LUAD	cis	rs4841134	0.684	rs878336	ENSG00000233609.3	RP11-62H7.2	-4.12	4.37e-05	0.00701	-0.15	-0.18	Age-related disease endophenotypes;	chr8:9368119	chr8:8961200~8979025:+
LUAD	cis	rs28386778	0.591	rs2584619	ENSG00000240280.5	TCAM1P	-4.12	4.37e-05	0.00701	-0.21	-0.18	Prudent dietary pattern;	chr17:63835855	chr17:63849292~63864379:+
LUAD	cis	rs9506514	0.509	rs9509279	ENSG00000238286.1	SLC35E1P1	4.12	4.37e-05	0.00701	0.22	0.18	Coronary artery calcification;	chr13:20559580	chr13:20607268~20608131:+
LUAD	cis	rs13113518	1	rs4865004	ENSG00000272969.1	RP11-528I4.2	4.12	4.38e-05	0.00702	0.19	0.18	Height;	chr4:55515118	chr4:55547112~55547889:+
LUAD	cis	rs2274273	0.661	rs8019978	ENSG00000258413.1	RP11-665C16.6	4.12	4.38e-05	0.00702	0.24	0.18	Protein biomarker;	chr14:55090566	chr14:55262767~55272075:-
LUAD	cis	rs3743162	0.553	rs12900463	ENSG00000259728.4	LINC00933	4.12	4.38e-05	0.00702	0.29	0.18	Alzheimer's disease (age of onset);	chr15:84872155	chr15:84570649~84580175:+
LUAD	cis	rs28714278	0.812	rs55735426	ENSG00000248508.5	SRP14-AS1	-4.12	4.38e-05	0.00702	-0.21	-0.18	Mean corpuscular hemoglobin;	chr15:40020414	chr15:40039311~40067290:+
LUAD	cis	rs2702164	0.814	rs916512	ENSG00000240661.1	RP11-174O3.3	4.12	4.38e-05	0.00702	0.22	0.18	Gut microbiome composition (winter);	chr3:120425217	chr3:120349510~120367998:+
LUAD	cis	rs6964587	1	rs9784993	ENSG00000188693.7	CYP51A1-AS1	-4.12	4.38e-05	0.00702	-0.21	-0.18	Breast cancer;	chr7:92043089	chr7:92134604~92180725:+
LUAD	cis	rs6964587	1	rs6979085	ENSG00000188693.7	CYP51A1-AS1	-4.12	4.38e-05	0.00702	-0.21	-0.18	Breast cancer;	chr7:92044309	chr7:92134604~92180725:+
LUAD	cis	rs6964587	1	rs36120033	ENSG00000188693.7	CYP51A1-AS1	-4.12	4.38e-05	0.00702	-0.21	-0.18	Breast cancer;	chr7:92049984	chr7:92134604~92180725:+
LUAD	cis	rs6964587	1	rs1859113	ENSG00000188693.7	CYP51A1-AS1	-4.12	4.38e-05	0.00702	-0.21	-0.18	Breast cancer;	chr7:92050573	chr7:92134604~92180725:+
LUAD	cis	rs7555523	0.887	rs4656461	ENSG00000224358.1	RP11-466F5.8	-4.12	4.38e-05	0.00702	-0.32	-0.18	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165717968	chr1:165768929~165775176:+
LUAD	cis	rs858239	0.57	rs10235467	ENSG00000226816.2	AC005082.12	4.12	4.38e-05	0.00702	0.24	0.18	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23206013~23208045:+
LUAD	cis	rs755249	0.565	rs2695324	ENSG00000228060.1	RP11-69E11.8	-4.12	4.38e-05	0.00702	-0.16	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39587969	chr1:39565160~39573203:+
LUAD	cis	rs28386778	0.897	rs1062791	ENSG00000240280.5	TCAM1P	-4.12	4.38e-05	0.00702	-0.21	-0.18	Prudent dietary pattern;	chr17:63819127	chr17:63849292~63864379:+
LUAD	cis	rs4819052	1	rs13052356	ENSG00000237664.1	LINC00316	-4.12	4.38e-05	0.00702	-0.23	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243673	chr21:45338590~45341990:-
LUAD	cis	rs4819052	1	rs28628220	ENSG00000237664.1	LINC00316	-4.12	4.38e-05	0.00702	-0.23	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243826	chr21:45338590~45341990:-
LUAD	cis	rs10463554	0.892	rs62362519	ENSG00000250682.4	LINC00491	4.12	4.38e-05	0.00702	0.22	0.18	Parkinson's disease;	chr5:102965759	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.853	rs2241565	ENSG00000250682.4	LINC00491	4.12	4.38e-05	0.00702	0.22	0.18	Parkinson's disease;	chr5:102966233	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.818	rs2241564	ENSG00000250682.4	LINC00491	4.12	4.38e-05	0.00702	0.22	0.18	Parkinson's disease;	chr5:102966547	chr5:102609156~102671559:-
LUAD	cis	rs12478296	0.786	rs55876934	ENSG00000261186.2	RP11-341N2.1	-4.12	4.38e-05	0.00703	-0.31	-0.18	Obesity-related traits;	chr2:242091665	chr2:242087351~242088457:-
LUAD	cis	rs12478296	0.681	rs55802421	ENSG00000261186.2	RP11-341N2.1	-4.12	4.38e-05	0.00703	-0.31	-0.18	Obesity-related traits;	chr2:242091811	chr2:242087351~242088457:-
LUAD	cis	rs12478296	0.681	rs56357900	ENSG00000261186.2	RP11-341N2.1	-4.12	4.38e-05	0.00703	-0.31	-0.18	Obesity-related traits;	chr2:242091815	chr2:242087351~242088457:-
LUAD	cis	rs8062405	0.558	rs231976	ENSG00000261766.1	RP11-22P6.2	-4.12	4.38e-05	0.00703	-0.15	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534266	chr16:28862166~28863340:-
LUAD	cis	rs6088590	1	rs11698996	ENSG00000276073.1	RP5-1125A11.7	-4.12	4.38e-05	0.00703	-0.2	-0.18	Coronary artery disease;	chr20:34861936	chr20:33985617~33988989:-
LUAD	cis	rs526231	0.853	rs2288786	ENSG00000175749.11	EIF3KP1	4.12	4.38e-05	0.00703	0.25	0.18	Primary biliary cholangitis;	chr5:103265053	chr5:103032376~103033031:+
LUAD	cis	rs4474465	1	rs2373199	ENSG00000251323.2	RP11-452H21.4	4.12	4.39e-05	0.00703	0.23	0.18	Alzheimer's disease (survival time);	chr11:78431936	chr11:78423982~78429836:-
LUAD	cis	rs116095464	0.558	rs28635197	ENSG00000248925.1	CTD-2083E4.6	4.12	4.39e-05	0.00703	0.32	0.18	Breast cancer;	chr5:278956	chr5:269858~271516:-
LUAD	cis	rs10129255	1	rs8010605	ENSG00000274576.2	IGHV2-70	4.12	4.39e-05	0.00704	0.17	0.18	Kawasaki disease;	chr14:106678742	chr14:106770577~106771020:-
LUAD	cis	rs2657294	1	rs2657294	ENSG00000226051.5	ZNF503-AS1	-4.12	4.39e-05	0.00704	-0.25	-0.18	Pneumonia;	chr10:75193267	chr10:75269819~75373500:+
LUAD	cis	rs2242116	0.796	rs9852082	ENSG00000271161.1	BOLA2P2	4.12	4.39e-05	0.00704	0.18	0.18	Birth weight;	chr3:46930887	chr3:47499841~47500407:+
LUAD	cis	rs4811196	0.748	rs760845	ENSG00000226144.2	RPS27AP3	4.12	4.39e-05	0.00704	0.2	0.18	Bone mineral density;	chr20:37863929	chr20:37049254~37049707:+
LUAD	cis	rs2439831	0.85	rs7179388	ENSG00000249839.1	AC011330.5	-4.12	4.39e-05	0.00704	-0.42	-0.18	Lung cancer in ever smokers;	chr15:43831747	chr15:43663654~43684339:-
LUAD	cis	rs6671200	0.607	rs2147587	ENSG00000228852.5	RP11-57H12.5	-4.12	4.39e-05	0.00704	-0.23	-0.18	Stearic acid (18:0) levels;	chr1:95249328	chr1:95243167~95278940:-
LUAD	cis	rs8073060	0.586	rs2523116	ENSG00000267592.1	CTC-507E2.2	4.12	4.39e-05	0.00704	0.27	0.18	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35698441	chr17:35596904~35597128:-
LUAD	cis	rs8073060	0.544	rs2626626	ENSG00000267592.1	CTC-507E2.2	4.12	4.39e-05	0.00704	0.27	0.18	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35699698	chr17:35596904~35597128:-
LUAD	cis	rs704795	0.902	rs11887784	ENSG00000234072.1	AC074117.10	-4.12	4.39e-05	0.00704	-0.14	-0.18	Menopause (age at onset);	chr2:27457052	chr2:27356246~27367622:+
LUAD	cis	rs73193808	0.901	rs1997569	ENSG00000215533.7	LINC00189	-4.12	4.4e-05	0.00705	-0.27	-0.18	Coronary artery disease;	chr21:29213027	chr21:29193480~29288205:+
LUAD	cis	rs73193808	0.901	rs2832262	ENSG00000215533.7	LINC00189	-4.12	4.4e-05	0.00705	-0.27	-0.18	Coronary artery disease;	chr21:29214771	chr21:29193480~29288205:+
LUAD	cis	rs6487679	0.543	rs34363	ENSG00000111788.10	RP11-22B23.1	-4.12	4.4e-05	0.00705	-0.29	-0.18	Non-alcoholic fatty liver disease histology (AST);	chr12:9238261	chr12:9277235~9313241:+
LUAD	cis	rs2235642	0.75	rs2859310	ENSG00000280231.1	LA16c-380F5.3	4.12	4.4e-05	0.00705	0.24	0.18	Coronary artery disease;	chr16:1606764	chr16:1553655~1554130:-
LUAD	cis	rs10463554	0.963	rs1552916	ENSG00000250682.4	LINC00491	4.12	4.4e-05	0.00705	0.22	0.18	Parkinson's disease;	chr5:103002036	chr5:102609156~102671559:-
LUAD	cis	rs6088580	0.619	rs1205335	ENSG00000276073.1	RP5-1125A11.7	4.12	4.4e-05	0.00705	0.18	0.18	Glomerular filtration rate (creatinine);	chr20:34339701	chr20:33985617~33988989:-
LUAD	cis	rs2836974	0.666	rs4818015	ENSG00000232608.1	TIMM9P2	-4.12	4.4e-05	0.00705	-0.22	-0.18	Cognitive function;	chr21:39303567	chr21:39216624~39217506:+
LUAD	cis	rs10129255	0.5	rs1974468	ENSG00000253209.1	IGHV3-65	4.12	4.4e-05	0.00705	0.15	0.18	Kawasaki disease;	chr14:106686149	chr14:106666092~106666532:-
LUAD	cis	rs2243480	1	rs316329	ENSG00000229886.1	RP5-1132H15.3	4.12	4.4e-05	0.00705	0.32	0.18	Diabetic kidney disease;	chr7:66143429	chr7:66025126~66031544:-
LUAD	cis	rs2243480	0.615	rs34363376	ENSG00000229886.1	RP5-1132H15.3	4.12	4.4e-05	0.00705	0.32	0.18	Diabetic kidney disease;	chr7:66474549	chr7:66025126~66031544:-
LUAD	cis	rs4713118	0.512	rs2622319	ENSG00000216901.1	AL022393.7	4.12	4.4e-05	0.00705	0.23	0.18	Parkinson's disease;	chr6:28152623	chr6:28176188~28176674:+
LUAD	cis	rs172166	0.694	rs1150666	ENSG00000216901.1	AL022393.7	4.12	4.4e-05	0.00705	0.23	0.18	Cardiac Troponin-T levels;	chr6:28156150	chr6:28176188~28176674:+
LUAD	cis	rs3742264	1	rs9526139	ENSG00000235903.6	CPB2-AS1	-4.12	4.4e-05	0.00705	-0.23	-0.18	Blood protein levels;	chr13:46069921	chr13:46052806~46113332:+
LUAD	cis	rs7760535	0.826	rs3851229	ENSG00000271789.1	RP5-1112D6.7	-4.12	4.41e-05	0.00706	-0.2	-0.18	Metabolic traits;	chr6:111533457	chr6:111297126~111298510:+
LUAD	cis	rs6754311	0.731	rs687670	ENSG00000226806.1	AC011893.3	4.12	4.41e-05	0.00706	0.23	0.18	Mosquito bite size;	chr2:135983330	chr2:135820191~135823087:+
LUAD	cis	rs9532580	0.614	rs17446614	ENSG00000229456.1	RLIMP1	-4.12	4.41e-05	0.00706	-0.26	-0.18	Mean corpuscular hemoglobin;	chr13:40565740	chr13:40618738~40621348:+
LUAD	cis	rs889398	0.904	rs6499244	ENSG00000226232.7	RP11-419C5.2	-4.12	4.41e-05	0.00706	-0.16	-0.18	Body mass index;	chr16:69701368	chr16:69976388~69996188:-
LUAD	cis	rs763121	0.853	rs9610986	ENSG00000225450.1	RP3-508I15.14	-4.12	4.41e-05	0.00706	-0.18	-0.18	Menopause (age at onset);	chr22:38629272	chr22:38739003~38749041:+
LUAD	cis	rs11089937	0.626	rs737841	ENSG00000211640.3	IGLV6-57	4.12	4.41e-05	0.00707	0.14	0.18	Periodontitis (PAL4Q3);	chr22:22162769	chr22:22195713~22196460:+
LUAD	cis	rs12478296	1	rs59036157	ENSG00000261186.2	RP11-341N2.1	-4.12	4.41e-05	0.00707	-0.33	-0.18	Obesity-related traits;	chr2:242098077	chr2:242087351~242088457:-
LUAD	cis	rs12073359	1	rs1339494	ENSG00000223945.2	RP11-458I7.1	4.12	4.41e-05	0.00707	0.25	0.18	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150029512	chr1:150053864~150055034:+
LUAD	cis	rs442309	0.875	rs192004	ENSG00000238280.1	RP11-436D10.3	-4.12	4.42e-05	0.00707	-0.21	-0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62745965	chr10:62793562~62805887:-
LUAD	cis	rs2898681	0.581	rs11938140	ENSG00000248375.1	RP11-177B4.1	-4.12	4.42e-05	0.00707	-0.28	-0.18	Optic nerve measurement (cup area);	chr4:52811890	chr4:52720081~52720831:-
LUAD	cis	rs6430553	0.929	rs1348792	ENSG00000224043.6	CCNT2-AS1	-4.12	4.42e-05	0.00708	-0.22	-0.18	Blood metabolite levels;	chr2:134903288	chr2:134735464~134918710:-
LUAD	cis	rs8056893	0.885	rs6499167	ENSG00000274698.1	RP11-71L14.4	4.12	4.42e-05	0.00708	0.21	0.18	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68303895	chr16:68450283~68452318:+
LUAD	cis	rs7555523	0.887	rs4657475	ENSG00000224358.1	RP11-466F5.8	-4.12	4.42e-05	0.00708	-0.32	-0.18	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165717938	chr1:165768929~165775176:+
LUAD	cis	rs6687821	0.515	rs12025384	ENSG00000261737.1	RP4-612B15.3	4.12	4.42e-05	0.00708	0.25	0.18	Yeast infection;	chr1:86972227	chr1:86703502~86704462:-
LUAD	cis	rs7172677	0.96	rs4334268	ENSG00000260269.4	CTD-2323K18.1	-4.12	4.42e-05	0.00708	-0.25	-0.18	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75114957	chr15:75527150~75601205:-
LUAD	cis	rs6088580	0.668	rs1205337	ENSG00000276073.1	RP5-1125A11.7	4.12	4.42e-05	0.00708	0.18	0.18	Glomerular filtration rate (creatinine);	chr20:34338235	chr20:33985617~33988989:-
LUAD	cis	rs6121246	0.559	rs6121243	ENSG00000230613.1	HM13-AS1	4.12	4.42e-05	0.00708	0.23	0.18	Mean corpuscular hemoglobin;	chr20:31827291	chr20:31567707~31573263:-
LUAD	cis	rs10197140	0.857	rs4849201	ENSG00000235721.1	AC013268.3	-4.12	4.42e-05	0.00708	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110900284	chr2:110007675~110010783:+
LUAD	cis	rs6940638	0.688	rs9393790	ENSG00000219392.1	RP1-265C24.5	4.12	4.42e-05	0.00708	0.23	0.18	Intelligence (multi-trait analysis);	chr6:27146273	chr6:28115628~28116551:+
LUAD	cis	rs2295359	1	rs963427	ENSG00000275678.1	RP4-547N15.3	-4.12	4.42e-05	0.00708	-0.19	-0.18	Psoriasis;	chr1:67143664	chr1:67121605~67123956:-
LUAD	cis	rs6964587	1	rs7811564	ENSG00000188693.7	CYP51A1-AS1	-4.12	4.42e-05	0.00708	-0.22	-0.18	Breast cancer;	chr7:92034050	chr7:92134604~92180725:+
LUAD	cis	rs2898681	0.874	rs4864691	ENSG00000248375.1	RP11-177B4.1	-4.12	4.43e-05	0.00709	-0.27	-0.18	Optic nerve measurement (cup area);	chr4:52889805	chr4:52720081~52720831:-
LUAD	cis	rs4819052	0.851	rs1006779	ENSG00000237664.1	LINC00316	-4.12	4.43e-05	0.00709	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250837	chr21:45338590~45341990:-
LUAD	cis	rs6570726	0.791	rs378937	ENSG00000235652.6	RP11-545I5.3	4.12	4.43e-05	0.00709	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145513609	chr6:145799409~145886585:+
LUAD	cis	rs6840360	0.615	rs113052419	ENSG00000270265.1	RP11-731D1.4	-4.12	4.43e-05	0.00709	-0.21	-0.18	Intelligence (multi-trait analysis);	chr4:151551856	chr4:151333775~151353224:-
LUAD	cis	rs641862	1	rs641862	ENSG00000255874.2	LINC00346	4.12	4.43e-05	0.00709	0.44	0.18	Obesity-related traits;	chr13:110137885	chr13:110863987~110870251:-
LUAD	cis	rs5770917	1	rs5770917	ENSG00000273272.1	CTA-384D8.34	4.12	4.43e-05	0.00709	0.42	0.18	Narcolepsy;	chr22:50578924	chr22:50542650~50543011:+
LUAD	cis	rs848490	0.681	rs12537271	ENSG00000214293.7	APTR	4.12	4.43e-05	0.00709	0.22	0.18	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77671409	chr7:77657660~77696265:-
LUAD	cis	rs2154319	0.836	rs61780429	ENSG00000235358.1	RP11-399E6.1	-4.12	4.43e-05	0.00709	-0.26	-0.18	Height;	chr1:40992021	chr1:41242373~41284861:+
LUAD	cis	rs875971	0.508	rs10950045	ENSG00000236529.1	RP13-254B10.1	-4.12	4.43e-05	0.0071	-0.18	-0.18	Aortic root size;	chr7:66601386	chr7:65840212~65840596:+
LUAD	cis	rs801193	0.839	rs6968619	ENSG00000236529.1	RP13-254B10.1	-4.12	4.43e-05	0.0071	-0.18	-0.18	Aortic root size;	chr7:66603880	chr7:65840212~65840596:+
LUAD	cis	rs8012947	0.916	rs11627199	ENSG00000279636.2	LINC00216	4.12	4.43e-05	0.0071	0.2	0.18	Alcohol consumption in current drinkers;	chr14:58386288	chr14:58288033~58289158:+
LUAD	cis	rs8028182	0.636	rs7184046	ENSG00000260269.4	CTD-2323K18.1	-4.12	4.43e-05	0.0071	-0.26	-0.18	Sudden cardiac arrest;	chr15:75573809	chr15:75527150~75601205:-
LUAD	cis	rs1350171	1	rs1048338	ENSG00000255471.1	RP11-736K20.5	-4.12	4.44e-05	0.0071	-0.31	-0.18	Hepatocellular carcinoma in hepatitis B infection;	chr11:86921775	chr11:86892214~86925037:-
LUAD	cis	rs5015933	0.778	rs867547	ENSG00000232630.1	PRPS1P2	-4.12	4.44e-05	0.0071	-0.17	-0.18	Body mass index;	chr9:125269184	chr9:125150653~125151589:+
LUAD	cis	rs6964587	1	rs28584017	ENSG00000188693.7	CYP51A1-AS1	-4.12	4.44e-05	0.0071	-0.21	-0.18	Breast cancer;	chr7:92089854	chr7:92134604~92180725:+
LUAD	cis	rs12935418	0.83	rs12928638	ENSG00000261838.4	RP11-303E16.6	4.12	4.44e-05	0.0071	0.34	0.18	Mean corpuscular volume;	chr16:81016195	chr16:81069854~81076598:+
LUAD	cis	rs12712133	0.552	rs11123915	ENSG00000234389.1	AC007278.3	-4.12	4.44e-05	0.0071	-0.18	-0.18	Primary biliary cholangitis;	chr2:102264363	chr2:102438713~102440475:+
LUAD	cis	rs11009175	0.512	rs6481830	ENSG00000273038.2	RP11-479G22.8	-4.12	4.44e-05	0.00711	-0.21	-0.18	Depression (quantitative trait);	chr10:33090872	chr10:32887255~32889311:-
LUAD	cis	rs11009175	0.512	rs6481831	ENSG00000273038.2	RP11-479G22.8	-4.12	4.44e-05	0.00711	-0.21	-0.18	Depression (quantitative trait);	chr10:33091030	chr10:32887255~32889311:-
LUAD	cis	rs240993	0.812	rs9374262	ENSG00000230177.1	RP5-1112D6.4	4.12	4.44e-05	0.00711	0.19	0.18	Inflammatory skin disease;Psoriasis;	chr6:111553772	chr6:111277932~111278742:+
LUAD	cis	rs6121246	0.512	rs6058384	ENSG00000230613.1	HM13-AS1	4.12	4.44e-05	0.00711	0.23	0.18	Mean corpuscular hemoglobin;	chr20:31688606	chr20:31567707~31573263:-
LUAD	cis	rs755249	0.701	rs4660823	ENSG00000237624.1	OXCT2P1	4.12	4.44e-05	0.00711	0.24	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39532851	chr1:39514956~39516490:+
LUAD	cis	rs28386778	0.897	rs1062787	ENSG00000240280.5	TCAM1P	-4.12	4.44e-05	0.00711	-0.21	-0.18	Prudent dietary pattern;	chr17:63818644	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.897	rs2584627	ENSG00000240280.5	TCAM1P	-4.12	4.44e-05	0.00711	-0.21	-0.18	Prudent dietary pattern;	chr17:63824079	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.83	rs2584625	ENSG00000240280.5	TCAM1P	-4.12	4.44e-05	0.00711	-0.21	-0.18	Prudent dietary pattern;	chr17:63826085	chr17:63849292~63864379:+
LUAD	cis	rs5758511	0.508	rs28715885	ENSG00000226450.2	CYP2D8P	4.12	4.44e-05	0.00711	0.18	0.18	Birth weight;	chr22:42045087	chr22:42149886~42155001:-
LUAD	cis	rs77633900	0.803	rs2469564	ENSG00000196274.5	Metazoa_SRP	4.12	4.44e-05	0.00711	0.25	0.18	Glioma;Non-glioblastoma glioma;	chr15:76197614	chr15:76230048~76230390:-
LUAD	cis	rs2836974	0.644	rs9978775	ENSG00000232608.1	TIMM9P2	4.12	4.45e-05	0.00711	0.22	0.18	Cognitive function;	chr21:39322600	chr21:39216624~39217506:+
LUAD	cis	rs2439831	0.867	rs2470134	ENSG00000249839.1	AC011330.5	4.12	4.45e-05	0.00711	0.35	0.18	Lung cancer in ever smokers;	chr15:43557688	chr15:43663654~43684339:-
LUAD	cis	rs7404843	0.852	rs111259294	ENSG00000183458.12	RP11-958N24.1	4.12	4.45e-05	0.00711	0.23	0.18	Testicular germ cell tumor;	chr16:15418073	chr16:14911551~14935708:+
LUAD	cis	rs853679	0.567	rs13209596	ENSG00000219392.1	RP1-265C24.5	-4.12	4.45e-05	0.00711	-0.25	-0.18	Depression;	chr6:28428413	chr6:28115628~28116551:+
LUAD	cis	rs4795519	1	rs1824902	ENSG00000266313.1	RP11-173M1.4	4.12	4.45e-05	0.00711	0.23	0.18	Chronic myeloid leukemia;	chr17:27171036	chr17:27333256~27348491:+
LUAD	cis	rs4795519	0.961	rs11514506	ENSG00000266313.1	RP11-173M1.4	4.12	4.45e-05	0.00711	0.23	0.18	Chronic myeloid leukemia;	chr17:27189061	chr17:27333256~27348491:+
LUAD	cis	rs453301	0.658	rs9329175	ENSG00000173295.6	FAM86B3P	-4.12	4.45e-05	0.00711	-0.2	-0.18	Joint mobility (Beighton score);	chr8:9009151	chr8:8228595~8244865:+
LUAD	cis	rs9951698	0.667	rs6505775	ENSG00000267480.1	RP11-703I16.1	-4.12	4.45e-05	0.00712	-0.23	-0.18	Intelligence (multi-trait analysis);	chr18:12978184	chr18:12031178~12032181:-
LUAD	cis	rs7430456	0.638	rs13071694	ENSG00000228221.4	LINC00578	-4.12	4.45e-05	0.00712	-0.22	-0.18	Breast cancer;	chr3:177775198	chr3:177441921~177752305:+
LUAD	cis	rs1005277	0.54	rs2145487	ENSG00000273019.1	RP11-508N22.13	-4.12	4.45e-05	0.00712	-0.21	-0.18	Extrinsic epigenetic age acceleration;	chr10:37721149	chr10:38149968~38150293:+
LUAD	cis	rs2274273	0.87	rs8018110	ENSG00000259318.1	RP11-454L9.2	4.12	4.45e-05	0.00712	0.16	0.18	Protein biomarker;	chr14:55174996	chr14:55394940~55395233:-
LUAD	cis	rs6957923	0.747	rs10950950	ENSG00000230658.1	KLHL7-AS1	4.12	4.45e-05	0.00712	0.22	0.18	Height;	chr7:23484124	chr7:23101228~23105703:-
LUAD	cis	rs12935418	0.83	rs12448368	ENSG00000261838.4	RP11-303E16.6	-4.12	4.45e-05	0.00712	-0.34	-0.18	Mean corpuscular volume;	chr16:81011342	chr16:81069854~81076598:+
LUAD	cis	rs13256369	1	rs10088439	ENSG00000253893.2	FAM85B	-4.12	4.45e-05	0.00712	-0.25	-0.18	Obesity-related traits;	chr8:8719189	chr8:8167819~8226614:-
LUAD	cis	rs6088580	0.634	rs4911151	ENSG00000276073.1	RP5-1125A11.7	4.12	4.45e-05	0.00712	0.18	0.18	Glomerular filtration rate (creatinine);	chr20:34344467	chr20:33985617~33988989:-
LUAD	cis	rs6088580	0.634	rs6088471	ENSG00000276073.1	RP5-1125A11.7	4.12	4.45e-05	0.00712	0.18	0.18	Glomerular filtration rate (creatinine);	chr20:34344837	chr20:33985617~33988989:-
LUAD	cis	rs2243480	1	rs2420170	ENSG00000229886.1	RP5-1132H15.3	-4.12	4.45e-05	0.00713	-0.32	-0.18	Diabetic kidney disease;	chr7:66191066	chr7:66025126~66031544:-
LUAD	cis	rs801193	1	rs10234018	ENSG00000237310.1	GS1-124K5.4	-4.12	4.46e-05	0.00713	-0.2	-0.18	Aortic root size;	chr7:66681297	chr7:66493706~66495474:+
LUAD	cis	rs10129255	0.957	rs10136817	ENSG00000274576.2	IGHV2-70	4.12	4.46e-05	0.00713	0.17	0.18	Kawasaki disease;	chr14:106787730	chr14:106770577~106771020:-
LUAD	cis	rs6012564	0.963	rs2075679	ENSG00000230758.1	SNAP23P	4.12	4.46e-05	0.00713	0.19	0.18	Anger;	chr20:49085052	chr20:49038357~49038602:-
LUAD	cis	rs6661961	0.686	rs1923491	ENSG00000237975.5	FLG-AS1	-4.12	4.46e-05	0.00713	-0.24	-0.18	Atopic dermatitis;	chr1:152412469	chr1:152168125~152445456:+
LUAD	cis	rs763121	0.853	rs2413546	ENSG00000225450.1	RP3-508I15.14	-4.12	4.46e-05	0.00714	-0.18	-0.18	Menopause (age at onset);	chr22:38710996	chr22:38739003~38749041:+
LUAD	cis	rs7829975	0.514	rs2979151	ENSG00000253981.4	ALG1L13P	-4.12	4.46e-05	0.00714	-0.21	-0.18	Mood instability;	chr8:8400509	chr8:8236003~8244667:-
LUAD	cis	rs13113518	0.812	rs2412648	ENSG00000272969.1	RP11-528I4.2	4.12	4.46e-05	0.00714	0.2	0.18	Height;	chr4:55454900	chr4:55547112~55547889:+
LUAD	cis	rs13113518	0.812	rs12512737	ENSG00000272969.1	RP11-528I4.2	4.12	4.46e-05	0.00714	0.2	0.18	Height;	chr4:55454938	chr4:55547112~55547889:+
LUAD	cis	rs13113518	0.812	rs13125984	ENSG00000272969.1	RP11-528I4.2	4.12	4.46e-05	0.00714	0.2	0.18	Height;	chr4:55455102	chr4:55547112~55547889:+
LUAD	cis	rs11671005	0.735	rs11668420	ENSG00000268543.1	CTD-2619J13.16	-4.12	4.46e-05	0.00714	-0.26	-0.18	Mean platelet volume;	chr19:58426469	chr19:58418560~58419310:+
LUAD	cis	rs12999542	0.706	rs11465673	ENSG00000234389.1	AC007278.3	4.12	4.46e-05	0.00714	0.3	0.18	Serum protein levels (sST2);	chr2:102418915	chr2:102438713~102440475:+
LUAD	cis	rs2274273	0.905	rs10134800	ENSG00000259318.1	RP11-454L9.2	4.12	4.46e-05	0.00714	0.16	0.18	Protein biomarker;	chr14:55168491	chr14:55394940~55395233:-
LUAD	cis	rs7688540	0.8	rs12506277	ENSG00000211553.1	AC253576.2	-4.12	4.46e-05	0.00714	-0.24	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:293860	chr4:136461~136568:+
LUAD	cis	rs7688540	0.8	rs12501727	ENSG00000211553.1	AC253576.2	-4.12	4.46e-05	0.00714	-0.24	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:294285	chr4:136461~136568:+
LUAD	cis	rs34929064	0.527	rs2961285	ENSG00000232949.1	AC002480.4	-4.12	4.46e-05	0.00714	-0.21	-0.18	Major depression and alcohol dependence;	chr7:22615349	chr7:22589705~22591622:+
LUAD	cis	rs862034	0.531	rs8008540	ENSG00000270000.1	RP3-449M8.9	4.12	4.46e-05	0.00714	0.21	0.18	Height;	chr14:74481477	chr14:74471930~74472360:-
LUAD	cis	rs262150	0.63	rs2730274	ENSG00000231419.5	LINC00689	-4.12	4.47e-05	0.00714	-0.23	-0.18	Facial morphology (factor 20);	chr7:159003371	chr7:159006522~159030195:+
LUAD	cis	rs2154319	0.666	rs3845571	ENSG00000235358.1	RP11-399E6.1	-4.12	4.47e-05	0.00715	-0.22	-0.18	Height;	chr1:41250367	chr1:41242373~41284861:+
LUAD	cis	rs62355900	0.627	rs16886403	ENSG00000271828.1	CTD-2310F14.1	4.12	4.47e-05	0.00715	0.34	0.18	Endometriosis;	chr5:56843419	chr5:56927874~56929573:+
LUAD	cis	rs1864585	0.52	rs77559025	ENSG00000255046.1	RP11-297N6.4	4.12	4.47e-05	0.00715	0.26	0.18	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10835251	chr8:11797928~11802568:-
LUAD	cis	rs1864585	0.52	rs55848210	ENSG00000255046.1	RP11-297N6.4	4.12	4.47e-05	0.00715	0.26	0.18	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10836217	chr8:11797928~11802568:-
LUAD	cis	rs73198271	0.603	rs570364	ENSG00000253893.2	FAM85B	4.12	4.47e-05	0.00715	0.23	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8736128	chr8:8167819~8226614:-
LUAD	cis	rs2018683	0.707	rs917216	ENSG00000228421.2	AC005013.5	4.12	4.47e-05	0.00715	0.21	0.18	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28931855	chr7:28957667~28959345:+
LUAD	cis	rs62355901	0.505	rs16886257	ENSG00000271828.1	CTD-2310F14.1	4.12	4.47e-05	0.00715	0.41	0.18	Breast cancer;	chr5:56766994	chr5:56927874~56929573:+
LUAD	cis	rs3742264	0.922	rs4942477	ENSG00000235903.6	CPB2-AS1	-4.12	4.48e-05	0.00716	-0.24	-0.18	Blood protein levels;	chr13:46077628	chr13:46052806~46113332:+
LUAD	cis	rs13276960	0.794	rs6988956	ENSG00000253328.2	SUMO2P19	-4.12	4.48e-05	0.00716	-0.22	-0.18	Schizophrenia;	chr8:102924273	chr8:102242040~102242619:-
LUAD	cis	rs2274273	0.624	rs7150234	ENSG00000258413.1	RP11-665C16.6	-4.12	4.48e-05	0.00716	-0.25	-0.18	Protein biomarker;	chr14:55335463	chr14:55262767~55272075:-
LUAD	cis	rs8073060	0.544	rs9912939	ENSG00000267592.1	CTC-507E2.2	4.12	4.48e-05	0.00716	0.27	0.18	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35678245	chr17:35596904~35597128:-
LUAD	cis	rs6736093	0.736	rs10195619	ENSG00000207383.1	Y_RNA	-4.12	4.48e-05	0.00716	-0.23	-0.18	Coronary artery disease;	chr2:112007985	chr2:112579484~112579584:-
LUAD	cis	rs3758785	0.697	rs3758789	ENSG00000255893.1	RP11-685N10.1	-4.12	4.48e-05	0.00716	-0.26	-0.18	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94399958	chr11:94472908~94473570:-
LUAD	cis	rs8098244	0.737	rs1258152	ENSG00000264745.1	TTC39C-AS1	-4.12	4.48e-05	0.00716	-0.24	-0.18	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23948377	chr18:23994213~24015339:-
LUAD	cis	rs453301	0.658	rs9329175	ENSG00000253893.2	FAM85B	4.12	4.48e-05	0.00716	0.24	0.18	Joint mobility (Beighton score);	chr8:9009151	chr8:8167819~8226614:-
LUAD	cis	rs4460629	0.742	rs6693477	ENSG00000160766.13	GBAP1	-4.12	4.48e-05	0.00716	-0.18	-0.18	Serum magnesium levels;	chr1:155109464	chr1:155213821~155227422:-
LUAD	cis	rs7107174	1	rs2248407	ENSG00000251323.2	RP11-452H21.4	4.12	4.48e-05	0.00717	0.24	0.18	Testicular germ cell tumor;	chr11:78226754	chr11:78423982~78429836:-
LUAD	cis	rs6738440	0.604	rs13034231	ENSG00000234624.2	AC016894.1	-4.12	4.48e-05	0.00717	-0.22	-0.18	F-cell distribution;	chr2:60450833	chr2:61416887~61417197:-
LUAD	cis	rs73198271	0.565	rs575895	ENSG00000253893.2	FAM85B	4.12	4.49e-05	0.00717	0.23	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8736737	chr8:8167819~8226614:-
LUAD	cis	rs73198271	0.565	rs575920	ENSG00000253893.2	FAM85B	4.12	4.49e-05	0.00717	0.23	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8736744	chr8:8167819~8226614:-
LUAD	cis	rs9847710	0.901	rs2564937	ENSG00000242142.1	SERBP1P3	4.12	4.49e-05	0.00717	0.2	0.18	Ulcerative colitis;	chr3:52991843	chr3:53064283~53065091:-
LUAD	cis	rs9847710	0.967	rs2564938	ENSG00000242142.1	SERBP1P3	4.12	4.49e-05	0.00717	0.2	0.18	Ulcerative colitis;	chr3:52992368	chr3:53064283~53065091:-
LUAD	cis	rs28386778	0.897	rs4968599	ENSG00000240280.5	TCAM1P	-4.12	4.49e-05	0.00717	-0.21	-0.18	Prudent dietary pattern;	chr17:63758632	chr17:63849292~63864379:+
LUAD	cis	rs7772486	0.764	rs2265468	ENSG00000235652.6	RP11-545I5.3	4.12	4.49e-05	0.00717	0.19	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145897210	chr6:145799409~145886585:+
LUAD	cis	rs4374383	0.847	rs4848918	ENSG00000207383.1	Y_RNA	-4.12	4.49e-05	0.00717	-0.22	-0.18	Hepatitis C induced liver fibrosis;	chr2:111981905	chr2:112579484~112579584:-
LUAD	cis	rs2348418	0.864	rs11049578	ENSG00000247934.4	RP11-967K21.1	4.12	4.49e-05	0.00717	0.21	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28414520	chr12:28163298~28190738:-
LUAD	cis	rs4699052	0.963	rs11733615	ENSG00000246560.2	RP11-10L12.4	4.12	4.49e-05	0.00717	0.23	0.18	Testicular germ cell tumor;	chr4:103236007	chr4:102828055~102844075:+
LUAD	cis	rs453301	0.686	rs11785819	ENSG00000233609.3	RP11-62H7.2	-4.12	4.49e-05	0.00717	-0.16	-0.18	Joint mobility (Beighton score);	chr8:9012868	chr8:8961200~8979025:+
LUAD	cis	rs6840258	0.76	rs340626	ENSG00000251411.1	RP11-397E7.4	4.12	4.49e-05	0.00718	0.21	0.18	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87035287	chr4:86913266~86914817:-
LUAD	cis	rs8062405	0.755	rs4787456	ENSG00000261419.1	RP11-57A19.4	-4.12	4.49e-05	0.00718	-0.2	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28659696~28740781:-
LUAD	cis	rs8062405	0.755	rs4788078	ENSG00000261419.1	RP11-57A19.4	-4.12	4.49e-05	0.00718	-0.2	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28659696~28740781:-
LUAD	cis	rs131777	0.547	rs131753	ENSG00000273272.1	CTA-384D8.34	4.12	4.49e-05	0.00718	0.21	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50584433	chr22:50542650~50543011:+
LUAD	cis	rs2288884	1	rs56808319	ENSG00000269959.1	SPACA6P-AS	-4.12	4.49e-05	0.00718	-0.25	-0.18	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52074621	chr19:51685363~51693456:-
LUAD	cis	rs10129255	0.957	rs12590735	ENSG00000211967.3	IGHV3-53	-4.12	4.49e-05	0.00718	-0.15	-0.18	Kawasaki disease;	chr14:106779660	chr14:106592676~106593347:-
LUAD	cis	rs34375054	0.573	rs12811438	ENSG00000279233.1	RP11-158L12.4	4.12	4.49e-05	0.00718	0.18	0.18	Post bronchodilator FEV1/FVC ratio;	chr12:125168944	chr12:125138245~125141711:+
LUAD	cis	rs7824557	0.564	rs2736293	ENSG00000255046.1	RP11-297N6.4	4.12	4.49e-05	0.00718	0.23	0.18	Retinal vascular caliber;	chr8:11377104	chr8:11797928~11802568:-
LUAD	cis	rs7824557	0.564	rs2736294	ENSG00000255046.1	RP11-297N6.4	4.12	4.49e-05	0.00718	0.23	0.18	Retinal vascular caliber;	chr8:11377117	chr8:11797928~11802568:-
LUAD	cis	rs2154319	0.832	rs61774715	ENSG00000235358.1	RP11-399E6.1	-4.12	4.49e-05	0.00718	-0.26	-0.18	Height;	chr1:41261355	chr1:41242373~41284861:+
LUAD	cis	rs9840812	0.769	rs489398	ENSG00000239213.4	NCK1-AS1	4.12	4.49e-05	0.00718	0.26	0.18	Fibrinogen levels;	chr3:136276656	chr3:136841726~136862054:-
LUAD	cis	rs7339483	1	rs2434836	ENSG00000268058.1	BNIP3P40	-4.12	4.5e-05	0.00718	-0.33	-0.18	Discordance in emotional problems in monozygotic twins;	chr19:24285901	chr19:24098425~24098980:-
LUAD	cis	rs6840360	0.642	rs2034061	ENSG00000270265.1	RP11-731D1.4	-4.12	4.5e-05	0.00718	-0.19	-0.18	Intelligence (multi-trait analysis);	chr4:151499604	chr4:151333775~151353224:-
LUAD	cis	rs4664293	1	rs6432542	ENSG00000230783.1	AC009961.2	-4.12	4.5e-05	0.00718	-0.23	-0.18	Monocyte percentage of white cells;	chr2:159624025	chr2:159689217~159690291:-
LUAD	cis	rs2028299	0.92	rs4932261	ENSG00000259677.1	RP11-493E3.1	4.12	4.5e-05	0.00718	0.22	0.18	Type 2 diabetes;	chr15:89887164	chr15:89876540~89877285:+
LUAD	cis	rs9876781	1	rs6810060	ENSG00000229759.1	MRPS18AP1	4.12	4.5e-05	0.00719	0.18	0.18	Longevity;	chr3:48393284	chr3:48256350~48256938:-
LUAD	cis	rs9876781	1	rs6770470	ENSG00000229759.1	MRPS18AP1	4.12	4.5e-05	0.00719	0.18	0.18	Longevity;	chr3:48393659	chr3:48256350~48256938:-
LUAD	cis	rs11051970	1	rs6488051	ENSG00000274964.1	RP11-817I4.1	-4.12	4.5e-05	0.00719	-0.2	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr12:32379799	chr12:32339368~32340724:+
LUAD	cis	rs4840086	1	rs4840086	ENSG00000219755.1	RP1-199J3.5	4.12	4.5e-05	0.00719	0.23	0.18	Menarche (age at onset);	chr6:99760562	chr6:99575712~99576456:+
LUAD	cis	rs74233809	0.605	rs999867	ENSG00000213277.3	MARCKSL1P1	4.12	4.5e-05	0.00719	0.31	0.18	Birth weight;	chr10:102744807	chr10:103175554~103176094:+
LUAD	cis	rs7178375	1	rs7178533	ENSG00000270015.1	RP11-540B6.6	4.12	4.5e-05	0.00719	0.17	0.18	Hypertriglyceridemia;	chr15:30923773	chr15:30926514~30928407:+
LUAD	cis	rs17818399	0.716	rs62134741	ENSG00000279254.1	RP11-536C12.1	-4.12	4.5e-05	0.00719	-0.23	-0.18	Height;	chr2:46555050	chr2:46668870~46670778:+
LUAD	cis	rs3096299	0.935	rs3114890	ENSG00000182376.2	RP5-1142A6.8	4.12	4.5e-05	0.00719	0.19	0.18	Multiple myeloma (IgH translocation);	chr16:89383138	chr16:88742767~88745748:+
LUAD	cis	rs6903823	0.508	rs1150724	ENSG00000219392.1	RP1-265C24.5	-4.12	4.5e-05	0.00719	-0.23	-0.18	Pulmonary function;	chr6:28282459	chr6:28115628~28116551:+
LUAD	cis	rs4578769	0.531	rs768793	ENSG00000265943.1	RP11-739L10.1	4.12	4.5e-05	0.00719	0.23	0.18	Eosinophil percentage of white cells;	chr18:22976640	chr18:22699481~22933764:-
LUAD	cis	rs74233809	0.71	rs4147157	ENSG00000213277.3	MARCKSL1P1	4.12	4.5e-05	0.00719	0.32	0.18	Birth weight;	chr10:102776603	chr10:103175554~103176094:+
LUAD	cis	rs780096	0.565	rs813592	ENSG00000234072.1	AC074117.10	-4.12	4.5e-05	0.00719	-0.14	-0.18	Total body bone mineral density;	chr2:27499104	chr2:27356246~27367622:+
LUAD	cis	rs7617773	0.817	rs17786132	ENSG00000199476.1	Y_RNA	-4.12	4.5e-05	0.00719	-0.24	-0.18	Coronary artery disease;	chr3:48207930	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.817	rs35456569	ENSG00000199476.1	Y_RNA	-4.12	4.5e-05	0.00719	-0.24	-0.18	Coronary artery disease;	chr3:48209409	chr3:48288587~48288694:+
LUAD	cis	rs17301013	0.827	rs1793309	ENSG00000227373.4	RP11-160H22.5	-4.12	4.5e-05	0.00719	-0.23	-0.18	Systemic lupus erythematosus;	chr1:174826199	chr1:174115300~174160004:-
LUAD	cis	rs2836974	0.931	rs13625	ENSG00000232608.1	TIMM9P2	-4.12	4.51e-05	0.0072	-0.22	-0.18	Cognitive function;	chr21:39297157	chr21:39216624~39217506:+
LUAD	cis	rs7824557	0.564	rs2572392	ENSG00000255046.1	RP11-297N6.4	4.12	4.51e-05	0.0072	0.23	0.18	Retinal vascular caliber;	chr8:11378096	chr8:11797928~11802568:-
LUAD	cis	rs9649213	0.593	rs3823740	ENSG00000272950.1	RP11-307C18.1	4.12	4.51e-05	0.0072	0.23	0.18	Prostate cancer (SNP x SNP interaction);	chr7:98327792	chr7:98322853~98323430:+
LUAD	cis	rs6840360	0.532	rs4235221	ENSG00000270265.1	RP11-731D1.4	-4.12	4.51e-05	0.0072	-0.21	-0.18	Intelligence (multi-trait analysis);	chr4:151590041	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.571	rs62327268	ENSG00000270265.1	RP11-731D1.4	-4.12	4.51e-05	0.0072	-0.21	-0.18	Intelligence (multi-trait analysis);	chr4:151601174	chr4:151333775~151353224:-
LUAD	cis	rs2348418	0.832	rs11049560	ENSG00000247934.4	RP11-967K21.1	4.12	4.51e-05	0.0072	0.21	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28372504	chr12:28163298~28190738:-
LUAD	cis	rs1876905	0.62	rs377716	ENSG00000230177.1	RP5-1112D6.4	-4.12	4.51e-05	0.0072	-0.22	-0.18	Mean corpuscular hemoglobin;	chr6:111181705	chr6:111277932~111278742:+
LUAD	cis	rs442309	0.875	rs224147	ENSG00000238280.1	RP11-436D10.3	4.12	4.51e-05	0.0072	0.21	0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62726055	chr10:62793562~62805887:-
LUAD	cis	rs7615952	0.515	rs7637246	ENSG00000241288.6	RP11-379B18.5	-4.12	4.51e-05	0.0072	-0.23	-0.18	Blood pressure (smoking interaction);	chr3:125959863	chr3:125827238~125916384:-
LUAD	cis	rs11673344	0.523	rs1402468	ENSG00000276846.1	CTD-3220F14.3	4.12	4.51e-05	0.0072	0.2	0.18	Obesity-related traits;	chr19:37129346	chr19:37314868~37315620:-
LUAD	cis	rs9341808	0.667	rs1575541	ENSG00000260645.1	RP11-250B2.5	4.12	4.51e-05	0.0072	0.17	0.18	Sitting height ratio;	chr6:80207768	chr6:80466958~80469080:+
LUAD	cis	rs4699052	0.893	rs4699058	ENSG00000246560.2	RP11-10L12.4	4.12	4.51e-05	0.0072	0.23	0.18	Testicular germ cell tumor;	chr4:103250164	chr4:102828055~102844075:+
LUAD	cis	rs6988985	0.678	rs28571827	ENSG00000247317.3	RP11-273G15.2	-4.12	4.51e-05	0.00721	-0.22	-0.18	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142921791	chr8:142981738~143018437:-
LUAD	cis	rs34779708	0.966	rs12782948	ENSG00000271335.4	RP11-324I22.4	4.12	4.51e-05	0.00721	0.2	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35161679	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.966	rs10827493	ENSG00000271335.4	RP11-324I22.4	4.12	4.51e-05	0.00721	0.2	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35166048	chr10:35314552~35336401:-
LUAD	cis	rs6840360	0.642	rs6855845	ENSG00000270265.1	RP11-731D1.4	-4.12	4.51e-05	0.00721	-0.19	-0.18	Intelligence (multi-trait analysis);	chr4:151496228	chr4:151333775~151353224:-
LUAD	cis	rs7204230	1	rs62048059	ENSG00000261291.1	RP11-295M3.2	4.12	4.51e-05	0.00721	0.23	0.18	Fibrinogen;	chr16:53214602	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs12597253	ENSG00000261291.1	RP11-295M3.2	4.12	4.51e-05	0.00721	0.23	0.18	Fibrinogen;	chr16:53222582	chr16:53168522~53169450:+
LUAD	cis	rs7204230	0.96	rs62049764	ENSG00000261291.1	RP11-295M3.2	4.12	4.51e-05	0.00721	0.23	0.18	Fibrinogen;	chr16:53225866	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs12597254	ENSG00000261291.1	RP11-295M3.2	4.12	4.51e-05	0.00721	0.23	0.18	Fibrinogen;	chr16:53232277	chr16:53168522~53169450:+
LUAD	cis	rs7204230	0.921	rs8061611	ENSG00000261291.1	RP11-295M3.2	4.12	4.51e-05	0.00721	0.23	0.18	Fibrinogen;	chr16:53233467	chr16:53168522~53169450:+
LUAD	cis	rs523522	0.962	rs10849754	ENSG00000278344.1	RP11-18C24.8	4.12	4.52e-05	0.00721	0.25	0.18	High light scatter reticulocyte count;	chr12:120502615	chr12:120500735~120501090:-
LUAD	cis	rs523522	0.962	rs7471	ENSG00000278344.1	RP11-18C24.8	4.12	4.52e-05	0.00721	0.25	0.18	High light scatter reticulocyte count;	chr12:120503412	chr12:120500735~120501090:-
LUAD	cis	rs523522	0.962	rs11065145	ENSG00000278344.1	RP11-18C24.8	4.12	4.52e-05	0.00721	0.25	0.18	High light scatter reticulocyte count;	chr12:120509616	chr12:120500735~120501090:-
LUAD	cis	rs523522	0.962	rs4766968	ENSG00000278344.1	RP11-18C24.8	4.12	4.52e-05	0.00721	0.25	0.18	High light scatter reticulocyte count;	chr12:120509985	chr12:120500735~120501090:-
LUAD	cis	rs523522	0.924	rs11065150	ENSG00000278344.1	RP11-18C24.8	4.12	4.52e-05	0.00721	0.25	0.18	High light scatter reticulocyte count;	chr12:120521072	chr12:120500735~120501090:-
LUAD	cis	rs523522	0.962	rs55848094	ENSG00000278344.1	RP11-18C24.8	4.12	4.52e-05	0.00721	0.25	0.18	High light scatter reticulocyte count;	chr12:120528856	chr12:120500735~120501090:-
LUAD	cis	rs523522	0.962	rs3742052	ENSG00000278344.1	RP11-18C24.8	4.12	4.52e-05	0.00721	0.25	0.18	High light scatter reticulocyte count;	chr12:120529118	chr12:120500735~120501090:-
LUAD	cis	rs7617773	0.707	rs13061269	ENSG00000199476.1	Y_RNA	-4.12	4.52e-05	0.00721	-0.25	-0.18	Coronary artery disease;	chr3:48331853	chr3:48288587~48288694:+
LUAD	cis	rs17301013	0.932	rs4233195	ENSG00000227373.4	RP11-160H22.5	-4.12	4.52e-05	0.00721	-0.23	-0.18	Systemic lupus erythematosus;	chr1:174806736	chr1:174115300~174160004:-
LUAD	cis	rs4664293	1	rs6432540	ENSG00000230783.1	AC009961.2	-4.12	4.52e-05	0.00722	-0.22	-0.18	Monocyte percentage of white cells;	chr2:159594192	chr2:159689217~159690291:-
LUAD	cis	rs6568686	0.627	rs4245546	ENSG00000255389.1	C6orf3	-4.12	4.52e-05	0.00722	-0.24	-0.18	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111582747	chr6:111599875~111602295:+
LUAD	cis	rs523522	0.962	rs3213565	ENSG00000278344.1	RP11-18C24.8	4.12	4.52e-05	0.00722	0.25	0.18	High light scatter reticulocyte count;	chr12:120554598	chr12:120500735~120501090:-
LUAD	cis	rs523522	0.962	rs4767914	ENSG00000278344.1	RP11-18C24.8	4.12	4.52e-05	0.00722	0.25	0.18	High light scatter reticulocyte count;	chr12:120556014	chr12:120500735~120501090:-
LUAD	cis	rs41271951	0.518	rs12142178	ENSG00000223945.2	RP11-458I7.1	-4.12	4.52e-05	0.00722	-0.3	-0.18	Blood protein levels;	chr1:150289680	chr1:150053864~150055034:+
LUAD	cis	rs1910358	0.919	rs1960853	ENSG00000248874.4	C5orf17	-4.12	4.53e-05	0.00722	-0.27	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr5:23872606	chr5:23951348~24178263:+
LUAD	cis	rs1910358	0.919	rs1960854	ENSG00000248874.4	C5orf17	-4.12	4.53e-05	0.00722	-0.27	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr5:23872617	chr5:23951348~24178263:+
LUAD	cis	rs642803	0.591	rs620088	ENSG00000254510.1	RP11-867G23.10	-4.12	4.53e-05	0.00722	-0.22	-0.18	Urate levels;	chr11:65741515	chr11:66409158~66417137:+
LUAD	cis	rs860295	0.702	rs12746592	ENSG00000225855.5	RUSC1-AS1	4.12	4.53e-05	0.00722	0.13	0.18	Body mass index;	chr1:155536176	chr1:155316863~155324176:-
LUAD	cis	rs860295	0.702	rs10752611	ENSG00000225855.5	RUSC1-AS1	4.12	4.53e-05	0.00722	0.13	0.18	Body mass index;	chr1:155539316	chr1:155316863~155324176:-
LUAD	cis	rs1044826	1	rs13089052	ENSG00000214280.3	RP11-553K23.2	-4.12	4.53e-05	0.00723	-0.22	-0.18	Obesity-related traits;	chr3:139508630	chr3:139582928~139583593:-
LUAD	cis	rs293748	0.771	rs34139494	ENSG00000250155.1	CTD-2353F22.1	-4.12	4.53e-05	0.00723	-0.25	-0.18	Obesity-related traits;	chr5:36802466	chr5:36666214~36725195:-
LUAD	cis	rs293748	0.771	rs34092841	ENSG00000250155.1	CTD-2353F22.1	-4.12	4.53e-05	0.00723	-0.25	-0.18	Obesity-related traits;	chr5:36803462	chr5:36666214~36725195:-
LUAD	cis	rs293748	0.771	rs35660956	ENSG00000250155.1	CTD-2353F22.1	-4.12	4.53e-05	0.00723	-0.25	-0.18	Obesity-related traits;	chr5:36803648	chr5:36666214~36725195:-
LUAD	cis	rs293748	0.771	rs292163	ENSG00000250155.1	CTD-2353F22.1	-4.12	4.53e-05	0.00723	-0.25	-0.18	Obesity-related traits;	chr5:36803847	chr5:36666214~36725195:-
LUAD	cis	rs293748	0.771	rs172384	ENSG00000250155.1	CTD-2353F22.1	-4.12	4.53e-05	0.00723	-0.25	-0.18	Obesity-related traits;	chr5:36804123	chr5:36666214~36725195:-
LUAD	cis	rs293748	0.771	rs292164	ENSG00000250155.1	CTD-2353F22.1	-4.12	4.53e-05	0.00723	-0.25	-0.18	Obesity-related traits;	chr5:36804643	chr5:36666214~36725195:-
LUAD	cis	rs9928842	0.765	rs2870467	ENSG00000261476.1	RP11-77K12.3	-4.12	4.53e-05	0.00723	-0.25	-0.18	Alcoholic chronic pancreatitis;	chr16:75189983	chr16:75458252~75460017:-
LUAD	cis	rs4841134	0.902	rs6999153	ENSG00000233609.3	RP11-62H7.2	-4.12	4.53e-05	0.00723	-0.15	-0.18	Age-related disease endophenotypes;	chr8:9335991	chr8:8961200~8979025:+
LUAD	cis	rs2749097	0.609	rs2360159	ENSG00000244256.3	RN7SL130P	-4.12	4.53e-05	0.00723	-0.25	-0.18	Alcohol consumption (transferrin glycosylation);	chr1:63653130	chr1:63655743~63656047:+
LUAD	cis	rs889398	0.802	rs2937121	ENSG00000226232.7	RP11-419C5.2	4.12	4.53e-05	0.00723	0.16	0.18	Body mass index;	chr16:69836506	chr16:69976388~69996188:-
LUAD	cis	rs5742933	0.817	rs7591929	ENSG00000253559.1	OSGEPL1-AS1	4.12	4.53e-05	0.00723	0.22	0.18	Ferritin levels;	chr2:189778531	chr2:189762704~189765556:+
LUAD	cis	rs910316	0.763	rs175016	ENSG00000259138.1	RP11-950C14.7	-4.12	4.53e-05	0.00723	-0.19	-0.18	Height;	chr14:74992930	chr14:75127153~75136930:+
LUAD	cis	rs7116495	1	rs548127	ENSG00000254682.1	RP11-660L16.2	4.12	4.53e-05	0.00723	0.38	0.18	Severe influenza A (H1N1) infection;	chr11:71864248	chr11:71448674~71452157:+
LUAD	cis	rs62025270	0.632	rs7181796	ENSG00000202081.1	RNU6-1280P	-4.12	4.54e-05	0.00724	-0.27	-0.18	Idiopathic pulmonary fibrosis;	chr15:85689778	chr15:85651522~85651628:-
LUAD	cis	rs2243480	1	rs4718269	ENSG00000229886.1	RP5-1132H15.3	-4.12	4.54e-05	0.00724	-0.32	-0.18	Diabetic kidney disease;	chr7:65735810	chr7:66025126~66031544:-
LUAD	cis	rs17772222	0.876	rs12587598	ENSG00000258789.1	RP11-507K2.3	-4.12	4.54e-05	0.00724	-0.24	-0.18	Coronary artery calcification;	chr14:88729474	chr14:88551597~88552493:+
LUAD	cis	rs911555	0.755	rs10148970	ENSG00000259775.1	RP11-45P15.4	-4.12	4.54e-05	0.00724	-0.24	-0.18	Intelligence (multi-trait analysis);	chr14:103425663	chr14:103331674~103332367:-
LUAD	cis	rs10863681	0.664	rs11118934	ENSG00000227925.1	RP11-191N8.2	4.12	4.54e-05	0.00724	0.22	0.18	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222070113	chr1:221827666~221840666:-
LUAD	cis	rs10863681	0.713	rs12134885	ENSG00000227925.1	RP11-191N8.2	4.12	4.54e-05	0.00724	0.22	0.18	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222071038	chr1:221827666~221840666:-
LUAD	cis	rs8062405	0.755	rs2077031	ENSG00000251417.2	RP11-1348G14.4	-4.12	4.54e-05	0.00724	-0.19	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28591847	chr16:28802743~28817828:+
LUAD	cis	rs2836974	0.8	rs73221174	ENSG00000232608.1	TIMM9P2	-4.12	4.54e-05	0.00724	-0.22	-0.18	Cognitive function;	chr21:39169013	chr21:39216624~39217506:+
LUAD	cis	rs2562152	0.706	rs216596	ENSG00000226942.2	IL9RP3	-4.12	4.54e-05	0.00724	-0.26	-0.18	Glioblastoma;	chr16:55320	chr16:29336~38321:-
LUAD	cis	rs516805	0.52	rs13437168	ENSG00000279453.1	RP3-425C14.4	-4.12	4.54e-05	0.00724	-0.19	-0.18	Lymphocyte counts;	chr6:122465918	chr6:122436789~122439223:-
LUAD	cis	rs5015933	0.815	rs3861866	ENSG00000232630.1	PRPS1P2	-4.12	4.54e-05	0.00724	-0.17	-0.18	Body mass index;	chr9:125258595	chr9:125150653~125151589:+
LUAD	cis	rs9649213	0.593	rs6465683	ENSG00000272950.1	RP11-307C18.1	4.12	4.54e-05	0.00725	0.23	0.18	Prostate cancer (SNP x SNP interaction);	chr7:98396780	chr7:98322853~98323430:+
LUAD	cis	rs7615952	0.688	rs7624806	ENSG00000241288.6	RP11-379B18.5	-4.12	4.54e-05	0.00725	-0.25	-0.18	Blood pressure (smoking interaction);	chr3:125880231	chr3:125827238~125916384:-
LUAD	cis	rs1061377	0.748	rs11096977	ENSG00000249685.1	RP11-360F5.3	4.12	4.54e-05	0.00725	0.22	0.18	Uric acid levels;	chr4:39106186	chr4:39133913~39135608:+
LUAD	cis	rs2243480	0.522	rs73150635	ENSG00000230295.1	RP11-458F8.2	-4.12	4.54e-05	0.00725	-0.26	-0.18	Diabetic kidney disease;	chr7:66507503	chr7:66880708~66882981:+
LUAD	cis	rs12468226	0.689	rs17656903	ENSG00000272966.1	RP11-686O6.1	-4.12	4.54e-05	0.00725	-0.31	-0.18	Urate levels;	chr2:202106312	chr2:202336739~202337200:+
LUAD	cis	rs9341808	0.617	rs9294170	ENSG00000260645.1	RP11-250B2.5	4.12	4.54e-05	0.00725	0.17	0.18	Sitting height ratio;	chr6:80104363	chr6:80466958~80469080:+
LUAD	cis	rs703842	1	rs11172335	ENSG00000270039.1	RP11-571M6.17	-4.12	4.54e-05	0.00725	-0.22	-0.18	Multiple sclerosis;	chr12:57781418	chr12:57803838~57804415:+
LUAD	cis	rs703842	0.964	rs2014886	ENSG00000270039.1	RP11-571M6.17	-4.12	4.54e-05	0.00725	-0.22	-0.18	Multiple sclerosis;	chr12:57783654	chr12:57803838~57804415:+
LUAD	cis	rs703842	1	rs1599932	ENSG00000270039.1	RP11-571M6.17	-4.12	4.54e-05	0.00725	-0.22	-0.18	Multiple sclerosis;	chr12:57784160	chr12:57803838~57804415:+
LUAD	cis	rs703842	1	rs11172342	ENSG00000270039.1	RP11-571M6.17	-4.12	4.54e-05	0.00725	-0.22	-0.18	Multiple sclerosis;	chr12:57793975	chr12:57803838~57804415:+
LUAD	cis	rs703842	1	rs11172343	ENSG00000270039.1	RP11-571M6.17	-4.12	4.54e-05	0.00725	-0.22	-0.18	Multiple sclerosis;	chr12:57794374	chr12:57803838~57804415:+
LUAD	cis	rs703842	1	rs1875124	ENSG00000270039.1	RP11-571M6.17	-4.12	4.54e-05	0.00725	-0.22	-0.18	Multiple sclerosis;	chr12:57803019	chr12:57803838~57804415:+
LUAD	cis	rs6495122	0.501	rs6495144	ENSG00000260269.4	CTD-2323K18.1	4.12	4.54e-05	0.00725	0.23	0.18	Diastolic blood pressure;Coffee consumption;Caffeine consumption;	chr15:75051097	chr15:75527150~75601205:-
LUAD	cis	rs9487094	0.922	rs2236582	ENSG00000260273.1	RP11-425D10.10	-4.12	4.54e-05	0.00725	-0.24	-0.18	Height;	chr6:109444615	chr6:109382795~109383666:+
LUAD	cis	rs4713118	0.869	rs7773070	ENSG00000280107.1	AL022393.9	-4.12	4.55e-05	0.00725	-0.23	-0.18	Parkinson's disease;	chr6:27761048	chr6:28170845~28172521:+
LUAD	cis	rs2354432	0.556	rs7525622	ENSG00000237188.3	RP11-337C18.8	4.12	4.55e-05	0.00725	0.33	0.18	Mitochondrial DNA levels;	chr1:147302425	chr1:147172771~147211568:+
LUAD	cis	rs683250	0.661	rs1943747	ENSG00000246067.6	RAB30-AS1	-4.12	4.55e-05	0.00726	-0.19	-0.18	Subcortical brain region volumes;	chr11:83410940	chr11:83072066~83106719:+
LUAD	cis	rs9840812	0.731	rs9647335	ENSG00000239213.4	NCK1-AS1	-4.12	4.55e-05	0.00726	-0.27	-0.18	Fibrinogen levels;	chr3:136161568	chr3:136841726~136862054:-
LUAD	cis	rs240993	0.812	rs9387013	ENSG00000271789.1	RP5-1112D6.7	4.12	4.55e-05	0.00726	0.23	0.18	Inflammatory skin disease;Psoriasis;	chr6:111512517	chr6:111297126~111298510:+
LUAD	cis	rs9291683	0.588	rs4280729	ENSG00000250413.1	RP11-448G15.1	-4.12	4.55e-05	0.00726	-0.23	-0.18	Bone mineral density;	chr4:10012237	chr4:10006482~10009725:+
LUAD	cis	rs9291683	0.552	rs10939656	ENSG00000250413.1	RP11-448G15.1	-4.12	4.55e-05	0.00726	-0.23	-0.18	Bone mineral density;	chr4:10013022	chr4:10006482~10009725:+
LUAD	cis	rs2278702	0.848	rs77593396	ENSG00000259495.2	RP11-210M15.2	-4.12	4.55e-05	0.00726	-0.29	-0.18	Bipolar disorder;	chr15:80387970	chr15:80344853~80403575:-
LUAD	cis	rs2243480	0.901	rs778732	ENSG00000232559.3	GS1-124K5.12	4.12	4.55e-05	0.00726	0.32	0.18	Diabetic kidney disease;	chr7:66357373	chr7:66554588~66576923:-
LUAD	cis	rs7824557	0.527	rs2736298	ENSG00000255046.1	RP11-297N6.4	4.12	4.55e-05	0.00726	0.23	0.18	Retinal vascular caliber;	chr8:11377627	chr8:11797928~11802568:-
LUAD	cis	rs4474465	1	rs10899509	ENSG00000251323.2	RP11-452H21.4	4.12	4.55e-05	0.00726	0.23	0.18	Alzheimer's disease (survival time);	chr11:78459765	chr11:78423982~78429836:-
LUAD	cis	rs4879677	1	rs10968050	ENSG00000215441.3	CTAGE12P	-4.12	4.55e-05	0.00726	-0.22	-0.18	Gut microbiome composition (summer and winter);	chr9:27677633	chr9:27608382~27610745:-
LUAD	cis	rs9649213	0.593	rs6947208	ENSG00000272950.1	RP11-307C18.1	4.12	4.55e-05	0.00726	0.23	0.18	Prostate cancer (SNP x SNP interaction);	chr7:98282892	chr7:98322853~98323430:+
LUAD	cis	rs1061377	0.748	rs12649085	ENSG00000249685.1	RP11-360F5.3	4.12	4.56e-05	0.00726	0.22	0.18	Uric acid levels;	chr4:39106459	chr4:39133913~39135608:+
LUAD	cis	rs4865762	0.617	rs251580	ENSG00000247796.2	CTD-2366F13.1	4.12	4.56e-05	0.00726	0.19	0.18	Intraocular pressure;	chr5:53191765	chr5:53109842~53115126:+
LUAD	cis	rs73193808	0.804	rs2832276	ENSG00000215533.7	LINC00189	-4.11	4.56e-05	0.00727	-0.26	-0.18	Coronary artery disease;	chr21:29236463	chr21:29193480~29288205:+
LUAD	cis	rs2243480	0.522	rs1638736	ENSG00000230295.1	RP11-458F8.2	-4.11	4.56e-05	0.00727	-0.25	-0.18	Diabetic kidney disease;	chr7:66627321	chr7:66880708~66882981:+
LUAD	cis	rs4795519	1	rs8081516	ENSG00000266313.1	RP11-173M1.4	4.11	4.56e-05	0.00727	0.23	0.18	Chronic myeloid leukemia;	chr17:27208195	chr17:27333256~27348491:+
LUAD	cis	rs2288073	0.965	rs36101491	ENSG00000242628.4	AC009228.1	4.11	4.56e-05	0.00727	0.26	0.18	Venous thromboembolism (SNP x SNP interaction);	chr2:24164663	chr2:24214381~24221516:+
LUAD	cis	rs4938303	0.549	rs12785772	ENSG00000254851.1	RP11-109L13.1	4.11	4.56e-05	0.00727	0.25	0.18	Triglycerides;	chr11:116692892	chr11:117135528~117138582:+
LUAD	cis	rs4938303	0.549	rs12420888	ENSG00000254851.1	RP11-109L13.1	4.11	4.56e-05	0.00727	0.25	0.18	Triglycerides;	chr11:116693106	chr11:117135528~117138582:+
LUAD	cis	rs7824557	0.564	rs2437152	ENSG00000255046.1	RP11-297N6.4	4.11	4.56e-05	0.00727	0.23	0.18	Retinal vascular caliber;	chr8:11377988	chr8:11797928~11802568:-
LUAD	cis	rs7824557	0.564	rs2736300	ENSG00000255046.1	RP11-297N6.4	4.11	4.56e-05	0.00727	0.23	0.18	Retinal vascular caliber;	chr8:11378070	chr8:11797928~11802568:-
LUAD	cis	rs17685	0.753	rs12531559	ENSG00000280388.1	RP11-229D13.3	4.11	4.56e-05	0.00727	0.17	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76002379	chr7:76043977~76045963:-
LUAD	cis	rs4664293	0.541	rs1425047	ENSG00000226266.5	AC009961.3	4.11	4.56e-05	0.00727	0.24	0.18	Monocyte percentage of white cells;	chr2:159517946	chr2:159670708~159712435:-
LUAD	cis	rs5758659	0.622	rs129856	ENSG00000182057.4	OGFRP1	4.11	4.56e-05	0.00727	0.22	0.18	Cognitive function;	chr22:42003392	chr22:42269753~42275196:+
LUAD	cis	rs5758659	0.652	rs133323	ENSG00000182057.4	OGFRP1	4.11	4.56e-05	0.00727	0.22	0.18	Cognitive function;	chr22:42009918	chr22:42269753~42275196:+
LUAD	cis	rs5758659	0.652	rs133327	ENSG00000182057.4	OGFRP1	4.11	4.56e-05	0.00727	0.22	0.18	Cognitive function;	chr22:42011685	chr22:42269753~42275196:+
LUAD	cis	rs1876905	0.597	rs354551	ENSG00000230177.1	RP5-1112D6.4	-4.11	4.56e-05	0.00727	-0.22	-0.18	Mean corpuscular hemoglobin;	chr6:111224337	chr6:111277932~111278742:+
LUAD	cis	rs7208859	0.623	rs216445	ENSG00000280069.1	CTD-2349P21.3	-4.11	4.56e-05	0.00727	-0.26	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606558	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs216446	ENSG00000280069.1	CTD-2349P21.3	-4.11	4.56e-05	0.00727	-0.26	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606700	chr17:30738182~30740275:+
LUAD	cis	rs2732480	0.577	rs1489109	ENSG00000257763.1	OR5BK1P	4.11	4.56e-05	0.00727	0.2	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344997	chr12:48355792~48356614:-
LUAD	cis	rs2732480	0.577	rs1489108	ENSG00000257763.1	OR5BK1P	4.11	4.56e-05	0.00727	0.2	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344998	chr12:48355792~48356614:-
LUAD	cis	rs2274273	0.967	rs8009670	ENSG00000258413.1	RP11-665C16.6	-4.11	4.56e-05	0.00727	-0.23	-0.18	Protein biomarker;	chr14:55116759	chr14:55262767~55272075:-
LUAD	cis	rs7870753	0.838	rs6477493	ENSG00000188801.9	ZNF322P1	4.11	4.56e-05	0.00727	0.25	0.18	Height;	chr9:96490800	chr9:97198303~97199511:-
LUAD	cis	rs2243480	1	rs34815098	ENSG00000232559.3	GS1-124K5.12	4.11	4.56e-05	0.00728	0.33	0.18	Diabetic kidney disease;	chr7:65827267	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs4548056	ENSG00000232559.3	GS1-124K5.12	4.11	4.56e-05	0.00728	0.33	0.18	Diabetic kidney disease;	chr7:65833886	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs7456042	ENSG00000232559.3	GS1-124K5.12	4.11	4.56e-05	0.00728	0.33	0.18	Diabetic kidney disease;	chr7:65834791	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs35735127	ENSG00000232559.3	GS1-124K5.12	4.11	4.56e-05	0.00728	0.33	0.18	Diabetic kidney disease;	chr7:65835436	chr7:66554588~66576923:-
LUAD	cis	rs2243480	0.901	rs35256305	ENSG00000232559.3	GS1-124K5.12	4.11	4.56e-05	0.00728	0.33	0.18	Diabetic kidney disease;	chr7:65841418	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs73142121	ENSG00000232559.3	GS1-124K5.12	4.11	4.56e-05	0.00728	0.33	0.18	Diabetic kidney disease;	chr7:65846219	chr7:66554588~66576923:-
LUAD	cis	rs2243480	0.803	rs34004500	ENSG00000232559.3	GS1-124K5.12	4.11	4.56e-05	0.00728	0.33	0.18	Diabetic kidney disease;	chr7:65847191	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs35825738	ENSG00000232559.3	GS1-124K5.12	4.11	4.56e-05	0.00728	0.33	0.18	Diabetic kidney disease;	chr7:65853040	chr7:66554588~66576923:-
LUAD	cis	rs10129255	1	rs10137758	ENSG00000211947.2	IGHV3-21	-4.11	4.57e-05	0.00728	-0.13	-0.18	Kawasaki disease;	chr14:106697673	chr14:106235064~106235594:-
LUAD	cis	rs7204230	1	rs8050349	ENSG00000261291.1	RP11-295M3.2	4.11	4.57e-05	0.00728	0.23	0.18	Fibrinogen;	chr16:53305964	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs12599349	ENSG00000261291.1	RP11-295M3.2	4.11	4.57e-05	0.00728	0.23	0.18	Fibrinogen;	chr16:53309159	chr16:53168522~53169450:+
LUAD	cis	rs28386778	0.724	rs35092235	ENSG00000240280.5	TCAM1P	-4.11	4.57e-05	0.00728	-0.21	-0.18	Prudent dietary pattern;	chr17:63867261	chr17:63849292~63864379:+
LUAD	cis	rs71636778	0.631	rs34924059	ENSG00000260063.1	RP5-968P14.2	-4.11	4.57e-05	0.00728	-0.24	-0.18	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26832353	chr1:26692132~26694131:-
LUAD	cis	rs7107174	1	rs7104222	ENSG00000251323.2	RP11-452H21.4	4.11	4.57e-05	0.00728	0.24	0.18	Testicular germ cell tumor;	chr11:78296123	chr11:78423982~78429836:-
LUAD	cis	rs9341808	0.718	rs9343978	ENSG00000260645.1	RP11-250B2.5	4.11	4.57e-05	0.00729	0.17	0.18	Sitting height ratio;	chr6:80262261	chr6:80466958~80469080:+
LUAD	cis	rs7824557	0.527	rs2736296	ENSG00000255046.1	RP11-297N6.4	4.11	4.57e-05	0.00729	0.23	0.18	Retinal vascular caliber;	chr8:11377335	chr8:11797928~11802568:-
LUAD	cis	rs7824557	0.51	rs2736297	ENSG00000255046.1	RP11-297N6.4	4.11	4.57e-05	0.00729	0.23	0.18	Retinal vascular caliber;	chr8:11377376	chr8:11797928~11802568:-
LUAD	cis	rs7824557	0.527	rs57629785	ENSG00000255046.1	RP11-297N6.4	4.11	4.57e-05	0.00729	0.23	0.18	Retinal vascular caliber;	chr8:11377641	chr8:11797928~11802568:-
LUAD	cis	rs12188164	0.965	rs56182240	ENSG00000225138.6	CTD-2228K2.7	4.11	4.57e-05	0.00729	0.18	0.18	Cystic fibrosis severity;	chr5:423054	chr5:473236~480884:+
LUAD	cis	rs12188164	0.965	rs56346498	ENSG00000225138.6	CTD-2228K2.7	4.11	4.57e-05	0.00729	0.18	0.18	Cystic fibrosis severity;	chr5:423480	chr5:473236~480884:+
LUAD	cis	rs12188164	0.965	rs55948934	ENSG00000225138.6	CTD-2228K2.7	4.11	4.57e-05	0.00729	0.18	0.18	Cystic fibrosis severity;	chr5:423556	chr5:473236~480884:+
LUAD	cis	rs12188164	0.897	rs55932239	ENSG00000225138.6	CTD-2228K2.7	4.11	4.57e-05	0.00729	0.18	0.18	Cystic fibrosis severity;	chr5:423791	chr5:473236~480884:+
LUAD	cis	rs12188164	0.931	rs72717407	ENSG00000225138.6	CTD-2228K2.7	4.11	4.57e-05	0.00729	0.18	0.18	Cystic fibrosis severity;	chr5:424538	chr5:473236~480884:+
LUAD	cis	rs12188164	1	rs12188678	ENSG00000225138.6	CTD-2228K2.7	4.11	4.57e-05	0.00729	0.18	0.18	Cystic fibrosis severity;	chr5:428116	chr5:473236~480884:+
LUAD	cis	rs12188164	1	rs12188164	ENSG00000225138.6	CTD-2228K2.7	4.11	4.57e-05	0.00729	0.18	0.18	Cystic fibrosis severity;	chr5:428121	chr5:473236~480884:+
LUAD	cis	rs12188164	1	rs72717411	ENSG00000225138.6	CTD-2228K2.7	4.11	4.57e-05	0.00729	0.18	0.18	Cystic fibrosis severity;	chr5:429009	chr5:473236~480884:+
LUAD	cis	rs12188164	1	rs72717412	ENSG00000225138.6	CTD-2228K2.7	4.11	4.57e-05	0.00729	0.18	0.18	Cystic fibrosis severity;	chr5:429266	chr5:473236~480884:+
LUAD	cis	rs12188164	0.965	rs72717415	ENSG00000225138.6	CTD-2228K2.7	4.11	4.57e-05	0.00729	0.18	0.18	Cystic fibrosis severity;	chr5:429944	chr5:473236~480884:+
LUAD	cis	rs10197140	0.925	rs10177582	ENSG00000235721.1	AC013268.3	4.11	4.57e-05	0.00729	0.2	0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110870975	chr2:110007675~110010783:+
LUAD	cis	rs34779708	1	rs34779708	ENSG00000271335.4	RP11-324I22.4	4.11	4.57e-05	0.00729	0.2	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35177257	chr10:35314552~35336401:-
LUAD	cis	rs1355223	0.902	rs1453387	ENSG00000271369.1	RP11-350D17.3	-4.11	4.57e-05	0.00729	-0.22	-0.18	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34686351	chr11:34709600~34710161:+
LUAD	cis	rs7560272	0.723	rs4346412	ENSG00000163016.8	ALMS1P	4.11	4.58e-05	0.00729	0.2	0.18	Schizophrenia;	chr2:73616444	chr2:73644919~73685576:+
LUAD	cis	rs116095464	0.558	rs6872854	ENSG00000248925.1	CTD-2083E4.6	4.11	4.58e-05	0.00729	0.31	0.18	Breast cancer;	chr5:208923	chr5:269858~271516:-
LUAD	cis	rs2274273	0.87	rs10134339	ENSG00000258413.1	RP11-665C16.6	-4.11	4.58e-05	0.00729	-0.23	-0.18	Protein biomarker;	chr14:55347662	chr14:55262767~55272075:-
LUAD	cis	rs858239	0.601	rs6461693	ENSG00000226816.2	AC005082.12	-4.11	4.58e-05	0.00729	-0.24	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23206013~23208045:+
LUAD	cis	rs1383484	0.545	rs7171383	ENSG00000259728.4	LINC00933	-4.11	4.58e-05	0.00729	-0.24	-0.18	Height;	chr15:83976087	chr15:84570649~84580175:+
LUAD	cis	rs10129255	0.913	rs10140943	ENSG00000211967.3	IGHV3-53	-4.11	4.58e-05	0.00729	-0.15	-0.18	Kawasaki disease;	chr14:106767441	chr14:106592676~106593347:-
LUAD	cis	rs2548724	0.617	rs1376905	ENSG00000250682.4	LINC00491	4.11	4.58e-05	0.00729	0.22	0.18	Type 2 diabetes;	chr5:102389132	chr5:102609156~102671559:-
LUAD	cis	rs853679	0.567	rs13196606	ENSG00000219392.1	RP1-265C24.5	-4.11	4.58e-05	0.00729	-0.24	-0.18	Depression;	chr6:28402301	chr6:28115628~28116551:+
LUAD	cis	rs6479891	1	rs72837070	ENSG00000232075.1	MRPL35P2	4.11	4.58e-05	0.00729	0.3	0.18	Arthritis (juvenile idiopathic);	chr10:63514919	chr10:63634317~63634827:-
LUAD	cis	rs1061377	0.748	rs6810770	ENSG00000249685.1	RP11-360F5.3	4.11	4.58e-05	0.0073	0.22	0.18	Uric acid levels;	chr4:39106545	chr4:39133913~39135608:+
LUAD	cis	rs1061377	0.748	rs6812316	ENSG00000249685.1	RP11-360F5.3	4.11	4.58e-05	0.0073	0.22	0.18	Uric acid levels;	chr4:39106617	chr4:39133913~39135608:+
LUAD	cis	rs6142102	0.961	rs2056990	ENSG00000275784.1	RP5-1125A11.6	-4.11	4.58e-05	0.0073	-0.21	-0.18	Skin pigmentation;	chr20:34035658	chr20:33989480~33991818:-
LUAD	cis	rs853679	0.598	rs9380054	ENSG00000226314.6	ZNF192P1	-4.11	4.58e-05	0.0073	-0.24	-0.18	Depression;	chr6:28099759	chr6:28161781~28169594:+
LUAD	cis	rs4713118	0.547	rs2116981	ENSG00000226314.6	ZNF192P1	-4.11	4.58e-05	0.0073	-0.24	-0.18	Parkinson's disease;	chr6:28100173	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs9368552	ENSG00000226314.6	ZNF192P1	-4.11	4.58e-05	0.0073	-0.24	-0.18	Depression;	chr6:28100648	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.542	rs34131763	ENSG00000226314.6	ZNF192P1	-4.11	4.58e-05	0.0073	-0.24	-0.18	Depression;	chr6:28107222	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs35193936	ENSG00000226314.6	ZNF192P1	-4.11	4.58e-05	0.0073	-0.24	-0.18	Depression;	chr6:28108492	chr6:28161781~28169594:+
LUAD	cis	rs41271951	0.518	rs16835780	ENSG00000223945.2	RP11-458I7.1	-4.11	4.58e-05	0.0073	-0.29	-0.18	Blood protein levels;	chr1:150291891	chr1:150053864~150055034:+
LUAD	cis	rs7208859	0.673	rs12103759	ENSG00000280069.1	CTD-2349P21.3	-4.11	4.58e-05	0.0073	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908669	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs59029591	ENSG00000280069.1	CTD-2349P21.3	-4.11	4.58e-05	0.0073	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908728	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs73265633	ENSG00000280069.1	CTD-2349P21.3	-4.11	4.58e-05	0.0073	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30909288	chr17:30738182~30740275:+
LUAD	cis	rs4374383	0.884	rs3811636	ENSG00000207383.1	Y_RNA	-4.11	4.58e-05	0.0073	-0.22	-0.18	Hepatitis C induced liver fibrosis;	chr2:111997632	chr2:112579484~112579584:-
LUAD	cis	rs4374383	0.884	rs3811637	ENSG00000207383.1	Y_RNA	-4.11	4.58e-05	0.0073	-0.22	-0.18	Hepatitis C induced liver fibrosis;	chr2:111997669	chr2:112579484~112579584:-
LUAD	cis	rs6951245	0.744	rs10275401	ENSG00000199023.2	MIR339	-4.11	4.58e-05	0.0073	-0.32	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1174307	chr7:1022935~1023045:-
LUAD	cis	rs9815354	0.951	rs6768438	ENSG00000273328.4	RP11-141M3.6	-4.11	4.58e-05	0.0073	-0.27	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41823863	chr3:42809414~42908105:+
LUAD	cis	rs9815354	0.68	rs7649989	ENSG00000273328.4	RP11-141M3.6	-4.11	4.58e-05	0.0073	-0.27	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41824351	chr3:42809414~42908105:+
LUAD	cis	rs860295	0.665	rs11264367	ENSG00000225855.5	RUSC1-AS1	4.11	4.59e-05	0.0073	0.13	0.18	Body mass index;	chr1:155367547	chr1:155316863~155324176:-
LUAD	cis	rs6951245	1	rs77868187	ENSG00000199023.2	MIR339	-4.11	4.59e-05	0.00731	-0.33	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054332	chr7:1022935~1023045:-
LUAD	cis	rs6951245	1	rs75016635	ENSG00000199023.2	MIR339	-4.11	4.59e-05	0.00731	-0.33	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054485	chr7:1022935~1023045:-
LUAD	cis	rs6951245	1	rs113066613	ENSG00000199023.2	MIR339	-4.11	4.59e-05	0.00731	-0.33	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054492	chr7:1022935~1023045:-
LUAD	cis	rs5769707	0.656	rs135878	ENSG00000235111.1	RP1-29C18.8	-4.11	4.59e-05	0.00731	-0.23	-0.18	Monocyte percentage of white cells;Monocyte count;	chr22:49620721	chr22:49612657~49615716:-
LUAD	cis	rs9876781	1	rs13071337	ENSG00000229759.1	MRPS18AP1	4.11	4.59e-05	0.00731	0.18	0.18	Longevity;	chr3:48396724	chr3:48256350~48256938:-
LUAD	cis	rs2153535	0.518	rs926533	ENSG00000230939.1	RP11-314C16.1	-4.11	4.59e-05	0.00731	-0.21	-0.18	Motion sickness;	chr6:8556529	chr6:8784178~8785445:+
LUAD	cis	rs1005277	0.522	rs1208681	ENSG00000273019.1	RP11-508N22.13	-4.11	4.59e-05	0.00731	-0.21	-0.18	Extrinsic epigenetic age acceleration;	chr10:37804047	chr10:38149968~38150293:+
LUAD	cis	rs4879677	1	rs642259	ENSG00000215441.3	CTAGE12P	-4.11	4.59e-05	0.00731	-0.22	-0.18	Gut microbiome composition (summer and winter);	chr9:27661755	chr9:27608382~27610745:-
LUAD	cis	rs7584330	0.868	rs6760842	ENSG00000222032.1	AC112721.2	-4.11	4.59e-05	0.00731	-0.22	-0.18	Prostate cancer;	chr2:237489522	chr2:237428920~237434822:-
LUAD	cis	rs858239	0.6	rs4321896	ENSG00000226816.2	AC005082.12	4.11	4.59e-05	0.00731	0.24	0.18	Cerebrospinal fluid biomarker levels;	chr7:23088437	chr7:23206013~23208045:+
LUAD	cis	rs911555	0.617	rs7156036	ENSG00000244691.1	RPL10AP1	4.11	4.6e-05	0.00732	0.25	0.18	Intelligence (multi-trait analysis);	chr14:103441805	chr14:103412119~103412761:-
LUAD	cis	rs911555	0.723	rs6575991	ENSG00000244691.1	RPL10AP1	4.11	4.6e-05	0.00732	0.25	0.18	Intelligence (multi-trait analysis);	chr14:103442096	chr14:103412119~103412761:-
LUAD	cis	rs2060793	0.712	rs11023310	ENSG00000251991.1	RNU7-49P	4.11	4.6e-05	0.00732	0.2	0.18	Vitamin D levels;	chr11:14703717	chr11:14478892~14478953:+
LUAD	cis	rs7617773	0.78	rs13084616	ENSG00000199476.1	Y_RNA	4.11	4.6e-05	0.00732	0.24	0.18	Coronary artery disease;	chr3:48298209	chr3:48288587~48288694:+
LUAD	cis	rs5015933	0.815	rs10124754	ENSG00000232630.1	PRPS1P2	-4.11	4.6e-05	0.00733	-0.17	-0.18	Body mass index;	chr9:125327479	chr9:125150653~125151589:+
LUAD	cis	rs6728302	0.557	rs73002000	ENSG00000244280.1	ECEL1P2	4.11	4.6e-05	0.00733	0.41	0.18	Height;	chr2:232389342	chr2:232385750~232387457:-
LUAD	cis	rs4144027	0.967	rs72712857	ENSG00000258534.1	CTD-2134A5.4	-4.11	4.6e-05	0.00733	-0.21	-0.18	Blood metabolite levels;	chr14:103896336	chr14:103854366~103880111:-
LUAD	cis	rs8098244	0.737	rs1154241	ENSG00000264745.1	TTC39C-AS1	-4.11	4.6e-05	0.00733	-0.24	-0.18	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23944675	chr18:23994213~24015339:-
LUAD	cis	rs9467773	0.967	rs1535276	ENSG00000261353.1	CTA-14H9.5	-4.11	4.6e-05	0.00733	-0.21	-0.18	Intelligence (multi-trait analysis);	chr6:26520713	chr6:26527063~26527404:+
LUAD	cis	rs12935418	0.672	rs12446810	ENSG00000261061.1	RP11-303E16.2	-4.11	4.6e-05	0.00733	-0.21	-0.18	Mean corpuscular volume;	chr16:81009369	chr16:81030770~81031485:+
LUAD	cis	rs3177980	0.673	rs10919255	ENSG00000239494.2	RN7SL333P	-4.11	4.61e-05	0.00733	-0.18	-0.18	Amyotrophic lateral sclerosis;	chr1:169847041	chr1:169859756~169860052:+
LUAD	cis	rs7937682	1	rs11608149	ENSG00000230911.1	PPIHP1	4.11	4.61e-05	0.00733	0.25	0.18	Primary sclerosing cholangitis;	chr11:111664378	chr11:112029858~112030367:-
LUAD	cis	rs950169	1	rs12916348	ENSG00000275120.1	RP11-182J1.17	4.11	4.61e-05	0.00733	0.29	0.18	Schizophrenia;	chr15:84096775	chr15:84599434~84606463:-
LUAD	cis	rs11673344	0.504	rs8105065	ENSG00000276846.1	CTD-3220F14.3	4.11	4.61e-05	0.00733	0.2	0.18	Obesity-related traits;	chr19:37141003	chr19:37314868~37315620:-
LUAD	cis	rs7210086	0.768	rs72849445	ENSG00000263893.2	CTD-3010D24.3	4.11	4.61e-05	0.00734	0.25	0.18	Ulcerative colitis;	chr17:72641846	chr17:72642731~72644490:+
LUAD	cis	rs6142102	0.812	rs761238	ENSG00000275784.1	RP5-1125A11.6	4.11	4.61e-05	0.00734	0.2	0.18	Skin pigmentation;	chr20:33932182	chr20:33989480~33991818:-
LUAD	cis	rs2243480	1	rs4718270	ENSG00000229886.1	RP5-1132H15.3	4.11	4.61e-05	0.00734	0.32	0.18	Diabetic kidney disease;	chr7:65737415	chr7:66025126~66031544:-
LUAD	cis	rs2243480	0.901	rs2900904	ENSG00000229886.1	RP5-1132H15.3	4.11	4.61e-05	0.00734	0.32	0.18	Diabetic kidney disease;	chr7:65739282	chr7:66025126~66031544:-
LUAD	cis	rs17596685	1	rs2324851	ENSG00000271216.1	LINC01050	4.11	4.61e-05	0.00734	0.26	0.18	C-reactive protein levels;	chr13:42586794	chr13:42810366~42812562:-
LUAD	cis	rs17772222	0.917	rs61984684	ENSG00000258789.1	RP11-507K2.3	-4.11	4.61e-05	0.00734	-0.26	-0.18	Coronary artery calcification;	chr14:88559104	chr14:88551597~88552493:+
LUAD	cis	rs34783982	0.96	rs4347601	ENSG00000261441.1	RP11-217B1.2	-4.11	4.61e-05	0.00734	-0.25	-0.18	Squamous cell lung carcinoma;	chr15:88967604	chr15:89335053~89336161:+
LUAD	cis	rs34783982	0.96	rs4932456	ENSG00000261441.1	RP11-217B1.2	-4.11	4.61e-05	0.00734	-0.25	-0.18	Squamous cell lung carcinoma;	chr15:88970920	chr15:89335053~89336161:+
LUAD	cis	rs34783982	0.96	rs4932457	ENSG00000261441.1	RP11-217B1.2	-4.11	4.61e-05	0.00734	-0.25	-0.18	Squamous cell lung carcinoma;	chr15:88971013	chr15:89335053~89336161:+
LUAD	cis	rs6964587	0.839	rs13246743	ENSG00000188693.7	CYP51A1-AS1	-4.11	4.61e-05	0.00734	-0.22	-0.18	Breast cancer;	chr7:91824631	chr7:92134604~92180725:+
LUAD	cis	rs7976269	0.559	rs1344853	ENSG00000257176.2	RP11-996F15.2	-4.11	4.61e-05	0.00734	-0.2	-0.18	Male-pattern baldness;	chr12:29058623	chr12:29280418~29317848:-
LUAD	cis	rs7119038	0.629	rs11217000	ENSG00000255239.1	AP002954.6	-4.11	4.61e-05	0.00734	-0.28	-0.18	Sjögren's syndrome;	chr11:118734275	chr11:118688039~118690600:-
LUAD	cis	rs13434995	0.513	rs550144	ENSG00000273257.1	RP11-177J6.1	4.11	4.61e-05	0.00734	0.24	0.18	Adiponectin levels;	chr4:55415317	chr4:55387949~55388271:+
LUAD	cis	rs7208859	0.673	rs73277967	ENSG00000280069.1	CTD-2349P21.3	-4.11	4.61e-05	0.00734	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30857148	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs60020217	ENSG00000280069.1	CTD-2349P21.3	-4.11	4.61e-05	0.00734	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30858036	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.573	rs73277974	ENSG00000280069.1	CTD-2349P21.3	-4.11	4.61e-05	0.00734	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862851	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs73277978	ENSG00000280069.1	CTD-2349P21.3	-4.11	4.61e-05	0.00734	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864431	chr17:30738182~30740275:+
LUAD	cis	rs17826219	0.706	rs9905827	ENSG00000280069.1	CTD-2349P21.3	-4.11	4.61e-05	0.00734	-0.27	-0.18	Body mass index;	chr17:30865150	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs11657391	ENSG00000280069.1	CTD-2349P21.3	-4.11	4.61e-05	0.00734	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30867269	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs58089675	ENSG00000280069.1	CTD-2349P21.3	-4.11	4.61e-05	0.00734	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869746	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs73263755	ENSG00000280069.1	CTD-2349P21.3	-4.11	4.61e-05	0.00734	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30871954	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs9899349	ENSG00000280069.1	CTD-2349P21.3	-4.11	4.61e-05	0.00734	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30873104	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs11652358	ENSG00000280069.1	CTD-2349P21.3	-4.11	4.61e-05	0.00734	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30878462	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs11656845	ENSG00000280069.1	CTD-2349P21.3	-4.11	4.61e-05	0.00734	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30879146	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs9891179	ENSG00000280069.1	CTD-2349P21.3	-4.11	4.61e-05	0.00734	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881142	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs9891413	ENSG00000280069.1	CTD-2349P21.3	-4.11	4.61e-05	0.00734	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881191	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs73263776	ENSG00000280069.1	CTD-2349P21.3	-4.11	4.61e-05	0.00734	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30884313	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs11650271	ENSG00000280069.1	CTD-2349P21.3	-4.11	4.61e-05	0.00734	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30886925	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs73263785	ENSG00000280069.1	CTD-2349P21.3	-4.11	4.61e-05	0.00734	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887790	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs55904046	ENSG00000280069.1	CTD-2349P21.3	-4.11	4.61e-05	0.00734	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888373	chr17:30738182~30740275:+
LUAD	cis	rs6142102	0.961	rs2235597	ENSG00000275784.1	RP5-1125A11.6	-4.11	4.61e-05	0.00734	-0.21	-0.18	Skin pigmentation;	chr20:34077808	chr20:33989480~33991818:-
LUAD	cis	rs8028182	0.636	rs4322627	ENSG00000260269.4	CTD-2323K18.1	-4.11	4.61e-05	0.00734	-0.26	-0.18	Sudden cardiac arrest;	chr15:75518318	chr15:75527150~75601205:-
LUAD	cis	rs13434995	0.755	rs1488941	ENSG00000249700.7	SRD5A3-AS1	-4.11	4.62e-05	0.00735	-0.26	-0.18	Adiponectin levels;	chr4:55517799	chr4:55363971~55395847:-
LUAD	cis	rs7181230	1	rs28587891	ENSG00000278621.1	CTD-2033D15.3	4.11	4.62e-05	0.00735	0.21	0.18	Dehydroepiandrosterone sulphate levels;	chr15:40072905	chr15:39588357~39588882:-
LUAD	cis	rs9907295	0.591	rs8069014	ENSG00000270977.1	AC015849.16	-4.11	4.62e-05	0.00735	-0.25	-0.18	Fibroblast growth factor basic levels;	chr17:35872994	chr17:35893707~35911023:-
LUAD	cis	rs28386778	0.897	rs8066754	ENSG00000240280.5	TCAM1P	-4.11	4.62e-05	0.00735	-0.21	-0.18	Prudent dietary pattern;	chr17:63739230	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.863	rs3826341	ENSG00000240280.5	TCAM1P	-4.11	4.62e-05	0.00735	-0.21	-0.18	Prudent dietary pattern;	chr17:63741862	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.863	rs3760256	ENSG00000240280.5	TCAM1P	-4.11	4.62e-05	0.00735	-0.21	-0.18	Prudent dietary pattern;	chr17:63743801	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.897	rs8069969	ENSG00000240280.5	TCAM1P	-4.11	4.62e-05	0.00735	-0.21	-0.18	Prudent dietary pattern;	chr17:63744863	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.863	rs9207	ENSG00000240280.5	TCAM1P	-4.11	4.62e-05	0.00735	-0.21	-0.18	Prudent dietary pattern;	chr17:63746539	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.897	rs3785572	ENSG00000240280.5	TCAM1P	-4.11	4.62e-05	0.00735	-0.21	-0.18	Prudent dietary pattern;	chr17:63752629	chr17:63849292~63864379:+
LUAD	cis	rs7772486	0.712	rs6570726	ENSG00000235652.6	RP11-545I5.3	4.11	4.62e-05	0.00735	0.19	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145838324	chr6:145799409~145886585:+
LUAD	cis	rs2898681	0.511	rs881743	ENSG00000248375.1	RP11-177B4.1	-4.11	4.62e-05	0.00735	-0.25	-0.18	Optic nerve measurement (cup area);	chr4:52861283	chr4:52720081~52720831:-
LUAD	cis	rs916888	0.779	rs199528	ENSG00000232300.1	FAM215B	4.11	4.62e-05	0.00735	0.29	0.18	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46558830~46562795:-
LUAD	cis	rs916888	0.821	rs199525	ENSG00000232300.1	FAM215B	4.11	4.62e-05	0.00735	0.29	0.18	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46558830~46562795:-
LUAD	cis	rs2735413	0.881	rs12921945	ENSG00000276007.1	RP11-358L22.3	-4.11	4.62e-05	0.00735	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78046236	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.846	rs12923626	ENSG00000276007.1	RP11-358L22.3	-4.11	4.62e-05	0.00735	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78046242	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.881	rs12927515	ENSG00000276007.1	RP11-358L22.3	-4.11	4.62e-05	0.00735	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78046244	chr16:78123243~78124332:+
LUAD	cis	rs7493	0.901	rs17883318	ENSG00000233942.1	AC004012.1	4.11	4.62e-05	0.00735	0.25	0.18	Yu-Zhi constitution type in type 2 diabetes;	chr7:95329000	chr7:95471835~95473998:+
LUAD	cis	rs8062405	0.755	rs4788076	ENSG00000251417.2	RP11-1348G14.4	-4.11	4.62e-05	0.00736	-0.19	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28802743~28817828:+
LUAD	cis	rs7521902	0.617	rs7412010	ENSG00000228397.1	RP1-224A6.3	-4.11	4.62e-05	0.00736	-0.33	-0.18	Endometriosis;Ovarian cancer;Bone mineral density;Hip circumference adjusted for BMI;	chr1:22109953	chr1:22023994~22024968:-
LUAD	cis	rs12986445	0.694	rs13422450	ENSG00000218682.1	AC010150.1	4.11	4.63e-05	0.00736	0.23	0.18	Multiple myeloma;Multiple myeloma and monoclonal gammopathy;	chr2:25859188	chr2:25856461~25856966:-
LUAD	cis	rs9549260	0.755	rs7338669	ENSG00000229456.1	RLIMP1	-4.11	4.63e-05	0.00736	-0.2	-0.18	Red blood cell count;	chr13:40625954	chr13:40618738~40621348:+
LUAD	cis	rs9435732	0.504	rs9787230	ENSG00000235241.1	RP11-108M9.5	4.11	4.63e-05	0.00736	0.24	0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:17044475	chr1:16889095~16889602:+
LUAD	cis	rs9309711	0.77	rs13409323	ENSG00000271868.1	RP11-1293J14.1	-4.11	4.63e-05	0.00736	-0.22	-0.18	Neurofibrillary tangles;	chr2:3484413	chr2:3496956~3497428:+
LUAD	cis	rs6723108	0.627	rs7589297	ENSG00000224043.6	CCNT2-AS1	-4.11	4.63e-05	0.00736	-0.23	-0.18	Type 2 diabetes;	chr2:134894829	chr2:134735464~134918710:-
LUAD	cis	rs6723108	0.627	rs1374292	ENSG00000224043.6	CCNT2-AS1	-4.11	4.63e-05	0.00736	-0.23	-0.18	Type 2 diabetes;	chr2:134896598	chr2:134735464~134918710:-
LUAD	cis	rs28386778	0.897	rs4968662	ENSG00000240280.5	TCAM1P	-4.11	4.63e-05	0.00737	-0.21	-0.18	Prudent dietary pattern;	chr17:63757177	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.897	rs4968598	ENSG00000240280.5	TCAM1P	-4.11	4.63e-05	0.00737	-0.21	-0.18	Prudent dietary pattern;	chr17:63758219	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.897	rs4968663	ENSG00000240280.5	TCAM1P	-4.11	4.63e-05	0.00737	-0.21	-0.18	Prudent dietary pattern;	chr17:63758243	chr17:63849292~63864379:+
LUAD	cis	rs1401999	1	rs2872249	ENSG00000223882.1	ABCC5-AS1	-4.11	4.63e-05	0.00737	-0.19	-0.18	Anterior chamber depth;	chr3:183918485	chr3:184006338~184011419:+
LUAD	cis	rs4474465	1	rs10899506	ENSG00000251323.2	RP11-452H21.4	4.11	4.63e-05	0.00737	0.24	0.18	Alzheimer's disease (survival time);	chr11:78457659	chr11:78423982~78429836:-
LUAD	cis	rs4474465	1	rs10793313	ENSG00000251323.2	RP11-452H21.4	4.11	4.63e-05	0.00737	0.24	0.18	Alzheimer's disease (survival time);	chr11:78458264	chr11:78423982~78429836:-
LUAD	cis	rs4474465	1	rs7935180	ENSG00000251323.2	RP11-452H21.4	4.11	4.63e-05	0.00737	0.24	0.18	Alzheimer's disease (survival time);	chr11:78458739	chr11:78423982~78429836:-
LUAD	cis	rs4474465	1	rs10899508	ENSG00000251323.2	RP11-452H21.4	4.11	4.63e-05	0.00737	0.24	0.18	Alzheimer's disease (survival time);	chr11:78459662	chr11:78423982~78429836:-
LUAD	cis	rs4474465	1	rs10899511	ENSG00000251323.2	RP11-452H21.4	4.11	4.63e-05	0.00737	0.24	0.18	Alzheimer's disease (survival time);	chr11:78459877	chr11:78423982~78429836:-
LUAD	cis	rs6088580	0.634	rs6058052	ENSG00000276073.1	RP5-1125A11.7	-4.11	4.64e-05	0.00737	-0.18	-0.18	Glomerular filtration rate (creatinine);	chr20:34459279	chr20:33985617~33988989:-
LUAD	cis	rs6088580	0.634	rs6059856	ENSG00000276073.1	RP5-1125A11.7	-4.11	4.64e-05	0.00737	-0.18	-0.18	Glomerular filtration rate (creatinine);	chr20:34470149	chr20:33985617~33988989:-
LUAD	cis	rs6088580	0.634	rs6087588	ENSG00000276073.1	RP5-1125A11.7	-4.11	4.64e-05	0.00737	-0.18	-0.18	Glomerular filtration rate (creatinine);	chr20:34478564	chr20:33985617~33988989:-
LUAD	cis	rs338389	0.542	rs7182139	ENSG00000260657.2	RP11-315D16.4	-4.11	4.64e-05	0.00737	-0.22	-0.18	Survival in rectal cancer;	chr15:67993116	chr15:68267792~68277994:-
LUAD	cis	rs910316	0.967	rs4903292	ENSG00000279594.1	RP11-950C14.10	4.11	4.64e-05	0.00737	0.21	0.18	Height;	chr14:75189542	chr14:75011269~75012851:-
LUAD	cis	rs4578769	0.55	rs12958492	ENSG00000265943.1	RP11-739L10.1	4.11	4.64e-05	0.00737	0.23	0.18	Eosinophil percentage of white cells;	chr18:22988974	chr18:22699481~22933764:-
LUAD	cis	rs7005380	0.62	rs13260933	ENSG00000279347.1	RP11-85I17.2	-4.11	4.64e-05	0.00738	-0.15	-0.18	Interstitial lung disease;	chr8:119895010	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.6	rs13261304	ENSG00000279347.1	RP11-85I17.2	-4.11	4.64e-05	0.00738	-0.15	-0.18	Interstitial lung disease;	chr8:119895180	chr8:119838736~119840385:-
LUAD	cis	rs2243480	1	rs316327	ENSG00000232559.3	GS1-124K5.12	-4.11	4.64e-05	0.00738	-0.31	-0.18	Diabetic kidney disease;	chr7:66144214	chr7:66554588~66576923:-
LUAD	cis	rs17597773	0.674	rs10863569	ENSG00000272823.1	RP11-295M18.6	-4.11	4.64e-05	0.00738	-0.25	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220845598	chr1:220828676~220829211:-
LUAD	cis	rs1046491	0.614	rs7243448	ENSG00000264964.1	RP11-888D10.3	4.11	4.64e-05	0.00738	0.4	0.18	Scarlet fever;	chr18:9321278	chr18:9315194~9334441:-
LUAD	cis	rs6964833	0.935	rs34630792	ENSG00000184616.8	AC004166.6	4.11	4.64e-05	0.00738	0.27	0.18	Menarche (age at onset);	chr7:74646869	chr7:74906673~74913256:-
LUAD	cis	rs4934494	0.768	rs34379399	ENSG00000240996.1	RP11-80H5.7	-4.11	4.64e-05	0.00738	-0.26	-0.18	Red blood cell count;	chr10:89683526	chr10:89694295~89697928:-
LUAD	cis	rs763121	1	rs763121	ENSG00000225450.1	RP3-508I15.14	4.11	4.64e-05	0.00738	0.17	0.18	Menopause (age at onset);	chr22:38483935	chr22:38739003~38749041:+
LUAD	cis	rs2018683	0.677	rs2057956	ENSG00000228421.2	AC005013.5	4.11	4.64e-05	0.00738	0.2	0.18	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28933843	chr7:28957667~28959345:+
LUAD	cis	rs4499344	0.696	rs2868154	ENSG00000201388.1	SNORA68	4.11	4.64e-05	0.00738	0.2	0.18	Mean platelet volume;	chr19:32608399	chr19:32608337~32608469:-
LUAD	cis	rs8062405	0.755	rs7193402	ENSG00000251417.2	RP11-1348G14.4	-4.11	4.64e-05	0.00738	-0.19	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28802743~28817828:+
LUAD	cis	rs7688540	0.8	rs11723492	ENSG00000211553.1	AC253576.2	-4.11	4.64e-05	0.00738	-0.23	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:222634	chr4:136461~136568:+
LUAD	cis	rs858239	0.6	rs61292332	ENSG00000226816.2	AC005082.12	4.11	4.64e-05	0.00738	0.24	0.18	Cerebrospinal fluid biomarker levels;	chr7:23092243	chr7:23206013~23208045:+
LUAD	cis	rs858239	0.6	rs59073109	ENSG00000226816.2	AC005082.12	4.11	4.64e-05	0.00738	0.24	0.18	Cerebrospinal fluid biomarker levels;	chr7:23093607	chr7:23206013~23208045:+
LUAD	cis	rs858239	0.6	rs7788821	ENSG00000226816.2	AC005082.12	4.11	4.64e-05	0.00738	0.24	0.18	Cerebrospinal fluid biomarker levels;	chr7:23094026	chr7:23206013~23208045:+
LUAD	cis	rs858239	0.6	rs6956595	ENSG00000226816.2	AC005082.12	4.11	4.64e-05	0.00738	0.24	0.18	Cerebrospinal fluid biomarker levels;	chr7:23094637	chr7:23206013~23208045:+
LUAD	cis	rs910316	0.836	rs6574212	ENSG00000279594.1	RP11-950C14.10	-4.11	4.64e-05	0.00738	-0.21	-0.18	Height;	chr14:75204956	chr14:75011269~75012851:-
LUAD	cis	rs2348418	0.715	rs10843206	ENSG00000247934.4	RP11-967K21.1	4.11	4.64e-05	0.00738	0.21	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28569823	chr12:28163298~28190738:-
LUAD	cis	rs2348418	0.681	rs10843207	ENSG00000247934.4	RP11-967K21.1	4.11	4.64e-05	0.00738	0.21	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28569929	chr12:28163298~28190738:-
LUAD	cis	rs2348418	0.715	rs7971717	ENSG00000247934.4	RP11-967K21.1	4.11	4.64e-05	0.00738	0.21	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28570087	chr12:28163298~28190738:-
LUAD	cis	rs67981189	0.529	rs17108862	ENSG00000269927.1	RP6-91H8.3	4.11	4.65e-05	0.00739	0.24	0.18	Schizophrenia;	chr14:70997949	chr14:71141125~71143253:-
LUAD	cis	rs9815354	1	rs7616844	ENSG00000273328.4	RP11-141M3.6	-4.11	4.65e-05	0.00739	-0.27	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41832851	chr3:42809414~42908105:+
LUAD	cis	rs9815354	1	rs9869207	ENSG00000273328.4	RP11-141M3.6	-4.11	4.65e-05	0.00739	-0.27	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41837169	chr3:42809414~42908105:+
LUAD	cis	rs5758659	0.679	rs134870	ENSG00000227370.1	RP4-669P10.19	-4.11	4.65e-05	0.00739	-0.16	-0.18	Cognitive function;	chr22:42256311	chr22:42132543~42132998:+
LUAD	cis	rs6723108	0.603	rs6430555	ENSG00000224043.6	CCNT2-AS1	-4.11	4.65e-05	0.00739	-0.23	-0.18	Type 2 diabetes;	chr2:134890089	chr2:134735464~134918710:-
LUAD	cis	rs7561273	0.609	rs2080727	ENSG00000242628.4	AC009228.1	4.11	4.65e-05	0.00739	0.23	0.18	Quantitative traits;	chr2:24128037	chr2:24214381~24221516:+
LUAD	cis	rs7561273	0.609	rs10197527	ENSG00000242628.4	AC009228.1	4.11	4.65e-05	0.00739	0.23	0.18	Quantitative traits;	chr2:24129528	chr2:24214381~24221516:+
LUAD	cis	rs7561273	0.561	rs35268318	ENSG00000242628.4	AC009228.1	4.11	4.65e-05	0.00739	0.23	0.18	Quantitative traits;	chr2:24129954	chr2:24214381~24221516:+
LUAD	cis	rs17301013	0.896	rs332773	ENSG00000227373.4	RP11-160H22.5	4.11	4.65e-05	0.00739	0.23	0.18	Systemic lupus erythematosus;	chr1:174695711	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.932	rs444678	ENSG00000227373.4	RP11-160H22.5	4.11	4.65e-05	0.00739	0.23	0.18	Systemic lupus erythematosus;	chr1:174706080	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.896	rs332791	ENSG00000227373.4	RP11-160H22.5	4.11	4.65e-05	0.00739	0.23	0.18	Systemic lupus erythematosus;	chr1:174709784	chr1:174115300~174160004:-
LUAD	cis	rs42490	0.557	rs426240	ENSG00000251136.7	RP11-37B2.1	-4.11	4.65e-05	0.00739	-0.19	-0.18	Leprosy;	chr8:89834573	chr8:89609409~89757727:-
LUAD	cis	rs957448	1	rs2381885	ENSG00000253175.1	RP11-267M23.6	4.11	4.65e-05	0.00739	0.23	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94499974	chr8:94565036~94565715:+
LUAD	cis	rs7121538	0.673	rs11023182	ENSG00000254418.1	RP11-21L19.1	4.11	4.65e-05	0.00739	0.31	0.18	HDL cholesterol;	chr11:14297284	chr11:14262846~14273691:-
LUAD	cis	rs10463554	0.963	rs17154953	ENSG00000250682.4	LINC00491	4.11	4.65e-05	0.0074	0.22	0.18	Parkinson's disease;	chr5:103019557	chr5:102609156~102671559:-
LUAD	cis	rs9400467	0.509	rs11153287	ENSG00000230177.1	RP5-1112D6.4	-4.11	4.65e-05	0.0074	-0.16	-0.18	Amino acid levels;Blood metabolite levels;	chr6:111383334	chr6:111277932~111278742:+
LUAD	cis	rs72772090	0.908	rs76539796	ENSG00000248734.2	CTD-2260A17.1	-4.11	4.66e-05	0.0074	-0.27	-0.18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96702971	chr5:96784777~96785999:+
LUAD	cis	rs2274273	0.87	rs28716725	ENSG00000258413.1	RP11-665C16.6	-4.11	4.66e-05	0.0074	-0.23	-0.18	Protein biomarker;	chr14:55349892	chr14:55262767~55272075:-
LUAD	cis	rs6479891	1	rs10733790	ENSG00000232075.1	MRPL35P2	-4.11	4.66e-05	0.0074	-0.3	-0.18	Arthritis (juvenile idiopathic);	chr10:63340574	chr10:63634317~63634827:-
LUAD	cis	rs858239	0.72	rs10227559	ENSG00000230042.1	AK3P3	-4.11	4.66e-05	0.0074	-0.24	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23232525	chr7:23129178~23129841:+
LUAD	cis	rs9659323	0.601	rs12033970	ENSG00000231365.4	RP11-418J17.1	-4.11	4.66e-05	0.0074	-0.22	-0.18	Body mass index;	chr1:119097778	chr1:119140396~119275973:+
LUAD	cis	rs6121246	0.559	rs6121172	ENSG00000230613.1	HM13-AS1	4.11	4.66e-05	0.0074	0.23	0.18	Mean corpuscular hemoglobin;	chr20:31708292	chr20:31567707~31573263:-
LUAD	cis	rs6691170	0.931	rs7556214	ENSG00000228437.4	RP11-400N13.2	4.11	4.66e-05	0.0074	0.22	0.18	Colorectal cancer;	chr1:221875291	chr1:221966341~221984964:+
LUAD	cis	rs2713579	0.562	rs2659698	ENSG00000239405.1	TMED10P2	4.11	4.66e-05	0.0074	0.26	0.18	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr3:128507521	chr3:128538020~128538631:+
LUAD	cis	rs848490	0.855	rs17155183	ENSG00000214293.7	APTR	4.11	4.66e-05	0.00741	0.23	0.18	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77571075	chr7:77657660~77696265:-
LUAD	cis	rs116095464	0.542	rs28650039	ENSG00000248925.1	CTD-2083E4.6	4.11	4.66e-05	0.00741	0.32	0.18	Breast cancer;	chr5:273839	chr5:269858~271516:-
LUAD	cis	rs6964587	0.869	rs34791781	ENSG00000188693.7	CYP51A1-AS1	4.11	4.66e-05	0.00741	0.22	0.18	Breast cancer;	chr7:91903406	chr7:92134604~92180725:+
LUAD	cis	rs6964587	0.869	rs6946764	ENSG00000188693.7	CYP51A1-AS1	4.11	4.66e-05	0.00741	0.22	0.18	Breast cancer;	chr7:91909689	chr7:92134604~92180725:+
LUAD	cis	rs6964587	1	rs10234434	ENSG00000188693.7	CYP51A1-AS1	-4.11	4.66e-05	0.00741	-0.21	-0.18	Breast cancer;	chr7:92043994	chr7:92134604~92180725:+
LUAD	cis	rs131777	0.575	rs963980	ENSG00000273272.1	CTA-384D8.34	4.11	4.67e-05	0.00741	0.21	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50583688	chr22:50542650~50543011:+
LUAD	cis	rs4819052	0.655	rs2330103	ENSG00000237664.1	LINC00316	-4.11	4.67e-05	0.00741	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45274599	chr21:45338590~45341990:-
LUAD	cis	rs17122278	1	rs73022058	ENSG00000243431.1	RPL5P30	4.11	4.67e-05	0.00741	0.23	0.18	Total cholesterol levels;	chr11:118552957	chr11:118560690~118561580:+
LUAD	cis	rs7940646	0.812	rs2052690	ENSG00000177112.6	MRVI1-AS1	-4.11	4.67e-05	0.00741	-0.24	-0.18	Platelet aggregation;	chr11:10642486	chr11:10541272~10599932:+
LUAD	cis	rs12701220	0.894	rs2141274	ENSG00000229043.2	AC091729.9	-4.11	4.67e-05	0.00741	-0.24	-0.18	Bronchopulmonary dysplasia;	chr7:995081	chr7:1160374~1165267:+
LUAD	cis	rs12188164	0.965	rs11742144	ENSG00000225138.6	CTD-2228K2.7	4.11	4.67e-05	0.00741	0.18	0.18	Cystic fibrosis severity;	chr5:422063	chr5:473236~480884:+
LUAD	cis	rs9341808	0.718	rs9448898	ENSG00000260645.1	RP11-250B2.5	4.11	4.67e-05	0.00741	0.17	0.18	Sitting height ratio;	chr6:80135624	chr6:80466958~80469080:+
LUAD	cis	rs454217	0.791	rs337650	ENSG00000277851.1	RP11-756G20.1	4.11	4.67e-05	0.00742	0.19	0.18	Smoking quantity;	chr12:92309130	chr12:92247756~92363832:-
LUAD	cis	rs12681420	0.668	rs1493202	ENSG00000223220.1	Y_RNA	4.11	4.67e-05	0.00742	0.21	0.18	Erythrocyte cadmium concentration in never smokers;	chr8:70993352	chr8:70780914~70781008:-
LUAD	cis	rs8028182	0.501	rs11072553	ENSG00000260269.4	CTD-2323K18.1	-4.11	4.67e-05	0.00742	-0.26	-0.18	Sudden cardiac arrest;	chr15:75640436	chr15:75527150~75601205:-
LUAD	cis	rs9847710	0.967	rs4687694	ENSG00000242142.1	SERBP1P3	4.11	4.67e-05	0.00742	0.2	0.18	Ulcerative colitis;	chr3:53015031	chr3:53064283~53065091:-
LUAD	cis	rs2735413	0.918	rs12918959	ENSG00000276007.1	RP11-358L22.3	-4.11	4.67e-05	0.00742	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78047822	chr16:78123243~78124332:+
LUAD	cis	rs853679	0.76	rs2299029	ENSG00000204709.4	LINC01556	4.11	4.68e-05	0.00743	0.27	0.18	Depression;	chr6:28231053	chr6:28943877~28944537:+
LUAD	cis	rs858239	0.6	rs4628176	ENSG00000226816.2	AC005082.12	4.11	4.68e-05	0.00743	0.24	0.18	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23206013~23208045:+
LUAD	cis	rs10971721	0.822	rs10971818	ENSG00000260947.1	RP11-384P7.7	-4.11	4.68e-05	0.00743	-0.37	-0.18	Body mass index;	chr9:33952155	chr9:33697459~33700986:+
LUAD	cis	rs6570726	0.967	rs1396648	ENSG00000235652.6	RP11-545I5.3	-4.11	4.68e-05	0.00743	-0.18	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145464112	chr6:145799409~145886585:+
LUAD	cis	rs9813712	0.585	rs16824839	ENSG00000249846.5	RP11-77P16.4	-4.11	4.68e-05	0.00743	-0.26	-0.18	Response to amphetamines;	chr3:130220886	chr3:130112550~130120579:+
LUAD	cis	rs7208859	0.673	rs11656462	ENSG00000266490.1	CTD-2349P21.9	4.11	4.68e-05	0.00743	0.27	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30833682	chr17:30792372~30792833:+
LUAD	cis	rs6496044	0.963	rs6496050	ENSG00000259407.1	RP11-158M2.3	-4.11	4.68e-05	0.00743	-0.17	-0.18	Interstitial lung disease;	chr15:85526019	chr15:85744109~85750281:-
LUAD	cis	rs6500602	0.893	rs8061742	ENSG00000280063.1	RP11-295D4.3	4.11	4.68e-05	0.00743	0.12	0.18	Schizophrenia;	chr16:4439435	chr16:4346694~4348648:-
LUAD	cis	rs8062405	0.755	rs4787455	ENSG00000251417.2	RP11-1348G14.4	-4.11	4.68e-05	0.00743	-0.19	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28802743~28817828:+
LUAD	cis	rs865483	0.895	rs2522972	ENSG00000276054.1	RP11-378E13.3	4.11	4.68e-05	0.00743	0.22	0.18	Monocyte count;	chr17:37478916	chr17:37386886~37387926:+
LUAD	cis	rs10197140	0.857	rs62159503	ENSG00000235721.1	AC013268.3	-4.11	4.68e-05	0.00744	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110902289	chr2:110007675~110010783:+
LUAD	cis	rs10197140	0.857	rs17466548	ENSG00000235721.1	AC013268.3	-4.11	4.68e-05	0.00744	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110902747	chr2:110007675~110010783:+
LUAD	cis	rs7615952	0.599	rs6766327	ENSG00000250012.1	RP11-124N2.1	-4.11	4.68e-05	0.00744	-0.26	-0.18	Blood pressure (smoking interaction);	chr3:126004834	chr3:126084220~126095349:+
LUAD	cis	rs7615952	0.641	rs12491577	ENSG00000250012.1	RP11-124N2.1	-4.11	4.68e-05	0.00744	-0.26	-0.18	Blood pressure (smoking interaction);	chr3:126012288	chr3:126084220~126095349:+
LUAD	cis	rs2098713	0.569	rs55822509	ENSG00000250155.1	CTD-2353F22.1	4.11	4.68e-05	0.00744	0.2	0.18	Telomere length;	chr5:37571908	chr5:36666214~36725195:-
LUAD	cis	rs726288	1	rs12243433	ENSG00000242600.5	MBL1P	-4.11	4.69e-05	0.00744	-0.31	-0.18	Rheumatoid arthritis;	chr10:79973021	chr10:79904898~79950336:+
LUAD	cis	rs726288	1	rs12264259	ENSG00000242600.5	MBL1P	-4.11	4.69e-05	0.00744	-0.31	-0.18	Rheumatoid arthritis;	chr10:79973032	chr10:79904898~79950336:+
LUAD	cis	rs726288	1	rs12245535	ENSG00000242600.5	MBL1P	-4.11	4.69e-05	0.00744	-0.31	-0.18	Rheumatoid arthritis;	chr10:79973248	chr10:79904898~79950336:+
LUAD	cis	rs8028182	0.636	rs8036758	ENSG00000260269.4	CTD-2323K18.1	-4.11	4.69e-05	0.00744	-0.26	-0.18	Sudden cardiac arrest;	chr15:75525221	chr15:75527150~75601205:-
LUAD	cis	rs10463554	0.892	rs10463988	ENSG00000250682.4	LINC00491	4.11	4.69e-05	0.00744	0.22	0.18	Parkinson's disease;	chr5:102913595	chr5:102609156~102671559:-
LUAD	cis	rs13631	0.965	rs9411307	ENSG00000268996.3	MAN1B1-AS1	4.11	4.69e-05	0.00744	0.22	0.18	Cerebrospinal fluid biomarker levels;	chr9:137100495	chr9:137084946~137086817:-
LUAD	cis	rs7107174	0.786	rs4945269	ENSG00000251323.2	RP11-452H21.4	4.11	4.69e-05	0.00745	0.22	0.18	Testicular germ cell tumor;	chr11:78336031	chr11:78423982~78429836:-
LUAD	cis	rs6142102	0.961	rs6059596	ENSG00000275784.1	RP5-1125A11.6	-4.11	4.69e-05	0.00745	-0.21	-0.18	Skin pigmentation;	chr20:33969313	chr20:33989480~33991818:-
LUAD	cis	rs4819052	0.635	rs2838808	ENSG00000215447.6	BX322557.10	-4.11	4.69e-05	0.00745	-0.23	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45201191	chr21:45288052~45291738:+
LUAD	cis	rs6142102	0.961	rs1007090	ENSG00000275784.1	RP5-1125A11.6	-4.11	4.69e-05	0.00745	-0.21	-0.18	Skin pigmentation;	chr20:33995065	chr20:33989480~33991818:-
LUAD	cis	rs6142102	0.923	rs2284377	ENSG00000275784.1	RP5-1125A11.6	-4.11	4.69e-05	0.00745	-0.21	-0.18	Skin pigmentation;	chr20:33998876	chr20:33989480~33991818:-
LUAD	cis	rs6142102	0.961	rs2284378	ENSG00000275784.1	RP5-1125A11.6	-4.11	4.69e-05	0.00745	-0.21	-0.18	Skin pigmentation;	chr20:34000289	chr20:33989480~33991818:-
LUAD	cis	rs2300206	1	rs2300206	ENSG00000275784.1	RP5-1125A11.6	-4.11	4.69e-05	0.00745	-0.21	-0.18	Cancer (pleiotropy);Cancer;	chr20:34002002	chr20:33989480~33991818:-
LUAD	cis	rs6142102	0.961	rs2284379	ENSG00000275784.1	RP5-1125A11.6	-4.11	4.69e-05	0.00745	-0.21	-0.18	Skin pigmentation;	chr20:34006836	chr20:33989480~33991818:-
LUAD	cis	rs6142102	0.961	rs2268080	ENSG00000275784.1	RP5-1125A11.6	-4.11	4.69e-05	0.00745	-0.21	-0.18	Skin pigmentation;	chr20:34009910	chr20:33989480~33991818:-
LUAD	cis	rs9593057	0.579	rs17051492	ENSG00000234835.1	PHBP13	-4.11	4.69e-05	0.00745	-0.39	-0.18	Lobe attachment (rater-scored or self-reported);	chr13:34997186	chr13:35251070~35251829:+
LUAD	cis	rs8180040	1	rs295461	ENSG00000271161.1	BOLA2P2	4.11	4.69e-05	0.00745	0.18	0.18	Colorectal cancer;	chr3:47326520	chr3:47499841~47500407:+
LUAD	cis	rs6964833	1	rs4717906	ENSG00000184616.8	AC004166.6	4.11	4.69e-05	0.00745	0.27	0.18	Menarche (age at onset);	chr7:74671923	chr7:74906673~74913256:-
LUAD	cis	rs6102185	0.572	rs6016464	ENSG00000229771.2	RP4-644L1.2	-4.11	4.7e-05	0.00745	-0.23	-0.18	IgG glycosylation;	chr20:40892147	chr20:40696499~40698616:-
LUAD	cis	rs72772090	0.908	rs6864233	ENSG00000248734.2	CTD-2260A17.1	4.11	4.7e-05	0.00746	0.25	0.18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96708977	chr5:96784777~96785999:+
LUAD	cis	rs8073060	0.586	rs225256	ENSG00000267592.1	CTC-507E2.2	4.11	4.7e-05	0.00746	0.27	0.18	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35628737	chr17:35596904~35597128:-
LUAD	cis	rs8073060	0.586	rs225257	ENSG00000267592.1	CTC-507E2.2	4.11	4.7e-05	0.00746	0.27	0.18	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35629606	chr17:35596904~35597128:-
LUAD	cis	rs950881	0.601	rs3771164	ENSG00000234389.1	AC007278.3	4.11	4.7e-05	0.00746	0.21	0.18	Allergy;	chr2:102375326	chr2:102438713~102440475:+
LUAD	cis	rs13113518	0.783	rs11943206	ENSG00000272969.1	RP11-528I4.2	4.11	4.7e-05	0.00746	0.2	0.18	Height;	chr4:55570843	chr4:55547112~55547889:+
LUAD	cis	rs2823962	0.727	rs11088586	ENSG00000270093.1	AP000473.8	-4.11	4.7e-05	0.00746	-0.19	-0.18	Amyotrophic lateral sclerosis;	chr21:16643794	chr21:16643529~16645065:+
LUAD	cis	rs2823962	0.759	rs12627594	ENSG00000270093.1	AP000473.8	-4.11	4.7e-05	0.00746	-0.19	-0.18	Amyotrophic lateral sclerosis;	chr21:16643808	chr21:16643529~16645065:+
LUAD	cis	rs2823962	0.759	rs12626359	ENSG00000270093.1	AP000473.8	-4.11	4.7e-05	0.00746	-0.19	-0.18	Amyotrophic lateral sclerosis;	chr21:16643812	chr21:16643529~16645065:+
LUAD	cis	rs2823962	0.759	rs12627437	ENSG00000270093.1	AP000473.8	-4.11	4.7e-05	0.00746	-0.19	-0.18	Amyotrophic lateral sclerosis;	chr21:16643824	chr21:16643529~16645065:+
LUAD	cis	rs9532669	0.926	rs9532689	ENSG00000168852.11	TPTE2P5	4.11	4.7e-05	0.00746	0.18	0.18	Cervical cancer;	chr13:40957990	chr13:40822296~40921749:-
LUAD	cis	rs4934494	0.635	rs12572869	ENSG00000240996.1	RP11-80H5.7	-4.11	4.7e-05	0.00747	-0.26	-0.18	Red blood cell count;	chr10:89653611	chr10:89694295~89697928:-
LUAD	cis	rs858239	1	rs156407	ENSG00000230042.1	AK3P3	-4.11	4.71e-05	0.00747	-0.23	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23129178~23129841:+
LUAD	cis	rs4664293	1	rs2357382	ENSG00000230783.1	AC009961.2	-4.11	4.71e-05	0.00747	-0.22	-0.18	Monocyte percentage of white cells;	chr2:159636614	chr2:159689217~159690291:-
LUAD	cis	rs2735413	0.918	rs4887932	ENSG00000276007.1	RP11-358L22.3	-4.11	4.71e-05	0.00747	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78044453	chr16:78123243~78124332:+
LUAD	cis	rs874460	0.808	rs402072	ENSG00000211513.4	MIR320E	4.11	4.71e-05	0.00747	0.3	0.18	Chronic lymphocytic leukemia;	chr19:46715865	chr19:46709271~46709382:-
LUAD	cis	rs853679	0.517	rs9393890	ENSG00000226314.6	ZNF192P1	-4.11	4.71e-05	0.00747	-0.24	-0.18	Depression;	chr6:28096077	chr6:28161781~28169594:+
LUAD	cis	rs2274273	0.588	rs7154831	ENSG00000258413.1	RP11-665C16.6	-4.11	4.71e-05	0.00747	-0.25	-0.18	Protein biomarker;	chr14:55357247	chr14:55262767~55272075:-
LUAD	cis	rs9341808	0.718	rs10080237	ENSG00000260645.1	RP11-250B2.5	4.11	4.71e-05	0.00747	0.17	0.18	Sitting height ratio;	chr6:80144753	chr6:80466958~80469080:+
LUAD	cis	rs2227564	0.794	rs2688607	ENSG00000271816.1	BMS1P4	-4.11	4.71e-05	0.00747	-0.17	-0.18	Crohn's disease;Inflammatory bowel disease;	chr10:73903978	chr10:73699151~73730487:-
LUAD	cis	rs7429990	0.813	rs7627568	ENSG00000228638.1	FCF1P2	4.11	4.71e-05	0.00748	0.22	0.18	Educational attainment (years of education);	chr3:48051562	chr3:48290793~48291375:-
LUAD	cis	rs2154319	0.836	rs213768	ENSG00000235358.1	RP11-399E6.1	4.11	4.71e-05	0.00748	0.25	0.18	Height;	chr1:41152770	chr1:41242373~41284861:+
LUAD	cis	rs7172677	0.96	rs12917304	ENSG00000260269.4	CTD-2323K18.1	-4.11	4.71e-05	0.00748	-0.25	-0.18	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75114534	chr15:75527150~75601205:-
LUAD	cis	rs7302981	0.967	rs11831413	ENSG00000200428.1	Y_RNA	-4.11	4.71e-05	0.00748	-0.23	-0.18	Systolic blood pressure;	chr12:50156600	chr12:50743568~50743684:+
LUAD	cis	rs7302981	0.719	rs836189	ENSG00000272368.2	RP4-605O3.4	4.11	4.71e-05	0.00748	0.21	0.18	Systolic blood pressure;	chr12:50067715	chr12:50112197~50165618:+
LUAD	cis	rs3770081	1	rs2278086	ENSG00000273080.1	RP11-301O19.1	-4.11	4.71e-05	0.00748	-0.42	-0.18	Facial emotion recognition (sad faces);	chr2:86054782	chr2:86195590~86196049:+
LUAD	cis	rs3770081	1	rs78646493	ENSG00000273080.1	RP11-301O19.1	-4.11	4.71e-05	0.00748	-0.42	-0.18	Facial emotion recognition (sad faces);	chr2:86056072	chr2:86195590~86196049:+
LUAD	cis	rs9309473	1	rs11899902	ENSG00000230002.2	ALMS1-IT1	4.11	4.71e-05	0.00748	0.23	0.18	Metabolite levels;	chr2:73404436	chr2:73456764~73459484:+
LUAD	cis	rs9309473	1	rs13428235	ENSG00000230002.2	ALMS1-IT1	4.11	4.71e-05	0.00748	0.23	0.18	Metabolite levels;	chr2:73406302	chr2:73456764~73459484:+
LUAD	cis	rs6738440	0.51	rs17028192	ENSG00000234624.2	AC016894.1	4.11	4.71e-05	0.00748	0.22	0.18	F-cell distribution;	chr2:60444204	chr2:61416887~61417197:-
LUAD	cis	rs10971721	0.584	rs72731217	ENSG00000260947.1	RP11-384P7.7	4.11	4.72e-05	0.00748	0.37	0.18	Body mass index;	chr9:34119555	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.584	rs72731218	ENSG00000260947.1	RP11-384P7.7	4.11	4.72e-05	0.00748	0.37	0.18	Body mass index;	chr9:34119678	chr9:33697459~33700986:+
LUAD	cis	rs13068223	0.905	rs344027	ENSG00000243926.1	TIPARP-AS1	-4.11	4.72e-05	0.00748	-0.19	-0.18	Age-related hearing impairment (SNP x SNP interaction);	chr3:156750604	chr3:156671862~156674378:-
LUAD	cis	rs865483	0.929	rs853225	ENSG00000276054.1	RP11-378E13.3	4.11	4.72e-05	0.00748	0.22	0.18	Monocyte count;	chr17:37431406	chr17:37386886~37387926:+
LUAD	cis	rs865483	0.86	rs860468	ENSG00000276054.1	RP11-378E13.3	4.11	4.72e-05	0.00748	0.22	0.18	Monocyte count;	chr17:37433186	chr17:37386886~37387926:+
LUAD	cis	rs7896471	0.546	rs80317711	ENSG00000227695.4	DNMBP-AS1	-4.11	4.72e-05	0.00748	-0.47	-0.18	Blood protein levels;	chr10:99949739	chr10:99927010~99958381:+
LUAD	cis	rs9435732	0.54	rs9325647	ENSG00000235241.1	RP11-108M9.5	4.11	4.72e-05	0.00748	0.24	0.18	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:17039305	chr1:16889095~16889602:+
LUAD	cis	rs2295359	1	rs4655684	ENSG00000275678.1	RP4-547N15.3	4.11	4.72e-05	0.00748	0.19	0.18	Psoriasis;	chr1:67146089	chr1:67121605~67123956:-
LUAD	cis	rs7937890	0.505	rs9971395	ENSG00000251991.1	RNU7-49P	4.11	4.72e-05	0.00748	0.2	0.18	Mitochondrial DNA levels;	chr11:14745580	chr11:14478892~14478953:+
LUAD	cis	rs7937890	0.506	rs10741655	ENSG00000251991.1	RNU7-49P	4.11	4.72e-05	0.00748	0.2	0.18	Mitochondrial DNA levels;	chr11:14746838	chr11:14478892~14478953:+
LUAD	cis	rs7204230	1	rs2041790	ENSG00000261291.1	RP11-295M3.2	4.11	4.72e-05	0.00748	0.23	0.18	Fibrinogen;	chr16:53285021	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs2041791	ENSG00000261291.1	RP11-295M3.2	4.11	4.72e-05	0.00748	0.23	0.18	Fibrinogen;	chr16:53285040	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs8057932	ENSG00000261291.1	RP11-295M3.2	4.11	4.72e-05	0.00748	0.23	0.18	Fibrinogen;	chr16:53285933	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs8056394	ENSG00000261291.1	RP11-295M3.2	4.11	4.72e-05	0.00748	0.23	0.18	Fibrinogen;	chr16:53286113	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs11864306	ENSG00000261291.1	RP11-295M3.2	4.11	4.72e-05	0.00748	0.23	0.18	Fibrinogen;	chr16:53287237	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs17394680	ENSG00000261291.1	RP11-295M3.2	4.11	4.72e-05	0.00748	0.23	0.18	Fibrinogen;	chr16:53288281	chr16:53168522~53169450:+
LUAD	cis	rs2548724	0.812	rs2600828	ENSG00000250682.4	LINC00491	-4.11	4.72e-05	0.00749	-0.25	-0.18	Type 2 diabetes;	chr5:102271899	chr5:102609156~102671559:-
LUAD	cis	rs7208859	0.673	rs78799101	ENSG00000263603.1	CTD-2349P21.5	-4.11	4.72e-05	0.00749	-0.33	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888142	chr17:30729469~30731202:+
LUAD	cis	rs10863681	0.52	rs10779468	ENSG00000228437.4	RP11-400N13.2	-4.11	4.72e-05	0.00749	-0.23	-0.18	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222109540	chr1:221966341~221984964:+
LUAD	cis	rs4601821	0.965	rs10891543	ENSG00000270179.1	RP11-159N11.4	-4.11	4.72e-05	0.00749	-0.19	-0.18	Alcoholic chronic pancreatitis;	chr11:113385173	chr11:113368478~113369117:+
LUAD	cis	rs7840202	0.961	rs2925786	ENSG00000253328.2	SUMO2P19	-4.11	4.72e-05	0.00749	-0.21	-0.18	Rate of cognitive decline in mild cognitive impairment (time interaction);Gestational age at birth in labor-initiated deliveries (child effect);	chr8:102304209	chr8:102242040~102242619:-
LUAD	cis	rs7840202	1	rs2925787	ENSG00000253328.2	SUMO2P19	-4.11	4.72e-05	0.00749	-0.21	-0.18	Rate of cognitive decline in mild cognitive impairment (time interaction);Gestational age at birth in labor-initiated deliveries (child effect);	chr8:102304266	chr8:102242040~102242619:-
LUAD	cis	rs7840202	1	rs2978421	ENSG00000253328.2	SUMO2P19	-4.11	4.72e-05	0.00749	-0.21	-0.18	Rate of cognitive decline in mild cognitive impairment (time interaction);Gestational age at birth in labor-initiated deliveries (child effect);	chr8:102328070	chr8:102242040~102242619:-
LUAD	cis	rs4578769	0.55	rs11082225	ENSG00000265943.1	RP11-739L10.1	4.11	4.72e-05	0.00749	0.23	0.18	Eosinophil percentage of white cells;	chr18:22963794	chr18:22699481~22933764:-
LUAD	cis	rs11065706	0.799	rs2028004	ENSG00000278993.1	RP3-424M6.4	-4.11	4.73e-05	0.00749	-0.23	-0.18	Heart rate;	chr12:110541734	chr12:110501614~110503441:+
LUAD	cis	rs5015933	0.815	rs28533069	ENSG00000232630.1	PRPS1P2	-4.11	4.73e-05	0.0075	-0.17	-0.18	Body mass index;	chr9:125251379	chr9:125150653~125151589:+
LUAD	cis	rs4819052	0.851	rs9979545	ENSG00000237664.1	LINC00316	-4.11	4.73e-05	0.0075	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259890	chr21:45338590~45341990:-
LUAD	cis	rs4819052	0.851	rs7276591	ENSG00000237664.1	LINC00316	-4.11	4.73e-05	0.0075	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260241	chr21:45338590~45341990:-
LUAD	cis	rs4237845	0.537	rs11172369	ENSG00000245651.2	RP11-620J15.2	4.11	4.73e-05	0.0075	0.19	0.18	Intelligence (multi-trait analysis);	chr12:57886809	chr12:57869835~57896482:-
LUAD	cis	rs5015933	0.807	rs7043132	ENSG00000232630.1	PRPS1P2	-4.11	4.73e-05	0.0075	-0.17	-0.18	Body mass index;	chr9:125255561	chr9:125150653~125151589:+
LUAD	cis	rs5015933	0.815	rs3896021	ENSG00000232630.1	PRPS1P2	-4.11	4.73e-05	0.0075	-0.17	-0.18	Body mass index;	chr9:125262019	chr9:125150653~125151589:+
LUAD	cis	rs10090774	0.664	rs10090373	ENSG00000280303.2	ERICD	-4.11	4.73e-05	0.0075	-0.21	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140685897	chr8:140636281~140638283:+
LUAD	cis	rs1005277	0.505	rs1208689	ENSG00000273019.1	RP11-508N22.13	-4.11	4.73e-05	0.0075	-0.21	-0.18	Extrinsic epigenetic age acceleration;	chr10:37808847	chr10:38149968~38150293:+
LUAD	cis	rs7204230	0.96	rs62048032	ENSG00000261291.1	RP11-295M3.2	4.11	4.73e-05	0.0075	0.23	0.18	Fibrinogen;	chr16:53180955	chr16:53168522~53169450:+
LUAD	cis	rs6832769	0.922	rs11133376	ENSG00000272969.1	RP11-528I4.2	4.11	4.73e-05	0.0075	0.2	0.18	Personality dimensions;	chr4:55386866	chr4:55547112~55547889:+
LUAD	cis	rs7551222	0.721	rs1460036	ENSG00000240219.1	RP11-430C7.5	4.11	4.73e-05	0.0075	0.2	0.18	Schizophrenia;	chr1:204558251	chr1:204626775~204629712:+
LUAD	cis	rs8056893	0.842	rs1111571	ENSG00000274698.1	RP11-71L14.4	-4.11	4.73e-05	0.0075	-0.2	-0.18	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68329278	chr16:68450283~68452318:+
LUAD	cis	rs1876905	0.539	rs190246	ENSG00000272356.1	RP5-1112D6.8	4.11	4.73e-05	0.00751	0.22	0.18	Mean corpuscular hemoglobin;	chr6:111277043	chr6:111309203~111313517:+
LUAD	cis	rs5769707	0.837	rs1573726	ENSG00000235111.1	RP1-29C18.8	-4.11	4.73e-05	0.00751	-0.2	-0.18	Monocyte percentage of white cells;Monocyte count;	chr22:49639224	chr22:49612657~49615716:-
LUAD	cis	rs9302635	0.513	rs8050238	ENSG00000260886.1	TAT-AS1	4.11	4.73e-05	0.00751	0.24	0.18	Blood protein levels;	chr16:72120288	chr16:71565789~71578187:+
LUAD	cis	rs703842	1	rs8181644	ENSG00000270039.1	RP11-571M6.17	-4.11	4.73e-05	0.00751	-0.22	-0.18	Multiple sclerosis;	chr12:57779683	chr12:57803838~57804415:+
LUAD	cis	rs763121	0.853	rs7289855	ENSG00000228274.3	RP3-508I15.9	-4.11	4.74e-05	0.00751	-0.18	-0.18	Menopause (age at onset);	chr22:38646216	chr22:38667585~38681820:-
LUAD	cis	rs4819052	0.851	rs9974891	ENSG00000223768.1	LINC00205	-4.11	4.74e-05	0.00751	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260852	chr21:45293285~45297354:+
LUAD	cis	rs877819	0.583	rs2663021	ENSG00000228403.1	RP11-563N6.6	-4.11	4.74e-05	0.00751	-0.19	-0.18	Systemic lupus erythematosus;	chr10:48870072	chr10:48878022~48878649:+
LUAD	cis	rs34034915	1	rs34034915	ENSG00000280107.1	AL022393.9	-4.11	4.74e-05	0.00751	-0.21	-0.18	Hepatitis A;	chr6:27752924	chr6:28170845~28172521:+
LUAD	cis	rs4713118	0.527	rs36042294	ENSG00000280107.1	AL022393.9	-4.11	4.74e-05	0.00751	-0.21	-0.18	Parkinson's disease;	chr6:27752933	chr6:28170845~28172521:+
LUAD	cis	rs1061377	0.748	rs12642261	ENSG00000249685.1	RP11-360F5.3	4.11	4.74e-05	0.00751	0.22	0.18	Uric acid levels;	chr4:39096278	chr4:39133913~39135608:+
LUAD	cis	rs10510102	0.516	rs11200300	ENSG00000276742.1	RP11-500G22.4	4.11	4.74e-05	0.00751	0.31	0.18	Breast cancer;	chr10:121977489	chr10:121956782~121957098:+
LUAD	cis	rs10938353	0.731	rs73191022	ENSG00000273369.1	RP11-700J17.1	4.11	4.74e-05	0.00751	0.27	0.18	Body mass index;	chr4:44616645	chr4:44693946~44694386:-
LUAD	cis	rs2395128	0.519	rs11001273	ENSG00000213731.2	RAB5CP1	4.11	4.74e-05	0.00751	0.37	0.18	Ulcerative colitis;Inflammatory bowel disease;	chr10:75063960	chr10:74423435~74424014:-
LUAD	cis	rs7178375	1	rs7178375	ENSG00000270015.1	RP11-540B6.6	4.11	4.74e-05	0.00751	0.17	0.18	Hypertriglyceridemia;	chr15:30923732	chr15:30926514~30928407:+
LUAD	cis	rs1322639	0.575	rs9294966	ENSG00000261039.2	RP11-417E7.2	-4.11	4.74e-05	0.00752	-0.3	-0.18	Pulse pressure;	chr6:169165223	chr6:169175304~169182740:-
LUAD	cis	rs911555	0.673	rs7144271	ENSG00000259775.1	RP11-45P15.4	-4.11	4.74e-05	0.00752	-0.24	-0.18	Intelligence (multi-trait analysis);	chr14:103424337	chr14:103331674~103332367:-
LUAD	cis	rs7616559	0.53	rs12638952	ENSG00000240875.4	LINC00886	-4.11	4.74e-05	0.00752	-0.2	-0.18	Carotid artery intima media thickness (sex interaction);	chr3:157004282	chr3:156747346~156817062:-
LUAD	cis	rs800160	1	rs1088986	ENSG00000236264.4	RPL26P30	-4.11	4.74e-05	0.00752	-0.24	-0.18	Bacteremia;	chr11:2356632	chr11:2335132~2335776:-
LUAD	cis	rs9467773	0.525	rs1535274	ENSG00000241549.7	GUSBP2	4.11	4.74e-05	0.00752	0.21	0.18	Intelligence (multi-trait analysis);	chr6:26520519	chr6:26871484~26956554:-
LUAD	cis	rs9467773	0.565	rs6925047	ENSG00000241549.7	GUSBP2	4.11	4.74e-05	0.00752	0.21	0.18	Intelligence (multi-trait analysis);	chr6:26521207	chr6:26871484~26956554:-
LUAD	cis	rs9467773	0.565	rs4343916	ENSG00000241549.7	GUSBP2	4.11	4.74e-05	0.00752	0.21	0.18	Intelligence (multi-trait analysis);	chr6:26522447	chr6:26871484~26956554:-
LUAD	cis	rs2243480	1	rs313809	ENSG00000229886.1	RP5-1132H15.3	4.11	4.74e-05	0.00752	0.32	0.18	Diabetic kidney disease;	chr7:66034996	chr7:66025126~66031544:-
LUAD	cis	rs8177876	0.658	rs2970077	ENSG00000261061.1	RP11-303E16.2	-4.11	4.74e-05	0.00752	-0.26	-0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81041195	chr16:81030770~81031485:+
LUAD	cis	rs7201929	0.801	rs9933198	ENSG00000251417.2	RP11-1348G14.4	4.11	4.75e-05	0.00752	0.21	0.18	QT interval;	chr16:28877088	chr16:28802743~28817828:+
LUAD	cis	rs2227564	0.678	rs2242256	ENSG00000271816.1	BMS1P4	-4.11	4.75e-05	0.00752	-0.18	-0.18	Crohn's disease;Inflammatory bowel disease;	chr10:73837788	chr10:73699151~73730487:-
LUAD	cis	rs2227564	0.678	rs2242257	ENSG00000271816.1	BMS1P4	-4.11	4.75e-05	0.00752	-0.18	-0.18	Crohn's disease;Inflammatory bowel disease;	chr10:73837847	chr10:73699151~73730487:-
LUAD	cis	rs2836974	0.799	rs13047550	ENSG00000232608.1	TIMM9P2	-4.11	4.75e-05	0.00752	-0.23	-0.18	Cognitive function;	chr21:39143569	chr21:39216624~39217506:+
LUAD	cis	rs9341808	0.935	rs2322633	ENSG00000260645.1	RP11-250B2.5	-4.11	4.75e-05	0.00752	-0.17	-0.18	Sitting height ratio;	chr6:80136272	chr6:80466958~80469080:+
LUAD	cis	rs30380	0.734	rs30376	ENSG00000272109.1	CTD-2260A17.3	-4.11	4.75e-05	0.00752	-0.21	-0.18	Cerebrospinal fluid biomarker levels;	chr5:96784555	chr5:96804353~96806105:+
LUAD	cis	rs28386778	0.966	rs2854206	ENSG00000240280.5	TCAM1P	-4.11	4.75e-05	0.00753	-0.21	-0.18	Prudent dietary pattern;	chr17:63869843	chr17:63849292~63864379:+
LUAD	cis	rs9341808	0.754	rs6918172	ENSG00000233967.5	RP11-250B2.3	4.11	4.75e-05	0.00753	0.18	0.18	Sitting height ratio;	chr6:80309525	chr6:80443344~80465927:+
LUAD	cis	rs2880765	0.545	rs17553734	ENSG00000259407.1	RP11-158M2.3	4.1	4.75e-05	0.00753	0.18	0.18	Coronary artery disease;	chr15:85469828	chr15:85744109~85750281:-
LUAD	cis	rs10129255	0.957	rs6576233	ENSG00000211947.2	IGHV3-21	-4.1	4.75e-05	0.00753	-0.12	-0.18	Kawasaki disease;	chr14:106787239	chr14:106235064~106235594:-
LUAD	cis	rs865483	1	rs865483	ENSG00000276054.1	RP11-378E13.3	4.1	4.75e-05	0.00753	0.23	0.18	Monocyte count;	chr17:37491071	chr17:37386886~37387926:+
LUAD	cis	rs721917	0.811	rs2256462	ENSG00000230091.5	TMEM254-AS1	4.1	4.75e-05	0.00753	0.22	0.18	Chronic obstructive pulmonary disease;	chr10:79925837	chr10:80046860~80078912:-
LUAD	cis	rs10208649	0.908	rs78244745	ENSG00000233266.1	HMGB1P31	4.1	4.75e-05	0.00753	0.55	0.18	Body mass index;	chr2:54056137	chr2:54051334~54051760:+
LUAD	cis	rs17507216	1	rs3850610	ENSG00000276710.3	CSPG4P8	4.1	4.75e-05	0.00753	0.19	0.18	Excessive daytime sleepiness;	chr15:82552642	chr15:82459472~82477258:+
LUAD	cis	rs911555	0.692	rs60235428	ENSG00000244691.1	RPL10AP1	4.1	4.75e-05	0.00753	0.25	0.18	Intelligence (multi-trait analysis);	chr14:103438013	chr14:103412119~103412761:-
LUAD	cis	rs911555	0.755	rs8016676	ENSG00000244691.1	RPL10AP1	4.1	4.75e-05	0.00753	0.25	0.18	Intelligence (multi-trait analysis);	chr14:103438505	chr14:103412119~103412761:-
LUAD	cis	rs9341808	0.714	rs9448911	ENSG00000260645.1	RP11-250B2.5	4.1	4.75e-05	0.00753	0.17	0.18	Sitting height ratio;	chr6:80204142	chr6:80466958~80469080:+
LUAD	cis	rs853679	0.517	rs9366715	ENSG00000226314.6	ZNF192P1	-4.1	4.75e-05	0.00753	-0.24	-0.18	Depression;	chr6:28096855	chr6:28161781~28169594:+
LUAD	cis	rs2274273	0.588	rs58296156	ENSG00000258413.1	RP11-665C16.6	-4.1	4.75e-05	0.00753	-0.25	-0.18	Protein biomarker;	chr14:55361609	chr14:55262767~55272075:-
LUAD	cis	rs2274273	0.588	rs7158791	ENSG00000258413.1	RP11-665C16.6	-4.1	4.75e-05	0.00753	-0.25	-0.18	Protein biomarker;	chr14:55361889	chr14:55262767~55272075:-
LUAD	cis	rs6565189	1	rs6565189	ENSG00000273724.1	RP11-347C12.12	4.1	4.76e-05	0.00753	0.2	0.18	Tonsillectomy;	chr16:30495944	chr16:30336400~30343336:+
LUAD	cis	rs853679	0.517	rs2281588	ENSG00000226314.6	ZNF192P1	-4.1	4.76e-05	0.00754	-0.24	-0.18	Depression;	chr6:28104824	chr6:28161781~28169594:+
LUAD	cis	rs9366999	0.713	rs1744414	ENSG00000235033.6	RP11-61I13.3	-4.1	4.76e-05	0.00754	-0.2	-0.18	Obesity-related traits;	chr6:39253964	chr6:39881804~39900071:-
LUAD	cis	rs12986445	0.843	rs9309427	ENSG00000218682.1	AC010150.1	4.1	4.76e-05	0.00754	0.23	0.18	Multiple myeloma;Multiple myeloma and monoclonal gammopathy;	chr2:25795865	chr2:25856461~25856966:-
LUAD	cis	rs8031584	1	rs35607976	ENSG00000259845.1	HERC2P10	4.1	4.76e-05	0.00754	0.23	0.18	Huntington's disease progression;	chr15:30985585	chr15:30815271~30844153:+
LUAD	cis	rs6479901	0.894	rs4518976	ENSG00000232075.1	MRPL35P2	-4.1	4.76e-05	0.00754	-0.26	-0.18	Intelligence (multi-trait analysis);	chr10:63319017	chr10:63634317~63634827:-
LUAD	cis	rs1348850	0.793	rs13027299	ENSG00000213963.5	AC074286.1	4.1	4.76e-05	0.00754	0.22	0.18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177590773	chr2:177283508~177392691:-
LUAD	cis	rs11853189	0.671	rs11853191	ENSG00000259562.2	RP11-762H8.2	4.1	4.76e-05	0.00755	0.18	0.18	Red cell distribution width;	chr15:78273499	chr15:78290527~78291221:-
LUAD	cis	rs7584330	0.826	rs72620825	ENSG00000222032.1	AC112721.2	4.1	4.76e-05	0.00755	0.23	0.18	Prostate cancer;	chr2:237472600	chr2:237428920~237434822:-
LUAD	cis	rs860295	0.557	rs11264371	ENSG00000225855.5	RUSC1-AS1	4.1	4.76e-05	0.00755	0.13	0.18	Body mass index;	chr1:155442246	chr1:155316863~155324176:-
LUAD	cis	rs6951245	0.706	rs28522260	ENSG00000199023.2	MIR339	-4.1	4.76e-05	0.00755	-0.32	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1144328	chr7:1022935~1023045:-
LUAD	cis	rs755249	0.701	rs1180342	ENSG00000237624.1	OXCT2P1	-4.1	4.77e-05	0.00755	-0.24	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39527206	chr1:39514956~39516490:+
LUAD	cis	rs9467773	0.62	rs9467810	ENSG00000241549.7	GUSBP2	4.1	4.77e-05	0.00755	0.2	0.18	Intelligence (multi-trait analysis);	chr6:26608033	chr6:26871484~26956554:-
LUAD	cis	rs1355223	0.872	rs913204	ENSG00000271369.1	RP11-350D17.3	4.1	4.77e-05	0.00755	0.22	0.18	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34684677	chr11:34709600~34710161:+
LUAD	cis	rs6004862	0.534	rs9306419	ENSG00000272977.1	CTA-390C10.10	-4.1	4.77e-05	0.00755	-0.24	-0.18	Urate levels in lean individuals;	chr22:25973392	chr22:25476218~25479971:+
LUAD	cis	rs8062405	0.792	rs12446550	ENSG00000261419.1	RP11-57A19.4	-4.1	4.77e-05	0.00755	-0.2	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28659696~28740781:-
LUAD	cis	rs7429990	0.901	rs6442091	ENSG00000228638.1	FCF1P2	4.1	4.77e-05	0.00756	0.22	0.18	Educational attainment (years of education);	chr3:48001568	chr3:48290793~48291375:-
LUAD	cis	rs34779708	0.897	rs4934716	ENSG00000271335.4	RP11-324I22.4	4.1	4.77e-05	0.00756	0.19	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35080371	chr10:35314552~35336401:-
LUAD	cis	rs7555523	0.887	rs2814471	ENSG00000224358.1	RP11-466F5.8	-4.1	4.77e-05	0.00756	-0.3	-0.18	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165770361	chr1:165768929~165775176:+
LUAD	cis	rs38055	0.846	rs454780	ENSG00000247796.2	CTD-2366F13.1	-4.1	4.77e-05	0.00756	-0.2	-0.18	Acne (severe);	chr5:53282178	chr5:53109842~53115126:+
LUAD	cis	rs7208859	0.524	rs73988172	ENSG00000280069.1	CTD-2349P21.3	-4.1	4.77e-05	0.00756	-0.25	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30738182~30740275:+
LUAD	cis	rs35160687	0.509	rs35723061	ENSG00000273080.1	RP11-301O19.1	-4.1	4.77e-05	0.00756	-0.21	-0.18	Night sleep phenotypes;	chr2:86321965	chr2:86195590~86196049:+
LUAD	cis	rs11992162	0.636	rs4841642	ENSG00000255046.1	RP11-297N6.4	-4.1	4.77e-05	0.00756	-0.23	-0.18	Monocyte count;	chr8:11940825	chr8:11797928~11802568:-
LUAD	cis	rs11992162	0.636	rs4841646	ENSG00000255046.1	RP11-297N6.4	-4.1	4.77e-05	0.00756	-0.23	-0.18	Monocyte count;	chr8:11941198	chr8:11797928~11802568:-
LUAD	cis	rs4568518	0.71	rs13230836	ENSG00000279048.1	RP11-511H23.2	4.1	4.77e-05	0.00756	0.15	0.18	Measles;	chr7:17974272	chr7:17940503~17942922:+
LUAD	cis	rs17301013	0.932	rs6689170	ENSG00000227373.4	RP11-160H22.5	4.1	4.78e-05	0.00756	0.23	0.18	Systemic lupus erythematosus;	chr1:174639596	chr1:174115300~174160004:-
LUAD	cis	rs10197140	0.857	rs72832894	ENSG00000235721.1	AC013268.3	-4.1	4.78e-05	0.00756	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110895175	chr2:110007675~110010783:+
LUAD	cis	rs10197140	0.857	rs62159500	ENSG00000235721.1	AC013268.3	-4.1	4.78e-05	0.00756	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110896008	chr2:110007675~110010783:+
LUAD	cis	rs10197140	0.857	rs62159501	ENSG00000235721.1	AC013268.3	-4.1	4.78e-05	0.00756	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110896064	chr2:110007675~110010783:+
LUAD	cis	rs10197140	0.826	rs62159502	ENSG00000235721.1	AC013268.3	-4.1	4.78e-05	0.00756	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110896108	chr2:110007675~110010783:+
LUAD	cis	rs10197140	0.857	rs28811027	ENSG00000235721.1	AC013268.3	-4.1	4.78e-05	0.00756	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110896360	chr2:110007675~110010783:+
LUAD	cis	rs10197140	0.857	rs6737631	ENSG00000235721.1	AC013268.3	-4.1	4.78e-05	0.00756	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110896544	chr2:110007675~110010783:+
LUAD	cis	rs10197140	0.857	rs6758344	ENSG00000235721.1	AC013268.3	-4.1	4.78e-05	0.00756	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110896640	chr2:110007675~110010783:+
LUAD	cis	rs10197140	0.857	rs6751930	ENSG00000235721.1	AC013268.3	-4.1	4.78e-05	0.00756	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110896727	chr2:110007675~110010783:+
LUAD	cis	rs10197140	0.816	rs28855178	ENSG00000235721.1	AC013268.3	-4.1	4.78e-05	0.00756	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110897092	chr2:110007675~110010783:+
LUAD	cis	rs10197140	0.857	rs28792074	ENSG00000235721.1	AC013268.3	-4.1	4.78e-05	0.00756	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110898057	chr2:110007675~110010783:+
LUAD	cis	rs847577	0.572	rs847573	ENSG00000272950.1	RP11-307C18.1	-4.1	4.78e-05	0.00756	-0.26	-0.18	Breast cancer;	chr7:98052449	chr7:98322853~98323430:+
LUAD	cis	rs35934224	0.71	rs56298833	ENSG00000232926.1	AC000078.5	4.1	4.78e-05	0.00756	0.23	0.18	Glaucoma (primary open-angle);	chr22:19864915	chr22:19887289~19887970:+
LUAD	cis	rs8031584	0.918	rs35396566	ENSG00000259845.1	HERC2P10	4.1	4.78e-05	0.00757	0.23	0.18	Huntington's disease progression;	chr15:30970854	chr15:30815271~30844153:+
LUAD	cis	rs7772486	0.79	rs9376970	ENSG00000235652.6	RP11-545I5.3	-4.1	4.78e-05	0.00757	-0.18	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145920336	chr6:145799409~145886585:+
LUAD	cis	rs4474465	1	rs4945282	ENSG00000251323.2	RP11-452H21.4	4.1	4.78e-05	0.00757	0.23	0.18	Alzheimer's disease (survival time);	chr11:78477749	chr11:78423982~78429836:-
LUAD	cis	rs2749097	0.609	rs2269233	ENSG00000244256.3	RN7SL130P	-4.1	4.78e-05	0.00757	-0.25	-0.18	Alcohol consumption (transferrin glycosylation);	chr1:63653675	chr1:63655743~63656047:+
LUAD	cis	rs10863681	0.664	rs10863680	ENSG00000200033.1	RNU6-403P	-4.1	4.78e-05	0.00757	-0.22	-0.18	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222071538	chr1:221837334~221837437:-
LUAD	cis	rs748404	0.626	rs62019432	ENSG00000205771.5	CATSPER2P1	-4.1	4.78e-05	0.00757	-0.28	-0.18	Lung cancer;	chr15:43316482	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.666	rs7181545	ENSG00000205771.5	CATSPER2P1	-4.1	4.78e-05	0.00757	-0.28	-0.18	Lung cancer;	chr15:43321363	chr15:43726918~43747094:-
LUAD	cis	rs748404	0.666	rs17723479	ENSG00000205771.5	CATSPER2P1	-4.1	4.78e-05	0.00757	-0.28	-0.18	Lung cancer;	chr15:43322114	chr15:43726918~43747094:-
LUAD	cis	rs13287066	0.692	rs7020852	ENSG00000227603.1	RP11-165J3.6	4.1	4.78e-05	0.00757	0.21	0.18	Intelligence (multi-trait analysis);	chr9:93400978	chr9:93435332~93437121:-
LUAD	cis	rs7617480	0.61	rs10865954	ENSG00000225399.4	RP11-3B7.1	4.1	4.78e-05	0.00757	0.25	0.18	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49174556	chr3:49260085~49261316:+
LUAD	cis	rs7308116	0.676	rs10861832	ENSG00000257951.1	RP11-554D14.4	4.1	4.78e-05	0.00757	0.21	0.18	Pelvic organ prolapse (moderate/severe);	chr12:107901658	chr12:107881242~107883382:+
LUAD	cis	rs238295	0.602	rs6053458	ENSG00000230563.2	RP5-828H9.1	-4.1	4.78e-05	0.00757	-0.24	-0.18	Occipital cortical area (total cortical area interaction);	chr20:5529539	chr20:5471207~5475182:+
LUAD	cis	rs780094	0.544	rs780110	ENSG00000234072.1	AC074117.10	-4.1	4.78e-05	0.00757	-0.14	-0.18	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27462521	chr2:27356246~27367622:+
LUAD	cis	rs8062405	0.723	rs113208333	ENSG00000251417.2	RP11-1348G14.4	-4.1	4.79e-05	0.00758	-0.19	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28594839	chr16:28802743~28817828:+
LUAD	cis	rs8062405	0.691	rs743590	ENSG00000251417.2	RP11-1348G14.4	-4.1	4.79e-05	0.00758	-0.19	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28596909	chr16:28802743~28817828:+
LUAD	cis	rs8133949	1	rs8133949	ENSG00000237232.6	ZNF295-AS1	4.1	4.79e-05	0.00758	0.23	0.18	Hand grip strength;	chr21:42001005	chr21:42009194~42024924:+
LUAD	cis	rs11671005	0.779	rs11670125	ENSG00000268912.1	CTD-2619J13.17	-4.1	4.79e-05	0.00758	-0.27	-0.18	Mean platelet volume;	chr19:58476023	chr19:58428632~58431148:-
LUAD	cis	rs9341808	0.667	rs583426	ENSG00000260645.1	RP11-250B2.5	-4.1	4.79e-05	0.00758	-0.17	-0.18	Sitting height ratio;	chr6:80236970	chr6:80466958~80469080:+
LUAD	cis	rs2274273	0.714	rs7154889	ENSG00000258413.1	RP11-665C16.6	-4.1	4.79e-05	0.00758	-0.24	-0.18	Protein biomarker;	chr14:55340167	chr14:55262767~55272075:-
LUAD	cis	rs889398	0.771	rs1500337	ENSG00000226232.7	RP11-419C5.2	4.1	4.79e-05	0.00758	0.16	0.18	Body mass index;	chr16:69867981	chr16:69976388~69996188:-
LUAD	cis	rs7688540	0.76	rs2883229	ENSG00000211553.1	AC253576.2	-4.1	4.79e-05	0.00758	-0.23	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:237955	chr4:136461~136568:+
LUAD	cis	rs6723108	0.627	rs2166480	ENSG00000224043.6	CCNT2-AS1	4.1	4.79e-05	0.00758	0.23	0.18	Type 2 diabetes;	chr2:134879768	chr2:134735464~134918710:-
LUAD	cis	rs911555	0.504	rs61995761	ENSG00000258851.1	RP11-894P9.2	-4.1	4.79e-05	0.00758	-0.22	-0.18	Intelligence (multi-trait analysis);	chr14:103609375	chr14:103553421~103561877:+
LUAD	cis	rs7107174	1	rs2511169	ENSG00000251323.2	RP11-452H21.4	4.1	4.79e-05	0.00758	0.23	0.18	Testicular germ cell tumor;	chr11:78254275	chr11:78423982~78429836:-
LUAD	cis	rs41369048	0.925	rs11588625	ENSG00000238078.1	LINC01352	-4.1	4.79e-05	0.00758	-0.29	-0.18	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220885504	chr1:220829255~220832429:+
LUAD	cis	rs7202877	0.706	rs2059257	ENSG00000280152.1	RP11-331F4.5	4.1	4.79e-05	0.00758	0.21	0.18	Type 1 diabetes;Type 2 diabetes;	chr16:75362478	chr16:75245994~75250077:-
LUAD	cis	rs6964587	1	rs10228334	ENSG00000188693.7	CYP51A1-AS1	-4.1	4.8e-05	0.00759	-0.21	-0.18	Breast cancer;	chr7:92084658	chr7:92134604~92180725:+
LUAD	cis	rs6964587	1	rs13239875	ENSG00000188693.7	CYP51A1-AS1	-4.1	4.8e-05	0.00759	-0.21	-0.18	Breast cancer;	chr7:92086790	chr7:92134604~92180725:+
LUAD	cis	rs1401999	1	rs2313217	ENSG00000223882.1	ABCC5-AS1	-4.1	4.8e-05	0.00759	-0.19	-0.18	Anterior chamber depth;	chr3:183918209	chr3:184006338~184011419:+
LUAD	cis	rs6964587	0.839	rs13229273	ENSG00000188693.7	CYP51A1-AS1	-4.1	4.8e-05	0.00759	-0.22	-0.18	Breast cancer;	chr7:91815158	chr7:92134604~92180725:+
LUAD	cis	rs6910061	1	rs6913027	ENSG00000247925.2	RP3-510L9.1	-4.1	4.8e-05	0.00759	-0.26	-0.18	Diabetic kidney disease;	chr6:11107043	chr6:11173452~11259099:+
LUAD	cis	rs7246657	0.943	rs10426666	ENSG00000226686.6	LINC01535	-4.1	4.8e-05	0.00759	-0.28	-0.18	Coronary artery calcification;	chr19:37337612	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.943	rs4969487	ENSG00000226686.6	LINC01535	-4.1	4.8e-05	0.00759	-0.28	-0.18	Coronary artery calcification;	chr19:37340137	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.943	rs28402338	ENSG00000226686.6	LINC01535	-4.1	4.8e-05	0.00759	-0.28	-0.18	Coronary artery calcification;	chr19:37343021	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.943	rs10424574	ENSG00000226686.6	LINC01535	-4.1	4.8e-05	0.00759	-0.28	-0.18	Coronary artery calcification;	chr19:37347491	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.943	rs10417503	ENSG00000226686.6	LINC01535	-4.1	4.8e-05	0.00759	-0.28	-0.18	Coronary artery calcification;	chr19:37351833	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.943	rs10403613	ENSG00000226686.6	LINC01535	-4.1	4.8e-05	0.00759	-0.28	-0.18	Coronary artery calcification;	chr19:37353404	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.943	rs9304566	ENSG00000226686.6	LINC01535	-4.1	4.8e-05	0.00759	-0.28	-0.18	Coronary artery calcification;	chr19:37354602	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.943	rs10422967	ENSG00000226686.6	LINC01535	-4.1	4.8e-05	0.00759	-0.28	-0.18	Coronary artery calcification;	chr19:37359235	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.943	rs4417644	ENSG00000226686.6	LINC01535	-4.1	4.8e-05	0.00759	-0.28	-0.18	Coronary artery calcification;	chr19:37361570	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.943	rs10405064	ENSG00000226686.6	LINC01535	-4.1	4.8e-05	0.00759	-0.28	-0.18	Coronary artery calcification;	chr19:37370959	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.943	rs8111782	ENSG00000226686.6	LINC01535	-4.1	4.8e-05	0.00759	-0.28	-0.18	Coronary artery calcification;	chr19:37377002	chr19:37251912~37265535:+
LUAD	cis	rs2933343	0.7	rs2249514	ENSG00000231305.3	RP11-723O4.2	4.1	4.8e-05	0.00759	0.2	0.18	IgG glycosylation;	chr3:128924969	chr3:128861313~128871540:-
LUAD	cis	rs2933343	0.7	rs2630257	ENSG00000231305.3	RP11-723O4.2	4.1	4.8e-05	0.00759	0.2	0.18	IgG glycosylation;	chr3:128925172	chr3:128861313~128871540:-
LUAD	cis	rs2933343	0.729	rs1680785	ENSG00000231305.3	RP11-723O4.2	4.1	4.8e-05	0.00759	0.2	0.18	IgG glycosylation;	chr3:128925973	chr3:128861313~128871540:-
LUAD	cis	rs2933343	0.729	rs1680786	ENSG00000231305.3	RP11-723O4.2	4.1	4.8e-05	0.00759	0.2	0.18	IgG glycosylation;	chr3:128925997	chr3:128861313~128871540:-
LUAD	cis	rs7246657	0.943	rs4452075	ENSG00000226686.6	LINC01535	-4.1	4.8e-05	0.0076	-0.28	-0.18	Coronary artery calcification;	chr19:37388687	chr19:37251912~37265535:+
LUAD	cis	rs2243480	1	rs2961102	ENSG00000229886.1	RP5-1132H15.3	4.1	4.8e-05	0.0076	0.32	0.18	Diabetic kidney disease;	chr7:65959671	chr7:66025126~66031544:-
LUAD	cis	rs9803723	0.682	rs61774796	ENSG00000261349.1	RP3-465N24.5	-4.1	4.8e-05	0.0076	-0.22	-0.18	Male-pattern baldness;	chr1:25121975	chr1:25266102~25267136:-
LUAD	cis	rs12935418	0.579	rs7197606	ENSG00000261061.1	RP11-303E16.2	-4.1	4.8e-05	0.0076	-0.2	-0.18	Mean corpuscular volume;	chr16:81019914	chr16:81030770~81031485:+
LUAD	cis	rs4664293	1	rs10184034	ENSG00000230783.1	AC009961.2	-4.1	4.8e-05	0.0076	-0.22	-0.18	Monocyte percentage of white cells;	chr2:159648916	chr2:159689217~159690291:-
LUAD	cis	rs4664293	1	rs4664293	ENSG00000230783.1	AC009961.2	-4.1	4.8e-05	0.0076	-0.22	-0.18	Monocyte percentage of white cells;	chr2:159649241	chr2:159689217~159690291:-
LUAD	cis	rs4664293	1	rs10193402	ENSG00000230783.1	AC009961.2	-4.1	4.8e-05	0.0076	-0.22	-0.18	Monocyte percentage of white cells;	chr2:159651271	chr2:159689217~159690291:-
LUAD	cis	rs4664293	1	rs11676412	ENSG00000230783.1	AC009961.2	-4.1	4.8e-05	0.0076	-0.22	-0.18	Monocyte percentage of white cells;	chr2:159651560	chr2:159689217~159690291:-
LUAD	cis	rs28386778	0.897	rs2665797	ENSG00000240280.5	TCAM1P	4.1	4.8e-05	0.0076	0.21	0.18	Prudent dietary pattern;	chr17:63845125	chr17:63849292~63864379:+
LUAD	cis	rs7200543	0.666	rs34955778	ENSG00000260735.1	RP11-72I8.1	-4.1	4.8e-05	0.0076	-0.19	-0.18	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15045737	chr16:15094411~15109197:+
LUAD	cis	rs911119	0.913	rs6048928	ENSG00000270001.1	RP11-218C14.8	-4.1	4.8e-05	0.0076	-0.28	-0.18	Chronic kidney disease;	chr20:23605351	chr20:23631826~23632316:-
LUAD	cis	rs4938303	0.756	rs12802944	ENSG00000280143.1	AP000892.6	-4.1	4.8e-05	0.0076	-0.25	-0.18	Triglycerides;	chr11:116705684	chr11:117204967~117210292:+
LUAD	cis	rs860295	0.58	rs11264361	ENSG00000225855.5	RUSC1-AS1	4.1	4.81e-05	0.0076	0.13	0.18	Body mass index;	chr1:155319754	chr1:155316863~155324176:-
LUAD	cis	rs2098713	0.544	rs2056871	ENSG00000250155.1	CTD-2353F22.1	4.1	4.81e-05	0.0076	0.21	0.18	Telomere length;	chr5:37424753	chr5:36666214~36725195:-
LUAD	cis	rs1499614	0.522	rs13247442	ENSG00000232559.3	GS1-124K5.12	4.1	4.81e-05	0.0076	0.37	0.18	Gout;	chr7:66723871	chr7:66554588~66576923:-
LUAD	cis	rs2506028	0.55	rs2487918	ENSG00000234944.1	RP11-124O11.1	4.1	4.81e-05	0.00761	0.23	0.18	Blood protein levels;	chr10:42929980	chr10:42871521~42874060:+
LUAD	cis	rs7308116	0.645	rs10861834	ENSG00000257951.1	RP11-554D14.4	4.1	4.81e-05	0.00761	0.21	0.18	Pelvic organ prolapse (moderate/severe);	chr12:107903134	chr12:107881242~107883382:+
LUAD	cis	rs16866061	0.89	rs72972401	ENSG00000228446.2	AC073052.1	-4.1	4.81e-05	0.00761	-0.2	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr2:224539951	chr2:224499387~224500100:-
LUAD	cis	rs16873450	0.9	rs6963050	ENSG00000234800.2	PCMTD1P3	4.1	4.81e-05	0.00761	0.21	0.18	Verbal memory performance (residualized delayed recall level);	chr7:23738590	chr7:23721311~23721782:-
LUAD	cis	rs4934494	0.768	rs1409357	ENSG00000240996.1	RP11-80H5.7	-4.1	4.81e-05	0.00761	-0.25	-0.18	Red blood cell count;	chr10:89669719	chr10:89694295~89697928:-
LUAD	cis	rs2288073	0.965	rs10185445	ENSG00000223754.1	AC008073.9	-4.1	4.81e-05	0.00761	-0.23	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr2:24188107	chr2:24199839~24201698:-
LUAD	cis	rs9467773	0.523	rs2498399	ENSG00000241549.7	GUSBP2	4.1	4.82e-05	0.00762	0.21	0.18	Intelligence (multi-trait analysis);	chr6:26795343	chr6:26871484~26956554:-
LUAD	cis	rs1864585	0.52	rs73208778	ENSG00000255046.1	RP11-297N6.4	4.1	4.82e-05	0.00762	0.26	0.18	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10812644	chr8:11797928~11802568:-
LUAD	cis	rs6531209	0.817	rs4666362	ENSG00000234378.1	AC098828.2	4.1	4.82e-05	0.00762	0.23	0.18	Amyotrophic lateral sclerosis (sporadic);	chr2:20137584	chr2:20063856~20106829:-
LUAD	cis	rs5015933	0.815	rs12338077	ENSG00000232630.1	PRPS1P2	-4.1	4.82e-05	0.00762	-0.17	-0.18	Body mass index;	chr9:125345427	chr9:125150653~125151589:+
LUAD	cis	rs5015933	0.815	rs10986716	ENSG00000232630.1	PRPS1P2	-4.1	4.82e-05	0.00762	-0.17	-0.18	Body mass index;	chr9:125345606	chr9:125150653~125151589:+
LUAD	cis	rs2548724	0.796	rs58644688	ENSG00000250682.4	LINC00491	4.1	4.82e-05	0.00762	0.25	0.18	Type 2 diabetes;	chr5:102375793	chr5:102609156~102671559:-
LUAD	cis	rs2657294	0.765	rs2804533	ENSG00000233313.2	HMGA1P5	-4.1	4.82e-05	0.00762	-0.23	-0.18	Pneumonia;	chr10:75207723	chr10:75276376~75276646:-
LUAD	cis	rs7580658	0.963	rs12991768	ENSG00000236682.1	AC068282.3	-4.1	4.82e-05	0.00763	-0.25	-0.18	Protein C levels;	chr2:127388669	chr2:127389130~127400580:+
LUAD	cis	rs39841	1	rs39841	ENSG00000272109.1	CTD-2260A17.3	-4.1	4.82e-05	0.00763	-0.21	-0.18	Inflammatory skin disease;	chr5:96784466	chr5:96804353~96806105:+
LUAD	cis	rs9341808	0.718	rs9448899	ENSG00000260645.1	RP11-250B2.5	4.1	4.82e-05	0.00763	0.17	0.18	Sitting height ratio;	chr6:80136147	chr6:80466958~80469080:+
LUAD	cis	rs4699052	1	rs6533060	ENSG00000246560.2	RP11-10L12.4	4.1	4.83e-05	0.00763	0.23	0.18	Testicular germ cell tumor;	chr4:103218839	chr4:102828055~102844075:+
LUAD	cis	rs2243480	1	rs906134	ENSG00000229886.1	RP5-1132H15.3	4.1	4.83e-05	0.00763	0.32	0.18	Diabetic kidney disease;	chr7:65979301	chr7:66025126~66031544:-
LUAD	cis	rs9341808	0.69	rs2322634	ENSG00000260645.1	RP11-250B2.5	4.1	4.83e-05	0.00763	0.17	0.18	Sitting height ratio;	chr6:80164297	chr6:80466958~80469080:+
LUAD	cis	rs17345786	0.906	rs11710016	ENSG00000244119.1	PDCL3P4	-4.1	4.83e-05	0.00763	-0.21	-0.18	Colonoscopy-negative controls vs population controls;	chr3:101401186	chr3:101712472~101713191:+
LUAD	cis	rs1964356	0.967	rs2953802	ENSG00000253893.2	FAM85B	-4.1	4.83e-05	0.00763	-0.24	-0.18	Mean corpuscular volume;	chr8:8994371	chr8:8167819~8226614:-
LUAD	cis	rs2274273	0.682	rs10145268	ENSG00000258413.1	RP11-665C16.6	-4.1	4.83e-05	0.00763	-0.23	-0.18	Protein biomarker;	chr14:55037796	chr14:55262767~55272075:-
LUAD	cis	rs2735413	0.846	rs72800943	ENSG00000276007.1	RP11-358L22.3	-4.1	4.83e-05	0.00764	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78045658	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.881	rs12923218	ENSG00000276007.1	RP11-358L22.3	-4.1	4.83e-05	0.00764	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78046377	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.875	rs12923229	ENSG00000276007.1	RP11-358L22.3	-4.1	4.83e-05	0.00764	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78046405	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.918	rs4888733	ENSG00000276007.1	RP11-358L22.3	-4.1	4.83e-05	0.00764	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78046626	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.752	rs11642442	ENSG00000276007.1	RP11-358L22.3	-4.1	4.83e-05	0.00764	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78046903	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.918	rs11643649	ENSG00000276007.1	RP11-358L22.3	-4.1	4.83e-05	0.00764	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78047302	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.918	rs56397244	ENSG00000276007.1	RP11-358L22.3	-4.1	4.83e-05	0.00764	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78047469	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.918	rs34094825	ENSG00000276007.1	RP11-358L22.3	-4.1	4.83e-05	0.00764	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78047495	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.918	rs12931394	ENSG00000276007.1	RP11-358L22.3	-4.1	4.83e-05	0.00764	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78047732	chr16:78123243~78124332:+
LUAD	cis	rs9549260	0.755	rs7335520	ENSG00000229456.1	RLIMP1	4.1	4.83e-05	0.00764	0.2	0.18	Red blood cell count;	chr13:40622270	chr13:40618738~40621348:+
LUAD	cis	rs4372836	0.964	rs17007191	ENSG00000226833.4	AC097724.3	-4.1	4.83e-05	0.00764	-0.21	-0.18	Body mass index;	chr2:28709636	chr2:28708953~28736205:-
LUAD	cis	rs11673344	0.542	rs826327	ENSG00000276846.1	CTD-3220F14.3	4.1	4.83e-05	0.00764	0.2	0.18	Obesity-related traits;	chr19:37004397	chr19:37314868~37315620:-
LUAD	cis	rs7829975	0.582	rs6983150	ENSG00000233609.3	RP11-62H7.2	-4.1	4.83e-05	0.00764	-0.15	-0.18	Mood instability;	chr8:8934916	chr8:8961200~8979025:+
LUAD	cis	rs2253762	0.507	rs10159582	ENSG00000276742.1	RP11-500G22.4	4.1	4.84e-05	0.00764	0.28	0.18	Breast cancer;	chr10:121993110	chr10:121956782~121957098:+
LUAD	cis	rs2253762	0.507	rs10159583	ENSG00000276742.1	RP11-500G22.4	4.1	4.84e-05	0.00764	0.28	0.18	Breast cancer;	chr10:121993154	chr10:121956782~121957098:+
LUAD	cis	rs2253762	0.507	rs75383663	ENSG00000276742.1	RP11-500G22.4	4.1	4.84e-05	0.00764	0.28	0.18	Breast cancer;	chr10:121993340	chr10:121956782~121957098:+
LUAD	cis	rs4372836	0.964	rs55721532	ENSG00000226833.4	AC097724.3	-4.1	4.84e-05	0.00764	-0.22	-0.18	Body mass index;	chr2:28716102	chr2:28708953~28736205:-
LUAD	cis	rs172166	0.694	rs1225716	ENSG00000216901.1	AL022393.7	4.1	4.84e-05	0.00765	0.23	0.18	Cardiac Troponin-T levels;	chr6:28145968	chr6:28176188~28176674:+
LUAD	cis	rs2823962	1	rs2823962	ENSG00000270093.1	AP000473.8	-4.1	4.84e-05	0.00765	-0.18	-0.18	Amyotrophic lateral sclerosis;	chr21:16673913	chr21:16643529~16645065:+
LUAD	cis	rs7772486	0.743	rs9403742	ENSG00000235652.6	RP11-545I5.3	4.1	4.84e-05	0.00765	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145739057	chr6:145799409~145886585:+
LUAD	cis	rs17772222	0.74	rs10150311	ENSG00000258789.1	RP11-507K2.3	-4.1	4.84e-05	0.00765	-0.23	-0.18	Coronary artery calcification;	chr14:88510128	chr14:88551597~88552493:+
LUAD	cis	rs34779708	0.931	rs11010130	ENSG00000271335.4	RP11-324I22.4	4.1	4.84e-05	0.00765	0.2	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35224379	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.897	rs11010131	ENSG00000271335.4	RP11-324I22.4	4.1	4.84e-05	0.00765	0.2	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35224388	chr10:35314552~35336401:-
LUAD	cis	rs2735413	0.875	rs12924402	ENSG00000276007.1	RP11-358L22.3	-4.1	4.84e-05	0.00766	-0.19	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78049580	chr16:78123243~78124332:+
LUAD	cis	rs8014204	0.836	rs888413	ENSG00000279594.1	RP11-950C14.10	4.1	4.85e-05	0.00766	0.2	0.18	Caffeine consumption;	chr14:74800693	chr14:75011269~75012851:-
LUAD	cis	rs6964587	1	rs10488512	ENSG00000188693.7	CYP51A1-AS1	-4.1	4.85e-05	0.00766	-0.22	-0.18	Breast cancer;	chr7:92124265	chr7:92134604~92180725:+
LUAD	cis	rs507080	0.769	rs645637	ENSG00000278376.1	RP11-158I9.8	-4.1	4.85e-05	0.00766	-0.2	-0.18	Serum metabolite levels;	chr11:118634373	chr11:118791254~118793137:+
LUAD	cis	rs6840360	0.726	rs6816292	ENSG00000270265.1	RP11-731D1.4	4.1	4.85e-05	0.00766	0.19	0.18	Intelligence (multi-trait analysis);	chr4:151809391	chr4:151333775~151353224:-
LUAD	cis	rs7302981	0.899	rs4883481	ENSG00000200428.1	Y_RNA	4.1	4.85e-05	0.00766	0.23	0.18	Systolic blood pressure;	chr12:50180528	chr12:50743568~50743684:+
LUAD	cis	rs9341808	0.667	rs742833	ENSG00000260645.1	RP11-250B2.5	4.1	4.85e-05	0.00766	0.17	0.18	Sitting height ratio;	chr6:80211729	chr6:80466958~80469080:+
LUAD	cis	rs13068223	0.819	rs8792	ENSG00000243926.1	TIPARP-AS1	-4.1	4.85e-05	0.00766	-0.19	-0.18	Age-related hearing impairment (SNP x SNP interaction);	chr3:156747639	chr3:156671862~156674378:-
LUAD	cis	rs6496044	0.568	rs6496039	ENSG00000259295.5	CSPG4P12	4.1	4.85e-05	0.00766	0.21	0.18	Interstitial lung disease;	chr15:85518732	chr15:85191438~85213905:+
LUAD	cis	rs1555322	0.53	rs932562	ENSG00000126005.14	MMP24-AS1	-4.1	4.85e-05	0.00766	-0.26	-0.18	Attention deficit hyperactivity disorder;	chr20:35283507	chr20:35216462~35278131:-
LUAD	cis	rs10129255	0.957	rs17113284	ENSG00000274576.2	IGHV2-70	-4.1	4.85e-05	0.00766	-0.17	-0.18	Kawasaki disease;	chr14:106684476	chr14:106770577~106771020:-
LUAD	cis	rs6671200	0.541	rs3738170	ENSG00000228852.5	RP11-57H12.5	-4.1	4.85e-05	0.00766	-0.22	-0.18	Stearic acid (18:0) levels;	chr1:95234048	chr1:95243167~95278940:-
LUAD	cis	rs7829975	0.582	rs6982832	ENSG00000233609.3	RP11-62H7.2	-4.1	4.85e-05	0.00766	-0.15	-0.18	Mood instability;	chr8:8934707	chr8:8961200~8979025:+
LUAD	cis	rs2060793	0.741	rs4344519	ENSG00000251991.1	RNU7-49P	4.1	4.85e-05	0.00767	0.2	0.18	Vitamin D levels;	chr11:14701347	chr11:14478892~14478953:+
LUAD	cis	rs875971	0.571	rs160641	ENSG00000222364.1	RNU6-96P	4.1	4.85e-05	0.00767	0.24	0.18	Aortic root size;	chr7:66112359	chr7:66395191~66395286:+
LUAD	cis	rs6840360	0.692	rs1838043	ENSG00000270265.1	RP11-731D1.4	-4.1	4.85e-05	0.00767	-0.19	-0.18	Intelligence (multi-trait analysis);	chr4:151490310	chr4:151333775~151353224:-
LUAD	cis	rs763121	0.657	rs5995603	ENSG00000225450.1	RP3-508I15.14	-4.1	4.85e-05	0.00767	-0.19	-0.18	Menopause (age at onset);	chr22:38644728	chr22:38739003~38749041:+
LUAD	cis	rs6142102	1	rs2378078	ENSG00000275784.1	RP5-1125A11.6	-4.1	4.85e-05	0.00767	-0.21	-0.18	Skin pigmentation;	chr20:34126922	chr20:33989480~33991818:-
LUAD	cis	rs28386778	0.897	rs2665823	ENSG00000240280.5	TCAM1P	-4.1	4.85e-05	0.00767	-0.21	-0.18	Prudent dietary pattern;	chr17:63808557	chr17:63849292~63864379:+
LUAD	cis	rs4691139	0.658	rs4690798	ENSG00000248632.1	RP11-366M4.11	4.1	4.86e-05	0.00767	0.22	0.18	Ovarian cancer in BRCA1 mutation carriers;	chr4:165005434	chr4:164968587~164970002:-
LUAD	cis	rs61542988	0.756	rs5013587	ENSG00000226329.2	AC005682.6	4.1	4.86e-05	0.00767	0.27	0.18	Fibrinogen levels;	chr7:22843041	chr7:22863874~22881350:-
LUAD	cis	rs911555	0.755	rs7148567	ENSG00000259775.1	RP11-45P15.4	-4.1	4.86e-05	0.00767	-0.24	-0.18	Intelligence (multi-trait analysis);	chr14:103415897	chr14:103331674~103332367:-
LUAD	cis	rs6964587	0.967	rs34863529	ENSG00000188693.7	CYP51A1-AS1	-4.1	4.86e-05	0.00768	-0.22	-0.18	Breast cancer;	chr7:92015027	chr7:92134604~92180725:+
LUAD	cis	rs12999542	0.706	rs80321720	ENSG00000234389.1	AC007278.3	4.1	4.86e-05	0.00768	0.3	0.18	Serum protein levels (sST2);	chr2:102408209	chr2:102438713~102440475:+
LUAD	cis	rs12999542	0.706	rs62152712	ENSG00000234389.1	AC007278.3	4.1	4.86e-05	0.00768	0.3	0.18	Serum protein levels (sST2);	chr2:102408697	chr2:102438713~102440475:+
LUAD	cis	rs763121	0.853	rs1065201	ENSG00000228274.3	RP3-508I15.9	-4.1	4.86e-05	0.00768	-0.18	-0.18	Menopause (age at onset);	chr22:38673505	chr22:38667585~38681820:-
LUAD	cis	rs4474465	1	rs1355921	ENSG00000251323.2	RP11-452H21.4	4.1	4.86e-05	0.00768	0.23	0.18	Alzheimer's disease (survival time);	chr11:78428233	chr11:78423982~78429836:-
LUAD	cis	rs2554380	0.628	rs12914377	ENSG00000259570.1	RP11-671M22.4	4.1	4.86e-05	0.00768	0.23	0.18	Height;	chr15:83791941	chr15:84394512~84395514:+
LUAD	cis	rs1005277	0.505	rs13503	ENSG00000273019.1	RP11-508N22.13	4.1	4.86e-05	0.00768	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:37950915	chr10:38149968~38150293:+
LUAD	cis	rs3096299	0.586	rs4572400	ENSG00000261118.1	RP11-104N10.1	4.1	4.86e-05	0.00768	0.19	0.18	Multiple myeloma (IgH translocation);	chr16:89467108	chr16:89492017~89504460:-
LUAD	cis	rs9646944	0.501	rs12991737	ENSG00000234389.1	AC007278.3	4.1	4.86e-05	0.00768	0.21	0.18	Blood protein levels;	chr2:102401668	chr2:102438713~102440475:+
LUAD	cis	rs7617773	0.78	rs11710257	ENSG00000199476.1	Y_RNA	-4.1	4.86e-05	0.00768	-0.25	-0.18	Coronary artery disease;	chr3:48331724	chr3:48288587~48288694:+
LUAD	cis	rs848490	0.889	rs10953356	ENSG00000214293.7	APTR	4.1	4.86e-05	0.00768	0.24	0.18	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77820281	chr7:77657660~77696265:-
LUAD	cis	rs4819052	0.851	rs1056100	ENSG00000215447.6	BX322557.10	-4.1	4.86e-05	0.00768	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258796	chr21:45288052~45291738:+
LUAD	cis	rs7216064	0.532	rs8065296	ENSG00000265055.1	AC145343.2	-4.1	4.87e-05	0.00768	-0.17	-0.18	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68022446	chr17:68096046~68101474:-
LUAD	cis	rs4763879	0.778	rs1044771	ENSG00000278635.1	CTD-2318O12.1	4.1	4.87e-05	0.00768	0.17	0.18	Type 1 diabetes;	chr12:9699333	chr12:9415641~9416718:+
LUAD	cis	rs7515577	0.812	rs2391139	ENSG00000223787.2	RP4-593M8.1	-4.1	4.87e-05	0.00768	-0.27	-0.18	Cholesterol, total;	chr1:92262053	chr1:92580476~92580821:-
LUAD	cis	rs6964587	0.869	rs2023784	ENSG00000188693.7	CYP51A1-AS1	4.1	4.87e-05	0.00769	0.22	0.18	Breast cancer;	chr7:91895363	chr7:92134604~92180725:+
LUAD	cis	rs6964587	0.869	rs401	ENSG00000188693.7	CYP51A1-AS1	4.1	4.87e-05	0.00769	0.22	0.18	Breast cancer;	chr7:91898631	chr7:92134604~92180725:+
LUAD	cis	rs4819052	0.851	rs8131143	ENSG00000237664.1	LINC00316	4.1	4.87e-05	0.00769	0.22	0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251731	chr21:45338590~45341990:-
LUAD	cis	rs7005380	0.62	rs13250594	ENSG00000279347.1	RP11-85I17.2	-4.1	4.87e-05	0.00769	-0.15	-0.18	Interstitial lung disease;	chr8:119894151	chr8:119838736~119840385:-
LUAD	cis	rs3177980	0.639	rs17529513	ENSG00000239494.2	RN7SL333P	-4.1	4.87e-05	0.00769	-0.18	-0.18	Amyotrophic lateral sclerosis;	chr1:169829604	chr1:169859756~169860052:+
LUAD	cis	rs8098244	0.603	rs1711456	ENSG00000264745.1	TTC39C-AS1	4.1	4.87e-05	0.00769	0.19	0.18	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23697390	chr18:23994213~24015339:-
LUAD	cis	rs957448	1	rs1992370	ENSG00000253175.1	RP11-267M23.6	4.1	4.87e-05	0.00769	0.22	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94546466	chr8:94565036~94565715:+
LUAD	cis	rs2348418	0.832	rs1552760	ENSG00000247934.4	RP11-967K21.1	4.1	4.87e-05	0.00769	0.21	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28383884	chr12:28163298~28190738:-
LUAD	cis	rs911555	0.539	rs4374097	ENSG00000258851.1	RP11-894P9.2	-4.1	4.87e-05	0.00769	-0.22	-0.18	Intelligence (multi-trait analysis);	chr14:103606429	chr14:103553421~103561877:+
LUAD	cis	rs453301	0.657	rs36056437	ENSG00000233609.3	RP11-62H7.2	-4.1	4.87e-05	0.00769	-0.16	-0.18	Joint mobility (Beighton score);	chr8:8935355	chr8:8961200~8979025:+
LUAD	cis	rs7208859	0.673	rs9889968	ENSG00000280069.1	CTD-2349P21.3	-4.1	4.87e-05	0.00769	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30893110	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs61348930	ENSG00000280069.1	CTD-2349P21.3	-4.1	4.87e-05	0.00769	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30894745	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.614	rs28758251	ENSG00000280069.1	CTD-2349P21.3	-4.1	4.87e-05	0.00769	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896294	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs9899943	ENSG00000280069.1	CTD-2349P21.3	-4.1	4.87e-05	0.00769	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896907	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs11080138	ENSG00000280069.1	CTD-2349P21.3	-4.1	4.87e-05	0.00769	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30897524	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs73265612	ENSG00000280069.1	CTD-2349P21.3	-4.1	4.87e-05	0.00769	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30898965	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs2433	ENSG00000280069.1	CTD-2349P21.3	-4.1	4.87e-05	0.00769	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30899210	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs11658435	ENSG00000280069.1	CTD-2349P21.3	-4.1	4.87e-05	0.00769	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30901543	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs73265624	ENSG00000280069.1	CTD-2349P21.3	-4.1	4.87e-05	0.00769	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905048	chr17:30738182~30740275:+
LUAD	cis	rs706293	0.512	rs7715323	ENSG00000261360.1	CTD-2165H16.4	-4.1	4.87e-05	0.00769	-0.17	-0.18	Urate levels (BMI interaction);	chr5:14839544	chr5:14661808~14664604:-
LUAD	cis	rs7617773	0.78	rs35297486	ENSG00000199476.1	Y_RNA	-4.1	4.87e-05	0.0077	-0.25	-0.18	Coronary artery disease;	chr3:48336657	chr3:48288587~48288694:+
LUAD	cis	rs10109025	0.701	rs10101292	ENSG00000255046.1	RP11-297N6.4	4.1	4.87e-05	0.0077	0.24	0.18	Joint mobility (Beighton score);	chr8:10998964	chr8:11797928~11802568:-
LUAD	cis	rs16944613	0.588	rs8030799	ENSG00000259212.1	CTD-3065B20.2	4.1	4.87e-05	0.0077	0.29	0.18	Colorectal cancer;	chr15:90566142	chr15:90595840~90596447:-
LUAD	cis	rs4947019	1	rs4947019	ENSG00000260273.1	RP11-425D10.10	4.1	4.88e-05	0.0077	0.37	0.18	Hematological parameters;	chr6:109768846	chr6:109382795~109383666:+
LUAD	cis	rs6964587	1	rs2299239	ENSG00000188693.7	CYP51A1-AS1	-4.1	4.88e-05	0.0077	-0.21	-0.18	Breast cancer;	chr7:92025303	chr7:92134604~92180725:+
LUAD	cis	rs10214930	0.697	rs6942908	ENSG00000235574.1	AC073150.6	-4.1	4.88e-05	0.0077	-0.22	-0.18	Hypospadias;	chr7:27866299	chr7:27491682~27492765:-
LUAD	cis	rs6688613	0.649	rs2294195	ENSG00000225171.2	DUTP6	-4.1	4.88e-05	0.0077	-0.23	-0.18	Refractive astigmatism;	chr1:166869044	chr1:166868748~166869209:+
LUAD	cis	rs7005380	0.62	rs13259990	ENSG00000279347.1	RP11-85I17.2	-4.1	4.88e-05	0.0077	-0.15	-0.18	Interstitial lung disease;	chr8:119894943	chr8:119838736~119840385:-
LUAD	cis	rs9532669	0.926	rs9532690	ENSG00000168852.11	TPTE2P5	4.1	4.88e-05	0.0077	0.18	0.18	Cervical cancer;	chr13:40968654	chr13:40822296~40921749:-
LUAD	cis	rs4795519	1	rs8071740	ENSG00000266313.1	RP11-173M1.4	4.1	4.88e-05	0.0077	0.23	0.18	Chronic myeloid leukemia;	chr17:27198705	chr17:27333256~27348491:+
LUAD	cis	rs7116495	0.867	rs674688	ENSG00000254682.1	RP11-660L16.2	4.1	4.88e-05	0.0077	0.37	0.18	Severe influenza A (H1N1) infection;	chr11:71867453	chr11:71448674~71452157:+
LUAD	cis	rs9649213	0.593	rs6963210	ENSG00000272950.1	RP11-307C18.1	4.1	4.88e-05	0.0077	0.23	0.18	Prostate cancer (SNP x SNP interaction);	chr7:98315674	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.574	rs9648908	ENSG00000272950.1	RP11-307C18.1	4.1	4.88e-05	0.0077	0.23	0.18	Prostate cancer (SNP x SNP interaction);	chr7:98315924	chr7:98322853~98323430:+
LUAD	cis	rs755249	0.51	rs613511	ENSG00000228060.1	RP11-69E11.8	-4.1	4.88e-05	0.0077	-0.17	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39367801	chr1:39565160~39573203:+
LUAD	cis	rs4660214	0.666	rs629093	ENSG00000228060.1	RP11-69E11.8	-4.1	4.88e-05	0.0077	-0.17	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39367831	chr1:39565160~39573203:+
LUAD	cis	rs4660214	0.666	rs663449	ENSG00000228060.1	RP11-69E11.8	-4.1	4.88e-05	0.0077	-0.17	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39378286	chr1:39565160~39573203:+
LUAD	cis	rs5015933	0.815	rs13291655	ENSG00000232630.1	PRPS1P2	-4.1	4.88e-05	0.00771	-0.17	-0.18	Body mass index;	chr9:125348274	chr9:125150653~125151589:+
LUAD	cis	rs6964833	0.786	rs35633336	ENSG00000184616.8	AC004166.6	4.1	4.88e-05	0.00771	0.27	0.18	Menarche (age at onset);	chr7:74643961	chr7:74906673~74913256:-
LUAD	cis	rs6964833	0.935	rs35735900	ENSG00000184616.8	AC004166.6	4.1	4.88e-05	0.00771	0.27	0.18	Menarche (age at onset);	chr7:74651887	chr7:74906673~74913256:-
LUAD	cis	rs2253762	0.507	rs11200310	ENSG00000276742.1	RP11-500G22.4	4.1	4.88e-05	0.00771	0.29	0.18	Breast cancer;	chr10:121989944	chr10:121956782~121957098:+
LUAD	cis	rs4819052	0.766	rs4819035	ENSG00000237664.1	LINC00316	-4.1	4.88e-05	0.00771	-0.24	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45225800	chr21:45338590~45341990:-
LUAD	cis	rs2898681	0.581	rs936690	ENSG00000248375.1	RP11-177B4.1	-4.1	4.88e-05	0.00771	-0.28	-0.18	Optic nerve measurement (cup area);	chr4:52824868	chr4:52720081~52720831:-
LUAD	cis	rs12999542	0.706	rs56151044	ENSG00000234389.1	AC007278.3	4.1	4.88e-05	0.00771	0.3	0.18	Serum protein levels (sST2);	chr2:102394869	chr2:102438713~102440475:+
LUAD	cis	rs10463554	1	rs12659870	ENSG00000250682.4	LINC00491	4.1	4.88e-05	0.00771	0.22	0.18	Parkinson's disease;	chr5:103000867	chr5:102609156~102671559:-
LUAD	cis	rs9815354	0.812	rs73079324	ENSG00000273328.4	RP11-141M3.6	-4.1	4.89e-05	0.00771	-0.26	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41823072	chr3:42809414~42908105:+
LUAD	cis	rs9815354	0.904	rs73079327	ENSG00000273328.4	RP11-141M3.6	-4.1	4.89e-05	0.00771	-0.26	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41823205	chr3:42809414~42908105:+
LUAD	cis	rs9815354	1	rs6790732	ENSG00000273328.4	RP11-141M3.6	-4.1	4.89e-05	0.00771	-0.26	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41823380	chr3:42809414~42908105:+
LUAD	cis	rs5015933	0.815	rs13291322	ENSG00000232630.1	PRPS1P2	-4.1	4.89e-05	0.00771	-0.17	-0.18	Body mass index;	chr9:125348076	chr9:125150653~125151589:+
LUAD	cis	rs6496932	1	rs2002642	ENSG00000259630.2	CTD-2262B20.1	4.1	4.89e-05	0.00771	0.25	0.18	Central corneal thickness;Corneal structure;	chr15:85284513	chr15:85415228~85415633:+
LUAD	cis	rs6496932	1	rs4842872	ENSG00000259630.2	CTD-2262B20.1	4.1	4.89e-05	0.00771	0.25	0.18	Central corneal thickness;Corneal structure;	chr15:85284825	chr15:85415228~85415633:+
LUAD	cis	rs5758511	0.573	rs2284082	ENSG00000227370.1	RP4-669P10.19	-4.1	4.89e-05	0.00772	-0.18	-0.18	Birth weight;	chr22:41844793	chr22:42132543~42132998:+
LUAD	cis	rs2032366	0.606	rs6567225	ENSG00000266920.1	ACTBP9	-4.1	4.89e-05	0.00772	-0.2	-0.18	Obesity-related traits;	chr18:61607418	chr18:62442028~62443126:+
LUAD	cis	rs12446554	0.509	rs56100071	ENSG00000261195.1	CTD-2380F24.1	-4.1	4.89e-05	0.00772	-0.26	-0.18	Obesity;	chr16:19698429	chr16:19761172~19766099:-
LUAD	cis	rs6496932	0.503	rs7164354	ENSG00000202081.1	RNU6-1280P	-4.1	4.89e-05	0.00772	-0.25	-0.18	Central corneal thickness;Corneal structure;	chr15:85405217	chr15:85651522~85651628:-
LUAD	cis	rs9545047	0.604	rs1616547	ENSG00000227354.5	RBM26-AS1	4.1	4.89e-05	0.00772	0.2	0.18	Schizophrenia;	chr13:79411901	chr13:79406309~79424328:+
LUAD	cis	rs847577	0.55	rs12670686	ENSG00000272950.1	RP11-307C18.1	4.1	4.89e-05	0.00772	0.23	0.18	Breast cancer;	chr7:98079085	chr7:98322853~98323430:+
LUAD	cis	rs6687821	0.515	rs11161914	ENSG00000261737.1	RP4-612B15.3	4.1	4.89e-05	0.00772	0.25	0.18	Yeast infection;	chr1:86977846	chr1:86703502~86704462:-
LUAD	cis	rs801193	1	rs3800812	ENSG00000222364.1	RNU6-96P	-4.1	4.89e-05	0.00772	-0.21	-0.18	Aortic root size;	chr7:66758474	chr7:66395191~66395286:+
LUAD	cis	rs801193	1	rs4279493	ENSG00000222364.1	RNU6-96P	-4.1	4.89e-05	0.00772	-0.21	-0.18	Aortic root size;	chr7:66761633	chr7:66395191~66395286:+
LUAD	cis	rs6724465	0.866	rs56034752	ENSG00000272644.1	RP11-33O4.1	4.1	4.9e-05	0.00772	0.27	0.18	Height;	chr2:219036419	chr2:219069354~219069809:-
LUAD	cis	rs80028505	0.908	rs16884660	ENSG00000271304.1	DPRXP2	4.1	4.9e-05	0.00773	0.34	0.18	Foot ulcer in diabetes and neuropathy;	chr6:36092434	chr6:35989515~35990436:-
LUAD	cis	rs7940646	0.812	rs11042906	ENSG00000177112.6	MRVI1-AS1	4.1	4.9e-05	0.00773	0.25	0.18	Platelet aggregation;	chr11:10643688	chr11:10541272~10599932:+
LUAD	cis	rs638893	0.947	rs515707	ENSG00000255239.1	AP002954.6	4.1	4.9e-05	0.00773	0.29	0.18	Vitiligo;	chr11:118814772	chr11:118688039~118690600:-
LUAD	cis	rs6142102	0.812	rs2377955	ENSG00000275784.1	RP5-1125A11.6	-4.1	4.9e-05	0.00773	-0.21	-0.18	Skin pigmentation;	chr20:33937564	chr20:33989480~33991818:-
LUAD	cis	rs8073060	0.586	rs225278	ENSG00000267592.1	CTC-507E2.2	4.1	4.9e-05	0.00773	0.27	0.18	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35647151	chr17:35596904~35597128:-
LUAD	cis	rs9649213	0.593	rs7797943	ENSG00000272950.1	RP11-307C18.1	4.1	4.9e-05	0.00773	0.23	0.18	Prostate cancer (SNP x SNP interaction);	chr7:98317590	chr7:98322853~98323430:+
LUAD	cis	rs17406451	0.759	rs11124935	ENSG00000279873.2	LINC01126	4.1	4.9e-05	0.00773	0.16	0.18	Mitochondrial DNA levels;	chr2:43425790	chr2:43227210~43228855:+
LUAD	cis	rs10129255	0.912	rs61997792	ENSG00000211967.3	IGHV3-53	-4.1	4.9e-05	0.00773	-0.15	-0.18	Kawasaki disease;	chr14:106799304	chr14:106592676~106593347:-
LUAD	cis	rs12468226	1	rs13426118	ENSG00000226261.1	AC064836.3	4.1	4.9e-05	0.00773	0.26	0.18	Urate levels;	chr2:202390762	chr2:202336024~202336727:-
LUAD	cis	rs526231	0.853	rs2561477	ENSG00000175749.11	EIF3KP1	4.1	4.9e-05	0.00773	0.25	0.18	Primary biliary cholangitis;	chr5:103273223	chr5:103032376~103033031:+
LUAD	cis	rs62355901	0.551	rs12659430	ENSG00000271828.1	CTD-2310F14.1	4.1	4.9e-05	0.00773	0.36	0.18	Breast cancer;	chr5:56736792	chr5:56927874~56929573:+
LUAD	cis	rs62355901	0.599	rs62355881	ENSG00000271828.1	CTD-2310F14.1	4.1	4.9e-05	0.00773	0.36	0.18	Breast cancer;	chr5:56737266	chr5:56927874~56929573:+
LUAD	cis	rs77688320	0.535	rs7575721	ENSG00000213090.2	AC007256.5	4.1	4.9e-05	0.00773	0.21	0.18	Breast cancer;	chr2:201392055	chr2:201410544~201413308:-
LUAD	cis	rs77688320	0.535	rs3815515	ENSG00000213090.2	AC007256.5	4.1	4.9e-05	0.00773	0.21	0.18	Breast cancer;	chr2:201393207	chr2:201410544~201413308:-
LUAD	cis	rs77688320	0.535	rs13001194	ENSG00000213090.2	AC007256.5	4.1	4.9e-05	0.00773	0.21	0.18	Breast cancer;	chr2:201396452	chr2:201410544~201413308:-
LUAD	cis	rs77688320	0.535	rs7571761	ENSG00000213090.2	AC007256.5	4.1	4.9e-05	0.00773	0.21	0.18	Breast cancer;	chr2:201396837	chr2:201410544~201413308:-
LUAD	cis	rs77688320	0.535	rs10931944	ENSG00000213090.2	AC007256.5	4.1	4.9e-05	0.00773	0.21	0.18	Breast cancer;	chr2:201398875	chr2:201410544~201413308:-
LUAD	cis	rs77688320	0.553	rs11681526	ENSG00000213090.2	AC007256.5	4.1	4.9e-05	0.00773	0.21	0.18	Breast cancer;	chr2:201399037	chr2:201410544~201413308:-
LUAD	cis	rs77688320	0.535	rs13022344	ENSG00000213090.2	AC007256.5	4.1	4.9e-05	0.00773	0.21	0.18	Breast cancer;	chr2:201399433	chr2:201410544~201413308:-
LUAD	cis	rs77688320	0.535	rs6732993	ENSG00000213090.2	AC007256.5	4.1	4.9e-05	0.00773	0.21	0.18	Breast cancer;	chr2:201399593	chr2:201410544~201413308:-
LUAD	cis	rs28386778	0.897	rs1877318	ENSG00000240280.5	TCAM1P	-4.1	4.9e-05	0.00773	-0.21	-0.18	Prudent dietary pattern;	chr17:63742600	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.897	rs8079818	ENSG00000240280.5	TCAM1P	-4.1	4.9e-05	0.00773	-0.21	-0.18	Prudent dietary pattern;	chr17:63747307	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.897	rs4638645	ENSG00000240280.5	TCAM1P	-4.1	4.9e-05	0.00773	-0.21	-0.18	Prudent dietary pattern;	chr17:63750989	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.805	rs9911714	ENSG00000240280.5	TCAM1P	-4.1	4.9e-05	0.00773	-0.21	-0.18	Prudent dietary pattern;	chr17:63751592	chr17:63849292~63864379:+
LUAD	cis	rs4934494	0.768	rs17125834	ENSG00000240996.1	RP11-80H5.7	-4.1	4.9e-05	0.00773	-0.26	-0.18	Red blood cell count;	chr10:89673405	chr10:89694295~89697928:-
LUAD	cis	rs4934494	0.768	rs12571918	ENSG00000240996.1	RP11-80H5.7	-4.1	4.9e-05	0.00773	-0.26	-0.18	Red blood cell count;	chr10:89674920	chr10:89694295~89697928:-
LUAD	cis	rs4934494	0.768	rs12776306	ENSG00000240996.1	RP11-80H5.7	-4.1	4.9e-05	0.00773	-0.26	-0.18	Red blood cell count;	chr10:89676300	chr10:89694295~89697928:-
LUAD	cis	rs4934494	0.768	rs7078321	ENSG00000240996.1	RP11-80H5.7	-4.1	4.9e-05	0.00773	-0.26	-0.18	Red blood cell count;	chr10:89678341	chr10:89694295~89697928:-
LUAD	cis	rs11673344	0.543	rs1818748	ENSG00000276846.1	CTD-3220F14.3	4.1	4.9e-05	0.00773	0.2	0.18	Obesity-related traits;	chr19:37065416	chr19:37314868~37315620:-
LUAD	cis	rs7572733	0.935	rs938929	ENSG00000222017.1	AC011997.1	-4.1	4.9e-05	0.00774	-0.23	-0.18	Dermatomyositis;	chr2:197916136	chr2:197693106~197774823:+
LUAD	cis	rs11742741	1	rs7722195	ENSG00000248874.4	C5orf17	-4.1	4.91e-05	0.00774	-0.23	-0.18	Educational attainment;	chr5:24173030	chr5:23951348~24178263:+
LUAD	cis	rs35740288	0.822	rs11629690	ENSG00000259407.1	RP11-158M2.3	-4.1	4.91e-05	0.00774	-0.19	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85744493	chr15:85744109~85750281:-
LUAD	cis	rs2274273	0.837	rs7146748	ENSG00000258413.1	RP11-665C16.6	-4.1	4.91e-05	0.00774	-0.23	-0.18	Protein biomarker;	chr14:55280368	chr14:55262767~55272075:-
LUAD	cis	rs7208859	0.673	rs9911989	ENSG00000266490.1	CTD-2349P21.9	-4.1	4.91e-05	0.00774	-0.28	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30792372~30792833:+
LUAD	cis	rs5771242	1	rs5771242	ENSG00000273253.2	RP3-402G11.26	-4.1	4.91e-05	0.00774	-0.19	-0.18	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);	chr22:50223440	chr22:50199090~50200837:-
LUAD	cis	rs2836974	0.583	rs2410124	ENSG00000232608.1	TIMM9P2	4.1	4.91e-05	0.00774	0.22	0.18	Cognitive function;	chr21:39332834	chr21:39216624~39217506:+
LUAD	cis	rs7121538	0.673	rs7942990	ENSG00000254418.1	RP11-21L19.1	4.1	4.91e-05	0.00774	0.31	0.18	HDL cholesterol;	chr11:14307132	chr11:14262846~14273691:-
LUAD	cis	rs7121538	0.673	rs16913823	ENSG00000254418.1	RP11-21L19.1	4.1	4.91e-05	0.00774	0.31	0.18	HDL cholesterol;	chr11:14321503	chr11:14262846~14273691:-
LUAD	cis	rs1023500	0.551	rs133371	ENSG00000205702.9	CYP2D7	4.1	4.91e-05	0.00774	0.15	0.18	Schizophrenia;	chr22:42069570	chr22:42140203~42144577:-
LUAD	cis	rs1023500	0.573	rs133374	ENSG00000205702.9	CYP2D7	4.1	4.91e-05	0.00774	0.15	0.18	Schizophrenia;	chr22:42069937	chr22:42140203~42144577:-
LUAD	cis	rs8141529	0.719	rs6005916	ENSG00000272858.1	CTA-292E10.8	-4.1	4.91e-05	0.00774	-0.21	-0.18	Lymphocyte counts;	chr22:28837354	chr22:28814914~28815662:+
LUAD	cis	rs5758659	0.652	rs133313	ENSG00000182057.4	OGFRP1	4.1	4.91e-05	0.00774	0.22	0.18	Cognitive function;	chr22:42005745	chr22:42269753~42275196:+
LUAD	cis	rs5758659	0.652	rs133314	ENSG00000182057.4	OGFRP1	4.1	4.91e-05	0.00774	0.22	0.18	Cognitive function;	chr22:42005837	chr22:42269753~42275196:+
LUAD	cis	rs5015933	0.815	rs937482	ENSG00000232630.1	PRPS1P2	-4.1	4.91e-05	0.00774	-0.17	-0.18	Body mass index;	chr9:125354538	chr9:125150653~125151589:+
LUAD	cis	rs9907295	0.584	rs9913559	ENSG00000270977.1	AC015849.16	-4.1	4.91e-05	0.00775	-0.3	-0.18	Fibroblast growth factor basic levels;	chr17:35930065	chr17:35893707~35911023:-
LUAD	cis	rs6683071	0.557	rs4240934	ENSG00000272750.1	RP11-378J18.8	4.1	4.91e-05	0.00775	0.26	0.18	Cognitive performance;	chr1:222730956	chr1:222658867~222661512:-
LUAD	cis	rs62025270	0.632	rs17636096	ENSG00000259416.2	RP11-158M2.5	-4.1	4.91e-05	0.00775	-0.25	-0.18	Idiopathic pulmonary fibrosis;	chr15:85675503	chr15:85754941~85756237:-
LUAD	cis	rs6570726	0.902	rs9390326	ENSG00000235652.6	RP11-545I5.3	-4.1	4.91e-05	0.00775	-0.18	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145470086	chr6:145799409~145886585:+
LUAD	cis	rs454217	0.846	rs1661029	ENSG00000277851.1	RP11-756G20.1	4.1	4.92e-05	0.00775	0.19	0.18	Smoking quantity;	chr12:92324197	chr12:92247756~92363832:-
LUAD	cis	rs8073060	0.66	rs34184070	ENSG00000267592.1	CTC-507E2.2	4.1	4.92e-05	0.00775	0.26	0.18	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35676791	chr17:35596904~35597128:-
LUAD	cis	rs8073060	0.66	rs58266733	ENSG00000267592.1	CTC-507E2.2	4.1	4.92e-05	0.00775	0.26	0.18	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35676793	chr17:35596904~35597128:-
LUAD	cis	rs8073060	0.545	rs3859282	ENSG00000267592.1	CTC-507E2.2	4.1	4.92e-05	0.00775	0.26	0.18	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35679092	chr17:35596904~35597128:-
LUAD	cis	rs8073060	0.559	rs10438814	ENSG00000267592.1	CTC-507E2.2	4.1	4.92e-05	0.00775	0.26	0.18	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35680046	chr17:35596904~35597128:-
LUAD	cis	rs2274273	0.84	rs7159144	ENSG00000258413.1	RP11-665C16.6	-4.1	4.92e-05	0.00775	-0.23	-0.18	Protein biomarker;	chr14:55354606	chr14:55262767~55272075:-
LUAD	cis	rs706293	0.512	rs31918	ENSG00000261360.1	CTD-2165H16.4	-4.1	4.92e-05	0.00775	-0.17	-0.18	Urate levels (BMI interaction);	chr5:14820818	chr5:14661808~14664604:-
LUAD	cis	rs3018712	0.59	rs2513304	ENSG00000227620.4	ALG1L8P	-4.1	4.92e-05	0.00775	-0.25	-0.18	Total body bone mineral density;	chr11:68693677	chr11:67785273~67792335:+
LUAD	cis	rs4374383	0.884	rs4353657	ENSG00000207383.1	Y_RNA	4.1	4.92e-05	0.00775	0.22	0.18	Hepatitis C induced liver fibrosis;	chr2:112003367	chr2:112579484~112579584:-
LUAD	cis	rs4474465	1	rs7121283	ENSG00000251323.2	RP11-452H21.4	4.1	4.92e-05	0.00776	0.22	0.18	Alzheimer's disease (survival time);	chr11:78438294	chr11:78423982~78429836:-
LUAD	cis	rs523522	0.962	rs4767903	ENSG00000278344.1	RP11-18C24.8	4.1	4.92e-05	0.00776	0.25	0.18	High light scatter reticulocyte count;	chr12:120492243	chr12:120500735~120501090:-
LUAD	cis	rs12073837	0.5	rs11118610	ENSG00000238078.1	LINC01352	-4.1	4.92e-05	0.00776	-0.2	-0.18	F-cell distribution;	chr1:220816744	chr1:220829255~220832429:+
LUAD	cis	rs1113500	0.787	rs2336126	ENSG00000226822.1	RP11-356N1.2	4.1	4.92e-05	0.00776	0.21	0.18	Growth-regulated protein alpha levels;	chr1:108098283	chr1:108071482~108074519:+
LUAD	cis	rs8177876	0.822	rs7203546	ENSG00000261061.1	RP11-303E16.2	4.1	4.92e-05	0.00776	0.27	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083317	chr16:81030770~81031485:+
LUAD	cis	rs7829975	0.533	rs13274028	ENSG00000173295.6	FAM86B3P	4.1	4.92e-05	0.00776	0.2	0.18	Mood instability;	chr8:8871683	chr8:8228595~8244865:+
LUAD	cis	rs13276960	0.794	rs7833563	ENSG00000253328.2	SUMO2P19	-4.1	4.92e-05	0.00776	-0.21	-0.18	Schizophrenia;	chr8:102932406	chr8:102242040~102242619:-
LUAD	cis	rs4374383	0.884	rs11690939	ENSG00000207383.1	Y_RNA	-4.1	4.92e-05	0.00776	-0.22	-0.18	Hepatitis C induced liver fibrosis;	chr2:111999848	chr2:112579484~112579584:-
LUAD	cis	rs4474465	0.833	rs11606128	ENSG00000251323.2	RP11-452H21.4	4.1	4.92e-05	0.00776	0.22	0.18	Alzheimer's disease (survival time);	chr11:78445914	chr11:78423982~78429836:-
LUAD	cis	rs763567	0.935	rs580487	ENSG00000271811.1	RP1-79C4.4	4.1	4.92e-05	0.00776	0.22	0.18	Tonsillectomy;	chr1:170640484	chr1:170667381~170669425:+
LUAD	cis	rs5015933	0.705	rs13288223	ENSG00000232630.1	PRPS1P2	-4.1	4.93e-05	0.00776	-0.17	-0.18	Body mass index;	chr9:125335388	chr9:125150653~125151589:+
LUAD	cis	rs5758659	0.652	rs4822084	ENSG00000227370.1	RP4-669P10.19	4.1	4.93e-05	0.00777	0.17	0.18	Cognitive function;	chr22:42039864	chr22:42132543~42132998:+
LUAD	cis	rs9921222	0.786	rs3848365	ENSG00000236829.8	Z97634.3	4.1	4.93e-05	0.00777	0.22	0.18	Bone mineral density (spine);Bone mineral density;	chr16:324617	chr16:382097~392960:+
LUAD	cis	rs4664293	0.836	rs2556102	ENSG00000226266.5	AC009961.3	-4.1	4.93e-05	0.00777	-0.26	-0.18	Monocyte percentage of white cells;	chr2:159798611	chr2:159670708~159712435:-
LUAD	cis	rs763121	0.853	rs4821811	ENSG00000228274.3	RP3-508I15.9	-4.1	4.93e-05	0.00777	-0.18	-0.18	Menopause (age at onset);	chr22:38679140	chr22:38667585~38681820:-
LUAD	cis	rs763121	0.853	rs3827357	ENSG00000228274.3	RP3-508I15.9	-4.1	4.93e-05	0.00777	-0.18	-0.18	Menopause (age at onset);	chr22:38683408	chr22:38667585~38681820:-
LUAD	cis	rs9341808	0.556	rs10455370	ENSG00000260645.1	RP11-250B2.5	-4.1	4.93e-05	0.00777	-0.17	-0.18	Sitting height ratio;	chr6:80331150	chr6:80466958~80469080:+
LUAD	cis	rs1075265	0.587	rs2542585	ENSG00000272156.1	RP11-477N3.1	-4.1	4.93e-05	0.00777	-0.22	-0.18	Chronotype;Morning vs. evening chronotype;	chr2:53786407	chr2:54082554~54085066:+
LUAD	cis	rs8177876	0.658	rs2911158	ENSG00000261061.1	RP11-303E16.2	4.1	4.93e-05	0.00777	0.25	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81057652	chr16:81030770~81031485:+
LUAD	cis	rs7617773	0.78	rs13066044	ENSG00000199476.1	Y_RNA	-4.1	4.93e-05	0.00777	-0.25	-0.18	Coronary artery disease;	chr3:48335786	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.78	rs11716848	ENSG00000199476.1	Y_RNA	-4.1	4.93e-05	0.00777	-0.25	-0.18	Coronary artery disease;	chr3:48337010	chr3:48288587~48288694:+
LUAD	cis	rs2732480	0.577	rs2634693	ENSG00000257763.1	OR5BK1P	4.1	4.93e-05	0.00777	0.2	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48312715	chr12:48355792~48356614:-
LUAD	cis	rs4819052	0.918	rs34886433	ENSG00000237664.1	LINC00316	-4.1	4.93e-05	0.00777	-0.24	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260623	chr21:45338590~45341990:-
LUAD	cis	rs6142102	0.961	rs1555075	ENSG00000275784.1	RP5-1125A11.6	-4.1	4.93e-05	0.00777	-0.21	-0.18	Skin pigmentation;	chr20:34022595	chr20:33989480~33991818:-
LUAD	cis	rs6687758	0.645	rs949618	ENSG00000227925.1	RP11-191N8.2	4.1	4.94e-05	0.00778	0.24	0.18	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221940598	chr1:221827666~221840666:-
LUAD	cis	rs2836974	0.796	rs77153312	ENSG00000232608.1	TIMM9P2	-4.1	4.94e-05	0.00778	-0.22	-0.18	Cognitive function;	chr21:39323573	chr21:39216624~39217506:+
LUAD	cis	rs2243480	0.803	rs36127118	ENSG00000229886.1	RP5-1132H15.3	4.1	4.94e-05	0.00778	0.31	0.18	Diabetic kidney disease;	chr7:66100518	chr7:66025126~66031544:-
LUAD	cis	rs77688320	0.535	rs2241118	ENSG00000213090.2	AC007256.5	4.1	4.94e-05	0.00778	0.21	0.18	Breast cancer;	chr2:201388993	chr2:201410544~201413308:-
LUAD	cis	rs62025270	0.688	rs11073516	ENSG00000202081.1	RNU6-1280P	-4.1	4.94e-05	0.00778	-0.27	-0.18	Idiopathic pulmonary fibrosis;	chr15:85741996	chr15:85651522~85651628:-
LUAD	cis	rs4554975	0.514	rs10881009	ENSG00000274723.1	RP11-618L22.1	-4.1	4.94e-05	0.00778	-0.22	-0.18	Metabolite levels (small molecules and protein measures);	chr12:46906861	chr12:46970504~46972155:+
LUAD	cis	rs9309473	0.519	rs2421583	ENSG00000163016.8	ALMS1P	-4.1	4.94e-05	0.00778	-0.2	-0.18	Metabolite levels;	chr2:73671658	chr2:73644919~73685576:+
LUAD	cis	rs4948102	0.551	rs4275190	ENSG00000275875.1	RP11-613E4.5	-4.1	4.94e-05	0.00778	-0.2	-0.18	Plasma homocysteine levels (post-methionine load test);	chr7:56036695	chr7:55741525~55741869:+
LUAD	cis	rs2274273	0.87	rs61210954	ENSG00000259318.1	RP11-454L9.2	4.1	4.94e-05	0.00778	0.16	0.18	Protein biomarker;	chr14:55298684	chr14:55394940~55395233:-
LUAD	cis	rs865483	0.895	rs4795203	ENSG00000276054.1	RP11-378E13.3	4.1	4.94e-05	0.00778	0.22	0.18	Monocyte count;	chr17:37468868	chr17:37386886~37387926:+
LUAD	cis	rs34783982	0.748	rs12438134	ENSG00000261441.1	RP11-217B1.2	-4.1	4.94e-05	0.00779	-0.24	-0.18	Squamous cell lung carcinoma;	chr15:88944287	chr15:89335053~89336161:+
LUAD	cis	rs7637701	0.967	rs9837038	ENSG00000240875.4	LINC00886	4.1	4.94e-05	0.00779	0.2	0.18	Breast cancer;	chr3:156850680	chr3:156747346~156817062:-
LUAD	cis	rs11051970	0.918	rs325417	ENSG00000274964.1	RP11-817I4.1	-4.1	4.94e-05	0.00779	-0.2	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr12:32421283	chr12:32339368~32340724:+
LUAD	cis	rs12935418	0.616	rs2602453	ENSG00000261061.1	RP11-303E16.2	4.1	4.94e-05	0.00779	0.19	0.18	Mean corpuscular volume;	chr16:80994358	chr16:81030770~81031485:+
LUAD	cis	rs7189233	1	rs62048544	ENSG00000279344.1	RP11-44F14.7	4.1	4.94e-05	0.00779	0.16	0.18	Intelligence (multi-trait analysis);	chr16:53503829	chr16:53478957~53481550:-
LUAD	cis	rs7204230	1	rs62048031	ENSG00000261291.1	RP11-295M3.2	4.1	4.94e-05	0.00779	0.23	0.18	Fibrinogen;	chr16:53180652	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs11863925	ENSG00000261291.1	RP11-295M3.2	4.1	4.94e-05	0.00779	0.23	0.18	Fibrinogen;	chr16:53181366	chr16:53168522~53169450:+
LUAD	cis	rs7204230	0.921	rs58988553	ENSG00000261291.1	RP11-295M3.2	4.1	4.94e-05	0.00779	0.23	0.18	Fibrinogen;	chr16:53188058	chr16:53168522~53169450:+
LUAD	cis	rs7204230	0.96	rs7205763	ENSG00000261291.1	RP11-295M3.2	4.1	4.94e-05	0.00779	0.23	0.18	Fibrinogen;	chr16:53189538	chr16:53168522~53169450:+
LUAD	cis	rs6921919	0.832	rs17312661	ENSG00000216901.1	AL022393.7	4.1	4.94e-05	0.00779	0.29	0.18	Autism spectrum disorder or schizophrenia;	chr6:28332559	chr6:28176188~28176674:+
LUAD	cis	rs6142102	0.961	rs4911401	ENSG00000275784.1	RP5-1125A11.6	-4.1	4.95e-05	0.00779	-0.21	-0.18	Skin pigmentation;	chr20:34066756	chr20:33989480~33991818:-
LUAD	cis	rs6142102	0.961	rs6088355	ENSG00000275784.1	RP5-1125A11.6	-4.1	4.95e-05	0.00779	-0.2	-0.18	Skin pigmentation;	chr20:33958081	chr20:33989480~33991818:-
LUAD	cis	rs6142102	0.961	rs6057957	ENSG00000275784.1	RP5-1125A11.6	-4.1	4.95e-05	0.00779	-0.2	-0.18	Skin pigmentation;	chr20:33962052	chr20:33989480~33991818:-
LUAD	cis	rs2657294	0.895	rs3088142	ENSG00000233313.2	HMGA1P5	-4.1	4.95e-05	0.00779	-0.23	-0.18	Pneumonia;	chr10:75094806	chr10:75276376~75276646:-
LUAD	cis	rs73198271	0.74	rs10092720	ENSG00000253893.2	FAM85B	4.1	4.95e-05	0.0078	0.24	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8791607	chr8:8167819~8226614:-
LUAD	cis	rs12446632	0.882	rs72771023	ENSG00000261195.1	CTD-2380F24.1	-4.1	4.95e-05	0.0078	-0.28	-0.18	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Menarche (age at onset);Obesity;Childhood body mass index;Waist circumference;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr16:19881243	chr16:19761172~19766099:-
LUAD	cis	rs8028182	0.636	rs7163907	ENSG00000260269.4	CTD-2323K18.1	-4.1	4.95e-05	0.0078	-0.26	-0.18	Sudden cardiac arrest;	chr15:75552756	chr15:75527150~75601205:-
LUAD	cis	rs34779708	0.966	rs878264	ENSG00000271335.4	RP11-324I22.4	4.09	4.95e-05	0.0078	0.19	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35151653	chr10:35314552~35336401:-
LUAD	cis	rs6570726	0.905	rs1355146	ENSG00000235652.6	RP11-545I5.3	-4.09	4.95e-05	0.0078	-0.18	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145460605	chr6:145799409~145886585:+
LUAD	cis	rs4554975	0.514	rs7963326	ENSG00000274723.1	RP11-618L22.1	-4.09	4.95e-05	0.0078	-0.22	-0.18	Metabolite levels (small molecules and protein measures);	chr12:46908278	chr12:46970504~46972155:+
LUAD	cis	rs4763879	0.634	rs12424826	ENSG00000278635.1	CTD-2318O12.1	4.09	4.95e-05	0.0078	0.16	0.18	Type 1 diabetes;	chr12:9701981	chr12:9415641~9416718:+
LUAD	cis	rs77688320	0.553	rs6761777	ENSG00000213090.2	AC007256.5	4.09	4.96e-05	0.0078	0.21	0.18	Breast cancer;	chr2:201399879	chr2:201410544~201413308:-
LUAD	cis	rs2153535	0.518	rs9392227	ENSG00000230939.1	RP11-314C16.1	-4.09	4.96e-05	0.00781	-0.22	-0.18	Motion sickness;	chr6:8581553	chr6:8784178~8785445:+
LUAD	cis	rs6088580	0.634	rs1205334	ENSG00000276073.1	RP5-1125A11.7	4.09	4.96e-05	0.00781	0.18	0.18	Glomerular filtration rate (creatinine);	chr20:34342563	chr20:33985617~33988989:-
LUAD	cis	rs8030379	1	rs1564474	ENSG00000230373.7	GOLGA6L5P	-4.09	4.96e-05	0.00781	-0.17	-0.18	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83901281	chr15:84507885~84516814:-
LUAD	cis	rs8030379	1	rs10152119	ENSG00000230373.7	GOLGA6L5P	-4.09	4.96e-05	0.00781	-0.17	-0.18	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83901629	chr15:84507885~84516814:-
LUAD	cis	rs8030379	1	rs1471552	ENSG00000230373.7	GOLGA6L5P	-4.09	4.96e-05	0.00781	-0.17	-0.18	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83901982	chr15:84507885~84516814:-
LUAD	cis	rs8030379	1	rs1471553	ENSG00000230373.7	GOLGA6L5P	-4.09	4.96e-05	0.00781	-0.17	-0.18	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83902286	chr15:84507885~84516814:-
LUAD	cis	rs2243480	0.803	rs35480979	ENSG00000232559.3	GS1-124K5.12	4.09	4.96e-05	0.00781	0.32	0.18	Diabetic kidney disease;	chr7:65892097	chr7:66554588~66576923:-
LUAD	cis	rs780096	0.506	rs56076827	ENSG00000234072.1	AC074117.10	-4.09	4.96e-05	0.00781	-0.14	-0.18	Total body bone mineral density;	chr2:27453420	chr2:27356246~27367622:+
LUAD	cis	rs4843747	0.671	rs28465438	ENSG00000205037.2	RP11-863P13.4	4.09	4.96e-05	0.00781	0.26	0.18	Menopause (age at onset);	chr16:88070108	chr16:88088041~88100985:-
LUAD	cis	rs3177980	0.639	rs12064636	ENSG00000239494.2	RN7SL333P	-4.09	4.96e-05	0.00781	-0.18	-0.18	Amyotrophic lateral sclerosis;	chr1:169838480	chr1:169859756~169860052:+
LUAD	cis	rs8073060	0.544	rs225252	ENSG00000267592.1	CTC-507E2.2	4.09	4.96e-05	0.00781	0.27	0.18	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35625382	chr17:35596904~35597128:-
LUAD	cis	rs6479901	0.639	rs10995450	ENSG00000232075.1	MRPL35P2	4.09	4.96e-05	0.00781	0.26	0.18	Intelligence (multi-trait analysis);	chr10:63129151	chr10:63634317~63634827:-
LUAD	cis	rs9815354	0.857	rs9816772	ENSG00000273328.4	RP11-141M3.6	-4.09	4.96e-05	0.00781	-0.27	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41831385	chr3:42809414~42908105:+
LUAD	cis	rs4660214	0.568	rs967530	ENSG00000228060.1	RP11-69E11.8	4.09	4.96e-05	0.00782	0.17	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39130465	chr1:39565160~39573203:+
LUAD	cis	rs9341808	0.718	rs2874829	ENSG00000260645.1	RP11-250B2.5	4.09	4.97e-05	0.00782	0.17	0.18	Sitting height ratio;	chr6:80146380	chr6:80466958~80469080:+
LUAD	cis	rs9649213	0.593	rs56286037	ENSG00000272950.1	RP11-307C18.1	4.09	4.97e-05	0.00782	0.23	0.18	Prostate cancer (SNP x SNP interaction);	chr7:98390210	chr7:98322853~98323430:+
LUAD	cis	rs3742264	1	rs9567614	ENSG00000235903.6	CPB2-AS1	-4.09	4.97e-05	0.00782	-0.23	-0.18	Blood protein levels;	chr13:46075318	chr13:46052806~46113332:+
LUAD	cis	rs4873772	0.743	rs4873529	ENSG00000253330.1	RP11-697N18.3	-4.09	4.97e-05	0.00782	-0.21	-0.18	Lobe attachment (rater-scored or self-reported);	chr8:47653224	chr8:47511034~47512141:-
LUAD	cis	rs1005277	0.505	rs7069702	ENSG00000273019.1	RP11-508N22.13	4.09	4.97e-05	0.00782	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:37958431	chr10:38149968~38150293:+
LUAD	cis	rs17767294	0.803	rs59701161	ENSG00000280107.1	AL022393.9	-4.09	4.97e-05	0.00782	-0.46	-0.18	Parkinson's disease;	chr6:27678338	chr6:28170845~28172521:+
LUAD	cis	rs4474465	1	rs7935292	ENSG00000251323.2	RP11-452H21.4	4.09	4.97e-05	0.00782	0.23	0.18	Alzheimer's disease (survival time);	chr11:78458839	chr11:78423982~78429836:-
LUAD	cis	rs2354432	0.607	rs11587707	ENSG00000226015.2	CCT8P1	4.09	4.97e-05	0.00782	0.37	0.18	Mitochondrial DNA levels;	chr1:147235538	chr1:147203276~147204932:-
LUAD	cis	rs2823962	1	rs7277443	ENSG00000270093.1	AP000473.8	-4.09	4.97e-05	0.00782	-0.19	-0.18	Amyotrophic lateral sclerosis;	chr21:16673559	chr21:16643529~16645065:+
LUAD	cis	rs2823962	1	rs7281422	ENSG00000270093.1	AP000473.8	-4.09	4.97e-05	0.00782	-0.19	-0.18	Amyotrophic lateral sclerosis;	chr21:16673813	chr21:16643529~16645065:+
LUAD	cis	rs9894429	1	rs4074916	ENSG00000263853.1	AC139530.1	4.09	4.97e-05	0.00782	0.18	0.18	Eye color traits;	chr17:81612222	chr17:81676001~81676086:+
LUAD	cis	rs4713118	0.869	rs9468214	ENSG00000280107.1	AL022393.9	-4.09	4.97e-05	0.00782	-0.23	-0.18	Parkinson's disease;	chr6:27745520	chr6:28170845~28172521:+
LUAD	cis	rs11971779	0.941	rs7800795	ENSG00000273391.1	RP11-634H22.1	4.09	4.97e-05	0.00783	0.22	0.18	Diisocyanate-induced asthma;	chr7:139395602	chr7:139359032~139359566:-
LUAD	cis	rs2732480	0.5	rs12829841	ENSG00000240399.1	RP1-228P16.1	4.09	4.97e-05	0.00783	0.19	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48234956	chr12:48054813~48055591:-
LUAD	cis	rs2732480	0.523	rs34286639	ENSG00000240399.1	RP1-228P16.1	4.09	4.97e-05	0.00783	0.19	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48235261	chr12:48054813~48055591:-
LUAD	cis	rs1387259	0.929	rs11168484	ENSG00000240399.1	RP1-228P16.1	4.09	4.97e-05	0.00783	0.19	0.18	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48239806	chr12:48054813~48055591:-
LUAD	cis	rs4873772	0.735	rs4873368	ENSG00000253330.1	RP11-697N18.3	-4.09	4.97e-05	0.00783	-0.21	-0.18	Lobe attachment (rater-scored or self-reported);	chr8:47495279	chr8:47511034~47512141:-
LUAD	cis	rs35740288	0.77	rs745191	ENSG00000259407.1	RP11-158M2.3	-4.09	4.98e-05	0.00783	-0.18	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85579939	chr15:85744109~85750281:-
LUAD	cis	rs5758659	0.652	rs133321	ENSG00000182057.4	OGFRP1	4.09	4.98e-05	0.00783	0.22	0.18	Cognitive function;	chr22:42009318	chr22:42269753~42275196:+
LUAD	cis	rs5758659	0.652	rs133324	ENSG00000182057.4	OGFRP1	4.09	4.98e-05	0.00783	0.22	0.18	Cognitive function;	chr22:42010367	chr22:42269753~42275196:+
LUAD	cis	rs5758659	0.652	rs133330	ENSG00000182057.4	OGFRP1	4.09	4.98e-05	0.00783	0.22	0.18	Cognitive function;	chr22:42013452	chr22:42269753~42275196:+
LUAD	cis	rs763121	0.853	rs5757232	ENSG00000228274.3	RP3-508I15.9	-4.09	4.98e-05	0.00783	-0.18	-0.18	Menopause (age at onset);	chr22:38675672	chr22:38667585~38681820:-
LUAD	cis	rs763121	0.853	rs9306329	ENSG00000228274.3	RP3-508I15.9	-4.09	4.98e-05	0.00783	-0.18	-0.18	Menopause (age at onset);	chr22:38676449	chr22:38667585~38681820:-
LUAD	cis	rs763121	0.853	rs5750662	ENSG00000228274.3	RP3-508I15.9	-4.09	4.98e-05	0.00783	-0.18	-0.18	Menopause (age at onset);	chr22:38676467	chr22:38667585~38681820:-
LUAD	cis	rs6688613	0.694	rs12062326	ENSG00000225171.2	DUTP6	-4.09	4.98e-05	0.00783	-0.23	-0.18	Refractive astigmatism;	chr1:166850949	chr1:166868748~166869209:+
LUAD	cis	rs4907240	0.921	rs2278563	ENSG00000237510.6	AC008268.2	-4.09	4.98e-05	0.00783	-0.26	-0.18	Event-related brain oscillations;	chr2:96546956	chr2:95789654~95800166:+
LUAD	cis	rs11009175	0.929	rs10430560	ENSG00000273038.2	RP11-479G22.8	-4.09	4.98e-05	0.00784	-0.3	-0.18	Depression (quantitative trait);	chr10:33051403	chr10:32887255~32889311:-
LUAD	cis	rs6125597	0.805	rs6063382	ENSG00000230758.1	SNAP23P	4.09	4.98e-05	0.00784	0.19	0.18	Intelligence (multi-trait analysis);	chr20:49273421	chr20:49038357~49038602:-
LUAD	cis	rs2836974	0.623	rs34240248	ENSG00000232608.1	TIMM9P2	4.09	4.98e-05	0.00784	0.22	0.18	Cognitive function;	chr21:39313313	chr21:39216624~39217506:+
LUAD	cis	rs7100689	0.56	rs10887891	ENSG00000226659.1	RP11-137H2.4	-4.09	4.98e-05	0.00784	-0.25	-0.18	Post bronchodilator FEV1;	chr10:80447961	chr10:80529597~80535942:-
LUAD	cis	rs7590268	0.606	rs11124932	ENSG00000279873.2	LINC01126	4.09	4.98e-05	0.00784	0.18	0.18	Orofacial clefts;	chr2:43418659	chr2:43227210~43228855:+
LUAD	cis	rs11089937	0.524	rs2877021	ENSG00000211640.3	IGLV6-57	4.09	4.98e-05	0.00784	0.13	0.18	Periodontitis (PAL4Q3);	chr22:22165909	chr22:22195713~22196460:+
LUAD	cis	rs5751168	0.736	rs5751179	ENSG00000211654.2	IGLV5-37	4.09	4.98e-05	0.00784	0.25	0.18	Prostate cancer (SNP x SNP interaction);	chr22:22499665	chr22:22427540~22428035:+
LUAD	cis	rs17685	0.632	rs1859793	ENSG00000280388.1	RP11-229D13.3	-4.09	4.99e-05	0.00784	-0.18	-0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76191965	chr7:76043977~76045963:-
LUAD	cis	rs1044826	1	rs3772877	ENSG00000214280.3	RP11-553K23.2	-4.09	4.99e-05	0.00784	-0.22	-0.18	Obesity-related traits;	chr3:139468784	chr3:139582928~139583593:-
LUAD	cis	rs801193	0.569	rs35070132	ENSG00000106610.13	STAG3L4	-4.09	4.99e-05	0.00785	-0.23	-0.18	Aortic root size;	chr7:66773096	chr7:67302621~67321526:+
LUAD	cis	rs2179367	0.959	rs9373589	ENSG00000216906.2	RP11-350J20.9	4.09	4.99e-05	0.00785	0.22	0.18	Dupuytren's disease;	chr6:149386152	chr6:149904243~149906418:+
LUAD	cis	rs865483	0.86	rs853228	ENSG00000276054.1	RP11-378E13.3	4.09	4.99e-05	0.00785	0.22	0.18	Monocyte count;	chr17:37439788	chr17:37386886~37387926:+
LUAD	cis	rs865483	0.895	rs853229	ENSG00000276054.1	RP11-378E13.3	4.09	4.99e-05	0.00785	0.22	0.18	Monocyte count;	chr17:37440818	chr17:37386886~37387926:+
LUAD	cis	rs4578769	0.55	rs930909	ENSG00000265943.1	RP11-739L10.1	4.09	4.99e-05	0.00785	0.23	0.18	Eosinophil percentage of white cells;	chr18:22976361	chr18:22699481~22933764:-
LUAD	cis	rs17345786	0.511	rs12639028	ENSG00000244119.1	PDCL3P4	4.09	4.99e-05	0.00785	0.19	0.18	Colonoscopy-negative controls vs population controls;	chr3:101627189	chr3:101712472~101713191:+
LUAD	cis	rs6964587	0.967	rs12538325	ENSG00000188693.7	CYP51A1-AS1	-4.09	4.99e-05	0.00785	-0.22	-0.18	Breast cancer;	chr7:92128165	chr7:92134604~92180725:+
LUAD	cis	rs7590268	0.789	rs34023310	ENSG00000279873.2	LINC01126	4.09	4.99e-05	0.00785	0.18	0.18	Orofacial clefts;	chr2:43405096	chr2:43227210~43228855:+
LUAD	cis	rs6531209	0.817	rs6531210	ENSG00000234378.1	AC098828.2	4.09	4.99e-05	0.00785	0.23	0.18	Amyotrophic lateral sclerosis (sporadic);	chr2:20138013	chr2:20063856~20106829:-
LUAD	cis	rs6531209	0.817	rs6531211	ENSG00000234378.1	AC098828.2	4.09	4.99e-05	0.00785	0.23	0.18	Amyotrophic lateral sclerosis (sporadic);	chr2:20138015	chr2:20063856~20106829:-
LUAD	cis	rs950169	0.92	rs2135551	ENSG00000275120.1	RP11-182J1.17	4.09	4.99e-05	0.00786	0.29	0.18	Schizophrenia;	chr15:84039099	chr15:84599434~84606463:-
LUAD	cis	rs7551222	0.752	rs4252677	ENSG00000240219.1	RP11-430C7.5	4.09	5e-05	0.00786	0.19	0.18	Schizophrenia;	chr1:204526125	chr1:204626775~204629712:+
LUAD	cis	rs7551222	0.752	rs4252685	ENSG00000240219.1	RP11-430C7.5	4.09	5e-05	0.00786	0.19	0.18	Schizophrenia;	chr1:204527728	chr1:204626775~204629712:+
LUAD	cis	rs7551222	0.681	rs4252686	ENSG00000240219.1	RP11-430C7.5	4.09	5e-05	0.00786	0.19	0.18	Schizophrenia;	chr1:204527767	chr1:204626775~204629712:+
LUAD	cis	rs2281636	0.754	rs7092699	ENSG00000233690.1	EBAG9P1	4.09	5e-05	0.00786	0.18	0.18	Obesity-related traits;	chr10:99605545	chr10:99697407~99697949:-
LUAD	cis	rs9860428	0.815	rs9865066	ENSG00000242770.2	RP11-180K7.1	4.09	5e-05	0.00786	0.2	0.18	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112858647	chr3:112802478~112812819:+
LUAD	cis	rs9860428	0.844	rs10934196	ENSG00000242770.2	RP11-180K7.1	4.09	5e-05	0.00786	0.2	0.18	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112861497	chr3:112802478~112812819:+
LUAD	cis	rs9860428	0.844	rs10154832	ENSG00000242770.2	RP11-180K7.1	4.09	5e-05	0.00786	0.2	0.18	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112862041	chr3:112802478~112812819:+
LUAD	cis	rs9860428	0.76	rs9816107	ENSG00000242770.2	RP11-180K7.1	4.09	5e-05	0.00786	0.2	0.18	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112863436	chr3:112802478~112812819:+
LUAD	cis	rs9860428	0.733	rs9816110	ENSG00000242770.2	RP11-180K7.1	4.09	5e-05	0.00786	0.2	0.18	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112863437	chr3:112802478~112812819:+
LUAD	cis	rs9860428	0.844	rs6782188	ENSG00000242770.2	RP11-180K7.1	4.09	5e-05	0.00786	0.2	0.18	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112864592	chr3:112802478~112812819:+
LUAD	cis	rs9549260	0.755	rs9532579	ENSG00000229456.1	RLIMP1	4.09	5e-05	0.00786	0.2	0.18	Red blood cell count;	chr13:40669321	chr13:40618738~40621348:+
LUAD	cis	rs138249	0.523	rs138229	ENSG00000273253.2	RP3-402G11.26	-4.09	5e-05	0.00786	-0.16	-0.18	Gestational age at birth in labor-initiated deliveries (child effect);	chr22:50118978	chr22:50199090~50200837:-
LUAD	cis	rs9322193	0.607	rs9322229	ENSG00000268592.3	RAET1E-AS1	4.09	5e-05	0.00786	0.26	0.18	Lung cancer;	chr6:149908949	chr6:149863494~149919507:+
LUAD	cis	rs35740288	0.73	rs12913266	ENSG00000259407.1	RP11-158M2.3	4.09	5e-05	0.00786	0.17	0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85750878	chr15:85744109~85750281:-
LUAD	cis	rs17301013	0.729	rs12094143	ENSG00000227373.4	RP11-160H22.5	4.09	5e-05	0.00786	0.23	0.18	Systemic lupus erythematosus;	chr1:174511986	chr1:174115300~174160004:-
LUAD	cis	rs76878669	0.561	rs6591215	ENSG00000213409.4	RP11-658F2.3	-4.09	5e-05	0.00786	-0.22	-0.18	Educational attainment (years of education);	chr11:66403140	chr11:66761575~66762399:-
LUAD	cis	rs11009175	0.547	rs12256126	ENSG00000273038.2	RP11-479G22.8	4.09	5e-05	0.00786	0.22	0.18	Depression (quantitative trait);	chr10:33106704	chr10:32887255~32889311:-
LUAD	cis	rs35740288	0.77	rs11630112	ENSG00000259407.1	RP11-158M2.3	-4.09	5e-05	0.00787	-0.18	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85577015	chr15:85744109~85750281:-
LUAD	cis	rs12681963	0.748	rs10097721	ENSG00000272375.1	RP11-51J9.6	-4.09	5e-05	0.00787	-0.25	-0.18	Migraine;	chr8:30034609	chr8:30197404~30198048:+
LUAD	cis	rs12681963	0.748	rs10954816	ENSG00000272375.1	RP11-51J9.6	-4.09	5e-05	0.00787	-0.25	-0.18	Migraine;	chr8:30035078	chr8:30197404~30198048:+
LUAD	cis	rs10129255	0.957	rs12590735	ENSG00000211947.2	IGHV3-21	-4.09	5e-05	0.00787	-0.12	-0.18	Kawasaki disease;	chr14:106779660	chr14:106235064~106235594:-
LUAD	cis	rs4835473	0.932	rs12503900	ENSG00000249741.2	RP11-673E1.3	4.09	5e-05	0.00787	0.22	0.18	Immature fraction of reticulocytes;	chr4:143812459	chr4:143911514~143912053:-
LUAD	cis	rs6095360	0.727	rs17448715	ENSG00000222365.1	SNORD12B	-4.09	5e-05	0.00787	-0.21	-0.18	Intelligence (multi-trait analysis);	chr20:49075206	chr20:49280319~49280409:+
LUAD	cis	rs7061710	0.789	rs6608453	ENSG00000271811.1	RP1-79C4.4	-4.09	5e-05	0.00787	-0.26	-0.18	Blood metabolite levels;	chr1:171148001	chr1:170667381~170669425:+
LUAD	cis	rs7061710	0.871	rs6608454	ENSG00000271811.1	RP1-79C4.4	-4.09	5e-05	0.00787	-0.26	-0.18	Blood metabolite levels;	chr1:171148031	chr1:170667381~170669425:+
LUAD	cis	rs301901	0.793	rs11750212	ENSG00000250155.1	CTD-2353F22.1	4.09	5e-05	0.00787	0.19	0.18	Height;	chr5:37463644	chr5:36666214~36725195:-
LUAD	cis	rs2554380	0.55	rs4842918	ENSG00000259570.1	RP11-671M22.4	-4.09	5.01e-05	0.00787	-0.24	-0.18	Height;	chr15:83868247	chr15:84394512~84395514:+
LUAD	cis	rs9309473	0.519	rs2421586	ENSG00000163016.8	ALMS1P	-4.09	5.01e-05	0.00788	-0.2	-0.18	Metabolite levels;	chr2:73672592	chr2:73644919~73685576:+
LUAD	cis	rs12195826	0.533	rs1680885	ENSG00000232654.1	FAM136BP	4.09	5.01e-05	0.00788	0.22	0.18	Obesity-related traits;	chr6:2524486	chr6:3045384~3045800:+
LUAD	cis	rs72634501	0.54	rs16826036	ENSG00000182109.6	RP11-69E11.4	4.09	5.01e-05	0.00788	0.23	0.18	HDL cholesterol;	chr1:39292127	chr1:39522280~39546187:-
LUAD	cis	rs755249	0.567	rs16826038	ENSG00000182109.6	RP11-69E11.4	4.09	5.01e-05	0.00788	0.23	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39292962	chr1:39522280~39546187:-
LUAD	cis	rs755249	0.567	rs61782157	ENSG00000182109.6	RP11-69E11.4	4.09	5.01e-05	0.00788	0.23	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39297217	chr1:39522280~39546187:-
LUAD	cis	rs755249	0.567	rs41270803	ENSG00000182109.6	RP11-69E11.4	4.09	5.01e-05	0.00788	0.23	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39300369	chr1:39522280~39546187:-
LUAD	cis	rs755249	0.567	rs61783376	ENSG00000182109.6	RP11-69E11.4	4.09	5.01e-05	0.00788	0.23	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39303328	chr1:39522280~39546187:-
LUAD	cis	rs755249	0.567	rs4660636	ENSG00000182109.6	RP11-69E11.4	4.09	5.01e-05	0.00788	0.23	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39304555	chr1:39522280~39546187:-
LUAD	cis	rs2749097	0.696	rs2013012	ENSG00000244256.3	RN7SL130P	4.09	5.01e-05	0.00788	0.24	0.18	Alcohol consumption (transferrin glycosylation);	chr1:63662538	chr1:63655743~63656047:+
LUAD	cis	rs8062405	0.755	rs4787457	ENSG00000251417.2	RP11-1348G14.4	-4.09	5.01e-05	0.00788	-0.18	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28802743~28817828:+
LUAD	cis	rs10129255	0.5	rs1024350	ENSG00000253209.1	IGHV3-65	4.09	5.01e-05	0.00788	0.14	0.18	Kawasaki disease;	chr14:106685105	chr14:106666092~106666532:-
LUAD	cis	rs11512640	1	rs118093992	ENSG00000254671.2	STT3A-AS1	4.09	5.01e-05	0.00788	0.43	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125515784	chr11:125570284~125592568:-
LUAD	cis	rs9475752	0.552	rs13203600	ENSG00000231441.1	RP11-472M19.2	4.09	5.02e-05	0.00788	0.29	0.18	Menarche (age at onset);	chr6:56880364	chr6:56844002~56864078:+
LUAD	cis	rs681343	1	rs679574	ENSG00000232871.7	SEC1P	4.09	5.02e-05	0.00788	0.2	0.18	Primary sclerosing cholangitis;Childhood ear infection;Lung adenocarcinoma;	chr19:48702851	chr19:48638071~48682245:+
LUAD	cis	rs8073060	0.586	rs2011897	ENSG00000267592.1	CTC-507E2.2	-4.09	5.02e-05	0.00788	-0.26	-0.18	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35727389	chr17:35596904~35597128:-
LUAD	cis	rs11742741	0.837	rs11743115	ENSG00000248874.4	C5orf17	-4.09	5.02e-05	0.00789	-0.23	-0.18	Educational attainment;	chr5:24093238	chr5:23951348~24178263:+
LUAD	cis	rs7590268	0.789	rs6751298	ENSG00000279873.2	LINC01126	4.09	5.02e-05	0.00789	0.18	0.18	Orofacial clefts;	chr2:43400521	chr2:43227210~43228855:+
LUAD	cis	rs1275468	0.954	rs1148002	ENSG00000257497.2	RP11-585P4.5	4.09	5.02e-05	0.00789	0.25	0.18	Polycystic ovary syndrome;	chr12:75539244	chr12:75483454~75489820:-
LUAD	cis	rs11250098	0.642	rs4841460	ENSG00000255310.2	AF131215.2	-4.09	5.02e-05	0.00789	-0.18	-0.18	Morning vs. evening chronotype;	chr8:10931983	chr8:11107788~11109726:-
LUAD	cis	rs12073359	0.954	rs72692902	ENSG00000223945.2	RP11-458I7.1	-4.09	5.02e-05	0.00789	-0.27	-0.18	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150086491	chr1:150053864~150055034:+
LUAD	cis	rs750134	0.901	rs17040895	ENSG00000257221.1	RP11-689B22.2	-4.09	5.02e-05	0.00789	-0.27	-0.18	Low high density lipoprotein cholesterol levels;	chr12:108699937	chr12:108628687~108641318:+
LUAD	cis	rs2115630	0.755	rs7169629	ENSG00000225151.9	GOLGA2P7	-4.09	5.02e-05	0.00789	-0.21	-0.18	P wave terminal force;	chr15:84648043	chr15:84199311~84230136:-
LUAD	cis	rs4763879	0.729	rs10844472	ENSG00000278635.1	CTD-2318O12.1	4.09	5.02e-05	0.0079	0.17	0.18	Type 1 diabetes;	chr12:9691137	chr12:9415641~9416718:+
LUAD	cis	rs453301	0.658	rs6986044	ENSG00000253893.2	FAM85B	4.09	5.02e-05	0.0079	0.24	0.18	Joint mobility (Beighton score);	chr8:9017276	chr8:8167819~8226614:-
LUAD	cis	rs12701220	0.595	rs12532837	ENSG00000229043.2	AC091729.9	-4.09	5.02e-05	0.0079	-0.25	-0.18	Bronchopulmonary dysplasia;	chr7:1083215	chr7:1160374~1165267:+
LUAD	cis	rs7394190	0.935	rs6480708	ENSG00000271848.1	RP11-464F9.21	-4.09	5.03e-05	0.0079	-0.24	-0.18	Incident atrial fibrillation;	chr10:73660356	chr10:73654039~73674719:+
LUAD	cis	rs8028182	0.636	rs4886716	ENSG00000260269.4	CTD-2323K18.1	-4.09	5.03e-05	0.0079	-0.26	-0.18	Sudden cardiac arrest;	chr15:75563681	chr15:75527150~75601205:-
LUAD	cis	rs847577	0.508	rs12538837	ENSG00000272950.1	RP11-307C18.1	4.09	5.03e-05	0.0079	0.26	0.18	Breast cancer;	chr7:98055156	chr7:98322853~98323430:+
LUAD	cis	rs10129255	0.5	rs4774008	ENSG00000253209.1	IGHV3-65	4.09	5.03e-05	0.0079	0.15	0.18	Kawasaki disease;	chr14:106681273	chr14:106666092~106666532:-
LUAD	cis	rs2304003	1	rs4667847	ENSG00000235192.1	AC009495.2	4.09	5.03e-05	0.0079	0.22	0.18	Social communication problems;	chr2:165858696	chr2:165794851~165810010:+
LUAD	cis	rs4723738	0.693	rs6462818	ENSG00000227191.5	TRGC2	-4.09	5.03e-05	0.0079	-0.2	-0.18	Treatment response for severe sepsis;	chr7:38211435	chr7:38239580~38368091:-
LUAD	cis	rs2735413	0.875	rs11649082	ENSG00000276007.1	RP11-358L22.3	-4.09	5.03e-05	0.0079	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78048359	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.918	rs11646244	ENSG00000276007.1	RP11-358L22.3	-4.09	5.03e-05	0.0079	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78048556	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.918	rs12918409	ENSG00000276007.1	RP11-358L22.3	-4.09	5.03e-05	0.0079	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78048784	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.881	rs12918547	ENSG00000276007.1	RP11-358L22.3	-4.09	5.03e-05	0.0079	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78048849	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.881	rs12919672	ENSG00000276007.1	RP11-358L22.3	-4.09	5.03e-05	0.0079	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78048863	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.881	rs12920025	ENSG00000276007.1	RP11-358L22.3	-4.09	5.03e-05	0.0079	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78049108	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.918	rs12924772	ENSG00000276007.1	RP11-358L22.3	-4.09	5.03e-05	0.0079	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78049218	chr16:78123243~78124332:+
LUAD	cis	rs2380205	0.666	rs11819695	ENSG00000232807.2	RP11-536K7.3	4.09	5.03e-05	0.00791	0.2	0.18	Breast cancer;	chr10:5845316	chr10:5934270~5945900:-
LUAD	cis	rs4879677	1	rs10968045	ENSG00000215441.3	CTAGE12P	-4.09	5.03e-05	0.00791	-0.22	-0.18	Gut microbiome composition (summer and winter);	chr9:27674262	chr9:27608382~27610745:-
LUAD	cis	rs4879677	1	rs10968046	ENSG00000215441.3	CTAGE12P	-4.09	5.03e-05	0.00791	-0.22	-0.18	Gut microbiome composition (summer and winter);	chr9:27674369	chr9:27608382~27610745:-
LUAD	cis	rs8077577	0.708	rs7498	ENSG00000273018.4	CTD-2303H24.2	-4.09	5.03e-05	0.00791	-0.26	-0.18	Obesity-related traits;	chr17:18245171	chr17:18511221~18551705:-
LUAD	cis	rs4940620	1	rs13381196	ENSG00000267390.1	RP11-635N19.1	4.09	5.03e-05	0.00791	0.29	0.18	RANTES levels;	chr18:64240575	chr18:63367328~63381629:+
LUAD	cis	rs7762018	1	rs4716380	ENSG00000231690.2	LINC00574	-4.09	5.04e-05	0.00791	-0.34	-0.18	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169690303	chr6:169790321~169802873:+
LUAD	cis	rs6840360	0.642	rs10454251	ENSG00000270265.1	RP11-731D1.4	-4.09	5.04e-05	0.00791	-0.18	-0.18	Intelligence (multi-trait analysis);	chr4:151462810	chr4:151333775~151353224:-
LUAD	cis	rs227275	0.525	rs7698608	ENSG00000251288.2	RP11-10L12.2	-4.09	5.04e-05	0.00791	-0.22	-0.18	Allergic disease (asthma, hay fever or eczema);	chr4:103016817	chr4:102751401~102752641:+
LUAD	cis	rs12216545	0.669	rs1879871	ENSG00000177590.7	GIMAP3P	-4.09	5.04e-05	0.00791	-0.19	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150603305	chr7:150746893~150747728:-
LUAD	cis	rs12216545	0.662	rs1879872	ENSG00000177590.7	GIMAP3P	-4.09	5.04e-05	0.00791	-0.19	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150603336	chr7:150746893~150747728:-
LUAD	cis	rs12216545	0.644	rs62491782	ENSG00000177590.7	GIMAP3P	-4.09	5.04e-05	0.00791	-0.19	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150612325	chr7:150746893~150747728:-
LUAD	cis	rs853679	0.517	rs9393891	ENSG00000280107.1	AL022393.9	-4.09	5.04e-05	0.00791	-0.24	-0.18	Depression;	chr6:28111382	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs9468286	ENSG00000280107.1	AL022393.9	-4.09	5.04e-05	0.00791	-0.24	-0.18	Depression;	chr6:28111650	chr6:28170845~28172521:+
LUAD	cis	rs10857712	0.754	rs2297031	ENSG00000273336.1	OR7M1P	-4.09	5.04e-05	0.00791	-0.27	-0.18	Systemic lupus erythematosus;	chr10:133419150	chr10:133481238~133481770:+
LUAD	cis	rs2836974	0.831	rs34592564	ENSG00000232608.1	TIMM9P2	-4.09	5.04e-05	0.00791	-0.23	-0.18	Cognitive function;	chr21:39144362	chr21:39216624~39217506:+
LUAD	cis	rs710913	0.774	rs2695319	ENSG00000228060.1	RP11-69E11.8	-4.09	5.04e-05	0.00791	-0.17	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39591028	chr1:39565160~39573203:+
LUAD	cis	rs16866061	1	rs72974219	ENSG00000228446.2	AC073052.1	-4.09	5.04e-05	0.00792	-0.2	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr2:224559067	chr2:224499387~224500100:-
LUAD	cis	rs16866061	1	rs72974222	ENSG00000228446.2	AC073052.1	-4.09	5.04e-05	0.00792	-0.2	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr2:224559426	chr2:224499387~224500100:-
LUAD	cis	rs16866061	1	rs10498163	ENSG00000228446.2	AC073052.1	-4.09	5.04e-05	0.00792	-0.2	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr2:224569728	chr2:224499387~224500100:-
LUAD	cis	rs4474465	0.915	rs12272791	ENSG00000251323.2	RP11-452H21.4	4.09	5.04e-05	0.00792	0.24	0.18	Alzheimer's disease (survival time);	chr11:78448380	chr11:78423982~78429836:-
LUAD	cis	rs4474465	1	rs11237500	ENSG00000251323.2	RP11-452H21.4	4.09	5.04e-05	0.00792	0.24	0.18	Alzheimer's disease (survival time);	chr11:78452590	chr11:78423982~78429836:-
LUAD	cis	rs2243480	1	rs7804223	ENSG00000229886.1	RP5-1132H15.3	-4.09	5.04e-05	0.00792	-0.32	-0.18	Diabetic kidney disease;	chr7:66199572	chr7:66025126~66031544:-
LUAD	cis	rs6121246	0.865	rs77130187	ENSG00000230613.1	HM13-AS1	4.09	5.04e-05	0.00792	0.29	0.18	Mean corpuscular hemoglobin;	chr20:31681257	chr20:31567707~31573263:-
LUAD	cis	rs1075265	0.553	rs2692532	ENSG00000272156.1	RP11-477N3.1	-4.09	5.04e-05	0.00792	-0.22	-0.18	Chronotype;Morning vs. evening chronotype;	chr2:53778962	chr2:54082554~54085066:+
LUAD	cis	rs865483	0.861	rs1063215	ENSG00000276054.1	RP11-378E13.3	4.09	5.04e-05	0.00792	0.22	0.18	Monocyte count;	chr17:37514833	chr17:37386886~37387926:+
LUAD	cis	rs2239547	0.522	rs9842974	ENSG00000243224.1	RP5-1157M23.2	-4.09	5.04e-05	0.00792	-0.21	-0.18	Schizophrenia;	chr3:52977034	chr3:52239258~52241097:+
LUAD	cis	rs10419113	0.567	rs6510095	ENSG00000269867.1	CTD-2583A14.8	4.09	5.04e-05	0.00792	0.16	0.18	Pediatric bone mineral density (spine);	chr19:57784793	chr19:57867038~57868172:-
LUAD	cis	rs2506028	0.55	rs2506025	ENSG00000234944.1	RP11-124O11.1	4.09	5.04e-05	0.00792	0.23	0.18	Blood protein levels;	chr10:42931577	chr10:42871521~42874060:+
LUAD	cis	rs6496932	1	rs12917518	ENSG00000259630.2	CTD-2262B20.1	4.09	5.05e-05	0.00792	0.25	0.18	Central corneal thickness;Corneal structure;	chr15:85284018	chr15:85415228~85415633:+
LUAD	cis	rs2692947	0.695	rs12464148	ENSG00000237510.6	AC008268.2	4.09	5.05e-05	0.00792	0.24	0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95930962	chr2:95789654~95800166:+
LUAD	cis	rs2692947	0.55	rs12623771	ENSG00000237510.6	AC008268.2	4.09	5.05e-05	0.00792	0.24	0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95967756	chr2:95789654~95800166:+
LUAD	cis	rs10129255	0.518	rs7143784	ENSG00000253209.1	IGHV3-65	4.09	5.05e-05	0.00793	0.14	0.18	Kawasaki disease;	chr14:106687277	chr14:106666092~106666532:-
LUAD	cis	rs1910358	0.747	rs1354169	ENSG00000248874.4	C5orf17	-4.09	5.05e-05	0.00793	-0.25	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr5:23965325	chr5:23951348~24178263:+
LUAD	cis	rs6723108	0.627	rs1348790	ENSG00000224043.6	CCNT2-AS1	-4.09	5.05e-05	0.00793	-0.23	-0.18	Type 2 diabetes;	chr2:134882405	chr2:134735464~134918710:-
LUAD	cis	rs6723108	0.627	rs4954193	ENSG00000224043.6	CCNT2-AS1	-4.09	5.05e-05	0.00793	-0.23	-0.18	Type 2 diabetes;	chr2:134884610	chr2:134735464~134918710:-
LUAD	cis	rs8030379	0.967	rs899926	ENSG00000230373.7	GOLGA6L5P	-4.09	5.05e-05	0.00794	-0.17	-0.18	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83904739	chr15:84507885~84516814:-
LUAD	cis	rs11064837	0.523	rs7972600	ENSG00000248636.5	RP11-768F21.1	4.09	5.06e-05	0.00794	0.22	0.18	Schizophrenia;	chr12:119657514	chr12:119387987~119668079:-
LUAD	cis	rs4713118	0.911	rs2394000	ENSG00000280107.1	AL022393.9	-4.09	5.06e-05	0.00794	-0.23	-0.18	Parkinson's disease;	chr6:27719212	chr6:28170845~28172521:+
LUAD	cis	rs4713118	0.955	rs9393847	ENSG00000280107.1	AL022393.9	-4.09	5.06e-05	0.00794	-0.23	-0.18	Parkinson's disease;	chr6:27720194	chr6:28170845~28172521:+
LUAD	cis	rs2070074	0.591	rs12352811	ENSG00000230074.1	RP11-195F19.9	4.09	5.06e-05	0.00794	0.38	0.18	CTACK levels;	chr9:34614684	chr9:34665665~34681298:+
LUAD	cis	rs7208859	0.524	rs77498725	ENSG00000280069.1	CTD-2349P21.3	-4.09	5.06e-05	0.00794	-0.26	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30736968	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.573	rs73267865	ENSG00000280069.1	CTD-2349P21.3	-4.09	5.06e-05	0.00794	-0.26	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737186	chr17:30738182~30740275:+
LUAD	cis	rs8030379	1	rs1564475	ENSG00000230373.7	GOLGA6L5P	-4.09	5.06e-05	0.00794	-0.17	-0.18	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83903477	chr15:84507885~84516814:-
LUAD	cis	rs8030379	1	rs7183263	ENSG00000230373.7	GOLGA6L5P	-4.09	5.06e-05	0.00794	-0.17	-0.18	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83904289	chr15:84507885~84516814:-
LUAD	cis	rs8030379	1	rs7178962	ENSG00000230373.7	GOLGA6L5P	-4.09	5.06e-05	0.00794	-0.17	-0.18	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83904496	chr15:84507885~84516814:-
LUAD	cis	rs8030379	0.967	rs8029387	ENSG00000230373.7	GOLGA6L5P	-4.09	5.06e-05	0.00794	-0.17	-0.18	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83906523	chr15:84507885~84516814:-
LUAD	cis	rs8030379	0.967	rs8028359	ENSG00000230373.7	GOLGA6L5P	-4.09	5.06e-05	0.00794	-0.17	-0.18	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83906593	chr15:84507885~84516814:-
LUAD	cis	rs8030379	1	rs940934	ENSG00000230373.7	GOLGA6L5P	-4.09	5.06e-05	0.00794	-0.17	-0.18	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83906776	chr15:84507885~84516814:-
LUAD	cis	rs8030379	0.935	rs1815172	ENSG00000230373.7	GOLGA6L5P	-4.09	5.06e-05	0.00794	-0.17	-0.18	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83907080	chr15:84507885~84516814:-
LUAD	cis	rs8030379	1	rs11853052	ENSG00000230373.7	GOLGA6L5P	-4.09	5.06e-05	0.00794	-0.17	-0.18	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83907407	chr15:84507885~84516814:-
LUAD	cis	rs8030379	1	rs2401172	ENSG00000230373.7	GOLGA6L5P	-4.09	5.06e-05	0.00794	-0.17	-0.18	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83908205	chr15:84507885~84516814:-
LUAD	cis	rs8030379	1	rs2401174	ENSG00000230373.7	GOLGA6L5P	-4.09	5.06e-05	0.00794	-0.17	-0.18	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83908240	chr15:84507885~84516814:-
LUAD	cis	rs763121	0.853	rs5757196	ENSG00000225450.1	RP3-508I15.14	-4.09	5.06e-05	0.00794	-0.18	-0.18	Menopause (age at onset);	chr22:38643850	chr22:38739003~38749041:+
LUAD	cis	rs763121	0.785	rs5757199	ENSG00000225450.1	RP3-508I15.14	-4.09	5.06e-05	0.00794	-0.18	-0.18	Menopause (age at onset);	chr22:38644612	chr22:38739003~38749041:+
LUAD	cis	rs763121	0.853	rs7289577	ENSG00000225450.1	RP3-508I15.14	-4.09	5.06e-05	0.00794	-0.18	-0.18	Menopause (age at onset);	chr22:38646209	chr22:38739003~38749041:+
LUAD	cis	rs763121	0.853	rs5757200	ENSG00000225450.1	RP3-508I15.14	-4.09	5.06e-05	0.00794	-0.18	-0.18	Menopause (age at onset);	chr22:38647486	chr22:38739003~38749041:+
LUAD	cis	rs763121	0.853	rs5757203	ENSG00000225450.1	RP3-508I15.14	-4.09	5.06e-05	0.00794	-0.18	-0.18	Menopause (age at onset);	chr22:38648147	chr22:38739003~38749041:+
LUAD	cis	rs763121	0.853	rs2205802	ENSG00000225450.1	RP3-508I15.14	-4.09	5.06e-05	0.00794	-0.18	-0.18	Menopause (age at onset);	chr22:38650322	chr22:38739003~38749041:+
LUAD	cis	rs763121	0.853	rs5757204	ENSG00000225450.1	RP3-508I15.14	-4.09	5.06e-05	0.00794	-0.18	-0.18	Menopause (age at onset);	chr22:38650695	chr22:38739003~38749041:+
LUAD	cis	rs763121	0.853	rs8138996	ENSG00000225450.1	RP3-508I15.14	-4.09	5.06e-05	0.00794	-0.18	-0.18	Menopause (age at onset);	chr22:38651430	chr22:38739003~38749041:+
LUAD	cis	rs763121	0.853	rs6001182	ENSG00000225450.1	RP3-508I15.14	-4.09	5.06e-05	0.00794	-0.18	-0.18	Menopause (age at onset);	chr22:38651438	chr22:38739003~38749041:+
LUAD	cis	rs6964587	1	rs7802668	ENSG00000188693.7	CYP51A1-AS1	-4.09	5.06e-05	0.00794	-0.21	-0.18	Breast cancer;	chr7:92019625	chr7:92134604~92180725:+
LUAD	cis	rs7500321	1	rs7500321	ENSG00000261419.1	RP11-57A19.4	4.09	5.06e-05	0.00794	0.22	0.18	Intelligence (multi-trait analysis);	chr16:28965699	chr16:28659696~28740781:-
LUAD	cis	rs6001482	0.679	rs1475928	ENSG00000223350.2	IGLV9-49	-4.09	5.06e-05	0.00794	-0.18	-0.18	Diastolic blood pressure;	chr22:22236137	chr22:22343187~22343732:+
LUAD	cis	rs17189298	0.934	rs13009596	ENSG00000231013.1	AC013275.2	4.09	5.06e-05	0.00794	0.19	0.18	Cerebrospinal T-tau levels;	chr2:119112657	chr2:119476448~119487346:+
LUAD	cis	rs10129255	0.957	rs2007467	ENSG00000253209.1	IGHV3-65	-4.09	5.06e-05	0.00794	-0.16	-0.18	Kawasaki disease;	chr14:106771605	chr14:106666092~106666532:-
LUAD	cis	rs7809950	0.954	rs2520243	ENSG00000238832.1	snoU109	-4.09	5.06e-05	0.00795	-0.27	-0.18	Coronary artery disease;	chr7:107496528	chr7:107603363~107603507:+
LUAD	cis	rs6687821	0.515	rs10782587	ENSG00000261737.1	RP4-612B15.3	4.09	5.07e-05	0.00795	0.25	0.18	Yeast infection;	chr1:86962204	chr1:86703502~86704462:-
LUAD	cis	rs4767841	0.868	rs2996028	ENSG00000248636.5	RP11-768F21.1	-4.09	5.07e-05	0.00795	-0.21	-0.18	Urgency urinary incontinence;	chr12:119727350	chr12:119387987~119668079:-
LUAD	cis	rs11089937	1	rs6001121	ENSG00000211640.3	IGLV6-57	4.09	5.07e-05	0.00795	0.12	0.18	Periodontitis (PAL4Q3);	chr22:22149505	chr22:22195713~22196460:+
LUAD	cis	rs7665090	0.87	rs228627	ENSG00000251288.2	RP11-10L12.2	4.09	5.07e-05	0.00795	0.22	0.18	Primary biliary cholangitis;	chr4:102651925	chr4:102751401~102752641:+
LUAD	cis	rs2665103	0.589	rs3858953	ENSG00000276710.3	CSPG4P8	-4.09	5.07e-05	0.00796	-0.17	-0.18	Intelligence (multi-trait analysis);	chr15:82238049	chr15:82459472~82477258:+
LUAD	cis	rs10091374	0.762	rs10087358	ENSG00000253967.1	RP11-333A23.4	4.09	5.07e-05	0.00796	0.21	0.18	Cardiac Troponin-T levels;	chr8:70475410	chr8:70471134~70485687:+
LUAD	cis	rs4819052	0.851	rs914214	ENSG00000237664.1	LINC00316	-4.09	5.07e-05	0.00796	-0.23	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45277905	chr21:45338590~45341990:-
LUAD	cis	rs6988985	0.678	rs28710914	ENSG00000247317.3	RP11-273G15.2	-4.09	5.07e-05	0.00796	-0.21	-0.18	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142921874	chr8:142981738~143018437:-
LUAD	cis	rs253959	0.545	rs6896147	ENSG00000272265.1	CTD-2287O16.4	-4.09	5.07e-05	0.00796	-0.22	-0.18	Bipolar disorder and schizophrenia;	chr5:116089699	chr5:116078110~116078570:-
LUAD	cis	rs6570726	0.934	rs9484995	ENSG00000235652.6	RP11-545I5.3	-4.09	5.07e-05	0.00796	-0.18	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145459978	chr6:145799409~145886585:+
LUAD	cis	rs6933660	0.8	rs963193	ENSG00000219395.2	HSPA8P15	4.09	5.07e-05	0.00796	0.17	0.18	Menarche (age at onset);	chr6:151468220	chr6:151411259~151413945:-
LUAD	cis	rs2243480	1	rs34970380	ENSG00000229886.1	RP5-1132H15.3	4.09	5.08e-05	0.00796	0.32	0.18	Diabetic kidney disease;	chr7:65966506	chr7:66025126~66031544:-
LUAD	cis	rs2243480	0.901	rs73148097	ENSG00000229886.1	RP5-1132H15.3	4.09	5.08e-05	0.00796	0.32	0.18	Diabetic kidney disease;	chr7:65966800	chr7:66025126~66031544:-
LUAD	cis	rs12908161	0.959	rs17598603	ENSG00000275120.1	RP11-182J1.17	-4.09	5.08e-05	0.00797	-0.27	-0.18	Schizophrenia;	chr15:84656980	chr15:84599434~84606463:-
LUAD	cis	rs9925964	0.804	rs9926533	ENSG00000232748.3	RP11-196G11.6	4.09	5.08e-05	0.00797	0.22	0.18	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31002858	chr16:31056460~31062803:+
LUAD	cis	rs3742264	1	rs17844080	ENSG00000235903.6	CPB2-AS1	-4.09	5.08e-05	0.00797	-0.23	-0.18	Blood protein levels;	chr13:46070270	chr13:46052806~46113332:+
LUAD	cis	rs4144027	0.904	rs10438242	ENSG00000258914.1	CTD-2134A5.3	4.09	5.08e-05	0.00797	0.22	0.18	Blood metabolite levels;	chr14:103878738	chr14:103875055~103877478:+
LUAD	cis	rs4925386	0.921	rs11204472	ENSG00000273619.1	RP5-908M14.9	4.09	5.08e-05	0.00797	0.17	0.18	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345831	chr20:62386303~62386970:-
LUAD	cis	rs35740288	0.752	rs11635956	ENSG00000259407.1	RP11-158M2.3	-4.09	5.08e-05	0.00797	-0.19	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85736697	chr15:85744109~85750281:-
LUAD	cis	rs7772486	0.79	rs1062067	ENSG00000235652.6	RP11-545I5.3	4.09	5.08e-05	0.00797	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145886427	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.79	rs2256998	ENSG00000235652.6	RP11-545I5.3	4.09	5.08e-05	0.00797	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145886521	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.79	rs2814880	ENSG00000235652.6	RP11-545I5.3	4.09	5.08e-05	0.00797	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145887801	chr6:145799409~145886585:+
LUAD	cis	rs703842	1	rs3825079	ENSG00000270039.1	RP11-571M6.17	-4.09	5.08e-05	0.00797	-0.22	-0.18	Multiple sclerosis;	chr12:57809571	chr12:57803838~57804415:+
LUAD	cis	rs404005	0.506	rs449383	ENSG00000227028.5	SLC8A1-AS1	-4.09	5.08e-05	0.00797	-0.24	-0.18	HIV-associated dementia;	chr2:40197304	chr2:39786453~40255209:+
LUAD	cis	rs6964587	0.934	rs12531561	ENSG00000188693.7	CYP51A1-AS1	-4.09	5.08e-05	0.00797	-0.21	-0.18	Breast cancer;	chr7:92078466	chr7:92134604~92180725:+
LUAD	cis	rs8028182	0.609	rs8038760	ENSG00000260269.4	CTD-2323K18.1	-4.09	5.08e-05	0.00798	-0.25	-0.18	Sudden cardiac arrest;	chr15:75449754	chr15:75527150~75601205:-
LUAD	cis	rs11673344	0.615	rs2921561	ENSG00000267309.1	CTD-2630F21.1	-4.09	5.09e-05	0.00798	-0.22	-0.18	Obesity-related traits;	chr19:37348969	chr19:36489649~36491040:+
LUAD	cis	rs6840360	0.642	rs4235219	ENSG00000270265.1	RP11-731D1.4	-4.09	5.09e-05	0.00798	-0.18	-0.18	Intelligence (multi-trait analysis);	chr4:151424951	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.642	rs6851814	ENSG00000270265.1	RP11-731D1.4	-4.09	5.09e-05	0.00798	-0.18	-0.18	Intelligence (multi-trait analysis);	chr4:151425285	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.606	rs10028035	ENSG00000270265.1	RP11-731D1.4	-4.09	5.09e-05	0.00798	-0.18	-0.18	Intelligence (multi-trait analysis);	chr4:151426673	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.667	rs4266275	ENSG00000270265.1	RP11-731D1.4	-4.09	5.09e-05	0.00798	-0.18	-0.18	Intelligence (multi-trait analysis);	chr4:151426912	chr4:151333775~151353224:-
LUAD	cis	rs16866061	1	rs3768886	ENSG00000228446.2	AC073052.1	-4.09	5.09e-05	0.00798	-0.2	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr2:224585444	chr2:224499387~224500100:-
LUAD	cis	rs16866061	1	rs72974267	ENSG00000228446.2	AC073052.1	-4.09	5.09e-05	0.00798	-0.2	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr2:224589492	chr2:224499387~224500100:-
LUAD	cis	rs2657294	0.965	rs10762658	ENSG00000226051.5	ZNF503-AS1	-4.09	5.09e-05	0.00798	-0.24	-0.18	Pneumonia;	chr10:75119804	chr10:75269819~75373500:+
LUAD	cis	rs10129255	1	rs10129255	ENSG00000211967.3	IGHV3-53	4.09	5.09e-05	0.00798	0.14	0.18	Kawasaki disease;	chr14:106767970	chr14:106592676~106593347:-
LUAD	cis	rs11242704	0.603	rs4431475	ENSG00000272279.1	RP11-157J24.2	-4.09	5.09e-05	0.00798	-0.27	-0.18	Response to hepatitis C treatment;	chr6:1532651	chr6:1528364~1528911:-
LUAD	cis	rs2274273	0.682	rs8008134	ENSG00000258413.1	RP11-665C16.6	-4.09	5.09e-05	0.00798	-0.23	-0.18	Protein biomarker;	chr14:55040802	chr14:55262767~55272075:-
LUAD	cis	rs6723226	0.765	rs12612824	ENSG00000276334.1	AL133243.1	-4.09	5.09e-05	0.00798	-0.22	-0.18	Intelligence (multi-trait analysis);	chr2:32354691	chr2:32521927~32523547:+
LUAD	cis	rs4819052	0.851	rs7279011	ENSG00000237664.1	LINC00316	-4.09	5.09e-05	0.00799	-0.23	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236080	chr21:45338590~45341990:-
LUAD	cis	rs2439831	0.681	rs524527	ENSG00000249839.1	AC011330.5	4.09	5.09e-05	0.00799	0.32	0.18	Lung cancer in ever smokers;	chr15:43306918	chr15:43663654~43684339:-
LUAD	cis	rs16866061	1	rs72974203	ENSG00000228446.2	AC073052.1	-4.09	5.09e-05	0.00799	-0.2	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr2:224543713	chr2:224499387~224500100:-
LUAD	cis	rs79166949	1	rs6099852	ENSG00000224635.1	RP4-564F22.5	4.09	5.1e-05	0.00799	0.46	0.18	Itch intensity from mosquito bite adjusted by bite size;	chr20:38474269	chr20:38406011~38416797:-
LUAD	cis	rs526231	0.853	rs187579	ENSG00000175749.11	EIF3KP1	4.09	5.1e-05	0.00799	0.25	0.18	Primary biliary cholangitis;	chr5:103269232	chr5:103032376~103033031:+
LUAD	cis	rs8098244	0.737	rs1154232	ENSG00000264745.1	TTC39C-AS1	-4.09	5.1e-05	0.00799	-0.23	-0.18	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23931070	chr18:23994213~24015339:-
LUAD	cis	rs9928842	0.823	rs889514	ENSG00000259972.2	AC009120.6	-4.09	5.1e-05	0.00799	-0.14	-0.18	Alcoholic chronic pancreatitis;	chr16:75238614	chr16:74305127~74335346:-
LUAD	cis	rs16866061	0.962	rs16866045	ENSG00000228446.2	AC073052.1	-4.09	5.1e-05	0.008	-0.2	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr2:224548303	chr2:224499387~224500100:-
LUAD	cis	rs12681366	1	rs2960122	ENSG00000253704.1	RP11-267M23.4	4.09	5.1e-05	0.008	0.22	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94419858	chr8:94553722~94569745:+
LUAD	cis	rs12681366	1	rs2930971	ENSG00000253704.1	RP11-267M23.4	4.09	5.1e-05	0.008	0.22	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94420319	chr8:94553722~94569745:+
LUAD	cis	rs6964587	0.869	rs11769294	ENSG00000188693.7	CYP51A1-AS1	-4.09	5.1e-05	0.008	-0.21	-0.18	Breast cancer;	chr7:91920623	chr7:92134604~92180725:+
LUAD	cis	rs2834288	0.535	rs4816468	ENSG00000237945.6	LINC00649	4.09	5.11e-05	0.008	0.24	0.18	Gut microbiota (bacterial taxa);	chr21:33952235	chr21:33915534~33977691:+
LUAD	cis	rs2834288	0.536	rs8129513	ENSG00000237945.6	LINC00649	4.09	5.11e-05	0.008	0.24	0.18	Gut microbiota (bacterial taxa);	chr21:33952615	chr21:33915534~33977691:+
LUAD	cis	rs6763768	0.962	rs3774414	ENSG00000274967.1	Y_RNA	4.09	5.11e-05	0.00801	0.2	0.18	Bacterial meningitis;	chr3:53498728	chr3:53290640~53290751:+
LUAD	cis	rs3814244	0.528	rs7952790	ENSG00000236946.2	HNRNPA1P70	-4.09	5.11e-05	0.00801	-0.16	-0.18	Itch intensity from mosquito bite adjusted by bite size;	chr12:68012672	chr12:68035767~68036853:+
LUAD	cis	rs914615	0.552	rs11264339	ENSG00000160766.13	GBAP1	4.09	5.11e-05	0.00801	0.19	0.18	Urinary albumin-to-creatinine ratio;	chr1:155168172	chr1:155213821~155227422:-
LUAD	cis	rs13068223	0.967	rs344035	ENSG00000243926.1	TIPARP-AS1	-4.09	5.11e-05	0.00801	-0.19	-0.18	Age-related hearing impairment (SNP x SNP interaction);	chr3:156743490	chr3:156671862~156674378:-
LUAD	cis	rs4237845	0.537	rs2002275	ENSG00000245651.2	RP11-620J15.2	4.09	5.11e-05	0.00801	0.19	0.18	Intelligence (multi-trait analysis);	chr12:57889602	chr12:57869835~57896482:-
LUAD	cis	rs6928977	0.5	rs3734213	ENSG00000231028.7	LINC00271	-4.09	5.11e-05	0.00801	-0.22	-0.18	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135620170	chr6:135497801~135716055:+
LUAD	cis	rs755249	0.51	rs582883	ENSG00000228060.1	RP11-69E11.8	-4.09	5.11e-05	0.00801	-0.16	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39369868	chr1:39565160~39573203:+
LUAD	cis	rs11240074	0.632	rs7551565	ENSG00000244371.2	PFN1P8	-4.09	5.11e-05	0.00801	-0.31	-0.18	Type 2 diabetes;	chr1:147481514	chr1:146957117~146957659:-
LUAD	cis	rs704	0.523	rs11080054	ENSG00000237575.4	PYY2	4.09	5.11e-05	0.00801	0.21	0.18	Osteoprotegerin levels;	chr17:28318965	chr17:28226563~28228065:+
LUAD	cis	rs2439831	0.702	rs28699233	ENSG00000249839.1	AC011330.5	-4.09	5.11e-05	0.00801	-0.43	-0.18	Lung cancer in ever smokers;	chr15:43830668	chr15:43663654~43684339:-
LUAD	cis	rs3096299	0.967	rs11648663	ENSG00000182376.2	RP5-1142A6.8	4.09	5.11e-05	0.00801	0.19	0.18	Multiple myeloma (IgH translocation);	chr16:89399899	chr16:88742767~88745748:+
LUAD	cis	rs7826238	0.517	rs35144760	ENSG00000253981.4	ALG1L13P	-4.09	5.11e-05	0.00801	-0.22	-0.18	Systolic blood pressure;	chr8:8504213	chr8:8236003~8244667:-
LUAD	cis	rs4713118	0.662	rs464312	ENSG00000280107.1	AL022393.9	-4.09	5.11e-05	0.00802	-0.23	-0.18	Parkinson's disease;	chr6:27999813	chr6:28170845~28172521:+
LUAD	cis	rs4713118	0.662	rs469228	ENSG00000280107.1	AL022393.9	-4.09	5.11e-05	0.00802	-0.23	-0.18	Parkinson's disease;	chr6:28002926	chr6:28170845~28172521:+
LUAD	cis	rs4713118	0.54	rs469227	ENSG00000280107.1	AL022393.9	-4.09	5.11e-05	0.00802	-0.23	-0.18	Parkinson's disease;	chr6:28002927	chr6:28170845~28172521:+
LUAD	cis	rs4713118	0.662	rs149948	ENSG00000280107.1	AL022393.9	-4.09	5.11e-05	0.00802	-0.23	-0.18	Parkinson's disease;	chr6:28007039	chr6:28170845~28172521:+
LUAD	cis	rs4601821	1	rs6589375	ENSG00000270179.1	RP11-159N11.4	-4.09	5.11e-05	0.00802	-0.19	-0.18	Alcoholic chronic pancreatitis;	chr11:113384389	chr11:113368478~113369117:+
LUAD	cis	rs7829975	0.572	rs28446104	ENSG00000253981.4	ALG1L13P	-4.09	5.11e-05	0.00802	-0.21	-0.18	Mood instability;	chr8:8938391	chr8:8236003~8244667:-
LUAD	cis	rs3743162	0.553	rs12915656	ENSG00000259728.4	LINC00933	4.09	5.12e-05	0.00802	0.28	0.18	Alzheimer's disease (age of onset);	chr15:84872349	chr15:84570649~84580175:+
LUAD	cis	rs9650657	0.589	rs6985109	ENSG00000255310.2	AF131215.2	4.09	5.12e-05	0.00802	0.18	0.18	Neuroticism;	chr8:10904075	chr8:11107788~11109726:-
LUAD	cis	rs4374383	0.926	rs4643544	ENSG00000207383.1	Y_RNA	-4.09	5.12e-05	0.00802	-0.22	-0.18	Hepatitis C induced liver fibrosis;	chr2:112021136	chr2:112579484~112579584:-
LUAD	cis	rs13113518	1	rs13113518	ENSG00000223305.1	RN7SKP30	4.09	5.12e-05	0.00802	0.2	0.18	Height;	chr4:55533481	chr4:55540502~55540835:-
LUAD	cis	rs2562456	0.876	rs2650844	ENSG00000268081.1	RP11-678G14.2	4.09	5.12e-05	0.00802	0.29	0.18	Pain;	chr19:21419288	chr19:21554640~21569237:-
LUAD	cis	rs4819052	0.84	rs914217	ENSG00000237664.1	LINC00316	-4.09	5.12e-05	0.00802	-0.24	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278384	chr21:45338590~45341990:-
LUAD	cis	rs9813712	0.595	rs1993217	ENSG00000228252.7	COL6A4P2	-4.09	5.12e-05	0.00802	-0.17	-0.18	Response to amphetamines;	chr3:130284832	chr3:130212823~130273806:+
LUAD	cis	rs9815354	1	rs7622259	ENSG00000273328.4	RP11-141M3.6	-4.09	5.12e-05	0.00802	-0.27	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41839859	chr3:42809414~42908105:+
LUAD	cis	rs9815354	1	rs114960066	ENSG00000273328.4	RP11-141M3.6	-4.09	5.12e-05	0.00802	-0.27	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41840831	chr3:42809414~42908105:+
LUAD	cis	rs9815354	0.68	rs114714860	ENSG00000273328.4	RP11-141M3.6	-4.09	5.12e-05	0.00802	-0.27	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41841413	chr3:42809414~42908105:+
LUAD	cis	rs9815354	1	rs9840532	ENSG00000273328.4	RP11-141M3.6	-4.09	5.12e-05	0.00802	-0.27	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41844205	chr3:42809414~42908105:+
LUAD	cis	rs9815354	1	rs11928580	ENSG00000273328.4	RP11-141M3.6	-4.09	5.12e-05	0.00802	-0.27	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41844230	chr3:42809414~42908105:+
LUAD	cis	rs9815354	0.767	rs11917248	ENSG00000273328.4	RP11-141M3.6	-4.09	5.12e-05	0.00802	-0.27	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41844231	chr3:42809414~42908105:+
LUAD	cis	rs6840360	0.642	rs7684462	ENSG00000270265.1	RP11-731D1.4	-4.09	5.12e-05	0.00802	-0.18	-0.18	Intelligence (multi-trait analysis);	chr4:151427270	chr4:151333775~151353224:-
LUAD	cis	rs4578769	0.569	rs3851822	ENSG00000265943.1	RP11-739L10.1	-4.09	5.12e-05	0.00802	-0.23	-0.18	Eosinophil percentage of white cells;	chr18:22882829	chr18:22699481~22933764:-
LUAD	cis	rs4499344	0.73	rs7246338	ENSG00000201388.1	SNORA68	4.09	5.12e-05	0.00802	0.19	0.18	Mean platelet volume;	chr19:32608598	chr19:32608337~32608469:-
LUAD	cis	rs4474465	1	rs7102316	ENSG00000251323.2	RP11-452H21.4	4.09	5.12e-05	0.00802	0.24	0.18	Alzheimer's disease (survival time);	chr11:78438319	chr11:78423982~78429836:-
LUAD	cis	rs523522	0.962	rs12309824	ENSG00000278344.1	RP11-18C24.8	4.09	5.12e-05	0.00802	0.25	0.18	High light scatter reticulocyte count;	chr12:120552779	chr12:120500735~120501090:-
LUAD	cis	rs6732426	0.548	rs6544650	ENSG00000279873.2	LINC01126	4.09	5.12e-05	0.00803	0.16	0.18	Hair morphology;	chr2:43389673	chr2:43227210~43228855:+
LUAD	cis	rs2274273	0.624	rs1972221	ENSG00000258413.1	RP11-665C16.6	-4.09	5.12e-05	0.00803	-0.25	-0.18	Protein biomarker;	chr14:55318663	chr14:55262767~55272075:-
LUAD	cis	rs7107174	1	rs12270434	ENSG00000251323.2	RP11-452H21.4	4.09	5.12e-05	0.00803	0.22	0.18	Testicular germ cell tumor;	chr11:78392254	chr11:78423982~78429836:-
LUAD	cis	rs76878669	0.538	rs1546358	ENSG00000213409.4	RP11-658F2.3	4.09	5.12e-05	0.00803	0.22	0.18	Educational attainment (years of education);	chr11:66407790	chr11:66761575~66762399:-
LUAD	cis	rs853679	0.607	rs34788973	ENSG00000219392.1	RP1-265C24.5	-4.09	5.12e-05	0.00803	-0.41	-0.18	Depression;	chr6:27911422	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.607	rs61742093	ENSG00000219392.1	RP1-265C24.5	-4.09	5.12e-05	0.00803	-0.41	-0.18	Depression;	chr6:27912204	chr6:28115628~28116551:+
LUAD	cis	rs10752881	0.935	rs3935221	ENSG00000224468.3	RP11-181K3.4	-4.09	5.13e-05	0.00803	-0.16	-0.18	Colorectal cancer;	chr1:182999875	chr1:183138402~183141282:-
LUAD	cis	rs10752881	1	rs10797800	ENSG00000224468.3	RP11-181K3.4	-4.09	5.13e-05	0.00803	-0.16	-0.18	Colorectal cancer;	chr1:183000693	chr1:183138402~183141282:-
LUAD	cis	rs10752881	1	rs4304541	ENSG00000224468.3	RP11-181K3.4	-4.09	5.13e-05	0.00803	-0.16	-0.18	Colorectal cancer;	chr1:183001103	chr1:183138402~183141282:-
LUAD	cis	rs6951245	0.935	rs113365567	ENSG00000199023.2	MIR339	-4.09	5.13e-05	0.00803	-0.33	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1069149	chr7:1022935~1023045:-
LUAD	cis	rs8062405	0.69	rs62034351	ENSG00000261419.1	RP11-57A19.4	-4.09	5.13e-05	0.00803	-0.2	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28659696~28740781:-
LUAD	cis	rs42490	0.716	rs40547	ENSG00000251136.7	RP11-37B2.1	-4.09	5.13e-05	0.00803	-0.19	-0.18	Leprosy;	chr8:89817685	chr8:89609409~89757727:-
LUAD	cis	rs600231	0.706	rs4244811	ENSG00000245532.5	NEAT1	-4.09	5.13e-05	0.00803	-0.15	-0.18	Bone mineral density;	chr11:65553309	chr11:65422774~65445540:+
LUAD	cis	rs8180040	0.966	rs11914795	ENSG00000271161.1	BOLA2P2	4.09	5.13e-05	0.00804	0.18	0.18	Colorectal cancer;	chr3:47516232	chr3:47499841~47500407:+
LUAD	cis	rs858239	1	rs199357	ENSG00000226816.2	AC005082.12	-4.09	5.13e-05	0.00804	-0.23	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23248690	chr7:23206013~23208045:+
LUAD	cis	rs62355901	0.505	rs55698001	ENSG00000271828.1	CTD-2310F14.1	4.09	5.13e-05	0.00804	0.39	0.18	Breast cancer;	chr5:56949313	chr5:56927874~56929573:+
LUAD	cis	rs12122100	0.526	rs12122534	ENSG00000244371.2	PFN1P8	-4.09	5.13e-05	0.00804	-0.21	-0.18	HIV-1 control;	chr1:147032846	chr1:146957117~146957659:-
LUAD	cis	rs7829975	0.742	rs1533059	ENSG00000173295.6	FAM86B3P	-4.09	5.13e-05	0.00804	-0.19	-0.18	Mood instability;	chr8:8827443	chr8:8228595~8244865:+
LUAD	cis	rs2235642	0.928	rs1057610	ENSG00000280231.1	LA16c-380F5.3	-4.09	5.13e-05	0.00804	-0.25	-0.18	Coronary artery disease;	chr16:1555536	chr16:1553655~1554130:-
LUAD	cis	rs9973361	1	rs9973899	ENSG00000232411.1	AC009495.3	-4.09	5.14e-05	0.00804	-0.22	-0.18	Total body bone mineral density;	chr2:165861072	chr2:165833048~165839098:-
LUAD	cis	rs1979679	0.842	rs35098487	ENSG00000278733.1	RP11-425D17.1	4.09	5.14e-05	0.00805	0.23	0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28191043	chr12:28185625~28186190:-
LUAD	cis	rs9633740	1	rs7896832	ENSG00000226659.1	RP11-137H2.4	-4.09	5.14e-05	0.00805	-0.3	-0.18	Post bronchodilator FEV1;	chr10:80497814	chr10:80529597~80535942:-
LUAD	cis	rs11642862	1	rs111954099	ENSG00000239791.1	AC002310.7	4.09	5.14e-05	0.00805	0.32	0.18	Tonsillectomy;	chr16:30778302	chr16:30572250~30583860:+
LUAD	cis	rs3847687	0.901	rs12370258	ENSG00000279993.1	RP11-76C10.3	4.09	5.14e-05	0.00805	0.19	0.18	Longevity;	chr12:131042756	chr12:131025561~131028060:-
LUAD	cis	rs6840258	0.76	rs340643	ENSG00000251411.1	RP11-397E7.4	-4.09	5.14e-05	0.00805	-0.21	-0.18	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87026006	chr4:86913266~86914817:-
LUAD	cis	rs17301013	0.932	rs2987869	ENSG00000227373.4	RP11-160H22.5	-4.09	5.14e-05	0.00805	-0.23	-0.18	Systemic lupus erythematosus;	chr1:174820269	chr1:174115300~174160004:-
LUAD	cis	rs2446066	0.872	rs111939932	ENSG00000257379.1	RP11-793H13.8	4.09	5.14e-05	0.00805	0.31	0.18	Red blood cell count;	chr12:53449987	chr12:53441741~53467528:+
LUAD	cis	rs728616	0.867	rs1054054	ENSG00000225484.5	NUTM2B-AS1	-4.09	5.14e-05	0.00805	-0.47	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79922972	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.867	rs61859766	ENSG00000225484.5	NUTM2B-AS1	-4.09	5.14e-05	0.00805	-0.47	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79923284	chr10:79663088~79826594:-
LUAD	cis	rs2834288	0.613	rs2834297	ENSG00000237945.6	LINC00649	-4.09	5.14e-05	0.00805	-0.23	-0.18	Gut microbiota (bacterial taxa);	chr21:33910534	chr21:33915534~33977691:+
LUAD	cis	rs2154319	0.836	rs61780431	ENSG00000235358.1	RP11-399E6.1	-4.09	5.14e-05	0.00805	-0.26	-0.18	Height;	chr1:40998462	chr1:41242373~41284861:+
LUAD	cis	rs62025270	1	rs62025270	ENSG00000202081.1	RNU6-1280P	-4.09	5.14e-05	0.00805	-0.27	-0.18	Idiopathic pulmonary fibrosis;	chr15:85756967	chr15:85651522~85651628:-
LUAD	cis	rs172166	0.694	rs9295760	ENSG00000216901.1	AL022393.7	4.09	5.14e-05	0.00806	0.23	0.18	Cardiac Troponin-T levels;	chr6:28179607	chr6:28176188~28176674:+
LUAD	cis	rs11673344	0.864	rs8110696	ENSG00000226686.6	LINC01535	4.09	5.15e-05	0.00806	0.24	0.18	Obesity-related traits;	chr19:37009449	chr19:37251912~37265535:+
LUAD	cis	rs8062405	0.54	rs480400	ENSG00000261766.1	RP11-22P6.2	-4.09	5.15e-05	0.00806	-0.15	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28563294	chr16:28862166~28863340:-
LUAD	cis	rs4984778	0.75	rs7198064	ENSG00000260182.1	RP11-616M22.5	4.09	5.15e-05	0.00806	0.23	0.18	Blood protein levels;	chr16:1222472	chr16:1257339~1258074:+
LUAD	cis	rs6570726	0.967	rs403584	ENSG00000235652.6	RP11-545I5.3	4.09	5.15e-05	0.00806	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145485874	chr6:145799409~145886585:+
LUAD	cis	rs301901	0.531	rs292171	ENSG00000250155.1	CTD-2353F22.1	-4.09	5.15e-05	0.00806	-0.21	-0.18	Height;	chr5:36816591	chr5:36666214~36725195:-
LUAD	cis	rs4713118	0.516	rs7739216	ENSG00000280107.1	AL022393.9	-4.09	5.15e-05	0.00806	-0.24	-0.18	Parkinson's disease;	chr6:28112168	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs35512245	ENSG00000280107.1	AL022393.9	-4.09	5.15e-05	0.00806	-0.24	-0.18	Depression;	chr6:28112175	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs9380055	ENSG00000280107.1	AL022393.9	-4.09	5.15e-05	0.00806	-0.24	-0.18	Depression;	chr6:28113851	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs9368553	ENSG00000280107.1	AL022393.9	-4.09	5.15e-05	0.00806	-0.24	-0.18	Depression;	chr6:28114487	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs9368554	ENSG00000280107.1	AL022393.9	-4.09	5.15e-05	0.00806	-0.24	-0.18	Depression;	chr6:28114933	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs4713137	ENSG00000280107.1	AL022393.9	-4.09	5.15e-05	0.00806	-0.24	-0.18	Depression;	chr6:28115743	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs9348793	ENSG00000280107.1	AL022393.9	-4.09	5.15e-05	0.00806	-0.24	-0.18	Depression;	chr6:28116411	chr6:28170845~28172521:+
LUAD	cis	rs4713118	0.586	rs6905516	ENSG00000280107.1	AL022393.9	-4.09	5.15e-05	0.00806	-0.24	-0.18	Parkinson's disease;	chr6:28118700	chr6:28170845~28172521:+
LUAD	cis	rs4713118	0.586	rs6905522	ENSG00000280107.1	AL022393.9	-4.09	5.15e-05	0.00806	-0.24	-0.18	Parkinson's disease;	chr6:28118701	chr6:28170845~28172521:+
LUAD	cis	rs4713118	0.586	rs9468290	ENSG00000280107.1	AL022393.9	-4.09	5.15e-05	0.00806	-0.24	-0.18	Parkinson's disease;	chr6:28119896	chr6:28170845~28172521:+
LUAD	cis	rs911555	0.755	rs8018400	ENSG00000244691.1	RPL10AP1	4.09	5.15e-05	0.00806	0.24	0.18	Intelligence (multi-trait analysis);	chr14:103434748	chr14:103412119~103412761:-
LUAD	cis	rs6964833	1	rs17515241	ENSG00000278416.1	PMS2L2	-4.09	5.15e-05	0.00806	-0.26	-0.18	Menarche (age at onset);	chr7:74717695	chr7:75344015~75359550:-
LUAD	cis	rs4499344	0.589	rs259233	ENSG00000201388.1	SNORA68	4.09	5.15e-05	0.00806	0.21	0.18	Mean platelet volume;	chr19:32636094	chr19:32608337~32608469:-
LUAD	cis	rs34779708	0.966	rs10827492	ENSG00000271335.4	RP11-324I22.4	-4.09	5.15e-05	0.00806	-0.19	-0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35140897	chr10:35314552~35336401:-
LUAD	cis	rs4639966	0.589	rs480958	ENSG00000278376.1	RP11-158I9.8	-4.09	5.15e-05	0.00807	-0.2	-0.18	Systemic lupus erythematosus;	chr11:118707281	chr11:118791254~118793137:+
LUAD	cis	rs7107174	1	rs2510047	ENSG00000251323.2	RP11-452H21.4	-4.09	5.15e-05	0.00807	-0.22	-0.18	Testicular germ cell tumor;	chr11:78277622	chr11:78423982~78429836:-
LUAD	cis	rs6088580	0.601	rs6059827	ENSG00000276073.1	RP5-1125A11.7	-4.09	5.15e-05	0.00807	-0.18	-0.18	Glomerular filtration rate (creatinine);	chr20:34428552	chr20:33985617~33988989:-
LUAD	cis	rs7829975	0.902	rs485107	ENSG00000173295.6	FAM86B3P	-4.09	5.15e-05	0.00807	-0.19	-0.18	Mood instability;	chr8:8723898	chr8:8228595~8244865:+
LUAD	cis	rs4713118	0.513	rs1225591	ENSG00000216901.1	AL022393.7	4.09	5.15e-05	0.00807	0.23	0.18	Parkinson's disease;	chr6:28180974	chr6:28176188~28176674:+
LUAD	cis	rs748404	0.629	rs34657657	ENSG00000205771.5	CATSPER2P1	-4.09	5.15e-05	0.00807	-0.28	-0.18	Lung cancer;	chr15:43315763	chr15:43726918~43747094:-
LUAD	cis	rs2243480	0.908	rs313822	ENSG00000229886.1	RP5-1132H15.3	4.09	5.16e-05	0.00807	0.32	0.18	Diabetic kidney disease;	chr7:66108952	chr7:66025126~66031544:-
LUAD	cis	rs1318937	0.915	rs3732728	ENSG00000224660.1	SH3BP5-AS1	-4.09	5.16e-05	0.00807	-0.13	-0.18	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15256447	chr3:15254184~15264493:+
LUAD	cis	rs12898179	0.53	rs61988189	ENSG00000258561.1	RP11-72M17.1	4.09	5.16e-05	0.00807	0.28	0.18	Glomerular filtration rate in chronic kidney disease;	chr14:67504257	chr14:66212810~66509394:-
LUAD	cis	rs7208859	0.623	rs7220289	ENSG00000280069.1	CTD-2349P21.3	-4.09	5.16e-05	0.00807	-0.25	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30776744	chr17:30738182~30740275:+
LUAD	cis	rs2904524	1	rs7980085	ENSG00000257815.4	RP11-611E13.2	4.09	5.16e-05	0.00807	0.25	0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70293850	chr12:69904033~70243360:-
LUAD	cis	rs7613875	0.58	rs3774745	ENSG00000234667.1	ACTBP13	4.09	5.16e-05	0.00807	0.2	0.18	Body mass index;	chr3:50167312	chr3:49873347~49877980:-
LUAD	cis	rs2154319	0.887	rs78124119	ENSG00000235358.1	RP11-399E6.1	-4.09	5.16e-05	0.00808	-0.25	-0.18	Height;	chr1:41166929	chr1:41242373~41284861:+
LUAD	cis	rs8056893	0.807	rs7203220	ENSG00000274698.1	RP11-71L14.4	4.09	5.16e-05	0.00808	0.2	0.18	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68322284	chr16:68450283~68452318:+
LUAD	cis	rs8056893	0.807	rs7194378	ENSG00000274698.1	RP11-71L14.4	4.09	5.16e-05	0.00808	0.2	0.18	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68325831	chr16:68450283~68452318:+
LUAD	cis	rs8056893	0.807	rs7200049	ENSG00000274698.1	RP11-71L14.4	4.09	5.16e-05	0.00808	0.2	0.18	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68326551	chr16:68450283~68452318:+
LUAD	cis	rs4713118	0.824	rs7759217	ENSG00000280107.1	AL022393.9	-4.09	5.16e-05	0.00808	-0.23	-0.18	Parkinson's disease;	chr6:27762684	chr6:28170845~28172521:+
LUAD	cis	rs4713118	0.784	rs9468219	ENSG00000280107.1	AL022393.9	-4.09	5.16e-05	0.00808	-0.23	-0.18	Parkinson's disease;	chr6:27763976	chr6:28170845~28172521:+
LUAD	cis	rs17772222	0.916	rs77306894	ENSG00000258789.1	RP11-507K2.3	-4.09	5.16e-05	0.00808	-0.25	-0.18	Coronary artery calcification;	chr14:88494507	chr14:88551597~88552493:+
LUAD	cis	rs4267450	0.697	rs11667683	ENSG00000267323.1	SLC25A1P5	4.09	5.16e-05	0.00808	0.32	0.18	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr19:28381856	chr19:27805423~27806205:-
LUAD	cis	rs42490	0.716	rs43135	ENSG00000251136.7	RP11-37B2.1	-4.09	5.16e-05	0.00808	-0.19	-0.18	Leprosy;	chr8:89823722	chr8:89609409~89757727:-
LUAD	cis	rs2333021	0.711	rs34518714	ENSG00000259015.1	RP11-109N23.6	4.09	5.16e-05	0.00808	0.17	0.18	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72992601	chr14:72960595~72961993:+
LUAD	cis	rs7208859	0.623	rs7219712	ENSG00000266490.1	CTD-2349P21.9	4.08	5.17e-05	0.00809	0.27	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753552	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.573	rs8078656	ENSG00000266490.1	CTD-2349P21.9	4.08	5.17e-05	0.00809	0.27	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753953	chr17:30792372~30792833:+
LUAD	cis	rs2333021	0.801	rs4903086	ENSG00000259015.1	RP11-109N23.6	4.08	5.17e-05	0.00809	0.17	0.18	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72995605	chr14:72960595~72961993:+
LUAD	cis	rs6496044	0.568	rs7166642	ENSG00000259295.5	CSPG4P12	4.08	5.17e-05	0.00809	0.21	0.18	Interstitial lung disease;	chr15:85518040	chr15:85191438~85213905:+
LUAD	cis	rs4664293	0.967	rs13397722	ENSG00000230783.1	AC009961.2	-4.08	5.17e-05	0.00809	-0.23	-0.18	Monocyte percentage of white cells;	chr2:159659140	chr2:159689217~159690291:-
LUAD	cis	rs9951698	0.728	rs35790309	ENSG00000267480.1	RP11-703I16.1	-4.08	5.17e-05	0.00809	-0.22	-0.18	Intelligence (multi-trait analysis);	chr18:13026121	chr18:12031178~12032181:-
LUAD	cis	rs2289583	0.503	rs113742359	ENSG00000261813.2	RP11-151H2.3	4.08	5.17e-05	0.00809	0.2	0.18	Systemic lupus erythematosus;	chr15:74969302	chr15:74976240~74976573:-
LUAD	cis	rs763121	0.853	rs5750664	ENSG00000228274.3	RP3-508I15.9	-4.08	5.17e-05	0.00809	-0.18	-0.18	Menopause (age at onset);	chr22:38676764	chr22:38667585~38681820:-
LUAD	cis	rs763121	0.626	rs5757236	ENSG00000228274.3	RP3-508I15.9	-4.08	5.17e-05	0.00809	-0.18	-0.18	Menopause (age at onset);	chr22:38677819	chr22:38667585~38681820:-
LUAD	cis	rs763121	0.853	rs6001191	ENSG00000228274.3	RP3-508I15.9	-4.08	5.17e-05	0.00809	-0.18	-0.18	Menopause (age at onset);	chr22:38678447	chr22:38667585~38681820:-
LUAD	cis	rs6496044	0.568	rs6496040	ENSG00000259295.5	CSPG4P12	4.08	5.18e-05	0.0081	0.21	0.18	Interstitial lung disease;	chr15:85520898	chr15:85191438~85213905:+
LUAD	cis	rs9295536	0.692	rs7760772	ENSG00000260455.1	NBAT1	4.08	5.18e-05	0.0081	0.22	0.18	Neuroblastoma;	chr6:22119590	chr6:22134957~22147193:-
LUAD	cis	rs8062405	0.754	rs28410083	ENSG00000251417.2	RP11-1348G14.4	4.08	5.18e-05	0.0081	0.18	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620039	chr16:28802743~28817828:+
LUAD	cis	rs8062405	0.789	rs1968751	ENSG00000251417.2	RP11-1348G14.4	4.08	5.18e-05	0.0081	0.18	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620438	chr16:28802743~28817828:+
LUAD	cis	rs4908769	0.553	rs301792	ENSG00000232912.4	RP5-1115A15.1	4.08	5.18e-05	0.0081	0.17	0.18	Allergy;	chr1:8408218	chr1:8424645~8434838:+
LUAD	cis	rs4908769	0.624	rs301790	ENSG00000232912.4	RP5-1115A15.1	4.08	5.18e-05	0.0081	0.17	0.18	Allergy;	chr1:8409224	chr1:8424645~8434838:+
LUAD	cis	rs4841134	0.967	rs4240623	ENSG00000233609.3	RP11-62H7.2	-4.08	5.18e-05	0.0081	-0.15	-0.18	Age-related disease endophenotypes;	chr8:9326692	chr8:8961200~8979025:+
LUAD	cis	rs8028182	0.636	rs12708519	ENSG00000260269.4	CTD-2323K18.1	-4.08	5.18e-05	0.0081	-0.25	-0.18	Sudden cardiac arrest;	chr15:75510859	chr15:75527150~75601205:-
LUAD	cis	rs8028182	0.636	rs8029112	ENSG00000260269.4	CTD-2323K18.1	-4.08	5.18e-05	0.0081	-0.25	-0.18	Sudden cardiac arrest;	chr15:75516631	chr15:75527150~75601205:-
LUAD	cis	rs1876905	0.597	rs354551	ENSG00000271789.1	RP5-1112D6.7	-4.08	5.18e-05	0.0081	-0.26	-0.18	Mean corpuscular hemoglobin;	chr6:111224337	chr6:111297126~111298510:+
LUAD	cis	rs2711721	1	rs2711724	ENSG00000276691.1	RP5-1057I20.5	-4.08	5.18e-05	0.00811	-0.2	-0.18	Prostate cancer (SNP x SNP interaction);	chr12:46976766	chr12:47788426~47788971:+
LUAD	cis	rs2711721	1	rs2522252	ENSG00000276691.1	RP5-1057I20.5	-4.08	5.18e-05	0.00811	-0.2	-0.18	Prostate cancer (SNP x SNP interaction);	chr12:46977587	chr12:47788426~47788971:+
LUAD	cis	rs9907295	0.688	rs28722787	ENSG00000270977.1	AC015849.16	-4.08	5.18e-05	0.00811	-0.27	-0.18	Fibroblast growth factor basic levels;	chr17:35922795	chr17:35893707~35911023:-
LUAD	cis	rs7551222	0.716	rs7541589	ENSG00000240219.1	RP11-430C7.5	4.08	5.18e-05	0.00811	0.19	0.18	Schizophrenia;	chr1:204573393	chr1:204626775~204629712:+
LUAD	cis	rs4372836	0.964	rs4408686	ENSG00000226833.4	AC097724.3	-4.08	5.19e-05	0.00811	-0.22	-0.18	Body mass index;	chr2:28717660	chr2:28708953~28736205:-
LUAD	cis	rs9840812	0.559	rs6439640	ENSG00000239213.4	NCK1-AS1	4.08	5.19e-05	0.00811	0.26	0.18	Fibrinogen levels;	chr3:136466838	chr3:136841726~136862054:-
LUAD	cis	rs1005277	0.683	rs7923868	ENSG00000263064.2	RP11-291L22.7	4.08	5.19e-05	0.00811	0.19	0.18	Extrinsic epigenetic age acceleration;	chr10:37700838	chr10:38448689~38448949:+
LUAD	cis	rs9646944	0.501	rs34946515	ENSG00000234389.1	AC007278.3	4.08	5.19e-05	0.00811	0.21	0.18	Blood protein levels;	chr2:102426860	chr2:102438713~102440475:+
LUAD	cis	rs9545047	0.604	rs943712	ENSG00000227354.5	RBM26-AS1	4.08	5.19e-05	0.00812	0.19	0.18	Schizophrenia;	chr13:79282671	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs943711	ENSG00000227354.5	RBM26-AS1	4.08	5.19e-05	0.00812	0.19	0.18	Schizophrenia;	chr13:79282886	chr13:79406309~79424328:+
LUAD	cis	rs9847710	0.818	rs6445558	ENSG00000242142.1	SERBP1P3	-4.08	5.19e-05	0.00812	-0.2	-0.18	Ulcerative colitis;	chr3:53063644	chr3:53064283~53065091:-
LUAD	cis	rs6723108	0.627	rs12469941	ENSG00000224043.6	CCNT2-AS1	4.08	5.19e-05	0.00812	0.23	0.18	Type 2 diabetes;	chr2:134872357	chr2:134735464~134918710:-
LUAD	cis	rs1431005	0.893	rs67136716	ENSG00000250658.1	RP11-138B4.1	4.08	5.19e-05	0.00812	0.23	0.18	Response to statin therapy;	chr4:187414928	chr4:187304083~187309682:-
LUAD	cis	rs10129255	0.744	rs28517388	ENSG00000211947.2	IGHV3-21	-4.08	5.19e-05	0.00812	-0.13	-0.18	Kawasaki disease;	chr14:106704323	chr14:106235064~106235594:-
LUAD	cis	rs11886999	0.812	rs4826	ENSG00000237510.6	AC008268.2	-4.08	5.19e-05	0.00812	-0.3	-0.18	Cardiac Troponin-T levels;	chr2:96185147	chr2:95789654~95800166:+
LUAD	cis	rs783540	0.656	rs783524	ENSG00000255769.6	GOLGA2P10	4.08	5.19e-05	0.00812	0.21	0.18	Schizophrenia;	chr15:82615393	chr15:82472993~82513950:-
LUAD	cis	rs2836974	0.627	rs9981301	ENSG00000232608.1	TIMM9P2	4.08	5.19e-05	0.00812	0.22	0.18	Cognitive function;	chr21:39314152	chr21:39216624~39217506:+
LUAD	cis	rs858239	0.539	rs6955969	ENSG00000226816.2	AC005082.12	4.08	5.19e-05	0.00812	0.24	0.18	Cerebrospinal fluid biomarker levels;	chr7:23147080	chr7:23206013~23208045:+
LUAD	cis	rs6964587	1	rs10234071	ENSG00000188693.7	CYP51A1-AS1	4.08	5.2e-05	0.00812	0.21	0.18	Breast cancer;	chr7:92015838	chr7:92134604~92180725:+
LUAD	cis	rs860818	1	rs858242	ENSG00000226816.2	AC005082.12	4.08	5.2e-05	0.00812	0.48	0.18	Initial pursuit acceleration;	chr7:23185723	chr7:23206013~23208045:+
LUAD	cis	rs860818	1	rs1637223	ENSG00000226816.2	AC005082.12	4.08	5.2e-05	0.00812	0.48	0.18	Initial pursuit acceleration;	chr7:23189050	chr7:23206013~23208045:+
LUAD	cis	rs860818	0.744	rs1728319	ENSG00000226816.2	AC005082.12	4.08	5.2e-05	0.00812	0.48	0.18	Initial pursuit acceleration;	chr7:23191580	chr7:23206013~23208045:+
LUAD	cis	rs860818	1	rs1637220	ENSG00000226816.2	AC005082.12	4.08	5.2e-05	0.00812	0.48	0.18	Initial pursuit acceleration;	chr7:23193232	chr7:23206013~23208045:+
LUAD	cis	rs34779708	0.931	rs11010083	ENSG00000271335.4	RP11-324I22.4	4.08	5.2e-05	0.00812	0.19	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35062603	chr10:35314552~35336401:-
LUAD	cis	rs9593057	0.579	rs58023138	ENSG00000234835.1	PHBP13	-4.08	5.2e-05	0.00813	-0.41	-0.18	Lobe attachment (rater-scored or self-reported);	chr13:34991129	chr13:35251070~35251829:+
LUAD	cis	rs516842	0.655	rs112114210	ENSG00000234835.1	PHBP13	-4.08	5.2e-05	0.00813	-0.41	-0.18	Lobe attachment (rater-scored or self-reported);	chr13:34992979	chr13:35251070~35251829:+
LUAD	cis	rs10197140	0.857	rs13424637	ENSG00000235721.1	AC013268.3	-4.08	5.2e-05	0.00813	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110867021	chr2:110007675~110010783:+
LUAD	cis	rs6964587	1	rs10281556	ENSG00000188693.7	CYP51A1-AS1	4.08	5.2e-05	0.00813	0.21	0.18	Breast cancer;	chr7:92030739	chr7:92134604~92180725:+
LUAD	cis	rs9815354	1	rs7624372	ENSG00000273328.4	RP11-141M3.6	-4.08	5.2e-05	0.00813	-0.27	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41839615	chr3:42809414~42908105:+
LUAD	cis	rs4713118	0.699	rs573179	ENSG00000226314.6	ZNF192P1	-4.08	5.2e-05	0.00813	-0.24	-0.18	Parkinson's disease;	chr6:27881898	chr6:28161781~28169594:+
LUAD	cis	rs8028182	0.636	rs28783769	ENSG00000260269.4	CTD-2323K18.1	-4.08	5.2e-05	0.00813	-0.26	-0.18	Sudden cardiac arrest;	chr15:75556668	chr15:75527150~75601205:-
LUAD	cis	rs5742933	0.725	rs1132360	ENSG00000253559.1	OSGEPL1-AS1	4.08	5.2e-05	0.00813	0.22	0.18	Ferritin levels;	chr2:189661498	chr2:189762704~189765556:+
LUAD	cis	rs2348418	0.83	rs7977418	ENSG00000247934.4	RP11-967K21.1	4.08	5.2e-05	0.00813	0.21	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28435309	chr12:28163298~28190738:-
LUAD	cis	rs9341808	0.905	rs3805903	ENSG00000260645.1	RP11-250B2.5	4.08	5.2e-05	0.00813	0.17	0.18	Sitting height ratio;	chr6:80266112	chr6:80466958~80469080:+
LUAD	cis	rs651907	0.557	rs17347644	ENSG00000244119.1	PDCL3P4	4.08	5.2e-05	0.00813	0.19	0.18	Colorectal cancer;	chr3:101828889	chr3:101712472~101713191:+
LUAD	cis	rs3020736	0.5	rs7292241	ENSG00000205702.9	CYP2D7	-4.08	5.2e-05	0.00813	-0.15	-0.18	Autism spectrum disorder or schizophrenia;	chr22:42096059	chr22:42140203~42144577:-
LUAD	cis	rs13434995	0.513	rs13134079	ENSG00000273257.1	RP11-177J6.1	4.08	5.2e-05	0.00813	0.24	0.18	Adiponectin levels;	chr4:55542021	chr4:55387949~55388271:+
LUAD	cis	rs4363385	0.55	rs6661932	ENSG00000223599.1	RP11-216N14.7	-4.08	5.2e-05	0.00814	-0.22	-0.18	Inflammatory skin disease;	chr1:152924258	chr1:153852106~153853414:-
LUAD	cis	rs523522	0.962	rs10849758	ENSG00000278344.1	RP11-18C24.8	4.08	5.2e-05	0.00814	0.25	0.18	High light scatter reticulocyte count;	chr12:120533346	chr12:120500735~120501090:-
LUAD	cis	rs523522	0.962	rs11065154	ENSG00000278344.1	RP11-18C24.8	4.08	5.2e-05	0.00814	0.25	0.18	High light scatter reticulocyte count;	chr12:120533614	chr12:120500735~120501090:-
LUAD	cis	rs523522	0.926	rs10774555	ENSG00000278344.1	RP11-18C24.8	4.08	5.2e-05	0.00814	0.25	0.18	High light scatter reticulocyte count;	chr12:120534175	chr12:120500735~120501090:-
LUAD	cis	rs523522	0.962	rs4767912	ENSG00000278344.1	RP11-18C24.8	4.08	5.2e-05	0.00814	0.25	0.18	High light scatter reticulocyte count;	chr12:120543399	chr12:120500735~120501090:-
LUAD	cis	rs523522	0.962	rs7488320	ENSG00000278344.1	RP11-18C24.8	4.08	5.2e-05	0.00814	0.25	0.18	High light scatter reticulocyte count;	chr12:120543827	chr12:120500735~120501090:-
LUAD	cis	rs13276960	0.868	rs7015831	ENSG00000253328.2	SUMO2P19	-4.08	5.21e-05	0.00814	-0.21	-0.18	Schizophrenia;	chr8:102922054	chr8:102242040~102242619:-
LUAD	cis	rs6723108	0.604	rs1374291	ENSG00000224043.6	CCNT2-AS1	-4.08	5.21e-05	0.00814	-0.23	-0.18	Type 2 diabetes;	chr2:134896768	chr2:134735464~134918710:-
LUAD	cis	rs2446066	0.799	rs76805893	ENSG00000257379.1	RP11-793H13.8	4.08	5.21e-05	0.00815	0.31	0.18	Red blood cell count;	chr12:53436335	chr12:53441741~53467528:+
LUAD	cis	rs1044826	1	rs747346	ENSG00000214280.3	RP11-553K23.2	-4.08	5.21e-05	0.00815	-0.21	-0.18	Obesity-related traits;	chr3:139513072	chr3:139582928~139583593:-
LUAD	cis	rs8073060	0.544	rs8072676	ENSG00000267592.1	CTC-507E2.2	4.08	5.21e-05	0.00815	0.26	0.18	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35672498	chr17:35596904~35597128:-
LUAD	cis	rs3743162	0.553	rs4842994	ENSG00000225151.9	GOLGA2P7	4.08	5.21e-05	0.00815	0.26	0.18	Alzheimer's disease (age of onset);	chr15:84872568	chr15:84199311~84230136:-
LUAD	cis	rs853679	0.517	rs4711164	ENSG00000280107.1	AL022393.9	-4.08	5.22e-05	0.00815	-0.25	-0.18	Depression;	chr6:28147378	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs4711165	ENSG00000280107.1	AL022393.9	-4.08	5.22e-05	0.00815	-0.25	-0.18	Depression;	chr6:28147406	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs4713148	ENSG00000280107.1	AL022393.9	-4.08	5.22e-05	0.00815	-0.25	-0.18	Depression;	chr6:28148143	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs9348794	ENSG00000280107.1	AL022393.9	-4.08	5.22e-05	0.00815	-0.25	-0.18	Depression;	chr6:28149979	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs9468297	ENSG00000280107.1	AL022393.9	-4.08	5.22e-05	0.00815	-0.25	-0.18	Depression;	chr6:28151096	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs9295758	ENSG00000280107.1	AL022393.9	-4.08	5.22e-05	0.00815	-0.25	-0.18	Depression;	chr6:28152885	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs17774663	ENSG00000280107.1	AL022393.9	-4.08	5.22e-05	0.00815	-0.25	-0.18	Depression;	chr6:28153120	chr6:28170845~28172521:+
LUAD	cis	rs2732480	0.577	rs1489109	ENSG00000240399.1	RP1-228P16.1	4.08	5.22e-05	0.00815	0.19	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344997	chr12:48054813~48055591:-
LUAD	cis	rs2732480	0.577	rs1489108	ENSG00000240399.1	RP1-228P16.1	4.08	5.22e-05	0.00815	0.19	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344998	chr12:48054813~48055591:-
LUAD	cis	rs6964587	1	rs10263309	ENSG00000188693.7	CYP51A1-AS1	-4.08	5.22e-05	0.00815	-0.21	-0.18	Breast cancer;	chr7:92015951	chr7:92134604~92180725:+
LUAD	cis	rs6964587	1	rs28410528	ENSG00000188693.7	CYP51A1-AS1	-4.08	5.22e-05	0.00815	-0.21	-0.18	Breast cancer;	chr7:92018076	chr7:92134604~92180725:+
LUAD	cis	rs6964587	1	rs2888851	ENSG00000188693.7	CYP51A1-AS1	-4.08	5.22e-05	0.00815	-0.21	-0.18	Breast cancer;	chr7:92019027	chr7:92134604~92180725:+
LUAD	cis	rs6964587	1	rs13231238	ENSG00000188693.7	CYP51A1-AS1	-4.08	5.22e-05	0.00815	-0.21	-0.18	Breast cancer;	chr7:92024537	chr7:92134604~92180725:+
LUAD	cis	rs6964587	1	rs2299238	ENSG00000188693.7	CYP51A1-AS1	-4.08	5.22e-05	0.00815	-0.21	-0.18	Breast cancer;	chr7:92025203	chr7:92134604~92180725:+
LUAD	cis	rs1401999	1	rs1533684	ENSG00000223882.1	ABCC5-AS1	-4.08	5.22e-05	0.00816	-0.19	-0.18	Anterior chamber depth;	chr3:183918027	chr3:184006338~184011419:+
LUAD	cis	rs4934494	0.768	rs2094214	ENSG00000240996.1	RP11-80H5.7	-4.08	5.22e-05	0.00816	-0.25	-0.18	Red blood cell count;	chr10:89649624	chr10:89694295~89697928:-
LUAD	cis	rs12935418	0.561	rs2287991	ENSG00000261061.1	RP11-303E16.2	-4.08	5.22e-05	0.00816	-0.21	-0.18	Mean corpuscular volume;	chr16:81006950	chr16:81030770~81031485:+
LUAD	cis	rs6142102	0.961	rs2284387	ENSG00000275784.1	RP5-1125A11.6	-4.08	5.22e-05	0.00816	-0.2	-0.18	Skin pigmentation;	chr20:34056782	chr20:33989480~33991818:-
LUAD	cis	rs7119038	0.774	rs11217001	ENSG00000255422.1	AP002954.4	4.08	5.22e-05	0.00816	0.29	0.18	Sjögren's syndrome;	chr11:118736337	chr11:118704607~118750263:+
LUAD	cis	rs12579720	0.868	rs7980003	ENSG00000255910.1	RP11-405A12.2	4.08	5.22e-05	0.00816	0.23	0.18	Diastolic blood pressure;	chr12:20039336	chr12:19775451~20009937:+
LUAD	cis	rs1005277	0.522	rs1208767	ENSG00000273019.1	RP11-508N22.13	-4.08	5.22e-05	0.00816	-0.21	-0.18	Extrinsic epigenetic age acceleration;	chr10:37753367	chr10:38149968~38150293:+
LUAD	cis	rs17122278	0.929	rs11216917	ENSG00000243431.1	RPL5P30	4.08	5.22e-05	0.00816	0.22	0.18	Total cholesterol levels;	chr11:118591445	chr11:118560690~118561580:+
LUAD	cis	rs17122278	1	rs11216925	ENSG00000243431.1	RPL5P30	4.08	5.22e-05	0.00816	0.22	0.18	Total cholesterol levels;	chr11:118600708	chr11:118560690~118561580:+
LUAD	cis	rs17122278	1	rs10892245	ENSG00000243431.1	RPL5P30	4.08	5.22e-05	0.00816	0.22	0.18	Total cholesterol levels;	chr11:118601639	chr11:118560690~118561580:+
LUAD	cis	rs17122278	1	rs17742	ENSG00000243431.1	RPL5P30	4.08	5.22e-05	0.00816	0.22	0.18	Total cholesterol levels;	chr11:118602670	chr11:118560690~118561580:+
LUAD	cis	rs4908768	0.52	rs11121216	ENSG00000270282.1	RP5-1115A15.2	4.08	5.22e-05	0.00816	0.2	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8678885	chr1:8512653~8513021:+
LUAD	cis	rs1044826	1	rs13074208	ENSG00000214280.3	RP11-553K23.2	-4.08	5.23e-05	0.00816	-0.22	-0.18	Obesity-related traits;	chr3:139488309	chr3:139582928~139583593:-
LUAD	cis	rs1044826	1	rs12695700	ENSG00000214280.3	RP11-553K23.2	-4.08	5.23e-05	0.00816	-0.22	-0.18	Obesity-related traits;	chr3:139493256	chr3:139582928~139583593:-
LUAD	cis	rs1044826	0.913	rs9860521	ENSG00000214280.3	RP11-553K23.2	-4.08	5.23e-05	0.00816	-0.22	-0.18	Obesity-related traits;	chr3:139495717	chr3:139582928~139583593:-
LUAD	cis	rs2711721	1	rs2522278	ENSG00000276691.1	RP5-1057I20.5	-4.08	5.23e-05	0.00816	-0.2	-0.18	Prostate cancer (SNP x SNP interaction);	chr12:46973299	chr12:47788426~47788971:+
LUAD	cis	rs9467773	1	rs1884949	ENSG00000261353.1	CTA-14H9.5	-4.08	5.23e-05	0.00817	-0.2	-0.18	Intelligence (multi-trait analysis);	chr6:26567839	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs9467796	ENSG00000261353.1	CTA-14H9.5	-4.08	5.23e-05	0.00817	-0.2	-0.18	Intelligence (multi-trait analysis);	chr6:26568183	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs9467797	ENSG00000261353.1	CTA-14H9.5	-4.08	5.23e-05	0.00817	-0.2	-0.18	Intelligence (multi-trait analysis);	chr6:26568245	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs1078679	ENSG00000261353.1	CTA-14H9.5	-4.08	5.23e-05	0.00817	-0.2	-0.18	Intelligence (multi-trait analysis);	chr6:26568513	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs6932156	ENSG00000261353.1	CTA-14H9.5	-4.08	5.23e-05	0.00817	-0.2	-0.18	Intelligence (multi-trait analysis);	chr6:26571278	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs6924838	ENSG00000261353.1	CTA-14H9.5	-4.08	5.23e-05	0.00817	-0.2	-0.18	Intelligence (multi-trait analysis);	chr6:26571528	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs6925895	ENSG00000261353.1	CTA-14H9.5	-4.08	5.23e-05	0.00817	-0.2	-0.18	Intelligence (multi-trait analysis);	chr6:26571937	chr6:26527063~26527404:+
LUAD	cis	rs133885	1	rs133885	ENSG00000272977.1	CTA-390C10.10	-4.08	5.23e-05	0.00817	-0.19	-0.18	Mathematical ability in children with dyslexia;	chr22:25763322	chr22:25476218~25479971:+
LUAD	cis	rs860818	1	rs860817	ENSG00000226816.2	AC005082.12	4.08	5.23e-05	0.00817	0.5	0.18	Initial pursuit acceleration;	chr7:23211850	chr7:23206013~23208045:+
LUAD	cis	rs6687821	0.515	rs61800752	ENSG00000261737.1	RP4-612B15.3	-4.08	5.23e-05	0.00817	-0.26	-0.18	Yeast infection;	chr1:86932001	chr1:86703502~86704462:-
LUAD	cis	rs6687821	0.515	rs56291917	ENSG00000261737.1	RP4-612B15.3	-4.08	5.23e-05	0.00817	-0.26	-0.18	Yeast infection;	chr1:86934926	chr1:86703502~86704462:-
LUAD	cis	rs11089937	0.857	rs5750580	ENSG00000211638.2	IGLV8-61	-4.08	5.23e-05	0.00817	-0.18	-0.18	Periodontitis (PAL4Q3);	chr22:22137471	chr22:22098700~22099212:+
LUAD	cis	rs3845817	0.868	rs702891	ENSG00000281920.1	RP11-418H16.1	4.08	5.23e-05	0.00817	0.23	0.18	Bipolar disorder;	chr2:65531316	chr2:65623272~65628424:+
LUAD	cis	rs763121	0.853	rs5757211	ENSG00000225450.1	RP3-508I15.14	-4.08	5.23e-05	0.00817	-0.18	-0.18	Menopause (age at onset);	chr22:38655700	chr22:38739003~38749041:+
LUAD	cis	rs7560272	0.549	rs2421554	ENSG00000163016.8	ALMS1P	4.08	5.23e-05	0.00817	0.2	0.18	Schizophrenia;	chr2:73579075	chr2:73644919~73685576:+
LUAD	cis	rs7870753	0.578	rs7861768	ENSG00000188801.9	ZNF322P1	4.08	5.23e-05	0.00817	0.28	0.18	Height;	chr9:96388497	chr9:97198303~97199511:-
LUAD	cis	rs7870753	0.578	rs7035328	ENSG00000188801.9	ZNF322P1	4.08	5.23e-05	0.00817	0.28	0.18	Height;	chr9:96389148	chr9:97198303~97199511:-
LUAD	cis	rs10197140	0.816	rs28855668	ENSG00000235721.1	AC013268.3	-4.08	5.23e-05	0.00817	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110898010	chr2:110007675~110010783:+
LUAD	cis	rs10463554	0.889	rs246899	ENSG00000250682.4	LINC00491	4.08	5.23e-05	0.00817	0.23	0.18	Parkinson's disease;	chr5:103241438	chr5:102609156~102671559:-
LUAD	cis	rs6496044	0.611	rs6496055	ENSG00000259295.5	CSPG4P12	4.08	5.23e-05	0.00818	0.21	0.18	Interstitial lung disease;	chr15:85527457	chr15:85191438~85213905:+
LUAD	cis	rs6840360	0.571	rs875668	ENSG00000270265.1	RP11-731D1.4	-4.08	5.23e-05	0.00818	-0.21	-0.18	Intelligence (multi-trait analysis);	chr4:151604509	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.571	rs4696275	ENSG00000270265.1	RP11-731D1.4	-4.08	5.23e-05	0.00818	-0.21	-0.18	Intelligence (multi-trait analysis);	chr4:151609829	chr4:151333775~151353224:-
LUAD	cis	rs7824557	0.564	rs2736290	ENSG00000255046.1	RP11-297N6.4	4.08	5.24e-05	0.00818	0.23	0.18	Retinal vascular caliber;	chr8:11376789	chr8:11797928~11802568:-
LUAD	cis	rs4474465	1	rs4944200	ENSG00000251323.2	RP11-452H21.4	4.08	5.24e-05	0.00818	0.23	0.18	Alzheimer's disease (survival time);	chr11:78455884	chr11:78423982~78429836:-
LUAD	cis	rs6832769	1	rs7677526	ENSG00000272969.1	RP11-528I4.2	4.08	5.24e-05	0.00818	0.19	0.18	Personality dimensions;	chr4:55483741	chr4:55547112~55547889:+
LUAD	cis	rs6496932	0.663	rs11074169	ENSG00000259630.2	CTD-2262B20.1	-4.08	5.24e-05	0.00818	-0.23	-0.18	Central corneal thickness;Corneal structure;	chr15:85375721	chr15:85415228~85415633:+
LUAD	cis	rs8056893	0.921	rs2863979	ENSG00000274698.1	RP11-71L14.4	4.08	5.24e-05	0.00818	0.21	0.18	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68297987	chr16:68450283~68452318:+
LUAD	cis	rs6452524	0.618	rs1478487	ENSG00000281327.1	LINC01338	4.08	5.24e-05	0.00818	0.19	0.18	Hypertension (SNP x SNP interaction);	chr5:83080900	chr5:82850864~82859836:-
LUAD	cis	rs34792	0.688	rs153782	ENSG00000207425.1	Y_RNA	4.08	5.24e-05	0.00818	0.22	0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15507763	chr16:14915457~14915556:-
LUAD	cis	rs10129255	0.957	rs11847726	ENSG00000274576.2	IGHV2-70	4.08	5.24e-05	0.00818	0.16	0.18	Kawasaki disease;	chr14:106779116	chr14:106770577~106771020:-
LUAD	cis	rs894638	0.636	rs73126488	ENSG00000263327.5	TAPT1-AS1	-4.08	5.24e-05	0.00818	-0.23	-0.18	Glomerular filtration rate in chronic kidney disease;	chr4:16118498	chr4:16226685~16320140:+
LUAD	cis	rs2243480	1	rs160646	ENSG00000229886.1	RP5-1132H15.3	4.08	5.24e-05	0.00819	0.31	0.18	Diabetic kidney disease;	chr7:66091293	chr7:66025126~66031544:-
LUAD	cis	rs11089937	0.597	rs4821772	ENSG00000211640.3	IGLV6-57	-4.08	5.24e-05	0.00819	-0.14	-0.18	Periodontitis (PAL4Q3);	chr22:22131383	chr22:22195713~22196460:+
LUAD	cis	rs6142102	0.961	rs4911389	ENSG00000275784.1	RP5-1125A11.6	-4.08	5.24e-05	0.00819	-0.21	-0.18	Skin pigmentation;	chr20:33977235	chr20:33989480~33991818:-
LUAD	cis	rs3742264	0.961	rs11620307	ENSG00000235903.6	CPB2-AS1	-4.08	5.24e-05	0.00819	-0.23	-0.18	Blood protein levels;	chr13:46075586	chr13:46052806~46113332:+
LUAD	cis	rs62025270	0.632	rs17571078	ENSG00000202081.1	RNU6-1280P	-4.08	5.24e-05	0.00819	-0.27	-0.18	Idiopathic pulmonary fibrosis;	chr15:85597248	chr15:85651522~85651628:-
LUAD	cis	rs9646944	0.501	rs10197310	ENSG00000234389.1	AC007278.3	-4.08	5.25e-05	0.00819	-0.21	-0.18	Blood protein levels;	chr2:102403570	chr2:102438713~102440475:+
LUAD	cis	rs34779708	0.966	rs34776628	ENSG00000271335.4	RP11-324I22.4	4.08	5.25e-05	0.00819	0.19	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35137396	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.966	rs17499247	ENSG00000271335.4	RP11-324I22.4	4.08	5.25e-05	0.00819	0.19	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35137827	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.966	rs10827491	ENSG00000271335.4	RP11-324I22.4	4.08	5.25e-05	0.00819	0.19	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35138467	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.966	rs4934732	ENSG00000271335.4	RP11-324I22.4	4.08	5.25e-05	0.00819	0.19	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35142756	chr10:35314552~35336401:-
LUAD	cis	rs6519955	0.86	rs8136098	ENSG00000231711.2	LINC00899	4.08	5.25e-05	0.00819	0.17	0.18	Dupuytren's disease;	chr22:46029766	chr22:46039907~46044853:-
LUAD	cis	rs1979679	0.801	rs1463571	ENSG00000278733.1	RP11-425D17.1	4.08	5.25e-05	0.00819	0.23	0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28144514	chr12:28185625~28186190:-
LUAD	cis	rs10510102	0.516	rs79528809	ENSG00000276742.1	RP11-500G22.4	4.08	5.25e-05	0.0082	0.3	0.18	Breast cancer;	chr10:121980309	chr10:121956782~121957098:+
LUAD	cis	rs728616	0.717	rs116884206	ENSG00000225484.5	NUTM2B-AS1	-4.08	5.25e-05	0.0082	-0.49	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80230790	chr10:79663088~79826594:-
LUAD	cis	rs950169	1	rs12902672	ENSG00000275120.1	RP11-182J1.17	4.08	5.25e-05	0.0082	0.29	0.18	Schizophrenia;	chr15:84048234	chr15:84599434~84606463:-
LUAD	cis	rs8014252	1	rs77867352	ENSG00000259158.2	ADAM20P1	-4.08	5.25e-05	0.0082	-0.29	-0.18	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70427904	chr14:70468881~70483756:-
LUAD	cis	rs8014252	1	rs12436464	ENSG00000259158.2	ADAM20P1	-4.08	5.25e-05	0.0082	-0.29	-0.18	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70449684	chr14:70468881~70483756:-
LUAD	cis	rs17301013	0.861	rs332789	ENSG00000227373.4	RP11-160H22.5	4.08	5.25e-05	0.0082	0.23	0.18	Systemic lupus erythematosus;	chr1:174735754	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.932	rs461910	ENSG00000227373.4	RP11-160H22.5	4.08	5.25e-05	0.0082	0.23	0.18	Systemic lupus erythematosus;	chr1:174736351	chr1:174115300~174160004:-
LUAD	cis	rs77688320	0.535	rs7579617	ENSG00000213090.2	AC007256.5	4.08	5.25e-05	0.0082	0.21	0.18	Breast cancer;	chr2:201384065	chr2:201410544~201413308:-
LUAD	cis	rs7560272	0.669	rs13008860	ENSG00000163016.8	ALMS1P	4.08	5.25e-05	0.0082	0.2	0.18	Schizophrenia;	chr2:73546892	chr2:73644919~73685576:+
LUAD	cis	rs8054556	0.74	rs8059619	ENSG00000183604.13	SMG1P5	-4.08	5.25e-05	0.0082	-0.18	-0.18	Autism spectrum disorder or schizophrenia;	chr16:29914124	chr16:30267553~30335374:-
LUAD	cis	rs8054556	0.74	rs10083738	ENSG00000183604.13	SMG1P5	-4.08	5.25e-05	0.0082	-0.18	-0.18	Autism spectrum disorder or schizophrenia;	chr16:29916381	chr16:30267553~30335374:-
LUAD	cis	rs2735413	0.564	rs78898310	ENSG00000276007.1	RP11-358L22.3	4.08	5.25e-05	0.0082	0.26	0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78081613	chr16:78123243~78124332:+
LUAD	cis	rs524281	0.731	rs10896075	ENSG00000255320.1	RP11-755F10.1	-4.08	5.26e-05	0.0082	-0.3	-0.18	Electroencephalogram traits;	chr11:66024742	chr11:66244840~66246239:-
LUAD	cis	rs394563	0.717	rs548848	ENSG00000216906.2	RP11-350J20.9	4.08	5.26e-05	0.0082	0.22	0.18	Dupuytren's disease;	chr6:149460873	chr6:149904243~149906418:+
LUAD	cis	rs4604732	0.812	rs6663238	ENSG00000227135.1	GCSAML-AS1	4.08	5.26e-05	0.0082	0.26	0.18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247461669	chr1:247524679~247526752:-
LUAD	cis	rs865483	0.895	rs2522966	ENSG00000276054.1	RP11-378E13.3	-4.08	5.26e-05	0.0082	-0.22	-0.18	Monocyte count;	chr17:37456514	chr17:37386886~37387926:+
LUAD	cis	rs9341808	0.538	rs9343980	ENSG00000260645.1	RP11-250B2.5	-4.08	5.26e-05	0.0082	-0.18	-0.18	Sitting height ratio;	chr6:80313715	chr6:80466958~80469080:+
LUAD	cis	rs6964833	1	rs4717907	ENSG00000184616.8	AC004166.6	4.08	5.26e-05	0.0082	0.26	0.18	Menarche (age at onset);	chr7:74672169	chr7:74906673~74913256:-
LUAD	cis	rs875971	0.545	rs1909508	ENSG00000222364.1	RNU6-96P	-4.08	5.26e-05	0.00821	-0.23	-0.18	Aortic root size;	chr7:66301366	chr7:66395191~66395286:+
LUAD	cis	rs12440869	1	rs6494640	ENSG00000270964.1	RP11-502I4.3	-4.08	5.26e-05	0.00821	-0.21	-0.18	Peak velocity of the mitral A-wave;	chr15:67247579	chr15:67541072~67542604:-
LUAD	cis	rs9549260	0.755	rs12585875	ENSG00000229456.1	RLIMP1	4.08	5.26e-05	0.00821	0.2	0.18	Red blood cell count;	chr13:40625394	chr13:40618738~40621348:+
LUAD	cis	rs6472235	0.586	rs4565445	ENSG00000200714.1	Y_RNA	4.08	5.26e-05	0.00821	0.24	0.18	Plateletcrit;Myopia (pathological);	chr8:66005841	chr8:65592731~65592820:+
LUAD	cis	rs11168618	0.561	rs4075258	ENSG00000240399.1	RP1-228P16.1	4.08	5.26e-05	0.00821	0.18	0.18	Adiponectin levels;	chr12:48525876	chr12:48054813~48055591:-
LUAD	cis	rs1799949	0.965	rs9646413	ENSG00000236383.6	LINC00854	-4.08	5.26e-05	0.00822	-0.14	-0.18	Menopause (age at onset);	chr17:43348789	chr17:43216941~43305976:-
LUAD	cis	rs12744310	1	rs12035012	ENSG00000235358.1	RP11-399E6.1	4.08	5.26e-05	0.00822	0.24	0.18	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41284976	chr1:41242373~41284861:+
LUAD	cis	rs12579720	0.601	rs10743356	ENSG00000255910.1	RP11-405A12.2	-4.08	5.26e-05	0.00822	-0.22	-0.18	Diastolic blood pressure;	chr12:20082105	chr12:19775451~20009937:+
LUAD	cis	rs10510102	0.516	rs3936070	ENSG00000276742.1	RP11-500G22.4	4.08	5.27e-05	0.00822	0.31	0.18	Breast cancer;	chr10:121974440	chr10:121956782~121957098:+
LUAD	cis	rs11220082	0.644	rs36143594	ENSG00000254671.2	STT3A-AS1	-4.08	5.27e-05	0.00822	-0.21	-0.18	Schizophrenia;	chr11:125457076	chr11:125570284~125592568:-
LUAD	cis	rs6840360	0.617	rs2724563	ENSG00000270265.1	RP11-731D1.4	-4.08	5.27e-05	0.00822	-0.18	-0.18	Intelligence (multi-trait analysis);	chr4:151428807	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.617	rs2724564	ENSG00000270265.1	RP11-731D1.4	-4.08	5.27e-05	0.00822	-0.18	-0.18	Intelligence (multi-trait analysis);	chr4:151428810	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.607	rs2724565	ENSG00000270265.1	RP11-731D1.4	-4.08	5.27e-05	0.00822	-0.18	-0.18	Intelligence (multi-trait analysis);	chr4:151429153	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.642	rs2724568	ENSG00000270265.1	RP11-731D1.4	-4.08	5.27e-05	0.00822	-0.18	-0.18	Intelligence (multi-trait analysis);	chr4:151431071	chr4:151333775~151353224:-
LUAD	cis	rs6964587	0.967	rs7783414	ENSG00000188693.7	CYP51A1-AS1	-4.08	5.27e-05	0.00822	-0.22	-0.18	Breast cancer;	chr7:92156643	chr7:92134604~92180725:+
LUAD	cis	rs7617480	0.61	rs4955420	ENSG00000225399.4	RP11-3B7.1	4.08	5.27e-05	0.00822	0.25	0.18	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49171432	chr3:49260085~49261316:+
LUAD	cis	rs7302981	0.845	rs56709084	ENSG00000272368.2	RP4-605O3.4	4.08	5.27e-05	0.00822	0.2	0.18	Systolic blood pressure;	chr12:50170107	chr12:50112197~50165618:+
LUAD	cis	rs6686842	0.56	rs213744	ENSG00000235358.1	RP11-399E6.1	4.08	5.27e-05	0.00822	0.22	0.18	Height;	chr1:41154222	chr1:41242373~41284861:+
LUAD	cis	rs12220238	0.722	rs10740440	ENSG00000226051.5	ZNF503-AS1	4.08	5.27e-05	0.00822	0.33	0.18	Soluble interleukin-2 receptor subunit alpha;	chr10:74620608	chr10:75269819~75373500:+
LUAD	cis	rs6940638	0.688	rs9393791	ENSG00000219392.1	RP1-265C24.5	-4.08	5.27e-05	0.00822	-0.23	-0.18	Intelligence (multi-trait analysis);	chr6:27164750	chr6:28115628~28116551:+
LUAD	cis	rs1979679	0.918	rs786707	ENSG00000278733.1	RP11-425D17.1	4.08	5.27e-05	0.00822	0.23	0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28420714	chr12:28185625~28186190:-
LUAD	cis	rs8180040	0.932	rs11711265	ENSG00000271161.1	BOLA2P2	4.08	5.27e-05	0.00822	0.18	0.18	Colorectal cancer;	chr3:47516958	chr3:47499841~47500407:+
LUAD	cis	rs950169	1	rs35297609	ENSG00000275120.1	RP11-182J1.17	4.08	5.27e-05	0.00823	0.29	0.18	Schizophrenia;	chr15:84104144	chr15:84599434~84606463:-
LUAD	cis	rs950169	1	rs62026530	ENSG00000275120.1	RP11-182J1.17	4.08	5.27e-05	0.00823	0.29	0.18	Schizophrenia;	chr15:84107088	chr15:84599434~84606463:-
LUAD	cis	rs8030379	1	rs11259929	ENSG00000230373.7	GOLGA6L5P	-4.08	5.27e-05	0.00823	-0.17	-0.18	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83908450	chr15:84507885~84516814:-
LUAD	cis	rs8030379	1	rs11259930	ENSG00000230373.7	GOLGA6L5P	-4.08	5.27e-05	0.00823	-0.17	-0.18	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83908598	chr15:84507885~84516814:-
LUAD	cis	rs8030379	1	rs1480827	ENSG00000230373.7	GOLGA6L5P	-4.08	5.27e-05	0.00823	-0.17	-0.18	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83909040	chr15:84507885~84516814:-
LUAD	cis	rs7107174	1	rs7113042	ENSG00000251323.2	RP11-452H21.4	-4.08	5.27e-05	0.00823	-0.21	-0.18	Testicular germ cell tumor;	chr11:78324786	chr11:78423982~78429836:-
LUAD	cis	rs8073060	0.614	rs72829932	ENSG00000267592.1	CTC-507E2.2	-4.08	5.27e-05	0.00823	-0.27	-0.18	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35728916	chr17:35596904~35597128:-
LUAD	cis	rs11073619	0.616	rs79416421	ENSG00000230373.7	GOLGA6L5P	-4.08	5.27e-05	0.00823	-0.29	-0.18	Positive affect;	chr15:84539090	chr15:84507885~84516814:-
LUAD	cis	rs12935418	0.616	rs2549858	ENSG00000261061.1	RP11-303E16.2	4.08	5.27e-05	0.00823	0.19	0.18	Mean corpuscular volume;	chr16:80993389	chr16:81030770~81031485:+
LUAD	cis	rs12935418	0.616	rs2549859	ENSG00000261061.1	RP11-303E16.2	4.08	5.27e-05	0.00823	0.19	0.18	Mean corpuscular volume;	chr16:80993398	chr16:81030770~81031485:+
LUAD	cis	rs7647973	0.58	rs12637576	ENSG00000225399.4	RP11-3B7.1	4.08	5.27e-05	0.00823	0.24	0.18	Menarche (age at onset);	chr3:49199901	chr3:49260085~49261316:+
LUAD	cis	rs3096299	0.967	rs2965827	ENSG00000182376.2	RP5-1142A6.8	-4.08	5.28e-05	0.00823	-0.18	-0.18	Multiple myeloma (IgH translocation);	chr16:89390942	chr16:88742767~88745748:+
LUAD	cis	rs6496044	0.568	rs2344436	ENSG00000259295.5	CSPG4P12	4.08	5.28e-05	0.00823	0.21	0.18	Interstitial lung disease;	chr15:85531675	chr15:85191438~85213905:+
LUAD	cis	rs6496044	0.568	rs6496065	ENSG00000259295.5	CSPG4P12	4.08	5.28e-05	0.00823	0.21	0.18	Interstitial lung disease;	chr15:85532141	chr15:85191438~85213905:+
LUAD	cis	rs6496044	0.568	rs6496066	ENSG00000259295.5	CSPG4P12	4.08	5.28e-05	0.00823	0.21	0.18	Interstitial lung disease;	chr15:85532231	chr15:85191438~85213905:+
LUAD	cis	rs41271951	0.542	rs942453	ENSG00000223945.2	RP11-458I7.1	4.08	5.28e-05	0.00824	0.28	0.18	Blood protein levels;	chr1:150284852	chr1:150053864~150055034:+
LUAD	cis	rs6001482	0.533	rs12484704	ENSG00000215456.5	BCRP4	4.08	5.28e-05	0.00824	0.25	0.18	Diastolic blood pressure;	chr22:22228856	chr22:22630061~22636153:+
LUAD	cis	rs853679	0.517	rs4713141	ENSG00000280107.1	AL022393.9	-4.08	5.28e-05	0.00824	-0.24	-0.18	Depression;	chr6:28133900	chr6:28170845~28172521:+
LUAD	cis	rs17345786	0.798	rs1609159	ENSG00000244119.1	PDCL3P4	4.08	5.28e-05	0.00824	0.18	0.18	Colonoscopy-negative controls vs population controls;	chr3:101557058	chr3:101712472~101713191:+
LUAD	cis	rs8177876	0.642	rs56032321	ENSG00000261061.1	RP11-303E16.2	-4.08	5.28e-05	0.00824	-0.31	-0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81084301	chr16:81030770~81031485:+
LUAD	cis	rs7129556	0.69	rs24356	ENSG00000241782.1	RP11-91P24.1	4.08	5.28e-05	0.00824	0.26	0.18	Weight loss (gastric bypass surgery);	chr11:77856482	chr11:77868722~77869195:-
LUAD	cis	rs2736345	0.516	rs9657551	ENSG00000270154.1	RP11-419I17.1	4.08	5.29e-05	0.00824	0.22	0.18	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11540674	chr8:12476462~12477122:+
LUAD	cis	rs80028505	0.908	rs7762483	ENSG00000271304.1	DPRXP2	4.08	5.29e-05	0.00824	0.33	0.18	Foot ulcer in diabetes and neuropathy;	chr6:36088164	chr6:35989515~35990436:-
LUAD	cis	rs2288884	1	rs76768215	ENSG00000269959.1	SPACA6P-AS	-4.08	5.29e-05	0.00824	-0.25	-0.18	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52069370	chr19:51685363~51693456:-
LUAD	cis	rs1023500	0.573	rs133380	ENSG00000273366.1	CTA-989H11.1	-4.08	5.29e-05	0.00824	-0.21	-0.18	Schizophrenia;	chr22:42072906	chr22:42278188~42278846:+
LUAD	cis	rs34929064	0.718	rs62447650	ENSG00000230658.1	KLHL7-AS1	4.08	5.29e-05	0.00825	0.27	0.18	Major depression and alcohol dependence;	chr7:22690132	chr7:23101228~23105703:-
LUAD	cis	rs12935418	0.672	rs9889194	ENSG00000261061.1	RP11-303E16.2	-4.08	5.29e-05	0.00825	-0.21	-0.18	Mean corpuscular volume;	chr16:81017212	chr16:81030770~81031485:+
LUAD	cis	rs1862618	0.853	rs832583	ENSG00000271828.1	CTD-2310F14.1	4.08	5.29e-05	0.00825	0.26	0.18	Initial pursuit acceleration;	chr5:56882390	chr5:56927874~56929573:+
LUAD	cis	rs1862618	0.853	rs832551	ENSG00000271828.1	CTD-2310F14.1	4.08	5.29e-05	0.00825	0.26	0.18	Initial pursuit acceleration;	chr5:56884285	chr5:56927874~56929573:+
LUAD	cis	rs1862618	0.713	rs832550	ENSG00000271828.1	CTD-2310F14.1	4.08	5.29e-05	0.00825	0.26	0.18	Initial pursuit acceleration;	chr5:56886762	chr5:56927874~56929573:+
LUAD	cis	rs1862618	0.713	rs832549	ENSG00000271828.1	CTD-2310F14.1	4.08	5.29e-05	0.00825	0.26	0.18	Initial pursuit acceleration;	chr5:56887715	chr5:56927874~56929573:+
LUAD	cis	rs1862618	0.756	rs832548	ENSG00000271828.1	CTD-2310F14.1	4.08	5.29e-05	0.00825	0.26	0.18	Initial pursuit acceleration;	chr5:56887810	chr5:56927874~56929573:+
LUAD	cis	rs1862618	0.802	rs832547	ENSG00000271828.1	CTD-2310F14.1	4.08	5.29e-05	0.00825	0.26	0.18	Initial pursuit acceleration;	chr5:56888114	chr5:56927874~56929573:+
LUAD	cis	rs1862618	0.853	rs866222	ENSG00000271828.1	CTD-2310F14.1	4.08	5.29e-05	0.00825	0.26	0.18	Initial pursuit acceleration;	chr5:56888617	chr5:56927874~56929573:+
LUAD	cis	rs1862618	0.853	rs861283	ENSG00000271828.1	CTD-2310F14.1	4.08	5.29e-05	0.00825	0.26	0.18	Initial pursuit acceleration;	chr5:56888783	chr5:56927874~56929573:+
LUAD	cis	rs1862618	0.802	rs252900	ENSG00000271828.1	CTD-2310F14.1	4.08	5.29e-05	0.00825	0.26	0.18	Initial pursuit acceleration;	chr5:56889454	chr5:56927874~56929573:+
LUAD	cis	rs35740288	0.822	rs11630549	ENSG00000259407.1	RP11-158M2.3	-4.08	5.29e-05	0.00825	-0.19	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85732565	chr15:85744109~85750281:-
LUAD	cis	rs8073060	0.586	rs7213804	ENSG00000267592.1	CTC-507E2.2	4.08	5.29e-05	0.00825	0.27	0.18	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35683912	chr17:35596904~35597128:-
LUAD	cis	rs8073060	0.586	rs3859284	ENSG00000267592.1	CTC-507E2.2	4.08	5.29e-05	0.00825	0.27	0.18	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35685773	chr17:35596904~35597128:-
LUAD	cis	rs8073060	0.586	rs7217533	ENSG00000267592.1	CTC-507E2.2	4.08	5.29e-05	0.00825	0.27	0.18	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35688857	chr17:35596904~35597128:-
LUAD	cis	rs8073060	0.586	rs226089	ENSG00000267592.1	CTC-507E2.2	4.08	5.29e-05	0.00825	0.27	0.18	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35689916	chr17:35596904~35597128:-
LUAD	cis	rs8073060	0.586	rs226087	ENSG00000267592.1	CTC-507E2.2	4.08	5.29e-05	0.00825	0.27	0.18	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35690633	chr17:35596904~35597128:-
LUAD	cis	rs8073060	0.586	rs226084	ENSG00000267592.1	CTC-507E2.2	4.08	5.29e-05	0.00825	0.27	0.18	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35692563	chr17:35596904~35597128:-
LUAD	cis	rs8073060	0.586	rs188959	ENSG00000267592.1	CTC-507E2.2	4.08	5.29e-05	0.00825	0.27	0.18	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35694288	chr17:35596904~35597128:-
LUAD	cis	rs17685	0.725	rs4476928	ENSG00000280388.1	RP11-229D13.3	4.08	5.29e-05	0.00825	0.17	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76012789	chr7:76043977~76045963:-
LUAD	cis	rs523522	0.962	rs10849759	ENSG00000278344.1	RP11-18C24.8	4.08	5.29e-05	0.00825	0.25	0.18	High light scatter reticulocyte count;	chr12:120556685	chr12:120500735~120501090:-
LUAD	cis	rs2060793	0.712	rs10741654	ENSG00000251991.1	RNU7-49P	4.08	5.29e-05	0.00825	0.2	0.18	Vitamin D levels;	chr11:14726506	chr11:14478892~14478953:+
LUAD	cis	rs17597773	0.674	rs12089958	ENSG00000272823.1	RP11-295M18.6	-4.08	5.29e-05	0.00825	-0.24	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220828021	chr1:220828676~220829211:-
LUAD	cis	rs1355223	0.867	rs7943755	ENSG00000271369.1	RP11-350D17.3	-4.08	5.29e-05	0.00825	-0.22	-0.18	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34669904	chr11:34709600~34710161:+
LUAD	cis	rs9341808	0.538	rs615585	ENSG00000260645.1	RP11-250B2.5	-4.08	5.3e-05	0.00826	-0.18	-0.18	Sitting height ratio;	chr6:80276436	chr6:80466958~80469080:+
LUAD	cis	rs2243480	1	rs316331	ENSG00000164669.11	INTS4P1	-4.08	5.3e-05	0.00826	-0.33	-0.18	Diabetic kidney disease;	chr7:66139635	chr7:65141225~65234216:+
LUAD	cis	rs9500256	0.711	rs6588685	ENSG00000272316.1	XXbac-BPGBPG55C20.2	4.08	5.3e-05	0.00826	0.16	0.18	Eosinophilic esophagitis (pediatric);	chr6:57993375	chr6:57908560~57913911:-
LUAD	cis	rs10197140	0.857	rs12474757	ENSG00000235721.1	AC013268.3	-4.08	5.3e-05	0.00826	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110889972	chr2:110007675~110010783:+
LUAD	cis	rs7189233	0.531	rs7199401	ENSG00000279344.1	RP11-44F14.7	4.08	5.3e-05	0.00826	0.15	0.18	Intelligence (multi-trait analysis);	chr16:53483038	chr16:53478957~53481550:-
LUAD	cis	rs34375054	0.573	rs12581813	ENSG00000279233.1	RP11-158L12.4	4.08	5.3e-05	0.00826	0.18	0.18	Post bronchodilator FEV1/FVC ratio;	chr12:125171856	chr12:125138245~125141711:+
LUAD	cis	rs7590268	0.848	rs7600177	ENSG00000279873.2	LINC01126	4.08	5.3e-05	0.00826	0.18	0.18	Orofacial clefts;	chr2:43400916	chr2:43227210~43228855:+
LUAD	cis	rs9646944	0.501	rs10181785	ENSG00000234389.1	AC007278.3	4.08	5.3e-05	0.00827	0.21	0.18	Blood protein levels;	chr2:102408814	chr2:102438713~102440475:+
LUAD	cis	rs9646944	0.54	rs12712148	ENSG00000234389.1	AC007278.3	4.08	5.3e-05	0.00827	0.21	0.18	Blood protein levels;	chr2:102409087	chr2:102438713~102440475:+
LUAD	cis	rs858239	0.665	rs858305	ENSG00000230042.1	AK3P3	4.08	5.3e-05	0.00827	0.22	0.18	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23129178~23129841:+
LUAD	cis	rs7746199	0.736	rs6904596	ENSG00000219392.1	RP1-265C24.5	-4.08	5.31e-05	0.00827	-0.35	-0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27523520	chr6:28115628~28116551:+
LUAD	cis	rs7617773	0.78	rs71323395	ENSG00000199476.1	Y_RNA	-4.08	5.31e-05	0.00827	-0.25	-0.18	Coronary artery disease;	chr3:48332587	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.743	rs71323397	ENSG00000199476.1	Y_RNA	-4.08	5.31e-05	0.00827	-0.25	-0.18	Coronary artery disease;	chr3:48333384	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.778	rs11715776	ENSG00000199476.1	Y_RNA	-4.08	5.31e-05	0.00827	-0.25	-0.18	Coronary artery disease;	chr3:48336121	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.778	rs11707997	ENSG00000199476.1	Y_RNA	-4.08	5.31e-05	0.00827	-0.25	-0.18	Coronary artery disease;	chr3:48336385	chr3:48288587~48288694:+
LUAD	cis	rs5758511	0.68	rs5758651	ENSG00000233903.2	Z83851.4	4.08	5.31e-05	0.00828	0.27	0.18	Birth weight;	chr22:42213142	chr22:42276355~42277052:+
LUAD	cis	rs5758511	0.68	rs5758652	ENSG00000233903.2	Z83851.4	4.08	5.31e-05	0.00828	0.27	0.18	Birth weight;	chr22:42216402	chr22:42276355~42277052:+
LUAD	cis	rs35740288	0.822	rs56322219	ENSG00000259407.1	RP11-158M2.3	-4.08	5.31e-05	0.00828	-0.19	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85733109	chr15:85744109~85750281:-
LUAD	cis	rs9921338	0.54	rs2868410	ENSG00000263080.1	RP11-485G7.5	4.08	5.31e-05	0.00828	0.23	0.18	Vein graft stenosis in coronary artery bypass grafting;	chr16:11334244	chr16:11341809~11345211:-
LUAD	cis	rs3177980	0.673	rs10489172	ENSG00000239494.2	RN7SL333P	-4.08	5.31e-05	0.00828	-0.18	-0.18	Amyotrophic lateral sclerosis;	chr1:169855238	chr1:169859756~169860052:+
LUAD	cis	rs2742234	0.504	rs7093409	ENSG00000273008.1	RP11-351D16.3	4.08	5.31e-05	0.00828	0.21	0.18	Hirschsprung disease;	chr10:43244619	chr10:43136824~43138334:-
LUAD	cis	rs750134	1	rs3825253	ENSG00000257221.1	RP11-689B22.2	4.08	5.32e-05	0.00828	0.27	0.18	Low high density lipoprotein cholesterol levels;	chr12:108715505	chr12:108628687~108641318:+
LUAD	cis	rs1910358	0.959	rs6881774	ENSG00000248874.4	C5orf17	-4.08	5.32e-05	0.00829	-0.27	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr5:23881735	chr5:23951348~24178263:+
LUAD	cis	rs1910358	0.959	rs10942011	ENSG00000248874.4	C5orf17	-4.08	5.32e-05	0.00829	-0.27	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr5:23885946	chr5:23951348~24178263:+
LUAD	cis	rs1910358	0.81	rs13164372	ENSG00000248874.4	C5orf17	-4.08	5.32e-05	0.00829	-0.27	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr5:23888589	chr5:23951348~24178263:+
LUAD	cis	rs1910358	0.959	rs1602370	ENSG00000248874.4	C5orf17	-4.08	5.32e-05	0.00829	-0.27	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr5:23891074	chr5:23951348~24178263:+
LUAD	cis	rs1910358	0.881	rs10063109	ENSG00000248874.4	C5orf17	-4.08	5.32e-05	0.00829	-0.27	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr5:23892083	chr5:23951348~24178263:+
LUAD	cis	rs4713118	0.516	rs6931858	ENSG00000226314.6	ZNF192P1	-4.08	5.32e-05	0.00829	-0.23	-0.18	Parkinson's disease;	chr6:28110633	chr6:28161781~28169594:+
LUAD	cis	rs12554020	0.681	rs77768484	ENSG00000227603.1	RP11-165J3.6	4.08	5.32e-05	0.00829	0.4	0.18	Schizophrenia;	chr9:93622011	chr9:93435332~93437121:-
LUAD	cis	rs12554020	0.681	rs79987346	ENSG00000227603.1	RP11-165J3.6	4.08	5.32e-05	0.00829	0.4	0.18	Schizophrenia;	chr9:93622467	chr9:93435332~93437121:-
LUAD	cis	rs7005380	0.581	rs7005888	ENSG00000279347.1	RP11-85I17.2	-4.08	5.32e-05	0.00829	-0.17	-0.18	Interstitial lung disease;	chr8:119919371	chr8:119838736~119840385:-
LUAD	cis	rs6951245	0.554	rs2070118	ENSG00000229043.2	AC091729.9	-4.08	5.32e-05	0.00829	-0.24	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1092869	chr7:1160374~1165267:+
LUAD	cis	rs17772222	1	rs17772288	ENSG00000258789.1	RP11-507K2.3	-4.08	5.33e-05	0.0083	-0.24	-0.18	Coronary artery calcification;	chr14:88361022	chr14:88551597~88552493:+
LUAD	cis	rs7712401	0.791	rs10071135	ENSG00000249996.1	RP11-359P5.1	4.08	5.33e-05	0.0083	0.21	0.18	Mean platelet volume;	chr5:122811283	chr5:123036271~123054667:+
LUAD	cis	rs12579720	0.711	rs7358616	ENSG00000255910.1	RP11-405A12.2	4.08	5.33e-05	0.0083	0.23	0.18	Diastolic blood pressure;	chr12:20075321	chr12:19775451~20009937:+
LUAD	cis	rs4811196	0.748	rs2344914	ENSG00000226144.2	RPS27AP3	4.08	5.33e-05	0.0083	0.19	0.18	Bone mineral density;	chr20:37868003	chr20:37049254~37049707:+
LUAD	cis	rs7119038	0.818	rs10892279	ENSG00000255422.1	AP002954.4	4.08	5.33e-05	0.0083	0.28	0.18	Sjögren's syndrome;	chr11:118741072	chr11:118704607~118750263:+
LUAD	cis	rs7202877	0.656	rs4888370	ENSG00000280152.1	RP11-331F4.5	4.08	5.33e-05	0.0083	0.21	0.18	Type 1 diabetes;Type 2 diabetes;	chr16:75274332	chr16:75245994~75250077:-
LUAD	cis	rs4499344	0.556	rs438268	ENSG00000201388.1	SNORA68	4.08	5.33e-05	0.0083	0.22	0.18	Mean platelet volume;	chr19:32618998	chr19:32608337~32608469:-
LUAD	cis	rs9341808	0.667	rs2476826	ENSG00000260645.1	RP11-250B2.5	4.08	5.33e-05	0.00831	0.17	0.18	Sitting height ratio;	chr6:80166347	chr6:80466958~80469080:+
LUAD	cis	rs4499344	0.73	rs35098593	ENSG00000201388.1	SNORA68	4.08	5.33e-05	0.00831	0.19	0.18	Mean platelet volume;	chr19:32613033	chr19:32608337~32608469:-
LUAD	cis	rs4499344	0.73	rs34270210	ENSG00000201388.1	SNORA68	4.08	5.33e-05	0.00831	0.19	0.18	Mean platelet volume;	chr19:32613039	chr19:32608337~32608469:-
LUAD	cis	rs4499344	0.73	rs434020	ENSG00000201388.1	SNORA68	4.08	5.33e-05	0.00831	0.19	0.18	Mean platelet volume;	chr19:32613164	chr19:32608337~32608469:-
LUAD	cis	rs4499344	0.696	rs398990	ENSG00000201388.1	SNORA68	4.08	5.33e-05	0.00831	0.19	0.18	Mean platelet volume;	chr19:32613338	chr19:32608337~32608469:-
LUAD	cis	rs2665103	0.61	rs56398167	ENSG00000276710.3	CSPG4P8	-4.08	5.33e-05	0.00831	-0.17	-0.18	Intelligence (multi-trait analysis);	chr15:82237482	chr15:82459472~82477258:+
LUAD	cis	rs6479891	1	rs10437345	ENSG00000232075.1	MRPL35P2	-4.08	5.33e-05	0.00831	-0.29	-0.18	Arthritis (juvenile idiopathic);	chr10:63443186	chr10:63634317~63634827:-
LUAD	cis	rs8177876	0.749	rs2911159	ENSG00000261061.1	RP11-303E16.2	4.08	5.34e-05	0.00831	0.25	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81057653	chr16:81030770~81031485:+
LUAD	cis	rs17189298	1	rs17189298	ENSG00000231013.1	AC013275.2	4.08	5.34e-05	0.00831	0.18	0.18	Cerebrospinal T-tau levels;	chr2:119087741	chr2:119476448~119487346:+
LUAD	cis	rs5758511	0.68	rs1033460	ENSG00000233903.2	Z83851.4	4.08	5.34e-05	0.00831	0.27	0.18	Birth weight;	chr22:42223302	chr22:42276355~42277052:+
LUAD	cis	rs8073060	0.614	rs225275	ENSG00000267592.1	CTC-507E2.2	4.08	5.34e-05	0.00831	0.27	0.18	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35645548	chr17:35596904~35597128:-
LUAD	cis	rs394563	0.775	rs412894	ENSG00000216906.2	RP11-350J20.9	4.08	5.34e-05	0.00831	0.22	0.18	Dupuytren's disease;	chr6:149460039	chr6:149904243~149906418:+
LUAD	cis	rs13113518	0.812	rs4865003	ENSG00000272969.1	RP11-528I4.2	4.08	5.34e-05	0.00831	0.2	0.18	Height;	chr4:55514802	chr4:55547112~55547889:+
LUAD	cis	rs2836974	0.644	rs11088471	ENSG00000232608.1	TIMM9P2	4.08	5.34e-05	0.00832	0.21	0.18	Cognitive function;	chr21:39327387	chr21:39216624~39217506:+
LUAD	cis	rs2414856	0.504	rs72742986	ENSG00000239465.1	RP11-330L19.2	4.08	5.34e-05	0.00832	0.38	0.18	Pulse pressure;Systolic blood pressure;	chr15:64695030	chr15:64631109~64631914:-
LUAD	cis	rs7119038	0.629	rs11216994	ENSG00000255239.1	AP002954.6	-4.08	5.34e-05	0.00832	-0.26	-0.18	Sjögren's syndrome;	chr11:118732811	chr11:118688039~118690600:-
LUAD	cis	rs7551222	0.752	rs6681905	ENSG00000240219.1	RP11-430C7.5	4.08	5.35e-05	0.00832	0.19	0.18	Schizophrenia;	chr1:204566661	chr1:204626775~204629712:+
LUAD	cis	rs7551222	0.752	rs6594016	ENSG00000240219.1	RP11-430C7.5	4.08	5.35e-05	0.00832	0.19	0.18	Schizophrenia;	chr1:204570334	chr1:204626775~204629712:+
LUAD	cis	rs9309473	0.519	rs2421574	ENSG00000163016.8	ALMS1P	-4.08	5.35e-05	0.00833	-0.19	-0.18	Metabolite levels;	chr2:73681640	chr2:73644919~73685576:+
LUAD	cis	rs9815354	1	rs1716685	ENSG00000273328.4	RP11-141M3.6	-4.08	5.35e-05	0.00833	-0.27	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41883809	chr3:42809414~42908105:+
LUAD	cis	rs8048589	1	rs16958964	ENSG00000175604.2	RP11-276H1.3	-4.08	5.35e-05	0.00833	-0.25	-0.18	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12092729	chr16:12086746~12090302:-
LUAD	cis	rs8048589	1	rs12599090	ENSG00000175604.2	RP11-276H1.3	-4.08	5.35e-05	0.00833	-0.25	-0.18	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12093484	chr16:12086746~12090302:-
LUAD	cis	rs1722141	0.633	rs2471552	ENSG00000229628.1	AC073115.7	4.08	5.35e-05	0.00833	0.28	0.18	Sitting height ratio;	chr7:45937574	chr7:45990905~46000898:+
LUAD	cis	rs17772222	0.917	rs7157149	ENSG00000258789.1	RP11-507K2.3	-4.08	5.35e-05	0.00833	-0.25	-0.18	Coronary artery calcification;	chr14:88765501	chr14:88551597~88552493:+
LUAD	cis	rs651907	0.535	rs36060163	ENSG00000244119.1	PDCL3P4	4.08	5.35e-05	0.00833	0.18	0.18	Colorectal cancer;	chr3:101642119	chr3:101712472~101713191:+
LUAD	cis	rs2898681	0.739	rs8287	ENSG00000248375.1	RP11-177B4.1	-4.08	5.35e-05	0.00833	-0.26	-0.18	Optic nerve measurement (cup area);	chr4:52866419	chr4:52720081~52720831:-
LUAD	cis	rs9393777	0.92	rs13196692	ENSG00000219392.1	RP1-265C24.5	-4.08	5.35e-05	0.00833	-0.38	-0.18	Intelligence (multi-trait analysis);	chr6:27411340	chr6:28115628~28116551:+
LUAD	cis	rs2657294	0.965	rs4746264	ENSG00000226051.5	ZNF503-AS1	-4.08	5.35e-05	0.00833	-0.24	-0.18	Pneumonia;	chr10:75114194	chr10:75269819~75373500:+
LUAD	cis	rs1355223	1	rs2221720	ENSG00000271369.1	RP11-350D17.3	4.08	5.35e-05	0.00834	0.22	0.18	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34733374	chr11:34709600~34710161:+
LUAD	cis	rs453301	0.522	rs2929455	ENSG00000253981.4	ALG1L13P	-4.08	5.36e-05	0.00834	-0.21	-0.18	Joint mobility (Beighton score);	chr8:9225923	chr8:8236003~8244667:-
LUAD	cis	rs950169	0.614	rs12911536	ENSG00000259570.1	RP11-671M22.4	4.08	5.36e-05	0.00834	0.27	0.18	Schizophrenia;	chr15:84004278	chr15:84394512~84395514:+
LUAD	cis	rs801193	0.761	rs2659888	ENSG00000222364.1	RNU6-96P	-4.08	5.36e-05	0.00834	-0.2	-0.18	Aortic root size;	chr7:66765184	chr7:66395191~66395286:+
LUAD	cis	rs1005277	0.522	rs7090858	ENSG00000273019.1	RP11-508N22.13	4.08	5.36e-05	0.00834	0.21	0.18	Extrinsic epigenetic age acceleration;	chr10:37714742	chr10:38149968~38150293:+
LUAD	cis	rs987724	0.593	rs11707914	ENSG00000240875.4	LINC00886	-4.08	5.36e-05	0.00834	-0.2	-0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156829982	chr3:156747346~156817062:-
LUAD	cis	rs10463554	1	rs1593842	ENSG00000250682.4	LINC00491	4.08	5.36e-05	0.00834	0.22	0.18	Parkinson's disease;	chr5:102999018	chr5:102609156~102671559:-
LUAD	cis	rs9341808	0.667	rs7745301	ENSG00000260645.1	RP11-250B2.5	4.08	5.36e-05	0.00834	0.17	0.18	Sitting height ratio;	chr6:80212844	chr6:80466958~80469080:+
LUAD	cis	rs7208859	0.623	rs7220289	ENSG00000266490.1	CTD-2349P21.9	4.08	5.36e-05	0.00835	0.27	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30776744	chr17:30792372~30792833:+
LUAD	cis	rs2823962	0.759	rs13051672	ENSG00000270093.1	AP000473.8	-4.08	5.36e-05	0.00835	-0.2	-0.18	Amyotrophic lateral sclerosis;	chr21:16644155	chr21:16643529~16645065:+
LUAD	cis	rs2823962	0.759	rs13052472	ENSG00000270093.1	AP000473.8	-4.08	5.36e-05	0.00835	-0.2	-0.18	Amyotrophic lateral sclerosis;	chr21:16644446	chr21:16643529~16645065:+
LUAD	cis	rs712022	0.933	rs7129430	ENSG00000246225.5	RP11-17A1.3	-4.08	5.36e-05	0.00835	-0.23	-0.18	Dialysis-related mortality;	chr11:22806924	chr11:22829380~22945393:+
LUAD	cis	rs875971	0.558	rs4433015	ENSG00000224316.1	RP11-479O9.2	-4.08	5.36e-05	0.00835	-0.18	-0.18	Aortic root size;	chr7:66174736	chr7:65773620~65802067:+
LUAD	cis	rs7688540	0.76	rs4510422	ENSG00000211553.1	AC253576.2	-4.08	5.36e-05	0.00835	-0.23	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238151	chr4:136461~136568:+
LUAD	cis	rs7660883	0.836	rs342453	ENSG00000251411.1	RP11-397E7.4	-4.08	5.36e-05	0.00835	-0.2	-0.18	HDL cholesterol levels;	chr4:87097337	chr4:86913266~86914817:-
LUAD	cis	rs7772486	0.743	rs1292339	ENSG00000235652.6	RP11-545I5.3	-4.08	5.36e-05	0.00835	-0.18	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145645950	chr6:145799409~145886585:+
LUAD	cis	rs9952991	0.654	rs34799913	ENSG00000260302.1	RP11-973H7.1	4.08	5.37e-05	0.00835	0.39	0.18	Inflammatory skin disease;	chr18:12863841	chr18:12774651~12775923:-
LUAD	cis	rs57104699	0.694	rs11769521	ENSG00000225541.1	AC002480.5	4.08	5.37e-05	0.00835	0.2	0.18	Multiple myeloma and monoclonal gammopathy;Multiple myeloma;	chr7:21885487	chr7:22571607~22661792:-
LUAD	cis	rs9890032	0.967	rs7342976	ENSG00000266490.1	CTD-2349P21.9	4.08	5.37e-05	0.00835	0.17	0.18	Hip circumference adjusted for BMI;	chr17:30863001	chr17:30792372~30792833:+
LUAD	cis	rs6787172	0.811	rs7648618	ENSG00000272087.1	RP11-379F4.7	4.08	5.37e-05	0.00835	0.2	0.18	Subjective well-being;	chr3:158505049	chr3:158693120~158693768:-
LUAD	cis	rs2711721	0.56	rs2522259	ENSG00000274723.1	RP11-618L22.1	4.08	5.37e-05	0.00835	0.23	0.18	Prostate cancer (SNP x SNP interaction);	chr12:46986857	chr12:46970504~46972155:+
LUAD	cis	rs2711721	0.56	rs2522260	ENSG00000274723.1	RP11-618L22.1	4.08	5.37e-05	0.00835	0.23	0.18	Prostate cancer (SNP x SNP interaction);	chr12:46986858	chr12:46970504~46972155:+
LUAD	cis	rs1520724	0.687	rs60781210	ENSG00000258172.1	RP11-1105G2.4	-4.08	5.37e-05	0.00835	-0.21	-0.18	Obesity-related traits;	chr12:94469475	chr12:94272150~94277195:-
LUAD	cis	rs7107174	0.901	rs11237459	ENSG00000251323.2	RP11-452H21.4	4.08	5.37e-05	0.00835	0.22	0.18	Testicular germ cell tumor;	chr11:78345227	chr11:78423982~78429836:-
LUAD	cis	rs7107174	1	rs11237460	ENSG00000251323.2	RP11-452H21.4	4.08	5.37e-05	0.00835	0.22	0.18	Testicular germ cell tumor;	chr11:78345228	chr11:78423982~78429836:-
LUAD	cis	rs12935418	0.672	rs12446304	ENSG00000261061.1	RP11-303E16.2	-4.08	5.37e-05	0.00835	-0.21	-0.18	Mean corpuscular volume;	chr16:81012730	chr16:81030770~81031485:+
LUAD	cis	rs12935418	0.672	rs9923948	ENSG00000261061.1	RP11-303E16.2	-4.08	5.37e-05	0.00835	-0.21	-0.18	Mean corpuscular volume;	chr16:81013814	chr16:81030770~81031485:+
LUAD	cis	rs35740288	0.77	rs11630968	ENSG00000259407.1	RP11-158M2.3	-4.08	5.37e-05	0.00835	-0.18	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85574770	chr15:85744109~85750281:-
LUAD	cis	rs2929278	0.617	rs694461	ENSG00000166763.7	STRCP1	-4.08	5.37e-05	0.00835	-0.22	-0.18	Schizophrenia;	chr15:43803865	chr15:43699488~43718184:-
LUAD	cis	rs2823962	0.697	rs9637008	ENSG00000270093.1	AP000473.8	-4.08	5.37e-05	0.00836	-0.2	-0.18	Amyotrophic lateral sclerosis;	chr21:16646119	chr21:16643529~16645065:+
LUAD	cis	rs12148488	0.966	rs12899062	ENSG00000260269.4	CTD-2323K18.1	4.08	5.37e-05	0.00836	0.22	0.18	Caffeine consumption;	chr15:75055300	chr15:75527150~75601205:-
LUAD	cis	rs3018712	0.564	rs7942697	ENSG00000227620.4	ALG1L8P	-4.08	5.37e-05	0.00836	-0.25	-0.18	Total body bone mineral density;	chr11:68727994	chr11:67785273~67792335:+
LUAD	cis	rs2242116	0.734	rs4683294	ENSG00000271161.1	BOLA2P2	-4.08	5.37e-05	0.00836	-0.17	-0.18	Birth weight;	chr3:46937523	chr3:47499841~47500407:+
LUAD	cis	rs2274273	0.84	rs6573013	ENSG00000258413.1	RP11-665C16.6	-4.08	5.37e-05	0.00836	-0.23	-0.18	Protein biomarker;	chr14:55269155	chr14:55262767~55272075:-
LUAD	cis	rs17826219	0.706	rs57698184	ENSG00000266490.1	CTD-2349P21.9	4.08	5.37e-05	0.00836	0.27	0.18	Body mass index;	chr17:30737900	chr17:30792372~30792833:+
LUAD	cis	rs17826219	0.706	rs9893922	ENSG00000266490.1	CTD-2349P21.9	4.08	5.37e-05	0.00836	0.27	0.18	Body mass index;	chr17:30741407	chr17:30792372~30792833:+
LUAD	cis	rs17826219	0.5	rs9891256	ENSG00000266490.1	CTD-2349P21.9	4.08	5.37e-05	0.00836	0.27	0.18	Body mass index;	chr17:30745674	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs7503335	ENSG00000266490.1	CTD-2349P21.9	4.08	5.37e-05	0.00836	0.27	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30792372~30792833:+
LUAD	cis	rs858239	0.601	rs3735228	ENSG00000226816.2	AC005082.12	4.08	5.38e-05	0.00837	0.24	0.18	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23206013~23208045:+
LUAD	cis	rs17507216	1	rs17356118	ENSG00000276710.3	CSPG4P8	-4.08	5.38e-05	0.00837	-0.2	-0.18	Excessive daytime sleepiness;	chr15:82569149	chr15:82459472~82477258:+
LUAD	cis	rs9788333	0.962	rs34853044	ENSG00000224429.6	LINC00539	-4.08	5.38e-05	0.00837	-0.17	-0.18	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr13:21309645	chr13:21303515~21348721:-
LUAD	cis	rs516805	0.52	rs12524	ENSG00000279453.1	RP3-425C14.4	-4.08	5.38e-05	0.00837	-0.19	-0.18	Lymphocyte counts;	chr6:122444803	chr6:122436789~122439223:-
LUAD	cis	rs7246657	0.943	rs7258692	ENSG00000226686.6	LINC01535	-4.08	5.38e-05	0.00837	-0.28	-0.18	Coronary artery calcification;	chr19:37327927	chr19:37251912~37265535:+
LUAD	cis	rs651907	0.514	rs10936744	ENSG00000244119.1	PDCL3P4	4.08	5.38e-05	0.00837	0.18	0.18	Colorectal cancer;	chr3:101714596	chr3:101712472~101713191:+
LUAD	cis	rs651907	0.514	rs12636047	ENSG00000244119.1	PDCL3P4	4.08	5.38e-05	0.00837	0.18	0.18	Colorectal cancer;	chr3:101715605	chr3:101712472~101713191:+
LUAD	cis	rs651907	0.557	rs7612283	ENSG00000244119.1	PDCL3P4	4.08	5.38e-05	0.00837	0.18	0.18	Colorectal cancer;	chr3:101716075	chr3:101712472~101713191:+
LUAD	cis	rs651907	0.557	rs34457525	ENSG00000244119.1	PDCL3P4	4.08	5.38e-05	0.00837	0.18	0.18	Colorectal cancer;	chr3:101716381	chr3:101712472~101713191:+
LUAD	cis	rs2348418	0.715	rs12307612	ENSG00000247934.4	RP11-967K21.1	4.08	5.38e-05	0.00837	0.21	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28566713	chr12:28163298~28190738:-
LUAD	cis	rs2348418	0.715	rs12307709	ENSG00000247934.4	RP11-967K21.1	4.08	5.38e-05	0.00837	0.21	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28566767	chr12:28163298~28190738:-
LUAD	cis	rs2348418	0.715	rs11049719	ENSG00000247934.4	RP11-967K21.1	4.08	5.38e-05	0.00837	0.21	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28567446	chr12:28163298~28190738:-
LUAD	cis	rs2348418	0.715	rs11049720	ENSG00000247934.4	RP11-967K21.1	4.08	5.38e-05	0.00837	0.21	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28567477	chr12:28163298~28190738:-
LUAD	cis	rs6964587	0.933	rs6465350	ENSG00000188693.7	CYP51A1-AS1	-4.07	5.38e-05	0.00837	-0.21	-0.18	Breast cancer;	chr7:92139301	chr7:92134604~92180725:+
LUAD	cis	rs7809950	1	rs3801948	ENSG00000238832.1	snoU109	-4.07	5.38e-05	0.00838	-0.27	-0.18	Coronary artery disease;	chr7:107598002	chr7:107603363~107603507:+
LUAD	cis	rs4713118	0.869	rs6902689	ENSG00000280107.1	AL022393.9	-4.07	5.39e-05	0.00838	-0.23	-0.18	Parkinson's disease;	chr6:27741662	chr6:28170845~28172521:+
LUAD	cis	rs293748	0.771	rs13174506	ENSG00000250155.1	CTD-2353F22.1	-4.07	5.39e-05	0.00838	-0.24	-0.18	Obesity-related traits;	chr5:36801678	chr5:36666214~36725195:-
LUAD	cis	rs293748	0.771	rs12654600	ENSG00000250155.1	CTD-2353F22.1	-4.07	5.39e-05	0.00838	-0.24	-0.18	Obesity-related traits;	chr5:36802066	chr5:36666214~36725195:-
LUAD	cis	rs1044826	1	rs17336869	ENSG00000214280.3	RP11-553K23.2	-4.07	5.39e-05	0.00838	-0.22	-0.18	Obesity-related traits;	chr3:139475405	chr3:139582928~139583593:-
LUAD	cis	rs1044826	1	rs34623690	ENSG00000214280.3	RP11-553K23.2	-4.07	5.39e-05	0.00838	-0.22	-0.18	Obesity-related traits;	chr3:139475543	chr3:139582928~139583593:-
LUAD	cis	rs1044826	1	rs2233815	ENSG00000214280.3	RP11-553K23.2	-4.07	5.39e-05	0.00838	-0.22	-0.18	Obesity-related traits;	chr3:139476335	chr3:139582928~139583593:-
LUAD	cis	rs1044826	0.956	rs2233811	ENSG00000214280.3	RP11-553K23.2	-4.07	5.39e-05	0.00838	-0.22	-0.18	Obesity-related traits;	chr3:139477018	chr3:139582928~139583593:-
LUAD	cis	rs1044826	1	rs973691	ENSG00000214280.3	RP11-553K23.2	-4.07	5.39e-05	0.00838	-0.22	-0.18	Obesity-related traits;	chr3:139479016	chr3:139582928~139583593:-
LUAD	cis	rs1044826	1	rs9289578	ENSG00000214280.3	RP11-553K23.2	-4.07	5.39e-05	0.00838	-0.22	-0.18	Obesity-related traits;	chr3:139481672	chr3:139582928~139583593:-
LUAD	cis	rs6479891	1	rs2893922	ENSG00000232075.1	MRPL35P2	-4.07	5.39e-05	0.00838	-0.3	-0.18	Arthritis (juvenile idiopathic);	chr10:63487259	chr10:63634317~63634827:-
LUAD	cis	rs9847710	0.967	rs2581778	ENSG00000242142.1	SERBP1P3	4.07	5.39e-05	0.00838	0.2	0.18	Ulcerative colitis;	chr3:53021295	chr3:53064283~53065091:-
LUAD	cis	rs9649213	0.593	rs62478233	ENSG00000272950.1	RP11-307C18.1	4.07	5.39e-05	0.00838	0.23	0.18	Prostate cancer (SNP x SNP interaction);	chr7:98393780	chr7:98322853~98323430:+
LUAD	cis	rs2235642	0.928	rs56289115	ENSG00000280231.1	LA16c-380F5.3	-4.07	5.39e-05	0.00838	-0.25	-0.18	Coronary artery disease;	chr16:1558933	chr16:1553655~1554130:-
LUAD	cis	rs9646944	0.501	rs10166330	ENSG00000234389.1	AC007278.3	4.07	5.39e-05	0.00838	0.2	0.18	Blood protein levels;	chr2:102433930	chr2:102438713~102440475:+
LUAD	cis	rs9646944	0.501	rs2110736	ENSG00000234389.1	AC007278.3	4.07	5.39e-05	0.00838	0.2	0.18	Blood protein levels;	chr2:102434395	chr2:102438713~102440475:+
LUAD	cis	rs1502337	0.532	rs3864937	ENSG00000278993.1	RP3-424M6.4	-4.07	5.39e-05	0.00838	-0.22	-0.18	Body mass index;	chr12:110645279	chr12:110501614~110503441:+
LUAD	cis	rs2749097	0.609	rs2269238	ENSG00000244256.3	RN7SL130P	4.07	5.39e-05	0.00838	0.24	0.18	Alcohol consumption (transferrin glycosylation);	chr1:63651866	chr1:63655743~63656047:+
LUAD	cis	rs10739663	0.52	rs3122935	ENSG00000232630.1	PRPS1P2	4.07	5.39e-05	0.00838	0.18	0.18	Resting heart rate;	chr9:125391924	chr9:125150653~125151589:+
LUAD	cis	rs453301	0.506	rs686189	ENSG00000253893.2	FAM85B	4.07	5.39e-05	0.00839	0.22	0.18	Joint mobility (Beighton score);	chr8:8766127	chr8:8167819~8226614:-
LUAD	cis	rs6001482	0.679	rs5757568	ENSG00000223350.2	IGLV9-49	-4.07	5.39e-05	0.00839	-0.17	-0.18	Diastolic blood pressure;	chr22:22229175	chr22:22343187~22343732:+
LUAD	cis	rs526231	0.819	rs26233	ENSG00000175749.11	EIF3KP1	4.07	5.4e-05	0.00839	0.25	0.18	Primary biliary cholangitis;	chr5:103261115	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.853	rs376286	ENSG00000175749.11	EIF3KP1	4.07	5.4e-05	0.00839	0.25	0.18	Primary biliary cholangitis;	chr5:103263689	chr5:103032376~103033031:+
LUAD	cis	rs2274273	0.837	rs6573017	ENSG00000258413.1	RP11-665C16.6	-4.07	5.4e-05	0.00839	-0.23	-0.18	Protein biomarker;	chr14:55335525	chr14:55262767~55272075:-
LUAD	cis	rs7772486	0.79	rs9497431	ENSG00000235652.6	RP11-545I5.3	-4.07	5.4e-05	0.00839	-0.18	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145927041	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.79	rs7753092	ENSG00000235652.6	RP11-545I5.3	-4.07	5.4e-05	0.00839	-0.18	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145927727	chr6:145799409~145886585:+
LUAD	cis	rs17122278	1	rs11216912	ENSG00000243431.1	RPL5P30	4.07	5.4e-05	0.00839	0.22	0.18	Total cholesterol levels;	chr11:118581619	chr11:118560690~118561580:+
LUAD	cis	rs17122278	1	rs17842763	ENSG00000243431.1	RPL5P30	4.07	5.4e-05	0.00839	0.22	0.18	Total cholesterol levels;	chr11:118583462	chr11:118560690~118561580:+
LUAD	cis	rs3096299	0.509	rs4785691	ENSG00000261118.1	RP11-104N10.1	4.07	5.4e-05	0.00839	0.18	0.18	Multiple myeloma (IgH translocation);	chr16:89530813	chr16:89492017~89504460:-
LUAD	cis	rs9341808	0.754	rs978814	ENSG00000260645.1	RP11-250B2.5	4.07	5.4e-05	0.00839	0.17	0.18	Sitting height ratio;	chr6:80250195	chr6:80466958~80469080:+
LUAD	cis	rs6964587	1	rs34548928	ENSG00000188693.7	CYP51A1-AS1	-4.07	5.4e-05	0.00839	-0.21	-0.18	Breast cancer;	chr7:92039051	chr7:92134604~92180725:+
LUAD	cis	rs10463554	1	rs3776864	ENSG00000250682.4	LINC00491	4.07	5.4e-05	0.00839	0.22	0.18	Parkinson's disease;	chr5:102992164	chr5:102609156~102671559:-
LUAD	cis	rs7102710	1	rs7102710	ENSG00000254418.1	RP11-21L19.1	4.07	5.4e-05	0.0084	0.42	0.18	Glucagon levels in response to oral glucose tolerance test (fasting);	chr11:14244067	chr11:14262846~14273691:-
LUAD	cis	rs7976269	0.559	rs10771473	ENSG00000257176.2	RP11-996F15.2	-4.07	5.4e-05	0.0084	-0.2	-0.18	Male-pattern baldness;	chr12:29068729	chr12:29280418~29317848:-
LUAD	cis	rs703842	0.892	rs1021469	ENSG00000245651.2	RP11-620J15.2	4.07	5.4e-05	0.0084	0.19	0.18	Multiple sclerosis;	chr12:57814381	chr12:57869835~57896482:-
LUAD	cis	rs4713118	0.955	rs9468200	ENSG00000280107.1	AL022393.9	-4.07	5.4e-05	0.0084	-0.23	-0.18	Parkinson's disease;	chr6:27715284	chr6:28170845~28172521:+
LUAD	cis	rs9487094	0.665	rs13207864	ENSG00000260273.1	RP11-425D10.10	4.07	5.4e-05	0.0084	0.27	0.18	Height;	chr6:109708527	chr6:109382795~109383666:+
LUAD	cis	rs9840812	0.592	rs1711161	ENSG00000239213.4	NCK1-AS1	4.07	5.4e-05	0.0084	0.23	0.18	Fibrinogen levels;	chr3:136361695	chr3:136841726~136862054:-
LUAD	cis	rs2688608	0.839	rs2675662	ENSG00000271816.1	BMS1P4	-4.07	5.4e-05	0.0084	-0.15	-0.18	Inflammatory bowel disease;	chr10:73839369	chr10:73699151~73730487:-
LUAD	cis	rs4660214	0.671	rs16826068	ENSG00000182109.6	RP11-69E11.4	4.07	5.4e-05	0.0084	0.25	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39326204	chr1:39522280~39546187:-
LUAD	cis	rs3779195	0.584	rs1688605	ENSG00000272950.1	RP11-307C18.1	-4.07	5.4e-05	0.0084	-0.33	-0.18	Sex hormone-binding globulin levels;	chr7:98410534	chr7:98322853~98323430:+
LUAD	cis	rs896854	0.738	rs527234	ENSG00000253528.2	RP11-347C18.4	-4.07	5.4e-05	0.0084	-0.19	-0.18	Type 2 diabetes;	chr8:94951570	chr8:94974573~94974853:-
LUAD	cis	rs8014252	0.711	rs58069917	ENSG00000259158.2	ADAM20P1	-4.07	5.41e-05	0.0084	-0.32	-0.18	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70576840	chr14:70468881~70483756:-
LUAD	cis	rs8014252	0.711	rs59044667	ENSG00000259158.2	ADAM20P1	-4.07	5.41e-05	0.0084	-0.32	-0.18	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70576987	chr14:70468881~70483756:-
LUAD	cis	rs3794924	1	rs35777565	ENSG00000266521.1	RP11-650P15.1	4.07	5.41e-05	0.0084	0.35	0.18	Survival in colon cancer;	chr18:31469409	chr18:31496645~31497195:-
LUAD	cis	rs6496044	0.568	rs2880765	ENSG00000259295.5	CSPG4P12	-4.07	5.41e-05	0.00841	-0.21	-0.18	Interstitial lung disease;	chr15:85513231	chr15:85191438~85213905:+
LUAD	cis	rs2880765	0.835	rs7180213	ENSG00000259416.2	RP11-158M2.5	4.07	5.41e-05	0.00841	0.19	0.18	Coronary artery disease;	chr15:85477956	chr15:85754941~85756237:-
LUAD	cis	rs62025270	0.576	rs62022925	ENSG00000259416.2	RP11-158M2.5	-4.07	5.41e-05	0.00841	-0.24	-0.18	Idiopathic pulmonary fibrosis;	chr15:85692835	chr15:85754941~85756237:-
LUAD	cis	rs35740288	0.822	rs10520599	ENSG00000259407.1	RP11-158M2.3	-4.07	5.41e-05	0.00841	-0.18	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85679866	chr15:85744109~85750281:-
LUAD	cis	rs77688320	1	rs2714486	ENSG00000213090.2	AC007256.5	-4.07	5.41e-05	0.00841	-0.27	-0.18	Breast cancer;	chr2:201384985	chr2:201410544~201413308:-
LUAD	cis	rs6479891	1	rs10761745	ENSG00000232075.1	MRPL35P2	-4.07	5.41e-05	0.00841	-0.29	-0.18	Arthritis (juvenile idiopathic);	chr10:63341311	chr10:63634317~63634827:-
LUAD	cis	rs7660883	0.897	rs236992	ENSG00000251411.1	RP11-397E7.4	-4.07	5.42e-05	0.00842	-0.2	-0.18	HDL cholesterol levels;	chr4:87095587	chr4:86913266~86914817:-
LUAD	cis	rs7660883	0.897	rs236993	ENSG00000251411.1	RP11-397E7.4	-4.07	5.42e-05	0.00842	-0.2	-0.18	HDL cholesterol levels;	chr4:87095722	chr4:86913266~86914817:-
LUAD	cis	rs35740288	0.787	rs35250181	ENSG00000259407.1	RP11-158M2.3	-4.07	5.42e-05	0.00842	-0.18	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85699431	chr15:85744109~85750281:-
LUAD	cis	rs4666360	1	rs4666294	ENSG00000234378.1	AC098828.2	-4.07	5.42e-05	0.00842	-0.22	-0.18	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);	chr2:20136992	chr2:20063856~20106829:-
LUAD	cis	rs9309473	1	rs56672945	ENSG00000230002.2	ALMS1-IT1	4.07	5.42e-05	0.00842	0.23	0.18	Metabolite levels;	chr2:73395535	chr2:73456764~73459484:+
LUAD	cis	rs9309473	1	rs60844734	ENSG00000230002.2	ALMS1-IT1	4.07	5.42e-05	0.00842	0.23	0.18	Metabolite levels;	chr2:73396077	chr2:73456764~73459484:+
LUAD	cis	rs7208859	0.573	rs56031503	ENSG00000280069.1	CTD-2349P21.3	-4.07	5.42e-05	0.00842	-0.25	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30738182~30740275:+
LUAD	cis	rs7107174	1	rs10899478	ENSG00000251323.2	RP11-452H21.4	4.07	5.42e-05	0.00842	0.22	0.18	Testicular germ cell tumor;	chr11:78341192	chr11:78423982~78429836:-
LUAD	cis	rs7107174	0.892	rs11237477	ENSG00000251323.2	RP11-452H21.4	4.07	5.42e-05	0.00842	0.22	0.18	Testicular germ cell tumor;	chr11:78384023	chr11:78423982~78429836:-
LUAD	cis	rs2732480	0.5	rs2732461	ENSG00000257763.1	OR5BK1P	4.07	5.42e-05	0.00842	0.2	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48299019	chr12:48355792~48356614:-
LUAD	cis	rs9646944	0.501	rs10174323	ENSG00000234389.1	AC007278.3	4.07	5.42e-05	0.00842	0.21	0.18	Blood protein levels;	chr2:102396321	chr2:102438713~102440475:+
LUAD	cis	rs9646944	0.501	rs3732127	ENSG00000234389.1	AC007278.3	4.07	5.42e-05	0.00842	0.21	0.18	Blood protein levels;	chr2:102397290	chr2:102438713~102440475:+
LUAD	cis	rs7665090	0.806	rs434644	ENSG00000251288.2	RP11-10L12.2	4.07	5.42e-05	0.00842	0.22	0.18	Primary biliary cholangitis;	chr4:102662032	chr4:102751401~102752641:+
LUAD	cis	rs7665090	0.806	rs413967	ENSG00000251288.2	RP11-10L12.2	4.07	5.42e-05	0.00842	0.22	0.18	Primary biliary cholangitis;	chr4:102662039	chr4:102751401~102752641:+
LUAD	cis	rs7665090	0.806	rs404574	ENSG00000251288.2	RP11-10L12.2	4.07	5.42e-05	0.00842	0.22	0.18	Primary biliary cholangitis;	chr4:102662051	chr4:102751401~102752641:+
LUAD	cis	rs9815354	1	rs1716657	ENSG00000273328.4	RP11-141M3.6	4.07	5.42e-05	0.00842	0.26	0.18	Pulse pressure;Diastolic blood pressure;	chr3:41876964	chr3:42809414~42908105:+
LUAD	cis	rs9815354	1	rs10865914	ENSG00000273328.4	RP11-141M3.6	4.07	5.42e-05	0.00842	0.26	0.18	Pulse pressure;Diastolic blood pressure;	chr3:41878007	chr3:42809414~42908105:+
LUAD	cis	rs9815354	0.909	rs6794477	ENSG00000273328.4	RP11-141M3.6	4.07	5.42e-05	0.00842	0.26	0.18	Pulse pressure;Diastolic blood pressure;	chr3:41878909	chr3:42809414~42908105:+
LUAD	cis	rs9815354	1	rs1607908	ENSG00000273328.4	RP11-141M3.6	-4.07	5.42e-05	0.00842	-0.26	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41863704	chr3:42809414~42908105:+
LUAD	cis	rs9815354	0.951	rs1716679	ENSG00000273328.4	RP11-141M3.6	-4.07	5.42e-05	0.00842	-0.26	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41863847	chr3:42809414~42908105:+
LUAD	cis	rs9815354	1	rs1717031	ENSG00000273328.4	RP11-141M3.6	-4.07	5.42e-05	0.00842	-0.26	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41864299	chr3:42809414~42908105:+
LUAD	cis	rs9815354	1	rs2625668	ENSG00000273328.4	RP11-141M3.6	-4.07	5.42e-05	0.00842	-0.26	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41864438	chr3:42809414~42908105:+
LUAD	cis	rs9815354	1	rs1613759	ENSG00000273328.4	RP11-141M3.6	-4.07	5.42e-05	0.00842	-0.26	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41864691	chr3:42809414~42908105:+
LUAD	cis	rs9815354	1	rs1615543	ENSG00000273328.4	RP11-141M3.6	-4.07	5.42e-05	0.00842	-0.26	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41864912	chr3:42809414~42908105:+
LUAD	cis	rs9815354	1	rs1716668	ENSG00000273328.4	RP11-141M3.6	-4.07	5.42e-05	0.00842	-0.26	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41866358	chr3:42809414~42908105:+
LUAD	cis	rs9815354	1	rs1716669	ENSG00000273328.4	RP11-141M3.6	-4.07	5.42e-05	0.00842	-0.26	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41867189	chr3:42809414~42908105:+
LUAD	cis	rs9815354	1	rs1717033	ENSG00000273328.4	RP11-141M3.6	-4.07	5.42e-05	0.00842	-0.26	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41868724	chr3:42809414~42908105:+
LUAD	cis	rs9815354	0.951	rs1717018	ENSG00000273328.4	RP11-141M3.6	-4.07	5.42e-05	0.00842	-0.26	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41872125	chr3:42809414~42908105:+
LUAD	cis	rs9815354	0.951	rs1617271	ENSG00000273328.4	RP11-141M3.6	-4.07	5.42e-05	0.00842	-0.26	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41872508	chr3:42809414~42908105:+
LUAD	cis	rs9815354	0.951	rs1619558	ENSG00000273328.4	RP11-141M3.6	-4.07	5.42e-05	0.00842	-0.26	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41872721	chr3:42809414~42908105:+
LUAD	cis	rs9815354	1	rs2683695	ENSG00000273328.4	RP11-141M3.6	-4.07	5.42e-05	0.00842	-0.26	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41873436	chr3:42809414~42908105:+
LUAD	cis	rs9815354	1	rs1717017	ENSG00000273328.4	RP11-141M3.6	-4.07	5.42e-05	0.00842	-0.26	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41874124	chr3:42809414~42908105:+
LUAD	cis	rs9815354	1	rs1717014	ENSG00000273328.4	RP11-141M3.6	-4.07	5.42e-05	0.00842	-0.26	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41875903	chr3:42809414~42908105:+
LUAD	cis	rs7615952	0.673	rs3811677	ENSG00000241288.6	RP11-379B18.5	-4.07	5.42e-05	0.00842	-0.23	-0.18	Blood pressure (smoking interaction);	chr3:125929237	chr3:125827238~125916384:-
LUAD	cis	rs12999542	0.706	rs11465650	ENSG00000234389.1	AC007278.3	4.07	5.42e-05	0.00842	0.29	0.18	Serum protein levels (sST2);	chr2:102387249	chr2:102438713~102440475:+
LUAD	cis	rs12999542	0.706	rs11465660	ENSG00000234389.1	AC007278.3	4.07	5.42e-05	0.00842	0.29	0.18	Serum protein levels (sST2);	chr2:102397854	chr2:102438713~102440475:+
LUAD	cis	rs2836950	0.565	rs2150413	ENSG00000232608.1	TIMM9P2	4.07	5.42e-05	0.00842	0.2	0.18	Menarche (age at onset);	chr21:39242952	chr21:39216624~39217506:+
LUAD	cis	rs950169	0.96	rs12905475	ENSG00000275120.1	RP11-182J1.17	4.07	5.42e-05	0.00842	0.29	0.18	Schizophrenia;	chr15:84131743	chr15:84599434~84606463:-
LUAD	cis	rs55951657	1	rs55951657	ENSG00000279026.1	RP3-414A15.12	-4.07	5.42e-05	0.00842	-0.31	-0.18	Hippocampal volume;	chr14:73608028	chr14:73580694~73582918:+
LUAD	cis	rs4499344	0.73	rs369859	ENSG00000201388.1	SNORA68	4.07	5.42e-05	0.00842	0.19	0.18	Mean platelet volume;	chr19:32613399	chr19:32608337~32608469:-
LUAD	cis	rs9928842	0.765	rs6564222	ENSG00000261476.1	RP11-77K12.3	-4.07	5.42e-05	0.00843	-0.25	-0.18	Alcoholic chronic pancreatitis;	chr16:75191146	chr16:75458252~75460017:-
LUAD	cis	rs4795519	0.778	rs4795493	ENSG00000266313.1	RP11-173M1.4	4.07	5.43e-05	0.00843	0.23	0.18	Chronic myeloid leukemia;	chr17:27149368	chr17:27333256~27348491:+
LUAD	cis	rs4795519	0.778	rs11655787	ENSG00000266313.1	RP11-173M1.4	4.07	5.43e-05	0.00843	0.23	0.18	Chronic myeloid leukemia;	chr17:27149726	chr17:27333256~27348491:+
LUAD	cis	rs4795519	0.71	rs115269161	ENSG00000266313.1	RP11-173M1.4	4.07	5.43e-05	0.00843	0.23	0.18	Chronic myeloid leukemia;	chr17:27150024	chr17:27333256~27348491:+
LUAD	cis	rs2834288	0.535	rs2834306	ENSG00000237945.6	LINC00649	-4.07	5.43e-05	0.00843	-0.23	-0.18	Gut microbiota (bacterial taxa);	chr21:33957563	chr21:33915534~33977691:+
LUAD	cis	rs11121022	1	rs11121022	ENSG00000269925.1	RP3-467L1.6	-4.07	5.43e-05	0.00843	-0.17	-0.18	Morning vs. evening chronotype;	chr1:7776599	chr1:7776383~7776775:+
LUAD	cis	rs638893	0.528	rs521910	ENSG00000255239.1	AP002954.6	-4.07	5.43e-05	0.00843	-0.29	-0.18	Vitiligo;	chr11:118739920	chr11:118688039~118690600:-
LUAD	cis	rs12073359	1	rs56349882	ENSG00000223945.2	RP11-458I7.1	-4.07	5.43e-05	0.00843	-0.27	-0.18	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150157804	chr1:150053864~150055034:+
LUAD	cis	rs8014252	1	rs78093131	ENSG00000259158.2	ADAM20P1	-4.07	5.43e-05	0.00843	-0.29	-0.18	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70454665	chr14:70468881~70483756:-
LUAD	cis	rs2337406	0.866	rs4773949	ENSG00000280411.1	IGHV1-69-2	4.07	5.43e-05	0.00843	0.16	0.18	Alzheimer's disease (late onset);	chr14:106808070	chr14:106762092~106762588:-
LUAD	cis	rs2060793	0.741	rs4757268	ENSG00000251991.1	RNU7-49P	4.07	5.43e-05	0.00843	0.2	0.18	Vitamin D levels;	chr11:14789216	chr11:14478892~14478953:+
LUAD	cis	rs7138803	0.644	rs751675	ENSG00000257464.1	RP11-161H23.8	-4.07	5.43e-05	0.00844	-0.19	-0.18	Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index;	chr12:49808637	chr12:49442424~49442652:-
LUAD	cis	rs9287719	0.967	rs10929688	ENSG00000243819.4	RN7SL832P	4.07	5.43e-05	0.00844	0.19	0.18	Prostate cancer;	chr2:10616524	chr2:10690344~10692099:+
LUAD	cis	rs4561483	0.603	rs17235629	ENSG00000261216.1	RP11-166B2.5	-4.07	5.43e-05	0.00844	-0.18	-0.18	Testicular germ cell tumor;	chr16:11838564	chr16:11908208~11908916:+
LUAD	cis	rs442309	0.846	rs224127	ENSG00000238280.1	RP11-436D10.3	-4.07	5.43e-05	0.00844	-0.22	-0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62701513	chr10:62793562~62805887:-
LUAD	cis	rs727479	0.962	rs7173595	ENSG00000259306.2	RP11-108K3.2	-4.07	5.44e-05	0.00844	-0.2	-0.18	Estradiol levels;	chr15:51241539	chr15:51315841~51321996:+
LUAD	cis	rs740698	0.714	rs4968617	ENSG00000264546.1	RP11-464D20.6	4.07	5.44e-05	0.00844	0.21	0.18	Pulse pressure;	chr17:62676543	chr17:62549726~62552121:+
LUAD	cis	rs7107174	1	rs7112234	ENSG00000251323.2	RP11-452H21.4	4.07	5.44e-05	0.00845	0.22	0.18	Testicular germ cell tumor;	chr11:78391424	chr11:78423982~78429836:-
LUAD	cis	rs9287719	0.967	rs1541573	ENSG00000243819.4	RN7SL832P	4.07	5.44e-05	0.00845	0.19	0.18	Prostate cancer;	chr2:10633259	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs1541574	ENSG00000243819.4	RN7SL832P	4.07	5.44e-05	0.00845	0.19	0.18	Prostate cancer;	chr2:10633382	chr2:10690344~10692099:+
LUAD	cis	rs526231	0.764	rs2569014	ENSG00000175749.11	EIF3KP1	4.07	5.44e-05	0.00845	0.24	0.18	Primary biliary cholangitis;	chr5:103302398	chr5:103032376~103033031:+
LUAD	cis	rs2880765	0.835	rs4842886	ENSG00000259416.2	RP11-158M2.5	4.07	5.44e-05	0.00845	0.19	0.18	Coronary artery disease;	chr15:85492542	chr15:85754941~85756237:-
LUAD	cis	rs2880765	0.835	rs4842887	ENSG00000259416.2	RP11-158M2.5	4.07	5.44e-05	0.00845	0.19	0.18	Coronary artery disease;	chr15:85492579	chr15:85754941~85756237:-
LUAD	cis	rs7772486	0.654	rs4896829	ENSG00000235652.6	RP11-545I5.3	4.07	5.44e-05	0.00845	0.19	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145632539	chr6:145799409~145886585:+
LUAD	cis	rs3096299	0.967	rs2965932	ENSG00000182376.2	RP5-1142A6.8	-4.07	5.44e-05	0.00845	-0.19	-0.18	Multiple myeloma (IgH translocation);	chr16:89410643	chr16:88742767~88745748:+
LUAD	cis	rs2933343	0.729	rs1680781	ENSG00000231305.3	RP11-723O4.2	4.07	5.44e-05	0.00845	0.2	0.18	IgG glycosylation;	chr3:128893987	chr3:128861313~128871540:-
LUAD	cis	rs2288884	1	rs76368799	ENSG00000269959.1	SPACA6P-AS	-4.07	5.45e-05	0.00846	-0.25	-0.18	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52058254	chr19:51685363~51693456:-
LUAD	cis	rs34779708	0.931	rs4934702	ENSG00000271335.4	RP11-324I22.4	4.07	5.45e-05	0.00846	0.19	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35034146	chr10:35314552~35336401:-
LUAD	cis	rs36093844	0.625	rs11234467	ENSG00000279742.1	RP11-700A24.1	-4.07	5.45e-05	0.00846	-0.2	-0.18	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85900141	chr11:85852557~85854943:-
LUAD	cis	rs2380205	0.58	rs980230	ENSG00000232807.2	RP11-536K7.3	4.07	5.45e-05	0.00846	0.2	0.18	Breast cancer;	chr10:5863268	chr10:5934270~5945900:-
LUAD	cis	rs34783982	0.919	rs12438809	ENSG00000261441.1	RP11-217B1.2	-4.07	5.45e-05	0.00846	-0.25	-0.18	Squamous cell lung carcinoma;	chr15:88964073	chr15:89335053~89336161:+
LUAD	cis	rs4374383	0.884	rs6739294	ENSG00000207383.1	Y_RNA	4.07	5.45e-05	0.00846	0.22	0.18	Hepatitis C induced liver fibrosis;	chr2:111995303	chr2:112579484~112579584:-
LUAD	cis	rs8028182	0.636	rs7171507	ENSG00000260269.4	CTD-2323K18.1	-4.07	5.45e-05	0.00847	-0.25	-0.18	Sudden cardiac arrest;	chr15:75444946	chr15:75527150~75601205:-
LUAD	cis	rs8073060	0.544	rs8071584	ENSG00000267592.1	CTC-507E2.2	4.07	5.45e-05	0.00847	0.26	0.18	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35672416	chr17:35596904~35597128:-
LUAD	cis	rs8073060	0.586	rs8064895	ENSG00000267592.1	CTC-507E2.2	4.07	5.45e-05	0.00847	0.26	0.18	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35674102	chr17:35596904~35597128:-
LUAD	cis	rs8073060	0.586	rs8077826	ENSG00000267592.1	CTC-507E2.2	4.07	5.45e-05	0.00847	0.26	0.18	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35674120	chr17:35596904~35597128:-
LUAD	cis	rs11089937	0.626	rs9619811	ENSG00000211640.3	IGLV6-57	4.07	5.45e-05	0.00847	0.14	0.18	Periodontitis (PAL4Q3);	chr22:22159186	chr22:22195713~22196460:+
LUAD	cis	rs755249	0.614	rs10888798	ENSG00000228060.1	RP11-69E11.8	4.07	5.45e-05	0.00847	0.16	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39492408	chr1:39565160~39573203:+
LUAD	cis	rs5771242	0.776	rs6010198	ENSG00000273253.2	RP3-402G11.26	4.07	5.46e-05	0.00847	0.18	0.18	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);	chr22:50172199	chr22:50199090~50200837:-
LUAD	cis	rs62025270	0.632	rs62022924	ENSG00000259416.2	RP11-158M2.5	-4.07	5.46e-05	0.00847	-0.24	-0.18	Idiopathic pulmonary fibrosis;	chr15:85692276	chr15:85754941~85756237:-
LUAD	cis	rs77688320	0.535	rs7597850	ENSG00000213090.2	AC007256.5	4.07	5.46e-05	0.00847	0.21	0.18	Breast cancer;	chr2:201396679	chr2:201410544~201413308:-
LUAD	cis	rs6142102	0.923	rs4911379	ENSG00000275784.1	RP5-1125A11.6	-4.07	5.46e-05	0.00847	-0.2	-0.18	Skin pigmentation;	chr20:33947499	chr20:33989480~33991818:-
LUAD	cis	rs1075265	0.704	rs10084374	ENSG00000272156.1	RP11-477N3.1	-4.07	5.46e-05	0.00847	-0.21	-0.18	Chronotype;Morning vs. evening chronotype;	chr2:54022175	chr2:54082554~54085066:+
LUAD	cis	rs2735413	0.881	rs12919818	ENSG00000276007.1	RP11-358L22.3	-4.07	5.46e-05	0.00848	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78048965	chr16:78123243~78124332:+
LUAD	cis	rs6723226	0.803	rs387780	ENSG00000276334.1	AL133243.1	4.07	5.46e-05	0.00848	0.22	0.18	Intelligence (multi-trait analysis);	chr2:32277426	chr2:32521927~32523547:+
LUAD	cis	rs2253762	0.54	rs10887051	ENSG00000276742.1	RP11-500G22.4	4.07	5.46e-05	0.00848	0.28	0.18	Breast cancer;	chr10:122026030	chr10:121956782~121957098:+
LUAD	cis	rs2098713	0.544	rs13188741	ENSG00000250155.1	CTD-2353F22.1	-4.07	5.46e-05	0.00848	-0.21	-0.18	Telomere length;	chr5:37432269	chr5:36666214~36725195:-
LUAD	cis	rs17772222	0.74	rs3783885	ENSG00000258983.2	RP11-507K2.2	4.07	5.46e-05	0.00848	0.21	0.18	Coronary artery calcification;	chr14:88510714	chr14:88499334~88515502:+
LUAD	cis	rs12928939	0.727	rs8053623	ENSG00000260886.1	TAT-AS1	4.07	5.46e-05	0.00848	0.22	0.18	Post bronchodilator FEV1;	chr16:71613626	chr16:71565789~71578187:+
LUAD	cis	rs2834288	0.575	rs2239564	ENSG00000237945.6	LINC00649	-4.07	5.46e-05	0.00848	-0.25	-0.18	Gut microbiota (bacterial taxa);	chr21:33908245	chr21:33915534~33977691:+
LUAD	cis	rs7119038	0.818	rs77209083	ENSG00000255422.1	AP002954.4	4.07	5.47e-05	0.00848	0.29	0.18	Sjögren's syndrome;	chr11:118736860	chr11:118704607~118750263:+
LUAD	cis	rs7119038	0.629	rs10892273	ENSG00000255239.1	AP002954.6	-4.07	5.47e-05	0.00848	-0.26	-0.18	Sjögren's syndrome;	chr11:118732100	chr11:118688039~118690600:-
LUAD	cis	rs453301	0.658	rs9650616	ENSG00000253981.4	ALG1L13P	-4.07	5.47e-05	0.00848	-0.22	-0.18	Joint mobility (Beighton score);	chr8:9011689	chr8:8236003~8244667:-
LUAD	cis	rs172166	0.694	rs203884	ENSG00000216901.1	AL022393.7	4.07	5.47e-05	0.00848	0.22	0.18	Cardiac Troponin-T levels;	chr6:28109596	chr6:28176188~28176674:+
LUAD	cis	rs7208859	0.673	rs79541516	ENSG00000280069.1	CTD-2349P21.3	-4.07	5.47e-05	0.00849	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913565	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs9895684	ENSG00000280069.1	CTD-2349P21.3	-4.07	5.47e-05	0.00849	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30915582	chr17:30738182~30740275:+
LUAD	cis	rs1044826	1	rs34742758	ENSG00000214280.3	RP11-553K23.2	-4.07	5.47e-05	0.00849	-0.22	-0.18	Obesity-related traits;	chr3:139499536	chr3:139582928~139583593:-
LUAD	cis	rs1044826	0.957	rs12494556	ENSG00000214280.3	RP11-553K23.2	-4.07	5.47e-05	0.00849	-0.22	-0.18	Obesity-related traits;	chr3:139504877	chr3:139582928~139583593:-
LUAD	cis	rs6723108	0.581	rs1446525	ENSG00000224043.6	CCNT2-AS1	-4.07	5.47e-05	0.00849	-0.23	-0.18	Type 2 diabetes;	chr2:134880277	chr2:134735464~134918710:-
LUAD	cis	rs6723108	0.627	rs6430554	ENSG00000224043.6	CCNT2-AS1	-4.07	5.47e-05	0.00849	-0.23	-0.18	Type 2 diabetes;	chr2:134880891	chr2:134735464~134918710:-
LUAD	cis	rs2735413	0.918	rs1922621	ENSG00000276007.1	RP11-358L22.3	-4.07	5.47e-05	0.00849	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78041118	chr16:78123243~78124332:+
LUAD	cis	rs2836974	0.666	rs1888487	ENSG00000232608.1	TIMM9P2	4.07	5.47e-05	0.00849	0.22	0.18	Cognitive function;	chr21:39311333	chr21:39216624~39217506:+
LUAD	cis	rs2281636	0.595	rs11190169	ENSG00000233690.1	EBAG9P1	4.07	5.48e-05	0.0085	0.2	0.18	Obesity-related traits;	chr10:99597878	chr10:99697407~99697949:-
LUAD	cis	rs755249	0.517	rs66880209	ENSG00000228060.1	RP11-69E11.8	-4.07	5.48e-05	0.0085	-0.2	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39254140	chr1:39565160~39573203:+
LUAD	cis	rs8014252	1	rs1959483	ENSG00000259158.2	ADAM20P1	-4.07	5.48e-05	0.0085	-0.28	-0.18	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70484971	chr14:70468881~70483756:-
LUAD	cis	rs1799955	1	rs1799955	ENSG00000215515.2	IFIT1P1	-4.07	5.48e-05	0.0085	-0.27	-0.18	LDL cholesterol levels;	chr13:32355095	chr13:32384660~32386108:+
LUAD	cis	rs13113518	1	rs4864548	ENSG00000273257.1	RP11-177J6.1	-4.07	5.48e-05	0.0085	-0.2	-0.18	Height;	chr4:55547636	chr4:55387949~55388271:+
LUAD	cis	rs34779708	0.801	rs12242110	ENSG00000271335.4	RP11-324I22.4	4.07	5.48e-05	0.0085	0.19	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35246767	chr10:35314552~35336401:-
LUAD	cis	rs877819	0.552	rs2127586	ENSG00000228403.1	RP11-563N6.6	-4.07	5.48e-05	0.0085	-0.19	-0.18	Systemic lupus erythematosus;	chr10:48871605	chr10:48878022~48878649:+
LUAD	cis	rs7714584	1	rs73282255	ENSG00000197083.10	ZNF300P1	4.07	5.48e-05	0.00851	0.34	0.18	Crohn's disease;	chr5:150844085	chr5:150930645~150946289:-
LUAD	cis	rs4604732	0.642	rs4400652	ENSG00000227135.1	GCSAML-AS1	-4.07	5.48e-05	0.00851	-0.26	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247473177	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.642	rs4472786	ENSG00000227135.1	GCSAML-AS1	-4.07	5.48e-05	0.00851	-0.26	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247473216	chr1:247524679~247526752:-
LUAD	cis	rs1334894	0.901	rs56353810	ENSG00000228559.1	RP3-340B19.3	-4.07	5.48e-05	0.00851	-0.38	-0.18	Coronary artery disease;	chr6:35553309	chr6:35544632~35545669:+
LUAD	cis	rs1334894	0.901	rs56062505	ENSG00000228559.1	RP3-340B19.3	-4.07	5.48e-05	0.00851	-0.38	-0.18	Coronary artery disease;	chr6:35553405	chr6:35544632~35545669:+
LUAD	cis	rs13434995	0.513	rs1021306	ENSG00000273257.1	RP11-177J6.1	4.07	5.49e-05	0.00851	0.24	0.18	Adiponectin levels;	chr4:55529777	chr4:55387949~55388271:+
LUAD	cis	rs11673344	0.562	rs256740	ENSG00000267254.4	ZNF790-AS1	4.07	5.49e-05	0.00851	0.24	0.18	Obesity-related traits;	chr19:37365451	chr19:36797518~36828115:+
LUAD	cis	rs7107174	1	rs7117238	ENSG00000251323.2	RP11-452H21.4	4.07	5.49e-05	0.00851	0.22	0.18	Testicular germ cell tumor;	chr11:78329213	chr11:78423982~78429836:-
LUAD	cis	rs848490	0.816	rs1636665	ENSG00000214293.7	APTR	-4.07	5.49e-05	0.00851	-0.24	-0.18	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77934500	chr7:77657660~77696265:-
LUAD	cis	rs35740288	0.822	rs4843090	ENSG00000259407.1	RP11-158M2.3	-4.07	5.49e-05	0.00851	-0.18	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85677398	chr15:85744109~85750281:-
LUAD	cis	rs7339483	0.702	rs10419660	ENSG00000268058.1	BNIP3P40	-4.07	5.49e-05	0.00851	-0.34	-0.18	Discordance in emotional problems in monozygotic twins;	chr19:24156851	chr19:24098425~24098980:-
LUAD	cis	rs8073060	0.586	rs7208672	ENSG00000267592.1	CTC-507E2.2	4.07	5.49e-05	0.00851	0.27	0.18	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35662740	chr17:35596904~35597128:-
LUAD	cis	rs7119038	0.629	rs10892271	ENSG00000255422.1	AP002954.4	4.07	5.49e-05	0.00852	0.28	0.18	Sjögren's syndrome;	chr11:118727835	chr11:118704607~118750263:+
LUAD	cis	rs42490	0.536	rs365871	ENSG00000251136.7	RP11-37B2.1	-4.07	5.49e-05	0.00852	-0.19	-0.18	Leprosy;	chr8:89861458	chr8:89609409~89757727:-
LUAD	cis	rs42490	0.536	rs386857	ENSG00000251136.7	RP11-37B2.1	-4.07	5.49e-05	0.00852	-0.19	-0.18	Leprosy;	chr8:89862824	chr8:89609409~89757727:-
LUAD	cis	rs42490	0.536	rs400571	ENSG00000251136.7	RP11-37B2.1	-4.07	5.49e-05	0.00852	-0.19	-0.18	Leprosy;	chr8:89863336	chr8:89609409~89757727:-
LUAD	cis	rs2032366	0.606	rs7226896	ENSG00000266920.1	ACTBP9	4.07	5.49e-05	0.00852	0.19	0.18	Obesity-related traits;	chr18:61608946	chr18:62442028~62443126:+
LUAD	cis	rs7551222	0.752	rs10900599	ENSG00000240219.1	RP11-430C7.5	4.07	5.49e-05	0.00852	0.19	0.18	Schizophrenia;	chr1:204572815	chr1:204626775~204629712:+
LUAD	cis	rs750134	0.901	rs12424287	ENSG00000257221.1	RP11-689B22.2	-4.07	5.49e-05	0.00852	-0.25	-0.18	Low high density lipoprotein cholesterol levels;	chr12:108833174	chr12:108628687~108641318:+
LUAD	cis	rs4763879	0.778	rs11052497	ENSG00000278635.1	CTD-2318O12.1	4.07	5.49e-05	0.00852	0.17	0.18	Type 1 diabetes;	chr12:9696679	chr12:9415641~9416718:+
LUAD	cis	rs62025270	0.632	rs56153788	ENSG00000259416.2	RP11-158M2.5	-4.07	5.49e-05	0.00852	-0.25	-0.18	Idiopathic pulmonary fibrosis;	chr15:85627761	chr15:85754941~85756237:-
LUAD	cis	rs116175783	0.557	rs16845844	ENSG00000227403.1	AC009299.3	-4.07	5.49e-05	0.00852	-0.32	-0.18	Intelligence (multi-trait analysis);	chr2:161408759	chr2:161244739~161249050:+
LUAD	cis	rs595244	1	rs1678982	ENSG00000259705.1	RP11-227D13.1	-4.07	5.49e-05	0.00852	-0.35	-0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48609223	chr15:48645951~48652016:+
LUAD	cis	rs6964587	1	rs12333563	ENSG00000188693.7	CYP51A1-AS1	-4.07	5.5e-05	0.00852	-0.21	-0.18	Breast cancer;	chr7:92038012	chr7:92134604~92180725:+
LUAD	cis	rs7017914	0.667	rs3816745	ENSG00000223220.1	Y_RNA	-4.07	5.5e-05	0.00852	-0.21	-0.18	Bone mineral density;	chr8:70594399	chr8:70780914~70781008:-
LUAD	cis	rs17189298	0.902	rs4849755	ENSG00000231013.1	AC013275.2	4.07	5.5e-05	0.00853	0.19	0.18	Cerebrospinal T-tau levels;	chr2:119116685	chr2:119476448~119487346:+
LUAD	cis	rs4664293	1	rs12692554	ENSG00000230783.1	AC009961.2	-4.07	5.5e-05	0.00853	-0.22	-0.18	Monocyte percentage of white cells;	chr2:159594777	chr2:159689217~159690291:-
LUAD	cis	rs35740288	0.753	rs4843095	ENSG00000259407.1	RP11-158M2.3	-4.07	5.5e-05	0.00853	-0.19	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85731900	chr15:85744109~85750281:-
LUAD	cis	rs12962334	0.555	rs9959556	ENSG00000265943.1	RP11-739L10.1	4.07	5.5e-05	0.00853	0.23	0.18	Breast cancer;	chr18:23011982	chr18:22699481~22933764:-
LUAD	cis	rs4578769	0.531	rs4800443	ENSG00000265943.1	RP11-739L10.1	4.07	5.5e-05	0.00853	0.23	0.18	Eosinophil percentage of white cells;	chr18:23015139	chr18:22699481~22933764:-
LUAD	cis	rs7893279	0.505	rs12770851	ENSG00000225527.1	RP11-383B4.4	4.07	5.5e-05	0.00853	0.27	0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18584223	chr10:18531849~18533336:-
LUAD	cis	rs42490	0.576	rs386587	ENSG00000251136.7	RP11-37B2.1	-4.07	5.5e-05	0.00853	-0.2	-0.18	Leprosy;	chr8:89862772	chr8:89609409~89757727:-
LUAD	cis	rs763121	0.853	rs3761454	ENSG00000228274.3	RP3-508I15.9	-4.07	5.51e-05	0.00853	-0.18	-0.18	Menopause (age at onset);	chr22:38670815	chr22:38667585~38681820:-
LUAD	cis	rs763121	0.853	rs3747170	ENSG00000228274.3	RP3-508I15.9	-4.07	5.51e-05	0.00853	-0.18	-0.18	Menopause (age at onset);	chr22:38671326	chr22:38667585~38681820:-
LUAD	cis	rs911555	0.723	rs6575986	ENSG00000259775.1	RP11-45P15.4	-4.07	5.51e-05	0.00853	-0.23	-0.18	Intelligence (multi-trait analysis);	chr14:103420334	chr14:103331674~103332367:-
LUAD	cis	rs2354432	0.607	rs7545467	ENSG00000226015.2	CCT8P1	4.07	5.51e-05	0.00854	0.34	0.18	Mitochondrial DNA levels;	chr1:147274585	chr1:147203276~147204932:-
LUAD	cis	rs2354432	0.607	rs12404113	ENSG00000226015.2	CCT8P1	4.07	5.51e-05	0.00854	0.34	0.18	Mitochondrial DNA levels;	chr1:147278670	chr1:147203276~147204932:-
LUAD	cis	rs12261331	1	rs12261331	ENSG00000226659.1	RP11-137H2.4	4.07	5.51e-05	0.00854	0.33	0.18	Post bronchodilator FEV1;	chr10:80527771	chr10:80529597~80535942:-
LUAD	cis	rs62229266	0.647	rs59397717	ENSG00000214914.3	RPL23AP3	4.07	5.51e-05	0.00854	0.22	0.18	Mitral valve prolapse;	chr21:36079427	chr21:36016079~36016546:-
LUAD	cis	rs4372836	0.828	rs6728459	ENSG00000226833.4	AC097724.3	4.07	5.51e-05	0.00854	0.22	0.18	Body mass index;	chr2:28776470	chr2:28708953~28736205:-
LUAD	cis	rs2348418	0.864	rs7295120	ENSG00000247934.4	RP11-967K21.1	4.07	5.51e-05	0.00854	0.21	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28565175	chr12:28163298~28190738:-
LUAD	cis	rs9990333	0.622	rs57783901	ENSG00000231464.1	AC024937.4	4.07	5.51e-05	0.00854	0.2	0.18	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196089486	chr3:195996738~195998233:+
LUAD	cis	rs67981189	0.558	rs56043821	ENSG00000269927.1	RP6-91H8.3	4.07	5.51e-05	0.00854	0.24	0.18	Schizophrenia;	chr14:71103835	chr14:71141125~71143253:-
LUAD	cis	rs9393777	0.513	rs61240102	ENSG00000219392.1	RP1-265C24.5	-4.07	5.51e-05	0.00854	-0.29	-0.18	Intelligence (multi-trait analysis);	chr6:27157125	chr6:28115628~28116551:+
LUAD	cis	rs950169	0.919	rs17300292	ENSG00000275120.1	RP11-182J1.17	4.07	5.51e-05	0.00854	0.29	0.18	Schizophrenia;	chr15:84093816	chr15:84599434~84606463:-
LUAD	cis	rs8133949	1	rs871546	ENSG00000237232.6	ZNF295-AS1	4.07	5.51e-05	0.00854	0.22	0.18	Hand grip strength;	chr21:41993444	chr21:42009194~42024924:+
LUAD	cis	rs875971	0.545	rs73378304	ENSG00000222364.1	RNU6-96P	-4.07	5.51e-05	0.00854	-0.23	-0.18	Aortic root size;	chr7:66175760	chr7:66395191~66395286:+
LUAD	cis	rs8062405	0.755	rs62031607	ENSG00000251417.2	RP11-1348G14.4	-4.07	5.51e-05	0.00855	-0.19	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620209	chr16:28802743~28817828:+
LUAD	cis	rs763121	0.853	rs3747172	ENSG00000228274.3	RP3-508I15.9	-4.07	5.51e-05	0.00855	-0.18	-0.18	Menopause (age at onset);	chr22:38671519	chr22:38667585~38681820:-
LUAD	cis	rs763121	0.853	rs5750659	ENSG00000228274.3	RP3-508I15.9	-4.07	5.51e-05	0.00855	-0.18	-0.18	Menopause (age at onset);	chr22:38672784	chr22:38667585~38681820:-
LUAD	cis	rs763121	0.819	rs3747173	ENSG00000228274.3	RP3-508I15.9	-4.07	5.51e-05	0.00855	-0.18	-0.18	Menopause (age at onset);	chr22:38673040	chr22:38667585~38681820:-
LUAD	cis	rs763121	0.853	rs3747174	ENSG00000228274.3	RP3-508I15.9	-4.07	5.51e-05	0.00855	-0.18	-0.18	Menopause (age at onset);	chr22:38673176	chr22:38667585~38681820:-
LUAD	cis	rs763121	0.853	rs5757226	ENSG00000228274.3	RP3-508I15.9	-4.07	5.51e-05	0.00855	-0.18	-0.18	Menopause (age at onset);	chr22:38674545	chr22:38667585~38681820:-
LUAD	cis	rs7647973	0.516	rs4308307	ENSG00000225399.4	RP11-3B7.1	4.07	5.51e-05	0.00855	0.24	0.18	Menarche (age at onset);	chr3:49155783	chr3:49260085~49261316:+
LUAD	cis	rs3805389	0.504	rs62308708	ENSG00000273257.1	RP11-177J6.1	-4.07	5.52e-05	0.00855	-0.3	-0.18	Waist-to-hip ratio adjusted for body mass index;	chr4:55626177	chr4:55387949~55388271:+
LUAD	cis	rs4667682	0.529	rs7562674	ENSG00000234061.1	AC007969.4	-4.07	5.52e-05	0.00855	-0.34	-0.18	Hippocampal atrophy;Body mass index;	chr2:171403177	chr2:171492905~171493095:+
LUAD	cis	rs911555	0.755	rs8014800	ENSG00000244691.1	RPL10AP1	4.07	5.52e-05	0.00855	0.24	0.18	Intelligence (multi-trait analysis);	chr14:103479965	chr14:103412119~103412761:-
LUAD	cis	rs12439619	0.705	rs17354185	ENSG00000276710.3	CSPG4P8	4.07	5.52e-05	0.00855	0.21	0.18	Intelligence (multi-trait analysis);	chr15:82133829	chr15:82459472~82477258:+
LUAD	cis	rs1979679	0.918	rs786711	ENSG00000278733.1	RP11-425D17.1	4.07	5.52e-05	0.00855	0.23	0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28406330	chr12:28185625~28186190:-
LUAD	cis	rs6840258	0.891	rs3755983	ENSG00000251411.1	RP11-397E7.4	-4.07	5.52e-05	0.00855	-0.23	-0.18	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87116640	chr4:86913266~86914817:-
LUAD	cis	rs7204230	1	rs62048054	ENSG00000261291.1	RP11-295M3.2	4.07	5.52e-05	0.00855	0.22	0.18	Fibrinogen;	chr16:53207851	chr16:53168522~53169450:+
LUAD	cis	rs7204230	0.921	rs62048055	ENSG00000261291.1	RP11-295M3.2	4.07	5.52e-05	0.00855	0.22	0.18	Fibrinogen;	chr16:53212092	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs62048058	ENSG00000261291.1	RP11-295M3.2	4.07	5.52e-05	0.00855	0.22	0.18	Fibrinogen;	chr16:53212641	chr16:53168522~53169450:+
LUAD	cis	rs10971721	0.584	rs72731212	ENSG00000260947.1	RP11-384P7.7	4.07	5.52e-05	0.00855	0.36	0.18	Body mass index;	chr9:34109710	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.584	rs12376939	ENSG00000260947.1	RP11-384P7.7	4.07	5.52e-05	0.00855	0.36	0.18	Body mass index;	chr9:34110139	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.584	rs72731214	ENSG00000260947.1	RP11-384P7.7	4.07	5.52e-05	0.00855	0.36	0.18	Body mass index;	chr9:34113019	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.584	rs117997985	ENSG00000260947.1	RP11-384P7.7	4.07	5.52e-05	0.00855	0.36	0.18	Body mass index;	chr9:34113176	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.584	rs72731216	ENSG00000260947.1	RP11-384P7.7	4.07	5.52e-05	0.00855	0.36	0.18	Body mass index;	chr9:34115066	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.584	rs10971933	ENSG00000260947.1	RP11-384P7.7	4.07	5.52e-05	0.00855	0.36	0.18	Body mass index;	chr9:34117073	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.584	rs10971935	ENSG00000260947.1	RP11-384P7.7	4.07	5.52e-05	0.00855	0.36	0.18	Body mass index;	chr9:34118147	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.584	rs10971936	ENSG00000260947.1	RP11-384P7.7	4.07	5.52e-05	0.00855	0.36	0.18	Body mass index;	chr9:34118988	chr9:33697459~33700986:+
LUAD	cis	rs12468579	0.74	rs11894425	ENSG00000235852.1	AC005540.3	4.07	5.52e-05	0.00855	0.2	0.18	JT interval (sulfonylurea treatment interaction);	chr2:190973115	chr2:190880797~190882059:-
LUAD	cis	rs6088580	0.634	rs13041646	ENSG00000276073.1	RP5-1125A11.7	-4.07	5.52e-05	0.00855	-0.18	-0.18	Glomerular filtration rate (creatinine);	chr20:34495076	chr20:33985617~33988989:-
LUAD	cis	rs860818	1	rs860818	ENSG00000226816.2	AC005082.12	4.07	5.52e-05	0.00856	0.48	0.18	Initial pursuit acceleration;	chr7:23210744	chr7:23206013~23208045:+
LUAD	cis	rs7829975	0.688	rs7827182	ENSG00000233609.3	RP11-62H7.2	4.07	5.52e-05	0.00856	0.15	0.18	Mood instability;	chr8:8522961	chr8:8961200~8979025:+
LUAD	cis	rs848490	0.962	rs11761324	ENSG00000214293.7	APTR	4.07	5.52e-05	0.00856	0.25	0.18	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77803597	chr7:77657660~77696265:-
LUAD	cis	rs10761482	0.601	rs7074460	ENSG00000254271.1	RP11-131N11.4	4.07	5.52e-05	0.00856	0.22	0.18	Schizophrenia;	chr10:60425085	chr10:60734342~60741828:+
LUAD	cis	rs34929064	0.671	rs13240836	ENSG00000230658.1	KLHL7-AS1	4.07	5.52e-05	0.00856	0.28	0.18	Major depression and alcohol dependence;	chr7:22704823	chr7:23101228~23105703:-
LUAD	cis	rs2998286	1	rs2807743	ENSG00000254635.4	WAC-AS1	4.07	5.52e-05	0.00856	0.21	0.18	Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts;	chr10:28491364	chr10:28522652~28532743:-
LUAD	cis	rs860295	0.836	rs35615695	ENSG00000160766.13	GBAP1	4.07	5.53e-05	0.00856	0.2	0.18	Body mass index;	chr1:155531223	chr1:155213821~155227422:-
LUAD	cis	rs7829975	0.535	rs4841005	ENSG00000253981.4	ALG1L13P	-4.07	5.53e-05	0.00856	-0.21	-0.18	Mood instability;	chr8:8643720	chr8:8236003~8244667:-
LUAD	cis	rs67981189	0.529	rs2158996	ENSG00000269927.1	RP6-91H8.3	4.07	5.53e-05	0.00856	0.24	0.18	Schizophrenia;	chr14:71062882	chr14:71141125~71143253:-
LUAD	cis	rs7893279	0.505	rs2130531	ENSG00000225527.1	RP11-383B4.4	4.07	5.53e-05	0.00856	0.27	0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18658450	chr10:18531849~18533336:-
LUAD	cis	rs6088580	0.634	rs4911420	ENSG00000276073.1	RP5-1125A11.7	4.07	5.53e-05	0.00856	0.18	0.18	Glomerular filtration rate (creatinine);	chr20:34410848	chr20:33985617~33988989:-
LUAD	cis	rs8141529	0.732	rs5997408	ENSG00000272858.1	CTA-292E10.8	-4.07	5.53e-05	0.00856	-0.21	-0.18	Lymphocyte counts;	chr22:28811927	chr22:28814914~28815662:+
LUAD	cis	rs4578769	0.513	rs9953640	ENSG00000265943.1	RP11-739L10.1	4.07	5.53e-05	0.00856	0.23	0.18	Eosinophil percentage of white cells;	chr18:22947856	chr18:22699481~22933764:-
LUAD	cis	rs9815354	1	rs6768128	ENSG00000273328.4	RP11-141M3.6	-4.07	5.53e-05	0.00857	-0.27	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41823588	chr3:42809414~42908105:+
LUAD	cis	rs9815354	0.951	rs6793520	ENSG00000273328.4	RP11-141M3.6	-4.07	5.53e-05	0.00857	-0.27	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41823797	chr3:42809414~42908105:+
LUAD	cis	rs9815354	1	rs56776628	ENSG00000273328.4	RP11-141M3.6	-4.07	5.53e-05	0.00857	-0.27	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41825364	chr3:42809414~42908105:+
LUAD	cis	rs9815354	0.951	rs9831404	ENSG00000273328.4	RP11-141M3.6	-4.07	5.53e-05	0.00857	-0.27	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41830333	chr3:42809414~42908105:+
LUAD	cis	rs8073060	0.586	rs4796101	ENSG00000267592.1	CTC-507E2.2	4.07	5.53e-05	0.00857	0.26	0.18	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35671574	chr17:35596904~35597128:-
LUAD	cis	rs5742933	0.817	rs1233297	ENSG00000253559.1	OSGEPL1-AS1	-4.07	5.53e-05	0.00857	-0.22	-0.18	Ferritin levels;	chr2:189829449	chr2:189762704~189765556:+
LUAD	cis	rs2836974	0.623	rs7280326	ENSG00000232608.1	TIMM9P2	4.07	5.53e-05	0.00857	0.21	0.18	Cognitive function;	chr21:39328482	chr21:39216624~39217506:+
LUAD	cis	rs2836974	0.644	rs2836986	ENSG00000232608.1	TIMM9P2	4.07	5.53e-05	0.00857	0.21	0.18	Cognitive function;	chr21:39330210	chr21:39216624~39217506:+
LUAD	cis	rs7760535	0.794	rs3851225	ENSG00000271789.1	RP5-1112D6.7	-4.07	5.53e-05	0.00857	-0.19	-0.18	Metabolic traits;	chr6:111503929	chr6:111297126~111298510:+
LUAD	cis	rs2018683	0.707	rs10279610	ENSG00000228421.2	AC005013.5	-4.07	5.53e-05	0.00857	-0.2	-0.18	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28936079	chr7:28957667~28959345:+
LUAD	cis	rs9341808	0.538	rs7756067	ENSG00000260645.1	RP11-250B2.5	-4.07	5.53e-05	0.00857	-0.17	-0.18	Sitting height ratio;	chr6:80310077	chr6:80466958~80469080:+
LUAD	cis	rs7772486	0.846	rs9403767	ENSG00000235652.6	RP11-545I5.3	4.07	5.53e-05	0.00857	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:146081250	chr6:145799409~145886585:+
LUAD	cis	rs3198697	0.663	rs12928099	ENSG00000207425.1	Y_RNA	4.07	5.54e-05	0.00858	0.24	0.18	Triglycerides;	chr16:15056648	chr16:14915457~14915556:-
LUAD	cis	rs7551222	0.752	rs12125533	ENSG00000240219.1	RP11-430C7.5	4.07	5.54e-05	0.00858	0.19	0.18	Schizophrenia;	chr1:204560174	chr1:204626775~204629712:+
LUAD	cis	rs763121	0.853	rs1065201	ENSG00000225450.1	RP3-508I15.14	-4.07	5.54e-05	0.00858	-0.18	-0.18	Menopause (age at onset);	chr22:38673505	chr22:38739003~38749041:+
LUAD	cis	rs2348418	0.932	rs6487685	ENSG00000247934.4	RP11-967K21.1	4.07	5.54e-05	0.00858	0.21	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28505417	chr12:28163298~28190738:-
LUAD	cis	rs7204230	1	rs17302707	ENSG00000261291.1	RP11-295M3.2	-4.07	5.54e-05	0.00858	-0.22	-0.18	Fibrinogen;	chr16:53177940	chr16:53168522~53169450:+
LUAD	cis	rs4934494	0.822	rs3962370	ENSG00000240996.1	RP11-80H5.7	-4.07	5.54e-05	0.00858	-0.24	-0.18	Red blood cell count;	chr10:89777763	chr10:89694295~89697928:-
LUAD	cis	rs16866061	0.855	rs11687736	ENSG00000228446.2	AC073052.1	-4.07	5.54e-05	0.00858	-0.2	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr2:224540405	chr2:224499387~224500100:-
LUAD	cis	rs2354432	0.556	rs7520661	ENSG00000226015.2	CCT8P1	4.07	5.54e-05	0.00858	0.32	0.18	Mitochondrial DNA levels;	chr1:147321430	chr1:147203276~147204932:-
LUAD	cis	rs1334894	1	rs755658	ENSG00000228559.1	RP3-340B19.3	4.07	5.54e-05	0.00859	0.37	0.18	Coronary artery disease;	chr6:35581893	chr6:35544632~35545669:+
LUAD	cis	rs379123	0.528	rs225215	ENSG00000278867.1	RP11-640N20.4	4.07	5.55e-05	0.00859	0.15	0.18	Local histogram emphysema pattern;	chr17:32569892	chr17:32051030~32053208:+
LUAD	cis	rs2243480	1	rs34702770	ENSG00000232559.3	GS1-124K5.12	4.07	5.55e-05	0.00859	0.32	0.18	Diabetic kidney disease;	chr7:65879836	chr7:66554588~66576923:-
LUAD	cis	rs2239547	0.522	rs6768844	ENSG00000243224.1	RP5-1157M23.2	4.07	5.55e-05	0.00859	0.2	0.18	Schizophrenia;	chr3:52970604	chr3:52239258~52241097:+
LUAD	cis	rs17826219	0.636	rs7221463	ENSG00000266490.1	CTD-2349P21.9	4.07	5.55e-05	0.00859	0.27	0.18	Body mass index;	chr17:30753533	chr17:30792372~30792833:+
LUAD	cis	rs791888	0.723	rs1980648	ENSG00000225913.2	RP11-57C13.6	-4.07	5.55e-05	0.00859	-0.23	-0.18	Magnesium levels;	chr10:87662612	chr10:87607985~87659279:+
LUAD	cis	rs791888	0.688	rs1980649	ENSG00000225913.2	RP11-57C13.6	-4.07	5.55e-05	0.00859	-0.23	-0.18	Magnesium levels;	chr10:87662618	chr10:87607985~87659279:+
LUAD	cis	rs6081541	0.921	rs6035258	ENSG00000179447.2	RP5-1027G4.3	4.07	5.55e-05	0.00859	0.23	0.18	Psychosis (atypical);	chr20:19225186	chr20:19242302~19284596:-
LUAD	cis	rs67340775	0.541	rs200979	ENSG00000280107.1	AL022393.9	-4.07	5.55e-05	0.00859	-0.29	-0.18	Lung cancer in ever smokers;	chr6:27884579	chr6:28170845~28172521:+
LUAD	cis	rs7690978	1	rs7690978	ENSG00000249717.1	RP11-44F21.3	4.07	5.55e-05	0.00859	0.22	0.18	Interferon gamma-induced protein 10 levels;	chr4:75066634	chr4:74955974~74970362:-
LUAD	cis	rs7560272	0.682	rs2421546	ENSG00000163016.8	ALMS1P	-4.07	5.55e-05	0.0086	-0.2	-0.18	Schizophrenia;	chr2:73413949	chr2:73644919~73685576:+
LUAD	cis	rs17301013	0.896	rs6425292	ENSG00000227373.4	RP11-160H22.5	4.07	5.55e-05	0.0086	0.23	0.18	Systemic lupus erythematosus;	chr1:174618364	chr1:174115300~174160004:-
LUAD	cis	rs2692947	0.76	rs2438924	ENSG00000237510.6	AC008268.2	4.07	5.55e-05	0.0086	0.23	0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95979321	chr2:95789654~95800166:+
LUAD	cis	rs2692947	0.826	rs7423942	ENSG00000237510.6	AC008268.2	4.07	5.55e-05	0.0086	0.23	0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95979509	chr2:95789654~95800166:+
LUAD	cis	rs5771040	0.521	rs5771039	ENSG00000273253.2	RP3-402G11.26	-4.07	5.55e-05	0.0086	-0.19	-0.18	IgG glycosylation;	chr22:50463105	chr22:50199090~50200837:-
LUAD	cis	rs7688540	0.8	rs12510827	ENSG00000211553.1	AC253576.2	-4.07	5.55e-05	0.0086	-0.23	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:259015	chr4:136461~136568:+
LUAD	cis	rs77688320	0.535	rs6751543	ENSG00000213090.2	AC007256.5	4.07	5.55e-05	0.0086	0.21	0.18	Breast cancer;	chr2:201400210	chr2:201410544~201413308:-
LUAD	cis	rs77688320	0.535	rs34625194	ENSG00000213090.2	AC007256.5	4.07	5.55e-05	0.0086	0.21	0.18	Breast cancer;	chr2:201406815	chr2:201410544~201413308:-
LUAD	cis	rs77688320	0.535	rs11691859	ENSG00000213090.2	AC007256.5	4.07	5.55e-05	0.0086	0.21	0.18	Breast cancer;	chr2:201407268	chr2:201410544~201413308:-
LUAD	cis	rs77688320	0.517	rs11691865	ENSG00000213090.2	AC007256.5	4.07	5.55e-05	0.0086	0.21	0.18	Breast cancer;	chr2:201407309	chr2:201410544~201413308:-
LUAD	cis	rs2911132	0.564	rs7356594	ENSG00000272109.1	CTD-2260A17.3	-4.07	5.56e-05	0.0086	-0.2	-0.18	Urate levels (BMI interaction);	chr5:96760485	chr5:96804353~96806105:+
LUAD	cis	rs2273156	0.57	rs8013540	ENSG00000226677.3	IGBP1P1	-4.07	5.56e-05	0.0086	-0.28	-0.18	Immunoglobulin light chain (AL) amyloidosis;	chr14:35044554	chr14:34939324~34940332:+
LUAD	cis	rs4474465	1	rs7950865	ENSG00000251323.2	RP11-452H21.4	4.07	5.56e-05	0.0086	0.22	0.18	Alzheimer's disease (survival time);	chr11:78446355	chr11:78423982~78429836:-
LUAD	cis	rs8177876	0.915	rs11866124	ENSG00000261061.1	RP11-303E16.2	4.07	5.56e-05	0.0086	0.3	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81093866	chr16:81030770~81031485:+
LUAD	cis	rs858239	0.539	rs6955726	ENSG00000226816.2	AC005082.12	4.07	5.56e-05	0.0086	0.24	0.18	Cerebrospinal fluid biomarker levels;	chr7:23147072	chr7:23206013~23208045:+
LUAD	cis	rs858239	0.539	rs6976957	ENSG00000226816.2	AC005082.12	4.07	5.56e-05	0.0086	0.24	0.18	Cerebrospinal fluid biomarker levels;	chr7:23147714	chr7:23206013~23208045:+
LUAD	cis	rs858239	0.539	rs6956828	ENSG00000226816.2	AC005082.12	4.07	5.56e-05	0.0086	0.24	0.18	Cerebrospinal fluid biomarker levels;	chr7:23147728	chr7:23206013~23208045:+
LUAD	cis	rs2236553	1	rs2236553	ENSG00000277496.1	RP11-93B14.9	-4.07	5.56e-05	0.00861	-0.21	-0.18	Menopause (age at onset);	chr20:62658391	chr20:62648961~62650767:-
LUAD	cis	rs703842	1	rs10877019	ENSG00000270039.1	RP11-571M6.17	4.07	5.56e-05	0.00861	0.22	0.18	Multiple sclerosis;	chr12:57779146	chr12:57803838~57804415:+
LUAD	cis	rs3812049	0.784	rs2568928	ENSG00000245937.6	LINC01184	-4.07	5.56e-05	0.00861	-0.26	-0.18	Lymphocyte counts;Red cell distribution width;	chr5:128151911	chr5:127940426~128083172:-
LUAD	cis	rs9815354	1	rs6805880	ENSG00000273328.4	RP11-141M3.6	-4.07	5.56e-05	0.00861	-0.27	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41823905	chr3:42809414~42908105:+
LUAD	cis	rs9815354	1	rs6768542	ENSG00000273328.4	RP11-141M3.6	-4.07	5.56e-05	0.00861	-0.27	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41823982	chr3:42809414~42908105:+
LUAD	cis	rs9815354	1	rs6768563	ENSG00000273328.4	RP11-141M3.6	-4.07	5.56e-05	0.00861	-0.27	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41824049	chr3:42809414~42908105:+
LUAD	cis	rs6071166	0.683	rs6027265	ENSG00000224635.1	RP4-564F22.5	-4.07	5.56e-05	0.00861	-0.21	-0.18	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38687350	chr20:38406011~38416797:-
LUAD	cis	rs6071166	0.683	rs6027270	ENSG00000224635.1	RP4-564F22.5	-4.07	5.56e-05	0.00861	-0.21	-0.18	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38687750	chr20:38406011~38416797:-
LUAD	cis	rs6071166	0.683	rs1154702	ENSG00000224635.1	RP4-564F22.5	-4.07	5.56e-05	0.00861	-0.21	-0.18	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38687958	chr20:38406011~38416797:-
LUAD	cis	rs9646944	0.531	rs17027029	ENSG00000234389.1	AC007278.3	4.07	5.56e-05	0.00861	0.21	0.18	Blood protein levels;	chr2:102374188	chr2:102438713~102440475:+
LUAD	cis	rs293748	0.724	rs55668350	ENSG00000250155.1	CTD-2353F22.1	-4.07	5.56e-05	0.00861	-0.24	-0.18	Obesity-related traits;	chr5:36801181	chr5:36666214~36725195:-
LUAD	cis	rs11242704	0.662	rs12201506	ENSG00000272279.1	RP11-157J24.2	-4.07	5.56e-05	0.00861	-0.27	-0.18	Response to hepatitis C treatment;	chr6:1536205	chr6:1528364~1528911:-
LUAD	cis	rs2836974	0.897	rs2776308	ENSG00000232608.1	TIMM9P2	-4.07	5.57e-05	0.00861	-0.22	-0.18	Cognitive function;	chr21:39343249	chr21:39216624~39217506:+
LUAD	cis	rs7829975	0.682	rs7013471	ENSG00000253893.2	FAM85B	4.07	5.57e-05	0.00861	0.22	0.18	Mood instability;	chr8:8829815	chr8:8167819~8226614:-
LUAD	cis	rs2836950	0.565	rs7278297	ENSG00000232608.1	TIMM9P2	4.07	5.57e-05	0.00861	0.2	0.18	Menarche (age at onset);	chr21:39253826	chr21:39216624~39217506:+
LUAD	cis	rs875971	0.545	rs4718348	ENSG00000222364.1	RNU6-96P	-4.07	5.57e-05	0.00861	-0.24	-0.18	Aortic root size;	chr7:66441589	chr7:66395191~66395286:+
LUAD	cis	rs5758659	0.967	rs5758670	ENSG00000273366.1	CTA-989H11.1	-4.07	5.57e-05	0.00861	-0.21	-0.18	Cognitive function;	chr22:42240681	chr22:42278188~42278846:+
LUAD	cis	rs3018712	0.532	rs2510397	ENSG00000212093.1	AP000807.1	-4.07	5.57e-05	0.00862	-0.24	-0.18	Total body bone mineral density;	chr11:68652091	chr11:68506083~68506166:-
LUAD	cis	rs9291683	0.551	rs2276961	ENSG00000250413.1	RP11-448G15.1	-4.07	5.57e-05	0.00862	-0.23	-0.18	Bone mineral density;	chr4:10021357	chr4:10006482~10009725:+
LUAD	cis	rs1910358	0.919	rs4701238	ENSG00000248874.4	C5orf17	-4.07	5.57e-05	0.00862	-0.26	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr5:23870710	chr5:23951348~24178263:+
LUAD	cis	rs1910358	0.919	rs4701239	ENSG00000248874.4	C5orf17	-4.07	5.57e-05	0.00862	-0.26	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr5:23871671	chr5:23951348~24178263:+
LUAD	cis	rs1910358	0.919	rs4701240	ENSG00000248874.4	C5orf17	-4.07	5.57e-05	0.00862	-0.26	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr5:23871818	chr5:23951348~24178263:+
LUAD	cis	rs6724465	0.866	rs16859493	ENSG00000272644.1	RP11-33O4.1	4.07	5.57e-05	0.00862	0.26	0.18	Height;	chr2:219033774	chr2:219069354~219069809:-
LUAD	cis	rs2098713	0.534	rs12188314	ENSG00000250155.1	CTD-2353F22.1	4.07	5.57e-05	0.00862	0.2	0.18	Telomere length;	chr5:37578577	chr5:36666214~36725195:-
LUAD	cis	rs7760535	0.763	rs10457241	ENSG00000266032.1	AL357515.1	4.07	5.57e-05	0.00862	0.24	0.18	Metabolic traits;	chr6:111527831	chr6:110969773~110969872:-
LUAD	cis	rs733592	0.599	rs12819124	ENSG00000240399.1	RP1-228P16.1	4.07	5.57e-05	0.00862	0.17	0.18	Plateletcrit;	chr12:48015271	chr12:48054813~48055591:-
LUAD	cis	rs12817211	0.502	rs7961065	ENSG00000272368.2	RP4-605O3.4	-4.07	5.57e-05	0.00862	-0.21	-0.18	Colorectal or endometrial cancer;	chr12:50119904	chr12:50112197~50165618:+
LUAD	cis	rs4907240	1	rs4907240	ENSG00000237510.6	AC008268.2	-4.07	5.57e-05	0.00862	-0.26	-0.18	Event-related brain oscillations;	chr2:96562302	chr2:95789654~95800166:+
LUAD	cis	rs5758511	0.68	rs5758688	ENSG00000227370.1	RP4-669P10.19	4.07	5.57e-05	0.00862	0.2	0.18	Birth weight;	chr22:42266495	chr22:42132543~42132998:+
LUAD	cis	rs889398	0.802	rs2291959	ENSG00000226232.7	RP11-419C5.2	-4.07	5.57e-05	0.00862	-0.16	-0.18	Body mass index;	chr16:69840089	chr16:69976388~69996188:-
LUAD	cis	rs703842	0.585	rs10877022	ENSG00000245651.2	RP11-620J15.2	4.07	5.57e-05	0.00862	0.19	0.18	Multiple sclerosis;	chr12:57830154	chr12:57869835~57896482:-
LUAD	cis	rs801193	1	rs2707854	ENSG00000222364.1	RNU6-96P	-4.07	5.58e-05	0.00863	-0.2	-0.18	Aortic root size;	chr7:66747610	chr7:66395191~66395286:+
LUAD	cis	rs11159086	1	rs11159087	ENSG00000270000.1	RP3-449M8.9	4.07	5.58e-05	0.00863	0.26	0.18	Advanced glycation end-product levels;	chr14:74504671	chr14:74471930~74472360:-
LUAD	cis	rs73193808	0.851	rs73342446	ENSG00000215533.7	LINC00189	-4.07	5.58e-05	0.00863	-0.25	-0.18	Coronary artery disease;	chr21:29234247	chr21:29193480~29288205:+
LUAD	cis	rs2562152	0.654	rs216600	ENSG00000226942.2	IL9RP3	-4.07	5.58e-05	0.00863	-0.27	-0.18	Glioblastoma;	chr16:60167	chr16:29336~38321:-
LUAD	cis	rs6942407	0.592	rs6966613	ENSG00000224046.1	AC005076.5	-4.07	5.58e-05	0.00863	-0.23	-0.18	Food allergy;	chr7:87164178	chr7:87151423~87152420:-
LUAD	cis	rs9815354	1	rs9830064	ENSG00000273328.4	RP11-141M3.6	-4.07	5.58e-05	0.00863	-0.26	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41840309	chr3:42809414~42908105:+
LUAD	cis	rs11064837	0.523	rs1978107	ENSG00000248636.5	RP11-768F21.1	4.07	5.58e-05	0.00863	0.22	0.18	Schizophrenia;	chr12:119663909	chr12:119387987~119668079:-
LUAD	cis	rs837841	0.864	rs1660903	ENSG00000233428.1	AC019050.1	-4.07	5.58e-05	0.00863	-0.19	-0.18	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);	chr2:129289106	chr2:129496297~129496788:+
LUAD	cis	rs35740288	0.77	rs36044792	ENSG00000259407.1	RP11-158M2.3	-4.07	5.58e-05	0.00864	-0.18	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85603320	chr15:85744109~85750281:-
LUAD	cis	rs2562456	0.833	rs11672583	ENSG00000268081.1	RP11-678G14.2	4.07	5.59e-05	0.00864	0.3	0.18	Pain;	chr19:21379363	chr19:21554640~21569237:-
LUAD	cis	rs5758511	0.633	rs5751258	ENSG00000227370.1	RP4-669P10.19	4.07	5.59e-05	0.00864	0.2	0.18	Birth weight;	chr22:42267865	chr22:42132543~42132998:+
LUAD	cis	rs858239	0.539	rs4294098	ENSG00000226816.2	AC005082.12	4.07	5.59e-05	0.00864	0.24	0.18	Cerebrospinal fluid biomarker levels;	chr7:23146376	chr7:23206013~23208045:+
LUAD	cis	rs752590	0.832	rs6542124	ENSG00000274877.1	RP11-65I12.1	-4.07	5.59e-05	0.00864	-0.48	-0.18	Mucinous ovarian carcinoma;	chr2:113194347	chr2:113237595~113240825:+
LUAD	cis	rs111321694	1	rs111321694	ENSG00000271390.1	RP11-89C3.3	4.07	5.59e-05	0.00864	0.3	0.18	Educational attainment (years of education);	chr11:111079662	chr11:111089870~111090368:-
LUAD	cis	rs801193	0.839	rs12534943	ENSG00000236529.1	RP13-254B10.1	-4.07	5.59e-05	0.00864	-0.18	-0.18	Aortic root size;	chr7:66605533	chr7:65840212~65840596:+
LUAD	cis	rs2638953	0.606	rs10843213	ENSG00000244712.1	RP11-874G11.1	-4.07	5.59e-05	0.00864	-0.26	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28582853	chr12:28564678~28565141:-
LUAD	cis	rs10771431	0.597	rs3759275	ENSG00000111788.10	RP11-22B23.1	4.07	5.59e-05	0.00864	0.16	0.18	Breast size;	chr12:9201232	chr12:9277235~9313241:+
LUAD	cis	rs10771431	0.597	rs3759274	ENSG00000111788.10	RP11-22B23.1	4.07	5.59e-05	0.00864	0.16	0.18	Breast size;	chr12:9201279	chr12:9277235~9313241:+
LUAD	cis	rs7204230	1	rs62048023	ENSG00000261291.1	RP11-295M3.2	4.07	5.59e-05	0.00864	0.22	0.18	Fibrinogen;	chr16:53168038	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs62048024	ENSG00000261291.1	RP11-295M3.2	4.07	5.59e-05	0.00864	0.22	0.18	Fibrinogen;	chr16:53168098	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs7195323	ENSG00000261291.1	RP11-295M3.2	4.07	5.59e-05	0.00864	0.22	0.18	Fibrinogen;	chr16:53169434	chr16:53168522~53169450:+
LUAD	cis	rs7204230	0.92	rs62048027	ENSG00000261291.1	RP11-295M3.2	4.07	5.59e-05	0.00864	0.22	0.18	Fibrinogen;	chr16:53171917	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs7202653	ENSG00000261291.1	RP11-295M3.2	4.07	5.59e-05	0.00864	0.22	0.18	Fibrinogen;	chr16:53173281	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs8047327	ENSG00000261291.1	RP11-295M3.2	4.07	5.59e-05	0.00864	0.22	0.18	Fibrinogen;	chr16:53173975	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs17302672	ENSG00000261291.1	RP11-295M3.2	4.07	5.59e-05	0.00864	0.22	0.18	Fibrinogen;	chr16:53176641	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs12596062	ENSG00000261291.1	RP11-295M3.2	4.07	5.59e-05	0.00864	0.22	0.18	Fibrinogen;	chr16:53177753	chr16:53168522~53169450:+
LUAD	cis	rs2299587	0.531	rs28839855	ENSG00000253671.1	RP11-806O11.1	-4.07	5.59e-05	0.00864	-0.21	-0.18	Economic and political preferences;	chr8:17998474	chr8:17808941~17820868:+
LUAD	cis	rs2243480	1	rs465359	ENSG00000229886.1	RP5-1132H15.3	4.07	5.59e-05	0.00864	0.31	0.18	Diabetic kidney disease;	chr7:66093177	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs462853	ENSG00000229886.1	RP5-1132H15.3	4.07	5.59e-05	0.00864	0.31	0.18	Diabetic kidney disease;	chr7:66093180	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs160644	ENSG00000229886.1	RP5-1132H15.3	4.07	5.59e-05	0.00864	0.31	0.18	Diabetic kidney disease;	chr7:66093199	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs160642	ENSG00000229886.1	RP5-1132H15.3	4.07	5.59e-05	0.00864	0.31	0.18	Diabetic kidney disease;	chr7:66093386	chr7:66025126~66031544:-
LUAD	cis	rs2243480	0.614	rs34032527	ENSG00000229886.1	RP5-1132H15.3	4.07	5.59e-05	0.00864	0.31	0.18	Diabetic kidney disease;	chr7:66100154	chr7:66025126~66031544:-
LUAD	cis	rs10129255	0.834	rs10139893	ENSG00000211967.3	IGHV3-53	-4.07	5.59e-05	0.00864	-0.15	-0.18	Kawasaki disease;	chr14:106711377	chr14:106592676~106593347:-
LUAD	cis	rs1075265	0.73	rs7559380	ENSG00000272156.1	RP11-477N3.1	-4.07	5.59e-05	0.00864	-0.22	-0.18	Chronotype;Morning vs. evening chronotype;	chr2:54129660	chr2:54082554~54085066:+
LUAD	cis	rs442309	0.687	rs10822052	ENSG00000238280.1	RP11-436D10.3	4.07	5.59e-05	0.00864	0.22	0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62696010	chr10:62793562~62805887:-
LUAD	cis	rs651907	0.557	rs12629954	ENSG00000244119.1	PDCL3P4	4.07	5.59e-05	0.00864	0.18	0.18	Colorectal cancer;	chr3:101641779	chr3:101712472~101713191:+
LUAD	cis	rs4713118	0.662	rs156744	ENSG00000280107.1	AL022393.9	-4.07	5.59e-05	0.00864	-0.24	-0.18	Parkinson's disease;	chr6:27999496	chr6:28170845~28172521:+
LUAD	cis	rs4713118	0.662	rs149947	ENSG00000280107.1	AL022393.9	-4.07	5.59e-05	0.00864	-0.24	-0.18	Parkinson's disease;	chr6:28004655	chr6:28170845~28172521:+
LUAD	cis	rs2243480	1	rs67728539	ENSG00000232559.3	GS1-124K5.12	4.07	5.59e-05	0.00865	0.32	0.18	Diabetic kidney disease;	chr7:65913137	chr7:66554588~66576923:-
LUAD	cis	rs7762018	0.941	rs4716387	ENSG00000231690.2	LINC00574	-4.07	5.59e-05	0.00865	-0.35	-0.18	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169736681	chr6:169790321~169802873:+
LUAD	cis	rs473651	0.716	rs548179	ENSG00000229915.1	AC016999.2	-4.07	5.59e-05	0.00865	-0.24	-0.18	Multiple system atrophy;	chr2:238411864	chr2:238427077~238427729:-
LUAD	cis	rs10463554	0.927	rs257308	ENSG00000250682.4	LINC00491	4.07	5.59e-05	0.00865	0.22	0.18	Parkinson's disease;	chr5:103082557	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.927	rs257311	ENSG00000250682.4	LINC00491	4.07	5.59e-05	0.00865	0.22	0.18	Parkinson's disease;	chr5:103083394	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.927	rs257314	ENSG00000250682.4	LINC00491	4.07	5.59e-05	0.00865	0.22	0.18	Parkinson's disease;	chr5:103085391	chr5:102609156~102671559:-
LUAD	cis	rs641862	1	rs641862	ENSG00000229152.2	ANKRD10-IT1	4.07	5.6e-05	0.00865	0.28	0.18	Obesity-related traits;	chr13:110137885	chr13:110894639~110899172:-
LUAD	cis	rs4819052	0.684	rs914216	ENSG00000215447.6	BX322557.10	-4.07	5.6e-05	0.00865	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278383	chr21:45288052~45291738:+
LUAD	cis	rs2692947	0.702	rs4907291	ENSG00000237510.6	AC008268.2	4.07	5.6e-05	0.00866	0.23	0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95988857	chr2:95789654~95800166:+
LUAD	cis	rs801193	1	rs2707850	ENSG00000222364.1	RNU6-96P	-4.07	5.6e-05	0.00866	-0.2	-0.18	Aortic root size;	chr7:66738883	chr7:66395191~66395286:+
LUAD	cis	rs801193	0.967	rs1110414	ENSG00000222364.1	RNU6-96P	-4.07	5.6e-05	0.00866	-0.2	-0.18	Aortic root size;	chr7:66740595	chr7:66395191~66395286:+
LUAD	cis	rs801193	1	rs7783924	ENSG00000222364.1	RNU6-96P	-4.07	5.6e-05	0.00866	-0.2	-0.18	Aortic root size;	chr7:66744070	chr7:66395191~66395286:+
LUAD	cis	rs801193	1	rs7789184	ENSG00000222364.1	RNU6-96P	-4.07	5.6e-05	0.00866	-0.2	-0.18	Aortic root size;	chr7:66745208	chr7:66395191~66395286:+
LUAD	cis	rs12188164	0.62	rs1043356	ENSG00000221990.4	EXOC3-AS1	-4.07	5.6e-05	0.00866	-0.19	-0.18	Cystic fibrosis severity;	chr5:480833	chr5:441498~443160:-
LUAD	cis	rs875971	0.862	rs2024192	ENSG00000273448.1	RP11-166O4.6	-4.07	5.6e-05	0.00866	-0.17	-0.18	Aortic root size;	chr7:66576460	chr7:67333047~67334383:+
LUAD	cis	rs875971	0.862	rs4718377	ENSG00000273448.1	RP11-166O4.6	-4.07	5.6e-05	0.00866	-0.17	-0.18	Aortic root size;	chr7:66584691	chr7:67333047~67334383:+
LUAD	cis	rs875971	0.862	rs10278014	ENSG00000273448.1	RP11-166O4.6	-4.07	5.6e-05	0.00866	-0.17	-0.18	Aortic root size;	chr7:66586277	chr7:67333047~67334383:+
LUAD	cis	rs6714710	0.603	rs12988571	ENSG00000230606.9	AC159540.1	-4.07	5.6e-05	0.00866	-0.19	-0.18	Posterior cortical atrophy and Alzheimer's disease;	chr2:97789232	chr2:97416165~97433527:-
LUAD	cis	rs36093844	0.799	rs12280977	ENSG00000279742.1	RP11-700A24.1	-4.07	5.6e-05	0.00866	-0.21	-0.18	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85887621	chr11:85852557~85854943:-
LUAD	cis	rs6723226	0.766	rs398290	ENSG00000276334.1	AL133243.1	4.07	5.61e-05	0.00867	0.21	0.18	Intelligence (multi-trait analysis);	chr2:32278457	chr2:32521927~32523547:+
LUAD	cis	rs10510102	0.608	rs4486560	ENSG00000226864.1	ATE1-AS1	4.07	5.61e-05	0.00867	0.26	0.18	Breast cancer;	chr10:121844840	chr10:121928312~121951965:+
LUAD	cis	rs7119038	0.629	rs11216995	ENSG00000255239.1	AP002954.6	-4.07	5.61e-05	0.00867	-0.26	-0.18	Sjögren's syndrome;	chr11:118732817	chr11:118688039~118690600:-
LUAD	cis	rs3096299	0.685	rs3803682	ENSG00000261118.1	RP11-104N10.1	4.07	5.61e-05	0.00867	0.18	0.18	Multiple myeloma (IgH translocation);	chr16:89478228	chr16:89492017~89504460:-
LUAD	cis	rs7551222	0.683	rs898386	ENSG00000236779.1	RP11-430C7.2	-4.06	5.61e-05	0.00867	-0.24	-0.18	Schizophrenia;	chr1:204610569	chr1:204528845~204529692:-
LUAD	cis	rs10800713	0.529	rs10919966	ENSG00000260088.1	RP11-92G12.3	4.06	5.61e-05	0.00867	0.31	0.18	Tandem gait;	chr1:200533441	chr1:200669507~200694250:+
LUAD	cis	rs9549260	0.755	rs2755216	ENSG00000229456.1	RLIMP1	4.06	5.61e-05	0.00867	0.2	0.18	Red blood cell count;	chr13:40582801	chr13:40618738~40621348:+
LUAD	cis	rs12149074	0.55	rs4889091	ENSG00000261390.4	RP11-345M22.2	-4.06	5.61e-05	0.00867	-0.24	-0.18	Bipolar disorder and eating disorder;Eating disorder in bipolar disorder;	chr16:80069901	chr16:79715232~79770563:-
LUAD	cis	rs3733309	0.648	rs10016631	ENSG00000269949.1	RP11-738E22.3	4.06	5.61e-05	0.00867	0.29	0.18	Height;	chr4:57019797	chr4:56960927~56961373:-
LUAD	cis	rs2253762	0.507	rs12264894	ENSG00000276742.1	RP11-500G22.4	4.06	5.61e-05	0.00868	0.28	0.18	Breast cancer;	chr10:121992087	chr10:121956782~121957098:+
LUAD	cis	rs2836974	0.899	rs2836957	ENSG00000232608.1	TIMM9P2	-4.06	5.61e-05	0.00868	-0.22	-0.18	Cognitive function;	chr21:39251208	chr21:39216624~39217506:+
LUAD	cis	rs2239908	0.718	rs241776	ENSG00000237575.4	PYY2	-4.06	5.61e-05	0.00868	-0.21	-0.18	Blood protein levels;	chr17:28317282	chr17:28226563~28228065:+
LUAD	cis	rs847577	0.569	rs12674083	ENSG00000272950.1	RP11-307C18.1	4.06	5.62e-05	0.00868	0.23	0.18	Breast cancer;	chr7:98067022	chr7:98322853~98323430:+
LUAD	cis	rs2657294	0.965	rs9299525	ENSG00000226051.5	ZNF503-AS1	-4.06	5.62e-05	0.00868	-0.24	-0.18	Pneumonia;	chr10:75118267	chr10:75269819~75373500:+
LUAD	cis	rs847577	0.569	rs35101190	ENSG00000272950.1	RP11-307C18.1	4.06	5.62e-05	0.00868	0.23	0.18	Breast cancer;	chr7:98066576	chr7:98322853~98323430:+
LUAD	cis	rs853679	0.598	rs9380054	ENSG00000280107.1	AL022393.9	-4.06	5.62e-05	0.00868	-0.24	-0.18	Depression;	chr6:28099759	chr6:28170845~28172521:+
LUAD	cis	rs4713118	0.547	rs2116981	ENSG00000280107.1	AL022393.9	-4.06	5.62e-05	0.00868	-0.24	-0.18	Parkinson's disease;	chr6:28100173	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs9368552	ENSG00000280107.1	AL022393.9	-4.06	5.62e-05	0.00868	-0.24	-0.18	Depression;	chr6:28100648	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.542	rs34131763	ENSG00000280107.1	AL022393.9	-4.06	5.62e-05	0.00868	-0.24	-0.18	Depression;	chr6:28107222	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs35193936	ENSG00000280107.1	AL022393.9	-4.06	5.62e-05	0.00868	-0.24	-0.18	Depression;	chr6:28108492	chr6:28170845~28172521:+
LUAD	cis	rs5758659	0.652	rs1063392	ENSG00000227370.1	RP4-669P10.19	4.06	5.62e-05	0.00868	0.17	0.18	Cognitive function;	chr22:42058946	chr22:42132543~42132998:+
LUAD	cis	rs1355223	0.867	rs1377495	ENSG00000271369.1	RP11-350D17.3	4.06	5.62e-05	0.00868	0.21	0.18	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34661415	chr11:34709600~34710161:+
LUAD	cis	rs5015933	0.815	rs35216121	ENSG00000232630.1	PRPS1P2	-4.06	5.62e-05	0.00868	-0.17	-0.18	Body mass index;	chr9:125263999	chr9:125150653~125151589:+
LUAD	cis	rs2880765	0.566	rs17553790	ENSG00000259630.2	CTD-2262B20.1	4.06	5.62e-05	0.00869	0.22	0.18	Coronary artery disease;	chr15:85470434	chr15:85415228~85415633:+
LUAD	cis	rs6687821	0.515	rs10873806	ENSG00000261737.1	RP4-612B15.3	4.06	5.62e-05	0.00869	0.25	0.18	Yeast infection;	chr1:86974915	chr1:86703502~86704462:-
LUAD	cis	rs7204230	1	rs9673875	ENSG00000261291.1	RP11-295M3.2	4.06	5.62e-05	0.00869	0.23	0.18	Fibrinogen;	chr16:53186663	chr16:53168522~53169450:+
LUAD	cis	rs12935418	1	rs62054589	ENSG00000261061.1	RP11-303E16.2	-4.06	5.62e-05	0.00869	-0.25	-0.18	Mean corpuscular volume;	chr16:81035143	chr16:81030770~81031485:+
LUAD	cis	rs72634501	0.574	rs111623477	ENSG00000182109.6	RP11-69E11.4	4.06	5.62e-05	0.00869	0.25	0.18	HDL cholesterol;	chr1:39345533	chr1:39522280~39546187:-
LUAD	cis	rs4072980	0.545	rs11210870	ENSG00000212541.1	RNU6-510P	4.06	5.63e-05	0.00869	0.25	0.18	Coronary artery disease;	chr1:37984238	chr1:37991462~37991569:+
LUAD	cis	rs12681366	0.592	rs4735291	ENSG00000253704.1	RP11-267M23.4	4.06	5.63e-05	0.00869	0.22	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94394914	chr8:94553722~94569745:+
LUAD	cis	rs62025270	0.688	rs62025297	ENSG00000259416.2	RP11-158M2.5	-4.06	5.63e-05	0.00869	-0.24	-0.18	Idiopathic pulmonary fibrosis;	chr15:85773708	chr15:85754941~85756237:-
LUAD	cis	rs62025270	0.688	rs62025298	ENSG00000259416.2	RP11-158M2.5	-4.06	5.63e-05	0.00869	-0.24	-0.18	Idiopathic pulmonary fibrosis;	chr15:85773921	chr15:85754941~85756237:-
LUAD	cis	rs12681963	1	rs12675542	ENSG00000272375.1	RP11-51J9.6	-4.06	5.63e-05	0.0087	-0.26	-0.18	Migraine;	chr8:30128938	chr8:30197404~30198048:+
LUAD	cis	rs2688608	0.967	rs9971038	ENSG00000271816.1	BMS1P4	4.06	5.63e-05	0.0087	0.15	0.18	Inflammatory bowel disease;	chr10:73901391	chr10:73699151~73730487:-
LUAD	cis	rs2688608	0.967	rs9971040	ENSG00000271816.1	BMS1P4	4.06	5.63e-05	0.0087	0.15	0.18	Inflammatory bowel disease;	chr10:73901404	chr10:73699151~73730487:-
LUAD	cis	rs13113518	0.841	rs11133400	ENSG00000272969.1	RP11-528I4.2	4.06	5.63e-05	0.0087	0.19	0.18	Height;	chr4:55578787	chr4:55547112~55547889:+
LUAD	cis	rs950169	1	rs1848093	ENSG00000275120.1	RP11-182J1.17	4.06	5.63e-05	0.0087	0.29	0.18	Schizophrenia;	chr15:84086775	chr15:84599434~84606463:-
LUAD	cis	rs600231	0.706	rs3782091	ENSG00000245532.5	NEAT1	-4.06	5.63e-05	0.0087	-0.14	-0.18	Bone mineral density;	chr11:65569012	chr11:65422774~65445540:+
LUAD	cis	rs9393777	0.513	rs6913660	ENSG00000219392.1	RP1-265C24.5	-4.06	5.63e-05	0.0087	-0.29	-0.18	Intelligence (multi-trait analysis);	chr6:27123646	chr6:28115628~28116551:+
LUAD	cis	rs7119038	0.818	rs6589685	ENSG00000255422.1	AP002954.4	4.06	5.64e-05	0.0087	0.28	0.18	Sjögren's syndrome;	chr11:118741488	chr11:118704607~118750263:+
LUAD	cis	rs7247513	0.79	rs17476839	ENSG00000230310.1	CTD-2192J16.11	4.06	5.64e-05	0.00871	0.21	0.18	Bipolar disorder;	chr19:12651969	chr19:12552597~12553644:+
LUAD	cis	rs453301	0.571	rs2929452	ENSG00000173295.6	FAM86B3P	-4.06	5.64e-05	0.00871	-0.19	-0.18	Joint mobility (Beighton score);	chr8:9226955	chr8:8228595~8244865:+
LUAD	cis	rs7727544	0.582	rs3828675	ENSG00000233006.5	AC034220.3	4.06	5.64e-05	0.00871	0.16	0.18	Blood metabolite levels;	chr5:132211175	chr5:132311285~132369916:-
LUAD	cis	rs7191700	0.712	rs7187741	ENSG00000262636.1	CTD-3088G3.4	-4.06	5.64e-05	0.00871	-0.21	-0.18	Multiple sclerosis;	chr16:11339246	chr16:11380859~11381118:-
LUAD	cis	rs4474465	1	rs7950756	ENSG00000251323.2	RP11-452H21.4	4.06	5.64e-05	0.00871	0.22	0.18	Alzheimer's disease (survival time);	chr11:78446263	chr11:78423982~78429836:-
LUAD	cis	rs7760535	0.794	rs3851225	ENSG00000266032.1	AL357515.1	4.06	5.64e-05	0.00871	0.23	0.18	Metabolic traits;	chr6:111503929	chr6:110969773~110969872:-
LUAD	cis	rs11742741	0.806	rs60920330	ENSG00000248874.4	C5orf17	-4.06	5.64e-05	0.00871	-0.23	-0.18	Educational attainment;	chr5:24047350	chr5:23951348~24178263:+
LUAD	cis	rs6558530	0.625	rs7459507	ENSG00000253982.1	CTD-2336O2.1	4.06	5.64e-05	0.00872	0.24	0.18	Systolic blood pressure;	chr8:1750026	chr8:1761990~1764502:-
LUAD	cis	rs10463554	0.963	rs3776859	ENSG00000250682.4	LINC00491	4.06	5.64e-05	0.00872	0.22	0.18	Parkinson's disease;	chr5:103016330	chr5:102609156~102671559:-
LUAD	cis	rs7617773	0.817	rs3731497	ENSG00000199476.1	Y_RNA	-4.06	5.64e-05	0.00872	-0.24	-0.18	Coronary artery disease;	chr3:48185063	chr3:48288587~48288694:+
LUAD	cis	rs8062405	0.757	rs2411453	ENSG00000251417.2	RP11-1348G14.4	4.06	5.65e-05	0.00872	0.19	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620700	chr16:28802743~28817828:+
LUAD	cis	rs42490	0.576	rs376962	ENSG00000251136.7	RP11-37B2.1	-4.06	5.65e-05	0.00872	-0.2	-0.18	Leprosy;	chr8:89862004	chr8:89609409~89757727:-
LUAD	cis	rs728616	0.867	rs12412257	ENSG00000225484.5	NUTM2B-AS1	-4.06	5.65e-05	0.00872	-0.46	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79969847	chr10:79663088~79826594:-
LUAD	cis	rs763121	0.853	rs5750630	ENSG00000225450.1	RP3-508I15.14	-4.06	5.65e-05	0.00872	-0.19	-0.18	Menopause (age at onset);	chr22:38589813	chr22:38739003~38749041:+
LUAD	cis	rs7829975	0.774	rs35039922	ENSG00000233609.3	RP11-62H7.2	4.06	5.65e-05	0.00873	0.15	0.18	Mood instability;	chr8:8817815	chr8:8961200~8979025:+
LUAD	cis	rs801193	0.805	rs12532355	ENSG00000236529.1	RP13-254B10.1	-4.06	5.66e-05	0.00873	-0.18	-0.18	Aortic root size;	chr7:66605597	chr7:65840212~65840596:+
LUAD	cis	rs4554975	0.63	rs11183644	ENSG00000274723.1	RP11-618L22.1	-4.06	5.66e-05	0.00873	-0.22	-0.18	Metabolite levels (small molecules and protein measures);	chr12:46892240	chr12:46970504~46972155:+
LUAD	cis	rs561341	1	rs7216102	ENSG00000265798.5	RP11-271K11.5	4.06	5.66e-05	0.00873	0.26	0.18	Hip circumference adjusted for BMI;	chr17:31932431	chr17:31038575~31059121:-
LUAD	cis	rs2032366	0.606	rs9965972	ENSG00000266920.1	ACTBP9	4.06	5.66e-05	0.00873	0.19	0.18	Obesity-related traits;	chr18:61609468	chr18:62442028~62443126:+
LUAD	cis	rs17597773	0.674	rs1335919	ENSG00000272823.1	RP11-295M18.6	-4.06	5.66e-05	0.00874	-0.24	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220845043	chr1:220828676~220829211:-
LUAD	cis	rs2548724	0.796	rs7734060	ENSG00000250682.4	LINC00491	4.06	5.66e-05	0.00874	0.26	0.18	Type 2 diabetes;	chr5:102444775	chr5:102609156~102671559:-
LUAD	cis	rs9894429	0.809	rs9889642	ENSG00000263853.1	AC139530.1	-4.06	5.66e-05	0.00874	-0.18	-0.18	Eye color traits;	chr17:81624736	chr17:81676001~81676086:+
LUAD	cis	rs2562456	0.52	rs660063	ENSG00000268081.1	RP11-678G14.2	-4.06	5.66e-05	0.00874	-0.29	-0.18	Pain;	chr19:21271103	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.52	rs279793	ENSG00000268081.1	RP11-678G14.2	4.06	5.66e-05	0.00874	0.29	0.18	Pain;	chr19:21272972	chr19:21554640~21569237:-
LUAD	cis	rs9341808	0.754	rs9341811	ENSG00000233967.5	RP11-250B2.3	4.06	5.66e-05	0.00874	0.18	0.18	Sitting height ratio;	chr6:80272984	chr6:80443344~80465927:+
LUAD	cis	rs8042680	0.592	rs2001217	ENSG00000259746.1	HSPE1P3	-4.06	5.66e-05	0.00874	-0.2	-0.18	Type 2 diabetes;	chr15:90955016	chr15:90634725~90635033:+
LUAD	cis	rs3096299	0.685	rs3803681	ENSG00000261118.1	RP11-104N10.1	4.06	5.67e-05	0.00875	0.18	0.18	Multiple myeloma (IgH translocation);	chr16:89478348	chr16:89492017~89504460:-
LUAD	cis	rs4934494	0.768	rs67111731	ENSG00000240996.1	RP11-80H5.7	-4.06	5.67e-05	0.00875	-0.25	-0.18	Red blood cell count;	chr10:89659528	chr10:89694295~89697928:-
LUAD	cis	rs4908768	0.539	rs1381928	ENSG00000270282.1	RP5-1115A15.2	4.06	5.67e-05	0.00875	0.2	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8630874	chr1:8512653~8513021:+
LUAD	cis	rs6671200	0.607	rs3753872	ENSG00000228852.5	RP11-57H12.5	-4.06	5.67e-05	0.00875	-0.22	-0.18	Stearic acid (18:0) levels;	chr1:95233628	chr1:95243167~95278940:-
LUAD	cis	rs12935418	0.583	rs2549861	ENSG00000261061.1	RP11-303E16.2	4.06	5.67e-05	0.00875	0.19	0.18	Mean corpuscular volume;	chr16:80994699	chr16:81030770~81031485:+
LUAD	cis	rs2060793	0.519	rs10832285	ENSG00000251991.1	RNU7-49P	4.06	5.67e-05	0.00875	0.19	0.18	Vitamin D levels;	chr11:14628031	chr11:14478892~14478953:+
LUAD	cis	rs1322639	0.614	rs6908401	ENSG00000261039.2	RP11-417E7.2	4.06	5.67e-05	0.00875	0.29	0.18	Pulse pressure;	chr6:169164621	chr6:169175304~169182740:-
LUAD	cis	rs4474465	0.915	rs10899503	ENSG00000251323.2	RP11-452H21.4	4.06	5.67e-05	0.00875	0.23	0.18	Alzheimer's disease (survival time);	chr11:78438915	chr11:78423982~78429836:-
LUAD	cis	rs4474465	1	rs7106080	ENSG00000251323.2	RP11-452H21.4	4.06	5.67e-05	0.00875	0.23	0.18	Alzheimer's disease (survival time);	chr11:78439546	chr11:78423982~78429836:-
LUAD	cis	rs2273156	0.57	rs79888893	ENSG00000226677.3	IGBP1P1	-4.06	5.67e-05	0.00876	-0.28	-0.18	Immunoglobulin light chain (AL) amyloidosis;	chr14:35041470	chr14:34939324~34940332:+
LUAD	cis	rs6964587	1	rs11982213	ENSG00000188693.7	CYP51A1-AS1	-4.06	5.67e-05	0.00876	-0.21	-0.18	Breast cancer;	chr7:92093652	chr7:92134604~92180725:+
LUAD	cis	rs1876905	0.68	rs1150082	ENSG00000230177.1	RP5-1112D6.4	-4.06	5.67e-05	0.00876	-0.21	-0.18	Mean corpuscular hemoglobin;	chr6:111189519	chr6:111277932~111278742:+
LUAD	cis	rs683250	0.598	rs578842	ENSG00000246067.6	RAB30-AS1	4.06	5.68e-05	0.00876	0.19	0.18	Subcortical brain region volumes;	chr11:83263868	chr11:83072066~83106719:+
LUAD	cis	rs2735413	0.837	rs12920830	ENSG00000276007.1	RP11-358L22.3	-4.06	5.68e-05	0.00876	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78049252	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.837	rs4888734	ENSG00000276007.1	RP11-358L22.3	-4.06	5.68e-05	0.00876	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78049788	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.837	rs4888735	ENSG00000276007.1	RP11-358L22.3	-4.06	5.68e-05	0.00876	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78049845	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.875	rs4888736	ENSG00000276007.1	RP11-358L22.3	-4.06	5.68e-05	0.00876	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78049887	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.875	rs4888737	ENSG00000276007.1	RP11-358L22.3	-4.06	5.68e-05	0.00876	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78049922	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.875	rs12925138	ENSG00000276007.1	RP11-358L22.3	-4.06	5.68e-05	0.00876	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78050026	chr16:78123243~78124332:+
LUAD	cis	rs987044	0.837	rs10746131	ENSG00000257221.1	RP11-689B22.2	-4.06	5.68e-05	0.00876	-0.15	-0.18	Mean platelet volume;	chr12:108790573	chr12:108628687~108641318:+
LUAD	cis	rs1555322	0.53	rs8122819	ENSG00000261582.1	RP4-614O4.11	-4.06	5.68e-05	0.00876	-0.23	-0.18	Attention deficit hyperactivity disorder;	chr20:35293783	chr20:35267885~35280043:-
LUAD	cis	rs728616	0.85	rs3889823	ENSG00000234382.2	RP11-40F6.1	-4.06	5.68e-05	0.00876	-0.45	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80158606	chr10:80233664~80245367:+
LUAD	cis	rs35740288	0.77	rs11635190	ENSG00000259407.1	RP11-158M2.3	-4.06	5.68e-05	0.00877	-0.18	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85605300	chr15:85744109~85750281:-
LUAD	cis	rs35740288	0.77	rs11631449	ENSG00000259407.1	RP11-158M2.3	-4.06	5.68e-05	0.00877	-0.18	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85605422	chr15:85744109~85750281:-
LUAD	cis	rs35740288	0.77	rs1871285	ENSG00000259407.1	RP11-158M2.3	-4.06	5.68e-05	0.00877	-0.18	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85609256	chr15:85744109~85750281:-
LUAD	cis	rs35740288	0.77	rs4843081	ENSG00000259407.1	RP11-158M2.3	-4.06	5.68e-05	0.00877	-0.18	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85609813	chr15:85744109~85750281:-
LUAD	cis	rs35740288	0.77	rs4843082	ENSG00000259407.1	RP11-158M2.3	-4.06	5.68e-05	0.00877	-0.18	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85610159	chr15:85744109~85750281:-
LUAD	cis	rs2708977	0.665	rs772173	ENSG00000237510.6	AC008268.2	4.06	5.68e-05	0.00877	0.23	0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96334658	chr2:95789654~95800166:+
LUAD	cis	rs11667325	0.727	rs10424234	ENSG00000268316.1	AC006272.2	-4.06	5.68e-05	0.00877	-0.2	-0.18	Neutrophil percentage of granulocytes;	chr19:51796174	chr19:51839771~51840945:-
LUAD	cis	rs7131987	0.565	rs7976227	ENSG00000257176.2	RP11-996F15.2	4.06	5.68e-05	0.00877	0.19	0.18	QT interval;	chr12:29264843	chr12:29280418~29317848:-
LUAD	cis	rs9928842	0.765	rs6564220	ENSG00000261476.1	RP11-77K12.3	-4.06	5.68e-05	0.00877	-0.25	-0.18	Alcoholic chronic pancreatitis;	chr16:75190296	chr16:75458252~75460017:-
LUAD	cis	rs7202877	0.706	rs247436	ENSG00000280152.1	RP11-331F4.5	-4.06	5.68e-05	0.00877	-0.21	-0.18	Type 1 diabetes;Type 2 diabetes;	chr16:75412073	chr16:75245994~75250077:-
LUAD	cis	rs61884328	0.733	rs17197710	ENSG00000254780.1	RP11-793I11.1	-4.06	5.68e-05	0.00877	-0.34	-0.18	Total body bone mineral density (age over 60);	chr11:47204445	chr11:47905323~47905607:-
LUAD	cis	rs858239	0.6	rs10488077	ENSG00000226816.2	AC005082.12	4.06	5.69e-05	0.00877	0.24	0.18	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23206013~23208045:+
LUAD	cis	rs3096299	0.719	rs2911262	ENSG00000261118.1	RP11-104N10.1	4.06	5.69e-05	0.00877	0.18	0.18	Multiple myeloma (IgH translocation);	chr16:89448633	chr16:89492017~89504460:-
LUAD	cis	rs9549260	0.755	rs2721066	ENSG00000229456.1	RLIMP1	-4.06	5.69e-05	0.00877	-0.19	-0.18	Red blood cell count;	chr13:40582051	chr13:40618738~40621348:+
LUAD	cis	rs2408955	0.521	rs1476607	ENSG00000257763.1	OR5BK1P	-4.06	5.69e-05	0.00877	-0.19	-0.18	Glycated hemoglobin levels;	chr12:48131021	chr12:48355792~48356614:-
LUAD	cis	rs11009175	0.547	rs10763911	ENSG00000273038.2	RP11-479G22.8	-4.06	5.69e-05	0.00877	-0.24	-0.18	Depression (quantitative trait);	chr10:33107195	chr10:32887255~32889311:-
LUAD	cis	rs11009175	0.628	rs10763912	ENSG00000273038.2	RP11-479G22.8	-4.06	5.69e-05	0.00877	-0.24	-0.18	Depression (quantitative trait);	chr10:33107208	chr10:32887255~32889311:-
LUAD	cis	rs11009175	0.547	rs10827198	ENSG00000273038.2	RP11-479G22.8	-4.06	5.69e-05	0.00877	-0.24	-0.18	Depression (quantitative trait);	chr10:33107269	chr10:32887255~32889311:-
LUAD	cis	rs11009175	0.547	rs7921479	ENSG00000273038.2	RP11-479G22.8	-4.06	5.69e-05	0.00877	-0.24	-0.18	Depression (quantitative trait);	chr10:33107767	chr10:32887255~32889311:-
LUAD	cis	rs11009175	0.547	rs56352977	ENSG00000273038.2	RP11-479G22.8	-4.06	5.69e-05	0.00877	-0.24	-0.18	Depression (quantitative trait);	chr10:33108616	chr10:32887255~32889311:-
LUAD	cis	rs11009175	0.547	rs7069449	ENSG00000273038.2	RP11-479G22.8	-4.06	5.69e-05	0.00877	-0.24	-0.18	Depression (quantitative trait);	chr10:33108895	chr10:32887255~32889311:-
LUAD	cis	rs11009175	0.547	rs7069499	ENSG00000273038.2	RP11-479G22.8	-4.06	5.69e-05	0.00877	-0.24	-0.18	Depression (quantitative trait);	chr10:33109043	chr10:32887255~32889311:-
LUAD	cis	rs11009175	0.547	rs7069765	ENSG00000273038.2	RP11-479G22.8	-4.06	5.69e-05	0.00877	-0.24	-0.18	Depression (quantitative trait);	chr10:33109136	chr10:32887255~32889311:-
LUAD	cis	rs11009175	0.547	rs7070343	ENSG00000273038.2	RP11-479G22.8	-4.06	5.69e-05	0.00877	-0.24	-0.18	Depression (quantitative trait);	chr10:33109323	chr10:32887255~32889311:-
LUAD	cis	rs10197140	0.925	rs13429892	ENSG00000235721.1	AC013268.3	-4.06	5.69e-05	0.00877	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110867189	chr2:110007675~110010783:+
LUAD	cis	rs7772486	0.79	rs11760	ENSG00000235652.6	RP11-545I5.3	4.06	5.69e-05	0.00878	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145884837	chr6:145799409~145886585:+
LUAD	cis	rs1075265	0.73	rs7597189	ENSG00000272156.1	RP11-477N3.1	-4.06	5.69e-05	0.00878	-0.21	-0.18	Chronotype;Morning vs. evening chronotype;	chr2:54014733	chr2:54082554~54085066:+
LUAD	cis	rs12986445	0.793	rs2271664	ENSG00000218682.1	AC010150.1	4.06	5.69e-05	0.00878	0.23	0.18	Multiple myeloma;Multiple myeloma and monoclonal gammopathy;	chr2:25868112	chr2:25856461~25856966:-
LUAD	cis	rs1714507	0.533	rs1714516	ENSG00000272087.1	RP11-379F4.7	4.06	5.69e-05	0.00878	0.2	0.18	Subjective well-being;	chr3:158575835	chr3:158693120~158693768:-
LUAD	cis	rs9894429	0.671	rs6565616	ENSG00000263853.1	AC139530.1	-4.06	5.69e-05	0.00878	-0.19	-0.18	Eye color traits;	chr17:81645135	chr17:81676001~81676086:+
LUAD	cis	rs62025270	0.688	rs17576534	ENSG00000202081.1	RNU6-1280P	-4.06	5.69e-05	0.00878	-0.27	-0.18	Idiopathic pulmonary fibrosis;	chr15:85742509	chr15:85651522~85651628:-
LUAD	cis	rs9341808	0.667	rs2490239	ENSG00000260645.1	RP11-250B2.5	4.06	5.69e-05	0.00878	0.17	0.18	Sitting height ratio;	chr6:80116572	chr6:80466958~80469080:+
LUAD	cis	rs7107174	1	rs4128206	ENSG00000251323.2	RP11-452H21.4	4.06	5.69e-05	0.00878	0.23	0.18	Testicular germ cell tumor;	chr11:78304906	chr11:78423982~78429836:-
LUAD	cis	rs7246657	0.943	rs1559229	ENSG00000226686.6	LINC01535	-4.06	5.69e-05	0.00878	-0.27	-0.18	Coronary artery calcification;	chr19:37385295	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.882	rs6508719	ENSG00000226686.6	LINC01535	-4.06	5.69e-05	0.00878	-0.27	-0.18	Coronary artery calcification;	chr19:37386517	chr19:37251912~37265535:+
LUAD	cis	rs8180040	1	rs295458	ENSG00000271161.1	BOLA2P2	4.06	5.69e-05	0.00878	0.17	0.18	Colorectal cancer;	chr3:47344095	chr3:47499841~47500407:+
LUAD	cis	rs453301	0.686	rs11785819	ENSG00000253893.2	FAM85B	4.06	5.69e-05	0.00878	0.24	0.18	Joint mobility (Beighton score);	chr8:9012868	chr8:8167819~8226614:-
LUAD	cis	rs28386778	0.83	rs6504180	ENSG00000240280.5	TCAM1P	-4.06	5.69e-05	0.00878	-0.21	-0.18	Prudent dietary pattern;	chr17:63735809	chr17:63849292~63864379:+
LUAD	cis	rs6921919	0.583	rs2071965	ENSG00000219392.1	RP1-265C24.5	-4.06	5.7e-05	0.00879	-0.24	-0.18	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28115628~28116551:+
LUAD	cis	rs9309473	0.95	rs6745480	ENSG00000230002.2	ALMS1-IT1	4.06	5.7e-05	0.00879	0.22	0.18	Metabolite levels;	chr2:73612928	chr2:73456764~73459484:+
LUAD	cis	rs10463554	0.927	rs34373	ENSG00000250682.4	LINC00491	4.06	5.7e-05	0.00879	0.22	0.18	Parkinson's disease;	chr5:103068590	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.927	rs158253	ENSG00000250682.4	LINC00491	4.06	5.7e-05	0.00879	0.22	0.18	Parkinson's disease;	chr5:103069502	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.892	rs158252	ENSG00000250682.4	LINC00491	4.06	5.7e-05	0.00879	0.22	0.18	Parkinson's disease;	chr5:103070546	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.927	rs154369	ENSG00000250682.4	LINC00491	4.06	5.7e-05	0.00879	0.22	0.18	Parkinson's disease;	chr5:103071140	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.892	rs158246	ENSG00000250682.4	LINC00491	4.06	5.7e-05	0.00879	0.22	0.18	Parkinson's disease;	chr5:103073145	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.927	rs158245	ENSG00000250682.4	LINC00491	4.06	5.7e-05	0.00879	0.22	0.18	Parkinson's disease;	chr5:103073801	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.857	rs158397	ENSG00000250682.4	LINC00491	4.06	5.7e-05	0.00879	0.22	0.18	Parkinson's disease;	chr5:103076497	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.927	rs158399	ENSG00000250682.4	LINC00491	4.06	5.7e-05	0.00879	0.22	0.18	Parkinson's disease;	chr5:103077564	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.927	rs158403	ENSG00000250682.4	LINC00491	4.06	5.7e-05	0.00879	0.22	0.18	Parkinson's disease;	chr5:103080064	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.927	rs158404	ENSG00000250682.4	LINC00491	4.06	5.7e-05	0.00879	0.22	0.18	Parkinson's disease;	chr5:103080206	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.892	rs257305	ENSG00000250682.4	LINC00491	4.06	5.7e-05	0.00879	0.22	0.18	Parkinson's disease;	chr5:103081533	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.927	rs257306	ENSG00000250682.4	LINC00491	4.06	5.7e-05	0.00879	0.22	0.18	Parkinson's disease;	chr5:103081770	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.892	rs257307	ENSG00000250682.4	LINC00491	4.06	5.7e-05	0.00879	0.22	0.18	Parkinson's disease;	chr5:103081805	chr5:102609156~102671559:-
LUAD	cis	rs17122278	1	rs11216906	ENSG00000243431.1	RPL5P30	4.06	5.7e-05	0.00879	0.22	0.18	Total cholesterol levels;	chr11:118573229	chr11:118560690~118561580:+
LUAD	cis	rs17122278	1	rs9736327	ENSG00000243431.1	RPL5P30	4.06	5.7e-05	0.00879	0.22	0.18	Total cholesterol levels;	chr11:118576865	chr11:118560690~118561580:+
LUAD	cis	rs17122278	1	rs9735421	ENSG00000243431.1	RPL5P30	4.06	5.7e-05	0.00879	0.22	0.18	Total cholesterol levels;	chr11:118576882	chr11:118560690~118561580:+
LUAD	cis	rs17122278	0.929	rs7126175	ENSG00000243431.1	RPL5P30	4.06	5.7e-05	0.00879	0.22	0.18	Total cholesterol levels;	chr11:118580160	chr11:118560690~118561580:+
LUAD	cis	rs2243480	1	rs313831	ENSG00000229886.1	RP5-1132H15.3	4.06	5.7e-05	0.00879	0.31	0.18	Diabetic kidney disease;	chr7:66086239	chr7:66025126~66031544:-
LUAD	cis	rs7208859	0.623	rs170051	ENSG00000280069.1	CTD-2349P21.3	-4.06	5.7e-05	0.00879	-0.26	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587135	chr17:30738182~30740275:+
LUAD	cis	rs8177876	0.658	rs16954505	ENSG00000261061.1	RP11-303E16.2	-4.06	5.7e-05	0.00879	-0.31	-0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81040555	chr16:81030770~81031485:+
LUAD	cis	rs17772222	0.958	rs17203789	ENSG00000258789.1	RP11-507K2.3	-4.06	5.7e-05	0.00879	-0.25	-0.18	Coronary artery calcification;	chr14:88541362	chr14:88551597~88552493:+
LUAD	cis	rs6908843	0.532	rs9459624	ENSG00000233365.2	RP4-655C5.4	-4.06	5.7e-05	0.00879	-0.33	-0.18	Macrophage inflammatory protein 1b levels;	chr6:166257520	chr6:166236969~166256947:+
LUAD	cis	rs8031584	0.706	rs798084	ENSG00000259845.1	HERC2P10	4.06	5.7e-05	0.00879	0.22	0.18	Huntington's disease progression;	chr15:30834732	chr15:30815271~30844153:+
LUAD	cis	rs9467773	0.62	rs2504571	ENSG00000241549.7	GUSBP2	4.06	5.7e-05	0.00879	0.2	0.18	Intelligence (multi-trait analysis);	chr6:26643207	chr6:26871484~26956554:-
LUAD	cis	rs256438	0.93	rs2434281	ENSG00000251050.1	RP11-168A11.4	-4.06	5.7e-05	0.0088	-0.19	-0.18	Serum thyroid-stimulating hormone levels;	chr5:80093870	chr5:80019609~80019920:+
LUAD	cis	rs35740288	0.77	rs10520592	ENSG00000259407.1	RP11-158M2.3	-4.06	5.7e-05	0.0088	-0.18	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85570911	chr15:85744109~85750281:-
LUAD	cis	rs11955398	0.502	rs3101879	ENSG00000272308.1	RP11-231G3.1	-4.06	5.7e-05	0.0088	-0.21	-0.18	Intelligence (multi-trait analysis);	chr5:60971048	chr5:60866457~60866935:-
LUAD	cis	rs7709377	0.556	rs10155643	ENSG00000248445.4	SEMA6A-AS1	-4.06	5.7e-05	0.0088	-0.16	-0.18	Metabolite levels  (X-11787);	chr5:116284322	chr5:116447547~116508276:+
LUAD	cis	rs2281636	0.754	rs4919364	ENSG00000233690.1	EBAG9P1	4.06	5.71e-05	0.0088	0.18	0.18	Obesity-related traits;	chr10:99604947	chr10:99697407~99697949:-
LUAD	cis	rs848490	0.889	rs11761707	ENSG00000214293.7	APTR	-4.06	5.71e-05	0.0088	-0.24	-0.18	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77608867	chr7:77657660~77696265:-
LUAD	cis	rs1714507	0.533	rs1620229	ENSG00000272087.1	RP11-379F4.7	4.06	5.71e-05	0.0088	0.2	0.18	Subjective well-being;	chr3:158575469	chr3:158693120~158693768:-
LUAD	cis	rs273259	0.583	rs17101968	ENSG00000235400.1	RP4-641G12.4	4.06	5.71e-05	0.0088	0.27	0.18	Febrile seizures (MMR vaccine-related);Febrile seizures;	chr1:78636747	chr1:78749073~78750659:+
LUAD	cis	rs17685	0.753	rs13240967	ENSG00000280388.1	RP11-229D13.3	4.06	5.71e-05	0.0088	0.17	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76028879	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.725	rs6947068	ENSG00000280388.1	RP11-229D13.3	4.06	5.71e-05	0.0088	0.17	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76032738	chr7:76043977~76045963:-
LUAD	cis	rs9341808	0.718	rs3812121	ENSG00000260645.1	RP11-250B2.5	4.06	5.71e-05	0.00881	0.17	0.18	Sitting height ratio;	chr6:80259010	chr6:80466958~80469080:+
LUAD	cis	rs9907295	0.688	rs2251660	ENSG00000270977.1	AC015849.16	-4.06	5.71e-05	0.00881	-0.26	-0.18	Fibroblast growth factor basic levels;	chr17:35925533	chr17:35893707~35911023:-
LUAD	cis	rs683250	0.629	rs657324	ENSG00000246067.6	RAB30-AS1	4.06	5.72e-05	0.00881	0.19	0.18	Subcortical brain region volumes;	chr11:83264088	chr11:83072066~83106719:+
LUAD	cis	rs683250	0.66	rs645169	ENSG00000246067.6	RAB30-AS1	4.06	5.72e-05	0.00881	0.19	0.18	Subcortical brain region volumes;	chr11:83264440	chr11:83072066~83106719:+
LUAD	cis	rs7551222	0.892	rs7539399	ENSG00000236779.1	RP11-430C7.2	4.06	5.72e-05	0.00881	0.23	0.18	Schizophrenia;	chr1:204620916	chr1:204528845~204529692:-
LUAD	cis	rs3814244	0.528	rs2906854	ENSG00000236946.2	HNRNPA1P70	4.06	5.72e-05	0.00881	0.15	0.18	Itch intensity from mosquito bite adjusted by bite size;	chr12:67993566	chr12:68035767~68036853:+
LUAD	cis	rs2153535	0.518	rs9285977	ENSG00000230939.1	RP11-314C16.1	-4.06	5.72e-05	0.00881	-0.21	-0.18	Motion sickness;	chr6:8572052	chr6:8784178~8785445:+
LUAD	cis	rs7714584	1	rs76548544	ENSG00000197083.10	ZNF300P1	4.06	5.72e-05	0.00882	0.34	0.18	Crohn's disease;	chr5:150843953	chr5:150930645~150946289:-
LUAD	cis	rs2652822	0.504	rs4619348	ENSG00000259498.1	RP11-244F12.3	4.06	5.72e-05	0.00882	0.21	0.18	Metabolic traits;	chr15:63067365	chr15:63046034~63049387:-
LUAD	cis	rs10197140	0.816	rs13429695	ENSG00000235721.1	AC013268.3	-4.06	5.72e-05	0.00882	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110867071	chr2:110007675~110010783:+
LUAD	cis	rs3096299	0.9	rs744327	ENSG00000182376.2	RP5-1142A6.8	4.06	5.72e-05	0.00882	0.19	0.18	Multiple myeloma (IgH translocation);	chr16:89372862	chr16:88742767~88745748:+
LUAD	cis	rs2554380	0.628	rs890311	ENSG00000259570.1	RP11-671M22.4	4.06	5.72e-05	0.00882	0.23	0.18	Height;	chr15:83772200	chr15:84394512~84395514:+
LUAD	cis	rs8040855	0.627	rs12905036	ENSG00000259774.1	RP11-182J1.13	4.06	5.73e-05	0.00882	0.24	0.18	Bulimia nervosa;	chr15:85094557	chr15:84422618~84425882:+
LUAD	cis	rs858239	0.601	rs6980224	ENSG00000226816.2	AC005082.12	4.06	5.73e-05	0.00882	0.24	0.18	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23206013~23208045:+
LUAD	cis	rs4819052	0.632	rs4819050	ENSG00000237664.1	LINC00316	-4.06	5.73e-05	0.00883	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273028	chr21:45338590~45341990:-
LUAD	cis	rs728616	0.867	rs4633405	ENSG00000234382.2	RP11-40F6.1	-4.06	5.73e-05	0.00883	-0.46	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80167690	chr10:80233664~80245367:+
LUAD	cis	rs1023500	0.505	rs134888	ENSG00000205702.9	CYP2D7	4.06	5.73e-05	0.00883	0.14	0.18	Schizophrenia;	chr22:42278275	chr22:42140203~42144577:-
LUAD	cis	rs2548724	0.812	rs452857	ENSG00000250682.4	LINC00491	4.06	5.73e-05	0.00883	0.24	0.18	Type 2 diabetes;	chr5:102260929	chr5:102609156~102671559:-
LUAD	cis	rs6689263	1	rs77167727	ENSG00000117242.7	PINK1-AS	4.06	5.73e-05	0.00883	0.39	0.18	Intelligence (multi-trait analysis);	chr1:20464313	chr1:20642657~20652193:-
LUAD	cis	rs526231	0.726	rs2288789	ENSG00000175749.11	EIF3KP1	4.06	5.73e-05	0.00883	0.24	0.18	Primary biliary cholangitis;	chr5:103264823	chr5:103032376~103033031:+
LUAD	cis	rs8062405	0.722	rs3785354	ENSG00000261419.1	RP11-57A19.4	-4.06	5.73e-05	0.00883	-0.2	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28659696~28740781:-
LUAD	cis	rs12935418	0.616	rs9937731	ENSG00000261061.1	RP11-303E16.2	-4.06	5.74e-05	0.00884	-0.19	-0.18	Mean corpuscular volume;	chr16:80978406	chr16:81030770~81031485:+
LUAD	cis	rs7216064	0.636	rs62084696	ENSG00000265055.1	AC145343.2	-4.06	5.74e-05	0.00884	-0.17	-0.18	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68042065	chr17:68096046~68101474:-
LUAD	cis	rs7216064	0.636	rs4638	ENSG00000265055.1	AC145343.2	-4.06	5.74e-05	0.00884	-0.17	-0.18	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68043234	chr17:68096046~68101474:-
LUAD	cis	rs7216064	0.601	rs35453056	ENSG00000265055.1	AC145343.2	-4.06	5.74e-05	0.00884	-0.17	-0.18	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68043552	chr17:68096046~68101474:-
LUAD	cis	rs7216064	0.628	rs62084702	ENSG00000265055.1	AC145343.2	-4.06	5.74e-05	0.00884	-0.17	-0.18	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68047041	chr17:68096046~68101474:-
LUAD	cis	rs651907	0.557	rs11914318	ENSG00000244119.1	PDCL3P4	4.06	5.74e-05	0.00884	0.18	0.18	Colorectal cancer;	chr3:101735014	chr3:101712472~101713191:+
LUAD	cis	rs2304003	1	rs12473573	ENSG00000235192.1	AC009495.2	4.06	5.74e-05	0.00884	0.22	0.18	Social communication problems;	chr2:165832382	chr2:165794851~165810010:+
LUAD	cis	rs2304003	1	rs2241462	ENSG00000235192.1	AC009495.2	4.06	5.74e-05	0.00884	0.22	0.18	Social communication problems;	chr2:165833126	chr2:165794851~165810010:+
LUAD	cis	rs516805	0.59	rs1430816	ENSG00000279453.1	RP3-425C14.4	-4.06	5.74e-05	0.00884	-0.27	-0.18	Lymphocyte counts;	chr6:122591978	chr6:122436789~122439223:-
LUAD	cis	rs77204473	0.744	rs117901629	ENSG00000280143.1	AP000892.6	-4.06	5.74e-05	0.00884	-0.44	-0.18	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117008963	chr11:117204967~117210292:+
LUAD	cis	rs8028182	0.636	rs28610581	ENSG00000260269.4	CTD-2323K18.1	-4.06	5.74e-05	0.00884	-0.25	-0.18	Sudden cardiac arrest;	chr15:75520133	chr15:75527150~75601205:-
LUAD	cis	rs7246657	0.943	rs4803347	ENSG00000226686.6	LINC01535	-4.06	5.74e-05	0.00884	-0.27	-0.18	Coronary artery calcification;	chr19:37357115	chr19:37251912~37265535:+
LUAD	cis	rs2243480	0.901	rs12530490	ENSG00000229886.1	RP5-1132H15.3	-4.06	5.74e-05	0.00885	-0.32	-0.18	Diabetic kidney disease;	chr7:66226660	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs7778911	ENSG00000229886.1	RP5-1132H15.3	-4.06	5.74e-05	0.00885	-0.32	-0.18	Diabetic kidney disease;	chr7:66229519	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs1979823	ENSG00000229886.1	RP5-1132H15.3	-4.06	5.74e-05	0.00885	-0.32	-0.18	Diabetic kidney disease;	chr7:66239626	chr7:66025126~66031544:-
LUAD	cis	rs41411047	1	rs41411047	ENSG00000271711.1	RP11-392O18.2	-4.06	5.74e-05	0.00885	-0.34	-0.18	Myocardial infarction;	chr3:149875124	chr3:150611262~150611877:-
LUAD	cis	rs2274273	0.84	rs6573020	ENSG00000259318.1	RP11-454L9.2	4.06	5.74e-05	0.00885	0.16	0.18	Protein biomarker;	chr14:55404734	chr14:55394940~55395233:-
LUAD	cis	rs7598759	0.548	rs1584462	ENSG00000223198.1	RNU2-22P	-4.06	5.75e-05	0.00885	-0.21	-0.18	Noise-induced hearing loss;	chr2:231505087	chr2:231501990~231502201:-
LUAD	cis	rs9287719	0.901	rs10210859	ENSG00000243819.4	RN7SL832P	4.06	5.75e-05	0.00885	0.19	0.18	Prostate cancer;	chr2:10593803	chr2:10690344~10692099:+
LUAD	cis	rs11064837	0.55	rs11064849	ENSG00000248636.5	RP11-768F21.1	4.06	5.75e-05	0.00886	0.22	0.18	Schizophrenia;	chr12:119616782	chr12:119387987~119668079:-
LUAD	cis	rs17607347	0.58	rs76513770	ENSG00000259209.3	RP5-991G20.2	4.06	5.75e-05	0.00886	0.31	0.18	Intelligence (multi-trait analysis);	chr16:72471635	chr16:72805998~72809872:+
LUAD	cis	rs7189233	0.531	rs13332071	ENSG00000279344.1	RP11-44F14.7	4.06	5.75e-05	0.00886	0.15	0.18	Intelligence (multi-trait analysis);	chr16:53409724	chr16:53478957~53481550:-
LUAD	cis	rs791888	0.858	rs1555434	ENSG00000225913.2	RP11-57C13.6	4.06	5.75e-05	0.00886	0.24	0.18	Magnesium levels;	chr10:87659386	chr10:87607985~87659279:+
LUAD	cis	rs13434995	0.513	rs17776975	ENSG00000273257.1	RP11-177J6.1	-4.06	5.75e-05	0.00886	-0.24	-0.18	Adiponectin levels;	chr4:55410728	chr4:55387949~55388271:+
LUAD	cis	rs8054556	0.669	rs9972866	ENSG00000214725.6	CDIPT-AS1	-4.06	5.75e-05	0.00886	-0.21	-0.18	Autism spectrum disorder or schizophrenia;	chr16:30007661	chr16:29863593~29868053:+
LUAD	cis	rs3096299	0.658	rs4291902	ENSG00000261118.1	RP11-104N10.1	4.06	5.75e-05	0.00886	0.18	0.18	Multiple myeloma (IgH translocation);	chr16:89493907	chr16:89492017~89504460:-
LUAD	cis	rs8028182	0.636	rs4545784	ENSG00000260269.4	CTD-2323K18.1	-4.06	5.75e-05	0.00886	-0.25	-0.18	Sudden cardiac arrest;	chr15:75463310	chr15:75527150~75601205:-
LUAD	cis	rs848490	0.962	rs11768148	ENSG00000214293.7	APTR	4.06	5.75e-05	0.00886	0.24	0.18	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77715977	chr7:77657660~77696265:-
LUAD	cis	rs7210086	0.768	rs4485409	ENSG00000263893.2	CTD-3010D24.3	4.06	5.75e-05	0.00886	0.25	0.18	Ulcerative colitis;	chr17:72644242	chr17:72642731~72644490:+
LUAD	cis	rs7210086	0.768	rs4395115	ENSG00000263893.2	CTD-3010D24.3	4.06	5.75e-05	0.00886	0.25	0.18	Ulcerative colitis;	chr17:72644243	chr17:72642731~72644490:+
LUAD	cis	rs11673344	0.504	rs2118208	ENSG00000276846.1	CTD-3220F14.3	4.06	5.76e-05	0.00887	0.2	0.18	Obesity-related traits;	chr19:37135573	chr19:37314868~37315620:-
LUAD	cis	rs11673344	0.504	rs2118209	ENSG00000276846.1	CTD-3220F14.3	4.06	5.76e-05	0.00887	0.2	0.18	Obesity-related traits;	chr19:37135618	chr19:37314868~37315620:-
LUAD	cis	rs11673344	0.504	rs4805204	ENSG00000276846.1	CTD-3220F14.3	4.06	5.76e-05	0.00887	0.2	0.18	Obesity-related traits;	chr19:37136666	chr19:37314868~37315620:-
LUAD	cis	rs11673344	0.504	rs4805205	ENSG00000276846.1	CTD-3220F14.3	4.06	5.76e-05	0.00887	0.2	0.18	Obesity-related traits;	chr19:37136693	chr19:37314868~37315620:-
LUAD	cis	rs62344088	0.744	rs76038312	ENSG00000250848.1	CTD-2083E4.5	-4.06	5.76e-05	0.00887	-0.39	-0.18	Asthma (childhood onset);	chr5:228890	chr5:288833~290321:-
LUAD	cis	rs412050	0.501	rs2876980	ENSG00000224086.5	LL22NC03-86G7.1	4.06	5.76e-05	0.00887	0.22	0.18	Attention deficit hyperactivity disorder;	chr22:21752246	chr22:21938293~21977632:+
LUAD	cis	rs7893279	0.505	rs12778992	ENSG00000225527.1	RP11-383B4.4	4.06	5.76e-05	0.00887	0.27	0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18611218	chr10:18531849~18533336:-
LUAD	cis	rs7893279	0.505	rs12785031	ENSG00000225527.1	RP11-383B4.4	4.06	5.76e-05	0.00887	0.27	0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18611240	chr10:18531849~18533336:-
LUAD	cis	rs910316	0.789	rs12894419	ENSG00000259138.1	RP11-950C14.7	4.06	5.76e-05	0.00887	0.19	0.18	Height;	chr14:75005099	chr14:75127153~75136930:+
LUAD	cis	rs10206020	0.921	rs72778005	ENSG00000231482.2	AC141930.2	-4.06	5.76e-05	0.00887	-0.24	-0.18	IgG glycosylation;	chr2:1569350	chr2:1572554~1580311:-
LUAD	cis	rs4873772	0.735	rs876915	ENSG00000253330.1	RP11-697N18.3	-4.06	5.76e-05	0.00887	-0.2	-0.18	Lobe attachment (rater-scored or self-reported);	chr8:47506069	chr8:47511034~47512141:-
LUAD	cis	rs10875976	0.905	rs11169166	ENSG00000257464.1	RP11-161H23.8	-4.06	5.76e-05	0.00887	-0.17	-0.18	Obesity;	chr12:49822122	chr12:49442424~49442652:-
LUAD	cis	rs1979679	1	rs1979679	ENSG00000278733.1	RP11-425D17.1	4.06	5.76e-05	0.00887	0.23	0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28253582	chr12:28185625~28186190:-
LUAD	cis	rs1979679	1	rs11049487	ENSG00000278733.1	RP11-425D17.1	4.06	5.76e-05	0.00887	0.23	0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28254157	chr12:28185625~28186190:-
LUAD	cis	rs28386778	0.933	rs2665804	ENSG00000240280.5	TCAM1P	-4.06	5.76e-05	0.00887	-0.21	-0.18	Prudent dietary pattern;	chr17:63874476	chr17:63849292~63864379:+
LUAD	cis	rs8028182	0.636	rs7495610	ENSG00000260269.4	CTD-2323K18.1	-4.06	5.76e-05	0.00887	-0.25	-0.18	Sudden cardiac arrest;	chr15:75492100	chr15:75527150~75601205:-
LUAD	cis	rs35740288	0.77	rs11631018	ENSG00000259407.1	RP11-158M2.3	-4.06	5.76e-05	0.00887	-0.18	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85597303	chr15:85744109~85750281:-
LUAD	cis	rs4374383	0.884	rs3761701	ENSG00000207383.1	Y_RNA	-4.06	5.76e-05	0.00887	-0.22	-0.18	Hepatitis C induced liver fibrosis;	chr2:111947580	chr2:112579484~112579584:-
LUAD	cis	rs4578769	0.55	rs9951410	ENSG00000265943.1	RP11-739L10.1	4.06	5.76e-05	0.00888	0.23	0.18	Eosinophil percentage of white cells;	chr18:22964944	chr18:22699481~22933764:-
LUAD	cis	rs4578769	0.505	rs9951982	ENSG00000265943.1	RP11-739L10.1	4.06	5.76e-05	0.00888	0.23	0.18	Eosinophil percentage of white cells;	chr18:22965607	chr18:22699481~22933764:-
LUAD	cis	rs4840086	1	rs6902345	ENSG00000219755.1	RP1-199J3.5	4.06	5.77e-05	0.00888	0.22	0.18	Menarche (age at onset);	chr6:99751901	chr6:99575712~99576456:+
LUAD	cis	rs8028182	0.609	rs10220738	ENSG00000246877.1	DNM1P35	-4.06	5.77e-05	0.00888	-0.24	-0.18	Sudden cardiac arrest;	chr15:75374205	chr15:75727670~75738623:-
LUAD	cis	rs4819052	1	rs733739	ENSG00000237664.1	LINC00316	-4.06	5.77e-05	0.00888	-0.23	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246295	chr21:45338590~45341990:-
LUAD	cis	rs853679	0.517	rs16893666	ENSG00000226314.6	ZNF192P1	4.06	5.77e-05	0.00888	0.24	0.18	Depression;	chr6:28086929	chr6:28161781~28169594:+
LUAD	cis	rs11742741	0.806	rs1354168	ENSG00000248874.4	C5orf17	-4.06	5.77e-05	0.00888	-0.23	-0.18	Educational attainment;	chr5:24047867	chr5:23951348~24178263:+
LUAD	cis	rs7061710	0.711	rs17565990	ENSG00000271811.1	RP1-79C4.4	-4.06	5.77e-05	0.00888	-0.27	-0.18	Blood metabolite levels;	chr1:171148887	chr1:170667381~170669425:+
LUAD	cis	rs8054556	0.74	rs8052502	ENSG00000183604.13	SMG1P5	-4.06	5.77e-05	0.00888	-0.18	-0.18	Autism spectrum disorder or schizophrenia;	chr16:29918407	chr16:30267553~30335374:-
LUAD	cis	rs11242704	0.632	rs2569829	ENSG00000272279.1	RP11-157J24.2	-4.06	5.77e-05	0.00889	-0.27	-0.18	Response to hepatitis C treatment;	chr6:1539293	chr6:1528364~1528911:-
LUAD	cis	rs561341	0.66	rs7406043	ENSG00000265798.5	RP11-271K11.5	4.06	5.77e-05	0.00889	0.27	0.18	Hip circumference adjusted for BMI;	chr17:31893133	chr17:31038575~31059121:-
LUAD	cis	rs561341	0.883	rs7406056	ENSG00000265798.5	RP11-271K11.5	4.06	5.77e-05	0.00889	0.27	0.18	Hip circumference adjusted for BMI;	chr17:31893205	chr17:31038575~31059121:-
LUAD	cis	rs10971721	0.731	rs72727392	ENSG00000260947.1	RP11-384P7.7	4.06	5.77e-05	0.00889	0.38	0.18	Body mass index;	chr9:33988921	chr9:33697459~33700986:+
LUAD	cis	rs642803	0.613	rs565427	ENSG00000254510.1	RP11-867G23.10	-4.06	5.77e-05	0.00889	-0.22	-0.18	Urate levels;	chr11:65765354	chr11:66409158~66417137:+
LUAD	cis	rs35740288	0.752	rs11636138	ENSG00000259407.1	RP11-158M2.3	-4.06	5.77e-05	0.00889	-0.19	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85744316	chr15:85744109~85750281:-
LUAD	cis	rs2279168	1	rs79270762	ENSG00000202081.1	RNU6-1280P	-4.06	5.77e-05	0.00889	-0.31	-0.18	Response to platinum-based chemotherapy (carboplatin);	chr15:85530945	chr15:85651522~85651628:-
LUAD	cis	rs7829975	0.742	rs1533058	ENSG00000253893.2	FAM85B	-4.06	5.77e-05	0.00889	-0.23	-0.18	Mood instability;	chr8:8827680	chr8:8167819~8226614:-
LUAD	cis	rs9341808	0.644	rs62408577	ENSG00000260645.1	RP11-250B2.5	-4.06	5.77e-05	0.00889	-0.17	-0.18	Sitting height ratio;	chr6:80232307	chr6:80466958~80469080:+
LUAD	cis	rs9341808	0.644	rs76102095	ENSG00000260645.1	RP11-250B2.5	-4.06	5.77e-05	0.00889	-0.17	-0.18	Sitting height ratio;	chr6:80232309	chr6:80466958~80469080:+
LUAD	cis	rs9341808	0.644	rs59371711	ENSG00000260645.1	RP11-250B2.5	-4.06	5.77e-05	0.00889	-0.17	-0.18	Sitting height ratio;	chr6:80232310	chr6:80466958~80469080:+
LUAD	cis	rs9910055	0.529	rs183462	ENSG00000267080.4	ASB16-AS1	4.06	5.78e-05	0.00889	0.17	0.18	Total body bone mineral density;	chr17:44106008	chr17:44175973~44186717:-
LUAD	cis	rs7339483	0.764	rs1830180	ENSG00000268058.1	BNIP3P40	-4.06	5.78e-05	0.00889	-0.27	-0.18	Discordance in emotional problems in monozygotic twins;	chr19:24273161	chr19:24098425~24098980:-
LUAD	cis	rs3764400	0.567	rs12936369	ENSG00000278765.1	RP5-890E16.5	4.06	5.78e-05	0.00889	0.33	0.18	Body mass index;	chr17:48193334	chr17:48066704~48067293:-
LUAD	cis	rs3764400	0.567	rs36071506	ENSG00000278765.1	RP5-890E16.5	4.06	5.78e-05	0.00889	0.33	0.18	Body mass index;	chr17:48202410	chr17:48066704~48067293:-
LUAD	cis	rs6964587	0.904	rs2023785	ENSG00000188693.7	CYP51A1-AS1	4.06	5.78e-05	0.00889	0.22	0.18	Breast cancer;	chr7:91918055	chr7:92134604~92180725:+
LUAD	cis	rs957448	1	rs957447	ENSG00000253175.1	RP11-267M23.6	4.06	5.78e-05	0.0089	0.22	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94528995	chr8:94565036~94565715:+
LUAD	cis	rs957448	1	rs72674852	ENSG00000253175.1	RP11-267M23.6	4.06	5.78e-05	0.0089	0.22	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94536523	chr8:94565036~94565715:+
LUAD	cis	rs1075265	0.836	rs1363063	ENSG00000272156.1	RP11-477N3.1	-4.06	5.78e-05	0.0089	-0.22	-0.18	Chronotype;Morning vs. evening chronotype;	chr2:54047433	chr2:54082554~54085066:+
LUAD	cis	rs783540	0.609	rs803686	ENSG00000255769.6	GOLGA2P10	4.06	5.78e-05	0.0089	0.21	0.18	Schizophrenia;	chr15:82550590	chr15:82472993~82513950:-
LUAD	cis	rs7247513	0.797	rs3815914	ENSG00000230310.1	CTD-2192J16.11	-4.06	5.78e-05	0.0089	-0.21	-0.18	Bipolar disorder;	chr19:12649850	chr19:12552597~12553644:+
LUAD	cis	rs7131987	0.565	rs10843372	ENSG00000257176.2	RP11-996F15.2	4.06	5.79e-05	0.0089	0.19	0.18	QT interval;	chr12:29262863	chr12:29280418~29317848:-
LUAD	cis	rs6964587	1	rs6952389	ENSG00000188693.7	CYP51A1-AS1	-4.06	5.79e-05	0.00891	-0.21	-0.18	Breast cancer;	chr7:92028680	chr7:92134604~92180725:+
LUAD	cis	rs4934494	0.768	rs12571268	ENSG00000240996.1	RP11-80H5.7	-4.06	5.79e-05	0.00891	-0.25	-0.18	Red blood cell count;	chr10:89698830	chr10:89694295~89697928:-
LUAD	cis	rs62025270	0.632	rs62022919	ENSG00000259416.2	RP11-158M2.5	-4.06	5.79e-05	0.00891	-0.25	-0.18	Idiopathic pulmonary fibrosis;	chr15:85675079	chr15:85754941~85756237:-
LUAD	cis	rs9973361	1	rs9973361	ENSG00000232411.1	AC009495.3	-4.06	5.79e-05	0.00891	-0.22	-0.18	Total body bone mineral density;	chr2:165859989	chr2:165833048~165839098:-
LUAD	cis	rs8177876	0.822	rs56119129	ENSG00000261061.1	RP11-303E16.2	-4.06	5.79e-05	0.00891	-0.31	-0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81084661	chr16:81030770~81031485:+
LUAD	cis	rs8177876	0.731	rs77145371	ENSG00000261061.1	RP11-303E16.2	-4.06	5.79e-05	0.00891	-0.31	-0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085055	chr16:81030770~81031485:+
LUAD	cis	rs8177876	0.908	rs80187824	ENSG00000261061.1	RP11-303E16.2	-4.06	5.79e-05	0.00891	-0.31	-0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085075	chr16:81030770~81031485:+
LUAD	cis	rs8177876	0.731	rs74882687	ENSG00000261061.1	RP11-303E16.2	-4.06	5.79e-05	0.00891	-0.31	-0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085315	chr16:81030770~81031485:+
LUAD	cis	rs8177876	0.642	rs76909932	ENSG00000261061.1	RP11-303E16.2	-4.06	5.79e-05	0.00891	-0.31	-0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085449	chr16:81030770~81031485:+
LUAD	cis	rs8177876	0.822	rs8177939	ENSG00000261061.1	RP11-303E16.2	-4.06	5.79e-05	0.00891	-0.31	-0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81085591	chr16:81030770~81031485:+
LUAD	cis	rs2836974	0.897	rs13047678	ENSG00000232608.1	TIMM9P2	-4.06	5.79e-05	0.00891	-0.23	-0.18	Cognitive function;	chr21:39336927	chr21:39216624~39217506:+
LUAD	cis	rs2911132	0.564	rs731827	ENSG00000272109.1	CTD-2260A17.3	-4.06	5.79e-05	0.00891	-0.21	-0.18	Urate levels (BMI interaction);	chr5:96751311	chr5:96804353~96806105:+
LUAD	cis	rs2836974	0.666	rs4624474	ENSG00000232608.1	TIMM9P2	4.06	5.79e-05	0.00891	0.21	0.18	Cognitive function;	chr21:39314401	chr21:39216624~39217506:+
LUAD	cis	rs7615952	0.641	rs66520539	ENSG00000250012.1	RP11-124N2.1	-4.06	5.79e-05	0.00891	-0.25	-0.18	Blood pressure (smoking interaction);	chr3:126061531	chr3:126084220~126095349:+
LUAD	cis	rs9467773	0.62	rs2101582	ENSG00000261353.1	CTA-14H9.5	-4.06	5.79e-05	0.00891	-0.2	-0.18	Intelligence (multi-trait analysis);	chr6:26622506	chr6:26527063~26527404:+
LUAD	cis	rs454217	0.818	rs381750	ENSG00000277851.1	RP11-756G20.1	4.06	5.79e-05	0.00891	0.18	0.18	Smoking quantity;	chr12:92323106	chr12:92247756~92363832:-
LUAD	cis	rs2836974	0.568	rs11910906	ENSG00000232608.1	TIMM9P2	4.06	5.79e-05	0.00891	0.21	0.18	Cognitive function;	chr21:39313736	chr21:39216624~39217506:+
LUAD	cis	rs4713118	0.869	rs6930992	ENSG00000280107.1	AL022393.9	-4.06	5.79e-05	0.00891	-0.23	-0.18	Parkinson's disease;	chr6:27744341	chr6:28170845~28172521:+
LUAD	cis	rs2292864	0.764	rs3892085	ENSG00000278765.1	RP5-890E16.5	4.06	5.79e-05	0.00892	0.34	0.18	Left atrial antero-posterior diameter;	chr17:47263114	chr17:48066704~48067293:-
LUAD	cis	rs12207986	1	rs12207986	ENSG00000260645.1	RP11-250B2.5	-4.06	5.8e-05	0.00892	-0.17	-0.18	Breast cancer;	chr6:80384570	chr6:80466958~80469080:+
LUAD	cis	rs12073359	1	rs12063281	ENSG00000223945.2	RP11-458I7.1	-4.06	5.8e-05	0.00892	-0.26	-0.18	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150030335	chr1:150053864~150055034:+
LUAD	cis	rs12073359	1	rs55840906	ENSG00000223945.2	RP11-458I7.1	-4.06	5.8e-05	0.00892	-0.26	-0.18	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150031159	chr1:150053864~150055034:+
LUAD	cis	rs17122278	1	rs4326835	ENSG00000243431.1	RPL5P30	4.06	5.8e-05	0.00892	0.23	0.18	Total cholesterol levels;	chr11:118561689	chr11:118560690~118561580:+
LUAD	cis	rs6871536	1	rs62383710	ENSG00000233006.5	AC034220.3	-4.06	5.8e-05	0.00892	-0.2	-0.18	Asthma (childhood onset);	chr5:132564905	chr5:132311285~132369916:-
LUAD	cis	rs3814244	0.528	rs56393928	ENSG00000236946.2	HNRNPA1P70	-4.06	5.8e-05	0.00892	-0.16	-0.18	Itch intensity from mosquito bite adjusted by bite size;	chr12:68029927	chr12:68035767~68036853:+
LUAD	cis	rs1005277	0.505	rs200931	ENSG00000273019.1	RP11-508N22.13	-4.06	5.8e-05	0.00892	-0.21	-0.18	Extrinsic epigenetic age acceleration;	chr10:37839506	chr10:38149968~38150293:+
LUAD	cis	rs5758659	0.652	rs133358	ENSG00000227370.1	RP4-669P10.19	-4.06	5.8e-05	0.00892	-0.17	-0.18	Cognitive function;	chr22:42046535	chr22:42132543~42132998:+
LUAD	cis	rs4578769	0.569	rs12605341	ENSG00000265943.1	RP11-739L10.1	-4.06	5.8e-05	0.00893	-0.22	-0.18	Eosinophil percentage of white cells;	chr18:22803011	chr18:22699481~22933764:-
LUAD	cis	rs1623879	0.524	rs839225	ENSG00000273493.1	RP11-80H18.4	4.06	5.8e-05	0.00893	0.3	0.18	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);	chr3:58059560	chr3:58329965~58330118:+
LUAD	cis	rs6661961	0.752	rs11205003	ENSG00000237975.5	FLG-AS1	-4.06	5.8e-05	0.00893	-0.25	-0.18	Atopic dermatitis;	chr1:152444154	chr1:152168125~152445456:+
LUAD	cis	rs8073060	0.586	rs7221203	ENSG00000267592.1	CTC-507E2.2	4.06	5.8e-05	0.00893	0.26	0.18	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35688513	chr17:35596904~35597128:-
LUAD	cis	rs12681963	0.748	rs12542809	ENSG00000272375.1	RP11-51J9.6	-4.06	5.8e-05	0.00893	-0.26	-0.18	Migraine;	chr8:30044608	chr8:30197404~30198048:+
LUAD	cis	rs9475752	0.552	rs17685045	ENSG00000231441.1	RP11-472M19.2	4.06	5.81e-05	0.00893	0.29	0.18	Menarche (age at onset);	chr6:56880135	chr6:56844002~56864078:+
LUAD	cis	rs4761702	0.527	rs11106988	ENSG00000257252.4	RP11-486A14.2	-4.06	5.81e-05	0.00893	-0.23	-0.18	Immature fraction of reticulocytes;	chr12:93340674	chr12:93317135~93377736:-
LUAD	cis	rs7615952	0.736	rs9862893	ENSG00000241288.6	RP11-379B18.5	-4.06	5.81e-05	0.00893	-0.26	-0.18	Blood pressure (smoking interaction);	chr3:125968131	chr3:125827238~125916384:-
LUAD	cis	rs35740288	0.77	rs12907126	ENSG00000259407.1	RP11-158M2.3	-4.06	5.81e-05	0.00893	-0.18	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85628126	chr15:85744109~85750281:-
LUAD	cis	rs4819052	0.684	rs914216	ENSG00000237664.1	LINC00316	-4.06	5.81e-05	0.00893	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278383	chr21:45338590~45341990:-
LUAD	cis	rs8048589	0.948	rs35053871	ENSG00000175604.2	RP11-276H1.3	-4.06	5.81e-05	0.00894	-0.25	-0.18	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12088580	chr16:12086746~12090302:-
LUAD	cis	rs77633900	0.892	rs2460158	ENSG00000196274.5	Metazoa_SRP	4.06	5.81e-05	0.00894	0.23	0.18	Glioma;Non-glioblastoma glioma;	chr15:76307881	chr15:76230048~76230390:-
LUAD	cis	rs4908769	0.66	rs301803	ENSG00000232912.4	RP5-1115A15.1	4.06	5.81e-05	0.00894	0.17	0.18	Allergy;	chr1:8438620	chr1:8424645~8434838:+
LUAD	cis	rs3814244	0.528	rs2870960	ENSG00000236946.2	HNRNPA1P70	-4.06	5.82e-05	0.00894	-0.16	-0.18	Itch intensity from mosquito bite adjusted by bite size;	chr12:68032848	chr12:68035767~68036853:+
LUAD	cis	rs1799955	0.935	rs11571836	ENSG00000215515.2	IFIT1P1	-4.06	5.82e-05	0.00895	-0.27	-0.18	LDL cholesterol levels;	chr13:32399302	chr13:32384660~32386108:+
LUAD	cis	rs9467773	0.935	rs1056668	ENSG00000261353.1	CTA-14H9.5	-4.06	5.82e-05	0.00895	-0.2	-0.18	Intelligence (multi-trait analysis);	chr6:26510377	chr6:26527063~26527404:+
LUAD	cis	rs7160336	0.568	rs10146294	ENSG00000259065.1	RP5-1021I20.1	-4.06	5.82e-05	0.00895	-0.21	-0.18	Blood protein levels;	chr14:74214679	chr14:73787360~73803270:+
LUAD	cis	rs67981189	0.529	rs2526872	ENSG00000269927.1	RP6-91H8.3	-4.06	5.82e-05	0.00895	-0.24	-0.18	Schizophrenia;	chr14:70918168	chr14:71141125~71143253:-
LUAD	cis	rs783540	0.592	rs2567632	ENSG00000255769.6	GOLGA2P10	4.06	5.82e-05	0.00895	0.21	0.18	Schizophrenia;	chr15:82616053	chr15:82472993~82513950:-
LUAD	cis	rs5762752	0.555	rs695629	ENSG00000272858.1	CTA-292E10.8	-4.06	5.82e-05	0.00895	-0.19	-0.18	Optic disc area;	chr22:28438781	chr22:28814914~28815662:+
LUAD	cis	rs7160336	0.555	rs7147523	ENSG00000259065.1	RP5-1021I20.1	4.06	5.82e-05	0.00895	0.22	0.18	Blood protein levels;	chr14:74034747	chr14:73787360~73803270:+
LUAD	cis	rs7107174	0.901	rs1046780	ENSG00000251323.2	RP11-452H21.4	4.06	5.82e-05	0.00895	0.23	0.18	Testicular germ cell tumor;	chr11:78215723	chr11:78423982~78429836:-
LUAD	cis	rs2974760	0.606	rs6600143	ENSG00000268836.1	LA16c-OS12.2	-4.06	5.82e-05	0.00895	-0.18	-0.18	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr16:151390	chr16:185748~186294:-
LUAD	cis	rs8030379	1	rs1810049	ENSG00000230373.7	GOLGA6L5P	-4.06	5.82e-05	0.00895	-0.17	-0.18	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83907300	chr15:84507885~84516814:-
LUAD	cis	rs17122278	1	rs17092756	ENSG00000243431.1	RPL5P30	4.06	5.82e-05	0.00895	0.22	0.18	Total cholesterol levels;	chr11:118586915	chr11:118560690~118561580:+
LUAD	cis	rs10197140	0.857	rs12471566	ENSG00000235721.1	AC013268.3	-4.06	5.82e-05	0.00895	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110889697	chr2:110007675~110010783:+
LUAD	cis	rs10197140	0.857	rs13426283	ENSG00000235721.1	AC013268.3	-4.06	5.82e-05	0.00895	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110889710	chr2:110007675~110010783:+
LUAD	cis	rs10197140	0.816	rs12329097	ENSG00000235721.1	AC013268.3	-4.06	5.82e-05	0.00895	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110890820	chr2:110007675~110010783:+
LUAD	cis	rs10197140	0.857	rs12329103	ENSG00000235721.1	AC013268.3	-4.06	5.82e-05	0.00895	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110890943	chr2:110007675~110010783:+
LUAD	cis	rs10197140	0.857	rs13427098	ENSG00000235721.1	AC013268.3	-4.06	5.82e-05	0.00895	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110891086	chr2:110007675~110010783:+
LUAD	cis	rs10197140	0.857	rs12477660	ENSG00000235721.1	AC013268.3	-4.06	5.82e-05	0.00895	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110891442	chr2:110007675~110010783:+
LUAD	cis	rs10197140	0.857	rs12329216	ENSG00000235721.1	AC013268.3	-4.06	5.82e-05	0.00895	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110892375	chr2:110007675~110010783:+
LUAD	cis	rs10197140	0.857	rs2220092	ENSG00000235721.1	AC013268.3	-4.06	5.82e-05	0.00895	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110892961	chr2:110007675~110010783:+
LUAD	cis	rs10197140	0.857	rs2200211	ENSG00000235721.1	AC013268.3	-4.06	5.82e-05	0.00895	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110893052	chr2:110007675~110010783:+
LUAD	cis	rs2243480	1	rs4718333	ENSG00000229886.1	RP5-1132H15.3	-4.06	5.82e-05	0.00895	-0.31	-0.18	Diabetic kidney disease;	chr7:66307771	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs7792391	ENSG00000229886.1	RP5-1132H15.3	-4.06	5.82e-05	0.00895	-0.31	-0.18	Diabetic kidney disease;	chr7:66308442	chr7:66025126~66031544:-
LUAD	cis	rs4713118	0.824	rs9366702	ENSG00000280107.1	AL022393.9	-4.06	5.82e-05	0.00895	-0.23	-0.18	Parkinson's disease;	chr6:27766691	chr6:28170845~28172521:+
LUAD	cis	rs62355901	0.556	rs2897972	ENSG00000271828.1	CTD-2310F14.1	4.06	5.83e-05	0.00896	0.39	0.18	Breast cancer;	chr5:56750525	chr5:56927874~56929573:+
LUAD	cis	rs1008375	0.932	rs11938710	ENSG00000249502.1	AC006160.5	4.06	5.83e-05	0.00896	0.18	0.18	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17669041	chr4:17587467~17614571:-
LUAD	cis	rs7551222	0.752	rs4951407	ENSG00000240219.1	RP11-430C7.5	-4.06	5.83e-05	0.00896	-0.19	-0.18	Schizophrenia;	chr1:204588942	chr1:204626775~204629712:+
LUAD	cis	rs755249	0.567	rs41270799	ENSG00000182109.6	RP11-69E11.4	4.06	5.83e-05	0.00896	0.23	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39282990	chr1:39522280~39546187:-
LUAD	cis	rs4578769	0.55	rs12954377	ENSG00000265943.1	RP11-739L10.1	4.06	5.83e-05	0.00897	0.23	0.18	Eosinophil percentage of white cells;	chr18:22940862	chr18:22699481~22933764:-
LUAD	cis	rs4578769	0.55	rs9957690	ENSG00000265943.1	RP11-739L10.1	4.06	5.83e-05	0.00897	0.23	0.18	Eosinophil percentage of white cells;	chr18:22942697	chr18:22699481~22933764:-
LUAD	cis	rs4578769	0.55	rs12956837	ENSG00000265943.1	RP11-739L10.1	4.06	5.83e-05	0.00897	0.23	0.18	Eosinophil percentage of white cells;	chr18:22946865	chr18:22699481~22933764:-
LUAD	cis	rs4578769	0.55	rs9953479	ENSG00000265943.1	RP11-739L10.1	4.06	5.83e-05	0.00897	0.23	0.18	Eosinophil percentage of white cells;	chr18:22962644	chr18:22699481~22933764:-
LUAD	cis	rs4578769	0.55	rs12971230	ENSG00000265943.1	RP11-739L10.1	4.06	5.83e-05	0.00897	0.23	0.18	Eosinophil percentage of white cells;	chr18:22962987	chr18:22699481~22933764:-
LUAD	cis	rs12291225	0.546	rs12291662	ENSG00000251991.1	RNU7-49P	4.06	5.83e-05	0.00897	0.2	0.18	Sense of smell;	chr11:14321403	chr11:14478892~14478953:+
LUAD	cis	rs12291225	0.545	rs11023187	ENSG00000251991.1	RNU7-49P	4.06	5.83e-05	0.00897	0.2	0.18	Sense of smell;	chr11:14324013	chr11:14478892~14478953:+
LUAD	cis	rs7762018	1	rs6459657	ENSG00000231690.2	LINC00574	-4.06	5.83e-05	0.00897	-0.35	-0.18	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169736358	chr6:169790321~169802873:+
LUAD	cis	rs780096	0.546	rs715325	ENSG00000234072.1	AC074117.10	-4.06	5.83e-05	0.00897	-0.14	-0.18	Total body bone mineral density;	chr2:27502705	chr2:27356246~27367622:+
LUAD	cis	rs7637701	0.773	rs4098	ENSG00000240875.4	LINC00886	-4.06	5.84e-05	0.00897	-0.2	-0.18	Breast cancer;	chr3:156783274	chr3:156747346~156817062:-
LUAD	cis	rs8040855	0.627	rs11630697	ENSG00000259774.1	RP11-182J1.13	4.06	5.84e-05	0.00897	0.23	0.18	Bulimia nervosa;	chr15:85063214	chr15:84422618~84425882:+
LUAD	cis	rs8062405	0.755	rs4788080	ENSG00000261419.1	RP11-57A19.4	-4.06	5.84e-05	0.00897	-0.2	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28659696~28740781:-
LUAD	cis	rs7618915	0.547	rs34017441	ENSG00000243224.1	RP5-1157M23.2	-4.06	5.84e-05	0.00898	-0.18	-0.18	Bipolar disorder;	chr3:52708397	chr3:52239258~52241097:+
LUAD	cis	rs7618915	0.57	rs11130319	ENSG00000243224.1	RP5-1157M23.2	-4.06	5.84e-05	0.00898	-0.18	-0.18	Bipolar disorder;	chr3:52721576	chr3:52239258~52241097:+
LUAD	cis	rs853679	0.517	rs868987	ENSG00000280107.1	AL022393.9	4.06	5.84e-05	0.00898	0.24	0.18	Depression;	chr6:28142370	chr6:28170845~28172521:+
LUAD	cis	rs6430553	0.929	rs3819121	ENSG00000224043.6	CCNT2-AS1	-4.06	5.84e-05	0.00898	-0.22	-0.18	Blood metabolite levels;	chr2:134865290	chr2:134735464~134918710:-
LUAD	cis	rs453301	0.686	rs28665409	ENSG00000173295.6	FAM86B3P	-4.06	5.84e-05	0.00898	-0.2	-0.18	Joint mobility (Beighton score);	chr8:9011767	chr8:8228595~8244865:+
LUAD	cis	rs10129255	0.518	rs12590732	ENSG00000253209.1	IGHV3-65	-4.06	5.84e-05	0.00898	-0.14	-0.18	Kawasaki disease;	chr14:106779612	chr14:106666092~106666532:-
LUAD	cis	rs11064837	0.523	rs7963248	ENSG00000248636.5	RP11-768F21.1	4.06	5.84e-05	0.00898	0.22	0.18	Schizophrenia;	chr12:119657881	chr12:119387987~119668079:-
LUAD	cis	rs11064837	0.523	rs10774511	ENSG00000248636.5	RP11-768F21.1	4.06	5.84e-05	0.00898	0.22	0.18	Schizophrenia;	chr12:119658127	chr12:119387987~119668079:-
LUAD	cis	rs910316	0.763	rs1548807	ENSG00000259138.1	RP11-950C14.7	4.06	5.85e-05	0.00898	0.19	0.18	Height;	chr14:75012879	chr14:75127153~75136930:+
LUAD	cis	rs6071166	0.683	rs6015631	ENSG00000224635.1	RP4-564F22.5	4.06	5.85e-05	0.00899	0.21	0.18	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38688270	chr20:38406011~38416797:-
LUAD	cis	rs13631	0.928	rs9411308	ENSG00000268996.3	MAN1B1-AS1	4.06	5.85e-05	0.00899	0.21	0.18	Cerebrospinal fluid biomarker levels;	chr9:137105663	chr9:137084946~137086817:-
LUAD	cis	rs9309473	0.607	rs1403412	ENSG00000163016.8	ALMS1P	4.05	5.85e-05	0.00899	0.2	0.18	Metabolite levels;	chr2:73370964	chr2:73644919~73685576:+
LUAD	cis	rs2243480	0.522	rs12698511	ENSG00000164669.11	INTS4P1	4.05	5.85e-05	0.00899	0.37	0.18	Diabetic kidney disease;	chr7:66009932	chr7:65141225~65234216:+
LUAD	cis	rs9341808	0.718	rs10943699	ENSG00000260645.1	RP11-250B2.5	4.05	5.85e-05	0.00899	0.17	0.18	Sitting height ratio;	chr6:80230824	chr6:80466958~80469080:+
LUAD	cis	rs7119	0.634	rs11635634	ENSG00000259362.2	RP11-307C19.1	4.05	5.85e-05	0.00899	0.23	0.18	Type 2 diabetes;	chr15:77571070	chr15:77525540~77534110:+
LUAD	cis	rs67981189	0.529	rs2810097	ENSG00000269927.1	RP6-91H8.3	-4.05	5.85e-05	0.00899	-0.24	-0.18	Schizophrenia;	chr14:70967397	chr14:71141125~71143253:-
LUAD	cis	rs11671005	0.735	rs11667591	ENSG00000268543.1	CTD-2619J13.16	-4.05	5.85e-05	0.00899	-0.26	-0.18	Mean platelet volume;	chr19:58426270	chr19:58418560~58419310:+
LUAD	cis	rs6479891	0.908	rs7078456	ENSG00000232075.1	MRPL35P2	-4.05	5.85e-05	0.00899	-0.29	-0.18	Arthritis (juvenile idiopathic);	chr10:63509719	chr10:63634317~63634827:-
LUAD	cis	rs28386778	0.897	rs2854208	ENSG00000240280.5	TCAM1P	-4.05	5.85e-05	0.00899	-0.21	-0.18	Prudent dietary pattern;	chr17:63869525	chr17:63849292~63864379:+
LUAD	cis	rs2834288	0.535	rs9982605	ENSG00000237945.6	LINC00649	4.05	5.85e-05	0.00899	0.23	0.18	Gut microbiota (bacterial taxa);	chr21:33961205	chr21:33915534~33977691:+
LUAD	cis	rs12935418	0.616	rs13336292	ENSG00000261061.1	RP11-303E16.2	-4.05	5.86e-05	0.009	-0.19	-0.18	Mean corpuscular volume;	chr16:80971795	chr16:81030770~81031485:+
LUAD	cis	rs9815354	0.951	rs17063653	ENSG00000273328.4	RP11-141M3.6	-4.05	5.86e-05	0.009	-0.26	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41822325	chr3:42809414~42908105:+
LUAD	cis	rs9815354	1	rs73079321	ENSG00000273328.4	RP11-141M3.6	-4.05	5.86e-05	0.009	-0.26	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41822418	chr3:42809414~42908105:+
LUAD	cis	rs9815354	0.638	rs111465678	ENSG00000273328.4	RP11-141M3.6	-4.05	5.86e-05	0.009	-0.26	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41822913	chr3:42809414~42908105:+
LUAD	cis	rs9815354	0.767	rs73079325	ENSG00000273328.4	RP11-141M3.6	-4.05	5.86e-05	0.009	-0.26	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41823073	chr3:42809414~42908105:+
LUAD	cis	rs9815354	0.951	rs73830511	ENSG00000273328.4	RP11-141M3.6	-4.05	5.86e-05	0.009	-0.26	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41823151	chr3:42809414~42908105:+
LUAD	cis	rs2274273	0.805	rs60972460	ENSG00000259318.1	RP11-454L9.2	4.05	5.86e-05	0.009	0.16	0.18	Protein biomarker;	chr14:55105055	chr14:55394940~55395233:-
LUAD	cis	rs2243480	1	rs160652	ENSG00000229886.1	RP5-1132H15.3	4.05	5.86e-05	0.009	0.31	0.18	Diabetic kidney disease;	chr7:66073444	chr7:66025126~66031544:-
LUAD	cis	rs7985	0.595	rs2032576	ENSG00000244625.4	MIATNB	4.05	5.86e-05	0.009	0.19	0.18	Electroencephalogram traits;	chr22:26693692	chr22:26672767~26780207:+
LUAD	cis	rs6544311	0.539	rs17025588	ENSG00000227028.5	SLC8A1-AS1	4.05	5.87e-05	0.00901	0.23	0.18	QT interval;	chr2:40217938	chr2:39786453~40255209:+
LUAD	cis	rs13113518	0.756	rs12510275	ENSG00000272969.1	RP11-528I4.2	4.05	5.87e-05	0.00901	0.19	0.18	Height;	chr4:55516548	chr4:55547112~55547889:+
LUAD	cis	rs13113518	0.812	rs12510327	ENSG00000272969.1	RP11-528I4.2	4.05	5.87e-05	0.00901	0.19	0.18	Height;	chr4:55516744	chr4:55547112~55547889:+
LUAD	cis	rs3096299	0.632	rs8051537	ENSG00000261118.1	RP11-104N10.1	4.05	5.87e-05	0.00901	0.18	0.18	Multiple myeloma (IgH translocation);	chr16:89477976	chr16:89492017~89504460:-
LUAD	cis	rs3096299	0.719	rs2353581	ENSG00000182376.2	RP5-1142A6.8	4.05	5.87e-05	0.00901	0.19	0.18	Multiple myeloma (IgH translocation);	chr16:89452500	chr16:88742767~88745748:+
LUAD	cis	rs11048434	0.518	rs7311509	ENSG00000256937.1	KRT17P8	-4.05	5.87e-05	0.00901	-0.2	-0.18	Sjögren's syndrome;	chr12:9026438	chr12:9127783~9128645:+
LUAD	cis	rs2880765	0.743	rs8028240	ENSG00000259416.2	RP11-158M2.5	4.05	5.87e-05	0.00901	0.19	0.18	Coronary artery disease;	chr15:85470017	chr15:85754941~85756237:-
LUAD	cis	rs10771431	0.597	rs10771412	ENSG00000111788.10	RP11-22B23.1	4.05	5.87e-05	0.00901	0.16	0.18	Breast size;	chr12:9201757	chr12:9277235~9313241:+
LUAD	cis	rs10771431	0.597	rs10771413	ENSG00000111788.10	RP11-22B23.1	4.05	5.87e-05	0.00901	0.16	0.18	Breast size;	chr12:9201817	chr12:9277235~9313241:+
LUAD	cis	rs10197140	0.925	rs17545048	ENSG00000235721.1	AC013268.3	-4.05	5.87e-05	0.00901	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110901034	chr2:110007675~110010783:+
LUAD	cis	rs1401999	1	rs2176824	ENSG00000223882.1	ABCC5-AS1	-4.05	5.87e-05	0.00902	-0.19	-0.18	Anterior chamber depth;	chr3:183936241	chr3:184006338~184011419:+
LUAD	cis	rs957448	1	rs1055797	ENSG00000253175.1	RP11-267M23.6	4.05	5.87e-05	0.00902	0.22	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94511005	chr8:94565036~94565715:+
LUAD	cis	rs8048589	1	rs13336687	ENSG00000175604.2	RP11-276H1.3	-4.05	5.87e-05	0.00902	-0.25	-0.18	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12093208	chr16:12086746~12090302:-
LUAD	cis	rs4499344	0.696	rs10402929	ENSG00000201388.1	SNORA68	4.05	5.87e-05	0.00902	0.19	0.18	Mean platelet volume;	chr19:32609339	chr19:32608337~32608469:-
LUAD	cis	rs4499344	0.73	rs7250272	ENSG00000201388.1	SNORA68	4.05	5.87e-05	0.00902	0.19	0.18	Mean platelet volume;	chr19:32609432	chr19:32608337~32608469:-
LUAD	cis	rs4499344	0.664	rs4286210	ENSG00000201388.1	SNORA68	4.05	5.87e-05	0.00902	0.19	0.18	Mean platelet volume;	chr19:32610315	chr19:32608337~32608469:-
LUAD	cis	rs4499344	0.73	rs7247597	ENSG00000201388.1	SNORA68	4.05	5.87e-05	0.00902	0.19	0.18	Mean platelet volume;	chr19:32611351	chr19:32608337~32608469:-
LUAD	cis	rs12073359	1	rs59607464	ENSG00000223945.2	RP11-458I7.1	-4.05	5.87e-05	0.00902	-0.27	-0.18	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150157887	chr1:150053864~150055034:+
LUAD	cis	rs7107174	1	rs2512542	ENSG00000251323.2	RP11-452H21.4	4.05	5.87e-05	0.00902	0.22	0.18	Testicular germ cell tumor;	chr11:78270734	chr11:78423982~78429836:-
LUAD	cis	rs4819052	1	rs3746980	ENSG00000237664.1	LINC00316	-4.05	5.87e-05	0.00902	-0.24	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291665	chr21:45338590~45341990:-
LUAD	cis	rs6661961	0.686	rs2146121	ENSG00000237975.5	FLG-AS1	-4.05	5.88e-05	0.00902	-0.24	-0.18	Atopic dermatitis;	chr1:152420787	chr1:152168125~152445456:+
LUAD	cis	rs2880765	0.743	rs8032488	ENSG00000259416.2	RP11-158M2.5	4.05	5.88e-05	0.00902	0.19	0.18	Coronary artery disease;	chr15:85469537	chr15:85754941~85756237:-
LUAD	cis	rs2562456	0.833	rs55961038	ENSG00000268081.1	RP11-678G14.2	4.05	5.88e-05	0.00902	0.3	0.18	Pain;	chr19:21375205	chr19:21554640~21569237:-
LUAD	cis	rs894638	0.577	rs16868298	ENSG00000263327.5	TAPT1-AS1	-4.05	5.88e-05	0.00903	-0.23	-0.18	Glomerular filtration rate in chronic kidney disease;	chr4:16121197	chr4:16226685~16320140:+
LUAD	cis	rs13113518	0.812	rs12649507	ENSG00000272969.1	RP11-528I4.2	-4.05	5.88e-05	0.00903	-0.2	-0.18	Height;	chr4:55514317	chr4:55547112~55547889:+
LUAD	cis	rs7204230	0.96	rs57536424	ENSG00000261291.1	RP11-295M3.2	4.05	5.88e-05	0.00903	0.23	0.18	Fibrinogen;	chr16:53254184	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs1362440	ENSG00000261291.1	RP11-295M3.2	4.05	5.88e-05	0.00903	0.23	0.18	Fibrinogen;	chr16:53256912	chr16:53168522~53169450:+
LUAD	cis	rs860295	0.702	rs12041534	ENSG00000225855.5	RUSC1-AS1	-4.05	5.88e-05	0.00903	-0.12	-0.18	Body mass index;	chr1:155437305	chr1:155316863~155324176:-
LUAD	cis	rs35740288	0.822	rs17574774	ENSG00000259407.1	RP11-158M2.3	4.05	5.88e-05	0.00903	0.18	0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85690139	chr15:85744109~85750281:-
LUAD	cis	rs853679	0.517	rs36078605	ENSG00000280107.1	AL022393.9	-4.05	5.89e-05	0.00903	-0.24	-0.18	Depression;	chr6:28110254	chr6:28170845~28172521:+
LUAD	cis	rs13434995	0.513	rs7660668	ENSG00000273257.1	RP11-177J6.1	4.05	5.89e-05	0.00904	0.24	0.18	Adiponectin levels;	chr4:55535530	chr4:55387949~55388271:+
LUAD	cis	rs13434995	0.513	rs7698022	ENSG00000273257.1	RP11-177J6.1	4.05	5.89e-05	0.00904	0.24	0.18	Adiponectin levels;	chr4:55541180	chr4:55387949~55388271:+
LUAD	cis	rs8177876	0.915	rs4889233	ENSG00000261061.1	RP11-303E16.2	4.05	5.89e-05	0.00904	0.29	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81093378	chr16:81030770~81031485:+
LUAD	cis	rs1667284	0.846	rs1667280	ENSG00000266521.1	RP11-650P15.1	4.05	5.89e-05	0.00904	0.21	0.18	Problematic alcohol use in trauma-exposed individuals;	chr18:31639209	chr18:31496645~31497195:-
LUAD	cis	rs2354432	0.607	rs55918563	ENSG00000237188.3	RP11-337C18.8	4.05	5.89e-05	0.00904	0.33	0.18	Mitochondrial DNA levels;	chr1:147247319	chr1:147172771~147211568:+
LUAD	cis	rs2354432	0.607	rs7511989	ENSG00000237188.3	RP11-337C18.8	4.05	5.89e-05	0.00904	0.33	0.18	Mitochondrial DNA levels;	chr1:147248504	chr1:147172771~147211568:+
LUAD	cis	rs561341	0.83	rs2301765	ENSG00000265798.5	RP11-271K11.5	-4.05	5.89e-05	0.00904	-0.27	-0.18	Hip circumference adjusted for BMI;	chr17:31875037	chr17:31038575~31059121:-
LUAD	cis	rs561341	0.883	rs7219239	ENSG00000265798.5	RP11-271K11.5	-4.05	5.89e-05	0.00904	-0.27	-0.18	Hip circumference adjusted for BMI;	chr17:31884997	chr17:31038575~31059121:-
LUAD	cis	rs214785	1	rs214781	ENSG00000234684.5	SDCBP2-AS1	-4.05	5.89e-05	0.00904	-0.23	-0.18	Basal cell carcinoma;	chr20:2300638	chr20:1325405~1378734:+
LUAD	cis	rs17772222	0.958	rs12436326	ENSG00000258789.1	RP11-507K2.3	-4.05	5.89e-05	0.00905	-0.25	-0.18	Coronary artery calcification;	chr14:88533632	chr14:88551597~88552493:+
LUAD	cis	rs12908161	0.515	rs12907646	ENSG00000225151.9	GOLGA2P7	-4.05	5.9e-05	0.00905	-0.26	-0.18	Schizophrenia;	chr15:84860265	chr15:84199311~84230136:-
LUAD	cis	rs1461503	0.512	rs4259833	ENSG00000199709.1	RNU4-23P	-4.05	5.9e-05	0.00905	-0.22	-0.18	Menarche (age at onset);	chr11:122938497	chr11:122927034~122927173:+
LUAD	cis	rs116095464	0.558	rs9654452	ENSG00000248925.1	CTD-2083E4.6	4.05	5.9e-05	0.00905	0.32	0.18	Breast cancer;	chr5:299446	chr5:269858~271516:-
LUAD	cis	rs17122278	1	rs11216922	ENSG00000243431.1	RPL5P30	4.05	5.9e-05	0.00905	0.22	0.18	Total cholesterol levels;	chr11:118594580	chr11:118560690~118561580:+
LUAD	cis	rs13434995	0.513	rs62305270	ENSG00000273257.1	RP11-177J6.1	-4.05	5.9e-05	0.00905	-0.24	-0.18	Adiponectin levels;	chr4:55507842	chr4:55387949~55388271:+
LUAD	cis	rs13434995	0.513	rs7681414	ENSG00000273257.1	RP11-177J6.1	-4.05	5.9e-05	0.00905	-0.24	-0.18	Adiponectin levels;	chr4:55508890	chr4:55387949~55388271:+
LUAD	cis	rs13434995	0.513	rs62305271	ENSG00000273257.1	RP11-177J6.1	-4.05	5.9e-05	0.00905	-0.24	-0.18	Adiponectin levels;	chr4:55509715	chr4:55387949~55388271:+
LUAD	cis	rs763121	0.819	rs6001205	ENSG00000225450.1	RP3-508I15.14	-4.05	5.9e-05	0.00905	-0.18	-0.18	Menopause (age at onset);	chr22:38704259	chr22:38739003~38749041:+
LUAD	cis	rs7551222	0.716	rs12041075	ENSG00000240219.1	RP11-430C7.5	4.05	5.9e-05	0.00905	0.19	0.18	Schizophrenia;	chr1:204523025	chr1:204626775~204629712:+
LUAD	cis	rs10463554	0.892	rs2195272	ENSG00000250682.4	LINC00491	4.05	5.91e-05	0.00906	0.22	0.18	Parkinson's disease;	chr5:102959800	chr5:102609156~102671559:-
LUAD	cis	rs2735413	0.846	rs12923290	ENSG00000276007.1	RP11-358L22.3	-4.05	5.91e-05	0.00906	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78046059	chr16:78123243~78124332:+
LUAD	cis	rs599083	0.53	rs686921	ENSG00000212093.1	AP000807.1	-4.05	5.91e-05	0.00906	-0.2	-0.18	Bone mineral density (spine);	chr11:68403365	chr11:68506083~68506166:-
LUAD	cis	rs7160336	0.641	rs10136002	ENSG00000259065.1	RP5-1021I20.1	-4.05	5.91e-05	0.00906	-0.21	-0.18	Blood protein levels;	chr14:74215072	chr14:73787360~73803270:+
LUAD	cis	rs10197140	0.925	rs10185326	ENSG00000235721.1	AC013268.3	-4.05	5.91e-05	0.00906	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110874658	chr2:110007675~110010783:+
LUAD	cis	rs7005380	0.62	rs6987580	ENSG00000279347.1	RP11-85I17.2	4.05	5.91e-05	0.00906	0.15	0.18	Interstitial lung disease;	chr8:119898140	chr8:119838736~119840385:-
LUAD	cis	rs780096	0.506	rs1262430	ENSG00000234072.1	AC074117.10	-4.05	5.91e-05	0.00906	-0.14	-0.18	Total body bone mineral density;	chr2:27450931	chr2:27356246~27367622:+
LUAD	cis	rs11148252	0.532	rs9536190	ENSG00000273784.3	RP11-78J21.7	-4.05	5.91e-05	0.00907	-0.22	-0.18	Lewy body disease;	chr13:52606909	chr13:52600042~52642542:+
LUAD	cis	rs853679	0.567	rs7740429	ENSG00000219392.1	RP1-265C24.5	-4.05	5.91e-05	0.00907	-0.24	-0.18	Depression;	chr6:28431469	chr6:28115628~28116551:+
LUAD	cis	rs6102185	0.647	rs6124288	ENSG00000229771.2	RP4-644L1.2	-4.05	5.91e-05	0.00907	-0.22	-0.18	IgG glycosylation;	chr20:40892977	chr20:40696499~40698616:-
LUAD	cis	rs35740288	0.721	rs4843093	ENSG00000259407.1	RP11-158M2.3	-4.05	5.91e-05	0.00907	-0.18	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85694202	chr15:85744109~85750281:-
LUAD	cis	rs1864585	0.52	rs56046029	ENSG00000255046.1	RP11-297N6.4	4.05	5.92e-05	0.00908	0.25	0.18	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10836293	chr8:11797928~11802568:-
LUAD	cis	rs7772486	0.79	rs3924499	ENSG00000235652.6	RP11-545I5.3	-4.05	5.92e-05	0.00908	-0.18	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145911842	chr6:145799409~145886585:+
LUAD	cis	rs7615952	0.599	rs60847438	ENSG00000250012.1	RP11-124N2.1	-4.05	5.92e-05	0.00908	-0.26	-0.18	Blood pressure (smoking interaction);	chr3:126027162	chr3:126084220~126095349:+
LUAD	cis	rs7615952	0.534	rs1503072	ENSG00000250012.1	RP11-124N2.1	-4.05	5.92e-05	0.00908	-0.26	-0.18	Blood pressure (smoking interaction);	chr3:126035848	chr3:126084220~126095349:+
LUAD	cis	rs7615952	0.599	rs7631268	ENSG00000250012.1	RP11-124N2.1	-4.05	5.92e-05	0.00908	-0.26	-0.18	Blood pressure (smoking interaction);	chr3:126036821	chr3:126084220~126095349:+
LUAD	cis	rs7937682	1	rs10502147	ENSG00000230911.1	PPIHP1	4.05	5.92e-05	0.00908	0.25	0.18	Primary sclerosing cholangitis;	chr11:111699207	chr11:112029858~112030367:-
LUAD	cis	rs853679	0.517	rs9380052	ENSG00000280107.1	AL022393.9	-4.05	5.92e-05	0.00908	-0.24	-0.18	Depression;	chr6:28096845	chr6:28170845~28172521:+
LUAD	cis	rs1552244	0.882	rs66559400	ENSG00000180385.7	EMC3-AS1	4.05	5.92e-05	0.00908	0.21	0.18	Alzheimer's disease;	chr3:9970867	chr3:9986893~10006990:+
LUAD	cis	rs1552244	0.882	rs68153882	ENSG00000180385.7	EMC3-AS1	4.05	5.92e-05	0.00908	0.21	0.18	Alzheimer's disease;	chr3:9971426	chr3:9986893~10006990:+
LUAD	cis	rs1552244	0.882	rs35056669	ENSG00000180385.7	EMC3-AS1	4.05	5.92e-05	0.00908	0.21	0.18	Alzheimer's disease;	chr3:9972487	chr3:9986893~10006990:+
LUAD	cis	rs1552244	0.882	rs7636817	ENSG00000180385.7	EMC3-AS1	4.05	5.92e-05	0.00908	0.21	0.18	Alzheimer's disease;	chr3:9973192	chr3:9986893~10006990:+
LUAD	cis	rs1552244	0.882	rs3732967	ENSG00000180385.7	EMC3-AS1	4.05	5.92e-05	0.00908	0.21	0.18	Alzheimer's disease;	chr3:9973753	chr3:9986893~10006990:+
LUAD	cis	rs1552244	0.882	rs3732966	ENSG00000180385.7	EMC3-AS1	4.05	5.92e-05	0.00908	0.21	0.18	Alzheimer's disease;	chr3:9974056	chr3:9986893~10006990:+
LUAD	cis	rs1552244	0.882	rs13062917	ENSG00000180385.7	EMC3-AS1	4.05	5.92e-05	0.00908	0.21	0.18	Alzheimer's disease;	chr3:9975348	chr3:9986893~10006990:+
LUAD	cis	rs1552244	0.816	rs13076197	ENSG00000180385.7	EMC3-AS1	4.05	5.92e-05	0.00908	0.21	0.18	Alzheimer's disease;	chr3:9978089	chr3:9986893~10006990:+
LUAD	cis	rs1552244	0.688	rs7645137	ENSG00000180385.7	EMC3-AS1	4.05	5.92e-05	0.00908	0.21	0.18	Alzheimer's disease;	chr3:9978865	chr3:9986893~10006990:+
LUAD	cis	rs1552244	0.882	rs34779351	ENSG00000180385.7	EMC3-AS1	4.05	5.92e-05	0.00908	0.21	0.18	Alzheimer's disease;	chr3:9980117	chr3:9986893~10006990:+
LUAD	cis	rs1552244	0.882	rs13077641	ENSG00000180385.7	EMC3-AS1	4.05	5.92e-05	0.00908	0.21	0.18	Alzheimer's disease;	chr3:9981251	chr3:9986893~10006990:+
LUAD	cis	rs1552244	0.882	rs13074282	ENSG00000180385.7	EMC3-AS1	4.05	5.92e-05	0.00908	0.21	0.18	Alzheimer's disease;	chr3:9983015	chr3:9986893~10006990:+
LUAD	cis	rs1552244	0.882	rs67895180	ENSG00000180385.7	EMC3-AS1	4.05	5.92e-05	0.00908	0.21	0.18	Alzheimer's disease;	chr3:9984395	chr3:9986893~10006990:+
LUAD	cis	rs1552244	0.882	rs3755782	ENSG00000180385.7	EMC3-AS1	4.05	5.92e-05	0.00908	0.21	0.18	Alzheimer's disease;	chr3:9987621	chr3:9986893~10006990:+
LUAD	cis	rs7210086	0.73	rs76126194	ENSG00000263893.2	CTD-3010D24.3	4.05	5.92e-05	0.00908	0.25	0.18	Ulcerative colitis;	chr17:72642585	chr17:72642731~72644490:+
LUAD	cis	rs8113308	0.81	rs56029016	ENSG00000269483.1	AC006272.1	4.05	5.92e-05	0.00908	0.29	0.18	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51949209	chr19:51839924~51843324:-
LUAD	cis	rs11673344	0.523	rs2891766	ENSG00000276846.1	CTD-3220F14.3	4.05	5.92e-05	0.00908	0.2	0.18	Obesity-related traits;	chr19:37037057	chr19:37314868~37315620:-
LUAD	cis	rs11673344	0.523	rs7245453	ENSG00000276846.1	CTD-3220F14.3	4.05	5.92e-05	0.00908	0.2	0.18	Obesity-related traits;	chr19:37043447	chr19:37314868~37315620:-
LUAD	cis	rs8054556	0.647	rs11649149	ENSG00000214725.6	CDIPT-AS1	-4.05	5.92e-05	0.00908	-0.21	-0.18	Autism spectrum disorder or schizophrenia;	chr16:29997323	chr16:29863593~29868053:+
LUAD	cis	rs10938353	0.68	rs6828324	ENSG00000273369.1	RP11-700J17.1	-4.05	5.92e-05	0.00908	-0.23	-0.18	Body mass index;	chr4:44776331	chr4:44693946~44694386:-
LUAD	cis	rs5758659	0.519	rs133307	ENSG00000182057.4	OGFRP1	4.05	5.92e-05	0.00908	0.22	0.18	Cognitive function;	chr22:42000564	chr22:42269753~42275196:+
LUAD	cis	rs5758659	0.652	rs5758537	ENSG00000182057.4	OGFRP1	4.05	5.92e-05	0.00908	0.22	0.18	Cognitive function;	chr22:42001038	chr22:42269753~42275196:+
LUAD	cis	rs7246657	0.943	rs10417844	ENSG00000226686.6	LINC01535	-4.05	5.92e-05	0.00908	-0.27	-0.18	Coronary artery calcification;	chr19:37346685	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.943	rs1373991	ENSG00000226686.6	LINC01535	-4.05	5.92e-05	0.00908	-0.27	-0.18	Coronary artery calcification;	chr19:37348009	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.943	rs10405407	ENSG00000226686.6	LINC01535	-4.05	5.92e-05	0.00908	-0.27	-0.18	Coronary artery calcification;	chr19:37348262	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.943	rs12709813	ENSG00000226686.6	LINC01535	-4.05	5.92e-05	0.00908	-0.27	-0.18	Coronary artery calcification;	chr19:37354081	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.943	rs13345116	ENSG00000226686.6	LINC01535	-4.05	5.92e-05	0.00908	-0.27	-0.18	Coronary artery calcification;	chr19:37356196	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.765	rs7247259	ENSG00000226686.6	LINC01535	-4.05	5.92e-05	0.00908	-0.27	-0.18	Coronary artery calcification;	chr19:37360188	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.943	rs3745765	ENSG00000226686.6	LINC01535	-4.05	5.92e-05	0.00908	-0.27	-0.18	Coronary artery calcification;	chr19:37363333	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.943	rs4803229	ENSG00000226686.6	LINC01535	-4.05	5.92e-05	0.00908	-0.27	-0.18	Coronary artery calcification;	chr19:37373780	chr19:37251912~37265535:+
LUAD	cis	rs4499344	0.73	rs10413061	ENSG00000201388.1	SNORA68	4.05	5.92e-05	0.00908	0.19	0.18	Mean platelet volume;	chr19:32612372	chr19:32608337~32608469:-
LUAD	cis	rs4499344	0.73	rs10410888	ENSG00000201388.1	SNORA68	4.05	5.92e-05	0.00908	0.19	0.18	Mean platelet volume;	chr19:32612422	chr19:32608337~32608469:-
LUAD	cis	rs516805	0.52	rs554482	ENSG00000279453.1	RP3-425C14.4	-4.05	5.92e-05	0.00908	-0.19	-0.18	Lymphocyte counts;	chr6:122419645	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.502	rs578868	ENSG00000279453.1	RP3-425C14.4	-4.05	5.92e-05	0.00908	-0.19	-0.18	Lymphocyte counts;	chr6:122421230	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.52	rs576247	ENSG00000279453.1	RP3-425C14.4	-4.05	5.92e-05	0.00908	-0.19	-0.18	Lymphocyte counts;	chr6:122425793	chr6:122436789~122439223:-
LUAD	cis	rs9633740	1	rs1902660	ENSG00000226659.1	RP11-137H2.4	-4.05	5.92e-05	0.00908	-0.29	-0.18	Post bronchodilator FEV1;	chr10:80503927	chr10:80529597~80535942:-
LUAD	cis	rs453301	0.686	rs28665409	ENSG00000253893.2	FAM85B	4.05	5.92e-05	0.00908	0.24	0.18	Joint mobility (Beighton score);	chr8:9011767	chr8:8167819~8226614:-
LUAD	cis	rs8028182	0.636	rs28432989	ENSG00000260269.4	CTD-2323K18.1	-4.05	5.92e-05	0.00909	-0.25	-0.18	Sudden cardiac arrest;	chr15:75475956	chr15:75527150~75601205:-
LUAD	cis	rs4499344	0.664	rs7258278	ENSG00000201388.1	SNORA68	4.05	5.92e-05	0.00909	0.19	0.18	Mean platelet volume;	chr19:32608617	chr19:32608337~32608469:-
LUAD	cis	rs4499344	0.73	rs28402742	ENSG00000201388.1	SNORA68	4.05	5.92e-05	0.00909	0.19	0.18	Mean platelet volume;	chr19:32608828	chr19:32608337~32608469:-
LUAD	cis	rs4499344	0.73	rs28416849	ENSG00000201388.1	SNORA68	4.05	5.92e-05	0.00909	0.19	0.18	Mean platelet volume;	chr19:32608852	chr19:32608337~32608469:-
LUAD	cis	rs6738440	0.539	rs12990774	ENSG00000234624.2	AC016894.1	4.05	5.93e-05	0.00909	0.21	0.18	F-cell distribution;	chr2:60442427	chr2:61416887~61417197:-
LUAD	cis	rs3758785	0.737	rs3758786	ENSG00000255893.1	RP11-685N10.1	-4.05	5.93e-05	0.00909	-0.26	-0.18	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94399118	chr11:94472908~94473570:-
LUAD	cis	rs6088580	0.602	rs6058064	ENSG00000276073.1	RP5-1125A11.7	-4.05	5.93e-05	0.00909	-0.18	-0.18	Glomerular filtration rate (creatinine);	chr20:34498817	chr20:33985617~33988989:-
LUAD	cis	rs77688320	0.535	rs10804115	ENSG00000213090.2	AC007256.5	4.05	5.93e-05	0.00909	0.21	0.18	Breast cancer;	chr2:201415510	chr2:201410544~201413308:-
LUAD	cis	rs2439831	0.867	rs2278860	ENSG00000249839.1	AC011330.5	4.05	5.93e-05	0.00909	0.32	0.18	Lung cancer in ever smokers;	chr15:43366848	chr15:43663654~43684339:-
LUAD	cis	rs10737909	1	rs10803369	ENSG00000278480.1	RP5-903E17.2	-4.05	5.93e-05	0.00909	-0.2	-0.18	Migraine;	chr1:15224029	chr1:15226373~15227549:+
LUAD	cis	rs17301013	0.9	rs1754351	ENSG00000227373.4	RP11-160H22.5	-4.05	5.93e-05	0.00909	-0.23	-0.18	Systemic lupus erythematosus;	chr1:174762458	chr1:174115300~174160004:-
LUAD	cis	rs651907	0.557	rs17411983	ENSG00000244119.1	PDCL3P4	-4.05	5.93e-05	0.0091	-0.18	-0.18	Colorectal cancer;	chr3:101680282	chr3:101712472~101713191:+
LUAD	cis	rs7191700	0.644	rs12149160	ENSG00000262636.1	CTD-3088G3.4	-4.05	5.93e-05	0.0091	-0.22	-0.18	Multiple sclerosis;	chr16:11345446	chr16:11380859~11381118:-
LUAD	cis	rs2154319	1	rs61774708	ENSG00000235358.1	RP11-399E6.1	-4.05	5.93e-05	0.0091	-0.25	-0.18	Height;	chr1:41249135	chr1:41242373~41284861:+
LUAD	cis	rs2154319	1	rs74714120	ENSG00000235358.1	RP11-399E6.1	-4.05	5.93e-05	0.0091	-0.25	-0.18	Height;	chr1:41249206	chr1:41242373~41284861:+
LUAD	cis	rs34783982	1	rs34783982	ENSG00000261441.1	RP11-217B1.2	-4.05	5.94e-05	0.0091	-0.25	-0.18	Squamous cell lung carcinoma;	chr15:88971932	chr15:89335053~89336161:+
LUAD	cis	rs34779708	0.966	rs7070427	ENSG00000271335.4	RP11-324I22.4	4.05	5.94e-05	0.0091	0.19	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35196761	chr10:35314552~35336401:-
LUAD	cis	rs7512552	0.839	rs696616	ENSG00000275557.1	RP11-353N4.6	4.05	5.94e-05	0.00911	0.21	0.18	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150363697	chr1:149607765~149612402:+
LUAD	cis	rs7208859	0.614	rs9914534	ENSG00000266490.1	CTD-2349P21.9	4.05	5.94e-05	0.00911	0.27	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30875646	chr17:30792372~30792833:+
LUAD	cis	rs9815354	1	rs1564716	ENSG00000273328.4	RP11-141M3.6	-4.05	5.94e-05	0.00911	-0.26	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41821121	chr3:42809414~42908105:+
LUAD	cis	rs9815354	1	rs2128835	ENSG00000273328.4	RP11-141M3.6	-4.05	5.94e-05	0.00911	-0.26	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41821381	chr3:42809414~42908105:+
LUAD	cis	rs9815354	1	rs17063649	ENSG00000273328.4	RP11-141M3.6	-4.05	5.94e-05	0.00911	-0.26	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41821914	chr3:42809414~42908105:+
LUAD	cis	rs9815354	1	rs28733681	ENSG00000273328.4	RP11-141M3.6	-4.05	5.94e-05	0.00911	-0.26	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41821952	chr3:42809414~42908105:+
LUAD	cis	rs453301	0.686	rs6987107	ENSG00000233609.3	RP11-62H7.2	-4.05	5.94e-05	0.00911	-0.15	-0.18	Joint mobility (Beighton score);	chr8:9036071	chr8:8961200~8979025:+
LUAD	cis	rs9815354	1	rs17063599	ENSG00000273328.4	RP11-141M3.6	-4.05	5.94e-05	0.00911	-0.26	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41820184	chr3:42809414~42908105:+
LUAD	cis	rs9815354	1	rs12639255	ENSG00000273328.4	RP11-141M3.6	-4.05	5.94e-05	0.00911	-0.26	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41820246	chr3:42809414~42908105:+
LUAD	cis	rs4819052	1	rs4818769	ENSG00000215447.6	BX322557.10	-4.05	5.94e-05	0.00911	-0.23	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45247536	chr21:45288052~45291738:+
LUAD	cis	rs858239	0.863	rs466225	ENSG00000230042.1	AK3P3	-4.05	5.95e-05	0.00911	-0.23	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23292784	chr7:23129178~23129841:+
LUAD	cis	rs950880	0.767	rs2287037	ENSG00000234389.1	AC007278.3	-4.05	5.95e-05	0.00911	-0.17	-0.18	Serum protein levels (sST2);	chr2:102362568	chr2:102438713~102440475:+
LUAD	cis	rs9543976	1	rs2296146	ENSG00000261105.4	LMO7-AS1	-4.05	5.95e-05	0.00912	-0.3	-0.18	Diabetic retinopathy;	chr13:75569436	chr13:75604700~75635994:-
LUAD	cis	rs72772090	1	rs11738135	ENSG00000248734.2	CTD-2260A17.1	-4.05	5.95e-05	0.00912	-0.25	-0.18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96712632	chr5:96784777~96785999:+
LUAD	cis	rs853679	0.517	rs9380056	ENSG00000280107.1	AL022393.9	-4.05	5.95e-05	0.00912	-0.24	-0.18	Depression;	chr6:28136698	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs9380057	ENSG00000280107.1	AL022393.9	-4.05	5.95e-05	0.00912	-0.24	-0.18	Depression;	chr6:28136856	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs6941992	ENSG00000280107.1	AL022393.9	-4.05	5.95e-05	0.00912	-0.24	-0.18	Depression;	chr6:28138363	chr6:28170845~28172521:+
LUAD	cis	rs4713118	0.516	rs4713142	ENSG00000280107.1	AL022393.9	-4.05	5.95e-05	0.00912	-0.24	-0.18	Parkinson's disease;	chr6:28138569	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs4713143	ENSG00000280107.1	AL022393.9	-4.05	5.95e-05	0.00912	-0.24	-0.18	Depression;	chr6:28138981	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs4713144	ENSG00000280107.1	AL022393.9	-4.05	5.95e-05	0.00912	-0.24	-0.18	Depression;	chr6:28139012	chr6:28170845~28172521:+
LUAD	cis	rs780096	0.526	rs11682621	ENSG00000234072.1	AC074117.10	-4.05	5.95e-05	0.00912	-0.14	-0.18	Total body bone mineral density;	chr2:27526802	chr2:27356246~27367622:+
LUAD	cis	rs651907	0.557	rs36002990	ENSG00000244119.1	PDCL3P4	4.05	5.95e-05	0.00912	0.18	0.18	Colorectal cancer;	chr3:101719018	chr3:101712472~101713191:+
LUAD	cis	rs651907	0.557	rs11720745	ENSG00000244119.1	PDCL3P4	4.05	5.95e-05	0.00912	0.18	0.18	Colorectal cancer;	chr3:101722846	chr3:101712472~101713191:+
LUAD	cis	rs651907	0.557	rs35117343	ENSG00000244119.1	PDCL3P4	4.05	5.95e-05	0.00912	0.18	0.18	Colorectal cancer;	chr3:101726282	chr3:101712472~101713191:+
LUAD	cis	rs2657294	0.965	rs2657291	ENSG00000226051.5	ZNF503-AS1	-4.05	5.95e-05	0.00912	-0.24	-0.18	Pneumonia;	chr10:75166945	chr10:75269819~75373500:+
LUAD	cis	rs2348418	0.864	rs6487688	ENSG00000247934.4	RP11-967K21.1	-4.05	5.95e-05	0.00912	-0.21	-0.18	Lung function (FEV1);Lung function (FVC);	chr12:28558278	chr12:28163298~28190738:-
LUAD	cis	rs62355901	0.505	rs12657615	ENSG00000271828.1	CTD-2310F14.1	4.05	5.95e-05	0.00912	0.4	0.18	Breast cancer;	chr5:56768306	chr5:56927874~56929573:+
LUAD	cis	rs4705962	0.8	rs6865485	ENSG00000233006.5	AC034220.3	4.05	5.95e-05	0.00912	0.18	0.18	Atopic dermatitis;	chr5:132699880	chr5:132311285~132369916:-
LUAD	cis	rs1555322	0.53	rs2250205	ENSG00000261582.1	RP4-614O4.11	-4.05	5.95e-05	0.00912	-0.23	-0.18	Attention deficit hyperactivity disorder;	chr20:35280121	chr20:35267885~35280043:-
LUAD	cis	rs3096299	0.589	rs3114898	ENSG00000182376.2	RP5-1142A6.8	4.05	5.96e-05	0.00913	0.19	0.18	Multiple myeloma (IgH translocation);	chr16:89325907	chr16:88742767~88745748:+
LUAD	cis	rs858239	0.601	rs929507	ENSG00000226816.2	AC005082.12	4.05	5.96e-05	0.00913	0.24	0.18	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23206013~23208045:+
LUAD	cis	rs858239	0.601	rs929508	ENSG00000226816.2	AC005082.12	4.05	5.96e-05	0.00913	0.24	0.18	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23206013~23208045:+
LUAD	cis	rs11779988	0.545	rs208749	ENSG00000253671.1	RP11-806O11.1	-4.05	5.96e-05	0.00913	-0.23	-0.18	Breast cancer;	chr8:17919695	chr8:17808941~17820868:+
LUAD	cis	rs6964587	1	rs6946356	ENSG00000188693.7	CYP51A1-AS1	-4.05	5.96e-05	0.00913	-0.21	-0.18	Breast cancer;	chr7:92098071	chr7:92134604~92180725:+
LUAD	cis	rs73198271	0.603	rs777705	ENSG00000253893.2	FAM85B	4.05	5.96e-05	0.00913	0.23	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8729358	chr8:8167819~8226614:-
LUAD	cis	rs6840360	0.615	rs9884167	ENSG00000270265.1	RP11-731D1.4	-4.05	5.96e-05	0.00914	-0.2	-0.18	Intelligence (multi-trait analysis);	chr4:151549647	chr4:151333775~151353224:-
LUAD	cis	rs801193	0.548	rs6975044	ENSG00000106610.13	STAG3L4	-4.05	5.96e-05	0.00914	-0.23	-0.18	Aortic root size;	chr7:66762495	chr7:67302621~67321526:+
LUAD	cis	rs8073060	0.586	rs7214250	ENSG00000267592.1	CTC-507E2.2	4.05	5.96e-05	0.00914	0.26	0.18	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35654685	chr17:35596904~35597128:-
LUAD	cis	rs8073060	0.586	rs7214742	ENSG00000267592.1	CTC-507E2.2	4.05	5.96e-05	0.00914	0.26	0.18	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35654950	chr17:35596904~35597128:-
LUAD	cis	rs2154319	0.887	rs61779269	ENSG00000235358.1	RP11-399E6.1	-4.05	5.97e-05	0.00914	-0.24	-0.18	Height;	chr1:41199784	chr1:41242373~41284861:+
LUAD	cis	rs2154319	0.887	rs61779270	ENSG00000235358.1	RP11-399E6.1	-4.05	5.97e-05	0.00914	-0.24	-0.18	Height;	chr1:41205234	chr1:41242373~41284861:+
LUAD	cis	rs6001482	0.702	rs5757581	ENSG00000223350.2	IGLV9-49	4.05	5.97e-05	0.00914	0.18	0.18	Diastolic blood pressure;	chr22:22234220	chr22:22343187~22343732:+
LUAD	cis	rs6088580	0.634	rs6059850	ENSG00000276073.1	RP5-1125A11.7	-4.05	5.97e-05	0.00915	-0.18	-0.18	Glomerular filtration rate (creatinine);	chr20:34456979	chr20:33985617~33988989:-
LUAD	cis	rs791888	0.76	rs10788561	ENSG00000225913.2	RP11-57C13.6	-4.05	5.97e-05	0.00915	-0.23	-0.18	Magnesium levels;	chr10:87663488	chr10:87607985~87659279:+
LUAD	cis	rs5758659	0.652	rs133305	ENSG00000182057.4	OGFRP1	4.05	5.97e-05	0.00915	0.22	0.18	Cognitive function;	chr22:41999956	chr22:42269753~42275196:+
LUAD	cis	rs5758659	0.682	rs133306	ENSG00000182057.4	OGFRP1	4.05	5.97e-05	0.00915	0.22	0.18	Cognitive function;	chr22:42000146	chr22:42269753~42275196:+
LUAD	cis	rs6496044	0.634	rs4843066	ENSG00000259295.5	CSPG4P12	4.05	5.97e-05	0.00915	0.21	0.18	Interstitial lung disease;	chr15:85519680	chr15:85191438~85213905:+
LUAD	cis	rs11240074	0.632	rs61841199	ENSG00000244371.2	PFN1P8	-4.05	5.97e-05	0.00915	-0.31	-0.18	Type 2 diabetes;	chr1:147482732	chr1:146957117~146957659:-
LUAD	cis	rs3741404	0.62	rs2236647	ENSG00000256789.1	RP11-697H9.2	4.05	5.97e-05	0.00915	0.19	0.18	Platelet count;	chr11:64197133	chr11:63637677~63658962:+
LUAD	cis	rs17596685	1	rs346589	ENSG00000271216.1	LINC01050	-4.05	5.97e-05	0.00915	-0.27	-0.18	C-reactive protein levels;	chr13:42592148	chr13:42810366~42812562:-
LUAD	cis	rs17596685	1	rs346590	ENSG00000271216.1	LINC01050	-4.05	5.97e-05	0.00915	-0.27	-0.18	C-reactive protein levels;	chr13:42592159	chr13:42810366~42812562:-
LUAD	cis	rs17596685	1	rs189398	ENSG00000271216.1	LINC01050	-4.05	5.97e-05	0.00915	-0.27	-0.18	C-reactive protein levels;	chr13:42592810	chr13:42810366~42812562:-
LUAD	cis	rs987044	0.807	rs888530	ENSG00000257221.1	RP11-689B22.2	-4.05	5.97e-05	0.00915	-0.15	-0.18	Mean platelet volume;	chr12:108750744	chr12:108628687~108641318:+
LUAD	cis	rs17711722	0.522	rs4642526	ENSG00000189316.3	RP11-797H7.5	-4.05	5.97e-05	0.00915	-0.2	-0.18	Calcium levels;	chr7:65751755	chr7:64888527~64890100:-
LUAD	cis	rs6568686	0.577	rs174394	ENSG00000255389.1	C6orf3	4.05	5.98e-05	0.00915	0.24	0.18	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111597796	chr6:111599875~111602295:+
LUAD	cis	rs6568686	0.577	rs174395	ENSG00000255389.1	C6orf3	4.05	5.98e-05	0.00915	0.24	0.18	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111597804	chr6:111599875~111602295:+
LUAD	cis	rs2933343	0.729	rs1680780	ENSG00000231305.3	RP11-723O4.2	4.05	5.98e-05	0.00915	0.2	0.18	IgG glycosylation;	chr3:128893816	chr3:128861313~128871540:-
LUAD	cis	rs910316	0.763	rs175047	ENSG00000259138.1	RP11-950C14.7	-4.05	5.98e-05	0.00915	-0.19	-0.18	Height;	chr14:75012336	chr14:75127153~75136930:+
LUAD	cis	rs4819052	0.851	rs914218	ENSG00000237664.1	LINC00316	-4.05	5.98e-05	0.00915	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278530	chr21:45338590~45341990:-
LUAD	cis	rs6125597	0.935	rs6067034	ENSG00000230758.1	SNAP23P	4.05	5.98e-05	0.00916	0.19	0.18	Intelligence (multi-trait analysis);	chr20:49283627	chr20:49038357~49038602:-
LUAD	cis	rs8031584	0.918	rs34095794	ENSG00000259845.1	HERC2P10	4.05	5.98e-05	0.00916	0.21	0.18	Huntington's disease progression;	chr15:30977488	chr15:30815271~30844153:+
LUAD	cis	rs651907	0.557	rs11917682	ENSG00000244119.1	PDCL3P4	4.05	5.98e-05	0.00916	0.18	0.18	Colorectal cancer;	chr3:101636583	chr3:101712472~101713191:+
LUAD	cis	rs7870753	0.636	rs10761006	ENSG00000188801.9	ZNF322P1	4.05	5.98e-05	0.00916	0.27	0.18	Height;	chr9:96416502	chr9:97198303~97199511:-
LUAD	cis	rs9928842	0.712	rs8057843	ENSG00000261476.1	RP11-77K12.3	-4.05	5.98e-05	0.00916	-0.25	-0.18	Alcoholic chronic pancreatitis;	chr16:75187657	chr16:75458252~75460017:-
LUAD	cis	rs11009175	0.929	rs6481825	ENSG00000273038.2	RP11-479G22.8	-4.05	5.98e-05	0.00916	-0.26	-0.18	Depression (quantitative trait);	chr10:33050595	chr10:32887255~32889311:-
LUAD	cis	rs950169	0.58	rs2271431	ENSG00000259295.5	CSPG4P12	4.05	5.98e-05	0.00916	0.25	0.18	Schizophrenia;	chr15:84646233	chr15:85191438~85213905:+
LUAD	cis	rs523522	0.923	rs2235217	ENSG00000278344.1	RP11-18C24.8	4.05	5.98e-05	0.00916	0.25	0.18	High light scatter reticulocyte count;	chr12:120446525	chr12:120500735~120501090:-
LUAD	cis	rs523522	0.962	rs10774549	ENSG00000278344.1	RP11-18C24.8	4.05	5.98e-05	0.00916	0.25	0.18	High light scatter reticulocyte count;	chr12:120453369	chr12:120500735~120501090:-
LUAD	cis	rs728616	1	rs12414891	ENSG00000225484.5	NUTM2B-AS1	-4.05	5.99e-05	0.00917	-0.47	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79930629	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.717	rs12415523	ENSG00000225484.5	NUTM2B-AS1	-4.05	5.99e-05	0.00917	-0.47	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79932220	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.764	rs75385771	ENSG00000225484.5	NUTM2B-AS1	-4.05	5.99e-05	0.00917	-0.47	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79933023	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.867	rs56000427	ENSG00000225484.5	NUTM2B-AS1	-4.05	5.99e-05	0.00917	-0.48	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80227190	chr10:79663088~79826594:-
LUAD	cis	rs4840086	0.935	rs17059754	ENSG00000219755.1	RP1-199J3.5	4.05	5.99e-05	0.00917	0.23	0.18	Menarche (age at onset);	chr6:99754758	chr6:99575712~99576456:+
LUAD	cis	rs2711721	0.56	rs2522256	ENSG00000274723.1	RP11-618L22.1	4.05	5.99e-05	0.00917	0.23	0.18	Prostate cancer (SNP x SNP interaction);	chr12:46980940	chr12:46970504~46972155:+
LUAD	cis	rs116095464	0.558	rs59113266	ENSG00000248925.1	CTD-2083E4.6	4.05	5.99e-05	0.00917	0.31	0.18	Breast cancer;	chr5:279850	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs11959126	ENSG00000248925.1	CTD-2083E4.6	4.05	5.99e-05	0.00917	0.31	0.18	Breast cancer;	chr5:283765	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs7356696	ENSG00000248925.1	CTD-2083E4.6	4.05	5.99e-05	0.00917	0.31	0.18	Breast cancer;	chr5:284136	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs7356561	ENSG00000248925.1	CTD-2083E4.6	4.05	5.99e-05	0.00917	0.31	0.18	Breast cancer;	chr5:284266	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs59284383	ENSG00000248925.1	CTD-2083E4.6	4.05	5.99e-05	0.00917	0.31	0.18	Breast cancer;	chr5:284410	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs7731089	ENSG00000248925.1	CTD-2083E4.6	4.05	5.99e-05	0.00917	0.31	0.18	Breast cancer;	chr5:290307	chr5:269858~271516:-
LUAD	cis	rs9381040	0.631	rs13216201	ENSG00000161912.16	ADCY10P1	4.05	5.99e-05	0.00917	0.18	0.18	Alzheimer's disease (late onset);	chr6:41194322	chr6:41101022~41140835:+
LUAD	cis	rs4374383	0.847	rs1516627	ENSG00000207383.1	Y_RNA	4.05	5.99e-05	0.00917	0.22	0.18	Hepatitis C induced liver fibrosis;	chr2:111946477	chr2:112579484~112579584:-
LUAD	cis	rs2562456	0.755	rs11670868	ENSG00000268081.1	RP11-678G14.2	4.05	5.99e-05	0.00917	0.3	0.18	Pain;	chr19:21373613	chr19:21554640~21569237:-
LUAD	cis	rs2562456	0.833	rs2358993	ENSG00000268081.1	RP11-678G14.2	4.05	5.99e-05	0.00917	0.3	0.18	Pain;	chr19:21375367	chr19:21554640~21569237:-
LUAD	cis	rs8042680	0.542	rs12440774	ENSG00000259746.1	HSPE1P3	4.05	5.99e-05	0.00917	0.2	0.18	Type 2 diabetes;	chr15:90939705	chr15:90634725~90635033:+
LUAD	cis	rs1322639	0.614	rs9364356	ENSG00000261039.2	RP11-417E7.2	-4.05	5.99e-05	0.00917	-0.31	-0.18	Pulse pressure;	chr6:169167013	chr6:169175304~169182740:-
LUAD	cis	rs338389	0.542	rs6494709	ENSG00000260657.2	RP11-315D16.4	-4.05	5.99e-05	0.00917	-0.22	-0.18	Survival in rectal cancer;	chr15:68001672	chr15:68267792~68277994:-
LUAD	cis	rs8062405	0.755	rs17640009	ENSG00000251417.2	RP11-1348G14.4	-4.05	5.99e-05	0.00918	-0.18	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28802743~28817828:+
LUAD	cis	rs10197140	0.857	rs6714299	ENSG00000235721.1	AC013268.3	-4.05	5.99e-05	0.00918	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110907103	chr2:110007675~110010783:+
LUAD	cis	rs1075265	0.73	rs7597188	ENSG00000272156.1	RP11-477N3.1	-4.05	6e-05	0.00918	-0.21	-0.18	Chronotype;Morning vs. evening chronotype;	chr2:54014732	chr2:54082554~54085066:+
LUAD	cis	rs7107174	1	rs2510043	ENSG00000251323.2	RP11-452H21.4	4.05	6e-05	0.00918	0.22	0.18	Testicular germ cell tumor;	chr11:78266435	chr11:78423982~78429836:-
LUAD	cis	rs77633900	1	rs2469214	ENSG00000196274.5	Metazoa_SRP	4.05	6e-05	0.00918	0.24	0.18	Glioma;Non-glioblastoma glioma;	chr15:76282287	chr15:76230048~76230390:-
LUAD	cis	rs651907	0.557	rs11917569	ENSG00000244119.1	PDCL3P4	4.05	6e-05	0.00918	0.18	0.18	Colorectal cancer;	chr3:101636219	chr3:101712472~101713191:+
LUAD	cis	rs6840360	0.571	rs4696276	ENSG00000270265.1	RP11-731D1.4	-4.05	6e-05	0.00918	-0.21	-0.18	Intelligence (multi-trait analysis);	chr4:151611530	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.571	rs62327270	ENSG00000270265.1	RP11-731D1.4	-4.05	6e-05	0.00918	-0.21	-0.18	Intelligence (multi-trait analysis);	chr4:151612466	chr4:151333775~151353224:-
LUAD	cis	rs62229266	0.605	rs11701331	ENSG00000214914.3	RPL23AP3	4.05	6e-05	0.00918	0.22	0.18	Mitral valve prolapse;	chr21:36086094	chr21:36016079~36016546:-
LUAD	cis	rs2288884	1	rs80278704	ENSG00000269959.1	SPACA6P-AS	-4.05	6e-05	0.00919	-0.25	-0.18	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52045930	chr19:51685363~51693456:-
LUAD	cis	rs2288884	1	rs11669540	ENSG00000269959.1	SPACA6P-AS	-4.05	6e-05	0.00919	-0.25	-0.18	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52046486	chr19:51685363~51693456:-
LUAD	cis	rs2288884	1	rs78543982	ENSG00000269959.1	SPACA6P-AS	-4.05	6e-05	0.00919	-0.25	-0.18	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52047614	chr19:51685363~51693456:-
LUAD	cis	rs2288884	0.943	rs3752120	ENSG00000269959.1	SPACA6P-AS	-4.05	6e-05	0.00919	-0.25	-0.18	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52048768	chr19:51685363~51693456:-
LUAD	cis	rs10463554	0.963	rs34772	ENSG00000250682.4	LINC00491	4.05	6.01e-05	0.00919	0.23	0.18	Parkinson's disease;	chr5:103114808	chr5:102609156~102671559:-
LUAD	cis	rs73230612	0.858	rs9880469	ENSG00000242767.1	ZBTB20-AS4	4.05	6.01e-05	0.00919	0.3	0.18	Type 2 diabetes;	chr3:115372971	chr3:115100423~115103061:+
LUAD	cis	rs2274273	0.901	rs8011288	ENSG00000258413.1	RP11-665C16.6	-4.05	6.01e-05	0.00919	-0.23	-0.18	Protein biomarker;	chr14:55268394	chr14:55262767~55272075:-
LUAD	cis	rs6128907	0.8	rs6129026	ENSG00000224635.1	RP4-564F22.5	4.05	6.01e-05	0.00919	0.32	0.18	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38787252	chr20:38406011~38416797:-
LUAD	cis	rs4578769	0.513	rs34623893	ENSG00000265943.1	RP11-739L10.1	4.05	6.01e-05	0.00919	0.23	0.18	Eosinophil percentage of white cells;	chr18:22967224	chr18:22699481~22933764:-
LUAD	cis	rs4578769	0.55	rs8087501	ENSG00000265943.1	RP11-739L10.1	4.05	6.01e-05	0.00919	0.23	0.18	Eosinophil percentage of white cells;	chr18:22970711	chr18:22699481~22933764:-
LUAD	cis	rs1044826	1	rs3821545	ENSG00000214280.3	RP11-553K23.2	-4.05	6.01e-05	0.00919	-0.22	-0.18	Obesity-related traits;	chr3:139464129	chr3:139582928~139583593:-
LUAD	cis	rs2880765	0.835	rs56406982	ENSG00000259416.2	RP11-158M2.5	4.05	6.01e-05	0.0092	0.19	0.18	Coronary artery disease;	chr15:85493148	chr15:85754941~85756237:-
LUAD	cis	rs7829975	0.572	rs28730413	ENSG00000253981.4	ALG1L13P	-4.05	6.01e-05	0.0092	-0.21	-0.18	Mood instability;	chr8:8937937	chr8:8236003~8244667:-
LUAD	cis	rs9987353	0.519	rs2929465	ENSG00000253893.2	FAM85B	4.05	6.01e-05	0.0092	0.23	0.18	Recombination measurement;	chr8:9206492	chr8:8167819~8226614:-
LUAD	cis	rs7005380	0.58	rs11781657	ENSG00000279347.1	RP11-85I17.2	-4.05	6.01e-05	0.0092	-0.15	-0.18	Interstitial lung disease;	chr8:119877002	chr8:119838736~119840385:-
LUAD	cis	rs9951698	0.678	rs11080620	ENSG00000267480.1	RP11-703I16.1	4.05	6.01e-05	0.0092	0.22	0.18	Intelligence (multi-trait analysis);	chr18:13029069	chr18:12031178~12032181:-
LUAD	cis	rs3120667	0.72	rs11579266	ENSG00000237975.5	FLG-AS1	4.05	6.01e-05	0.0092	0.33	0.18	Eating disorders;	chr1:152439337	chr1:152168125~152445456:+
LUAD	cis	rs6964587	0.839	rs9656002	ENSG00000188693.7	CYP51A1-AS1	4.05	6.02e-05	0.0092	0.22	0.18	Breast cancer;	chr7:91845693	chr7:92134604~92180725:+
LUAD	cis	rs365302	0.951	rs1762101	ENSG00000235086.1	FNDC1-IT1	4.05	6.02e-05	0.00921	0.24	0.18	Coronary heart disease;	chr6:159222960	chr6:159240786~159243329:+
LUAD	cis	rs365302	1	rs449385	ENSG00000235086.1	FNDC1-IT1	4.05	6.02e-05	0.00921	0.24	0.18	Coronary heart disease;	chr6:159223286	chr6:159240786~159243329:+
LUAD	cis	rs365302	1	rs444708	ENSG00000235086.1	FNDC1-IT1	4.05	6.02e-05	0.00921	0.24	0.18	Coronary heart disease;	chr6:159223798	chr6:159240786~159243329:+
LUAD	cis	rs365302	1	rs411814	ENSG00000235086.1	FNDC1-IT1	4.05	6.02e-05	0.00921	0.24	0.18	Coronary heart disease;	chr6:159223811	chr6:159240786~159243329:+
LUAD	cis	rs6951245	0.744	rs10265758	ENSG00000229043.2	AC091729.9	-4.05	6.02e-05	0.00921	-0.26	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1132882	chr7:1160374~1165267:+
LUAD	cis	rs4819052	0.851	rs1056101	ENSG00000223768.1	LINC00205	-4.05	6.02e-05	0.00921	-0.21	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258787	chr21:45293285~45297354:+
LUAD	cis	rs6840360	0.967	rs1511170	ENSG00000270265.1	RP11-731D1.4	-4.05	6.02e-05	0.00921	-0.18	-0.18	Intelligence (multi-trait analysis);	chr4:151779958	chr4:151333775~151353224:-
LUAD	cis	rs62355901	0.505	rs61193961	ENSG00000271828.1	CTD-2310F14.1	4.05	6.02e-05	0.00921	0.39	0.18	Breast cancer;	chr5:56792343	chr5:56927874~56929573:+
LUAD	cis	rs2348418	0.932	rs10843190	ENSG00000247934.4	RP11-967K21.1	4.05	6.02e-05	0.00921	0.21	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28507412	chr12:28163298~28190738:-
LUAD	cis	rs651907	0.557	rs7645391	ENSG00000244119.1	PDCL3P4	4.05	6.02e-05	0.00921	0.18	0.18	Colorectal cancer;	chr3:101642662	chr3:101712472~101713191:+
LUAD	cis	rs7216064	0.532	rs3890640	ENSG00000265055.1	AC145343.2	-4.05	6.02e-05	0.00921	-0.17	-0.18	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68056912	chr17:68096046~68101474:-
LUAD	cis	rs2904524	1	rs58974570	ENSG00000257815.4	RP11-611E13.2	-4.05	6.02e-05	0.00921	-0.27	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70363568	chr12:69904033~70243360:-
LUAD	cis	rs12216545	0.765	rs10235836	ENSG00000177590.7	GIMAP3P	4.05	6.02e-05	0.00921	0.18	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150534285	chr7:150746893~150747728:-
LUAD	cis	rs17122278	1	rs11216891	ENSG00000243431.1	RPL5P30	4.05	6.02e-05	0.00921	0.22	0.18	Total cholesterol levels;	chr11:118551519	chr11:118560690~118561580:+
LUAD	cis	rs910316	1	rs10149880	ENSG00000279594.1	RP11-950C14.10	-4.05	6.02e-05	0.00921	-0.21	-0.18	Height;	chr14:75166305	chr14:75011269~75012851:-
LUAD	cis	rs12291225	0.585	rs4757250	ENSG00000251991.1	RNU7-49P	4.05	6.02e-05	0.00921	0.2	0.18	Sense of smell;	chr11:14354137	chr11:14478892~14478953:+
LUAD	cis	rs2274273	0.563	rs79163357	ENSG00000258413.1	RP11-665C16.6	-4.05	6.03e-05	0.00922	-0.25	-0.18	Protein biomarker;	chr14:55271731	chr14:55262767~55272075:-
LUAD	cis	rs750134	0.901	rs17040894	ENSG00000257221.1	RP11-689B22.2	-4.05	6.03e-05	0.00922	-0.26	-0.18	Low high density lipoprotein cholesterol levels;	chr12:108698941	chr12:108628687~108641318:+
LUAD	cis	rs12744310	0.945	rs1343776	ENSG00000235358.1	RP11-399E6.1	4.05	6.03e-05	0.00922	0.24	0.18	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41292046	chr1:41242373~41284861:+
LUAD	cis	rs7208859	0.623	rs11657662	ENSG00000280069.1	CTD-2349P21.3	4.05	6.03e-05	0.00922	0.25	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30738182~30740275:+
LUAD	cis	rs7618501	0.519	rs3774750	ENSG00000234667.1	ACTBP13	4.05	6.03e-05	0.00922	0.2	0.18	Intelligence (multi-trait analysis);	chr3:50170973	chr3:49873347~49877980:-
LUAD	cis	rs2904524	1	rs12313398	ENSG00000257815.4	RP11-611E13.2	-4.05	6.03e-05	0.00922	-0.25	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70320891	chr12:69904033~70243360:-
LUAD	cis	rs2904524	1	rs7300901	ENSG00000257815.4	RP11-611E13.2	-4.05	6.03e-05	0.00922	-0.25	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70323451	chr12:69904033~70243360:-
LUAD	cis	rs727479	1	rs727479	ENSG00000259306.2	RP11-108K3.2	-4.05	6.03e-05	0.00922	-0.2	-0.18	Estradiol levels;	chr15:51242350	chr15:51315841~51321996:+
LUAD	cis	rs7824557	0.564	rs2572394	ENSG00000255046.1	RP11-297N6.4	4.05	6.03e-05	0.00923	0.22	0.18	Retinal vascular caliber;	chr8:11377884	chr8:11797928~11802568:-
LUAD	cis	rs2295359	1	rs4655682	ENSG00000275678.1	RP4-547N15.3	-4.05	6.04e-05	0.00923	-0.19	-0.18	Psoriasis;	chr1:67145284	chr1:67121605~67123956:-
LUAD	cis	rs651907	0.514	rs34301719	ENSG00000244119.1	PDCL3P4	4.05	6.04e-05	0.00923	0.19	0.18	Colorectal cancer;	chr3:101699149	chr3:101712472~101713191:+
LUAD	cis	rs7512552	0.809	rs2794685	ENSG00000275557.1	RP11-353N4.6	4.05	6.04e-05	0.00923	0.21	0.18	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150339792	chr1:149607765~149612402:+
LUAD	cis	rs7512552	0.839	rs1625468	ENSG00000275557.1	RP11-353N4.6	4.05	6.04e-05	0.00923	0.21	0.18	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150349010	chr1:149607765~149612402:+
LUAD	cis	rs7512552	0.78	rs2794681	ENSG00000275557.1	RP11-353N4.6	4.05	6.04e-05	0.00923	0.21	0.18	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150349475	chr1:149607765~149612402:+
LUAD	cis	rs6700559	0.595	rs11581339	ENSG00000260088.1	RP11-92G12.3	4.05	6.04e-05	0.00923	0.23	0.18	Coronary artery disease;	chr1:200686105	chr1:200669507~200694250:+
LUAD	cis	rs6479901	0.793	rs7070693	ENSG00000232075.1	MRPL35P2	-4.05	6.04e-05	0.00924	-0.26	-0.18	Intelligence (multi-trait analysis);	chr10:63256402	chr10:63634317~63634827:-
LUAD	cis	rs950169	0.579	rs11633088	ENSG00000259728.4	LINC00933	-4.05	6.04e-05	0.00924	-0.27	-0.18	Schizophrenia;	chr15:84003429	chr15:84570649~84580175:+
LUAD	cis	rs2732480	0.517	rs2634676	ENSG00000240399.1	RP1-228P16.1	4.05	6.04e-05	0.00924	0.18	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344453	chr12:48054813~48055591:-
LUAD	cis	rs6951245	0.872	rs76713558	ENSG00000199023.2	MIR339	-4.05	6.04e-05	0.00924	-0.33	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056230	chr7:1022935~1023045:-
LUAD	cis	rs6951245	0.748	rs79658522	ENSG00000199023.2	MIR339	-4.05	6.04e-05	0.00924	-0.33	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056241	chr7:1022935~1023045:-
LUAD	cis	rs6951245	0.935	rs76525951	ENSG00000199023.2	MIR339	-4.05	6.04e-05	0.00924	-0.33	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056377	chr7:1022935~1023045:-
LUAD	cis	rs6951245	1	rs79683221	ENSG00000199023.2	MIR339	-4.05	6.04e-05	0.00924	-0.33	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056503	chr7:1022935~1023045:-
LUAD	cis	rs6951245	1	rs78185801	ENSG00000199023.2	MIR339	-4.05	6.04e-05	0.00924	-0.33	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056731	chr7:1022935~1023045:-
LUAD	cis	rs8180040	1	rs807810	ENSG00000271161.1	BOLA2P2	-4.05	6.04e-05	0.00924	-0.17	-0.18	Colorectal cancer;	chr3:47362402	chr3:47499841~47500407:+
LUAD	cis	rs9309473	0.5	rs4852952	ENSG00000163016.8	ALMS1P	-4.05	6.05e-05	0.00924	-0.2	-0.18	Metabolite levels;	chr2:73642780	chr2:73644919~73685576:+
LUAD	cis	rs9309473	0.5	rs4852953	ENSG00000163016.8	ALMS1P	-4.05	6.05e-05	0.00924	-0.2	-0.18	Metabolite levels;	chr2:73642781	chr2:73644919~73685576:+
LUAD	cis	rs6125597	0.967	rs6063380	ENSG00000230758.1	SNAP23P	4.05	6.05e-05	0.00924	0.19	0.18	Intelligence (multi-trait analysis);	chr20:49265044	chr20:49038357~49038602:-
LUAD	cis	rs6125597	0.967	rs6122779	ENSG00000230758.1	SNAP23P	4.05	6.05e-05	0.00924	0.19	0.18	Intelligence (multi-trait analysis);	chr20:49276477	chr20:49038357~49038602:-
LUAD	cis	rs9467773	0.549	rs9461273	ENSG00000241549.7	GUSBP2	-4.05	6.05e-05	0.00924	-0.2	-0.18	Intelligence (multi-trait analysis);	chr6:26584298	chr6:26871484~26956554:-
LUAD	cis	rs67478160	0.619	rs10083370	ENSG00000272533.1	SNORA28	-4.05	6.05e-05	0.00924	-0.19	-0.18	Schizophrenia;	chr14:103847845	chr14:103337849~103337974:+
LUAD	cis	rs67478160	0.619	rs10083367	ENSG00000272533.1	SNORA28	-4.05	6.05e-05	0.00924	-0.19	-0.18	Schizophrenia;	chr14:103847846	chr14:103337849~103337974:+
LUAD	cis	rs1150668	0.699	rs2394049	ENSG00000176933.5	TOB2P1	-4.05	6.05e-05	0.00924	-0.2	-0.18	Pubertal anthropometrics;	chr6:28271903	chr6:28217643~28218634:-
LUAD	cis	rs7119	0.651	rs12902449	ENSG00000259362.2	RP11-307C19.1	-4.05	6.05e-05	0.00924	-0.23	-0.18	Type 2 diabetes;	chr15:77558584	chr15:77525540~77534110:+
LUAD	cis	rs7122539	0.506	rs10791896	ENSG00000213409.4	RP11-658F2.3	-4.05	6.05e-05	0.00925	-0.21	-0.18	HIV-1 susceptibility;	chr11:66921769	chr11:66761575~66762399:-
LUAD	cis	rs3213758	0.588	rs10521294	ENSG00000275191.1	RP11-36I17.2	4.05	6.05e-05	0.00925	0.31	0.18	Vitiligo (non-segmental);	chr16:53528683	chr16:53628256~53628816:-
LUAD	cis	rs338389	1	rs338389	ENSG00000260657.2	RP11-315D16.4	-4.05	6.05e-05	0.00925	-0.21	-0.18	Survival in rectal cancer;	chr15:67967670	chr15:68267792~68277994:-
LUAD	cis	rs338389	1	rs338388	ENSG00000260657.2	RP11-315D16.4	-4.05	6.05e-05	0.00925	-0.21	-0.18	Survival in rectal cancer;	chr15:67967876	chr15:68267792~68277994:-
LUAD	cis	rs9393777	0.92	rs66462181	ENSG00000219392.1	RP1-265C24.5	-4.05	6.05e-05	0.00925	-0.42	-0.18	Intelligence (multi-trait analysis);	chr6:27123882	chr6:28115628~28116551:+
LUAD	cis	rs6951245	1	rs11763793	ENSG00000199023.2	MIR339	-4.05	6.05e-05	0.00925	-0.33	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054706	chr7:1022935~1023045:-
LUAD	cis	rs6951245	1	rs11763835	ENSG00000199023.2	MIR339	-4.05	6.05e-05	0.00925	-0.33	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054877	chr7:1022935~1023045:-
LUAD	cis	rs6951245	1	rs78861357	ENSG00000199023.2	MIR339	-4.05	6.05e-05	0.00925	-0.33	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1055782	chr7:1022935~1023045:-
LUAD	cis	rs8098244	0.706	rs6508004	ENSG00000264745.1	TTC39C-AS1	4.05	6.06e-05	0.00925	0.19	0.18	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23884153	chr18:23994213~24015339:-
LUAD	cis	rs2333021	0.934	rs12879195	ENSG00000259015.1	RP11-109N23.6	4.05	6.06e-05	0.00926	0.17	0.18	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73006248	chr14:72960595~72961993:+
LUAD	cis	rs17772222	0.74	rs10138139	ENSG00000258983.2	RP11-507K2.2	4.05	6.06e-05	0.00926	0.21	0.18	Coronary artery calcification;	chr14:88510027	chr14:88499334~88515502:+
LUAD	cis	rs2273156	0.517	rs7159324	ENSG00000226677.3	IGBP1P1	4.05	6.06e-05	0.00926	0.27	0.18	Immunoglobulin light chain (AL) amyloidosis;	chr14:35157791	chr14:34939324~34940332:+
LUAD	cis	rs11048434	0.518	rs17730331	ENSG00000256937.1	KRT17P8	-4.05	6.06e-05	0.00926	-0.2	-0.18	Sjögren's syndrome;	chr12:9025836	chr12:9127783~9128645:+
LUAD	cis	rs4811196	0.748	rs6068052	ENSG00000226144.2	RPS27AP3	-4.05	6.06e-05	0.00926	-0.2	-0.18	Bone mineral density;	chr20:37890001	chr20:37049254~37049707:+
LUAD	cis	rs4925386	1	rs6089351	ENSG00000273619.1	RP5-908M14.9	4.05	6.06e-05	0.00926	0.17	0.18	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62341097	chr20:62386303~62386970:-
LUAD	cis	rs9860428	0.844	rs6763318	ENSG00000242770.2	RP11-180K7.1	-4.05	6.06e-05	0.00926	-0.2	-0.18	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112848305	chr3:112802478~112812819:+
LUAD	cis	rs7247513	0.701	rs8107642	ENSG00000230310.1	CTD-2192J16.11	-4.05	6.06e-05	0.00926	-0.2	-0.18	Bipolar disorder;	chr19:12655556	chr19:12552597~12553644:+
LUAD	cis	rs7429990	0.965	rs4858887	ENSG00000228638.1	FCF1P2	4.05	6.06e-05	0.00926	0.22	0.18	Educational attainment (years of education);	chr3:48050527	chr3:48290793~48291375:-
LUAD	cis	rs853679	0.546	rs71537572	ENSG00000219392.1	RP1-265C24.5	-4.05	6.06e-05	0.00926	-0.4	-0.18	Depression;	chr6:28002937	chr6:28115628~28116551:+
LUAD	cis	rs2057178	0.929	rs7121219	ENSG00000183242.10	WT1-AS	4.05	6.06e-05	0.00927	0.27	0.18	Tuberculosis;	chr11:32320971	chr11:32435518~32458769:+
LUAD	cis	rs9467773	1	rs9295695	ENSG00000261353.1	CTA-14H9.5	4.05	6.07e-05	0.00927	0.2	0.18	Intelligence (multi-trait analysis);	chr6:26528022	chr6:26527063~26527404:+
LUAD	cis	rs7688540	0.8	rs9328738	ENSG00000211553.1	AC253576.2	4.05	6.07e-05	0.00927	0.23	0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:284407	chr4:136461~136568:+
LUAD	cis	rs17772222	0.917	rs17260415	ENSG00000258789.1	RP11-507K2.3	-4.05	6.07e-05	0.00927	-0.25	-0.18	Coronary artery calcification;	chr14:88745629	chr14:88551597~88552493:+
LUAD	cis	rs4474465	0.915	rs10899512	ENSG00000251323.2	RP11-452H21.4	4.05	6.07e-05	0.00927	0.22	0.18	Alzheimer's disease (survival time);	chr11:78460292	chr11:78423982~78429836:-
LUAD	cis	rs957448	0.554	rs10956919	ENSG00000253175.1	RP11-267M23.6	4.05	6.07e-05	0.00927	0.2	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94572945	chr8:94565036~94565715:+
LUAD	cis	rs2735413	0.881	rs11150036	ENSG00000276007.1	RP11-358L22.3	-4.05	6.07e-05	0.00927	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78041790	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.918	rs11150037	ENSG00000276007.1	RP11-358L22.3	-4.05	6.07e-05	0.00927	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78041877	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.918	rs4888725	ENSG00000276007.1	RP11-358L22.3	-4.05	6.07e-05	0.00927	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78042864	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.881	rs4888727	ENSG00000276007.1	RP11-358L22.3	-4.05	6.07e-05	0.00927	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78043141	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.918	rs36068555	ENSG00000276007.1	RP11-358L22.3	-4.05	6.07e-05	0.00927	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78043185	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.918	rs4888728	ENSG00000276007.1	RP11-358L22.3	-4.05	6.07e-05	0.00927	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78043302	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.813	rs11644471	ENSG00000276007.1	RP11-358L22.3	-4.05	6.07e-05	0.00927	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78043340	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.781	rs11649473	ENSG00000276007.1	RP11-358L22.3	-4.05	6.07e-05	0.00927	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78043341	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.918	rs7190752	ENSG00000276007.1	RP11-358L22.3	-4.05	6.07e-05	0.00927	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78043533	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.918	rs2344494	ENSG00000276007.1	RP11-358L22.3	-4.05	6.07e-05	0.00927	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78044214	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.918	rs12598024	ENSG00000276007.1	RP11-358L22.3	-4.05	6.07e-05	0.00927	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78045217	chr16:78123243~78124332:+
LUAD	cis	rs847577	0.569	rs2394817	ENSG00000272950.1	RP11-307C18.1	4.05	6.07e-05	0.00927	0.23	0.18	Breast cancer;	chr7:98061126	chr7:98322853~98323430:+
LUAD	cis	rs7191700	0.511	rs243330	ENSG00000262703.1	RP11-485G7.6	4.05	6.07e-05	0.00927	0.17	0.18	Multiple sclerosis;	chr16:11257134	chr16:11348143~11349321:-
LUAD	cis	rs7208859	0.524	rs59923796	ENSG00000280069.1	CTD-2349P21.3	-4.05	6.07e-05	0.00927	-0.25	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737901	chr17:30738182~30740275:+
LUAD	cis	rs17826219	0.5	rs57005940	ENSG00000280069.1	CTD-2349P21.3	-4.05	6.07e-05	0.00927	-0.25	-0.18	Body mass index;	chr17:30739311	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.573	rs73267872	ENSG00000280069.1	CTD-2349P21.3	-4.05	6.07e-05	0.00927	-0.25	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30740189	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs56812022	ENSG00000280069.1	CTD-2349P21.3	-4.05	6.07e-05	0.00927	-0.25	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741715	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.524	rs57670615	ENSG00000280069.1	CTD-2349P21.3	-4.05	6.07e-05	0.00927	-0.25	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30742480	chr17:30738182~30740275:+
LUAD	cis	rs17826219	0.5	rs2874724	ENSG00000280069.1	CTD-2349P21.3	-4.05	6.07e-05	0.00927	-0.25	-0.18	Body mass index;	chr17:30745415	chr17:30738182~30740275:+
LUAD	cis	rs17826219	0.568	rs9898097	ENSG00000280069.1	CTD-2349P21.3	-4.05	6.07e-05	0.00927	-0.25	-0.18	Body mass index;	chr17:30745654	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs9911490	ENSG00000280069.1	CTD-2349P21.3	-4.05	6.07e-05	0.00927	-0.25	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30745995	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs7503542	ENSG00000280069.1	CTD-2349P21.3	-4.05	6.07e-05	0.00927	-0.25	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746812	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.573	rs11656278	ENSG00000280069.1	CTD-2349P21.3	-4.05	6.07e-05	0.00927	-0.25	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748170	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs6505207	ENSG00000280069.1	CTD-2349P21.3	-4.05	6.07e-05	0.00927	-0.25	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749553	chr17:30738182~30740275:+
LUAD	cis	rs4819052	0.851	rs8127834	ENSG00000223768.1	LINC00205	-4.05	6.07e-05	0.00927	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45276194	chr21:45293285~45297354:+
LUAD	cis	rs16873450	0.527	rs7792188	ENSG00000234800.2	PCMTD1P3	-4.05	6.07e-05	0.00928	-0.2	-0.18	Verbal memory performance (residualized delayed recall level);	chr7:23790140	chr7:23721311~23721782:-
LUAD	cis	rs1387259	0.929	rs11168460	ENSG00000257763.1	OR5BK1P	4.05	6.07e-05	0.00928	0.19	0.18	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48203582	chr12:48355792~48356614:-
LUAD	cis	rs7129556	0.737	rs2154972	ENSG00000241782.1	RP11-91P24.1	4.05	6.07e-05	0.00928	0.25	0.18	Weight loss (gastric bypass surgery);	chr11:77777779	chr11:77868722~77869195:-
LUAD	cis	rs7129556	0.701	rs4945220	ENSG00000241782.1	RP11-91P24.1	-4.05	6.07e-05	0.00928	-0.25	-0.18	Weight loss (gastric bypass surgery);	chr11:77817115	chr11:77868722~77869195:-
LUAD	cis	rs7129556	0.737	rs7951033	ENSG00000241782.1	RP11-91P24.1	-4.05	6.07e-05	0.00928	-0.25	-0.18	Weight loss (gastric bypass surgery);	chr11:77823398	chr11:77868722~77869195:-
LUAD	cis	rs7129556	0.737	rs614495	ENSG00000241782.1	RP11-91P24.1	4.05	6.07e-05	0.00928	0.25	0.18	Weight loss (gastric bypass surgery);	chr11:77825840	chr11:77868722~77869195:-
LUAD	cis	rs7204230	1	rs62048052	ENSG00000261291.1	RP11-295M3.2	4.05	6.08e-05	0.00928	0.22	0.18	Fibrinogen;	chr16:53206497	chr16:53168522~53169450:+
LUAD	cis	rs2098713	0.569	rs55758014	ENSG00000250155.1	CTD-2353F22.1	4.05	6.08e-05	0.00928	0.2	0.18	Telomere length;	chr5:37565674	chr5:36666214~36725195:-
LUAD	cis	rs6661961	0.752	rs7548609	ENSG00000237975.5	FLG-AS1	-4.05	6.08e-05	0.00928	-0.24	-0.18	Atopic dermatitis;	chr1:152457705	chr1:152168125~152445456:+
LUAD	cis	rs6661961	0.752	rs4845438	ENSG00000237975.5	FLG-AS1	-4.05	6.08e-05	0.00928	-0.24	-0.18	Atopic dermatitis;	chr1:152458037	chr1:152168125~152445456:+
LUAD	cis	rs853679	0.517	rs7755442	ENSG00000226314.6	ZNF192P1	-4.05	6.08e-05	0.00928	-0.24	-0.18	Depression;	chr6:28071237	chr6:28161781~28169594:+
LUAD	cis	rs2657294	0.796	rs1259499	ENSG00000233313.2	HMGA1P5	-4.05	6.08e-05	0.00929	-0.23	-0.18	Pneumonia;	chr10:75228308	chr10:75276376~75276646:-
LUAD	cis	rs7172677	1	rs55662404	ENSG00000260269.4	CTD-2323K18.1	4.05	6.08e-05	0.00929	0.25	0.18	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75140000	chr15:75527150~75601205:-
LUAD	cis	rs858239	1	rs199347	ENSG00000230042.1	AK3P3	-4.05	6.09e-05	0.00929	-0.22	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23254127	chr7:23129178~23129841:+
LUAD	cis	rs4819052	0.918	rs34886433	ENSG00000223768.1	LINC00205	-4.05	6.09e-05	0.00929	-0.24	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260623	chr21:45293285~45297354:+
LUAD	cis	rs3018712	0.59	rs10791992	ENSG00000227620.4	ALG1L8P	-4.05	6.09e-05	0.0093	-0.25	-0.18	Total body bone mineral density;	chr11:68721705	chr11:67785273~67792335:+
LUAD	cis	rs4934494	0.727	rs1590566	ENSG00000240996.1	RP11-80H5.7	-4.05	6.09e-05	0.0093	-0.24	-0.18	Red blood cell count;	chr10:89778781	chr10:89694295~89697928:-
LUAD	cis	rs11644601	1	rs11644601	ENSG00000260735.1	RP11-72I8.1	-4.05	6.09e-05	0.0093	-0.21	-0.18	Metabolite levels (lipid measures);	chr16:15078261	chr16:15094411~15109197:+
LUAD	cis	rs4819052	0.851	rs7276828	ENSG00000237664.1	LINC00316	-4.05	6.09e-05	0.0093	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275124	chr21:45338590~45341990:-
LUAD	cis	rs4819052	0.851	rs7281263	ENSG00000237664.1	LINC00316	-4.05	6.09e-05	0.0093	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275691	chr21:45338590~45341990:-
LUAD	cis	rs1431005	1	rs72723294	ENSG00000250658.1	RP11-138B4.1	4.05	6.09e-05	0.0093	0.23	0.18	Response to statin therapy;	chr4:187426641	chr4:187304083~187309682:-
LUAD	cis	rs219780	0.784	rs219778	ENSG00000230479.1	AP000695.6	4.05	6.09e-05	0.0093	0.21	0.18	Kidney stones;	chr21:36462343	chr21:36430360~36481070:+
LUAD	cis	rs219780	0.784	rs219776	ENSG00000230479.1	AP000695.6	4.05	6.09e-05	0.0093	0.21	0.18	Kidney stones;	chr21:36462537	chr21:36430360~36481070:+
LUAD	cis	rs219780	0.75	rs2835363	ENSG00000230479.1	AP000695.6	4.05	6.09e-05	0.0093	0.21	0.18	Kidney stones;	chr21:36462616	chr21:36430360~36481070:+
LUAD	cis	rs219780	0.75	rs219775	ENSG00000230479.1	AP000695.6	4.05	6.09e-05	0.0093	0.21	0.18	Kidney stones;	chr21:36462646	chr21:36430360~36481070:+
LUAD	cis	rs2380205	0.689	rs12769593	ENSG00000232807.2	RP11-536K7.3	4.05	6.09e-05	0.0093	0.2	0.18	Breast cancer;	chr10:5856030	chr10:5934270~5945900:-
LUAD	cis	rs78487399	0.808	rs75386849	ENSG00000234936.1	AC010883.5	4.05	6.09e-05	0.0093	0.27	0.18	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43496144	chr2:43229573~43233394:+
LUAD	cis	rs1979679	0.65	rs3963302	ENSG00000278733.1	RP11-425D17.1	4.05	6.09e-05	0.0093	0.26	0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28367813	chr12:28185625~28186190:-
LUAD	cis	rs7762018	1	rs11961560	ENSG00000231690.2	LINC00574	-4.04	6.09e-05	0.0093	-0.34	-0.18	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169730025	chr6:169790321~169802873:+
LUAD	cis	rs6087771	0.89	rs6089056	ENSG00000230613.1	HM13-AS1	4.04	6.1e-05	0.00931	0.22	0.18	Putamen volume;Subcortical brain region volumes;	chr20:31737970	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.559	rs6060919	ENSG00000230613.1	HM13-AS1	4.04	6.1e-05	0.00931	0.22	0.18	Mean corpuscular hemoglobin;	chr20:31744119	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.559	rs6060922	ENSG00000230613.1	HM13-AS1	4.04	6.1e-05	0.00931	0.22	0.18	Mean corpuscular hemoglobin;	chr20:31746106	chr20:31567707~31573263:-
LUAD	cis	rs7202877	0.61	rs7202284	ENSG00000280152.1	RP11-331F4.5	4.04	6.1e-05	0.00931	0.21	0.18	Type 1 diabetes;Type 2 diabetes;	chr16:75340448	chr16:75245994~75250077:-
LUAD	cis	rs80028505	0.908	rs56133220	ENSG00000271304.1	DPRXP2	4.04	6.1e-05	0.00931	0.33	0.18	Foot ulcer in diabetes and neuropathy;	chr6:36064891	chr6:35989515~35990436:-
LUAD	cis	rs853679	0.517	rs2273564	ENSG00000226314.6	ZNF192P1	-4.04	6.1e-05	0.00931	-0.24	-0.18	Depression;	chr6:28089816	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs1853097	ENSG00000226314.6	ZNF192P1	-4.04	6.1e-05	0.00931	-0.24	-0.18	Depression;	chr6:28090857	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs9393887	ENSG00000226314.6	ZNF192P1	-4.04	6.1e-05	0.00931	-0.24	-0.18	Depression;	chr6:28091242	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs9393888	ENSG00000226314.6	ZNF192P1	-4.04	6.1e-05	0.00931	-0.24	-0.18	Depression;	chr6:28091439	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs3734573	ENSG00000226314.6	ZNF192P1	-4.04	6.1e-05	0.00931	-0.24	-0.18	Depression;	chr6:28091659	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs9357063	ENSG00000226314.6	ZNF192P1	-4.04	6.1e-05	0.00931	-0.24	-0.18	Depression;	chr6:28092227	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs3823180	ENSG00000226314.6	ZNF192P1	-4.04	6.1e-05	0.00931	-0.24	-0.18	Depression;	chr6:28093966	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs9368551	ENSG00000226314.6	ZNF192P1	-4.04	6.1e-05	0.00931	-0.24	-0.18	Depression;	chr6:28094014	chr6:28161781~28169594:+
LUAD	cis	rs780096	0.526	rs780117	ENSG00000234072.1	AC074117.10	-4.04	6.1e-05	0.00931	-0.14	-0.18	Total body bone mineral density;	chr2:27475476	chr2:27356246~27367622:+
LUAD	cis	rs4934494	0.768	rs768805	ENSG00000240996.1	RP11-80H5.7	-4.04	6.1e-05	0.00931	-0.25	-0.18	Red blood cell count;	chr10:89695448	chr10:89694295~89697928:-
LUAD	cis	rs8062405	0.723	rs4788079	ENSG00000261419.1	RP11-57A19.4	-4.04	6.1e-05	0.00931	-0.2	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28659696~28740781:-
LUAD	cis	rs12073359	0.955	rs7521768	ENSG00000223945.2	RP11-458I7.1	4.04	6.1e-05	0.00931	0.26	0.18	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150170954	chr1:150053864~150055034:+
LUAD	cis	rs794185	0.592	rs304078	ENSG00000231249.1	ITPR1-AS1	-4.04	6.1e-05	0.00931	-0.2	-0.18	Multiple sclerosis--Brain Glutamate Levels;	chr3:4491474	chr3:4490891~4493163:-
LUAD	cis	rs12073837	0.5	rs4143772	ENSG00000238078.1	LINC01352	-4.04	6.1e-05	0.00931	-0.19	-0.18	F-cell distribution;	chr1:220815004	chr1:220829255~220832429:+
LUAD	cis	rs448720	0.684	rs2448134	ENSG00000260657.2	RP11-315D16.4	-4.04	6.11e-05	0.00932	-0.2	-0.18	Cognitive performance;	chr15:67930702	chr15:68267792~68277994:-
LUAD	cis	rs3177980	0.632	rs1062976	ENSG00000239494.2	RN7SL333P	-4.04	6.11e-05	0.00932	-0.18	-0.18	Amyotrophic lateral sclerosis;	chr1:169854519	chr1:169859756~169860052:+
LUAD	cis	rs858239	1	rs858240	ENSG00000230042.1	AK3P3	-4.04	6.11e-05	0.00932	-0.22	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23129178~23129841:+
LUAD	cis	rs812925	0.859	rs2593624	ENSG00000271889.1	RP11-493E12.1	-4.04	6.11e-05	0.00932	-0.23	-0.18	Immature fraction of reticulocytes;	chr2:61325349	chr2:61151433~61162105:-
LUAD	cis	rs365302	0.951	rs439251	ENSG00000235086.1	FNDC1-IT1	4.04	6.11e-05	0.00932	0.24	0.18	Coronary heart disease;	chr6:159223166	chr6:159240786~159243329:+
LUAD	cis	rs4873772	0.735	rs12544329	ENSG00000253330.1	RP11-697N18.3	-4.04	6.11e-05	0.00932	-0.21	-0.18	Lobe attachment (rater-scored or self-reported);	chr8:47511278	chr8:47511034~47512141:-
LUAD	cis	rs17597773	0.635	rs1494368	ENSG00000272823.1	RP11-295M18.6	-4.04	6.11e-05	0.00933	-0.24	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220830826	chr1:220828676~220829211:-
LUAD	cis	rs34779708	0.931	rs12261654	ENSG00000271335.4	RP11-324I22.4	4.04	6.11e-05	0.00933	0.19	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35033096	chr10:35314552~35336401:-
LUAD	cis	rs6565180	0.926	rs8046445	ENSG00000273724.1	RP11-347C12.12	-4.04	6.11e-05	0.00933	-0.19	-0.18	Tonsillectomy;	chr16:30374941	chr16:30336400~30343336:+
LUAD	cis	rs4819052	1	rs733738	ENSG00000223768.1	LINC00205	4.04	6.11e-05	0.00933	0.23	0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246481	chr21:45293285~45297354:+
LUAD	cis	rs61160187	0.517	rs7709522	ENSG00000215032.2	GNL3LP1	4.04	6.11e-05	0.00933	0.22	0.18	Educational attainment (years of education);Educational attainment (college completion);	chr5:61022188	chr5:60891935~60893577:-
LUAD	cis	rs8050896	1	rs9926258	ENSG00000260695.1	RP11-513N24.1	-4.04	6.12e-05	0.00933	-0.32	-0.18	Response to antipsychotic treatment;	chr16:66120526	chr16:65861112~65863784:-
LUAD	cis	rs17122278	1	rs3825055	ENSG00000243431.1	RPL5P30	4.04	6.12e-05	0.00933	0.22	0.18	Total cholesterol levels;	chr11:118545358	chr11:118560690~118561580:+
LUAD	cis	rs858239	0.669	rs1990365	ENSG00000230042.1	AK3P3	-4.04	6.12e-05	0.00933	-0.22	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23076347	chr7:23129178~23129841:+
LUAD	cis	rs10129255	1	rs10134517	ENSG00000211967.3	IGHV3-53	-4.04	6.12e-05	0.00933	-0.14	-0.18	Kawasaki disease;	chr14:106718498	chr14:106592676~106593347:-
LUAD	cis	rs7617773	0.78	rs71323396	ENSG00000199476.1	Y_RNA	-4.04	6.12e-05	0.00933	-0.24	-0.18	Coronary artery disease;	chr3:48333244	chr3:48288587~48288694:+
LUAD	cis	rs2439831	0.85	rs67541383	ENSG00000249839.1	AC011330.5	-4.04	6.12e-05	0.00933	-0.43	-0.18	Lung cancer in ever smokers;	chr15:43880350	chr15:43663654~43684339:-
LUAD	cis	rs853679	0.517	rs12174753	ENSG00000280107.1	AL022393.9	-4.04	6.12e-05	0.00934	-0.24	-0.18	Depression;	chr6:28074687	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs55747925	ENSG00000280107.1	AL022393.9	-4.04	6.12e-05	0.00934	-0.24	-0.18	Depression;	chr6:28076559	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs56310871	ENSG00000280107.1	AL022393.9	-4.04	6.12e-05	0.00934	-0.24	-0.18	Depression;	chr6:28076704	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs34716816	ENSG00000280107.1	AL022393.9	-4.04	6.12e-05	0.00934	-0.24	-0.18	Depression;	chr6:28078391	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs9393884	ENSG00000280107.1	AL022393.9	-4.04	6.12e-05	0.00934	-0.24	-0.18	Depression;	chr6:28079011	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs9380049	ENSG00000280107.1	AL022393.9	-4.04	6.12e-05	0.00934	-0.24	-0.18	Depression;	chr6:28080757	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs9380050	ENSG00000280107.1	AL022393.9	-4.04	6.12e-05	0.00934	-0.24	-0.18	Depression;	chr6:28080760	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs9393885	ENSG00000280107.1	AL022393.9	-4.04	6.12e-05	0.00934	-0.24	-0.18	Depression;	chr6:28082231	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs9393886	ENSG00000280107.1	AL022393.9	-4.04	6.12e-05	0.00934	-0.24	-0.18	Depression;	chr6:28082261	chr6:28170845~28172521:+
LUAD	cis	rs4713118	0.515	rs9368549	ENSG00000280107.1	AL022393.9	-4.04	6.12e-05	0.00934	-0.24	-0.18	Parkinson's disease;	chr6:28082269	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs56364346	ENSG00000280107.1	AL022393.9	-4.04	6.12e-05	0.00934	-0.24	-0.18	Depression;	chr6:28082984	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs9357061	ENSG00000280107.1	AL022393.9	-4.04	6.12e-05	0.00934	-0.24	-0.18	Depression;	chr6:28083994	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs9368550	ENSG00000280107.1	AL022393.9	-4.04	6.12e-05	0.00934	-0.24	-0.18	Depression;	chr6:28084025	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.542	rs2295594	ENSG00000280107.1	AL022393.9	-4.04	6.12e-05	0.00934	-0.24	-0.18	Depression;	chr6:28085319	chr6:28170845~28172521:+
LUAD	cis	rs854765	0.647	rs2056842	ENSG00000223979.2	SMCR2	-4.04	6.12e-05	0.00934	-0.21	-0.18	Total body bone mineral density;	chr17:18105714	chr17:17674026~17677688:-
LUAD	cis	rs6969780	0.915	rs886339	ENSG00000233429.8	HOTAIRM1	-4.04	6.12e-05	0.00934	-0.3	-0.18	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27151051	chr7:27095647~27100265:+
LUAD	cis	rs4819052	1	rs9984901	ENSG00000237664.1	LINC00316	-4.04	6.12e-05	0.00934	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244037	chr21:45338590~45341990:-
LUAD	cis	rs10771431	0.597	rs7976807	ENSG00000111788.10	RP11-22B23.1	4.04	6.13e-05	0.00934	0.16	0.18	Breast size;	chr12:9199863	chr12:9277235~9313241:+
LUAD	cis	rs11742741	0.765	rs6862766	ENSG00000248874.4	C5orf17	-4.04	6.13e-05	0.00934	-0.23	-0.18	Educational attainment;	chr5:24156823	chr5:23951348~24178263:+
LUAD	cis	rs77204473	0.549	rs12280210	ENSG00000280143.1	AP000892.6	-4.04	6.13e-05	0.00935	-0.31	-0.18	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117069733	chr11:117204967~117210292:+
LUAD	cis	rs77972916	0.517	rs17406126	ENSG00000234936.1	AC010883.5	4.04	6.13e-05	0.00935	0.25	0.18	Granulocyte percentage of myeloid white cells;	chr2:43319493	chr2:43229573~43233394:+
LUAD	cis	rs34421088	0.548	rs2618443	ENSG00000255046.1	RP11-297N6.4	4.04	6.13e-05	0.00935	0.22	0.18	Neuroticism;	chr8:11527047	chr8:11797928~11802568:-
LUAD	cis	rs11992162	0.56	rs13276386	ENSG00000255046.1	RP11-297N6.4	-4.04	6.13e-05	0.00935	-0.22	-0.18	Monocyte count;	chr8:11939912	chr8:11797928~11802568:-
LUAD	cis	rs256438	0.93	rs2438640	ENSG00000251050.1	RP11-168A11.4	-4.04	6.13e-05	0.00935	-0.19	-0.18	Serum thyroid-stimulating hormone levels;	chr5:80093861	chr5:80019609~80019920:+
LUAD	cis	rs4372836	1	rs7579277	ENSG00000226833.4	AC097724.3	4.04	6.13e-05	0.00935	0.21	0.18	Body mass index;	chr2:28773429	chr2:28708953~28736205:-
LUAD	cis	rs10429558	0.619	rs78174934	ENSG00000227603.1	RP11-165J3.6	4.04	6.13e-05	0.00935	0.4	0.18	Neuroticism;	chr9:93627397	chr9:93435332~93437121:-
LUAD	cis	rs10429558	0.619	rs111522793	ENSG00000227603.1	RP11-165J3.6	4.04	6.13e-05	0.00935	0.4	0.18	Neuroticism;	chr9:93627518	chr9:93435332~93437121:-
LUAD	cis	rs17301013	0.932	rs1653626	ENSG00000227373.4	RP11-160H22.5	-4.04	6.13e-05	0.00935	-0.23	-0.18	Systemic lupus erythematosus;	chr1:174770348	chr1:174115300~174160004:-
LUAD	cis	rs7107174	0.901	rs2450138	ENSG00000251323.2	RP11-452H21.4	4.04	6.13e-05	0.00935	0.24	0.18	Testicular germ cell tumor;	chr11:78213824	chr11:78423982~78429836:-
LUAD	cis	rs4879677	1	rs12237023	ENSG00000215441.3	CTAGE12P	-4.04	6.13e-05	0.00936	-0.22	-0.18	Gut microbiome composition (summer and winter);	chr9:27674972	chr9:27608382~27610745:-
LUAD	cis	rs2348418	0.832	rs11611406	ENSG00000247934.4	RP11-967K21.1	4.04	6.13e-05	0.00936	0.21	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28310910	chr12:28163298~28190738:-
LUAD	cis	rs2348418	0.832	rs11611382	ENSG00000247934.4	RP11-967K21.1	4.04	6.13e-05	0.00936	0.21	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28310959	chr12:28163298~28190738:-
LUAD	cis	rs763121	0.853	rs4821808	ENSG00000228274.3	RP3-508I15.9	-4.04	6.14e-05	0.00936	-0.18	-0.18	Menopause (age at onset);	chr22:38669734	chr22:38667585~38681820:-
LUAD	cis	rs763121	0.853	rs4821809	ENSG00000228274.3	RP3-508I15.9	-4.04	6.14e-05	0.00936	-0.18	-0.18	Menopause (age at onset);	chr22:38669738	chr22:38667585~38681820:-
LUAD	cis	rs4819052	0.851	rs2838858	ENSG00000237664.1	LINC00316	-4.04	6.14e-05	0.00936	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261178	chr21:45338590~45341990:-
LUAD	cis	rs10463554	0.963	rs34777	ENSG00000250682.4	LINC00491	4.04	6.14e-05	0.00936	0.22	0.18	Parkinson's disease;	chr5:103116554	chr5:102609156~102671559:-
LUAD	cis	rs12935418	0.583	rs2549856	ENSG00000261061.1	RP11-303E16.2	4.04	6.14e-05	0.00936	0.19	0.18	Mean corpuscular volume;	chr16:80993322	chr16:81030770~81031485:+
LUAD	cis	rs8046148	0.789	rs6500285	ENSG00000279356.1	RP11-429P3.8	-4.04	6.14e-05	0.00936	-0.19	-0.18	Testicular germ cell tumor;	chr16:50112742	chr16:50072862~50074986:+
LUAD	cis	rs763121	0.853	rs4821812	ENSG00000228274.3	RP3-508I15.9	-4.04	6.14e-05	0.00937	-0.18	-0.18	Menopause (age at onset);	chr22:38679230	chr22:38667585~38681820:-
LUAD	cis	rs763121	0.853	rs9607566	ENSG00000228274.3	RP3-508I15.9	-4.04	6.14e-05	0.00937	-0.18	-0.18	Menopause (age at onset);	chr22:38679429	chr22:38667585~38681820:-
LUAD	cis	rs1056107	0.763	rs10759529	ENSG00000225513.1	RP11-165N19.2	-4.04	6.14e-05	0.00937	-0.2	-0.18	Colorectal cancer;	chr9:112176651	chr9:112173522~112173971:-
LUAD	cis	rs8048589	0.898	rs8063329	ENSG00000175604.2	RP11-276H1.3	-4.04	6.14e-05	0.00937	-0.25	-0.18	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12092190	chr16:12086746~12090302:-
LUAD	cis	rs9925964	0.933	rs11150604	ENSG00000232748.3	RP11-196G11.6	4.04	6.14e-05	0.00937	0.22	0.18	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31025699	chr16:31056460~31062803:+
LUAD	cis	rs11955398	0.502	rs158914	ENSG00000272308.1	RP11-231G3.1	4.04	6.14e-05	0.00937	0.2	0.18	Intelligence (multi-trait analysis);	chr5:60950582	chr5:60866457~60866935:-
LUAD	cis	rs7829975	0.777	rs560544	ENSG00000253981.4	ALG1L13P	-4.04	6.15e-05	0.00937	-0.21	-0.18	Mood instability;	chr8:8779919	chr8:8236003~8244667:-
LUAD	cis	rs10197140	0.925	rs10208020	ENSG00000235721.1	AC013268.3	-4.04	6.15e-05	0.00937	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110871159	chr2:110007675~110010783:+
LUAD	cis	rs2562152	0.613	rs216599	ENSG00000226942.2	IL9RP3	-4.04	6.15e-05	0.00937	-0.27	-0.18	Glioblastoma;	chr16:59673	chr16:29336~38321:-
LUAD	cis	rs7712401	0.511	rs30068	ENSG00000263432.2	RN7SL689P	4.04	6.15e-05	0.00937	0.21	0.18	Mean platelet volume;	chr5:122957914	chr5:123022487~123022783:-
LUAD	cis	rs800160	1	rs2651807	ENSG00000236264.4	RPL26P30	-4.04	6.15e-05	0.00937	-0.24	-0.18	Bacteremia;	chr11:2357610	chr11:2335132~2335776:-
LUAD	cis	rs800160	1	rs1088987	ENSG00000236264.4	RPL26P30	-4.04	6.15e-05	0.00937	-0.24	-0.18	Bacteremia;	chr11:2357966	chr11:2335132~2335776:-
LUAD	cis	rs9652601	0.843	rs7204643	ENSG00000274038.1	RP11-66H6.4	4.04	6.15e-05	0.00937	0.22	0.18	Systemic lupus erythematosus;	chr16:11073746	chr16:11056556~11057034:+
LUAD	cis	rs8062405	0.755	rs4788080	ENSG00000251417.2	RP11-1348G14.4	-4.04	6.15e-05	0.00937	-0.18	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28802743~28817828:+
LUAD	cis	rs9952991	0.654	rs12969241	ENSG00000260302.1	RP11-973H7.1	4.04	6.15e-05	0.00937	0.39	0.18	Inflammatory skin disease;	chr18:12842481	chr18:12774651~12775923:-
LUAD	cis	rs9952991	0.654	rs35967540	ENSG00000260302.1	RP11-973H7.1	4.04	6.15e-05	0.00937	0.39	0.18	Inflammatory skin disease;	chr18:12842568	chr18:12774651~12775923:-
LUAD	cis	rs9952991	0.654	rs35320197	ENSG00000260302.1	RP11-973H7.1	4.04	6.15e-05	0.00937	0.39	0.18	Inflammatory skin disease;	chr18:12842682	chr18:12774651~12775923:-
LUAD	cis	rs73193808	0.851	rs2018158	ENSG00000215533.7	LINC00189	-4.04	6.15e-05	0.00937	-0.26	-0.18	Coronary artery disease;	chr21:29216482	chr21:29193480~29288205:+
LUAD	cis	rs9287719	0.967	rs6432112	ENSG00000243819.4	RN7SL832P	-4.04	6.15e-05	0.00937	-0.19	-0.18	Prostate cancer;	chr2:10604748	chr2:10690344~10692099:+
LUAD	cis	rs939960	0.69	rs34585329	ENSG00000279536.1	RP11-445N20.2	4.04	6.15e-05	0.00938	0.24	0.18	Neutrophil percentage of white cells;	chr7:150664849	chr7:149881477~149882105:+
LUAD	cis	rs13113518	0.934	rs10866425	ENSG00000272969.1	RP11-528I4.2	4.04	6.15e-05	0.00938	0.19	0.18	Height;	chr4:55582068	chr4:55547112~55547889:+
LUAD	cis	rs4474465	1	rs11237509	ENSG00000251323.2	RP11-452H21.4	4.04	6.15e-05	0.00938	0.22	0.18	Alzheimer's disease (survival time);	chr11:78462393	chr11:78423982~78429836:-
LUAD	cis	rs11955398	0.502	rs10052649	ENSG00000272308.1	RP11-231G3.1	4.04	6.15e-05	0.00938	0.21	0.18	Intelligence (multi-trait analysis);	chr5:60859157	chr5:60866457~60866935:-
LUAD	cis	rs10938353	0.731	rs17600732	ENSG00000273369.1	RP11-700J17.1	-4.04	6.15e-05	0.00938	-0.26	-0.18	Body mass index;	chr4:44619710	chr4:44693946~44694386:-
LUAD	cis	rs9847710	0.967	rs2581824	ENSG00000242142.1	SERBP1P3	-4.04	6.15e-05	0.00938	-0.19	-0.18	Ulcerative colitis;	chr3:52988392	chr3:53064283~53065091:-
LUAD	cis	rs6840360	0.571	rs4696273	ENSG00000270265.1	RP11-731D1.4	-4.04	6.16e-05	0.00938	-0.21	-0.18	Intelligence (multi-trait analysis);	chr4:151607325	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.571	rs4696274	ENSG00000270265.1	RP11-731D1.4	-4.04	6.16e-05	0.00938	-0.21	-0.18	Intelligence (multi-trait analysis);	chr4:151607326	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.571	rs4696101	ENSG00000270265.1	RP11-731D1.4	-4.04	6.16e-05	0.00938	-0.21	-0.18	Intelligence (multi-trait analysis);	chr4:151607361	chr4:151333775~151353224:-
LUAD	cis	rs17818399	0.547	rs4953400	ENSG00000279254.1	RP11-536C12.1	-4.04	6.16e-05	0.00938	-0.22	-0.18	Height;	chr2:46550069	chr2:46668870~46670778:+
LUAD	cis	rs11992162	0.621	rs13268810	ENSG00000255046.1	RP11-297N6.4	-4.04	6.16e-05	0.00938	-0.22	-0.18	Monocyte count;	chr8:11939921	chr8:11797928~11802568:-
LUAD	cis	rs2657294	0.796	rs4746272	ENSG00000233313.2	HMGA1P5	-4.04	6.16e-05	0.00938	-0.23	-0.18	Pneumonia;	chr10:75203869	chr10:75276376~75276646:-
LUAD	cis	rs1555322	0.53	rs2425044	ENSG00000279253.1	RP4-614O4.13	-4.04	6.16e-05	0.00938	-0.23	-0.18	Attention deficit hyperactivity disorder;	chr20:35281932	chr20:35262727~35264187:-
LUAD	cis	rs6957923	0.967	rs10950947	ENSG00000230658.1	KLHL7-AS1	-4.04	6.16e-05	0.00939	-0.22	-0.18	Height;	chr7:23464135	chr7:23101228~23105703:-
LUAD	cis	rs8073060	0.586	rs6505484	ENSG00000267592.1	CTC-507E2.2	4.04	6.16e-05	0.00939	0.26	0.18	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35666133	chr17:35596904~35597128:-
LUAD	cis	rs9813712	0.585	rs10934929	ENSG00000228252.7	COL6A4P2	4.04	6.16e-05	0.00939	0.21	0.18	Response to amphetamines;	chr3:130225231	chr3:130212823~130273806:+
LUAD	cis	rs6467136	0.539	rs61544985	ENSG00000224138.1	AC000123.4	4.04	6.16e-05	0.00939	0.17	0.18	Type 2 diabetes;	chr7:127462627	chr7:127350128~127351523:+
LUAD	cis	rs2243480	0.522	rs1638736	ENSG00000232559.3	GS1-124K5.12	4.04	6.16e-05	0.00939	0.36	0.18	Diabetic kidney disease;	chr7:66627321	chr7:66554588~66576923:-
LUAD	cis	rs7772486	0.79	rs1062068	ENSG00000235652.6	RP11-545I5.3	4.04	6.17e-05	0.0094	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145886329	chr6:145799409~145886585:+
LUAD	cis	rs9860428	0.844	rs6765575	ENSG00000242770.2	RP11-180K7.1	4.04	6.17e-05	0.0094	0.2	0.18	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112854322	chr3:112802478~112812819:+
LUAD	cis	rs9291683	0.588	rs12647117	ENSG00000250413.1	RP11-448G15.1	-4.04	6.17e-05	0.0094	-0.23	-0.18	Bone mineral density;	chr4:10020435	chr4:10006482~10009725:+
LUAD	cis	rs6479891	0.778	rs7896676	ENSG00000232075.1	MRPL35P2	-4.04	6.17e-05	0.0094	-0.3	-0.18	Arthritis (juvenile idiopathic);	chr10:63305542	chr10:63634317~63634827:-
LUAD	cis	rs6479891	0.915	rs7896677	ENSG00000232075.1	MRPL35P2	-4.04	6.17e-05	0.0094	-0.3	-0.18	Arthritis (juvenile idiopathic);	chr10:63305545	chr10:63634317~63634827:-
LUAD	cis	rs7204230	1	rs8053150	ENSG00000261291.1	RP11-295M3.2	4.04	6.17e-05	0.0094	0.22	0.18	Fibrinogen;	chr16:53257765	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs7201867	ENSG00000261291.1	RP11-295M3.2	4.04	6.17e-05	0.0094	0.22	0.18	Fibrinogen;	chr16:53259299	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs12597624	ENSG00000261291.1	RP11-295M3.2	4.04	6.17e-05	0.0094	0.22	0.18	Fibrinogen;	chr16:53263773	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs12598372	ENSG00000261291.1	RP11-295M3.2	4.04	6.17e-05	0.0094	0.22	0.18	Fibrinogen;	chr16:53265463	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs17394498	ENSG00000261291.1	RP11-295M3.2	4.04	6.17e-05	0.0094	0.22	0.18	Fibrinogen;	chr16:53266575	chr16:53168522~53169450:+
LUAD	cis	rs5758659	1	rs134873	ENSG00000273366.1	CTA-989H11.1	-4.04	6.17e-05	0.0094	-0.21	-0.18	Cognitive function;	chr22:42261560	chr22:42278188~42278846:+
LUAD	cis	rs9876781	0.967	rs1459249	ENSG00000229759.1	MRPS18AP1	4.04	6.17e-05	0.00941	0.17	0.18	Longevity;	chr3:48438208	chr3:48256350~48256938:-
LUAD	cis	rs780096	0.565	rs780104	ENSG00000234072.1	AC074117.10	-4.04	6.18e-05	0.00941	-0.14	-0.18	Total body bone mineral density;	chr2:27454824	chr2:27356246~27367622:+
LUAD	cis	rs780096	0.526	rs780106	ENSG00000234072.1	AC074117.10	-4.04	6.18e-05	0.00941	-0.14	-0.18	Total body bone mineral density;	chr2:27458731	chr2:27356246~27367622:+
LUAD	cis	rs780096	0.526	rs780107	ENSG00000234072.1	AC074117.10	-4.04	6.18e-05	0.00941	-0.14	-0.18	Total body bone mineral density;	chr2:27461867	chr2:27356246~27367622:+
LUAD	cis	rs780096	0.526	rs1647276	ENSG00000234072.1	AC074117.10	-4.04	6.18e-05	0.00941	-0.14	-0.18	Total body bone mineral density;	chr2:27465734	chr2:27356246~27367622:+
LUAD	cis	rs780096	0.526	rs1406295	ENSG00000234072.1	AC074117.10	-4.04	6.18e-05	0.00941	-0.14	-0.18	Total body bone mineral density;	chr2:27466833	chr2:27356246~27367622:+
LUAD	cis	rs780096	0.506	rs1647265	ENSG00000234072.1	AC074117.10	-4.04	6.18e-05	0.00941	-0.14	-0.18	Total body bone mineral density;	chr2:27469394	chr2:27356246~27367622:+
LUAD	cis	rs780096	0.526	rs1647266	ENSG00000234072.1	AC074117.10	-4.04	6.18e-05	0.00941	-0.14	-0.18	Total body bone mineral density;	chr2:27470618	chr2:27356246~27367622:+
LUAD	cis	rs11673344	0.8	rs8108214	ENSG00000267309.1	CTD-2630F21.1	4.04	6.18e-05	0.00941	0.22	0.18	Obesity-related traits;	chr19:37025184	chr19:36489649~36491040:+
LUAD	cis	rs2243480	1	rs781150	ENSG00000229886.1	RP5-1132H15.3	4.04	6.18e-05	0.00941	0.31	0.18	Diabetic kidney disease;	chr7:66015986	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs313798	ENSG00000229886.1	RP5-1132H15.3	4.04	6.18e-05	0.00941	0.31	0.18	Diabetic kidney disease;	chr7:66028044	chr7:66025126~66031544:-
LUAD	cis	rs6964587	1	rs12540565	ENSG00000188693.7	CYP51A1-AS1	-4.04	6.18e-05	0.00941	-0.21	-0.18	Breast cancer;	chr7:92003899	chr7:92134604~92180725:+
LUAD	cis	rs6964587	1	rs7455444	ENSG00000188693.7	CYP51A1-AS1	-4.04	6.18e-05	0.00941	-0.21	-0.18	Breast cancer;	chr7:92009999	chr7:92134604~92180725:+
LUAD	cis	rs727479	0.76	rs8024515	ENSG00000259306.2	RP11-108K3.2	-4.04	6.18e-05	0.00941	-0.2	-0.18	Estradiol levels;	chr15:51240079	chr15:51315841~51321996:+
LUAD	cis	rs6964587	1	rs12531366	ENSG00000188693.7	CYP51A1-AS1	-4.04	6.18e-05	0.00941	-0.21	-0.18	Breast cancer;	chr7:92054535	chr7:92134604~92180725:+
LUAD	cis	rs4578769	0.55	rs12964830	ENSG00000265943.1	RP11-739L10.1	4.04	6.18e-05	0.00941	0.23	0.18	Eosinophil percentage of white cells;	chr18:22938970	chr18:22699481~22933764:-
LUAD	cis	rs12817211	0.502	rs1554844	ENSG00000272368.2	RP4-605O3.4	-4.04	6.18e-05	0.00941	-0.21	-0.18	Colorectal or endometrial cancer;	chr12:50120582	chr12:50112197~50165618:+
LUAD	cis	rs34779708	0.931	rs35388511	ENSG00000271335.4	RP11-324I22.4	4.04	6.18e-05	0.00941	0.19	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35007688	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.931	rs34815241	ENSG00000271335.4	RP11-324I22.4	4.04	6.18e-05	0.00941	0.19	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35007748	chr10:35314552~35336401:-
LUAD	cis	rs6701713	0.959	rs1408077	ENSG00000274245.1	RP11-357P18.2	-4.04	6.18e-05	0.00942	-0.28	-0.18	Alzheimer's disease (late onset);	chr1:207630796	chr1:207372559~207373252:+
LUAD	cis	rs12439619	0.53	rs7162177	ENSG00000259429.4	UBE2Q2P2	-4.04	6.18e-05	0.00942	-0.15	-0.18	Intelligence (multi-trait analysis);	chr15:82181728	chr15:82355142~82420075:+
LUAD	cis	rs11168618	0.74	rs12425460	ENSG00000240399.1	RP1-228P16.1	4.04	6.18e-05	0.00942	0.17	0.18	Adiponectin levels;	chr12:48526013	chr12:48054813~48055591:-
LUAD	cis	rs11168618	0.74	rs10875826	ENSG00000240399.1	RP1-228P16.1	4.04	6.18e-05	0.00942	0.17	0.18	Adiponectin levels;	chr12:48527377	chr12:48054813~48055591:-
LUAD	cis	rs11168618	0.74	rs7299323	ENSG00000240399.1	RP1-228P16.1	4.04	6.18e-05	0.00942	0.17	0.18	Adiponectin levels;	chr12:48527750	chr12:48054813~48055591:-
LUAD	cis	rs11220082	0.644	rs34435097	ENSG00000254671.2	STT3A-AS1	-4.04	6.18e-05	0.00942	-0.21	-0.18	Schizophrenia;	chr11:125469075	chr11:125570284~125592568:-
LUAD	cis	rs2834288	0.535	rs8132681	ENSG00000237945.6	LINC00649	4.04	6.19e-05	0.00942	0.23	0.18	Gut microbiota (bacterial taxa);	chr21:33950035	chr21:33915534~33977691:+
LUAD	cis	rs4578769	0.55	rs4800442	ENSG00000265943.1	RP11-739L10.1	4.04	6.19e-05	0.00942	0.23	0.18	Eosinophil percentage of white cells;	chr18:22958337	chr18:22699481~22933764:-
LUAD	cis	rs9549260	0.62	rs12583418	ENSG00000229456.1	RLIMP1	4.04	6.19e-05	0.00942	0.2	0.18	Red blood cell count;	chr13:40621274	chr13:40618738~40621348:+
LUAD	cis	rs6487679	0.543	rs972110	ENSG00000111788.10	RP11-22B23.1	4.04	6.19e-05	0.00943	0.27	0.18	Non-alcoholic fatty liver disease histology (AST);	chr12:9221750	chr12:9277235~9313241:+
LUAD	cis	rs8177876	0.915	rs6420421	ENSG00000261061.1	RP11-303E16.2	4.04	6.19e-05	0.00943	0.29	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81094601	chr16:81030770~81031485:+
LUAD	cis	rs8177876	0.749	rs5023849	ENSG00000261061.1	RP11-303E16.2	4.04	6.19e-05	0.00943	0.29	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81094694	chr16:81030770~81031485:+
LUAD	cis	rs4448343	0.963	rs10512248	ENSG00000271155.1	RP11-435O5.5	-4.04	6.19e-05	0.00943	-0.22	-0.18	Height;	chr9:95497421	chr9:95506235~95507636:+
LUAD	cis	rs8028182	0.636	rs4886712	ENSG00000260269.4	CTD-2323K18.1	-4.04	6.19e-05	0.00943	-0.25	-0.18	Sudden cardiac arrest;	chr15:75520547	chr15:75527150~75601205:-
LUAD	cis	rs8028182	0.636	rs8030802	ENSG00000260269.4	CTD-2323K18.1	-4.04	6.19e-05	0.00943	-0.25	-0.18	Sudden cardiac arrest;	chr15:75520812	chr15:75527150~75601205:-
LUAD	cis	rs8028182	0.577	rs8023268	ENSG00000260269.4	CTD-2323K18.1	-4.04	6.19e-05	0.00943	-0.25	-0.18	Sudden cardiac arrest;	chr15:75522331	chr15:75527150~75601205:-
LUAD	cis	rs8028182	0.636	rs8023815	ENSG00000260269.4	CTD-2323K18.1	-4.04	6.19e-05	0.00943	-0.25	-0.18	Sudden cardiac arrest;	chr15:75522363	chr15:75527150~75601205:-
LUAD	cis	rs28386778	0.863	rs1376110	ENSG00000240280.5	TCAM1P	-4.04	6.19e-05	0.00943	-0.21	-0.18	Prudent dietary pattern;	chr17:63702567	chr17:63849292~63864379:+
LUAD	cis	rs10197140	0.925	rs7563488	ENSG00000235721.1	AC013268.3	-4.04	6.19e-05	0.00943	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110875340	chr2:110007675~110010783:+
LUAD	cis	rs9649213	0.555	rs7785612	ENSG00000272950.1	RP11-307C18.1	4.04	6.19e-05	0.00943	0.23	0.18	Prostate cancer (SNP x SNP interaction);	chr7:98304555	chr7:98322853~98323430:+
LUAD	cis	rs17772222	0.958	rs17798341	ENSG00000258789.1	RP11-507K2.3	-4.04	6.19e-05	0.00943	-0.25	-0.18	Coronary artery calcification;	chr14:88548201	chr14:88551597~88552493:+
LUAD	cis	rs1910358	0.881	rs1490758	ENSG00000248874.4	C5orf17	-4.04	6.2e-05	0.00944	-0.26	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr5:23884331	chr5:23951348~24178263:+
LUAD	cis	rs11971779	0.646	rs58682779	ENSG00000273391.1	RP11-634H22.1	4.04	6.2e-05	0.00944	0.21	0.18	Diisocyanate-induced asthma;	chr7:139399966	chr7:139359032~139359566:-
LUAD	cis	rs1431005	1	rs72499925	ENSG00000250658.1	RP11-138B4.1	4.04	6.2e-05	0.00944	0.23	0.18	Response to statin therapy;	chr4:187432596	chr4:187304083~187309682:-
LUAD	cis	rs12935418	0.616	rs874054	ENSG00000261061.1	RP11-303E16.2	-4.04	6.2e-05	0.00944	-0.19	-0.18	Mean corpuscular volume;	chr16:80972245	chr16:81030770~81031485:+
LUAD	cis	rs10197140	0.857	rs7609002	ENSG00000235721.1	AC013268.3	4.04	6.2e-05	0.00944	0.2	0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110902083	chr2:110007675~110010783:+
LUAD	cis	rs11673344	0.523	rs36096221	ENSG00000276846.1	CTD-3220F14.3	4.04	6.2e-05	0.00944	0.2	0.18	Obesity-related traits;	chr19:37060838	chr19:37314868~37315620:-
LUAD	cis	rs853679	0.517	rs9366715	ENSG00000280107.1	AL022393.9	-4.04	6.2e-05	0.00944	-0.24	-0.18	Depression;	chr6:28096855	chr6:28170845~28172521:+
LUAD	cis	rs9341808	0.621	rs2322627	ENSG00000260645.1	RP11-250B2.5	4.04	6.2e-05	0.00944	0.17	0.18	Sitting height ratio;	chr6:80096624	chr6:80466958~80469080:+
LUAD	cis	rs4591358	0.569	rs6718998	ENSG00000223466.1	AC064834.2	-4.04	6.2e-05	0.00944	-0.3	-0.18	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195578245	chr2:195533035~195538681:+
LUAD	cis	rs8177876	0.822	rs1563075	ENSG00000261061.1	RP11-303E16.2	-4.04	6.2e-05	0.00944	-0.3	-0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074143	chr16:81030770~81031485:+
LUAD	cis	rs853679	0.517	rs1340004	ENSG00000280107.1	AL022393.9	-4.04	6.2e-05	0.00945	-0.24	-0.18	Depression;	chr6:28135913	chr6:28170845~28172521:+
LUAD	cis	rs6495122	0.501	rs12148488	ENSG00000260269.4	CTD-2323K18.1	4.04	6.2e-05	0.00945	0.22	0.18	Diastolic blood pressure;Coffee consumption;Caffeine consumption;	chr15:75090201	chr15:75527150~75601205:-
LUAD	cis	rs4879677	0.92	rs1826742	ENSG00000215441.3	CTAGE12P	-4.04	6.21e-05	0.00945	-0.22	-0.18	Gut microbiome composition (summer and winter);	chr9:27654052	chr9:27608382~27610745:-
LUAD	cis	rs13113518	0.702	rs78829811	ENSG00000273257.1	RP11-177J6.1	4.04	6.21e-05	0.00945	0.2	0.18	Height;	chr4:55558258	chr4:55387949~55388271:+
LUAD	cis	rs13113518	0.702	rs75801206	ENSG00000273257.1	RP11-177J6.1	4.04	6.21e-05	0.00945	0.2	0.18	Height;	chr4:55558259	chr4:55387949~55388271:+
LUAD	cis	rs13113518	0.702	rs34658078	ENSG00000273257.1	RP11-177J6.1	4.04	6.21e-05	0.00945	0.2	0.18	Height;	chr4:55558261	chr4:55387949~55388271:+
LUAD	cis	rs2274273	0.87	rs7158768	ENSG00000259318.1	RP11-454L9.2	4.04	6.21e-05	0.00945	0.16	0.18	Protein biomarker;	chr14:55296894	chr14:55394940~55395233:-
LUAD	cis	rs2274273	0.87	rs10142547	ENSG00000259318.1	RP11-454L9.2	4.04	6.21e-05	0.00945	0.16	0.18	Protein biomarker;	chr14:55297245	chr14:55394940~55395233:-
LUAD	cis	rs7584330	0.826	rs72620824	ENSG00000222032.1	AC112721.2	4.04	6.21e-05	0.00946	0.23	0.18	Prostate cancer;	chr2:237472440	chr2:237428920~237434822:-
LUAD	cis	rs853679	0.556	rs13200214	ENSG00000219392.1	RP1-265C24.5	-4.04	6.21e-05	0.00946	-0.4	-0.18	Depression;	chr6:28049472	chr6:28115628~28116551:+
LUAD	cis	rs9322193	0.607	rs9371228	ENSG00000268592.3	RAET1E-AS1	-4.04	6.21e-05	0.00946	-0.27	-0.18	Lung cancer;	chr6:149921977	chr6:149863494~149919507:+
LUAD	cis	rs4819052	0.851	rs1056100	ENSG00000223768.1	LINC00205	-4.04	6.21e-05	0.00946	-0.21	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258796	chr21:45293285~45297354:+
LUAD	cis	rs4705962	0.837	rs1468215	ENSG00000233006.5	AC034220.3	4.04	6.21e-05	0.00946	0.18	0.18	Atopic dermatitis;	chr5:132700797	chr5:132311285~132369916:-
LUAD	cis	rs4705962	0.701	rs3213639	ENSG00000233006.5	AC034220.3	4.04	6.21e-05	0.00946	0.18	0.18	Atopic dermatitis;	chr5:132702507	chr5:132311285~132369916:-
LUAD	cis	rs11992162	0.569	rs11786149	ENSG00000255046.1	RP11-297N6.4	4.04	6.22e-05	0.00946	0.23	0.18	Monocyte count;	chr8:11943309	chr8:11797928~11802568:-
LUAD	cis	rs7870753	0.529	rs10760999	ENSG00000188801.9	ZNF322P1	4.04	6.22e-05	0.00947	0.27	0.18	Height;	chr9:96412669	chr9:97198303~97199511:-
LUAD	cis	rs9309473	0.579	rs1852644	ENSG00000163016.8	ALMS1P	4.04	6.22e-05	0.00947	0.2	0.18	Metabolite levels;	chr2:73370590	chr2:73644919~73685576:+
LUAD	cis	rs5758511	0.573	rs4501042	ENSG00000227370.1	RP4-669P10.19	-4.04	6.22e-05	0.00947	-0.18	-0.18	Birth weight;	chr22:41849759	chr22:42132543~42132998:+
LUAD	cis	rs11742741	0.777	rs1346495	ENSG00000248874.4	C5orf17	-4.04	6.22e-05	0.00947	-0.22	-0.18	Educational attainment;	chr5:24064630	chr5:23951348~24178263:+
LUAD	cis	rs683250	0.598	rs647200	ENSG00000246067.6	RAB30-AS1	4.04	6.23e-05	0.00947	0.19	0.18	Subcortical brain region volumes;	chr11:83267482	chr11:83072066~83106719:+
LUAD	cis	rs17711722	0.522	rs4642526	ENSG00000273024.4	INTS4P2	-4.04	6.23e-05	0.00947	-0.19	-0.18	Calcium levels;	chr7:65751755	chr7:65647864~65715661:+
LUAD	cis	rs473651	0.837	rs563458	ENSG00000229915.1	AC016999.2	-4.04	6.23e-05	0.00947	-0.24	-0.18	Multiple system atrophy;	chr2:238436972	chr2:238427077~238427729:-
LUAD	cis	rs7772486	0.79	rs4280983	ENSG00000235652.6	RP11-545I5.3	-4.04	6.23e-05	0.00947	-0.18	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145959654	chr6:145799409~145886585:+
LUAD	cis	rs10857712	0.703	rs12253520	ENSG00000273336.1	OR7M1P	-4.04	6.23e-05	0.00947	-0.27	-0.18	Systemic lupus erythematosus;	chr10:133421817	chr10:133481238~133481770:+
LUAD	cis	rs10857712	0.703	rs1056521	ENSG00000273336.1	OR7M1P	-4.04	6.23e-05	0.00947	-0.27	-0.18	Systemic lupus erythematosus;	chr10:133422386	chr10:133481238~133481770:+
LUAD	cis	rs7204230	1	rs62049780	ENSG00000261291.1	RP11-295M3.2	4.04	6.23e-05	0.00947	0.22	0.18	Fibrinogen;	chr16:53245099	chr16:53168522~53169450:+
LUAD	cis	rs6701713	0.959	rs1830763	ENSG00000274245.1	RP11-357P18.2	-4.04	6.23e-05	0.00947	-0.29	-0.18	Alzheimer's disease (late onset);	chr1:207627044	chr1:207372559~207373252:+
LUAD	cis	rs6701713	0.959	rs1408078	ENSG00000274245.1	RP11-357P18.2	-4.04	6.23e-05	0.00947	-0.29	-0.18	Alzheimer's disease (late onset);	chr1:207627210	chr1:207372559~207373252:+
LUAD	cis	rs2354432	0.607	rs3766524	ENSG00000226015.2	CCT8P1	4.04	6.23e-05	0.00948	0.34	0.18	Mitochondrial DNA levels;	chr1:147257439	chr1:147203276~147204932:-
LUAD	cis	rs4706831	0.647	rs9350847	ENSG00000272129.1	RP11-250B2.6	4.04	6.23e-05	0.00948	0.22	0.18	Joint mobility (Beighton score);	chr6:80179300	chr6:80355424~80356859:+
LUAD	cis	rs853679	0.517	rs1340004	ENSG00000226314.6	ZNF192P1	-4.04	6.23e-05	0.00948	-0.24	-0.18	Depression;	chr6:28135913	chr6:28161781~28169594:+
LUAD	cis	rs6691170	0.965	rs7556228	ENSG00000228437.4	RP11-400N13.2	4.04	6.23e-05	0.00948	0.22	0.18	Colorectal cancer;	chr1:221875323	chr1:221966341~221984964:+
LUAD	cis	rs2274273	0.934	rs10144418	ENSG00000258413.1	RP11-665C16.6	-4.04	6.23e-05	0.00948	-0.23	-0.18	Protein biomarker;	chr14:55350990	chr14:55262767~55272075:-
LUAD	cis	rs6683071	0.557	rs2378605	ENSG00000272750.1	RP11-378J18.8	-4.04	6.23e-05	0.00948	-0.26	-0.18	Cognitive performance;	chr1:222732211	chr1:222658867~222661512:-
LUAD	cis	rs227584	0.501	rs62078931	ENSG00000267080.4	ASB16-AS1	4.04	6.24e-05	0.00949	0.16	0.18	Bone mineral density;Bone mineral density (hip);	chr17:44120691	chr17:44175973~44186717:-
LUAD	cis	rs442309	0.875	rs224068	ENSG00000238280.1	RP11-436D10.3	-4.04	6.24e-05	0.00949	-0.21	-0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62748340	chr10:62793562~62805887:-
LUAD	cis	rs4795519	0.778	rs66888646	ENSG00000266313.1	RP11-173M1.4	4.04	6.24e-05	0.00949	0.23	0.18	Chronic myeloid leukemia;	chr17:27148890	chr17:27333256~27348491:+
LUAD	cis	rs2904524	1	rs12309104	ENSG00000257815.4	RP11-611E13.2	-4.04	6.24e-05	0.00949	-0.25	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70318084	chr12:69904033~70243360:-
LUAD	cis	rs2904524	0.881	rs940429	ENSG00000257815.4	RP11-611E13.2	-4.04	6.24e-05	0.00949	-0.25	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70319028	chr12:69904033~70243360:-
LUAD	cis	rs6496044	0.527	rs7163068	ENSG00000259295.5	CSPG4P12	4.04	6.24e-05	0.00949	0.21	0.18	Interstitial lung disease;	chr15:85529235	chr15:85191438~85213905:+
LUAD	cis	rs73242632	1	rs10002090	ENSG00000269949.1	RP11-738E22.3	4.04	6.24e-05	0.00949	0.45	0.18	Congenital heart disease (maternal effect);	chr4:56993426	chr4:56960927~56961373:-
LUAD	cis	rs858239	0.899	rs28458177	ENSG00000230042.1	AK3P3	-4.04	6.24e-05	0.0095	-0.23	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23255253	chr7:23129178~23129841:+
LUAD	cis	rs7429990	0.965	rs1550914	ENSG00000228638.1	FCF1P2	-4.04	6.24e-05	0.0095	-0.21	-0.18	Educational attainment (years of education);	chr3:47953678	chr3:48290793~48291375:-
LUAD	cis	rs9287719	0.935	rs61424402	ENSG00000243819.4	RN7SL832P	4.04	6.25e-05	0.0095	0.19	0.18	Prostate cancer;	chr2:10618245	chr2:10690344~10692099:+
LUAD	cis	rs755249	1	rs4660293	ENSG00000182109.6	RP11-69E11.4	-4.04	6.25e-05	0.0095	-0.21	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39562508	chr1:39522280~39546187:-
LUAD	cis	rs853679	0.542	rs9393892	ENSG00000280107.1	AL022393.9	-4.04	6.25e-05	0.00951	-0.24	-0.18	Depression;	chr6:28113616	chr6:28170845~28172521:+
LUAD	cis	rs28386778	0.863	rs9897229	ENSG00000240280.5	TCAM1P	-4.04	6.25e-05	0.00951	-0.21	-0.18	Prudent dietary pattern;	chr17:63704965	chr17:63849292~63864379:+
LUAD	cis	rs7647973	0.58	rs2334958	ENSG00000225399.4	RP11-3B7.1	4.04	6.25e-05	0.00951	0.23	0.18	Menarche (age at onset);	chr3:49214931	chr3:49260085~49261316:+
LUAD	cis	rs2243480	0.901	rs778732	ENSG00000229886.1	RP5-1132H15.3	4.04	6.25e-05	0.00951	0.31	0.18	Diabetic kidney disease;	chr7:66357373	chr7:66025126~66031544:-
LUAD	cis	rs34638952	0.534	rs797955	ENSG00000264808.1	RP11-802D6.1	4.04	6.26e-05	0.00951	0.21	0.18	Sitting height ratio;	chr17:29308457	chr17:29369717~29390777:-
LUAD	cis	rs2274273	0.84	rs66486619	ENSG00000259318.1	RP11-454L9.2	4.04	6.26e-05	0.00952	0.16	0.18	Protein biomarker;	chr14:55402837	chr14:55394940~55395233:-
LUAD	cis	rs453301	0.522	rs1964356	ENSG00000253893.2	FAM85B	-4.04	6.26e-05	0.00952	-0.24	-0.18	Joint mobility (Beighton score);	chr8:8995760	chr8:8167819~8226614:-
LUAD	cis	rs34779708	0.931	rs7897457	ENSG00000271335.4	RP11-324I22.4	4.04	6.26e-05	0.00952	0.19	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35097112	chr10:35314552~35336401:-
LUAD	cis	rs17772222	0.917	rs61984683	ENSG00000258789.1	RP11-507K2.3	-4.04	6.26e-05	0.00952	-0.25	-0.18	Coronary artery calcification;	chr14:88553162	chr14:88551597~88552493:+
LUAD	cis	rs2613514	0.892	rs1079120	ENSG00000204282.4	TNRC6C-AS1	-4.04	6.26e-05	0.00952	-0.28	-0.18	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr17:78096453	chr17:78107398~78111799:-
LUAD	cis	rs4879677	0.959	rs2150021	ENSG00000215441.3	CTAGE12P	4.04	6.26e-05	0.00952	0.22	0.18	Gut microbiome composition (summer and winter);	chr9:27688292	chr9:27608382~27610745:-
LUAD	cis	rs7208859	0.623	rs216434	ENSG00000280069.1	CTD-2349P21.3	-4.04	6.27e-05	0.00953	-0.26	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595317	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs216436	ENSG00000280069.1	CTD-2349P21.3	-4.04	6.27e-05	0.00953	-0.26	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595882	chr17:30738182~30740275:+
LUAD	cis	rs6754311	0.731	rs3754686	ENSG00000226806.1	AC011893.3	-4.04	6.27e-05	0.00953	-0.23	-0.18	Mosquito bite size;	chr2:135845706	chr2:135820191~135823087:+
LUAD	cis	rs2836974	0.83	rs2735309	ENSG00000232608.1	TIMM9P2	-4.04	6.27e-05	0.00953	-0.22	-0.18	Cognitive function;	chr21:39343387	chr21:39216624~39217506:+
LUAD	cis	rs6951245	1	rs74887741	ENSG00000199023.2	MIR339	-4.04	6.27e-05	0.00953	-0.33	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1071022	chr7:1022935~1023045:-
LUAD	cis	rs6951245	1	rs79617366	ENSG00000199023.2	MIR339	-4.04	6.27e-05	0.00953	-0.33	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1072322	chr7:1022935~1023045:-
LUAD	cis	rs6951245	1	rs111899361	ENSG00000199023.2	MIR339	-4.04	6.27e-05	0.00953	-0.33	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1072712	chr7:1022935~1023045:-
LUAD	cis	rs253959	0.502	rs10478275	ENSG00000272265.1	CTD-2287O16.4	4.04	6.27e-05	0.00953	0.21	0.18	Bipolar disorder and schizophrenia;	chr5:116092399	chr5:116078110~116078570:-
LUAD	cis	rs4713118	0.869	rs6456802	ENSG00000280107.1	AL022393.9	-4.04	6.27e-05	0.00953	-0.23	-0.18	Parkinson's disease;	chr6:27730576	chr6:28170845~28172521:+
LUAD	cis	rs4713118	0.869	rs9393851	ENSG00000280107.1	AL022393.9	-4.04	6.27e-05	0.00953	-0.23	-0.18	Parkinson's disease;	chr6:27731802	chr6:28170845~28172521:+
LUAD	cis	rs4713118	0.869	rs9461400	ENSG00000280107.1	AL022393.9	-4.04	6.27e-05	0.00953	-0.23	-0.18	Parkinson's disease;	chr6:27732780	chr6:28170845~28172521:+
LUAD	cis	rs4713118	0.869	rs9295742	ENSG00000280107.1	AL022393.9	-4.04	6.27e-05	0.00953	-0.23	-0.18	Parkinson's disease;	chr6:27735053	chr6:28170845~28172521:+
LUAD	cis	rs4713118	0.869	rs9461401	ENSG00000280107.1	AL022393.9	-4.04	6.27e-05	0.00953	-0.23	-0.18	Parkinson's disease;	chr6:27735512	chr6:28170845~28172521:+
LUAD	cis	rs4713118	0.869	rs6914924	ENSG00000280107.1	AL022393.9	-4.04	6.27e-05	0.00953	-0.23	-0.18	Parkinson's disease;	chr6:27743751	chr6:28170845~28172521:+
LUAD	cis	rs6142102	0.961	rs6088361	ENSG00000275784.1	RP5-1125A11.6	-4.04	6.27e-05	0.00953	-0.2	-0.18	Skin pigmentation;	chr20:33969520	chr20:33989480~33991818:-
LUAD	cis	rs28735056	0.572	rs4799100	ENSG00000261126.6	RP11-795F19.1	-4.04	6.27e-05	0.00953	-0.19	-0.18	Schizophrenia;	chr18:79880207	chr18:80046900~80095482:+
LUAD	cis	rs3018712	0.59	rs2513272	ENSG00000227620.4	ALG1L8P	-4.04	6.27e-05	0.00953	-0.24	-0.18	Total body bone mineral density;	chr11:68706701	chr11:67785273~67792335:+
LUAD	cis	rs7824557	0.564	rs2572395	ENSG00000255046.1	RP11-297N6.4	4.04	6.27e-05	0.00953	0.22	0.18	Retinal vascular caliber;	chr8:11377851	chr8:11797928~11802568:-
LUAD	cis	rs3785309	0.519	rs7196484	ENSG00000268836.1	LA16c-OS12.2	-4.04	6.27e-05	0.00953	-0.31	-0.18	Immature fraction of reticulocytes;	chr16:226188	chr16:185748~186294:-
LUAD	cis	rs7122539	0.506	rs7944999	ENSG00000213409.4	RP11-658F2.3	-4.04	6.27e-05	0.00953	-0.21	-0.18	HIV-1 susceptibility;	chr11:66920392	chr11:66761575~66762399:-
LUAD	cis	rs2348418	0.966	rs7316797	ENSG00000244712.1	RP11-874G11.1	4.04	6.27e-05	0.00953	0.21	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28529776	chr12:28564678~28565141:-
LUAD	cis	rs338389	0.777	rs2448139	ENSG00000260657.2	RP11-315D16.4	-4.04	6.27e-05	0.00953	-0.2	-0.18	Survival in rectal cancer;	chr15:67955630	chr15:68267792~68277994:-
LUAD	cis	rs728616	0.717	rs12412999	ENSG00000225484.5	NUTM2B-AS1	-4.04	6.27e-05	0.00953	-0.48	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80248385	chr10:79663088~79826594:-
LUAD	cis	rs2274273	0.87	rs17741542	ENSG00000258413.1	RP11-665C16.6	4.04	6.27e-05	0.00954	0.23	0.18	Protein biomarker;	chr14:55339143	chr14:55262767~55272075:-
LUAD	cis	rs6928977	0.5	rs6941629	ENSG00000231028.7	LINC00271	-4.04	6.28e-05	0.00954	-0.22	-0.18	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135621634	chr6:135497801~135716055:+
LUAD	cis	rs2708977	0.588	rs11164062	ENSG00000237510.6	AC008268.2	-4.04	6.28e-05	0.00954	-0.26	-0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96185381	chr2:95789654~95800166:+
LUAD	cis	rs848490	1	rs17385641	ENSG00000214293.7	APTR	-4.04	6.28e-05	0.00954	-0.23	-0.18	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77733172	chr7:77657660~77696265:-
LUAD	cis	rs13108904	0.875	rs1564509	ENSG00000196810.4	CTBP1-AS2	4.04	6.28e-05	0.00955	0.22	0.18	Obesity-related traits;	chr4:1242774	chr4:1249300~1288291:+
LUAD	cis	rs728616	0.867	rs118134654	ENSG00000225484.5	NUTM2B-AS1	-4.04	6.28e-05	0.00955	-0.45	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79984625	chr10:79663088~79826594:-
LUAD	cis	rs6479891	0.915	rs9415699	ENSG00000232075.1	MRPL35P2	-4.04	6.28e-05	0.00955	-0.29	-0.18	Arthritis (juvenile idiopathic);	chr10:63383798	chr10:63634317~63634827:-
LUAD	cis	rs1401999	0.966	rs2139560	ENSG00000223882.1	ABCC5-AS1	-4.04	6.29e-05	0.00955	-0.19	-0.18	Anterior chamber depth;	chr3:183936081	chr3:184006338~184011419:+
LUAD	cis	rs2235642	0.592	rs743963	ENSG00000280231.1	LA16c-380F5.3	-4.04	6.29e-05	0.00955	-0.25	-0.18	Coronary artery disease;	chr16:1607349	chr16:1553655~1554130:-
LUAD	cis	rs2638953	0.924	rs1841962	ENSG00000278733.1	RP11-425D17.1	4.04	6.29e-05	0.00955	0.21	0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28220919	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs7969582	ENSG00000278733.1	RP11-425D17.1	4.04	6.29e-05	0.00955	0.21	0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28236725	chr12:28185625~28186190:-
LUAD	cis	rs13434995	0.513	rs6554283	ENSG00000273257.1	RP11-177J6.1	4.04	6.29e-05	0.00955	0.24	0.18	Adiponectin levels;	chr4:55521053	chr4:55387949~55388271:+
LUAD	cis	rs13434995	0.513	rs1546004	ENSG00000273257.1	RP11-177J6.1	4.04	6.29e-05	0.00955	0.24	0.18	Adiponectin levels;	chr4:55521612	chr4:55387949~55388271:+
LUAD	cis	rs13434995	0.513	rs4865006	ENSG00000273257.1	RP11-177J6.1	4.04	6.29e-05	0.00955	0.24	0.18	Adiponectin levels;	chr4:55526112	chr4:55387949~55388271:+
LUAD	cis	rs10895275	0.886	rs2187525	ENSG00000277459.1	RP11-732A21.3	4.04	6.29e-05	0.00955	0.22	0.18	Migraine;	chr11:102178985	chr11:102109827~102110457:-
LUAD	cis	rs10208649	0.611	rs12620667	ENSG00000272156.1	RP11-477N3.1	4.04	6.29e-05	0.00955	0.36	0.18	Body mass index;	chr2:54063860	chr2:54082554~54085066:+
LUAD	cis	rs5758511	0.68	rs56111723	ENSG00000227370.1	RP4-669P10.19	4.04	6.29e-05	0.00955	0.2	0.18	Birth weight;	chr22:42268877	chr22:42132543~42132998:+
LUAD	cis	rs6479901	0.895	rs7093899	ENSG00000232075.1	MRPL35P2	-4.04	6.29e-05	0.00956	-0.25	-0.18	Intelligence (multi-trait analysis);	chr10:63294576	chr10:63634317~63634827:-
LUAD	cis	rs9896933	0.83	rs607544	ENSG00000262663.1	RP11-497H17.1	4.04	6.29e-05	0.00956	0.21	0.18	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr17:82810884	chr17:82918282~82918785:+
LUAD	cis	rs116095464	0.558	rs62347678	ENSG00000248925.1	CTD-2083E4.6	4.04	6.29e-05	0.00956	0.3	0.18	Breast cancer;	chr5:227381	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs73031482	ENSG00000248925.1	CTD-2083E4.6	4.04	6.29e-05	0.00956	0.3	0.18	Breast cancer;	chr5:227479	chr5:269858~271516:-
LUAD	cis	rs6088580	0.634	rs6058073	ENSG00000276073.1	RP5-1125A11.7	-4.04	6.29e-05	0.00956	-0.17	-0.18	Glomerular filtration rate (creatinine);	chr20:34528678	chr20:33985617~33988989:-
LUAD	cis	rs9287719	0.967	rs4519489	ENSG00000243819.4	RN7SL832P	4.04	6.29e-05	0.00956	0.19	0.18	Prostate cancer;	chr2:10598961	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs4453662	ENSG00000243819.4	RN7SL832P	4.04	6.29e-05	0.00956	0.19	0.18	Prostate cancer;	chr2:10599002	chr2:10690344~10692099:+
LUAD	cis	rs453301	0.686	rs1045527	ENSG00000233609.3	RP11-62H7.2	-4.04	6.29e-05	0.00956	-0.15	-0.18	Joint mobility (Beighton score);	chr8:9032531	chr8:8961200~8979025:+
LUAD	cis	rs6479901	0.793	rs10761725	ENSG00000232075.1	MRPL35P2	-4.04	6.29e-05	0.00956	-0.24	-0.18	Intelligence (multi-trait analysis);	chr10:63214777	chr10:63634317~63634827:-
LUAD	cis	rs7727544	0.582	rs7703009	ENSG00000233006.5	AC034220.3	4.04	6.29e-05	0.00956	0.16	0.18	Blood metabolite levels;	chr5:132216692	chr5:132311285~132369916:-
LUAD	cis	rs9322193	0.607	rs6557165	ENSG00000268592.3	RAET1E-AS1	-4.04	6.29e-05	0.00956	-0.26	-0.18	Lung cancer;	chr6:149906883	chr6:149863494~149919507:+
LUAD	cis	rs12122100	0.651	rs12737860	ENSG00000244371.2	PFN1P8	4.04	6.3e-05	0.00956	0.23	0.18	HIV-1 control;	chr1:147074795	chr1:146957117~146957659:-
LUAD	cis	rs7204230	1	rs8053957	ENSG00000261291.1	RP11-295M3.2	4.04	6.3e-05	0.00957	0.22	0.18	Fibrinogen;	chr16:53209351	chr16:53168522~53169450:+
LUAD	cis	rs6951245	0.935	rs61910751	ENSG00000199023.2	MIR339	-4.04	6.3e-05	0.00957	-0.33	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1058259	chr7:1022935~1023045:-
LUAD	cis	rs6951245	0.872	rs77434655	ENSG00000199023.2	MIR339	-4.04	6.3e-05	0.00957	-0.33	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1058769	chr7:1022935~1023045:-
LUAD	cis	rs6951245	0.872	rs75398423	ENSG00000199023.2	MIR339	-4.04	6.3e-05	0.00957	-0.33	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1058778	chr7:1022935~1023045:-
LUAD	cis	rs6951245	0.872	rs112309216	ENSG00000199023.2	MIR339	-4.04	6.3e-05	0.00957	-0.33	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1060660	chr7:1022935~1023045:-
LUAD	cis	rs6951245	0.872	rs76161580	ENSG00000199023.2	MIR339	-4.04	6.3e-05	0.00957	-0.33	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1060671	chr7:1022935~1023045:-
LUAD	cis	rs6951245	1	rs76388414	ENSG00000199023.2	MIR339	-4.04	6.3e-05	0.00957	-0.33	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061058	chr7:1022935~1023045:-
LUAD	cis	rs6951245	1	rs77305932	ENSG00000199023.2	MIR339	-4.04	6.3e-05	0.00957	-0.33	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061225	chr7:1022935~1023045:-
LUAD	cis	rs6951245	0.872	rs11768486	ENSG00000199023.2	MIR339	-4.04	6.3e-05	0.00957	-0.33	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061654	chr7:1022935~1023045:-
LUAD	cis	rs6951245	1	rs11766526	ENSG00000199023.2	MIR339	-4.04	6.3e-05	0.00957	-0.33	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061797	chr7:1022935~1023045:-
LUAD	cis	rs6951245	1	rs76214082	ENSG00000199023.2	MIR339	-4.04	6.3e-05	0.00957	-0.33	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1062461	chr7:1022935~1023045:-
LUAD	cis	rs6951245	1	rs80094748	ENSG00000199023.2	MIR339	-4.04	6.3e-05	0.00957	-0.33	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1064322	chr7:1022935~1023045:-
LUAD	cis	rs6951245	0.938	rs113642700	ENSG00000199023.2	MIR339	-4.04	6.3e-05	0.00957	-0.33	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1066018	chr7:1022935~1023045:-
LUAD	cis	rs5758659	0.714	rs2413668	ENSG00000182057.4	OGFRP1	-4.04	6.3e-05	0.00957	-0.21	-0.18	Cognitive function;	chr22:42109837	chr22:42269753~42275196:+
LUAD	cis	rs5758659	0.657	rs5758587	ENSG00000182057.4	OGFRP1	-4.04	6.3e-05	0.00957	-0.21	-0.18	Cognitive function;	chr22:42121632	chr22:42269753~42275196:+
LUAD	cis	rs13434995	0.513	rs12509047	ENSG00000273257.1	RP11-177J6.1	4.04	6.3e-05	0.00957	0.24	0.18	Adiponectin levels;	chr4:55545245	chr4:55387949~55388271:+
LUAD	cis	rs7976269	0.559	rs10771473	ENSG00000275476.1	RP11-996F15.4	-4.04	6.3e-05	0.00957	-0.2	-0.18	Male-pattern baldness;	chr12:29068729	chr12:29277397~29277882:-
LUAD	cis	rs7208859	0.51	rs216402	ENSG00000280069.1	CTD-2349P21.3	-4.04	6.3e-05	0.00957	-0.26	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30590108	chr17:30738182~30740275:+
LUAD	cis	rs703842	1	rs10877013	ENSG00000270039.1	RP11-571M6.17	-4.04	6.3e-05	0.00957	-0.21	-0.18	Multiple sclerosis;	chr12:57771302	chr12:57803838~57804415:+
LUAD	cis	rs7191700	0.673	rs12325495	ENSG00000262636.1	CTD-3088G3.4	4.04	6.3e-05	0.00957	0.22	0.18	Multiple sclerosis;	chr16:11324471	chr16:11380859~11381118:-
LUAD	cis	rs73193808	0.901	rs1997570	ENSG00000215533.7	LINC00189	-4.04	6.3e-05	0.00957	-0.26	-0.18	Coronary artery disease;	chr21:29212989	chr21:29193480~29288205:+
LUAD	cis	rs73193808	0.901	rs1997568	ENSG00000215533.7	LINC00189	-4.04	6.3e-05	0.00957	-0.26	-0.18	Coronary artery disease;	chr21:29213260	chr21:29193480~29288205:+
LUAD	cis	rs755249	0.567	rs4660214	ENSG00000182109.6	RP11-69E11.4	4.04	6.3e-05	0.00957	0.23	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39265878	chr1:39522280~39546187:-
LUAD	cis	rs7107174	1	rs948662	ENSG00000251323.2	RP11-452H21.4	4.04	6.3e-05	0.00957	0.24	0.18	Testicular germ cell tumor;	chr11:78268783	chr11:78423982~78429836:-
LUAD	cis	rs6496044	0.548	rs7163032	ENSG00000259295.5	CSPG4P12	4.04	6.3e-05	0.00957	0.21	0.18	Interstitial lung disease;	chr15:85529188	chr15:85191438~85213905:+
LUAD	cis	rs11992162	0.613	rs6998690	ENSG00000255046.1	RP11-297N6.4	-4.04	6.3e-05	0.00957	-0.22	-0.18	Monocyte count;	chr8:11941287	chr8:11797928~11802568:-
LUAD	cis	rs2274273	0.837	rs7148171	ENSG00000259318.1	RP11-454L9.2	4.04	6.3e-05	0.00957	0.16	0.18	Protein biomarker;	chr14:55304026	chr14:55394940~55395233:-
LUAD	cis	rs9876781	1	rs2885510	ENSG00000229759.1	MRPS18AP1	-4.04	6.31e-05	0.00958	-0.17	-0.18	Longevity;	chr3:48376736	chr3:48256350~48256938:-
LUAD	cis	rs9876781	1	rs725309	ENSG00000229759.1	MRPS18AP1	-4.04	6.31e-05	0.00958	-0.17	-0.18	Longevity;	chr3:48377218	chr3:48256350~48256938:-
LUAD	cis	rs853679	0.506	rs1150693	ENSG00000226314.6	ZNF192P1	-4.04	6.31e-05	0.00958	-0.24	-0.18	Depression;	chr6:28206812	chr6:28161781~28169594:+
LUAD	cis	rs12468579	0.77	rs13395505	ENSG00000235852.1	AC005540.3	-4.04	6.31e-05	0.00958	-0.2	-0.18	JT interval (sulfonylurea treatment interaction);	chr2:190973788	chr2:190880797~190882059:-
LUAD	cis	rs4706831	0.647	rs627240	ENSG00000279022.1	RP11-250B2.4	-4.04	6.31e-05	0.00958	-0.21	-0.18	Joint mobility (Beighton score);	chr6:80276168	chr6:80440730~80441172:+
LUAD	cis	rs453301	0.507	rs2929306	ENSG00000253981.4	ALG1L13P	-4.04	6.31e-05	0.00958	-0.21	-0.18	Joint mobility (Beighton score);	chr8:9227399	chr8:8236003~8244667:-
LUAD	cis	rs10463554	0.857	rs34376	ENSG00000250682.4	LINC00491	4.04	6.31e-05	0.00958	0.22	0.18	Parkinson's disease;	chr5:103065409	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.927	rs34375	ENSG00000250682.4	LINC00491	4.04	6.31e-05	0.00958	0.22	0.18	Parkinson's disease;	chr5:103065419	chr5:102609156~102671559:-
LUAD	cis	rs11051970	0.918	rs1055876	ENSG00000274964.1	RP11-817I4.1	-4.04	6.31e-05	0.00958	-0.21	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr12:32383266	chr12:32339368~32340724:+
LUAD	cis	rs7819412	0.654	rs34741518	ENSG00000255046.1	RP11-297N6.4	4.04	6.31e-05	0.00958	0.22	0.18	Triglycerides;	chr8:10919350	chr8:11797928~11802568:-
LUAD	cis	rs3213758	0.588	rs10521295	ENSG00000275191.1	RP11-36I17.2	-4.04	6.31e-05	0.00958	-0.3	-0.18	Vitiligo (non-segmental);	chr16:53529064	chr16:53628256~53628816:-
LUAD	cis	rs7829975	0.688	rs6601703	ENSG00000233609.3	RP11-62H7.2	4.04	6.31e-05	0.00958	0.15	0.18	Mood instability;	chr8:8522714	chr8:8961200~8979025:+
LUAD	cis	rs4795519	1	rs936571	ENSG00000266313.1	RP11-173M1.4	4.04	6.31e-05	0.00958	0.22	0.18	Chronic myeloid leukemia;	chr17:27153219	chr17:27333256~27348491:+
LUAD	cis	rs1009115	0.692	rs4720778	ENSG00000229970.3	AC007128.1	4.04	6.31e-05	0.00959	0.23	0.18	Post bronchodilator FEV1;	chr7:8385295	chr7:8262264~8344516:+
LUAD	cis	rs858239	0.632	rs13438452	ENSG00000226816.2	AC005082.12	4.04	6.31e-05	0.00959	0.24	0.18	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23206013~23208045:+
LUAD	cis	rs494562	1	rs494562	ENSG00000234155.1	RP11-30P6.6	-4.04	6.32e-05	0.00959	-0.35	-0.18	Metabolic traits;Blood metabolite levels;	chr6:85407411	chr6:85387219~85390186:-
LUAD	cis	rs9309473	0.514	rs62149659	ENSG00000230002.2	ALMS1-IT1	4.04	6.32e-05	0.00959	0.28	0.18	Metabolite levels;	chr2:73358068	chr2:73456764~73459484:+
LUAD	cis	rs1431005	0.964	rs59345911	ENSG00000250658.1	RP11-138B4.1	4.04	6.32e-05	0.00959	0.22	0.18	Response to statin therapy;	chr4:187436078	chr4:187304083~187309682:-
LUAD	cis	rs2579519	0.547	rs2463560	ENSG00000237510.6	AC008268.2	4.04	6.32e-05	0.00959	0.23	0.18	Diastolic blood pressure;	chr2:95929841	chr2:95789654~95800166:+
LUAD	cis	rs559928	0.847	rs11601738	ENSG00000236935.1	AP003774.1	4.04	6.32e-05	0.00959	0.23	0.18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64391835	chr11:64325050~64329504:-
LUAD	cis	rs2354432	0.607	rs66486822	ENSG00000226015.2	CCT8P1	4.04	6.32e-05	0.00959	0.33	0.18	Mitochondrial DNA levels;	chr1:147330922	chr1:147203276~147204932:-
LUAD	cis	rs2354432	0.607	rs72692962	ENSG00000226015.2	CCT8P1	4.04	6.32e-05	0.00959	0.33	0.18	Mitochondrial DNA levels;	chr1:147330943	chr1:147203276~147204932:-
LUAD	cis	rs2354432	0.607	rs6677679	ENSG00000226015.2	CCT8P1	4.04	6.32e-05	0.00959	0.33	0.18	Mitochondrial DNA levels;	chr1:147331900	chr1:147203276~147204932:-
LUAD	cis	rs12928939	0.517	rs17358402	ENSG00000260886.1	TAT-AS1	4.04	6.32e-05	0.00959	0.24	0.18	Post bronchodilator FEV1;	chr16:71934024	chr16:71565789~71578187:+
LUAD	cis	rs6142102	0.923	rs6059586	ENSG00000275784.1	RP5-1125A11.6	-4.04	6.32e-05	0.00959	-0.2	-0.18	Skin pigmentation;	chr20:33952695	chr20:33989480~33991818:-
LUAD	cis	rs9467773	0.935	rs11752946	ENSG00000261353.1	CTA-14H9.5	-4.04	6.32e-05	0.00959	-0.21	-0.18	Intelligence (multi-trait analysis);	chr6:26560136	chr6:26527063~26527404:+
LUAD	cis	rs4873772	0.735	rs12549996	ENSG00000253330.1	RP11-697N18.3	-4.04	6.32e-05	0.0096	-0.21	-0.18	Lobe attachment (rater-scored or self-reported);	chr8:47505644	chr8:47511034~47512141:-
LUAD	cis	rs10463554	0.892	rs11952337	ENSG00000250682.4	LINC00491	4.04	6.32e-05	0.0096	0.22	0.18	Parkinson's disease;	chr5:102928043	chr5:102609156~102671559:-
LUAD	cis	rs853679	0.517	rs12174753	ENSG00000226314.6	ZNF192P1	-4.04	6.32e-05	0.0096	-0.24	-0.18	Depression;	chr6:28074687	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs55747925	ENSG00000226314.6	ZNF192P1	-4.04	6.32e-05	0.0096	-0.24	-0.18	Depression;	chr6:28076559	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs56310871	ENSG00000226314.6	ZNF192P1	-4.04	6.32e-05	0.0096	-0.24	-0.18	Depression;	chr6:28076704	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs34716816	ENSG00000226314.6	ZNF192P1	-4.04	6.32e-05	0.0096	-0.24	-0.18	Depression;	chr6:28078391	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs9393884	ENSG00000226314.6	ZNF192P1	-4.04	6.32e-05	0.0096	-0.24	-0.18	Depression;	chr6:28079011	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs9380049	ENSG00000226314.6	ZNF192P1	-4.04	6.32e-05	0.0096	-0.24	-0.18	Depression;	chr6:28080757	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs9380050	ENSG00000226314.6	ZNF192P1	-4.04	6.32e-05	0.0096	-0.24	-0.18	Depression;	chr6:28080760	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs9393885	ENSG00000226314.6	ZNF192P1	-4.04	6.32e-05	0.0096	-0.24	-0.18	Depression;	chr6:28082231	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs9393886	ENSG00000226314.6	ZNF192P1	-4.04	6.32e-05	0.0096	-0.24	-0.18	Depression;	chr6:28082261	chr6:28161781~28169594:+
LUAD	cis	rs4713118	0.515	rs9368549	ENSG00000226314.6	ZNF192P1	-4.04	6.32e-05	0.0096	-0.24	-0.18	Parkinson's disease;	chr6:28082269	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs56364346	ENSG00000226314.6	ZNF192P1	-4.04	6.32e-05	0.0096	-0.24	-0.18	Depression;	chr6:28082984	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs9357061	ENSG00000226314.6	ZNF192P1	-4.04	6.32e-05	0.0096	-0.24	-0.18	Depression;	chr6:28083994	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs9368550	ENSG00000226314.6	ZNF192P1	-4.04	6.32e-05	0.0096	-0.24	-0.18	Depression;	chr6:28084025	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.542	rs2295594	ENSG00000226314.6	ZNF192P1	-4.04	6.32e-05	0.0096	-0.24	-0.18	Depression;	chr6:28085319	chr6:28161781~28169594:+
LUAD	cis	rs4474465	1	rs10899502	ENSG00000251323.2	RP11-452H21.4	4.04	6.32e-05	0.0096	0.23	0.18	Alzheimer's disease (survival time);	chr11:78429975	chr11:78423982~78429836:-
LUAD	cis	rs10419113	0.522	rs13037	ENSG00000269867.1	CTD-2583A14.8	4.04	6.32e-05	0.0096	0.16	0.18	Pediatric bone mineral density (spine);	chr19:57757805	chr19:57867038~57868172:-
LUAD	cis	rs8048589	0.948	rs35318501	ENSG00000175604.2	RP11-276H1.3	-4.04	6.32e-05	0.0096	-0.25	-0.18	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12088674	chr16:12086746~12090302:-
LUAD	cis	rs911555	0.504	rs745079	ENSG00000258851.1	RP11-894P9.2	-4.04	6.32e-05	0.0096	-0.21	-0.18	Intelligence (multi-trait analysis);	chr14:103607214	chr14:103553421~103561877:+
LUAD	cis	rs801193	1	rs2707856	ENSG00000224316.1	RP11-479O9.2	4.04	6.33e-05	0.0096	0.18	0.18	Aortic root size;	chr7:66746023	chr7:65773620~65802067:+
LUAD	cis	rs12935418	0.616	rs13332902	ENSG00000261061.1	RP11-303E16.2	-4.04	6.33e-05	0.0096	-0.19	-0.18	Mean corpuscular volume;	chr16:80971903	chr16:81030770~81031485:+
LUAD	cis	rs6088580	0.634	rs4258875	ENSG00000276073.1	RP5-1125A11.7	4.04	6.33e-05	0.0096	0.18	0.18	Glomerular filtration rate (creatinine);	chr20:34337089	chr20:33985617~33988989:-
LUAD	cis	rs6071166	0.683	rs6027232	ENSG00000224635.1	RP4-564F22.5	-4.04	6.33e-05	0.0096	-0.2	-0.18	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38681360	chr20:38406011~38416797:-
LUAD	cis	rs897200	0.689	rs7575463	ENSG00000280083.1	RP11-317J9.1	4.04	6.33e-05	0.0096	0.25	0.18	Behcet's disease;	chr2:191156591	chr2:191154118~191156070:-
LUAD	cis	rs8056893	0.879	rs3961282	ENSG00000274698.1	RP11-71L14.4	4.04	6.33e-05	0.00961	0.21	0.18	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68331254	chr16:68450283~68452318:+
LUAD	cis	rs2492286	0.597	rs1126828	ENSG00000242551.2	POU5F1P6	-4.04	6.33e-05	0.00961	-0.23	-0.18	Eosinophil counts;	chr3:128625943	chr3:128674735~128677005:-
LUAD	cis	rs7615952	0.599	rs1875683	ENSG00000250012.1	RP11-124N2.1	-4.04	6.33e-05	0.00961	-0.25	-0.18	Blood pressure (smoking interaction);	chr3:126013638	chr3:126084220~126095349:+
LUAD	cis	rs77688320	0.535	rs12468504	ENSG00000213090.2	AC007256.5	-4.04	6.33e-05	0.00961	-0.21	-0.18	Breast cancer;	chr2:201393746	chr2:201410544~201413308:-
LUAD	cis	rs2274273	0.553	rs56166765	ENSG00000258413.1	RP11-665C16.6	-4.04	6.33e-05	0.00961	-0.25	-0.18	Protein biomarker;	chr14:55271300	chr14:55262767~55272075:-
LUAD	cis	rs9649213	0.574	rs62478236	ENSG00000272950.1	RP11-307C18.1	4.04	6.33e-05	0.00961	0.23	0.18	Prostate cancer (SNP x SNP interaction);	chr7:98401065	chr7:98322853~98323430:+
LUAD	cis	rs9649213	0.593	rs1076272	ENSG00000272950.1	RP11-307C18.1	4.04	6.33e-05	0.00961	0.23	0.18	Prostate cancer (SNP x SNP interaction);	chr7:98401693	chr7:98322853~98323430:+
LUAD	cis	rs848490	1	rs56400413	ENSG00000214293.7	APTR	4.04	6.33e-05	0.00961	0.24	0.18	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77711504	chr7:77657660~77696265:-
LUAD	cis	rs1555322	0.53	rs932562	ENSG00000279253.1	RP4-614O4.13	-4.04	6.33e-05	0.00961	-0.23	-0.18	Attention deficit hyperactivity disorder;	chr20:35283507	chr20:35262727~35264187:-
LUAD	cis	rs7976269	0.537	rs10843308	ENSG00000257176.2	RP11-996F15.2	-4.04	6.34e-05	0.00962	-0.2	-0.18	Male-pattern baldness;	chr12:29075172	chr12:29280418~29317848:-
LUAD	cis	rs17301013	0.612	rs56199565	ENSG00000227373.4	RP11-160H22.5	4.04	6.34e-05	0.00962	0.23	0.18	Systemic lupus erythematosus;	chr1:174640992	chr1:174115300~174160004:-
LUAD	cis	rs9649213	0.593	rs11760930	ENSG00000272950.1	RP11-307C18.1	4.04	6.34e-05	0.00962	0.23	0.18	Prostate cancer (SNP x SNP interaction);	chr7:98286477	chr7:98322853~98323430:+
LUAD	cis	rs17406451	1	rs17406451	ENSG00000279873.2	LINC01126	4.04	6.34e-05	0.00962	0.16	0.18	Mitochondrial DNA levels;	chr2:43405337	chr2:43227210~43228855:+
LUAD	cis	rs6570726	0.846	rs973856	ENSG00000235652.6	RP11-545I5.3	-4.04	6.34e-05	0.00962	-0.18	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145460780	chr6:145799409~145886585:+
LUAD	cis	rs2898290	0.578	rs34163377	ENSG00000255046.1	RP11-297N6.4	-4.04	6.34e-05	0.00962	-0.23	-0.18	Systolic blood pressure;	chr8:11592704	chr8:11797928~11802568:-
LUAD	cis	rs8024893	0.764	rs8035110	ENSG00000270055.1	CTD-3092A11.2	4.04	6.34e-05	0.00962	0.24	0.18	Red cell distribution width;	chr15:31241884	chr15:30487963~30490313:+
LUAD	cis	rs8024893	0.764	rs8036245	ENSG00000270055.1	CTD-3092A11.2	4.04	6.34e-05	0.00962	0.24	0.18	Red cell distribution width;	chr15:31242211	chr15:30487963~30490313:+
LUAD	cis	rs7129556	0.728	rs628668	ENSG00000241782.1	RP11-91P24.1	4.04	6.34e-05	0.00962	0.25	0.18	Weight loss (gastric bypass surgery);	chr11:77866448	chr11:77868722~77869195:-
LUAD	cis	rs828999	0.872	rs663045	ENSG00000280186.1	RP11-483I13.6	4.04	6.34e-05	0.00962	0.21	0.18	Monocyte percentage of white cells;	chr1:108200437	chr1:108200413~108202743:+
LUAD	cis	rs7512552	0.839	rs1694362	ENSG00000275557.1	RP11-353N4.6	4.04	6.34e-05	0.00963	0.21	0.18	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150394487	chr1:149607765~149612402:+
LUAD	cis	rs7688540	0.515	rs28415975	ENSG00000211553.1	AC253576.2	-4.04	6.35e-05	0.00963	-0.24	-0.18	Facial morphology (factor 6, height of vermillion lower lip);	chr4:266377	chr4:136461~136568:+
LUAD	cis	rs12439619	0.705	rs4778665	ENSG00000276710.3	CSPG4P8	-4.04	6.35e-05	0.00963	-0.21	-0.18	Intelligence (multi-trait analysis);	chr15:82144163	chr15:82459472~82477258:+
LUAD	cis	rs7762018	1	rs6942332	ENSG00000231690.2	LINC00574	-4.04	6.35e-05	0.00963	-0.33	-0.18	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169731838	chr6:169790321~169802873:+
LUAD	cis	rs2836974	0.605	rs2836988	ENSG00000232608.1	TIMM9P2	4.04	6.35e-05	0.00963	0.21	0.18	Cognitive function;	chr21:39336049	chr21:39216624~39217506:+
LUAD	cis	rs2274273	0.84	rs11626751	ENSG00000258413.1	RP11-665C16.6	-4.04	6.35e-05	0.00963	-0.23	-0.18	Protein biomarker;	chr14:55368509	chr14:55262767~55272075:-
LUAD	cis	rs2638953	0.924	rs4573721	ENSG00000278733.1	RP11-425D17.1	-4.04	6.35e-05	0.00963	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28194746	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs4554927	ENSG00000278733.1	RP11-425D17.1	-4.04	6.35e-05	0.00963	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28194844	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs61920243	ENSG00000278733.1	RP11-425D17.1	-4.04	6.35e-05	0.00963	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195333	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.679	rs7974882	ENSG00000278733.1	RP11-425D17.1	-4.04	6.35e-05	0.00963	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195415	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.679	rs7961395	ENSG00000278733.1	RP11-425D17.1	-4.04	6.35e-05	0.00963	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195420	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs7961407	ENSG00000278733.1	RP11-425D17.1	-4.04	6.35e-05	0.00963	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195482	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs7974904	ENSG00000278733.1	RP11-425D17.1	-4.04	6.35e-05	0.00963	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195491	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs7974979	ENSG00000278733.1	RP11-425D17.1	-4.04	6.35e-05	0.00963	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195496	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs7974701	ENSG00000278733.1	RP11-425D17.1	-4.04	6.35e-05	0.00963	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195579	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.886	rs7961769	ENSG00000278733.1	RP11-425D17.1	-4.04	6.35e-05	0.00963	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195772	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.886	rs61920244	ENSG00000278733.1	RP11-425D17.1	-4.04	6.35e-05	0.00963	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195992	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs34378873	ENSG00000278733.1	RP11-425D17.1	-4.04	6.35e-05	0.00963	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196124	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs11049438	ENSG00000278733.1	RP11-425D17.1	-4.04	6.35e-05	0.00963	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196205	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs11049439	ENSG00000278733.1	RP11-425D17.1	-4.04	6.35e-05	0.00963	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196369	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs11049440	ENSG00000278733.1	RP11-425D17.1	-4.04	6.35e-05	0.00963	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196474	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs11049441	ENSG00000278733.1	RP11-425D17.1	-4.04	6.35e-05	0.00963	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196476	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.853	rs11049442	ENSG00000278733.1	RP11-425D17.1	-4.04	6.35e-05	0.00963	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197211	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs11049443	ENSG00000278733.1	RP11-425D17.1	-4.04	6.35e-05	0.00963	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197269	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs11049444	ENSG00000278733.1	RP11-425D17.1	-4.04	6.35e-05	0.00963	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197447	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs11049445	ENSG00000278733.1	RP11-425D17.1	-4.04	6.35e-05	0.00963	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197449	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.962	rs60193273	ENSG00000278733.1	RP11-425D17.1	-4.04	6.35e-05	0.00963	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197638	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs11049446	ENSG00000278733.1	RP11-425D17.1	-4.04	6.35e-05	0.00963	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197951	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs11049447	ENSG00000278733.1	RP11-425D17.1	-4.04	6.35e-05	0.00963	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28197970	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.886	rs10843123	ENSG00000278733.1	RP11-425D17.1	-4.04	6.35e-05	0.00963	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28198004	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs10843124	ENSG00000278733.1	RP11-425D17.1	-4.04	6.35e-05	0.00963	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28198189	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs10843125	ENSG00000278733.1	RP11-425D17.1	-4.04	6.35e-05	0.00963	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28198308	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs11049448	ENSG00000278733.1	RP11-425D17.1	-4.04	6.35e-05	0.00963	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28198975	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs10843126	ENSG00000278733.1	RP11-425D17.1	-4.04	6.35e-05	0.00963	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28199112	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs10843127	ENSG00000278733.1	RP11-425D17.1	-4.04	6.35e-05	0.00963	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28199124	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.85	rs10843128	ENSG00000278733.1	RP11-425D17.1	-4.04	6.35e-05	0.00963	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28199377	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs10843130	ENSG00000278733.1	RP11-425D17.1	-4.04	6.35e-05	0.00963	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28199793	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs61920253	ENSG00000278733.1	RP11-425D17.1	-4.04	6.35e-05	0.00963	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28202039	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.888	rs11612143	ENSG00000278733.1	RP11-425D17.1	-4.04	6.35e-05	0.00963	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28202694	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.813	rs11609999	ENSG00000278733.1	RP11-425D17.1	-4.04	6.35e-05	0.00963	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28202721	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.888	rs11610011	ENSG00000278733.1	RP11-425D17.1	-4.04	6.35e-05	0.00963	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28202801	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs11049453	ENSG00000278733.1	RP11-425D17.1	-4.04	6.35e-05	0.00963	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28202996	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.886	rs7957059	ENSG00000278733.1	RP11-425D17.1	-4.04	6.35e-05	0.00963	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28203390	chr12:28185625~28186190:-
LUAD	cis	rs2836950	0.527	rs2836958	ENSG00000232608.1	TIMM9P2	4.04	6.35e-05	0.00963	0.2	0.18	Menarche (age at onset);	chr21:39251600	chr21:39216624~39217506:+
LUAD	cis	rs10510102	0.516	rs12256693	ENSG00000276742.1	RP11-500G22.4	4.03	6.35e-05	0.00963	0.31	0.18	Breast cancer;	chr10:121976839	chr10:121956782~121957098:+
LUAD	cis	rs10129255	0.784	rs7147210	ENSG00000211967.3	IGHV3-53	-4.03	6.35e-05	0.00963	-0.14	-0.18	Kawasaki disease;	chr14:106705271	chr14:106592676~106593347:-
LUAD	cis	rs7107174	1	rs2512546	ENSG00000251323.2	RP11-452H21.4	4.03	6.35e-05	0.00963	0.22	0.18	Testicular germ cell tumor;	chr11:78246230	chr11:78423982~78429836:-
LUAD	cis	rs7200786	0.546	rs11640227	ENSG00000274038.1	RP11-66H6.4	-4.03	6.35e-05	0.00963	-0.23	-0.18	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11134371	chr16:11056556~11057034:+
LUAD	cis	rs9926296	0.605	rs6500453	ENSG00000260259.1	RP11-368I7.4	-4.03	6.35e-05	0.00963	-0.18	-0.18	Vitiligo;	chr16:89792249	chr16:89682620~89686569:-
LUAD	cis	rs848490	0.962	rs55869229	ENSG00000214293.7	APTR	4.03	6.35e-05	0.00963	0.24	0.18	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77721148	chr7:77657660~77696265:-
LUAD	cis	rs2274273	0.624	rs8014477	ENSG00000258413.1	RP11-665C16.6	4.03	6.35e-05	0.00963	0.24	0.18	Protein biomarker;	chr14:55374759	chr14:55262767~55272075:-
LUAD	cis	rs6430553	0.929	rs74265413	ENSG00000224043.6	CCNT2-AS1	-4.03	6.36e-05	0.00964	-0.22	-0.18	Blood metabolite levels;	chr2:134892083	chr2:134735464~134918710:-
LUAD	cis	rs12541335	0.639	rs11779277	ENSG00000254064.1	CTD-2530N21.4	4.03	6.36e-05	0.00964	0.18	0.18	Hypertriglyceridemia;	chr8:22343170	chr8:22254576~22275162:-
LUAD	cis	rs6671200	0.607	rs3767315	ENSG00000228852.5	RP11-57H12.5	-4.03	6.36e-05	0.00964	-0.22	-0.18	Stearic acid (18:0) levels;	chr1:95240416	chr1:95243167~95278940:-
LUAD	cis	rs6671200	0.607	rs7528790	ENSG00000228852.5	RP11-57H12.5	-4.03	6.36e-05	0.00964	-0.22	-0.18	Stearic acid (18:0) levels;	chr1:95243518	chr1:95243167~95278940:-
LUAD	cis	rs11216126	0.818	rs4938304	ENSG00000280143.1	AP000892.6	-4.03	6.36e-05	0.00964	-0.32	-0.18	HDL cholesterol;	chr11:116717709	chr11:117204967~117210292:+
LUAD	cis	rs7191700	0.583	rs243314	ENSG00000262636.1	CTD-3088G3.4	4.03	6.36e-05	0.00964	0.22	0.18	Multiple sclerosis;	chr16:11291247	chr16:11380859~11381118:-
LUAD	cis	rs9649213	0.574	rs60077733	ENSG00000272950.1	RP11-307C18.1	4.03	6.36e-05	0.00964	0.23	0.18	Prostate cancer (SNP x SNP interaction);	chr7:98340825	chr7:98322853~98323430:+
LUAD	cis	rs7172677	0.961	rs34511319	ENSG00000260269.4	CTD-2323K18.1	-4.03	6.36e-05	0.00964	-0.24	-0.18	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75137376	chr15:75527150~75601205:-
LUAD	cis	rs7172677	1	rs62027286	ENSG00000260269.4	CTD-2323K18.1	-4.03	6.36e-05	0.00964	-0.24	-0.18	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75137379	chr15:75527150~75601205:-
LUAD	cis	rs7172677	0.961	rs62027287	ENSG00000260269.4	CTD-2323K18.1	-4.03	6.36e-05	0.00964	-0.24	-0.18	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75137380	chr15:75527150~75601205:-
LUAD	cis	rs7172677	1	rs2415159	ENSG00000260269.4	CTD-2323K18.1	-4.03	6.36e-05	0.00964	-0.24	-0.18	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75138374	chr15:75527150~75601205:-
LUAD	cis	rs7172677	1	rs8032208	ENSG00000260269.4	CTD-2323K18.1	-4.03	6.36e-05	0.00964	-0.24	-0.18	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75138904	chr15:75527150~75601205:-
LUAD	cis	rs7674212	0.833	rs61075040	ENSG00000251288.2	RP11-10L12.2	-4.03	6.36e-05	0.00964	-0.23	-0.18	Type 2 diabetes;	chr4:103052804	chr4:102751401~102752641:+
LUAD	cis	rs17301013	0.9	rs1793300	ENSG00000227373.4	RP11-160H22.5	-4.03	6.36e-05	0.00964	-0.23	-0.18	Systemic lupus erythematosus;	chr1:174768559	chr1:174115300~174160004:-
LUAD	cis	rs889398	0.77	rs8052225	ENSG00000226232.7	RP11-419C5.2	-4.03	6.36e-05	0.00964	-0.16	-0.18	Body mass index;	chr16:69849750	chr16:69976388~69996188:-
LUAD	cis	rs6452524	0.534	rs17284134	ENSG00000281327.1	LINC01338	-4.03	6.36e-05	0.00965	-0.19	-0.18	Hypertension (SNP x SNP interaction);	chr5:83068325	chr5:82850864~82859836:-
LUAD	cis	rs6121246	0.559	rs12479491	ENSG00000230613.1	HM13-AS1	4.03	6.36e-05	0.00965	0.22	0.18	Mean corpuscular hemoglobin;	chr20:31677647	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.559	rs6058352	ENSG00000230613.1	HM13-AS1	4.03	6.36e-05	0.00965	0.22	0.18	Mean corpuscular hemoglobin;	chr20:31681376	chr20:31567707~31573263:-
LUAD	cis	rs7204230	0.961	rs59160806	ENSG00000261291.1	RP11-295M3.2	4.03	6.37e-05	0.00965	0.22	0.18	Fibrinogen;	chr16:53241238	chr16:53168522~53169450:+
LUAD	cis	rs7551222	0.721	rs4951080	ENSG00000240219.1	RP11-430C7.5	4.03	6.37e-05	0.00965	0.19	0.18	Schizophrenia;	chr1:204564156	chr1:204626775~204629712:+
LUAD	cis	rs6088580	0.634	rs6120644	ENSG00000276073.1	RP5-1125A11.7	-4.03	6.37e-05	0.00966	-0.18	-0.18	Glomerular filtration rate (creatinine);	chr20:34436005	chr20:33985617~33988989:-
LUAD	cis	rs6088580	0.624	rs6120645	ENSG00000276073.1	RP5-1125A11.7	-4.03	6.37e-05	0.00966	-0.18	-0.18	Glomerular filtration rate (creatinine);	chr20:34437366	chr20:33985617~33988989:-
LUAD	cis	rs6088580	0.602	rs6059840	ENSG00000276073.1	RP5-1125A11.7	-4.03	6.37e-05	0.00966	-0.18	-0.18	Glomerular filtration rate (creatinine);	chr20:34442600	chr20:33985617~33988989:-
LUAD	cis	rs2692947	0.86	rs2579520	ENSG00000237510.6	AC008268.2	-4.03	6.37e-05	0.00966	-0.23	-0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:95994552	chr2:95789654~95800166:+
LUAD	cis	rs1461503	0.511	rs4129007	ENSG00000199709.1	RNU4-23P	-4.03	6.37e-05	0.00966	-0.22	-0.18	Menarche (age at onset);	chr11:122941104	chr11:122927034~122927173:+
LUAD	cis	rs11168618	0.846	rs11168580	ENSG00000240399.1	RP1-228P16.1	4.03	6.37e-05	0.00966	0.18	0.18	Adiponectin levels;	chr12:48456641	chr12:48054813~48055591:-
LUAD	cis	rs4819052	0.851	rs2838855	ENSG00000215447.6	BX322557.10	4.03	6.37e-05	0.00966	0.22	0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260651	chr21:45288052~45291738:+
LUAD	cis	rs6787172	0.783	rs12489496	ENSG00000272087.1	RP11-379F4.7	4.03	6.37e-05	0.00966	0.19	0.18	Subjective well-being;	chr3:158518455	chr3:158693120~158693768:-
LUAD	cis	rs256438	0.896	rs2438637	ENSG00000251050.1	RP11-168A11.4	-4.03	6.37e-05	0.00966	-0.19	-0.18	Serum thyroid-stimulating hormone levels;	chr5:80094553	chr5:80019609~80019920:+
LUAD	cis	rs7107174	1	rs2511168	ENSG00000251323.2	RP11-452H21.4	4.03	6.38e-05	0.00966	0.25	0.18	Testicular germ cell tumor;	chr11:78254035	chr11:78423982~78429836:-
LUAD	cis	rs13287066	0.692	rs4563950	ENSG00000227603.1	RP11-165J3.6	4.03	6.38e-05	0.00966	0.21	0.18	Intelligence (multi-trait analysis);	chr9:93405359	chr9:93435332~93437121:-
LUAD	cis	rs17122278	1	rs3741320	ENSG00000243431.1	RPL5P30	4.03	6.38e-05	0.00966	0.22	0.18	Total cholesterol levels;	chr11:118545132	chr11:118560690~118561580:+
LUAD	cis	rs17122278	1	rs3741319	ENSG00000243431.1	RPL5P30	4.03	6.38e-05	0.00966	0.22	0.18	Total cholesterol levels;	chr11:118545133	chr11:118560690~118561580:+
LUAD	cis	rs34779708	0.771	rs12098283	ENSG00000271335.4	RP11-324I22.4	4.03	6.38e-05	0.00967	0.19	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35189187	chr10:35314552~35336401:-
LUAD	cis	rs853679	0.517	rs9380052	ENSG00000226314.6	ZNF192P1	-4.03	6.38e-05	0.00967	-0.23	-0.18	Depression;	chr6:28096845	chr6:28161781~28169594:+
LUAD	cis	rs6088580	0.634	rs6087587	ENSG00000276073.1	RP5-1125A11.7	-4.03	6.38e-05	0.00967	-0.18	-0.18	Glomerular filtration rate (creatinine);	chr20:34470823	chr20:33985617~33988989:-
LUAD	cis	rs35740288	0.721	rs11636347	ENSG00000259407.1	RP11-158M2.3	-4.03	6.38e-05	0.00967	-0.18	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85698002	chr15:85744109~85750281:-
LUAD	cis	rs11971779	0.816	rs11979272	ENSG00000273391.1	RP11-634H22.1	4.03	6.38e-05	0.00967	0.21	0.18	Diisocyanate-induced asthma;	chr7:139389323	chr7:139359032~139359566:-
LUAD	cis	rs1005277	0.54	rs7903942	ENSG00000263064.2	RP11-291L22.7	-4.03	6.38e-05	0.00967	-0.19	-0.18	Extrinsic epigenetic age acceleration;	chr10:37640348	chr10:38448689~38448949:+
LUAD	cis	rs6723108	0.603	rs3769023	ENSG00000224043.6	CCNT2-AS1	-4.03	6.39e-05	0.00968	-0.23	-0.18	Type 2 diabetes;	chr2:134956133	chr2:134735464~134918710:-
LUAD	cis	rs5752773	0.564	rs5762670	ENSG00000272858.1	CTA-292E10.8	4.03	6.39e-05	0.00968	0.2	0.18	Vertical cup-disc ratio;	chr22:28524663	chr22:28814914~28815662:+
LUAD	cis	rs11886999	0.68	rs6756208	ENSG00000237510.6	AC008268.2	-4.03	6.39e-05	0.00968	-0.32	-0.18	Cardiac Troponin-T levels;	chr2:96166961	chr2:95789654~95800166:+
LUAD	cis	rs17122278	1	rs73023350	ENSG00000243431.1	RPL5P30	4.03	6.39e-05	0.00968	0.22	0.18	Total cholesterol levels;	chr11:118578681	chr11:118560690~118561580:+
LUAD	cis	rs6840360	0.642	rs2709822	ENSG00000270265.1	RP11-731D1.4	-4.03	6.39e-05	0.00968	-0.18	-0.18	Intelligence (multi-trait analysis);	chr4:151430348	chr4:151333775~151353224:-
LUAD	cis	rs9475752	0.552	rs13205022	ENSG00000231441.1	RP11-472M19.2	-4.03	6.39e-05	0.00968	-0.27	-0.18	Menarche (age at onset);	chr6:56875620	chr6:56844002~56864078:+
LUAD	cis	rs3018712	0.522	rs4930595	ENSG00000227620.4	ALG1L8P	-4.03	6.39e-05	0.00968	-0.24	-0.18	Total body bone mineral density;	chr11:68668359	chr11:67785273~67792335:+
LUAD	cis	rs9309473	0.5	rs11688718	ENSG00000163016.8	ALMS1P	4.03	6.39e-05	0.00968	0.19	0.18	Metabolite levels;	chr2:73533812	chr2:73644919~73685576:+
LUAD	cis	rs2243480	1	rs313820	ENSG00000229886.1	RP5-1132H15.3	4.03	6.39e-05	0.00968	0.31	0.18	Diabetic kidney disease;	chr7:66109479	chr7:66025126~66031544:-
LUAD	cis	rs17122278	0.696	rs562780	ENSG00000243431.1	RPL5P30	-4.03	6.39e-05	0.00968	-0.23	-0.18	Total cholesterol levels;	chr11:118491699	chr11:118560690~118561580:+
LUAD	cis	rs2299587	0.585	rs2285304	ENSG00000253671.1	RP11-806O11.1	-4.03	6.39e-05	0.00968	-0.21	-0.18	Economic and political preferences;	chr8:17940422	chr8:17808941~17820868:+
LUAD	cis	rs6088580	0.634	rs3736762	ENSG00000276073.1	RP5-1125A11.7	-4.03	6.39e-05	0.00968	-0.18	-0.18	Glomerular filtration rate (creatinine);	chr20:34449531	chr20:33985617~33988989:-
LUAD	cis	rs6088580	0.634	rs6120650	ENSG00000276073.1	RP5-1125A11.7	-4.03	6.39e-05	0.00968	-0.18	-0.18	Glomerular filtration rate (creatinine);	chr20:34452168	chr20:33985617~33988989:-
LUAD	cis	rs6088580	0.634	rs6058051	ENSG00000276073.1	RP5-1125A11.7	-4.03	6.39e-05	0.00968	-0.18	-0.18	Glomerular filtration rate (creatinine);	chr20:34457057	chr20:33985617~33988989:-
LUAD	cis	rs3120667	0.79	rs1923493	ENSG00000237975.5	FLG-AS1	4.03	6.39e-05	0.00968	0.3	0.18	Eating disorders;	chr1:152411727	chr1:152168125~152445456:+
LUAD	cis	rs3120667	0.79	rs7521839	ENSG00000237975.5	FLG-AS1	4.03	6.39e-05	0.00968	0.3	0.18	Eating disorders;	chr1:152412283	chr1:152168125~152445456:+
LUAD	cis	rs256438	0.93	rs2438638	ENSG00000251050.1	RP11-168A11.4	4.03	6.39e-05	0.00969	0.19	0.18	Serum thyroid-stimulating hormone levels;	chr5:80094377	chr5:80019609~80019920:+
LUAD	cis	rs17772222	1	rs17772064	ENSG00000258983.2	RP11-507K2.2	4.03	6.4e-05	0.00969	0.21	0.18	Coronary artery calcification;	chr14:88356527	chr14:88499334~88515502:+
LUAD	cis	rs7122539	0.506	rs11227625	ENSG00000213409.4	RP11-658F2.3	-4.03	6.4e-05	0.00969	-0.21	-0.18	HIV-1 susceptibility;	chr11:66916680	chr11:66761575~66762399:-
LUAD	cis	rs2243480	1	rs437889	ENSG00000229886.1	RP5-1132H15.3	4.03	6.4e-05	0.00969	0.31	0.18	Diabetic kidney disease;	chr7:66044247	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs402418	ENSG00000229886.1	RP5-1132H15.3	4.03	6.4e-05	0.00969	0.31	0.18	Diabetic kidney disease;	chr7:66044482	chr7:66025126~66031544:-
LUAD	cis	rs2243480	0.803	rs423187	ENSG00000229886.1	RP5-1132H15.3	4.03	6.4e-05	0.00969	0.31	0.18	Diabetic kidney disease;	chr7:66044512	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs1499614	ENSG00000229886.1	RP5-1132H15.3	4.03	6.4e-05	0.00969	0.3	0.18	Diabetic kidney disease;	chr7:66265811	chr7:66025126~66031544:-
LUAD	cis	rs4474465	1	rs7124092	ENSG00000251323.2	RP11-452H21.4	4.03	6.4e-05	0.0097	0.22	0.18	Alzheimer's disease (survival time);	chr11:78444040	chr11:78423982~78429836:-
LUAD	cis	rs10127852	0.541	rs12057661	ENSG00000122432.15	SPATA1	4.03	6.4e-05	0.0097	0.34	0.18	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:84795003	chr1:84506291~84566194:+
LUAD	cis	rs7727544	0.514	rs3846728	ENSG00000233006.5	AC034220.3	4.03	6.4e-05	0.0097	0.16	0.18	Blood metabolite levels;	chr5:132100524	chr5:132311285~132369916:-
LUAD	cis	rs17685	0.712	rs56965035	ENSG00000280388.1	RP11-229D13.3	-4.03	6.4e-05	0.0097	-0.17	-0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76166352	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.672	rs56343450	ENSG00000280388.1	RP11-229D13.3	-4.03	6.4e-05	0.0097	-0.17	-0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76166917	chr7:76043977~76045963:-
LUAD	cis	rs12478296	1	rs66612947	ENSG00000261186.2	RP11-341N2.1	-4.03	6.41e-05	0.0097	-0.31	-0.18	Obesity-related traits;	chr2:242093811	chr2:242087351~242088457:-
LUAD	cis	rs8177876	0.822	rs4889225	ENSG00000261061.1	RP11-303E16.2	4.03	6.41e-05	0.00971	0.26	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81074891	chr16:81030770~81031485:+
LUAD	cis	rs2154319	0.887	rs61780435	ENSG00000235358.1	RP11-399E6.1	-4.03	6.41e-05	0.00971	-0.25	-0.18	Height;	chr1:41009899	chr1:41242373~41284861:+
LUAD	cis	rs2239547	0.603	rs6805298	ENSG00000243224.1	RP5-1157M23.2	4.03	6.41e-05	0.00971	0.2	0.18	Schizophrenia;	chr3:53062536	chr3:52239258~52241097:+
LUAD	cis	rs6558530	0.653	rs7001282	ENSG00000253982.1	CTD-2336O2.1	4.03	6.41e-05	0.00971	0.24	0.18	Systolic blood pressure;	chr8:1752022	chr8:1761990~1764502:-
LUAD	cis	rs10466239	0.892	rs74701654	ENSG00000230555.2	RP11-517P14.2	4.03	6.41e-05	0.00971	0.35	0.18	Telomere length;	chr10:43350863	chr10:43420738~43422100:+
LUAD	cis	rs10466239	0.892	rs17153534	ENSG00000230555.2	RP11-517P14.2	4.03	6.41e-05	0.00971	0.35	0.18	Telomere length;	chr10:43353203	chr10:43420738~43422100:+
LUAD	cis	rs8042680	0.592	rs4381579	ENSG00000259746.1	HSPE1P3	4.03	6.41e-05	0.00971	0.2	0.18	Type 2 diabetes;	chr15:90955051	chr15:90634725~90635033:+
LUAD	cis	rs8042680	0.592	rs4505290	ENSG00000259746.1	HSPE1P3	4.03	6.41e-05	0.00971	0.2	0.18	Type 2 diabetes;	chr15:90955063	chr15:90634725~90635033:+
LUAD	cis	rs11742741	0.806	rs2134237	ENSG00000248874.4	C5orf17	-4.03	6.42e-05	0.00971	-0.22	-0.18	Educational attainment;	chr5:24056641	chr5:23951348~24178263:+
LUAD	cis	rs3845817	0.838	rs697150	ENSG00000281920.1	RP11-418H16.1	-4.03	6.42e-05	0.00972	-0.22	-0.18	Bipolar disorder;	chr2:65522950	chr2:65623272~65628424:+
LUAD	cis	rs7119038	0.818	rs56758835	ENSG00000255239.1	AP002954.6	-4.03	6.42e-05	0.00972	-0.28	-0.18	Sjögren's syndrome;	chr11:118744631	chr11:118688039~118690600:-
LUAD	cis	rs1874124	0.577	rs2807853	ENSG00000257551.1	HLX-AS1	4.03	6.42e-05	0.00972	0.26	0.18	Cholesterol, total;	chr1:220851011	chr1:220832763~220880140:-
LUAD	cis	rs1874124	0.504	rs2491257	ENSG00000257551.1	HLX-AS1	4.03	6.42e-05	0.00972	0.26	0.18	Cholesterol, total;	chr1:220855900	chr1:220832763~220880140:-
LUAD	cis	rs11903757	0.738	rs10931515	ENSG00000230611.1	HMGB1P27	-4.03	6.42e-05	0.00972	-0.24	-0.18	Colorectal cancer;	chr2:191710385	chr2:191174233~191174835:+
LUAD	cis	rs7937682	1	rs12363179	ENSG00000230911.1	PPIHP1	4.03	6.42e-05	0.00972	0.25	0.18	Primary sclerosing cholangitis;	chr11:111697367	chr11:112029858~112030367:-
LUAD	cis	rs7937682	1	rs7121011	ENSG00000230911.1	PPIHP1	4.03	6.42e-05	0.00972	0.25	0.18	Primary sclerosing cholangitis;	chr11:111697957	chr11:112029858~112030367:-
LUAD	cis	rs950880	1	rs1420101	ENSG00000234389.1	AC007278.3	-4.03	6.42e-05	0.00972	-0.17	-0.18	Serum protein levels (sST2);	chr2:102341256	chr2:102438713~102440475:+
LUAD	cis	rs6088580	0.634	rs6059860	ENSG00000276073.1	RP5-1125A11.7	-4.03	6.42e-05	0.00972	-0.18	-0.18	Glomerular filtration rate (creatinine);	chr20:34476025	chr20:33985617~33988989:-
LUAD	cis	rs6088580	0.57	rs6058057	ENSG00000276073.1	RP5-1125A11.7	-4.03	6.42e-05	0.00972	-0.18	-0.18	Glomerular filtration rate (creatinine);	chr20:34477478	chr20:33985617~33988989:-
LUAD	cis	rs7617773	0.78	rs7645425	ENSG00000199476.1	Y_RNA	-4.03	6.42e-05	0.00972	-0.24	-0.18	Coronary artery disease;	chr3:48320879	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.78	rs6793223	ENSG00000199476.1	Y_RNA	-4.03	6.42e-05	0.00972	-0.24	-0.18	Coronary artery disease;	chr3:48322611	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.78	rs4541431	ENSG00000199476.1	Y_RNA	-4.03	6.42e-05	0.00972	-0.24	-0.18	Coronary artery disease;	chr3:48323728	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.78	rs11714944	ENSG00000199476.1	Y_RNA	-4.03	6.42e-05	0.00972	-0.24	-0.18	Coronary artery disease;	chr3:48325481	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.743	rs13071960	ENSG00000199476.1	Y_RNA	-4.03	6.42e-05	0.00972	-0.24	-0.18	Coronary artery disease;	chr3:48326047	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.743	rs4632568	ENSG00000199476.1	Y_RNA	-4.03	6.42e-05	0.00972	-0.24	-0.18	Coronary artery disease;	chr3:48326329	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.78	rs11130164	ENSG00000199476.1	Y_RNA	-4.03	6.42e-05	0.00972	-0.24	-0.18	Coronary artery disease;	chr3:48327544	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.78	rs7653336	ENSG00000199476.1	Y_RNA	-4.03	6.42e-05	0.00972	-0.24	-0.18	Coronary artery disease;	chr3:48327974	chr3:48288587~48288694:+
LUAD	cis	rs7302981	0.719	rs836188	ENSG00000272368.2	RP4-605O3.4	4.03	6.42e-05	0.00972	0.2	0.18	Systolic blood pressure;	chr12:50067569	chr12:50112197~50165618:+
LUAD	cis	rs6088580	0.634	rs6088508	ENSG00000276073.1	RP5-1125A11.7	-4.03	6.42e-05	0.00972	-0.18	-0.18	Glomerular filtration rate (creatinine);	chr20:34472276	chr20:33985617~33988989:-
LUAD	cis	rs4713118	0.869	rs10214440	ENSG00000280107.1	AL022393.9	-4.03	6.42e-05	0.00973	-0.23	-0.18	Parkinson's disease;	chr6:27734661	chr6:28170845~28172521:+
LUAD	cis	rs6951245	0.58	rs10257426	ENSG00000229043.2	AC091729.9	-4.03	6.42e-05	0.00973	-0.26	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1174058	chr7:1160374~1165267:+
LUAD	cis	rs17772222	1	rs56987357	ENSG00000258789.1	RP11-507K2.3	-4.03	6.43e-05	0.00973	-0.24	-0.18	Coronary artery calcification;	chr14:88358019	chr14:88551597~88552493:+
LUAD	cis	rs7201929	1	rs12920514	ENSG00000251417.2	RP11-1348G14.4	4.03	6.43e-05	0.00973	0.21	0.18	QT interval;	chr16:28824579	chr16:28802743~28817828:+
LUAD	cis	rs957448	1	rs10956915	ENSG00000253175.1	RP11-267M23.6	4.03	6.43e-05	0.00974	0.22	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94502362	chr8:94565036~94565715:+
LUAD	cis	rs2944755	0.58	rs13251004	ENSG00000279766.1	RP11-642A1.2	-4.03	6.43e-05	0.00974	-0.21	-0.18	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140576027	chr8:140572142~140572812:-
LUAD	cis	rs7976269	0.537	rs10843303	ENSG00000257176.2	RP11-996F15.2	-4.03	6.43e-05	0.00974	-0.2	-0.18	Male-pattern baldness;	chr12:29069435	chr12:29280418~29317848:-
LUAD	cis	rs7976269	0.537	rs2117992	ENSG00000257176.2	RP11-996F15.2	-4.03	6.43e-05	0.00974	-0.2	-0.18	Male-pattern baldness;	chr12:29070611	chr12:29280418~29317848:-
LUAD	cis	rs7976269	0.559	rs10843304	ENSG00000257176.2	RP11-996F15.2	-4.03	6.43e-05	0.00974	-0.2	-0.18	Male-pattern baldness;	chr12:29071226	chr12:29280418~29317848:-
LUAD	cis	rs9341808	0.754	rs9341810	ENSG00000260645.1	RP11-250B2.5	4.03	6.43e-05	0.00974	0.17	0.18	Sitting height ratio;	chr6:80265121	chr6:80466958~80469080:+
LUAD	cis	rs9341808	0.7	rs12215236	ENSG00000260645.1	RP11-250B2.5	4.03	6.43e-05	0.00974	0.17	0.18	Sitting height ratio;	chr6:80265341	chr6:80466958~80469080:+
LUAD	cis	rs7172677	1	rs4479194	ENSG00000260269.4	CTD-2323K18.1	-4.03	6.43e-05	0.00974	-0.24	-0.18	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75129790	chr15:75527150~75601205:-
LUAD	cis	rs858239	0.539	rs6461695	ENSG00000226816.2	AC005082.12	4.03	6.43e-05	0.00974	0.25	0.18	Cerebrospinal fluid biomarker levels;	chr7:23158165	chr7:23206013~23208045:+
LUAD	cis	rs13113518	0.783	rs34534635	ENSG00000272969.1	RP11-528I4.2	4.03	6.44e-05	0.00974	0.19	0.18	Height;	chr4:55573424	chr4:55547112~55547889:+
LUAD	cis	rs9926296	0.605	rs8046243	ENSG00000260259.1	RP11-368I7.4	-4.03	6.44e-05	0.00974	-0.18	-0.18	Vitiligo;	chr16:89785725	chr16:89682620~89686569:-
LUAD	cis	rs4660214	0.666	rs1984143	ENSG00000182109.6	RP11-69E11.4	-4.03	6.44e-05	0.00974	-0.2	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39290645	chr1:39522280~39546187:-
LUAD	cis	rs9341808	0.754	rs1324121	ENSG00000260645.1	RP11-250B2.5	4.03	6.44e-05	0.00975	0.17	0.18	Sitting height ratio;	chr6:80236360	chr6:80466958~80469080:+
LUAD	cis	rs728616	0.867	rs61860412	ENSG00000225484.5	NUTM2B-AS1	-4.03	6.44e-05	0.00975	-0.45	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79968730	chr10:79663088~79826594:-
LUAD	cis	rs651907	0.557	rs1031710	ENSG00000244119.1	PDCL3P4	4.03	6.44e-05	0.00975	0.18	0.18	Colorectal cancer;	chr3:101745051	chr3:101712472~101713191:+
LUAD	cis	rs651907	0.535	rs13065944	ENSG00000244119.1	PDCL3P4	4.03	6.44e-05	0.00975	0.18	0.18	Colorectal cancer;	chr3:101754244	chr3:101712472~101713191:+
LUAD	cis	rs797680	0.586	rs2281525	ENSG00000223745.6	RP4-717I23.3	4.03	6.44e-05	0.00975	0.15	0.18	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93129749	chr1:93262186~93346025:-
LUAD	cis	rs4144027	0.791	rs11160770	ENSG00000258534.1	CTD-2134A5.4	-4.03	6.44e-05	0.00975	-0.2	-0.18	Blood metabolite levels;	chr14:103895954	chr14:103854366~103880111:-
LUAD	cis	rs9921222	0.565	rs10903014	ENSG00000236829.8	Z97634.3	4.03	6.44e-05	0.00975	0.21	0.18	Bone mineral density (spine);Bone mineral density;	chr16:327623	chr16:382097~392960:+
LUAD	cis	rs8180040	1	rs4858888	ENSG00000271161.1	BOLA2P2	-4.03	6.44e-05	0.00975	-0.17	-0.18	Colorectal cancer;	chr3:47363815	chr3:47499841~47500407:+
LUAD	cis	rs9894429	1	rs9674872	ENSG00000263853.1	AC139530.1	-4.03	6.44e-05	0.00975	-0.18	-0.18	Eye color traits;	chr17:81614905	chr17:81676001~81676086:+
LUAD	cis	rs6688613	0.649	rs2280995	ENSG00000225171.2	DUTP6	-4.03	6.44e-05	0.00975	-0.22	-0.18	Refractive astigmatism;	chr1:166876832	chr1:166868748~166869209:+
LUAD	cis	rs6687821	0.749	rs166416	ENSG00000267734.1	RP4-604K5.3	4.03	6.44e-05	0.00975	0.22	0.18	Yeast infection;	chr1:86760172	chr1:86932199~86934891:-
LUAD	cis	rs6687821	0.749	rs59016838	ENSG00000267734.1	RP4-604K5.3	4.03	6.44e-05	0.00975	0.22	0.18	Yeast infection;	chr1:86760579	chr1:86932199~86934891:-
LUAD	cis	rs453301	0.686	rs28665409	ENSG00000253981.4	ALG1L13P	-4.03	6.44e-05	0.00975	-0.22	-0.18	Joint mobility (Beighton score);	chr8:9011767	chr8:8236003~8244667:-
LUAD	cis	rs6964587	0.869	rs406	ENSG00000188693.7	CYP51A1-AS1	4.03	6.44e-05	0.00975	0.22	0.18	Breast cancer;	chr7:91917212	chr7:92134604~92180725:+
LUAD	cis	rs1799949	1	rs9646412	ENSG00000236383.6	LINC00854	-4.03	6.45e-05	0.00975	-0.15	-0.18	Menopause (age at onset);	chr17:43348525	chr17:43216941~43305976:-
LUAD	cis	rs13434995	0.513	rs9993599	ENSG00000273257.1	RP11-177J6.1	4.03	6.45e-05	0.00975	0.24	0.18	Adiponectin levels;	chr4:55586798	chr4:55387949~55388271:+
LUAD	cis	rs6661961	0.752	rs4557976	ENSG00000237975.5	FLG-AS1	-4.03	6.45e-05	0.00975	-0.25	-0.18	Atopic dermatitis;	chr1:152442590	chr1:152168125~152445456:+
LUAD	cis	rs7598759	0.527	rs7571691	ENSG00000223198.1	RNU2-22P	-4.03	6.45e-05	0.00976	-0.2	-0.18	Noise-induced hearing loss;	chr2:231504690	chr2:231501990~231502201:-
LUAD	cis	rs2243480	1	rs1723269	ENSG00000229886.1	RP5-1132H15.3	4.03	6.45e-05	0.00976	0.31	0.18	Diabetic kidney disease;	chr7:66007799	chr7:66025126~66031544:-
LUAD	cis	rs12999542	0.5	rs13019263	ENSG00000234389.1	AC007278.3	4.03	6.45e-05	0.00976	0.27	0.18	Serum protein levels (sST2);	chr2:102305996	chr2:102438713~102440475:+
LUAD	cis	rs7119	0.637	rs2667775	ENSG00000259362.2	RP11-307C19.1	4.03	6.45e-05	0.00976	0.23	0.18	Type 2 diabetes;	chr15:77572460	chr15:77525540~77534110:+
LUAD	cis	rs603446	0.967	rs180375	ENSG00000254851.1	RP11-109L13.1	4.03	6.45e-05	0.00976	0.22	0.18	Triglycerides;	chr11:116720324	chr11:117135528~117138582:+
LUAD	cis	rs13434995	0.513	rs6554285	ENSG00000273257.1	RP11-177J6.1	4.03	6.45e-05	0.00976	0.24	0.18	Adiponectin levels;	chr4:55533953	chr4:55387949~55388271:+
LUAD	cis	rs12216545	0.765	rs7787639	ENSG00000177590.7	GIMAP3P	-4.03	6.45e-05	0.00976	-0.19	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150529528	chr7:150746893~150747728:-
LUAD	cis	rs12216545	0.737	rs7788962	ENSG00000177590.7	GIMAP3P	-4.03	6.45e-05	0.00976	-0.19	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150530139	chr7:150746893~150747728:-
LUAD	cis	rs71636778	0.584	rs17162316	ENSG00000260063.1	RP5-968P14.2	-4.03	6.45e-05	0.00976	-0.23	-0.18	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26851416	chr1:26692132~26694131:-
LUAD	cis	rs7809950	1	rs2395883	ENSG00000238832.1	snoU109	-4.03	6.45e-05	0.00976	-0.26	-0.18	Coronary artery disease;	chr7:107449225	chr7:107603363~107603507:+
LUAD	cis	rs7122539	0.768	rs7931485	ENSG00000213409.4	RP11-658F2.3	-4.03	6.45e-05	0.00976	-0.22	-0.18	HIV-1 susceptibility;	chr11:66811164	chr11:66761575~66762399:-
LUAD	cis	rs9900062	0.507	rs7225993	ENSG00000270714.1	MINOS1P2	-4.03	6.46e-05	0.00976	-0.24	-0.18	QT interval;	chr17:64712166	chr17:64747264~64747492:-
LUAD	cis	rs256438	0.93	rs34338186	ENSG00000251050.1	RP11-168A11.4	-4.03	6.46e-05	0.00977	-0.2	-0.18	Serum thyroid-stimulating hormone levels;	chr5:80095173	chr5:80019609~80019920:+
LUAD	cis	rs7181230	1	rs9972424	ENSG00000278621.1	CTD-2033D15.3	4.03	6.46e-05	0.00977	0.2	0.18	Dehydroepiandrosterone sulphate levels;	chr15:40073650	chr15:39588357~39588882:-
LUAD	cis	rs5758511	0.68	rs5758657	ENSG00000233903.2	Z83851.4	4.03	6.46e-05	0.00977	0.27	0.18	Birth weight;	chr22:42222663	chr22:42276355~42277052:+
LUAD	cis	rs5758511	0.68	rs1033459	ENSG00000233903.2	Z83851.4	4.03	6.46e-05	0.00977	0.27	0.18	Birth weight;	chr22:42223061	chr22:42276355~42277052:+
LUAD	cis	rs3018712	0.547	rs4930237	ENSG00000212093.1	AP000807.1	-4.03	6.46e-05	0.00977	-0.23	-0.18	Total body bone mineral density;	chr11:68646570	chr11:68506083~68506166:-
LUAD	cis	rs2179367	0.959	rs2262617	ENSG00000216906.2	RP11-350J20.9	4.03	6.46e-05	0.00977	0.22	0.18	Dupuytren's disease;	chr6:149438590	chr6:149904243~149906418:+
LUAD	cis	rs6840360	0.615	rs7695412	ENSG00000270265.1	RP11-731D1.4	-4.03	6.46e-05	0.00978	-0.2	-0.18	Intelligence (multi-trait analysis);	chr4:151566923	chr4:151333775~151353224:-
LUAD	cis	rs763121	0.651	rs738249	ENSG00000225450.1	RP3-508I15.14	-4.03	6.46e-05	0.00978	-0.18	-0.18	Menopause (age at onset);	chr22:38641974	chr22:38739003~38749041:+
LUAD	cis	rs13434995	0.513	rs67963898	ENSG00000273257.1	RP11-177J6.1	-4.03	6.46e-05	0.00978	-0.24	-0.18	Adiponectin levels;	chr4:55475520	chr4:55387949~55388271:+
LUAD	cis	rs13434995	0.513	rs62303718	ENSG00000273257.1	RP11-177J6.1	-4.03	6.46e-05	0.00978	-0.24	-0.18	Adiponectin levels;	chr4:55476770	chr4:55387949~55388271:+
LUAD	cis	rs13434995	0.513	rs17722870	ENSG00000273257.1	RP11-177J6.1	-4.03	6.46e-05	0.00978	-0.24	-0.18	Adiponectin levels;	chr4:55478519	chr4:55387949~55388271:+
LUAD	cis	rs4908769	0.624	rs3765971	ENSG00000232912.4	RP5-1115A15.1	-4.03	6.47e-05	0.00978	-0.16	-0.18	Allergy;	chr1:8385300	chr1:8424645~8434838:+
LUAD	cis	rs9973361	0.55	rs10930185	ENSG00000232411.1	AC009495.3	-4.03	6.47e-05	0.00978	-0.2	-0.18	Total body bone mineral density;	chr2:165852469	chr2:165833048~165839098:-
LUAD	cis	rs7615952	0.576	rs2276727	ENSG00000250012.1	RP11-124N2.1	-4.03	6.47e-05	0.00978	-0.25	-0.18	Blood pressure (smoking interaction);	chr3:126107400	chr3:126084220~126095349:+
LUAD	cis	rs4664293	0.541	rs1863218	ENSG00000226266.5	AC009961.3	4.03	6.47e-05	0.00978	0.24	0.18	Monocyte percentage of white cells;	chr2:159512276	chr2:159670708~159712435:-
LUAD	cis	rs7429990	0.965	rs4296617	ENSG00000228638.1	FCF1P2	4.03	6.47e-05	0.00978	0.22	0.18	Educational attainment (years of education);	chr3:48026818	chr3:48290793~48291375:-
LUAD	cis	rs780096	0.546	rs2293572	ENSG00000234072.1	AC074117.10	4.03	6.47e-05	0.00979	0.14	0.18	Total body bone mineral density;	chr2:27505910	chr2:27356246~27367622:+
LUAD	cis	rs651907	0.535	rs11711903	ENSG00000244119.1	PDCL3P4	4.03	6.48e-05	0.00979	0.18	0.18	Colorectal cancer;	chr3:101781904	chr3:101712472~101713191:+
LUAD	cis	rs6688613	0.759	rs61815132	ENSG00000225171.2	DUTP6	-4.03	6.48e-05	0.00979	-0.22	-0.18	Refractive astigmatism;	chr1:166951674	chr1:166868748~166869209:+
LUAD	cis	rs865483	0.895	rs853208	ENSG00000276054.1	RP11-378E13.3	4.03	6.48e-05	0.00979	0.22	0.18	Monocyte count;	chr17:37466352	chr17:37386886~37387926:+
LUAD	cis	rs865483	0.895	rs853211	ENSG00000276054.1	RP11-378E13.3	4.03	6.48e-05	0.00979	0.22	0.18	Monocyte count;	chr17:37468060	chr17:37386886~37387926:+
LUAD	cis	rs865483	0.86	rs2522968	ENSG00000276054.1	RP11-378E13.3	4.03	6.48e-05	0.00979	0.22	0.18	Monocyte count;	chr17:37470196	chr17:37386886~37387926:+
LUAD	cis	rs865483	0.895	rs6607275	ENSG00000276054.1	RP11-378E13.3	4.03	6.48e-05	0.00979	0.22	0.18	Monocyte count;	chr17:37473104	chr17:37386886~37387926:+
LUAD	cis	rs865483	0.895	rs2107104	ENSG00000276054.1	RP11-378E13.3	4.03	6.48e-05	0.00979	0.22	0.18	Monocyte count;	chr17:37474926	chr17:37386886~37387926:+
LUAD	cis	rs865483	0.895	rs2107105	ENSG00000276054.1	RP11-378E13.3	4.03	6.48e-05	0.00979	0.22	0.18	Monocyte count;	chr17:37474975	chr17:37386886~37387926:+
LUAD	cis	rs6964587	1	rs12539231	ENSG00000188693.7	CYP51A1-AS1	-4.03	6.48e-05	0.00979	-0.21	-0.18	Breast cancer;	chr7:92005649	chr7:92134604~92180725:+
LUAD	cis	rs6964587	0.967	rs28399886	ENSG00000188693.7	CYP51A1-AS1	-4.03	6.48e-05	0.00979	-0.21	-0.18	Breast cancer;	chr7:92009137	chr7:92134604~92180725:+
LUAD	cis	rs2711721	1	rs2711721	ENSG00000276691.1	RP5-1057I20.5	-4.03	6.48e-05	0.00979	-0.2	-0.18	Prostate cancer (SNP x SNP interaction);	chr12:46978487	chr12:47788426~47788971:+
LUAD	cis	rs9894429	1	rs7223613	ENSG00000263853.1	AC139530.1	4.03	6.48e-05	0.00979	0.18	0.18	Eye color traits;	chr17:81607777	chr17:81676001~81676086:+
LUAD	cis	rs9894429	0.934	rs35868252	ENSG00000263853.1	AC139530.1	4.03	6.48e-05	0.00979	0.18	0.18	Eye color traits;	chr17:81608446	chr17:81676001~81676086:+
LUAD	cis	rs9894429	1	rs11651264	ENSG00000263853.1	AC139530.1	4.03	6.48e-05	0.00979	0.18	0.18	Eye color traits;	chr17:81609368	chr17:81676001~81676086:+
LUAD	cis	rs9894429	1	rs35435780	ENSG00000263853.1	AC139530.1	-4.03	6.48e-05	0.00979	-0.18	-0.18	Eye color traits;	chr17:81612576	chr17:81676001~81676086:+
LUAD	cis	rs9894429	1	rs3935543	ENSG00000263853.1	AC139530.1	-4.03	6.48e-05	0.00979	-0.18	-0.18	Eye color traits;	chr17:81612848	chr17:81676001~81676086:+
LUAD	cis	rs9894429	0.966	rs6565601	ENSG00000263853.1	AC139530.1	-4.03	6.48e-05	0.00979	-0.18	-0.18	Eye color traits;	chr17:81613147	chr17:81676001~81676086:+
LUAD	cis	rs9894429	1	rs7209180	ENSG00000263853.1	AC139530.1	-4.03	6.48e-05	0.00979	-0.18	-0.18	Eye color traits;	chr17:81614493	chr17:81676001~81676086:+
LUAD	cis	rs9894429	1	rs7213129	ENSG00000263853.1	AC139530.1	-4.03	6.48e-05	0.00979	-0.18	-0.18	Eye color traits;	chr17:81614547	chr17:81676001~81676086:+
LUAD	cis	rs9894429	1	rs7503679	ENSG00000263853.1	AC139530.1	-4.03	6.48e-05	0.00979	-0.18	-0.18	Eye color traits;	chr17:81616817	chr17:81676001~81676086:+
LUAD	cis	rs9894429	1	rs9747349	ENSG00000263853.1	AC139530.1	-4.03	6.48e-05	0.00979	-0.18	-0.18	Eye color traits;	chr17:81617271	chr17:81676001~81676086:+
LUAD	cis	rs8028182	0.636	rs6495182	ENSG00000260269.4	CTD-2323K18.1	-4.03	6.48e-05	0.00979	-0.25	-0.18	Sudden cardiac arrest;	chr15:75522047	chr15:75527150~75601205:-
LUAD	cis	rs2288884	1	rs72483951	ENSG00000269959.1	SPACA6P-AS	-4.03	6.48e-05	0.00979	-0.24	-0.18	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52070429	chr19:51685363~51693456:-
LUAD	cis	rs755249	0.567	rs1537817	ENSG00000182109.6	RP11-69E11.4	-4.03	6.48e-05	0.00979	-0.22	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39173981	chr1:39522280~39546187:-
LUAD	cis	rs17772222	0.876	rs12587528	ENSG00000258789.1	RP11-507K2.3	-4.03	6.48e-05	0.0098	-0.25	-0.18	Coronary artery calcification;	chr14:88487652	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.837	rs1864748	ENSG00000258789.1	RP11-507K2.3	-4.03	6.48e-05	0.0098	-0.25	-0.18	Coronary artery calcification;	chr14:88488847	chr14:88551597~88552493:+
LUAD	cis	rs7005380	0.581	rs9987142	ENSG00000279347.1	RP11-85I17.2	4.03	6.48e-05	0.0098	0.17	0.18	Interstitial lung disease;	chr8:119924781	chr8:119838736~119840385:-
LUAD	cis	rs1167832	0.645	rs1167829	ENSG00000127957.15	PMS2P3	-4.03	6.48e-05	0.0098	-0.2	-0.18	Ankle injury;	chr7:75535697	chr7:75502930~75528148:-
LUAD	cis	rs2638953	1	rs2638953	ENSG00000278733.1	RP11-425D17.1	4.03	6.48e-05	0.0098	0.21	0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28381482	chr12:28185625~28186190:-
LUAD	cis	rs3785309	0.519	rs111794747	ENSG00000268836.1	LA16c-OS12.2	-4.03	6.48e-05	0.0098	-0.31	-0.18	Immature fraction of reticulocytes;	chr16:227007	chr16:185748~186294:-
LUAD	cis	rs62025270	0.632	rs62022920	ENSG00000259416.2	RP11-158M2.5	-4.03	6.48e-05	0.0098	-0.24	-0.18	Idiopathic pulmonary fibrosis;	chr15:85680159	chr15:85754941~85756237:-
LUAD	cis	rs4474465	0.915	rs10899504	ENSG00000251323.2	RP11-452H21.4	4.03	6.48e-05	0.0098	0.23	0.18	Alzheimer's disease (survival time);	chr11:78446937	chr11:78423982~78429836:-
LUAD	cis	rs4474465	0.915	rs12288436	ENSG00000251323.2	RP11-452H21.4	4.03	6.48e-05	0.0098	0.23	0.18	Alzheimer's disease (survival time);	chr11:78450384	chr11:78423982~78429836:-
LUAD	cis	rs4474465	1	rs7943673	ENSG00000251323.2	RP11-452H21.4	4.03	6.48e-05	0.0098	0.23	0.18	Alzheimer's disease (survival time);	chr11:78461940	chr11:78423982~78429836:-
LUAD	cis	rs7870753	0.578	rs2145985	ENSG00000188801.9	ZNF322P1	4.03	6.48e-05	0.0098	0.27	0.18	Height;	chr9:96412249	chr9:97198303~97199511:-
LUAD	cis	rs2905347	0.726	rs2905321	ENSG00000179428.2	AC073072.5	-4.03	6.48e-05	0.0098	-0.21	-0.18	Major depression and alcohol dependence;	chr7:22664968	chr7:22725395~22727620:-
LUAD	cis	rs12999542	1	rs1946131	ENSG00000234389.1	AC007278.3	4.03	6.49e-05	0.0098	0.26	0.18	Serum protein levels (sST2);	chr2:102345469	chr2:102438713~102440475:+
LUAD	cis	rs8062405	0.824	rs4788083	ENSG00000261419.1	RP11-57A19.4	-4.03	6.49e-05	0.00981	-0.19	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28659696~28740781:-
LUAD	cis	rs748404	1	rs748404	ENSG00000205771.5	CATSPER2P1	-4.03	6.49e-05	0.00981	-0.26	-0.18	Lung cancer;	chr15:43267033	chr15:43726918~43747094:-
LUAD	cis	rs13434995	0.513	rs62309729	ENSG00000273257.1	RP11-177J6.1	-4.03	6.49e-05	0.00981	-0.24	-0.18	Adiponectin levels;	chr4:55536679	chr4:55387949~55388271:+
LUAD	cis	rs7968440	0.715	rs7957659	ENSG00000200428.1	Y_RNA	4.03	6.49e-05	0.00981	0.21	0.18	Fibrinogen;	chr12:50245027	chr12:50743568~50743684:+
LUAD	cis	rs9341808	0.754	rs1015158	ENSG00000260645.1	RP11-250B2.5	4.03	6.49e-05	0.00981	0.17	0.18	Sitting height ratio;	chr6:80236028	chr6:80466958~80469080:+
LUAD	cis	rs481331	0.736	rs73253954	ENSG00000185904.10	LINC00839	4.03	6.49e-05	0.00981	0.31	0.18	Systemic juvenile idiopathic arthritis;	chr10:42472273	chr10:42475543~42495336:+
LUAD	cis	rs11642862	1	rs11642862	ENSG00000260911.2	RP11-196G11.2	-4.03	6.49e-05	0.00981	-0.23	-0.18	Tonsillectomy;	chr16:30774503	chr16:31043150~31049868:+
LUAD	cis	rs4934494	0.768	rs12771413	ENSG00000240996.1	RP11-80H5.7	4.03	6.49e-05	0.00981	0.25	0.18	Red blood cell count;	chr10:89633010	chr10:89694295~89697928:-
LUAD	cis	rs35740288	0.694	rs17618909	ENSG00000259407.1	RP11-158M2.3	-4.03	6.5e-05	0.00982	-0.17	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85552231	chr15:85744109~85750281:-
LUAD	cis	rs12908161	0.683	rs12903256	ENSG00000275120.1	RP11-182J1.17	4.03	6.5e-05	0.00982	0.25	0.18	Schizophrenia;	chr15:84764910	chr15:84599434~84606463:-
LUAD	cis	rs4840086	0.967	rs62434874	ENSG00000219755.1	RP1-199J3.5	4.03	6.5e-05	0.00982	0.22	0.18	Menarche (age at onset);	chr6:99754532	chr6:99575712~99576456:+
LUAD	cis	rs763121	0.853	rs2072796	ENSG00000228274.3	RP3-508I15.9	-4.03	6.5e-05	0.00982	-0.18	-0.18	Menopause (age at onset);	chr22:38668225	chr22:38667585~38681820:-
LUAD	cis	rs801193	1	rs2659915	ENSG00000222364.1	RNU6-96P	-4.03	6.5e-05	0.00982	-0.2	-0.18	Aortic root size;	chr7:66688114	chr7:66395191~66395286:+
LUAD	cis	rs9341808	0.791	rs1324122	ENSG00000260645.1	RP11-250B2.5	4.03	6.5e-05	0.00982	0.17	0.18	Sitting height ratio;	chr6:80236344	chr6:80466958~80469080:+
LUAD	cis	rs3814244	0.528	rs12228471	ENSG00000236946.2	HNRNPA1P70	-4.03	6.5e-05	0.00982	-0.16	-0.18	Itch intensity from mosquito bite adjusted by bite size;	chr12:68027842	chr12:68035767~68036853:+
LUAD	cis	rs1075265	0.563	rs2692536	ENSG00000272156.1	RP11-477N3.1	-4.03	6.5e-05	0.00982	-0.22	-0.18	Chronotype;Morning vs. evening chronotype;	chr2:53788266	chr2:54082554~54085066:+
LUAD	cis	rs7493	0.755	rs34774523	ENSG00000233942.1	AC004012.1	4.03	6.5e-05	0.00983	0.26	0.18	Yu-Zhi constitution type in type 2 diabetes;	chr7:95332830	chr7:95471835~95473998:+
LUAD	cis	rs10995356	0.844	rs12218430	ENSG00000238280.1	RP11-436D10.3	-4.03	6.51e-05	0.00983	-0.22	-0.18	Temperament;	chr10:62931881	chr10:62793562~62805887:-
LUAD	cis	rs9341808	1	rs9341808	ENSG00000260645.1	RP11-250B2.5	4.03	6.51e-05	0.00983	0.17	0.18	Sitting height ratio;	chr6:80243540	chr6:80466958~80469080:+
LUAD	cis	rs853679	0.517	rs12332979	ENSG00000226314.6	ZNF192P1	-4.03	6.51e-05	0.00983	-0.24	-0.18	Depression;	chr6:28173770	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs67878650	ENSG00000226314.6	ZNF192P1	-4.03	6.51e-05	0.00983	-0.24	-0.18	Depression;	chr6:28174809	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.569	rs9348798	ENSG00000226314.6	ZNF192P1	-4.03	6.51e-05	0.00983	-0.24	-0.18	Depression;	chr6:28175233	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs9380065	ENSG00000226314.6	ZNF192P1	-4.03	6.51e-05	0.00983	-0.24	-0.18	Depression;	chr6:28176973	chr6:28161781~28169594:+
LUAD	cis	rs321358	0.848	rs78087740	ENSG00000271390.1	RP11-89C3.3	4.03	6.51e-05	0.00983	0.29	0.18	Body mass index;	chr11:111079016	chr11:111089870~111090368:-
LUAD	cis	rs321358	0.848	rs73015146	ENSG00000271390.1	RP11-89C3.3	4.03	6.51e-05	0.00983	0.29	0.18	Body mass index;	chr11:111079143	chr11:111089870~111090368:-
LUAD	cis	rs1555322	0.53	rs2425053	ENSG00000261582.1	RP4-614O4.11	-4.03	6.51e-05	0.00983	-0.23	-0.18	Attention deficit hyperactivity disorder;	chr20:35294017	chr20:35267885~35280043:-
LUAD	cis	rs10971721	0.584	rs10971938	ENSG00000260947.1	RP11-384P7.7	-4.03	6.51e-05	0.00984	-0.35	-0.18	Body mass index;	chr9:34120722	chr9:33697459~33700986:+
LUAD	cis	rs34779708	0.931	rs34954932	ENSG00000271335.4	RP11-324I22.4	4.03	6.51e-05	0.00984	0.19	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35121879	chr10:35314552~35336401:-
LUAD	cis	rs9900280	1	rs9891759	ENSG00000264808.1	RP11-802D6.1	4.03	6.51e-05	0.00984	0.22	0.18	Mean platelet volume;	chr17:29367830	chr17:29369717~29390777:-
LUAD	cis	rs16866061	0.888	rs6748341	ENSG00000228446.2	AC073052.1	-4.03	6.52e-05	0.00984	-0.2	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr2:224512857	chr2:224499387~224500100:-
LUAD	cis	rs17597773	0.598	rs11118616	ENSG00000272823.1	RP11-295M18.6	-4.03	6.52e-05	0.00984	-0.24	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220832314	chr1:220828676~220829211:-
LUAD	cis	rs853679	0.517	rs7755442	ENSG00000280107.1	AL022393.9	-4.03	6.52e-05	0.00984	-0.24	-0.18	Depression;	chr6:28071237	chr6:28170845~28172521:+
LUAD	cis	rs12986445	0.744	rs3845680	ENSG00000218682.1	AC010150.1	4.03	6.52e-05	0.00984	0.23	0.18	Multiple myeloma;Multiple myeloma and monoclonal gammopathy;	chr2:25876144	chr2:25856461~25856966:-
LUAD	cis	rs728616	0.717	rs61860016	ENSG00000234382.2	RP11-40F6.1	-4.03	6.52e-05	0.00984	-0.45	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80156133	chr10:80233664~80245367:+
LUAD	cis	rs2765539	0.701	rs6671822	ENSG00000226172.2	RP4-712E4.1	-4.03	6.52e-05	0.00984	-0.23	-0.18	Waist-hip ratio;	chr1:119118898	chr1:119000344~119001392:-
LUAD	cis	rs34929064	0.629	rs17375307	ENSG00000230658.1	KLHL7-AS1	4.03	6.52e-05	0.00985	0.26	0.18	Major depression and alcohol dependence;	chr7:22689757	chr7:23101228~23105703:-
LUAD	cis	rs1005277	0.522	rs11011343	ENSG00000273019.1	RP11-508N22.13	-4.03	6.52e-05	0.00985	-0.2	-0.18	Extrinsic epigenetic age acceleration;	chr10:37713770	chr10:38149968~38150293:+
LUAD	cis	rs853679	0.517	rs4713146	ENSG00000280107.1	AL022393.9	-4.03	6.52e-05	0.00985	-0.25	-0.18	Depression;	chr6:28143758	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs9393894	ENSG00000280107.1	AL022393.9	-4.03	6.52e-05	0.00985	-0.25	-0.18	Depression;	chr6:28144784	chr6:28170845~28172521:+
LUAD	cis	rs2446066	0.799	rs11610326	ENSG00000257379.1	RP11-793H13.8	4.03	6.52e-05	0.00985	0.31	0.18	Red blood cell count;	chr12:53448070	chr12:53441741~53467528:+
LUAD	cis	rs4268898	0.76	rs4665675	ENSG00000242628.4	AC009228.1	4.03	6.52e-05	0.00985	0.23	0.18	Asthma;	chr2:24245263	chr2:24214381~24221516:+
LUAD	cis	rs9601248	0.756	rs9601252	ENSG00000227354.5	RBM26-AS1	-4.03	6.52e-05	0.00985	-0.2	-0.18	Major depressive disorder;	chr13:79615607	chr13:79406309~79424328:+
LUAD	cis	rs2304003	1	rs2304003	ENSG00000235192.1	AC009495.2	4.03	6.52e-05	0.00985	0.22	0.18	Social communication problems;	chr2:165857571	chr2:165794851~165810010:+
LUAD	cis	rs4666360	1	rs4666295	ENSG00000234378.1	AC098828.2	-4.03	6.52e-05	0.00985	-0.22	-0.18	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);	chr2:20137383	chr2:20063856~20106829:-
LUAD	cis	rs3785309	0.519	rs72765805	ENSG00000268836.1	LA16c-OS12.2	-4.03	6.53e-05	0.00985	-0.31	-0.18	Immature fraction of reticulocytes;	chr16:227065	chr16:185748~186294:-
LUAD	cis	rs1555322	0.53	rs6060347	ENSG00000126005.14	MMP24-AS1	-4.03	6.53e-05	0.00985	-0.25	-0.18	Attention deficit hyperactivity disorder;	chr20:35286348	chr20:35216462~35278131:-
LUAD	cis	rs273909	0.686	rs77335401	ENSG00000233006.5	AC034220.3	-4.03	6.53e-05	0.00985	-0.3	-0.18	Coronary artery disease;	chr5:132424133	chr5:132311285~132369916:-
LUAD	cis	rs7674212	0.57	rs2069274	ENSG00000251288.2	RP11-10L12.2	-4.03	6.53e-05	0.00986	-0.22	-0.18	Type 2 diabetes;	chr4:103099624	chr4:102751401~102752641:+
LUAD	cis	rs14027	0.961	rs7017279	ENSG00000279347.1	RP11-85I17.2	4.03	6.53e-05	0.00986	0.16	0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119847580	chr8:119838736~119840385:-
LUAD	cis	rs36423	0.841	rs17178946	ENSG00000266869.1	RP6-114E22.1	4.03	6.53e-05	0.00986	0.32	0.18	Heart rate variability traits (RMSSD);Heart rate variability traits (SDNN);	chr14:71899050	chr14:71848606~71908430:+
LUAD	cis	rs8014252	0.803	rs17108201	ENSG00000259158.2	ADAM20P1	-4.03	6.53e-05	0.00986	-0.33	-0.18	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70522214	chr14:70468881~70483756:-
LUAD	cis	rs854765	0.587	rs12936927	ENSG00000264177.1	RP1-37N7.1	4.03	6.53e-05	0.00986	0.18	0.18	Total body bone mineral density;	chr17:17823651	chr17:18379855~18388984:-
LUAD	cis	rs848490	0.889	rs17156247	ENSG00000214293.7	APTR	-4.03	6.53e-05	0.00986	-0.22	-0.18	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77668224	chr7:77657660~77696265:-
LUAD	cis	rs4819052	0.679	rs2236450	ENSG00000215447.6	BX322557.10	-4.03	6.54e-05	0.00987	-0.21	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45282638	chr21:45288052~45291738:+
LUAD	cis	rs7660883	0.836	rs442177	ENSG00000251411.1	RP11-397E7.4	-4.03	6.54e-05	0.00987	-0.2	-0.18	HDL cholesterol levels;	chr4:87109109	chr4:86913266~86914817:-
LUAD	cis	rs1431005	0.893	rs12501227	ENSG00000250658.1	RP11-138B4.1	4.03	6.54e-05	0.00987	0.23	0.18	Response to statin therapy;	chr4:187401223	chr4:187304083~187309682:-
LUAD	cis	rs7119038	0.774	rs11217037	ENSG00000255422.1	AP002954.4	4.03	6.54e-05	0.00987	0.28	0.18	Sjögren's syndrome;	chr11:118806377	chr11:118704607~118750263:+
LUAD	cis	rs6088580	0.634	rs6088502	ENSG00000276073.1	RP5-1125A11.7	-4.03	6.54e-05	0.00987	-0.18	-0.18	Glomerular filtration rate (creatinine);	chr20:34449839	chr20:33985617~33988989:-
LUAD	cis	rs2243480	1	rs160639	ENSG00000229886.1	RP5-1132H15.3	4.03	6.54e-05	0.00987	0.31	0.18	Diabetic kidney disease;	chr7:66115000	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs313824	ENSG00000229886.1	RP5-1132H15.3	4.03	6.54e-05	0.00987	0.31	0.18	Diabetic kidney disease;	chr7:66116220	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs186378	ENSG00000229886.1	RP5-1132H15.3	4.03	6.54e-05	0.00987	0.31	0.18	Diabetic kidney disease;	chr7:66117071	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs160637	ENSG00000229886.1	RP5-1132H15.3	4.03	6.54e-05	0.00987	0.31	0.18	Diabetic kidney disease;	chr7:66119331	chr7:66025126~66031544:-
LUAD	cis	rs9467773	0.933	rs35355150	ENSG00000261353.1	CTA-14H9.5	-4.03	6.54e-05	0.00987	-0.2	-0.18	Intelligence (multi-trait analysis);	chr6:26525811	chr6:26527063~26527404:+
LUAD	cis	rs360798	0.723	rs4671049	ENSG00000231609.4	AC009501.4	4.03	6.54e-05	0.00987	0.22	0.18	Coronary artery disease;	chr2:62675813	chr2:63043922~63048640:-
LUAD	cis	rs1075265	0.68	rs6715488	ENSG00000272156.1	RP11-477N3.1	-4.03	6.54e-05	0.00987	-0.21	-0.18	Chronotype;Morning vs. evening chronotype;	chr2:54004130	chr2:54082554~54085066:+
LUAD	cis	rs11073619	0.616	rs116163737	ENSG00000230373.7	GOLGA6L5P	-4.03	6.54e-05	0.00987	-0.29	-0.18	Positive affect;	chr15:84531745	chr15:84507885~84516814:-
LUAD	cis	rs728616	0.867	rs1923534	ENSG00000225484.5	NUTM2B-AS1	-4.03	6.54e-05	0.00987	-0.45	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79950729	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.557	rs17107449	ENSG00000225484.5	NUTM2B-AS1	-4.03	6.54e-05	0.00987	-0.45	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955940	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.867	rs76239460	ENSG00000225484.5	NUTM2B-AS1	-4.03	6.54e-05	0.00987	-0.45	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79963471	chr10:79663088~79826594:-
LUAD	cis	rs763121	0.819	rs6001205	ENSG00000228274.3	RP3-508I15.9	-4.03	6.54e-05	0.00987	-0.18	-0.18	Menopause (age at onset);	chr22:38704259	chr22:38667585~38681820:-
LUAD	cis	rs7572733	0.901	rs13011918	ENSG00000222017.1	AC011997.1	-4.03	6.54e-05	0.00987	-0.23	-0.18	Dermatomyositis;	chr2:197914359	chr2:197693106~197774823:+
LUAD	cis	rs7572733	0.935	rs1401093	ENSG00000222017.1	AC011997.1	-4.03	6.54e-05	0.00987	-0.23	-0.18	Dermatomyositis;	chr2:197915115	chr2:197693106~197774823:+
LUAD	cis	rs7572733	0.935	rs1401094	ENSG00000222017.1	AC011997.1	-4.03	6.54e-05	0.00987	-0.23	-0.18	Dermatomyositis;	chr2:197915125	chr2:197693106~197774823:+
LUAD	cis	rs7955901	0.904	rs1512991	ENSG00000258053.1	CTD-2021H9.3	-4.03	6.54e-05	0.00987	-0.21	-0.18	Type 2 diabetes;	chr12:71028988	chr12:71047402~71118247:-
LUAD	cis	rs4819052	0.724	rs1304487	ENSG00000237664.1	LINC00316	4.03	6.54e-05	0.00987	0.22	0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45237368	chr21:45338590~45341990:-
LUAD	cis	rs4819052	0.808	rs2246697	ENSG00000237664.1	LINC00316	-4.03	6.54e-05	0.00988	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270084	chr21:45338590~45341990:-
LUAD	cis	rs4819052	0.819	rs7279136	ENSG00000237664.1	LINC00316	-4.03	6.54e-05	0.00988	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45272372	chr21:45338590~45341990:-
LUAD	cis	rs4819052	0.788	rs4819051	ENSG00000237664.1	LINC00316	-4.03	6.54e-05	0.00988	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273213	chr21:45338590~45341990:-
LUAD	cis	rs4819052	0.819	rs8134084	ENSG00000237664.1	LINC00316	-4.03	6.54e-05	0.00988	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273380	chr21:45338590~45341990:-
LUAD	cis	rs7160336	0.641	rs17782448	ENSG00000259065.1	RP5-1021I20.1	-4.03	6.54e-05	0.00988	-0.21	-0.18	Blood protein levels;	chr14:74215998	chr14:73787360~73803270:+
LUAD	cis	rs1874124	0.577	rs2807872	ENSG00000257551.1	HLX-AS1	-4.03	6.54e-05	0.00988	-0.26	-0.18	Cholesterol, total;	chr1:220866908	chr1:220832763~220880140:-
LUAD	cis	rs62355901	0.545	rs16886260	ENSG00000271828.1	CTD-2310F14.1	-4.03	6.55e-05	0.00988	-0.35	-0.18	Breast cancer;	chr5:56769629	chr5:56927874~56929573:+
LUAD	cis	rs2836950	0.585	rs1029004	ENSG00000232608.1	TIMM9P2	4.03	6.55e-05	0.00988	0.2	0.18	Menarche (age at onset);	chr21:39243417	chr21:39216624~39217506:+
LUAD	cis	rs7617773	0.747	rs34076262	ENSG00000199476.1	Y_RNA	-4.03	6.55e-05	0.00988	-0.24	-0.18	Coronary artery disease;	chr3:48328926	chr3:48288587~48288694:+
LUAD	cis	rs8113308	0.81	rs56029016	ENSG00000269235.1	ZNF350-AS1	4.03	6.55e-05	0.00988	0.32	0.18	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51949209	chr19:51949134~51981367:+
LUAD	cis	rs2926621	1	rs2926621	ENSG00000263812.4	LINC00908	4.03	6.55e-05	0.00988	0.22	0.18	Night sleep phenotypes;	chr18:75908215	chr18:76528655~76610968:+
LUAD	cis	rs8062405	0.723	rs12445744	ENSG00000251417.2	RP11-1348G14.4	-4.03	6.55e-05	0.00988	-0.18	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28802743~28817828:+
LUAD	cis	rs7942368	0.941	rs737185	ENSG00000254632.1	RP11-21L23.4	4.03	6.55e-05	0.00988	0.19	0.18	Endometriosis;	chr11:76774314	chr11:76759916~76768223:-
LUAD	cis	rs7572733	0.935	rs12995110	ENSG00000222017.1	AC011997.1	-4.03	6.55e-05	0.00989	-0.23	-0.18	Dermatomyositis;	chr2:197924289	chr2:197693106~197774823:+
LUAD	cis	rs7572733	0.935	rs4850816	ENSG00000222017.1	AC011997.1	-4.03	6.55e-05	0.00989	-0.23	-0.18	Dermatomyositis;	chr2:197925041	chr2:197693106~197774823:+
LUAD	cis	rs1015362	0.581	rs4911373	ENSG00000275784.1	RP5-1125A11.6	-4.03	6.55e-05	0.00989	-0.24	-0.18	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33920952	chr20:33989480~33991818:-
LUAD	cis	rs5758511	0.573	rs2267438	ENSG00000227370.1	RP4-669P10.19	-4.03	6.55e-05	0.00989	-0.18	-0.18	Birth weight;	chr22:41841561	chr22:42132543~42132998:+
LUAD	cis	rs5758511	0.573	rs2267439	ENSG00000227370.1	RP4-669P10.19	-4.03	6.55e-05	0.00989	-0.18	-0.18	Birth weight;	chr22:41841765	chr22:42132543~42132998:+
LUAD	cis	rs4474465	0.92	rs12271198	ENSG00000251323.2	RP11-452H21.4	4.03	6.55e-05	0.00989	0.23	0.18	Alzheimer's disease (survival time);	chr11:78447897	chr11:78423982~78429836:-
LUAD	cis	rs4474465	0.92	rs9804428	ENSG00000251323.2	RP11-452H21.4	4.03	6.55e-05	0.00989	0.23	0.18	Alzheimer's disease (survival time);	chr11:78447902	chr11:78423982~78429836:-
LUAD	cis	rs9584850	0.54	rs61969457	ENSG00000231194.1	FARP1-AS1	4.03	6.55e-05	0.00989	0.26	0.18	Neuroticism;	chr13:98524488	chr13:98435405~98435840:-
LUAD	cis	rs6452524	0.618	rs2306336	ENSG00000281327.1	LINC01338	4.03	6.55e-05	0.00989	0.19	0.18	Hypertension (SNP x SNP interaction);	chr5:83064964	chr5:82850864~82859836:-
LUAD	cis	rs6452524	0.589	rs6882386	ENSG00000281327.1	LINC01338	4.03	6.55e-05	0.00989	0.19	0.18	Hypertension (SNP x SNP interaction);	chr5:83065555	chr5:82850864~82859836:-
LUAD	cis	rs6452524	0.618	rs6860752	ENSG00000281327.1	LINC01338	4.03	6.55e-05	0.00989	0.19	0.18	Hypertension (SNP x SNP interaction);	chr5:83065587	chr5:82850864~82859836:-
LUAD	cis	rs6452524	0.618	rs3899556	ENSG00000281327.1	LINC01338	4.03	6.55e-05	0.00989	0.19	0.18	Hypertension (SNP x SNP interaction);	chr5:83067862	chr5:82850864~82859836:-
LUAD	cis	rs6452524	0.618	rs7723639	ENSG00000281327.1	LINC01338	4.03	6.56e-05	0.00989	0.19	0.18	Hypertension (SNP x SNP interaction);	chr5:83062610	chr5:82850864~82859836:-
LUAD	cis	rs10857712	0.754	rs2297033	ENSG00000273336.1	OR7M1P	-4.03	6.56e-05	0.00989	-0.27	-0.18	Systemic lupus erythematosus;	chr10:133421344	chr10:133481238~133481770:+
LUAD	cis	rs6678676	1	rs6678676	ENSG00000260088.1	RP11-92G12.3	-4.03	6.56e-05	0.00989	-0.27	-0.18	Schizophrenia;	chr1:200297375	chr1:200669507~200694250:+
LUAD	cis	rs7742369	0.586	rs2797961	ENSG00000276404.1	MIR6835	4.03	6.56e-05	0.00989	0.21	0.18	Birth weight;Height;	chr6:34270020	chr6:34240673~34240736:+
LUAD	cis	rs10197140	0.925	rs3789130	ENSG00000235721.1	AC013268.3	-4.03	6.56e-05	0.00989	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110934358	chr2:110007675~110010783:+
LUAD	cis	rs4819052	1	rs4818769	ENSG00000237664.1	LINC00316	-4.03	6.56e-05	0.0099	-0.23	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45247536	chr21:45338590~45341990:-
LUAD	cis	rs5758659	0.716	rs86669	ENSG00000227370.1	RP4-669P10.19	-4.03	6.56e-05	0.0099	-0.16	-0.18	Cognitive function;	chr22:42284794	chr22:42132543~42132998:+
LUAD	cis	rs6452524	0.618	rs1871203	ENSG00000281327.1	LINC01338	4.03	6.56e-05	0.0099	0.19	0.18	Hypertension (SNP x SNP interaction);	chr5:83059567	chr5:82850864~82859836:-
LUAD	cis	rs6452524	0.618	rs6867727	ENSG00000281327.1	LINC01338	4.03	6.56e-05	0.0099	0.19	0.18	Hypertension (SNP x SNP interaction);	chr5:83061333	chr5:82850864~82859836:-
LUAD	cis	rs5015933	0.815	rs4991998	ENSG00000232630.1	PRPS1P2	-4.03	6.56e-05	0.0099	-0.17	-0.18	Body mass index;	chr9:125314702	chr9:125150653~125151589:+
LUAD	cis	rs6787172	0.811	rs28375539	ENSG00000272087.1	RP11-379F4.7	4.03	6.56e-05	0.0099	0.19	0.18	Subjective well-being;	chr3:158527108	chr3:158693120~158693768:-
LUAD	cis	rs4295623	0.553	rs11250163	ENSG00000255046.1	RP11-297N6.4	-4.03	6.57e-05	0.0099	-0.22	-0.18	Morning vs. evening chronotype;	chr8:11738928	chr8:11797928~11802568:-
LUAD	cis	rs10208649	0.706	rs75833613	ENSG00000272156.1	RP11-477N3.1	4.03	6.57e-05	0.0099	0.36	0.18	Body mass index;	chr2:54065224	chr2:54082554~54085066:+
LUAD	cis	rs4767841	0.868	rs1318272	ENSG00000248636.5	RP11-768F21.1	-4.03	6.57e-05	0.00991	-0.21	-0.18	Urgency urinary incontinence;	chr12:119751883	chr12:119387987~119668079:-
LUAD	cis	rs4767841	0.901	rs904654	ENSG00000248636.5	RP11-768F21.1	-4.03	6.57e-05	0.00991	-0.21	-0.18	Urgency urinary incontinence;	chr12:119752083	chr12:119387987~119668079:-
LUAD	cis	rs9815354	1	rs2272007	ENSG00000273328.4	RP11-141M3.6	4.03	6.57e-05	0.00991	0.26	0.18	Pulse pressure;Diastolic blood pressure;	chr3:41954644	chr3:42809414~42908105:+
LUAD	cis	rs2765539	0.7	rs4659147	ENSG00000226172.2	RP4-712E4.1	-4.03	6.57e-05	0.00991	-0.23	-0.18	Waist-hip ratio;	chr1:119103412	chr1:119000344~119001392:-
LUAD	cis	rs6570726	0.967	rs418662	ENSG00000235652.6	RP11-545I5.3	4.03	6.57e-05	0.00991	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145527696	chr6:145799409~145886585:+
LUAD	cis	rs9925964	0.9	rs9934438	ENSG00000232748.3	RP11-196G11.6	4.03	6.57e-05	0.00991	0.22	0.18	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31093557	chr16:31056460~31062803:+
LUAD	cis	rs5015933	0.815	rs16928051	ENSG00000232630.1	PRPS1P2	-4.03	6.57e-05	0.00991	-0.17	-0.18	Body mass index;	chr9:125308738	chr9:125150653~125151589:+
LUAD	cis	rs9593057	0.579	rs7321833	ENSG00000234835.1	PHBP13	-4.03	6.57e-05	0.00991	-0.41	-0.18	Lobe attachment (rater-scored or self-reported);	chr13:34999225	chr13:35251070~35251829:+
LUAD	cis	rs897984	0.806	rs1458202	ENSG00000232748.3	RP11-196G11.6	-4.03	6.57e-05	0.00991	-0.22	-0.18	Dementia with Lewy bodies;	chr16:30941881	chr16:31056460~31062803:+
LUAD	cis	rs28386778	0.897	rs11079510	ENSG00000240280.5	TCAM1P	-4.03	6.58e-05	0.00992	-0.21	-0.18	Prudent dietary pattern;	chr17:63743542	chr17:63849292~63864379:+
LUAD	cis	rs6903823	0.508	rs1778484	ENSG00000219392.1	RP1-265C24.5	-4.03	6.58e-05	0.00992	-0.22	-0.18	Pulmonary function;	chr6:28273021	chr6:28115628~28116551:+
LUAD	cis	rs42490	0.727	rs42481	ENSG00000251136.7	RP11-37B2.1	4.03	6.58e-05	0.00992	0.19	0.18	Leprosy;	chr8:89825486	chr8:89609409~89757727:-
LUAD	cis	rs2239547	0.522	rs9846976	ENSG00000243224.1	RP5-1157M23.2	-4.03	6.58e-05	0.00992	-0.2	-0.18	Schizophrenia;	chr3:52973979	chr3:52239258~52241097:+
LUAD	cis	rs4664293	0.836	rs73967923	ENSG00000226266.5	AC009961.3	-4.03	6.58e-05	0.00992	-0.25	-0.18	Monocyte percentage of white cells;	chr2:159801754	chr2:159670708~159712435:-
LUAD	cis	rs10129255	0.912	rs61997792	ENSG00000274576.2	IGHV2-70	4.03	6.58e-05	0.00992	0.16	0.18	Kawasaki disease;	chr14:106799304	chr14:106770577~106771020:-
LUAD	cis	rs9393777	0.92	rs34150729	ENSG00000219392.1	RP1-265C24.5	-4.03	6.58e-05	0.00992	-0.38	-0.18	Intelligence (multi-trait analysis);	chr6:27420975	chr6:28115628~28116551:+
LUAD	cis	rs9393777	0.92	rs13191227	ENSG00000219392.1	RP1-265C24.5	-4.03	6.58e-05	0.00992	-0.38	-0.18	Intelligence (multi-trait analysis);	chr6:27422336	chr6:28115628~28116551:+
LUAD	cis	rs8030379	0.967	rs7182563	ENSG00000230373.7	GOLGA6L5P	-4.03	6.58e-05	0.00992	-0.17	-0.18	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83879994	chr15:84507885~84516814:-
LUAD	cis	rs8030379	0.967	rs11629657	ENSG00000230373.7	GOLGA6L5P	-4.03	6.58e-05	0.00992	-0.17	-0.18	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83880228	chr15:84507885~84516814:-
LUAD	cis	rs8030379	0.967	rs7181926	ENSG00000230373.7	GOLGA6L5P	-4.03	6.58e-05	0.00992	-0.17	-0.18	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83880676	chr15:84507885~84516814:-
LUAD	cis	rs8030379	0.967	rs6603000	ENSG00000230373.7	GOLGA6L5P	-4.03	6.58e-05	0.00992	-0.17	-0.18	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83883142	chr15:84507885~84516814:-
LUAD	cis	rs8030379	0.967	rs12916223	ENSG00000230373.7	GOLGA6L5P	-4.03	6.58e-05	0.00992	-0.17	-0.18	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83883742	chr15:84507885~84516814:-
LUAD	cis	rs8030379	0.875	rs28801104	ENSG00000230373.7	GOLGA6L5P	-4.03	6.58e-05	0.00992	-0.17	-0.18	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83884091	chr15:84507885~84516814:-
LUAD	cis	rs8030379	0.967	rs12900412	ENSG00000230373.7	GOLGA6L5P	-4.03	6.58e-05	0.00992	-0.17	-0.18	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83884314	chr15:84507885~84516814:-
LUAD	cis	rs8030379	0.967	rs2401171	ENSG00000230373.7	GOLGA6L5P	-4.03	6.58e-05	0.00992	-0.17	-0.18	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83888924	chr15:84507885~84516814:-
LUAD	cis	rs4268898	0.722	rs34565113	ENSG00000223754.1	AC008073.9	-4.03	6.59e-05	0.00993	-0.22	-0.18	Asthma;	chr2:24200207	chr2:24199839~24201698:-
LUAD	cis	rs2810114	1	rs2810114	ENSG00000269927.1	RP6-91H8.3	-4.03	6.59e-05	0.00993	-0.24	-0.18	Alcohol dependence;	chr14:70928887	chr14:71141125~71143253:-
LUAD	cis	rs1167832	0.645	rs1167828	ENSG00000278416.1	PMS2L2	-4.03	6.59e-05	0.00994	-0.27	-0.18	Ankle injury;	chr7:75534076	chr7:75344015~75359550:-
LUAD	cis	rs3096299	0.754	rs2965816	ENSG00000261118.1	RP11-104N10.1	-4.03	6.6e-05	0.00994	-0.18	-0.18	Multiple myeloma (IgH translocation);	chr16:89447775	chr16:89492017~89504460:-
LUAD	cis	rs9309473	0.5	rs2421582	ENSG00000163016.8	ALMS1P	-4.03	6.6e-05	0.00994	-0.19	-0.18	Metabolite levels;	chr2:73671293	chr2:73644919~73685576:+
LUAD	cis	rs7551222	0.789	rs2290855	ENSG00000240219.1	RP11-430C7.5	4.03	6.6e-05	0.00994	0.19	0.18	Schizophrenia;	chr1:204546735	chr1:204626775~204629712:+
LUAD	cis	rs9393777	0.513	rs13219181	ENSG00000219392.1	RP1-265C24.5	-4.03	6.6e-05	0.00994	-0.29	-0.18	Intelligence (multi-trait analysis);	chr6:27168446	chr6:28115628~28116551:+
LUAD	cis	rs911186	0.891	rs6914824	ENSG00000219392.1	RP1-265C24.5	-4.03	6.6e-05	0.00994	-0.29	-0.18	Autism spectrum disorder or schizophrenia;	chr6:27171269	chr6:28115628~28116551:+
LUAD	cis	rs9649213	0.593	rs2107716	ENSG00000272950.1	RP11-307C18.1	4.03	6.6e-05	0.00994	0.23	0.18	Prostate cancer (SNP x SNP interaction);	chr7:98315432	chr7:98322853~98323430:+
LUAD	cis	rs7208859	0.573	rs7223803	ENSG00000280069.1	CTD-2349P21.3	-4.03	6.6e-05	0.00994	-0.25	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750175	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs55814012	ENSG00000280069.1	CTD-2349P21.3	-4.03	6.6e-05	0.00994	-0.25	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750679	chr17:30738182~30740275:+
LUAD	cis	rs17826219	0.5	rs2449749	ENSG00000280069.1	CTD-2349P21.3	-4.03	6.6e-05	0.00994	-0.25	-0.18	Body mass index;	chr17:30751280	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs9894709	ENSG00000280069.1	CTD-2349P21.3	-4.03	6.6e-05	0.00994	-0.25	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751436	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs9896603	ENSG00000280069.1	CTD-2349P21.3	-4.03	6.6e-05	0.00994	-0.25	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751494	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs8080882	ENSG00000280069.1	CTD-2349P21.3	-4.03	6.6e-05	0.00994	-0.25	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30754128	chr17:30738182~30740275:+
LUAD	cis	rs7107174	0.901	rs7937277	ENSG00000251323.2	RP11-452H21.4	4.03	6.6e-05	0.00994	0.24	0.18	Testicular germ cell tumor;	chr11:78403931	chr11:78423982~78429836:-
LUAD	cis	rs7172677	0.737	rs8033754	ENSG00000260269.4	CTD-2323K18.1	4.03	6.6e-05	0.00994	0.23	0.18	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75147439	chr15:75527150~75601205:-
LUAD	cis	rs2638953	0.886	rs10843137	ENSG00000278733.1	RP11-425D17.1	-4.03	6.6e-05	0.00995	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28218788	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs10843138	ENSG00000278733.1	RP11-425D17.1	-4.03	6.6e-05	0.00995	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28219210	chr12:28185625~28186190:-
LUAD	cis	rs10463554	0.963	rs34774	ENSG00000250682.4	LINC00491	4.03	6.6e-05	0.00995	0.22	0.18	Parkinson's disease;	chr5:103115116	chr5:102609156~102671559:-
LUAD	cis	rs17301013	0.932	rs67967476	ENSG00000227373.4	RP11-160H22.5	4.03	6.6e-05	0.00995	0.23	0.18	Systemic lupus erythematosus;	chr1:174616119	chr1:174115300~174160004:-
LUAD	cis	rs7189233	0.531	rs17801498	ENSG00000279344.1	RP11-44F14.7	4.03	6.6e-05	0.00995	0.15	0.18	Intelligence (multi-trait analysis);	chr16:53479540	chr16:53478957~53481550:-
LUAD	cis	rs6088580	0.634	rs6058041	ENSG00000276073.1	RP5-1125A11.7	-4.03	6.6e-05	0.00995	-0.18	-0.18	Glomerular filtration rate (creatinine);	chr20:34430202	chr20:33985617~33988989:-
LUAD	cis	rs6840360	0.642	rs1470281	ENSG00000270265.1	RP11-731D1.4	-4.03	6.61e-05	0.00995	-0.18	-0.18	Intelligence (multi-trait analysis);	chr4:151510400	chr4:151333775~151353224:-
LUAD	cis	rs8031584	0.918	rs61997139	ENSG00000259845.1	HERC2P10	4.03	6.61e-05	0.00995	0.21	0.18	Huntington's disease progression;	chr15:30981399	chr15:30815271~30844153:+
LUAD	cis	rs4267450	0.69	rs10422617	ENSG00000267323.1	SLC25A1P5	4.03	6.61e-05	0.00995	0.32	0.18	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr19:28371341	chr19:27805423~27806205:-
LUAD	cis	rs7204230	0.96	rs3803658	ENSG00000261291.1	RP11-295M3.2	-4.03	6.61e-05	0.00996	-0.22	-0.18	Fibrinogen;	chr16:53314671	chr16:53168522~53169450:+
LUAD	cis	rs6964587	0.839	rs10808086	ENSG00000188693.7	CYP51A1-AS1	-4.03	6.61e-05	0.00996	-0.22	-0.18	Breast cancer;	chr7:91818201	chr7:92134604~92180725:+
LUAD	cis	rs4374383	0.884	rs4519530	ENSG00000207383.1	Y_RNA	-4.03	6.61e-05	0.00996	-0.22	-0.18	Hepatitis C induced liver fibrosis;	chr2:112001605	chr2:112579484~112579584:-
LUAD	cis	rs1150668	0.768	rs1150716	ENSG00000176933.5	TOB2P1	-4.03	6.61e-05	0.00996	-0.2	-0.18	Pubertal anthropometrics;	chr6:28294921	chr6:28217643~28218634:-
LUAD	cis	rs8073060	0.586	rs4796100	ENSG00000267592.1	CTC-507E2.2	-4.03	6.61e-05	0.00996	-0.26	-0.18	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35670638	chr17:35596904~35597128:-
LUAD	cis	rs4374383	0.884	rs1554214	ENSG00000207383.1	Y_RNA	4.03	6.61e-05	0.00996	0.22	0.18	Hepatitis C induced liver fibrosis;	chr2:111986340	chr2:112579484~112579584:-
LUAD	cis	rs1044826	1	rs9289576	ENSG00000214280.3	RP11-553K23.2	-4.03	6.61e-05	0.00996	-0.21	-0.18	Obesity-related traits;	chr3:139481484	chr3:139582928~139583593:-
LUAD	cis	rs1044826	1	rs9289577	ENSG00000214280.3	RP11-553K23.2	-4.03	6.61e-05	0.00996	-0.21	-0.18	Obesity-related traits;	chr3:139481485	chr3:139582928~139583593:-
LUAD	cis	rs516805	0.52	rs487098	ENSG00000279453.1	RP3-425C14.4	-4.03	6.61e-05	0.00996	-0.19	-0.18	Lymphocyte counts;	chr6:122444760	chr6:122436789~122439223:-
LUAD	cis	rs9467773	0.873	rs55930917	ENSG00000124549.13	BTN2A3P	4.03	6.62e-05	0.00996	0.17	0.18	Intelligence (multi-trait analysis);	chr6:26576958	chr6:26421391~26432383:+
LUAD	cis	rs2274273	0.588	rs2880103	ENSG00000258413.1	RP11-665C16.6	-4.03	6.62e-05	0.00997	-0.25	-0.18	Protein biomarker;	chr14:55271114	chr14:55262767~55272075:-
LUAD	cis	rs4713118	0.869	rs2056925	ENSG00000280107.1	AL022393.9	-4.03	6.62e-05	0.00997	-0.23	-0.18	Parkinson's disease;	chr6:27723126	chr6:28170845~28172521:+
LUAD	cis	rs7968440	1	rs2684900	ENSG00000272368.2	RP4-605O3.4	4.03	6.62e-05	0.00997	0.21	0.18	Fibrinogen;	chr12:50625773	chr12:50112197~50165618:+
LUAD	cis	rs4763879	0.634	rs7974396	ENSG00000256582.1	RP11-75L1.1	-4.03	6.62e-05	0.00997	-0.19	-0.18	Type 1 diabetes;	chr12:9708101	chr12:9704077~9709350:+
LUAD	cis	rs7107174	0.892	rs4291702	ENSG00000251323.2	RP11-452H21.4	4.02	6.62e-05	0.00997	0.22	0.18	Testicular germ cell tumor;	chr11:78290202	chr11:78423982~78429836:-
LUAD	cis	rs9549260	0.564	rs9549279	ENSG00000229456.1	RLIMP1	-4.02	6.62e-05	0.00997	-0.19	-0.18	Red blood cell count;	chr13:40741446	chr13:40618738~40621348:+
LUAD	cis	rs7923837	0.687	rs1111875	ENSG00000236493.2	EIF2S2P3	4.02	6.62e-05	0.00997	0.2	0.18	Multiple sclerosis;Body mass index;	chr10:92703125	chr10:92668745~92669743:-
LUAD	cis	rs6951245	1	rs80031817	ENSG00000199023.2	MIR339	-4.02	6.62e-05	0.00998	-0.33	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057157	chr7:1022935~1023045:-
LUAD	cis	rs6951245	1	rs78143408	ENSG00000199023.2	MIR339	-4.02	6.62e-05	0.00998	-0.33	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057210	chr7:1022935~1023045:-
LUAD	cis	rs6951245	0.938	rs78351779	ENSG00000199023.2	MIR339	-4.02	6.62e-05	0.00998	-0.33	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057387	chr7:1022935~1023045:-
LUAD	cis	rs6951245	1	rs11761941	ENSG00000199023.2	MIR339	-4.02	6.62e-05	0.00998	-0.33	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057547	chr7:1022935~1023045:-
LUAD	cis	rs6951245	1	rs11767527	ENSG00000199023.2	MIR339	-4.02	6.62e-05	0.00998	-0.33	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057758	chr7:1022935~1023045:-
LUAD	cis	rs7551222	0.752	rs4951400	ENSG00000240219.1	RP11-430C7.5	4.02	6.63e-05	0.00998	0.19	0.18	Schizophrenia;	chr1:204565443	chr1:204626775~204629712:+
LUAD	cis	rs7551222	0.721	rs4951402	ENSG00000240219.1	RP11-430C7.5	4.02	6.63e-05	0.00998	0.19	0.18	Schizophrenia;	chr1:204569994	chr1:204626775~204629712:+
LUAD	cis	rs4460629	0.71	rs11264318	ENSG00000160766.13	GBAP1	-4.02	6.63e-05	0.00998	-0.18	-0.18	Serum magnesium levels;	chr1:155111241	chr1:155213821~155227422:-
LUAD	cis	rs10857712	0.754	rs1052582	ENSG00000273336.1	OR7M1P	-4.02	6.63e-05	0.00998	-0.27	-0.18	Systemic lupus erythematosus;	chr10:133420336	chr10:133481238~133481770:+
LUAD	cis	rs10857712	0.754	rs2297032	ENSG00000273336.1	OR7M1P	-4.02	6.63e-05	0.00998	-0.27	-0.18	Systemic lupus erythematosus;	chr10:133421076	chr10:133481238~133481770:+
LUAD	cis	rs62025270	0.632	rs62022918	ENSG00000259416.2	RP11-158M2.5	-4.02	6.63e-05	0.00998	-0.24	-0.18	Idiopathic pulmonary fibrosis;	chr15:85675053	chr15:85754941~85756237:-
LUAD	cis	rs62025270	0.632	rs111906684	ENSG00000259416.2	RP11-158M2.5	-4.02	6.63e-05	0.00998	-0.24	-0.18	Idiopathic pulmonary fibrosis;	chr15:85678705	chr15:85754941~85756237:-
LUAD	cis	rs7512552	0.839	rs1498308	ENSG00000275557.1	RP11-353N4.6	4.02	6.63e-05	0.00998	0.2	0.18	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150322682	chr1:149607765~149612402:+
LUAD	cis	rs12701220	0.689	rs12530960	ENSG00000229043.2	AC091729.9	-4.02	6.63e-05	0.00998	-0.26	-0.18	Bronchopulmonary dysplasia;	chr7:1055835	chr7:1160374~1165267:+
LUAD	cis	rs4578769	0.55	rs9961760	ENSG00000265943.1	RP11-739L10.1	4.02	6.63e-05	0.00998	0.23	0.18	Eosinophil percentage of white cells;	chr18:23021545	chr18:22699481~22933764:-
LUAD	cis	rs6732565	0.706	rs1114540	ENSG00000235721.1	AC013268.3	4.02	6.63e-05	0.00999	0.2	0.18	Rheumatoid arthritis;	chr2:110894999	chr2:110007675~110010783:+
LUAD	cis	rs4843747	0.671	rs28451517	ENSG00000205037.2	RP11-863P13.4	4.02	6.63e-05	0.00999	0.25	0.18	Menopause (age at onset);	chr16:88075521	chr16:88088041~88100985:-
LUAD	cis	rs1910358	0.919	rs2331690	ENSG00000248874.4	C5orf17	4.02	6.64e-05	0.00999	0.25	0.18	Venous thromboembolism (SNP x SNP interaction);	chr5:23865627	chr5:23951348~24178263:+
LUAD	cis	rs34779708	0.931	rs12268745	ENSG00000271335.4	RP11-324I22.4	4.02	6.64e-05	0.00999	0.19	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35017061	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.931	rs7923172	ENSG00000271335.4	RP11-324I22.4	4.02	6.64e-05	0.00999	0.19	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35020439	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.931	rs3740083	ENSG00000271335.4	RP11-324I22.4	4.02	6.64e-05	0.00999	0.19	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35031455	chr10:35314552~35336401:-
LUAD	cis	rs10131894	0.611	rs175000	ENSG00000259138.1	RP11-950C14.7	-4.02	6.64e-05	0.00999	-0.19	-0.18	Coronary artery disease;	chr14:74969664	chr14:75127153~75136930:+
LUAD	cis	rs6563842	0.563	rs9603786	ENSG00000229456.1	RLIMP1	4.02	6.64e-05	0.00999	0.19	0.18	Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr13:40742228	chr13:40618738~40621348:+
LUAD	cis	rs6981523	0.553	rs2409730	ENSG00000255046.1	RP11-297N6.4	4.02	6.64e-05	0.00999	0.22	0.18	Neuroticism;	chr8:11203129	chr8:11797928~11802568:-
LUAD	cis	rs13434995	0.513	rs55885973	ENSG00000273257.1	RP11-177J6.1	-4.02	6.64e-05	0.01	-0.24	-0.18	Adiponectin levels;	chr4:55480054	chr4:55387949~55388271:+
LUAD	cis	rs6964587	0.967	rs7786031	ENSG00000188693.7	CYP51A1-AS1	-4.02	6.64e-05	0.01	-0.21	-0.18	Breast cancer;	chr7:92019687	chr7:92134604~92180725:+
LUAD	cis	rs8054556	0.647	rs4077410	ENSG00000214725.6	CDIPT-AS1	-4.02	6.64e-05	0.01	-0.21	-0.18	Autism spectrum disorder or schizophrenia;	chr16:29986879	chr16:29863593~29868053:+
LUAD	cis	rs523522	0.962	rs4767905	ENSG00000278344.1	RP11-18C24.8	4.02	6.64e-05	0.01	0.25	0.18	High light scatter reticulocyte count;	chr12:120493032	chr12:120500735~120501090:-
LUAD	cis	rs523522	0.962	rs3759394	ENSG00000278344.1	RP11-18C24.8	4.02	6.64e-05	0.01	0.25	0.18	High light scatter reticulocyte count;	chr12:120495370	chr12:120500735~120501090:-
LUAD	cis	rs523522	0.962	rs2233676	ENSG00000278344.1	RP11-18C24.8	4.02	6.64e-05	0.01	0.25	0.18	High light scatter reticulocyte count;	chr12:120495804	chr12:120500735~120501090:-
LUAD	cis	rs523522	0.923	rs3916065	ENSG00000278344.1	RP11-18C24.8	4.02	6.64e-05	0.01	0.25	0.18	High light scatter reticulocyte count;	chr12:120496821	chr12:120500735~120501090:-
LUAD	cis	rs523522	0.962	rs9788155	ENSG00000278344.1	RP11-18C24.8	4.02	6.64e-05	0.01	0.25	0.18	High light scatter reticulocyte count;	chr12:120500605	chr12:120500735~120501090:-
LUAD	cis	rs523522	0.923	rs10774553	ENSG00000278344.1	RP11-18C24.8	4.02	6.64e-05	0.01	0.25	0.18	High light scatter reticulocyte count;	chr12:120517181	chr12:120500735~120501090:-
LUAD	cis	rs523522	0.962	rs11065149	ENSG00000278344.1	RP11-18C24.8	4.02	6.64e-05	0.01	0.25	0.18	High light scatter reticulocyte count;	chr12:120519160	chr12:120500735~120501090:-
LUAD	cis	rs523522	0.962	rs10849757	ENSG00000278344.1	RP11-18C24.8	4.02	6.64e-05	0.01	0.25	0.18	High light scatter reticulocyte count;	chr12:120526211	chr12:120500735~120501090:-
LUAD	cis	rs9549260	0.755	rs3892360	ENSG00000229456.1	RLIMP1	4.02	6.64e-05	0.01	0.2	0.18	Red blood cell count;	chr13:40609941	chr13:40618738~40621348:+
LUAD	cis	rs8054556	0.669	rs12931955	ENSG00000214725.6	CDIPT-AS1	-4.02	6.64e-05	0.01	-0.21	-0.18	Autism spectrum disorder or schizophrenia;	chr16:30001745	chr16:29863593~29868053:+
LUAD	cis	rs9341808	0.556	rs1535075	ENSG00000260645.1	RP11-250B2.5	4.02	6.64e-05	0.01	0.17	0.18	Sitting height ratio;	chr6:80325089	chr6:80466958~80469080:+
LUAD	cis	rs2702164	0.814	rs916509	ENSG00000240661.1	RP11-174O3.3	4.02	6.64e-05	0.01	0.22	0.18	Gut microbiome composition (winter);	chr3:120424980	chr3:120349510~120367998:+
LUAD	cis	rs853679	0.517	rs9393896	ENSG00000226314.6	ZNF192P1	-4.02	6.65e-05	0.01	-0.24	-0.18	Depression;	chr6:28159925	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs9393897	ENSG00000226314.6	ZNF192P1	-4.02	6.65e-05	0.01	-0.24	-0.18	Depression;	chr6:28159932	chr6:28161781~28169594:+
LUAD	cis	rs8141529	0.778	rs7287806	ENSG00000272858.1	CTA-292E10.8	-4.02	6.65e-05	0.01	-0.2	-0.18	Lymphocyte counts;	chr22:28817023	chr22:28814914~28815662:+
LUAD	cis	rs8048589	1	rs8059989	ENSG00000175604.2	RP11-276H1.3	-4.02	6.65e-05	0.01	-0.24	-0.18	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12091889	chr16:12086746~12090302:-
LUAD	cis	rs228614	0.509	rs223486	ENSG00000251288.2	RP11-10L12.2	-4.02	6.65e-05	0.01	-0.22	-0.18	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102763796	chr4:102751401~102752641:+
LUAD	cis	rs6661961	0.752	rs7531606	ENSG00000237975.5	FLG-AS1	-4.02	6.65e-05	0.01	-0.24	-0.18	Atopic dermatitis;	chr1:152454394	chr1:152168125~152445456:+
LUAD	cis	rs17122278	0.929	rs113739713	ENSG00000243431.1	RPL5P30	4.02	6.65e-05	0.01	0.22	0.18	Total cholesterol levels;	chr11:118549386	chr11:118560690~118561580:+
LUAD	cis	rs911555	0.755	rs2756135	ENSG00000244691.1	RPL10AP1	4.02	6.65e-05	0.01	0.24	0.18	Intelligence (multi-trait analysis);	chr14:103496242	chr14:103412119~103412761:-
LUAD	cis	rs27434	0.615	rs61112531	ENSG00000272109.1	CTD-2260A17.3	4.02	6.65e-05	0.01	0.26	0.18	Ankylosing spondylitis;	chr5:96856117	chr5:96804353~96806105:+
LUAD	cis	rs4934494	0.681	rs12572928	ENSG00000240996.1	RP11-80H5.7	-4.02	6.65e-05	0.01	-0.25	-0.18	Red blood cell count;	chr10:89793792	chr10:89694295~89697928:-
LUAD	cis	rs12898179	0.53	rs10133655	ENSG00000258561.1	RP11-72M17.1	4.02	6.65e-05	0.01	0.28	0.18	Glomerular filtration rate in chronic kidney disease;	chr14:67508211	chr14:66212810~66509394:-
LUAD	cis	rs17772222	0.701	rs453112	ENSG00000258789.1	RP11-507K2.3	4.02	6.65e-05	0.01	0.23	0.18	Coronary artery calcification;	chr14:88392657	chr14:88551597~88552493:+
LUAD	cis	rs2243480	1	rs6958420	ENSG00000229886.1	RP5-1132H15.3	-4.02	6.65e-05	0.01	-0.31	-0.18	Diabetic kidney disease;	chr7:66286184	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs1392104	ENSG00000229886.1	RP5-1132H15.3	-4.02	6.65e-05	0.01	-0.31	-0.18	Diabetic kidney disease;	chr7:66294120	chr7:66025126~66031544:-
LUAD	cis	rs7647973	0.58	rs11130184	ENSG00000225399.4	RP11-3B7.1	4.02	6.65e-05	0.01	0.23	0.18	Menarche (age at onset);	chr3:49192497	chr3:49260085~49261316:+
LUAD	cis	rs3743162	1	rs12909280	ENSG00000225151.9	GOLGA2P7	-4.02	6.66e-05	0.01	-0.26	-0.18	Alzheimer's disease (age of onset);	chr15:84886125	chr15:84199311~84230136:-
LUAD	cis	rs6142102	0.812	rs761236	ENSG00000275784.1	RP5-1125A11.6	-4.02	6.66e-05	0.01	-0.2	-0.18	Skin pigmentation;	chr20:33932245	chr20:33989480~33991818:-
LUAD	cis	rs13068223	1	rs34111024	ENSG00000243926.1	TIPARP-AS1	4.02	6.66e-05	0.01	0.19	0.18	Age-related hearing impairment (SNP x SNP interaction);	chr3:156748947	chr3:156671862~156674378:-
LUAD	cis	rs13068223	1	rs36126086	ENSG00000243926.1	TIPARP-AS1	4.02	6.66e-05	0.01	0.19	0.18	Age-related hearing impairment (SNP x SNP interaction);	chr3:156749028	chr3:156671862~156674378:-
LUAD	cis	rs12073359	1	rs11589922	ENSG00000223945.2	RP11-458I7.1	-4.02	6.67e-05	0.01	-0.27	-0.18	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150161125	chr1:150053864~150055034:+
LUAD	cis	rs8028182	0.636	rs4299117	ENSG00000260269.4	CTD-2323K18.1	-4.02	6.67e-05	0.01	-0.25	-0.18	Sudden cardiac arrest;	chr15:75497103	chr15:75527150~75601205:-
LUAD	cis	rs8028182	0.636	rs11637586	ENSG00000260269.4	CTD-2323K18.1	-4.02	6.67e-05	0.01	-0.25	-0.18	Sudden cardiac arrest;	chr15:75498771	chr15:75527150~75601205:-
LUAD	cis	rs1005277	0.638	rs1005278	ENSG00000263064.2	RP11-291L22.7	-4.02	6.67e-05	0.01	-0.2	-0.18	Extrinsic epigenetic age acceleration;	chr10:37929820	chr10:38448689~38448949:+
LUAD	cis	rs6840360	0.582	rs2724555	ENSG00000270265.1	RP11-731D1.4	-4.02	6.67e-05	0.01	-0.18	-0.18	Intelligence (multi-trait analysis);	chr4:151420726	chr4:151333775~151353224:-
LUAD	cis	rs737008	0.922	rs28567501	ENSG00000262703.1	RP11-485G7.6	-4.02	6.67e-05	0.01	-0.17	-0.18	Obesity-related traits;	chr16:11285071	chr16:11348143~11349321:-
LUAD	cis	rs4578769	0.531	rs9951973	ENSG00000266850.1	RP11-370A5.1	-4.02	6.67e-05	0.01	-0.23	-0.18	Eosinophil percentage of white cells;	chr18:22974353	chr18:22723491~22907721:-
LUAD	cis	rs4499344	0.73	rs2903755	ENSG00000201388.1	SNORA68	4.02	6.67e-05	0.01	0.19	0.18	Mean platelet volume;	chr19:32607964	chr19:32608337~32608469:-
LUAD	cis	rs4499344	0.73	rs2868150	ENSG00000201388.1	SNORA68	4.02	6.67e-05	0.01	0.19	0.18	Mean platelet volume;	chr19:32607969	chr19:32608337~32608469:-
LUAD	cis	rs6095360	0.69	rs35649484	ENSG00000177410.11	ZFAS1	4.02	6.67e-05	0.01	0.2	0.18	Intelligence (multi-trait analysis);	chr20:49138625	chr20:49278178~49295738:+
LUAD	cis	rs34779708	0.966	rs1057108	ENSG00000271335.4	RP11-324I22.4	4.02	6.67e-05	0.01	0.19	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35196021	chr10:35314552~35336401:-
LUAD	cis	rs9287719	0.87	rs728135	ENSG00000243819.4	RN7SL832P	4.02	6.67e-05	0.01	0.19	0.18	Prostate cancer;	chr2:10605006	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs963831	ENSG00000243819.4	RN7SL832P	4.02	6.67e-05	0.01	0.19	0.18	Prostate cancer;	chr2:10605058	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs728134	ENSG00000243819.4	RN7SL832P	4.02	6.67e-05	0.01	0.19	0.18	Prostate cancer;	chr2:10605061	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs2884233	ENSG00000243819.4	RN7SL832P	4.02	6.67e-05	0.01	0.19	0.18	Prostate cancer;	chr2:10605177	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.839	rs12692415	ENSG00000243819.4	RN7SL832P	4.02	6.67e-05	0.01	0.19	0.18	Prostate cancer;	chr2:10605348	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.934	rs12692416	ENSG00000243819.4	RN7SL832P	4.02	6.67e-05	0.01	0.19	0.18	Prostate cancer;	chr2:10605501	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs12692417	ENSG00000243819.4	RN7SL832P	4.02	6.67e-05	0.01	0.19	0.18	Prostate cancer;	chr2:10605592	chr2:10690344~10692099:+
LUAD	cis	rs7200786	0.567	rs6498166	ENSG00000274038.1	RP11-66H6.4	-4.02	6.68e-05	0.01	-0.23	-0.18	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11120259	chr16:11056556~11057034:+
LUAD	cis	rs12701220	0.689	rs12533004	ENSG00000229043.2	AC091729.9	-4.02	6.68e-05	0.01	-0.26	-0.18	Bronchopulmonary dysplasia;	chr7:1055774	chr7:1160374~1165267:+
LUAD	cis	rs9973361	0.55	rs58562881	ENSG00000232411.1	AC009495.3	-4.02	6.68e-05	0.01	-0.2	-0.18	Total body bone mineral density;	chr2:165838008	chr2:165833048~165839098:-
LUAD	cis	rs801193	0.548	rs6975044	ENSG00000273448.1	RP11-166O4.6	4.02	6.68e-05	0.01	0.17	0.18	Aortic root size;	chr7:66762495	chr7:67333047~67334383:+
LUAD	cis	rs7208859	0.673	rs2269915	ENSG00000280069.1	CTD-2349P21.3	-4.02	6.68e-05	0.01	-0.26	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906326	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs2269916	ENSG00000280069.1	CTD-2349P21.3	-4.02	6.68e-05	0.01	-0.26	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906745	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.673	rs11649765	ENSG00000280069.1	CTD-2349P21.3	-4.02	6.68e-05	0.01	-0.26	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906870	chr17:30738182~30740275:+
LUAD	cis	rs2153535	0.518	rs1998265	ENSG00000230939.1	RP11-314C16.1	-4.02	6.68e-05	0.01	-0.21	-0.18	Motion sickness;	chr6:8651929	chr6:8784178~8785445:+
LUAD	cis	rs1910358	0.959	rs10065366	ENSG00000248874.4	C5orf17	-4.02	6.68e-05	0.01	-0.26	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr5:23908240	chr5:23951348~24178263:+
LUAD	cis	rs9601248	0.627	rs9545151	ENSG00000227676.3	LINC01068	-4.02	6.68e-05	0.01	-0.23	-0.18	Major depressive disorder;	chr13:79608400	chr13:79566727~79571436:+
LUAD	cis	rs9646944	1	rs11677452	ENSG00000234389.1	AC007278.3	4.02	6.68e-05	0.01	0.2	0.18	Blood protein levels;	chr2:102248776	chr2:102438713~102440475:+
LUAD	cis	rs35740288	0.77	rs67253156	ENSG00000259407.1	RP11-158M2.3	-4.02	6.68e-05	0.01	-0.17	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85561814	chr15:85744109~85750281:-
LUAD	cis	rs10266483	0.883	rs683689	ENSG00000227986.1	TRIM60P18	-4.02	6.68e-05	0.0101	-0.21	-0.18	Response to statin therapy;	chr7:64282165	chr7:64355078~64356199:+
LUAD	cis	rs6964587	0.839	rs2049314	ENSG00000188693.7	CYP51A1-AS1	-4.02	6.68e-05	0.0101	-0.22	-0.18	Breast cancer;	chr7:91834820	chr7:92134604~92180725:+
LUAD	cis	rs848490	1	rs11770446	ENSG00000214293.7	APTR	4.02	6.68e-05	0.0101	0.24	0.18	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77728755	chr7:77657660~77696265:-
LUAD	cis	rs34779708	0.868	rs2384352	ENSG00000271335.4	RP11-324I22.4	4.02	6.68e-05	0.0101	0.19	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35203904	chr10:35314552~35336401:-
LUAD	cis	rs2251260	0.685	rs2246850	ENSG00000250548.5	RP11-47I22.2	4.02	6.69e-05	0.0101	0.23	0.18	Yeast infection;	chr14:61542888	chr14:61556313~61570653:-
LUAD	cis	rs4853525	0.62	rs6751868	ENSG00000235852.1	AC005540.3	4.02	6.69e-05	0.0101	0.22	0.18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190877222	chr2:190880797~190882059:-
LUAD	cis	rs7119	0.604	rs2682927	ENSG00000259362.2	RP11-307C19.1	4.02	6.69e-05	0.0101	0.23	0.18	Type 2 diabetes;	chr15:77566826	chr15:77525540~77534110:+
LUAD	cis	rs7061710	0.703	rs10910879	ENSG00000271811.1	RP1-79C4.4	-4.02	6.69e-05	0.0101	-0.27	-0.18	Blood metabolite levels;	chr1:171084012	chr1:170667381~170669425:+
LUAD	cis	rs727479	0.585	rs12911554	ENSG00000259306.2	RP11-108K3.2	-4.02	6.69e-05	0.0101	-0.18	-0.18	Estradiol levels;	chr15:51250560	chr15:51315841~51321996:+
LUAD	cis	rs5742933	0.817	rs4667297	ENSG00000253559.1	OSGEPL1-AS1	4.02	6.69e-05	0.0101	0.22	0.18	Ferritin levels;	chr2:189664270	chr2:189762704~189765556:+
LUAD	cis	rs4925386	0.681	rs2427294	ENSG00000273619.1	RP5-908M14.9	-4.02	6.69e-05	0.0101	-0.19	-0.18	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62352201	chr20:62386303~62386970:-
LUAD	cis	rs2380205	0.689	rs12779398	ENSG00000232807.2	RP11-536K7.3	4.02	6.69e-05	0.0101	0.2	0.18	Breast cancer;	chr10:5854662	chr10:5934270~5945900:-
LUAD	cis	rs11846409	0.86	rs17112419	ENSG00000223648.3	IGHV3-64	4.02	6.69e-05	0.0101	0.21	0.18	Rheumatic heart disease;	chr14:106633260	chr14:106643132~106658258:-
LUAD	cis	rs2732480	0.577	rs2634691	ENSG00000257763.1	OR5BK1P	4.02	6.69e-05	0.0101	0.2	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48314476	chr12:48355792~48356614:-
LUAD	cis	rs28510890	0.828	rs77955994	ENSG00000260337.3	RP11-386M24.6	4.02	6.69e-05	0.0101	0.23	0.18	Lung cancer in ever smokers;	chr15:92582299	chr15:92592574~92596462:-
LUAD	cis	rs2732480	0.577	rs2732486	ENSG00000240399.1	RP1-228P16.1	4.02	6.7e-05	0.0101	0.18	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344051	chr12:48054813~48055591:-
LUAD	cis	rs2731006	0.64	rs2730999	ENSG00000257114.2	RP11-25I15.3	-4.02	6.7e-05	0.0101	-0.28	-0.18	Panic disorder;	chr12:42787027	chr12:42692216~42717119:+
LUAD	cis	rs4130344	0.874	rs7666007	ENSG00000271817.2	U3	-4.02	6.7e-05	0.0101	-0.19	-0.18	Intelligence (multi-trait analysis);	chr4:158756560	chr4:158700691~158700909:+
LUAD	cis	rs4130344	0.874	rs2069052	ENSG00000271817.2	U3	-4.02	6.7e-05	0.0101	-0.19	-0.18	Intelligence (multi-trait analysis);	chr4:158758422	chr4:158700691~158700909:+
LUAD	cis	rs7044106	0.512	rs7873848	ENSG00000238181.2	AHCYP2	-4.02	6.7e-05	0.0101	-0.24	-0.18	Hip circumference adjusted for BMI;	chr9:120591944	chr9:120720673~120721972:+
LUAD	cis	rs1023500	0.573	rs133370	ENSG00000205702.9	CYP2D7	4.02	6.7e-05	0.0101	0.15	0.18	Schizophrenia;	chr22:42069256	chr22:42140203~42144577:-
LUAD	cis	rs4819052	0.788	rs35323494	ENSG00000237664.1	LINC00316	-4.02	6.7e-05	0.0101	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45283824	chr21:45338590~45341990:-
LUAD	cis	rs6671200	0.607	rs10874908	ENSG00000228852.5	RP11-57H12.5	-4.02	6.7e-05	0.0101	-0.22	-0.18	Stearic acid (18:0) levels;	chr1:95238595	chr1:95243167~95278940:-
LUAD	cis	rs9549260	0.755	rs9549255	ENSG00000229456.1	RLIMP1	4.02	6.7e-05	0.0101	0.19	0.18	Red blood cell count;	chr13:40661076	chr13:40618738~40621348:+
LUAD	cis	rs877356	0.748	rs1465292	ENSG00000250378.1	RP11-119J18.1	-4.02	6.7e-05	0.0101	-0.31	-0.18	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (dichotomous);	chr5:135812343	chr5:135812667~135826582:+
LUAD	cis	rs8048589	0.898	rs11648235	ENSG00000175604.2	RP11-276H1.3	-4.02	6.7e-05	0.0101	-0.25	-0.18	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12087222	chr16:12086746~12090302:-
LUAD	cis	rs911186	0.679	rs67330695	ENSG00000219392.1	RP1-265C24.5	-4.02	6.7e-05	0.0101	-0.29	-0.18	Autism spectrum disorder or schizophrenia;	chr6:27135875	chr6:28115628~28116551:+
LUAD	cis	rs7512552	0.78	rs55823828	ENSG00000275557.1	RP11-353N4.6	4.02	6.7e-05	0.0101	0.2	0.18	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150494820	chr1:149607765~149612402:+
LUAD	cis	rs10197140	0.857	rs4849165	ENSG00000235721.1	AC013268.3	-4.02	6.7e-05	0.0101	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110882012	chr2:110007675~110010783:+
LUAD	cis	rs10446497	0.61	rs12497046	ENSG00000272359.1	U4	4.02	6.7e-05	0.0101	0.21	0.18	Schizophrenia;	chr3:196816775	chr3:196747192~196747324:-
LUAD	cis	rs7824557	0.564	rs2572386	ENSG00000255046.1	RP11-297N6.4	4.02	6.71e-05	0.0101	0.22	0.18	Retinal vascular caliber;	chr8:11379466	chr8:11797928~11802568:-
LUAD	cis	rs73242632	1	rs2271807	ENSG00000269949.1	RP11-738E22.3	4.02	6.71e-05	0.0101	0.43	0.18	Congenital heart disease (maternal effect);	chr4:57032563	chr4:56960927~56961373:-
LUAD	cis	rs12935418	0.55	rs35595567	ENSG00000261061.1	RP11-303E16.2	-4.02	6.71e-05	0.0101	-0.24	-0.18	Mean corpuscular volume;	chr16:80999761	chr16:81030770~81031485:+
LUAD	cis	rs13434995	0.513	rs17779627	ENSG00000273257.1	RP11-177J6.1	-4.02	6.71e-05	0.0101	-0.24	-0.18	Adiponectin levels;	chr4:55483775	chr4:55387949~55388271:+
LUAD	cis	rs13434995	0.513	rs62303726	ENSG00000273257.1	RP11-177J6.1	-4.02	6.71e-05	0.0101	-0.24	-0.18	Adiponectin levels;	chr4:55490415	chr4:55387949~55388271:+
LUAD	cis	rs13434995	0.513	rs55729020	ENSG00000273257.1	RP11-177J6.1	-4.02	6.71e-05	0.0101	-0.24	-0.18	Adiponectin levels;	chr4:55491681	chr4:55387949~55388271:+
LUAD	cis	rs13434995	0.513	rs3805156	ENSG00000273257.1	RP11-177J6.1	-4.02	6.71e-05	0.0101	-0.24	-0.18	Adiponectin levels;	chr4:55497925	chr4:55387949~55388271:+
LUAD	cis	rs13434995	0.513	rs62303731	ENSG00000273257.1	RP11-177J6.1	-4.02	6.71e-05	0.0101	-0.24	-0.18	Adiponectin levels;	chr4:55499667	chr4:55387949~55388271:+
LUAD	cis	rs13434995	0.513	rs62303732	ENSG00000273257.1	RP11-177J6.1	-4.02	6.71e-05	0.0101	-0.24	-0.18	Adiponectin levels;	chr4:55499868	chr4:55387949~55388271:+
LUAD	cis	rs13434995	0.513	rs56196624	ENSG00000273257.1	RP11-177J6.1	-4.02	6.71e-05	0.0101	-0.24	-0.18	Adiponectin levels;	chr4:55500340	chr4:55387949~55388271:+
LUAD	cis	rs13434995	0.513	rs62305264	ENSG00000273257.1	RP11-177J6.1	-4.02	6.71e-05	0.0101	-0.24	-0.18	Adiponectin levels;	chr4:55502968	chr4:55387949~55388271:+
LUAD	cis	rs13434995	0.513	rs62305265	ENSG00000273257.1	RP11-177J6.1	-4.02	6.71e-05	0.0101	-0.24	-0.18	Adiponectin levels;	chr4:55503474	chr4:55387949~55388271:+
LUAD	cis	rs6088590	1	rs6088615	ENSG00000275784.1	RP5-1125A11.6	4.02	6.71e-05	0.0101	0.19	0.18	Coronary artery disease;	chr20:34812671	chr20:33989480~33991818:-
LUAD	cis	rs16866061	1	rs72974269	ENSG00000228446.2	AC073052.1	-4.02	6.71e-05	0.0101	-0.2	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr2:224590190	chr2:224499387~224500100:-
LUAD	cis	rs1910358	0.959	rs10059638	ENSG00000248874.4	C5orf17	-4.02	6.72e-05	0.0101	-0.26	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr5:23900326	chr5:23951348~24178263:+
LUAD	cis	rs1910358	0.959	rs34959020	ENSG00000248874.4	C5orf17	-4.02	6.72e-05	0.0101	-0.26	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr5:23902454	chr5:23951348~24178263:+
LUAD	cis	rs1910358	1	rs1910358	ENSG00000248874.4	C5orf17	-4.02	6.72e-05	0.0101	-0.26	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr5:23907464	chr5:23951348~24178263:+
LUAD	cis	rs783540	0.521	rs1259176	ENSG00000255769.6	GOLGA2P10	4.02	6.72e-05	0.0101	0.21	0.18	Schizophrenia;	chr15:82602149	chr15:82472993~82513950:-
LUAD	cis	rs6496044	0.568	rs1351196	ENSG00000259295.5	CSPG4P12	4.02	6.72e-05	0.0101	0.21	0.18	Interstitial lung disease;	chr15:85534173	chr15:85191438~85213905:+
LUAD	cis	rs9400467	0.528	rs1989574	ENSG00000230177.1	RP5-1112D6.4	-4.02	6.72e-05	0.0101	-0.16	-0.18	Amino acid levels;Blood metabolite levels;	chr6:111407330	chr6:111277932~111278742:+
LUAD	cis	rs2242663	0.531	rs2511225	ENSG00000213409.4	RP11-658F2.3	-4.02	6.72e-05	0.0101	-0.21	-0.18	Bipolar disorder;	chr11:66480960	chr11:66761575~66762399:-
LUAD	cis	rs2348418	0.831	rs7299042	ENSG00000244712.1	RP11-874G11.1	4.02	6.72e-05	0.0101	0.21	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28571750	chr12:28564678~28565141:-
LUAD	cis	rs34638952	0.507	rs2429243	ENSG00000264808.1	RP11-802D6.1	4.02	6.72e-05	0.0101	0.21	0.18	Sitting height ratio;	chr17:29301961	chr17:29369717~29390777:-
LUAD	cis	rs1044826	0.956	rs13086868	ENSG00000214280.3	RP11-553K23.2	-4.02	6.72e-05	0.0101	-0.22	-0.18	Obesity-related traits;	chr3:139520802	chr3:139582928~139583593:-
LUAD	cis	rs35740288	0.77	rs11634707	ENSG00000259407.1	RP11-158M2.3	-4.02	6.72e-05	0.0101	-0.18	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85608636	chr15:85744109~85750281:-
LUAD	cis	rs1322639	0.614	rs6903921	ENSG00000261039.2	RP11-417E7.2	-4.02	6.73e-05	0.0101	-0.29	-0.18	Pulse pressure;	chr6:169163862	chr6:169175304~169182740:-
LUAD	cis	rs1322639	0.614	rs6925950	ENSG00000261039.2	RP11-417E7.2	-4.02	6.73e-05	0.0101	-0.29	-0.18	Pulse pressure;	chr6:169163863	chr6:169175304~169182740:-
LUAD	cis	rs7809950	1	rs2520264	ENSG00000238832.1	snoU109	-4.02	6.73e-05	0.0101	-0.26	-0.18	Coronary artery disease;	chr7:107538899	chr7:107603363~107603507:+
LUAD	cis	rs12565755	0.556	rs4075690	ENSG00000226476.2	RP11-776H12.1	4.02	6.73e-05	0.0101	0.28	0.18	Response to tocilizumab in rheumatoid arthritis;	chr1:60486434	chr1:60540249~60640491:-
LUAD	cis	rs34638952	0.534	rs1638005	ENSG00000264808.1	RP11-802D6.1	4.02	6.73e-05	0.0101	0.21	0.18	Sitting height ratio;	chr17:29246079	chr17:29369717~29390777:-
LUAD	cis	rs28374715	0.58	rs8030228	ENSG00000247556.5	OIP5-AS1	4.02	6.73e-05	0.0101	0.22	0.18	Ulcerative colitis;	chr15:41344669	chr15:41283990~41309737:+
LUAD	cis	rs6964587	0.869	rs10256780	ENSG00000188693.7	CYP51A1-AS1	4.02	6.73e-05	0.0101	0.21	0.18	Breast cancer;	chr7:91897862	chr7:92134604~92180725:+
LUAD	cis	rs6964587	0.869	rs10241720	ENSG00000188693.7	CYP51A1-AS1	4.02	6.73e-05	0.0101	0.21	0.18	Breast cancer;	chr7:91898053	chr7:92134604~92180725:+
LUAD	cis	rs860295	0.665	rs12028416	ENSG00000225855.5	RUSC1-AS1	4.02	6.73e-05	0.0101	0.13	0.18	Body mass index;	chr1:155431370	chr1:155316863~155324176:-
LUAD	cis	rs860295	0.629	rs12026638	ENSG00000225855.5	RUSC1-AS1	4.02	6.73e-05	0.0101	0.13	0.18	Body mass index;	chr1:155431469	chr1:155316863~155324176:-
LUAD	cis	rs80028505	0.764	rs1967966	ENSG00000271304.1	DPRXP2	4.02	6.73e-05	0.0101	0.34	0.18	Foot ulcer in diabetes and neuropathy;	chr6:36104395	chr6:35989515~35990436:-
LUAD	cis	rs4268898	0.76	rs7597919	ENSG00000242628.4	AC009228.1	-4.02	6.73e-05	0.0101	-0.23	-0.18	Asthma;	chr2:24340777	chr2:24214381~24221516:+
LUAD	cis	rs2060793	0.552	rs939968	ENSG00000251991.1	RNU7-49P	4.02	6.74e-05	0.0101	0.19	0.18	Vitamin D levels;	chr11:14608134	chr11:14478892~14478953:+
LUAD	cis	rs853679	0.76	rs11962305	ENSG00000204709.4	LINC01556	4.02	6.74e-05	0.0101	0.26	0.18	Depression;	chr6:28232159	chr6:28943877~28944537:+
LUAD	cis	rs4713118	0.513	rs156739	ENSG00000216901.1	AL022393.7	4.02	6.74e-05	0.0101	0.21	0.18	Parkinson's disease;	chr6:28045632	chr6:28176188~28176674:+
LUAD	cis	rs2239547	0.522	rs6792578	ENSG00000243224.1	RP5-1157M23.2	-4.02	6.74e-05	0.0101	-0.2	-0.18	Schizophrenia;	chr3:52970588	chr3:52239258~52241097:+
LUAD	cis	rs10419113	0.567	rs6510095	ENSG00000270804.1	CTD-2583A14.11	4.02	6.74e-05	0.0101	0.17	0.18	Pediatric bone mineral density (spine);	chr19:57784793	chr19:57867885~57868834:+
LUAD	cis	rs4879677	1	rs12235880	ENSG00000215441.3	CTAGE12P	-4.02	6.74e-05	0.0101	-0.22	-0.18	Gut microbiome composition (summer and winter);	chr9:27674779	chr9:27608382~27610745:-
LUAD	cis	rs853679	0.567	rs6905380	ENSG00000219392.1	RP1-265C24.5	-4.02	6.74e-05	0.0101	-0.24	-0.18	Depression;	chr6:28407125	chr6:28115628~28116551:+
LUAD	cis	rs13403656	1	rs13403656	ENSG00000240350.2	AC017002.1	4.02	6.74e-05	0.0101	0.25	0.18	Allergic disease (asthma, hay fever or eczema);	chr2:111511550	chr2:111491273~111570974:+
LUAD	cis	rs13068223	0.904	rs13322900	ENSG00000243926.1	TIPARP-AS1	4.02	6.75e-05	0.0101	0.19	0.18	Age-related hearing impairment (SNP x SNP interaction);	chr3:156732229	chr3:156671862~156674378:-
LUAD	cis	rs13113518	0.812	rs11939580	ENSG00000272969.1	RP11-528I4.2	4.02	6.75e-05	0.0101	0.19	0.18	Height;	chr4:55517185	chr4:55547112~55547889:+
LUAD	cis	rs28374715	0.635	rs112547435	ENSG00000247556.5	OIP5-AS1	4.02	6.75e-05	0.0101	0.21	0.18	Ulcerative colitis;	chr15:41356539	chr15:41283990~41309737:+
LUAD	cis	rs651907	0.535	rs58658478	ENSG00000244119.1	PDCL3P4	4.02	6.75e-05	0.0101	0.19	0.18	Colorectal cancer;	chr3:101792823	chr3:101712472~101713191:+
LUAD	cis	rs35740288	0.787	rs11635418	ENSG00000259407.1	RP11-158M2.3	-4.02	6.75e-05	0.0101	-0.18	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85700947	chr15:85744109~85750281:-
LUAD	cis	rs1346081	1	rs1346081	ENSG00000250075.4	RP11-584P21.2	-4.02	6.75e-05	0.0101	-0.2	-0.18	Intelligence (multi-trait analysis);	chr4:67169001	chr4:67417305~67468251:-
LUAD	cis	rs13287066	0.692	rs10761225	ENSG00000227603.1	RP11-165J3.6	4.02	6.75e-05	0.0101	0.21	0.18	Intelligence (multi-trait analysis);	chr9:93404358	chr9:93435332~93437121:-
LUAD	cis	rs1431005	0.963	rs72725287	ENSG00000250658.1	RP11-138B4.1	4.02	6.75e-05	0.0101	0.22	0.18	Response to statin therapy;	chr4:187477151	chr4:187304083~187309682:-
LUAD	cis	rs2554380	0.843	rs1426162	ENSG00000259570.1	RP11-671M22.4	4.02	6.75e-05	0.0101	0.26	0.18	Height;	chr15:83717251	chr15:84394512~84395514:+
LUAD	cis	rs1799955	1	rs9567600	ENSG00000215515.2	IFIT1P1	-4.02	6.75e-05	0.0101	-0.27	-0.18	LDL cholesterol levels;	chr13:32359789	chr13:32384660~32386108:+
LUAD	cis	rs1799949	0.602	rs8176257	ENSG00000267340.1	RP11-242D8.3	4.02	6.75e-05	0.0101	0.21	0.18	Menopause (age at onset);	chr17:43064188	chr17:43169880~43170077:-
LUAD	cis	rs17772222	0.682	rs1864744	ENSG00000258789.1	RP11-507K2.3	4.02	6.75e-05	0.0101	0.22	0.18	Coronary artery calcification;	chr14:88484662	chr14:88551597~88552493:+
LUAD	cis	rs1502337	0.532	rs11065688	ENSG00000278993.1	RP3-424M6.4	-4.02	6.75e-05	0.0101	-0.23	-0.18	Body mass index;	chr12:110644337	chr12:110501614~110503441:+
LUAD	cis	rs6496044	0.568	rs7176291	ENSG00000259295.5	CSPG4P12	4.02	6.75e-05	0.0101	0.21	0.18	Interstitial lung disease;	chr15:85524167	chr15:85191438~85213905:+
LUAD	cis	rs77688320	0.517	rs7573536	ENSG00000213090.2	AC007256.5	4.02	6.75e-05	0.0101	0.21	0.18	Breast cancer;	chr2:201469676	chr2:201410544~201413308:-
LUAD	cis	rs73108077	1	rs73108042	ENSG00000281376.1	ABALON	-4.02	6.76e-05	0.0101	-0.34	-0.18	Red blood cell density in sickle cell anemia;	chr20:31403854	chr20:31721507~31723409:+
LUAD	cis	rs9381040	0.674	rs4711657	ENSG00000161912.16	ADCY10P1	4.02	6.76e-05	0.0101	0.17	0.18	Alzheimer's disease (late onset);	chr6:41194977	chr6:41101022~41140835:+
LUAD	cis	rs11210359	0.528	rs11210362	ENSG00000272864.1	RP11-17E13.2	4.02	6.76e-05	0.0101	0.22	0.18	Bipolar disorder and schizophrenia;	chr1:73883031	chr1:74698769~74699333:-
LUAD	cis	rs116095464	0.614	rs4371799	ENSG00000248925.1	CTD-2083E4.6	4.02	6.76e-05	0.0101	0.3	0.18	Breast cancer;	chr5:268077	chr5:269858~271516:-
LUAD	cis	rs1541160	0.913	rs621437	ENSG00000239494.2	RN7SL333P	-4.02	6.76e-05	0.0101	-0.17	-0.18	Amyotrophic lateral sclerosis;	chr1:169955618	chr1:169859756~169860052:+
LUAD	cis	rs1355223	0.872	rs12802798	ENSG00000271369.1	RP11-350D17.3	-4.02	6.76e-05	0.0101	-0.21	-0.18	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34725887	chr11:34709600~34710161:+
LUAD	cis	rs12962334	0.57	rs4800434	ENSG00000265943.1	RP11-739L10.1	4.02	6.76e-05	0.0101	0.23	0.18	Breast cancer;	chr18:22848311	chr18:22699481~22933764:-
LUAD	cis	rs860295	0.702	rs56675301	ENSG00000225855.5	RUSC1-AS1	4.02	6.76e-05	0.0101	0.13	0.18	Body mass index;	chr1:155394536	chr1:155316863~155324176:-
LUAD	cis	rs42490	0.789	rs51331	ENSG00000251136.7	RP11-37B2.1	-4.02	6.76e-05	0.0102	-0.18	-0.18	Leprosy;	chr8:89801900	chr8:89609409~89757727:-
LUAD	cis	rs9868873	0.704	rs9860720	ENSG00000273454.1	RP11-797D24.3	4.02	6.76e-05	0.0102	0.3	0.18	Esophageal cancer;	chr3:123005524	chr3:123277353~123277904:+
LUAD	cis	rs17685	0.712	rs60232511	ENSG00000280388.1	RP11-229D13.3	-4.02	6.76e-05	0.0102	-0.17	-0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76170764	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.743	rs10277259	ENSG00000280388.1	RP11-229D13.3	-4.02	6.76e-05	0.0102	-0.17	-0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76173356	chr7:76043977~76045963:-
LUAD	cis	rs17695224	0.565	rs28800315	ENSG00000269483.1	AC006272.1	4.02	6.77e-05	0.0102	0.19	0.18	HDL cholesterol;HDL cholesterol levels;	chr19:51805837	chr19:51839924~51843324:-
LUAD	cis	rs6964587	0.869	rs10278155	ENSG00000188693.7	CYP51A1-AS1	4.02	6.77e-05	0.0102	0.21	0.18	Breast cancer;	chr7:91903142	chr7:92134604~92180725:+
LUAD	cis	rs763121	0.888	rs2235229	ENSG00000225450.1	RP3-508I15.14	-4.02	6.77e-05	0.0102	-0.16	-0.18	Menopause (age at onset);	chr22:38728907	chr22:38739003~38749041:+
LUAD	cis	rs10419113	0.522	rs10422444	ENSG00000270804.1	CTD-2583A14.11	-4.02	6.77e-05	0.0102	-0.17	-0.18	Pediatric bone mineral density (spine);	chr19:57767061	chr19:57867885~57868834:+
LUAD	cis	rs7017914	0.69	rs2639942	ENSG00000223220.1	Y_RNA	4.02	6.77e-05	0.0102	0.21	0.18	Bone mineral density;	chr8:71000939	chr8:70780914~70781008:-
LUAD	cis	rs763121	0.853	rs5750672	ENSG00000228274.3	RP3-508I15.9	4.02	6.77e-05	0.0102	0.18	0.18	Menopause (age at onset);	chr22:38708163	chr22:38667585~38681820:-
LUAD	cis	rs2348418	0.733	rs11049508	ENSG00000247934.4	RP11-967K21.1	4.02	6.77e-05	0.0102	0.21	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28289633	chr12:28163298~28190738:-
LUAD	cis	rs4474465	0.915	rs11237505	ENSG00000251323.2	RP11-452H21.4	4.02	6.77e-05	0.0102	0.23	0.18	Alzheimer's disease (survival time);	chr11:78460215	chr11:78423982~78429836:-
LUAD	cis	rs4474465	1	rs10899513	ENSG00000251323.2	RP11-452H21.4	4.02	6.77e-05	0.0102	0.23	0.18	Alzheimer's disease (survival time);	chr11:78461307	chr11:78423982~78429836:-
LUAD	cis	rs12122100	0.862	rs6689542	ENSG00000244371.2	PFN1P8	4.02	6.78e-05	0.0102	0.22	0.18	HIV-1 control;	chr1:147035327	chr1:146957117~146957659:-
LUAD	cis	rs1598856	1	rs93059	ENSG00000246560.2	RP11-10L12.4	4.02	6.78e-05	0.0102	0.23	0.18	Primary biliary cholangitis;	chr4:102547361	chr4:102828055~102844075:+
LUAD	cis	rs780096	0.546	rs4425043	ENSG00000234072.1	AC074117.10	-4.02	6.78e-05	0.0102	-0.14	-0.18	Total body bone mineral density;	chr2:27510585	chr2:27356246~27367622:+
LUAD	cis	rs7208859	0.673	rs9896095	ENSG00000266490.1	CTD-2349P21.9	4.02	6.78e-05	0.0102	0.26	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30860479	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.573	rs58920731	ENSG00000266490.1	CTD-2349P21.9	4.02	6.78e-05	0.0102	0.26	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864728	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs73277984	ENSG00000266490.1	CTD-2349P21.9	4.02	6.78e-05	0.0102	0.26	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869115	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs73277986	ENSG00000266490.1	CTD-2349P21.9	4.02	6.78e-05	0.0102	0.26	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869179	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs12103588	ENSG00000266490.1	CTD-2349P21.9	4.02	6.78e-05	0.0102	0.26	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30870442	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs4131618	ENSG00000266490.1	CTD-2349P21.9	4.02	6.78e-05	0.0102	0.26	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30877783	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs11658344	ENSG00000266490.1	CTD-2349P21.9	4.02	6.78e-05	0.0102	0.26	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30880727	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs9900144	ENSG00000266490.1	CTD-2349P21.9	4.02	6.78e-05	0.0102	0.26	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881371	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.573	rs11656121	ENSG00000266490.1	CTD-2349P21.9	4.02	6.78e-05	0.0102	0.26	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887025	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs11650973	ENSG00000266490.1	CTD-2349P21.9	4.02	6.78e-05	0.0102	0.26	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887027	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs56085216	ENSG00000266490.1	CTD-2349P21.9	4.02	6.78e-05	0.0102	0.26	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30890216	chr17:30792372~30792833:+
LUAD	cis	rs9926296	0.542	rs12599531	ENSG00000260259.1	RP11-368I7.4	4.02	6.78e-05	0.0102	0.18	0.18	Vitiligo;	chr16:89842993	chr16:89682620~89686569:-
LUAD	cis	rs4272382	1	rs4272382	ENSG00000253426.4	RP11-10A14.4	-4.02	6.78e-05	0.0102	-0.37	-0.18	Response to cytidine analogues (gemcitabine);	chr8:8575978	chr8:9151742~9168136:+
LUAD	cis	rs4474465	1	rs12280198	ENSG00000251323.2	RP11-452H21.4	4.02	6.78e-05	0.0102	0.22	0.18	Alzheimer's disease (survival time);	chr11:78450315	chr11:78423982~78429836:-
LUAD	cis	rs17772222	0.653	rs1346996	ENSG00000258983.2	RP11-507K2.2	4.02	6.78e-05	0.0102	0.21	0.18	Coronary artery calcification;	chr14:88507174	chr14:88499334~88515502:+
LUAD	cis	rs17772222	0.74	rs7160471	ENSG00000258983.2	RP11-507K2.2	4.02	6.78e-05	0.0102	0.21	0.18	Coronary artery calcification;	chr14:88507241	chr14:88499334~88515502:+
LUAD	cis	rs17772222	0.74	rs9323830	ENSG00000258983.2	RP11-507K2.2	4.02	6.78e-05	0.0102	0.21	0.18	Coronary artery calcification;	chr14:88507260	chr14:88499334~88515502:+
LUAD	cis	rs2711721	1	rs2522279	ENSG00000276691.1	RP5-1057I20.5	-4.02	6.78e-05	0.0102	-0.19	-0.18	Prostate cancer (SNP x SNP interaction);	chr12:46973328	chr12:47788426~47788971:+
LUAD	cis	rs7429990	0.932	rs12493348	ENSG00000228638.1	FCF1P2	4.02	6.78e-05	0.0102	0.21	0.18	Educational attainment (years of education);	chr3:48102048	chr3:48290793~48291375:-
LUAD	cis	rs1667284	0.846	rs1667279	ENSG00000266521.1	RP11-650P15.1	4.02	6.78e-05	0.0102	0.21	0.18	Problematic alcohol use in trauma-exposed individuals;	chr18:31638910	chr18:31496645~31497195:-
LUAD	cis	rs2749097	0.735	rs7548548	ENSG00000244256.3	RN7SL130P	-4.02	6.78e-05	0.0102	-0.24	-0.18	Alcohol consumption (transferrin glycosylation);	chr1:63685698	chr1:63655743~63656047:+
LUAD	cis	rs2749097	0.735	rs7548664	ENSG00000244256.3	RN7SL130P	-4.02	6.78e-05	0.0102	-0.24	-0.18	Alcohol consumption (transferrin glycosylation);	chr1:63685977	chr1:63655743~63656047:+
LUAD	cis	rs34779708	0.931	rs7099593	ENSG00000271335.4	RP11-324I22.4	4.02	6.78e-05	0.0102	0.19	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35077950	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.931	rs13376801	ENSG00000271335.4	RP11-324I22.4	4.02	6.78e-05	0.0102	0.19	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35081515	chr10:35314552~35336401:-
LUAD	cis	rs1930961	0.702	rs8141065	ENSG00000100058.11	CRYBB2P1	-4.02	6.79e-05	0.0102	-0.29	-0.18	Bipolar disorder with mood-incongruent psychosis;	chr22:25489221	chr22:25448105~25520854:+
LUAD	cis	rs7578361	0.959	rs6435556	ENSG00000231969.1	AC144449.1	-4.02	6.79e-05	0.0102	-0.27	-0.18	Acute lymphoblastic leukemia (childhood);	chr2:149562326	chr2:149587196~149848233:+
LUAD	cis	rs848490	0.734	rs12531933	ENSG00000214293.7	APTR	4.02	6.79e-05	0.0102	0.22	0.18	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77671171	chr7:77657660~77696265:-
LUAD	cis	rs11971779	0.818	rs12056045	ENSG00000273391.1	RP11-634H22.1	4.02	6.79e-05	0.0102	0.22	0.18	Diisocyanate-induced asthma;	chr7:139340684	chr7:139359032~139359566:-
LUAD	cis	rs853679	0.567	rs16894091	ENSG00000219392.1	RP1-265C24.5	4.02	6.79e-05	0.0102	0.24	0.18	Depression;	chr6:28422360	chr6:28115628~28116551:+
LUAD	cis	rs9860428	1	rs9860428	ENSG00000242770.2	RP11-180K7.1	4.02	6.79e-05	0.0102	0.19	0.18	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112852072	chr3:112802478~112812819:+
LUAD	cis	rs6964587	1	rs7805077	ENSG00000188693.7	CYP51A1-AS1	-4.02	6.79e-05	0.0102	-0.21	-0.18	Breast cancer;	chr7:92015239	chr7:92134604~92180725:+
LUAD	cis	rs8058578	0.945	rs8058961	ENSG00000232748.3	RP11-196G11.6	-4.02	6.79e-05	0.0102	-0.23	-0.18	Multiple myeloma;	chr16:30797742	chr16:31056460~31062803:+
LUAD	cis	rs7512552	0.839	rs11587575	ENSG00000275557.1	RP11-353N4.6	4.02	6.79e-05	0.0102	0.2	0.18	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150479387	chr1:149607765~149612402:+
LUAD	cis	rs7551222	0.752	rs10900596	ENSG00000240219.1	RP11-430C7.5	4.02	6.79e-05	0.0102	0.19	0.18	Schizophrenia;	chr1:204553329	chr1:204626775~204629712:+
LUAD	cis	rs1005277	0.505	rs200931	ENSG00000263064.2	RP11-291L22.7	4.02	6.8e-05	0.0102	0.19	0.18	Extrinsic epigenetic age acceleration;	chr10:37839506	chr10:38448689~38448949:+
LUAD	cis	rs6688613	0.649	rs11584352	ENSG00000225171.2	DUTP6	-4.02	6.8e-05	0.0102	-0.22	-0.18	Refractive astigmatism;	chr1:166881135	chr1:166868748~166869209:+
LUAD	cis	rs12291225	0.585	rs10832242	ENSG00000251991.1	RNU7-49P	-4.02	6.8e-05	0.0102	-0.19	-0.18	Sense of smell;	chr11:14318958	chr11:14478892~14478953:+
LUAD	cis	rs7829975	0.902	rs777707	ENSG00000233609.3	RP11-62H7.2	4.02	6.8e-05	0.0102	0.15	0.18	Mood instability;	chr8:8726834	chr8:8961200~8979025:+
LUAD	cis	rs9287719	0.934	rs12692418	ENSG00000243819.4	RN7SL832P	4.02	6.8e-05	0.0102	0.19	0.18	Prostate cancer;	chr2:10605744	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs6755548	ENSG00000243819.4	RN7SL832P	4.02	6.8e-05	0.0102	0.19	0.18	Prostate cancer;	chr2:10606000	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs6761678	ENSG00000243819.4	RN7SL832P	4.02	6.8e-05	0.0102	0.19	0.18	Prostate cancer;	chr2:10606215	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs6759100	ENSG00000243819.4	RN7SL832P	4.02	6.8e-05	0.0102	0.19	0.18	Prostate cancer;	chr2:10606584	chr2:10690344~10692099:+
LUAD	cis	rs17685	0.753	rs10233282	ENSG00000280388.1	RP11-229D13.3	-4.02	6.8e-05	0.0102	-0.17	-0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76160763	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.753	rs10251863	ENSG00000280388.1	RP11-229D13.3	-4.02	6.8e-05	0.0102	-0.17	-0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76160874	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.753	rs9691174	ENSG00000280388.1	RP11-229D13.3	-4.02	6.8e-05	0.0102	-0.17	-0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76161087	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.664	rs9801113	ENSG00000280388.1	RP11-229D13.3	-4.02	6.8e-05	0.0102	-0.17	-0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76162713	chr7:76043977~76045963:-
LUAD	cis	rs17685	0.558	rs60787921	ENSG00000280388.1	RP11-229D13.3	-4.02	6.8e-05	0.0102	-0.17	-0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76163526	chr7:76043977~76045963:-
LUAD	cis	rs950169	1	rs12915234	ENSG00000275120.1	RP11-182J1.17	4.02	6.8e-05	0.0102	0.29	0.18	Schizophrenia;	chr15:84089549	chr15:84599434~84606463:-
LUAD	cis	rs950169	1	rs34751999	ENSG00000275120.1	RP11-182J1.17	4.02	6.8e-05	0.0102	0.29	0.18	Schizophrenia;	chr15:84089667	chr15:84599434~84606463:-
LUAD	cis	rs7396835	0.551	rs10750098	ENSG00000280143.1	AP000892.6	4.02	6.8e-05	0.0102	0.29	0.18	Quantitative traits;	chr11:116834852	chr11:117204967~117210292:+
LUAD	cis	rs4873772	0.702	rs6982620	ENSG00000253330.1	RP11-697N18.3	-4.02	6.81e-05	0.0102	-0.2	-0.18	Lobe attachment (rater-scored or self-reported);	chr8:47483717	chr8:47511034~47512141:-
LUAD	cis	rs2976388	0.507	rs2572874	ENSG00000253741.1	CTD-2292P10.4	-4.02	6.81e-05	0.0102	-0.22	-0.18	Urinary tract infection frequency;	chr8:142755801	chr8:142702252~142726973:-
LUAD	cis	rs9309473	0.948	rs10183818	ENSG00000230002.2	ALMS1-IT1	4.02	6.81e-05	0.0102	0.23	0.18	Metabolite levels;	chr2:73487429	chr2:73456764~73459484:+
LUAD	cis	rs6723108	0.603	rs10166142	ENSG00000224043.6	CCNT2-AS1	-4.02	6.81e-05	0.0102	-0.23	-0.18	Type 2 diabetes;	chr2:134952752	chr2:134735464~134918710:-
LUAD	cis	rs6723108	0.603	rs3814354	ENSG00000224043.6	CCNT2-AS1	-4.02	6.81e-05	0.0102	-0.23	-0.18	Type 2 diabetes;	chr2:134954087	chr2:134735464~134918710:-
LUAD	cis	rs9341808	0.754	rs9361591	ENSG00000260645.1	RP11-250B2.5	4.02	6.81e-05	0.0102	0.17	0.18	Sitting height ratio;	chr6:80243538	chr6:80466958~80469080:+
LUAD	cis	rs1023500	0.573	rs133382	ENSG00000205702.9	CYP2D7	4.02	6.81e-05	0.0102	0.15	0.18	Schizophrenia;	chr22:42075770	chr22:42140203~42144577:-
LUAD	cis	rs755249	0.567	rs16826069	ENSG00000182109.6	RP11-69E11.4	4.02	6.81e-05	0.0102	0.22	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39331383	chr1:39522280~39546187:-
LUAD	cis	rs2179367	0.959	rs628488	ENSG00000216906.2	RP11-350J20.9	4.02	6.82e-05	0.0102	0.22	0.18	Dupuytren's disease;	chr6:149398264	chr6:149904243~149906418:+
LUAD	cis	rs860818	1	rs10634	ENSG00000226816.2	AC005082.12	-4.02	6.82e-05	0.0102	-0.45	-0.18	Initial pursuit acceleration;	chr7:23200977	chr7:23206013~23208045:+
LUAD	cis	rs910316	0.934	rs8016330	ENSG00000259138.1	RP11-950C14.7	-4.02	6.82e-05	0.0102	-0.19	-0.18	Height;	chr14:75190804	chr14:75127153~75136930:+
LUAD	cis	rs910316	0.967	rs11624893	ENSG00000259138.1	RP11-950C14.7	-4.02	6.82e-05	0.0102	-0.19	-0.18	Height;	chr14:75193421	chr14:75127153~75136930:+
LUAD	cis	rs7551222	0.752	rs35270244	ENSG00000240219.1	RP11-430C7.5	4.02	6.82e-05	0.0102	0.19	0.18	Schizophrenia;	chr1:204579288	chr1:204626775~204629712:+
LUAD	cis	rs2732480	0.5	rs1387257	ENSG00000257763.1	OR5BK1P	4.02	6.82e-05	0.0102	0.19	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48242883	chr12:48355792~48356614:-
LUAD	cis	rs7178375	0.607	rs7171212	ENSG00000259845.1	HERC2P10	4.02	6.82e-05	0.0102	0.33	0.18	Hypertriglyceridemia;	chr15:30915508	chr15:30815271~30844153:+
LUAD	cis	rs6964587	1	rs12530646	ENSG00000188693.7	CYP51A1-AS1	4.02	6.82e-05	0.0102	0.21	0.18	Breast cancer;	chr7:91958722	chr7:92134604~92180725:+
LUAD	cis	rs6964587	0.967	rs17164315	ENSG00000188693.7	CYP51A1-AS1	-4.02	6.82e-05	0.0102	-0.21	-0.18	Breast cancer;	chr7:92029836	chr7:92134604~92180725:+
LUAD	cis	rs404005	0.559	rs371492	ENSG00000227028.5	SLC8A1-AS1	-4.02	6.82e-05	0.0102	-0.24	-0.18	HIV-associated dementia;	chr2:40229290	chr2:39786453~40255209:+
LUAD	cis	rs7893279	0.505	rs11015435	ENSG00000225527.1	RP11-383B4.4	4.02	6.82e-05	0.0102	0.26	0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18659143	chr10:18531849~18533336:-
LUAD	cis	rs4908768	0.906	rs12409937	ENSG00000232912.4	RP5-1115A15.1	-4.02	6.82e-05	0.0102	-0.21	-0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8478242	chr1:8424645~8434838:+
LUAD	cis	rs4908768	0.906	rs12402539	ENSG00000232912.4	RP5-1115A15.1	-4.02	6.82e-05	0.0102	-0.21	-0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8478243	chr1:8424645~8434838:+
LUAD	cis	rs10197140	0.925	rs28769005	ENSG00000235721.1	AC013268.3	-4.02	6.82e-05	0.0102	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110898376	chr2:110007675~110010783:+
LUAD	cis	rs7613875	0.654	rs3774751	ENSG00000234667.1	ACTBP13	4.02	6.82e-05	0.0102	0.2	0.18	Body mass index;	chr3:50171620	chr3:49873347~49877980:-
LUAD	cis	rs642803	0.933	rs644740	ENSG00000255557.1	RP11-770G2.2	-4.02	6.82e-05	0.0102	-0.22	-0.18	Urate levels;	chr11:65793997	chr11:65745729~65771585:+
LUAD	cis	rs7617773	0.851	rs7647817	ENSG00000199476.1	Y_RNA	-4.02	6.82e-05	0.0102	-0.24	-0.18	Coronary artery disease;	chr3:48195017	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.817	rs11707606	ENSG00000199476.1	Y_RNA	-4.02	6.82e-05	0.0102	-0.24	-0.18	Coronary artery disease;	chr3:48195597	chr3:48288587~48288694:+
LUAD	cis	rs1401999	0.714	rs1533683	ENSG00000223882.1	ABCC5-AS1	-4.02	6.83e-05	0.0102	-0.19	-0.18	Anterior chamber depth;	chr3:183917700	chr3:184006338~184011419:+
LUAD	cis	rs11671005	0.696	rs73066211	ENSG00000268912.1	CTD-2619J13.17	-4.02	6.83e-05	0.0102	-0.26	-0.18	Mean platelet volume;	chr19:58485712	chr19:58428632~58431148:-
LUAD	cis	rs7615952	0.641	rs7632497	ENSG00000250012.1	RP11-124N2.1	-4.02	6.83e-05	0.0102	-0.25	-0.18	Blood pressure (smoking interaction);	chr3:126064243	chr3:126084220~126095349:+
LUAD	cis	rs728616	0.717	rs116884206	ENSG00000234382.2	RP11-40F6.1	-4.02	6.83e-05	0.0102	-0.46	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80230790	chr10:80233664~80245367:+
LUAD	cis	rs703842	0.616	rs7489290	ENSG00000270039.1	RP11-571M6.17	-4.02	6.83e-05	0.0102	-0.21	-0.18	Multiple sclerosis;	chr12:57834805	chr12:57803838~57804415:+
LUAD	cis	rs7119038	0.629	rs73001429	ENSG00000255239.1	AP002954.6	-4.02	6.83e-05	0.0102	-0.25	-0.18	Sjögren's syndrome;	chr11:118732456	chr11:118688039~118690600:-
LUAD	cis	rs7647973	0.6	rs12631989	ENSG00000225399.4	RP11-3B7.1	4.02	6.83e-05	0.0102	0.24	0.18	Menarche (age at onset);	chr3:49236563	chr3:49260085~49261316:+
LUAD	cis	rs7647973	0.6	rs13064780	ENSG00000225399.4	RP11-3B7.1	4.02	6.83e-05	0.0102	0.24	0.18	Menarche (age at onset);	chr3:49237393	chr3:49260085~49261316:+
LUAD	cis	rs2657294	0.931	rs2804522	ENSG00000233313.2	HMGA1P5	-4.02	6.83e-05	0.0102	-0.23	-0.18	Pneumonia;	chr10:75159132	chr10:75276376~75276646:-
LUAD	cis	rs1541160	0.879	rs2474708	ENSG00000239494.2	RN7SL333P	4.02	6.83e-05	0.0102	0.17	0.18	Amyotrophic lateral sclerosis;	chr1:170007222	chr1:169859756~169860052:+
LUAD	cis	rs1541160	1	rs7539241	ENSG00000239494.2	RN7SL333P	4.02	6.83e-05	0.0102	0.17	0.18	Amyotrophic lateral sclerosis;	chr1:170010174	chr1:169859756~169860052:+
LUAD	cis	rs473651	0.904	rs10929275	ENSG00000229915.1	AC016999.2	-4.02	6.84e-05	0.0102	-0.24	-0.18	Multiple system atrophy;	chr2:238414528	chr2:238427077~238427729:-
LUAD	cis	rs1400816	0.718	rs1543168	ENSG00000228389.1	AC068039.4	4.02	6.84e-05	0.0102	0.3	0.18	Amyotrophic lateral sclerosis (sporadic);	chr2:171749698	chr2:171773482~171775844:+
LUAD	cis	rs1400816	0.718	rs1517678	ENSG00000228389.1	AC068039.4	4.02	6.84e-05	0.0102	0.3	0.18	Amyotrophic lateral sclerosis (sporadic);	chr2:171753325	chr2:171773482~171775844:+
LUAD	cis	rs1400816	0.85	rs1607253	ENSG00000228389.1	AC068039.4	4.02	6.84e-05	0.0102	0.3	0.18	Amyotrophic lateral sclerosis (sporadic);	chr2:171769728	chr2:171773482~171775844:+
LUAD	cis	rs2281603	0.808	rs10132424	ENSG00000259116.1	RP11-973N13.4	-4.02	6.84e-05	0.0102	-0.16	-0.18	Lymphocyte counts;	chr14:64527157	chr14:64514154~64540368:-
LUAD	cis	rs4819052	0.851	rs2255774	ENSG00000237664.1	LINC00316	-4.02	6.84e-05	0.0102	-0.21	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263936	chr21:45338590~45341990:-
LUAD	cis	rs1056107	0.574	rs9886804	ENSG00000225513.1	RP11-165N19.2	4.02	6.84e-05	0.0102	0.2	0.18	Colorectal cancer;	chr9:112159787	chr9:112173522~112173971:-
LUAD	cis	rs10971721	0.822	rs7856487	ENSG00000260947.1	RP11-384P7.7	4.02	6.84e-05	0.0103	0.37	0.18	Body mass index;	chr9:33870942	chr9:33697459~33700986:+
LUAD	cis	rs865483	0.929	rs853194	ENSG00000276054.1	RP11-378E13.3	4.02	6.84e-05	0.0103	0.21	0.18	Monocyte count;	chr17:37487939	chr17:37386886~37387926:+
LUAD	cis	rs17596685	1	rs9566989	ENSG00000271216.1	LINC01050	4.02	6.84e-05	0.0103	0.26	0.18	C-reactive protein levels;	chr13:42589159	chr13:42810366~42812562:-
LUAD	cis	rs12596233	0.611	rs67114359	ENSG00000279129.1	RP11-264L1.2	4.02	6.85e-05	0.0103	0.25	0.18	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr16:78625796	chr16:78550739~78553296:-
LUAD	cis	rs11051970	0.527	rs7313432	ENSG00000274964.1	RP11-817I4.1	-4.02	6.85e-05	0.0103	-0.24	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr12:32419335	chr12:32339368~32340724:+
LUAD	cis	rs7647973	0.58	rs35218722	ENSG00000225399.4	RP11-3B7.1	4.02	6.85e-05	0.0103	0.24	0.18	Menarche (age at onset);	chr3:49238372	chr3:49260085~49261316:+
LUAD	cis	rs7107174	0.792	rs10751287	ENSG00000251323.2	RP11-452H21.4	4.02	6.85e-05	0.0103	0.22	0.18	Testicular germ cell tumor;	chr11:78361430	chr11:78423982~78429836:-
LUAD	cis	rs12928939	0.517	rs12934512	ENSG00000260886.1	TAT-AS1	4.02	6.85e-05	0.0103	0.24	0.18	Post bronchodilator FEV1;	chr16:71931327	chr16:71565789~71578187:+
LUAD	cis	rs12928939	0.517	rs12445641	ENSG00000260886.1	TAT-AS1	4.02	6.85e-05	0.0103	0.24	0.18	Post bronchodilator FEV1;	chr16:71933880	chr16:71565789~71578187:+
LUAD	cis	rs12928939	0.517	rs12149307	ENSG00000260886.1	TAT-AS1	4.02	6.85e-05	0.0103	0.24	0.18	Post bronchodilator FEV1;	chr16:71934188	chr16:71565789~71578187:+
LUAD	cis	rs12928939	0.517	rs12149325	ENSG00000260886.1	TAT-AS1	4.02	6.85e-05	0.0103	0.24	0.18	Post bronchodilator FEV1;	chr16:71934244	chr16:71565789~71578187:+
LUAD	cis	rs12928939	0.517	rs10852507	ENSG00000260886.1	TAT-AS1	4.02	6.85e-05	0.0103	0.24	0.18	Post bronchodilator FEV1;	chr16:71937997	chr16:71565789~71578187:+
LUAD	cis	rs10129255	1	rs11621409	ENSG00000211947.2	IGHV3-21	-4.02	6.85e-05	0.0103	-0.12	-0.18	Kawasaki disease;	chr14:106695603	chr14:106235064~106235594:-
LUAD	cis	rs7968440	0.521	rs7303452	ENSG00000200428.1	Y_RNA	4.02	6.85e-05	0.0103	0.21	0.18	Fibrinogen;	chr12:50913366	chr12:50743568~50743684:+
LUAD	cis	rs12234571	1	rs6961117	ENSG00000214293.7	APTR	4.02	6.85e-05	0.0103	0.37	0.18	Obesity-related traits;	chr7:77769464	chr7:77657660~77696265:-
LUAD	cis	rs34787248	1	rs34787248	ENSG00000204709.4	LINC01556	4.02	6.86e-05	0.0103	0.26	0.18	Autism spectrum disorder or schizophrenia;	chr6:28230108	chr6:28943877~28944537:+
LUAD	cis	rs73193808	0.95	rs12627426	ENSG00000215533.7	LINC00189	-4.02	6.86e-05	0.0103	-0.26	-0.18	Coronary artery disease;	chr21:29147136	chr21:29193480~29288205:+
LUAD	cis	rs442309	0.846	rs224125	ENSG00000238280.1	RP11-436D10.3	-4.02	6.86e-05	0.0103	-0.22	-0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62694329	chr10:62793562~62805887:-
LUAD	cis	rs7660883	0.897	rs342454	ENSG00000251411.1	RP11-397E7.4	-4.02	6.86e-05	0.0103	-0.2	-0.18	HDL cholesterol levels;	chr4:87100348	chr4:86913266~86914817:-
LUAD	cis	rs2834288	0.5	rs7283594	ENSG00000237945.6	LINC00649	-4.02	6.86e-05	0.0103	-0.23	-0.18	Gut microbiota (bacterial taxa);	chr21:33962798	chr21:33915534~33977691:+
LUAD	cis	rs4713118	0.869	rs9366700	ENSG00000280107.1	AL022393.9	-4.02	6.86e-05	0.0103	-0.23	-0.18	Parkinson's disease;	chr6:27729172	chr6:28170845~28172521:+
LUAD	cis	rs950169	1	rs1818950	ENSG00000275120.1	RP11-182J1.17	4.02	6.86e-05	0.0103	0.28	0.18	Schizophrenia;	chr15:84053769	chr15:84599434~84606463:-
LUAD	cis	rs9393777	0.844	rs72839477	ENSG00000219392.1	RP1-265C24.5	-4.02	6.86e-05	0.0103	-0.39	-0.18	Intelligence (multi-trait analysis);	chr6:27359221	chr6:28115628~28116551:+
LUAD	cis	rs73230612	0.858	rs10934286	ENSG00000242767.1	ZBTB20-AS4	4.02	6.86e-05	0.0103	0.29	0.18	Type 2 diabetes;	chr3:115371258	chr3:115100423~115103061:+
LUAD	cis	rs73230612	0.858	rs10934287	ENSG00000242767.1	ZBTB20-AS4	4.02	6.86e-05	0.0103	0.29	0.18	Type 2 diabetes;	chr3:115371263	chr3:115100423~115103061:+
LUAD	cis	rs73230612	0.858	rs10934288	ENSG00000242767.1	ZBTB20-AS4	4.02	6.86e-05	0.0103	0.29	0.18	Type 2 diabetes;	chr3:115373684	chr3:115100423~115103061:+
LUAD	cis	rs62355900	0.5	rs832401	ENSG00000271828.1	CTD-2310F14.1	-4.02	6.86e-05	0.0103	-0.33	-0.18	Endometriosis;	chr5:56968297	chr5:56927874~56929573:+
LUAD	cis	rs13434995	0.513	rs17722979	ENSG00000273257.1	RP11-177J6.1	-4.02	6.86e-05	0.0103	-0.24	-0.18	Adiponectin levels;	chr4:55480244	chr4:55387949~55388271:+
LUAD	cis	rs9341808	0.754	rs10806185	ENSG00000260645.1	RP11-250B2.5	4.02	6.87e-05	0.0103	0.17	0.18	Sitting height ratio;	chr6:80244794	chr6:80466958~80469080:+
LUAD	cis	rs9813712	0.595	rs16825656	ENSG00000228252.7	COL6A4P2	-4.02	6.87e-05	0.0103	-0.17	-0.18	Response to amphetamines;	chr3:130286225	chr3:130212823~130273806:+
LUAD	cis	rs4947019	1	rs74975304	ENSG00000260273.1	RP11-425D10.10	4.02	6.87e-05	0.0103	0.36	0.18	Hematological parameters;	chr6:109772836	chr6:109382795~109383666:+
LUAD	cis	rs5758659	0.594	rs739292	ENSG00000227370.1	RP4-669P10.19	-4.02	6.87e-05	0.0103	-0.17	-0.18	Cognitive function;	chr22:41972853	chr22:42132543~42132998:+
LUAD	cis	rs4705952	0.775	rs72797340	ENSG00000233006.5	AC034220.3	-4.02	6.87e-05	0.0103	-0.21	-0.18	C-reactive protein levels;	chr5:132531873	chr5:132311285~132369916:-
LUAD	cis	rs16866061	1	rs7588380	ENSG00000228446.2	AC073052.1	4.02	6.87e-05	0.0103	0.19	0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr2:224476587	chr2:224499387~224500100:-
LUAD	cis	rs73607972	0.518	rs8060020	ENSG00000275191.1	RP11-36I17.2	-4.02	6.87e-05	0.0103	-0.22	-0.18	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53554152	chr16:53628256~53628816:-
LUAD	cis	rs848490	0.889	rs55689723	ENSG00000214293.7	APTR	4.02	6.87e-05	0.0103	0.24	0.18	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77616939	chr7:77657660~77696265:-
LUAD	cis	rs7160336	0.604	rs10149539	ENSG00000259065.1	RP5-1021I20.1	-4.02	6.87e-05	0.0103	-0.21	-0.18	Blood protein levels;	chr14:74215524	chr14:73787360~73803270:+
LUAD	cis	rs6430553	0.929	rs6430547	ENSG00000224043.6	CCNT2-AS1	4.02	6.87e-05	0.0103	0.22	0.18	Blood metabolite levels;	chr2:134854852	chr2:134735464~134918710:-
LUAD	cis	rs16940212	0.618	rs495348	ENSG00000242747.1	RP11-30K9.1	-4.02	6.87e-05	0.0103	-0.25	-0.18	HDL cholesterol;HDL cholesterol levels;	chr15:58395591	chr15:58869659~58870134:+
LUAD	cis	rs4819052	0.679	rs4819053	ENSG00000223768.1	LINC00205	4.02	6.88e-05	0.0103	0.21	0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291442	chr21:45293285~45297354:+
LUAD	cis	rs4819052	0.918	rs2330013	ENSG00000237664.1	LINC00316	-4.02	6.88e-05	0.0103	-0.23	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238747	chr21:45338590~45341990:-
LUAD	cis	rs9473147	0.747	rs9395288	ENSG00000270761.1	RP11-385F7.1	-4.02	6.88e-05	0.0103	-0.21	-0.18	Platelet distribution width;Mean platelet volume;	chr6:47630389	chr6:47477243~47477572:-
LUAD	cis	rs6688613	0.545	rs10800270	ENSG00000225171.2	DUTP6	-4.02	6.88e-05	0.0103	-0.22	-0.18	Refractive astigmatism;	chr1:166858365	chr1:166868748~166869209:+
LUAD	cis	rs11009175	0.547	rs16934017	ENSG00000273038.2	RP11-479G22.8	-4.02	6.88e-05	0.0103	-0.22	-0.18	Depression (quantitative trait);	chr10:33106196	chr10:32887255~32889311:-
LUAD	cis	rs858239	0.6	rs7456915	ENSG00000226816.2	AC005082.12	4.02	6.88e-05	0.0103	0.23	0.18	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23206013~23208045:+
LUAD	cis	rs2153535	0.518	rs9406187	ENSG00000230939.1	RP11-314C16.1	-4.02	6.88e-05	0.0103	-0.21	-0.18	Motion sickness;	chr6:8654376	chr6:8784178~8785445:+
LUAD	cis	rs7829975	0.617	rs4841071	ENSG00000233609.3	RP11-62H7.2	4.02	6.88e-05	0.0103	0.14	0.18	Mood instability;	chr8:8933634	chr8:8961200~8979025:+
LUAD	cis	rs7968440	0.591	rs6580732	ENSG00000200428.1	Y_RNA	4.02	6.88e-05	0.0103	0.21	0.18	Fibrinogen;	chr12:50252496	chr12:50743568~50743684:+
LUAD	cis	rs6832769	0.922	rs28665088	ENSG00000272969.1	RP11-528I4.2	4.02	6.89e-05	0.0103	0.19	0.18	Personality dimensions;	chr4:55384913	chr4:55547112~55547889:+
LUAD	cis	rs1383484	0.958	rs5016012	ENSG00000259728.4	LINC00933	-4.02	6.89e-05	0.0103	-0.23	-0.18	Height;	chr15:83843253	chr15:84570649~84580175:+
LUAD	cis	rs2974760	0.606	rs2858918	ENSG00000226942.2	IL9RP3	-4.02	6.89e-05	0.0103	-0.23	-0.18	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr16:151184	chr16:29336~38321:-
LUAD	cis	rs9287719	0.967	rs715247	ENSG00000243819.4	RN7SL832P	4.02	6.89e-05	0.0103	0.19	0.18	Prostate cancer;	chr2:10596165	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs715246	ENSG00000243819.4	RN7SL832P	4.02	6.89e-05	0.0103	0.19	0.18	Prostate cancer;	chr2:10596229	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs2010073	ENSG00000243819.4	RN7SL832P	4.02	6.89e-05	0.0103	0.19	0.18	Prostate cancer;	chr2:10596352	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs2010080	ENSG00000243819.4	RN7SL832P	4.02	6.89e-05	0.0103	0.19	0.18	Prostate cancer;	chr2:10596426	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.901	rs6432109	ENSG00000243819.4	RN7SL832P	4.02	6.89e-05	0.0103	0.19	0.18	Prostate cancer;	chr2:10596695	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.934	rs6432110	ENSG00000243819.4	RN7SL832P	4.02	6.89e-05	0.0103	0.19	0.18	Prostate cancer;	chr2:10597892	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs7605461	ENSG00000243819.4	RN7SL832P	4.02	6.89e-05	0.0103	0.19	0.18	Prostate cancer;	chr2:10598008	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs7593496	ENSG00000243819.4	RN7SL832P	4.02	6.89e-05	0.0103	0.19	0.18	Prostate cancer;	chr2:10598050	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs7608498	ENSG00000243819.4	RN7SL832P	4.02	6.89e-05	0.0103	0.19	0.18	Prostate cancer;	chr2:10598302	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs7582775	ENSG00000243819.4	RN7SL832P	4.02	6.89e-05	0.0103	0.19	0.18	Prostate cancer;	chr2:10598323	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs6750891	ENSG00000243819.4	RN7SL832P	4.02	6.89e-05	0.0103	0.19	0.18	Prostate cancer;	chr2:10598437	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs6733416	ENSG00000243819.4	RN7SL832P	4.02	6.89e-05	0.0103	0.19	0.18	Prostate cancer;	chr2:10598558	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs6751398	ENSG00000243819.4	RN7SL832P	4.02	6.89e-05	0.0103	0.19	0.18	Prostate cancer;	chr2:10598846	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.901	rs13034017	ENSG00000243819.4	RN7SL832P	4.02	6.89e-05	0.0103	0.19	0.18	Prostate cancer;	chr2:10599466	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs13034061	ENSG00000243819.4	RN7SL832P	4.02	6.89e-05	0.0103	0.19	0.18	Prostate cancer;	chr2:10599525	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.935	rs7600495	ENSG00000243819.4	RN7SL832P	4.02	6.89e-05	0.0103	0.19	0.18	Prostate cancer;	chr2:10599674	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs7600587	ENSG00000243819.4	RN7SL832P	4.02	6.89e-05	0.0103	0.19	0.18	Prostate cancer;	chr2:10599725	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.839	rs7600695	ENSG00000243819.4	RN7SL832P	4.02	6.89e-05	0.0103	0.19	0.18	Prostate cancer;	chr2:10599819	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs7587114	ENSG00000243819.4	RN7SL832P	4.02	6.89e-05	0.0103	0.19	0.18	Prostate cancer;	chr2:10599837	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs7600728	ENSG00000243819.4	RN7SL832P	4.02	6.89e-05	0.0103	0.19	0.18	Prostate cancer;	chr2:10599873	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs7600820	ENSG00000243819.4	RN7SL832P	4.02	6.89e-05	0.0103	0.19	0.18	Prostate cancer;	chr2:10599918	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs7587231	ENSG00000243819.4	RN7SL832P	4.02	6.89e-05	0.0103	0.19	0.18	Prostate cancer;	chr2:10599967	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs4668691	ENSG00000243819.4	RN7SL832P	4.02	6.89e-05	0.0103	0.19	0.18	Prostate cancer;	chr2:10600368	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.934	rs10181806	ENSG00000243819.4	RN7SL832P	4.02	6.89e-05	0.0103	0.19	0.18	Prostate cancer;	chr2:10601015	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs11687023	ENSG00000243819.4	RN7SL832P	4.02	6.89e-05	0.0103	0.19	0.18	Prostate cancer;	chr2:10601286	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs10454738	ENSG00000243819.4	RN7SL832P	4.02	6.89e-05	0.0103	0.19	0.18	Prostate cancer;	chr2:10601923	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs6706542	ENSG00000243819.4	RN7SL832P	4.02	6.89e-05	0.0103	0.19	0.18	Prostate cancer;	chr2:10602365	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs2287061	ENSG00000243819.4	RN7SL832P	4.02	6.89e-05	0.0103	0.19	0.18	Prostate cancer;	chr2:10603027	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs2287062	ENSG00000243819.4	RN7SL832P	4.02	6.89e-05	0.0103	0.19	0.18	Prostate cancer;	chr2:10603065	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.935	rs1309	ENSG00000243819.4	RN7SL832P	4.02	6.89e-05	0.0103	0.19	0.18	Prostate cancer;	chr2:10603420	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs3815521	ENSG00000243819.4	RN7SL832P	4.02	6.89e-05	0.0103	0.19	0.18	Prostate cancer;	chr2:10603528	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs10929686	ENSG00000243819.4	RN7SL832P	4.02	6.89e-05	0.0103	0.19	0.18	Prostate cancer;	chr2:10603579	chr2:10690344~10692099:+
LUAD	cis	rs6686842	0.56	rs17357905	ENSG00000235358.1	RP11-399E6.1	4.02	6.89e-05	0.0103	0.21	0.18	Height;	chr1:41018645	chr1:41242373~41284861:+
LUAD	cis	rs6547741	0.935	rs6547738	ENSG00000223522.1	AC093690.1	4.02	6.89e-05	0.0103	0.17	0.18	Oral cavity cancer;	chr2:27629770	chr2:28307691~28310459:-
LUAD	cis	rs1023500	0.505	rs134901	ENSG00000273366.1	CTA-989H11.1	-4.02	6.89e-05	0.0103	-0.21	-0.18	Schizophrenia;	chr22:42287514	chr22:42278188~42278846:+
LUAD	cis	rs10129255	0.917	rs7142373	ENSG00000211967.3	IGHV3-53	-4.02	6.89e-05	0.0103	-0.14	-0.18	Kawasaki disease;	chr14:106708947	chr14:106592676~106593347:-
LUAD	cis	rs12935418	0.616	rs13336629	ENSG00000261061.1	RP11-303E16.2	-4.02	6.89e-05	0.0103	-0.19	-0.18	Mean corpuscular volume;	chr16:80971909	chr16:81030770~81031485:+
LUAD	cis	rs10129255	0.536	rs6576201	ENSG00000253209.1	IGHV3-65	-4.02	6.89e-05	0.0103	-0.14	-0.18	Kawasaki disease;	chr14:106683696	chr14:106666092~106666532:-
LUAD	cis	rs8054556	0.74	rs4407079	ENSG00000183604.13	SMG1P5	-4.02	6.89e-05	0.0103	-0.18	-0.18	Autism spectrum disorder or schizophrenia;	chr16:29920578	chr16:30267553~30335374:-
LUAD	cis	rs2299587	0.662	rs6586671	ENSG00000253671.1	RP11-806O11.1	-4.02	6.89e-05	0.0103	-0.2	-0.18	Economic and political preferences;	chr8:17918575	chr8:17808941~17820868:+
LUAD	cis	rs16944613	0.541	rs4566137	ENSG00000259212.1	CTD-3065B20.2	4.01	6.89e-05	0.0103	0.28	0.18	Colorectal cancer;	chr15:90554732	chr15:90595840~90596447:-
LUAD	cis	rs6903823	0.508	rs1150718	ENSG00000219392.1	RP1-265C24.5	-4.01	6.9e-05	0.0103	-0.22	-0.18	Pulmonary function;	chr6:28289170	chr6:28115628~28116551:+
LUAD	cis	rs6903823	0.508	rs1233660	ENSG00000219392.1	RP1-265C24.5	-4.01	6.9e-05	0.0103	-0.22	-0.18	Pulmonary function;	chr6:28292472	chr6:28115628~28116551:+
LUAD	cis	rs1355223	0.872	rs7116409	ENSG00000271369.1	RP11-350D17.3	-4.01	6.9e-05	0.0103	-0.21	-0.18	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34729460	chr11:34709600~34710161:+
LUAD	cis	rs6081541	1	rs6081544	ENSG00000179447.2	RP5-1027G4.3	-4.01	6.9e-05	0.0103	-0.23	-0.18	Psychosis (atypical);	chr20:19236132	chr20:19242302~19284596:-
LUAD	cis	rs4819052	0.851	rs2838855	ENSG00000237664.1	LINC00316	4.01	6.9e-05	0.0103	0.22	0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260651	chr21:45338590~45341990:-
LUAD	cis	rs950880	1	rs12479210	ENSG00000234389.1	AC007278.3	-4.01	6.9e-05	0.0103	-0.17	-0.18	Serum protein levels (sST2);	chr2:102332701	chr2:102438713~102440475:+
LUAD	cis	rs9291683	0.588	rs35866697	ENSG00000250413.1	RP11-448G15.1	-4.01	6.9e-05	0.0103	-0.23	-0.18	Bone mineral density;	chr4:10016980	chr4:10006482~10009725:+
LUAD	cis	rs9291683	0.588	rs35099040	ENSG00000250413.1	RP11-448G15.1	-4.01	6.9e-05	0.0103	-0.23	-0.18	Bone mineral density;	chr4:10017215	chr4:10006482~10009725:+
LUAD	cis	rs11614913	0.509	rs12300425	ENSG00000248265.1	FLJ12825	4.01	6.9e-05	0.0103	0.21	0.18	Waist circumference adjusted for body mass index;	chr12:54001298	chr12:54058254~54122234:+
LUAD	cis	rs7976269	0.609	rs10743641	ENSG00000257176.2	RP11-996F15.2	-4.01	6.91e-05	0.0103	-0.19	-0.18	Male-pattern baldness;	chr12:29050819	chr12:29280418~29317848:-
LUAD	cis	rs7976269	0.609	rs4930846	ENSG00000257176.2	RP11-996F15.2	-4.01	6.91e-05	0.0103	-0.19	-0.18	Male-pattern baldness;	chr12:29051306	chr12:29280418~29317848:-
LUAD	cis	rs848490	1	rs10279537	ENSG00000214293.7	APTR	4.01	6.91e-05	0.0103	0.24	0.18	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77845644	chr7:77657660~77696265:-
LUAD	cis	rs11089937	0.609	rs2213158	ENSG00000211640.3	IGLV6-57	4.01	6.91e-05	0.0103	0.13	0.18	Periodontitis (PAL4Q3);	chr22:22138099	chr22:22195713~22196460:+
LUAD	cis	rs11089937	0.637	rs2213159	ENSG00000211640.3	IGLV6-57	4.01	6.91e-05	0.0103	0.13	0.18	Periodontitis (PAL4Q3);	chr22:22138100	chr22:22195713~22196460:+
LUAD	cis	rs9322193	0.923	rs9767105	ENSG00000268592.3	RAET1E-AS1	4.01	6.91e-05	0.0103	0.22	0.18	Lung cancer;	chr6:149659591	chr6:149863494~149919507:+
LUAD	cis	rs6724465	1	rs6741325	ENSG00000272644.1	RP11-33O4.1	-4.01	6.91e-05	0.0103	-0.27	-0.18	Height;	chr2:219042977	chr2:219069354~219069809:-
LUAD	cis	rs6088580	0.634	rs6059779	ENSG00000276073.1	RP5-1125A11.7	4.01	6.91e-05	0.0103	0.18	0.18	Glomerular filtration rate (creatinine);	chr20:34362519	chr20:33985617~33988989:-
LUAD	cis	rs1707322	0.638	rs1416706	ENSG00000280836.1	AL355480.1	4.01	6.91e-05	0.0103	0.23	0.18	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46137172	chr1:45581219~45581321:-
LUAD	cis	rs12754538	0.739	rs12567502	ENSG00000232912.4	RP5-1115A15.1	-4.01	6.91e-05	0.0103	-0.18	-0.18	Subjective well-being;	chr1:8748761	chr1:8424645~8434838:+
LUAD	cis	rs2836950	0.545	rs11701805	ENSG00000232608.1	TIMM9P2	4.01	6.92e-05	0.0104	0.2	0.18	Menarche (age at onset);	chr21:39246757	chr21:39216624~39217506:+
LUAD	cis	rs35740288	0.731	rs12898964	ENSG00000259407.1	RP11-158M2.3	-4.01	6.92e-05	0.0104	-0.17	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85618046	chr15:85744109~85750281:-
LUAD	cis	rs35740288	0.731	rs2344440	ENSG00000259407.1	RP11-158M2.3	-4.01	6.92e-05	0.0104	-0.17	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85618334	chr15:85744109~85750281:-
LUAD	cis	rs35740288	0.77	rs1157519	ENSG00000259407.1	RP11-158M2.3	-4.01	6.92e-05	0.0104	-0.17	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85618427	chr15:85744109~85750281:-
LUAD	cis	rs36093844	0.698	rs7106577	ENSG00000279742.1	RP11-700A24.1	-4.01	6.92e-05	0.0104	-0.21	-0.18	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85904559	chr11:85852557~85854943:-
LUAD	cis	rs12935418	0.672	rs11866803	ENSG00000261061.1	RP11-303E16.2	-4.01	6.93e-05	0.0104	-0.2	-0.18	Mean corpuscular volume;	chr16:81017598	chr16:81030770~81031485:+
LUAD	cis	rs9287719	0.967	rs4613248	ENSG00000243819.4	RN7SL832P	4.01	6.93e-05	0.0104	0.19	0.18	Prostate cancer;	chr2:10603925	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs10191883	ENSG00000243819.4	RN7SL832P	4.01	6.93e-05	0.0104	0.19	0.18	Prostate cancer;	chr2:10604010	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.934	rs4629131	ENSG00000243819.4	RN7SL832P	4.01	6.93e-05	0.0104	0.19	0.18	Prostate cancer;	chr2:10604033	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.901	rs4555317	ENSG00000243819.4	RN7SL832P	4.01	6.93e-05	0.0104	0.19	0.18	Prostate cancer;	chr2:10604121	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs4555318	ENSG00000243819.4	RN7SL832P	4.01	6.93e-05	0.0104	0.19	0.18	Prostate cancer;	chr2:10604169	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.934	rs4622695	ENSG00000243819.4	RN7SL832P	4.01	6.93e-05	0.0104	0.19	0.18	Prostate cancer;	chr2:10604201	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.934	rs6432111	ENSG00000243819.4	RN7SL832P	4.01	6.93e-05	0.0104	0.19	0.18	Prostate cancer;	chr2:10604494	chr2:10690344~10692099:+
LUAD	cis	rs2617170	1	rs2617170	ENSG00000245648.1	RP11-277P12.20	-4.01	6.93e-05	0.0104	-0.22	-0.18	Behcet's disease;	chr12:10408358	chr12:10363769~10398506:+
LUAD	cis	rs1910358	0.919	rs34315763	ENSG00000248874.4	C5orf17	-4.01	6.93e-05	0.0104	-0.26	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr5:23868813	chr5:23951348~24178263:+
LUAD	cis	rs2732480	0.5	rs12828309	ENSG00000257763.1	OR5BK1P	4.01	6.93e-05	0.0104	0.19	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48247377	chr12:48355792~48356614:-
LUAD	cis	rs2911132	0.506	rs7705827	ENSG00000272109.1	CTD-2260A17.3	-4.01	6.93e-05	0.0104	-0.19	-0.18	Urate levels (BMI interaction);	chr5:96746729	chr5:96804353~96806105:+
LUAD	cis	rs2252586	0.792	rs6946428	ENSG00000226278.1	PSPHP1	-4.01	6.94e-05	0.0104	-0.22	-0.18	Glioma;	chr7:54890916	chr7:55764797~55773288:+
LUAD	cis	rs8037818	1	rs4544214	ENSG00000261064.1	RP11-1000B6.3	4.01	6.94e-05	0.0104	0.25	0.18	Obesity-related traits;	chr15:32639703	chr15:32536047~32587613:+
LUAD	cis	rs3753275	0.628	rs4581300	ENSG00000232912.4	RP5-1115A15.1	-4.01	6.94e-05	0.0104	-0.21	-0.18	Educational attainment;	chr1:8550446	chr1:8424645~8434838:+
LUAD	cis	rs4578769	0.55	rs4474794	ENSG00000266850.1	RP11-370A5.1	4.01	6.94e-05	0.0104	0.23	0.18	Eosinophil percentage of white cells;	chr18:22987010	chr18:22723491~22907721:-
LUAD	cis	rs6479901	0.843	rs9414802	ENSG00000232075.1	MRPL35P2	4.01	6.94e-05	0.0104	0.26	0.18	Intelligence (multi-trait analysis);	chr10:63391622	chr10:63634317~63634827:-
LUAD	cis	rs7178909	0.933	rs7183156	ENSG00000259677.1	RP11-493E3.1	4.01	6.94e-05	0.0104	0.2	0.18	Common traits (Other);	chr15:89902214	chr15:89876540~89877285:+
LUAD	cis	rs11651753	0.935	rs2525109	ENSG00000264920.1	RP11-6N17.4	4.01	6.94e-05	0.0104	0.21	0.18	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47964961	chr17:47891255~47895812:-
LUAD	cis	rs11651753	0.935	rs2525110	ENSG00000264920.1	RP11-6N17.4	4.01	6.94e-05	0.0104	0.21	0.18	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47964999	chr17:47891255~47895812:-
LUAD	cis	rs1005277	0.54	rs1814077	ENSG00000273019.1	RP11-508N22.13	-4.01	6.94e-05	0.0104	-0.2	-0.18	Extrinsic epigenetic age acceleration;	chr10:37703090	chr10:38149968~38150293:+
LUAD	cis	rs2243480	1	rs1499613	ENSG00000229886.1	RP5-1132H15.3	-4.01	6.94e-05	0.0104	-0.31	-0.18	Diabetic kidney disease;	chr7:66265873	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs1553174	ENSG00000229886.1	RP5-1132H15.3	-4.01	6.94e-05	0.0104	-0.31	-0.18	Diabetic kidney disease;	chr7:66266207	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs10950032	ENSG00000229886.1	RP5-1132H15.3	-4.01	6.94e-05	0.0104	-0.31	-0.18	Diabetic kidney disease;	chr7:66273604	chr7:66025126~66031544:-
LUAD	cis	rs7512552	0.839	rs1260421	ENSG00000275557.1	RP11-353N4.6	4.01	6.94e-05	0.0104	0.21	0.18	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150385304	chr1:149607765~149612402:+
LUAD	cis	rs7512552	0.839	rs1627235	ENSG00000275557.1	RP11-353N4.6	4.01	6.94e-05	0.0104	0.21	0.18	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150386382	chr1:149607765~149612402:+
LUAD	cis	rs9840812	0.535	rs695983	ENSG00000239213.4	NCK1-AS1	4.01	6.94e-05	0.0104	0.22	0.18	Fibrinogen levels;	chr3:136345705	chr3:136841726~136862054:-
LUAD	cis	rs7557067	0.671	rs6711016	ENSG00000233005.1	AC067959.1	4.01	6.94e-05	0.0104	0.22	0.18	Triglycerides;	chr2:20923592	chr2:21221175~21970959:+
LUAD	cis	rs2354432	0.556	rs2883319	ENSG00000237188.3	RP11-337C18.8	4.01	6.94e-05	0.0104	0.33	0.18	Mitochondrial DNA levels;	chr1:147366462	chr1:147172771~147211568:+
LUAD	cis	rs853679	0.517	rs4713152	ENSG00000226314.6	ZNF192P1	-4.01	6.94e-05	0.0104	-0.24	-0.18	Depression;	chr6:28169676	chr6:28161781~28169594:+
LUAD	cis	rs7512552	0.809	rs1694363	ENSG00000275557.1	RP11-353N4.6	4.01	6.94e-05	0.0104	0.21	0.18	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150396201	chr1:149607765~149612402:+
LUAD	cis	rs7302981	0.741	rs10783342	ENSG00000200428.1	Y_RNA	-4.01	6.94e-05	0.0104	-0.21	-0.18	Systolic blood pressure;	chr12:50234683	chr12:50743568~50743684:+
LUAD	cis	rs6472235	0.564	rs62506650	ENSG00000200714.1	Y_RNA	-4.01	6.95e-05	0.0104	-0.24	-0.18	Plateletcrit;Myopia (pathological);	chr8:66004267	chr8:65592731~65592820:+
LUAD	cis	rs6472235	0.586	rs11984602	ENSG00000200714.1	Y_RNA	-4.01	6.95e-05	0.0104	-0.24	-0.18	Plateletcrit;Myopia (pathological);	chr8:66004338	chr8:65592731~65592820:+
LUAD	cis	rs6472235	0.586	rs7812439	ENSG00000200714.1	Y_RNA	-4.01	6.95e-05	0.0104	-0.24	-0.18	Plateletcrit;Myopia (pathological);	chr8:66005465	chr8:65592731~65592820:+
LUAD	cis	rs62246343	0.605	rs7650141	ENSG00000206573.7	THUMPD3-AS1	-4.01	6.95e-05	0.0104	-0.17	-0.18	Fibrinogen levels;	chr3:9407726	chr3:9349689~9398579:-
LUAD	cis	rs755249	0.642	rs11206430	ENSG00000237624.1	OXCT2P1	4.01	6.95e-05	0.0104	0.24	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39609695	chr1:39514956~39516490:+
LUAD	cis	rs4795519	0.645	rs67890467	ENSG00000266313.1	RP11-173M1.4	4.01	6.95e-05	0.0104	0.23	0.18	Chronic myeloid leukemia;	chr17:27172495	chr17:27333256~27348491:+
LUAD	cis	rs12936587	0.564	rs7208561	ENSG00000223979.2	SMCR2	-4.01	6.95e-05	0.0104	-0.2	-0.18	Coronary heart disease;Coronary artery disease or large artery stroke;Coronary artery disease;Hip circumference;	chr17:17712214	chr17:17674026~17677688:-
LUAD	cis	rs6001482	0.656	rs1894237	ENSG00000223350.2	IGLV9-49	-4.01	6.95e-05	0.0104	-0.17	-0.18	Diastolic blood pressure;	chr22:22235546	chr22:22343187~22343732:+
LUAD	cis	rs11168618	1	rs11168618	ENSG00000240399.1	RP1-228P16.1	4.01	6.95e-05	0.0104	0.18	0.18	Adiponectin levels;	chr12:48539450	chr12:48054813~48055591:-
LUAD	cis	rs7394190	0.748	rs3740293	ENSG00000271848.1	RP11-464F9.21	-4.01	6.95e-05	0.0104	-0.25	-0.18	Incident atrial fibrillation;	chr10:73646383	chr10:73654039~73674719:+
LUAD	cis	rs854765	0.647	rs854809	ENSG00000223979.2	SMCR2	-4.01	6.95e-05	0.0104	-0.21	-0.18	Total body bone mineral density;	chr17:18103225	chr17:17674026~17677688:-
LUAD	cis	rs854765	0.647	rs854808	ENSG00000223979.2	SMCR2	-4.01	6.95e-05	0.0104	-0.21	-0.18	Total body bone mineral density;	chr17:18103320	chr17:17674026~17677688:-
LUAD	cis	rs9287719	0.967	rs6432114	ENSG00000243819.4	RN7SL832P	4.01	6.96e-05	0.0104	0.19	0.18	Prostate cancer;	chr2:10604804	chr2:10690344~10692099:+
LUAD	cis	rs10208649	0.656	rs12623097	ENSG00000272156.1	RP11-477N3.1	4.01	6.96e-05	0.0104	0.36	0.18	Body mass index;	chr2:54071182	chr2:54082554~54085066:+
LUAD	cis	rs736801	0.964	rs17622656	ENSG00000233006.5	AC034220.3	-4.01	6.96e-05	0.0104	-0.16	-0.18	Mosquito bite size;Breast cancer;	chr5:132485305	chr5:132311285~132369916:-
LUAD	cis	rs2378497	0.564	rs115883774	ENSG00000228437.4	RP11-400N13.2	4.01	6.96e-05	0.0104	0.22	0.18	Serum thyroid-stimulating hormone levels;	chr1:221986970	chr1:221966341~221984964:+
LUAD	cis	rs8050896	1	rs8050896	ENSG00000260695.1	RP11-513N24.1	-4.01	6.96e-05	0.0104	-0.31	-0.18	Response to antipsychotic treatment;	chr16:66124833	chr16:65861112~65863784:-
LUAD	cis	rs2154319	0.887	rs6696524	ENSG00000235358.1	RP11-399E6.1	4.01	6.96e-05	0.0104	0.25	0.18	Height;	chr1:41073822	chr1:41242373~41284861:+
LUAD	cis	rs17772222	0.958	rs10134008	ENSG00000258789.1	RP11-507K2.3	-4.01	6.96e-05	0.0104	-0.25	-0.18	Coronary artery calcification;	chr14:88549183	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.958	rs891750	ENSG00000258789.1	RP11-507K2.3	-4.01	6.96e-05	0.0104	-0.25	-0.18	Coronary artery calcification;	chr14:88550856	chr14:88551597~88552493:+
LUAD	cis	rs17772222	0.958	rs891749	ENSG00000258789.1	RP11-507K2.3	-4.01	6.96e-05	0.0104	-0.25	-0.18	Coronary artery calcification;	chr14:88550893	chr14:88551597~88552493:+
LUAD	cis	rs12935418	0.672	rs9888895	ENSG00000261061.1	RP11-303E16.2	-4.01	6.96e-05	0.0104	-0.2	-0.18	Mean corpuscular volume;	chr16:81017496	chr16:81030770~81031485:+
LUAD	cis	rs62025270	0.522	rs16943120	ENSG00000259416.2	RP11-158M2.5	-4.01	6.96e-05	0.0104	-0.24	-0.18	Idiopathic pulmonary fibrosis;	chr15:85683066	chr15:85754941~85756237:-
LUAD	cis	rs1790761	0.667	rs598811	ENSG00000184224.3	C11orf72	4.01	6.96e-05	0.0104	0.2	0.18	Mean corpuscular volume;	chr11:67544205	chr11:67602880~67606706:-
LUAD	cis	rs2348418	0.966	rs11049699	ENSG00000247934.4	RP11-967K21.1	4.01	6.96e-05	0.0104	0.21	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28535487	chr12:28163298~28190738:-
LUAD	cis	rs4819052	0.851	rs3673	ENSG00000223768.1	LINC00205	-4.01	6.97e-05	0.0104	-0.21	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261860	chr21:45293285~45297354:+
LUAD	cis	rs62025270	0.632	rs16943251	ENSG00000259416.2	RP11-158M2.5	-4.01	6.97e-05	0.0104	-0.24	-0.18	Idiopathic pulmonary fibrosis;	chr15:85692004	chr15:85754941~85756237:-
LUAD	cis	rs8014252	0.803	rs11158863	ENSG00000259158.2	ADAM20P1	4.01	6.97e-05	0.0104	0.3	0.18	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70514449	chr14:70468881~70483756:-
LUAD	cis	rs2243480	0.522	rs431168	ENSG00000230295.1	RP11-458F8.2	-4.01	6.97e-05	0.0104	-0.25	-0.18	Diabetic kidney disease;	chr7:66046617	chr7:66880708~66882981:+
LUAD	cis	rs763121	0.853	rs3788545	ENSG00000228274.3	RP3-508I15.9	-4.01	6.97e-05	0.0104	-0.18	-0.18	Menopause (age at onset);	chr22:38669167	chr22:38667585~38681820:-
LUAD	cis	rs34779708	0.931	rs13377158	ENSG00000271335.4	RP11-324I22.4	-4.01	6.97e-05	0.0104	-0.19	-0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35081537	chr10:35314552~35336401:-
LUAD	cis	rs2274273	0.84	rs2341622	ENSG00000258413.1	RP11-665C16.6	-4.01	6.97e-05	0.0104	-0.23	-0.18	Protein biomarker;	chr14:55270525	chr14:55262767~55272075:-
LUAD	cis	rs8113308	0.81	rs55810059	ENSG00000269483.1	AC006272.1	4.01	6.98e-05	0.0104	0.3	0.18	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51947475	chr19:51839924~51843324:-
LUAD	cis	rs4660214	0.671	rs72637904	ENSG00000182109.6	RP11-69E11.4	4.01	6.98e-05	0.0104	0.25	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39203010	chr1:39522280~39546187:-
LUAD	cis	rs4660214	0.671	rs17491275	ENSG00000182109.6	RP11-69E11.4	4.01	6.98e-05	0.0104	0.25	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39206873	chr1:39522280~39546187:-
LUAD	cis	rs727479	0.962	rs2414095	ENSG00000259306.2	RP11-108K3.2	-4.01	6.98e-05	0.0104	-0.2	-0.18	Estradiol levels;	chr15:51232095	chr15:51315841~51321996:+
LUAD	cis	rs17406451	0.819	rs7589033	ENSG00000279873.2	LINC01126	4.01	6.98e-05	0.0104	0.16	0.18	Mitochondrial DNA levels;	chr2:43422089	chr2:43227210~43228855:+
LUAD	cis	rs11159086	0.941	rs11846588	ENSG00000259005.1	RP3-449M8.6	4.01	6.98e-05	0.0104	0.23	0.18	Advanced glycation end-product levels;	chr14:74505398	chr14:74474007~74474864:-
LUAD	cis	rs4971059	0.629	rs11264333	ENSG00000160766.13	GBAP1	-4.01	6.98e-05	0.0104	-0.18	-0.18	Breast cancer;	chr1:155135811	chr1:155213821~155227422:-
LUAD	cis	rs10197140	0.857	rs900556	ENSG00000235721.1	AC013268.3	-4.01	6.98e-05	0.0104	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110904107	chr2:110007675~110010783:+
LUAD	cis	rs10197140	0.857	rs900557	ENSG00000235721.1	AC013268.3	-4.01	6.98e-05	0.0104	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110904233	chr2:110007675~110010783:+
LUAD	cis	rs10197140	0.857	rs4332932	ENSG00000235721.1	AC013268.3	-4.01	6.98e-05	0.0104	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110904878	chr2:110007675~110010783:+
LUAD	cis	rs7615952	1	rs7616044	ENSG00000241288.6	RP11-379B18.5	-4.01	6.98e-05	0.0104	-0.23	-0.18	Blood pressure (smoking interaction);	chr3:125930511	chr3:125827238~125916384:-
LUAD	cis	rs7590268	0.697	rs6741434	ENSG00000279873.2	LINC01126	4.01	6.98e-05	0.0104	0.18	0.18	Orofacial clefts;	chr2:43468009	chr2:43227210~43228855:+
LUAD	cis	rs727479	0.612	rs2899470	ENSG00000259306.2	RP11-108K3.2	-4.01	6.98e-05	0.0104	-0.19	-0.18	Estradiol levels;	chr15:51211480	chr15:51315841~51321996:+
LUAD	cis	rs6964587	0.839	rs6950538	ENSG00000188693.7	CYP51A1-AS1	-4.01	6.99e-05	0.0104	-0.22	-0.18	Breast cancer;	chr7:91788501	chr7:92134604~92180725:+
LUAD	cis	rs16866061	1	rs72974205	ENSG00000228446.2	AC073052.1	-4.01	6.99e-05	0.0104	-0.2	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr2:224543751	chr2:224499387~224500100:-
LUAD	cis	rs12999542	0.5	rs3771179	ENSG00000234389.1	AC007278.3	4.01	6.99e-05	0.0104	0.27	0.18	Serum protein levels (sST2);	chr2:102337432	chr2:102438713~102440475:+
LUAD	cis	rs2732480	0.5	rs1552550	ENSG00000257763.1	OR5BK1P	4.01	6.99e-05	0.0104	0.19	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48249568	chr12:48355792~48356614:-
LUAD	cis	rs2732480	0.557	rs2732441	ENSG00000257763.1	OR5BK1P	4.01	6.99e-05	0.0104	0.19	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48329541	chr12:48355792~48356614:-
LUAD	cis	rs11742741	0.806	rs1346494	ENSG00000248874.4	C5orf17	-4.01	6.99e-05	0.0104	-0.22	-0.18	Educational attainment;	chr5:24064714	chr5:23951348~24178263:+
LUAD	cis	rs2657294	0.761	rs1259498	ENSG00000233313.2	HMGA1P5	-4.01	6.99e-05	0.0104	-0.23	-0.18	Pneumonia;	chr10:75226983	chr10:75276376~75276646:-
LUAD	cis	rs1552244	0.51	rs13075308	ENSG00000180385.7	EMC3-AS1	4.01	6.99e-05	0.0104	0.21	0.18	Alzheimer's disease;	chr3:9993241	chr3:9986893~10006990:+
LUAD	cis	rs1552244	0.808	rs7615088	ENSG00000180385.7	EMC3-AS1	4.01	6.99e-05	0.0104	0.21	0.18	Alzheimer's disease;	chr3:9994212	chr3:9986893~10006990:+
LUAD	cis	rs1552244	0.882	rs61429272	ENSG00000180385.7	EMC3-AS1	4.01	6.99e-05	0.0104	0.21	0.18	Alzheimer's disease;	chr3:9995636	chr3:9986893~10006990:+
LUAD	cis	rs1552244	0.626	rs2886396	ENSG00000180385.7	EMC3-AS1	4.01	6.99e-05	0.0104	0.21	0.18	Alzheimer's disease;	chr3:9995986	chr3:9986893~10006990:+
LUAD	cis	rs1552244	0.882	rs9757159	ENSG00000180385.7	EMC3-AS1	4.01	6.99e-05	0.0104	0.21	0.18	Alzheimer's disease;	chr3:9997482	chr3:9986893~10006990:+
LUAD	cis	rs1552244	0.816	rs17050701	ENSG00000180385.7	EMC3-AS1	4.01	6.99e-05	0.0104	0.21	0.18	Alzheimer's disease;	chr3:9999870	chr3:9986893~10006990:+
LUAD	cis	rs1552244	0.882	rs55840655	ENSG00000180385.7	EMC3-AS1	4.01	6.99e-05	0.0104	0.21	0.18	Alzheimer's disease;	chr3:10001006	chr3:9986893~10006990:+
LUAD	cis	rs1552244	0.816	rs56387520	ENSG00000180385.7	EMC3-AS1	4.01	6.99e-05	0.0104	0.21	0.18	Alzheimer's disease;	chr3:10001098	chr3:9986893~10006990:+
LUAD	cis	rs1552244	0.882	rs56224841	ENSG00000180385.7	EMC3-AS1	4.01	6.99e-05	0.0104	0.21	0.18	Alzheimer's disease;	chr3:10002330	chr3:9986893~10006990:+
LUAD	cis	rs1552244	0.882	rs13088350	ENSG00000180385.7	EMC3-AS1	4.01	6.99e-05	0.0104	0.21	0.18	Alzheimer's disease;	chr3:10002942	chr3:9986893~10006990:+
LUAD	cis	rs116095464	0.558	rs55776650	ENSG00000248925.1	CTD-2083E4.6	4.01	7e-05	0.0104	0.31	0.18	Breast cancer;	chr5:273711	chr5:269858~271516:-
LUAD	cis	rs7208859	0.623	rs216439	ENSG00000280069.1	CTD-2349P21.3	-4.01	7e-05	0.0104	-0.25	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30600866	chr17:30738182~30740275:+
LUAD	cis	rs4795519	1	rs11080056	ENSG00000266313.1	RP11-173M1.4	4.01	7e-05	0.0104	0.22	0.18	Chronic myeloid leukemia;	chr17:27077023	chr17:27333256~27348491:+
LUAD	cis	rs8014204	0.604	rs11625594	ENSG00000279594.1	RP11-950C14.10	4.01	7e-05	0.0104	0.22	0.18	Caffeine consumption;	chr14:74923130	chr14:75011269~75012851:-
LUAD	cis	rs6781182	0.517	rs13083357	ENSG00000236452.1	AC123023.1	4.01	7e-05	0.0104	0.2	0.18	Visceral adipose tissue adjusted for BMI;	chr3:34199019	chr3:34203244~34268811:+
LUAD	cis	rs259282	0.652	rs2161458	ENSG00000201388.1	SNORA68	4.01	7e-05	0.0104	0.18	0.18	Schizophrenia;	chr19:32638132	chr19:32608337~32608469:-
LUAD	cis	rs2299587	0.65	rs12548412	ENSG00000253671.1	RP11-806O11.1	-4.01	7e-05	0.0105	-0.21	-0.18	Economic and political preferences;	chr8:17939461	chr8:17808941~17820868:+
LUAD	cis	rs853679	0.76	rs11967137	ENSG00000204709.4	LINC01556	4.01	7e-05	0.0105	0.26	0.18	Depression;	chr6:28231986	chr6:28943877~28944537:+
LUAD	cis	rs2788032	1	rs2788032	ENSG00000224680.4	PLA2G12AP1	4.01	7.01e-05	0.0105	0.35	0.18	Body mass index (alcohol intake interaction);	chr1:53311959	chr1:52368677~52369244:+
LUAD	cis	rs7937127	0.557	rs72898959	ENSG00000254907.1	RP11-484D2.2	4.01	7.01e-05	0.0105	0.32	0.18	Fibrinogen levels;	chr11:43308887	chr11:43328748~43359296:-
LUAD	cis	rs2657294	0.796	rs2804535	ENSG00000233313.2	HMGA1P5	4.01	7.01e-05	0.0105	0.22	0.18	Pneumonia;	chr10:75212086	chr10:75276376~75276646:-
LUAD	cis	rs7208859	0.573	rs7214313	ENSG00000280069.1	CTD-2349P21.3	-4.01	7.01e-05	0.0105	-0.24	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811578	chr17:30738182~30740275:+
LUAD	cis	rs763121	0.853	rs2413547	ENSG00000228274.3	RP3-508I15.9	-4.01	7.01e-05	0.0105	-0.18	-0.18	Menopause (age at onset);	chr22:38711333	chr22:38667585~38681820:-
LUAD	cis	rs9650657	0.74	rs7002282	ENSG00000255046.1	RP11-297N6.4	4.01	7.01e-05	0.0105	0.23	0.18	Neuroticism;	chr8:10809483	chr8:11797928~11802568:-
LUAD	cis	rs7119038	0.629	rs11216993	ENSG00000255239.1	AP002954.6	-4.01	7.01e-05	0.0105	-0.27	-0.18	Sjögren's syndrome;	chr11:118732786	chr11:118688039~118690600:-
LUAD	cis	rs2657294	0.965	rs2657291	ENSG00000233313.2	HMGA1P5	-4.01	7.01e-05	0.0105	-0.23	-0.18	Pneumonia;	chr10:75166945	chr10:75276376~75276646:-
LUAD	cis	rs34929064	0.718	rs1476483	ENSG00000230658.1	KLHL7-AS1	-4.01	7.01e-05	0.0105	-0.26	-0.18	Major depression and alcohol dependence;	chr7:22691580	chr7:23101228~23105703:-
LUAD	cis	rs10510102	0.516	rs12242799	ENSG00000276742.1	RP11-500G22.4	4.01	7.01e-05	0.0105	0.3	0.18	Breast cancer;	chr10:121980067	chr10:121956782~121957098:+
LUAD	cis	rs7216064	0.684	rs62084675	ENSG00000265055.1	AC145343.2	-4.01	7.02e-05	0.0105	-0.17	-0.18	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68030909	chr17:68096046~68101474:-
LUAD	cis	rs526231	0.819	rs403214	ENSG00000175749.11	EIF3KP1	4.01	7.02e-05	0.0105	0.24	0.18	Primary biliary cholangitis;	chr5:103268000	chr5:103032376~103033031:+
LUAD	cis	rs7005380	0.531	rs7018038	ENSG00000279347.1	RP11-85I17.2	4.01	7.02e-05	0.0105	0.17	0.18	Interstitial lung disease;	chr8:119922664	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.581	rs6469876	ENSG00000279347.1	RP11-85I17.2	4.01	7.02e-05	0.0105	0.17	0.18	Interstitial lung disease;	chr8:119923011	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.581	rs4871786	ENSG00000279347.1	RP11-85I17.2	4.01	7.02e-05	0.0105	0.17	0.18	Interstitial lung disease;	chr8:119924171	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.581	rs9297607	ENSG00000279347.1	RP11-85I17.2	4.01	7.02e-05	0.0105	0.17	0.18	Interstitial lung disease;	chr8:119924831	chr8:119838736~119840385:-
LUAD	cis	rs858239	0.6	rs7785842	ENSG00000226816.2	AC005082.12	4.01	7.02e-05	0.0105	0.23	0.18	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23206013~23208045:+
LUAD	cis	rs6832769	0.922	rs60797008	ENSG00000272969.1	RP11-528I4.2	-4.01	7.02e-05	0.0105	-0.19	-0.18	Personality dimensions;	chr4:55522505	chr4:55547112~55547889:+
LUAD	cis	rs10129255	1	rs10141557	ENSG00000211967.3	IGHV3-53	-4.01	7.03e-05	0.0105	-0.14	-0.18	Kawasaki disease;	chr14:106767990	chr14:106592676~106593347:-
LUAD	cis	rs8031584	1	rs1474380	ENSG00000259845.1	HERC2P10	4.01	7.03e-05	0.0105	0.2	0.18	Huntington's disease progression;	chr15:30977032	chr15:30815271~30844153:+
LUAD	cis	rs1400816	0.85	rs2292813	ENSG00000228389.1	AC068039.4	4.01	7.03e-05	0.0105	0.3	0.18	Amyotrophic lateral sclerosis (sporadic);	chr2:171787719	chr2:171773482~171775844:+
LUAD	cis	rs783540	0.632	rs17356528	ENSG00000255769.6	GOLGA2P10	4.01	7.03e-05	0.0105	0.21	0.18	Schizophrenia;	chr15:82636799	chr15:82472993~82513950:-
LUAD	cis	rs1075265	0.73	rs6711105	ENSG00000272156.1	RP11-477N3.1	-4.01	7.03e-05	0.0105	-0.21	-0.18	Chronotype;Morning vs. evening chronotype;	chr2:54017775	chr2:54082554~54085066:+
LUAD	cis	rs1075265	0.704	rs6711217	ENSG00000272156.1	RP11-477N3.1	-4.01	7.03e-05	0.0105	-0.21	-0.18	Chronotype;Morning vs. evening chronotype;	chr2:54017892	chr2:54082554~54085066:+
LUAD	cis	rs507080	0.769	rs570952	ENSG00000278376.1	RP11-158I9.8	-4.01	7.03e-05	0.0105	-0.2	-0.18	Serum metabolite levels;	chr11:118629477	chr11:118791254~118793137:+
LUAD	cis	rs6940638	0.606	rs6456771	ENSG00000219392.1	RP1-265C24.5	-4.01	7.03e-05	0.0105	-0.23	-0.18	Intelligence (multi-trait analysis);	chr6:27264616	chr6:28115628~28116551:+
LUAD	cis	rs9532669	0.89	rs4941999	ENSG00000239827.7	SUGT1P3	-4.01	7.03e-05	0.0105	-0.21	-0.18	Cervical cancer;	chr13:40859926	chr13:40908159~40921774:-
LUAD	cis	rs2288884	1	rs79817140	ENSG00000269959.1	SPACA6P-AS	-4.01	7.04e-05	0.0105	-0.24	-0.18	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52068404	chr19:51685363~51693456:-
LUAD	cis	rs2288884	1	rs11669385	ENSG00000269959.1	SPACA6P-AS	-4.01	7.04e-05	0.0105	-0.24	-0.18	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52068699	chr19:51685363~51693456:-
LUAD	cis	rs11822910	0.737	rs2584858	ENSG00000265566.2	RN7SL605P	4.01	7.04e-05	0.0105	0.23	0.18	Platelet distribution width;	chr11:57439604	chr11:57528085~57528365:-
LUAD	cis	rs2348418	0.932	rs61922464	ENSG00000247934.4	RP11-967K21.1	4.01	7.04e-05	0.0105	0.21	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28485665	chr12:28163298~28190738:-
LUAD	cis	rs2348418	0.932	rs11049661	ENSG00000247934.4	RP11-967K21.1	4.01	7.04e-05	0.0105	0.21	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28486215	chr12:28163298~28190738:-
LUAD	cis	rs2348418	0.932	rs11049662	ENSG00000247934.4	RP11-967K21.1	4.01	7.04e-05	0.0105	0.21	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28487344	chr12:28163298~28190738:-
LUAD	cis	rs2348418	0.932	rs7306581	ENSG00000247934.4	RP11-967K21.1	4.01	7.04e-05	0.0105	0.21	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28488641	chr12:28163298~28190738:-
LUAD	cis	rs6964587	0.839	rs6952459	ENSG00000188693.7	CYP51A1-AS1	-4.01	7.04e-05	0.0105	-0.22	-0.18	Breast cancer;	chr7:91806506	chr7:92134604~92180725:+
LUAD	cis	rs12701220	0.739	rs2293523	ENSG00000229043.2	AC091729.9	-4.01	7.04e-05	0.0105	-0.26	-0.18	Bronchopulmonary dysplasia;	chr7:1058882	chr7:1160374~1165267:+
LUAD	cis	rs865483	0.895	rs1016678	ENSG00000276054.1	RP11-378E13.3	4.01	7.04e-05	0.0105	0.22	0.18	Monocyte count;	chr17:37514090	chr17:37386886~37387926:+
LUAD	cis	rs36093844	0.747	rs11234420	ENSG00000279742.1	RP11-700A24.1	-4.01	7.04e-05	0.0105	-0.22	-0.18	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85817537	chr11:85852557~85854943:-
LUAD	cis	rs55692468	0.606	rs6759772	ENSG00000213197.3	AC012066.1	-4.01	7.04e-05	0.0105	-0.21	-0.18	Intraocular pressure;	chr2:152466210	chr2:152389937~152390630:+
LUAD	cis	rs5742933	0.857	rs10931430	ENSG00000253559.1	OSGEPL1-AS1	4.01	7.04e-05	0.0105	0.22	0.18	Ferritin levels;	chr2:189677460	chr2:189762704~189765556:+
LUAD	cis	rs4268898	0.722	rs6723257	ENSG00000223754.1	AC008073.9	-4.01	7.04e-05	0.0105	-0.22	-0.18	Asthma;	chr2:24168260	chr2:24199839~24201698:-
LUAD	cis	rs4666002	0.789	rs13023094	ENSG00000223522.1	AC093690.1	-4.01	7.04e-05	0.0105	-0.2	-0.18	Phospholipid levels (plasma);	chr2:27687839	chr2:28307691~28310459:-
LUAD	cis	rs12444979	0.517	rs720173	ENSG00000261195.1	CTD-2380F24.1	-4.01	7.04e-05	0.0105	-0.25	-0.18	Body mass index;	chr16:19710484	chr16:19761172~19766099:-
LUAD	cis	rs17597773	0.674	rs10863568	ENSG00000272823.1	RP11-295M18.6	-4.01	7.05e-05	0.0105	-0.24	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220844737	chr1:220828676~220829211:-
LUAD	cis	rs2060793	0.519	rs10766187	ENSG00000251991.1	RNU7-49P	4.01	7.05e-05	0.0105	0.19	0.18	Vitamin D levels;	chr11:14603836	chr11:14478892~14478953:+
LUAD	cis	rs2179367	0.959	rs237034	ENSG00000216906.2	RP11-350J20.9	4.01	7.05e-05	0.0105	0.22	0.18	Dupuytren's disease;	chr6:149390726	chr6:149904243~149906418:+
LUAD	cis	rs17826219	0.568	rs2626985	ENSG00000266490.1	CTD-2349P21.9	4.01	7.05e-05	0.0105	0.26	0.18	Body mass index;	chr17:30750419	chr17:30792372~30792833:+
LUAD	cis	rs442309	0.875	rs224067	ENSG00000238280.1	RP11-436D10.3	4.01	7.05e-05	0.0105	0.21	0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62747211	chr10:62793562~62805887:-
LUAD	cis	rs847577	0.722	rs6951277	ENSG00000272950.1	RP11-307C18.1	4.01	7.05e-05	0.0105	0.23	0.18	Breast cancer;	chr7:98082471	chr7:98322853~98323430:+
LUAD	cis	rs847577	0.722	rs7790736	ENSG00000272950.1	RP11-307C18.1	4.01	7.05e-05	0.0105	0.23	0.18	Breast cancer;	chr7:98083727	chr7:98322853~98323430:+
LUAD	cis	rs7208859	0.673	rs75142521	ENSG00000266490.1	CTD-2349P21.9	4.01	7.05e-05	0.0105	0.27	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913519	chr17:30792372~30792833:+
LUAD	cis	rs7560272	0.695	rs13022149	ENSG00000163016.8	ALMS1P	-4.01	7.05e-05	0.0105	-0.19	-0.18	Schizophrenia;	chr2:73414387	chr2:73644919~73685576:+
LUAD	cis	rs10197140	0.925	rs11123227	ENSG00000235721.1	AC013268.3	-4.01	7.05e-05	0.0105	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110890437	chr2:110007675~110010783:+
LUAD	cis	rs8031584	0.706	rs798084	ENSG00000260128.5	ULK4P2	-4.01	7.05e-05	0.0105	-0.24	-0.18	Huntington's disease progression;	chr15:30834732	chr15:30572738~30600647:+
LUAD	cis	rs36350	0.5	rs12590831	ENSG00000266869.1	RP6-114E22.1	-4.01	7.05e-05	0.0105	-0.2	-0.18	Autism spectrum disorder or schizophrenia;	chr14:71988105	chr14:71848606~71908430:+
LUAD	cis	rs8002861	0.87	rs1348671	ENSG00000274001.1	RP11-5G9.5	4.01	7.05e-05	0.0105	0.19	0.18	Leprosy;	chr13:43875369	chr13:43877715~43878163:-
LUAD	cis	rs12682352	0.715	rs332039	ENSG00000233609.3	RP11-62H7.2	4.01	7.05e-05	0.0105	0.15	0.18	Neuroticism;	chr8:8866141	chr8:8961200~8979025:+
LUAD	cis	rs17772222	1	rs1955599	ENSG00000258789.1	RP11-507K2.3	-4.01	7.05e-05	0.0105	-0.24	-0.18	Coronary artery calcification;	chr14:88358788	chr14:88551597~88552493:+
LUAD	cis	rs17772222	1	rs1955600	ENSG00000258789.1	RP11-507K2.3	-4.01	7.05e-05	0.0105	-0.24	-0.18	Coronary artery calcification;	chr14:88359040	chr14:88551597~88552493:+
LUAD	cis	rs1729407	0.706	rs1268354	ENSG00000280143.1	AP000892.6	4.01	7.06e-05	0.0105	0.2	0.18	Apolipoprotein A-IV levels;	chr11:116819862	chr11:117204967~117210292:+
LUAD	cis	rs7590268	0.895	rs35114568	ENSG00000279873.2	LINC01126	4.01	7.06e-05	0.0105	0.19	0.18	Orofacial clefts;	chr2:43448153	chr2:43227210~43228855:+
LUAD	cis	rs11742741	1	rs7709087	ENSG00000248874.4	C5orf17	-4.01	7.06e-05	0.0105	-0.22	-0.18	Educational attainment;	chr5:24172941	chr5:23951348~24178263:+
LUAD	cis	rs11742741	0.935	rs72745797	ENSG00000248874.4	C5orf17	-4.01	7.06e-05	0.0105	-0.22	-0.18	Educational attainment;	chr5:24175533	chr5:23951348~24178263:+
LUAD	cis	rs761746	0.614	rs8141214	ENSG00000236132.1	CTA-440B3.1	-4.01	7.06e-05	0.0105	-0.24	-0.18	Intelligence;	chr22:31800195	chr22:31816379~31817491:-
LUAD	cis	rs6832769	1	rs9312662	ENSG00000272969.1	RP11-528I4.2	-4.01	7.06e-05	0.0105	-0.19	-0.18	Personality dimensions;	chr4:55520204	chr4:55547112~55547889:+
LUAD	cis	rs12986445	0.793	rs9309437	ENSG00000218682.1	AC010150.1	-4.01	7.06e-05	0.0105	-0.23	-0.18	Multiple myeloma;Multiple myeloma and monoclonal gammopathy;	chr2:25879728	chr2:25856461~25856966:-
LUAD	cis	rs7107174	1	rs1399196	ENSG00000251323.2	RP11-452H21.4	4.01	7.06e-05	0.0105	0.21	0.18	Testicular germ cell tumor;	chr11:78360830	chr11:78423982~78429836:-
LUAD	cis	rs4568518	0.71	rs6966083	ENSG00000279048.1	RP11-511H23.2	4.01	7.06e-05	0.0105	0.15	0.18	Measles;	chr7:17976921	chr7:17940503~17942922:+
LUAD	cis	rs6496932	1	rs6496932	ENSG00000259630.2	CTD-2262B20.1	4.01	7.06e-05	0.0105	0.24	0.18	Central corneal thickness;Corneal structure;	chr15:85282336	chr15:85415228~85415633:+
LUAD	cis	rs2732480	0.577	rs2732448	ENSG00000257763.1	OR5BK1P	4.01	7.06e-05	0.0105	0.19	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48336817	chr12:48355792~48356614:-
LUAD	cis	rs9287719	0.967	rs7592691	ENSG00000243819.4	RN7SL832P	4.01	7.06e-05	0.0105	0.19	0.18	Prostate cancer;	chr2:10597300	chr2:10690344~10692099:+
LUAD	cis	rs4795519	0.778	rs4794850	ENSG00000266313.1	RP11-173M1.4	4.01	7.06e-05	0.0105	0.23	0.18	Chronic myeloid leukemia;	chr17:27174649	chr17:27333256~27348491:+
LUAD	cis	rs911119	0.866	rs6048920	ENSG00000270001.1	RP11-218C14.8	-4.01	7.07e-05	0.0105	-0.27	-0.18	Chronic kidney disease;	chr20:23596207	chr20:23631826~23632316:-
LUAD	cis	rs6686842	0.56	rs213765	ENSG00000235358.1	RP11-399E6.1	4.01	7.07e-05	0.0105	0.21	0.18	Height;	chr1:41116334	chr1:41242373~41284861:+
LUAD	cis	rs9549260	0.755	rs4943798	ENSG00000229456.1	RLIMP1	4.01	7.07e-05	0.0105	0.19	0.18	Red blood cell count;	chr13:40628811	chr13:40618738~40621348:+
LUAD	cis	rs8077577	0.638	rs4386179	ENSG00000273018.4	CTD-2303H24.2	4.01	7.07e-05	0.0105	0.26	0.18	Obesity-related traits;	chr17:18231460	chr17:18511221~18551705:-
LUAD	cis	rs2732480	0.577	rs2634684	ENSG00000240399.1	RP1-228P16.1	-4.01	7.07e-05	0.0105	-0.18	-0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48337092	chr12:48054813~48055591:-
LUAD	cis	rs6568686	0.735	rs7762054	ENSG00000255389.1	C6orf3	4.01	7.07e-05	0.0105	0.24	0.18	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111549539	chr6:111599875~111602295:+
LUAD	cis	rs10208649	0.611	rs7583626	ENSG00000272156.1	RP11-477N3.1	4.01	7.08e-05	0.0105	0.36	0.18	Body mass index;	chr2:54063635	chr2:54082554~54085066:+
LUAD	cis	rs412658	0.504	rs17769372	ENSG00000269345.1	VN1R85P	4.01	7.08e-05	0.0105	0.21	0.18	Telomere length;	chr19:21931902	chr19:22174766~22175191:-
LUAD	cis	rs10197140	0.857	rs10196268	ENSG00000235721.1	AC013268.3	-4.01	7.08e-05	0.0105	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110887579	chr2:110007675~110010783:+
LUAD	cis	rs10197140	0.857	rs13416355	ENSG00000235721.1	AC013268.3	-4.01	7.08e-05	0.0105	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110888153	chr2:110007675~110010783:+
LUAD	cis	rs4372836	0.928	rs55836936	ENSG00000226833.4	AC097724.3	-4.01	7.08e-05	0.0105	-0.21	-0.18	Body mass index;	chr2:28699967	chr2:28708953~28736205:-
LUAD	cis	rs1348850	0.872	rs12991272	ENSG00000213963.5	AC074286.1	4.01	7.08e-05	0.0105	0.22	0.18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177592611	chr2:177283508~177392691:-
LUAD	cis	rs875971	0.66	rs10263935	ENSG00000222364.1	RNU6-96P	-4.01	7.08e-05	0.0106	-0.2	-0.18	Aortic root size;	chr7:66631041	chr7:66395191~66395286:+
LUAD	cis	rs763121	0.853	rs35565791	ENSG00000228274.3	RP3-508I15.9	-4.01	7.08e-05	0.0106	-0.18	-0.18	Menopause (age at onset);	chr22:38667006	chr22:38667585~38681820:-
LUAD	cis	rs763121	0.853	rs35522482	ENSG00000228274.3	RP3-508I15.9	-4.01	7.08e-05	0.0106	-0.18	-0.18	Menopause (age at onset);	chr22:38667010	chr22:38667585~38681820:-
LUAD	cis	rs6910061	0.957	rs6916541	ENSG00000247925.2	RP3-510L9.1	-4.01	7.08e-05	0.0106	-0.25	-0.18	Diabetic kidney disease;	chr6:11095025	chr6:11173452~11259099:+
LUAD	cis	rs6910061	1	rs6938867	ENSG00000247925.2	RP3-510L9.1	-4.01	7.08e-05	0.0106	-0.25	-0.18	Diabetic kidney disease;	chr6:11095070	chr6:11173452~11259099:+
LUAD	cis	rs6910061	1	rs6938870	ENSG00000247925.2	RP3-510L9.1	-4.01	7.08e-05	0.0106	-0.25	-0.18	Diabetic kidney disease;	chr6:11095084	chr6:11173452~11259099:+
LUAD	cis	rs6910061	1	rs9468412	ENSG00000247925.2	RP3-510L9.1	-4.01	7.08e-05	0.0106	-0.25	-0.18	Diabetic kidney disease;	chr6:11095643	chr6:11173452~11259099:+
LUAD	cis	rs6910061	1	rs34846077	ENSG00000247925.2	RP3-510L9.1	-4.01	7.08e-05	0.0106	-0.25	-0.18	Diabetic kidney disease;	chr6:11096328	chr6:11173452~11259099:+
LUAD	cis	rs6910061	1	rs9468415	ENSG00000247925.2	RP3-510L9.1	-4.01	7.08e-05	0.0106	-0.25	-0.18	Diabetic kidney disease;	chr6:11100652	chr6:11173452~11259099:+
LUAD	cis	rs6910061	1	rs9468416	ENSG00000247925.2	RP3-510L9.1	-4.01	7.08e-05	0.0106	-0.25	-0.18	Diabetic kidney disease;	chr6:11100745	chr6:11173452~11259099:+
LUAD	cis	rs2732480	0.5	rs2450991	ENSG00000257763.1	OR5BK1P	4.01	7.09e-05	0.0106	0.19	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48257838	chr12:48355792~48356614:-
LUAD	cis	rs9341808	0.622	rs684283	ENSG00000260645.1	RP11-250B2.5	-4.01	7.09e-05	0.0106	-0.17	-0.18	Sitting height ratio;	chr6:80257600	chr6:80466958~80469080:+
LUAD	cis	rs1862618	0.754	rs252899	ENSG00000271828.1	CTD-2310F14.1	4.01	7.09e-05	0.0106	0.26	0.18	Initial pursuit acceleration;	chr5:56892742	chr5:56927874~56929573:+
LUAD	cis	rs1862618	0.853	rs252898	ENSG00000271828.1	CTD-2310F14.1	4.01	7.09e-05	0.0106	0.26	0.18	Initial pursuit acceleration;	chr5:56893104	chr5:56927874~56929573:+
LUAD	cis	rs1862618	0.802	rs194058	ENSG00000271828.1	CTD-2310F14.1	4.01	7.09e-05	0.0106	0.26	0.18	Initial pursuit acceleration;	chr5:56893150	chr5:56927874~56929573:+
LUAD	cis	rs2274273	0.773	rs8006525	ENSG00000258413.1	RP11-665C16.6	-4.01	7.09e-05	0.0106	-0.23	-0.18	Protein biomarker;	chr14:55346676	chr14:55262767~55272075:-
LUAD	cis	rs11216126	1	rs11216129	ENSG00000254851.1	RP11-109L13.1	4.01	7.09e-05	0.0106	0.34	0.18	HDL cholesterol;	chr11:116749540	chr11:117135528~117138582:+
LUAD	cis	rs12935418	0.616	rs2549853	ENSG00000261061.1	RP11-303E16.2	4.01	7.09e-05	0.0106	0.19	0.18	Mean corpuscular volume;	chr16:80992850	chr16:81030770~81031485:+
LUAD	cis	rs2933343	0.679	rs789229	ENSG00000231305.3	RP11-723O4.2	4.01	7.09e-05	0.0106	0.2	0.18	IgG glycosylation;	chr3:128883683	chr3:128861313~128871540:-
LUAD	cis	rs2933343	0.729	rs789230	ENSG00000231305.3	RP11-723O4.2	4.01	7.09e-05	0.0106	0.2	0.18	IgG glycosylation;	chr3:128883715	chr3:128861313~128871540:-
LUAD	cis	rs2933343	0.729	rs6790091	ENSG00000231305.3	RP11-723O4.2	4.01	7.09e-05	0.0106	0.2	0.18	IgG glycosylation;	chr3:128889908	chr3:128861313~128871540:-
LUAD	cis	rs7893279	0.505	rs4748499	ENSG00000225527.1	RP11-383B4.4	4.01	7.09e-05	0.0106	0.26	0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18621441	chr10:18531849~18533336:-
LUAD	cis	rs7893279	0.505	rs12769425	ENSG00000225527.1	RP11-383B4.4	4.01	7.09e-05	0.0106	0.26	0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18622185	chr10:18531849~18533336:-
LUAD	cis	rs4268898	0.562	rs17046192	ENSG00000242628.4	AC009228.1	-4.01	7.09e-05	0.0106	-0.22	-0.18	Asthma;	chr2:24238465	chr2:24214381~24221516:+
LUAD	cis	rs17818399	0.547	rs62134736	ENSG00000279254.1	RP11-536C12.1	-4.01	7.09e-05	0.0106	-0.22	-0.18	Height;	chr2:46539307	chr2:46668870~46670778:+
LUAD	cis	rs2732480	0.538	rs1387260	ENSG00000240399.1	RP1-228P16.1	4.01	7.09e-05	0.0106	0.19	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309308	chr12:48054813~48055591:-
LUAD	cis	rs753274	0.65	rs72998945	ENSG00000267147.2	CTC-548K16.1	-4.01	7.09e-05	0.0106	-0.22	-0.18	Tumor necrosis factor beta levels;	chr19:14307629	chr19:14333743~14343916:+
LUAD	cis	rs4595586	1	rs4595586	ENSG00000257718.1	RP11-396F22.1	-4.01	7.09e-05	0.0106	-0.22	-0.18	Morning vs. evening chronotype;	chr12:38832189	chr12:38906451~38909592:+
LUAD	cis	rs4819052	0.851	rs914214	ENSG00000215447.6	BX322557.10	-4.01	7.09e-05	0.0106	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45277905	chr21:45288052~45291738:+
LUAD	cis	rs9341808	0.714	rs4256394	ENSG00000272129.1	RP11-250B2.6	4.01	7.09e-05	0.0106	0.22	0.18	Sitting height ratio;	chr6:80172425	chr6:80355424~80356859:+
LUAD	cis	rs728616	0.867	rs56000427	ENSG00000234382.2	RP11-40F6.1	-4.01	7.09e-05	0.0106	-0.46	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80227190	chr10:80233664~80245367:+
LUAD	cis	rs7937890	0.559	rs2597196	ENSG00000254418.1	RP11-21L19.1	-4.01	7.1e-05	0.0106	-0.21	-0.18	Mitochondrial DNA levels;	chr11:14470055	chr11:14262846~14273691:-
LUAD	cis	rs9309473	0.514	rs62149630	ENSG00000230002.2	ALMS1-IT1	4.01	7.1e-05	0.0106	0.28	0.18	Metabolite levels;	chr2:73354627	chr2:73456764~73459484:+
LUAD	cis	rs7512552	0.809	rs698923	ENSG00000275557.1	RP11-353N4.6	4.01	7.1e-05	0.0106	0.21	0.18	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150406683	chr1:149607765~149612402:+
LUAD	cis	rs9400467	0.528	rs457492	ENSG00000230177.1	RP5-1112D6.4	-4.01	7.1e-05	0.0106	-0.16	-0.18	Amino acid levels;Blood metabolite levels;	chr6:111320647	chr6:111277932~111278742:+
LUAD	cis	rs10129255	0.5	rs8006888	ENSG00000253209.1	IGHV3-65	4.01	7.1e-05	0.0106	0.14	0.18	Kawasaki disease;	chr14:106782219	chr14:106666092~106666532:-
LUAD	cis	rs10129255	0.536	rs10142951	ENSG00000253209.1	IGHV3-65	4.01	7.1e-05	0.0106	0.14	0.18	Kawasaki disease;	chr14:106782337	chr14:106666092~106666532:-
LUAD	cis	rs4713118	0.955	rs9368529	ENSG00000280107.1	AL022393.9	-4.01	7.1e-05	0.0106	-0.23	-0.18	Parkinson's disease;	chr6:27716852	chr6:28170845~28172521:+
LUAD	cis	rs72772090	1	rs72772090	ENSG00000248734.2	CTD-2260A17.1	-4.01	7.1e-05	0.0106	-0.27	-0.18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96700607	chr5:96784777~96785999:+
LUAD	cis	rs2295359	1	rs10889664	ENSG00000275678.1	RP4-547N15.3	-4.01	7.1e-05	0.0106	-0.19	-0.18	Psoriasis;	chr1:67169792	chr1:67121605~67123956:-
LUAD	cis	rs12439619	0.508	rs8023960	ENSG00000259429.4	UBE2Q2P2	-4.01	7.1e-05	0.0106	-0.15	-0.18	Intelligence (multi-trait analysis);	chr15:82206704	chr15:82355142~82420075:+
LUAD	cis	rs2235642	0.601	rs2235647	ENSG00000280231.1	LA16c-380F5.3	-4.01	7.1e-05	0.0106	-0.25	-0.18	Coronary artery disease;	chr16:1551330	chr16:1553655~1554130:-
LUAD	cis	rs2235642	0.701	rs2281230	ENSG00000280231.1	LA16c-380F5.3	-4.01	7.1e-05	0.0106	-0.25	-0.18	Coronary artery disease;	chr16:1551766	chr16:1553655~1554130:-
LUAD	cis	rs4925386	1	rs4925386	ENSG00000273619.1	RP5-908M14.9	-4.01	7.1e-05	0.0106	-0.16	-0.18	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345988	chr20:62386303~62386970:-
LUAD	cis	rs62025270	0.688	rs55738258	ENSG00000259416.2	RP11-158M2.5	-4.01	7.11e-05	0.0106	-0.24	-0.18	Idiopathic pulmonary fibrosis;	chr15:85773000	chr15:85754941~85756237:-
LUAD	cis	rs62025270	0.688	rs55957626	ENSG00000259416.2	RP11-158M2.5	-4.01	7.11e-05	0.0106	-0.24	-0.18	Idiopathic pulmonary fibrosis;	chr15:85773486	chr15:85754941~85756237:-
LUAD	cis	rs17772222	0.958	rs74074098	ENSG00000258789.1	RP11-507K2.3	-4.01	7.11e-05	0.0106	-0.25	-0.18	Coronary artery calcification;	chr14:88484213	chr14:88551597~88552493:+
LUAD	cis	rs2548724	0.741	rs11948335	ENSG00000250682.4	LINC00491	4.01	7.11e-05	0.0106	0.24	0.18	Type 2 diabetes;	chr5:102368475	chr5:102609156~102671559:-
LUAD	cis	rs8064024	0.676	rs2075467	ENSG00000267077.1	RP11-127I20.5	-4.01	7.11e-05	0.0106	-0.21	-0.18	Cancer;	chr16:4823241	chr16:4795265~4796532:-
LUAD	cis	rs11742741	1	rs1428544	ENSG00000248874.4	C5orf17	-4.01	7.11e-05	0.0106	-0.22	-0.18	Educational attainment;	chr5:24154446	chr5:23951348~24178263:+
LUAD	cis	rs6910061	0.956	rs9468419	ENSG00000247925.2	RP3-510L9.1	-4.01	7.11e-05	0.0106	-0.25	-0.18	Diabetic kidney disease;	chr6:11102343	chr6:11173452~11259099:+
LUAD	cis	rs9876781	1	rs6442117	ENSG00000229759.1	MRPS18AP1	-4.01	7.11e-05	0.0106	-0.17	-0.18	Longevity;	chr3:48378407	chr3:48256350~48256938:-
LUAD	cis	rs763121	0.853	rs2281019	ENSG00000228274.3	RP3-508I15.9	-4.01	7.11e-05	0.0106	-0.18	-0.18	Menopause (age at onset);	chr22:38668373	chr22:38667585~38681820:-
LUAD	cis	rs763121	0.853	rs2281020	ENSG00000228274.3	RP3-508I15.9	-4.01	7.11e-05	0.0106	-0.18	-0.18	Menopause (age at onset);	chr22:38668401	chr22:38667585~38681820:-
LUAD	cis	rs763121	0.853	rs2281021	ENSG00000228274.3	RP3-508I15.9	-4.01	7.11e-05	0.0106	-0.18	-0.18	Menopause (age at onset);	chr22:38668662	chr22:38667585~38681820:-
LUAD	cis	rs763121	0.853	rs5995610	ENSG00000228274.3	RP3-508I15.9	-4.01	7.11e-05	0.0106	-0.18	-0.18	Menopause (age at onset);	chr22:38668676	chr22:38667585~38681820:-
LUAD	cis	rs2274273	0.805	rs28612464	ENSG00000258413.1	RP11-665C16.6	-4.01	7.11e-05	0.0106	-0.23	-0.18	Protein biomarker;	chr14:55349693	chr14:55262767~55272075:-
LUAD	cis	rs2274273	0.773	rs28430823	ENSG00000258413.1	RP11-665C16.6	-4.01	7.11e-05	0.0106	-0.23	-0.18	Protein biomarker;	chr14:55349842	chr14:55262767~55272075:-
LUAD	cis	rs2274273	0.87	rs17741831	ENSG00000258413.1	RP11-665C16.6	-4.01	7.11e-05	0.0106	-0.23	-0.18	Protein biomarker;	chr14:55349997	chr14:55262767~55272075:-
LUAD	cis	rs10129255	0.5	rs8022547	ENSG00000253209.1	IGHV3-65	4.01	7.11e-05	0.0106	0.14	0.18	Kawasaki disease;	chr14:106781985	chr14:106666092~106666532:-
LUAD	cis	rs848490	0.889	rs55708205	ENSG00000214293.7	APTR	4.01	7.11e-05	0.0106	0.23	0.18	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77560753	chr7:77657660~77696265:-
LUAD	cis	rs13434995	0.513	rs1979604	ENSG00000273257.1	RP11-177J6.1	4.01	7.11e-05	0.0106	0.24	0.18	Adiponectin levels;	chr4:55552588	chr4:55387949~55388271:+
LUAD	cis	rs13434995	0.537	rs4865012	ENSG00000273257.1	RP11-177J6.1	4.01	7.11e-05	0.0106	0.24	0.18	Adiponectin levels;	chr4:55554619	chr4:55387949~55388271:+
LUAD	cis	rs13434995	0.513	rs6846764	ENSG00000273257.1	RP11-177J6.1	4.01	7.11e-05	0.0106	0.24	0.18	Adiponectin levels;	chr4:55557322	chr4:55387949~55388271:+
LUAD	cis	rs13434995	0.513	rs6853506	ENSG00000273257.1	RP11-177J6.1	4.01	7.11e-05	0.0106	0.24	0.18	Adiponectin levels;	chr4:55558207	chr4:55387949~55388271:+
LUAD	cis	rs1552244	0.882	rs13099136	ENSG00000180385.7	EMC3-AS1	4.01	7.11e-05	0.0106	0.21	0.18	Alzheimer's disease;	chr3:9989747	chr3:9986893~10006990:+
LUAD	cis	rs17406451	0.759	rs11124934	ENSG00000279873.2	LINC01126	4.01	7.11e-05	0.0106	0.15	0.18	Mitochondrial DNA levels;	chr2:43425783	chr2:43227210~43228855:+
LUAD	cis	rs9309473	0.95	rs6546859	ENSG00000230002.2	ALMS1-IT1	4.01	7.11e-05	0.0106	0.22	0.18	Metabolite levels;	chr2:73614928	chr2:73456764~73459484:+
LUAD	cis	rs2834288	0.535	rs7278341	ENSG00000237945.6	LINC00649	4.01	7.11e-05	0.0106	0.23	0.18	Gut microbiota (bacterial taxa);	chr21:33961692	chr21:33915534~33977691:+
LUAD	cis	rs2834288	0.535	rs7279183	ENSG00000237945.6	LINC00649	4.01	7.11e-05	0.0106	0.23	0.18	Gut microbiota (bacterial taxa);	chr21:33961701	chr21:33915534~33977691:+
LUAD	cis	rs4699052	0.963	rs6533066	ENSG00000246560.2	RP11-10L12.4	4.01	7.12e-05	0.0106	0.23	0.18	Testicular germ cell tumor;	chr4:103242450	chr4:102828055~102844075:+
LUAD	cis	rs36350	0.5	rs4569194	ENSG00000266869.1	RP6-114E22.1	-4.01	7.12e-05	0.0106	-0.2	-0.18	Autism spectrum disorder or schizophrenia;	chr14:71986673	chr14:71848606~71908430:+
LUAD	cis	rs7208859	0.673	rs11654331	ENSG00000266490.1	CTD-2349P21.9	4.01	7.12e-05	0.0106	0.26	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837999	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs73277964	ENSG00000266490.1	CTD-2349P21.9	4.01	7.12e-05	0.0106	0.26	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30852183	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs11652409	ENSG00000266490.1	CTD-2349P21.9	4.01	7.12e-05	0.0106	0.26	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855689	chr17:30792372~30792833:+
LUAD	cis	rs794728	0.522	rs7709651	ENSG00000249031.1	SUMO2P6	-4.01	7.12e-05	0.0106	-0.2	-0.18	Depressive symptoms (SSRI exposure interaction);	chr5:174435012	chr5:174561776~174562063:+
LUAD	cis	rs858239	0.738	rs13225593	ENSG00000226816.2	AC005082.12	4.01	7.12e-05	0.0106	0.24	0.18	Cerebrospinal fluid biomarker levels;	chr7:23220688	chr7:23206013~23208045:+
LUAD	cis	rs1005277	0.522	rs289647	ENSG00000263064.2	RP11-291L22.7	4.01	7.12e-05	0.0106	0.19	0.18	Extrinsic epigenetic age acceleration;	chr10:37679350	chr10:38448689~38448949:+
LUAD	cis	rs10463554	0.892	rs6871715	ENSG00000250682.4	LINC00491	4.01	7.12e-05	0.0106	0.22	0.18	Parkinson's disease;	chr5:102930398	chr5:102609156~102671559:-
LUAD	cis	rs2243480	0.522	rs12698511	ENSG00000230295.1	RP11-458F8.2	-4.01	7.12e-05	0.0106	-0.25	-0.18	Diabetic kidney disease;	chr7:66009932	chr7:66880708~66882981:+
LUAD	cis	rs2018683	0.834	rs733485	ENSG00000228421.2	AC005013.5	4.01	7.12e-05	0.0106	0.2	0.18	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28987069	chr7:28957667~28959345:+
LUAD	cis	rs34779708	0.931	rs11010132	ENSG00000271335.4	RP11-324I22.4	4.01	7.12e-05	0.0106	0.19	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35228337	chr10:35314552~35336401:-
LUAD	cis	rs1023500	0.529	rs133375	ENSG00000205702.9	CYP2D7	4.01	7.13e-05	0.0106	0.15	0.18	Schizophrenia;	chr22:42070505	chr22:42140203~42144577:-
LUAD	cis	rs4713118	0.506	rs9366697	ENSG00000219392.1	RP1-265C24.5	-4.01	7.13e-05	0.0106	-0.22	-0.18	Parkinson's disease;	chr6:27665239	chr6:28115628~28116551:+
LUAD	cis	rs4561483	0.667	rs3743590	ENSG00000261216.1	RP11-166B2.5	-4.01	7.13e-05	0.0106	-0.18	-0.18	Testicular germ cell tumor;	chr16:11836480	chr16:11908208~11908916:+
LUAD	cis	rs12422267	0.609	rs10128884	ENSG00000256576.2	RP13-977J11.2	4.01	7.13e-05	0.0106	0.25	0.18	Plasma amyloid beta peptide concentrations (ABx-40);	chr12:132137079	chr12:132186735~132189695:-
LUAD	cis	rs780096	0.527	rs12471703	ENSG00000234072.1	AC074117.10	-4.01	7.13e-05	0.0106	-0.14	-0.18	Total body bone mineral density;	chr2:27515987	chr2:27356246~27367622:+
LUAD	cis	rs17301013	0.932	rs332795	ENSG00000227373.4	RP11-160H22.5	4.01	7.13e-05	0.0106	0.23	0.18	Systemic lupus erythematosus;	chr1:174726785	chr1:174115300~174160004:-
LUAD	cis	rs2921073	0.605	rs2976933	ENSG00000253893.2	FAM85B	-4.01	7.13e-05	0.0106	-0.23	-0.18	Parkinson's disease;	chr8:8397365	chr8:8167819~8226614:-
LUAD	cis	rs2242116	0.796	rs4683297	ENSG00000271161.1	BOLA2P2	-4.01	7.13e-05	0.0106	-0.17	-0.18	Birth weight;	chr3:46932183	chr3:47499841~47500407:+
LUAD	cis	rs2242116	0.796	rs4683296	ENSG00000271161.1	BOLA2P2	-4.01	7.13e-05	0.0106	-0.17	-0.18	Birth weight;	chr3:46932330	chr3:47499841~47500407:+
LUAD	cis	rs2242116	0.796	rs7623898	ENSG00000271161.1	BOLA2P2	-4.01	7.13e-05	0.0106	-0.17	-0.18	Birth weight;	chr3:46932682	chr3:47499841~47500407:+
LUAD	cis	rs853679	0.567	rs7774981	ENSG00000219392.1	RP1-265C24.5	-4.01	7.13e-05	0.0106	-0.24	-0.18	Depression;	chr6:28379133	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.567	rs7754960	ENSG00000219392.1	RP1-265C24.5	-4.01	7.13e-05	0.0106	-0.24	-0.18	Depression;	chr6:28379168	chr6:28115628~28116551:+
LUAD	cis	rs5015933	0.815	rs10819041	ENSG00000232630.1	PRPS1P2	-4.01	7.14e-05	0.0106	-0.17	-0.18	Body mass index;	chr9:125268558	chr9:125150653~125151589:+
LUAD	cis	rs853679	0.607	rs13205911	ENSG00000219392.1	RP1-265C24.5	-4.01	7.14e-05	0.0106	-0.4	-0.18	Depression;	chr6:28156336	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.607	rs13197176	ENSG00000219392.1	RP1-265C24.5	-4.01	7.14e-05	0.0106	-0.4	-0.18	Depression;	chr6:28161454	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.607	rs13201308	ENSG00000219392.1	RP1-265C24.5	-4.01	7.14e-05	0.0106	-0.4	-0.18	Depression;	chr6:28162311	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.607	rs34765154	ENSG00000219392.1	RP1-265C24.5	-4.01	7.14e-05	0.0106	-0.4	-0.18	Depression;	chr6:28162672	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.607	rs34505829	ENSG00000219392.1	RP1-265C24.5	-4.01	7.14e-05	0.0106	-0.4	-0.18	Depression;	chr6:28165461	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.607	rs35098436	ENSG00000219392.1	RP1-265C24.5	-4.01	7.14e-05	0.0106	-0.4	-0.18	Depression;	chr6:28166443	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.607	rs72846794	ENSG00000219392.1	RP1-265C24.5	-4.01	7.14e-05	0.0106	-0.4	-0.18	Depression;	chr6:28169721	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.607	rs13217984	ENSG00000219392.1	RP1-265C24.5	-4.01	7.14e-05	0.0106	-0.4	-0.18	Depression;	chr6:28171932	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.556	rs67297533	ENSG00000219392.1	RP1-265C24.5	-4.01	7.14e-05	0.0106	-0.4	-0.18	Depression;	chr6:28173475	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.505	rs35781323	ENSG00000219392.1	RP1-265C24.5	-4.01	7.14e-05	0.0106	-0.4	-0.18	Depression;	chr6:28177054	chr6:28115628~28116551:+
LUAD	cis	rs858239	0.539	rs4504540	ENSG00000226816.2	AC005082.12	4.01	7.14e-05	0.0106	0.24	0.18	Cerebrospinal fluid biomarker levels;	chr7:23146579	chr7:23206013~23208045:+
LUAD	cis	rs858239	0.509	rs6975524	ENSG00000226816.2	AC005082.12	4.01	7.14e-05	0.0106	0.24	0.18	Cerebrospinal fluid biomarker levels;	chr7:23146833	chr7:23206013~23208045:+
LUAD	cis	rs5758659	0.633	rs762995	ENSG00000227370.1	RP4-669P10.19	-4.01	7.14e-05	0.0106	-0.16	-0.18	Cognitive function;	chr22:42276118	chr22:42132543~42132998:+
LUAD	cis	rs1387259	0.899	rs7307566	ENSG00000257763.1	OR5BK1P	4.01	7.14e-05	0.0106	0.19	0.18	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48210899	chr12:48355792~48356614:-
LUAD	cis	rs1552244	0.882	rs17050660	ENSG00000180385.7	EMC3-AS1	-4.01	7.14e-05	0.0106	-0.2	-0.18	Alzheimer's disease;	chr3:9960088	chr3:9986893~10006990:+
LUAD	cis	rs7121538	0.756	rs1003077	ENSG00000254418.1	RP11-21L19.1	4.01	7.14e-05	0.0106	0.27	0.18	HDL cholesterol;	chr11:14386594	chr11:14262846~14273691:-
LUAD	cis	rs2274273	0.624	rs7151754	ENSG00000258413.1	RP11-665C16.6	-4.01	7.14e-05	0.0106	-0.25	-0.18	Protein biomarker;	chr14:55321783	chr14:55262767~55272075:-
LUAD	cis	rs9633740	1	rs7910643	ENSG00000226659.1	RP11-137H2.4	-4.01	7.14e-05	0.0106	-0.29	-0.18	Post bronchodilator FEV1;	chr10:80492013	chr10:80529597~80535942:-
LUAD	cis	rs13256369	1	rs12550762	ENSG00000253893.2	FAM85B	-4.01	7.15e-05	0.0106	-0.24	-0.18	Obesity-related traits;	chr8:8719025	chr8:8167819~8226614:-
LUAD	cis	rs6668534	1	rs6668534	ENSG00000244682.6	FCGR2C	-4.01	7.15e-05	0.0106	-0.17	-0.18	Blood protein levels;	chr1:161702205	chr1:161581339~161605662:+
LUAD	cis	rs1850744	0.536	rs6843869	ENSG00000163612.10	FAM86KP	-4.01	7.15e-05	0.0106	-0.51	-0.18	Economic and political preferences;	chr4:9632827	chr4:9153296~9165451:+
LUAD	cis	rs1510272	1	rs1510272	ENSG00000243926.1	TIPARP-AS1	-4.01	7.15e-05	0.0106	-0.2	-0.18	Testicular germ cell tumor;	chr3:156582935	chr3:156671862~156674378:-
LUAD	cis	rs6479891	1	rs61853336	ENSG00000232075.1	MRPL35P2	4.01	7.15e-05	0.0106	0.29	0.18	Arthritis (juvenile idiopathic);	chr10:63140115	chr10:63634317~63634827:-
LUAD	cis	rs6479891	1	rs4746994	ENSG00000232075.1	MRPL35P2	4.01	7.15e-05	0.0106	0.29	0.18	Arthritis (juvenile idiopathic);	chr10:63145564	chr10:63634317~63634827:-
LUAD	cis	rs6479891	1	rs12415984	ENSG00000232075.1	MRPL35P2	4.01	7.15e-05	0.0106	0.29	0.18	Arthritis (juvenile idiopathic);	chr10:63150528	chr10:63634317~63634827:-
LUAD	cis	rs9287719	0.934	rs6727884	ENSG00000243819.4	RN7SL832P	-4.01	7.15e-05	0.0106	-0.19	-0.18	Prostate cancer;	chr2:10617431	chr2:10690344~10692099:+
LUAD	cis	rs35740288	0.689	rs11630688	ENSG00000259407.1	RP11-158M2.3	-4.01	7.15e-05	0.0106	-0.18	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85710048	chr15:85744109~85750281:-
LUAD	cis	rs4819052	0.679	rs4819053	ENSG00000215447.6	BX322557.10	4.01	7.15e-05	0.0106	0.2	0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291442	chr21:45288052~45291738:+
LUAD	cis	rs638893	0.617	rs4938558	ENSG00000255422.1	AP002954.4	-4.01	7.15e-05	0.0106	-0.25	-0.18	Vitiligo;	chr11:118847220	chr11:118704607~118750263:+
LUAD	cis	rs7674212	0.541	rs2720448	ENSG00000251288.2	RP11-10L12.2	-4.01	7.15e-05	0.0106	-0.22	-0.18	Type 2 diabetes;	chr4:103109432	chr4:102751401~102752641:+
LUAD	cis	rs7674212	0.541	rs2623064	ENSG00000251288.2	RP11-10L12.2	-4.01	7.15e-05	0.0106	-0.22	-0.18	Type 2 diabetes;	chr4:103109635	chr4:102751401~102752641:+
LUAD	cis	rs3020736	0.5	rs6002614	ENSG00000205702.9	CYP2D7	-4.01	7.15e-05	0.0106	-0.15	-0.18	Autism spectrum disorder or schizophrenia;	chr22:42105798	chr22:42140203~42144577:-
LUAD	cis	rs3020736	0.5	rs2413669	ENSG00000205702.9	CYP2D7	-4.01	7.15e-05	0.0106	-0.15	-0.18	Autism spectrum disorder or schizophrenia;	chr22:42111744	chr22:42140203~42144577:-
LUAD	cis	rs3020736	0.5	rs6002618	ENSG00000205702.9	CYP2D7	-4.01	7.15e-05	0.0106	-0.15	-0.18	Autism spectrum disorder or schizophrenia;	chr22:42111855	chr22:42140203~42144577:-
LUAD	cis	rs1023500	0.551	rs61665536	ENSG00000205702.9	CYP2D7	-4.01	7.15e-05	0.0106	-0.15	-0.18	Schizophrenia;	chr22:42116609	chr22:42140203~42144577:-
LUAD	cis	rs3020736	0.5	rs2413672	ENSG00000205702.9	CYP2D7	-4.01	7.15e-05	0.0106	-0.15	-0.18	Autism spectrum disorder or schizophrenia;	chr22:42117257	chr22:42140203~42144577:-
LUAD	cis	rs3020736	0.5	rs6002623	ENSG00000205702.9	CYP2D7	-4.01	7.15e-05	0.0106	-0.15	-0.18	Autism spectrum disorder or schizophrenia;	chr22:42117757	chr22:42140203~42144577:-
LUAD	cis	rs3020736	0.5	rs11090076	ENSG00000205702.9	CYP2D7	-4.01	7.15e-05	0.0106	-0.15	-0.18	Autism spectrum disorder or schizophrenia;	chr22:42118186	chr22:42140203~42144577:-
LUAD	cis	rs3020736	0.519	rs5996116	ENSG00000205702.9	CYP2D7	-4.01	7.15e-05	0.0106	-0.15	-0.18	Autism spectrum disorder or schizophrenia;	chr22:42121488	chr22:42140203~42144577:-
LUAD	cis	rs3020736	0.5	rs764481	ENSG00000205702.9	CYP2D7	-4.01	7.15e-05	0.0106	-0.15	-0.18	Autism spectrum disorder or schizophrenia;	chr22:42122422	chr22:42140203~42144577:-
LUAD	cis	rs877819	0.583	rs1904595	ENSG00000228403.1	RP11-563N6.6	4.01	7.15e-05	0.0106	0.18	0.18	Systemic lupus erythematosus;	chr10:48877222	chr10:48878022~48878649:+
LUAD	cis	rs75920871	0.589	rs2306473	ENSG00000254851.1	RP11-109L13.1	-4.01	7.15e-05	0.0106	-0.3	-0.18	Subjective well-being;	chr11:117227236	chr11:117135528~117138582:+
LUAD	cis	rs11673344	0.583	rs7254411	ENSG00000276846.1	CTD-3220F14.3	4.01	7.16e-05	0.0106	0.2	0.18	Obesity-related traits;	chr19:37034969	chr19:37314868~37315620:-
LUAD	cis	rs17122278	1	rs3741325	ENSG00000243431.1	RPL5P30	4.01	7.16e-05	0.0106	0.23	0.18	Total cholesterol levels;	chr11:118535274	chr11:118560690~118561580:+
LUAD	cis	rs7647973	0.58	rs12629759	ENSG00000225399.4	RP11-3B7.1	4.01	7.16e-05	0.0106	0.23	0.18	Menarche (age at onset);	chr3:49199961	chr3:49260085~49261316:+
LUAD	cis	rs9910055	0.529	rs228746	ENSG00000267080.4	ASB16-AS1	4.01	7.16e-05	0.0106	0.17	0.18	Total body bone mineral density;	chr17:44096384	chr17:44175973~44186717:-
LUAD	cis	rs11971779	0.938	rs11981688	ENSG00000273391.1	RP11-634H22.1	4.01	7.16e-05	0.0106	0.21	0.18	Diisocyanate-induced asthma;	chr7:139404149	chr7:139359032~139359566:-
LUAD	cis	rs9894429	1	rs9748176	ENSG00000263853.1	AC139530.1	-4.01	7.16e-05	0.0106	-0.18	-0.18	Eye color traits;	chr17:81617017	chr17:81676001~81676086:+
LUAD	cis	rs10876993	0.715	rs2169987	ENSG00000245651.2	RP11-620J15.2	4.01	7.16e-05	0.0107	0.19	0.18	Celiac disease or Rheumatoid arthritis;	chr12:57618328	chr12:57869835~57896482:-
LUAD	cis	rs9649213	0.593	rs6465665	ENSG00000272950.1	RP11-307C18.1	4.01	7.16e-05	0.0107	0.22	0.18	Prostate cancer (SNP x SNP interaction);	chr7:98304838	chr7:98322853~98323430:+
LUAD	cis	rs12291225	0.585	rs12270374	ENSG00000251991.1	RNU7-49P	4.01	7.17e-05	0.0107	0.2	0.18	Sense of smell;	chr11:14353533	chr11:14478892~14478953:+
LUAD	cis	rs7560272	0.588	rs4852965	ENSG00000163016.8	ALMS1P	-4.01	7.17e-05	0.0107	-0.19	-0.18	Schizophrenia;	chr2:73684042	chr2:73644919~73685576:+
LUAD	cis	rs7551222	0.752	rs10900597	ENSG00000240219.1	RP11-430C7.5	4.01	7.17e-05	0.0107	0.19	0.18	Schizophrenia;	chr1:204553361	chr1:204626775~204629712:+
LUAD	cis	rs7551222	0.752	rs12741351	ENSG00000240219.1	RP11-430C7.5	4.01	7.17e-05	0.0107	0.19	0.18	Schizophrenia;	chr1:204559128	chr1:204626775~204629712:+
LUAD	cis	rs853679	0.517	rs1904841	ENSG00000280107.1	AL022393.9	-4.01	7.17e-05	0.0107	-0.24	-0.18	Depression;	chr6:28140307	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs1904840	ENSG00000280107.1	AL022393.9	-4.01	7.17e-05	0.0107	-0.24	-0.18	Depression;	chr6:28140454	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs9368555	ENSG00000280107.1	AL022393.9	-4.01	7.17e-05	0.0107	-0.24	-0.18	Depression;	chr6:28141189	chr6:28170845~28172521:+
LUAD	cis	rs877356	0.51	rs35798467	ENSG00000250378.1	RP11-119J18.1	-4.01	7.17e-05	0.0107	-0.36	-0.18	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (dichotomous);	chr5:135823318	chr5:135812667~135826582:+
LUAD	cis	rs1401999	1	rs6804242	ENSG00000223882.1	ABCC5-AS1	-4.01	7.17e-05	0.0107	-0.19	-0.18	Anterior chamber depth;	chr3:183941675	chr3:184006338~184011419:+
LUAD	cis	rs5769707	0.967	rs17182154	ENSG00000235111.1	RP1-29C18.8	-4.01	7.18e-05	0.0107	-0.19	-0.18	Monocyte percentage of white cells;Monocyte count;	chr22:49596822	chr22:49612657~49615716:-
LUAD	cis	rs910316	0.935	rs2268620	ENSG00000279594.1	RP11-950C14.10	-4.01	7.18e-05	0.0107	-0.21	-0.18	Height;	chr14:75173700	chr14:75011269~75012851:-
LUAD	cis	rs13434995	0.513	rs62303728	ENSG00000273257.1	RP11-177J6.1	-4.01	7.18e-05	0.0107	-0.24	-0.18	Adiponectin levels;	chr4:55495762	chr4:55387949~55388271:+
LUAD	cis	rs116095464	0.614	rs28736753	ENSG00000248925.1	CTD-2083E4.6	4.01	7.18e-05	0.0107	0.31	0.18	Breast cancer;	chr5:273966	chr5:269858~271516:-
LUAD	cis	rs6540731	0.967	rs2884512	ENSG00000229983.1	RP11-15I11.2	4.01	7.18e-05	0.0107	0.22	0.18	Intelligence (childhood);	chr1:212229848	chr1:212168207~212190259:+
LUAD	cis	rs4713118	0.614	rs9380007	ENSG00000219392.1	RP1-265C24.5	-4.01	7.18e-05	0.0107	-0.22	-0.18	Parkinson's disease;	chr6:27692729	chr6:28115628~28116551:+
LUAD	cis	rs7760535	0.826	rs3777905	ENSG00000230177.1	RP5-1112D6.4	-4.01	7.18e-05	0.0107	-0.16	-0.18	Metabolic traits;	chr6:111549385	chr6:111277932~111278742:+
LUAD	cis	rs42490	0.653	rs40247	ENSG00000251136.7	RP11-37B2.1	-4	7.18e-05	0.0107	-0.19	-0.18	Leprosy;	chr8:89789744	chr8:89609409~89757727:-
LUAD	cis	rs2274273	0.6	rs10134317	ENSG00000258413.1	RP11-665C16.6	-4	7.18e-05	0.0107	-0.24	-0.18	Protein biomarker;	chr14:55326730	chr14:55262767~55272075:-
LUAD	cis	rs853679	0.517	rs9393890	ENSG00000280107.1	AL022393.9	-4	7.19e-05	0.0107	-0.24	-0.18	Depression;	chr6:28096077	chr6:28170845~28172521:+
LUAD	cis	rs9980	0.576	rs889400	ENSG00000226232.7	RP11-419C5.2	4	7.19e-05	0.0107	0.17	0.18	Blood osmolality (transformed sodium);	chr16:69521973	chr16:69976388~69996188:-
LUAD	cis	rs897984	0.683	rs8050330	ENSG00000260911.2	RP11-196G11.2	4	7.19e-05	0.0107	0.16	0.18	Dementia with Lewy bodies;	chr16:30813649	chr16:31043150~31049868:+
LUAD	cis	rs7976269	0.609	rs4402335	ENSG00000257176.2	RP11-996F15.2	-4	7.19e-05	0.0107	-0.19	-0.18	Male-pattern baldness;	chr12:29052836	chr12:29280418~29317848:-
LUAD	cis	rs7968440	0.715	rs7967954	ENSG00000200428.1	Y_RNA	4	7.19e-05	0.0107	0.21	0.18	Fibrinogen;	chr12:50279701	chr12:50743568~50743684:+
LUAD	cis	rs2880765	0.706	rs7172006	ENSG00000259295.5	CSPG4P12	4	7.2e-05	0.0107	0.24	0.18	Coronary artery disease;	chr15:85510128	chr15:85191438~85213905:+
LUAD	cis	rs6601327	1	rs6601327	ENSG00000233609.3	RP11-62H7.2	-4	7.2e-05	0.0107	-0.14	-0.18	Multiple myeloma (hyperdiploidy);	chr8:9538022	chr8:8961200~8979025:+
LUAD	cis	rs6787172	0.811	rs6441204	ENSG00000272087.1	RP11-379F4.7	4	7.2e-05	0.0107	0.19	0.18	Subjective well-being;	chr3:158482424	chr3:158693120~158693768:-
LUAD	cis	rs6787172	0.755	rs6778202	ENSG00000272087.1	RP11-379F4.7	4	7.2e-05	0.0107	0.19	0.18	Subjective well-being;	chr3:158482786	chr3:158693120~158693768:-
LUAD	cis	rs860295	0.557	rs11264372	ENSG00000225855.5	RUSC1-AS1	4	7.2e-05	0.0107	0.13	0.18	Body mass index;	chr1:155443139	chr1:155316863~155324176:-
LUAD	cis	rs11742741	0.605	rs28594809	ENSG00000248874.4	C5orf17	-4	7.2e-05	0.0107	-0.23	-0.18	Educational attainment;	chr5:24057825	chr5:23951348~24178263:+
LUAD	cis	rs2732480	0.577	rs2634681	ENSG00000257735.1	RP11-370I10.6	-4	7.2e-05	0.0107	-0.21	-0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339301	chr12:48350945~48442411:+
LUAD	cis	rs4819052	1	rs2838830	ENSG00000237664.1	LINC00316	-4	7.2e-05	0.0107	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244312	chr21:45338590~45341990:-
LUAD	cis	rs1046491	0.614	rs8082834	ENSG00000264964.1	RP11-888D10.3	4	7.21e-05	0.0107	0.39	0.18	Scarlet fever;	chr18:9324485	chr18:9315194~9334441:-
LUAD	cis	rs189798	1	rs189798	ENSG00000173295.6	FAM86B3P	-4	7.21e-05	0.0107	-0.2	-0.18	Myopia (pathological);	chr8:9133067	chr8:8228595~8244865:+
LUAD	cis	rs911555	0.755	rs12435516	ENSG00000244691.1	RPL10AP1	4	7.21e-05	0.0107	0.24	0.18	Intelligence (multi-trait analysis);	chr14:103488067	chr14:103412119~103412761:-
LUAD	cis	rs4713118	0.662	rs149969	ENSG00000280107.1	AL022393.9	-4	7.21e-05	0.0107	-0.22	-0.18	Parkinson's disease;	chr6:28009959	chr6:28170845~28172521:+
LUAD	cis	rs10463554	0.927	rs7717343	ENSG00000250682.4	LINC00491	4	7.21e-05	0.0107	0.22	0.18	Parkinson's disease;	chr5:103026279	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.963	rs7721530	ENSG00000250682.4	LINC00491	4	7.21e-05	0.0107	0.22	0.18	Parkinson's disease;	chr5:103026488	chr5:102609156~102671559:-
LUAD	cis	rs7121538	0.673	rs3900595	ENSG00000254418.1	RP11-21L19.1	4	7.21e-05	0.0107	0.3	0.18	HDL cholesterol;	chr11:14291783	chr11:14262846~14273691:-
LUAD	cis	rs2235642	0.928	rs9932984	ENSG00000280231.1	LA16c-380F5.3	-4	7.21e-05	0.0107	-0.24	-0.18	Coronary artery disease;	chr16:1555050	chr16:1553655~1554130:-
LUAD	cis	rs5758511	0.508	rs2413667	ENSG00000226450.2	CYP2D8P	4	7.21e-05	0.0107	0.18	0.18	Birth weight;	chr22:42076233	chr22:42149886~42155001:-
LUAD	cis	rs2274273	0.868	rs1572611	ENSG00000258413.1	RP11-665C16.6	-4	7.21e-05	0.0107	-0.23	-0.18	Protein biomarker;	chr14:55367156	chr14:55262767~55272075:-
LUAD	cis	rs2243480	1	rs313832	ENSG00000229886.1	RP5-1132H15.3	4	7.21e-05	0.0107	0.31	0.18	Diabetic kidney disease;	chr7:66085904	chr7:66025126~66031544:-
LUAD	cis	rs9341808	0.718	rs2179842	ENSG00000272129.1	RP11-250B2.6	4	7.21e-05	0.0107	0.22	0.18	Sitting height ratio;	chr6:80269336	chr6:80355424~80356859:+
LUAD	cis	rs6754311	0.773	rs309125	ENSG00000226806.1	AC011893.3	4	7.21e-05	0.0107	0.22	0.18	Mosquito bite size;	chr2:135885985	chr2:135820191~135823087:+
LUAD	cis	rs8180040	0.676	rs13098228	ENSG00000271161.1	BOLA2P2	4	7.22e-05	0.0107	0.17	0.18	Colorectal cancer;	chr3:47096763	chr3:47499841~47500407:+
LUAD	cis	rs858239	0.932	rs858272	ENSG00000230042.1	AK3P3	-4	7.22e-05	0.0107	-0.22	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23129178~23129841:+
LUAD	cis	rs75920871	0.764	rs4938338	ENSG00000254851.1	RP11-109L13.1	-4	7.22e-05	0.0107	-0.39	-0.18	Subjective well-being;	chr11:117102178	chr11:117135528~117138582:+
LUAD	cis	rs1401999	0.714	rs1000002	ENSG00000223882.1	ABCC5-AS1	4	7.22e-05	0.0107	0.19	0.18	Anterior chamber depth;	chr3:183917980	chr3:184006338~184011419:+
LUAD	cis	rs9813712	0.595	rs1453239	ENSG00000228252.7	COL6A4P2	-4	7.22e-05	0.0107	-0.17	-0.18	Response to amphetamines;	chr3:130288915	chr3:130212823~130273806:+
LUAD	cis	rs6471393	0.964	rs2914940	ENSG00000253848.1	RP11-10N23.5	4	7.22e-05	0.0107	0.22	0.18	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93719598	chr8:93741193~93744534:+
LUAD	cis	rs35343117	1	rs35343117	ENSG00000202081.1	RNU6-1280P	4	7.22e-05	0.0107	0.22	0.18	Psoriasis;	chr15:85535884	chr15:85651522~85651628:-
LUAD	cis	rs4819052	0.851	rs1056099	ENSG00000215447.6	BX322557.10	-4	7.22e-05	0.0107	-0.21	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258977	chr21:45288052~45291738:+
LUAD	cis	rs2905347	0.737	rs2010437	ENSG00000232949.1	AC002480.4	4	7.22e-05	0.0107	0.21	0.18	Major depression and alcohol dependence;	chr7:22591561	chr7:22589705~22591622:+
LUAD	cis	rs17767294	0.612	rs12332927	ENSG00000280107.1	AL022393.9	-4	7.22e-05	0.0107	-0.31	-0.18	Parkinson's disease;	chr6:27987337	chr6:28170845~28172521:+
LUAD	cis	rs11216126	1	rs4938307	ENSG00000280143.1	AP000892.6	-4	7.22e-05	0.0107	-0.31	-0.18	HDL cholesterol;	chr11:116733798	chr11:117204967~117210292:+
LUAD	cis	rs17772222	0.74	rs10143744	ENSG00000258983.2	RP11-507K2.2	4	7.22e-05	0.0107	0.2	0.18	Coronary artery calcification;	chr14:88508073	chr14:88499334~88515502:+
LUAD	cis	rs17772222	0.74	rs1999177	ENSG00000258983.2	RP11-507K2.2	4	7.22e-05	0.0107	0.2	0.18	Coronary artery calcification;	chr14:88508298	chr14:88499334~88515502:+
LUAD	cis	rs17772222	0.74	rs1999176	ENSG00000258983.2	RP11-507K2.2	4	7.22e-05	0.0107	0.2	0.18	Coronary artery calcification;	chr14:88508371	chr14:88499334~88515502:+
LUAD	cis	rs17772222	0.74	rs1864746	ENSG00000258983.2	RP11-507K2.2	4	7.22e-05	0.0107	0.2	0.18	Coronary artery calcification;	chr14:88508455	chr14:88499334~88515502:+
LUAD	cis	rs17772222	0.74	rs1864747	ENSG00000258983.2	RP11-507K2.2	4	7.22e-05	0.0107	0.2	0.18	Coronary artery calcification;	chr14:88508523	chr14:88499334~88515502:+
LUAD	cis	rs17772222	0.74	rs7151164	ENSG00000258983.2	RP11-507K2.2	4	7.22e-05	0.0107	0.2	0.18	Coronary artery calcification;	chr14:88509329	chr14:88499334~88515502:+
LUAD	cis	rs17772222	0.74	rs12433026	ENSG00000258983.2	RP11-507K2.2	4	7.22e-05	0.0107	0.2	0.18	Coronary artery calcification;	chr14:88509495	chr14:88499334~88515502:+
LUAD	cis	rs2179367	0.959	rs544947	ENSG00000216906.2	RP11-350J20.9	4	7.22e-05	0.0107	0.22	0.18	Dupuytren's disease;	chr6:149402412	chr6:149904243~149906418:+
LUAD	cis	rs7551222	0.752	rs10793766	ENSG00000240219.1	RP11-430C7.5	4	7.22e-05	0.0107	0.19	0.18	Schizophrenia;	chr1:204580368	chr1:204626775~204629712:+
LUAD	cis	rs10129255	0.957	rs10136560	ENSG00000274576.2	IGHV2-70	4	7.22e-05	0.0107	0.16	0.18	Kawasaki disease;	chr14:106787630	chr14:106770577~106771020:-
LUAD	cis	rs7760535	0.763	rs10457240	ENSG00000266032.1	AL357515.1	4	7.22e-05	0.0107	0.23	0.18	Metabolic traits;	chr6:111527671	chr6:110969773~110969872:-
LUAD	cis	rs2657294	0.895	rs2002023	ENSG00000226051.5	ZNF503-AS1	-4	7.23e-05	0.0107	-0.24	-0.18	Pneumonia;	chr10:75088766	chr10:75269819~75373500:+
LUAD	cis	rs34779708	0.966	rs12775799	ENSG00000271335.4	RP11-324I22.4	4	7.23e-05	0.0107	0.19	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35199336	chr10:35314552~35336401:-
LUAD	cis	rs17122278	1	rs57438673	ENSG00000243431.1	RPL5P30	4	7.23e-05	0.0107	0.22	0.18	Total cholesterol levels;	chr11:118588324	chr11:118560690~118561580:+
LUAD	cis	rs5742933	0.857	rs893784	ENSG00000253559.1	OSGEPL1-AS1	-4	7.23e-05	0.0107	-0.21	-0.18	Ferritin levels;	chr2:189671557	chr2:189762704~189765556:+
LUAD	cis	rs10938353	0.68	rs1371240	ENSG00000273369.1	RP11-700J17.1	4	7.23e-05	0.0107	0.25	0.18	Body mass index;	chr4:44621681	chr4:44693946~44694386:-
LUAD	cis	rs6095360	0.727	rs35334143	ENSG00000222365.1	SNORD12B	-4	7.23e-05	0.0107	-0.21	-0.18	Intelligence (multi-trait analysis);	chr20:48914171	chr20:49280319~49280409:+
LUAD	cis	rs2243480	1	rs34637256	ENSG00000232559.3	GS1-124K5.12	4	7.23e-05	0.0107	0.32	0.18	Diabetic kidney disease;	chr7:65895144	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs35391607	ENSG00000232559.3	GS1-124K5.12	4	7.23e-05	0.0107	0.32	0.18	Diabetic kidney disease;	chr7:65895842	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs13220979	ENSG00000232559.3	GS1-124K5.12	4	7.23e-05	0.0107	0.32	0.18	Diabetic kidney disease;	chr7:65898217	chr7:66554588~66576923:-
LUAD	cis	rs2243480	1	rs34974928	ENSG00000232559.3	GS1-124K5.12	4	7.23e-05	0.0107	0.32	0.18	Diabetic kidney disease;	chr7:65899019	chr7:66554588~66576923:-
LUAD	cis	rs858239	0.6	rs10241208	ENSG00000226816.2	AC005082.12	4	7.23e-05	0.0107	0.23	0.18	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23206013~23208045:+
LUAD	cis	rs6531209	0.784	rs10185277	ENSG00000234378.1	AC098828.2	4	7.23e-05	0.0107	0.22	0.18	Amyotrophic lateral sclerosis (sporadic);	chr2:20139003	chr2:20063856~20106829:-
LUAD	cis	rs9876781	1	rs28824259	ENSG00000229759.1	MRPS18AP1	4	7.24e-05	0.0107	0.17	0.18	Longevity;	chr3:48384185	chr3:48256350~48256938:-
LUAD	cis	rs9876781	1	rs12487542	ENSG00000229759.1	MRPS18AP1	4	7.24e-05	0.0107	0.17	0.18	Longevity;	chr3:48384586	chr3:48256350~48256938:-
LUAD	cis	rs9876781	1	rs73074358	ENSG00000229759.1	MRPS18AP1	4	7.24e-05	0.0107	0.17	0.18	Longevity;	chr3:48385757	chr3:48256350~48256938:-
LUAD	cis	rs9876781	0.967	rs34761139	ENSG00000229759.1	MRPS18AP1	4	7.24e-05	0.0107	0.17	0.18	Longevity;	chr3:48386489	chr3:48256350~48256938:-
LUAD	cis	rs9876781	0.868	rs9875280	ENSG00000229759.1	MRPS18AP1	4	7.24e-05	0.0107	0.17	0.18	Longevity;	chr3:48387420	chr3:48256350~48256938:-
LUAD	cis	rs9876781	1	rs6796491	ENSG00000229759.1	MRPS18AP1	4	7.24e-05	0.0107	0.17	0.18	Longevity;	chr3:48388977	chr3:48256350~48256938:-
LUAD	cis	rs9876781	1	rs9826195	ENSG00000229759.1	MRPS18AP1	4	7.24e-05	0.0107	0.17	0.18	Longevity;	chr3:48392157	chr3:48256350~48256938:-
LUAD	cis	rs9876781	0.967	rs9864815	ENSG00000229759.1	MRPS18AP1	4	7.24e-05	0.0107	0.17	0.18	Longevity;	chr3:48392588	chr3:48256350~48256938:-
LUAD	cis	rs9876781	1	rs9809843	ENSG00000229759.1	MRPS18AP1	4	7.24e-05	0.0107	0.17	0.18	Longevity;	chr3:48392923	chr3:48256350~48256938:-
LUAD	cis	rs12817211	0.502	rs12369049	ENSG00000272368.2	RP4-605O3.4	-4	7.24e-05	0.0107	-0.21	-0.18	Colorectal or endometrial cancer;	chr12:50116679	chr12:50112197~50165618:+
LUAD	cis	rs6001482	0.647	rs8140302	ENSG00000223350.2	IGLV9-49	-4	7.24e-05	0.0107	-0.17	-0.18	Diastolic blood pressure;	chr22:22234843	chr22:22343187~22343732:+
LUAD	cis	rs17301013	0.932	rs6671824	ENSG00000227373.4	RP11-160H22.5	4	7.24e-05	0.0107	0.23	0.18	Systemic lupus erythematosus;	chr1:174603721	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.861	rs6672148	ENSG00000227373.4	RP11-160H22.5	4	7.24e-05	0.0107	0.23	0.18	Systemic lupus erythematosus;	chr1:174604016	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.932	rs10912813	ENSG00000227373.4	RP11-160H22.5	4	7.24e-05	0.0107	0.23	0.18	Systemic lupus erythematosus;	chr1:174607342	chr1:174115300~174160004:-
LUAD	cis	rs6993244	1	rs6993244	ENSG00000253981.4	ALG1L13P	4	7.24e-05	0.0107	0.21	0.18	Mean corpuscular hemoglobin;	chr8:9005549	chr8:8236003~8244667:-
LUAD	cis	rs7714584	1	rs11749391	ENSG00000197083.10	ZNF300P1	4	7.24e-05	0.0107	0.34	0.18	Crohn's disease;	chr5:150849504	chr5:150930645~150946289:-
LUAD	cis	rs11671005	0.651	rs35117909	ENSG00000268543.1	CTD-2619J13.16	-4	7.24e-05	0.0107	-0.27	-0.18	Mean platelet volume;	chr19:58401539	chr19:58418560~58419310:+
LUAD	cis	rs8098244	0.516	rs7236486	ENSG00000264745.1	TTC39C-AS1	4	7.24e-05	0.0107	0.19	0.18	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23685001	chr18:23994213~24015339:-
LUAD	cis	rs812925	0.784	rs7588041	ENSG00000271889.1	RP11-493E12.1	-4	7.24e-05	0.0107	-0.22	-0.18	Immature fraction of reticulocytes;	chr2:61234277	chr2:61151433~61162105:-
LUAD	cis	rs11671005	0.735	rs11084544	ENSG00000268543.1	CTD-2619J13.16	-4	7.25e-05	0.0108	-0.25	-0.18	Mean platelet volume;	chr19:58428760	chr19:58418560~58419310:+
LUAD	cis	rs2153535	0.518	rs1328859	ENSG00000230939.1	RP11-314C16.1	-4	7.25e-05	0.0108	-0.21	-0.18	Motion sickness;	chr6:8562582	chr6:8784178~8785445:+
LUAD	cis	rs9500256	0.655	rs12191043	ENSG00000272316.1	XXbac-BPGBPG55C20.2	4	7.25e-05	0.0108	0.15	0.18	Eosinophilic esophagitis (pediatric);	chr6:58020205	chr6:57908560~57913911:-
LUAD	cis	rs6840360	0.837	rs4696294	ENSG00000270265.1	RP11-731D1.4	4	7.25e-05	0.0108	0.18	0.18	Intelligence (multi-trait analysis);	chr4:151791937	chr4:151333775~151353224:-
LUAD	cis	rs1023500	0.505	rs2143139	ENSG00000273366.1	CTA-989H11.1	-4	7.25e-05	0.0108	-0.21	-0.18	Schizophrenia;	chr22:42218395	chr22:42278188~42278846:+
LUAD	cis	rs7201929	1	rs8061877	ENSG00000251417.2	RP11-1348G14.4	4	7.25e-05	0.0108	0.21	0.18	QT interval;	chr16:28845498	chr16:28802743~28817828:+
LUAD	cis	rs7512552	0.839	rs1694369	ENSG00000275557.1	RP11-353N4.6	4	7.25e-05	0.0108	0.2	0.18	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150378625	chr1:149607765~149612402:+
LUAD	cis	rs6088580	0.634	rs6059867	ENSG00000276073.1	RP5-1125A11.7	-4	7.25e-05	0.0108	-0.18	-0.18	Glomerular filtration rate (creatinine);	chr20:34490298	chr20:33985617~33988989:-
LUAD	cis	rs2274273	0.87	rs1109170	ENSG00000259318.1	RP11-454L9.2	4	7.26e-05	0.0108	0.16	0.18	Protein biomarker;	chr14:55319070	chr14:55394940~55395233:-
LUAD	cis	rs2274273	0.837	rs10141483	ENSG00000259318.1	RP11-454L9.2	4	7.26e-05	0.0108	0.16	0.18	Protein biomarker;	chr14:55320153	chr14:55394940~55395233:-
LUAD	cis	rs2274273	0.837	rs10131913	ENSG00000259318.1	RP11-454L9.2	4	7.26e-05	0.0108	0.16	0.18	Protein biomarker;	chr14:55320702	chr14:55394940~55395233:-
LUAD	cis	rs6688613	0.579	rs4657609	ENSG00000225171.2	DUTP6	-4	7.26e-05	0.0108	-0.22	-0.18	Refractive astigmatism;	chr1:166869937	chr1:166868748~166869209:+
LUAD	cis	rs2688608	0.934	rs2675679	ENSG00000271816.1	BMS1P4	4	7.26e-05	0.0108	0.15	0.18	Inflammatory bowel disease;	chr10:73898823	chr10:73699151~73730487:-
LUAD	cis	rs75920871	0.61	rs888246	ENSG00000254851.1	RP11-109L13.1	-4	7.26e-05	0.0108	-0.4	-0.18	Subjective well-being;	chr11:116853516	chr11:117135528~117138582:+
LUAD	cis	rs2836974	0.584	rs34436313	ENSG00000232608.1	TIMM9P2	4	7.26e-05	0.0108	0.21	0.18	Cognitive function;	chr21:39313320	chr21:39216624~39217506:+
LUAD	cis	rs7976269	0.609	rs2082943	ENSG00000257176.2	RP11-996F15.2	-4	7.26e-05	0.0108	-0.19	-0.18	Male-pattern baldness;	chr12:29050251	chr12:29280418~29317848:-
LUAD	cis	rs10463554	0.927	rs40061	ENSG00000250682.4	LINC00491	4	7.26e-05	0.0108	0.22	0.18	Parkinson's disease;	chr5:103067412	chr5:102609156~102671559:-
LUAD	cis	rs6728642	1	rs73959416	ENSG00000230606.9	AC159540.1	4	7.26e-05	0.0108	0.28	0.18	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96938781	chr2:97416165~97433527:-
LUAD	cis	rs1476587	0.573	rs13236712	ENSG00000224046.1	AC005076.5	4	7.26e-05	0.0108	0.22	0.18	Brachial circumference;	chr7:87084647	chr7:87151423~87152420:-
LUAD	cis	rs12291225	0.585	rs10832246	ENSG00000251991.1	RNU7-49P	4	7.26e-05	0.0108	0.2	0.18	Sense of smell;	chr11:14359282	chr11:14478892~14478953:+
LUAD	cis	rs763121	0.853	rs8142098	ENSG00000228274.3	RP3-508I15.9	-4	7.26e-05	0.0108	-0.18	-0.18	Menopause (age at onset);	chr22:38662752	chr22:38667585~38681820:-
LUAD	cis	rs3096299	0.967	rs28644774	ENSG00000182376.2	RP5-1142A6.8	4	7.26e-05	0.0108	0.18	0.18	Multiple myeloma (IgH translocation);	chr16:89405773	chr16:88742767~88745748:+
LUAD	cis	rs116139393	0.571	rs3801035	ENSG00000187953.9	PMS2CL	-4	7.26e-05	0.0108	-0.28	-0.18	Alzheimer's disease (APOE e4 interaction);	chr7:6695903	chr7:6710128~6753862:+
LUAD	cis	rs116139393	0.634	rs17789828	ENSG00000187953.9	PMS2CL	-4	7.26e-05	0.0108	-0.28	-0.18	Alzheimer's disease (APOE e4 interaction);	chr7:6699006	chr7:6710128~6753862:+
LUAD	cis	rs9467773	1	rs9357010	ENSG00000241549.7	GUSBP2	4	7.27e-05	0.0108	0.19	0.18	Intelligence (multi-trait analysis);	chr6:26527717	chr6:26871484~26956554:-
LUAD	cis	rs28386778	0.933	rs2665801	ENSG00000240280.5	TCAM1P	-4	7.27e-05	0.0108	-0.2	-0.18	Prudent dietary pattern;	chr17:63874740	chr17:63849292~63864379:+
LUAD	cis	rs28386778	0.901	rs2854194	ENSG00000240280.5	TCAM1P	-4	7.27e-05	0.0108	-0.2	-0.18	Prudent dietary pattern;	chr17:63874750	chr17:63849292~63864379:+
LUAD	cis	rs2749592	0.55	rs7917262	ENSG00000263064.2	RP11-291L22.7	-4	7.27e-05	0.0108	-0.19	-0.18	Age-related hearing impairment (SNP x SNP interaction);	chr10:37585674	chr10:38448689~38448949:+
LUAD	cis	rs7829975	0.514	rs2979151	ENSG00000233609.3	RP11-62H7.2	-4	7.27e-05	0.0108	-0.15	-0.18	Mood instability;	chr8:8400509	chr8:8961200~8979025:+
LUAD	cis	rs9309473	0.95	rs1052162	ENSG00000230002.2	ALMS1-IT1	-4	7.27e-05	0.0108	-0.22	-0.18	Metabolite levels;	chr2:73602245	chr2:73456764~73459484:+
LUAD	cis	rs9287719	0.967	rs12622765	ENSG00000243819.4	RN7SL832P	4	7.27e-05	0.0108	0.19	0.18	Prostate cancer;	chr2:10588205	chr2:10690344~10692099:+
LUAD	cis	rs9549260	0.755	rs2755219	ENSG00000229456.1	RLIMP1	4	7.28e-05	0.0108	0.19	0.18	Red blood cell count;	chr13:40595488	chr13:40618738~40621348:+
LUAD	cis	rs780096	0.546	rs35073769	ENSG00000234072.1	AC074117.10	-4	7.28e-05	0.0108	-0.14	-0.18	Total body bone mineral density;	chr2:27508509	chr2:27356246~27367622:+
LUAD	cis	rs17301013	0.896	rs6425287	ENSG00000227373.4	RP11-160H22.5	4	7.28e-05	0.0108	0.23	0.18	Systemic lupus erythematosus;	chr1:174566264	chr1:174115300~174160004:-
LUAD	cis	rs526231	0.747	rs434830	ENSG00000175749.11	EIF3KP1	4	7.28e-05	0.0108	0.24	0.18	Primary biliary cholangitis;	chr5:103263605	chr5:103032376~103033031:+
LUAD	cis	rs7302981	0.692	rs1979702	ENSG00000272368.2	RP4-605O3.4	-4	7.28e-05	0.0108	-0.2	-0.18	Systolic blood pressure;	chr12:50068864	chr12:50112197~50165618:+
LUAD	cis	rs853679	0.55	rs1233701	ENSG00000226314.6	ZNF192P1	4	7.28e-05	0.0108	0.23	0.18	Depression;	chr6:28200948	chr6:28161781~28169594:+
LUAD	cis	rs11668609	0.81	rs17000162	ENSG00000268442.1	CTD-2027I19.2	4	7.28e-05	0.0108	0.26	0.18	Response to taxane treatment (docetaxel);	chr19:24185347	chr19:24162370~24163425:-
LUAD	cis	rs9876781	1	rs1563736	ENSG00000229759.1	MRPS18AP1	4	7.28e-05	0.0108	0.17	0.18	Longevity;	chr3:48395329	chr3:48256350~48256938:-
LUAD	cis	rs7208859	0.623	rs73263788	ENSG00000266490.1	CTD-2349P21.9	4	7.28e-05	0.0108	0.26	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889472	chr17:30792372~30792833:+
LUAD	cis	rs8031584	1	rs35811129	ENSG00000259845.1	HERC2P10	4	7.29e-05	0.0108	0.23	0.18	Huntington's disease progression;	chr15:30949143	chr15:30815271~30844153:+
LUAD	cis	rs13113518	0.783	rs12510400	ENSG00000272969.1	RP11-528I4.2	4	7.29e-05	0.0108	0.19	0.18	Height;	chr4:55577294	chr4:55547112~55547889:+
LUAD	cis	rs6878284	0.818	rs13358778	ENSG00000250682.4	LINC00491	4	7.29e-05	0.0108	0.25	0.18	Schizophrenia;	chr5:102410273	chr5:102609156~102671559:-
LUAD	cis	rs17695224	0.545	rs10406732	ENSG00000269483.1	AC006272.1	4	7.29e-05	0.0108	0.2	0.18	HDL cholesterol;HDL cholesterol levels;	chr19:51833974	chr19:51839924~51843324:-
LUAD	cis	rs17695224	0.527	rs2903546	ENSG00000269483.1	AC006272.1	4	7.29e-05	0.0108	0.2	0.18	HDL cholesterol;HDL cholesterol levels;	chr19:51834082	chr19:51839924~51843324:-
LUAD	cis	rs17695224	0.527	rs7250063	ENSG00000269483.1	AC006272.1	4	7.29e-05	0.0108	0.2	0.18	HDL cholesterol;HDL cholesterol levels;	chr19:51834447	chr19:51839924~51843324:-
LUAD	cis	rs4554975	0.624	rs2263486	ENSG00000274723.1	RP11-618L22.1	4	7.29e-05	0.0108	0.21	0.18	Metabolite levels (small molecules and protein measures);	chr12:46858534	chr12:46970504~46972155:+
LUAD	cis	rs2286492	1	rs2286492	ENSG00000226329.2	AC005682.6	4	7.29e-05	0.0108	0.32	0.18	Bipolar disorder;	chr7:22945391	chr7:22863874~22881350:-
LUAD	cis	rs13108904	0.557	rs1250086	ENSG00000196810.4	CTBP1-AS2	-4	7.29e-05	0.0108	-0.23	-0.18	Obesity-related traits;	chr4:1254263	chr4:1249300~1288291:+
LUAD	cis	rs4845570	1	rs4845356	ENSG00000203288.3	RP11-98D18.9	4	7.29e-05	0.0108	0.26	0.18	Coronary artery disease;	chr1:151786747	chr1:151790804~151794402:+
LUAD	cis	rs6840360	0.806	rs11932383	ENSG00000270265.1	RP11-731D1.4	4	7.29e-05	0.0108	0.18	0.18	Intelligence (multi-trait analysis);	chr4:151794984	chr4:151333775~151353224:-
LUAD	cis	rs7216064	0.589	rs8072723	ENSG00000265055.1	AC145343.2	-4	7.29e-05	0.0108	-0.17	-0.18	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:68060854	chr17:68096046~68101474:-
LUAD	cis	rs4713118	0.869	rs6901520	ENSG00000280107.1	AL022393.9	-4	7.29e-05	0.0108	-0.23	-0.18	Parkinson's disease;	chr6:27746796	chr6:28170845~28172521:+
LUAD	cis	rs1799955	1	rs11571725	ENSG00000215515.2	IFIT1P1	4	7.29e-05	0.0108	0.26	0.18	LDL cholesterol levels;	chr13:32364744	chr13:32384660~32386108:+
LUAD	cis	rs7893279	0.505	rs4748496	ENSG00000225527.1	RP11-383B4.4	4	7.3e-05	0.0108	0.26	0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18618028	chr10:18531849~18533336:-
LUAD	cis	rs5758511	0.573	rs1883205	ENSG00000227370.1	RP4-669P10.19	-4	7.3e-05	0.0108	-0.18	-0.18	Birth weight;	chr22:41847016	chr22:42132543~42132998:+
LUAD	cis	rs10751647	0.804	rs3809112	ENSG00000254910.1	RP11-326C3.7	4	7.3e-05	0.0108	0.2	0.18	Monocyte count;	chr11:307036	chr11:310139~311141:-
LUAD	cis	rs72772090	0.908	rs11750510	ENSG00000248734.2	CTD-2260A17.1	-4	7.3e-05	0.0108	-0.26	-0.18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96706391	chr5:96784777~96785999:+
LUAD	cis	rs2014572	0.967	rs10418480	ENSG00000268379.1	CTC-360J11.4	4	7.3e-05	0.0108	0.21	0.18	Hyperactive-impulsive symptoms;	chr19:57243687	chr19:57175233~57177921:+
LUAD	cis	rs9928842	0.771	rs4888363	ENSG00000259972.2	AC009120.6	-4	7.3e-05	0.0108	-0.13	-0.18	Alcoholic chronic pancreatitis;	chr16:75243446	chr16:74305127~74335346:-
LUAD	cis	rs3812049	0.784	rs6889311	ENSG00000245937.6	LINC01184	4	7.3e-05	0.0108	0.26	0.18	Lymphocyte counts;Red cell distribution width;	chr5:128095593	chr5:127940426~128083172:-
LUAD	cis	rs3812049	0.826	rs2409110	ENSG00000245937.6	LINC01184	4	7.3e-05	0.0108	0.26	0.18	Lymphocyte counts;Red cell distribution width;	chr5:128097355	chr5:127940426~128083172:-
LUAD	cis	rs4819052	0.851	rs2838858	ENSG00000223768.1	LINC00205	-4	7.3e-05	0.0108	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261178	chr21:45293285~45297354:+
LUAD	cis	rs801193	0.742	rs9969300	ENSG00000236529.1	RP13-254B10.1	-4	7.3e-05	0.0108	-0.18	-0.18	Aortic root size;	chr7:66316659	chr7:65840212~65840596:+
LUAD	cis	rs7061710	0.711	rs10489229	ENSG00000271811.1	RP1-79C4.4	-4	7.31e-05	0.0108	-0.27	-0.18	Blood metabolite levels;	chr1:171150686	chr1:170667381~170669425:+
LUAD	cis	rs3849150	0.95	rs17699605	ENSG00000235939.1	RP11-123B3.2	4	7.31e-05	0.0108	0.27	0.18	Subclinical atherosclerosis traits (other);	chr10:48878899	chr10:49419277~49472903:+
LUAD	cis	rs12999542	0.706	rs6756407	ENSG00000234389.1	AC007278.3	4	7.31e-05	0.0108	0.29	0.18	Serum protein levels (sST2);	chr2:102419641	chr2:102438713~102440475:+
LUAD	cis	rs2243480	1	rs4149468	ENSG00000229886.1	RP5-1132H15.3	4	7.31e-05	0.0108	0.31	0.18	Diabetic kidney disease;	chr7:66360703	chr7:66025126~66031544:-
LUAD	cis	rs2929278	0.617	rs693919	ENSG00000166763.7	STRCP1	-4	7.31e-05	0.0108	-0.21	-0.18	Schizophrenia;	chr15:43810130	chr15:43699488~43718184:-
LUAD	cis	rs9860428	0.844	rs11711087	ENSG00000242770.2	RP11-180K7.1	4	7.31e-05	0.0108	0.19	0.18	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112868702	chr3:112802478~112812819:+
LUAD	cis	rs9890032	1	rs3764419	ENSG00000266490.1	CTD-2349P21.9	4	7.31e-05	0.0108	0.16	0.18	Hip circumference adjusted for BMI;	chr17:30837005	chr17:30792372~30792833:+
LUAD	cis	rs404005	1	rs404005	ENSG00000227028.5	SLC8A1-AS1	4	7.31e-05	0.0108	0.23	0.18	HIV-associated dementia;	chr2:40168938	chr2:39786453~40255209:+
LUAD	cis	rs7208859	0.623	rs426434	ENSG00000280069.1	CTD-2349P21.3	-4	7.31e-05	0.0108	-0.24	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30598335	chr17:30738182~30740275:+
LUAD	cis	rs6496932	0.663	rs2062238	ENSG00000202081.1	RNU6-1280P	-4	7.32e-05	0.0108	-0.23	-0.18	Central corneal thickness;Corneal structure;	chr15:85376002	chr15:85651522~85651628:-
LUAD	cis	rs853679	0.517	rs4713135	ENSG00000226314.6	ZNF192P1	-4	7.32e-05	0.0108	-0.24	-0.18	Depression;	chr6:28071808	chr6:28161781~28169594:+
LUAD	cis	rs3018712	0.532	rs2513282	ENSG00000212093.1	AP000807.1	-4	7.32e-05	0.0108	-0.24	-0.18	Total body bone mineral density;	chr11:68650843	chr11:68506083~68506166:-
LUAD	cis	rs7200786	0.565	rs10852330	ENSG00000274038.1	RP11-66H6.4	-4	7.32e-05	0.0108	-0.23	-0.18	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11122201	chr16:11056556~11057034:+
LUAD	cis	rs6121246	0.609	rs6060983	ENSG00000230613.1	HM13-AS1	4	7.32e-05	0.0108	0.23	0.18	Mean corpuscular hemoglobin;	chr20:31833121	chr20:31567707~31573263:-
LUAD	cis	rs853679	0.607	rs35749575	ENSG00000219392.1	RP1-265C24.5	-4	7.32e-05	0.0108	-0.4	-0.18	Depression;	chr6:28147040	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.607	rs72846780	ENSG00000219392.1	RP1-265C24.5	-4	7.32e-05	0.0108	-0.4	-0.18	Depression;	chr6:28151277	chr6:28115628~28116551:+
LUAD	cis	rs13434995	0.513	rs1021307	ENSG00000273257.1	RP11-177J6.1	4	7.32e-05	0.0108	0.24	0.18	Adiponectin levels;	chr4:55529547	chr4:55387949~55388271:+
LUAD	cis	rs9970334	0.596	rs709209	ENSG00000225077.2	LINC00337	-4	7.32e-05	0.0108	-0.18	-0.18	Resting heart rate;	chr1:6218354	chr1:6236240~6239444:+
LUAD	cis	rs4819052	0.851	rs2236446	ENSG00000215447.6	BX322557.10	-4	7.32e-05	0.0108	-0.21	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259070	chr21:45288052~45291738:+
LUAD	cis	rs10859871	0.536	rs3751272	ENSG00000216306.3	KRT19P2	4	7.32e-05	0.0108	0.23	0.18	Endometriosis;	chr12:95257317	chr12:94834147~94835158:+
LUAD	cis	rs4713118	0.869	rs4713121	ENSG00000280107.1	AL022393.9	-4	7.32e-05	0.0109	-0.23	-0.18	Parkinson's disease;	chr6:27754285	chr6:28170845~28172521:+
LUAD	cis	rs8062405	0.755	rs4787456	ENSG00000251417.2	RP11-1348G14.4	-4	7.32e-05	0.0109	-0.18	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28802743~28817828:+
LUAD	cis	rs8062405	0.755	rs4788078	ENSG00000251417.2	RP11-1348G14.4	-4	7.32e-05	0.0109	-0.18	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28802743~28817828:+
LUAD	cis	rs4356203	0.519	rs214097	ENSG00000272034.1	SNORD14A	-4	7.33e-05	0.0109	-0.16	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17269952	chr11:17074654~17074744:-
LUAD	cis	rs4784934	0.531	rs2042402	ENSG00000260186.4	RP11-481J2.2	4	7.33e-05	0.0109	0.21	0.18	QT interval;	chr16:58430011	chr16:58421326~58462470:+
LUAD	cis	rs6452524	0.618	rs10462394	ENSG00000281327.1	LINC01338	4	7.33e-05	0.0109	0.19	0.18	Hypertension (SNP x SNP interaction);	chr5:83058735	chr5:82850864~82859836:-
LUAD	cis	rs910316	0.819	rs175461	ENSG00000279594.1	RP11-950C14.10	-4	7.33e-05	0.0109	-0.21	-0.18	Height;	chr14:75115113	chr14:75011269~75012851:-
LUAD	cis	rs12073359	0.909	rs72692870	ENSG00000223945.2	RP11-458I7.1	-4	7.34e-05	0.0109	-0.26	-0.18	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150047081	chr1:150053864~150055034:+
LUAD	cis	rs4604732	0.642	rs10802514	ENSG00000227135.1	GCSAML-AS1	-4	7.34e-05	0.0109	-0.25	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247474447	chr1:247524679~247526752:-
LUAD	cis	rs2638953	0.779	rs61920241	ENSG00000278733.1	RP11-425D17.1	-4	7.34e-05	0.0109	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28195184	chr12:28185625~28186190:-
LUAD	cis	rs2179367	0.919	rs4897124	ENSG00000216906.2	RP11-350J20.9	4	7.34e-05	0.0109	0.22	0.18	Dupuytren's disease;	chr6:149442073	chr6:149904243~149906418:+
LUAD	cis	rs4601821	0.895	rs1055075	ENSG00000270179.1	RP11-159N11.4	-4	7.34e-05	0.0109	-0.19	-0.18	Alcoholic chronic pancreatitis;	chr11:113368790	chr11:113368478~113369117:+
LUAD	cis	rs8040855	0.627	rs4980357	ENSG00000259774.1	RP11-182J1.13	4	7.34e-05	0.0109	0.23	0.18	Bulimia nervosa;	chr15:85064878	chr15:84422618~84425882:+
LUAD	cis	rs8040855	0.627	rs4980356	ENSG00000259774.1	RP11-182J1.13	4	7.34e-05	0.0109	0.23	0.18	Bulimia nervosa;	chr15:85064901	chr15:84422618~84425882:+
LUAD	cis	rs1023500	0.505	rs134899	ENSG00000205702.9	CYP2D7	4	7.34e-05	0.0109	0.14	0.18	Schizophrenia;	chr22:42287024	chr22:42140203~42144577:-
LUAD	cis	rs2348418	1	rs2348418	ENSG00000247934.4	RP11-967K21.1	4	7.34e-05	0.0109	0.21	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28536581	chr12:28163298~28190738:-
LUAD	cis	rs4819052	1	rs733739	ENSG00000215447.6	BX322557.10	-4	7.35e-05	0.0109	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246295	chr21:45288052~45291738:+
LUAD	cis	rs17685	0.753	rs4728586	ENSG00000280388.1	RP11-229D13.3	-4	7.35e-05	0.0109	-0.17	-0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76173551	chr7:76043977~76045963:-
LUAD	cis	rs10463554	0.963	rs257294	ENSG00000250682.4	LINC00491	4	7.35e-05	0.0109	0.22	0.18	Parkinson's disease;	chr5:103131563	chr5:102609156~102671559:-
LUAD	cis	rs7590268	0.697	rs11124938	ENSG00000279873.2	LINC01126	4	7.35e-05	0.0109	0.18	0.18	Orofacial clefts;	chr2:43470836	chr2:43227210~43228855:+
LUAD	cis	rs8028182	0.636	rs11637068	ENSG00000260269.4	CTD-2323K18.1	-4	7.35e-05	0.0109	-0.25	-0.18	Sudden cardiac arrest;	chr15:75450661	chr15:75527150~75601205:-
LUAD	cis	rs73193808	1	rs8127464	ENSG00000215533.7	LINC00189	-4	7.35e-05	0.0109	-0.26	-0.18	Coronary artery disease;	chr21:29187381	chr21:29193480~29288205:+
LUAD	cis	rs17597773	0.674	rs12117818	ENSG00000272823.1	RP11-295M18.6	-4	7.35e-05	0.0109	-0.24	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220828141	chr1:220828676~220829211:-
LUAD	cis	rs7208859	0.623	rs11651857	ENSG00000280069.1	CTD-2349P21.3	-4	7.35e-05	0.0109	-0.25	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30599344	chr17:30738182~30740275:+
LUAD	cis	rs9803723	0.648	rs17370926	ENSG00000261349.1	RP3-465N24.5	-4	7.35e-05	0.0109	-0.21	-0.18	Male-pattern baldness;	chr1:25131248	chr1:25266102~25267136:-
LUAD	cis	rs7623788	1	rs7623788	ENSG00000238755.3	RP11-23D24.2	4	7.35e-05	0.0109	0.32	0.18	IgG glycosylation;	chr3:153632327	chr3:153384934~153980186:-
LUAD	cis	rs7208859	0.673	rs11650305	ENSG00000266490.1	CTD-2349P21.9	4	7.35e-05	0.0109	0.26	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902343	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs11654914	ENSG00000266490.1	CTD-2349P21.9	4	7.35e-05	0.0109	0.26	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902406	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs9914271	ENSG00000266490.1	CTD-2349P21.9	4	7.35e-05	0.0109	0.26	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905607	chr17:30792372~30792833:+
LUAD	cis	rs17122278	1	rs11216887	ENSG00000243431.1	RPL5P30	4	7.35e-05	0.0109	0.22	0.18	Total cholesterol levels;	chr11:118550021	chr11:118560690~118561580:+
LUAD	cis	rs9309473	0.519	rs2421584	ENSG00000163016.8	ALMS1P	-4	7.36e-05	0.0109	-0.19	-0.18	Metabolite levels;	chr2:73671725	chr2:73644919~73685576:+
LUAD	cis	rs10129255	0.5	rs2105989	ENSG00000232216.1	IGHV3-43	4	7.36e-05	0.0109	0.14	0.18	Kawasaki disease;	chr14:106682199	chr14:106470264~106470800:-
LUAD	cis	rs6687821	0.515	rs1970607	ENSG00000261737.1	RP4-612B15.3	-4	7.36e-05	0.0109	-0.24	-0.18	Yeast infection;	chr1:86962619	chr1:86703502~86704462:-
LUAD	cis	rs6479891	1	rs12413415	ENSG00000232075.1	MRPL35P2	4	7.36e-05	0.0109	0.29	0.18	Arthritis (juvenile idiopathic);	chr10:63159751	chr10:63634317~63634827:-
LUAD	cis	rs6689263	1	rs112660177	ENSG00000117242.7	PINK1-AS	4	7.36e-05	0.0109	0.38	0.18	Intelligence (multi-trait analysis);	chr1:20469726	chr1:20642657~20652193:-
LUAD	cis	rs2274273	0.967	rs2340931	ENSG00000259318.1	RP11-454L9.2	4	7.36e-05	0.0109	0.16	0.18	Protein biomarker;	chr14:55150219	chr14:55394940~55395233:-
LUAD	cis	rs2015599	0.549	rs7134187	ENSG00000257176.2	RP11-996F15.2	-4	7.36e-05	0.0109	-0.18	-0.18	Platelet count;Mean platelet volume;	chr12:29294113	chr12:29280418~29317848:-
LUAD	cis	rs916888	0.773	rs199535	ENSG00000232300.1	FAM215B	4	7.36e-05	0.0109	0.27	0.18	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46558830~46562795:-
LUAD	cis	rs67478160	0.619	rs28698555	ENSG00000272533.1	SNORA28	-4	7.36e-05	0.0109	-0.19	-0.18	Schizophrenia;	chr14:103850149	chr14:103337849~103337974:+
LUAD	cis	rs6951245	1	rs75488469	ENSG00000199023.2	MIR339	-4	7.36e-05	0.0109	-0.33	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1062486	chr7:1022935~1023045:-
LUAD	cis	rs4691139	0.658	rs1401398	ENSG00000248632.1	RP11-366M4.11	4	7.36e-05	0.0109	0.22	0.18	Ovarian cancer in BRCA1 mutation carriers;	chr4:165006580	chr4:164968587~164970002:-
LUAD	cis	rs2243480	1	rs431318	ENSG00000229886.1	RP5-1132H15.3	4	7.36e-05	0.0109	0.31	0.18	Diabetic kidney disease;	chr7:66046610	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs313803	ENSG00000229886.1	RP5-1132H15.3	4	7.36e-05	0.0109	0.31	0.18	Diabetic kidney disease;	chr7:66049744	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs313802	ENSG00000229886.1	RP5-1132H15.3	4	7.36e-05	0.0109	0.31	0.18	Diabetic kidney disease;	chr7:66051386	chr7:66025126~66031544:-
LUAD	cis	rs2243480	0.803	rs403089	ENSG00000229886.1	RP5-1132H15.3	4	7.36e-05	0.0109	0.31	0.18	Diabetic kidney disease;	chr7:66052736	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs458291	ENSG00000229886.1	RP5-1132H15.3	4	7.36e-05	0.0109	0.31	0.18	Diabetic kidney disease;	chr7:66055492	chr7:66025126~66031544:-
LUAD	cis	rs2243480	1	rs466983	ENSG00000229886.1	RP5-1132H15.3	4	7.36e-05	0.0109	0.31	0.18	Diabetic kidney disease;	chr7:66055509	chr7:66025126~66031544:-
LUAD	cis	rs4660214	0.666	rs2275188	ENSG00000182109.6	RP11-69E11.4	-4	7.36e-05	0.0109	-0.19	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39283249	chr1:39522280~39546187:-
LUAD	cis	rs11971779	0.941	rs74299967	ENSG00000273391.1	RP11-634H22.1	4	7.36e-05	0.0109	0.21	0.18	Diisocyanate-induced asthma;	chr7:139359023	chr7:139359032~139359566:-
LUAD	cis	rs7208859	0.623	rs9895785	ENSG00000280069.1	CTD-2349P21.3	4	7.36e-05	0.0109	0.25	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30738182~30740275:+
LUAD	cis	rs651907	0.557	rs12629658	ENSG00000244119.1	PDCL3P4	4	7.36e-05	0.0109	0.18	0.18	Colorectal cancer;	chr3:101637691	chr3:101712472~101713191:+
LUAD	cis	rs17772222	0.917	rs10143767	ENSG00000258789.1	RP11-507K2.3	-4	7.36e-05	0.0109	-0.24	-0.18	Coronary artery calcification;	chr14:88514867	chr14:88551597~88552493:+
LUAD	cis	rs7674212	0.512	rs2720462	ENSG00000251288.2	RP11-10L12.2	-4	7.36e-05	0.0109	-0.22	-0.18	Type 2 diabetes;	chr4:103135053	chr4:102751401~102752641:+
LUAD	cis	rs7551222	0.752	rs1380576	ENSG00000240219.1	RP11-430C7.5	4	7.37e-05	0.0109	0.19	0.18	Schizophrenia;	chr1:204519150	chr1:204626775~204629712:+
LUAD	cis	rs2562456	0.833	rs2650801	ENSG00000268081.1	RP11-678G14.2	4	7.37e-05	0.0109	0.26	0.18	Pain;	chr19:21452553	chr19:21554640~21569237:-
LUAD	cis	rs1008375	1	rs917665	ENSG00000249502.1	AC006160.5	4	7.37e-05	0.0109	0.17	0.18	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17666881	chr4:17587467~17614571:-
LUAD	cis	rs2354432	0.556	rs66501488	ENSG00000237188.3	RP11-337C18.8	4	7.37e-05	0.0109	0.33	0.18	Mitochondrial DNA levels;	chr1:147382270	chr1:147172771~147211568:+
LUAD	cis	rs2354432	0.505	rs7551766	ENSG00000237188.3	RP11-337C18.8	4	7.37e-05	0.0109	0.33	0.18	Mitochondrial DNA levels;	chr1:147387237	chr1:147172771~147211568:+
LUAD	cis	rs7520050	0.966	rs10890361	ENSG00000227857.2	RP4-533D7.5	4	7.37e-05	0.0109	0.19	0.18	Reticulocyte count;Red blood cell count;	chr1:45880562	chr1:46134531~46139081:+
LUAD	cis	rs12122100	0.507	rs1925343	ENSG00000227242.3	NBPF13P	-4	7.37e-05	0.0109	-0.21	-0.18	HIV-1 control;	chr1:147033981	chr1:147021320~147124525:-
LUAD	cis	rs7826238	0.517	rs35144760	ENSG00000233609.3	RP11-62H7.2	-4	7.37e-05	0.0109	-0.15	-0.18	Systolic blood pressure;	chr8:8504213	chr8:8961200~8979025:+
LUAD	cis	rs7551222	0.716	rs10900601	ENSG00000236779.1	RP11-430C7.2	-4	7.38e-05	0.0109	-0.24	-0.18	Schizophrenia;	chr1:204602922	chr1:204528845~204529692:-
LUAD	cis	rs17301013	0.932	rs6683602	ENSG00000227373.4	RP11-160H22.5	4	7.38e-05	0.0109	0.23	0.18	Systemic lupus erythematosus;	chr1:174617615	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.932	rs6696197	ENSG00000227373.4	RP11-160H22.5	4	7.38e-05	0.0109	0.23	0.18	Systemic lupus erythematosus;	chr1:174617860	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.73	rs12060177	ENSG00000227373.4	RP11-160H22.5	4	7.38e-05	0.0109	0.23	0.18	Systemic lupus erythematosus;	chr1:174618545	chr1:174115300~174160004:-
LUAD	cis	rs4266144	0.926	rs4368453	ENSG00000244515.1	KRT18P34	-4	7.38e-05	0.0109	-0.23	-0.18	Coronary artery disease;	chr3:157134352	chr3:157162663~157163932:-
LUAD	cis	rs8002861	0.87	rs4942251	ENSG00000274001.1	RP11-5G9.5	4	7.38e-05	0.0109	0.19	0.18	Leprosy;	chr13:43865912	chr13:43877715~43878163:-
LUAD	cis	rs4934494	0.768	rs12572608	ENSG00000240996.1	RP11-80H5.7	4	7.38e-05	0.0109	0.24	0.18	Red blood cell count;	chr10:89647170	chr10:89694295~89697928:-
LUAD	cis	rs4268898	0.662	rs12052954	ENSG00000242628.4	AC009228.1	-4	7.38e-05	0.0109	-0.25	-0.18	Asthma;	chr2:24202751	chr2:24214381~24221516:+
LUAD	cis	rs34779708	0.931	rs12773169	ENSG00000271335.4	RP11-324I22.4	4	7.38e-05	0.0109	0.19	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35077534	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.931	rs7084196	ENSG00000271335.4	RP11-324I22.4	4	7.38e-05	0.0109	0.19	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35078233	chr10:35314552~35336401:-
LUAD	cis	rs11893307	0.537	rs3771319	ENSG00000235852.1	AC005540.3	4	7.38e-05	0.0109	0.23	0.18	Mean platelet volume;	chr2:190660507	chr2:190880797~190882059:-
LUAD	cis	rs9341808	0.539	rs2490253	ENSG00000260645.1	RP11-250B2.5	4	7.38e-05	0.0109	0.17	0.18	Sitting height ratio;	chr6:80186153	chr6:80466958~80469080:+
LUAD	cis	rs847577	0.674	rs7790479	ENSG00000272950.1	RP11-307C18.1	4	7.39e-05	0.0109	0.22	0.18	Breast cancer;	chr7:98083789	chr7:98322853~98323430:+
LUAD	cis	rs5769707	0.967	rs5769698	ENSG00000235111.1	RP1-29C18.8	-4	7.39e-05	0.0109	-0.19	-0.18	Monocyte percentage of white cells;Monocyte count;	chr22:49604058	chr22:49612657~49615716:-
LUAD	cis	rs1541160	1	rs28441321	ENSG00000239494.2	RN7SL333P	4	7.39e-05	0.0109	0.18	0.18	Amyotrophic lateral sclerosis;	chr1:170020827	chr1:169859756~169860052:+
LUAD	cis	rs7551222	0.752	rs4252694	ENSG00000240219.1	RP11-430C7.5	4	7.39e-05	0.0109	0.19	0.18	Schizophrenia;	chr1:204529928	chr1:204626775~204629712:+
LUAD	cis	rs9341808	0.935	rs2298307	ENSG00000260645.1	RP11-250B2.5	4	7.39e-05	0.0109	0.16	0.18	Sitting height ratio;	chr6:80106579	chr6:80466958~80469080:+
LUAD	cis	rs2548724	0.617	rs3114659	ENSG00000250682.4	LINC00491	-4	7.39e-05	0.0109	-0.21	-0.18	Type 2 diabetes;	chr5:102295888	chr5:102609156~102671559:-
LUAD	cis	rs755249	0.642	rs28788506	ENSG00000237624.1	OXCT2P1	4	7.39e-05	0.0109	0.24	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39611108	chr1:39514956~39516490:+
LUAD	cis	rs755249	0.669	rs4660311	ENSG00000237624.1	OXCT2P1	4	7.39e-05	0.0109	0.24	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39613442	chr1:39514956~39516490:+
LUAD	cis	rs3018712	0.532	rs2513280	ENSG00000212093.1	AP000807.1	-4	7.39e-05	0.0109	-0.24	-0.18	Total body bone mineral density;	chr11:68649439	chr11:68506083~68506166:-
LUAD	cis	rs10463554	0.856	rs26522	ENSG00000250682.4	LINC00491	-4	7.39e-05	0.0109	-0.21	-0.18	Parkinson's disease;	chr5:103148695	chr5:102609156~102671559:-
LUAD	cis	rs3808502	0.647	rs7821302	ENSG00000255046.1	RP11-297N6.4	4	7.39e-05	0.0109	0.22	0.18	Neuroticism;	chr8:11379063	chr8:11797928~11802568:-
LUAD	cis	rs7572733	0.84	rs4850808	ENSG00000222017.1	AC011997.1	4	7.39e-05	0.0109	0.22	0.18	Dermatomyositis;	chr2:197711418	chr2:197693106~197774823:+
LUAD	cis	rs62025270	0.576	rs55639123	ENSG00000259416.2	RP11-158M2.5	-4	7.4e-05	0.0109	-0.25	-0.18	Idiopathic pulmonary fibrosis;	chr15:85617037	chr15:85754941~85756237:-
LUAD	cis	rs6964587	0.869	rs2374519	ENSG00000188693.7	CYP51A1-AS1	4	7.4e-05	0.0109	0.21	0.18	Breast cancer;	chr7:91912167	chr7:92134604~92180725:+
LUAD	cis	rs2154319	1	rs61774713	ENSG00000235358.1	RP11-399E6.1	-4	7.4e-05	0.0109	-0.25	-0.18	Height;	chr1:41256724	chr1:41242373~41284861:+
LUAD	cis	rs270601	0.661	rs10036208	ENSG00000263597.1	MIR3936	4	7.4e-05	0.0109	0.19	0.18	Acylcarnitine levels;	chr5:132235630	chr5:132365490~132365599:-
LUAD	cis	rs8028182	0.636	rs11638974	ENSG00000246877.1	DNM1P35	4	7.4e-05	0.0109	0.24	0.18	Sudden cardiac arrest;	chr15:75506965	chr15:75727670~75738623:-
LUAD	cis	rs10463554	0.963	rs6883113	ENSG00000250682.4	LINC00491	4	7.4e-05	0.0109	0.22	0.18	Parkinson's disease;	chr5:103042185	chr5:102609156~102671559:-
LUAD	cis	rs8062405	0.823	rs7202948	ENSG00000251417.2	RP11-1348G14.4	-4	7.4e-05	0.0109	-0.18	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28802743~28817828:+
LUAD	cis	rs8002861	0.84	rs7989353	ENSG00000274001.1	RP11-5G9.5	4	7.4e-05	0.0109	0.19	0.18	Leprosy;	chr13:43864821	chr13:43877715~43878163:-
LUAD	cis	rs2735413	0.67	rs4522431	ENSG00000276007.1	RP11-358L22.3	4	7.4e-05	0.0109	0.21	0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78077255	chr16:78123243~78124332:+
LUAD	cis	rs7178424	0.805	rs5006593	ENSG00000259251.2	RP11-643M14.1	4	7.4e-05	0.0109	0.19	0.18	Height;	chr15:61957809	chr15:62060503~62062434:+
LUAD	cis	rs481331	0.799	rs58501815	ENSG00000185904.10	LINC00839	4	7.4e-05	0.0109	0.3	0.18	Systemic juvenile idiopathic arthritis;	chr10:42475382	chr10:42475543~42495336:+
LUAD	cis	rs683250	0.629	rs1151243	ENSG00000246067.6	RAB30-AS1	4	7.4e-05	0.011	0.19	0.18	Subcortical brain region volumes;	chr11:83265369	chr11:83072066~83106719:+
LUAD	cis	rs9649213	0.593	rs2394854	ENSG00000272950.1	RP11-307C18.1	4	7.41e-05	0.011	0.23	0.18	Prostate cancer (SNP x SNP interaction);	chr7:98397994	chr7:98322853~98323430:+
LUAD	cis	rs2657294	0.931	rs2804522	ENSG00000226051.5	ZNF503-AS1	-4	7.41e-05	0.011	-0.24	-0.18	Pneumonia;	chr10:75159132	chr10:75269819~75373500:+
LUAD	cis	rs8062405	0.789	rs2106480	ENSG00000261419.1	RP11-57A19.4	-4	7.41e-05	0.011	-0.19	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28659696~28740781:-
LUAD	cis	rs4763879	0.634	rs917913	ENSG00000256582.1	RP11-75L1.1	-4	7.41e-05	0.011	-0.18	-0.18	Type 1 diabetes;	chr12:9707040	chr12:9704077~9709350:+
LUAD	cis	rs2836950	0.545	rs2297256	ENSG00000232608.1	TIMM9P2	4	7.41e-05	0.011	0.2	0.18	Menarche (age at onset);	chr21:39186495	chr21:39216624~39217506:+
LUAD	cis	rs7260598	0.642	rs4313914	ENSG00000269421.1	ZNF92P3	-4	7.41e-05	0.011	-0.27	-0.18	Response to taxane treatment (placlitaxel);	chr19:23994194	chr19:23935220~23936173:+
LUAD	cis	rs13434995	0.513	rs62305268	ENSG00000273257.1	RP11-177J6.1	-4	7.42e-05	0.011	-0.24	-0.18	Adiponectin levels;	chr4:55506991	chr4:55387949~55388271:+
LUAD	cis	rs7762018	1	rs7746598	ENSG00000231690.2	LINC00574	-4	7.42e-05	0.011	-0.33	-0.18	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169684837	chr6:169790321~169802873:+
LUAD	cis	rs172166	0.61	rs156737	ENSG00000219392.1	RP1-265C24.5	-4	7.42e-05	0.011	-0.22	-0.18	Cardiac Troponin-T levels;	chr6:27927435	chr6:28115628~28116551:+
LUAD	cis	rs9287719	0.967	rs759402	ENSG00000243819.4	RN7SL832P	4	7.42e-05	0.011	0.19	0.18	Prostate cancer;	chr2:10589428	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs759403	ENSG00000243819.4	RN7SL832P	4	7.42e-05	0.011	0.19	0.18	Prostate cancer;	chr2:10589771	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs11674433	ENSG00000243819.4	RN7SL832P	4	7.42e-05	0.011	0.19	0.18	Prostate cancer;	chr2:10590713	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs2024431	ENSG00000243819.4	RN7SL832P	4	7.42e-05	0.011	0.19	0.18	Prostate cancer;	chr2:10591201	chr2:10690344~10692099:+
LUAD	cis	rs896854	0.608	rs6991067	ENSG00000253528.2	RP11-347C18.4	4	7.42e-05	0.011	0.17	0.18	Type 2 diabetes;	chr8:94863448	chr8:94974573~94974853:-
LUAD	cis	rs1502337	0.532	rs4766501	ENSG00000278993.1	RP3-424M6.4	-4	7.42e-05	0.011	-0.22	-0.18	Body mass index;	chr12:110560408	chr12:110501614~110503441:+
LUAD	cis	rs13434995	0.513	rs62303730	ENSG00000273257.1	RP11-177J6.1	-4	7.42e-05	0.011	-0.24	-0.18	Adiponectin levels;	chr4:55498948	chr4:55387949~55388271:+
LUAD	cis	rs338389	0.542	rs12594726	ENSG00000260657.2	RP11-315D16.4	-4	7.42e-05	0.011	-0.22	-0.18	Survival in rectal cancer;	chr15:67994440	chr15:68267792~68277994:-
LUAD	cis	rs8037818	1	rs8037102	ENSG00000261064.1	RP11-1000B6.3	-4	7.42e-05	0.011	-0.24	-0.18	Obesity-related traits;	chr15:32640449	chr15:32536047~32587613:+
LUAD	cis	rs763121	0.853	rs9610993	ENSG00000225450.1	RP3-508I15.14	-4	7.42e-05	0.011	-0.18	-0.18	Menopause (age at onset);	chr22:38646813	chr22:38739003~38749041:+
LUAD	cis	rs6981523	0.553	rs11783890	ENSG00000255046.1	RP11-297N6.4	4	7.42e-05	0.011	0.23	0.18	Neuroticism;	chr8:11198879	chr8:11797928~11802568:-
LUAD	cis	rs10463554	0.892	rs17154860	ENSG00000250682.4	LINC00491	4	7.42e-05	0.011	0.22	0.18	Parkinson's disease;	chr5:102955441	chr5:102609156~102671559:-
LUAD	cis	rs481331	0.799	rs3928822	ENSG00000185904.10	LINC00839	4	7.43e-05	0.011	0.31	0.18	Systemic juvenile idiopathic arthritis;	chr10:42471984	chr10:42475543~42495336:+
LUAD	cis	rs8040855	0.627	rs12904238	ENSG00000259774.1	RP11-182J1.13	4	7.43e-05	0.011	0.23	0.18	Bulimia nervosa;	chr15:85096610	chr15:84422618~84425882:+
LUAD	cis	rs9341808	0.667	rs6938280	ENSG00000260645.1	RP11-250B2.5	4	7.43e-05	0.011	0.17	0.18	Sitting height ratio;	chr6:80188065	chr6:80466958~80469080:+
LUAD	cis	rs7572733	0.905	rs6718039	ENSG00000222017.1	AC011997.1	4	7.43e-05	0.011	0.22	0.18	Dermatomyositis;	chr2:197896918	chr2:197693106~197774823:+
LUAD	cis	rs6703335	0.544	rs4658558	ENSG00000253326.2	RP11-261C10.7	-4	7.43e-05	0.011	-0.21	-0.18	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;	chr1:243342539	chr1:243054861~243056394:-
LUAD	cis	rs2274273	0.84	rs7153110	ENSG00000259318.1	RP11-454L9.2	4	7.43e-05	0.011	0.16	0.18	Protein biomarker;	chr14:55353910	chr14:55394940~55395233:-
LUAD	cis	rs1876905	0.764	rs4947106	ENSG00000272356.1	RP5-1112D6.8	4	7.44e-05	0.011	0.19	0.18	Mean corpuscular hemoglobin;	chr6:111100163	chr6:111309203~111313517:+
LUAD	cis	rs812925	0.714	rs1900573	ENSG00000271889.1	RP11-493E12.1	-4	7.44e-05	0.011	-0.22	-0.18	Immature fraction of reticulocytes;	chr2:61369777	chr2:61151433~61162105:-
LUAD	cis	rs8014252	0.803	rs58777530	ENSG00000259158.2	ADAM20P1	-4	7.44e-05	0.011	-0.3	-0.18	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70534505	chr14:70468881~70483756:-
LUAD	cis	rs8014252	0.803	rs73282153	ENSG00000259158.2	ADAM20P1	-4	7.44e-05	0.011	-0.3	-0.18	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70535593	chr14:70468881~70483756:-
LUAD	cis	rs7809950	1	rs2712200	ENSG00000238832.1	snoU109	-4	7.44e-05	0.011	-0.26	-0.18	Coronary artery disease;	chr7:107501990	chr7:107603363~107603507:+
LUAD	cis	rs7809950	0.953	rs3094383	ENSG00000238832.1	snoU109	-4	7.44e-05	0.011	-0.26	-0.18	Coronary artery disease;	chr7:107502719	chr7:107603363~107603507:+
LUAD	cis	rs2688608	0.967	rs1815076	ENSG00000271816.1	BMS1P4	4	7.44e-05	0.011	0.15	0.18	Inflammatory bowel disease;	chr10:73900128	chr10:73699151~73730487:-
LUAD	cis	rs2688608	0.967	rs2675663	ENSG00000271816.1	BMS1P4	4	7.44e-05	0.011	0.15	0.18	Inflammatory bowel disease;	chr10:73900512	chr10:73699151~73730487:-
LUAD	cis	rs595244	1	rs79307111	ENSG00000259705.1	RP11-227D13.1	4	7.44e-05	0.011	0.4	0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48449204	chr15:48645951~48652016:+
LUAD	cis	rs516805	0.52	rs1267947	ENSG00000279453.1	RP3-425C14.4	-4	7.44e-05	0.011	-0.19	-0.18	Lymphocyte counts;	chr6:122450892	chr6:122436789~122439223:-
LUAD	cis	rs4713118	0.955	rs9380010	ENSG00000280107.1	AL022393.9	-4	7.44e-05	0.011	-0.23	-0.18	Parkinson's disease;	chr6:27715793	chr6:28170845~28172521:+
LUAD	cis	rs4713118	0.955	rs9368528	ENSG00000280107.1	AL022393.9	-4	7.44e-05	0.011	-0.23	-0.18	Parkinson's disease;	chr6:27716019	chr6:28170845~28172521:+
LUAD	cis	rs4713118	0.955	rs9380011	ENSG00000280107.1	AL022393.9	-4	7.44e-05	0.011	-0.23	-0.18	Parkinson's disease;	chr6:27716145	chr6:28170845~28172521:+
LUAD	cis	rs4713118	0.955	rs9380012	ENSG00000280107.1	AL022393.9	-4	7.44e-05	0.011	-0.23	-0.18	Parkinson's disease;	chr6:27716875	chr6:28170845~28172521:+
LUAD	cis	rs8114671	0.933	rs6142327	ENSG00000269202.1	RP4-614O4.12	4	7.44e-05	0.011	0.18	0.18	Height;	chr20:35205344	chr20:35201747~35203288:-
LUAD	cis	rs865483	0.895	rs853191	ENSG00000276054.1	RP11-378E13.3	4	7.44e-05	0.011	0.21	0.18	Monocyte count;	chr17:37461654	chr17:37386886~37387926:+
LUAD	cis	rs8062405	0.755	rs1074631	ENSG00000251417.2	RP11-1348G14.4	4	7.44e-05	0.011	0.18	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28802743~28817828:+
LUAD	cis	rs17301013	0.896	rs3118980	ENSG00000227373.4	RP11-160H22.5	-4	7.44e-05	0.011	-0.23	-0.18	Systemic lupus erythematosus;	chr1:174793701	chr1:174115300~174160004:-
LUAD	cis	rs77688320	0.5	rs6755428	ENSG00000213090.2	AC007256.5	4	7.44e-05	0.011	0.2	0.18	Breast cancer;	chr2:201431043	chr2:201410544~201413308:-
LUAD	cis	rs875971	0.545	rs10950025	ENSG00000222364.1	RNU6-96P	-4	7.45e-05	0.011	-0.23	-0.18	Aortic root size;	chr7:66158946	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.52	rs12666485	ENSG00000222364.1	RNU6-96P	-4	7.45e-05	0.011	-0.23	-0.18	Aortic root size;	chr7:66160135	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.545	rs67688847	ENSG00000222364.1	RNU6-96P	-4	7.45e-05	0.011	-0.23	-0.18	Aortic root size;	chr7:66161064	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.545	rs7787063	ENSG00000222364.1	RNU6-96P	-4	7.45e-05	0.011	-0.23	-0.18	Aortic root size;	chr7:66164012	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.545	rs12673308	ENSG00000222364.1	RNU6-96P	-4	7.45e-05	0.011	-0.23	-0.18	Aortic root size;	chr7:66166374	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.545	rs67397473	ENSG00000222364.1	RNU6-96P	-4	7.45e-05	0.011	-0.23	-0.18	Aortic root size;	chr7:66168318	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.545	rs10950027	ENSG00000222364.1	RNU6-96P	-4	7.45e-05	0.011	-0.23	-0.18	Aortic root size;	chr7:66169164	chr7:66395191~66395286:+
LUAD	cis	rs6430585	0.702	rs2015532	ENSG00000226806.1	AC011893.3	-4	7.45e-05	0.011	-0.27	-0.18	Corneal structure;	chr2:135797955	chr2:135820191~135823087:+
LUAD	cis	rs7129556	0.702	rs7123080	ENSG00000241782.1	RP11-91P24.1	4	7.45e-05	0.011	0.25	0.18	Weight loss (gastric bypass surgery);	chr11:77788341	chr11:77868722~77869195:-
LUAD	cis	rs1355223	0.872	rs7112608	ENSG00000271369.1	RP11-350D17.3	-4	7.45e-05	0.011	-0.21	-0.18	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34677722	chr11:34709600~34710161:+
LUAD	cis	rs6728302	0.557	rs7600132	ENSG00000244280.1	ECEL1P2	4	7.45e-05	0.011	0.4	0.18	Height;	chr2:232383488	chr2:232385750~232387457:-
LUAD	cis	rs2153535	0.536	rs78180822	ENSG00000230939.1	RP11-314C16.1	-4	7.46e-05	0.011	-0.2	-0.18	Motion sickness;	chr6:8620941	chr6:8784178~8785445:+
LUAD	cis	rs9646944	0.501	rs13030642	ENSG00000234389.1	AC007278.3	4	7.46e-05	0.011	0.2	0.18	Blood protein levels;	chr2:102475126	chr2:102438713~102440475:+
LUAD	cis	rs9646944	0.501	rs13030675	ENSG00000234389.1	AC007278.3	4	7.46e-05	0.011	0.2	0.18	Blood protein levels;	chr2:102475159	chr2:102438713~102440475:+
LUAD	cis	rs7955901	0.904	rs4760894	ENSG00000258053.1	CTD-2021H9.3	-4	7.46e-05	0.011	-0.21	-0.18	Type 2 diabetes;	chr12:71045143	chr12:71047402~71118247:-
LUAD	cis	rs1862618	0.853	rs252910	ENSG00000271828.1	CTD-2310F14.1	4	7.46e-05	0.011	0.26	0.18	Initial pursuit acceleration;	chr5:56897156	chr5:56927874~56929573:+
LUAD	cis	rs4713118	0.662	rs175954	ENSG00000280107.1	AL022393.9	-4	7.46e-05	0.011	-0.23	-0.18	Parkinson's disease;	chr6:28043807	chr6:28170845~28172521:+
LUAD	cis	rs11168618	1	rs10875833	ENSG00000240399.1	RP1-228P16.1	4	7.46e-05	0.011	0.18	0.18	Adiponectin levels;	chr12:48559585	chr12:48054813~48055591:-
LUAD	cis	rs11168618	1	rs11168637	ENSG00000240399.1	RP1-228P16.1	4	7.46e-05	0.011	0.18	0.18	Adiponectin levels;	chr12:48559721	chr12:48054813~48055591:-
LUAD	cis	rs9341808	0.6	rs668329	ENSG00000260645.1	RP11-250B2.5	-4	7.46e-05	0.011	-0.17	-0.18	Sitting height ratio;	chr6:80258861	chr6:80466958~80469080:+
LUAD	cis	rs7674212	0.541	rs2623070	ENSG00000251288.2	RP11-10L12.2	4	7.46e-05	0.011	0.22	0.18	Type 2 diabetes;	chr4:103116231	chr4:102751401~102752641:+
LUAD	cis	rs11159086	1	rs72730186	ENSG00000259005.1	RP3-449M8.6	4	7.47e-05	0.011	0.27	0.18	Advanced glycation end-product levels;	chr14:74475610	chr14:74474007~74474864:-
LUAD	cis	rs62025270	0.632	rs1807309	ENSG00000259416.2	RP11-158M2.5	-4	7.47e-05	0.011	-0.24	-0.18	Idiopathic pulmonary fibrosis;	chr15:85668526	chr15:85754941~85756237:-
LUAD	cis	rs12681963	1	rs1355412	ENSG00000272375.1	RP11-51J9.6	4	7.47e-05	0.011	0.23	0.18	Migraine;	chr8:30128167	chr8:30197404~30198048:+
LUAD	cis	rs2243480	1	rs160655	ENSG00000232559.3	GS1-124K5.12	4	7.47e-05	0.011	0.3	0.18	Diabetic kidney disease;	chr7:66068227	chr7:66554588~66576923:-
LUAD	cis	rs35740288	0.571	rs11633790	ENSG00000259407.1	RP11-158M2.3	-4	7.47e-05	0.011	-0.2	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85783139	chr15:85744109~85750281:-
LUAD	cis	rs10197140	0.816	rs28806919	ENSG00000235721.1	AC013268.3	-4	7.47e-05	0.011	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110898267	chr2:110007675~110010783:+
LUAD	cis	rs442309	0.812	rs224123	ENSG00000238280.1	RP11-436D10.3	-4	7.47e-05	0.011	-0.22	-0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62691473	chr10:62793562~62805887:-
LUAD	cis	rs1552244	0.832	rs3732968	ENSG00000180385.7	EMC3-AS1	4	7.47e-05	0.011	0.21	0.18	Alzheimer's disease;	chr3:9971589	chr3:9986893~10006990:+
LUAD	cis	rs9847710	0.967	rs2564931	ENSG00000242142.1	SERBP1P3	4	7.47e-05	0.011	0.19	0.18	Ulcerative colitis;	chr3:52986543	chr3:53064283~53065091:-
LUAD	cis	rs6479901	0.557	rs7920768	ENSG00000232075.1	MRPL35P2	-4	7.47e-05	0.011	-0.29	-0.18	Intelligence (multi-trait analysis);	chr10:63300754	chr10:63634317~63634827:-
LUAD	cis	rs442309	0.812	rs224090	ENSG00000238280.1	RP11-436D10.3	4	7.48e-05	0.011	0.21	0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62781559	chr10:62793562~62805887:-
LUAD	cis	rs7324557	0.719	rs7325364	ENSG00000205861.10	C1QTNF9B-AS1	-4	7.48e-05	0.011	-0.24	-0.18	Visceral adipose tissue adjusted for BMI;	chr13:23805008	chr13:23888889~23897263:+
LUAD	cis	rs6071166	0.683	rs7344456	ENSG00000224635.1	RP4-564F22.5	-4	7.48e-05	0.011	-0.2	-0.18	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38678651	chr20:38406011~38416797:-
LUAD	cis	rs494562	0.892	rs638745	ENSG00000234155.1	RP11-30P6.6	-4	7.48e-05	0.011	-0.35	-0.18	Metabolic traits;Blood metabolite levels;	chr6:85405869	chr6:85387219~85390186:-
LUAD	cis	rs494562	0.892	rs550499	ENSG00000234155.1	RP11-30P6.6	-4	7.48e-05	0.011	-0.35	-0.18	Metabolic traits;Blood metabolite levels;	chr6:85405884	chr6:85387219~85390186:-
LUAD	cis	rs4819052	0.766	rs4819035	ENSG00000223768.1	LINC00205	-4	7.48e-05	0.011	-0.24	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45225800	chr21:45293285~45297354:+
LUAD	cis	rs7674212	0.541	rs2720458	ENSG00000251288.2	RP11-10L12.2	-4	7.48e-05	0.011	-0.22	-0.18	Type 2 diabetes;	chr4:103131806	chr4:102751401~102752641:+
LUAD	cis	rs12188164	0.93	rs72717436	ENSG00000225138.6	CTD-2228K2.7	4	7.48e-05	0.011	0.18	0.18	Cystic fibrosis severity;	chr5:448176	chr5:473236~480884:+
LUAD	cis	rs12188164	0.965	rs72717438	ENSG00000225138.6	CTD-2228K2.7	4	7.48e-05	0.011	0.18	0.18	Cystic fibrosis severity;	chr5:448548	chr5:473236~480884:+
LUAD	cis	rs12188164	0.93	rs72717440	ENSG00000225138.6	CTD-2228K2.7	4	7.48e-05	0.011	0.18	0.18	Cystic fibrosis severity;	chr5:449586	chr5:473236~480884:+
LUAD	cis	rs12188164	0.965	rs11743639	ENSG00000225138.6	CTD-2228K2.7	4	7.48e-05	0.011	0.18	0.18	Cystic fibrosis severity;	chr5:450595	chr5:473236~480884:+
LUAD	cis	rs12188164	0.965	rs11745789	ENSG00000225138.6	CTD-2228K2.7	4	7.48e-05	0.011	0.18	0.18	Cystic fibrosis severity;	chr5:450662	chr5:473236~480884:+
LUAD	cis	rs12188164	0.965	rs11744539	ENSG00000225138.6	CTD-2228K2.7	4	7.48e-05	0.011	0.18	0.18	Cystic fibrosis severity;	chr5:451310	chr5:473236~480884:+
LUAD	cis	rs3794924	0.925	rs35427815	ENSG00000266521.1	RP11-650P15.1	4	7.48e-05	0.011	0.35	0.18	Survival in colon cancer;	chr18:31466438	chr18:31496645~31497195:-
LUAD	cis	rs3794924	0.925	rs35293326	ENSG00000266521.1	RP11-650P15.1	4	7.48e-05	0.011	0.35	0.18	Survival in colon cancer;	chr18:31466467	chr18:31496645~31497195:-
LUAD	cis	rs2836974	1	rs2836974	ENSG00000232608.1	TIMM9P2	4	7.48e-05	0.011	0.21	0.18	Cognitive function;	chr21:39291255	chr21:39216624~39217506:+
LUAD	cis	rs13434995	0.513	rs6554282	ENSG00000273257.1	RP11-177J6.1	4	7.48e-05	0.011	0.24	0.18	Adiponectin levels;	chr4:55519812	chr4:55387949~55388271:+
LUAD	cis	rs7005380	0.733	rs9987332	ENSG00000279347.1	RP11-85I17.2	4	7.48e-05	0.011	0.15	0.18	Interstitial lung disease;	chr8:119921723	chr8:119838736~119840385:-
LUAD	cis	rs10090774	0.71	rs9324533	ENSG00000280303.2	ERICD	-4	7.48e-05	0.011	-0.2	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140681905	chr8:140636281~140638283:+
LUAD	cis	rs12898179	0.53	rs61988190	ENSG00000258561.1	RP11-72M17.1	4	7.48e-05	0.0111	0.27	0.18	Glomerular filtration rate in chronic kidney disease;	chr14:67504419	chr14:66212810~66509394:-
LUAD	cis	rs4705962	0.837	rs2285700	ENSG00000233006.5	AC034220.3	4	7.48e-05	0.0111	0.17	0.18	Atopic dermatitis;	chr5:132703440	chr5:132311285~132369916:-
LUAD	cis	rs4840086	1	rs10485227	ENSG00000219755.1	RP1-199J3.5	-3.99	7.48e-05	0.0111	-0.22	-0.18	Menarche (age at onset);	chr6:99759451	chr6:99575712~99576456:+
LUAD	cis	rs7086627	0.515	rs1870147	ENSG00000226659.1	RP11-137H2.4	-3.99	7.48e-05	0.0111	-0.24	-0.18	Post bronchodilator FEV1;	chr10:80452785	chr10:80529597~80535942:-
LUAD	cis	rs761746	0.543	rs5998122	ENSG00000236132.1	CTA-440B3.1	-3.99	7.48e-05	0.0111	-0.24	-0.18	Intelligence;	chr22:31777067	chr22:31816379~31817491:-
LUAD	cis	rs761746	0.579	rs5998126	ENSG00000236132.1	CTA-440B3.1	-3.99	7.48e-05	0.0111	-0.24	-0.18	Intelligence;	chr22:31782416	chr22:31816379~31817491:-
LUAD	cis	rs761746	0.614	rs2108108	ENSG00000236132.1	CTA-440B3.1	-3.99	7.48e-05	0.0111	-0.24	-0.18	Intelligence;	chr22:31785951	chr22:31816379~31817491:-
LUAD	cis	rs34779708	0.966	rs4934735	ENSG00000271335.4	RP11-324I22.4	-3.99	7.49e-05	0.0111	-0.19	-0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35207802	chr10:35314552~35336401:-
LUAD	cis	rs11121152	1	rs11121152	ENSG00000232912.4	RP5-1115A15.1	-3.99	7.49e-05	0.0111	-0.18	-0.18	Inflammatory skin disease;	chr1:8297161	chr1:8424645~8434838:+
LUAD	cis	rs8062405	0.723	rs4788077	ENSG00000261419.1	RP11-57A19.4	-3.99	7.49e-05	0.0111	-0.2	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28659696~28740781:-
LUAD	cis	rs916888	0.61	rs199529	ENSG00000232300.1	FAM215B	3.99	7.49e-05	0.0111	0.26	0.18	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46558830~46562795:-
LUAD	cis	rs7202877	0.706	rs1540	ENSG00000280152.1	RP11-331F4.5	-3.99	7.49e-05	0.0111	-0.22	-0.18	Type 1 diabetes;Type 2 diabetes;	chr16:75447287	chr16:75245994~75250077:-
LUAD	cis	rs853679	0.556	rs13197633	ENSG00000219392.1	RP1-265C24.5	-3.99	7.49e-05	0.0111	-0.4	-0.18	Depression;	chr6:28206979	chr6:28115628~28116551:+
LUAD	cis	rs2732480	0.5	rs7297824	ENSG00000257763.1	OR5BK1P	3.99	7.49e-05	0.0111	0.19	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48204867	chr12:48355792~48356614:-
LUAD	cis	rs860295	0.702	rs2025669	ENSG00000225855.5	RUSC1-AS1	3.99	7.49e-05	0.0111	0.13	0.18	Body mass index;	chr1:155387818	chr1:155316863~155324176:-
LUAD	cis	rs860295	0.702	rs12081067	ENSG00000225855.5	RUSC1-AS1	3.99	7.49e-05	0.0111	0.13	0.18	Body mass index;	chr1:155389191	chr1:155316863~155324176:-
LUAD	cis	rs860295	0.702	rs10908465	ENSG00000225855.5	RUSC1-AS1	3.99	7.49e-05	0.0111	0.13	0.18	Body mass index;	chr1:155419897	chr1:155316863~155324176:-
LUAD	cis	rs1401999	0.966	rs2037379	ENSG00000223882.1	ABCC5-AS1	-3.99	7.49e-05	0.0111	-0.19	-0.18	Anterior chamber depth;	chr3:183932542	chr3:184006338~184011419:+
LUAD	cis	rs55670112	0.843	rs1479351	ENSG00000271797.1	CTC-428G20.6	-3.99	7.49e-05	0.0111	-0.19	-0.18	Epilepsy;	chr5:114828758	chr5:115262505~115263448:+
LUAD	cis	rs12681963	0.514	rs4733102	ENSG00000271869.1	RP11-51J9.5	-3.99	7.49e-05	0.0111	-0.22	-0.18	Migraine;	chr8:30036395	chr8:30155830~30156232:-
LUAD	cis	rs858239	0.601	rs15775	ENSG00000226816.2	AC005082.12	3.99	7.49e-05	0.0111	0.23	0.18	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23206013~23208045:+
LUAD	cis	rs73193808	0.802	rs2832275	ENSG00000215533.7	LINC00189	-3.99	7.49e-05	0.0111	-0.25	-0.18	Coronary artery disease;	chr21:29230673	chr21:29193480~29288205:+
LUAD	cis	rs853679	0.517	rs4713145	ENSG00000280107.1	AL022393.9	-3.99	7.49e-05	0.0111	-0.24	-0.18	Depression;	chr6:28139049	chr6:28170845~28172521:+
LUAD	cis	rs149866169	1	rs149866169	ENSG00000219392.1	RP1-265C24.5	-3.99	7.5e-05	0.0111	-0.34	-0.18	Subjective well-being (multi-trait analysis);Lung cancer;Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Squamous cell lung carcinoma;	chr6:27473944	chr6:28115628~28116551:+
LUAD	cis	rs6940638	0.688	rs2022272	ENSG00000219392.1	RP1-265C24.5	-3.99	7.5e-05	0.0111	-0.23	-0.18	Intelligence (multi-trait analysis);	chr6:27135801	chr6:28115628~28116551:+
LUAD	cis	rs116095464	0.558	rs10052012	ENSG00000248925.1	CTD-2083E4.6	3.99	7.5e-05	0.0111	0.3	0.18	Breast cancer;	chr5:231793	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs10077076	ENSG00000248925.1	CTD-2083E4.6	3.99	7.5e-05	0.0111	0.3	0.18	Breast cancer;	chr5:231825	chr5:269858~271516:-
LUAD	cis	rs3845817	0.843	rs11678288	ENSG00000281920.1	RP11-418H16.1	-3.99	7.5e-05	0.0111	-0.21	-0.18	Bipolar disorder;	chr2:65547553	chr2:65623272~65628424:+
LUAD	cis	rs4948102	0.599	rs2230197	ENSG00000275875.1	RP11-613E4.5	-3.99	7.5e-05	0.0111	-0.2	-0.18	Plasma homocysteine levels (post-methionine load test);	chr7:56058667	chr7:55741525~55741869:+
LUAD	cis	rs9584850	0.609	rs17574495	ENSG00000231194.1	FARP1-AS1	3.99	7.5e-05	0.0111	0.24	0.18	Neuroticism;	chr13:98502859	chr13:98435405~98435840:-
LUAD	cis	rs9584850	0.609	rs7983408	ENSG00000231194.1	FARP1-AS1	3.99	7.5e-05	0.0111	0.24	0.18	Neuroticism;	chr13:98503339	chr13:98435405~98435840:-
LUAD	cis	rs875971	0.862	rs801194	ENSG00000273448.1	RP11-166O4.6	-3.99	7.5e-05	0.0111	-0.17	-0.18	Aortic root size;	chr7:66563508	chr7:67333047~67334383:+
LUAD	cis	rs2732480	0.577	rs2732481	ENSG00000240399.1	RP1-228P16.1	3.99	7.5e-05	0.0111	0.18	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343202	chr12:48054813~48055591:-
LUAD	cis	rs2732480	0.557	rs2732484	ENSG00000240399.1	RP1-228P16.1	3.99	7.5e-05	0.0111	0.18	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343462	chr12:48054813~48055591:-
LUAD	cis	rs853679	0.55	rs1233699	ENSG00000226314.6	ZNF192P1	-3.99	7.5e-05	0.0111	-0.23	-0.18	Depression;	chr6:28201380	chr6:28161781~28169594:+
LUAD	cis	rs73186030	0.764	rs55744726	ENSG00000272758.4	RP11-299J3.8	3.99	7.5e-05	0.0111	0.24	0.18	Serum parathyroid hormone levels;	chr3:122368907	chr3:122416207~122443180:+
LUAD	cis	rs73186030	0.764	rs73186095	ENSG00000272758.4	RP11-299J3.8	3.99	7.5e-05	0.0111	0.24	0.18	Serum parathyroid hormone levels;	chr3:122372769	chr3:122416207~122443180:+
LUAD	cis	rs73186030	0.764	rs67446552	ENSG00000272758.4	RP11-299J3.8	3.99	7.5e-05	0.0111	0.24	0.18	Serum parathyroid hormone levels;	chr3:122377448	chr3:122416207~122443180:+
LUAD	cis	rs73186030	0.764	rs67706840	ENSG00000272758.4	RP11-299J3.8	3.99	7.5e-05	0.0111	0.24	0.18	Serum parathyroid hormone levels;	chr3:122377717	chr3:122416207~122443180:+
LUAD	cis	rs73186030	0.764	rs16833078	ENSG00000272758.4	RP11-299J3.8	3.99	7.5e-05	0.0111	0.24	0.18	Serum parathyroid hormone levels;	chr3:122380747	chr3:122416207~122443180:+
LUAD	cis	rs858239	0.6	rs13438179	ENSG00000226816.2	AC005082.12	3.99	7.5e-05	0.0111	0.23	0.18	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23206013~23208045:+
LUAD	cis	rs8177876	0.596	rs2317087	ENSG00000261061.1	RP11-303E16.2	3.99	7.51e-05	0.0111	0.33	0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81104753	chr16:81030770~81031485:+
LUAD	cis	rs4713118	0.955	rs34752872	ENSG00000280107.1	AL022393.9	-3.99	7.51e-05	0.0111	-0.23	-0.18	Parkinson's disease;	chr6:27715465	chr6:28170845~28172521:+
LUAD	cis	rs1075265	0.704	rs9631059	ENSG00000272156.1	RP11-477N3.1	-3.99	7.51e-05	0.0111	-0.21	-0.18	Chronotype;Morning vs. evening chronotype;	chr2:54015160	chr2:54082554~54085066:+
LUAD	cis	rs8046148	0.703	rs6500291	ENSG00000279356.1	RP11-429P3.8	-3.99	7.51e-05	0.0111	-0.19	-0.18	Testicular germ cell tumor;	chr16:50120902	chr16:50072862~50074986:+
LUAD	cis	rs6988985	0.647	rs28459852	ENSG00000247317.3	RP11-273G15.2	-3.99	7.51e-05	0.0111	-0.21	-0.18	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142905020	chr8:142981738~143018437:-
LUAD	cis	rs6988985	0.647	rs28558934	ENSG00000247317.3	RP11-273G15.2	-3.99	7.51e-05	0.0111	-0.21	-0.18	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142905139	chr8:142981738~143018437:-
LUAD	cis	rs7615952	0.576	rs4646748	ENSG00000250012.1	RP11-124N2.1	-3.99	7.51e-05	0.0111	-0.25	-0.18	Blood pressure (smoking interaction);	chr3:126107486	chr3:126084220~126095349:+
LUAD	cis	rs728616	0.867	rs55835350	ENSG00000225484.5	NUTM2B-AS1	-3.99	7.52e-05	0.0111	-0.38	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80041972	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.867	rs79904324	ENSG00000225484.5	NUTM2B-AS1	-3.99	7.52e-05	0.0111	-0.38	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80044932	chr10:79663088~79826594:-
LUAD	cis	rs7674212	0.57	rs2711899	ENSG00000251288.2	RP11-10L12.2	-3.99	7.52e-05	0.0111	-0.22	-0.18	Type 2 diabetes;	chr4:103141257	chr4:102751401~102752641:+
LUAD	cis	rs6125597	0.967	rs6067037	ENSG00000230758.1	SNAP23P	3.99	7.52e-05	0.0111	0.19	0.18	Intelligence (multi-trait analysis);	chr20:49297041	chr20:49038357~49038602:-
LUAD	cis	rs9543976	1	rs55927305	ENSG00000261105.4	LMO7-AS1	-3.99	7.52e-05	0.0111	-0.3	-0.18	Diabetic retinopathy;	chr13:75561213	chr13:75604700~75635994:-
LUAD	cis	rs404005	0.736	rs4952532	ENSG00000227028.5	SLC8A1-AS1	-3.99	7.52e-05	0.0111	-0.22	-0.18	HIV-associated dementia;	chr2:40177005	chr2:39786453~40255209:+
LUAD	cis	rs7560272	0.723	rs62153184	ENSG00000163016.8	ALMS1P	3.99	7.52e-05	0.0111	0.19	0.18	Schizophrenia;	chr2:73546742	chr2:73644919~73685576:+
LUAD	cis	rs11671005	0.693	rs11669665	ENSG00000268543.1	CTD-2619J13.16	-3.99	7.53e-05	0.0111	-0.25	-0.18	Mean platelet volume;	chr19:58420518	chr19:58418560~58419310:+
LUAD	cis	rs11671005	0.735	rs11084543	ENSG00000268543.1	CTD-2619J13.16	-3.99	7.53e-05	0.0111	-0.25	-0.18	Mean platelet volume;	chr19:58421334	chr19:58418560~58419310:+
LUAD	cis	rs11671005	0.735	rs11881000	ENSG00000268543.1	CTD-2619J13.16	-3.99	7.53e-05	0.0111	-0.25	-0.18	Mean platelet volume;	chr19:58421421	chr19:58418560~58419310:+
LUAD	cis	rs11671005	0.735	rs12981875	ENSG00000268543.1	CTD-2619J13.16	-3.99	7.53e-05	0.0111	-0.25	-0.18	Mean platelet volume;	chr19:58423763	chr19:58418560~58419310:+
LUAD	cis	rs13113518	1	rs7691799	ENSG00000272969.1	RP11-528I4.2	3.99	7.53e-05	0.0111	0.18	0.18	Height;	chr4:55545574	chr4:55547112~55547889:+
LUAD	cis	rs12446554	0.511	rs72769544	ENSG00000261195.1	CTD-2380F24.1	-3.99	7.53e-05	0.0111	-0.25	-0.18	Obesity;	chr16:19765915	chr16:19761172~19766099:-
LUAD	cis	rs6787172	0.755	rs9819134	ENSG00000272087.1	RP11-379F4.7	3.99	7.53e-05	0.0111	0.19	0.18	Subjective well-being;	chr3:158510483	chr3:158693120~158693768:-
LUAD	cis	rs6787172	0.811	rs9857535	ENSG00000272087.1	RP11-379F4.7	3.99	7.53e-05	0.0111	0.19	0.18	Subjective well-being;	chr3:158511008	chr3:158693120~158693768:-
LUAD	cis	rs6452524	0.618	rs7722924	ENSG00000281327.1	LINC01338	3.99	7.53e-05	0.0111	0.19	0.18	Hypertension (SNP x SNP interaction);	chr5:83060223	chr5:82850864~82859836:-
LUAD	cis	rs2732480	0.5	rs11168468	ENSG00000257763.1	OR5BK1P	3.99	7.53e-05	0.0111	0.19	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48218682	chr12:48355792~48356614:-
LUAD	cis	rs911119	0.837	rs2208289	ENSG00000270001.1	RP11-218C14.8	3.99	7.53e-05	0.0111	0.26	0.18	Chronic kidney disease;	chr20:23598889	chr20:23631826~23632316:-
LUAD	cis	rs858239	0.601	rs4599714	ENSG00000226816.2	AC005082.12	3.99	7.53e-05	0.0111	0.23	0.18	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23206013~23208045:+
LUAD	cis	rs858239	0.601	rs10278776	ENSG00000226816.2	AC005082.12	3.99	7.53e-05	0.0111	0.23	0.18	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23206013~23208045:+
LUAD	cis	rs172166	0.694	rs2791332	ENSG00000216901.1	AL022393.7	3.99	7.53e-05	0.0111	0.22	0.18	Cardiac Troponin-T levels;	chr6:28141010	chr6:28176188~28176674:+
LUAD	cis	rs57221529	0.766	rs72703070	ENSG00000248925.1	CTD-2083E4.6	3.99	7.53e-05	0.0111	0.28	0.18	Lung disease severity in cystic fibrosis;	chr5:590343	chr5:269858~271516:-
LUAD	cis	rs57221529	0.713	rs72703072	ENSG00000248925.1	CTD-2083E4.6	3.99	7.53e-05	0.0111	0.28	0.18	Lung disease severity in cystic fibrosis;	chr5:590511	chr5:269858~271516:-
LUAD	cis	rs57221529	0.713	rs12522724	ENSG00000248925.1	CTD-2083E4.6	3.99	7.53e-05	0.0111	0.28	0.18	Lung disease severity in cystic fibrosis;	chr5:590627	chr5:269858~271516:-
LUAD	cis	rs12999542	0.706	rs17651485	ENSG00000234389.1	AC007278.3	3.99	7.53e-05	0.0111	0.29	0.18	Serum protein levels (sST2);	chr2:102385190	chr2:102438713~102440475:+
LUAD	cis	rs7210086	0.768	rs4075985	ENSG00000263893.2	CTD-3010D24.3	3.99	7.53e-05	0.0111	0.24	0.18	Ulcerative colitis;	chr17:72644734	chr17:72642731~72644490:+
LUAD	cis	rs7210086	0.768	rs4072716	ENSG00000263893.2	CTD-3010D24.3	3.99	7.53e-05	0.0111	0.24	0.18	Ulcerative colitis;	chr17:72644794	chr17:72642731~72644490:+
LUAD	cis	rs7630852	1	rs7630852	ENSG00000272359.1	U4	-3.99	7.53e-05	0.0111	-0.19	-0.18	Eosinophil counts;	chr3:196781680	chr3:196747192~196747324:-
LUAD	cis	rs6787172	0.811	rs6780010	ENSG00000272087.1	RP11-379F4.7	3.99	7.53e-05	0.0111	0.19	0.18	Subjective well-being;	chr3:158517627	chr3:158693120~158693768:-
LUAD	cis	rs6088580	0.634	rs6059878	ENSG00000276073.1	RP5-1125A11.7	-3.99	7.54e-05	0.0111	-0.18	-0.18	Glomerular filtration rate (creatinine);	chr20:34499361	chr20:33985617~33988989:-
LUAD	cis	rs6088580	0.634	rs6120666	ENSG00000276073.1	RP5-1125A11.7	-3.99	7.54e-05	0.0111	-0.18	-0.18	Glomerular filtration rate (creatinine);	chr20:34502913	chr20:33985617~33988989:-
LUAD	cis	rs6088580	0.601	rs6120668	ENSG00000276073.1	RP5-1125A11.7	-3.99	7.54e-05	0.0111	-0.18	-0.18	Glomerular filtration rate (creatinine);	chr20:34511988	chr20:33985617~33988989:-
LUAD	cis	rs6088580	0.609	rs2378205	ENSG00000276073.1	RP5-1125A11.7	-3.99	7.54e-05	0.0111	-0.18	-0.18	Glomerular filtration rate (creatinine);	chr20:34522998	chr20:33985617~33988989:-
LUAD	cis	rs6688613	0.685	rs61815130	ENSG00000225171.2	DUTP6	-3.99	7.54e-05	0.0111	-0.23	-0.18	Refractive astigmatism;	chr1:166941228	chr1:166868748~166869209:+
LUAD	cis	rs11992186	0.505	rs7845203	ENSG00000253981.4	ALG1L13P	3.99	7.54e-05	0.0111	0.19	0.18	Neuroticism;	chr8:8287918	chr8:8236003~8244667:-
LUAD	cis	rs2836974	0.583	rs9636957	ENSG00000232608.1	TIMM9P2	3.99	7.54e-05	0.0111	0.21	0.18	Cognitive function;	chr21:39333921	chr21:39216624~39217506:+
LUAD	cis	rs2836974	0.602	rs8130854	ENSG00000232608.1	TIMM9P2	3.99	7.54e-05	0.0111	0.21	0.18	Cognitive function;	chr21:39335115	chr21:39216624~39217506:+
LUAD	cis	rs8062405	0.755	rs62034325	ENSG00000261419.1	RP11-57A19.4	-3.99	7.54e-05	0.0111	-0.2	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28659696~28740781:-
LUAD	cis	rs911119	0.913	rs4815222	ENSG00000270001.1	RP11-218C14.8	3.99	7.54e-05	0.0111	0.26	0.18	Chronic kidney disease;	chr20:23596327	chr20:23631826~23632316:-
LUAD	cis	rs6787172	0.677	rs6441206	ENSG00000272087.1	RP11-379F4.7	3.99	7.54e-05	0.0111	0.19	0.18	Subjective well-being;	chr3:158523282	chr3:158693120~158693768:-
LUAD	cis	rs6787172	0.748	rs7639678	ENSG00000272087.1	RP11-379F4.7	3.99	7.54e-05	0.0111	0.19	0.18	Subjective well-being;	chr3:158523664	chr3:158693120~158693768:-
LUAD	cis	rs6787172	0.811	rs1595029	ENSG00000272087.1	RP11-379F4.7	3.99	7.54e-05	0.0111	0.19	0.18	Subjective well-being;	chr3:158523978	chr3:158693120~158693768:-
LUAD	cis	rs6787172	0.777	rs1595028	ENSG00000272087.1	RP11-379F4.7	3.99	7.54e-05	0.0111	0.19	0.18	Subjective well-being;	chr3:158524109	chr3:158693120~158693768:-
LUAD	cis	rs6787172	0.755	rs58733163	ENSG00000272087.1	RP11-379F4.7	3.99	7.54e-05	0.0111	0.19	0.18	Subjective well-being;	chr3:158526407	chr3:158693120~158693768:-
LUAD	cis	rs9649213	0.574	rs7802541	ENSG00000272950.1	RP11-307C18.1	3.99	7.54e-05	0.0111	0.23	0.18	Prostate cancer (SNP x SNP interaction);	chr7:98304543	chr7:98322853~98323430:+
LUAD	cis	rs7551222	0.691	rs11240760	ENSG00000240219.1	RP11-430C7.5	3.99	7.55e-05	0.0111	0.19	0.18	Schizophrenia;	chr1:204578140	chr1:204626775~204629712:+
LUAD	cis	rs2904524	0.541	rs11178209	ENSG00000257815.4	RP11-611E13.2	-3.99	7.55e-05	0.0111	-0.23	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70378864	chr12:69904033~70243360:-
LUAD	cis	rs2904524	0.541	rs11531260	ENSG00000257815.4	RP11-611E13.2	-3.99	7.55e-05	0.0111	-0.23	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70379155	chr12:69904033~70243360:-
LUAD	cis	rs11971779	0.688	rs1862880	ENSG00000273391.1	RP11-634H22.1	3.99	7.55e-05	0.0111	0.19	0.18	Diisocyanate-induced asthma;	chr7:139335354	chr7:139359032~139359566:-
LUAD	cis	rs17695224	0.519	rs2159654	ENSG00000269483.1	AC006272.1	3.99	7.55e-05	0.0111	0.2	0.18	HDL cholesterol;HDL cholesterol levels;	chr19:51834004	chr19:51839924~51843324:-
LUAD	cis	rs17695224	0.5	rs2159655	ENSG00000269483.1	AC006272.1	3.99	7.55e-05	0.0111	0.2	0.18	HDL cholesterol;HDL cholesterol levels;	chr19:51834006	chr19:51839924~51843324:-
LUAD	cis	rs2153535	0.518	rs9393051	ENSG00000230939.1	RP11-314C16.1	-3.99	7.55e-05	0.0111	-0.21	-0.18	Motion sickness;	chr6:8638726	chr6:8784178~8785445:+
LUAD	cis	rs11742741	0.774	rs55708874	ENSG00000248874.4	C5orf17	-3.99	7.55e-05	0.0111	-0.22	-0.18	Educational attainment;	chr5:24050808	chr5:23951348~24178263:+
LUAD	cis	rs1154275	0.524	rs12495583	ENSG00000242770.2	RP11-180K7.1	3.99	7.55e-05	0.0111	0.18	0.18	Takotsubo syndrome;	chr3:112783457	chr3:112802478~112812819:+
LUAD	cis	rs13434995	0.513	rs1522109	ENSG00000273257.1	RP11-177J6.1	-3.99	7.55e-05	0.0111	-0.24	-0.18	Adiponectin levels;	chr4:55514403	chr4:55387949~55388271:+
LUAD	cis	rs2638953	0.924	rs11049437	ENSG00000278733.1	RP11-425D17.1	-3.99	7.55e-05	0.0111	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196192	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.85	rs10843129	ENSG00000278733.1	RP11-425D17.1	-3.99	7.55e-05	0.0111	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28199378	chr12:28185625~28186190:-
LUAD	cis	rs2098713	0.569	rs16903666	ENSG00000250155.1	CTD-2353F22.1	3.99	7.55e-05	0.0111	0.19	0.18	Telomere length;	chr5:37557648	chr5:36666214~36725195:-
LUAD	cis	rs7590268	0.606	rs13015058	ENSG00000279873.2	LINC01126	3.99	7.55e-05	0.0111	0.17	0.18	Orofacial clefts;	chr2:43416772	chr2:43227210~43228855:+
LUAD	cis	rs7829975	0.714	rs4840362	ENSG00000233609.3	RP11-62H7.2	-3.99	7.55e-05	0.0111	-0.14	-0.18	Mood instability;	chr8:8812572	chr8:8961200~8979025:+
LUAD	cis	rs7302981	1	rs7308356	ENSG00000200428.1	Y_RNA	3.99	7.55e-05	0.0111	0.22	0.18	Systolic blood pressure;	chr12:50145828	chr12:50743568~50743684:+
LUAD	cis	rs7302981	0.934	rs7301649	ENSG00000200428.1	Y_RNA	3.99	7.55e-05	0.0111	0.22	0.18	Systolic blood pressure;	chr12:50147087	chr12:50743568~50743684:+
LUAD	cis	rs7302981	0.934	rs7294548	ENSG00000200428.1	Y_RNA	3.99	7.55e-05	0.0111	0.22	0.18	Systolic blood pressure;	chr12:50149418	chr12:50743568~50743684:+
LUAD	cis	rs3018712	0.522	rs4930593	ENSG00000227620.4	ALG1L8P	-3.99	7.56e-05	0.0111	-0.24	-0.18	Total body bone mineral density;	chr11:68666713	chr11:67785273~67792335:+
LUAD	cis	rs9341808	0.622	rs682482	ENSG00000260645.1	RP11-250B2.5	-3.99	7.56e-05	0.0111	-0.17	-0.18	Sitting height ratio;	chr6:80251422	chr6:80466958~80469080:+
LUAD	cis	rs703842	0.928	rs724834	ENSG00000270039.1	RP11-571M6.17	-3.99	7.56e-05	0.0111	-0.22	-0.18	Multiple sclerosis;	chr12:57786633	chr12:57803838~57804415:+
LUAD	cis	rs6754311	0.731	rs2322660	ENSG00000226806.1	AC011893.3	3.99	7.56e-05	0.0111	0.22	0.18	Mosquito bite size;	chr2:135799749	chr2:135820191~135823087:+
LUAD	cis	rs2060793	0.519	rs7931378	ENSG00000251991.1	RNU7-49P	3.99	7.56e-05	0.0111	0.19	0.18	Vitamin D levels;	chr11:14592869	chr11:14478892~14478953:+
LUAD	cis	rs3096299	0.933	rs747485	ENSG00000182376.2	RP5-1142A6.8	3.99	7.56e-05	0.0111	0.18	0.18	Multiple myeloma (IgH translocation);	chr16:89407686	chr16:88742767~88745748:+
LUAD	cis	rs9926296	0.624	rs1110331	ENSG00000260259.1	RP11-368I7.4	3.99	7.56e-05	0.0111	0.17	0.18	Vitiligo;	chr16:89707988	chr16:89682620~89686569:-
LUAD	cis	rs6071166	0.646	rs6027244	ENSG00000224635.1	RP4-564F22.5	-3.99	7.56e-05	0.0112	-0.2	-0.18	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38683366	chr20:38406011~38416797:-
LUAD	cis	rs2243480	1	rs2243480	ENSG00000164669.11	INTS4P1	3.99	7.56e-05	0.0112	0.32	0.18	Diabetic kidney disease;	chr7:66134209	chr7:65141225~65234216:+
LUAD	cis	rs80226907	0.634	rs75716622	ENSG00000239686.1	RP11-665C16.1	3.99	7.56e-05	0.0112	0.34	0.18	Mean platelet volume;	chr14:55446872	chr14:55282296~55282643:-
LUAD	cis	rs875971	0.505	rs6955582	ENSG00000273142.1	RP11-458F8.4	-3.99	7.56e-05	0.0112	-0.12	-0.18	Aortic root size;	chr7:65966699	chr7:66902857~66906297:+
LUAD	cis	rs10971721	0.731	rs10971819	ENSG00000260947.1	RP11-384P7.7	3.99	7.56e-05	0.0112	0.37	0.18	Body mass index;	chr9:33954149	chr9:33697459~33700986:+
LUAD	cis	rs1167832	0.645	rs1167828	ENSG00000127957.15	PMS2P3	-3.99	7.56e-05	0.0112	-0.2	-0.18	Ankle injury;	chr7:75534076	chr7:75502930~75528148:-
LUAD	cis	rs206548	0.561	rs9946039	ENSG00000252680.1	RNA5SP449	3.99	7.57e-05	0.0112	0.23	0.18	Serum protein levels (sST2);	chr18:10384056	chr18:9844717~9844846:-
LUAD	cis	rs9353324	1	rs9362273	ENSG00000203875.9	SNHG5	-3.99	7.57e-05	0.0112	-0.48	-0.18	Interferon gamma-induced protein 10 levels;	chr6:86120789	chr6:85660950~85678736:-
LUAD	cis	rs6832769	0.925	rs60992571	ENSG00000272969.1	RP11-528I4.2	-3.99	7.57e-05	0.0112	-0.18	-0.18	Personality dimensions;	chr4:55574645	chr4:55547112~55547889:+
LUAD	cis	rs2735413	0.564	rs6564508	ENSG00000276007.1	RP11-358L22.3	3.99	7.57e-05	0.0112	0.25	0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78082678	chr16:78123243~78124332:+
LUAD	cis	rs1150668	0.799	rs853684	ENSG00000176933.5	TOB2P1	-3.99	7.57e-05	0.0112	-0.2	-0.18	Pubertal anthropometrics;	chr6:28326773	chr6:28217643~28218634:-
LUAD	cis	rs2933343	0.661	rs2630259	ENSG00000231305.3	RP11-723O4.2	3.99	7.57e-05	0.0112	0.2	0.18	IgG glycosylation;	chr3:128887479	chr3:128861313~128871540:-
LUAD	cis	rs6088580	0.609	rs6059844	ENSG00000276073.1	RP5-1125A11.7	-3.99	7.57e-05	0.0112	-0.17	-0.18	Glomerular filtration rate (creatinine);	chr20:34448677	chr20:33985617~33988989:-
LUAD	cis	rs62025270	0.848	rs62025269	ENSG00000202081.1	RNU6-1280P	-3.99	7.57e-05	0.0112	-0.25	-0.18	Idiopathic pulmonary fibrosis;	chr15:85756859	chr15:85651522~85651628:-
LUAD	cis	rs4660214	0.671	rs72661956	ENSG00000182109.6	RP11-69E11.4	3.99	7.57e-05	0.0112	0.25	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39319216	chr1:39522280~39546187:-
LUAD	cis	rs17695224	0.565	rs7248523	ENSG00000269483.1	AC006272.1	3.99	7.57e-05	0.0112	0.2	0.18	HDL cholesterol;HDL cholesterol levels;	chr19:51833888	chr19:51839924~51843324:-
LUAD	cis	rs17695224	0.585	rs10406893	ENSG00000269483.1	AC006272.1	3.99	7.57e-05	0.0112	0.2	0.18	HDL cholesterol;HDL cholesterol levels;	chr19:51833901	chr19:51839924~51843324:-
LUAD	cis	rs2274273	0.84	rs1045002	ENSG00000258413.1	RP11-665C16.6	-3.99	7.57e-05	0.0112	-0.23	-0.18	Protein biomarker;	chr14:55351799	chr14:55262767~55272075:-
LUAD	cis	rs6832769	1	rs28514423	ENSG00000272969.1	RP11-528I4.2	-3.99	7.57e-05	0.0112	-0.18	-0.18	Personality dimensions;	chr4:55563072	chr4:55547112~55547889:+
LUAD	cis	rs6452524	0.618	rs255561	ENSG00000281327.1	LINC01338	3.99	7.57e-05	0.0112	0.19	0.18	Hypertension (SNP x SNP interaction);	chr5:83054991	chr5:82850864~82859836:-
LUAD	cis	rs1559040	0.932	rs28368466	ENSG00000272156.1	RP11-477N3.1	-3.99	7.57e-05	0.0112	-0.31	-0.18	Sudden cardiac arrest;	chr2:54061824	chr2:54082554~54085066:+
LUAD	cis	rs10197140	0.857	rs62159553	ENSG00000235721.1	AC013268.3	-3.99	7.57e-05	0.0112	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110905931	chr2:110007675~110010783:+
LUAD	cis	rs10197140	0.857	rs6720503	ENSG00000235721.1	AC013268.3	-3.99	7.57e-05	0.0112	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110907560	chr2:110007675~110010783:+
LUAD	cis	rs17826219	0.706	rs2322197	ENSG00000280069.1	CTD-2349P21.3	-3.99	7.58e-05	0.0112	-0.24	-0.18	Body mass index;	chr17:30778787	chr17:30738182~30740275:+
LUAD	cis	rs8014252	0.803	rs12587714	ENSG00000259158.2	ADAM20P1	-3.99	7.58e-05	0.0112	-0.3	-0.18	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70537659	chr14:70468881~70483756:-
LUAD	cis	rs9900280	1	rs2138852	ENSG00000264808.1	RP11-802D6.1	3.99	7.58e-05	0.0112	0.21	0.18	Mean platelet volume;	chr17:29376331	chr17:29369717~29390777:-
LUAD	cis	rs6570726	0.967	rs450973	ENSG00000235652.6	RP11-545I5.3	3.99	7.59e-05	0.0112	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145541929	chr6:145799409~145886585:+
LUAD	cis	rs853679	0.513	rs9468296	ENSG00000280107.1	AL022393.9	-3.99	7.59e-05	0.0112	-0.24	-0.18	Depression;	chr6:28145952	chr6:28170845~28172521:+
LUAD	cis	rs7762018	0.66	rs41265385	ENSG00000231690.2	LINC00574	-3.99	7.59e-05	0.0112	-0.35	-0.18	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169667990	chr6:169790321~169802873:+
LUAD	cis	rs6754311	0.731	rs309134	ENSG00000226806.1	AC011893.3	-3.99	7.59e-05	0.0112	-0.23	-0.18	Mosquito bite size;	chr2:135998114	chr2:135820191~135823087:+
LUAD	cis	rs2836974	0.965	rs8131126	ENSG00000232608.1	TIMM9P2	-3.99	7.59e-05	0.0112	-0.22	-0.18	Cognitive function;	chr21:39283828	chr21:39216624~39217506:+
LUAD	cis	rs7590268	0.697	rs35953885	ENSG00000279873.2	LINC01126	3.99	7.59e-05	0.0112	0.18	0.18	Orofacial clefts;	chr2:43381763	chr2:43227210~43228855:+
LUAD	cis	rs11640436	0.614	rs4887901	ENSG00000261707.1	RP11-264M12.2	-3.99	7.59e-05	0.0112	-0.18	-0.18	Lobe attachment (rater-scored or self-reported);	chr16:77285479	chr16:77741468~77743000:-
LUAD	cis	rs1355223	0.902	rs7129089	ENSG00000271369.1	RP11-350D17.3	-3.99	7.59e-05	0.0112	-0.21	-0.18	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34678152	chr11:34709600~34710161:+
LUAD	cis	rs13113518	1	rs13113518	ENSG00000273257.1	RP11-177J6.1	3.99	7.59e-05	0.0112	0.19	0.18	Height;	chr4:55533481	chr4:55387949~55388271:+
LUAD	cis	rs7923837	0.663	rs7903302	ENSG00000236493.2	EIF2S2P3	3.99	7.59e-05	0.0112	0.2	0.18	Multiple sclerosis;Body mass index;	chr10:92669754	chr10:92668745~92669743:-
LUAD	cis	rs2143950	0.512	rs77772792	ENSG00000226677.3	IGBP1P1	-3.99	7.59e-05	0.0112	-0.22	-0.18	Atopic dermatitis;	chr14:35050921	chr14:34939324~34940332:+
LUAD	cis	rs6688613	0.685	rs742048	ENSG00000225171.2	DUTP6	3.99	7.59e-05	0.0112	0.23	0.18	Refractive astigmatism;	chr1:166940908	chr1:166868748~166869209:+
LUAD	cis	rs6723108	0.603	rs1592	ENSG00000224043.6	CCNT2-AS1	-3.99	7.59e-05	0.0112	-0.22	-0.18	Type 2 diabetes;	chr2:134964573	chr2:134735464~134918710:-
LUAD	cis	rs1541160	0.956	rs72715936	ENSG00000239494.2	RN7SL333P	-3.99	7.59e-05	0.0112	-0.18	-0.18	Amyotrophic lateral sclerosis;	chr1:170014706	chr1:169859756~169860052:+
LUAD	cis	rs6088580	0.634	rs6059824	ENSG00000276073.1	RP5-1125A11.7	-3.99	7.59e-05	0.0112	-0.17	-0.18	Glomerular filtration rate (creatinine);	chr20:34426737	chr20:33985617~33988989:-
LUAD	cis	rs7617773	0.817	rs34225441	ENSG00000199476.1	Y_RNA	-3.99	7.59e-05	0.0112	-0.24	-0.18	Coronary artery disease;	chr3:48267401	chr3:48288587~48288694:+
LUAD	cis	rs7660883	0.897	rs236985	ENSG00000251411.1	RP11-397E7.4	3.99	7.6e-05	0.0112	0.19	0.18	HDL cholesterol levels;	chr4:87087630	chr4:86913266~86914817:-
LUAD	cis	rs9393777	0.513	rs67540232	ENSG00000219392.1	RP1-265C24.5	-3.99	7.6e-05	0.0112	-0.29	-0.18	Intelligence (multi-trait analysis);	chr6:27173087	chr6:28115628~28116551:+
LUAD	cis	rs1799955	1	rs11571717	ENSG00000215515.2	IFIT1P1	-3.99	7.6e-05	0.0112	-0.27	-0.18	LDL cholesterol levels;	chr13:32360774	chr13:32384660~32386108:+
LUAD	cis	rs10419113	0.641	rs12983947	ENSG00000270804.1	CTD-2583A14.11	3.99	7.6e-05	0.0112	0.17	0.18	Pediatric bone mineral density (spine);	chr19:57763541	chr19:57867885~57868834:+
LUAD	cis	rs6723108	0.517	rs4954192	ENSG00000224043.6	CCNT2-AS1	-3.99	7.6e-05	0.0112	-0.22	-0.18	Type 2 diabetes;	chr2:134875411	chr2:134735464~134918710:-
LUAD	cis	rs10197140	0.925	rs10169926	ENSG00000235721.1	AC013268.3	-3.99	7.6e-05	0.0112	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110870903	chr2:110007675~110010783:+
LUAD	cis	rs10080237	0.564	rs2490224	ENSG00000260645.1	RP11-250B2.5	3.99	7.6e-05	0.0112	0.17	0.18	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;	chr6:80100116	chr6:80466958~80469080:+
LUAD	cis	rs7615952	0.688	rs17334074	ENSG00000241288.6	RP11-379B18.5	3.99	7.61e-05	0.0112	0.22	0.18	Blood pressure (smoking interaction);	chr3:125821617	chr3:125827238~125916384:-
LUAD	cis	rs77688320	0.535	rs13027669	ENSG00000213090.2	AC007256.5	3.99	7.61e-05	0.0112	0.2	0.18	Breast cancer;	chr2:201382596	chr2:201410544~201413308:-
LUAD	cis	rs2554380	0.891	rs1896816	ENSG00000230373.7	GOLGA6L5P	-3.99	7.61e-05	0.0112	-0.22	-0.18	Height;	chr15:83630619	chr15:84507885~84516814:-
LUAD	cis	rs7976269	0.609	rs11050010	ENSG00000257176.2	RP11-996F15.2	-3.99	7.61e-05	0.0112	-0.19	-0.18	Male-pattern baldness;	chr12:29061952	chr12:29280418~29317848:-
LUAD	cis	rs2243480	1	rs35820085	ENSG00000229886.1	RP5-1132H15.3	3.99	7.61e-05	0.0112	0.31	0.18	Diabetic kidney disease;	chr7:65977771	chr7:66025126~66031544:-
LUAD	cis	rs12935418	0.616	rs9936366	ENSG00000261061.1	RP11-303E16.2	-3.99	7.61e-05	0.0112	-0.2	-0.18	Mean corpuscular volume;	chr16:81011657	chr16:81030770~81031485:+
LUAD	cis	rs9659323	0.632	rs10802074	ENSG00000231365.4	RP11-418J17.1	-3.99	7.61e-05	0.0112	-0.21	-0.18	Body mass index;	chr1:119082373	chr1:119140396~119275973:+
LUAD	cis	rs561341	0.769	rs9899093	ENSG00000265798.5	RP11-271K11.5	3.99	7.61e-05	0.0112	0.29	0.18	Hip circumference adjusted for BMI;	chr17:31864935	chr17:31038575~31059121:-
LUAD	cis	rs2733201	1	rs11070419	ENSG00000205771.5	CATSPER2P1	3.99	7.61e-05	0.0112	0.42	0.18	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44034981	chr15:43726918~43747094:-
LUAD	cis	rs11638352	1	rs4924734	ENSG00000205771.5	CATSPER2P1	3.99	7.61e-05	0.0112	0.42	0.18	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44035872	chr15:43726918~43747094:-
LUAD	cis	rs11638352	1	rs2899103	ENSG00000205771.5	CATSPER2P1	3.99	7.61e-05	0.0112	0.42	0.18	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44048357	chr15:43726918~43747094:-
LUAD	cis	rs801193	0.967	rs2707853	ENSG00000222364.1	RNU6-96P	-3.99	7.61e-05	0.0112	-0.2	-0.18	Aortic root size;	chr7:66749023	chr7:66395191~66395286:+
LUAD	cis	rs801193	1	rs2659889	ENSG00000222364.1	RNU6-96P	-3.99	7.61e-05	0.0112	-0.2	-0.18	Aortic root size;	chr7:66752125	chr7:66395191~66395286:+
LUAD	cis	rs8012947	1	rs11158203	ENSG00000279636.2	LINC00216	-3.99	7.61e-05	0.0112	-0.2	-0.18	Alcohol consumption in current drinkers;	chr14:58303305	chr14:58288033~58289158:+
LUAD	cis	rs8012947	1	rs10145280	ENSG00000279636.2	LINC00216	-3.99	7.61e-05	0.0112	-0.2	-0.18	Alcohol consumption in current drinkers;	chr14:58303337	chr14:58288033~58289158:+
LUAD	cis	rs11051970	0.918	rs7309115	ENSG00000274964.1	RP11-817I4.1	-3.99	7.61e-05	0.0112	-0.21	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr12:32388307	chr12:32339368~32340724:+
LUAD	cis	rs10411262	0.935	rs2871987	ENSG00000211513.4	MIR320E	-3.99	7.61e-05	0.0112	-0.19	-0.18	Tonsillectomy;	chr19:46672271	chr19:46709271~46709382:-
LUAD	cis	rs755249	0.567	rs16826000	ENSG00000182109.6	RP11-69E11.4	3.99	7.61e-05	0.0112	0.22	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39248188	chr1:39522280~39546187:-
LUAD	cis	rs755249	0.567	rs16826009	ENSG00000182109.6	RP11-69E11.4	3.99	7.61e-05	0.0112	0.22	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39251230	chr1:39522280~39546187:-
LUAD	cis	rs755249	0.567	rs4660208	ENSG00000182109.6	RP11-69E11.4	3.99	7.61e-05	0.0112	0.22	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39256542	chr1:39522280~39546187:-
LUAD	cis	rs4819052	0.819	rs13046807	ENSG00000215447.6	BX322557.10	-3.99	7.62e-05	0.0112	-0.21	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252371	chr21:45288052~45291738:+
LUAD	cis	rs7976269	0.609	rs2196480	ENSG00000257176.2	RP11-996F15.2	-3.99	7.62e-05	0.0112	-0.19	-0.18	Male-pattern baldness;	chr12:29062850	chr12:29280418~29317848:-
LUAD	cis	rs7976269	0.537	rs10743642	ENSG00000257176.2	RP11-996F15.2	-3.99	7.62e-05	0.0112	-0.19	-0.18	Male-pattern baldness;	chr12:29063557	chr12:29280418~29317848:-
LUAD	cis	rs7976269	0.609	rs10771472	ENSG00000257176.2	RP11-996F15.2	-3.99	7.62e-05	0.0112	-0.19	-0.18	Male-pattern baldness;	chr12:29063930	chr12:29280418~29317848:-
LUAD	cis	rs9467773	0.935	rs1884947	ENSG00000261353.1	CTA-14H9.5	-3.99	7.62e-05	0.0112	-0.2	-0.18	Intelligence (multi-trait analysis);	chr6:26553045	chr6:26527063~26527404:+
LUAD	cis	rs2154319	0.887	rs213745	ENSG00000235358.1	RP11-399E6.1	3.99	7.62e-05	0.0112	0.24	0.18	Height;	chr1:41165657	chr1:41242373~41284861:+
LUAD	cis	rs2154319	0.887	rs61781831	ENSG00000235358.1	RP11-399E6.1	-3.99	7.62e-05	0.0112	-0.24	-0.18	Height;	chr1:41168110	chr1:41242373~41284861:+
LUAD	cis	rs2154319	0.887	rs61781832	ENSG00000235358.1	RP11-399E6.1	-3.99	7.62e-05	0.0112	-0.24	-0.18	Height;	chr1:41171252	chr1:41242373~41284861:+
LUAD	cis	rs9341808	0.53	rs3805877	ENSG00000233967.5	RP11-250B2.3	3.99	7.62e-05	0.0112	0.18	0.18	Sitting height ratio;	chr6:80321812	chr6:80443344~80465927:+
LUAD	cis	rs62355901	0.505	rs72759712	ENSG00000271828.1	CTD-2310F14.1	3.99	7.62e-05	0.0112	0.37	0.18	Breast cancer;	chr5:56906519	chr5:56927874~56929573:+
LUAD	cis	rs7870753	0.628	rs10820597	ENSG00000188801.9	ZNF322P1	3.99	7.62e-05	0.0112	0.27	0.18	Height;	chr9:96426065	chr9:97198303~97199511:-
LUAD	cis	rs7870753	0.628	rs2406001	ENSG00000188801.9	ZNF322P1	3.99	7.62e-05	0.0112	0.27	0.18	Height;	chr9:96426688	chr9:97198303~97199511:-
LUAD	cis	rs7870753	0.628	rs7857610	ENSG00000188801.9	ZNF322P1	3.99	7.62e-05	0.0112	0.27	0.18	Height;	chr9:96427671	chr9:97198303~97199511:-
LUAD	cis	rs10510102	0.516	rs11200306	ENSG00000276742.1	RP11-500G22.4	3.99	7.62e-05	0.0112	0.28	0.18	Breast cancer;	chr10:121980862	chr10:121956782~121957098:+
LUAD	cis	rs2836974	0.899	rs68004583	ENSG00000232608.1	TIMM9P2	-3.99	7.63e-05	0.0112	-0.21	-0.18	Cognitive function;	chr21:39287661	chr21:39216624~39217506:+
LUAD	cis	rs853679	0.517	rs2273564	ENSG00000280107.1	AL022393.9	-3.99	7.63e-05	0.0112	-0.24	-0.18	Depression;	chr6:28089816	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs1853097	ENSG00000280107.1	AL022393.9	-3.99	7.63e-05	0.0112	-0.24	-0.18	Depression;	chr6:28090857	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs9393887	ENSG00000280107.1	AL022393.9	-3.99	7.63e-05	0.0112	-0.24	-0.18	Depression;	chr6:28091242	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs9393888	ENSG00000280107.1	AL022393.9	-3.99	7.63e-05	0.0112	-0.24	-0.18	Depression;	chr6:28091439	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs3734573	ENSG00000280107.1	AL022393.9	-3.99	7.63e-05	0.0112	-0.24	-0.18	Depression;	chr6:28091659	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs9357063	ENSG00000280107.1	AL022393.9	-3.99	7.63e-05	0.0112	-0.24	-0.18	Depression;	chr6:28092227	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs3823180	ENSG00000280107.1	AL022393.9	-3.99	7.63e-05	0.0112	-0.24	-0.18	Depression;	chr6:28093966	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs9368551	ENSG00000280107.1	AL022393.9	-3.99	7.63e-05	0.0112	-0.24	-0.18	Depression;	chr6:28094014	chr6:28170845~28172521:+
LUAD	cis	rs6840360	0.582	rs2709823	ENSG00000270265.1	RP11-731D1.4	-3.99	7.63e-05	0.0112	-0.18	-0.18	Intelligence (multi-trait analysis);	chr4:151419294	chr4:151333775~151353224:-
LUAD	cis	rs2933343	0.729	rs789228	ENSG00000231305.3	RP11-723O4.2	3.99	7.63e-05	0.0112	0.2	0.18	IgG glycosylation;	chr3:128882207	chr3:128861313~128871540:-
LUAD	cis	rs17301013	0.932	rs10912807	ENSG00000227373.4	RP11-160H22.5	3.99	7.63e-05	0.0112	0.23	0.18	Systemic lupus erythematosus;	chr1:174547228	chr1:174115300~174160004:-
LUAD	cis	rs6964587	0.839	rs62466159	ENSG00000188693.7	CYP51A1-AS1	-3.99	7.63e-05	0.0112	-0.22	-0.18	Breast cancer;	chr7:91821193	chr7:92134604~92180725:+
LUAD	cis	rs755249	0.567	rs3818806	ENSG00000182109.6	RP11-69E11.4	3.99	7.63e-05	0.0112	0.22	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39282599	chr1:39522280~39546187:-
LUAD	cis	rs442309	0.846	rs224070	ENSG00000238280.1	RP11-436D10.3	-3.99	7.63e-05	0.0112	-0.21	-0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62748658	chr10:62793562~62805887:-
LUAD	cis	rs7551222	0.752	rs885012	ENSG00000240219.1	RP11-430C7.5	3.99	7.63e-05	0.0112	0.19	0.18	Schizophrenia;	chr1:204574873	chr1:204626775~204629712:+
LUAD	cis	rs735539	0.521	rs2762998	ENSG00000275485.1	RP11-261P13.6	-3.99	7.63e-05	0.0112	-0.22	-0.18	Dental caries;	chr13:20801613	chr13:20768876~20769375:-
LUAD	cis	rs2731006	0.544	rs2252131	ENSG00000257114.2	RP11-25I15.3	3.99	7.63e-05	0.0112	0.29	0.18	Panic disorder;	chr12:42772934	chr12:42692216~42717119:+
LUAD	cis	rs6472235	0.586	rs7818219	ENSG00000200714.1	Y_RNA	-3.99	7.64e-05	0.0112	-0.24	-0.18	Plateletcrit;Myopia (pathological);	chr8:66006888	chr8:65592731~65592820:+
LUAD	cis	rs2253762	0.54	rs10159634	ENSG00000276742.1	RP11-500G22.4	-3.99	7.64e-05	0.0112	-0.27	-0.18	Breast cancer;	chr10:121994520	chr10:121956782~121957098:+
LUAD	cis	rs10266483	0.739	rs11765764	ENSG00000227986.1	TRIM60P18	3.99	7.64e-05	0.0112	0.22	0.18	Response to statin therapy;	chr7:64368163	chr7:64355078~64356199:+
LUAD	cis	rs6121246	0.909	rs4518038	ENSG00000230613.1	HM13-AS1	3.99	7.64e-05	0.0112	0.28	0.18	Mean corpuscular hemoglobin;	chr20:31831248	chr20:31567707~31573263:-
LUAD	cis	rs10129255	0.957	rs28887506	ENSG00000211967.3	IGHV3-53	-3.99	7.65e-05	0.0113	-0.14	-0.18	Kawasaki disease;	chr14:106785589	chr14:106592676~106593347:-
LUAD	cis	rs2274273	0.712	rs9806049	ENSG00000258413.1	RP11-665C16.6	-3.99	7.65e-05	0.0113	-0.22	-0.18	Protein biomarker;	chr14:55058871	chr14:55262767~55272075:-
LUAD	cis	rs11259403	1	rs11259403	ENSG00000281186.1	LINC00706	-3.99	7.65e-05	0.0113	-0.2	-0.18	Body mass index in asthmatics;	chr10:6530263	chr10:6774307~6779180:-
LUAD	cis	rs4699052	1	rs6533059	ENSG00000246560.2	RP11-10L12.4	3.99	7.65e-05	0.0113	0.23	0.18	Testicular germ cell tumor;	chr4:103212219	chr4:102828055~102844075:+
LUAD	cis	rs7208859	0.573	rs73277960	ENSG00000266490.1	CTD-2349P21.9	3.99	7.65e-05	0.0113	0.26	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30850423	chr17:30792372~30792833:+
LUAD	cis	rs1334894	0.901	rs7768163	ENSG00000228559.1	RP3-340B19.3	-3.99	7.66e-05	0.0113	-0.38	-0.18	Coronary artery disease;	chr6:35524963	chr6:35544632~35545669:+
LUAD	cis	rs13113518	1	rs9312661	ENSG00000272969.1	RP11-528I4.2	3.99	7.66e-05	0.0113	0.18	0.18	Height;	chr4:55476159	chr4:55547112~55547889:+
LUAD	cis	rs865483	0.929	rs9906140	ENSG00000276054.1	RP11-378E13.3	-3.99	7.66e-05	0.0113	-0.21	-0.18	Monocyte count;	chr17:37497045	chr17:37386886~37387926:+
LUAD	cis	rs11671005	0.693	rs11084542	ENSG00000268543.1	CTD-2619J13.16	-3.99	7.66e-05	0.0113	-0.25	-0.18	Mean platelet volume;	chr19:58420732	chr19:58418560~58419310:+
LUAD	cis	rs13113518	0.841	rs7699867	ENSG00000272969.1	RP11-528I4.2	3.99	7.66e-05	0.0113	0.19	0.18	Height;	chr4:55483718	chr4:55547112~55547889:+
LUAD	cis	rs2242116	1	rs1138518	ENSG00000271161.1	BOLA2P2	3.99	7.66e-05	0.0113	0.18	0.18	Birth weight;	chr3:46902784	chr3:47499841~47500407:+
LUAD	cis	rs4705962	0.796	rs6864396	ENSG00000233006.5	AC034220.3	3.99	7.66e-05	0.0113	0.17	0.18	Atopic dermatitis;	chr5:132712183	chr5:132311285~132369916:-
LUAD	cis	rs34929064	0.718	rs60783174	ENSG00000230658.1	KLHL7-AS1	3.99	7.66e-05	0.0113	0.26	0.18	Major depression and alcohol dependence;	chr7:22686270	chr7:23101228~23105703:-
LUAD	cis	rs8062405	0.755	rs62031607	ENSG00000261419.1	RP11-57A19.4	-3.99	7.66e-05	0.0113	-0.2	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620209	chr16:28659696~28740781:-
LUAD	cis	rs2834288	0.734	rs743336	ENSG00000237945.6	LINC00649	-3.99	7.67e-05	0.0113	-0.25	-0.18	Gut microbiota (bacterial taxa);	chr21:33893080	chr21:33915534~33977691:+
LUAD	cis	rs2834288	0.734	rs743337	ENSG00000237945.6	LINC00649	-3.99	7.67e-05	0.0113	-0.25	-0.18	Gut microbiota (bacterial taxa);	chr21:33893220	chr21:33915534~33977691:+
LUAD	cis	rs7189233	0.531	rs1861351	ENSG00000279344.1	RP11-44F14.7	3.99	7.67e-05	0.0113	0.15	0.18	Intelligence (multi-trait analysis);	chr16:53499315	chr16:53478957~53481550:-
LUAD	cis	rs6674176	0.628	rs4660758	ENSG00000237950.1	RP11-7O11.3	3.99	7.67e-05	0.0113	0.23	0.18	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43959207	chr1:43944370~43946551:-
LUAD	cis	rs9650657	0.601	rs10903330	ENSG00000255046.1	RP11-297N6.4	-3.99	7.67e-05	0.0113	-0.23	-0.18	Neuroticism;	chr8:10815594	chr8:11797928~11802568:-
LUAD	cis	rs516805	0.545	rs1267948	ENSG00000279453.1	RP3-425C14.4	-3.99	7.67e-05	0.0113	-0.19	-0.18	Lymphocyte counts;	chr6:122452490	chr6:122436789~122439223:-
LUAD	cis	rs17608059	0.545	rs736261	ENSG00000236088.8	COX10-AS1	-3.99	7.67e-05	0.0113	-0.19	-0.18	Temperament;	chr17:14033087	chr17:13756478~14069495:-
LUAD	cis	rs2911132	0.564	rs13181579	ENSG00000272109.1	CTD-2260A17.3	-3.99	7.67e-05	0.0113	-0.2	-0.18	Urate levels (BMI interaction);	chr5:96755234	chr5:96804353~96806105:+
LUAD	cis	rs6787172	0.811	rs7620927	ENSG00000272087.1	RP11-379F4.7	3.99	7.67e-05	0.0113	0.19	0.18	Subjective well-being;	chr3:158528094	chr3:158693120~158693768:-
LUAD	cis	rs6787172	0.811	rs12637678	ENSG00000272087.1	RP11-379F4.7	3.99	7.67e-05	0.0113	0.19	0.18	Subjective well-being;	chr3:158530833	chr3:158693120~158693768:-
LUAD	cis	rs7555523	0.887	rs7518099	ENSG00000224358.1	RP11-466F5.8	-3.99	7.67e-05	0.0113	-0.3	-0.18	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165767643	chr1:165768929~165775176:+
LUAD	cis	rs62246343	0.541	rs17050396	ENSG00000206573.7	THUMPD3-AS1	-3.99	7.67e-05	0.0113	-0.16	-0.18	Fibrinogen levels;	chr3:9492652	chr3:9349689~9398579:-
LUAD	cis	rs28386778	1	rs3020613	ENSG00000240280.5	TCAM1P	-3.99	7.67e-05	0.0113	-0.2	-0.18	Prudent dietary pattern;	chr17:63878623	chr17:63849292~63864379:+
LUAD	cis	rs9341808	0.53	rs3805876	ENSG00000233967.5	RP11-250B2.3	3.99	7.68e-05	0.0113	0.18	0.18	Sitting height ratio;	chr6:80321822	chr6:80443344~80465927:+
LUAD	cis	rs6568686	0.577	rs174400	ENSG00000255389.1	C6orf3	3.99	7.68e-05	0.0113	0.24	0.18	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111601776	chr6:111599875~111602295:+
LUAD	cis	rs2834288	0.734	rs8126669	ENSG00000237945.6	LINC00649	-3.99	7.68e-05	0.0113	-0.25	-0.18	Gut microbiota (bacterial taxa);	chr21:33895836	chr21:33915534~33977691:+
LUAD	cis	rs2834288	0.734	rs8126592	ENSG00000237945.6	LINC00649	-3.99	7.68e-05	0.0113	-0.25	-0.18	Gut microbiota (bacterial taxa);	chr21:33895961	chr21:33915534~33977691:+
LUAD	cis	rs219780	0.784	rs219779	ENSG00000230479.1	AP000695.6	3.99	7.68e-05	0.0113	0.21	0.18	Kidney stones;	chr21:36461453	chr21:36430360~36481070:+
LUAD	cis	rs9584850	0.52	rs10508036	ENSG00000231194.1	FARP1-AS1	-3.99	7.68e-05	0.0113	-0.24	-0.18	Neuroticism;	chr13:98505144	chr13:98435405~98435840:-
LUAD	cis	rs9517320	1	rs9584856	ENSG00000231194.1	FARP1-AS1	3.99	7.68e-05	0.0113	0.2	0.18	Longevity;	chr13:98474297	chr13:98435405~98435840:-
LUAD	cis	rs6840258	0.831	rs3775211	ENSG00000251411.1	RP11-397E7.4	-3.99	7.68e-05	0.0113	-0.22	-0.18	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87117939	chr4:86913266~86914817:-
LUAD	cis	rs11672691	0.829	rs8112363	ENSG00000267107.5	PCAT19	3.99	7.68e-05	0.0113	0.22	0.18	Prostate cancer;	chr19:41483803	chr19:41454169~41500649:-
LUAD	cis	rs972578	1	rs2038062	ENSG00000230319.1	AL022476.2	3.99	7.68e-05	0.0113	0.19	0.18	Mean platelet volume;	chr22:43001960	chr22:43038585~43052366:+
LUAD	cis	rs34638952	0.507	rs2429244	ENSG00000264808.1	RP11-802D6.1	3.99	7.68e-05	0.0113	0.21	0.18	Sitting height ratio;	chr17:29270268	chr17:29369717~29390777:-
LUAD	cis	rs853679	0.55	rs1225599	ENSG00000226314.6	ZNF192P1	-3.99	7.69e-05	0.0113	-0.23	-0.18	Depression;	chr6:28197412	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.574	rs1233705	ENSG00000226314.6	ZNF192P1	-3.99	7.69e-05	0.0113	-0.23	-0.18	Depression;	chr6:28198669	chr6:28161781~28169594:+
LUAD	cis	rs875971	0.862	rs6955837	ENSG00000273448.1	RP11-166O4.6	-3.99	7.69e-05	0.0113	-0.17	-0.18	Aortic root size;	chr7:66578155	chr7:67333047~67334383:+
LUAD	cis	rs875971	0.825	rs10281499	ENSG00000273448.1	RP11-166O4.6	-3.99	7.69e-05	0.0113	-0.17	-0.18	Aortic root size;	chr7:66583979	chr7:67333047~67334383:+
LUAD	cis	rs848490	0.889	rs11764525	ENSG00000214293.7	APTR	3.99	7.69e-05	0.0113	0.23	0.18	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77648608	chr7:77657660~77696265:-
LUAD	cis	rs12073359	1	rs72692861	ENSG00000223945.2	RP11-458I7.1	-3.99	7.69e-05	0.0113	-0.26	-0.18	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150033260	chr1:150053864~150055034:+
LUAD	cis	rs897984	0.806	rs9319588	ENSG00000232748.3	RP11-196G11.6	3.99	7.69e-05	0.0113	0.22	0.18	Dementia with Lewy bodies;	chr16:30919662	chr16:31056460~31062803:+
LUAD	cis	rs897984	0.77	rs12930657	ENSG00000232748.3	RP11-196G11.6	3.99	7.69e-05	0.0113	0.22	0.18	Dementia with Lewy bodies;	chr16:30920647	chr16:31056460~31062803:+
LUAD	cis	rs494562	0.892	rs7753711	ENSG00000234155.1	RP11-30P6.6	3.99	7.69e-05	0.0113	0.34	0.18	Metabolic traits;Blood metabolite levels;	chr6:85420981	chr6:85387219~85390186:-
LUAD	cis	rs7119038	0.818	rs1048024	ENSG00000255239.1	AP002954.6	-3.99	7.7e-05	0.0113	-0.27	-0.18	Sjögren's syndrome;	chr11:118748067	chr11:118688039~118690600:-
LUAD	cis	rs6661961	0.686	rs7555924	ENSG00000237975.5	FLG-AS1	-3.99	7.7e-05	0.0113	-0.24	-0.18	Atopic dermatitis;	chr1:152424593	chr1:152168125~152445456:+
LUAD	cis	rs2239557	1	rs7153160	ENSG00000259065.1	RP5-1021I20.1	-3.99	7.7e-05	0.0113	-0.21	-0.18	Common traits (Other);	chr14:74042674	chr14:73787360~73803270:+
LUAD	cis	rs9894429	0.966	rs10871499	ENSG00000263853.1	AC139530.1	-3.99	7.7e-05	0.0113	-0.18	-0.18	Eye color traits;	chr17:81621980	chr17:81676001~81676086:+
LUAD	cis	rs7493	0.95	rs11977702	ENSG00000233942.1	AC004012.1	3.99	7.7e-05	0.0113	0.26	0.18	Yu-Zhi constitution type in type 2 diabetes;	chr7:95400455	chr7:95471835~95473998:+
LUAD	cis	rs2732480	0.577	rs2732479	ENSG00000240399.1	RP1-228P16.1	3.99	7.7e-05	0.0113	0.18	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342477	chr12:48054813~48055591:-
LUAD	cis	rs2732480	0.537	rs1061986	ENSG00000240399.1	RP1-228P16.1	3.99	7.7e-05	0.0113	0.18	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342656	chr12:48054813~48055591:-
LUAD	cis	rs2836754	1	rs2836753	ENSG00000205622.8	AF064858.6	-3.99	7.7e-05	0.0113	-0.2	-0.18	Body mass index;Crohn's disease;	chr21:38919263	chr21:38863676~38956467:-
LUAD	cis	rs12073359	1	rs58426216	ENSG00000223945.2	RP11-458I7.1	-3.99	7.7e-05	0.0113	-0.26	-0.18	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150152425	chr1:150053864~150055034:+
LUAD	cis	rs2274273	0.901	rs10140801	ENSG00000258413.1	RP11-665C16.6	-3.99	7.7e-05	0.0113	-0.23	-0.18	Protein biomarker;	chr14:55263686	chr14:55262767~55272075:-
LUAD	cis	rs7551222	0.752	rs12039454	ENSG00000240219.1	RP11-430C7.5	-3.99	7.7e-05	0.0113	-0.19	-0.18	Schizophrenia;	chr1:204573452	chr1:204626775~204629712:+
LUAD	cis	rs853679	0.76	rs9468317	ENSG00000204709.4	LINC01556	3.99	7.7e-05	0.0113	0.26	0.18	Depression;	chr6:28230678	chr6:28943877~28944537:+
LUAD	cis	rs1790761	0.504	rs61894496	ENSG00000184224.3	C11orf72	3.99	7.71e-05	0.0113	0.21	0.18	Mean corpuscular volume;	chr11:67624436	chr11:67602880~67606706:-
LUAD	cis	rs10463554	0.963	rs257115	ENSG00000250682.4	LINC00491	3.99	7.71e-05	0.0113	0.21	0.18	Parkinson's disease;	chr5:103196107	chr5:102609156~102671559:-
LUAD	cis	rs10419113	0.522	rs2158013	ENSG00000270804.1	CTD-2583A14.11	3.99	7.71e-05	0.0113	0.17	0.18	Pediatric bone mineral density (spine);	chr19:57779860	chr19:57867885~57868834:+
LUAD	cis	rs9309473	1	rs7585004	ENSG00000230002.2	ALMS1-IT1	3.99	7.71e-05	0.0113	0.23	0.18	Metabolite levels;	chr2:73439517	chr2:73456764~73459484:+
LUAD	cis	rs9637599	0.967	rs4693209	ENSG00000246375.2	RP11-10L7.1	3.99	7.71e-05	0.0113	0.23	0.18	Metabolite levels (small molecules and protein measures);	chr4:88265916	chr4:88284942~88331421:+
LUAD	cis	rs2299587	0.56	rs391299	ENSG00000253671.1	RP11-806O11.1	-3.99	7.71e-05	0.0113	-0.2	-0.18	Economic and political preferences;	chr8:17921413	chr8:17808941~17820868:+
LUAD	cis	rs7809950	1	rs4727680	ENSG00000238832.1	snoU109	-3.99	7.71e-05	0.0113	-0.26	-0.18	Coronary artery disease;	chr7:107446962	chr7:107603363~107603507:+
LUAD	cis	rs6570726	0.902	rs973855	ENSG00000235652.6	RP11-545I5.3	-3.99	7.71e-05	0.0113	-0.18	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145460714	chr6:145799409~145886585:+
LUAD	cis	rs9649213	0.593	rs6947340	ENSG00000272950.1	RP11-307C18.1	-3.99	7.71e-05	0.0113	-0.22	-0.18	Prostate cancer (SNP x SNP interaction);	chr7:98282929	chr7:98322853~98323430:+
LUAD	cis	rs5758659	0.652	rs129857	ENSG00000270083.1	RP1-257I20.14	-3.99	7.72e-05	0.0113	-0.17	-0.18	Cognitive function;	chr22:42003682	chr22:42089630~42090028:-
LUAD	cis	rs910316	0.763	rs4556	ENSG00000259138.1	RP11-950C14.7	3.99	7.72e-05	0.0113	0.19	0.18	Height;	chr14:75009368	chr14:75127153~75136930:+
LUAD	cis	rs10197140	0.857	rs1513826	ENSG00000235721.1	AC013268.3	-3.99	7.72e-05	0.0113	-0.19	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110903133	chr2:110007675~110010783:+
LUAD	cis	rs853679	0.517	rs3757187	ENSG00000280107.1	AL022393.9	-3.99	7.72e-05	0.0113	-0.24	-0.18	Depression;	chr6:28139876	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs3757185	ENSG00000280107.1	AL022393.9	-3.99	7.72e-05	0.0113	-0.24	-0.18	Depression;	chr6:28139998	chr6:28170845~28172521:+
LUAD	cis	rs4835473	0.932	rs12512649	ENSG00000249741.2	RP11-673E1.3	3.99	7.72e-05	0.0113	0.21	0.18	Immature fraction of reticulocytes;	chr4:143736745	chr4:143911514~143912053:-
LUAD	cis	rs8054556	0.647	rs8048433	ENSG00000214725.6	CDIPT-AS1	-3.99	7.72e-05	0.0114	-0.21	-0.18	Autism spectrum disorder or schizophrenia;	chr16:29920272	chr16:29863593~29868053:+
LUAD	cis	rs6088580	0.601	rs6059872	ENSG00000276073.1	RP5-1125A11.7	-3.99	7.72e-05	0.0114	-0.18	-0.18	Glomerular filtration rate (creatinine);	chr20:34494970	chr20:33985617~33988989:-
LUAD	cis	rs7204230	1	rs17303428	ENSG00000261291.1	RP11-295M3.2	3.99	7.72e-05	0.0114	0.22	0.18	Fibrinogen;	chr16:53283844	chr16:53168522~53169450:+
LUAD	cis	rs6689263	0.932	rs75810319	ENSG00000117242.7	PINK1-AS	3.99	7.73e-05	0.0114	0.38	0.18	Intelligence (multi-trait analysis);	chr1:20480580	chr1:20642657~20652193:-
LUAD	cis	rs858239	0.799	rs10279941	ENSG00000226816.2	AC005082.12	3.99	7.73e-05	0.0114	0.24	0.18	Cerebrospinal fluid biomarker levels;	chr7:23330889	chr7:23206013~23208045:+
LUAD	cis	rs2617170	0.922	rs2250877	ENSG00000245648.1	RP11-277P12.20	3.99	7.73e-05	0.0114	0.22	0.18	Behcet's disease;	chr12:10393659	chr12:10363769~10398506:+
LUAD	cis	rs2657294	0.965	rs2395140	ENSG00000226051.5	ZNF503-AS1	-3.99	7.73e-05	0.0114	-0.24	-0.18	Pneumonia;	chr10:75139253	chr10:75269819~75373500:+
LUAD	cis	rs2657294	0.965	rs2997754	ENSG00000226051.5	ZNF503-AS1	-3.99	7.73e-05	0.0114	-0.24	-0.18	Pneumonia;	chr10:75144379	chr10:75269819~75373500:+
LUAD	cis	rs2657294	0.965	rs2047951	ENSG00000226051.5	ZNF503-AS1	-3.99	7.73e-05	0.0114	-0.24	-0.18	Pneumonia;	chr10:75161310	chr10:75269819~75373500:+
LUAD	cis	rs2657294	0.965	rs2804523	ENSG00000226051.5	ZNF503-AS1	-3.99	7.73e-05	0.0114	-0.24	-0.18	Pneumonia;	chr10:75161584	chr10:75269819~75373500:+
LUAD	cis	rs11673344	0.832	rs77772684	ENSG00000267309.1	CTD-2630F21.1	-3.99	7.73e-05	0.0114	-0.23	-0.18	Obesity-related traits;	chr19:37055838	chr19:36489649~36491040:+
LUAD	cis	rs9815354	1	rs17063584	ENSG00000273328.4	RP11-141M3.6	-3.99	7.73e-05	0.0114	-0.26	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41819971	chr3:42809414~42908105:+
LUAD	cis	rs12073359	1	rs72692896	ENSG00000223945.2	RP11-458I7.1	-3.99	7.73e-05	0.0114	-0.26	-0.18	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150076793	chr1:150053864~150055034:+
LUAD	cis	rs3764021	1	rs7977720	ENSG00000256582.1	RP11-75L1.1	3.99	7.73e-05	0.0114	0.18	0.18	Type 1 diabetes;	chr12:9713753	chr12:9704077~9709350:+
LUAD	cis	rs812925	0.784	rs1177304	ENSG00000271889.1	RP11-493E12.1	3.99	7.73e-05	0.0114	0.22	0.18	Immature fraction of reticulocytes;	chr2:61161029	chr2:61151433~61162105:-
LUAD	cis	rs7647973	0.56	rs7638154	ENSG00000225399.4	RP11-3B7.1	3.99	7.73e-05	0.0114	0.23	0.18	Menarche (age at onset);	chr3:49261942	chr3:49260085~49261316:+
LUAD	cis	rs2354432	0.556	rs72710311	ENSG00000226015.2	CCT8P1	3.99	7.74e-05	0.0114	0.36	0.18	Mitochondrial DNA levels;	chr1:147226659	chr1:147203276~147204932:-
LUAD	cis	rs7955901	0.904	rs7313973	ENSG00000258053.1	CTD-2021H9.3	-3.99	7.74e-05	0.0114	-0.21	-0.18	Type 2 diabetes;	chr12:71050278	chr12:71047402~71118247:-
LUAD	cis	rs6479891	1	rs11817689	ENSG00000232075.1	MRPL35P2	-3.99	7.74e-05	0.0114	-0.29	-0.18	Arthritis (juvenile idiopathic);	chr10:63164457	chr10:63634317~63634827:-
LUAD	cis	rs2904524	0.867	rs17107870	ENSG00000257613.1	LINC01481	-3.99	7.74e-05	0.0114	-0.32	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70251669	chr12:70219132~70221862:-
LUAD	cis	rs728616	0.867	rs34870056	ENSG00000225484.5	NUTM2B-AS1	-3.99	7.74e-05	0.0114	-0.46	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80188299	chr10:79663088~79826594:-
LUAD	cis	rs6088580	0.634	rs6088512	ENSG00000276073.1	RP5-1125A11.7	-3.99	7.74e-05	0.0114	-0.17	-0.18	Glomerular filtration rate (creatinine);	chr20:34508086	chr20:33985617~33988989:-
LUAD	cis	rs6088580	0.634	rs6059896	ENSG00000276073.1	RP5-1125A11.7	-3.99	7.74e-05	0.0114	-0.17	-0.18	Glomerular filtration rate (creatinine);	chr20:34523978	chr20:33985617~33988989:-
LUAD	cis	rs7200786	0.546	rs11643622	ENSG00000274038.1	RP11-66H6.4	-3.99	7.74e-05	0.0114	-0.23	-0.18	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11131658	chr16:11056556~11057034:+
LUAD	cis	rs853679	0.55	rs9295762	ENSG00000280107.1	AL022393.9	3.99	7.74e-05	0.0114	0.22	0.18	Depression;	chr6:28187640	chr6:28170845~28172521:+
LUAD	cis	rs6840360	0.642	rs2724567	ENSG00000270265.1	RP11-731D1.4	3.99	7.74e-05	0.0114	0.18	0.18	Intelligence (multi-trait analysis);	chr4:151430008	chr4:151333775~151353224:-
LUAD	cis	rs853679	0.517	rs9468298	ENSG00000226314.6	ZNF192P1	-3.99	7.75e-05	0.0114	-0.24	-0.18	Depression;	chr6:28154567	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs9295759	ENSG00000226314.6	ZNF192P1	-3.99	7.75e-05	0.0114	-0.24	-0.18	Depression;	chr6:28156691	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs9348796	ENSG00000226314.6	ZNF192P1	-3.99	7.75e-05	0.0114	-0.24	-0.18	Depression;	chr6:28158424	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs11552219	ENSG00000226314.6	ZNF192P1	-3.99	7.75e-05	0.0114	-0.24	-0.18	Depression;	chr6:28159056	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs9380058	ENSG00000226314.6	ZNF192P1	-3.99	7.75e-05	0.0114	-0.24	-0.18	Depression;	chr6:28159666	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs9393895	ENSG00000226314.6	ZNF192P1	-3.99	7.75e-05	0.0114	-0.24	-0.18	Depression;	chr6:28159843	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs9357066	ENSG00000226314.6	ZNF192P1	-3.99	7.75e-05	0.0114	-0.24	-0.18	Depression;	chr6:28162053	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs9393898	ENSG00000226314.6	ZNF192P1	-3.99	7.75e-05	0.0114	-0.24	-0.18	Depression;	chr6:28162598	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs9368556	ENSG00000226314.6	ZNF192P1	-3.99	7.75e-05	0.0114	-0.24	-0.18	Depression;	chr6:28163375	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs9368557	ENSG00000226314.6	ZNF192P1	-3.99	7.75e-05	0.0114	-0.24	-0.18	Depression;	chr6:28163759	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs9380059	ENSG00000226314.6	ZNF192P1	-3.99	7.75e-05	0.0114	-0.24	-0.18	Depression;	chr6:28164580	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs9380060	ENSG00000226314.6	ZNF192P1	-3.99	7.75e-05	0.0114	-0.24	-0.18	Depression;	chr6:28164825	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs35227624	ENSG00000226314.6	ZNF192P1	-3.99	7.75e-05	0.0114	-0.24	-0.18	Depression;	chr6:28164948	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs9380061	ENSG00000226314.6	ZNF192P1	-3.99	7.75e-05	0.0114	-0.24	-0.18	Depression;	chr6:28165025	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs9368558	ENSG00000226314.6	ZNF192P1	-3.99	7.75e-05	0.0114	-0.24	-0.18	Depression;	chr6:28165528	chr6:28161781~28169594:+
LUAD	cis	rs4713118	0.587	rs9393899	ENSG00000226314.6	ZNF192P1	-3.99	7.75e-05	0.0114	-0.24	-0.18	Parkinson's disease;	chr6:28165750	chr6:28161781~28169594:+
LUAD	cis	rs4713118	0.527	rs4713151	ENSG00000226314.6	ZNF192P1	-3.99	7.75e-05	0.0114	-0.24	-0.18	Parkinson's disease;	chr6:28168578	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs9393901	ENSG00000226314.6	ZNF192P1	-3.99	7.75e-05	0.0114	-0.24	-0.18	Depression;	chr6:28169019	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs3173443	ENSG00000226314.6	ZNF192P1	-3.99	7.75e-05	0.0114	-0.24	-0.18	Depression;	chr6:28169249	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs9348797	ENSG00000226314.6	ZNF192P1	-3.99	7.75e-05	0.0114	-0.24	-0.18	Depression;	chr6:28169755	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.517	rs9380062	ENSG00000226314.6	ZNF192P1	-3.99	7.75e-05	0.0114	-0.24	-0.18	Depression;	chr6:28169791	chr6:28161781~28169594:+
LUAD	cis	rs853679	0.542	rs9380063	ENSG00000226314.6	ZNF192P1	-3.99	7.75e-05	0.0114	-0.24	-0.18	Depression;	chr6:28170075	chr6:28161781~28169594:+
LUAD	cis	rs860295	0.702	rs10908471	ENSG00000225855.5	RUSC1-AS1	3.99	7.75e-05	0.0114	0.13	0.18	Body mass index;	chr1:155573151	chr1:155316863~155324176:-
LUAD	cis	rs860295	0.702	rs10908472	ENSG00000225855.5	RUSC1-AS1	3.99	7.75e-05	0.0114	0.13	0.18	Body mass index;	chr1:155574465	chr1:155316863~155324176:-
LUAD	cis	rs860295	0.702	rs11264383	ENSG00000225855.5	RUSC1-AS1	3.99	7.75e-05	0.0114	0.13	0.18	Body mass index;	chr1:155575555	chr1:155316863~155324176:-
LUAD	cis	rs7208859	0.528	rs3764416	ENSG00000263603.1	CTD-2349P21.5	3.99	7.75e-05	0.0114	0.29	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30573690	chr17:30729469~30731202:+
LUAD	cis	rs4594175	0.565	rs4078417	ENSG00000258955.1	LINC00519	-3.99	7.75e-05	0.0114	-0.21	-0.18	Cancer;	chr14:51290164	chr14:51304416~51328386:-
LUAD	cis	rs13113518	0.812	rs12505880	ENSG00000272969.1	RP11-528I4.2	3.99	7.75e-05	0.0114	0.19	0.18	Height;	chr4:55440988	chr4:55547112~55547889:+
LUAD	cis	rs6495122	0.501	rs12904227	ENSG00000260269.4	CTD-2323K18.1	3.99	7.75e-05	0.0114	0.22	0.18	Diastolic blood pressure;Coffee consumption;Caffeine consumption;	chr15:75094707	chr15:75527150~75601205:-
LUAD	cis	rs1346081	1	rs6552079	ENSG00000250075.4	RP11-584P21.2	-3.99	7.75e-05	0.0114	-0.2	-0.18	Intelligence (multi-trait analysis);	chr4:67160674	chr4:67417305~67468251:-
LUAD	cis	rs10129255	0.957	rs4387509	ENSG00000211967.3	IGHV3-53	-3.99	7.75e-05	0.0114	-0.14	-0.18	Kawasaki disease;	chr14:106704386	chr14:106592676~106593347:-
LUAD	cis	rs6951245	1	rs80212261	ENSG00000199023.2	MIR339	-3.99	7.75e-05	0.0114	-0.32	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1074376	chr7:1022935~1023045:-
LUAD	cis	rs9894429	0.966	rs6565604	ENSG00000263853.1	AC139530.1	-3.99	7.75e-05	0.0114	-0.18	-0.18	Eye color traits;	chr17:81622216	chr17:81676001~81676086:+
LUAD	cis	rs7178424	0.811	rs12593844	ENSG00000259251.2	RP11-643M14.1	3.99	7.75e-05	0.0114	0.18	0.18	Height;	chr15:61954868	chr15:62060503~62062434:+
LUAD	cis	rs453301	0.506	rs476845	ENSG00000253893.2	FAM85B	3.99	7.75e-05	0.0114	0.21	0.18	Joint mobility (Beighton score);	chr8:8765367	chr8:8167819~8226614:-
LUAD	cis	rs7512552	0.839	rs2647373	ENSG00000275557.1	RP11-353N4.6	3.99	7.76e-05	0.0114	0.2	0.18	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150348094	chr1:149607765~149612402:+
LUAD	cis	rs7512552	0.839	rs2794684	ENSG00000275557.1	RP11-353N4.6	3.99	7.76e-05	0.0114	0.2	0.18	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150348095	chr1:149607765~149612402:+
LUAD	cis	rs6088580	0.634	rs6059875	ENSG00000276073.1	RP5-1125A11.7	-3.99	7.76e-05	0.0114	-0.17	-0.18	Glomerular filtration rate (creatinine);	chr20:34498285	chr20:33985617~33988989:-
LUAD	cis	rs2638953	0.962	rs73261702	ENSG00000278733.1	RP11-425D17.1	-3.99	7.76e-05	0.0114	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28204118	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs11049455	ENSG00000278733.1	RP11-425D17.1	-3.99	7.76e-05	0.0114	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28204758	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs11049457	ENSG00000278733.1	RP11-425D17.1	-3.99	7.76e-05	0.0114	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205050	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.886	rs10843131	ENSG00000278733.1	RP11-425D17.1	-3.99	7.76e-05	0.0114	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205259	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs10843132	ENSG00000278733.1	RP11-425D17.1	-3.99	7.76e-05	0.0114	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205348	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs10843133	ENSG00000278733.1	RP11-425D17.1	-3.99	7.76e-05	0.0114	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205571	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs10843135	ENSG00000278733.1	RP11-425D17.1	-3.99	7.76e-05	0.0114	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205809	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.886	rs11049458	ENSG00000278733.1	RP11-425D17.1	-3.99	7.76e-05	0.0114	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205834	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs11049459	ENSG00000278733.1	RP11-425D17.1	-3.99	7.76e-05	0.0114	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206011	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs11049460	ENSG00000278733.1	RP11-425D17.1	-3.99	7.76e-05	0.0114	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206021	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs1824767	ENSG00000278733.1	RP11-425D17.1	-3.99	7.76e-05	0.0114	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206653	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs1824766	ENSG00000278733.1	RP11-425D17.1	-3.99	7.76e-05	0.0114	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206655	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs1585682	ENSG00000278733.1	RP11-425D17.1	-3.99	7.76e-05	0.0114	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206841	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.888	rs9645745	ENSG00000278733.1	RP11-425D17.1	-3.99	7.76e-05	0.0114	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28207082	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs7973516	ENSG00000278733.1	RP11-425D17.1	-3.99	7.76e-05	0.0114	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28207523	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs7973656	ENSG00000278733.1	RP11-425D17.1	-3.99	7.76e-05	0.0114	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28207679	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs7971033	ENSG00000278733.1	RP11-425D17.1	-3.99	7.76e-05	0.0114	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28208420	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs7956418	ENSG00000278733.1	RP11-425D17.1	-3.99	7.76e-05	0.0114	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28208566	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs11519094	ENSG00000278733.1	RP11-425D17.1	-3.99	7.76e-05	0.0114	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209430	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs11513465	ENSG00000278733.1	RP11-425D17.1	-3.99	7.76e-05	0.0114	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209483	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs11513250	ENSG00000278733.1	RP11-425D17.1	-3.99	7.76e-05	0.0114	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209500	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs11519330	ENSG00000278733.1	RP11-425D17.1	-3.99	7.76e-05	0.0114	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209720	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.85	rs11519331	ENSG00000278733.1	RP11-425D17.1	-3.99	7.76e-05	0.0114	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209995	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.888	rs11513466	ENSG00000278733.1	RP11-425D17.1	-3.99	7.76e-05	0.0114	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210111	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs7298652	ENSG00000278733.1	RP11-425D17.1	-3.99	7.76e-05	0.0114	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210620	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs6487669	ENSG00000278733.1	RP11-425D17.1	-3.99	7.76e-05	0.0114	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210827	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs6487671	ENSG00000278733.1	RP11-425D17.1	-3.99	7.76e-05	0.0114	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210902	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs11049464	ENSG00000278733.1	RP11-425D17.1	-3.99	7.76e-05	0.0114	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28211637	chr12:28185625~28186190:-
LUAD	cis	rs453301	0.686	rs28665409	ENSG00000233609.3	RP11-62H7.2	-3.99	7.76e-05	0.0114	-0.15	-0.18	Joint mobility (Beighton score);	chr8:9011767	chr8:8961200~8979025:+
LUAD	cis	rs7204230	1	rs1558682	ENSG00000261291.1	RP11-295M3.2	3.99	7.76e-05	0.0114	0.22	0.18	Fibrinogen;	chr16:53250525	chr16:53168522~53169450:+
LUAD	cis	rs2732480	0.5	rs7315820	ENSG00000257763.1	OR5BK1P	3.99	7.76e-05	0.0114	0.19	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48205155	chr12:48355792~48356614:-
LUAD	cis	rs9650657	0.589	rs12542037	ENSG00000255046.1	RP11-297N6.4	-3.99	7.76e-05	0.0114	-0.22	-0.18	Neuroticism;	chr8:10900986	chr8:11797928~11802568:-
LUAD	cis	rs62103177	0.608	rs4442895	ENSG00000274828.1	RP11-567M16.6	3.99	7.76e-05	0.0114	0.22	0.18	Opioid sensitivity;	chr18:80066399	chr18:79677287~79679358:-
LUAD	cis	rs858239	0.508	rs7805071	ENSG00000226816.2	AC005082.12	3.99	7.76e-05	0.0114	0.24	0.18	Cerebrospinal fluid biomarker levels;	chr7:23150593	chr7:23206013~23208045:+
LUAD	cis	rs858239	0.508	rs7805085	ENSG00000226816.2	AC005082.12	3.99	7.76e-05	0.0114	0.24	0.18	Cerebrospinal fluid biomarker levels;	chr7:23150624	chr7:23206013~23208045:+
LUAD	cis	rs6479901	0.895	rs7909555	ENSG00000232075.1	MRPL35P2	-3.99	7.76e-05	0.0114	-0.25	-0.18	Intelligence (multi-trait analysis);	chr10:63273348	chr10:63634317~63634827:-
LUAD	cis	rs3764400	0.508	rs2240121	ENSG00000278765.1	RP5-890E16.5	3.99	7.76e-05	0.0114	0.33	0.18	Body mass index;	chr17:48074960	chr17:48066704~48067293:-
LUAD	cis	rs2153535	0.585	rs1328874	ENSG00000230939.1	RP11-314C16.1	-3.99	7.77e-05	0.0114	-0.2	-0.18	Motion sickness;	chr6:8621010	chr6:8784178~8785445:+
LUAD	cis	rs2273156	0.57	rs78207779	ENSG00000226677.3	IGBP1P1	-3.99	7.77e-05	0.0114	-0.28	-0.18	Immunoglobulin light chain (AL) amyloidosis;	chr14:35037181	chr14:34939324~34940332:+
LUAD	cis	rs2273156	0.501	rs5014384	ENSG00000226677.3	IGBP1P1	-3.99	7.77e-05	0.0114	-0.28	-0.18	Immunoglobulin light chain (AL) amyloidosis;	chr14:35038468	chr14:34939324~34940332:+
LUAD	cis	rs2273156	0.57	rs4594164	ENSG00000226677.3	IGBP1P1	-3.99	7.77e-05	0.0114	-0.28	-0.18	Immunoglobulin light chain (AL) amyloidosis;	chr14:35040365	chr14:34939324~34940332:+
LUAD	cis	rs9901225	1	rs9901225	ENSG00000108785.7	HSD17B1P1	-3.99	7.77e-05	0.0114	-0.19	-0.18	Colorectal or endometrial cancer;	chr17:42603793	chr17:42546764~42548706:+
LUAD	cis	rs6472235	0.586	rs2357570	ENSG00000200714.1	Y_RNA	-3.99	7.77e-05	0.0114	-0.24	-0.18	Plateletcrit;Myopia (pathological);	chr8:66005760	chr8:65592731~65592820:+
LUAD	cis	rs858239	0.6	rs13438188	ENSG00000226816.2	AC005082.12	-3.99	7.77e-05	0.0114	-0.22	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23206013~23208045:+
LUAD	cis	rs6479901	0.512	rs7100372	ENSG00000232075.1	MRPL35P2	-3.99	7.77e-05	0.0114	-0.29	-0.18	Intelligence (multi-trait analysis);	chr10:63304484	chr10:63634317~63634827:-
LUAD	cis	rs6921919	0.551	rs13201753	ENSG00000219392.1	RP1-265C24.5	-3.99	7.77e-05	0.0114	-0.23	-0.18	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28115628~28116551:+
LUAD	cis	rs911119	0.866	rs6048925	ENSG00000270001.1	RP11-218C14.8	-3.99	7.77e-05	0.0114	-0.26	-0.18	Chronic kidney disease;	chr20:23598419	chr20:23631826~23632316:-
LUAD	cis	rs728616	0.717	rs12412999	ENSG00000234382.2	RP11-40F6.1	-3.99	7.77e-05	0.0114	-0.46	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80248385	chr10:80233664~80245367:+
LUAD	cis	rs763121	0.853	rs2294296	ENSG00000225450.1	RP3-508I15.14	-3.99	7.77e-05	0.0114	-0.18	-0.18	Menopause (age at onset);	chr22:38657044	chr22:38739003~38749041:+
LUAD	cis	rs2348418	0.798	rs7310297	ENSG00000247934.4	RP11-967K21.1	3.99	7.78e-05	0.0114	0.21	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28313638	chr12:28163298~28190738:-
LUAD	cis	rs9393777	0.764	rs35565446	ENSG00000219392.1	RP1-265C24.5	-3.99	7.78e-05	0.0114	-0.41	-0.18	Intelligence (multi-trait analysis);	chr6:27177562	chr6:28115628~28116551:+
LUAD	cis	rs9633740	1	rs1870138	ENSG00000226659.1	RP11-137H2.4	-3.99	7.78e-05	0.0114	-0.29	-0.18	Post bronchodilator FEV1;	chr10:80509855	chr10:80529597~80535942:-
LUAD	cis	rs2348418	0.715	rs1912782	ENSG00000247934.4	RP11-967K21.1	3.99	7.79e-05	0.0114	0.21	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28568774	chr12:28163298~28190738:-
LUAD	cis	rs6071166	0.683	rs6071049	ENSG00000224635.1	RP4-564F22.5	-3.99	7.79e-05	0.0114	-0.2	-0.18	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38677386	chr20:38406011~38416797:-
LUAD	cis	rs638893	0.947	rs1170396	ENSG00000255239.1	AP002954.6	3.99	7.79e-05	0.0114	0.29	0.18	Vitiligo;	chr11:118833108	chr11:118688039~118690600:-
LUAD	cis	rs77688320	0.535	rs10460403	ENSG00000213090.2	AC007256.5	3.99	7.79e-05	0.0114	0.2	0.18	Breast cancer;	chr2:201478014	chr2:201410544~201413308:-
LUAD	cis	rs360798	0.656	rs1997246	ENSG00000231609.4	AC009501.4	3.99	7.79e-05	0.0114	0.2	0.18	Coronary artery disease;	chr2:62640212	chr2:63043922~63048640:-
LUAD	cis	rs7762018	1	rs6912959	ENSG00000231690.2	LINC00574	-3.99	7.79e-05	0.0114	-0.34	-0.18	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169726128	chr6:169790321~169802873:+
LUAD	cis	rs7580658	0.891	rs55998967	ENSG00000236682.1	AC068282.3	-3.98	7.8e-05	0.0114	-0.24	-0.18	Protein C levels;	chr2:127291098	chr2:127389130~127400580:+
LUAD	cis	rs394563	0.591	rs237026	ENSG00000216906.2	RP11-350J20.9	3.98	7.8e-05	0.0114	0.21	0.18	Dupuytren's disease;	chr6:149399545	chr6:149904243~149906418:+
LUAD	cis	rs7937890	0.559	rs2575853	ENSG00000254418.1	RP11-21L19.1	3.98	7.8e-05	0.0114	0.21	0.18	Mitochondrial DNA levels;	chr11:14512417	chr11:14262846~14273691:-
LUAD	cis	rs9295536	0.58	rs16885627	ENSG00000260455.1	NBAT1	3.98	7.8e-05	0.0114	0.22	0.18	Neuroblastoma;	chr6:22115568	chr6:22134957~22147193:-
LUAD	cis	rs2354432	0.607	rs9661159	ENSG00000237188.3	RP11-337C18.8	3.98	7.8e-05	0.0114	0.34	0.18	Mitochondrial DNA levels;	chr1:147286246	chr1:147172771~147211568:+
LUAD	cis	rs35740288	0.822	rs34734963	ENSG00000259407.1	RP11-158M2.3	-3.98	7.8e-05	0.0114	-0.18	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85674413	chr15:85744109~85750281:-
LUAD	cis	rs2153535	0.585	rs7762631	ENSG00000230939.1	RP11-314C16.1	3.98	7.8e-05	0.0114	0.2	0.18	Motion sickness;	chr6:8635339	chr6:8784178~8785445:+
LUAD	cis	rs17122278	1	rs2277295	ENSG00000243431.1	RPL5P30	3.98	7.8e-05	0.0114	0.22	0.18	Total cholesterol levels;	chr11:118545538	chr11:118560690~118561580:+
LUAD	cis	rs2274273	0.84	rs2009291	ENSG00000258413.1	RP11-665C16.6	3.98	7.8e-05	0.0114	0.23	0.18	Protein biomarker;	chr14:55371512	chr14:55262767~55272075:-
LUAD	cis	rs6661961	0.752	rs16834090	ENSG00000237975.5	FLG-AS1	-3.98	7.8e-05	0.0114	-0.24	-0.18	Atopic dermatitis;	chr1:152460428	chr1:152168125~152445456:+
LUAD	cis	rs2153535	0.518	rs4959493	ENSG00000230939.1	RP11-314C16.1	-3.98	7.8e-05	0.0114	-0.21	-0.18	Motion sickness;	chr6:8588503	chr6:8784178~8785445:+
LUAD	cis	rs7551222	0.752	rs2369244	ENSG00000240219.1	RP11-430C7.5	-3.98	7.8e-05	0.0115	-0.19	-0.18	Schizophrenia;	chr1:204546171	chr1:204626775~204629712:+
LUAD	cis	rs253959	0.545	rs4921057	ENSG00000272265.1	CTD-2287O16.4	3.98	7.81e-05	0.0115	0.21	0.18	Bipolar disorder and schizophrenia;	chr5:116090723	chr5:116078110~116078570:-
LUAD	cis	rs1075265	0.62	rs2542584	ENSG00000272156.1	RP11-477N3.1	-3.98	7.81e-05	0.0115	-0.22	-0.18	Chronotype;Morning vs. evening chronotype;	chr2:53782707	chr2:54082554~54085066:+
LUAD	cis	rs9545047	0.604	rs9545052	ENSG00000227354.5	RBM26-AS1	3.98	7.81e-05	0.0115	0.19	0.18	Schizophrenia;	chr13:79294875	chr13:79406309~79424328:+
LUAD	cis	rs12898179	0.53	rs17093620	ENSG00000258561.1	RP11-72M17.1	3.98	7.81e-05	0.0115	0.27	0.18	Glomerular filtration rate in chronic kidney disease;	chr14:67506205	chr14:66212810~66509394:-
LUAD	cis	rs13276960	0.794	rs28613197	ENSG00000253328.2	SUMO2P19	-3.98	7.82e-05	0.0115	-0.21	-0.18	Schizophrenia;	chr8:102926713	chr8:102242040~102242619:-
LUAD	cis	rs13276960	0.794	rs6468847	ENSG00000253328.2	SUMO2P19	-3.98	7.82e-05	0.0115	-0.21	-0.18	Schizophrenia;	chr8:102927991	chr8:102242040~102242619:-
LUAD	cis	rs8014252	0.803	rs7157618	ENSG00000259158.2	ADAM20P1	-3.98	7.82e-05	0.0115	-0.29	-0.18	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70543449	chr14:70468881~70483756:-
LUAD	cis	rs2638953	0.886	rs11049429	ENSG00000278733.1	RP11-425D17.1	-3.98	7.82e-05	0.0115	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28194332	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.779	rs11049432	ENSG00000278733.1	RP11-425D17.1	-3.98	7.82e-05	0.0115	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28194454	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.85	rs4284426	ENSG00000278733.1	RP11-425D17.1	-3.98	7.82e-05	0.0115	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28194543	chr12:28185625~28186190:-
LUAD	cis	rs4699052	0.625	rs10212959	ENSG00000246560.2	RP11-10L12.4	-3.98	7.82e-05	0.0115	-0.23	-0.18	Testicular germ cell tumor;	chr4:103379778	chr4:102828055~102844075:+
LUAD	cis	rs2446066	0.872	rs36065378	ENSG00000257379.1	RP11-793H13.8	3.98	7.82e-05	0.0115	0.3	0.18	Red blood cell count;	chr12:53380995	chr12:53441741~53467528:+
LUAD	cis	rs12908161	0.515	rs12907646	ENSG00000259295.5	CSPG4P12	3.98	7.82e-05	0.0115	0.27	0.18	Schizophrenia;	chr15:84860265	chr15:85191438~85213905:+
LUAD	cis	rs14027	0.536	rs28827321	ENSG00000279347.1	RP11-85I17.2	-3.98	7.82e-05	0.0115	-0.16	-0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119709534	chr8:119838736~119840385:-
LUAD	cis	rs7119038	0.818	rs10892288	ENSG00000255239.1	AP002954.6	-3.98	7.83e-05	0.0115	-0.27	-0.18	Sjögren's syndrome;	chr11:118773985	chr11:118688039~118690600:-
LUAD	cis	rs7119038	0.818	rs10892289	ENSG00000255239.1	AP002954.6	-3.98	7.83e-05	0.0115	-0.27	-0.18	Sjögren's syndrome;	chr11:118775294	chr11:118688039~118690600:-
LUAD	cis	rs728616	0.867	rs12413715	ENSG00000225484.5	NUTM2B-AS1	-3.98	7.83e-05	0.0115	-0.47	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79927604	chr10:79663088~79826594:-
LUAD	cis	rs6663390	0.51	rs73072979	ENSG00000203709.8	C1orf132	3.98	7.83e-05	0.0115	0.25	0.18	Facial morphology (factor 18);	chr1:207898712	chr1:207801518~207869150:-
LUAD	cis	rs394563	0.622	rs237024	ENSG00000216906.2	RP11-350J20.9	3.98	7.83e-05	0.0115	0.21	0.18	Dupuytren's disease;	chr6:149400829	chr6:149904243~149906418:+
LUAD	cis	rs6570726	0.967	rs439017	ENSG00000235652.6	RP11-545I5.3	3.98	7.83e-05	0.0115	0.17	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145484987	chr6:145799409~145886585:+
LUAD	cis	rs2153535	0.518	rs9505503	ENSG00000230939.1	RP11-314C16.1	-3.98	7.83e-05	0.0115	-0.21	-0.18	Motion sickness;	chr6:8638572	chr6:8784178~8785445:+
LUAD	cis	rs1023500	0.596	rs133352	ENSG00000205702.9	CYP2D7	3.98	7.84e-05	0.0115	0.14	0.18	Schizophrenia;	chr22:42038018	chr22:42140203~42144577:-
LUAD	cis	rs6479901	0.793	rs4335432	ENSG00000232075.1	MRPL35P2	-3.98	7.84e-05	0.0115	-0.24	-0.18	Intelligence (multi-trait analysis);	chr10:63226057	chr10:63634317~63634827:-
LUAD	cis	rs6479901	0.841	rs6479889	ENSG00000232075.1	MRPL35P2	-3.98	7.84e-05	0.0115	-0.24	-0.18	Intelligence (multi-trait analysis);	chr10:63228867	chr10:63634317~63634827:-
LUAD	cis	rs2274273	0.624	rs8003279	ENSG00000258413.1	RP11-665C16.6	-3.98	7.84e-05	0.0115	-0.25	-0.18	Protein biomarker;	chr14:55397412	chr14:55262767~55272075:-
LUAD	cis	rs1355223	0.752	rs17359064	ENSG00000271369.1	RP11-350D17.3	-3.98	7.84e-05	0.0115	-0.21	-0.18	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34652337	chr11:34709600~34710161:+
LUAD	cis	rs860818	1	rs2529002	ENSG00000226816.2	AC005082.12	3.98	7.84e-05	0.0115	0.47	0.18	Initial pursuit acceleration;	chr7:23193704	chr7:23206013~23208045:+
LUAD	cis	rs860818	1	rs6955117	ENSG00000226816.2	AC005082.12	3.98	7.84e-05	0.0115	0.47	0.18	Initial pursuit acceleration;	chr7:23194521	chr7:23206013~23208045:+
LUAD	cis	rs16866061	1	rs2047134	ENSG00000228446.2	AC073052.1	-3.98	7.84e-05	0.0115	-0.2	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr2:224482996	chr2:224499387~224500100:-
LUAD	cis	rs3794924	0.925	rs16961977	ENSG00000266521.1	RP11-650P15.1	3.98	7.84e-05	0.0115	0.34	0.18	Survival in colon cancer;	chr18:31468251	chr18:31496645~31497195:-
LUAD	cis	rs2933343	0.729	rs789231	ENSG00000231305.3	RP11-723O4.2	3.98	7.84e-05	0.0115	0.2	0.18	IgG glycosylation;	chr3:128884004	chr3:128861313~128871540:-
LUAD	cis	rs6832769	0.925	rs4865018	ENSG00000272969.1	RP11-528I4.2	-3.98	7.84e-05	0.0115	-0.19	-0.18	Personality dimensions;	chr4:55591024	chr4:55547112~55547889:+
LUAD	cis	rs7172677	0.711	rs8035588	ENSG00000260269.4	CTD-2323K18.1	-3.98	7.84e-05	0.0115	-0.23	-0.18	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75144502	chr15:75527150~75601205:-
LUAD	cis	rs9322193	0.607	rs12209310	ENSG00000268592.3	RAET1E-AS1	3.98	7.84e-05	0.0115	0.27	0.18	Lung cancer;	chr6:149904882	chr6:149863494~149919507:+
LUAD	cis	rs4713118	0.868	rs35069907	ENSG00000280107.1	AL022393.9	-3.98	7.84e-05	0.0115	-0.24	-0.18	Parkinson's disease;	chr6:27778913	chr6:28170845~28172521:+
LUAD	cis	rs2898681	0.77	rs62336795	ENSG00000248375.1	RP11-177B4.1	-3.98	7.84e-05	0.0115	-0.25	-0.18	Optic nerve measurement (cup area);	chr4:52871605	chr4:52720081~52720831:-
LUAD	cis	rs854462	1	rs2015086	ENSG00000274767.1	AC131056.3	3.98	7.84e-05	0.0115	0.27	0.18	Blood protein levels;	chr17:36064257	chr17:36183235~36196471:+
LUAD	cis	rs6964587	1	rs35317449	ENSG00000188693.7	CYP51A1-AS1	-3.98	7.84e-05	0.0115	-0.21	-0.18	Breast cancer;	chr7:92007696	chr7:92134604~92180725:+
LUAD	cis	rs11051970	0.918	rs73084099	ENSG00000274964.1	RP11-817I4.1	-3.98	7.84e-05	0.0115	-0.21	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr12:32386817	chr12:32339368~32340724:+
LUAD	cis	rs7429990	0.932	rs6803741	ENSG00000228638.1	FCF1P2	3.98	7.84e-05	0.0115	0.21	0.18	Educational attainment (years of education);	chr3:48082050	chr3:48290793~48291375:-
LUAD	cis	rs17685	0.672	rs55807301	ENSG00000280388.1	RP11-229D13.3	-3.98	7.85e-05	0.0115	-0.17	-0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76178083	chr7:76043977~76045963:-
LUAD	cis	rs4660214	0.666	rs2275186	ENSG00000182109.6	RP11-69E11.4	-3.98	7.85e-05	0.0115	-0.19	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39300383	chr1:39522280~39546187:-
LUAD	cis	rs6921919	0.945	rs61289879	ENSG00000216901.1	AL022393.7	3.98	7.85e-05	0.0115	0.25	0.18	Autism spectrum disorder or schizophrenia;	chr6:28451385	chr6:28176188~28176674:+
LUAD	cis	rs1401999	1	rs9858774	ENSG00000223882.1	ABCC5-AS1	-3.98	7.86e-05	0.0115	-0.19	-0.18	Anterior chamber depth;	chr3:183934948	chr3:184006338~184011419:+
LUAD	cis	rs3018712	0.532	rs10791988	ENSG00000212093.1	AP000807.1	-3.98	7.86e-05	0.0115	-0.23	-0.18	Total body bone mineral density;	chr11:68648583	chr11:68506083~68506166:-
LUAD	cis	rs8028182	0.549	rs7402293	ENSG00000246877.1	DNM1P35	-3.98	7.86e-05	0.0115	-0.23	-0.18	Sudden cardiac arrest;	chr15:75343796	chr15:75727670~75738623:-
LUAD	cis	rs7955901	1	rs7955901	ENSG00000258053.1	CTD-2021H9.3	-3.98	7.86e-05	0.0115	-0.21	-0.18	Type 2 diabetes;	chr12:71039513	chr12:71047402~71118247:-
LUAD	cis	rs4934494	0.768	rs17126269	ENSG00000240996.1	RP11-80H5.7	-3.98	7.86e-05	0.0115	-0.25	-0.18	Red blood cell count;	chr10:89694974	chr10:89694295~89697928:-
LUAD	cis	rs12122100	0.955	rs12142005	ENSG00000244371.2	PFN1P8	3.98	7.86e-05	0.0115	0.23	0.18	HIV-1 control;	chr1:147035137	chr1:146957117~146957659:-
LUAD	cis	rs35740288	0.539	rs4843100	ENSG00000259407.1	RP11-158M2.3	-3.98	7.86e-05	0.0115	-0.19	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85795979	chr15:85744109~85750281:-
LUAD	cis	rs4705952	0.832	rs2706391	ENSG00000233006.5	AC034220.3	-3.98	7.86e-05	0.0115	-0.21	-0.18	C-reactive protein levels;	chr5:132507614	chr5:132311285~132369916:-
LUAD	cis	rs2645424	1	rs7009302	ENSG00000255046.1	RP11-297N6.4	3.98	7.86e-05	0.0115	0.22	0.18	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11828472	chr8:11797928~11802568:-
LUAD	cis	rs9649213	0.593	rs7812180	ENSG00000272950.1	RP11-307C18.1	-3.98	7.86e-05	0.0115	-0.22	-0.18	Prostate cancer (SNP x SNP interaction);	chr7:98339828	chr7:98322853~98323430:+
LUAD	cis	rs6547741	0.935	rs12714204	ENSG00000223522.1	AC093690.1	3.98	7.86e-05	0.0115	0.17	0.18	Oral cavity cancer;	chr2:27564673	chr2:28307691~28310459:-
LUAD	cis	rs2467099	0.504	rs2666005	ENSG00000267801.1	RP11-552F3.9	3.98	7.87e-05	0.0115	0.19	0.18	Systolic blood pressure;	chr17:75948515	chr17:75876372~75879546:+
LUAD	cis	rs848490	0.889	rs11769259	ENSG00000214293.7	APTR	3.98	7.87e-05	0.0115	0.23	0.18	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77666013	chr7:77657660~77696265:-
LUAD	cis	rs13434995	0.513	rs2130040	ENSG00000273257.1	RP11-177J6.1	3.98	7.87e-05	0.0115	0.24	0.18	Adiponectin levels;	chr4:55564036	chr4:55387949~55388271:+
LUAD	cis	rs10463554	0.963	rs26261	ENSG00000250682.4	LINC00491	3.98	7.87e-05	0.0115	0.21	0.18	Parkinson's disease;	chr5:103209992	chr5:102609156~102671559:-
LUAD	cis	rs360798	0.723	rs1038570	ENSG00000231609.4	AC009501.4	3.98	7.87e-05	0.0115	0.21	0.18	Coronary artery disease;	chr2:62663036	chr2:63043922~63048640:-
LUAD	cis	rs10129255	1	rs61997605	ENSG00000274576.2	IGHV2-70	3.98	7.87e-05	0.0115	0.16	0.18	Kawasaki disease;	chr14:106678368	chr14:106770577~106771020:-
LUAD	cis	rs10129255	1	rs8012033	ENSG00000274576.2	IGHV2-70	3.98	7.87e-05	0.0115	0.16	0.18	Kawasaki disease;	chr14:106678854	chr14:106770577~106771020:-
LUAD	cis	rs4374383	0.884	rs1131244	ENSG00000207383.1	Y_RNA	-3.98	7.87e-05	0.0115	-0.21	-0.18	Hepatitis C induced liver fibrosis;	chr2:112008396	chr2:112579484~112579584:-
LUAD	cis	rs853679	0.517	rs9295761	ENSG00000226314.6	ZNF192P1	-3.98	7.87e-05	0.0115	-0.24	-0.18	Depression;	chr6:28180209	chr6:28161781~28169594:+
LUAD	cis	rs9545047	0.604	rs943709	ENSG00000227354.5	RBM26-AS1	3.98	7.87e-05	0.0115	0.19	0.18	Schizophrenia;	chr13:79282990	chr13:79406309~79424328:+
LUAD	cis	rs6951245	1	rs113146460	ENSG00000199023.2	MIR339	-3.98	7.87e-05	0.0115	-0.32	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1065528	chr7:1022935~1023045:-
LUAD	cis	rs6951245	0.935	rs61753396	ENSG00000199023.2	MIR339	-3.98	7.87e-05	0.0115	-0.32	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1065736	chr7:1022935~1023045:-
LUAD	cis	rs6951245	1	rs79327308	ENSG00000199023.2	MIR339	-3.98	7.87e-05	0.0115	-0.32	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1068505	chr7:1022935~1023045:-
LUAD	cis	rs6951245	0.938	rs117729148	ENSG00000199023.2	MIR339	-3.98	7.87e-05	0.0115	-0.32	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1068895	chr7:1022935~1023045:-
LUAD	cis	rs11955398	0.522	rs329624	ENSG00000272308.1	RP11-231G3.1	-3.98	7.87e-05	0.0115	-0.21	-0.18	Intelligence (multi-trait analysis);	chr5:60989310	chr5:60866457~60866935:-
LUAD	cis	rs11955398	0.502	rs162251	ENSG00000272308.1	RP11-231G3.1	-3.98	7.87e-05	0.0115	-0.21	-0.18	Intelligence (multi-trait analysis);	chr5:60996457	chr5:60866457~60866935:-
LUAD	cis	rs11955398	0.502	rs162249	ENSG00000272308.1	RP11-231G3.1	-3.98	7.87e-05	0.0115	-0.21	-0.18	Intelligence (multi-trait analysis);	chr5:60999753	chr5:60866457~60866935:-
LUAD	cis	rs28735056	0.62	rs12456484	ENSG00000261126.6	RP11-795F19.1	3.98	7.88e-05	0.0115	0.18	0.18	Schizophrenia;	chr18:79917315	chr18:80046900~80095482:+
LUAD	cis	rs34792	0.637	rs34793	ENSG00000207425.1	Y_RNA	3.98	7.88e-05	0.0115	0.22	0.18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15491779	chr16:14915457~14915556:-
LUAD	cis	rs7015630	0.618	rs28405481	ENSG00000251136.7	RP11-37B2.1	-3.98	7.88e-05	0.0115	-0.23	-0.18	Inflammatory bowel disease;Crohn's disease;	chr8:89807501	chr8:89609409~89757727:-
LUAD	cis	rs12440869	1	rs8035235	ENSG00000270964.1	RP11-502I4.3	-3.98	7.88e-05	0.0115	-0.21	-0.18	Peak velocity of the mitral A-wave;	chr15:67262699	chr15:67541072~67542604:-
LUAD	cis	rs2446066	0.872	rs11170558	ENSG00000257379.1	RP11-793H13.8	3.98	7.88e-05	0.0115	0.3	0.18	Red blood cell count;	chr12:53441251	chr12:53441741~53467528:+
LUAD	cis	rs6479891	0.818	rs9415700	ENSG00000232075.1	MRPL35P2	3.98	7.88e-05	0.0115	0.3	0.18	Arthritis (juvenile idiopathic);	chr10:63385805	chr10:63634317~63634827:-
LUAD	cis	rs6479891	1	rs9415701	ENSG00000232075.1	MRPL35P2	3.98	7.88e-05	0.0115	0.3	0.18	Arthritis (juvenile idiopathic);	chr10:63391749	chr10:63634317~63634827:-
LUAD	cis	rs1401999	1	rs7632670	ENSG00000223882.1	ABCC5-AS1	-3.98	7.88e-05	0.0115	-0.19	-0.18	Anterior chamber depth;	chr3:183996089	chr3:184006338~184011419:+
LUAD	cis	rs4130344	0.874	rs10003054	ENSG00000271817.2	U3	-3.98	7.88e-05	0.0115	-0.19	-0.18	Intelligence (multi-trait analysis);	chr4:158776594	chr4:158700691~158700909:+
LUAD	cis	rs6479901	0.841	rs10995505	ENSG00000232075.1	MRPL35P2	3.98	7.89e-05	0.0116	0.24	0.18	Intelligence (multi-trait analysis);	chr10:63331399	chr10:63634317~63634827:-
LUAD	cis	rs4664293	0.565	rs10165197	ENSG00000230783.1	AC009961.2	3.98	7.89e-05	0.0116	0.21	0.18	Monocyte percentage of white cells;	chr2:159537137	chr2:159689217~159690291:-
LUAD	cis	rs10208649	0.611	rs58851686	ENSG00000272156.1	RP11-477N3.1	3.98	7.89e-05	0.0116	0.35	0.18	Body mass index;	chr2:54057179	chr2:54082554~54085066:+
LUAD	cis	rs10208649	0.611	rs1363060	ENSG00000272156.1	RP11-477N3.1	3.98	7.89e-05	0.0116	0.35	0.18	Body mass index;	chr2:54057447	chr2:54082554~54085066:+
LUAD	cis	rs780096	0.545	rs11695549	ENSG00000234072.1	AC074117.10	-3.98	7.89e-05	0.0116	-0.14	-0.18	Total body bone mineral density;	chr2:27363288	chr2:27356246~27367622:+
LUAD	cis	rs13434995	0.513	rs10462033	ENSG00000273257.1	RP11-177J6.1	-3.98	7.89e-05	0.0116	-0.24	-0.18	Adiponectin levels;	chr4:55511552	chr4:55387949~55388271:+
LUAD	cis	rs13434995	0.513	rs1915905	ENSG00000273257.1	RP11-177J6.1	-3.98	7.89e-05	0.0116	-0.24	-0.18	Adiponectin levels;	chr4:55512381	chr4:55387949~55388271:+
LUAD	cis	rs1799955	0.935	rs3764791	ENSG00000215515.2	IFIT1P1	-3.98	7.89e-05	0.0116	-0.26	-0.18	LDL cholesterol levels;	chr13:32376974	chr13:32384660~32386108:+
LUAD	cis	rs2911132	0.506	rs10037212	ENSG00000272109.1	CTD-2260A17.3	3.98	7.89e-05	0.0116	0.2	0.18	Urate levels (BMI interaction);	chr5:96749072	chr5:96804353~96806105:+
LUAD	cis	rs2901790	0.82	rs66496128	ENSG00000223387.5	RP11-408H1.3	-3.98	7.89e-05	0.0116	-0.24	-0.18	Gait speed in old age;	chr3:172502807	chr3:172560888~172595607:-
LUAD	cis	rs8113308	0.81	rs7255377	ENSG00000269483.1	AC006272.1	3.98	7.89e-05	0.0116	0.29	0.18	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51948085	chr19:51839924~51843324:-
LUAD	cis	rs8113308	0.81	rs7254930	ENSG00000269483.1	AC006272.1	3.98	7.89e-05	0.0116	0.29	0.18	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51948274	chr19:51839924~51843324:-
LUAD	cis	rs2731006	0.64	rs973001	ENSG00000257114.2	RP11-25I15.3	3.98	7.89e-05	0.0116	0.28	0.18	Panic disorder;	chr12:42786388	chr12:42692216~42717119:+
LUAD	cis	rs7131987	0.622	rs7294598	ENSG00000275476.1	RP11-996F15.4	3.98	7.89e-05	0.0116	0.2	0.18	QT interval;	chr12:29379056	chr12:29277397~29277882:-
LUAD	cis	rs7762018	0.769	rs7766146	ENSG00000231690.2	LINC00574	-3.98	7.89e-05	0.0116	-0.35	-0.18	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169670039	chr6:169790321~169802873:+
LUAD	cis	rs1577917	0.655	rs6454472	ENSG00000220563.1	PKMP3	3.98	7.9e-05	0.0116	0.16	0.18	Response to antipsychotic treatment;	chr6:85514335	chr6:85659892~85660606:-
LUAD	cis	rs7615952	0.599	rs67566088	ENSG00000250012.1	RP11-124N2.1	-3.98	7.9e-05	0.0116	-0.25	-0.18	Blood pressure (smoking interaction);	chr3:126050130	chr3:126084220~126095349:+
LUAD	cis	rs7615952	0.641	rs12495947	ENSG00000250012.1	RP11-124N2.1	-3.98	7.9e-05	0.0116	-0.25	-0.18	Blood pressure (smoking interaction);	chr3:126052855	chr3:126084220~126095349:+
LUAD	cis	rs7615952	0.641	rs6805074	ENSG00000250012.1	RP11-124N2.1	-3.98	7.9e-05	0.0116	-0.25	-0.18	Blood pressure (smoking interaction);	chr3:126053431	chr3:126084220~126095349:+
LUAD	cis	rs7615952	0.641	rs4422257	ENSG00000250012.1	RP11-124N2.1	-3.98	7.9e-05	0.0116	-0.25	-0.18	Blood pressure (smoking interaction);	chr3:126055520	chr3:126084220~126095349:+
LUAD	cis	rs9287719	0.649	rs58633964	ENSG00000243819.4	RN7SL832P	3.98	7.9e-05	0.0116	0.19	0.18	Prostate cancer;	chr2:10596256	chr2:10690344~10692099:+
LUAD	cis	rs853679	0.517	rs1947863	ENSG00000280107.1	AL022393.9	-3.98	7.9e-05	0.0116	-0.24	-0.18	Depression;	chr6:28131566	chr6:28170845~28172521:+
LUAD	cis	rs5762752	0.521	rs134544	ENSG00000272858.1	CTA-292E10.8	3.98	7.9e-05	0.0116	0.19	0.18	Optic disc area;	chr22:28402691	chr22:28814914~28815662:+
LUAD	cis	rs12440869	1	rs8038044	ENSG00000270964.1	RP11-502I4.3	-3.98	7.9e-05	0.0116	-0.21	-0.18	Peak velocity of the mitral A-wave;	chr15:67272058	chr15:67541072~67542604:-
LUAD	cis	rs12220238	0.722	rs7921187	ENSG00000226051.5	ZNF503-AS1	3.98	7.9e-05	0.0116	0.32	0.18	Soluble interleukin-2 receptor subunit alpha;	chr10:74617743	chr10:75269819~75373500:+
LUAD	cis	rs7712401	0.791	rs10063253	ENSG00000249996.1	RP11-359P5.1	3.98	7.9e-05	0.0116	0.22	0.18	Mean platelet volume;	chr5:122793016	chr5:123036271~123054667:+
LUAD	cis	rs41271951	0.518	rs12139286	ENSG00000223945.2	RP11-458I7.1	-3.98	7.9e-05	0.0116	-0.28	-0.18	Blood protein levels;	chr1:150290036	chr1:150053864~150055034:+
LUAD	cis	rs7208859	0.673	rs12949860	ENSG00000266490.1	CTD-2349P21.9	3.98	7.9e-05	0.0116	0.26	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896014	chr17:30792372~30792833:+
LUAD	cis	rs8028182	0.549	rs4886696	ENSG00000246877.1	DNM1P35	-3.98	7.9e-05	0.0116	-0.23	-0.18	Sudden cardiac arrest;	chr15:75372229	chr15:75727670~75738623:-
LUAD	cis	rs238295	0.881	rs6116869	ENSG00000230563.2	RP5-828H9.1	-3.98	7.9e-05	0.0116	-0.24	-0.18	Occipital cortical area (total cortical area interaction);	chr20:5613786	chr20:5471207~5475182:+
LUAD	cis	rs5758511	0.68	rs1107553	ENSG00000233903.2	Z83851.4	3.98	7.91e-05	0.0116	0.26	0.18	Birth weight;	chr22:42271467	chr22:42276355~42277052:+
LUAD	cis	rs7512552	0.809	rs828783	ENSG00000275557.1	RP11-353N4.6	3.98	7.91e-05	0.0116	0.2	0.18	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150404501	chr1:149607765~149612402:+
LUAD	cis	rs735539	0.521	rs2585897	ENSG00000275485.1	RP11-261P13.6	3.98	7.91e-05	0.0116	0.23	0.18	Dental caries;	chr13:20824840	chr13:20768876~20769375:-
LUAD	cis	rs603446	0.901	rs180344	ENSG00000254851.1	RP11-109L13.1	-3.98	7.91e-05	0.0116	-0.22	-0.18	Triglycerides;	chr11:116742468	chr11:117135528~117138582:+
LUAD	cis	rs2494663	0.585	rs11264996	ENSG00000223599.1	RP11-216N14.7	3.98	7.91e-05	0.0116	0.22	0.18	Mean platelet volume;	chr1:154071080	chr1:153852106~153853414:-
LUAD	cis	rs35343117	1	rs35343117	ENSG00000259407.1	RP11-158M2.3	-3.98	7.91e-05	0.0116	-0.17	-0.18	Psoriasis;	chr15:85535884	chr15:85744109~85750281:-
LUAD	cis	rs447735	0.565	rs10852626	ENSG00000260259.1	RP11-368I7.4	-3.98	7.91e-05	0.0116	-0.18	-0.18	Hemoglobin concentration;	chr16:89848225	chr16:89682620~89686569:-
LUAD	cis	rs847577	0.722	rs1013886	ENSG00000272950.1	RP11-307C18.1	-3.98	7.91e-05	0.0116	-0.22	-0.18	Breast cancer;	chr7:98080549	chr7:98322853~98323430:+
LUAD	cis	rs2295359	0.963	rs12030867	ENSG00000275678.1	RP4-547N15.3	-3.98	7.91e-05	0.0116	-0.19	-0.18	Psoriasis;	chr1:67161937	chr1:67121605~67123956:-
LUAD	cis	rs9322193	0.607	rs7764677	ENSG00000268592.3	RAET1E-AS1	3.98	7.91e-05	0.0116	0.26	0.18	Lung cancer;	chr6:149906197	chr6:149863494~149919507:+
LUAD	cis	rs858239	0.539	rs4559148	ENSG00000226816.2	AC005082.12	3.98	7.91e-05	0.0116	0.24	0.18	Cerebrospinal fluid biomarker levels;	chr7:23146348	chr7:23206013~23208045:+
LUAD	cis	rs858239	0.539	rs4377861	ENSG00000226816.2	AC005082.12	3.98	7.91e-05	0.0116	0.24	0.18	Cerebrospinal fluid biomarker levels;	chr7:23146350	chr7:23206013~23208045:+
LUAD	cis	rs2274273	0.84	rs10136596	ENSG00000258413.1	RP11-665C16.6	-3.98	7.91e-05	0.0116	-0.23	-0.18	Protein biomarker;	chr14:55370055	chr14:55262767~55272075:-
LUAD	cis	rs7985	0.544	rs6005130	ENSG00000244625.4	MIATNB	3.98	7.91e-05	0.0116	0.19	0.18	Electroencephalogram traits;	chr22:26677296	chr22:26672767~26780207:+
LUAD	cis	rs728616	0.867	rs56198874	ENSG00000225484.5	NUTM2B-AS1	-3.98	7.92e-05	0.0116	-0.47	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79926732	chr10:79663088~79826594:-
LUAD	cis	rs11742741	0.806	rs59394630	ENSG00000248874.4	C5orf17	-3.98	7.92e-05	0.0116	-0.22	-0.18	Educational attainment;	chr5:24049355	chr5:23951348~24178263:+
LUAD	cis	rs9646944	0.501	rs36049530	ENSG00000234389.1	AC007278.3	3.98	7.92e-05	0.0116	0.2	0.18	Blood protein levels;	chr2:102463528	chr2:102438713~102440475:+
LUAD	cis	rs6832769	0.767	rs6850524	ENSG00000272969.1	RP11-528I4.2	3.98	7.92e-05	0.0116	0.19	0.18	Personality dimensions;	chr4:55515830	chr4:55547112~55547889:+
LUAD	cis	rs6832769	0.767	rs11133394	ENSG00000272969.1	RP11-528I4.2	3.98	7.92e-05	0.0116	0.19	0.18	Personality dimensions;	chr4:55517071	chr4:55547112~55547889:+
LUAD	cis	rs2274273	0.84	rs28568813	ENSG00000258413.1	RP11-665C16.6	-3.98	7.92e-05	0.0116	-0.23	-0.18	Protein biomarker;	chr14:55327396	chr14:55262767~55272075:-
LUAD	cis	rs6687821	0.515	rs12734749	ENSG00000261737.1	RP4-612B15.3	3.98	7.92e-05	0.0116	0.25	0.18	Yeast infection;	chr1:86971063	chr1:86703502~86704462:-
LUAD	cis	rs7208859	0.623	rs9914242	ENSG00000265443.1	CTD-2349P21.6	-3.98	7.92e-05	0.0116	-0.3	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889227	chr17:30726305~30727564:-
LUAD	cis	rs6762	0.719	rs1130698	ENSG00000279672.1	CMB9-55F22.1	3.98	7.92e-05	0.0116	0.2	0.18	Mean platelet volume;	chr11:838542	chr11:779617~780755:+
LUAD	cis	rs6674176	0.593	rs6675620	ENSG00000237950.1	RP11-7O11.3	3.98	7.92e-05	0.0116	0.23	0.18	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43951958	chr1:43944370~43946551:-
LUAD	cis	rs62355901	0.599	rs62355875	ENSG00000271828.1	CTD-2310F14.1	3.98	7.92e-05	0.0116	0.35	0.18	Breast cancer;	chr5:56729353	chr5:56927874~56929573:+
LUAD	cis	rs62355901	0.599	rs62355876	ENSG00000271828.1	CTD-2310F14.1	3.98	7.92e-05	0.0116	0.35	0.18	Breast cancer;	chr5:56729373	chr5:56927874~56929573:+
LUAD	cis	rs877356	0.748	rs1465291	ENSG00000250378.1	RP11-119J18.1	-3.98	7.92e-05	0.0116	-0.31	-0.18	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (dichotomous);	chr5:135812683	chr5:135812667~135826582:+
LUAD	cis	rs7221109	0.857	rs11658582	ENSG00000278834.1	RP11-458J1.1	3.98	7.92e-05	0.0116	0.21	0.18	Type 1 diabetes;	chr17:40606948	chr17:40648300~40649718:+
LUAD	cis	rs6840360	0.582	rs6535796	ENSG00000270265.1	RP11-731D1.4	-3.98	7.92e-05	0.0116	-0.18	-0.18	Intelligence (multi-trait analysis);	chr4:151383576	chr4:151333775~151353224:-
LUAD	cis	rs2014572	0.967	rs7248000	ENSG00000268379.1	CTC-360J11.4	3.98	7.92e-05	0.0116	0.21	0.18	Hyperactive-impulsive symptoms;	chr19:57250771	chr19:57175233~57177921:+
LUAD	cis	rs2274273	0.87	rs13379169	ENSG00000259318.1	RP11-454L9.2	3.98	7.93e-05	0.0116	0.16	0.18	Protein biomarker;	chr14:55274569	chr14:55394940~55395233:-
LUAD	cis	rs2337406	0.538	rs10141701	ENSG00000223648.3	IGHV3-64	3.98	7.93e-05	0.0116	0.2	0.18	Alzheimer's disease (late onset);	chr14:106633467	chr14:106643132~106658258:-
LUAD	cis	rs8180040	0.932	rs1038394	ENSG00000271161.1	BOLA2P2	3.98	7.93e-05	0.0116	0.17	0.18	Colorectal cancer;	chr3:47422632	chr3:47499841~47500407:+
LUAD	cis	rs6001482	0.679	rs1894238	ENSG00000223350.2	IGLV9-49	-3.98	7.93e-05	0.0116	-0.18	-0.18	Diastolic blood pressure;	chr22:22235704	chr22:22343187~22343732:+
LUAD	cis	rs12908161	0.853	rs12912342	ENSG00000275120.1	RP11-182J1.17	3.98	7.93e-05	0.0116	0.25	0.18	Schizophrenia;	chr15:84704985	chr15:84599434~84606463:-
LUAD	cis	rs6496044	0.568	rs4842888	ENSG00000259295.5	CSPG4P12	-3.98	7.93e-05	0.0116	-0.21	-0.18	Interstitial lung disease;	chr15:85519902	chr15:85191438~85213905:+
LUAD	cis	rs9926296	0.585	rs8045232	ENSG00000260259.1	RP11-368I7.4	-3.98	7.93e-05	0.0116	-0.17	-0.18	Vitiligo;	chr16:89791140	chr16:89682620~89686569:-
LUAD	cis	rs1910358	0.734	rs7720774	ENSG00000248874.4	C5orf17	-3.98	7.93e-05	0.0116	-0.23	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr5:23962634	chr5:23951348~24178263:+
LUAD	cis	rs4713118	0.614	rs9380007	ENSG00000216901.1	AL022393.7	3.98	7.93e-05	0.0116	0.21	0.18	Parkinson's disease;	chr6:27692729	chr6:28176188~28176674:+
LUAD	cis	rs728616	0.867	rs61860044	ENSG00000225484.5	NUTM2B-AS1	-3.98	7.93e-05	0.0116	-0.47	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80186782	chr10:79663088~79826594:-
LUAD	cis	rs5769707	0.839	rs73176988	ENSG00000235111.1	RP1-29C18.8	-3.98	7.93e-05	0.0116	-0.19	-0.18	Monocyte percentage of white cells;Monocyte count;	chr22:49596001	chr22:49612657~49615716:-
LUAD	cis	rs6840360	0.615	rs4696267	ENSG00000270265.1	RP11-731D1.4	-3.98	7.93e-05	0.0116	-0.2	-0.18	Intelligence (multi-trait analysis);	chr4:151543348	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.615	rs4696268	ENSG00000270265.1	RP11-731D1.4	-3.98	7.93e-05	0.0116	-0.2	-0.18	Intelligence (multi-trait analysis);	chr4:151543571	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.615	rs10021407	ENSG00000270265.1	RP11-731D1.4	-3.98	7.93e-05	0.0116	-0.2	-0.18	Intelligence (multi-trait analysis);	chr4:151543850	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.615	rs58977077	ENSG00000270265.1	RP11-731D1.4	-3.98	7.93e-05	0.0116	-0.2	-0.18	Intelligence (multi-trait analysis);	chr4:151549087	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.554	rs62329088	ENSG00000270265.1	RP11-731D1.4	-3.98	7.93e-05	0.0116	-0.2	-0.18	Intelligence (multi-trait analysis);	chr4:151550137	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.615	rs66852535	ENSG00000270265.1	RP11-731D1.4	-3.98	7.93e-05	0.0116	-0.2	-0.18	Intelligence (multi-trait analysis);	chr4:151551075	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.593	rs10033405	ENSG00000270265.1	RP11-731D1.4	-3.98	7.93e-05	0.0116	-0.2	-0.18	Intelligence (multi-trait analysis);	chr4:151553337	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.615	rs4696096	ENSG00000270265.1	RP11-731D1.4	-3.98	7.93e-05	0.0116	-0.2	-0.18	Intelligence (multi-trait analysis);	chr4:151554235	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.615	rs1962910	ENSG00000270265.1	RP11-731D1.4	-3.98	7.93e-05	0.0116	-0.2	-0.18	Intelligence (multi-trait analysis);	chr4:151558240	chr4:151333775~151353224:-
LUAD	cis	rs4713118	0.662	rs149946	ENSG00000280107.1	AL022393.9	3.98	7.93e-05	0.0116	0.23	0.18	Parkinson's disease;	chr6:28002253	chr6:28170845~28172521:+
LUAD	cis	rs911119	0.913	rs6048924	ENSG00000270001.1	RP11-218C14.8	-3.98	7.94e-05	0.0116	-0.26	-0.18	Chronic kidney disease;	chr20:23598359	chr20:23631826~23632316:-
LUAD	cis	rs8091660	0.624	rs8099285	ENSG00000278983.1	RP11-426J5.3	3.98	7.94e-05	0.0116	0.23	0.18	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48551434	chr18:48564795~48568342:+
LUAD	cis	rs2657294	0.796	rs2804534	ENSG00000233313.2	HMGA1P5	3.98	7.94e-05	0.0116	0.22	0.18	Pneumonia;	chr10:75208023	chr10:75276376~75276646:-
LUAD	cis	rs6496044	0.568	rs10468112	ENSG00000259295.5	CSPG4P12	3.98	7.94e-05	0.0116	0.21	0.18	Interstitial lung disease;	chr15:85530193	chr15:85191438~85213905:+
LUAD	cis	rs10129255	0.869	rs7150549	ENSG00000211967.3	IGHV3-53	-3.98	7.94e-05	0.0116	-0.14	-0.18	Kawasaki disease;	chr14:106705441	chr14:106592676~106593347:-
LUAD	cis	rs773506	0.589	rs773507	ENSG00000237422.1	RP11-305L7.3	3.98	7.94e-05	0.0116	0.23	0.18	Type 2 diabetes nephropathy;	chr9:91212271	chr9:91119138~91163087:-
LUAD	cis	rs6951245	0.58	rs10257426	ENSG00000199023.2	MIR339	-3.98	7.94e-05	0.0116	-0.29	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1174058	chr7:1022935~1023045:-
LUAD	cis	rs7210086	0.821	rs3935123	ENSG00000263893.2	CTD-3010D24.3	-3.98	7.94e-05	0.0116	-0.24	-0.18	Ulcerative colitis;	chr17:72645044	chr17:72642731~72644490:+
LUAD	cis	rs748404	0.666	rs7177892	ENSG00000205771.5	CATSPER2P1	-3.98	7.95e-05	0.0116	-0.27	-0.18	Lung cancer;	chr15:43321171	chr15:43726918~43747094:-
LUAD	cis	rs2235642	0.75	rs2974845	ENSG00000280231.1	LA16c-380F5.3	-3.98	7.95e-05	0.0116	-0.24	-0.18	Coronary artery disease;	chr16:1598161	chr16:1553655~1554130:-
LUAD	cis	rs1799949	0.602	rs8176235	ENSG00000267340.1	RP11-242D8.3	3.98	7.95e-05	0.0116	0.21	0.18	Menopause (age at onset);	chr17:43067543	chr17:43169880~43170077:-
LUAD	cis	rs7546668	1	rs12124078	ENSG00000272510.1	RP4-680D5.8	3.98	7.95e-05	0.0116	0.22	0.18	Glomerular filtration rate (creatinine);	chr1:15543404	chr1:15565611~15565956:-
LUAD	cis	rs12291225	0.585	rs4517475	ENSG00000251991.1	RNU7-49P	3.98	7.95e-05	0.0116	0.2	0.18	Sense of smell;	chr11:14364599	chr11:14478892~14478953:+
LUAD	cis	rs8049040	0.609	rs16972805	ENSG00000260886.1	TAT-AS1	-3.98	7.95e-05	0.0116	-0.22	-0.18	Blood protein levels;	chr16:71444346	chr16:71565789~71578187:+
LUAD	cis	rs6479891	0.841	rs7085869	ENSG00000232075.1	MRPL35P2	-3.98	7.96e-05	0.0116	-0.29	-0.18	Arthritis (juvenile idiopathic);	chr10:63310403	chr10:63634317~63634827:-
LUAD	cis	rs6479891	0.818	rs9299455	ENSG00000232075.1	MRPL35P2	-3.98	7.96e-05	0.0116	-0.29	-0.18	Arthritis (juvenile idiopathic);	chr10:63313841	chr10:63634317~63634827:-
LUAD	cis	rs6479891	1	rs7899715	ENSG00000232075.1	MRPL35P2	-3.98	7.96e-05	0.0116	-0.29	-0.18	Arthritis (juvenile idiopathic);	chr10:63318695	chr10:63634317~63634827:-
LUAD	cis	rs6479891	1	rs4525102	ENSG00000232075.1	MRPL35P2	-3.98	7.96e-05	0.0116	-0.29	-0.18	Arthritis (juvenile idiopathic);	chr10:63326513	chr10:63634317~63634827:-
LUAD	cis	rs2880765	0.546	rs11637726	ENSG00000202081.1	RNU6-1280P	-3.98	7.96e-05	0.0116	-0.22	-0.18	Coronary artery disease;	chr15:85516040	chr15:85651522~85651628:-
LUAD	cis	rs6951245	1	rs77346188	ENSG00000199023.2	MIR339	-3.98	7.96e-05	0.0116	-0.32	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1074387	chr7:1022935~1023045:-
LUAD	cis	rs365302	0.953	rs389041	ENSG00000235086.1	FNDC1-IT1	3.98	7.96e-05	0.0116	0.24	0.18	Coronary heart disease;	chr6:159225821	chr6:159240786~159243329:+
LUAD	cis	rs9314614	0.933	rs2741098	ENSG00000245857.2	GS1-24F4.2	-3.98	7.96e-05	0.0116	-0.2	-0.18	White blood cell count (basophil);IgA nephropathy;	chr8:6832754	chr8:6835554~6885276:+
LUAD	cis	rs67478160	0.643	rs11160762	ENSG00000272533.1	SNORA28	-3.98	7.96e-05	0.0116	-0.18	-0.18	Schizophrenia;	chr14:103788746	chr14:103337849~103337974:+
LUAD	cis	rs7429990	0.965	rs7430879	ENSG00000228638.1	FCF1P2	3.98	7.96e-05	0.0116	0.21	0.18	Educational attainment (years of education);	chr3:47997224	chr3:48290793~48291375:-
LUAD	cis	rs6728642	1	rs11900461	ENSG00000230606.9	AC159540.1	3.98	7.96e-05	0.0116	0.31	0.18	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96950256	chr2:97416165~97433527:-
LUAD	cis	rs526231	0.67	rs253756	ENSG00000175749.11	EIF3KP1	3.98	7.96e-05	0.0116	0.23	0.18	Primary biliary cholangitis;	chr5:103284771	chr5:103032376~103033031:+
LUAD	cis	rs6570726	0.846	rs397311	ENSG00000235652.6	RP11-545I5.3	-3.98	7.97e-05	0.0116	-0.18	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145485565	chr6:145799409~145886585:+
LUAD	cis	rs6430585	0.583	rs9636213	ENSG00000231890.6	DARS-AS1	3.98	7.97e-05	0.0116	0.28	0.18	Corneal structure;	chr2:135831708	chr2:135985176~136022593:+
LUAD	cis	rs8040855	0.547	rs17611171	ENSG00000259774.1	RP11-182J1.13	3.98	7.97e-05	0.0117	0.23	0.18	Bulimia nervosa;	chr15:85029468	chr15:84422618~84425882:+
LUAD	cis	rs848490	1	rs11765986	ENSG00000214293.7	APTR	3.98	7.97e-05	0.0117	0.24	0.18	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77727957	chr7:77657660~77696265:-
LUAD	cis	rs10863681	0.738	rs12561821	ENSG00000238042.4	RP11-815M8.1	3.98	7.97e-05	0.0117	0.21	0.18	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222087887	chr1:221880981~221978523:-
LUAD	cis	rs67981189	0.529	rs2526868	ENSG00000269927.1	RP6-91H8.3	-3.98	7.97e-05	0.0117	-0.24	-0.18	Schizophrenia;	chr14:70923672	chr14:71141125~71143253:-
LUAD	cis	rs5758511	0.679	rs55867855	ENSG00000233903.2	Z83851.4	3.98	7.97e-05	0.0117	0.27	0.18	Birth weight;	chr22:42227252	chr22:42276355~42277052:+
LUAD	cis	rs8180040	1	rs8180040	ENSG00000271161.1	BOLA2P2	3.98	7.97e-05	0.0117	0.17	0.18	Colorectal cancer;	chr3:47347457	chr3:47499841~47500407:+
LUAD	cis	rs2933343	0.951	rs9871612	ENSG00000231305.3	RP11-723O4.2	3.98	7.97e-05	0.0117	0.22	0.18	IgG glycosylation;	chr3:128851559	chr3:128861313~128871540:-
LUAD	cis	rs12468579	1	rs12468579	ENSG00000235852.1	AC005540.3	3.98	7.97e-05	0.0117	0.2	0.18	JT interval (sulfonylurea treatment interaction);	chr2:190967538	chr2:190880797~190882059:-
LUAD	cis	rs9309473	0.95	rs6546858	ENSG00000230002.2	ALMS1-IT1	3.98	7.97e-05	0.0117	0.22	0.18	Metabolite levels;	chr2:73611486	chr2:73456764~73459484:+
LUAD	cis	rs454217	0.773	rs518009	ENSG00000277851.1	RP11-756G20.1	3.98	7.97e-05	0.0117	0.19	0.18	Smoking quantity;	chr12:92339730	chr12:92247756~92363832:-
LUAD	cis	rs791888	0.728	rs2255682	ENSG00000225913.2	RP11-57C13.6	3.98	7.98e-05	0.0117	0.23	0.18	Magnesium levels;	chr10:87660116	chr10:87607985~87659279:+
LUAD	cis	rs2803122	0.501	rs10811140	ENSG00000272842.1	RP11-513M16.7	-3.98	7.98e-05	0.0117	-0.21	-0.18	Pulse pressure;	chr9:19230401	chr9:19371386~19371945:-
LUAD	cis	rs2911132	0.506	rs1862609	ENSG00000272109.1	CTD-2260A17.3	-3.98	7.98e-05	0.0117	-0.2	-0.18	Urate levels (BMI interaction);	chr5:96750986	chr5:96804353~96806105:+
LUAD	cis	rs7429990	0.965	rs2166770	ENSG00000228638.1	FCF1P2	-3.98	7.98e-05	0.0117	-0.21	-0.18	Educational attainment (years of education);	chr3:47964183	chr3:48290793~48291375:-
LUAD	cis	rs7208859	0.673	rs11655623	ENSG00000266490.1	CTD-2349P21.9	3.98	7.98e-05	0.0117	0.26	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30835155	chr17:30792372~30792833:+
LUAD	cis	rs17826219	0.636	rs4055314	ENSG00000280069.1	CTD-2349P21.3	-3.98	7.98e-05	0.0117	-0.25	-0.18	Body mass index;	chr17:30752751	chr17:30738182~30740275:+
LUAD	cis	rs6832769	1	rs17085889	ENSG00000272969.1	RP11-528I4.2	-3.98	7.98e-05	0.0117	-0.18	-0.18	Personality dimensions;	chr4:55535948	chr4:55547112~55547889:+
LUAD	cis	rs6832769	1	rs10005989	ENSG00000272969.1	RP11-528I4.2	-3.98	7.98e-05	0.0117	-0.18	-0.18	Personality dimensions;	chr4:55539039	chr4:55547112~55547889:+
LUAD	cis	rs885518	0.852	rs10965124	ENSG00000265194.1	RP11-70L8.4	3.98	7.98e-05	0.0117	0.23	0.18	Lung adenocarcinoma;	chr9:21776616	chr9:21858910~21861926:-
LUAD	cis	rs9650657	0.589	rs10107145	ENSG00000255046.1	RP11-297N6.4	3.98	7.98e-05	0.0117	0.22	0.18	Neuroticism;	chr8:10900703	chr8:11797928~11802568:-
LUAD	cis	rs28386778	0.897	rs2665795	ENSG00000240280.5	TCAM1P	3.98	7.99e-05	0.0117	0.2	0.18	Prudent dietary pattern;	chr17:63847912	chr17:63849292~63864379:+
LUAD	cis	rs2880765	0.566	rs12911430	ENSG00000259407.1	RP11-158M2.3	-3.98	7.99e-05	0.0117	-0.17	-0.18	Coronary artery disease;	chr15:85468033	chr15:85744109~85750281:-
LUAD	cis	rs4795519	0.778	rs1824901	ENSG00000266313.1	RP11-173M1.4	-3.98	7.99e-05	0.0117	-0.22	-0.18	Chronic myeloid leukemia;	chr17:27145539	chr17:27333256~27348491:+
LUAD	cis	rs7809950	0.953	rs28687365	ENSG00000238832.1	snoU109	-3.98	7.99e-05	0.0117	-0.26	-0.18	Coronary artery disease;	chr7:107466267	chr7:107603363~107603507:+
LUAD	cis	rs6121246	0.609	rs6060843	ENSG00000230613.1	HM13-AS1	3.98	7.99e-05	0.0117	0.22	0.18	Mean corpuscular hemoglobin;	chr20:31709244	chr20:31567707~31573263:-
LUAD	cis	rs1876905	0.68	rs783085	ENSG00000230177.1	RP5-1112D6.4	-3.98	7.99e-05	0.0117	-0.21	-0.18	Mean corpuscular hemoglobin;	chr6:111155482	chr6:111277932~111278742:+
LUAD	cis	rs3018712	0.59	rs11228330	ENSG00000227620.4	ALG1L8P	-3.98	7.99e-05	0.0117	-0.24	-0.18	Total body bone mineral density;	chr11:68717751	chr11:67785273~67792335:+
LUAD	cis	rs62025270	0.632	rs3169119	ENSG00000259416.2	RP11-158M2.5	-3.98	7.99e-05	0.0117	-0.24	-0.18	Idiopathic pulmonary fibrosis;	chr15:85748038	chr15:85754941~85756237:-
LUAD	cis	rs1275468	0.731	rs3912214	ENSG00000257497.2	RP11-585P4.5	-3.98	7.99e-05	0.0117	-0.27	-0.18	Polycystic ovary syndrome;	chr12:75550245	chr12:75483454~75489820:-
LUAD	cis	rs17122278	1	rs11216916	ENSG00000243431.1	RPL5P30	3.98	8e-05	0.0117	0.22	0.18	Total cholesterol levels;	chr11:118590890	chr11:118560690~118561580:+
LUAD	cis	rs6468852	0.602	rs1913026	ENSG00000254281.1	KB-1507C5.4	-3.98	8e-05	0.0117	-0.3	-0.18	Alzheimer's disease (late onset);	chr8:102966831	chr8:102978785~103000184:+
LUAD	cis	rs2253762	0.54	rs11200324	ENSG00000276742.1	RP11-500G22.4	-3.98	8e-05	0.0117	-0.27	-0.18	Breast cancer;	chr10:122009999	chr10:121956782~121957098:+
LUAD	cis	rs10863681	0.664	rs11118934	ENSG00000200033.1	RNU6-403P	3.98	8e-05	0.0117	0.21	0.18	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222070113	chr1:221837334~221837437:-
LUAD	cis	rs10863681	0.713	rs12134885	ENSG00000200033.1	RNU6-403P	3.98	8e-05	0.0117	0.21	0.18	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222071038	chr1:221837334~221837437:-
LUAD	cis	rs10197140	0.857	rs9308692	ENSG00000235721.1	AC013268.3	-3.98	8e-05	0.0117	-0.19	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110883686	chr2:110007675~110010783:+
LUAD	cis	rs9549260	0.755	rs2721045	ENSG00000229456.1	RLIMP1	3.98	8e-05	0.0117	0.19	0.18	Red blood cell count;	chr13:40588495	chr13:40618738~40621348:+
LUAD	cis	rs1167827	0.68	rs1167800	ENSG00000165178.9	NCF1C	3.98	8.01e-05	0.0117	0.15	0.18	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75546898	chr7:75156639~75172044:-
LUAD	cis	rs7615952	0.641	rs12488180	ENSG00000241288.6	RP11-379B18.5	-3.98	8.01e-05	0.0117	-0.23	-0.18	Blood pressure (smoking interaction);	chr3:126063393	chr3:125827238~125916384:-
LUAD	cis	rs7119	0.604	rs907383	ENSG00000259362.2	RP11-307C19.1	3.98	8.01e-05	0.0117	0.23	0.18	Type 2 diabetes;	chr15:77578304	chr15:77525540~77534110:+
LUAD	cis	rs7463659	0.512	rs62524716	ENSG00000259820.1	AC083843.1	-3.98	8.01e-05	0.0117	-0.18	-0.18	Colonoscopy-negative controls vs population controls;	chr8:134438135	chr8:134792020~134798272:-
LUAD	cis	rs55692468	0.606	rs1878632	ENSG00000213197.3	AC012066.1	-3.98	8.01e-05	0.0117	-0.21	-0.18	Intraocular pressure;	chr2:152466644	chr2:152389937~152390630:+
LUAD	cis	rs6964587	0.633	rs13231620	ENSG00000188693.7	CYP51A1-AS1	3.98	8.01e-05	0.0117	0.22	0.18	Breast cancer;	chr7:91878545	chr7:92134604~92180725:+
LUAD	cis	rs6689263	0.929	rs76440167	ENSG00000117242.7	PINK1-AS	3.98	8.01e-05	0.0117	0.39	0.18	Intelligence (multi-trait analysis);	chr1:20557089	chr1:20642657~20652193:-
LUAD	cis	rs1355223	0.902	rs6484726	ENSG00000271369.1	RP11-350D17.3	-3.98	8.02e-05	0.0117	-0.21	-0.18	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34676011	chr11:34709600~34710161:+
LUAD	cis	rs10197140	0.857	rs10188169	ENSG00000235721.1	AC013268.3	-3.98	8.02e-05	0.0117	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110887018	chr2:110007675~110010783:+
LUAD	cis	rs2732480	0.577	rs2732466	ENSG00000257763.1	OR5BK1P	3.98	8.02e-05	0.0117	0.19	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48338676	chr12:48355792~48356614:-
LUAD	cis	rs73108077	1	rs73105976	ENSG00000281376.1	ABALON	-3.98	8.02e-05	0.0117	-0.31	-0.18	Red blood cell density in sickle cell anemia;	chr20:31378130	chr20:31721507~31723409:+
LUAD	cis	rs6121246	0.609	rs6087783	ENSG00000230613.1	HM13-AS1	3.98	8.02e-05	0.0117	0.23	0.18	Mean corpuscular hemoglobin;	chr20:31833421	chr20:31567707~31573263:-
LUAD	cis	rs2153535	0.585	rs1814213	ENSG00000230939.1	RP11-314C16.1	-3.98	8.02e-05	0.0117	-0.2	-0.18	Motion sickness;	chr6:8619632	chr6:8784178~8785445:+
LUAD	cis	rs4819052	0.851	rs7275468	ENSG00000237664.1	LINC00316	-3.98	8.02e-05	0.0117	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236584	chr21:45338590~45341990:-
LUAD	cis	rs2252586	0.792	rs6945082	ENSG00000226278.1	PSPHP1	-3.98	8.02e-05	0.0117	-0.22	-0.18	Glioma;	chr7:54890765	chr7:55764797~55773288:+
LUAD	cis	rs1348850	0.837	rs12619074	ENSG00000213963.5	AC074286.1	3.98	8.02e-05	0.0117	0.21	0.18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177607608	chr2:177283508~177392691:-
LUAD	cis	rs1355223	1	rs1396883	ENSG00000271369.1	RP11-350D17.3	-3.98	8.02e-05	0.0117	-0.21	-0.18	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34735900	chr11:34709600~34710161:+
LUAD	cis	rs11742741	0.774	rs60092664	ENSG00000248874.4	C5orf17	-3.98	8.02e-05	0.0117	-0.22	-0.18	Educational attainment;	chr5:24059203	chr5:23951348~24178263:+
LUAD	cis	rs7615952	0.932	rs13086087	ENSG00000241288.6	RP11-379B18.5	-3.98	8.02e-05	0.0117	-0.23	-0.18	Blood pressure (smoking interaction);	chr3:125927438	chr3:125827238~125916384:-
LUAD	cis	rs12744310	1	rs12035913	ENSG00000235358.1	RP11-399E6.1	-3.98	8.02e-05	0.0117	-0.23	-0.18	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41291385	chr1:41242373~41284861:+
LUAD	cis	rs7762018	1	rs73242927	ENSG00000231690.2	LINC00574	-3.98	8.03e-05	0.0117	-0.33	-0.18	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169729477	chr6:169790321~169802873:+
LUAD	cis	rs9549260	0.785	rs6563842	ENSG00000229456.1	RLIMP1	3.98	8.03e-05	0.0117	0.2	0.18	Red blood cell count;	chr13:40670160	chr13:40618738~40621348:+
LUAD	cis	rs847577	0.569	rs7804318	ENSG00000272950.1	RP11-307C18.1	-3.98	8.03e-05	0.0117	-0.22	-0.18	Breast cancer;	chr7:98167323	chr7:98322853~98323430:+
LUAD	cis	rs17301013	0.896	rs13375788	ENSG00000227373.4	RP11-160H22.5	3.98	8.03e-05	0.0117	0.22	0.18	Systemic lupus erythematosus;	chr1:174524207	chr1:174115300~174160004:-
LUAD	cis	rs8062405	1	rs2008514	ENSG00000261419.1	RP11-57A19.4	3.98	8.03e-05	0.0117	0.2	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28659696~28740781:-
LUAD	cis	rs7829975	0.711	rs1039916	ENSG00000253893.2	FAM85B	-3.98	8.03e-05	0.0117	-0.22	-0.18	Mood instability;	chr8:8828344	chr8:8167819~8226614:-
LUAD	cis	rs6499129	1	rs7185709	ENSG00000280214.1	CTD-2012K14.5	-3.98	8.03e-05	0.0117	-0.21	-0.18	Waist-to-hip ratio adjusted for body mass index;	chr16:67495446	chr16:67550815~67552935:-
LUAD	cis	rs17772222	0.917	rs2004329	ENSG00000258789.1	RP11-507K2.3	-3.98	8.03e-05	0.0117	-0.24	-0.18	Coronary artery calcification;	chr14:88532965	chr14:88551597~88552493:+
LUAD	cis	rs853679	0.517	rs9393893	ENSG00000280107.1	AL022393.9	-3.98	8.03e-05	0.0117	-0.24	-0.18	Depression;	chr6:28141484	chr6:28170845~28172521:+
LUAD	cis	rs256438	0.93	rs2434283	ENSG00000251050.1	RP11-168A11.4	-3.98	8.04e-05	0.0117	-0.19	-0.18	Serum thyroid-stimulating hormone levels;	chr5:80094902	chr5:80019609~80019920:+
LUAD	cis	rs256438	0.93	rs2438636	ENSG00000251050.1	RP11-168A11.4	-3.98	8.04e-05	0.0117	-0.19	-0.18	Serum thyroid-stimulating hormone levels;	chr5:80094981	chr5:80019609~80019920:+
LUAD	cis	rs17826219	0.706	rs28469200	ENSG00000280069.1	CTD-2349P21.3	-3.98	8.04e-05	0.0117	-0.24	-0.18	Body mass index;	chr17:30806554	chr17:30738182~30740275:+
LUAD	cis	rs2976388	0.566	rs6998746	ENSG00000253741.1	CTD-2292P10.4	-3.98	8.04e-05	0.0117	-0.21	-0.18	Urinary tract infection frequency;	chr8:142721038	chr8:142702252~142726973:-
LUAD	cis	rs11742741	0.806	rs12153719	ENSG00000248874.4	C5orf17	-3.98	8.04e-05	0.0117	-0.22	-0.18	Educational attainment;	chr5:24014779	chr5:23951348~24178263:+
LUAD	cis	rs4268898	0.795	rs12470303	ENSG00000223754.1	AC008073.9	3.98	8.04e-05	0.0117	0.21	0.18	Asthma;	chr2:24397014	chr2:24199839~24201698:-
LUAD	cis	rs10463554	0.963	rs67068617	ENSG00000250682.4	LINC00491	3.98	8.04e-05	0.0117	0.22	0.18	Parkinson's disease;	chr5:103039977	chr5:102609156~102671559:-
LUAD	cis	rs4660214	0.666	rs12025847	ENSG00000182109.6	RP11-69E11.4	-3.98	8.04e-05	0.0117	-0.19	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39300977	chr1:39522280~39546187:-
LUAD	cis	rs73193808	0.851	rs4315609	ENSG00000215533.7	LINC00189	-3.98	8.04e-05	0.0117	-0.24	-0.18	Coronary artery disease;	chr21:29232768	chr21:29193480~29288205:+
LUAD	cis	rs77688320	0.5	rs4129010	ENSG00000213090.2	AC007256.5	3.98	8.04e-05	0.0117	0.2	0.18	Breast cancer;	chr2:201443602	chr2:201410544~201413308:-
LUAD	cis	rs77688320	0.5	rs4129011	ENSG00000213090.2	AC007256.5	3.98	8.04e-05	0.0117	0.2	0.18	Breast cancer;	chr2:201443863	chr2:201410544~201413308:-
LUAD	cis	rs1799955	0.935	rs3764792	ENSG00000215515.2	IFIT1P1	-3.98	8.05e-05	0.0117	-0.26	-0.18	LDL cholesterol levels;	chr13:32376978	chr13:32384660~32386108:+
LUAD	cis	rs9635324	0.516	rs7165012	ENSG00000223313.1	RNU6-516P	-3.98	8.05e-05	0.0118	-0.21	-0.18	Blood metabolite ratios;Blood metabolite levels;	chr15:40361837	chr15:40529570~40529673:+
LUAD	cis	rs3018712	0.532	rs2510396	ENSG00000212093.1	AP000807.1	-3.98	8.05e-05	0.0118	-0.24	-0.18	Total body bone mineral density;	chr11:68650184	chr11:68506083~68506166:-
LUAD	cis	rs2904524	1	rs7311497	ENSG00000257815.4	RP11-611E13.2	-3.98	8.05e-05	0.0118	-0.24	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70343818	chr12:69904033~70243360:-
LUAD	cis	rs2904524	1	rs11178195	ENSG00000257815.4	RP11-611E13.2	-3.98	8.05e-05	0.0118	-0.24	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70345715	chr12:69904033~70243360:-
LUAD	cis	rs9366999	0.713	rs1744417	ENSG00000235033.6	RP11-61I13.3	-3.98	8.06e-05	0.0118	-0.19	-0.18	Obesity-related traits;	chr6:39254144	chr6:39881804~39900071:-
LUAD	cis	rs848490	0.889	rs11763798	ENSG00000214293.7	APTR	3.98	8.06e-05	0.0118	0.23	0.18	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77605323	chr7:77657660~77696265:-
LUAD	cis	rs2749592	0.55	rs10764135	ENSG00000263064.2	RP11-291L22.7	-3.98	8.06e-05	0.0118	-0.19	-0.18	Age-related hearing impairment (SNP x SNP interaction);	chr10:37577917	chr10:38448689~38448949:+
LUAD	cis	rs11742741	0.742	rs12152957	ENSG00000248874.4	C5orf17	-3.98	8.06e-05	0.0118	-0.22	-0.18	Educational attainment;	chr5:24015053	chr5:23951348~24178263:+
LUAD	cis	rs12188164	0.965	rs72717435	ENSG00000225138.6	CTD-2228K2.7	3.98	8.06e-05	0.0118	0.18	0.18	Cystic fibrosis severity;	chr5:448087	chr5:473236~480884:+
LUAD	cis	rs6802315	0.712	rs7615751	ENSG00000272247.1	RP11-379F4.9	-3.98	8.06e-05	0.0118	-0.19	-0.18	Periodontitis (CDC/AAP);	chr3:158792041	chr3:158801257~158801935:-
LUAD	cis	rs17301013	0.932	rs332771	ENSG00000227373.4	RP11-160H22.5	3.98	8.06e-05	0.0118	0.23	0.18	Systemic lupus erythematosus;	chr1:174704141	chr1:174115300~174160004:-
LUAD	cis	rs270601	0.69	rs162907	ENSG00000263597.1	MIR3936	-3.98	8.06e-05	0.0118	-0.19	-0.18	Acylcarnitine levels;	chr5:132244459	chr5:132365490~132365599:-
LUAD	cis	rs6951245	0.744	rs10265758	ENSG00000199023.2	MIR339	-3.98	8.07e-05	0.0118	-0.3	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1132882	chr7:1022935~1023045:-
LUAD	cis	rs853679	0.55	rs1150692	ENSG00000226314.6	ZNF192P1	-3.98	8.07e-05	0.0118	-0.23	-0.18	Depression;	chr6:28206179	chr6:28161781~28169594:+
LUAD	cis	rs10090774	0.71	rs4413752	ENSG00000280303.2	ERICD	-3.98	8.07e-05	0.0118	-0.2	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140678873	chr8:140636281~140638283:+
LUAD	cis	rs595982	0.51	rs3826817	ENSG00000235191.1	NUCB1-AS1	3.98	8.07e-05	0.0118	0.2	0.18	Red cell distribution width;	chr19:48898187	chr19:48910930~48918891:-
LUAD	cis	rs595982	0.546	rs10401443	ENSG00000235191.1	NUCB1-AS1	3.98	8.07e-05	0.0118	0.2	0.18	Red cell distribution width;	chr19:48898802	chr19:48910930~48918891:-
LUAD	cis	rs210138	1	rs6900408	ENSG00000197251.3	LINC00336	3.98	8.07e-05	0.0118	0.28	0.18	Testicular germ cell tumor;	chr6:33584387	chr6:33586106~33593338:-
LUAD	cis	rs72802342	0.51	rs12932952	ENSG00000280152.1	RP11-331F4.5	3.98	8.07e-05	0.0118	0.2	0.18	Advanced age-related macular degeneration;	chr16:75331588	chr16:75245994~75250077:-
LUAD	cis	rs17406451	1	rs6544653	ENSG00000279873.2	LINC01126	3.98	8.07e-05	0.0118	0.16	0.18	Mitochondrial DNA levels;	chr2:43405811	chr2:43227210~43228855:+
LUAD	cis	rs6787172	0.811	rs939117	ENSG00000272087.1	RP11-379F4.7	-3.98	8.07e-05	0.0118	-0.19	-0.18	Subjective well-being;	chr3:158483080	chr3:158693120~158693768:-
LUAD	cis	rs7557067	1	rs6754295	ENSG00000233005.1	AC067959.1	-3.98	8.08e-05	0.0118	-0.21	-0.18	Triglycerides;	chr2:20983311	chr2:21221175~21970959:+
LUAD	cis	rs1552244	0.882	rs2030564	ENSG00000180385.7	EMC3-AS1	3.98	8.08e-05	0.0118	0.21	0.18	Alzheimer's disease;	chr3:9997360	chr3:9986893~10006990:+
LUAD	cis	rs6568686	0.53	rs56340018	ENSG00000255389.1	C6orf3	3.98	8.08e-05	0.0118	0.25	0.18	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111620092	chr6:111599875~111602295:+
LUAD	cis	rs6531209	0.817	rs2348314	ENSG00000234378.1	AC098828.2	3.98	8.08e-05	0.0118	0.22	0.18	Amyotrophic lateral sclerosis (sporadic);	chr2:20138493	chr2:20063856~20106829:-
LUAD	cis	rs6531209	0.817	rs2348315	ENSG00000234378.1	AC098828.2	3.98	8.08e-05	0.0118	0.22	0.18	Amyotrophic lateral sclerosis (sporadic);	chr2:20138743	chr2:20063856~20106829:-
LUAD	cis	rs6531209	0.817	rs4666364	ENSG00000234378.1	AC098828.2	3.98	8.08e-05	0.0118	0.22	0.18	Amyotrophic lateral sclerosis (sporadic);	chr2:20138838	chr2:20063856~20106829:-
LUAD	cis	rs6531209	0.817	rs4666365	ENSG00000234378.1	AC098828.2	3.98	8.08e-05	0.0118	0.22	0.18	Amyotrophic lateral sclerosis (sporadic);	chr2:20138853	chr2:20063856~20106829:-
LUAD	cis	rs3814244	0.528	rs1468487	ENSG00000236946.2	HNRNPA1P70	3.98	8.08e-05	0.0118	0.15	0.18	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996602	chr12:68035767~68036853:+
LUAD	cis	rs3814244	0.528	rs2860609	ENSG00000236946.2	HNRNPA1P70	3.98	8.08e-05	0.0118	0.15	0.18	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997215	chr12:68035767~68036853:+
LUAD	cis	rs7960884	0.629	rs979062	ENSG00000177359.16	RP11-551L14.1	3.98	8.08e-05	0.0118	0.19	0.18	Systolic blood pressure response to hydrochlorothiazide in hypertension;	chr12:31229755	chr12:31111652~31206154:-
LUAD	cis	rs7960884	0.655	rs979064	ENSG00000177359.16	RP11-551L14.1	3.98	8.08e-05	0.0118	0.19	0.18	Systolic blood pressure response to hydrochlorothiazide in hypertension;	chr12:31229824	chr12:31111652~31206154:-
LUAD	cis	rs1431005	0.963	rs58289169	ENSG00000250658.1	RP11-138B4.1	3.98	8.08e-05	0.0118	0.22	0.18	Response to statin therapy;	chr4:187476388	chr4:187304083~187309682:-
LUAD	cis	rs11220082	0.666	rs56398391	ENSG00000254671.2	STT3A-AS1	-3.98	8.08e-05	0.0118	-0.2	-0.18	Schizophrenia;	chr11:125444220	chr11:125570284~125592568:-
LUAD	cis	rs17767294	0.612	rs9461425	ENSG00000219392.1	RP1-265C24.5	-3.98	8.08e-05	0.0118	-0.34	-0.18	Parkinson's disease;	chr6:27951910	chr6:28115628~28116551:+
LUAD	cis	rs73198271	0.653	rs10087742	ENSG00000253893.2	FAM85B	3.98	8.08e-05	0.0118	0.23	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802964	chr8:8167819~8226614:-
LUAD	cis	rs7515577	0.898	rs3131815	ENSG00000223787.2	RP4-593M8.1	3.98	8.08e-05	0.0118	0.28	0.18	Cholesterol, total;	chr1:92199409	chr1:92580476~92580821:-
LUAD	cis	rs875971	0.545	rs17138149	ENSG00000222364.1	RNU6-96P	-3.98	8.08e-05	0.0118	-0.22	-0.18	Aortic root size;	chr7:66228193	chr7:66395191~66395286:+
LUAD	cis	rs7617773	0.78	rs35411187	ENSG00000199476.1	Y_RNA	-3.98	8.08e-05	0.0118	-0.24	-0.18	Coronary artery disease;	chr3:48318527	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.78	rs11714176	ENSG00000199476.1	Y_RNA	-3.98	8.08e-05	0.0118	-0.24	-0.18	Coronary artery disease;	chr3:48319372	chr3:48288587~48288694:+
LUAD	cis	rs9309473	0.607	rs1522926	ENSG00000163016.8	ALMS1P	3.98	8.08e-05	0.0118	0.2	0.18	Metabolite levels;	chr2:73364113	chr2:73644919~73685576:+
LUAD	cis	rs791888	0.965	rs791877	ENSG00000225913.2	RP11-57C13.6	-3.98	8.08e-05	0.0118	-0.23	-0.18	Magnesium levels;	chr10:87647106	chr10:87607985~87659279:+
LUAD	cis	rs5758659	0.714	rs2284087	ENSG00000182057.4	OGFRP1	-3.98	8.09e-05	0.0118	-0.21	-0.18	Cognitive function;	chr22:42089667	chr22:42269753~42275196:+
LUAD	cis	rs6910061	0.956	rs61185321	ENSG00000247925.2	RP3-510L9.1	-3.98	8.09e-05	0.0118	-0.25	-0.18	Diabetic kidney disease;	chr6:11102870	chr6:11173452~11259099:+
LUAD	cis	rs2904524	1	rs74716820	ENSG00000257815.4	RP11-611E13.2	-3.98	8.09e-05	0.0118	-0.27	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70246074	chr12:69904033~70243360:-
LUAD	cis	rs9549260	0.755	rs4429172	ENSG00000229456.1	RLIMP1	3.98	8.09e-05	0.0118	0.19	0.18	Red blood cell count;	chr13:40615006	chr13:40618738~40621348:+
LUAD	cis	rs9545047	0.604	rs4573813	ENSG00000227354.5	RBM26-AS1	3.98	8.09e-05	0.0118	0.19	0.18	Schizophrenia;	chr13:79293357	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs2147566	ENSG00000227354.5	RBM26-AS1	3.98	8.09e-05	0.0118	0.19	0.18	Schizophrenia;	chr13:79296580	chr13:79406309~79424328:+
LUAD	cis	rs7200786	0.692	rs9935445	ENSG00000274038.1	RP11-66H6.4	-3.98	8.09e-05	0.0118	-0.21	-0.18	Systemic lupus erythematosus;Multiple sclerosis;	chr16:10995532	chr16:11056556~11057034:+
LUAD	cis	rs848490	0.889	rs6960913	ENSG00000214293.7	APTR	3.98	8.1e-05	0.0118	0.23	0.18	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77647943	chr7:77657660~77696265:-
LUAD	cis	rs858239	0.602	rs6953996	ENSG00000226816.2	AC005082.12	3.98	8.1e-05	0.0118	0.24	0.18	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23206013~23208045:+
LUAD	cis	rs2354432	0.607	rs6593751	ENSG00000226015.2	CCT8P1	3.98	8.1e-05	0.0118	0.33	0.18	Mitochondrial DNA levels;	chr1:147254368	chr1:147203276~147204932:-
LUAD	cis	rs3018712	0.532	rs2513281	ENSG00000212093.1	AP000807.1	-3.98	8.1e-05	0.0118	-0.24	-0.18	Total body bone mineral density;	chr11:68649626	chr11:68506083~68506166:-
LUAD	cis	rs9894429	0.646	rs7220310	ENSG00000263853.1	AC139530.1	-3.98	8.1e-05	0.0118	-0.18	-0.18	Eye color traits;	chr17:81639030	chr17:81676001~81676086:+
LUAD	cis	rs8014252	0.901	rs73293935	ENSG00000259158.2	ADAM20P1	-3.98	8.1e-05	0.0118	-0.27	-0.18	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70484816	chr14:70468881~70483756:-
LUAD	cis	rs10214930	1	rs42104	ENSG00000235574.1	AC073150.6	-3.98	8.1e-05	0.0118	-0.24	-0.18	Hypospadias;	chr7:27680896	chr7:27491682~27492765:-
LUAD	cis	rs801193	0.742	rs9969300	ENSG00000232546.1	RP11-458F8.1	3.98	8.1e-05	0.0118	0.16	0.18	Aortic root size;	chr7:66316659	chr7:66848496~66858136:+
LUAD	cis	rs214785	1	rs214775	ENSG00000234684.5	SDCBP2-AS1	3.98	8.11e-05	0.0118	0.22	0.18	Basal cell carcinoma;	chr20:2299709	chr20:1325405~1378734:+
LUAD	cis	rs2657294	0.895	rs2395137	ENSG00000226051.5	ZNF503-AS1	-3.98	8.11e-05	0.0118	-0.24	-0.18	Pneumonia;	chr10:75088235	chr10:75269819~75373500:+
LUAD	cis	rs137603	0.562	rs470080	ENSG00000225450.1	RP3-508I15.14	-3.98	8.11e-05	0.0118	-0.16	-0.18	Primary biliary cholangitis;	chr22:39316363	chr22:38739003~38749041:+
LUAD	cis	rs7760535	0.826	rs3851229	ENSG00000266032.1	AL357515.1	3.98	8.11e-05	0.0118	0.23	0.18	Metabolic traits;	chr6:111533457	chr6:110969773~110969872:-
LUAD	cis	rs71520386	1	rs71520386	ENSG00000228649.7	AC005682.5	-3.98	8.11e-05	0.0118	-0.29	-0.18	Fibrinogen levels;	chr7:22813902	chr7:22854178~22861579:+
LUAD	cis	rs12681963	1	rs10954872	ENSG00000272375.1	RP11-51J9.6	-3.98	8.11e-05	0.0118	-0.24	-0.18	Migraine;	chr8:30121096	chr8:30197404~30198048:+
LUAD	cis	rs11051970	0.879	rs2733682	ENSG00000274964.1	RP11-817I4.1	-3.98	8.11e-05	0.0118	-0.19	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr12:32421674	chr12:32339368~32340724:+
LUAD	cis	rs4819052	0.851	rs2838832	ENSG00000237664.1	LINC00316	3.98	8.11e-05	0.0118	0.21	0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244989	chr21:45338590~45341990:-
LUAD	cis	rs763121	0.719	rs9610995	ENSG00000228274.3	RP3-508I15.9	-3.98	8.11e-05	0.0118	-0.18	-0.18	Menopause (age at onset);	chr22:38661758	chr22:38667585~38681820:-
LUAD	cis	rs763121	0.853	rs2413544	ENSG00000228274.3	RP3-508I15.9	-3.98	8.11e-05	0.0118	-0.18	-0.18	Menopause (age at onset);	chr22:38663399	chr22:38667585~38681820:-
LUAD	cis	rs763121	0.752	rs5757222	ENSG00000228274.3	RP3-508I15.9	-3.98	8.11e-05	0.0118	-0.18	-0.18	Menopause (age at onset);	chr22:38664468	chr22:38667585~38681820:-
LUAD	cis	rs763121	0.819	rs5750658	ENSG00000228274.3	RP3-508I15.9	-3.98	8.11e-05	0.0118	-0.18	-0.18	Menopause (age at onset);	chr22:38664912	chr22:38667585~38681820:-
LUAD	cis	rs763121	0.819	rs8137829	ENSG00000228274.3	RP3-508I15.9	-3.98	8.11e-05	0.0118	-0.18	-0.18	Menopause (age at onset);	chr22:38665025	chr22:38667585~38681820:-
LUAD	cis	rs11742741	0.837	rs12153104	ENSG00000248874.4	C5orf17	-3.98	8.11e-05	0.0118	-0.22	-0.18	Educational attainment;	chr5:24016402	chr5:23951348~24178263:+
LUAD	cis	rs5758659	1	rs5751255	ENSG00000273366.1	CTA-989H11.1	-3.98	8.11e-05	0.0118	-0.2	-0.18	Cognitive function;	chr22:42252402	chr22:42278188~42278846:+
LUAD	cis	rs11148252	0.532	rs9536185	ENSG00000273784.3	RP11-78J21.7	-3.98	8.11e-05	0.0118	-0.21	-0.18	Lewy body disease;	chr13:52605666	chr13:52600042~52642542:+
LUAD	cis	rs8040855	1	rs8040855	ENSG00000259774.1	RP11-182J1.13	-3.98	8.11e-05	0.0118	-0.21	-0.18	Bulimia nervosa;	chr15:85155976	chr15:84422618~84425882:+
LUAD	cis	rs6088580	0.608	rs8114616	ENSG00000276073.1	RP5-1125A11.7	3.98	8.11e-05	0.0118	0.18	0.18	Glomerular filtration rate (creatinine);	chr20:34381286	chr20:33985617~33988989:-
LUAD	cis	rs9860428	0.844	rs28782232	ENSG00000242770.2	RP11-180K7.1	3.98	8.11e-05	0.0118	0.2	0.18	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112849314	chr3:112802478~112812819:+
LUAD	cis	rs9860428	0.844	rs6806976	ENSG00000242770.2	RP11-180K7.1	3.98	8.11e-05	0.0118	0.2	0.18	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112852143	chr3:112802478~112812819:+
LUAD	cis	rs6674176	0.628	rs3791116	ENSG00000237950.1	RP11-7O11.3	3.98	8.11e-05	0.0118	0.23	0.18	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43948484	chr1:43944370~43946551:-
LUAD	cis	rs17772222	0.74	rs7160647	ENSG00000258983.2	RP11-507K2.2	3.98	8.11e-05	0.0118	0.2	0.18	Coronary artery calcification;	chr14:88507340	chr14:88499334~88515502:+
LUAD	cis	rs2880765	0.566	rs55899824	ENSG00000259630.2	CTD-2262B20.1	-3.98	8.12e-05	0.0118	-0.21	-0.18	Coronary artery disease;	chr15:85460860	chr15:85415228~85415633:+
LUAD	cis	rs2880765	0.631	rs55767890	ENSG00000259630.2	CTD-2262B20.1	-3.98	8.12e-05	0.0118	-0.21	-0.18	Coronary artery disease;	chr15:85460911	chr15:85415228~85415633:+
LUAD	cis	rs1023500	0.551	rs133355	ENSG00000205702.9	CYP2D7	3.98	8.12e-05	0.0118	0.14	0.18	Schizophrenia;	chr22:42044281	chr22:42140203~42144577:-
LUAD	cis	rs2548724	0.66	rs62369343	ENSG00000250682.4	LINC00491	3.98	8.12e-05	0.0118	0.23	0.18	Type 2 diabetes;	chr5:102405249	chr5:102609156~102671559:-
LUAD	cis	rs755249	0.727	rs12028034	ENSG00000237624.1	OXCT2P1	-3.98	8.12e-05	0.0118	-0.23	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39574035	chr1:39514956~39516490:+
LUAD	cis	rs7615952	0.599	rs12486459	ENSG00000250012.1	RP11-124N2.1	-3.97	8.12e-05	0.0118	-0.25	-0.18	Blood pressure (smoking interaction);	chr3:126022622	chr3:126084220~126095349:+
LUAD	cis	rs7615952	0.599	rs67575510	ENSG00000250012.1	RP11-124N2.1	-3.97	8.12e-05	0.0118	-0.25	-0.18	Blood pressure (smoking interaction);	chr3:126023512	chr3:126084220~126095349:+
LUAD	cis	rs7870753	0.628	rs10820598	ENSG00000188801.9	ZNF322P1	3.97	8.12e-05	0.0118	0.27	0.18	Height;	chr9:96426973	chr9:97198303~97199511:-
LUAD	cis	rs9910055	0.529	rs368328	ENSG00000267080.4	ASB16-AS1	3.97	8.12e-05	0.0118	0.17	0.18	Total body bone mineral density;	chr17:44092921	chr17:44175973~44186717:-
LUAD	cis	rs7512552	0.839	rs834229	ENSG00000275557.1	RP11-353N4.6	3.97	8.12e-05	0.0118	0.2	0.18	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150412189	chr1:149607765~149612402:+
LUAD	cis	rs9287719	0.699	rs4669602	ENSG00000243819.4	RN7SL832P	3.97	8.12e-05	0.0118	0.19	0.18	Prostate cancer;	chr2:10647841	chr2:10690344~10692099:+
LUAD	cis	rs2492286	0.597	rs2712407	ENSG00000242551.2	POU5F1P6	-3.97	8.12e-05	0.0118	-0.25	-0.18	Eosinophil counts;	chr3:128607964	chr3:128674735~128677005:-
LUAD	cis	rs1023500	0.573	rs133378	ENSG00000205702.9	CYP2D7	3.97	8.12e-05	0.0118	0.14	0.18	Schizophrenia;	chr22:42071691	chr22:42140203~42144577:-
LUAD	cis	rs2115630	0.754	rs12595321	ENSG00000225151.9	GOLGA2P7	3.97	8.12e-05	0.0118	0.2	0.18	P wave terminal force;	chr15:84788038	chr15:84199311~84230136:-
LUAD	cis	rs7551222	0.752	rs10793767	ENSG00000240219.1	RP11-430C7.5	3.97	8.12e-05	0.0118	0.19	0.18	Schizophrenia;	chr1:204580436	chr1:204626775~204629712:+
LUAD	cis	rs911555	0.755	rs2273702	ENSG00000259775.1	RP11-45P15.4	3.97	8.13e-05	0.0118	0.23	0.18	Intelligence (multi-trait analysis);	chr14:103451845	chr14:103331674~103332367:-
LUAD	cis	rs2562456	0.833	rs55875743	ENSG00000268081.1	RP11-678G14.2	3.97	8.13e-05	0.0118	0.3	0.18	Pain;	chr19:21383393	chr19:21554640~21569237:-
LUAD	cis	rs6663390	0.51	rs2267897	ENSG00000203709.8	C1orf132	3.97	8.13e-05	0.0118	0.25	0.18	Facial morphology (factor 18);	chr1:207902033	chr1:207801518~207869150:-
LUAD	cis	rs4321325	1	rs4321325	ENSG00000236682.1	AC068282.3	-3.97	8.13e-05	0.0118	-0.3	-0.18	Protein C levels;	chr2:127193421	chr2:127389130~127400580:+
LUAD	cis	rs10129255	0.784	rs7147210	ENSG00000211947.2	IGHV3-21	-3.97	8.13e-05	0.0119	-0.12	-0.18	Kawasaki disease;	chr14:106705271	chr14:106235064~106235594:-
LUAD	cis	rs8113308	0.81	rs11879040	ENSG00000269483.1	AC006272.1	3.97	8.13e-05	0.0119	0.28	0.18	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51946856	chr19:51839924~51843324:-
LUAD	cis	rs728616	0.867	rs17884637	ENSG00000225484.5	NUTM2B-AS1	-3.97	8.13e-05	0.0119	-0.47	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79928166	chr10:79663088~79826594:-
LUAD	cis	rs7976269	0.609	rs4931137	ENSG00000257176.2	RP11-996F15.2	-3.97	8.13e-05	0.0119	-0.19	-0.18	Male-pattern baldness;	chr12:29049701	chr12:29280418~29317848:-
LUAD	cis	rs4474465	1	rs2063728	ENSG00000251323.2	RP11-452H21.4	3.97	8.13e-05	0.0119	0.23	0.18	Alzheimer's disease (survival time);	chr11:78474590	chr11:78423982~78429836:-
LUAD	cis	rs7208859	0.725	rs9891656	ENSG00000263603.1	CTD-2349P21.5	-3.97	8.13e-05	0.0119	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916337	chr17:30729469~30731202:+
LUAD	cis	rs6840360	0.582	rs2724553	ENSG00000270265.1	RP11-731D1.4	-3.97	8.13e-05	0.0119	-0.18	-0.18	Intelligence (multi-trait analysis);	chr4:151400729	chr4:151333775~151353224:-
LUAD	cis	rs7621025	0.675	rs34602896	ENSG00000239213.4	NCK1-AS1	-3.97	8.14e-05	0.0119	-0.23	-0.18	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136627543	chr3:136841726~136862054:-
LUAD	cis	rs703842	1	rs703842	ENSG00000270039.1	RP11-571M6.17	3.97	8.14e-05	0.0119	0.21	0.18	Multiple sclerosis;	chr12:57768956	chr12:57803838~57804415:+
LUAD	cis	rs7119038	0.818	rs10892280	ENSG00000255239.1	AP002954.6	-3.97	8.14e-05	0.0119	-0.27	-0.18	Sjögren's syndrome;	chr11:118741108	chr11:118688039~118690600:-
LUAD	cis	rs7141336	0.965	rs8017072	ENSG00000258884.1	CTD-3035D6.2	-3.97	8.14e-05	0.0119	-0.18	-0.18	Anxiety disorder;	chr14:90814615	chr14:90822365~90828128:-
LUAD	cis	rs4474465	1	rs11237508	ENSG00000251323.2	RP11-452H21.4	3.97	8.14e-05	0.0119	0.23	0.18	Alzheimer's disease (survival time);	chr11:78462251	chr11:78423982~78429836:-
LUAD	cis	rs4474465	1	rs11237510	ENSG00000251323.2	RP11-452H21.4	3.97	8.14e-05	0.0119	0.23	0.18	Alzheimer's disease (survival time);	chr11:78462538	chr11:78423982~78429836:-
LUAD	cis	rs4474465	0.915	rs12273367	ENSG00000251323.2	RP11-452H21.4	3.97	8.14e-05	0.0119	0.23	0.18	Alzheimer's disease (survival time);	chr11:78462789	chr11:78423982~78429836:-
LUAD	cis	rs4474465	1	rs10793314	ENSG00000251323.2	RP11-452H21.4	3.97	8.14e-05	0.0119	0.23	0.18	Alzheimer's disease (survival time);	chr11:78463150	chr11:78423982~78429836:-
LUAD	cis	rs9309473	0.797	rs6723247	ENSG00000230002.2	ALMS1-IT1	3.97	8.14e-05	0.0119	0.22	0.18	Metabolite levels;	chr2:73619622	chr2:73456764~73459484:+
LUAD	cis	rs1881797	0.872	rs2141544	ENSG00000221953.5	C1orf229	-3.97	8.14e-05	0.0119	-0.23	-0.18	Acute lymphoblastic leukemia (childhood);	chr1:247527498	chr1:247110160~247112417:-
LUAD	cis	rs651907	0.514	rs12636046	ENSG00000244119.1	PDCL3P4	3.97	8.14e-05	0.0119	0.18	0.18	Colorectal cancer;	chr3:101715604	chr3:101712472~101713191:+
LUAD	cis	rs11874381	1	rs9955622	ENSG00000266696.1	RP11-30L3.2	3.97	8.15e-05	0.0119	0.2	0.18	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);	chr18:49677585	chr18:49205912~49208781:+
LUAD	cis	rs6840258	0.76	rs58633957	ENSG00000251411.1	RP11-397E7.4	-3.97	8.15e-05	0.0119	-0.2	-0.18	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87047827	chr4:86913266~86914817:-
LUAD	cis	rs858239	0.539	rs57864591	ENSG00000226816.2	AC005082.12	3.97	8.15e-05	0.0119	0.24	0.18	Cerebrospinal fluid biomarker levels;	chr7:23144805	chr7:23206013~23208045:+
LUAD	cis	rs7100689	0.58	rs7083519	ENSG00000226659.1	RP11-137H2.4	-3.97	8.15e-05	0.0119	-0.24	-0.18	Post bronchodilator FEV1;	chr10:80447768	chr10:80529597~80535942:-
LUAD	cis	rs7824557	0.545	rs2572380	ENSG00000255046.1	RP11-297N6.4	3.97	8.15e-05	0.0119	0.22	0.18	Retinal vascular caliber;	chr8:11379968	chr8:11797928~11802568:-
LUAD	cis	rs2098713	0.569	rs7700431	ENSG00000250155.1	CTD-2353F22.1	3.97	8.15e-05	0.0119	0.19	0.18	Telomere length;	chr5:37552750	chr5:36666214~36725195:-
LUAD	cis	rs7968440	1	rs10747586	ENSG00000272368.2	RP4-605O3.4	-3.97	8.15e-05	0.0119	-0.21	-0.18	Fibrinogen;	chr12:50589782	chr12:50112197~50165618:+
LUAD	cis	rs897984	0.77	rs3813020	ENSG00000232748.3	RP11-196G11.6	3.97	8.15e-05	0.0119	0.22	0.18	Dementia with Lewy bodies;	chr16:30922754	chr16:31056460~31062803:+
LUAD	cis	rs8040855	0.597	rs12902942	ENSG00000259774.1	RP11-182J1.13	3.97	8.15e-05	0.0119	0.23	0.18	Bulimia nervosa;	chr15:85041573	chr15:84422618~84425882:+
LUAD	cis	rs2060793	0.741	rs10741656	ENSG00000251991.1	RNU7-49P	3.97	8.15e-05	0.0119	0.19	0.18	Vitamin D levels;	chr11:14803699	chr11:14478892~14478953:+
LUAD	cis	rs6951245	0.744	rs10265736	ENSG00000199023.2	MIR339	-3.97	8.16e-05	0.0119	-0.3	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1132829	chr7:1022935~1023045:-
LUAD	cis	rs11216126	1	rs11216126	ENSG00000254851.1	RP11-109L13.1	3.97	8.16e-05	0.0119	0.33	0.18	HDL cholesterol;	chr11:116746524	chr11:117135528~117138582:+
LUAD	cis	rs7615952	0.599	rs6766327	ENSG00000241288.6	RP11-379B18.5	-3.97	8.16e-05	0.0119	-0.23	-0.18	Blood pressure (smoking interaction);	chr3:126004834	chr3:125827238~125916384:-
LUAD	cis	rs7615952	0.641	rs12491577	ENSG00000241288.6	RP11-379B18.5	-3.97	8.16e-05	0.0119	-0.23	-0.18	Blood pressure (smoking interaction);	chr3:126012288	chr3:125827238~125916384:-
LUAD	cis	rs7178375	1	rs7176351	ENSG00000270015.1	RP11-540B6.6	3.97	8.16e-05	0.0119	0.17	0.18	Hypertriglyceridemia;	chr15:30916524	chr15:30926514~30928407:+
LUAD	cis	rs853679	0.567	rs9969098	ENSG00000219392.1	RP1-265C24.5	-3.97	8.16e-05	0.0119	-0.24	-0.18	Depression;	chr6:28430971	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.567	rs16894106	ENSG00000219392.1	RP1-265C24.5	-3.97	8.16e-05	0.0119	-0.24	-0.18	Depression;	chr6:28432562	chr6:28115628~28116551:+
LUAD	cis	rs748404	0.666	rs12906481	ENSG00000249839.1	AC011330.5	-3.97	8.16e-05	0.0119	-0.28	-0.18	Lung cancer;	chr15:43467356	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.666	rs35958032	ENSG00000249839.1	AC011330.5	-3.97	8.16e-05	0.0119	-0.28	-0.18	Lung cancer;	chr15:43494397	chr15:43663654~43684339:-
LUAD	cis	rs721917	0.531	rs2256703	ENSG00000230091.5	TMEM254-AS1	-3.97	8.17e-05	0.0119	-0.23	-0.18	Chronic obstructive pulmonary disease;	chr10:79924588	chr10:80046860~80078912:-
LUAD	cis	rs1044826	1	rs4683818	ENSG00000214280.3	RP11-553K23.2	-3.97	8.17e-05	0.0119	-0.21	-0.18	Obesity-related traits;	chr3:139510777	chr3:139582928~139583593:-
LUAD	cis	rs73242632	1	rs3775083	ENSG00000269949.1	RP11-738E22.3	3.97	8.17e-05	0.0119	0.44	0.18	Congenital heart disease (maternal effect);	chr4:57002020	chr4:56960927~56961373:-
LUAD	cis	rs73242632	1	rs28474684	ENSG00000269949.1	RP11-738E22.3	3.97	8.17e-05	0.0119	0.44	0.18	Congenital heart disease (maternal effect);	chr4:57009303	chr4:56960927~56961373:-
LUAD	cis	rs73242632	1	rs56798906	ENSG00000269949.1	RP11-738E22.3	3.97	8.17e-05	0.0119	0.44	0.18	Congenital heart disease (maternal effect);	chr4:57009559	chr4:56960927~56961373:-
LUAD	cis	rs73242632	0.867	rs28545156	ENSG00000269949.1	RP11-738E22.3	3.97	8.17e-05	0.0119	0.44	0.18	Congenital heart disease (maternal effect);	chr4:57013174	chr4:56960927~56961373:-
LUAD	cis	rs73242632	1	rs28719609	ENSG00000269949.1	RP11-738E22.3	3.97	8.17e-05	0.0119	0.44	0.18	Congenital heart disease (maternal effect);	chr4:57015696	chr4:56960927~56961373:-
LUAD	cis	rs73242632	1	rs2271806	ENSG00000269949.1	RP11-738E22.3	3.97	8.17e-05	0.0119	0.44	0.18	Congenital heart disease (maternal effect);	chr4:57020984	chr4:56960927~56961373:-
LUAD	cis	rs73242632	1	rs28681160	ENSG00000269949.1	RP11-738E22.3	3.97	8.17e-05	0.0119	0.44	0.18	Congenital heart disease (maternal effect);	chr4:57023000	chr4:56960927~56961373:-
LUAD	cis	rs2273156	0.57	rs7154306	ENSG00000226677.3	IGBP1P1	-3.97	8.17e-05	0.0119	-0.28	-0.18	Immunoglobulin light chain (AL) amyloidosis;	chr14:35071293	chr14:34939324~34940332:+
LUAD	cis	rs4578769	0.55	rs4473296	ENSG00000265943.1	RP11-739L10.1	-3.97	8.17e-05	0.0119	-0.22	-0.18	Eosinophil percentage of white cells;	chr18:22986421	chr18:22699481~22933764:-
LUAD	cis	rs860295	0.676	rs11264374	ENSG00000225855.5	RUSC1-AS1	3.97	8.17e-05	0.0119	0.12	0.18	Body mass index;	chr1:155451721	chr1:155316863~155324176:-
LUAD	cis	rs10971721	0.584	rs72731221	ENSG00000260947.1	RP11-384P7.7	3.97	8.18e-05	0.0119	0.36	0.18	Body mass index;	chr9:34122376	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.584	rs72731222	ENSG00000260947.1	RP11-384P7.7	3.97	8.18e-05	0.0119	0.36	0.18	Body mass index;	chr9:34122864	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.584	rs10971939	ENSG00000260947.1	RP11-384P7.7	3.97	8.18e-05	0.0119	0.36	0.18	Body mass index;	chr9:34123437	chr9:33697459~33700986:+
LUAD	cis	rs28735056	0.609	rs4799099	ENSG00000261126.6	RP11-795F19.1	3.97	8.18e-05	0.0119	0.19	0.18	Schizophrenia;	chr18:79879585	chr18:80046900~80095482:+
LUAD	cis	rs17685	0.753	rs7788763	ENSG00000280388.1	RP11-229D13.3	3.97	8.18e-05	0.0119	0.17	0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76022347	chr7:76043977~76045963:-
LUAD	cis	rs736801	0.607	rs11739135	ENSG00000233006.5	AC034220.3	3.97	8.19e-05	0.0119	0.16	0.18	Mosquito bite size;Breast cancer;	chr5:132397705	chr5:132311285~132369916:-
LUAD	cis	rs34779708	0.931	rs4934704	ENSG00000271335.4	RP11-324I22.4	3.97	8.19e-05	0.0119	0.19	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35043236	chr10:35314552~35336401:-
LUAD	cis	rs2333021	0.866	rs10133784	ENSG00000259015.1	RP11-109N23.6	3.97	8.19e-05	0.0119	0.17	0.18	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73003328	chr14:72960595~72961993:+
LUAD	cis	rs6088580	0.634	rs1205336	ENSG00000276073.1	RP5-1125A11.7	3.97	8.19e-05	0.0119	0.17	0.18	Glomerular filtration rate (creatinine);	chr20:34338530	chr20:33985617~33988989:-
LUAD	cis	rs5769707	0.521	rs7285764	ENSG00000235111.1	RP1-29C18.8	-3.97	8.19e-05	0.0119	-0.21	-0.18	Monocyte percentage of white cells;Monocyte count;	chr22:49664913	chr22:49612657~49615716:-
LUAD	cis	rs5769707	0.521	rs9616715	ENSG00000235111.1	RP1-29C18.8	-3.97	8.19e-05	0.0119	-0.21	-0.18	Monocyte percentage of white cells;Monocyte count;	chr22:49664934	chr22:49612657~49615716:-
LUAD	cis	rs5769707	0.521	rs6009805	ENSG00000235111.1	RP1-29C18.8	-3.97	8.19e-05	0.0119	-0.21	-0.18	Monocyte percentage of white cells;Monocyte count;	chr22:49665067	chr22:49612657~49615716:-
LUAD	cis	rs5769707	0.521	rs6009807	ENSG00000235111.1	RP1-29C18.8	-3.97	8.19e-05	0.0119	-0.21	-0.18	Monocyte percentage of white cells;Monocyte count;	chr22:49665274	chr22:49612657~49615716:-
LUAD	cis	rs2235642	0.75	rs2755185	ENSG00000280231.1	LA16c-380F5.3	-3.97	8.19e-05	0.0119	-0.24	-0.18	Coronary artery disease;	chr16:1595826	chr16:1553655~1554130:-
LUAD	cis	rs2657294	0.796	rs2657290	ENSG00000233313.2	HMGA1P5	-3.97	8.19e-05	0.0119	-0.22	-0.18	Pneumonia;	chr10:75207404	chr10:75276376~75276646:-
LUAD	cis	rs2239547	0.603	rs17304995	ENSG00000243224.1	RP5-1157M23.2	-3.97	8.19e-05	0.0119	-0.21	-0.18	Schizophrenia;	chr3:53036739	chr3:52239258~52241097:+
LUAD	cis	rs321358	0.895	rs7131434	ENSG00000271390.1	RP11-89C3.3	3.97	8.19e-05	0.0119	0.29	0.18	Body mass index;	chr11:111085693	chr11:111089870~111090368:-
LUAD	cis	rs2060793	0.712	rs6486202	ENSG00000251991.1	RNU7-49P	3.97	8.2e-05	0.0119	0.2	0.18	Vitamin D levels;	chr11:14777260	chr11:14478892~14478953:+
LUAD	cis	rs5742933	0.75	rs10197331	ENSG00000253559.1	OSGEPL1-AS1	3.97	8.2e-05	0.0119	0.22	0.18	Ferritin levels;	chr2:189768112	chr2:189762704~189765556:+
LUAD	cis	rs6964587	1	rs6956596	ENSG00000188693.7	CYP51A1-AS1	-3.97	8.2e-05	0.0119	-0.22	-0.18	Breast cancer;	chr7:92120793	chr7:92134604~92180725:+
LUAD	cis	rs6964587	1	rs6974607	ENSG00000188693.7	CYP51A1-AS1	-3.97	8.2e-05	0.0119	-0.22	-0.18	Breast cancer;	chr7:92120802	chr7:92134604~92180725:+
LUAD	cis	rs2479106	0.656	rs7857196	ENSG00000236901.4	MIR600HG	-3.97	8.2e-05	0.0119	-0.13	-0.18	Polycystic ovary syndrome;	chr9:123703679	chr9:123109494~123115477:-
LUAD	cis	rs7339483	0.557	rs7248894	ENSG00000268058.1	BNIP3P40	-3.97	8.2e-05	0.0119	-0.34	-0.18	Discordance in emotional problems in monozygotic twins;	chr19:24134002	chr19:24098425~24098980:-
LUAD	cis	rs2749592	0.505	rs7915670	ENSG00000263064.2	RP11-291L22.7	-3.97	8.2e-05	0.0119	-0.19	-0.18	Age-related hearing impairment (SNP x SNP interaction);	chr10:37581284	chr10:38448689~38448949:+
LUAD	cis	rs6964587	1	rs6964587	ENSG00000188693.7	CYP51A1-AS1	-3.97	8.2e-05	0.0119	-0.21	-0.18	Breast cancer;	chr7:92001306	chr7:92134604~92180725:+
LUAD	cis	rs34779708	0.966	rs11010122	ENSG00000271335.4	RP11-324I22.4	3.97	8.2e-05	0.0119	0.19	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35204590	chr10:35314552~35336401:-
LUAD	cis	rs2731006	0.64	rs2468326	ENSG00000257114.2	RP11-25I15.3	3.97	8.2e-05	0.0119	0.29	0.18	Panic disorder;	chr12:42785698	chr12:42692216~42717119:+
LUAD	cis	rs10498514	1	rs76202452	ENSG00000270878.1	CTD-2302E22.5	3.97	8.2e-05	0.0119	0.44	0.18	Cognitive performance;	chr14:64560634	chr14:63594031~63595291:-
LUAD	cis	rs1910358	0.569	rs56184010	ENSG00000248874.4	C5orf17	-3.97	8.21e-05	0.0119	-0.23	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr5:23954614	chr5:23951348~24178263:+
LUAD	cis	rs9646944	0.501	rs2075186	ENSG00000234389.1	AC007278.3	3.97	8.21e-05	0.0119	0.2	0.18	Blood protein levels;	chr2:102440791	chr2:102438713~102440475:+
LUAD	cis	rs2348418	0.831	rs7137119	ENSG00000247934.4	RP11-967K21.1	3.97	8.21e-05	0.0119	0.2	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28565058	chr12:28163298~28190738:-
LUAD	cis	rs2834288	0.535	rs8129694	ENSG00000237945.6	LINC00649	-3.97	8.21e-05	0.0119	-0.23	-0.18	Gut microbiota (bacterial taxa);	chr21:33954795	chr21:33915534~33977691:+
LUAD	cis	rs9545047	0.604	rs9530891	ENSG00000227354.5	RBM26-AS1	3.97	8.21e-05	0.012	0.19	0.18	Schizophrenia;	chr13:79284750	chr13:79406309~79424328:+
LUAD	cis	rs7260598	0.642	rs28537609	ENSG00000269421.1	ZNF92P3	-3.97	8.21e-05	0.012	-0.27	-0.18	Response to taxane treatment (placlitaxel);	chr19:23928662	chr19:23935220~23936173:+
LUAD	cis	rs10129255	0.834	rs10139893	ENSG00000211947.2	IGHV3-21	-3.97	8.22e-05	0.012	-0.12	-0.18	Kawasaki disease;	chr14:106711377	chr14:106235064~106235594:-
LUAD	cis	rs4664293	0.867	rs7606046	ENSG00000230783.1	AC009961.2	-3.97	8.22e-05	0.012	-0.22	-0.18	Monocyte percentage of white cells;	chr2:159719647	chr2:159689217~159690291:-
LUAD	cis	rs71636778	0.722	rs12746395	ENSG00000260063.1	RP5-968P14.2	-3.97	8.22e-05	0.012	-0.23	-0.18	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26841697	chr1:26692132~26694131:-
LUAD	cis	rs1461503	0.534	rs7944405	ENSG00000199709.1	RNU4-23P	-3.97	8.22e-05	0.012	-0.21	-0.18	Menarche (age at onset);	chr11:122945391	chr11:122927034~122927173:+
LUAD	cis	rs13068223	0.819	rs11917436	ENSG00000243926.1	TIPARP-AS1	3.97	8.22e-05	0.012	0.18	0.18	Age-related hearing impairment (SNP x SNP interaction);	chr3:156747839	chr3:156671862~156674378:-
LUAD	cis	rs831571	0.55	rs153734	ENSG00000280620.1	SCAANT1	3.97	8.22e-05	0.012	0.24	0.18	Type 2 diabetes;	chr3:64092333	chr3:63911518~63911772:-
LUAD	cis	rs4266144	1	rs12487629	ENSG00000244515.1	KRT18P34	-3.97	8.22e-05	0.012	-0.23	-0.18	Coronary artery disease;	chr3:157134416	chr3:157162663~157163932:-
LUAD	cis	rs10463554	0.892	rs17154859	ENSG00000250682.4	LINC00491	-3.97	8.22e-05	0.012	-0.21	-0.18	Parkinson's disease;	chr5:102955208	chr5:102609156~102671559:-
LUAD	cis	rs910316	0.673	rs2012627	ENSG00000259138.1	RP11-950C14.7	3.97	8.22e-05	0.012	0.19	0.18	Height;	chr14:74976400	chr14:75127153~75136930:+
LUAD	cis	rs7615952	0.599	rs12485717	ENSG00000241288.6	RP11-379B18.5	3.97	8.22e-05	0.012	0.24	0.18	Blood pressure (smoking interaction);	chr3:125988232	chr3:125827238~125916384:-
LUAD	cis	rs7809950	1	rs2520271	ENSG00000238832.1	snoU109	-3.97	8.23e-05	0.012	-0.26	-0.18	Coronary artery disease;	chr7:107554504	chr7:107603363~107603507:+
LUAD	cis	rs2554380	0.8	rs2585068	ENSG00000259570.1	RP11-671M22.4	3.97	8.23e-05	0.012	0.25	0.18	Height;	chr15:83735705	chr15:84394512~84395514:+
LUAD	cis	rs6787172	0.811	rs10936146	ENSG00000272087.1	RP11-379F4.7	3.97	8.23e-05	0.012	0.19	0.18	Subjective well-being;	chr3:158485679	chr3:158693120~158693768:-
LUAD	cis	rs6787172	0.811	rs9835244	ENSG00000272087.1	RP11-379F4.7	3.97	8.23e-05	0.012	0.19	0.18	Subjective well-being;	chr3:158486005	chr3:158693120~158693768:-
LUAD	cis	rs761746	0.739	rs140081	ENSG00000236132.1	CTA-440B3.1	-3.97	8.23e-05	0.012	-0.25	-0.18	Intelligence;	chr22:31716475	chr22:31816379~31817491:-
LUAD	cis	rs7824557	0.564	rs34389419	ENSG00000255046.1	RP11-297N6.4	3.97	8.23e-05	0.012	0.22	0.18	Retinal vascular caliber;	chr8:11371810	chr8:11797928~11802568:-
LUAD	cis	rs6840258	0.8	rs6839933	ENSG00000251411.1	RP11-397E7.4	-3.97	8.23e-05	0.012	-0.2	-0.18	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87043211	chr4:86913266~86914817:-
LUAD	cis	rs853679	0.517	rs9380047	ENSG00000280107.1	AL022393.9	-3.97	8.23e-05	0.012	-0.24	-0.18	Depression;	chr6:28070115	chr6:28170845~28172521:+
LUAD	cis	rs7893279	0.543	rs11597737	ENSG00000225527.1	RP11-383B4.4	3.97	8.23e-05	0.012	0.26	0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18670162	chr10:18531849~18533336:-
LUAD	cis	rs8040855	0.627	rs12909130	ENSG00000259774.1	RP11-182J1.13	3.97	8.23e-05	0.012	0.23	0.18	Bulimia nervosa;	chr15:85047270	chr15:84422618~84425882:+
LUAD	cis	rs6674176	0.628	rs2301993	ENSG00000237950.1	RP11-7O11.3	3.97	8.24e-05	0.012	0.23	0.18	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43960353	chr1:43944370~43946551:-
LUAD	cis	rs6674176	0.628	rs3828146	ENSG00000237950.1	RP11-7O11.3	3.97	8.24e-05	0.012	0.23	0.18	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43963043	chr1:43944370~43946551:-
LUAD	cis	rs6674176	0.628	rs3791119	ENSG00000237950.1	RP11-7O11.3	3.97	8.24e-05	0.012	0.23	0.18	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43965690	chr1:43944370~43946551:-
LUAD	cis	rs6674176	0.593	rs3791120	ENSG00000237950.1	RP11-7O11.3	3.97	8.24e-05	0.012	0.23	0.18	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43966043	chr1:43944370~43946551:-
LUAD	cis	rs6674176	0.628	rs4660759	ENSG00000237950.1	RP11-7O11.3	3.97	8.24e-05	0.012	0.23	0.18	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43966828	chr1:43944370~43946551:-
LUAD	cis	rs5758659	1	rs5758660	ENSG00000273366.1	CTA-989H11.1	-3.97	8.24e-05	0.012	-0.2	-0.18	Cognitive function;	chr22:42227712	chr22:42278188~42278846:+
LUAD	cis	rs4266144	1	rs4561781	ENSG00000244515.1	KRT18P34	3.97	8.24e-05	0.012	0.22	0.18	Coronary artery disease;	chr3:157135154	chr3:157162663~157163932:-
LUAD	cis	rs9322193	0.566	rs4870118	ENSG00000268592.3	RAET1E-AS1	-3.97	8.24e-05	0.012	-0.26	-0.18	Lung cancer;	chr6:149923877	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.566	rs4869767	ENSG00000268592.3	RAET1E-AS1	-3.97	8.24e-05	0.012	-0.26	-0.18	Lung cancer;	chr6:149923974	chr6:149863494~149919507:+
LUAD	cis	rs9322193	0.566	rs4869768	ENSG00000268592.3	RAET1E-AS1	-3.97	8.24e-05	0.012	-0.26	-0.18	Lung cancer;	chr6:149924067	chr6:149863494~149919507:+
LUAD	cis	rs2732480	0.577	rs2732486	ENSG00000257763.1	OR5BK1P	3.97	8.24e-05	0.012	0.19	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344051	chr12:48355792~48356614:-
LUAD	cis	rs7551222	0.752	rs12130686	ENSG00000240219.1	RP11-430C7.5	3.97	8.24e-05	0.012	0.18	0.18	Schizophrenia;	chr1:204584929	chr1:204626775~204629712:+
LUAD	cis	rs16873450	0.72	rs9655237	ENSG00000234800.2	PCMTD1P3	3.97	8.24e-05	0.012	0.21	0.18	Verbal memory performance (residualized delayed recall level);	chr7:23720459	chr7:23721311~23721782:-
LUAD	cis	rs727479	0.962	rs4775935	ENSG00000259306.2	RP11-108K3.2	-3.97	8.24e-05	0.012	-0.19	-0.18	Estradiol levels;	chr15:51227079	chr15:51315841~51321996:+
LUAD	cis	rs9633740	1	rs7097656	ENSG00000226659.1	RP11-137H2.4	-3.97	8.24e-05	0.012	-0.29	-0.18	Post bronchodilator FEV1;	chr10:80491075	chr10:80529597~80535942:-
LUAD	cis	rs7131987	0.565	rs6487792	ENSG00000257176.2	RP11-996F15.2	3.97	8.24e-05	0.012	0.18	0.18	QT interval;	chr12:29259743	chr12:29280418~29317848:-
LUAD	cis	rs7131987	0.585	rs2194517	ENSG00000257176.2	RP11-996F15.2	3.97	8.24e-05	0.012	0.18	0.18	QT interval;	chr12:29260002	chr12:29280418~29317848:-
LUAD	cis	rs1005277	0.522	rs289650	ENSG00000273019.1	RP11-508N22.13	-3.97	8.24e-05	0.012	-0.19	-0.18	Extrinsic epigenetic age acceleration;	chr10:37686577	chr10:38149968~38150293:+
LUAD	cis	rs11673344	0.504	rs2385375	ENSG00000276846.1	CTD-3220F14.3	3.97	8.24e-05	0.012	0.19	0.18	Obesity-related traits;	chr19:37087620	chr19:37314868~37315620:-
LUAD	cis	rs9516	1	rs2367995	ENSG00000213333.3	NPM1P50	3.97	8.25e-05	0.012	0.19	0.18	Facial morphology (factor 15, philtrum width);	chr11:74452791	chr11:75079265~75080131:-
LUAD	cis	rs6763848	0.598	rs2314421	ENSG00000214073.2	RPL21P17	-3.97	8.25e-05	0.012	-0.17	-0.18	Prostate cancer (SNP x SNP interaction);	chr3:1458153	chr3:1905651~1906125:+
LUAD	cis	rs151234	0.741	rs151229	ENSG00000259982.1	CDC37P1	-3.97	8.25e-05	0.012	-0.33	-0.18	Platelet distribution width;	chr16:28573616	chr16:28700294~28701540:-
LUAD	cis	rs10829156	0.66	rs11014830	ENSG00000240291.1	RP11-499P20.2	3.97	8.26e-05	0.012	0.16	0.18	Sudden cardiac arrest;	chr10:18551504	chr10:18513115~18545651:-
LUAD	cis	rs7615952	0.546	rs2979306	ENSG00000243429.1	OR7E29P	3.97	8.26e-05	0.012	0.24	0.18	Blood pressure (smoking interaction);	chr3:125593286	chr3:125712139~125713045:+
LUAD	cis	rs11250098	0.541	rs6997997	ENSG00000255310.2	AF131215.2	-3.97	8.26e-05	0.012	-0.18	-0.18	Morning vs. evening chronotype;	chr8:10908572	chr8:11107788~11109726:-
LUAD	cis	rs860295	0.871	rs6688636	ENSG00000160766.13	GBAP1	3.97	8.26e-05	0.012	0.19	0.18	Body mass index;	chr1:155509106	chr1:155213821~155227422:-
LUAD	cis	rs7647973	0.621	rs3774800	ENSG00000225399.4	RP11-3B7.1	-3.97	8.26e-05	0.012	-0.23	-0.18	Menarche (age at onset);	chr3:49297335	chr3:49260085~49261316:+
LUAD	cis	rs6142102	0.923	rs4911383	ENSG00000275784.1	RP5-1125A11.6	-3.97	8.26e-05	0.012	-0.2	-0.18	Skin pigmentation;	chr20:33967973	chr20:33989480~33991818:-
LUAD	cis	rs3925075	0.5	rs11645526	ENSG00000260911.2	RP11-196G11.2	-3.97	8.26e-05	0.012	-0.16	-0.18	IgA nephropathy;	chr16:31256918	chr16:31043150~31049868:+
LUAD	cis	rs7005380	0.62	rs4871012	ENSG00000279347.1	RP11-85I17.2	-3.97	8.26e-05	0.012	-0.15	-0.18	Interstitial lung disease;	chr8:119895734	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.62	rs4871013	ENSG00000279347.1	RP11-85I17.2	-3.97	8.26e-05	0.012	-0.15	-0.18	Interstitial lung disease;	chr8:119895750	chr8:119838736~119840385:-
LUAD	cis	rs2333021	0.78	rs2806042	ENSG00000259015.1	RP11-109N23.6	-3.97	8.26e-05	0.012	-0.16	-0.18	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72947939	chr14:72960595~72961993:+
LUAD	cis	rs3020736	0.5	rs6002604	ENSG00000205702.9	CYP2D7	-3.97	8.26e-05	0.012	-0.14	-0.18	Autism spectrum disorder or schizophrenia;	chr22:42097077	chr22:42140203~42144577:-
LUAD	cis	rs3020736	0.5	rs5996109	ENSG00000205702.9	CYP2D7	-3.97	8.26e-05	0.012	-0.14	-0.18	Autism spectrum disorder or schizophrenia;	chr22:42097094	chr22:42140203~42144577:-
LUAD	cis	rs3020736	0.5	rs5996110	ENSG00000205702.9	CYP2D7	-3.97	8.26e-05	0.012	-0.14	-0.18	Autism spectrum disorder or schizophrenia;	chr22:42097763	chr22:42140203~42144577:-
LUAD	cis	rs3020736	0.5	rs9620026	ENSG00000205702.9	CYP2D7	-3.97	8.26e-05	0.012	-0.14	-0.18	Autism spectrum disorder or schizophrenia;	chr22:42102574	chr22:42140203~42144577:-
LUAD	cis	rs3020736	0.5	rs28791586	ENSG00000205702.9	CYP2D7	-3.97	8.26e-05	0.012	-0.14	-0.18	Autism spectrum disorder or schizophrenia;	chr22:42104479	chr22:42140203~42144577:-
LUAD	cis	rs3020736	0.5	rs2839708	ENSG00000205702.9	CYP2D7	-3.97	8.26e-05	0.012	-0.14	-0.18	Autism spectrum disorder or schizophrenia;	chr22:42104741	chr22:42140203~42144577:-
LUAD	cis	rs3020736	0.5	rs6519306	ENSG00000205702.9	CYP2D7	-3.97	8.26e-05	0.012	-0.14	-0.18	Autism spectrum disorder or schizophrenia;	chr22:42105213	chr22:42140203~42144577:-
LUAD	cis	rs4819052	0.851	rs914218	ENSG00000215447.6	BX322557.10	-3.97	8.27e-05	0.012	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278530	chr21:45288052~45291738:+
LUAD	cis	rs2253762	0.54	rs79586669	ENSG00000276742.1	RP11-500G22.4	3.97	8.27e-05	0.012	0.28	0.18	Breast cancer;	chr10:122015153	chr10:121956782~121957098:+
LUAD	cis	rs6121246	0.511	rs879982	ENSG00000230613.1	HM13-AS1	3.97	8.27e-05	0.012	0.22	0.18	Mean corpuscular hemoglobin;	chr20:31810707	chr20:31567707~31573263:-
LUAD	cis	rs17507216	0.667	rs13379724	ENSG00000255769.6	GOLGA2P10	-3.97	8.27e-05	0.012	-0.22	-0.18	Excessive daytime sleepiness;	chr15:82619892	chr15:82472993~82513950:-
LUAD	cis	rs6689263	0.929	rs79582714	ENSG00000117242.7	PINK1-AS	3.97	8.27e-05	0.012	0.39	0.18	Intelligence (multi-trait analysis);	chr1:20557115	chr1:20642657~20652193:-
LUAD	cis	rs2154319	0.943	rs61774689	ENSG00000235358.1	RP11-399E6.1	-3.97	8.27e-05	0.012	-0.24	-0.18	Height;	chr1:41219750	chr1:41242373~41284861:+
LUAD	cis	rs2154319	0.943	rs17358122	ENSG00000235358.1	RP11-399E6.1	-3.97	8.27e-05	0.012	-0.24	-0.18	Height;	chr1:41225651	chr1:41242373~41284861:+
LUAD	cis	rs9813712	0.597	rs62281648	ENSG00000228252.7	COL6A4P2	-3.97	8.27e-05	0.012	-0.17	-0.18	Response to amphetamines;	chr3:130244794	chr3:130212823~130273806:+
LUAD	cis	rs7809950	0.798	rs10281535	ENSG00000238832.1	snoU109	3.97	8.27e-05	0.012	0.26	0.18	Coronary artery disease;	chr7:107589173	chr7:107603363~107603507:+
LUAD	cis	rs7809950	0.954	rs2189839	ENSG00000238832.1	snoU109	3.97	8.27e-05	0.012	0.26	0.18	Coronary artery disease;	chr7:107589581	chr7:107603363~107603507:+
LUAD	cis	rs62458065	0.85	rs62458098	ENSG00000226468.2	AC018641.7	3.97	8.27e-05	0.012	0.3	0.18	Metabolite levels (HVA/MHPG ratio);	chr7:32431517	chr7:32456963~32457758:-
LUAD	cis	rs62458065	0.85	rs73096034	ENSG00000226468.2	AC018641.7	3.97	8.27e-05	0.012	0.3	0.18	Metabolite levels (HVA/MHPG ratio);	chr7:32432436	chr7:32456963~32457758:-
LUAD	cis	rs62458065	0.85	rs62458099	ENSG00000226468.2	AC018641.7	3.97	8.27e-05	0.012	0.3	0.18	Metabolite levels (HVA/MHPG ratio);	chr7:32432783	chr7:32456963~32457758:-
LUAD	cis	rs4713118	0.55	rs9368527	ENSG00000219392.1	RP1-265C24.5	-3.97	8.27e-05	0.012	-0.22	-0.18	Parkinson's disease;	chr6:27711666	chr6:28115628~28116551:+
LUAD	cis	rs8141529	0.778	rs5762795	ENSG00000272858.1	CTA-292E10.8	-3.97	8.27e-05	0.012	-0.2	-0.18	Lymphocyte counts;	chr22:28786512	chr22:28814914~28815662:+
LUAD	cis	rs7202877	0.61	rs3844219	ENSG00000280152.1	RP11-331F4.5	3.97	8.27e-05	0.012	0.2	0.18	Type 1 diabetes;Type 2 diabetes;	chr16:75336332	chr16:75245994~75250077:-
LUAD	cis	rs6787172	0.811	rs1978779	ENSG00000272087.1	RP11-379F4.7	3.97	8.28e-05	0.012	0.19	0.18	Subjective well-being;	chr3:158493502	chr3:158693120~158693768:-
LUAD	cis	rs10090774	0.687	rs11784281	ENSG00000280303.2	ERICD	-3.97	8.28e-05	0.012	-0.2	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140655911	chr8:140636281~140638283:+
LUAD	cis	rs10197140	0.845	rs12476335	ENSG00000235721.1	AC013268.3	-3.97	8.28e-05	0.012	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110865653	chr2:110007675~110010783:+
LUAD	cis	rs5758659	0.714	rs5758574	ENSG00000182057.4	OGFRP1	-3.97	8.28e-05	0.012	-0.21	-0.18	Cognitive function;	chr22:42085396	chr22:42269753~42275196:+
LUAD	cis	rs8098244	0.737	rs1154243	ENSG00000264745.1	TTC39C-AS1	-3.97	8.28e-05	0.012	-0.23	-0.18	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23963824	chr18:23994213~24015339:-
LUAD	cis	rs8098244	0.708	rs1154245	ENSG00000264745.1	TTC39C-AS1	-3.97	8.28e-05	0.012	-0.23	-0.18	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23964250	chr18:23994213~24015339:-
LUAD	cis	rs11671005	0.695	rs11673069	ENSG00000268543.1	CTD-2619J13.16	-3.97	8.28e-05	0.012	-0.25	-0.18	Mean platelet volume;	chr19:58423551	chr19:58418560~58419310:+
LUAD	cis	rs10129255	1	rs9324091	ENSG00000274576.2	IGHV2-70	3.97	8.28e-05	0.012	0.16	0.18	Kawasaki disease;	chr14:106676625	chr14:106770577~106771020:-
LUAD	cis	rs4853525	0.522	rs6434412	ENSG00000235852.1	AC005540.3	3.97	8.28e-05	0.012	0.2	0.18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190720549	chr2:190880797~190882059:-
LUAD	cis	rs6570726	0.846	rs7773939	ENSG00000235652.6	RP11-545I5.3	-3.97	8.28e-05	0.012	-0.18	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145606248	chr6:145799409~145886585:+
LUAD	cis	rs7584330	0.784	rs1463795	ENSG00000222032.1	AC112721.2	-3.97	8.29e-05	0.012	-0.2	-0.18	Prostate cancer;	chr2:237503749	chr2:237428920~237434822:-
LUAD	cis	rs6496932	0.663	rs12915663	ENSG00000259630.2	CTD-2262B20.1	-3.97	8.29e-05	0.012	-0.22	-0.18	Central corneal thickness;Corneal structure;	chr15:85362249	chr15:85415228~85415633:+
LUAD	cis	rs12754538	0.85	rs7545384	ENSG00000232912.4	RP5-1115A15.1	3.97	8.29e-05	0.012	0.19	0.18	Subjective well-being;	chr1:8520901	chr1:8424645~8434838:+
LUAD	cis	rs3742264	1	rs9526140	ENSG00000235903.6	CPB2-AS1	-3.97	8.29e-05	0.012	-0.22	-0.18	Blood protein levels;	chr13:46070017	chr13:46052806~46113332:+
LUAD	cis	rs17597773	0.674	rs12073837	ENSG00000272823.1	RP11-295M18.6	-3.97	8.29e-05	0.0121	-0.24	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220836863	chr1:220828676~220829211:-
LUAD	cis	rs17597773	0.674	rs11118619	ENSG00000272823.1	RP11-295M18.6	-3.97	8.29e-05	0.0121	-0.24	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220838921	chr1:220828676~220829211:-
LUAD	cis	rs17597773	0.674	rs1494372	ENSG00000272823.1	RP11-295M18.6	-3.97	8.29e-05	0.0121	-0.24	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220841279	chr1:220828676~220829211:-
LUAD	cis	rs7131987	0.526	rs7954375	ENSG00000257176.2	RP11-996F15.2	3.97	8.29e-05	0.0121	0.18	0.18	QT interval;	chr12:29241487	chr12:29280418~29317848:-
LUAD	cis	rs56875752	1	rs72811292	ENSG00000263648.1	RP11-471L13.3	3.97	8.29e-05	0.0121	0.34	0.18	Fear of pain;Fear of severe pain;	chr17:12711716	chr17:12115547~12115885:+
LUAD	cis	rs867371	0.519	rs1566560	ENSG00000259429.4	UBE2Q2P2	-3.97	8.3e-05	0.0121	-0.15	-0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232116	chr15:82355142~82420075:+
LUAD	cis	rs867371	0.519	rs1566559	ENSG00000259429.4	UBE2Q2P2	-3.97	8.3e-05	0.0121	-0.15	-0.18	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82232120	chr15:82355142~82420075:+
LUAD	cis	rs7246657	0.943	rs10415937	ENSG00000226686.6	LINC01535	-3.97	8.3e-05	0.0121	-0.27	-0.18	Coronary artery calcification;	chr19:37339162	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.943	rs10414904	ENSG00000226686.6	LINC01535	-3.97	8.3e-05	0.0121	-0.27	-0.18	Coronary artery calcification;	chr19:37339186	chr19:37251912~37265535:+
LUAD	cis	rs4713118	0.513	rs202908	ENSG00000216901.1	AL022393.7	3.97	8.3e-05	0.0121	0.21	0.18	Parkinson's disease;	chr6:28043773	chr6:28176188~28176674:+
LUAD	cis	rs4423214	0.879	rs10898144	ENSG00000226627.1	SHANK2-AS1	3.97	8.3e-05	0.0121	0.22	0.18	Vitamin D levels;	chr11:71440494	chr11:70631094~70635490:+
LUAD	cis	rs10876993	0.928	rs1689595	ENSG00000270039.1	RP11-571M6.17	3.97	8.3e-05	0.0121	0.21	0.18	Celiac disease or Rheumatoid arthritis;	chr12:57662980	chr12:57803838~57804415:+
LUAD	cis	rs1552244	0.744	rs6763366	ENSG00000180385.7	EMC3-AS1	3.97	8.3e-05	0.0121	0.21	0.18	Alzheimer's disease;	chr3:9991860	chr3:9986893~10006990:+
LUAD	cis	rs6121246	0.559	rs10439608	ENSG00000230613.1	HM13-AS1	3.97	8.3e-05	0.0121	0.22	0.18	Mean corpuscular hemoglobin;	chr20:31671011	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.559	rs6119652	ENSG00000230613.1	HM13-AS1	3.97	8.3e-05	0.0121	0.22	0.18	Mean corpuscular hemoglobin;	chr20:31671642	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.559	rs6060621	ENSG00000230613.1	HM13-AS1	3.97	8.3e-05	0.0121	0.22	0.18	Mean corpuscular hemoglobin;	chr20:31673759	chr20:31567707~31573263:-
LUAD	cis	rs11671005	0.695	rs8106061	ENSG00000268543.1	CTD-2619J13.16	-3.97	8.3e-05	0.0121	-0.25	-0.18	Mean platelet volume;	chr19:58406623	chr19:58418560~58419310:+
LUAD	cis	rs2898681	0.642	rs62336790	ENSG00000248375.1	RP11-177B4.1	-3.97	8.3e-05	0.0121	-0.25	-0.18	Optic nerve measurement (cup area);	chr4:52861833	chr4:52720081~52720831:-
LUAD	cis	rs2657294	1	rs2657294	ENSG00000233313.2	HMGA1P5	-3.97	8.3e-05	0.0121	-0.23	-0.18	Pneumonia;	chr10:75193267	chr10:75276376~75276646:-
LUAD	cis	rs7005380	0.6	rs4871772	ENSG00000279347.1	RP11-85I17.2	-3.97	8.3e-05	0.0121	-0.15	-0.18	Interstitial lung disease;	chr8:119895655	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.6	rs4871773	ENSG00000279347.1	RP11-85I17.2	-3.97	8.3e-05	0.0121	-0.15	-0.18	Interstitial lung disease;	chr8:119895671	chr8:119838736~119840385:-
LUAD	cis	rs1555322	0.53	rs2297789	ENSG00000279253.1	RP4-614O4.13	-3.97	8.31e-05	0.0121	-0.22	-0.18	Attention deficit hyperactivity disorder;	chr20:35279445	chr20:35262727~35264187:-
LUAD	cis	rs7826238	0.502	rs10503377	ENSG00000253893.2	FAM85B	-3.97	8.31e-05	0.0121	-0.25	-0.18	Systolic blood pressure;	chr8:8520912	chr8:8167819~8226614:-
LUAD	cis	rs12744310	1	rs12029950	ENSG00000235358.1	RP11-399E6.1	3.97	8.31e-05	0.0121	0.23	0.18	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41287493	chr1:41242373~41284861:+
LUAD	cis	rs12744310	0.943	rs12027685	ENSG00000235358.1	RP11-399E6.1	3.97	8.31e-05	0.0121	0.23	0.18	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41290626	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs12024413	ENSG00000235358.1	RP11-399E6.1	3.97	8.31e-05	0.0121	0.23	0.18	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41290744	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs34027267	ENSG00000235358.1	RP11-399E6.1	3.97	8.31e-05	0.0121	0.23	0.18	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41291005	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs12722758	ENSG00000235358.1	RP11-399E6.1	3.97	8.31e-05	0.0121	0.23	0.18	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41291343	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs12723893	ENSG00000235358.1	RP11-399E6.1	3.97	8.31e-05	0.0121	0.23	0.18	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41291368	chr1:41242373~41284861:+
LUAD	cis	rs9467773	1	rs6922824	ENSG00000261353.1	CTA-14H9.5	3.97	8.31e-05	0.0121	0.2	0.18	Intelligence (multi-trait analysis);	chr6:26553587	chr6:26527063~26527404:+
LUAD	cis	rs561341	0.883	rs1034626	ENSG00000265798.5	RP11-271K11.5	-3.97	8.31e-05	0.0121	-0.26	-0.18	Hip circumference adjusted for BMI;	chr17:31892481	chr17:31038575~31059121:-
LUAD	cis	rs8177876	0.749	rs12927239	ENSG00000261061.1	RP11-303E16.2	-3.97	8.31e-05	0.0121	-0.27	-0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81053883	chr16:81030770~81031485:+
LUAD	cis	rs9894429	1	rs4074915	ENSG00000263853.1	AC139530.1	3.97	8.32e-05	0.0121	0.17	0.18	Eye color traits;	chr17:81612204	chr17:81676001~81676086:+
LUAD	cis	rs6964587	1	rs13245393	ENSG00000188693.7	CYP51A1-AS1	-3.97	8.32e-05	0.0121	-0.21	-0.18	Breast cancer;	chr7:92012614	chr7:92134604~92180725:+
LUAD	cis	rs6964587	1	rs6944591	ENSG00000188693.7	CYP51A1-AS1	-3.97	8.32e-05	0.0121	-0.21	-0.18	Breast cancer;	chr7:92013400	chr7:92134604~92180725:+
LUAD	cis	rs911119	0.913	rs3810575	ENSG00000270001.1	RP11-218C14.8	-3.97	8.32e-05	0.0121	-0.26	-0.18	Chronic kidney disease;	chr20:23602755	chr20:23631826~23632316:-
LUAD	cis	rs8062405	0.824	rs62034326	ENSG00000261419.1	RP11-57A19.4	-3.97	8.32e-05	0.0121	-0.19	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28659696~28740781:-
LUAD	cis	rs8062405	0.824	rs4788084	ENSG00000261419.1	RP11-57A19.4	-3.97	8.32e-05	0.0121	-0.19	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28659696~28740781:-
LUAD	cis	rs6088580	0.634	rs6059880	ENSG00000276073.1	RP5-1125A11.7	-3.97	8.32e-05	0.0121	-0.17	-0.18	Glomerular filtration rate (creatinine);	chr20:34500864	chr20:33985617~33988989:-
LUAD	cis	rs2033711	0.905	rs1077420	ENSG00000268912.1	CTD-2619J13.17	-3.97	8.32e-05	0.0121	-0.19	-0.18	Uric acid clearance;	chr19:58457508	chr19:58428632~58431148:-
LUAD	cis	rs9545047	0.604	rs9545048	ENSG00000227354.5	RBM26-AS1	3.97	8.32e-05	0.0121	0.19	0.18	Schizophrenia;	chr13:79285593	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs1626333	ENSG00000227354.5	RBM26-AS1	3.97	8.32e-05	0.0121	0.19	0.18	Schizophrenia;	chr13:79286932	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.567	rs1856996	ENSG00000227354.5	RBM26-AS1	3.97	8.32e-05	0.0121	0.19	0.18	Schizophrenia;	chr13:79287453	chr13:79406309~79424328:+
LUAD	cis	rs8002861	0.87	rs2121030	ENSG00000274001.1	RP11-5G9.5	-3.97	8.32e-05	0.0121	-0.19	-0.18	Leprosy;	chr13:43870438	chr13:43877715~43878163:-
LUAD	cis	rs763121	1	rs138457	ENSG00000225450.1	RP3-508I15.14	3.97	8.32e-05	0.0121	0.17	0.18	Menopause (age at onset);	chr22:38502046	chr22:38739003~38749041:+
LUAD	cis	rs7617773	0.817	rs11709691	ENSG00000199476.1	Y_RNA	-3.97	8.32e-05	0.0121	-0.24	-0.18	Coronary artery disease;	chr3:48262179	chr3:48288587~48288694:+
LUAD	cis	rs2278702	0.943	rs57384130	ENSG00000259495.2	RP11-210M15.2	-3.97	8.32e-05	0.0121	-0.28	-0.18	Bipolar disorder;	chr15:80392604	chr15:80344853~80403575:-
LUAD	cis	rs2732480	0.577	rs2732479	ENSG00000257763.1	OR5BK1P	3.97	8.32e-05	0.0121	0.19	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342477	chr12:48355792~48356614:-
LUAD	cis	rs2732480	0.537	rs1061986	ENSG00000257763.1	OR5BK1P	3.97	8.32e-05	0.0121	0.19	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342656	chr12:48355792~48356614:-
LUAD	cis	rs34929064	1	rs34929064	ENSG00000230658.1	KLHL7-AS1	3.97	8.33e-05	0.0121	0.24	0.18	Major depression and alcohol dependence;	chr7:22688653	chr7:23101228~23105703:-
LUAD	cis	rs28386778	0.966	rs2008053	ENSG00000240280.5	TCAM1P	-3.97	8.33e-05	0.0121	-0.2	-0.18	Prudent dietary pattern;	chr17:63877558	chr17:63849292~63864379:+
LUAD	cis	rs1355223	0.902	rs11607035	ENSG00000271369.1	RP11-350D17.3	-3.97	8.33e-05	0.0121	-0.21	-0.18	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34697364	chr11:34709600~34710161:+
LUAD	cis	rs7274811	0.744	rs209665	ENSG00000231795.1	ITCH-IT1	3.97	8.33e-05	0.0121	0.2	0.18	Height;	chr20:33541083	chr20:34450930~34454552:+
LUAD	cis	rs755249	0.567	rs4660543	ENSG00000182109.6	RP11-69E11.4	3.97	8.33e-05	0.0121	0.22	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39213318	chr1:39522280~39546187:-
LUAD	cis	rs2732480	0.517	rs2634676	ENSG00000257763.1	OR5BK1P	3.97	8.33e-05	0.0121	0.19	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344453	chr12:48355792~48356614:-
LUAD	cis	rs911119	0.955	rs4815224	ENSG00000270001.1	RP11-218C14.8	-3.97	8.33e-05	0.0121	-0.27	-0.18	Chronic kidney disease;	chr20:23613475	chr20:23631826~23632316:-
LUAD	cis	rs2562152	0.786	rs216594	ENSG00000226942.2	IL9RP3	-3.97	8.33e-05	0.0121	-0.27	-0.18	Glioblastoma;	chr16:53009	chr16:29336~38321:-
LUAD	cis	rs4713118	0.614	rs9380007	ENSG00000280107.1	AL022393.9	-3.97	8.33e-05	0.0121	-0.21	-0.18	Parkinson's disease;	chr6:27692729	chr6:28170845~28172521:+
LUAD	cis	rs3096299	0.781	rs2965819	ENSG00000261118.1	RP11-104N10.1	-3.97	8.33e-05	0.0121	-0.18	-0.18	Multiple myeloma (IgH translocation);	chr16:89434622	chr16:89492017~89504460:-
LUAD	cis	rs6012564	0.928	rs6095396	ENSG00000230758.1	SNAP23P	-3.97	8.33e-05	0.0121	-0.19	-0.18	Anger;	chr20:49010633	chr20:49038357~49038602:-
LUAD	cis	rs2115630	0.791	rs2008262	ENSG00000225151.9	GOLGA2P7	3.97	8.33e-05	0.0121	0.2	0.18	P wave terminal force;	chr15:84762039	chr15:84199311~84230136:-
LUAD	cis	rs17406451	0.788	rs7609003	ENSG00000279873.2	LINC01126	-3.97	8.33e-05	0.0121	-0.15	-0.18	Mitochondrial DNA levels;	chr2:43478723	chr2:43227210~43228855:+
LUAD	cis	rs7617773	0.78	rs13067450	ENSG00000199476.1	Y_RNA	-3.97	8.34e-05	0.0121	-0.24	-0.18	Coronary artery disease;	chr3:48295716	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.78	rs4479622	ENSG00000199476.1	Y_RNA	-3.97	8.34e-05	0.0121	-0.24	-0.18	Coronary artery disease;	chr3:48296683	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.78	rs34946886	ENSG00000199476.1	Y_RNA	-3.97	8.34e-05	0.0121	-0.24	-0.18	Coronary artery disease;	chr3:48296997	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.78	rs34589064	ENSG00000199476.1	Y_RNA	-3.97	8.34e-05	0.0121	-0.24	-0.18	Coronary artery disease;	chr3:48298059	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.78	rs2541	ENSG00000199476.1	Y_RNA	-3.97	8.34e-05	0.0121	-0.24	-0.18	Coronary artery disease;	chr3:48298128	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.78	rs13085251	ENSG00000199476.1	Y_RNA	-3.97	8.34e-05	0.0121	-0.24	-0.18	Coronary artery disease;	chr3:48298555	chr3:48288587~48288694:+
LUAD	cis	rs2395128	0.507	rs4746256	ENSG00000213731.2	RAB5CP1	3.97	8.34e-05	0.0121	0.36	0.18	Ulcerative colitis;Inflammatory bowel disease;	chr10:75058170	chr10:74423435~74424014:-
LUAD	cis	rs4683346	1	rs11129978	ENSG00000173811.9	CCDC13-AS1	3.97	8.34e-05	0.0121	0.19	0.18	Granulocyte percentage of myeloid white cells;	chr3:42842084	chr3:42732575~42746768:+
LUAD	cis	rs2439831	1	rs9920763	ENSG00000249839.1	AC011330.5	-3.97	8.34e-05	0.0121	-0.39	-0.18	Lung cancer in ever smokers;	chr15:43468310	chr15:43663654~43684339:-
LUAD	cis	rs2354432	0.607	rs11579626	ENSG00000237188.3	RP11-337C18.8	3.97	8.34e-05	0.0121	0.34	0.18	Mitochondrial DNA levels;	chr1:147270300	chr1:147172771~147211568:+
LUAD	cis	rs2354432	0.607	rs6685775	ENSG00000237188.3	RP11-337C18.8	3.97	8.34e-05	0.0121	0.34	0.18	Mitochondrial DNA levels;	chr1:147272633	chr1:147172771~147211568:+
LUAD	cis	rs2354432	0.607	rs6694347	ENSG00000237188.3	RP11-337C18.8	3.97	8.34e-05	0.0121	0.34	0.18	Mitochondrial DNA levels;	chr1:147279467	chr1:147172771~147211568:+
LUAD	cis	rs2354432	0.556	rs59180647	ENSG00000226015.2	CCT8P1	3.97	8.34e-05	0.0121	0.32	0.18	Mitochondrial DNA levels;	chr1:147300364	chr1:147203276~147204932:-
LUAD	cis	rs2354432	0.607	rs11239980	ENSG00000226015.2	CCT8P1	3.97	8.34e-05	0.0121	0.32	0.18	Mitochondrial DNA levels;	chr1:147310982	chr1:147203276~147204932:-
LUAD	cis	rs2354432	0.607	rs58941651	ENSG00000226015.2	CCT8P1	3.97	8.34e-05	0.0121	0.32	0.18	Mitochondrial DNA levels;	chr1:147313199	chr1:147203276~147204932:-
LUAD	cis	rs67981189	0.896	rs2526882	ENSG00000269927.1	RP6-91H8.3	-3.97	8.34e-05	0.0121	-0.23	-0.18	Schizophrenia;	chr14:70907985	chr14:71141125~71143253:-
LUAD	cis	rs2732480	0.577	rs2634680	ENSG00000257763.1	OR5BK1P	3.97	8.34e-05	0.0121	0.19	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48340781	chr12:48355792~48356614:-
LUAD	cis	rs2732480	0.577	rs2634678	ENSG00000257763.1	OR5BK1P	3.97	8.34e-05	0.0121	0.19	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48341755	chr12:48355792~48356614:-
LUAD	cis	rs4763879	0.778	rs7977940	ENSG00000278635.1	CTD-2318O12.1	3.97	8.34e-05	0.0121	0.16	0.18	Type 1 diabetes;	chr12:9686320	chr12:9415641~9416718:+
LUAD	cis	rs11671005	0.693	rs34023391	ENSG00000268543.1	CTD-2619J13.16	-3.97	8.34e-05	0.0121	-0.26	-0.18	Mean platelet volume;	chr19:58402001	chr19:58418560~58419310:+
LUAD	cis	rs6706648	0.582	rs13011256	ENSG00000234624.2	AC016894.1	3.97	8.34e-05	0.0121	0.21	0.18	F-cell distribution;	chr2:60429857	chr2:61416887~61417197:-
LUAD	cis	rs910316	0.967	rs12147532	ENSG00000259138.1	RP11-950C14.7	-3.97	8.34e-05	0.0121	-0.19	-0.18	Height;	chr14:75185155	chr14:75127153~75136930:+
LUAD	cis	rs62025270	0.688	rs17577869	ENSG00000259416.2	RP11-158M2.5	-3.97	8.35e-05	0.0121	-0.24	-0.18	Idiopathic pulmonary fibrosis;	chr15:85771142	chr15:85754941~85756237:-
LUAD	cis	rs2274273	0.87	rs61210954	ENSG00000258413.1	RP11-665C16.6	-3.97	8.35e-05	0.0121	-0.23	-0.18	Protein biomarker;	chr14:55298684	chr14:55262767~55272075:-
LUAD	cis	rs9951698	0.703	rs6505776	ENSG00000267480.1	RP11-703I16.1	-3.97	8.35e-05	0.0121	-0.22	-0.18	Intelligence (multi-trait analysis);	chr18:12984145	chr18:12031178~12032181:-
LUAD	cis	rs7590268	0.606	rs6737690	ENSG00000279873.2	LINC01126	3.97	8.35e-05	0.0121	0.17	0.18	Orofacial clefts;	chr2:43416726	chr2:43227210~43228855:+
LUAD	cis	rs7138803	0.616	rs73114137	ENSG00000257464.1	RP11-161H23.8	-3.97	8.35e-05	0.0121	-0.18	-0.18	Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index;	chr12:49817791	chr12:49442424~49442652:-
LUAD	cis	rs911555	0.755	rs2273702	ENSG00000244691.1	RPL10AP1	3.97	8.35e-05	0.0121	0.23	0.18	Intelligence (multi-trait analysis);	chr14:103451845	chr14:103412119~103412761:-
LUAD	cis	rs2919009	0.664	rs17591472	ENSG00000271670.1	RP11-95I16.4	3.97	8.35e-05	0.0121	0.22	0.18	Obesity-related traits;	chr10:120785735	chr10:120879256~120880667:-
LUAD	cis	rs2919009	0.664	rs61872418	ENSG00000271670.1	RP11-95I16.4	3.97	8.35e-05	0.0121	0.22	0.18	Obesity-related traits;	chr10:120785859	chr10:120879256~120880667:-
LUAD	cis	rs3198697	0.663	rs12928099	ENSG00000260735.1	RP11-72I8.1	-3.97	8.36e-05	0.0121	-0.21	-0.18	Triglycerides;	chr16:15056648	chr16:15094411~15109197:+
LUAD	cis	rs9894429	1	rs11652797	ENSG00000263853.1	AC139530.1	-3.97	8.36e-05	0.0121	-0.17	-0.18	Eye color traits;	chr17:81607098	chr17:81676001~81676086:+
LUAD	cis	rs2904524	0.867	rs17107870	ENSG00000257815.4	RP11-611E13.2	-3.97	8.37e-05	0.0121	-0.27	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70251669	chr12:69904033~70243360:-
LUAD	cis	rs853679	0.517	rs4713135	ENSG00000280107.1	AL022393.9	-3.97	8.37e-05	0.0121	-0.24	-0.18	Depression;	chr6:28071808	chr6:28170845~28172521:+
LUAD	cis	rs9309473	0.519	rs4852950	ENSG00000163016.8	ALMS1P	-3.97	8.37e-05	0.0121	-0.19	-0.18	Metabolite levels;	chr2:73637543	chr2:73644919~73685576:+
LUAD	cis	rs4474465	1	rs11237499	ENSG00000251323.2	RP11-452H21.4	3.97	8.37e-05	0.0121	0.22	0.18	Alzheimer's disease (survival time);	chr11:78452118	chr11:78423982~78429836:-
LUAD	cis	rs10463554	0.963	rs62364874	ENSG00000250682.4	LINC00491	3.97	8.37e-05	0.0121	0.21	0.18	Parkinson's disease;	chr5:103056475	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.963	rs62364876	ENSG00000250682.4	LINC00491	3.97	8.37e-05	0.0121	0.21	0.18	Parkinson's disease;	chr5:103058454	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.963	rs158254	ENSG00000250682.4	LINC00491	3.97	8.37e-05	0.0121	0.21	0.18	Parkinson's disease;	chr5:103059179	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.963	rs34381	ENSG00000250682.4	LINC00491	3.97	8.37e-05	0.0121	0.21	0.18	Parkinson's disease;	chr5:103060852	chr5:102609156~102671559:-
LUAD	cis	rs7940866	0.838	rs7949071	ENSG00000255262.3	TCEB2P2	3.97	8.37e-05	0.0121	0.2	0.18	Schizophrenia;	chr11:131007583	chr11:130032866~130033220:-
LUAD	cis	rs4374383	0.962	rs11887259	ENSG00000207383.1	Y_RNA	-3.97	8.37e-05	0.0121	-0.21	-0.18	Hepatitis C induced liver fibrosis;	chr2:112016617	chr2:112579484~112579584:-
LUAD	cis	rs2735413	0.563	rs72800910	ENSG00000276007.1	RP11-358L22.3	3.97	8.37e-05	0.0121	0.25	0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78014005	chr16:78123243~78124332:+
LUAD	cis	rs7119038	0.818	rs11826521	ENSG00000255239.1	AP002954.6	-3.97	8.37e-05	0.0121	-0.27	-0.18	Sjögren's syndrome;	chr11:118739840	chr11:118688039~118690600:-
LUAD	cis	rs293748	0.771	rs35263618	ENSG00000250155.1	CTD-2353F22.1	-3.97	8.37e-05	0.0121	-0.24	-0.18	Obesity-related traits;	chr5:36795112	chr5:36666214~36725195:-
LUAD	cis	rs2281636	0.858	rs7068079	ENSG00000233690.1	EBAG9P1	-3.97	8.37e-05	0.0121	-0.17	-0.18	Obesity-related traits;	chr10:99607558	chr10:99697407~99697949:-
LUAD	cis	rs7809950	1	rs7786801	ENSG00000238832.1	snoU109	-3.97	8.38e-05	0.0122	-0.26	-0.18	Coronary artery disease;	chr7:107445444	chr7:107603363~107603507:+
LUAD	cis	rs2412819	0.571	rs2930529	ENSG00000166763.7	STRCP1	-3.97	8.38e-05	0.0122	-0.25	-0.18	Lung cancer;	chr15:43819467	chr15:43699488~43718184:-
LUAD	cis	rs2412819	0.571	rs2930530	ENSG00000166763.7	STRCP1	-3.97	8.38e-05	0.0122	-0.25	-0.18	Lung cancer;	chr15:43823268	chr15:43699488~43718184:-
LUAD	cis	rs10463554	0.716	rs152136	ENSG00000250682.4	LINC00491	3.97	8.38e-05	0.0122	0.21	0.18	Parkinson's disease;	chr5:103248167	chr5:102609156~102671559:-
LUAD	cis	rs8028182	0.636	rs11637068	ENSG00000246877.1	DNM1P35	3.97	8.38e-05	0.0122	0.23	0.18	Sudden cardiac arrest;	chr15:75450661	chr15:75727670~75738623:-
LUAD	cis	rs2274273	0.967	rs1009978	ENSG00000259318.1	RP11-454L9.2	3.97	8.38e-05	0.0122	0.15	0.18	Protein biomarker;	chr14:55136343	chr14:55394940~55395233:-
LUAD	cis	rs7824557	0.564	rs2736304	ENSG00000255046.1	RP11-297N6.4	3.97	8.38e-05	0.0122	0.22	0.18	Retinal vascular caliber;	chr8:11379455	chr8:11797928~11802568:-
LUAD	cis	rs11742741	1	rs35670153	ENSG00000248874.4	C5orf17	-3.97	8.38e-05	0.0122	-0.22	-0.18	Educational attainment;	chr5:24176102	chr5:23951348~24178263:+
LUAD	cis	rs9287719	0.967	rs6721739	ENSG00000243819.4	RN7SL832P	-3.97	8.38e-05	0.0122	-0.19	-0.18	Prostate cancer;	chr2:10611120	chr2:10690344~10692099:+
LUAD	cis	rs9341808	0.935	rs4706113	ENSG00000260645.1	RP11-250B2.5	3.97	8.38e-05	0.0122	0.16	0.18	Sitting height ratio;	chr6:80129598	chr6:80466958~80469080:+
LUAD	cis	rs6951245	0.935	rs118132455	ENSG00000199023.2	MIR339	-3.97	8.38e-05	0.0122	-0.32	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1028596	chr7:1022935~1023045:-
LUAD	cis	rs6951245	1	rs11768761	ENSG00000199023.2	MIR339	-3.97	8.38e-05	0.0122	-0.32	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1030171	chr7:1022935~1023045:-
LUAD	cis	rs4499344	0.696	rs2868153	ENSG00000201388.1	SNORA68	3.97	8.38e-05	0.0122	0.19	0.18	Mean platelet volume;	chr19:32608371	chr19:32608337~32608469:-
LUAD	cis	rs7976269	0.559	rs10771471	ENSG00000257176.2	RP11-996F15.2	-3.97	8.38e-05	0.0122	-0.19	-0.18	Male-pattern baldness;	chr12:29050894	chr12:29280418~29317848:-
LUAD	cis	rs4713118	0.55	rs9368527	ENSG00000216901.1	AL022393.7	3.97	8.38e-05	0.0122	0.21	0.18	Parkinson's disease;	chr6:27711666	chr6:28176188~28176674:+
LUAD	cis	rs3018712	0.564	rs3136547	ENSG00000227620.4	ALG1L8P	-3.97	8.38e-05	0.0122	-0.24	-0.18	Total body bone mineral density;	chr11:68694191	chr11:67785273~67792335:+
LUAD	cis	rs523522	0.962	rs9040	ENSG00000278344.1	RP11-18C24.8	3.97	8.38e-05	0.0122	0.24	0.18	High light scatter reticulocyte count;	chr12:120462471	chr12:120500735~120501090:-
LUAD	cis	rs12935418	0.672	rs7197370	ENSG00000261061.1	RP11-303E16.2	-3.97	8.39e-05	0.0122	-0.2	-0.18	Mean corpuscular volume;	chr16:81017520	chr16:81030770~81031485:+
LUAD	cis	rs4699052	1	rs7694190	ENSG00000246560.2	RP11-10L12.4	3.97	8.39e-05	0.0122	0.23	0.18	Testicular germ cell tumor;	chr4:103246860	chr4:102828055~102844075:+
LUAD	cis	rs7178375	1	rs35162264	ENSG00000270015.1	RP11-540B6.6	3.97	8.39e-05	0.0122	0.16	0.18	Hypertriglyceridemia;	chr15:30908480	chr15:30926514~30928407:+
LUAD	cis	rs11240074	0.516	rs2353953	ENSG00000244371.2	PFN1P8	-3.97	8.39e-05	0.0122	-0.29	-0.18	Type 2 diabetes;	chr1:147473687	chr1:146957117~146957659:-
LUAD	cis	rs783540	0.681	rs1259178	ENSG00000255769.6	GOLGA2P10	3.97	8.39e-05	0.0122	0.2	0.18	Schizophrenia;	chr15:82603127	chr15:82472993~82513950:-
LUAD	cis	rs642803	1	rs557675	ENSG00000255557.1	RP11-770G2.2	3.97	8.39e-05	0.0122	0.21	0.18	Urate levels;	chr11:65799248	chr11:65745729~65771585:+
LUAD	cis	rs3770081	1	rs111295372	ENSG00000273080.1	RP11-301O19.1	-3.97	8.39e-05	0.0122	-0.41	-0.18	Facial emotion recognition (sad faces);	chr2:86056234	chr2:86195590~86196049:+
LUAD	cis	rs3770081	0.793	rs60719866	ENSG00000273080.1	RP11-301O19.1	-3.97	8.39e-05	0.0122	-0.41	-0.18	Facial emotion recognition (sad faces);	chr2:86057255	chr2:86195590~86196049:+
LUAD	cis	rs3770081	1	rs76081054	ENSG00000273080.1	RP11-301O19.1	-3.97	8.39e-05	0.0122	-0.41	-0.18	Facial emotion recognition (sad faces);	chr2:86057914	chr2:86195590~86196049:+
LUAD	cis	rs3770081	1	rs59947468	ENSG00000273080.1	RP11-301O19.1	-3.97	8.39e-05	0.0122	-0.41	-0.18	Facial emotion recognition (sad faces);	chr2:86062313	chr2:86195590~86196049:+
LUAD	cis	rs507080	0.769	rs571001	ENSG00000278376.1	RP11-158I9.8	-3.97	8.39e-05	0.0122	-0.19	-0.18	Serum metabolite levels;	chr11:118629457	chr11:118791254~118793137:+
LUAD	cis	rs8141529	0.732	rs6005872	ENSG00000272858.1	CTA-292E10.8	-3.97	8.39e-05	0.0122	-0.2	-0.18	Lymphocyte counts;	chr22:28776910	chr22:28814914~28815662:+
LUAD	cis	rs638893	0.717	rs622690	ENSG00000255239.1	AP002954.6	3.97	8.39e-05	0.0122	0.28	0.18	Vitiligo;	chr11:118833556	chr11:118688039~118690600:-
LUAD	cis	rs6479891	0.915	rs7091664	ENSG00000232075.1	MRPL35P2	-3.97	8.39e-05	0.0122	-0.29	-0.18	Arthritis (juvenile idiopathic);	chr10:63342040	chr10:63634317~63634827:-
LUAD	cis	rs6479891	1	rs7081275	ENSG00000232075.1	MRPL35P2	-3.97	8.39e-05	0.0122	-0.29	-0.18	Arthritis (juvenile idiopathic);	chr10:63346791	chr10:63634317~63634827:-
LUAD	cis	rs6479891	1	rs7895348	ENSG00000232075.1	MRPL35P2	-3.97	8.39e-05	0.0122	-0.29	-0.18	Arthritis (juvenile idiopathic);	chr10:63349781	chr10:63634317~63634827:-
LUAD	cis	rs8062405	0.755	rs62034358	ENSG00000251417.2	RP11-1348G14.4	-3.97	8.4e-05	0.0122	-0.18	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28802743~28817828:+
LUAD	cis	rs8062405	0.755	rs12445823	ENSG00000251417.2	RP11-1348G14.4	-3.97	8.4e-05	0.0122	-0.18	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28802743~28817828:+
LUAD	cis	rs494459	0.536	rs57719838	ENSG00000278376.1	RP11-158I9.8	-3.97	8.4e-05	0.0122	-0.19	-0.18	Height;	chr11:118854014	chr11:118791254~118793137:+
LUAD	cis	rs11886999	0.951	rs11551400	ENSG00000237510.6	AC008268.2	-3.97	8.4e-05	0.0122	-0.28	-0.18	Cardiac Troponin-T levels;	chr2:96248898	chr2:95789654~95800166:+
LUAD	cis	rs71636778	0.631	rs12747620	ENSG00000260063.1	RP5-968P14.2	-3.97	8.4e-05	0.0122	-0.23	-0.18	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26855770	chr1:26692132~26694131:-
LUAD	cis	rs17826219	0.568	rs11658027	ENSG00000266490.1	CTD-2349P21.9	-3.97	8.4e-05	0.0122	-0.26	-0.18	Body mass index;	chr17:30767864	chr17:30792372~30792833:+
LUAD	cis	rs4767841	0.874	rs7294387	ENSG00000248636.5	RP11-768F21.1	-3.97	8.4e-05	0.0122	-0.21	-0.18	Urgency urinary incontinence;	chr12:119769607	chr12:119387987~119668079:-
LUAD	cis	rs7647973	0.6	rs11920267	ENSG00000225399.4	RP11-3B7.1	3.97	8.4e-05	0.0122	0.23	0.18	Menarche (age at onset);	chr3:49238531	chr3:49260085~49261316:+
LUAD	cis	rs6477493	0.526	rs10820447	ENSG00000188801.9	ZNF322P1	3.97	8.4e-05	0.0122	0.27	0.18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;	chr9:96369762	chr9:97198303~97199511:-
LUAD	cis	rs6687821	0.749	rs263490	ENSG00000267734.1	RP4-604K5.3	3.97	8.4e-05	0.0122	0.21	0.18	Yeast infection;	chr1:86761733	chr1:86932199~86934891:-
LUAD	cis	rs6687821	0.749	rs263488	ENSG00000267734.1	RP4-604K5.3	3.97	8.4e-05	0.0122	0.21	0.18	Yeast infection;	chr1:86762118	chr1:86932199~86934891:-
LUAD	cis	rs7208859	0.623	rs7219361	ENSG00000280069.1	CTD-2349P21.3	-3.97	8.4e-05	0.0122	-0.25	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30738182~30740275:+
LUAD	cis	rs860295	0.702	rs1556488	ENSG00000225855.5	RUSC1-AS1	3.97	8.4e-05	0.0122	0.12	0.18	Body mass index;	chr1:155570869	chr1:155316863~155324176:-
LUAD	cis	rs2657294	0.965	rs10824285	ENSG00000226051.5	ZNF503-AS1	-3.97	8.4e-05	0.0122	-0.24	-0.18	Pneumonia;	chr10:75153271	chr10:75269819~75373500:+
LUAD	cis	rs2731006	0.592	rs908657	ENSG00000257114.2	RP11-25I15.3	-3.97	8.41e-05	0.0122	-0.28	-0.18	Panic disorder;	chr12:42774843	chr12:42692216~42717119:+
LUAD	cis	rs6910061	1	rs28860023	ENSG00000247925.2	RP3-510L9.1	-3.97	8.41e-05	0.0122	-0.25	-0.18	Diabetic kidney disease;	chr6:11106532	chr6:11173452~11259099:+
LUAD	cis	rs6910061	1	rs28542236	ENSG00000247925.2	RP3-510L9.1	-3.97	8.41e-05	0.0122	-0.25	-0.18	Diabetic kidney disease;	chr6:11106733	chr6:11173452~11259099:+
LUAD	cis	rs6910061	0.913	rs28712814	ENSG00000247925.2	RP3-510L9.1	-3.97	8.41e-05	0.0122	-0.25	-0.18	Diabetic kidney disease;	chr6:11108512	chr6:11173452~11259099:+
LUAD	cis	rs4795519	0.778	rs1829662	ENSG00000266313.1	RP11-173M1.4	3.97	8.41e-05	0.0122	0.22	0.18	Chronic myeloid leukemia;	chr17:27075137	chr17:27333256~27348491:+
LUAD	cis	rs13113518	0.812	rs56055342	ENSG00000273257.1	RP11-177J6.1	3.97	8.42e-05	0.0122	0.2	0.18	Height;	chr4:55540928	chr4:55387949~55388271:+
LUAD	cis	rs2732480	0.577	rs1489109	ENSG00000273765.1	RP11-370I10.11	3.97	8.42e-05	0.0122	0.2	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344997	chr12:48360920~48361377:+
LUAD	cis	rs2732480	0.577	rs1489108	ENSG00000273765.1	RP11-370I10.11	3.97	8.42e-05	0.0122	0.2	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344998	chr12:48360920~48361377:+
LUAD	cis	rs1876905	0.68	rs187130	ENSG00000255389.1	C6orf3	3.97	8.42e-05	0.0122	0.23	0.18	Mean corpuscular hemoglobin;	chr6:111188360	chr6:111599875~111602295:+
LUAD	cis	rs2638953	0.924	rs12320545	ENSG00000278733.1	RP11-425D17.1	3.97	8.42e-05	0.0122	0.22	0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28248047	chr12:28185625~28186190:-
LUAD	cis	rs2823962	0.727	rs2027623	ENSG00000270093.1	AP000473.8	-3.97	8.42e-05	0.0122	-0.18	-0.18	Amyotrophic lateral sclerosis;	chr21:16641441	chr21:16643529~16645065:+
LUAD	cis	rs4819052	1	rs2838847	ENSG00000237664.1	LINC00316	-3.97	8.42e-05	0.0122	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251043	chr21:45338590~45341990:-
LUAD	cis	rs7580658	0.963	rs4233583	ENSG00000236682.1	AC068282.3	-3.97	8.43e-05	0.0122	-0.24	-0.18	Protein C levels;	chr2:127302492	chr2:127389130~127400580:+
LUAD	cis	rs7129556	0.813	rs11237249	ENSG00000241782.1	RP11-91P24.1	3.97	8.43e-05	0.0122	0.24	0.18	Weight loss (gastric bypass surgery);	chr11:77630090	chr11:77868722~77869195:-
LUAD	cis	rs2898681	0.874	rs6852148	ENSG00000248375.1	RP11-177B4.1	-3.97	8.43e-05	0.0122	-0.26	-0.18	Optic nerve measurement (cup area);	chr4:52883835	chr4:52720081~52720831:-
LUAD	cis	rs860295	0.702	rs12239100	ENSG00000225855.5	RUSC1-AS1	3.97	8.43e-05	0.0122	0.12	0.18	Body mass index;	chr1:155458685	chr1:155316863~155324176:-
LUAD	cis	rs28374715	0.681	rs7168307	ENSG00000247556.5	OIP5-AS1	3.97	8.43e-05	0.0122	0.21	0.18	Ulcerative colitis;	chr15:41328336	chr15:41283990~41309737:+
LUAD	cis	rs2274273	0.773	rs8006525	ENSG00000259318.1	RP11-454L9.2	3.97	8.43e-05	0.0122	0.16	0.18	Protein biomarker;	chr14:55346676	chr14:55394940~55395233:-
LUAD	cis	rs875971	0.545	rs7783889	ENSG00000222364.1	RNU6-96P	-3.97	8.43e-05	0.0122	-0.23	-0.18	Aortic root size;	chr7:66283366	chr7:66395191~66395286:+
LUAD	cis	rs73198271	0.681	rs35457364	ENSG00000253893.2	FAM85B	3.97	8.43e-05	0.0122	0.24	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792280	chr8:8167819~8226614:-
LUAD	cis	rs73198271	0.681	rs11987924	ENSG00000253893.2	FAM85B	3.97	8.43e-05	0.0122	0.24	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792462	chr8:8167819~8226614:-
LUAD	cis	rs4374383	0.884	rs10210692	ENSG00000207383.1	Y_RNA	-3.97	8.43e-05	0.0122	-0.21	-0.18	Hepatitis C induced liver fibrosis;	chr2:112008685	chr2:112579484~112579584:-
LUAD	cis	rs2732480	0.577	rs2732481	ENSG00000257763.1	OR5BK1P	3.97	8.43e-05	0.0122	0.19	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343202	chr12:48355792~48356614:-
LUAD	cis	rs2732480	0.557	rs2732484	ENSG00000257763.1	OR5BK1P	3.97	8.43e-05	0.0122	0.19	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343462	chr12:48355792~48356614:-
LUAD	cis	rs858239	0.539	rs7791200	ENSG00000226816.2	AC005082.12	3.97	8.43e-05	0.0122	0.24	0.18	Cerebrospinal fluid biomarker levels;	chr7:23142502	chr7:23206013~23208045:+
LUAD	cis	rs2904524	0.541	rs1603221	ENSG00000257815.4	RP11-611E13.2	-3.97	8.43e-05	0.0122	-0.22	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70379617	chr12:69904033~70243360:-
LUAD	cis	rs3812049	0.737	rs790155	ENSG00000245937.6	LINC01184	3.97	8.43e-05	0.0122	0.26	0.18	Lymphocyte counts;Red cell distribution width;	chr5:128162688	chr5:127940426~128083172:-
LUAD	cis	rs3812049	0.737	rs790154	ENSG00000245937.6	LINC01184	3.97	8.43e-05	0.0122	0.26	0.18	Lymphocyte counts;Red cell distribution width;	chr5:128165543	chr5:127940426~128083172:-
LUAD	cis	rs5742933	1	rs3791767	ENSG00000253559.1	OSGEPL1-AS1	3.97	8.43e-05	0.0122	0.24	0.18	Ferritin levels;	chr2:189775189	chr2:189762704~189765556:+
LUAD	cis	rs10971721	0.731	rs10971750	ENSG00000260947.1	RP11-384P7.7	3.97	8.43e-05	0.0122	0.37	0.18	Body mass index;	chr9:33869783	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs10971753	ENSG00000260947.1	RP11-384P7.7	3.97	8.43e-05	0.0122	0.37	0.18	Body mass index;	chr9:33870438	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs10971754	ENSG00000260947.1	RP11-384P7.7	3.97	8.43e-05	0.0122	0.37	0.18	Body mass index;	chr9:33871714	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs10971755	ENSG00000260947.1	RP11-384P7.7	3.97	8.43e-05	0.0122	0.37	0.18	Body mass index;	chr9:33872007	chr9:33697459~33700986:+
LUAD	cis	rs11018904	0.636	rs61903695	ENSG00000280385.1	AP000648.5	-3.97	8.43e-05	0.0122	-0.22	-0.18	Intelligence (multi-trait analysis);	chr11:90189249	chr11:90193614~90198120:+
LUAD	cis	rs67981189	0.806	rs2810107	ENSG00000269927.1	RP6-91H8.3	-3.97	8.44e-05	0.0122	-0.22	-0.18	Schizophrenia;	chr14:70954340	chr14:71141125~71143253:-
LUAD	cis	rs67981189	0.896	rs2526846	ENSG00000269927.1	RP6-91H8.3	-3.97	8.44e-05	0.0122	-0.22	-0.18	Schizophrenia;	chr14:70957538	chr14:71141125~71143253:-
LUAD	cis	rs2281558	0.833	rs55792313	ENSG00000125804.12	FAM182A	-3.97	8.44e-05	0.0122	-0.24	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25540619	chr20:26054655~26086917:+
LUAD	cis	rs2657294	0.965	rs2395140	ENSG00000233313.2	HMGA1P5	-3.97	8.44e-05	0.0122	-0.22	-0.18	Pneumonia;	chr10:75139253	chr10:75276376~75276646:-
LUAD	cis	rs2657294	0.965	rs2997754	ENSG00000233313.2	HMGA1P5	-3.97	8.44e-05	0.0122	-0.22	-0.18	Pneumonia;	chr10:75144379	chr10:75276376~75276646:-
LUAD	cis	rs2657294	0.965	rs2047951	ENSG00000233313.2	HMGA1P5	-3.97	8.44e-05	0.0122	-0.22	-0.18	Pneumonia;	chr10:75161310	chr10:75276376~75276646:-
LUAD	cis	rs2657294	0.965	rs2804523	ENSG00000233313.2	HMGA1P5	-3.97	8.44e-05	0.0122	-0.22	-0.18	Pneumonia;	chr10:75161584	chr10:75276376~75276646:-
LUAD	cis	rs17826219	0.568	rs2626985	ENSG00000280069.1	CTD-2349P21.3	-3.97	8.44e-05	0.0122	-0.24	-0.18	Body mass index;	chr17:30750419	chr17:30738182~30740275:+
LUAD	cis	rs17711722	0.583	rs10085415	ENSG00000236529.1	RP13-254B10.1	-3.97	8.44e-05	0.0122	-0.18	-0.18	Calcium levels;	chr7:65628655	chr7:65840212~65840596:+
LUAD	cis	rs7302981	0.746	rs2272391	ENSG00000272368.2	RP4-605O3.4	-3.97	8.44e-05	0.0122	-0.2	-0.18	Systolic blood pressure;	chr12:50077847	chr12:50112197~50165618:+
LUAD	cis	rs7893279	0.543	rs34237250	ENSG00000225527.1	RP11-383B4.4	3.97	8.44e-05	0.0122	0.26	0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18602785	chr10:18531849~18533336:-
LUAD	cis	rs77688320	0.517	rs10931949	ENSG00000213090.2	AC007256.5	3.97	8.44e-05	0.0122	0.2	0.18	Breast cancer;	chr2:201459730	chr2:201410544~201413308:-
LUAD	cis	rs2638953	0.924	rs11049415	ENSG00000278733.1	RP11-425D17.1	-3.97	8.44e-05	0.0122	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28190188	chr12:28185625~28186190:-
LUAD	cis	rs34638952	0.507	rs1712654	ENSG00000264808.1	RP11-802D6.1	3.97	8.45e-05	0.0122	0.21	0.18	Sitting height ratio;	chr17:29273630	chr17:29369717~29390777:-
LUAD	cis	rs7119038	0.818	rs2077579	ENSG00000255239.1	AP002954.6	-3.97	8.45e-05	0.0122	-0.27	-0.18	Sjögren's syndrome;	chr11:118748338	chr11:118688039~118690600:-
LUAD	cis	rs9659323	0.717	rs61806238	ENSG00000231365.4	RP11-418J17.1	-3.97	8.45e-05	0.0122	-0.23	-0.18	Body mass index;	chr1:118993755	chr1:119140396~119275973:+
LUAD	cis	rs6832769	0.857	rs28377791	ENSG00000272969.1	RP11-528I4.2	-3.97	8.45e-05	0.0122	-0.19	-0.18	Personality dimensions;	chr4:55607014	chr4:55547112~55547889:+
LUAD	cis	rs5742933	1	rs1550388	ENSG00000253559.1	OSGEPL1-AS1	3.97	8.45e-05	0.0122	0.24	0.18	Ferritin levels;	chr2:189739054	chr2:189762704~189765556:+
LUAD	cis	rs2273156	0.57	rs11156875	ENSG00000226677.3	IGBP1P1	-3.97	8.45e-05	0.0122	-0.27	-0.18	Immunoglobulin light chain (AL) amyloidosis;	chr14:35150610	chr14:34939324~34940332:+
LUAD	cis	rs2337406	0.866	rs8003852	ENSG00000280411.1	IGHV1-69-2	-3.97	8.45e-05	0.0122	-0.16	-0.18	Alzheimer's disease (late onset);	chr14:106776648	chr14:106762092~106762588:-
LUAD	cis	rs2337406	0.866	rs988131	ENSG00000280411.1	IGHV1-69-2	-3.97	8.45e-05	0.0122	-0.16	-0.18	Alzheimer's disease (late onset);	chr14:106776833	chr14:106762092~106762588:-
LUAD	cis	rs2337406	0.866	rs8005518	ENSG00000280411.1	IGHV1-69-2	-3.97	8.45e-05	0.0122	-0.16	-0.18	Alzheimer's disease (late onset);	chr14:106777009	chr14:106762092~106762588:-
LUAD	cis	rs2337406	0.866	rs57684263	ENSG00000280411.1	IGHV1-69-2	-3.97	8.45e-05	0.0122	-0.16	-0.18	Alzheimer's disease (late onset);	chr14:106777263	chr14:106762092~106762588:-
LUAD	cis	rs2337406	0.866	rs7152809	ENSG00000280411.1	IGHV1-69-2	-3.97	8.45e-05	0.0122	-0.16	-0.18	Alzheimer's disease (late onset);	chr14:106778385	chr14:106762092~106762588:-
LUAD	cis	rs2337406	0.866	rs7152832	ENSG00000280411.1	IGHV1-69-2	-3.97	8.45e-05	0.0122	-0.16	-0.18	Alzheimer's disease (late onset);	chr14:106778427	chr14:106762092~106762588:-
LUAD	cis	rs2337406	0.5	rs7152934	ENSG00000280411.1	IGHV1-69-2	-3.97	8.45e-05	0.0122	-0.16	-0.18	Alzheimer's disease (late onset);	chr14:106778702	chr14:106762092~106762588:-
LUAD	cis	rs2337406	0.789	rs12050392	ENSG00000280411.1	IGHV1-69-2	-3.97	8.45e-05	0.0122	-0.16	-0.18	Alzheimer's disease (late onset);	chr14:106779073	chr14:106762092~106762588:-
LUAD	cis	rs2337406	0.866	rs74092505	ENSG00000280411.1	IGHV1-69-2	-3.97	8.45e-05	0.0122	-0.16	-0.18	Alzheimer's disease (late onset);	chr14:106779163	chr14:106762092~106762588:-
LUAD	cis	rs2337406	0.789	rs74092507	ENSG00000280411.1	IGHV1-69-2	-3.97	8.45e-05	0.0122	-0.16	-0.18	Alzheimer's disease (late onset);	chr14:106779174	chr14:106762092~106762588:-
LUAD	cis	rs2337406	0.866	rs74092511	ENSG00000280411.1	IGHV1-69-2	-3.97	8.45e-05	0.0122	-0.16	-0.18	Alzheimer's disease (late onset);	chr14:106779234	chr14:106762092~106762588:-
LUAD	cis	rs67478160	0.643	rs4906369	ENSG00000272533.1	SNORA28	3.96	8.46e-05	0.0122	0.18	0.18	Schizophrenia;	chr14:103776121	chr14:103337849~103337974:+
LUAD	cis	rs189798	0.807	rs330912	ENSG00000253893.2	FAM85B	-3.96	8.46e-05	0.0122	-0.26	-0.18	Myopia (pathological);	chr8:9138784	chr8:8167819~8226614:-
LUAD	cis	rs763121	0.853	rs2064088	ENSG00000225450.1	RP3-508I15.14	-3.96	8.46e-05	0.0122	-0.18	-0.18	Menopause (age at onset);	chr22:38657377	chr22:38739003~38749041:+
LUAD	cis	rs763121	0.853	rs5757213	ENSG00000225450.1	RP3-508I15.14	-3.96	8.46e-05	0.0122	-0.18	-0.18	Menopause (age at onset);	chr22:38657883	chr22:38739003~38749041:+
LUAD	cis	rs2348418	0.832	rs4244844	ENSG00000247934.4	RP11-967K21.1	3.96	8.46e-05	0.0122	0.2	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28434062	chr12:28163298~28190738:-
LUAD	cis	rs9309473	0.851	rs6546850	ENSG00000230002.2	ALMS1-IT1	3.96	8.46e-05	0.0122	0.22	0.18	Metabolite levels;	chr2:73604020	chr2:73456764~73459484:+
LUAD	cis	rs9309473	0.898	rs6546852	ENSG00000230002.2	ALMS1-IT1	3.96	8.46e-05	0.0122	0.22	0.18	Metabolite levels;	chr2:73606304	chr2:73456764~73459484:+
LUAD	cis	rs2098713	0.569	rs58038848	ENSG00000250155.1	CTD-2353F22.1	3.96	8.46e-05	0.0122	0.2	0.18	Telomere length;	chr5:37502860	chr5:36666214~36725195:-
LUAD	cis	rs2098713	0.535	rs4541679	ENSG00000250155.1	CTD-2353F22.1	3.96	8.46e-05	0.0122	0.2	0.18	Telomere length;	chr5:37503120	chr5:36666214~36725195:-
LUAD	cis	rs240993	0.812	rs459809	ENSG00000271789.1	RP5-1112D6.7	-3.96	8.46e-05	0.0122	-0.22	-0.18	Inflammatory skin disease;Psoriasis;	chr6:111331964	chr6:111297126~111298510:+
LUAD	cis	rs10197140	0.857	rs10186753	ENSG00000235721.1	AC013268.3	-3.96	8.46e-05	0.0123	-0.19	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110885635	chr2:110007675~110010783:+
LUAD	cis	rs10197140	0.857	rs10182055	ENSG00000235721.1	AC013268.3	-3.96	8.46e-05	0.0123	-0.19	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110885677	chr2:110007675~110010783:+
LUAD	cis	rs10197140	0.857	rs10184452	ENSG00000235721.1	AC013268.3	-3.96	8.46e-05	0.0123	-0.19	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110885715	chr2:110007675~110010783:+
LUAD	cis	rs10197140	0.857	rs28448691	ENSG00000235721.1	AC013268.3	-3.96	8.46e-05	0.0123	-0.19	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110886036	chr2:110007675~110010783:+
LUAD	cis	rs7617773	0.817	rs3729577	ENSG00000199476.1	Y_RNA	-3.96	8.46e-05	0.0123	-0.24	-0.18	Coronary artery disease;	chr3:48187504	chr3:48288587~48288694:+
LUAD	cis	rs9309711	0.698	rs9750503	ENSG00000271868.1	RP11-1293J14.1	3.96	8.46e-05	0.0123	0.21	0.18	Neurofibrillary tangles;	chr2:3488001	chr2:3496956~3497428:+
LUAD	cis	rs12999542	1	rs13014644	ENSG00000234389.1	AC007278.3	3.96	8.47e-05	0.0123	0.26	0.18	Serum protein levels (sST2);	chr2:102354903	chr2:102438713~102440475:+
LUAD	cis	rs12999542	1	rs11465567	ENSG00000234389.1	AC007278.3	3.96	8.47e-05	0.0123	0.26	0.18	Serum protein levels (sST2);	chr2:102361940	chr2:102438713~102440475:+
LUAD	cis	rs12999542	1	rs11465572	ENSG00000234389.1	AC007278.3	3.96	8.47e-05	0.0123	0.26	0.18	Serum protein levels (sST2);	chr2:102363763	chr2:102438713~102440475:+
LUAD	cis	rs6714710	0.663	rs71429376	ENSG00000230606.9	AC159540.1	-3.96	8.47e-05	0.0123	-0.19	-0.18	Posterior cortical atrophy and Alzheimer's disease;	chr2:97917949	chr2:97416165~97433527:-
LUAD	cis	rs7119038	0.818	rs715412	ENSG00000255239.1	AP002954.6	-3.96	8.47e-05	0.0123	-0.26	-0.18	Sjögren's syndrome;	chr11:118813901	chr11:118688039~118690600:-
LUAD	cis	rs4925386	0.959	rs6121989	ENSG00000273619.1	RP5-908M14.9	3.96	8.47e-05	0.0123	0.16	0.18	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62341657	chr20:62386303~62386970:-
LUAD	cis	rs8047014	1	rs8047014	ENSG00000260459.2	FTLP14	3.96	8.47e-05	0.0123	0.21	0.18	Attention deficit hyperactivity disorder;	chr16:69101146	chr16:68822587~68823070:+
LUAD	cis	rs9890032	0.934	rs7225461	ENSG00000266490.1	CTD-2349P21.9	3.96	8.47e-05	0.0123	0.16	0.18	Hip circumference adjusted for BMI;	chr17:30932881	chr17:30792372~30792833:+
LUAD	cis	rs4372836	0.796	rs7580078	ENSG00000226833.4	AC097724.3	3.96	8.47e-05	0.0123	0.21	0.18	Body mass index;	chr2:28774135	chr2:28708953~28736205:-
LUAD	cis	rs6663390	0.51	rs2267895	ENSG00000203709.8	C1orf132	3.96	8.47e-05	0.0123	0.25	0.18	Facial morphology (factor 18);	chr1:207907718	chr1:207801518~207869150:-
LUAD	cis	rs2057178	0.697	rs10835879	ENSG00000183242.10	WT1-AS	3.96	8.47e-05	0.0123	0.28	0.18	Tuberculosis;	chr11:32294886	chr11:32435518~32458769:+
LUAD	cis	rs7561273	0.609	rs6545285	ENSG00000242628.4	AC009228.1	3.96	8.47e-05	0.0123	0.23	0.18	Quantitative traits;	chr2:24117159	chr2:24214381~24221516:+
LUAD	cis	rs11671005	0.737	rs11673101	ENSG00000268912.1	CTD-2619J13.17	-3.96	8.47e-05	0.0123	-0.26	-0.18	Mean platelet volume;	chr19:58483686	chr19:58428632~58431148:-
LUAD	cis	rs1061377	0.56	rs6531690	ENSG00000249685.1	RP11-360F5.3	3.96	8.47e-05	0.0123	0.21	0.18	Uric acid levels;	chr4:39072583	chr4:39133913~39135608:+
LUAD	cis	rs6802315	0.712	rs7615751	ENSG00000272087.1	RP11-379F4.7	3.96	8.47e-05	0.0123	0.19	0.18	Periodontitis (CDC/AAP);	chr3:158792041	chr3:158693120~158693768:-
LUAD	cis	rs141753469	1	rs141753469	ENSG00000239335.4	LLPH-AS1	3.96	8.47e-05	0.0123	0.28	0.18	Chin dimples;	chr12:66003386	chr12:66130751~66134449:+
LUAD	cis	rs2904524	1	rs58612372	ENSG00000257815.4	RP11-611E13.2	-3.96	8.48e-05	0.0123	-0.27	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70276566	chr12:69904033~70243360:-
LUAD	cis	rs12291225	0.679	rs11369	ENSG00000251991.1	RNU7-49P	3.96	8.48e-05	0.0123	0.2	0.18	Sense of smell;	chr11:14266550	chr11:14478892~14478953:+
LUAD	cis	rs7772486	0.79	rs6926657	ENSG00000235652.6	RP11-545I5.3	-3.96	8.48e-05	0.0123	-0.18	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145934658	chr6:145799409~145886585:+
LUAD	cis	rs2836950	0.501	rs62223052	ENSG00000232608.1	TIMM9P2	3.96	8.48e-05	0.0123	0.2	0.18	Menarche (age at onset);	chr21:39336776	chr21:39216624~39217506:+
LUAD	cis	rs1790761	0.505	rs6591256	ENSG00000184224.3	C11orf72	-3.96	8.48e-05	0.0123	-0.2	-0.18	Mean corpuscular volume;	chr11:67582428	chr11:67602880~67606706:-
LUAD	cis	rs11742741	0.869	rs12187619	ENSG00000248874.4	C5orf17	-3.96	8.48e-05	0.0123	-0.22	-0.18	Educational attainment;	chr5:24092634	chr5:23951348~24178263:+
LUAD	cis	rs8054556	0.633	rs12928610	ENSG00000214725.6	CDIPT-AS1	-3.96	8.48e-05	0.0123	-0.21	-0.18	Autism spectrum disorder or schizophrenia;	chr16:30004701	chr16:29863593~29868053:+
LUAD	cis	rs9813712	0.571	rs9846596	ENSG00000228252.7	COL6A4P2	-3.96	8.48e-05	0.0123	-0.17	-0.18	Response to amphetamines;	chr3:130288318	chr3:130212823~130273806:+
LUAD	cis	rs79149102	0.522	rs11072499	ENSG00000259264.4	RP11-60L3.1	3.96	8.48e-05	0.0123	0.33	0.18	Lung cancer;	chr15:74676532	chr15:74202705~74221557:+
LUAD	cis	rs2154319	0.836	rs41268101	ENSG00000235358.1	RP11-399E6.1	-3.96	8.48e-05	0.0123	-0.25	-0.18	Height;	chr1:41001492	chr1:41242373~41284861:+
LUAD	cis	rs17767294	1	rs17767294	ENSG00000226314.6	ZNF192P1	-3.96	8.48e-05	0.0123	-0.39	-0.18	Parkinson's disease;	chr6:28086420	chr6:28161781~28169594:+
LUAD	cis	rs728616	0.867	rs3088308	ENSG00000234382.2	RP11-40F6.1	-3.96	8.48e-05	0.0123	-0.43	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79938112	chr10:80233664~80245367:+
LUAD	cis	rs728616	0.867	rs17879726	ENSG00000234382.2	RP11-40F6.1	-3.96	8.48e-05	0.0123	-0.43	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79938967	chr10:80233664~80245367:+
LUAD	cis	rs763121	0.853	rs6519120	ENSG00000228274.3	RP3-508I15.9	3.96	8.49e-05	0.0123	0.18	0.18	Menopause (age at onset);	chr22:38595388	chr22:38667585~38681820:-
LUAD	cis	rs950880	1	rs13001325	ENSG00000234389.1	AC007278.3	-3.96	8.49e-05	0.0123	-0.17	-0.18	Serum protein levels (sST2);	chr2:102322576	chr2:102438713~102440475:+
LUAD	cis	rs4767841	0.935	rs2952403	ENSG00000248636.5	RP11-768F21.1	-3.96	8.49e-05	0.0123	-0.21	-0.18	Urgency urinary incontinence;	chr12:119738080	chr12:119387987~119668079:-
LUAD	cis	rs9487094	0.922	rs9885646	ENSG00000260273.1	RP11-425D10.10	3.96	8.49e-05	0.0123	0.23	0.18	Height;	chr6:109421257	chr6:109382795~109383666:+
LUAD	cis	rs4767841	0.935	rs2952444	ENSG00000248636.5	RP11-768F21.1	-3.96	8.49e-05	0.0123	-0.21	-0.18	Urgency urinary incontinence;	chr12:119737986	chr12:119387987~119668079:-
LUAD	cis	rs7551222	0.634	rs12139477	ENSG00000240219.1	RP11-430C7.5	3.96	8.49e-05	0.0123	0.18	0.18	Schizophrenia;	chr1:204583976	chr1:204626775~204629712:+
LUAD	cis	rs9322193	0.607	rs915140	ENSG00000268592.3	RAET1E-AS1	3.96	8.49e-05	0.0123	0.27	0.18	Lung cancer;	chr6:149899674	chr6:149863494~149919507:+
LUAD	cis	rs494562	1	rs527670	ENSG00000234155.1	RP11-30P6.6	-3.96	8.5e-05	0.0123	-0.34	-0.18	Metabolic traits;Blood metabolite levels;	chr6:85406061	chr6:85387219~85390186:-
LUAD	cis	rs4130344	0.874	rs13114888	ENSG00000271817.2	U3	-3.96	8.5e-05	0.0123	-0.19	-0.18	Intelligence (multi-trait analysis);	chr4:158760407	chr4:158700691~158700909:+
LUAD	cis	rs703842	1	rs11172349	ENSG00000270039.1	RP11-571M6.17	-3.96	8.5e-05	0.0123	-0.22	-0.18	Multiple sclerosis;	chr12:57818745	chr12:57803838~57804415:+
LUAD	cis	rs10863681	0.764	rs10495184	ENSG00000238042.4	RP11-815M8.1	3.96	8.5e-05	0.0123	0.21	0.18	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222086335	chr1:221880981~221978523:-
LUAD	cis	rs9545047	0.604	rs4885625	ENSG00000227354.5	RBM26-AS1	3.96	8.51e-05	0.0123	0.19	0.18	Schizophrenia;	chr13:79290355	chr13:79406309~79424328:+
LUAD	cis	rs9545047	0.604	rs1324873	ENSG00000227354.5	RBM26-AS1	3.96	8.51e-05	0.0123	0.19	0.18	Schizophrenia;	chr13:79292246	chr13:79406309~79424328:+
LUAD	cis	rs259282	0.524	rs4805006	ENSG00000201388.1	SNORA68	3.96	8.51e-05	0.0123	0.18	0.18	Schizophrenia;	chr19:32633230	chr19:32608337~32608469:-
LUAD	cis	rs2278702	0.943	rs17315116	ENSG00000259495.2	RP11-210M15.2	-3.96	8.51e-05	0.0123	-0.28	-0.18	Bipolar disorder;	chr15:80396263	chr15:80344853~80403575:-
LUAD	cis	rs4267450	0.842	rs11666652	ENSG00000267323.1	SLC25A1P5	3.96	8.51e-05	0.0123	0.32	0.18	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr19:28397433	chr19:27805423~27806205:-
LUAD	cis	rs13113518	0.729	rs13120134	ENSG00000272969.1	RP11-528I4.2	3.96	8.51e-05	0.0123	0.2	0.18	Height;	chr4:55415153	chr4:55547112~55547889:+
LUAD	cis	rs7394190	0.748	rs11000728	ENSG00000271848.1	RP11-464F9.21	-3.96	8.51e-05	0.0123	-0.26	-0.18	Incident atrial fibrillation;	chr10:73644542	chr10:73654039~73674719:+
LUAD	cis	rs11673344	0.504	rs10403728	ENSG00000276846.1	CTD-3220F14.3	3.96	8.52e-05	0.0123	0.19	0.18	Obesity-related traits;	chr19:37091569	chr19:37314868~37315620:-
LUAD	cis	rs5015933	0.778	rs10819045	ENSG00000232630.1	PRPS1P2	-3.96	8.52e-05	0.0123	-0.17	-0.18	Body mass index;	chr9:125321886	chr9:125150653~125151589:+
LUAD	cis	rs913672	0.609	rs6122895	ENSG00000229222.1	KRT18P4	-3.96	8.52e-05	0.0123	-0.22	-0.18	Monocyte count;	chr20:50283557	chr20:49956745~49958032:+
LUAD	cis	rs7647973	0.58	rs11716334	ENSG00000225399.4	RP11-3B7.1	3.96	8.52e-05	0.0123	0.23	0.18	Menarche (age at onset);	chr3:49192663	chr3:49260085~49261316:+
LUAD	cis	rs12744310	1	rs1343775	ENSG00000235358.1	RP11-399E6.1	3.96	8.52e-05	0.0123	0.24	0.18	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41292321	chr1:41242373~41284861:+
LUAD	cis	rs6125597	0.967	rs6067030	ENSG00000230758.1	SNAP23P	3.96	8.52e-05	0.0123	0.18	0.18	Intelligence (multi-trait analysis);	chr20:49267866	chr20:49038357~49038602:-
LUAD	cis	rs1876905	0.524	rs1084639	ENSG00000230177.1	RP5-1112D6.4	-3.96	8.52e-05	0.0123	-0.21	-0.18	Mean corpuscular hemoglobin;	chr6:111165240	chr6:111277932~111278742:+
LUAD	cis	rs6472235	0.586	rs950729	ENSG00000200714.1	Y_RNA	-3.96	8.52e-05	0.0123	-0.23	-0.18	Plateletcrit;Myopia (pathological);	chr8:66005518	chr8:65592731~65592820:+
LUAD	cis	rs2098713	0.534	rs4086257	ENSG00000250155.1	CTD-2353F22.1	3.96	8.53e-05	0.0123	0.2	0.18	Telomere length;	chr5:37504695	chr5:36666214~36725195:-
LUAD	cis	rs7202877	0.706	rs247450	ENSG00000280152.1	RP11-331F4.5	-3.96	8.53e-05	0.0123	-0.21	-0.18	Type 1 diabetes;Type 2 diabetes;	chr16:75456119	chr16:75245994~75250077:-
LUAD	cis	rs9291683	0.588	rs12506364	ENSG00000250413.1	RP11-448G15.1	-3.96	8.53e-05	0.0123	-0.22	-0.18	Bone mineral density;	chr4:10021824	chr4:10006482~10009725:+
LUAD	cis	rs6121246	0.609	rs2149281	ENSG00000230613.1	HM13-AS1	3.96	8.53e-05	0.0123	0.22	0.18	Mean corpuscular hemoglobin;	chr20:31830115	chr20:31567707~31573263:-
LUAD	cis	rs8062405	0.824	rs4788085	ENSG00000261419.1	RP11-57A19.4	-3.96	8.53e-05	0.0123	-0.19	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28659696~28740781:-
LUAD	cis	rs8062405	0.824	rs28772958	ENSG00000261419.1	RP11-57A19.4	-3.96	8.53e-05	0.0123	-0.19	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28659696~28740781:-
LUAD	cis	rs4925386	0.625	rs3810550	ENSG00000273619.1	RP5-908M14.9	-3.96	8.53e-05	0.0123	-0.19	-0.18	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62337061	chr20:62386303~62386970:-
LUAD	cis	rs9341808	0.586	rs3805869	ENSG00000260645.1	RP11-250B2.5	3.96	8.53e-05	0.0123	0.17	0.18	Sitting height ratio;	chr6:80336200	chr6:80466958~80469080:+
LUAD	cis	rs4706831	0.663	rs1984242	ENSG00000260645.1	RP11-250B2.5	3.96	8.53e-05	0.0123	0.17	0.18	Joint mobility (Beighton score);	chr6:80341528	chr6:80466958~80469080:+
LUAD	cis	rs755249	0.583	rs61779328	ENSG00000237624.1	OXCT2P1	3.96	8.53e-05	0.0123	0.29	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39487795	chr1:39514956~39516490:+
LUAD	cis	rs9314614	0.901	rs2978902	ENSG00000245857.2	GS1-24F4.2	-3.96	8.53e-05	0.0123	-0.2	-0.18	White blood cell count (basophil);IgA nephropathy;	chr8:6832651	chr8:6835554~6885276:+
LUAD	cis	rs6125597	0.967	rs6063378	ENSG00000230758.1	SNAP23P	3.96	8.54e-05	0.0123	0.18	0.18	Intelligence (multi-trait analysis);	chr20:49249874	chr20:49038357~49038602:-
LUAD	cis	rs2662776	0.967	rs4291481	ENSG00000232995.6	RGS5	3.96	8.54e-05	0.0123	0.16	0.18	Lead levels in blood;	chr1:163182051	chr1:163244505~163321894:-
LUAD	cis	rs7772486	0.79	rs4896852	ENSG00000235652.6	RP11-545I5.3	-3.96	8.54e-05	0.0123	-0.18	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145963485	chr6:145799409~145886585:+
LUAD	cis	rs17189298	0.867	rs4849754	ENSG00000231013.1	AC013275.2	3.96	8.54e-05	0.0124	0.19	0.18	Cerebrospinal T-tau levels;	chr2:119116672	chr2:119476448~119487346:+
LUAD	cis	rs9813712	0.595	rs12490957	ENSG00000228252.7	COL6A4P2	3.96	8.54e-05	0.0124	0.17	0.18	Response to amphetamines;	chr3:130287851	chr3:130212823~130273806:+
LUAD	cis	rs703842	1	rs11172351	ENSG00000270039.1	RP11-571M6.17	-3.96	8.54e-05	0.0124	-0.22	-0.18	Multiple sclerosis;	chr12:57819702	chr12:57803838~57804415:+
LUAD	cis	rs595244	1	rs1018148	ENSG00000259705.1	RP11-227D13.1	-3.96	8.54e-05	0.0124	-0.36	-0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48610929	chr15:48645951~48652016:+
LUAD	cis	rs137603	0.623	rs470075	ENSG00000225450.1	RP3-508I15.14	-3.96	8.55e-05	0.0124	-0.16	-0.18	Primary biliary cholangitis;	chr22:39290801	chr22:38739003~38749041:+
LUAD	cis	rs7772486	0.79	rs2265917	ENSG00000235652.6	RP11-545I5.3	3.96	8.55e-05	0.0124	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145891149	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.79	rs2265469	ENSG00000235652.6	RP11-545I5.3	3.96	8.55e-05	0.0124	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145897913	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.79	rs2265918	ENSG00000235652.6	RP11-545I5.3	3.96	8.55e-05	0.0124	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145898028	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.79	rs2265472	ENSG00000235652.6	RP11-545I5.3	3.96	8.55e-05	0.0124	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145899622	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.79	rs2265919	ENSG00000235652.6	RP11-545I5.3	3.96	8.55e-05	0.0124	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145900617	chr6:145799409~145886585:+
LUAD	cis	rs10129255	0.957	rs8009073	ENSG00000274576.2	IGHV2-70	3.96	8.55e-05	0.0124	0.16	0.18	Kawasaki disease;	chr14:106777278	chr14:106770577~106771020:-
LUAD	cis	rs4499344	0.556	rs259219	ENSG00000201388.1	SNORA68	3.96	8.55e-05	0.0124	0.2	0.18	Mean platelet volume;	chr19:32647161	chr19:32608337~32608469:-
LUAD	cis	rs7302981	0.719	rs844347	ENSG00000272368.2	RP4-605O3.4	3.96	8.55e-05	0.0124	0.2	0.18	Systolic blood pressure;	chr12:50067893	chr12:50112197~50165618:+
LUAD	cis	rs6700559	0.679	rs7520407	ENSG00000260088.1	RP11-92G12.3	3.96	8.55e-05	0.0124	0.22	0.18	Coronary artery disease;	chr1:200686600	chr1:200669507~200694250:+
LUAD	cis	rs6700559	0.679	rs12076946	ENSG00000260088.1	RP11-92G12.3	3.96	8.55e-05	0.0124	0.22	0.18	Coronary artery disease;	chr1:200693707	chr1:200669507~200694250:+
LUAD	cis	rs4374383	0.884	rs11683409	ENSG00000207383.1	Y_RNA	-3.96	8.56e-05	0.0124	-0.21	-0.18	Hepatitis C induced liver fibrosis;	chr2:112012557	chr2:112579484~112579584:-
LUAD	cis	rs481331	0.799	rs7893674	ENSG00000185904.10	LINC00839	3.96	8.56e-05	0.0124	0.31	0.18	Systemic juvenile idiopathic arthritis;	chr10:42478995	chr10:42475543~42495336:+
LUAD	cis	rs4849121	0.535	rs10180551	ENSG00000235721.1	AC013268.3	-3.96	8.56e-05	0.0124	-0.2	-0.18	IgA nephropathy;	chr2:110844469	chr2:110007675~110010783:+
LUAD	cis	rs10214930	0.671	rs3944121	ENSG00000235574.1	AC073150.6	-3.96	8.56e-05	0.0124	-0.22	-0.18	Hypospadias;	chr7:27841269	chr7:27491682~27492765:-
LUAD	cis	rs2613514	0.892	rs9913902	ENSG00000204282.4	TNRC6C-AS1	-3.96	8.56e-05	0.0124	-0.29	-0.18	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr17:78095812	chr17:78107398~78111799:-
LUAD	cis	rs1910358	0.959	rs6452172	ENSG00000248874.4	C5orf17	-3.96	8.56e-05	0.0124	-0.26	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr5:23911876	chr5:23951348~24178263:+
LUAD	cis	rs7107174	1	rs10793302	ENSG00000251323.2	RP11-452H21.4	3.96	8.56e-05	0.0124	0.22	0.18	Testicular germ cell tumor;	chr11:78329915	chr11:78423982~78429836:-
LUAD	cis	rs9393777	0.92	rs35768595	ENSG00000219392.1	RP1-265C24.5	-3.96	8.56e-05	0.0124	-0.41	-0.18	Intelligence (multi-trait analysis);	chr6:27174125	chr6:28115628~28116551:+
LUAD	cis	rs6142102	0.923	rs4911394	ENSG00000275784.1	RP5-1125A11.6	-3.96	8.57e-05	0.0124	-0.2	-0.18	Skin pigmentation;	chr20:33989521	chr20:33989480~33991818:-
LUAD	cis	rs11051970	0.918	rs7309706	ENSG00000274964.1	RP11-817I4.1	-3.96	8.57e-05	0.0124	-0.21	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr12:32385274	chr12:32339368~32340724:+
LUAD	cis	rs11051970	0.918	rs76930558	ENSG00000274964.1	RP11-817I4.1	-3.96	8.57e-05	0.0124	-0.21	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr12:32385905	chr12:32339368~32340724:+
LUAD	cis	rs3764021	1	rs7977720	ENSG00000256673.1	RP11-599J14.2	-3.96	8.57e-05	0.0124	-0.2	-0.18	Type 1 diabetes;	chr12:9713753	chr12:9398355~9414851:-
LUAD	cis	rs875971	0.54	rs35510581	ENSG00000164669.11	INTS4P1	3.96	8.57e-05	0.0124	0.22	0.18	Aortic root size;	chr7:66113790	chr7:65141225~65234216:+
LUAD	cis	rs7590268	0.666	rs12185693	ENSG00000279873.2	LINC01126	3.96	8.57e-05	0.0124	0.17	0.18	Orofacial clefts;	chr2:43477937	chr2:43227210~43228855:+
LUAD	cis	rs7005380	0.581	rs4871795	ENSG00000279347.1	RP11-85I17.2	3.96	8.57e-05	0.0124	0.17	0.18	Interstitial lung disease;	chr8:119929425	chr8:119838736~119840385:-
LUAD	cis	rs8040855	0.575	rs12912860	ENSG00000259774.1	RP11-182J1.13	3.96	8.58e-05	0.0124	0.23	0.18	Bulimia nervosa;	chr15:85030267	chr15:84422618~84425882:+
LUAD	cis	rs3764400	0.567	rs1452662	ENSG00000278765.1	RP5-890E16.5	3.96	8.58e-05	0.0124	0.32	0.18	Body mass index;	chr17:48215948	chr17:48066704~48067293:-
LUAD	cis	rs3764400	0.564	rs1452663	ENSG00000278765.1	RP5-890E16.5	3.96	8.58e-05	0.0124	0.32	0.18	Body mass index;	chr17:48216024	chr17:48066704~48067293:-
LUAD	cis	rs3764400	0.567	rs16953941	ENSG00000278765.1	RP5-890E16.5	3.96	8.58e-05	0.0124	0.32	0.18	Body mass index;	chr17:48218842	chr17:48066704~48067293:-
LUAD	cis	rs3764400	0.567	rs67345313	ENSG00000278765.1	RP5-890E16.5	3.96	8.58e-05	0.0124	0.32	0.18	Body mass index;	chr17:48224839	chr17:48066704~48067293:-
LUAD	cis	rs3764400	0.567	rs12939334	ENSG00000278765.1	RP5-890E16.5	3.96	8.58e-05	0.0124	0.32	0.18	Body mass index;	chr17:48225307	chr17:48066704~48067293:-
LUAD	cis	rs3764400	0.567	rs12946208	ENSG00000278765.1	RP5-890E16.5	3.96	8.58e-05	0.0124	0.32	0.18	Body mass index;	chr17:48234767	chr17:48066704~48067293:-
LUAD	cis	rs3764400	0.567	rs3897789	ENSG00000278765.1	RP5-890E16.5	3.96	8.58e-05	0.0124	0.32	0.18	Body mass index;	chr17:48235415	chr17:48066704~48067293:-
LUAD	cis	rs2115630	1	rs11854313	ENSG00000259728.4	LINC00933	-3.96	8.58e-05	0.0124	-0.22	-0.18	P wave terminal force;	chr15:84760817	chr15:84570649~84580175:+
LUAD	cis	rs262150	0.788	rs2657389	ENSG00000231419.5	LINC00689	-3.96	8.58e-05	0.0124	-0.21	-0.18	Facial morphology (factor 20);	chr7:158971104	chr7:159006522~159030195:+
LUAD	cis	rs4448343	0.963	rs28457763	ENSG00000271155.1	RP11-435O5.5	-3.96	8.58e-05	0.0124	-0.22	-0.18	Height;	chr9:95498232	chr9:95506235~95507636:+
LUAD	cis	rs4561483	0.624	rs2215928	ENSG00000261216.1	RP11-166B2.5	-3.96	8.58e-05	0.0124	-0.18	-0.18	Testicular germ cell tumor;	chr16:11834061	chr16:11908208~11908916:+
LUAD	cis	rs77633900	0.73	rs2456054	ENSG00000196274.5	Metazoa_SRP	3.96	8.59e-05	0.0124	0.24	0.18	Glioma;Non-glioblastoma glioma;	chr15:76181876	chr15:76230048~76230390:-
LUAD	cis	rs858239	0.539	rs10280815	ENSG00000226816.2	AC005082.12	3.96	8.59e-05	0.0124	0.23	0.18	Cerebrospinal fluid biomarker levels;	chr7:23148751	chr7:23206013~23208045:+
LUAD	cis	rs7674212	0.541	rs2720464	ENSG00000251288.2	RP11-10L12.2	-3.96	8.59e-05	0.0124	-0.22	-0.18	Type 2 diabetes;	chr4:103152044	chr4:102751401~102752641:+
LUAD	cis	rs10971721	0.584	rs55857848	ENSG00000260947.1	RP11-384P7.7	3.96	8.59e-05	0.0124	0.35	0.18	Body mass index;	chr9:34121512	chr9:33697459~33700986:+
LUAD	cis	rs7017914	0.632	rs2035196	ENSG00000223220.1	Y_RNA	3.96	8.59e-05	0.0124	0.21	0.18	Bone mineral density;	chr8:70573115	chr8:70780914~70781008:-
LUAD	cis	rs6688613	0.694	rs3820387	ENSG00000225171.2	DUTP6	-3.96	8.59e-05	0.0124	-0.22	-0.18	Refractive astigmatism;	chr1:166851047	chr1:166868748~166869209:+
LUAD	cis	rs8054556	0.647	rs4788211	ENSG00000214725.6	CDIPT-AS1	-3.96	8.59e-05	0.0124	-0.21	-0.18	Autism spectrum disorder or schizophrenia;	chr16:30004244	chr16:29863593~29868053:+
LUAD	cis	rs9549260	0.755	rs7328677	ENSG00000229456.1	RLIMP1	3.96	8.59e-05	0.0124	0.19	0.18	Red blood cell count;	chr13:40655768	chr13:40618738~40621348:+
LUAD	cis	rs159572	0.747	rs159059	ENSG00000250853.1	RNF138P1	3.96	8.59e-05	0.0124	0.22	0.18	Post-traumatic stress disorder;	chr5:56263811	chr5:55530156~55530701:-
LUAD	cis	rs7131987	0.65	rs4331146	ENSG00000275476.1	RP11-996F15.4	-3.96	8.59e-05	0.0124	-0.2	-0.18	QT interval;	chr12:29287150	chr12:29277397~29277882:-
LUAD	cis	rs801193	0.569	rs11772819	ENSG00000273448.1	RP11-166O4.6	3.96	8.6e-05	0.0124	0.17	0.18	Aortic root size;	chr7:66752983	chr7:67333047~67334383:+
LUAD	cis	rs801193	0.569	rs7800620	ENSG00000273448.1	RP11-166O4.6	3.96	8.6e-05	0.0124	0.17	0.18	Aortic root size;	chr7:66758701	chr7:67333047~67334383:+
LUAD	cis	rs7819412	0.691	rs73198970	ENSG00000255046.1	RP11-297N6.4	3.96	8.6e-05	0.0124	0.22	0.18	Triglycerides;	chr8:11182707	chr8:11797928~11802568:-
LUAD	cis	rs3096299	0.719	rs2965945	ENSG00000261118.1	RP11-104N10.1	3.96	8.6e-05	0.0124	0.18	0.18	Multiple myeloma (IgH translocation);	chr16:89447609	chr16:89492017~89504460:-
LUAD	cis	rs6001482	0.686	rs9623125	ENSG00000223350.2	IGLV9-49	-3.96	8.6e-05	0.0124	-0.17	-0.18	Diastolic blood pressure;	chr22:22234600	chr22:22343187~22343732:+
LUAD	cis	rs6001482	0.702	rs9623126	ENSG00000223350.2	IGLV9-49	-3.96	8.6e-05	0.0124	-0.17	-0.18	Diastolic blood pressure;	chr22:22234624	chr22:22343187~22343732:+
LUAD	cis	rs4925386	0.84	rs6143036	ENSG00000273619.1	RP5-908M14.9	-3.96	8.6e-05	0.0124	-0.18	-0.18	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62346665	chr20:62386303~62386970:-
LUAD	cis	rs2380205	0.689	rs12359234	ENSG00000232807.2	RP11-536K7.3	-3.96	8.6e-05	0.0124	-0.19	-0.18	Breast cancer;	chr10:5860748	chr10:5934270~5945900:-
LUAD	cis	rs6142102	1	rs6059673	ENSG00000275784.1	RP5-1125A11.6	-3.96	8.6e-05	0.0124	-0.2	-0.18	Skin pigmentation;	chr20:34117755	chr20:33989480~33991818:-
LUAD	cis	rs4474465	1	rs1567889	ENSG00000251323.2	RP11-452H21.4	3.96	8.6e-05	0.0124	0.23	0.18	Alzheimer's disease (survival time);	chr11:78436009	chr11:78423982~78429836:-
LUAD	cis	rs875971	0.545	rs73376401	ENSG00000222364.1	RNU6-96P	-3.96	8.6e-05	0.0124	-0.23	-0.18	Aortic root size;	chr7:66174841	chr7:66395191~66395286:+
LUAD	cis	rs11051970	0.879	rs2728682	ENSG00000274964.1	RP11-817I4.1	-3.96	8.61e-05	0.0124	-0.19	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr12:32427259	chr12:32339368~32340724:+
LUAD	cis	rs11051970	0.879	rs2651379	ENSG00000274964.1	RP11-817I4.1	-3.96	8.61e-05	0.0124	-0.19	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr12:32428844	chr12:32339368~32340724:+
LUAD	cis	rs11051970	0.879	rs2651378	ENSG00000274964.1	RP11-817I4.1	-3.96	8.61e-05	0.0124	-0.19	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr12:32428860	chr12:32339368~32340724:+
LUAD	cis	rs10971721	0.822	rs72725398	ENSG00000260947.1	RP11-384P7.7	3.96	8.61e-05	0.0124	0.37	0.18	Body mass index;	chr9:33875920	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs10971758	ENSG00000260947.1	RP11-384P7.7	3.96	8.61e-05	0.0124	0.37	0.18	Body mass index;	chr9:33876071	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.731	rs72725402	ENSG00000260947.1	RP11-384P7.7	3.96	8.61e-05	0.0124	0.37	0.18	Body mass index;	chr9:33878358	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.731	rs72727303	ENSG00000260947.1	RP11-384P7.7	3.96	8.61e-05	0.0124	0.37	0.18	Body mass index;	chr9:33878378	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs10971763	ENSG00000260947.1	RP11-384P7.7	3.96	8.61e-05	0.0124	0.37	0.18	Body mass index;	chr9:33879779	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs10971764	ENSG00000260947.1	RP11-384P7.7	3.96	8.61e-05	0.0124	0.37	0.18	Body mass index;	chr9:33880102	chr9:33697459~33700986:+
LUAD	cis	rs4713118	0.513	rs149878	ENSG00000216901.1	AL022393.7	3.96	8.61e-05	0.0124	0.22	0.18	Parkinson's disease;	chr6:27910960	chr6:28176188~28176674:+
LUAD	cis	rs7903456	0.648	rs4934290	ENSG00000200253.1	RNU6-529P	3.96	8.61e-05	0.0124	0.22	0.18	Gout;Renal underexcretion gout;	chr10:87040504	chr10:87041238~87041341:-
LUAD	cis	rs7119038	0.818	rs4936444	ENSG00000255239.1	AP002954.6	3.96	8.61e-05	0.0124	0.26	0.18	Sjögren's syndrome;	chr11:118872629	chr11:118688039~118690600:-
LUAD	cis	rs950169	0.919	rs12915589	ENSG00000275120.1	RP11-182J1.17	3.96	8.61e-05	0.0124	0.28	0.18	Schizophrenia;	chr15:84065712	chr15:84599434~84606463:-
LUAD	cis	rs950169	0.959	rs66801143	ENSG00000275120.1	RP11-182J1.17	3.96	8.61e-05	0.0124	0.28	0.18	Schizophrenia;	chr15:84067905	chr15:84599434~84606463:-
LUAD	cis	rs950169	1	rs35648189	ENSG00000275120.1	RP11-182J1.17	3.96	8.61e-05	0.0124	0.28	0.18	Schizophrenia;	chr15:84071996	chr15:84599434~84606463:-
LUAD	cis	rs7824557	0.564	rs1435275	ENSG00000255046.1	RP11-297N6.4	3.96	8.61e-05	0.0124	0.22	0.18	Retinal vascular caliber;	chr8:11378226	chr8:11797928~11802568:-
LUAD	cis	rs28386778	1	rs2665849	ENSG00000240280.5	TCAM1P	-3.96	8.62e-05	0.0124	-0.2	-0.18	Prudent dietary pattern;	chr17:63876310	chr17:63849292~63864379:+
LUAD	cis	rs28386778	1	rs2665851	ENSG00000240280.5	TCAM1P	-3.96	8.62e-05	0.0124	-0.2	-0.18	Prudent dietary pattern;	chr17:63879663	chr17:63849292~63864379:+
LUAD	cis	rs4423214	0.879	rs1792264	ENSG00000226627.1	SHANK2-AS1	3.96	8.62e-05	0.0124	0.21	0.18	Vitamin D levels;	chr11:71439201	chr11:70631094~70635490:+
LUAD	cis	rs4819052	0.808	rs2246697	ENSG00000215447.6	BX322557.10	-3.96	8.62e-05	0.0124	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270084	chr21:45288052~45291738:+
LUAD	cis	rs4819052	0.819	rs7279136	ENSG00000215447.6	BX322557.10	-3.96	8.62e-05	0.0124	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45272372	chr21:45288052~45291738:+
LUAD	cis	rs4819052	0.788	rs4819051	ENSG00000215447.6	BX322557.10	-3.96	8.62e-05	0.0124	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273213	chr21:45288052~45291738:+
LUAD	cis	rs4819052	0.819	rs8134084	ENSG00000215447.6	BX322557.10	-3.96	8.62e-05	0.0124	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273380	chr21:45288052~45291738:+
LUAD	cis	rs911119	0.913	rs6048926	ENSG00000270001.1	RP11-218C14.8	-3.96	8.62e-05	0.0124	-0.26	-0.18	Chronic kidney disease;	chr20:23600350	chr20:23631826~23632316:-
LUAD	cis	rs10463554	0.927	rs12055075	ENSG00000250682.4	LINC00491	3.96	8.62e-05	0.0124	0.22	0.18	Parkinson's disease;	chr5:103044553	chr5:102609156~102671559:-
LUAD	cis	rs9549260	0.664	rs1360719	ENSG00000229456.1	RLIMP1	3.96	8.62e-05	0.0124	0.19	0.18	Red blood cell count;	chr13:40651737	chr13:40618738~40621348:+
LUAD	cis	rs8180040	1	rs295449	ENSG00000271161.1	BOLA2P2	3.96	8.62e-05	0.0124	0.17	0.18	Colorectal cancer;	chr3:47334465	chr3:47499841~47500407:+
LUAD	cis	rs1552244	0.882	rs2130813	ENSG00000180385.7	EMC3-AS1	3.96	8.62e-05	0.0125	0.21	0.18	Alzheimer's disease;	chr3:9997022	chr3:9986893~10006990:+
LUAD	cis	rs35740288	0.77	rs11638379	ENSG00000259407.1	RP11-158M2.3	-3.96	8.62e-05	0.0125	-0.17	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85568059	chr15:85744109~85750281:-
LUAD	cis	rs10995356	0.844	rs10822089	ENSG00000238280.1	RP11-436D10.3	3.96	8.63e-05	0.0125	0.21	0.18	Temperament;	chr10:62935383	chr10:62793562~62805887:-
LUAD	cis	rs2281558	0.876	rs12625157	ENSG00000125804.12	FAM182A	-3.96	8.63e-05	0.0125	-0.25	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25364913	chr20:26054655~26086917:+
LUAD	cis	rs7580658	0.963	rs12463451	ENSG00000236682.1	AC068282.3	-3.96	8.63e-05	0.0125	-0.24	-0.18	Protein C levels;	chr2:127296307	chr2:127389130~127400580:+
LUAD	cis	rs7580658	0.963	rs4233584	ENSG00000236682.1	AC068282.3	-3.96	8.63e-05	0.0125	-0.24	-0.18	Protein C levels;	chr2:127302587	chr2:127389130~127400580:+
LUAD	cis	rs526231	0.764	rs599447	ENSG00000175749.11	EIF3KP1	3.96	8.63e-05	0.0125	0.23	0.18	Primary biliary cholangitis;	chr5:103302154	chr5:103032376~103033031:+
LUAD	cis	rs6964587	0.9	rs4279	ENSG00000188693.7	CYP51A1-AS1	-3.96	8.63e-05	0.0125	-0.21	-0.18	Breast cancer;	chr7:92134814	chr7:92134604~92180725:+
LUAD	cis	rs875971	0.545	rs11767262	ENSG00000222364.1	RNU6-96P	-3.96	8.63e-05	0.0125	-0.23	-0.18	Aortic root size;	chr7:66302237	chr7:66395191~66395286:+
LUAD	cis	rs17695224	0.5	rs4802876	ENSG00000269483.1	AC006272.1	3.96	8.63e-05	0.0125	0.19	0.18	HDL cholesterol;HDL cholesterol levels;	chr19:51831964	chr19:51839924~51843324:-
LUAD	cis	rs853679	0.607	rs13199649	ENSG00000219392.1	RP1-265C24.5	-3.96	8.64e-05	0.0125	-0.39	-0.18	Depression;	chr6:27901014	chr6:28115628~28116551:+
LUAD	cis	rs1862618	0.853	rs832584	ENSG00000271828.1	CTD-2310F14.1	-3.96	8.64e-05	0.0125	-0.25	-0.18	Initial pursuit acceleration;	chr5:56883385	chr5:56927874~56929573:+
LUAD	cis	rs12478296	1	rs56292923	ENSG00000261186.2	RP11-341N2.1	-3.96	8.64e-05	0.0125	-0.3	-0.18	Obesity-related traits;	chr2:242097835	chr2:242087351~242088457:-
LUAD	cis	rs3213758	0.5	rs8054063	ENSG00000275191.1	RP11-36I17.2	-3.96	8.64e-05	0.0125	-0.27	-0.18	Vitiligo (non-segmental);	chr16:53628978	chr16:53628256~53628816:-
LUAD	cis	rs7937682	0.961	rs4936682	ENSG00000230911.1	PPIHP1	3.96	8.64e-05	0.0125	0.24	0.18	Primary sclerosing cholangitis;	chr11:111759019	chr11:112029858~112030367:-
LUAD	cis	rs453301	0.653	rs7016139	ENSG00000233609.3	RP11-62H7.2	-3.96	8.64e-05	0.0125	-0.15	-0.18	Joint mobility (Beighton score);	chr8:9037960	chr8:8961200~8979025:+
LUAD	cis	rs2446066	0.872	rs10876450	ENSG00000257379.1	RP11-793H13.8	-3.96	8.65e-05	0.0125	-0.29	-0.18	Red blood cell count;	chr12:53417250	chr12:53441741~53467528:+
LUAD	cis	rs6942407	0.741	rs35015367	ENSG00000224046.1	AC005076.5	-3.96	8.65e-05	0.0125	-0.21	-0.18	Food allergy;	chr7:87234096	chr7:87151423~87152420:-
LUAD	cis	rs2708977	0.637	rs618454	ENSG00000237510.6	AC008268.2	-3.96	8.65e-05	0.0125	-0.23	-0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96414356	chr2:95789654~95800166:+
LUAD	cis	rs8064024	0.676	rs9926458	ENSG00000267077.1	RP11-127I20.5	3.96	8.66e-05	0.0125	0.21	0.18	Cancer;	chr16:4822627	chr16:4795265~4796532:-
LUAD	cis	rs4227	0.565	rs10438740	ENSG00000233223.2	AC113189.5	-3.96	8.66e-05	0.0125	-0.19	-0.18	IgA nephropathy;	chr17:7569566	chr17:7581964~7584072:-
LUAD	cis	rs6479901	0.841	rs7913332	ENSG00000232075.1	MRPL35P2	-3.96	8.66e-05	0.0125	-0.25	-0.18	Intelligence (multi-trait analysis);	chr10:63293890	chr10:63634317~63634827:-
LUAD	cis	rs9549260	0.755	rs17061450	ENSG00000229456.1	RLIMP1	3.96	8.66e-05	0.0125	0.19	0.18	Red blood cell count;	chr13:40609579	chr13:40618738~40621348:+
LUAD	cis	rs3096299	0.667	rs2965947	ENSG00000261118.1	RP11-104N10.1	3.96	8.66e-05	0.0125	0.18	0.18	Multiple myeloma (IgH translocation);	chr16:89452262	chr16:89492017~89504460:-
LUAD	cis	rs11146838	1	rs11146838	ENSG00000275858.1	RP11-291L22.8	3.96	8.66e-05	0.0125	0.2	0.18	Breast cancer;	chr10:38856846	chr10:38450738~38451069:-
LUAD	cis	rs563519	0.583	rs595004	ENSG00000254905.1	RP11-712L6.7	3.96	8.67e-05	0.0125	0.28	0.18	Heart failure;	chr11:126150215	chr11:126292922~126294254:-
LUAD	cis	rs4776997	0.559	rs12902904	ENSG00000270964.1	RP11-502I4.3	3.96	8.67e-05	0.0125	0.22	0.18	Verbal declarative memory;	chr15:67784195	chr15:67541072~67542604:-
LUAD	cis	rs9291683	0.552	rs11736410	ENSG00000250413.1	RP11-448G15.1	-3.96	8.67e-05	0.0125	-0.22	-0.18	Bone mineral density;	chr4:10015617	chr4:10006482~10009725:+
LUAD	cis	rs9903692	0.505	rs208008	ENSG00000278765.1	RP5-890E16.5	-3.96	8.67e-05	0.0125	-0.32	-0.18	Pulse pressure;	chr17:48153476	chr17:48066704~48067293:-
LUAD	cis	rs2295359	1	rs9729046	ENSG00000275678.1	RP4-547N15.3	-3.96	8.67e-05	0.0125	-0.18	-0.18	Psoriasis;	chr1:67141399	chr1:67121605~67123956:-
LUAD	cis	rs9376098	0.825	rs6922541	ENSG00000232876.1	CTA-212D2.2	-3.96	8.67e-05	0.0125	-0.21	-0.18	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135161681	chr6:135055033~135060550:+
LUAD	cis	rs7829975	0.606	rs6422352	ENSG00000253981.4	ALG1L13P	-3.96	8.67e-05	0.0125	-0.2	-0.18	Mood instability;	chr8:8936683	chr8:8236003~8244667:-
LUAD	cis	rs9487094	1	rs9487094	ENSG00000260273.1	RP11-425D10.10	3.96	8.68e-05	0.0125	0.23	0.18	Height;	chr6:109420812	chr6:109382795~109383666:+
LUAD	cis	rs7772486	0.79	rs9376971	ENSG00000235652.6	RP11-545I5.3	-3.96	8.68e-05	0.0125	-0.18	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145938369	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.79	rs4314514	ENSG00000235652.6	RP11-545I5.3	-3.96	8.68e-05	0.0125	-0.18	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145938874	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.72	rs9403757	ENSG00000235652.6	RP11-545I5.3	-3.96	8.68e-05	0.0125	-0.18	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145940135	chr6:145799409~145886585:+
LUAD	cis	rs4849121	0.535	rs11892748	ENSG00000235721.1	AC013268.3	-3.96	8.68e-05	0.0125	-0.2	-0.18	IgA nephropathy;	chr2:110843417	chr2:110007675~110010783:+
LUAD	cis	rs1401999	0.966	rs2313216	ENSG00000223882.1	ABCC5-AS1	-3.96	8.68e-05	0.0125	-0.18	-0.18	Anterior chamber depth;	chr3:183919463	chr3:184006338~184011419:+
LUAD	cis	rs42490	0.553	rs380425	ENSG00000251136.7	RP11-37B2.1	-3.96	8.68e-05	0.0125	-0.2	-0.18	Leprosy;	chr8:89849814	chr8:89609409~89757727:-
LUAD	cis	rs7829975	0.606	rs891570	ENSG00000233609.3	RP11-62H7.2	-3.96	8.68e-05	0.0125	-0.14	-0.18	Mood instability;	chr8:8936944	chr8:8961200~8979025:+
LUAD	cis	rs6951245	0.872	rs74360401	ENSG00000199023.2	MIR339	-3.96	8.68e-05	0.0125	-0.32	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1027767	chr7:1022935~1023045:-
LUAD	cis	rs7829975	0.681	rs2271342	ENSG00000233609.3	RP11-62H7.2	3.96	8.68e-05	0.0125	0.15	0.18	Mood instability;	chr8:8786428	chr8:8961200~8979025:+
LUAD	cis	rs9646944	0.501	rs10176820	ENSG00000234389.1	AC007278.3	3.96	8.69e-05	0.0125	0.2	0.18	Blood protein levels;	chr2:102437960	chr2:102438713~102440475:+
LUAD	cis	rs1908814	0.516	rs4841641	ENSG00000255046.1	RP11-297N6.4	-3.96	8.69e-05	0.0125	-0.22	-0.18	Neuroticism;	chr8:11940718	chr8:11797928~11802568:-
LUAD	cis	rs240993	0.812	rs2025269	ENSG00000271789.1	RP5-1112D6.7	-3.96	8.69e-05	0.0125	-0.22	-0.18	Inflammatory skin disease;Psoriasis;	chr6:111489237	chr6:111297126~111298510:+
LUAD	cis	rs453301	0.658	rs9650616	ENSG00000233609.3	RP11-62H7.2	-3.96	8.69e-05	0.0125	-0.15	-0.18	Joint mobility (Beighton score);	chr8:9011689	chr8:8961200~8979025:+
LUAD	cis	rs8028182	0.636	rs62027209	ENSG00000260269.4	CTD-2323K18.1	-3.96	8.69e-05	0.0125	-0.25	-0.18	Sudden cardiac arrest;	chr15:75579285	chr15:75527150~75601205:-
LUAD	cis	rs4795519	0.736	rs57273338	ENSG00000266313.1	RP11-173M1.4	3.96	8.69e-05	0.0125	0.22	0.18	Chronic myeloid leukemia;	chr17:27148606	chr17:27333256~27348491:+
LUAD	cis	rs4795519	1	rs11652672	ENSG00000266313.1	RP11-173M1.4	3.96	8.69e-05	0.0125	0.22	0.18	Chronic myeloid leukemia;	chr17:27149541	chr17:27333256~27348491:+
LUAD	cis	rs8031584	1	rs35239376	ENSG00000259845.1	HERC2P10	3.96	8.69e-05	0.0125	0.22	0.18	Huntington's disease progression;	chr15:30998335	chr15:30815271~30844153:+
LUAD	cis	rs7339483	0.85	rs10424627	ENSG00000268058.1	BNIP3P40	-3.96	8.69e-05	0.0125	-0.35	-0.18	Discordance in emotional problems in monozygotic twins;	chr19:24270319	chr19:24098425~24098980:-
LUAD	cis	rs62355901	0.505	rs72758017	ENSG00000271828.1	CTD-2310F14.1	3.96	8.69e-05	0.0125	0.38	0.18	Breast cancer;	chr5:56797732	chr5:56927874~56929573:+
LUAD	cis	rs3219474	0.614	rs114562368	ENSG00000234329.1	RP11-767N6.2	3.96	8.69e-05	0.0125	0.29	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:45433506	chr1:45651039~45651826:-
LUAD	cis	rs7615952	0.599	rs2333408	ENSG00000241288.6	RP11-379B18.5	-3.96	8.7e-05	0.0125	-0.22	-0.18	Blood pressure (smoking interaction);	chr3:126013255	chr3:125827238~125916384:-
LUAD	cis	rs4763879	0.778	rs1056151	ENSG00000278635.1	CTD-2318O12.1	3.96	8.7e-05	0.0125	0.16	0.18	Type 1 diabetes;	chr12:9698427	chr12:9415641~9416718:+
LUAD	cis	rs6001482	0.662	rs6001526	ENSG00000223350.2	IGLV9-49	-3.96	8.7e-05	0.0125	-0.17	-0.18	Diastolic blood pressure;	chr22:22234518	chr22:22343187~22343732:+
LUAD	cis	rs875971	0.66	rs1860468	ENSG00000273142.1	RP11-458F8.4	3.96	8.7e-05	0.0125	0.12	0.18	Aortic root size;	chr7:66642265	chr7:66902857~66906297:+
LUAD	cis	rs17695224	0.5	rs4802877	ENSG00000269483.1	AC006272.1	3.96	8.7e-05	0.0125	0.19	0.18	HDL cholesterol;HDL cholesterol levels;	chr19:51831991	chr19:51839924~51843324:-
LUAD	cis	rs17695224	0.52	rs4801898	ENSG00000269483.1	AC006272.1	3.96	8.7e-05	0.0125	0.19	0.18	HDL cholesterol;HDL cholesterol levels;	chr19:51832064	chr19:51839924~51843324:-
LUAD	cis	rs17695224	0.545	rs17761960	ENSG00000269483.1	AC006272.1	3.96	8.7e-05	0.0125	0.19	0.18	HDL cholesterol;HDL cholesterol levels;	chr19:51832275	chr19:51839924~51843324:-
LUAD	cis	rs2115630	1	rs1030863	ENSG00000259728.4	LINC00933	-3.96	8.7e-05	0.0125	-0.22	-0.18	P wave terminal force;	chr15:84739404	chr15:84570649~84580175:+
LUAD	cis	rs13113518	0.557	rs13142096	ENSG00000273257.1	RP11-177J6.1	3.96	8.7e-05	0.0125	0.21	0.18	Height;	chr4:55566291	chr4:55387949~55388271:+
LUAD	cis	rs1555322	0.505	rs591590	ENSG00000279253.1	RP4-614O4.13	3.96	8.7e-05	0.0125	0.22	0.18	Attention deficit hyperactivity disorder;	chr20:35278225	chr20:35262727~35264187:-
LUAD	cis	rs7615952	0.932	rs13314869	ENSG00000241288.6	RP11-379B18.5	-3.96	8.71e-05	0.0126	-0.23	-0.18	Blood pressure (smoking interaction);	chr3:125925826	chr3:125827238~125916384:-
LUAD	cis	rs12935418	0.616	rs2549863	ENSG00000261061.1	RP11-303E16.2	3.96	8.71e-05	0.0126	0.19	0.18	Mean corpuscular volume;	chr16:80995762	chr16:81030770~81031485:+
LUAD	cis	rs2901790	0.82	rs3181139	ENSG00000223387.5	RP11-408H1.3	-3.96	8.71e-05	0.0126	-0.24	-0.18	Gait speed in old age;	chr3:172510115	chr3:172560888~172595607:-
LUAD	cis	rs4604732	0.642	rs10925047	ENSG00000227135.1	GCSAML-AS1	-3.96	8.71e-05	0.0126	-0.25	-0.18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247476841	chr1:247524679~247526752:-
LUAD	cis	rs7107174	0.892	rs10899482	ENSG00000251323.2	RP11-452H21.4	3.96	8.71e-05	0.0126	0.22	0.18	Testicular germ cell tumor;	chr11:78349035	chr11:78423982~78429836:-
LUAD	cis	rs10129255	0.957	rs12590799	ENSG00000211947.2	IGHV3-21	-3.96	8.72e-05	0.0126	-0.12	-0.18	Kawasaki disease;	chr14:106779713	chr14:106235064~106235594:-
LUAD	cis	rs10829156	0.699	rs4747353	ENSG00000240291.1	RP11-499P20.2	3.96	8.72e-05	0.0126	0.16	0.18	Sudden cardiac arrest;	chr10:18548028	chr10:18513115~18545651:-
LUAD	cis	rs4142110	0.628	rs180870	ENSG00000271216.1	LINC01050	-3.96	8.72e-05	0.0126	-0.21	-0.18	Nephrolithiasis;	chr13:42219343	chr13:42810366~42812562:-
LUAD	cis	rs728616	0.702	rs78734698	ENSG00000234382.2	RP11-40F6.1	-3.96	8.72e-05	0.0126	-0.44	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79996693	chr10:80233664~80245367:+
LUAD	cis	rs2337406	0.539	rs2583292	ENSG00000223648.3	IGHV3-64	3.96	8.72e-05	0.0126	0.2	0.18	Alzheimer's disease (late onset);	chr14:106649040	chr14:106643132~106658258:-
LUAD	cis	rs853679	0.607	rs66868086	ENSG00000219392.1	RP1-265C24.5	-3.96	8.72e-05	0.0126	-0.4	-0.18	Depression;	chr6:27898124	chr6:28115628~28116551:+
LUAD	cis	rs6687758	0.687	rs17011146	ENSG00000227925.1	RP11-191N8.2	3.96	8.73e-05	0.0126	0.24	0.18	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221940306	chr1:221827666~221840666:-
LUAD	cis	rs7617773	0.815	rs6793150	ENSG00000199476.1	Y_RNA	-3.96	8.73e-05	0.0126	-0.24	-0.18	Coronary artery disease;	chr3:48310070	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.78	rs6793239	ENSG00000199476.1	Y_RNA	-3.96	8.73e-05	0.0126	-0.24	-0.18	Coronary artery disease;	chr3:48310128	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.78	rs6782166	ENSG00000199476.1	Y_RNA	-3.96	8.73e-05	0.0126	-0.24	-0.18	Coronary artery disease;	chr3:48310193	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.78	rs4130522	ENSG00000199476.1	Y_RNA	-3.96	8.73e-05	0.0126	-0.24	-0.18	Coronary artery disease;	chr3:48310823	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.78	rs13081169	ENSG00000199476.1	Y_RNA	-3.96	8.73e-05	0.0126	-0.24	-0.18	Coronary artery disease;	chr3:48315307	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.643	rs78159520	ENSG00000199476.1	Y_RNA	-3.96	8.73e-05	0.0126	-0.24	-0.18	Coronary artery disease;	chr3:48307533	chr3:48288587~48288694:+
LUAD	cis	rs7561273	0.609	rs1056122	ENSG00000242628.4	AC009228.1	-3.96	8.73e-05	0.0126	-0.22	-0.18	Quantitative traits;	chr2:24119635	chr2:24214381~24221516:+
LUAD	cis	rs73186030	0.764	rs66508963	ENSG00000272758.4	RP11-299J3.8	3.96	8.74e-05	0.0126	0.24	0.18	Serum parathyroid hormone levels;	chr3:122365682	chr3:122416207~122443180:+
LUAD	cis	rs2832077	0.689	rs2832055	ENSG00000232855.5	AF131217.1	-3.96	8.74e-05	0.0126	-0.18	-0.18	Cognitive test performance;	chr21:28760060	chr21:28439346~28674848:-
LUAD	cis	rs494459	0.504	rs7929520	ENSG00000278376.1	RP11-158I9.8	-3.96	8.74e-05	0.0126	-0.19	-0.18	Height;	chr11:118859432	chr11:118791254~118793137:+
LUAD	cis	rs62025270	0.806	rs62025266	ENSG00000259416.2	RP11-158M2.5	-3.96	8.74e-05	0.0126	-0.23	-0.18	Idiopathic pulmonary fibrosis;	chr15:85755217	chr15:85754941~85756237:-
LUAD	cis	rs9291683	0.588	rs2240722	ENSG00000250413.1	RP11-448G15.1	-3.96	8.74e-05	0.0126	-0.22	-0.18	Bone mineral density;	chr4:10019133	chr4:10006482~10009725:+
LUAD	cis	rs4713118	0.615	rs57252182	ENSG00000280107.1	AL022393.9	-3.96	8.74e-05	0.0126	-0.21	-0.18	Parkinson's disease;	chr6:27752470	chr6:28170845~28172521:+
LUAD	cis	rs950880	0.767	rs6543119	ENSG00000234389.1	AC007278.3	-3.96	8.74e-05	0.0126	-0.16	-0.18	Serum protein levels (sST2);	chr2:102346612	chr2:102438713~102440475:+
LUAD	cis	rs950880	0.767	rs13017455	ENSG00000234389.1	AC007278.3	-3.96	8.74e-05	0.0126	-0.16	-0.18	Serum protein levels (sST2);	chr2:102348282	chr2:102438713~102440475:+
LUAD	cis	rs62246343	0.605	rs3898760	ENSG00000254485.4	RP11-380O24.1	3.96	8.75e-05	0.0126	0.23	0.18	Fibrinogen levels;	chr3:9453435	chr3:9292588~9363303:-
LUAD	cis	rs4908768	0.501	rs6577513	ENSG00000270282.1	RP5-1115A15.2	3.96	8.75e-05	0.0126	0.19	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8642694	chr1:8512653~8513021:+
LUAD	cis	rs8014252	1	rs8015163	ENSG00000259158.2	ADAM20P1	-3.96	8.75e-05	0.0126	-0.28	-0.18	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70463845	chr14:70468881~70483756:-
LUAD	cis	rs115344852	0.585	rs1016069	ENSG00000216901.1	AL022393.7	3.96	8.75e-05	0.0126	0.23	0.18	Epithelial ovarian cancer;	chr6:28472641	chr6:28176188~28176674:+
LUAD	cis	rs2255336	0.81	rs10772267	ENSG00000245648.1	RP11-277P12.20	3.96	8.75e-05	0.0126	0.31	0.18	Blood protein levels;	chr12:10357969	chr12:10363769~10398506:+
LUAD	cis	rs2255336	0.81	rs10743886	ENSG00000245648.1	RP11-277P12.20	3.96	8.75e-05	0.0126	0.31	0.18	Blood protein levels;	chr12:10359063	chr12:10363769~10398506:+
LUAD	cis	rs365302	1	rs444245	ENSG00000235086.1	FNDC1-IT1	3.96	8.75e-05	0.0126	0.24	0.18	Coronary heart disease;	chr6:159221931	chr6:159240786~159243329:+
LUAD	cis	rs7017914	0.652	rs441890	ENSG00000246366.5	RP11-382J12.1	3.96	8.75e-05	0.0126	0.16	0.18	Bone mineral density;	chr8:70652432	chr8:70608577~70663279:+
LUAD	cis	rs6687821	0.774	rs11161891	ENSG00000267734.1	RP4-604K5.3	3.96	8.75e-05	0.0126	0.25	0.18	Yeast infection;	chr1:86791615	chr1:86932199~86934891:-
LUAD	cis	rs62481355	0.68	rs10487482	ENSG00000224138.1	AC000123.4	-3.96	8.75e-05	0.0126	-0.17	-0.18	Type 2 diabetes;	chr7:127433905	chr7:127350128~127351523:+
LUAD	cis	rs1061377	0.513	rs2566162	ENSG00000249685.1	RP11-360F5.3	3.96	8.75e-05	0.0126	0.25	0.18	Uric acid levels;	chr4:39126453	chr4:39133913~39135608:+
LUAD	cis	rs7714584	1	rs11950957	ENSG00000197083.10	ZNF300P1	3.96	8.76e-05	0.0126	0.33	0.18	Crohn's disease;	chr5:150874352	chr5:150930645~150946289:-
LUAD	cis	rs7714584	0.793	rs11958146	ENSG00000197083.10	ZNF300P1	3.96	8.76e-05	0.0126	0.33	0.18	Crohn's disease;	chr5:150874596	chr5:150930645~150946289:-
LUAD	cis	rs7714584	1	rs10061105	ENSG00000197083.10	ZNF300P1	3.96	8.76e-05	0.0126	0.33	0.18	Crohn's disease;	chr5:150875623	chr5:150930645~150946289:-
LUAD	cis	rs7404843	0.777	rs6498552	ENSG00000263335.1	AF001548.5	-3.96	8.76e-05	0.0126	-0.37	-0.18	Testicular germ cell tumor;	chr16:15446044	chr16:15726674~15732993:+
LUAD	cis	rs7404843	0.85	rs6498553	ENSG00000263335.1	AF001548.5	-3.96	8.76e-05	0.0126	-0.37	-0.18	Testicular germ cell tumor;	chr16:15446045	chr16:15726674~15732993:+
LUAD	cis	rs7429990	0.965	rs4858880	ENSG00000228638.1	FCF1P2	3.96	8.76e-05	0.0126	0.21	0.18	Educational attainment (years of education);	chr3:48062959	chr3:48290793~48291375:-
LUAD	cis	rs5015933	0.815	rs1333055	ENSG00000232630.1	PRPS1P2	-3.96	8.76e-05	0.0126	-0.17	-0.18	Body mass index;	chr9:125307948	chr9:125150653~125151589:+
LUAD	cis	rs2337406	0.714	rs2337463	ENSG00000211972.2	IGHV3-66	3.96	8.76e-05	0.0126	0.19	0.18	Alzheimer's disease (late onset);	chr14:106816066	chr14:106675017~106675544:-
LUAD	cis	rs10510102	0.516	rs11200301	ENSG00000276742.1	RP11-500G22.4	3.96	8.76e-05	0.0126	0.29	0.18	Breast cancer;	chr10:121977976	chr10:121956782~121957098:+
LUAD	cis	rs77204473	0.557	rs7111854	ENSG00000280143.1	AP000892.6	-3.96	8.76e-05	0.0126	-0.3	-0.18	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116906110	chr11:117204967~117210292:+
LUAD	cis	rs7647973	0.6	rs35174559	ENSG00000225399.4	RP11-3B7.1	3.96	8.76e-05	0.0126	0.23	0.18	Menarche (age at onset);	chr3:49250326	chr3:49260085~49261316:+
LUAD	cis	rs10863681	0.738	rs12140558	ENSG00000227925.1	RP11-191N8.2	3.96	8.77e-05	0.0126	0.21	0.18	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222100978	chr1:221827666~221840666:-
LUAD	cis	rs12474201	0.619	rs17821827	ENSG00000279254.1	RP11-536C12.1	-3.96	8.77e-05	0.0126	-0.22	-0.18	Height;	chr2:46691543	chr2:46668870~46670778:+
LUAD	cis	rs4713118	0.824	rs9468225	ENSG00000280107.1	AL022393.9	-3.96	8.77e-05	0.0126	-0.22	-0.18	Parkinson's disease;	chr6:27777940	chr6:28170845~28172521:+
LUAD	cis	rs5015933	0.815	rs12553785	ENSG00000232630.1	PRPS1P2	-3.96	8.77e-05	0.0126	-0.17	-0.18	Body mass index;	chr9:125314262	chr9:125150653~125151589:+
LUAD	cis	rs1864585	0.52	rs17776946	ENSG00000255046.1	RP11-297N6.4	3.96	8.77e-05	0.0126	0.25	0.18	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr8:10825164	chr8:11797928~11802568:-
LUAD	cis	rs4374383	0.962	rs6541998	ENSG00000207383.1	Y_RNA	-3.96	8.77e-05	0.0126	-0.22	-0.18	Hepatitis C induced liver fibrosis;	chr2:112027660	chr2:112579484~112579584:-
LUAD	cis	rs4925386	1	rs6121990	ENSG00000273619.1	RP5-908M14.9	3.96	8.77e-05	0.0126	0.16	0.18	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62344207	chr20:62386303~62386970:-
LUAD	cis	rs7712401	0.755	rs965821	ENSG00000249996.1	RP11-359P5.1	3.96	8.77e-05	0.0126	0.21	0.18	Mean platelet volume;	chr5:122802013	chr5:123036271~123054667:+
LUAD	cis	rs1154275	0.549	rs13082976	ENSG00000242770.2	RP11-180K7.1	3.96	8.77e-05	0.0126	0.18	0.18	Takotsubo syndrome;	chr3:112786839	chr3:112802478~112812819:+
LUAD	cis	rs1154275	0.524	rs6784760	ENSG00000242770.2	RP11-180K7.1	3.96	8.77e-05	0.0126	0.18	0.18	Takotsubo syndrome;	chr3:112787877	chr3:112802478~112812819:+
LUAD	cis	rs11051970	0.879	rs2171373	ENSG00000274964.1	RP11-817I4.1	-3.96	8.78e-05	0.0126	-0.19	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr12:32422843	chr12:32339368~32340724:+
LUAD	cis	rs11051970	0.879	rs2243815	ENSG00000274964.1	RP11-817I4.1	-3.96	8.78e-05	0.0126	-0.19	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr12:32423224	chr12:32339368~32340724:+
LUAD	cis	rs2731006	0.592	rs2730997	ENSG00000257114.2	RP11-25I15.3	3.96	8.78e-05	0.0126	0.28	0.18	Panic disorder;	chr12:42785916	chr12:42692216~42717119:+
LUAD	cis	rs2638953	0.924	rs12146881	ENSG00000278733.1	RP11-425D17.1	-3.96	8.78e-05	0.0126	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28198436	chr12:28185625~28186190:-
LUAD	cis	rs13113518	1	rs2279458	ENSG00000272969.1	RP11-528I4.2	3.96	8.78e-05	0.0126	0.19	0.18	Height;	chr4:55562653	chr4:55547112~55547889:+
LUAD	cis	rs1075265	0.704	rs10181999	ENSG00000272156.1	RP11-477N3.1	-3.96	8.78e-05	0.0126	-0.21	-0.18	Chronotype;Morning vs. evening chronotype;	chr2:54025360	chr2:54082554~54085066:+
LUAD	cis	rs860295	0.702	rs11264386	ENSG00000225855.5	RUSC1-AS1	3.96	8.78e-05	0.0126	0.13	0.18	Body mass index;	chr1:155589379	chr1:155316863~155324176:-
LUAD	cis	rs13434995	0.513	rs62303711	ENSG00000273257.1	RP11-177J6.1	-3.96	8.79e-05	0.0127	-0.24	-0.18	Adiponectin levels;	chr4:55458325	chr4:55387949~55388271:+
LUAD	cis	rs137603	0.623	rs137657	ENSG00000225450.1	RP3-508I15.14	-3.96	8.79e-05	0.0127	-0.16	-0.18	Primary biliary cholangitis;	chr22:39337237	chr22:38739003~38749041:+
LUAD	cis	rs5850	0.602	rs1005786	ENSG00000230042.1	AK3P3	-3.96	8.79e-05	0.0127	-0.22	-0.18	Blood protein levels;	chr7:23106218	chr7:23129178~23129841:+
LUAD	cis	rs690037	0.528	rs568833	ENSG00000271964.1	RP11-415F23.2	-3.96	8.79e-05	0.0127	-0.14	-0.18	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16326329	chr3:16314439~16314987:+
LUAD	cis	rs853679	0.517	rs9380047	ENSG00000226314.6	ZNF192P1	-3.96	8.79e-05	0.0127	-0.24	-0.18	Depression;	chr6:28070115	chr6:28161781~28169594:+
LUAD	cis	rs9910055	0.529	rs575798	ENSG00000267080.4	ASB16-AS1	3.96	8.79e-05	0.0127	0.17	0.18	Total body bone mineral density;	chr17:44104428	chr17:44175973~44186717:-
LUAD	cis	rs9910055	0.529	rs408282	ENSG00000267080.4	ASB16-AS1	3.96	8.79e-05	0.0127	0.17	0.18	Total body bone mineral density;	chr17:44104899	chr17:44175973~44186717:-
LUAD	cis	rs9980	0.553	rs4783719	ENSG00000226232.7	RP11-419C5.2	3.96	8.79e-05	0.0127	0.16	0.18	Blood osmolality (transformed sodium);	chr16:69525412	chr16:69976388~69996188:-
LUAD	cis	rs763121	0.819	rs4560233	ENSG00000225450.1	RP3-508I15.14	-3.96	8.8e-05	0.0127	-0.17	-0.18	Menopause (age at onset);	chr22:38586437	chr22:38739003~38749041:+
LUAD	cis	rs853679	0.607	rs35001169	ENSG00000219392.1	RP1-265C24.5	-3.96	8.8e-05	0.0127	-0.4	-0.18	Depression;	chr6:28219854	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.546	rs35656932	ENSG00000219392.1	RP1-265C24.5	-3.96	8.8e-05	0.0127	-0.4	-0.18	Depression;	chr6:28223510	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.607	rs34243448	ENSG00000219392.1	RP1-265C24.5	-3.96	8.8e-05	0.0127	-0.4	-0.18	Depression;	chr6:28225324	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.607	rs13204012	ENSG00000219392.1	RP1-265C24.5	-3.96	8.8e-05	0.0127	-0.4	-0.18	Depression;	chr6:28233753	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.607	rs13205211	ENSG00000219392.1	RP1-265C24.5	-3.96	8.8e-05	0.0127	-0.4	-0.18	Depression;	chr6:28235278	chr6:28115628~28116551:+
LUAD	cis	rs10863681	0.664	rs11118934	ENSG00000238042.4	RP11-815M8.1	3.96	8.8e-05	0.0127	0.21	0.18	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222070113	chr1:221880981~221978523:-
LUAD	cis	rs10863681	0.713	rs12134885	ENSG00000238042.4	RP11-815M8.1	3.96	8.8e-05	0.0127	0.21	0.18	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222071038	chr1:221880981~221978523:-
LUAD	cis	rs17597773	0.527	rs2484698	ENSG00000238078.1	LINC01352	3.96	8.8e-05	0.0127	0.19	0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220912723	chr1:220829255~220832429:+
LUAD	cis	rs8141529	0.753	rs5752813	ENSG00000272858.1	CTA-292E10.8	-3.95	8.8e-05	0.0127	-0.2	-0.18	Lymphocyte counts;	chr22:28830582	chr22:28814914~28815662:+
LUAD	cis	rs1167827	0.71	rs1167836	ENSG00000165178.9	NCF1C	3.95	8.81e-05	0.0127	0.15	0.18	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75539580	chr7:75156639~75172044:-
LUAD	cis	rs4853525	0.651	rs1921908	ENSG00000235852.1	AC005540.3	3.95	8.81e-05	0.0127	0.22	0.18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190870481	chr2:190880797~190882059:-
LUAD	cis	rs2098713	0.569	rs56264101	ENSG00000250155.1	CTD-2353F22.1	3.95	8.81e-05	0.0127	0.2	0.18	Telomere length;	chr5:37540792	chr5:36666214~36725195:-
LUAD	cis	rs2098713	0.569	rs55716037	ENSG00000250155.1	CTD-2353F22.1	3.95	8.81e-05	0.0127	0.2	0.18	Telomere length;	chr5:37540805	chr5:36666214~36725195:-
LUAD	cis	rs3770081	1	rs60479377	ENSG00000273080.1	RP11-301O19.1	-3.95	8.81e-05	0.0127	-0.41	-0.18	Facial emotion recognition (sad faces);	chr2:86056825	chr2:86195590~86196049:+
LUAD	cis	rs3020736	0.5	rs4147641	ENSG00000205702.9	CYP2D7	-3.95	8.81e-05	0.0127	-0.14	-0.18	Autism spectrum disorder or schizophrenia;	chr22:42086498	chr22:42140203~42144577:-
LUAD	cis	rs1023500	0.507	rs6002600	ENSG00000205702.9	CYP2D7	-3.95	8.81e-05	0.0127	-0.14	-0.18	Schizophrenia;	chr22:42092902	chr22:42140203~42144577:-
LUAD	cis	rs16944613	0.541	rs6496688	ENSG00000259212.1	CTD-3065B20.2	3.95	8.81e-05	0.0127	0.29	0.18	Colorectal cancer;	chr15:90547149	chr15:90595840~90596447:-
LUAD	cis	rs116095464	0.558	rs6882584	ENSG00000248925.1	CTD-2083E4.6	3.95	8.81e-05	0.0127	0.3	0.18	Breast cancer;	chr5:223296	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs3213838	ENSG00000248925.1	CTD-2083E4.6	3.95	8.81e-05	0.0127	0.3	0.18	Breast cancer;	chr5:223775	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs6555052	ENSG00000248925.1	CTD-2083E4.6	3.95	8.81e-05	0.0127	0.3	0.18	Breast cancer;	chr5:224153	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs61689490	ENSG00000248925.1	CTD-2083E4.6	3.95	8.81e-05	0.0127	0.3	0.18	Breast cancer;	chr5:224789	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs61492827	ENSG00000248925.1	CTD-2083E4.6	3.95	8.81e-05	0.0127	0.3	0.18	Breast cancer;	chr5:225659	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs56342538	ENSG00000248925.1	CTD-2083E4.6	3.95	8.81e-05	0.0127	0.3	0.18	Breast cancer;	chr5:225681	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs6555055	ENSG00000248925.1	CTD-2083E4.6	3.95	8.81e-05	0.0127	0.3	0.18	Breast cancer;	chr5:226045	chr5:269858~271516:-
LUAD	cis	rs875971	0.522	rs1617484	ENSG00000273142.1	RP11-458F8.4	-3.95	8.82e-05	0.0127	-0.12	-0.18	Aortic root size;	chr7:65998108	chr7:66902857~66906297:+
LUAD	cis	rs17767294	0.612	rs9461424	ENSG00000280107.1	AL022393.9	-3.95	8.82e-05	0.0127	-0.33	-0.18	Parkinson's disease;	chr6:27951623	chr6:28170845~28172521:+
LUAD	cis	rs3020736	0.5	rs6002601	ENSG00000205702.9	CYP2D7	-3.95	8.82e-05	0.0127	-0.14	-0.18	Autism spectrum disorder or schizophrenia;	chr22:42093054	chr22:42140203~42144577:-
LUAD	cis	rs6951245	0.706	rs1133116	ENSG00000199023.2	MIR339	-3.95	8.82e-05	0.0127	-0.3	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1155579	chr7:1022935~1023045:-
LUAD	cis	rs8014204	0.804	rs7154845	ENSG00000279594.1	RP11-950C14.10	3.95	8.82e-05	0.0127	0.2	0.18	Caffeine consumption;	chr14:74781043	chr14:75011269~75012851:-
LUAD	cis	rs853679	0.517	rs1947862	ENSG00000280107.1	AL022393.9	-3.95	8.82e-05	0.0127	-0.24	-0.18	Depression;	chr6:28137418	chr6:28170845~28172521:+
LUAD	cis	rs6088580	0.634	rs6059829	ENSG00000276073.1	RP5-1125A11.7	-3.95	8.83e-05	0.0127	-0.17	-0.18	Glomerular filtration rate (creatinine);	chr20:34429268	chr20:33985617~33988989:-
LUAD	cis	rs6088580	0.602	rs6059834	ENSG00000276073.1	RP5-1125A11.7	-3.95	8.83e-05	0.0127	-0.17	-0.18	Glomerular filtration rate (creatinine);	chr20:34431493	chr20:33985617~33988989:-
LUAD	cis	rs17596685	1	rs9525645	ENSG00000271216.1	LINC01050	3.95	8.83e-05	0.0127	0.25	0.18	C-reactive protein levels;	chr13:42585789	chr13:42810366~42812562:-
LUAD	cis	rs3018712	0.526	rs6591351	ENSG00000227620.4	ALG1L8P	-3.95	8.83e-05	0.0127	-0.24	-0.18	Total body bone mineral density;	chr11:68720040	chr11:67785273~67792335:+
LUAD	cis	rs2713579	0.512	rs2659699	ENSG00000239405.1	TMED10P2	-3.95	8.83e-05	0.0127	-0.25	-0.18	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr3:128506688	chr3:128538020~128538631:+
LUAD	cis	rs6951245	1	rs78628466	ENSG00000199023.2	MIR339	-3.95	8.83e-05	0.0127	-0.32	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1028817	chr7:1022935~1023045:-
LUAD	cis	rs1355223	1	rs11601205	ENSG00000271369.1	RP11-350D17.3	-3.95	8.83e-05	0.0127	-0.21	-0.18	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34746932	chr11:34709600~34710161:+
LUAD	cis	rs4934494	0.677	rs7905163	ENSG00000232936.4	RP11-80H5.2	3.95	8.83e-05	0.0127	0.24	0.18	Red blood cell count;	chr10:89624173	chr10:89645282~89650667:+
LUAD	cis	rs4795519	0.71	rs11654238	ENSG00000266313.1	RP11-173M1.4	3.95	8.83e-05	0.0127	0.23	0.18	Chronic myeloid leukemia;	chr17:27175379	chr17:27333256~27348491:+
LUAD	cis	rs6487679	0.526	rs972111	ENSG00000111788.10	RP11-22B23.1	3.95	8.83e-05	0.0127	0.16	0.18	Non-alcoholic fatty liver disease histology (AST);	chr12:9221777	chr12:9277235~9313241:+
LUAD	cis	rs2742234	0.794	rs17153156	ENSG00000273008.1	RP11-351D16.3	3.95	8.83e-05	0.0127	0.18	0.18	Hirschsprung disease;	chr10:43209189	chr10:43136824~43138334:-
LUAD	cis	rs5742933	0.857	rs13021611	ENSG00000253559.1	OSGEPL1-AS1	3.95	8.83e-05	0.0127	0.22	0.18	Ferritin levels;	chr2:189700038	chr2:189762704~189765556:+
LUAD	cis	rs12922040	1	rs12922040	ENSG00000279866.1	CTB-193M12.4	3.95	8.83e-05	0.0127	0.18	0.18	Serum uric acid levels in response to allopurinol in gout;	chr16:15775609	chr16:15704410~15705984:+
LUAD	cis	rs1577917	0.629	rs9450285	ENSG00000220563.1	PKMP3	3.95	8.84e-05	0.0127	0.16	0.18	Response to antipsychotic treatment;	chr6:85498378	chr6:85659892~85660606:-
LUAD	cis	rs17772222	1	rs60310240	ENSG00000258789.1	RP11-507K2.3	-3.95	8.84e-05	0.0127	-0.24	-0.18	Coronary artery calcification;	chr14:88356365	chr14:88551597~88552493:+
LUAD	cis	rs848490	0.814	rs11770844	ENSG00000214293.7	APTR	3.95	8.84e-05	0.0127	0.23	0.18	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77598997	chr7:77657660~77696265:-
LUAD	cis	rs17772222	0.958	rs2274737	ENSG00000258789.1	RP11-507K2.3	-3.95	8.84e-05	0.0127	-0.24	-0.18	Coronary artery calcification;	chr14:88469307	chr14:88551597~88552493:+
LUAD	cis	rs526231	0.543	rs27361	ENSG00000250682.4	LINC00491	3.95	8.84e-05	0.0127	0.22	0.18	Primary biliary cholangitis;	chr5:103213266	chr5:102609156~102671559:-
LUAD	cis	rs847577	0.722	rs7790120	ENSG00000272950.1	RP11-307C18.1	3.95	8.84e-05	0.0127	0.22	0.18	Breast cancer;	chr7:98083519	chr7:98322853~98323430:+
LUAD	cis	rs9549260	0.755	rs9577091	ENSG00000229456.1	RLIMP1	3.95	8.84e-05	0.0127	0.19	0.18	Red blood cell count;	chr13:40653728	chr13:40618738~40621348:+
LUAD	cis	rs4374383	0.884	rs4848933	ENSG00000207383.1	Y_RNA	-3.95	8.84e-05	0.0127	-0.21	-0.18	Hepatitis C induced liver fibrosis;	chr2:112004076	chr2:112579484~112579584:-
LUAD	cis	rs523522	0.847	rs11065132	ENSG00000278344.1	RP11-18C24.8	3.95	8.84e-05	0.0127	0.24	0.18	High light scatter reticulocyte count;	chr12:120470656	chr12:120500735~120501090:-
LUAD	cis	rs523522	0.962	rs4767902	ENSG00000278344.1	RP11-18C24.8	3.95	8.84e-05	0.0127	0.24	0.18	High light scatter reticulocyte count;	chr12:120472201	chr12:120500735~120501090:-
LUAD	cis	rs523522	0.962	rs10849753	ENSG00000278344.1	RP11-18C24.8	3.95	8.84e-05	0.0127	0.24	0.18	High light scatter reticulocyte count;	chr12:120473010	chr12:120500735~120501090:-
LUAD	cis	rs8067545	0.641	rs203466	ENSG00000270091.1	RP11-78O7.2	3.95	8.84e-05	0.0127	0.15	0.18	Schizophrenia;	chr17:19906640	chr17:19896590~19897287:-
LUAD	cis	rs6087771	0.926	rs6058431	ENSG00000230613.1	HM13-AS1	3.95	8.84e-05	0.0127	0.22	0.18	Putamen volume;Subcortical brain region volumes;	chr20:31709330	chr20:31567707~31573263:-
LUAD	cis	rs7714584	1	rs11951694	ENSG00000197083.10	ZNF300P1	3.95	8.85e-05	0.0127	0.33	0.18	Crohn's disease;	chr5:150874776	chr5:150930645~150946289:-
LUAD	cis	rs7714584	1	rs11955172	ENSG00000197083.10	ZNF300P1	3.95	8.85e-05	0.0127	0.33	0.18	Crohn's disease;	chr5:150874816	chr5:150930645~150946289:-
LUAD	cis	rs7714584	0.793	rs11955174	ENSG00000197083.10	ZNF300P1	3.95	8.85e-05	0.0127	0.33	0.18	Crohn's disease;	chr5:150874829	chr5:150930645~150946289:-
LUAD	cis	rs6494488	0.5	rs72742950	ENSG00000239465.1	RP11-330L19.2	3.95	8.85e-05	0.0127	0.38	0.18	Coronary artery disease;	chr15:64604198	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs118175183	ENSG00000239465.1	RP11-330L19.2	3.95	8.85e-05	0.0127	0.38	0.18	Coronary artery disease;	chr15:64607142	chr15:64631109~64631914:-
LUAD	cis	rs4925386	0.959	rs4925385	ENSG00000273619.1	RP5-908M14.9	3.95	8.85e-05	0.0127	0.16	0.18	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345568	chr20:62386303~62386970:-
LUAD	cis	rs7326068	0.558	rs4770071	ENSG00000275485.1	RP11-261P13.6	-3.95	8.85e-05	0.0127	-0.23	-0.18	Schizophrenia, bipolar disorder and depression (combined);	chr13:20756744	chr13:20768876~20769375:-
LUAD	cis	rs2274273	0.744	rs8011808	ENSG00000258413.1	RP11-665C16.6	-3.95	8.85e-05	0.0127	-0.23	-0.18	Protein biomarker;	chr14:55356626	chr14:55262767~55272075:-
LUAD	cis	rs9900280	1	rs8081584	ENSG00000264808.1	RP11-802D6.1	3.95	8.85e-05	0.0127	0.21	0.18	Mean platelet volume;	chr17:29367389	chr17:29369717~29390777:-
LUAD	cis	rs6951245	0.638	rs74976697	ENSG00000199023.2	MIR339	-3.95	8.85e-05	0.0127	-0.3	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1120869	chr7:1022935~1023045:-
LUAD	cis	rs9815354	1	rs9856088	ENSG00000273328.4	RP11-141M3.6	-3.95	8.85e-05	0.0127	-0.26	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41818990	chr3:42809414~42908105:+
LUAD	cis	rs9815354	1	rs9855965	ENSG00000273328.4	RP11-141M3.6	-3.95	8.85e-05	0.0127	-0.26	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41819016	chr3:42809414~42908105:+
LUAD	cis	rs9815354	1	rs9818169	ENSG00000273328.4	RP11-141M3.6	-3.95	8.85e-05	0.0127	-0.26	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41819107	chr3:42809414~42908105:+
LUAD	cis	rs2976388	0.556	rs2572876	ENSG00000253741.1	CTD-2292P10.4	3.95	8.85e-05	0.0127	0.21	0.18	Urinary tract infection frequency;	chr8:142749181	chr8:142702252~142726973:-
LUAD	cis	rs116095464	0.558	rs10475136	ENSG00000248925.1	CTD-2083E4.6	3.95	8.85e-05	0.0127	0.3	0.18	Breast cancer;	chr5:232681	chr5:269858~271516:-
LUAD	cis	rs7590268	0.895	rs6544648	ENSG00000279873.2	LINC01126	3.95	8.85e-05	0.0127	0.18	0.18	Orofacial clefts;	chr2:43372919	chr2:43227210~43228855:+
LUAD	cis	rs2657294	0.895	rs4746262	ENSG00000226051.5	ZNF503-AS1	-3.95	8.85e-05	0.0127	-0.24	-0.18	Pneumonia;	chr10:75093631	chr10:75269819~75373500:+
LUAD	cis	rs404005	0.764	rs13390338	ENSG00000227028.5	SLC8A1-AS1	-3.95	8.85e-05	0.0127	-0.22	-0.18	HIV-associated dementia;	chr2:40174265	chr2:39786453~40255209:+
LUAD	cis	rs1008375	0.932	rs11935124	ENSG00000249502.1	AC006160.5	3.95	8.86e-05	0.0127	0.17	0.18	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17666577	chr4:17587467~17614571:-
LUAD	cis	rs6495122	0.501	rs6495151	ENSG00000260269.4	CTD-2323K18.1	3.95	8.86e-05	0.0127	0.22	0.18	Diastolic blood pressure;Coffee consumption;Caffeine consumption;	chr15:75093649	chr15:75527150~75601205:-
LUAD	cis	rs911119	0.913	rs6106685	ENSG00000270001.1	RP11-218C14.8	-3.95	8.86e-05	0.0127	-0.26	-0.18	Chronic kidney disease;	chr20:23600975	chr20:23631826~23632316:-
LUAD	cis	rs7107174	1	rs11237468	ENSG00000251323.2	RP11-452H21.4	3.95	8.86e-05	0.0127	0.21	0.18	Testicular germ cell tumor;	chr11:78361787	chr11:78423982~78429836:-
LUAD	cis	rs9813712	0.595	rs1453238	ENSG00000249846.5	RP11-77P16.4	3.95	8.86e-05	0.0127	0.21	0.18	Response to amphetamines;	chr3:130290494	chr3:130112550~130120579:+
LUAD	cis	rs4499344	0.556	rs259236	ENSG00000201388.1	SNORA68	3.95	8.86e-05	0.0127	0.21	0.18	Mean platelet volume;	chr19:32625216	chr19:32608337~32608469:-
LUAD	cis	rs8014252	1	rs17108176	ENSG00000274818.1	RP1-292L20.3	-3.95	8.86e-05	0.0127	-0.28	-0.18	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70468823	chr14:70906657~70907111:-
LUAD	cis	rs910316	0.712	rs175037	ENSG00000259138.1	RP11-950C14.7	-3.95	8.86e-05	0.0127	-0.19	-0.18	Height;	chr14:74998335	chr14:75127153~75136930:+
LUAD	cis	rs1559040	1	rs10172916	ENSG00000272156.1	RP11-477N3.1	-3.95	8.86e-05	0.0127	-0.3	-0.18	Sudden cardiac arrest;	chr2:54101831	chr2:54082554~54085066:+
LUAD	cis	rs7824557	0.603	rs11250130	ENSG00000255046.1	RP11-297N6.4	3.95	8.86e-05	0.0127	0.22	0.18	Retinal vascular caliber;	chr8:11356946	chr8:11797928~11802568:-
LUAD	cis	rs910316	0.763	rs175036	ENSG00000259138.1	RP11-950C14.7	-3.95	8.86e-05	0.0127	-0.19	-0.18	Height;	chr14:74997592	chr14:75127153~75136930:+
LUAD	cis	rs17711722	0.51	rs11767457	ENSG00000273024.4	INTS4P2	-3.95	8.86e-05	0.0127	-0.19	-0.18	Calcium levels;	chr7:65825628	chr7:65647864~65715661:+
LUAD	cis	rs6081541	1	rs62201127	ENSG00000179447.2	RP5-1027G4.3	-3.95	8.86e-05	0.0127	-0.23	-0.18	Psychosis (atypical);	chr20:19245192	chr20:19242302~19284596:-
LUAD	cis	rs9309711	0.737	rs9284795	ENSG00000271868.1	RP11-1293J14.1	-3.95	8.86e-05	0.0127	-0.21	-0.18	Neurofibrillary tangles;	chr2:3488294	chr2:3496956~3497428:+
LUAD	cis	rs9341808	0.621	rs2322627	ENSG00000272129.1	RP11-250B2.6	3.95	8.87e-05	0.0127	0.22	0.18	Sitting height ratio;	chr6:80096624	chr6:80355424~80356859:+
LUAD	cis	rs7208859	0.673	rs12103759	ENSG00000266490.1	CTD-2349P21.9	3.95	8.87e-05	0.0127	0.28	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908669	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.623	rs59029591	ENSG00000266490.1	CTD-2349P21.9	3.95	8.87e-05	0.0127	0.28	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908728	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs73265633	ENSG00000266490.1	CTD-2349P21.9	3.95	8.87e-05	0.0127	0.28	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30909288	chr17:30792372~30792833:+
LUAD	cis	rs7515577	0.533	rs17578954	ENSG00000223787.2	RP4-593M8.1	3.95	8.87e-05	0.0127	0.37	0.18	Cholesterol, total;	chr1:92300508	chr1:92580476~92580821:-
LUAD	cis	rs116095464	0.558	rs56127718	ENSG00000248925.1	CTD-2083E4.6	3.95	8.87e-05	0.0127	0.3	0.18	Breast cancer;	chr5:270158	chr5:269858~271516:-
LUAD	cis	rs116095464	0.614	rs10061564	ENSG00000248925.1	CTD-2083E4.6	3.95	8.87e-05	0.0127	0.3	0.18	Breast cancer;	chr5:271214	chr5:269858~271516:-
LUAD	cis	rs1198430	0.925	rs487859	ENSG00000232482.2	RP4-654C18.1	-3.95	8.87e-05	0.0128	-0.3	-0.18	Total cholesterol levels;	chr1:23474608	chr1:23410832~23412146:+
LUAD	cis	rs1198430	0.852	rs909537	ENSG00000232482.2	RP4-654C18.1	-3.95	8.87e-05	0.0128	-0.3	-0.18	Total cholesterol levels;	chr1:23483570	chr1:23410832~23412146:+
LUAD	cis	rs9309473	0.95	rs6546849	ENSG00000230002.2	ALMS1-IT1	3.95	8.87e-05	0.0128	0.22	0.18	Metabolite levels;	chr2:73603910	chr2:73456764~73459484:+
LUAD	cis	rs10129255	0.744	rs28517388	ENSG00000211967.3	IGHV3-53	-3.95	8.87e-05	0.0128	-0.14	-0.18	Kawasaki disease;	chr14:106704323	chr14:106592676~106593347:-
LUAD	cis	rs5995756	0.627	rs1008677	ENSG00000227188.1	MGAT3-AS1	-3.95	8.87e-05	0.0128	-0.19	-0.18	Autism spectrum disorder or schizophrenia;	chr22:39613331	chr22:39475807~39476822:-
LUAD	cis	rs4691139	0.557	rs4485779	ENSG00000248632.1	RP11-366M4.11	3.95	8.87e-05	0.0128	0.22	0.18	Ovarian cancer in BRCA1 mutation carriers;	chr4:165002877	chr4:164968587~164970002:-
LUAD	cis	rs7394190	0.935	rs4746140	ENSG00000271848.1	RP11-464F9.21	-3.95	8.87e-05	0.0128	-0.23	-0.18	Incident atrial fibrillation;	chr10:73657491	chr10:73654039~73674719:+
LUAD	cis	rs9500256	0.683	rs10458024	ENSG00000239650.4	GUSBP4	3.95	8.87e-05	0.0128	0.21	0.18	Eosinophilic esophagitis (pediatric);	chr6:57997811	chr6:57919784~57930291:-
LUAD	cis	rs763121	0.853	rs2179142	ENSG00000225450.1	RP3-508I15.14	-3.95	8.87e-05	0.0128	-0.17	-0.18	Menopause (age at onset);	chr22:38641949	chr22:38739003~38749041:+
LUAD	cis	rs73242632	1	rs114513553	ENSG00000269949.1	RP11-738E22.3	3.95	8.87e-05	0.0128	0.44	0.18	Congenital heart disease (maternal effect);	chr4:56992292	chr4:56960927~56961373:-
LUAD	cis	rs1850744	1	rs1533615	ENSG00000163612.10	FAM86KP	3.95	8.87e-05	0.0128	0.5	0.18	Economic and political preferences;	chr4:9802900	chr4:9153296~9165451:+
LUAD	cis	rs3213758	0.541	rs17838423	ENSG00000275191.1	RP11-36I17.2	-3.95	8.88e-05	0.0128	-0.27	-0.18	Vitiligo (non-segmental);	chr16:53525818	chr16:53628256~53628816:-
LUAD	cis	rs5758659	0.967	rs5751250	ENSG00000273366.1	CTA-989H11.1	-3.95	8.88e-05	0.0128	-0.21	-0.18	Cognitive function;	chr22:42243639	chr22:42278188~42278846:+
LUAD	cis	rs375066	0.935	rs454559	ENSG00000278917.1	RP11-15A1.4	-3.95	8.88e-05	0.0128	-0.19	-0.18	Breast cancer;	chr19:43924968	chr19:43891233~43895411:+
LUAD	cis	rs10129255	0.869	rs7150549	ENSG00000211947.2	IGHV3-21	-3.95	8.88e-05	0.0128	-0.12	-0.18	Kawasaki disease;	chr14:106705441	chr14:106235064~106235594:-
LUAD	cis	rs137603	0.644	rs94852	ENSG00000230149.2	RP3-508I15.19	-3.95	8.88e-05	0.0128	-0.14	-0.18	Primary biliary cholangitis;	chr22:39316329	chr22:38734730~38738990:+
LUAD	cis	rs2274273	0.905	rs2147961	ENSG00000258413.1	RP11-665C16.6	-3.95	8.89e-05	0.0128	-0.23	-0.18	Protein biomarker;	chr14:55118663	chr14:55262767~55272075:-
LUAD	cis	rs5015933	0.815	rs10986718	ENSG00000232630.1	PRPS1P2	-3.95	8.89e-05	0.0128	-0.17	-0.18	Body mass index;	chr9:125350617	chr9:125150653~125151589:+
LUAD	cis	rs595244	1	rs1678981	ENSG00000259705.1	RP11-227D13.1	3.95	8.89e-05	0.0128	0.37	0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48607900	chr15:48645951~48652016:+
LUAD	cis	rs9656709	0.528	rs4948054	ENSG00000226278.1	PSPHP1	3.95	8.89e-05	0.0128	0.2	0.18	Behavioural disinhibition (generation interaction);	chr7:55663907	chr7:55764797~55773288:+
LUAD	cis	rs4713118	0.662	rs149901	ENSG00000280107.1	AL022393.9	-3.95	8.89e-05	0.0128	-0.23	-0.18	Parkinson's disease;	chr6:27997725	chr6:28170845~28172521:+
LUAD	cis	rs5771040	0.56	rs738683	ENSG00000273253.2	RP3-402G11.26	-3.95	8.89e-05	0.0128	-0.18	-0.18	IgG glycosylation;	chr22:50472446	chr22:50199090~50200837:-
LUAD	cis	rs3753275	0.69	rs6577500	ENSG00000232912.4	RP5-1115A15.1	3.95	8.89e-05	0.0128	0.2	0.18	Educational attainment;	chr1:8554512	chr1:8424645~8434838:+
LUAD	cis	rs9894429	0.966	rs7405901	ENSG00000263853.1	AC139530.1	-3.95	8.89e-05	0.0128	-0.17	-0.18	Eye color traits;	chr17:81620787	chr17:81676001~81676086:+
LUAD	cis	rs11671005	0.779	rs3794971	ENSG00000268912.1	CTD-2619J13.17	-3.95	8.89e-05	0.0128	-0.25	-0.18	Mean platelet volume;	chr19:58474499	chr19:58428632~58431148:-
LUAD	cis	rs12986445	0.846	rs2176182	ENSG00000218682.1	AC010150.1	3.95	8.89e-05	0.0128	0.21	0.18	Multiple myeloma;Multiple myeloma and monoclonal gammopathy;	chr2:25886533	chr2:25856461~25856966:-
LUAD	cis	rs7647973	0.516	rs12490393	ENSG00000225399.4	RP11-3B7.1	3.95	8.89e-05	0.0128	0.23	0.18	Menarche (age at onset);	chr3:49158699	chr3:49260085~49261316:+
LUAD	cis	rs8030379	1	rs1564473	ENSG00000230373.7	GOLGA6L5P	-3.95	8.89e-05	0.0128	-0.16	-0.18	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83901190	chr15:84507885~84516814:-
LUAD	cis	rs17597773	0.674	rs1494371	ENSG00000272823.1	RP11-295M18.6	-3.95	8.9e-05	0.0128	-0.23	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220841256	chr1:220828676~220829211:-
LUAD	cis	rs4691139	0.619	rs7441550	ENSG00000248632.1	RP11-366M4.11	3.95	8.9e-05	0.0128	0.22	0.18	Ovarian cancer in BRCA1 mutation carriers;	chr4:165003160	chr4:164968587~164970002:-
LUAD	cis	rs6832769	1	rs28582059	ENSG00000272969.1	RP11-528I4.2	-3.95	8.9e-05	0.0128	-0.18	-0.18	Personality dimensions;	chr4:55542237	chr4:55547112~55547889:+
LUAD	cis	rs1334894	0.71	rs3777746	ENSG00000228559.1	RP3-340B19.3	3.95	8.9e-05	0.0128	0.34	0.18	Coronary artery disease;	chr6:35501096	chr6:35544632~35545669:+
LUAD	cis	rs6840258	0.831	rs236676	ENSG00000251411.1	RP11-397E7.4	3.95	8.9e-05	0.0128	0.22	0.18	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87088468	chr4:86913266~86914817:-
LUAD	cis	rs7463659	0.512	rs6992045	ENSG00000259820.1	AC083843.1	-3.95	8.9e-05	0.0128	-0.18	-0.18	Colonoscopy-negative controls vs population controls;	chr8:134436506	chr8:134792020~134798272:-
LUAD	cis	rs5758659	1	rs5758677	ENSG00000273366.1	CTA-989H11.1	-3.95	8.9e-05	0.0128	-0.2	-0.18	Cognitive function;	chr22:42247033	chr22:42278188~42278846:+
LUAD	cis	rs831571	1	rs17069791	ENSG00000280620.1	SCAANT1	3.95	8.9e-05	0.0128	0.27	0.18	Type 2 diabetes;	chr3:64066603	chr3:63911518~63911772:-
LUAD	cis	rs5015933	0.778	rs10819046	ENSG00000232630.1	PRPS1P2	-3.95	8.9e-05	0.0128	-0.17	-0.18	Body mass index;	chr9:125349961	chr9:125150653~125151589:+
LUAD	cis	rs7200786	0.593	rs1700819	ENSG00000274038.1	RP11-66H6.4	-3.95	8.9e-05	0.0128	-0.22	-0.18	Systemic lupus erythematosus;Multiple sclerosis;	chr16:10963066	chr16:11056556~11057034:+
LUAD	cis	rs9633740	1	rs7900536	ENSG00000226659.1	RP11-137H2.4	-3.95	8.91e-05	0.0128	-0.28	-0.18	Post bronchodilator FEV1;	chr10:80493945	chr10:80529597~80535942:-
LUAD	cis	rs17301013	0.761	rs332805	ENSG00000227373.4	RP11-160H22.5	3.95	8.91e-05	0.0128	0.23	0.18	Systemic lupus erythematosus;	chr1:174652487	chr1:174115300~174160004:-
LUAD	cis	rs9952991	0.654	rs12955302	ENSG00000260302.1	RP11-973H7.1	3.95	8.91e-05	0.0128	0.38	0.18	Inflammatory skin disease;	chr18:12864763	chr18:12774651~12775923:-
LUAD	cis	rs11671005	0.57	rs73062110	ENSG00000268543.1	CTD-2619J13.16	-3.95	8.91e-05	0.0128	-0.25	-0.18	Mean platelet volume;	chr19:58425275	chr19:58418560~58419310:+
LUAD	cis	rs28374715	0.681	rs77187862	ENSG00000247556.5	OIP5-AS1	3.95	8.91e-05	0.0128	0.22	0.18	Ulcerative colitis;	chr15:41327078	chr15:41283990~41309737:+
LUAD	cis	rs3096299	0.9	rs3114867	ENSG00000182376.2	RP5-1142A6.8	3.95	8.91e-05	0.0128	0.18	0.18	Multiple myeloma (IgH translocation);	chr16:89362559	chr16:88742767~88745748:+
LUAD	cis	rs7712401	0.791	rs4836244	ENSG00000249996.1	RP11-359P5.1	3.95	8.91e-05	0.0128	0.21	0.18	Mean platelet volume;	chr5:122780537	chr5:123036271~123054667:+
LUAD	cis	rs10463554	0.927	rs257317	ENSG00000250682.4	LINC00491	3.95	8.91e-05	0.0128	0.21	0.18	Parkinson's disease;	chr5:103086881	chr5:102609156~102671559:-
LUAD	cis	rs7824557	0.564	rs2572389	ENSG00000255046.1	RP11-297N6.4	3.95	8.91e-05	0.0128	0.22	0.18	Retinal vascular caliber;	chr8:11378883	chr8:11797928~11802568:-
LUAD	cis	rs7824557	0.564	rs2736301	ENSG00000255046.1	RP11-297N6.4	3.95	8.91e-05	0.0128	0.22	0.18	Retinal vascular caliber;	chr8:11378904	chr8:11797928~11802568:-
LUAD	cis	rs7824557	0.564	rs2736302	ENSG00000255046.1	RP11-297N6.4	3.95	8.91e-05	0.0128	0.22	0.18	Retinal vascular caliber;	chr8:11378910	chr8:11797928~11802568:-
LUAD	cis	rs440932	1	rs440932	ENSG00000254340.1	RP11-10A14.3	3.95	8.92e-05	0.0128	0.22	0.18	High light scatter reticulocyte percentage of red cells;	chr8:9169419	chr8:9141424~9145435:+
LUAD	cis	rs12579720	0.631	rs10743355	ENSG00000255910.1	RP11-405A12.2	3.95	8.92e-05	0.0128	0.22	0.18	Diastolic blood pressure;	chr12:20082004	chr12:19775451~20009937:+
LUAD	cis	rs2354432	0.556	rs11239964	ENSG00000237188.3	RP11-337C18.8	3.95	8.92e-05	0.0128	0.34	0.18	Mitochondrial DNA levels;	chr1:147282229	chr1:147172771~147211568:+
LUAD	cis	rs8062405	0.755	rs55792032	ENSG00000251417.2	RP11-1348G14.4	-3.95	8.92e-05	0.0128	-0.18	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28802743~28817828:+
LUAD	cis	rs12541335	0.639	rs7003478	ENSG00000254064.1	CTD-2530N21.4	3.95	8.92e-05	0.0128	0.18	0.18	Hypertriglyceridemia;	chr8:22343610	chr8:22254576~22275162:-
LUAD	cis	rs4132509	0.516	rs10927031	ENSG00000236031.1	RP11-269F20.1	3.95	8.92e-05	0.0128	0.28	0.18	RR interval (heart rate);	chr1:243522458	chr1:243545532~243548329:+
LUAD	cis	rs3750965	0.92	rs11828017	ENSG00000260895.1	RP11-554A11.7	3.95	8.92e-05	0.0128	0.21	0.18	Hair color;	chr11:69051149	chr11:69103493~69109094:+
LUAD	cis	rs11742741	1	rs4701426	ENSG00000248874.4	C5orf17	-3.95	8.93e-05	0.0128	-0.22	-0.18	Educational attainment;	chr5:24177655	chr5:23951348~24178263:+
LUAD	cis	rs4237845	0.513	rs7134797	ENSG00000245651.2	RP11-620J15.2	3.95	8.93e-05	0.0128	0.19	0.18	Intelligence (multi-trait analysis);	chr12:57870069	chr12:57869835~57896482:-
LUAD	cis	rs6452524	0.618	rs10051445	ENSG00000281327.1	LINC01338	3.95	8.93e-05	0.0128	0.19	0.18	Hypertension (SNP x SNP interaction);	chr5:83060280	chr5:82850864~82859836:-
LUAD	cis	rs1005277	0.54	rs1987431	ENSG00000273019.1	RP11-508N22.13	-3.95	8.93e-05	0.0128	-0.2	-0.18	Extrinsic epigenetic age acceleration;	chr10:37699959	chr10:38149968~38150293:+
LUAD	cis	rs4713118	0.738	rs200465	ENSG00000280107.1	AL022393.9	-3.95	8.93e-05	0.0128	-0.22	-0.18	Parkinson's disease;	chr6:27789875	chr6:28170845~28172521:+
LUAD	cis	rs5758511	0.68	rs5758687	ENSG00000227370.1	RP4-669P10.19	3.95	8.93e-05	0.0128	0.2	0.18	Birth weight;	chr22:42260582	chr22:42132543~42132998:+
LUAD	cis	rs8040855	0.627	rs12913859	ENSG00000259774.1	RP11-182J1.13	3.95	8.94e-05	0.0128	0.23	0.18	Bulimia nervosa;	chr15:85095187	chr15:84422618~84425882:+
LUAD	cis	rs7615952	0.866	rs1976459	ENSG00000241288.6	RP11-379B18.5	-3.95	8.94e-05	0.0128	-0.23	-0.18	Blood pressure (smoking interaction);	chr3:125928643	chr3:125827238~125916384:-
LUAD	cis	rs7615952	0.932	rs1976458	ENSG00000241288.6	RP11-379B18.5	-3.95	8.94e-05	0.0128	-0.23	-0.18	Blood pressure (smoking interaction);	chr3:125928669	chr3:125827238~125916384:-
LUAD	cis	rs9650657	0.506	rs7823296	ENSG00000255046.1	RP11-297N6.4	3.95	8.94e-05	0.0128	0.22	0.18	Neuroticism;	chr8:10921036	chr8:11797928~11802568:-
LUAD	cis	rs77633900	0.73	rs2469568	ENSG00000196274.5	Metazoa_SRP	3.95	8.94e-05	0.0128	0.24	0.18	Glioma;Non-glioblastoma glioma;	chr15:76185927	chr15:76230048~76230390:-
LUAD	cis	rs12579720	0.711	rs7358622	ENSG00000255910.1	RP11-405A12.2	3.95	8.94e-05	0.0128	0.22	0.18	Diastolic blood pressure;	chr12:20075492	chr12:19775451~20009937:+
LUAD	cis	rs16873450	0.685	rs10233021	ENSG00000234800.2	PCMTD1P3	3.95	8.95e-05	0.0128	0.21	0.18	Verbal memory performance (residualized delayed recall level);	chr7:23722910	chr7:23721311~23721782:-
LUAD	cis	rs7976269	0.559	rs4930848	ENSG00000257176.2	RP11-996F15.2	-3.95	8.95e-05	0.0128	-0.19	-0.18	Male-pattern baldness;	chr12:29068441	chr12:29280418~29317848:-
LUAD	cis	rs6495122	0.501	rs12101482	ENSG00000260269.4	CTD-2323K18.1	3.95	8.95e-05	0.0128	0.22	0.18	Diastolic blood pressure;Coffee consumption;Caffeine consumption;	chr15:75052443	chr15:75527150~75601205:-
LUAD	cis	rs10214930	0.697	rs757396	ENSG00000235574.1	AC073150.6	-3.95	8.95e-05	0.0128	-0.22	-0.18	Hypospadias;	chr7:27868707	chr7:27491682~27492765:-
LUAD	cis	rs2274273	0.905	rs28429419	ENSG00000258413.1	RP11-665C16.6	-3.95	8.95e-05	0.0128	-0.23	-0.18	Protein biomarker;	chr14:55108075	chr14:55262767~55272075:-
LUAD	cis	rs7615952	0.641	rs7618515	ENSG00000250012.1	RP11-124N2.1	-3.95	8.95e-05	0.0128	-0.25	-0.18	Blood pressure (smoking interaction);	chr3:126071735	chr3:126084220~126095349:+
LUAD	cis	rs3020736	0.5	rs4147640	ENSG00000205702.9	CYP2D7	-3.95	8.96e-05	0.0129	-0.14	-0.18	Autism spectrum disorder or schizophrenia;	chr22:42089288	chr22:42140203~42144577:-
LUAD	cis	rs2239547	0.522	rs6771610	ENSG00000243224.1	RP5-1157M23.2	-3.95	8.96e-05	0.0129	-0.19	-0.18	Schizophrenia;	chr3:52992088	chr3:52239258~52241097:+
LUAD	cis	rs8040855	0.658	rs11634877	ENSG00000259774.1	RP11-182J1.13	3.95	8.96e-05	0.0129	0.23	0.18	Bulimia nervosa;	chr15:85068246	chr15:84422618~84425882:+
LUAD	cis	rs8040855	0.627	rs11632175	ENSG00000259774.1	RP11-182J1.13	3.95	8.96e-05	0.0129	0.23	0.18	Bulimia nervosa;	chr15:85068449	chr15:84422618~84425882:+
LUAD	cis	rs8040855	0.627	rs62019482	ENSG00000259774.1	RP11-182J1.13	3.95	8.96e-05	0.0129	0.23	0.18	Bulimia nervosa;	chr15:85071796	chr15:84422618~84425882:+
LUAD	cis	rs910316	0.737	rs175499	ENSG00000259138.1	RP11-950C14.7	-3.95	8.96e-05	0.0129	-0.19	-0.18	Height;	chr14:75069224	chr14:75127153~75136930:+
LUAD	cis	rs3892630	0.62	rs10413279	ENSG00000267475.1	CTD-2538C1.2	-3.95	8.96e-05	0.0129	-0.26	-0.18	Red blood cell traits;	chr19:32691840	chr19:32687089~32691750:-
LUAD	cis	rs6763848	0.923	rs9310453	ENSG00000214073.2	RPL21P17	-3.95	8.97e-05	0.0129	-0.18	-0.18	Prostate cancer (SNP x SNP interaction);	chr3:1474168	chr3:1905651~1906125:+
LUAD	cis	rs10197140	0.925	rs11898005	ENSG00000235721.1	AC013268.3	-3.95	8.97e-05	0.0129	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110862673	chr2:110007675~110010783:+
LUAD	cis	rs7429990	0.932	rs4293721	ENSG00000228638.1	FCF1P2	3.95	8.97e-05	0.0129	0.21	0.18	Educational attainment (years of education);	chr3:48003647	chr3:48290793~48291375:-
LUAD	cis	rs17711722	0.583	rs10085415	ENSG00000237310.1	GS1-124K5.4	-3.95	8.98e-05	0.0129	-0.19	-0.18	Calcium levels;	chr7:65628655	chr7:66493706~66495474:+
LUAD	cis	rs34779708	0.75	rs35032841	ENSG00000271335.4	RP11-324I22.4	3.95	8.98e-05	0.0129	0.18	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35023759	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.742	rs35912711	ENSG00000271335.4	RP11-324I22.4	3.95	8.98e-05	0.0129	0.18	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35024068	chr10:35314552~35336401:-
LUAD	cis	rs2289583	0.5	rs67168917	ENSG00000260269.4	CTD-2323K18.1	3.95	8.98e-05	0.0129	0.21	0.18	Systemic lupus erythematosus;	chr15:75099153	chr15:75527150~75601205:-
LUAD	cis	rs2742417	0.532	rs2673053	ENSG00000230530.1	LIMD1-AS1	3.95	8.98e-05	0.0129	0.21	0.18	Response to anti-depressant treatment in major depressive disorder;	chr3:45690552	chr3:45679043~45689134:-
LUAD	cis	rs9896933	0.775	rs615630	ENSG00000262663.1	RP11-497H17.1	-3.95	8.98e-05	0.0129	-0.21	-0.18	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr17:82772651	chr17:82918282~82918785:+
LUAD	cis	rs7138803	0.644	rs73114127	ENSG00000257464.1	RP11-161H23.8	-3.95	8.98e-05	0.0129	-0.18	-0.18	Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index;	chr12:49811719	chr12:49442424~49442652:-
LUAD	cis	rs6121246	0.865	rs6089055	ENSG00000230613.1	HM13-AS1	3.95	8.98e-05	0.0129	0.27	0.18	Mean corpuscular hemoglobin;	chr20:31736242	chr20:31567707~31573263:-
LUAD	cis	rs801193	1	rs2707845	ENSG00000222364.1	RNU6-96P	-3.95	8.98e-05	0.0129	-0.2	-0.18	Aortic root size;	chr7:66733811	chr7:66395191~66395286:+
LUAD	cis	rs8028182	0.636	rs8034317	ENSG00000260269.4	CTD-2323K18.1	-3.95	8.98e-05	0.0129	-0.24	-0.18	Sudden cardiac arrest;	chr15:75472002	chr15:75527150~75601205:-
LUAD	cis	rs8028182	0.636	rs28737338	ENSG00000260269.4	CTD-2323K18.1	-3.95	8.98e-05	0.0129	-0.24	-0.18	Sudden cardiac arrest;	chr15:75476338	chr15:75527150~75601205:-
LUAD	cis	rs2274273	0.84	rs6573014	ENSG00000258413.1	RP11-665C16.6	3.95	8.98e-05	0.0129	0.23	0.18	Protein biomarker;	chr14:55269174	chr14:55262767~55272075:-
LUAD	cis	rs6479891	1	rs11814792	ENSG00000232075.1	MRPL35P2	3.95	8.98e-05	0.0129	0.29	0.18	Arthritis (juvenile idiopathic);	chr10:63157799	chr10:63634317~63634827:-
LUAD	cis	rs12822507	0.783	rs10772585	ENSG00000180861.8	LINC01559	3.95	8.99e-05	0.0129	0.19	0.18	Systemic lupus erythematosus;	chr12:12619799	chr12:13371089~13387167:-
LUAD	cis	rs12822507	0.783	rs10772586	ENSG00000180861.8	LINC01559	3.95	8.99e-05	0.0129	0.19	0.18	Systemic lupus erythematosus;	chr12:12619932	chr12:13371089~13387167:-
LUAD	cis	rs73242632	1	rs73242625	ENSG00000269949.1	RP11-738E22.3	3.95	8.99e-05	0.0129	0.44	0.18	Congenital heart disease (maternal effect);	chr4:56990173	chr4:56960927~56961373:-
LUAD	cis	rs7746199	0.668	rs7749305	ENSG00000219392.1	RP1-265C24.5	-3.95	8.99e-05	0.0129	-0.34	-0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27478787	chr6:28115628~28116551:+
LUAD	cis	rs7746199	0.668	rs34864796	ENSG00000219392.1	RP1-265C24.5	-3.95	8.99e-05	0.0129	-0.34	-0.18	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27492144	chr6:28115628~28116551:+
LUAD	cis	rs6452524	0.534	rs10061690	ENSG00000281327.1	LINC01338	3.95	8.99e-05	0.0129	0.19	0.18	Hypertension (SNP x SNP interaction);	chr5:83063226	chr5:82850864~82859836:-
LUAD	cis	rs8031584	0.679	rs34017474	ENSG00000269930.1	RP11-932O9.9	-3.95	8.99e-05	0.0129	-0.19	-0.18	Huntington's disease progression;	chr15:30938408	chr15:30616958~30617749:+
LUAD	cis	rs6001482	0.778	rs1012819	ENSG00000223350.2	IGLV9-49	-3.95	9e-05	0.0129	-0.17	-0.18	Diastolic blood pressure;	chr22:22238997	chr22:22343187~22343732:+
LUAD	cis	rs9925964	0.933	rs2303223	ENSG00000232748.3	RP11-196G11.6	3.95	9e-05	0.0129	0.21	0.18	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31063854	chr16:31056460~31062803:+
LUAD	cis	rs7551222	0.663	rs1563828	ENSG00000240219.1	RP11-430C7.5	3.95	9e-05	0.0129	0.18	0.18	Schizophrenia;	chr1:204547449	chr1:204626775~204629712:+
LUAD	cis	rs62246343	0.605	rs17746498	ENSG00000254485.4	RP11-380O24.1	3.95	9e-05	0.0129	0.24	0.18	Fibrinogen levels;	chr3:9411976	chr3:9292588~9363303:-
LUAD	cis	rs2348418	0.715	rs1581076	ENSG00000247934.4	RP11-967K21.1	3.95	9e-05	0.0129	0.2	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28570724	chr12:28163298~28190738:-
LUAD	cis	rs6095360	1	rs1885163	ENSG00000222365.1	SNORD12B	-3.95	9e-05	0.0129	-0.18	-0.18	Intelligence (multi-trait analysis);	chr20:49085228	chr20:49280319~49280409:+
LUAD	cis	rs755249	0.567	rs41270807	ENSG00000182109.6	RP11-69E11.4	3.95	9.01e-05	0.0129	0.22	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39336143	chr1:39522280~39546187:-
LUAD	cis	rs1853665	0.58	rs6557200	ENSG00000231760.4	RP11-350J20.5	-3.95	9.01e-05	0.0129	-0.29	-0.18	Radiation response;	chr6:149951396	chr6:149796151~149826294:-
LUAD	cis	rs4776997	0.559	rs11071960	ENSG00000270964.1	RP11-502I4.3	3.95	9.01e-05	0.0129	0.22	0.18	Verbal declarative memory;	chr15:67784784	chr15:67541072~67542604:-
LUAD	cis	rs4683346	0.616	rs2372110	ENSG00000173811.9	CCDC13-AS1	-3.95	9.01e-05	0.0129	-0.2	-0.18	Granulocyte percentage of myeloid white cells;	chr3:42778365	chr3:42732575~42746768:+
LUAD	cis	rs7116495	0.748	rs481355	ENSG00000254682.1	RP11-660L16.2	-3.95	9.02e-05	0.0129	-0.37	-0.18	Severe influenza A (H1N1) infection;	chr11:71867310	chr11:71448674~71452157:+
LUAD	cis	rs7116495	0.867	rs481300	ENSG00000254682.1	RP11-660L16.2	-3.95	9.02e-05	0.0129	-0.37	-0.18	Severe influenza A (H1N1) infection;	chr11:71867337	chr11:71448674~71452157:+
LUAD	cis	rs7116495	0.867	rs662649	ENSG00000254682.1	RP11-660L16.2	-3.95	9.02e-05	0.0129	-0.37	-0.18	Severe influenza A (H1N1) infection;	chr11:71867829	chr11:71448674~71452157:+
LUAD	cis	rs34421088	0.56	rs1478898	ENSG00000255046.1	RP11-297N6.4	3.95	9.02e-05	0.0129	0.22	0.18	Neuroticism;	chr8:11537570	chr8:11797928~11802568:-
LUAD	cis	rs8073060	0.544	rs225246	ENSG00000267592.1	CTC-507E2.2	3.95	9.02e-05	0.0129	0.26	0.18	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35617754	chr17:35596904~35597128:-
LUAD	cis	rs848490	0.889	rs35392227	ENSG00000214293.7	APTR	3.95	9.02e-05	0.0129	0.23	0.18	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77648452	chr7:77657660~77696265:-
LUAD	cis	rs4118325	0.69	rs1537702	ENSG00000224550.1	RP11-270C12.3	-3.95	9.02e-05	0.0129	-0.22	-0.18	AIDS;	chr1:107089117	chr1:107505203~107505448:+
LUAD	cis	rs4118325	0.743	rs1537704	ENSG00000224550.1	RP11-270C12.3	-3.95	9.02e-05	0.0129	-0.22	-0.18	AIDS;	chr1:107089455	chr1:107505203~107505448:+
LUAD	cis	rs3018712	0.59	rs6591350	ENSG00000227620.4	ALG1L8P	-3.95	9.02e-05	0.0129	-0.24	-0.18	Total body bone mineral density;	chr11:68701202	chr11:67785273~67792335:+
LUAD	cis	rs8076336	1	rs8076336	ENSG00000264177.1	RP1-37N7.1	3.95	9.02e-05	0.0129	0.17	0.18	Parental longevity (combined parental age at death);	chr17:18309300	chr17:18379855~18388984:-
LUAD	cis	rs7615952	0.576	rs12497295	ENSG00000250012.1	RP11-124N2.1	-3.95	9.02e-05	0.0129	-0.26	-0.18	Blood pressure (smoking interaction);	chr3:126099807	chr3:126084220~126095349:+
LUAD	cis	rs7937682	0.961	rs4935790	ENSG00000230911.1	PPIHP1	3.95	9.02e-05	0.0129	0.24	0.18	Primary sclerosing cholangitis;	chr11:111762290	chr11:112029858~112030367:-
LUAD	cis	rs7714584	1	rs10041072	ENSG00000197083.10	ZNF300P1	3.95	9.02e-05	0.0129	0.32	0.18	Crohn's disease;	chr5:150880080	chr5:150930645~150946289:-
LUAD	cis	rs763121	0.819	rs5757133	ENSG00000228274.3	RP3-508I15.9	3.95	9.02e-05	0.0129	0.17	0.18	Menopause (age at onset);	chr22:38551830	chr22:38667585~38681820:-
LUAD	cis	rs6088580	0.634	rs6059835	ENSG00000276073.1	RP5-1125A11.7	-3.95	9.03e-05	0.0129	-0.17	-0.18	Glomerular filtration rate (creatinine);	chr20:34432335	chr20:33985617~33988989:-
LUAD	cis	rs2486288	0.656	rs12911186	ENSG00000259479.5	SORD2P	-3.95	9.03e-05	0.0129	-0.21	-0.18	Glomerular filtration rate;	chr15:45259225	chr15:44826371~44884694:-
LUAD	cis	rs2486288	0.656	rs12915314	ENSG00000259479.5	SORD2P	-3.95	9.03e-05	0.0129	-0.21	-0.18	Glomerular filtration rate;	chr15:45259293	chr15:44826371~44884694:-
LUAD	cis	rs2486288	0.656	rs8039138	ENSG00000259479.5	SORD2P	-3.95	9.03e-05	0.0129	-0.21	-0.18	Glomerular filtration rate;	chr15:45259394	chr15:44826371~44884694:-
LUAD	cis	rs2976388	0.578	rs4736324	ENSG00000253741.1	CTD-2292P10.4	3.95	9.03e-05	0.0129	0.21	0.18	Urinary tract infection frequency;	chr8:142749044	chr8:142702252~142726973:-
LUAD	cis	rs1056107	0.731	rs7047547	ENSG00000225513.1	RP11-165N19.2	-3.95	9.03e-05	0.0129	-0.19	-0.18	Colorectal cancer;	chr9:112173568	chr9:112173522~112173971:-
LUAD	cis	rs6012953	0.874	rs6063534	ENSG00000231715.1	COX6CP2	3.95	9.03e-05	0.0129	0.18	0.18	Vitiligo;	chr20:50572631	chr20:50479767~50479991:+
LUAD	cis	rs755249	0.567	rs17264671	ENSG00000182109.6	RP11-69E11.4	3.95	9.03e-05	0.0129	0.22	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39352380	chr1:39522280~39546187:-
LUAD	cis	rs755249	0.567	rs4660690	ENSG00000182109.6	RP11-69E11.4	3.95	9.03e-05	0.0129	0.22	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39353831	chr1:39522280~39546187:-
LUAD	cis	rs6071166	0.683	rs6015611	ENSG00000224635.1	RP4-564F22.5	-3.95	9.03e-05	0.0129	-0.2	-0.18	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38679658	chr20:38406011~38416797:-
LUAD	cis	rs10752881	1	rs12753817	ENSG00000224468.3	RP11-181K3.4	-3.95	9.03e-05	0.013	-0.15	-0.18	Colorectal cancer;	chr1:183001202	chr1:183138402~183141282:-
LUAD	cis	rs950880	0.767	rs12712142	ENSG00000234389.1	AC007278.3	3.95	9.04e-05	0.013	0.16	0.18	Serum protein levels (sST2);	chr2:102344124	chr2:102438713~102440475:+
LUAD	cis	rs2749592	0.531	rs994804	ENSG00000263064.2	RP11-291L22.7	-3.95	9.04e-05	0.013	-0.18	-0.18	Age-related hearing impairment (SNP x SNP interaction);	chr10:37611212	chr10:38448689~38448949:+
LUAD	cis	rs561341	1	rs2344312	ENSG00000265798.5	RP11-271K11.5	3.95	9.04e-05	0.013	0.25	0.18	Hip circumference adjusted for BMI;	chr17:31916564	chr17:31038575~31059121:-
LUAD	cis	rs202072	0.527	rs366904	ENSG00000272379.1	RP1-257A7.5	3.95	9.04e-05	0.013	0.29	0.18	HIV-1 viral setpoint;	chr6:13267449	chr6:13290018~13290490:-
LUAD	cis	rs3794924	1	rs35242229	ENSG00000266521.1	RP11-650P15.1	3.95	9.04e-05	0.013	0.34	0.18	Survival in colon cancer;	chr18:31472920	chr18:31496645~31497195:-
LUAD	cis	rs7809950	0.953	rs2253271	ENSG00000238832.1	snoU109	-3.95	9.04e-05	0.013	-0.26	-0.18	Coronary artery disease;	chr7:107560807	chr7:107603363~107603507:+
LUAD	cis	rs7178375	1	rs7169064	ENSG00000270015.1	RP11-540B6.6	3.95	9.04e-05	0.013	0.16	0.18	Hypertriglyceridemia;	chr15:30918659	chr15:30926514~30928407:+
LUAD	cis	rs62025270	0.848	rs62025269	ENSG00000259416.2	RP11-158M2.5	-3.95	9.05e-05	0.013	-0.23	-0.18	Idiopathic pulmonary fibrosis;	chr15:85756859	chr15:85754941~85756237:-
LUAD	cis	rs1559040	0.858	rs11695936	ENSG00000272156.1	RP11-477N3.1	-3.95	9.05e-05	0.013	-0.3	-0.18	Sudden cardiac arrest;	chr2:54090135	chr2:54082554~54085066:+
LUAD	cis	rs10129255	0.957	rs10136817	ENSG00000211967.3	IGHV3-53	-3.95	9.05e-05	0.013	-0.14	-0.18	Kawasaki disease;	chr14:106787730	chr14:106592676~106593347:-
LUAD	cis	rs2348418	0.932	rs16932850	ENSG00000247934.4	RP11-967K21.1	3.95	9.05e-05	0.013	0.2	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28457941	chr12:28163298~28190738:-
LUAD	cis	rs2348418	0.932	rs11049623	ENSG00000247934.4	RP11-967K21.1	3.95	9.05e-05	0.013	0.2	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28458374	chr12:28163298~28190738:-
LUAD	cis	rs4660214	0.666	rs596062	ENSG00000182109.6	RP11-69E11.4	3.95	9.05e-05	0.013	0.19	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39360333	chr1:39522280~39546187:-
LUAD	cis	rs8062405	0.755	rs62034350	ENSG00000251417.2	RP11-1348G14.4	-3.95	9.06e-05	0.013	-0.18	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28802743~28817828:+
LUAD	cis	rs7712401	0.791	rs4835897	ENSG00000249996.1	RP11-359P5.1	3.95	9.06e-05	0.013	0.21	0.18	Mean platelet volume;	chr5:122785809	chr5:123036271~123054667:+
LUAD	cis	rs11048434	0.518	rs1805669	ENSG00000256937.1	KRT17P8	-3.95	9.06e-05	0.013	-0.2	-0.18	Sjögren's syndrome;	chr12:9027655	chr12:9127783~9128645:+
LUAD	cis	rs8040855	0.627	rs11631548	ENSG00000259774.1	RP11-182J1.13	3.95	9.06e-05	0.013	0.23	0.18	Bulimia nervosa;	chr15:85076017	chr15:84422618~84425882:+
LUAD	cis	rs8040855	0.627	rs1532776	ENSG00000259774.1	RP11-182J1.13	3.95	9.06e-05	0.013	0.23	0.18	Bulimia nervosa;	chr15:85081383	chr15:84422618~84425882:+
LUAD	cis	rs1020064	0.636	rs2576750	ENSG00000235319.1	AC012360.4	-3.95	9.06e-05	0.013	-0.21	-0.18	AIDS;	chr2:105300178	chr2:105324210~105330529:+
LUAD	cis	rs10129255	0.956	rs10137268	ENSG00000211947.2	IGHV3-21	-3.95	9.06e-05	0.013	-0.12	-0.18	Kawasaki disease;	chr14:106697402	chr14:106235064~106235594:-
LUAD	cis	rs77688320	0.517	rs6717641	ENSG00000213090.2	AC007256.5	3.95	9.06e-05	0.013	0.2	0.18	Breast cancer;	chr2:201450484	chr2:201410544~201413308:-
LUAD	cis	rs4925386	1	rs4925382	ENSG00000273619.1	RP5-908M14.9	3.95	9.07e-05	0.013	0.16	0.18	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62343486	chr20:62386303~62386970:-
LUAD	cis	rs7560272	0.538	rs12233112	ENSG00000163016.8	ALMS1P	-3.95	9.07e-05	0.013	-0.19	-0.18	Schizophrenia;	chr2:73704637	chr2:73644919~73685576:+
LUAD	cis	rs6787172	0.811	rs1978781	ENSG00000272087.1	RP11-379F4.7	3.95	9.07e-05	0.013	0.19	0.18	Subjective well-being;	chr3:158488994	chr3:158693120~158693768:-
LUAD	cis	rs6787172	0.782	rs4431160	ENSG00000272087.1	RP11-379F4.7	3.95	9.07e-05	0.013	0.19	0.18	Subjective well-being;	chr3:158491277	chr3:158693120~158693768:-
LUAD	cis	rs8014204	0.804	rs2241274	ENSG00000279594.1	RP11-950C14.10	3.95	9.07e-05	0.013	0.2	0.18	Caffeine consumption;	chr14:74784628	chr14:75011269~75012851:-
LUAD	cis	rs2412819	0.571	rs56226333	ENSG00000166763.7	STRCP1	3.95	9.07e-05	0.013	0.27	0.18	Lung cancer;	chr15:43632410	chr15:43699488~43718184:-
LUAD	cis	rs3845817	1	rs3845817	ENSG00000281920.1	RP11-418H16.1	3.95	9.07e-05	0.013	0.21	0.18	Bipolar disorder;	chr2:65531391	chr2:65623272~65628424:+
LUAD	cis	rs10463554	0.892	rs158408	ENSG00000250682.4	LINC00491	3.95	9.07e-05	0.013	0.21	0.18	Parkinson's disease;	chr5:103071670	chr5:102609156~102671559:-
LUAD	cis	rs6496667	0.632	rs6496658	ENSG00000214433.4	GOLGA2P8	3.95	9.07e-05	0.013	0.23	0.18	Rheumatoid arthritis;	chr15:90340873	chr15:90291962~90295683:+
LUAD	cis	rs494459	0.536	rs11217063	ENSG00000278376.1	RP11-158I9.8	-3.95	9.07e-05	0.013	-0.19	-0.18	Height;	chr11:118855233	chr11:118791254~118793137:+
LUAD	cis	rs494459	0.536	rs11217065	ENSG00000278376.1	RP11-158I9.8	-3.95	9.07e-05	0.013	-0.19	-0.18	Height;	chr11:118855938	chr11:118791254~118793137:+
LUAD	cis	rs526231	0.543	rs246909	ENSG00000250682.4	LINC00491	3.95	9.07e-05	0.013	0.23	0.18	Primary biliary cholangitis;	chr5:103227976	chr5:102609156~102671559:-
LUAD	cis	rs8014252	0.803	rs1959477	ENSG00000259158.2	ADAM20P1	-3.95	9.07e-05	0.013	-0.29	-0.18	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70567499	chr14:70468881~70483756:-
LUAD	cis	rs8014252	0.803	rs2877672	ENSG00000259158.2	ADAM20P1	-3.95	9.07e-05	0.013	-0.29	-0.18	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70569542	chr14:70468881~70483756:-
LUAD	cis	rs62514666	1	rs62514704	ENSG00000261693.1	RP13-467H17.1	-3.95	9.08e-05	0.013	-0.4	-0.18	Facial morphology (factor 19);	chr8:142145516	chr8:142403652~142407028:+
LUAD	cis	rs875971	0.545	rs1796226	ENSG00000222364.1	RNU6-96P	-3.95	9.08e-05	0.013	-0.22	-0.18	Aortic root size;	chr7:66622723	chr7:66395191~66395286:+
LUAD	cis	rs4554975	0.689	rs7315771	ENSG00000274723.1	RP11-618L22.1	-3.95	9.08e-05	0.013	-0.21	-0.18	Metabolite levels (small molecules and protein measures);	chr12:46848016	chr12:46970504~46972155:+
LUAD	cis	rs736801	0.569	rs12517950	ENSG00000233006.5	AC034220.3	3.95	9.08e-05	0.013	0.16	0.18	Mosquito bite size;Breast cancer;	chr5:132395634	chr5:132311285~132369916:-
LUAD	cis	rs4713118	0.662	rs149970	ENSG00000280107.1	AL022393.9	-3.95	9.09e-05	0.013	-0.23	-0.18	Parkinson's disease;	chr6:28012442	chr6:28170845~28172521:+
LUAD	cis	rs4819052	0.851	rs2838856	ENSG00000215447.6	BX322557.10	-3.95	9.09e-05	0.013	-0.21	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260851	chr21:45288052~45291738:+
LUAD	cis	rs1910358	0.959	rs10044926	ENSG00000248874.4	C5orf17	-3.95	9.09e-05	0.013	-0.26	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr5:23909870	chr5:23951348~24178263:+
LUAD	cis	rs4374383	0.962	rs3811638	ENSG00000207383.1	Y_RNA	-3.95	9.09e-05	0.013	-0.21	-0.18	Hepatitis C induced liver fibrosis;	chr2:112019149	chr2:112579484~112579584:-
LUAD	cis	rs9876781	1	rs11712561	ENSG00000229759.1	MRPS18AP1	3.95	9.09e-05	0.013	0.17	0.18	Longevity;	chr3:48393807	chr3:48256350~48256938:-
LUAD	cis	rs875971	0.861	rs801215	ENSG00000273448.1	RP11-166O4.6	-3.95	9.09e-05	0.013	-0.17	-0.18	Aortic root size;	chr7:66546951	chr7:67333047~67334383:+
LUAD	cis	rs2143950	0.512	rs79000843	ENSG00000226677.3	IGBP1P1	-3.95	9.09e-05	0.013	-0.22	-0.18	Atopic dermatitis;	chr14:35041694	chr14:34939324~34940332:+
LUAD	cis	rs2717559	0.542	rs11774823	ENSG00000253741.1	CTD-2292P10.4	3.95	9.09e-05	0.013	0.21	0.18	Urinary tract infection frequency;	chr8:142806152	chr8:142702252~142726973:-
LUAD	cis	rs3096299	0.781	rs3102381	ENSG00000182376.2	RP5-1142A6.8	3.95	9.09e-05	0.013	0.18	0.18	Multiple myeloma (IgH translocation);	chr16:89343312	chr16:88742767~88745748:+
LUAD	cis	rs2348418	0.864	rs6487688	ENSG00000244712.1	RP11-874G11.1	-3.95	9.09e-05	0.013	-0.21	-0.18	Lung function (FEV1);Lung function (FVC);	chr12:28558278	chr12:28564678~28565141:-
LUAD	cis	rs116095464	1	rs3777237	ENSG00000250848.1	CTD-2083E4.5	-3.95	9.09e-05	0.013	-0.38	-0.18	Breast cancer;	chr5:307526	chr5:288833~290321:-
LUAD	cis	rs2749592	0.55	rs4934881	ENSG00000263064.2	RP11-291L22.7	-3.95	9.09e-05	0.013	-0.19	-0.18	Age-related hearing impairment (SNP x SNP interaction);	chr10:37625418	chr10:38448689~38448949:+
LUAD	cis	rs8073060	0.544	rs225287	ENSG00000267592.1	CTC-507E2.2	3.95	9.09e-05	0.013	0.26	0.18	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35602468	chr17:35596904~35597128:-
LUAD	cis	rs4908769	0.624	rs2120461	ENSG00000232912.4	RP5-1115A15.1	-3.95	9.1e-05	0.013	-0.16	-0.18	Allergy;	chr1:8387662	chr1:8424645~8434838:+
LUAD	cis	rs3112357	0.62	rs3110816	ENSG00000223718.3	AC093107.7	3.95	9.1e-05	0.013	0.27	0.18	Plantar warts;	chr7:135719781	chr7:135660039~135660647:+
LUAD	cis	rs73198271	0.653	rs10099808	ENSG00000253893.2	FAM85B	-3.95	9.1e-05	0.013	-0.23	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802363	chr8:8167819~8226614:-
LUAD	cis	rs4819052	0.851	rs7276828	ENSG00000215447.6	BX322557.10	-3.95	9.1e-05	0.013	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275124	chr21:45288052~45291738:+
LUAD	cis	rs4819052	0.851	rs7281263	ENSG00000215447.6	BX322557.10	-3.95	9.1e-05	0.013	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275691	chr21:45288052~45291738:+
LUAD	cis	rs7613875	0.578	rs4688753	ENSG00000234667.1	ACTBP13	3.95	9.1e-05	0.013	0.2	0.18	Body mass index;	chr3:50037340	chr3:49873347~49877980:-
LUAD	cis	rs7613875	0.578	rs2526749	ENSG00000234667.1	ACTBP13	3.95	9.1e-05	0.013	0.2	0.18	Body mass index;	chr3:50039301	chr3:49873347~49877980:-
LUAD	cis	rs7613875	0.62	rs7430334	ENSG00000234667.1	ACTBP13	3.95	9.1e-05	0.013	0.2	0.18	Body mass index;	chr3:50040788	chr3:49873347~49877980:-
LUAD	cis	rs7613875	0.641	rs6793528	ENSG00000234667.1	ACTBP13	3.95	9.1e-05	0.013	0.2	0.18	Body mass index;	chr3:50062755	chr3:49873347~49877980:-
LUAD	cis	rs7613875	0.578	rs2624822	ENSG00000234667.1	ACTBP13	3.95	9.1e-05	0.013	0.2	0.18	Body mass index;	chr3:50069786	chr3:49873347~49877980:-
LUAD	cis	rs3753275	0.69	rs2297867	ENSG00000232912.4	RP5-1115A15.1	3.95	9.11e-05	0.013	0.2	0.18	Educational attainment;	chr1:8526504	chr1:8424645~8434838:+
LUAD	cis	rs1045529	0.524	rs34251783	ENSG00000233609.3	RP11-62H7.2	-3.95	9.11e-05	0.013	-0.15	-0.18	Myopia (pathological);Myopia;	chr8:9033866	chr8:8961200~8979025:+
LUAD	cis	rs453301	0.719	rs34004903	ENSG00000233609.3	RP11-62H7.2	-3.95	9.11e-05	0.013	-0.15	-0.18	Joint mobility (Beighton score);	chr8:9035094	chr8:8961200~8979025:+
LUAD	cis	rs853679	0.517	rs4713150	ENSG00000226314.6	ZNF192P1	-3.95	9.11e-05	0.013	-0.24	-0.18	Depression;	chr6:28168434	chr6:28161781~28169594:+
LUAD	cis	rs9467773	0.596	rs2451750	ENSG00000241549.7	GUSBP2	3.95	9.11e-05	0.013	0.19	0.18	Intelligence (multi-trait analysis);	chr6:26646351	chr6:26871484~26956554:-
LUAD	cis	rs9467773	0.596	rs2451751	ENSG00000241549.7	GUSBP2	3.95	9.11e-05	0.013	0.19	0.18	Intelligence (multi-trait analysis);	chr6:26646486	chr6:26871484~26956554:-
LUAD	cis	rs9467773	0.62	rs2504600	ENSG00000241549.7	GUSBP2	3.95	9.11e-05	0.013	0.19	0.18	Intelligence (multi-trait analysis);	chr6:26648106	chr6:26871484~26956554:-
LUAD	cis	rs9467773	0.62	rs2130657	ENSG00000241549.7	GUSBP2	3.95	9.11e-05	0.013	0.19	0.18	Intelligence (multi-trait analysis);	chr6:26650598	chr6:26871484~26956554:-
LUAD	cis	rs9467773	0.62	rs2498351	ENSG00000241549.7	GUSBP2	3.95	9.11e-05	0.013	0.19	0.18	Intelligence (multi-trait analysis);	chr6:26659414	chr6:26871484~26956554:-
LUAD	cis	rs9467773	0.62	rs2504566	ENSG00000241549.7	GUSBP2	3.95	9.11e-05	0.013	0.19	0.18	Intelligence (multi-trait analysis);	chr6:26660260	chr6:26871484~26956554:-
LUAD	cis	rs9467773	0.62	rs2494716	ENSG00000241549.7	GUSBP2	3.95	9.11e-05	0.013	0.19	0.18	Intelligence (multi-trait analysis);	chr6:26662508	chr6:26871484~26956554:-
LUAD	cis	rs916888	0.773	rs9896243	ENSG00000260075.1	NSFP1	-3.95	9.11e-05	0.013	-0.29	-0.18	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46372855~46487141:+
LUAD	cis	rs1577917	0.629	rs6927475	ENSG00000220563.1	PKMP3	3.95	9.11e-05	0.013	0.16	0.18	Response to antipsychotic treatment;	chr6:85497055	chr6:85659892~85660606:-
LUAD	cis	rs6479901	0.841	rs1904297	ENSG00000232075.1	MRPL35P2	-3.95	9.11e-05	0.0131	-0.25	-0.18	Intelligence (multi-trait analysis);	chr10:63255428	chr10:63634317~63634827:-
LUAD	cis	rs703842	1	rs10877012	ENSG00000245651.2	RP11-620J15.2	3.95	9.12e-05	0.0131	0.19	0.18	Multiple sclerosis;	chr12:57768302	chr12:57869835~57896482:-
LUAD	cis	rs13434995	0.513	rs1048004	ENSG00000273257.1	RP11-177J6.1	-3.95	9.12e-05	0.0131	-0.23	-0.18	Adiponectin levels;	chr4:55434042	chr4:55387949~55388271:+
LUAD	cis	rs13434995	0.513	rs1801260	ENSG00000273257.1	RP11-177J6.1	-3.95	9.12e-05	0.0131	-0.23	-0.18	Adiponectin levels;	chr4:55435202	chr4:55387949~55388271:+
LUAD	cis	rs13434995	0.513	rs17721215	ENSG00000273257.1	RP11-177J6.1	-3.95	9.12e-05	0.0131	-0.23	-0.18	Adiponectin levels;	chr4:55437620	chr4:55387949~55388271:+
LUAD	cis	rs11242704	0.632	rs2816291	ENSG00000272279.1	RP11-157J24.2	-3.95	9.12e-05	0.0131	-0.25	-0.18	Response to hepatitis C treatment;	chr6:1537887	chr6:1528364~1528911:-
LUAD	cis	rs35740288	0.721	rs17637276	ENSG00000259407.1	RP11-158M2.3	-3.95	9.12e-05	0.0131	-0.18	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85700289	chr15:85744109~85750281:-
LUAD	cis	rs453301	0.686	rs6748	ENSG00000233609.3	RP11-62H7.2	-3.95	9.12e-05	0.0131	-0.15	-0.18	Joint mobility (Beighton score);	chr8:9033292	chr8:8961200~8979025:+
LUAD	cis	rs6903823	0.508	rs1150721	ENSG00000219392.1	RP1-265C24.5	-3.95	9.12e-05	0.0131	-0.22	-0.18	Pulmonary function;	chr6:28287263	chr6:28115628~28116551:+
LUAD	cis	rs6754311	0.731	rs3769005	ENSG00000226806.1	AC011893.3	-3.95	9.12e-05	0.0131	-0.22	-0.18	Mosquito bite size;	chr2:135845796	chr2:135820191~135823087:+
LUAD	cis	rs2295359	1	rs11465753	ENSG00000275678.1	RP4-547N15.3	-3.95	9.12e-05	0.0131	-0.19	-0.18	Psoriasis;	chr1:67165740	chr1:67121605~67123956:-
LUAD	cis	rs6142102	0.961	rs4911385	ENSG00000275784.1	RP5-1125A11.6	-3.95	9.12e-05	0.0131	-0.2	-0.18	Skin pigmentation;	chr20:33970787	chr20:33989480~33991818:-
LUAD	cis	rs3753275	0.579	rs10779703	ENSG00000232912.4	RP5-1115A15.1	3.95	9.13e-05	0.0131	0.2	0.18	Educational attainment;	chr1:8536123	chr1:8424645~8434838:+
LUAD	cis	rs763121	0.853	rs5757187	ENSG00000225450.1	RP3-508I15.14	3.95	9.13e-05	0.0131	0.17	0.18	Menopause (age at onset);	chr22:38625517	chr22:38739003~38749041:+
LUAD	cis	rs6793245	0.843	rs35231307	ENSG00000229589.1	ACVR2B-AS1	-3.95	9.13e-05	0.0131	-0.23	-0.18	QT interval;	chr3:38547917	chr3:38451027~38454820:-
LUAD	cis	rs848	1	rs20541	ENSG00000233006.5	AC034220.3	-3.95	9.13e-05	0.0131	-0.19	-0.18	Allergic disease (asthma, hay fever or eczema);Alopecia areata;	chr5:132660272	chr5:132311285~132369916:-
LUAD	cis	rs11220082	0.644	rs12577961	ENSG00000254671.2	STT3A-AS1	-3.95	9.13e-05	0.0131	-0.21	-0.18	Schizophrenia;	chr11:125438943	chr11:125570284~125592568:-
LUAD	cis	rs710913	0.774	rs2695319	ENSG00000182109.6	RP11-69E11.4	3.95	9.14e-05	0.0131	0.2	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39591028	chr1:39522280~39546187:-
LUAD	cis	rs4499344	0.73	rs12460663	ENSG00000201388.1	SNORA68	3.95	9.14e-05	0.0131	0.19	0.18	Mean platelet volume;	chr19:32607332	chr19:32608337~32608469:-
LUAD	cis	rs9646944	0.501	rs10169676	ENSG00000234389.1	AC007278.3	3.95	9.14e-05	0.0131	0.2	0.18	Blood protein levels;	chr2:102458459	chr2:102438713~102440475:+
LUAD	cis	rs950881	0.562	rs11692335	ENSG00000234389.1	AC007278.3	3.95	9.14e-05	0.0131	0.2	0.18	Allergy;	chr2:102461433	chr2:102438713~102440475:+
LUAD	cis	rs9646944	0.501	rs10186052	ENSG00000234389.1	AC007278.3	3.95	9.14e-05	0.0131	0.2	0.18	Blood protein levels;	chr2:102463148	chr2:102438713~102440475:+
LUAD	cis	rs9646944	0.501	rs17027246	ENSG00000234389.1	AC007278.3	3.95	9.14e-05	0.0131	0.2	0.18	Blood protein levels;	chr2:102463595	chr2:102438713~102440475:+
LUAD	cis	rs9876781	1	rs10470686	ENSG00000229759.1	MRPS18AP1	3.95	9.14e-05	0.0131	0.17	0.18	Longevity;	chr3:48408549	chr3:48256350~48256938:-
LUAD	cis	rs7246657	0.551	rs10407224	ENSG00000267309.1	CTD-2630F21.1	3.95	9.14e-05	0.0131	0.3	0.18	Coronary artery calcification;	chr19:37160568	chr19:36489649~36491040:+
LUAD	cis	rs12073359	1	rs7550350	ENSG00000223945.2	RP11-458I7.1	3.95	9.14e-05	0.0131	0.24	0.18	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150031555	chr1:150053864~150055034:+
LUAD	cis	rs34779708	0.931	rs7099036	ENSG00000271335.4	RP11-324I22.4	3.95	9.14e-05	0.0131	0.19	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35060646	chr10:35314552~35336401:-
LUAD	cis	rs2243480	1	rs1404147	ENSG00000226002.1	RP11-460N20.5	-3.95	9.14e-05	0.0131	-0.27	-0.18	Diabetic kidney disease;	chr7:65799537	chr7:65084103~65100232:+
LUAD	cis	rs9309473	0.95	rs6546853	ENSG00000230002.2	ALMS1-IT1	3.95	9.14e-05	0.0131	0.22	0.18	Metabolite levels;	chr2:73606612	chr2:73456764~73459484:+
LUAD	cis	rs8085804	0.597	rs8084832	ENSG00000276174.1	RP11-687E1.2	-3.95	9.14e-05	0.0131	-0.23	-0.18	Cognitive performance;	chr18:42669061	chr18:42052705~42053030:+
LUAD	cis	rs1953600	0.645	rs2573351	ENSG00000226659.1	RP11-137H2.4	-3.95	9.14e-05	0.0131	-0.23	-0.18	Sarcoidosis;	chr10:80171685	chr10:80529597~80535942:-
LUAD	cis	rs10090774	0.687	rs11995049	ENSG00000280303.2	ERICD	-3.95	9.15e-05	0.0131	-0.2	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140682990	chr8:140636281~140638283:+
LUAD	cis	rs8030379	0.967	rs62027761	ENSG00000230373.7	GOLGA6L5P	-3.95	9.15e-05	0.0131	-0.16	-0.18	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83903845	chr15:84507885~84516814:-
LUAD	cis	rs55670112	0.77	rs2247497	ENSG00000271797.1	CTC-428G20.6	-3.95	9.15e-05	0.0131	-0.19	-0.18	Epilepsy;	chr5:114794764	chr5:115262505~115263448:+
LUAD	cis	rs7107174	0.901	rs2450137	ENSG00000251323.2	RP11-452H21.4	3.95	9.15e-05	0.0131	0.23	0.18	Testicular germ cell tumor;	chr11:78214187	chr11:78423982~78429836:-
LUAD	cis	rs7107174	0.901	rs2450136	ENSG00000251323.2	RP11-452H21.4	3.95	9.15e-05	0.0131	0.23	0.18	Testicular germ cell tumor;	chr11:78214227	chr11:78423982~78429836:-
LUAD	cis	rs7107174	0.901	rs1055248	ENSG00000251323.2	RP11-452H21.4	3.95	9.15e-05	0.0131	0.23	0.18	Testicular germ cell tumor;	chr11:78214527	chr11:78423982~78429836:-
LUAD	cis	rs4795519	0.778	rs11657685	ENSG00000266313.1	RP11-173M1.4	3.95	9.15e-05	0.0131	0.23	0.18	Chronic myeloid leukemia;	chr17:27169586	chr17:27333256~27348491:+
LUAD	cis	rs7202877	0.656	rs8048677	ENSG00000280152.1	RP11-331F4.5	3.95	9.15e-05	0.0131	0.21	0.18	Type 1 diabetes;Type 2 diabetes;	chr16:75358130	chr16:75245994~75250077:-
LUAD	cis	rs7202877	0.706	rs8054586	ENSG00000280152.1	RP11-331F4.5	3.95	9.15e-05	0.0131	0.21	0.18	Type 1 diabetes;Type 2 diabetes;	chr16:75376807	chr16:75245994~75250077:-
LUAD	cis	rs9925964	0.967	rs14235	ENSG00000232748.3	RP11-196G11.6	3.95	9.15e-05	0.0131	0.22	0.18	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31110472	chr16:31056460~31062803:+
LUAD	cis	rs6964587	0.967	rs2040499	ENSG00000188693.7	CYP51A1-AS1	3.95	9.16e-05	0.0131	0.21	0.18	Breast cancer;	chr7:92180343	chr7:92134604~92180725:+
LUAD	cis	rs301901	0.501	rs10805626	ENSG00000250155.1	CTD-2353F22.1	3.95	9.16e-05	0.0131	0.2	0.18	Height;	chr5:37499115	chr5:36666214~36725195:-
LUAD	cis	rs7129556	0.737	rs4344516	ENSG00000241782.1	RP11-91P24.1	3.95	9.16e-05	0.0131	0.25	0.18	Weight loss (gastric bypass surgery);	chr11:77727014	chr11:77868722~77869195:-
LUAD	cis	rs301800	0.52	rs4908767	ENSG00000232912.4	RP5-1115A15.1	3.95	9.16e-05	0.0131	0.21	0.18	Educational attainment (years of education);	chr1:8594658	chr1:8424645~8434838:+
LUAD	cis	rs3753275	0.568	rs4908504	ENSG00000232912.4	RP5-1115A15.1	3.95	9.16e-05	0.0131	0.21	0.18	Educational attainment;	chr1:8597140	chr1:8424645~8434838:+
LUAD	cis	rs3764400	0.567	rs2240120	ENSG00000278765.1	RP5-890E16.5	3.95	9.16e-05	0.0131	0.31	0.18	Body mass index;	chr17:48064782	chr17:48066704~48067293:-
LUAD	cis	rs4853525	0.651	rs12623559	ENSG00000235852.1	AC005540.3	3.95	9.16e-05	0.0131	0.22	0.18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190868617	chr2:190880797~190882059:-
LUAD	cis	rs7617773	0.78	rs3731489	ENSG00000199476.1	Y_RNA	-3.95	9.16e-05	0.0131	-0.23	-0.18	Coronary artery disease;	chr3:48187416	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.779	rs3731487	ENSG00000199476.1	Y_RNA	-3.95	9.16e-05	0.0131	-0.23	-0.18	Coronary artery disease;	chr3:48188134	chr3:48288587~48288694:+
LUAD	cis	rs6732426	0.721	rs35491011	ENSG00000279873.2	LINC01126	3.95	9.17e-05	0.0131	0.15	0.18	Hair morphology;	chr2:43386851	chr2:43227210~43228855:+
LUAD	cis	rs2927438	0.571	rs2965106	ENSG00000266903.1	CTB-171A8.1	-3.95	9.17e-05	0.0131	-0.22	-0.18	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);	chr19:44729108	chr19:44632199~44718759:-
LUAD	cis	rs7005380	0.733	rs4871787	ENSG00000279347.1	RP11-85I17.2	3.95	9.17e-05	0.0131	0.15	0.18	Interstitial lung disease;	chr8:119924178	chr8:119838736~119840385:-
LUAD	cis	rs853679	0.55	rs1233707	ENSG00000226314.6	ZNF192P1	-3.95	9.17e-05	0.0131	-0.23	-0.18	Depression;	chr6:28205175	chr6:28161781~28169594:+
LUAD	cis	rs4474465	0.79	rs10793325	ENSG00000251323.2	RP11-452H21.4	-3.94	9.17e-05	0.0131	-0.21	-0.18	Alzheimer's disease (survival time);	chr11:78541529	chr11:78423982~78429836:-
LUAD	cis	rs12122100	0.696	rs12752148	ENSG00000244371.2	PFN1P8	3.94	9.17e-05	0.0131	0.23	0.18	HIV-1 control;	chr1:147085526	chr1:146957117~146957659:-
LUAD	cis	rs9876781	1	rs6794875	ENSG00000229759.1	MRPS18AP1	3.94	9.17e-05	0.0131	0.17	0.18	Longevity;	chr3:48414217	chr3:48256350~48256938:-
LUAD	cis	rs2749592	0.531	rs10764134	ENSG00000263064.2	RP11-291L22.7	-3.94	9.17e-05	0.0131	-0.19	-0.18	Age-related hearing impairment (SNP x SNP interaction);	chr10:37567732	chr10:38448689~38448949:+
LUAD	cis	rs1876905	0.597	rs354538	ENSG00000271789.1	RP5-1112D6.7	-3.94	9.17e-05	0.0131	-0.25	-0.18	Mean corpuscular hemoglobin;	chr6:111196863	chr6:111297126~111298510:+
LUAD	cis	rs6661961	0.686	rs4845766	ENSG00000237975.5	FLG-AS1	-3.94	9.18e-05	0.0131	-0.23	-0.18	Atopic dermatitis;	chr1:152418806	chr1:152168125~152445456:+
LUAD	cis	rs4835473	0.932	rs5015760	ENSG00000249741.2	RP11-673E1.3	3.94	9.18e-05	0.0131	0.21	0.18	Immature fraction of reticulocytes;	chr4:143737955	chr4:143911514~143912053:-
LUAD	cis	rs1541160	0.957	rs6694304	ENSG00000239494.2	RN7SL333P	3.94	9.18e-05	0.0131	0.17	0.18	Amyotrophic lateral sclerosis;	chr1:170040496	chr1:169859756~169860052:+
LUAD	cis	rs3764021	0.87	rs7970116	ENSG00000214776.8	RP11-726G1.1	-3.94	9.18e-05	0.0131	-0.19	-0.18	Type 1 diabetes;	chr12:9727518	chr12:9467552~9576275:+
LUAD	cis	rs812925	1	rs812925	ENSG00000271889.1	RP11-493E12.1	-3.94	9.18e-05	0.0131	-0.22	-0.18	Immature fraction of reticulocytes;	chr2:61453858	chr2:61151433~61162105:-
LUAD	cis	rs4965272	0.83	rs4633693	ENSG00000272808.2	RP11-66B24.7	3.94	9.18e-05	0.0131	0.23	0.18	Gastroesophageal reflux disease;	chr15:100053384	chr15:100849831~100865457:+
LUAD	cis	rs2014572	0.967	rs8106734	ENSG00000268379.1	CTC-360J11.4	3.94	9.18e-05	0.0131	0.21	0.18	Hyperactive-impulsive symptoms;	chr19:57252178	chr19:57175233~57177921:+
LUAD	cis	rs3026445	0.519	rs10492229	ENSG00000278993.1	RP3-424M6.4	-3.94	9.18e-05	0.0131	-0.21	-0.18	QT interval;	chr12:110164368	chr12:110501614~110503441:+
LUAD	cis	rs12148477	0.623	rs4775942	ENSG00000259668.4	RP11-707P17.2	-3.94	9.18e-05	0.0131	-0.13	-0.18	Follicule stimulating hormone;	chr15:51371400	chr15:51457286~51460582:+
LUAD	cis	rs28386778	0.83	rs7209321	ENSG00000240280.5	TCAM1P	-3.94	9.19e-05	0.0131	-0.21	-0.18	Prudent dietary pattern;	chr17:63778308	chr17:63849292~63864379:+
LUAD	cis	rs2898681	0.642	rs11538878	ENSG00000248375.1	RP11-177B4.1	-3.94	9.19e-05	0.0131	-0.25	-0.18	Optic nerve measurement (cup area);	chr4:52862357	chr4:52720081~52720831:-
LUAD	cis	rs6479901	0.846	rs7907462	ENSG00000232075.1	MRPL35P2	-3.94	9.19e-05	0.0131	-0.25	-0.18	Intelligence (multi-trait analysis);	chr10:63295773	chr10:63634317~63634827:-
LUAD	cis	rs6088580	0.608	rs1205342	ENSG00000276073.1	RP5-1125A11.7	3.94	9.19e-05	0.0131	0.17	0.18	Glomerular filtration rate (creatinine);	chr20:34334036	chr20:33985617~33988989:-
LUAD	cis	rs6787172	0.811	rs9810114	ENSG00000272087.1	RP11-379F4.7	3.94	9.19e-05	0.0131	0.19	0.18	Subjective well-being;	chr3:158494266	chr3:158693120~158693768:-
LUAD	cis	rs35065479	1	rs12938842	ENSG00000263004.1	RP11-166P13.3	-3.94	9.19e-05	0.0131	-0.22	-0.18	Schizophrenia;	chr17:57658444	chr17:57078298~57085024:-
LUAD	cis	rs911555	0.755	rs35233301	ENSG00000259775.1	RP11-45P15.4	3.94	9.19e-05	0.0131	0.23	0.18	Intelligence (multi-trait analysis);	chr14:103418954	chr14:103331674~103332367:-
LUAD	cis	rs11992162	0.636	rs13265816	ENSG00000255046.1	RP11-297N6.4	-3.94	9.19e-05	0.0131	-0.22	-0.18	Monocyte count;	chr8:11939976	chr8:11797928~11802568:-
LUAD	cis	rs4713118	0.539	rs200988	ENSG00000280107.1	AL022393.9	-3.94	9.2e-05	0.0131	-0.22	-0.18	Parkinson's disease;	chr6:27851575	chr6:28170845~28172521:+
LUAD	cis	rs9302635	0.513	rs7198572	ENSG00000260886.1	TAT-AS1	3.94	9.2e-05	0.0131	0.23	0.18	Blood protein levels;	chr16:72149321	chr16:71565789~71578187:+
LUAD	cis	rs524281	0.814	rs2270448	ENSG00000255320.1	RP11-755F10.1	3.94	9.2e-05	0.0132	0.27	0.18	Electroencephalogram traits;	chr11:66068460	chr11:66244840~66246239:-
LUAD	cis	rs4795519	0.645	rs2169957	ENSG00000266313.1	RP11-173M1.4	3.94	9.2e-05	0.0132	0.23	0.18	Chronic myeloid leukemia;	chr17:27156084	chr17:27333256~27348491:+
LUAD	cis	rs12701220	0.504	rs12702092	ENSG00000229043.2	AC091729.9	-3.94	9.2e-05	0.0132	-0.23	-0.18	Bronchopulmonary dysplasia;	chr7:1106232	chr7:1160374~1165267:+
LUAD	cis	rs4144027	0.967	rs72712857	ENSG00000258914.1	CTD-2134A5.3	-3.94	9.2e-05	0.0132	-0.21	-0.18	Blood metabolite levels;	chr14:103896336	chr14:103875055~103877478:+
LUAD	cis	rs4849121	0.535	rs999641	ENSG00000235721.1	AC013268.3	-3.94	9.2e-05	0.0132	-0.2	-0.18	IgA nephropathy;	chr2:110840830	chr2:110007675~110010783:+
LUAD	cis	rs860295	0.702	rs10796943	ENSG00000225855.5	RUSC1-AS1	3.94	9.2e-05	0.0132	0.12	0.18	Body mass index;	chr1:155444938	chr1:155316863~155324176:-
LUAD	cis	rs7760535	0.826	rs7753887	ENSG00000230177.1	RP5-1112D6.4	-3.94	9.2e-05	0.0132	-0.16	-0.18	Metabolic traits;	chr6:111533904	chr6:111277932~111278742:+
LUAD	cis	rs453301	0.598	rs1025395	ENSG00000233609.3	RP11-62H7.2	3.94	9.21e-05	0.0132	0.14	0.18	Joint mobility (Beighton score);	chr8:8979093	chr8:8961200~8979025:+
LUAD	cis	rs2657294	0.796	rs7082123	ENSG00000226051.5	ZNF503-AS1	-3.94	9.21e-05	0.0132	-0.24	-0.18	Pneumonia;	chr10:75091101	chr10:75269819~75373500:+
LUAD	cis	rs6088580	0.634	rs11700221	ENSG00000276073.1	RP5-1125A11.7	3.94	9.21e-05	0.0132	0.17	0.18	Glomerular filtration rate (creatinine);	chr20:34352514	chr20:33985617~33988989:-
LUAD	cis	rs10129255	0.957	rs28887506	ENSG00000274576.2	IGHV2-70	3.94	9.21e-05	0.0132	0.16	0.18	Kawasaki disease;	chr14:106785589	chr14:106770577~106771020:-
LUAD	cis	rs62458065	0.85	rs28693551	ENSG00000226468.2	AC018641.7	3.94	9.21e-05	0.0132	0.29	0.18	Metabolite levels (HVA/MHPG ratio);	chr7:32429775	chr7:32456963~32457758:-
LUAD	cis	rs62458065	0.85	rs28677012	ENSG00000226468.2	AC018641.7	3.94	9.21e-05	0.0132	0.29	0.18	Metabolite levels (HVA/MHPG ratio);	chr7:32430199	chr7:32456963~32457758:-
LUAD	cis	rs2060793	0.506	rs10741658	ENSG00000251991.1	RNU7-49P	3.94	9.21e-05	0.0132	0.19	0.18	Vitamin D levels;	chr11:14903190	chr11:14478892~14478953:+
LUAD	cis	rs2242116	0.932	rs7646906	ENSG00000271161.1	BOLA2P2	3.94	9.21e-05	0.0132	0.17	0.18	Birth weight;	chr3:46907889	chr3:47499841~47500407:+
LUAD	cis	rs131777	0.575	rs131760	ENSG00000272666.1	CTA-384D8.35	3.94	9.21e-05	0.0132	0.21	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50573507	chr22:50542305~50542906:-
LUAD	cis	rs442309	0.841	rs224042	ENSG00000238280.1	RP11-436D10.3	-3.94	9.21e-05	0.0132	-0.21	-0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62764530	chr10:62793562~62805887:-
LUAD	cis	rs6840258	0.891	rs3775209	ENSG00000251411.1	RP11-397E7.4	-3.94	9.21e-05	0.0132	-0.22	-0.18	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87125794	chr4:86913266~86914817:-
LUAD	cis	rs750134	0.515	rs12316621	ENSG00000257221.1	RP11-689B22.2	-3.94	9.21e-05	0.0132	-0.19	-0.18	Low high density lipoprotein cholesterol levels;	chr12:108817255	chr12:108628687~108641318:+
LUAD	cis	rs1552244	0.882	rs17081288	ENSG00000180385.7	EMC3-AS1	3.94	9.22e-05	0.0132	0.21	0.18	Alzheimer's disease;	chr3:10000429	chr3:9986893~10006990:+
LUAD	cis	rs1552244	0.816	rs56271597	ENSG00000180385.7	EMC3-AS1	3.94	9.22e-05	0.0132	0.21	0.18	Alzheimer's disease;	chr3:10001106	chr3:9986893~10006990:+
LUAD	cis	rs453301	0.624	rs2288673	ENSG00000253893.2	FAM85B	-3.94	9.22e-05	0.0132	-0.23	-0.18	Joint mobility (Beighton score);	chr8:9002766	chr8:8167819~8226614:-
LUAD	cis	rs2153535	0.518	rs9505510	ENSG00000230939.1	RP11-314C16.1	-3.94	9.22e-05	0.0132	-0.21	-0.18	Motion sickness;	chr6:8657603	chr6:8784178~8785445:+
LUAD	cis	rs9876781	1	rs6804774	ENSG00000229759.1	MRPS18AP1	3.94	9.22e-05	0.0132	0.17	0.18	Longevity;	chr3:48389129	chr3:48256350~48256938:-
LUAD	cis	rs17507216	1	rs17158413	ENSG00000276710.3	CSPG4P8	-3.94	9.22e-05	0.0132	-0.19	-0.18	Excessive daytime sleepiness;	chr15:82566658	chr15:82459472~82477258:+
LUAD	cis	rs7726839	0.794	rs10474792	ENSG00000248925.1	CTD-2083E4.6	3.94	9.22e-05	0.0132	0.25	0.18	Obesity-related traits;	chr5:599943	chr5:269858~271516:-
LUAD	cis	rs4879677	1	rs10435785	ENSG00000215441.3	CTAGE12P	-3.94	9.22e-05	0.0132	-0.21	-0.18	Gut microbiome composition (summer and winter);	chr9:27683815	chr9:27608382~27610745:-
LUAD	cis	rs11051970	1	rs11051970	ENSG00000274964.1	RP11-817I4.1	-3.94	9.22e-05	0.0132	-0.19	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr12:32384554	chr12:32339368~32340724:+
LUAD	cis	rs7208859	0.673	rs3816780	ENSG00000263603.1	CTD-2349P21.5	-3.94	9.22e-05	0.0132	-0.3	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834340	chr17:30729469~30731202:+
LUAD	cis	rs11992162	0.56	rs7846248	ENSG00000255046.1	RP11-297N6.4	-3.94	9.22e-05	0.0132	-0.22	-0.18	Monocyte count;	chr8:11936540	chr8:11797928~11802568:-
LUAD	cis	rs763121	0.853	rs2179142	ENSG00000228274.3	RP3-508I15.9	-3.94	9.22e-05	0.0132	-0.17	-0.18	Menopause (age at onset);	chr22:38641949	chr22:38667585~38681820:-
LUAD	cis	rs9487094	1	rs9480953	ENSG00000260273.1	RP11-425D10.10	3.94	9.22e-05	0.0132	0.23	0.18	Height;	chr6:109417941	chr6:109382795~109383666:+
LUAD	cis	rs1023500	0.573	rs1807494	ENSG00000205702.9	CYP2D7	-3.94	9.22e-05	0.0132	-0.14	-0.18	Schizophrenia;	chr22:42078134	chr22:42140203~42144577:-
LUAD	cis	rs1023500	0.573	rs8135801	ENSG00000205702.9	CYP2D7	-3.94	9.22e-05	0.0132	-0.14	-0.18	Schizophrenia;	chr22:42079564	chr22:42140203~42144577:-
LUAD	cis	rs848490	0.889	rs56265941	ENSG00000214293.7	APTR	3.94	9.23e-05	0.0132	0.23	0.18	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77593621	chr7:77657660~77696265:-
LUAD	cis	rs4819052	0.959	rs8130866	ENSG00000237664.1	LINC00316	-3.94	9.23e-05	0.0132	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252197	chr21:45338590~45341990:-
LUAD	cis	rs7493	0.901	rs11764079	ENSG00000233942.1	AC004012.1	-3.94	9.23e-05	0.0132	-0.24	-0.18	Yu-Zhi constitution type in type 2 diabetes;	chr7:95396917	chr7:95471835~95473998:+
LUAD	cis	rs4699052	0.507	rs6533085	ENSG00000246560.2	RP11-10L12.4	3.94	9.23e-05	0.0132	0.25	0.18	Testicular germ cell tumor;	chr4:103360429	chr4:102828055~102844075:+
LUAD	cis	rs7107174	0.892	rs2511167	ENSG00000251323.2	RP11-452H21.4	3.94	9.23e-05	0.0132	0.24	0.18	Testicular germ cell tumor;	chr11:78253652	chr11:78423982~78429836:-
LUAD	cis	rs2154319	0.887	rs213753	ENSG00000235358.1	RP11-399E6.1	3.94	9.23e-05	0.0132	0.24	0.18	Height;	chr1:41141659	chr1:41242373~41284861:+
LUAD	cis	rs2154319	0.79	rs213750	ENSG00000235358.1	RP11-399E6.1	3.94	9.23e-05	0.0132	0.24	0.18	Height;	chr1:41145142	chr1:41242373~41284861:+
LUAD	cis	rs2154319	0.836	rs213749	ENSG00000235358.1	RP11-399E6.1	3.94	9.23e-05	0.0132	0.24	0.18	Height;	chr1:41148218	chr1:41242373~41284861:+
LUAD	cis	rs2154319	0.887	rs213743	ENSG00000235358.1	RP11-399E6.1	3.94	9.23e-05	0.0132	0.24	0.18	Height;	chr1:41154715	chr1:41242373~41284861:+
LUAD	cis	rs2154319	0.887	rs213741	ENSG00000235358.1	RP11-399E6.1	3.94	9.23e-05	0.0132	0.24	0.18	Height;	chr1:41155713	chr1:41242373~41284861:+
LUAD	cis	rs35740288	0.545	rs11637283	ENSG00000202081.1	RNU6-1280P	3.94	9.23e-05	0.0132	0.25	0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85772872	chr15:85651522~85651628:-
LUAD	cis	rs1005277	0.522	rs289648	ENSG00000263064.2	RP11-291L22.7	3.94	9.23e-05	0.0132	0.19	0.18	Extrinsic epigenetic age acceleration;	chr10:37682909	chr10:38448689~38448949:+
LUAD	cis	rs8062405	0.723	rs4788079	ENSG00000251417.2	RP11-1348G14.4	-3.94	9.23e-05	0.0132	-0.18	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28802743~28817828:+
LUAD	cis	rs6957923	0.933	rs10950948	ENSG00000230658.1	KLHL7-AS1	-3.94	9.24e-05	0.0132	-0.21	-0.18	Height;	chr7:23466386	chr7:23101228~23105703:-
LUAD	cis	rs939960	0.571	rs62490361	ENSG00000279536.1	RP11-445N20.2	3.94	9.24e-05	0.0132	0.24	0.18	Neutrophil percentage of white cells;	chr7:150669350	chr7:149881477~149882105:+
LUAD	cis	rs10863681	0.764	rs12038701	ENSG00000227925.1	RP11-191N8.2	-3.94	9.24e-05	0.0132	-0.2	-0.18	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222069435	chr1:221827666~221840666:-
LUAD	cis	rs7429990	0.965	rs6791834	ENSG00000228638.1	FCF1P2	3.94	9.24e-05	0.0132	0.2	0.18	Educational attainment (years of education);	chr3:48073598	chr3:48290793~48291375:-
LUAD	cis	rs7429990	0.965	rs35689209	ENSG00000228638.1	FCF1P2	3.94	9.24e-05	0.0132	0.2	0.18	Educational attainment (years of education);	chr3:48078273	chr3:48290793~48291375:-
LUAD	cis	rs3096299	0.967	rs753852	ENSG00000182376.2	RP5-1142A6.8	3.94	9.24e-05	0.0132	0.19	0.18	Multiple myeloma (IgH translocation);	chr16:89380011	chr16:88742767~88745748:+
LUAD	cis	rs3096299	0.967	rs753853	ENSG00000182376.2	RP5-1142A6.8	3.94	9.24e-05	0.0132	0.19	0.18	Multiple myeloma (IgH translocation);	chr16:89380117	chr16:88742767~88745748:+
LUAD	cis	rs2227564	0.672	rs2459449	ENSG00000271816.1	BMS1P4	3.94	9.25e-05	0.0132	0.17	0.18	Crohn's disease;Inflammatory bowel disease;	chr10:73909255	chr10:73699151~73730487:-
LUAD	cis	rs2227564	0.761	rs2227552	ENSG00000271816.1	BMS1P4	3.94	9.25e-05	0.0132	0.17	0.18	Crohn's disease;Inflammatory bowel disease;	chr10:73909561	chr10:73699151~73730487:-
LUAD	cis	rs10504130	0.932	rs11787229	ENSG00000253475.1	RP11-110G21.2	-3.94	9.25e-05	0.0132	-0.31	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr8:51935311	chr8:51895957~51896374:-
LUAD	cis	rs10504130	0.932	rs79067987	ENSG00000253475.1	RP11-110G21.2	-3.94	9.25e-05	0.0132	-0.31	-0.18	Venous thromboembolism (SNP x SNP interaction);	chr8:51935697	chr8:51895957~51896374:-
LUAD	cis	rs8062405	0.573	rs7140	ENSG00000261419.1	RP11-57A19.4	3.94	9.25e-05	0.0132	0.21	0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28984436	chr16:28659696~28740781:-
LUAD	cis	rs7809950	1	rs7778270	ENSG00000238832.1	snoU109	3.94	9.25e-05	0.0132	0.26	0.18	Coronary artery disease;	chr7:107584222	chr7:107603363~107603507:+
LUAD	cis	rs1541160	1	rs1541160	ENSG00000239494.2	RN7SL333P	3.94	9.25e-05	0.0132	0.17	0.18	Amyotrophic lateral sclerosis;	chr1:170026661	chr1:169859756~169860052:+
LUAD	cis	rs7893279	0.505	rs12762481	ENSG00000225527.1	RP11-383B4.4	3.94	9.25e-05	0.0132	0.26	0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18640251	chr10:18531849~18533336:-
LUAD	cis	rs62355901	0.505	rs115495921	ENSG00000271828.1	CTD-2310F14.1	3.94	9.25e-05	0.0132	0.38	0.18	Breast cancer;	chr5:56833021	chr5:56927874~56929573:+
LUAD	cis	rs7809950	1	rs2712189	ENSG00000238832.1	snoU109	-3.94	9.25e-05	0.0132	-0.26	-0.18	Coronary artery disease;	chr7:107555302	chr7:107603363~107603507:+
LUAD	cis	rs7809950	1	rs2237676	ENSG00000238832.1	snoU109	-3.94	9.25e-05	0.0132	-0.26	-0.18	Coronary artery disease;	chr7:107557634	chr7:107603363~107603507:+
LUAD	cis	rs2395128	0.915	rs4746229	ENSG00000233313.2	HMGA1P5	3.94	9.26e-05	0.0132	0.34	0.18	Ulcerative colitis;Inflammatory bowel disease;	chr10:74770712	chr10:75276376~75276646:-
LUAD	cis	rs9890032	1	rs9890032	ENSG00000266490.1	CTD-2349P21.9	-3.94	9.26e-05	0.0132	-0.16	-0.18	Hip circumference adjusted for BMI;	chr17:30838916	chr17:30792372~30792833:+
LUAD	cis	rs5769707	0.935	rs1109320	ENSG00000235111.1	RP1-29C18.8	-3.94	9.26e-05	0.0132	-0.19	-0.18	Monocyte percentage of white cells;Monocyte count;	chr22:49595458	chr22:49612657~49615716:-
LUAD	cis	rs473651	0.935	rs520765	ENSG00000229915.1	AC016999.2	-3.94	9.26e-05	0.0132	-0.24	-0.18	Multiple system atrophy;	chr2:238446071	chr2:238427077~238427729:-
LUAD	cis	rs7429990	0.965	rs4858881	ENSG00000228638.1	FCF1P2	3.94	9.26e-05	0.0132	0.2	0.18	Educational attainment (years of education);	chr3:48082306	chr3:48290793~48291375:-
LUAD	cis	rs7940646	0.906	rs4442541	ENSG00000177112.6	MRVI1-AS1	3.94	9.26e-05	0.0132	0.23	0.18	Platelet aggregation;	chr11:10647625	chr11:10541272~10599932:+
LUAD	cis	rs3814244	0.515	rs2906856	ENSG00000236946.2	HNRNPA1P70	3.94	9.26e-05	0.0132	0.15	0.18	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996421	chr12:68035767~68036853:+
LUAD	cis	rs10197140	0.81	rs13413838	ENSG00000235721.1	AC013268.3	-3.94	9.26e-05	0.0132	-0.21	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110937220	chr2:110007675~110010783:+
LUAD	cis	rs7107174	0.901	rs4945275	ENSG00000251323.2	RP11-452H21.4	3.94	9.26e-05	0.0132	0.22	0.18	Testicular germ cell tumor;	chr11:78408776	chr11:78423982~78429836:-
LUAD	cis	rs4767841	0.935	rs7131914	ENSG00000248636.5	RP11-768F21.1	-3.94	9.27e-05	0.0132	-0.2	-0.18	Urgency urinary incontinence;	chr12:119717772	chr12:119387987~119668079:-
LUAD	cis	rs4660214	0.627	rs16837533	ENSG00000182109.6	RP11-69E11.4	3.94	9.27e-05	0.0132	0.24	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39238175	chr1:39522280~39546187:-
LUAD	cis	rs7107174	0.901	rs2510053	ENSG00000251323.2	RP11-452H21.4	3.94	9.27e-05	0.0132	0.22	0.18	Testicular germ cell tumor;	chr11:78248389	chr11:78423982~78429836:-
LUAD	cis	rs2803122	0.967	rs10123206	ENSG00000273226.1	RP11-513M16.8	3.94	9.27e-05	0.0132	0.19	0.18	Pulse pressure;	chr9:19246846	chr9:19375451~19375996:+
LUAD	cis	rs12681963	0.535	rs76136891	ENSG00000272375.1	RP11-51J9.6	3.94	9.28e-05	0.0132	0.38	0.18	Migraine;	chr8:30099694	chr8:30197404~30198048:+
LUAD	cis	rs8062405	0.755	rs4788073	ENSG00000251417.2	RP11-1348G14.4	-3.94	9.28e-05	0.0132	-0.18	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28802743~28817828:+
LUAD	cis	rs6951245	0.554	rs118191017	ENSG00000229043.2	AC091729.9	-3.94	9.28e-05	0.0132	-0.22	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1116210	chr7:1160374~1165267:+
LUAD	cis	rs10754283	0.557	rs1215508	ENSG00000231613.1	RP5-943J3.1	3.94	9.28e-05	0.0132	0.18	0.18	Amyotrophic lateral sclerosis (sporadic);	chr1:89623138	chr1:89788914~89790492:+
LUAD	cis	rs4987094	0.505	rs7928201	ENSG00000270179.1	RP11-159N11.4	3.94	9.28e-05	0.0132	0.23	0.18	Schizophrenia;	chr11:113342347	chr11:113368478~113369117:+
LUAD	cis	rs860295	0.702	rs5005770	ENSG00000225855.5	RUSC1-AS1	-3.94	9.28e-05	0.0133	-0.12	-0.18	Body mass index;	chr1:155375252	chr1:155316863~155324176:-
LUAD	cis	rs2098713	0.537	rs36190855	ENSG00000250155.1	CTD-2353F22.1	3.94	9.28e-05	0.0133	0.2	0.18	Telomere length;	chr5:37528407	chr5:36666214~36725195:-
LUAD	cis	rs42490	0.716	rs40638	ENSG00000251136.7	RP11-37B2.1	-3.94	9.29e-05	0.0133	-0.18	-0.18	Leprosy;	chr8:89815824	chr8:89609409~89757727:-
LUAD	cis	rs42490	0.716	rs370282	ENSG00000251136.7	RP11-37B2.1	-3.94	9.29e-05	0.0133	-0.18	-0.18	Leprosy;	chr8:89816117	chr8:89609409~89757727:-
LUAD	cis	rs2348418	0.966	rs7315631	ENSG00000247934.4	RP11-967K21.1	3.94	9.29e-05	0.0133	0.2	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28545311	chr12:28163298~28190738:-
LUAD	cis	rs7202877	0.706	rs4993971	ENSG00000280152.1	RP11-331F4.5	-3.94	9.29e-05	0.0133	-0.2	-0.18	Type 1 diabetes;Type 2 diabetes;	chr16:75377736	chr16:75245994~75250077:-
LUAD	cis	rs7208859	0.673	rs9913782	ENSG00000266490.1	CTD-2349P21.9	3.94	9.29e-05	0.0133	0.28	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910366	chr17:30792372~30792833:+
LUAD	cis	rs7189233	0.531	rs8055642	ENSG00000279344.1	RP11-44F14.7	3.94	9.29e-05	0.0133	0.15	0.18	Intelligence (multi-trait analysis);	chr16:53503669	chr16:53478957~53481550:-
LUAD	cis	rs6832769	0.961	rs2412646	ENSG00000272969.1	RP11-528I4.2	3.94	9.3e-05	0.0133	0.18	0.18	Personality dimensions;	chr4:55452605	chr4:55547112~55547889:+
LUAD	cis	rs6832769	1	rs11733864	ENSG00000272969.1	RP11-528I4.2	3.94	9.3e-05	0.0133	0.18	0.18	Personality dimensions;	chr4:55455363	chr4:55547112~55547889:+
LUAD	cis	rs7246657	0.943	rs13343502	ENSG00000226686.6	LINC01535	-3.94	9.3e-05	0.0133	-0.27	-0.18	Coronary artery calcification;	chr19:37471390	chr19:37251912~37265535:+
LUAD	cis	rs13434995	0.513	rs11240	ENSG00000273257.1	RP11-177J6.1	-3.94	9.3e-05	0.0133	-0.23	-0.18	Adiponectin levels;	chr4:55453183	chr4:55387949~55388271:+
LUAD	cis	rs13434995	0.513	rs7676245	ENSG00000273257.1	RP11-177J6.1	-3.94	9.3e-05	0.0133	-0.23	-0.18	Adiponectin levels;	chr4:55455150	chr4:55387949~55388271:+
LUAD	cis	rs910316	0.737	rs175045	ENSG00000279594.1	RP11-950C14.10	-3.94	9.3e-05	0.0133	-0.21	-0.18	Height;	chr14:75008572	chr14:75011269~75012851:-
LUAD	cis	rs12413361	0.967	rs10763841	ENSG00000272914.1	RP11-330O11.3	-3.94	9.3e-05	0.0133	-0.21	-0.18	Height;	chr10:30826078	chr10:30831828~30833387:-
LUAD	cis	rs520525	0.963	rs600093	ENSG00000271811.1	RP1-79C4.4	3.94	9.3e-05	0.0133	0.23	0.18	Atrial fibrillation;	chr1:170660697	chr1:170667381~170669425:+
LUAD	cis	rs8040855	0.627	rs17540307	ENSG00000259774.1	RP11-182J1.13	3.94	9.3e-05	0.0133	0.23	0.18	Bulimia nervosa;	chr15:85090614	chr15:84422618~84425882:+
LUAD	cis	rs7726839	0.794	rs6883536	ENSG00000248925.1	CTD-2083E4.6	3.94	9.3e-05	0.0133	0.24	0.18	Obesity-related traits;	chr5:599159	chr5:269858~271516:-
LUAD	cis	rs2098713	0.569	rs11957546	ENSG00000250155.1	CTD-2353F22.1	-3.94	9.3e-05	0.0133	-0.2	-0.18	Telomere length;	chr5:37506230	chr5:36666214~36725195:-
LUAD	cis	rs6840360	0.642	rs7676493	ENSG00000270265.1	RP11-731D1.4	-3.94	9.31e-05	0.0133	-0.18	-0.18	Intelligence (multi-trait analysis);	chr4:151505613	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.642	rs11735957	ENSG00000270265.1	RP11-731D1.4	-3.94	9.31e-05	0.0133	-0.18	-0.18	Intelligence (multi-trait analysis);	chr4:151506354	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.607	rs6815320	ENSG00000270265.1	RP11-731D1.4	-3.94	9.31e-05	0.0133	-0.18	-0.18	Intelligence (multi-trait analysis);	chr4:151511348	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.642	rs11726254	ENSG00000270265.1	RP11-731D1.4	-3.94	9.31e-05	0.0133	-0.18	-0.18	Intelligence (multi-trait analysis);	chr4:151517698	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.642	rs2053566	ENSG00000270265.1	RP11-731D1.4	-3.94	9.31e-05	0.0133	-0.18	-0.18	Intelligence (multi-trait analysis);	chr4:151524679	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.607	rs1561918	ENSG00000270265.1	RP11-731D1.4	-3.94	9.31e-05	0.0133	-0.18	-0.18	Intelligence (multi-trait analysis);	chr4:151525680	chr4:151333775~151353224:-
LUAD	cis	rs73108077	1	rs58925751	ENSG00000281376.1	ABALON	-3.94	9.31e-05	0.0133	-0.3	-0.18	Red blood cell density in sickle cell anemia;	chr20:31459409	chr20:31721507~31723409:+
LUAD	cis	rs10197140	0.857	rs10186144	ENSG00000235721.1	AC013268.3	-3.94	9.31e-05	0.0133	-0.19	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110883726	chr2:110007675~110010783:+
LUAD	cis	rs889398	0.774	rs6499263	ENSG00000226232.7	RP11-419C5.2	-3.94	9.31e-05	0.0133	-0.15	-0.18	Body mass index;	chr16:69856246	chr16:69976388~69996188:-
LUAD	cis	rs7208859	0.673	rs216420	ENSG00000280069.1	CTD-2349P21.3	-3.94	9.31e-05	0.0133	-0.21	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30611490	chr17:30738182~30740275:+
LUAD	cis	rs6964587	1	rs7791138	ENSG00000188693.7	CYP51A1-AS1	-3.94	9.31e-05	0.0133	-0.21	-0.18	Breast cancer;	chr7:92057475	chr7:92134604~92180725:+
LUAD	cis	rs6871536	1	rs10463893	ENSG00000233006.5	AC034220.3	-3.94	9.31e-05	0.0133	-0.2	-0.18	Asthma (childhood onset);	chr5:132592347	chr5:132311285~132369916:-
LUAD	cis	rs7615952	0.599	rs1875683	ENSG00000241288.6	RP11-379B18.5	-3.94	9.32e-05	0.0133	-0.23	-0.18	Blood pressure (smoking interaction);	chr3:126013638	chr3:125827238~125916384:-
LUAD	cis	rs875971	0.862	rs35378740	ENSG00000273448.1	RP11-166O4.6	3.94	9.32e-05	0.0133	0.17	0.18	Aortic root size;	chr7:66522725	chr7:67333047~67334383:+
LUAD	cis	rs875971	0.862	rs10950043	ENSG00000273448.1	RP11-166O4.6	3.94	9.32e-05	0.0133	0.17	0.18	Aortic root size;	chr7:66523623	chr7:67333047~67334383:+
LUAD	cis	rs875971	0.862	rs17747530	ENSG00000273448.1	RP11-166O4.6	3.94	9.32e-05	0.0133	0.17	0.18	Aortic root size;	chr7:66529742	chr7:67333047~67334383:+
LUAD	cis	rs875971	0.862	rs13226170	ENSG00000273448.1	RP11-166O4.6	3.94	9.32e-05	0.0133	0.17	0.18	Aortic root size;	chr7:66534311	chr7:67333047~67334383:+
LUAD	cis	rs875971	0.862	rs2420611	ENSG00000273448.1	RP11-166O4.6	3.94	9.32e-05	0.0133	0.17	0.18	Aortic root size;	chr7:66534333	chr7:67333047~67334383:+
LUAD	cis	rs7208859	0.573	rs216442	ENSG00000280069.1	CTD-2349P21.3	-3.94	9.32e-05	0.0133	-0.25	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604179	chr17:30738182~30740275:+
LUAD	cis	rs7404843	0.925	rs7404803	ENSG00000183458.12	RP11-958N24.1	-3.94	9.32e-05	0.0133	-0.22	-0.18	Testicular germ cell tumor;	chr16:15436597	chr16:14911551~14935708:+
LUAD	cis	rs865483	0.826	rs853198	ENSG00000276054.1	RP11-378E13.3	3.94	9.32e-05	0.0133	0.21	0.18	Monocyte count;	chr17:37489236	chr17:37386886~37387926:+
LUAD	cis	rs73198271	0.74	rs964771	ENSG00000253893.2	FAM85B	-3.94	9.32e-05	0.0133	-0.23	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793429	chr8:8167819~8226614:-
LUAD	cis	rs4268898	0.722	rs7564420	ENSG00000223754.1	AC008073.9	3.94	9.32e-05	0.0133	0.21	0.18	Asthma;	chr2:24191133	chr2:24199839~24201698:-
LUAD	cis	rs7138300	0.526	rs17226898	ENSG00000258053.1	CTD-2021H9.3	3.94	9.33e-05	0.0133	0.21	0.18	Type 2 diabetes;	chr12:71191963	chr12:71047402~71118247:-
LUAD	cis	rs11673344	0.832	rs11084871	ENSG00000267309.1	CTD-2630F21.1	-3.94	9.33e-05	0.0133	-0.22	-0.18	Obesity-related traits;	chr19:37042023	chr19:36489649~36491040:+
LUAD	cis	rs10463554	0.892	rs1561404	ENSG00000250682.4	LINC00491	3.94	9.33e-05	0.0133	0.22	0.18	Parkinson's disease;	chr5:102963647	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.892	rs1560040	ENSG00000250682.4	LINC00491	3.94	9.33e-05	0.0133	0.22	0.18	Parkinson's disease;	chr5:102964363	chr5:102609156~102671559:-
LUAD	cis	rs7178424	0.875	rs28513564	ENSG00000259251.2	RP11-643M14.1	-3.94	9.33e-05	0.0133	-0.19	-0.18	Height;	chr15:61940161	chr15:62060503~62062434:+
LUAD	cis	rs6840360	0.642	rs11099819	ENSG00000270265.1	RP11-731D1.4	-3.94	9.33e-05	0.0133	-0.18	-0.18	Intelligence (multi-trait analysis);	chr4:151509026	chr4:151333775~151353224:-
LUAD	cis	rs2024714	0.902	rs1535140	ENSG00000273812.1	WI2-87327B8.2	3.94	9.33e-05	0.0133	0.19	0.18	Longevity;	chr20:61643148	chr20:62596732~62603115:-
LUAD	cis	rs9467773	0.595	rs2451736	ENSG00000261353.1	CTA-14H9.5	-3.94	9.33e-05	0.0133	-0.2	-0.18	Intelligence (multi-trait analysis);	chr6:26620316	chr6:26527063~26527404:+
LUAD	cis	rs11051970	0.918	rs11051969	ENSG00000274964.1	RP11-817I4.1	-3.94	9.33e-05	0.0133	-0.2	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr12:32384189	chr12:32339368~32340724:+
LUAD	cis	rs1355223	0.902	rs7121272	ENSG00000271369.1	RP11-350D17.3	-3.94	9.34e-05	0.0133	-0.21	-0.18	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34731015	chr11:34709600~34710161:+
LUAD	cis	rs7976269	0.609	rs10771478	ENSG00000257176.2	RP11-996F15.2	3.94	9.34e-05	0.0133	0.19	0.18	Male-pattern baldness;	chr12:29075351	chr12:29280418~29317848:-
LUAD	cis	rs7131987	0.546	rs7299648	ENSG00000257176.2	RP11-996F15.2	3.94	9.34e-05	0.0133	0.18	0.18	QT interval;	chr12:29256797	chr12:29280418~29317848:-
LUAD	cis	rs7131987	0.565	rs7300032	ENSG00000257176.2	RP11-996F15.2	3.94	9.34e-05	0.0133	0.18	0.18	QT interval;	chr12:29256859	chr12:29280418~29317848:-
LUAD	cis	rs7131987	0.547	rs4370971	ENSG00000257176.2	RP11-996F15.2	3.94	9.34e-05	0.0133	0.18	0.18	QT interval;	chr12:29257066	chr12:29280418~29317848:-
LUAD	cis	rs7131987	0.565	rs7316026	ENSG00000257176.2	RP11-996F15.2	3.94	9.34e-05	0.0133	0.18	0.18	QT interval;	chr12:29258881	chr12:29280418~29317848:-
LUAD	cis	rs972578	0.837	rs3788601	ENSG00000230319.1	AL022476.2	3.94	9.34e-05	0.0133	0.18	0.18	Mean platelet volume;	chr22:42931520	chr22:43038585~43052366:+
LUAD	cis	rs2836974	0.932	rs2150415	ENSG00000232608.1	TIMM9P2	-3.94	9.34e-05	0.0133	-0.22	-0.18	Cognitive function;	chr21:39243441	chr21:39216624~39217506:+
LUAD	cis	rs10435719	0.902	rs11250179	ENSG00000255046.1	RP11-297N6.4	-3.94	9.34e-05	0.0133	-0.22	-0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11942823	chr8:11797928~11802568:-
LUAD	cis	rs10129255	0.556	rs9324093	ENSG00000253209.1	IGHV3-65	3.94	9.34e-05	0.0133	0.14	0.18	Kawasaki disease;	chr14:106683893	chr14:106666092~106666532:-
LUAD	cis	rs7937890	0.559	rs10766184	ENSG00000254418.1	RP11-21L19.1	3.94	9.34e-05	0.0133	0.21	0.18	Mitochondrial DNA levels;	chr11:14521031	chr11:14262846~14273691:-
LUAD	cis	rs11673344	0.562	rs7250507	ENSG00000276846.1	CTD-3220F14.3	3.94	9.35e-05	0.0133	0.19	0.18	Obesity-related traits;	chr19:37095772	chr19:37314868~37315620:-
LUAD	cis	rs7200786	0.546	rs7184083	ENSG00000274038.1	RP11-66H6.4	3.94	9.35e-05	0.0133	0.23	0.18	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11134057	chr16:11056556~11057034:+
LUAD	cis	rs6430549	0.518	rs41521049	ENSG00000224043.6	CCNT2-AS1	-3.94	9.35e-05	0.0133	-0.24	-0.18	Hematocrit;	chr2:134935499	chr2:134735464~134918710:-
LUAD	cis	rs5742933	0.817	rs11679767	ENSG00000253559.1	OSGEPL1-AS1	3.94	9.35e-05	0.0133	0.21	0.18	Ferritin levels;	chr2:189681574	chr2:189762704~189765556:+
LUAD	cis	rs10129255	0.536	rs10139058	ENSG00000253209.1	IGHV3-65	3.94	9.35e-05	0.0133	0.14	0.18	Kawasaki disease;	chr14:106685899	chr14:106666092~106666532:-
LUAD	cis	rs9803723	0.682	rs7514417	ENSG00000261349.1	RP3-465N24.5	-3.94	9.35e-05	0.0133	-0.2	-0.18	Male-pattern baldness;	chr1:25120898	chr1:25266102~25267136:-
LUAD	cis	rs9291683	0.551	rs2240720	ENSG00000250413.1	RP11-448G15.1	-3.94	9.35e-05	0.0133	-0.22	-0.18	Bone mineral density;	chr4:10018856	chr4:10006482~10009725:+
LUAD	cis	rs9291683	0.588	rs2240721	ENSG00000250413.1	RP11-448G15.1	-3.94	9.35e-05	0.0133	-0.22	-0.18	Bone mineral density;	chr4:10018940	chr4:10006482~10009725:+
LUAD	cis	rs6071166	0.683	rs6064884	ENSG00000224635.1	RP4-564F22.5	-3.94	9.35e-05	0.0133	-0.2	-0.18	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38691352	chr20:38406011~38416797:-
LUAD	cis	rs9907295	0.688	rs2376287	ENSG00000270977.1	AC015849.16	-3.94	9.35e-05	0.0133	-0.26	-0.18	Fibroblast growth factor basic levels;	chr17:35919865	chr17:35893707~35911023:-
LUAD	cis	rs9907295	0.688	rs4796133	ENSG00000270977.1	AC015849.16	-3.94	9.35e-05	0.0133	-0.26	-0.18	Fibroblast growth factor basic levels;	chr17:35920505	chr17:35893707~35911023:-
LUAD	cis	rs9907295	0.688	rs7213636	ENSG00000270977.1	AC015849.16	-3.94	9.35e-05	0.0133	-0.26	-0.18	Fibroblast growth factor basic levels;	chr17:35920944	chr17:35893707~35911023:-
LUAD	cis	rs12530	0.54	rs5998471	ENSG00000230736.2	RP1-149A16.3	-3.94	9.35e-05	0.0133	-0.18	-0.18	IgG glycosylation;	chr22:32390230	chr22:32376664~32384343:+
LUAD	cis	rs6964587	1	rs7785095	ENSG00000188693.7	CYP51A1-AS1	3.94	9.35e-05	0.0133	0.21	0.18	Breast cancer;	chr7:92011459	chr7:92134604~92180725:+
LUAD	cis	rs8062405	0.754	rs62034323	ENSG00000261419.1	RP11-57A19.4	-3.94	9.35e-05	0.0133	-0.19	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28659696~28740781:-
LUAD	cis	rs8062405	0.824	rs62034324	ENSG00000261419.1	RP11-57A19.4	-3.94	9.35e-05	0.0133	-0.19	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28659696~28740781:-
LUAD	cis	rs417065	0.516	rs11121129	ENSG00000227634.1	RP11-431K24.3	3.94	9.35e-05	0.0133	0.24	0.18	Psoriasis;	chr1:8208035	chr1:8208672~8215210:+
LUAD	cis	rs9925964	0.933	rs9923231	ENSG00000232748.3	RP11-196G11.6	3.94	9.36e-05	0.0133	0.22	0.18	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31096368	chr16:31056460~31062803:+
LUAD	cis	rs467650	0.817	rs977028	ENSG00000248489.1	CTD-2007H13.3	3.94	9.36e-05	0.0133	0.19	0.18	Venous thromboembolism (SNP x SNP interaction);	chr5:98720804	chr5:98929171~98995013:+
LUAD	cis	rs71007656	1	rs71007656	ENSG00000263064.2	RP11-291L22.7	3.94	9.36e-05	0.0133	0.19	0.18	Extrinsic epigenetic age acceleration;	chr10:37681922	chr10:38448689~38448949:+
LUAD	cis	rs7560272	0.538	rs4852975	ENSG00000163016.8	ALMS1P	-3.94	9.36e-05	0.0133	-0.19	-0.18	Schizophrenia;	chr2:73705338	chr2:73644919~73685576:+
LUAD	cis	rs6706648	0.582	rs13013119	ENSG00000234624.2	AC016894.1	3.94	9.36e-05	0.0133	0.21	0.18	F-cell distribution;	chr2:60424926	chr2:61416887~61417197:-
LUAD	cis	rs3743162	0.553	rs12915656	ENSG00000225151.9	GOLGA2P7	-3.94	9.36e-05	0.0133	-0.26	-0.18	Alzheimer's disease (age of onset);	chr15:84872349	chr15:84199311~84230136:-
LUAD	cis	rs703842	1	rs3782130	ENSG00000245651.2	RP11-620J15.2	3.94	9.36e-05	0.0133	0.18	0.18	Multiple sclerosis;	chr12:57768115	chr12:57869835~57896482:-
LUAD	cis	rs6502050	0.835	rs11077971	ENSG00000275966.1	RP11-1055B8.9	-3.94	9.36e-05	0.0133	-0.18	-0.18	Life satisfaction;	chr17:82132753	chr17:81345476~81345966:-
LUAD	cis	rs12440869	1	rs7176337	ENSG00000270964.1	RP11-502I4.3	-3.94	9.36e-05	0.0134	-0.2	-0.18	Peak velocity of the mitral A-wave;	chr15:67257462	chr15:67541072~67542604:-
LUAD	cis	rs4819052	0.851	rs9979545	ENSG00000215447.6	BX322557.10	-3.94	9.37e-05	0.0134	-0.21	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259890	chr21:45288052~45291738:+
LUAD	cis	rs4819052	0.851	rs7276591	ENSG00000215447.6	BX322557.10	-3.94	9.37e-05	0.0134	-0.21	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260241	chr21:45288052~45291738:+
LUAD	cis	rs737008	0.5	rs7189239	ENSG00000262703.1	RP11-485G7.6	3.94	9.37e-05	0.0134	0.16	0.18	Obesity-related traits;	chr16:11308658	chr16:11348143~11349321:-
LUAD	cis	rs4938303	0.549	rs12291024	ENSG00000254851.1	RP11-109L13.1	3.94	9.37e-05	0.0134	0.24	0.18	Triglycerides;	chr11:116689951	chr11:117135528~117138582:+
LUAD	cis	rs2274273	0.87	rs28716725	ENSG00000259318.1	RP11-454L9.2	3.94	9.37e-05	0.0134	0.15	0.18	Protein biomarker;	chr14:55349892	chr14:55394940~55395233:-
LUAD	cis	rs7647973	0.58	rs4955432	ENSG00000225399.4	RP11-3B7.1	3.94	9.37e-05	0.0134	0.23	0.18	Menarche (age at onset);	chr3:49229339	chr3:49260085~49261316:+
LUAD	cis	rs7131987	0.565	rs4412790	ENSG00000257176.2	RP11-996F15.2	3.94	9.37e-05	0.0134	0.18	0.18	QT interval;	chr12:29253828	chr12:29280418~29317848:-
LUAD	cis	rs7131987	0.565	rs10743651	ENSG00000257176.2	RP11-996F15.2	3.94	9.37e-05	0.0134	0.18	0.18	QT interval;	chr12:29255006	chr12:29280418~29317848:-
LUAD	cis	rs9973361	1	rs9677856	ENSG00000232411.1	AC009495.3	-3.94	9.37e-05	0.0134	-0.2	-0.18	Total body bone mineral density;	chr2:165859347	chr2:165833048~165839098:-
LUAD	cis	rs7520050	0.645	rs1768809	ENSG00000234329.1	RP11-767N6.2	-3.94	9.37e-05	0.0134	-0.17	-0.18	Reticulocyte count;Red blood cell count;	chr1:46037164	chr1:45651039~45651826:-
LUAD	cis	rs4907240	0.731	rs11900310	ENSG00000237510.6	AC008268.2	3.94	9.37e-05	0.0134	0.24	0.18	Event-related brain oscillations;	chr2:96476093	chr2:95789654~95800166:+
LUAD	cis	rs2665103	0.589	rs2134046	ENSG00000276710.3	CSPG4P8	-3.94	9.37e-05	0.0134	-0.17	-0.18	Intelligence (multi-trait analysis);	chr15:82232203	chr15:82459472~82477258:+
LUAD	cis	rs7617773	0.817	rs13068265	ENSG00000199476.1	Y_RNA	-3.94	9.37e-05	0.0134	-0.23	-0.18	Coronary artery disease;	chr3:48260124	chr3:48288587~48288694:+
LUAD	cis	rs11073619	0.616	rs2401427	ENSG00000230373.7	GOLGA6L5P	-3.94	9.37e-05	0.0134	-0.27	-0.18	Positive affect;	chr15:84402427	chr15:84507885~84516814:-
LUAD	cis	rs2836950	0.501	rs11702505	ENSG00000232608.1	TIMM9P2	3.94	9.37e-05	0.0134	0.2	0.18	Menarche (age at onset);	chr21:39328688	chr21:39216624~39217506:+
LUAD	cis	rs2836950	0.501	rs2836985	ENSG00000232608.1	TIMM9P2	3.94	9.37e-05	0.0134	0.2	0.18	Menarche (age at onset);	chr21:39329243	chr21:39216624~39217506:+
LUAD	cis	rs10129255	0.957	rs12590667	ENSG00000211967.3	IGHV3-53	3.94	9.38e-05	0.0134	0.13	0.18	Kawasaki disease;	chr14:106779223	chr14:106592676~106593347:-
LUAD	cis	rs7200786	0.546	rs794425	ENSG00000274038.1	RP11-66H6.4	-3.94	9.38e-05	0.0134	-0.23	-0.18	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11148990	chr16:11056556~11057034:+
LUAD	cis	rs2273156	0.587	rs8014377	ENSG00000226677.3	IGBP1P1	-3.94	9.38e-05	0.0134	-0.27	-0.18	Immunoglobulin light chain (AL) amyloidosis;	chr14:35061851	chr14:34939324~34940332:+
LUAD	cis	rs4845570	0.92	rs1521185	ENSG00000203288.3	RP11-98D18.9	3.94	9.38e-05	0.0134	0.25	0.18	Coronary artery disease;	chr1:151791573	chr1:151790804~151794402:+
LUAD	cis	rs9513627	0.573	rs12431100	ENSG00000280710.1	RP11-214F16.8	-3.94	9.38e-05	0.0134	-0.27	-0.18	Obesity-related traits;	chr13:99532664	chr13:99498524~99501315:+
LUAD	cis	rs10411262	0.868	rs7250264	ENSG00000211513.4	MIR320E	-3.94	9.38e-05	0.0134	-0.19	-0.18	Tonsillectomy;	chr19:46684181	chr19:46709271~46709382:-
LUAD	cis	rs910316	0.737	rs175510	ENSG00000259138.1	RP11-950C14.7	-3.94	9.39e-05	0.0134	-0.19	-0.18	Height;	chr14:75058136	chr14:75127153~75136930:+
LUAD	cis	rs1799949	0.587	rs1824890	ENSG00000267340.1	RP11-242D8.3	3.94	9.39e-05	0.0134	0.21	0.18	Menopause (age at onset);	chr17:43344536	chr17:43169880~43170077:-
LUAD	cis	rs7551222	0.752	rs12133735	ENSG00000240219.1	RP11-430C7.5	3.94	9.39e-05	0.0134	0.18	0.18	Schizophrenia;	chr1:204587708	chr1:204626775~204629712:+
LUAD	cis	rs7551222	0.752	rs12566957	ENSG00000240219.1	RP11-430C7.5	3.94	9.39e-05	0.0134	0.18	0.18	Schizophrenia;	chr1:204587830	chr1:204626775~204629712:+
LUAD	cis	rs9467773	0.62	rs2451737	ENSG00000261353.1	CTA-14H9.5	-3.94	9.39e-05	0.0134	-0.2	-0.18	Intelligence (multi-trait analysis);	chr6:26618813	chr6:26527063~26527404:+
LUAD	cis	rs9467773	0.596	rs2494693	ENSG00000261353.1	CTA-14H9.5	-3.94	9.39e-05	0.0134	-0.2	-0.18	Intelligence (multi-trait analysis);	chr6:26618998	chr6:26527063~26527404:+
LUAD	cis	rs9467773	0.62	rs2494694	ENSG00000261353.1	CTA-14H9.5	-3.94	9.39e-05	0.0134	-0.2	-0.18	Intelligence (multi-trait analysis);	chr6:26619100	chr6:26527063~26527404:+
LUAD	cis	rs8180040	0.966	rs6792488	ENSG00000271161.1	BOLA2P2	-3.94	9.39e-05	0.0134	-0.17	-0.18	Colorectal cancer;	chr3:47461859	chr3:47499841~47500407:+
LUAD	cis	rs6487679	0.543	rs7956661	ENSG00000111788.10	RP11-22B23.1	3.94	9.39e-05	0.0134	0.26	0.18	Non-alcoholic fatty liver disease histology (AST);	chr12:9201988	chr12:9277235~9313241:+
LUAD	cis	rs7429990	0.932	rs7620736	ENSG00000228638.1	FCF1P2	3.94	9.39e-05	0.0134	0.2	0.18	Educational attainment (years of education);	chr3:48068479	chr3:48290793~48291375:-
LUAD	cis	rs2554380	0.76	rs1946367	ENSG00000259570.1	RP11-671M22.4	3.94	9.39e-05	0.0134	0.25	0.18	Height;	chr15:83756511	chr15:84394512~84395514:+
LUAD	cis	rs2239547	0.522	rs2581780	ENSG00000243224.1	RP5-1157M23.2	3.94	9.39e-05	0.0134	0.2	0.18	Schizophrenia;	chr3:53024944	chr3:52239258~52241097:+
LUAD	cis	rs828999	1	rs828999	ENSG00000280186.1	RP11-483I13.6	-3.94	9.39e-05	0.0134	-0.21	-0.18	Monocyte percentage of white cells;	chr1:108202312	chr1:108200413~108202743:+
LUAD	cis	rs9302635	0.513	rs3812987	ENSG00000260886.1	TAT-AS1	3.94	9.39e-05	0.0134	0.23	0.18	Blood protein levels;	chr16:72125021	chr16:71565789~71578187:+
LUAD	cis	rs561341	0.883	rs4450460	ENSG00000265798.5	RP11-271K11.5	-3.94	9.39e-05	0.0134	-0.26	-0.18	Hip circumference adjusted for BMI;	chr17:31874290	chr17:31038575~31059121:-
LUAD	cis	rs561341	0.883	rs4795661	ENSG00000265798.5	RP11-271K11.5	-3.94	9.39e-05	0.0134	-0.26	-0.18	Hip circumference adjusted for BMI;	chr17:31874755	chr17:31038575~31059121:-
LUAD	cis	rs561341	0.831	rs11658469	ENSG00000265798.5	RP11-271K11.5	-3.94	9.39e-05	0.0134	-0.26	-0.18	Hip circumference adjusted for BMI;	chr17:31879407	chr17:31038575~31059121:-
LUAD	cis	rs262150	0.837	rs2657404	ENSG00000231419.5	LINC00689	-3.94	9.4e-05	0.0134	-0.21	-0.18	Facial morphology (factor 20);	chr7:158990464	chr7:159006522~159030195:+
LUAD	cis	rs3764400	0.567	rs1979897	ENSG00000278765.1	RP5-890E16.5	3.94	9.4e-05	0.0134	0.32	0.18	Body mass index;	chr17:48232184	chr17:48066704~48067293:-
LUAD	cis	rs1046491	0.901	rs35587943	ENSG00000264964.1	RP11-888D10.3	3.94	9.4e-05	0.0134	0.37	0.18	Scarlet fever;	chr18:9105524	chr18:9315194~9334441:-
LUAD	cis	rs6840360	0.642	rs1443089	ENSG00000270265.1	RP11-731D1.4	-3.94	9.4e-05	0.0134	-0.18	-0.18	Intelligence (multi-trait analysis);	chr4:151529148	chr4:151333775~151353224:-
LUAD	cis	rs6964587	1	rs10225885	ENSG00000188693.7	CYP51A1-AS1	-3.94	9.4e-05	0.0134	-0.21	-0.18	Breast cancer;	chr7:92041693	chr7:92134604~92180725:+
LUAD	cis	rs6964587	0.9	rs6972027	ENSG00000188693.7	CYP51A1-AS1	-3.94	9.4e-05	0.0134	-0.21	-0.18	Breast cancer;	chr7:92152066	chr7:92134604~92180725:+
LUAD	cis	rs6964587	0.935	rs9770444	ENSG00000188693.7	CYP51A1-AS1	-3.94	9.4e-05	0.0134	-0.21	-0.18	Breast cancer;	chr7:92153848	chr7:92134604~92180725:+
LUAD	cis	rs6871536	0.805	rs2245460	ENSG00000233006.5	AC034220.3	-3.94	9.41e-05	0.0134	-0.19	-0.18	Asthma (childhood onset);	chr5:132612834	chr5:132311285~132369916:-
LUAD	cis	rs804280	0.509	rs4841639	ENSG00000255046.1	RP11-297N6.4	-3.94	9.41e-05	0.0134	-0.22	-0.18	Myopia (pathological);	chr8:11938584	chr8:11797928~11802568:-
LUAD	cis	rs7809950	0.954	rs2520247	ENSG00000238832.1	snoU109	-3.94	9.41e-05	0.0134	-0.26	-0.18	Coronary artery disease;	chr7:107503501	chr7:107603363~107603507:+
LUAD	cis	rs6964587	0.967	rs2282969	ENSG00000188693.7	CYP51A1-AS1	3.94	9.41e-05	0.0134	0.21	0.18	Breast cancer;	chr7:91954458	chr7:92134604~92180725:+
LUAD	cis	rs4853525	0.522	rs10490538	ENSG00000235852.1	AC005540.3	-3.94	9.41e-05	0.0134	-0.2	-0.18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190725340	chr2:190880797~190882059:-
LUAD	cis	rs7551222	0.752	rs10793765	ENSG00000240219.1	RP11-430C7.5	3.94	9.42e-05	0.0134	0.19	0.18	Schizophrenia;	chr1:204580247	chr1:204626775~204629712:+
LUAD	cis	rs2901790	0.78	rs34988670	ENSG00000223387.5	RP11-408H1.3	-3.94	9.42e-05	0.0134	-0.24	-0.18	Gait speed in old age;	chr3:172503516	chr3:172560888~172595607:-
LUAD	cis	rs1979679	0.918	rs10771429	ENSG00000278733.1	RP11-425D17.1	-3.94	9.42e-05	0.0134	-0.22	-0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28468573	chr12:28185625~28186190:-
LUAD	cis	rs7202877	0.61	rs8053632	ENSG00000280152.1	RP11-331F4.5	3.94	9.42e-05	0.0134	0.2	0.18	Type 1 diabetes;Type 2 diabetes;	chr16:75331042	chr16:75245994~75250077:-
LUAD	cis	rs10510102	0.608	rs4752607	ENSG00000226864.1	ATE1-AS1	-3.94	9.42e-05	0.0134	-0.26	-0.18	Breast cancer;	chr10:121835426	chr10:121928312~121951965:+
LUAD	cis	rs3018712	0.505	rs7102308	ENSG00000212093.1	AP000807.1	-3.94	9.42e-05	0.0134	-0.23	-0.18	Total body bone mineral density;	chr11:68645762	chr11:68506083~68506166:-
LUAD	cis	rs3018712	0.532	rs7932726	ENSG00000212093.1	AP000807.1	-3.94	9.42e-05	0.0134	-0.23	-0.18	Total body bone mineral density;	chr11:68647259	chr11:68506083~68506166:-
LUAD	cis	rs3018712	0.532	rs4930587	ENSG00000212093.1	AP000807.1	-3.94	9.42e-05	0.0134	-0.23	-0.18	Total body bone mineral density;	chr11:68647667	chr11:68506083~68506166:-
LUAD	cis	rs3018712	0.532	rs4930588	ENSG00000212093.1	AP000807.1	3.94	9.42e-05	0.0134	0.23	0.18	Total body bone mineral density;	chr11:68647767	chr11:68506083~68506166:-
LUAD	cis	rs3018712	0.532	rs4930589	ENSG00000212093.1	AP000807.1	-3.94	9.42e-05	0.0134	-0.23	-0.18	Total body bone mineral density;	chr11:68647789	chr11:68506083~68506166:-
LUAD	cis	rs3018712	0.532	rs11228312	ENSG00000212093.1	AP000807.1	-3.94	9.42e-05	0.0134	-0.23	-0.18	Total body bone mineral density;	chr11:68648049	chr11:68506083~68506166:-
LUAD	cis	rs71636778	0.524	rs78614739	ENSG00000260063.1	RP5-968P14.2	-3.94	9.42e-05	0.0134	-0.23	-0.18	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26847689	chr1:26692132~26694131:-
LUAD	cis	rs3925075	0.5	rs8057320	ENSG00000260911.2	RP11-196G11.2	-3.94	9.42e-05	0.0134	-0.16	-0.18	IgA nephropathy;	chr16:31258230	chr16:31043150~31049868:+
LUAD	cis	rs2742417	0.532	rs2742424	ENSG00000230530.1	LIMD1-AS1	-3.94	9.43e-05	0.0134	-0.2	-0.18	Response to anti-depressant treatment in major depressive disorder;	chr3:45693726	chr3:45679043~45689134:-
LUAD	cis	rs6088580	0.634	rs6059851	ENSG00000276073.1	RP5-1125A11.7	-3.94	9.43e-05	0.0134	-0.17	-0.18	Glomerular filtration rate (creatinine);	chr20:34460140	chr20:33985617~33988989:-
LUAD	cis	rs6088590	0.502	rs6059861	ENSG00000276073.1	RP5-1125A11.7	-3.94	9.43e-05	0.0134	-0.17	-0.18	Coronary artery disease;	chr20:34480758	chr20:33985617~33988989:-
LUAD	cis	rs9815354	0.857	rs13087502	ENSG00000273328.4	RP11-141M3.6	-3.94	9.43e-05	0.0134	-0.28	-0.18	Pulse pressure;Diastolic blood pressure;	chr3:41973618	chr3:42809414~42908105:+
LUAD	cis	rs853679	0.542	rs6934769	ENSG00000280107.1	AL022393.9	-3.94	9.43e-05	0.0134	-0.23	-0.18	Depression;	chr6:28123153	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs17711801	ENSG00000280107.1	AL022393.9	-3.94	9.43e-05	0.0134	-0.23	-0.18	Depression;	chr6:28124529	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs6922063	ENSG00000280107.1	AL022393.9	-3.94	9.43e-05	0.0134	-0.23	-0.18	Depression;	chr6:28126588	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs2275508	ENSG00000280107.1	AL022393.9	-3.94	9.43e-05	0.0134	-0.23	-0.18	Depression;	chr6:28126953	chr6:28170845~28172521:+
LUAD	cis	rs4713118	0.527	rs9461433	ENSG00000280107.1	AL022393.9	-3.94	9.43e-05	0.0134	-0.23	-0.18	Parkinson's disease;	chr6:28127394	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs9468292	ENSG00000280107.1	AL022393.9	-3.94	9.43e-05	0.0134	-0.23	-0.18	Depression;	chr6:28127577	chr6:28170845~28172521:+
LUAD	cis	rs9467773	0.62	rs2101581	ENSG00000261353.1	CTA-14H9.5	-3.94	9.43e-05	0.0134	-0.2	-0.18	Intelligence (multi-trait analysis);	chr6:26622541	chr6:26527063~26527404:+
LUAD	cis	rs7590268	0.577	rs11897432	ENSG00000279873.2	LINC01126	3.94	9.43e-05	0.0134	0.18	0.18	Orofacial clefts;	chr2:43590366	chr2:43227210~43228855:+
LUAD	cis	rs7762018	1	rs4716378	ENSG00000231690.2	LINC00574	-3.94	9.44e-05	0.0134	-0.32	-0.18	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169686472	chr6:169790321~169802873:+
LUAD	cis	rs467650	0.817	rs61637015	ENSG00000248489.1	CTD-2007H13.3	3.94	9.44e-05	0.0134	0.19	0.18	Venous thromboembolism (SNP x SNP interaction);	chr5:98716535	chr5:98929171~98995013:+
LUAD	cis	rs7005380	0.62	rs7388508	ENSG00000279347.1	RP11-85I17.2	-3.94	9.44e-05	0.0134	-0.15	-0.18	Interstitial lung disease;	chr8:119913913	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.6	rs1607624	ENSG00000279347.1	RP11-85I17.2	-3.94	9.44e-05	0.0134	-0.15	-0.18	Interstitial lung disease;	chr8:119917049	chr8:119838736~119840385:-
LUAD	cis	rs35740288	0.77	rs55740125	ENSG00000259407.1	RP11-158M2.3	-3.94	9.45e-05	0.0134	-0.17	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85612505	chr15:85744109~85750281:-
LUAD	cis	rs35740288	0.77	rs4843085	ENSG00000259407.1	RP11-158M2.3	-3.94	9.45e-05	0.0134	-0.17	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85615268	chr15:85744109~85750281:-
LUAD	cis	rs926392	0.896	rs742276	ENSG00000274825.1	RP4-616B8.5	-3.94	9.45e-05	0.0134	-0.21	-0.18	Dialysis-related mortality;	chr20:39051206	chr20:38955910~38956547:+
LUAD	cis	rs7429990	0.965	rs7427418	ENSG00000228638.1	FCF1P2	3.94	9.45e-05	0.0135	0.21	0.18	Educational attainment (years of education);	chr3:47981217	chr3:48290793~48291375:-
LUAD	cis	rs7429990	0.965	rs13074973	ENSG00000228638.1	FCF1P2	3.94	9.45e-05	0.0135	0.21	0.18	Educational attainment (years of education);	chr3:47986654	chr3:48290793~48291375:-
LUAD	cis	rs2274273	0.588	rs11158037	ENSG00000258413.1	RP11-665C16.6	-3.94	9.45e-05	0.0135	-0.24	-0.18	Protein biomarker;	chr14:55365434	chr14:55262767~55272075:-
LUAD	cis	rs8046148	0.637	rs9746549	ENSG00000279356.1	RP11-429P3.8	-3.94	9.45e-05	0.0135	-0.18	-0.18	Testicular germ cell tumor;	chr16:50118545	chr16:50072862~50074986:+
LUAD	cis	rs1862618	0.853	rs33325	ENSG00000271828.1	CTD-2310F14.1	3.94	9.45e-05	0.0135	0.25	0.18	Initial pursuit acceleration;	chr5:56846720	chr5:56927874~56929573:+
LUAD	cis	rs1862618	0.802	rs42769	ENSG00000271828.1	CTD-2310F14.1	3.94	9.45e-05	0.0135	0.25	0.18	Initial pursuit acceleration;	chr5:56848325	chr5:56927874~56929573:+
LUAD	cis	rs2274273	0.684	rs2340921	ENSG00000259318.1	RP11-454L9.2	3.94	9.46e-05	0.0135	0.16	0.18	Protein biomarker;	chr14:55096987	chr14:55394940~55395233:-
LUAD	cis	rs4711350	0.723	rs549652	ENSG00000224557.6	HLA-DPB2	-3.94	9.46e-05	0.0135	-0.32	-0.18	Schizophrenia;	chr6:33718326	chr6:33112451~33129084:+
LUAD	cis	rs1979679	0.918	rs7135922	ENSG00000278733.1	RP11-425D17.1	-3.94	9.46e-05	0.0135	-0.22	-0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28469148	chr12:28185625~28186190:-
LUAD	cis	rs10419113	0.522	rs6510102	ENSG00000269867.1	CTD-2583A14.8	3.94	9.46e-05	0.0135	0.16	0.18	Pediatric bone mineral density (spine);	chr19:57797273	chr19:57867038~57868172:-
LUAD	cis	rs3096299	0.719	rs2965817	ENSG00000182376.2	RP5-1142A6.8	3.94	9.46e-05	0.0135	0.18	0.18	Multiple myeloma (IgH translocation);	chr16:89446826	chr16:88742767~88745748:+
LUAD	cis	rs7674212	0.57	rs2126470	ENSG00000251288.2	RP11-10L12.2	-3.94	9.46e-05	0.0135	-0.22	-0.18	Type 2 diabetes;	chr4:103140605	chr4:102751401~102752641:+
LUAD	cis	rs9649213	0.555	rs6948346	ENSG00000272950.1	RP11-307C18.1	3.94	9.46e-05	0.0135	0.22	0.18	Prostate cancer (SNP x SNP interaction);	chr7:98330644	chr7:98322853~98323430:+
LUAD	cis	rs6121246	0.559	rs6060932	ENSG00000230613.1	HM13-AS1	3.94	9.47e-05	0.0135	0.22	0.18	Mean corpuscular hemoglobin;	chr20:31762742	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.583	rs28815498	ENSG00000230613.1	HM13-AS1	3.94	9.47e-05	0.0135	0.22	0.18	Mean corpuscular hemoglobin;	chr20:31763757	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.559	rs6060933	ENSG00000230613.1	HM13-AS1	3.94	9.47e-05	0.0135	0.22	0.18	Mean corpuscular hemoglobin;	chr20:31764100	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.512	rs6060938	ENSG00000230613.1	HM13-AS1	3.94	9.47e-05	0.0135	0.22	0.18	Mean corpuscular hemoglobin;	chr20:31775842	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.512	rs6060941	ENSG00000230613.1	HM13-AS1	3.94	9.47e-05	0.0135	0.22	0.18	Mean corpuscular hemoglobin;	chr20:31779580	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.559	rs6087779	ENSG00000230613.1	HM13-AS1	3.94	9.47e-05	0.0135	0.22	0.18	Mean corpuscular hemoglobin;	chr20:31782763	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.559	rs6060944	ENSG00000230613.1	HM13-AS1	3.94	9.47e-05	0.0135	0.22	0.18	Mean corpuscular hemoglobin;	chr20:31784311	chr20:31567707~31573263:-
LUAD	cis	rs4474465	0.831	rs12287010	ENSG00000251323.2	RP11-452H21.4	-3.94	9.47e-05	0.0135	-0.23	-0.18	Alzheimer's disease (survival time);	chr11:78450406	chr11:78423982~78429836:-
LUAD	cis	rs3018712	0.59	rs11228331	ENSG00000227620.4	ALG1L8P	-3.94	9.47e-05	0.0135	-0.24	-0.18	Total body bone mineral density;	chr11:68717757	chr11:67785273~67792335:+
LUAD	cis	rs2348418	0.932	rs7968515	ENSG00000247934.4	RP11-967K21.1	3.94	9.47e-05	0.0135	0.21	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28542914	chr12:28163298~28190738:-
LUAD	cis	rs4363385	0.51	rs2339386	ENSG00000223599.1	RP11-216N14.7	-3.94	9.47e-05	0.0135	-0.21	-0.18	Inflammatory skin disease;	chr1:152919831	chr1:153852106~153853414:-
LUAD	cis	rs2836974	0.602	rs2836987	ENSG00000232608.1	TIMM9P2	3.94	9.47e-05	0.0135	0.21	0.18	Cognitive function;	chr21:39334668	chr21:39216624~39217506:+
LUAD	cis	rs722599	0.847	rs2058919	ENSG00000279594.1	RP11-950C14.10	-3.94	9.47e-05	0.0135	-0.2	-0.18	IgG glycosylation;	chr14:74844109	chr14:75011269~75012851:-
LUAD	cis	rs253959	0.672	rs1133186	ENSG00000272265.1	CTD-2287O16.4	3.94	9.47e-05	0.0135	0.19	0.18	Bipolar disorder and schizophrenia;	chr5:116084718	chr5:116078110~116078570:-
LUAD	cis	rs3002142	0.554	rs79024999	ENSG00000272750.1	RP11-378J18.8	3.94	9.47e-05	0.0135	0.28	0.18	LDL peak particle diameter (total fat intake interaction);	chr1:222664266	chr1:222658867~222661512:-
LUAD	cis	rs2274273	0.84	rs11547116	ENSG00000259318.1	RP11-454L9.2	3.94	9.47e-05	0.0135	0.15	0.18	Protein biomarker;	chr14:55271447	chr14:55394940~55395233:-
LUAD	cis	rs9650657	0.538	rs6984496	ENSG00000255310.2	AF131215.2	-3.94	9.48e-05	0.0135	-0.17	-0.18	Neuroticism;	chr8:10938583	chr8:11107788~11109726:-
LUAD	cis	rs8031584	0.958	rs35256769	ENSG00000259845.1	HERC2P10	3.94	9.48e-05	0.0135	0.2	0.18	Huntington's disease progression;	chr15:30945573	chr15:30815271~30844153:+
LUAD	cis	rs8031584	0.958	rs11629793	ENSG00000259845.1	HERC2P10	3.94	9.48e-05	0.0135	0.2	0.18	Huntington's disease progression;	chr15:30946220	chr15:30815271~30844153:+
LUAD	cis	rs801193	0.935	rs11772264	ENSG00000222364.1	RNU6-96P	-3.94	9.48e-05	0.0135	-0.2	-0.18	Aortic root size;	chr7:66711400	chr7:66395191~66395286:+
LUAD	cis	rs10129255	0.826	rs7150693	ENSG00000211967.3	IGHV3-53	-3.94	9.48e-05	0.0135	-0.14	-0.18	Kawasaki disease;	chr14:106705382	chr14:106592676~106593347:-
LUAD	cis	rs12049351	0.774	rs34551512	ENSG00000229367.1	HMGN2P19	3.94	9.48e-05	0.0135	0.26	0.18	Circulating myeloperoxidase levels (plasma);	chr1:229483141	chr1:229570532~229570796:+
LUAD	cis	rs4699052	0.787	rs2169508	ENSG00000251288.2	RP11-10L12.2	-3.94	9.49e-05	0.0135	-0.22	-0.18	Testicular germ cell tumor;	chr4:103145733	chr4:102751401~102752641:+
LUAD	cis	rs6701713	0.919	rs2296160	ENSG00000274245.1	RP11-357P18.2	-3.94	9.49e-05	0.0135	-0.28	-0.18	Alzheimer's disease (late onset);	chr1:207621975	chr1:207372559~207373252:+
LUAD	cis	rs7017914	0.567	rs17758721	ENSG00000223220.1	Y_RNA	-3.94	9.49e-05	0.0135	-0.19	-0.18	Bone mineral density;	chr8:70552316	chr8:70780914~70781008:-
LUAD	cis	rs2834288	0.535	rs7275560	ENSG00000237945.6	LINC00649	-3.94	9.49e-05	0.0135	-0.23	-0.18	Gut microbiota (bacterial taxa);	chr21:33956140	chr21:33915534~33977691:+
LUAD	cis	rs10266483	1	rs10266483	ENSG00000227986.1	TRIM60P18	-3.94	9.49e-05	0.0135	-0.21	-0.18	Response to statin therapy;	chr7:64272953	chr7:64355078~64356199:+
LUAD	cis	rs2412819	0.52	rs17727763	ENSG00000166763.7	STRCP1	3.94	9.5e-05	0.0135	0.28	0.18	Lung cancer;	chr15:43623873	chr15:43699488~43718184:-
LUAD	cis	rs4664293	0.747	rs7600347	ENSG00000226266.5	AC009961.3	-3.94	9.5e-05	0.0135	-0.24	-0.18	Monocyte percentage of white cells;	chr2:159800981	chr2:159670708~159712435:-
LUAD	cis	rs2299587	0.56	rs7814692	ENSG00000253671.1	RP11-806O11.1	-3.94	9.5e-05	0.0135	-0.21	-0.18	Economic and political preferences;	chr8:17922648	chr8:17808941~17820868:+
LUAD	cis	rs13434995	0.536	rs62303712	ENSG00000273257.1	RP11-177J6.1	-3.94	9.5e-05	0.0135	-0.24	-0.18	Adiponectin levels;	chr4:55460484	chr4:55387949~55388271:+
LUAD	cis	rs9840812	0.773	rs61789601	ENSG00000239213.4	NCK1-AS1	-3.94	9.5e-05	0.0135	-0.25	-0.18	Fibrinogen levels;	chr3:136236137	chr3:136841726~136862054:-
LUAD	cis	rs34929064	0.671	rs34743674	ENSG00000230658.1	KLHL7-AS1	3.94	9.51e-05	0.0135	0.27	0.18	Major depression and alcohol dependence;	chr7:22703193	chr7:23101228~23105703:-
LUAD	cis	rs34929064	0.671	rs34198632	ENSG00000230658.1	KLHL7-AS1	3.94	9.51e-05	0.0135	0.27	0.18	Major depression and alcohol dependence;	chr7:22704182	chr7:23101228~23105703:-
LUAD	cis	rs12579720	0.868	rs10770608	ENSG00000255910.1	RP11-405A12.2	3.94	9.51e-05	0.0135	0.22	0.18	Diastolic blood pressure;	chr12:20031007	chr12:19775451~20009937:+
LUAD	cis	rs12579720	0.909	rs4762920	ENSG00000255910.1	RP11-405A12.2	3.94	9.51e-05	0.0135	0.22	0.18	Diastolic blood pressure;	chr12:20031590	chr12:19775451~20009937:+
LUAD	cis	rs2904524	1	rs2870881	ENSG00000257815.4	RP11-611E13.2	-3.94	9.51e-05	0.0135	-0.27	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70257881	chr12:69904033~70243360:-
LUAD	cis	rs2904524	1	rs76608560	ENSG00000257815.4	RP11-611E13.2	-3.94	9.51e-05	0.0135	-0.27	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70259132	chr12:69904033~70243360:-
LUAD	cis	rs2904524	1	rs75401536	ENSG00000257815.4	RP11-611E13.2	-3.94	9.51e-05	0.0135	-0.27	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70264369	chr12:69904033~70243360:-
LUAD	cis	rs2904524	1	rs1524245	ENSG00000257815.4	RP11-611E13.2	-3.94	9.51e-05	0.0135	-0.27	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70265048	chr12:69904033~70243360:-
LUAD	cis	rs2904524	1	rs4761191	ENSG00000257815.4	RP11-611E13.2	-3.94	9.51e-05	0.0135	-0.27	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70268594	chr12:69904033~70243360:-
LUAD	cis	rs2904524	1	rs56970859	ENSG00000257815.4	RP11-611E13.2	-3.94	9.51e-05	0.0135	-0.27	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70270576	chr12:69904033~70243360:-
LUAD	cis	rs2665103	0.715	rs16973457	ENSG00000255769.6	GOLGA2P10	-3.94	9.51e-05	0.0135	-0.19	-0.18	Intelligence (multi-trait analysis);	chr15:82271650	chr15:82472993~82513950:-
LUAD	cis	rs865483	0.929	rs8064314	ENSG00000276054.1	RP11-378E13.3	3.94	9.51e-05	0.0135	0.21	0.18	Monocyte count;	chr17:37498286	chr17:37386886~37387926:+
LUAD	cis	rs10197140	1	rs12151613	ENSG00000235721.1	AC013268.3	-3.94	9.51e-05	0.0135	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110851808	chr2:110007675~110010783:+
LUAD	cis	rs1355223	0.902	rs12801509	ENSG00000271369.1	RP11-350D17.3	-3.94	9.51e-05	0.0135	-0.21	-0.18	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34725789	chr11:34709600~34710161:+
LUAD	cis	rs2506028	0.55	rs2051044	ENSG00000234944.1	RP11-124O11.1	3.94	9.51e-05	0.0135	0.22	0.18	Blood protein levels;	chr10:42903150	chr10:42871521~42874060:+
LUAD	cis	rs526231	0.784	rs28157	ENSG00000175749.11	EIF3KP1	3.94	9.51e-05	0.0135	0.24	0.18	Primary biliary cholangitis;	chr5:103260136	chr5:103032376~103033031:+
LUAD	cis	rs8180040	0.726	rs7625070	ENSG00000271161.1	BOLA2P2	3.94	9.52e-05	0.0135	0.17	0.18	Colorectal cancer;	chr3:47054028	chr3:47499841~47500407:+
LUAD	cis	rs67981189	0.896	rs2526890	ENSG00000269927.1	RP6-91H8.3	-3.94	9.52e-05	0.0135	-0.22	-0.18	Schizophrenia;	chr14:70963410	chr14:71141125~71143253:-
LUAD	cis	rs67981189	0.896	rs2810100	ENSG00000269927.1	RP6-91H8.3	-3.94	9.52e-05	0.0135	-0.22	-0.18	Schizophrenia;	chr14:70965455	chr14:71141125~71143253:-
LUAD	cis	rs7829975	0.514	rs2920983	ENSG00000173295.6	FAM86B3P	3.94	9.52e-05	0.0135	0.19	0.18	Mood instability;	chr8:8410553	chr8:8228595~8244865:+
LUAD	cis	rs4601821	0.895	rs2155464	ENSG00000270179.1	RP11-159N11.4	-3.94	9.53e-05	0.0135	-0.18	-0.18	Alcoholic chronic pancreatitis;	chr11:113371726	chr11:113368478~113369117:+
LUAD	cis	rs12122100	0.837	rs6681167	ENSG00000244371.2	PFN1P8	-3.94	9.53e-05	0.0135	-0.22	-0.18	HIV-1 control;	chr1:147035308	chr1:146957117~146957659:-
LUAD	cis	rs9914544	0.544	rs4244595	ENSG00000273018.4	CTD-2303H24.2	-3.94	9.53e-05	0.0135	-0.21	-0.18	Educational attainment (years of education);	chr17:18774016	chr17:18511221~18551705:-
LUAD	cis	rs210152	0.588	rs1755040	ENSG00000224557.6	HLA-DPB2	3.94	9.53e-05	0.0135	0.48	0.18	Schizophrenia;	chr6:33527398	chr6:33112451~33129084:+
LUAD	cis	rs210152	0.588	rs449978	ENSG00000224557.6	HLA-DPB2	3.94	9.53e-05	0.0135	0.48	0.18	Schizophrenia;	chr6:33528283	chr6:33112451~33129084:+
LUAD	cis	rs7809950	0.834	rs2712199	ENSG00000238832.1	snoU109	-3.94	9.53e-05	0.0136	-0.26	-0.18	Coronary artery disease;	chr7:107499794	chr7:107603363~107603507:+
LUAD	cis	rs950880	0.767	rs11123923	ENSG00000234389.1	AC007278.3	-3.94	9.53e-05	0.0136	-0.17	-0.18	Serum protein levels (sST2);	chr2:102351384	chr2:102438713~102440475:+
LUAD	cis	rs4499344	0.556	rs259230	ENSG00000201388.1	SNORA68	3.94	9.53e-05	0.0136	0.2	0.18	Mean platelet volume;	chr19:32642959	chr19:32608337~32608469:-
LUAD	cis	rs11642862	1	rs11642862	ENSG00000239791.1	AC002310.7	-3.94	9.53e-05	0.0136	-0.3	-0.18	Tonsillectomy;	chr16:30774503	chr16:30572250~30583860:+
LUAD	cis	rs4691139	0.658	rs11100589	ENSG00000248632.1	RP11-366M4.11	3.94	9.54e-05	0.0136	0.21	0.18	Ovarian cancer in BRCA1 mutation carriers;	chr4:165003568	chr4:164968587~164970002:-
LUAD	cis	rs17301013	0.932	rs1016466	ENSG00000227373.4	RP11-160H22.5	3.94	9.54e-05	0.0136	0.22	0.18	Systemic lupus erythematosus;	chr1:174570652	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.932	rs10753086	ENSG00000227373.4	RP11-160H22.5	3.94	9.54e-05	0.0136	0.22	0.18	Systemic lupus erythematosus;	chr1:174580802	chr1:174115300~174160004:-
LUAD	cis	rs2486288	0.656	rs8039540	ENSG00000259479.5	SORD2P	-3.94	9.54e-05	0.0136	-0.21	-0.18	Glomerular filtration rate;	chr15:45259644	chr15:44826371~44884694:-
LUAD	cis	rs2486288	0.656	rs8040185	ENSG00000259479.5	SORD2P	-3.94	9.54e-05	0.0136	-0.21	-0.18	Glomerular filtration rate;	chr15:45259883	chr15:44826371~44884694:-
LUAD	cis	rs9860428	0.844	rs2220397	ENSG00000242770.2	RP11-180K7.1	3.94	9.54e-05	0.0136	0.19	0.18	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112895600	chr3:112802478~112812819:+
LUAD	cis	rs2295359	1	rs736197	ENSG00000275678.1	RP4-547N15.3	-3.94	9.54e-05	0.0136	-0.18	-0.18	Psoriasis;	chr1:67141452	chr1:67121605~67123956:-
LUAD	cis	rs2732480	0.557	rs2409004	ENSG00000273765.1	RP11-370I10.11	3.94	9.54e-05	0.0136	0.19	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48327668	chr12:48360920~48361377:+
LUAD	cis	rs2834288	0.7	rs2834292	ENSG00000237945.6	LINC00649	-3.94	9.54e-05	0.0136	-0.24	-0.18	Gut microbiota (bacterial taxa);	chr21:33901909	chr21:33915534~33977691:+
LUAD	cis	rs9487094	1	rs35056702	ENSG00000260273.1	RP11-425D10.10	3.94	9.54e-05	0.0136	0.23	0.18	Height;	chr6:109415123	chr6:109382795~109383666:+
LUAD	cis	rs910316	0.904	rs7156089	ENSG00000279594.1	RP11-950C14.10	-3.94	9.54e-05	0.0136	-0.21	-0.18	Height;	chr14:75178824	chr14:75011269~75012851:-
LUAD	cis	rs7429990	0.965	rs5012971	ENSG00000228638.1	FCF1P2	3.94	9.55e-05	0.0136	0.21	0.18	Educational attainment (years of education);	chr3:48033057	chr3:48290793~48291375:-
LUAD	cis	rs2810114	0.834	rs36559	ENSG00000269927.1	RP6-91H8.3	3.93	9.55e-05	0.0136	0.25	0.18	Alcohol dependence;	chr14:70888232	chr14:71141125~71143253:-
LUAD	cis	rs9921338	0.961	rs66555362	ENSG00000262703.1	RP11-485G7.6	-3.93	9.55e-05	0.0136	-0.18	-0.18	Vein graft stenosis in coronary artery bypass grafting;	chr16:11294976	chr16:11348143~11349321:-
LUAD	cis	rs13434995	0.513	rs62303722	ENSG00000273257.1	RP11-177J6.1	-3.93	9.55e-05	0.0136	-0.23	-0.18	Adiponectin levels;	chr4:55482076	chr4:55387949~55388271:+
LUAD	cis	rs7005380	0.62	rs7387694	ENSG00000279347.1	RP11-85I17.2	-3.93	9.55e-05	0.0136	-0.14	-0.18	Interstitial lung disease;	chr8:119885261	chr8:119838736~119840385:-
LUAD	cis	rs2274273	0.87	rs10134339	ENSG00000259318.1	RP11-454L9.2	3.93	9.55e-05	0.0136	0.15	0.18	Protein biomarker;	chr14:55347662	chr14:55394940~55395233:-
LUAD	cis	rs17122278	1	rs73022042	ENSG00000243431.1	RPL5P30	3.93	9.55e-05	0.0136	0.22	0.18	Total cholesterol levels;	chr11:118538178	chr11:118560690~118561580:+
LUAD	cis	rs858239	0.539	rs10225608	ENSG00000226816.2	AC005082.12	3.93	9.55e-05	0.0136	0.23	0.18	Cerebrospinal fluid biomarker levels;	chr7:23149289	chr7:23206013~23208045:+
LUAD	cis	rs600231	0.542	rs11227198	ENSG00000245532.5	NEAT1	3.93	9.55e-05	0.0136	0.16	0.18	Bone mineral density;	chr11:65470503	chr11:65422774~65445540:+
LUAD	cis	rs600231	0.542	rs11227199	ENSG00000245532.5	NEAT1	3.93	9.55e-05	0.0136	0.16	0.18	Bone mineral density;	chr11:65470650	chr11:65422774~65445540:+
LUAD	cis	rs600231	0.542	rs12360896	ENSG00000245532.5	NEAT1	3.93	9.55e-05	0.0136	0.16	0.18	Bone mineral density;	chr11:65470835	chr11:65422774~65445540:+
LUAD	cis	rs600231	0.542	rs34527830	ENSG00000245532.5	NEAT1	3.93	9.55e-05	0.0136	0.16	0.18	Bone mineral density;	chr11:65473392	chr11:65422774~65445540:+
LUAD	cis	rs600231	0.577	rs35826299	ENSG00000245532.5	NEAT1	3.93	9.55e-05	0.0136	0.16	0.18	Bone mineral density;	chr11:65473493	chr11:65422774~65445540:+
LUAD	cis	rs17695224	0.5	rs55843033	ENSG00000269483.1	AC006272.1	3.93	9.55e-05	0.0136	0.19	0.18	HDL cholesterol;HDL cholesterol levels;	chr19:51818280	chr19:51839924~51843324:-
LUAD	cis	rs5758659	0.714	rs5758589	ENSG00000182057.4	OGFRP1	-3.93	9.55e-05	0.0136	-0.21	-0.18	Cognitive function;	chr22:42122378	chr22:42269753~42275196:+
LUAD	cis	rs11971779	0.941	rs1127424	ENSG00000273391.1	RP11-634H22.1	3.93	9.56e-05	0.0136	0.21	0.18	Diisocyanate-induced asthma;	chr7:139422914	chr7:139359032~139359566:-
LUAD	cis	rs4819052	0.851	rs9974891	ENSG00000215447.6	BX322557.10	-3.93	9.56e-05	0.0136	-0.21	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260852	chr21:45288052~45291738:+
LUAD	cis	rs7107174	1	rs2292573	ENSG00000251323.2	RP11-452H21.4	3.93	9.56e-05	0.0136	0.22	0.18	Testicular germ cell tumor;	chr11:78342093	chr11:78423982~78429836:-
LUAD	cis	rs6951245	1	rs76833820	ENSG00000199023.2	MIR339	-3.93	9.56e-05	0.0136	-0.32	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1030642	chr7:1022935~1023045:-
LUAD	cis	rs6951245	1	rs28379681	ENSG00000199023.2	MIR339	-3.93	9.56e-05	0.0136	-0.32	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1030903	chr7:1022935~1023045:-
LUAD	cis	rs6951245	1	rs28399710	ENSG00000199023.2	MIR339	-3.93	9.56e-05	0.0136	-0.32	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1030995	chr7:1022935~1023045:-
LUAD	cis	rs6951245	1	rs28528096	ENSG00000199023.2	MIR339	-3.93	9.56e-05	0.0136	-0.32	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1031276	chr7:1022935~1023045:-
LUAD	cis	rs6951245	1	rs74369356	ENSG00000199023.2	MIR339	-3.93	9.56e-05	0.0136	-0.32	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1032075	chr7:1022935~1023045:-
LUAD	cis	rs6951245	1	rs77083167	ENSG00000199023.2	MIR339	-3.93	9.56e-05	0.0136	-0.32	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1032187	chr7:1022935~1023045:-
LUAD	cis	rs6951245	1	rs74347384	ENSG00000199023.2	MIR339	-3.93	9.56e-05	0.0136	-0.32	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1032804	chr7:1022935~1023045:-
LUAD	cis	rs7208859	0.673	rs3816780	ENSG00000266490.1	CTD-2349P21.9	3.93	9.56e-05	0.0136	0.26	0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834340	chr17:30792372~30792833:+
LUAD	cis	rs3892630	0.612	rs10413282	ENSG00000267475.1	CTD-2538C1.2	-3.93	9.56e-05	0.0136	-0.26	-0.18	Red blood cell traits;	chr19:32691845	chr19:32687089~32691750:-
LUAD	cis	rs34638952	0.596	rs7226022	ENSG00000264808.1	RP11-802D6.1	3.93	9.56e-05	0.0136	0.21	0.18	Sitting height ratio;	chr17:29240799	chr17:29369717~29390777:-
LUAD	cis	rs7809950	0.954	rs2520245	ENSG00000238832.1	snoU109	-3.93	9.56e-05	0.0136	-0.26	-0.18	Coronary artery disease;	chr7:107496983	chr7:107603363~107603507:+
LUAD	cis	rs853679	0.567	rs1005126	ENSG00000219392.1	RP1-265C24.5	-3.93	9.57e-05	0.0136	-0.23	-0.18	Depression;	chr6:28399846	chr6:28115628~28116551:+
LUAD	cis	rs9813712	0.597	rs11711883	ENSG00000228252.7	COL6A4P2	-3.93	9.57e-05	0.0136	-0.17	-0.18	Response to amphetamines;	chr3:130241367	chr3:130212823~130273806:+
LUAD	cis	rs9813712	0.574	rs62281647	ENSG00000228252.7	COL6A4P2	-3.93	9.57e-05	0.0136	-0.17	-0.18	Response to amphetamines;	chr3:130242670	chr3:130212823~130273806:+
LUAD	cis	rs14027	0.512	rs28711081	ENSG00000279347.1	RP11-85I17.2	-3.93	9.57e-05	0.0136	-0.15	-0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119713469	chr8:119838736~119840385:-
LUAD	cis	rs14027	0.512	rs10103886	ENSG00000279347.1	RP11-85I17.2	-3.93	9.57e-05	0.0136	-0.15	-0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119715158	chr8:119838736~119840385:-
LUAD	cis	rs5769707	0.933	rs2157444	ENSG00000235111.1	RP1-29C18.8	-3.93	9.57e-05	0.0136	-0.19	-0.18	Monocyte percentage of white cells;Monocyte count;	chr22:49600644	chr22:49612657~49615716:-
LUAD	cis	rs507080	0.769	rs7389	ENSG00000278376.1	RP11-158I9.8	3.93	9.57e-05	0.0136	0.19	0.18	Serum metabolite levels;	chr11:118657756	chr11:118791254~118793137:+
LUAD	cis	rs7121538	0.673	rs731274	ENSG00000254418.1	RP11-21L19.1	-3.93	9.57e-05	0.0136	-0.29	-0.18	HDL cholesterol;	chr11:14252131	chr11:14262846~14273691:-
LUAD	cis	rs4819052	0.634	rs8128636	ENSG00000215447.6	BX322557.10	-3.93	9.57e-05	0.0136	-0.21	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270718	chr21:45288052~45291738:+
LUAD	cis	rs763121	0.925	rs5757251	ENSG00000273076.1	RP3-508I15.22	3.93	9.57e-05	0.0136	0.16	0.18	Menopause (age at onset);	chr22:38704123	chr22:38743495~38743910:+
LUAD	cis	rs6496044	1	rs6496044	ENSG00000259407.1	RP11-158M2.3	-3.93	9.57e-05	0.0136	-0.16	-0.18	Interstitial lung disease;	chr15:85524075	chr15:85744109~85750281:-
LUAD	cis	rs4987094	0.505	rs4938011	ENSG00000270179.1	RP11-159N11.4	3.93	9.58e-05	0.0136	0.24	0.18	Schizophrenia;	chr11:113376510	chr11:113368478~113369117:+
LUAD	cis	rs2745572	0.688	rs2816294	ENSG00000272279.1	RP11-157J24.2	3.93	9.58e-05	0.0136	0.22	0.18	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1538546	chr6:1528364~1528911:-
LUAD	cis	rs7246657	0.943	rs7408563	ENSG00000226686.6	LINC01535	-3.93	9.58e-05	0.0136	-0.27	-0.18	Coronary artery calcification;	chr19:37317683	chr19:37251912~37265535:+
LUAD	cis	rs6479891	1	rs9414780	ENSG00000232075.1	MRPL35P2	3.93	9.58e-05	0.0136	0.29	0.18	Arthritis (juvenile idiopathic);	chr10:63241673	chr10:63634317~63634827:-
LUAD	cis	rs1355223	0.844	rs12809046	ENSG00000271369.1	RP11-350D17.3	-3.93	9.58e-05	0.0136	-0.21	-0.18	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34726714	chr11:34709600~34710161:+
LUAD	cis	rs4374383	0.884	rs4303721	ENSG00000207383.1	Y_RNA	-3.93	9.58e-05	0.0136	-0.21	-0.18	Hepatitis C induced liver fibrosis;	chr2:112003457	chr2:112579484~112579584:-
LUAD	cis	rs2057178	1	rs61889187	ENSG00000183242.10	WT1-AS	3.93	9.58e-05	0.0136	0.28	0.18	Tuberculosis;	chr11:32348057	chr11:32435518~32458769:+
LUAD	cis	rs17301013	0.9	rs56347239	ENSG00000227373.4	RP11-160H22.5	3.93	9.58e-05	0.0136	0.22	0.18	Systemic lupus erythematosus;	chr1:174564476	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.932	rs7542389	ENSG00000227373.4	RP11-160H22.5	3.93	9.58e-05	0.0136	0.22	0.18	Systemic lupus erythematosus;	chr1:174565104	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.932	rs12074753	ENSG00000227373.4	RP11-160H22.5	3.93	9.58e-05	0.0136	0.22	0.18	Systemic lupus erythematosus;	chr1:174565768	chr1:174115300~174160004:-
LUAD	cis	rs7202877	0.706	rs8055609	ENSG00000280152.1	RP11-331F4.5	3.93	9.58e-05	0.0136	0.2	0.18	Type 1 diabetes;Type 2 diabetes;	chr16:75368190	chr16:75245994~75250077:-
LUAD	cis	rs6479901	0.793	rs10822154	ENSG00000232075.1	MRPL35P2	-3.93	9.58e-05	0.0136	-0.25	-0.18	Intelligence (multi-trait analysis);	chr10:63299284	chr10:63634317~63634827:-
LUAD	cis	rs916888	0.773	rs199533	ENSG00000260075.1	NSFP1	-3.93	9.58e-05	0.0136	-0.3	-0.18	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46372855~46487141:+
LUAD	cis	rs9341808	0.538	rs9443742	ENSG00000260645.1	RP11-250B2.5	-3.93	9.59e-05	0.0136	-0.17	-0.18	Sitting height ratio;	chr6:80307212	chr6:80466958~80469080:+
LUAD	cis	rs17772222	0.917	rs12588535	ENSG00000258789.1	RP11-507K2.3	-3.93	9.59e-05	0.0136	-0.25	-0.18	Coronary artery calcification;	chr14:88781900	chr14:88551597~88552493:+
LUAD	cis	rs133885	1	rs133890	ENSG00000272977.1	CTA-390C10.10	-3.93	9.59e-05	0.0136	-0.18	-0.18	Mathematical ability in children with dyslexia;	chr22:25764194	chr22:25476218~25479971:+
LUAD	cis	rs2348418	0.798	rs11049546	ENSG00000247934.4	RP11-967K21.1	3.93	9.59e-05	0.0136	0.2	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28346942	chr12:28163298~28190738:-
LUAD	cis	rs7712401	0.755	rs10071705	ENSG00000249996.1	RP11-359P5.1	3.93	9.59e-05	0.0136	0.21	0.18	Mean platelet volume;	chr5:122797030	chr5:123036271~123054667:+
LUAD	cis	rs4699052	0.739	rs6855777	ENSG00000251288.2	RP11-10L12.2	3.93	9.59e-05	0.0136	0.21	0.18	Testicular germ cell tumor;	chr4:103321207	chr4:102751401~102752641:+
LUAD	cis	rs321358	1	rs73019214	ENSG00000271390.1	RP11-89C3.3	3.93	9.59e-05	0.0136	0.3	0.18	Body mass index;	chr11:111131680	chr11:111089870~111090368:-
LUAD	cis	rs9876781	1	rs725310	ENSG00000229759.1	MRPS18AP1	-3.93	9.59e-05	0.0136	-0.17	-0.18	Longevity;	chr3:48377081	chr3:48256350~48256938:-
LUAD	cis	rs651907	0.557	rs11924013	ENSG00000244119.1	PDCL3P4	3.93	9.59e-05	0.0136	0.17	0.18	Colorectal cancer;	chr3:101647854	chr3:101712472~101713191:+
LUAD	cis	rs7617773	0.815	rs9825637	ENSG00000199476.1	Y_RNA	-3.93	9.59e-05	0.0136	-0.23	-0.18	Coronary artery disease;	chr3:48330792	chr3:48288587~48288694:+
LUAD	cis	rs2749592	0.513	rs1208708	ENSG00000276805.1	RP11-291L22.6	3.93	9.6e-05	0.0136	0.17	0.18	Age-related hearing impairment (SNP x SNP interaction);	chr10:37796648	chr10:38451030~38451785:+
LUAD	cis	rs8050896	0.59	rs79959438	ENSG00000260695.1	RP11-513N24.1	-3.93	9.6e-05	0.0136	-0.37	-0.18	Response to antipsychotic treatment;	chr16:66143675	chr16:65861112~65863784:-
LUAD	cis	rs12682352	0.652	rs1567398	ENSG00000253981.4	ALG1L13P	-3.93	9.6e-05	0.0136	-0.2	-0.18	Neuroticism;	chr8:8869294	chr8:8236003~8244667:-
LUAD	cis	rs8014204	0.57	rs7147721	ENSG00000279594.1	RP11-950C14.10	3.93	9.6e-05	0.0136	0.2	0.18	Caffeine consumption;	chr14:74719307	chr14:75011269~75012851:-
LUAD	cis	rs62246343	0.605	rs9832810	ENSG00000206573.7	THUMPD3-AS1	-3.93	9.6e-05	0.0136	-0.16	-0.18	Fibrinogen levels;	chr3:9424095	chr3:9349689~9398579:-
LUAD	cis	rs6071166	0.683	rs1885460	ENSG00000224635.1	RP4-564F22.5	-3.93	9.6e-05	0.0136	-0.2	-0.18	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38685827	chr20:38406011~38416797:-
LUAD	cis	rs6071166	0.683	rs1885459	ENSG00000224635.1	RP4-564F22.5	-3.93	9.6e-05	0.0136	-0.2	-0.18	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38686293	chr20:38406011~38416797:-
LUAD	cis	rs728616	0.702	rs78734698	ENSG00000225484.5	NUTM2B-AS1	-3.93	9.6e-05	0.0136	-0.46	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79996693	chr10:79663088~79826594:-
LUAD	cis	rs7968440	1	rs2731443	ENSG00000272368.2	RP4-605O3.4	3.93	9.6e-05	0.0136	0.21	0.18	Fibrinogen;	chr12:50700355	chr12:50112197~50165618:+
LUAD	cis	rs854462	0.852	rs854638	ENSG00000274767.1	AC131056.3	-3.93	9.6e-05	0.0136	-0.27	-0.18	Blood protein levels;	chr17:36045331	chr17:36183235~36196471:+
LUAD	cis	rs4374383	0.884	rs10180345	ENSG00000207383.1	Y_RNA	-3.93	9.61e-05	0.0136	-0.21	-0.18	Hepatitis C induced liver fibrosis;	chr2:111983716	chr2:112579484~112579584:-
LUAD	cis	rs4664293	0.631	rs13024749	ENSG00000226266.5	AC009961.3	3.93	9.61e-05	0.0136	0.23	0.18	Monocyte percentage of white cells;	chr2:159799606	chr2:159670708~159712435:-
LUAD	cis	rs7572733	0.935	rs6753450	ENSG00000222017.1	AC011997.1	3.93	9.61e-05	0.0136	0.22	0.18	Dermatomyositis;	chr2:197870307	chr2:197693106~197774823:+
LUAD	cis	rs35740288	0.742	rs4843087	ENSG00000259407.1	RP11-158M2.3	-3.93	9.61e-05	0.0136	-0.17	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85629624	chr15:85744109~85750281:-
LUAD	cis	rs35740288	0.77	rs62022867	ENSG00000259407.1	RP11-158M2.3	-3.93	9.61e-05	0.0136	-0.17	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85630050	chr15:85744109~85750281:-
LUAD	cis	rs115344852	0.598	rs2191035	ENSG00000216901.1	AL022393.7	3.93	9.61e-05	0.0136	0.22	0.18	Epithelial ovarian cancer;	chr6:28467166	chr6:28176188~28176674:+
LUAD	cis	rs115344852	0.598	rs2531815	ENSG00000216901.1	AL022393.7	3.93	9.61e-05	0.0136	0.22	0.18	Epithelial ovarian cancer;	chr6:28468283	chr6:28176188~28176674:+
LUAD	cis	rs8073060	0.586	rs9303690	ENSG00000267592.1	CTC-507E2.2	3.93	9.61e-05	0.0136	0.25	0.18	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35678494	chr17:35596904~35597128:-
LUAD	cis	rs17122278	0.929	rs73023341	ENSG00000243431.1	RPL5P30	3.93	9.62e-05	0.0137	0.22	0.18	Total cholesterol levels;	chr11:118574870	chr11:118560690~118561580:+
LUAD	cis	rs6531209	0.817	rs6531212	ENSG00000234378.1	AC098828.2	3.93	9.62e-05	0.0137	0.22	0.18	Amyotrophic lateral sclerosis (sporadic);	chr2:20138259	chr2:20063856~20106829:-
LUAD	cis	rs2929278	0.588	rs688009	ENSG00000166763.7	STRCP1	3.93	9.62e-05	0.0137	0.21	0.18	Schizophrenia;	chr15:43864104	chr15:43699488~43718184:-
LUAD	cis	rs4908768	0.906	rs12122851	ENSG00000232912.4	RP5-1115A15.1	3.93	9.62e-05	0.0137	0.2	0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8574231	chr1:8424645~8434838:+
LUAD	cis	rs7176527	0.848	rs72630462	ENSG00000259570.1	RP11-671M22.4	-3.93	9.62e-05	0.0137	-0.27	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84706886	chr15:84394512~84395514:+
LUAD	cis	rs7637701	0.773	rs7623691	ENSG00000240875.4	LINC00886	3.93	9.62e-05	0.0137	0.19	0.18	Breast cancer;	chr3:156790921	chr3:156747346~156817062:-
LUAD	cis	rs75920871	0.841	rs78442878	ENSG00000254851.1	RP11-109L13.1	-3.93	9.62e-05	0.0137	-0.33	-0.18	Subjective well-being;	chr11:117052138	chr11:117135528~117138582:+
LUAD	cis	rs11742741	1	rs6859733	ENSG00000248874.4	C5orf17	-3.93	9.63e-05	0.0137	-0.22	-0.18	Educational attainment;	chr5:24165535	chr5:23951348~24178263:+
LUAD	cis	rs1355223	0.902	rs61881050	ENSG00000271369.1	RP11-350D17.3	-3.93	9.63e-05	0.0137	-0.21	-0.18	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34698202	chr11:34709600~34710161:+
LUAD	cis	rs4272382	1	rs4272382	ENSG00000279949.1	RP11-10A14.9	-3.93	9.63e-05	0.0137	-0.36	-0.18	Response to cytidine analogues (gemcitabine);	chr8:8575978	chr8:9158063~9158621:+
LUAD	cis	rs7191700	0.578	rs243324	ENSG00000262636.1	CTD-3088G3.4	3.93	9.63e-05	0.0137	0.22	0.18	Multiple sclerosis;	chr16:11261113	chr16:11380859~11381118:-
LUAD	cis	rs2243480	1	rs35396113	ENSG00000229886.1	RP5-1132H15.3	3.93	9.63e-05	0.0137	0.3	0.18	Diabetic kidney disease;	chr7:66030474	chr7:66025126~66031544:-
LUAD	cis	rs2274273	0.87	rs11851169	ENSG00000258413.1	RP11-665C16.6	-3.93	9.63e-05	0.0137	-0.23	-0.18	Protein biomarker;	chr14:55349214	chr14:55262767~55272075:-
LUAD	cis	rs7615952	0.932	rs3811679	ENSG00000241288.6	RP11-379B18.5	-3.93	9.64e-05	0.0137	-0.23	-0.18	Blood pressure (smoking interaction);	chr3:125929440	chr3:125827238~125916384:-
LUAD	cis	rs9309473	0.519	rs1881246	ENSG00000163016.8	ALMS1P	-3.93	9.64e-05	0.0137	-0.19	-0.18	Metabolite levels;	chr2:73422994	chr2:73644919~73685576:+
LUAD	cis	rs6479891	1	rs4745706	ENSG00000232075.1	MRPL35P2	3.93	9.64e-05	0.0137	0.29	0.18	Arthritis (juvenile idiopathic);	chr10:63399820	chr10:63634317~63634827:-
LUAD	cis	rs6479891	1	rs12415038	ENSG00000232075.1	MRPL35P2	3.93	9.64e-05	0.0137	0.29	0.18	Arthritis (juvenile idiopathic);	chr10:63401098	chr10:63634317~63634827:-
LUAD	cis	rs2836950	0.501	rs2836980	ENSG00000232608.1	TIMM9P2	3.93	9.64e-05	0.0137	0.2	0.18	Menarche (age at onset);	chr21:39315692	chr21:39216624~39217506:+
LUAD	cis	rs2836950	0.501	rs11088470	ENSG00000232608.1	TIMM9P2	3.93	9.64e-05	0.0137	0.2	0.18	Menarche (age at onset);	chr21:39317236	chr21:39216624~39217506:+
LUAD	cis	rs2836950	0.501	rs2836983	ENSG00000232608.1	TIMM9P2	3.93	9.64e-05	0.0137	0.2	0.18	Menarche (age at onset);	chr21:39317410	chr21:39216624~39217506:+
LUAD	cis	rs728616	0.867	rs7080405	ENSG00000234382.2	RP11-40F6.1	-3.93	9.64e-05	0.0137	-0.43	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80142187	chr10:80233664~80245367:+
LUAD	cis	rs9813712	0.597	rs1453255	ENSG00000228252.7	COL6A4P2	-3.93	9.64e-05	0.0137	-0.17	-0.18	Response to amphetamines;	chr3:130258815	chr3:130212823~130273806:+
LUAD	cis	rs2688608	0.901	rs2675671	ENSG00000271816.1	BMS1P4	3.93	9.65e-05	0.0137	0.15	0.18	Inflammatory bowel disease;	chr10:73873002	chr10:73699151~73730487:-
LUAD	cis	rs2657294	0.861	rs6480769	ENSG00000226051.5	ZNF503-AS1	-3.93	9.65e-05	0.0137	-0.24	-0.18	Pneumonia;	chr10:75091745	chr10:75269819~75373500:+
LUAD	cis	rs2880765	0.566	rs11630381	ENSG00000259407.1	RP11-158M2.3	-3.93	9.65e-05	0.0137	-0.17	-0.18	Coronary artery disease;	chr15:85469272	chr15:85744109~85750281:-
LUAD	cis	rs9876781	1	rs3214041	ENSG00000229759.1	MRPS18AP1	3.93	9.65e-05	0.0137	0.17	0.18	Longevity;	chr3:48413059	chr3:48256350~48256938:-
LUAD	cis	rs7893279	0.505	rs7071300	ENSG00000225527.1	RP11-383B4.4	3.93	9.65e-05	0.0137	0.26	0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18594736	chr10:18531849~18533336:-
LUAD	cis	rs7893279	0.505	rs7074644	ENSG00000225527.1	RP11-383B4.4	3.93	9.65e-05	0.0137	0.26	0.18	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18594778	chr10:18531849~18533336:-
LUAD	cis	rs6928977	0.538	rs9494290	ENSG00000231028.7	LINC00271	-3.93	9.65e-05	0.0137	-0.2	-0.18	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135596407	chr6:135497801~135716055:+
LUAD	cis	rs2657294	0.965	rs10824285	ENSG00000233313.2	HMGA1P5	-3.93	9.65e-05	0.0137	-0.22	-0.18	Pneumonia;	chr10:75153271	chr10:75276376~75276646:-
LUAD	cis	rs9549260	0.651	rs9549251	ENSG00000229456.1	RLIMP1	3.93	9.65e-05	0.0137	0.19	0.18	Red blood cell count;	chr13:40654513	chr13:40618738~40621348:+
LUAD	cis	rs11742741	0.774	rs1428204	ENSG00000248874.4	C5orf17	-3.93	9.65e-05	0.0137	-0.22	-0.18	Educational attainment;	chr5:24081270	chr5:23951348~24178263:+
LUAD	cis	rs10266483	1	rs1960321	ENSG00000227986.1	TRIM60P18	-3.93	9.65e-05	0.0137	-0.21	-0.18	Response to statin therapy;	chr7:64270906	chr7:64355078~64356199:+
LUAD	cis	rs10761482	0.645	rs10761498	ENSG00000254271.1	RP11-131N11.4	3.93	9.65e-05	0.0137	0.21	0.18	Schizophrenia;	chr10:60423627	chr10:60734342~60741828:+
LUAD	cis	rs6688613	0.694	rs2075946	ENSG00000225171.2	DUTP6	-3.93	9.66e-05	0.0137	-0.22	-0.18	Refractive astigmatism;	chr1:166849329	chr1:166868748~166869209:+
LUAD	cis	rs1154275	0.524	rs6438105	ENSG00000242770.2	RP11-180K7.1	3.93	9.66e-05	0.0137	0.18	0.18	Takotsubo syndrome;	chr3:112788040	chr3:112802478~112812819:+
LUAD	cis	rs7246657	0.943	rs4803460	ENSG00000226686.6	LINC01535	-3.93	9.66e-05	0.0137	-0.26	-0.18	Coronary artery calcification;	chr19:37394326	chr19:37251912~37265535:+
LUAD	cis	rs4660214	0.666	rs597311	ENSG00000182109.6	RP11-69E11.4	3.93	9.66e-05	0.0137	0.19	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39355254	chr1:39522280~39546187:-
LUAD	cis	rs4660214	0.615	rs597708	ENSG00000182109.6	RP11-69E11.4	3.93	9.66e-05	0.0137	0.19	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39355291	chr1:39522280~39546187:-
LUAD	cis	rs4660214	0.666	rs636156	ENSG00000182109.6	RP11-69E11.4	3.93	9.66e-05	0.0137	0.19	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39356065	chr1:39522280~39546187:-
LUAD	cis	rs442177	0.524	rs16930	ENSG00000251411.1	RP11-397E7.4	3.93	9.66e-05	0.0137	0.18	0.18	Triglycerides;Hemoglobin concentration;	chr4:87122793	chr4:86913266~86914817:-
LUAD	cis	rs301901	0.965	rs2886201	ENSG00000250155.1	CTD-2353F22.1	-3.93	9.67e-05	0.0137	-0.19	-0.18	Height;	chr5:36796728	chr5:36666214~36725195:-
LUAD	cis	rs957448	1	rs12543207	ENSG00000254315.1	RP11-267M23.3	3.93	9.67e-05	0.0137	0.23	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94485202	chr8:94533628~94534391:+
LUAD	cis	rs7122539	0.646	rs9633985	ENSG00000213409.4	RP11-658F2.3	-3.93	9.67e-05	0.0137	-0.22	-0.18	HIV-1 susceptibility;	chr11:66753137	chr11:66761575~66762399:-
LUAD	cis	rs7615952	0.932	rs6438948	ENSG00000241288.6	RP11-379B18.5	3.93	9.67e-05	0.0137	0.22	0.18	Blood pressure (smoking interaction);	chr3:125931202	chr3:125827238~125916384:-
LUAD	cis	rs7762018	0.77	rs3823466	ENSG00000231690.2	LINC00574	-3.93	9.68e-05	0.0137	-0.3	-0.18	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169789830	chr6:169790321~169802873:+
LUAD	cis	rs1979679	0.842	rs4931730	ENSG00000278733.1	RP11-425D17.1	3.93	9.68e-05	0.0137	0.22	0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28146343	chr12:28185625~28186190:-
LUAD	cis	rs761746	0.705	rs10154390	ENSG00000236132.1	CTA-440B3.1	-3.93	9.68e-05	0.0137	-0.25	-0.18	Intelligence;	chr22:31655103	chr22:31816379~31817491:-
LUAD	cis	rs2731006	0.544	rs2252129	ENSG00000257114.2	RP11-25I15.3	3.93	9.68e-05	0.0137	0.28	0.18	Panic disorder;	chr12:42772899	chr12:42692216~42717119:+
LUAD	cis	rs442309	0.807	rs224029	ENSG00000238280.1	RP11-436D10.3	-3.93	9.68e-05	0.0137	-0.21	-0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62759539	chr10:62793562~62805887:-
LUAD	cis	rs794728	0.543	rs1863956	ENSG00000249031.1	SUMO2P6	3.93	9.68e-05	0.0137	0.19	0.18	Depressive symptoms (SSRI exposure interaction);	chr5:174432200	chr5:174561776~174562063:+
LUAD	cis	rs2836950	0.501	rs4818018	ENSG00000232608.1	TIMM9P2	3.93	9.68e-05	0.0137	0.2	0.18	Menarche (age at onset);	chr21:39322146	chr21:39216624~39217506:+
LUAD	cis	rs2836950	0.501	rs4818019	ENSG00000232608.1	TIMM9P2	3.93	9.68e-05	0.0137	0.2	0.18	Menarche (age at onset);	chr21:39322530	chr21:39216624~39217506:+
LUAD	cis	rs1075265	0.547	rs7557799	ENSG00000272156.1	RP11-477N3.1	3.93	9.68e-05	0.0137	0.21	0.18	Chronotype;Morning vs. evening chronotype;	chr2:53674760	chr2:54082554~54085066:+
LUAD	cis	rs1075265	0.811	rs805322	ENSG00000272156.1	RP11-477N3.1	3.93	9.68e-05	0.0137	0.21	0.18	Chronotype;Morning vs. evening chronotype;	chr2:53912758	chr2:54082554~54085066:+
LUAD	cis	rs12216545	0.765	rs1851435	ENSG00000177590.7	GIMAP3P	-3.93	9.68e-05	0.0137	-0.18	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150531697	chr7:150746893~150747728:-
LUAD	cis	rs12216545	0.737	rs4339548	ENSG00000177590.7	GIMAP3P	-3.93	9.68e-05	0.0137	-0.18	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150532227	chr7:150746893~150747728:-
LUAD	cis	rs12216545	0.765	rs4607525	ENSG00000177590.7	GIMAP3P	-3.93	9.68e-05	0.0137	-0.18	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150532262	chr7:150746893~150747728:-
LUAD	cis	rs763121	0.853	rs5750673	ENSG00000225450.1	RP3-508I15.14	-3.93	9.68e-05	0.0137	-0.18	-0.18	Menopause (age at onset);	chr22:38714119	chr22:38739003~38749041:+
LUAD	cis	rs6494488	0.5	rs16948182	ENSG00000239465.1	RP11-330L19.2	3.93	9.68e-05	0.0137	0.32	0.18	Coronary artery disease;	chr15:64687183	chr15:64631109~64631914:-
LUAD	cis	rs7829975	0.517	rs12542733	ENSG00000253981.4	ALG1L13P	-3.93	9.68e-05	0.0137	-0.2	-0.18	Mood instability;	chr8:8967348	chr8:8236003~8244667:-
LUAD	cis	rs6494488	0.5	rs72742927	ENSG00000239465.1	RP11-330L19.2	3.93	9.69e-05	0.0137	0.38	0.18	Coronary artery disease;	chr15:64574106	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs72742928	ENSG00000239465.1	RP11-330L19.2	3.93	9.69e-05	0.0137	0.38	0.18	Coronary artery disease;	chr15:64576281	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs72742931	ENSG00000239465.1	RP11-330L19.2	3.93	9.69e-05	0.0137	0.38	0.18	Coronary artery disease;	chr15:64579797	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs72742934	ENSG00000239465.1	RP11-330L19.2	3.93	9.69e-05	0.0137	0.38	0.18	Coronary artery disease;	chr15:64583524	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs117686856	ENSG00000239465.1	RP11-330L19.2	3.93	9.69e-05	0.0137	0.38	0.18	Coronary artery disease;	chr15:64593046	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs72742943	ENSG00000239465.1	RP11-330L19.2	3.93	9.69e-05	0.0137	0.38	0.18	Coronary artery disease;	chr15:64597264	chr15:64631109~64631914:-
LUAD	cis	rs9601248	0.627	rs2876741	ENSG00000227676.3	LINC01068	-3.93	9.69e-05	0.0137	-0.22	-0.18	Major depressive disorder;	chr13:79612577	chr13:79566727~79571436:+
LUAD	cis	rs1876905	0.539	rs240980	ENSG00000230177.1	RP5-1112D6.4	3.93	9.69e-05	0.0137	0.22	0.18	Mean corpuscular hemoglobin;	chr6:111288707	chr6:111277932~111278742:+
LUAD	cis	rs600231	0.542	rs10896009	ENSG00000245532.5	NEAT1	-3.93	9.69e-05	0.0137	-0.16	-0.18	Bone mineral density;	chr11:65478583	chr11:65422774~65445540:+
LUAD	cis	rs3753275	0.69	rs4908762	ENSG00000232912.4	RP5-1115A15.1	3.93	9.69e-05	0.0137	0.2	0.18	Educational attainment;	chr1:8503603	chr1:8424645~8434838:+
LUAD	cis	rs9549260	0.755	rs2721044	ENSG00000229456.1	RLIMP1	3.93	9.7e-05	0.0137	0.19	0.18	Red blood cell count;	chr13:40588088	chr13:40618738~40621348:+
LUAD	cis	rs3020736	0.5	rs8138678	ENSG00000205702.9	CYP2D7	-3.93	9.7e-05	0.0138	-0.14	-0.18	Autism spectrum disorder or schizophrenia;	chr22:42120225	chr22:42140203~42144577:-
LUAD	cis	rs8056893	0.714	rs1868159	ENSG00000260441.4	RP11-96D1.7	3.93	9.7e-05	0.0138	0.21	0.18	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68353593	chr16:68256162~68260443:-
LUAD	cis	rs2408955	0.522	rs11168408	ENSG00000257763.1	OR5BK1P	-3.93	9.7e-05	0.0138	-0.19	-0.18	Glycated hemoglobin levels;	chr12:48104544	chr12:48355792~48356614:-
LUAD	cis	rs1476587	0.92	rs10487071	ENSG00000224046.1	AC005076.5	3.93	9.71e-05	0.0138	0.23	0.18	Brachial circumference;	chr7:87108266	chr7:87151423~87152420:-
LUAD	cis	rs7302981	1	rs7302981	ENSG00000200428.1	Y_RNA	3.93	9.71e-05	0.0138	0.22	0.18	Systolic blood pressure;	chr12:50144032	chr12:50743568~50743684:+
LUAD	cis	rs913672	0.637	rs2274951	ENSG00000229222.1	KRT18P4	-3.93	9.71e-05	0.0138	-0.22	-0.18	Monocyte count;	chr20:50277933	chr20:49956745~49958032:+
LUAD	cis	rs5758511	0.573	rs738248	ENSG00000227370.1	RP4-669P10.19	-3.93	9.71e-05	0.0138	-0.18	-0.18	Birth weight;	chr22:41800463	chr22:42132543~42132998:+
LUAD	cis	rs5758511	0.541	rs6002494	ENSG00000227370.1	RP4-669P10.19	-3.93	9.71e-05	0.0138	-0.18	-0.18	Birth weight;	chr22:41803856	chr22:42132543~42132998:+
LUAD	cis	rs5758511	0.573	rs5996069	ENSG00000227370.1	RP4-669P10.19	-3.93	9.71e-05	0.0138	-0.18	-0.18	Birth weight;	chr22:41805181	chr22:42132543~42132998:+
LUAD	cis	rs9890032	1	rs28539246	ENSG00000266490.1	CTD-2349P21.9	3.93	9.71e-05	0.0138	0.16	0.18	Hip circumference adjusted for BMI;	chr17:30899612	chr17:30792372~30792833:+
LUAD	cis	rs9890032	0.967	rs9897628	ENSG00000266490.1	CTD-2349P21.9	3.93	9.71e-05	0.0138	0.16	0.18	Hip circumference adjusted for BMI;	chr17:30899634	chr17:30792372~30792833:+
LUAD	cis	rs6723226	0.842	rs1901355	ENSG00000276334.1	AL133243.1	-3.93	9.71e-05	0.0138	-0.21	-0.18	Intelligence (multi-trait analysis);	chr2:32610597	chr2:32521927~32523547:+
LUAD	cis	rs7615952	0.546	rs2979306	ENSG00000241288.6	RP11-379B18.5	-3.93	9.71e-05	0.0138	-0.22	-0.18	Blood pressure (smoking interaction);	chr3:125593286	chr3:125827238~125916384:-
LUAD	cis	rs4667682	0.529	rs62181342	ENSG00000234061.1	AC007969.4	-3.93	9.71e-05	0.0138	-0.34	-0.18	Hippocampal atrophy;Body mass index;	chr2:171309915	chr2:171492905~171493095:+
LUAD	cis	rs3020736	0.5	rs1801311	ENSG00000205702.9	CYP2D7	-3.93	9.72e-05	0.0138	-0.14	-0.18	Autism spectrum disorder or schizophrenia;	chr22:42090719	chr22:42140203~42144577:-
LUAD	cis	rs8014204	0.804	rs35641442	ENSG00000279594.1	RP11-950C14.10	3.93	9.72e-05	0.0138	0.2	0.18	Caffeine consumption;	chr14:74740560	chr14:75011269~75012851:-
LUAD	cis	rs763121	0.889	rs9610971	ENSG00000225450.1	RP3-508I15.14	-3.93	9.72e-05	0.0138	-0.18	-0.18	Menopause (age at onset);	chr22:38514805	chr22:38739003~38749041:+
LUAD	cis	rs2467099	0.504	rs55956362	ENSG00000267801.1	RP11-552F3.9	3.93	9.72e-05	0.0138	0.2	0.18	Systolic blood pressure;	chr17:75905213	chr17:75876372~75879546:+
LUAD	cis	rs11742741	0.807	rs4484388	ENSG00000248874.4	C5orf17	-3.93	9.72e-05	0.0138	-0.22	-0.18	Educational attainment;	chr5:24123095	chr5:23951348~24178263:+
LUAD	cis	rs11742741	0.967	rs6883969	ENSG00000248874.4	C5orf17	-3.93	9.72e-05	0.0138	-0.22	-0.18	Educational attainment;	chr5:24127022	chr5:23951348~24178263:+
LUAD	cis	rs11742741	0.902	rs2059825	ENSG00000248874.4	C5orf17	-3.93	9.72e-05	0.0138	-0.22	-0.18	Educational attainment;	chr5:24131708	chr5:23951348~24178263:+
LUAD	cis	rs7181230	0.961	rs7183977	ENSG00000275636.1	RP11-521C20.5	-3.93	9.72e-05	0.0138	-0.22	-0.18	Dehydroepiandrosterone sulphate levels;	chr15:40084891	chr15:40078892~40079347:+
LUAD	cis	rs2638953	0.776	rs11513467	ENSG00000278733.1	RP11-425D17.1	-3.93	9.73e-05	0.0138	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210252	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.776	rs11519332	ENSG00000278733.1	RP11-425D17.1	-3.93	9.73e-05	0.0138	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28210254	chr12:28185625~28186190:-
LUAD	cis	rs858239	0.738	rs7807879	ENSG00000226816.2	AC005082.12	3.93	9.73e-05	0.0138	0.23	0.18	Cerebrospinal fluid biomarker levels;	chr7:23220969	chr7:23206013~23208045:+
LUAD	cis	rs2098713	0.534	rs11746259	ENSG00000250155.1	CTD-2353F22.1	3.93	9.73e-05	0.0138	0.19	0.18	Telomere length;	chr5:37488801	chr5:36666214~36725195:-
LUAD	cis	rs2098713	0.502	rs55872839	ENSG00000250155.1	CTD-2353F22.1	3.93	9.73e-05	0.0138	0.19	0.18	Telomere length;	chr5:37488967	chr5:36666214~36725195:-
LUAD	cis	rs2098713	0.501	rs12652895	ENSG00000250155.1	CTD-2353F22.1	3.93	9.73e-05	0.0138	0.19	0.18	Telomere length;	chr5:37489269	chr5:36666214~36725195:-
LUAD	cis	rs2098713	0.569	rs12657090	ENSG00000250155.1	CTD-2353F22.1	3.93	9.73e-05	0.0138	0.19	0.18	Telomere length;	chr5:37489340	chr5:36666214~36725195:-
LUAD	cis	rs2098713	0.501	rs55758219	ENSG00000250155.1	CTD-2353F22.1	3.93	9.73e-05	0.0138	0.19	0.18	Telomere length;	chr5:37489681	chr5:36666214~36725195:-
LUAD	cis	rs2098713	0.534	rs56307385	ENSG00000250155.1	CTD-2353F22.1	3.93	9.73e-05	0.0138	0.19	0.18	Telomere length;	chr5:37490062	chr5:36666214~36725195:-
LUAD	cis	rs2098713	0.569	rs7727005	ENSG00000250155.1	CTD-2353F22.1	3.93	9.73e-05	0.0138	0.19	0.18	Telomere length;	chr5:37490325	chr5:36666214~36725195:-
LUAD	cis	rs2098713	0.569	rs7727685	ENSG00000250155.1	CTD-2353F22.1	3.93	9.73e-05	0.0138	0.19	0.18	Telomere length;	chr5:37490694	chr5:36666214~36725195:-
LUAD	cis	rs2098713	0.569	rs11958226	ENSG00000250155.1	CTD-2353F22.1	3.93	9.73e-05	0.0138	0.19	0.18	Telomere length;	chr5:37491418	chr5:36666214~36725195:-
LUAD	cis	rs2098713	0.569	rs7733244	ENSG00000250155.1	CTD-2353F22.1	3.93	9.73e-05	0.0138	0.19	0.18	Telomere length;	chr5:37491825	chr5:36666214~36725195:-
LUAD	cis	rs11089937	0.616	rs7291684	ENSG00000211638.2	IGLV8-61	-3.93	9.73e-05	0.0138	-0.19	-0.18	Periodontitis (PAL4Q3);	chr22:22183834	chr22:22098700~22099212:+
LUAD	cis	rs11089937	0.616	rs6001219	ENSG00000211638.2	IGLV8-61	-3.93	9.73e-05	0.0138	-0.19	-0.18	Periodontitis (PAL4Q3);	chr22:22184348	chr22:22098700~22099212:+
LUAD	cis	rs11089937	0.616	rs5995615	ENSG00000211638.2	IGLV8-61	-3.93	9.73e-05	0.0138	-0.19	-0.18	Periodontitis (PAL4Q3);	chr22:22185250	chr22:22098700~22099212:+
LUAD	cis	rs11089937	0.616	rs6001223	ENSG00000211638.2	IGLV8-61	-3.93	9.73e-05	0.0138	-0.19	-0.18	Periodontitis (PAL4Q3);	chr22:22185359	chr22:22098700~22099212:+
LUAD	cis	rs11089937	0.616	rs928895	ENSG00000211638.2	IGLV8-61	-3.93	9.73e-05	0.0138	-0.19	-0.18	Periodontitis (PAL4Q3);	chr22:22185915	chr22:22098700~22099212:+
LUAD	cis	rs11089937	0.616	rs928896	ENSG00000211638.2	IGLV8-61	-3.93	9.73e-05	0.0138	-0.19	-0.18	Periodontitis (PAL4Q3);	chr22:22185929	chr22:22098700~22099212:+
LUAD	cis	rs11089937	0.616	rs6001224	ENSG00000211638.2	IGLV8-61	-3.93	9.73e-05	0.0138	-0.19	-0.18	Periodontitis (PAL4Q3);	chr22:22186042	chr22:22098700~22099212:+
LUAD	cis	rs12681963	0.686	rs75451240	ENSG00000272375.1	RP11-51J9.6	3.93	9.73e-05	0.0138	0.31	0.18	Migraine;	chr8:30123733	chr8:30197404~30198048:+
LUAD	cis	rs3018712	0.59	rs7110468	ENSG00000227620.4	ALG1L8P	-3.93	9.73e-05	0.0138	-0.24	-0.18	Total body bone mineral density;	chr11:68716546	chr11:67785273~67792335:+
LUAD	cis	rs6121246	0.559	rs6060716	ENSG00000230613.1	HM13-AS1	3.93	9.73e-05	0.0138	0.22	0.18	Mean corpuscular hemoglobin;	chr20:31687044	chr20:31567707~31573263:-
LUAD	cis	rs4908768	0.906	rs7539382	ENSG00000232912.4	RP5-1115A15.1	-3.93	9.73e-05	0.0138	-0.2	-0.18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8519242	chr1:8424645~8434838:+
LUAD	cis	rs595244	1	rs77105137	ENSG00000259705.1	RP11-227D13.1	3.93	9.74e-05	0.0138	0.4	0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48463275	chr15:48645951~48652016:+
LUAD	cis	rs6841258	0.572	rs16852326	ENSG00000249241.1	AC195454.1	3.93	9.74e-05	0.0138	0.25	0.18	Mosquito bite size;	chr4:40551287	chr4:40316485~40330419:+
LUAD	cis	rs957448	1	rs56716157	ENSG00000254315.1	RP11-267M23.3	3.93	9.74e-05	0.0138	0.23	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94530644	chr8:94533628~94534391:+
LUAD	cis	rs1979679	0.581	rs1405812	ENSG00000278733.1	RP11-425D17.1	-3.93	9.74e-05	0.0138	-0.25	-0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28476043	chr12:28185625~28186190:-
LUAD	cis	rs6964587	1	rs61244255	ENSG00000188693.7	CYP51A1-AS1	-3.93	9.74e-05	0.0138	-0.21	-0.18	Breast cancer;	chr7:92122348	chr7:92134604~92180725:+
LUAD	cis	rs761746	0.579	rs5998121	ENSG00000236132.1	CTA-440B3.1	-3.93	9.74e-05	0.0138	-0.24	-0.18	Intelligence;	chr22:31776381	chr22:31816379~31817491:-
LUAD	cis	rs2880765	0.545	rs11631739	ENSG00000259407.1	RP11-158M2.3	-3.93	9.75e-05	0.0138	-0.17	-0.18	Coronary artery disease;	chr15:85469347	chr15:85744109~85750281:-
LUAD	cis	rs10129255	0.5	rs6576230	ENSG00000253209.1	IGHV3-65	3.93	9.75e-05	0.0138	0.14	0.18	Kawasaki disease;	chr14:106778539	chr14:106666092~106666532:-
LUAD	cis	rs10129255	0.518	rs11847766	ENSG00000253209.1	IGHV3-65	3.93	9.75e-05	0.0138	0.14	0.18	Kawasaki disease;	chr14:106779186	chr14:106666092~106666532:-
LUAD	cis	rs12122100	1	rs12122100	ENSG00000244371.2	PFN1P8	3.93	9.75e-05	0.0138	0.22	0.18	HIV-1 control;	chr1:147037378	chr1:146957117~146957659:-
LUAD	cis	rs651907	0.535	rs13059470	ENSG00000244119.1	PDCL3P4	-3.93	9.75e-05	0.0138	-0.17	-0.18	Colorectal cancer;	chr3:101705956	chr3:101712472~101713191:+
LUAD	cis	rs1348850	0.958	rs1548067	ENSG00000213963.5	AC074286.1	3.93	9.75e-05	0.0138	0.2	0.18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177598186	chr2:177283508~177392691:-
LUAD	cis	rs10090774	0.71	rs10088475	ENSG00000280303.2	ERICD	-3.93	9.76e-05	0.0138	-0.19	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140660167	chr8:140636281~140638283:+
LUAD	cis	rs7617773	0.817	rs13094727	ENSG00000199476.1	Y_RNA	-3.93	9.76e-05	0.0138	-0.24	-0.18	Coronary artery disease;	chr3:48281999	chr3:48288587~48288694:+
LUAD	cis	rs338389	0.814	rs426705	ENSG00000260657.2	RP11-315D16.4	3.93	9.76e-05	0.0138	0.2	0.18	Survival in rectal cancer;	chr15:67956910	chr15:68267792~68277994:-
LUAD	cis	rs9951698	0.703	rs7233600	ENSG00000267480.1	RP11-703I16.1	-3.93	9.76e-05	0.0138	-0.22	-0.18	Intelligence (multi-trait analysis);	chr18:12986001	chr18:12031178~12032181:-
LUAD	cis	rs9860428	0.844	rs6807722	ENSG00000242770.2	RP11-180K7.1	3.93	9.76e-05	0.0138	0.19	0.18	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112896320	chr3:112802478~112812819:+
LUAD	cis	rs7515577	0.898	rs1487539	ENSG00000223787.2	RP4-593M8.1	-3.93	9.76e-05	0.0138	-0.27	-0.18	Cholesterol, total;	chr1:92274142	chr1:92580476~92580821:-
LUAD	cis	rs7849270	0.679	rs10988217	ENSG00000268707.1	RP11-247A12.7	-3.93	9.76e-05	0.0138	-0.19	-0.18	Blood metabolite ratios;	chr9:129125837	chr9:129170434~129170940:+
LUAD	cis	rs6802315	0.74	rs9822005	ENSG00000272087.1	RP11-379F4.7	3.93	9.76e-05	0.0138	0.19	0.18	Periodontitis (CDC/AAP);	chr3:158794592	chr3:158693120~158693768:-
LUAD	cis	rs477895	0.568	rs34838337	ENSG00000236935.1	AP003774.1	-3.93	9.76e-05	0.0138	-0.21	-0.18	Mean platelet volume;	chr11:64103420	chr11:64325050~64329504:-
LUAD	cis	rs7107174	1	rs11601590	ENSG00000251323.2	RP11-452H21.4	3.93	9.77e-05	0.0138	0.21	0.18	Testicular germ cell tumor;	chr11:78362242	chr11:78423982~78429836:-
LUAD	cis	rs7107174	1	rs11603112	ENSG00000251323.2	RP11-452H21.4	3.93	9.77e-05	0.0138	0.21	0.18	Testicular germ cell tumor;	chr11:78362445	chr11:78423982~78429836:-
LUAD	cis	rs35740288	0.703	rs10520598	ENSG00000259407.1	RP11-158M2.3	-3.93	9.77e-05	0.0138	-0.17	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85630150	chr15:85744109~85750281:-
LUAD	cis	rs35740288	0.77	rs11635587	ENSG00000259407.1	RP11-158M2.3	-3.93	9.77e-05	0.0138	-0.17	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85630402	chr15:85744109~85750281:-
LUAD	cis	rs35740288	0.77	rs35447727	ENSG00000259407.1	RP11-158M2.3	-3.93	9.77e-05	0.0138	-0.17	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85631168	chr15:85744109~85750281:-
LUAD	cis	rs35740288	0.77	rs34058174	ENSG00000259407.1	RP11-158M2.3	-3.93	9.77e-05	0.0138	-0.17	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85631231	chr15:85744109~85750281:-
LUAD	cis	rs35740288	0.587	rs4843089	ENSG00000259407.1	RP11-158M2.3	-3.93	9.77e-05	0.0138	-0.17	-0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85632905	chr15:85744109~85750281:-
LUAD	cis	rs7291412	0.54	rs9627391	ENSG00000231711.2	LINC00899	3.93	9.77e-05	0.0138	0.16	0.18	Dupuytren's disease;Subjective well-being;	chr22:46051217	chr22:46039907~46044853:-
LUAD	cis	rs17695224	0.545	rs4802872	ENSG00000269483.1	AC006272.1	3.93	9.77e-05	0.0138	0.19	0.18	HDL cholesterol;HDL cholesterol levels;	chr19:51817790	chr19:51839924~51843324:-
LUAD	cis	rs338389	0.814	rs338384	ENSG00000260657.2	RP11-315D16.4	-3.93	9.77e-05	0.0138	-0.2	-0.18	Survival in rectal cancer;	chr15:67955168	chr15:68267792~68277994:-
LUAD	cis	rs6088580	0.609	rs6059845	ENSG00000276073.1	RP5-1125A11.7	-3.93	9.77e-05	0.0138	-0.17	-0.18	Glomerular filtration rate (creatinine);	chr20:34448695	chr20:33985617~33988989:-
LUAD	cis	rs7107174	0.901	rs10899473	ENSG00000251323.2	RP11-452H21.4	3.93	9.78e-05	0.0138	0.21	0.18	Testicular germ cell tumor;	chr11:78331937	chr11:78423982~78429836:-
LUAD	cis	rs117623576	0.941	rs17230172	ENSG00000234335.1	RPS4XP11	-3.93	9.78e-05	0.0138	-0.27	-0.18	Anti-saccade response;	chr10:32149562	chr10:32102522~32103293:-
LUAD	cis	rs10876993	0.928	rs10082911	ENSG00000270039.1	RP11-571M6.17	3.93	9.78e-05	0.0138	0.21	0.18	Celiac disease or Rheumatoid arthritis;	chr12:57710321	chr12:57803838~57804415:+
LUAD	cis	rs2976388	0.524	rs7012804	ENSG00000253741.1	CTD-2292P10.4	-3.93	9.78e-05	0.0138	-0.21	-0.18	Urinary tract infection frequency;	chr8:142763232	chr8:142702252~142726973:-
LUAD	cis	rs2836754	0.647	rs11088456	ENSG00000205622.8	AF064858.6	-3.93	9.78e-05	0.0138	-0.2	-0.18	Body mass index;Crohn's disease;	chr21:38921027	chr21:38863676~38956467:-
LUAD	cis	rs273259	0.583	rs3818763	ENSG00000235400.1	RP4-641G12.4	3.93	9.78e-05	0.0138	0.26	0.18	Febrile seizures (MMR vaccine-related);Febrile seizures;	chr1:78629235	chr1:78749073~78750659:+
LUAD	cis	rs2548724	0.716	rs6881112	ENSG00000250682.4	LINC00491	3.93	9.78e-05	0.0139	0.22	0.18	Type 2 diabetes;	chr5:102440038	chr5:102609156~102671559:-
LUAD	cis	rs13113518	1	rs55699500	ENSG00000273257.1	RP11-177J6.1	3.93	9.78e-05	0.0139	0.19	0.18	Height;	chr4:55540912	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs56362210	ENSG00000273257.1	RP11-177J6.1	3.93	9.78e-05	0.0139	0.19	0.18	Height;	chr4:55540972	chr4:55387949~55388271:+
LUAD	cis	rs9650657	0.571	rs11783247	ENSG00000255310.2	AF131215.2	-3.93	9.78e-05	0.0139	-0.18	-0.18	Neuroticism;	chr8:10931365	chr8:11107788~11109726:-
LUAD	cis	rs7580658	0.929	rs11886231	ENSG00000236682.1	AC068282.3	-3.93	9.79e-05	0.0139	-0.24	-0.18	Protein C levels;	chr2:127270554	chr2:127389130~127400580:+
LUAD	cis	rs7119038	0.774	rs2004781	ENSG00000255239.1	AP002954.6	-3.93	9.79e-05	0.0139	-0.27	-0.18	Sjögren's syndrome;	chr11:118748544	chr11:118688039~118690600:-
LUAD	cis	rs7119038	0.818	rs3889239	ENSG00000255239.1	AP002954.6	-3.93	9.79e-05	0.0139	-0.27	-0.18	Sjögren's syndrome;	chr11:118749251	chr11:118688039~118690600:-
LUAD	cis	rs7976269	0.609	rs4931141	ENSG00000257176.2	RP11-996F15.2	-3.93	9.79e-05	0.0139	-0.19	-0.18	Male-pattern baldness;	chr12:29057763	chr12:29280418~29317848:-
LUAD	cis	rs7617773	0.674	rs13069029	ENSG00000199476.1	Y_RNA	-3.93	9.79e-05	0.0139	-0.24	-0.18	Coronary artery disease;	chr3:48313534	chr3:48288587~48288694:+
LUAD	cis	rs2239547	0.522	rs2581823	ENSG00000243224.1	RP5-1157M23.2	3.93	9.79e-05	0.0139	0.19	0.18	Schizophrenia;	chr3:52988060	chr3:52239258~52241097:+
LUAD	cis	rs11673344	0.504	rs4806408	ENSG00000276846.1	CTD-3220F14.3	3.93	9.79e-05	0.0139	0.19	0.18	Obesity-related traits;	chr19:37097875	chr19:37314868~37315620:-
LUAD	cis	rs4711350	0.723	rs608971	ENSG00000224557.6	HLA-DPB2	-3.93	9.8e-05	0.0139	-0.31	-0.18	Schizophrenia;	chr6:33734302	chr6:33112451~33129084:+
LUAD	cis	rs1150668	0.768	rs1233713	ENSG00000176933.5	TOB2P1	-3.93	9.8e-05	0.0139	-0.2	-0.18	Pubertal anthropometrics;	chr6:28230503	chr6:28217643~28218634:-
LUAD	cis	rs791888	1	rs791888	ENSG00000225913.2	RP11-57C13.6	3.93	9.8e-05	0.0139	0.22	0.18	Magnesium levels;	chr10:87652818	chr10:87607985~87659279:+
LUAD	cis	rs8031584	0.958	rs1043742	ENSG00000259845.1	HERC2P10	3.93	9.8e-05	0.0139	0.2	0.18	Huntington's disease progression;	chr15:30940378	chr15:30815271~30844153:+
LUAD	cis	rs116095464	0.558	rs10080225	ENSG00000248925.1	CTD-2083E4.6	3.93	9.8e-05	0.0139	0.3	0.18	Breast cancer;	chr5:232060	chr5:269858~271516:-
LUAD	cis	rs748404	0.666	rs12900259	ENSG00000249839.1	AC011330.5	-3.93	9.81e-05	0.0139	-0.27	-0.18	Lung cancer;	chr15:43427369	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.666	rs34921640	ENSG00000249839.1	AC011330.5	-3.93	9.81e-05	0.0139	-0.27	-0.18	Lung cancer;	chr15:43429187	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.666	rs62020574	ENSG00000249839.1	AC011330.5	-3.93	9.81e-05	0.0139	-0.27	-0.18	Lung cancer;	chr15:43429380	chr15:43663654~43684339:-
LUAD	cis	rs6496932	0.635	rs28559998	ENSG00000218052.5	ADAMTS7P4	-3.93	9.81e-05	0.0139	-0.2	-0.18	Central corneal thickness;Corneal structure;	chr15:85360605	chr15:85255369~85330334:-
LUAD	cis	rs4934494	0.768	rs11330	ENSG00000240996.1	RP11-80H5.7	3.93	9.81e-05	0.0139	0.24	0.18	Red blood cell count;	chr10:89634322	chr10:89694295~89697928:-
LUAD	cis	rs858239	0.6	rs10256524	ENSG00000226816.2	AC005082.12	3.93	9.81e-05	0.0139	0.23	0.18	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23206013~23208045:+
LUAD	cis	rs10270805	0.892	rs4721500	ENSG00000229108.1	MEOX2-AS1	-3.93	9.81e-05	0.0139	-0.36	-0.18	Response to statin therapy;	chr7:16445278	chr7:15688378~15695491:+
LUAD	cis	rs9487094	0.813	rs6920962	ENSG00000260273.1	RP11-425D10.10	3.93	9.81e-05	0.0139	0.22	0.18	Height;	chr6:109403287	chr6:109382795~109383666:+
LUAD	cis	rs2274273	0.588	rs17675223	ENSG00000258413.1	RP11-665C16.6	-3.93	9.81e-05	0.0139	-0.24	-0.18	Protein biomarker;	chr14:55395518	chr14:55262767~55272075:-
LUAD	cis	rs7512552	0.839	rs486275	ENSG00000275557.1	RP11-353N4.6	-3.93	9.81e-05	0.0139	-0.2	-0.18	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150310350	chr1:149607765~149612402:+
LUAD	cis	rs7512552	0.768	rs7517441	ENSG00000275557.1	RP11-353N4.6	-3.93	9.81e-05	0.0139	-0.2	-0.18	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150311206	chr1:149607765~149612402:+
LUAD	cis	rs2274273	0.673	rs2209808	ENSG00000258413.1	RP11-665C16.6	-3.93	9.81e-05	0.0139	-0.23	-0.18	Protein biomarker;	chr14:55340977	chr14:55262767~55272075:-
LUAD	cis	rs812925	0.559	rs2600667	ENSG00000271889.1	RP11-493E12.1	3.93	9.81e-05	0.0139	0.23	0.18	Immature fraction of reticulocytes;	chr2:61177796	chr2:61151433~61162105:-
LUAD	cis	rs6479901	0.895	rs10740112	ENSG00000232075.1	MRPL35P2	-3.93	9.82e-05	0.0139	-0.25	-0.18	Intelligence (multi-trait analysis);	chr10:63322315	chr10:63634317~63634827:-
LUAD	cis	rs6479901	0.895	rs10740113	ENSG00000232075.1	MRPL35P2	-3.93	9.82e-05	0.0139	-0.25	-0.18	Intelligence (multi-trait analysis);	chr10:63322516	chr10:63634317~63634827:-
LUAD	cis	rs6479901	0.895	rs10740114	ENSG00000232075.1	MRPL35P2	-3.93	9.82e-05	0.0139	-0.25	-0.18	Intelligence (multi-trait analysis);	chr10:63322659	chr10:63634317~63634827:-
LUAD	cis	rs9876781	1	rs2362450	ENSG00000229759.1	MRPS18AP1	3.93	9.82e-05	0.0139	0.17	0.18	Longevity;	chr3:48419904	chr3:48256350~48256938:-
LUAD	cis	rs17711722	0.522	rs4642526	ENSG00000228409.4	CCT6P1	-3.93	9.82e-05	0.0139	-0.15	-0.18	Calcium levels;	chr7:65751755	chr7:65751142~65763354:+
LUAD	cis	rs6479901	0.841	rs4469770	ENSG00000232075.1	MRPL35P2	-3.93	9.82e-05	0.0139	-0.24	-0.18	Intelligence (multi-trait analysis);	chr10:63254152	chr10:63634317~63634827:-
LUAD	cis	rs8030379	1	rs117031571	ENSG00000230373.7	GOLGA6L5P	-3.93	9.82e-05	0.0139	-0.16	-0.18	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83903902	chr15:84507885~84516814:-
LUAD	cis	rs7760535	0.794	rs12529158	ENSG00000266032.1	AL357515.1	-3.93	9.82e-05	0.0139	-0.23	-0.18	Metabolic traits;	chr6:111501244	chr6:110969773~110969872:-
LUAD	cis	rs2732480	0.557	rs923397	ENSG00000273765.1	RP11-370I10.11	3.93	9.82e-05	0.0139	0.19	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48326609	chr12:48360920~48361377:+
LUAD	cis	rs56309584	0.597	rs78296773	ENSG00000226871.1	AC135178.7	3.93	9.82e-05	0.0139	0.26	0.18	Initial pursuit acceleration;	chr17:8264644	chr17:8318088~8318712:-
LUAD	cis	rs453301	0.658	rs9650616	ENSG00000173295.6	FAM86B3P	-3.93	9.82e-05	0.0139	-0.19	-0.18	Joint mobility (Beighton score);	chr8:9011689	chr8:8228595~8244865:+
LUAD	cis	rs7551222	0.716	rs10494852	ENSG00000240219.1	RP11-430C7.5	-3.93	9.82e-05	0.0139	-0.18	-0.18	Schizophrenia;	chr1:204488658	chr1:204626775~204629712:+
LUAD	cis	rs6081541	0.689	rs1547100	ENSG00000179447.2	RP5-1027G4.3	3.93	9.83e-05	0.0139	0.2	0.18	Psychosis (atypical);	chr20:19220625	chr20:19242302~19284596:-
LUAD	cis	rs1790761	0.505	rs2370141	ENSG00000184224.3	C11orf72	-3.93	9.83e-05	0.0139	-0.2	-0.18	Mean corpuscular volume;	chr11:67581058	chr11:67602880~67606706:-
LUAD	cis	rs9308731	0.591	rs3898882	ENSG00000227992.1	AC108463.2	-3.93	9.83e-05	0.0139	-0.21	-0.18	Chronic lymphocytic leukemia;	chr2:111189890	chr2:111203964~111206215:-
LUAD	cis	rs9923856	0.519	rs7197754	ENSG00000280153.1	RP11-876N24.3	-3.93	9.83e-05	0.0139	-0.12	-0.18	Atopic dermatitis;Adult asthma;	chr16:11036522	chr16:10933903~10936280:+
LUAD	cis	rs11671005	0.735	rs12986387	ENSG00000268543.1	CTD-2619J13.16	-3.93	9.83e-05	0.0139	-0.25	-0.18	Mean platelet volume;	chr19:58415848	chr19:58418560~58419310:+
LUAD	cis	rs11671005	0.735	rs11667723	ENSG00000268543.1	CTD-2619J13.16	-3.93	9.83e-05	0.0139	-0.25	-0.18	Mean platelet volume;	chr19:58416122	chr19:58418560~58419310:+
LUAD	cis	rs11671005	0.735	rs11668789	ENSG00000268543.1	CTD-2619J13.16	-3.93	9.83e-05	0.0139	-0.25	-0.18	Mean platelet volume;	chr19:58416942	chr19:58418560~58419310:+
LUAD	cis	rs11671005	0.735	rs35652377	ENSG00000268543.1	CTD-2619J13.16	-3.93	9.83e-05	0.0139	-0.25	-0.18	Mean platelet volume;	chr19:58417833	chr19:58418560~58419310:+
LUAD	cis	rs11671005	0.735	rs3764532	ENSG00000268543.1	CTD-2619J13.16	-3.93	9.83e-05	0.0139	-0.25	-0.18	Mean platelet volume;	chr19:58417855	chr19:58418560~58419310:+
LUAD	cis	rs11671005	0.735	rs3088284	ENSG00000268543.1	CTD-2619J13.16	-3.93	9.83e-05	0.0139	-0.25	-0.18	Mean platelet volume;	chr19:58418060	chr19:58418560~58419310:+
LUAD	cis	rs11671005	0.735	rs12981649	ENSG00000268543.1	CTD-2619J13.16	-3.93	9.83e-05	0.0139	-0.25	-0.18	Mean platelet volume;	chr19:58418676	chr19:58418560~58419310:+
LUAD	cis	rs2688608	0.839	rs2633310	ENSG00000271816.1	BMS1P4	-3.93	9.84e-05	0.0139	-0.15	-0.18	Inflammatory bowel disease;	chr10:73834292	chr10:73699151~73730487:-
LUAD	cis	rs8031584	0.678	rs798125	ENSG00000260128.5	ULK4P2	3.93	9.84e-05	0.0139	0.24	0.18	Huntington's disease progression;	chr15:30824597	chr15:30572738~30600647:+
LUAD	cis	rs2179367	0.959	rs9390677	ENSG00000216906.2	RP11-350J20.9	3.93	9.84e-05	0.0139	0.22	0.18	Dupuytren's disease;	chr6:149389361	chr6:149904243~149906418:+
LUAD	cis	rs3096299	0.685	rs2911244	ENSG00000261118.1	RP11-104N10.1	3.93	9.84e-05	0.0139	0.18	0.18	Multiple myeloma (IgH translocation);	chr16:89455452	chr16:89492017~89504460:-
LUAD	cis	rs9341808	0.538	rs620147	ENSG00000233967.5	RP11-250B2.3	-3.93	9.84e-05	0.0139	-0.18	-0.18	Sitting height ratio;	chr6:80282373	chr6:80443344~80465927:+
LUAD	cis	rs6921919	0.525	rs11760133	ENSG00000219392.1	RP1-265C24.5	-3.93	9.84e-05	0.0139	-0.23	-0.18	Autism spectrum disorder or schizophrenia;	chr6:28418962	chr6:28115628~28116551:+
LUAD	cis	rs11742741	0.714	rs6878191	ENSG00000248874.4	C5orf17	-3.93	9.84e-05	0.0139	-0.22	-0.18	Educational attainment;	chr5:24134711	chr5:23951348~24178263:+
LUAD	cis	rs7017914	0.967	rs6982406	ENSG00000246366.5	RP11-382J12.1	3.93	9.84e-05	0.0139	0.16	0.18	Bone mineral density;	chr8:70742373	chr8:70608577~70663279:+
LUAD	cis	rs62025270	0.593	rs7166540	ENSG00000259416.2	RP11-158M2.5	-3.93	9.84e-05	0.0139	-0.23	-0.18	Idiopathic pulmonary fibrosis;	chr15:85700854	chr15:85754941~85756237:-
LUAD	cis	rs6142102	0.923	rs2268078	ENSG00000275784.1	RP5-1125A11.6	-3.93	9.84e-05	0.0139	-0.2	-0.18	Skin pigmentation;	chr20:34008898	chr20:33989480~33991818:-
LUAD	cis	rs6840360	0.573	rs2407171	ENSG00000270265.1	RP11-731D1.4	-3.93	9.85e-05	0.0139	-0.18	-0.18	Intelligence (multi-trait analysis);	chr4:151335630	chr4:151333775~151353224:-
LUAD	cis	rs6001482	0.573	rs4990163	ENSG00000223350.2	IGLV9-49	-3.93	9.85e-05	0.0139	-0.17	-0.18	Diastolic blood pressure;	chr22:22233778	chr22:22343187~22343732:+
LUAD	cis	rs9309473	0.95	rs11126412	ENSG00000230002.2	ALMS1-IT1	3.93	9.85e-05	0.0139	0.23	0.18	Metabolite levels;	chr2:73660507	chr2:73456764~73459484:+
LUAD	cis	rs11637445	0.677	rs4539549	ENSG00000270964.1	RP11-502I4.3	3.93	9.85e-05	0.0139	0.19	0.18	Posterior cortical atrophy and Alzheimer's disease;	chr15:67778281	chr15:67541072~67542604:-
LUAD	cis	rs7302981	0.746	rs836177	ENSG00000272368.2	RP4-605O3.4	3.93	9.85e-05	0.0139	0.2	0.18	Systolic blood pressure;	chr12:50098038	chr12:50112197~50165618:+
LUAD	cis	rs6687758	0.687	rs17011141	ENSG00000227925.1	RP11-191N8.2	3.93	9.85e-05	0.0139	0.23	0.18	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221939292	chr1:221827666~221840666:-
LUAD	cis	rs6088580	0.634	rs2184836	ENSG00000276073.1	RP5-1125A11.7	3.93	9.86e-05	0.0139	0.17	0.18	Glomerular filtration rate (creatinine);	chr20:34375563	chr20:33985617~33988989:-
LUAD	cis	rs6088580	0.609	rs945674	ENSG00000276073.1	RP5-1125A11.7	3.93	9.86e-05	0.0139	0.17	0.18	Glomerular filtration rate (creatinine);	chr20:34376441	chr20:33985617~33988989:-
LUAD	cis	rs6088580	0.609	rs6058029	ENSG00000276073.1	RP5-1125A11.7	3.93	9.86e-05	0.0139	0.17	0.18	Glomerular filtration rate (creatinine);	chr20:34381837	chr20:33985617~33988989:-
LUAD	cis	rs6088580	0.634	rs6088478	ENSG00000276073.1	RP5-1125A11.7	3.93	9.86e-05	0.0139	0.17	0.18	Glomerular filtration rate (creatinine);	chr20:34383913	chr20:33985617~33988989:-
LUAD	cis	rs6088580	0.608	rs2105109	ENSG00000276073.1	RP5-1125A11.7	3.93	9.86e-05	0.0139	0.17	0.18	Glomerular filtration rate (creatinine);	chr20:34384126	chr20:33985617~33988989:-
LUAD	cis	rs6496932	0.635	rs12900455	ENSG00000202081.1	RNU6-1280P	-3.93	9.86e-05	0.0139	-0.22	-0.18	Central corneal thickness;Corneal structure;	chr15:85362345	chr15:85651522~85651628:-
LUAD	cis	rs7937890	0.559	rs2597187	ENSG00000254418.1	RP11-21L19.1	3.93	9.86e-05	0.0139	0.21	0.18	Mitochondrial DNA levels;	chr11:14495473	chr11:14262846~14273691:-
LUAD	cis	rs763121	0.853	rs3761454	ENSG00000225450.1	RP3-508I15.14	-3.93	9.86e-05	0.0139	-0.17	-0.18	Menopause (age at onset);	chr22:38670815	chr22:38739003~38749041:+
LUAD	cis	rs763121	0.853	rs3747170	ENSG00000225450.1	RP3-508I15.14	-3.93	9.86e-05	0.0139	-0.17	-0.18	Menopause (age at onset);	chr22:38671326	chr22:38739003~38749041:+
LUAD	cis	rs12986445	0.947	rs12713690	ENSG00000218682.1	AC010150.1	3.93	9.86e-05	0.0139	0.21	0.18	Multiple myeloma;Multiple myeloma and monoclonal gammopathy;	chr2:25895227	chr2:25856461~25856966:-
LUAD	cis	rs9500256	0.655	rs12208465	ENSG00000266579.1	RP1-71H19.2	-3.93	9.86e-05	0.0139	-0.24	-0.18	Eosinophilic esophagitis (pediatric);	chr6:58004603	chr6:57493855~57497691:+
LUAD	cis	rs13113518	0.783	rs13111128	ENSG00000272969.1	RP11-528I4.2	3.93	9.86e-05	0.0139	0.19	0.18	Height;	chr4:55578154	chr4:55547112~55547889:+
LUAD	cis	rs11779988	0.571	rs208052	ENSG00000253671.1	RP11-806O11.1	-3.93	9.86e-05	0.0139	-0.21	-0.18	Breast cancer;	chr8:17968050	chr8:17808941~17820868:+
LUAD	cis	rs7580658	0.929	rs4150477	ENSG00000236682.1	AC068282.3	3.93	9.86e-05	0.0139	0.24	0.18	Protein C levels;	chr2:127274970	chr2:127389130~127400580:+
LUAD	cis	rs11089937	0.667	rs9622981	ENSG00000211640.3	IGLV6-57	3.93	9.86e-05	0.0139	0.14	0.18	Periodontitis (PAL4Q3);	chr22:22150100	chr22:22195713~22196460:+
LUAD	cis	rs6840360	0.571	rs7695866	ENSG00000270265.1	RP11-731D1.4	-3.93	9.87e-05	0.0139	-0.2	-0.18	Intelligence (multi-trait analysis);	chr4:151566958	chr4:151333775~151353224:-
LUAD	cis	rs6500602	0.702	rs9929475	ENSG00000280063.1	RP11-295D4.3	-3.93	9.87e-05	0.0139	-0.11	-0.18	Schizophrenia;	chr16:4490884	chr16:4346694~4348648:-
LUAD	cis	rs7637701	0.967	rs9865905	ENSG00000240875.4	LINC00886	-3.93	9.87e-05	0.014	-0.19	-0.18	Breast cancer;	chr3:156931805	chr3:156747346~156817062:-
LUAD	cis	rs2735413	0.918	rs12925605	ENSG00000276007.1	RP11-358L22.3	-3.93	9.87e-05	0.014	-0.18	-0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78037818	chr16:78123243~78124332:+
LUAD	cis	rs7647973	0.516	rs4955419	ENSG00000225399.4	RP11-3B7.1	3.93	9.87e-05	0.014	0.23	0.18	Menarche (age at onset);	chr3:49163259	chr3:49260085~49261316:+
LUAD	cis	rs3805389	0.504	rs10017749	ENSG00000273257.1	RP11-177J6.1	-3.93	9.87e-05	0.014	-0.28	-0.18	Waist-to-hip ratio adjusted for body mass index;	chr4:55613007	chr4:55387949~55388271:+
LUAD	cis	rs3805389	0.504	rs3805385	ENSG00000273257.1	RP11-177J6.1	-3.93	9.87e-05	0.014	-0.28	-0.18	Waist-to-hip ratio adjusted for body mass index;	chr4:55613821	chr4:55387949~55388271:+
LUAD	cis	rs3805389	0.504	rs3805386	ENSG00000273257.1	RP11-177J6.1	-3.93	9.87e-05	0.014	-0.28	-0.18	Waist-to-hip ratio adjusted for body mass index;	chr4:55613838	chr4:55387949~55388271:+
LUAD	cis	rs3805389	0.504	rs3805387	ENSG00000273257.1	RP11-177J6.1	-3.93	9.87e-05	0.014	-0.28	-0.18	Waist-to-hip ratio adjusted for body mass index;	chr4:55613841	chr4:55387949~55388271:+
LUAD	cis	rs3805389	0.504	rs3805388	ENSG00000273257.1	RP11-177J6.1	-3.93	9.87e-05	0.014	-0.28	-0.18	Waist-to-hip ratio adjusted for body mass index;	chr4:55614754	chr4:55387949~55388271:+
LUAD	cis	rs1334894	1	rs16878812	ENSG00000228559.1	RP3-340B19.3	-3.93	9.87e-05	0.014	-0.3	-0.18	Coronary artery disease;	chr6:35601785	chr6:35544632~35545669:+
LUAD	cis	rs7138803	0.616	rs73114141	ENSG00000257464.1	RP11-161H23.8	-3.93	9.87e-05	0.014	-0.18	-0.18	Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index;	chr12:49820030	chr12:49442424~49442652:-
LUAD	cis	rs6910061	1	rs13214777	ENSG00000247925.2	RP3-510L9.1	-3.93	9.88e-05	0.014	-0.25	-0.18	Diabetic kidney disease;	chr6:11103364	chr6:11173452~11259099:+
LUAD	cis	rs6568686	0.786	rs6929494	ENSG00000255389.1	C6orf3	-3.93	9.88e-05	0.014	-0.24	-0.18	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111536127	chr6:111599875~111602295:+
LUAD	cis	rs10863681	0.738	rs12140558	ENSG00000200033.1	RNU6-403P	3.93	9.88e-05	0.014	0.2	0.18	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222100978	chr1:221837334~221837437:-
LUAD	cis	rs4268898	0.76	rs55863105	ENSG00000242628.4	AC009228.1	-3.93	9.88e-05	0.014	-0.22	-0.18	Asthma;	chr2:24347826	chr2:24214381~24221516:+
LUAD	cis	rs12216545	0.765	rs7792574	ENSG00000177590.7	GIMAP3P	-3.93	9.88e-05	0.014	-0.18	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150527118	chr7:150746893~150747728:-
LUAD	cis	rs9291683	0.517	rs11736479	ENSG00000250413.1	RP11-448G15.1	-3.93	9.88e-05	0.014	-0.22	-0.18	Bone mineral density;	chr4:10015763	chr4:10006482~10009725:+
LUAD	cis	rs9291683	0.588	rs13113730	ENSG00000250413.1	RP11-448G15.1	-3.93	9.88e-05	0.014	-0.22	-0.18	Bone mineral density;	chr4:10016004	chr4:10006482~10009725:+
LUAD	cis	rs9291683	0.588	rs6857693	ENSG00000250413.1	RP11-448G15.1	-3.93	9.88e-05	0.014	-0.22	-0.18	Bone mineral density;	chr4:10016811	chr4:10006482~10009725:+
LUAD	cis	rs9291683	0.588	rs6844329	ENSG00000250413.1	RP11-448G15.1	-3.93	9.88e-05	0.014	-0.22	-0.18	Bone mineral density;	chr4:10016920	chr4:10006482~10009725:+
LUAD	cis	rs9291683	0.588	rs3796829	ENSG00000250413.1	RP11-448G15.1	-3.93	9.88e-05	0.014	-0.22	-0.18	Bone mineral density;	chr4:10017514	chr4:10006482~10009725:+
LUAD	cis	rs3733585	0.773	rs13107466	ENSG00000250413.1	RP11-448G15.1	-3.93	9.88e-05	0.014	-0.22	-0.18	Cleft plate (environmental tobacco smoke interaction);	chr4:10017766	chr4:10006482~10009725:+
LUAD	cis	rs9291683	0.588	rs13133766	ENSG00000250413.1	RP11-448G15.1	-3.93	9.88e-05	0.014	-0.22	-0.18	Bone mineral density;	chr4:10018108	chr4:10006482~10009725:+
LUAD	cis	rs4356203	0.543	rs214081	ENSG00000272034.1	SNORD14A	-3.93	9.88e-05	0.014	-0.16	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17278107	chr11:17074654~17074744:-
LUAD	cis	rs858239	0.899	rs10262243	ENSG00000230042.1	AK3P3	-3.93	9.89e-05	0.014	-0.23	-0.18	Cerebrospinal fluid biomarker levels;	chr7:23251368	chr7:23129178~23129841:+
LUAD	cis	rs12744310	1	rs60552457	ENSG00000235358.1	RP11-399E6.1	3.93	9.89e-05	0.014	0.23	0.18	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41293827	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs12739950	ENSG00000235358.1	RP11-399E6.1	3.93	9.89e-05	0.014	0.23	0.18	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41294219	chr1:41242373~41284861:+
LUAD	cis	rs12744310	0.945	rs12740093	ENSG00000235358.1	RP11-399E6.1	3.93	9.89e-05	0.014	0.23	0.18	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41294329	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs12038894	ENSG00000235358.1	RP11-399E6.1	3.93	9.89e-05	0.014	0.23	0.18	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41294535	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs12038924	ENSG00000235358.1	RP11-399E6.1	3.93	9.89e-05	0.014	0.23	0.18	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41294645	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs12032514	ENSG00000235358.1	RP11-399E6.1	3.93	9.89e-05	0.014	0.23	0.18	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41294890	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs12039767	ENSG00000235358.1	RP11-399E6.1	3.93	9.89e-05	0.014	0.23	0.18	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41295188	chr1:41242373~41284861:+
LUAD	cis	rs11048434	0.518	rs34651717	ENSG00000256937.1	KRT17P8	-3.93	9.89e-05	0.014	-0.2	-0.18	Sjögren's syndrome;	chr12:9025154	chr12:9127783~9128645:+
LUAD	cis	rs11048434	0.518	rs35176717	ENSG00000256937.1	KRT17P8	-3.93	9.89e-05	0.014	-0.2	-0.18	Sjögren's syndrome;	chr12:9025170	chr12:9127783~9128645:+
LUAD	cis	rs11048434	0.518	rs34533518	ENSG00000256937.1	KRT17P8	-3.93	9.89e-05	0.014	-0.2	-0.18	Sjögren's syndrome;	chr12:9025302	chr12:9127783~9128645:+
LUAD	cis	rs2235642	0.891	rs2281231	ENSG00000280231.1	LA16c-380F5.3	-3.93	9.89e-05	0.014	-0.23	-0.18	Coronary artery disease;	chr16:1551878	chr16:1553655~1554130:-
LUAD	cis	rs2243480	1	rs160643	ENSG00000232559.3	GS1-124K5.12	3.93	9.89e-05	0.014	0.28	0.18	Diabetic kidney disease;	chr7:66093235	chr7:66554588~66576923:-
LUAD	cis	rs36093844	0.625	rs725459	ENSG00000279742.1	RP11-700A24.1	-3.93	9.89e-05	0.014	-0.19	-0.18	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85899066	chr11:85852557~85854943:-
LUAD	cis	rs11846409	0.932	rs2015469	ENSG00000223648.3	IGHV3-64	3.93	9.89e-05	0.014	0.2	0.18	Rheumatic heart disease;	chr14:106631857	chr14:106643132~106658258:-
LUAD	cis	rs11846409	0.932	rs56167903	ENSG00000223648.3	IGHV3-64	3.93	9.89e-05	0.014	0.2	0.18	Rheumatic heart disease;	chr14:106632070	chr14:106643132~106658258:-
LUAD	cis	rs2337406	0.866	rs988130	ENSG00000280411.1	IGHV1-69-2	-3.93	9.89e-05	0.014	-0.16	-0.18	Alzheimer's disease (late onset);	chr14:106777154	chr14:106762092~106762588:-
LUAD	cis	rs7637701	1	rs7637701	ENSG00000240875.4	LINC00886	-3.93	9.9e-05	0.014	-0.19	-0.18	Breast cancer;	chr3:156927968	chr3:156747346~156817062:-
LUAD	cis	rs7976269	0.609	rs10771475	ENSG00000257176.2	RP11-996F15.2	-3.93	9.9e-05	0.014	-0.19	-0.18	Male-pattern baldness;	chr12:29071077	chr12:29280418~29317848:-
LUAD	cis	rs7976269	0.609	rs10843305	ENSG00000257176.2	RP11-996F15.2	-3.93	9.9e-05	0.014	-0.19	-0.18	Male-pattern baldness;	chr12:29073147	chr12:29280418~29317848:-
LUAD	cis	rs7976269	0.609	rs10843306	ENSG00000257176.2	RP11-996F15.2	-3.93	9.9e-05	0.014	-0.19	-0.18	Male-pattern baldness;	chr12:29073417	chr12:29280418~29317848:-
LUAD	cis	rs7580658	0.963	rs867304	ENSG00000236682.1	AC068282.3	-3.93	9.9e-05	0.014	-0.24	-0.18	Protein C levels;	chr2:127320912	chr2:127389130~127400580:+
LUAD	cis	rs853679	0.599	rs13193295	ENSG00000219392.1	RP1-265C24.5	-3.93	9.9e-05	0.014	-0.39	-0.18	Depression;	chr6:28035450	chr6:28115628~28116551:+
LUAD	cis	rs1400816	0.718	rs13012103	ENSG00000228389.1	AC068039.4	3.93	9.9e-05	0.014	0.3	0.18	Amyotrophic lateral sclerosis (sporadic);	chr2:171771262	chr2:171773482~171775844:+
LUAD	cis	rs8064024	0.901	rs930855	ENSG00000267077.1	RP11-127I20.5	3.93	9.9e-05	0.014	0.2	0.18	Cancer;	chr16:4814178	chr16:4795265~4796532:-
LUAD	cis	rs3742264	1	rs9534312	ENSG00000235903.6	CPB2-AS1	-3.93	9.9e-05	0.014	-0.22	-0.18	Blood protein levels;	chr13:46076084	chr13:46052806~46113332:+
LUAD	cis	rs3812049	0.784	rs7734927	ENSG00000245937.6	LINC01184	3.93	9.9e-05	0.014	0.26	0.18	Lymphocyte counts;Red cell distribution width;	chr5:128118043	chr5:127940426~128083172:-
LUAD	cis	rs6687821	0.515	rs1199726	ENSG00000261737.1	RP4-612B15.3	-3.93	9.9e-05	0.014	-0.25	-0.18	Yeast infection;	chr1:86951691	chr1:86703502~86704462:-
LUAD	cis	rs4474465	1	rs10899521	ENSG00000251323.2	RP11-452H21.4	3.93	9.91e-05	0.014	0.22	0.18	Alzheimer's disease (survival time);	chr11:78473514	chr11:78423982~78429836:-
LUAD	cis	rs7727544	0.582	rs3805681	ENSG00000233006.5	AC034220.3	3.93	9.91e-05	0.014	0.16	0.18	Blood metabolite levels;	chr5:132202167	chr5:132311285~132369916:-
LUAD	cis	rs2446066	0.872	rs10876447	ENSG00000257379.1	RP11-793H13.8	3.93	9.91e-05	0.014	0.3	0.18	Red blood cell count;	chr12:53377157	chr12:53441741~53467528:+
LUAD	cis	rs10129255	0.957	rs10138532	ENSG00000274576.2	IGHV2-70	3.93	9.91e-05	0.014	0.16	0.18	Kawasaki disease;	chr14:106803901	chr14:106770577~106771020:-
LUAD	cis	rs10761482	0.638	rs10761507	ENSG00000254271.1	RP11-131N11.4	-3.93	9.91e-05	0.014	-0.21	-0.18	Schizophrenia;	chr10:60483474	chr10:60734342~60741828:+
LUAD	cis	rs2243480	0.522	rs431168	ENSG00000232559.3	GS1-124K5.12	3.93	9.91e-05	0.014	0.35	0.18	Diabetic kidney disease;	chr7:66046617	chr7:66554588~66576923:-
LUAD	cis	rs4965272	0.83	rs28760316	ENSG00000272808.2	RP11-66B24.7	3.93	9.91e-05	0.014	0.23	0.18	Gastroesophageal reflux disease;	chr15:100053364	chr15:100849831~100865457:+
LUAD	cis	rs7824557	0.564	rs7821459	ENSG00000255046.1	RP11-297N6.4	3.93	9.91e-05	0.014	0.22	0.18	Retinal vascular caliber;	chr8:11379172	chr8:11797928~11802568:-
LUAD	cis	rs7824557	0.564	rs7834572	ENSG00000255046.1	RP11-297N6.4	3.93	9.91e-05	0.014	0.22	0.18	Retinal vascular caliber;	chr8:11379176	chr8:11797928~11802568:-
LUAD	cis	rs7824557	0.564	rs4631424	ENSG00000255046.1	RP11-297N6.4	3.93	9.91e-05	0.014	0.22	0.18	Retinal vascular caliber;	chr8:11379300	chr8:11797928~11802568:-
LUAD	cis	rs9628987	0.53	rs301793	ENSG00000232912.4	RP5-1115A15.1	3.93	9.91e-05	0.014	0.2	0.18	Breast cancer;	chr1:8407474	chr1:8424645~8434838:+
LUAD	cis	rs7017914	0.934	rs7015035	ENSG00000246366.5	RP11-382J12.1	3.93	9.91e-05	0.014	0.16	0.18	Bone mineral density;	chr8:70741366	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.967	rs34905858	ENSG00000246366.5	RP11-382J12.1	3.93	9.91e-05	0.014	0.16	0.18	Bone mineral density;	chr8:70747215	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.934	rs6998024	ENSG00000246366.5	RP11-382J12.1	3.93	9.91e-05	0.014	0.16	0.18	Bone mineral density;	chr8:70748605	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.967	rs35960437	ENSG00000246366.5	RP11-382J12.1	3.93	9.91e-05	0.014	0.16	0.18	Bone mineral density;	chr8:70749725	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.967	rs34409123	ENSG00000246366.5	RP11-382J12.1	3.93	9.91e-05	0.014	0.16	0.18	Bone mineral density;	chr8:70749881	chr8:70608577~70663279:+
LUAD	cis	rs6840258	0.891	rs66477840	ENSG00000251411.1	RP11-397E7.4	-3.93	9.92e-05	0.014	-0.22	-0.18	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87142207	chr4:86913266~86914817:-
LUAD	cis	rs338389	0.677	rs338380	ENSG00000260657.2	RP11-315D16.4	-3.93	9.92e-05	0.014	-0.2	-0.18	Survival in rectal cancer;	chr15:67951268	chr15:68267792~68277994:-
LUAD	cis	rs9926296	0.605	rs6500449	ENSG00000260259.1	RP11-368I7.4	-3.93	9.92e-05	0.014	-0.17	-0.18	Vitiligo;	chr16:89789985	chr16:89682620~89686569:-
LUAD	cis	rs17122278	1	rs11216910	ENSG00000243431.1	RPL5P30	3.93	9.92e-05	0.014	0.22	0.18	Total cholesterol levels;	chr11:118579331	chr11:118560690~118561580:+
LUAD	cis	rs858239	0.539	rs10247268	ENSG00000226816.2	AC005082.12	3.93	9.92e-05	0.014	0.24	0.18	Cerebrospinal fluid biomarker levels;	chr7:23147560	chr7:23206013~23208045:+
LUAD	cis	rs858239	0.539	rs6461694	ENSG00000226816.2	AC005082.12	3.93	9.92e-05	0.014	0.24	0.18	Cerebrospinal fluid biomarker levels;	chr7:23148160	chr7:23206013~23208045:+
LUAD	cis	rs6674176	0.597	rs6671164	ENSG00000237950.1	RP11-7O11.3	3.93	9.92e-05	0.014	0.22	0.18	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43937817	chr1:43944370~43946551:-
LUAD	cis	rs34421088	0.56	rs2248315	ENSG00000255046.1	RP11-297N6.4	3.93	9.92e-05	0.014	0.22	0.18	Neuroticism;	chr8:11539577	chr8:11797928~11802568:-
LUAD	cis	rs6142102	0.923	rs6057961	ENSG00000275784.1	RP5-1125A11.6	-3.93	9.92e-05	0.014	-0.2	-0.18	Skin pigmentation;	chr20:33986005	chr20:33989480~33991818:-
LUAD	cis	rs7714584	1	rs6579803	ENSG00000197083.10	ZNF300P1	3.93	9.92e-05	0.014	0.33	0.18	Crohn's disease;	chr5:150875997	chr5:150930645~150946289:-
LUAD	cis	rs7714584	1	rs6579804	ENSG00000197083.10	ZNF300P1	3.93	9.92e-05	0.014	0.33	0.18	Crohn's disease;	chr5:150876369	chr5:150930645~150946289:-
LUAD	cis	rs7714584	1	rs7734928	ENSG00000197083.10	ZNF300P1	3.93	9.92e-05	0.014	0.33	0.18	Crohn's disease;	chr5:150877051	chr5:150930645~150946289:-
LUAD	cis	rs9291683	0.588	rs3756238	ENSG00000250413.1	RP11-448G15.1	-3.93	9.92e-05	0.014	-0.22	-0.18	Bone mineral density;	chr4:10011578	chr4:10006482~10009725:+
LUAD	cis	rs9291683	0.588	rs3756237	ENSG00000250413.1	RP11-448G15.1	-3.93	9.92e-05	0.014	-0.22	-0.18	Bone mineral density;	chr4:10011754	chr4:10006482~10009725:+
LUAD	cis	rs9291683	0.588	rs3756236	ENSG00000250413.1	RP11-448G15.1	-3.93	9.92e-05	0.014	-0.22	-0.18	Bone mineral density;	chr4:10011839	chr4:10006482~10009725:+
LUAD	cis	rs9291683	0.552	rs10939655	ENSG00000250413.1	RP11-448G15.1	-3.93	9.92e-05	0.014	-0.22	-0.18	Bone mineral density;	chr4:10013018	chr4:10006482~10009725:+
LUAD	cis	rs8024893	0.764	rs7182721	ENSG00000270055.1	CTD-3092A11.2	3.93	9.92e-05	0.014	0.23	0.18	Red cell distribution width;	chr15:31239730	chr15:30487963~30490313:+
LUAD	cis	rs2638953	0.85	rs11049428	ENSG00000278733.1	RP11-425D17.1	-3.93	9.92e-05	0.014	-0.21	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28194267	chr12:28185625~28186190:-
LUAD	cis	rs5758659	0.714	rs5751216	ENSG00000182057.4	OGFRP1	-3.93	9.93e-05	0.014	-0.21	-0.18	Cognitive function;	chr22:42112933	chr22:42269753~42275196:+
LUAD	cis	rs1334894	0.901	rs76489311	ENSG00000228559.1	RP3-340B19.3	-3.93	9.93e-05	0.014	-0.36	-0.18	Coronary artery disease;	chr6:35539641	chr6:35544632~35545669:+
LUAD	cis	rs7615952	0.688	rs4422259	ENSG00000241288.6	RP11-379B18.5	-3.93	9.93e-05	0.014	-0.22	-0.18	Blood pressure (smoking interaction);	chr3:125826988	chr3:125827238~125916384:-
LUAD	cis	rs6121246	0.559	rs6087782	ENSG00000230613.1	HM13-AS1	3.93	9.93e-05	0.014	0.22	0.18	Mean corpuscular hemoglobin;	chr20:31803777	chr20:31567707~31573263:-
LUAD	cis	rs60695258	0.726	rs1471251	ENSG00000251411.1	RP11-397E7.4	3.93	9.93e-05	0.014	0.18	0.18	Hematocrit;	chr4:87055207	chr4:86913266~86914817:-
LUAD	cis	rs889398	0.802	rs8050414	ENSG00000226232.7	RP11-419C5.2	-3.93	9.93e-05	0.014	-0.15	-0.18	Body mass index;	chr16:69852910	chr16:69976388~69996188:-
LUAD	cis	rs889398	0.802	rs8051168	ENSG00000226232.7	RP11-419C5.2	-3.93	9.93e-05	0.014	-0.15	-0.18	Body mass index;	chr16:69853371	chr16:69976388~69996188:-
LUAD	cis	rs651907	0.557	rs13077925	ENSG00000244119.1	PDCL3P4	3.93	9.93e-05	0.014	0.17	0.18	Colorectal cancer;	chr3:101769337	chr3:101712472~101713191:+
LUAD	cis	rs6832769	1	rs10034433	ENSG00000272969.1	RP11-528I4.2	-3.93	9.94e-05	0.014	-0.18	-0.18	Personality dimensions;	chr4:55555009	chr4:55547112~55547889:+
LUAD	cis	rs858239	0.539	rs6975852	ENSG00000226816.2	AC005082.12	3.92	9.94e-05	0.014	0.24	0.18	Cerebrospinal fluid biomarker levels;	chr7:23147035	chr7:23206013~23208045:+
LUAD	cis	rs7831492	0.548	rs10958699	ENSG00000253133.1	RP11-360L9.4	-3.92	9.94e-05	0.014	-0.23	-0.18	Colorectal cancer;	chr8:41790840	chr8:41534155~41578368:-
LUAD	cis	rs10208649	0.611	rs3929001	ENSG00000272156.1	RP11-477N3.1	-3.92	9.94e-05	0.014	-0.33	-0.18	Body mass index;	chr2:54055750	chr2:54082554~54085066:+
LUAD	cis	rs7760535	0.794	rs12529158	ENSG00000271789.1	RP5-1112D6.7	3.92	9.94e-05	0.014	0.19	0.18	Metabolic traits;	chr6:111501244	chr6:111297126~111298510:+
LUAD	cis	rs35065479	1	rs4530197	ENSG00000263004.1	RP11-166P13.3	-3.92	9.94e-05	0.014	-0.21	-0.18	Schizophrenia;	chr17:57657987	chr17:57078298~57085024:-
LUAD	cis	rs10129255	0.826	rs7150693	ENSG00000211947.2	IGHV3-21	-3.92	9.94e-05	0.014	-0.12	-0.18	Kawasaki disease;	chr14:106705382	chr14:106235064~106235594:-
LUAD	cis	rs3126085	0.515	rs10788837	ENSG00000237975.5	FLG-AS1	3.92	9.94e-05	0.014	0.28	0.18	Atopic dermatitis;	chr1:152379011	chr1:152168125~152445456:+
LUAD	cis	rs2333021	0.689	rs2998006	ENSG00000259015.1	RP11-109N23.6	-3.92	9.94e-05	0.014	-0.17	-0.18	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72962406	chr14:72960595~72961993:+
LUAD	cis	rs2333021	0.689	rs8010674	ENSG00000259015.1	RP11-109N23.6	-3.92	9.94e-05	0.014	-0.17	-0.18	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72962458	chr14:72960595~72961993:+
LUAD	cis	rs699371	0.503	rs12894033	ENSG00000270000.1	RP3-449M8.9	3.92	9.95e-05	0.014	0.19	0.18	Height;	chr14:74428651	chr14:74471930~74472360:-
LUAD	cis	rs6496932	0.663	rs7182814	ENSG00000218052.5	ADAMTS7P4	-3.92	9.95e-05	0.014	-0.2	-0.18	Central corneal thickness;Corneal structure;	chr15:85362840	chr15:85255369~85330334:-
LUAD	cis	rs7824557	0.65	rs2572406	ENSG00000255046.1	RP11-297N6.4	-3.92	9.95e-05	0.014	-0.21	-0.18	Retinal vascular caliber;	chr8:11234743	chr8:11797928~11802568:-
LUAD	cis	rs9910816	1	rs9910816	ENSG00000267659.4	LINC01482	-3.92	9.95e-05	0.0141	-0.2	-0.18	Bipolar disorder (inflammation and infection response interaction);	chr17:68348562	chr17:68591796~68763882:+
LUAD	cis	rs6661961	0.651	rs3753446	ENSG00000237975.5	FLG-AS1	-3.92	9.95e-05	0.0141	-0.23	-0.18	Atopic dermatitis;	chr1:152415999	chr1:152168125~152445456:+
LUAD	cis	rs35000415	0.688	rs13232316	ENSG00000275106.1	RP11-309L24.10	-3.92	9.95e-05	0.0141	-0.32	-0.18	Systemic lupus erythematosus;	chr7:129075245	chr7:128952527~128953316:-
LUAD	cis	rs9309473	1	rs11674602	ENSG00000230002.2	ALMS1-IT1	3.92	9.95e-05	0.0141	0.23	0.18	Metabolite levels;	chr2:73496058	chr2:73456764~73459484:+
LUAD	cis	rs9309473	1	rs10187192	ENSG00000230002.2	ALMS1-IT1	3.92	9.96e-05	0.0141	0.23	0.18	Metabolite levels;	chr2:73486373	chr2:73456764~73459484:+
LUAD	cis	rs7829975	0.582	rs11783950	ENSG00000253893.2	FAM85B	3.92	9.96e-05	0.0141	0.22	0.18	Mood instability;	chr8:8740321	chr8:8167819~8226614:-
LUAD	cis	rs875971	0.862	rs13536	ENSG00000273448.1	RP11-166O4.6	-3.92	9.96e-05	0.0141	-0.17	-0.18	Aortic root size;	chr7:66554203	chr7:67333047~67334383:+
LUAD	cis	rs875971	0.862	rs801209	ENSG00000273448.1	RP11-166O4.6	-3.92	9.96e-05	0.0141	-0.17	-0.18	Aortic root size;	chr7:66554403	chr7:67333047~67334383:+
LUAD	cis	rs875971	0.862	rs801206	ENSG00000273448.1	RP11-166O4.6	-3.92	9.96e-05	0.0141	-0.17	-0.18	Aortic root size;	chr7:66556979	chr7:67333047~67334383:+
LUAD	cis	rs875971	0.862	rs801204	ENSG00000273448.1	RP11-166O4.6	-3.92	9.96e-05	0.0141	-0.17	-0.18	Aortic root size;	chr7:66557934	chr7:67333047~67334383:+
LUAD	cis	rs875971	0.862	rs801203	ENSG00000273448.1	RP11-166O4.6	-3.92	9.96e-05	0.0141	-0.17	-0.18	Aortic root size;	chr7:66558025	chr7:67333047~67334383:+
LUAD	cis	rs7829975	0.606	rs11776838	ENSG00000233609.3	RP11-62H7.2	-3.92	9.96e-05	0.0141	-0.14	-0.18	Mood instability;	chr8:8937291	chr8:8961200~8979025:+
LUAD	cis	rs55692468	0.54	rs4664586	ENSG00000213197.3	AC012066.1	-3.92	9.96e-05	0.0141	-0.21	-0.18	Intraocular pressure;	chr2:152467557	chr2:152389937~152390630:+
LUAD	cis	rs8091660	0.624	rs9952398	ENSG00000278983.1	RP11-426J5.3	3.92	9.96e-05	0.0141	0.22	0.18	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48550407	chr18:48564795~48568342:+
LUAD	cis	rs1150668	0.799	rs9301	ENSG00000176933.5	TOB2P1	-3.92	9.97e-05	0.0141	-0.2	-0.18	Pubertal anthropometrics;	chr6:28324929	chr6:28217643~28218634:-
LUAD	cis	rs4568518	0.742	rs13245422	ENSG00000279048.1	RP11-511H23.2	3.92	9.97e-05	0.0141	0.15	0.18	Measles;	chr7:17976352	chr7:17940503~17942922:+
LUAD	cis	rs9487094	0.744	rs12661287	ENSG00000260273.1	RP11-425D10.10	3.92	9.97e-05	0.0141	0.25	0.18	Height;	chr6:109732047	chr6:109382795~109383666:+
LUAD	cis	rs8062405	0.69	rs4787458	ENSG00000261419.1	RP11-57A19.4	-3.92	9.97e-05	0.0141	-0.2	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28519966	chr16:28659696~28740781:-
LUAD	cis	rs7142881	0.729	rs7159758	ENSG00000250365.5	CTD-2213F21.2	3.92	9.97e-05	0.0141	0.2	0.18	Response to iloperidone treatment (QT prolongation);	chr14:31787253	chr14:31420286~31452883:+
LUAD	cis	rs2735413	0.563	rs56214776	ENSG00000276007.1	RP11-358L22.3	3.92	9.97e-05	0.0141	0.24	0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78011892	chr16:78123243~78124332:+
LUAD	cis	rs858239	0.508	rs2390754	ENSG00000226816.2	AC005082.12	3.92	9.98e-05	0.0141	0.24	0.18	Cerebrospinal fluid biomarker levels;	chr7:23150875	chr7:23206013~23208045:+
LUAD	cis	rs17301013	0.932	rs7555533	ENSG00000227373.4	RP11-160H22.5	3.92	9.98e-05	0.0141	0.22	0.18	Systemic lupus erythematosus;	chr1:174589983	chr1:174115300~174160004:-
LUAD	cis	rs7590268	0.789	rs58583407	ENSG00000279873.2	LINC01126	3.92	9.98e-05	0.0141	0.17	0.18	Orofacial clefts;	chr2:43405198	chr2:43227210~43228855:+
LUAD	cis	rs7129556	0.775	rs623907	ENSG00000241782.1	RP11-91P24.1	3.92	9.98e-05	0.0141	0.25	0.18	Weight loss (gastric bypass surgery);	chr11:77790402	chr11:77868722~77869195:-
LUAD	cis	rs1538970	0.962	rs9429076	ENSG00000234329.1	RP11-767N6.2	3.92	9.98e-05	0.0141	0.2	0.18	Platelet count;	chr1:45353817	chr1:45651039~45651826:-
LUAD	cis	rs763121	0.925	rs9835	ENSG00000225450.1	RP3-508I15.14	-3.92	9.98e-05	0.0141	-0.16	-0.18	Menopause (age at onset);	chr22:38734966	chr22:38739003~38749041:+
LUAD	cis	rs34929064	0.512	rs2157958	ENSG00000179428.2	AC073072.5	3.92	9.98e-05	0.0141	0.21	0.18	Major depression and alcohol dependence;	chr7:22667088	chr7:22725395~22727620:-
LUAD	cis	rs7829975	0.514	rs2920991	ENSG00000253981.4	ALG1L13P	3.92	9.98e-05	0.0141	0.2	0.18	Mood instability;	chr8:8401607	chr8:8236003~8244667:-
LUAD	cis	rs5015933	0.902	rs2270746	ENSG00000232630.1	PRPS1P2	3.92	9.98e-05	0.0141	0.16	0.18	Body mass index;	chr9:125359313	chr9:125150653~125151589:+
LUAD	cis	rs6490294	0.904	rs60217649	ENSG00000234608.6	MAPKAPK5-AS1	3.92	9.99e-05	0.0141	0.21	0.18	Mean platelet volume;	chr12:111973116	chr12:111839764~111842902:-
LUAD	cis	rs801193	1	rs7782320	ENSG00000222364.1	RNU6-96P	-3.92	9.99e-05	0.0141	-0.2	-0.18	Aortic root size;	chr7:66712111	chr7:66395191~66395286:+
LUAD	cis	rs7824557	0.564	rs2572379	ENSG00000255046.1	RP11-297N6.4	3.92	9.99e-05	0.0141	0.22	0.18	Retinal vascular caliber;	chr8:11379971	chr8:11797928~11802568:-
LUAD	cis	rs950880	0.767	rs12999364	ENSG00000234389.1	AC007278.3	-3.92	9.99e-05	0.0141	-0.17	-0.18	Serum protein levels (sST2);	chr2:102357669	chr2:102438713~102440475:+
LUAD	cis	rs950880	0.767	rs12998521	ENSG00000234389.1	AC007278.3	-3.92	9.99e-05	0.0141	-0.17	-0.18	Serum protein levels (sST2);	chr2:102357957	chr2:102438713~102440475:+
LUAD	cis	rs7870753	0.53	rs117847766	ENSG00000188801.9	ZNF322P1	3.92	9.99e-05	0.0141	0.27	0.18	Height;	chr9:96429373	chr9:97198303~97199511:-
LUAD	cis	rs7870753	0.628	rs10820604	ENSG00000188801.9	ZNF322P1	3.92	9.99e-05	0.0141	0.27	0.18	Height;	chr9:96430212	chr9:97198303~97199511:-
LUAD	cis	rs7870753	0.628	rs2406004	ENSG00000188801.9	ZNF322P1	3.92	9.99e-05	0.0141	0.27	0.18	Height;	chr9:96430928	chr9:97198303~97199511:-
LUAD	cis	rs858239	0.601	rs10239760	ENSG00000226816.2	AC005082.12	3.92	9.99e-05	0.0141	0.23	0.18	Cerebrospinal fluid biomarker levels;	chr7:23110331	chr7:23206013~23208045:+
LUAD	cis	rs911119	0.913	rs6036461	ENSG00000270001.1	RP11-218C14.8	-3.92	9.99e-05	0.0141	-0.26	-0.18	Chronic kidney disease;	chr20:23596117	chr20:23631826~23632316:-
LUAD	cis	rs2904524	1	rs74716820	ENSG00000257613.1	LINC01481	-3.92	9.99e-05	0.0141	-0.32	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70246074	chr12:70219132~70221862:-
LUAD	cis	rs4819052	1	rs13047688	ENSG00000237664.1	LINC00316	-3.92	9.99e-05	0.0141	-0.22	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249375	chr21:45338590~45341990:-
LUAD	cis	rs725613	0.512	rs4781033	ENSG00000274038.1	RP11-66H6.4	-3.92	1e-04	0.0141	-0.21	-0.18	Primary sclerosing cholangitis;	chr16:10993045	chr16:11056556~11057034:+
LUAD	cis	rs806321	0.587	rs2740516	ENSG00000237152.3	DLEU7-AS1	-3.92	1e-04	0.0141	-0.22	-0.18	Multiple sclerosis;	chr13:50187483	chr13:50807856~50849905:+
LUAD	cis	rs7617773	0.78	rs35297395	ENSG00000199476.1	Y_RNA	-3.92	1e-04	0.0141	-0.24	-0.18	Coronary artery disease;	chr3:48301392	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.78	rs36075665	ENSG00000199476.1	Y_RNA	-3.92	1e-04	0.0141	-0.24	-0.18	Coronary artery disease;	chr3:48301597	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.78	rs34630841	ENSG00000199476.1	Y_RNA	-3.92	1e-04	0.0141	-0.24	-0.18	Coronary artery disease;	chr3:48301771	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.78	rs35190747	ENSG00000199476.1	Y_RNA	-3.92	1e-04	0.0141	-0.24	-0.18	Coronary artery disease;	chr3:48301800	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.743	rs7621785	ENSG00000199476.1	Y_RNA	-3.92	1e-04	0.0141	-0.24	-0.18	Coronary artery disease;	chr3:48302218	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.78	rs4511915	ENSG00000199476.1	Y_RNA	-3.92	1e-04	0.0141	-0.24	-0.18	Coronary artery disease;	chr3:48302368	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.78	rs13066758	ENSG00000199476.1	Y_RNA	-3.92	1e-04	0.0141	-0.24	-0.18	Coronary artery disease;	chr3:48302387	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.78	rs4392440	ENSG00000199476.1	Y_RNA	-3.92	1e-04	0.0141	-0.24	-0.18	Coronary artery disease;	chr3:48302430	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.78	rs13082859	ENSG00000199476.1	Y_RNA	-3.92	1e-04	0.0141	-0.24	-0.18	Coronary artery disease;	chr3:48303185	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.78	rs36121690	ENSG00000199476.1	Y_RNA	-3.92	1e-04	0.0141	-0.24	-0.18	Coronary artery disease;	chr3:48304021	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.78	rs35778847	ENSG00000199476.1	Y_RNA	-3.92	1e-04	0.0141	-0.24	-0.18	Coronary artery disease;	chr3:48305495	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.78	rs34749846	ENSG00000199476.1	Y_RNA	-3.92	1e-04	0.0141	-0.24	-0.18	Coronary artery disease;	chr3:48305678	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.78	rs7632297	ENSG00000199476.1	Y_RNA	-3.92	1e-04	0.0141	-0.24	-0.18	Coronary artery disease;	chr3:48306673	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.78	rs79089926	ENSG00000199476.1	Y_RNA	-3.92	1e-04	0.0141	-0.24	-0.18	Coronary artery disease;	chr3:48307074	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.78	rs4511916	ENSG00000199476.1	Y_RNA	-3.92	1e-04	0.0141	-0.24	-0.18	Coronary artery disease;	chr3:48308876	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.815	rs7624450	ENSG00000199476.1	Y_RNA	-3.92	1e-04	0.0141	-0.24	-0.18	Coronary artery disease;	chr3:48308885	chr3:48288587~48288694:+
LUAD	cis	rs10463554	0.892	rs1438687	ENSG00000250682.4	LINC00491	3.92	1e-04	0.0141	0.21	0.18	Parkinson's disease;	chr5:102968792	chr5:102609156~102671559:-
LUAD	cis	rs2645424	1	rs962366	ENSG00000255046.1	RP11-297N6.4	3.92	1e-04	0.0141	0.21	0.18	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11826894	chr8:11797928~11802568:-
LUAD	cis	rs9309711	0.544	rs9752130	ENSG00000271868.1	RP11-1293J14.1	-3.92	1e-04	0.0141	-0.19	-0.18	Neurofibrillary tangles;	chr2:3484731	chr2:3496956~3497428:+
LUAD	cis	rs11673344	0.523	rs2562599	ENSG00000276846.1	CTD-3220F14.3	-3.92	1e-04	0.0141	-0.19	-0.18	Obesity-related traits;	chr19:37025472	chr19:37314868~37315620:-
LUAD	cis	rs2251260	0.685	rs1088673	ENSG00000250548.5	RP11-47I22.2	-3.92	1e-04	0.0141	-0.23	-0.18	Yeast infection;	chr14:61538930	chr14:61556313~61570653:-
LUAD	cis	rs4356203	0.519	rs214082	ENSG00000272034.1	SNORD14A	-3.92	1e-04	0.0141	-0.16	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17277843	chr11:17074654~17074744:-
LUAD	cis	rs4853525	0.62	rs1914408	ENSG00000235852.1	AC005540.3	-3.92	1e-04	0.0141	-0.23	-0.18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190975250	chr2:190880797~190882059:-
LUAD	cis	rs6471393	0.964	rs2914953	ENSG00000253848.1	RP11-10N23.5	3.92	1e-04	0.0141	0.22	0.18	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93730122	chr8:93741193~93744534:+
LUAD	cis	rs755249	0.701	rs4660823	ENSG00000228060.1	RP11-69E11.8	-3.92	1e-04	0.0141	-0.15	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39532851	chr1:39565160~39573203:+
LUAD	cis	rs2836974	0.666	rs35182074	ENSG00000232608.1	TIMM9P2	3.92	1e-04	0.0141	0.21	0.18	Cognitive function;	chr21:39313358	chr21:39216624~39217506:+
LUAD	cis	rs7200786	0.692	rs8054758	ENSG00000274038.1	RP11-66H6.4	-3.92	1e-04	0.0141	-0.21	-0.18	Systemic lupus erythematosus;Multiple sclerosis;	chr16:10997269	chr16:11056556~11057034:+
LUAD	cis	rs240993	0.812	rs7766610	ENSG00000271789.1	RP5-1112D6.7	-3.92	1e-04	0.0141	-0.22	-0.18	Inflammatory skin disease;Psoriasis;	chr6:111386618	chr6:111297126~111298510:+
LUAD	cis	rs206548	0.524	rs1529355	ENSG00000252680.1	RNA5SP449	3.92	1e-04	0.0141	0.22	0.18	Serum protein levels (sST2);	chr18:10380427	chr18:9844717~9844846:-
LUAD	cis	rs2658084	0.626	rs925208	ENSG00000271715.1	CTD-2256P15.5	-3.92	1e-04	0.0141	-0.21	-0.18	Iris color (L* coordinate);	chr5:10141238	chr5:10269489~10269918:-
LUAD	cis	rs17772222	0.74	rs10138002	ENSG00000258983.2	RP11-507K2.2	-3.92	1e-04	0.0141	-0.2	-0.18	Coronary artery calcification;	chr14:88510071	chr14:88499334~88515502:+
LUAD	cis	rs10794657	0.527	rs946672	ENSG00000261326.2	LINC01355	-3.92	1e-04	0.0141	-0.16	-0.18	Adiponectin levels;	chr1:24285308	chr1:23281309~23286752:-
LUAD	cis	rs6568686	0.527	rs174396	ENSG00000255389.1	C6orf3	3.92	1e-04	0.0141	0.23	0.18	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111598131	chr6:111599875~111602295:+
LUAD	cis	rs2115630	0.846	rs8024538	ENSG00000259728.4	LINC00933	-3.92	1e-04	0.0141	-0.21	-0.18	P wave terminal force;	chr15:84825188	chr15:84570649~84580175:+
LUAD	cis	rs5015933	0.788	rs10114684	ENSG00000232630.1	PRPS1P2	-3.92	1e-04	0.0142	-0.16	-0.18	Body mass index;	chr9:125340586	chr9:125150653~125151589:+
LUAD	cis	rs877819	0.552	rs2620878	ENSG00000228403.1	RP11-563N6.6	-3.92	1e-04	0.0142	-0.18	-0.18	Systemic lupus erythematosus;	chr10:48879727	chr10:48878022~48878649:+
LUAD	cis	rs12440869	1	rs1052488	ENSG00000270964.1	RP11-502I4.3	3.92	1e-04	0.0142	0.2	0.18	Peak velocity of the mitral A-wave;	chr15:67194509	chr15:67541072~67542604:-
LUAD	cis	rs10463554	0.892	rs464591	ENSG00000250682.4	LINC00491	3.92	1e-04	0.0142	0.22	0.18	Parkinson's disease;	chr5:103111600	chr5:102609156~102671559:-
LUAD	cis	rs7429990	0.965	rs11130154	ENSG00000228638.1	FCF1P2	3.92	1e-04	0.0142	0.21	0.18	Educational attainment (years of education);	chr3:48027752	chr3:48290793~48291375:-
LUAD	cis	rs9889262	0.828	rs28406364	ENSG00000251179.1	TMEM92-AS1	-3.92	1e-04	0.0142	-0.18	-0.18	Eosinophil percentage of granulocytes;Allergic disease (asthma, hay fever or eczema);Eosinophil counts;	chr17:49377145	chr17:50281577~50287855:-
LUAD	cis	rs9889262	0.865	rs28412876	ENSG00000251179.1	TMEM92-AS1	-3.92	1e-04	0.0142	-0.18	-0.18	Eosinophil percentage of granulocytes;Allergic disease (asthma, hay fever or eczema);Eosinophil counts;	chr17:49377153	chr17:50281577~50287855:-
LUAD	cis	rs2014572	0.967	rs10411941	ENSG00000268379.1	CTC-360J11.4	3.92	1e-04	0.0142	0.21	0.18	Hyperactive-impulsive symptoms;	chr19:57251518	chr19:57175233~57177921:+
LUAD	cis	rs2014572	0.967	rs11667407	ENSG00000268379.1	CTC-360J11.4	3.92	1e-04	0.0142	0.21	0.18	Hyperactive-impulsive symptoms;	chr19:57251754	chr19:57175233~57177921:+
LUAD	cis	rs2014572	0.967	rs10413671	ENSG00000268379.1	CTC-360J11.4	3.92	1e-04	0.0142	0.21	0.18	Hyperactive-impulsive symptoms;	chr19:57252121	chr19:57175233~57177921:+
LUAD	cis	rs2014572	0.967	rs10421632	ENSG00000268379.1	CTC-360J11.4	3.92	1e-04	0.0142	0.21	0.18	Hyperactive-impulsive symptoms;	chr19:57253402	chr19:57175233~57177921:+
LUAD	cis	rs2014572	0.967	rs8100154	ENSG00000268379.1	CTC-360J11.4	3.92	1e-04	0.0142	0.21	0.18	Hyperactive-impulsive symptoms;	chr19:57254064	chr19:57175233~57177921:+
LUAD	cis	rs6964587	0.869	rs2013334	ENSG00000188693.7	CYP51A1-AS1	3.92	1e-04	0.0142	0.21	0.18	Breast cancer;	chr7:91920343	chr7:92134604~92180725:+
LUAD	cis	rs12565755	0.556	rs12747527	ENSG00000226476.2	RP11-776H12.1	3.92	1e-04	0.0142	0.27	0.18	Response to tocilizumab in rheumatoid arthritis;	chr1:60488337	chr1:60540249~60640491:-
LUAD	cis	rs2638953	0.888	rs1871152	ENSG00000278733.1	RP11-425D17.1	3.92	1e-04	0.0142	0.21	0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28226893	chr12:28185625~28186190:-
LUAD	cis	rs6479901	0.841	rs10733787	ENSG00000232075.1	MRPL35P2	-3.92	1e-04	0.0142	-0.24	-0.18	Intelligence (multi-trait analysis);	chr10:63147078	chr10:63634317~63634827:-
LUAD	cis	rs6479901	0.67	rs12240740	ENSG00000232075.1	MRPL35P2	-3.92	1e-04	0.0142	-0.24	-0.18	Intelligence (multi-trait analysis);	chr10:63147478	chr10:63634317~63634827:-
LUAD	cis	rs57104699	0.668	rs4636103	ENSG00000225541.1	AC002480.5	-3.92	0.000101	0.0142	-0.19	-0.18	Multiple myeloma and monoclonal gammopathy;Multiple myeloma;	chr7:21898370	chr7:22571607~22661792:-
LUAD	cis	rs6763768	0.814	rs998411	ENSG00000274967.1	Y_RNA	-3.92	0.000101	0.0142	-0.2	-0.18	Bacterial meningitis;	chr3:53485740	chr3:53290640~53290751:+
LUAD	cis	rs4237845	0.837	rs7971877	ENSG00000245651.2	RP11-620J15.2	3.92	0.000101	0.0142	0.17	0.18	Intelligence (multi-trait analysis);	chr12:57893847	chr12:57869835~57896482:-
LUAD	cis	rs4499344	0.623	rs11670818	ENSG00000201388.1	SNORA68	3.92	0.000101	0.0142	0.21	0.18	Mean platelet volume;	chr19:32608948	chr19:32608337~32608469:-
LUAD	cis	rs9302635	0.513	rs12444701	ENSG00000260886.1	TAT-AS1	3.92	0.000101	0.0142	0.22	0.18	Blood protein levels;	chr16:72121341	chr16:71565789~71578187:+
LUAD	cis	rs16866061	1	rs72974238	ENSG00000228446.2	AC073052.1	-3.92	0.000101	0.0142	-0.19	-0.18	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr2:224567753	chr2:224499387~224500100:-
LUAD	cis	rs8014252	0.803	rs60860517	ENSG00000259158.2	ADAM20P1	-3.92	0.000101	0.0142	-0.29	-0.18	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70563202	chr14:70468881~70483756:-
LUAD	cis	rs8014252	0.803	rs10135356	ENSG00000259158.2	ADAM20P1	-3.92	0.000101	0.0142	-0.29	-0.18	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70563638	chr14:70468881~70483756:-
LUAD	cis	rs1874124	0.577	rs2807880	ENSG00000257551.1	HLX-AS1	3.92	0.000101	0.0142	0.26	0.18	Cholesterol, total;	chr1:220869661	chr1:220832763~220880140:-
LUAD	cis	rs875971	0.545	rs10950036	ENSG00000222364.1	RNU6-96P	-3.92	0.000101	0.0142	-0.22	-0.18	Aortic root size;	chr7:66353241	chr7:66395191~66395286:+
LUAD	cis	rs6479891	1	rs4747045	ENSG00000232075.1	MRPL35P2	3.92	0.000101	0.0142	0.29	0.18	Arthritis (juvenile idiopathic);	chr10:63166722	chr10:63634317~63634827:-
LUAD	cis	rs6479891	1	rs4466712	ENSG00000232075.1	MRPL35P2	3.92	0.000101	0.0142	0.29	0.18	Arthritis (juvenile idiopathic);	chr10:63173508	chr10:63634317~63634827:-
LUAD	cis	rs2929278	0.562	rs8033846	ENSG00000166763.7	STRCP1	-3.92	0.000101	0.0142	-0.21	-0.18	Schizophrenia;	chr15:43743165	chr15:43699488~43718184:-
LUAD	cis	rs2929278	0.589	rs7174732	ENSG00000166763.7	STRCP1	-3.92	0.000101	0.0142	-0.21	-0.18	Schizophrenia;	chr15:43746265	chr15:43699488~43718184:-
LUAD	cis	rs10863681	1	rs12135862	ENSG00000228437.4	RP11-400N13.2	-3.92	0.000101	0.0142	-0.21	-0.18	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222072045	chr1:221966341~221984964:+
LUAD	cis	rs6479901	0.895	rs1579045	ENSG00000232075.1	MRPL35P2	-3.92	0.000101	0.0142	-0.25	-0.18	Intelligence (multi-trait analysis);	chr10:63210688	chr10:63634317~63634827:-
LUAD	cis	rs10266483	0.96	rs679883	ENSG00000227986.1	TRIM60P18	3.92	0.000101	0.0142	0.2	0.18	Response to statin therapy;	chr7:64289990	chr7:64355078~64356199:+
LUAD	cis	rs6964587	1	rs926192	ENSG00000188693.7	CYP51A1-AS1	-3.92	0.000101	0.0142	-0.21	-0.18	Breast cancer;	chr7:92042539	chr7:92134604~92180725:+
LUAD	cis	rs6964587	1	rs6950470	ENSG00000188693.7	CYP51A1-AS1	-3.92	0.000101	0.0142	-0.21	-0.18	Breast cancer;	chr7:92051327	chr7:92134604~92180725:+
LUAD	cis	rs10463554	0.963	rs1595553	ENSG00000250682.4	LINC00491	3.92	0.000101	0.0142	0.21	0.18	Parkinson's disease;	chr5:103043164	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.963	rs12655592	ENSG00000250682.4	LINC00491	3.92	0.000101	0.0142	0.21	0.18	Parkinson's disease;	chr5:103043715	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.963	rs12054848	ENSG00000250682.4	LINC00491	3.92	0.000101	0.0142	0.21	0.18	Parkinson's disease;	chr5:103044736	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.963	rs11242484	ENSG00000250682.4	LINC00491	3.92	0.000101	0.0142	0.21	0.18	Parkinson's disease;	chr5:103046172	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.963	rs11242485	ENSG00000250682.4	LINC00491	3.92	0.000101	0.0142	0.21	0.18	Parkinson's disease;	chr5:103046330	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.892	rs10434791	ENSG00000250682.4	LINC00491	3.92	0.000101	0.0142	0.21	0.18	Parkinson's disease;	chr5:103053768	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.963	rs34382	ENSG00000250682.4	LINC00491	3.92	0.000101	0.0142	0.21	0.18	Parkinson's disease;	chr5:103060521	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.963	rs34380	ENSG00000250682.4	LINC00491	3.92	0.000101	0.0142	0.21	0.18	Parkinson's disease;	chr5:103061245	chr5:102609156~102671559:-
LUAD	cis	rs2380205	0.689	rs907690	ENSG00000232807.2	RP11-536K7.3	3.92	0.000101	0.0142	0.19	0.18	Breast cancer;	chr10:5859404	chr10:5934270~5945900:-
LUAD	cis	rs2348418	0.832	rs7136426	ENSG00000247934.4	RP11-967K21.1	3.92	0.000101	0.0142	0.2	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28400129	chr12:28163298~28190738:-
LUAD	cis	rs412050	0.547	rs5999842	ENSG00000224086.5	LL22NC03-86G7.1	-3.92	0.000101	0.0142	-0.23	-0.18	Attention deficit hyperactivity disorder;	chr22:21860600	chr22:21938293~21977632:+
LUAD	cis	rs8037818	1	rs4643284	ENSG00000261064.1	RP11-1000B6.3	-3.92	0.000101	0.0142	-0.23	-0.18	Obesity-related traits;	chr15:32639897	chr15:32536047~32587613:+
LUAD	cis	rs2154319	0.887	rs61780439	ENSG00000235358.1	RP11-399E6.1	-3.92	0.000101	0.0142	-0.24	-0.18	Height;	chr1:41024505	chr1:41242373~41284861:+
LUAD	cis	rs4700393	0.517	rs71592686	ENSG00000272308.1	RP11-231G3.1	3.92	0.000101	0.0142	0.22	0.18	Intelligence (multi-trait analysis);	chr5:60825444	chr5:60866457~60866935:-
LUAD	cis	rs116095464	0.558	rs2288459	ENSG00000248925.1	CTD-2083E4.6	3.92	0.000101	0.0142	0.3	0.18	Breast cancer;	chr5:231028	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs2288457	ENSG00000248925.1	CTD-2083E4.6	3.92	0.000101	0.0142	0.3	0.18	Breast cancer;	chr5:231155	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs7736600	ENSG00000248925.1	CTD-2083E4.6	3.92	0.000101	0.0142	0.3	0.18	Breast cancer;	chr5:231222	chr5:269858~271516:-
LUAD	cis	rs7204230	1	rs62049819	ENSG00000261291.1	RP11-295M3.2	3.92	0.000101	0.0142	0.21	0.18	Fibrinogen;	chr16:53337551	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs7187151	ENSG00000261291.1	RP11-295M3.2	3.92	0.000101	0.0142	0.21	0.18	Fibrinogen;	chr16:53338049	chr16:53168522~53169450:+
LUAD	cis	rs137603	0.602	rs137654	ENSG00000225450.1	RP3-508I15.14	-3.92	0.000101	0.0142	-0.15	-0.18	Primary biliary cholangitis;	chr22:39336408	chr22:38739003~38749041:+
LUAD	cis	rs6142102	1	rs6059672	ENSG00000275784.1	RP5-1125A11.6	-3.92	0.000101	0.0142	-0.2	-0.18	Skin pigmentation;	chr20:34117662	chr20:33989480~33991818:-
LUAD	cis	rs6430585	0.793	rs11684545	ENSG00000226806.1	AC011893.3	-3.92	0.000101	0.0142	-0.22	-0.18	Corneal structure;	chr2:135781552	chr2:135820191~135823087:+
LUAD	cis	rs76382185	0.756	rs11577369	ENSG00000233184.5	RP11-421L21.3	3.92	0.000101	0.0142	0.33	0.18	Lymphocyte counts;	chr1:101122255	chr1:101025878~101087268:+
LUAD	cis	rs7017914	0.702	rs36047866	ENSG00000223220.1	Y_RNA	3.92	0.000101	0.0142	0.2	0.18	Bone mineral density;	chr8:70644815	chr8:70780914~70781008:-
LUAD	cis	rs9309473	0.555	rs2901437	ENSG00000163016.8	ALMS1P	3.92	0.000101	0.0142	0.2	0.18	Metabolite levels;	chr2:73369896	chr2:73644919~73685576:+
LUAD	cis	rs911555	0.755	rs17841064	ENSG00000244691.1	RPL10AP1	-3.92	0.000101	0.0142	-0.23	-0.18	Intelligence (multi-trait analysis);	chr14:103434272	chr14:103412119~103412761:-
LUAD	cis	rs8014252	0.614	rs28612538	ENSG00000259158.2	ADAM20P1	-3.92	0.000101	0.0142	-0.29	-0.18	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70558489	chr14:70468881~70483756:-
LUAD	cis	rs7191700	0.601	rs243329	ENSG00000262636.1	CTD-3088G3.4	3.92	0.000101	0.0142	0.22	0.18	Multiple sclerosis;	chr16:11258456	chr16:11380859~11381118:-
LUAD	cis	rs7829975	0.871	rs572307	ENSG00000173295.6	FAM86B3P	-3.92	0.000101	0.0142	-0.18	-0.18	Mood instability;	chr8:8721301	chr8:8228595~8244865:+
LUAD	cis	rs4705962	0.837	rs6864565	ENSG00000233006.5	AC034220.3	3.92	0.000101	0.0142	0.17	0.18	Atopic dermatitis;	chr5:132712279	chr5:132311285~132369916:-
LUAD	cis	rs7404843	0.789	rs222909	ENSG00000207425.1	Y_RNA	-3.92	0.000101	0.0142	-0.31	-0.18	Testicular germ cell tumor;	chr16:15405432	chr16:14915457~14915556:-
LUAD	cis	rs10197140	0.925	rs3761710	ENSG00000235721.1	AC013268.3	-3.92	0.000101	0.0142	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110933891	chr2:110007675~110010783:+
LUAD	cis	rs2836974	0.899	rs114399588	ENSG00000232608.1	TIMM9P2	-3.92	0.000101	0.0142	-0.21	-0.18	Cognitive function;	chr21:39282032	chr21:39216624~39217506:+
LUAD	cis	rs801193	0.613	rs2016325	ENSG00000272831.1	RP11-792A8.4	-3.92	0.000101	0.0142	-0.17	-0.18	Aortic root size;	chr7:66858513	chr7:66739829~66740385:-
LUAD	cis	rs4713118	0.696	rs2394002	ENSG00000280107.1	AL022393.9	-3.92	0.000101	0.0142	-0.22	-0.18	Parkinson's disease;	chr6:27780236	chr6:28170845~28172521:+
LUAD	cis	rs3864261	0.515	rs12186995	ENSG00000272081.1	CTD-2376I4.2	3.92	0.000101	0.0142	0.23	0.18	Discordance in emotional problems in monozygotic twins;	chr5:73039500	chr5:72955206~72955699:-
LUAD	cis	rs2242116	1	rs2168443	ENSG00000271161.1	BOLA2P2	-3.92	0.000101	0.0142	-0.17	-0.18	Birth weight;	chr3:46905597	chr3:47499841~47500407:+
LUAD	cis	rs73198271	0.641	rs34473848	ENSG00000253893.2	FAM85B	3.92	0.000101	0.0142	0.23	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792327	chr8:8167819~8226614:-
LUAD	cis	rs73198271	0.601	rs11997731	ENSG00000253893.2	FAM85B	3.92	0.000101	0.0142	0.23	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792338	chr8:8167819~8226614:-
LUAD	cis	rs338389	0.516	rs4777016	ENSG00000270964.1	RP11-502I4.3	-3.92	0.000101	0.0142	-0.18	-0.18	Survival in rectal cancer;	chr15:68022581	chr15:67541072~67542604:-
LUAD	cis	rs78572108	0.925	rs12470582	ENSG00000214691.7	AC104654.1	3.92	0.000101	0.0142	0.31	0.18	Total body bone mineral density;	chr2:42049312	chr2:41877074~41894046:+
LUAD	cis	rs9462027	0.597	rs6940215	ENSG00000225339.3	RP11-513I15.6	-3.92	0.000101	0.0142	-0.21	-0.18	Systemic lupus erythematosus;	chr6:34738581	chr6:34248568~34286768:+
LUAD	cis	rs10411262	0.935	rs2312289	ENSG00000211513.4	MIR320E	-3.92	0.000101	0.0142	-0.19	-0.18	Tonsillectomy;	chr19:46672358	chr19:46709271~46709382:-
LUAD	cis	rs6500602	0.893	rs4785962	ENSG00000280063.1	RP11-295D4.3	3.92	0.000101	0.0142	0.12	0.18	Schizophrenia;	chr16:4434327	chr16:4346694~4348648:-
LUAD	cis	rs7005380	0.733	rs10107579	ENSG00000279347.1	RP11-85I17.2	3.92	0.000101	0.0143	0.15	0.18	Interstitial lung disease;	chr8:119922329	chr8:119838736~119840385:-
LUAD	cis	rs453301	0.686	rs28482034	ENSG00000253893.2	FAM85B	3.92	0.000101	0.0143	0.23	0.18	Joint mobility (Beighton score);	chr8:9012154	chr8:8167819~8226614:-
LUAD	cis	rs17772222	0.74	rs10150986	ENSG00000258983.2	RP11-507K2.2	3.92	0.000101	0.0143	0.2	0.18	Coronary artery calcification;	chr14:88517326	chr14:88499334~88515502:+
LUAD	cis	rs9309473	1	rs7598396	ENSG00000230002.2	ALMS1-IT1	3.92	0.000101	0.0143	0.22	0.18	Metabolite levels;	chr2:73425500	chr2:73456764~73459484:+
LUAD	cis	rs7246967	0.673	rs937078	ENSG00000236312.3	RPL34P34	3.92	0.000101	0.0143	0.24	0.18	Bronchopulmonary dysplasia;	chr19:22628865	chr19:22368599~22368952:-
LUAD	cis	rs7246967	0.673	rs12978794	ENSG00000236312.3	RPL34P34	3.92	0.000101	0.0143	0.24	0.18	Bronchopulmonary dysplasia;	chr19:22629332	chr19:22368599~22368952:-
LUAD	cis	rs7246967	0.673	rs4932782	ENSG00000236312.3	RPL34P34	3.92	0.000101	0.0143	0.24	0.18	Bronchopulmonary dysplasia;	chr19:22629999	chr19:22368599~22368952:-
LUAD	cis	rs7246967	0.673	rs4933017	ENSG00000236312.3	RPL34P34	3.92	0.000101	0.0143	0.24	0.18	Bronchopulmonary dysplasia;	chr19:22630178	chr19:22368599~22368952:-
LUAD	cis	rs7246967	0.611	rs66866654	ENSG00000236312.3	RPL34P34	3.92	0.000101	0.0143	0.24	0.18	Bronchopulmonary dysplasia;	chr19:22630937	chr19:22368599~22368952:-
LUAD	cis	rs7246967	0.673	rs73028776	ENSG00000236312.3	RPL34P34	3.92	0.000101	0.0143	0.24	0.18	Bronchopulmonary dysplasia;	chr19:22630938	chr19:22368599~22368952:-
LUAD	cis	rs42490	0.664	rs394108	ENSG00000251136.7	RP11-37B2.1	-3.92	0.000101	0.0143	-0.18	-0.18	Leprosy;	chr8:89812991	chr8:89609409~89757727:-
LUAD	cis	rs4841134	0.704	rs2169386	ENSG00000233609.3	RP11-62H7.2	-3.92	0.000101	0.0143	-0.14	-0.18	Age-related disease endophenotypes;	chr8:9340770	chr8:8961200~8979025:+
LUAD	cis	rs2014572	0.967	rs4801452	ENSG00000268379.1	CTC-360J11.4	3.92	0.000101	0.0143	0.21	0.18	Hyperactive-impulsive symptoms;	chr19:57256698	chr19:57175233~57177921:+
LUAD	cis	rs321358	0.895	rs17457076	ENSG00000271390.1	RP11-89C3.3	3.92	0.000101	0.0143	0.28	0.18	Body mass index;	chr11:111081030	chr11:111089870~111090368:-
LUAD	cis	rs997295	0.504	rs12905397	ENSG00000270964.1	RP11-502I4.3	-3.92	0.000101	0.0143	-0.19	-0.18	Motion sickness;	chr15:67741812	chr15:67541072~67542604:-
LUAD	cis	rs11072089	0.818	rs9635370	ENSG00000259286.3	RP11-696L21.2	-3.92	0.000101	0.0143	-0.32	-0.18	Bipolar disorder and schizophrenia;	chr15:69372921	chr15:68833830~68834749:+
LUAD	cis	rs4971059	0.629	rs4246529	ENSG00000160766.13	GBAP1	-3.92	0.000101	0.0143	-0.18	-0.18	Breast cancer;	chr1:155142784	chr1:155213821~155227422:-
LUAD	cis	rs2346177	0.875	rs12986585	ENSG00000279254.1	RP11-536C12.1	-3.92	0.000101	0.0143	-0.19	-0.18	HDL cholesterol;	chr2:46416982	chr2:46668870~46670778:+
LUAD	cis	rs4938303	0.718	rs4938300	ENSG00000280143.1	AP000892.6	-3.92	0.000101	0.0143	-0.25	-0.18	Triglycerides;	chr11:116696903	chr11:117204967~117210292:+
LUAD	cis	rs6121246	0.954	rs73241710	ENSG00000230613.1	HM13-AS1	3.92	0.000101	0.0143	0.25	0.18	Mean corpuscular hemoglobin;	chr20:31837153	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.908	rs17093657	ENSG00000230613.1	HM13-AS1	3.92	0.000101	0.0143	0.25	0.18	Mean corpuscular hemoglobin;	chr20:31841091	chr20:31567707~31573263:-
LUAD	cis	rs4713118	0.955	rs9393848	ENSG00000280107.1	AL022393.9	-3.92	0.000101	0.0143	-0.22	-0.18	Parkinson's disease;	chr6:27720590	chr6:28170845~28172521:+
LUAD	cis	rs9925964	0.933	rs12448321	ENSG00000232748.3	RP11-196G11.6	3.92	0.000101	0.0143	0.21	0.18	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31036959	chr16:31056460~31062803:+
LUAD	cis	rs755249	1	rs755249	ENSG00000182109.6	RP11-69E11.4	3.92	0.000101	0.0143	0.21	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39529402	chr1:39522280~39546187:-
LUAD	cis	rs2638953	0.64	rs11049726	ENSG00000244712.1	RP11-874G11.1	-3.92	0.000101	0.0143	-0.25	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28582703	chr12:28564678~28565141:-
LUAD	cis	rs950880	0.767	rs4851569	ENSG00000234389.1	AC007278.3	-3.92	0.000101	0.0143	-0.17	-0.18	Serum protein levels (sST2);	chr2:102366787	chr2:102438713~102440475:+
LUAD	cis	rs865483	0.86	rs12603185	ENSG00000276054.1	RP11-378E13.3	3.92	0.000102	0.0143	0.21	0.18	Monocyte count;	chr17:37508198	chr17:37386886~37387926:+
LUAD	cis	rs7202877	0.706	rs247434	ENSG00000280152.1	RP11-331F4.5	-3.92	0.000102	0.0143	-0.21	-0.18	Type 1 diabetes;Type 2 diabetes;	chr16:75411406	chr16:75245994~75250077:-
LUAD	cis	rs6724465	0.636	rs72951772	ENSG00000272644.1	RP11-33O4.1	3.92	0.000102	0.0143	0.26	0.18	Height;	chr2:219126275	chr2:219069354~219069809:-
LUAD	cis	rs5758659	0.652	rs133301	ENSG00000270083.1	RP1-257I20.14	3.92	0.000102	0.0143	0.17	0.18	Cognitive function;	chr22:41994089	chr22:42089630~42090028:-
LUAD	cis	rs338389	0.521	rs8031161	ENSG00000260657.2	RP11-315D16.4	-3.92	0.000102	0.0143	-0.22	-0.18	Survival in rectal cancer;	chr15:67990789	chr15:68267792~68277994:-
LUAD	cis	rs755249	0.567	rs61783378	ENSG00000182109.6	RP11-69E11.4	3.92	0.000102	0.0143	0.22	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39311487	chr1:39522280~39546187:-
LUAD	cis	rs651907	0.535	rs1460097	ENSG00000244119.1	PDCL3P4	3.92	0.000102	0.0143	0.17	0.18	Colorectal cancer;	chr3:101778725	chr3:101712472~101713191:+
LUAD	cis	rs10129255	0.536	rs3944157	ENSG00000253209.1	IGHV3-65	3.92	0.000102	0.0143	0.14	0.18	Kawasaki disease;	chr14:106682286	chr14:106666092~106666532:-
LUAD	cis	rs7615952	0.741	rs13314845	ENSG00000241288.6	RP11-379B18.5	-3.92	0.000102	0.0143	-0.23	-0.18	Blood pressure (smoking interaction);	chr3:125925939	chr3:125827238~125916384:-
LUAD	cis	rs7615952	0.733	rs13314847	ENSG00000241288.6	RP11-379B18.5	-3.92	0.000102	0.0143	-0.23	-0.18	Blood pressure (smoking interaction);	chr3:125925945	chr3:125827238~125916384:-
LUAD	cis	rs7615952	0.8	rs13086460	ENSG00000241288.6	RP11-379B18.5	-3.92	0.000102	0.0143	-0.23	-0.18	Blood pressure (smoking interaction);	chr3:125927574	chr3:125827238~125916384:-
LUAD	cis	rs2098713	0.536	rs2366419	ENSG00000250155.1	CTD-2353F22.1	3.92	0.000102	0.0143	0.19	0.18	Telomere length;	chr5:37529948	chr5:36666214~36725195:-
LUAD	cis	rs739496	0.579	rs57046217	ENSG00000234608.6	MAPKAPK5-AS1	3.92	0.000102	0.0143	0.2	0.18	Platelet count;	chr12:111847312	chr12:111839764~111842902:-
LUAD	cis	rs9287719	0.967	rs6432126	ENSG00000243819.4	RN7SL832P	3.92	0.000102	0.0143	0.18	0.18	Prostate cancer;	chr2:10616975	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.904	rs55738250	ENSG00000243819.4	RN7SL832P	3.92	0.000102	0.0143	0.18	0.18	Prostate cancer;	chr2:10617006	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs6727768	ENSG00000243819.4	RN7SL832P	3.92	0.000102	0.0143	0.18	0.18	Prostate cancer;	chr2:10617353	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs10167129	ENSG00000243819.4	RN7SL832P	3.92	0.000102	0.0143	0.18	0.18	Prostate cancer;	chr2:10618449	chr2:10690344~10692099:+
LUAD	cis	rs10214930	0.697	rs7806169	ENSG00000235574.1	AC073150.6	3.92	0.000102	0.0143	0.21	0.18	Hypospadias;	chr7:27867974	chr7:27491682~27492765:-
LUAD	cis	rs67981189	0.896	rs2526877	ENSG00000269927.1	RP6-91H8.3	-3.92	0.000102	0.0143	-0.22	-0.18	Schizophrenia;	chr14:70966605	chr14:71141125~71143253:-
LUAD	cis	rs1007190	0.881	rs12941832	ENSG00000267505.1	CTC-296K1.3	3.92	0.000102	0.0143	0.3	0.18	DNA methylation (variation);	chr17:44910114	chr17:44793199~44794474:+
LUAD	cis	rs2836974	0.644	rs61300849	ENSG00000232608.1	TIMM9P2	3.92	0.000102	0.0143	0.2	0.18	Cognitive function;	chr21:39308268	chr21:39216624~39217506:+
LUAD	cis	rs780096	0.565	rs8179252	ENSG00000234072.1	AC074117.10	-3.92	0.000102	0.0143	-0.13	-0.18	Total body bone mineral density;	chr2:27523965	chr2:27356246~27367622:+
LUAD	cis	rs6840258	0.943	rs10029915	ENSG00000251411.1	RP11-397E7.4	-3.92	0.000102	0.0143	-0.22	-0.18	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87138465	chr4:86913266~86914817:-
LUAD	cis	rs7615952	0.641	rs12487875	ENSG00000250012.1	RP11-124N2.1	-3.92	0.000102	0.0143	-0.25	-0.18	Blood pressure (smoking interaction);	chr3:126068381	chr3:126084220~126095349:+
LUAD	cis	rs7512552	0.809	rs1694377	ENSG00000275557.1	RP11-353N4.6	3.92	0.000102	0.0143	0.2	0.18	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150320705	chr1:149607765~149612402:+
LUAD	cis	rs865483	0.929	rs853214	ENSG00000276054.1	RP11-378E13.3	3.92	0.000102	0.0143	0.21	0.18	Monocyte count;	chr17:37500858	chr17:37386886~37387926:+
LUAD	cis	rs865483	0.929	rs853215	ENSG00000276054.1	RP11-378E13.3	3.92	0.000102	0.0143	0.21	0.18	Monocyte count;	chr17:37501027	chr17:37386886~37387926:+
LUAD	cis	rs4925386	0.84	rs6143034	ENSG00000273619.1	RP5-908M14.9	-3.92	0.000102	0.0143	-0.18	-0.18	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345489	chr20:62386303~62386970:-
LUAD	cis	rs26232	0.526	rs61654927	ENSG00000250682.4	LINC00491	3.92	0.000102	0.0143	0.21	0.18	Rheumatoid arthritis;	chr5:103047021	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.892	rs59292735	ENSG00000250682.4	LINC00491	3.92	0.000102	0.0143	0.21	0.18	Parkinson's disease;	chr5:103047047	chr5:102609156~102671559:-
LUAD	cis	rs28386778	0.863	rs6919	ENSG00000240280.5	TCAM1P	3.92	0.000102	0.0143	0.2	0.18	Prudent dietary pattern;	chr17:63832125	chr17:63849292~63864379:+
LUAD	cis	rs1552244	0.882	rs67762674	ENSG00000180385.7	EMC3-AS1	3.92	0.000102	0.0143	0.21	0.18	Alzheimer's disease;	chr3:9972801	chr3:9986893~10006990:+
LUAD	cis	rs13434995	0.838	rs73236165	ENSG00000273257.1	RP11-177J6.1	-3.92	0.000102	0.0143	-0.28	-0.18	Adiponectin levels;	chr4:55617617	chr4:55387949~55388271:+
LUAD	cis	rs7503168	0.558	rs11651380	ENSG00000267592.1	CTC-507E2.2	3.92	0.000102	0.0143	0.38	0.18	Plateletcrit;	chr17:35654677	chr17:35596904~35597128:-
LUAD	cis	rs1541160	0.879	rs2065950	ENSG00000239494.2	RN7SL333P	3.92	0.000102	0.0143	0.17	0.18	Amyotrophic lateral sclerosis;	chr1:170046125	chr1:169859756~169860052:+
LUAD	cis	rs972578	0.561	rs5759113	ENSG00000230319.1	AL022476.2	3.92	0.000102	0.0143	0.19	0.18	Mean platelet volume;	chr22:43047946	chr22:43038585~43052366:+
LUAD	cis	rs7202877	0.706	rs247447	ENSG00000280152.1	RP11-331F4.5	-3.92	0.000102	0.0143	-0.21	-0.18	Type 1 diabetes;Type 2 diabetes;	chr16:75452750	chr16:75245994~75250077:-
LUAD	cis	rs6496932	0.635	rs8023859	ENSG00000218052.5	ADAMTS7P4	-3.92	0.000102	0.0143	-0.2	-0.18	Central corneal thickness;Corneal structure;	chr15:85361540	chr15:85255369~85330334:-
LUAD	cis	rs36093844	0.625	rs11234468	ENSG00000279742.1	RP11-700A24.1	-3.92	0.000102	0.0143	-0.19	-0.18	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85901214	chr11:85852557~85854943:-
LUAD	cis	rs507080	0.769	rs483283	ENSG00000278376.1	RP11-158I9.8	-3.92	0.000102	0.0143	-0.19	-0.18	Serum metabolite levels;	chr11:118635684	chr11:118791254~118793137:+
LUAD	cis	rs2836974	0.931	rs2836968	ENSG00000232608.1	TIMM9P2	-3.92	0.000102	0.0143	-0.21	-0.18	Cognitive function;	chr21:39270460	chr21:39216624~39217506:+
LUAD	cis	rs2836974	0.931	rs7283569	ENSG00000232608.1	TIMM9P2	-3.92	0.000102	0.0143	-0.21	-0.18	Cognitive function;	chr21:39272136	chr21:39216624~39217506:+
LUAD	cis	rs7178375	0.941	rs4779796	ENSG00000270015.1	RP11-540B6.6	3.92	0.000102	0.0143	0.16	0.18	Hypertriglyceridemia;	chr15:30915847	chr15:30926514~30928407:+
LUAD	cis	rs507080	0.922	rs4936433	ENSG00000278376.1	RP11-158I9.8	3.92	0.000102	0.0143	0.2	0.18	Serum metabolite levels;	chr11:118681711	chr11:118791254~118793137:+
LUAD	cis	rs595982	0.517	rs4801779	ENSG00000235191.1	NUCB1-AS1	3.92	0.000102	0.0143	0.19	0.18	Red cell distribution width;	chr19:48903394	chr19:48910930~48918891:-
LUAD	cis	rs7560272	0.512	rs4530394	ENSG00000163016.8	ALMS1P	-3.92	0.000102	0.0143	-0.19	-0.18	Schizophrenia;	chr2:73702523	chr2:73644919~73685576:+
LUAD	cis	rs12935418	0.552	rs2123626	ENSG00000261061.1	RP11-303E16.2	3.92	0.000102	0.0143	0.19	0.18	Mean corpuscular volume;	chr16:80988205	chr16:81030770~81031485:+
LUAD	cis	rs7178375	1	rs12907055	ENSG00000270015.1	RP11-540B6.6	3.92	0.000102	0.0143	0.16	0.18	Hypertriglyceridemia;	chr15:30912091	chr15:30926514~30928407:+
LUAD	cis	rs2749097	0.609	rs2269239	ENSG00000244256.3	RN7SL130P	3.92	0.000102	0.0143	0.23	0.18	Alcohol consumption (transferrin glycosylation);	chr1:63643688	chr1:63655743~63656047:+
LUAD	cis	rs73198271	0.653	rs3827811	ENSG00000253893.2	FAM85B	3.92	0.000102	0.0143	0.23	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8801528	chr8:8167819~8226614:-
LUAD	cis	rs2154319	0.887	rs61780436	ENSG00000235358.1	RP11-399E6.1	-3.92	0.000102	0.0143	-0.24	-0.18	Height;	chr1:41010508	chr1:41242373~41284861:+
LUAD	cis	rs2154319	0.887	rs6670087	ENSG00000235358.1	RP11-399E6.1	-3.92	0.000102	0.0143	-0.24	-0.18	Height;	chr1:41019774	chr1:41242373~41284861:+
LUAD	cis	rs2154319	0.887	rs6678816	ENSG00000235358.1	RP11-399E6.1	-3.92	0.000102	0.0143	-0.24	-0.18	Height;	chr1:41019917	chr1:41242373~41284861:+
LUAD	cis	rs2154319	0.887	rs17357954	ENSG00000235358.1	RP11-399E6.1	-3.92	0.000102	0.0143	-0.24	-0.18	Height;	chr1:41021665	chr1:41242373~41284861:+
LUAD	cis	rs860295	0.651	rs12239114	ENSG00000225855.5	RUSC1-AS1	3.92	0.000102	0.0143	0.12	0.18	Body mass index;	chr1:155352351	chr1:155316863~155324176:-
LUAD	cis	rs7617773	0.78	rs7653152	ENSG00000199476.1	Y_RNA	-3.92	0.000102	0.0144	-0.24	-0.18	Coronary artery disease;	chr3:48320607	chr3:48288587~48288694:+
LUAD	cis	rs9900280	1	rs7222766	ENSG00000264808.1	RP11-802D6.1	3.92	0.000102	0.0144	0.21	0.18	Mean platelet volume;	chr17:29352707	chr17:29369717~29390777:-
LUAD	cis	rs9925964	0.9	rs56813533	ENSG00000232748.3	RP11-196G11.6	3.92	0.000102	0.0144	0.21	0.18	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31059160	chr16:31056460~31062803:+
LUAD	cis	rs7335046	0.708	rs912128	ENSG00000280710.1	RP11-214F16.8	3.92	0.000102	0.0144	0.31	0.18	Basal cell carcinoma;	chr13:99422127	chr13:99498524~99501315:+
LUAD	cis	rs151234	0.741	rs11647881	ENSG00000259982.1	CDC37P1	-3.92	0.000102	0.0144	-0.34	-0.18	Platelet distribution width;	chr16:28594852	chr16:28700294~28701540:-
LUAD	cis	rs9291683	0.588	rs2240724	ENSG00000250413.1	RP11-448G15.1	-3.92	0.000102	0.0144	-0.22	-0.18	Bone mineral density;	chr4:10019666	chr4:10006482~10009725:+
LUAD	cis	rs8054556	0.765	rs11150574	ENSG00000183604.13	SMG1P5	-3.92	0.000102	0.0144	-0.17	-0.18	Autism spectrum disorder or schizophrenia;	chr16:29923498	chr16:30267553~30335374:-
LUAD	cis	rs12530	0.54	rs2294312	ENSG00000230736.2	RP1-149A16.3	-3.92	0.000102	0.0144	-0.18	-0.18	IgG glycosylation;	chr22:32397397	chr22:32376664~32384343:+
LUAD	cis	rs801193	0.569	rs35070132	ENSG00000273448.1	RP11-166O4.6	3.92	0.000102	0.0144	0.17	0.18	Aortic root size;	chr7:66773096	chr7:67333047~67334383:+
LUAD	cis	rs858239	0.6	rs6461691	ENSG00000226816.2	AC005082.12	3.92	0.000102	0.0144	0.23	0.18	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23206013~23208045:+
LUAD	cis	rs6871536	1	rs56668723	ENSG00000233006.5	AC034220.3	-3.92	0.000102	0.0144	-0.2	-0.18	Asthma (childhood onset);	chr5:132571498	chr5:132311285~132369916:-
LUAD	cis	rs9309473	0.95	rs10189885	ENSG00000230002.2	ALMS1-IT1	3.92	0.000102	0.0144	0.23	0.18	Metabolite levels;	chr2:73649928	chr2:73456764~73459484:+
LUAD	cis	rs6499129	1	rs7195790	ENSG00000280214.1	CTD-2012K14.5	-3.92	0.000102	0.0144	-0.21	-0.18	Waist-to-hip ratio adjusted for body mass index;	chr16:67488386	chr16:67550815~67552935:-
LUAD	cis	rs10197140	0.857	rs4849164	ENSG00000235721.1	AC013268.3	-3.92	0.000102	0.0144	-0.19	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110881913	chr2:110007675~110010783:+
LUAD	cis	rs73193808	1	rs2832249	ENSG00000215533.7	LINC00189	-3.92	0.000102	0.0144	-0.25	-0.18	Coronary artery disease;	chr21:29185330	chr21:29193480~29288205:+
LUAD	cis	rs8028182	0.636	rs8028277	ENSG00000260269.4	CTD-2323K18.1	-3.92	0.000102	0.0144	-0.25	-0.18	Sudden cardiac arrest;	chr15:75391744	chr15:75527150~75601205:-
LUAD	cis	rs1056107	0.763	rs7024998	ENSG00000225513.1	RP11-165N19.2	-3.92	0.000102	0.0144	-0.19	-0.18	Colorectal cancer;	chr9:112175379	chr9:112173522~112173971:-
LUAD	cis	rs763121	0.853	rs5750626	ENSG00000225450.1	RP3-508I15.14	-3.92	0.000102	0.0144	-0.18	-0.18	Menopause (age at onset);	chr22:38581885	chr22:38739003~38749041:+
LUAD	cis	rs73219805	0.536	rs77690628	ENSG00000228451.3	SDAD1P1	-3.92	0.000102	0.0144	-0.43	-0.18	Schizophrenia;	chr8:26331707	chr8:26379259~26382953:-
LUAD	cis	rs877819	0.583	rs2889699	ENSG00000228403.1	RP11-563N6.6	-3.92	0.000102	0.0144	-0.18	-0.18	Systemic lupus erythematosus;	chr10:48854659	chr10:48878022~48878649:+
LUAD	cis	rs7611694	0.846	rs1567780	ENSG00000242770.2	RP11-180K7.1	-3.92	0.000102	0.0144	-0.17	-0.18	Prostate cancer;	chr3:113575635	chr3:112802478~112812819:+
LUAD	cis	rs34929064	0.958	rs35263987	ENSG00000230658.1	KLHL7-AS1	3.92	0.000102	0.0144	0.24	0.18	Major depression and alcohol dependence;	chr7:22688229	chr7:23101228~23105703:-
LUAD	cis	rs1005277	0.522	rs9417256	ENSG00000273019.1	RP11-508N22.13	-3.92	0.000102	0.0144	-0.2	-0.18	Extrinsic epigenetic age acceleration;	chr10:37688062	chr10:38149968~38150293:+
LUAD	cis	rs5758511	0.513	rs7292782	ENSG00000227370.1	RP4-669P10.19	-3.92	0.000102	0.0144	-0.18	-0.18	Birth weight;	chr22:41804320	chr22:42132543~42132998:+
LUAD	cis	rs801193	1	rs2707856	ENSG00000222364.1	RNU6-96P	-3.92	0.000102	0.0144	-0.2	-0.18	Aortic root size;	chr7:66746023	chr7:66395191~66395286:+
LUAD	cis	rs9928842	0.765	rs6564223	ENSG00000261476.1	RP11-77K12.3	-3.92	0.000102	0.0144	-0.24	-0.18	Alcoholic chronic pancreatitis;	chr16:75192001	chr16:75458252~75460017:-
LUAD	cis	rs6701713	0.959	rs10863420	ENSG00000274245.1	RP11-357P18.2	-3.92	0.000102	0.0144	-0.28	-0.18	Alzheimer's disease (late onset);	chr1:207626529	chr1:207372559~207373252:+
LUAD	cis	rs6471393	0.964	rs12056877	ENSG00000253848.1	RP11-10N23.5	-3.92	0.000102	0.0144	-0.21	-0.18	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93710234	chr8:93741193~93744534:+
LUAD	cis	rs10435719	0.902	rs7459983	ENSG00000255046.1	RP11-297N6.4	-3.92	0.000102	0.0144	-0.22	-0.18	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11949712	chr8:11797928~11802568:-
LUAD	cis	rs9926296	0.605	rs12448860	ENSG00000260259.1	RP11-368I7.4	-3.92	0.000102	0.0144	-0.17	-0.18	Vitiligo;	chr16:89783221	chr16:89682620~89686569:-
LUAD	cis	rs11672691	0.756	rs8107333	ENSG00000270164.1	LINC01480	-3.92	0.000102	0.0144	-0.16	-0.18	Prostate cancer;	chr19:41481965	chr19:41535183~41536904:+
LUAD	cis	rs13006833	0.739	rs291472	ENSG00000227542.1	AC092614.2	-3.92	0.000102	0.0144	-0.21	-0.18	Urinary metabolites;	chr2:190325879	chr2:191229165~191246172:-
LUAD	cis	rs9659323	0.804	rs10923722	ENSG00000231365.4	RP11-418J17.1	-3.92	0.000103	0.0144	-0.21	-0.18	Body mass index;	chr1:119000863	chr1:119140396~119275973:+
LUAD	cis	rs9659323	0.745	rs10923723	ENSG00000231365.4	RP11-418J17.1	-3.92	0.000103	0.0144	-0.21	-0.18	Body mass index;	chr1:119001379	chr1:119140396~119275973:+
LUAD	cis	rs1008375	0.9	rs13101742	ENSG00000249502.1	AC006160.5	3.92	0.000103	0.0144	0.17	0.18	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17699674	chr4:17587467~17614571:-
LUAD	cis	rs7208859	0.623	rs8067035	ENSG00000280069.1	CTD-2349P21.3	-3.92	0.000103	0.0144	-0.24	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775170	chr17:30738182~30740275:+
LUAD	cis	rs7968440	1	rs2700485	ENSG00000272368.2	RP4-605O3.4	3.92	0.000103	0.0144	0.21	0.18	Fibrinogen;	chr12:50710209	chr12:50112197~50165618:+
LUAD	cis	rs7968440	1	rs2250752	ENSG00000272368.2	RP4-605O3.4	3.92	0.000103	0.0144	0.21	0.18	Fibrinogen;	chr12:50712308	chr12:50112197~50165618:+
LUAD	cis	rs755249	0.756	rs72637908	ENSG00000182109.6	RP11-69E11.4	3.92	0.000103	0.0144	0.2	0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39557375	chr1:39522280~39546187:-
LUAD	cis	rs2060793	0.684	rs1597689	ENSG00000251991.1	RNU7-49P	3.92	0.000103	0.0144	0.19	0.18	Vitamin D levels;	chr11:14824638	chr11:14478892~14478953:+
LUAD	cis	rs6736093	0.901	rs11675946	ENSG00000207383.1	Y_RNA	3.92	0.000103	0.0144	0.22	0.18	Coronary artery disease;	chr2:111985456	chr2:112579484~112579584:-
LUAD	cis	rs12122100	0.837	rs12742539	ENSG00000244371.2	PFN1P8	3.92	0.000103	0.0144	0.22	0.18	HIV-1 control;	chr1:147036289	chr1:146957117~146957659:-
LUAD	cis	rs820077	0.736	rs820069	ENSG00000232909.1	RP3-510O8.4	-3.92	0.000103	0.0144	-0.26	-0.18	Systemic lupus erythematosus;	chr6:35072089	chr6:35733867~35736947:-
LUAD	cis	rs916888	0.773	rs199445	ENSG00000232300.1	FAM215B	3.92	0.000103	0.0144	0.27	0.18	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46558830~46562795:-
LUAD	cis	rs916888	0.773	rs199443	ENSG00000232300.1	FAM215B	3.92	0.000103	0.0144	0.27	0.18	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46558830~46562795:-
LUAD	cis	rs6832769	1	rs6851838	ENSG00000272969.1	RP11-528I4.2	-3.92	0.000103	0.0144	-0.18	-0.18	Personality dimensions;	chr4:55554580	chr4:55547112~55547889:+
LUAD	cis	rs2732480	0.577	rs2634681	ENSG00000240399.1	RP1-228P16.1	-3.92	0.000103	0.0144	-0.17	-0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339301	chr12:48054813~48055591:-
LUAD	cis	rs10876993	0.89	rs10783844	ENSG00000270039.1	RP11-571M6.17	3.92	0.000103	0.0144	0.21	0.18	Celiac disease or Rheumatoid arthritis;	chr12:57704642	chr12:57803838~57804415:+
LUAD	cis	rs523522	0.962	rs3893104	ENSG00000278344.1	RP11-18C24.8	3.92	0.000103	0.0144	0.24	0.18	High light scatter reticulocyte count;	chr12:120466133	chr12:120500735~120501090:-
LUAD	cis	rs7119038	0.731	rs10892283	ENSG00000255239.1	AP002954.6	-3.92	0.000103	0.0144	-0.27	-0.18	Sjögren's syndrome;	chr11:118766272	chr11:118688039~118690600:-
LUAD	cis	rs7119038	0.774	rs11217020	ENSG00000255239.1	AP002954.6	-3.92	0.000103	0.0144	-0.27	-0.18	Sjögren's syndrome;	chr11:118768644	chr11:118688039~118690600:-
LUAD	cis	rs7119038	0.818	rs10892286	ENSG00000255239.1	AP002954.6	-3.92	0.000103	0.0144	-0.27	-0.18	Sjögren's syndrome;	chr11:118771376	chr11:118688039~118690600:-
LUAD	cis	rs6964587	1	rs9691325	ENSG00000188693.7	CYP51A1-AS1	-3.92	0.000103	0.0144	-0.21	-0.18	Breast cancer;	chr7:92101733	chr7:92134604~92180725:+
LUAD	cis	rs8141529	0.748	rs5997412	ENSG00000272858.1	CTA-292E10.8	-3.92	0.000103	0.0144	-0.2	-0.18	Lymphocyte counts;	chr22:28880759	chr22:28814914~28815662:+
LUAD	cis	rs9650657	0.655	rs10093774	ENSG00000255046.1	RP11-297N6.4	-3.92	0.000103	0.0144	-0.22	-0.18	Neuroticism;	chr8:10845783	chr8:11797928~11802568:-
LUAD	cis	rs12935418	0.583	rs2970086	ENSG00000261061.1	RP11-303E16.2	3.92	0.000103	0.0144	0.19	0.18	Mean corpuscular volume;	chr16:80994835	chr16:81030770~81031485:+
LUAD	cis	rs12935418	0.583	rs2970085	ENSG00000261061.1	RP11-303E16.2	3.92	0.000103	0.0144	0.19	0.18	Mean corpuscular volume;	chr16:80994842	chr16:81030770~81031485:+
LUAD	cis	rs2836974	0.897	rs8133146	ENSG00000232608.1	TIMM9P2	-3.92	0.000103	0.0144	-0.21	-0.18	Cognitive function;	chr21:39242372	chr21:39216624~39217506:+
LUAD	cis	rs28386778	0.83	rs2854210	ENSG00000240280.5	TCAM1P	-3.92	0.000103	0.0144	-0.2	-0.18	Prudent dietary pattern;	chr17:63868978	chr17:63849292~63864379:+
LUAD	cis	rs7578361	0.959	rs10198177	ENSG00000231969.1	AC144449.1	-3.92	0.000103	0.0144	-0.26	-0.18	Acute lymphoblastic leukemia (childhood);	chr2:149565686	chr2:149587196~149848233:+
LUAD	cis	rs2300747	0.872	rs758518	ENSG00000177173.5	NAP1L4P1	3.92	0.000103	0.0145	0.28	0.18	Primary biliary cholangitis;Multiple sclerosis;	chr1:116539188	chr1:116532936~116534092:-
LUAD	cis	rs642803	0.613	rs489574	ENSG00000254510.1	RP11-867G23.10	-3.92	0.000103	0.0145	-0.21	-0.18	Urate levels;	chr11:65775268	chr11:66409158~66417137:+
LUAD	cis	rs34421088	0.603	rs10086064	ENSG00000255046.1	RP11-297N6.4	-3.92	0.000103	0.0145	-0.22	-0.18	Neuroticism;	chr8:11726332	chr8:11797928~11802568:-
LUAD	cis	rs8141529	0.748	rs5752826	ENSG00000272858.1	CTA-292E10.8	-3.92	0.000103	0.0145	-0.2	-0.18	Lymphocyte counts;	chr22:28873820	chr22:28814914~28815662:+
LUAD	cis	rs7772486	0.79	rs2247429	ENSG00000235652.6	RP11-545I5.3	3.92	0.000103	0.0145	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145896633	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.79	rs2247666	ENSG00000235652.6	RP11-545I5.3	3.92	0.000103	0.0145	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:145899273	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.79	rs3923579	ENSG00000235652.6	RP11-545I5.3	-3.92	0.000103	0.0145	-0.18	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145909096	chr6:145799409~145886585:+
LUAD	cis	rs2446066	0.872	rs3741651	ENSG00000257379.1	RP11-793H13.8	3.92	0.000103	0.0145	0.28	0.18	Red blood cell count;	chr12:53383387	chr12:53441741~53467528:+
LUAD	cis	rs948562	0.647	rs71486418	ENSG00000280010.1	AP001350.4	3.92	0.000103	0.0145	0.2	0.18	Lymphoma;	chr11:58472660	chr11:58627435~58628528:+
LUAD	cis	rs8177876	0.822	rs4306521	ENSG00000261061.1	RP11-303E16.2	-3.92	0.000103	0.0145	-0.29	-0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081288	chr16:81030770~81031485:+
LUAD	cis	rs8177876	0.822	rs4324142	ENSG00000261061.1	RP11-303E16.2	-3.92	0.000103	0.0145	-0.29	-0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081298	chr16:81030770~81031485:+
LUAD	cis	rs8177876	0.642	rs4324143	ENSG00000261061.1	RP11-303E16.2	-3.92	0.000103	0.0145	-0.29	-0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081383	chr16:81030770~81031485:+
LUAD	cis	rs8177876	0.818	rs59177227	ENSG00000261061.1	RP11-303E16.2	-3.92	0.000103	0.0145	-0.29	-0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081524	chr16:81030770~81031485:+
LUAD	cis	rs8177876	0.822	rs59685942	ENSG00000261061.1	RP11-303E16.2	-3.92	0.000103	0.0145	-0.29	-0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081534	chr16:81030770~81031485:+
LUAD	cis	rs8177876	0.822	rs10514515	ENSG00000261061.1	RP11-303E16.2	-3.92	0.000103	0.0145	-0.29	-0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81081717	chr16:81030770~81031485:+
LUAD	cis	rs8177876	0.822	rs1410	ENSG00000261061.1	RP11-303E16.2	-3.92	0.000103	0.0145	-0.29	-0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082228	chr16:81030770~81031485:+
LUAD	cis	rs8177876	0.822	rs1412	ENSG00000261061.1	RP11-303E16.2	-3.92	0.000103	0.0145	-0.29	-0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082237	chr16:81030770~81031485:+
LUAD	cis	rs8177876	0.822	rs1414	ENSG00000261061.1	RP11-303E16.2	-3.92	0.000103	0.0145	-0.29	-0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81082252	chr16:81030770~81031485:+
LUAD	cis	rs8177876	0.822	rs8177950	ENSG00000261061.1	RP11-303E16.2	-3.92	0.000103	0.0145	-0.29	-0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083290	chr16:81030770~81031485:+
LUAD	cis	rs8177876	0.731	rs8177948	ENSG00000261061.1	RP11-303E16.2	-3.92	0.000103	0.0145	-0.29	-0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083315	chr16:81030770~81031485:+
LUAD	cis	rs8177876	0.822	rs8177940	ENSG00000261061.1	RP11-303E16.2	-3.92	0.000103	0.0145	-0.29	-0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083789	chr16:81030770~81031485:+
LUAD	cis	rs8177876	0.73	rs76656387	ENSG00000261061.1	RP11-303E16.2	-3.92	0.000103	0.0145	-0.29	-0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81083862	chr16:81030770~81031485:+
LUAD	cis	rs7647973	0.516	rs4499638	ENSG00000225399.4	RP11-3B7.1	3.92	0.000103	0.0145	0.23	0.18	Menarche (age at onset);	chr3:49165349	chr3:49260085~49261316:+
LUAD	cis	rs6121246	0.559	rs6060915	ENSG00000230613.1	HM13-AS1	3.92	0.000103	0.0145	0.22	0.18	Mean corpuscular hemoglobin;	chr20:31742503	chr20:31567707~31573263:-
LUAD	cis	rs4718428	0.705	rs12698547	ENSG00000230295.1	RP11-458F8.2	-3.92	0.000103	0.0145	-0.16	-0.18	Corneal structure;	chr7:66813271	chr7:66880708~66882981:+
LUAD	cis	rs728616	0.867	rs34870056	ENSG00000234382.2	RP11-40F6.1	-3.92	0.000103	0.0145	-0.44	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80188299	chr10:80233664~80245367:+
LUAD	cis	rs763121	0.962	rs2071887	ENSG00000225450.1	RP3-508I15.14	-3.92	0.000103	0.0145	-0.16	-0.18	Menopause (age at onset);	chr22:38483005	chr22:38739003~38749041:+
LUAD	cis	rs8058578	0.832	rs35969813	ENSG00000232748.3	RP11-196G11.6	-3.92	0.000103	0.0145	-0.23	-0.18	Multiple myeloma;	chr16:30703096	chr16:31056460~31062803:+
LUAD	cis	rs9813712	0.597	rs10934931	ENSG00000228252.7	COL6A4P2	-3.92	0.000103	0.0145	-0.16	-0.18	Response to amphetamines;	chr3:130261365	chr3:130212823~130273806:+
LUAD	cis	rs2304003	0.561	rs13024739	ENSG00000235192.1	AC009495.2	-3.92	0.000103	0.0145	-0.19	-0.18	Social communication problems;	chr2:165795854	chr2:165794851~165810010:+
LUAD	cis	rs6438234	0.778	rs4465915	ENSG00000242767.1	ZBTB20-AS4	3.92	0.000103	0.0145	0.22	0.18	Type 2 diabetes;	chr3:115239314	chr3:115100423~115103061:+
LUAD	cis	rs7617773	0.817	rs13059037	ENSG00000199476.1	Y_RNA	-3.92	0.000103	0.0145	-0.23	-0.18	Coronary artery disease;	chr3:48246389	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.817	rs35414021	ENSG00000199476.1	Y_RNA	-3.92	0.000103	0.0145	-0.23	-0.18	Coronary artery disease;	chr3:48252034	chr3:48288587~48288694:+
LUAD	cis	rs11051970	0.879	rs2467065	ENSG00000274964.1	RP11-817I4.1	-3.92	0.000103	0.0145	-0.19	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr12:32433131	chr12:32339368~32340724:+
LUAD	cis	rs494562	0.892	rs522915	ENSG00000234155.1	RP11-30P6.6	-3.92	0.000103	0.0145	-0.34	-0.18	Metabolic traits;Blood metabolite levels;	chr6:85406603	chr6:85387219~85390186:-
LUAD	cis	rs494562	0.892	rs520090	ENSG00000234155.1	RP11-30P6.6	-3.92	0.000103	0.0145	-0.34	-0.18	Metabolic traits;Blood metabolite levels;	chr6:85406917	chr6:85387219~85390186:-
LUAD	cis	rs494562	0.892	rs498289	ENSG00000234155.1	RP11-30P6.6	-3.92	0.000103	0.0145	-0.34	-0.18	Metabolic traits;Blood metabolite levels;	chr6:85407003	chr6:85387219~85390186:-
LUAD	cis	rs3096299	0.685	rs8050512	ENSG00000261118.1	RP11-104N10.1	3.92	0.000103	0.0145	0.18	0.18	Multiple myeloma (IgH translocation);	chr16:89485912	chr16:89492017~89504460:-
LUAD	cis	rs11853189	1	rs78994386	ENSG00000259562.2	RP11-762H8.2	3.92	0.000103	0.0145	0.2	0.18	Red cell distribution width;	chr15:78278383	chr15:78290527~78291221:-
LUAD	cis	rs7119038	0.629	rs10892271	ENSG00000255239.1	AP002954.6	-3.92	0.000103	0.0145	-0.26	-0.18	Sjögren's syndrome;	chr11:118727835	chr11:118688039~118690600:-
LUAD	cis	rs6688537	0.508	rs12093821	ENSG00000233355.5	CHRM3-AS2	3.92	0.000103	0.0145	0.14	0.18	Lung function (FEV1/FVC);	chr1:239660948	chr1:239703381~239730465:-
LUAD	cis	rs4937333	0.647	rs7939247	ENSG00000254703.2	SENCR	-3.92	0.000103	0.0145	-0.19	-0.18	Plateletcrit;Platelet count;	chr11:128456155	chr11:128691672~128696023:-
LUAD	cis	rs2060793	0.519	rs2597212	ENSG00000251991.1	RNU7-49P	-3.92	0.000103	0.0145	-0.18	-0.18	Vitamin D levels;	chr11:14560216	chr11:14478892~14478953:+
LUAD	cis	rs6671200	0.607	rs2296308	ENSG00000228852.5	RP11-57H12.5	3.92	0.000103	0.0145	0.2	0.18	Stearic acid (18:0) levels;	chr1:95244383	chr1:95243167~95278940:-
LUAD	cis	rs4356203	0.519	rs214084	ENSG00000272034.1	SNORD14A	-3.92	0.000103	0.0145	-0.16	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17277267	chr11:17074654~17074744:-
LUAD	cis	rs4356203	0.519	rs214083	ENSG00000272034.1	SNORD14A	-3.92	0.000103	0.0145	-0.16	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17277312	chr11:17074654~17074744:-
LUAD	cis	rs6479901	0.789	rs7081614	ENSG00000232075.1	MRPL35P2	-3.92	0.000103	0.0145	-0.25	-0.18	Intelligence (multi-trait analysis);	chr10:63252088	chr10:63634317~63634827:-
LUAD	cis	rs761746	0.739	rs5994420	ENSG00000236132.1	CTA-440B3.1	-3.92	0.000103	0.0145	-0.25	-0.18	Intelligence;	chr22:31674765	chr22:31816379~31817491:-
LUAD	cis	rs4925386	1	rs4925389	ENSG00000273619.1	RP5-908M14.9	3.92	0.000103	0.0145	0.16	0.18	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62347456	chr20:62386303~62386970:-
LUAD	cis	rs357894	1	rs357894	ENSG00000266696.1	RP11-30L3.2	3.92	0.000103	0.0145	0.19	0.18	Dental caries;	chr18:49053600	chr18:49205912~49208781:+
LUAD	cis	rs9894429	0.646	rs9905639	ENSG00000263853.1	AC139530.1	-3.92	0.000103	0.0145	-0.18	-0.18	Eye color traits;	chr17:81647128	chr17:81676001~81676086:+
LUAD	cis	rs7819412	0.668	rs4841507	ENSG00000255046.1	RP11-297N6.4	3.92	0.000103	0.0145	0.21	0.18	Triglycerides;	chr8:11188885	chr8:11797928~11802568:-
LUAD	cis	rs442309	0.846	rs382412	ENSG00000238280.1	RP11-436D10.3	-3.92	0.000103	0.0145	-0.21	-0.18	Vogt-Koyanagi-Harada syndrome;	chr10:62730004	chr10:62793562~62805887:-
LUAD	cis	rs9341808	0.667	rs806783	ENSG00000260645.1	RP11-250B2.5	-3.92	0.000103	0.0145	-0.16	-0.18	Sitting height ratio;	chr6:80233226	chr6:80466958~80469080:+
LUAD	cis	rs17301013	0.861	rs34819375	ENSG00000227373.4	RP11-160H22.5	3.92	0.000103	0.0145	0.22	0.18	Systemic lupus erythematosus;	chr1:174654958	chr1:174115300~174160004:-
LUAD	cis	rs9287719	0.837	rs4233883	ENSG00000243819.4	RN7SL832P	3.92	0.000103	0.0145	0.18	0.18	Prostate cancer;	chr2:10615470	chr2:10690344~10692099:+
LUAD	cis	rs4713118	0.869	rs9283883	ENSG00000280107.1	AL022393.9	-3.92	0.000103	0.0145	-0.22	-0.18	Parkinson's disease;	chr6:27747691	chr6:28170845~28172521:+
LUAD	cis	rs6706648	0.582	rs10490070	ENSG00000234624.2	AC016894.1	3.92	0.000103	0.0145	0.21	0.18	F-cell distribution;	chr2:60428544	chr2:61416887~61417197:-
LUAD	cis	rs4474465	0.915	rs12274873	ENSG00000251323.2	RP11-452H21.4	3.91	0.000103	0.0145	0.22	0.18	Alzheimer's disease (survival time);	chr11:78471969	chr11:78423982~78429836:-
LUAD	cis	rs2613514	1	rs2613514	ENSG00000204282.4	TNRC6C-AS1	-3.91	0.000103	0.0145	-0.25	-0.18	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr17:78114437	chr17:78107398~78111799:-
LUAD	cis	rs6688537	0.508	rs16838637	ENSG00000233355.5	CHRM3-AS2	-3.91	0.000103	0.0145	-0.13	-0.18	Lung function (FEV1/FVC);	chr1:239665050	chr1:239703381~239730465:-
LUAD	cis	rs4865762	0.514	rs1823072	ENSG00000272416.1	CTD-2081C10.7	-3.91	0.000104	0.0145	-0.19	-0.18	Intraocular pressure;	chr5:53133976	chr5:53880293~53881051:-
LUAD	cis	rs4474465	0.79	rs4945290	ENSG00000251323.2	RP11-452H21.4	-3.91	0.000104	0.0145	-0.21	-0.18	Alzheimer's disease (survival time);	chr11:78541203	chr11:78423982~78429836:-
LUAD	cis	rs3773445	0.934	rs1631354	ENSG00000238225.1	CRIP1P2	3.91	0.000104	0.0145	0.18	0.18	Airway responsiveness in chronic obstructive pulmonary disease;	chr3:25578429	chr3:25686896~25687123:+
LUAD	cis	rs62025270	0.806	rs62025262	ENSG00000202081.1	RNU6-1280P	-3.91	0.000104	0.0145	-0.25	-0.18	Idiopathic pulmonary fibrosis;	chr15:85750002	chr15:85651522~85651628:-
LUAD	cis	rs6471393	0.964	rs2914944	ENSG00000253848.1	RP11-10N23.5	-3.91	0.000104	0.0145	-0.21	-0.18	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93711815	chr8:93741193~93744534:+
LUAD	cis	rs6471393	0.964	rs2914942	ENSG00000253848.1	RP11-10N23.5	-3.91	0.000104	0.0145	-0.21	-0.18	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93714189	chr8:93741193~93744534:+
LUAD	cis	rs7824557	0.547	rs2409745	ENSG00000255046.1	RP11-297N6.4	-3.91	0.000104	0.0145	-0.21	-0.18	Retinal vascular caliber;	chr8:11219126	chr8:11797928~11802568:-
LUAD	cis	rs11089937	0.963	rs2073454	ENSG00000211638.2	IGLV8-61	-3.91	0.000104	0.0145	-0.18	-0.18	Periodontitis (PAL4Q3);	chr22:22163086	chr22:22098700~22099212:+
LUAD	cis	rs9487094	1	rs10080429	ENSG00000260273.1	RP11-425D10.10	3.91	0.000104	0.0145	0.23	0.18	Height;	chr6:109416903	chr6:109382795~109383666:+
LUAD	cis	rs728616	0.867	rs61860034	ENSG00000225484.5	NUTM2B-AS1	-3.91	0.000104	0.0145	-0.46	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80172092	chr10:79663088~79826594:-
LUAD	cis	rs73193808	0.851	rs66654103	ENSG00000215533.7	LINC00189	-3.91	0.000104	0.0145	-0.24	-0.18	Coronary artery disease;	chr21:29231454	chr21:29193480~29288205:+
LUAD	cis	rs1876905	0.68	rs1150082	ENSG00000255389.1	C6orf3	3.91	0.000104	0.0145	0.23	0.18	Mean corpuscular hemoglobin;	chr6:111189519	chr6:111599875~111602295:+
LUAD	cis	rs6095360	0.69	rs35888516	ENSG00000177410.11	ZFAS1	3.91	0.000104	0.0145	0.2	0.18	Intelligence (multi-trait analysis);	chr20:49147738	chr20:49278178~49295738:+
LUAD	cis	rs394563	0.81	rs480870	ENSG00000216906.2	RP11-350J20.9	3.91	0.000104	0.0145	0.21	0.18	Dupuytren's disease;	chr6:149463682	chr6:149904243~149906418:+
LUAD	cis	rs394563	0.775	rs420430	ENSG00000216906.2	RP11-350J20.9	3.91	0.000104	0.0145	0.21	0.18	Dupuytren's disease;	chr6:149464403	chr6:149904243~149906418:+
LUAD	cis	rs394563	0.775	rs448420	ENSG00000216906.2	RP11-350J20.9	3.91	0.000104	0.0145	0.21	0.18	Dupuytren's disease;	chr6:149464666	chr6:149904243~149906418:+
LUAD	cis	rs1908814	0.516	rs11996277	ENSG00000255046.1	RP11-297N6.4	-3.91	0.000104	0.0145	-0.22	-0.18	Neuroticism;	chr8:11942522	chr8:11797928~11802568:-
LUAD	cis	rs73242632	0.5	rs11726321	ENSG00000269949.1	RP11-738E22.3	-3.91	0.000104	0.0145	-0.33	-0.18	Congenital heart disease (maternal effect);	chr4:57054738	chr4:56960927~56961373:-
LUAD	cis	rs73242632	0.5	rs1718873	ENSG00000269949.1	RP11-738E22.3	-3.91	0.000104	0.0145	-0.33	-0.18	Congenital heart disease (maternal effect);	chr4:57054933	chr4:56960927~56961373:-
LUAD	cis	rs73242632	0.5	rs1718874	ENSG00000269949.1	RP11-738E22.3	-3.91	0.000104	0.0145	-0.33	-0.18	Congenital heart disease (maternal effect);	chr4:57054967	chr4:56960927~56961373:-
LUAD	cis	rs8014204	0.773	rs2241275	ENSG00000279594.1	RP11-950C14.10	-3.91	0.000104	0.0145	-0.2	-0.18	Caffeine consumption;	chr14:74784737	chr14:75011269~75012851:-
LUAD	cis	rs7107174	1	rs55761949	ENSG00000251323.2	RP11-452H21.4	3.91	0.000104	0.0145	0.23	0.18	Testicular germ cell tumor;	chr11:78282814	chr11:78423982~78429836:-
LUAD	cis	rs2274273	0.624	rs7151581	ENSG00000258413.1	RP11-665C16.6	3.91	0.000104	0.0145	0.24	0.18	Protein biomarker;	chr14:55321727	chr14:55262767~55272075:-
LUAD	cis	rs7615952	0.576	rs6780025	ENSG00000250012.1	RP11-124N2.1	-3.91	0.000104	0.0145	-0.25	-0.18	Blood pressure (smoking interaction);	chr3:126096781	chr3:126084220~126095349:+
LUAD	cis	rs7615952	0.576	rs6804482	ENSG00000250012.1	RP11-124N2.1	-3.91	0.000104	0.0145	-0.25	-0.18	Blood pressure (smoking interaction);	chr3:126096919	chr3:126084220~126095349:+
LUAD	cis	rs1150668	0.796	rs2531825	ENSG00000176933.5	TOB2P1	-3.91	0.000104	0.0145	-0.2	-0.18	Pubertal anthropometrics;	chr6:28381487	chr6:28217643~28218634:-
LUAD	cis	rs1401999	0.966	rs1533682	ENSG00000223882.1	ABCC5-AS1	-3.91	0.000104	0.0145	-0.19	-0.18	Anterior chamber depth;	chr3:183917091	chr3:184006338~184011419:+
LUAD	cis	rs8002861	0.81	rs2275252	ENSG00000274001.1	RP11-5G9.5	3.91	0.000104	0.0146	0.18	0.18	Leprosy;	chr13:43880238	chr13:43877715~43878163:-
LUAD	cis	rs638893	0.636	rs493720	ENSG00000255422.1	AP002954.4	-3.91	0.000104	0.0146	-0.3	-0.18	Vitiligo;	chr11:118733969	chr11:118704607~118750263:+
LUAD	cis	rs638893	0.636	rs526850	ENSG00000255422.1	AP002954.4	-3.91	0.000104	0.0146	-0.3	-0.18	Vitiligo;	chr11:118734418	chr11:118704607~118750263:+
LUAD	cis	rs6095360	0.966	rs13037557	ENSG00000222365.1	SNORD12B	-3.91	0.000104	0.0146	-0.18	-0.18	Intelligence (multi-trait analysis);	chr20:48918053	chr20:49280319~49280409:+
LUAD	cis	rs9341808	1	rs1359239	ENSG00000260645.1	RP11-250B2.5	3.91	0.000104	0.0146	0.16	0.18	Sitting height ratio;	chr6:80246429	chr6:80466958~80469080:+
LUAD	cis	rs6840258	0.891	rs10023056	ENSG00000251411.1	RP11-397E7.4	-3.91	0.000104	0.0146	-0.22	-0.18	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87143314	chr4:86913266~86914817:-
LUAD	cis	rs8073060	0.544	rs225283	ENSG00000267592.1	CTC-507E2.2	3.91	0.000104	0.0146	0.26	0.18	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35607893	chr17:35596904~35597128:-
LUAD	cis	rs1334894	0.892	rs72896709	ENSG00000228559.1	RP3-340B19.3	-3.91	0.000104	0.0146	-0.42	-0.18	Coronary artery disease;	chr6:35505541	chr6:35544632~35545669:+
LUAD	cis	rs7515577	0.898	rs1384614	ENSG00000223787.2	RP4-593M8.1	3.91	0.000104	0.0146	0.27	0.18	Cholesterol, total;	chr1:92204569	chr1:92580476~92580821:-
LUAD	cis	rs10463554	0.963	rs34771	ENSG00000250682.4	LINC00491	3.91	0.000104	0.0146	0.21	0.18	Parkinson's disease;	chr5:103114713	chr5:102609156~102671559:-
LUAD	cis	rs4713118	0.513	rs149942	ENSG00000216901.1	AL022393.7	3.91	0.000104	0.0146	0.21	0.18	Parkinson's disease;	chr6:28033832	chr6:28176188~28176674:+
LUAD	cis	rs4713118	0.513	rs149944	ENSG00000216901.1	AL022393.7	3.91	0.000104	0.0146	0.21	0.18	Parkinson's disease;	chr6:28035040	chr6:28176188~28176674:+
LUAD	cis	rs4713118	0.513	rs149945	ENSG00000216901.1	AL022393.7	3.91	0.000104	0.0146	0.21	0.18	Parkinson's disease;	chr6:28035075	chr6:28176188~28176674:+
LUAD	cis	rs10129255	0.5	rs8011115	ENSG00000274576.2	IGHV2-70	-3.91	0.000104	0.0146	-0.14	-0.18	Kawasaki disease;	chr14:106786292	chr14:106770577~106771020:-
LUAD	cis	rs2390582	0.722	rs12048611	ENSG00000233593.5	RP4-665J23.1	-3.91	0.000104	0.0146	-0.25	-0.18	Coronary artery calcification;	chr1:90561526	chr1:90782986~90851650:-
LUAD	cis	rs7762018	1	rs6941766	ENSG00000231690.2	LINC00574	-3.91	0.000104	0.0146	-0.33	-0.18	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169731557	chr6:169790321~169802873:+
LUAD	cis	rs763121	0.853	rs3788544	ENSG00000225450.1	RP3-508I15.14	-3.91	0.000104	0.0146	-0.18	-0.18	Menopause (age at onset);	chr22:38668961	chr22:38739003~38749041:+
LUAD	cis	rs7660883	0.86	rs10023050	ENSG00000251411.1	RP11-397E7.4	3.91	0.000104	0.0146	0.19	0.18	HDL cholesterol levels;	chr4:87143279	chr4:86913266~86914817:-
LUAD	cis	rs34929064	1	rs6942430	ENSG00000230658.1	KLHL7-AS1	3.91	0.000104	0.0146	0.24	0.18	Major depression and alcohol dependence;	chr7:22685025	chr7:23101228~23105703:-
LUAD	cis	rs7615952	0.599	rs6438955	ENSG00000241288.6	RP11-379B18.5	-3.91	0.000104	0.0146	-0.22	-0.18	Blood pressure (smoking interaction);	chr3:126011490	chr3:125827238~125916384:-
LUAD	cis	rs595244	0.908	rs2118181	ENSG00000259705.1	RP11-227D13.1	-3.91	0.000104	0.0146	-0.28	-0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48623687	chr15:48645951~48652016:+
LUAD	cis	rs2274273	0.84	rs7159144	ENSG00000259318.1	RP11-454L9.2	3.91	0.000104	0.0146	0.15	0.18	Protein biomarker;	chr14:55354606	chr14:55394940~55395233:-
LUAD	cis	rs6840258	0.891	rs1842685	ENSG00000251411.1	RP11-397E7.4	-3.91	0.000104	0.0146	-0.22	-0.18	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87139680	chr4:86913266~86914817:-
LUAD	cis	rs6964587	1	rs7784248	ENSG00000188693.7	CYP51A1-AS1	-3.91	0.000104	0.0146	-0.21	-0.18	Breast cancer;	chr7:92128797	chr7:92134604~92180725:+
LUAD	cis	rs8014204	0.72	rs34752362	ENSG00000279594.1	RP11-950C14.10	3.91	0.000104	0.0146	0.2	0.18	Caffeine consumption;	chr14:74765603	chr14:75011269~75012851:-
LUAD	cis	rs12935418	0.672	rs2602423	ENSG00000261061.1	RP11-303E16.2	3.91	0.000104	0.0146	0.19	0.18	Mean corpuscular volume;	chr16:81008423	chr16:81030770~81031485:+
LUAD	cis	rs6832769	1	rs13121235	ENSG00000272969.1	RP11-528I4.2	3.91	0.000104	0.0146	0.18	0.18	Personality dimensions;	chr4:55445780	chr4:55547112~55547889:+
LUAD	cis	rs12744310	0.945	rs72665696	ENSG00000235358.1	RP11-399E6.1	3.91	0.000104	0.0146	0.23	0.18	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41309757	chr1:41242373~41284861:+
LUAD	cis	rs12744310	0.943	rs12751511	ENSG00000235358.1	RP11-399E6.1	3.91	0.000104	0.0146	0.23	0.18	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41310731	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs34073585	ENSG00000235358.1	RP11-399E6.1	3.91	0.000104	0.0146	0.23	0.18	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41311527	chr1:41242373~41284861:+
LUAD	cis	rs2274273	0.868	rs9919926	ENSG00000258413.1	RP11-665C16.6	-3.91	0.000104	0.0146	-0.23	-0.18	Protein biomarker;	chr14:55347172	chr14:55262767~55272075:-
LUAD	cis	rs10466239	0.73	rs12221341	ENSG00000230555.2	RP11-517P14.2	3.91	0.000104	0.0146	0.27	0.18	Telomere length;	chr10:43361882	chr10:43420738~43422100:+
LUAD	cis	rs4763879	0.634	rs2012643	ENSG00000256582.1	RP11-75L1.1	-3.91	0.000104	0.0146	-0.18	-0.18	Type 1 diabetes;	chr12:9707128	chr12:9704077~9709350:+
LUAD	cis	rs4819052	0.704	rs2297283	ENSG00000237664.1	LINC00316	-3.91	0.000104	0.0146	-0.21	-0.18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263675	chr21:45338590~45341990:-
LUAD	cis	rs7674212	0.539	rs6533056	ENSG00000251288.2	RP11-10L12.2	-3.91	0.000104	0.0146	-0.22	-0.18	Type 2 diabetes;	chr4:103199840	chr4:102751401~102752641:+
LUAD	cis	rs7674212	0.539	rs6815783	ENSG00000251288.2	RP11-10L12.2	-3.91	0.000104	0.0146	-0.22	-0.18	Type 2 diabetes;	chr4:103200989	chr4:102751401~102752641:+
LUAD	cis	rs6479901	0.894	rs10822165	ENSG00000232075.1	MRPL35P2	-3.91	0.000104	0.0146	-0.24	-0.18	Intelligence (multi-trait analysis);	chr10:63387199	chr10:63634317~63634827:-
LUAD	cis	rs13434995	0.513	rs880358	ENSG00000273257.1	RP11-177J6.1	-3.91	0.000104	0.0146	-0.23	-0.18	Adiponectin levels;	chr4:55410311	chr4:55387949~55388271:+
LUAD	cis	rs3096299	0.719	rs2911265	ENSG00000261118.1	RP11-104N10.1	3.91	0.000104	0.0146	0.18	0.18	Multiple myeloma (IgH translocation);	chr16:89444920	chr16:89492017~89504460:-
LUAD	cis	rs7617773	0.78	rs3197223	ENSG00000199476.1	Y_RNA	-3.91	0.000104	0.0146	-0.24	-0.18	Coronary artery disease;	chr3:48294367	chr3:48288587~48288694:+
LUAD	cis	rs34286592	0.929	rs9932653	ENSG00000214725.6	CDIPT-AS1	-3.91	0.000104	0.0146	-0.29	-0.18	Multiple sclerosis;	chr16:29854352	chr16:29863593~29868053:+
LUAD	cis	rs9287719	0.967	rs10206225	ENSG00000243819.4	RN7SL832P	3.91	0.000104	0.0146	0.18	0.18	Prostate cancer;	chr2:10618531	chr2:10690344~10692099:+
LUAD	cis	rs10129255	0.536	rs8004835	ENSG00000253209.1	IGHV3-65	3.91	0.000104	0.0146	0.14	0.18	Kawasaki disease;	chr14:106686361	chr14:106666092~106666532:-
LUAD	cis	rs7809950	0.954	rs12673675	ENSG00000238832.1	snoU109	-3.91	0.000104	0.0146	-0.25	-0.18	Coronary artery disease;	chr7:107472775	chr7:107603363~107603507:+
LUAD	cis	rs9549260	0.755	rs2151785	ENSG00000229456.1	RLIMP1	3.91	0.000105	0.0146	0.19	0.18	Red blood cell count;	chr13:40669523	chr13:40618738~40621348:+
LUAD	cis	rs8077577	0.671	rs6502641	ENSG00000273018.4	CTD-2303H24.2	3.91	0.000105	0.0146	0.25	0.18	Obesity-related traits;	chr17:18229665	chr17:18511221~18551705:-
LUAD	cis	rs4660214	0.666	rs7414381	ENSG00000182109.6	RP11-69E11.4	-3.91	0.000105	0.0146	-0.19	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39275848	chr1:39522280~39546187:-
LUAD	cis	rs4660214	0.666	rs3116387	ENSG00000182109.6	RP11-69E11.4	-3.91	0.000105	0.0146	-0.19	-0.18	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39277197	chr1:39522280~39546187:-
LUAD	cis	rs7172809	0.607	rs79590310	ENSG00000259362.2	RP11-307C19.1	3.91	0.000105	0.0146	0.22	0.18	Glucose homeostasis traits;	chr15:77549753	chr15:77525540~77534110:+
LUAD	cis	rs7172809	0.607	rs78928643	ENSG00000259362.2	RP11-307C19.1	3.91	0.000105	0.0146	0.22	0.18	Glucose homeostasis traits;	chr15:77549955	chr15:77525540~77534110:+
LUAD	cis	rs7172809	0.607	rs78510848	ENSG00000259362.2	RP11-307C19.1	3.91	0.000105	0.0146	0.22	0.18	Glucose homeostasis traits;	chr15:77549966	chr15:77525540~77534110:+
LUAD	cis	rs7172809	0.607	rs77744673	ENSG00000259362.2	RP11-307C19.1	3.91	0.000105	0.0146	0.22	0.18	Glucose homeostasis traits;	chr15:77549969	chr15:77525540~77534110:+
LUAD	cis	rs440932	1	rs365309	ENSG00000254340.1	RP11-10A14.3	-3.91	0.000105	0.0146	-0.22	-0.18	High light scatter reticulocyte percentage of red cells;	chr8:9169430	chr8:9141424~9145435:+
LUAD	cis	rs4795519	0.744	rs6505117	ENSG00000266313.1	RP11-173M1.4	3.91	0.000105	0.0146	0.23	0.18	Chronic myeloid leukemia;	chr17:27170270	chr17:27333256~27348491:+
LUAD	cis	rs748404	0.666	rs12906017	ENSG00000249839.1	AC011330.5	-3.91	0.000105	0.0146	-0.28	-0.18	Lung cancer;	chr15:43504710	chr15:43663654~43684339:-
LUAD	cis	rs5770917	1	rs3213446	ENSG00000273272.1	CTA-384D8.34	3.91	0.000105	0.0146	0.38	0.18	Narcolepsy;	chr22:50577245	chr22:50542650~50543011:+
LUAD	cis	rs7976269	0.559	rs10843313	ENSG00000257176.2	RP11-996F15.2	-3.91	0.000105	0.0146	-0.19	-0.18	Male-pattern baldness;	chr12:29078317	chr12:29280418~29317848:-
LUAD	cis	rs10129255	0.5	rs34326748	ENSG00000253209.1	IGHV3-65	3.91	0.000105	0.0146	0.14	0.18	Kawasaki disease;	chr14:106782523	chr14:106666092~106666532:-
LUAD	cis	rs10129255	0.5	rs10143385	ENSG00000253209.1	IGHV3-65	3.91	0.000105	0.0146	0.14	0.18	Kawasaki disease;	chr14:106782559	chr14:106666092~106666532:-
LUAD	cis	rs4561483	0.549	rs33657	ENSG00000261560.1	RP11-166B2.3	-3.91	0.000105	0.0146	-0.16	-0.18	Testicular germ cell tumor;	chr16:11875867	chr16:11881075~11882569:-
LUAD	cis	rs7615952	0.599	rs2279821	ENSG00000241288.6	RP11-379B18.5	-3.91	0.000105	0.0146	-0.23	-0.18	Blood pressure (smoking interaction);	chr3:126015465	chr3:125827238~125916384:-
LUAD	cis	rs206548	0.561	rs1940924	ENSG00000252680.1	RNA5SP449	3.91	0.000105	0.0146	0.22	0.18	Serum protein levels (sST2);	chr18:10380127	chr18:9844717~9844846:-
LUAD	cis	rs6951245	1	rs78185558	ENSG00000199023.2	MIR339	-3.91	0.000105	0.0147	-0.31	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1050547	chr7:1022935~1023045:-
LUAD	cis	rs7772486	0.875	rs6934467	ENSG00000235652.6	RP11-545I5.3	3.91	0.000105	0.0147	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:146089393	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.84	rs11155451	ENSG00000235652.6	RP11-545I5.3	3.91	0.000105	0.0147	0.18	0.18	Lobe attachment (rater-scored or self-reported);	chr6:146101388	chr6:145799409~145886585:+
LUAD	cis	rs11853189	0.938	rs79827225	ENSG00000259562.2	RP11-762H8.2	3.91	0.000105	0.0147	0.2	0.18	Red cell distribution width;	chr15:78263640	chr15:78290527~78291221:-
LUAD	cis	rs853679	0.517	rs9357065	ENSG00000226314.6	ZNF192P1	-3.91	0.000105	0.0147	-0.24	-0.18	Depression;	chr6:28161802	chr6:28161781~28169594:+
LUAD	cis	rs7617773	0.817	rs11710861	ENSG00000199476.1	Y_RNA	-3.91	0.000105	0.0147	-0.23	-0.18	Coronary artery disease;	chr3:48256070	chr3:48288587~48288694:+
LUAD	cis	rs11742741	0.967	rs1582945	ENSG00000248874.4	C5orf17	-3.91	0.000105	0.0147	-0.22	-0.18	Educational attainment;	chr5:24119452	chr5:23951348~24178263:+
LUAD	cis	rs6121246	0.609	rs1009453	ENSG00000230613.1	HM13-AS1	3.91	0.000105	0.0147	0.22	0.18	Mean corpuscular hemoglobin;	chr20:31817037	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.559	rs6119728	ENSG00000230613.1	HM13-AS1	3.91	0.000105	0.0147	0.22	0.18	Mean corpuscular hemoglobin;	chr20:31825318	chr20:31567707~31573263:-
LUAD	cis	rs11846409	0.86	rs10150951	ENSG00000223648.3	IGHV3-64	3.91	0.000105	0.0147	0.2	0.18	Rheumatic heart disease;	chr14:106632988	chr14:106643132~106658258:-
LUAD	cis	rs11846409	0.932	rs2583329	ENSG00000223648.3	IGHV3-64	-3.91	0.000105	0.0147	-0.2	-0.18	Rheumatic heart disease;	chr14:106632971	chr14:106643132~106658258:-
LUAD	cis	rs2354432	0.556	rs11239965	ENSG00000237188.3	RP11-337C18.8	3.91	0.000105	0.0147	0.34	0.18	Mitochondrial DNA levels;	chr1:147282234	chr1:147172771~147211568:+
LUAD	cis	rs8073060	0.592	rs225306	ENSG00000267592.1	CTC-507E2.2	-3.91	0.000105	0.0147	-0.21	-0.18	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35593017	chr17:35596904~35597128:-
LUAD	cis	rs4699052	0.927	rs1870888	ENSG00000246560.2	RP11-10L12.4	3.91	0.000105	0.0147	0.22	0.18	Testicular germ cell tumor;	chr4:103248169	chr4:102828055~102844075:+
LUAD	cis	rs9549260	0.755	rs58919811	ENSG00000229456.1	RLIMP1	3.91	0.000105	0.0147	0.19	0.18	Red blood cell count;	chr13:40652348	chr13:40618738~40621348:+
LUAD	cis	rs9549260	0.651	rs57735994	ENSG00000229456.1	RLIMP1	3.91	0.000105	0.0147	0.19	0.18	Red blood cell count;	chr13:40652424	chr13:40618738~40621348:+
LUAD	cis	rs4683346	0.616	rs12639142	ENSG00000173811.9	CCDC13-AS1	-3.91	0.000105	0.0147	-0.2	-0.18	Granulocyte percentage of myeloid white cells;	chr3:42790040	chr3:42732575~42746768:+
LUAD	cis	rs4683346	0.616	rs34868846	ENSG00000173811.9	CCDC13-AS1	-3.91	0.000105	0.0147	-0.2	-0.18	Granulocyte percentage of myeloid white cells;	chr3:42791723	chr3:42732575~42746768:+
LUAD	cis	rs7772486	0.754	rs9497434	ENSG00000235652.6	RP11-545I5.3	-3.91	0.000105	0.0147	-0.18	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145939617	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.79	rs6924159	ENSG00000235652.6	RP11-545I5.3	-3.91	0.000105	0.0147	-0.18	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145946737	chr6:145799409~145886585:+
LUAD	cis	rs2032366	0.63	rs6567226	ENSG00000266920.1	ACTBP9	3.91	0.000105	0.0147	0.18	0.18	Obesity-related traits;	chr18:61635689	chr18:62442028~62443126:+
LUAD	cis	rs910316	0.737	rs175071	ENSG00000259138.1	RP11-950C14.7	-3.91	0.000105	0.0147	-0.18	-0.18	Height;	chr14:75031474	chr14:75127153~75136930:+
LUAD	cis	rs7617773	0.817	rs13100815	ENSG00000199476.1	Y_RNA	-3.91	0.000105	0.0147	-0.24	-0.18	Coronary artery disease;	chr3:48245959	chr3:48288587~48288694:+
LUAD	cis	rs3764400	0.567	rs8071879	ENSG00000278765.1	RP5-890E16.5	-3.91	0.000105	0.0147	-0.31	-0.18	Body mass index;	chr17:48140095	chr17:48066704~48067293:-
LUAD	cis	rs3764400	0.567	rs2325804	ENSG00000278765.1	RP5-890E16.5	-3.91	0.000105	0.0147	-0.31	-0.18	Body mass index;	chr17:48141183	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.505	rs208009	ENSG00000278765.1	RP5-890E16.5	-3.91	0.000105	0.0147	-0.31	-0.18	Pulse pressure;	chr17:48152329	chr17:48066704~48067293:-
LUAD	cis	rs9903692	0.505	rs208005	ENSG00000278765.1	RP5-890E16.5	-3.91	0.000105	0.0147	-0.31	-0.18	Pulse pressure;	chr17:48162623	chr17:48066704~48067293:-
LUAD	cis	rs2836974	0.681	rs8128827	ENSG00000232608.1	TIMM9P2	-3.91	0.000105	0.0147	-0.21	-0.18	Cognitive function;	chr21:39338621	chr21:39216624~39217506:+
LUAD	cis	rs2274273	0.592	rs2878174	ENSG00000258413.1	RP11-665C16.6	-3.91	0.000105	0.0147	-0.21	-0.18	Protein biomarker;	chr14:55003906	chr14:55262767~55272075:-
LUAD	cis	rs1816752	0.875	rs59686377	ENSG00000273628.1	RP11-756A22.7	3.91	0.000105	0.0147	0.2	0.18	Obesity-related traits;	chr13:24475869	chr13:24933006~24936796:+
LUAD	cis	rs9322193	0.566	rs5024811	ENSG00000268592.3	RAET1E-AS1	-3.91	0.000105	0.0147	-0.25	-0.18	Lung cancer;	chr6:149924898	chr6:149863494~149919507:+
LUAD	cis	rs7870753	0.578	rs10990980	ENSG00000188801.9	ZNF322P1	3.91	0.000105	0.0147	0.27	0.18	Height;	chr9:96408619	chr9:97198303~97199511:-
LUAD	cis	rs7870753	0.578	rs10820564	ENSG00000188801.9	ZNF322P1	3.91	0.000105	0.0147	0.27	0.18	Height;	chr9:96409349	chr9:97198303~97199511:-
LUAD	cis	rs8028182	0.525	rs9920028	ENSG00000260269.4	CTD-2323K18.1	-3.91	0.000105	0.0147	-0.24	-0.18	Sudden cardiac arrest;	chr15:75635376	chr15:75527150~75601205:-
LUAD	cis	rs7580658	0.963	rs12622436	ENSG00000236682.1	AC068282.3	-3.91	0.000105	0.0147	-0.24	-0.18	Protein C levels;	chr2:127324106	chr2:127389130~127400580:+
LUAD	cis	rs2243480	0.522	rs778717	ENSG00000232559.3	GS1-124K5.12	3.91	0.000105	0.0147	0.35	0.18	Diabetic kidney disease;	chr7:66383164	chr7:66554588~66576923:-
LUAD	cis	rs7208859	0.573	rs73277960	ENSG00000280069.1	CTD-2349P21.3	-3.91	0.000105	0.0147	-0.24	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30850423	chr17:30738182~30740275:+
LUAD	cis	rs6951245	1	rs1997243	ENSG00000199023.2	MIR339	-3.91	0.000105	0.0147	-0.31	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1044141	chr7:1022935~1023045:-
LUAD	cis	rs6951245	1	rs77760339	ENSG00000199023.2	MIR339	-3.91	0.000105	0.0147	-0.31	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1044291	chr7:1022935~1023045:-
LUAD	cis	rs6951245	1	rs113575110	ENSG00000199023.2	MIR339	-3.91	0.000105	0.0147	-0.31	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1044758	chr7:1022935~1023045:-
LUAD	cis	rs6951245	1	rs1881123	ENSG00000199023.2	MIR339	-3.91	0.000105	0.0147	-0.31	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1045070	chr7:1022935~1023045:-
LUAD	cis	rs794185	0.681	rs711635	ENSG00000231249.1	ITPR1-AS1	-3.91	0.000105	0.0147	-0.19	-0.18	Multiple sclerosis--Brain Glutamate Levels;	chr3:4448829	chr3:4490891~4493163:-
LUAD	cis	rs1348850	0.757	rs4893969	ENSG00000213963.5	AC074286.1	3.91	0.000105	0.0147	0.21	0.18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177613748	chr2:177283508~177392691:-
LUAD	cis	rs13434995	0.513	rs4336288	ENSG00000273257.1	RP11-177J6.1	3.91	0.000105	0.0147	0.24	0.18	Adiponectin levels;	chr4:55584088	chr4:55387949~55388271:+
LUAD	cis	rs897984	0.762	rs1870293	ENSG00000232748.3	RP11-196G11.6	3.91	0.000105	0.0147	0.22	0.18	Dementia with Lewy bodies;	chr16:30959620	chr16:31056460~31062803:+
LUAD	cis	rs745109	0.504	rs17027169	ENSG00000273080.1	RP11-301O19.1	3.91	0.000105	0.0147	0.29	0.18	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86368710	chr2:86195590~86196049:+
LUAD	cis	rs526231	0.819	rs568999	ENSG00000175749.11	EIF3KP1	3.91	0.000105	0.0147	0.23	0.18	Primary biliary cholangitis;	chr5:103265657	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.819	rs411648	ENSG00000175749.11	EIF3KP1	3.91	0.000105	0.0147	0.23	0.18	Primary biliary cholangitis;	chr5:103267201	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.819	rs2569016	ENSG00000175749.11	EIF3KP1	3.91	0.000105	0.0147	0.23	0.18	Primary biliary cholangitis;	chr5:103267431	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.853	rs377192	ENSG00000175749.11	EIF3KP1	3.91	0.000105	0.0147	0.23	0.18	Primary biliary cholangitis;	chr5:103267853	chr5:103032376~103033031:+
LUAD	cis	rs9376098	0.825	rs7764187	ENSG00000232876.1	CTA-212D2.2	-3.91	0.000105	0.0147	-0.21	-0.18	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135162604	chr6:135055033~135060550:+
LUAD	cis	rs11673344	0.523	rs7258438	ENSG00000276846.1	CTD-3220F14.3	3.91	0.000105	0.0147	0.19	0.18	Obesity-related traits;	chr19:37032534	chr19:37314868~37315620:-
LUAD	cis	rs11673344	0.503	rs10414520	ENSG00000276846.1	CTD-3220F14.3	3.91	0.000105	0.0147	0.19	0.18	Obesity-related traits;	chr19:37057279	chr19:37314868~37315620:-
LUAD	cis	rs17406451	0.759	rs35340152	ENSG00000279873.2	LINC01126	3.91	0.000105	0.0147	0.15	0.18	Mitochondrial DNA levels;	chr2:43430371	chr2:43227210~43228855:+
LUAD	cis	rs8014204	0.748	rs12889277	ENSG00000279594.1	RP11-950C14.10	3.91	0.000105	0.0147	0.2	0.18	Caffeine consumption;	chr14:74762673	chr14:75011269~75012851:-
LUAD	cis	rs10197140	0.885	rs3789131	ENSG00000235721.1	AC013268.3	-3.91	0.000105	0.0147	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110927840	chr2:110007675~110010783:+
LUAD	cis	rs10197140	0.925	rs10168046	ENSG00000235721.1	AC013268.3	-3.91	0.000105	0.0147	-0.2	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110928601	chr2:110007675~110010783:+
LUAD	cis	rs6964587	0.839	rs12536702	ENSG00000188693.7	CYP51A1-AS1	-3.91	0.000105	0.0147	-0.21	-0.18	Breast cancer;	chr7:91842262	chr7:92134604~92180725:+
LUAD	cis	rs854765	0.693	rs11657074	ENSG00000264177.1	RP1-37N7.1	3.91	0.000105	0.0147	0.17	0.18	Total body bone mineral density;	chr17:17867041	chr17:18379855~18388984:-
LUAD	cis	rs2657294	0.965	rs2657286	ENSG00000233313.2	HMGA1P5	3.91	0.000105	0.0147	0.22	0.18	Pneumonia;	chr10:75145940	chr10:75276376~75276646:-
LUAD	cis	rs4499344	0.73	rs8103269	ENSG00000201388.1	SNORA68	3.91	0.000105	0.0147	0.19	0.18	Mean platelet volume;	chr19:32606597	chr19:32608337~32608469:-
LUAD	cis	rs4499344	0.73	rs12460624	ENSG00000201388.1	SNORA68	3.91	0.000105	0.0147	0.19	0.18	Mean platelet volume;	chr19:32607136	chr19:32608337~32608469:-
LUAD	cis	rs7107174	1	rs2373115	ENSG00000251323.2	RP11-452H21.4	3.91	0.000105	0.0147	0.21	0.18	Testicular germ cell tumor;	chr11:78380104	chr11:78423982~78429836:-
LUAD	cis	rs7674212	0.772	rs13113099	ENSG00000251288.2	RP11-10L12.2	-3.91	0.000105	0.0147	-0.22	-0.18	Type 2 diabetes;	chr4:103052965	chr4:102751401~102752641:+
LUAD	cis	rs7829975	0.714	rs60315134	ENSG00000233609.3	RP11-62H7.2	3.91	0.000105	0.0147	0.14	0.18	Mood instability;	chr8:8813089	chr8:8961200~8979025:+
LUAD	cis	rs6964587	1	rs3753109	ENSG00000188693.7	CYP51A1-AS1	-3.91	0.000105	0.0147	-0.2	-0.18	Breast cancer;	chr7:92000687	chr7:92134604~92180725:+
LUAD	cis	rs2024714	1	rs2024714	ENSG00000273812.1	WI2-87327B8.2	3.91	0.000105	0.0147	0.18	0.18	Longevity;	chr20:61637438	chr20:62596732~62603115:-
LUAD	cis	rs9341808	0.935	rs9343974	ENSG00000260645.1	RP11-250B2.5	3.91	0.000105	0.0147	0.16	0.18	Sitting height ratio;	chr6:80214928	chr6:80466958~80469080:+
LUAD	cis	rs9309711	0.772	rs9752251	ENSG00000271868.1	RP11-1293J14.1	-3.91	0.000105	0.0147	-0.21	-0.18	Neurofibrillary tangles;	chr2:3486098	chr2:3496956~3497428:+
LUAD	cis	rs34783982	0.748	rs907781	ENSG00000261441.1	RP11-217B1.2	-3.91	0.000105	0.0147	-0.22	-0.18	Squamous cell lung carcinoma;	chr15:88951711	chr15:89335053~89336161:+
LUAD	cis	rs10129255	0.518	rs10136903	ENSG00000253209.1	IGHV3-65	3.91	0.000106	0.0147	0.14	0.18	Kawasaki disease;	chr14:106778866	chr14:106666092~106666532:-
LUAD	cis	rs9287719	0.934	rs6710033	ENSG00000243819.4	RN7SL832P	3.91	0.000106	0.0147	0.18	0.18	Prostate cancer;	chr2:10617551	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs4669598	ENSG00000243819.4	RN7SL832P	3.91	0.000106	0.0147	0.18	0.18	Prostate cancer;	chr2:10617712	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs4669599	ENSG00000243819.4	RN7SL832P	3.91	0.000106	0.0147	0.18	0.18	Prostate cancer;	chr2:10617903	chr2:10690344~10692099:+
LUAD	cis	rs10197140	0.845	rs17525147	ENSG00000235721.1	AC013268.3	-3.91	0.000106	0.0147	-0.19	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110861945	chr2:110007675~110010783:+
LUAD	cis	rs11157436	0.602	rs11157435	ENSG00000211812.1	TRAV26-2	-3.91	0.000106	0.0148	-0.18	-0.18	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22168888	chr14:22202583~22203368:+
LUAD	cis	rs7017914	0.934	rs7814274	ENSG00000246366.5	RP11-382J12.1	-3.91	0.000106	0.0148	-0.16	-0.18	Bone mineral density;	chr8:70658176	chr8:70608577~70663279:+
LUAD	cis	rs10129255	0.5	rs988134	ENSG00000253209.1	IGHV3-65	3.91	0.000106	0.0148	0.14	0.18	Kawasaki disease;	chr14:106776698	chr14:106666092~106666532:-
LUAD	cis	rs10129255	0.5	rs988133	ENSG00000253209.1	IGHV3-65	3.91	0.000106	0.0148	0.14	0.18	Kawasaki disease;	chr14:106776724	chr14:106666092~106666532:-
LUAD	cis	rs7726839	0.718	rs6887972	ENSG00000248925.1	CTD-2083E4.6	3.91	0.000106	0.0148	0.24	0.18	Obesity-related traits;	chr5:597159	chr5:269858~271516:-
LUAD	cis	rs13434995	0.945	rs28473211	ENSG00000273257.1	RP11-177J6.1	-3.91	0.000106	0.0148	-0.28	-0.18	Adiponectin levels;	chr4:55615808	chr4:55387949~55388271:+
LUAD	cis	rs10463554	0.963	rs187427	ENSG00000250682.4	LINC00491	3.91	0.000106	0.0148	0.21	0.18	Parkinson's disease;	chr5:103177102	chr5:102609156~102671559:-
LUAD	cis	rs806321	0.587	rs2066632	ENSG00000237152.3	DLEU7-AS1	3.91	0.000106	0.0148	0.22	0.18	Multiple sclerosis;	chr13:50187807	chr13:50807856~50849905:+
LUAD	cis	rs897984	0.806	rs4889571	ENSG00000232748.3	RP11-196G11.6	3.91	0.000106	0.0148	0.22	0.18	Dementia with Lewy bodies;	chr16:30937726	chr16:31056460~31062803:+
LUAD	cis	rs897984	0.806	rs11640534	ENSG00000232748.3	RP11-196G11.6	3.91	0.000106	0.0148	0.22	0.18	Dementia with Lewy bodies;	chr16:30938194	chr16:31056460~31062803:+
LUAD	cis	rs2098713	0.534	rs6867424	ENSG00000250155.1	CTD-2353F22.1	3.91	0.000106	0.0148	0.2	0.18	Telomere length;	chr5:37534771	chr5:36666214~36725195:-
LUAD	cis	rs3812049	0.784	rs2250127	ENSG00000245937.6	LINC01184	-3.91	0.000106	0.0148	-0.26	-0.18	Lymphocyte counts;Red cell distribution width;	chr5:128053152	chr5:127940426~128083172:-
LUAD	cis	rs6452524	0.56	rs6895174	ENSG00000281327.1	LINC01338	3.91	0.000106	0.0148	0.18	0.18	Hypertension (SNP x SNP interaction);	chr5:83071606	chr5:82850864~82859836:-
LUAD	cis	rs8180040	1	rs1024037	ENSG00000271161.1	BOLA2P2	-3.91	0.000106	0.0148	-0.17	-0.18	Colorectal cancer;	chr3:47276959	chr3:47499841~47500407:+
LUAD	cis	rs365302	0.904	rs409843	ENSG00000235086.1	FNDC1-IT1	3.91	0.000106	0.0148	0.23	0.18	Coronary heart disease;	chr6:159227800	chr6:159240786~159243329:+
LUAD	cis	rs365302	1	rs418902	ENSG00000235086.1	FNDC1-IT1	3.91	0.000106	0.0148	0.23	0.18	Coronary heart disease;	chr6:159227832	chr6:159240786~159243329:+
LUAD	cis	rs365302	1	rs418901	ENSG00000235086.1	FNDC1-IT1	3.91	0.000106	0.0148	0.23	0.18	Coronary heart disease;	chr6:159227837	chr6:159240786~159243329:+
LUAD	cis	rs2732480	0.577	rs2450994	ENSG00000273765.1	RP11-370I10.11	3.91	0.000106	0.0148	0.19	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48328049	chr12:48360920~48361377:+
LUAD	cis	rs7176527	0.579	rs366717	ENSG00000259570.1	RP11-671M22.4	-3.91	0.000106	0.0148	-0.23	-0.18	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84544848	chr15:84394512~84395514:+
LUAD	cis	rs2732480	0.557	rs2634682	ENSG00000257763.1	OR5BK1P	3.91	0.000106	0.0148	0.19	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339160	chr12:48355792~48356614:-
LUAD	cis	rs4561483	0.583	rs11075030	ENSG00000261216.1	RP11-166B2.5	3.91	0.000106	0.0148	0.18	0.18	Testicular germ cell tumor;	chr16:11882557	chr16:11908208~11908916:+
LUAD	cis	rs7829975	0.871	rs777709	ENSG00000233609.3	RP11-62H7.2	-3.91	0.000106	0.0148	-0.14	-0.18	Mood instability;	chr8:8726362	chr8:8961200~8979025:+
LUAD	cis	rs6840258	0.891	rs10032710	ENSG00000251411.1	RP11-397E7.4	-3.91	0.000106	0.0148	-0.22	-0.18	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87145107	chr4:86913266~86914817:-
LUAD	cis	rs7551222	0.716	rs4951083	ENSG00000236779.1	RP11-430C7.2	-3.91	0.000106	0.0148	-0.23	-0.18	Schizophrenia;	chr1:204613602	chr1:204528845~204529692:-
LUAD	cis	rs8031584	0.697	rs798080	ENSG00000260128.5	ULK4P2	3.91	0.000106	0.0148	0.23	0.18	Huntington's disease progression;	chr15:30829966	chr15:30572738~30600647:+
LUAD	cis	rs9322193	0.566	rs9397070	ENSG00000268592.3	RAET1E-AS1	-3.91	0.000106	0.0148	-0.26	-0.18	Lung cancer;	chr6:149922073	chr6:149863494~149919507:+
LUAD	cis	rs875971	0.756	rs2901210	ENSG00000273448.1	RP11-166O4.6	-3.91	0.000106	0.0148	-0.17	-0.18	Aortic root size;	chr7:66552518	chr7:67333047~67334383:+
LUAD	cis	rs1046491	0.803	rs11081459	ENSG00000264964.1	RP11-888D10.3	3.91	0.000106	0.0148	0.37	0.18	Scarlet fever;	chr18:9107817	chr18:9315194~9334441:-
LUAD	cis	rs1046491	0.667	rs6506641	ENSG00000264964.1	RP11-888D10.3	3.91	0.000106	0.0148	0.37	0.18	Scarlet fever;	chr18:9111440	chr18:9315194~9334441:-
LUAD	cis	rs1046491	0.901	rs10502390	ENSG00000264964.1	RP11-888D10.3	3.91	0.000106	0.0148	0.37	0.18	Scarlet fever;	chr18:9113232	chr18:9315194~9334441:-
LUAD	cis	rs2154319	0.887	rs11555079	ENSG00000235358.1	RP11-399E6.1	-3.91	0.000106	0.0148	-0.24	-0.18	Height;	chr1:41028077	chr1:41242373~41284861:+
LUAD	cis	rs763121	0.853	rs6001188	ENSG00000228274.3	RP3-508I15.9	-3.91	0.000106	0.0148	-0.17	-0.18	Menopause (age at onset);	chr22:38666189	chr22:38667585~38681820:-
LUAD	cis	rs6687758	1	rs12739936	ENSG00000238042.4	RP11-815M8.1	3.91	0.000106	0.0148	0.25	0.18	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222009847	chr1:221880981~221978523:-
LUAD	cis	rs2732480	0.577	rs2732466	ENSG00000273765.1	RP11-370I10.11	3.91	0.000106	0.0148	0.19	0.18	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48338676	chr12:48360920~48361377:+
LUAD	cis	rs911119	0.913	rs13043610	ENSG00000270001.1	RP11-218C14.8	-3.91	0.000106	0.0148	-0.27	-0.18	Chronic kidney disease;	chr20:23606304	chr20:23631826~23632316:-
LUAD	cis	rs9583531	0.509	rs12184676	ENSG00000229152.2	ANKRD10-IT1	-3.91	0.000106	0.0148	-0.17	-0.18	Coronary artery disease;	chr13:110744137	chr13:110894639~110899172:-
LUAD	cis	rs2348418	0.647	rs938081	ENSG00000247934.4	RP11-967K21.1	3.91	0.000106	0.0148	0.2	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28567680	chr12:28163298~28190738:-
LUAD	cis	rs7937682	0.961	rs11601674	ENSG00000230911.1	PPIHP1	-3.91	0.000106	0.0148	-0.23	-0.18	Primary sclerosing cholangitis;	chr11:111763630	chr11:112029858~112030367:-
LUAD	cis	rs2904524	0.588	rs60881781	ENSG00000257815.4	RP11-611E13.2	-3.91	0.000106	0.0148	-0.22	-0.18	Amyotrophic lateral sclerosis (age of onset);	chr12:70373544	chr12:69904033~70243360:-
LUAD	cis	rs2836974	0.897	rs2026267	ENSG00000232608.1	TIMM9P2	-3.91	0.000106	0.0148	-0.21	-0.18	Cognitive function;	chr21:39339551	chr21:39216624~39217506:+
LUAD	cis	rs2836974	0.897	rs35123057	ENSG00000232608.1	TIMM9P2	-3.91	0.000106	0.0148	-0.21	-0.18	Cognitive function;	chr21:39339763	chr21:39216624~39217506:+
LUAD	cis	rs9309473	1	rs7580825	ENSG00000230002.2	ALMS1-IT1	3.91	0.000106	0.0148	0.23	0.18	Metabolite levels;	chr2:73408020	chr2:73456764~73459484:+
LUAD	cis	rs2688608	1	rs2688608	ENSG00000271816.1	BMS1P4	3.91	0.000106	0.0148	0.14	0.18	Inflammatory bowel disease;	chr10:73898591	chr10:73699151~73730487:-
LUAD	cis	rs5742933	0.817	rs1055091	ENSG00000253559.1	OSGEPL1-AS1	3.91	0.000106	0.0148	0.21	0.18	Ferritin levels;	chr2:189770417	chr2:189762704~189765556:+
LUAD	cis	rs5742933	0.817	rs6942	ENSG00000253559.1	OSGEPL1-AS1	3.91	0.000106	0.0148	0.21	0.18	Ferritin levels;	chr2:189771685	chr2:189762704~189765556:+
LUAD	cis	rs7017914	0.967	rs1902614	ENSG00000246366.5	RP11-382J12.1	3.91	0.000106	0.0148	0.16	0.18	Bone mineral density;	chr8:70743932	chr8:70608577~70663279:+
LUAD	cis	rs9928842	0.765	rs6564221	ENSG00000261476.1	RP11-77K12.3	-3.91	0.000106	0.0148	-0.24	-0.18	Alcoholic chronic pancreatitis;	chr16:75191073	chr16:75458252~75460017:-
LUAD	cis	rs3770081	1	rs12617717	ENSG00000273080.1	RP11-301O19.1	-3.91	0.000106	0.0148	-0.43	-0.18	Facial emotion recognition (sad faces);	chr2:86115180	chr2:86195590~86196049:+
LUAD	cis	rs61542988	0.57	rs62448267	ENSG00000228649.7	AC005682.5	3.91	0.000106	0.0148	0.26	0.18	Fibrinogen levels;	chr7:22782882	chr7:22854178~22861579:+
LUAD	cis	rs9467773	0.62	rs2451711	ENSG00000241549.7	GUSBP2	3.91	0.000106	0.0148	0.19	0.18	Intelligence (multi-trait analysis);	chr6:26662882	chr6:26871484~26956554:-
LUAD	cis	rs7503168	0.558	rs71381469	ENSG00000267592.1	CTC-507E2.2	3.91	0.000106	0.0148	0.37	0.18	Plateletcrit;	chr17:35712127	chr17:35596904~35597128:-
LUAD	cis	rs11051970	0.879	rs73081911	ENSG00000274964.1	RP11-817I4.1	-3.91	0.000106	0.0148	-0.21	-0.18	Response to tocilizumab in rheumatoid arthritis;	chr12:32386190	chr12:32339368~32340724:+
LUAD	cis	rs7572733	0.935	rs700669	ENSG00000222017.1	AC011997.1	3.91	0.000106	0.0148	0.22	0.18	Dermatomyositis;	chr2:197819743	chr2:197693106~197774823:+
LUAD	cis	rs67981189	0.727	rs221903	ENSG00000269927.1	RP6-91H8.3	-3.91	0.000106	0.0148	-0.22	-0.18	Schizophrenia;	chr14:71133491	chr14:71141125~71143253:-
LUAD	cis	rs8014252	0.803	rs74062733	ENSG00000259158.2	ADAM20P1	-3.91	0.000106	0.0148	-0.31	-0.18	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70528677	chr14:70468881~70483756:-
LUAD	cis	rs4268898	0.722	rs12185638	ENSG00000223754.1	AC008073.9	-3.91	0.000106	0.0148	-0.21	-0.18	Asthma;	chr2:24159160	chr2:24199839~24201698:-
LUAD	cis	rs4268898	0.722	rs4665253	ENSG00000223754.1	AC008073.9	-3.91	0.000106	0.0148	-0.21	-0.18	Asthma;	chr2:24159676	chr2:24199839~24201698:-
LUAD	cis	rs2333021	0.833	rs10141389	ENSG00000259015.1	RP11-109N23.6	3.91	0.000106	0.0148	0.17	0.18	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73000413	chr14:72960595~72961993:+
LUAD	cis	rs683250	0.63	rs2507851	ENSG00000246067.6	RAB30-AS1	-3.91	0.000106	0.0148	-0.18	-0.18	Subcortical brain region volumes;	chr11:83408070	chr11:83072066~83106719:+
LUAD	cis	rs9650657	0.537	rs7016385	ENSG00000255046.1	RP11-297N6.4	-3.91	0.000106	0.0148	-0.22	-0.18	Neuroticism;	chr8:10921962	chr8:11797928~11802568:-
LUAD	cis	rs1862618	0.853	rs252922	ENSG00000271828.1	CTD-2310F14.1	3.91	0.000106	0.0148	0.25	0.18	Initial pursuit acceleration;	chr5:56840516	chr5:56927874~56929573:+
LUAD	cis	rs9287719	0.967	rs12467642	ENSG00000243819.4	RN7SL832P	3.91	0.000106	0.0148	0.18	0.18	Prostate cancer;	chr2:10621358	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs12464908	ENSG00000243819.4	RN7SL832P	3.91	0.000106	0.0148	0.18	0.18	Prostate cancer;	chr2:10621370	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs7563816	ENSG00000243819.4	RN7SL832P	3.91	0.000106	0.0148	0.18	0.18	Prostate cancer;	chr2:10623274	chr2:10690344~10692099:+
LUAD	cis	rs12216545	0.765	rs6464080	ENSG00000177590.7	GIMAP3P	-3.91	0.000106	0.0148	-0.18	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150563300	chr7:150746893~150747728:-
LUAD	cis	rs4474465	1	rs11237514	ENSG00000251323.2	RP11-452H21.4	3.91	0.000106	0.0148	0.23	0.18	Alzheimer's disease (survival time);	chr11:78469133	chr11:78423982~78429836:-
LUAD	cis	rs8067545	0.641	rs1638525	ENSG00000270091.1	RP11-78O7.2	-3.91	0.000106	0.0148	-0.15	-0.18	Schizophrenia;	chr17:19945281	chr17:19896590~19897287:-
LUAD	cis	rs12554020	0.686	rs12553775	ENSG00000227603.1	RP11-165J3.6	3.91	0.000106	0.0148	0.34	0.18	Schizophrenia;	chr9:93630107	chr9:93435332~93437121:-
LUAD	cis	rs7429990	0.901	rs7431567	ENSG00000228638.1	FCF1P2	3.91	0.000106	0.0148	0.22	0.18	Educational attainment (years of education);	chr3:47986342	chr3:48290793~48291375:-
LUAD	cis	rs7119038	0.818	rs10892294	ENSG00000255422.1	AP002954.4	-3.91	0.000106	0.0148	-0.26	-0.18	Sjögren's syndrome;	chr11:118796648	chr11:118704607~118750263:+
LUAD	cis	rs13260300	0.533	rs890219	ENSG00000249395.2	CASC9	3.91	0.000106	0.0148	0.2	0.18	Breast cancer-free interval (treatment with aromatase inhibitor);	chr8:74581235	chr8:75223404~75324741:-
LUAD	cis	rs5015933	0.902	rs13291306	ENSG00000232630.1	PRPS1P2	-3.91	0.000106	0.0148	-0.16	-0.18	Body mass index;	chr9:125362519	chr9:125150653~125151589:+
LUAD	cis	rs7617773	0.78	rs11718350	ENSG00000199476.1	Y_RNA	-3.91	0.000106	0.0148	-0.24	-0.18	Coronary artery disease;	chr3:48319502	chr3:48288587~48288694:+
LUAD	cis	rs67981189	0.896	rs2526878	ENSG00000269927.1	RP6-91H8.3	-3.91	0.000106	0.0148	-0.22	-0.18	Schizophrenia;	chr14:70910578	chr14:71141125~71143253:-
LUAD	cis	rs67981189	0.865	rs2526876	ENSG00000269927.1	RP6-91H8.3	-3.91	0.000106	0.0148	-0.22	-0.18	Schizophrenia;	chr14:70911471	chr14:71141125~71143253:-
LUAD	cis	rs67981189	0.896	rs2526874	ENSG00000269927.1	RP6-91H8.3	-3.91	0.000106	0.0148	-0.22	-0.18	Schizophrenia;	chr14:70914502	chr14:71141125~71143253:-
LUAD	cis	rs6964587	1	rs9785013	ENSG00000188693.7	CYP51A1-AS1	-3.91	0.000106	0.0149	-0.2	-0.18	Breast cancer;	chr7:92044988	chr7:92134604~92180725:+
LUAD	cis	rs11089937	0.589	rs4239891	ENSG00000211640.3	IGLV6-57	3.91	0.000106	0.0149	0.12	0.18	Periodontitis (PAL4Q3);	chr22:22165674	chr22:22195713~22196460:+
LUAD	cis	rs7942368	0.793	rs12273016	ENSG00000254632.1	RP11-21L23.4	-3.91	0.000106	0.0149	-0.18	-0.18	Endometriosis;	chr11:76779672	chr11:76759916~76768223:-
LUAD	cis	rs5015933	0.788	rs372225	ENSG00000232630.1	PRPS1P2	-3.91	0.000106	0.0149	-0.17	-0.18	Body mass index;	chr9:125261770	chr9:125150653~125151589:+
LUAD	cis	rs2098713	0.569	rs62359006	ENSG00000250155.1	CTD-2353F22.1	3.91	0.000106	0.0149	0.19	0.18	Telomere length;	chr5:37510947	chr5:36666214~36725195:-
LUAD	cis	rs2098713	0.569	rs35624889	ENSG00000250155.1	CTD-2353F22.1	3.91	0.000106	0.0149	0.19	0.18	Telomere length;	chr5:37514162	chr5:36666214~36725195:-
LUAD	cis	rs2098713	0.569	rs36186847	ENSG00000250155.1	CTD-2353F22.1	3.91	0.000106	0.0149	0.19	0.18	Telomere length;	chr5:37514268	chr5:36666214~36725195:-
LUAD	cis	rs2098713	0.534	rs12515702	ENSG00000250155.1	CTD-2353F22.1	3.91	0.000106	0.0149	0.19	0.18	Telomere length;	chr5:37520773	chr5:36666214~36725195:-
LUAD	cis	rs2348418	0.932	rs7136429	ENSG00000247934.4	RP11-967K21.1	3.91	0.000106	0.0149	0.2	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28460306	chr12:28163298~28190738:-
LUAD	cis	rs6951245	0.745	rs79788515	ENSG00000199023.2	MIR339	-3.91	0.000106	0.0149	-0.32	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061443	chr7:1022935~1023045:-
LUAD	cis	rs2731006	0.591	rs73130905	ENSG00000257114.2	RP11-25I15.3	3.91	0.000106	0.0149	0.29	0.18	Panic disorder;	chr12:42811200	chr12:42692216~42717119:+
LUAD	cis	rs2554380	0.843	rs2554386	ENSG00000259570.1	RP11-671M22.4	3.91	0.000106	0.0149	0.25	0.18	Height;	chr15:83734770	chr15:84394512~84395514:+
LUAD	cis	rs7829975	0.667	rs1877119	ENSG00000253981.4	ALG1L13P	3.91	0.000106	0.0149	0.2	0.18	Mood instability;	chr8:8849687	chr8:8236003~8244667:-
LUAD	cis	rs10129255	0.719	rs7156660	ENSG00000211947.2	IGHV3-21	-3.91	0.000107	0.0149	-0.12	-0.18	Kawasaki disease;	chr14:106673171	chr14:106235064~106235594:-
LUAD	cis	rs1542829	0.516	rs2198387	ENSG00000253540.4	FAM86HP	3.91	0.000107	0.0149	0.22	0.18	Body mass index;	chr3:130400820	chr3:130099092~130111472:-
LUAD	cis	rs9341808	0.935	rs942381	ENSG00000260645.1	RP11-250B2.5	3.91	0.000107	0.0149	0.16	0.18	Sitting height ratio;	chr6:80170433	chr6:80466958~80469080:+
LUAD	cis	rs6095360	0.727	rs7274612	ENSG00000177410.11	ZFAS1	-3.91	0.000107	0.0149	-0.19	-0.18	Intelligence (multi-trait analysis);	chr20:49086284	chr20:49278178~49295738:+
LUAD	cis	rs4705962	0.765	rs10036532	ENSG00000233006.5	AC034220.3	3.91	0.000107	0.0149	0.17	0.18	Atopic dermatitis;	chr5:132710123	chr5:132311285~132369916:-
LUAD	cis	rs4705962	0.796	rs11740584	ENSG00000233006.5	AC034220.3	3.91	0.000107	0.0149	0.17	0.18	Atopic dermatitis;	chr5:132711097	chr5:132311285~132369916:-
LUAD	cis	rs7937127	0.744	rs10501297	ENSG00000254907.1	RP11-484D2.2	3.91	0.000107	0.0149	0.31	0.18	Fibrinogen levels;	chr11:43400172	chr11:43328748~43359296:-
LUAD	cis	rs3096299	0.563	rs4600467	ENSG00000261118.1	RP11-104N10.1	3.91	0.000107	0.0149	0.18	0.18	Multiple myeloma (IgH translocation);	chr16:89496108	chr16:89492017~89504460:-
LUAD	cis	rs13113518	0.812	rs13116035	ENSG00000273257.1	RP11-177J6.1	3.91	0.000107	0.0149	0.2	0.18	Height;	chr4:55561218	chr4:55387949~55388271:+
LUAD	cis	rs2299587	0.527	rs7843715	ENSG00000253671.1	RP11-806O11.1	-3.91	0.000107	0.0149	-0.17	-0.18	Economic and political preferences;	chr8:17876017	chr8:17808941~17820868:+
LUAD	cis	rs6071166	0.901	rs6027421	ENSG00000224635.1	RP4-564F22.5	-3.91	0.000107	0.0149	-0.19	-0.18	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38703616	chr20:38406011~38416797:-
LUAD	cis	rs4499344	0.556	rs259228	ENSG00000201388.1	SNORA68	3.91	0.000107	0.0149	0.2	0.18	Mean platelet volume;	chr19:32643729	chr19:32608337~32608469:-
LUAD	cis	rs453301	0.538	rs7830804	ENSG00000254340.1	RP11-10A14.3	-3.91	0.000107	0.0149	-0.21	-0.18	Joint mobility (Beighton score);	chr8:9113252	chr8:9141424~9145435:+
LUAD	cis	rs189798	0.738	rs330908	ENSG00000253893.2	FAM85B	-3.91	0.000107	0.0149	-0.23	-0.18	Myopia (pathological);	chr8:9137656	chr8:8167819~8226614:-
LUAD	cis	rs7119038	0.818	rs56043232	ENSG00000255239.1	AP002954.6	-3.91	0.000107	0.0149	-0.26	-0.18	Sjögren's syndrome;	chr11:118777664	chr11:118688039~118690600:-
LUAD	cis	rs10208649	0.831	rs75447473	ENSG00000233266.1	HMGB1P31	3.91	0.000107	0.0149	0.52	0.18	Body mass index;	chr2:54077507	chr2:54051334~54051760:+
LUAD	cis	rs17772222	1	rs17772064	ENSG00000258789.1	RP11-507K2.3	-3.91	0.000107	0.0149	-0.23	-0.18	Coronary artery calcification;	chr14:88356527	chr14:88551597~88552493:+
LUAD	cis	rs7829975	1	rs7829975	ENSG00000173295.6	FAM86B3P	-3.91	0.000107	0.0149	-0.18	-0.18	Mood instability;	chr8:8690607	chr8:8228595~8244865:+
LUAD	cis	rs12440869	1	rs10851773	ENSG00000270964.1	RP11-502I4.3	-3.91	0.000107	0.0149	-0.2	-0.18	Peak velocity of the mitral A-wave;	chr15:67298007	chr15:67541072~67542604:-
LUAD	cis	rs12440869	1	rs4776918	ENSG00000270964.1	RP11-502I4.3	-3.91	0.000107	0.0149	-0.2	-0.18	Peak velocity of the mitral A-wave;	chr15:67312152	chr15:67541072~67542604:-
LUAD	cis	rs12440869	1	rs975946	ENSG00000270964.1	RP11-502I4.3	-3.91	0.000107	0.0149	-0.2	-0.18	Peak velocity of the mitral A-wave;	chr15:67316267	chr15:67541072~67542604:-
LUAD	cis	rs2731006	0.64	rs1517672	ENSG00000257114.2	RP11-25I15.3	3.91	0.000107	0.0149	0.28	0.18	Panic disorder;	chr12:42780156	chr12:42692216~42717119:+
LUAD	cis	rs858239	0.6	rs10266123	ENSG00000226816.2	AC005082.12	3.91	0.000107	0.0149	0.23	0.18	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23206013~23208045:+
LUAD	cis	rs17164851	0.636	rs67016751	ENSG00000226380.6	AC058791.1	3.91	0.000107	0.0149	0.28	0.18	Age-related hearing impairment (SNP x SNP interaction);	chr7:130347941	chr7:130876809~130913310:-
LUAD	cis	rs7302981	0.746	rs836172	ENSG00000200428.1	Y_RNA	-3.91	0.000107	0.0149	-0.21	-0.18	Systolic blood pressure;	chr12:50096316	chr12:50743568~50743684:+
LUAD	cis	rs8012947	1	rs10145481	ENSG00000279636.2	LINC00216	-3.91	0.000107	0.0149	-0.19	-0.18	Alcohol consumption in current drinkers;	chr14:58303671	chr14:58288033~58289158:+
LUAD	cis	rs8012947	0.959	rs1951204	ENSG00000279636.2	LINC00216	-3.91	0.000107	0.0149	-0.19	-0.18	Alcohol consumption in current drinkers;	chr14:58303983	chr14:58288033~58289158:+
LUAD	cis	rs11671005	0.735	rs56292587	ENSG00000268543.1	CTD-2619J13.16	-3.91	0.000107	0.0149	-0.25	-0.18	Mean platelet volume;	chr19:58407699	chr19:58418560~58419310:+
LUAD	cis	rs11671005	0.735	rs56290606	ENSG00000268543.1	CTD-2619J13.16	-3.91	0.000107	0.0149	-0.25	-0.18	Mean platelet volume;	chr19:58407953	chr19:58418560~58419310:+
LUAD	cis	rs11671005	0.735	rs11878198	ENSG00000268543.1	CTD-2619J13.16	-3.91	0.000107	0.0149	-0.25	-0.18	Mean platelet volume;	chr19:58408935	chr19:58418560~58419310:+
LUAD	cis	rs11671005	0.735	rs11666716	ENSG00000268543.1	CTD-2619J13.16	-3.91	0.000107	0.0149	-0.25	-0.18	Mean platelet volume;	chr19:58409585	chr19:58418560~58419310:+
LUAD	cis	rs11671005	0.735	rs34511020	ENSG00000268543.1	CTD-2619J13.16	-3.91	0.000107	0.0149	-0.25	-0.18	Mean platelet volume;	chr19:58409929	chr19:58418560~58419310:+
LUAD	cis	rs11671005	0.735	rs11666303	ENSG00000268543.1	CTD-2619J13.16	-3.91	0.000107	0.0149	-0.25	-0.18	Mean platelet volume;	chr19:58411135	chr19:58418560~58419310:+
LUAD	cis	rs11671005	0.735	rs34152946	ENSG00000268543.1	CTD-2619J13.16	-3.91	0.000107	0.0149	-0.25	-0.18	Mean platelet volume;	chr19:58411896	chr19:58418560~58419310:+
LUAD	cis	rs791888	1	rs2762521	ENSG00000225913.2	RP11-57C13.6	3.91	0.000107	0.0149	0.22	0.18	Magnesium levels;	chr10:87655166	chr10:87607985~87659279:+
LUAD	cis	rs2613514	1	rs60105040	ENSG00000204282.4	TNRC6C-AS1	-3.91	0.000107	0.0149	-0.28	-0.18	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr17:78102867	chr17:78107398~78111799:-
LUAD	cis	rs7512552	0.839	rs4581308	ENSG00000275557.1	RP11-353N4.6	-3.91	0.000107	0.0149	-0.2	-0.18	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150304444	chr1:149607765~149612402:+
LUAD	cis	rs2929278	0.736	rs2412823	ENSG00000166763.7	STRCP1	-3.91	0.000107	0.0149	-0.2	-0.18	Schizophrenia;	chr15:43935072	chr15:43699488~43718184:-
LUAD	cis	rs6487679	0.526	rs7305336	ENSG00000111788.10	RP11-22B23.1	3.91	0.000107	0.0149	0.16	0.18	Non-alcoholic fatty liver disease histology (AST);	chr12:9222493	chr12:9277235~9313241:+
LUAD	cis	rs2625529	0.652	rs2899775	ENSG00000260173.1	RP11-2I17.4	3.91	0.000107	0.0149	0.21	0.18	Red blood cell count;	chr15:71976013	chr15:72140504~72155459:-
LUAD	cis	rs706293	0.512	rs17318936	ENSG00000261360.1	CTD-2165H16.4	-3.91	0.000107	0.0149	-0.16	-0.18	Urate levels (BMI interaction);	chr5:14840291	chr5:14661808~14664604:-
LUAD	cis	rs6910061	0.512	rs67794216	ENSG00000247925.2	RP3-510L9.1	-3.91	0.000107	0.0149	-0.25	-0.18	Diabetic kidney disease;	chr6:11113976	chr6:11173452~11259099:+
LUAD	cis	rs896854	0.552	rs2515236	ENSG00000253528.2	RP11-347C18.4	-3.91	0.000107	0.0149	-0.19	-0.18	Type 2 diabetes;	chr8:94922679	chr8:94974573~94974853:-
LUAD	cis	rs11089937	0.626	rs4821784	ENSG00000211640.3	IGLV6-57	3.91	0.000107	0.0149	0.14	0.18	Periodontitis (PAL4Q3);	chr22:22143513	chr22:22195713~22196460:+
LUAD	cis	rs1023500	0.552	rs133368	ENSG00000205702.9	CYP2D7	3.91	0.000107	0.015	0.14	0.18	Schizophrenia;	chr22:42067685	chr22:42140203~42144577:-
LUAD	cis	rs6071166	0.774	rs6027213	ENSG00000224635.1	RP4-564F22.5	-3.91	0.000107	0.015	-0.19	-0.18	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38676778	chr20:38406011~38416797:-
LUAD	cis	rs13434995	0.513	rs41324951	ENSG00000273257.1	RP11-177J6.1	3.91	0.000107	0.015	0.23	0.18	Adiponectin levels;	chr4:55422576	chr4:55387949~55388271:+
LUAD	cis	rs73242632	0.881	rs10034395	ENSG00000269949.1	RP11-738E22.3	3.91	0.000107	0.015	0.43	0.18	Congenital heart disease (maternal effect);	chr4:56996965	chr4:56960927~56961373:-
LUAD	cis	rs73242632	1	rs73242632	ENSG00000269949.1	RP11-738E22.3	3.91	0.000107	0.015	0.43	0.18	Congenital heart disease (maternal effect);	chr4:57027604	chr4:56960927~56961373:-
LUAD	cis	rs73242632	1	rs28623722	ENSG00000269949.1	RP11-738E22.3	3.91	0.000107	0.015	0.43	0.18	Congenital heart disease (maternal effect);	chr4:57029598	chr4:56960927~56961373:-
LUAD	cis	rs9287719	0.967	rs6735074	ENSG00000243819.4	RN7SL832P	-3.91	0.000107	0.015	-0.18	-0.18	Prostate cancer;	chr2:10594640	chr2:10690344~10692099:+
LUAD	cis	rs2274273	0.624	rs10143136	ENSG00000258413.1	RP11-665C16.6	-3.91	0.000107	0.015	-0.24	-0.18	Protein biomarker;	chr14:55276810	chr14:55262767~55272075:-
LUAD	cis	rs7172677	0.737	rs7178625	ENSG00000260269.4	CTD-2323K18.1	-3.91	0.000107	0.015	-0.23	-0.18	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75148676	chr15:75527150~75601205:-
LUAD	cis	rs7824557	0.527	rs2736305	ENSG00000255046.1	RP11-297N6.4	3.91	0.000107	0.015	0.22	0.18	Retinal vascular caliber;	chr8:11380264	chr8:11797928~11802568:-
LUAD	cis	rs7772486	0.782	rs7747576	ENSG00000235652.6	RP11-545I5.3	-3.91	0.000107	0.015	-0.18	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145956691	chr6:145799409~145886585:+
LUAD	cis	rs9926296	0.605	rs12709094	ENSG00000260259.1	RP11-368I7.4	-3.91	0.000107	0.015	-0.17	-0.18	Vitiligo;	chr16:89786609	chr16:89682620~89686569:-
LUAD	cis	rs360798	0.723	rs1386400	ENSG00000231609.4	AC009501.4	3.91	0.000107	0.015	0.2	0.18	Coronary artery disease;	chr2:62671513	chr2:63043922~63048640:-
LUAD	cis	rs7674212	0.539	rs6821617	ENSG00000251288.2	RP11-10L12.2	-3.91	0.000107	0.015	-0.22	-0.18	Type 2 diabetes;	chr4:103207253	chr4:102751401~102752641:+
LUAD	cis	rs7590268	0.806	rs6544652	ENSG00000279873.2	LINC01126	3.91	0.000107	0.015	0.17	0.18	Orofacial clefts;	chr2:43399073	chr2:43227210~43228855:+
LUAD	cis	rs638893	0.898	rs587816	ENSG00000255239.1	AP002954.6	3.91	0.000107	0.015	0.27	0.18	Vitiligo;	chr11:118819162	chr11:118688039~118690600:-
LUAD	cis	rs14027	0.512	rs6469841	ENSG00000279347.1	RP11-85I17.2	-3.91	0.000107	0.015	-0.15	-0.18	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119721889	chr8:119838736~119840385:-
LUAD	cis	rs7178375	1	rs10163148	ENSG00000270015.1	RP11-540B6.6	3.91	0.000107	0.015	0.16	0.18	Hypertriglyceridemia;	chr15:30920481	chr15:30926514~30928407:+
LUAD	cis	rs287982	0.611	rs79276033	ENSG00000269973.1	RP11-95D17.1	-3.91	0.000107	0.015	-0.25	-0.18	Nonsyndromic cleft lip with cleft palate;	chr2:9835868	chr2:9936360~9939590:+
LUAD	cis	rs4072980	0.545	rs7528185	ENSG00000212541.1	RNU6-510P	3.91	0.000107	0.015	0.23	0.18	Coronary artery disease;	chr1:37986387	chr1:37991462~37991569:+
LUAD	cis	rs6964587	1	rs13231578	ENSG00000188693.7	CYP51A1-AS1	-3.91	0.000107	0.015	-0.2	-0.18	Breast cancer;	chr7:92033952	chr7:92134604~92180725:+
LUAD	cis	rs911555	0.723	rs11160751	ENSG00000244691.1	RPL10AP1	-3.91	0.000107	0.015	-0.23	-0.18	Intelligence (multi-trait analysis);	chr14:103459403	chr14:103412119~103412761:-
LUAD	cis	rs10129255	0.957	rs4387509	ENSG00000211947.2	IGHV3-21	-3.91	0.000107	0.015	-0.12	-0.18	Kawasaki disease;	chr14:106704386	chr14:106235064~106235594:-
LUAD	cis	rs116095464	0.558	rs2288458	ENSG00000248925.1	CTD-2083E4.6	3.91	0.000108	0.015	0.29	0.18	Breast cancer;	chr5:231145	chr5:269858~271516:-
LUAD	cis	rs10463554	0.857	rs3776871	ENSG00000250682.4	LINC00491	3.91	0.000108	0.015	0.21	0.18	Parkinson's disease;	chr5:102956507	chr5:102609156~102671559:-
LUAD	cis	rs7578361	1	rs6744828	ENSG00000231969.1	AC144449.1	-3.91	0.000108	0.015	-0.26	-0.18	Acute lymphoblastic leukemia (childhood);	chr2:149574824	chr2:149587196~149848233:+
LUAD	cis	rs7578361	0.959	rs4413131	ENSG00000231969.1	AC144449.1	-3.91	0.000108	0.015	-0.26	-0.18	Acute lymphoblastic leukemia (childhood);	chr2:149577445	chr2:149587196~149848233:+
LUAD	cis	rs7578361	0.959	rs7580915	ENSG00000231969.1	AC144449.1	-3.91	0.000108	0.015	-0.26	-0.18	Acute lymphoblastic leukemia (childhood);	chr2:149581520	chr2:149587196~149848233:+
LUAD	cis	rs30380	0.573	rs469783	ENSG00000272109.1	CTD-2260A17.3	-3.91	0.000108	0.015	-0.18	-0.18	Cerebrospinal fluid biomarker levels;	chr5:96785820	chr5:96804353~96806105:+
LUAD	cis	rs11742741	1	rs2331579	ENSG00000248874.4	C5orf17	-3.91	0.000108	0.015	-0.22	-0.18	Educational attainment;	chr5:24157646	chr5:23951348~24178263:+
LUAD	cis	rs11742741	0.967	rs56043326	ENSG00000248874.4	C5orf17	-3.91	0.000108	0.015	-0.22	-0.18	Educational attainment;	chr5:24158848	chr5:23951348~24178263:+
LUAD	cis	rs2274273	0.901	rs112870553	ENSG00000258413.1	RP11-665C16.6	-3.91	0.000108	0.015	-0.22	-0.18	Protein biomarker;	chr14:55323344	chr14:55262767~55272075:-
LUAD	cis	rs12073837	0.5	rs4143772	ENSG00000272823.1	RP11-295M18.6	-3.91	0.000108	0.015	-0.19	-0.18	F-cell distribution;	chr1:220815004	chr1:220828676~220829211:-
LUAD	cis	rs939960	0.69	rs56279394	ENSG00000279536.1	RP11-445N20.2	3.91	0.000108	0.015	0.24	0.18	Neutrophil percentage of white cells;	chr7:150678124	chr7:149881477~149882105:+
LUAD	cis	rs2708977	0.608	rs631033	ENSG00000237510.6	AC008268.2	-3.91	0.000108	0.015	-0.23	-0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96424693	chr2:95789654~95800166:+
LUAD	cis	rs7674212	0.539	rs6850461	ENSG00000251288.2	RP11-10L12.2	-3.91	0.000108	0.015	-0.22	-0.18	Type 2 diabetes;	chr4:103198884	chr4:102751401~102752641:+
LUAD	cis	rs6088580	0.634	rs2424992	ENSG00000276073.1	RP5-1125A11.7	-3.9	0.000108	0.015	-0.17	-0.18	Glomerular filtration rate (creatinine);	chr20:34424254	chr20:33985617~33988989:-
LUAD	cis	rs6088580	0.634	rs6119497	ENSG00000276073.1	RP5-1125A11.7	-3.9	0.000108	0.015	-0.17	-0.18	Glomerular filtration rate (creatinine);	chr20:34424723	chr20:33985617~33988989:-
LUAD	cis	rs6088580	0.634	rs6120642	ENSG00000276073.1	RP5-1125A11.7	-3.9	0.000108	0.015	-0.17	-0.18	Glomerular filtration rate (creatinine);	chr20:34424725	chr20:33985617~33988989:-
LUAD	cis	rs4879677	1	rs4879677	ENSG00000215441.3	CTAGE12P	3.9	0.000108	0.015	0.22	0.18	Gut microbiome composition (summer and winter);	chr9:27664434	chr9:27608382~27610745:-
LUAD	cis	rs5015933	0.815	rs10114168	ENSG00000232630.1	PRPS1P2	-3.9	0.000108	0.015	-0.16	-0.18	Body mass index;	chr9:125273170	chr9:125150653~125151589:+
LUAD	cis	rs6951245	0.872	rs75493422	ENSG00000199023.2	MIR339	-3.9	0.000108	0.015	-0.31	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1033254	chr7:1022935~1023045:-
LUAD	cis	rs6951245	1	rs79765398	ENSG00000199023.2	MIR339	-3.9	0.000108	0.015	-0.31	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1034128	chr7:1022935~1023045:-
LUAD	cis	rs17818399	0.547	rs13020299	ENSG00000279254.1	RP11-536C12.1	-3.9	0.000108	0.015	-0.2	-0.18	Height;	chr2:46531578	chr2:46668870~46670778:+
LUAD	cis	rs17711722	0.565	rs4275112	ENSG00000273024.4	INTS4P2	3.9	0.000108	0.015	0.19	0.18	Calcium levels;	chr7:65733651	chr7:65647864~65715661:+
LUAD	cis	rs3018712	0.526	rs6591352	ENSG00000227620.4	ALG1L8P	-3.9	0.000108	0.015	-0.24	-0.18	Total body bone mineral density;	chr11:68720045	chr11:67785273~67792335:+
LUAD	cis	rs2625529	0.73	rs2929527	ENSG00000260173.1	RP11-2I17.4	3.9	0.000108	0.015	0.21	0.18	Red blood cell count;	chr15:71989929	chr15:72140504~72155459:-
LUAD	cis	rs6964587	0.933	rs10271174	ENSG00000188693.7	CYP51A1-AS1	-3.9	0.000108	0.015	-0.21	-0.18	Breast cancer;	chr7:92156656	chr7:92134604~92180725:+
LUAD	cis	rs703842	0.616	rs4760171	ENSG00000245651.2	RP11-620J15.2	3.9	0.000108	0.015	0.18	0.18	Multiple sclerosis;	chr12:57832121	chr12:57869835~57896482:-
LUAD	cis	rs523522	0.962	rs1050187	ENSG00000278344.1	RP11-18C24.8	-3.9	0.000108	0.015	-0.24	-0.18	High light scatter reticulocyte count;	chr12:120464308	chr12:120500735~120501090:-
LUAD	cis	rs7129556	0.645	rs684813	ENSG00000241782.1	RP11-91P24.1	3.9	0.000108	0.015	0.26	0.18	Weight loss (gastric bypass surgery);	chr11:77783708	chr11:77868722~77869195:-
LUAD	cis	rs73198271	0.74	rs10100066	ENSG00000253893.2	FAM85B	3.9	0.000108	0.015	0.23	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792883	chr8:8167819~8226614:-
LUAD	cis	rs73198271	0.74	rs10110711	ENSG00000253893.2	FAM85B	3.9	0.000108	0.015	0.23	0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792946	chr8:8167819~8226614:-
LUAD	cis	rs12754538	0.677	rs6690548	ENSG00000232912.4	RP5-1115A15.1	-3.9	0.000108	0.015	-0.2	-0.18	Subjective well-being;	chr1:8342951	chr1:8424645~8434838:+
LUAD	cis	rs9549260	0.755	rs17061491	ENSG00000229456.1	RLIMP1	3.9	0.000108	0.015	0.19	0.18	Red blood cell count;	chr13:40654073	chr13:40618738~40621348:+
LUAD	cis	rs7829975	0.714	rs6994038	ENSG00000233609.3	RP11-62H7.2	3.9	0.000108	0.015	0.14	0.18	Mood instability;	chr8:8803028	chr8:8961200~8979025:+
LUAD	cis	rs6964587	0.9	rs7783674	ENSG00000188693.7	CYP51A1-AS1	-3.9	0.000108	0.015	-0.21	-0.18	Breast cancer;	chr7:92154898	chr7:92134604~92180725:+
LUAD	cis	rs7005380	0.579	rs7465181	ENSG00000279347.1	RP11-85I17.2	-3.9	0.000108	0.015	-0.15	-0.18	Interstitial lung disease;	chr8:119896349	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.62	rs7462250	ENSG00000279347.1	RP11-85I17.2	-3.9	0.000108	0.015	-0.15	-0.18	Interstitial lung disease;	chr8:119896367	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.62	rs13281299	ENSG00000279347.1	RP11-85I17.2	-3.9	0.000108	0.015	-0.15	-0.18	Interstitial lung disease;	chr8:119897253	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.62	rs7832923	ENSG00000279347.1	RP11-85I17.2	-3.9	0.000108	0.015	-0.15	-0.18	Interstitial lung disease;	chr8:119897540	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.62	rs6469861	ENSG00000279347.1	RP11-85I17.2	-3.9	0.000108	0.015	-0.15	-0.18	Interstitial lung disease;	chr8:119897673	chr8:119838736~119840385:-
LUAD	cis	rs2745572	0.752	rs7739648	ENSG00000272279.1	RP11-157J24.2	3.9	0.000108	0.015	0.22	0.18	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1540248	chr6:1528364~1528911:-
LUAD	cis	rs875971	0.862	rs1968126	ENSG00000273448.1	RP11-166O4.6	-3.9	0.000108	0.015	-0.17	-0.18	Aortic root size;	chr7:66592017	chr7:67333047~67334383:+
LUAD	cis	rs748404	1	rs17779494	ENSG00000205771.5	CATSPER2P1	3.9	0.000108	0.015	0.25	0.18	Lung cancer;	chr15:43287025	chr15:43726918~43747094:-
LUAD	cis	rs4667682	0.646	rs72625232	ENSG00000234061.1	AC007969.4	-3.9	0.000108	0.015	-0.36	-0.18	Hippocampal atrophy;Body mass index;	chr2:171277257	chr2:171492905~171493095:+
LUAD	cis	rs7339483	0.85	rs10423435	ENSG00000268058.1	BNIP3P40	-3.9	0.000108	0.015	-0.35	-0.18	Discordance in emotional problems in monozygotic twins;	chr19:24270265	chr19:24098425~24098980:-
LUAD	cis	rs6802315	0.74	rs9822005	ENSG00000272247.1	RP11-379F4.9	-3.9	0.000108	0.015	-0.19	-0.18	Periodontitis (CDC/AAP);	chr3:158794592	chr3:158801257~158801935:-
LUAD	cis	rs9549260	0.755	rs7986407	ENSG00000229456.1	RLIMP1	3.9	0.000108	0.015	0.19	0.18	Red blood cell count;	chr13:40605661	chr13:40618738~40621348:+
LUAD	cis	rs13113518	0.783	rs12504300	ENSG00000273257.1	RP11-177J6.1	3.9	0.000108	0.015	0.21	0.18	Height;	chr4:55482360	chr4:55387949~55388271:+
LUAD	cis	rs12216545	0.765	rs2272092	ENSG00000177590.7	GIMAP3P	-3.9	0.000108	0.015	-0.18	-0.18	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150567557	chr7:150746893~150747728:-
LUAD	cis	rs10197140	0.925	rs9308691	ENSG00000235721.1	AC013268.3	-3.9	0.000108	0.015	-0.19	-0.18	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110883561	chr2:110007675~110010783:+
LUAD	cis	rs34779708	0.966	rs2045917	ENSG00000271335.4	RP11-324I22.4	3.9	0.000108	0.015	0.19	0.18	Inflammatory bowel disease;Crohn's disease;	chr10:35129598	chr10:35314552~35336401:-
LUAD	cis	rs526231	0.725	rs487937	ENSG00000175749.11	EIF3KP1	3.9	0.000108	0.015	0.23	0.18	Primary biliary cholangitis;	chr5:103302541	chr5:103032376~103033031:+
LUAD	cis	rs2708977	0.637	rs654224	ENSG00000237510.6	AC008268.2	-3.9	0.000108	0.015	-0.22	-0.18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96414386	chr2:95789654~95800166:+
LUAD	cis	rs9925964	0.933	rs881929	ENSG00000232748.3	RP11-196G11.6	3.9	0.000108	0.015	0.21	0.18	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31068050	chr16:31056460~31062803:+
LUAD	cis	rs3733418	0.929	rs1401401	ENSG00000248632.1	RP11-366M4.11	3.9	0.000108	0.015	0.28	0.18	Obesity-related traits;	chr4:165006804	chr4:164968587~164970002:-
LUAD	cis	rs1850744	0.609	rs6448959	ENSG00000163612.10	FAM86KP	-3.9	0.000108	0.015	-0.5	-0.18	Economic and political preferences;	chr4:9682303	chr4:9153296~9165451:+
LUAD	cis	rs1850744	0.702	rs13104360	ENSG00000163612.10	FAM86KP	-3.9	0.000108	0.015	-0.5	-0.18	Economic and political preferences;	chr4:9683180	chr4:9153296~9165451:+
LUAD	cis	rs1150668	0.799	rs2142730	ENSG00000176933.5	TOB2P1	-3.9	0.000108	0.015	-0.2	-0.18	Pubertal anthropometrics;	chr6:28298372	chr6:28217643~28218634:-
LUAD	cis	rs2657294	0.895	rs3088142	ENSG00000226051.5	ZNF503-AS1	-3.9	0.000108	0.015	-0.24	-0.18	Pneumonia;	chr10:75094806	chr10:75269819~75373500:+
LUAD	cis	rs2554380	0.843	rs1019665	ENSG00000259570.1	RP11-671M22.4	3.9	0.000108	0.0151	0.25	0.18	Height;	chr15:83711867	chr15:84394512~84395514:+
LUAD	cis	rs2554380	0.843	rs1019667	ENSG00000259570.1	RP11-671M22.4	3.9	0.000108	0.0151	0.25	0.18	Height;	chr15:83712097	chr15:84394512~84395514:+
LUAD	cis	rs11671005	0.693	rs11668757	ENSG00000268543.1	CTD-2619J13.16	-3.9	0.000108	0.0151	-0.25	-0.18	Mean platelet volume;	chr19:58416932	chr19:58418560~58419310:+
LUAD	cis	rs5742933	0.817	rs3816196	ENSG00000253559.1	OSGEPL1-AS1	3.9	0.000108	0.0151	0.21	0.18	Ferritin levels;	chr2:189775749	chr2:189762704~189765556:+
LUAD	cis	rs6500602	0.927	rs7200817	ENSG00000280063.1	RP11-295D4.3	3.9	0.000108	0.0151	0.11	0.18	Schizophrenia;	chr16:4430597	chr16:4346694~4348648:-
LUAD	cis	rs1502337	0.504	rs61942632	ENSG00000278993.1	RP3-424M6.4	3.9	0.000108	0.0151	0.22	0.18	Body mass index;	chr12:110672958	chr12:110501614~110503441:+
LUAD	cis	rs1862618	0.853	rs252921	ENSG00000271828.1	CTD-2310F14.1	3.9	0.000108	0.0151	0.25	0.18	Initial pursuit acceleration;	chr5:56841960	chr5:56927874~56929573:+
LUAD	cis	rs6452524	0.618	rs4266384	ENSG00000281327.1	LINC01338	3.9	0.000108	0.0151	0.18	0.18	Hypertension (SNP x SNP interaction);	chr5:83080872	chr5:82850864~82859836:-
LUAD	cis	rs6964587	1	rs1063243	ENSG00000188693.7	CYP51A1-AS1	-3.9	0.000108	0.0151	-0.2	-0.18	Breast cancer;	chr7:92097613	chr7:92134604~92180725:+
LUAD	cis	rs2235573	0.527	rs139884	ENSG00000235237.1	RP1-151B14.6	-3.9	0.000108	0.0151	-0.18	-0.18	Glioma;Glioblastoma;	chr22:37973969	chr22:37166757~37182850:+
LUAD	cis	rs2638953	0.962	rs9300176	ENSG00000278733.1	RP11-425D17.1	3.9	0.000108	0.0151	0.21	0.18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28368584	chr12:28185625~28186190:-
LUAD	cis	rs2274273	0.806	rs7146752	ENSG00000258413.1	RP11-665C16.6	-3.9	0.000108	0.0151	-0.22	-0.18	Protein biomarker;	chr14:55272189	chr14:55262767~55272075:-
LUAD	cis	rs10129255	0.912	rs8011090	ENSG00000274576.2	IGHV2-70	3.9	0.000108	0.0151	0.16	0.18	Kawasaki disease;	chr14:106678896	chr14:106770577~106771020:-
LUAD	cis	rs61989804	0.536	rs1123493	ENSG00000258878.1	CTD-2509G16.3	3.9	0.000108	0.0151	0.33	0.18	Midgestational circulating levels of PCBs (fetal genetic effect);	chr14:65200828	chr14:65234515~65235101:-
LUAD	cis	rs3770081	1	rs74607112	ENSG00000273080.1	RP11-301O19.1	-3.9	0.000108	0.0151	-0.4	-0.18	Facial emotion recognition (sad faces);	chr2:86078411	chr2:86195590~86196049:+
LUAD	cis	rs638893	0.578	rs500254	ENSG00000255239.1	AP002954.6	-3.9	0.000108	0.0151	-0.28	-0.18	Vitiligo;	chr11:118808071	chr11:118688039~118690600:-
LUAD	cis	rs17508449	0.505	rs78491726	ENSG00000232450.1	RP4-730K3.3	-3.9	0.000108	0.0151	-0.25	-0.18	Leprosy;	chr1:113784847	chr1:113698884~113699631:-
LUAD	cis	rs4691139	0.595	rs10000199	ENSG00000248632.1	RP11-366M4.11	3.9	0.000108	0.0151	0.21	0.18	Ovarian cancer in BRCA1 mutation carriers;	chr4:165001813	chr4:164968587~164970002:-
LUAD	cis	rs11089937	0.554	rs5995628	ENSG00000211638.2	IGLV8-61	-3.9	0.000108	0.0151	-0.19	-0.18	Periodontitis (PAL4Q3);	chr22:22194768	chr22:22098700~22099212:+
LUAD	cis	rs453301	0.624	rs4841083	ENSG00000253893.2	FAM85B	-3.9	0.000108	0.0151	-0.23	-0.18	Joint mobility (Beighton score);	chr8:9012918	chr8:8167819~8226614:-
LUAD	cis	rs591584	0.617	rs608972	ENSG00000255893.1	RP11-685N10.1	3.9	0.000108	0.0151	0.2	0.18	Macrophage Migration Inhibitory Factor levels;	chr11:94602964	chr11:94472908~94473570:-
LUAD	cis	rs137603	0.644	rs94852	ENSG00000225450.1	RP3-508I15.14	-3.9	0.000108	0.0151	-0.15	-0.18	Primary biliary cholangitis;	chr22:39316329	chr22:38739003~38749041:+
LUAD	cis	rs11742741	0.774	rs1469416	ENSG00000248874.4	C5orf17	-3.9	0.000108	0.0151	-0.22	-0.18	Educational attainment;	chr5:24117673	chr5:23951348~24178263:+
LUAD	cis	rs4691139	0.619	rs2139218	ENSG00000248632.1	RP11-366M4.11	3.9	0.000109	0.0151	0.21	0.18	Ovarian cancer in BRCA1 mutation carriers;	chr4:165001275	chr4:164968587~164970002:-
LUAD	cis	rs1401999	0.932	rs4148557	ENSG00000223882.1	ABCC5-AS1	-3.9	0.000109	0.0151	-0.18	-0.18	Anterior chamber depth;	chr3:184015996	chr3:184006338~184011419:+
LUAD	cis	rs916888	0.773	rs199533	ENSG00000232300.1	FAM215B	3.9	0.000109	0.0151	0.27	0.18	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46558830~46562795:-
LUAD	cis	rs7107174	0.892	rs1007837	ENSG00000251323.2	RP11-452H21.4	3.9	0.000109	0.0151	0.22	0.18	Testicular germ cell tumor;	chr11:78230030	chr11:78423982~78429836:-
LUAD	cis	rs8062405	0.824	rs62034319	ENSG00000261419.1	RP11-57A19.4	-3.9	0.000109	0.0151	-0.19	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28659696~28740781:-
LUAD	cis	rs1541160	1	rs614044	ENSG00000239494.2	RN7SL333P	-3.9	0.000109	0.0151	-0.17	-0.18	Amyotrophic lateral sclerosis;	chr1:169993945	chr1:169859756~169860052:+
LUAD	cis	rs1541160	1	rs628436	ENSG00000239494.2	RN7SL333P	-3.9	0.000109	0.0151	-0.17	-0.18	Amyotrophic lateral sclerosis;	chr1:169994869	chr1:169859756~169860052:+
LUAD	cis	rs7119	0.604	rs2682921	ENSG00000259362.2	RP11-307C19.1	3.9	0.000109	0.0151	0.22	0.18	Type 2 diabetes;	chr15:77573117	chr15:77525540~77534110:+
LUAD	cis	rs6964587	1	rs2282975	ENSG00000188693.7	CYP51A1-AS1	-3.9	0.000109	0.0151	-0.21	-0.18	Breast cancer;	chr7:92132324	chr7:92134604~92180725:+
LUAD	cis	rs5769707	0.706	rs2071903	ENSG00000235111.1	RP1-29C18.8	-3.9	0.000109	0.0151	-0.21	-0.18	Monocyte percentage of white cells;Monocyte count;	chr22:49640869	chr22:49612657~49615716:-
LUAD	cis	rs7138803	0.588	rs7977000	ENSG00000257464.1	RP11-161H23.8	-3.9	0.000109	0.0151	-0.18	-0.18	Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index;	chr12:49815747	chr12:49442424~49442652:-
LUAD	cis	rs2880765	0.566	rs17553790	ENSG00000259407.1	RP11-158M2.3	3.9	0.000109	0.0151	0.17	0.18	Coronary artery disease;	chr15:85470434	chr15:85744109~85750281:-
LUAD	cis	rs6121246	0.559	rs6060950	ENSG00000230613.1	HM13-AS1	3.9	0.000109	0.0151	0.22	0.18	Mean corpuscular hemoglobin;	chr20:31790228	chr20:31567707~31573263:-
LUAD	cis	rs12681366	0.763	rs3019277	ENSG00000254057.1	RP3-388N13.3	3.9	0.000109	0.0151	0.19	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94428195	chr8:93834454~93846743:-
LUAD	cis	rs10463554	0.889	rs34775	ENSG00000250682.4	LINC00491	3.9	0.000109	0.0151	0.22	0.18	Parkinson's disease;	chr5:103115572	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.927	rs34776	ENSG00000250682.4	LINC00491	3.9	0.000109	0.0151	0.22	0.18	Parkinson's disease;	chr5:103116090	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.667	rs34782	ENSG00000250682.4	LINC00491	3.9	0.000109	0.0151	0.22	0.18	Parkinson's disease;	chr5:103118766	chr5:102609156~102671559:-
LUAD	cis	rs11637445	0.677	rs11631864	ENSG00000270964.1	RP11-502I4.3	-3.9	0.000109	0.0151	-0.19	-0.18	Posterior cortical atrophy and Alzheimer's disease;	chr15:67775424	chr15:67541072~67542604:-
LUAD	cis	rs1015362	0.503	rs4911371	ENSG00000275784.1	RP5-1125A11.6	-3.9	0.000109	0.0151	-0.24	-0.18	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33904096	chr20:33989480~33991818:-
LUAD	cis	rs6496932	0.913	rs4843037	ENSG00000259630.2	CTD-2262B20.1	3.9	0.000109	0.0151	0.24	0.18	Central corneal thickness;Corneal structure;	chr15:85274674	chr15:85415228~85415633:+
LUAD	cis	rs5758511	0.633	rs5758689	ENSG00000233903.2	Z83851.4	3.9	0.000109	0.0151	0.26	0.18	Birth weight;	chr22:42268966	chr22:42276355~42277052:+
LUAD	cis	rs2657294	0.965	rs2657285	ENSG00000233313.2	HMGA1P5	-3.9	0.000109	0.0151	-0.22	-0.18	Pneumonia;	chr10:75164166	chr10:75276376~75276646:-
LUAD	cis	rs2929278	0.617	rs11070410	ENSG00000166763.7	STRCP1	-3.9	0.000109	0.0151	-0.21	-0.18	Schizophrenia;	chr15:43764847	chr15:43699488~43718184:-
LUAD	cis	rs5769707	0.632	rs5770601	ENSG00000235111.1	RP1-29C18.8	-3.9	0.000109	0.0151	-0.22	-0.18	Monocyte percentage of white cells;Monocyte count;	chr22:49628255	chr22:49612657~49615716:-
LUAD	cis	rs516805	0.561	rs9482260	ENSG00000279453.1	RP3-425C14.4	3.9	0.000109	0.0151	0.25	0.18	Lymphocyte counts;	chr6:122606981	chr6:122436789~122439223:-
LUAD	cis	rs6460942	0.908	rs112049544	ENSG00000226690.5	AC005281.1	3.9	0.000109	0.0151	0.34	0.18	Coronary artery disease;	chr7:12202925	chr7:12496429~12541910:+
LUAD	cis	rs10129255	0.957	rs28887506	ENSG00000211947.2	IGHV3-21	-3.9	0.000109	0.0151	-0.12	-0.18	Kawasaki disease;	chr14:106785589	chr14:106235064~106235594:-
LUAD	cis	rs8085804	0.556	rs7228411	ENSG00000276174.1	RP11-687E1.2	-3.9	0.000109	0.0151	-0.23	-0.18	Cognitive performance;	chr18:42625341	chr18:42052705~42053030:+
LUAD	cis	rs8085804	0.556	rs12454240	ENSG00000276174.1	RP11-687E1.2	-3.9	0.000109	0.0151	-0.23	-0.18	Cognitive performance;	chr18:42625391	chr18:42052705~42053030:+
LUAD	cis	rs6951245	1	rs78896566	ENSG00000199023.2	MIR339	-3.9	0.000109	0.0151	-0.31	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1040546	chr7:1022935~1023045:-
LUAD	cis	rs6951245	1	rs79422648	ENSG00000199023.2	MIR339	-3.9	0.000109	0.0151	-0.31	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1040605	chr7:1022935~1023045:-
LUAD	cis	rs6951245	0.872	rs113119264	ENSG00000199023.2	MIR339	-3.9	0.000109	0.0151	-0.31	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1040928	chr7:1022935~1023045:-
LUAD	cis	rs6951245	1	rs76804143	ENSG00000199023.2	MIR339	-3.9	0.000109	0.0151	-0.31	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1042385	chr7:1022935~1023045:-
LUAD	cis	rs7772486	0.79	rs6917482	ENSG00000235652.6	RP11-545I5.3	-3.9	0.000109	0.0151	-0.18	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145922445	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.754	rs4566902	ENSG00000235652.6	RP11-545I5.3	-3.9	0.000109	0.0151	-0.18	-0.18	Lobe attachment (rater-scored or self-reported);	chr6:145922992	chr6:145799409~145886585:+
LUAD	cis	rs2278702	0.568	rs80102939	ENSG00000259495.2	RP11-210M15.2	-3.9	0.000109	0.0151	-0.31	-0.18	Bipolar disorder;	chr15:80383266	chr15:80344853~80403575:-
LUAD	cis	rs2143950	0.831	rs80031420	ENSG00000226677.3	IGBP1P1	-3.9	0.000109	0.0151	-0.27	-0.18	Atopic dermatitis;	chr14:35086915	chr14:34939324~34940332:+
LUAD	cis	rs2273156	0.57	rs79702597	ENSG00000226677.3	IGBP1P1	-3.9	0.000109	0.0151	-0.27	-0.18	Immunoglobulin light chain (AL) amyloidosis;	chr14:35089650	chr14:34939324~34940332:+
LUAD	cis	rs7017914	0.905	rs2639957	ENSG00000246366.5	RP11-382J12.1	3.9	0.000109	0.0151	0.16	0.18	Bone mineral density;	chr8:71010967	chr8:70608577~70663279:+
LUAD	cis	rs7129556	0.702	rs650171	ENSG00000241782.1	RP11-91P24.1	3.9	0.000109	0.0151	0.24	0.18	Weight loss (gastric bypass surgery);	chr11:77787440	chr11:77868722~77869195:-
LUAD	cis	rs9341808	0.718	rs2179842	ENSG00000260645.1	RP11-250B2.5	3.9	0.000109	0.0151	0.16	0.18	Sitting height ratio;	chr6:80269336	chr6:80466958~80469080:+
LUAD	cis	rs2836974	0.644	rs719230	ENSG00000232608.1	TIMM9P2	3.9	0.000109	0.0151	0.2	0.18	Cognitive function;	chr21:39304381	chr21:39216624~39217506:+
LUAD	cis	rs2625529	0.652	rs2957745	ENSG00000260173.1	RP11-2I17.4	3.9	0.000109	0.0151	0.21	0.18	Red blood cell count;	chr15:71995736	chr15:72140504~72155459:-
LUAD	cis	rs9840812	0.68	rs17252498	ENSG00000239213.4	NCK1-AS1	-3.9	0.000109	0.0151	-0.25	-0.18	Fibrinogen levels;	chr3:136295356	chr3:136841726~136862054:-
LUAD	cis	rs526231	0.543	rs62362884	ENSG00000250682.4	LINC00491	3.9	0.000109	0.0151	0.22	0.18	Primary biliary cholangitis;	chr5:103231754	chr5:102609156~102671559:-
LUAD	cis	rs763121	0.853	rs5757162	ENSG00000225450.1	RP3-508I15.14	-3.9	0.000109	0.0151	-0.18	-0.18	Menopause (age at onset);	chr22:38597365	chr22:38739003~38749041:+
LUAD	cis	rs12073359	1	rs72694908	ENSG00000223945.2	RP11-458I7.1	-3.9	0.000109	0.0151	-0.25	-0.18	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150095972	chr1:150053864~150055034:+
LUAD	cis	rs7630852	1	rs9852432	ENSG00000272359.1	U4	-3.9	0.000109	0.0151	-0.19	-0.18	Eosinophil counts;	chr3:196780210	chr3:196747192~196747324:-
LUAD	cis	rs8073060	0.963	rs4795082	ENSG00000267592.1	CTC-507E2.2	-3.9	0.000109	0.0151	-0.22	-0.18	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35546482	chr17:35596904~35597128:-
LUAD	cis	rs2348418	0.966	rs7316351	ENSG00000247934.4	RP11-967K21.1	3.9	0.000109	0.0151	0.2	0.18	Lung function (FEV1);Lung function (FVC);	chr12:28545595	chr12:28163298~28190738:-
LUAD	cis	rs2253762	0.54	rs79547192	ENSG00000276742.1	RP11-500G22.4	3.9	0.000109	0.0152	0.27	0.18	Breast cancer;	chr10:121998664	chr10:121956782~121957098:+
LUAD	cis	rs62025270	0.593	rs62022926	ENSG00000259416.2	RP11-158M2.5	-3.9	0.000109	0.0152	-0.24	-0.18	Idiopathic pulmonary fibrosis;	chr15:85696261	chr15:85754941~85756237:-
LUAD	cis	rs6479901	0.947	rs6479897	ENSG00000232075.1	MRPL35P2	-3.9	0.000109	0.0152	-0.24	-0.18	Intelligence (multi-trait analysis);	chr10:63376868	chr10:63634317~63634827:-
LUAD	cis	rs6427528	0.546	rs1503846	ENSG00000232879.2	RP11-544M22.3	-3.9	0.000109	0.0152	-0.28	-0.18	Response to anti-TNF therapy in rheumatoid arthritis;	chr1:160607830	chr1:161034834~161035006:+
LUAD	cis	rs2274273	0.745	rs56262555	ENSG00000259318.1	RP11-454L9.2	3.9	0.000109	0.0152	0.16	0.18	Protein biomarker;	chr14:55095244	chr14:55394940~55395233:-
LUAD	cis	rs7178375	1	rs28881289	ENSG00000270015.1	RP11-540B6.6	3.9	0.000109	0.0152	0.16	0.18	Hypertriglyceridemia;	chr15:30931752	chr15:30926514~30928407:+
LUAD	cis	rs7178375	0.941	rs35497908	ENSG00000270015.1	RP11-540B6.6	3.9	0.000109	0.0152	0.16	0.18	Hypertriglyceridemia;	chr15:30931868	chr15:30926514~30928407:+
LUAD	cis	rs2836950	0.545	rs2836952	ENSG00000232608.1	TIMM9P2	3.9	0.000109	0.0152	0.2	0.18	Menarche (age at onset);	chr21:39244725	chr21:39216624~39217506:+
LUAD	cis	rs7829975	0.84	rs572366	ENSG00000233609.3	RP11-62H7.2	3.9	0.000109	0.0152	0.14	0.18	Mood instability;	chr8:8721284	chr8:8961200~8979025:+
LUAD	cis	rs34638952	0.507	rs797966	ENSG00000264808.1	RP11-802D6.1	3.9	0.000109	0.0152	0.2	0.18	Sitting height ratio;	chr17:29281756	chr17:29369717~29390777:-
LUAD	cis	rs8062405	0.755	rs111693583	ENSG00000251417.2	RP11-1348G14.4	-3.9	0.000109	0.0152	-0.18	-0.18	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28802743~28817828:+
LUAD	cis	rs12579720	0.859	rs10841437	ENSG00000255910.1	RP11-405A12.2	3.9	0.000109	0.0152	0.22	0.18	Diastolic blood pressure;	chr12:20027383	chr12:19775451~20009937:+
LUAD	cis	rs12554020	0.582	rs7033532	ENSG00000227603.1	RP11-165J3.6	3.9	0.000109	0.0152	0.36	0.18	Schizophrenia;	chr9:93644962	chr9:93435332~93437121:-
LUAD	cis	rs12554020	0.582	rs7038310	ENSG00000227603.1	RP11-165J3.6	3.9	0.000109	0.0152	0.36	0.18	Schizophrenia;	chr9:93645638	chr9:93435332~93437121:-
LUAD	cis	rs4795519	0.778	rs7211074	ENSG00000266313.1	RP11-173M1.4	3.9	0.000109	0.0152	0.22	0.18	Chronic myeloid leukemia;	chr17:27072406	chr17:27333256~27348491:+
LUAD	cis	rs287982	0.611	rs7568330	ENSG00000269973.1	RP11-95D17.1	-3.9	0.000109	0.0152	-0.24	-0.18	Nonsyndromic cleft lip with cleft palate;	chr2:9835428	chr2:9936360~9939590:+
LUAD	cis	rs4713118	0.868	rs760587	ENSG00000280107.1	AL022393.9	-3.9	0.000109	0.0152	-0.23	-0.18	Parkinson's disease;	chr6:27772521	chr6:28170845~28172521:+
LUAD	cis	rs6832769	0.925	rs1965467	ENSG00000272969.1	RP11-528I4.2	3.9	0.000109	0.0152	0.18	0.18	Personality dimensions;	chr4:55456573	chr4:55547112~55547889:+
LUAD	cis	rs10829156	0.625	rs10828906	ENSG00000240291.1	RP11-499P20.2	3.9	0.000109	0.0152	0.16	0.18	Sudden cardiac arrest;	chr10:18552866	chr10:18513115~18545651:-
LUAD	cis	rs9549260	0.567	rs7332730	ENSG00000168852.11	TPTE2P5	3.9	0.000109	0.0152	0.17	0.18	Red blood cell count;	chr13:40691843	chr13:40822296~40921749:-
LUAD	cis	rs6001482	0.507	rs5750779	ENSG00000215456.5	BCRP4	3.9	0.000109	0.0152	0.24	0.18	Diastolic blood pressure;	chr22:22230928	chr22:22630061~22636153:+
LUAD	cis	rs2836974	0.965	rs2836967	ENSG00000232608.1	TIMM9P2	-3.9	0.000109	0.0152	-0.21	-0.18	Cognitive function;	chr21:39267176	chr21:39216624~39217506:+
LUAD	cis	rs2836974	0.965	rs8130984	ENSG00000232608.1	TIMM9P2	-3.9	0.000109	0.0152	-0.21	-0.18	Cognitive function;	chr21:39268040	chr21:39216624~39217506:+
LUAD	cis	rs17685	0.753	rs6976532	ENSG00000280388.1	RP11-229D13.3	-3.9	0.000109	0.0152	-0.16	-0.18	Coffee consumption (cups per day);Coffee consumption;	chr7:76051776	chr7:76043977~76045963:-
LUAD	cis	rs595244	1	rs655015	ENSG00000259705.1	RP11-227D13.1	3.9	0.000109	0.0152	0.35	0.18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48598910	chr15:48645951~48652016:+
LUAD	cis	rs6787172	0.783	rs12638438	ENSG00000272087.1	RP11-379F4.7	3.9	0.000109	0.0152	0.19	0.18	Subjective well-being;	chr3:158502045	chr3:158693120~158693768:-
LUAD	cis	rs6787172	0.811	rs9810887	ENSG00000272087.1	RP11-379F4.7	3.9	0.000109	0.0152	0.19	0.18	Subjective well-being;	chr3:158503921	chr3:158693120~158693768:-
LUAD	cis	rs6787172	0.811	rs7623732	ENSG00000272087.1	RP11-379F4.7	3.9	0.000109	0.0152	0.19	0.18	Subjective well-being;	chr3:158504647	chr3:158693120~158693768:-
LUAD	cis	rs5742933	0.817	rs2033870	ENSG00000253559.1	OSGEPL1-AS1	-3.9	0.000109	0.0152	-0.21	-0.18	Ferritin levels;	chr2:189739104	chr2:189762704~189765556:+
LUAD	cis	rs1355223	0.934	rs5010670	ENSG00000271369.1	RP11-350D17.3	-3.9	0.000109	0.0152	-0.21	-0.18	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34745102	chr11:34709600~34710161:+
LUAD	cis	rs1355223	1	rs11602909	ENSG00000271369.1	RP11-350D17.3	-3.9	0.000109	0.0152	-0.21	-0.18	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34746456	chr11:34709600~34710161:+
LUAD	cis	rs7580658	0.891	rs3768866	ENSG00000236682.1	AC068282.3	-3.9	0.000109	0.0152	-0.24	-0.18	Protein C levels;	chr2:127287839	chr2:127389130~127400580:+
LUAD	cis	rs7615952	0.599	rs7652883	ENSG00000241288.6	RP11-379B18.5	-3.9	0.000109	0.0152	-0.22	-0.18	Blood pressure (smoking interaction);	chr3:125989134	chr3:125827238~125916384:-
LUAD	cis	rs9302635	0.513	rs12928732	ENSG00000260886.1	TAT-AS1	3.9	0.000109	0.0152	0.23	0.18	Blood protein levels;	chr16:72154784	chr16:71565789~71578187:+
LUAD	cis	rs516805	0.561	rs7772659	ENSG00000279453.1	RP3-425C14.4	3.9	0.000109	0.0152	0.27	0.18	Lymphocyte counts;	chr6:122608055	chr6:122436789~122439223:-
LUAD	cis	rs889398	0.738	rs7196842	ENSG00000226232.7	RP11-419C5.2	-3.9	0.000109	0.0152	-0.15	-0.18	Body mass index;	chr16:69889430	chr16:69976388~69996188:-
LUAD	cis	rs6071166	0.683	rs6071101	ENSG00000224635.1	RP4-564F22.5	-3.9	0.000109	0.0152	-0.2	-0.18	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38689335	chr20:38406011~38416797:-
LUAD	cis	rs6071166	0.683	rs6015637	ENSG00000224635.1	RP4-564F22.5	-3.9	0.000109	0.0152	-0.2	-0.18	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38689862	chr20:38406011~38416797:-
LUAD	cis	rs10208649	0.831	rs77308271	ENSG00000233266.1	HMGB1P31	3.9	0.00011	0.0152	0.52	0.18	Body mass index;	chr2:54075827	chr2:54051334~54051760:+
LUAD	cis	rs35740288	0.77	rs12906580	ENSG00000259407.1	RP11-158M2.3	3.9	0.00011	0.0152	0.17	0.18	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85612056	chr15:85744109~85750281:-
LUAD	cis	rs6121246	0.559	rs6058465	ENSG00000230613.1	HM13-AS1	3.9	0.00011	0.0152	0.22	0.18	Mean corpuscular hemoglobin;	chr20:31809888	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.559	rs6060962	ENSG00000230613.1	HM13-AS1	3.9	0.00011	0.0152	0.22	0.18	Mean corpuscular hemoglobin;	chr20:31810044	chr20:31567707~31573263:-
LUAD	cis	rs6951245	0.507	rs11763865	ENSG00000229043.2	AC091729.9	-3.9	0.00011	0.0152	-0.22	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1154638	chr7:1160374~1165267:+
LUAD	cis	rs12530	0.54	rs737779	ENSG00000230736.2	RP1-149A16.3	-3.9	0.00011	0.0152	-0.18	-0.18	IgG glycosylation;	chr22:32400260	chr22:32376664~32384343:+
LUAD	cis	rs603446	0.678	rs664059	ENSG00000254851.1	RP11-109L13.1	-3.9	0.00011	0.0152	-0.22	-0.18	Triglycerides;	chr11:116771421	chr11:117135528~117138582:+
LUAD	cis	rs9549260	0.755	rs9549241	ENSG00000229456.1	RLIMP1	3.9	0.00011	0.0152	0.19	0.18	Red blood cell count;	chr13:40635904	chr13:40618738~40621348:+
LUAD	cis	rs13108904	0.535	rs1250101	ENSG00000196810.4	CTBP1-AS2	-3.9	0.00011	0.0152	-0.23	-0.18	Obesity-related traits;	chr4:1242323	chr4:1249300~1288291:+
LUAD	cis	rs10129255	0.518	rs8010020	ENSG00000253209.1	IGHV3-65	3.9	0.00011	0.0152	0.14	0.18	Kawasaki disease;	chr14:106778016	chr14:106666092~106666532:-
LUAD	cis	rs10129255	0.5	rs6576225	ENSG00000253209.1	IGHV3-65	3.9	0.00011	0.0152	0.14	0.18	Kawasaki disease;	chr14:106778120	chr14:106666092~106666532:-
LUAD	cis	rs10129255	0.5	rs6576226	ENSG00000253209.1	IGHV3-65	3.9	0.00011	0.0152	0.14	0.18	Kawasaki disease;	chr14:106778135	chr14:106666092~106666532:-
LUAD	cis	rs2617170	0.885	rs7978962	ENSG00000245648.1	RP11-277P12.20	3.9	0.00011	0.0152	0.22	0.18	Behcet's disease;	chr12:10372225	chr12:10363769~10398506:+
LUAD	cis	rs728616	0.867	rs17096197	ENSG00000225484.5	NUTM2B-AS1	-3.9	0.00011	0.0152	-0.37	-0.18	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80048428	chr10:79663088~79826594:-
LUAD	cis	rs1908814	0.516	rs58869268	ENSG00000255046.1	RP11-297N6.4	-3.9	0.00011	0.0152	-0.22	-0.18	Neuroticism;	chr8:11939586	chr8:11797928~11802568:-
LUAD	cis	rs7208859	0.725	rs7342938	ENSG00000263603.1	CTD-2349P21.5	-3.9	0.00011	0.0152	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862812	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.725	rs6505215	ENSG00000263603.1	CTD-2349P21.5	-3.9	0.00011	0.0152	-0.27	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862885	chr17:30729469~30731202:+
LUAD	cis	rs1908814	0.516	rs35391955	ENSG00000255046.1	RP11-297N6.4	-3.9	0.00011	0.0152	-0.22	-0.18	Neuroticism;	chr8:11939219	chr8:11797928~11802568:-
LUAD	cis	rs13434995	0.513	rs73236153	ENSG00000273257.1	RP11-177J6.1	-3.9	0.00011	0.0152	-0.24	-0.18	Adiponectin levels;	chr4:55585600	chr4:55387949~55388271:+
LUAD	cis	rs2333021	0.689	rs2535901	ENSG00000259015.1	RP11-109N23.6	-3.9	0.00011	0.0152	-0.17	-0.18	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72965734	chr14:72960595~72961993:+
LUAD	cis	rs12291225	0.585	rs11023194	ENSG00000251991.1	RNU7-49P	3.9	0.00011	0.0152	0.19	0.18	Sense of smell;	chr11:14348223	chr11:14478892~14478953:+
LUAD	cis	rs6121246	0.954	rs6060989	ENSG00000230613.1	HM13-AS1	3.9	0.00011	0.0152	0.25	0.18	Mean corpuscular hemoglobin;	chr20:31841960	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.954	rs6060992	ENSG00000230613.1	HM13-AS1	3.9	0.00011	0.0152	0.25	0.18	Mean corpuscular hemoglobin;	chr20:31843452	chr20:31567707~31573263:-
LUAD	cis	rs7617773	0.78	rs13079728	ENSG00000199476.1	Y_RNA	-3.9	0.00011	0.0152	-0.23	-0.18	Coronary artery disease;	chr3:48297870	chr3:48288587~48288694:+
LUAD	cis	rs7138803	0.616	rs11611070	ENSG00000257464.1	RP11-161H23.8	-3.9	0.00011	0.0152	-0.18	-0.18	Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index;	chr12:49805691	chr12:49442424~49442652:-
LUAD	cis	rs1124769	0.502	rs12440167	ENSG00000259378.1	DCAF13P3	3.9	0.00011	0.0152	0.25	0.18	Cognitive performance;	chr15:50770936	chr15:50944663~50945996:+
LUAD	cis	rs7617773	0.817	rs13072018	ENSG00000199476.1	Y_RNA	-3.9	0.00011	0.0152	-0.23	-0.18	Coronary artery disease;	chr3:48278842	chr3:48288587~48288694:+
LUAD	cis	rs6496932	0.635	rs12900455	ENSG00000259630.2	CTD-2262B20.1	-3.9	0.00011	0.0152	-0.21	-0.18	Central corneal thickness;Corneal structure;	chr15:85362345	chr15:85415228~85415633:+
LUAD	cis	rs11242704	0.632	rs7744406	ENSG00000272279.1	RP11-157J24.2	-3.9	0.00011	0.0152	-0.26	-0.18	Response to hepatitis C treatment;	chr6:1540572	chr6:1528364~1528911:-
LUAD	cis	rs9952991	0.654	rs34153303	ENSG00000260302.1	RP11-973H7.1	3.9	0.00011	0.0152	0.37	0.18	Inflammatory skin disease;	chr18:12855865	chr18:12774651~12775923:-
LUAD	cis	rs860295	0.729	rs4971072	ENSG00000160766.13	GBAP1	3.9	0.00011	0.0152	0.19	0.18	Body mass index;	chr1:155304078	chr1:155213821~155227422:-
LUAD	cis	rs6832769	1	rs3805154	ENSG00000272969.1	RP11-528I4.2	3.9	0.00011	0.0152	0.18	0.18	Personality dimensions;	chr4:55497760	chr4:55547112~55547889:+
LUAD	cis	rs6832769	1	rs7670225	ENSG00000272969.1	RP11-528I4.2	3.9	0.00011	0.0152	0.18	0.18	Personality dimensions;	chr4:55501851	chr4:55547112~55547889:+
LUAD	cis	rs73230612	0.858	rs6766064	ENSG00000242767.1	ZBTB20-AS4	3.9	0.00011	0.0152	0.26	0.18	Type 2 diabetes;	chr3:115378233	chr3:115100423~115103061:+
LUAD	cis	rs6568490	0.556	rs1464215	ENSG00000203801.7	LINC00222	3.9	0.00011	0.0152	0.26	0.18	Lymphocyte counts;	chr6:107773148	chr6:108751654~108769942:+
LUAD	cis	rs875971	0.66	rs801217	ENSG00000222364.1	RNU6-96P	3.9	0.00011	0.0152	0.19	0.18	Aortic root size;	chr7:66545590	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.638	rs801216	ENSG00000222364.1	RNU6-96P	3.9	0.00011	0.0152	0.19	0.18	Aortic root size;	chr7:66546680	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.66	rs801211	ENSG00000222364.1	RNU6-96P	3.9	0.00011	0.0152	0.19	0.18	Aortic root size;	chr7:66550702	chr7:66395191~66395286:+
LUAD	cis	rs10876993	0.855	rs10877007	ENSG00000270039.1	RP11-571M6.17	3.9	0.00011	0.0152	0.21	0.18	Celiac disease or Rheumatoid arthritis;	chr12:57706275	chr12:57803838~57804415:+
LUAD	cis	rs8085804	0.529	rs72895369	ENSG00000276174.1	RP11-687E1.2	-3.9	0.00011	0.0152	-0.23	-0.18	Cognitive performance;	chr18:42623198	chr18:42052705~42053030:+
LUAD	cis	rs10463554	0.927	rs62362489	ENSG00000250682.4	LINC00491	3.9	0.00011	0.0152	0.21	0.18	Parkinson's disease;	chr5:102909841	chr5:102609156~102671559:-
LUAD	cis	rs8180040	1	rs7613282	ENSG00000271161.1	BOLA2P2	-3.9	0.00011	0.0153	-0.17	-0.18	Colorectal cancer;	chr3:47347919	chr3:47499841~47500407:+
LUAD	cis	rs6840360	0.642	rs56301462	ENSG00000270265.1	RP11-731D1.4	-3.9	0.00011	0.0153	-0.18	-0.18	Intelligence (multi-trait analysis);	chr4:151530976	chr4:151333775~151353224:-
LUAD	cis	rs9840812	0.725	rs3821445	ENSG00000239213.4	NCK1-AS1	-3.9	0.00011	0.0153	-0.25	-0.18	Fibrinogen levels;	chr3:136283967	chr3:136841726~136862054:-
LUAD	cis	rs10129255	0.957	rs10142918	ENSG00000211947.2	IGHV3-21	-3.9	0.00011	0.0153	-0.12	-0.18	Kawasaki disease;	chr14:106782206	chr14:106235064~106235594:-
LUAD	cis	rs11009175	0.547	rs7070020	ENSG00000273038.2	RP11-479G22.8	-3.9	0.00011	0.0153	-0.23	-0.18	Depression (quantitative trait);	chr10:33109108	chr10:32887255~32889311:-
LUAD	cis	rs10129255	1	rs11627342	ENSG00000274576.2	IGHV2-70	3.9	0.00011	0.0153	0.16	0.18	Kawasaki disease;	chr14:106675823	chr14:106770577~106771020:-
LUAD	cis	rs67981189	0.896	rs34049963	ENSG00000269927.1	RP6-91H8.3	3.9	0.00011	0.0153	0.22	0.18	Schizophrenia;	chr14:70974029	chr14:71141125~71143253:-
LUAD	cis	rs9467773	1	rs1884949	ENSG00000241549.7	GUSBP2	3.9	0.00011	0.0153	0.19	0.18	Intelligence (multi-trait analysis);	chr6:26567839	chr6:26871484~26956554:-
LUAD	cis	rs9467773	1	rs9467796	ENSG00000241549.7	GUSBP2	3.9	0.00011	0.0153	0.19	0.18	Intelligence (multi-trait analysis);	chr6:26568183	chr6:26871484~26956554:-
LUAD	cis	rs9467773	1	rs9467797	ENSG00000241549.7	GUSBP2	3.9	0.00011	0.0153	0.19	0.18	Intelligence (multi-trait analysis);	chr6:26568245	chr6:26871484~26956554:-
LUAD	cis	rs9467773	1	rs1078679	ENSG00000241549.7	GUSBP2	3.9	0.00011	0.0153	0.19	0.18	Intelligence (multi-trait analysis);	chr6:26568513	chr6:26871484~26956554:-
LUAD	cis	rs9467773	1	rs6932156	ENSG00000241549.7	GUSBP2	3.9	0.00011	0.0153	0.19	0.18	Intelligence (multi-trait analysis);	chr6:26571278	chr6:26871484~26956554:-
LUAD	cis	rs9467773	1	rs6924838	ENSG00000241549.7	GUSBP2	3.9	0.00011	0.0153	0.19	0.18	Intelligence (multi-trait analysis);	chr6:26571528	chr6:26871484~26956554:-
LUAD	cis	rs9467773	1	rs6925895	ENSG00000241549.7	GUSBP2	3.9	0.00011	0.0153	0.19	0.18	Intelligence (multi-trait analysis);	chr6:26571937	chr6:26871484~26956554:-
LUAD	cis	rs1979679	0.918	rs786712	ENSG00000278733.1	RP11-425D17.1	3.9	0.00011	0.0153	0.22	0.18	Ossification of the posterior longitudinal ligament of the spine;	chr12:28399664	chr12:28185625~28186190:-
LUAD	cis	rs5758511	0.68	rs5758681	ENSG00000233903.2	Z83851.4	3.9	0.00011	0.0153	0.26	0.18	Birth weight;	chr22:42249085	chr22:42276355~42277052:+
LUAD	cis	rs4237845	0.537	rs12312955	ENSG00000245651.2	RP11-620J15.2	3.9	0.00011	0.0153	0.18	0.18	Intelligence (multi-trait analysis);	chr12:57871440	chr12:57869835~57896482:-
LUAD	cis	rs8028182	0.636	rs4451914	ENSG00000260269.4	CTD-2323K18.1	-3.9	0.00011	0.0153	-0.24	-0.18	Sudden cardiac arrest;	chr15:75447483	chr15:75527150~75601205:-
LUAD	cis	rs9926296	0.605	rs7205053	ENSG00000260259.1	RP11-368I7.4	-3.9	0.00011	0.0153	-0.17	-0.18	Vitiligo;	chr16:89790355	chr16:89682620~89686569:-
LUAD	cis	rs2731006	0.64	rs2730976	ENSG00000257114.2	RP11-25I15.3	3.9	0.00011	0.0153	0.28	0.18	Panic disorder;	chr12:42773413	chr12:42692216~42717119:+
LUAD	cis	rs7714584	1	rs1428551	ENSG00000197083.10	ZNF300P1	3.9	0.00011	0.0153	0.33	0.18	Crohn's disease;	chr5:150880270	chr5:150930645~150946289:-
LUAD	cis	rs2274273	0.901	rs112870553	ENSG00000259318.1	RP11-454L9.2	3.9	0.00011	0.0153	0.15	0.18	Protein biomarker;	chr14:55323344	chr14:55394940~55395233:-
LUAD	cis	rs7208859	0.673	rs11655623	ENSG00000280069.1	CTD-2349P21.3	-3.9	0.00011	0.0153	-0.24	-0.18	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30835155	chr17:30738182~30740275:+
LUAD	cis	rs911555	0.713	rs10162425	ENSG00000244691.1	RPL10AP1	-3.9	0.00011	0.0153	-0.23	-0.18	Intelligence (multi-trait analysis);	chr14:103465284	chr14:103412119~103412761:-
LUAD	cis	rs8031584	0.958	rs34909055	ENSG00000259845.1	HERC2P10	3.9	0.00011	0.0153	0.2	0.18	Huntington's disease progression;	chr15:30991967	chr15:30815271~30844153:+
LUAD	cis	rs7762018	1	rs60253563	ENSG00000231690.2	LINC00574	-3.9	0.00011	0.0153	-0.32	-0.18	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169682923	chr6:169790321~169802873:+
LUAD	cis	rs1541160	1	rs973015	ENSG00000239494.2	RN7SL333P	3.9	0.00011	0.0153	0.17	0.18	Amyotrophic lateral sclerosis;	chr1:170063476	chr1:169859756~169860052:+
LUAD	cis	rs8098244	0.565	rs2850205	ENSG00000264745.1	TTC39C-AS1	3.9	0.00011	0.0153	0.18	0.18	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23677531	chr18:23994213~24015339:-
LUAD	cis	rs6121246	0.609	rs6088997	ENSG00000230613.1	HM13-AS1	-3.9	0.00011	0.0153	-0.22	-0.18	Mean corpuscular hemoglobin;	chr20:31702021	chr20:31567707~31573263:-
LUAD	cis	rs10752881	1	rs10752885	ENSG00000224468.3	RP11-181K3.4	-3.9	0.00011	0.0153	-0.15	-0.18	Colorectal cancer;	chr1:183013743	chr1:183138402~183141282:-
LUAD	cis	rs2880765	0.545	rs17553734	ENSG00000259630.2	CTD-2262B20.1	3.9	0.00011	0.0153	0.21	0.18	Coronary artery disease;	chr15:85469828	chr15:85415228~85415633:+
LUAD	cis	rs4356203	0.543	rs214088	ENSG00000272034.1	SNORD14A	-3.9	0.00011	0.0153	-0.16	-0.18	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17276578	chr11:17074654~17074744:-
LUAD	cis	rs950880	0.767	rs13001714	ENSG00000234389.1	AC007278.3	-3.9	0.00011	0.0153	-0.16	-0.18	Serum protein levels (sST2);	chr2:102344025	chr2:102438713~102440475:+
LUAD	cis	rs9907295	0.591	rs4239252	ENSG00000270977.1	AC015849.16	3.9	0.00011	0.0153	0.23	0.18	Fibroblast growth factor basic levels;	chr17:35836561	chr17:35893707~35911023:-
LUAD	cis	rs4374383	0.962	rs10187041	ENSG00000207383.1	Y_RNA	-3.9	0.00011	0.0153	-0.21	-0.18	Hepatitis C induced liver fibrosis;	chr2:112018075	chr2:112579484~112579584:-
LUAD	cis	rs2115630	1	rs10220733	ENSG00000259728.4	LINC00933	-3.9	0.00011	0.0153	-0.21	-0.18	P wave terminal force;	chr15:84737633	chr15:84570649~84580175:+
LUAD	cis	rs12744310	1	rs35318047	ENSG00000235358.1	RP11-399E6.1	3.9	0.00011	0.0153	0.23	0.18	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41289494	chr1:41242373~41284861:+
LUAD	cis	rs12744310	0.943	rs35493284	ENSG00000235358.1	RP11-399E6.1	3.9	0.00011	0.0153	0.23	0.18	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41289517	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs12025254	ENSG00000235358.1	RP11-399E6.1	3.9	0.00011	0.0153	0.23	0.18	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41291234	chr1:41242373~41284861:+
LUAD	cis	rs7674212	0.541	rs2720471	ENSG00000251288.2	RP11-10L12.2	-3.9	0.00011	0.0153	-0.22	-0.18	Type 2 diabetes;	chr4:103102683	chr4:102751401~102752641:+
LUAD	cis	rs7202877	0.656	rs9923834	ENSG00000280152.1	RP11-331F4.5	3.9	0.00011	0.0153	0.2	0.18	Type 1 diabetes;Type 2 diabetes;	chr16:75473355	chr16:75245994~75250077:-
LUAD	cis	rs2911132	0.564	rs731827	ENSG00000248734.2	CTD-2260A17.1	3.9	0.00011	0.0153	0.19	0.18	Urate levels (BMI interaction);	chr5:96751311	chr5:96784777~96785999:+
LUAD	cis	rs6125597	0.967	rs6122781	ENSG00000230758.1	SNAP23P	3.9	0.00011	0.0153	0.18	0.18	Intelligence (multi-trait analysis);	chr20:49287289	chr20:49038357~49038602:-
LUAD	cis	rs6125597	0.967	rs6125610	ENSG00000230758.1	SNAP23P	3.9	0.00011	0.0153	0.18	0.18	Intelligence (multi-trait analysis);	chr20:49287761	chr20:49038357~49038602:-
LUAD	cis	rs6125597	0.967	rs6125611	ENSG00000230758.1	SNAP23P	3.9	0.00011	0.0153	0.18	0.18	Intelligence (multi-trait analysis);	chr20:49288197	chr20:49038357~49038602:-
LUAD	cis	rs6125597	0.901	rs6125612	ENSG00000230758.1	SNAP23P	3.9	0.00011	0.0153	0.18	0.18	Intelligence (multi-trait analysis);	chr20:49290021	chr20:49038357~49038602:-
LUAD	cis	rs11121152	0.5	rs966134	ENSG00000232912.4	RP5-1115A15.1	3.9	0.00011	0.0153	0.16	0.18	Inflammatory skin disease;	chr1:8313148	chr1:8424645~8434838:+
LUAD	cis	rs17711722	0.522	rs6957759	ENSG00000237310.1	GS1-124K5.4	3.9	0.00011	0.0153	0.18	0.18	Calcium levels;	chr7:65806798	chr7:66493706~66495474:+
LUAD	cis	rs910316	0.737	rs175084	ENSG00000259138.1	RP11-950C14.7	-3.9	0.00011	0.0153	-0.19	-0.18	Height;	chr14:75052472	chr14:75127153~75136930:+
LUAD	cis	rs8180040	0.966	rs1872164	ENSG00000271161.1	BOLA2P2	-3.9	0.00011	0.0153	-0.17	-0.18	Colorectal cancer;	chr3:47373610	chr3:47499841~47500407:+
LUAD	cis	rs6674176	0.66	rs6680421	ENSG00000237950.1	RP11-7O11.3	-3.9	0.00011	0.0153	-0.22	-0.18	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43943297	chr1:43944370~43946551:-
LUAD	cis	rs2274273	0.806	rs7146752	ENSG00000259318.1	RP11-454L9.2	3.9	0.00011	0.0153	0.15	0.18	Protein biomarker;	chr14:55272189	chr14:55394940~55395233:-
LUAD	cis	rs2014572	0.87	rs10426580	ENSG00000268379.1	CTC-360J11.4	3.9	0.00011	0.0153	0.21	0.18	Hyperactive-impulsive symptoms;	chr19:57244853	chr19:57175233~57177921:+
LUAD	cis	rs4474465	0.92	rs10128743	ENSG00000251323.2	RP11-452H21.4	3.9	0.00011	0.0153	0.22	0.18	Alzheimer's disease (survival time);	chr11:78503627	chr11:78423982~78429836:-
LUAD	cis	rs7824557	0.51	rs1435274	ENSG00000255046.1	RP11-297N6.4	3.9	0.00011	0.0153	0.22	0.18	Retinal vascular caliber;	chr8:11378401	chr8:11797928~11802568:-
LUAD	cis	rs12440869	0.959	rs3743343	ENSG00000270964.1	RP11-502I4.3	3.9	0.00011	0.0153	0.2	0.18	Peak velocity of the mitral A-wave;	chr15:67194437	chr15:67541072~67542604:-
LUAD	cis	rs8040855	0.627	rs3816105	ENSG00000259774.1	RP11-182J1.13	3.9	0.00011	0.0153	0.22	0.18	Bulimia nervosa;	chr15:85097680	chr15:84422618~84425882:+
LUAD	cis	rs8040855	0.627	rs2304418	ENSG00000259774.1	RP11-182J1.13	3.9	0.00011	0.0153	0.22	0.18	Bulimia nervosa;	chr15:85097752	chr15:84422618~84425882:+
LUAD	cis	rs11671005	0.735	rs11670871	ENSG00000268543.1	CTD-2619J13.16	3.9	0.00011	0.0153	0.24	0.18	Mean platelet volume;	chr19:58429147	chr19:58418560~58419310:+
LUAD	cis	rs703842	0.963	rs2069506	ENSG00000270039.1	RP11-571M6.17	-3.9	0.00011	0.0153	-0.21	-0.18	Multiple sclerosis;	chr12:57749071	chr12:57803838~57804415:+
LUAD	cis	rs4227	0.565	rs858526	ENSG00000233223.2	AC113189.5	-3.9	0.00011	0.0153	-0.19	-0.18	IgA nephropathy;	chr17:7596064	chr17:7581964~7584072:-
LUAD	cis	rs2836974	0.931	rs8132285	ENSG00000232608.1	TIMM9P2	-3.9	0.00011	0.0153	-0.21	-0.18	Cognitive function;	chr21:39283826	chr21:39216624~39217506:+
LUAD	cis	rs2274273	0.87	rs13379169	ENSG00000258413.1	RP11-665C16.6	-3.9	0.00011	0.0153	-0.23	-0.18	Protein biomarker;	chr14:55274569	chr14:55262767~55272075:-
LUAD	cis	rs6502050	0.74	rs4789748	ENSG00000275966.1	RP11-1055B8.9	-3.9	0.00011	0.0153	-0.18	-0.18	Life satisfaction;	chr17:82135185	chr17:81345476~81345966:-
LUAD	cis	rs6787172	0.811	rs9812624	ENSG00000272087.1	RP11-379F4.7	3.9	0.00011	0.0153	0.19	0.18	Subjective well-being;	chr3:158491861	chr3:158693120~158693768:-
LUAD	cis	rs2735413	0.75	rs67126435	ENSG00000276007.1	RP11-358L22.3	3.9	0.00011	0.0153	0.22	0.18	Systolic blood pressure (alcohol consumption interaction);	chr16:78032540	chr16:78123243~78124332:+
LUAD	cis	rs8177876	0.915	rs12444974	ENSG00000261061.1	RP11-303E16.2	-3.9	0.00011	0.0153	-0.31	-0.18	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81094625	chr16:81030770~81031485:+
LUAD	cis	rs12681366	0.761	rs2930963	ENSG00000254057.1	RP3-388N13.3	3.9	0.00011	0.0153	0.19	0.18	Nonsyndromic cleft lip with cleft palate;	chr8:94434892	chr8:93834454~93846743:-
LUAD	cis	rs2738459	0.569	rs2738458	ENSG00000267174.4	CTC-510F12.4	3.9	0.00011	0.0153	0.23	0.18	LDL cholesterol;	chr19:11126620	chr19:11300777~11324441:-
LUAD	cis	rs6001482	0.702	rs5757581	ENSG00000253818.1	IGLV1-41	3.9	0.000111	0.0153	0.19	0.18	Diastolic blood pressure;	chr22:22234220	chr22:22404207~22404721:+
LUAD	cis	rs6951245	0.786	rs77943789	ENSG00000199023.2	MIR339	-3.9	0.000111	0.0153	-0.3	-0.18	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1100522	chr7:1022935~1023045:-
LUAD	cis	rs11673344	0.503	rs1829603	ENSG00000276846.1	CTD-3220F14.3	3.9	0.000111	0.0153	0.19	0.18	Obesity-related traits;	chr19:37065396	chr19:37314868~37315620:-
LUAD	cis	rs2657294	0.965	rs2657285	ENSG00000226051.5	ZNF503-AS1	-3.9	0.000111	0.0153	-0.23	-0.18	Pneumonia;	chr10:75164166	chr10:75269819~75373500:+
LUAD	cis	rs848490	0.889	rs12113982	ENSG00000214293.7	APTR	3.9	0.000111	0.0153	0.23	0.18	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77547073	chr7:77657660~77696265:-
LUAD	cis	rs848490	1	rs10215453	ENSG00000214293.7	APTR	3.9	0.000111	0.0153	0.23	0.18	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77859361	chr7:77657660~77696265:-
LUAD	cis	rs219780	0.796	rs219793	ENSG00000233818.1	AP000695.4	-3.9	0.000111	0.0153	-0.23	-0.18	Kidney stones;	chr21:36454012	chr21:36445731~36532408:+
LUAD	cis	rs683250	0.568	rs651786	ENSG00000246067.6	RAB30-AS1	3.9	0.000111	0.0153	0.19	0.18	Subcortical brain region volumes;	chr11:83252105	chr11:83072066~83106719:+
LUAD	cis	rs4268898	0.735	rs34125395	ENSG00000242628.4	AC009228.1	-3.9	0.000111	0.0153	-0.22	-0.18	Asthma;	chr2:24335373	chr2:24214381~24221516:+
LUAD	cis	rs2836950	0.545	rs8132424	ENSG00000232608.1	TIMM9P2	-3.9	0.000111	0.0153	-0.2	-0.18	Menarche (age at onset);	chr21:39212486	chr21:39216624~39217506:+
LUAD	cis	rs7762018	1	rs6904601	ENSG00000231690.2	LINC00574	-3.9	0.000111	0.0153	-0.33	-0.18	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169731809	chr6:169790321~169802873:+
LUAD	cis	rs3018712	0.508	rs4930582	ENSG00000212093.1	AP000807.1	-3.9	0.000111	0.0153	-0.23	-0.18	Total body bone mineral density;	chr11:68643636	chr11:68506083~68506166:-
LUAD	cis	rs11064837	0.504	rs11064846	ENSG00000248636.5	RP11-768F21.1	3.9	0.000111	0.0153	0.2	0.18	Schizophrenia;	chr12:119616346	chr12:119387987~119668079:-
LUAD	cis	rs17122278	1	rs7108845	ENSG00000243431.1	RPL5P30	3.9	0.000111	0.0153	0.22	0.18	Total cholesterol levels;	chr11:118536808	chr11:118560690~118561580:+
LUAD	cis	rs4268898	0.608	rs72793980	ENSG00000242628.4	AC009228.1	3.9	0.000111	0.0153	0.24	0.18	Asthma;	chr2:24205990	chr2:24214381~24221516:+
LUAD	cis	rs6088580	0.634	rs6059890	ENSG00000276073.1	RP5-1125A11.7	-3.9	0.000111	0.0153	-0.17	-0.17	Glomerular filtration rate (creatinine);	chr20:34513848	chr20:33985617~33988989:-
LUAD	cis	rs13113518	1	rs13122619	ENSG00000273257.1	RP11-177J6.1	3.9	0.000111	0.0153	0.19	0.17	Height;	chr4:55479339	chr4:55387949~55388271:+
LUAD	cis	rs6502050	0.835	rs8077772	ENSG00000275966.1	RP11-1055B8.9	3.9	0.000111	0.0153	0.18	0.17	Life satisfaction;	chr17:82159344	chr17:81345476~81345966:-
LUAD	cis	rs73193808	1	rs66716206	ENSG00000215533.7	LINC00189	-3.9	0.000111	0.0153	-0.25	-0.17	Coronary artery disease;	chr21:29183333	chr21:29193480~29288205:+
LUAD	cis	rs7613875	0.654	rs3774751	ENSG00000280382.1	RP11-804H8.7	3.9	0.000111	0.0153	0.19	0.17	Body mass index;	chr3:50171620	chr3:50599879~50601148:-
LUAD	cis	rs10090774	0.71	rs10104479	ENSG00000280303.2	ERICD	-3.9	0.000111	0.0153	-0.2	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140683972	chr8:140636281~140638283:+
LUAD	cis	rs1348850	0.958	rs4893965	ENSG00000213963.5	AC074286.1	3.9	0.000111	0.0153	0.21	0.17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177599124	chr2:177283508~177392691:-
LUAD	cis	rs1348850	0.958	rs4528793	ENSG00000213963.5	AC074286.1	3.9	0.000111	0.0153	0.21	0.17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177599543	chr2:177283508~177392691:-
LUAD	cis	rs35740288	0.77	rs11638278	ENSG00000259407.1	RP11-158M2.3	-3.9	0.000111	0.0153	-0.17	-0.17	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85668173	chr15:85744109~85750281:-
LUAD	cis	rs2154319	0.887	rs4660500	ENSG00000235358.1	RP11-399E6.1	3.9	0.000111	0.0154	0.24	0.17	Height;	chr1:41058997	chr1:41242373~41284861:+
LUAD	cis	rs2154319	0.887	rs6669542	ENSG00000235358.1	RP11-399E6.1	3.9	0.000111	0.0154	0.24	0.17	Height;	chr1:41060098	chr1:41242373~41284861:+
LUAD	cis	rs2154319	0.836	rs6669737	ENSG00000235358.1	RP11-399E6.1	3.9	0.000111	0.0154	0.24	0.17	Height;	chr1:41060218	chr1:41242373~41284861:+
LUAD	cis	rs4660214	0.666	rs61783383	ENSG00000182109.6	RP11-69E11.4	-3.9	0.000111	0.0154	-0.19	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39341346	chr1:39522280~39546187:-
LUAD	cis	rs12549025	0.536	rs9644075	ENSG00000253390.1	CTC-756D1.2	-3.9	0.000111	0.0154	-0.26	-0.17	Reticulocyte fraction of red cells;	chr8:23502448	chr8:23458601~23484971:+
LUAD	cis	rs8056893	0.885	rs56372488	ENSG00000274698.1	RP11-71L14.4	3.9	0.000111	0.0154	0.2	0.17	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68305831	chr16:68450283~68452318:+
LUAD	cis	rs1790761	0.505	rs17593068	ENSG00000184224.3	C11orf72	-3.9	0.000111	0.0154	-0.2	-0.17	Mean corpuscular volume;	chr11:67583461	chr11:67602880~67606706:-
LUAD	cis	rs8012947	1	rs12323535	ENSG00000279636.2	LINC00216	-3.9	0.000111	0.0154	-0.19	-0.17	Alcohol consumption in current drinkers;	chr14:58303137	chr14:58288033~58289158:+
LUAD	cis	rs11822910	0.724	rs60961847	ENSG00000265566.2	RN7SL605P	3.9	0.000111	0.0154	0.26	0.17	Platelet distribution width;	chr11:57416751	chr11:57528085~57528365:-
LUAD	cis	rs453301	0.624	rs2979256	ENSG00000253981.4	ALG1L13P	3.9	0.000111	0.0154	0.21	0.17	Joint mobility (Beighton score);	chr8:9014200	chr8:8236003~8244667:-
LUAD	cis	rs2836950	0.52	rs59916147	ENSG00000232608.1	TIMM9P2	3.9	0.000111	0.0154	0.2	0.17	Menarche (age at onset);	chr21:39262776	chr21:39216624~39217506:+
LUAD	cis	rs1552244	0.882	rs13063929	ENSG00000180385.7	EMC3-AS1	3.9	0.000111	0.0154	0.2	0.17	Alzheimer's disease;	chr3:9968624	chr3:9986893~10006990:+
LUAD	cis	rs10090774	0.71	rs13274713	ENSG00000280303.2	ERICD	-3.9	0.000111	0.0154	-0.19	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140655098	chr8:140636281~140638283:+
LUAD	cis	rs10090774	0.672	rs11784581	ENSG00000280303.2	ERICD	-3.9	0.000111	0.0154	-0.19	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140657122	chr8:140636281~140638283:+
LUAD	cis	rs10090774	0.664	rs11774042	ENSG00000280303.2	ERICD	-3.9	0.000111	0.0154	-0.19	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140657279	chr8:140636281~140638283:+
LUAD	cis	rs10090774	0.71	rs7460	ENSG00000280303.2	ERICD	-3.9	0.000111	0.0154	-0.19	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140658761	chr8:140636281~140638283:+
LUAD	cis	rs10863681	0.764	rs6678715	ENSG00000238042.4	RP11-815M8.1	3.9	0.000111	0.0154	0.2	0.17	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222103941	chr1:221880981~221978523:-
LUAD	cis	rs1198430	0.683	rs1077514	ENSG00000232482.2	RP4-654C18.1	3.9	0.000111	0.0154	0.24	0.17	Total cholesterol levels;	chr1:23439740	chr1:23410832~23412146:+
LUAD	cis	rs7246657	0.943	rs8109038	ENSG00000267470.4	ZNF571-AS1	-3.9	0.000111	0.0154	-0.24	-0.17	Coronary artery calcification;	chr19:37524807	chr19:37548914~37587348:+
LUAD	cis	rs3177980	0.528	rs6427232	ENSG00000239494.2	RN7SL333P	3.9	0.000111	0.0154	0.17	0.17	Amyotrophic lateral sclerosis;	chr1:170072580	chr1:169859756~169860052:+
LUAD	cis	rs1541160	1	rs522444	ENSG00000239494.2	RN7SL333P	3.9	0.000111	0.0154	0.17	0.17	Amyotrophic lateral sclerosis;	chr1:170074763	chr1:169859756~169860052:+
LUAD	cis	rs728616	0.867	rs117139504	ENSG00000234382.2	RP11-40F6.1	-3.9	0.000111	0.0154	-0.43	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79974451	chr10:80233664~80245367:+
LUAD	cis	rs7208859	0.673	rs216411	ENSG00000280069.1	CTD-2349P21.3	3.9	0.000111	0.0154	0.2	0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576475	chr17:30738182~30740275:+
LUAD	cis	rs5758659	0.714	rs2413668	ENSG00000273366.1	CTA-989H11.1	3.9	0.000111	0.0154	0.2	0.17	Cognitive function;	chr22:42109837	chr22:42278188~42278846:+
LUAD	cis	rs5758659	0.657	rs5758587	ENSG00000273366.1	CTA-989H11.1	3.9	0.000111	0.0154	0.2	0.17	Cognitive function;	chr22:42121632	chr22:42278188~42278846:+
LUAD	cis	rs2354432	0.607	rs6689243	ENSG00000226015.2	CCT8P1	3.9	0.000111	0.0154	0.34	0.17	Mitochondrial DNA levels;	chr1:147238910	chr1:147203276~147204932:-
LUAD	cis	rs5015933	0.788	rs13289976	ENSG00000232630.1	PRPS1P2	-3.9	0.000111	0.0154	-0.16	-0.17	Body mass index;	chr9:125293178	chr9:125150653~125151589:+
LUAD	cis	rs10129255	0.5	rs59939897	ENSG00000253209.1	IGHV3-65	3.9	0.000111	0.0154	0.14	0.17	Kawasaki disease;	chr14:106783414	chr14:106666092~106666532:-
LUAD	cis	rs10129255	0.5	rs8014529	ENSG00000253209.1	IGHV3-65	3.9	0.000111	0.0154	0.14	0.17	Kawasaki disease;	chr14:106784065	chr14:106666092~106666532:-
LUAD	cis	rs10129255	0.5	rs12101190	ENSG00000253209.1	IGHV3-65	3.9	0.000111	0.0154	0.14	0.17	Kawasaki disease;	chr14:106784149	chr14:106666092~106666532:-
LUAD	cis	rs10129255	0.518	rs8004895	ENSG00000253209.1	IGHV3-65	3.9	0.000111	0.0154	0.14	0.17	Kawasaki disease;	chr14:106785139	chr14:106666092~106666532:-
LUAD	cis	rs4767841	0.874	rs6490269	ENSG00000248636.5	RP11-768F21.1	-3.9	0.000111	0.0154	-0.21	-0.17	Urgency urinary incontinence;	chr12:119769371	chr12:119387987~119668079:-
LUAD	cis	rs2901790	0.82	rs10804846	ENSG00000223387.5	RP11-408H1.3	-3.9	0.000111	0.0154	-0.23	-0.17	Gait speed in old age;	chr3:172497221	chr3:172560888~172595607:-
LUAD	cis	rs28386778	0.742	rs3020617	ENSG00000240280.5	TCAM1P	-3.9	0.000111	0.0154	-0.2	-0.17	Prudent dietary pattern;	chr17:63869943	chr17:63849292~63864379:+
LUAD	cis	rs4237845	0.537	rs10877031	ENSG00000245651.2	RP11-620J15.2	3.9	0.000111	0.0154	0.18	0.17	Intelligence (multi-trait analysis);	chr12:57872912	chr12:57869835~57896482:-
LUAD	cis	rs524281	0.729	rs12790034	ENSG00000255320.1	RP11-755F10.1	-3.9	0.000111	0.0154	-0.27	-0.17	Electroencephalogram traits;	chr11:66018268	chr11:66244840~66246239:-
LUAD	cis	rs7208859	0.623	rs73263788	ENSG00000280069.1	CTD-2349P21.3	-3.9	0.000111	0.0154	-0.24	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889472	chr17:30738182~30740275:+
LUAD	cis	rs1862618	0.853	rs832578	ENSG00000271828.1	CTD-2310F14.1	3.9	0.000111	0.0154	0.25	0.17	Initial pursuit acceleration;	chr5:56868396	chr5:56927874~56929573:+
LUAD	cis	rs7005380	0.62	rs6469862	ENSG00000279347.1	RP11-85I17.2	-3.9	0.000111	0.0154	-0.15	-0.17	Interstitial lung disease;	chr8:119897796	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.62	rs6469863	ENSG00000279347.1	RP11-85I17.2	-3.9	0.000111	0.0154	-0.15	-0.17	Interstitial lung disease;	chr8:119897910	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.62	rs6469864	ENSG00000279347.1	RP11-85I17.2	-3.9	0.000111	0.0154	-0.15	-0.17	Interstitial lung disease;	chr8:119897985	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.62	rs6469865	ENSG00000279347.1	RP11-85I17.2	-3.9	0.000111	0.0154	-0.15	-0.17	Interstitial lung disease;	chr8:119897995	chr8:119838736~119840385:-
LUAD	cis	rs214785	1	rs214755	ENSG00000234684.5	SDCBP2-AS1	3.9	0.000111	0.0154	0.21	0.17	Basal cell carcinoma;	chr20:2293341	chr20:1325405~1378734:+
LUAD	cis	rs214785	1	rs214756	ENSG00000234684.5	SDCBP2-AS1	3.9	0.000111	0.0154	0.21	0.17	Basal cell carcinoma;	chr20:2293735	chr20:1325405~1378734:+
LUAD	cis	rs12754538	0.777	rs12029303	ENSG00000232912.4	RP5-1115A15.1	3.9	0.000111	0.0154	0.18	0.17	Subjective well-being;	chr1:8578607	chr1:8424645~8434838:+
LUAD	cis	rs2980439	0.818	rs2948294	ENSG00000233609.3	RP11-62H7.2	3.9	0.000111	0.0154	0.15	0.17	Neuroticism;	chr8:8237439	chr8:8961200~8979025:+
LUAD	cis	rs6832769	0.925	rs3817444	ENSG00000272969.1	RP11-528I4.2	3.9	0.000111	0.0154	0.18	0.17	Personality dimensions;	chr4:55509814	chr4:55547112~55547889:+
LUAD	cis	rs8180040	0.9	rs4858894	ENSG00000271161.1	BOLA2P2	3.9	0.000111	0.0154	0.17	0.17	Colorectal cancer;	chr3:47443463	chr3:47499841~47500407:+
LUAD	cis	rs2836950	0.52	rs8133927	ENSG00000232608.1	TIMM9P2	3.9	0.000111	0.0154	0.2	0.17	Menarche (age at onset);	chr21:39318035	chr21:39216624~39217506:+
LUAD	cis	rs2836950	0.52	rs8133928	ENSG00000232608.1	TIMM9P2	3.9	0.000111	0.0154	0.2	0.17	Menarche (age at onset);	chr21:39318037	chr21:39216624~39217506:+
LUAD	cis	rs8012947	0.92	rs7154498	ENSG00000279636.2	LINC00216	-3.9	0.000111	0.0154	-0.19	-0.17	Alcohol consumption in current drinkers;	chr14:58295814	chr14:58288033~58289158:+
LUAD	cis	rs8012947	0.92	rs7155825	ENSG00000279636.2	LINC00216	-3.9	0.000111	0.0154	-0.19	-0.17	Alcohol consumption in current drinkers;	chr14:58295819	chr14:58288033~58289158:+
LUAD	cis	rs2348418	0.832	rs2126894	ENSG00000247934.4	RP11-967K21.1	3.9	0.000111	0.0154	0.2	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28323914	chr12:28163298~28190738:-
LUAD	cis	rs10864907	0.806	rs879711	ENSG00000227368.1	AC079753.5	3.9	0.000111	0.0154	0.19	0.17	Pulmonary function;	chr2:112958677	chr2:112932625~112933171:+
LUAD	cis	rs638893	0.898	rs577121	ENSG00000255239.1	AP002954.6	3.9	0.000111	0.0154	0.27	0.17	Vitiligo;	chr11:118819841	chr11:118688039~118690600:-
LUAD	cis	rs11742741	1	rs1469417	ENSG00000248874.4	C5orf17	-3.9	0.000111	0.0154	-0.22	-0.17	Educational attainment;	chr5:24136065	chr5:23951348~24178263:+
LUAD	cis	rs11742741	1	rs57263486	ENSG00000248874.4	C5orf17	-3.9	0.000111	0.0154	-0.22	-0.17	Educational attainment;	chr5:24136583	chr5:23951348~24178263:+
LUAD	cis	rs6840258	0.831	rs3755980	ENSG00000251411.1	RP11-397E7.4	3.9	0.000111	0.0154	0.21	0.17	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87121099	chr4:86913266~86914817:-
LUAD	cis	rs9308731	0.591	rs7572367	ENSG00000227992.1	AC108463.2	-3.9	0.000111	0.0154	-0.21	-0.17	Chronic lymphocytic leukemia;	chr2:111185394	chr2:111203964~111206215:-
LUAD	cis	rs9308731	0.591	rs9808225	ENSG00000227992.1	AC108463.2	-3.9	0.000111	0.0154	-0.21	-0.17	Chronic lymphocytic leukemia;	chr2:111185937	chr2:111203964~111206215:-
LUAD	cis	rs9308731	0.591	rs9308742	ENSG00000227992.1	AC108463.2	-3.9	0.000111	0.0154	-0.21	-0.17	Chronic lymphocytic leukemia;	chr2:111186044	chr2:111203964~111206215:-
LUAD	cis	rs9308731	0.591	rs7565473	ENSG00000227992.1	AC108463.2	-3.9	0.000111	0.0154	-0.21	-0.17	Chronic lymphocytic leukemia;	chr2:111186213	chr2:111203964~111206215:-
LUAD	cis	rs9308731	0.591	rs7569300	ENSG00000227992.1	AC108463.2	-3.9	0.000111	0.0154	-0.21	-0.17	Chronic lymphocytic leukemia;	chr2:111187296	chr2:111203964~111206215:-
LUAD	cis	rs9308731	0.569	rs7585054	ENSG00000227992.1	AC108463.2	-3.9	0.000111	0.0154	-0.21	-0.17	Chronic lymphocytic leukemia;	chr2:111187350	chr2:111203964~111206215:-
LUAD	cis	rs9308731	0.591	rs7588534	ENSG00000227992.1	AC108463.2	-3.9	0.000111	0.0154	-0.21	-0.17	Chronic lymphocytic leukemia;	chr2:111187510	chr2:111203964~111206215:-
LUAD	cis	rs9813712	0.547	rs6807290	ENSG00000249846.5	RP11-77P16.4	3.9	0.000111	0.0154	0.21	0.17	Response to amphetamines;	chr3:130297952	chr3:130112550~130120579:+
LUAD	cis	rs2153535	0.585	rs1328858	ENSG00000230939.1	RP11-314C16.1	3.9	0.000111	0.0154	0.19	0.17	Motion sickness;	chr6:8563218	chr6:8784178~8785445:+
LUAD	cis	rs7937890	1	rs7937890	ENSG00000251991.1	RNU7-49P	3.9	0.000111	0.0154	0.18	0.17	Mitochondrial DNA levels;	chr11:14374939	chr11:14478892~14478953:+
LUAD	cis	rs780096	0.546	rs8179225	ENSG00000234072.1	AC074117.10	-3.9	0.000111	0.0154	-0.13	-0.17	Total body bone mineral density;	chr2:27514314	chr2:27356246~27367622:+
LUAD	cis	rs10510102	0.507	rs12244092	ENSG00000276742.1	RP11-500G22.4	3.9	0.000111	0.0154	0.27	0.17	Breast cancer;	chr10:122005769	chr10:121956782~121957098:+
LUAD	cis	rs9813712	0.523	rs9866942	ENSG00000228252.7	COL6A4P2	-3.9	0.000111	0.0154	-0.17	-0.17	Response to amphetamines;	chr3:130297796	chr3:130212823~130273806:+
LUAD	cis	rs6686842	0.56	rs213758	ENSG00000235358.1	RP11-399E6.1	3.9	0.000111	0.0154	0.21	0.17	Height;	chr1:41128452	chr1:41242373~41284861:+
LUAD	cis	rs2731006	0.901	rs2731007	ENSG00000257114.2	RP11-25I15.3	-3.9	0.000111	0.0154	-0.27	-0.17	Panic disorder;	chr12:42767101	chr12:42692216~42717119:+
LUAD	cis	rs10863681	0.875	rs1890759	ENSG00000228437.4	RP11-400N13.2	3.9	0.000111	0.0154	0.21	0.17	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222081282	chr1:221966341~221984964:+
LUAD	cis	rs10466239	0.803	rs10899794	ENSG00000230555.2	RP11-517P14.2	3.9	0.000112	0.0154	0.28	0.17	Telomere length;	chr10:43371916	chr10:43420738~43422100:+
LUAD	cis	rs6142102	0.812	rs6059578	ENSG00000275784.1	RP5-1125A11.6	-3.9	0.000112	0.0154	-0.2	-0.17	Skin pigmentation;	chr20:33939900	chr20:33989480~33991818:-
LUAD	cis	rs61542988	0.532	rs12673996	ENSG00000226816.2	AC005082.12	-3.9	0.000112	0.0154	-0.25	-0.17	Fibrinogen levels;	chr7:22793781	chr7:23206013~23208045:+
LUAD	cis	rs13068223	0.663	rs12107178	ENSG00000243926.1	TIPARP-AS1	3.9	0.000112	0.0154	0.19	0.17	Age-related hearing impairment (SNP x SNP interaction);	chr3:156756735	chr3:156671862~156674378:-
LUAD	cis	rs7202877	0.656	rs247427	ENSG00000280152.1	RP11-331F4.5	-3.9	0.000112	0.0154	-0.21	-0.17	Type 1 diabetes;Type 2 diabetes;	chr16:75405234	chr16:75245994~75250077:-
LUAD	cis	rs494562	1	rs495472	ENSG00000234155.1	RP11-30P6.6	-3.9	0.000112	0.0154	-0.34	-0.17	Metabolic traits;Blood metabolite levels;	chr6:85407303	chr6:85387219~85390186:-
LUAD	cis	rs494562	1	rs495469	ENSG00000234155.1	RP11-30P6.6	-3.9	0.000112	0.0154	-0.34	-0.17	Metabolic traits;Blood metabolite levels;	chr6:85407307	chr6:85387219~85390186:-
LUAD	cis	rs10463554	0.927	rs39666	ENSG00000250682.4	LINC00491	3.9	0.000112	0.0154	0.22	0.17	Parkinson's disease;	chr5:103111423	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.927	rs34769	ENSG00000250682.4	LINC00491	3.9	0.000112	0.0154	0.22	0.17	Parkinson's disease;	chr5:103111523	chr5:102609156~102671559:-
LUAD	cis	rs7551222	0.662	rs4951399	ENSG00000240219.1	RP11-430C7.5	3.9	0.000112	0.0155	0.18	0.17	Schizophrenia;	chr1:204564127	chr1:204626775~204629712:+
LUAD	cis	rs3764400	0.567	rs741058	ENSG00000278765.1	RP5-890E16.5	-3.9	0.000112	0.0155	-0.31	-0.17	Body mass index;	chr17:48127991	chr17:48066704~48067293:-
LUAD	cis	rs3764400	0.567	rs2109983	ENSG00000278765.1	RP5-890E16.5	-3.9	0.000112	0.0155	-0.31	-0.17	Body mass index;	chr17:48129786	chr17:48066704~48067293:-
LUAD	cis	rs3764400	0.517	rs7209042	ENSG00000278765.1	RP5-890E16.5	-3.9	0.000112	0.0155	-0.31	-0.17	Body mass index;	chr17:48130430	chr17:48066704~48067293:-
LUAD	cis	rs600231	0.508	rs11227202	ENSG00000245532.5	NEAT1	3.9	0.000112	0.0155	0.16	0.17	Bone mineral density;	chr11:65475246	chr11:65422774~65445540:+
LUAD	cis	rs7727544	0.642	rs7705189	ENSG00000233006.5	AC034220.3	-3.9	0.000112	0.0155	-0.15	-0.17	Blood metabolite levels;	chr5:132287665	chr5:132311285~132369916:-
LUAD	cis	rs8073060	0.586	rs225288	ENSG00000267592.1	CTC-507E2.2	3.9	0.000112	0.0155	0.26	0.17	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35602272	chr17:35596904~35597128:-
LUAD	cis	rs8073060	0.586	rs225286	ENSG00000267592.1	CTC-507E2.2	3.9	0.000112	0.0155	0.26	0.17	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35603439	chr17:35596904~35597128:-
LUAD	cis	rs12304921	0.639	rs1112391	ENSG00000277201.1	AC087884.1	-3.9	0.000112	0.0155	-0.17	-0.17	Type 2 diabetes;	chr12:51082180	chr12:51049921~51050025:+
LUAD	cis	rs2274273	0.84	rs28568813	ENSG00000259318.1	RP11-454L9.2	3.9	0.000112	0.0155	0.15	0.17	Protein biomarker;	chr14:55327396	chr14:55394940~55395233:-
LUAD	cis	rs8014252	0.803	rs73283917	ENSG00000259158.2	ADAM20P1	-3.9	0.000112	0.0155	-0.29	-0.17	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70566439	chr14:70468881~70483756:-
LUAD	cis	rs8014252	0.803	rs7145530	ENSG00000259158.2	ADAM20P1	-3.9	0.000112	0.0155	-0.29	-0.17	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70569793	chr14:70468881~70483756:-
LUAD	cis	rs5758659	0.622	rs6519298	ENSG00000227370.1	RP4-669P10.19	-3.9	0.000112	0.0155	-0.16	-0.17	Cognitive function;	chr22:41968993	chr22:42132543~42132998:+
LUAD	cis	rs733592	0.599	rs12819124	ENSG00000257735.1	RP11-370I10.6	3.9	0.000112	0.0155	0.2	0.17	Plateletcrit;	chr12:48015271	chr12:48350945~48442411:+
LUAD	cis	rs7429990	0.965	rs13075795	ENSG00000228638.1	FCF1P2	3.9	0.000112	0.0155	0.21	0.17	Educational attainment (years of education);	chr3:47983139	chr3:48290793~48291375:-
LUAD	cis	rs7937682	0.961	rs7106104	ENSG00000230911.1	PPIHP1	3.9	0.000112	0.0155	0.24	0.17	Primary sclerosing cholangitis;	chr11:111764931	chr11:112029858~112030367:-
LUAD	cis	rs12200782	0.505	rs9295696	ENSG00000241549.7	GUSBP2	3.9	0.000112	0.0155	0.24	0.17	Small cell lung carcinoma;	chr6:26550060	chr6:26871484~26956554:-
LUAD	cis	rs13434995	0.945	rs55849318	ENSG00000273257.1	RP11-177J6.1	-3.9	0.000112	0.0155	-0.29	-0.17	Adiponectin levels;	chr4:55615826	chr4:55387949~55388271:+
LUAD	cis	rs7129556	0.701	rs4322421	ENSG00000241782.1	RP11-91P24.1	3.9	0.000112	0.0155	0.25	0.17	Weight loss (gastric bypass surgery);	chr11:77748349	chr11:77868722~77869195:-
LUAD	cis	rs7129556	0.737	rs10899404	ENSG00000241782.1	RP11-91P24.1	3.9	0.000112	0.0155	0.25	0.17	Weight loss (gastric bypass surgery);	chr11:77751747	chr11:77868722~77869195:-
LUAD	cis	rs7129556	0.737	rs537811	ENSG00000241782.1	RP11-91P24.1	3.9	0.000112	0.0155	0.25	0.17	Weight loss (gastric bypass surgery);	chr11:77757043	chr11:77868722~77869195:-
LUAD	cis	rs8014252	0.803	rs8006487	ENSG00000259158.2	ADAM20P1	-3.9	0.000112	0.0155	-0.29	-0.17	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70545217	chr14:70468881~70483756:-
LUAD	cis	rs6001482	0.679	rs6001528	ENSG00000223350.2	IGLV9-49	-3.9	0.000112	0.0155	-0.17	-0.17	Diastolic blood pressure;	chr22:22236511	chr22:22343187~22343732:+
LUAD	cis	rs76878669	0.606	rs1785639	ENSG00000213409.4	RP11-658F2.3	3.9	0.000112	0.0155	0.21	0.17	Educational attainment (years of education);	chr11:66332959	chr11:66761575~66762399:-
LUAD	cis	rs72772090	0.908	rs17086588	ENSG00000248734.2	CTD-2260A17.1	3.9	0.000112	0.0155	0.23	0.17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96709210	chr5:96784777~96785999:+
LUAD	cis	rs2274273	0.84	rs6573013	ENSG00000259318.1	RP11-454L9.2	3.9	0.000112	0.0155	0.15	0.17	Protein biomarker;	chr14:55269155	chr14:55394940~55395233:-
LUAD	cis	rs7107174	1	rs10899455	ENSG00000251323.2	RP11-452H21.4	3.9	0.000112	0.0155	0.22	0.17	Testicular germ cell tumor;	chr11:78288117	chr11:78423982~78429836:-
LUAD	cis	rs4683346	0.616	rs11922832	ENSG00000173811.9	CCDC13-AS1	-3.9	0.000112	0.0155	-0.19	-0.17	Granulocyte percentage of myeloid white cells;	chr3:42775829	chr3:42732575~42746768:+
LUAD	cis	rs11250098	0.51	rs4840525	ENSG00000255310.2	AF131215.2	-3.9	0.000112	0.0155	-0.18	-0.17	Morning vs. evening chronotype;	chr8:10908125	chr8:11107788~11109726:-
LUAD	cis	rs763121	0.853	rs5750668	ENSG00000228274.3	RP3-508I15.9	-3.9	0.000112	0.0155	-0.18	-0.17	Menopause (age at onset);	chr22:38683959	chr22:38667585~38681820:-
LUAD	cis	rs7762018	1	rs41265383	ENSG00000231690.2	LINC00574	-3.9	0.000112	0.0155	-0.32	-0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169667929	chr6:169790321~169802873:+
LUAD	cis	rs7762018	1	rs4509126	ENSG00000231690.2	LINC00574	-3.9	0.000112	0.0155	-0.32	-0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169667962	chr6:169790321~169802873:+
LUAD	cis	rs7762018	1	rs7747645	ENSG00000231690.2	LINC00574	-3.9	0.000112	0.0155	-0.32	-0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169670195	chr6:169790321~169802873:+
LUAD	cis	rs939960	0.69	rs36065681	ENSG00000279536.1	RP11-445N20.2	3.9	0.000112	0.0155	0.24	0.17	Neutrophil percentage of white cells;	chr7:150671646	chr7:149881477~149882105:+
LUAD	cis	rs11742741	1	rs11742741	ENSG00000248874.4	C5orf17	-3.9	0.000112	0.0155	-0.22	-0.17	Educational attainment;	chr5:24162832	chr5:23951348~24178263:+
LUAD	cis	rs321358	0.895	rs73015151	ENSG00000271390.1	RP11-89C3.3	3.9	0.000112	0.0155	0.28	0.17	Body mass index;	chr11:111084669	chr11:111089870~111090368:-
LUAD	cis	rs321358	0.895	rs17535886	ENSG00000271390.1	RP11-89C3.3	3.9	0.000112	0.0155	0.28	0.17	Body mass index;	chr11:111084852	chr11:111089870~111090368:-
LUAD	cis	rs1044826	0.518	rs295488	ENSG00000214280.3	RP11-553K23.2	-3.9	0.000112	0.0155	-0.19	-0.17	Obesity-related traits;	chr3:139520481	chr3:139582928~139583593:-
LUAD	cis	rs2098713	0.501	rs1829293	ENSG00000250155.1	CTD-2353F22.1	3.9	0.000112	0.0155	0.19	0.17	Telomere length;	chr5:37505469	chr5:36666214~36725195:-
LUAD	cis	rs607541	0.85	rs1017518	ENSG00000259520.4	CTD-2651B20.3	-3.9	0.000112	0.0155	-0.32	-0.17	Obesity-related traits;	chr15:45641109	chr15:45251580~45279251:-
LUAD	cis	rs7005380	0.746	rs1464276	ENSG00000279347.1	RP11-85I17.2	3.89	0.000112	0.0155	0.14	0.17	Interstitial lung disease;	chr8:119924801	chr8:119838736~119840385:-
LUAD	cis	rs4925386	0.84	rs6142738	ENSG00000273619.1	RP5-908M14.9	3.89	0.000112	0.0155	0.17	0.17	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62344904	chr20:62386303~62386970:-
LUAD	cis	rs2235573	0.527	rs139862	ENSG00000235237.1	RP1-151B14.6	-3.89	0.000112	0.0155	-0.18	-0.17	Glioma;Glioblastoma;	chr22:37955979	chr22:37166757~37182850:+
LUAD	cis	rs755249	0.958	rs61781370	ENSG00000182109.6	RP11-69E11.4	3.89	0.000112	0.0155	0.21	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39579628	chr1:39522280~39546187:-
LUAD	cis	rs7615952	0.551	rs6438945	ENSG00000241288.6	RP11-379B18.5	-3.89	0.000112	0.0155	-0.24	-0.17	Blood pressure (smoking interaction);	chr3:125915630	chr3:125827238~125916384:-
LUAD	cis	rs7615952	0.673	rs7632557	ENSG00000241288.6	RP11-379B18.5	-3.89	0.000112	0.0155	-0.24	-0.17	Blood pressure (smoking interaction);	chr3:125916038	chr3:125827238~125916384:-
LUAD	cis	rs7615952	0.932	rs9841157	ENSG00000241288.6	RP11-379B18.5	-3.89	0.000112	0.0155	-0.24	-0.17	Blood pressure (smoking interaction);	chr3:125916812	chr3:125827238~125916384:-
LUAD	cis	rs7615952	0.551	rs12695470	ENSG00000241288.6	RP11-379B18.5	-3.89	0.000112	0.0155	-0.24	-0.17	Blood pressure (smoking interaction);	chr3:125916875	chr3:125827238~125916384:-
LUAD	cis	rs8180040	0.902	rs73081205	ENSG00000271161.1	BOLA2P2	-3.89	0.000112	0.0155	-0.17	-0.17	Colorectal cancer;	chr3:47476180	chr3:47499841~47500407:+
LUAD	cis	rs6479901	0.895	rs7073932	ENSG00000232075.1	MRPL35P2	-3.89	0.000112	0.0155	-0.24	-0.17	Intelligence (multi-trait analysis);	chr10:63350160	chr10:63634317~63634827:-
LUAD	cis	rs3018712	0.59	rs10750832	ENSG00000227620.4	ALG1L8P	-3.89	0.000112	0.0155	-0.24	-0.17	Total body bone mineral density;	chr11:68710739	chr11:67785273~67792335:+
LUAD	cis	rs3794924	1	rs3810005	ENSG00000266521.1	RP11-650P15.1	3.89	0.000112	0.0155	0.33	0.17	Survival in colon cancer;	chr18:31473913	chr18:31496645~31497195:-
LUAD	cis	rs6951245	1	rs78308415	ENSG00000199023.2	MIR339	-3.89	0.000112	0.0155	-0.31	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1032998	chr7:1022935~1023045:-
LUAD	cis	rs6546537	0.911	rs4852898	ENSG00000231024.1	AC092431.3	3.89	0.000112	0.0155	0.23	0.17	Serum thyroid-stimulating hormone levels;	chr2:69645665	chr2:69700192~69713847:-
LUAD	cis	rs763121	0.853	rs5757181	ENSG00000225450.1	RP3-508I15.14	-3.89	0.000112	0.0155	-0.18	-0.17	Menopause (age at onset);	chr22:38617517	chr22:38739003~38749041:+
LUAD	cis	rs10466239	0.803	rs60739384	ENSG00000230555.2	RP11-517P14.2	3.89	0.000112	0.0155	0.28	0.17	Telomere length;	chr10:43372581	chr10:43420738~43422100:+
LUAD	cis	rs6446298	0.738	rs6446296	ENSG00000234667.1	ACTBP13	-3.89	0.000112	0.0155	-0.23	-0.17	Intelligence (multi-trait analysis);	chr3:49800619	chr3:49873347~49877980:-
LUAD	cis	rs7674212	0.57	rs1031804	ENSG00000251288.2	RP11-10L12.2	-3.89	0.000112	0.0155	-0.22	-0.17	Type 2 diabetes;	chr4:103144892	chr4:102751401~102752641:+
LUAD	cis	rs4237845	0.804	rs10877034	ENSG00000245651.2	RP11-620J15.2	3.89	0.000112	0.0155	0.17	0.17	Intelligence (multi-trait analysis);	chr12:57892661	chr12:57869835~57896482:-
LUAD	cis	rs7968440	1	rs7977690	ENSG00000272368.2	RP4-605O3.4	3.89	0.000112	0.0155	0.2	0.17	Fibrinogen;	chr12:50736631	chr12:50112197~50165618:+
LUAD	cis	rs12539814	1	rs12539814	ENSG00000244198.4	RP4-545C24.1	3.89	0.000112	0.0155	0.3	0.17	Diastolic blood pressure;	chr7:144433417	chr7:144194858~144280547:+
LUAD	cis	rs2901790	0.78	rs13089978	ENSG00000223387.5	RP11-408H1.3	-3.89	0.000112	0.0155	-0.23	-0.17	Gait speed in old age;	chr3:172504458	chr3:172560888~172595607:-
LUAD	cis	rs848490	0.851	rs1130039	ENSG00000214293.7	APTR	3.89	0.000112	0.0155	0.23	0.17	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77657810	chr7:77657660~77696265:-
LUAD	cis	rs848490	0.888	rs56100966	ENSG00000214293.7	APTR	3.89	0.000112	0.0155	0.23	0.17	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77661233	chr7:77657660~77696265:-
LUAD	cis	rs11168618	0.74	rs4409884	ENSG00000240399.1	RP1-228P16.1	3.89	0.000112	0.0155	0.17	0.17	Adiponectin levels;	chr12:48533758	chr12:48054813~48055591:-
LUAD	cis	rs6763848	0.923	rs9310451	ENSG00000214073.2	RPL21P17	-3.89	0.000112	0.0155	-0.18	-0.17	Prostate cancer (SNP x SNP interaction);	chr3:1473988	chr3:1905651~1906125:+
LUAD	cis	rs9923856	0.519	rs720130	ENSG00000280153.1	RP11-876N24.3	3.89	0.000112	0.0155	0.12	0.17	Atopic dermatitis;Adult asthma;	chr16:11038776	chr16:10933903~10936280:+
LUAD	cis	rs4363385	0.55	rs2050673	ENSG00000223599.1	RP11-216N14.7	-3.89	0.000112	0.0155	-0.21	-0.17	Inflammatory skin disease;	chr1:152951222	chr1:153852106~153853414:-
LUAD	cis	rs2732480	0.557	rs2634682	ENSG00000273765.1	RP11-370I10.11	3.89	0.000112	0.0155	0.19	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339160	chr12:48360920~48361377:+
LUAD	cis	rs1862618	0.853	rs863840	ENSG00000271828.1	CTD-2310F14.1	3.89	0.000112	0.0155	0.25	0.17	Initial pursuit acceleration;	chr5:56833172	chr5:56927874~56929573:+
LUAD	cis	rs28712821	0.93	rs11940694	ENSG00000249207.1	RP11-360F5.1	-3.89	0.000112	0.0156	-0.19	-0.17	Alcohol consumption;	chr4:39413373	chr4:39112677~39126818:-
LUAD	cis	rs4819052	0.851	rs2236443	ENSG00000223768.1	LINC00205	-3.89	0.000112	0.0156	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258259	chr21:45293285~45297354:+
LUAD	cis	rs7246657	0.551	rs4806414	ENSG00000267309.1	CTD-2630F21.1	3.89	0.000112	0.0156	0.29	0.17	Coronary artery calcification;	chr19:37147886	chr19:36489649~36491040:+
LUAD	cis	rs7178424	0.743	rs8032681	ENSG00000259251.2	RP11-643M14.1	-3.89	0.000113	0.0156	-0.17	-0.17	Height;	chr15:61870044	chr15:62060503~62062434:+
LUAD	cis	rs7178424	0.742	rs12908081	ENSG00000259251.2	RP11-643M14.1	-3.89	0.000113	0.0156	-0.17	-0.17	Height;	chr15:61870065	chr15:62060503~62062434:+
LUAD	cis	rs7142881	0.844	rs4981865	ENSG00000258525.1	RP11-829H16.3	-3.89	0.000113	0.0156	-0.2	-0.17	Response to iloperidone treatment (QT prolongation);	chr14:31621461	chr14:30876179~30889808:-
LUAD	cis	rs7200786	0.546	rs794426	ENSG00000274038.1	RP11-66H6.4	-3.89	0.000113	0.0156	-0.22	-0.17	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11149001	chr16:11056556~11057034:+
LUAD	cis	rs6502050	0.835	rs4789665	ENSG00000266654.1	RP11-1376P16.1	-3.89	0.000113	0.0156	-0.19	-0.17	Life satisfaction;	chr17:82210221	chr17:82160056~82160452:+
LUAD	cis	rs854765	0.927	rs4925138	ENSG00000223979.2	SMCR2	3.89	0.000113	0.0156	0.2	0.17	Total body bone mineral density;	chr17:18089479	chr17:17674026~17677688:-
LUAD	cis	rs1799955	0.935	rs9634672	ENSG00000215515.2	IFIT1P1	-3.89	0.000113	0.0156	-0.25	-0.17	LDL cholesterol levels;	chr13:32369919	chr13:32384660~32386108:+
LUAD	cis	rs727479	0.962	rs7175531	ENSG00000259306.2	RP11-108K3.2	-3.89	0.000113	0.0156	-0.19	-0.17	Estradiol levels;	chr15:51241858	chr15:51315841~51321996:+
LUAD	cis	rs13113518	0.729	rs11133377	ENSG00000272969.1	RP11-528I4.2	3.89	0.000113	0.0156	0.2	0.17	Height;	chr4:55413708	chr4:55547112~55547889:+
LUAD	cis	rs7107174	0.901	rs10899493	ENSG00000251323.2	RP11-452H21.4	3.89	0.000113	0.0156	0.21	0.17	Testicular germ cell tumor;	chr11:78406488	chr11:78423982~78429836:-
LUAD	cis	rs453301	0.658	rs9650616	ENSG00000253893.2	FAM85B	3.89	0.000113	0.0156	0.23	0.17	Joint mobility (Beighton score);	chr8:9011689	chr8:8167819~8226614:-
LUAD	cis	rs911119	0.913	rs6048922	ENSG00000270001.1	RP11-218C14.8	-3.89	0.000113	0.0156	-0.25	-0.17	Chronic kidney disease;	chr20:23597479	chr20:23631826~23632316:-
LUAD	cis	rs7674212	0.541	rs2251322	ENSG00000251288.2	RP11-10L12.2	-3.89	0.000113	0.0156	-0.22	-0.17	Type 2 diabetes;	chr4:103158267	chr4:102751401~102752641:+
LUAD	cis	rs12935418	0.672	rs2602424	ENSG00000261061.1	RP11-303E16.2	3.89	0.000113	0.0156	0.19	0.17	Mean corpuscular volume;	chr16:81009600	chr16:81030770~81031485:+
LUAD	cis	rs214785	1	rs214778	ENSG00000234684.5	SDCBP2-AS1	3.89	0.000113	0.0156	0.22	0.17	Basal cell carcinoma;	chr20:2299969	chr20:1325405~1378734:+
LUAD	cis	rs897984	0.806	rs10782002	ENSG00000232748.3	RP11-196G11.6	3.89	0.000113	0.0156	0.22	0.17	Dementia with Lewy bodies;	chr16:30935185	chr16:31056460~31062803:+
LUAD	cis	rs7674212	0.54	rs2711897	ENSG00000251288.2	RP11-10L12.2	-3.89	0.000113	0.0156	-0.22	-0.17	Type 2 diabetes;	chr4:103102410	chr4:102751401~102752641:+
LUAD	cis	rs12935418	0.672	rs1453328	ENSG00000261061.1	RP11-303E16.2	-3.89	0.000113	0.0156	-0.19	-0.17	Mean corpuscular volume;	chr16:81019240	chr16:81030770~81031485:+
LUAD	cis	rs10129255	0.957	rs10142859	ENSG00000211947.2	IGHV3-21	-3.89	0.000113	0.0156	-0.12	-0.17	Kawasaki disease;	chr14:106782238	chr14:106235064~106235594:-
LUAD	cis	rs11742741	0.837	rs72745762	ENSG00000248874.4	C5orf17	-3.89	0.000113	0.0156	-0.22	-0.17	Educational attainment;	chr5:24117377	chr5:23951348~24178263:+
LUAD	cis	rs11742741	0.875	rs1582946	ENSG00000248874.4	C5orf17	-3.89	0.000113	0.0156	-0.22	-0.17	Educational attainment;	chr5:24122900	chr5:23951348~24178263:+
LUAD	cis	rs11742741	0.777	rs62350792	ENSG00000248874.4	C5orf17	-3.89	0.000113	0.0156	-0.22	-0.17	Educational attainment;	chr5:24123069	chr5:23951348~24178263:+
LUAD	cis	rs11742741	0.837	rs6888084	ENSG00000248874.4	C5orf17	-3.89	0.000113	0.0156	-0.22	-0.17	Educational attainment;	chr5:24126959	chr5:23951348~24178263:+
LUAD	cis	rs7772486	0.875	rs2748483	ENSG00000235652.6	RP11-545I5.3	-3.89	0.000113	0.0156	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:146014424	chr6:145799409~145886585:+
LUAD	cis	rs10829156	0.66	rs10828901	ENSG00000240291.1	RP11-499P20.2	3.89	0.000113	0.0156	0.16	0.17	Sudden cardiac arrest;	chr10:18552161	chr10:18513115~18545651:-
LUAD	cis	rs1334894	0.71	rs9689798	ENSG00000228559.1	RP3-340B19.3	-3.89	0.000113	0.0156	-0.34	-0.17	Coronary artery disease;	chr6:35505247	chr6:35544632~35545669:+
LUAD	cis	rs4601821	0.895	rs2282511	ENSG00000270179.1	RP11-159N11.4	-3.89	0.000113	0.0156	-0.18	-0.17	Alcoholic chronic pancreatitis;	chr11:113373455	chr11:113368478~113369117:+
LUAD	cis	rs599083	0.53	rs640569	ENSG00000212093.1	AP000807.1	-3.89	0.000113	0.0156	-0.19	-0.17	Bone mineral density (spine);	chr11:68417352	chr11:68506083~68506166:-
LUAD	cis	rs599083	0.53	rs2472415	ENSG00000212093.1	AP000807.1	-3.89	0.000113	0.0156	-0.19	-0.17	Bone mineral density (spine);	chr11:68418148	chr11:68506083~68506166:-
LUAD	cis	rs10129255	0.518	rs8009594	ENSG00000253209.1	IGHV3-65	3.89	0.000113	0.0156	0.14	0.17	Kawasaki disease;	chr14:106777494	chr14:106666092~106666532:-
LUAD	cis	rs7590268	0.697	rs3884504	ENSG00000279873.2	LINC01126	3.89	0.000113	0.0156	0.18	0.17	Orofacial clefts;	chr2:43468414	chr2:43227210~43228855:+
LUAD	cis	rs11742741	0.714	rs1428200	ENSG00000248874.4	C5orf17	-3.89	0.000113	0.0156	-0.22	-0.17	Educational attainment;	chr5:24138128	chr5:23951348~24178263:+
LUAD	cis	rs11742741	0.69	rs60235942	ENSG00000248874.4	C5orf17	-3.89	0.000113	0.0156	-0.22	-0.17	Educational attainment;	chr5:24138735	chr5:23951348~24178263:+
LUAD	cis	rs6688613	0.685	rs4657613	ENSG00000225171.2	DUTP6	-3.89	0.000113	0.0156	-0.21	-0.17	Refractive astigmatism;	chr1:166901641	chr1:166868748~166869209:+
LUAD	cis	rs7647973	0.516	rs4536858	ENSG00000225399.4	RP11-3B7.1	3.89	0.000113	0.0156	0.23	0.17	Menarche (age at onset);	chr3:49155648	chr3:49260085~49261316:+
LUAD	cis	rs10876993	0.68	rs2277322	ENSG00000245651.2	RP11-620J15.2	3.89	0.000113	0.0156	0.18	0.17	Celiac disease or Rheumatoid arthritis;	chr12:57615419	chr12:57869835~57896482:-
LUAD	cis	rs6088580	0.634	rs6059887	ENSG00000276073.1	RP5-1125A11.7	-3.89	0.000113	0.0156	-0.17	-0.17	Glomerular filtration rate (creatinine);	chr20:34513297	chr20:33985617~33988989:-
LUAD	cis	rs6088580	0.634	rs6120669	ENSG00000276073.1	RP5-1125A11.7	-3.89	0.000113	0.0156	-0.17	-0.17	Glomerular filtration rate (creatinine);	chr20:34517223	chr20:33985617~33988989:-
LUAD	cis	rs6088580	0.634	rs6059892	ENSG00000276073.1	RP5-1125A11.7	-3.89	0.000113	0.0156	-0.17	-0.17	Glomerular filtration rate (creatinine);	chr20:34517961	chr20:33985617~33988989:-
LUAD	cis	rs7463659	0.512	rs7840196	ENSG00000259820.1	AC083843.1	3.89	0.000113	0.0156	0.17	0.17	Colonoscopy-negative controls vs population controls;	chr8:134437128	chr8:134792020~134798272:-
LUAD	cis	rs6088580	0.634	rs6059868	ENSG00000276073.1	RP5-1125A11.7	-3.89	0.000113	0.0156	-0.17	-0.17	Glomerular filtration rate (creatinine);	chr20:34491655	chr20:33985617~33988989:-
LUAD	cis	rs2235573	0.527	rs139878	ENSG00000235237.1	RP1-151B14.6	-3.89	0.000113	0.0156	-0.18	-0.17	Glioma;Glioblastoma;	chr22:37965552	chr22:37166757~37182850:+
LUAD	cis	rs4713118	0.539	rs200988	ENSG00000216901.1	AL022393.7	3.89	0.000113	0.0156	0.21	0.17	Parkinson's disease;	chr6:27851575	chr6:28176188~28176674:+
LUAD	cis	rs270601	0.633	rs733300	ENSG00000263597.1	MIR3936	3.89	0.000113	0.0156	0.19	0.17	Acylcarnitine levels;	chr5:132236550	chr5:132365490~132365599:-
LUAD	cis	rs270601	0.633	rs4535443	ENSG00000263597.1	MIR3936	3.89	0.000113	0.0156	0.19	0.17	Acylcarnitine levels;	chr5:132236868	chr5:132365490~132365599:-
LUAD	cis	rs8062405	0.69	rs7187604	ENSG00000251417.2	RP11-1348G14.4	-3.89	0.000113	0.0156	-0.18	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28802743~28817828:+
LUAD	cis	rs4784934	0.513	rs2042400	ENSG00000260186.4	RP11-481J2.2	3.89	0.000113	0.0156	0.2	0.17	QT interval;	chr16:58430436	chr16:58421326~58462470:+
LUAD	cis	rs11051970	0.879	rs2728669	ENSG00000274964.1	RP11-817I4.1	-3.89	0.000113	0.0156	-0.19	-0.17	Response to tocilizumab in rheumatoid arthritis;	chr12:32437717	chr12:32339368~32340724:+
LUAD	cis	rs9310995	0.542	rs11927331	ENSG00000271020.1	RP11-10C24.1	-3.89	0.000113	0.0156	-0.23	-0.17	Pulmonary function;	chr3:32895516	chr3:33797149~33797681:-
LUAD	cis	rs6781182	0.5	rs7627333	ENSG00000236452.1	AC123023.1	3.89	0.000113	0.0157	0.19	0.17	Visceral adipose tissue adjusted for BMI;	chr3:34179985	chr3:34203244~34268811:+
LUAD	cis	rs2834288	0.535	rs881228	ENSG00000237945.6	LINC00649	3.89	0.000113	0.0157	0.23	0.17	Gut microbiota (bacterial taxa);	chr21:33950387	chr21:33915534~33977691:+
LUAD	cis	rs10129255	0.5	rs988132	ENSG00000253209.1	IGHV3-65	3.89	0.000113	0.0157	0.14	0.17	Kawasaki disease;	chr14:106776758	chr14:106666092~106666532:-
LUAD	cis	rs520525	0.963	rs524877	ENSG00000271811.1	RP1-79C4.4	3.89	0.000113	0.0157	0.22	0.17	Atrial fibrillation;	chr1:170659294	chr1:170667381~170669425:+
LUAD	cis	rs453301	0.624	rs2979256	ENSG00000253893.2	FAM85B	-3.89	0.000113	0.0157	-0.23	-0.17	Joint mobility (Beighton score);	chr8:9014200	chr8:8167819~8226614:-
LUAD	cis	rs1044826	1	rs2349059	ENSG00000214280.3	RP11-553K23.2	-3.89	0.000113	0.0157	-0.21	-0.17	Obesity-related traits;	chr3:139458090	chr3:139582928~139583593:-
LUAD	cis	rs2286720	0.932	rs73071756	ENSG00000173811.9	CCDC13-AS1	3.89	0.000113	0.0157	0.3	0.17	Response to antipsychotic treatment in schizophrenia (reasoning);	chr3:42406618	chr3:42732575~42746768:+
LUAD	cis	rs2735413	0.711	rs12921476	ENSG00000276007.1	RP11-358L22.3	-3.89	0.000113	0.0157	-0.18	-0.17	Systolic blood pressure (alcohol consumption interaction);	chr16:78045949	chr16:78123243~78124332:+
LUAD	cis	rs7674212	0.541	rs2615539	ENSG00000251288.2	RP11-10L12.2	-3.89	0.000113	0.0157	-0.22	-0.17	Type 2 diabetes;	chr4:103159949	chr4:102751401~102752641:+
LUAD	cis	rs7674212	0.57	rs2251634	ENSG00000251288.2	RP11-10L12.2	-3.89	0.000113	0.0157	-0.22	-0.17	Type 2 diabetes;	chr4:103161192	chr4:102751401~102752641:+
LUAD	cis	rs2348418	0.831	rs1581074	ENSG00000244712.1	RP11-874G11.1	3.89	0.000113	0.0157	0.21	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28571031	chr12:28564678~28565141:-
LUAD	cis	rs73198271	0.7	rs10090152	ENSG00000253893.2	FAM85B	3.89	0.000113	0.0157	0.23	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794594	chr8:8167819~8226614:-
LUAD	cis	rs6088580	0.634	rs6088475	ENSG00000276073.1	RP5-1125A11.7	3.89	0.000113	0.0157	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34377181	chr20:33985617~33988989:-
LUAD	cis	rs6088580	0.634	rs6142153	ENSG00000276073.1	RP5-1125A11.7	3.89	0.000113	0.0157	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34380941	chr20:33985617~33988989:-
LUAD	cis	rs6088580	0.634	rs6142164	ENSG00000276073.1	RP5-1125A11.7	3.89	0.000113	0.0157	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34418791	chr20:33985617~33988989:-
LUAD	cis	rs1075265	0.62	rs10192626	ENSG00000272156.1	RP11-477N3.1	-3.89	0.000113	0.0157	-0.21	-0.17	Chronotype;Morning vs. evening chronotype;	chr2:53760885	chr2:54082554~54085066:+
LUAD	cis	rs259282	0.524	rs1559180	ENSG00000201388.1	SNORA68	3.89	0.000113	0.0157	0.17	0.17	Schizophrenia;	chr19:32636537	chr19:32608337~32608469:-
LUAD	cis	rs911119	0.913	rs13043266	ENSG00000270001.1	RP11-218C14.8	-3.89	0.000114	0.0157	-0.27	-0.17	Chronic kidney disease;	chr20:23607490	chr20:23631826~23632316:-
LUAD	cis	rs2692947	1	rs2692947	ENSG00000237510.6	AC008268.2	3.89	0.000114	0.0157	0.23	0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96008368	chr2:95789654~95800166:+
LUAD	cis	rs3096299	0.606	rs8052103	ENSG00000182376.2	RP5-1142A6.8	-3.89	0.000114	0.0157	-0.2	-0.17	Multiple myeloma (IgH translocation);	chr16:89474835	chr16:88742767~88745748:+
LUAD	cis	rs9646944	0.836	rs10178214	ENSG00000234389.1	AC007278.3	3.89	0.000114	0.0157	0.2	0.17	Blood protein levels;	chr2:102242461	chr2:102438713~102440475:+
LUAD	cis	rs2243480	1	rs10807701	ENSG00000229886.1	RP5-1132H15.3	-3.89	0.000114	0.0157	-0.3	-0.17	Diabetic kidney disease;	chr7:66259699	chr7:66025126~66031544:-
LUAD	cis	rs11838267	0.527	rs1990477	ENSG00000205885.6	C1RL-AS1	-3.89	0.000114	0.0157	-0.17	-0.17	Coronary artery disease;	chr12:7056109	chr12:7108052~7122501:+
LUAD	cis	rs4879677	0.96	rs9695050	ENSG00000215441.3	CTAGE12P	3.89	0.000114	0.0157	0.21	0.17	Gut microbiome composition (summer and winter);	chr9:27671900	chr9:27608382~27610745:-
LUAD	cis	rs4795519	0.922	rs11658775	ENSG00000266313.1	RP11-173M1.4	3.89	0.000114	0.0157	0.22	0.17	Chronic myeloid leukemia;	chr17:27169538	chr17:27333256~27348491:+
LUAD	cis	rs7840202	1	rs2925778	ENSG00000253328.2	SUMO2P19	-3.89	0.000114	0.0157	-0.2	-0.17	Rate of cognitive decline in mild cognitive impairment (time interaction);Gestational age at birth in labor-initiated deliveries (child effect);	chr8:102269593	chr8:102242040~102242619:-
LUAD	cis	rs7017914	0.967	rs13257800	ENSG00000246366.5	RP11-382J12.1	3.89	0.000114	0.0157	0.16	0.17	Bone mineral density;	chr8:70801898	chr8:70608577~70663279:+
LUAD	cis	rs34929064	0.718	rs17302823	ENSG00000230658.1	KLHL7-AS1	3.89	0.000114	0.0157	0.26	0.17	Major depression and alcohol dependence;	chr7:22679790	chr7:23101228~23105703:-
LUAD	cis	rs7955901	0.904	rs7298255	ENSG00000258053.1	CTD-2021H9.3	3.89	0.000114	0.0157	0.2	0.17	Type 2 diabetes;	chr12:71034289	chr12:71047402~71118247:-
LUAD	cis	rs9287719	0.81	rs1990612	ENSG00000243819.4	RN7SL832P	3.89	0.000114	0.0157	0.18	0.17	Prostate cancer;	chr2:10641818	chr2:10690344~10692099:+
LUAD	cis	rs7178424	0.774	rs13379947	ENSG00000259251.2	RP11-643M14.1	3.89	0.000114	0.0157	0.17	0.17	Height;	chr15:61892602	chr15:62060503~62062434:+
LUAD	cis	rs2378497	1	rs2790762	ENSG00000232679.1	RP11-400N13.3	-3.89	0.000114	0.0157	-0.26	-0.17	Serum thyroid-stimulating hormone levels;	chr1:222023668	chr1:222041705~222064763:-
LUAD	cis	rs1910358	0.621	rs12109110	ENSG00000248874.4	C5orf17	-3.89	0.000114	0.0157	-0.24	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr5:23845772	chr5:23951348~24178263:+
LUAD	cis	rs62246343	0.605	rs34665459	ENSG00000254485.4	RP11-380O24.1	3.89	0.000114	0.0157	0.22	0.17	Fibrinogen levels;	chr3:9423041	chr3:9292588~9363303:-
LUAD	cis	rs6787172	0.782	rs6780782	ENSG00000272087.1	RP11-379F4.7	3.89	0.000114	0.0157	0.18	0.17	Subjective well-being;	chr3:158468546	chr3:158693120~158693768:-
LUAD	cis	rs6787172	0.728	rs7649463	ENSG00000272087.1	RP11-379F4.7	3.89	0.000114	0.0157	0.18	0.17	Subjective well-being;	chr3:158472524	chr3:158693120~158693768:-
LUAD	cis	rs6787172	0.811	rs1595030	ENSG00000272087.1	RP11-379F4.7	3.89	0.000114	0.0157	0.18	0.17	Subjective well-being;	chr3:158475878	chr3:158693120~158693768:-
LUAD	cis	rs6787172	0.811	rs6441203	ENSG00000272087.1	RP11-379F4.7	3.89	0.000114	0.0157	0.18	0.17	Subjective well-being;	chr3:158476351	chr3:158693120~158693768:-
LUAD	cis	rs6787172	0.811	rs11714821	ENSG00000272087.1	RP11-379F4.7	3.89	0.000114	0.0157	0.18	0.17	Subjective well-being;	chr3:158476896	chr3:158693120~158693768:-
LUAD	cis	rs7762018	1	rs74900588	ENSG00000231690.2	LINC00574	-3.89	0.000114	0.0157	-0.32	-0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169702084	chr6:169790321~169802873:+
LUAD	cis	rs4683346	0.731	rs760193	ENSG00000173811.9	CCDC13-AS1	3.89	0.000114	0.0157	0.2	0.17	Granulocyte percentage of myeloid white cells;	chr3:42876805	chr3:42732575~42746768:+
LUAD	cis	rs11168351	0.927	rs11168342	ENSG00000240399.1	RP1-228P16.1	3.89	0.000114	0.0157	0.17	0.17	Bipolar disorder and schizophrenia;	chr12:47990014	chr12:48054813~48055591:-
LUAD	cis	rs9302635	0.55	rs35959677	ENSG00000260886.1	TAT-AS1	3.89	0.000114	0.0157	0.23	0.17	Blood protein levels;	chr16:72166902	chr16:71565789~71578187:+
LUAD	cis	rs7302981	0.51	rs860698	ENSG00000272368.2	RP4-605O3.4	3.89	0.000114	0.0157	0.2	0.17	Systolic blood pressure;	chr12:50092539	chr12:50112197~50165618:+
LUAD	cis	rs4795519	1	rs6505101	ENSG00000266313.1	RP11-173M1.4	3.89	0.000114	0.0157	0.21	0.17	Chronic myeloid leukemia;	chr17:27142828	chr17:27333256~27348491:+
LUAD	cis	rs516805	0.52	rs549302	ENSG00000279453.1	RP3-425C14.4	-3.89	0.000114	0.0157	-0.18	-0.17	Lymphocyte counts;	chr6:122413827	chr6:122436789~122439223:-
LUAD	cis	rs2153535	0.518	rs1328868	ENSG00000230939.1	RP11-314C16.1	-3.89	0.000114	0.0157	-0.2	-0.17	Motion sickness;	chr6:8652345	chr6:8784178~8785445:+
LUAD	cis	rs9309711	0.772	rs9309714	ENSG00000271868.1	RP11-1293J14.1	-3.89	0.000114	0.0157	-0.21	-0.17	Neurofibrillary tangles;	chr2:3488059	chr2:3496956~3497428:+
LUAD	cis	rs3018712	0.59	rs4433574	ENSG00000227620.4	ALG1L8P	3.89	0.000114	0.0157	0.24	0.17	Total body bone mineral density;	chr11:68731558	chr11:67785273~67792335:+
LUAD	cis	rs6088580	0.634	rs6058070	ENSG00000276073.1	RP5-1125A11.7	-3.89	0.000114	0.0157	-0.17	-0.17	Glomerular filtration rate (creatinine);	chr20:34515716	chr20:33985617~33988989:-
LUAD	cis	rs4971059	0.654	rs4971073	ENSG00000160766.13	GBAP1	-3.89	0.000114	0.0157	-0.17	-0.17	Breast cancer;	chr1:155140628	chr1:155213821~155227422:-
LUAD	cis	rs911555	0.723	rs12436956	ENSG00000244691.1	RPL10AP1	3.89	0.000114	0.0157	0.24	0.17	Intelligence (multi-trait analysis);	chr14:103386270	chr14:103412119~103412761:-
LUAD	cis	rs34779708	0.931	rs4934721	ENSG00000271335.4	RP11-324I22.4	3.89	0.000114	0.0157	0.18	0.17	Inflammatory bowel disease;Crohn's disease;	chr10:35088787	chr10:35314552~35336401:-
LUAD	cis	rs1355223	0.902	rs11605785	ENSG00000271369.1	RP11-350D17.3	-3.89	0.000114	0.0157	-0.21	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34729840	chr11:34709600~34710161:+
LUAD	cis	rs6687758	1	rs35805428	ENSG00000238042.4	RP11-815M8.1	3.89	0.000114	0.0157	0.25	0.17	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222015280	chr1:221880981~221978523:-
LUAD	cis	rs7142881	0.815	rs6571435	ENSG00000258525.1	RP11-829H16.3	3.89	0.000114	0.0157	0.2	0.17	Response to iloperidone treatment (QT prolongation);	chr14:31567212	chr14:30876179~30889808:-
LUAD	cis	rs9637599	0.967	rs7656367	ENSG00000246375.2	RP11-10L7.1	3.89	0.000114	0.0157	0.22	0.17	Metabolite levels (small molecules and protein measures);	chr4:88275669	chr4:88284942~88331421:+
LUAD	cis	rs412050	0.895	rs2329886	ENSG00000224086.5	LL22NC03-86G7.1	-3.89	0.000114	0.0157	-0.22	-0.17	Attention deficit hyperactivity disorder;	chr22:21944102	chr22:21938293~21977632:+
LUAD	cis	rs7260598	0.642	rs10407805	ENSG00000269421.1	ZNF92P3	-3.89	0.000114	0.0157	-0.27	-0.17	Response to taxane treatment (placlitaxel);	chr19:23982903	chr19:23935220~23936173:+
LUAD	cis	rs9467773	0.525	rs1535274	ENSG00000261353.1	CTA-14H9.5	-3.89	0.000114	0.0157	-0.2	-0.17	Intelligence (multi-trait analysis);	chr6:26520519	chr6:26527063~26527404:+
LUAD	cis	rs9467773	0.565	rs6925047	ENSG00000261353.1	CTA-14H9.5	-3.89	0.000114	0.0157	-0.2	-0.17	Intelligence (multi-trait analysis);	chr6:26521207	chr6:26527063~26527404:+
LUAD	cis	rs9467773	0.565	rs4343916	ENSG00000261353.1	CTA-14H9.5	-3.89	0.000114	0.0157	-0.2	-0.17	Intelligence (multi-trait analysis);	chr6:26522447	chr6:26527063~26527404:+
LUAD	cis	rs440932	1	rs378974	ENSG00000254340.1	RP11-10A14.3	3.89	0.000114	0.0157	0.22	0.17	High light scatter reticulocyte percentage of red cells;	chr8:9169129	chr8:9141424~9145435:+
LUAD	cis	rs6471393	0.964	rs2976366	ENSG00000253848.1	RP11-10N23.5	-3.89	0.000114	0.0157	-0.22	-0.17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93708829	chr8:93741193~93744534:+
LUAD	cis	rs7777677	1	rs7777677	ENSG00000276953.1	TRBV12-4	3.89	0.000114	0.0157	0.16	0.17	Alcoholic chronic pancreatitis;	chr7:142663616	chr7:142563740~142564245:+
LUAD	cis	rs4908769	0.55	rs2029706	ENSG00000270282.1	RP5-1115A15.2	3.89	0.000114	0.0157	0.2	0.17	Allergy;	chr1:8807242	chr1:8512653~8513021:+
LUAD	cis	rs11242704	0.632	rs3000065	ENSG00000272279.1	RP11-157J24.2	-3.89	0.000114	0.0158	-0.26	-0.17	Response to hepatitis C treatment;	chr6:1536463	chr6:1528364~1528911:-
LUAD	cis	rs4423214	0.879	rs1790324	ENSG00000226627.1	SHANK2-AS1	3.89	0.000114	0.0158	0.21	0.17	Vitamin D levels;	chr11:71439474	chr11:70631094~70635490:+
LUAD	cis	rs12554020	0.582	rs79049472	ENSG00000227603.1	RP11-165J3.6	3.89	0.000114	0.0158	0.36	0.17	Schizophrenia;	chr9:93647116	chr9:93435332~93437121:-
LUAD	cis	rs2274273	0.934	rs10140869	ENSG00000258413.1	RP11-665C16.6	-3.89	0.000114	0.0158	-0.23	-0.17	Protein biomarker;	chr14:55328565	chr14:55262767~55272075:-
LUAD	cis	rs2548724	0.716	rs62370977	ENSG00000250682.4	LINC00491	3.89	0.000114	0.0158	0.22	0.17	Type 2 diabetes;	chr5:102433366	chr5:102609156~102671559:-
LUAD	cis	rs9813712	0.595	rs1901787	ENSG00000249846.5	RP11-77P16.4	3.89	0.000114	0.0158	0.21	0.17	Response to amphetamines;	chr3:130288678	chr3:130112550~130120579:+
LUAD	cis	rs3750082	0.632	rs7811630	ENSG00000231952.3	DPY19L1P2	3.89	0.000114	0.0158	0.25	0.17	Glomerular filtration rate (creatinine);	chr7:32921106	chr7:32812757~32838570:+
LUAD	cis	rs3750082	0.603	rs2278818	ENSG00000231952.3	DPY19L1P2	3.89	0.000114	0.0158	0.25	0.17	Glomerular filtration rate (creatinine);	chr7:32921568	chr7:32812757~32838570:+
LUAD	cis	rs5742933	0.857	rs7571089	ENSG00000253559.1	OSGEPL1-AS1	3.89	0.000114	0.0158	0.21	0.17	Ferritin levels;	chr2:189697067	chr2:189762704~189765556:+
LUAD	cis	rs4795519	1	rs2046021	ENSG00000266313.1	RP11-173M1.4	3.89	0.000114	0.0158	0.21	0.17	Chronic myeloid leukemia;	chr17:27143435	chr17:27333256~27348491:+
LUAD	cis	rs4795519	1	rs2127282	ENSG00000266313.1	RP11-173M1.4	3.89	0.000114	0.0158	0.21	0.17	Chronic myeloid leukemia;	chr17:27143764	chr17:27333256~27348491:+
LUAD	cis	rs4795519	0.961	rs6505102	ENSG00000266313.1	RP11-173M1.4	3.89	0.000114	0.0158	0.21	0.17	Chronic myeloid leukemia;	chr17:27144238	chr17:27333256~27348491:+
LUAD	cis	rs7762018	1	rs6923339	ENSG00000231690.2	LINC00574	-3.89	0.000114	0.0158	-0.33	-0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169727937	chr6:169790321~169802873:+
LUAD	cis	rs897984	0.76	rs11076	ENSG00000232748.3	RP11-196G11.6	3.89	0.000114	0.0158	0.22	0.17	Dementia with Lewy bodies;	chr16:30984207	chr16:31056460~31062803:+
LUAD	cis	rs287982	0.611	rs80268780	ENSG00000269973.1	RP11-95D17.1	-3.89	0.000114	0.0158	-0.25	-0.17	Nonsyndromic cleft lip with cleft palate;	chr2:9840948	chr2:9936360~9939590:+
LUAD	cis	rs7015630	0.505	rs11989430	ENSG00000251136.7	RP11-37B2.1	-3.89	0.000114	0.0158	-0.24	-0.17	Inflammatory bowel disease;Crohn's disease;	chr8:89806387	chr8:89609409~89757727:-
LUAD	cis	rs2554380	0.843	rs2562783	ENSG00000259570.1	RP11-671M22.4	3.89	0.000114	0.0158	0.25	0.17	Height;	chr15:83719174	chr15:84394512~84395514:+
LUAD	cis	rs2554380	0.843	rs2562779	ENSG00000259570.1	RP11-671M22.4	3.89	0.000114	0.0158	0.25	0.17	Height;	chr15:83722223	chr15:84394512~84395514:+
LUAD	cis	rs2554380	0.843	rs1365198	ENSG00000259570.1	RP11-671M22.4	3.89	0.000114	0.0158	0.25	0.17	Height;	chr15:83730151	chr15:84394512~84395514:+
LUAD	cis	rs968451	0.619	rs2267407	ENSG00000280216.1	RP3-333H23.9	3.89	0.000114	0.0158	0.21	0.17	Primary biliary cholangitis;	chr22:39351045	chr22:39379610~39380015:+
LUAD	cis	rs818427	0.593	rs153551	ENSG00000279522.1	CTC-487M23.6	3.89	0.000114	0.0158	0.2	0.17	Total body bone mineral density;	chr5:112899137	chr5:112894933~112896531:+
LUAD	cis	rs7551222	0.752	rs2290854	ENSG00000240219.1	RP11-430C7.5	3.89	0.000114	0.0158	0.19	0.17	Schizophrenia;	chr1:204546897	chr1:204626775~204629712:+
LUAD	cis	rs77633900	0.803	rs2956875	ENSG00000196274.5	Metazoa_SRP	3.89	0.000114	0.0158	0.23	0.17	Glioma;Non-glioblastoma glioma;	chr15:76306700	chr15:76230048~76230390:-
LUAD	cis	rs77633900	0.803	rs2469211	ENSG00000196274.5	Metazoa_SRP	3.89	0.000114	0.0158	0.23	0.17	Glioma;Non-glioblastoma glioma;	chr15:76307551	chr15:76230048~76230390:-
LUAD	cis	rs11671005	0.779	rs731259	ENSG00000268912.1	CTD-2619J13.17	-3.89	0.000114	0.0158	-0.25	-0.17	Mean platelet volume;	chr19:58478057	chr19:58428632~58431148:-
LUAD	cis	rs11073619	0.616	rs17597076	ENSG00000230373.7	GOLGA6L5P	-3.89	0.000114	0.0158	-0.28	-0.17	Positive affect;	chr15:84572704	chr15:84507885~84516814:-
LUAD	cis	rs2274273	0.84	rs10467798	ENSG00000258413.1	RP11-665C16.6	-3.89	0.000114	0.0158	-0.22	-0.17	Protein biomarker;	chr14:55258209	chr14:55262767~55272075:-
LUAD	cis	rs2274273	0.934	rs2341621	ENSG00000258413.1	RP11-665C16.6	-3.89	0.000114	0.0158	-0.22	-0.17	Protein biomarker;	chr14:55259707	chr14:55262767~55272075:-
LUAD	cis	rs2548724	0.755	rs78368500	ENSG00000250682.4	LINC00491	3.89	0.000114	0.0158	0.23	0.17	Type 2 diabetes;	chr5:102332591	chr5:102609156~102671559:-
LUAD	cis	rs2548724	0.755	rs76146936	ENSG00000250682.4	LINC00491	3.89	0.000114	0.0158	0.23	0.17	Type 2 diabetes;	chr5:102332592	chr5:102609156~102671559:-
LUAD	cis	rs2548724	0.796	rs2400800	ENSG00000250682.4	LINC00491	3.89	0.000114	0.0158	0.23	0.17	Type 2 diabetes;	chr5:102343026	chr5:102609156~102671559:-
LUAD	cis	rs8031584	0.958	rs7168641	ENSG00000259845.1	HERC2P10	3.89	0.000114	0.0158	0.2	0.17	Huntington's disease progression;	chr15:30943249	chr15:30815271~30844153:+
LUAD	cis	rs6479901	0.895	rs10761746	ENSG00000232075.1	MRPL35P2	-3.89	0.000115	0.0158	-0.24	-0.17	Intelligence (multi-trait analysis);	chr10:63345134	chr10:63634317~63634827:-
LUAD	cis	rs12541335	0.639	rs35068739	ENSG00000254064.1	CTD-2530N21.4	3.89	0.000115	0.0158	0.18	0.17	Hypertriglyceridemia;	chr8:22344206	chr8:22254576~22275162:-
LUAD	cis	rs4604732	0.642	rs6426252	ENSG00000227135.1	GCSAML-AS1	-3.89	0.000115	0.0158	-0.24	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247476585	chr1:247524679~247526752:-
LUAD	cis	rs6763848	0.962	rs11713863	ENSG00000214073.2	RPL21P17	-3.89	0.000115	0.0158	-0.18	-0.17	Prostate cancer (SNP x SNP interaction);	chr3:1471983	chr3:1905651~1906125:+
LUAD	cis	rs8028182	0.636	rs4886707	ENSG00000260269.4	CTD-2323K18.1	-3.89	0.000115	0.0158	-0.24	-0.17	Sudden cardiac arrest;	chr15:75463126	chr15:75527150~75601205:-
LUAD	cis	rs1113500	0.805	rs11185248	ENSG00000226822.1	RP11-356N1.2	-3.89	0.000115	0.0158	-0.2	-0.17	Growth-regulated protein alpha levels;	chr1:108068379	chr1:108071482~108074519:+
LUAD	cis	rs911555	0.504	rs4906340	ENSG00000269958.1	RP11-73M18.8	-3.89	0.000115	0.0158	-0.17	-0.17	Intelligence (multi-trait analysis);	chr14:103610308	chr14:103696353~103697163:+
LUAD	cis	rs10510102	1	rs10510102	ENSG00000276742.1	RP11-500G22.4	-3.89	0.000115	0.0158	-0.26	-0.17	Breast cancer;	chr10:121865675	chr10:121956782~121957098:+
LUAD	cis	rs7726839	0.794	rs10053310	ENSG00000248925.1	CTD-2083E4.6	3.89	0.000115	0.0158	0.24	0.17	Obesity-related traits;	chr5:595546	chr5:269858~271516:-
LUAD	cis	rs9309473	0.519	rs13022145	ENSG00000163016.8	ALMS1P	-3.89	0.000115	0.0158	-0.19	-0.17	Metabolite levels;	chr2:73636346	chr2:73644919~73685576:+
LUAD	cis	rs2348418	0.832	rs1405811	ENSG00000247934.4	RP11-967K21.1	3.89	0.000115	0.0158	0.2	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28428169	chr12:28163298~28190738:-
LUAD	cis	rs67981189	0.896	rs2010061	ENSG00000269927.1	RP6-91H8.3	-3.89	0.000115	0.0158	-0.22	-0.17	Schizophrenia;	chr14:70899479	chr14:71141125~71143253:-
LUAD	cis	rs2179367	0.959	rs9373592	ENSG00000216906.2	RP11-350J20.9	3.89	0.000115	0.0158	0.22	0.17	Dupuytren's disease;	chr6:149412119	chr6:149904243~149906418:+
LUAD	cis	rs7246657	0.823	rs4802236	ENSG00000226686.6	LINC01535	-3.89	0.000115	0.0158	-0.26	-0.17	Coronary artery calcification;	chr19:37428344	chr19:37251912~37265535:+
LUAD	cis	rs858239	0.539	rs2390757	ENSG00000226816.2	AC005082.12	3.89	0.000115	0.0158	0.24	0.17	Cerebrospinal fluid biomarker levels;	chr7:23151873	chr7:23206013~23208045:+
LUAD	cis	rs6781182	0.517	rs10510658	ENSG00000236452.1	AC123023.1	3.89	0.000115	0.0158	0.19	0.17	Visceral adipose tissue adjusted for BMI;	chr3:34180697	chr3:34203244~34268811:+
LUAD	cis	rs7615952	0.611	rs2947646	ENSG00000241288.6	RP11-379B18.5	3.89	0.000115	0.0158	0.27	0.17	Blood pressure (smoking interaction);	chr3:125874759	chr3:125827238~125916384:-
LUAD	cis	rs2235642	0.75	rs1894649	ENSG00000280231.1	LA16c-380F5.3	-3.89	0.000115	0.0158	-0.23	-0.17	Coronary artery disease;	chr16:1607283	chr16:1553655~1554130:-
LUAD	cis	rs62025270	0.632	rs62022942	ENSG00000259416.2	RP11-158M2.5	-3.89	0.000115	0.0158	-0.23	-0.17	Idiopathic pulmonary fibrosis;	chr15:85715337	chr15:85754941~85756237:-
LUAD	cis	rs7202877	0.706	rs8046184	ENSG00000280152.1	RP11-331F4.5	3.89	0.000115	0.0158	0.2	0.17	Type 1 diabetes;Type 2 diabetes;	chr16:75377827	chr16:75245994~75250077:-
LUAD	cis	rs14027	0.512	rs7825803	ENSG00000279347.1	RP11-85I17.2	-3.89	0.000115	0.0158	-0.15	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119716558	chr8:119838736~119840385:-
LUAD	cis	rs14027	0.512	rs13252708	ENSG00000279347.1	RP11-85I17.2	-3.89	0.000115	0.0158	-0.15	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119718283	chr8:119838736~119840385:-
LUAD	cis	rs1075265	0.744	rs10203576	ENSG00000272156.1	RP11-477N3.1	-3.89	0.000115	0.0158	-0.21	-0.17	Chronotype;Morning vs. evening chronotype;	chr2:54060939	chr2:54082554~54085066:+
LUAD	cis	rs7976269	0.583	rs2117997	ENSG00000257176.2	RP11-996F15.2	3.89	0.000115	0.0158	0.2	0.17	Male-pattern baldness;	chr12:29143428	chr12:29280418~29317848:-
LUAD	cis	rs896854	0.608	rs7004862	ENSG00000253528.2	RP11-347C18.4	3.89	0.000115	0.0158	0.17	0.17	Type 2 diabetes;	chr8:94864735	chr8:94974573~94974853:-
LUAD	cis	rs7617773	0.743	rs13081633	ENSG00000199476.1	Y_RNA	-3.89	0.000115	0.0158	-0.23	-0.17	Coronary artery disease;	chr3:48315791	chr3:48288587~48288694:+
LUAD	cis	rs12541335	0.59	rs11136002	ENSG00000254064.1	CTD-2530N21.4	3.89	0.000115	0.0158	0.18	0.17	Hypertriglyceridemia;	chr8:22359569	chr8:22254576~22275162:-
LUAD	cis	rs853679	0.607	rs66886492	ENSG00000219392.1	RP1-265C24.5	-3.89	0.000115	0.0158	-0.39	-0.17	Depression;	chr6:28121953	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.607	rs35345226	ENSG00000219392.1	RP1-265C24.5	-3.89	0.000115	0.0158	-0.39	-0.17	Depression;	chr6:28123802	chr6:28115628~28116551:+
LUAD	cis	rs6951245	0.706	rs28483034	ENSG00000199023.2	MIR339	-3.89	0.000115	0.0158	-0.3	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1130535	chr7:1022935~1023045:-
LUAD	cis	rs7584330	0.78	rs9973650	ENSG00000222032.1	AC112721.2	3.89	0.000115	0.0158	0.21	0.17	Prostate cancer;	chr2:237471623	chr2:237428920~237434822:-
LUAD	cis	rs858239	0.601	rs764534	ENSG00000226816.2	AC005082.12	3.89	0.000115	0.0158	0.23	0.17	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23206013~23208045:+
LUAD	cis	rs858239	0.601	rs2068459	ENSG00000226816.2	AC005082.12	3.89	0.000115	0.0158	0.23	0.17	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23206013~23208045:+
LUAD	cis	rs858239	0.601	rs73272053	ENSG00000226816.2	AC005082.12	3.89	0.000115	0.0158	0.23	0.17	Cerebrospinal fluid biomarker levels;	chr7:23115906	chr7:23206013~23208045:+
LUAD	cis	rs4767841	0.806	rs1122119	ENSG00000248636.5	RP11-768F21.1	-3.89	0.000115	0.0158	-0.2	-0.17	Urgency urinary incontinence;	chr12:119748903	chr12:119387987~119668079:-
LUAD	cis	rs11157436	0.56	rs2031071	ENSG00000211812.1	TRAV26-2	-3.89	0.000115	0.0158	-0.17	-0.17	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22157547	chr14:22202583~22203368:+
LUAD	cis	rs8180040	0.967	rs4858890	ENSG00000271161.1	BOLA2P2	-3.89	0.000115	0.0158	-0.17	-0.17	Colorectal cancer;	chr3:47363966	chr3:47499841~47500407:+
LUAD	cis	rs9876781	1	rs13314659	ENSG00000229759.1	MRPS18AP1	-3.89	0.000115	0.0158	-0.17	-0.17	Longevity;	chr3:48407742	chr3:48256350~48256938:-
LUAD	cis	rs116095464	0.558	rs7713524	ENSG00000248925.1	CTD-2083E4.6	-3.89	0.000115	0.0158	-0.29	-0.17	Breast cancer;	chr5:276085	chr5:269858~271516:-
LUAD	cis	rs7937890	0.535	rs2575857	ENSG00000254418.1	RP11-21L19.1	3.89	0.000115	0.0158	0.2	0.17	Mitochondrial DNA levels;	chr11:14479750	chr11:14262846~14273691:-
LUAD	cis	rs6095360	1	rs1997854	ENSG00000222365.1	SNORD12B	3.89	0.000115	0.0158	0.18	0.17	Intelligence (multi-trait analysis);	chr20:48985802	chr20:49280319~49280409:+
LUAD	cis	rs4843747	0.671	rs9921236	ENSG00000205037.2	RP11-863P13.4	3.89	0.000115	0.0158	0.24	0.17	Menopause (age at onset);	chr16:88083409	chr16:88088041~88100985:-
LUAD	cis	rs6787172	0.628	rs58363161	ENSG00000272087.1	RP11-379F4.7	3.89	0.000115	0.0159	0.19	0.17	Subjective well-being;	chr3:158540523	chr3:158693120~158693768:-
LUAD	cis	rs683250	0.661	rs2507854	ENSG00000246067.6	RAB30-AS1	-3.89	0.000115	0.0159	-0.19	-0.17	Subcortical brain region volumes;	chr11:83417189	chr11:83072066~83106719:+
LUAD	cis	rs17711722	0.701	rs4467826	ENSG00000273142.1	RP11-458F8.4	-3.89	0.000115	0.0159	-0.12	-0.17	Calcium levels;	chr7:65903721	chr7:66902857~66906297:+
LUAD	cis	rs7772486	0.875	rs1125461	ENSG00000235652.6	RP11-545I5.3	3.89	0.000115	0.0159	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:146096517	chr6:145799409~145886585:+
LUAD	cis	rs7557067	1	rs4564803	ENSG00000233005.1	AC067959.1	-3.89	0.000115	0.0159	-0.2	-0.17	Triglycerides;	chr2:20982630	chr2:21221175~21970959:+
LUAD	cis	rs1334894	0.818	rs72899794	ENSG00000228559.1	RP3-340B19.3	-3.89	0.000115	0.0159	-0.37	-0.17	Coronary artery disease;	chr6:35547457	chr6:35544632~35545669:+
LUAD	cis	rs1334894	0.901	rs72899796	ENSG00000228559.1	RP3-340B19.3	-3.89	0.000115	0.0159	-0.37	-0.17	Coronary artery disease;	chr6:35547659	chr6:35544632~35545669:+
LUAD	cis	rs1334894	0.901	rs72911380	ENSG00000228559.1	RP3-340B19.3	-3.89	0.000115	0.0159	-0.37	-0.17	Coronary artery disease;	chr6:35551706	chr6:35544632~35545669:+
LUAD	cis	rs9656709	0.528	rs4320501	ENSG00000226278.1	PSPHP1	3.89	0.000115	0.0159	0.2	0.17	Behavioural disinhibition (generation interaction);	chr7:55662529	chr7:55764797~55773288:+
LUAD	cis	rs9549260	0.755	rs7985364	ENSG00000229456.1	RLIMP1	3.89	0.000115	0.0159	0.19	0.17	Red blood cell count;	chr13:40605443	chr13:40618738~40621348:+
LUAD	cis	rs2554380	0.8	rs8032414	ENSG00000259570.1	RP11-671M22.4	3.89	0.000115	0.0159	0.25	0.17	Height;	chr15:83727217	chr15:84394512~84395514:+
LUAD	cis	rs7674212	0.539	rs2866635	ENSG00000251288.2	RP11-10L12.2	-3.89	0.000115	0.0159	-0.22	-0.17	Type 2 diabetes;	chr4:103200419	chr4:102751401~102752641:+
LUAD	cis	rs7976269	0.609	rs2196482	ENSG00000275476.1	RP11-996F15.4	-3.89	0.000115	0.0159	-0.19	-0.17	Male-pattern baldness;	chr12:29052559	chr12:29277397~29277882:-
LUAD	cis	rs7976269	0.609	rs2217906	ENSG00000275476.1	RP11-996F15.4	-3.89	0.000115	0.0159	-0.19	-0.17	Male-pattern baldness;	chr12:29052626	chr12:29277397~29277882:-
LUAD	cis	rs17122278	1	rs11216907	ENSG00000243431.1	RPL5P30	3.89	0.000115	0.0159	0.22	0.17	Total cholesterol levels;	chr11:118573810	chr11:118560690~118561580:+
LUAD	cis	rs2439831	0.681	rs28578454	ENSG00000249839.1	AC011330.5	-3.89	0.000115	0.0159	-0.34	-0.17	Lung cancer in ever smokers;	chr15:43310834	chr15:43663654~43684339:-
LUAD	cis	rs57104699	0.668	rs11763709	ENSG00000225541.1	AC002480.5	3.89	0.000115	0.0159	0.2	0.17	Multiple myeloma and monoclonal gammopathy;Multiple myeloma;	chr7:21886360	chr7:22571607~22661792:-
LUAD	cis	rs4363385	0.53	rs58298199	ENSG00000223599.1	RP11-216N14.7	-3.89	0.000115	0.0159	-0.21	-0.17	Inflammatory skin disease;	chr1:152936338	chr1:153852106~153853414:-
LUAD	cis	rs9549260	0.564	rs9577107	ENSG00000229456.1	RLIMP1	3.89	0.000115	0.0159	0.19	0.17	Red blood cell count;	chr13:40697540	chr13:40618738~40621348:+
LUAD	cis	rs4130344	0.874	rs11942564	ENSG00000271817.2	U3	-3.89	0.000115	0.0159	-0.18	-0.17	Intelligence (multi-trait analysis);	chr4:158784715	chr4:158700691~158700909:+
LUAD	cis	rs8141529	0.748	rs7287918	ENSG00000272858.1	CTA-292E10.8	-3.89	0.000115	0.0159	-0.19	-0.17	Lymphocyte counts;	chr22:28885722	chr22:28814914~28815662:+
LUAD	cis	rs8141529	0.748	rs1318025	ENSG00000272858.1	CTA-292E10.8	-3.89	0.000115	0.0159	-0.19	-0.17	Lymphocyte counts;	chr22:28887769	chr22:28814914~28815662:+
LUAD	cis	rs3177980	0.529	rs648576	ENSG00000239494.2	RN7SL333P	3.89	0.000115	0.0159	0.16	0.17	Amyotrophic lateral sclerosis;	chr1:169930286	chr1:169859756~169860052:+
LUAD	cis	rs6724465	0.866	rs58131656	ENSG00000272644.1	RP11-33O4.1	3.89	0.000115	0.0159	0.26	0.17	Height;	chr2:219036086	chr2:219069354~219069809:-
LUAD	cis	rs10510102	0.516	rs2420976	ENSG00000276742.1	RP11-500G22.4	-3.89	0.000115	0.0159	-0.29	-0.17	Breast cancer;	chr10:121986932	chr10:121956782~121957098:+
LUAD	cis	rs6558530	0.666	rs4242538	ENSG00000253982.1	CTD-2336O2.1	3.89	0.000115	0.0159	0.23	0.17	Systolic blood pressure;	chr8:1745844	chr8:1761990~1764502:-
LUAD	cis	rs9549260	0.785	rs2253001	ENSG00000229456.1	RLIMP1	3.89	0.000115	0.0159	0.19	0.17	Red blood cell count;	chr13:40571193	chr13:40618738~40621348:+
LUAD	cis	rs9341808	0.905	rs9343977	ENSG00000260645.1	RP11-250B2.5	3.89	0.000115	0.0159	0.16	0.17	Sitting height ratio;	chr6:80257284	chr6:80466958~80469080:+
LUAD	cis	rs7584330	0.744	rs10929235	ENSG00000222032.1	AC112721.2	3.89	0.000115	0.0159	0.22	0.17	Prostate cancer;	chr2:237471629	chr2:237428920~237434822:-
LUAD	cis	rs7968440	1	rs7968440	ENSG00000272368.2	RP4-605O3.4	3.89	0.000115	0.0159	0.2	0.17	Fibrinogen;	chr12:50740958	chr12:50112197~50165618:+
LUAD	cis	rs9467773	0.967	rs6941022	ENSG00000241549.7	GUSBP2	3.89	0.000115	0.0159	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26553303	chr6:26871484~26956554:-
LUAD	cis	rs9467773	1	rs2224380	ENSG00000241549.7	GUSBP2	3.89	0.000115	0.0159	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26553715	chr6:26871484~26956554:-
LUAD	cis	rs9467773	1	rs6930120	ENSG00000241549.7	GUSBP2	3.89	0.000115	0.0159	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26555256	chr6:26871484~26956554:-
LUAD	cis	rs9467773	1	rs10484442	ENSG00000241549.7	GUSBP2	3.89	0.000115	0.0159	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26555651	chr6:26871484~26956554:-
LUAD	cis	rs9467773	1	rs767471	ENSG00000241549.7	GUSBP2	3.89	0.000115	0.0159	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26557626	chr6:26871484~26956554:-
LUAD	cis	rs2749592	0.55	rs12255038	ENSG00000263064.2	RP11-291L22.7	-3.89	0.000115	0.0159	-0.18	-0.17	Age-related hearing impairment (SNP x SNP interaction);	chr10:37580404	chr10:38448689~38448949:+
LUAD	cis	rs2446066	0.872	rs12582170	ENSG00000257379.1	RP11-793H13.8	-3.89	0.000115	0.0159	-0.27	-0.17	Red blood cell count;	chr12:53364047	chr12:53441741~53467528:+
LUAD	cis	rs2348418	0.715	rs1355471	ENSG00000244712.1	RP11-874G11.1	-3.89	0.000115	0.0159	-0.2	-0.17	Lung function (FEV1);Lung function (FVC);	chr12:28568792	chr12:28564678~28565141:-
LUAD	cis	rs71718386	1	rs71718386	ENSG00000229456.1	RLIMP1	3.89	0.000115	0.0159	0.19	0.17	Eosinophil counts;	chr13:40650154	chr13:40618738~40621348:+
LUAD	cis	rs7512552	0.803	rs11205385	ENSG00000275557.1	RP11-353N4.6	3.89	0.000115	0.0159	0.2	0.17	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150504040	chr1:149607765~149612402:+
LUAD	cis	rs7512552	0.803	rs3738487	ENSG00000275557.1	RP11-353N4.6	3.89	0.000115	0.0159	0.2	0.17	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150504585	chr1:149607765~149612402:+
LUAD	cis	rs7100689	0.58	rs10736366	ENSG00000226659.1	RP11-137H2.4	-3.89	0.000115	0.0159	-0.24	-0.17	Post bronchodilator FEV1;	chr10:80448165	chr10:80529597~80535942:-
LUAD	cis	rs7100689	0.58	rs2168721	ENSG00000226659.1	RP11-137H2.4	-3.89	0.000115	0.0159	-0.24	-0.17	Post bronchodilator FEV1;	chr10:80448436	chr10:80529597~80535942:-
LUAD	cis	rs748404	0.666	rs12908460	ENSG00000249839.1	AC011330.5	-3.89	0.000115	0.0159	-0.27	-0.17	Lung cancer;	chr15:43413472	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.666	rs2230451	ENSG00000249839.1	AC011330.5	-3.89	0.000115	0.0159	-0.27	-0.17	Lung cancer;	chr15:43415610	chr15:43663654~43684339:-
LUAD	cis	rs6793245	0.843	rs11129795	ENSG00000229589.1	ACVR2B-AS1	-3.89	0.000115	0.0159	-0.23	-0.17	QT interval;	chr3:38547672	chr3:38451027~38454820:-
LUAD	cis	rs763121	0.853	rs10135	ENSG00000228274.3	RP3-508I15.9	3.89	0.000116	0.0159	0.16	0.17	Menopause (age at onset);	chr22:38686169	chr22:38667585~38681820:-
LUAD	cis	rs17406451	0.819	rs12465064	ENSG00000279873.2	LINC01126	3.89	0.000116	0.0159	0.15	0.17	Mitochondrial DNA levels;	chr2:43419000	chr2:43227210~43228855:+
LUAD	cis	rs4237845	0.844	rs4628718	ENSG00000224713.4	AC025165.8	-3.89	0.000116	0.0159	-0.19	-0.17	Intelligence (multi-trait analysis);	chr12:57907817	chr12:57612118~57619638:-
LUAD	cis	rs7560272	0.538	rs17350056	ENSG00000163016.8	ALMS1P	-3.89	0.000116	0.0159	-0.19	-0.17	Schizophrenia;	chr2:73695750	chr2:73644919~73685576:+
LUAD	cis	rs6988985	0.678	rs9643358	ENSG00000247317.3	RP11-273G15.2	-3.89	0.000116	0.0159	-0.21	-0.17	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142921722	chr8:142981738~143018437:-
LUAD	cis	rs2253762	0.54	rs7358186	ENSG00000276742.1	RP11-500G22.4	3.89	0.000116	0.0159	0.27	0.17	Breast cancer;	chr10:122000816	chr10:121956782~121957098:+
LUAD	cis	rs2439831	0.681	rs2278858	ENSG00000249839.1	AC011330.5	-3.89	0.000116	0.0159	-0.34	-0.17	Lung cancer in ever smokers;	chr15:43340557	chr15:43663654~43684339:-
LUAD	cis	rs13434995	0.513	rs13133077	ENSG00000273257.1	RP11-177J6.1	3.89	0.000116	0.0159	0.24	0.17	Adiponectin levels;	chr4:55577642	chr4:55387949~55388271:+
LUAD	cis	rs13434995	0.513	rs7665286	ENSG00000273257.1	RP11-177J6.1	3.89	0.000116	0.0159	0.24	0.17	Adiponectin levels;	chr4:55578765	chr4:55387949~55388271:+
LUAD	cis	rs13434995	0.513	rs7683997	ENSG00000273257.1	RP11-177J6.1	3.89	0.000116	0.0159	0.24	0.17	Adiponectin levels;	chr4:55581272	chr4:55387949~55388271:+
LUAD	cis	rs3764400	0.567	rs4995899	ENSG00000278765.1	RP5-890E16.5	3.89	0.000116	0.0159	0.31	0.17	Body mass index;	chr17:48073368	chr17:48066704~48067293:-
LUAD	cis	rs3764400	0.567	rs16951519	ENSG00000278765.1	RP5-890E16.5	3.89	0.000116	0.0159	0.31	0.17	Body mass index;	chr17:48074929	chr17:48066704~48067293:-
LUAD	cis	rs3764400	0.567	rs12946143	ENSG00000278765.1	RP5-890E16.5	3.89	0.000116	0.0159	0.31	0.17	Body mass index;	chr17:48077581	chr17:48066704~48067293:-
LUAD	cis	rs9302635	0.513	rs13334151	ENSG00000260886.1	TAT-AS1	3.89	0.000116	0.0159	0.23	0.17	Blood protein levels;	chr16:72155828	chr16:71565789~71578187:+
LUAD	cis	rs858239	0.601	rs73272048	ENSG00000226816.2	AC005082.12	3.89	0.000116	0.0159	0.23	0.17	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23206013~23208045:+
LUAD	cis	rs950880	0.767	rs1420098	ENSG00000234389.1	AC007278.3	-3.89	0.000116	0.0159	-0.16	-0.17	Serum protein levels (sST2);	chr2:102367819	chr2:102438713~102440475:+
LUAD	cis	rs950880	0.699	rs1882348	ENSG00000234389.1	AC007278.3	-3.89	0.000116	0.0159	-0.16	-0.17	Serum protein levels (sST2);	chr2:102368211	chr2:102438713~102440475:+
LUAD	cis	rs3812049	0.737	rs1112956	ENSG00000245937.6	LINC01184	-3.89	0.000116	0.0159	-0.25	-0.17	Lymphocyte counts;Red cell distribution width;	chr5:128098106	chr5:127940426~128083172:-
LUAD	cis	rs7674212	0.865	rs13149311	ENSG00000251288.2	RP11-10L12.2	-3.89	0.000116	0.0159	-0.22	-0.17	Type 2 diabetes;	chr4:103056543	chr4:102751401~102752641:+
LUAD	cis	rs2115630	0.645	rs1107179	ENSG00000259728.4	LINC00933	3.89	0.000116	0.0159	0.22	0.17	P wave terminal force;	chr15:84655131	chr15:84570649~84580175:+
LUAD	cis	rs12478296	0.892	rs11893879	ENSG00000261186.2	RP11-341N2.1	-3.89	0.000116	0.0159	-0.27	-0.17	Obesity-related traits;	chr2:242068260	chr2:242087351~242088457:-
LUAD	cis	rs7714584	1	rs10065172	ENSG00000197083.10	ZNF300P1	3.89	0.000116	0.0159	0.33	0.17	Crohn's disease;	chr5:150848436	chr5:150930645~150946289:-
LUAD	cis	rs7714584	1	rs7705542	ENSG00000197083.10	ZNF300P1	3.89	0.000116	0.0159	0.33	0.17	Crohn's disease;	chr5:150848756	chr5:150930645~150946289:-
LUAD	cis	rs6601306	1	rs6601306	ENSG00000233609.3	RP11-62H7.2	-3.89	0.000116	0.0159	-0.24	-0.17	Response to inhaled corticosteroid treatment in asthma (change in FEV1);	chr8:9407201	chr8:8961200~8979025:+
LUAD	cis	rs6095360	0.727	rs13037063	ENSG00000222365.1	SNORD12B	-3.89	0.000116	0.0159	-0.2	-0.17	Intelligence (multi-trait analysis);	chr20:48909128	chr20:49280319~49280409:+
LUAD	cis	rs6095360	0.727	rs13037942	ENSG00000222365.1	SNORD12B	-3.89	0.000116	0.0159	-0.2	-0.17	Intelligence (multi-trait analysis);	chr20:48909134	chr20:49280319~49280409:+
LUAD	cis	rs6500602	0.964	rs13335685	ENSG00000280063.1	RP11-295D4.3	3.89	0.000116	0.0159	0.12	0.17	Schizophrenia;	chr16:4419283	chr16:4346694~4348648:-
LUAD	cis	rs12908161	0.959	rs62019472	ENSG00000254414.1	RP11-182J1.1	3.89	0.000116	0.0159	0.23	0.17	Schizophrenia;	chr15:84788262	chr15:84631898~84633987:-
LUAD	cis	rs897984	0.762	rs7206511	ENSG00000232748.3	RP11-196G11.6	3.89	0.000116	0.0159	0.22	0.17	Dementia with Lewy bodies;	chr16:30939031	chr16:31056460~31062803:+
LUAD	cis	rs8049040	0.609	rs7188858	ENSG00000260886.1	TAT-AS1	3.89	0.000116	0.0159	0.21	0.17	Blood protein levels;	chr16:71434992	chr16:71565789~71578187:+
LUAD	cis	rs957448	0.507	rs1984711	ENSG00000253175.1	RP11-267M23.6	3.89	0.000116	0.0159	0.2	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94600276	chr8:94565036~94565715:+
LUAD	cis	rs10090774	0.71	rs11995103	ENSG00000280303.2	ERICD	-3.89	0.000116	0.0159	-0.2	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140683162	chr8:140636281~140638283:+
LUAD	cis	rs35740288	0.731	rs11638407	ENSG00000259407.1	RP11-158M2.3	-3.89	0.000116	0.0159	-0.17	-0.17	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85551424	chr15:85744109~85750281:-
LUAD	cis	rs360798	0.688	rs1038573	ENSG00000231609.4	AC009501.4	3.89	0.000116	0.0159	0.21	0.17	Coronary artery disease;	chr2:62674879	chr2:63043922~63048640:-
LUAD	cis	rs3864261	0.515	rs57149385	ENSG00000272081.1	CTD-2376I4.2	3.89	0.000116	0.0159	0.23	0.17	Discordance in emotional problems in monozygotic twins;	chr5:73060354	chr5:72955206~72955699:-
LUAD	cis	rs3864261	0.515	rs10942539	ENSG00000272081.1	CTD-2376I4.2	3.89	0.000116	0.0159	0.23	0.17	Discordance in emotional problems in monozygotic twins;	chr5:73061259	chr5:72955206~72955699:-
LUAD	cis	rs17301013	0.932	rs2987874	ENSG00000227373.4	RP11-160H22.5	-3.89	0.000116	0.016	-0.22	-0.17	Systemic lupus erythematosus;	chr1:174801053	chr1:174115300~174160004:-
LUAD	cis	rs1979679	0.659	rs11049461	ENSG00000278733.1	RP11-425D17.1	3.89	0.000116	0.016	0.24	0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28207688	chr12:28185625~28186190:-
LUAD	cis	rs8028182	0.636	rs62027209	ENSG00000246877.1	DNM1P35	3.89	0.000116	0.016	0.23	0.17	Sudden cardiac arrest;	chr15:75579285	chr15:75727670~75738623:-
LUAD	cis	rs7615952	0.512	rs1077621	ENSG00000250012.1	RP11-124N2.1	-3.89	0.000116	0.016	-0.25	-0.17	Blood pressure (smoking interaction);	chr3:126100956	chr3:126084220~126095349:+
LUAD	cis	rs7615952	0.512	rs4646765	ENSG00000250012.1	RP11-124N2.1	-3.89	0.000116	0.016	-0.25	-0.17	Blood pressure (smoking interaction);	chr3:126101864	chr3:126084220~126095349:+
LUAD	cis	rs7615952	0.576	rs4646763	ENSG00000250012.1	RP11-124N2.1	-3.89	0.000116	0.016	-0.25	-0.17	Blood pressure (smoking interaction);	chr3:126103286	chr3:126084220~126095349:+
LUAD	cis	rs7615952	0.576	rs4646759	ENSG00000250012.1	RP11-124N2.1	-3.89	0.000116	0.016	-0.25	-0.17	Blood pressure (smoking interaction);	chr3:126104103	chr3:126084220~126095349:+
LUAD	cis	rs9467773	1	rs1570059	ENSG00000241549.7	GUSBP2	3.89	0.000116	0.016	0.2	0.17	Intelligence (multi-trait analysis);	chr6:26573097	chr6:26871484~26956554:-
LUAD	cis	rs9467773	1	rs6456735	ENSG00000241549.7	GUSBP2	3.89	0.000116	0.016	0.2	0.17	Intelligence (multi-trait analysis);	chr6:26573921	chr6:26871484~26956554:-
LUAD	cis	rs453301	0.624	rs4841083	ENSG00000253981.4	ALG1L13P	3.89	0.000116	0.016	0.21	0.17	Joint mobility (Beighton score);	chr8:9012918	chr8:8236003~8244667:-
LUAD	cis	rs2239547	0.603	rs2276825	ENSG00000243224.1	RP5-1157M23.2	-3.89	0.000116	0.016	-0.2	-0.17	Schizophrenia;	chr3:52852589	chr3:52239258~52241097:+
LUAD	cis	rs17507216	0.958	rs28648832	ENSG00000276710.3	CSPG4P8	-3.89	0.000116	0.016	-0.19	-0.17	Excessive daytime sleepiness;	chr15:82567642	chr15:82459472~82477258:+
LUAD	cis	rs10090774	0.71	rs11166992	ENSG00000280303.2	ERICD	-3.89	0.000116	0.016	-0.19	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140667371	chr8:140636281~140638283:+
LUAD	cis	rs2243480	1	rs464895	ENSG00000229886.1	RP5-1132H15.3	3.89	0.000116	0.016	0.3	0.17	Diabetic kidney disease;	chr7:66062119	chr7:66025126~66031544:-
LUAD	cis	rs116095464	0.558	rs2162870	ENSG00000248925.1	CTD-2083E4.6	3.89	0.000116	0.016	0.29	0.17	Breast cancer;	chr5:228014	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs28729548	ENSG00000248925.1	CTD-2083E4.6	3.89	0.000116	0.016	0.29	0.17	Breast cancer;	chr5:228910	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs9688136	ENSG00000248925.1	CTD-2083E4.6	3.89	0.000116	0.016	0.29	0.17	Breast cancer;	chr5:229233	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs62347683	ENSG00000248925.1	CTD-2083E4.6	3.89	0.000116	0.016	0.29	0.17	Breast cancer;	chr5:230216	chr5:269858~271516:-
LUAD	cis	rs116095464	0.51	rs55750776	ENSG00000248925.1	CTD-2083E4.6	3.89	0.000116	0.016	0.29	0.17	Breast cancer;	chr5:230352	chr5:269858~271516:-
LUAD	cis	rs116095464	0.764	rs10069197	ENSG00000248925.1	CTD-2083E4.6	3.89	0.000116	0.016	0.29	0.17	Breast cancer;	chr5:230707	chr5:269858~271516:-
LUAD	cis	rs116095464	0.867	rs10074958	ENSG00000248925.1	CTD-2083E4.6	3.89	0.000116	0.016	0.29	0.17	Breast cancer;	chr5:230713	chr5:269858~271516:-
LUAD	cis	rs2274273	0.661	rs2147964	ENSG00000259318.1	RP11-454L9.2	3.89	0.000116	0.016	0.16	0.17	Protein biomarker;	chr14:55097677	chr14:55394940~55395233:-
LUAD	cis	rs3018712	0.59	rs4930601	ENSG00000227620.4	ALG1L8P	-3.89	0.000116	0.016	-0.24	-0.17	Total body bone mineral density;	chr11:68729903	chr11:67785273~67792335:+
LUAD	cis	rs786425	0.966	rs4456350	ENSG00000278112.1	RP11-972P1.11	3.89	0.000116	0.016	0.16	0.17	Pubertal anthropometrics;	chr12:123573942	chr12:123519390~123519856:-
LUAD	cis	rs71636778	1	rs71636778	ENSG00000260063.1	RP5-968P14.2	-3.89	0.000116	0.016	-0.23	-0.17	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26778121	chr1:26692132~26694131:-
LUAD	cis	rs4664293	0.715	rs13002625	ENSG00000224152.1	AC009506.1	3.89	0.000116	0.016	0.17	0.17	Monocyte percentage of white cells;	chr2:159648114	chr2:159615296~159617082:+
LUAD	cis	rs875971	0.522	rs781144	ENSG00000273142.1	RP11-458F8.4	-3.89	0.000116	0.016	-0.12	-0.17	Aortic root size;	chr7:65975357	chr7:66902857~66906297:+
LUAD	cis	rs11675251	0.68	rs3933629	ENSG00000273456.1	RP11-686O6.2	3.89	0.000116	0.016	0.17	0.17	Butyrylcholinesterase levels;	chr2:202901644	chr2:202374932~202375604:-
LUAD	cis	rs3794924	1	rs8091481	ENSG00000266521.1	RP11-650P15.1	3.89	0.000116	0.016	0.33	0.17	Survival in colon cancer;	chr18:31471714	chr18:31496645~31497195:-
LUAD	cis	rs12935418	0.616	rs2549855	ENSG00000261061.1	RP11-303E16.2	-3.89	0.000116	0.016	-0.18	-0.17	Mean corpuscular volume;	chr16:80993247	chr16:81030770~81031485:+
LUAD	cis	rs10463554	0.963	rs34773	ENSG00000250682.4	LINC00491	3.89	0.000116	0.016	0.21	0.17	Parkinson's disease;	chr5:103114872	chr5:102609156~102671559:-
LUAD	cis	rs2235573	0.527	rs139866	ENSG00000235237.1	RP1-151B14.6	-3.89	0.000116	0.016	-0.18	-0.17	Glioma;Glioblastoma;	chr22:37958677	chr22:37166757~37182850:+
LUAD	cis	rs4764487	0.622	rs2268014	ENSG00000202318.1	Y_RNA	-3.89	0.000116	0.016	-0.18	-0.17	Mean platelet volume;	chr12:6216416	chr12:6234345~6234455:-
LUAD	cis	rs801193	0.569	rs11761542	ENSG00000273448.1	RP11-166O4.6	3.89	0.000116	0.016	0.17	0.17	Aortic root size;	chr7:66753209	chr7:67333047~67334383:+
LUAD	cis	rs9487094	0.744	rs13211604	ENSG00000260273.1	RP11-425D10.10	3.89	0.000116	0.016	0.26	0.17	Height;	chr6:109712525	chr6:109382795~109383666:+
LUAD	cis	rs7429990	0.932	rs2166772	ENSG00000228638.1	FCF1P2	3.89	0.000116	0.016	0.2	0.17	Educational attainment (years of education);	chr3:48006384	chr3:48290793~48291375:-
LUAD	cis	rs911119	0.866	rs4815223	ENSG00000270001.1	RP11-218C14.8	-3.89	0.000116	0.016	-0.25	-0.17	Chronic kidney disease;	chr20:23596475	chr20:23631826~23632316:-
LUAD	cis	rs6964587	1	rs12540055	ENSG00000188693.7	CYP51A1-AS1	-3.89	0.000116	0.016	-0.2	-0.17	Breast cancer;	chr7:92078607	chr7:92134604~92180725:+
LUAD	cis	rs6787172	0.811	rs1369562	ENSG00000272087.1	RP11-379F4.7	3.89	0.000116	0.016	0.18	0.17	Subjective well-being;	chr3:158490771	chr3:158693120~158693768:-
LUAD	cis	rs41298997	1	rs41298997	ENSG00000261000.1	RP11-534L20.5	-3.89	0.000116	0.016	-0.23	-0.17	Psoriasis;	chr1:206481989	chr1:206503948~206504456:+
LUAD	cis	rs1979679	0.744	rs2348236	ENSG00000278733.1	RP11-425D17.1	-3.89	0.000116	0.016	-0.22	-0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28441640	chr12:28185625~28186190:-
LUAD	cis	rs8067545	0.641	rs169412	ENSG00000270091.1	RP11-78O7.2	-3.89	0.000116	0.016	-0.15	-0.17	Schizophrenia;	chr17:19948562	chr17:19896590~19897287:-
LUAD	cis	rs7551222	0.752	rs4252687	ENSG00000240219.1	RP11-430C7.5	3.89	0.000116	0.016	0.19	0.17	Schizophrenia;	chr1:204528207	chr1:204626775~204629712:+
LUAD	cis	rs13434995	0.513	rs73236142	ENSG00000273257.1	RP11-177J6.1	-3.89	0.000116	0.016	-0.23	-0.17	Adiponectin levels;	chr4:55446143	chr4:55387949~55388271:+
LUAD	cis	rs2657294	0.929	rs6480771	ENSG00000226051.5	ZNF503-AS1	-3.89	0.000116	0.016	-0.23	-0.17	Pneumonia;	chr10:75101922	chr10:75269819~75373500:+
LUAD	cis	rs6706648	0.582	rs35355441	ENSG00000234624.2	AC016894.1	3.89	0.000116	0.016	0.2	0.17	F-cell distribution;	chr2:60433114	chr2:61416887~61417197:-
LUAD	cis	rs6706648	0.582	rs17402912	ENSG00000234624.2	AC016894.1	3.89	0.000116	0.016	0.2	0.17	F-cell distribution;	chr2:60433387	chr2:61416887~61417197:-
LUAD	cis	rs753274	0.65	rs28497965	ENSG00000267147.2	CTC-548K16.1	-3.89	0.000116	0.016	-0.21	-0.17	Tumor necrosis factor beta levels;	chr19:14306590	chr19:14333743~14343916:+
LUAD	cis	rs9646944	0.501	rs11465736	ENSG00000234389.1	AC007278.3	3.89	0.000116	0.016	0.2	0.17	Blood protein levels;	chr2:102451470	chr2:102438713~102440475:+
LUAD	cis	rs11089937	0.963	rs2226943	ENSG00000211638.2	IGLV8-61	-3.89	0.000116	0.016	-0.18	-0.17	Periodontitis (PAL4Q3);	chr22:22143100	chr22:22098700~22099212:+
LUAD	cis	rs2657294	0.965	rs7899946	ENSG00000226051.5	ZNF503-AS1	-3.89	0.000117	0.016	-0.23	-0.17	Pneumonia;	chr10:75166013	chr10:75269819~75373500:+
LUAD	cis	rs10448080	0.879	rs240946	ENSG00000259366.1	CTD-2647L4.4	3.89	0.000117	0.016	0.15	0.17	Height;	chr8:28711388	chr8:29055935~29056685:+
LUAD	cis	rs7578361	0.959	rs4299305	ENSG00000231969.1	AC144449.1	3.89	0.000117	0.016	0.25	0.17	Acute lymphoblastic leukemia (childhood);	chr2:149584701	chr2:149587196~149848233:+
LUAD	cis	rs6964587	0.839	rs6949881	ENSG00000188693.7	CYP51A1-AS1	-3.89	0.000117	0.016	-0.21	-0.17	Breast cancer;	chr7:91804513	chr7:92134604~92180725:+
LUAD	cis	rs219780	0.784	rs219781	ENSG00000230479.1	AP000695.6	3.89	0.000117	0.016	0.2	0.17	Kidney stones;	chr21:36460323	chr21:36430360~36481070:+
LUAD	cis	rs11671005	0.651	rs11878203	ENSG00000268543.1	CTD-2619J13.16	-3.89	0.000117	0.016	-0.25	-0.17	Mean platelet volume;	chr19:58408683	chr19:58418560~58419310:+
LUAD	cis	rs6871536	1	rs59568225	ENSG00000233006.5	AC034220.3	-3.89	0.000117	0.016	-0.2	-0.17	Asthma (childhood onset);	chr5:132610053	chr5:132311285~132369916:-
LUAD	cis	rs6871536	1	rs10520114	ENSG00000233006.5	AC034220.3	-3.89	0.000117	0.016	-0.2	-0.17	Asthma (childhood onset);	chr5:132613199	chr5:132311285~132369916:-
LUAD	cis	rs7119038	0.818	rs10892293	ENSG00000255422.1	AP002954.4	3.89	0.000117	0.016	0.27	0.17	Sjögren's syndrome;	chr11:118794866	chr11:118704607~118750263:+
LUAD	cis	rs7829975	0.572	rs7005000	ENSG00000233609.3	RP11-62H7.2	-3.89	0.000117	0.016	-0.14	-0.17	Mood instability;	chr8:8939092	chr8:8961200~8979025:+
LUAD	cis	rs7429990	0.93	rs7374516	ENSG00000228638.1	FCF1P2	-3.89	0.000117	0.016	-0.2	-0.17	Educational attainment (years of education);	chr3:47961150	chr3:48290793~48291375:-
LUAD	cis	rs7017914	0.967	rs2732091	ENSG00000246366.5	RP11-382J12.1	-3.89	0.000117	0.016	-0.16	-0.17	Bone mineral density;	chr8:71006188	chr8:70608577~70663279:+
LUAD	cis	rs9393777	0.513	rs13194053	ENSG00000219392.1	RP1-265C24.5	-3.89	0.000117	0.016	-0.28	-0.17	Intelligence (multi-trait analysis);	chr6:27176104	chr6:28115628~28116551:+
LUAD	cis	rs7204230	1	rs11075923	ENSG00000261291.1	RP11-295M3.2	3.88	0.000117	0.016	0.21	0.17	Fibrinogen;	chr16:53334264	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs7190909	ENSG00000261291.1	RP11-295M3.2	3.88	0.000117	0.016	0.21	0.17	Fibrinogen;	chr16:53335375	chr16:53168522~53169450:+
LUAD	cis	rs2278702	0.943	rs77597614	ENSG00000259495.2	RP11-210M15.2	-3.88	0.000117	0.016	-0.28	-0.17	Bipolar disorder;	chr15:80394618	chr15:80344853~80403575:-
LUAD	cis	rs3198697	1	rs3198697	ENSG00000260735.1	RP11-72I8.1	-3.88	0.000117	0.016	-0.18	-0.17	Triglycerides;	chr16:15036083	chr16:15094411~15109197:+
LUAD	cis	rs7493	0.755	rs13223537	ENSG00000233942.1	AC004012.1	-3.88	0.000117	0.016	-0.25	-0.17	Yu-Zhi constitution type in type 2 diabetes;	chr7:95336855	chr7:95471835~95473998:+
LUAD	cis	rs17772222	0.74	rs11847417	ENSG00000258983.2	RP11-507K2.2	-3.88	0.000117	0.016	-0.2	-0.17	Coronary artery calcification;	chr14:88510606	chr14:88499334~88515502:+
LUAD	cis	rs55670112	0.739	rs10041078	ENSG00000271797.1	CTC-428G20.6	-3.88	0.000117	0.016	-0.18	-0.17	Epilepsy;	chr5:114797604	chr5:115262505~115263448:+
LUAD	cis	rs71636778	0.722	rs34502618	ENSG00000260063.1	RP5-968P14.2	-3.88	0.000117	0.016	-0.23	-0.17	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26767665	chr1:26692132~26694131:-
LUAD	cis	rs2836950	0.501	rs2836984	ENSG00000232608.1	TIMM9P2	3.88	0.000117	0.016	0.2	0.17	Menarche (age at onset);	chr21:39329023	chr21:39216624~39217506:+
LUAD	cis	rs34779708	0.931	rs7079205	ENSG00000271335.4	RP11-324I22.4	3.88	0.000117	0.0161	0.18	0.17	Inflammatory bowel disease;Crohn's disease;	chr10:35035691	chr10:35314552~35336401:-
LUAD	cis	rs7714584	1	rs10463307	ENSG00000197083.10	ZNF300P1	3.88	0.000117	0.0161	0.34	0.17	Crohn's disease;	chr5:150875058	chr5:150930645~150946289:-
LUAD	cis	rs10463554	1	rs11949145	ENSG00000250682.4	LINC00491	3.88	0.000117	0.0161	0.21	0.17	Parkinson's disease;	chr5:102994552	chr5:102609156~102671559:-
LUAD	cis	rs7726839	0.794	rs11739663	ENSG00000248925.1	CTD-2083E4.6	3.88	0.000117	0.0161	0.24	0.17	Obesity-related traits;	chr5:593968	chr5:269858~271516:-
LUAD	cis	rs137603	0.562	rs137644	ENSG00000225450.1	RP3-508I15.14	-3.88	0.000117	0.0161	-0.15	-0.17	Primary biliary cholangitis;	chr22:39332134	chr22:38739003~38749041:+
LUAD	cis	rs6840360	0.642	rs2724577	ENSG00000270265.1	RP11-731D1.4	-3.88	0.000117	0.0161	-0.2	-0.17	Intelligence (multi-trait analysis);	chr4:151433753	chr4:151333775~151353224:-
LUAD	cis	rs2297363	1	rs2297363	ENSG00000213073.4	RP11-288H12.3	-3.88	0.000117	0.0161	-0.21	-0.17	Total cholesterol levels;Blood protein levels;	chr6:160085430	chr6:160093082~160096212:+
LUAD	cis	rs6001482	0.679	rs5750786	ENSG00000223350.2	IGLV9-49	-3.88	0.000117	0.0161	-0.17	-0.17	Diastolic blood pressure;	chr22:22235358	chr22:22343187~22343732:+
LUAD	cis	rs2836974	0.965	rs9941894	ENSG00000232608.1	TIMM9P2	-3.88	0.000117	0.0161	-0.21	-0.17	Cognitive function;	chr21:39262132	chr21:39216624~39217506:+
LUAD	cis	rs6832769	0.961	rs11735267	ENSG00000272969.1	RP11-528I4.2	3.88	0.000117	0.0161	0.18	0.17	Personality dimensions;	chr4:55481120	chr4:55547112~55547889:+
LUAD	cis	rs6452524	0.532	rs26263	ENSG00000281327.1	LINC01338	3.88	0.000117	0.0161	0.19	0.17	Hypertension (SNP x SNP interaction);	chr5:83044465	chr5:82850864~82859836:-
LUAD	cis	rs8180040	0.966	rs60369822	ENSG00000271161.1	BOLA2P2	-3.88	0.000117	0.0161	-0.17	-0.17	Colorectal cancer;	chr3:47438245	chr3:47499841~47500407:+
LUAD	cis	rs8180040	0.934	rs4858811	ENSG00000271161.1	BOLA2P2	-3.88	0.000117	0.0161	-0.17	-0.17	Colorectal cancer;	chr3:47439034	chr3:47499841~47500407:+
LUAD	cis	rs2190016	0.636	rs55896892	ENSG00000236078.1	LINC01447	-3.88	0.000117	0.0161	-0.21	-0.17	Mammographic density (non-dense area);	chr7:46853450	chr7:47621939~47629893:+
LUAD	cis	rs11921451	0.924	rs11714732	ENSG00000244215.1	RP11-88I21.2	-3.88	0.000117	0.0161	-0.22	-0.17	Amyotrophic lateral sclerosis (sporadic);	chr3:127082893	chr3:127322307~127390670:-
LUAD	cis	rs17711722	0.522	rs62469933	ENSG00000237310.1	GS1-124K5.4	3.88	0.000117	0.0161	0.18	0.17	Calcium levels;	chr7:65800652	chr7:66493706~66495474:+
LUAD	cis	rs2348418	0.864	rs6487690	ENSG00000244712.1	RP11-874G11.1	3.88	0.000117	0.0161	0.21	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28560407	chr12:28564678~28565141:-
LUAD	cis	rs2292864	0.764	rs1969269	ENSG00000278765.1	RP5-890E16.5	3.88	0.000117	0.0161	0.32	0.17	Left atrial antero-posterior diameter;	chr17:47258171	chr17:48066704~48067293:-
LUAD	cis	rs9549260	0.564	rs7998086	ENSG00000229456.1	RLIMP1	3.88	0.000117	0.0161	0.19	0.17	Red blood cell count;	chr13:40694788	chr13:40618738~40621348:+
LUAD	cis	rs4130344	0.874	rs35350460	ENSG00000271817.2	U3	-3.88	0.000117	0.0161	-0.18	-0.17	Intelligence (multi-trait analysis);	chr4:158766232	chr4:158700691~158700909:+
LUAD	cis	rs2348418	0.932	rs7136886	ENSG00000247934.4	RP11-967K21.1	3.88	0.000117	0.0161	0.2	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28460684	chr12:28163298~28190738:-
LUAD	cis	rs7107174	0.901	rs10899496	ENSG00000251323.2	RP11-452H21.4	3.88	0.000117	0.0161	0.21	0.17	Testicular germ cell tumor;	chr11:78412785	chr11:78423982~78429836:-
LUAD	cis	rs453301	0.653	rs11784393	ENSG00000233609.3	RP11-62H7.2	3.88	0.000117	0.0161	0.14	0.17	Joint mobility (Beighton score);	chr8:9045624	chr8:8961200~8979025:+
LUAD	cis	rs6547741	1	rs6547734	ENSG00000223522.1	AC093690.1	3.88	0.000117	0.0161	0.17	0.17	Oral cavity cancer;	chr2:27608123	chr2:28307691~28310459:-
LUAD	cis	rs12291225	0.679	rs11023172	ENSG00000251991.1	RNU7-49P	3.88	0.000117	0.0161	0.2	0.17	Sense of smell;	chr11:14273821	chr11:14478892~14478953:+
LUAD	cis	rs13287066	0.692	rs7031032	ENSG00000227603.1	RP11-165J3.6	3.88	0.000117	0.0161	0.2	0.17	Intelligence (multi-trait analysis);	chr9:93412186	chr9:93435332~93437121:-
LUAD	cis	rs2911132	0.568	rs3797814	ENSG00000272109.1	CTD-2260A17.3	-3.88	0.000117	0.0161	-0.2	-0.17	Urate levels (BMI interaction);	chr5:96756222	chr5:96804353~96806105:+
LUAD	cis	rs34929064	0.536	rs2905307	ENSG00000232949.1	AC002480.4	3.88	0.000117	0.0161	0.2	0.17	Major depression and alcohol dependence;	chr7:22599344	chr7:22589705~22591622:+
LUAD	cis	rs4767841	0.874	rs10129003	ENSG00000248636.5	RP11-768F21.1	-3.88	0.000117	0.0161	-0.2	-0.17	Urgency urinary incontinence;	chr12:119759912	chr12:119387987~119668079:-
LUAD	cis	rs7210086	0.948	rs17780256	ENSG00000263893.2	CTD-3010D24.3	3.88	0.000117	0.0161	0.26	0.17	Ulcerative colitis;	chr17:72646784	chr17:72642731~72644490:+
LUAD	cis	rs2115536	0.606	rs8024713	ENSG00000278600.1	RP11-81A1.6	-3.88	0.000117	0.0161	-0.14	-0.17	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79914616	chr15:79920195~79922455:-
LUAD	cis	rs858239	0.601	rs4140959	ENSG00000226816.2	AC005082.12	3.88	0.000117	0.0161	0.23	0.17	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23206013~23208045:+
LUAD	cis	rs2115630	0.764	rs11073716	ENSG00000225151.9	GOLGA2P7	3.88	0.000117	0.0161	0.2	0.17	P wave terminal force;	chr15:84792543	chr15:84199311~84230136:-
LUAD	cis	rs7208859	0.673	rs12949860	ENSG00000280069.1	CTD-2349P21.3	-3.88	0.000117	0.0161	-0.24	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896014	chr17:30738182~30740275:+
LUAD	cis	rs8113308	0.81	rs11881650	ENSG00000269483.1	AC006272.1	-3.88	0.000117	0.0161	-0.28	-0.17	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51946886	chr19:51839924~51843324:-
LUAD	cis	rs7512552	0.839	rs12042229	ENSG00000275557.1	RP11-353N4.6	3.88	0.000117	0.0161	0.2	0.17	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150474922	chr1:149607765~149612402:+
LUAD	cis	rs2115630	1	rs7183401	ENSG00000259728.4	LINC00933	-3.88	0.000117	0.0161	-0.21	-0.17	P wave terminal force;	chr15:84828713	chr15:84570649~84580175:+
LUAD	cis	rs4908769	0.55	rs7546225	ENSG00000270282.1	RP5-1115A15.2	-3.88	0.000117	0.0161	-0.2	-0.17	Allergy;	chr1:8811906	chr1:8512653~8513021:+
LUAD	cis	rs8046148	0.694	rs6500282	ENSG00000279356.1	RP11-429P3.8	3.88	0.000117	0.0161	0.18	0.17	Testicular germ cell tumor;	chr16:50104189	chr16:50072862~50074986:+
LUAD	cis	rs6547741	1	rs7604798	ENSG00000223522.1	AC093690.1	3.88	0.000117	0.0161	0.17	0.17	Oral cavity cancer;	chr2:27602073	chr2:28307691~28310459:-
LUAD	cis	rs7584330	0.74	rs12471291	ENSG00000222032.1	AC112721.2	3.88	0.000117	0.0161	0.2	0.17	Prostate cancer;	chr2:237533108	chr2:237428920~237434822:-
LUAD	cis	rs6840360	0.642	rs1470280	ENSG00000270265.1	RP11-731D1.4	-3.88	0.000117	0.0161	-0.18	-0.17	Intelligence (multi-trait analysis);	chr4:151510618	chr4:151333775~151353224:-
LUAD	cis	rs9584850	0.574	rs61969454	ENSG00000231194.1	FARP1-AS1	3.88	0.000117	0.0161	0.23	0.17	Neuroticism;	chr13:98517978	chr13:98435405~98435840:-
LUAD	cis	rs4132509	0.553	rs12140414	ENSG00000236031.1	RP11-269F20.1	3.88	0.000117	0.0161	0.27	0.17	RR interval (heart rate);	chr1:243511085	chr1:243545532~243548329:+
LUAD	cis	rs2346177	0.846	rs6714738	ENSG00000279254.1	RP11-536C12.1	-3.88	0.000117	0.0161	-0.18	-0.17	HDL cholesterol;	chr2:46419025	chr2:46668870~46670778:+
LUAD	cis	rs7176527	0.519	rs12148368	ENSG00000229212.6	RP11-561C5.4	3.88	0.000117	0.0161	0.22	0.17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84563274	chr15:85205440~85234795:-
LUAD	cis	rs2255336	0.684	rs6416265	ENSG00000245648.1	RP11-277P12.20	3.88	0.000117	0.0161	0.3	0.17	Blood protein levels;	chr12:10344268	chr12:10363769~10398506:+
LUAD	cis	rs9467773	1	rs6456733	ENSG00000241549.7	GUSBP2	3.88	0.000118	0.0161	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26566576	chr6:26871484~26956554:-
LUAD	cis	rs4819052	0.788	rs13049700	ENSG00000184274.3	LINC00315	-3.88	0.000118	0.0161	-0.25	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45281994	chr21:45300245~45305257:-
LUAD	cis	rs791888	0.698	rs7893652	ENSG00000225913.2	RP11-57C13.6	3.88	0.000118	0.0161	0.23	0.17	Magnesium levels;	chr10:87671303	chr10:87607985~87659279:+
LUAD	cis	rs7615952	0.599	rs6779141	ENSG00000250012.1	RP11-124N2.1	-3.88	0.000118	0.0161	-0.25	-0.17	Blood pressure (smoking interaction);	chr3:125991152	chr3:126084220~126095349:+
LUAD	cis	rs11051970	0.877	rs2728671	ENSG00000274964.1	RP11-817I4.1	-3.88	0.000118	0.0161	-0.19	-0.17	Response to tocilizumab in rheumatoid arthritis;	chr12:32436781	chr12:32339368~32340724:+
LUAD	cis	rs4118325	0.609	rs1762487	ENSG00000224550.1	RP11-270C12.3	-3.88	0.000118	0.0161	-0.22	-0.17	AIDS;	chr1:107087344	chr1:107505203~107505448:+
LUAD	cis	rs4268898	0.662	rs2891382	ENSG00000242628.4	AC009228.1	3.88	0.000118	0.0161	0.25	0.17	Asthma;	chr2:24288622	chr2:24214381~24221516:+
LUAD	cis	rs6071166	0.683	rs6027274	ENSG00000224635.1	RP4-564F22.5	-3.88	0.000118	0.0162	-0.2	-0.17	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38688536	chr20:38406011~38416797:-
LUAD	cis	rs6071166	0.708	rs6027284	ENSG00000224635.1	RP4-564F22.5	-3.88	0.000118	0.0162	-0.2	-0.17	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38689716	chr20:38406011~38416797:-
LUAD	cis	rs14027	0.554	rs6998058	ENSG00000279347.1	RP11-85I17.2	-3.88	0.000118	0.0162	-0.15	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119743079	chr8:119838736~119840385:-
LUAD	cis	rs2665103	0.715	rs11639440	ENSG00000255769.6	GOLGA2P10	-3.88	0.000118	0.0162	-0.19	-0.17	Intelligence (multi-trait analysis);	chr15:82278705	chr15:82472993~82513950:-
LUAD	cis	rs35934224	0.769	rs17745314	ENSG00000232926.1	AC000078.5	3.88	0.000118	0.0162	0.24	0.17	Glaucoma (primary open-angle);	chr22:19869819	chr22:19887289~19887970:+
LUAD	cis	rs6539288	0.705	rs1053051	ENSG00000260329.1	RP11-412D9.4	-3.88	0.000118	0.0162	-0.19	-0.17	Total body bone mineral density;	chr12:106973447	chr12:106954029~106955497:-
LUAD	cis	rs6951245	0.935	rs79143504	ENSG00000224079.1	AC091729.7	-3.88	0.000118	0.0162	-0.28	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1070576	chr7:1074450~1078036:+
LUAD	cis	rs7968440	1	rs2252589	ENSG00000272368.2	RP4-605O3.4	3.88	0.000118	0.0162	0.2	0.17	Fibrinogen;	chr12:50648174	chr12:50112197~50165618:+
LUAD	cis	rs848490	0.889	rs11767942	ENSG00000214293.7	APTR	3.88	0.000118	0.0162	0.22	0.17	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77589922	chr7:77657660~77696265:-
LUAD	cis	rs12073359	1	rs3208509	ENSG00000223945.2	RP11-458I7.1	3.88	0.000118	0.0162	0.23	0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150157141	chr1:150053864~150055034:+
LUAD	cis	rs2380205	1	rs2380205	ENSG00000232807.2	RP11-536K7.3	3.88	0.000118	0.0162	0.18	0.17	Breast cancer;	chr10:5844771	chr10:5934270~5945900:-
LUAD	cis	rs17122278	0.932	rs11216921	ENSG00000243431.1	RPL5P30	3.88	0.000118	0.0162	0.22	0.17	Total cholesterol levels;	chr11:118594100	chr11:118560690~118561580:+
LUAD	cis	rs76878669	0.561	rs1784029	ENSG00000213409.4	RP11-658F2.3	3.88	0.000118	0.0162	0.21	0.17	Educational attainment (years of education);	chr11:66332516	chr11:66761575~66762399:-
LUAD	cis	rs9894429	0.646	rs6565609	ENSG00000263853.1	AC139530.1	-3.88	0.000118	0.0162	-0.18	-0.17	Eye color traits;	chr17:81625241	chr17:81676001~81676086:+
LUAD	cis	rs7829975	0.711	rs4481596	ENSG00000233609.3	RP11-62H7.2	3.88	0.000118	0.0162	0.14	0.17	Mood instability;	chr8:8846820	chr8:8961200~8979025:+
LUAD	cis	rs1790761	0.505	rs7927657	ENSG00000184224.3	C11orf72	-3.88	0.000118	0.0162	-0.2	-0.17	Mean corpuscular volume;	chr11:67579517	chr11:67602880~67606706:-
LUAD	cis	rs1790761	0.505	rs7941395	ENSG00000184224.3	C11orf72	-3.88	0.000118	0.0162	-0.2	-0.17	Mean corpuscular volume;	chr11:67579946	chr11:67602880~67606706:-
LUAD	cis	rs1790761	0.505	rs7941648	ENSG00000184224.3	C11orf72	-3.88	0.000118	0.0162	-0.2	-0.17	Mean corpuscular volume;	chr11:67580124	chr11:67602880~67606706:-
LUAD	cis	rs1790761	0.505	rs7945035	ENSG00000184224.3	C11orf72	-3.88	0.000118	0.0162	-0.2	-0.17	Mean corpuscular volume;	chr11:67580691	chr11:67602880~67606706:-
LUAD	cis	rs7976269	0.609	rs7979788	ENSG00000275476.1	RP11-996F15.4	-3.88	0.000118	0.0162	-0.19	-0.17	Male-pattern baldness;	chr12:29064827	chr12:29277397~29277882:-
LUAD	cis	rs3812049	0.784	rs1560637	ENSG00000245937.6	LINC01184	3.88	0.000118	0.0162	0.26	0.17	Lymphocyte counts;Red cell distribution width;	chr5:128112374	chr5:127940426~128083172:-
LUAD	cis	rs2043112	0.867	rs1239344	ENSG00000249740.1	OSMR-AS1	3.88	0.000118	0.0162	0.2	0.17	Obesity-related traits;	chr5:38933647	chr5:38736055~38845829:-
LUAD	cis	rs7572733	0.935	rs10198606	ENSG00000222017.1	AC011997.1	-3.88	0.000118	0.0162	-0.22	-0.17	Dermatomyositis;	chr2:197905015	chr2:197693106~197774823:+
LUAD	cis	rs72843166	0.812	rs1588366	ENSG00000226797.1	AC015923.1	-3.88	0.000118	0.0162	-0.21	-0.17	Intelligence (multi-trait analysis);	chr17:62999067	chr17:63381231~63414312:-
LUAD	cis	rs62244186	0.516	rs11922470	ENSG00000233509.2	ZNF197-AS1	3.88	0.000118	0.0162	0.19	0.17	Depressive symptoms;	chr3:44736303	chr3:44617128~44624797:-
LUAD	cis	rs7829975	0.623	rs10087493	ENSG00000233609.3	RP11-62H7.2	-3.88	0.000118	0.0162	-0.15	-0.17	Mood instability;	chr8:8516047	chr8:8961200~8979025:+
LUAD	cis	rs11838267	0.527	rs3919533	ENSG00000205885.6	C1RL-AS1	-3.88	0.000118	0.0162	-0.17	-0.17	Coronary artery disease;	chr12:7055497	chr12:7108052~7122501:+
LUAD	cis	rs4835473	0.932	rs2218791	ENSG00000249741.2	RP11-673E1.3	3.88	0.000118	0.0162	0.2	0.17	Immature fraction of reticulocytes;	chr4:143749300	chr4:143911514~143912053:-
LUAD	cis	rs115769866	0.609	rs2191037	ENSG00000216901.1	AL022393.7	3.88	0.000118	0.0162	0.24	0.17	Bipolar disorder;	chr6:28499211	chr6:28176188~28176674:+
LUAD	cis	rs17749155	0.663	rs7844551	ENSG00000255310.2	AF131215.2	3.88	0.000118	0.0162	0.2	0.17	Barrett's esophagus;Barrett's esophagus  or Esophageal adenocarcinoma;	chr8:10207280	chr8:11107788~11109726:-
LUAD	cis	rs8002861	0.84	rs1819597	ENSG00000274001.1	RP11-5G9.5	3.88	0.000118	0.0162	0.19	0.17	Leprosy;	chr13:43855417	chr13:43877715~43878163:-
LUAD	cis	rs8002861	0.84	rs1819596	ENSG00000274001.1	RP11-5G9.5	3.88	0.000118	0.0162	0.19	0.17	Leprosy;	chr13:43855418	chr13:43877715~43878163:-
LUAD	cis	rs7647973	0.58	rs2117938	ENSG00000225399.4	RP11-3B7.1	-3.88	0.000118	0.0162	-0.22	-0.17	Menarche (age at onset);	chr3:49226417	chr3:49260085~49261316:+
LUAD	cis	rs7772486	0.686	rs9373473	ENSG00000235652.6	RP11-545I5.3	3.88	0.000118	0.0162	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145761146	chr6:145799409~145886585:+
LUAD	cis	rs2486288	0.656	rs11629807	ENSG00000259479.5	SORD2P	-3.88	0.000118	0.0162	-0.21	-0.17	Glomerular filtration rate;	chr15:45254839	chr15:44826371~44884694:-
LUAD	cis	rs2486288	0.587	rs12899942	ENSG00000259479.5	SORD2P	-3.88	0.000118	0.0162	-0.21	-0.17	Glomerular filtration rate;	chr15:45255082	chr15:44826371~44884694:-
LUAD	cis	rs2486288	0.656	rs12899058	ENSG00000259479.5	SORD2P	-3.88	0.000118	0.0162	-0.21	-0.17	Glomerular filtration rate;	chr15:45255126	chr15:44826371~44884694:-
LUAD	cis	rs2486288	0.656	rs12904150	ENSG00000259479.5	SORD2P	-3.88	0.000118	0.0162	-0.21	-0.17	Glomerular filtration rate;	chr15:45255407	chr15:44826371~44884694:-
LUAD	cis	rs2486288	0.656	rs9920290	ENSG00000259479.5	SORD2P	-3.88	0.000118	0.0162	-0.21	-0.17	Glomerular filtration rate;	chr15:45255837	chr15:44826371~44884694:-
LUAD	cis	rs9467773	0.62	rs9461275	ENSG00000241549.7	GUSBP2	3.88	0.000118	0.0162	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26590573	chr6:26871484~26956554:-
LUAD	cis	rs73198271	0.74	rs11781430	ENSG00000253893.2	FAM85B	3.88	0.000118	0.0162	0.23	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8794223	chr8:8167819~8226614:-
LUAD	cis	rs6940638	0.744	rs858964	ENSG00000219392.1	RP1-265C24.5	3.88	0.000118	0.0162	0.22	0.17	Intelligence (multi-trait analysis);	chr6:27174835	chr6:28115628~28116551:+
LUAD	cis	rs7762018	1	rs4716375	ENSG00000231690.2	LINC00574	-3.88	0.000118	0.0162	-0.32	-0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169671122	chr6:169790321~169802873:+
LUAD	cis	rs6479891	1	rs868798	ENSG00000232075.1	MRPL35P2	3.88	0.000118	0.0162	0.28	0.17	Arthritis (juvenile idiopathic);	chr10:63135250	chr10:63634317~63634827:-
LUAD	cis	rs11089937	0.626	rs4820337	ENSG00000211640.3	IGLV6-57	-3.88	0.000118	0.0162	-0.13	-0.17	Periodontitis (PAL4Q3);	chr22:22164374	chr22:22195713~22196460:+
LUAD	cis	rs9951698	0.693	rs9949682	ENSG00000267480.1	RP11-703I16.1	-3.88	0.000118	0.0162	-0.21	-0.17	Intelligence (multi-trait analysis);	chr18:12999822	chr18:12031178~12032181:-
LUAD	cis	rs755249	0.958	rs2068663	ENSG00000182109.6	RP11-69E11.4	3.88	0.000118	0.0162	0.21	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572899	chr1:39522280~39546187:-
LUAD	cis	rs8073060	0.586	rs2626625	ENSG00000267592.1	CTC-507E2.2	3.88	0.000118	0.0162	0.25	0.17	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35700588	chr17:35596904~35597128:-
LUAD	cis	rs8073060	0.586	rs226090	ENSG00000267592.1	CTC-507E2.2	3.88	0.000118	0.0162	0.25	0.17	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35707040	chr17:35596904~35597128:-
LUAD	cis	rs4666360	1	rs10196396	ENSG00000234378.1	AC098828.2	-3.88	0.000118	0.0162	-0.21	-0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);	chr2:20137274	chr2:20063856~20106829:-
LUAD	cis	rs67981189	0.892	rs221899	ENSG00000269927.1	RP6-91H8.3	3.88	0.000118	0.0162	0.22	0.17	Schizophrenia;	chr14:71138551	chr14:71141125~71143253:-
LUAD	cis	rs7260598	0.642	rs8101310	ENSG00000269421.1	ZNF92P3	-3.88	0.000118	0.0162	-0.27	-0.17	Response to taxane treatment (placlitaxel);	chr19:23961137	chr19:23935220~23936173:+
LUAD	cis	rs2904524	1	rs74993103	ENSG00000257815.4	RP11-611E13.2	-3.88	0.000118	0.0162	-0.26	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70259786	chr12:69904033~70243360:-
LUAD	cis	rs8127691	0.563	rs4818890	ENSG00000237604.1	AP001056.1	-3.88	0.000118	0.0162	-0.21	-0.17	Inflammatory bowel disease;	chr21:44226373	chr21:44175489~44176453:+
LUAD	cis	rs72717009	0.825	rs12722986	ENSG00000225217.1	HSPA7	-3.88	0.000118	0.0162	-0.24	-0.17	Rheumatoid arthritis;	chr1:161495630	chr1:161606291~161608217:+
LUAD	cis	rs11971779	0.793	rs11772447	ENSG00000273391.1	RP11-634H22.1	3.88	0.000118	0.0162	0.19	0.17	Diisocyanate-induced asthma;	chr7:139348843	chr7:139359032~139359566:-
LUAD	cis	rs11009175	0.799	rs2457703	ENSG00000273038.2	RP11-479G22.8	-3.88	0.000118	0.0162	-0.24	-0.17	Depression (quantitative trait);	chr10:33050611	chr10:32887255~32889311:-
LUAD	cis	rs11009175	0.746	rs2756023	ENSG00000273038.2	RP11-479G22.8	-3.88	0.000118	0.0162	-0.24	-0.17	Depression (quantitative trait);	chr10:33050726	chr10:32887255~32889311:-
LUAD	cis	rs11009175	0.799	rs2756022	ENSG00000273038.2	RP11-479G22.8	-3.88	0.000118	0.0162	-0.24	-0.17	Depression (quantitative trait);	chr10:33051028	chr10:32887255~32889311:-
LUAD	cis	rs2274273	0.805	rs10131926	ENSG00000258413.1	RP11-665C16.6	-3.88	0.000118	0.0162	-0.22	-0.17	Protein biomarker;	chr14:55246528	chr14:55262767~55272075:-
LUAD	cis	rs12122100	0.545	rs1984615	ENSG00000227242.3	NBPF13P	-3.88	0.000118	0.0162	-0.2	-0.17	HIV-1 control;	chr1:147034652	chr1:147021320~147124525:-
LUAD	cis	rs6088580	0.634	rs2378133	ENSG00000276073.1	RP5-1125A11.7	3.88	0.000118	0.0162	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34331699	chr20:33985617~33988989:-
LUAD	cis	rs7546668	0.744	rs1800615	ENSG00000272510.1	RP4-680D5.8	3.88	0.000118	0.0162	0.22	0.17	Glomerular filtration rate (creatinine);	chr1:15505786	chr1:15565611~15565956:-
LUAD	cis	rs8040855	0.597	rs994989	ENSG00000259774.1	RP11-182J1.13	3.88	0.000118	0.0162	0.23	0.17	Bulimia nervosa;	chr15:85117485	chr15:84422618~84425882:+
LUAD	cis	rs13113518	1	rs7660980	ENSG00000273257.1	RP11-177J6.1	-3.88	0.000118	0.0162	-0.19	-0.17	Height;	chr4:55542948	chr4:55387949~55388271:+
LUAD	cis	rs7942368	1	rs1837679	ENSG00000254632.1	RP11-21L23.4	3.88	0.000118	0.0162	0.19	0.17	Endometriosis;	chr11:76790513	chr11:76759916~76768223:-
LUAD	cis	rs8113308	0.81	rs8105910	ENSG00000269483.1	AC006272.1	3.88	0.000119	0.0163	0.29	0.17	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51943815	chr19:51839924~51843324:-
LUAD	cis	rs8031584	0.723	rs711224	ENSG00000260128.5	ULK4P2	3.88	0.000119	0.0163	0.23	0.17	Huntington's disease progression;	chr15:30835718	chr15:30572738~30600647:+
LUAD	cis	rs6479901	0.895	rs7897326	ENSG00000232075.1	MRPL35P2	-3.88	0.000119	0.0163	-0.25	-0.17	Intelligence (multi-trait analysis);	chr10:63306059	chr10:63634317~63634827:-
LUAD	cis	rs6071166	0.683	rs1885458	ENSG00000224635.1	RP4-564F22.5	-3.88	0.000119	0.0163	-0.2	-0.17	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38691891	chr20:38406011~38416797:-
LUAD	cis	rs1551277	1	rs6963565	ENSG00000146666.5	LINC00525	3.88	0.000119	0.0163	0.2	0.17	Anxiety disorder;	chr7:47788888	chr7:47761476~47766772:+
LUAD	cis	rs12188164	1	rs56104584	ENSG00000225138.6	CTD-2228K2.7	3.88	0.000119	0.0163	0.17	0.17	Cystic fibrosis severity;	chr5:437427	chr5:473236~480884:+
LUAD	cis	rs12188164	1	rs55842567	ENSG00000225138.6	CTD-2228K2.7	3.88	0.000119	0.0163	0.17	0.17	Cystic fibrosis severity;	chr5:437471	chr5:473236~480884:+
LUAD	cis	rs12188164	1	rs56042615	ENSG00000225138.6	CTD-2228K2.7	3.88	0.000119	0.0163	0.17	0.17	Cystic fibrosis severity;	chr5:437552	chr5:473236~480884:+
LUAD	cis	rs12188164	1	rs34847072	ENSG00000225138.6	CTD-2228K2.7	3.88	0.000119	0.0163	0.17	0.17	Cystic fibrosis severity;	chr5:437747	chr5:473236~480884:+
LUAD	cis	rs17122278	1	rs73022038	ENSG00000243431.1	RPL5P30	3.88	0.000119	0.0163	0.21	0.17	Total cholesterol levels;	chr11:118537756	chr11:118560690~118561580:+
LUAD	cis	rs17122278	1	rs73022041	ENSG00000243431.1	RPL5P30	3.88	0.000119	0.0163	0.21	0.17	Total cholesterol levels;	chr11:118538074	chr11:118560690~118561580:+
LUAD	cis	rs17122278	1	rs7128587	ENSG00000243431.1	RPL5P30	3.88	0.000119	0.0163	0.21	0.17	Total cholesterol levels;	chr11:118538587	chr11:118560690~118561580:+
LUAD	cis	rs17122278	1	rs11216883	ENSG00000243431.1	RPL5P30	3.88	0.000119	0.0163	0.21	0.17	Total cholesterol levels;	chr11:118539753	chr11:118560690~118561580:+
LUAD	cis	rs17122278	1	rs11216884	ENSG00000243431.1	RPL5P30	3.88	0.000119	0.0163	0.21	0.17	Total cholesterol levels;	chr11:118539773	chr11:118560690~118561580:+
LUAD	cis	rs17122278	1	rs11216886	ENSG00000243431.1	RPL5P30	3.88	0.000119	0.0163	0.21	0.17	Total cholesterol levels;	chr11:118540709	chr11:118560690~118561580:+
LUAD	cis	rs17122278	1	rs61290697	ENSG00000243431.1	RPL5P30	3.88	0.000119	0.0163	0.21	0.17	Total cholesterol levels;	chr11:118541643	chr11:118560690~118561580:+
LUAD	cis	rs7189233	1	rs62048520	ENSG00000279344.1	RP11-44F14.7	3.88	0.000119	0.0163	0.15	0.17	Intelligence (multi-trait analysis);	chr16:53457183	chr16:53478957~53481550:-
LUAD	cis	rs2274273	0.901	rs7147136	ENSG00000258413.1	RP11-665C16.6	-3.88	0.000119	0.0163	-0.23	-0.17	Protein biomarker;	chr14:55359970	chr14:55262767~55272075:-
LUAD	cis	rs1334894	0.792	rs72894781	ENSG00000228559.1	RP3-340B19.3	-3.88	0.000119	0.0163	-0.42	-0.17	Coronary artery disease;	chr6:35494090	chr6:35544632~35545669:+
LUAD	cis	rs1334894	0.681	rs72894784	ENSG00000228559.1	RP3-340B19.3	-3.88	0.000119	0.0163	-0.42	-0.17	Coronary artery disease;	chr6:35494528	chr6:35544632~35545669:+
LUAD	cis	rs1334894	0.792	rs12665445	ENSG00000228559.1	RP3-340B19.3	-3.88	0.000119	0.0163	-0.42	-0.17	Coronary artery disease;	chr6:35500262	chr6:35544632~35545669:+
LUAD	cis	rs860295	0.812	rs11264363	ENSG00000160766.13	GBAP1	-3.88	0.000119	0.0163	-0.19	-0.17	Body mass index;	chr1:155348517	chr1:155213821~155227422:-
LUAD	cis	rs2380205	0.689	rs11255602	ENSG00000232807.2	RP11-536K7.3	3.88	0.000119	0.0163	0.19	0.17	Breast cancer;	chr10:5861754	chr10:5934270~5945900:-
LUAD	cis	rs5758511	0.68	rs58654759	ENSG00000233903.2	Z83851.4	3.88	0.000119	0.0163	0.26	0.17	Birth weight;	chr22:42246570	chr22:42276355~42277052:+
LUAD	cis	rs6964587	0.967	rs2299235	ENSG00000188693.7	CYP51A1-AS1	-3.88	0.000119	0.0163	-0.2	-0.17	Breast cancer;	chr7:91998186	chr7:92134604~92180725:+
LUAD	cis	rs4474465	1	rs4945281	ENSG00000251323.2	RP11-452H21.4	3.88	0.000119	0.0163	0.22	0.17	Alzheimer's disease (survival time);	chr11:78477581	chr11:78423982~78429836:-
LUAD	cis	rs5850	0.557	rs10270788	ENSG00000226816.2	AC005082.12	3.88	0.000119	0.0163	0.23	0.17	Blood protein levels;	chr7:23149381	chr7:23206013~23208045:+
LUAD	cis	rs858239	0.539	rs28716381	ENSG00000226816.2	AC005082.12	3.88	0.000119	0.0163	0.23	0.17	Cerebrospinal fluid biomarker levels;	chr7:23149396	chr7:23206013~23208045:+
LUAD	cis	rs10463554	0.963	rs26816	ENSG00000250682.4	LINC00491	3.88	0.000119	0.0163	0.21	0.17	Parkinson's disease;	chr5:103204821	chr5:102609156~102671559:-
LUAD	cis	rs67478160	0.619	rs11160761	ENSG00000272533.1	SNORA28	3.88	0.000119	0.0163	0.18	0.17	Schizophrenia;	chr14:103788519	chr14:103337849~103337974:+
LUAD	cis	rs9876781	1	rs1459242	ENSG00000229759.1	MRPS18AP1	-3.88	0.000119	0.0163	-0.17	-0.17	Longevity;	chr3:48372047	chr3:48256350~48256938:-
LUAD	cis	rs2235573	0.527	rs139879	ENSG00000235237.1	RP1-151B14.6	-3.88	0.000119	0.0163	-0.18	-0.17	Glioma;Glioblastoma;	chr22:37968545	chr22:37166757~37182850:+
LUAD	cis	rs116095464	0.681	rs9687745	ENSG00000248925.1	CTD-2083E4.6	3.88	0.000119	0.0163	0.29	0.17	Breast cancer;	chr5:229194	chr5:269858~271516:-
LUAD	cis	rs638893	0.636	rs493720	ENSG00000255239.1	AP002954.6	3.88	0.000119	0.0163	0.29	0.17	Vitiligo;	chr11:118733969	chr11:118688039~118690600:-
LUAD	cis	rs638893	0.636	rs526850	ENSG00000255239.1	AP002954.6	3.88	0.000119	0.0163	0.29	0.17	Vitiligo;	chr11:118734418	chr11:118688039~118690600:-
LUAD	cis	rs7107174	1	rs2510051	ENSG00000251323.2	RP11-452H21.4	3.88	0.000119	0.0163	0.23	0.17	Testicular germ cell tumor;	chr11:78270125	chr11:78423982~78429836:-
LUAD	cis	rs7107174	1	rs2512541	ENSG00000251323.2	RP11-452H21.4	3.88	0.000119	0.0163	0.23	0.17	Testicular germ cell tumor;	chr11:78270701	chr11:78423982~78429836:-
LUAD	cis	rs8073060	0.963	rs35614987	ENSG00000267592.1	CTC-507E2.2	-3.88	0.000119	0.0163	-0.22	-0.17	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35542447	chr17:35596904~35597128:-
LUAD	cis	rs4660214	0.59	rs11205885	ENSG00000182109.6	RP11-69E11.4	-3.88	0.000119	0.0163	-0.19	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39306633	chr1:39522280~39546187:-
LUAD	cis	rs4660214	0.666	rs3116398	ENSG00000182109.6	RP11-69E11.4	-3.88	0.000119	0.0163	-0.19	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39314130	chr1:39522280~39546187:-
LUAD	cis	rs728616	0.867	rs12414096	ENSG00000234382.2	RP11-40F6.1	-3.88	0.000119	0.0163	-0.43	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79953873	chr10:80233664~80245367:+
LUAD	cis	rs7219021	0.55	rs35929648	ENSG00000234494.6	SP2-AS1	3.88	0.000119	0.0163	0.2	0.17	Schizophrenia or bipolar disorder;	chr17:48925181	chr17:47897330~47941410:-
LUAD	cis	rs4268898	0.722	rs11691212	ENSG00000223754.1	AC008073.9	-3.88	0.000119	0.0163	-0.21	-0.17	Asthma;	chr2:24181864	chr2:24199839~24201698:-
LUAD	cis	rs3925075	0.5	rs11641624	ENSG00000260911.2	RP11-196G11.2	-3.88	0.000119	0.0163	-0.16	-0.17	IgA nephropathy;	chr16:31257664	chr16:31043150~31049868:+
LUAD	cis	rs3750965	0.65	rs61882972	ENSG00000260895.1	RP11-554A11.7	3.88	0.000119	0.0163	0.21	0.17	Hair color;	chr11:69119685	chr11:69103493~69109094:+
LUAD	cis	rs9847710	1	rs2564956	ENSG00000242142.1	SERBP1P3	3.88	0.000119	0.0163	0.18	0.17	Ulcerative colitis;	chr3:53036446	chr3:53064283~53065091:-
LUAD	cis	rs75920871	0.614	rs117287138	ENSG00000254851.1	RP11-109L13.1	-3.88	0.000119	0.0163	-0.38	-0.17	Subjective well-being;	chr11:116924163	chr11:117135528~117138582:+
LUAD	cis	rs5758659	0.652	rs5751195	ENSG00000182057.4	OGFRP1	3.88	0.000119	0.0163	0.21	0.17	Cognitive function;	chr22:41983997	chr22:42269753~42275196:+
LUAD	cis	rs6479901	0.947	rs10822150	ENSG00000232075.1	MRPL35P2	-3.88	0.000119	0.0163	-0.24	-0.17	Intelligence (multi-trait analysis);	chr10:63257736	chr10:63634317~63634827:-
LUAD	cis	rs6479901	0.895	rs4417159	ENSG00000232075.1	MRPL35P2	-3.88	0.000119	0.0163	-0.24	-0.17	Intelligence (multi-trait analysis);	chr10:63285938	chr10:63634317~63634827:-
LUAD	cis	rs6479901	0.947	rs10995493	ENSG00000232075.1	MRPL35P2	-3.88	0.000119	0.0163	-0.24	-0.17	Intelligence (multi-trait analysis);	chr10:63287266	chr10:63634317~63634827:-
LUAD	cis	rs853679	0.607	rs67040724	ENSG00000219392.1	RP1-265C24.5	-3.88	0.000119	0.0163	-0.39	-0.17	Depression;	chr6:27937731	chr6:28115628~28116551:+
LUAD	cis	rs13108904	0.901	rs6851528	ENSG00000196810.4	CTBP1-AS2	3.88	0.000119	0.0163	0.2	0.17	Obesity-related traits;	chr4:1302221	chr4:1249300~1288291:+
LUAD	cis	rs8177876	0.822	rs1563077	ENSG00000261061.1	RP11-303E16.2	-3.88	0.000119	0.0163	-0.29	-0.17	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81073951	chr16:81030770~81031485:+
LUAD	cis	rs6964587	1	rs2282968	ENSG00000188693.7	CYP51A1-AS1	3.88	0.000119	0.0163	0.21	0.17	Breast cancer;	chr7:91950973	chr7:92134604~92180725:+
LUAD	cis	rs6736093	0.871	rs35471545	ENSG00000207383.1	Y_RNA	-3.88	0.000119	0.0163	-0.22	-0.17	Coronary artery disease;	chr2:111999134	chr2:112579484~112579584:-
LUAD	cis	rs9549260	0.709	rs4581585	ENSG00000229456.1	RLIMP1	3.88	0.000119	0.0163	0.19	0.17	Red blood cell count;	chr13:40629768	chr13:40618738~40621348:+
LUAD	cis	rs34779708	0.897	rs4934527	ENSG00000271335.4	RP11-324I22.4	3.88	0.000119	0.0163	0.18	0.17	Inflammatory bowel disease;Crohn's disease;	chr10:34992190	chr10:35314552~35336401:-
LUAD	cis	rs7121538	0.673	rs2303975	ENSG00000254418.1	RP11-21L19.1	3.88	0.000119	0.0163	0.3	0.17	HDL cholesterol;	chr11:14255453	chr11:14262846~14273691:-
LUAD	cis	rs595244	1	rs686861	ENSG00000259705.1	RP11-227D13.1	3.88	0.000119	0.0163	0.34	0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48592808	chr15:48645951~48652016:+
LUAD	cis	rs2731006	0.64	rs2678103	ENSG00000257114.2	RP11-25I15.3	3.88	0.000119	0.0163	0.28	0.17	Panic disorder;	chr12:42773492	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.64	rs908656	ENSG00000257114.2	RP11-25I15.3	3.88	0.000119	0.0163	0.28	0.17	Panic disorder;	chr12:42773827	chr12:42692216~42717119:+
LUAD	cis	rs1400816	0.85	rs3770457	ENSG00000228389.1	AC068039.4	3.88	0.000119	0.0163	0.29	0.17	Amyotrophic lateral sclerosis (sporadic);	chr2:171795700	chr2:171773482~171775844:+
LUAD	cis	rs1400816	0.718	rs949548	ENSG00000228389.1	AC068039.4	3.88	0.000119	0.0163	0.29	0.17	Amyotrophic lateral sclerosis (sporadic);	chr2:171798099	chr2:171773482~171775844:+
LUAD	cis	rs2274273	0.837	rs6573010	ENSG00000258413.1	RP11-665C16.6	-3.88	0.000119	0.0163	-0.22	-0.17	Protein biomarker;	chr14:55254874	chr14:55262767~55272075:-
LUAD	cis	rs2898681	0.874	rs4864688	ENSG00000248375.1	RP11-177B4.1	-3.88	0.000119	0.0163	-0.25	-0.17	Optic nerve measurement (cup area);	chr4:52876469	chr4:52720081~52720831:-
LUAD	cis	rs6781182	0.517	rs17280068	ENSG00000236452.1	AC123023.1	3.88	0.000119	0.0163	0.2	0.17	Visceral adipose tissue adjusted for BMI;	chr3:34190437	chr3:34203244~34268811:+
LUAD	cis	rs5769707	0.542	rs739242	ENSG00000235111.1	RP1-29C18.8	-3.88	0.000119	0.0163	-0.21	-0.17	Monocyte percentage of white cells;Monocyte count;	chr22:49663468	chr22:49612657~49615716:-
LUAD	cis	rs11134654	0.877	rs10055432	ENSG00000253966.1	CTC-455F18.3	-3.88	0.000119	0.0163	-0.3	-0.17	Smooth-surface caries;	chr5:170819865	chr5:170896929~170904461:+
LUAD	cis	rs79040073	0.765	rs7169304	ENSG00000259531.2	RP11-295H24.3	3.88	0.000119	0.0163	0.23	0.17	Lung cancer in ever smokers;	chr15:49186829	chr15:49365124~49366685:-
LUAD	cis	rs2439831	0.867	rs3809481	ENSG00000249839.1	AC011330.5	-3.88	0.000119	0.0163	-0.34	-0.17	Lung cancer in ever smokers;	chr15:43370631	chr15:43663654~43684339:-
LUAD	cis	rs6121246	0.609	rs6089054	ENSG00000230613.1	HM13-AS1	3.88	0.000119	0.0163	0.22	0.17	Mean corpuscular hemoglobin;	chr20:31735338	chr20:31567707~31573263:-
LUAD	cis	rs6087771	0.851	rs6087775	ENSG00000230613.1	HM13-AS1	3.88	0.000119	0.0163	0.22	0.17	Putamen volume;Subcortical brain region volumes;	chr20:31737962	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.609	rs4453755	ENSG00000230613.1	HM13-AS1	3.88	0.000119	0.0163	0.22	0.17	Mean corpuscular hemoglobin;	chr20:31743244	chr20:31567707~31573263:-
LUAD	cis	rs2279440	0.585	rs7651326	ENSG00000254485.4	RP11-380O24.1	3.88	0.000119	0.0163	0.29	0.17	Glucose homeostasis traits;	chr3:9459629	chr3:9292588~9363303:-
LUAD	cis	rs77320796	1	rs7542907	ENSG00000182109.6	RP11-69E11.4	-3.88	0.000119	0.0163	-0.2	-0.17	Platelet count;	chr1:39926080	chr1:39522280~39546187:-
LUAD	cis	rs516805	0.847	rs520867	ENSG00000279114.1	RP3-425C14.5	-3.88	0.000119	0.0163	-0.19	-0.17	Lymphocyte counts;	chr6:122465501	chr6:122471923~122484161:+
LUAD	cis	rs516805	0.961	rs693669	ENSG00000279114.1	RP3-425C14.5	-3.88	0.000119	0.0163	-0.19	-0.17	Lymphocyte counts;	chr6:122465690	chr6:122471923~122484161:+
LUAD	cis	rs67478160	0.575	rs8014294	ENSG00000272533.1	SNORA28	3.88	0.000119	0.0163	0.19	0.17	Schizophrenia;	chr14:103856646	chr14:103337849~103337974:+
LUAD	cis	rs937213	0.781	rs28515996	ENSG00000275636.1	RP11-521C20.5	3.88	0.000119	0.0163	0.23	0.17	Endometrial cancer;Endometrial endometrioid carcinoma;	chr15:40005018	chr15:40078892~40079347:+
LUAD	cis	rs4716602	0.633	rs10249382	ENSG00000235029.1	MNX1-AS2	-3.88	0.000119	0.0163	-0.21	-0.17	Anti-saccade response;	chr7:156366655	chr7:157006307~157007132:+
LUAD	cis	rs6832769	1	rs6853192	ENSG00000272969.1	RP11-528I4.2	-3.88	0.000119	0.0163	-0.18	-0.17	Personality dimensions;	chr4:55543087	chr4:55547112~55547889:+
LUAD	cis	rs7142881	0.844	rs1947004	ENSG00000258525.1	RP11-829H16.3	3.88	0.000119	0.0163	0.2	0.17	Response to iloperidone treatment (QT prolongation);	chr14:31565616	chr14:30876179~30889808:-
LUAD	cis	rs7215564	0.908	rs9908112	ENSG00000232083.3	RPL31P7	-3.88	0.000119	0.0163	-0.32	-0.17	Myopia (pathological);	chr17:80779655	chr17:80602549~80602926:-
LUAD	cis	rs7215564	0.822	rs2340769	ENSG00000232083.3	RPL31P7	-3.88	0.000119	0.0163	-0.32	-0.17	Myopia (pathological);	chr17:80781471	chr17:80602549~80602926:-
LUAD	cis	rs6738440	0.51	rs17331017	ENSG00000234624.2	AC016894.1	3.88	0.000119	0.0163	0.21	0.17	F-cell distribution;	chr2:60435014	chr2:61416887~61417197:-
LUAD	cis	rs17597773	0.674	rs2279638	ENSG00000272823.1	RP11-295M18.6	-3.88	0.000119	0.0163	-0.23	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220828445	chr1:220828676~220829211:-
LUAD	cis	rs10463554	0.927	rs158250	ENSG00000250682.4	LINC00491	3.88	0.000119	0.0163	0.21	0.17	Parkinson's disease;	chr5:103071075	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.927	rs464702	ENSG00000250682.4	LINC00491	3.88	0.000119	0.0163	0.21	0.17	Parkinson's disease;	chr5:103071180	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.927	rs464720	ENSG00000250682.4	LINC00491	3.88	0.000119	0.0163	0.21	0.17	Parkinson's disease;	chr5:103071183	chr5:102609156~102671559:-
LUAD	cis	rs7208859	0.623	rs9898084	ENSG00000266490.1	CTD-2349P21.9	3.88	0.000119	0.0163	0.26	0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30792372~30792833:+
LUAD	cis	rs62355901	0.505	rs62355944	ENSG00000271828.1	CTD-2310F14.1	3.88	0.000119	0.0163	0.37	0.17	Breast cancer;	chr5:56816871	chr5:56927874~56929573:+
LUAD	cis	rs8073060	0.586	rs35542792	ENSG00000267592.1	CTC-507E2.2	-3.88	0.000119	0.0163	-0.25	-0.17	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35576867	chr17:35596904~35597128:-
LUAD	cis	rs6832769	0.857	rs61072181	ENSG00000272969.1	RP11-528I4.2	-3.88	0.000119	0.0163	-0.19	-0.17	Personality dimensions;	chr4:55617210	chr4:55547112~55547889:+
LUAD	cis	rs10129255	0.789	rs61997796	ENSG00000211967.3	IGHV3-53	-3.88	0.000119	0.0163	-0.14	-0.17	Kawasaki disease;	chr14:106813798	chr14:106592676~106593347:-
LUAD	cis	rs854765	0.583	rs5002487	ENSG00000264177.1	RP1-37N7.1	-3.88	0.000119	0.0163	-0.17	-0.17	Total body bone mineral density;	chr17:17929146	chr17:18379855~18388984:-
LUAD	cis	rs897984	0.759	rs13708	ENSG00000232748.3	RP11-196G11.6	3.88	0.000119	0.0164	0.22	0.17	Dementia with Lewy bodies;	chr16:30989488	chr16:31056460~31062803:+
LUAD	cis	rs8028182	0.549	rs4886696	ENSG00000260269.4	CTD-2323K18.1	3.88	0.000119	0.0164	0.25	0.17	Sudden cardiac arrest;	chr15:75372229	chr15:75527150~75601205:-
LUAD	cis	rs9549260	0.755	rs59308928	ENSG00000229456.1	RLIMP1	3.88	0.000119	0.0164	0.19	0.17	Red blood cell count;	chr13:40670942	chr13:40618738~40621348:+
LUAD	cis	rs2494663	0.61	rs11588942	ENSG00000223599.1	RP11-216N14.7	3.88	0.000119	0.0164	0.21	0.17	Mean platelet volume;	chr1:154072067	chr1:153852106~153853414:-
LUAD	cis	rs2494663	0.61	rs7514662	ENSG00000223599.1	RP11-216N14.7	3.88	0.000119	0.0164	0.21	0.17	Mean platelet volume;	chr1:154072239	chr1:153852106~153853414:-
LUAD	cis	rs987044	0.7	rs10861957	ENSG00000257221.1	RP11-689B22.2	3.88	0.000119	0.0164	0.15	0.17	Mean platelet volume;	chr12:108662601	chr12:108628687~108641318:+
LUAD	cis	rs12554020	0.582	rs7038293	ENSG00000227603.1	RP11-165J3.6	3.88	0.00012	0.0164	0.36	0.17	Schizophrenia;	chr9:93646314	chr9:93435332~93437121:-
LUAD	cis	rs8002861	0.781	rs7322781	ENSG00000274001.1	RP11-5G9.5	3.88	0.00012	0.0164	0.18	0.17	Leprosy;	chr13:43868102	chr13:43877715~43878163:-
LUAD	cis	rs10129255	0.556	rs8010005	ENSG00000253209.1	IGHV3-65	3.88	0.00012	0.0164	0.14	0.17	Kawasaki disease;	chr14:106777987	chr14:106666092~106666532:-
LUAD	cis	rs10129255	0.556	rs6576224	ENSG00000253209.1	IGHV3-65	3.88	0.00012	0.0164	0.14	0.17	Kawasaki disease;	chr14:106777997	chr14:106666092~106666532:-
LUAD	cis	rs4554975	0.662	rs3989940	ENSG00000274723.1	RP11-618L22.1	-3.88	0.00012	0.0164	-0.2	-0.17	Metabolite levels (small molecules and protein measures);	chr12:46888748	chr12:46970504~46972155:+
LUAD	cis	rs6472235	0.656	rs11994927	ENSG00000200714.1	Y_RNA	-3.88	0.00012	0.0164	-0.23	-0.17	Plateletcrit;Myopia (pathological);	chr8:65970615	chr8:65592731~65592820:+
LUAD	cis	rs1056107	0.797	rs4979087	ENSG00000225513.1	RP11-165N19.2	-3.88	0.00012	0.0164	-0.19	-0.17	Colorectal cancer;	chr9:112179920	chr9:112173522~112173971:-
LUAD	cis	rs41411047	0.826	rs112661097	ENSG00000271711.1	RP11-392O18.2	3.88	0.00012	0.0164	0.35	0.17	Myocardial infarction;	chr3:149918659	chr3:150611262~150611877:-
LUAD	cis	rs5742933	0.652	rs10210345	ENSG00000253559.1	OSGEPL1-AS1	3.88	0.00012	0.0164	0.21	0.17	Ferritin levels;	chr2:189754760	chr2:189762704~189765556:+
LUAD	cis	rs5742933	0.744	rs13009889	ENSG00000253559.1	OSGEPL1-AS1	3.88	0.00012	0.0164	0.21	0.17	Ferritin levels;	chr2:189763842	chr2:189762704~189765556:+
LUAD	cis	rs7560272	0.538	rs2001436	ENSG00000163016.8	ALMS1P	-3.88	0.00012	0.0164	-0.18	-0.17	Schizophrenia;	chr2:73701838	chr2:73644919~73685576:+
LUAD	cis	rs7560272	0.512	rs12998980	ENSG00000163016.8	ALMS1P	-3.88	0.00012	0.0164	-0.18	-0.17	Schizophrenia;	chr2:73703599	chr2:73644919~73685576:+
LUAD	cis	rs5015933	0.788	rs568409	ENSG00000232630.1	PRPS1P2	-3.88	0.00012	0.0164	-0.16	-0.17	Body mass index;	chr9:125309994	chr9:125150653~125151589:+
LUAD	cis	rs9308731	0.591	rs55878194	ENSG00000227992.1	AC108463.2	-3.88	0.00012	0.0164	-0.21	-0.17	Chronic lymphocytic leukemia;	chr2:111182897	chr2:111203964~111206215:-
LUAD	cis	rs9815354	1	rs7648578	ENSG00000273328.4	RP11-141M3.6	-3.88	0.00012	0.0164	-0.25	-0.17	Pulse pressure;Diastolic blood pressure;	chr3:41817239	chr3:42809414~42908105:+
LUAD	cis	rs916888	0.779	rs199528	ENSG00000260075.1	NSFP1	-3.88	0.00012	0.0164	-0.3	-0.17	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46372855~46487141:+
LUAD	cis	rs916888	0.821	rs199525	ENSG00000260075.1	NSFP1	-3.88	0.00012	0.0164	-0.3	-0.17	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46372855~46487141:+
LUAD	cis	rs4727027	0.704	rs2269972	ENSG00000244560.5	RP4-800G7.2	3.88	0.00012	0.0164	0.11	0.17	Neutrophil percentage of granulocytes;Eosinophil counts;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr7:149216955	chr7:149285281~149297312:+
LUAD	cis	rs12280210	0.557	rs12284696	ENSG00000280143.1	AP000892.6	-3.88	0.00012	0.0164	-0.31	-0.17	Lobe attachment (rater-scored or self-reported);	chr11:117008803	chr11:117204967~117210292:+
LUAD	cis	rs2098713	0.534	rs57424532	ENSG00000250155.1	CTD-2353F22.1	3.88	0.00012	0.0164	0.19	0.17	Telomere length;	chr5:37497184	chr5:36666214~36725195:-
LUAD	cis	rs2098713	0.569	rs2102828	ENSG00000250155.1	CTD-2353F22.1	3.88	0.00012	0.0164	0.19	0.17	Telomere length;	chr5:37498313	chr5:36666214~36725195:-
LUAD	cis	rs9302635	0.513	rs8061282	ENSG00000260886.1	TAT-AS1	3.88	0.00012	0.0164	0.22	0.17	Blood protein levels;	chr16:72122039	chr16:71565789~71578187:+
LUAD	cis	rs9302635	0.513	rs8061459	ENSG00000260886.1	TAT-AS1	3.88	0.00012	0.0164	0.22	0.17	Blood protein levels;	chr16:72122164	chr16:71565789~71578187:+
LUAD	cis	rs7945705	0.791	rs6484484	ENSG00000254860.4	TMEM9B-AS1	-3.88	0.00012	0.0164	-0.2	-0.17	Hemoglobin concentration;	chr11:8795659	chr11:8964675~8977527:+
LUAD	cis	rs6706648	0.582	rs12467056	ENSG00000234624.2	AC016894.1	3.88	0.00012	0.0164	0.2	0.17	F-cell distribution;	chr2:60436574	chr2:61416887~61417197:-
LUAD	cis	rs7772486	0.738	rs9485039	ENSG00000235652.6	RP11-545I5.3	3.88	0.00012	0.0164	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145998251	chr6:145799409~145886585:+
LUAD	cis	rs12073359	0.909	rs72694905	ENSG00000223945.2	RP11-458I7.1	-3.88	0.00012	0.0164	-0.25	-0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150090550	chr1:150053864~150055034:+
LUAD	cis	rs73198271	0.653	rs10087633	ENSG00000253893.2	FAM85B	3.88	0.00012	0.0164	0.22	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802934	chr8:8167819~8226614:-
LUAD	cis	rs2154319	0.79	rs11209376	ENSG00000235358.1	RP11-399E6.1	3.88	0.00012	0.0164	0.24	0.17	Height;	chr1:41032676	chr1:41242373~41284861:+
LUAD	cis	rs6502050	0.805	rs4789721	ENSG00000266654.1	RP11-1376P16.1	-3.88	0.00012	0.0164	-0.19	-0.17	Life satisfaction;	chr17:82199577	chr17:82160056~82160452:+
LUAD	cis	rs6502050	0.731	rs12150589	ENSG00000266654.1	RP11-1376P16.1	-3.88	0.00012	0.0164	-0.19	-0.17	Life satisfaction;	chr17:82200357	chr17:82160056~82160452:+
LUAD	cis	rs6502050	0.835	rs8065037	ENSG00000266654.1	RP11-1376P16.1	-3.88	0.00012	0.0164	-0.19	-0.17	Life satisfaction;	chr17:82201090	chr17:82160056~82160452:+
LUAD	cis	rs603446	0.583	rs180377	ENSG00000280143.1	AP000892.6	3.88	0.00012	0.0164	0.2	0.17	Triglycerides;	chr11:116718411	chr11:117204967~117210292:+
LUAD	cis	rs9876781	1	rs9864371	ENSG00000229759.1	MRPS18AP1	3.88	0.00012	0.0164	0.17	0.17	Longevity;	chr3:48385276	chr3:48256350~48256938:-
LUAD	cis	rs6964587	0.967	rs7801058	ENSG00000188693.7	CYP51A1-AS1	-3.88	0.00012	0.0164	-0.2	-0.17	Breast cancer;	chr7:92155067	chr7:92134604~92180725:+
LUAD	cis	rs1387259	0.931	rs11168474	ENSG00000257763.1	OR5BK1P	3.88	0.00012	0.0164	0.18	0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48227601	chr12:48355792~48356614:-
LUAD	cis	rs17685	0.712	rs11764119	ENSG00000280388.1	RP11-229D13.3	-3.88	0.00012	0.0164	-0.16	-0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76183040	chr7:76043977~76045963:-
LUAD	cis	rs7339483	0.702	rs3891560	ENSG00000268058.1	BNIP3P40	-3.88	0.00012	0.0164	-0.35	-0.17	Discordance in emotional problems in monozygotic twins;	chr19:24228173	chr19:24098425~24098980:-
LUAD	cis	rs7557067	0.525	rs11680233	ENSG00000233005.1	AC067959.1	3.88	0.00012	0.0164	0.2	0.17	Triglycerides;	chr2:21017159	chr2:21221175~21970959:+
LUAD	cis	rs2904524	1	rs2870881	ENSG00000257613.1	LINC01481	-3.88	0.00012	0.0164	-0.31	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70257881	chr12:70219132~70221862:-
LUAD	cis	rs2904524	1	rs76608560	ENSG00000257613.1	LINC01481	-3.88	0.00012	0.0164	-0.31	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70259132	chr12:70219132~70221862:-
LUAD	cis	rs2904524	1	rs75401536	ENSG00000257613.1	LINC01481	-3.88	0.00012	0.0164	-0.31	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70264369	chr12:70219132~70221862:-
LUAD	cis	rs2904524	1	rs1524245	ENSG00000257613.1	LINC01481	-3.88	0.00012	0.0164	-0.31	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70265048	chr12:70219132~70221862:-
LUAD	cis	rs2904524	1	rs4761191	ENSG00000257613.1	LINC01481	-3.88	0.00012	0.0164	-0.31	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70268594	chr12:70219132~70221862:-
LUAD	cis	rs2904524	1	rs56970859	ENSG00000257613.1	LINC01481	-3.88	0.00012	0.0164	-0.31	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70270576	chr12:70219132~70221862:-
LUAD	cis	rs877356	0.748	rs7703565	ENSG00000250378.1	RP11-119J18.1	-3.88	0.00012	0.0164	-0.3	-0.17	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (dichotomous);	chr5:135832851	chr5:135812667~135826582:+
LUAD	cis	rs8046148	0.789	rs4785383	ENSG00000279356.1	RP11-429P3.8	-3.88	0.00012	0.0164	-0.18	-0.17	Testicular germ cell tumor;	chr16:50113891	chr16:50072862~50074986:+
LUAD	cis	rs8046148	0.789	rs4785384	ENSG00000279356.1	RP11-429P3.8	-3.88	0.00012	0.0164	-0.18	-0.17	Testicular germ cell tumor;	chr16:50114082	chr16:50072862~50074986:+
LUAD	cis	rs6438234	0.778	rs6795273	ENSG00000242767.1	ZBTB20-AS4	3.88	0.00012	0.0164	0.22	0.17	Type 2 diabetes;	chr3:115228411	chr3:115100423~115103061:+
LUAD	cis	rs7940866	0.809	rs2324317	ENSG00000255262.3	TCEB2P2	3.88	0.00012	0.0164	0.2	0.17	Schizophrenia;	chr11:131007247	chr11:130032866~130033220:-
LUAD	cis	rs8002861	0.901	rs9525867	ENSG00000274001.1	RP11-5G9.5	3.88	0.00012	0.0164	0.18	0.17	Leprosy;	chr13:43889421	chr13:43877715~43878163:-
LUAD	cis	rs9900280	0.935	rs4794853	ENSG00000264808.1	RP11-802D6.1	3.88	0.00012	0.0164	0.21	0.17	Mean platelet volume;	chr17:29365721	chr17:29369717~29390777:-
LUAD	cis	rs78572108	0.858	rs4952584	ENSG00000214691.7	AC104654.1	3.88	0.00012	0.0164	0.28	0.17	Total body bone mineral density;	chr2:42042147	chr2:41877074~41894046:+
LUAD	cis	rs7107174	1	rs7939646	ENSG00000251323.2	RP11-452H21.4	-3.88	0.00012	0.0164	-0.21	-0.17	Testicular germ cell tumor;	chr11:78400567	chr11:78423982~78429836:-
LUAD	cis	rs4713118	0.869	rs9283880	ENSG00000280107.1	AL022393.9	-3.88	0.00012	0.0164	-0.22	-0.17	Parkinson's disease;	chr6:27747464	chr6:28170845~28172521:+
LUAD	cis	rs4713118	0.869	rs9283881	ENSG00000280107.1	AL022393.9	-3.88	0.00012	0.0164	-0.22	-0.17	Parkinson's disease;	chr6:27747476	chr6:28170845~28172521:+
LUAD	cis	rs4713118	0.869	rs9283882	ENSG00000280107.1	AL022393.9	-3.88	0.00012	0.0164	-0.22	-0.17	Parkinson's disease;	chr6:27747479	chr6:28170845~28172521:+
LUAD	cis	rs2412819	0.545	rs35822148	ENSG00000166763.7	STRCP1	3.88	0.00012	0.0164	0.28	0.17	Lung cancer;	chr15:43808084	chr15:43699488~43718184:-
LUAD	cis	rs6763768	0.888	rs1264098	ENSG00000274967.1	Y_RNA	-3.88	0.00012	0.0164	-0.2	-0.17	Bacterial meningitis;	chr3:53488287	chr3:53290640~53290751:+
LUAD	cis	rs13108904	0.935	rs13148614	ENSG00000196810.4	CTBP1-AS2	3.88	0.00012	0.0164	0.21	0.17	Obesity-related traits;	chr4:1254569	chr4:1249300~1288291:+
LUAD	cis	rs10129255	0.957	rs10140904	ENSG00000274576.2	IGHV2-70	3.88	0.00012	0.0164	0.16	0.17	Kawasaki disease;	chr14:106776558	chr14:106770577~106771020:-
LUAD	cis	rs2098713	0.569	rs7707460	ENSG00000250155.1	CTD-2353F22.1	3.88	0.00012	0.0164	0.19	0.17	Telomere length;	chr5:37504164	chr5:36666214~36725195:-
LUAD	cis	rs7580658	0.929	rs4662575	ENSG00000236682.1	AC068282.3	-3.88	0.00012	0.0164	-0.24	-0.17	Protein C levels;	chr2:127264639	chr2:127389130~127400580:+
LUAD	cis	rs7508	0.511	rs208056	ENSG00000253671.1	RP11-806O11.1	-3.88	0.00012	0.0164	-0.2	-0.17	Atrial fibrillation;	chr8:17965375	chr8:17808941~17820868:+
LUAD	cis	rs10859871	0.536	rs7309226	ENSG00000216306.3	KRT19P2	3.88	0.00012	0.0164	0.23	0.17	Endometriosis;	chr12:95293652	chr12:94834147~94835158:+
LUAD	cis	rs4499344	0.633	rs259239	ENSG00000201388.1	SNORA68	3.88	0.00012	0.0164	0.18	0.17	Mean platelet volume;	chr19:32650184	chr19:32608337~32608469:-
LUAD	cis	rs1150668	0.796	rs9468372	ENSG00000176933.5	TOB2P1	-3.88	0.00012	0.0164	-0.19	-0.17	Pubertal anthropometrics;	chr6:28411584	chr6:28217643~28218634:-
LUAD	cis	rs6687758	1	rs11118926	ENSG00000238042.4	RP11-815M8.1	3.88	0.00012	0.0164	0.24	0.17	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222013781	chr1:221880981~221978523:-
LUAD	cis	rs6687758	1	rs17495159	ENSG00000238042.4	RP11-815M8.1	3.88	0.00012	0.0164	0.24	0.17	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222016251	chr1:221880981~221978523:-
LUAD	cis	rs6687758	1	rs35212520	ENSG00000238042.4	RP11-815M8.1	3.88	0.00012	0.0164	0.24	0.17	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222016322	chr1:221880981~221978523:-
LUAD	cis	rs6472235	0.564	rs35753080	ENSG00000200714.1	Y_RNA	-3.88	0.00012	0.0164	-0.23	-0.17	Plateletcrit;Myopia (pathological);	chr8:66000762	chr8:65592731~65592820:+
LUAD	cis	rs6472235	0.586	rs7814933	ENSG00000200714.1	Y_RNA	-3.88	0.00012	0.0164	-0.23	-0.17	Plateletcrit;Myopia (pathological);	chr8:66000992	chr8:65592731~65592820:+
LUAD	cis	rs9876781	1	rs4858793	ENSG00000229759.1	MRPS18AP1	-3.88	0.00012	0.0164	-0.17	-0.17	Longevity;	chr3:48373517	chr3:48256350~48256938:-
LUAD	cis	rs8073060	0.586	rs6505486	ENSG00000267592.1	CTC-507E2.2	3.88	0.00012	0.0164	0.25	0.17	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35669757	chr17:35596904~35597128:-
LUAD	cis	rs7520050	0.807	rs4353138	ENSG00000234329.1	RP11-767N6.2	-3.88	0.00012	0.0164	-0.16	-0.17	Reticulocyte count;Red blood cell count;	chr1:45754131	chr1:45651039~45651826:-
LUAD	cis	rs9876781	1	rs7651407	ENSG00000229759.1	MRPS18AP1	3.88	0.00012	0.0164	0.17	0.17	Longevity;	chr3:48402409	chr3:48256350~48256938:-
LUAD	cis	rs12446632	0.882	rs11639988	ENSG00000261195.1	CTD-2380F24.1	-3.88	0.00012	0.0164	-0.24	-0.17	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Menarche (age at onset);Obesity;Childhood body mass index;Waist circumference;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr16:19933041	chr16:19761172~19766099:-
LUAD	cis	rs6479891	0.841	rs7092504	ENSG00000232075.1	MRPL35P2	-3.88	0.00012	0.0164	-0.28	-0.17	Arthritis (juvenile idiopathic);	chr10:63329679	chr10:63634317~63634827:-
LUAD	cis	rs13276960	0.909	rs7841632	ENSG00000253328.2	SUMO2P19	-3.88	0.00012	0.0164	-0.2	-0.17	Schizophrenia;	chr8:102916522	chr8:102242040~102242619:-
LUAD	cis	rs2390582	0.679	rs1538136	ENSG00000233593.5	RP4-665J23.1	3.88	0.00012	0.0164	0.25	0.17	Coronary artery calcification;	chr1:90573802	chr1:90782986~90851650:-
LUAD	cis	rs4595586	0.967	rs11169807	ENSG00000257718.1	RP11-396F22.1	3.88	0.00012	0.0164	0.21	0.17	Morning vs. evening chronotype;	chr12:38850359	chr12:38906451~38909592:+
LUAD	cis	rs6964587	0.869	rs7812219	ENSG00000188693.7	CYP51A1-AS1	3.88	0.00012	0.0164	0.21	0.17	Breast cancer;	chr7:91916413	chr7:92134604~92180725:+
LUAD	cis	rs738722	0.514	rs6005790	ENSG00000272858.1	CTA-292E10.8	3.88	0.00012	0.0164	0.19	0.17	Optic cup area;Esophageal cancer and gastric cancer;	chr22:28480182	chr22:28814914~28815662:+
LUAD	cis	rs7646881	0.544	rs59492803	ENSG00000240207.5	RP11-379F4.4	-3.88	0.00012	0.0164	-0.24	-0.17	Tetralogy of Fallot;	chr3:158702908	chr3:158732263~158784070:+
LUAD	cis	rs7615952	0.599	rs2279821	ENSG00000250012.1	RP11-124N2.1	-3.88	0.00012	0.0164	-0.25	-0.17	Blood pressure (smoking interaction);	chr3:126015465	chr3:126084220~126095349:+
LUAD	cis	rs9308731	0.591	rs13398360	ENSG00000227992.1	AC108463.2	-3.88	0.00012	0.0164	-0.21	-0.17	Chronic lymphocytic leukemia;	chr2:111180363	chr2:111203964~111206215:-
LUAD	cis	rs1816752	0.524	rs1965154	ENSG00000273628.1	RP11-756A22.7	-3.88	0.00012	0.0165	-0.2	-0.17	Obesity-related traits;	chr13:24498062	chr13:24933006~24936796:+
LUAD	cis	rs9876781	1	rs4858817	ENSG00000229759.1	MRPS18AP1	-3.88	0.00012	0.0165	-0.17	-0.17	Longevity;	chr3:48375266	chr3:48256350~48256938:-
LUAD	cis	rs12220777	0.818	rs7918223	ENSG00000230091.5	TMEM254-AS1	3.88	0.00012	0.0165	0.27	0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80090023	chr10:80046860~80078912:-
LUAD	cis	rs6661961	0.752	rs4636462	ENSG00000237975.5	FLG-AS1	-3.88	0.00012	0.0165	-0.24	-0.17	Atopic dermatitis;	chr1:152442732	chr1:152168125~152445456:+
LUAD	cis	rs1346081	1	rs2114033	ENSG00000250075.4	RP11-584P21.2	-3.88	0.00012	0.0165	-0.19	-0.17	Intelligence (multi-trait analysis);	chr4:67162823	chr4:67417305~67468251:-
LUAD	cis	rs10129255	0.518	rs8009612	ENSG00000253209.1	IGHV3-65	3.88	0.00012	0.0165	0.14	0.17	Kawasaki disease;	chr14:106777510	chr14:106666092~106666532:-
LUAD	cis	rs9302635	0.513	rs7184169	ENSG00000260886.1	TAT-AS1	3.88	0.00012	0.0165	0.23	0.17	Blood protein levels;	chr16:72119034	chr16:71565789~71578187:+
LUAD	cis	rs6452524	0.532	rs27363	ENSG00000281327.1	LINC01338	3.88	0.00012	0.0165	0.19	0.17	Hypertension (SNP x SNP interaction);	chr5:83040943	chr5:82850864~82859836:-
LUAD	cis	rs7005380	0.62	rs7459671	ENSG00000279347.1	RP11-85I17.2	-3.88	0.00012	0.0165	-0.14	-0.17	Interstitial lung disease;	chr8:119896646	chr8:119838736~119840385:-
LUAD	cis	rs6502050	0.83	rs7219036	ENSG00000266654.1	RP11-1376P16.1	-3.88	0.00012	0.0165	-0.19	-0.17	Life satisfaction;	chr17:82203243	chr17:82160056~82160452:+
LUAD	cis	rs2380205	0.689	rs867053	ENSG00000232807.2	RP11-536K7.3	3.88	0.00012	0.0165	0.19	0.17	Breast cancer;	chr10:5845207	chr10:5934270~5945900:-
LUAD	cis	rs7590268	0.806	rs12477823	ENSG00000279873.2	LINC01126	3.88	0.00012	0.0165	0.17	0.17	Orofacial clefts;	chr2:43393181	chr2:43227210~43228855:+
LUAD	cis	rs10463554	0.963	rs1011454	ENSG00000250682.4	LINC00491	3.88	0.00012	0.0165	0.21	0.17	Parkinson's disease;	chr5:103032551	chr5:102609156~102671559:-
LUAD	cis	rs10197140	0.816	rs4849162	ENSG00000235721.1	AC013268.3	-3.88	0.000121	0.0165	-0.19	-0.17	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110881658	chr2:110007675~110010783:+
LUAD	cis	rs1555322	0.505	rs639763	ENSG00000126005.14	MMP24-AS1	-3.88	0.000121	0.0165	-0.25	-0.17	Attention deficit hyperactivity disorder;	chr20:35274101	chr20:35216462~35278131:-
LUAD	cis	rs6502050	0.835	rs9898697	ENSG00000275966.1	RP11-1055B8.9	-3.88	0.000121	0.0165	-0.18	-0.17	Life satisfaction;	chr17:82142622	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs4789678	ENSG00000275966.1	RP11-1055B8.9	-3.88	0.000121	0.0165	-0.18	-0.17	Life satisfaction;	chr17:82143202	chr17:81345476~81345966:-
LUAD	cis	rs8073060	0.821	rs11080355	ENSG00000267592.1	CTC-507E2.2	-3.88	0.000121	0.0165	-0.22	-0.17	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35545675	chr17:35596904~35597128:-
LUAD	cis	rs7246657	0.943	rs2291004	ENSG00000267470.4	ZNF571-AS1	3.88	0.000121	0.0165	0.25	0.17	Coronary artery calcification;	chr19:37507050	chr19:37548914~37587348:+
LUAD	cis	rs9295536	0.651	rs9460707	ENSG00000260455.1	NBAT1	-3.88	0.000121	0.0165	-0.21	-0.17	Neuroblastoma;	chr6:22137419	chr6:22134957~22147193:-
LUAD	cis	rs7660883	0.86	rs236984	ENSG00000251411.1	RP11-397E7.4	3.88	0.000121	0.0165	0.19	0.17	HDL cholesterol levels;	chr4:87087462	chr4:86913266~86914817:-
LUAD	cis	rs12554020	0.582	rs75018698	ENSG00000227603.1	RP11-165J3.6	3.88	0.000121	0.0165	0.36	0.17	Schizophrenia;	chr9:93647025	chr9:93435332~93437121:-
LUAD	cis	rs2904524	0.867	rs10879121	ENSG00000257815.4	RP11-611E13.2	-3.88	0.000121	0.0165	-0.26	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70277447	chr12:69904033~70243360:-
LUAD	cis	rs10045504	0.502	rs72746051	ENSG00000251189.1	CTD-2196P11.2	3.88	0.000121	0.0165	0.32	0.17	Night sleep phenotypes;	chr5:38759715	chr5:38682070~38685126:+
LUAD	cis	rs9308731	0.556	rs10166773	ENSG00000227992.1	AC108463.2	-3.88	0.000121	0.0165	-0.21	-0.17	Chronic lymphocytic leukemia;	chr2:111179358	chr2:111203964~111206215:-
LUAD	cis	rs9308731	0.548	rs7581735	ENSG00000227992.1	AC108463.2	-3.88	0.000121	0.0165	-0.21	-0.17	Chronic lymphocytic leukemia;	chr2:111180137	chr2:111203964~111206215:-
LUAD	cis	rs9876781	0.967	rs2885509	ENSG00000229759.1	MRPS18AP1	-3.88	0.000121	0.0165	-0.17	-0.17	Longevity;	chr3:48376729	chr3:48256350~48256938:-
LUAD	cis	rs10419113	0.544	rs7255898	ENSG00000269867.1	CTD-2583A14.8	3.88	0.000121	0.0165	0.16	0.17	Pediatric bone mineral density (spine);	chr19:57802208	chr19:57867038~57868172:-
LUAD	cis	rs6687758	1	rs6695584	ENSG00000238042.4	RP11-815M8.1	3.88	0.000121	0.0165	0.24	0.17	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221988647	chr1:221880981~221978523:-
LUAD	cis	rs17407555	0.697	rs73212821	ENSG00000250413.1	RP11-448G15.1	3.88	0.000121	0.0165	0.28	0.17	Schizophrenia (age at onset);	chr4:10067827	chr4:10006482~10009725:+
LUAD	cis	rs2153535	0.518	rs9328485	ENSG00000230939.1	RP11-314C16.1	-3.88	0.000121	0.0165	-0.21	-0.17	Motion sickness;	chr6:8524831	chr6:8784178~8785445:+
LUAD	cis	rs2733201	1	rs4923972	ENSG00000205771.5	CATSPER2P1	3.88	0.000121	0.0165	0.42	0.17	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44037058	chr15:43726918~43747094:-
LUAD	cis	rs8028182	0.636	rs62027181	ENSG00000260269.4	CTD-2323K18.1	-3.88	0.000121	0.0165	-0.24	-0.17	Sudden cardiac arrest;	chr15:75547611	chr15:75527150~75601205:-
LUAD	cis	rs8062405	0.755	rs12447461	ENSG00000251417.2	RP11-1348G14.4	-3.88	0.000121	0.0165	-0.18	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28802743~28817828:+
LUAD	cis	rs875971	0.862	rs13232191	ENSG00000273448.1	RP11-166O4.6	3.88	0.000121	0.0165	0.17	0.17	Aortic root size;	chr7:66521661	chr7:67333047~67334383:+
LUAD	cis	rs728616	0.867	rs56123058	ENSG00000225484.5	NUTM2B-AS1	-3.88	0.000121	0.0165	-0.37	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80051316	chr10:79663088~79826594:-
LUAD	cis	rs34792	0.688	rs153782	ENSG00000275910.1	RP11-680G24.6	3.88	0.000121	0.0165	0.17	0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15507763	chr16:15015828~15016390:-
LUAD	cis	rs7616559	0.512	rs6799034	ENSG00000240875.4	LINC00886	-3.88	0.000121	0.0165	-0.19	-0.17	Carotid artery intima media thickness (sex interaction);	chr3:157000091	chr3:156747346~156817062:-
LUAD	cis	rs8180040	0.726	rs34344887	ENSG00000271161.1	BOLA2P2	3.88	0.000121	0.0165	0.17	0.17	Colorectal cancer;	chr3:47000671	chr3:47499841~47500407:+
LUAD	cis	rs9309473	0.948	rs2421577	ENSG00000230002.2	ALMS1-IT1	3.88	0.000121	0.0165	0.21	0.17	Metabolite levels;	chr2:73613871	chr2:73456764~73459484:+
LUAD	cis	rs7131987	0.605	rs1120528	ENSG00000257176.2	RP11-996F15.2	3.88	0.000121	0.0165	0.18	0.17	QT interval;	chr12:29264237	chr12:29280418~29317848:-
LUAD	cis	rs7131987	0.585	rs6487795	ENSG00000257176.2	RP11-996F15.2	3.88	0.000121	0.0165	0.18	0.17	QT interval;	chr12:29266228	chr12:29280418~29317848:-
LUAD	cis	rs6495122	0.501	rs8039755	ENSG00000260269.4	CTD-2323K18.1	3.88	0.000121	0.0165	0.22	0.17	Diastolic blood pressure;Coffee consumption;Caffeine consumption;	chr15:75045085	chr15:75527150~75601205:-
LUAD	cis	rs10492201	0.529	rs4913390	ENSG00000255733.4	IFNG-AS1	-3.88	0.000121	0.0165	-0.18	-0.17	Itch intensity from mosquito bite adjusted by bite size;	chr12:67993696	chr12:67989445~68234686:+
LUAD	cis	rs10492201	0.529	rs11176998	ENSG00000255733.4	IFNG-AS1	-3.88	0.000121	0.0165	-0.18	-0.17	Itch intensity from mosquito bite adjusted by bite size;	chr12:67993774	chr12:67989445~68234686:+
LUAD	cis	rs3764021	0.933	rs2268146	ENSG00000278635.1	CTD-2318O12.1	-3.88	0.000121	0.0165	-0.15	-0.17	Type 1 diabetes;	chr12:9716675	chr12:9415641~9416718:+
LUAD	cis	rs6001482	0.638	rs5757574	ENSG00000223350.2	IGLV9-49	-3.88	0.000121	0.0165	-0.17	-0.17	Diastolic blood pressure;	chr22:22231597	chr22:22343187~22343732:+
LUAD	cis	rs1401999	0.898	rs6443928	ENSG00000223882.1	ABCC5-AS1	-3.88	0.000121	0.0165	-0.18	-0.17	Anterior chamber depth;	chr3:184011699	chr3:184006338~184011419:+
LUAD	cis	rs1401999	0.898	rs9876143	ENSG00000223882.1	ABCC5-AS1	-3.88	0.000121	0.0165	-0.18	-0.17	Anterior chamber depth;	chr3:184013574	chr3:184006338~184011419:+
LUAD	cis	rs603446	0.703	rs1263151	ENSG00000254851.1	RP11-109L13.1	-3.88	0.000121	0.0165	-0.22	-0.17	Triglycerides;	chr11:116770312	chr11:117135528~117138582:+
LUAD	cis	rs7119038	0.774	rs73005423	ENSG00000255239.1	AP002954.6	-3.88	0.000121	0.0165	-0.26	-0.17	Sjögren's syndrome;	chr11:118810370	chr11:118688039~118690600:-
LUAD	cis	rs2098713	0.569	rs56305849	ENSG00000250155.1	CTD-2353F22.1	3.88	0.000121	0.0165	0.19	0.17	Telomere length;	chr5:37506445	chr5:36666214~36725195:-
LUAD	cis	rs13434995	0.513	rs60097207	ENSG00000273257.1	RP11-177J6.1	-3.88	0.000121	0.0165	-0.23	-0.17	Adiponectin levels;	chr4:55406696	chr4:55387949~55388271:+
LUAD	cis	rs7260598	0.892	rs67180860	ENSG00000268442.1	CTD-2027I19.2	3.88	0.000121	0.0165	0.27	0.17	Response to taxane treatment (placlitaxel);	chr19:24023433	chr19:24162370~24163425:-
LUAD	cis	rs13631	0.965	rs7853589	ENSG00000268996.3	MAN1B1-AS1	-3.88	0.000121	0.0165	-0.2	-0.17	Cerebrospinal fluid biomarker levels;	chr9:137109392	chr9:137084946~137086817:-
LUAD	cis	rs116095464	0.558	rs12173244	ENSG00000248925.1	CTD-2083E4.6	3.88	0.000121	0.0165	0.3	0.17	Breast cancer;	chr5:269409	chr5:269858~271516:-
LUAD	cis	rs11673344	0.563	rs256744	ENSG00000267254.4	ZNF790-AS1	3.88	0.000121	0.0165	0.23	0.17	Obesity-related traits;	chr19:37364586	chr19:36797518~36828115:+
LUAD	cis	rs4388249	0.687	rs6877418	ENSG00000271849.1	CTC-332L22.1	-3.88	0.000121	0.0165	-0.24	-0.17	Schizophrenia;	chr5:109738408	chr5:109687802~109688329:-
LUAD	cis	rs9633740	1	rs9633740	ENSG00000226659.1	RP11-137H2.4	-3.88	0.000121	0.0165	-0.28	-0.17	Post bronchodilator FEV1;	chr10:80505515	chr10:80529597~80535942:-
LUAD	cis	rs16866061	1	rs34345163	ENSG00000228446.2	AC073052.1	-3.88	0.000121	0.0165	-0.19	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr2:224594363	chr2:224499387~224500100:-
LUAD	cis	rs62025270	0.632	rs7177107	ENSG00000259416.2	RP11-158M2.5	-3.88	0.000121	0.0165	-0.24	-0.17	Idiopathic pulmonary fibrosis;	chr15:85580133	chr15:85754941~85756237:-
LUAD	cis	rs10771431	0.597	rs10843142	ENSG00000111788.10	RP11-22B23.1	3.88	0.000121	0.0165	0.15	0.17	Breast size;	chr12:9204906	chr12:9277235~9313241:+
LUAD	cis	rs6121246	0.559	rs1062794	ENSG00000230613.1	HM13-AS1	3.88	0.000121	0.0165	0.21	0.17	Mean corpuscular hemoglobin;	chr20:31793955	chr20:31567707~31573263:-
LUAD	cis	rs6743068	0.541	rs13014235	ENSG00000234842.1	AC007163.8	-3.88	0.000121	0.0165	-0.2	-0.17	Lymphocyte percentage of white cells;	chr2:201350769	chr2:201549631~201550307:+
LUAD	cis	rs7242404	0.57	rs11080598	ENSG00000267654.1	RP11-973H7.4	3.88	0.000121	0.0165	0.2	0.17	Interleukin-9 levels;Macrophage inflammatory protein 1a levels;	chr18:12751824	chr18:12739490~12749421:-
LUAD	cis	rs1046491	0.901	rs35002591	ENSG00000264964.1	RP11-888D10.3	3.88	0.000121	0.0165	0.37	0.17	Scarlet fever;	chr18:9103799	chr18:9315194~9334441:-
LUAD	cis	rs4713118	0.505	rs156740	ENSG00000219392.1	RP1-265C24.5	-3.88	0.000121	0.0165	-0.21	-0.17	Parkinson's disease;	chr6:27992657	chr6:28115628~28116551:+
LUAD	cis	rs7674212	0.57	rs2711898	ENSG00000251288.2	RP11-10L12.2	-3.88	0.000121	0.0165	-0.21	-0.17	Type 2 diabetes;	chr4:103141914	chr4:102751401~102752641:+
LUAD	cis	rs8028182	0.636	rs4243034	ENSG00000260269.4	CTD-2323K18.1	-3.88	0.000121	0.0165	-0.24	-0.17	Sudden cardiac arrest;	chr15:75458628	chr15:75527150~75601205:-
LUAD	cis	rs9467773	0.62	rs2504565	ENSG00000241549.7	GUSBP2	3.88	0.000121	0.0166	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26656662	chr6:26871484~26956554:-
LUAD	cis	rs6787172	0.811	rs9859129	ENSG00000272087.1	RP11-379F4.7	3.88	0.000121	0.0166	0.19	0.17	Subjective well-being;	chr3:158506005	chr3:158693120~158693768:-
LUAD	cis	rs67981189	0.752	rs221902	ENSG00000269927.1	RP6-91H8.3	-3.88	0.000121	0.0166	-0.22	-0.17	Schizophrenia;	chr14:71134362	chr14:71141125~71143253:-
LUAD	cis	rs651386	0.529	rs576736	ENSG00000271811.1	RP1-79C4.4	3.88	0.000121	0.0166	0.21	0.17	Atrial fibrillation;	chr1:170618074	chr1:170667381~170669425:+
LUAD	cis	rs4268898	0.662	rs17733015	ENSG00000242628.4	AC009228.1	3.88	0.000121	0.0166	0.25	0.17	Asthma;	chr2:24286501	chr2:24214381~24221516:+
LUAD	cis	rs3018712	0.59	rs4930597	ENSG00000227620.4	ALG1L8P	3.88	0.000121	0.0166	0.24	0.17	Total body bone mineral density;	chr11:68708543	chr11:67785273~67792335:+
LUAD	cis	rs12999542	0.5	rs3755278	ENSG00000234389.1	AC007278.3	3.88	0.000121	0.0166	0.26	0.17	Serum protein levels (sST2);	chr2:102335757	chr2:102438713~102440475:+
LUAD	cis	rs12999542	0.5	rs3755277	ENSG00000234389.1	AC007278.3	3.88	0.000121	0.0166	0.26	0.17	Serum protein levels (sST2);	chr2:102336338	chr2:102438713~102440475:+
LUAD	cis	rs2235642	0.75	rs763152	ENSG00000280231.1	LA16c-380F5.3	-3.88	0.000121	0.0166	-0.23	-0.17	Coronary artery disease;	chr16:1608055	chr16:1553655~1554130:-
LUAD	cis	rs2235642	0.717	rs9937922	ENSG00000280231.1	LA16c-380F5.3	-3.88	0.000121	0.0166	-0.23	-0.17	Coronary artery disease;	chr16:1608153	chr16:1553655~1554130:-
LUAD	cis	rs1005224	0.963	rs2302592	ENSG00000242952.1	RP11-187O7.1	3.88	0.000121	0.0166	0.16	0.17	Large artery stroke;	chr14:75662944	chr14:76634775~76635661:-
LUAD	cis	rs2657294	0.965	rs7899946	ENSG00000233313.2	HMGA1P5	-3.88	0.000121	0.0166	-0.22	-0.17	Pneumonia;	chr10:75166013	chr10:75276376~75276646:-
LUAD	cis	rs7829975	0.502	rs7820738	ENSG00000253981.4	ALG1L13P	-3.88	0.000121	0.0166	-0.19	-0.17	Mood instability;	chr8:8845097	chr8:8236003~8244667:-
LUAD	cis	rs6558530	0.666	rs7845723	ENSG00000253982.1	CTD-2336O2.1	3.88	0.000121	0.0166	0.23	0.17	Systolic blood pressure;	chr8:1748920	chr8:1761990~1764502:-
LUAD	cis	rs8031584	0.958	rs3512	ENSG00000260128.5	ULK4P2	-3.88	0.000121	0.0166	-0.22	-0.17	Huntington's disease progression;	chr15:30942802	chr15:30572738~30600647:+
LUAD	cis	rs10197140	0.857	rs17545166	ENSG00000235721.1	AC013268.3	3.88	0.000121	0.0166	0.19	0.17	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110902985	chr2:110007675~110010783:+
LUAD	cis	rs7674212	0.57	rs6813563	ENSG00000251288.2	RP11-10L12.2	-3.88	0.000121	0.0166	-0.22	-0.17	Type 2 diabetes;	chr4:103177953	chr4:102751401~102752641:+
LUAD	cis	rs8180040	0.966	rs878659	ENSG00000271161.1	BOLA2P2	3.87	0.000121	0.0166	0.17	0.17	Colorectal cancer;	chr3:47459172	chr3:47499841~47500407:+
LUAD	cis	rs67981189	0.835	rs2526855	ENSG00000269927.1	RP6-91H8.3	-3.87	0.000121	0.0166	-0.22	-0.17	Schizophrenia;	chr14:70946629	chr14:71141125~71143253:-
LUAD	cis	rs67981189	0.766	rs2526852	ENSG00000269927.1	RP6-91H8.3	-3.87	0.000121	0.0166	-0.22	-0.17	Schizophrenia;	chr14:70949450	chr14:71141125~71143253:-
LUAD	cis	rs17406451	1	rs6714067	ENSG00000279873.2	LINC01126	-3.87	0.000121	0.0166	-0.15	-0.17	Mitochondrial DNA levels;	chr2:43405061	chr2:43227210~43228855:+
LUAD	cis	rs9925964	0.933	rs10871454	ENSG00000232748.3	RP11-196G11.6	3.87	0.000121	0.0166	0.21	0.17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31036758	chr16:31056460~31062803:+
LUAD	cis	rs6964587	1	rs13224513	ENSG00000188693.7	CYP51A1-AS1	-3.87	0.000121	0.0166	-0.2	-0.17	Breast cancer;	chr7:91972151	chr7:92134604~92180725:+
LUAD	cis	rs2274273	0.773	rs10147765	ENSG00000258413.1	RP11-665C16.6	-3.87	0.000121	0.0166	-0.23	-0.17	Protein biomarker;	chr14:55361108	chr14:55262767~55272075:-
LUAD	cis	rs8062405	1	rs8061590	ENSG00000261419.1	RP11-57A19.4	-3.87	0.000122	0.0166	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28883809	chr16:28659696~28740781:-
LUAD	cis	rs9900280	0.905	rs12945717	ENSG00000264808.1	RP11-802D6.1	3.87	0.000122	0.0166	0.21	0.17	Mean platelet volume;	chr17:29375034	chr17:29369717~29390777:-
LUAD	cis	rs10050311	0.746	rs969734	ENSG00000261496.1	RP13-514E23.1	-3.87	0.000122	0.0166	-0.2	-0.17	Insulin-related traits;	chr4:86744231	chr4:86012296~86013874:-
LUAD	cis	rs3096299	0.933	rs3114848	ENSG00000182376.2	RP5-1142A6.8	3.87	0.000122	0.0166	0.18	0.17	Multiple myeloma (IgH translocation);	chr16:89386363	chr16:88742767~88745748:+
LUAD	cis	rs1334894	0.892	rs9689799	ENSG00000228559.1	RP3-340B19.3	-3.87	0.000122	0.0166	-0.41	-0.17	Coronary artery disease;	chr6:35505280	chr6:35544632~35545669:+
LUAD	cis	rs62246343	0.719	rs62246275	ENSG00000206573.7	THUMPD3-AS1	-3.87	0.000122	0.0166	-0.18	-0.17	Fibrinogen levels;	chr3:9399496	chr3:9349689~9398579:-
LUAD	cis	rs451417	1	rs236115	ENSG00000275632.1	RP5-967N21.11	3.87	0.000122	0.0166	0.22	0.17	Menopause (age at onset);	chr20:5954803	chr20:6000418~6000941:+
LUAD	cis	rs8180040	0.726	rs2305634	ENSG00000271161.1	BOLA2P2	-3.87	0.000122	0.0166	-0.17	-0.17	Colorectal cancer;	chr3:47002048	chr3:47499841~47500407:+
LUAD	cis	rs7580658	0.929	rs4150496	ENSG00000236682.1	AC068282.3	-3.87	0.000122	0.0166	-0.24	-0.17	Protein C levels;	chr2:127271927	chr2:127389130~127400580:+
LUAD	cis	rs3812049	0.784	rs3749748	ENSG00000245937.6	LINC01184	-3.87	0.000122	0.0166	-0.26	-0.17	Lymphocyte counts;Red cell distribution width;	chr5:128014857	chr5:127940426~128083172:-
LUAD	cis	rs73193808	0.901	rs2065274	ENSG00000215533.7	LINC00189	-3.87	0.000122	0.0166	-0.26	-0.17	Coronary artery disease;	chr21:29197521	chr21:29193480~29288205:+
LUAD	cis	rs14027	0.64	rs6994604	ENSG00000279347.1	RP11-85I17.2	-3.87	0.000122	0.0166	-0.15	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119746463	chr8:119838736~119840385:-
LUAD	cis	rs14027	0.64	rs7837213	ENSG00000279347.1	RP11-85I17.2	-3.87	0.000122	0.0166	-0.15	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119750459	chr8:119838736~119840385:-
LUAD	cis	rs14027	0.64	rs16893109	ENSG00000279347.1	RP11-85I17.2	-3.87	0.000122	0.0166	-0.15	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119756309	chr8:119838736~119840385:-
LUAD	cis	rs14027	0.64	rs7011974	ENSG00000279347.1	RP11-85I17.2	-3.87	0.000122	0.0166	-0.15	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119759623	chr8:119838736~119840385:-
LUAD	cis	rs14027	0.64	rs9693207	ENSG00000279347.1	RP11-85I17.2	-3.87	0.000122	0.0166	-0.15	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119759815	chr8:119838736~119840385:-
LUAD	cis	rs10971721	0.822	rs12377078	ENSG00000260947.1	RP11-384P7.7	-3.87	0.000122	0.0166	-0.36	-0.17	Body mass index;	chr9:33934823	chr9:33697459~33700986:+
LUAD	cis	rs651907	0.557	rs11710533	ENSG00000244119.1	PDCL3P4	3.87	0.000122	0.0166	0.18	0.17	Colorectal cancer;	chr3:101632628	chr3:101712472~101713191:+
LUAD	cis	rs911555	0.755	rs34411783	ENSG00000244691.1	RPL10AP1	3.87	0.000122	0.0166	0.23	0.17	Intelligence (multi-trait analysis);	chr14:103434302	chr14:103412119~103412761:-
LUAD	cis	rs8002861	0.81	rs9533664	ENSG00000274001.1	RP11-5G9.5	3.87	0.000122	0.0166	0.18	0.17	Leprosy;	chr13:43866391	chr13:43877715~43878163:-
LUAD	cis	rs712039	0.958	rs11868673	ENSG00000276054.1	RP11-378E13.3	3.87	0.000122	0.0166	0.23	0.17	Tuberculosis;	chr17:37517559	chr17:37386886~37387926:+
LUAD	cis	rs643506	1	rs643506	ENSG00000230911.1	PPIHP1	-3.87	0.000122	0.0166	-0.22	-0.17	Breast cancer;	chr11:111765903	chr11:112029858~112030367:-
LUAD	cis	rs8180040	0.966	rs12486969	ENSG00000271161.1	BOLA2P2	-3.87	0.000122	0.0166	-0.17	-0.17	Colorectal cancer;	chr3:47387513	chr3:47499841~47500407:+
LUAD	cis	rs7572733	0.935	rs696814	ENSG00000222017.1	AC011997.1	3.87	0.000122	0.0166	0.22	0.17	Dermatomyositis;	chr2:197823175	chr2:197693106~197774823:+
LUAD	cis	rs11779988	0.545	rs208759	ENSG00000253671.1	RP11-806O11.1	-3.87	0.000122	0.0166	-0.21	-0.17	Breast cancer;	chr8:17950420	chr8:17808941~17820868:+
LUAD	cis	rs12073359	1	rs12058090	ENSG00000223945.2	RP11-458I7.1	-3.87	0.000122	0.0166	-0.25	-0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150039173	chr1:150053864~150055034:+
LUAD	cis	rs12073359	1	rs12060211	ENSG00000223945.2	RP11-458I7.1	-3.87	0.000122	0.0166	-0.25	-0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150039351	chr1:150053864~150055034:+
LUAD	cis	rs253959	0.607	rs1396497	ENSG00000272265.1	CTD-2287O16.4	3.87	0.000122	0.0166	0.2	0.17	Bipolar disorder and schizophrenia;	chr5:116091719	chr5:116078110~116078570:-
LUAD	cis	rs6964587	1	rs9690208	ENSG00000188693.7	CYP51A1-AS1	-3.87	0.000122	0.0166	-0.2	-0.17	Breast cancer;	chr7:92106299	chr7:92134604~92180725:+
LUAD	cis	rs6964587	1	rs60147309	ENSG00000188693.7	CYP51A1-AS1	-3.87	0.000122	0.0166	-0.2	-0.17	Breast cancer;	chr7:92106784	chr7:92134604~92180725:+
LUAD	cis	rs6964587	1	rs10274756	ENSG00000188693.7	CYP51A1-AS1	-3.87	0.000122	0.0166	-0.2	-0.17	Breast cancer;	chr7:92111482	chr7:92134604~92180725:+
LUAD	cis	rs494562	0.892	rs522129	ENSG00000234155.1	RP11-30P6.6	-3.87	0.000122	0.0166	-0.34	-0.17	Metabolic traits;Blood metabolite levels;	chr6:85406663	chr6:85387219~85390186:-
LUAD	cis	rs7824557	0.564	rs35009431	ENSG00000255046.1	RP11-297N6.4	3.87	0.000122	0.0166	0.22	0.17	Retinal vascular caliber;	chr8:11375279	chr8:11797928~11802568:-
LUAD	cis	rs5742933	0.857	rs1437891	ENSG00000253559.1	OSGEPL1-AS1	-3.87	0.000122	0.0166	-0.21	-0.17	Ferritin levels;	chr2:189697982	chr2:189762704~189765556:+
LUAD	cis	rs35740288	0.688	rs12904047	ENSG00000259407.1	RP11-158M2.3	-3.87	0.000122	0.0166	-0.17	-0.17	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85669635	chr15:85744109~85750281:-
LUAD	cis	rs6969780	0.915	rs11983200	ENSG00000233429.8	HOTAIRM1	3.87	0.000122	0.0166	0.32	0.17	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27146977	chr7:27095647~27100265:+
LUAD	cis	rs12234571	1	rs77445032	ENSG00000214293.7	APTR	3.87	0.000122	0.0166	0.36	0.17	Obesity-related traits;	chr7:77758177	chr7:77657660~77696265:-
LUAD	cis	rs3617	0.625	rs7652667	ENSG00000242142.1	SERBP1P3	-3.87	0.000122	0.0166	-0.19	-0.17	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52832519	chr3:53064283~53065091:-
LUAD	cis	rs3617	0.559	rs11915546	ENSG00000242142.1	SERBP1P3	-3.87	0.000122	0.0166	-0.19	-0.17	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52832829	chr3:53064283~53065091:-
LUAD	cis	rs2273156	0.587	rs61125355	ENSG00000226677.3	IGBP1P1	-3.87	0.000122	0.0166	-0.27	-0.17	Immunoglobulin light chain (AL) amyloidosis;	chr14:35065995	chr14:34939324~34940332:+
LUAD	cis	rs2273156	0.587	rs7145474	ENSG00000226677.3	IGBP1P1	-3.87	0.000122	0.0166	-0.27	-0.17	Immunoglobulin light chain (AL) amyloidosis;	chr14:35067909	chr14:34939324~34940332:+
LUAD	cis	rs755249	0.917	rs61781393	ENSG00000182109.6	RP11-69E11.4	3.87	0.000122	0.0166	0.22	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39622092	chr1:39522280~39546187:-
LUAD	cis	rs7762018	1	rs73242910	ENSG00000231690.2	LINC00574	-3.87	0.000122	0.0166	-0.32	-0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169714574	chr6:169790321~169802873:+
LUAD	cis	rs2638953	0.924	rs11049409	ENSG00000278733.1	RP11-425D17.1	-3.87	0.000122	0.0166	-0.21	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28182686	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs61920228	ENSG00000278733.1	RP11-425D17.1	-3.87	0.000122	0.0166	-0.21	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28183780	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs7306838	ENSG00000278733.1	RP11-425D17.1	-3.87	0.000122	0.0166	-0.21	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28184449	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs7138173	ENSG00000278733.1	RP11-425D17.1	-3.87	0.000122	0.0166	-0.21	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28184970	chr12:28185625~28186190:-
LUAD	cis	rs516805	0.561	rs9490494	ENSG00000279453.1	RP3-425C14.4	3.87	0.000122	0.0166	0.27	0.17	Lymphocyte counts;	chr6:122612860	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.561	rs9490495	ENSG00000279453.1	RP3-425C14.4	3.87	0.000122	0.0166	0.27	0.17	Lymphocyte counts;	chr6:122613043	chr6:122436789~122439223:-
LUAD	cis	rs516805	0.561	rs9320881	ENSG00000279453.1	RP3-425C14.4	3.87	0.000122	0.0166	0.27	0.17	Lymphocyte counts;	chr6:122613577	chr6:122436789~122439223:-
LUAD	cis	rs1541160	1	rs546894	ENSG00000239494.2	RN7SL333P	-3.87	0.000122	0.0166	-0.16	-0.17	Amyotrophic lateral sclerosis;	chr1:169987309	chr1:169859756~169860052:+
LUAD	cis	rs599083	0.53	rs576118	ENSG00000212093.1	AP000807.1	-3.87	0.000122	0.0166	-0.19	-0.17	Bone mineral density (spine);	chr11:68410240	chr11:68506083~68506166:-
LUAD	cis	rs375092	0.543	rs6461708	ENSG00000230658.1	KLHL7-AS1	-3.87	0.000122	0.0166	-0.26	-0.17	Personality dimensions;	chr7:23375698	chr7:23101228~23105703:-
LUAD	cis	rs2390582	0.722	rs17131097	ENSG00000233593.5	RP4-665J23.1	3.87	0.000122	0.0166	0.26	0.17	Coronary artery calcification;	chr1:90610093	chr1:90782986~90851650:-
LUAD	cis	rs9926296	0.605	rs3743859	ENSG00000260259.1	RP11-368I7.4	3.87	0.000122	0.0166	0.17	0.17	Vitiligo;	chr16:89779642	chr16:89682620~89686569:-
LUAD	cis	rs365302	0.767	rs412690	ENSG00000235086.1	FNDC1-IT1	3.87	0.000122	0.0167	0.24	0.17	Coronary heart disease;	chr6:159192512	chr6:159240786~159243329:+
LUAD	cis	rs9393777	0.557	rs36034627	ENSG00000219392.1	RP1-265C24.5	-3.87	0.000122	0.0167	-0.26	-0.17	Intelligence (multi-trait analysis);	chr6:27269584	chr6:28115628~28116551:+
LUAD	cis	rs7301826	1	rs4759787	ENSG00000256250.1	RP11-989F5.1	-3.87	0.000122	0.0167	-0.34	-0.17	Plasma plasminogen activator levels;	chr12:130805635	chr12:130810606~130812438:+
LUAD	cis	rs9467603	0.925	rs35436081	ENSG00000272345.1	RP1-30M3.5	-3.87	0.000122	0.0167	-0.33	-0.17	Intelligence (multi-trait analysis);	chr6:25700114	chr6:24700907~24701793:-
LUAD	cis	rs67340775	0.834	rs13218875	ENSG00000219392.1	RP1-265C24.5	-3.87	0.000122	0.0167	-0.39	-0.17	Lung cancer in ever smokers;	chr6:27916234	chr6:28115628~28116551:+
LUAD	cis	rs7762018	0.941	rs4716384	ENSG00000231690.2	LINC00574	-3.87	0.000122	0.0167	-0.32	-0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169709088	chr6:169790321~169802873:+
LUAD	cis	rs5758511	0.68	rs17002902	ENSG00000233903.2	Z83851.4	3.87	0.000122	0.0167	0.26	0.17	Birth weight;	chr22:42229503	chr22:42276355~42277052:+
LUAD	cis	rs5758511	0.68	rs5758662	ENSG00000233903.2	Z83851.4	3.87	0.000122	0.0167	0.26	0.17	Birth weight;	chr22:42232082	chr22:42276355~42277052:+
LUAD	cis	rs7005380	0.58	rs1467044	ENSG00000279347.1	RP11-85I17.2	-3.87	0.000122	0.0167	-0.14	-0.17	Interstitial lung disease;	chr8:119874801	chr8:119838736~119840385:-
LUAD	cis	rs2834288	0.7	rs11088263	ENSG00000237945.6	LINC00649	-3.87	0.000122	0.0167	-0.24	-0.17	Gut microbiota (bacterial taxa);	chr21:33918486	chr21:33915534~33977691:+
LUAD	cis	rs71636778	0.722	rs12729652	ENSG00000260063.1	RP5-968P14.2	-3.87	0.000122	0.0167	-0.23	-0.17	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26720491	chr1:26692132~26694131:-
LUAD	cis	rs7937682	0.961	rs7119563	ENSG00000230911.1	PPIHP1	3.87	0.000122	0.0167	0.24	0.17	Primary sclerosing cholangitis;	chr11:111673192	chr11:112029858~112030367:-
LUAD	cis	rs11893307	0.509	rs6726273	ENSG00000235852.1	AC005540.3	3.87	0.000122	0.0167	0.22	0.17	Mean platelet volume;	chr2:190664970	chr2:190880797~190882059:-
LUAD	cis	rs11893307	0.509	rs62179690	ENSG00000235852.1	AC005540.3	3.87	0.000122	0.0167	0.22	0.17	Mean platelet volume;	chr2:190665147	chr2:190880797~190882059:-
LUAD	cis	rs11893307	0.509	rs2109958	ENSG00000235852.1	AC005540.3	3.87	0.000122	0.0167	0.22	0.17	Mean platelet volume;	chr2:190668388	chr2:190880797~190882059:-
LUAD	cis	rs11893307	0.509	rs11895262	ENSG00000235852.1	AC005540.3	3.87	0.000122	0.0167	0.22	0.17	Mean platelet volume;	chr2:190669136	chr2:190880797~190882059:-
LUAD	cis	rs11893307	0.509	rs12612904	ENSG00000235852.1	AC005540.3	3.87	0.000122	0.0167	0.22	0.17	Mean platelet volume;	chr2:190670121	chr2:190880797~190882059:-
LUAD	cis	rs11893307	0.509	rs2109957	ENSG00000235852.1	AC005540.3	3.87	0.000122	0.0167	0.22	0.17	Mean platelet volume;	chr2:190670585	chr2:190880797~190882059:-
LUAD	cis	rs11893307	0.509	rs4368360	ENSG00000235852.1	AC005540.3	3.87	0.000122	0.0167	0.22	0.17	Mean platelet volume;	chr2:190671327	chr2:190880797~190882059:-
LUAD	cis	rs4499344	0.693	rs8106944	ENSG00000201388.1	SNORA68	3.87	0.000122	0.0167	0.18	0.17	Mean platelet volume;	chr19:32606877	chr19:32608337~32608469:-
LUAD	cis	rs4499344	0.693	rs8106502	ENSG00000201388.1	SNORA68	3.87	0.000122	0.0167	0.18	0.17	Mean platelet volume;	chr19:32606890	chr19:32608337~32608469:-
LUAD	cis	rs2348418	0.832	rs1907692	ENSG00000247934.4	RP11-967K21.1	3.87	0.000122	0.0167	0.2	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28385178	chr12:28163298~28190738:-
LUAD	cis	rs801193	0.569	rs13226966	ENSG00000273448.1	RP11-166O4.6	3.87	0.000122	0.0167	0.17	0.17	Aortic root size;	chr7:66768636	chr7:67333047~67334383:+
LUAD	cis	rs2749097	0.511	rs855330	ENSG00000244256.3	RN7SL130P	-3.87	0.000122	0.0167	-0.2	-0.17	Alcohol consumption (transferrin glycosylation);	chr1:63648218	chr1:63655743~63656047:+
LUAD	cis	rs214785	1	rs214782	ENSG00000234684.5	SDCBP2-AS1	3.87	0.000122	0.0167	0.21	0.17	Basal cell carcinoma;	chr20:2301324	chr20:1325405~1378734:+
LUAD	cis	rs10214930	0.697	rs10256550	ENSG00000235574.1	AC073150.6	-3.87	0.000122	0.0167	-0.21	-0.17	Hypospadias;	chr7:27867308	chr7:27491682~27492765:-
LUAD	cis	rs939960	0.61	rs56138121	ENSG00000279536.1	RP11-445N20.2	3.87	0.000122	0.0167	0.24	0.17	Neutrophil percentage of white cells;	chr7:150678313	chr7:149881477~149882105:+
LUAD	cis	rs860295	0.729	rs11264369	ENSG00000225855.5	RUSC1-AS1	-3.87	0.000122	0.0167	-0.12	-0.17	Body mass index;	chr1:155390039	chr1:155316863~155324176:-
LUAD	cis	rs7172677	0.737	rs7169545	ENSG00000260269.4	CTD-2323K18.1	-3.87	0.000122	0.0167	-0.23	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75143782	chr15:75527150~75601205:-
LUAD	cis	rs8062405	0.691	rs11646653	ENSG00000261419.1	RP11-57A19.4	3.87	0.000122	0.0167	0.19	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28659696~28740781:-
LUAD	cis	rs2638953	0.744	rs11049426	ENSG00000278733.1	RP11-425D17.1	-3.87	0.000123	0.0167	-0.2	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28193573	chr12:28185625~28186190:-
LUAD	cis	rs365302	1	rs433171	ENSG00000235086.1	FNDC1-IT1	3.87	0.000123	0.0167	0.23	0.17	Coronary heart disease;	chr6:159224346	chr6:159240786~159243329:+
LUAD	cis	rs365302	1	rs374973	ENSG00000235086.1	FNDC1-IT1	3.87	0.000123	0.0167	0.23	0.17	Coronary heart disease;	chr6:159224530	chr6:159240786~159243329:+
LUAD	cis	rs365302	1	rs432598	ENSG00000235086.1	FNDC1-IT1	3.87	0.000123	0.0167	0.23	0.17	Coronary heart disease;	chr6:159224723	chr6:159240786~159243329:+
LUAD	cis	rs365302	1	rs401578	ENSG00000235086.1	FNDC1-IT1	3.87	0.000123	0.0167	0.23	0.17	Coronary heart disease;	chr6:159224751	chr6:159240786~159243329:+
LUAD	cis	rs365302	1	rs445227	ENSG00000235086.1	FNDC1-IT1	3.87	0.000123	0.0167	0.23	0.17	Coronary heart disease;	chr6:159224856	chr6:159240786~159243329:+
LUAD	cis	rs365302	1	rs378194	ENSG00000235086.1	FNDC1-IT1	3.87	0.000123	0.0167	0.23	0.17	Coronary heart disease;	chr6:159225291	chr6:159240786~159243329:+
LUAD	cis	rs365302	1	rs375512	ENSG00000235086.1	FNDC1-IT1	3.87	0.000123	0.0167	0.23	0.17	Coronary heart disease;	chr6:159225418	chr6:159240786~159243329:+
LUAD	cis	rs365302	1	rs475074	ENSG00000235086.1	FNDC1-IT1	3.87	0.000123	0.0167	0.23	0.17	Coronary heart disease;	chr6:159227026	chr6:159240786~159243329:+
LUAD	cis	rs365302	1	rs474108	ENSG00000235086.1	FNDC1-IT1	3.87	0.000123	0.0167	0.23	0.17	Coronary heart disease;	chr6:159227122	chr6:159240786~159243329:+
LUAD	cis	rs365302	1	rs531165	ENSG00000235086.1	FNDC1-IT1	3.87	0.000123	0.0167	0.23	0.17	Coronary heart disease;	chr6:159227188	chr6:159240786~159243329:+
LUAD	cis	rs73193808	1	rs2832230	ENSG00000215533.7	LINC00189	3.87	0.000123	0.0167	0.25	0.17	Coronary artery disease;	chr21:29164391	chr21:29193480~29288205:+
LUAD	cis	rs2274273	0.805	rs60972460	ENSG00000258413.1	RP11-665C16.6	-3.87	0.000123	0.0167	-0.22	-0.17	Protein biomarker;	chr14:55105055	chr14:55262767~55272075:-
LUAD	cis	rs6445967	0.689	rs11714574	ENSG00000273493.1	RP11-80H18.4	-3.87	0.000123	0.0167	-0.2	-0.17	Platelet count;	chr3:58394738	chr3:58329965~58330118:+
LUAD	cis	rs67478160	0.619	rs12897150	ENSG00000272533.1	SNORA28	3.87	0.000123	0.0167	0.18	0.17	Schizophrenia;	chr14:103853193	chr14:103337849~103337974:+
LUAD	cis	rs7674212	0.865	rs1481279	ENSG00000251288.2	RP11-10L12.2	3.87	0.000123	0.0167	0.21	0.17	Type 2 diabetes;	chr4:103056781	chr4:102751401~102752641:+
LUAD	cis	rs34779708	0.931	rs17591135	ENSG00000271335.4	RP11-324I22.4	3.87	0.000123	0.0167	0.19	0.17	Inflammatory bowel disease;Crohn's disease;	chr10:35176262	chr10:35314552~35336401:-
LUAD	cis	rs6832769	1	rs4580704	ENSG00000272969.1	RP11-528I4.2	-3.87	0.000123	0.0167	-0.18	-0.17	Personality dimensions;	chr4:55460540	chr4:55547112~55547889:+
LUAD	cis	rs73198271	0.74	rs10103163	ENSG00000253893.2	FAM85B	3.87	0.000123	0.0167	0.23	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793165	chr8:8167819~8226614:-
LUAD	cis	rs2708977	0.637	rs675239	ENSG00000237510.6	AC008268.2	-3.87	0.000123	0.0167	-0.22	-0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96410819	chr2:95789654~95800166:+
LUAD	cis	rs7580658	0.963	rs62157555	ENSG00000236682.1	AC068282.3	-3.87	0.000123	0.0167	-0.24	-0.17	Protein C levels;	chr2:127349600	chr2:127389130~127400580:+
LUAD	cis	rs763121	0.853	rs5757208	ENSG00000225450.1	RP3-508I15.14	-3.87	0.000123	0.0167	-0.17	-0.17	Menopause (age at onset);	chr22:38653225	chr22:38739003~38749041:+
LUAD	cis	rs763121	0.853	rs6001184	ENSG00000225450.1	RP3-508I15.14	-3.87	0.000123	0.0167	-0.17	-0.17	Menopause (age at onset);	chr22:38656111	chr22:38739003~38749041:+
LUAD	cis	rs763121	0.853	rs6001185	ENSG00000225450.1	RP3-508I15.14	-3.87	0.000123	0.0167	-0.17	-0.17	Menopause (age at onset);	chr22:38656150	chr22:38739003~38749041:+
LUAD	cis	rs12478296	1	rs113129906	ENSG00000261186.2	RP11-341N2.1	-3.87	0.000123	0.0167	-0.33	-0.17	Obesity-related traits;	chr2:242062102	chr2:242087351~242088457:-
LUAD	cis	rs12744310	1	rs12031169	ENSG00000235358.1	RP11-399E6.1	3.87	0.000123	0.0167	0.23	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41302579	chr1:41242373~41284861:+
LUAD	cis	rs12744310	0.943	rs35502198	ENSG00000235358.1	RP11-399E6.1	3.87	0.000123	0.0167	0.23	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41302869	chr1:41242373~41284861:+
LUAD	cis	rs1479119	0.78	rs7971776	ENSG00000180861.8	LINC01559	3.87	0.000123	0.0167	0.2	0.17	Intelligence (multi-trait analysis);	chr12:13347962	chr12:13371089~13387167:-
LUAD	cis	rs6754311	0.731	rs309164	ENSG00000226806.1	AC011893.3	3.87	0.000123	0.0167	0.22	0.17	Mosquito bite size;	chr2:135934255	chr2:135820191~135823087:+
LUAD	cis	rs858239	0.539	rs2103281	ENSG00000226816.2	AC005082.12	3.87	0.000123	0.0167	0.23	0.17	Cerebrospinal fluid biomarker levels;	chr7:23154612	chr7:23206013~23208045:+
LUAD	cis	rs1633360	1	rs1633360	ENSG00000270039.1	RP11-571M6.17	3.87	0.000123	0.0167	0.2	0.17	Rheumatoid arthritis;	chr12:57714269	chr12:57803838~57804415:+
LUAD	cis	rs12141041	0.934	rs6670497	ENSG00000224238.2	WARS2-IT1	-3.87	0.000123	0.0167	-0.21	-0.17	Blood metabolite levels;	chr1:119385346	chr1:119047405~119064785:+
LUAD	cis	rs11846409	0.799	rs10467899	ENSG00000211972.2	IGHV3-66	3.87	0.000123	0.0167	0.18	0.17	Rheumatic heart disease;	chr14:106644012	chr14:106675017~106675544:-
LUAD	cis	rs11512640	0.826	rs11220091	ENSG00000254671.2	STT3A-AS1	3.87	0.000123	0.0167	0.41	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125491242	chr11:125570284~125592568:-
LUAD	cis	rs7260598	0.606	rs72483177	ENSG00000269421.1	ZNF92P3	-3.87	0.000123	0.0167	-0.27	-0.17	Response to taxane treatment (placlitaxel);	chr19:23970913	chr19:23935220~23936173:+
LUAD	cis	rs7339483	0.702	rs10412212	ENSG00000268058.1	BNIP3P40	-3.87	0.000123	0.0167	-0.34	-0.17	Discordance in emotional problems in monozygotic twins;	chr19:24223200	chr19:24098425~24098980:-
LUAD	cis	rs1401999	0.898	rs4148564	ENSG00000223882.1	ABCC5-AS1	-3.87	0.000123	0.0167	-0.18	-0.17	Anterior chamber depth;	chr3:184008194	chr3:184006338~184011419:+
LUAD	cis	rs6787172	0.811	rs6795376	ENSG00000272087.1	RP11-379F4.7	3.87	0.000123	0.0167	0.18	0.17	Subjective well-being;	chr3:158496682	chr3:158693120~158693768:-
LUAD	cis	rs6787172	0.811	rs6762860	ENSG00000272087.1	RP11-379F4.7	3.87	0.000123	0.0167	0.18	0.17	Subjective well-being;	chr3:158497753	chr3:158693120~158693768:-
LUAD	cis	rs4873772	0.735	rs1106607	ENSG00000253330.1	RP11-697N18.3	-3.87	0.000123	0.0168	-0.2	-0.17	Lobe attachment (rater-scored or self-reported);	chr8:47492781	chr8:47511034~47512141:-
LUAD	cis	rs6964587	0.967	rs6465353	ENSG00000188693.7	CYP51A1-AS1	3.87	0.000123	0.0168	0.2	0.17	Breast cancer;	chr7:92150657	chr7:92134604~92180725:+
LUAD	cis	rs4908768	0.906	rs56163601	ENSG00000232912.4	RP5-1115A15.1	-3.87	0.000123	0.0168	-0.21	-0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8691838	chr1:8424645~8434838:+
LUAD	cis	rs5758659	0.569	rs133293	ENSG00000182057.4	OGFRP1	3.87	0.000123	0.0168	0.21	0.17	Cognitive function;	chr22:41986793	chr22:42269753~42275196:+
LUAD	cis	rs116095464	0.614	rs56299325	ENSG00000248925.1	CTD-2083E4.6	3.87	0.000123	0.0168	0.29	0.17	Breast cancer;	chr5:220479	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs62346526	ENSG00000248925.1	CTD-2083E4.6	3.87	0.000123	0.0168	0.29	0.17	Breast cancer;	chr5:220499	chr5:269858~271516:-
LUAD	cis	rs7429990	0.93	rs13075457	ENSG00000228638.1	FCF1P2	3.87	0.000123	0.0168	0.21	0.17	Educational attainment (years of education);	chr3:48013063	chr3:48290793~48291375:-
LUAD	cis	rs6688537	0.622	rs7551001	ENSG00000233355.5	CHRM3-AS2	-3.87	0.000123	0.0168	-0.14	-0.17	Lung function (FEV1/FVC);	chr1:239681300	chr1:239703381~239730465:-
LUAD	cis	rs8054556	0.74	rs11649612	ENSG00000183604.13	SMG1P5	-3.87	0.000123	0.0168	-0.17	-0.17	Autism spectrum disorder or schizophrenia;	chr16:29935349	chr16:30267553~30335374:-
LUAD	cis	rs523522	0.962	rs2168319	ENSG00000278344.1	RP11-18C24.8	3.87	0.000123	0.0168	0.24	0.17	High light scatter reticulocyte count;	chr12:120495414	chr12:120500735~120501090:-
LUAD	cis	rs910316	0.712	rs175015	ENSG00000279594.1	RP11-950C14.10	-3.87	0.000123	0.0168	-0.2	-0.17	Height;	chr14:74990372	chr14:75011269~75012851:-
LUAD	cis	rs12935418	0.634	rs9934940	ENSG00000261061.1	RP11-303E16.2	-3.87	0.000123	0.0168	-0.19	-0.17	Mean corpuscular volume;	chr16:81016021	chr16:81030770~81031485:+
LUAD	cis	rs7134599	1	rs723403	ENSG00000240087.3	RP11-254B13.1	3.87	0.000123	0.0168	0.15	0.17	Inflammatory bowel disease;Ulcerative colitis;	chr12:68107674	chr12:68552995~68553882:-
LUAD	cis	rs7131987	0.565	rs7971296	ENSG00000257176.2	RP11-996F15.2	3.87	0.000123	0.0168	0.18	0.17	QT interval;	chr12:29263297	chr12:29280418~29317848:-
LUAD	cis	rs7772486	0.875	rs6914813	ENSG00000235652.6	RP11-545I5.3	3.87	0.000123	0.0168	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:146076662	chr6:145799409~145886585:+
LUAD	cis	rs516805	0.961	rs483933	ENSG00000279114.1	RP3-425C14.5	-3.87	0.000123	0.0168	-0.19	-0.17	Lymphocyte counts;	chr6:122460377	chr6:122471923~122484161:+
LUAD	cis	rs13113518	0.702	rs78829811	ENSG00000249700.7	SRD5A3-AS1	3.87	0.000123	0.0168	0.18	0.17	Height;	chr4:55558258	chr4:55363971~55395847:-
LUAD	cis	rs13113518	0.702	rs75801206	ENSG00000249700.7	SRD5A3-AS1	3.87	0.000123	0.0168	0.18	0.17	Height;	chr4:55558259	chr4:55363971~55395847:-
LUAD	cis	rs13113518	0.702	rs34658078	ENSG00000249700.7	SRD5A3-AS1	3.87	0.000123	0.0168	0.18	0.17	Height;	chr4:55558261	chr4:55363971~55395847:-
LUAD	cis	rs11955398	0.502	rs290513	ENSG00000272308.1	RP11-231G3.1	-3.87	0.000123	0.0168	-0.2	-0.17	Intelligence (multi-trait analysis);	chr5:61014936	chr5:60866457~60866935:-
LUAD	cis	rs11955398	0.502	rs248688	ENSG00000272308.1	RP11-231G3.1	-3.87	0.000123	0.0168	-0.2	-0.17	Intelligence (multi-trait analysis);	chr5:61021606	chr5:60866457~60866935:-
LUAD	cis	rs10197140	0.925	rs10188079	ENSG00000235721.1	AC013268.3	3.87	0.000123	0.0168	0.19	0.17	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110886898	chr2:110007675~110010783:+
LUAD	cis	rs812925	0.784	rs6735081	ENSG00000271889.1	RP11-493E12.1	-3.87	0.000123	0.0168	-0.21	-0.17	Immature fraction of reticulocytes;	chr2:61233582	chr2:61151433~61162105:-
LUAD	cis	rs8056893	0.885	rs6499166	ENSG00000274698.1	RP11-71L14.4	3.87	0.000123	0.0168	0.2	0.17	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68293014	chr16:68450283~68452318:+
LUAD	cis	rs9910055	0.529	rs190144	ENSG00000267080.4	ASB16-AS1	3.87	0.000123	0.0168	0.16	0.17	Total body bone mineral density;	chr17:44087216	chr17:44175973~44186717:-
LUAD	cis	rs1061377	0.585	rs2163271	ENSG00000249685.1	RP11-360F5.3	3.87	0.000123	0.0168	0.21	0.17	Uric acid levels;	chr4:39076525	chr4:39133913~39135608:+
LUAD	cis	rs728616	0.867	rs61860400	ENSG00000234382.2	RP11-40F6.1	-3.87	0.000123	0.0168	-0.43	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79963671	chr10:80233664~80245367:+
LUAD	cis	rs801193	0.569	rs11772819	ENSG00000106610.13	STAG3L4	-3.87	0.000123	0.0168	-0.22	-0.17	Aortic root size;	chr7:66752983	chr7:67302621~67321526:+
LUAD	cis	rs801193	0.569	rs7800620	ENSG00000106610.13	STAG3L4	-3.87	0.000123	0.0168	-0.22	-0.17	Aortic root size;	chr7:66758701	chr7:67302621~67321526:+
LUAD	cis	rs2024714	0.868	rs4925264	ENSG00000273812.1	WI2-87327B8.2	-3.87	0.000123	0.0168	-0.19	-0.17	Longevity;	chr20:61640911	chr20:62596732~62603115:-
LUAD	cis	rs6479901	0.895	rs10761728	ENSG00000232075.1	MRPL35P2	-3.87	0.000123	0.0168	-0.24	-0.17	Intelligence (multi-trait analysis);	chr10:63235808	chr10:63634317~63634827:-
LUAD	cis	rs875971	0.545	rs17138156	ENSG00000224316.1	RP11-479O9.2	3.87	0.000123	0.0168	0.2	0.17	Aortic root size;	chr7:66249708	chr7:65773620~65802067:+
LUAD	cis	rs2836950	0.52	rs11911087	ENSG00000232608.1	TIMM9P2	3.87	0.000123	0.0168	0.19	0.17	Menarche (age at onset);	chr21:39293266	chr21:39216624~39217506:+
LUAD	cis	rs8062405	1	rs3088215	ENSG00000261419.1	RP11-57A19.4	-3.87	0.000123	0.0168	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28659696~28740781:-
LUAD	cis	rs8062405	1	rs28403629	ENSG00000261419.1	RP11-57A19.4	-3.87	0.000123	0.0168	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28659696~28740781:-
LUAD	cis	rs8062405	1	rs61737565	ENSG00000261419.1	RP11-57A19.4	-3.87	0.000123	0.0168	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28659696~28740781:-
LUAD	cis	rs8062405	1	rs4788099	ENSG00000261419.1	RP11-57A19.4	-3.87	0.000123	0.0168	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28659696~28740781:-
LUAD	cis	rs12935418	0.616	rs1469123	ENSG00000261061.1	RP11-303E16.2	3.87	0.000123	0.0168	0.18	0.17	Mean corpuscular volume;	chr16:80995944	chr16:81030770~81031485:+
LUAD	cis	rs12935418	0.583	rs1469124	ENSG00000261061.1	RP11-303E16.2	3.87	0.000123	0.0168	0.18	0.17	Mean corpuscular volume;	chr16:80996049	chr16:81030770~81031485:+
LUAD	cis	rs12935418	0.583	rs1469125	ENSG00000261061.1	RP11-303E16.2	3.87	0.000123	0.0168	0.18	0.17	Mean corpuscular volume;	chr16:80996163	chr16:81030770~81031485:+
LUAD	cis	rs12935418	0.523	rs1469126	ENSG00000261061.1	RP11-303E16.2	3.87	0.000123	0.0168	0.18	0.17	Mean corpuscular volume;	chr16:80996284	chr16:81030770~81031485:+
LUAD	cis	rs1707322	0.638	rs9429095	ENSG00000234329.1	RP11-767N6.2	-3.87	0.000123	0.0168	-0.18	-0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46137676	chr1:45651039~45651826:-
LUAD	cis	rs7430456	0.87	rs9864169	ENSG00000231574.4	RP11-91K9.1	-3.87	0.000123	0.0168	-0.2	-0.17	Breast cancer;	chr3:177746841	chr3:177816865~177899224:+
LUAD	cis	rs7430456	0.901	rs12696448	ENSG00000231574.4	RP11-91K9.1	-3.87	0.000123	0.0168	-0.2	-0.17	Breast cancer;	chr3:177746860	chr3:177816865~177899224:+
LUAD	cis	rs2906856	0.921	rs1019076	ENSG00000236946.2	HNRNPA1P70	3.87	0.000123	0.0168	0.15	0.17	Mosquito bite size;	chr12:68004338	chr12:68035767~68036853:+
LUAD	cis	rs3814244	0.515	rs2906862	ENSG00000236946.2	HNRNPA1P70	3.87	0.000123	0.0168	0.15	0.17	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005371	chr12:68035767~68036853:+
LUAD	cis	rs9593057	0.579	rs73490336	ENSG00000234835.1	PHBP13	-3.87	0.000123	0.0168	-0.39	-0.17	Lobe attachment (rater-scored or self-reported);	chr13:34963344	chr13:35251070~35251829:+
LUAD	cis	rs9593057	0.579	rs73490346	ENSG00000234835.1	PHBP13	-3.87	0.000123	0.0168	-0.39	-0.17	Lobe attachment (rater-scored or self-reported);	chr13:34967477	chr13:35251070~35251829:+
LUAD	cis	rs6120849	0.754	rs6120819	ENSG00000202150.1	RNU6-407P	3.87	0.000123	0.0168	0.25	0.17	Protein C levels;	chr20:35065235	chr20:35030317~35030420:-
LUAD	cis	rs9341808	0.519	rs660888	ENSG00000260645.1	RP11-250B2.5	3.87	0.000123	0.0168	0.17	0.17	Sitting height ratio;	chr6:80273495	chr6:80466958~80469080:+
LUAD	cis	rs1979679	0.842	rs12049916	ENSG00000278733.1	RP11-425D17.1	3.87	0.000123	0.0168	0.22	0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28207052	chr12:28185625~28186190:-
LUAD	cis	rs728616	0.85	rs3889823	ENSG00000225484.5	NUTM2B-AS1	-3.87	0.000123	0.0168	-0.44	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80158606	chr10:79663088~79826594:-
LUAD	cis	rs2735413	0.881	rs4888732	ENSG00000276007.1	RP11-358L22.3	-3.87	0.000123	0.0168	-0.18	-0.17	Systolic blood pressure (alcohol consumption interaction);	chr16:78046608	chr16:78123243~78124332:+
LUAD	cis	rs2281603	0.57	rs10136732	ENSG00000259116.1	RP11-973N13.4	-3.87	0.000123	0.0168	-0.14	-0.17	Lymphocyte counts;	chr14:64484255	chr14:64514154~64540368:-
LUAD	cis	rs526231	0.512	rs34797	ENSG00000250682.4	LINC00491	3.87	0.000123	0.0168	0.21	0.17	Primary biliary cholangitis;	chr5:103090023	chr5:102609156~102671559:-
LUAD	cis	rs526231	0.543	rs34801	ENSG00000250682.4	LINC00491	3.87	0.000123	0.0168	0.21	0.17	Primary biliary cholangitis;	chr5:103090809	chr5:102609156~102671559:-
LUAD	cis	rs10971721	0.822	rs72725374	ENSG00000260947.1	RP11-384P7.7	3.87	0.000123	0.0168	0.36	0.17	Body mass index;	chr9:33840651	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.749	rs72725375	ENSG00000260947.1	RP11-384P7.7	3.87	0.000123	0.0168	0.36	0.17	Body mass index;	chr9:33840706	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs72725376	ENSG00000260947.1	RP11-384P7.7	3.87	0.000123	0.0168	0.36	0.17	Body mass index;	chr9:33841931	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs72725377	ENSG00000260947.1	RP11-384P7.7	3.87	0.000123	0.0168	0.36	0.17	Body mass index;	chr9:33842228	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs72725378	ENSG00000260947.1	RP11-384P7.7	3.87	0.000123	0.0168	0.36	0.17	Body mass index;	chr9:33842896	chr9:33697459~33700986:+
LUAD	cis	rs9928842	0.771	rs2870471	ENSG00000259972.2	AC009120.6	3.87	0.000123	0.0168	0.13	0.17	Alcoholic chronic pancreatitis;	chr16:75240384	chr16:74305127~74335346:-
LUAD	cis	rs9659323	0.73	rs10923720	ENSG00000231365.4	RP11-418J17.1	-3.87	0.000123	0.0168	-0.2	-0.17	Body mass index;	chr1:118999256	chr1:119140396~119275973:+
LUAD	cis	rs9659323	0.612	rs10923721	ENSG00000231365.4	RP11-418J17.1	-3.87	0.000123	0.0168	-0.2	-0.17	Body mass index;	chr1:118999564	chr1:119140396~119275973:+
LUAD	cis	rs526231	0.819	rs2288787	ENSG00000175749.11	EIF3KP1	3.87	0.000123	0.0168	0.23	0.17	Primary biliary cholangitis;	chr5:103265005	chr5:103032376~103033031:+
LUAD	cis	rs2732480	0.538	rs2468943	ENSG00000257763.1	OR5BK1P	-3.87	0.000124	0.0168	-0.18	-0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48353466	chr12:48355792~48356614:-
LUAD	cis	rs8014252	0.803	rs8012025	ENSG00000259158.2	ADAM20P1	-3.87	0.000124	0.0168	-0.29	-0.17	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70545488	chr14:70468881~70483756:-
LUAD	cis	rs728616	0.717	rs61860016	ENSG00000225484.5	NUTM2B-AS1	-3.87	0.000124	0.0168	-0.45	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80156133	chr10:79663088~79826594:-
LUAD	cis	rs7809615	0.515	rs10257273	ENSG00000244219.5	GS1-259H13.2	-3.87	0.000124	0.0168	-0.29	-0.17	Blood metabolite ratios;	chr7:99590966	chr7:99598066~99610813:+
LUAD	cis	rs9467773	1	rs9467799	ENSG00000241549.7	GUSBP2	3.87	0.000124	0.0168	0.2	0.17	Intelligence (multi-trait analysis);	chr6:26578136	chr6:26871484~26956554:-
LUAD	cis	rs9467773	0.967	rs10223792	ENSG00000241549.7	GUSBP2	3.87	0.000124	0.0168	0.2	0.17	Intelligence (multi-trait analysis);	chr6:26579388	chr6:26871484~26956554:-
LUAD	cis	rs9467773	0.967	rs9461272	ENSG00000241549.7	GUSBP2	3.87	0.000124	0.0168	0.2	0.17	Intelligence (multi-trait analysis);	chr6:26579420	chr6:26871484~26956554:-
LUAD	cis	rs3794924	1	rs7236589	ENSG00000266521.1	RP11-650P15.1	3.87	0.000124	0.0168	0.33	0.17	Survival in colon cancer;	chr18:31475207	chr18:31496645~31497195:-
LUAD	cis	rs2976388	0.59	rs7828042	ENSG00000253741.1	CTD-2292P10.4	3.87	0.000124	0.0168	0.2	0.17	Urinary tract infection frequency;	chr8:142737965	chr8:142702252~142726973:-
LUAD	cis	rs6951245	0.938	rs112425403	ENSG00000199023.2	MIR339	-3.87	0.000124	0.0168	-0.31	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1031895	chr7:1022935~1023045:-
LUAD	cis	rs2486288	0.656	rs11632724	ENSG00000259479.5	SORD2P	-3.87	0.000124	0.0168	-0.21	-0.17	Glomerular filtration rate;	chr15:45258593	chr15:44826371~44884694:-
LUAD	cis	rs2486288	0.656	rs11632651	ENSG00000259479.5	SORD2P	-3.87	0.000124	0.0168	-0.21	-0.17	Glomerular filtration rate;	chr15:45258640	chr15:44826371~44884694:-
LUAD	cis	rs2486288	0.656	rs11637920	ENSG00000259479.5	SORD2P	-3.87	0.000124	0.0168	-0.21	-0.17	Glomerular filtration rate;	chr15:45258707	chr15:44826371~44884694:-
LUAD	cis	rs2486288	0.656	rs11632777	ENSG00000259479.5	SORD2P	-3.87	0.000124	0.0168	-0.21	-0.17	Glomerular filtration rate;	chr15:45258847	chr15:44826371~44884694:-
LUAD	cis	rs2486288	0.656	rs11632778	ENSG00000259479.5	SORD2P	-3.87	0.000124	0.0168	-0.21	-0.17	Glomerular filtration rate;	chr15:45258858	chr15:44826371~44884694:-
LUAD	cis	rs2486288	0.656	rs11632752	ENSG00000259479.5	SORD2P	-3.87	0.000124	0.0168	-0.21	-0.17	Glomerular filtration rate;	chr15:45258942	chr15:44826371~44884694:-
LUAD	cis	rs6479891	0.908	rs11819167	ENSG00000232075.1	MRPL35P2	3.87	0.000124	0.0168	0.28	0.17	Arthritis (juvenile idiopathic);	chr10:63216409	chr10:63634317~63634827:-
LUAD	cis	rs6479891	1	rs1904295	ENSG00000232075.1	MRPL35P2	-3.87	0.000124	0.0168	-0.28	-0.17	Arthritis (juvenile idiopathic);	chr10:63223116	chr10:63634317~63634827:-
LUAD	cis	rs6479901	0.512	rs6415875	ENSG00000232075.1	MRPL35P2	-3.87	0.000124	0.0168	-0.28	-0.17	Intelligence (multi-trait analysis);	chr10:63226657	chr10:63634317~63634827:-
LUAD	cis	rs6479891	0.915	rs4281380	ENSG00000232075.1	MRPL35P2	-3.87	0.000124	0.0168	-0.28	-0.17	Arthritis (juvenile idiopathic);	chr10:63227938	chr10:63634317~63634827:-
LUAD	cis	rs6479901	0.512	rs4439410	ENSG00000232075.1	MRPL35P2	-3.87	0.000124	0.0168	-0.28	-0.17	Intelligence (multi-trait analysis);	chr10:63239012	chr10:63634317~63634827:-
LUAD	cis	rs600231	0.577	rs12269965	ENSG00000245532.5	NEAT1	3.87	0.000124	0.0168	0.16	0.17	Bone mineral density;	chr11:65464616	chr11:65422774~65445540:+
LUAD	cis	rs600231	0.542	rs11227196	ENSG00000245532.5	NEAT1	3.87	0.000124	0.0168	0.16	0.17	Bone mineral density;	chr11:65467451	chr11:65422774~65445540:+
LUAD	cis	rs3812049	0.693	rs9327468	ENSG00000245937.6	LINC01184	3.87	0.000124	0.0168	0.26	0.17	Lymphocyte counts;Red cell distribution width;	chr5:128106169	chr5:127940426~128083172:-
LUAD	cis	rs7512552	0.839	rs3896342	ENSG00000275557.1	RP11-353N4.6	3.87	0.000124	0.0168	0.2	0.17	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150438836	chr1:149607765~149612402:+
LUAD	cis	rs8180040	0.966	rs11711824	ENSG00000271161.1	BOLA2P2	3.87	0.000124	0.0168	0.17	0.17	Colorectal cancer;	chr3:47426771	chr3:47499841~47500407:+
LUAD	cis	rs523522	0.962	rs4767904	ENSG00000278344.1	RP11-18C24.8	3.87	0.000124	0.0168	0.23	0.17	High light scatter reticulocyte count;	chr12:120492995	chr12:120500735~120501090:-
LUAD	cis	rs9467773	0.595	rs7767847	ENSG00000241549.7	GUSBP2	3.87	0.000124	0.0168	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26597665	chr6:26871484~26956554:-
LUAD	cis	rs11673344	0.864	rs2263167	ENSG00000267309.1	CTD-2630F21.1	-3.87	0.000124	0.0168	-0.22	-0.17	Obesity-related traits;	chr19:37030025	chr19:36489649~36491040:+
LUAD	cis	rs6547741	0.967	rs4665995	ENSG00000223522.1	AC093690.1	3.87	0.000124	0.0168	0.17	0.17	Oral cavity cancer;	chr2:27590960	chr2:28307691~28310459:-
LUAD	cis	rs6547741	0.967	rs4665996	ENSG00000223522.1	AC093690.1	3.87	0.000124	0.0168	0.17	0.17	Oral cavity cancer;	chr2:27591476	chr2:28307691~28310459:-
LUAD	cis	rs4795519	1	rs10853131	ENSG00000266313.1	RP11-173M1.4	3.87	0.000124	0.0168	0.21	0.17	Chronic myeloid leukemia;	chr17:27154266	chr17:27333256~27348491:+
LUAD	cis	rs2354432	0.607	rs2353999	ENSG00000237188.3	RP11-337C18.8	3.87	0.000124	0.0168	0.32	0.17	Mitochondrial DNA levels;	chr1:147358974	chr1:147172771~147211568:+
LUAD	cis	rs1908814	0.516	rs60176945	ENSG00000255046.1	RP11-297N6.4	-3.87	0.000124	0.0168	-0.22	-0.17	Neuroticism;	chr8:11939165	chr8:11797928~11802568:-
LUAD	cis	rs1908814	0.516	rs56102998	ENSG00000255046.1	RP11-297N6.4	-3.87	0.000124	0.0168	-0.22	-0.17	Neuroticism;	chr8:11939166	chr8:11797928~11802568:-
LUAD	cis	rs6494488	0.5	rs1133357	ENSG00000239465.1	RP11-330L19.2	3.87	0.000124	0.0168	0.36	0.17	Coronary artery disease;	chr15:64695371	chr15:64631109~64631914:-
LUAD	cis	rs9973361	0.559	rs10196217	ENSG00000232411.1	AC009495.3	-3.87	0.000124	0.0168	-0.25	-0.17	Total body bone mineral density;	chr2:165878661	chr2:165833048~165839098:-
LUAD	cis	rs7017914	0.967	rs4628281	ENSG00000246366.5	RP11-382J12.1	3.87	0.000124	0.0168	0.16	0.17	Bone mineral density;	chr8:70926929	chr8:70608577~70663279:+
LUAD	cis	rs7968440	1	rs2684898	ENSG00000272368.2	RP4-605O3.4	3.87	0.000124	0.0168	0.21	0.17	Fibrinogen;	chr12:50653042	chr12:50112197~50165618:+
LUAD	cis	rs9467773	0.62	rs2451741	ENSG00000241549.7	GUSBP2	3.87	0.000124	0.0168	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26629176	chr6:26871484~26956554:-
LUAD	cis	rs17596685	1	rs1022927	ENSG00000271216.1	LINC01050	3.87	0.000124	0.0169	0.25	0.17	C-reactive protein levels;	chr13:42584736	chr13:42810366~42812562:-
LUAD	cis	rs34783982	0.881	rs8032849	ENSG00000261441.1	RP11-217B1.2	-3.87	0.000124	0.0169	-0.21	-0.17	Squamous cell lung carcinoma;	chr15:88951935	chr15:89335053~89336161:+
LUAD	cis	rs1198430	1	rs946268	ENSG00000232482.2	RP4-654C18.1	-3.87	0.000124	0.0169	-0.27	-0.17	Total cholesterol levels;	chr1:23421273	chr1:23410832~23412146:+
LUAD	cis	rs6871536	0.951	rs12652920	ENSG00000233006.5	AC034220.3	-3.87	0.000124	0.0169	-0.19	-0.17	Asthma (childhood onset);	chr5:132549548	chr5:132311285~132369916:-
LUAD	cis	rs1383484	1	rs12443111	ENSG00000259728.4	LINC00933	-3.87	0.000124	0.0169	-0.23	-0.17	Height;	chr15:83835727	chr15:84570649~84580175:+
LUAD	cis	rs1383484	1	rs11259921	ENSG00000259728.4	LINC00933	-3.87	0.000124	0.0169	-0.23	-0.17	Height;	chr15:83836734	chr15:84570649~84580175:+
LUAD	cis	rs13113518	0.902	rs12505266	ENSG00000273257.1	RP11-177J6.1	3.87	0.000124	0.0169	0.19	0.17	Height;	chr4:55546002	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs56154935	ENSG00000273257.1	RP11-177J6.1	3.87	0.000124	0.0169	0.19	0.17	Height;	chr4:55546378	chr4:55387949~55388271:+
LUAD	cis	rs1876905	0.62	rs354530	ENSG00000271789.1	RP5-1112D6.7	-3.87	0.000124	0.0169	-0.24	-0.17	Mean corpuscular hemoglobin;	chr6:111183286	chr6:111297126~111298510:+
LUAD	cis	rs5771040	0.56	rs5771044	ENSG00000273253.2	RP3-402G11.26	-3.87	0.000124	0.0169	-0.18	-0.17	IgG glycosylation;	chr22:50469426	chr22:50199090~50200837:-
LUAD	cis	rs365302	1	rs684052	ENSG00000235086.1	FNDC1-IT1	3.87	0.000124	0.0169	0.23	0.17	Coronary heart disease;	chr6:159230215	chr6:159240786~159243329:+
LUAD	cis	rs365302	1	rs485626	ENSG00000235086.1	FNDC1-IT1	3.87	0.000124	0.0169	0.23	0.17	Coronary heart disease;	chr6:159230247	chr6:159240786~159243329:+
LUAD	cis	rs365302	1	rs485557	ENSG00000235086.1	FNDC1-IT1	3.87	0.000124	0.0169	0.23	0.17	Coronary heart disease;	chr6:159230271	chr6:159240786~159243329:+
LUAD	cis	rs7429990	0.965	rs7430913	ENSG00000228638.1	FCF1P2	3.87	0.000124	0.0169	0.2	0.17	Educational attainment (years of education);	chr3:47990867	chr3:48290793~48291375:-
LUAD	cis	rs73242632	0.881	rs73242603	ENSG00000269949.1	RP11-738E22.3	3.87	0.000124	0.0169	0.46	0.17	Congenital heart disease (maternal effect);	chr4:56859896	chr4:56960927~56961373:-
LUAD	cis	rs73242632	0.881	rs28472594	ENSG00000269949.1	RP11-738E22.3	3.87	0.000124	0.0169	0.46	0.17	Congenital heart disease (maternal effect);	chr4:56859977	chr4:56960927~56961373:-
LUAD	cis	rs2274273	0.714	rs7154889	ENSG00000259318.1	RP11-454L9.2	3.87	0.000124	0.0169	0.15	0.17	Protein biomarker;	chr14:55340167	chr14:55394940~55395233:-
LUAD	cis	rs848490	0.851	rs56052251	ENSG00000214293.7	APTR	3.87	0.000124	0.0169	0.23	0.17	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77626547	chr7:77657660~77696265:-
LUAD	cis	rs1056107	0.831	rs7856196	ENSG00000225513.1	RP11-165N19.2	-3.87	0.000124	0.0169	-0.19	-0.17	Colorectal cancer;	chr9:112181635	chr9:112173522~112173971:-
LUAD	cis	rs5758511	0.68	rs5758667	ENSG00000233903.2	Z83851.4	3.87	0.000124	0.0169	0.26	0.17	Birth weight;	chr22:42237198	chr22:42276355~42277052:+
LUAD	cis	rs12999542	0.5	rs13012000	ENSG00000234389.1	AC007278.3	3.87	0.000124	0.0169	0.26	0.17	Serum protein levels (sST2);	chr2:102304806	chr2:102438713~102440475:+
LUAD	cis	rs6754311	0.861	rs12475139	ENSG00000226806.1	AC011893.3	3.87	0.000124	0.0169	0.21	0.17	Mosquito bite size;	chr2:136029081	chr2:135820191~135823087:+
LUAD	cis	rs7674212	0.537	rs2623060	ENSG00000251288.2	RP11-10L12.2	-3.87	0.000124	0.0169	-0.22	-0.17	Type 2 diabetes;	chr4:103126347	chr4:102751401~102752641:+
LUAD	cis	rs6088590	0.965	rs6058108	ENSG00000275784.1	RP5-1125A11.6	-3.87	0.000124	0.0169	-0.19	-0.17	Coronary artery disease;	chr20:34700851	chr20:33989480~33991818:-
LUAD	cis	rs12681366	1	rs10956911	ENSG00000253704.1	RP11-267M23.4	3.87	0.000124	0.0169	0.21	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94371647	chr8:94553722~94569745:+
LUAD	cis	rs12681366	1	rs67808321	ENSG00000253704.1	RP11-267M23.4	3.87	0.000124	0.0169	0.21	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94373317	chr8:94553722~94569745:+
LUAD	cis	rs854765	0.693	rs9907246	ENSG00000264177.1	RP1-37N7.1	3.87	0.000124	0.0169	0.17	0.17	Total body bone mineral density;	chr17:17867651	chr17:18379855~18388984:-
LUAD	cis	rs3748682	0.821	rs12030690	ENSG00000212541.1	RNU6-510P	-3.87	0.000124	0.0169	-0.23	-0.17	Hypothyroidism;	chr1:37792335	chr1:37991462~37991569:+
LUAD	cis	rs6951245	0.678	rs28600085	ENSG00000199023.2	MIR339	-3.87	0.000124	0.0169	-0.29	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1130000	chr7:1022935~1023045:-
LUAD	cis	rs11122895	1	rs11691123	ENSG00000236307.2	EEF1E1P1	3.87	0.000124	0.0169	0.2	0.17	Allergic sensitization;	chr2:111705533	chr2:111887914~111888741:+
LUAD	cis	rs8067545	0.616	rs203465	ENSG00000270091.1	RP11-78O7.2	-3.87	0.000124	0.0169	-0.15	-0.17	Schizophrenia;	chr17:19907407	chr17:19896590~19897287:-
LUAD	cis	rs7178375	0.607	rs34178381	ENSG00000259845.1	HERC2P10	3.87	0.000124	0.0169	0.32	0.17	Hypertriglyceridemia;	chr15:30930382	chr15:30815271~30844153:+
LUAD	cis	rs17301013	0.869	rs3133270	ENSG00000227373.4	RP11-160H22.5	-3.87	0.000124	0.0169	-0.22	-0.17	Systemic lupus erythematosus;	chr1:174819547	chr1:174115300~174160004:-
LUAD	cis	rs5762752	0.524	rs9613609	ENSG00000272858.1	CTA-292E10.8	-3.87	0.000124	0.0169	-0.18	-0.17	Optic disc area;	chr22:28417477	chr22:28814914~28815662:+
LUAD	cis	rs11673344	0.864	rs2562606	ENSG00000267309.1	CTD-2630F21.1	-3.87	0.000124	0.0169	-0.22	-0.17	Obesity-related traits;	chr19:37029628	chr19:36489649~36491040:+
LUAD	cis	rs2380205	0.935	rs2380201	ENSG00000232807.2	RP11-536K7.3	3.87	0.000124	0.0169	0.18	0.17	Breast cancer;	chr10:5852687	chr10:5934270~5945900:-
LUAD	cis	rs6689263	0.929	rs77645371	ENSG00000117242.7	PINK1-AS	3.87	0.000124	0.0169	0.4	0.17	Intelligence (multi-trait analysis);	chr1:20492190	chr1:20642657~20652193:-
LUAD	cis	rs4666002	0.665	rs2305929	ENSG00000223522.1	AC093690.1	3.87	0.000124	0.0169	0.21	0.17	Phospholipid levels (plasma);	chr2:27891044	chr2:28307691~28310459:-
LUAD	cis	rs9549260	0.755	rs9532577	ENSG00000229456.1	RLIMP1	3.87	0.000124	0.0169	0.19	0.17	Red blood cell count;	chr13:40657405	chr13:40618738~40621348:+
LUAD	cis	rs2154319	0.672	rs475390	ENSG00000235358.1	RP11-399E6.1	3.87	0.000124	0.0169	0.24	0.17	Height;	chr1:41104787	chr1:41242373~41284861:+
LUAD	cis	rs858239	0.632	rs1985769	ENSG00000226816.2	AC005082.12	3.87	0.000124	0.0169	0.23	0.17	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23206013~23208045:+
LUAD	cis	rs858239	0.6	rs28499396	ENSG00000226816.2	AC005082.12	3.87	0.000124	0.0169	0.23	0.17	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23206013~23208045:+
LUAD	cis	rs858239	0.6	rs7789237	ENSG00000226816.2	AC005082.12	3.87	0.000124	0.0169	0.23	0.17	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23206013~23208045:+
LUAD	cis	rs10752881	1	rs4233192	ENSG00000224468.3	RP11-181K3.4	3.87	0.000124	0.0169	0.15	0.17	Colorectal cancer;	chr1:183001702	chr1:183138402~183141282:-
LUAD	cis	rs9646944	0.501	rs741284	ENSG00000234389.1	AC007278.3	3.87	0.000124	0.0169	0.2	0.17	Blood protein levels;	chr2:102466864	chr2:102438713~102440475:+
LUAD	cis	rs9646944	0.501	rs10172116	ENSG00000234389.1	AC007278.3	3.87	0.000124	0.0169	0.2	0.17	Blood protein levels;	chr2:102471113	chr2:102438713~102440475:+
LUAD	cis	rs9646944	0.501	rs1403552	ENSG00000234389.1	AC007278.3	3.87	0.000124	0.0169	0.2	0.17	Blood protein levels;	chr2:102472317	chr2:102438713~102440475:+
LUAD	cis	rs10129255	0.957	rs10138532	ENSG00000211967.3	IGHV3-53	-3.87	0.000124	0.0169	-0.14	-0.17	Kawasaki disease;	chr14:106803901	chr14:106592676~106593347:-
LUAD	cis	rs17772222	0.958	rs2297128	ENSG00000258789.1	RP11-507K2.3	-3.87	0.000124	0.0169	-0.24	-0.17	Coronary artery calcification;	chr14:88469910	chr14:88551597~88552493:+
LUAD	cis	rs7107174	1	rs10793304	ENSG00000251323.2	RP11-452H21.4	3.87	0.000124	0.0169	0.22	0.17	Testicular germ cell tumor;	chr11:78353861	chr11:78423982~78429836:-
LUAD	cis	rs9366999	0.809	rs1651106	ENSG00000235033.6	RP11-61I13.3	3.87	0.000124	0.0169	0.19	0.17	Obesity-related traits;	chr6:39251524	chr6:39881804~39900071:-
LUAD	cis	rs12291225	0.679	rs4757245	ENSG00000251991.1	RNU7-49P	3.87	0.000124	0.0169	0.2	0.17	Sense of smell;	chr11:14276326	chr11:14478892~14478953:+
LUAD	cis	rs9303542	0.918	rs7207928	ENSG00000264920.1	RP11-6N17.4	-3.87	0.000125	0.0169	-0.23	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48355250	chr17:47891255~47895812:-
LUAD	cis	rs6496044	0.963	rs11853972	ENSG00000259407.1	RP11-158M2.3	-3.87	0.000125	0.0169	-0.16	-0.17	Interstitial lung disease;	chr15:85519209	chr15:85744109~85750281:-
LUAD	cis	rs3925075	0.524	rs889549	ENSG00000260911.2	RP11-196G11.2	-3.87	0.000125	0.0169	-0.16	-0.17	IgA nephropathy;	chr16:31255630	chr16:31043150~31049868:+
LUAD	cis	rs4907240	0.961	rs10460601	ENSG00000237510.6	AC008268.2	-3.87	0.000125	0.0169	-0.25	-0.17	Event-related brain oscillations;	chr2:96586707	chr2:95789654~95800166:+
LUAD	cis	rs6479901	0.895	rs10733788	ENSG00000232075.1	MRPL35P2	-3.87	0.000125	0.0169	-0.24	-0.17	Intelligence (multi-trait analysis);	chr10:63158105	chr10:63634317~63634827:-
LUAD	cis	rs3096299	0.719	rs2965818	ENSG00000261118.1	RP11-104N10.1	3.87	0.000125	0.0169	0.18	0.17	Multiple myeloma (IgH translocation);	chr16:89444086	chr16:89492017~89504460:-
LUAD	cis	rs1876905	0.62	rs377716	ENSG00000271789.1	RP5-1112D6.7	-3.87	0.000125	0.0169	-0.25	-0.17	Mean corpuscular hemoglobin;	chr6:111181705	chr6:111297126~111298510:+
LUAD	cis	rs7107174	0.792	rs10899488	ENSG00000251323.2	RP11-452H21.4	3.87	0.000125	0.0169	0.22	0.17	Testicular germ cell tumor;	chr11:78377708	chr11:78423982~78429836:-
LUAD	cis	rs7184046	0.797	rs13737	ENSG00000260269.4	CTD-2323K18.1	-3.87	0.000125	0.0169	-0.24	-0.17	Height;	chr15:75639788	chr15:75527150~75601205:-
LUAD	cis	rs11779988	0.571	rs208053	ENSG00000253671.1	RP11-806O11.1	-3.87	0.000125	0.0169	-0.2	-0.17	Breast cancer;	chr8:17967818	chr8:17808941~17820868:+
LUAD	cis	rs7107174	1	rs2450123	ENSG00000251323.2	RP11-452H21.4	3.87	0.000125	0.0169	0.24	0.17	Testicular germ cell tumor;	chr11:78241725	chr11:78423982~78429836:-
LUAD	cis	rs16944613	0.541	rs13313427	ENSG00000259212.1	CTD-3065B20.2	3.87	0.000125	0.0169	0.28	0.17	Colorectal cancer;	chr15:90547536	chr15:90595840~90596447:-
LUAD	cis	rs2120243	0.504	rs114107407	ENSG00000244515.1	KRT18P34	-3.87	0.000125	0.0169	-0.21	-0.17	Hepatocellular carcinoma in hepatitis B infection;	chr3:157344846	chr3:157162663~157163932:-
LUAD	cis	rs11673344	0.832	rs76781063	ENSG00000267309.1	CTD-2630F21.1	-3.87	0.000125	0.0169	-0.22	-0.17	Obesity-related traits;	chr19:37036040	chr19:36489649~36491040:+
LUAD	cis	rs11673344	0.618	rs4420645	ENSG00000267309.1	CTD-2630F21.1	-3.87	0.000125	0.0169	-0.22	-0.17	Obesity-related traits;	chr19:37054086	chr19:36489649~36491040:+
LUAD	cis	rs11673344	0.832	rs2011475	ENSG00000267309.1	CTD-2630F21.1	-3.87	0.000125	0.0169	-0.22	-0.17	Obesity-related traits;	chr19:37054712	chr19:36489649~36491040:+
LUAD	cis	rs7246657	0.551	rs10404069	ENSG00000267309.1	CTD-2630F21.1	3.87	0.000125	0.017	0.29	0.17	Coronary artery calcification;	chr19:37147502	chr19:36489649~36491040:+
LUAD	cis	rs4711890	1	rs4711890	ENSG00000270761.1	RP11-385F7.1	-3.87	0.000125	0.017	-0.2	-0.17	Platelet count;	chr6:47638976	chr6:47477243~47477572:-
LUAD	cis	rs7107174	0.892	rs2510038	ENSG00000251323.2	RP11-452H21.4	3.87	0.000125	0.017	0.23	0.17	Testicular germ cell tumor;	chr11:78254988	chr11:78423982~78429836:-
LUAD	cis	rs1707322	0.638	rs1707302	ENSG00000280836.1	AL355480.1	3.87	0.000125	0.017	0.22	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46135245	chr1:45581219~45581321:-
LUAD	cis	rs10197140	0.857	rs7569806	ENSG00000235721.1	AC013268.3	-3.87	0.000125	0.017	-0.19	-0.17	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110880894	chr2:110007675~110010783:+
LUAD	cis	rs10197140	0.816	rs9308689	ENSG00000235721.1	AC013268.3	-3.87	0.000125	0.017	-0.19	-0.17	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110881198	chr2:110007675~110010783:+
LUAD	cis	rs10197140	0.857	rs9308690	ENSG00000235721.1	AC013268.3	-3.87	0.000125	0.017	-0.19	-0.17	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110881321	chr2:110007675~110010783:+
LUAD	cis	rs9925964	0.933	rs9939417	ENSG00000232748.3	RP11-196G11.6	3.87	0.000125	0.017	0.21	0.17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31042146	chr16:31056460~31062803:+
LUAD	cis	rs10129255	0.833	rs61997797	ENSG00000211974.3	IGHV2-70	3.87	0.000125	0.017	0.18	0.17	Kawasaki disease;	chr14:106815190	chr14:106723574~106724093:-
LUAD	cis	rs253959	0.629	rs10054121	ENSG00000272265.1	CTD-2287O16.4	3.87	0.000125	0.017	0.19	0.17	Bipolar disorder and schizophrenia;	chr5:116084271	chr5:116078110~116078570:-
LUAD	cis	rs6781182	0.535	rs11710773	ENSG00000236452.1	AC123023.1	3.87	0.000125	0.017	0.2	0.17	Visceral adipose tissue adjusted for BMI;	chr3:34187630	chr3:34203244~34268811:+
LUAD	cis	rs6781182	0.535	rs11927965	ENSG00000236452.1	AC123023.1	3.87	0.000125	0.017	0.2	0.17	Visceral adipose tissue adjusted for BMI;	chr3:34188208	chr3:34203244~34268811:+
LUAD	cis	rs10463554	0.927	rs257316	ENSG00000250682.4	LINC00491	-3.87	0.000125	0.017	-0.21	-0.17	Parkinson's disease;	chr5:103086739	chr5:102609156~102671559:-
LUAD	cis	rs7107174	0.892	rs2510033	ENSG00000251323.2	RP11-452H21.4	3.87	0.000125	0.017	0.24	0.17	Testicular germ cell tumor;	chr11:78230725	chr11:78423982~78429836:-
LUAD	cis	rs13113518	0.812	rs12500601	ENSG00000272969.1	RP11-528I4.2	3.87	0.000125	0.017	0.19	0.17	Height;	chr4:55451489	chr4:55547112~55547889:+
LUAD	cis	rs2749592	0.55	rs9733309	ENSG00000263064.2	RP11-291L22.7	-3.87	0.000125	0.017	-0.18	-0.17	Age-related hearing impairment (SNP x SNP interaction);	chr10:37593477	chr10:38448689~38448949:+
LUAD	cis	rs7260598	0.642	rs10403746	ENSG00000269421.1	ZNF92P3	-3.87	0.000125	0.017	-0.27	-0.17	Response to taxane treatment (placlitaxel);	chr19:23924452	chr19:23935220~23936173:+
LUAD	cis	rs7260598	0.685	rs67534545	ENSG00000269421.1	ZNF92P3	-3.87	0.000125	0.017	-0.27	-0.17	Response to taxane treatment (placlitaxel);	chr19:23927339	chr19:23935220~23936173:+
LUAD	cis	rs7772486	0.875	rs2180192	ENSG00000235652.6	RP11-545I5.3	3.87	0.000125	0.017	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:146001148	chr6:145799409~145886585:+
LUAD	cis	rs73242632	0.867	rs73242634	ENSG00000269949.1	RP11-738E22.3	3.87	0.000125	0.017	0.46	0.17	Congenital heart disease (maternal effect);	chr4:57069355	chr4:56960927~56961373:-
LUAD	cis	rs9549260	0.577	rs6563841	ENSG00000229456.1	RLIMP1	3.87	0.000125	0.017	0.19	0.17	Red blood cell count;	chr13:40665041	chr13:40618738~40621348:+
LUAD	cis	rs889398	0.771	rs8048550	ENSG00000226232.7	RP11-419C5.2	-3.87	0.000125	0.017	-0.15	-0.17	Body mass index;	chr16:69857856	chr16:69976388~69996188:-
LUAD	cis	rs6928977	0.896	rs2614287	ENSG00000231028.7	LINC00271	3.87	0.000125	0.017	0.19	0.17	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135371709	chr6:135497801~135716055:+
LUAD	cis	rs13113518	1	rs7662966	ENSG00000273257.1	RP11-177J6.1	3.87	0.000125	0.017	0.19	0.17	Height;	chr4:55548261	chr4:55387949~55388271:+
LUAD	cis	rs9860428	0.844	rs6798395	ENSG00000242770.2	RP11-180K7.1	3.87	0.000125	0.017	0.19	0.17	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112897190	chr3:112802478~112812819:+
LUAD	cis	rs9860428	0.815	rs11717778	ENSG00000242770.2	RP11-180K7.1	3.87	0.000125	0.017	0.19	0.17	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112853801	chr3:112802478~112812819:+
LUAD	cis	rs9467773	1	rs10214634	ENSG00000241549.7	GUSBP2	3.87	0.000125	0.017	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26564354	chr6:26871484~26956554:-
LUAD	cis	rs8031584	0.56	rs7171208	ENSG00000259845.1	HERC2P10	-3.87	0.000125	0.017	-0.19	-0.17	Huntington's disease progression;	chr15:30906726	chr15:30815271~30844153:+
LUAD	cis	rs5753618	1	rs5753618	ENSG00000236132.1	CTA-440B3.1	-3.87	0.000125	0.017	-0.22	-0.17	Colorectal cancer;	chr22:31442532	chr22:31816379~31817491:-
LUAD	cis	rs780096	0.587	rs4665969	ENSG00000234072.1	AC074117.10	3.87	0.000125	0.017	0.13	0.17	Total body bone mineral density;	chr2:27352086	chr2:27356246~27367622:+
LUAD	cis	rs4499344	0.521	rs259222	ENSG00000201388.1	SNORA68	3.87	0.000125	0.017	0.2	0.17	Mean platelet volume;	chr19:32645989	chr19:32608337~32608469:-
LUAD	cis	rs6964587	0.9	rs11984136	ENSG00000188693.7	CYP51A1-AS1	-3.87	0.000125	0.017	-0.2	-0.17	Breast cancer;	chr7:92137639	chr7:92134604~92180725:+
LUAD	cis	rs2136690	0.51	rs4273327	ENSG00000243926.1	TIPARP-AS1	3.87	0.000125	0.017	0.18	0.17	Breast cancer;	chr3:156654883	chr3:156671862~156674378:-
LUAD	cis	rs17122278	1	rs2277291	ENSG00000243431.1	RPL5P30	3.87	0.000125	0.017	0.22	0.17	Total cholesterol levels;	chr11:118565041	chr11:118560690~118561580:+
LUAD	cis	rs2274273	0.804	rs28428911	ENSG00000259318.1	RP11-454L9.2	3.87	0.000125	0.017	0.15	0.17	Protein biomarker;	chr14:55376878	chr14:55394940~55395233:-
LUAD	cis	rs7116495	0.867	rs562621	ENSG00000254682.1	RP11-660L16.2	-3.87	0.000125	0.017	-0.37	-0.17	Severe influenza A (H1N1) infection;	chr11:71868167	chr11:71448674~71452157:+
LUAD	cis	rs9341808	0.519	rs59232999	ENSG00000260645.1	RP11-250B2.5	-3.87	0.000125	0.017	-0.17	-0.17	Sitting height ratio;	chr6:80309066	chr6:80466958~80469080:+
LUAD	cis	rs11874381	0.931	rs56207265	ENSG00000266696.1	RP11-30L3.2	-3.87	0.000125	0.017	-0.19	-0.17	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);	chr18:49680836	chr18:49205912~49208781:+
LUAD	cis	rs9876781	1	rs7653691	ENSG00000229759.1	MRPS18AP1	-3.87	0.000125	0.017	-0.17	-0.17	Longevity;	chr3:48378199	chr3:48256350~48256938:-
LUAD	cis	rs7630852	1	rs7626440	ENSG00000272359.1	U4	-3.87	0.000125	0.017	-0.18	-0.17	Eosinophil counts;	chr3:196778019	chr3:196747192~196747324:-
LUAD	cis	rs494562	0.892	rs490079	ENSG00000234155.1	RP11-30P6.6	-3.87	0.000125	0.017	-0.34	-0.17	Metabolic traits;Blood metabolite levels;	chr6:85407881	chr6:85387219~85390186:-
LUAD	cis	rs494562	0.892	rs575477	ENSG00000234155.1	RP11-30P6.6	-3.87	0.000125	0.017	-0.34	-0.17	Metabolic traits;Blood metabolite levels;	chr6:85408346	chr6:85387219~85390186:-
LUAD	cis	rs494562	0.892	rs573892	ENSG00000234155.1	RP11-30P6.6	-3.87	0.000125	0.017	-0.34	-0.17	Metabolic traits;Blood metabolite levels;	chr6:85408471	chr6:85387219~85390186:-
LUAD	cis	rs494562	0.892	rs573737	ENSG00000234155.1	RP11-30P6.6	-3.87	0.000125	0.017	-0.34	-0.17	Metabolic traits;Blood metabolite levels;	chr6:85408515	chr6:85387219~85390186:-
LUAD	cis	rs494562	1	rs7763191	ENSG00000234155.1	RP11-30P6.6	-3.87	0.000125	0.017	-0.34	-0.17	Metabolic traits;Blood metabolite levels;	chr6:85408599	chr6:85387219~85390186:-
LUAD	cis	rs494562	0.892	rs547963	ENSG00000234155.1	RP11-30P6.6	-3.87	0.000125	0.017	-0.34	-0.17	Metabolic traits;Blood metabolite levels;	chr6:85409025	chr6:85387219~85390186:-
LUAD	cis	rs494562	0.892	rs547052	ENSG00000234155.1	RP11-30P6.6	-3.87	0.000125	0.017	-0.34	-0.17	Metabolic traits;Blood metabolite levels;	chr6:85409122	chr6:85387219~85390186:-
LUAD	cis	rs494562	0.892	rs544408	ENSG00000234155.1	RP11-30P6.6	-3.87	0.000125	0.017	-0.34	-0.17	Metabolic traits;Blood metabolite levels;	chr6:85409392	chr6:85387219~85390186:-
LUAD	cis	rs494562	0.892	rs544403	ENSG00000234155.1	RP11-30P6.6	-3.87	0.000125	0.017	-0.34	-0.17	Metabolic traits;Blood metabolite levels;	chr6:85409398	chr6:85387219~85390186:-
LUAD	cis	rs494562	0.892	rs515980	ENSG00000234155.1	RP11-30P6.6	-3.87	0.000125	0.017	-0.34	-0.17	Metabolic traits;Blood metabolite levels;	chr6:85410199	chr6:85387219~85390186:-
LUAD	cis	rs494562	0.892	rs618448	ENSG00000234155.1	RP11-30P6.6	-3.87	0.000125	0.017	-0.34	-0.17	Metabolic traits;Blood metabolite levels;	chr6:85411606	chr6:85387219~85390186:-
LUAD	cis	rs494562	0.892	rs619299	ENSG00000234155.1	RP11-30P6.6	-3.87	0.000125	0.017	-0.34	-0.17	Metabolic traits;Blood metabolite levels;	chr6:85411764	chr6:85387219~85390186:-
LUAD	cis	rs10080237	0.564	rs2490232	ENSG00000272129.1	RP11-250B2.6	-3.87	0.000125	0.017	-0.21	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;	chr6:80105085	chr6:80355424~80356859:+
LUAD	cis	rs10197140	0.737	rs10186627	ENSG00000235721.1	AC013268.3	-3.87	0.000125	0.017	-0.19	-0.17	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110885488	chr2:110007675~110010783:+
LUAD	cis	rs10197140	0.857	rs10189620	ENSG00000235721.1	AC013268.3	-3.87	0.000125	0.017	-0.19	-0.17	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110885502	chr2:110007675~110010783:+
LUAD	cis	rs10197140	0.857	rs10181923	ENSG00000235721.1	AC013268.3	-3.87	0.000125	0.017	-0.19	-0.17	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110885512	chr2:110007675~110010783:+
LUAD	cis	rs159572	0.747	rs611390	ENSG00000250853.1	RNF138P1	3.87	0.000125	0.017	0.21	0.17	Post-traumatic stress disorder;	chr5:56254857	chr5:55530156~55530701:-
LUAD	cis	rs159572	0.747	rs407311	ENSG00000250853.1	RNF138P1	3.87	0.000125	0.017	0.21	0.17	Post-traumatic stress disorder;	chr5:56255066	chr5:55530156~55530701:-
LUAD	cis	rs7646881	0.583	rs2115942	ENSG00000240207.5	RP11-379F4.4	-3.87	0.000125	0.017	-0.23	-0.17	Tetralogy of Fallot;	chr3:158588841	chr3:158732263~158784070:+
LUAD	cis	rs7646881	0.544	rs73022798	ENSG00000240207.5	RP11-379F4.4	-3.87	0.000125	0.017	-0.23	-0.17	Tetralogy of Fallot;	chr3:158590099	chr3:158732263~158784070:+
LUAD	cis	rs11216126	1	rs4938307	ENSG00000254851.1	RP11-109L13.1	3.87	0.000125	0.017	0.34	0.17	HDL cholesterol;	chr11:116733798	chr11:117135528~117138582:+
LUAD	cis	rs875971	0.577	rs34888281	ENSG00000164669.11	INTS4P1	3.87	0.000125	0.017	0.21	0.17	Aortic root size;	chr7:66120784	chr7:65141225~65234216:+
LUAD	cis	rs1876905	0.569	rs354542	ENSG00000255389.1	C6orf3	3.87	0.000125	0.017	0.23	0.17	Mean corpuscular hemoglobin;	chr6:111193483	chr6:111599875~111602295:+
LUAD	cis	rs1876905	0.68	rs1216020	ENSG00000255389.1	C6orf3	3.87	0.000125	0.017	0.23	0.17	Mean corpuscular hemoglobin;	chr6:111194004	chr6:111599875~111602295:+
LUAD	cis	rs1876905	0.569	rs354541	ENSG00000255389.1	C6orf3	3.87	0.000125	0.017	0.23	0.17	Mean corpuscular hemoglobin;	chr6:111195262	chr6:111599875~111602295:+
LUAD	cis	rs1876905	0.68	rs354537	ENSG00000255389.1	C6orf3	3.87	0.000125	0.017	0.23	0.17	Mean corpuscular hemoglobin;	chr6:111197097	chr6:111599875~111602295:+
LUAD	cis	rs1876905	0.68	rs354536	ENSG00000255389.1	C6orf3	3.87	0.000125	0.017	0.23	0.17	Mean corpuscular hemoglobin;	chr6:111197808	chr6:111599875~111602295:+
LUAD	cis	rs1876905	0.68	rs557028	ENSG00000255389.1	C6orf3	3.87	0.000125	0.017	0.23	0.17	Mean corpuscular hemoglobin;	chr6:111201606	chr6:111599875~111602295:+
LUAD	cis	rs2243480	1	rs160633	ENSG00000229886.1	RP5-1132H15.3	3.87	0.000125	0.017	0.3	0.17	Diabetic kidney disease;	chr7:66063241	chr7:66025126~66031544:-
LUAD	cis	rs2731006	0.64	rs2468325	ENSG00000257114.2	RP11-25I15.3	3.87	0.000125	0.017	0.27	0.17	Panic disorder;	chr12:42785706	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.64	rs2678145	ENSG00000257114.2	RP11-25I15.3	3.87	0.000125	0.017	0.27	0.17	Panic disorder;	chr12:42786534	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.64	rs2730998	ENSG00000257114.2	RP11-25I15.3	3.87	0.000125	0.017	0.27	0.17	Panic disorder;	chr12:42786603	chr12:42692216~42717119:+
LUAD	cis	rs2554380	0.843	rs2098904	ENSG00000259570.1	RP11-671M22.4	3.87	0.000125	0.017	0.25	0.17	Height;	chr15:83737503	chr15:84394512~84395514:+
LUAD	cis	rs2554380	0.783	rs2554385	ENSG00000259570.1	RP11-671M22.4	3.87	0.000125	0.017	0.25	0.17	Height;	chr15:83737835	chr15:84394512~84395514:+
LUAD	cis	rs9309473	0.607	rs10196402	ENSG00000230002.2	ALMS1-IT1	3.87	0.000125	0.017	0.2	0.17	Metabolite levels;	chr2:73344953	chr2:73456764~73459484:+
LUAD	cis	rs2645424	0.93	rs1293315	ENSG00000255046.1	RP11-297N6.4	-3.87	0.000125	0.017	-0.22	-0.17	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11832913	chr8:11797928~11802568:-
LUAD	cis	rs806321	0.501	rs2066626	ENSG00000237152.3	DLEU7-AS1	-3.87	0.000125	0.017	-0.22	-0.17	Multiple sclerosis;	chr13:50180079	chr13:50807856~50849905:+
LUAD	cis	rs2348418	0.868	rs12302861	ENSG00000247934.4	RP11-967K21.1	3.87	0.000125	0.017	0.2	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28516269	chr12:28163298~28190738:-
LUAD	cis	rs453301	0.686	rs10217044	ENSG00000233609.3	RP11-62H7.2	-3.87	0.000125	0.017	-0.15	-0.17	Joint mobility (Beighton score);	chr8:9037242	chr8:8961200~8979025:+
LUAD	cis	rs1113500	0.633	rs1777451	ENSG00000226822.1	RP11-356N1.2	-3.87	0.000125	0.017	-0.2	-0.17	Growth-regulated protein alpha levels;	chr1:108035560	chr1:108071482~108074519:+
LUAD	cis	rs2243480	1	rs6964245	ENSG00000229886.1	RP5-1132H15.3	-3.87	0.000126	0.017	-0.3	-0.17	Diabetic kidney disease;	chr7:66253730	chr7:66025126~66031544:-
LUAD	cis	rs8054556	0.513	rs12596042	ENSG00000183604.13	SMG1P5	-3.87	0.000126	0.017	-0.17	-0.17	Autism spectrum disorder or schizophrenia;	chr16:29923433	chr16:30267553~30335374:-
LUAD	cis	rs8054556	0.74	rs9936474	ENSG00000183604.13	SMG1P5	-3.87	0.000126	0.017	-0.17	-0.17	Autism spectrum disorder or schizophrenia;	chr16:29921370	chr16:30267553~30335374:-
LUAD	cis	rs42490	0.576	rs377897	ENSG00000251136.7	RP11-37B2.1	-3.87	0.000126	0.017	-0.19	-0.17	Leprosy;	chr8:89852734	chr8:89609409~89757727:-
LUAD	cis	rs2390582	0.891	rs12726749	ENSG00000233593.5	RP4-665J23.1	-3.87	0.000126	0.0171	-0.25	-0.17	Coronary artery calcification;	chr1:90487547	chr1:90782986~90851650:-
LUAD	cis	rs6964587	0.872	rs57969083	ENSG00000188693.7	CYP51A1-AS1	-3.87	0.000126	0.0171	-0.2	-0.17	Breast cancer;	chr7:92036313	chr7:92134604~92180725:+
LUAD	cis	rs9910055	0.529	rs228764	ENSG00000267080.4	ASB16-AS1	3.87	0.000126	0.0171	0.16	0.17	Total body bone mineral density;	chr17:44108101	chr17:44175973~44186717:-
LUAD	cis	rs9910055	0.529	rs228765	ENSG00000267080.4	ASB16-AS1	3.87	0.000126	0.0171	0.16	0.17	Total body bone mineral density;	chr17:44109054	chr17:44175973~44186717:-
LUAD	cis	rs4849121	0.535	rs4849120	ENSG00000235721.1	AC013268.3	-3.87	0.000126	0.0171	-0.2	-0.17	IgA nephropathy;	chr2:110842024	chr2:110007675~110010783:+
LUAD	cis	rs8028182	0.636	rs12909863	ENSG00000260269.4	CTD-2323K18.1	-3.87	0.000126	0.0171	-0.24	-0.17	Sudden cardiac arrest;	chr15:75533481	chr15:75527150~75601205:-
LUAD	cis	rs6095360	0.69	rs1115535	ENSG00000222365.1	SNORD12B	-3.87	0.000126	0.0171	-0.2	-0.17	Intelligence (multi-trait analysis);	chr20:48974027	chr20:49280319~49280409:+
LUAD	cis	rs8056893	0.885	rs4381598	ENSG00000260441.4	RP11-96D1.7	-3.87	0.000126	0.0171	-0.2	-0.17	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68319761	chr16:68256162~68260443:-
LUAD	cis	rs2904524	1	rs76044745	ENSG00000257815.4	RP11-611E13.2	-3.87	0.000126	0.0171	-0.26	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70345310	chr12:69904033~70243360:-
LUAD	cis	rs10971721	0.822	rs72725381	ENSG00000260947.1	RP11-384P7.7	3.87	0.000126	0.0171	0.37	0.17	Body mass index;	chr9:33851167	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.642	rs10971736	ENSG00000260947.1	RP11-384P7.7	3.87	0.000126	0.0171	0.37	0.17	Body mass index;	chr9:33854376	chr9:33697459~33700986:+
LUAD	cis	rs9341808	0.69	rs2505932	ENSG00000260645.1	RP11-250B2.5	3.87	0.000126	0.0171	0.16	0.17	Sitting height ratio;	chr6:80129535	chr6:80466958~80469080:+
LUAD	cis	rs11673344	0.504	rs7258360	ENSG00000276846.1	CTD-3220F14.3	3.87	0.000126	0.0171	0.19	0.17	Obesity-related traits;	chr19:37115015	chr19:37314868~37315620:-
LUAD	cis	rs11971779	0.793	rs11543827	ENSG00000273391.1	RP11-634H22.1	3.87	0.000126	0.0171	0.19	0.17	Diisocyanate-induced asthma;	chr7:139347947	chr7:139359032~139359566:-
LUAD	cis	rs12291225	0.585	rs11023197	ENSG00000251991.1	RNU7-49P	3.87	0.000126	0.0171	0.19	0.17	Sense of smell;	chr11:14359452	chr11:14478892~14478953:+
LUAD	cis	rs6499129	1	rs9922624	ENSG00000280214.1	CTD-2012K14.5	-3.87	0.000126	0.0171	-0.2	-0.17	Waist-to-hip ratio adjusted for body mass index;	chr16:67445073	chr16:67550815~67552935:-
LUAD	cis	rs38055	1	rs38056	ENSG00000247796.2	CTD-2366F13.1	3.87	0.000126	0.0171	0.19	0.17	Acne (severe);	chr5:53264155	chr5:53109842~53115126:+
LUAD	cis	rs9291683	0.588	rs17247314	ENSG00000250413.1	RP11-448G15.1	-3.87	0.000126	0.0171	-0.22	-0.17	Bone mineral density;	chr4:10003119	chr4:10006482~10009725:+
LUAD	cis	rs2554380	0.891	rs2562781	ENSG00000230373.7	GOLGA6L5P	-3.87	0.000126	0.0171	-0.21	-0.17	Height;	chr15:83643816	chr15:84507885~84516814:-
LUAD	cis	rs3002131	0.688	rs2936040	ENSG00000272750.1	RP11-378J18.8	3.87	0.000126	0.0171	0.23	0.17	Interleukin-10 levels;	chr1:222590319	chr1:222658867~222661512:-
LUAD	cis	rs6142102	0.651	rs6088412	ENSG00000275784.1	RP5-1125A11.6	3.87	0.000126	0.0171	0.22	0.17	Skin pigmentation;	chr20:34154262	chr20:33989480~33991818:-
LUAD	cis	rs10129255	0.5	rs2105991	ENSG00000274576.2	IGHV2-70	-3.87	0.000126	0.0171	-0.14	-0.17	Kawasaki disease;	chr14:106682022	chr14:106770577~106771020:-
LUAD	cis	rs7714584	1	rs75774363	ENSG00000197083.10	ZNF300P1	3.87	0.000126	0.0171	0.34	0.17	Crohn's disease;	chr5:150844160	chr5:150930645~150946289:-
LUAD	cis	rs8067545	0.641	rs2108978	ENSG00000270091.1	RP11-78O7.2	-3.87	0.000126	0.0171	-0.15	-0.17	Schizophrenia;	chr17:19958145	chr17:19896590~19897287:-
LUAD	cis	rs2548724	0.947	rs438617	ENSG00000250682.4	LINC00491	-3.87	0.000126	0.0171	-0.24	-0.17	Type 2 diabetes;	chr5:102249030	chr5:102609156~102671559:-
LUAD	cis	rs2548724	0.947	rs420900	ENSG00000250682.4	LINC00491	-3.87	0.000126	0.0171	-0.24	-0.17	Type 2 diabetes;	chr5:102250985	chr5:102609156~102671559:-
LUAD	cis	rs877819	0.583	rs2620890	ENSG00000228403.1	RP11-563N6.6	-3.87	0.000126	0.0171	-0.18	-0.17	Systemic lupus erythematosus;	chr10:48851723	chr10:48878022~48878649:+
LUAD	cis	rs7302981	0.667	rs7308692	ENSG00000200428.1	Y_RNA	3.87	0.000126	0.0171	0.2	0.17	Systolic blood pressure;	chr12:50233871	chr12:50743568~50743684:+
LUAD	cis	rs8012947	1	rs8012947	ENSG00000279636.2	LINC00216	-3.87	0.000126	0.0171	-0.19	-0.17	Alcohol consumption in current drinkers;	chr14:58317737	chr14:58288033~58289158:+
LUAD	cis	rs6951245	1	rs118059236	ENSG00000199023.2	MIR339	-3.87	0.000126	0.0171	-0.31	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1033566	chr7:1022935~1023045:-
LUAD	cis	rs6951245	1	rs113858334	ENSG00000199023.2	MIR339	-3.87	0.000126	0.0171	-0.31	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1033840	chr7:1022935~1023045:-
LUAD	cis	rs10129255	0.5	rs6576231	ENSG00000253209.1	IGHV3-65	3.87	0.000126	0.0171	0.14	0.17	Kawasaki disease;	chr14:106783693	chr14:106666092~106666532:-
LUAD	cis	rs7247513	1	rs12459123	ENSG00000230310.1	CTD-2192J16.11	-3.87	0.000126	0.0171	-0.2	-0.17	Bipolar disorder;	chr19:12578927	chr19:12552597~12553644:+
LUAD	cis	rs990171	0.538	rs12712153	ENSG00000234389.1	AC007278.3	3.87	0.000126	0.0171	0.17	0.17	Lymphocyte counts;	chr2:102495302	chr2:102438713~102440475:+
LUAD	cis	rs56309584	0.521	rs11651599	ENSG00000226871.1	AC135178.7	3.87	0.000126	0.0171	0.25	0.17	Initial pursuit acceleration;	chr17:8276194	chr17:8318088~8318712:-
LUAD	cis	rs12908161	0.959	rs61074241	ENSG00000259654.1	RP11-245C17.2	-3.87	0.000126	0.0171	-0.26	-0.17	Schizophrenia;	chr15:84790165	chr15:84685884~84686946:+
LUAD	cis	rs73108077	1	rs73108027	ENSG00000281376.1	ABALON	-3.87	0.000126	0.0171	-0.3	-0.17	Red blood cell density in sickle cell anemia;	chr20:31398778	chr20:31721507~31723409:+
LUAD	cis	rs7637701	0.773	rs9859058	ENSG00000240875.4	LINC00886	-3.87	0.000126	0.0171	-0.19	-0.17	Breast cancer;	chr3:156795028	chr3:156747346~156817062:-
LUAD	cis	rs2346177	0.875	rs1447565	ENSG00000279254.1	RP11-536C12.1	-3.87	0.000126	0.0171	-0.18	-0.17	HDL cholesterol;	chr2:46416543	chr2:46668870~46670778:+
LUAD	cis	rs4811196	0.748	rs4811233	ENSG00000226144.2	RPS27AP3	3.87	0.000126	0.0171	0.19	0.17	Bone mineral density;	chr20:37857818	chr20:37049254~37049707:+
LUAD	cis	rs12216545	0.765	rs1879865	ENSG00000177590.7	GIMAP3P	-3.87	0.000126	0.0171	-0.18	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150561335	chr7:150746893~150747728:-
LUAD	cis	rs7968440	0.931	rs2251024	ENSG00000272368.2	RP4-605O3.4	3.87	0.000126	0.0171	0.2	0.17	Fibrinogen;	chr12:50709850	chr12:50112197~50165618:+
LUAD	cis	rs11673344	0.523	rs2562609	ENSG00000276846.1	CTD-3220F14.3	3.87	0.000126	0.0171	0.19	0.17	Obesity-related traits;	chr19:37036255	chr19:37314868~37315620:-
LUAD	cis	rs6724465	0.789	rs7572866	ENSG00000272644.1	RP11-33O4.1	3.87	0.000126	0.0171	0.26	0.17	Height;	chr2:219033004	chr2:219069354~219069809:-
LUAD	cis	rs7870753	0.578	rs10990975	ENSG00000188801.9	ZNF322P1	3.87	0.000126	0.0171	0.27	0.17	Height;	chr9:96407137	chr9:97198303~97199511:-
LUAD	cis	rs755249	1	rs4660293	ENSG00000237624.1	OXCT2P1	-3.87	0.000126	0.0171	-0.25	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39562508	chr1:39514956~39516490:+
LUAD	cis	rs35520189	0.592	rs12471839	ENSG00000227368.1	AC079753.5	3.87	0.000126	0.0171	0.21	0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112954912	chr2:112932625~112933171:+
LUAD	cis	rs4664293	0.764	rs1425044	ENSG00000224152.1	AC009506.1	-3.87	0.000126	0.0171	-0.17	-0.17	Monocyte percentage of white cells;	chr2:159618426	chr2:159615296~159617082:+
LUAD	cis	rs11742741	0.806	rs1032760	ENSG00000248874.4	C5orf17	3.87	0.000126	0.0171	0.22	0.17	Educational attainment;	chr5:24016911	chr5:23951348~24178263:+
LUAD	cis	rs10129255	0.5	rs7161740	ENSG00000253209.1	IGHV3-65	3.87	0.000126	0.0171	0.14	0.17	Kawasaki disease;	chr14:106776119	chr14:106666092~106666532:-
LUAD	cis	rs10129255	0.556	rs6576222	ENSG00000253209.1	IGHV3-65	3.87	0.000126	0.0171	0.14	0.17	Kawasaki disease;	chr14:106776442	chr14:106666092~106666532:-
LUAD	cis	rs10129255	0.536	rs6576223	ENSG00000253209.1	IGHV3-65	3.87	0.000126	0.0171	0.14	0.17	Kawasaki disease;	chr14:106776448	chr14:106666092~106666532:-
LUAD	cis	rs4934494	0.681	rs1129777	ENSG00000240996.1	RP11-80H5.7	-3.87	0.000126	0.0171	-0.24	-0.17	Red blood cell count;	chr10:89709168	chr10:89694295~89697928:-
LUAD	cis	rs4934494	0.727	rs3824607	ENSG00000240996.1	RP11-80H5.7	-3.87	0.000126	0.0171	-0.24	-0.17	Red blood cell count;	chr10:89711258	chr10:89694295~89697928:-
LUAD	cis	rs4934494	0.681	rs3740035	ENSG00000240996.1	RP11-80H5.7	-3.87	0.000126	0.0171	-0.24	-0.17	Red blood cell count;	chr10:89716708	chr10:89694295~89697928:-
LUAD	cis	rs4934494	0.681	rs34591435	ENSG00000240996.1	RP11-80H5.7	-3.87	0.000126	0.0171	-0.24	-0.17	Red blood cell count;	chr10:89721691	chr10:89694295~89697928:-
LUAD	cis	rs4934494	0.727	rs12783845	ENSG00000240996.1	RP11-80H5.7	-3.87	0.000126	0.0171	-0.24	-0.17	Red blood cell count;	chr10:89722872	chr10:89694295~89697928:-
LUAD	cis	rs1355223	1	rs1355222	ENSG00000271369.1	RP11-350D17.3	-3.87	0.000126	0.0171	-0.21	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34737169	chr11:34709600~34710161:+
LUAD	cis	rs6142102	0.924	rs6059662	ENSG00000275784.1	RP5-1125A11.6	3.87	0.000126	0.0171	0.19	0.17	Skin pigmentation;	chr20:34087921	chr20:33989480~33991818:-
LUAD	cis	rs6479891	1	rs9414793	ENSG00000232075.1	MRPL35P2	-3.87	0.000126	0.0171	-0.28	-0.17	Arthritis (juvenile idiopathic);	chr10:63315349	chr10:63634317~63634827:-
LUAD	cis	rs7809950	0.953	rs2520263	ENSG00000238832.1	snoU109	-3.87	0.000126	0.0171	-0.26	-0.17	Coronary artery disease;	chr7:107538674	chr7:107603363~107603507:+
LUAD	cis	rs7714584	1	rs10078968	ENSG00000197083.10	ZNF300P1	3.87	0.000126	0.0171	0.32	0.17	Crohn's disease;	chr5:150864711	chr5:150930645~150946289:-
LUAD	cis	rs7714584	1	rs1896709	ENSG00000197083.10	ZNF300P1	3.87	0.000126	0.0171	0.32	0.17	Crohn's disease;	chr5:150865470	chr5:150930645~150946289:-
LUAD	cis	rs7714584	1	rs1896707	ENSG00000197083.10	ZNF300P1	3.87	0.000126	0.0171	0.32	0.17	Crohn's disease;	chr5:150865567	chr5:150930645~150946289:-
LUAD	cis	rs7714584	1	rs7709388	ENSG00000197083.10	ZNF300P1	3.87	0.000126	0.0171	0.32	0.17	Crohn's disease;	chr5:150866977	chr5:150930645~150946289:-
LUAD	cis	rs7714584	0.793	rs7709721	ENSG00000197083.10	ZNF300P1	3.87	0.000126	0.0171	0.32	0.17	Crohn's disease;	chr5:150867296	chr5:150930645~150946289:-
LUAD	cis	rs9584850	0.574	rs60492361	ENSG00000231194.1	FARP1-AS1	3.87	0.000126	0.0171	0.24	0.17	Neuroticism;	chr13:98520399	chr13:98435405~98435840:-
LUAD	cis	rs2274273	0.688	rs6573001	ENSG00000259318.1	RP11-454L9.2	3.87	0.000126	0.0171	0.16	0.17	Protein biomarker;	chr14:55089784	chr14:55394940~55395233:-
LUAD	cis	rs8028182	0.636	rs7163451	ENSG00000260269.4	CTD-2323K18.1	-3.87	0.000126	0.0171	-0.24	-0.17	Sudden cardiac arrest;	chr15:75568735	chr15:75527150~75601205:-
LUAD	cis	rs8028182	0.636	rs8036884	ENSG00000260269.4	CTD-2323K18.1	-3.87	0.000126	0.0171	-0.24	-0.17	Sudden cardiac arrest;	chr15:75570552	chr15:75527150~75601205:-
LUAD	cis	rs8028182	0.636	rs4075522	ENSG00000260269.4	CTD-2323K18.1	-3.87	0.000126	0.0171	-0.24	-0.17	Sudden cardiac arrest;	chr15:75571994	chr15:75527150~75601205:-
LUAD	cis	rs11742741	0.87	rs12186522	ENSG00000248874.4	C5orf17	-3.87	0.000126	0.0171	-0.22	-0.17	Educational attainment;	chr5:24082800	chr5:23951348~24178263:+
LUAD	cis	rs6479891	1	rs9415697	ENSG00000232075.1	MRPL35P2	3.87	0.000126	0.0171	0.28	0.17	Arthritis (juvenile idiopathic);	chr10:63375377	chr10:63634317~63634827:-
LUAD	cis	rs6479891	1	rs724553	ENSG00000232075.1	MRPL35P2	3.87	0.000126	0.0171	0.28	0.17	Arthritis (juvenile idiopathic);	chr10:63380624	chr10:63634317~63634827:-
LUAD	cis	rs9309473	1	rs1534471	ENSG00000230002.2	ALMS1-IT1	3.87	0.000126	0.0171	0.22	0.17	Metabolite levels;	chr2:73420380	chr2:73456764~73459484:+
LUAD	cis	rs4268898	0.722	rs2288072	ENSG00000223754.1	AC008073.9	-3.87	0.000126	0.0171	-0.21	-0.17	Asthma;	chr2:24167648	chr2:24199839~24201698:-
LUAD	cis	rs987044	0.807	rs2008955	ENSG00000257221.1	RP11-689B22.2	-3.87	0.000126	0.0171	-0.14	-0.17	Mean platelet volume;	chr12:108767569	chr12:108628687~108641318:+
LUAD	cis	rs16944613	0.541	rs10852135	ENSG00000259212.1	CTD-3065B20.2	3.87	0.000126	0.0171	0.28	0.17	Colorectal cancer;	chr15:90563180	chr15:90595840~90596447:-
LUAD	cis	rs9309473	0.95	rs6546860	ENSG00000230002.2	ALMS1-IT1	3.87	0.000126	0.0171	0.21	0.17	Metabolite levels;	chr2:73617122	chr2:73456764~73459484:+
LUAD	cis	rs4374383	0.884	rs908518	ENSG00000207383.1	Y_RNA	3.87	0.000126	0.0171	0.21	0.17	Hepatitis C induced liver fibrosis;	chr2:111920049	chr2:112579484~112579584:-
LUAD	cis	rs3002142	0.554	rs17163384	ENSG00000272750.1	RP11-378J18.8	3.87	0.000126	0.0171	0.27	0.17	LDL peak particle diameter (total fat intake interaction);	chr1:222661880	chr1:222658867~222661512:-
LUAD	cis	rs3749855	0.679	rs13213233	ENSG00000220920.1	RP3-525L6.2	3.87	0.000126	0.0171	0.35	0.17	Glucose homeostasis traits;	chr6:17250131	chr6:17953572~17953930:+
LUAD	cis	rs3749855	0.596	rs13205462	ENSG00000220920.1	RP3-525L6.2	3.87	0.000126	0.0171	0.35	0.17	Glucose homeostasis traits;	chr6:17250718	chr6:17953572~17953930:+
LUAD	cis	rs17660992	0.603	rs59485321	ENSG00000273837.1	LLNLR-470E3.1	-3.87	0.000126	0.0171	-0.2	-0.17	Blood protein levels;	chr19:51660710	chr19:51639478~51639931:-
LUAD	cis	rs9532580	0.614	rs2180961	ENSG00000229456.1	RLIMP1	3.87	0.000126	0.0171	0.26	0.17	Mean corpuscular hemoglobin;	chr13:40565907	chr13:40618738~40621348:+
LUAD	cis	rs683250	0.6	rs566703	ENSG00000246067.6	RAB30-AS1	3.87	0.000126	0.0171	0.18	0.17	Subcortical brain region volumes;	chr11:83282141	chr11:83072066~83106719:+
LUAD	cis	rs17596685	0.818	rs7984965	ENSG00000271216.1	LINC01050	3.86	0.000126	0.0171	0.26	0.17	C-reactive protein levels;	chr13:42558231	chr13:42810366~42812562:-
LUAD	cis	rs17596685	1	rs9525639	ENSG00000271216.1	LINC01050	3.86	0.000126	0.0171	0.26	0.17	C-reactive protein levels;	chr13:42558743	chr13:42810366~42812562:-
LUAD	cis	rs2239547	0.521	rs9682464	ENSG00000243224.1	RP5-1157M23.2	-3.86	0.000126	0.0171	-0.19	-0.17	Schizophrenia;	chr3:52854469	chr3:52239258~52241097:+
LUAD	cis	rs17767294	0.612	rs9461425	ENSG00000280107.1	AL022393.9	-3.86	0.000126	0.0171	-0.31	-0.17	Parkinson's disease;	chr6:27951910	chr6:28170845~28172521:+
LUAD	cis	rs12579720	0.83	rs4762921	ENSG00000255910.1	RP11-405A12.2	3.86	0.000126	0.0171	0.22	0.17	Diastolic blood pressure;	chr12:20031605	chr12:19775451~20009937:+
LUAD	cis	rs10463554	1	rs12656131	ENSG00000250682.4	LINC00491	-3.86	0.000126	0.0171	-0.21	-0.17	Parkinson's disease;	chr5:102990174	chr5:102609156~102671559:-
LUAD	cis	rs7580658	0.963	rs6732279	ENSG00000236682.1	AC068282.3	-3.86	0.000126	0.0171	-0.24	-0.17	Protein C levels;	chr2:127331964	chr2:127389130~127400580:+
LUAD	cis	rs9584850	0.507	rs59704350	ENSG00000231194.1	FARP1-AS1	3.86	0.000126	0.0171	0.23	0.17	Neuroticism;	chr13:98508176	chr13:98435405~98435840:-
LUAD	cis	rs891378	0.883	rs6671700	ENSG00000274245.1	RP11-357P18.2	-3.86	0.000126	0.0171	-0.22	-0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207316614	chr1:207372559~207373252:+
LUAD	cis	rs875971	0.545	rs66594357	ENSG00000222364.1	RNU6-96P	-3.86	0.000126	0.0171	-0.22	-0.17	Aortic root size;	chr7:66327797	chr7:66395191~66395286:+
LUAD	cis	rs2018683	0.7	rs13227954	ENSG00000228421.2	AC005013.5	-3.86	0.000126	0.0171	-0.19	-0.17	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28977572	chr7:28957667~28959345:+
LUAD	cis	rs16866061	1	rs16866061	ENSG00000228446.2	AC073052.1	-3.86	0.000126	0.0171	-0.19	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr2:224575127	chr2:224499387~224500100:-
LUAD	cis	rs2554380	0.8	rs8034055	ENSG00000259570.1	RP11-671M22.4	3.86	0.000126	0.0171	0.25	0.17	Height;	chr15:83743143	chr15:84394512~84395514:+
LUAD	cis	rs7615952	0.641	rs61048217	ENSG00000250012.1	RP11-124N2.1	-3.86	0.000126	0.0171	-0.25	-0.17	Blood pressure (smoking interaction);	chr3:126089062	chr3:126084220~126095349:+
LUAD	cis	rs7615952	0.641	rs60839048	ENSG00000250012.1	RP11-124N2.1	-3.86	0.000126	0.0171	-0.25	-0.17	Blood pressure (smoking interaction);	chr3:126089095	chr3:126084220~126095349:+
LUAD	cis	rs7615952	0.641	rs7640158	ENSG00000250012.1	RP11-124N2.1	-3.86	0.000126	0.0171	-0.25	-0.17	Blood pressure (smoking interaction);	chr3:126089168	chr3:126084220~126095349:+
LUAD	cis	rs7615952	0.641	rs2365019	ENSG00000250012.1	RP11-124N2.1	-3.86	0.000126	0.0171	-0.25	-0.17	Blood pressure (smoking interaction);	chr3:126089292	chr3:126084220~126095349:+
LUAD	cis	rs3849150	0.821	rs11101559	ENSG00000235939.1	RP11-123B3.2	-3.86	0.000126	0.0171	-0.23	-0.17	Subclinical atherosclerosis traits (other);	chr10:48905097	chr10:49419277~49472903:+
LUAD	cis	rs2278702	0.943	rs78815690	ENSG00000259495.2	RP11-210M15.2	-3.86	0.000127	0.0172	-0.27	-0.17	Bipolar disorder;	chr15:80391946	chr15:80344853~80403575:-
LUAD	cis	rs2278702	0.943	rs57525871	ENSG00000259495.2	RP11-210M15.2	-3.86	0.000127	0.0172	-0.27	-0.17	Bipolar disorder;	chr15:80392605	chr15:80344853~80403575:-
LUAD	cis	rs6964587	1	rs28735847	ENSG00000188693.7	CYP51A1-AS1	-3.86	0.000127	0.0172	-0.2	-0.17	Breast cancer;	chr7:91963441	chr7:92134604~92180725:+
LUAD	cis	rs6964587	1	rs2188154	ENSG00000188693.7	CYP51A1-AS1	-3.86	0.000127	0.0172	-0.2	-0.17	Breast cancer;	chr7:91965824	chr7:92134604~92180725:+
LUAD	cis	rs6964587	1	rs6952671	ENSG00000188693.7	CYP51A1-AS1	-3.86	0.000127	0.0172	-0.2	-0.17	Breast cancer;	chr7:91968620	chr7:92134604~92180725:+
LUAD	cis	rs9532669	0.926	rs4942014	ENSG00000168852.11	TPTE2P5	3.86	0.000127	0.0172	0.17	0.17	Cervical cancer;	chr13:40966366	chr13:40822296~40921749:-
LUAD	cis	rs6081541	1	rs6081547	ENSG00000179447.2	RP5-1027G4.3	-3.86	0.000127	0.0172	-0.23	-0.17	Psychosis (atypical);	chr20:19243943	chr20:19242302~19284596:-
LUAD	cis	rs6496932	0.676	rs7183651	ENSG00000218052.5	ADAMTS7P4	-3.86	0.000127	0.0172	-0.19	-0.17	Central corneal thickness;Corneal structure;	chr15:85352490	chr15:85255369~85330334:-
LUAD	cis	rs12440869	1	rs7177772	ENSG00000270964.1	RP11-502I4.3	-3.86	0.000127	0.0172	-0.2	-0.17	Peak velocity of the mitral A-wave;	chr15:67321156	chr15:67541072~67542604:-
LUAD	cis	rs4266144	0.562	rs56357317	ENSG00000244515.1	KRT18P34	-3.86	0.000127	0.0172	-0.24	-0.17	Coronary artery disease;	chr3:157117385	chr3:157162663~157163932:-
LUAD	cis	rs4795519	0.778	rs8076645	ENSG00000266313.1	RP11-173M1.4	3.86	0.000127	0.0172	0.22	0.17	Chronic myeloid leukemia;	chr17:27072995	chr17:27333256~27348491:+
LUAD	cis	rs4795519	0.778	rs4795428	ENSG00000266313.1	RP11-173M1.4	3.86	0.000127	0.0172	0.22	0.17	Chronic myeloid leukemia;	chr17:27074761	chr17:27333256~27348491:+
LUAD	cis	rs12681366	0.839	rs3019282	ENSG00000254057.1	RP3-388N13.3	3.86	0.000127	0.0172	0.19	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94439898	chr8:93834454~93846743:-
LUAD	cis	rs6964587	0.934	rs7798973	ENSG00000188693.7	CYP51A1-AS1	-3.86	0.000127	0.0172	-0.2	-0.17	Breast cancer;	chr7:91959046	chr7:92134604~92180725:+
LUAD	cis	rs2494663	0.61	rs7526558	ENSG00000223599.1	RP11-216N14.7	3.86	0.000127	0.0172	0.21	0.17	Mean platelet volume;	chr1:154042952	chr1:153852106~153853414:-
LUAD	cis	rs7131987	0.617	rs3764953	ENSG00000275476.1	RP11-996F15.4	-3.86	0.000127	0.0172	-0.2	-0.17	QT interval;	chr12:29349303	chr12:29277397~29277882:-
LUAD	cis	rs2638953	0.924	rs12372059	ENSG00000278733.1	RP11-425D17.1	-3.86	0.000127	0.0172	-0.2	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28192370	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs12372073	ENSG00000278733.1	RP11-425D17.1	-3.86	0.000127	0.0172	-0.2	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28192462	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs56318627	ENSG00000278733.1	RP11-425D17.1	-3.86	0.000127	0.0172	-0.2	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28192719	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.814	rs11049419	ENSG00000278733.1	RP11-425D17.1	-3.86	0.000127	0.0172	-0.2	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28192951	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.85	rs11049420	ENSG00000278733.1	RP11-425D17.1	-3.86	0.000127	0.0172	-0.2	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28193179	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.744	rs11049421	ENSG00000278733.1	RP11-425D17.1	-3.86	0.000127	0.0172	-0.2	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28193324	chr12:28185625~28186190:-
LUAD	cis	rs367615	0.501	rs447849	ENSG00000249476.1	CTD-2587M2.1	-3.86	0.000127	0.0172	-0.19	-0.17	Colorectal cancer (SNP x SNP interaction);	chr5:109615489	chr5:109237120~109326369:-
LUAD	cis	rs6732565	0.706	rs1606588	ENSG00000235721.1	AC013268.3	3.86	0.000127	0.0172	0.19	0.17	Rheumatoid arthritis;	chr2:110890677	chr2:110007675~110010783:+
LUAD	cis	rs10129255	0.5	rs10131875	ENSG00000253209.1	IGHV3-65	3.86	0.000127	0.0172	0.14	0.17	Kawasaki disease;	chr14:106792798	chr14:106666092~106666532:-
LUAD	cis	rs4713118	0.516	rs6931858	ENSG00000280107.1	AL022393.9	-3.86	0.000127	0.0172	-0.22	-0.17	Parkinson's disease;	chr6:28110633	chr6:28170845~28172521:+
LUAD	cis	rs8180040	0.726	rs4078466	ENSG00000271161.1	BOLA2P2	3.86	0.000127	0.0172	0.17	0.17	Colorectal cancer;	chr3:47085053	chr3:47499841~47500407:+
LUAD	cis	rs9876781	1	rs2362452	ENSG00000229759.1	MRPS18AP1	-3.86	0.000127	0.0172	-0.17	-0.17	Longevity;	chr3:48376724	chr3:48256350~48256938:-
LUAD	cis	rs1346081	1	rs1346075	ENSG00000250075.4	RP11-584P21.2	-3.86	0.000127	0.0172	-0.19	-0.17	Intelligence (multi-trait analysis);	chr4:67163204	chr4:67417305~67468251:-
LUAD	cis	rs2153535	0.518	rs9392232	ENSG00000230939.1	RP11-314C16.1	-3.86	0.000127	0.0172	-0.2	-0.17	Motion sickness;	chr6:8636211	chr6:8784178~8785445:+
LUAD	cis	rs7580658	0.926	rs79789049	ENSG00000236682.1	AC068282.3	-3.86	0.000127	0.0172	-0.24	-0.17	Protein C levels;	chr2:127387896	chr2:127389130~127400580:+
LUAD	cis	rs9467773	0.62	rs2494696	ENSG00000261353.1	CTA-14H9.5	-3.86	0.000127	0.0172	-0.19	-0.17	Intelligence (multi-trait analysis);	chr6:26620666	chr6:26527063~26527404:+
LUAD	cis	rs449789	0.619	rs2341553	ENSG00000235086.1	FNDC1-IT1	-3.86	0.000127	0.0172	-0.29	-0.17	Pulse pressure;	chr6:159368176	chr6:159240786~159243329:+
LUAD	cis	rs4601821	0.895	rs7130431	ENSG00000270179.1	RP11-159N11.4	-3.86	0.000127	0.0172	-0.18	-0.17	Alcoholic chronic pancreatitis;	chr11:113367501	chr11:113368478~113369117:+
LUAD	cis	rs324126	0.743	rs34221182	ENSG00000277977.1	CTD-3018O17.5	3.86	0.000127	0.0172	0.18	0.17	Colonoscopy-negative controls vs population controls;	chr19:52378107	chr19:52392659~52392755:+
LUAD	cis	rs3096299	0.838	rs3102376	ENSG00000182376.2	RP5-1142A6.8	3.86	0.000127	0.0172	0.18	0.17	Multiple myeloma (IgH translocation);	chr16:89336065	chr16:88742767~88745748:+
LUAD	cis	rs9813712	0.574	rs35856399	ENSG00000228252.7	COL6A4P2	-3.86	0.000127	0.0172	-0.16	-0.17	Response to amphetamines;	chr3:130241961	chr3:130212823~130273806:+
LUAD	cis	rs7845219	0.539	rs13271644	ENSG00000253528.2	RP11-347C18.4	3.86	0.000127	0.0172	0.18	0.17	Type 2 diabetes;	chr8:94841720	chr8:94974573~94974853:-
LUAD	cis	rs7178424	0.846	rs13379492	ENSG00000259251.2	RP11-643M14.1	-3.86	0.000127	0.0172	-0.18	-0.17	Height;	chr15:61892437	chr15:62060503~62062434:+
LUAD	cis	rs6496932	1	rs28374025	ENSG00000218052.5	ADAMTS7P4	3.86	0.000127	0.0172	0.21	0.17	Central corneal thickness;Corneal structure;	chr15:85284107	chr15:85255369~85330334:-
LUAD	cis	rs6496932	1	rs12917495	ENSG00000218052.5	ADAMTS7P4	3.86	0.000127	0.0172	0.21	0.17	Central corneal thickness;Corneal structure;	chr15:85286330	chr15:85255369~85330334:-
LUAD	cis	rs453301	0.624	rs6987558	ENSG00000233609.3	RP11-62H7.2	3.86	0.000127	0.0172	0.15	0.17	Joint mobility (Beighton score);	chr8:9005011	chr8:8961200~8979025:+
LUAD	cis	rs2732480	0.577	rs2732457	ENSG00000240399.1	RP1-228P16.1	-3.86	0.000127	0.0172	-0.18	-0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48364596	chr12:48054813~48055591:-
LUAD	cis	rs4144027	0.935	rs8008020	ENSG00000258534.1	CTD-2134A5.4	3.86	0.000127	0.0172	0.2	0.17	Blood metabolite levels;	chr14:103889546	chr14:103854366~103880111:-
LUAD	cis	rs4819052	0.851	rs3673	ENSG00000215447.6	BX322557.10	-3.86	0.000127	0.0172	-0.2	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261860	chr21:45288052~45291738:+
LUAD	cis	rs41411047	0.702	rs79477075	ENSG00000271711.1	RP11-392O18.2	3.86	0.000127	0.0172	0.33	0.17	Myocardial infarction;	chr3:149781106	chr3:150611262~150611877:-
LUAD	cis	rs12541335	0.639	rs4871994	ENSG00000254064.1	CTD-2530N21.4	3.86	0.000127	0.0172	0.17	0.17	Hypertriglyceridemia;	chr8:22348525	chr8:22254576~22275162:-
LUAD	cis	rs736801	0.569	rs11748193	ENSG00000233006.5	AC034220.3	3.86	0.000127	0.0172	0.16	0.17	Mosquito bite size;Breast cancer;	chr5:132389637	chr5:132311285~132369916:-
LUAD	cis	rs9341808	0.667	rs7745301	ENSG00000272129.1	RP11-250B2.6	3.86	0.000127	0.0172	0.21	0.17	Sitting height ratio;	chr6:80212844	chr6:80355424~80356859:+
LUAD	cis	rs6840360	0.809	rs6846809	ENSG00000270265.1	RP11-731D1.4	3.86	0.000127	0.0172	0.18	0.17	Intelligence (multi-trait analysis);	chr4:151809049	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.809	rs6847303	ENSG00000270265.1	RP11-731D1.4	3.86	0.000127	0.0172	0.18	0.17	Intelligence (multi-trait analysis);	chr4:151809069	chr4:151333775~151353224:-
LUAD	cis	rs13434995	0.513	rs6802	ENSG00000273257.1	RP11-177J6.1	-3.86	0.000127	0.0172	-0.23	-0.17	Adiponectin levels;	chr4:55425934	chr4:55387949~55388271:+
LUAD	cis	rs9803723	0.826	rs12735622	ENSG00000261349.1	RP3-465N24.5	-3.86	0.000127	0.0172	-0.2	-0.17	Male-pattern baldness;	chr1:25139490	chr1:25266102~25267136:-
LUAD	cis	rs6539288	0.63	rs10778520	ENSG00000260329.1	RP11-412D9.4	3.86	0.000127	0.0172	0.18	0.17	Total body bone mineral density;	chr12:106971095	chr12:106954029~106955497:-
LUAD	cis	rs12073359	0.913	rs12138231	ENSG00000223945.2	RP11-458I7.1	3.86	0.000127	0.0172	0.23	0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150143220	chr1:150053864~150055034:+
LUAD	cis	rs7119038	0.818	rs77209083	ENSG00000255239.1	AP002954.6	-3.86	0.000127	0.0172	-0.27	-0.17	Sjögren's syndrome;	chr11:118736860	chr11:118688039~118690600:-
LUAD	cis	rs7515577	0.842	rs3131816	ENSG00000223787.2	RP4-593M8.1	3.86	0.000127	0.0172	0.27	0.17	Cholesterol, total;	chr1:92202917	chr1:92580476~92580821:-
LUAD	cis	rs10859871	0.536	rs4762347	ENSG00000216306.3	KRT19P2	3.86	0.000127	0.0172	0.23	0.17	Endometriosis;	chr12:95301865	chr12:94834147~94835158:+
LUAD	cis	rs7772486	0.79	rs9403755	ENSG00000235652.6	RP11-545I5.3	-3.86	0.000127	0.0172	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145910334	chr6:145799409~145886585:+
LUAD	cis	rs7580658	0.963	rs12479003	ENSG00000236682.1	AC068282.3	-3.86	0.000127	0.0172	-0.24	-0.17	Protein C levels;	chr2:127360977	chr2:127389130~127400580:+
LUAD	cis	rs7580658	0.963	rs10803585	ENSG00000236682.1	AC068282.3	-3.86	0.000127	0.0172	-0.24	-0.17	Protein C levels;	chr2:127372532	chr2:127389130~127400580:+
LUAD	cis	rs7580658	0.963	rs2090574	ENSG00000236682.1	AC068282.3	-3.86	0.000127	0.0172	-0.24	-0.17	Protein C levels;	chr2:127373815	chr2:127389130~127400580:+
LUAD	cis	rs736408	0.57	rs11130327	ENSG00000243224.1	RP5-1157M23.2	-3.86	0.000127	0.0172	-0.18	-0.17	Bipolar disorder;	chr3:52759223	chr3:52239258~52241097:+
LUAD	cis	rs8012947	1	rs7154076	ENSG00000279636.2	LINC00216	-3.86	0.000127	0.0172	-0.19	-0.17	Alcohol consumption in current drinkers;	chr14:58295564	chr14:58288033~58289158:+
LUAD	cis	rs875971	0.767	rs61348003	ENSG00000273448.1	RP11-166O4.6	3.86	0.000127	0.0172	0.17	0.17	Aortic root size;	chr7:66540947	chr7:67333047~67334383:+
LUAD	cis	rs8014204	0.804	rs34956813	ENSG00000279594.1	RP11-950C14.10	3.86	0.000127	0.0172	0.19	0.17	Caffeine consumption;	chr14:74787464	chr14:75011269~75012851:-
LUAD	cis	rs8014204	0.743	rs35809608	ENSG00000279594.1	RP11-950C14.10	3.86	0.000127	0.0172	0.19	0.17	Caffeine consumption;	chr14:74788059	chr14:75011269~75012851:-
LUAD	cis	rs8014204	0.804	rs35769520	ENSG00000279594.1	RP11-950C14.10	3.86	0.000127	0.0172	0.19	0.17	Caffeine consumption;	chr14:74788412	chr14:75011269~75012851:-
LUAD	cis	rs4474465	0.92	rs4945285	ENSG00000251323.2	RP11-452H21.4	-3.86	0.000127	0.0172	-0.22	-0.17	Alzheimer's disease (survival time);	chr11:78510652	chr11:78423982~78429836:-
LUAD	cis	rs3764400	0.508	rs978263	ENSG00000278765.1	RP5-890E16.5	-3.86	0.000127	0.0172	-0.31	-0.17	Body mass index;	chr17:48103302	chr17:48066704~48067293:-
LUAD	cis	rs3764400	0.567	rs12600980	ENSG00000278765.1	RP5-890E16.5	-3.86	0.000127	0.0172	-0.31	-0.17	Body mass index;	chr17:48109779	chr17:48066704~48067293:-
LUAD	cis	rs603446	0.967	rs108533	ENSG00000254851.1	RP11-109L13.1	3.86	0.000127	0.0172	0.21	0.17	Triglycerides;	chr11:116730995	chr11:117135528~117138582:+
LUAD	cis	rs1346081	0.874	rs6824562	ENSG00000250075.4	RP11-584P21.2	-3.86	0.000127	0.0172	-0.19	-0.17	Intelligence (multi-trait analysis);	chr4:67192311	chr4:67417305~67468251:-
LUAD	cis	rs202072	0.652	rs1223393	ENSG00000272379.1	RP1-257A7.5	-3.86	0.000127	0.0172	-0.29	-0.17	HIV-1 viral setpoint;	chr6:13265102	chr6:13290018~13290490:-
LUAD	cis	rs910316	0.503	rs12894709	ENSG00000259138.1	RP11-950C14.7	3.86	0.000127	0.0172	0.18	0.17	Height;	chr14:74975031	chr14:75127153~75136930:+
LUAD	cis	rs12440869	1	rs7166809	ENSG00000270964.1	RP11-502I4.3	-3.86	0.000127	0.0172	-0.2	-0.17	Peak velocity of the mitral A-wave;	chr15:67282366	chr15:67541072~67542604:-
LUAD	cis	rs7667	0.853	rs10799808	ENSG00000270728.1	RP4-657E11.10	-3.86	0.000127	0.0172	-0.16	-0.17	Crohn's disease and psoriasis;	chr1:19396016	chr1:19297080~19297903:+
LUAD	cis	rs116095464	0.867	rs7726582	ENSG00000248925.1	CTD-2083E4.6	3.86	0.000127	0.0172	0.29	0.17	Breast cancer;	chr5:215234	chr5:269858~271516:-
LUAD	cis	rs116095464	0.619	rs2303741	ENSG00000248925.1	CTD-2083E4.6	3.86	0.000127	0.0172	0.29	0.17	Breast cancer;	chr5:218241	chr5:269858~271516:-
LUAD	cis	rs116095464	0.614	rs10067482	ENSG00000248925.1	CTD-2083E4.6	3.86	0.000127	0.0172	0.29	0.17	Breast cancer;	chr5:219213	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs56043030	ENSG00000248925.1	CTD-2083E4.6	3.86	0.000127	0.0172	0.29	0.17	Breast cancer;	chr5:220802	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs10067021	ENSG00000248925.1	CTD-2083E4.6	3.86	0.000127	0.0172	0.29	0.17	Breast cancer;	chr5:221375	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs9312977	ENSG00000248925.1	CTD-2083E4.6	3.86	0.000127	0.0172	0.29	0.17	Breast cancer;	chr5:221801	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs6881920	ENSG00000248925.1	CTD-2083E4.6	3.86	0.000127	0.0172	0.29	0.17	Breast cancer;	chr5:222296	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs6878061	ENSG00000248925.1	CTD-2083E4.6	3.86	0.000127	0.0172	0.29	0.17	Breast cancer;	chr5:222957	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs6555056	ENSG00000248925.1	CTD-2083E4.6	3.86	0.000127	0.0172	0.29	0.17	Breast cancer;	chr5:226107	chr5:269858~271516:-
LUAD	cis	rs4947019	1	rs12192279	ENSG00000260273.1	RP11-425D10.10	-3.86	0.000127	0.0172	-0.33	-0.17	Hematological parameters;	chr6:109734110	chr6:109382795~109383666:+
LUAD	cis	rs34638952	0.507	rs797963	ENSG00000264808.1	RP11-802D6.1	3.86	0.000127	0.0172	0.2	0.17	Sitting height ratio;	chr17:29283579	chr17:29369717~29390777:-
LUAD	cis	rs61884328	0.657	rs12578030	ENSG00000254780.1	RP11-793I11.1	3.86	0.000127	0.0172	0.34	0.17	Total body bone mineral density (age over 60);	chr11:47213050	chr11:47905323~47905607:-
LUAD	cis	rs875971	0.571	rs160641	ENSG00000224316.1	RP11-479O9.2	-3.86	0.000127	0.0173	-0.21	-0.17	Aortic root size;	chr7:66112359	chr7:65773620~65802067:+
LUAD	cis	rs7202877	0.61	rs11149814	ENSG00000280152.1	RP11-331F4.5	3.86	0.000127	0.0173	0.2	0.17	Type 1 diabetes;Type 2 diabetes;	chr16:75299083	chr16:75245994~75250077:-
LUAD	cis	rs847577	0.748	rs940432	ENSG00000272950.1	RP11-307C18.1	3.86	0.000127	0.0173	0.22	0.17	Breast cancer;	chr7:98087171	chr7:98322853~98323430:+
LUAD	cis	rs847577	0.748	rs940431	ENSG00000272950.1	RP11-307C18.1	3.86	0.000127	0.0173	0.22	0.17	Breast cancer;	chr7:98087183	chr7:98322853~98323430:+
LUAD	cis	rs847577	0.748	rs940430	ENSG00000272950.1	RP11-307C18.1	3.86	0.000127	0.0173	0.22	0.17	Breast cancer;	chr7:98087228	chr7:98322853~98323430:+
LUAD	cis	rs847577	0.748	rs55784506	ENSG00000272950.1	RP11-307C18.1	3.86	0.000127	0.0173	0.22	0.17	Breast cancer;	chr7:98088889	chr7:98322853~98323430:+
LUAD	cis	rs847577	0.748	rs13221897	ENSG00000272950.1	RP11-307C18.1	3.86	0.000127	0.0173	0.22	0.17	Breast cancer;	chr7:98090387	chr7:98322853~98323430:+
LUAD	cis	rs2281636	0.894	rs1541598	ENSG00000233690.1	EBAG9P1	-3.86	0.000128	0.0173	-0.17	-0.17	Obesity-related traits;	chr10:99630733	chr10:99697407~99697949:-
LUAD	cis	rs7674212	0.539	rs7676041	ENSG00000251288.2	RP11-10L12.2	-3.86	0.000128	0.0173	-0.21	-0.17	Type 2 diabetes;	chr4:103205264	chr4:102751401~102752641:+
LUAD	cis	rs7829975	0.514	rs2920983	ENSG00000253981.4	ALG1L13P	3.86	0.000128	0.0173	0.2	0.17	Mood instability;	chr8:8410553	chr8:8236003~8244667:-
LUAD	cis	rs6951245	0.744	rs10265758	ENSG00000226291.1	AC091729.8	-3.86	0.000128	0.0173	-0.28	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1132882	chr7:1080863~1082178:+
LUAD	cis	rs2467099	0.504	rs2608881	ENSG00000267801.1	RP11-552F3.9	3.86	0.000128	0.0173	0.19	0.17	Systolic blood pressure;	chr17:75940572	chr17:75876372~75879546:+
LUAD	cis	rs11157436	0.697	rs4334205	ENSG00000211813.2	TRAV34	-3.86	0.000128	0.0173	-0.19	-0.17	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22155699	chr14:22207522~22208129:+
LUAD	cis	rs10971721	0.822	rs56253239	ENSG00000260947.1	RP11-384P7.7	3.86	0.000128	0.0173	0.37	0.17	Body mass index;	chr9:33860068	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs115554740	ENSG00000260947.1	RP11-384P7.7	3.86	0.000128	0.0173	0.37	0.17	Body mass index;	chr9:33860888	chr9:33697459~33700986:+
LUAD	cis	rs11512640	1	rs117178435	ENSG00000254671.2	STT3A-AS1	3.86	0.000128	0.0173	0.41	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125514351	chr11:125570284~125592568:-
LUAD	cis	rs7845219	0.539	rs10441538	ENSG00000253528.2	RP11-347C18.4	3.86	0.000128	0.0173	0.17	0.17	Type 2 diabetes;	chr8:94856380	chr8:94974573~94974853:-
LUAD	cis	rs2735413	0.563	rs72800909	ENSG00000276007.1	RP11-358L22.3	3.86	0.000128	0.0173	0.24	0.17	Systolic blood pressure (alcohol consumption interaction);	chr16:78013605	chr16:78123243~78124332:+
LUAD	cis	rs12908161	0.683	rs12903256	ENSG00000230373.7	GOLGA6L5P	-3.86	0.000128	0.0173	-0.18	-0.17	Schizophrenia;	chr15:84764910	chr15:84507885~84516814:-
LUAD	cis	rs10197140	1	rs12468564	ENSG00000235721.1	AC013268.3	-3.86	0.000128	0.0173	-0.19	-0.17	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110852042	chr2:110007675~110010783:+
LUAD	cis	rs10197140	1	rs10197140	ENSG00000235721.1	AC013268.3	-3.86	0.000128	0.0173	-0.19	-0.17	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110852366	chr2:110007675~110010783:+
LUAD	cis	rs10197140	1	rs10193050	ENSG00000235721.1	AC013268.3	-3.86	0.000128	0.0173	-0.19	-0.17	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110853521	chr2:110007675~110010783:+
LUAD	cis	rs897984	0.762	rs12930545	ENSG00000232748.3	RP11-196G11.6	3.86	0.000128	0.0173	0.21	0.17	Dementia with Lewy bodies;	chr16:30927490	chr16:31056460~31062803:+
LUAD	cis	rs6728642	0.901	rs10179966	ENSG00000230606.9	AC159540.1	3.86	0.000128	0.0173	0.27	0.17	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97179363	chr2:97416165~97433527:-
LUAD	cis	rs8180040	0.966	rs922957	ENSG00000271161.1	BOLA2P2	-3.86	0.000128	0.0173	-0.17	-0.17	Colorectal cancer;	chr3:47380662	chr3:47499841~47500407:+
LUAD	cis	rs8180040	0.966	rs56351005	ENSG00000271161.1	BOLA2P2	-3.86	0.000128	0.0173	-0.17	-0.17	Colorectal cancer;	chr3:47388696	chr3:47499841~47500407:+
LUAD	cis	rs2337406	0.866	rs4280141	ENSG00000280411.1	IGHV1-69-2	3.86	0.000128	0.0173	0.16	0.17	Alzheimer's disease (late onset);	chr14:106780476	chr14:106762092~106762588:-
LUAD	cis	rs7107174	1	rs57738705	ENSG00000251323.2	RP11-452H21.4	3.86	0.000128	0.0173	0.23	0.17	Testicular germ cell tumor;	chr11:78283443	chr11:78423982~78429836:-
LUAD	cis	rs9309473	0.519	rs6730785	ENSG00000163016.8	ALMS1P	-3.86	0.000128	0.0173	-0.19	-0.17	Metabolite levels;	chr2:73415275	chr2:73644919~73685576:+
LUAD	cis	rs8062405	0.755	rs7186573	ENSG00000251417.2	RP11-1348G14.4	-3.86	0.000128	0.0173	-0.18	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28802743~28817828:+
LUAD	cis	rs7202877	0.706	rs4888393	ENSG00000280152.1	RP11-331F4.5	3.86	0.000128	0.0173	0.2	0.17	Type 1 diabetes;Type 2 diabetes;	chr16:75379775	chr16:75245994~75250077:-
LUAD	cis	rs7202877	0.656	rs4888394	ENSG00000280152.1	RP11-331F4.5	3.86	0.000128	0.0173	0.2	0.17	Type 1 diabetes;Type 2 diabetes;	chr16:75379811	chr16:75245994~75250077:-
LUAD	cis	rs7202877	0.611	rs4888395	ENSG00000280152.1	RP11-331F4.5	3.86	0.000128	0.0173	0.2	0.17	Type 1 diabetes;Type 2 diabetes;	chr16:75379817	chr16:75245994~75250077:-
LUAD	cis	rs9459805	0.92	rs9355607	ENSG00000232082.1	RPS6KA2-IT1	-3.86	0.000128	0.0173	-0.28	-0.17	Endometrial cancer;	chr6:166928286	chr6:166460663~166465383:-
LUAD	cis	rs10129255	0.957	rs8009948	ENSG00000211947.2	IGHV3-21	-3.86	0.000128	0.0173	-0.12	-0.17	Kawasaki disease;	chr14:106805607	chr14:106235064~106235594:-
LUAD	cis	rs939960	0.69	rs954395	ENSG00000279536.1	RP11-445N20.2	3.86	0.000128	0.0173	0.24	0.17	Neutrophil percentage of white cells;	chr7:150673167	chr7:149881477~149882105:+
LUAD	cis	rs1056107	0.7	rs10981292	ENSG00000225513.1	RP11-165N19.2	-3.86	0.000128	0.0173	-0.19	-0.17	Colorectal cancer;	chr9:112168294	chr9:112173522~112173971:-
LUAD	cis	rs950169	0.92	rs17300048	ENSG00000275120.1	RP11-182J1.17	3.86	0.000128	0.0173	0.28	0.17	Schizophrenia;	chr15:84080725	chr15:84599434~84606463:-
LUAD	cis	rs2944755	0.919	rs2944754	ENSG00000279766.1	RP11-642A1.2	3.86	0.000128	0.0173	0.21	0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140564251	chr8:140572142~140572812:-
LUAD	cis	rs6452524	0.618	rs6452502	ENSG00000281327.1	LINC01338	3.86	0.000128	0.0173	0.18	0.17	Hypertension (SNP x SNP interaction);	chr5:83074578	chr5:82850864~82859836:-
LUAD	cis	rs7760535	0.763	rs10457241	ENSG00000271789.1	RP5-1112D6.7	-3.86	0.000128	0.0173	-0.19	-0.17	Metabolic traits;	chr6:111527831	chr6:111297126~111298510:+
LUAD	cis	rs7937890	0.507	rs4463820	ENSG00000254418.1	RP11-21L19.1	3.86	0.000128	0.0173	0.2	0.17	Mitochondrial DNA levels;	chr11:14534796	chr11:14262846~14273691:-
LUAD	cis	rs6095360	1	rs6019671	ENSG00000222365.1	SNORD12B	3.86	0.000128	0.0173	0.18	0.17	Intelligence (multi-trait analysis);	chr20:49198690	chr20:49280319~49280409:+
LUAD	cis	rs11671005	0.735	rs1122955	ENSG00000268543.1	CTD-2619J13.16	-3.86	0.000128	0.0173	-0.25	-0.17	Mean platelet volume;	chr19:58434836	chr19:58418560~58419310:+
LUAD	cis	rs11671005	0.735	rs11668814	ENSG00000268543.1	CTD-2619J13.16	-3.86	0.000128	0.0173	-0.25	-0.17	Mean platelet volume;	chr19:58435466	chr19:58418560~58419310:+
LUAD	cis	rs17189298	0.935	rs330776	ENSG00000231013.1	AC013275.2	-3.86	0.000128	0.0173	-0.17	-0.17	Cerebrospinal T-tau levels;	chr2:119089360	chr2:119476448~119487346:+
LUAD	cis	rs4268898	0.697	rs6714652	ENSG00000223754.1	AC008073.9	-3.86	0.000128	0.0173	-0.21	-0.17	Asthma;	chr2:24160189	chr2:24199839~24201698:-
LUAD	cis	rs939960	0.69	rs62490366	ENSG00000279536.1	RP11-445N20.2	3.86	0.000128	0.0173	0.24	0.17	Neutrophil percentage of white cells;	chr7:150677653	chr7:149881477~149882105:+
LUAD	cis	rs394563	0.967	rs447025	ENSG00000216906.2	RP11-350J20.9	3.86	0.000128	0.0173	0.21	0.17	Dupuytren's disease;	chr6:149477992	chr6:149904243~149906418:+
LUAD	cis	rs2354432	0.607	rs6658763	ENSG00000226015.2	CCT8P1	3.86	0.000128	0.0173	0.34	0.17	Mitochondrial DNA levels;	chr1:147220795	chr1:147203276~147204932:-
LUAD	cis	rs9650657	0.589	rs6985109	ENSG00000255046.1	RP11-297N6.4	-3.86	0.000128	0.0173	-0.21	-0.17	Neuroticism;	chr8:10904075	chr8:11797928~11802568:-
LUAD	cis	rs1167832	1	rs1167832	ENSG00000123965.13	PMS2P5	3.86	0.000128	0.0173	0.31	0.17	Ankle injury;	chr7:75537904	chr7:74894116~74897835:+
LUAD	cis	rs3733418	0.929	rs1401399	ENSG00000248632.1	RP11-366M4.11	3.86	0.000128	0.0173	0.28	0.17	Obesity-related traits;	chr4:165006754	chr4:164968587~164970002:-
LUAD	cis	rs3733418	0.929	rs1401400	ENSG00000248632.1	RP11-366M4.11	3.86	0.000128	0.0173	0.28	0.17	Obesity-related traits;	chr4:165006759	chr4:164968587~164970002:-
LUAD	cis	rs253959	0.545	rs4920905	ENSG00000272265.1	CTD-2287O16.4	3.86	0.000128	0.0173	0.2	0.17	Bipolar disorder and schizophrenia;	chr5:116090771	chr5:116078110~116078570:-
LUAD	cis	rs11853189	0.938	rs16969703	ENSG00000259562.2	RP11-762H8.2	3.86	0.000128	0.0173	0.19	0.17	Red cell distribution width;	chr15:78299694	chr15:78290527~78291221:-
LUAD	cis	rs10971721	0.822	rs12380143	ENSG00000260947.1	RP11-384P7.7	3.86	0.000128	0.0173	0.37	0.17	Body mass index;	chr9:33847588	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs10971735	ENSG00000260947.1	RP11-384P7.7	3.86	0.000128	0.0173	0.37	0.17	Body mass index;	chr9:33851801	chr9:33697459~33700986:+
LUAD	cis	rs6691170	0.864	rs6604678	ENSG00000228437.4	RP11-400N13.2	3.86	0.000128	0.0173	0.2	0.17	Colorectal cancer;	chr1:221878587	chr1:221966341~221984964:+
LUAD	cis	rs1056107	0.763	rs60623018	ENSG00000225513.1	RP11-165N19.2	-3.86	0.000128	0.0173	-0.19	-0.17	Colorectal cancer;	chr9:112175922	chr9:112173522~112173971:-
LUAD	cis	rs8049040	0.547	rs891131	ENSG00000260886.1	TAT-AS1	3.86	0.000128	0.0173	0.21	0.17	Blood protein levels;	chr16:71398514	chr16:71565789~71578187:+
LUAD	cis	rs4594175	0.707	rs12432912	ENSG00000258955.1	LINC00519	-3.86	0.000128	0.0173	-0.21	-0.17	Cancer;	chr14:51272677	chr14:51304416~51328386:-
LUAD	cis	rs4268898	0.722	rs10445893	ENSG00000223754.1	AC008073.9	-3.86	0.000128	0.0173	-0.21	-0.17	Asthma;	chr2:24184259	chr2:24199839~24201698:-
LUAD	cis	rs9900280	0.875	rs4794852	ENSG00000264808.1	RP11-802D6.1	3.86	0.000128	0.0173	0.21	0.17	Mean platelet volume;	chr17:29365718	chr17:29369717~29390777:-
LUAD	cis	rs5015933	0.788	rs558352	ENSG00000232630.1	PRPS1P2	-3.86	0.000128	0.0174	-0.16	-0.17	Body mass index;	chr9:125258497	chr9:125150653~125151589:+
LUAD	cis	rs6964587	0.967	rs6974827	ENSG00000188693.7	CYP51A1-AS1	-3.86	0.000128	0.0174	-0.2	-0.17	Breast cancer;	chr7:92143631	chr7:92134604~92180725:+
LUAD	cis	rs6964587	0.9	rs6465352	ENSG00000188693.7	CYP51A1-AS1	-3.86	0.000128	0.0174	-0.2	-0.17	Breast cancer;	chr7:92145803	chr7:92134604~92180725:+
LUAD	cis	rs6964587	0.967	rs6973896	ENSG00000188693.7	CYP51A1-AS1	-3.86	0.000128	0.0174	-0.2	-0.17	Breast cancer;	chr7:92149151	chr7:92134604~92180725:+
LUAD	cis	rs6964587	0.967	rs1978061	ENSG00000188693.7	CYP51A1-AS1	-3.86	0.000128	0.0174	-0.2	-0.17	Breast cancer;	chr7:92149928	chr7:92134604~92180725:+
LUAD	cis	rs10197140	0.807	rs932077	ENSG00000235721.1	AC013268.3	-3.86	0.000128	0.0174	-0.19	-0.17	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110863541	chr2:110007675~110010783:+
LUAD	cis	rs10197140	0.925	rs11123211	ENSG00000235721.1	AC013268.3	-3.86	0.000128	0.0174	-0.19	-0.17	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110863986	chr2:110007675~110010783:+
LUAD	cis	rs17596685	1	rs7988338	ENSG00000271216.1	LINC01050	-3.86	0.000128	0.0174	-0.26	-0.17	C-reactive protein levels;	chr13:42570706	chr13:42810366~42812562:-
LUAD	cis	rs6964587	1	rs12533199	ENSG00000188693.7	CYP51A1-AS1	-3.86	0.000128	0.0174	-0.21	-0.17	Breast cancer;	chr7:92128079	chr7:92134604~92180725:+
LUAD	cis	rs9549260	0.604	rs56302456	ENSG00000168852.11	TPTE2P5	3.86	0.000128	0.0174	0.22	0.17	Red blood cell count;	chr13:40721751	chr13:40822296~40921749:-
LUAD	cis	rs7107174	1	rs731600	ENSG00000251323.2	RP11-452H21.4	3.86	0.000128	0.0174	0.21	0.17	Testicular germ cell tumor;	chr11:78252087	chr11:78423982~78429836:-
LUAD	cis	rs7637701	0.901	rs13071598	ENSG00000240875.4	LINC00886	-3.86	0.000128	0.0174	-0.19	-0.17	Breast cancer;	chr3:156854426	chr3:156747346~156817062:-
LUAD	cis	rs8141529	0.719	rs9625619	ENSG00000272858.1	CTA-292E10.8	-3.86	0.000128	0.0174	-0.19	-0.17	Lymphocyte counts;	chr22:28876340	chr22:28814914~28815662:+
LUAD	cis	rs159572	0.784	rs159060	ENSG00000250853.1	RNF138P1	3.86	0.000128	0.0174	0.21	0.17	Post-traumatic stress disorder;	chr5:56264311	chr5:55530156~55530701:-
LUAD	cis	rs7580658	0.929	rs2276583	ENSG00000236682.1	AC068282.3	-3.86	0.000128	0.0174	-0.23	-0.17	Protein C levels;	chr2:127257108	chr2:127389130~127400580:+
LUAD	cis	rs7302981	0.967	rs7136570	ENSG00000200428.1	Y_RNA	3.86	0.000128	0.0174	0.22	0.17	Systolic blood pressure;	chr12:50136153	chr12:50743568~50743684:+
LUAD	cis	rs240993	0.516	rs1002481	ENSG00000271789.1	RP5-1112D6.7	-3.86	0.000128	0.0174	-0.25	-0.17	Inflammatory skin disease;Psoriasis;	chr6:111390819	chr6:111297126~111298510:+
LUAD	cis	rs6504108	0.624	rs3792694	ENSG00000278765.1	RP5-890E16.5	3.86	0.000129	0.0174	0.2	0.17	Body mass index;	chr17:48183080	chr17:48066704~48067293:-
LUAD	cis	rs442309	0.846	rs224143	ENSG00000238280.1	RP11-436D10.3	-3.86	0.000129	0.0174	-0.21	-0.17	Vogt-Koyanagi-Harada syndrome;	chr10:62718076	chr10:62793562~62805887:-
LUAD	cis	rs9309473	0.5	rs10865398	ENSG00000163016.8	ALMS1P	-3.86	0.000129	0.0174	-0.19	-0.17	Metabolite levels;	chr2:73514370	chr2:73644919~73685576:+
LUAD	cis	rs7282265	0.646	rs9981615	ENSG00000260583.1	AP000223.42	3.86	0.000129	0.0174	0.32	0.17	Chronic sinus infection;	chr21:25395156	chr21:25582770~25583326:-
LUAD	cis	rs1979679	0.918	rs10771430	ENSG00000278733.1	RP11-425D17.1	-3.86	0.000129	0.0174	-0.22	-0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28470505	chr12:28185625~28186190:-
LUAD	cis	rs17301013	0.861	rs332770	ENSG00000227373.4	RP11-160H22.5	3.86	0.000129	0.0174	0.22	0.17	Systemic lupus erythematosus;	chr1:174681511	chr1:174115300~174160004:-
LUAD	cis	rs1198872	0.503	rs1627163	ENSG00000272275.1	RP11-791G15.2	-3.86	0.000129	0.0174	-0.22	-0.17	Cardiac Troponin-T levels;	chr2:10814718	chr2:10767875~10770058:-
LUAD	cis	rs2486288	0.656	rs2413773	ENSG00000259479.5	SORD2P	-3.86	0.000129	0.0174	-0.21	-0.17	Glomerular filtration rate;	chr15:45257244	chr15:44826371~44884694:-
LUAD	cis	rs795484	0.683	rs572869	ENSG00000275409.1	RP11-131L12.4	-3.86	0.000129	0.0174	-0.19	-0.17	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118370362	chr12:118430147~118430699:+
LUAD	cis	rs2638953	0.924	rs11049417	ENSG00000278733.1	RP11-425D17.1	-3.86	0.000129	0.0174	-0.2	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28192152	chr12:28185625~28186190:-
LUAD	cis	rs61884328	0.733	rs78998999	ENSG00000254780.1	RP11-793I11.1	3.86	0.000129	0.0174	0.34	0.17	Total body bone mineral density (age over 60);	chr11:47206852	chr11:47905323~47905607:-
LUAD	cis	rs61884328	0.733	rs61897855	ENSG00000254780.1	RP11-793I11.1	3.86	0.000129	0.0174	0.34	0.17	Total body bone mineral density (age over 60);	chr11:47209489	chr11:47905323~47905607:-
LUAD	cis	rs6479891	1	rs9415696	ENSG00000232075.1	MRPL35P2	3.86	0.000129	0.0174	0.28	0.17	Arthritis (juvenile idiopathic);	chr10:63374588	chr10:63634317~63634827:-
LUAD	cis	rs10463554	0.892	rs66505956	ENSG00000250682.4	LINC00491	3.86	0.000129	0.0174	0.21	0.17	Parkinson's disease;	chr5:102943853	chr5:102609156~102671559:-
LUAD	cis	rs6502050	0.835	rs7502676	ENSG00000275966.1	RP11-1055B8.9	-3.86	0.000129	0.0174	-0.18	-0.17	Life satisfaction;	chr17:82135557	chr17:81345476~81345966:-
LUAD	cis	rs8092503	0.951	rs1833281	ENSG00000267325.1	LINC01415	-3.86	0.000129	0.0174	-0.22	-0.17	Childhood body mass index;	chr18:54831570	chr18:55776727~55781721:-
LUAD	cis	rs73198271	0.74	rs1039912	ENSG00000253893.2	FAM85B	3.86	0.000129	0.0174	0.23	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790719	chr8:8167819~8226614:-
LUAD	cis	rs62246343	0.605	rs34665459	ENSG00000206573.7	THUMPD3-AS1	-3.86	0.000129	0.0174	-0.16	-0.17	Fibrinogen levels;	chr3:9423041	chr3:9349689~9398579:-
LUAD	cis	rs10463554	0.963	rs257319	ENSG00000250682.4	LINC00491	3.86	0.000129	0.0174	0.21	0.17	Parkinson's disease;	chr5:103110123	chr5:102609156~102671559:-
LUAD	cis	rs7584330	0.78	rs2292884	ENSG00000222032.1	AC112721.2	3.86	0.000129	0.0174	0.2	0.17	Prostate cancer;	chr2:237534583	chr2:237428920~237434822:-
LUAD	cis	rs7246657	0.943	rs35540940	ENSG00000226686.6	LINC01535	-3.86	0.000129	0.0174	-0.26	-0.17	Coronary artery calcification;	chr19:37517333	chr19:37251912~37265535:+
LUAD	cis	rs8113308	0.688	rs7259507	ENSG00000269483.1	AC006272.1	3.86	0.000129	0.0174	0.29	0.17	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51942475	chr19:51839924~51843324:-
LUAD	cis	rs8113308	0.81	rs7259622	ENSG00000269483.1	AC006272.1	3.86	0.000129	0.0174	0.29	0.17	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51942484	chr19:51839924~51843324:-
LUAD	cis	rs12291225	0.679	rs11238	ENSG00000251991.1	RNU7-49P	-3.86	0.000129	0.0174	-0.2	-0.17	Sense of smell;	chr11:14266582	chr11:14478892~14478953:+
LUAD	cis	rs6964587	1	rs10245095	ENSG00000188693.7	CYP51A1-AS1	-3.86	0.000129	0.0174	-0.2	-0.17	Breast cancer;	chr7:92081531	chr7:92134604~92180725:+
LUAD	cis	rs6701713	0.804	rs4266886	ENSG00000274245.1	RP11-357P18.2	-3.86	0.000129	0.0174	-0.26	-0.17	Alzheimer's disease (late onset);	chr1:207512441	chr1:207372559~207373252:+
LUAD	cis	rs9467773	0.62	rs9461276	ENSG00000241549.7	GUSBP2	3.86	0.000129	0.0174	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26594940	chr6:26871484~26956554:-
LUAD	cis	rs2613964	0.504	rs3995917	ENSG00000244144.1	RP11-757F18.3	-3.86	0.000129	0.0174	-0.2	-0.17	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113133767	chr3:112185480~112185998:-
LUAD	cis	rs2731006	0.901	rs2678115	ENSG00000257114.2	RP11-25I15.3	3.86	0.000129	0.0174	0.26	0.17	Panic disorder;	chr12:42766492	chr12:42692216~42717119:+
LUAD	cis	rs1876905	0.68	rs434034	ENSG00000230177.1	RP5-1112D6.4	-3.86	0.000129	0.0174	-0.21	-0.17	Mean corpuscular hemoglobin;	chr6:111204180	chr6:111277932~111278742:+
LUAD	cis	rs600231	0.706	rs11227221	ENSG00000245532.5	NEAT1	-3.86	0.000129	0.0174	-0.14	-0.17	Bone mineral density;	chr11:65551794	chr11:65422774~65445540:+
LUAD	cis	rs12995491	0.843	rs1878809	ENSG00000244575.3	IGKV1-27	-3.86	0.000129	0.0174	-0.13	-0.17	Response to metformin (IC50);	chr2:88218796	chr2:89213423~89213928:-
LUAD	cis	rs7829975	0.577	rs79495969	ENSG00000253893.2	FAM85B	3.86	0.000129	0.0174	0.22	0.17	Mood instability;	chr8:8687740	chr8:8167819~8226614:-
LUAD	cis	rs6964587	1	rs7811873	ENSG00000188693.7	CYP51A1-AS1	-3.86	0.000129	0.0174	-0.21	-0.17	Breast cancer;	chr7:92121806	chr7:92134604~92180725:+
LUAD	cis	rs6964587	1	rs2269727	ENSG00000188693.7	CYP51A1-AS1	-3.86	0.000129	0.0174	-0.21	-0.17	Breast cancer;	chr7:92123376	chr7:92134604~92180725:+
LUAD	cis	rs9467773	0.549	rs9467805	ENSG00000261353.1	CTA-14H9.5	-3.86	0.000129	0.0174	-0.19	-0.17	Intelligence (multi-trait analysis);	chr6:26583138	chr6:26527063~26527404:+
LUAD	cis	rs67981189	0.896	rs17108804	ENSG00000269927.1	RP6-91H8.3	-3.86	0.000129	0.0174	-0.21	-0.17	Schizophrenia;	chr14:70974807	chr14:71141125~71143253:-
LUAD	cis	rs11779988	0.503	rs411173	ENSG00000253671.1	RP11-806O11.1	-3.86	0.000129	0.0174	-0.21	-0.17	Breast cancer;	chr8:17910755	chr8:17808941~17820868:+
LUAD	cis	rs11779988	0.545	rs375203	ENSG00000253671.1	RP11-806O11.1	-3.86	0.000129	0.0174	-0.21	-0.17	Breast cancer;	chr8:17911545	chr8:17808941~17820868:+
LUAD	cis	rs8031584	0.541	rs2955797	ENSG00000259845.1	HERC2P10	-3.86	0.000129	0.0174	-0.19	-0.17	Huntington's disease progression;	chr15:30918778	chr15:30815271~30844153:+
LUAD	cis	rs13113518	1	rs4864548	ENSG00000223305.1	RN7SKP30	-3.86	0.000129	0.0174	-0.2	-0.17	Height;	chr4:55547636	chr4:55540502~55540835:-
LUAD	cis	rs2243480	1	rs160634	ENSG00000229886.1	RP5-1132H15.3	-3.86	0.000129	0.0174	-0.28	-0.17	Diabetic kidney disease;	chr7:66063677	chr7:66025126~66031544:-
LUAD	cis	rs11673344	0.931	rs7256746	ENSG00000267309.1	CTD-2630F21.1	-3.86	0.000129	0.0174	-0.2	-0.17	Obesity-related traits;	chr19:37175073	chr19:36489649~36491040:+
LUAD	cis	rs748404	0.666	rs62021180	ENSG00000249839.1	AC011330.5	-3.86	0.000129	0.0174	-0.27	-0.17	Lung cancer;	chr15:43420139	chr15:43663654~43684339:-
LUAD	cis	rs2880765	0.527	rs35184622	ENSG00000202081.1	RNU6-1280P	3.86	0.000129	0.0174	0.21	0.17	Coronary artery disease;	chr15:85529804	chr15:85651522~85651628:-
LUAD	cis	rs2880765	0.527	rs1483578	ENSG00000202081.1	RNU6-1280P	3.86	0.000129	0.0174	0.21	0.17	Coronary artery disease;	chr15:85532186	chr15:85651522~85651628:-
LUAD	cis	rs2880765	0.835	rs4281668	ENSG00000259416.2	RP11-158M2.5	3.86	0.000129	0.0174	0.18	0.17	Coronary artery disease;	chr15:85504055	chr15:85754941~85756237:-
LUAD	cis	rs6964587	1	rs17164275	ENSG00000188693.7	CYP51A1-AS1	-3.86	0.000129	0.0174	-0.2	-0.17	Breast cancer;	chr7:91961094	chr7:92134604~92180725:+
LUAD	cis	rs12440869	1	rs12438251	ENSG00000270964.1	RP11-502I4.3	3.86	0.000129	0.0174	0.2	0.17	Peak velocity of the mitral A-wave;	chr15:67264781	chr15:67541072~67542604:-
LUAD	cis	rs2115630	0.967	rs12595786	ENSG00000259728.4	LINC00933	-3.86	0.000129	0.0174	-0.21	-0.17	P wave terminal force;	chr15:84793439	chr15:84570649~84580175:+
LUAD	cis	rs2274273	0.905	rs17128183	ENSG00000259318.1	RP11-454L9.2	-3.86	0.000129	0.0175	-0.15	-0.17	Protein biomarker;	chr14:55112795	chr14:55394940~55395233:-
LUAD	cis	rs76878669	0.561	rs6591217	ENSG00000213409.4	RP11-658F2.3	-3.86	0.000129	0.0175	-0.21	-0.17	Educational attainment (years of education);	chr11:66407182	chr11:66761575~66762399:-
LUAD	cis	rs11118883	0.922	rs12726661	ENSG00000228437.4	RP11-400N13.2	3.86	0.000129	0.0175	0.22	0.17	Colorectal cancer;	chr1:221894446	chr1:221966341~221984964:+
LUAD	cis	rs4660214	0.666	rs6704246	ENSG00000182109.6	RP11-69E11.4	-3.86	0.000129	0.0175	-0.19	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39343612	chr1:39522280~39546187:-
LUAD	cis	rs62458065	0.85	rs7808992	ENSG00000226468.2	AC018641.7	3.86	0.000129	0.0175	0.29	0.17	Metabolite levels (HVA/MHPG ratio);	chr7:32431065	chr7:32456963~32457758:-
LUAD	cis	rs848490	0.817	rs17467232	ENSG00000214293.7	APTR	3.86	0.000129	0.0175	0.23	0.17	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77626624	chr7:77657660~77696265:-
LUAD	cis	rs36093844	0.654	rs79753303	ENSG00000279742.1	RP11-700A24.1	-3.86	0.000129	0.0175	-0.25	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85809537	chr11:85852557~85854943:-
LUAD	cis	rs253959	0.545	rs7734133	ENSG00000272265.1	CTD-2287O16.4	3.86	0.000129	0.0175	0.21	0.17	Bipolar disorder and schizophrenia;	chr5:116096418	chr5:116078110~116078570:-
LUAD	cis	rs253959	0.545	rs10072417	ENSG00000272265.1	CTD-2287O16.4	3.86	0.000129	0.0175	0.21	0.17	Bipolar disorder and schizophrenia;	chr5:116097906	chr5:116078110~116078570:-
LUAD	cis	rs2243480	1	rs709607	ENSG00000164669.11	INTS4P1	-3.86	0.000129	0.0175	-0.3	-0.17	Diabetic kidney disease;	chr7:65984554	chr7:65141225~65234216:+
LUAD	cis	rs67981189	0.896	rs7146591	ENSG00000269927.1	RP6-91H8.3	-3.86	0.000129	0.0175	-0.22	-0.17	Schizophrenia;	chr14:70971511	chr14:71141125~71143253:-
LUAD	cis	rs516842	0.826	rs73487638	ENSG00000234835.1	PHBP13	-3.86	0.000129	0.0175	-0.39	-0.17	Lobe attachment (rater-scored or self-reported);	chr13:35007524	chr13:35251070~35251829:+
LUAD	cis	rs1005277	0.522	rs289648	ENSG00000273019.1	RP11-508N22.13	-3.86	0.000129	0.0175	-0.2	-0.17	Extrinsic epigenetic age acceleration;	chr10:37682909	chr10:38149968~38150293:+
LUAD	cis	rs9473147	1	rs9473147	ENSG00000270761.1	RP11-385F7.1	-3.86	0.000129	0.0175	-0.2	-0.17	Platelet distribution width;Mean platelet volume;	chr6:47641856	chr6:47477243~47477572:-
LUAD	cis	rs2731006	0.591	rs12227600	ENSG00000257114.2	RP11-25I15.3	3.86	0.000129	0.0175	0.29	0.17	Panic disorder;	chr12:42812674	chr12:42692216~42717119:+
LUAD	cis	rs7584330	0.704	rs7602387	ENSG00000222032.1	AC112721.2	3.86	0.000129	0.0175	0.2	0.17	Prostate cancer;	chr2:237448152	chr2:237428920~237434822:-
LUAD	cis	rs10050311	0.698	rs4693780	ENSG00000261496.1	RP13-514E23.1	3.86	0.000129	0.0175	0.2	0.17	Insulin-related traits;	chr4:86720066	chr4:86012296~86013874:-
LUAD	cis	rs8180040	0.966	rs6792461	ENSG00000271161.1	BOLA2P2	-3.86	0.000129	0.0175	-0.17	-0.17	Colorectal cancer;	chr3:47431678	chr3:47499841~47500407:+
LUAD	cis	rs2333021	0.78	rs2243596	ENSG00000259015.1	RP11-109N23.6	-3.86	0.000129	0.0175	-0.16	-0.17	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72961952	chr14:72960595~72961993:+
LUAD	cis	rs10463554	0.927	rs257312	ENSG00000250682.4	LINC00491	3.86	0.000129	0.0175	0.21	0.17	Parkinson's disease;	chr5:103083923	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.927	rs185387	ENSG00000250682.4	LINC00491	3.86	0.000129	0.0175	0.21	0.17	Parkinson's disease;	chr5:103084315	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.892	rs257313	ENSG00000250682.4	LINC00491	3.86	0.000129	0.0175	0.21	0.17	Parkinson's disease;	chr5:103084943	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.927	rs257315	ENSG00000250682.4	LINC00491	3.86	0.000129	0.0175	0.21	0.17	Parkinson's disease;	chr5:103085725	chr5:102609156~102671559:-
LUAD	cis	rs9308731	0.614	rs6755484	ENSG00000227992.1	AC108463.2	-3.86	0.000129	0.0175	-0.22	-0.17	Chronic lymphocytic leukemia;	chr2:111191519	chr2:111203964~111206215:-
LUAD	cis	rs11673344	0.504	rs35162188	ENSG00000276846.1	CTD-3220F14.3	3.86	0.00013	0.0175	0.19	0.17	Obesity-related traits;	chr19:37088908	chr19:37314868~37315620:-
LUAD	cis	rs2976388	0.59	rs3736011	ENSG00000253741.1	CTD-2292P10.4	3.86	0.00013	0.0175	0.2	0.17	Urinary tract infection frequency;	chr8:142736371	chr8:142702252~142726973:-
LUAD	cis	rs11089937	0.616	rs4145537	ENSG00000211638.2	IGLV8-61	3.86	0.00013	0.0175	0.18	0.17	Periodontitis (PAL4Q3);	chr22:22182550	chr22:22098700~22099212:+
LUAD	cis	rs7274811	0.744	rs6141411	ENSG00000231795.1	ITCH-IT1	3.86	0.00013	0.0175	0.2	0.17	Height;	chr20:33570128	chr20:34450930~34454552:+
LUAD	cis	rs2274459	0.722	rs10947443	ENSG00000272288.4	RP11-140K17.3	3.86	0.00013	0.0175	0.2	0.17	Obesity (extreme);	chr6:33823453	chr6:34696317~34697470:+
LUAD	cis	rs7134599	1	rs2193041	ENSG00000240087.3	RP11-254B13.1	3.86	0.00013	0.0175	0.15	0.17	Inflammatory bowel disease;Ulcerative colitis;	chr12:68108330	chr12:68552995~68553882:-
LUAD	cis	rs7829975	0.514	rs2976929	ENSG00000253981.4	ALG1L13P	3.86	0.00013	0.0175	0.2	0.17	Mood instability;	chr8:8401202	chr8:8236003~8244667:-
LUAD	cis	rs7772486	0.79	rs7753696	ENSG00000235652.6	RP11-545I5.3	-3.86	0.00013	0.0175	-0.18	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145957962	chr6:145799409~145886585:+
LUAD	cis	rs34792	0.637	rs2450356	ENSG00000207425.1	Y_RNA	3.86	0.00013	0.0175	0.21	0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15477487	chr16:14915457~14915556:-
LUAD	cis	rs1032726	0.716	rs9828321	ENSG00000242770.2	RP11-180K7.1	3.86	0.00013	0.0175	0.18	0.17	Sum eosinophil basophil counts;Eosinophil counts;	chr3:112962018	chr3:112802478~112812819:+
LUAD	cis	rs763121	1	rs138464	ENSG00000225450.1	RP3-508I15.14	3.86	0.00013	0.0175	0.16	0.17	Menopause (age at onset);	chr22:38510427	chr22:38739003~38749041:+
LUAD	cis	rs2252586	0.916	rs7793297	ENSG00000226278.1	PSPHP1	-3.86	0.00013	0.0175	-0.21	-0.17	Glioma;	chr7:54898410	chr7:55764797~55773288:+
LUAD	cis	rs5758511	0.68	rs5758686	ENSG00000227370.1	RP4-669P10.19	3.86	0.00013	0.0175	0.19	0.17	Birth weight;	chr22:42259371	chr22:42132543~42132998:+
LUAD	cis	rs10129255	0.917	rs7142373	ENSG00000211947.2	IGHV3-21	-3.86	0.00013	0.0175	-0.12	-0.17	Kawasaki disease;	chr14:106708947	chr14:106235064~106235594:-
LUAD	cis	rs9847710	1	rs2581817	ENSG00000242142.1	SERBP1P3	3.86	0.00013	0.0175	0.18	0.17	Ulcerative colitis;	chr3:53037781	chr3:53064283~53065091:-
LUAD	cis	rs2288073	1	rs6708328	ENSG00000223754.1	AC008073.9	3.86	0.00013	0.0175	0.22	0.17	Venous thromboembolism (SNP x SNP interaction);	chr2:24189544	chr2:24199839~24201698:-
LUAD	cis	rs10197140	0.925	rs6720034	ENSG00000235721.1	AC013268.3	-3.86	0.00013	0.0175	-0.19	-0.17	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110907179	chr2:110007675~110010783:+
LUAD	cis	rs6964833	0.873	rs4717905	ENSG00000278416.1	PMS2L2	3.86	0.00013	0.0175	0.25	0.17	Menarche (age at onset);	chr7:74668903	chr7:75344015~75359550:-
LUAD	cis	rs2243480	1	rs160643	ENSG00000229886.1	RP5-1132H15.3	3.86	0.00013	0.0175	0.28	0.17	Diabetic kidney disease;	chr7:66093235	chr7:66025126~66031544:-
LUAD	cis	rs17818399	0.547	rs4952831	ENSG00000279254.1	RP11-536C12.1	-3.86	0.00013	0.0175	-0.21	-0.17	Height;	chr2:46534042	chr2:46668870~46670778:+
LUAD	cis	rs11048434	0.518	rs7311267	ENSG00000256937.1	KRT17P8	3.86	0.00013	0.0175	0.2	0.17	Sjögren's syndrome;	chr12:9026082	chr12:9127783~9128645:+
LUAD	cis	rs4691139	0.634	rs4583719	ENSG00000248632.1	RP11-366M4.11	3.86	0.00013	0.0175	0.21	0.17	Ovarian cancer in BRCA1 mutation carriers;	chr4:165003505	chr4:164968587~164970002:-
LUAD	cis	rs4691139	0.611	rs11100590	ENSG00000248632.1	RP11-366M4.11	3.86	0.00013	0.0175	0.21	0.17	Ovarian cancer in BRCA1 mutation carriers;	chr4:165003635	chr4:164968587~164970002:-
LUAD	cis	rs561341	0.71	rs9900031	ENSG00000265798.5	RP11-271K11.5	-3.86	0.00013	0.0175	-0.27	-0.17	Hip circumference adjusted for BMI;	chr17:31872518	chr17:31038575~31059121:-
LUAD	cis	rs7429990	0.965	rs7651237	ENSG00000228638.1	FCF1P2	3.86	0.00013	0.0175	0.22	0.17	Educational attainment (years of education);	chr3:48064038	chr3:48290793~48291375:-
LUAD	cis	rs9549260	0.609	rs9315780	ENSG00000168852.11	TPTE2P5	3.86	0.00013	0.0175	0.17	0.17	Red blood cell count;	chr13:40689824	chr13:40822296~40921749:-
LUAD	cis	rs9549260	0.609	rs9315781	ENSG00000168852.11	TPTE2P5	3.86	0.00013	0.0175	0.17	0.17	Red blood cell count;	chr13:40689917	chr13:40822296~40921749:-
LUAD	cis	rs10129255	0.957	rs8009948	ENSG00000274576.2	IGHV2-70	3.86	0.00013	0.0175	0.16	0.17	Kawasaki disease;	chr14:106805607	chr14:106770577~106771020:-
LUAD	cis	rs12986445	0.894	rs12713700	ENSG00000218682.1	AC010150.1	3.86	0.00013	0.0175	0.21	0.17	Multiple myeloma;Multiple myeloma and monoclonal gammopathy;	chr2:25913127	chr2:25856461~25856966:-
LUAD	cis	rs7017914	0.905	rs2639956	ENSG00000246366.5	RP11-382J12.1	3.86	0.00013	0.0175	0.16	0.17	Bone mineral density;	chr8:71011856	chr8:70608577~70663279:+
LUAD	cis	rs3808502	0.503	rs2061830	ENSG00000255046.1	RP11-297N6.4	-3.86	0.00013	0.0175	-0.22	-0.17	Neuroticism;	chr8:11539948	chr8:11797928~11802568:-
LUAD	cis	rs2354432	0.607	rs59606861	ENSG00000237188.3	RP11-337C18.8	3.86	0.00013	0.0175	0.31	0.17	Mitochondrial DNA levels;	chr1:147289796	chr1:147172771~147211568:+
LUAD	cis	rs847577	0.651	rs10464490	ENSG00000272950.1	RP11-307C18.1	3.86	0.00013	0.0175	0.22	0.17	Breast cancer;	chr7:98086007	chr7:98322853~98323430:+
LUAD	cis	rs13113518	0.812	rs7667741	ENSG00000273257.1	RP11-177J6.1	3.86	0.00013	0.0175	0.2	0.17	Height;	chr4:55544621	chr4:55387949~55388271:+
LUAD	cis	rs6547741	0.967	rs4665999	ENSG00000223522.1	AC093690.1	3.86	0.00013	0.0175	0.17	0.17	Oral cavity cancer;	chr2:27611577	chr2:28307691~28310459:-
LUAD	cis	rs4924997	0.772	rs2018675	ENSG00000228157.4	AC007952.5	-3.86	0.00013	0.0175	-0.21	-0.17	Lymphocyte counts;	chr17:19538218	chr17:19092974~19096837:+
LUAD	cis	rs6479901	0.512	rs7082090	ENSG00000232075.1	MRPL35P2	3.86	0.00013	0.0175	0.28	0.17	Intelligence (multi-trait analysis);	chr10:63239252	chr10:63634317~63634827:-
LUAD	cis	rs34929064	0.536	rs2961279	ENSG00000232949.1	AC002480.4	-3.86	0.00013	0.0175	-0.2	-0.17	Major depression and alcohol dependence;	chr7:22598535	chr7:22589705~22591622:+
LUAD	cis	rs6540731	0.967	rs1472226	ENSG00000229983.1	RP11-15I11.2	3.86	0.00013	0.0175	0.21	0.17	Intelligence (childhood);	chr1:212229238	chr1:212168207~212190259:+
LUAD	cis	rs4144027	0.875	rs6576010	ENSG00000258914.1	CTD-2134A5.3	3.86	0.00013	0.0176	0.21	0.17	Blood metabolite levels;	chr14:103883265	chr14:103875055~103877478:+
LUAD	cis	rs7955901	0.837	rs1877527	ENSG00000258053.1	CTD-2021H9.3	-3.86	0.00013	0.0176	-0.2	-0.17	Type 2 diabetes;	chr12:71011426	chr12:71047402~71118247:-
LUAD	cis	rs12440869	1	rs11636197	ENSG00000270964.1	RP11-502I4.3	-3.86	0.00013	0.0176	-0.2	-0.17	Peak velocity of the mitral A-wave;	chr15:67295030	chr15:67541072~67542604:-
LUAD	cis	rs12440869	1	rs2044329	ENSG00000270964.1	RP11-502I4.3	-3.86	0.00013	0.0176	-0.2	-0.17	Peak velocity of the mitral A-wave;	chr15:67308616	chr15:67541072~67542604:-
LUAD	cis	rs5015933	0.778	rs2184062	ENSG00000232630.1	PRPS1P2	-3.86	0.00013	0.0176	-0.16	-0.17	Body mass index;	chr9:125308231	chr9:125150653~125151589:+
LUAD	cis	rs7131987	0.65	rs7957339	ENSG00000275476.1	RP11-996F15.4	-3.86	0.00013	0.0176	-0.2	-0.17	QT interval;	chr12:29303562	chr12:29277397~29277882:-
LUAD	cis	rs9393777	0.623	rs13211166	ENSG00000219392.1	RP1-265C24.5	-3.86	0.00013	0.0176	-0.26	-0.17	Intelligence (multi-trait analysis);	chr6:27298161	chr6:28115628~28116551:+
LUAD	cis	rs4268898	0.662	rs17789375	ENSG00000242628.4	AC009228.1	3.86	0.00013	0.0176	0.25	0.17	Asthma;	chr2:24279685	chr2:24214381~24221516:+
LUAD	cis	rs9308731	0.583	rs4848406	ENSG00000227992.1	AC108463.2	-3.86	0.00013	0.0176	-0.2	-0.17	Chronic lymphocytic leukemia;	chr2:111176181	chr2:111203964~111206215:-
LUAD	cis	rs12216545	0.765	rs2204129	ENSG00000177590.7	GIMAP3P	-3.86	0.00013	0.0176	-0.18	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150554351	chr7:150746893~150747728:-
LUAD	cis	rs1850744	1	rs1850744	ENSG00000163612.10	FAM86KP	-3.86	0.00013	0.0176	-0.5	-0.17	Economic and political preferences;	chr4:9789088	chr4:9153296~9165451:+
LUAD	cis	rs11159086	1	rs4899516	ENSG00000270000.1	RP3-449M8.9	3.86	0.00013	0.0176	0.25	0.17	Advanced glycation end-product levels;	chr14:74492825	chr14:74471930~74472360:-
LUAD	cis	rs12744310	0.887	rs1892419	ENSG00000235358.1	RP11-399E6.1	3.86	0.00013	0.0176	0.23	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41315479	chr1:41242373~41284861:+
LUAD	cis	rs12744310	0.887	rs1892420	ENSG00000235358.1	RP11-399E6.1	3.86	0.00013	0.0176	0.23	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41315738	chr1:41242373~41284861:+
LUAD	cis	rs5771040	0.56	rs4824152	ENSG00000273253.2	RP3-402G11.26	-3.86	0.00013	0.0176	-0.18	-0.17	IgG glycosylation;	chr22:50473447	chr22:50199090~50200837:-
LUAD	cis	rs9656709	1	rs9656709	ENSG00000226278.1	PSPHP1	-3.86	0.00013	0.0176	-0.19	-0.17	Behavioural disinhibition (generation interaction);	chr7:55656752	chr7:55764797~55773288:+
LUAD	cis	rs911555	0.755	rs11620897	ENSG00000244691.1	RPL10AP1	-3.86	0.000131	0.0176	-0.23	-0.17	Intelligence (multi-trait analysis);	chr14:103478524	chr14:103412119~103412761:-
LUAD	cis	rs5758511	0.817	rs133291	ENSG00000233903.2	Z83851.4	3.86	0.000131	0.0176	0.24	0.17	Birth weight;	chr22:41873624	chr22:42276355~42277052:+
LUAD	cis	rs12579720	0.868	rs55780032	ENSG00000255910.1	RP11-405A12.2	3.86	0.000131	0.0176	0.22	0.17	Diastolic blood pressure;	chr12:20030149	chr12:19775451~20009937:+
LUAD	cis	rs12579720	0.868	rs6487056	ENSG00000255910.1	RP11-405A12.2	3.86	0.000131	0.0176	0.22	0.17	Diastolic blood pressure;	chr12:20030167	chr12:19775451~20009937:+
LUAD	cis	rs12579720	0.868	rs6487057	ENSG00000255910.1	RP11-405A12.2	3.86	0.000131	0.0176	0.22	0.17	Diastolic blood pressure;	chr12:20030169	chr12:19775451~20009937:+
LUAD	cis	rs7142881	0.569	rs12436891	ENSG00000258525.1	RP11-829H16.3	3.86	0.000131	0.0176	0.19	0.17	Response to iloperidone treatment (QT prolongation);	chr14:31778459	chr14:30876179~30889808:-
LUAD	cis	rs801193	1	rs2659906	ENSG00000222364.1	RNU6-96P	-3.86	0.000131	0.0176	-0.19	-0.17	Aortic root size;	chr7:66700323	chr7:66395191~66395286:+
LUAD	cis	rs10129255	0.509	rs756583	ENSG00000253209.1	IGHV3-65	3.86	0.000131	0.0176	0.14	0.17	Kawasaki disease;	chr14:106680002	chr14:106666092~106666532:-
LUAD	cis	rs10131894	0.611	rs175002	ENSG00000259138.1	RP11-950C14.7	3.86	0.000131	0.0176	0.18	0.17	Coronary artery disease;	chr14:74969763	chr14:75127153~75136930:+
LUAD	cis	rs6787172	0.811	rs6780896	ENSG00000272087.1	RP11-379F4.7	3.86	0.000131	0.0176	0.18	0.17	Subjective well-being;	chr3:158477606	chr3:158693120~158693768:-
LUAD	cis	rs6787172	0.728	rs6783284	ENSG00000272087.1	RP11-379F4.7	3.86	0.000131	0.0176	0.18	0.17	Subjective well-being;	chr3:158477761	chr3:158693120~158693768:-
LUAD	cis	rs9341808	0.667	rs12209624	ENSG00000260645.1	RP11-250B2.5	3.86	0.000131	0.0176	0.16	0.17	Sitting height ratio;	chr6:80209416	chr6:80466958~80469080:+
LUAD	cis	rs6840360	0.582	rs1372976	ENSG00000270265.1	RP11-731D1.4	-3.86	0.000131	0.0176	-0.18	-0.17	Intelligence (multi-trait analysis);	chr4:151530301	chr4:151333775~151353224:-
LUAD	cis	rs11742741	1	rs62350797	ENSG00000248874.4	C5orf17	-3.86	0.000131	0.0176	-0.21	-0.17	Educational attainment;	chr5:24147593	chr5:23951348~24178263:+
LUAD	cis	rs11673344	0.542	rs2562598	ENSG00000276846.1	CTD-3220F14.3	3.86	0.000131	0.0176	0.19	0.17	Obesity-related traits;	chr19:37025318	chr19:37314868~37315620:-
LUAD	cis	rs7893279	0.505	rs7897159	ENSG00000225527.1	RP11-383B4.4	3.86	0.000131	0.0176	0.25	0.17	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18642651	chr10:18531849~18533336:-
LUAD	cis	rs6964587	0.839	rs62466809	ENSG00000188693.7	CYP51A1-AS1	-3.86	0.000131	0.0176	-0.21	-0.17	Breast cancer;	chr7:91843487	chr7:92134604~92180725:+
LUAD	cis	rs7617773	0.817	rs936427	ENSG00000199476.1	Y_RNA	3.86	0.000131	0.0176	0.23	0.17	Coronary artery disease;	chr3:48259584	chr3:48288587~48288694:+
LUAD	cis	rs56050415	1	rs56142310	ENSG00000277144.1	RP11-59H7.4	3.86	0.000131	0.0176	0.31	0.17	Metabolite levels (lipoprotein measures);	chr15:58282759	chr15:59115547~59116089:-
LUAD	cis	rs8014252	0.803	rs60555424	ENSG00000259158.2	ADAM20P1	-3.86	0.000131	0.0176	-0.3	-0.17	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70574785	chr14:70468881~70483756:-
LUAD	cis	rs1023500	0.551	rs2854837	ENSG00000273366.1	CTA-989H11.1	-3.86	0.000131	0.0176	-0.21	-0.17	Schizophrenia;	chr22:42062477	chr22:42278188~42278846:+
LUAD	cis	rs7119038	0.774	rs11217001	ENSG00000255239.1	AP002954.6	-3.86	0.000131	0.0176	-0.27	-0.17	Sjögren's syndrome;	chr11:118736337	chr11:118688039~118690600:-
LUAD	cis	rs7107174	1	rs2511186	ENSG00000251323.2	RP11-452H21.4	3.86	0.000131	0.0176	0.23	0.17	Testicular germ cell tumor;	chr11:78273260	chr11:78423982~78429836:-
LUAD	cis	rs7937890	0.505	rs4403769	ENSG00000254418.1	RP11-21L19.1	3.86	0.000131	0.0176	0.2	0.17	Mitochondrial DNA levels;	chr11:14428630	chr11:14262846~14273691:-
LUAD	cis	rs2638953	0.925	rs11049412	ENSG00000278733.1	RP11-425D17.1	-3.86	0.000131	0.0176	-0.2	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28186199	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs2061758	ENSG00000278733.1	RP11-425D17.1	-3.86	0.000131	0.0176	-0.2	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28186575	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs12366932	ENSG00000278733.1	RP11-425D17.1	-3.86	0.000131	0.0176	-0.2	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28188953	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs1478336	ENSG00000278733.1	RP11-425D17.1	-3.86	0.000131	0.0176	-0.2	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28189186	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs1478335	ENSG00000278733.1	RP11-425D17.1	-3.86	0.000131	0.0176	-0.2	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28189244	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs1478334	ENSG00000278733.1	RP11-425D17.1	-3.86	0.000131	0.0176	-0.2	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28189425	chr12:28185625~28186190:-
LUAD	cis	rs2283792	0.73	rs2083565	ENSG00000211640.3	IGLV6-57	-3.86	0.000131	0.0176	-0.11	-0.17	Multiple sclerosis;	chr22:21929985	chr22:22195713~22196460:+
LUAD	cis	rs3018712	0.59	rs10896362	ENSG00000227620.4	ALG1L8P	-3.86	0.000131	0.0176	-0.24	-0.17	Total body bone mineral density;	chr11:68725775	chr11:67785273~67792335:+
LUAD	cis	rs3018712	0.59	rs7930683	ENSG00000227620.4	ALG1L8P	-3.86	0.000131	0.0176	-0.24	-0.17	Total body bone mineral density;	chr11:68728172	chr11:67785273~67792335:+
LUAD	cis	rs2625529	0.652	rs2957735	ENSG00000260173.1	RP11-2I17.4	3.86	0.000131	0.0176	0.21	0.17	Red blood cell count;	chr15:71972832	chr15:72140504~72155459:-
LUAD	cis	rs12744310	1	rs2364535	ENSG00000235358.1	RP11-399E6.1	3.86	0.000131	0.0176	0.23	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41300564	chr1:41242373~41284861:+
LUAD	cis	rs858239	0.539	rs28624974	ENSG00000226816.2	AC005082.12	3.86	0.000131	0.0176	0.23	0.17	Cerebrospinal fluid biomarker levels;	chr7:23149317	chr7:23206013~23208045:+
LUAD	cis	rs9287719	0.781	rs6714413	ENSG00000243819.4	RN7SL832P	3.86	0.000131	0.0176	0.18	0.17	Prostate cancer;	chr2:10618733	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.746	rs6742448	ENSG00000243819.4	RN7SL832P	3.86	0.000131	0.0176	0.18	0.17	Prostate cancer;	chr2:10619000	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.781	rs6732671	ENSG00000243819.4	RN7SL832P	3.86	0.000131	0.0176	0.18	0.17	Prostate cancer;	chr2:10619023	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.753	rs2018512	ENSG00000243819.4	RN7SL832P	3.86	0.000131	0.0176	0.18	0.17	Prostate cancer;	chr2:10619153	chr2:10690344~10692099:+
LUAD	cis	rs755249	0.517	rs56809193	ENSG00000182109.6	RP11-69E11.4	3.86	0.000131	0.0176	0.23	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39143626	chr1:39522280~39546187:-
LUAD	cis	rs3805389	0.504	rs59571323	ENSG00000273257.1	RP11-177J6.1	-3.86	0.000131	0.0176	-0.27	-0.17	Waist-to-hip ratio adjusted for body mass index;	chr4:55611187	chr4:55387949~55388271:+
LUAD	cis	rs13434995	0.838	rs57178140	ENSG00000273257.1	RP11-177J6.1	-3.86	0.000131	0.0176	-0.27	-0.17	Adiponectin levels;	chr4:55611361	chr4:55387949~55388271:+
LUAD	cis	rs6502050	0.835	rs7208673	ENSG00000266654.1	RP11-1376P16.1	-3.86	0.000131	0.0176	-0.19	-0.17	Life satisfaction;	chr17:82208032	chr17:82160056~82160452:+
LUAD	cis	rs5762752	0.521	rs695709	ENSG00000272858.1	CTA-292E10.8	-3.86	0.000131	0.0176	-0.18	-0.17	Optic disc area;	chr22:28516867	chr22:28814914~28815662:+
LUAD	cis	rs7208859	0.615	rs216462	ENSG00000263603.1	CTD-2349P21.5	3.86	0.000131	0.0176	0.31	0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30568879	chr17:30729469~30731202:+
LUAD	cis	rs6001482	0.533	rs5757621	ENSG00000223350.2	IGLV9-49	-3.86	0.000131	0.0177	-0.2	-0.17	Diastolic blood pressure;	chr22:22240976	chr22:22343187~22343732:+
LUAD	cis	rs2115630	0.967	rs11073702	ENSG00000259728.4	LINC00933	-3.86	0.000131	0.0177	-0.21	-0.17	P wave terminal force;	chr15:84766840	chr15:84570649~84580175:+
LUAD	cis	rs7772486	0.79	rs6923545	ENSG00000235652.6	RP11-545I5.3	-3.86	0.000131	0.0177	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145923607	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.754	rs6922507	ENSG00000235652.6	RP11-545I5.3	-3.86	0.000131	0.0177	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145929019	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.79	rs4075694	ENSG00000235652.6	RP11-545I5.3	-3.86	0.000131	0.0177	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145929972	chr6:145799409~145886585:+
LUAD	cis	rs11671005	0.736	rs11668201	ENSG00000268912.1	CTD-2619J13.17	-3.86	0.000131	0.0177	-0.23	-0.17	Mean platelet volume;	chr19:58492265	chr19:58428632~58431148:-
LUAD	cis	rs8141529	0.764	rs5762854	ENSG00000272858.1	CTA-292E10.8	-3.86	0.000131	0.0177	-0.19	-0.17	Lymphocyte counts;	chr22:28850290	chr22:28814914~28815662:+
LUAD	cis	rs6781182	0.535	rs13066843	ENSG00000236452.1	AC123023.1	3.86	0.000131	0.0177	0.2	0.17	Visceral adipose tissue adjusted for BMI;	chr3:34190845	chr3:34203244~34268811:+
LUAD	cis	rs7116495	0.609	rs1791449	ENSG00000254682.1	RP11-660L16.2	-3.86	0.000131	0.0177	-0.37	-0.17	Severe influenza A (H1N1) infection;	chr11:71868616	chr11:71448674~71452157:+
LUAD	cis	rs6661961	0.752	rs1923496	ENSG00000237975.5	FLG-AS1	3.86	0.000131	0.0177	0.23	0.17	Atopic dermatitis;	chr1:152452372	chr1:152168125~152445456:+
LUAD	cis	rs2625529	0.607	rs2912231	ENSG00000260173.1	RP11-2I17.4	-3.86	0.000131	0.0177	-0.23	-0.17	Red blood cell count;	chr15:72275616	chr15:72140504~72155459:-
LUAD	cis	rs7142881	0.815	rs35427690	ENSG00000258525.1	RP11-829H16.3	-3.86	0.000131	0.0177	-0.2	-0.17	Response to iloperidone treatment (QT prolongation);	chr14:31695618	chr14:30876179~30889808:-
LUAD	cis	rs2554380	0.891	rs2554383	ENSG00000230373.7	GOLGA6L5P	-3.86	0.000131	0.0177	-0.22	-0.17	Height;	chr15:83687564	chr15:84507885~84516814:-
LUAD	cis	rs6840360	0.642	rs7666571	ENSG00000270265.1	RP11-731D1.4	-3.86	0.000131	0.0177	-0.18	-0.17	Intelligence (multi-trait analysis);	chr4:151522121	chr4:151333775~151353224:-
LUAD	cis	rs8028182	0.636	rs4564532	ENSG00000246877.1	DNM1P35	3.86	0.000131	0.0177	0.22	0.17	Sudden cardiac arrest;	chr15:75413955	chr15:75727670~75738623:-
LUAD	cis	rs801193	1	rs62466793	ENSG00000222364.1	RNU6-96P	-3.86	0.000131	0.0177	-0.19	-0.17	Aortic root size;	chr7:66726530	chr7:66395191~66395286:+
LUAD	cis	rs2278702	0.943	rs77271632	ENSG00000259495.2	RP11-210M15.2	-3.86	0.000131	0.0177	-0.28	-0.17	Bipolar disorder;	chr15:80396735	chr15:80344853~80403575:-
LUAD	cis	rs4907240	0.883	rs11678174	ENSG00000237510.6	AC008268.2	-3.86	0.000131	0.0177	-0.25	-0.17	Event-related brain oscillations;	chr2:96583366	chr2:95789654~95800166:+
LUAD	cis	rs6964587	1	rs2961020	ENSG00000188693.7	CYP51A1-AS1	3.86	0.000131	0.0177	0.21	0.17	Breast cancer;	chr7:91943994	chr7:92134604~92180725:+
LUAD	cis	rs12413361	0.967	rs10826875	ENSG00000272914.1	RP11-330O11.3	-3.86	0.000131	0.0177	-0.2	-0.17	Height;	chr10:30830785	chr10:30831828~30833387:-
LUAD	cis	rs7637701	0.967	rs6784421	ENSG00000240875.4	LINC00886	-3.86	0.000131	0.0177	-0.19	-0.17	Breast cancer;	chr3:156937705	chr3:156747346~156817062:-
LUAD	cis	rs4713118	0.955	rs9468203	ENSG00000280107.1	AL022393.9	-3.86	0.000131	0.0177	-0.21	-0.17	Parkinson's disease;	chr6:27720888	chr6:28170845~28172521:+
LUAD	cis	rs9900280	1	rs1712652	ENSG00000264808.1	RP11-802D6.1	-3.86	0.000131	0.0177	-0.21	-0.17	Mean platelet volume;	chr17:29342515	chr17:29369717~29390777:-
LUAD	cis	rs9900280	1	rs8064434	ENSG00000264808.1	RP11-802D6.1	3.86	0.000131	0.0177	0.21	0.17	Mean platelet volume;	chr17:29344359	chr17:29369717~29390777:-
LUAD	cis	rs9900280	1	rs11651639	ENSG00000264808.1	RP11-802D6.1	3.86	0.000131	0.0177	0.21	0.17	Mean platelet volume;	chr17:29345302	chr17:29369717~29390777:-
LUAD	cis	rs9900280	1	rs9901247	ENSG00000264808.1	RP11-802D6.1	3.86	0.000131	0.0177	0.21	0.17	Mean platelet volume;	chr17:29345625	chr17:29369717~29390777:-
LUAD	cis	rs853679	0.517	rs9393896	ENSG00000280107.1	AL022393.9	-3.86	0.000131	0.0177	-0.23	-0.17	Depression;	chr6:28159925	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs9393897	ENSG00000280107.1	AL022393.9	-3.86	0.000131	0.0177	-0.23	-0.17	Depression;	chr6:28159932	chr6:28170845~28172521:+
LUAD	cis	rs2638953	0.962	rs11049621	ENSG00000278733.1	RP11-425D17.1	-3.86	0.000131	0.0177	-0.2	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28456074	chr12:28185625~28186190:-
LUAD	cis	rs6832769	0.885	rs6815516	ENSG00000272969.1	RP11-528I4.2	-3.86	0.000131	0.0177	-0.18	-0.17	Personality dimensions;	chr4:55533017	chr4:55547112~55547889:+
LUAD	cis	rs7618915	0.547	rs11130323	ENSG00000243224.1	RP5-1157M23.2	-3.86	0.000131	0.0177	-0.18	-0.17	Bipolar disorder;	chr3:52736261	chr3:52239258~52241097:+
LUAD	cis	rs4237845	0.742	rs3751330	ENSG00000245651.2	RP11-620J15.2	3.86	0.000131	0.0177	0.17	0.17	Intelligence (multi-trait analysis);	chr12:57896443	chr12:57869835~57896482:-
LUAD	cis	rs6540731	1	rs6540731	ENSG00000229983.1	RP11-15I11.2	-3.86	0.000131	0.0177	-0.2	-0.17	Intelligence (childhood);	chr1:212218821	chr1:212168207~212190259:+
LUAD	cis	rs1431005	0.893	rs68010462	ENSG00000250658.1	RP11-138B4.1	3.86	0.000131	0.0177	0.22	0.17	Response to statin therapy;	chr4:187418181	chr4:187304083~187309682:-
LUAD	cis	rs28374715	0.681	rs8037574	ENSG00000247556.5	OIP5-AS1	3.86	0.000131	0.0177	0.21	0.17	Ulcerative colitis;	chr15:41338572	chr15:41283990~41309737:+
LUAD	cis	rs9467773	0.649	rs2145318	ENSG00000124549.13	BTN2A3P	3.86	0.000131	0.0177	0.16	0.17	Intelligence (multi-trait analysis);	chr6:26496375	chr6:26421391~26432383:+
LUAD	cis	rs4499344	0.556	rs259220	ENSG00000201388.1	SNORA68	3.86	0.000131	0.0177	0.2	0.17	Mean platelet volume;	chr19:32646723	chr19:32608337~32608469:-
LUAD	cis	rs728616	0.867	rs61860034	ENSG00000234382.2	RP11-40F6.1	-3.86	0.000131	0.0177	-0.44	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80172092	chr10:80233664~80245367:+
LUAD	cis	rs2274273	0.87	rs2016931	ENSG00000259318.1	RP11-454L9.2	3.86	0.000131	0.0177	0.15	0.17	Protein biomarker;	chr14:55375614	chr14:55394940~55395233:-
LUAD	cis	rs2273788	0.527	rs4978448	ENSG00000204173.9	LRRC37A5P	3.86	0.000131	0.0177	0.18	0.17	Monocyte count;	chr9:111580861	chr9:111602831~111631289:-
LUAD	cis	rs12754538	0.778	rs61787660	ENSG00000232912.4	RP5-1115A15.1	3.86	0.000131	0.0177	0.19	0.17	Subjective well-being;	chr1:8369164	chr1:8424645~8434838:+
LUAD	cis	rs9309473	0.5	rs11126402	ENSG00000163016.8	ALMS1P	3.86	0.000131	0.0177	0.19	0.17	Metabolite levels;	chr2:73549455	chr2:73644919~73685576:+
LUAD	cis	rs6071166	0.683	rs1475095	ENSG00000224635.1	RP4-564F22.5	-3.86	0.000131	0.0177	-0.19	-0.17	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38684071	chr20:38406011~38416797:-
LUAD	cis	rs7819412	0.645	rs10156356	ENSG00000255046.1	RP11-297N6.4	3.86	0.000131	0.0177	0.21	0.17	Triglycerides;	chr8:11188700	chr8:11797928~11802568:-
LUAD	cis	rs8050896	0.793	rs77806981	ENSG00000260695.1	RP11-513N24.1	-3.86	0.000131	0.0177	-0.37	-0.17	Response to antipsychotic treatment;	chr16:66128275	chr16:65861112~65863784:-
LUAD	cis	rs2735413	0.564	rs73574780	ENSG00000276007.1	RP11-358L22.3	3.85	0.000131	0.0177	0.23	0.17	Systolic blood pressure (alcohol consumption interaction);	chr16:78054207	chr16:78123243~78124332:+
LUAD	cis	rs6871536	1	rs56798121	ENSG00000233006.5	AC034220.3	-3.85	0.000131	0.0177	-0.2	-0.17	Asthma (childhood onset);	chr5:132589482	chr5:132311285~132369916:-
LUAD	cis	rs2749592	0.513	rs1208708	ENSG00000273019.1	RP11-508N22.13	-3.85	0.000132	0.0177	-0.2	-0.17	Age-related hearing impairment (SNP x SNP interaction);	chr10:37796648	chr10:38149968~38150293:+
LUAD	cis	rs2255336	0.657	rs11053765	ENSG00000245648.1	RP11-277P12.20	3.85	0.000132	0.0177	0.31	0.17	Blood protein levels;	chr12:10351365	chr12:10363769~10398506:+
LUAD	cis	rs10829156	0.66	rs7918933	ENSG00000240291.1	RP11-499P20.2	3.85	0.000132	0.0177	0.15	0.17	Sudden cardiac arrest;	chr10:18517434	chr10:18513115~18545651:-
LUAD	cis	rs7617773	0.78	rs77044321	ENSG00000199476.1	Y_RNA	-3.85	0.000132	0.0177	-0.23	-0.17	Coronary artery disease;	chr3:48307824	chr3:48288587~48288694:+
LUAD	cis	rs2836974	0.931	rs2776309	ENSG00000232608.1	TIMM9P2	-3.85	0.000132	0.0177	-0.22	-0.17	Cognitive function;	chr21:39343865	chr21:39216624~39217506:+
LUAD	cis	rs28386778	0.897	rs11654841	ENSG00000240280.5	TCAM1P	-3.85	0.000132	0.0177	-0.2	-0.17	Prudent dietary pattern;	chr17:63760899	chr17:63849292~63864379:+
LUAD	cis	rs5015933	0.902	rs1969045	ENSG00000232630.1	PRPS1P2	-3.85	0.000132	0.0177	-0.16	-0.17	Body mass index;	chr9:125368261	chr9:125150653~125151589:+
LUAD	cis	rs453301	0.571	rs2929453	ENSG00000253981.4	ALG1L13P	-3.85	0.000132	0.0177	-0.2	-0.17	Joint mobility (Beighton score);	chr8:9226831	chr8:8236003~8244667:-
LUAD	cis	rs4118325	0.734	rs1335057	ENSG00000224550.1	RP11-270C12.3	-3.85	0.000132	0.0177	-0.21	-0.17	AIDS;	chr1:107089732	chr1:107505203~107505448:+
LUAD	cis	rs4118325	0.734	rs1730848	ENSG00000224550.1	RP11-270C12.3	-3.85	0.000132	0.0177	-0.21	-0.17	AIDS;	chr1:107089774	chr1:107505203~107505448:+
LUAD	cis	rs73198271	0.74	rs67766414	ENSG00000253893.2	FAM85B	3.85	0.000132	0.0177	0.23	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8792023	chr8:8167819~8226614:-
LUAD	cis	rs7061710	0.871	rs11812061	ENSG00000271811.1	RP1-79C4.4	-3.85	0.000132	0.0177	-0.25	-0.17	Blood metabolite levels;	chr1:171146506	chr1:170667381~170669425:+
LUAD	cis	rs7172677	0.737	rs6495154	ENSG00000260269.4	CTD-2323K18.1	-3.85	0.000132	0.0177	-0.22	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75144921	chr15:75527150~75601205:-
LUAD	cis	rs7172677	0.737	rs12442410	ENSG00000260269.4	CTD-2323K18.1	-3.85	0.000132	0.0177	-0.22	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75145169	chr15:75527150~75601205:-
LUAD	cis	rs7172677	0.737	rs12910348	ENSG00000260269.4	CTD-2323K18.1	-3.85	0.000132	0.0177	-0.22	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75145301	chr15:75527150~75601205:-
LUAD	cis	rs304029	0.512	rs56269779	ENSG00000231249.1	ITPR1-AS1	-3.85	0.000132	0.0177	-0.21	-0.17	Diabetic kidney disease;	chr3:4503408	chr3:4490891~4493163:-
LUAD	cis	rs585510	1	rs585510	ENSG00000278344.1	RP11-18C24.8	3.85	0.000132	0.0177	0.23	0.17	Reticulocyte fraction of red cells;	chr12:120562330	chr12:120500735~120501090:-
LUAD	cis	rs4144027	0.791	rs11160770	ENSG00000258914.1	CTD-2134A5.3	-3.85	0.000132	0.0177	-0.2	-0.17	Blood metabolite levels;	chr14:103895954	chr14:103875055~103877478:+
LUAD	cis	rs2613964	0.504	rs9288972	ENSG00000244144.1	RP11-757F18.3	3.85	0.000132	0.0177	0.2	0.17	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113131422	chr3:112185480~112185998:-
LUAD	cis	rs2613964	0.504	rs9838215	ENSG00000244144.1	RP11-757F18.3	3.85	0.000132	0.0177	0.2	0.17	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113131616	chr3:112185480~112185998:-
LUAD	cis	rs2613964	0.504	rs9838253	ENSG00000244144.1	RP11-757F18.3	3.85	0.000132	0.0177	0.2	0.17	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113131678	chr3:112185480~112185998:-
LUAD	cis	rs2613964	0.504	rs17317945	ENSG00000244144.1	RP11-757F18.3	3.85	0.000132	0.0177	0.2	0.17	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113131934	chr3:112185480~112185998:-
LUAD	cis	rs2613964	0.504	rs12695288	ENSG00000244144.1	RP11-757F18.3	3.85	0.000132	0.0177	0.2	0.17	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113132668	chr3:112185480~112185998:-
LUAD	cis	rs7968440	1	rs2731442	ENSG00000272368.2	RP4-605O3.4	3.85	0.000132	0.0177	0.2	0.17	Fibrinogen;	chr12:50660872	chr12:50112197~50165618:+
LUAD	cis	rs2348418	0.864	rs2175464	ENSG00000247934.4	RP11-967K21.1	-3.85	0.000132	0.0177	-0.19	-0.17	Lung function (FEV1);Lung function (FVC);	chr12:28564178	chr12:28163298~28190738:-
LUAD	cis	rs8050896	1	rs78582984	ENSG00000260695.1	RP11-513N24.1	-3.85	0.000132	0.0177	-0.36	-0.17	Response to antipsychotic treatment;	chr16:66124160	chr16:65861112~65863784:-
LUAD	cis	rs12935418	0.616	rs2602446	ENSG00000261061.1	RP11-303E16.2	3.85	0.000132	0.0177	0.18	0.17	Mean corpuscular volume;	chr16:80984310	chr16:81030770~81031485:+
LUAD	cis	rs11673344	0.523	rs17206540	ENSG00000276846.1	CTD-3220F14.3	3.85	0.000132	0.0177	0.19	0.17	Obesity-related traits;	chr19:37069009	chr19:37314868~37315620:-
LUAD	cis	rs11064837	0.504	rs7311445	ENSG00000248636.5	RP11-768F21.1	3.85	0.000132	0.0177	0.2	0.17	Schizophrenia;	chr12:119616292	chr12:119387987~119668079:-
LUAD	cis	rs78905543	0.967	rs4242388	ENSG00000253616.4	RP11-875O11.3	3.85	0.000132	0.0177	0.21	0.17	Mean corpuscular volume;	chr8:23075198	chr8:23071377~23074488:-
LUAD	cis	rs12534093	0.67	rs13229167	ENSG00000234286.1	AC006026.13	-3.85	0.000132	0.0177	-0.25	-0.17	Infant length;Height;	chr7:23552243	chr7:23680195~23680786:-
LUAD	cis	rs1334894	1	rs58062737	ENSG00000228559.1	RP3-340B19.3	-3.85	0.000132	0.0177	-0.29	-0.17	Coronary artery disease;	chr6:35559780	chr6:35544632~35545669:+
LUAD	cis	rs4865762	0.514	rs30093	ENSG00000272416.1	CTD-2081C10.7	-3.85	0.000132	0.0177	-0.19	-0.17	Intraocular pressure;	chr5:53127408	chr5:53880293~53881051:-
LUAD	cis	rs3026445	0.821	rs28637922	ENSG00000278993.1	RP3-424M6.4	3.85	0.000132	0.0178	0.19	0.17	QT interval;	chr12:110381334	chr12:110501614~110503441:+
LUAD	cis	rs73198271	0.599	rs10103169	ENSG00000253893.2	FAM85B	3.85	0.000132	0.0178	0.23	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793188	chr8:8167819~8226614:-
LUAD	cis	rs73198271	0.7	rs10103282	ENSG00000253893.2	FAM85B	3.85	0.000132	0.0178	0.23	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8793247	chr8:8167819~8226614:-
LUAD	cis	rs11512640	0.826	rs74878577	ENSG00000254671.2	STT3A-AS1	3.85	0.000132	0.0178	0.41	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125493917	chr11:125570284~125592568:-
LUAD	cis	rs9309473	0.5	rs2421664	ENSG00000163016.8	ALMS1P	-3.85	0.000132	0.0178	-0.19	-0.17	Metabolite levels;	chr2:73631754	chr2:73644919~73685576:+
LUAD	cis	rs10463554	0.927	rs158396	ENSG00000250682.4	LINC00491	3.85	0.000132	0.0178	0.21	0.17	Parkinson's disease;	chr5:103076015	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.892	rs158401	ENSG00000250682.4	LINC00491	3.85	0.000132	0.0178	0.21	0.17	Parkinson's disease;	chr5:103079764	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.927	rs257304	ENSG00000250682.4	LINC00491	3.85	0.000132	0.0178	0.21	0.17	Parkinson's disease;	chr5:103081114	chr5:102609156~102671559:-
LUAD	cis	rs67981189	0.529	rs17093738	ENSG00000269927.1	RP6-91H8.3	3.85	0.000132	0.0178	0.23	0.17	Schizophrenia;	chr14:71119931	chr14:71141125~71143253:-
LUAD	cis	rs13434995	0.562	rs73236140	ENSG00000273257.1	RP11-177J6.1	-3.85	0.000132	0.0178	-0.23	-0.17	Adiponectin levels;	chr4:55440049	chr4:55387949~55388271:+
LUAD	cis	rs13434995	0.513	rs62303691	ENSG00000273257.1	RP11-177J6.1	-3.85	0.000132	0.0178	-0.23	-0.17	Adiponectin levels;	chr4:55442085	chr4:55387949~55388271:+
LUAD	cis	rs11742741	1	rs72745787	ENSG00000248874.4	C5orf17	-3.85	0.000132	0.0178	-0.21	-0.17	Educational attainment;	chr5:24147359	chr5:23951348~24178263:+
LUAD	cis	rs11742741	1	rs11749981	ENSG00000248874.4	C5orf17	-3.85	0.000132	0.0178	-0.21	-0.17	Educational attainment;	chr5:24148460	chr5:23951348~24178263:+
LUAD	cis	rs4767841	0.904	rs278110	ENSG00000248636.5	RP11-768F21.1	-3.85	0.000132	0.0178	-0.2	-0.17	Urgency urinary incontinence;	chr12:119734722	chr12:119387987~119668079:-
LUAD	cis	rs8180040	0.966	rs11130128	ENSG00000271161.1	BOLA2P2	-3.85	0.000132	0.0178	-0.17	-0.17	Colorectal cancer;	chr3:47445142	chr3:47499841~47500407:+
LUAD	cis	rs8180040	0.966	rs11130129	ENSG00000271161.1	BOLA2P2	-3.85	0.000132	0.0178	-0.17	-0.17	Colorectal cancer;	chr3:47448395	chr3:47499841~47500407:+
LUAD	cis	rs8028182	0.636	rs4564532	ENSG00000260269.4	CTD-2323K18.1	-3.85	0.000132	0.0178	-0.24	-0.17	Sudden cardiac arrest;	chr15:75413955	chr15:75527150~75601205:-
LUAD	cis	rs9894429	0.634	rs9709130	ENSG00000263853.1	AC139530.1	-3.85	0.000132	0.0178	-0.18	-0.17	Eye color traits;	chr17:81616922	chr17:81676001~81676086:+
LUAD	cis	rs4925386	0.84	rs6143035	ENSG00000273619.1	RP5-908M14.9	3.85	0.000132	0.0178	0.17	0.17	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62345644	chr20:62386303~62386970:-
LUAD	cis	rs896854	0.516	rs12679044	ENSG00000253528.2	RP11-347C18.4	3.85	0.000132	0.0178	0.17	0.17	Type 2 diabetes;	chr8:94879128	chr8:94974573~94974853:-
LUAD	cis	rs9896933	0.615	rs2379354	ENSG00000262663.1	RP11-497H17.1	3.85	0.000132	0.0178	0.21	0.17	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr17:82746509	chr17:82918282~82918785:+
LUAD	cis	rs7580658	0.963	rs12052483	ENSG00000236682.1	AC068282.3	-3.85	0.000132	0.0178	-0.23	-0.17	Protein C levels;	chr2:127379244	chr2:127389130~127400580:+
LUAD	cis	rs7580658	0.963	rs9789510	ENSG00000236682.1	AC068282.3	-3.85	0.000132	0.0178	-0.23	-0.17	Protein C levels;	chr2:127379436	chr2:127389130~127400580:+
LUAD	cis	rs7580658	0.926	rs4662725	ENSG00000236682.1	AC068282.3	-3.85	0.000132	0.0178	-0.23	-0.17	Protein C levels;	chr2:127383744	chr2:127389130~127400580:+
LUAD	cis	rs6121246	0.609	rs6060627	ENSG00000230613.1	HM13-AS1	3.85	0.000132	0.0178	0.21	0.17	Mean corpuscular hemoglobin;	chr20:31674356	chr20:31567707~31573263:-
LUAD	cis	rs71007656	1	rs71007656	ENSG00000273019.1	RP11-508N22.13	-3.85	0.000132	0.0178	-0.2	-0.17	Extrinsic epigenetic age acceleration;	chr10:37681922	chr10:38149968~38150293:+
LUAD	cis	rs7714584	1	rs6862814	ENSG00000197083.10	ZNF300P1	3.85	0.000132	0.0178	0.32	0.17	Crohn's disease;	chr5:150865697	chr5:150930645~150946289:-
LUAD	cis	rs4499344	0.73	rs2545357	ENSG00000201388.1	SNORA68	3.85	0.000132	0.0178	0.18	0.17	Mean platelet volume;	chr19:32613704	chr19:32608337~32608469:-
LUAD	cis	rs4908769	0.624	rs301796	ENSG00000232912.4	RP5-1115A15.1	3.85	0.000132	0.0178	0.16	0.17	Allergy;	chr1:8406670	chr1:8424645~8434838:+
LUAD	cis	rs4908769	0.587	rs301795	ENSG00000232912.4	RP5-1115A15.1	3.85	0.000132	0.0178	0.16	0.17	Allergy;	chr1:8407293	chr1:8424645~8434838:+
LUAD	cis	rs4908769	0.624	rs301789	ENSG00000232912.4	RP5-1115A15.1	3.85	0.000132	0.0178	0.16	0.17	Allergy;	chr1:8409277	chr1:8424645~8434838:+
LUAD	cis	rs2115630	0.936	rs11073663	ENSG00000259728.4	LINC00933	-3.85	0.000132	0.0178	-0.21	-0.17	P wave terminal force;	chr15:84717037	chr15:84570649~84580175:+
LUAD	cis	rs2688608	0.901	rs2459446	ENSG00000271816.1	BMS1P4	-3.85	0.000132	0.0178	-0.15	-0.17	Inflammatory bowel disease;	chr10:73841838	chr10:73699151~73730487:-
LUAD	cis	rs7061710	0.871	rs72712685	ENSG00000271811.1	RP1-79C4.4	-3.85	0.000132	0.0178	-0.25	-0.17	Blood metabolite levels;	chr1:171146344	chr1:170667381~170669425:+
LUAD	cis	rs7061710	0.871	rs11812044	ENSG00000271811.1	RP1-79C4.4	-3.85	0.000132	0.0178	-0.25	-0.17	Blood metabolite levels;	chr1:171146428	chr1:170667381~170669425:+
LUAD	cis	rs9435732	0.62	rs12045097	ENSG00000215908.6	CROCCP2	-3.85	0.000132	0.0178	-0.17	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:17019382	chr1:16618262~16644683:-
LUAD	cis	rs287982	0.611	rs79083459	ENSG00000269973.1	RP11-95D17.1	-3.85	0.000132	0.0178	-0.25	-0.17	Nonsyndromic cleft lip with cleft palate;	chr2:9838286	chr2:9936360~9939590:+
LUAD	cis	rs287982	0.611	rs78401890	ENSG00000269973.1	RP11-95D17.1	-3.85	0.000132	0.0178	-0.25	-0.17	Nonsyndromic cleft lip with cleft palate;	chr2:9838332	chr2:9936360~9939590:+
LUAD	cis	rs240993	0.516	rs181294	ENSG00000271789.1	RP5-1112D6.7	-3.85	0.000132	0.0178	-0.23	-0.17	Inflammatory skin disease;Psoriasis;	chr6:111298999	chr6:111297126~111298510:+
LUAD	cis	rs911555	0.504	rs8021368	ENSG00000258851.1	RP11-894P9.2	-3.85	0.000132	0.0178	-0.2	-0.17	Intelligence (multi-trait analysis);	chr14:103608473	chr14:103553421~103561877:+
LUAD	cis	rs13434995	0.513	rs2412658	ENSG00000273257.1	RP11-177J6.1	3.85	0.000132	0.0178	0.23	0.17	Adiponectin levels;	chr4:55577050	chr4:55387949~55388271:+
LUAD	cis	rs28510890	0.789	rs10852176	ENSG00000260337.3	RP11-386M24.6	3.85	0.000132	0.0178	0.22	0.17	Lung cancer in ever smokers;	chr15:92588701	chr15:92592574~92596462:-
LUAD	cis	rs3770081	0.59	rs12622715	ENSG00000273080.1	RP11-301O19.1	-3.85	0.000132	0.0178	-0.39	-0.17	Facial emotion recognition (sad faces);	chr2:86226440	chr2:86195590~86196049:+
LUAD	cis	rs2486288	0.656	rs11637838	ENSG00000259479.5	SORD2P	-3.85	0.000132	0.0178	-0.21	-0.17	Glomerular filtration rate;	chr15:45258459	chr15:44826371~44884694:-
LUAD	cis	rs13108904	0.557	rs1680030	ENSG00000196810.4	CTBP1-AS2	-3.85	0.000133	0.0178	-0.22	-0.17	Obesity-related traits;	chr4:1251712	chr4:1249300~1288291:+
LUAD	cis	rs9341808	0.6	rs590641	ENSG00000272129.1	RP11-250B2.6	3.85	0.000133	0.0178	0.21	0.17	Sitting height ratio;	chr6:80256766	chr6:80355424~80356859:+
LUAD	cis	rs12681366	0.801	rs2919668	ENSG00000254057.1	RP3-388N13.3	3.85	0.000133	0.0178	0.19	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94449193	chr8:93834454~93846743:-
LUAD	cis	rs3213758	0.541	rs7200859	ENSG00000275191.1	RP11-36I17.2	-3.85	0.000133	0.0178	-0.26	-0.17	Vitiligo (non-segmental);	chr16:53634663	chr16:53628256~53628816:-
LUAD	cis	rs7772486	0.79	rs4435956	ENSG00000235652.6	RP11-545I5.3	-3.85	0.000133	0.0178	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145911267	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.79	rs6926076	ENSG00000235652.6	RP11-545I5.3	-3.85	0.000133	0.0178	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145911668	chr6:145799409~145886585:+
LUAD	cis	rs9467773	0.62	rs2494700	ENSG00000241549.7	GUSBP2	3.85	0.000133	0.0178	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26631078	chr6:26871484~26956554:-
LUAD	cis	rs9467773	0.584	rs1021372	ENSG00000241549.7	GUSBP2	3.85	0.000133	0.0178	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26632216	chr6:26871484~26956554:-
LUAD	cis	rs9467773	0.583	rs1021373	ENSG00000241549.7	GUSBP2	3.85	0.000133	0.0178	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26632229	chr6:26871484~26956554:-
LUAD	cis	rs9467773	0.62	rs2451744	ENSG00000241549.7	GUSBP2	3.85	0.000133	0.0178	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26633235	chr6:26871484~26956554:-
LUAD	cis	rs9467773	0.62	rs2494701	ENSG00000241549.7	GUSBP2	3.85	0.000133	0.0178	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26634204	chr6:26871484~26956554:-
LUAD	cis	rs9467773	0.62	rs1027204	ENSG00000241549.7	GUSBP2	3.85	0.000133	0.0178	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26639385	chr6:26871484~26956554:-
LUAD	cis	rs13113518	1	rs4864542	ENSG00000273257.1	RP11-177J6.1	-3.85	0.000133	0.0178	-0.19	-0.17	Height;	chr4:55487920	chr4:55387949~55388271:+
LUAD	cis	rs4713118	0.539	rs510987	ENSG00000280107.1	AL022393.9	-3.85	0.000133	0.0179	-0.21	-0.17	Parkinson's disease;	chr6:27879739	chr6:28170845~28172521:+
LUAD	cis	rs34435647	1	rs34435647	ENSG00000230783.1	AC009961.2	-3.85	0.000133	0.0179	-0.21	-0.17	Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;	chr2:159661779	chr2:159689217~159690291:-
LUAD	cis	rs9309473	0.519	rs35421685	ENSG00000163016.8	ALMS1P	-3.85	0.000133	0.0179	-0.18	-0.17	Metabolite levels;	chr2:73683011	chr2:73644919~73685576:+
LUAD	cis	rs2304003	0.561	rs1465678	ENSG00000235192.1	AC009495.2	3.85	0.000133	0.0179	0.19	0.17	Social communication problems;	chr2:165804360	chr2:165794851~165810010:+
LUAD	cis	rs17407555	0.789	rs12648610	ENSG00000250413.1	RP11-448G15.1	3.85	0.000133	0.0179	0.24	0.17	Schizophrenia (age at onset);	chr4:10113188	chr4:10006482~10009725:+
LUAD	cis	rs6502050	0.835	rs4789751	ENSG00000275966.1	RP11-1055B8.9	-3.85	0.000133	0.0179	-0.18	-0.17	Life satisfaction;	chr17:82134497	chr17:81345476~81345966:-
LUAD	cis	rs801193	0.591	rs9986881	ENSG00000230295.1	RP11-458F8.2	3.85	0.000133	0.0179	0.14	0.17	Aortic root size;	chr7:66708053	chr7:66880708~66882981:+
LUAD	cis	rs17818399	0.547	rs7607308	ENSG00000279254.1	RP11-536C12.1	-3.85	0.000133	0.0179	-0.2	-0.17	Height;	chr2:46531965	chr2:46668870~46670778:+
LUAD	cis	rs13256369	0.95	rs1522839	ENSG00000253893.2	FAM85B	-3.85	0.000133	0.0179	-0.24	-0.17	Obesity-related traits;	chr8:8722943	chr8:8167819~8226614:-
LUAD	cis	rs10145110	1	rs28549828	ENSG00000258521.1	RP11-638I2.9	3.85	0.000133	0.0179	0.35	0.17	Amyotrophic lateral sclerosis (sporadic);	chr14:101017687	chr14:100339832~100340554:+
LUAD	cis	rs73198271	0.71	rs7837843	ENSG00000253893.2	FAM85B	3.85	0.000133	0.0179	0.22	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8798975	chr8:8167819~8226614:-
LUAD	cis	rs73198271	0.64	rs7838012	ENSG00000253893.2	FAM85B	3.85	0.000133	0.0179	0.22	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8799120	chr8:8167819~8226614:-
LUAD	cis	rs5770917	0.522	rs3752393	ENSG00000273272.1	CTA-384D8.34	3.85	0.000133	0.0179	0.32	0.17	Narcolepsy;	chr22:50577128	chr22:50542650~50543011:+
LUAD	cis	rs13108904	0.935	rs4974575	ENSG00000196810.4	CTBP1-AS2	3.85	0.000133	0.0179	0.2	0.17	Obesity-related traits;	chr4:1258240	chr4:1249300~1288291:+
LUAD	cis	rs9341808	0.667	rs2505944	ENSG00000260645.1	RP11-250B2.5	3.85	0.000133	0.0179	0.16	0.17	Sitting height ratio;	chr6:80178693	chr6:80466958~80469080:+
LUAD	cis	rs2823962	0.927	rs2017275	ENSG00000270093.1	AP000473.8	-3.85	0.000133	0.0179	-0.18	-0.17	Amyotrophic lateral sclerosis;	chr21:16655071	chr21:16643529~16645065:+
LUAD	cis	rs9341808	0.935	rs2322633	ENSG00000272129.1	RP11-250B2.6	-3.85	0.000133	0.0179	-0.2	-0.17	Sitting height ratio;	chr6:80136272	chr6:80355424~80356859:+
LUAD	cis	rs67478160	0.704	rs12894254	ENSG00000272533.1	SNORA28	3.85	0.000133	0.0179	0.18	0.17	Schizophrenia;	chr14:103824612	chr14:103337849~103337974:+
LUAD	cis	rs910316	0.763	rs13712	ENSG00000259138.1	RP11-950C14.7	3.85	0.000133	0.0179	0.18	0.17	Height;	chr14:75017109	chr14:75127153~75136930:+
LUAD	cis	rs4474465	0.646	rs10793334	ENSG00000251323.2	RP11-452H21.4	3.85	0.000133	0.0179	0.21	0.17	Alzheimer's disease (survival time);	chr11:78567746	chr11:78423982~78429836:-
LUAD	cis	rs2273156	0.929	rs8017225	ENSG00000226677.3	IGBP1P1	-3.85	0.000133	0.0179	-0.24	-0.17	Immunoglobulin light chain (AL) amyloidosis;	chr14:35000843	chr14:34939324~34940332:+
LUAD	cis	rs564309	0.681	rs7513530	ENSG00000269934.1	RP5-1139B12.3	-3.85	0.000133	0.0179	-0.25	-0.17	Hip circumference (psychosocial stress interaction);	chr1:228431382	chr1:228274584~228276066:-
LUAD	cis	rs6496932	0.503	rs10220820	ENSG00000259630.2	CTD-2262B20.1	-3.85	0.000133	0.0179	-0.22	-0.17	Central corneal thickness;Corneal structure;	chr15:85441932	chr15:85415228~85415633:+
LUAD	cis	rs12440869	1	rs10438290	ENSG00000270964.1	RP11-502I4.3	-3.85	0.000133	0.0179	-0.2	-0.17	Peak velocity of the mitral A-wave;	chr15:67304477	chr15:67541072~67542604:-
LUAD	cis	rs12440869	1	rs11071947	ENSG00000270964.1	RP11-502I4.3	-3.85	0.000133	0.0179	-0.2	-0.17	Peak velocity of the mitral A-wave;	chr15:67313329	chr15:67541072~67542604:-
LUAD	cis	rs8014204	0.836	rs11159099	ENSG00000279594.1	RP11-950C14.10	3.85	0.000133	0.0179	0.2	0.17	Caffeine consumption;	chr14:74768694	chr14:75011269~75012851:-
LUAD	cis	rs2657294	0.765	rs2804533	ENSG00000226051.5	ZNF503-AS1	-3.85	0.000133	0.0179	-0.23	-0.17	Pneumonia;	chr10:75207723	chr10:75269819~75373500:+
LUAD	cis	rs6871536	1	rs11749376	ENSG00000233006.5	AC034220.3	-3.85	0.000133	0.0179	-0.2	-0.17	Asthma (childhood onset);	chr5:132607996	chr5:132311285~132369916:-
LUAD	cis	rs7968440	1	rs66644594	ENSG00000272368.2	RP4-605O3.4	3.85	0.000133	0.0179	0.2	0.17	Fibrinogen;	chr12:50539200	chr12:50112197~50165618:+
LUAD	cis	rs12935418	0.616	rs55776427	ENSG00000261061.1	RP11-303E16.2	-3.85	0.000133	0.0179	-0.18	-0.17	Mean corpuscular volume;	chr16:80971999	chr16:81030770~81031485:+
LUAD	cis	rs11673344	0.523	rs7245520	ENSG00000276846.1	CTD-3220F14.3	3.85	0.000133	0.0179	0.19	0.17	Obesity-related traits;	chr19:37036416	chr19:37314868~37315620:-
LUAD	cis	rs11673344	0.523	rs2082010	ENSG00000276846.1	CTD-3220F14.3	3.85	0.000133	0.0179	0.19	0.17	Obesity-related traits;	chr19:37039874	chr19:37314868~37315620:-
LUAD	cis	rs11673344	0.523	rs7256380	ENSG00000276846.1	CTD-3220F14.3	3.85	0.000133	0.0179	0.19	0.17	Obesity-related traits;	chr19:37041178	chr19:37314868~37315620:-
LUAD	cis	rs8062405	0.824	rs153106	ENSG00000261419.1	RP11-57A19.4	-3.85	0.000133	0.0179	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28659696~28740781:-
LUAD	cis	rs5742933	0.512	rs80277863	ENSG00000253559.1	OSGEPL1-AS1	-3.85	0.000133	0.0179	-0.23	-0.17	Ferritin levels;	chr2:189766733	chr2:189762704~189765556:+
LUAD	cis	rs9322193	0.607	rs12210822	ENSG00000268592.3	RAET1E-AS1	3.85	0.000133	0.0179	0.26	0.17	Lung cancer;	chr6:149905356	chr6:149863494~149919507:+
LUAD	cis	rs1061377	0.513	rs6840214	ENSG00000249685.1	RP11-360F5.3	-3.85	0.000133	0.0179	-0.24	-0.17	Uric acid levels;	chr4:39118999	chr4:39133913~39135608:+
LUAD	cis	rs7829975	0.606	rs11776838	ENSG00000253981.4	ALG1L13P	-3.85	0.000133	0.0179	-0.2	-0.17	Mood instability;	chr8:8937291	chr8:8236003~8244667:-
LUAD	cis	rs12468226	0.808	rs73992849	ENSG00000226261.1	AC064836.3	3.85	0.000133	0.0179	0.27	0.17	Urate levels;	chr2:202152444	chr2:202336024~202336727:-
LUAD	cis	rs2346177	0.513	rs1530625	ENSG00000279254.1	RP11-536C12.1	-3.85	0.000133	0.0179	-0.18	-0.17	HDL cholesterol;	chr2:46430928	chr2:46668870~46670778:+
LUAD	cis	rs523522	0.962	rs7136951	ENSG00000278344.1	RP11-18C24.8	3.85	0.000133	0.0179	0.23	0.17	High light scatter reticulocyte count;	chr12:120504124	chr12:120500735~120501090:-
LUAD	cis	rs858239	0.699	rs955187	ENSG00000230042.1	AK3P3	3.85	0.000133	0.0179	0.22	0.17	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23129178~23129841:+
LUAD	cis	rs7202877	0.61	rs4536500	ENSG00000280152.1	RP11-331F4.5	-3.85	0.000133	0.0179	-0.19	-0.17	Type 1 diabetes;Type 2 diabetes;	chr16:75309299	chr16:75245994~75250077:-
LUAD	cis	rs2974760	0.606	rs2858918	ENSG00000268836.1	LA16c-OS12.2	3.85	0.000133	0.0179	0.18	0.17	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr16:151184	chr16:185748~186294:-
LUAD	cis	rs7119	0.637	rs12913005	ENSG00000259362.2	RP11-307C19.1	-3.85	0.000133	0.0179	-0.22	-0.17	Type 2 diabetes;	chr15:77564229	chr15:77525540~77534110:+
LUAD	cis	rs7712401	0.755	rs3213794	ENSG00000249996.1	RP11-359P5.1	3.85	0.000133	0.0179	0.21	0.17	Mean platelet volume;	chr5:122825943	chr5:123036271~123054667:+
LUAD	cis	rs9487094	0.744	rs13212535	ENSG00000260273.1	RP11-425D10.10	3.85	0.000133	0.0179	0.26	0.17	Height;	chr6:109713188	chr6:109382795~109383666:+
LUAD	cis	rs12474201	0.816	rs35809007	ENSG00000279254.1	RP11-536C12.1	-3.85	0.000133	0.0179	-0.2	-0.17	Height;	chr2:46792382	chr2:46668870~46670778:+
LUAD	cis	rs1979679	0.842	rs36097532	ENSG00000278733.1	RP11-425D17.1	3.85	0.000133	0.0179	0.22	0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28228557	chr12:28185625~28186190:-
LUAD	cis	rs12446632	0.882	rs6497416	ENSG00000261195.1	CTD-2380F24.1	-3.85	0.000133	0.0179	-0.27	-0.17	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Menarche (age at onset);Obesity;Childhood body mass index;Waist circumference;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr16:19864823	chr16:19761172~19766099:-
LUAD	cis	rs875971	0.528	rs801213	ENSG00000222364.1	RNU6-96P	3.85	0.000133	0.0179	0.22	0.17	Aortic root size;	chr7:66549931	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.545	rs801212	ENSG00000222364.1	RNU6-96P	3.85	0.000133	0.0179	0.22	0.17	Aortic root size;	chr7:66550643	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.545	rs801199	ENSG00000222364.1	RNU6-96P	3.85	0.000133	0.0179	0.22	0.17	Aortic root size;	chr7:66560286	chr7:66395191~66395286:+
LUAD	cis	rs7777677	0.925	rs73543808	ENSG00000276953.1	TRBV12-4	3.85	0.000133	0.0179	0.16	0.17	Alcoholic chronic pancreatitis;	chr7:142660024	chr7:142563740~142564245:+
LUAD	cis	rs2554380	0.843	rs1426160	ENSG00000259570.1	RP11-671M22.4	3.85	0.000133	0.0179	0.24	0.17	Height;	chr15:83739882	chr15:84394512~84395514:+
LUAD	cis	rs7615952	0.932	rs13325495	ENSG00000241288.6	RP11-379B18.5	-3.85	0.000133	0.0179	-0.24	-0.17	Blood pressure (smoking interaction);	chr3:125918573	chr3:125827238~125916384:-
LUAD	cis	rs17818399	0.547	rs35178974	ENSG00000279254.1	RP11-536C12.1	-3.85	0.000133	0.0179	-0.21	-0.17	Height;	chr2:46536759	chr2:46668870~46670778:+
LUAD	cis	rs8028182	0.636	rs4886703	ENSG00000260269.4	CTD-2323K18.1	-3.85	0.000133	0.0179	-0.24	-0.17	Sudden cardiac arrest;	chr15:75438025	chr15:75527150~75601205:-
LUAD	cis	rs7824557	0.564	rs55758514	ENSG00000255046.1	RP11-297N6.4	3.85	0.000133	0.0179	0.22	0.17	Retinal vascular caliber;	chr8:11372750	chr8:11797928~11802568:-
LUAD	cis	rs7107174	0.901	rs2511162	ENSG00000251323.2	RP11-452H21.4	3.85	0.000133	0.0179	0.22	0.17	Testicular germ cell tumor;	chr11:78216055	chr11:78423982~78429836:-
LUAD	cis	rs7005380	0.58	rs13265546	ENSG00000279347.1	RP11-85I17.2	-3.85	0.000134	0.0179	-0.14	-0.17	Interstitial lung disease;	chr8:119907735	chr8:119838736~119840385:-
LUAD	cis	rs11902236	1	rs11902236	ENSG00000243819.4	RN7SL832P	-3.85	0.000134	0.0179	-0.19	-0.17	Prostate cancer;	chr2:9977740	chr2:10690344~10692099:+
LUAD	cis	rs10971721	0.822	rs72725387	ENSG00000260947.1	RP11-384P7.7	3.85	0.000134	0.0179	0.36	0.17	Body mass index;	chr9:33863673	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.731	rs72725388	ENSG00000260947.1	RP11-384P7.7	3.85	0.000134	0.0179	0.36	0.17	Body mass index;	chr9:33864624	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs117687546	ENSG00000260947.1	RP11-384P7.7	3.85	0.000134	0.0179	0.36	0.17	Body mass index;	chr9:33864931	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs56172788	ENSG00000260947.1	RP11-384P7.7	3.85	0.000134	0.0179	0.36	0.17	Body mass index;	chr9:33865752	chr9:33697459~33700986:+
LUAD	cis	rs6502050	0.805	rs7503095	ENSG00000275966.1	RP11-1055B8.9	-3.85	0.000134	0.0179	-0.18	-0.17	Life satisfaction;	chr17:82149478	chr17:81345476~81345966:-
LUAD	cis	rs7017914	0.902	rs3098866	ENSG00000246366.5	RP11-382J12.1	3.85	0.000134	0.018	0.16	0.17	Bone mineral density;	chr8:71004339	chr8:70608577~70663279:+
LUAD	cis	rs858239	0.6	rs28646184	ENSG00000226816.2	AC005082.12	3.85	0.000134	0.018	0.23	0.17	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23206013~23208045:+
LUAD	cis	rs2354432	0.505	rs3737845	ENSG00000226015.2	CCT8P1	-3.85	0.000134	0.018	-0.32	-0.17	Mitochondrial DNA levels;	chr1:147252753	chr1:147203276~147204932:-
LUAD	cis	rs911555	0.755	rs4906329	ENSG00000259775.1	RP11-45P15.4	3.85	0.000134	0.018	0.23	0.17	Intelligence (multi-trait analysis);	chr14:103476332	chr14:103331674~103332367:-
LUAD	cis	rs6088580	0.634	rs4911153	ENSG00000276073.1	RP5-1125A11.7	3.85	0.000134	0.018	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34373741	chr20:33985617~33988989:-
LUAD	cis	rs7647973	0.516	rs4955418	ENSG00000225399.4	RP11-3B7.1	3.85	0.000134	0.018	0.23	0.17	Menarche (age at onset);	chr3:49163194	chr3:49260085~49261316:+
LUAD	cis	rs2333021	0.689	rs12878701	ENSG00000259015.1	RP11-109N23.6	3.85	0.000134	0.018	0.17	0.17	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72976068	chr14:72960595~72961993:+
LUAD	cis	rs800160	1	rs800160	ENSG00000236264.4	RPL26P30	3.85	0.000134	0.018	0.22	0.17	Bacteremia;	chr11:2358904	chr11:2335132~2335776:-
LUAD	cis	rs683250	0.598	rs590847	ENSG00000246067.6	RAB30-AS1	3.85	0.000134	0.018	0.18	0.17	Subcortical brain region volumes;	chr11:83255127	chr11:83072066~83106719:+
LUAD	cis	rs6964587	0.967	rs9656003	ENSG00000188693.7	CYP51A1-AS1	-3.85	0.000134	0.018	-0.2	-0.17	Breast cancer;	chr7:92137008	chr7:92134604~92180725:+
LUAD	cis	rs6964587	0.933	rs28671255	ENSG00000188693.7	CYP51A1-AS1	-3.85	0.000134	0.018	-0.2	-0.17	Breast cancer;	chr7:92141391	chr7:92134604~92180725:+
LUAD	cis	rs875971	0.597	rs11771318	ENSG00000236529.1	RP13-254B10.1	-3.85	0.000134	0.018	-0.18	-0.17	Aortic root size;	chr7:66597493	chr7:65840212~65840596:+
LUAD	cis	rs858239	0.899	rs10085838	ENSG00000230042.1	AK3P3	-3.85	0.000134	0.018	-0.22	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23258796	chr7:23129178~23129841:+
LUAD	cis	rs4374383	0.962	rs6710591	ENSG00000207383.1	Y_RNA	-3.85	0.000134	0.018	-0.21	-0.17	Hepatitis C induced liver fibrosis;	chr2:112015789	chr2:112579484~112579584:-
LUAD	cis	rs13287066	0.692	rs72743489	ENSG00000227603.1	RP11-165J3.6	3.85	0.000134	0.018	0.2	0.17	Intelligence (multi-trait analysis);	chr9:93406201	chr9:93435332~93437121:-
LUAD	cis	rs911555	0.546	rs28798508	ENSG00000258851.1	RP11-894P9.2	-3.85	0.000134	0.018	-0.2	-0.17	Intelligence (multi-trait analysis);	chr14:103602633	chr14:103553421~103561877:+
LUAD	cis	rs36093844	0.576	rs12287170	ENSG00000279742.1	RP11-700A24.1	-3.85	0.000134	0.018	-0.2	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86024179	chr11:85852557~85854943:-
LUAD	cis	rs35934224	0.714	rs75224199	ENSG00000232926.1	AC000078.5	3.85	0.000134	0.018	0.24	0.17	Glaucoma (primary open-angle);	chr22:19863641	chr22:19887289~19887970:+
LUAD	cis	rs35934224	0.769	rs76802530	ENSG00000232926.1	AC000078.5	3.85	0.000134	0.018	0.24	0.17	Glaucoma (primary open-angle);	chr22:19865883	chr22:19887289~19887970:+
LUAD	cis	rs6738440	0.51	rs13028627	ENSG00000234624.2	AC016894.1	3.85	0.000134	0.018	0.2	0.17	F-cell distribution;	chr2:60435517	chr2:61416887~61417197:-
LUAD	cis	rs9633740	0.947	rs7096909	ENSG00000226659.1	RP11-137H2.4	3.85	0.000134	0.018	0.28	0.17	Post bronchodilator FEV1;	chr10:80524756	chr10:80529597~80535942:-
LUAD	cis	rs703842	0.616	rs1875125	ENSG00000270039.1	RP11-571M6.17	-3.85	0.000134	0.018	-0.21	-0.17	Multiple sclerosis;	chr12:57833458	chr12:57803838~57804415:+
LUAD	cis	rs10435719	0.899	rs11250177	ENSG00000255046.1	RP11-297N6.4	-3.85	0.000134	0.018	-0.22	-0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11941590	chr8:11797928~11802568:-
LUAD	cis	rs7903456	0.648	rs6586053	ENSG00000200253.1	RNU6-529P	3.85	0.000134	0.018	0.2	0.17	Gout;Renal underexcretion gout;	chr10:87070115	chr10:87041238~87041341:-
LUAD	cis	rs2933343	0.729	rs813945	ENSG00000261159.1	RP11-723O4.9	3.85	0.000134	0.018	0.19	0.17	IgG glycosylation;	chr3:128942094	chr3:128859716~128860526:-
LUAD	cis	rs706293	0.537	rs61394862	ENSG00000261360.1	CTD-2165H16.4	-3.85	0.000134	0.018	-0.16	-0.17	Urate levels (BMI interaction);	chr5:14850985	chr5:14661808~14664604:-
LUAD	cis	rs7617773	0.78	rs13090538	ENSG00000199476.1	Y_RNA	-3.85	0.000134	0.018	-0.23	-0.17	Coronary artery disease;	chr3:48329279	chr3:48288587~48288694:+
LUAD	cis	rs7829975	0.711	rs1039916	ENSG00000233609.3	RP11-62H7.2	3.85	0.000134	0.018	0.14	0.17	Mood instability;	chr8:8828344	chr8:8961200~8979025:+
LUAD	cis	rs638893	0.636	rs7119702	ENSG00000255422.1	AP002954.4	-3.85	0.000134	0.018	-0.3	-0.17	Vitiligo;	chr11:118736985	chr11:118704607~118750263:+
LUAD	cis	rs11089937	0.929	rs2236727	ENSG00000211640.3	IGLV6-57	3.85	0.000134	0.018	0.11	0.17	Periodontitis (PAL4Q3);	chr22:22156654	chr22:22195713~22196460:+
LUAD	cis	rs910316	0.967	rs12147532	ENSG00000279594.1	RP11-950C14.10	-3.85	0.000134	0.018	-0.2	-0.17	Height;	chr14:75185155	chr14:75011269~75012851:-
LUAD	cis	rs73108077	1	rs73116222	ENSG00000281376.1	ABALON	-3.85	0.000134	0.018	-0.3	-0.17	Red blood cell density in sickle cell anemia;	chr20:31444393	chr20:31721507~31723409:+
LUAD	cis	rs73108077	1	rs73116224	ENSG00000281376.1	ABALON	-3.85	0.000134	0.018	-0.3	-0.17	Red blood cell density in sickle cell anemia;	chr20:31444913	chr20:31721507~31723409:+
LUAD	cis	rs73108077	1	rs73116226	ENSG00000281376.1	ABALON	-3.85	0.000134	0.018	-0.3	-0.17	Red blood cell density in sickle cell anemia;	chr20:31445905	chr20:31721507~31723409:+
LUAD	cis	rs73108077	1	rs73116229	ENSG00000281376.1	ABALON	-3.85	0.000134	0.018	-0.3	-0.17	Red blood cell density in sickle cell anemia;	chr20:31446433	chr20:31721507~31723409:+
LUAD	cis	rs11168351	0.926	rs10875719	ENSG00000257763.1	OR5BK1P	3.85	0.000134	0.018	0.18	0.17	Bipolar disorder and schizophrenia;	chr12:48017375	chr12:48355792~48356614:-
LUAD	cis	rs848490	0.889	rs55641721	ENSG00000214293.7	APTR	3.85	0.000134	0.018	0.22	0.17	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77559584	chr7:77657660~77696265:-
LUAD	cis	rs2179367	0.959	rs480034	ENSG00000216906.2	RP11-350J20.9	-3.85	0.000134	0.018	-0.22	-0.17	Dupuytren's disease;	chr6:149414294	chr6:149904243~149906418:+
LUAD	cis	rs13113518	1	rs13115828	ENSG00000273257.1	RP11-177J6.1	3.85	0.000134	0.018	0.19	0.17	Height;	chr4:55551447	chr4:55387949~55388271:+
LUAD	cis	rs28472312	0.723	rs1137843	ENSG00000246465.1	RP11-57A19.2	3.85	0.000134	0.018	0.2	0.17	Intelligence (multi-trait analysis);	chr16:28966392	chr16:28284885~28292064:-
LUAD	cis	rs877819	0.583	rs2663033	ENSG00000228403.1	RP11-563N6.6	-3.85	0.000134	0.018	-0.18	-0.17	Systemic lupus erythematosus;	chr10:48876623	chr10:48878022~48878649:+
LUAD	cis	rs6502050	0.835	rs4523985	ENSG00000266654.1	RP11-1376P16.1	-3.85	0.000134	0.018	-0.19	-0.17	Life satisfaction;	chr17:82196590	chr17:82160056~82160452:+
LUAD	cis	rs7107174	0.892	rs2512519	ENSG00000251323.2	RP11-452H21.4	3.85	0.000134	0.018	0.24	0.17	Testicular germ cell tumor;	chr11:78241969	chr11:78423982~78429836:-
LUAD	cis	rs957448	0.561	rs4734282	ENSG00000253175.1	RP11-267M23.6	3.85	0.000134	0.018	0.19	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94603827	chr8:94565036~94565715:+
LUAD	cis	rs219780	0.679	rs219787	ENSG00000230479.1	AP000695.6	3.85	0.000134	0.018	0.2	0.17	Kidney stones;	chr21:36457210	chr21:36430360~36481070:+
LUAD	cis	rs4594175	0.677	rs7149846	ENSG00000258955.1	LINC00519	-3.85	0.000134	0.018	-0.21	-0.17	Cancer;	chr14:51272936	chr14:51304416~51328386:-
LUAD	cis	rs651907	0.557	rs3806654	ENSG00000244119.1	PDCL3P4	3.85	0.000134	0.018	0.17	0.17	Colorectal cancer;	chr3:101677685	chr3:101712472~101713191:+
LUAD	cis	rs2242116	0.592	rs6442039	ENSG00000271161.1	BOLA2P2	3.85	0.000134	0.018	0.19	0.17	Birth weight;	chr3:46919307	chr3:47499841~47500407:+
LUAD	cis	rs4499344	0.556	rs259227	ENSG00000201388.1	SNORA68	3.85	0.000134	0.018	0.2	0.17	Mean platelet volume;	chr19:32643885	chr19:32608337~32608469:-
LUAD	cis	rs2836974	0.931	rs2836972	ENSG00000232608.1	TIMM9P2	-3.85	0.000134	0.018	-0.2	-0.17	Cognitive function;	chr21:39280216	chr21:39216624~39217506:+
LUAD	cis	rs2836974	0.965	rs7354783	ENSG00000232608.1	TIMM9P2	-3.85	0.000134	0.018	-0.2	-0.17	Cognitive function;	chr21:39281066	chr21:39216624~39217506:+
LUAD	cis	rs7017914	0.967	rs3098867	ENSG00000246366.5	RP11-382J12.1	3.85	0.000134	0.018	0.16	0.17	Bone mineral density;	chr8:71004636	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.934	rs2639904	ENSG00000246366.5	RP11-382J12.1	3.85	0.000134	0.018	0.16	0.17	Bone mineral density;	chr8:71004895	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.967	rs2639901	ENSG00000246366.5	RP11-382J12.1	3.85	0.000134	0.018	0.16	0.17	Bone mineral density;	chr8:71005516	chr8:70608577~70663279:+
LUAD	cis	rs11637445	0.626	rs1878699	ENSG00000270964.1	RP11-502I4.3	-3.85	0.000134	0.018	-0.2	-0.17	Posterior cortical atrophy and Alzheimer's disease;	chr15:67608545	chr15:67541072~67542604:-
LUAD	cis	rs10129255	0.828	rs10140989	ENSG00000274576.2	IGHV2-70	3.85	0.000134	0.018	0.16	0.17	Kawasaki disease;	chr14:106668657	chr14:106770577~106771020:-
LUAD	cis	rs78472555	0.789	rs2603229	ENSG00000259341.1	RP11-20G13.1	3.85	0.000134	0.018	0.21	0.17	Post bronchodilator FEV1/FVC ratio in COPD;	chr15:99723294	chr15:99427009~99431028:-
LUAD	cis	rs9584850	0.574	rs17471079	ENSG00000231194.1	FARP1-AS1	3.85	0.000134	0.018	0.24	0.17	Neuroticism;	chr13:98516467	chr13:98435405~98435840:-
LUAD	cis	rs6472235	0.586	rs34464051	ENSG00000200714.1	Y_RNA	-3.85	0.000134	0.018	-0.23	-0.17	Plateletcrit;Myopia (pathological);	chr8:65989769	chr8:65592731~65592820:+
LUAD	cis	rs4660214	0.671	rs16826012	ENSG00000182109.6	RP11-69E11.4	-3.85	0.000134	0.018	-0.23	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39253847	chr1:39522280~39546187:-
LUAD	cis	rs62025270	0.632	rs17571078	ENSG00000259416.2	RP11-158M2.5	-3.85	0.000135	0.018	-0.23	-0.17	Idiopathic pulmonary fibrosis;	chr15:85597248	chr15:85754941~85756237:-
LUAD	cis	rs7578361	0.879	rs4667421	ENSG00000231969.1	AC144449.1	-3.85	0.000135	0.0181	-0.25	-0.17	Acute lymphoblastic leukemia (childhood);	chr2:149564291	chr2:149587196~149848233:+
LUAD	cis	rs287982	0.611	rs111636862	ENSG00000269973.1	RP11-95D17.1	-3.85	0.000135	0.0181	-0.25	-0.17	Nonsyndromic cleft lip with cleft palate;	chr2:9840128	chr2:9936360~9939590:+
LUAD	cis	rs61629263	0.618	rs851056	ENSG00000267151.3	RP11-100E5.2	3.85	0.000135	0.0181	0.19	0.17	Facial morphology (factor 17, height of vermillion upper lip);	chr17:43759814	chr17:43444707~43451200:+
LUAD	cis	rs4538475	0.745	rs6842052	ENSG00000249234.1	RP11-452J21.2	3.85	0.000135	0.0181	0.23	0.17	Parkinson's disease;	chr4:15717077	chr4:16178939~16183120:+
LUAD	cis	rs9467773	0.62	rs4368798	ENSG00000241549.7	GUSBP2	3.85	0.000135	0.0181	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26593243	chr6:26871484~26956554:-
LUAD	cis	rs4443100	1	rs4443100	ENSG00000207832.1	AC245028.1	3.85	0.000135	0.0181	0.16	0.17	Serum parathyroid hormone levels;	chr22:23030688	chr22:22856545~22856638:+
LUAD	cis	rs4795519	0.778	rs1829661	ENSG00000266313.1	RP11-173M1.4	3.85	0.000135	0.0181	0.22	0.17	Chronic myeloid leukemia;	chr17:27075003	chr17:27333256~27348491:+
LUAD	cis	rs253959	0.576	rs1588268	ENSG00000272265.1	CTD-2287O16.4	3.85	0.000135	0.0181	0.21	0.17	Bipolar disorder and schizophrenia;	chr5:116101091	chr5:116078110~116078570:-
LUAD	cis	rs253959	0.545	rs2416425	ENSG00000272265.1	CTD-2287O16.4	3.85	0.000135	0.0181	0.21	0.17	Bipolar disorder and schizophrenia;	chr5:116101727	chr5:116078110~116078570:-
LUAD	cis	rs4938303	0.633	rs35681250	ENSG00000254851.1	RP11-109L13.1	3.85	0.000135	0.0181	0.27	0.17	Triglycerides;	chr11:116684670	chr11:117135528~117138582:+
LUAD	cis	rs4499344	0.73	rs417823	ENSG00000201388.1	SNORA68	3.85	0.000135	0.0181	0.18	0.17	Mean platelet volume;	chr19:32613655	chr19:32608337~32608469:-
LUAD	cis	rs858239	0.601	rs1034963	ENSG00000226816.2	AC005082.12	3.85	0.000135	0.0181	0.22	0.17	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23206013~23208045:+
LUAD	cis	rs950169	0.579	rs881983	ENSG00000259570.1	RP11-671M22.4	3.85	0.000135	0.0181	0.25	0.17	Schizophrenia;	chr15:83978556	chr15:84394512~84395514:+
LUAD	cis	rs683250	0.598	rs1945128	ENSG00000246067.6	RAB30-AS1	-3.85	0.000135	0.0181	-0.18	-0.17	Subcortical brain region volumes;	chr11:83337632	chr11:83072066~83106719:+
LUAD	cis	rs62355901	0.545	rs16886263	ENSG00000271828.1	CTD-2310F14.1	-3.85	0.000135	0.0181	-0.32	-0.17	Breast cancer;	chr5:56769680	chr5:56927874~56929573:+
LUAD	cis	rs3018712	0.59	rs10791993	ENSG00000227620.4	ALG1L8P	-3.85	0.000135	0.0181	-0.24	-0.17	Total body bone mineral density;	chr11:68726244	chr11:67785273~67792335:+
LUAD	cis	rs35851103	0.627	rs58602899	ENSG00000255046.1	RP11-297N6.4	-3.85	0.000135	0.0181	-0.21	-0.17	Neuroticism;	chr8:11991324	chr8:11797928~11802568:-
LUAD	cis	rs8028182	0.636	rs10152155	ENSG00000246877.1	DNM1P35	3.85	0.000135	0.0181	0.22	0.17	Sudden cardiac arrest;	chr15:75409213	chr15:75727670~75738623:-
LUAD	cis	rs9467773	1	rs9461271	ENSG00000241549.7	GUSBP2	3.85	0.000135	0.0181	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26554740	chr6:26871484~26956554:-
LUAD	cis	rs9467773	1	rs9467787	ENSG00000241549.7	GUSBP2	3.85	0.000135	0.0181	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26556541	chr6:26871484~26956554:-
LUAD	cis	rs7829975	0.755	rs3789849	ENSG00000173295.6	FAM86B3P	3.85	0.000135	0.0181	0.19	0.17	Mood instability;	chr8:8829544	chr8:8228595~8244865:+
LUAD	cis	rs11679640	0.61	rs4130172	ENSG00000226491.1	FTOP1	-3.85	0.000135	0.0181	-0.17	-0.17	White matter hyperintensity burden;	chr2:42889285	chr2:42797225~42798712:-
LUAD	cis	rs761746	0.695	rs3804087	ENSG00000236132.1	CTA-440B3.1	3.85	0.000135	0.0181	0.25	0.17	Intelligence;	chr22:31683317	chr22:31816379~31817491:-
LUAD	cis	rs11971779	0.941	rs6954453	ENSG00000273391.1	RP11-634H22.1	3.85	0.000135	0.0181	0.21	0.17	Diisocyanate-induced asthma;	chr7:139347048	chr7:139359032~139359566:-
LUAD	cis	rs11971779	0.941	rs4732368	ENSG00000273391.1	RP11-634H22.1	3.85	0.000135	0.0181	0.21	0.17	Diisocyanate-induced asthma;	chr7:139349461	chr7:139359032~139359566:-
LUAD	cis	rs524281	0.731	rs12576969	ENSG00000255320.1	RP11-755F10.1	-3.85	0.000135	0.0181	-0.27	-0.17	Electroencephalogram traits;	chr11:66035007	chr11:66244840~66246239:-
LUAD	cis	rs7824557	0.564	rs34964435	ENSG00000255046.1	RP11-297N6.4	3.85	0.000135	0.0181	0.22	0.17	Retinal vascular caliber;	chr8:11372697	chr8:11797928~11802568:-
LUAD	cis	rs6095360	0.903	rs6012557	ENSG00000222365.1	SNORD12B	-3.85	0.000135	0.0181	-0.17	-0.17	Intelligence (multi-trait analysis);	chr20:48914617	chr20:49280319~49280409:+
LUAD	cis	rs2239557	0.508	rs10483857	ENSG00000259065.1	RP5-1021I20.1	3.85	0.000135	0.0181	0.23	0.17	Common traits (Other);	chr14:73899508	chr14:73787360~73803270:+
LUAD	cis	rs1979679	0.959	rs75757272	ENSG00000278733.1	RP11-425D17.1	3.85	0.000135	0.0181	0.23	0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28251809	chr12:28185625~28186190:-
LUAD	cis	rs4594175	0.707	rs4901102	ENSG00000258955.1	LINC00519	3.85	0.000135	0.0181	0.21	0.17	Cancer;	chr14:51279887	chr14:51304416~51328386:-
LUAD	cis	rs3814244	0.528	rs2906859	ENSG00000236946.2	HNRNPA1P70	-3.85	0.000135	0.0181	-0.15	-0.17	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002355	chr12:68035767~68036853:+
LUAD	cis	rs897984	0.806	rs10782001	ENSG00000232748.3	RP11-196G11.6	3.85	0.000135	0.0181	0.21	0.17	Dementia with Lewy bodies;	chr16:30931304	chr16:31056460~31062803:+
LUAD	cis	rs897984	0.806	rs12928852	ENSG00000232748.3	RP11-196G11.6	3.85	0.000135	0.0181	0.21	0.17	Dementia with Lewy bodies;	chr16:30932667	chr16:31056460~31062803:+
LUAD	cis	rs11971779	0.878	rs4732378	ENSG00000273391.1	RP11-634H22.1	3.85	0.000135	0.0181	0.2	0.17	Diisocyanate-induced asthma;	chr7:139435649	chr7:139359032~139359566:-
LUAD	cis	rs7824557	0.603	rs2246606	ENSG00000255046.1	RP11-297N6.4	-3.85	0.000135	0.0181	-0.21	-0.17	Retinal vascular caliber;	chr8:11361825	chr8:11797928~11802568:-
LUAD	cis	rs34779708	0.966	rs12761675	ENSG00000271335.4	RP11-324I22.4	-3.85	0.000135	0.0181	-0.18	-0.17	Inflammatory bowel disease;Crohn's disease;	chr10:35149409	chr10:35314552~35336401:-
LUAD	cis	rs1876905	0.68	rs1215848	ENSG00000255389.1	C6orf3	3.85	0.000135	0.0181	0.22	0.17	Mean corpuscular hemoglobin;	chr6:111204333	chr6:111599875~111602295:+
LUAD	cis	rs1876905	0.68	rs402940	ENSG00000255389.1	C6orf3	3.85	0.000135	0.0181	0.22	0.17	Mean corpuscular hemoglobin;	chr6:111206785	chr6:111599875~111602295:+
LUAD	cis	rs1234598	1	rs1234598	ENSG00000255389.1	C6orf3	3.85	0.000135	0.0181	0.22	0.17	Mean corpuscular volume;	chr6:111208250	chr6:111599875~111602295:+
LUAD	cis	rs1876905	0.68	rs354543	ENSG00000255389.1	C6orf3	3.85	0.000135	0.0181	0.22	0.17	Mean corpuscular hemoglobin;	chr6:111209050	chr6:111599875~111602295:+
LUAD	cis	rs7429990	0.965	rs9811277	ENSG00000228638.1	FCF1P2	-3.85	0.000135	0.0181	-0.2	-0.17	Educational attainment (years of education);	chr3:47970148	chr3:48290793~48291375:-
LUAD	cis	rs7429990	0.965	rs9814961	ENSG00000228638.1	FCF1P2	-3.85	0.000135	0.0181	-0.2	-0.17	Educational attainment (years of education);	chr3:47976127	chr3:48290793~48291375:-
LUAD	cis	rs7580658	0.55	rs62160290	ENSG00000236682.1	AC068282.3	-3.85	0.000135	0.0181	-0.23	-0.17	Protein C levels;	chr2:127443119	chr2:127389130~127400580:+
LUAD	cis	rs453301	0.686	rs4840389	ENSG00000233609.3	RP11-62H7.2	-3.85	0.000135	0.0181	-0.15	-0.17	Joint mobility (Beighton score);	chr8:9026993	chr8:8961200~8979025:+
LUAD	cis	rs7515577	0.797	rs6676141	ENSG00000223787.2	RP4-593M8.1	3.85	0.000135	0.0181	0.24	0.17	Cholesterol, total;	chr1:92473660	chr1:92580476~92580821:-
LUAD	cis	rs7142881	0.815	rs11156691	ENSG00000258525.1	RP11-829H16.3	-3.85	0.000135	0.0181	-0.2	-0.17	Response to iloperidone treatment (QT prolongation);	chr14:31586263	chr14:30876179~30889808:-
LUAD	cis	rs4144027	0.904	rs10438243	ENSG00000258914.1	CTD-2134A5.3	3.85	0.000135	0.0181	0.21	0.17	Blood metabolite levels;	chr14:103879485	chr14:103875055~103877478:+
LUAD	cis	rs2252586	0.833	rs77799804	ENSG00000226278.1	PSPHP1	-3.85	0.000135	0.0181	-0.21	-0.17	Glioma;	chr7:54897151	chr7:55764797~55773288:+
LUAD	cis	rs2348418	0.832	rs11611406	ENSG00000244712.1	RP11-874G11.1	3.85	0.000135	0.0181	0.21	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28310910	chr12:28564678~28565141:-
LUAD	cis	rs2348418	0.832	rs11611382	ENSG00000244712.1	RP11-874G11.1	3.85	0.000135	0.0181	0.21	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28310959	chr12:28564678~28565141:-
LUAD	cis	rs2348418	0.798	rs10771423	ENSG00000247934.4	RP11-967K21.1	3.85	0.000135	0.0181	0.2	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28396205	chr12:28163298~28190738:-
LUAD	cis	rs4474465	1	rs2063729	ENSG00000251323.2	RP11-452H21.4	3.85	0.000135	0.0181	0.22	0.17	Alzheimer's disease (survival time);	chr11:78474923	chr11:78423982~78429836:-
LUAD	cis	rs8073060	0.544	rs7211724	ENSG00000267592.1	CTC-507E2.2	3.85	0.000135	0.0181	0.25	0.17	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35666395	chr17:35596904~35597128:-
LUAD	cis	rs8073060	0.586	rs7212488	ENSG00000267592.1	CTC-507E2.2	3.85	0.000135	0.0181	0.25	0.17	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35666457	chr17:35596904~35597128:-
LUAD	cis	rs6479901	0.841	rs10822148	ENSG00000232075.1	MRPL35P2	-3.85	0.000135	0.0181	-0.24	-0.17	Intelligence (multi-trait analysis);	chr10:63219487	chr10:63634317~63634827:-
LUAD	cis	rs4604732	0.603	rs4546958	ENSG00000227135.1	GCSAML-AS1	-3.85	0.000135	0.0181	-0.24	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247476176	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.642	rs7515859	ENSG00000227135.1	GCSAML-AS1	-3.85	0.000135	0.0181	-0.24	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247476755	chr1:247524679~247526752:-
LUAD	cis	rs4604732	0.642	rs7549312	ENSG00000227135.1	GCSAML-AS1	-3.85	0.000135	0.0181	-0.24	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247476776	chr1:247524679~247526752:-
LUAD	cis	rs77204473	0.557	rs9971422	ENSG00000280143.1	AP000892.6	-3.85	0.000135	0.0181	-0.29	-0.17	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116966657	chr11:117204967~117210292:+
LUAD	cis	rs10463554	0.927	rs6862616	ENSG00000250682.4	LINC00491	3.85	0.000135	0.0181	0.21	0.17	Parkinson's disease;	chr5:102910334	chr5:102609156~102671559:-
LUAD	cis	rs7512552	0.839	rs11205357	ENSG00000275557.1	RP11-353N4.6	-3.85	0.000135	0.0181	-0.2	-0.17	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150295378	chr1:149607765~149612402:+
LUAD	cis	rs42490	0.576	rs381456	ENSG00000251136.7	RP11-37B2.1	-3.85	0.000135	0.0181	-0.19	-0.17	Leprosy;	chr8:89865176	chr8:89609409~89757727:-
LUAD	cis	rs11146838	1	rs11146838	ENSG00000276805.1	RP11-291L22.6	3.85	0.000135	0.0181	0.17	0.17	Breast cancer;	chr10:38856846	chr10:38451030~38451785:+
LUAD	cis	rs17685	0.712	rs1859794	ENSG00000280388.1	RP11-229D13.3	-3.85	0.000135	0.0181	-0.16	-0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76192226	chr7:76043977~76045963:-
LUAD	cis	rs7326068	0.61	rs3924006	ENSG00000275485.1	RP11-261P13.6	-3.85	0.000135	0.0181	-0.23	-0.17	Schizophrenia, bipolar disorder and depression (combined);	chr13:20757640	chr13:20768876~20769375:-
LUAD	cis	rs8073060	0.855	rs12150450	ENSG00000267592.1	CTC-507E2.2	-3.85	0.000135	0.0181	-0.22	-0.17	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35541877	chr17:35596904~35597128:-
LUAD	cis	rs7017914	1	rs7017914	ENSG00000246366.5	RP11-382J12.1	3.85	0.000135	0.0181	0.16	0.17	Bone mineral density;	chr8:70678968	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.967	rs13256250	ENSG00000246366.5	RP11-382J12.1	3.85	0.000135	0.0181	0.16	0.17	Bone mineral density;	chr8:70683958	chr8:70608577~70663279:+
LUAD	cis	rs2638953	0.924	rs11049398	ENSG00000278733.1	RP11-425D17.1	-3.85	0.000135	0.0181	-0.21	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28172371	chr12:28185625~28186190:-
LUAD	cis	rs62458065	0.85	rs62458100	ENSG00000226468.2	AC018641.7	3.85	0.000135	0.0181	0.29	0.17	Metabolite levels (HVA/MHPG ratio);	chr7:32433530	chr7:32456963~32457758:-
LUAD	cis	rs2625529	0.652	rs2957728	ENSG00000260173.1	RP11-2I17.4	3.85	0.000135	0.0182	0.21	0.17	Red blood cell count;	chr15:71944091	chr15:72140504~72155459:-
LUAD	cis	rs6496044	0.591	rs979825	ENSG00000259407.1	RP11-158M2.3	-3.85	0.000135	0.0182	-0.16	-0.17	Interstitial lung disease;	chr15:85537394	chr15:85744109~85750281:-
LUAD	cis	rs453301	0.658	rs13271797	ENSG00000233609.3	RP11-62H7.2	-3.85	0.000135	0.0182	-0.15	-0.17	Joint mobility (Beighton score);	chr8:9028444	chr8:8961200~8979025:+
LUAD	cis	rs11672691	0.792	rs7248215	ENSG00000267107.5	PCAT19	3.85	0.000136	0.0182	0.22	0.17	Prostate cancer;	chr19:41493212	chr19:41454169~41500649:-
LUAD	cis	rs4499344	0.519	rs259226	ENSG00000201388.1	SNORA68	3.85	0.000136	0.0182	0.2	0.17	Mean platelet volume;	chr19:32644059	chr19:32608337~32608469:-
LUAD	cis	rs7017914	0.934	rs3110239	ENSG00000246366.5	RP11-382J12.1	3.85	0.000136	0.0182	0.16	0.17	Bone mineral density;	chr8:71004510	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.934	rs2732092	ENSG00000246366.5	RP11-382J12.1	3.85	0.000136	0.0182	0.16	0.17	Bone mineral density;	chr8:71006364	chr8:70608577~70663279:+
LUAD	cis	rs11742741	1	rs17445131	ENSG00000248874.4	C5orf17	-3.85	0.000136	0.0182	-0.21	-0.17	Educational attainment;	chr5:24143245	chr5:23951348~24178263:+
LUAD	cis	rs6547741	0.967	rs4665986	ENSG00000223522.1	AC093690.1	3.85	0.000136	0.0182	0.16	0.17	Oral cavity cancer;	chr2:27532301	chr2:28307691~28310459:-
LUAD	cis	rs8040855	0.965	rs11073990	ENSG00000259774.1	RP11-182J1.13	3.85	0.000136	0.0182	0.2	0.17	Bulimia nervosa;	chr15:85168070	chr15:84422618~84425882:+
LUAD	cis	rs17772222	0.917	rs61984736	ENSG00000258789.1	RP11-507K2.3	-3.85	0.000136	0.0182	-0.24	-0.17	Coronary artery calcification;	chr14:88626359	chr14:88551597~88552493:+
LUAD	cis	rs4072705	1	rs13283284	ENSG00000236643.1	RP11-175D17.3	-3.85	0.000136	0.0182	-0.2	-0.17	Menarche (age at onset);	chr9:124753898	chr9:124770123~124772927:+
LUAD	cis	rs894638	0.519	rs73126494	ENSG00000263327.5	TAPT1-AS1	-3.85	0.000136	0.0182	-0.22	-0.17	Glomerular filtration rate in chronic kidney disease;	chr4:16124279	chr4:16226685~16320140:+
LUAD	cis	rs8113308	0.81	rs73582180	ENSG00000269483.1	AC006272.1	3.85	0.000136	0.0182	0.28	0.17	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51943284	chr19:51839924~51843324:-
LUAD	cis	rs4246307	0.817	rs4548838	ENSG00000254744.3	CTD-3076O17.1	3.85	0.000136	0.0182	0.2	0.17	Hip circumference adjusted for BMI;	chr15:100220985	chr15:99970215~99974010:+
LUAD	cis	rs801193	1	rs1553610	ENSG00000222364.1	RNU6-96P	-3.85	0.000136	0.0182	-0.19	-0.17	Aortic root size;	chr7:66732246	chr7:66395191~66395286:+
LUAD	cis	rs1348850	0.958	rs1405713	ENSG00000213963.5	AC074286.1	3.85	0.000136	0.0182	0.2	0.17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177596832	chr2:177283508~177392691:-
LUAD	cis	rs1348850	0.958	rs10497501	ENSG00000213963.5	AC074286.1	3.85	0.000136	0.0182	0.2	0.17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177597571	chr2:177283508~177392691:-
LUAD	cis	rs73186030	0.687	rs55636509	ENSG00000272758.4	RP11-299J3.8	3.85	0.000136	0.0182	0.24	0.17	Serum parathyroid hormone levels;	chr3:122351816	chr3:122416207~122443180:+
LUAD	cis	rs4499344	0.556	rs259225	ENSG00000201388.1	SNORA68	3.85	0.000136	0.0182	0.2	0.17	Mean platelet volume;	chr19:32644552	chr19:32608337~32608469:-
LUAD	cis	rs6479891	1	rs72829170	ENSG00000232075.1	MRPL35P2	3.85	0.000136	0.0182	0.28	0.17	Arthritis (juvenile idiopathic);	chr10:63180529	chr10:63634317~63634827:-
LUAD	cis	rs6479891	1	rs61855465	ENSG00000232075.1	MRPL35P2	3.85	0.000136	0.0182	0.28	0.17	Arthritis (juvenile idiopathic);	chr10:63196847	chr10:63634317~63634827:-
LUAD	cis	rs6479891	1	rs12413730	ENSG00000232075.1	MRPL35P2	3.85	0.000136	0.0182	0.28	0.17	Arthritis (juvenile idiopathic);	chr10:63204388	chr10:63634317~63634827:-
LUAD	cis	rs6121246	0.633	rs6060986	ENSG00000230613.1	HM13-AS1	3.85	0.000136	0.0182	0.21	0.17	Mean corpuscular hemoglobin;	chr20:31838494	chr20:31567707~31573263:-
LUAD	cis	rs12493885	0.654	rs61792350	ENSG00000243069.6	ARHGEF26-AS1	-3.85	0.000136	0.0182	-0.29	-0.17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:153995170	chr3:154024401~154121332:-
LUAD	cis	rs6479891	1	rs4746974	ENSG00000232075.1	MRPL35P2	3.85	0.000136	0.0182	0.28	0.17	Arthritis (juvenile idiopathic);	chr10:63132292	chr10:63634317~63634827:-
LUAD	cis	rs2281558	0.837	rs56238023	ENSG00000125804.12	FAM182A	-3.85	0.000136	0.0182	-0.24	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25536311	chr20:26054655~26086917:+
LUAD	cis	rs2281558	0.833	rs12480853	ENSG00000125804.12	FAM182A	-3.85	0.000136	0.0182	-0.24	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25542323	chr20:26054655~26086917:+
LUAD	cis	rs10463554	0.963	rs28301	ENSG00000250682.4	LINC00491	3.85	0.000136	0.0182	0.21	0.17	Parkinson's disease;	chr5:103105778	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.963	rs34828	ENSG00000250682.4	LINC00491	3.85	0.000136	0.0182	0.21	0.17	Parkinson's disease;	chr5:103107209	chr5:102609156~102671559:-
LUAD	cis	rs7937890	0.559	rs2575836	ENSG00000254418.1	RP11-21L19.1	3.85	0.000136	0.0182	0.2	0.17	Mitochondrial DNA levels;	chr11:14476318	chr11:14262846~14273691:-
LUAD	cis	rs7937890	0.531	rs2575859	ENSG00000254418.1	RP11-21L19.1	3.85	0.000136	0.0182	0.2	0.17	Mitochondrial DNA levels;	chr11:14489190	chr11:14262846~14273691:-
LUAD	cis	rs7937890	0.559	rs2597188	ENSG00000254418.1	RP11-21L19.1	3.85	0.000136	0.0182	0.2	0.17	Mitochondrial DNA levels;	chr11:14495360	chr11:14262846~14273691:-
LUAD	cis	rs7937890	0.504	rs2575822	ENSG00000254418.1	RP11-21L19.1	3.85	0.000136	0.0182	0.2	0.17	Mitochondrial DNA levels;	chr11:14498305	chr11:14262846~14273691:-
LUAD	cis	rs7937890	0.559	rs2575823	ENSG00000254418.1	RP11-21L19.1	3.85	0.000136	0.0182	0.2	0.17	Mitochondrial DNA levels;	chr11:14499808	chr11:14262846~14273691:-
LUAD	cis	rs7937890	0.559	rs2597221	ENSG00000254418.1	RP11-21L19.1	3.85	0.000136	0.0182	0.2	0.17	Mitochondrial DNA levels;	chr11:14505529	chr11:14262846~14273691:-
LUAD	cis	rs7937890	0.559	rs6486197	ENSG00000254418.1	RP11-21L19.1	3.85	0.000136	0.0182	0.2	0.17	Mitochondrial DNA levels;	chr11:14508328	chr11:14262846~14273691:-
LUAD	cis	rs7937890	0.559	rs2597219	ENSG00000254418.1	RP11-21L19.1	3.85	0.000136	0.0182	0.2	0.17	Mitochondrial DNA levels;	chr11:14509320	chr11:14262846~14273691:-
LUAD	cis	rs7937890	0.559	rs2575852	ENSG00000254418.1	RP11-21L19.1	3.85	0.000136	0.0182	0.2	0.17	Mitochondrial DNA levels;	chr11:14511822	chr11:14262846~14273691:-
LUAD	cis	rs7937890	0.531	rs2597216	ENSG00000254418.1	RP11-21L19.1	3.85	0.000136	0.0182	0.2	0.17	Mitochondrial DNA levels;	chr11:14512370	chr11:14262846~14273691:-
LUAD	cis	rs7937890	0.559	rs1548074	ENSG00000254418.1	RP11-21L19.1	3.85	0.000136	0.0182	0.2	0.17	Mitochondrial DNA levels;	chr11:14513279	chr11:14262846~14273691:-
LUAD	cis	rs7937890	0.561	rs2575849	ENSG00000254418.1	RP11-21L19.1	3.85	0.000136	0.0182	0.2	0.17	Mitochondrial DNA levels;	chr11:14518093	chr11:14262846~14273691:-
LUAD	cis	rs1876905	0.68	rs354547	ENSG00000230177.1	RP5-1112D6.4	3.85	0.000136	0.0182	0.19	0.17	Mean corpuscular hemoglobin;	chr6:111213919	chr6:111277932~111278742:+
LUAD	cis	rs8014204	0.836	rs7154256	ENSG00000279594.1	RP11-950C14.10	3.85	0.000136	0.0182	0.19	0.17	Caffeine consumption;	chr14:74785884	chr14:75011269~75012851:-
LUAD	cis	rs301901	0.581	rs6881383	ENSG00000250155.1	CTD-2353F22.1	3.85	0.000136	0.0182	0.18	0.17	Height;	chr5:37545897	chr5:36666214~36725195:-
LUAD	cis	rs9381040	0.655	rs6903444	ENSG00000161912.16	ADCY10P1	-3.85	0.000136	0.0182	-0.15	-0.17	Alzheimer's disease (late onset);	chr6:41046481	chr6:41101022~41140835:+
LUAD	cis	rs34929064	0.718	rs34788132	ENSG00000230658.1	KLHL7-AS1	3.85	0.000136	0.0182	0.26	0.17	Major depression and alcohol dependence;	chr7:22699298	chr7:23101228~23105703:-
LUAD	cis	rs4499344	0.768	rs10411319	ENSG00000201388.1	SNORA68	3.85	0.000136	0.0182	0.18	0.17	Mean platelet volume;	chr19:32611899	chr19:32608337~32608469:-
LUAD	cis	rs9287719	0.781	rs6714795	ENSG00000243819.4	RN7SL832P	3.85	0.000136	0.0182	0.18	0.17	Prostate cancer;	chr2:10619008	chr2:10690344~10692099:+
LUAD	cis	rs6460942	0.908	rs78374554	ENSG00000226690.5	AC005281.1	3.85	0.000136	0.0182	0.34	0.17	Coronary artery disease;	chr7:12202659	chr7:12496429~12541910:+
LUAD	cis	rs7829975	0.572	rs7005000	ENSG00000253981.4	ALG1L13P	-3.85	0.000136	0.0182	-0.2	-0.17	Mood instability;	chr8:8939092	chr8:8236003~8244667:-
LUAD	cis	rs7107174	1	rs58565853	ENSG00000251323.2	RP11-452H21.4	3.85	0.000136	0.0182	0.21	0.17	Testicular germ cell tumor;	chr11:78325661	chr11:78423982~78429836:-
LUAD	cis	rs651907	0.557	rs3864012	ENSG00000244119.1	PDCL3P4	3.85	0.000136	0.0182	0.17	0.17	Colorectal cancer;	chr3:101678779	chr3:101712472~101713191:+
LUAD	cis	rs990171	0.538	rs11687071	ENSG00000234389.1	AC007278.3	3.85	0.000136	0.0182	0.17	0.17	Lymphocyte counts;	chr2:102495461	chr2:102438713~102440475:+
LUAD	cis	rs9309473	1	rs6546835	ENSG00000230002.2	ALMS1-IT1	3.85	0.000136	0.0182	0.21	0.17	Metabolite levels;	chr2:73437587	chr2:73456764~73459484:+
LUAD	cis	rs9309473	1	rs2901438	ENSG00000230002.2	ALMS1-IT1	3.85	0.000136	0.0182	0.21	0.17	Metabolite levels;	chr2:73438528	chr2:73456764~73459484:+
LUAD	cis	rs72634501	0.517	rs6684217	ENSG00000182109.6	RP11-69E11.4	-3.85	0.000136	0.0182	-0.19	-0.17	HDL cholesterol;	chr1:39121606	chr1:39522280~39546187:-
LUAD	cis	rs9309473	0.5	rs4852308	ENSG00000163016.8	ALMS1P	-3.85	0.000136	0.0182	-0.19	-0.17	Metabolite levels;	chr2:73606908	chr2:73644919~73685576:+
LUAD	cis	rs76904798	0.536	rs117762348	ENSG00000260943.1	RP11-476D10.1	3.85	0.000136	0.0182	0.39	0.17	Parkinson's disease;	chr12:40203810	chr12:40140926~40142876:-
LUAD	cis	rs76904798	0.536	rs11564273	ENSG00000260943.1	RP11-476D10.1	3.85	0.000136	0.0182	0.39	0.17	Parkinson's disease;	chr12:40204350	chr12:40140926~40142876:-
LUAD	cis	rs4718428	0.705	rs68168107	ENSG00000230295.1	RP11-458F8.2	-3.85	0.000136	0.0182	-0.15	-0.17	Corneal structure;	chr7:66790251	chr7:66880708~66882981:+
LUAD	cis	rs7208859	0.673	rs75142521	ENSG00000263603.1	CTD-2349P21.5	-3.85	0.000136	0.0182	-0.3	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913519	chr17:30729469~30731202:+
LUAD	cis	rs4683346	0.752	rs4683341	ENSG00000173811.9	CCDC13-AS1	-3.85	0.000136	0.0182	-0.18	-0.17	Granulocyte percentage of myeloid white cells;	chr3:42835902	chr3:42732575~42746768:+
LUAD	cis	rs2239547	0.657	rs7620706	ENSG00000243224.1	RP5-1157M23.2	-3.85	0.000136	0.0182	-0.2	-0.17	Schizophrenia;	chr3:52857740	chr3:52239258~52241097:+
LUAD	cis	rs2274273	0.624	rs8014540	ENSG00000258413.1	RP11-665C16.6	-3.85	0.000136	0.0182	-0.23	-0.17	Protein biomarker;	chr14:55374970	chr14:55262767~55272075:-
LUAD	cis	rs9341808	0.519	rs607130	ENSG00000233967.5	RP11-250B2.3	-3.85	0.000136	0.0182	-0.17	-0.17	Sitting height ratio;	chr6:80289516	chr6:80443344~80465927:+
LUAD	cis	rs875971	0.825	rs801202	ENSG00000273448.1	RP11-166O4.6	-3.85	0.000136	0.0182	-0.17	-0.17	Aortic root size;	chr7:66558942	chr7:67333047~67334383:+
LUAD	cis	rs603446	0.967	rs2849179	ENSG00000254851.1	RP11-109L13.1	-3.85	0.000136	0.0182	-0.21	-0.17	Triglycerides;	chr11:116750080	chr11:117135528~117138582:+
LUAD	cis	rs8180040	0.676	rs11130114	ENSG00000271161.1	BOLA2P2	3.85	0.000136	0.0182	0.16	0.17	Colorectal cancer;	chr3:47113161	chr3:47499841~47500407:+
LUAD	cis	rs8028182	0.609	rs10220738	ENSG00000260269.4	CTD-2323K18.1	3.85	0.000136	0.0182	0.24	0.17	Sudden cardiac arrest;	chr15:75374205	chr15:75527150~75601205:-
LUAD	cis	rs6502050	0.626	rs11868521	ENSG00000275966.1	RP11-1055B8.9	3.85	0.000136	0.0182	0.18	0.17	Life satisfaction;	chr17:82142319	chr17:81345476~81345966:-
LUAD	cis	rs9951698	0.667	rs9783859	ENSG00000267480.1	RP11-703I16.1	-3.85	0.000136	0.0182	-0.21	-0.17	Intelligence (multi-trait analysis);	chr18:12998930	chr18:12031178~12032181:-
LUAD	cis	rs9951698	0.703	rs9949589	ENSG00000267480.1	RP11-703I16.1	-3.85	0.000136	0.0182	-0.21	-0.17	Intelligence (multi-trait analysis);	chr18:12999755	chr18:12031178~12032181:-
LUAD	cis	rs9951698	0.703	rs9783903	ENSG00000267480.1	RP11-703I16.1	-3.85	0.000136	0.0182	-0.21	-0.17	Intelligence (multi-trait analysis);	chr18:13000211	chr18:12031178~12032181:-
LUAD	cis	rs4819052	0.62	rs421619	ENSG00000237664.1	LINC00316	-3.85	0.000136	0.0182	-0.23	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45126200	chr21:45338590~45341990:-
LUAD	cis	rs7200786	0.528	rs193751	ENSG00000274038.1	RP11-66H6.4	-3.85	0.000136	0.0182	-0.22	-0.17	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11149645	chr16:11056556~11057034:+
LUAD	cis	rs3738443	0.904	rs10924968	ENSG00000259865.1	RP11-488L18.10	3.85	0.000136	0.0182	0.18	0.17	Alcohol dependence;	chr1:247236957	chr1:247187281~247188526:-
LUAD	cis	rs2098713	0.534	rs11952015	ENSG00000250155.1	CTD-2353F22.1	3.85	0.000136	0.0182	0.19	0.17	Telomere length;	chr5:37539402	chr5:36666214~36725195:-
LUAD	cis	rs12073359	0.954	rs72692895	ENSG00000223945.2	RP11-458I7.1	-3.85	0.000136	0.0182	-0.25	-0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150075781	chr1:150053864~150055034:+
LUAD	cis	rs12073359	1	rs72692897	ENSG00000223945.2	RP11-458I7.1	-3.85	0.000136	0.0182	-0.25	-0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150077856	chr1:150053864~150055034:+
LUAD	cis	rs494459	0.536	rs34561290	ENSG00000278376.1	RP11-158I9.8	-3.85	0.000136	0.0182	-0.18	-0.17	Height;	chr11:118860890	chr11:118791254~118793137:+
LUAD	cis	rs494459	0.536	rs11217072	ENSG00000278376.1	RP11-158I9.8	-3.85	0.000136	0.0182	-0.18	-0.17	Height;	chr11:118861053	chr11:118791254~118793137:+
LUAD	cis	rs1910358	0.769	rs7730678	ENSG00000248874.4	C5orf17	-3.85	0.000136	0.0182	-0.23	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr5:23997930	chr5:23951348~24178263:+
LUAD	cis	rs1910358	0.769	rs1501943	ENSG00000248874.4	C5orf17	-3.85	0.000136	0.0182	-0.23	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr5:23998687	chr5:23951348~24178263:+
LUAD	cis	rs2274273	0.837	rs8011329	ENSG00000259318.1	RP11-454L9.2	3.85	0.000136	0.0182	0.15	0.17	Protein biomarker;	chr14:55210537	chr14:55394940~55395233:-
LUAD	cis	rs6121246	0.567	rs6060247	ENSG00000230613.1	HM13-AS1	3.85	0.000136	0.0182	0.27	0.17	Mean corpuscular hemoglobin;	chr20:31602917	chr20:31567707~31573263:-
LUAD	cis	rs6674176	0.66	rs3791112	ENSG00000237950.1	RP11-7O11.3	3.85	0.000136	0.0182	0.22	0.17	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43913576	chr1:43944370~43946551:-
LUAD	cis	rs6964587	1	rs7806184	ENSG00000188693.7	CYP51A1-AS1	-3.85	0.000136	0.0182	-0.2	-0.17	Breast cancer;	chr7:91972664	chr7:92134604~92180725:+
LUAD	cis	rs2274273	0.87	rs10149420	ENSG00000258413.1	RP11-665C16.6	-3.85	0.000136	0.0182	-0.22	-0.17	Protein biomarker;	chr14:55387539	chr14:55262767~55272075:-
LUAD	cis	rs11072089	0.786	rs7168811	ENSG00000259286.3	RP11-696L21.2	3.85	0.000136	0.0182	0.4	0.17	Bipolar disorder and schizophrenia;	chr15:69342180	chr15:68833830~68834749:+
LUAD	cis	rs12444979	0.515	rs8046628	ENSG00000261195.1	CTD-2380F24.1	-3.85	0.000136	0.0182	-0.23	-0.17	Body mass index;	chr16:19770638	chr16:19761172~19766099:-
LUAD	cis	rs6452524	0.618	rs2075685	ENSG00000281327.1	LINC01338	3.85	0.000136	0.0182	0.18	0.17	Hypertension (SNP x SNP interaction);	chr5:83076846	chr5:82850864~82859836:-
LUAD	cis	rs7829975	0.871	rs7829826	ENSG00000233609.3	RP11-62H7.2	-3.85	0.000136	0.0182	-0.14	-0.17	Mood instability;	chr8:8720610	chr8:8961200~8979025:+
LUAD	cis	rs7618501	0.519	rs3774749	ENSG00000280382.1	RP11-804H8.7	3.85	0.000136	0.0182	0.19	0.17	Intelligence (multi-trait analysis);	chr3:50169794	chr3:50599879~50601148:-
LUAD	cis	rs5758659	0.652	rs133305	ENSG00000270083.1	RP1-257I20.14	3.85	0.000136	0.0183	0.17	0.17	Cognitive function;	chr22:41999956	chr22:42089630~42090028:-
LUAD	cis	rs5758659	0.682	rs133306	ENSG00000270083.1	RP1-257I20.14	3.85	0.000136	0.0183	0.17	0.17	Cognitive function;	chr22:42000146	chr22:42089630~42090028:-
LUAD	cis	rs794728	0.502	rs62394137	ENSG00000249031.1	SUMO2P6	-3.85	0.000136	0.0183	-0.19	-0.17	Depressive symptoms (SSRI exposure interaction);	chr5:174437035	chr5:174561776~174562063:+
LUAD	cis	rs7829975	0.633	rs2979181	ENSG00000233609.3	RP11-62H7.2	3.85	0.000136	0.0183	0.14	0.17	Mood instability;	chr8:8465578	chr8:8961200~8979025:+
LUAD	cis	rs10971721	0.822	rs72725392	ENSG00000260947.1	RP11-384P7.7	3.85	0.000136	0.0183	0.36	0.17	Body mass index;	chr9:33867780	chr9:33697459~33700986:+
LUAD	cis	rs1400816	1	rs1400816	ENSG00000228389.1	AC068039.4	3.85	0.000136	0.0183	0.29	0.17	Amyotrophic lateral sclerosis (sporadic);	chr2:171824168	chr2:171773482~171775844:+
LUAD	cis	rs240993	0.516	rs369594	ENSG00000271789.1	RP5-1112D6.7	-3.85	0.000136	0.0183	-0.23	-0.17	Inflammatory skin disease;Psoriasis;	chr6:111303197	chr6:111297126~111298510:+
LUAD	cis	rs818427	0.964	rs465454	ENSG00000279522.1	CTC-487M23.6	3.85	0.000136	0.0183	0.2	0.17	Total body bone mineral density;	chr5:112894634	chr5:112894933~112896531:+
LUAD	cis	rs28374715	0.681	rs7163989	ENSG00000247556.5	OIP5-AS1	3.85	0.000136	0.0183	0.21	0.17	Ulcerative colitis;	chr15:41322423	chr15:41283990~41309737:+
LUAD	cis	rs8062405	0.558	rs151228	ENSG00000261766.1	RP11-22P6.2	-3.85	0.000136	0.0183	-0.15	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28551705	chr16:28862166~28863340:-
LUAD	cis	rs9646944	0.501	rs10210176	ENSG00000234389.1	AC007278.3	-3.85	0.000136	0.0183	-0.19	-0.17	Blood protein levels;	chr2:102463056	chr2:102438713~102440475:+
LUAD	cis	rs34779708	0.931	rs2384287	ENSG00000271335.4	RP11-324I22.4	3.85	0.000136	0.0183	0.18	0.17	Inflammatory bowel disease;Crohn's disease;	chr10:35051631	chr10:35314552~35336401:-
LUAD	cis	rs7107174	0.786	rs2450134	ENSG00000251323.2	RP11-452H21.4	3.85	0.000136	0.0183	0.22	0.17	Testicular germ cell tumor;	chr11:78214732	chr11:78423982~78429836:-
LUAD	cis	rs13434995	0.513	rs6554291	ENSG00000273257.1	RP11-177J6.1	-3.85	0.000136	0.0183	-0.23	-0.17	Adiponectin levels;	chr4:55571204	chr4:55387949~55388271:+
LUAD	cis	rs9500256	0.655	rs12210275	ENSG00000266579.1	RP1-71H19.2	-3.85	0.000136	0.0183	-0.23	-0.17	Eosinophilic esophagitis (pediatric);	chr6:58005481	chr6:57493855~57497691:+
LUAD	cis	rs2348418	0.966	rs1527578	ENSG00000247934.4	RP11-967K21.1	3.85	0.000136	0.0183	0.2	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28536903	chr12:28163298~28190738:-
LUAD	cis	rs2348418	0.966	rs16932891	ENSG00000247934.4	RP11-967K21.1	3.85	0.000136	0.0183	0.2	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28537055	chr12:28163298~28190738:-
LUAD	cis	rs2348418	0.966	rs2881910	ENSG00000247934.4	RP11-967K21.1	3.85	0.000136	0.0183	0.2	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28544459	chr12:28163298~28190738:-
LUAD	cis	rs9467773	1	rs1001687	ENSG00000241549.7	GUSBP2	3.85	0.000137	0.0183	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26572990	chr6:26871484~26956554:-
LUAD	cis	rs9467773	1	rs1570060	ENSG00000241549.7	GUSBP2	3.85	0.000137	0.0183	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26573334	chr6:26871484~26956554:-
LUAD	cis	rs9467773	1	rs1977201	ENSG00000241549.7	GUSBP2	3.85	0.000137	0.0183	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26573446	chr6:26871484~26956554:-
LUAD	cis	rs9467773	0.967	rs1321482	ENSG00000241549.7	GUSBP2	3.85	0.000137	0.0183	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26574926	chr6:26871484~26956554:-
LUAD	cis	rs9467773	1	rs9467798	ENSG00000241549.7	GUSBP2	3.85	0.000137	0.0183	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26575469	chr6:26871484~26956554:-
LUAD	cis	rs9467773	1	rs1570061	ENSG00000241549.7	GUSBP2	3.85	0.000137	0.0183	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26575758	chr6:26871484~26956554:-
LUAD	cis	rs9467773	1	rs6913462	ENSG00000241549.7	GUSBP2	3.85	0.000137	0.0183	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26577302	chr6:26871484~26956554:-
LUAD	cis	rs2032366	0.606	rs1452597	ENSG00000266920.1	ACTBP9	3.85	0.000137	0.0183	0.18	0.17	Obesity-related traits;	chr18:61590985	chr18:62442028~62443126:+
LUAD	cis	rs28374715	1	rs28374715	ENSG00000247556.5	OIP5-AS1	3.85	0.000137	0.0183	0.22	0.17	Ulcerative colitis;	chr15:41271752	chr15:41283990~41309737:+
LUAD	cis	rs916888	0.773	rs199534	ENSG00000232300.1	FAM215B	3.85	0.000137	0.0183	0.27	0.17	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46558830~46562795:-
LUAD	cis	rs4227	0.565	rs1642772	ENSG00000233223.2	AC113189.5	3.85	0.000137	0.0183	0.19	0.17	IgA nephropathy;	chr17:7600841	chr17:7581964~7584072:-
LUAD	cis	rs2288884	0.581	rs9636144	ENSG00000269959.1	SPACA6P-AS	-3.85	0.000137	0.0183	-0.18	-0.17	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52057881	chr19:51685363~51693456:-
LUAD	cis	rs442309	0.783	rs224095	ENSG00000238280.1	RP11-436D10.3	-3.85	0.000137	0.0183	-0.21	-0.17	Vogt-Koyanagi-Harada syndrome;	chr10:62782299	chr10:62793562~62805887:-
LUAD	cis	rs4237845	0.537	rs7312623	ENSG00000245651.2	RP11-620J15.2	3.85	0.000137	0.0183	0.18	0.17	Intelligence (multi-trait analysis);	chr12:57868740	chr12:57869835~57896482:-
LUAD	cis	rs2880765	0.527	rs35184622	ENSG00000259407.1	RP11-158M2.3	-3.85	0.000137	0.0183	-0.17	-0.17	Coronary artery disease;	chr15:85529804	chr15:85744109~85750281:-
LUAD	cis	rs2880765	0.527	rs1483578	ENSG00000259407.1	RP11-158M2.3	-3.85	0.000137	0.0183	-0.17	-0.17	Coronary artery disease;	chr15:85532186	chr15:85744109~85750281:-
LUAD	cis	rs67478160	0.643	rs12434686	ENSG00000272533.1	SNORA28	-3.85	0.000137	0.0183	-0.18	-0.17	Schizophrenia;	chr14:103849696	chr14:103337849~103337974:+
LUAD	cis	rs67478160	0.625	rs7141473	ENSG00000272533.1	SNORA28	-3.85	0.000137	0.0183	-0.18	-0.17	Schizophrenia;	chr14:103849718	chr14:103337849~103337974:+
LUAD	cis	rs10971721	0.584	rs10971940	ENSG00000260947.1	RP11-384P7.7	3.85	0.000137	0.0183	0.34	0.17	Body mass index;	chr9:34127213	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.584	rs72731226	ENSG00000260947.1	RP11-384P7.7	3.85	0.000137	0.0183	0.34	0.17	Body mass index;	chr9:34128832	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.584	rs10971944	ENSG00000260947.1	RP11-384P7.7	3.85	0.000137	0.0183	0.34	0.17	Body mass index;	chr9:34129008	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.543	rs72731230	ENSG00000260947.1	RP11-384P7.7	3.85	0.000137	0.0183	0.34	0.17	Body mass index;	chr9:34133733	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.631	rs74450404	ENSG00000260947.1	RP11-384P7.7	3.85	0.000137	0.0183	0.34	0.17	Body mass index;	chr9:34134666	chr9:33697459~33700986:+
LUAD	cis	rs2154319	0.836	rs578348	ENSG00000235358.1	RP11-399E6.1	3.85	0.000137	0.0183	0.24	0.17	Height;	chr1:41105645	chr1:41242373~41284861:+
LUAD	cis	rs9926296	0.527	rs1800335	ENSG00000260259.1	RP11-368I7.4	-3.85	0.000137	0.0183	-0.17	-0.17	Vitiligo;	chr16:89779787	chr16:89682620~89686569:-
LUAD	cis	rs642803	1	rs642803	ENSG00000255557.1	RP11-770G2.2	-3.85	0.000137	0.0183	-0.21	-0.17	Urate levels;	chr11:65793149	chr11:65745729~65771585:+
LUAD	cis	rs6088580	0.584	rs2378203	ENSG00000276073.1	RP5-1125A11.7	3.85	0.000137	0.0183	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34406040	chr20:33985617~33988989:-
LUAD	cis	rs3227	0.626	rs3818528	ENSG00000197251.3	LINC00336	3.85	0.000137	0.0183	0.22	0.17	Educational attainment;	chr6:33693314	chr6:33586106~33593338:-
LUAD	cis	rs638893	0.636	rs7119702	ENSG00000255239.1	AP002954.6	3.85	0.000137	0.0183	0.29	0.17	Vitiligo;	chr11:118736985	chr11:118688039~118690600:-
LUAD	cis	rs2929278	0.617	rs575082	ENSG00000166763.7	STRCP1	-3.84	0.000137	0.0183	-0.21	-0.17	Schizophrenia;	chr15:43817944	chr15:43699488~43718184:-
LUAD	cis	rs2929278	0.617	rs2955969	ENSG00000166763.7	STRCP1	-3.84	0.000137	0.0183	-0.21	-0.17	Schizophrenia;	chr15:43822329	chr15:43699488~43718184:-
LUAD	cis	rs1023500	0.552	rs5758566	ENSG00000205702.9	CYP2D7	3.84	0.000137	0.0183	0.14	0.17	Schizophrenia;	chr22:42058350	chr22:42140203~42144577:-
LUAD	cis	rs1816752	0.669	rs7984513	ENSG00000273628.1	RP11-756A22.7	-3.84	0.000137	0.0183	-0.2	-0.17	Obesity-related traits;	chr13:24445117	chr13:24933006~24936796:+
LUAD	cis	rs4767841	0.904	rs2074052	ENSG00000248636.5	RP11-768F21.1	-3.84	0.000137	0.0183	-0.2	-0.17	Urgency urinary incontinence;	chr12:119758409	chr12:119387987~119668079:-
LUAD	cis	rs4295623	0.531	rs2898295	ENSG00000255046.1	RP11-297N6.4	3.84	0.000137	0.0183	0.21	0.17	Morning vs. evening chronotype;	chr8:11738460	chr8:11797928~11802568:-
LUAD	cis	rs12468226	1	rs111542497	ENSG00000226261.1	AC064836.3	3.84	0.000137	0.0183	0.25	0.17	Urate levels;	chr2:202330369	chr2:202336024~202336727:-
LUAD	cis	rs5758659	0.519	rs133307	ENSG00000270083.1	RP1-257I20.14	3.84	0.000137	0.0183	0.17	0.17	Cognitive function;	chr22:42000564	chr22:42089630~42090028:-
LUAD	cis	rs5758659	0.652	rs5758537	ENSG00000270083.1	RP1-257I20.14	3.84	0.000137	0.0183	0.17	0.17	Cognitive function;	chr22:42001038	chr22:42089630~42090028:-
LUAD	cis	rs9309473	0.95	rs2947860	ENSG00000230002.2	ALMS1-IT1	3.84	0.000137	0.0183	0.22	0.17	Metabolite levels;	chr2:73628259	chr2:73456764~73459484:+
LUAD	cis	rs73193808	1	rs73193808	ENSG00000215533.7	LINC00189	-3.84	0.000137	0.0183	-0.25	-0.17	Coronary artery disease;	chr21:29162981	chr21:29193480~29288205:+
LUAD	cis	rs62514666	1	rs62514711	ENSG00000261693.1	RP13-467H17.1	-3.84	0.000137	0.0183	-0.4	-0.17	Facial morphology (factor 19);	chr8:142149068	chr8:142403652~142407028:+
LUAD	cis	rs62514666	1	rs62514712	ENSG00000261693.1	RP13-467H17.1	-3.84	0.000137	0.0183	-0.4	-0.17	Facial morphology (factor 19);	chr8:142150054	chr8:142403652~142407028:+
LUAD	cis	rs950027	0.549	rs11636114	ENSG00000259479.5	SORD2P	3.84	0.000137	0.0183	0.22	0.17	Response to fenofibrate (adiponectin levels);	chr15:45309214	chr15:44826371~44884694:-
LUAD	cis	rs2274273	0.805	rs28660594	ENSG00000259318.1	RP11-454L9.2	3.84	0.000137	0.0183	0.15	0.17	Protein biomarker;	chr14:55379456	chr14:55394940~55395233:-
LUAD	cis	rs4713118	0.869	rs9295743	ENSG00000280107.1	AL022393.9	-3.84	0.000137	0.0183	-0.22	-0.17	Parkinson's disease;	chr6:27747323	chr6:28170845~28172521:+
LUAD	cis	rs7560272	0.538	rs13000788	ENSG00000163016.8	ALMS1P	-3.84	0.000137	0.0183	-0.18	-0.17	Schizophrenia;	chr2:73691185	chr2:73644919~73685576:+
LUAD	cis	rs7246657	0.943	rs10422074	ENSG00000226686.6	LINC01535	-3.84	0.000137	0.0183	-0.26	-0.17	Coronary artery calcification;	chr19:37403334	chr19:37251912~37265535:+
LUAD	cis	rs651907	0.557	rs2288272	ENSG00000244119.1	PDCL3P4	3.84	0.000137	0.0183	0.17	0.17	Colorectal cancer;	chr3:101659632	chr3:101712472~101713191:+
LUAD	cis	rs8177376	0.581	rs512577	ENSG00000254905.1	RP11-712L6.7	-3.84	0.000137	0.0183	-0.21	-0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr11:126222046	chr11:126292922~126294254:-
LUAD	cis	rs990171	0.538	rs6705272	ENSG00000234389.1	AC007278.3	3.84	0.000137	0.0183	0.17	0.17	Lymphocyte counts;	chr2:102490110	chr2:102438713~102440475:+
LUAD	cis	rs2834288	0.734	rs9984514	ENSG00000237945.6	LINC00649	3.84	0.000137	0.0183	0.23	0.17	Gut microbiota (bacterial taxa);	chr21:33892370	chr21:33915534~33977691:+
LUAD	cis	rs2904524	0.541	rs10784839	ENSG00000257815.4	RP11-611E13.2	-3.84	0.000137	0.0183	-0.21	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70380985	chr12:69904033~70243360:-
LUAD	cis	rs9813712	0.585	rs10934929	ENSG00000249846.5	RP11-77P16.4	3.84	0.000137	0.0183	0.24	0.17	Response to amphetamines;	chr3:130225231	chr3:130112550~130120579:+
LUAD	cis	rs875971	0.545	rs2420456	ENSG00000224316.1	RP11-479O9.2	3.84	0.000137	0.0183	0.2	0.17	Aortic root size;	chr7:66280619	chr7:65773620~65802067:+
LUAD	cis	rs1400816	0.85	rs3821096	ENSG00000228389.1	AC068039.4	3.84	0.000137	0.0183	0.29	0.17	Amyotrophic lateral sclerosis (sporadic);	chr2:171807510	chr2:171773482~171775844:+
LUAD	cis	rs4908768	0.871	rs7553298	ENSG00000232912.4	RP5-1115A15.1	-3.84	0.000137	0.0183	-0.19	-0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8710824	chr1:8424645~8434838:+
LUAD	cis	rs1958023	0.606	rs8016331	ENSG00000259045.1	RP11-320M16.1	3.84	0.000137	0.0183	0.19	0.17	Mitochondrial DNA levels;	chr14:33175723	chr14:32484098~32484800:-
LUAD	cis	rs76878669	0.561	rs7115577	ENSG00000213409.4	RP11-658F2.3	-3.84	0.000137	0.0183	-0.21	-0.17	Educational attainment (years of education);	chr11:66404787	chr11:66761575~66762399:-
LUAD	cis	rs865483	0.895	rs853234	ENSG00000276054.1	RP11-378E13.3	-3.84	0.000137	0.0183	-0.21	-0.17	Monocyte count;	chr17:37482945	chr17:37386886~37387926:+
LUAD	cis	rs938554	0.612	rs9991278	ENSG00000163612.10	FAM86KP	-3.84	0.000137	0.0183	-0.26	-0.17	Blood metabolite levels;	chr4:10001041	chr4:9153296~9165451:+
LUAD	cis	rs854765	0.724	rs2955371	ENSG00000223979.2	SMCR2	3.84	0.000137	0.0183	0.2	0.17	Total body bone mineral density;	chr17:18064083	chr17:17674026~17677688:-
LUAD	cis	rs73242632	1	rs73242623	ENSG00000269949.1	RP11-738E22.3	3.84	0.000137	0.0183	0.43	0.17	Congenital heart disease (maternal effect);	chr4:56974377	chr4:56960927~56961373:-
LUAD	cis	rs73242632	1	rs2276896	ENSG00000269949.1	RP11-738E22.3	3.84	0.000137	0.0183	0.43	0.17	Congenital heart disease (maternal effect);	chr4:56978925	chr4:56960927~56961373:-
LUAD	cis	rs6964587	0.839	rs11767135	ENSG00000188693.7	CYP51A1-AS1	3.84	0.000137	0.0183	0.2	0.17	Breast cancer;	chr7:91921931	chr7:92134604~92180725:+
LUAD	cis	rs6964587	0.869	rs13237856	ENSG00000188693.7	CYP51A1-AS1	3.84	0.000137	0.0183	0.2	0.17	Breast cancer;	chr7:91922474	chr7:92134604~92180725:+
LUAD	cis	rs6540731	1	rs4500383	ENSG00000229983.1	RP11-15I11.2	3.84	0.000137	0.0184	0.21	0.17	Intelligence (childhood);	chr1:212218254	chr1:212168207~212190259:+
LUAD	cis	rs6471393	0.964	rs10504930	ENSG00000253848.1	RP11-10N23.5	-3.84	0.000137	0.0184	-0.2	-0.17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93732585	chr8:93741193~93744534:+
LUAD	cis	rs7394190	0.748	rs4746139	ENSG00000271848.1	RP11-464F9.21	-3.84	0.000137	0.0184	-0.26	-0.17	Incident atrial fibrillation;	chr10:73647891	chr10:73654039~73674719:+
LUAD	cis	rs3126085	0.515	rs4322234	ENSG00000237975.5	FLG-AS1	3.84	0.000137	0.0184	0.27	0.17	Atopic dermatitis;	chr1:152381292	chr1:152168125~152445456:+
LUAD	cis	rs36093844	0.527	rs10128700	ENSG00000279742.1	RP11-700A24.1	-3.84	0.000137	0.0184	-0.2	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86043350	chr11:85852557~85854943:-
LUAD	cis	rs1862618	0.853	rs252887	ENSG00000271828.1	CTD-2310F14.1	3.84	0.000137	0.0184	0.25	0.17	Initial pursuit acceleration;	chr5:56870361	chr5:56927874~56929573:+
LUAD	cis	rs11610206	1	rs12296395	ENSG00000258181.1	RP11-493L12.4	-3.84	0.000137	0.0184	-0.29	-0.17	Alzheimer's disease;	chr12:47241084	chr12:47248124~47257539:+
LUAD	cis	rs4809760	0.692	rs8118160	ENSG00000229222.1	KRT18P4	3.84	0.000137	0.0184	0.19	0.17	Gut microbiota (beta diversity);	chr20:49818099	chr20:49956745~49958032:+
LUAD	cis	rs11089937	0.616	rs7286793	ENSG00000211638.2	IGLV8-61	-3.84	0.000137	0.0184	-0.18	-0.17	Periodontitis (PAL4Q3);	chr22:22182951	chr22:22098700~22099212:+
LUAD	cis	rs7017914	0.967	rs12679261	ENSG00000246366.5	RP11-382J12.1	3.84	0.000137	0.0184	0.16	0.17	Bone mineral density;	chr8:70932414	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.967	rs10089583	ENSG00000246366.5	RP11-382J12.1	3.84	0.000137	0.0184	0.16	0.17	Bone mineral density;	chr8:70937249	chr8:70608577~70663279:+
LUAD	cis	rs755249	0.567	rs16825942	ENSG00000182109.6	RP11-69E11.4	3.84	0.000137	0.0184	0.21	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39196946	chr1:39522280~39546187:-
LUAD	cis	rs11089937	0.597	rs5750582	ENSG00000211640.3	IGLV6-57	3.84	0.000137	0.0184	0.13	0.17	Periodontitis (PAL4Q3);	chr22:22137690	chr22:22195713~22196460:+
LUAD	cis	rs11089937	0.626	rs5757028	ENSG00000211640.3	IGLV6-57	3.84	0.000137	0.0184	0.13	0.17	Periodontitis (PAL4Q3);	chr22:22137699	chr22:22195713~22196460:+
LUAD	cis	rs6001482	0.523	rs5757595	ENSG00000223350.2	IGLV9-49	-3.84	0.000137	0.0184	-0.17	-0.17	Diastolic blood pressure;	chr22:22235017	chr22:22343187~22343732:+
LUAD	cis	rs6921919	0.609	rs9461455	ENSG00000219392.1	RP1-265C24.5	-3.84	0.000138	0.0184	-0.22	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28115628~28116551:+
LUAD	cis	rs42490	0.536	rs366867	ENSG00000251136.7	RP11-37B2.1	-3.84	0.000138	0.0184	-0.19	-0.17	Leprosy;	chr8:89851946	chr8:89609409~89757727:-
LUAD	cis	rs42490	0.609	rs367640	ENSG00000251136.7	RP11-37B2.1	-3.84	0.000138	0.0184	-0.19	-0.17	Leprosy;	chr8:89852168	chr8:89609409~89757727:-
LUAD	cis	rs42490	0.576	rs425140	ENSG00000251136.7	RP11-37B2.1	-3.84	0.000138	0.0184	-0.19	-0.17	Leprosy;	chr8:89852397	chr8:89609409~89757727:-
LUAD	cis	rs755249	0.917	rs61779331	ENSG00000237624.1	OXCT2P1	3.84	0.000138	0.0184	0.26	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39505256	chr1:39514956~39516490:+
LUAD	cis	rs7200543	1	rs4500751	ENSG00000260735.1	RP11-72I8.1	-3.84	0.000138	0.0184	-0.19	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15046354	chr16:15094411~15109197:+
LUAD	cis	rs7845219	0.539	rs713113	ENSG00000253528.2	RP11-347C18.4	-3.84	0.000138	0.0184	-0.17	-0.17	Type 2 diabetes;	chr8:94865559	chr8:94974573~94974853:-
LUAD	cis	rs11134654	1	rs6871931	ENSG00000253966.1	CTC-455F18.3	-3.84	0.000138	0.0184	-0.27	-0.17	Smooth-surface caries;	chr5:170828587	chr5:170896929~170904461:+
LUAD	cis	rs17596685	1	rs12585014	ENSG00000271216.1	LINC01050	-3.84	0.000138	0.0184	-0.26	-0.17	C-reactive protein levels;	chr13:42566423	chr13:42810366~42812562:-
LUAD	cis	rs11637445	1	rs11637445	ENSG00000270964.1	RP11-502I4.3	-3.84	0.000138	0.0184	-0.2	-0.17	Posterior cortical atrophy and Alzheimer's disease;	chr15:67699268	chr15:67541072~67542604:-
LUAD	cis	rs712022	0.868	rs10833819	ENSG00000246225.5	RP11-17A1.3	-3.84	0.000138	0.0184	-0.22	-0.17	Dialysis-related mortality;	chr11:22801736	chr11:22829380~22945393:+
LUAD	cis	rs12073359	1	rs72694906	ENSG00000223945.2	RP11-458I7.1	-3.84	0.000138	0.0184	-0.25	-0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150093191	chr1:150053864~150055034:+
LUAD	cis	rs12073359	1	rs56188926	ENSG00000223945.2	RP11-458I7.1	-3.84	0.000138	0.0184	-0.25	-0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150101152	chr1:150053864~150055034:+
LUAD	cis	rs137603	0.602	rs137654	ENSG00000235209.1	CTA-150C2.13	-3.84	0.000138	0.0184	-0.18	-0.17	Primary biliary cholangitis;	chr22:39336408	chr22:38921227~38924708:+
LUAD	cis	rs2280018	1	rs2280017	ENSG00000183458.12	RP11-958N24.1	3.84	0.000138	0.0184	0.13	0.17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15057504	chr16:14911551~14935708:+
LUAD	cis	rs12822507	0.732	rs4763855	ENSG00000275963.1	RP11-180M15.6	3.84	0.000138	0.0184	0.2	0.17	Systemic lupus erythematosus;	chr12:12614824	chr12:12648939~12649713:+
LUAD	cis	rs7107174	1	rs10899475	ENSG00000251323.2	RP11-452H21.4	3.84	0.000138	0.0184	0.21	0.17	Testicular germ cell tumor;	chr11:78340564	chr11:78423982~78429836:-
LUAD	cis	rs595982	0.517	rs10404905	ENSG00000235191.1	NUCB1-AS1	-3.84	0.000138	0.0184	-0.19	-0.17	Red cell distribution width;	chr19:48902918	chr19:48910930~48918891:-
LUAD	cis	rs1124769	0.502	rs34354799	ENSG00000259378.1	DCAF13P3	3.84	0.000138	0.0184	0.24	0.17	Cognitive performance;	chr15:50774380	chr15:50944663~50945996:+
LUAD	cis	rs1124769	0.502	rs8042982	ENSG00000259378.1	DCAF13P3	3.84	0.000138	0.0184	0.24	0.17	Cognitive performance;	chr15:50774816	chr15:50944663~50945996:+
LUAD	cis	rs1124769	0.502	rs737031	ENSG00000259378.1	DCAF13P3	3.84	0.000138	0.0184	0.24	0.17	Cognitive performance;	chr15:50775340	chr15:50944663~50945996:+
LUAD	cis	rs9309473	1	rs6755217	ENSG00000230002.2	ALMS1-IT1	3.84	0.000138	0.0184	0.22	0.17	Metabolite levels;	chr2:73414157	chr2:73456764~73459484:+
LUAD	cis	rs7968440	1	rs2700479	ENSG00000272368.2	RP4-605O3.4	3.84	0.000138	0.0184	0.2	0.17	Fibrinogen;	chr12:50626688	chr12:50112197~50165618:+
LUAD	cis	rs7017914	0.967	rs1348535	ENSG00000246366.5	RP11-382J12.1	3.84	0.000138	0.0184	0.16	0.17	Bone mineral density;	chr8:70750506	chr8:70608577~70663279:+
LUAD	cis	rs801193	0.935	rs2659899	ENSG00000222364.1	RNU6-96P	-3.84	0.000138	0.0184	-0.19	-0.17	Aortic root size;	chr7:66721734	chr7:66395191~66395286:+
LUAD	cis	rs801193	1	rs62466794	ENSG00000222364.1	RNU6-96P	-3.84	0.000138	0.0184	-0.19	-0.17	Aortic root size;	chr7:66726592	chr7:66395191~66395286:+
LUAD	cis	rs35934224	0.769	rs76945759	ENSG00000232926.1	AC000078.5	3.84	0.000138	0.0184	0.25	0.17	Glaucoma (primary open-angle);	chr22:19873454	chr22:19887289~19887970:+
LUAD	cis	rs11264213	0.901	rs7542179	ENSG00000116883.8	RP11-268J15.5	3.84	0.000138	0.0184	0.25	0.17	Schizophrenia;	chr1:35995521	chr1:36323734~36329221:+
LUAD	cis	rs2823962	0.727	rs2211991	ENSG00000270093.1	AP000473.8	-3.84	0.000138	0.0184	-0.18	-0.17	Amyotrophic lateral sclerosis;	chr21:16652303	chr21:16643529~16645065:+
LUAD	cis	rs2823962	0.892	rs2211993	ENSG00000270093.1	AP000473.8	-3.84	0.000138	0.0184	-0.18	-0.17	Amyotrophic lateral sclerosis;	chr21:16652447	chr21:16643529~16645065:+
LUAD	cis	rs2823962	0.927	rs11911892	ENSG00000270093.1	AP000473.8	-3.84	0.000138	0.0184	-0.18	-0.17	Amyotrophic lateral sclerosis;	chr21:16652861	chr21:16643529~16645065:+
LUAD	cis	rs6547741	1	rs13026621	ENSG00000223522.1	AC093690.1	3.84	0.000138	0.0184	0.16	0.17	Oral cavity cancer;	chr2:27584757	chr2:28307691~28310459:-
LUAD	cis	rs860295	0.871	rs11582072	ENSG00000160766.13	GBAP1	3.84	0.000138	0.0184	0.19	0.17	Body mass index;	chr1:155507779	chr1:155213821~155227422:-
LUAD	cis	rs860295	0.871	rs6696888	ENSG00000160766.13	GBAP1	3.84	0.000138	0.0184	0.19	0.17	Body mass index;	chr1:155539091	chr1:155213821~155227422:-
LUAD	cis	rs1355223	0.902	rs12802120	ENSG00000271369.1	RP11-350D17.3	-3.84	0.000138	0.0184	-0.2	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34726103	chr11:34709600~34710161:+
LUAD	cis	rs1355223	0.902	rs12802323	ENSG00000271369.1	RP11-350D17.3	-3.84	0.000138	0.0184	-0.2	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34726192	chr11:34709600~34710161:+
LUAD	cis	rs9467773	1	rs6456734	ENSG00000241549.7	GUSBP2	3.84	0.000138	0.0184	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26566737	chr6:26871484~26956554:-
LUAD	cis	rs9467773	1	rs1535277	ENSG00000241549.7	GUSBP2	3.84	0.000138	0.0184	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26567574	chr6:26871484~26956554:-
LUAD	cis	rs9467773	1	rs1884948	ENSG00000241549.7	GUSBP2	3.84	0.000138	0.0184	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26567760	chr6:26871484~26956554:-
LUAD	cis	rs801193	1	rs1553609	ENSG00000222364.1	RNU6-96P	-3.84	0.000138	0.0184	-0.19	-0.17	Aortic root size;	chr7:66732152	chr7:66395191~66395286:+
LUAD	cis	rs10266483	0.96	rs13221291	ENSG00000228653.2	HNRNPCP7	-3.84	0.000138	0.0184	-0.19	-0.17	Response to statin therapy;	chr7:64279114	chr7:64500825~64501729:+
LUAD	cis	rs7332672	0.62	rs4319612	ENSG00000228889.5	UBAC2-AS1	-3.84	0.000138	0.0184	-0.22	-0.17	Eosinophil counts;	chr13:99411911	chr13:99196377~99200710:-
LUAD	cis	rs2665103	0.715	rs7403041	ENSG00000255769.6	GOLGA2P10	3.84	0.000138	0.0184	0.18	0.17	Intelligence (multi-trait analysis);	chr15:82287841	chr15:82472993~82513950:-
LUAD	cis	rs17608059	0.566	rs6502327	ENSG00000236088.8	COX10-AS1	-3.84	0.000138	0.0184	-0.19	-0.17	Temperament;	chr17:14042870	chr17:13756478~14069495:-
LUAD	cis	rs950173	1	rs13000153	ENSG00000228389.1	AC068039.4	3.84	0.000138	0.0184	0.29	0.17	Hippocampal volume;	chr2:171729557	chr2:171773482~171775844:+
LUAD	cis	rs858239	0.6	rs2072369	ENSG00000226816.2	AC005082.12	3.84	0.000138	0.0184	0.23	0.17	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23206013~23208045:+
LUAD	cis	rs5758659	0.622	rs5758527	ENSG00000182057.4	OGFRP1	3.84	0.000138	0.0184	0.21	0.17	Cognitive function;	chr22:41979757	chr22:42269753~42275196:+
LUAD	cis	rs35934224	0.71	rs73877376	ENSG00000232926.1	AC000078.5	3.84	0.000138	0.0184	0.23	0.17	Glaucoma (primary open-angle);	chr22:19869684	chr22:19887289~19887970:+
LUAD	cis	rs1167832	1	rs1167832	ENSG00000127957.15	PMS2P3	3.84	0.000138	0.0184	0.22	0.17	Ankle injury;	chr7:75537904	chr7:75502930~75528148:-
LUAD	cis	rs7178424	0.742	rs12915825	ENSG00000259251.2	RP11-643M14.1	-3.84	0.000138	0.0184	-0.17	-0.17	Height;	chr15:61883437	chr15:62060503~62062434:+
LUAD	cis	rs2904524	1	rs58612372	ENSG00000257613.1	LINC01481	-3.84	0.000138	0.0184	-0.31	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70276566	chr12:70219132~70221862:-
LUAD	cis	rs1823913	0.637	rs4853569	ENSG00000230611.1	HMGB1P27	3.84	0.000138	0.0184	0.2	0.17	Obesity-related traits;	chr2:191266970	chr2:191174233~191174835:+
LUAD	cis	rs8180040	1	rs1076394	ENSG00000271161.1	BOLA2P2	-3.84	0.000138	0.0184	-0.16	-0.17	Colorectal cancer;	chr3:47281291	chr3:47499841~47500407:+
LUAD	cis	rs8180040	0.966	rs17476234	ENSG00000271161.1	BOLA2P2	-3.84	0.000138	0.0184	-0.16	-0.17	Colorectal cancer;	chr3:47284808	chr3:47499841~47500407:+
LUAD	cis	rs62049817	0.544	rs7189599	ENSG00000261291.1	RP11-295M3.2	3.84	0.000138	0.0184	0.21	0.17	Granulocyte percentage of myeloid white cells;	chr16:53170059	chr16:53168522~53169450:+
LUAD	cis	rs3095008	0.902	rs3095011	ENSG00000243004.4	AC005062.2	3.84	0.000138	0.0184	0.19	0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide);	chr7:20203540	chr7:19918981~20140453:-
LUAD	cis	rs516805	0.961	rs9385248	ENSG00000279114.1	RP3-425C14.5	-3.84	0.000138	0.0184	-0.19	-0.17	Lymphocyte counts;	chr6:122490982	chr6:122471923~122484161:+
LUAD	cis	rs853679	0.607	rs67662114	ENSG00000219392.1	RP1-265C24.5	-3.84	0.000138	0.0184	-0.39	-0.17	Depression;	chr6:27964523	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.607	rs13216117	ENSG00000219392.1	RP1-265C24.5	-3.84	0.000138	0.0184	-0.39	-0.17	Depression;	chr6:27970706	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.607	rs36101351	ENSG00000219392.1	RP1-265C24.5	-3.84	0.000138	0.0184	-0.39	-0.17	Depression;	chr6:27975591	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.607	rs28360499	ENSG00000219392.1	RP1-265C24.5	-3.84	0.000138	0.0184	-0.39	-0.17	Depression;	chr6:27977618	chr6:28115628~28116551:+
LUAD	cis	rs7017914	0.934	rs17689585	ENSG00000246366.5	RP11-382J12.1	3.84	0.000138	0.0184	0.16	0.17	Bone mineral density;	chr8:70906566	chr8:70608577~70663279:+
LUAD	cis	rs4144027	0.791	rs67727470	ENSG00000258534.1	CTD-2134A5.4	-3.84	0.000138	0.0184	-0.19	-0.17	Blood metabolite levels;	chr14:103895659	chr14:103854366~103880111:-
LUAD	cis	rs1508798	0.539	rs3798092	ENSG00000250786.1	SNHG18	-3.84	0.000138	0.0184	-0.2	-0.17	Coronary artery disease;	chr5:9541581	chr5:9546200~9550609:+
LUAD	cis	rs12188164	1	rs34453673	ENSG00000225138.6	CTD-2228K2.7	3.84	0.000138	0.0184	0.17	0.17	Cystic fibrosis severity;	chr5:434607	chr5:473236~480884:+
LUAD	cis	rs4386084	0.963	rs10519250	ENSG00000242737.1	RP11-562A8.1	3.84	0.000138	0.0184	0.23	0.17	Basophil percentage of granulocytes;Basophil percentage of white cells;	chr15:49977276	chr15:50466738~50467096:+
LUAD	cis	rs7178424	0.777	rs8033816	ENSG00000259251.2	RP11-643M14.1	-3.84	0.000138	0.0184	-0.17	-0.17	Height;	chr15:61940968	chr15:62060503~62062434:+
LUAD	cis	rs6738440	0.51	rs10490072	ENSG00000234624.2	AC016894.1	3.84	0.000138	0.0184	0.21	0.17	F-cell distribution;	chr2:60442796	chr2:61416887~61417197:-
LUAD	cis	rs7580658	0.929	rs13029237	ENSG00000236682.1	AC068282.3	-3.84	0.000138	0.0184	-0.24	-0.17	Protein C levels;	chr2:127390278	chr2:127389130~127400580:+
LUAD	cis	rs338389	0.516	rs6416484	ENSG00000270964.1	RP11-502I4.3	-3.84	0.000138	0.0184	-0.18	-0.17	Survival in rectal cancer;	chr15:68020438	chr15:67541072~67542604:-
LUAD	cis	rs17098356	0.885	rs1957892	ENSG00000258926.1	RP11-47I22.1	-3.84	0.000138	0.0184	-0.16	-0.17	Reading and spelling;	chr14:61429779	chr14:61537508~61545287:-
LUAD	cis	rs7512552	0.803	rs9435997	ENSG00000275557.1	RP11-353N4.6	-3.84	0.000138	0.0184	-0.2	-0.17	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150317053	chr1:149607765~149612402:+
LUAD	cis	rs2304003	0.561	rs12151689	ENSG00000235192.1	AC009495.2	3.84	0.000138	0.0185	0.19	0.17	Social communication problems;	chr2:165799645	chr2:165794851~165810010:+
LUAD	cis	rs8180040	0.932	rs62248599	ENSG00000271161.1	BOLA2P2	-3.84	0.000138	0.0185	-0.17	-0.17	Colorectal cancer;	chr3:47475238	chr3:47499841~47500407:+
LUAD	cis	rs8180040	0.966	rs59586735	ENSG00000271161.1	BOLA2P2	-3.84	0.000138	0.0185	-0.17	-0.17	Colorectal cancer;	chr3:47476835	chr3:47499841~47500407:+
LUAD	cis	rs8014252	0.803	rs7158201	ENSG00000259158.2	ADAM20P1	3.84	0.000138	0.0185	0.27	0.17	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70543829	chr14:70468881~70483756:-
LUAD	cis	rs75920871	0.688	rs1473326	ENSG00000254851.1	RP11-109L13.1	-3.84	0.000138	0.0185	-0.38	-0.17	Subjective well-being;	chr11:116952956	chr11:117135528~117138582:+
LUAD	cis	rs853679	0.607	rs71559070	ENSG00000219392.1	RP1-265C24.5	-3.84	0.000138	0.0185	-0.38	-0.17	Depression;	chr6:28071151	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.607	rs35902873	ENSG00000219392.1	RP1-265C24.5	-3.84	0.000138	0.0185	-0.38	-0.17	Depression;	chr6:28091171	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.607	rs13197574	ENSG00000219392.1	RP1-265C24.5	-3.84	0.000138	0.0185	-0.38	-0.17	Depression;	chr6:28092461	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.607	rs34166054	ENSG00000219392.1	RP1-265C24.5	-3.84	0.000138	0.0185	-0.38	-0.17	Depression;	chr6:28098023	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.607	rs34662244	ENSG00000219392.1	RP1-265C24.5	-3.84	0.000138	0.0185	-0.38	-0.17	Depression;	chr6:28106103	chr6:28115628~28116551:+
LUAD	cis	rs35952432	1	rs35952432	ENSG00000219392.1	RP1-265C24.5	-3.84	0.000138	0.0185	-0.38	-0.17	Lung cancer;	chr6:28107123	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.607	rs13203816	ENSG00000219392.1	RP1-265C24.5	-3.84	0.000138	0.0185	-0.38	-0.17	Depression;	chr6:28111820	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.556	rs34588114	ENSG00000219392.1	RP1-265C24.5	-3.84	0.000138	0.0185	-0.38	-0.17	Depression;	chr6:28112850	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.546	rs34371502	ENSG00000219392.1	RP1-265C24.5	-3.84	0.000138	0.0185	-0.38	-0.17	Depression;	chr6:28113980	chr6:28115628~28116551:+
LUAD	cis	rs67478160	0.643	rs12878868	ENSG00000272533.1	SNORA28	3.84	0.000138	0.0185	0.18	0.17	Schizophrenia;	chr14:103767388	chr14:103337849~103337974:+
LUAD	cis	rs9287719	0.839	rs11683335	ENSG00000243819.4	RN7SL832P	3.84	0.000138	0.0185	0.18	0.17	Prostate cancer;	chr2:10616539	chr2:10690344~10692099:+
LUAD	cis	rs6502050	0.799	rs6502088	ENSG00000266654.1	RP11-1376P16.1	-3.84	0.000138	0.0185	-0.19	-0.17	Life satisfaction;	chr17:82211608	chr17:82160056~82160452:+
LUAD	cis	rs6832769	0.961	rs2177127	ENSG00000272969.1	RP11-528I4.2	3.84	0.000138	0.0185	0.18	0.17	Personality dimensions;	chr4:55513792	chr4:55547112~55547889:+
LUAD	cis	rs73193808	1	rs2832228	ENSG00000215533.7	LINC00189	-3.84	0.000138	0.0185	-0.25	-0.17	Coronary artery disease;	chr21:29162364	chr21:29193480~29288205:+
LUAD	cis	rs9287719	0.967	rs7563894	ENSG00000243819.4	RN7SL832P	3.84	0.000138	0.0185	0.18	0.17	Prostate cancer;	chr2:10614523	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs7566767	ENSG00000243819.4	RN7SL832P	3.84	0.000138	0.0185	0.18	0.17	Prostate cancer;	chr2:10614537	chr2:10690344~10692099:+
LUAD	cis	rs801193	0.967	rs34356500	ENSG00000222364.1	RNU6-96P	-3.84	0.000138	0.0185	-0.19	-0.17	Aortic root size;	chr7:66771620	chr7:66395191~66395286:+
LUAD	cis	rs6951245	1	rs79443843	ENSG00000199023.2	MIR339	-3.84	0.000138	0.0185	-0.31	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1035609	chr7:1022935~1023045:-
LUAD	cis	rs3742264	1	rs9534307	ENSG00000235903.6	CPB2-AS1	-3.84	0.000138	0.0185	-0.22	-0.17	Blood protein levels;	chr13:46069995	chr13:46052806~46113332:+
LUAD	cis	rs7200786	0.528	rs28087	ENSG00000274038.1	RP11-66H6.4	3.84	0.000138	0.0185	0.22	0.17	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11158972	chr16:11056556~11057034:+
LUAD	cis	rs7394190	0.688	rs3812629	ENSG00000271848.1	RP11-464F9.21	-3.84	0.000138	0.0185	-0.25	-0.17	Incident atrial fibrillation;	chr10:73647532	chr10:73654039~73674719:+
LUAD	cis	rs11051970	0.659	rs1809913	ENSG00000275854.1	RP11-278C7.5	-3.84	0.000138	0.0185	-0.18	-0.17	Response to tocilizumab in rheumatoid arthritis;	chr12:32438692	chr12:32736930~32737660:-
LUAD	cis	rs9341808	0.714	rs4256394	ENSG00000233967.5	RP11-250B2.3	3.84	0.000138	0.0185	0.17	0.17	Sitting height ratio;	chr6:80172425	chr6:80443344~80465927:+
LUAD	cis	rs2179367	0.632	rs9285520	ENSG00000216906.2	RP11-350J20.9	-3.84	0.000138	0.0185	-0.25	-0.17	Dupuytren's disease;	chr6:149372001	chr6:149904243~149906418:+
LUAD	cis	rs6840360	0.806	rs13149588	ENSG00000270265.1	RP11-731D1.4	3.84	0.000138	0.0185	0.17	0.17	Intelligence (multi-trait analysis);	chr4:151796605	chr4:151333775~151353224:-
LUAD	cis	rs6785206	0.667	rs6439139	ENSG00000242551.2	POU5F1P6	-3.84	0.000139	0.0185	-0.33	-0.17	Lymphocyte percentage of white cells;	chr3:128691442	chr3:128674735~128677005:-
LUAD	cis	rs6785206	1	rs6785206	ENSG00000242551.2	POU5F1P6	-3.84	0.000139	0.0185	-0.33	-0.17	Lymphocyte percentage of white cells;	chr3:128693181	chr3:128674735~128677005:-
LUAD	cis	rs10446497	0.585	rs13074050	ENSG00000272359.1	U4	3.84	0.000139	0.0185	0.21	0.17	Schizophrenia;	chr3:196816270	chr3:196747192~196747324:-
LUAD	cis	rs9287719	0.967	rs6759714	ENSG00000243819.4	RN7SL832P	3.84	0.000139	0.0185	0.18	0.17	Prostate cancer;	chr2:10607081	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs6744854	ENSG00000243819.4	RN7SL832P	3.84	0.000139	0.0185	0.18	0.17	Prostate cancer;	chr2:10607120	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs6759740	ENSG00000243819.4	RN7SL832P	3.84	0.000139	0.0185	0.18	0.17	Prostate cancer;	chr2:10607145	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs6709466	ENSG00000243819.4	RN7SL832P	3.84	0.000139	0.0185	0.18	0.17	Prostate cancer;	chr2:10608131	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs6719701	ENSG00000243819.4	RN7SL832P	3.84	0.000139	0.0185	0.18	0.17	Prostate cancer;	chr2:10608157	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.934	rs6432115	ENSG00000243819.4	RN7SL832P	3.84	0.000139	0.0185	0.18	0.17	Prostate cancer;	chr2:10608217	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs6432116	ENSG00000243819.4	RN7SL832P	3.84	0.000139	0.0185	0.18	0.17	Prostate cancer;	chr2:10608489	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs2110776	ENSG00000243819.4	RN7SL832P	3.84	0.000139	0.0185	0.18	0.17	Prostate cancer;	chr2:10608684	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs2110778	ENSG00000243819.4	RN7SL832P	3.84	0.000139	0.0185	0.18	0.17	Prostate cancer;	chr2:10608844	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs6432117	ENSG00000243819.4	RN7SL832P	3.84	0.000139	0.0185	0.18	0.17	Prostate cancer;	chr2:10609233	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs6432118	ENSG00000243819.4	RN7SL832P	3.84	0.000139	0.0185	0.18	0.17	Prostate cancer;	chr2:10609315	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.935	rs728283	ENSG00000243819.4	RN7SL832P	3.84	0.000139	0.0185	0.18	0.17	Prostate cancer;	chr2:10609964	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs728282	ENSG00000243819.4	RN7SL832P	3.84	0.000139	0.0185	0.18	0.17	Prostate cancer;	chr2:10610177	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs728281	ENSG00000243819.4	RN7SL832P	3.84	0.000139	0.0185	0.18	0.17	Prostate cancer;	chr2:10610229	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.934	rs6721510	ENSG00000243819.4	RN7SL832P	3.84	0.000139	0.0185	0.18	0.17	Prostate cancer;	chr2:10610920	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs6721514	ENSG00000243819.4	RN7SL832P	3.84	0.000139	0.0185	0.18	0.17	Prostate cancer;	chr2:10610936	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.934	rs6706763	ENSG00000243819.4	RN7SL832P	3.84	0.000139	0.0185	0.18	0.17	Prostate cancer;	chr2:10611281	chr2:10690344~10692099:+
LUAD	cis	rs9287719	1	rs9679122	ENSG00000243819.4	RN7SL832P	3.84	0.000139	0.0185	0.18	0.17	Prostate cancer;	chr2:10611584	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs9679581	ENSG00000243819.4	RN7SL832P	3.84	0.000139	0.0185	0.18	0.17	Prostate cancer;	chr2:10611610	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs10203664	ENSG00000243819.4	RN7SL832P	3.84	0.000139	0.0185	0.18	0.17	Prostate cancer;	chr2:10612251	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.934	rs10201077	ENSG00000243819.4	RN7SL832P	3.84	0.000139	0.0185	0.18	0.17	Prostate cancer;	chr2:10612300	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs10203785	ENSG00000243819.4	RN7SL832P	3.84	0.000139	0.0185	0.18	0.17	Prostate cancer;	chr2:10612382	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs9287720	ENSG00000243819.4	RN7SL832P	3.84	0.000139	0.0185	0.18	0.17	Prostate cancer;	chr2:10612538	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.87	rs10167676	ENSG00000243819.4	RN7SL832P	3.84	0.000139	0.0185	0.18	0.17	Prostate cancer;	chr2:10613014	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs12995159	ENSG00000243819.4	RN7SL832P	3.84	0.000139	0.0185	0.18	0.17	Prostate cancer;	chr2:10613197	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs12995602	ENSG00000243819.4	RN7SL832P	3.84	0.000139	0.0185	0.18	0.17	Prostate cancer;	chr2:10613416	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs6432119	ENSG00000243819.4	RN7SL832P	3.84	0.000139	0.0185	0.18	0.17	Prostate cancer;	chr2:10613561	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs6432120	ENSG00000243819.4	RN7SL832P	3.84	0.000139	0.0185	0.18	0.17	Prostate cancer;	chr2:10613645	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs6432122	ENSG00000243819.4	RN7SL832P	3.84	0.000139	0.0185	0.18	0.17	Prostate cancer;	chr2:10613718	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs6712304	ENSG00000243819.4	RN7SL832P	3.84	0.000139	0.0185	0.18	0.17	Prostate cancer;	chr2:10614249	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs6712406	ENSG00000243819.4	RN7SL832P	3.84	0.000139	0.0185	0.18	0.17	Prostate cancer;	chr2:10614294	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs10195802	ENSG00000243819.4	RN7SL832P	3.84	0.000139	0.0185	0.18	0.17	Prostate cancer;	chr2:10614406	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs7566875	ENSG00000243819.4	RN7SL832P	3.84	0.000139	0.0185	0.18	0.17	Prostate cancer;	chr2:10614666	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.934	rs4371336	ENSG00000243819.4	RN7SL832P	3.84	0.000139	0.0185	0.18	0.17	Prostate cancer;	chr2:10615597	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.967	rs4405729	ENSG00000243819.4	RN7SL832P	3.84	0.000139	0.0185	0.18	0.17	Prostate cancer;	chr2:10615653	chr2:10690344~10692099:+
LUAD	cis	rs848490	0.855	rs55860308	ENSG00000214293.7	APTR	3.84	0.000139	0.0185	0.23	0.17	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77616657	chr7:77657660~77696265:-
LUAD	cis	rs2273156	0.587	rs3809449	ENSG00000226677.3	IGBP1P1	-3.84	0.000139	0.0185	-0.26	-0.17	Immunoglobulin light chain (AL) amyloidosis;	chr14:35045751	chr14:34939324~34940332:+
LUAD	cis	rs2273156	0.587	rs76767804	ENSG00000226677.3	IGBP1P1	-3.84	0.000139	0.0185	-0.26	-0.17	Immunoglobulin light chain (AL) amyloidosis;	chr14:35050161	chr14:34939324~34940332:+
LUAD	cis	rs10863681	1	rs10863681	ENSG00000228437.4	RP11-400N13.2	3.84	0.000139	0.0185	0.21	0.17	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222071916	chr1:221966341~221984964:+
LUAD	cis	rs2638953	0.814	rs11049413	ENSG00000278733.1	RP11-425D17.1	-3.84	0.000139	0.0185	-0.2	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28186322	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.85	rs11049414	ENSG00000278733.1	RP11-425D17.1	-3.84	0.000139	0.0185	-0.2	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28186325	chr12:28185625~28186190:-
LUAD	cis	rs6964587	1	rs2157747	ENSG00000188693.7	CYP51A1-AS1	-3.84	0.000139	0.0185	-0.2	-0.17	Breast cancer;	chr7:92121264	chr7:92134604~92180725:+
LUAD	cis	rs9803723	0.789	rs12744222	ENSG00000261349.1	RP3-465N24.5	-3.84	0.000139	0.0185	-0.2	-0.17	Male-pattern baldness;	chr1:25137360	chr1:25266102~25267136:-
LUAD	cis	rs8180040	0.967	rs17411375	ENSG00000271161.1	BOLA2P2	-3.84	0.000139	0.0185	-0.16	-0.17	Colorectal cancer;	chr3:47353645	chr3:47499841~47500407:+
LUAD	cis	rs1799949	0.628	rs4474733	ENSG00000267340.1	RP11-242D8.3	3.84	0.000139	0.0185	0.2	0.17	Menopause (age at onset);	chr17:43356292	chr17:43169880~43170077:-
LUAD	cis	rs151234	0.676	rs151320	ENSG00000259982.1	CDC37P1	3.84	0.000139	0.0185	0.31	0.17	Platelet distribution width;	chr16:28557357	chr16:28700294~28701540:-
LUAD	cis	rs62025270	0.688	rs62025272	ENSG00000259416.2	RP11-158M2.5	-3.84	0.000139	0.0185	-0.22	-0.17	Idiopathic pulmonary fibrosis;	chr15:85770391	chr15:85754941~85756237:-
LUAD	cis	rs7692995	1	rs12503997	ENSG00000235413.3	KRT18P63	-3.84	0.000139	0.0185	-0.27	-0.17	Height;	chr4:17946466	chr4:17911674~17912976:+
LUAD	cis	rs11893307	0.537	rs7571572	ENSG00000235852.1	AC005540.3	3.84	0.000139	0.0185	0.21	0.17	Mean platelet volume;	chr2:190688911	chr2:190880797~190882059:-
LUAD	cis	rs4130344	0.574	rs11737459	ENSG00000271817.2	U3	3.84	0.000139	0.0185	0.19	0.17	Intelligence (multi-trait analysis);	chr4:158937584	chr4:158700691~158700909:+
LUAD	cis	rs35934224	0.769	rs117985725	ENSG00000232926.1	AC000078.5	3.84	0.000139	0.0185	0.25	0.17	Glaucoma (primary open-angle);	chr22:19873329	chr22:19887289~19887970:+
LUAD	cis	rs7760535	1	rs7760535	ENSG00000266032.1	AL357515.1	-3.84	0.000139	0.0185	-0.22	-0.17	Metabolic traits;	chr6:111425880	chr6:110969773~110969872:-
LUAD	cis	rs6121246	0.609	rs2376998	ENSG00000230613.1	HM13-AS1	3.84	0.000139	0.0185	0.21	0.17	Mean corpuscular hemoglobin;	chr20:31752860	chr20:31567707~31573263:-
LUAD	cis	rs7809615	0.748	rs10240199	ENSG00000244219.5	GS1-259H13.2	-3.84	0.000139	0.0185	-0.31	-0.17	Blood metabolite ratios;	chr7:99599555	chr7:99598066~99610813:+
LUAD	cis	rs36093844	0.527	rs55697624	ENSG00000279742.1	RP11-700A24.1	-3.84	0.000139	0.0185	-0.21	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85930497	chr11:85852557~85854943:-
LUAD	cis	rs7777677	0.925	rs4726546	ENSG00000276953.1	TRBV12-4	3.84	0.000139	0.0185	0.16	0.17	Alcoholic chronic pancreatitis;	chr7:142660485	chr7:142563740~142564245:+
LUAD	cis	rs7777677	0.925	rs6956756	ENSG00000276953.1	TRBV12-4	3.84	0.000139	0.0185	0.16	0.17	Alcoholic chronic pancreatitis;	chr7:142661832	chr7:142563740~142564245:+
LUAD	cis	rs7777677	0.889	rs6975391	ENSG00000276953.1	TRBV12-4	3.84	0.000139	0.0185	0.16	0.17	Alcoholic chronic pancreatitis;	chr7:142662001	chr7:142563740~142564245:+
LUAD	cis	rs7777677	0.925	rs9655661	ENSG00000276953.1	TRBV12-4	3.84	0.000139	0.0185	0.16	0.17	Alcoholic chronic pancreatitis;	chr7:142662291	chr7:142563740~142564245:+
LUAD	cis	rs7777677	0.888	rs9655574	ENSG00000276953.1	TRBV12-4	3.84	0.000139	0.0185	0.16	0.17	Alcoholic chronic pancreatitis;	chr7:142662412	chr7:142563740~142564245:+
LUAD	cis	rs7777677	0.963	rs4726550	ENSG00000276953.1	TRBV12-4	3.84	0.000139	0.0185	0.16	0.17	Alcoholic chronic pancreatitis;	chr7:142662932	chr7:142563740~142564245:+
LUAD	cis	rs7777677	0.963	rs7796324	ENSG00000276953.1	TRBV12-4	3.84	0.000139	0.0185	0.16	0.17	Alcoholic chronic pancreatitis;	chr7:142663708	chr7:142563740~142564245:+
LUAD	cis	rs875971	0.52	rs160645	ENSG00000224316.1	RP11-479O9.2	-3.84	0.000139	0.0185	-0.21	-0.17	Aortic root size;	chr7:66091320	chr7:65773620~65802067:+
LUAD	cis	rs11874381	1	rs12965497	ENSG00000266696.1	RP11-30L3.2	-3.84	0.000139	0.0185	-0.19	-0.17	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);	chr18:49687147	chr18:49205912~49208781:+
LUAD	cis	rs10498514	1	rs76202452	ENSG00000258824.2	CTD-2555O16.2	3.84	0.000139	0.0185	0.4	0.17	Cognitive performance;	chr14:64560634	chr14:64422935~64448557:-
LUAD	cis	rs9517320	1	rs9517322	ENSG00000231194.1	FARP1-AS1	3.84	0.000139	0.0185	0.2	0.17	Longevity;	chr13:98474084	chr13:98435405~98435840:-
LUAD	cis	rs2731006	0.64	rs1517670	ENSG00000257114.2	RP11-25I15.3	3.84	0.000139	0.0185	0.28	0.17	Panic disorder;	chr12:42780510	chr12:42692216~42717119:+
LUAD	cis	rs6832769	0.826	rs10462035	ENSG00000272969.1	RP11-528I4.2	3.84	0.000139	0.0185	0.18	0.17	Personality dimensions;	chr4:55513011	chr4:55547112~55547889:+
LUAD	cis	rs62244186	0.545	rs725866	ENSG00000233509.2	ZNF197-AS1	3.84	0.000139	0.0185	0.19	0.17	Depressive symptoms;	chr3:44724041	chr3:44617128~44624797:-
LUAD	cis	rs7503168	0.558	rs11654542	ENSG00000267592.1	CTC-507E2.2	3.84	0.000139	0.0185	0.37	0.17	Plateletcrit;	chr17:35662289	chr17:35596904~35597128:-
LUAD	cis	rs365302	1	rs419281	ENSG00000235086.1	FNDC1-IT1	3.84	0.000139	0.0185	0.23	0.17	Coronary heart disease;	chr6:159221828	chr6:159240786~159243329:+
LUAD	cis	rs6928977	0.675	rs9399148	ENSG00000231028.7	LINC00271	3.84	0.000139	0.0185	0.2	0.17	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135523221	chr6:135497801~135716055:+
LUAD	cis	rs4237845	0.636	rs11172371	ENSG00000245651.2	RP11-620J15.2	3.84	0.000139	0.0185	0.18	0.17	Intelligence (multi-trait analysis);	chr12:57892405	chr12:57869835~57896482:-
LUAD	cis	rs8030379	1	rs10152139	ENSG00000230373.7	GOLGA6L5P	-3.84	0.000139	0.0185	-0.16	-0.17	Waist circumference;Waist circumference adjusted for body mass index;	chr15:83901510	chr15:84507885~84516814:-
LUAD	cis	rs748404	0.601	rs502157	ENSG00000205771.5	CATSPER2P1	3.84	0.000139	0.0185	0.21	0.17	Lung cancer;	chr15:43236375	chr15:43726918~43747094:-
LUAD	cis	rs7937682	0.961	rs11828343	ENSG00000230911.1	PPIHP1	3.84	0.000139	0.0185	0.23	0.17	Primary sclerosing cholangitis;	chr11:111620598	chr11:112029858~112030367:-
LUAD	cis	rs73108077	1	rs73108009	ENSG00000281376.1	ABALON	-3.84	0.000139	0.0185	-0.3	-0.17	Red blood cell density in sickle cell anemia;	chr20:31390409	chr20:31721507~31723409:+
LUAD	cis	rs7429990	0.965	rs7653368	ENSG00000228638.1	FCF1P2	-3.84	0.000139	0.0185	-0.2	-0.17	Educational attainment (years of education);	chr3:47943871	chr3:48290793~48291375:-
LUAD	cis	rs6969780	0.915	rs17471520	ENSG00000233429.8	HOTAIRM1	3.84	0.000139	0.0185	0.3	0.17	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27139171	chr7:27095647~27100265:+
LUAD	cis	rs2657294	0.965	rs2657286	ENSG00000226051.5	ZNF503-AS1	3.84	0.000139	0.0185	0.23	0.17	Pneumonia;	chr10:75145940	chr10:75269819~75373500:+
LUAD	cis	rs7617773	0.817	rs11928691	ENSG00000199476.1	Y_RNA	-3.84	0.000139	0.0185	-0.22	-0.17	Coronary artery disease;	chr3:48245275	chr3:48288587~48288694:+
LUAD	cis	rs10971721	0.908	rs10971722	ENSG00000260947.1	RP11-384P7.7	3.84	0.000139	0.0185	0.36	0.17	Body mass index;	chr9:33828166	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs10971723	ENSG00000260947.1	RP11-384P7.7	3.84	0.000139	0.0185	0.36	0.17	Body mass index;	chr9:33829604	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.908	rs12376055	ENSG00000260947.1	RP11-384P7.7	3.84	0.000139	0.0185	0.36	0.17	Body mass index;	chr9:33831957	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.908	rs55684780	ENSG00000260947.1	RP11-384P7.7	3.84	0.000139	0.0185	0.36	0.17	Body mass index;	chr9:33833210	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.908	rs10971728	ENSG00000260947.1	RP11-384P7.7	3.84	0.000139	0.0185	0.36	0.17	Body mass index;	chr9:33834635	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.642	rs114466241	ENSG00000260947.1	RP11-384P7.7	3.84	0.000139	0.0185	0.36	0.17	Body mass index;	chr9:33835731	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.731	rs12378261	ENSG00000260947.1	RP11-384P7.7	3.84	0.000139	0.0185	0.36	0.17	Body mass index;	chr9:33837174	chr9:33697459~33700986:+
LUAD	cis	rs13108904	0.557	rs1680033	ENSG00000196810.4	CTBP1-AS2	-3.84	0.000139	0.0185	-0.22	-0.17	Obesity-related traits;	chr4:1249616	chr4:1249300~1288291:+
LUAD	cis	rs877819	0.583	rs2620881	ENSG00000228403.1	RP11-563N6.6	-3.84	0.000139	0.0185	-0.18	-0.17	Systemic lupus erythematosus;	chr10:48875066	chr10:48878022~48878649:+
LUAD	cis	rs2638953	0.962	rs10843171	ENSG00000278733.1	RP11-425D17.1	-3.84	0.000139	0.0185	-0.21	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28435583	chr12:28185625~28186190:-
LUAD	cis	rs2682471	0.605	rs10772275	ENSG00000245648.1	RP11-277P12.20	3.84	0.000139	0.0185	0.21	0.17	Macrophage inflammatory protein 1a levels;	chr12:10410993	chr12:10363769~10398506:+
LUAD	cis	rs4218	0.587	rs1446237	ENSG00000277144.1	RP11-59H7.4	-3.84	0.000139	0.0185	-0.21	-0.17	Social communication problems;	chr15:59052603	chr15:59115547~59116089:-
LUAD	cis	rs67478160	0.595	rs1475007	ENSG00000272533.1	SNORA28	3.84	0.000139	0.0185	0.18	0.17	Schizophrenia;	chr14:103830810	chr14:103337849~103337974:+
LUAD	cis	rs854765	0.647	rs854814	ENSG00000223979.2	SMCR2	-3.84	0.000139	0.0185	-0.21	-0.17	Total body bone mineral density;	chr17:18100334	chr17:17674026~17677688:-
LUAD	cis	rs11673344	0.523	rs6510585	ENSG00000276846.1	CTD-3220F14.3	3.84	0.000139	0.0185	0.19	0.17	Obesity-related traits;	chr19:37063081	chr19:37314868~37315620:-
LUAD	cis	rs3018712	0.547	rs4930583	ENSG00000212093.1	AP000807.1	-3.84	0.000139	0.0185	-0.22	-0.17	Total body bone mineral density;	chr11:68643711	chr11:68506083~68506166:-
LUAD	cis	rs10754283	0.557	rs1215511	ENSG00000231613.1	RP5-943J3.1	3.84	0.000139	0.0185	0.17	0.17	Amyotrophic lateral sclerosis (sporadic);	chr1:89621984	chr1:89788914~89790492:+
LUAD	cis	rs4499344	0.73	rs421607	ENSG00000201388.1	SNORA68	3.84	0.000139	0.0185	0.18	0.17	Mean platelet volume;	chr19:32614045	chr19:32608337~32608469:-
LUAD	cis	rs12440869	1	rs8029582	ENSG00000270964.1	RP11-502I4.3	-3.84	0.000139	0.0185	-0.2	-0.17	Peak velocity of the mitral A-wave;	chr15:67283207	chr15:67541072~67542604:-
LUAD	cis	rs9467773	0.901	rs1407045	ENSG00000124549.13	BTN2A3P	3.84	0.000139	0.0185	0.16	0.17	Intelligence (multi-trait analysis);	chr6:26475927	chr6:26421391~26432383:+
LUAD	cis	rs8180040	0.966	rs11716763	ENSG00000271161.1	BOLA2P2	-3.84	0.000139	0.0185	-0.17	-0.17	Colorectal cancer;	chr3:47476776	chr3:47499841~47500407:+
LUAD	cis	rs74024059	1	rs335729	ENSG00000260269.4	CTD-2323K18.1	-3.84	0.000139	0.0185	-0.47	-0.17	Red blood cell count;Hematocrit;	chr15:75955362	chr15:75527150~75601205:-
LUAD	cis	rs6558530	0.666	rs10113471	ENSG00000253982.1	CTD-2336O2.1	3.84	0.000139	0.0185	0.23	0.17	Systolic blood pressure;	chr8:1747661	chr8:1761990~1764502:-
LUAD	cis	rs524281	0.773	rs11227448	ENSG00000255320.1	RP11-755F10.1	3.84	0.000139	0.0185	0.27	0.17	Electroencephalogram traits;	chr11:66281020	chr11:66244840~66246239:-
LUAD	cis	rs4237845	0.514	rs4760339	ENSG00000245651.2	RP11-620J15.2	3.84	0.000139	0.0185	0.18	0.17	Intelligence (multi-trait analysis);	chr12:57874366	chr12:57869835~57896482:-
LUAD	cis	rs7131987	0.621	rs11050181	ENSG00000275476.1	RP11-996F15.4	-3.84	0.000139	0.0185	-0.19	-0.17	QT interval;	chr12:29314736	chr12:29277397~29277882:-
LUAD	cis	rs7131987	0.65	rs10843384	ENSG00000275476.1	RP11-996F15.4	-3.84	0.000139	0.0185	-0.19	-0.17	QT interval;	chr12:29319476	chr12:29277397~29277882:-
LUAD	cis	rs7131987	0.65	rs11050188	ENSG00000275476.1	RP11-996F15.4	-3.84	0.000139	0.0185	-0.19	-0.17	QT interval;	chr12:29320175	chr12:29277397~29277882:-
LUAD	cis	rs7131987	0.683	rs12366505	ENSG00000275476.1	RP11-996F15.4	-3.84	0.000139	0.0185	-0.19	-0.17	QT interval;	chr12:29321177	chr12:29277397~29277882:-
LUAD	cis	rs7131987	0.65	rs12366527	ENSG00000275476.1	RP11-996F15.4	-3.84	0.000139	0.0185	-0.19	-0.17	QT interval;	chr12:29321323	chr12:29277397~29277882:-
LUAD	cis	rs7131987	0.65	rs7311912	ENSG00000275476.1	RP11-996F15.4	-3.84	0.000139	0.0185	-0.19	-0.17	QT interval;	chr12:29322770	chr12:29277397~29277882:-
LUAD	cis	rs7246657	0.943	rs7255952	ENSG00000226686.6	LINC01535	-3.84	0.000139	0.0185	-0.26	-0.17	Coronary artery calcification;	chr19:37497895	chr19:37251912~37265535:+
LUAD	cis	rs62355901	0.551	rs60856350	ENSG00000271828.1	CTD-2310F14.1	3.84	0.000139	0.0185	0.33	0.17	Breast cancer;	chr5:56727093	chr5:56927874~56929573:+
LUAD	cis	rs13113518	1	rs13136282	ENSG00000273257.1	RP11-177J6.1	3.84	0.000139	0.0186	0.19	0.17	Height;	chr4:55551845	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs11934897	ENSG00000273257.1	RP11-177J6.1	3.84	0.000139	0.0186	0.19	0.17	Height;	chr4:55553396	chr4:55387949~55388271:+
LUAD	cis	rs13113518	0.934	rs11932293	ENSG00000273257.1	RP11-177J6.1	3.84	0.000139	0.0186	0.19	0.17	Height;	chr4:55554025	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs4865011	ENSG00000273257.1	RP11-177J6.1	3.84	0.000139	0.0186	0.19	0.17	Height;	chr4:55554456	chr4:55387949~55388271:+
LUAD	cis	rs8098244	0.565	rs1711446	ENSG00000264745.1	TTC39C-AS1	3.84	0.000139	0.0186	0.18	0.17	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23674776	chr18:23994213~24015339:-
LUAD	cis	rs2732480	0.577	rs2634684	ENSG00000257763.1	OR5BK1P	-3.84	0.000139	0.0186	-0.18	-0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48337092	chr12:48355792~48356614:-
LUAD	cis	rs6502050	0.835	rs3088177	ENSG00000275966.1	RP11-1055B8.9	-3.84	0.000139	0.0186	-0.18	-0.17	Life satisfaction;	chr17:82153848	chr17:81345476~81345966:-
LUAD	cis	rs9341808	0.667	rs3805919	ENSG00000272129.1	RP11-250B2.6	3.84	0.000139	0.0186	0.21	0.17	Sitting height ratio;	chr6:80197092	chr6:80355424~80356859:+
LUAD	cis	rs4906332	1	rs4900574	ENSG00000244691.1	RPL10AP1	3.84	0.000139	0.0186	0.22	0.17	Coronary artery disease;	chr14:103412687	chr14:103412119~103412761:-
LUAD	cis	rs12744310	1	rs12731400	ENSG00000235358.1	RP11-399E6.1	3.84	0.000139	0.0186	0.23	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41295680	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs12032756	ENSG00000235358.1	RP11-399E6.1	3.84	0.000139	0.0186	0.23	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41295757	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs55859000	ENSG00000235358.1	RP11-399E6.1	3.84	0.000139	0.0186	0.23	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41295769	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs12030372	ENSG00000235358.1	RP11-399E6.1	3.84	0.000139	0.0186	0.23	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41296357	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs12032162	ENSG00000235358.1	RP11-399E6.1	3.84	0.000139	0.0186	0.23	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41297263	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs12031417	ENSG00000235358.1	RP11-399E6.1	3.84	0.000139	0.0186	0.23	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41297356	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs12037588	ENSG00000235358.1	RP11-399E6.1	3.84	0.000139	0.0186	0.23	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41298283	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs12037657	ENSG00000235358.1	RP11-399E6.1	3.84	0.000139	0.0186	0.23	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41298503	chr1:41242373~41284861:+
LUAD	cis	rs12744310	0.832	rs12027990	ENSG00000235358.1	RP11-399E6.1	3.84	0.000139	0.0186	0.23	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41298765	chr1:41242373~41284861:+
LUAD	cis	rs9309473	1	rs11903916	ENSG00000230002.2	ALMS1-IT1	3.84	0.000139	0.0186	0.21	0.17	Metabolite levels;	chr2:73588201	chr2:73456764~73459484:+
LUAD	cis	rs227584	0.663	rs3180912	ENSG00000267080.4	ASB16-AS1	-3.84	0.00014	0.0186	-0.15	-0.17	Bone mineral density;Bone mineral density (hip);	chr17:44182095	chr17:44175973~44186717:-
LUAD	cis	rs2732480	0.577	rs2732448	ENSG00000273765.1	RP11-370I10.11	3.84	0.00014	0.0186	0.19	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48336817	chr12:48360920~48361377:+
LUAD	cis	rs3743162	0.553	rs12900463	ENSG00000225151.9	GOLGA2P7	-3.84	0.00014	0.0186	-0.25	-0.17	Alzheimer's disease (age of onset);	chr15:84872155	chr15:84199311~84230136:-
LUAD	cis	rs9951698	0.703	rs7243660	ENSG00000267480.1	RP11-703I16.1	-3.84	0.00014	0.0186	-0.21	-0.17	Intelligence (multi-trait analysis);	chr18:13002197	chr18:12031178~12032181:-
LUAD	cis	rs7178424	0.806	rs1425270	ENSG00000259251.2	RP11-643M14.1	3.84	0.00014	0.0186	0.17	0.17	Height;	chr15:61945511	chr15:62060503~62062434:+
LUAD	cis	rs2279440	0.759	rs7642020	ENSG00000206573.7	THUMPD3-AS1	3.84	0.00014	0.0186	0.17	0.17	Glucose homeostasis traits;	chr3:9480796	chr3:9349689~9398579:-
LUAD	cis	rs651907	0.557	rs7651406	ENSG00000244119.1	PDCL3P4	3.84	0.00014	0.0186	0.17	0.17	Colorectal cancer;	chr3:101674452	chr3:101712472~101713191:+
LUAD	cis	rs442309	0.812	rs224089	ENSG00000238280.1	RP11-436D10.3	-3.84	0.00014	0.0186	-0.2	-0.17	Vogt-Koyanagi-Harada syndrome;	chr10:62780161	chr10:62793562~62805887:-
LUAD	cis	rs1056107	0.763	rs10115594	ENSG00000225513.1	RP11-165N19.2	-3.84	0.00014	0.0186	-0.19	-0.17	Colorectal cancer;	chr9:112174198	chr9:112173522~112173971:-
LUAD	cis	rs14027	0.512	rs6997976	ENSG00000279347.1	RP11-85I17.2	3.84	0.00014	0.0186	0.15	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119722044	chr8:119838736~119840385:-
LUAD	cis	rs365302	1	rs422470	ENSG00000235086.1	FNDC1-IT1	3.84	0.00014	0.0186	0.23	0.17	Coronary heart disease;	chr6:159228628	chr6:159240786~159243329:+
LUAD	cis	rs6540731	1	rs951623	ENSG00000229983.1	RP11-15I11.2	3.84	0.00014	0.0186	0.21	0.17	Intelligence (childhood);	chr1:212225720	chr1:212168207~212190259:+
LUAD	cis	rs202072	1	rs202073	ENSG00000272379.1	RP1-257A7.5	-3.84	0.00014	0.0186	-0.25	-0.17	HIV-1 viral setpoint;	chr6:13268373	chr6:13290018~13290490:-
LUAD	cis	rs12440869	1	rs2120837	ENSG00000270964.1	RP11-502I4.3	-3.84	0.00014	0.0186	-0.2	-0.17	Peak velocity of the mitral A-wave;	chr15:67284457	chr15:67541072~67542604:-
LUAD	cis	rs2742417	0.532	rs2742433	ENSG00000230530.1	LIMD1-AS1	3.84	0.00014	0.0186	0.2	0.17	Response to anti-depressant treatment in major depressive disorder;	chr3:45696615	chr3:45679043~45689134:-
LUAD	cis	rs7394190	0.748	rs34163229	ENSG00000271848.1	RP11-464F9.21	-3.84	0.00014	0.0186	-0.25	-0.17	Incident atrial fibrillation;	chr10:73647154	chr10:73654039~73674719:+
LUAD	cis	rs1476587	0.92	rs10480551	ENSG00000224046.1	AC005076.5	3.84	0.00014	0.0186	0.23	0.17	Brachial circumference;	chr7:87111521	chr7:87151423~87152420:-
LUAD	cis	rs8031584	0.678	rs798127	ENSG00000260128.5	ULK4P2	3.84	0.00014	0.0186	0.23	0.17	Huntington's disease progression;	chr15:30825200	chr15:30572738~30600647:+
LUAD	cis	rs7572733	0.935	rs10192466	ENSG00000222017.1	AC011997.1	3.84	0.00014	0.0186	0.22	0.17	Dermatomyositis;	chr2:197873295	chr2:197693106~197774823:+
LUAD	cis	rs7572733	0.935	rs2217837	ENSG00000222017.1	AC011997.1	3.84	0.00014	0.0186	0.22	0.17	Dermatomyositis;	chr2:197881535	chr2:197693106~197774823:+
LUAD	cis	rs7572733	0.901	rs6734096	ENSG00000222017.1	AC011997.1	3.84	0.00014	0.0186	0.22	0.17	Dermatomyositis;	chr2:197891735	chr2:197693106~197774823:+
LUAD	cis	rs736801	0.607	rs11746555	ENSG00000233006.5	AC034220.3	3.84	0.00014	0.0186	0.16	0.17	Mosquito bite size;Breast cancer;	chr5:132391341	chr5:132311285~132369916:-
LUAD	cis	rs13434995	0.513	rs2101476	ENSG00000273257.1	RP11-177J6.1	-3.84	0.00014	0.0186	-0.23	-0.17	Adiponectin levels;	chr4:55578961	chr4:55387949~55388271:+
LUAD	cis	rs8058578	0.945	rs34480360	ENSG00000232748.3	RP11-196G11.6	-3.84	0.00014	0.0186	-0.22	-0.17	Multiple myeloma;	chr16:30787368	chr16:31056460~31062803:+
LUAD	cis	rs4268898	0.662	rs72793208	ENSG00000242628.4	AC009228.1	3.84	0.00014	0.0186	0.25	0.17	Asthma;	chr2:24287415	chr2:24214381~24221516:+
LUAD	cis	rs763121	0.962	rs909564	ENSG00000225450.1	RP3-508I15.14	-3.84	0.00014	0.0186	-0.16	-0.17	Menopause (age at onset);	chr22:38730503	chr22:38739003~38749041:+
LUAD	cis	rs2486288	0.656	rs11854325	ENSG00000259479.5	SORD2P	-3.84	0.00014	0.0186	-0.21	-0.17	Glomerular filtration rate;	chr15:45256761	chr15:44826371~44884694:-
LUAD	cis	rs3026445	0.503	rs12426216	ENSG00000278993.1	RP3-424M6.4	3.84	0.00014	0.0186	0.21	0.17	QT interval;	chr12:110066285	chr12:110501614~110503441:+
LUAD	cis	rs6502050	0.835	rs4247357	ENSG00000266654.1	RP11-1376P16.1	-3.84	0.00014	0.0186	-0.19	-0.17	Life satisfaction;	chr17:82209113	chr17:82160056~82160452:+
LUAD	cis	rs10129255	0.957	rs10136560	ENSG00000211947.2	IGHV3-21	-3.84	0.00014	0.0186	-0.12	-0.17	Kawasaki disease;	chr14:106787630	chr14:106235064~106235594:-
LUAD	cis	rs17507216	0.958	rs72751643	ENSG00000276710.3	CSPG4P8	-3.84	0.00014	0.0186	-0.19	-0.17	Excessive daytime sleepiness;	chr15:82559444	chr15:82459472~82477258:+
LUAD	cis	rs9840812	0.598	rs33999043	ENSG00000239213.4	NCK1-AS1	3.84	0.00014	0.0186	0.25	0.17	Fibrinogen levels;	chr3:136381198	chr3:136841726~136862054:-
LUAD	cis	rs442177	0.524	rs342435	ENSG00000251411.1	RP11-397E7.4	-3.84	0.00014	0.0186	-0.18	-0.17	Triglycerides;Hemoglobin concentration;	chr4:87122054	chr4:86913266~86914817:-
LUAD	cis	rs6840360	0.642	rs1443090	ENSG00000270265.1	RP11-731D1.4	-3.84	0.00014	0.0186	-0.18	-0.17	Intelligence (multi-trait analysis);	chr4:151530667	chr4:151333775~151353224:-
LUAD	cis	rs2832270	1	rs73193868	ENSG00000174680.8	GRIK1-AS1	3.84	0.00014	0.0186	0.36	0.17	Response to mTOR inhibitor (everolimus);	chr21:29227903	chr21:29748175~29764002:+
LUAD	cis	rs638893	0.617	rs4938561	ENSG00000255422.1	AP002954.4	-3.84	0.00014	0.0186	-0.24	-0.17	Vitiligo;	chr11:118847776	chr11:118704607~118750263:+
LUAD	cis	rs17818399	0.547	rs12997164	ENSG00000279254.1	RP11-536C12.1	-3.84	0.00014	0.0186	-0.19	-0.17	Height;	chr2:46531607	chr2:46668870~46670778:+
LUAD	cis	rs2354432	0.607	rs7516430	ENSG00000237188.3	RP11-337C18.8	3.84	0.00014	0.0186	0.27	0.17	Mitochondrial DNA levels;	chr1:147295381	chr1:147172771~147211568:+
LUAD	cis	rs1401999	0.864	rs4148563	ENSG00000223882.1	ABCC5-AS1	-3.84	0.00014	0.0186	-0.18	-0.17	Anterior chamber depth;	chr3:184008211	chr3:184006338~184011419:+
LUAD	cis	rs1401999	0.898	rs4148561	ENSG00000223882.1	ABCC5-AS1	-3.84	0.00014	0.0186	-0.18	-0.17	Anterior chamber depth;	chr3:184008591	chr3:184006338~184011419:+
LUAD	cis	rs10165862	0.572	rs11674212	ENSG00000163016.8	ALMS1P	3.84	0.00014	0.0186	0.22	0.17	Intelligence (multi-trait analysis);	chr2:73684053	chr2:73644919~73685576:+
LUAD	cis	rs6120849	0.573	rs3746429	ENSG00000202150.1	RNU6-407P	-3.84	0.00014	0.0186	-0.27	-0.17	Protein C levels;	chr20:35115804	chr20:35030317~35030420:-
LUAD	cis	rs12908161	0.959	rs34342559	ENSG00000254414.1	RP11-182J1.1	3.84	0.00014	0.0186	0.22	0.17	Schizophrenia;	chr15:84788040	chr15:84631898~84633987:-
LUAD	cis	rs12908161	0.959	rs35557864	ENSG00000254414.1	RP11-182J1.1	3.84	0.00014	0.0186	0.22	0.17	Schizophrenia;	chr15:84788398	chr15:84631898~84633987:-
LUAD	cis	rs11242704	0.559	rs11242706	ENSG00000272279.1	RP11-157J24.2	-3.84	0.00014	0.0186	-0.25	-0.17	Response to hepatitis C treatment;	chr6:1539877	chr6:1528364~1528911:-
LUAD	cis	rs4795519	0.736	rs16964439	ENSG00000266313.1	RP11-173M1.4	3.84	0.00014	0.0186	0.22	0.17	Chronic myeloid leukemia;	chr17:27107360	chr17:27333256~27348491:+
LUAD	cis	rs12122100	0.651	rs12129691	ENSG00000244371.2	PFN1P8	3.84	0.00014	0.0186	0.22	0.17	HIV-1 control;	chr1:147082598	chr1:146957117~146957659:-
LUAD	cis	rs2657294	0.965	rs4746264	ENSG00000233313.2	HMGA1P5	-3.84	0.00014	0.0186	-0.22	-0.17	Pneumonia;	chr10:75114194	chr10:75276376~75276646:-
LUAD	cis	rs523522	0.962	rs2235218	ENSG00000278344.1	RP11-18C24.8	3.84	0.00014	0.0186	0.23	0.17	High light scatter reticulocyte count;	chr12:120450816	chr12:120500735~120501090:-
LUAD	cis	rs7017914	0.622	rs34022947	ENSG00000246366.5	RP11-382J12.1	3.84	0.00014	0.0186	0.17	0.17	Bone mineral density;	chr8:71072373	chr8:70608577~70663279:+
LUAD	cis	rs8031584	0.958	rs11293	ENSG00000260128.5	ULK4P2	-3.84	0.00014	0.0186	-0.22	-0.17	Huntington's disease progression;	chr15:30942778	chr15:30572738~30600647:+
LUAD	cis	rs2731006	0.64	rs908659	ENSG00000257114.2	RP11-25I15.3	3.84	0.00014	0.0186	0.28	0.17	Panic disorder;	chr12:42775216	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.64	rs908660	ENSG00000257114.2	RP11-25I15.3	3.84	0.00014	0.0186	0.28	0.17	Panic disorder;	chr12:42775218	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.64	rs908661	ENSG00000257114.2	RP11-25I15.3	3.84	0.00014	0.0186	0.28	0.17	Panic disorder;	chr12:42775255	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.64	rs908662	ENSG00000257114.2	RP11-25I15.3	3.84	0.00014	0.0186	0.28	0.17	Panic disorder;	chr12:42775273	chr12:42692216~42717119:+
LUAD	cis	rs481331	0.866	rs11499093	ENSG00000185904.10	LINC00839	-3.84	0.00014	0.0186	-0.28	-0.17	Systemic juvenile idiopathic arthritis;	chr10:42487342	chr10:42475543~42495336:+
LUAD	cis	rs1348850	0.958	rs10930799	ENSG00000213963.5	AC074286.1	3.84	0.00014	0.0186	0.21	0.17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177594597	chr2:177283508~177392691:-
LUAD	cis	rs4130344	0.874	rs13133730	ENSG00000271817.2	U3	-3.84	0.00014	0.0187	-0.18	-0.17	Intelligence (multi-trait analysis);	chr4:158768071	chr4:158700691~158700909:+
LUAD	cis	rs240993	0.812	rs9398272	ENSG00000230177.1	RP5-1112D6.4	3.84	0.00014	0.0187	0.17	0.17	Inflammatory skin disease;Psoriasis;	chr6:111522345	chr6:111277932~111278742:+
LUAD	cis	rs8180040	0.966	rs2101247	ENSG00000271161.1	BOLA2P2	-3.84	0.00014	0.0187	-0.17	-0.17	Colorectal cancer;	chr3:47452813	chr3:47499841~47500407:+
LUAD	cis	rs9549260	0.664	rs9532575	ENSG00000229456.1	RLIMP1	3.84	0.00014	0.0187	0.19	0.17	Red blood cell count;	chr13:40651224	chr13:40618738~40621348:+
LUAD	cis	rs73198271	0.613	rs11249892	ENSG00000253893.2	FAM85B	3.84	0.00014	0.0187	0.22	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8799730	chr8:8167819~8226614:-
LUAD	cis	rs11893307	0.507	rs1465305	ENSG00000235852.1	AC005540.3	3.84	0.00014	0.0187	0.2	0.17	Mean platelet volume;	chr2:190720666	chr2:190880797~190882059:-
LUAD	cis	rs11893307	0.507	rs1465303	ENSG00000235852.1	AC005540.3	3.84	0.00014	0.0187	0.2	0.17	Mean platelet volume;	chr2:190720714	chr2:190880797~190882059:-
LUAD	cis	rs155076	1	rs155076	ENSG00000224429.6	LINC00539	3.84	0.00014	0.0187	0.21	0.17	White matter hyperintensity burden;	chr13:21295975	chr13:21303515~21348721:-
LUAD	cis	rs7181230	1	rs28620926	ENSG00000278621.1	CTD-2033D15.3	3.84	0.00014	0.0187	0.2	0.17	Dehydroepiandrosterone sulphate levels;	chr15:40064970	chr15:39588357~39588882:-
LUAD	cis	rs8040855	0.965	rs6496766	ENSG00000259774.1	RP11-182J1.13	-3.84	0.00014	0.0187	-0.2	-0.17	Bulimia nervosa;	chr15:85159144	chr15:84422618~84425882:+
LUAD	cis	rs4718428	1	rs1830070	ENSG00000272831.1	RP11-792A8.4	3.84	0.00014	0.0187	0.17	0.17	Corneal structure;	chr7:66884684	chr7:66739829~66740385:-
LUAD	cis	rs5758511	0.68	rs5758682	ENSG00000233903.2	Z83851.4	3.84	0.000141	0.0187	0.26	0.17	Birth weight;	chr22:42249196	chr22:42276355~42277052:+
LUAD	cis	rs4604732	0.685	rs4925673	ENSG00000227135.1	GCSAML-AS1	-3.84	0.000141	0.0187	-0.24	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247473498	chr1:247524679~247526752:-
LUAD	cis	rs10090774	0.786	rs11776239	ENSG00000280303.2	ERICD	-3.84	0.000141	0.0187	-0.19	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140708602	chr8:140636281~140638283:+
LUAD	cis	rs516805	0.52	rs1741820	ENSG00000279453.1	RP3-425C14.4	-3.84	0.000141	0.0187	-0.18	-0.17	Lymphocyte counts;	chr6:122400365	chr6:122436789~122439223:-
LUAD	cis	rs67981189	0.896	rs3814871	ENSG00000269927.1	RP6-91H8.3	3.84	0.000141	0.0187	0.21	0.17	Schizophrenia;	chr14:70978071	chr14:71141125~71143253:-
LUAD	cis	rs11048434	0.518	rs11048496	ENSG00000256937.1	KRT17P8	-3.84	0.000141	0.0187	-0.19	-0.17	Sjögren's syndrome;	chr12:9019825	chr12:9127783~9128645:+
LUAD	cis	rs6762477	0.715	rs12631337	ENSG00000234667.1	ACTBP13	3.84	0.000141	0.0187	0.19	0.17	Menarche (age at onset);	chr3:50161104	chr3:49873347~49877980:-
LUAD	cis	rs34638952	0.507	rs797959	ENSG00000264808.1	RP11-802D6.1	3.84	0.000141	0.0187	0.2	0.17	Sitting height ratio;	chr17:29289576	chr17:29369717~29390777:-
LUAD	cis	rs7142881	0.815	rs11627332	ENSG00000258525.1	RP11-829H16.3	3.84	0.000141	0.0187	0.19	0.17	Response to iloperidone treatment (QT prolongation);	chr14:31606544	chr14:30876179~30889808:-
LUAD	cis	rs2348418	0.767	rs1478332	ENSG00000244712.1	RP11-874G11.1	-3.84	0.000141	0.0187	-0.2	-0.17	Lung function (FEV1);Lung function (FVC);	chr12:28255432	chr12:28564678~28565141:-
LUAD	cis	rs4474465	0.92	rs10899535	ENSG00000251323.2	RP11-452H21.4	-3.84	0.000141	0.0187	-0.21	-0.17	Alzheimer's disease (survival time);	chr11:78505191	chr11:78423982~78429836:-
LUAD	cis	rs7618501	0.521	rs6774354	ENSG00000234667.1	ACTBP13	-3.84	0.000141	0.0187	-0.19	-0.17	Intelligence (multi-trait analysis);	chr3:49924347	chr3:49873347~49877980:-
LUAD	cis	rs7246967	0.673	rs34676724	ENSG00000236312.3	RPL34P34	3.84	0.000141	0.0187	0.24	0.17	Bronchopulmonary dysplasia;	chr19:22735671	chr19:22368599~22368952:-
LUAD	cis	rs7636293	0.592	rs10934881	ENSG00000270773.1	RP13-685P2.7	3.84	0.000141	0.0187	0.26	0.17	Height;	chr3:129324739	chr3:129345411~129346164:+
LUAD	cis	rs7551222	0.716	rs6679311	ENSG00000240219.1	RP11-430C7.5	3.84	0.000141	0.0187	0.2	0.17	Schizophrenia;	chr1:204590548	chr1:204626775~204629712:+
LUAD	cis	rs4660214	0.789	rs1984142	ENSG00000182109.6	RP11-69E11.4	-3.84	0.000141	0.0187	-0.19	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39279936	chr1:39522280~39546187:-
LUAD	cis	rs7829975	0.686	rs907180	ENSG00000253981.4	ALG1L13P	3.84	0.000141	0.0187	0.19	0.17	Mood instability;	chr8:8845317	chr8:8236003~8244667:-
LUAD	cis	rs17596685	0.932	rs6561058	ENSG00000271216.1	LINC01050	3.84	0.000141	0.0187	0.25	0.17	C-reactive protein levels;	chr13:42552037	chr13:42810366~42812562:-
LUAD	cis	rs8028182	0.537	rs4371118	ENSG00000260269.4	CTD-2323K18.1	-3.84	0.000141	0.0187	-0.24	-0.17	Sudden cardiac arrest;	chr15:75606549	chr15:75527150~75601205:-
LUAD	cis	rs4713118	0.824	rs13211701	ENSG00000280107.1	AL022393.9	-3.84	0.000141	0.0187	-0.22	-0.17	Parkinson's disease;	chr6:27782300	chr6:28170845~28172521:+
LUAD	cis	rs4713118	0.824	rs9468229	ENSG00000280107.1	AL022393.9	-3.84	0.000141	0.0187	-0.22	-0.17	Parkinson's disease;	chr6:27782307	chr6:28170845~28172521:+
LUAD	cis	rs12908161	1	rs17601029	ENSG00000254414.1	RP11-182J1.1	3.84	0.000141	0.0187	0.22	0.17	Schizophrenia;	chr15:84804478	chr15:84631898~84633987:-
LUAD	cis	rs9341808	0.667	rs7746917	ENSG00000260645.1	RP11-250B2.5	3.84	0.000141	0.0187	0.16	0.17	Sitting height ratio;	chr6:80221786	chr6:80466958~80469080:+
LUAD	cis	rs9549260	0.591	rs9577108	ENSG00000229456.1	RLIMP1	3.84	0.000141	0.0187	0.18	0.17	Red blood cell count;	chr13:40697628	chr13:40618738~40621348:+
LUAD	cis	rs4561483	0.549	rs33659	ENSG00000261560.1	RP11-166B2.3	-3.84	0.000141	0.0187	-0.15	-0.17	Testicular germ cell tumor;	chr16:11869504	chr16:11881075~11882569:-
LUAD	cis	rs7107174	1	rs2511170	ENSG00000251323.2	RP11-452H21.4	3.84	0.000141	0.0187	0.23	0.17	Testicular germ cell tumor;	chr11:78269536	chr11:78423982~78429836:-
LUAD	cis	rs9287719	0.967	rs7355649	ENSG00000243819.4	RN7SL832P	3.84	0.000141	0.0187	0.18	0.17	Prostate cancer;	chr2:10607968	chr2:10690344~10692099:+
LUAD	cis	rs2243480	1	rs160634	ENSG00000226002.1	RP11-460N20.5	3.84	0.000141	0.0187	0.27	0.17	Diabetic kidney disease;	chr7:66063677	chr7:65084103~65100232:+
LUAD	cis	rs9900062	1	rs9900062	ENSG00000214174.7	AMZ2P1	3.84	0.000141	0.0187	0.27	0.17	QT interval;	chr17:64743456	chr17:64966550~64975576:-
LUAD	cis	rs2731006	0.64	rs2468321	ENSG00000257114.2	RP11-25I15.3	-3.84	0.000141	0.0187	-0.27	-0.17	Panic disorder;	chr12:42803164	chr12:42692216~42717119:+
LUAD	cis	rs763121	0.888	rs2235229	ENSG00000273076.1	RP3-508I15.22	3.84	0.000141	0.0187	0.15	0.17	Menopause (age at onset);	chr22:38728907	chr22:38743495~38743910:+
LUAD	cis	rs2548724	0.673	rs709370	ENSG00000250682.4	LINC00491	-3.84	0.000141	0.0187	-0.21	-0.17	Type 2 diabetes;	chr5:102288689	chr5:102609156~102671559:-
LUAD	cis	rs2979489	0.773	rs2915617	ENSG00000254152.1	CTD-3107M8.2	3.84	0.000141	0.0187	0.22	0.17	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Mean corpuscular hemoglobin;Plateletcrit;Sum neutrophil eosinophil counts;Mean corpuscular volume;	chr8:30414794	chr8:30349866~30350347:-
LUAD	cis	rs9287719	0.781	rs12472807	ENSG00000243819.4	RN7SL832P	3.84	0.000141	0.0187	0.18	0.17	Prostate cancer;	chr2:10641479	chr2:10690344~10692099:+
LUAD	cis	rs728616	0.867	rs41297151	ENSG00000225484.5	NUTM2B-AS1	-3.84	0.000141	0.0187	-0.37	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80047411	chr10:79663088~79826594:-
LUAD	cis	rs67478160	0.643	rs8003653	ENSG00000272533.1	SNORA28	3.84	0.000141	0.0187	0.18	0.17	Schizophrenia;	chr14:103832499	chr14:103337849~103337974:+
LUAD	cis	rs10466239	0.73	rs2243492	ENSG00000230555.2	RP11-517P14.2	3.84	0.000141	0.0187	0.25	0.17	Telomere length;	chr10:43353910	chr10:43420738~43422100:+
LUAD	cis	rs526231	0.736	rs6886092	ENSG00000175749.11	EIF3KP1	3.84	0.000141	0.0187	0.22	0.17	Primary biliary cholangitis;	chr5:103298328	chr5:103032376~103033031:+
LUAD	cis	rs17122278	1	rs55844025	ENSG00000243431.1	RPL5P30	3.84	0.000141	0.0187	0.22	0.17	Total cholesterol levels;	chr11:118575583	chr11:118560690~118561580:+
LUAD	cis	rs17122278	1	rs9735449	ENSG00000243431.1	RPL5P30	3.84	0.000141	0.0187	0.22	0.17	Total cholesterol levels;	chr11:118577372	chr11:118560690~118561580:+
LUAD	cis	rs7976269	0.609	rs6487744	ENSG00000257176.2	RP11-996F15.2	-3.84	0.000141	0.0187	-0.19	-0.17	Male-pattern baldness;	chr12:29030756	chr12:29280418~29317848:-
LUAD	cis	rs11089937	0.626	rs11704092	ENSG00000211640.3	IGLV6-57	3.84	0.000141	0.0187	0.13	0.17	Periodontitis (PAL4Q3);	chr22:22135815	chr22:22195713~22196460:+
LUAD	cis	rs11089937	0.667	rs78549985	ENSG00000211640.3	IGLV6-57	3.84	0.000141	0.0187	0.13	0.17	Periodontitis (PAL4Q3);	chr22:22139152	chr22:22195713~22196460:+
LUAD	cis	rs8058578	1	rs7204278	ENSG00000232748.3	RP11-196G11.6	-3.84	0.000141	0.0187	-0.21	-0.17	Multiple myeloma;	chr16:30718953	chr16:31056460~31062803:+
LUAD	cis	rs4819052	0.959	rs9976074	ENSG00000237664.1	LINC00316	-3.84	0.000141	0.0187	-0.22	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235723	chr21:45338590~45341990:-
LUAD	cis	rs2749592	0.531	rs1208559	ENSG00000273019.1	RP11-508N22.13	3.84	0.000141	0.0188	0.2	0.17	Age-related hearing impairment (SNP x SNP interaction);	chr10:37932442	chr10:38149968~38150293:+
LUAD	cis	rs4388249	0.659	rs10078710	ENSG00000271849.1	CTC-332L22.1	3.84	0.000141	0.0188	0.24	0.17	Schizophrenia;	chr5:109748057	chr5:109687802~109688329:-
LUAD	cis	rs1044826	1	rs9812192	ENSG00000214280.3	RP11-553K23.2	-3.84	0.000141	0.0188	-0.21	-0.17	Obesity-related traits;	chr3:139458755	chr3:139582928~139583593:-
LUAD	cis	rs3096299	0.617	rs2353030	ENSG00000261574.1	RP1-168P16.2	-3.84	0.000141	0.0188	-0.19	-0.17	Multiple myeloma (IgH translocation);	chr16:89339419	chr16:89392375~89412564:-
LUAD	cis	rs6781182	0.517	rs11714556	ENSG00000236452.1	AC123023.1	3.84	0.000141	0.0188	0.19	0.17	Visceral adipose tissue adjusted for BMI;	chr3:34195758	chr3:34203244~34268811:+
LUAD	cis	rs8050896	1	rs1125845	ENSG00000260695.1	RP11-513N24.1	3.84	0.000141	0.0188	0.31	0.17	Response to antipsychotic treatment;	chr16:66122223	chr16:65861112~65863784:-
LUAD	cis	rs2281603	0.517	rs10134770	ENSG00000259116.1	RP11-973N13.4	-3.84	0.000141	0.0188	-0.15	-0.17	Lymphocyte counts;	chr14:64596597	chr14:64514154~64540368:-
LUAD	cis	rs8062405	1	rs7498555	ENSG00000261419.1	RP11-57A19.4	-3.84	0.000141	0.0188	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28882250	chr16:28659696~28740781:-
LUAD	cis	rs73193808	0.951	rs1999323	ENSG00000215533.7	LINC00189	-3.84	0.000141	0.0188	-0.25	-0.17	Coronary artery disease;	chr21:29161807	chr21:29193480~29288205:+
LUAD	cis	rs36093844	0.527	rs2084077	ENSG00000279742.1	RP11-700A24.1	-3.84	0.000141	0.0188	-0.2	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85941884	chr11:85852557~85854943:-
LUAD	cis	rs1355223	0.816	rs2136506	ENSG00000271369.1	RP11-350D17.3	-3.84	0.000141	0.0188	-0.2	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34726713	chr11:34709600~34710161:+
LUAD	cis	rs1355223	0.902	rs10501134	ENSG00000271369.1	RP11-350D17.3	-3.84	0.000141	0.0188	-0.2	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34727590	chr11:34709600~34710161:+
LUAD	cis	rs1355223	0.902	rs7130325	ENSG00000271369.1	RP11-350D17.3	-3.84	0.000141	0.0188	-0.2	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34729412	chr11:34709600~34710161:+
LUAD	cis	rs7590268	0.697	rs13029044	ENSG00000279873.2	LINC01126	3.84	0.000141	0.0188	0.18	0.17	Orofacial clefts;	chr2:43469414	chr2:43227210~43228855:+
LUAD	cis	rs73193808	0.901	rs2056864	ENSG00000215533.7	LINC00189	-3.84	0.000141	0.0188	-0.25	-0.17	Coronary artery disease;	chr21:29196085	chr21:29193480~29288205:+
LUAD	cis	rs7302981	0.667	rs7136648	ENSG00000200428.1	Y_RNA	-3.84	0.000141	0.0188	-0.2	-0.17	Systolic blood pressure;	chr12:50231039	chr12:50743568~50743684:+
LUAD	cis	rs6964587	1	rs2237568	ENSG00000188693.7	CYP51A1-AS1	-3.84	0.000141	0.0188	-0.2	-0.17	Breast cancer;	chr7:91993362	chr7:92134604~92180725:+
LUAD	cis	rs4118325	0.708	rs1537703	ENSG00000224550.1	RP11-270C12.3	-3.84	0.000141	0.0188	-0.21	-0.17	AIDS;	chr1:107089320	chr1:107505203~107505448:+
LUAD	cis	rs875971	0.54	rs736270	ENSG00000273142.1	RP11-458F8.4	-3.84	0.000141	0.0188	-0.12	-0.17	Aortic root size;	chr7:65963835	chr7:66902857~66906297:+
LUAD	cis	rs10971721	0.749	rs10971741	ENSG00000260947.1	RP11-384P7.7	3.84	0.000141	0.0188	0.36	0.17	Body mass index;	chr9:33856869	chr9:33697459~33700986:+
LUAD	cis	rs853679	0.607	rs33932084	ENSG00000219392.1	RP1-265C24.5	-3.84	0.000141	0.0188	-0.37	-0.17	Depression;	chr6:28301047	chr6:28115628~28116551:+
LUAD	cis	rs2286492	0.881	rs78433057	ENSG00000226329.2	AC005682.6	-3.84	0.000141	0.0188	-0.34	-0.17	Bipolar disorder;	chr7:22890619	chr7:22863874~22881350:-
LUAD	cis	rs365302	0.904	rs392551	ENSG00000235086.1	FNDC1-IT1	3.84	0.000141	0.0188	0.23	0.17	Coronary heart disease;	chr6:159229142	chr6:159240786~159243329:+
LUAD	cis	rs516805	0.561	rs7754101	ENSG00000279453.1	RP3-425C14.4	3.84	0.000142	0.0188	0.27	0.17	Lymphocyte counts;	chr6:122607828	chr6:122436789~122439223:-
LUAD	cis	rs7772486	0.79	rs9399571	ENSG00000235652.6	RP11-545I5.3	-3.84	0.000142	0.0188	-0.18	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145960925	chr6:145799409~145886585:+
LUAD	cis	rs7546668	1	rs6686966	ENSG00000272510.1	RP4-680D5.8	3.84	0.000142	0.0188	0.22	0.17	Glomerular filtration rate (creatinine);	chr1:15508977	chr1:15565611~15565956:-
LUAD	cis	rs10971721	0.749	rs72725371	ENSG00000260947.1	RP11-384P7.7	3.84	0.000142	0.0188	0.36	0.17	Body mass index;	chr9:33825013	chr9:33697459~33700986:+
LUAD	cis	rs4474465	1	rs10899514	ENSG00000251323.2	RP11-452H21.4	3.84	0.000142	0.0188	0.22	0.17	Alzheimer's disease (survival time);	chr11:78461649	chr11:78423982~78429836:-
LUAD	cis	rs7968440	1	rs66597435	ENSG00000272368.2	RP4-605O3.4	3.84	0.000142	0.0188	0.2	0.17	Fibrinogen;	chr12:50551486	chr12:50112197~50165618:+
LUAD	cis	rs2390582	0.739	rs10922877	ENSG00000233593.5	RP4-665J23.1	3.84	0.000142	0.0188	0.24	0.17	Coronary artery calcification;	chr1:90577704	chr1:90782986~90851650:-
LUAD	cis	rs9847710	1	rs4687697	ENSG00000242142.1	SERBP1P3	-3.84	0.000142	0.0188	-0.18	-0.17	Ulcerative colitis;	chr3:53056474	chr3:53064283~53065091:-
LUAD	cis	rs10463554	0.892	rs32842	ENSG00000250682.4	LINC00491	3.84	0.000142	0.0188	0.21	0.17	Parkinson's disease;	chr5:103142298	chr5:102609156~102671559:-
LUAD	cis	rs2708977	0.637	rs679414	ENSG00000237510.6	AC008268.2	-3.84	0.000142	0.0188	-0.23	-0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96422051	chr2:95789654~95800166:+
LUAD	cis	rs2299587	0.56	rs12718385	ENSG00000253671.1	RP11-806O11.1	-3.84	0.000142	0.0188	-0.2	-0.17	Economic and political preferences;	chr8:17923748	chr8:17808941~17820868:+
LUAD	cis	rs6502050	0.805	rs4789720	ENSG00000266654.1	RP11-1376P16.1	-3.84	0.000142	0.0188	-0.19	-0.17	Life satisfaction;	chr17:82199614	chr17:82160056~82160452:+
LUAD	cis	rs6502050	0.734	rs7217625	ENSG00000266654.1	RP11-1376P16.1	-3.84	0.000142	0.0188	-0.19	-0.17	Life satisfaction;	chr17:82199890	chr17:82160056~82160452:+
LUAD	cis	rs6502050	0.835	rs8074267	ENSG00000266654.1	RP11-1376P16.1	-3.84	0.000142	0.0188	-0.19	-0.17	Life satisfaction;	chr17:82200449	chr17:82160056~82160452:+
LUAD	cis	rs6502050	0.83	rs8074436	ENSG00000266654.1	RP11-1376P16.1	-3.84	0.000142	0.0188	-0.19	-0.17	Life satisfaction;	chr17:82200546	chr17:82160056~82160452:+
LUAD	cis	rs6502050	0.764	rs7215277	ENSG00000266654.1	RP11-1376P16.1	-3.84	0.000142	0.0188	-0.19	-0.17	Life satisfaction;	chr17:82201407	chr17:82160056~82160452:+
LUAD	cis	rs2239557	0.885	rs4899502	ENSG00000259065.1	RP5-1021I20.1	3.84	0.000142	0.0188	0.2	0.17	Common traits (Other);	chr14:74203190	chr14:73787360~73803270:+
LUAD	cis	rs2007126	0.706	rs112586081	ENSG00000224797.1	RP11-57C19.6	3.84	0.000142	0.0188	0.32	0.17	LDL peak particle diameter (total fat intake interaction);	chr9:129955523	chr9:130724786~130725050:-
LUAD	cis	rs8073060	0.586	rs72829922	ENSG00000267592.1	CTC-507E2.2	-3.84	0.000142	0.0188	-0.25	-0.17	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35717790	chr17:35596904~35597128:-
LUAD	cis	rs8073060	0.586	rs72829923	ENSG00000267592.1	CTC-507E2.2	-3.84	0.000142	0.0188	-0.25	-0.17	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35718070	chr17:35596904~35597128:-
LUAD	cis	rs8073060	0.586	rs4796104	ENSG00000267592.1	CTC-507E2.2	-3.84	0.000142	0.0188	-0.25	-0.17	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35719813	chr17:35596904~35597128:-
LUAD	cis	rs8073060	0.586	rs72829927	ENSG00000267592.1	CTC-507E2.2	-3.84	0.000142	0.0188	-0.25	-0.17	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35722973	chr17:35596904~35597128:-
LUAD	cis	rs8073060	0.586	rs9649	ENSG00000267592.1	CTC-507E2.2	-3.84	0.000142	0.0188	-0.25	-0.17	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35723915	chr17:35596904~35597128:-
LUAD	cis	rs7178424	0.742	rs1981916	ENSG00000259251.2	RP11-643M14.1	-3.84	0.000142	0.0188	-0.17	-0.17	Height;	chr15:61879280	chr15:62060503~62062434:+
LUAD	cis	rs7829975	0.658	rs907181	ENSG00000253893.2	FAM85B	-3.84	0.000142	0.0188	-0.21	-0.17	Mood instability;	chr8:8845365	chr8:8167819~8226614:-
LUAD	cis	rs7134599	1	rs12829089	ENSG00000240087.3	RP11-254B13.1	3.84	0.000142	0.0188	0.15	0.17	Inflammatory bowel disease;Ulcerative colitis;	chr12:68108725	chr12:68552995~68553882:-
LUAD	cis	rs2657294	0.965	rs4746270	ENSG00000226051.5	ZNF503-AS1	-3.84	0.000142	0.0188	-0.23	-0.17	Pneumonia;	chr10:75185189	chr10:75269819~75373500:+
LUAD	cis	rs2638953	0.924	rs11049475	ENSG00000278733.1	RP11-425D17.1	-3.84	0.000142	0.0188	-0.2	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28239731	chr12:28185625~28186190:-
LUAD	cis	rs7429990	0.965	rs7649981	ENSG00000228638.1	FCF1P2	-3.84	0.000142	0.0188	-0.2	-0.17	Educational attainment (years of education);	chr3:47957847	chr3:48290793~48291375:-
LUAD	cis	rs7429990	0.965	rs2053767	ENSG00000228638.1	FCF1P2	-3.84	0.000142	0.0188	-0.2	-0.17	Educational attainment (years of education);	chr3:47958184	chr3:48290793~48291375:-
LUAD	cis	rs7429990	0.965	rs6770467	ENSG00000228638.1	FCF1P2	3.84	0.000142	0.0188	0.2	0.17	Educational attainment (years of education);	chr3:47977742	chr3:48290793~48291375:-
LUAD	cis	rs7429990	0.932	rs6770477	ENSG00000228638.1	FCF1P2	3.84	0.000142	0.0188	0.2	0.17	Educational attainment (years of education);	chr3:47977768	chr3:48290793~48291375:-
LUAD	cis	rs7429990	0.965	rs28637561	ENSG00000228638.1	FCF1P2	3.84	0.000142	0.0188	0.2	0.17	Educational attainment (years of education);	chr3:47979528	chr3:48290793~48291375:-
LUAD	cis	rs7429990	0.965	rs7431572	ENSG00000228638.1	FCF1P2	3.84	0.000142	0.0188	0.2	0.17	Educational attainment (years of education);	chr3:47986361	chr3:48290793~48291375:-
LUAD	cis	rs35417517	1	rs35417517	ENSG00000188693.7	CYP51A1-AS1	-3.84	0.000142	0.0188	-0.2	-0.17	Breast cancer;	chr7:92143417	chr7:92134604~92180725:+
LUAD	cis	rs867371	0.614	rs1814739	ENSG00000259429.4	UBE2Q2P2	-3.84	0.000142	0.0188	-0.18	-0.17	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82234283	chr15:82355142~82420075:+
LUAD	cis	rs9467773	1	rs12526680	ENSG00000241549.7	GUSBP2	3.84	0.000142	0.0188	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26550726	chr6:26871484~26956554:-
LUAD	cis	rs2380205	0.517	rs12774228	ENSG00000232807.2	RP11-536K7.3	-3.84	0.000142	0.0188	-0.19	-0.17	Breast cancer;	chr10:5935312	chr10:5934270~5945900:-
LUAD	cis	rs1198430	1	rs1198432	ENSG00000232482.2	RP4-654C18.1	3.84	0.000142	0.0188	0.27	0.17	Total cholesterol levels;	chr1:23429662	chr1:23410832~23412146:+
LUAD	cis	rs5758511	0.633	rs5758690	ENSG00000233903.2	Z83851.4	3.84	0.000142	0.0188	0.25	0.17	Birth weight;	chr22:42272289	chr22:42276355~42277052:+
LUAD	cis	rs34779708	0.833	rs12777517	ENSG00000271335.4	RP11-324I22.4	3.84	0.000142	0.0188	0.18	0.17	Inflammatory bowel disease;Crohn's disease;	chr10:35184999	chr10:35314552~35336401:-
LUAD	cis	rs131777	0.577	rs5770928	ENSG00000272666.1	CTA-384D8.35	3.84	0.000142	0.0188	0.21	0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50590662	chr22:50542305~50542906:-
LUAD	cis	rs10463554	0.963	rs32850	ENSG00000250682.4	LINC00491	3.84	0.000142	0.0188	0.21	0.17	Parkinson's disease;	chr5:103134325	chr5:102609156~102671559:-
LUAD	cis	rs8049040	0.609	rs11866859	ENSG00000260886.1	TAT-AS1	3.84	0.000142	0.0188	0.21	0.17	Blood protein levels;	chr16:71444985	chr16:71565789~71578187:+
LUAD	cis	rs7630852	0.841	rs9325377	ENSG00000272359.1	U4	-3.84	0.000142	0.0188	-0.18	-0.17	Eosinophil counts;	chr3:196779282	chr3:196747192~196747324:-
LUAD	cis	rs4713118	0.739	rs2893931	ENSG00000280107.1	AL022393.9	-3.84	0.000142	0.0188	-0.22	-0.17	Parkinson's disease;	chr6:27780231	chr6:28170845~28172521:+
LUAD	cis	rs4713118	0.824	rs2092075	ENSG00000280107.1	AL022393.9	-3.84	0.000142	0.0188	-0.22	-0.17	Parkinson's disease;	chr6:27781551	chr6:28170845~28172521:+
LUAD	cis	rs726288	1	rs11200985	ENSG00000242600.5	MBL1P	3.84	0.000142	0.0188	0.28	0.17	Rheumatoid arthritis;	chr10:79972897	chr10:79904898~79950336:+
LUAD	cis	rs523522	0.962	rs603574	ENSG00000278344.1	RP11-18C24.8	3.84	0.000142	0.0188	0.23	0.17	High light scatter reticulocyte count;	chr12:120560640	chr12:120500735~120501090:-
LUAD	cis	rs12440869	1	rs7162340	ENSG00000270964.1	RP11-502I4.3	-3.84	0.000142	0.0189	-0.2	-0.17	Peak velocity of the mitral A-wave;	chr15:67340091	chr15:67541072~67542604:-
LUAD	cis	rs9926296	0.605	rs8047486	ENSG00000260259.1	RP11-368I7.4	-3.84	0.000142	0.0189	-0.17	-0.17	Vitiligo;	chr16:89787617	chr16:89682620~89686569:-
LUAD	cis	rs6723108	0.603	rs1947112	ENSG00000224043.6	CCNT2-AS1	-3.84	0.000142	0.0189	-0.21	-0.17	Type 2 diabetes;	chr2:134958387	chr2:134735464~134918710:-
LUAD	cis	rs7520050	0.966	rs12760175	ENSG00000234329.1	RP11-767N6.2	-3.84	0.000142	0.0189	-0.16	-0.17	Reticulocyte count;Red blood cell count;	chr1:45982168	chr1:45651039~45651826:-
LUAD	cis	rs728616	0.867	rs28365998	ENSG00000225484.5	NUTM2B-AS1	-3.84	0.000142	0.0189	-0.46	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80205680	chr10:79663088~79826594:-
LUAD	cis	rs6471393	0.929	rs56108220	ENSG00000253848.1	RP11-10N23.5	3.84	0.000142	0.0189	0.21	0.17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93736965	chr8:93741193~93744534:+
LUAD	cis	rs159572	0.747	rs469755	ENSG00000250853.1	RNF138P1	3.84	0.000142	0.0189	0.21	0.17	Post-traumatic stress disorder;	chr5:56256558	chr5:55530156~55530701:-
LUAD	cis	rs4474465	0.85	rs10899545	ENSG00000251323.2	RP11-452H21.4	-3.84	0.000142	0.0189	-0.2	-0.17	Alzheimer's disease (survival time);	chr11:78539325	chr11:78423982~78429836:-
LUAD	cis	rs6142102	0.778	rs6059581	ENSG00000275784.1	RP5-1125A11.6	-3.84	0.000142	0.0189	-0.19	-0.17	Skin pigmentation;	chr20:33940582	chr20:33989480~33991818:-
LUAD	cis	rs7200543	1	rs6498541	ENSG00000260735.1	RP11-72I8.1	-3.84	0.000142	0.0189	-0.19	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15046800	chr16:15094411~15109197:+
LUAD	cis	rs1541160	1	rs541896	ENSG00000239494.2	RN7SL333P	-3.84	0.000142	0.0189	-0.17	-0.17	Amyotrophic lateral sclerosis;	chr1:169999279	chr1:169859756~169860052:+
LUAD	cis	rs8054556	0.716	rs11642933	ENSG00000183604.13	SMG1P5	-3.83	0.000142	0.0189	-0.17	-0.17	Autism spectrum disorder or schizophrenia;	chr16:29935387	chr16:30267553~30335374:-
LUAD	cis	rs957448	0.561	rs13258635	ENSG00000253175.1	RP11-267M23.6	3.83	0.000142	0.0189	0.19	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94595629	chr8:94565036~94565715:+
LUAD	cis	rs957448	0.561	rs7459558	ENSG00000253175.1	RP11-267M23.6	3.83	0.000142	0.0189	0.19	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94598618	chr8:94565036~94565715:+
LUAD	cis	rs957448	0.561	rs34471170	ENSG00000253175.1	RP11-267M23.6	3.83	0.000142	0.0189	0.19	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94601135	chr8:94565036~94565715:+
LUAD	cis	rs957448	0.561	rs9642927	ENSG00000253175.1	RP11-267M23.6	3.83	0.000142	0.0189	0.19	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94601414	chr8:94565036~94565715:+
LUAD	cis	rs957448	0.561	rs1808488	ENSG00000253175.1	RP11-267M23.6	3.83	0.000142	0.0189	0.19	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94602636	chr8:94565036~94565715:+
LUAD	cis	rs957448	0.583	rs754275	ENSG00000253175.1	RP11-267M23.6	3.83	0.000142	0.0189	0.19	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94602741	chr8:94565036~94565715:+
LUAD	cis	rs957448	0.561	rs1426172	ENSG00000253175.1	RP11-267M23.6	3.83	0.000142	0.0189	0.19	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94602988	chr8:94565036~94565715:+
LUAD	cis	rs10435719	0.718	rs7813935	ENSG00000255046.1	RP11-297N6.4	-3.83	0.000142	0.0189	-0.22	-0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11938127	chr8:11797928~11802568:-
LUAD	cis	rs62025270	0.688	rs11073516	ENSG00000259416.2	RP11-158M2.5	-3.83	0.000142	0.0189	-0.23	-0.17	Idiopathic pulmonary fibrosis;	chr15:85741996	chr15:85754941~85756237:-
LUAD	cis	rs10463554	0.927	rs34798	ENSG00000250682.4	LINC00491	3.83	0.000142	0.0189	0.24	0.17	Parkinson's disease;	chr5:103090047	chr5:102609156~102671559:-
LUAD	cis	rs12935418	0.583	rs2911150	ENSG00000261061.1	RP11-303E16.2	-3.83	0.000142	0.0189	-0.18	-0.17	Mean corpuscular volume;	chr16:80995194	chr16:81030770~81031485:+
LUAD	cis	rs2412819	0.571	rs8038068	ENSG00000166763.7	STRCP1	3.83	0.000142	0.0189	0.26	0.17	Lung cancer;	chr15:43622175	chr15:43699488~43718184:-
LUAD	cis	rs2412819	0.571	rs56246169	ENSG00000166763.7	STRCP1	3.83	0.000142	0.0189	0.26	0.17	Lung cancer;	chr15:43628358	chr15:43699488~43718184:-
LUAD	cis	rs2412819	0.571	rs17727853	ENSG00000166763.7	STRCP1	3.83	0.000142	0.0189	0.26	0.17	Lung cancer;	chr15:43630299	chr15:43699488~43718184:-
LUAD	cis	rs2412819	0.571	rs62018900	ENSG00000166763.7	STRCP1	3.83	0.000142	0.0189	0.26	0.17	Lung cancer;	chr15:43633252	chr15:43699488~43718184:-
LUAD	cis	rs2412819	0.545	rs35333173	ENSG00000166763.7	STRCP1	3.83	0.000142	0.0189	0.26	0.17	Lung cancer;	chr15:43640818	chr15:43699488~43718184:-
LUAD	cis	rs2412819	0.571	rs112667279	ENSG00000166763.7	STRCP1	3.83	0.000142	0.0189	0.26	0.17	Lung cancer;	chr15:43649258	chr15:43699488~43718184:-
LUAD	cis	rs151234	0.741	rs56236750	ENSG00000259982.1	CDC37P1	-3.83	0.000142	0.0189	-0.32	-0.17	Platelet distribution width;	chr16:28583390	chr16:28700294~28701540:-
LUAD	cis	rs7107174	0.748	rs2063730	ENSG00000251323.2	RP11-452H21.4	3.83	0.000142	0.0189	0.22	0.17	Testicular germ cell tumor;	chr11:78337478	chr11:78423982~78429836:-
LUAD	cis	rs17695224	0.545	rs4802871	ENSG00000269483.1	AC006272.1	3.83	0.000142	0.0189	0.19	0.17	HDL cholesterol;HDL cholesterol levels;	chr19:51817487	chr19:51839924~51843324:-
LUAD	cis	rs7017914	0.967	rs2732090	ENSG00000246366.5	RP11-382J12.1	-3.83	0.000142	0.0189	-0.16	-0.17	Bone mineral density;	chr8:71006022	chr8:70608577~70663279:+
LUAD	cis	rs4948102	0.599	rs2230197	ENSG00000226278.1	PSPHP1	-3.83	0.000142	0.0189	-0.2	-0.17	Plasma homocysteine levels (post-methionine load test);	chr7:56058667	chr7:55764797~55773288:+
LUAD	cis	rs73198271	0.773	rs66618176	ENSG00000253893.2	FAM85B	3.83	0.000142	0.0189	0.23	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8789464	chr8:8167819~8226614:-
LUAD	cis	rs9803723	0.716	rs11248986	ENSG00000261349.1	RP3-465N24.5	-3.83	0.000142	0.0189	-0.2	-0.17	Male-pattern baldness;	chr1:25133253	chr1:25266102~25267136:-
LUAD	cis	rs6723226	0.882	rs13035097	ENSG00000276334.1	AL133243.1	-3.83	0.000142	0.0189	-0.2	-0.17	Intelligence (multi-trait analysis);	chr2:32611295	chr2:32521927~32523547:+
LUAD	cis	rs3753275	0.69	rs6697997	ENSG00000232912.4	RP5-1115A15.1	3.83	0.000142	0.0189	0.19	0.17	Educational attainment;	chr1:8549052	chr1:8424645~8434838:+
LUAD	cis	rs812925	0.793	rs1405490	ENSG00000271889.1	RP11-493E12.1	-3.83	0.000143	0.0189	-0.23	-0.17	Immature fraction of reticulocytes;	chr2:61332945	chr2:61151433~61162105:-
LUAD	cis	rs8014204	0.869	rs2070599	ENSG00000279594.1	RP11-950C14.10	-3.83	0.000143	0.0189	-0.2	-0.17	Caffeine consumption;	chr14:74894474	chr14:75011269~75012851:-
LUAD	cis	rs1400816	0.85	rs114304988	ENSG00000228389.1	AC068039.4	-3.83	0.000143	0.0189	-0.34	-0.17	Amyotrophic lateral sclerosis (sporadic);	chr2:171841408	chr2:171773482~171775844:+
LUAD	cis	rs8046148	0.789	rs7184940	ENSG00000279356.1	RP11-429P3.8	-3.83	0.000143	0.0189	-0.18	-0.17	Testicular germ cell tumor;	chr16:50117550	chr16:50072862~50074986:+
LUAD	cis	rs10936632	0.565	rs6794467	ENSG00000242578.1	RP11-469J4.3	-3.83	0.000143	0.0189	-0.18	-0.17	Prostate cancer;	chr3:170430203	chr3:170410512~170418615:+
LUAD	cis	rs2657294	0.965	rs10762658	ENSG00000233313.2	HMGA1P5	-3.83	0.000143	0.0189	-0.22	-0.17	Pneumonia;	chr10:75119804	chr10:75276376~75276646:-
LUAD	cis	rs8105815	0.867	rs8101139	ENSG00000279759.1	CTC-425O23.5	3.83	0.000143	0.0189	0.22	0.17	Prion diseases;	chr19:41157969	chr19:40355842~40360606:+
LUAD	cis	rs6471393	0.895	rs58103546	ENSG00000253848.1	RP11-10N23.5	3.83	0.000143	0.0189	0.22	0.17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93749483	chr8:93741193~93744534:+
LUAD	cis	rs7560272	0.538	rs11126414	ENSG00000163016.8	ALMS1P	-3.83	0.000143	0.0189	-0.18	-0.17	Schizophrenia;	chr2:73704917	chr2:73644919~73685576:+
LUAD	cis	rs897984	0.806	rs11150600	ENSG00000232748.3	RP11-196G11.6	3.83	0.000143	0.0189	0.21	0.17	Dementia with Lewy bodies;	chr16:30929010	chr16:31056460~31062803:+
LUAD	cis	rs7172677	0.793	rs8029712	ENSG00000260269.4	CTD-2323K18.1	-3.83	0.000143	0.0189	-0.23	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75125829	chr15:75527150~75601205:-
LUAD	cis	rs10911232	0.507	rs10797829	ENSG00000224468.3	RP11-181K3.4	3.83	0.000143	0.0189	0.15	0.17	Hypertriglyceridemia;	chr1:183064093	chr1:183138402~183141282:-
LUAD	cis	rs6763848	0.962	rs36125090	ENSG00000214073.2	RPL21P17	-3.83	0.000143	0.0189	-0.17	-0.17	Prostate cancer (SNP x SNP interaction);	chr3:1473301	chr3:1905651~1906125:+
LUAD	cis	rs12149074	0.55	rs1842024	ENSG00000261390.4	RP11-345M22.2	-3.83	0.000143	0.0189	-0.23	-0.17	Bipolar disorder and eating disorder;Eating disorder in bipolar disorder;	chr16:80068865	chr16:79715232~79770563:-
LUAD	cis	rs12935418	0.672	rs9934957	ENSG00000261061.1	RP11-303E16.2	3.83	0.000143	0.0189	0.19	0.17	Mean corpuscular volume;	chr16:81016078	chr16:81030770~81031485:+
LUAD	cis	rs8141529	0.748	rs1318026	ENSG00000272858.1	CTA-292E10.8	-3.83	0.000143	0.0189	-0.19	-0.17	Lymphocyte counts;	chr22:28887530	chr22:28814914~28815662:+
LUAD	cis	rs683250	0.598	rs11233566	ENSG00000246067.6	RAB30-AS1	-3.83	0.000143	0.0189	-0.18	-0.17	Subcortical brain region volumes;	chr11:83337053	chr11:83072066~83106719:+
LUAD	cis	rs7129556	0.69	rs668701	ENSG00000241782.1	RP11-91P24.1	3.83	0.000143	0.0189	0.23	0.17	Weight loss (gastric bypass surgery);	chr11:77872430	chr11:77868722~77869195:-
LUAD	cis	rs6840360	0.571	rs11099823	ENSG00000270265.1	RP11-731D1.4	-3.83	0.000143	0.0189	-0.19	-0.17	Intelligence (multi-trait analysis);	chr4:151589413	chr4:151333775~151353224:-
LUAD	cis	rs2283792	0.73	rs738858	ENSG00000211640.3	IGLV6-57	-3.83	0.000143	0.0189	-0.11	-0.17	Multiple sclerosis;	chr22:21926544	chr22:22195713~22196460:+
LUAD	cis	rs507080	0.769	rs2077173	ENSG00000278376.1	RP11-158I9.8	-3.83	0.000143	0.0189	-0.19	-0.17	Serum metabolite levels;	chr11:118621876	chr11:118791254~118793137:+
LUAD	cis	rs987044	0.664	rs1861641	ENSG00000257221.1	RP11-689B22.2	-3.83	0.000143	0.0189	-0.15	-0.17	Mean platelet volume;	chr12:108658167	chr12:108628687~108641318:+
LUAD	cis	rs1075265	0.756	rs2542576	ENSG00000272156.1	RP11-477N3.1	-3.83	0.000143	0.0189	-0.2	-0.17	Chronotype;Morning vs. evening chronotype;	chr2:53821659	chr2:54082554~54085066:+
LUAD	cis	rs6806253	0.715	rs4857906	ENSG00000279507.1	RP11-723O4.7	-3.83	0.000143	0.0189	-0.24	-0.17	Pit-and-Fissure caries;	chr3:128556616	chr3:128914833~128915060:-
LUAD	cis	rs1862618	0.853	rs860580	ENSG00000271828.1	CTD-2310F14.1	-3.83	0.000143	0.0189	-0.24	-0.17	Initial pursuit acceleration;	chr5:56853602	chr5:56927874~56929573:+
LUAD	cis	rs1023500	0.505	rs134878	ENSG00000273366.1	CTA-989H11.1	-3.83	0.000143	0.0189	-0.2	-0.17	Schizophrenia;	chr22:42267868	chr22:42278188~42278846:+
LUAD	cis	rs12073359	1	rs11205321	ENSG00000223945.2	RP11-458I7.1	-3.83	0.000143	0.0189	-0.25	-0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150054225	chr1:150053864~150055034:+
LUAD	cis	rs12073359	1	rs7550323	ENSG00000223945.2	RP11-458I7.1	-3.83	0.000143	0.0189	-0.25	-0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150055018	chr1:150053864~150055034:+
LUAD	cis	rs7546668	0.948	rs12736181	ENSG00000272510.1	RP4-680D5.8	3.83	0.000143	0.0189	0.22	0.17	Glomerular filtration rate (creatinine);	chr1:15542789	chr1:15565611~15565956:-
LUAD	cis	rs27434	0.605	rs1230366	ENSG00000272109.1	CTD-2260A17.3	-3.83	0.000143	0.0189	-0.26	-0.17	Ankylosing spondylitis;	chr5:96859577	chr5:96804353~96806105:+
LUAD	cis	rs794728	0.522	rs1863957	ENSG00000249031.1	SUMO2P6	-3.83	0.000143	0.0189	-0.19	-0.17	Depressive symptoms (SSRI exposure interaction);	chr5:174432363	chr5:174561776~174562063:+
LUAD	cis	rs1559040	1	rs72800725	ENSG00000272156.1	RP11-477N3.1	-3.83	0.000143	0.0189	-0.29	-0.17	Sudden cardiac arrest;	chr2:54074000	chr2:54082554~54085066:+
LUAD	cis	rs9295536	0.62	rs6901879	ENSG00000260455.1	NBAT1	3.83	0.000143	0.0189	0.21	0.17	Neuroblastoma;	chr6:22137318	chr6:22134957~22147193:-
LUAD	cis	rs404005	0.572	rs12104840	ENSG00000227028.5	SLC8A1-AS1	3.83	0.000143	0.0189	0.21	0.17	HIV-associated dementia;	chr2:40192989	chr2:39786453~40255209:+
LUAD	cis	rs12935418	0.579	rs1477381	ENSG00000278985.1	RP11-303E16.9	-3.83	0.000143	0.0189	-0.16	-0.17	Mean corpuscular volume;	chr16:80981095	chr16:80982319~80984094:-
LUAD	cis	rs12935418	0.616	rs1127390	ENSG00000278985.1	RP11-303E16.9	3.83	0.000143	0.0189	0.16	0.17	Mean corpuscular volume;	chr16:80976176	chr16:80982319~80984094:-
LUAD	cis	rs2283792	0.73	rs894095	ENSG00000211640.3	IGLV6-57	-3.83	0.000143	0.0189	-0.11	-0.17	Multiple sclerosis;	chr22:21928404	chr22:22195713~22196460:+
LUAD	cis	rs4118325	0.734	rs1730849	ENSG00000224550.1	RP11-270C12.3	-3.83	0.000143	0.0189	-0.21	-0.17	AIDS;	chr1:107089746	chr1:107505203~107505448:+
LUAD	cis	rs453193	0.624	rs439614	ENSG00000229727.5	AC013460.1	-3.83	0.000143	0.0189	-0.21	-0.17	Granulocyte percentage of myeloid white cells;	chr2:8311349	chr2:7421261~7450254:+
LUAD	cis	rs11089937	0.626	rs2213161	ENSG00000211640.3	IGLV6-57	3.83	0.000143	0.0189	0.14	0.17	Periodontitis (PAL4Q3);	chr22:22143005	chr22:22195713~22196460:+
LUAD	cis	rs365302	1	rs2245986	ENSG00000235086.1	FNDC1-IT1	3.83	0.000143	0.0189	0.23	0.17	Coronary heart disease;	chr6:159227629	chr6:159240786~159243329:+
LUAD	cis	rs365302	1	rs416321	ENSG00000235086.1	FNDC1-IT1	3.83	0.000143	0.0189	0.23	0.17	Coronary heart disease;	chr6:159227875	chr6:159240786~159243329:+
LUAD	cis	rs365302	1	rs375423	ENSG00000235086.1	FNDC1-IT1	3.83	0.000143	0.0189	0.23	0.17	Coronary heart disease;	chr6:159227924	chr6:159240786~159243329:+
LUAD	cis	rs365302	0.904	rs422232	ENSG00000235086.1	FNDC1-IT1	3.83	0.000143	0.0189	0.23	0.17	Coronary heart disease;	chr6:159228713	chr6:159240786~159243329:+
LUAD	cis	rs365302	0.904	rs410879	ENSG00000235086.1	FNDC1-IT1	3.83	0.000143	0.0189	0.23	0.17	Coronary heart disease;	chr6:159228715	chr6:159240786~159243329:+
LUAD	cis	rs365302	1	rs375150	ENSG00000235086.1	FNDC1-IT1	3.83	0.000143	0.0189	0.23	0.17	Coronary heart disease;	chr6:159228993	chr6:159240786~159243329:+
LUAD	cis	rs365302	1	rs486468	ENSG00000235086.1	FNDC1-IT1	3.83	0.000143	0.0189	0.23	0.17	Coronary heart disease;	chr6:159230173	chr6:159240786~159243329:+
LUAD	cis	rs365302	1	rs485368	ENSG00000235086.1	FNDC1-IT1	3.83	0.000143	0.0189	0.23	0.17	Coronary heart disease;	chr6:159230329	chr6:159240786~159243329:+
LUAD	cis	rs365302	1	rs483575	ENSG00000235086.1	FNDC1-IT1	3.83	0.000143	0.0189	0.23	0.17	Coronary heart disease;	chr6:159230515	chr6:159240786~159243329:+
LUAD	cis	rs365302	1	rs481899	ENSG00000235086.1	FNDC1-IT1	3.83	0.000143	0.0189	0.23	0.17	Coronary heart disease;	chr6:159230639	chr6:159240786~159243329:+
LUAD	cis	rs365302	1	rs480052	ENSG00000235086.1	FNDC1-IT1	3.83	0.000143	0.0189	0.23	0.17	Coronary heart disease;	chr6:159230837	chr6:159240786~159243329:+
LUAD	cis	rs365302	1	rs542031	ENSG00000235086.1	FNDC1-IT1	3.83	0.000143	0.0189	0.23	0.17	Coronary heart disease;	chr6:159230935	chr6:159240786~159243329:+
LUAD	cis	rs365302	0.909	rs12191109	ENSG00000235086.1	FNDC1-IT1	-3.83	0.000143	0.0189	-0.23	-0.17	Coronary heart disease;	chr6:159231071	chr6:159240786~159243329:+
LUAD	cis	rs365302	1	rs823903	ENSG00000235086.1	FNDC1-IT1	-3.83	0.000143	0.0189	-0.23	-0.17	Coronary heart disease;	chr6:159231413	chr6:159240786~159243329:+
LUAD	cis	rs4474465	0.85	rs4482052	ENSG00000251323.2	RP11-452H21.4	-3.83	0.000143	0.0189	-0.21	-0.17	Alzheimer's disease (survival time);	chr11:78552285	chr11:78423982~78429836:-
LUAD	cis	rs5758659	0.7	rs739294	ENSG00000227370.1	RP4-669P10.19	-3.83	0.000143	0.019	-0.16	-0.17	Cognitive function;	chr22:41985722	chr22:42132543~42132998:+
LUAD	cis	rs2732480	0.5	rs11168464	ENSG00000257763.1	OR5BK1P	3.83	0.000143	0.019	0.18	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48208332	chr12:48355792~48356614:-
LUAD	cis	rs12935418	0.504	rs1549288	ENSG00000278985.1	RP11-303E16.9	3.83	0.000143	0.019	0.16	0.17	Mean corpuscular volume;	chr16:81027156	chr16:80982319~80984094:-
LUAD	cis	rs9341808	0.935	rs9448894	ENSG00000260645.1	RP11-250B2.5	3.83	0.000143	0.019	0.16	0.17	Sitting height ratio;	chr6:80127536	chr6:80466958~80469080:+
LUAD	cis	rs35740288	0.73	rs35560431	ENSG00000259407.1	RP11-158M2.3	-3.83	0.000143	0.019	-0.16	-0.17	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85750980	chr15:85744109~85750281:-
LUAD	cis	rs526231	0.578	rs10515337	ENSG00000250682.4	LINC00491	-3.83	0.000143	0.019	-0.21	-0.17	Primary biliary cholangitis;	chr5:102965664	chr5:102609156~102671559:-
LUAD	cis	rs2288884	0.779	rs10411428	ENSG00000269959.1	SPACA6P-AS	-3.83	0.000143	0.019	-0.2	-0.17	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52104512	chr19:51685363~51693456:-
LUAD	cis	rs115769866	0.569	rs2859358	ENSG00000216901.1	AL022393.7	3.83	0.000143	0.019	0.24	0.17	Bipolar disorder;	chr6:28505044	chr6:28176188~28176674:+
LUAD	cis	rs10510102	0.516	rs12244921	ENSG00000276742.1	RP11-500G22.4	3.83	0.000143	0.019	0.27	0.17	Breast cancer;	chr10:121990342	chr10:121956782~121957098:+
LUAD	cis	rs442309	0.875	rs224063	ENSG00000238280.1	RP11-436D10.3	3.83	0.000143	0.019	0.2	0.17	Vogt-Koyanagi-Harada syndrome;	chr10:62743589	chr10:62793562~62805887:-
LUAD	cis	rs875971	0.545	rs73136346	ENSG00000224316.1	RP11-479O9.2	-3.83	0.000143	0.019	-0.21	-0.17	Aortic root size;	chr7:66101095	chr7:65773620~65802067:+
LUAD	cis	rs7162943	0.887	rs11858077	ENSG00000260123.1	RP11-326A19.4	-3.83	0.000143	0.019	-0.2	-0.17	Mean platelet volume;	chr15:89068326	chr15:89041223~89082819:+
LUAD	cis	rs2243480	1	rs316315	ENSG00000229886.1	RP5-1132H15.3	-3.83	0.000143	0.019	-0.26	-0.17	Diabetic kidney disease;	chr7:66126218	chr7:66025126~66031544:-
LUAD	cis	rs548181	0.536	rs503288	ENSG00000254671.2	STT3A-AS1	3.83	0.000143	0.019	0.26	0.17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr11:125591892	chr11:125570284~125592568:-
LUAD	cis	rs6568686	0.578	rs56103131	ENSG00000255389.1	C6orf3	3.83	0.000143	0.019	0.23	0.17	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111614545	chr6:111599875~111602295:+
LUAD	cis	rs2041895	0.509	rs10861674	ENSG00000260329.1	RP11-412D9.4	-3.83	0.000143	0.019	-0.22	-0.17	Glaucoma (low intraocular pressure);	chr12:106910259	chr12:106954029~106955497:-
LUAD	cis	rs2702164	1	rs2702164	ENSG00000240661.1	RP11-174O3.3	-3.83	0.000143	0.019	-0.21	-0.17	Gut microbiome composition (winter);	chr3:120382680	chr3:120349510~120367998:+
LUAD	cis	rs253959	0.595	rs11241361	ENSG00000272265.1	CTD-2287O16.4	3.83	0.000143	0.019	0.21	0.17	Bipolar disorder and schizophrenia;	chr5:116112611	chr5:116078110~116078570:-
LUAD	cis	rs253959	0.545	rs11241362	ENSG00000272265.1	CTD-2287O16.4	3.83	0.000143	0.019	0.21	0.17	Bipolar disorder and schizophrenia;	chr5:116112630	chr5:116078110~116078570:-
LUAD	cis	rs9987353	0.566	rs13260067	ENSG00000253893.2	FAM85B	3.83	0.000143	0.019	0.23	0.17	Recombination measurement;	chr8:9213523	chr8:8167819~8226614:-
LUAD	cis	rs7512552	0.839	rs1260405	ENSG00000275557.1	RP11-353N4.6	3.83	0.000143	0.019	0.2	0.17	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150332310	chr1:149607765~149612402:+
LUAD	cis	rs10864907	0.806	rs10188477	ENSG00000227368.1	AC079753.5	3.83	0.000143	0.019	0.18	0.17	Pulmonary function;	chr2:112957875	chr2:112932625~112933171:+
LUAD	cis	rs9467773	0.62	rs2451731	ENSG00000261353.1	CTA-14H9.5	-3.83	0.000143	0.019	-0.19	-0.17	Intelligence (multi-trait analysis);	chr6:26624594	chr6:26527063~26527404:+
LUAD	cis	rs9467773	0.62	rs9295701	ENSG00000261353.1	CTA-14H9.5	-3.83	0.000143	0.019	-0.19	-0.17	Intelligence (multi-trait analysis);	chr6:26627280	chr6:26527063~26527404:+
LUAD	cis	rs2115630	0.967	rs8027779	ENSG00000259728.4	LINC00933	-3.83	0.000143	0.019	-0.21	-0.17	P wave terminal force;	chr15:84712154	chr15:84570649~84580175:+
LUAD	cis	rs12908161	1	rs12903134	ENSG00000254414.1	RP11-182J1.1	3.83	0.000143	0.019	0.22	0.17	Schizophrenia;	chr15:84794468	chr15:84631898~84633987:-
LUAD	cis	rs12908161	1	rs35726233	ENSG00000254414.1	RP11-182J1.1	3.83	0.000143	0.019	0.22	0.17	Schizophrenia;	chr15:84794569	chr15:84631898~84633987:-
LUAD	cis	rs2486288	0.656	rs11629858	ENSG00000259479.5	SORD2P	-3.83	0.000143	0.019	-0.21	-0.17	Glomerular filtration rate;	chr15:45254916	chr15:44826371~44884694:-
LUAD	cis	rs2486288	0.656	rs11629859	ENSG00000259479.5	SORD2P	-3.83	0.000143	0.019	-0.21	-0.17	Glomerular filtration rate;	chr15:45254923	chr15:44826371~44884694:-
LUAD	cis	rs7829975	0.514	rs2979139	ENSG00000253981.4	ALG1L13P	3.83	0.000143	0.019	0.2	0.17	Mood instability;	chr8:8410803	chr8:8236003~8244667:-
LUAD	cis	rs12744310	1	rs35529558	ENSG00000235358.1	RP11-399E6.1	3.83	0.000143	0.019	0.23	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41301350	chr1:41242373~41284861:+
LUAD	cis	rs9303542	1	rs12948017	ENSG00000264920.1	RP11-6N17.4	3.83	0.000143	0.019	0.22	0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48361884	chr17:47891255~47895812:-
LUAD	cis	rs12216545	0.737	rs6464075	ENSG00000177590.7	GIMAP3P	-3.83	0.000143	0.019	-0.18	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150537453	chr7:150746893~150747728:-
LUAD	cis	rs7107174	1	rs10899453	ENSG00000251323.2	RP11-452H21.4	3.83	0.000143	0.019	0.23	0.17	Testicular germ cell tumor;	chr11:78286436	chr11:78423982~78429836:-
LUAD	cis	rs853679	0.517	rs16893666	ENSG00000280107.1	AL022393.9	3.83	0.000143	0.019	0.23	0.17	Depression;	chr6:28086929	chr6:28170845~28172521:+
LUAD	cis	rs8085804	0.624	rs891567	ENSG00000276174.1	RP11-687E1.2	-3.83	0.000143	0.019	-0.23	-0.17	Cognitive performance;	chr18:42674998	chr18:42052705~42053030:+
LUAD	cis	rs2836974	0.583	rs2776306	ENSG00000232608.1	TIMM9P2	-3.83	0.000143	0.019	-0.19	-0.17	Cognitive function;	chr21:39341828	chr21:39216624~39217506:+
LUAD	cis	rs7131987	0.65	rs10843377	ENSG00000275476.1	RP11-996F15.4	3.83	0.000144	0.019	0.2	0.17	QT interval;	chr12:29284120	chr12:29277397~29277882:-
LUAD	cis	rs8031584	0.672	rs17815726	ENSG00000260382.1	RP11-540B6.2	-3.83	0.000144	0.019	-0.23	-0.17	Huntington's disease progression;	chr15:31021049	chr15:30882267~30883231:-
LUAD	cis	rs848490	0.851	rs57394986	ENSG00000214293.7	APTR	3.83	0.000144	0.019	0.22	0.17	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77587686	chr7:77657660~77696265:-
LUAD	cis	rs6964587	1	rs10225892	ENSG00000188693.7	CYP51A1-AS1	-3.83	0.000144	0.019	-0.2	-0.17	Breast cancer;	chr7:92041706	chr7:92134604~92180725:+
LUAD	cis	rs9907295	0.688	rs9890583	ENSG00000270977.1	AC015849.16	-3.83	0.000144	0.019	-0.25	-0.17	Fibroblast growth factor basic levels;	chr17:35919389	chr17:35893707~35911023:-
LUAD	cis	rs1005277	0.54	rs7903942	ENSG00000273019.1	RP11-508N22.13	3.83	0.000144	0.019	0.2	0.17	Extrinsic epigenetic age acceleration;	chr10:37640348	chr10:38149968~38150293:+
LUAD	cis	rs860295	0.702	rs10796946	ENSG00000225855.5	RUSC1-AS1	3.83	0.000144	0.019	0.12	0.17	Body mass index;	chr1:155459699	chr1:155316863~155324176:-
LUAD	cis	rs860295	0.676	rs10908466	ENSG00000225855.5	RUSC1-AS1	3.83	0.000144	0.019	0.12	0.17	Body mass index;	chr1:155459934	chr1:155316863~155324176:-
LUAD	cis	rs10829156	0.898	rs7095666	ENSG00000240291.1	RP11-499P20.2	-3.83	0.000144	0.019	-0.15	-0.17	Sudden cardiac arrest;	chr10:18650538	chr10:18513115~18545651:-
LUAD	cis	rs12468579	0.74	rs12693588	ENSG00000235852.1	AC005540.3	3.83	0.000144	0.019	0.19	0.17	JT interval (sulfonylurea treatment interaction);	chr2:190967766	chr2:190880797~190882059:-
LUAD	cis	rs1979679	0.682	rs4359252	ENSG00000278733.1	RP11-425D17.1	-3.83	0.000144	0.019	-0.23	-0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28434298	chr12:28185625~28186190:-
LUAD	cis	rs6060987	1	rs6060987	ENSG00000230613.1	HM13-AS1	3.83	0.000144	0.019	0.24	0.17	Mean corpuscular volume;	chr20:31839274	chr20:31567707~31573263:-
LUAD	cis	rs6088580	0.634	rs4911423	ENSG00000276073.1	RP5-1125A11.7	3.83	0.000144	0.019	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34411580	chr20:33985617~33988989:-
LUAD	cis	rs6088580	0.634	rs6141471	ENSG00000276073.1	RP5-1125A11.7	3.83	0.000144	0.019	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34418924	chr20:33985617~33988989:-
LUAD	cis	rs10197140	0.925	rs1872062	ENSG00000235721.1	AC013268.3	-3.83	0.000144	0.019	-0.19	-0.17	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110872912	chr2:110007675~110010783:+
LUAD	cis	rs10197140	0.925	rs750225	ENSG00000235721.1	AC013268.3	-3.83	0.000144	0.019	-0.19	-0.17	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110876290	chr2:110007675~110010783:+
LUAD	cis	rs10197140	0.925	rs62159474	ENSG00000235721.1	AC013268.3	-3.83	0.000144	0.019	-0.19	-0.17	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110877502	chr2:110007675~110010783:+
LUAD	cis	rs10197140	0.885	rs7355443	ENSG00000235721.1	AC013268.3	-3.83	0.000144	0.019	-0.19	-0.17	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110880279	chr2:110007675~110010783:+
LUAD	cis	rs8050896	0.59	rs11866581	ENSG00000260695.1	RP11-513N24.1	-3.83	0.000144	0.019	-0.37	-0.17	Response to antipsychotic treatment;	chr16:66130620	chr16:65861112~65863784:-
LUAD	cis	rs741668	0.641	rs9534306	ENSG00000235903.6	CPB2-AS1	3.83	0.000144	0.019	0.22	0.17	Cerebrospinal fluid clusterin levels;	chr13:46069100	chr13:46052806~46113332:+
LUAD	cis	rs8056893	0.686	rs4783558	ENSG00000260441.4	RP11-96D1.7	-3.83	0.000144	0.019	-0.2	-0.17	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68370063	chr16:68256162~68260443:-
LUAD	cis	rs17660992	0.603	rs8108345	ENSG00000273837.1	LLNLR-470E3.1	-3.83	0.000144	0.019	-0.2	-0.17	Blood protein levels;	chr19:51661033	chr19:51639478~51639931:-
LUAD	cis	rs17660992	0.603	rs2167422	ENSG00000273837.1	LLNLR-470E3.1	-3.83	0.000144	0.019	-0.2	-0.17	Blood protein levels;	chr19:51661130	chr19:51639478~51639931:-
LUAD	cis	rs11240074	0.57	rs12406389	ENSG00000244371.2	PFN1P8	-3.83	0.000144	0.019	-0.28	-0.17	Type 2 diabetes;	chr1:147484044	chr1:146957117~146957659:-
LUAD	cis	rs4795519	0.736	rs1842171	ENSG00000266313.1	RP11-173M1.4	3.83	0.000144	0.019	0.22	0.17	Chronic myeloid leukemia;	chr17:27106436	chr17:27333256~27348491:+
LUAD	cis	rs7819412	0.521	rs9329238	ENSG00000255046.1	RP11-297N6.4	3.83	0.000144	0.019	0.21	0.17	Triglycerides;	chr8:11176228	chr8:11797928~11802568:-
LUAD	cis	rs603446	0.934	rs180351	ENSG00000254851.1	RP11-109L13.1	-3.83	0.000144	0.019	-0.21	-0.17	Triglycerides;	chr11:116736925	chr11:117135528~117138582:+
LUAD	cis	rs2836950	0.501	rs2056844	ENSG00000232608.1	TIMM9P2	3.83	0.000144	0.019	0.19	0.17	Menarche (age at onset);	chr21:39298534	chr21:39216624~39217506:+
LUAD	cis	rs2479106	0.656	rs1857393	ENSG00000236901.4	MIR600HG	3.83	0.000144	0.019	0.12	0.17	Polycystic ovary syndrome;	chr9:123734983	chr9:123109494~123115477:-
LUAD	cis	rs2836950	0.565	rs2150414	ENSG00000232608.1	TIMM9P2	3.83	0.000144	0.0191	0.19	0.17	Menarche (age at onset);	chr21:39243062	chr21:39216624~39217506:+
LUAD	cis	rs683250	0.538	rs11233584	ENSG00000246067.6	RAB30-AS1	-3.83	0.000144	0.0191	-0.18	-0.17	Subcortical brain region volumes;	chr11:83362214	chr11:83072066~83106719:+
LUAD	cis	rs10197140	0.771	rs4848344	ENSG00000235721.1	AC013268.3	-3.83	0.000144	0.0191	-0.2	-0.17	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110937767	chr2:110007675~110010783:+
LUAD	cis	rs338389	0.814	rs399914	ENSG00000260657.2	RP11-315D16.4	-3.83	0.000144	0.0191	-0.19	-0.17	Survival in rectal cancer;	chr15:67974505	chr15:68267792~68277994:-
LUAD	cis	rs6496932	0.663	rs7496211	ENSG00000202081.1	RNU6-1280P	-3.83	0.000144	0.0191	-0.22	-0.17	Central corneal thickness;Corneal structure;	chr15:85379358	chr15:85651522~85651628:-
LUAD	cis	rs17122278	1	rs7115634	ENSG00000243431.1	RPL5P30	3.83	0.000144	0.0191	0.22	0.17	Total cholesterol levels;	chr11:118595534	chr11:118560690~118561580:+
LUAD	cis	rs17122278	1	rs11216924	ENSG00000243431.1	RPL5P30	3.83	0.000144	0.0191	0.22	0.17	Total cholesterol levels;	chr11:118599377	chr11:118560690~118561580:+
LUAD	cis	rs12744310	0.887	rs28541673	ENSG00000235358.1	RP11-399E6.1	3.83	0.000144	0.0191	0.22	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41316322	chr1:41242373~41284861:+
LUAD	cis	rs7246657	0.943	rs10407084	ENSG00000226686.6	LINC01535	-3.83	0.000144	0.0191	-0.26	-0.17	Coronary artery calcification;	chr19:37416890	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.943	rs7252099	ENSG00000226686.6	LINC01535	-3.83	0.000144	0.0191	-0.26	-0.17	Coronary artery calcification;	chr19:37442878	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.943	rs7255972	ENSG00000226686.6	LINC01535	-3.83	0.000144	0.0191	-0.26	-0.17	Coronary artery calcification;	chr19:37442939	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.943	rs1015849	ENSG00000226686.6	LINC01535	-3.83	0.000144	0.0191	-0.26	-0.17	Coronary artery calcification;	chr19:37455278	chr19:37251912~37265535:+
LUAD	cis	rs7142881	0.815	rs12433808	ENSG00000258525.1	RP11-829H16.3	-3.83	0.000144	0.0191	-0.2	-0.17	Response to iloperidone treatment (QT prolongation);	chr14:31695495	chr14:30876179~30889808:-
LUAD	cis	rs9608946	0.957	rs35102600	ENSG00000279699.1	RP1-102K2.9	3.83	0.000144	0.0191	0.25	0.17	Red cell distribution width;	chr22:30530334	chr22:30275215~30276951:-
LUAD	cis	rs9549260	0.564	rs7997896	ENSG00000229456.1	RLIMP1	3.83	0.000144	0.0191	0.19	0.17	Red blood cell count;	chr13:40694687	chr13:40618738~40621348:+
LUAD	cis	rs8177876	0.822	rs28672349	ENSG00000261061.1	RP11-303E16.2	-3.83	0.000144	0.0191	-0.29	-0.17	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080768	chr16:81030770~81031485:+
LUAD	cis	rs7429990	0.965	rs9846062	ENSG00000228638.1	FCF1P2	-3.83	0.000144	0.0191	-0.2	-0.17	Educational attainment (years of education);	chr3:47957476	chr3:48290793~48291375:-
LUAD	cis	rs755249	1	rs4660303	ENSG00000182109.6	RP11-69E11.4	3.83	0.000144	0.0191	0.22	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39594801	chr1:39522280~39546187:-
LUAD	cis	rs1862618	0.853	rs2432195	ENSG00000271828.1	CTD-2310F14.1	3.83	0.000144	0.0191	0.25	0.17	Initial pursuit acceleration;	chr5:56824586	chr5:56927874~56929573:+
LUAD	cis	rs2243480	0.522	rs431168	ENSG00000164669.11	INTS4P1	3.83	0.000144	0.0191	0.35	0.17	Diabetic kidney disease;	chr7:66046617	chr7:65141225~65234216:+
LUAD	cis	rs4908768	0.68	rs11121225	ENSG00000232912.4	RP5-1115A15.1	-3.83	0.000144	0.0191	-0.22	-0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8756379	chr1:8424645~8434838:+
LUAD	cis	rs4268898	0.61	rs72791170	ENSG00000242628.4	AC009228.1	3.83	0.000144	0.0191	0.25	0.17	Asthma;	chr2:24226907	chr2:24214381~24221516:+
LUAD	cis	rs3814244	0.54	rs2159064	ENSG00000236946.2	HNRNPA1P70	3.83	0.000144	0.0191	0.14	0.17	Itch intensity from mosquito bite adjusted by bite size;	chr12:68017126	chr12:68035767~68036853:+
LUAD	cis	rs4118325	0.734	rs1762489	ENSG00000224550.1	RP11-270C12.3	-3.83	0.000144	0.0191	-0.21	-0.17	AIDS;	chr1:107089752	chr1:107505203~107505448:+
LUAD	cis	rs7809950	1	rs12667527	ENSG00000238832.1	snoU109	-3.83	0.000144	0.0191	-0.25	-0.17	Coronary artery disease;	chr7:107446524	chr7:107603363~107603507:+
LUAD	cis	rs8073060	0.586	rs225300	ENSG00000267592.1	CTC-507E2.2	3.83	0.000144	0.0191	0.25	0.17	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35595409	chr17:35596904~35597128:-
LUAD	cis	rs8073060	0.586	rs225294	ENSG00000267592.1	CTC-507E2.2	3.83	0.000144	0.0191	0.25	0.17	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35598743	chr17:35596904~35597128:-
LUAD	cis	rs12744310	1	rs12030762	ENSG00000235358.1	RP11-399E6.1	3.83	0.000144	0.0191	0.23	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41301089	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs55707527	ENSG00000235358.1	RP11-399E6.1	3.83	0.000144	0.0191	0.23	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303441	chr1:41242373~41284861:+
LUAD	cis	rs9515203	0.596	rs9521731	ENSG00000224821.5	COL4A2-AS2	3.83	0.000144	0.0191	0.22	0.17	Coronary artery disease;	chr13:110380352	chr13:110456396~110463287:-
LUAD	cis	rs8028182	0.636	rs12708520	ENSG00000260269.4	CTD-2323K18.1	-3.83	0.000144	0.0191	-0.24	-0.17	Sudden cardiac arrest;	chr15:75538198	chr15:75527150~75601205:-
LUAD	cis	rs1160985	0.967	rs760136	ENSG00000214855.8	APOC1P1	-3.83	0.000144	0.0191	-0.2	-0.17	C-reactive protein;LDL cholesterol;Lipid traits;Gut microbiota (functional units);LDL cholesterol levels;	chr19:44900601	chr19:44926804~44931386:+
LUAD	cis	rs1160985	0.967	rs1038026	ENSG00000214855.8	APOC1P1	-3.83	0.000144	0.0191	-0.2	-0.17	C-reactive protein;LDL cholesterol;Lipid traits;Gut microbiota (functional units);LDL cholesterol levels;	chr19:44901805	chr19:44926804~44931386:+
LUAD	cis	rs755249	0.567	rs1126313	ENSG00000182109.6	RP11-69E11.4	-3.83	0.000144	0.0191	-0.21	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39174072	chr1:39522280~39546187:-
LUAD	cis	rs6137287	0.667	rs4815035	ENSG00000227063.5	RPL41P1	-3.83	0.000144	0.0191	-0.23	-0.17	Height;	chr20:21277481	chr20:21755270~21755350:+
LUAD	cis	rs6806253	0.73	rs4857855	ENSG00000279507.1	RP11-723O4.7	-3.83	0.000144	0.0191	-0.26	-0.17	Pit-and-Fissure caries;	chr3:128541707	chr3:128914833~128915060:-
LUAD	cis	rs6674176	0.561	rs12127226	ENSG00000237950.1	RP11-7O11.3	3.83	0.000144	0.0191	0.21	0.17	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43929637	chr1:43944370~43946551:-
LUAD	cis	rs8046148	0.619	rs4785386	ENSG00000279356.1	RP11-429P3.8	-3.83	0.000144	0.0191	-0.18	-0.17	Testicular germ cell tumor;	chr16:50130138	chr16:50072862~50074986:+
LUAD	cis	rs8028182	0.636	rs7166737	ENSG00000260269.4	CTD-2323K18.1	-3.83	0.000144	0.0191	-0.24	-0.17	Sudden cardiac arrest;	chr15:75390172	chr15:75527150~75601205:-
LUAD	cis	rs12440869	1	rs2414945	ENSG00000270964.1	RP11-502I4.3	3.83	0.000144	0.0191	0.2	0.17	Peak velocity of the mitral A-wave;	chr15:67275230	chr15:67541072~67542604:-
LUAD	cis	rs4819052	0.851	rs2838864	ENSG00000215447.6	BX322557.10	3.83	0.000144	0.0191	0.21	0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291559	chr21:45288052~45291738:+
LUAD	cis	rs9549260	0.592	rs9315783	ENSG00000168852.11	TPTE2P5	3.83	0.000144	0.0191	0.17	0.17	Red blood cell count;	chr13:40715028	chr13:40822296~40921749:-
LUAD	cis	rs9549260	0.564	rs9315784	ENSG00000168852.11	TPTE2P5	3.83	0.000144	0.0191	0.17	0.17	Red blood cell count;	chr13:40715030	chr13:40822296~40921749:-
LUAD	cis	rs2342371	0.816	rs11707744	ENSG00000273013.1	CTD-2002J20.1	3.83	0.000144	0.0191	0.22	0.17	Fat distribution (HIV);	chr3:196486984	chr3:196474801~196475394:+
LUAD	cis	rs6088580	0.634	rs6088483	ENSG00000276073.1	RP5-1125A11.7	3.83	0.000145	0.0191	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34396908	chr20:33985617~33988989:-
LUAD	cis	rs651907	0.557	rs13066768	ENSG00000244119.1	PDCL3P4	-3.83	0.000145	0.0191	-0.16	-0.17	Colorectal cancer;	chr3:101768076	chr3:101712472~101713191:+
LUAD	cis	rs3749855	0.679	rs13215982	ENSG00000220920.1	RP3-525L6.2	3.83	0.000145	0.0191	0.35	0.17	Glucose homeostasis traits;	chr6:17250666	chr6:17953572~17953930:+
LUAD	cis	rs3749855	0.679	rs13215991	ENSG00000220920.1	RP3-525L6.2	3.83	0.000145	0.0191	0.35	0.17	Glucose homeostasis traits;	chr6:17250693	chr6:17953572~17953930:+
LUAD	cis	rs1075265	0.547	rs6743627	ENSG00000272156.1	RP11-477N3.1	3.83	0.000145	0.0191	0.21	0.17	Chronotype;Morning vs. evening chronotype;	chr2:53687024	chr2:54082554~54085066:+
LUAD	cis	rs2041895	0.509	rs7970139	ENSG00000260329.1	RP11-412D9.4	-3.83	0.000145	0.0191	-0.22	-0.17	Glaucoma (low intraocular pressure);	chr12:106918652	chr12:106954029~106955497:-
LUAD	cis	rs7714584	1	rs1428555	ENSG00000197083.10	ZNF300P1	-3.83	0.000145	0.0191	-0.31	-0.17	Crohn's disease;	chr5:150877829	chr5:150930645~150946289:-
LUAD	cis	rs7819412	0.522	rs10088853	ENSG00000255046.1	RP11-297N6.4	3.83	0.000145	0.0191	0.22	0.17	Triglycerides;	chr8:11130457	chr8:11797928~11802568:-
LUAD	cis	rs7200543	1	rs6498540	ENSG00000260735.1	RP11-72I8.1	-3.83	0.000145	0.0191	-0.19	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036737	chr16:15094411~15109197:+
LUAD	cis	rs7178424	0.711	rs4283171	ENSG00000259251.2	RP11-643M14.1	-3.83	0.000145	0.0191	-0.17	-0.17	Height;	chr15:61880185	chr15:62060503~62062434:+
LUAD	cis	rs7176527	1	rs3762168	ENSG00000259570.1	RP11-671M22.4	-3.83	0.000145	0.0191	-0.25	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84599416	chr15:84394512~84395514:+
LUAD	cis	rs7017914	0.967	rs1838393	ENSG00000246366.5	RP11-382J12.1	3.83	0.000145	0.0191	0.16	0.17	Bone mineral density;	chr8:70790356	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.935	rs7826483	ENSG00000246366.5	RP11-382J12.1	3.83	0.000145	0.0191	0.16	0.17	Bone mineral density;	chr8:70790658	chr8:70608577~70663279:+
LUAD	cis	rs1401999	0.668	rs6806313	ENSG00000223882.1	ABCC5-AS1	-3.83	0.000145	0.0191	-0.17	-0.17	Anterior chamber depth;	chr3:183924364	chr3:184006338~184011419:+
LUAD	cis	rs34929064	0.718	rs2097676	ENSG00000230658.1	KLHL7-AS1	3.83	0.000145	0.0191	0.25	0.17	Major depression and alcohol dependence;	chr7:22693186	chr7:23101228~23105703:-
LUAD	cis	rs7208859	0.673	rs216418	ENSG00000280069.1	CTD-2349P21.3	-3.83	0.000145	0.0191	-0.2	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30609519	chr17:30738182~30740275:+
LUAD	cis	rs321358	0.895	rs17457375	ENSG00000271390.1	RP11-89C3.3	3.83	0.000145	0.0191	0.27	0.17	Body mass index;	chr11:111085100	chr11:111089870~111090368:-
LUAD	cis	rs2274273	0.624	rs72717738	ENSG00000258413.1	RP11-665C16.6	-3.83	0.000145	0.0191	-0.23	-0.17	Protein biomarker;	chr14:55376043	chr14:55262767~55272075:-
LUAD	cis	rs440932	0.887	rs398801	ENSG00000254340.1	RP11-10A14.3	-3.83	0.000145	0.0191	-0.22	-0.17	High light scatter reticulocyte percentage of red cells;	chr8:9174194	chr8:9141424~9145435:+
LUAD	cis	rs6763848	0.847	rs7649046	ENSG00000214073.2	RPL21P17	-3.83	0.000145	0.0191	-0.18	-0.17	Prostate cancer (SNP x SNP interaction);	chr3:1483906	chr3:1905651~1906125:+
LUAD	cis	rs1879248	0.539	rs536127	ENSG00000242808.6	SOX2-OT	3.83	0.000145	0.0191	0.19	0.17	Schizophrenia;	chr3:180933174	chr3:180989770~181836880:+
LUAD	cis	rs7551222	0.752	rs12138846	ENSG00000240219.1	RP11-430C7.5	3.83	0.000145	0.0191	0.18	0.17	Schizophrenia;	chr1:204587350	chr1:204626775~204629712:+
LUAD	cis	rs12216545	0.765	rs1851435	ENSG00000241134.3	BET1P1	-3.83	0.000145	0.0191	-0.18	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150531697	chr7:150749736~150750094:+
LUAD	cis	rs12216545	0.737	rs4339548	ENSG00000241134.3	BET1P1	-3.83	0.000145	0.0191	-0.18	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150532227	chr7:150749736~150750094:+
LUAD	cis	rs12216545	0.765	rs4607525	ENSG00000241134.3	BET1P1	-3.83	0.000145	0.0191	-0.18	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150532262	chr7:150749736~150750094:+
LUAD	cis	rs6142102	0.961	rs1319363	ENSG00000275784.1	RP5-1125A11.6	-3.83	0.000145	0.0191	-0.19	-0.17	Skin pigmentation;	chr20:33954070	chr20:33989480~33991818:-
LUAD	cis	rs11920570	0.959	rs4315641	ENSG00000272758.4	RP11-299J3.8	3.83	0.000145	0.0191	0.17	0.17	Resting heart rate;	chr3:122350028	chr3:122416207~122443180:+
LUAD	cis	rs9366999	0.809	rs1744413	ENSG00000235033.6	RP11-61I13.3	-3.83	0.000145	0.0192	-0.18	-0.17	Obesity-related traits;	chr6:39253810	chr6:39881804~39900071:-
LUAD	cis	rs7976269	0.609	rs1344855	ENSG00000257176.2	RP11-996F15.2	3.83	0.000145	0.0192	0.19	0.17	Male-pattern baldness;	chr12:29065605	chr12:29280418~29317848:-
LUAD	cis	rs801193	0.548	rs2659904	ENSG00000232559.3	GS1-124K5.12	3.83	0.000145	0.0192	0.2	0.17	Aortic root size;	chr7:66713615	chr7:66554588~66576923:-
LUAD	cis	rs449789	0.524	rs3904936	ENSG00000235086.1	FNDC1-IT1	-3.83	0.000145	0.0192	-0.24	-0.17	Pulse pressure;	chr6:159356910	chr6:159240786~159243329:+
LUAD	cis	rs62246343	0.605	rs4328788	ENSG00000206573.7	THUMPD3-AS1	-3.83	0.000145	0.0192	-0.16	-0.17	Fibrinogen levels;	chr3:9415577	chr3:9349689~9398579:-
LUAD	cis	rs62246343	0.605	rs4308263	ENSG00000206573.7	THUMPD3-AS1	-3.83	0.000145	0.0192	-0.16	-0.17	Fibrinogen levels;	chr3:9415674	chr3:9349689~9398579:-
LUAD	cis	rs7674212	0.531	rs2866416	ENSG00000230069.3	LRRC37A15P	-3.83	0.000145	0.0192	-0.19	-0.17	Type 2 diabetes;	chr4:102959554	chr4:102727274~102730721:-
LUAD	cis	rs703842	1	rs4646536	ENSG00000270039.1	RP11-571M6.17	-3.83	0.000145	0.0192	-0.2	-0.17	Multiple sclerosis;	chr12:57764205	chr12:57803838~57804415:+
LUAD	cis	rs10197140	0.857	rs7355554	ENSG00000235721.1	AC013268.3	-3.83	0.000145	0.0192	-0.19	-0.17	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110882716	chr2:110007675~110010783:+
LUAD	cis	rs287982	0.611	rs7580521	ENSG00000269973.1	RP11-95D17.1	-3.83	0.000145	0.0192	-0.25	-0.17	Nonsyndromic cleft lip with cleft palate;	chr2:9835555	chr2:9936360~9939590:+
LUAD	cis	rs287982	0.611	rs80336909	ENSG00000269973.1	RP11-95D17.1	-3.83	0.000145	0.0192	-0.25	-0.17	Nonsyndromic cleft lip with cleft palate;	chr2:9835645	chr2:9936360~9939590:+
LUAD	cis	rs287982	0.611	rs76624418	ENSG00000269973.1	RP11-95D17.1	-3.83	0.000145	0.0192	-0.25	-0.17	Nonsyndromic cleft lip with cleft palate;	chr2:9836389	chr2:9936360~9939590:+
LUAD	cis	rs287982	0.611	rs76011221	ENSG00000269973.1	RP11-95D17.1	-3.83	0.000145	0.0192	-0.25	-0.17	Nonsyndromic cleft lip with cleft palate;	chr2:9837504	chr2:9936360~9939590:+
LUAD	cis	rs287982	0.611	rs75809337	ENSG00000269973.1	RP11-95D17.1	-3.83	0.000145	0.0192	-0.25	-0.17	Nonsyndromic cleft lip with cleft palate;	chr2:9837684	chr2:9936360~9939590:+
LUAD	cis	rs287982	0.611	rs78100109	ENSG00000269973.1	RP11-95D17.1	-3.83	0.000145	0.0192	-0.25	-0.17	Nonsyndromic cleft lip with cleft palate;	chr2:9838280	chr2:9936360~9939590:+
LUAD	cis	rs287982	0.611	rs112561492	ENSG00000269973.1	RP11-95D17.1	-3.83	0.000145	0.0192	-0.25	-0.17	Nonsyndromic cleft lip with cleft palate;	chr2:9838991	chr2:9936360~9939590:+
LUAD	cis	rs287982	0.611	rs77359699	ENSG00000269973.1	RP11-95D17.1	-3.83	0.000145	0.0192	-0.25	-0.17	Nonsyndromic cleft lip with cleft palate;	chr2:9839170	chr2:9936360~9939590:+
LUAD	cis	rs287982	0.611	rs75277217	ENSG00000269973.1	RP11-95D17.1	-3.83	0.000145	0.0192	-0.25	-0.17	Nonsyndromic cleft lip with cleft palate;	chr2:9839275	chr2:9936360~9939590:+
LUAD	cis	rs738722	1	rs738722	ENSG00000272858.1	CTA-292E10.8	3.83	0.000145	0.0192	0.2	0.17	Optic cup area;Esophageal cancer and gastric cancer;	chr22:28734024	chr22:28814914~28815662:+
LUAD	cis	rs868153	0.506	rs9372676	ENSG00000279453.1	RP3-425C14.4	-3.83	0.000145	0.0192	-0.18	-0.17	Vertical cup-disc ratio;	chr6:122066375	chr6:122436789~122439223:-
LUAD	cis	rs56046484	0.871	rs35000527	ENSG00000259630.2	CTD-2262B20.1	-3.83	0.000145	0.0192	-0.26	-0.17	Testicular germ cell tumor;	chr15:85010550	chr15:85415228~85415633:+
LUAD	cis	rs56046484	0.826	rs35816571	ENSG00000259630.2	CTD-2262B20.1	-3.83	0.000145	0.0192	-0.26	-0.17	Testicular germ cell tumor;	chr15:85010891	chr15:85415228~85415633:+
LUAD	cis	rs3805389	0.504	rs13434995	ENSG00000273257.1	RP11-177J6.1	-3.83	0.000145	0.0192	-0.27	-0.17	Waist-to-hip ratio adjusted for body mass index;	chr4:55601047	chr4:55387949~55388271:+
LUAD	cis	rs910316	0.712	rs175074	ENSG00000259138.1	RP11-950C14.7	-3.83	0.000145	0.0192	-0.18	-0.17	Height;	chr14:75037751	chr14:75127153~75136930:+
LUAD	cis	rs11673344	0.504	rs10403975	ENSG00000276846.1	CTD-3220F14.3	3.83	0.000145	0.0192	0.19	0.17	Obesity-related traits;	chr19:37082172	chr19:37314868~37315620:-
LUAD	cis	rs739496	0.579	rs75080921	ENSG00000234608.6	MAPKAPK5-AS1	3.83	0.000145	0.0192	0.2	0.17	Platelet count;	chr12:111861168	chr12:111839764~111842902:-
LUAD	cis	rs2251260	0.685	rs2246700	ENSG00000250548.5	RP11-47I22.2	3.83	0.000145	0.0192	0.23	0.17	Yeast infection;	chr14:61541429	chr14:61556313~61570653:-
LUAD	cis	rs6496044	0.568	rs4842888	ENSG00000259416.2	RP11-158M2.5	-3.83	0.000145	0.0192	-0.18	-0.17	Interstitial lung disease;	chr15:85519902	chr15:85754941~85756237:-
LUAD	cis	rs1959536	1	rs1959536	ENSG00000214900.7	LINC01588	3.83	0.000145	0.0192	0.39	0.17	Psychosis (atypical);	chr14:50980053	chr14:49981712~50007520:-
LUAD	cis	rs11048434	0.518	rs1805707	ENSG00000256937.1	KRT17P8	-3.83	0.000145	0.0192	-0.2	-0.17	Sjögren's syndrome;	chr12:9029110	chr12:9127783~9128645:+
LUAD	cis	rs6502050	0.835	rs7218857	ENSG00000266654.1	RP11-1376P16.1	-3.83	0.000145	0.0192	-0.19	-0.17	Life satisfaction;	chr17:82203124	chr17:82160056~82160452:+
LUAD	cis	rs9467773	1	rs12663883	ENSG00000241549.7	GUSBP2	3.83	0.000145	0.0192	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26577098	chr6:26871484~26956554:-
LUAD	cis	rs9467773	0.967	rs6913877	ENSG00000241549.7	GUSBP2	3.83	0.000145	0.0192	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26577260	chr6:26871484~26956554:-
LUAD	cis	rs9467773	1	rs6918506	ENSG00000241549.7	GUSBP2	3.83	0.000145	0.0192	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26577629	chr6:26871484~26956554:-
LUAD	cis	rs9467773	1	rs6918360	ENSG00000241549.7	GUSBP2	3.83	0.000145	0.0192	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26577639	chr6:26871484~26956554:-
LUAD	cis	rs9467773	1	rs6918854	ENSG00000241549.7	GUSBP2	3.83	0.000145	0.0192	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26577696	chr6:26871484~26956554:-
LUAD	cis	rs9467773	1	rs9467800	ENSG00000241549.7	GUSBP2	3.83	0.000145	0.0192	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26578297	chr6:26871484~26956554:-
LUAD	cis	rs9467773	0.901	rs10223789	ENSG00000241549.7	GUSBP2	3.83	0.000145	0.0192	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26579381	chr6:26871484~26956554:-
LUAD	cis	rs9467773	1	rs9467802	ENSG00000241549.7	GUSBP2	3.83	0.000145	0.0192	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26580940	chr6:26871484~26956554:-
LUAD	cis	rs12122100	0.774	rs12723253	ENSG00000244371.2	PFN1P8	3.83	0.000145	0.0192	0.22	0.17	HIV-1 control;	chr1:147051741	chr1:146957117~146957659:-
LUAD	cis	rs4787951	0.56	rs3024530	ENSG00000259940.2	CTD-3203P2.1	3.83	0.000145	0.0192	0.19	0.17	Eosinophil percentage of white cells;	chr16:27339366	chr16:27213308~27214993:-
LUAD	cis	rs6860806	1	rs6860806	ENSG00000263597.1	MIR3936	-3.83	0.000145	0.0192	-0.17	-0.17	Breast cancer;	chr5:132304843	chr5:132365490~132365599:-
LUAD	cis	rs9467773	0.62	rs3800303	ENSG00000241549.7	GUSBP2	3.83	0.000145	0.0192	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26597960	chr6:26871484~26956554:-
LUAD	cis	rs7017914	0.69	rs62506036	ENSG00000246366.5	RP11-382J12.1	3.83	0.000145	0.0192	0.16	0.17	Bone mineral density;	chr8:71066890	chr8:70608577~70663279:+
LUAD	cis	rs9900280	1	rs1568373	ENSG00000264808.1	RP11-802D6.1	-3.83	0.000145	0.0192	-0.2	-0.17	Mean platelet volume;	chr17:29433125	chr17:29369717~29390777:-
LUAD	cis	rs7674212	0.556	rs223401	ENSG00000230069.3	LRRC37A15P	-3.83	0.000145	0.0192	-0.18	-0.17	Type 2 diabetes;	chr4:102817815	chr4:102727274~102730721:-
LUAD	cis	rs2732480	0.557	rs2732441	ENSG00000273765.1	RP11-370I10.11	3.83	0.000145	0.0192	0.19	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48329541	chr12:48360920~48361377:+
LUAD	cis	rs12935418	0.616	rs2549828	ENSG00000261061.1	RP11-303E16.2	3.83	0.000145	0.0192	0.18	0.17	Mean corpuscular volume;	chr16:80985378	chr16:81030770~81031485:+
LUAD	cis	rs910316	0.737	rs175072	ENSG00000259138.1	RP11-950C14.7	-3.83	0.000146	0.0192	-0.18	-0.17	Height;	chr14:75036124	chr14:75127153~75136930:+
LUAD	cis	rs28472312	0.855	rs2071342	ENSG00000246465.1	RP11-57A19.2	3.83	0.000146	0.0192	0.2	0.17	Intelligence (multi-trait analysis);	chr16:28904112	chr16:28284885~28292064:-
LUAD	cis	rs34792	0.688	rs153785	ENSG00000275910.1	RP11-680G24.6	3.83	0.000146	0.0192	0.17	0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15499435	chr16:15015828~15016390:-
LUAD	cis	rs11051970	0.918	rs73084101	ENSG00000274964.1	RP11-817I4.1	-3.83	0.000146	0.0192	-0.2	-0.17	Response to tocilizumab in rheumatoid arthritis;	chr12:32391405	chr12:32339368~32340724:+
LUAD	cis	rs12935418	0.583	rs2549843	ENSG00000261061.1	RP11-303E16.2	3.83	0.000146	0.0192	0.18	0.17	Mean corpuscular volume;	chr16:80990140	chr16:81030770~81031485:+
LUAD	cis	rs11089937	0.626	rs2213157	ENSG00000211640.3	IGLV6-57	3.83	0.000146	0.0192	0.13	0.17	Periodontitis (PAL4Q3);	chr22:22137997	chr22:22195713~22196460:+
LUAD	cis	rs28374715	0.681	rs59000092	ENSG00000247556.5	OIP5-AS1	3.83	0.000146	0.0192	0.21	0.17	Ulcerative colitis;	chr15:41333950	chr15:41283990~41309737:+
LUAD	cis	rs28374715	0.681	rs11629979	ENSG00000247556.5	OIP5-AS1	3.83	0.000146	0.0192	0.21	0.17	Ulcerative colitis;	chr15:41334381	chr15:41283990~41309737:+
LUAD	cis	rs17596685	1	rs1325800	ENSG00000271216.1	LINC01050	-3.83	0.000146	0.0192	-0.25	-0.17	C-reactive protein levels;	chr13:42568165	chr13:42810366~42812562:-
LUAD	cis	rs17596685	1	rs17639305	ENSG00000271216.1	LINC01050	-3.83	0.000146	0.0192	-0.25	-0.17	C-reactive protein levels;	chr13:42572051	chr13:42810366~42812562:-
LUAD	cis	rs12935418	0.616	rs9931292	ENSG00000261061.1	RP11-303E16.2	-3.83	0.000146	0.0192	-0.18	-0.17	Mean corpuscular volume;	chr16:80975671	chr16:81030770~81031485:+
LUAD	cis	rs2444896	0.515	rs1869609	ENSG00000245970.2	KB-1208A12.3	-3.83	0.000146	0.0192	-0.15	-0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);	chr8:97978993	chr8:98041726~98044121:+
LUAD	cis	rs13113518	1	rs4865013	ENSG00000273257.1	RP11-177J6.1	3.83	0.000146	0.0192	0.19	0.17	Height;	chr4:55559957	chr4:55387949~55388271:+
LUAD	cis	rs62244186	0.566	rs6766221	ENSG00000233509.2	ZNF197-AS1	3.83	0.000146	0.0192	0.19	0.17	Depressive symptoms;	chr3:44841292	chr3:44617128~44624797:-
LUAD	cis	rs9393777	0.668	rs3800318	ENSG00000219392.1	RP1-265C24.5	-3.83	0.000146	0.0192	-0.26	-0.17	Intelligence (multi-trait analysis);	chr6:27295862	chr6:28115628~28116551:+
LUAD	cis	rs116095464	0.558	rs7708182	ENSG00000248925.1	CTD-2083E4.6	3.83	0.000146	0.0192	0.29	0.17	Breast cancer;	chr5:234673	chr5:269858~271516:-
LUAD	cis	rs1348850	0.958	rs11689550	ENSG00000271825.1	RP11-337N6.2	3.83	0.000146	0.0192	0.22	0.17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177591570	chr2:177300600~177302006:+
LUAD	cis	rs5742933	1	rs2289404	ENSG00000253559.1	OSGEPL1-AS1	-3.83	0.000146	0.0192	-0.24	-0.17	Ferritin levels;	chr2:189771288	chr2:189762704~189765556:+
LUAD	cis	rs5742933	1	rs12622902	ENSG00000253559.1	OSGEPL1-AS1	-3.83	0.000146	0.0192	-0.24	-0.17	Ferritin levels;	chr2:189776263	chr2:189762704~189765556:+
LUAD	cis	rs4268898	0.61	rs55860688	ENSG00000242628.4	AC009228.1	3.83	0.000146	0.0193	0.25	0.17	Asthma;	chr2:24228665	chr2:24214381~24221516:+
LUAD	cis	rs7071275	0.6	rs11200052	ENSG00000226864.1	ATE1-AS1	3.83	0.000146	0.0193	0.33	0.17	Dupuytren's disease;	chr10:121642723	chr10:121928312~121951965:+
LUAD	cis	rs2468186	0.934	rs7000127	ENSG00000281641.1	SAMD12-AS1	3.83	0.000146	0.0193	0.23	0.17	Osteoprotegerin levels;	chr8:119203374	chr8:118621001~118858218:+
LUAD	cis	rs6540731	1	rs11119884	ENSG00000229983.1	RP11-15I11.2	3.83	0.000146	0.0193	0.21	0.17	Intelligence (childhood);	chr1:212226804	chr1:212168207~212190259:+
LUAD	cis	rs9549260	0.755	rs12585277	ENSG00000229456.1	RLIMP1	3.83	0.000146	0.0193	0.19	0.17	Red blood cell count;	chr13:40650676	chr13:40618738~40621348:+
LUAD	cis	rs9549260	0.522	rs4245401	ENSG00000229456.1	RLIMP1	3.83	0.000146	0.0193	0.18	0.17	Red blood cell count;	chr13:40703600	chr13:40618738~40621348:+
LUAD	cis	rs6563842	0.563	rs4575411	ENSG00000229456.1	RLIMP1	3.83	0.000146	0.0193	0.18	0.17	Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr13:40703658	chr13:40618738~40621348:+
LUAD	cis	rs9500256	0.711	rs6588685	ENSG00000239650.4	GUSBP4	3.83	0.000146	0.0193	0.2	0.17	Eosinophilic esophagitis (pediatric);	chr6:57993375	chr6:57919784~57930291:-
LUAD	cis	rs7017914	0.967	rs2933853	ENSG00000246366.5	RP11-382J12.1	3.83	0.000146	0.0193	0.16	0.17	Bone mineral density;	chr8:70996987	chr8:70608577~70663279:+
LUAD	cis	rs11210359	0.528	rs2124032	ENSG00000272864.1	RP11-17E13.2	3.83	0.000146	0.0193	0.21	0.17	Bipolar disorder and schizophrenia;	chr1:73880474	chr1:74698769~74699333:-
LUAD	cis	rs6088580	0.634	rs6088484	ENSG00000276073.1	RP5-1125A11.7	3.83	0.000146	0.0193	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34398155	chr20:33985617~33988989:-
LUAD	cis	rs6500602	0.702	rs17761816	ENSG00000280063.1	RP11-295D4.3	3.83	0.000146	0.0193	0.11	0.17	Schizophrenia;	chr16:4498831	chr16:4346694~4348648:-
LUAD	cis	rs9517320	0.934	rs9517319	ENSG00000231194.1	FARP1-AS1	3.83	0.000146	0.0193	0.2	0.17	Longevity;	chr13:98473702	chr13:98435405~98435840:-
LUAD	cis	rs13113518	0.783	rs2171618	ENSG00000273257.1	RP11-177J6.1	3.83	0.000146	0.0193	0.2	0.17	Height;	chr4:55564241	chr4:55387949~55388271:+
LUAD	cis	rs11897432	0.592	rs6743581	ENSG00000279873.2	LINC01126	3.83	0.000146	0.0193	0.16	0.17	DNA methylation (variation);	chr2:43389671	chr2:43227210~43228855:+
LUAD	cis	rs8028182	0.636	rs28623700	ENSG00000260269.4	CTD-2323K18.1	-3.83	0.000146	0.0193	-0.24	-0.17	Sudden cardiac arrest;	chr15:75557373	chr15:75527150~75601205:-
LUAD	cis	rs8028182	0.577	rs28693593	ENSG00000260269.4	CTD-2323K18.1	-3.83	0.000146	0.0193	-0.24	-0.17	Sudden cardiac arrest;	chr15:75557435	chr15:75527150~75601205:-
LUAD	cis	rs9494145	0.638	rs6934903	ENSG00000232876.1	CTA-212D2.2	3.83	0.000146	0.0193	0.25	0.17	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135130426	chr6:135055033~135060550:+
LUAD	cis	rs9467773	0.62	rs1490488	ENSG00000261353.1	CTA-14H9.5	-3.83	0.000146	0.0193	-0.19	-0.17	Intelligence (multi-trait analysis);	chr6:26614580	chr6:26527063~26527404:+
LUAD	cis	rs9467773	0.62	rs2494692	ENSG00000261353.1	CTA-14H9.5	-3.83	0.000146	0.0193	-0.19	-0.17	Intelligence (multi-trait analysis);	chr6:26614995	chr6:26527063~26527404:+
LUAD	cis	rs4819052	0.851	rs12626188	ENSG00000215447.6	BX322557.10	-3.83	0.000146	0.0193	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249343	chr21:45288052~45291738:+
LUAD	cis	rs34779708	0.931	rs4934709	ENSG00000271335.4	RP11-324I22.4	-3.83	0.000146	0.0193	-0.18	-0.17	Inflammatory bowel disease;Crohn's disease;	chr10:35050396	chr10:35314552~35336401:-
LUAD	cis	rs12822507	0.732	rs873218	ENSG00000275963.1	RP11-180M15.6	3.83	0.000146	0.0193	0.2	0.17	Systemic lupus erythematosus;	chr12:12612669	chr12:12648939~12649713:+
LUAD	cis	rs76878669	0.561	rs4930362	ENSG00000213409.4	RP11-658F2.3	3.83	0.000146	0.0193	0.21	0.17	Educational attainment (years of education);	chr11:66386889	chr11:66761575~66762399:-
LUAD	cis	rs76878669	0.561	rs4930179	ENSG00000213409.4	RP11-658F2.3	3.83	0.000146	0.0193	0.21	0.17	Educational attainment (years of education);	chr11:66389961	chr11:66761575~66762399:-
LUAD	cis	rs7829975	0.617	rs4841071	ENSG00000253981.4	ALG1L13P	3.83	0.000146	0.0193	0.19	0.17	Mood instability;	chr8:8933634	chr8:8236003~8244667:-
LUAD	cis	rs678347	0.677	rs646514	ENSG00000261087.1	KB-1460A1.5	3.83	0.000146	0.0193	0.24	0.17	Rheumatoid arthritis;	chr8:101453833	chr8:101166805~101169629:-
LUAD	cis	rs11742741	1	rs6864120	ENSG00000248874.4	C5orf17	3.83	0.000146	0.0193	0.21	0.17	Educational attainment;	chr5:24176407	chr5:23951348~24178263:+
LUAD	cis	rs10090774	0.735	rs10108814	ENSG00000280303.2	ERICD	-3.83	0.000146	0.0193	-0.19	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140708215	chr8:140636281~140638283:+
LUAD	cis	rs703842	1	rs10877014	ENSG00000270039.1	RP11-571M6.17	-3.83	0.000146	0.0193	-0.2	-0.17	Multiple sclerosis;	chr12:57773878	chr12:57803838~57804415:+
LUAD	cis	rs11089937	0.667	rs10483108	ENSG00000211640.3	IGLV6-57	3.83	0.000146	0.0193	0.14	0.17	Periodontitis (PAL4Q3);	chr22:22152664	chr22:22195713~22196460:+
LUAD	cis	rs1355223	1	rs11601923	ENSG00000271369.1	RP11-350D17.3	-3.83	0.000146	0.0193	-0.21	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34742807	chr11:34709600~34710161:+
LUAD	cis	rs2307394	0.716	rs10497022	ENSG00000281469.1	RP11-567F11.1	-3.83	0.000146	0.0193	-0.2	-0.17	Urate levels;	chr2:147773176	chr2:148044380~148044894:+
LUAD	cis	rs853679	0.517	rs4713152	ENSG00000280107.1	AL022393.9	-3.83	0.000146	0.0193	-0.23	-0.17	Depression;	chr6:28169676	chr6:28170845~28172521:+
LUAD	cis	rs7142881	0.626	rs56142831	ENSG00000250365.5	CTD-2213F21.2	3.83	0.000146	0.0193	0.2	0.17	Response to iloperidone treatment (QT prolongation);	chr14:31803465	chr14:31420286~31452883:+
LUAD	cis	rs12935418	0.672	rs2549879	ENSG00000261061.1	RP11-303E16.2	3.83	0.000146	0.0193	0.19	0.17	Mean corpuscular volume;	chr16:81012496	chr16:81030770~81031485:+
LUAD	cis	rs12908161	0.959	rs61074241	ENSG00000259295.5	CSPG4P12	3.83	0.000146	0.0193	0.25	0.17	Schizophrenia;	chr15:84790165	chr15:85191438~85213905:+
LUAD	cis	rs6840360	0.642	rs7682837	ENSG00000270265.1	RP11-731D1.4	-3.83	0.000146	0.0193	-0.17	-0.17	Intelligence (multi-trait analysis);	chr4:151506534	chr4:151333775~151353224:-
LUAD	cis	rs7015630	0.603	rs2189025	ENSG00000251136.7	RP11-37B2.1	-3.83	0.000146	0.0193	-0.22	-0.17	Inflammatory bowel disease;Crohn's disease;	chr8:89836956	chr8:89609409~89757727:-
LUAD	cis	rs7714584	1	rs13361189	ENSG00000197083.10	ZNF300P1	3.83	0.000146	0.0193	0.31	0.17	Crohn's disease;	chr5:150843825	chr5:150930645~150946289:-
LUAD	cis	rs12744310	1	rs36143444	ENSG00000235358.1	RP11-399E6.1	3.83	0.000146	0.0193	0.23	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41298638	chr1:41242373~41284861:+
LUAD	cis	rs12304921	0.639	rs970097	ENSG00000277201.1	AC087884.1	-3.83	0.000146	0.0193	-0.17	-0.17	Type 2 diabetes;	chr12:51085630	chr12:51049921~51050025:+
LUAD	cis	rs4819052	0.851	rs2236445	ENSG00000215447.6	BX322557.10	-3.83	0.000146	0.0193	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258538	chr21:45288052~45291738:+
LUAD	cis	rs8073060	0.533	rs178736	ENSG00000267592.1	CTC-507E2.2	3.83	0.000146	0.0193	0.25	0.17	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35601139	chr17:35596904~35597128:-
LUAD	cis	rs10463554	0.927	rs56361326	ENSG00000250682.4	LINC00491	3.83	0.000146	0.0193	0.2	0.17	Parkinson's disease;	chr5:103054184	chr5:102609156~102671559:-
LUAD	cis	rs73173548	0.502	rs12189501	ENSG00000247828.6	TMEM161B-AS1	-3.83	0.000146	0.0193	-0.2	-0.17	Macular telangiectasia type 2;	chr5:88462208	chr5:88268895~88436685:+
LUAD	cis	rs11853189	0.938	rs75281351	ENSG00000259562.2	RP11-762H8.2	3.83	0.000146	0.0193	0.19	0.17	Red cell distribution width;	chr15:78287308	chr15:78290527~78291221:-
LUAD	cis	rs11853189	0.938	rs2277551	ENSG00000259562.2	RP11-762H8.2	3.83	0.000146	0.0193	0.19	0.17	Red cell distribution width;	chr15:78288139	chr15:78290527~78291221:-
LUAD	cis	rs11853189	0.938	rs1879152	ENSG00000259562.2	RP11-762H8.2	3.83	0.000146	0.0193	0.19	0.17	Red cell distribution width;	chr15:78289498	chr15:78290527~78291221:-
LUAD	cis	rs321358	1	rs321365	ENSG00000271390.1	RP11-89C3.3	3.83	0.000146	0.0193	0.28	0.17	Body mass index;	chr11:111126676	chr11:111089870~111090368:-
LUAD	cis	rs2235642	0.717	rs2236269	ENSG00000280231.1	LA16c-380F5.3	-3.83	0.000146	0.0193	-0.23	-0.17	Coronary artery disease;	chr16:1602613	chr16:1553655~1554130:-
LUAD	cis	rs7119	0.604	rs939488	ENSG00000259362.2	RP11-307C19.1	3.83	0.000146	0.0193	0.22	0.17	Type 2 diabetes;	chr15:77575438	chr15:77525540~77534110:+
LUAD	cis	rs7204230	1	rs12596717	ENSG00000261291.1	RP11-295M3.2	3.83	0.000146	0.0193	0.21	0.17	Fibrinogen;	chr16:53334892	chr16:53168522~53169450:+
LUAD	cis	rs6840360	0.571	rs12647566	ENSG00000270265.1	RP11-731D1.4	-3.83	0.000146	0.0193	-0.19	-0.17	Intelligence (multi-trait analysis);	chr4:151561373	chr4:151333775~151353224:-
LUAD	cis	rs13256369	1	rs9329165	ENSG00000253893.2	FAM85B	3.83	0.000146	0.0193	0.23	0.17	Obesity-related traits;	chr8:8719132	chr8:8167819~8226614:-
LUAD	cis	rs3018712	0.508	rs4930581	ENSG00000212093.1	AP000807.1	-3.83	0.000147	0.0193	-0.22	-0.17	Total body bone mineral density;	chr11:68643625	chr11:68506083~68506166:-
LUAD	cis	rs2239557	0.845	rs11622838	ENSG00000259065.1	RP5-1021I20.1	3.83	0.000147	0.0193	0.2	0.17	Common traits (Other);	chr14:74202656	chr14:73787360~73803270:+
LUAD	cis	rs875971	0.862	rs6460306	ENSG00000273448.1	RP11-166O4.6	-3.83	0.000147	0.0193	-0.16	-0.17	Aortic root size;	chr7:66595806	chr7:67333047~67334383:+
LUAD	cis	rs71636778	0.631	rs71636787	ENSG00000260063.1	RP5-968P14.2	-3.83	0.000147	0.0193	-0.23	-0.17	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26858624	chr1:26692132~26694131:-
LUAD	cis	rs71636778	0.631	rs71636788	ENSG00000260063.1	RP5-968P14.2	-3.83	0.000147	0.0193	-0.23	-0.17	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26859994	chr1:26692132~26694131:-
LUAD	cis	rs2735413	0.709	rs1319049	ENSG00000276007.1	RP11-358L22.3	3.83	0.000147	0.0193	0.18	0.17	Systolic blood pressure (alcohol consumption interaction);	chr16:78050713	chr16:78123243~78124332:+
LUAD	cis	rs7005380	0.581	rs10099088	ENSG00000279347.1	RP11-85I17.2	-3.83	0.000147	0.0193	-0.16	-0.17	Interstitial lung disease;	chr8:119927418	chr8:119838736~119840385:-
LUAD	cis	rs6832769	0.961	rs11133382	ENSG00000272969.1	RP11-528I4.2	3.83	0.000147	0.0193	0.18	0.17	Personality dimensions;	chr4:55450813	chr4:55547112~55547889:+
LUAD	cis	rs3847687	0.869	rs11061300	ENSG00000279128.1	RP11-76C10.4	3.83	0.000147	0.0193	0.19	0.17	Longevity;	chr12:131038716	chr12:131022769~131024741:-
LUAD	cis	rs2301573	0.504	rs1708933	ENSG00000253540.4	FAM86HP	3.83	0.000147	0.0193	0.28	0.17	Hip circumference;	chr3:129904396	chr3:130099092~130111472:-
LUAD	cis	rs17406451	0.759	rs11124936	ENSG00000279873.2	LINC01126	3.83	0.000147	0.0193	0.15	0.17	Mitochondrial DNA levels;	chr2:43425861	chr2:43227210~43228855:+
LUAD	cis	rs77633900	0.892	rs2469539	ENSG00000196274.5	Metazoa_SRP	3.83	0.000147	0.0193	0.23	0.17	Glioma;Non-glioblastoma glioma;	chr15:76275143	chr15:76230048~76230390:-
LUAD	cis	rs6496932	1	rs6496932	ENSG00000218052.5	ADAMTS7P4	3.83	0.000147	0.0194	0.21	0.17	Central corneal thickness;Corneal structure;	chr15:85282336	chr15:85255369~85330334:-
LUAD	cis	rs7976269	0.559	rs1344853	ENSG00000275476.1	RP11-996F15.4	-3.83	0.000147	0.0194	-0.19	-0.17	Male-pattern baldness;	chr12:29058623	chr12:29277397~29277882:-
LUAD	cis	rs7572733	0.935	rs10048735	ENSG00000222017.1	AC011997.1	3.83	0.000147	0.0194	0.22	0.17	Dermatomyositis;	chr2:197877801	chr2:197693106~197774823:+
LUAD	cis	rs7572733	0.935	rs9288281	ENSG00000222017.1	AC011997.1	3.83	0.000147	0.0194	0.22	0.17	Dermatomyositis;	chr2:197879642	chr2:197693106~197774823:+
LUAD	cis	rs7572733	0.935	rs1369511	ENSG00000222017.1	AC011997.1	3.83	0.000147	0.0194	0.22	0.17	Dermatomyositis;	chr2:197881391	chr2:197693106~197774823:+
LUAD	cis	rs7572733	0.935	rs6742782	ENSG00000222017.1	AC011997.1	3.83	0.000147	0.0194	0.22	0.17	Dermatomyositis;	chr2:197890297	chr2:197693106~197774823:+
LUAD	cis	rs2904524	1	rs74809484	ENSG00000257815.4	RP11-611E13.2	-3.83	0.000147	0.0194	-0.26	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70299136	chr12:69904033~70243360:-
LUAD	cis	rs12744310	1	rs68132196	ENSG00000235358.1	RP11-399E6.1	3.83	0.000147	0.0194	0.23	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41304948	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs56381773	ENSG00000235358.1	RP11-399E6.1	3.83	0.000147	0.0194	0.23	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41305046	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs56096486	ENSG00000235358.1	RP11-399E6.1	3.83	0.000147	0.0194	0.23	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41305558	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs57529969	ENSG00000235358.1	RP11-399E6.1	3.83	0.000147	0.0194	0.23	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41306011	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs60825180	ENSG00000235358.1	RP11-399E6.1	3.83	0.000147	0.0194	0.23	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41306072	chr1:41242373~41284861:+
LUAD	cis	rs12744310	0.778	rs61477144	ENSG00000235358.1	RP11-399E6.1	3.83	0.000147	0.0194	0.23	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41306121	chr1:41242373~41284861:+
LUAD	cis	rs12744310	0.943	rs7521544	ENSG00000235358.1	RP11-399E6.1	3.83	0.000147	0.0194	0.23	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41306454	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs7513682	ENSG00000235358.1	RP11-399E6.1	3.83	0.000147	0.0194	0.23	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41306495	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs56409354	ENSG00000235358.1	RP11-399E6.1	3.83	0.000147	0.0194	0.23	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41307299	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs34008156	ENSG00000235358.1	RP11-399E6.1	3.83	0.000147	0.0194	0.23	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41307510	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs12744310	ENSG00000235358.1	RP11-399E6.1	3.83	0.000147	0.0194	0.23	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41307830	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs56077539	ENSG00000235358.1	RP11-399E6.1	3.83	0.000147	0.0194	0.23	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41308270	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs55892603	ENSG00000235358.1	RP11-399E6.1	3.83	0.000147	0.0194	0.23	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41308322	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs55929643	ENSG00000235358.1	RP11-399E6.1	3.83	0.000147	0.0194	0.23	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41308540	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs34759578	ENSG00000235358.1	RP11-399E6.1	3.83	0.000147	0.0194	0.23	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41308678	chr1:41242373~41284861:+
LUAD	cis	rs12744310	0.945	rs72665690	ENSG00000235358.1	RP11-399E6.1	3.83	0.000147	0.0194	0.23	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41309564	chr1:41242373~41284861:+
LUAD	cis	rs12744310	0.945	rs72665691	ENSG00000235358.1	RP11-399E6.1	3.83	0.000147	0.0194	0.23	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41309573	chr1:41242373~41284861:+
LUAD	cis	rs12744310	0.945	rs72665692	ENSG00000235358.1	RP11-399E6.1	3.83	0.000147	0.0194	0.23	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41309707	chr1:41242373~41284861:+
LUAD	cis	rs12744310	0.887	rs72665694	ENSG00000235358.1	RP11-399E6.1	3.83	0.000147	0.0194	0.23	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41309712	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs12756822	ENSG00000235358.1	RP11-399E6.1	3.83	0.000147	0.0194	0.23	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41311655	chr1:41242373~41284861:+
LUAD	cis	rs67478160	0.595	rs8022783	ENSG00000272533.1	SNORA28	3.83	0.000147	0.0194	0.18	0.17	Schizophrenia;	chr14:103779236	chr14:103337849~103337974:+
LUAD	cis	rs67478160	0.608	rs11160760	ENSG00000272533.1	SNORA28	3.83	0.000147	0.0194	0.18	0.17	Schizophrenia;	chr14:103782601	chr14:103337849~103337974:+
LUAD	cis	rs12499086	0.541	rs10050189	ENSG00000249635.1	RP11-710F7.3	-3.83	0.000147	0.0194	-0.18	-0.17	Economic and political preferences (time);	chr4:105480932	chr4:106003317~106022478:-
LUAD	cis	rs7809950	1	rs28714607	ENSG00000238832.1	snoU109	-3.83	0.000147	0.0194	-0.25	-0.17	Coronary artery disease;	chr7:107465808	chr7:107603363~107603507:+
LUAD	cis	rs7942368	1	rs3758711	ENSG00000254632.1	RP11-21L23.4	3.83	0.000147	0.0194	0.19	0.17	Endometriosis;	chr11:76784516	chr11:76759916~76768223:-
LUAD	cis	rs7646881	0.544	rs4368546	ENSG00000240207.5	RP11-379F4.4	-3.83	0.000147	0.0194	-0.23	-0.17	Tetralogy of Fallot;	chr3:158574361	chr3:158732263~158784070:+
LUAD	cis	rs7646881	0.544	rs73022770	ENSG00000240207.5	RP11-379F4.4	-3.83	0.000147	0.0194	-0.23	-0.17	Tetralogy of Fallot;	chr3:158576506	chr3:158732263~158784070:+
LUAD	cis	rs9921222	1	rs10794639	ENSG00000236829.8	Z97634.3	3.83	0.000147	0.0194	0.2	0.17	Bone mineral density (spine);Bone mineral density;	chr16:327367	chr16:382097~392960:+
LUAD	cis	rs638893	0.636	rs2186781	ENSG00000255422.1	AP002954.4	-3.83	0.000147	0.0194	-0.3	-0.17	Vitiligo;	chr11:118734738	chr11:118704607~118750263:+
LUAD	cis	rs5742933	0.779	rs1899025	ENSG00000253559.1	OSGEPL1-AS1	3.83	0.000147	0.0194	0.21	0.17	Ferritin levels;	chr2:189784856	chr2:189762704~189765556:+
LUAD	cis	rs4374383	0.884	rs6726639	ENSG00000207383.1	Y_RNA	-3.83	0.000147	0.0194	-0.21	-0.17	Hepatitis C induced liver fibrosis;	chr2:111995520	chr2:112579484~112579584:-
LUAD	cis	rs1894292	0.715	rs17805665	ENSG00000221639.1	SNORA3	-3.83	0.000147	0.0194	-0.18	-0.17	Prostate cancer;	chr4:73606551	chr4:73263960~73264084:+
LUAD	cis	rs4604732	0.642	rs4266925	ENSG00000227135.1	GCSAML-AS1	-3.83	0.000147	0.0194	-0.24	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247475863	chr1:247524679~247526752:-
LUAD	cis	rs7208859	0.615	rs216462	ENSG00000280069.1	CTD-2349P21.3	3.83	0.000147	0.0194	0.24	0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30568879	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.524	rs8069400	ENSG00000280069.1	CTD-2349P21.3	-3.83	0.000147	0.0194	-0.25	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748949	chr17:30738182~30740275:+
LUAD	cis	rs9309473	1	rs6740223	ENSG00000230002.2	ALMS1-IT1	3.83	0.000147	0.0194	0.21	0.17	Metabolite levels;	chr2:73426204	chr2:73456764~73459484:+
LUAD	cis	rs9309473	1	rs6707722	ENSG00000230002.2	ALMS1-IT1	3.83	0.000147	0.0194	0.21	0.17	Metabolite levels;	chr2:73427235	chr2:73456764~73459484:+
LUAD	cis	rs5758659	0.622	rs129856	ENSG00000270083.1	RP1-257I20.14	3.83	0.000147	0.0194	0.17	0.17	Cognitive function;	chr22:42003392	chr22:42089630~42090028:-
LUAD	cis	rs5758659	0.652	rs133323	ENSG00000270083.1	RP1-257I20.14	3.83	0.000147	0.0194	0.17	0.17	Cognitive function;	chr22:42009918	chr22:42089630~42090028:-
LUAD	cis	rs5758659	0.652	rs133327	ENSG00000270083.1	RP1-257I20.14	3.83	0.000147	0.0194	0.17	0.17	Cognitive function;	chr22:42011685	chr22:42089630~42090028:-
LUAD	cis	rs9467773	0.62	rs2494700	ENSG00000261353.1	CTA-14H9.5	-3.83	0.000147	0.0194	-0.19	-0.17	Intelligence (multi-trait analysis);	chr6:26631078	chr6:26527063~26527404:+
LUAD	cis	rs9467773	0.584	rs1021372	ENSG00000261353.1	CTA-14H9.5	-3.83	0.000147	0.0194	-0.19	-0.17	Intelligence (multi-trait analysis);	chr6:26632216	chr6:26527063~26527404:+
LUAD	cis	rs9467773	0.583	rs1021373	ENSG00000261353.1	CTA-14H9.5	-3.83	0.000147	0.0194	-0.19	-0.17	Intelligence (multi-trait analysis);	chr6:26632229	chr6:26527063~26527404:+
LUAD	cis	rs9467773	0.62	rs2451744	ENSG00000261353.1	CTA-14H9.5	-3.83	0.000147	0.0194	-0.19	-0.17	Intelligence (multi-trait analysis);	chr6:26633235	chr6:26527063~26527404:+
LUAD	cis	rs9467773	0.62	rs2494701	ENSG00000261353.1	CTA-14H9.5	-3.83	0.000147	0.0194	-0.19	-0.17	Intelligence (multi-trait analysis);	chr6:26634204	chr6:26527063~26527404:+
LUAD	cis	rs9467773	0.62	rs1027204	ENSG00000261353.1	CTA-14H9.5	-3.83	0.000147	0.0194	-0.19	-0.17	Intelligence (multi-trait analysis);	chr6:26639385	chr6:26527063~26527404:+
LUAD	cis	rs3018712	0.59	rs4930584	ENSG00000212093.1	AP000807.1	-3.83	0.000147	0.0194	-0.22	-0.17	Total body bone mineral density;	chr11:68643828	chr11:68506083~68506166:-
LUAD	cis	rs3018712	0.59	rs4930585	ENSG00000212093.1	AP000807.1	-3.83	0.000147	0.0194	-0.22	-0.17	Total body bone mineral density;	chr11:68643879	chr11:68506083~68506166:-
LUAD	cis	rs2147959	0.824	rs10916313	ENSG00000269934.1	RP5-1139B12.3	-3.83	0.000147	0.0194	-0.23	-0.17	Adult asthma;	chr1:228438181	chr1:228274584~228276066:-
LUAD	cis	rs2613514	1	rs2613513	ENSG00000204282.4	TNRC6C-AS1	3.83	0.000147	0.0194	0.29	0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr17:78109650	chr17:78107398~78111799:-
LUAD	cis	rs6438234	0.71	rs9860393	ENSG00000242767.1	ZBTB20-AS4	3.83	0.000147	0.0194	0.22	0.17	Type 2 diabetes;	chr3:115247574	chr3:115100423~115103061:+
LUAD	cis	rs2554380	0.943	rs2585052	ENSG00000230373.7	GOLGA6L5P	-3.83	0.000147	0.0194	-0.21	-0.17	Height;	chr15:83687238	chr15:84507885~84516814:-
LUAD	cis	rs7512552	0.839	rs2873669	ENSG00000275557.1	RP11-353N4.6	-3.83	0.000147	0.0194	-0.19	-0.17	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150453748	chr1:149607765~149612402:+
LUAD	cis	rs2731006	0.591	rs981248	ENSG00000257114.2	RP11-25I15.3	3.83	0.000147	0.0194	0.28	0.17	Panic disorder;	chr12:42779811	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.64	rs1517671	ENSG00000257114.2	RP11-25I15.3	3.83	0.000147	0.0194	0.28	0.17	Panic disorder;	chr12:42780186	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.64	rs17091970	ENSG00000257114.2	RP11-25I15.3	3.83	0.000147	0.0194	0.28	0.17	Panic disorder;	chr12:42780366	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.64	rs2678151	ENSG00000257114.2	RP11-25I15.3	3.83	0.000147	0.0194	0.28	0.17	Panic disorder;	chr12:42780701	chr12:42692216~42717119:+
LUAD	cis	rs7772486	0.875	rs854146	ENSG00000235652.6	RP11-545I5.3	3.83	0.000147	0.0194	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:146019897	chr6:145799409~145886585:+
LUAD	cis	rs2243480	0.706	rs6460257	ENSG00000222364.1	RNU6-96P	-3.83	0.000147	0.0194	-0.25	-0.17	Diabetic kidney disease;	chr7:65731813	chr7:66395191~66395286:+
LUAD	cis	rs6479891	1	rs9415680	ENSG00000232075.1	MRPL35P2	-3.83	0.000147	0.0194	-0.28	-0.17	Arthritis (juvenile idiopathic);	chr10:63261130	chr10:63634317~63634827:-
LUAD	cis	rs10129255	0.5	rs8021941	ENSG00000232216.1	IGHV3-43	3.83	0.000147	0.0194	0.14	0.17	Kawasaki disease;	chr14:106781490	chr14:106470264~106470800:-
LUAD	cis	rs1559040	1	rs11677951	ENSG00000272156.1	RP11-477N3.1	-3.83	0.000147	0.0194	-0.31	-0.17	Sudden cardiac arrest;	chr2:54075538	chr2:54082554~54085066:+
LUAD	cis	rs9303029	1	rs9898723	ENSG00000265458.1	RP13-20L14.6	3.83	0.000147	0.0194	0.32	0.17	Protein quantitative trait loci;	chr17:82482031	chr17:82454273~82458521:-
LUAD	cis	rs4795519	0.778	rs7211706	ENSG00000266313.1	RP11-173M1.4	3.83	0.000147	0.0194	0.22	0.17	Chronic myeloid leukemia;	chr17:27113809	chr17:27333256~27348491:+
LUAD	cis	rs2548724	0.947	rs1593077	ENSG00000250682.4	LINC00491	-3.83	0.000147	0.0194	-0.24	-0.17	Type 2 diabetes;	chr5:102267021	chr5:102609156~102671559:-
LUAD	cis	rs2548724	0.853	rs3096194	ENSG00000250682.4	LINC00491	-3.83	0.000147	0.0194	-0.24	-0.17	Type 2 diabetes;	chr5:102267707	chr5:102609156~102671559:-
LUAD	cis	rs10540	1	rs12418639	ENSG00000254739.1	RP13-46H24.1	-3.83	0.000147	0.0194	-0.31	-0.17	Body mass index;	chr11:473300	chr11:528907~529659:+
LUAD	cis	rs6832769	1	rs35767091	ENSG00000272969.1	RP11-528I4.2	3.83	0.000147	0.0194	0.18	0.17	Personality dimensions;	chr4:55480556	chr4:55547112~55547889:+
LUAD	cis	rs6071166	0.708	rs2902891	ENSG00000224635.1	RP4-564F22.5	-3.83	0.000147	0.0194	-0.19	-0.17	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38681144	chr20:38406011~38416797:-
LUAD	cis	rs6071166	0.683	rs1040898	ENSG00000224635.1	RP4-564F22.5	-3.83	0.000147	0.0194	-0.19	-0.17	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38681211	chr20:38406011~38416797:-
LUAD	cis	rs6071166	0.683	rs6027233	ENSG00000224635.1	RP4-564F22.5	-3.83	0.000147	0.0194	-0.19	-0.17	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38681439	chr20:38406011~38416797:-
LUAD	cis	rs6071166	0.683	rs6015618	ENSG00000224635.1	RP4-564F22.5	-3.83	0.000147	0.0194	-0.19	-0.17	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38681739	chr20:38406011~38416797:-
LUAD	cis	rs6071166	0.611	rs1033515	ENSG00000224635.1	RP4-564F22.5	-3.83	0.000147	0.0194	-0.19	-0.17	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38681866	chr20:38406011~38416797:-
LUAD	cis	rs6071166	0.646	rs1033514	ENSG00000224635.1	RP4-564F22.5	-3.83	0.000147	0.0194	-0.19	-0.17	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38681871	chr20:38406011~38416797:-
LUAD	cis	rs6071166	0.646	rs1475096	ENSG00000224635.1	RP4-564F22.5	-3.83	0.000147	0.0194	-0.19	-0.17	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38682284	chr20:38406011~38416797:-
LUAD	cis	rs4845570	0.85	rs11204892	ENSG00000203288.3	RP11-98D18.9	3.83	0.000147	0.0194	0.24	0.17	Coronary artery disease;	chr1:151795572	chr1:151790804~151794402:+
LUAD	cis	rs2625529	0.73	rs2929528	ENSG00000260173.1	RP11-2I17.4	3.83	0.000147	0.0194	0.21	0.17	Red blood cell count;	chr15:71976996	chr15:72140504~72155459:-
LUAD	cis	rs875971	0.66	rs79009421	ENSG00000222364.1	RNU6-96P	3.83	0.000147	0.0194	0.19	0.17	Aortic root size;	chr7:66603522	chr7:66395191~66395286:+
LUAD	cis	rs800160	0.748	rs2651811	ENSG00000236264.4	RPL26P30	-3.83	0.000147	0.0194	-0.24	-0.17	Bacteremia;	chr11:2355407	chr11:2335132~2335776:-
LUAD	cis	rs7660883	0.897	rs342438	ENSG00000251411.1	RP11-397E7.4	-3.83	0.000147	0.0194	-0.18	-0.17	HDL cholesterol levels;	chr4:87119254	chr4:86913266~86914817:-
LUAD	cis	rs911119	0.818	rs67862677	ENSG00000270001.1	RP11-218C14.8	-3.83	0.000147	0.0194	-0.26	-0.17	Chronic kidney disease;	chr20:23610449	chr20:23631826~23632316:-
LUAD	cis	rs10090774	0.71	rs10107434	ENSG00000280303.2	ERICD	-3.83	0.000147	0.0194	-0.19	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140662466	chr8:140636281~140638283:+
LUAD	cis	rs4356203	0.543	rs214093	ENSG00000272034.1	SNORD14A	-3.83	0.000147	0.0194	-0.15	-0.17	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17273241	chr11:17074654~17074744:-
LUAD	cis	rs4356203	0.519	rs214092	ENSG00000272034.1	SNORD14A	-3.83	0.000147	0.0194	-0.15	-0.17	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17273499	chr11:17074654~17074744:-
LUAD	cis	rs7189233	0.955	rs8054299	ENSG00000279344.1	RP11-44F14.7	-3.83	0.000147	0.0194	-0.16	-0.17	Intelligence (multi-trait analysis);	chr16:53464743	chr16:53478957~53481550:-
LUAD	cis	rs1551277	1	rs6463447	ENSG00000146666.5	LINC00525	-3.83	0.000147	0.0194	-0.19	-0.17	Anxiety disorder;	chr7:47791672	chr7:47761476~47766772:+
LUAD	cis	rs6687821	0.5	rs2753270	ENSG00000261737.1	RP4-612B15.3	-3.83	0.000147	0.0194	-0.24	-0.17	Yeast infection;	chr1:86947874	chr1:86703502~86704462:-
LUAD	cis	rs7215564	0.908	rs7503757	ENSG00000232083.3	RPL31P7	3.83	0.000147	0.0194	0.32	0.17	Myopia (pathological);	chr17:80711799	chr17:80602549~80602926:-
LUAD	cis	rs7762018	1	rs1127489	ENSG00000231690.2	LINC00574	-3.83	0.000147	0.0194	-0.31	-0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169707606	chr6:169790321~169802873:+
LUAD	cis	rs7762018	0.943	rs11546265	ENSG00000231690.2	LINC00574	-3.83	0.000147	0.0194	-0.31	-0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169708267	chr6:169790321~169802873:+
LUAD	cis	rs794185	0.561	rs304028	ENSG00000231249.1	ITPR1-AS1	-3.83	0.000147	0.0194	-0.19	-0.17	Multiple sclerosis--Brain Glutamate Levels;	chr3:4504076	chr3:4490891~4493163:-
LUAD	cis	rs12962334	0.508	rs9966036	ENSG00000265943.1	RP11-739L10.1	3.83	0.000147	0.0194	0.22	0.17	Breast cancer;	chr18:22936105	chr18:22699481~22933764:-
LUAD	cis	rs67478160	0.643	rs6575999	ENSG00000272533.1	SNORA28	3.83	0.000148	0.0194	0.18	0.17	Schizophrenia;	chr14:103784272	chr14:103337849~103337974:+
LUAD	cis	rs12899618	0.605	rs2138292	ENSG00000259503.1	RP11-543G18.1	-3.83	0.000148	0.0194	-0.22	-0.17	Pulmonary function (smoking interaction);Pulmonary function;	chr15:71299850	chr15:70321576~70326742:+
LUAD	cis	rs2944755	1	rs2944755	ENSG00000279766.1	RP11-642A1.2	3.83	0.000148	0.0194	0.21	0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr8:140564095	chr8:140572142~140572812:-
LUAD	cis	rs8050896	0.793	rs11862026	ENSG00000260695.1	RP11-513N24.1	-3.83	0.000148	0.0194	-0.37	-0.17	Response to antipsychotic treatment;	chr16:66126573	chr16:65861112~65863784:-
LUAD	cis	rs34779708	0.966	rs12769484	ENSG00000271335.4	RP11-324I22.4	3.83	0.000148	0.0194	0.18	0.17	Inflammatory bowel disease;Crohn's disease;	chr10:35176818	chr10:35314552~35336401:-
LUAD	cis	rs17275866	0.928	rs2217855	ENSG00000251584.1	RP11-440I14.3	3.83	0.000148	0.0194	0.23	0.17	Chin dimples;	chr4:174146514	chr4:174536640~174540784:+
LUAD	cis	rs12073359	1	rs11205316	ENSG00000223945.2	RP11-458I7.1	3.83	0.000148	0.0194	0.23	0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150035140	chr1:150053864~150055034:+
LUAD	cis	rs4601821	0.823	rs4938015	ENSG00000270179.1	RP11-159N11.4	3.83	0.000148	0.0194	0.18	0.17	Alcoholic chronic pancreatitis;	chr11:113393922	chr11:113368478~113369117:+
LUAD	cis	rs6001482	0.702	rs5757586	ENSG00000253818.1	IGLV1-41	-3.83	0.000148	0.0194	-0.18	-0.17	Diastolic blood pressure;	chr22:22234458	chr22:22404207~22404721:+
LUAD	cis	rs703842	1	rs2072052	ENSG00000270039.1	RP11-571M6.17	-3.83	0.000148	0.0195	-0.21	-0.17	Multiple sclerosis;	chr12:57752936	chr12:57803838~57804415:+
LUAD	cis	rs6781182	0.517	rs62248461	ENSG00000236452.1	AC123023.1	3.83	0.000148	0.0195	0.19	0.17	Visceral adipose tissue adjusted for BMI;	chr3:34194908	chr3:34203244~34268811:+
LUAD	cis	rs6781182	0.5	rs13059714	ENSG00000236452.1	AC123023.1	3.83	0.000148	0.0195	0.19	0.17	Visceral adipose tissue adjusted for BMI;	chr3:34195141	chr3:34203244~34268811:+
LUAD	cis	rs36093844	0.626	rs11234492	ENSG00000279742.1	RP11-700A24.1	-3.83	0.000148	0.0195	-0.2	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85953768	chr11:85852557~85854943:-
LUAD	cis	rs4474465	0.85	rs7127028	ENSG00000251323.2	RP11-452H21.4	-3.83	0.000148	0.0195	-0.21	-0.17	Alzheimer's disease (survival time);	chr11:78551278	chr11:78423982~78429836:-
LUAD	cis	rs12146727	0.786	rs7962629	ENSG00000205885.6	C1RL-AS1	3.83	0.000148	0.0195	0.18	0.17	Blood protein levels;	chr12:7059466	chr12:7108052~7122501:+
LUAD	cis	rs755249	0.917	rs61781393	ENSG00000237624.1	OXCT2P1	3.83	0.000148	0.0195	0.27	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39622092	chr1:39514956~39516490:+
LUAD	cis	rs6479901	0.789	rs10822146	ENSG00000232075.1	MRPL35P2	-3.83	0.000148	0.0195	-0.23	-0.17	Intelligence (multi-trait analysis);	chr10:63191707	chr10:63634317~63634827:-
LUAD	cis	rs6981523	0.553	rs11989369	ENSG00000255046.1	RP11-297N6.4	-3.83	0.000148	0.0195	-0.21	-0.17	Neuroticism;	chr8:11197876	chr8:11797928~11802568:-
LUAD	cis	rs1799955	0.935	rs9567609	ENSG00000215515.2	IFIT1P1	-3.83	0.000148	0.0195	-0.25	-0.17	LDL cholesterol levels;	chr13:32371580	chr13:32384660~32386108:+
LUAD	cis	rs453301	0.598	rs1025395	ENSG00000253981.4	ALG1L13P	3.83	0.000148	0.0195	0.2	0.17	Joint mobility (Beighton score);	chr8:8979093	chr8:8236003~8244667:-
LUAD	cis	rs7577599	0.568	rs6731296	ENSG00000224220.1	AC104699.1	3.83	0.000148	0.0195	0.11	0.17	Multiple myeloma (IgH translocation);Multiple myeloma;	chr2:25411958	chr2:25421117~25427643:+
LUAD	cis	rs2074409	0.509	rs9890344	ENSG00000276054.1	RP11-378E13.3	-3.83	0.000148	0.0195	-0.21	-0.17	Response to angiotensin II receptor blocker therapy;	chr17:37405930	chr17:37386886~37387926:+
LUAD	cis	rs116095464	0.558	rs7708515	ENSG00000248925.1	CTD-2083E4.6	3.83	0.000148	0.0195	0.28	0.17	Breast cancer;	chr5:234874	chr5:269858~271516:-
LUAD	cis	rs304029	0.87	rs304032	ENSG00000231249.1	ITPR1-AS1	3.83	0.000148	0.0195	0.19	0.17	Diabetic kidney disease;	chr3:4505089	chr3:4490891~4493163:-
LUAD	cis	rs17596685	1	rs4942143	ENSG00000271216.1	LINC01050	3.83	0.000148	0.0195	0.25	0.17	C-reactive protein levels;	chr13:42580670	chr13:42810366~42812562:-
LUAD	cis	rs11686241	0.938	rs284550	ENSG00000232485.2	AC098820.3	3.83	0.000148	0.0195	0.21	0.17	Cancer;	chr2:216446907	chr2:216479030~216498761:-
LUAD	cis	rs1348850	0.958	rs10930801	ENSG00000213963.5	AC074286.1	3.83	0.000148	0.0195	0.21	0.17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177595133	chr2:177283508~177392691:-
LUAD	cis	rs1400816	0.702	rs58565148	ENSG00000228389.1	AC068039.4	-3.83	0.000148	0.0195	-0.28	-0.17	Amyotrophic lateral sclerosis (sporadic);	chr2:171678886	chr2:171773482~171775844:+
LUAD	cis	rs2548724	0.812	rs390614	ENSG00000250682.4	LINC00491	-3.83	0.000148	0.0195	-0.22	-0.17	Type 2 diabetes;	chr5:102260540	chr5:102609156~102671559:-
LUAD	cis	rs6496044	0.527	rs7163068	ENSG00000259416.2	RP11-158M2.5	3.83	0.000148	0.0195	0.18	0.17	Interstitial lung disease;	chr15:85529235	chr15:85754941~85756237:-
LUAD	cis	rs938554	0.513	rs1014290	ENSG00000163612.10	FAM86KP	-3.83	0.000148	0.0195	-0.25	-0.17	Blood metabolite levels;	chr4:10000237	chr4:9153296~9165451:+
LUAD	cis	rs301901	0.581	rs10941343	ENSG00000250155.1	CTD-2353F22.1	3.83	0.000148	0.0195	0.18	0.17	Height;	chr5:37543239	chr5:36666214~36725195:-
LUAD	cis	rs301901	0.573	rs12652433	ENSG00000250155.1	CTD-2353F22.1	3.83	0.000148	0.0195	0.18	0.17	Height;	chr5:37543358	chr5:36666214~36725195:-
LUAD	cis	rs67478160	0.619	rs11160759	ENSG00000272533.1	SNORA28	3.83	0.000148	0.0195	0.18	0.17	Schizophrenia;	chr14:103765205	chr14:103337849~103337974:+
LUAD	cis	rs67478160	0.619	rs12878682	ENSG00000272533.1	SNORA28	3.83	0.000148	0.0195	0.18	0.17	Schizophrenia;	chr14:103767290	chr14:103337849~103337974:+
LUAD	cis	rs67478160	0.643	rs11626377	ENSG00000272533.1	SNORA28	3.83	0.000148	0.0195	0.18	0.17	Schizophrenia;	chr14:103768020	chr14:103337849~103337974:+
LUAD	cis	rs67478160	0.643	rs876002	ENSG00000272533.1	SNORA28	3.83	0.000148	0.0195	0.18	0.17	Schizophrenia;	chr14:103773360	chr14:103337849~103337974:+
LUAD	cis	rs153852	0.59	rs36733	ENSG00000243806.1	RPL7P18	3.82	0.000148	0.0195	0.21	0.17	Cancer;	chr5:94832585	chr5:94825961~94826694:-
LUAD	cis	rs12216545	0.737	rs2103034	ENSG00000177590.7	GIMAP3P	-3.82	0.000148	0.0195	-0.18	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150540829	chr7:150746893~150747728:-
LUAD	cis	rs12216545	0.737	rs1522598	ENSG00000177590.7	GIMAP3P	-3.82	0.000148	0.0195	-0.18	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150542748	chr7:150746893~150747728:-
LUAD	cis	rs12216545	0.737	rs1916007	ENSG00000177590.7	GIMAP3P	-3.82	0.000148	0.0195	-0.18	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150543201	chr7:150746893~150747728:-
LUAD	cis	rs12216545	0.737	rs1916006	ENSG00000177590.7	GIMAP3P	-3.82	0.000148	0.0195	-0.18	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150543468	chr7:150746893~150747728:-
LUAD	cis	rs7829975	0.871	rs777709	ENSG00000253981.4	ALG1L13P	-3.82	0.000148	0.0195	-0.2	-0.17	Mood instability;	chr8:8726362	chr8:8236003~8244667:-
LUAD	cis	rs910316	0.763	rs175435	ENSG00000259138.1	RP11-950C14.7	3.82	0.000148	0.0195	0.18	0.17	Height;	chr14:75145322	chr14:75127153~75136930:+
LUAD	cis	rs17695224	0.545	rs66634805	ENSG00000269483.1	AC006272.1	3.82	0.000148	0.0195	0.19	0.17	HDL cholesterol;HDL cholesterol levels;	chr19:51816080	chr19:51839924~51843324:-
LUAD	cis	rs12468226	1	rs77435512	ENSG00000226261.1	AC064836.3	3.82	0.000148	0.0195	0.25	0.17	Urate levels;	chr2:202334165	chr2:202336024~202336727:-
LUAD	cis	rs4268898	0.636	rs9636438	ENSG00000242628.4	AC009228.1	-3.82	0.000148	0.0195	-0.25	-0.17	Asthma;	chr2:24237697	chr2:24214381~24221516:+
LUAD	cis	rs4130344	0.874	rs7695844	ENSG00000271817.2	U3	-3.82	0.000148	0.0195	-0.18	-0.17	Intelligence (multi-trait analysis);	chr4:158776796	chr4:158700691~158700909:+
LUAD	cis	rs910316	0.763	rs735452	ENSG00000259138.1	RP11-950C14.7	-3.82	0.000148	0.0195	-0.18	-0.17	Height;	chr14:75031281	chr14:75127153~75136930:+
LUAD	cis	rs4853525	0.522	rs6744420	ENSG00000235852.1	AC005540.3	-3.82	0.000148	0.0195	-0.2	-0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190724356	chr2:190880797~190882059:-
LUAD	cis	rs4578769	0.691	rs28594790	ENSG00000265943.1	RP11-739L10.1	-3.82	0.000148	0.0195	-0.22	-0.17	Eosinophil percentage of white cells;	chr18:22985463	chr18:22699481~22933764:-
LUAD	cis	rs6494488	0.5	rs55960029	ENSG00000239465.1	RP11-330L19.2	3.82	0.000148	0.0195	0.36	0.17	Coronary artery disease;	chr15:64754881	chr15:64631109~64631914:-
LUAD	cis	rs526231	0.543	rs40092	ENSG00000250682.4	LINC00491	3.82	0.000148	0.0195	0.21	0.17	Primary biliary cholangitis;	chr5:103088509	chr5:102609156~102671559:-
LUAD	cis	rs875971	0.508	rs10258739	ENSG00000236529.1	RP13-254B10.1	-3.82	0.000148	0.0195	-0.17	-0.17	Aortic root size;	chr7:66597948	chr7:65840212~65840596:+
LUAD	cis	rs7515577	0.898	rs10782838	ENSG00000223787.2	RP4-593M8.1	-3.82	0.000148	0.0195	-0.26	-0.17	Cholesterol, total;	chr1:92358041	chr1:92580476~92580821:-
LUAD	cis	rs2554380	0.628	rs11853983	ENSG00000259570.1	RP11-671M22.4	-3.82	0.000148	0.0195	-0.21	-0.17	Height;	chr15:83794058	chr15:84394512~84395514:+
LUAD	cis	rs2278702	0.943	rs3743408	ENSG00000259495.2	RP11-210M15.2	3.82	0.000148	0.0195	0.26	0.17	Bipolar disorder;	chr15:80397993	chr15:80344853~80403575:-
LUAD	cis	rs6787172	0.84	rs1656376	ENSG00000272087.1	RP11-379F4.7	3.82	0.000148	0.0195	0.18	0.17	Subjective well-being;	chr3:158566892	chr3:158693120~158693768:-
LUAD	cis	rs1908814	0.504	rs7830734	ENSG00000255046.1	RP11-297N6.4	-3.82	0.000148	0.0195	-0.22	-0.17	Neuroticism;	chr8:11938130	chr8:11797928~11802568:-
LUAD	cis	rs5770917	1	rs3213445	ENSG00000273272.1	CTA-384D8.34	3.82	0.000148	0.0195	0.38	0.17	Narcolepsy;	chr22:50577409	chr22:50542650~50543011:+
LUAD	cis	rs683250	0.599	rs12795811	ENSG00000246067.6	RAB30-AS1	-3.82	0.000148	0.0195	-0.18	-0.17	Subcortical brain region volumes;	chr11:83366943	chr11:83072066~83106719:+
LUAD	cis	rs6479891	1	rs7070052	ENSG00000232075.1	MRPL35P2	-3.82	0.000148	0.0195	-0.28	-0.17	Arthritis (juvenile idiopathic);	chr10:63144054	chr10:63634317~63634827:-
LUAD	cis	rs3617	0.625	rs2071042	ENSG00000242142.1	SERBP1P3	3.82	0.000148	0.0195	0.18	0.17	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52830568	chr3:53064283~53065091:-
LUAD	cis	rs6479891	1	rs10761730	ENSG00000232075.1	MRPL35P2	-3.82	0.000148	0.0195	-0.28	-0.17	Arthritis (juvenile idiopathic);	chr10:63257293	chr10:63634317~63634827:-
LUAD	cis	rs6479891	1	rs7916282	ENSG00000232075.1	MRPL35P2	-3.82	0.000148	0.0195	-0.28	-0.17	Arthritis (juvenile idiopathic);	chr10:63272051	chr10:63634317~63634827:-
LUAD	cis	rs6479891	0.915	rs9415682	ENSG00000232075.1	MRPL35P2	-3.82	0.000148	0.0195	-0.28	-0.17	Arthritis (juvenile idiopathic);	chr10:63274057	chr10:63634317~63634827:-
LUAD	cis	rs6479891	0.778	rs10761735	ENSG00000232075.1	MRPL35P2	-3.82	0.000148	0.0195	-0.28	-0.17	Arthritis (juvenile idiopathic);	chr10:63284158	chr10:63634317~63634827:-
LUAD	cis	rs6479891	1	rs9414786	ENSG00000232075.1	MRPL35P2	-3.82	0.000148	0.0195	-0.28	-0.17	Arthritis (juvenile idiopathic);	chr10:63284562	chr10:63634317~63634827:-
LUAD	cis	rs6781182	0.517	rs968103	ENSG00000236452.1	AC123023.1	-3.82	0.000148	0.0195	-0.19	-0.17	Visceral adipose tissue adjusted for BMI;	chr3:34193081	chr3:34203244~34268811:+
LUAD	cis	rs7618915	0.547	rs33967311	ENSG00000243224.1	RP5-1157M23.2	-3.82	0.000148	0.0195	-0.17	-0.17	Bipolar disorder;	chr3:52649848	chr3:52239258~52241097:+
LUAD	cis	rs7674212	0.531	rs6816370	ENSG00000230069.3	LRRC37A15P	-3.82	0.000148	0.0195	-0.19	-0.17	Type 2 diabetes;	chr4:103018276	chr4:102727274~102730721:-
LUAD	cis	rs911119	0.913	rs1158167	ENSG00000270001.1	RP11-218C14.8	3.82	0.000148	0.0195	0.25	0.17	Chronic kidney disease;	chr20:23597552	chr20:23631826~23632316:-
LUAD	cis	rs5758659	0.652	rs5751195	ENSG00000270083.1	RP1-257I20.14	3.82	0.000149	0.0195	0.17	0.17	Cognitive function;	chr22:41983997	chr22:42089630~42090028:-
LUAD	cis	rs10045504	0.502	rs10512692	ENSG00000251189.1	CTD-2196P11.2	3.82	0.000149	0.0195	0.32	0.17	Night sleep phenotypes;	chr5:38762891	chr5:38682070~38685126:+
LUAD	cis	rs11673344	0.832	rs8104296	ENSG00000267309.1	CTD-2630F21.1	-3.82	0.000149	0.0195	-0.22	-0.17	Obesity-related traits;	chr19:37025634	chr19:36489649~36491040:+
LUAD	cis	rs11951515	0.508	rs10065689	ENSG00000248240.1	RP11-159F24.5	-3.82	0.000149	0.0195	-0.18	-0.17	Metabolite levels  (X-11787);	chr5:43604156	chr5:43515274~43525310:+
LUAD	cis	rs6496932	0.913	rs7403354	ENSG00000259630.2	CTD-2262B20.1	3.82	0.000149	0.0195	0.23	0.17	Central corneal thickness;Corneal structure;	chr15:85277624	chr15:85415228~85415633:+
LUAD	cis	rs7107174	1	rs2510040	ENSG00000251323.2	RP11-452H21.4	3.82	0.000149	0.0195	0.24	0.17	Testicular germ cell tumor;	chr11:78233502	chr11:78423982~78429836:-
LUAD	cis	rs12073359	0.955	rs12124898	ENSG00000223945.2	RP11-458I7.1	-3.82	0.000149	0.0196	-0.23	-0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150182112	chr1:150053864~150055034:+
LUAD	cis	rs7578361	0.959	rs10932467	ENSG00000231969.1	AC144449.1	-3.82	0.000149	0.0196	-0.25	-0.17	Acute lymphoblastic leukemia (childhood);	chr2:149575955	chr2:149587196~149848233:+
LUAD	cis	rs7578361	0.959	rs10932470	ENSG00000231969.1	AC144449.1	-3.82	0.000149	0.0196	-0.25	-0.17	Acute lymphoblastic leukemia (childhood);	chr2:149576176	chr2:149587196~149848233:+
LUAD	cis	rs7578361	0.959	rs11680630	ENSG00000231969.1	AC144449.1	-3.82	0.000149	0.0196	-0.25	-0.17	Acute lymphoblastic leukemia (childhood);	chr2:149576614	chr2:149587196~149848233:+
LUAD	cis	rs4965272	1	rs4965273	ENSG00000259219.1	CTD-3076O17.2	-3.82	0.000149	0.0196	-0.21	-0.17	Gastroesophageal reflux disease;	chr15:100044613	chr15:99976481~99980774:+
LUAD	cis	rs2625529	0.652	rs2957740	ENSG00000260173.1	RP11-2I17.4	3.82	0.000149	0.0196	0.21	0.17	Red blood cell count;	chr15:72015350	chr15:72140504~72155459:-
LUAD	cis	rs5015933	0.815	rs10819043	ENSG00000232630.1	PRPS1P2	-3.82	0.000149	0.0196	-0.16	-0.17	Body mass index;	chr9:125274966	chr9:125150653~125151589:+
LUAD	cis	rs6691170	0.897	rs10863664	ENSG00000228437.4	RP11-400N13.2	3.82	0.000149	0.0196	0.21	0.17	Colorectal cancer;	chr1:221853848	chr1:221966341~221984964:+
LUAD	cis	rs9393777	0.547	rs2893910	ENSG00000219392.1	RP1-265C24.5	-3.82	0.000149	0.0196	-0.26	-0.17	Intelligence (multi-trait analysis);	chr6:27315475	chr6:28115628~28116551:+
LUAD	cis	rs7429990	0.965	rs34750113	ENSG00000228638.1	FCF1P2	-3.82	0.000149	0.0196	-0.21	-0.17	Educational attainment (years of education);	chr3:47944902	chr3:48290793~48291375:-
LUAD	cis	rs4474465	0.541	rs11237527	ENSG00000251323.2	RP11-452H21.4	-3.82	0.000149	0.0196	-0.22	-0.17	Alzheimer's disease (survival time);	chr11:78508618	chr11:78423982~78429836:-
LUAD	cis	rs4474465	0.92	rs12222907	ENSG00000251323.2	RP11-452H21.4	-3.82	0.000149	0.0196	-0.22	-0.17	Alzheimer's disease (survival time);	chr11:78508680	chr11:78423982~78429836:-
LUAD	cis	rs4474465	0.85	rs7942371	ENSG00000251323.2	RP11-452H21.4	-3.82	0.000149	0.0196	-0.22	-0.17	Alzheimer's disease (survival time);	chr11:78508929	chr11:78423982~78429836:-
LUAD	cis	rs4474465	0.85	rs4441045	ENSG00000251323.2	RP11-452H21.4	-3.82	0.000149	0.0196	-0.22	-0.17	Alzheimer's disease (survival time);	chr11:78509390	chr11:78423982~78429836:-
LUAD	cis	rs4474465	0.85	rs4944203	ENSG00000251323.2	RP11-452H21.4	-3.82	0.000149	0.0196	-0.22	-0.17	Alzheimer's disease (survival time);	chr11:78509583	chr11:78423982~78429836:-
LUAD	cis	rs4474465	0.915	rs4944204	ENSG00000251323.2	RP11-452H21.4	-3.82	0.000149	0.0196	-0.22	-0.17	Alzheimer's disease (survival time);	chr11:78510967	chr11:78423982~78429836:-
LUAD	cis	rs4474465	0.679	rs10899537	ENSG00000251323.2	RP11-452H21.4	-3.82	0.000149	0.0196	-0.22	-0.17	Alzheimer's disease (survival time);	chr11:78511378	chr11:78423982~78429836:-
LUAD	cis	rs897984	0.762	rs2054213	ENSG00000232748.3	RP11-196G11.6	3.82	0.000149	0.0196	0.21	0.17	Dementia with Lewy bodies;	chr16:30960489	chr16:31056460~31062803:+
LUAD	cis	rs13108904	0.557	rs1250098	ENSG00000196810.4	CTBP1-AS2	-3.82	0.000149	0.0196	-0.22	-0.17	Obesity-related traits;	chr4:1244468	chr4:1249300~1288291:+
LUAD	cis	rs13108904	0.557	rs1250097	ENSG00000196810.4	CTBP1-AS2	-3.82	0.000149	0.0196	-0.22	-0.17	Obesity-related traits;	chr4:1244550	chr4:1249300~1288291:+
LUAD	cis	rs13108904	0.557	rs1680041	ENSG00000196810.4	CTBP1-AS2	-3.82	0.000149	0.0196	-0.22	-0.17	Obesity-related traits;	chr4:1244733	chr4:1249300~1288291:+
LUAD	cis	rs13108904	0.557	rs1250095	ENSG00000196810.4	CTBP1-AS2	-3.82	0.000149	0.0196	-0.22	-0.17	Obesity-related traits;	chr4:1245524	chr4:1249300~1288291:+
LUAD	cis	rs6871536	1	rs62383757	ENSG00000233006.5	AC034220.3	-3.82	0.000149	0.0196	-0.19	-0.17	Asthma (childhood onset);	chr5:132626157	chr5:132311285~132369916:-
LUAD	cis	rs6871536	1	rs62383758	ENSG00000233006.5	AC034220.3	-3.82	0.000149	0.0196	-0.19	-0.17	Asthma (childhood onset);	chr5:132626278	chr5:132311285~132369916:-
LUAD	cis	rs6502050	0.835	rs3935129	ENSG00000275966.1	RP11-1055B8.9	-3.82	0.000149	0.0196	-0.18	-0.17	Life satisfaction;	chr17:82155505	chr17:81345476~81345966:-
LUAD	cis	rs1876905	0.68	rs373526	ENSG00000255389.1	C6orf3	-3.82	0.000149	0.0196	-0.22	-0.17	Mean corpuscular hemoglobin;	chr6:111190261	chr6:111599875~111602295:+
LUAD	cis	rs6988985	0.678	rs7831617	ENSG00000247317.3	RP11-273G15.2	-3.82	0.000149	0.0196	-0.2	-0.17	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142920867	chr8:142981738~143018437:-
LUAD	cis	rs7772486	0.632	rs9386128	ENSG00000235652.6	RP11-545I5.3	-3.82	0.000149	0.0196	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145727917	chr6:145799409~145886585:+
LUAD	cis	rs9650657	0.538	rs11250093	ENSG00000255310.2	AF131215.2	3.82	0.000149	0.0196	0.18	0.17	Neuroticism;	chr8:10941318	chr8:11107788~11109726:-
LUAD	cis	rs4934494	0.636	rs34408087	ENSG00000240996.1	RP11-80H5.7	-3.82	0.000149	0.0196	-0.24	-0.17	Red blood cell count;	chr10:89783794	chr10:89694295~89697928:-
LUAD	cis	rs2154319	0.887	rs1740610	ENSG00000235358.1	RP11-399E6.1	3.82	0.000149	0.0196	0.23	0.17	Height;	chr1:41037008	chr1:41242373~41284861:+
LUAD	cis	rs2154319	0.887	rs7518880	ENSG00000235358.1	RP11-399E6.1	3.82	0.000149	0.0196	0.23	0.17	Height;	chr1:41038148	chr1:41242373~41284861:+
LUAD	cis	rs2154319	0.836	rs9326087	ENSG00000235358.1	RP11-399E6.1	3.82	0.000149	0.0196	0.23	0.17	Height;	chr1:41038523	chr1:41242373~41284861:+
LUAD	cis	rs2154319	0.887	rs10489522	ENSG00000235358.1	RP11-399E6.1	3.82	0.000149	0.0196	0.23	0.17	Height;	chr1:41038770	chr1:41242373~41284861:+
LUAD	cis	rs2154319	0.836	rs7553037	ENSG00000235358.1	RP11-399E6.1	3.82	0.000149	0.0196	0.23	0.17	Height;	chr1:41041729	chr1:41242373~41284861:+
LUAD	cis	rs11210359	0.528	rs1023862	ENSG00000272864.1	RP11-17E13.2	3.82	0.000149	0.0196	0.21	0.17	Bipolar disorder and schizophrenia;	chr1:73881184	chr1:74698769~74699333:-
LUAD	cis	rs3794924	1	rs71372018	ENSG00000266521.1	RP11-650P15.1	3.82	0.000149	0.0196	0.33	0.17	Survival in colon cancer;	chr18:31473571	chr18:31496645~31497195:-
LUAD	cis	rs8114671	0.967	rs1415773	ENSG00000269202.1	RP4-614O4.12	-3.82	0.000149	0.0196	-0.17	-0.17	Height;	chr20:35177782	chr20:35201747~35203288:-
LUAD	cis	rs8114671	0.935	rs6060282	ENSG00000269202.1	RP4-614O4.12	-3.82	0.000149	0.0196	-0.17	-0.17	Height;	chr20:35179263	chr20:35201747~35203288:-
LUAD	cis	rs8114671	0.967	rs2065978	ENSG00000269202.1	RP4-614O4.12	-3.82	0.000149	0.0196	-0.17	-0.17	Height;	chr20:35179488	chr20:35201747~35203288:-
LUAD	cis	rs8114671	0.967	rs2065979	ENSG00000269202.1	RP4-614O4.12	-3.82	0.000149	0.0196	-0.17	-0.17	Height;	chr20:35179887	chr20:35201747~35203288:-
LUAD	cis	rs2836974	0.604	rs2854727	ENSG00000232608.1	TIMM9P2	-3.82	0.000149	0.0196	-0.19	-0.17	Cognitive function;	chr21:39341861	chr21:39216624~39217506:+
LUAD	cis	rs9876781	1	rs11130170	ENSG00000229759.1	MRPS18AP1	3.82	0.000149	0.0196	0.16	0.17	Longevity;	chr3:48408490	chr3:48256350~48256938:-
LUAD	cis	rs7017914	0.84	rs1481804	ENSG00000246366.5	RP11-382J12.1	3.82	0.000149	0.0196	0.16	0.17	Bone mineral density;	chr8:71057195	chr8:70608577~70663279:+
LUAD	cis	rs875971	0.522	rs6960048	ENSG00000222364.1	RNU6-96P	-3.82	0.000149	0.0196	-0.19	-0.17	Aortic root size;	chr7:65943052	chr7:66395191~66395286:+
LUAD	cis	rs321358	0.895	rs12419745	ENSG00000271390.1	RP11-89C3.3	3.82	0.000149	0.0196	0.28	0.17	Body mass index;	chr11:111090741	chr11:111089870~111090368:-
LUAD	cis	rs6951245	0.678	rs28600085	ENSG00000226291.1	AC091729.8	-3.82	0.000149	0.0196	-0.28	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1130000	chr7:1080863~1082178:+
LUAD	cis	rs7131987	0.565	rs7968883	ENSG00000257176.2	RP11-996F15.2	3.82	0.000149	0.0196	0.17	0.17	QT interval;	chr12:29241258	chr12:29280418~29317848:-
LUAD	cis	rs11051970	0.879	rs2728680	ENSG00000274964.1	RP11-817I4.1	-3.82	0.000149	0.0196	-0.19	-0.17	Response to tocilizumab in rheumatoid arthritis;	chr12:32430578	chr12:32339368~32340724:+
LUAD	cis	rs7246657	0.943	rs10420722	ENSG00000226686.6	LINC01535	-3.82	0.000149	0.0196	-0.26	-0.17	Coronary artery calcification;	chr19:37482872	chr19:37251912~37265535:+
LUAD	cis	rs1009115	0.62	rs42950	ENSG00000229970.3	AC007128.1	3.82	0.000149	0.0196	0.23	0.17	Post bronchodilator FEV1;	chr7:8382756	chr7:8262264~8344516:+
LUAD	cis	rs4908768	0.906	rs11121182	ENSG00000232912.4	RP5-1115A15.1	-3.82	0.000149	0.0196	-0.2	-0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8462493	chr1:8424645~8434838:+
LUAD	cis	rs957448	0.539	rs9643346	ENSG00000253175.1	RP11-267M23.6	3.82	0.000149	0.0196	0.19	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94601587	chr8:94565036~94565715:+
LUAD	cis	rs12216545	0.737	rs10238055	ENSG00000177590.7	GIMAP3P	-3.82	0.000149	0.0196	-0.18	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150552641	chr7:150746893~150747728:-
LUAD	cis	rs12216545	0.765	rs12538773	ENSG00000177590.7	GIMAP3P	-3.82	0.000149	0.0196	-0.18	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150552967	chr7:150746893~150747728:-
LUAD	cis	rs703842	0.616	rs10877023	ENSG00000245651.2	RP11-620J15.2	3.82	0.000149	0.0196	0.18	0.17	Multiple sclerosis;	chr12:57830416	chr12:57869835~57896482:-
LUAD	cis	rs2731006	0.69	rs2730965	ENSG00000257114.2	RP11-25I15.3	3.82	0.000149	0.0196	0.28	0.17	Panic disorder;	chr12:42781765	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.64	rs2678149	ENSG00000257114.2	RP11-25I15.3	3.82	0.000149	0.0196	0.28	0.17	Panic disorder;	chr12:42783114	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.591	rs2678147	ENSG00000257114.2	RP11-25I15.3	3.82	0.000149	0.0196	0.28	0.17	Panic disorder;	chr12:42783805	chr12:42692216~42717119:+
LUAD	cis	rs7246657	0.891	rs2279149	ENSG00000226686.6	LINC01535	-3.82	0.000149	0.0196	-0.25	-0.17	Coronary artery calcification;	chr19:37533465	chr19:37251912~37265535:+
LUAD	cis	rs7208859	0.725	rs7210904	ENSG00000263603.1	CTD-2349P21.5	-3.82	0.000149	0.0196	-0.26	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843187	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.725	rs9915802	ENSG00000263603.1	CTD-2349P21.5	-3.82	0.000149	0.0196	-0.26	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846040	chr17:30729469~30731202:+
LUAD	cis	rs7551222	0.716	rs11240751	ENSG00000240219.1	RP11-430C7.5	3.82	0.000149	0.0196	0.18	0.17	Schizophrenia;	chr1:204492922	chr1:204626775~204629712:+
LUAD	cis	rs6674176	0.66	rs2108202	ENSG00000237950.1	RP11-7O11.3	-3.82	0.000149	0.0196	-0.21	-0.17	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43930114	chr1:43944370~43946551:-
LUAD	cis	rs2153535	0.518	rs6925765	ENSG00000230939.1	RP11-314C16.1	-3.82	0.000149	0.0196	-0.2	-0.17	Motion sickness;	chr6:8566471	chr6:8784178~8785445:+
LUAD	cis	rs2836974	0.583	rs2735307	ENSG00000232608.1	TIMM9P2	-3.82	0.000149	0.0196	-0.19	-0.17	Cognitive function;	chr21:39341432	chr21:39216624~39217506:+
LUAD	cis	rs4218	0.734	rs12912071	ENSG00000259732.1	RP11-59H7.3	-3.82	0.000149	0.0196	-0.2	-0.17	Social communication problems;	chr15:59150951	chr15:59121034~59133250:+
LUAD	cis	rs1876905	0.68	rs354547	ENSG00000255389.1	C6orf3	-3.82	0.000149	0.0196	-0.21	-0.17	Mean corpuscular hemoglobin;	chr6:111213919	chr6:111599875~111602295:+
LUAD	cis	rs4713118	0.669	rs200997	ENSG00000216901.1	AL022393.7	3.82	0.000149	0.0196	0.2	0.17	Parkinson's disease;	chr6:27844037	chr6:28176188~28176674:+
LUAD	cis	rs3002142	0.643	rs78547020	ENSG00000272750.1	RP11-378J18.8	3.82	0.000149	0.0196	0.27	0.17	LDL peak particle diameter (total fat intake interaction);	chr1:222677912	chr1:222658867~222661512:-
LUAD	cis	rs10129255	0.5	rs10142931	ENSG00000232216.1	IGHV3-43	3.82	0.000149	0.0196	0.14	0.17	Kawasaki disease;	chr14:106782288	chr14:106470264~106470800:-
LUAD	cis	rs1876905	0.524	rs1084639	ENSG00000271789.1	RP5-1112D6.7	-3.82	0.000149	0.0196	-0.24	-0.17	Mean corpuscular hemoglobin;	chr6:111165240	chr6:111297126~111298510:+
LUAD	cis	rs8180040	0.9	rs10865946	ENSG00000271161.1	BOLA2P2	3.82	0.000149	0.0196	0.17	0.17	Colorectal cancer;	chr3:47383570	chr3:47499841~47500407:+
LUAD	cis	rs8180040	0.966	rs11719877	ENSG00000271161.1	BOLA2P2	3.82	0.000149	0.0196	0.17	0.17	Colorectal cancer;	chr3:47383983	chr3:47499841~47500407:+
LUAD	cis	rs7122539	0.839	rs6591223	ENSG00000213409.4	RP11-658F2.3	-3.82	0.000149	0.0196	-0.21	-0.17	HIV-1 susceptibility;	chr11:66841818	chr11:66761575~66762399:-
LUAD	cis	rs523522	0.962	rs10744752	ENSG00000278344.1	RP11-18C24.8	3.82	0.000149	0.0196	0.23	0.17	High light scatter reticulocyte count;	chr12:120462751	chr12:120500735~120501090:-
LUAD	cis	rs7829975	0.658	rs907181	ENSG00000253981.4	ALG1L13P	3.82	0.000149	0.0196	0.19	0.17	Mood instability;	chr8:8845365	chr8:8236003~8244667:-
LUAD	cis	rs703842	0.642	rs73123375	ENSG00000270039.1	RP11-571M6.17	-3.82	0.000149	0.0196	-0.22	-0.17	Multiple sclerosis;	chr12:57669881	chr12:57803838~57804415:+
LUAD	cis	rs71636778	0.543	rs113002196	ENSG00000260063.1	RP5-968P14.2	-3.82	0.000149	0.0196	-0.23	-0.17	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26873665	chr1:26692132~26694131:-
LUAD	cis	rs6496932	1	rs12917518	ENSG00000218052.5	ADAMTS7P4	3.82	0.000149	0.0196	0.21	0.17	Central corneal thickness;Corneal structure;	chr15:85284018	chr15:85255369~85330334:-
LUAD	cis	rs11742741	0.967	rs10520917	ENSG00000248874.4	C5orf17	-3.82	0.000149	0.0197	-0.21	-0.17	Educational attainment;	chr5:24139826	chr5:23951348~24178263:+
LUAD	cis	rs1150668	0.699	rs12214383	ENSG00000176933.5	TOB2P1	3.82	0.000149	0.0197	0.19	0.17	Pubertal anthropometrics;	chr6:28255953	chr6:28217643~28218634:-
LUAD	cis	rs7893279	0.505	rs2228645	ENSG00000225527.1	RP11-383B4.4	3.82	0.000149	0.0197	0.25	0.17	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18539442	chr10:18531849~18533336:-
LUAD	cis	rs473651	0.74	rs502349	ENSG00000229915.1	AC016999.2	-3.82	0.00015	0.0197	-0.23	-0.17	Multiple system atrophy;	chr2:238409748	chr2:238427077~238427729:-
LUAD	cis	rs858239	0.539	rs1358442	ENSG00000226816.2	AC005082.12	3.82	0.00015	0.0197	0.23	0.17	Cerebrospinal fluid biomarker levels;	chr7:23150120	chr7:23206013~23208045:+
LUAD	cis	rs62025270	0.806	rs62025266	ENSG00000202081.1	RNU6-1280P	-3.82	0.00015	0.0197	-0.24	-0.17	Idiopathic pulmonary fibrosis;	chr15:85755217	chr15:85651522~85651628:-
LUAD	cis	rs853679	0.517	rs12332979	ENSG00000280107.1	AL022393.9	-3.82	0.00015	0.0197	-0.23	-0.17	Depression;	chr6:28173770	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs67878650	ENSG00000280107.1	AL022393.9	-3.82	0.00015	0.0197	-0.23	-0.17	Depression;	chr6:28174809	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.569	rs9348798	ENSG00000280107.1	AL022393.9	-3.82	0.00015	0.0197	-0.23	-0.17	Depression;	chr6:28175233	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs9380065	ENSG00000280107.1	AL022393.9	-3.82	0.00015	0.0197	-0.23	-0.17	Depression;	chr6:28176973	chr6:28170845~28172521:+
LUAD	cis	rs10971721	0.822	rs12376279	ENSG00000260947.1	RP11-384P7.7	3.82	0.00015	0.0197	0.36	0.17	Body mass index;	chr9:33804256	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.731	rs12377117	ENSG00000260947.1	RP11-384P7.7	3.82	0.00015	0.0197	0.36	0.17	Body mass index;	chr9:33806586	chr9:33697459~33700986:+
LUAD	cis	rs8073060	0.586	rs4796098	ENSG00000267592.1	CTC-507E2.2	-3.82	0.00015	0.0197	-0.25	-0.17	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35586417	chr17:35596904~35597128:-
LUAD	cis	rs2252586	0.916	rs7793272	ENSG00000226278.1	PSPHP1	-3.82	0.00015	0.0197	-0.21	-0.17	Glioma;	chr7:54898366	chr7:55764797~55773288:+
LUAD	cis	rs683250	0.629	rs647030	ENSG00000246067.6	RAB30-AS1	3.82	0.00015	0.0197	0.18	0.17	Subcortical brain region volumes;	chr11:83277674	chr11:83072066~83106719:+
LUAD	cis	rs683250	0.629	rs2846424	ENSG00000246067.6	RAB30-AS1	3.82	0.00015	0.0197	0.18	0.17	Subcortical brain region volumes;	chr11:83278123	chr11:83072066~83106719:+
LUAD	cis	rs11742741	0.837	rs1428196	ENSG00000248874.4	C5orf17	-3.82	0.00015	0.0197	-0.21	-0.17	Educational attainment;	chr5:24128751	chr5:23951348~24178263:+
LUAD	cis	rs1023500	0.506	rs6002625	ENSG00000205702.9	CYP2D7	-3.82	0.00015	0.0197	-0.14	-0.17	Schizophrenia;	chr22:42121685	chr22:42140203~42144577:-
LUAD	cis	rs8073060	0.544	rs7210966	ENSG00000267592.1	CTC-507E2.2	3.82	0.00015	0.0197	0.25	0.17	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35659315	chr17:35596904~35597128:-
LUAD	cis	rs755249	0.53	rs16826087	ENSG00000182109.6	RP11-69E11.4	3.82	0.00015	0.0197	0.21	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39346846	chr1:39522280~39546187:-
LUAD	cis	rs755249	0.567	rs3754346	ENSG00000182109.6	RP11-69E11.4	3.82	0.00015	0.0197	0.21	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349288	chr1:39522280~39546187:-
LUAD	cis	rs755249	0.567	rs16826093	ENSG00000182109.6	RP11-69E11.4	3.82	0.00015	0.0197	0.21	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349471	chr1:39522280~39546187:-
LUAD	cis	rs755249	0.567	rs41270811	ENSG00000182109.6	RP11-69E11.4	3.82	0.00015	0.0197	0.21	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39349672	chr1:39522280~39546187:-
LUAD	cis	rs755249	0.567	rs61779274	ENSG00000182109.6	RP11-69E11.4	3.82	0.00015	0.0197	0.21	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39351269	chr1:39522280~39546187:-
LUAD	cis	rs9467773	1	rs6940053	ENSG00000241549.7	GUSBP2	3.82	0.00015	0.0197	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26561894	chr6:26871484~26956554:-
LUAD	cis	rs12822507	0.732	rs10492241	ENSG00000180861.8	LINC01559	3.82	0.00015	0.0197	0.19	0.17	Systemic lupus erythematosus;	chr12:12597575	chr12:13371089~13387167:-
LUAD	cis	rs7339483	0.618	rs4986345	ENSG00000268058.1	BNIP3P40	-3.82	0.00015	0.0197	-0.28	-0.17	Discordance in emotional problems in monozygotic twins;	chr19:24174884	chr19:24098425~24098980:-
LUAD	cis	rs7339483	0.618	rs8101765	ENSG00000268058.1	BNIP3P40	-3.82	0.00015	0.0197	-0.28	-0.17	Discordance in emotional problems in monozygotic twins;	chr19:24175711	chr19:24098425~24098980:-
LUAD	cis	rs911119	0.955	rs6036474	ENSG00000270001.1	RP11-218C14.8	-3.82	0.00015	0.0197	-0.26	-0.17	Chronic kidney disease;	chr20:23623777	chr20:23631826~23632316:-
LUAD	cis	rs8177876	0.749	rs935942	ENSG00000261061.1	RP11-303E16.2	3.82	0.00015	0.0197	0.25	0.17	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078531	chr16:81030770~81031485:+
LUAD	cis	rs7560272	0.538	rs12233115	ENSG00000163016.8	ALMS1P	-3.82	0.00015	0.0197	-0.18	-0.17	Schizophrenia;	chr2:73704764	chr2:73644919~73685576:+
LUAD	cis	rs911555	0.755	rs11627446	ENSG00000244691.1	RPL10AP1	-3.82	0.00015	0.0197	-0.23	-0.17	Intelligence (multi-trait analysis);	chr14:103480113	chr14:103412119~103412761:-
LUAD	cis	rs599083	0.53	rs2508834	ENSG00000212093.1	AP000807.1	-3.82	0.00015	0.0197	-0.19	-0.17	Bone mineral density (spine);	chr11:68407886	chr11:68506083~68506166:-
LUAD	cis	rs214785	1	rs214774	ENSG00000234684.5	SDCBP2-AS1	3.82	0.00015	0.0197	0.21	0.17	Basal cell carcinoma;	chr20:2299654	chr20:1325405~1378734:+
LUAD	cis	rs12681366	0.881	rs3019150	ENSG00000254057.1	RP3-388N13.3	3.82	0.00015	0.0197	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94420055	chr8:93834454~93846743:-
LUAD	cis	rs13256369	0.853	rs13256216	ENSG00000253893.2	FAM85B	-3.82	0.00015	0.0197	-0.24	-0.17	Obesity-related traits;	chr8:8720373	chr8:8167819~8226614:-
LUAD	cis	rs2243480	1	rs1618893	ENSG00000229886.1	RP5-1132H15.3	3.82	0.00015	0.0197	0.27	0.17	Diabetic kidney disease;	chr7:66631132	chr7:66025126~66031544:-
LUAD	cis	rs1400816	0.85	rs6433313	ENSG00000228389.1	AC068039.4	3.82	0.00015	0.0197	0.29	0.17	Amyotrophic lateral sclerosis (sporadic);	chr2:171801186	chr2:171773482~171775844:+
LUAD	cis	rs10129255	0.5	rs11627315	ENSG00000253209.1	IGHV3-65	3.82	0.00015	0.0197	0.14	0.17	Kawasaki disease;	chr14:106802182	chr14:106666092~106666532:-
LUAD	cis	rs8180040	0.739	rs11719306	ENSG00000271161.1	BOLA2P2	3.82	0.00015	0.0197	0.16	0.17	Colorectal cancer;	chr3:47142692	chr3:47499841~47500407:+
LUAD	cis	rs7192380	0.931	rs9302604	ENSG00000226232.7	RP11-419C5.2	-3.82	0.00015	0.0197	-0.15	-0.17	Sjögren's syndrome;	chr16:69542991	chr16:69976388~69996188:-
LUAD	cis	rs6910061	1	rs73445479	ENSG00000247925.2	RP3-510L9.1	-3.82	0.00015	0.0197	-0.24	-0.17	Diabetic kidney disease;	chr6:11114537	chr6:11173452~11259099:+
LUAD	cis	rs6910061	1	rs6456868	ENSG00000247925.2	RP3-510L9.1	-3.82	0.00015	0.0197	-0.24	-0.17	Diabetic kidney disease;	chr6:11114950	chr6:11173452~11259099:+
LUAD	cis	rs6910061	1	rs10080950	ENSG00000247925.2	RP3-510L9.1	-3.82	0.00015	0.0197	-0.24	-0.17	Diabetic kidney disease;	chr6:11116234	chr6:11173452~11259099:+
LUAD	cis	rs12440869	1	rs11071943	ENSG00000270964.1	RP11-502I4.3	3.82	0.00015	0.0197	0.2	0.17	Peak velocity of the mitral A-wave;	chr15:67243658	chr15:67541072~67542604:-
LUAD	cis	rs10197140	0.857	rs10197548	ENSG00000235721.1	AC013268.3	-3.82	0.00015	0.0197	-0.19	-0.17	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110883390	chr2:110007675~110010783:+
LUAD	cis	rs9921338	0.961	rs57579443	ENSG00000263080.1	RP11-485G7.5	3.82	0.00015	0.0197	0.23	0.17	Vein graft stenosis in coronary artery bypass grafting;	chr16:11349140	chr16:11341809~11345211:-
LUAD	cis	rs17301013	0.932	rs10912804	ENSG00000227373.4	RP11-160H22.5	3.82	0.00015	0.0197	0.22	0.17	Systemic lupus erythematosus;	chr1:174527412	chr1:174115300~174160004:-
LUAD	cis	rs17301013	0.9	rs12088073	ENSG00000227373.4	RP11-160H22.5	3.82	0.00015	0.0197	0.22	0.17	Systemic lupus erythematosus;	chr1:174528504	chr1:174115300~174160004:-
LUAD	cis	rs897984	0.683	rs729482	ENSG00000232748.3	RP11-196G11.6	-3.82	0.00015	0.0197	-0.22	-0.17	Dementia with Lewy bodies;	chr16:31005649	chr16:31056460~31062803:+
LUAD	cis	rs4474465	1	rs57042969	ENSG00000251323.2	RP11-452H21.4	3.82	0.00015	0.0197	0.21	0.17	Alzheimer's disease (survival time);	chr11:78449074	chr11:78423982~78429836:-
LUAD	cis	rs13434995	0.589	rs62305201	ENSG00000273257.1	RP11-177J6.1	-3.82	0.00015	0.0197	-0.23	-0.17	Adiponectin levels;	chr4:55386778	chr4:55387949~55388271:+
LUAD	cis	rs11673344	0.966	rs56330606	ENSG00000267309.1	CTD-2630F21.1	-3.82	0.00015	0.0197	-0.22	-0.17	Obesity-related traits;	chr19:37183051	chr19:36489649~36491040:+
LUAD	cis	rs6832769	0.925	rs6554292	ENSG00000272969.1	RP11-528I4.2	-3.82	0.00015	0.0197	-0.18	-0.17	Personality dimensions;	chr4:55584943	chr4:55547112~55547889:+
LUAD	cis	rs6832769	0.961	rs10026692	ENSG00000272969.1	RP11-528I4.2	-3.82	0.00015	0.0197	-0.18	-0.17	Personality dimensions;	chr4:55586539	chr4:55547112~55547889:+
LUAD	cis	rs36093844	0.626	rs10501603	ENSG00000279742.1	RP11-700A24.1	-3.82	0.00015	0.0197	-0.2	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85970873	chr11:85852557~85854943:-
LUAD	cis	rs9467773	0.62	rs2451731	ENSG00000241549.7	GUSBP2	3.82	0.00015	0.0197	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26624594	chr6:26871484~26956554:-
LUAD	cis	rs9467773	0.62	rs9295701	ENSG00000241549.7	GUSBP2	3.82	0.00015	0.0197	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26627280	chr6:26871484~26956554:-
LUAD	cis	rs7061710	0.871	rs2281008	ENSG00000271811.1	RP1-79C4.4	-3.82	0.00015	0.0197	-0.25	-0.17	Blood metabolite levels;	chr1:171144813	chr1:170667381~170669425:+
LUAD	cis	rs2236295	0.503	rs10822064	ENSG00000238280.1	RP11-436D10.3	3.82	0.00015	0.0197	0.22	0.17	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr10:62849964	chr10:62793562~62805887:-
LUAD	cis	rs858239	0.899	rs28635122	ENSG00000230042.1	AK3P3	-3.82	0.00015	0.0197	-0.22	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23270562	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.899	rs7794684	ENSG00000230042.1	AK3P3	-3.82	0.00015	0.0197	-0.22	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23271186	chr7:23129178~23129841:+
LUAD	cis	rs6964587	0.839	rs17731846	ENSG00000188693.7	CYP51A1-AS1	-3.82	0.00015	0.0197	-0.21	-0.17	Breast cancer;	chr7:91811028	chr7:92134604~92180725:+
LUAD	cis	rs62025270	0.632	rs78572940	ENSG00000259416.2	RP11-158M2.5	-3.82	0.00015	0.0197	-0.23	-0.17	Idiopathic pulmonary fibrosis;	chr15:85696539	chr15:85754941~85756237:-
LUAD	cis	rs1722141	0.598	rs2453849	ENSG00000229628.1	AC073115.7	3.82	0.00015	0.0197	0.26	0.17	Sitting height ratio;	chr7:45935066	chr7:45990905~46000898:+
LUAD	cis	rs3733829	1	rs3733829	ENSG00000233622.1	CYP2T1P	3.82	0.00015	0.0197	0.23	0.17	Smoking behavior;	chr19:40804666	chr19:40808525~40811390:-
LUAD	cis	rs6496044	0.548	rs7163032	ENSG00000259416.2	RP11-158M2.5	3.82	0.00015	0.0197	0.18	0.17	Interstitial lung disease;	chr15:85529188	chr15:85754941~85756237:-
LUAD	cis	rs755249	0.917	rs61232586	ENSG00000182109.6	RP11-69E11.4	3.82	0.00015	0.0197	0.22	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39620685	chr1:39522280~39546187:-
LUAD	cis	rs17596685	1	rs4572282	ENSG00000271216.1	LINC01050	3.82	0.00015	0.0197	0.25	0.17	C-reactive protein levels;	chr13:42560846	chr13:42810366~42812562:-
LUAD	cis	rs17596685	1	rs4531631	ENSG00000271216.1	LINC01050	3.82	0.00015	0.0197	0.25	0.17	C-reactive protein levels;	chr13:42560995	chr13:42810366~42812562:-
LUAD	cis	rs4591358	1	rs4591358	ENSG00000223466.1	AC064834.2	-3.82	0.00015	0.0197	-0.22	-0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195501166	chr2:195533035~195538681:+
LUAD	cis	rs4591358	1	rs6713576	ENSG00000223466.1	AC064834.2	-3.82	0.00015	0.0197	-0.22	-0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195501522	chr2:195533035~195538681:+
LUAD	cis	rs17711722	0.565	rs4717276	ENSG00000229886.1	RP5-1132H15.3	-3.82	0.00015	0.0198	-0.2	-0.17	Calcium levels;	chr7:65829754	chr7:66025126~66031544:-
LUAD	cis	rs4718428	0.705	rs62465692	ENSG00000230295.1	RP11-458F8.2	-3.82	0.00015	0.0198	-0.15	-0.17	Corneal structure;	chr7:66830758	chr7:66880708~66882981:+
LUAD	cis	rs6071166	0.683	rs6071127	ENSG00000224635.1	RP4-564F22.5	-3.82	0.00015	0.0198	-0.2	-0.17	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38693614	chr20:38406011~38416797:-
LUAD	cis	rs6687758	0.687	rs12137323	ENSG00000238042.4	RP11-815M8.1	3.82	0.00015	0.0198	0.24	0.17	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221952186	chr1:221880981~221978523:-
LUAD	cis	rs5742933	0.744	rs12693557	ENSG00000253559.1	OSGEPL1-AS1	3.82	0.000151	0.0198	0.21	0.17	Ferritin levels;	chr2:189726211	chr2:189762704~189765556:+
LUAD	cis	rs5742933	0.817	rs13035966	ENSG00000253559.1	OSGEPL1-AS1	3.82	0.000151	0.0198	0.21	0.17	Ferritin levels;	chr2:189726507	chr2:189762704~189765556:+
LUAD	cis	rs77972916	0.609	rs72790907	ENSG00000234936.1	AC010883.5	3.82	0.000151	0.0198	0.24	0.17	Granulocyte percentage of myeloid white cells;	chr2:43348056	chr2:43229573~43233394:+
LUAD	cis	rs1124609	1	rs1365506	ENSG00000244879.4	GABPB1-AS1	3.82	0.000151	0.0198	0.24	0.17	Subjective well-being;	chr15:50184942	chr15:50354959~50372202:+
LUAD	cis	rs9549260	0.567	rs7332730	ENSG00000229456.1	RLIMP1	3.82	0.000151	0.0198	0.18	0.17	Red blood cell count;	chr13:40691843	chr13:40618738~40621348:+
LUAD	cis	rs3096299	0.933	rs2930219	ENSG00000182376.2	RP5-1142A6.8	3.82	0.000151	0.0198	0.18	0.17	Multiple myeloma (IgH translocation);	chr16:89425641	chr16:88742767~88745748:+
LUAD	cis	rs10129255	1	rs11621409	ENSG00000211967.3	IGHV3-53	-3.82	0.000151	0.0198	-0.14	-0.17	Kawasaki disease;	chr14:106695603	chr14:106592676~106593347:-
LUAD	cis	rs755249	0.917	rs61779330	ENSG00000237624.1	OXCT2P1	3.82	0.000151	0.0198	0.26	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39501551	chr1:39514956~39516490:+
LUAD	cis	rs755249	0.876	rs72662001	ENSG00000237624.1	OXCT2P1	3.82	0.000151	0.0198	0.26	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39501608	chr1:39514956~39516490:+
LUAD	cis	rs219780	0.768	rs219784	ENSG00000230479.1	AP000695.6	3.82	0.000151	0.0198	0.21	0.17	Kidney stones;	chr21:36459569	chr21:36430360~36481070:+
LUAD	cis	rs6479901	0.894	rs10761748	ENSG00000232075.1	MRPL35P2	-3.82	0.000151	0.0198	-0.24	-0.17	Intelligence (multi-trait analysis);	chr10:63350216	chr10:63634317~63634827:-
LUAD	cis	rs4660214	0.639	rs6699928	ENSG00000182109.6	RP11-69E11.4	-3.82	0.000151	0.0198	-0.19	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39267827	chr1:39522280~39546187:-
LUAD	cis	rs3120667	0.79	rs10888486	ENSG00000237975.5	FLG-AS1	3.82	0.000151	0.0198	0.29	0.17	Eating disorders;	chr1:152409586	chr1:152168125~152445456:+
LUAD	cis	rs6494488	0.5	rs72742916	ENSG00000239465.1	RP11-330L19.2	3.82	0.000151	0.0198	0.36	0.17	Coronary artery disease;	chr15:64558476	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs55990268	ENSG00000239465.1	RP11-330L19.2	3.82	0.000151	0.0198	0.36	0.17	Coronary artery disease;	chr15:64562105	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs72742921	ENSG00000239465.1	RP11-330L19.2	3.82	0.000151	0.0198	0.36	0.17	Coronary artery disease;	chr15:64563357	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs72742923	ENSG00000239465.1	RP11-330L19.2	3.82	0.000151	0.0198	0.36	0.17	Coronary artery disease;	chr15:64563497	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs72742925	ENSG00000239465.1	RP11-330L19.2	3.82	0.000151	0.0198	0.36	0.17	Coronary artery disease;	chr15:64571104	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs72742926	ENSG00000239465.1	RP11-330L19.2	3.82	0.000151	0.0198	0.36	0.17	Coronary artery disease;	chr15:64572262	chr15:64631109~64631914:-
LUAD	cis	rs2299587	0.554	rs7815429	ENSG00000253671.1	RP11-806O11.1	-3.82	0.000151	0.0198	-0.17	-0.17	Economic and political preferences;	chr8:17879848	chr8:17808941~17820868:+
LUAD	cis	rs7200786	0.557	rs8057040	ENSG00000274038.1	RP11-66H6.4	-3.82	0.000151	0.0198	-0.21	-0.17	Systemic lupus erythematosus;Multiple sclerosis;	chr16:10997502	chr16:11056556~11057034:+
LUAD	cis	rs6087771	0.651	rs6060775	ENSG00000230613.1	HM13-AS1	3.82	0.000151	0.0198	0.2	0.17	Putamen volume;Subcortical brain region volumes;	chr20:31698388	chr20:31567707~31573263:-
LUAD	cis	rs1541160	1	rs6668310	ENSG00000239494.2	RN7SL333P	3.82	0.000151	0.0198	0.17	0.17	Amyotrophic lateral sclerosis;	chr1:170062713	chr1:169859756~169860052:+
LUAD	cis	rs1876905	0.68	rs354540	ENSG00000255389.1	C6orf3	3.82	0.000151	0.0198	0.22	0.17	Mean corpuscular hemoglobin;	chr6:111195827	chr6:111599875~111602295:+
LUAD	cis	rs7674212	0.507	rs223361	ENSG00000230069.3	LRRC37A15P	-3.82	0.000151	0.0198	-0.18	-0.17	Type 2 diabetes;	chr4:102848147	chr4:102727274~102730721:-
LUAD	cis	rs950169	0.922	rs11635505	ENSG00000188388.10	GOLGA6L3	-3.82	0.000151	0.0198	-0.23	-0.17	Schizophrenia;	chr15:84553803	chr15:85240472~85247170:+
LUAD	cis	rs647161	0.516	rs607488	ENSG00000247627.2	MTND4P12	-3.82	0.000151	0.0198	-0.2	-0.17	Colorectal cancer;	chr5:135140217	chr5:134926660~134928036:-
LUAD	cis	rs321358	1	rs419633	ENSG00000271390.1	RP11-89C3.3	3.82	0.000151	0.0198	0.29	0.17	Body mass index;	chr11:111132187	chr11:111089870~111090368:-
LUAD	cis	rs321358	1	rs429803	ENSG00000271390.1	RP11-89C3.3	3.82	0.000151	0.0198	0.29	0.17	Body mass index;	chr11:111132263	chr11:111089870~111090368:-
LUAD	cis	rs321358	0.943	rs402820	ENSG00000271390.1	RP11-89C3.3	3.82	0.000151	0.0198	0.29	0.17	Body mass index;	chr11:111132480	chr11:111089870~111090368:-
LUAD	cis	rs12680842	0.842	rs34691145	ENSG00000253175.1	RP11-267M23.6	3.82	0.000151	0.0198	0.19	0.17	Body mass index;	chr8:94597715	chr8:94565036~94565715:+
LUAD	cis	rs8113308	0.81	rs16983256	ENSG00000269483.1	AC006272.1	3.82	0.000151	0.0198	0.28	0.17	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51946228	chr19:51839924~51843324:-
LUAD	cis	rs8113308	0.81	rs8100521	ENSG00000269483.1	AC006272.1	3.82	0.000151	0.0198	0.28	0.17	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51946390	chr19:51839924~51843324:-
LUAD	cis	rs8113308	0.81	rs8100541	ENSG00000269483.1	AC006272.1	3.82	0.000151	0.0198	0.28	0.17	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51946442	chr19:51839924~51843324:-
LUAD	cis	rs8058578	1	rs8058578	ENSG00000232748.3	RP11-196G11.6	-3.82	0.000151	0.0198	-0.21	-0.17	Multiple myeloma;	chr16:30714927	chr16:31056460~31062803:+
LUAD	cis	rs11637445	0.677	rs10152422	ENSG00000270964.1	RP11-502I4.3	-3.82	0.000151	0.0198	-0.19	-0.17	Posterior cortical atrophy and Alzheimer's disease;	chr15:67810591	chr15:67541072~67542604:-
LUAD	cis	rs2255336	0.81	rs7976624	ENSG00000245648.1	RP11-277P12.20	3.82	0.000151	0.0198	0.3	0.17	Blood protein levels;	chr12:10359392	chr12:10363769~10398506:+
LUAD	cis	rs7512898	0.522	rs10800743	ENSG00000260088.1	RP11-92G12.3	-3.82	0.000151	0.0198	-0.23	-0.17	Electrocardiographic conduction measures;	chr1:200852408	chr1:200669507~200694250:+
LUAD	cis	rs6570726	0.846	rs870491	ENSG00000235652.6	RP11-545I5.3	3.82	0.000151	0.0198	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145612254	chr6:145799409~145886585:+
LUAD	cis	rs6840360	0.539	rs1443087	ENSG00000270265.1	RP11-731D1.4	-3.82	0.000151	0.0198	-0.17	-0.17	Intelligence (multi-trait analysis);	chr4:151528943	chr4:151333775~151353224:-
LUAD	cis	rs9545047	0.716	rs7140027	ENSG00000227354.5	RBM26-AS1	3.82	0.000151	0.0198	0.18	0.17	Schizophrenia;	chr13:79281162	chr13:79406309~79424328:+
LUAD	cis	rs12188164	0.965	rs77101200	ENSG00000221990.4	EXOC3-AS1	3.82	0.000151	0.0198	0.17	0.17	Cystic fibrosis severity;	chr5:442944	chr5:441498~443160:-
LUAD	cis	rs6840360	0.571	rs17275536	ENSG00000270265.1	RP11-731D1.4	-3.82	0.000151	0.0198	-0.19	-0.17	Intelligence (multi-trait analysis);	chr4:151577473	chr4:151333775~151353224:-
LUAD	cis	rs7560272	0.501	rs6755500	ENSG00000163016.8	ALMS1P	-3.82	0.000151	0.0198	-0.18	-0.17	Schizophrenia;	chr2:73715106	chr2:73644919~73685576:+
LUAD	cis	rs877819	0.583	rs2663030	ENSG00000228403.1	RP11-563N6.6	-3.82	0.000151	0.0198	-0.18	-0.17	Systemic lupus erythematosus;	chr10:48879413	chr10:48878022~48878649:+
LUAD	cis	rs12550612	0.614	rs4268128	ENSG00000253200.1	RP11-582J16.5	-3.82	0.000151	0.0198	-0.17	-0.17	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23080343	chr8:22613908~22616657:-
LUAD	cis	rs5015933	0.778	rs1759434	ENSG00000232630.1	PRPS1P2	-3.82	0.000151	0.0198	-0.16	-0.17	Body mass index;	chr9:125325260	chr9:125150653~125151589:+
LUAD	cis	rs6723226	0.961	rs13010404	ENSG00000276334.1	AL133243.1	-3.82	0.000151	0.0198	-0.2	-0.17	Intelligence (multi-trait analysis);	chr2:32623787	chr2:32521927~32523547:+
LUAD	cis	rs7615952	0.599	rs12486459	ENSG00000241288.6	RP11-379B18.5	-3.82	0.000151	0.0198	-0.23	-0.17	Blood pressure (smoking interaction);	chr3:126022622	chr3:125827238~125916384:-
LUAD	cis	rs7615952	0.599	rs67575510	ENSG00000241288.6	RP11-379B18.5	-3.82	0.000151	0.0198	-0.23	-0.17	Blood pressure (smoking interaction);	chr3:126023512	chr3:125827238~125916384:-
LUAD	cis	rs9921338	0.961	rs57579443	ENSG00000262703.1	RP11-485G7.6	-3.82	0.000151	0.0198	-0.18	-0.17	Vein graft stenosis in coronary artery bypass grafting;	chr16:11349140	chr16:11348143~11349321:-
LUAD	cis	rs2494663	0.61	rs11264974	ENSG00000223599.1	RP11-216N14.7	3.82	0.000151	0.0198	0.21	0.17	Mean platelet volume;	chr1:154063657	chr1:153852106~153853414:-
LUAD	cis	rs4853525	0.59	rs2355576	ENSG00000235852.1	AC005540.3	3.82	0.000151	0.0198	0.21	0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190850374	chr2:190880797~190882059:-
LUAD	cis	rs4853525	0.59	rs4513327	ENSG00000235852.1	AC005540.3	3.82	0.000151	0.0198	0.21	0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190850695	chr2:190880797~190882059:-
LUAD	cis	rs9549260	0.755	rs1413482	ENSG00000229456.1	RLIMP1	3.82	0.000151	0.0198	0.19	0.17	Red blood cell count;	chr13:40644314	chr13:40618738~40621348:+
LUAD	cis	rs9549260	0.755	rs7993233	ENSG00000229456.1	RLIMP1	3.82	0.000151	0.0198	0.19	0.17	Red blood cell count;	chr13:40645297	chr13:40618738~40621348:+
LUAD	cis	rs9659323	1	rs10923714	ENSG00000226172.2	RP4-712E4.1	-3.82	0.000151	0.0198	-0.18	-0.17	Body mass index;	chr1:118970290	chr1:119000344~119001392:-
LUAD	cis	rs5015933	0.762	rs515985	ENSG00000232630.1	PRPS1P2	-3.82	0.000151	0.0198	-0.16	-0.17	Body mass index;	chr9:125300583	chr9:125150653~125151589:+
LUAD	cis	rs6840360	0.642	rs1443088	ENSG00000270265.1	RP11-731D1.4	-3.82	0.000151	0.0198	-0.17	-0.17	Intelligence (multi-trait analysis);	chr4:151528974	chr4:151333775~151353224:-
LUAD	cis	rs35740288	0.77	rs11632750	ENSG00000259407.1	RP11-158M2.3	-3.82	0.000151	0.0198	-0.17	-0.17	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85672383	chr15:85744109~85750281:-
LUAD	cis	rs10419113	0.544	rs7255898	ENSG00000270804.1	CTD-2583A14.11	3.82	0.000151	0.0198	0.16	0.17	Pediatric bone mineral density (spine);	chr19:57802208	chr19:57867885~57868834:+
LUAD	cis	rs7560272	0.723	rs7562047	ENSG00000163016.8	ALMS1P	3.82	0.000151	0.0198	0.19	0.17	Schizophrenia;	chr2:73498041	chr2:73644919~73685576:+
LUAD	cis	rs7260181	1	rs7260181	ENSG00000269637.1	RPL12P41	-3.82	0.000151	0.0199	-0.18	-0.17	Late-onset Alzheimer's disease;	chr19:46595170	chr19:46219423~46219920:+
LUAD	cis	rs6570726	0.791	rs4332001	ENSG00000235652.6	RP11-545I5.3	3.82	0.000151	0.0199	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145613705	chr6:145799409~145886585:+
LUAD	cis	rs7590268	0.789	rs34992473	ENSG00000279873.2	LINC01126	3.82	0.000151	0.0199	0.18	0.17	Orofacial clefts;	chr2:43413064	chr2:43227210~43228855:+
LUAD	cis	rs7572733	0.905	rs6735214	ENSG00000222017.1	AC011997.1	3.82	0.000151	0.0199	0.22	0.17	Dermatomyositis;	chr2:197895783	chr2:197693106~197774823:+
LUAD	cis	rs8028182	0.636	rs10152155	ENSG00000260269.4	CTD-2323K18.1	-3.82	0.000151	0.0199	-0.24	-0.17	Sudden cardiac arrest;	chr15:75409213	chr15:75527150~75601205:-
LUAD	cis	rs9926296	0.508	rs1558184	ENSG00000260259.1	RP11-368I7.4	-3.82	0.000151	0.0199	-0.17	-0.17	Vitiligo;	chr16:89775966	chr16:89682620~89686569:-
LUAD	cis	rs4499344	0.73	rs380320	ENSG00000201388.1	SNORA68	3.82	0.000151	0.0199	0.19	0.17	Mean platelet volume;	chr19:32614998	chr19:32608337~32608469:-
LUAD	cis	rs7772486	0.875	rs10457793	ENSG00000235652.6	RP11-545I5.3	3.82	0.000151	0.0199	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:146094267	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.875	rs10457794	ENSG00000235652.6	RP11-545I5.3	3.82	0.000151	0.0199	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:146094472	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.875	rs1331640	ENSG00000235652.6	RP11-545I5.3	3.82	0.000151	0.0199	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:146106114	chr6:145799409~145886585:+
LUAD	cis	rs7976269	0.515	rs9300183	ENSG00000275476.1	RP11-996F15.4	-3.82	0.000151	0.0199	-0.19	-0.17	Male-pattern baldness;	chr12:29002316	chr12:29277397~29277882:-
LUAD	cis	rs12368653	0.591	rs1038914	ENSG00000245651.2	RP11-620J15.2	3.82	0.000151	0.0199	0.17	0.17	Multiple sclerosis;	chr12:57617283	chr12:57869835~57896482:-
LUAD	cis	rs4130344	0.874	rs13116697	ENSG00000271817.2	U3	-3.82	0.000151	0.0199	-0.18	-0.17	Intelligence (multi-trait analysis);	chr4:158770991	chr4:158700691~158700909:+
LUAD	cis	rs4130344	0.874	rs6852508	ENSG00000271817.2	U3	-3.82	0.000151	0.0199	-0.18	-0.17	Intelligence (multi-trait analysis);	chr4:158776184	chr4:158700691~158700909:+
LUAD	cis	rs13068223	0.935	rs1560414	ENSG00000243926.1	TIPARP-AS1	3.82	0.000151	0.0199	0.18	0.17	Age-related hearing impairment (SNP x SNP interaction);	chr3:156723960	chr3:156671862~156674378:-
LUAD	cis	rs8062405	0.755	rs17707300	ENSG00000261419.1	RP11-57A19.4	-3.82	0.000151	0.0199	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28659696~28740781:-
LUAD	cis	rs412050	0.895	rs240065	ENSG00000224086.5	LL22NC03-86G7.1	-3.82	0.000151	0.0199	-0.21	-0.17	Attention deficit hyperactivity disorder;	chr22:21941747	chr22:21938293~21977632:+
LUAD	cis	rs412050	0.895	rs6000236	ENSG00000224086.5	LL22NC03-86G7.1	-3.82	0.000151	0.0199	-0.21	-0.17	Attention deficit hyperactivity disorder;	chr22:21942087	chr22:21938293~21977632:+
LUAD	cis	rs2390582	0.843	rs1415141	ENSG00000233593.5	RP4-665J23.1	3.82	0.000151	0.0199	0.25	0.17	Coronary artery calcification;	chr1:90503769	chr1:90782986~90851650:-
LUAD	cis	rs6438234	0.778	rs7641283	ENSG00000242767.1	ZBTB20-AS4	3.82	0.000151	0.0199	0.22	0.17	Type 2 diabetes;	chr3:115241192	chr3:115100423~115103061:+
LUAD	cis	rs6438234	0.778	rs1380361	ENSG00000242767.1	ZBTB20-AS4	3.82	0.000151	0.0199	0.22	0.17	Type 2 diabetes;	chr3:115241412	chr3:115100423~115103061:+
LUAD	cis	rs6438234	0.778	rs6790326	ENSG00000242767.1	ZBTB20-AS4	3.82	0.000151	0.0199	0.22	0.17	Type 2 diabetes;	chr3:115244989	chr3:115100423~115103061:+
LUAD	cis	rs6438234	0.778	rs6438237	ENSG00000242767.1	ZBTB20-AS4	3.82	0.000151	0.0199	0.22	0.17	Type 2 diabetes;	chr3:115245469	chr3:115100423~115103061:+
LUAD	cis	rs6438234	0.778	rs4831200	ENSG00000242767.1	ZBTB20-AS4	3.82	0.000151	0.0199	0.22	0.17	Type 2 diabetes;	chr3:115246402	chr3:115100423~115103061:+
LUAD	cis	rs6438234	0.778	rs2219522	ENSG00000242767.1	ZBTB20-AS4	3.82	0.000151	0.0199	0.22	0.17	Type 2 diabetes;	chr3:115247127	chr3:115100423~115103061:+
LUAD	cis	rs875971	0.522	rs4718285	ENSG00000222364.1	RNU6-96P	-3.82	0.000151	0.0199	-0.19	-0.17	Aortic root size;	chr7:65827018	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.522	rs4718286	ENSG00000222364.1	RNU6-96P	-3.82	0.000151	0.0199	-0.19	-0.17	Aortic root size;	chr7:65827777	chr7:66395191~66395286:+
LUAD	cis	rs9860428	0.844	rs9846377	ENSG00000242770.2	RP11-180K7.1	3.82	0.000152	0.0199	0.19	0.17	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112902091	chr3:112802478~112812819:+
LUAD	cis	rs2880765	0.546	rs36098649	ENSG00000202081.1	RNU6-1280P	3.82	0.000152	0.0199	0.21	0.17	Coronary artery disease;	chr15:85513576	chr15:85651522~85651628:-
LUAD	cis	rs9549260	0.755	rs8001443	ENSG00000229456.1	RLIMP1	-3.82	0.000152	0.0199	-0.18	-0.17	Red blood cell count;	chr13:40642509	chr13:40618738~40621348:+
LUAD	cis	rs6732565	0.706	rs13029175	ENSG00000235721.1	AC013268.3	3.82	0.000152	0.0199	0.19	0.17	Rheumatoid arthritis;	chr2:110871548	chr2:110007675~110010783:+
LUAD	cis	rs1876905	0.539	rs240987	ENSG00000230177.1	RP5-1112D6.4	-3.82	0.000152	0.0199	-0.21	-0.17	Mean corpuscular hemoglobin;	chr6:111268552	chr6:111277932~111278742:+
LUAD	cis	rs7246657	0.943	rs10420430	ENSG00000226686.6	LINC01535	-3.82	0.000152	0.0199	-0.26	-0.17	Coronary artery calcification;	chr19:37403292	chr19:37251912~37265535:+
LUAD	cis	rs6832769	0.961	rs11133379	ENSG00000272969.1	RP11-528I4.2	3.82	0.000152	0.0199	0.18	0.17	Personality dimensions;	chr4:55439944	chr4:55547112~55547889:+
LUAD	cis	rs6832769	0.961	rs3736545	ENSG00000272969.1	RP11-528I4.2	3.82	0.000152	0.0199	0.18	0.17	Personality dimensions;	chr4:55444176	chr4:55547112~55547889:+
LUAD	cis	rs6832769	1	rs12643926	ENSG00000272969.1	RP11-528I4.2	3.82	0.000152	0.0199	0.18	0.17	Personality dimensions;	chr4:55444454	chr4:55547112~55547889:+
LUAD	cis	rs6832769	0.961	rs12647034	ENSG00000272969.1	RP11-528I4.2	3.82	0.000152	0.0199	0.18	0.17	Personality dimensions;	chr4:55444455	chr4:55547112~55547889:+
LUAD	cis	rs6674176	0.628	rs2240447	ENSG00000237950.1	RP11-7O11.3	3.82	0.000152	0.0199	0.21	0.17	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43949743	chr1:43944370~43946551:-
LUAD	cis	rs6674176	0.628	rs7556565	ENSG00000237950.1	RP11-7O11.3	3.82	0.000152	0.0199	0.21	0.17	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43950418	chr1:43944370~43946551:-
LUAD	cis	rs1355223	0.867	rs3818514	ENSG00000271369.1	RP11-350D17.3	-3.82	0.000152	0.0199	-0.2	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34658506	chr11:34709600~34710161:+
LUAD	cis	rs703842	0.616	rs10877024	ENSG00000270039.1	RP11-571M6.17	-3.82	0.000152	0.0199	-0.21	-0.17	Multiple sclerosis;	chr12:57832926	chr12:57803838~57804415:+
LUAD	cis	rs494562	0.892	rs7771860	ENSG00000234155.1	RP11-30P6.6	-3.82	0.000152	0.0199	-0.33	-0.17	Metabolic traits;Blood metabolite levels;	chr6:85421011	chr6:85387219~85390186:-
LUAD	cis	rs9549260	0.591	rs9577115	ENSG00000229456.1	RLIMP1	3.82	0.000152	0.0199	0.18	0.17	Red blood cell count;	chr13:40702417	chr13:40618738~40621348:+
LUAD	cis	rs6430585	0.583	rs2304371	ENSG00000226806.1	AC011893.3	3.82	0.000152	0.0199	0.23	0.17	Corneal structure;	chr2:135803987	chr2:135820191~135823087:+
LUAD	cis	rs4474465	0.736	rs11237541	ENSG00000251323.2	RP11-452H21.4	-3.82	0.000152	0.0199	-0.21	-0.17	Alzheimer's disease (survival time);	chr11:78550657	chr11:78423982~78429836:-
LUAD	cis	rs4474465	0.79	rs6592790	ENSG00000251323.2	RP11-452H21.4	-3.82	0.000152	0.0199	-0.21	-0.17	Alzheimer's disease (survival time);	chr11:78551572	chr11:78423982~78429836:-
LUAD	cis	rs35160687	0.509	rs13024436	ENSG00000273080.1	RP11-301O19.1	-3.82	0.000152	0.0199	-0.2	-0.17	Night sleep phenotypes;	chr2:86307398	chr2:86195590~86196049:+
LUAD	cis	rs3742264	0.925	rs1087	ENSG00000235903.6	CPB2-AS1	3.82	0.000152	0.0199	0.21	0.17	Blood protein levels;	chr13:46053304	chr13:46052806~46113332:+
LUAD	cis	rs2795502	0.938	rs3121324	ENSG00000234944.1	RP11-124O11.1	-3.82	0.000152	0.0199	-0.27	-0.17	Blood protein levels;	chr10:42884067	chr10:42871521~42874060:+
LUAD	cis	rs17597773	0.638	rs12139139	ENSG00000272823.1	RP11-295M18.6	-3.82	0.000152	0.0199	-0.22	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220827284	chr1:220828676~220829211:-
LUAD	cis	rs13260300	0.533	rs12548780	ENSG00000249395.2	CASC9	-3.82	0.000152	0.0199	-0.2	-0.17	Breast cancer-free interval (treatment with aromatase inhibitor);	chr8:74582379	chr8:75223404~75324741:-
LUAD	cis	rs2274273	0.87	rs8013713	ENSG00000259318.1	RP11-454L9.2	-3.82	0.000152	0.0199	-0.15	-0.17	Protein biomarker;	chr14:55374534	chr14:55394940~55395233:-
LUAD	cis	rs4731367	0.898	rs11761076	ENSG00000224138.1	AC000123.4	3.82	0.000152	0.0199	0.16	0.17	Parental longevity (mother's age at death);	chr7:127553613	chr7:127350128~127351523:+
LUAD	cis	rs847577	0.722	rs1013887	ENSG00000272950.1	RP11-307C18.1	3.82	0.000152	0.0199	0.21	0.17	Breast cancer;	chr7:98080033	chr7:98322853~98323430:+
LUAD	cis	rs8073060	0.586	rs4795086	ENSG00000267592.1	CTC-507E2.2	-3.82	0.000152	0.0199	-0.25	-0.17	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35715171	chr17:35596904~35597128:-
LUAD	cis	rs8073060	0.559	rs72829925	ENSG00000267592.1	CTC-507E2.2	-3.82	0.000152	0.0199	-0.25	-0.17	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35722759	chr17:35596904~35597128:-
LUAD	cis	rs13256369	1	rs9329166	ENSG00000253893.2	FAM85B	-3.82	0.000152	0.0199	-0.23	-0.17	Obesity-related traits;	chr8:8719145	chr8:8167819~8226614:-
LUAD	cis	rs651907	0.557	rs3094297	ENSG00000244119.1	PDCL3P4	3.82	0.000152	0.0199	0.17	0.17	Colorectal cancer;	chr3:101680416	chr3:101712472~101713191:+
LUAD	cis	rs1881797	1	rs10925069	ENSG00000221953.5	C1orf229	3.82	0.000152	0.0199	0.23	0.17	Acute lymphoblastic leukemia (childhood);	chr1:247518011	chr1:247110160~247112417:-
LUAD	cis	rs6832769	0.922	rs28726308	ENSG00000272969.1	RP11-528I4.2	3.82	0.000152	0.0199	0.19	0.17	Personality dimensions;	chr4:55368239	chr4:55547112~55547889:+
LUAD	cis	rs12822507	0.732	rs10845596	ENSG00000275963.1	RP11-180M15.6	3.82	0.000152	0.0199	0.2	0.17	Systemic lupus erythematosus;	chr12:12627456	chr12:12648939~12649713:+
LUAD	cis	rs12822507	0.708	rs10845597	ENSG00000275963.1	RP11-180M15.6	3.82	0.000152	0.0199	0.2	0.17	Systemic lupus erythematosus;	chr12:12629134	chr12:12648939~12649713:+
LUAD	cis	rs9549260	0.755	rs2297627	ENSG00000229456.1	RLIMP1	3.82	0.000152	0.0199	0.19	0.17	Red blood cell count;	chr13:40659794	chr13:40618738~40621348:+
LUAD	cis	rs7005380	0.62	rs10093230	ENSG00000279347.1	RP11-85I17.2	-3.82	0.000152	0.0199	-0.14	-0.17	Interstitial lung disease;	chr8:119900606	chr8:119838736~119840385:-
LUAD	cis	rs4267450	0.842	rs11666278	ENSG00000267323.1	SLC25A1P5	3.82	0.000152	0.0199	0.3	0.17	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr19:28363434	chr19:27805423~27806205:-
LUAD	cis	rs911186	0.782	rs34569203	ENSG00000219392.1	RP1-265C24.5	-3.82	0.000152	0.0199	-0.28	-0.17	Autism spectrum disorder or schizophrenia;	chr6:27186205	chr6:28115628~28116551:+
LUAD	cis	rs4218	0.734	rs12912071	ENSG00000277144.1	RP11-59H7.4	-3.82	0.000152	0.0199	-0.2	-0.17	Social communication problems;	chr15:59150951	chr15:59115547~59116089:-
LUAD	cis	rs911555	0.504	rs4444269	ENSG00000258851.1	RP11-894P9.2	-3.82	0.000152	0.0199	-0.2	-0.17	Intelligence (multi-trait analysis);	chr14:103606387	chr14:103553421~103561877:+
LUAD	cis	rs638893	0.617	rs7103314	ENSG00000255422.1	AP002954.4	-3.82	0.000152	0.0199	-0.24	-0.17	Vitiligo;	chr11:118852828	chr11:118704607~118750263:+
LUAD	cis	rs9341808	0.556	rs1474791	ENSG00000233967.5	RP11-250B2.3	3.82	0.000152	0.0199	0.17	0.17	Sitting height ratio;	chr6:80323380	chr6:80443344~80465927:+
LUAD	cis	rs2638953	0.888	rs11049407	ENSG00000278733.1	RP11-425D17.1	-3.82	0.000152	0.0199	-0.2	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28181431	chr12:28185625~28186190:-
LUAD	cis	rs2933343	0.729	rs1683780	ENSG00000231305.3	RP11-723O4.2	3.82	0.000152	0.0199	0.19	0.17	IgG glycosylation;	chr3:128921396	chr3:128861313~128871540:-
LUAD	cis	rs3096299	0.967	rs3102341	ENSG00000182376.2	RP5-1142A6.8	3.82	0.000152	0.0199	0.18	0.17	Multiple myeloma (IgH translocation);	chr16:89384336	chr16:88742767~88745748:+
LUAD	cis	rs806321	0.587	rs2740518	ENSG00000237152.3	DLEU7-AS1	-3.82	0.000152	0.0199	-0.21	-0.17	Multiple sclerosis;	chr13:50188809	chr13:50807856~50849905:+
LUAD	cis	rs6964587	1	rs10264666	ENSG00000188693.7	CYP51A1-AS1	3.82	0.000152	0.0199	0.21	0.17	Breast cancer;	chr7:91949325	chr7:92134604~92180725:+
LUAD	cis	rs6942407	1	rs6942407	ENSG00000224046.1	AC005076.5	-3.82	0.000152	0.0199	-0.2	-0.17	Food allergy;	chr7:87231997	chr7:87151423~87152420:-
LUAD	cis	rs763121	0.853	rs2072795	ENSG00000225450.1	RP3-508I15.14	3.82	0.000152	0.0199	0.17	0.17	Menopause (age at onset);	chr22:38668204	chr22:38739003~38749041:+
LUAD	cis	rs9549260	0.755	rs3900833	ENSG00000229456.1	RLIMP1	3.82	0.000152	0.0199	0.19	0.17	Red blood cell count;	chr13:40614155	chr13:40618738~40621348:+
LUAD	cis	rs13113518	1	rs7691799	ENSG00000273257.1	RP11-177J6.1	3.82	0.000152	0.0199	0.19	0.17	Height;	chr4:55545574	chr4:55387949~55388271:+
LUAD	cis	rs2702164	1	rs1621291	ENSG00000240661.1	RP11-174O3.3	-3.82	0.000152	0.0199	-0.2	-0.17	Gut microbiome composition (winter);	chr3:120386855	chr3:120349510~120367998:+
LUAD	cis	rs11048434	0.518	rs4883206	ENSG00000256937.1	KRT17P8	-3.82	0.000152	0.0199	-0.19	-0.17	Sjögren's syndrome;	chr12:9021169	chr12:9127783~9128645:+
LUAD	cis	rs875971	0.545	rs1267814	ENSG00000222364.1	RNU6-96P	3.82	0.000152	0.02	0.22	0.17	Aortic root size;	chr7:66579422	chr7:66395191~66395286:+
LUAD	cis	rs36093844	0.576	rs57125313	ENSG00000279742.1	RP11-700A24.1	-3.82	0.000152	0.02	-0.2	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85962793	chr11:85852557~85854943:-
LUAD	cis	rs4819052	0.635	rs2838808	ENSG00000223768.1	LINC00205	-3.82	0.000152	0.02	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45201191	chr21:45293285~45297354:+
LUAD	cis	rs7826238	0.72	rs12546760	ENSG00000253893.2	FAM85B	3.82	0.000152	0.02	0.21	0.17	Systolic blood pressure;	chr8:8517326	chr8:8167819~8226614:-
LUAD	cis	rs4660456	0.576	rs2780948	ENSG00000237899.1	RP4-739H11.3	-3.82	0.000152	0.02	-0.19	-0.17	Platelet count;	chr1:40776205	chr1:40669089~40687588:-
LUAD	cis	rs12744310	1	rs12036554	ENSG00000235358.1	RP11-399E6.1	3.82	0.000152	0.02	0.23	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41312317	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs12036555	ENSG00000235358.1	RP11-399E6.1	3.82	0.000152	0.02	0.23	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41312318	chr1:41242373~41284861:+
LUAD	cis	rs4716602	0.596	rs10275400	ENSG00000235029.1	MNX1-AS2	-3.82	0.000152	0.02	-0.21	-0.17	Anti-saccade response;	chr7:156368856	chr7:157006307~157007132:+
LUAD	cis	rs7142881	0.815	rs11628555	ENSG00000258525.1	RP11-829H16.3	-3.82	0.000152	0.02	-0.2	-0.17	Response to iloperidone treatment (QT prolongation);	chr14:31690343	chr14:30876179~30889808:-
LUAD	cis	rs897984	0.762	rs11150601	ENSG00000232748.3	RP11-196G11.6	3.82	0.000152	0.02	0.21	0.17	Dementia with Lewy bodies;	chr16:30966478	chr16:31056460~31062803:+
LUAD	cis	rs477895	0.713	rs12575642	ENSG00000236935.1	AP003774.1	-3.82	0.000152	0.02	-0.21	-0.17	Mean platelet volume;	chr11:64212171	chr11:64325050~64329504:-
LUAD	cis	rs8056893	0.885	rs7199750	ENSG00000274698.1	RP11-71L14.4	3.82	0.000152	0.02	0.19	0.17	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68317956	chr16:68450283~68452318:+
LUAD	cis	rs375066	0.935	rs399098	ENSG00000278917.1	RP11-15A1.4	-3.82	0.000152	0.02	-0.18	-0.17	Breast cancer;	chr19:43914672	chr19:43891233~43895411:+
LUAD	cis	rs11673344	0.704	rs1644711	ENSG00000267309.1	CTD-2630F21.1	-3.82	0.000152	0.02	-0.21	-0.17	Obesity-related traits;	chr19:36926420	chr19:36489649~36491040:+
LUAD	cis	rs11673344	0.704	rs826262	ENSG00000267309.1	CTD-2630F21.1	-3.82	0.000152	0.02	-0.21	-0.17	Obesity-related traits;	chr19:36928540	chr19:36489649~36491040:+
LUAD	cis	rs11673344	0.704	rs485034	ENSG00000267309.1	CTD-2630F21.1	-3.82	0.000152	0.02	-0.21	-0.17	Obesity-related traits;	chr19:36931455	chr19:36489649~36491040:+
LUAD	cis	rs11673344	0.704	rs517110	ENSG00000267309.1	CTD-2630F21.1	-3.82	0.000152	0.02	-0.21	-0.17	Obesity-related traits;	chr19:36931492	chr19:36489649~36491040:+
LUAD	cis	rs2115630	0.905	rs6496401	ENSG00000259728.4	LINC00933	-3.82	0.000152	0.02	-0.21	-0.17	P wave terminal force;	chr15:84754562	chr15:84570649~84580175:+
LUAD	cis	rs6802315	0.604	rs9861938	ENSG00000272087.1	RP11-379F4.7	3.82	0.000152	0.02	0.19	0.17	Periodontitis (CDC/AAP);	chr3:158745257	chr3:158693120~158693768:-
LUAD	cis	rs7976269	0.609	rs7310276	ENSG00000275476.1	RP11-996F15.4	3.82	0.000153	0.02	0.19	0.17	Male-pattern baldness;	chr12:29054128	chr12:29277397~29277882:-
LUAD	cis	rs11673344	0.523	rs7248948	ENSG00000276846.1	CTD-3220F14.3	3.82	0.000153	0.02	0.19	0.17	Obesity-related traits;	chr19:37056317	chr19:37314868~37315620:-
LUAD	cis	rs2154319	0.836	rs213732	ENSG00000235358.1	RP11-399E6.1	3.82	0.000153	0.02	0.24	0.17	Height;	chr1:41112442	chr1:41242373~41284861:+
LUAD	cis	rs8180040	0.654	rs13078131	ENSG00000271161.1	BOLA2P2	3.82	0.000153	0.02	0.16	0.17	Colorectal cancer;	chr3:47163449	chr3:47499841~47500407:+
LUAD	cis	rs56875752	1	rs55831402	ENSG00000263648.1	RP11-471L13.3	3.82	0.000153	0.02	0.33	0.17	Fear of pain;Fear of severe pain;	chr17:12713965	chr17:12115547~12115885:+
LUAD	cis	rs865483	0.929	rs853195	ENSG00000276054.1	RP11-378E13.3	3.82	0.000153	0.02	0.2	0.17	Monocyte count;	chr17:37488149	chr17:37386886~37387926:+
LUAD	cis	rs8054556	0.692	rs12716973	ENSG00000183604.13	SMG1P5	-3.82	0.000153	0.02	-0.17	-0.17	Autism spectrum disorder or schizophrenia;	chr16:29926331	chr16:30267553~30335374:-
LUAD	cis	rs7772486	0.686	rs9386131	ENSG00000235652.6	RP11-545I5.3	3.82	0.000153	0.02	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145800472	chr6:145799409~145886585:+
LUAD	cis	rs6540731	1	rs12402397	ENSG00000229983.1	RP11-15I11.2	3.82	0.000153	0.02	0.21	0.17	Intelligence (childhood);	chr1:212222602	chr1:212168207~212190259:+
LUAD	cis	rs7937890	1	rs2970334	ENSG00000251991.1	RNU7-49P	-3.82	0.000153	0.02	-0.18	-0.17	Mitochondrial DNA levels;	chr11:14307809	chr11:14478892~14478953:+
LUAD	cis	rs14027	0.512	rs6992632	ENSG00000279347.1	RP11-85I17.2	-3.82	0.000153	0.02	-0.15	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119711969	chr8:119838736~119840385:-
LUAD	cis	rs14027	0.512	rs10095282	ENSG00000279347.1	RP11-85I17.2	-3.82	0.000153	0.02	-0.15	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119712629	chr8:119838736~119840385:-
LUAD	cis	rs7246657	0.943	rs12981532	ENSG00000226686.6	LINC01535	-3.82	0.000153	0.02	-0.26	-0.17	Coronary artery calcification;	chr19:37398378	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.943	rs7246993	ENSG00000226686.6	LINC01535	-3.82	0.000153	0.02	-0.26	-0.17	Coronary artery calcification;	chr19:37399252	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.943	rs10413602	ENSG00000226686.6	LINC01535	-3.82	0.000153	0.02	-0.26	-0.17	Coronary artery calcification;	chr19:37400590	chr19:37251912~37265535:+
LUAD	cis	rs12908161	0.959	rs3748376	ENSG00000254414.1	RP11-182J1.1	3.82	0.000153	0.02	0.22	0.17	Schizophrenia;	chr15:84785121	chr15:84631898~84633987:-
LUAD	cis	rs10859871	0.536	rs12305760	ENSG00000216306.3	KRT19P2	3.82	0.000153	0.02	0.23	0.17	Endometriosis;	chr12:95263160	chr12:94834147~94835158:+
LUAD	cis	rs3893377	1	rs9998153	ENSG00000214846.4	RP11-115L11.1	3.82	0.000153	0.02	0.28	0.17	Current cigarettes per day in chronic obstructive pulmonary disease;	chr4:15742049	chr4:15730962~15731627:-
LUAD	cis	rs2836974	0.897	rs3945	ENSG00000232608.1	TIMM9P2	-3.82	0.000153	0.02	-0.21	-0.17	Cognitive function;	chr21:39194141	chr21:39216624~39217506:+
LUAD	cis	rs10129255	0.957	rs10136817	ENSG00000211947.2	IGHV3-21	-3.82	0.000153	0.02	-0.12	-0.17	Kawasaki disease;	chr14:106787730	chr14:106235064~106235594:-
LUAD	cis	rs8002861	0.754	rs4053664	ENSG00000274001.1	RP11-5G9.5	3.82	0.000153	0.02	0.18	0.17	Leprosy;	chr13:43855036	chr13:43877715~43878163:-
LUAD	cis	rs8002861	0.87	rs9525855	ENSG00000274001.1	RP11-5G9.5	3.82	0.000153	0.02	0.18	0.17	Leprosy;	chr13:43857524	chr13:43877715~43878163:-
LUAD	cis	rs8002861	0.781	rs9525857	ENSG00000274001.1	RP11-5G9.5	3.82	0.000153	0.02	0.18	0.17	Leprosy;	chr13:43862936	chr13:43877715~43878163:-
LUAD	cis	rs683250	0.599	rs1943741	ENSG00000246067.6	RAB30-AS1	-3.82	0.000153	0.02	-0.18	-0.17	Subcortical brain region volumes;	chr11:83369295	chr11:83072066~83106719:+
LUAD	cis	rs599083	0.53	rs583545	ENSG00000212093.1	AP000807.1	-3.82	0.000153	0.02	-0.19	-0.17	Bone mineral density (spine);	chr11:68411167	chr11:68506083~68506166:-
LUAD	cis	rs599083	0.53	rs689179	ENSG00000212093.1	AP000807.1	-3.82	0.000153	0.02	-0.19	-0.17	Bone mineral density (spine);	chr11:68411698	chr11:68506083~68506166:-
LUAD	cis	rs2390582	0.722	rs1361010	ENSG00000233593.5	RP4-665J23.1	3.82	0.000153	0.02	0.25	0.17	Coronary artery calcification;	chr1:90527685	chr1:90782986~90851650:-
LUAD	cis	rs6964587	0.782	rs13221571	ENSG00000188693.7	CYP51A1-AS1	3.82	0.000153	0.02	0.2	0.17	Breast cancer;	chr7:91870922	chr7:92134604~92180725:+
LUAD	cis	rs38055	0.837	rs37777	ENSG00000247796.2	CTD-2366F13.1	-3.82	0.000153	0.02	-0.19	-0.17	Acne (severe);	chr5:53332520	chr5:53109842~53115126:+
LUAD	cis	rs7617773	0.746	rs4371540	ENSG00000199476.1	Y_RNA	-3.82	0.000153	0.02	-0.23	-0.17	Coronary artery disease;	chr3:48312053	chr3:48288587~48288694:+
LUAD	cis	rs11051970	0.659	rs904917	ENSG00000275854.1	RP11-278C7.5	-3.82	0.000153	0.02	-0.18	-0.17	Response to tocilizumab in rheumatoid arthritis;	chr12:32438368	chr12:32736930~32737660:-
LUAD	cis	rs8177876	0.822	rs74437879	ENSG00000261061.1	RP11-303E16.2	-3.82	0.000153	0.02	-0.29	-0.17	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078987	chr16:81030770~81031485:+
LUAD	cis	rs8177876	0.822	rs76948085	ENSG00000261061.1	RP11-303E16.2	-3.82	0.000153	0.02	-0.29	-0.17	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079199	chr16:81030770~81031485:+
LUAD	cis	rs8177876	0.822	rs80315956	ENSG00000261061.1	RP11-303E16.2	-3.82	0.000153	0.02	-0.29	-0.17	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079254	chr16:81030770~81031485:+
LUAD	cis	rs8177876	0.642	rs16954572	ENSG00000261061.1	RP11-303E16.2	-3.82	0.000153	0.02	-0.29	-0.17	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079299	chr16:81030770~81031485:+
LUAD	cis	rs8177876	0.822	rs9929586	ENSG00000261061.1	RP11-303E16.2	-3.82	0.000153	0.02	-0.29	-0.17	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079416	chr16:81030770~81031485:+
LUAD	cis	rs8177876	0.822	rs9938965	ENSG00000261061.1	RP11-303E16.2	-3.82	0.000153	0.02	-0.29	-0.17	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079558	chr16:81030770~81031485:+
LUAD	cis	rs8177876	0.822	rs7204040	ENSG00000261061.1	RP11-303E16.2	-3.82	0.000153	0.02	-0.29	-0.17	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81079888	chr16:81030770~81031485:+
LUAD	cis	rs8177876	0.731	rs7188508	ENSG00000261061.1	RP11-303E16.2	-3.82	0.000153	0.02	-0.29	-0.17	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080097	chr16:81030770~81031485:+
LUAD	cis	rs4474465	0.85	rs11237537	ENSG00000251323.2	RP11-452H21.4	3.82	0.000153	0.02	0.21	0.17	Alzheimer's disease (survival time);	chr11:78537351	chr11:78423982~78429836:-
LUAD	cis	rs76934034	0.522	rs117488236	ENSG00000237840.5	FAM21FP	-3.82	0.000153	0.02	-0.29	-0.17	Prostate cancer;	chr10:45546587	chr10:45706431~45727231:-
LUAD	cis	rs9860428	0.591	rs11711794	ENSG00000242770.2	RP11-180K7.1	3.82	0.000153	0.02	0.19	0.17	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112948640	chr3:112802478~112812819:+
LUAD	cis	rs9860428	0.591	rs9869203	ENSG00000242770.2	RP11-180K7.1	3.82	0.000153	0.02	0.19	0.17	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112950820	chr3:112802478~112812819:+
LUAD	cis	rs7829975	0.606	rs10112585	ENSG00000233609.3	RP11-62H7.2	-3.82	0.000153	0.02	-0.14	-0.17	Mood instability;	chr8:8937520	chr8:8961200~8979025:+
LUAD	cis	rs7520050	0.966	rs10890383	ENSG00000234329.1	RP11-767N6.2	-3.82	0.000153	0.02	-0.16	-0.17	Reticulocyte count;Red blood cell count;	chr1:46122831	chr1:45651039~45651826:-
LUAD	cis	rs61884328	0.733	rs74898661	ENSG00000254780.1	RP11-793I11.1	3.82	0.000153	0.02	0.33	0.17	Total body bone mineral density (age over 60);	chr11:47204179	chr11:47905323~47905607:-
LUAD	cis	rs7976269	0.537	rs10843303	ENSG00000275476.1	RP11-996F15.4	-3.82	0.000153	0.02	-0.19	-0.17	Male-pattern baldness;	chr12:29069435	chr12:29277397~29277882:-
LUAD	cis	rs7976269	0.537	rs2117992	ENSG00000275476.1	RP11-996F15.4	-3.82	0.000153	0.02	-0.19	-0.17	Male-pattern baldness;	chr12:29070611	chr12:29277397~29277882:-
LUAD	cis	rs7976269	0.559	rs10843304	ENSG00000275476.1	RP11-996F15.4	-3.82	0.000153	0.02	-0.19	-0.17	Male-pattern baldness;	chr12:29071226	chr12:29277397~29277882:-
LUAD	cis	rs62025270	0.747	rs12324721	ENSG00000259416.2	RP11-158M2.5	-3.82	0.000153	0.02	-0.22	-0.17	Idiopathic pulmonary fibrosis;	chr15:85767741	chr15:85754941~85756237:-
LUAD	cis	rs5758511	0.817	rs133291	ENSG00000227370.1	RP4-669P10.19	3.82	0.000153	0.02	0.18	0.17	Birth weight;	chr22:41873624	chr22:42132543~42132998:+
LUAD	cis	rs2274273	0.744	rs8011808	ENSG00000259318.1	RP11-454L9.2	3.82	0.000153	0.02	0.15	0.17	Protein biomarker;	chr14:55356626	chr14:55394940~55395233:-
LUAD	cis	rs321358	0.945	rs7931995	ENSG00000271390.1	RP11-89C3.3	3.82	0.000153	0.02	0.29	0.17	Body mass index;	chr11:111117691	chr11:111089870~111090368:-
LUAD	cis	rs7208859	0.623	rs216423	ENSG00000280069.1	CTD-2349P21.3	-3.82	0.000153	0.02	-0.2	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30615091	chr17:30738182~30740275:+
LUAD	cis	rs6928977	0.675	rs7750586	ENSG00000231028.7	LINC00271	3.82	0.000153	0.0201	0.2	0.17	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135506535	chr6:135497801~135716055:+
LUAD	cis	rs3758785	0.512	rs4753597	ENSG00000255893.1	RP11-685N10.1	3.82	0.000153	0.0201	0.22	0.17	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94367092	chr11:94472908~94473570:-
LUAD	cis	rs17711722	0.51	rs11767457	ENSG00000229886.1	RP5-1132H15.3	-3.82	0.000153	0.0201	-0.2	-0.17	Calcium levels;	chr7:65825628	chr7:66025126~66031544:-
LUAD	cis	rs865483	0.895	rs853192	ENSG00000276054.1	RP11-378E13.3	3.82	0.000153	0.0201	0.21	0.17	Monocyte count;	chr17:37461827	chr17:37386886~37387926:+
LUAD	cis	rs9309473	0.898	rs6546851	ENSG00000230002.2	ALMS1-IT1	3.82	0.000153	0.0201	0.21	0.17	Metabolite levels;	chr2:73606156	chr2:73456764~73459484:+
LUAD	cis	rs2243480	1	rs316315	ENSG00000164669.11	INTS4P1	-3.82	0.000153	0.0201	-0.27	-0.17	Diabetic kidney disease;	chr7:66126218	chr7:65141225~65234216:+
LUAD	cis	rs1150668	0.699	rs1531681	ENSG00000176933.5	TOB2P1	-3.82	0.000153	0.0201	-0.19	-0.17	Pubertal anthropometrics;	chr6:28259100	chr6:28217643~28218634:-
LUAD	cis	rs1979679	0.808	rs71452082	ENSG00000278733.1	RP11-425D17.1	3.82	0.000153	0.0201	0.21	0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28221647	chr12:28185625~28186190:-
LUAD	cis	rs4819052	0.765	rs2838854	ENSG00000215447.6	BX322557.10	-3.82	0.000153	0.0201	-0.2	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260449	chr21:45288052~45291738:+
LUAD	cis	rs7023329	0.811	rs3928894	ENSG00000264801.1	ERVFRD-3	3.82	0.000153	0.0201	0.19	0.17	Melanoma;	chr9:21818311	chr9:21929457~21931073:+
LUAD	cis	rs7512552	0.839	rs11587116	ENSG00000275557.1	RP11-353N4.6	3.82	0.000153	0.0201	0.19	0.17	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150479422	chr1:149607765~149612402:+
LUAD	cis	rs73108077	0.915	rs746053	ENSG00000281376.1	ABALON	-3.82	0.000153	0.0201	-0.3	-0.17	Red blood cell density in sickle cell anemia;	chr20:31440944	chr20:31721507~31723409:+
LUAD	cis	rs9987353	0.84	rs329994	ENSG00000254340.1	RP11-10A14.3	-3.82	0.000153	0.0201	-0.21	-0.17	Recombination measurement;	chr8:9265723	chr8:9141424~9145435:+
LUAD	cis	rs7772486	0.686	rs9390347	ENSG00000235652.6	RP11-545I5.3	-3.82	0.000153	0.0201	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145723611	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.686	rs9390348	ENSG00000235652.6	RP11-545I5.3	-3.82	0.000153	0.0201	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145723612	chr6:145799409~145886585:+
LUAD	cis	rs7200786	0.585	rs41371	ENSG00000274038.1	RP11-66H6.4	-3.82	0.000153	0.0201	-0.23	-0.17	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11164978	chr16:11056556~11057034:+
LUAD	cis	rs2239557	0.539	rs2302118	ENSG00000259065.1	RP5-1021I20.1	-3.82	0.000153	0.0201	-0.23	-0.17	Common traits (Other);	chr14:73955626	chr14:73787360~73803270:+
LUAD	cis	rs7246967	0.673	rs2112610	ENSG00000236312.3	RPL34P34	3.82	0.000153	0.0201	0.24	0.17	Bronchopulmonary dysplasia;	chr19:22734049	chr19:22368599~22368952:-
LUAD	cis	rs1044826	1	rs12695699	ENSG00000214280.3	RP11-553K23.2	-3.82	0.000154	0.0201	-0.21	-0.17	Obesity-related traits;	chr3:139457267	chr3:139582928~139583593:-
LUAD	cis	rs1044826	0.957	rs9882014	ENSG00000214280.3	RP11-553K23.2	-3.82	0.000154	0.0201	-0.21	-0.17	Obesity-related traits;	chr3:139457693	chr3:139582928~139583593:-
LUAD	cis	rs7107174	1	rs11237471	ENSG00000251323.2	RP11-452H21.4	3.82	0.000154	0.0201	0.21	0.17	Testicular germ cell tumor;	chr11:78371558	chr11:78423982~78429836:-
LUAD	cis	rs7772486	0.686	rs7739735	ENSG00000235652.6	RP11-545I5.3	3.82	0.000154	0.0201	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145802400	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.686	rs7744014	ENSG00000235652.6	RP11-545I5.3	3.82	0.000154	0.0201	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145802682	chr6:145799409~145886585:+
LUAD	cis	rs7246657	0.653	rs4805208	ENSG00000267309.1	CTD-2630F21.1	3.82	0.000154	0.0201	0.28	0.17	Coronary artery calcification;	chr19:37183357	chr19:36489649~36491040:+
LUAD	cis	rs13113518	1	rs4864994	ENSG00000273257.1	RP11-177J6.1	3.82	0.000154	0.0201	0.19	0.17	Height;	chr4:55451955	chr4:55387949~55388271:+
LUAD	cis	rs2731006	0.64	rs908663	ENSG00000257114.2	RP11-25I15.3	3.82	0.000154	0.0201	0.28	0.17	Panic disorder;	chr12:42775650	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.544	rs1554252	ENSG00000257114.2	RP11-25I15.3	3.82	0.000154	0.0201	0.28	0.17	Panic disorder;	chr12:42775853	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.64	rs952056	ENSG00000257114.2	RP11-25I15.3	3.82	0.000154	0.0201	0.28	0.17	Panic disorder;	chr12:42776100	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.64	rs952054	ENSG00000257114.2	RP11-25I15.3	3.82	0.000154	0.0201	0.28	0.17	Panic disorder;	chr12:42776209	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.597	rs1400811	ENSG00000257114.2	RP11-25I15.3	3.82	0.000154	0.0201	0.28	0.17	Panic disorder;	chr12:42776473	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.64	rs1009431	ENSG00000257114.2	RP11-25I15.3	3.82	0.000154	0.0201	0.28	0.17	Panic disorder;	chr12:42778619	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.64	rs1554248	ENSG00000257114.2	RP11-25I15.3	3.82	0.000154	0.0201	0.28	0.17	Panic disorder;	chr12:42778750	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.64	rs2678153	ENSG00000257114.2	RP11-25I15.3	3.82	0.000154	0.0201	0.28	0.17	Panic disorder;	chr12:42779053	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.592	rs2255712	ENSG00000257114.2	RP11-25I15.3	3.82	0.000154	0.0201	0.28	0.17	Panic disorder;	chr12:42779424	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.64	rs2255713	ENSG00000257114.2	RP11-25I15.3	3.82	0.000154	0.0201	0.28	0.17	Panic disorder;	chr12:42779430	chr12:42692216~42717119:+
LUAD	cis	rs7809950	1	rs4730245	ENSG00000238832.1	snoU109	-3.82	0.000154	0.0201	-0.25	-0.17	Coronary artery disease;	chr7:107446849	chr7:107603363~107603507:+
LUAD	cis	rs2921073	0.509	rs2976931	ENSG00000253981.4	ALG1L13P	3.82	0.000154	0.0201	0.2	0.17	Parkinson's disease;	chr8:8399807	chr8:8236003~8244667:-
LUAD	cis	rs2735413	0.918	rs4309408	ENSG00000276007.1	RP11-358L22.3	-3.82	0.000154	0.0201	-0.17	-0.17	Systolic blood pressure (alcohol consumption interaction);	chr16:78037610	chr16:78123243~78124332:+
LUAD	cis	rs7617773	0.817	rs3731513	ENSG00000199476.1	Y_RNA	-3.82	0.000154	0.0201	-0.23	-0.17	Coronary artery disease;	chr3:48178047	chr3:48288587~48288694:+
LUAD	cis	rs10864907	0.806	rs879710	ENSG00000227368.1	AC079753.5	3.82	0.000154	0.0201	0.18	0.17	Pulmonary function;	chr2:112958645	chr2:112932625~112933171:+
LUAD	cis	rs2803122	0.871	rs3802333	ENSG00000273226.1	RP11-513M16.8	-3.82	0.000154	0.0201	-0.18	-0.17	Pulse pressure;	chr9:19232137	chr9:19375451~19375996:+
LUAD	cis	rs9633740	1	rs6586028	ENSG00000226659.1	RP11-137H2.4	-3.82	0.000154	0.0201	-0.28	-0.17	Post bronchodilator FEV1;	chr10:80494228	chr10:80529597~80535942:-
LUAD	cis	rs6500602	0.893	rs4786490	ENSG00000280063.1	RP11-295D4.3	-3.82	0.000154	0.0201	-0.11	-0.17	Schizophrenia;	chr16:4441189	chr16:4346694~4348648:-
LUAD	cis	rs2274273	0.901	rs17674563	ENSG00000258413.1	RP11-665C16.6	-3.82	0.000154	0.0201	-0.22	-0.17	Protein biomarker;	chr14:55364407	chr14:55262767~55272075:-
LUAD	cis	rs9303542	0.959	rs7216971	ENSG00000264920.1	RP11-6N17.4	-3.82	0.000154	0.0201	-0.22	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48369945	chr17:47891255~47895812:-
LUAD	cis	rs3198697	0.617	rs11075253	ENSG00000260735.1	RP11-72I8.1	-3.82	0.000154	0.0201	-0.2	-0.17	Triglycerides;	chr16:15054789	chr16:15094411~15109197:+
LUAD	cis	rs12565755	0.596	rs34030705	ENSG00000226476.2	RP11-776H12.1	3.82	0.000154	0.0201	0.27	0.17	Response to tocilizumab in rheumatoid arthritis;	chr1:60499420	chr1:60540249~60640491:-
LUAD	cis	rs12565755	0.556	rs78702116	ENSG00000226476.2	RP11-776H12.1	3.82	0.000154	0.0201	0.27	0.17	Response to tocilizumab in rheumatoid arthritis;	chr1:60499580	chr1:60540249~60640491:-
LUAD	cis	rs8073060	0.572	rs1634683	ENSG00000267592.1	CTC-507E2.2	3.82	0.000154	0.0201	0.25	0.17	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35614541	chr17:35596904~35597128:-
LUAD	cis	rs6479901	0.841	rs10465990	ENSG00000232075.1	MRPL35P2	-3.82	0.000154	0.0201	-0.23	-0.17	Intelligence (multi-trait analysis);	chr10:63200776	chr10:63634317~63634827:-
LUAD	cis	rs6547741	1	rs1919125	ENSG00000223522.1	AC093690.1	3.82	0.000154	0.0201	0.16	0.17	Oral cavity cancer;	chr2:27578536	chr2:28307691~28310459:-
LUAD	cis	rs6547741	1	rs1919126	ENSG00000223522.1	AC093690.1	3.82	0.000154	0.0201	0.16	0.17	Oral cavity cancer;	chr2:27578551	chr2:28307691~28310459:-
LUAD	cis	rs4714556	1	rs4714556	ENSG00000231113.2	RP3-475N16.1	-3.82	0.000154	0.0201	-0.18	-0.17	HDL cholesterol levels;	chr6:42025491	chr6:42940364~42948360:+
LUAD	cis	rs2486288	0.656	rs1060896	ENSG00000259479.5	SORD2P	-3.82	0.000154	0.0201	-0.21	-0.17	Glomerular filtration rate;	chr15:45262069	chr15:44826371~44884694:-
LUAD	cis	rs36093844	0.565	rs17744938	ENSG00000279742.1	RP11-700A24.1	-3.82	0.000154	0.0201	-0.2	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85965523	chr11:85852557~85854943:-
LUAD	cis	rs6964587	0.967	rs2188153	ENSG00000188693.7	CYP51A1-AS1	-3.82	0.000154	0.0201	-0.2	-0.17	Breast cancer;	chr7:91965803	chr7:92134604~92180725:+
LUAD	cis	rs4718428	0.662	rs34577323	ENSG00000230295.1	RP11-458F8.2	-3.82	0.000154	0.0201	-0.15	-0.17	Corneal structure;	chr7:66845054	chr7:66880708~66882981:+
LUAD	cis	rs7590268	0.789	rs35234516	ENSG00000279873.2	LINC01126	3.82	0.000154	0.0201	0.17	0.17	Orofacial clefts;	chr2:43415866	chr2:43227210~43228855:+
LUAD	cis	rs7772486	0.686	rs9390357	ENSG00000235652.6	RP11-545I5.3	3.82	0.000154	0.0201	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145808211	chr6:145799409~145886585:+
LUAD	cis	rs7712401	0.791	rs3822367	ENSG00000249996.1	RP11-359P5.1	-3.82	0.000154	0.0201	-0.21	-0.17	Mean platelet volume;	chr5:122810577	chr5:123036271~123054667:+
LUAD	cis	rs448720	1	rs440341	ENSG00000260657.2	RP11-315D16.4	-3.81	0.000154	0.0201	-0.19	-0.17	Cognitive performance;	chr15:67918621	chr15:68267792~68277994:-
LUAD	cis	rs780096	0.565	rs13022659	ENSG00000234072.1	AC074117.10	-3.81	0.000154	0.0201	-0.13	-0.17	Total body bone mineral density;	chr2:27520763	chr2:27356246~27367622:+
LUAD	cis	rs62458065	0.85	rs10239812	ENSG00000226468.2	AC018641.7	3.81	0.000154	0.0201	0.29	0.17	Metabolite levels (HVA/MHPG ratio);	chr7:32420736	chr7:32456963~32457758:-
LUAD	cis	rs860295	0.776	rs11264362	ENSG00000160766.13	GBAP1	3.81	0.000154	0.0201	0.18	0.17	Body mass index;	chr1:155345824	chr1:155213821~155227422:-
LUAD	cis	rs12440869	1	rs9806386	ENSG00000270964.1	RP11-502I4.3	-3.81	0.000154	0.0201	-0.2	-0.17	Peak velocity of the mitral A-wave;	chr15:67319831	chr15:67541072~67542604:-
LUAD	cis	rs4759375	1	rs11057223	ENSG00000235423.7	RP11-282O18.3	3.81	0.000154	0.0201	0.31	0.17	HDL cholesterol;	chr12:123270508	chr12:123252030~123261483:-
LUAD	cis	rs7960884	0.655	rs979063	ENSG00000177359.16	RP11-551L14.1	3.81	0.000154	0.0201	0.19	0.17	Systolic blood pressure response to hydrochlorothiazide in hypertension;	chr12:31229812	chr12:31111652~31206154:-
LUAD	cis	rs10936632	0.565	rs7610584	ENSG00000242578.1	RP11-469J4.3	-3.81	0.000154	0.0201	-0.19	-0.17	Prostate cancer;	chr3:170435395	chr3:170410512~170418615:+
LUAD	cis	rs2299587	0.585	rs394343	ENSG00000253671.1	RP11-806O11.1	-3.81	0.000154	0.0201	-0.19	-0.17	Economic and political preferences;	chr8:17915657	chr8:17808941~17820868:+
LUAD	cis	rs8002861	0.935	rs7319725	ENSG00000274001.1	RP11-5G9.5	3.81	0.000154	0.0202	0.18	0.17	Leprosy;	chr13:43871285	chr13:43877715~43878163:-
LUAD	cis	rs6951245	0.706	rs28483034	ENSG00000226291.1	AC091729.8	-3.81	0.000154	0.0202	-0.28	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1130535	chr7:1080863~1082178:+
LUAD	cis	rs6840258	0.891	rs17012512	ENSG00000251411.1	RP11-397E7.4	-3.81	0.000154	0.0202	-0.22	-0.17	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:87146352	chr4:86913266~86914817:-
LUAD	cis	rs6964587	1	rs17164263	ENSG00000188693.7	CYP51A1-AS1	3.81	0.000154	0.0202	0.2	0.17	Breast cancer;	chr7:91952252	chr7:92134604~92180725:+
LUAD	cis	rs8062405	1	rs4788095	ENSG00000261419.1	RP11-57A19.4	-3.81	0.000154	0.0202	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28659696~28740781:-
LUAD	cis	rs8062405	0.964	rs72793809	ENSG00000261419.1	RP11-57A19.4	-3.81	0.000154	0.0202	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28659696~28740781:-
LUAD	cis	rs8062405	1	rs62036620	ENSG00000261419.1	RP11-57A19.4	-3.81	0.000154	0.0202	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28659696~28740781:-
LUAD	cis	rs8062405	1	rs62036621	ENSG00000261419.1	RP11-57A19.4	-3.81	0.000154	0.0202	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28659696~28740781:-
LUAD	cis	rs12304921	0.639	rs2306732	ENSG00000277201.1	AC087884.1	3.81	0.000154	0.0202	0.17	0.17	Type 2 diabetes;	chr12:51061956	chr12:51049921~51050025:+
LUAD	cis	rs4784934	0.589	rs12932284	ENSG00000260186.4	RP11-481J2.2	3.81	0.000154	0.0202	0.2	0.17	QT interval;	chr16:58434675	chr16:58421326~58462470:+
LUAD	cis	rs5758659	0.622	rs6519298	ENSG00000182057.4	OGFRP1	3.81	0.000154	0.0202	0.21	0.17	Cognitive function;	chr22:41968993	chr22:42269753~42275196:+
LUAD	cis	rs13113518	0.783	rs6843722	ENSG00000273257.1	RP11-177J6.1	3.81	0.000154	0.0202	0.19	0.17	Height;	chr4:55465165	chr4:55387949~55388271:+
LUAD	cis	rs7829975	0.711	rs4841051	ENSG00000233609.3	RP11-62H7.2	-3.81	0.000154	0.0202	-0.14	-0.17	Mood instability;	chr8:8828136	chr8:8961200~8979025:+
LUAD	cis	rs7242404	0.57	rs11660242	ENSG00000267654.1	RP11-973H7.4	-3.81	0.000154	0.0202	-0.19	-0.17	Interleukin-9 levels;Macrophage inflammatory protein 1a levels;	chr18:12761429	chr18:12739490~12749421:-
LUAD	cis	rs7216064	1	rs8079754	ENSG00000266717.1	RP11-855A2.3	3.81	0.000154	0.0202	0.21	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67891780	chr17:67950885~67951746:-
LUAD	cis	rs4601821	0.858	rs2298489	ENSG00000270179.1	RP11-159N11.4	3.81	0.000154	0.0202	0.18	0.17	Alcoholic chronic pancreatitis;	chr11:113364697	chr11:113368478~113369117:+
LUAD	cis	rs9549260	0.755	rs7317254	ENSG00000229456.1	RLIMP1	3.81	0.000154	0.0202	0.19	0.17	Red blood cell count;	chr13:40643712	chr13:40618738~40621348:+
LUAD	cis	rs10758892	0.557	rs10739141	ENSG00000230581.2	ACTG1P14	3.81	0.000154	0.0202	0.37	0.17	Myopia (pathological);	chr9:7750727	chr9:6834456~6835577:+
LUAD	cis	rs8050896	1	rs9926420	ENSG00000260695.1	RP11-513N24.1	-3.81	0.000154	0.0202	-0.3	-0.17	Response to antipsychotic treatment;	chr16:66120672	chr16:65861112~65863784:-
LUAD	cis	rs6964587	1	rs2282974	ENSG00000188693.7	CYP51A1-AS1	-3.81	0.000154	0.0202	-0.2	-0.17	Breast cancer;	chr7:92132303	chr7:92134604~92180725:+
LUAD	cis	rs6964587	0.967	rs55801687	ENSG00000188693.7	CYP51A1-AS1	-3.81	0.000154	0.0202	-0.2	-0.17	Breast cancer;	chr7:92133315	chr7:92134604~92180725:+
LUAD	cis	rs7637701	0.967	rs10936043	ENSG00000240875.4	LINC00886	-3.81	0.000154	0.0202	-0.19	-0.17	Breast cancer;	chr3:156978717	chr3:156747346~156817062:-
LUAD	cis	rs34286592	0.929	rs1057451	ENSG00000214725.6	CDIPT-AS1	-3.81	0.000154	0.0202	-0.26	-0.17	Multiple sclerosis;	chr16:29822167	chr16:29863593~29868053:+
LUAD	cis	rs990171	0.513	rs6543152	ENSG00000234389.1	AC007278.3	3.81	0.000154	0.0202	0.17	0.17	Lymphocyte counts;	chr2:102497584	chr2:102438713~102440475:+
LUAD	cis	rs7246657	0.943	rs7255952	ENSG00000267470.4	ZNF571-AS1	3.81	0.000154	0.0202	0.24	0.17	Coronary artery calcification;	chr19:37497895	chr19:37548914~37587348:+
LUAD	cis	rs1476587	0.92	rs10480552	ENSG00000224046.1	AC005076.5	3.81	0.000154	0.0202	0.23	0.17	Brachial circumference;	chr7:87111546	chr7:87151423~87152420:-
LUAD	cis	rs2274273	0.622	rs11846809	ENSG00000258413.1	RP11-665C16.6	-3.81	0.000154	0.0202	-0.21	-0.17	Protein biomarker;	chr14:54935064	chr14:55262767~55272075:-
LUAD	cis	rs6964587	1	rs756647	ENSG00000188693.7	CYP51A1-AS1	-3.81	0.000154	0.0202	-0.2	-0.17	Breast cancer;	chr7:91957075	chr7:92134604~92180725:+
LUAD	cis	rs6964587	1	rs10235941	ENSG00000188693.7	CYP51A1-AS1	-3.81	0.000154	0.0202	-0.2	-0.17	Breast cancer;	chr7:91957736	chr7:92134604~92180725:+
LUAD	cis	rs911119	0.955	rs6114201	ENSG00000270001.1	RP11-218C14.8	-3.81	0.000155	0.0202	-0.25	-0.17	Chronic kidney disease;	chr20:23626594	chr20:23631826~23632316:-
LUAD	cis	rs911119	0.955	rs6048952	ENSG00000270001.1	RP11-218C14.8	-3.81	0.000155	0.0202	-0.25	-0.17	Chronic kidney disease;	chr20:23626620	chr20:23631826~23632316:-
LUAD	cis	rs9467773	0.62	rs6925087	ENSG00000241549.7	GUSBP2	3.81	0.000155	0.0202	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26592625	chr6:26871484~26956554:-
LUAD	cis	rs12935418	0.672	rs3784814	ENSG00000261061.1	RP11-303E16.2	-3.81	0.000155	0.0202	-0.19	-0.17	Mean corpuscular volume;	chr16:81007652	chr16:81030770~81031485:+
LUAD	cis	rs8012947	0.916	rs4901853	ENSG00000279636.2	LINC00216	3.81	0.000155	0.0202	0.19	0.17	Alcohol consumption in current drinkers;	chr14:58382581	chr14:58288033~58289158:+
LUAD	cis	rs34783982	0.96	rs12440184	ENSG00000261441.1	RP11-217B1.2	-3.81	0.000155	0.0202	-0.23	-0.17	Squamous cell lung carcinoma;	chr15:88964460	chr15:89335053~89336161:+
LUAD	cis	rs133885	0.696	rs133901	ENSG00000272977.1	CTA-390C10.10	3.81	0.000155	0.0202	0.2	0.17	Mathematical ability in children with dyslexia;	chr22:25768029	chr22:25476218~25479971:+
LUAD	cis	rs6088580	0.634	rs6088488	ENSG00000276073.1	RP5-1125A11.7	3.81	0.000155	0.0202	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34404825	chr20:33985617~33988989:-
LUAD	cis	rs6088580	0.634	rs4911418	ENSG00000276073.1	RP5-1125A11.7	3.81	0.000155	0.0202	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34406451	chr20:33985617~33988989:-
LUAD	cis	rs6088580	0.634	rs6579165	ENSG00000276073.1	RP5-1125A11.7	3.81	0.000155	0.0202	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34406909	chr20:33985617~33988989:-
LUAD	cis	rs6088580	0.634	rs4911419	ENSG00000276073.1	RP5-1125A11.7	3.81	0.000155	0.0202	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34408067	chr20:33985617~33988989:-
LUAD	cis	rs6088580	0.561	rs3761147	ENSG00000276073.1	RP5-1125A11.7	3.81	0.000155	0.0202	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34408883	chr20:33985617~33988989:-
LUAD	cis	rs6088580	0.634	rs4911421	ENSG00000276073.1	RP5-1125A11.7	3.81	0.000155	0.0202	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34411142	chr20:33985617~33988989:-
LUAD	cis	rs6088580	0.634	rs4911422	ENSG00000276073.1	RP5-1125A11.7	3.81	0.000155	0.0202	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34411539	chr20:33985617~33988989:-
LUAD	cis	rs6088580	0.634	rs2225837	ENSG00000276073.1	RP5-1125A11.7	3.81	0.000155	0.0202	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34417828	chr20:33985617~33988989:-
LUAD	cis	rs7246657	0.943	rs13343471	ENSG00000226686.6	LINC01535	-3.81	0.000155	0.0202	-0.28	-0.17	Coronary artery calcification;	chr19:37441228	chr19:37251912~37265535:+
LUAD	cis	rs8180040	0.966	rs13075233	ENSG00000271161.1	BOLA2P2	3.81	0.000155	0.0202	0.16	0.17	Colorectal cancer;	chr3:47379137	chr3:47499841~47500407:+
LUAD	cis	rs10752881	1	rs4233193	ENSG00000224468.3	RP11-181K3.4	-3.81	0.000155	0.0202	-0.15	-0.17	Colorectal cancer;	chr1:183001730	chr1:183138402~183141282:-
LUAD	cis	rs4795519	0.922	rs2061894	ENSG00000266313.1	RP11-173M1.4	3.81	0.000155	0.0202	0.21	0.17	Chronic myeloid leukemia;	chr17:27069208	chr17:27333256~27348491:+
LUAD	cis	rs7546668	1	rs4646061	ENSG00000272510.1	RP4-680D5.8	3.81	0.000155	0.0202	0.22	0.17	Glomerular filtration rate (creatinine);	chr1:15503421	chr1:15565611~15565956:-
LUAD	cis	rs17275866	0.963	rs873371	ENSG00000251584.1	RP11-440I14.3	3.81	0.000155	0.0202	0.23	0.17	Chin dimples;	chr4:174148404	chr4:174536640~174540784:+
LUAD	cis	rs17122278	0.722	rs60837962	ENSG00000243431.1	RPL5P30	3.81	0.000155	0.0202	0.22	0.17	Total cholesterol levels;	chr11:118567733	chr11:118560690~118561580:+
LUAD	cis	rs2919009	0.509	rs17100858	ENSG00000271670.1	RP11-95I16.4	3.81	0.000155	0.0202	0.21	0.17	Obesity-related traits;	chr10:120783858	chr10:120879256~120880667:-
LUAD	cis	rs7829975	0.514	rs2945873	ENSG00000173295.6	FAM86B3P	3.81	0.000155	0.0202	0.18	0.17	Mood instability;	chr8:8402935	chr8:8228595~8244865:+
LUAD	cis	rs12073359	0.954	rs12063059	ENSG00000223945.2	RP11-458I7.1	-3.81	0.000155	0.0202	-0.24	-0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150041153	chr1:150053864~150055034:+
LUAD	cis	rs12073359	1	rs12065681	ENSG00000223945.2	RP11-458I7.1	-3.81	0.000155	0.0202	-0.24	-0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150041680	chr1:150053864~150055034:+
LUAD	cis	rs12073359	1	rs12064532	ENSG00000223945.2	RP11-458I7.1	-3.81	0.000155	0.0202	-0.24	-0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150042102	chr1:150053864~150055034:+
LUAD	cis	rs12073359	1	rs72692865	ENSG00000223945.2	RP11-458I7.1	-3.81	0.000155	0.0202	-0.24	-0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150043194	chr1:150053864~150055034:+
LUAD	cis	rs12073359	0.909	rs12066132	ENSG00000223945.2	RP11-458I7.1	-3.81	0.000155	0.0202	-0.24	-0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150043281	chr1:150053864~150055034:+
LUAD	cis	rs12073359	1	rs12066293	ENSG00000223945.2	RP11-458I7.1	-3.81	0.000155	0.0202	-0.24	-0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150043653	chr1:150053864~150055034:+
LUAD	cis	rs12073359	1	rs12067422	ENSG00000223945.2	RP11-458I7.1	-3.81	0.000155	0.0202	-0.24	-0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150043833	chr1:150053864~150055034:+
LUAD	cis	rs12073359	1	rs72692866	ENSG00000223945.2	RP11-458I7.1	-3.81	0.000155	0.0202	-0.24	-0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150045258	chr1:150053864~150055034:+
LUAD	cis	rs12073359	1	rs11205319	ENSG00000223945.2	RP11-458I7.1	-3.81	0.000155	0.0202	-0.24	-0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150045847	chr1:150053864~150055034:+
LUAD	cis	rs12073359	1	rs28753817	ENSG00000223945.2	RP11-458I7.1	-3.81	0.000155	0.0202	-0.24	-0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150046397	chr1:150053864~150055034:+
LUAD	cis	rs12073359	1	rs9662055	ENSG00000223945.2	RP11-458I7.1	-3.81	0.000155	0.0202	-0.24	-0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150046744	chr1:150053864~150055034:+
LUAD	cis	rs12073359	1	rs72692869	ENSG00000223945.2	RP11-458I7.1	-3.81	0.000155	0.0202	-0.24	-0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150047061	chr1:150053864~150055034:+
LUAD	cis	rs6964587	0.967	rs10279943	ENSG00000188693.7	CYP51A1-AS1	-3.81	0.000155	0.0202	-0.2	-0.17	Breast cancer;	chr7:91958163	chr7:92134604~92180725:+
LUAD	cis	rs6964587	0.967	rs6465341	ENSG00000188693.7	CYP51A1-AS1	-3.81	0.000155	0.0202	-0.2	-0.17	Breast cancer;	chr7:91966807	chr7:92134604~92180725:+
LUAD	cis	rs8067545	0.641	rs1479129	ENSG00000270091.1	RP11-78O7.2	-3.81	0.000155	0.0202	-0.15	-0.17	Schizophrenia;	chr17:19942456	chr17:19896590~19897287:-
LUAD	cis	rs7660883	0.897	rs2125787	ENSG00000251411.1	RP11-397E7.4	3.81	0.000155	0.0202	0.18	0.17	HDL cholesterol levels;	chr4:87075471	chr4:86913266~86914817:-
LUAD	cis	rs72615157	0.612	rs7786505	ENSG00000078319.8	PMS2P1	-3.81	0.000155	0.0202	-0.2	-0.17	Lung function (FEV1/FVC);	chr7:100219962	chr7:100320992~100341908:-
LUAD	cis	rs7246657	0.653	rs10414983	ENSG00000267309.1	CTD-2630F21.1	3.81	0.000155	0.0202	0.28	0.17	Coronary artery calcification;	chr19:37174830	chr19:36489649~36491040:+
LUAD	cis	rs7246657	0.598	rs10405372	ENSG00000267309.1	CTD-2630F21.1	3.81	0.000155	0.0202	0.28	0.17	Coronary artery calcification;	chr19:37177873	chr19:36489649~36491040:+
LUAD	cis	rs7246657	0.653	rs10425441	ENSG00000267309.1	CTD-2630F21.1	3.81	0.000155	0.0202	0.28	0.17	Coronary artery calcification;	chr19:37179746	chr19:36489649~36491040:+
LUAD	cis	rs7246657	0.653	rs4805207	ENSG00000267309.1	CTD-2630F21.1	3.81	0.000155	0.0202	0.28	0.17	Coronary artery calcification;	chr19:37182831	chr19:36489649~36491040:+
LUAD	cis	rs1056107	0.831	rs10125827	ENSG00000225513.1	RP11-165N19.2	3.81	0.000155	0.0202	0.18	0.17	Colorectal cancer;	chr9:112182226	chr9:112173522~112173971:-
LUAD	cis	rs9633740	1	rs10748526	ENSG00000226659.1	RP11-137H2.4	-3.81	0.000155	0.0202	-0.27	-0.17	Post bronchodilator FEV1;	chr10:80513323	chr10:80529597~80535942:-
LUAD	cis	rs4819052	0.54	rs7282639	ENSG00000223768.1	LINC00205	3.81	0.000155	0.0202	0.21	0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45071240	chr21:45293285~45297354:+
LUAD	cis	rs13113518	0.812	rs11945371	ENSG00000273257.1	RP11-177J6.1	3.81	0.000155	0.0202	0.19	0.17	Height;	chr4:55409063	chr4:55387949~55388271:+
LUAD	cis	rs11853189	1	rs11853189	ENSG00000259562.2	RP11-762H8.2	3.81	0.000155	0.0202	0.19	0.17	Red cell distribution width;	chr15:78273478	chr15:78290527~78291221:-
LUAD	cis	rs8062405	0.755	rs56209193	ENSG00000251417.2	RP11-1348G14.4	-3.81	0.000155	0.0202	-0.18	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28802743~28817828:+
LUAD	cis	rs6964587	1	rs415	ENSG00000188693.7	CYP51A1-AS1	3.81	0.000155	0.0202	0.2	0.17	Breast cancer;	chr7:91951176	chr7:92134604~92180725:+
LUAD	cis	rs516805	0.923	rs538457	ENSG00000279114.1	RP3-425C14.5	-3.81	0.000155	0.0202	-0.19	-0.17	Lymphocyte counts;	chr6:122485610	chr6:122471923~122484161:+
LUAD	cis	rs12908161	0.853	rs12912342	ENSG00000230373.7	GOLGA6L5P	-3.81	0.000155	0.0202	-0.18	-0.17	Schizophrenia;	chr15:84704985	chr15:84507885~84516814:-
LUAD	cis	rs2554380	0.55	rs62025831	ENSG00000259570.1	RP11-671M22.4	-3.81	0.000155	0.0202	-0.23	-0.17	Height;	chr15:83876933	chr15:84394512~84395514:+
LUAD	cis	rs9341808	0.667	rs10943698	ENSG00000260645.1	RP11-250B2.5	3.81	0.000155	0.0202	0.16	0.17	Sitting height ratio;	chr6:80224584	chr6:80466958~80469080:+
LUAD	cis	rs7618915	0.547	rs8906	ENSG00000243224.1	RP5-1157M23.2	-3.81	0.000155	0.0202	-0.18	-0.17	Bipolar disorder;	chr3:52705504	chr3:52239258~52241097:+
LUAD	cis	rs7616559	0.53	rs7616314	ENSG00000240875.4	LINC00886	3.81	0.000155	0.0202	0.18	0.17	Carotid artery intima media thickness (sex interaction);	chr3:157010741	chr3:156747346~156817062:-
LUAD	cis	rs17507216	0.56	rs2871011	ENSG00000255769.6	GOLGA2P10	-3.81	0.000155	0.0203	-0.18	-0.17	Excessive daytime sleepiness;	chr15:82560792	chr15:82472993~82513950:-
LUAD	cis	rs11637445	0.677	rs12441598	ENSG00000270964.1	RP11-502I4.3	3.81	0.000155	0.0203	0.19	0.17	Posterior cortical atrophy and Alzheimer's disease;	chr15:67780867	chr15:67541072~67542604:-
LUAD	cis	rs2286720	1	rs2286719	ENSG00000173811.9	CCDC13-AS1	3.81	0.000155	0.0203	0.3	0.17	Response to antipsychotic treatment in schizophrenia (reasoning);	chr3:42404948	chr3:42732575~42746768:+
LUAD	cis	rs950880	0.767	rs6710885	ENSG00000234389.1	AC007278.3	3.81	0.000155	0.0203	0.16	0.17	Serum protein levels (sST2);	chr2:102361077	chr2:102438713~102440475:+
LUAD	cis	rs4144027	0.791	rs67727470	ENSG00000258914.1	CTD-2134A5.3	-3.81	0.000155	0.0203	-0.2	-0.17	Blood metabolite levels;	chr14:103895659	chr14:103875055~103877478:+
LUAD	cis	rs2638953	0.924	rs11049405	ENSG00000278733.1	RP11-425D17.1	-3.81	0.000155	0.0203	-0.21	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28181003	chr12:28185625~28186190:-
LUAD	cis	rs647161	0.616	rs57804432	ENSG00000247627.2	MTND4P12	-3.81	0.000155	0.0203	-0.21	-0.17	Colorectal cancer;	chr5:135143533	chr5:134926660~134928036:-
LUAD	cis	rs12908161	1	rs35630683	ENSG00000254414.1	RP11-182J1.1	3.81	0.000155	0.0203	0.22	0.17	Schizophrenia;	chr15:84806000	chr15:84631898~84633987:-
LUAD	cis	rs853679	0.517	rs9468298	ENSG00000280107.1	AL022393.9	-3.81	0.000155	0.0203	-0.23	-0.17	Depression;	chr6:28154567	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs9295759	ENSG00000280107.1	AL022393.9	-3.81	0.000155	0.0203	-0.23	-0.17	Depression;	chr6:28156691	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs9348796	ENSG00000280107.1	AL022393.9	-3.81	0.000155	0.0203	-0.23	-0.17	Depression;	chr6:28158424	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs11552219	ENSG00000280107.1	AL022393.9	-3.81	0.000155	0.0203	-0.23	-0.17	Depression;	chr6:28159056	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs9380058	ENSG00000280107.1	AL022393.9	-3.81	0.000155	0.0203	-0.23	-0.17	Depression;	chr6:28159666	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs9393895	ENSG00000280107.1	AL022393.9	-3.81	0.000155	0.0203	-0.23	-0.17	Depression;	chr6:28159843	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs9357066	ENSG00000280107.1	AL022393.9	-3.81	0.000155	0.0203	-0.23	-0.17	Depression;	chr6:28162053	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs9393898	ENSG00000280107.1	AL022393.9	-3.81	0.000155	0.0203	-0.23	-0.17	Depression;	chr6:28162598	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs9368556	ENSG00000280107.1	AL022393.9	-3.81	0.000155	0.0203	-0.23	-0.17	Depression;	chr6:28163375	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs9368557	ENSG00000280107.1	AL022393.9	-3.81	0.000155	0.0203	-0.23	-0.17	Depression;	chr6:28163759	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs9380059	ENSG00000280107.1	AL022393.9	-3.81	0.000155	0.0203	-0.23	-0.17	Depression;	chr6:28164580	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs9380060	ENSG00000280107.1	AL022393.9	-3.81	0.000155	0.0203	-0.23	-0.17	Depression;	chr6:28164825	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs35227624	ENSG00000280107.1	AL022393.9	-3.81	0.000155	0.0203	-0.23	-0.17	Depression;	chr6:28164948	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs9380061	ENSG00000280107.1	AL022393.9	-3.81	0.000155	0.0203	-0.23	-0.17	Depression;	chr6:28165025	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs9368558	ENSG00000280107.1	AL022393.9	-3.81	0.000155	0.0203	-0.23	-0.17	Depression;	chr6:28165528	chr6:28170845~28172521:+
LUAD	cis	rs4713118	0.587	rs9393899	ENSG00000280107.1	AL022393.9	-3.81	0.000155	0.0203	-0.23	-0.17	Parkinson's disease;	chr6:28165750	chr6:28170845~28172521:+
LUAD	cis	rs4713118	0.527	rs4713151	ENSG00000280107.1	AL022393.9	-3.81	0.000155	0.0203	-0.23	-0.17	Parkinson's disease;	chr6:28168578	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs9393901	ENSG00000280107.1	AL022393.9	-3.81	0.000155	0.0203	-0.23	-0.17	Depression;	chr6:28169019	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs3173443	ENSG00000280107.1	AL022393.9	-3.81	0.000155	0.0203	-0.23	-0.17	Depression;	chr6:28169249	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs9348797	ENSG00000280107.1	AL022393.9	-3.81	0.000155	0.0203	-0.23	-0.17	Depression;	chr6:28169755	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.517	rs9380062	ENSG00000280107.1	AL022393.9	-3.81	0.000155	0.0203	-0.23	-0.17	Depression;	chr6:28169791	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.542	rs9380063	ENSG00000280107.1	AL022393.9	-3.81	0.000155	0.0203	-0.23	-0.17	Depression;	chr6:28170075	chr6:28170845~28172521:+
LUAD	cis	rs12681963	0.702	rs2136958	ENSG00000272375.1	RP11-51J9.6	3.81	0.000155	0.0203	0.21	0.17	Migraine;	chr8:30054156	chr8:30197404~30198048:+
LUAD	cis	rs1400816	0.85	rs16859721	ENSG00000228389.1	AC068039.4	-3.81	0.000155	0.0203	-0.28	-0.17	Amyotrophic lateral sclerosis (sporadic);	chr2:171679662	chr2:171773482~171775844:+
LUAD	cis	rs1023500	0.529	rs133375	ENSG00000273366.1	CTA-989H11.1	-3.81	0.000155	0.0203	-0.2	-0.17	Schizophrenia;	chr22:42070505	chr22:42278188~42278846:+
LUAD	cis	rs987044	0.726	rs10746130	ENSG00000257221.1	RP11-689B22.2	3.81	0.000155	0.0203	0.14	0.17	Mean platelet volume;	chr12:108720305	chr12:108628687~108641318:+
LUAD	cis	rs3018712	0.532	rs7116363	ENSG00000212093.1	AP000807.1	-3.81	0.000155	0.0203	-0.22	-0.17	Total body bone mineral density;	chr11:68645330	chr11:68506083~68506166:-
LUAD	cis	rs137603	0.562	rs470080	ENSG00000230149.2	RP3-508I15.19	-3.81	0.000155	0.0203	-0.14	-0.17	Primary biliary cholangitis;	chr22:39316363	chr22:38734730~38738990:+
LUAD	cis	rs6142102	0.812	rs725478	ENSG00000275784.1	RP5-1125A11.6	3.81	0.000155	0.0203	0.19	0.17	Skin pigmentation;	chr20:33930548	chr20:33989480~33991818:-
LUAD	cis	rs6832769	0.922	rs819271	ENSG00000272969.1	RP11-528I4.2	3.81	0.000155	0.0203	0.19	0.17	Personality dimensions;	chr4:55372680	chr4:55547112~55547889:+
LUAD	cis	rs683250	0.629	rs524441	ENSG00000246067.6	RAB30-AS1	3.81	0.000155	0.0203	0.18	0.17	Subcortical brain region volumes;	chr11:83250016	chr11:83072066~83106719:+
LUAD	cis	rs8002861	0.869	rs7989857	ENSG00000274001.1	RP11-5G9.5	3.81	0.000155	0.0203	0.18	0.17	Leprosy;	chr13:43889954	chr13:43877715~43878163:-
LUAD	cis	rs8002861	0.902	rs1445557	ENSG00000274001.1	RP11-5G9.5	3.81	0.000155	0.0203	0.18	0.17	Leprosy;	chr13:43890691	chr13:43877715~43878163:-
LUAD	cis	rs12935229	1	rs17712992	ENSG00000261330.1	RP11-281J9.1	3.81	0.000155	0.0203	0.25	0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77292494	chr16:77892422~77892915:+
LUAD	cis	rs1383484	0.606	rs9329364	ENSG00000259728.4	LINC00933	-3.81	0.000155	0.0203	-0.22	-0.17	Height;	chr15:83974490	chr15:84570649~84580175:+
LUAD	cis	rs12073359	0.954	rs12061856	ENSG00000223945.2	RP11-458I7.1	-3.81	0.000155	0.0203	-0.25	-0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150029941	chr1:150053864~150055034:+
LUAD	cis	rs4664293	0.632	rs2059697	ENSG00000226266.5	AC009961.3	3.81	0.000155	0.0203	0.22	0.17	Monocyte percentage of white cells;	chr2:159799079	chr2:159670708~159712435:-
LUAD	cis	rs858239	0.806	rs10268610	ENSG00000230042.1	AK3P3	-3.81	0.000155	0.0203	-0.22	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23235145	chr7:23129178~23129841:+
LUAD	cis	rs858239	0.6	rs9691762	ENSG00000226816.2	AC005082.12	3.81	0.000155	0.0203	0.23	0.17	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23206013~23208045:+
LUAD	cis	rs10090774	0.804	rs4355822	ENSG00000280303.2	ERICD	3.81	0.000155	0.0203	0.19	0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140736225	chr8:140636281~140638283:+
LUAD	cis	rs2921073	0.51	rs2976945	ENSG00000233609.3	RP11-62H7.2	3.81	0.000156	0.0203	0.14	0.17	Parkinson's disease;	chr8:8413361	chr8:8961200~8979025:+
LUAD	cis	rs7615952	0.543	rs4645102	ENSG00000171084.14	FAM86JP	3.81	0.000156	0.0203	0.22	0.17	Blood pressure (smoking interaction);	chr3:125705597	chr3:125916620~125930024:+
LUAD	cis	rs7394190	1	rs7394190	ENSG00000271848.1	RP11-464F9.21	-3.81	0.000156	0.0203	-0.22	-0.17	Incident atrial fibrillation;	chr10:73661890	chr10:73654039~73674719:+
LUAD	cis	rs7615952	0.599	rs6438953	ENSG00000241288.6	RP11-379B18.5	-3.81	0.000156	0.0203	-0.21	-0.17	Blood pressure (smoking interaction);	chr3:126006108	chr3:125827238~125916384:-
LUAD	cis	rs7615952	0.599	rs1044215	ENSG00000241288.6	RP11-379B18.5	-3.81	0.000156	0.0203	-0.21	-0.17	Blood pressure (smoking interaction);	chr3:126006716	chr3:125827238~125916384:-
LUAD	cis	rs6095360	1	rs6095360	ENSG00000222365.1	SNORD12B	-3.81	0.000156	0.0203	-0.17	-0.17	Intelligence (multi-trait analysis);	chr20:48915999	chr20:49280319~49280409:+
LUAD	cis	rs62355901	0.545	rs57850701	ENSG00000271828.1	CTD-2310F14.1	3.81	0.000156	0.0203	0.33	0.17	Breast cancer;	chr5:56728529	chr5:56927874~56929573:+
LUAD	cis	rs67478160	0.619	rs11628481	ENSG00000272533.1	SNORA28	3.81	0.000156	0.0203	0.18	0.17	Schizophrenia;	chr14:103775162	chr14:103337849~103337974:+
LUAD	cis	rs12908161	0.96	rs11633450	ENSG00000259295.5	CSPG4P12	3.81	0.000156	0.0203	0.24	0.17	Schizophrenia;	chr15:84764056	chr15:85191438~85213905:+
LUAD	cis	rs7107174	0.748	rs7105835	ENSG00000251323.2	RP11-452H21.4	3.81	0.000156	0.0203	0.21	0.17	Testicular germ cell tumor;	chr11:78364679	chr11:78423982~78429836:-
LUAD	cis	rs9549260	0.755	rs2701863	ENSG00000229456.1	RLIMP1	3.81	0.000156	0.0203	0.19	0.17	Red blood cell count;	chr13:40596003	chr13:40618738~40621348:+
LUAD	cis	rs638893	1	rs583905	ENSG00000255239.1	AP002954.6	3.81	0.000156	0.0203	0.28	0.17	Vitiligo;	chr11:118825199	chr11:118688039~118690600:-
LUAD	cis	rs683250	0.629	rs509815	ENSG00000246067.6	RAB30-AS1	3.81	0.000156	0.0203	0.18	0.17	Subcortical brain region volumes;	chr11:83280450	chr11:83072066~83106719:+
LUAD	cis	rs683250	0.629	rs682579	ENSG00000246067.6	RAB30-AS1	3.81	0.000156	0.0203	0.18	0.17	Subcortical brain region volumes;	chr11:83284862	chr11:83072066~83106719:+
LUAD	cis	rs4144027	0.791	rs66473563	ENSG00000258534.1	CTD-2134A5.4	-3.81	0.000156	0.0203	-0.19	-0.17	Blood metabolite levels;	chr14:103895534	chr14:103854366~103880111:-
LUAD	cis	rs5015933	0.815	rs10819044	ENSG00000232630.1	PRPS1P2	-3.81	0.000156	0.0203	-0.16	-0.17	Body mass index;	chr9:125278750	chr9:125150653~125151589:+
LUAD	cis	rs2274273	0.638	rs3825614	ENSG00000258413.1	RP11-665C16.6	-3.81	0.000156	0.0203	-0.24	-0.17	Protein biomarker;	chr14:55262669	chr14:55262767~55272075:-
LUAD	cis	rs11673344	0.523	rs8108509	ENSG00000276846.1	CTD-3220F14.3	3.81	0.000156	0.0203	0.19	0.17	Obesity-related traits;	chr19:37060370	chr19:37314868~37315620:-
LUAD	cis	rs3617	0.591	rs11918800	ENSG00000242142.1	SERBP1P3	-3.81	0.000156	0.0203	-0.18	-0.17	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52834129	chr3:53064283~53065091:-
LUAD	cis	rs8002861	0.967	rs9525871	ENSG00000274001.1	RP11-5G9.5	3.81	0.000156	0.0203	0.18	0.17	Leprosy;	chr13:43903576	chr13:43877715~43878163:-
LUAD	cis	rs854765	0.604	rs12948749	ENSG00000223979.2	SMCR2	3.81	0.000156	0.0203	0.2	0.17	Total body bone mineral density;	chr17:18046488	chr17:17674026~17677688:-
LUAD	cis	rs2239547	0.563	rs9876403	ENSG00000243224.1	RP5-1157M23.2	-3.81	0.000156	0.0203	-0.19	-0.17	Schizophrenia;	chr3:52882900	chr3:52239258~52241097:+
LUAD	cis	rs2039553	0.87	rs1577404	ENSG00000227676.3	LINC01068	-3.81	0.000156	0.0203	-0.2	-0.17	Pancreatic cancer;	chr13:79736636	chr13:79566727~79571436:+
LUAD	cis	rs683250	0.598	rs626875	ENSG00000246067.6	RAB30-AS1	-3.81	0.000156	0.0203	-0.18	-0.17	Subcortical brain region volumes;	chr11:83304206	chr11:83072066~83106719:+
LUAD	cis	rs2227564	0.649	rs2688626	ENSG00000271816.1	BMS1P4	3.81	0.000156	0.0203	0.17	0.17	Crohn's disease;Inflammatory bowel disease;	chr10:73851332	chr10:73699151~73730487:-
LUAD	cis	rs8180040	0.764	rs11716539	ENSG00000271161.1	BOLA2P2	3.81	0.000156	0.0203	0.16	0.17	Colorectal cancer;	chr3:47145013	chr3:47499841~47500407:+
LUAD	cis	rs11018904	0.906	rs61903722	ENSG00000280367.1	RP11-121L10.2	3.81	0.000156	0.0203	0.22	0.17	Intelligence (multi-trait analysis);	chr11:90233874	chr11:90223153~90226538:+
LUAD	cis	rs6951245	0.58	rs10257426	ENSG00000226291.1	AC091729.8	-3.81	0.000156	0.0203	-0.27	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1174058	chr7:1080863~1082178:+
LUAD	cis	rs2288073	0.965	rs10173173	ENSG00000223754.1	AC008073.9	-3.81	0.000156	0.0203	-0.22	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr2:24192592	chr2:24199839~24201698:-
LUAD	cis	rs4716602	0.596	rs10458244	ENSG00000235029.1	MNX1-AS2	-3.81	0.000156	0.0203	-0.21	-0.17	Anti-saccade response;	chr7:156371591	chr7:157006307~157007132:+
LUAD	cis	rs7429990	0.965	rs4599334	ENSG00000228638.1	FCF1P2	3.81	0.000156	0.0203	0.21	0.17	Educational attainment (years of education);	chr3:48024910	chr3:48290793~48291375:-
LUAD	cis	rs6964587	1	rs6956431	ENSG00000188693.7	CYP51A1-AS1	-3.81	0.000156	0.0203	-0.2	-0.17	Breast cancer;	chr7:92120702	chr7:92134604~92180725:+
LUAD	cis	rs137603	0.623	rs137657	ENSG00000235209.1	CTA-150C2.13	-3.81	0.000156	0.0203	-0.18	-0.17	Primary biliary cholangitis;	chr22:39337237	chr22:38921227~38924708:+
LUAD	cis	rs9487094	0.922	rs9487098	ENSG00000260273.1	RP11-425D10.10	3.81	0.000156	0.0203	0.23	0.17	Height;	chr6:109422189	chr6:109382795~109383666:+
LUAD	cis	rs526231	0.782	rs434816	ENSG00000175749.11	EIF3KP1	3.81	0.000156	0.0203	0.23	0.17	Primary biliary cholangitis;	chr5:103263627	chr5:103032376~103033031:+
LUAD	cis	rs9341808	0.538	rs613588	ENSG00000260645.1	RP11-250B2.5	-3.81	0.000156	0.0203	-0.17	-0.17	Sitting height ratio;	chr6:80269211	chr6:80466958~80469080:+
LUAD	cis	rs412658	0.535	rs1651558	ENSG00000269345.1	VN1R85P	-3.81	0.000156	0.0203	-0.2	-0.17	Telomere length;	chr19:21906773	chr19:22174766~22175191:-
LUAD	cis	rs10463554	1	rs3776862	ENSG00000250682.4	LINC00491	3.81	0.000156	0.0204	0.2	0.17	Parkinson's disease;	chr5:102996017	chr5:102609156~102671559:-
LUAD	cis	rs11051970	0.879	rs2651362	ENSG00000274964.1	RP11-817I4.1	-3.81	0.000156	0.0204	-0.18	-0.17	Response to tocilizumab in rheumatoid arthritis;	chr12:32434917	chr12:32339368~32340724:+
LUAD	cis	rs11051970	0.879	rs950080	ENSG00000274964.1	RP11-817I4.1	-3.81	0.000156	0.0204	-0.18	-0.17	Response to tocilizumab in rheumatoid arthritis;	chr12:32435569	chr12:32339368~32340724:+
LUAD	cis	rs11051970	0.879	rs950079	ENSG00000274964.1	RP11-817I4.1	-3.81	0.000156	0.0204	-0.18	-0.17	Response to tocilizumab in rheumatoid arthritis;	chr12:32435686	chr12:32339368~32340724:+
LUAD	cis	rs7560272	0.723	rs7585119	ENSG00000163016.8	ALMS1P	3.81	0.000156	0.0204	0.19	0.17	Schizophrenia;	chr2:73497552	chr2:73644919~73685576:+
LUAD	cis	rs12935418	0.523	rs2549840	ENSG00000261061.1	RP11-303E16.2	3.81	0.000156	0.0204	0.18	0.17	Mean corpuscular volume;	chr16:80989817	chr16:81030770~81031485:+
LUAD	cis	rs6964587	1	rs411	ENSG00000188693.7	CYP51A1-AS1	3.81	0.000156	0.0204	0.2	0.17	Breast cancer;	chr7:91928444	chr7:92134604~92180725:+
LUAD	cis	rs6964587	0.967	rs10246036	ENSG00000188693.7	CYP51A1-AS1	3.81	0.000156	0.0204	0.2	0.17	Breast cancer;	chr7:91929209	chr7:92134604~92180725:+
LUAD	cis	rs6964587	0.967	rs12671991	ENSG00000188693.7	CYP51A1-AS1	3.81	0.000156	0.0204	0.2	0.17	Breast cancer;	chr7:91930167	chr7:92134604~92180725:+
LUAD	cis	rs61160187	0.582	rs28436304	ENSG00000215032.2	GNL3LP1	3.81	0.000156	0.0204	0.21	0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:61038584	chr5:60891935~60893577:-
LUAD	cis	rs2031365	0.727	rs9294363	ENSG00000216990.2	HSPD1P10	3.81	0.000156	0.0204	0.24	0.17	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);	chr6:87080342	chr6:87298772~87300447:+
LUAD	cis	rs4835473	0.832	rs35398499	ENSG00000249741.2	RP11-673E1.3	3.81	0.000156	0.0204	0.21	0.17	Immature fraction of reticulocytes;	chr4:143737715	chr4:143911514~143912053:-
LUAD	cis	rs4835473	0.832	rs35763177	ENSG00000249741.2	RP11-673E1.3	3.81	0.000156	0.0204	0.21	0.17	Immature fraction of reticulocytes;	chr4:143737717	chr4:143911514~143912053:-
LUAD	cis	rs1355223	0.867	rs2281908	ENSG00000271369.1	RP11-350D17.3	-3.81	0.000156	0.0204	-0.2	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34662031	chr11:34709600~34710161:+
LUAD	cis	rs9341808	0.667	rs742833	ENSG00000272129.1	RP11-250B2.6	3.81	0.000156	0.0204	0.21	0.17	Sitting height ratio;	chr6:80211729	chr6:80355424~80356859:+
LUAD	cis	rs7577696	0.813	rs212723	ENSG00000276334.1	AL133243.1	3.81	0.000156	0.0204	0.2	0.17	Inflammatory biomarkers;	chr2:32242079	chr2:32521927~32523547:+
LUAD	cis	rs11064837	0.504	rs11064845	ENSG00000248636.5	RP11-768F21.1	-3.81	0.000156	0.0204	-0.2	-0.17	Schizophrenia;	chr12:119614124	chr12:119387987~119668079:-
LUAD	cis	rs6547741	1	rs6737921	ENSG00000223522.1	AC093690.1	3.81	0.000156	0.0204	0.16	0.17	Oral cavity cancer;	chr2:27616240	chr2:28307691~28310459:-
LUAD	cis	rs3788317	0.526	rs879033	ENSG00000232926.1	AC000078.5	-3.81	0.000156	0.0204	-0.19	-0.17	Glaucoma (primary angle closure);	chr22:19896516	chr22:19887289~19887970:+
LUAD	cis	rs2836974	0.831	rs2836964	ENSG00000232608.1	TIMM9P2	-3.81	0.000156	0.0204	-0.2	-0.17	Cognitive function;	chr21:39259080	chr21:39216624~39217506:+
LUAD	cis	rs17711722	0.701	rs4467826	ENSG00000222364.1	RNU6-96P	-3.81	0.000156	0.0204	-0.19	-0.17	Calcium levels;	chr7:65903721	chr7:66395191~66395286:+
LUAD	cis	rs8049040	0.524	rs12445377	ENSG00000260886.1	TAT-AS1	3.81	0.000156	0.0204	0.21	0.17	Blood protein levels;	chr16:71394698	chr16:71565789~71578187:+
LUAD	cis	rs8049040	0.524	rs12445403	ENSG00000260886.1	TAT-AS1	3.81	0.000156	0.0204	0.21	0.17	Blood protein levels;	chr16:71394767	chr16:71565789~71578187:+
LUAD	cis	rs6964587	0.869	rs10250641	ENSG00000188693.7	CYP51A1-AS1	-3.81	0.000156	0.0204	-0.2	-0.17	Breast cancer;	chr7:91861432	chr7:92134604~92180725:+
LUAD	cis	rs7200543	1	rs16966947	ENSG00000260735.1	RP11-72I8.1	-3.81	0.000156	0.0204	-0.19	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15047188	chr16:15094411~15109197:+
LUAD	cis	rs6933660	0.745	rs3778608	ENSG00000219395.2	HSPA8P15	-3.81	0.000156	0.0204	-0.16	-0.17	Menarche (age at onset);	chr6:151416996	chr6:151411259~151413945:-
LUAD	cis	rs2274273	0.661	rs8019978	ENSG00000259318.1	RP11-454L9.2	-3.81	0.000156	0.0204	-0.15	-0.17	Protein biomarker;	chr14:55090566	chr14:55394940~55395233:-
LUAD	cis	rs755249	0.567	rs16825939	ENSG00000182109.6	RP11-69E11.4	3.81	0.000156	0.0204	0.21	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39196836	chr1:39522280~39546187:-
LUAD	cis	rs755249	0.567	rs67020650	ENSG00000182109.6	RP11-69E11.4	3.81	0.000156	0.0204	0.21	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39202343	chr1:39522280~39546187:-
LUAD	cis	rs755249	0.567	rs72661925	ENSG00000182109.6	RP11-69E11.4	3.81	0.000156	0.0204	0.21	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39203865	chr1:39522280~39546187:-
LUAD	cis	rs7512552	0.724	rs7002	ENSG00000275557.1	RP11-353N4.6	3.81	0.000156	0.0204	0.19	0.17	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150473343	chr1:149607765~149612402:+
LUAD	cis	rs909814	0.965	rs2744744	ENSG00000231105.1	RP5-1071N3.1	-3.81	0.000156	0.0204	-0.17	-0.17	Testosterone levels;IgG glycosylation;	chr1:22242254	chr1:21293290~21299774:+
LUAD	cis	rs8180040	0.966	rs13064843	ENSG00000271161.1	BOLA2P2	3.81	0.000156	0.0204	0.16	0.17	Colorectal cancer;	chr3:47373977	chr3:47499841~47500407:+
LUAD	cis	rs8180040	0.966	rs6787422	ENSG00000271161.1	BOLA2P2	3.81	0.000156	0.0204	0.16	0.17	Colorectal cancer;	chr3:47377019	chr3:47499841~47500407:+
LUAD	cis	rs12935418	0.583	rs2167889	ENSG00000261061.1	RP11-303E16.2	3.81	0.000156	0.0204	0.18	0.17	Mean corpuscular volume;	chr16:80987867	chr16:81030770~81031485:+
LUAD	cis	rs12935418	0.552	rs2911148	ENSG00000261061.1	RP11-303E16.2	3.81	0.000156	0.0204	0.18	0.17	Mean corpuscular volume;	chr16:80988289	chr16:81030770~81031485:+
LUAD	cis	rs12935418	0.552	rs2549833	ENSG00000261061.1	RP11-303E16.2	3.81	0.000156	0.0204	0.18	0.17	Mean corpuscular volume;	chr16:80988627	chr16:81030770~81031485:+
LUAD	cis	rs12935418	0.552	rs2602448	ENSG00000261061.1	RP11-303E16.2	3.81	0.000156	0.0204	0.18	0.17	Mean corpuscular volume;	chr16:80989067	chr16:81030770~81031485:+
LUAD	cis	rs262150	1	rs262149	ENSG00000231419.5	LINC00689	3.81	0.000156	0.0204	0.2	0.17	Facial morphology (factor 20);	chr7:158985565	chr7:159006522~159030195:+
LUAD	cis	rs17818399	0.547	rs4952833	ENSG00000279254.1	RP11-536C12.1	-3.81	0.000156	0.0204	-0.21	-0.17	Height;	chr2:46534895	chr2:46668870~46670778:+
LUAD	cis	rs638893	0.617	rs7116715	ENSG00000255422.1	AP002954.4	-3.81	0.000156	0.0204	-0.24	-0.17	Vitiligo;	chr11:118849033	chr11:118704607~118750263:+
LUAD	cis	rs73108077	1	rs73108095	ENSG00000281376.1	ABALON	-3.81	0.000156	0.0204	-0.3	-0.17	Red blood cell density in sickle cell anemia;	chr20:31428519	chr20:31721507~31723409:+
LUAD	cis	rs73108077	0.915	rs73110028	ENSG00000281376.1	ABALON	-3.81	0.000156	0.0204	-0.3	-0.17	Red blood cell density in sickle cell anemia;	chr20:31439633	chr20:31721507~31723409:+
LUAD	cis	rs28472312	0.723	rs11150675	ENSG00000246465.1	RP11-57A19.2	3.81	0.000156	0.0204	0.2	0.17	Intelligence (multi-trait analysis);	chr16:28969210	chr16:28284885~28292064:-
LUAD	cis	rs28472312	0.685	rs4788111	ENSG00000246465.1	RP11-57A19.2	3.81	0.000156	0.0204	0.2	0.17	Intelligence (multi-trait analysis);	chr16:28969372	chr16:28284885~28292064:-
LUAD	cis	rs4237845	0.837	rs7963992	ENSG00000257159.1	RP11-58A17.3	3.81	0.000156	0.0204	0.2	0.17	Intelligence (multi-trait analysis);	chr12:57902166	chr12:57967058~57968399:+
LUAD	cis	rs61160187	0.583	rs6449503	ENSG00000272308.1	RP11-231G3.1	3.81	0.000156	0.0204	0.18	0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:60799445	chr5:60866457~60866935:-
LUAD	cis	rs73108077	1	rs73116264	ENSG00000281376.1	ABALON	-3.81	0.000157	0.0204	-0.3	-0.17	Red blood cell density in sickle cell anemia;	chr20:31456926	chr20:31721507~31723409:+
LUAD	cis	rs860295	0.836	rs1360554	ENSG00000160766.13	GBAP1	3.81	0.000157	0.0204	0.18	0.17	Body mass index;	chr1:155503565	chr1:155213821~155227422:-
LUAD	cis	rs763121	0.962	rs138703	ENSG00000225450.1	RP3-508I15.14	-3.81	0.000157	0.0204	-0.16	-0.17	Menopause (age at onset);	chr22:38736743	chr22:38739003~38749041:+
LUAD	cis	rs5015933	0.788	rs490978	ENSG00000232630.1	PRPS1P2	-3.81	0.000157	0.0204	-0.16	-0.17	Body mass index;	chr9:125265972	chr9:125150653~125151589:+
LUAD	cis	rs9659323	1	rs9659323	ENSG00000226172.2	RP4-712E4.1	-3.81	0.000157	0.0204	-0.18	-0.17	Body mass index;	chr1:118961738	chr1:119000344~119001392:-
LUAD	cis	rs9659323	1	rs9658899	ENSG00000226172.2	RP4-712E4.1	-3.81	0.000157	0.0204	-0.18	-0.17	Body mass index;	chr1:118961920	chr1:119000344~119001392:-
LUAD	cis	rs9659323	1	rs12073056	ENSG00000226172.2	RP4-712E4.1	-3.81	0.000157	0.0204	-0.18	-0.17	Body mass index;	chr1:118965777	chr1:119000344~119001392:-
LUAD	cis	rs11250098	0.541	rs6997839	ENSG00000255310.2	AF131215.2	-3.81	0.000157	0.0204	-0.17	-0.17	Morning vs. evening chronotype;	chr8:10908518	chr8:11107788~11109726:-
LUAD	cis	rs451417	0.841	rs12106220	ENSG00000275632.1	RP5-967N21.11	3.81	0.000157	0.0204	0.22	0.17	Menopause (age at onset);	chr20:5963609	chr20:6000418~6000941:+
LUAD	cis	rs2486288	0.656	rs8039354	ENSG00000259479.5	SORD2P	3.81	0.000157	0.0204	0.21	0.17	Glomerular filtration rate;	chr15:45259558	chr15:44826371~44884694:-
LUAD	cis	rs3018712	0.532	rs2510398	ENSG00000212093.1	AP000807.1	-3.81	0.000157	0.0204	-0.23	-0.17	Total body bone mineral density;	chr11:68653948	chr11:68506083~68506166:-
LUAD	cis	rs7560272	0.501	rs11894953	ENSG00000163016.8	ALMS1P	3.81	0.000157	0.0204	0.18	0.17	Schizophrenia;	chr2:73737504	chr2:73644919~73685576:+
LUAD	cis	rs5771225	0.563	rs738334	ENSG00000273253.2	RP3-402G11.26	-3.81	0.000157	0.0204	-0.17	-0.17	Late-onset Alzheimer's disease;	chr22:50249806	chr22:50199090~50200837:-
LUAD	cis	rs8062405	1	rs62036617	ENSG00000261419.1	RP11-57A19.4	-3.81	0.000157	0.0204	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28659696~28740781:-
LUAD	cis	rs6964587	0.967	rs4729015	ENSG00000188693.7	CYP51A1-AS1	3.81	0.000157	0.0204	0.2	0.17	Breast cancer;	chr7:91932278	chr7:92134604~92180725:+
LUAD	cis	rs1150668	0.699	rs1736895	ENSG00000176933.5	TOB2P1	-3.81	0.000157	0.0204	-0.19	-0.17	Pubertal anthropometrics;	chr6:28252048	chr6:28217643~28218634:-
LUAD	cis	rs8141529	1	rs8141529	ENSG00000226471.5	CTA-292E10.6	-3.81	0.000157	0.0204	-0.21	-0.17	Lymphocyte counts;	chr22:28873704	chr22:28800683~28848559:+
LUAD	cis	rs17406451	0.759	rs7588221	ENSG00000279873.2	LINC01126	3.81	0.000157	0.0204	0.14	0.17	Mitochondrial DNA levels;	chr2:43427177	chr2:43227210~43228855:+
LUAD	cis	rs28510890	0.754	rs11074080	ENSG00000260337.3	RP11-386M24.6	3.81	0.000157	0.0204	0.22	0.17	Lung cancer in ever smokers;	chr15:92595272	chr15:92592574~92596462:-
LUAD	cis	rs2253762	0.54	rs11200353	ENSG00000276742.1	RP11-500G22.4	3.81	0.000157	0.0204	0.27	0.17	Breast cancer;	chr10:122030181	chr10:121956782~121957098:+
LUAD	cis	rs2253762	0.54	rs10887053	ENSG00000276742.1	RP11-500G22.4	3.81	0.000157	0.0204	0.27	0.17	Breast cancer;	chr10:122030997	chr10:121956782~121957098:+
LUAD	cis	rs7202877	0.656	rs977986	ENSG00000280152.1	RP11-331F4.5	3.81	0.000157	0.0204	0.2	0.17	Type 1 diabetes;Type 2 diabetes;	chr16:75472798	chr16:75245994~75250077:-
LUAD	cis	rs4683346	0.731	rs11923822	ENSG00000173811.9	CCDC13-AS1	-3.81	0.000157	0.0204	-0.2	-0.17	Granulocyte percentage of myeloid white cells;	chr3:42880685	chr3:42732575~42746768:+
LUAD	cis	rs7968440	1	rs2251603	ENSG00000272368.2	RP4-605O3.4	-3.81	0.000157	0.0204	-0.2	-0.17	Fibrinogen;	chr12:50655870	chr12:50112197~50165618:+
LUAD	cis	rs875971	0.66	rs10272357	ENSG00000222364.1	RNU6-96P	3.81	0.000157	0.0204	0.19	0.17	Aortic root size;	chr7:66598087	chr7:66395191~66395286:+
LUAD	cis	rs2274273	0.773	rs8012380	ENSG00000259318.1	RP11-454L9.2	3.81	0.000157	0.0204	0.15	0.17	Protein biomarker;	chr14:55268292	chr14:55394940~55395233:-
LUAD	cis	rs7760535	0.764	rs240994	ENSG00000230177.1	RP5-1112D6.4	-3.81	0.000157	0.0204	-0.15	-0.17	Metabolic traits;	chr6:111354554	chr6:111277932~111278742:+
LUAD	cis	rs2708977	1	rs34029026	ENSG00000237510.6	AC008268.2	3.81	0.000157	0.0204	0.25	0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96584305	chr2:95789654~95800166:+
LUAD	cis	rs8141529	0.748	rs5762874	ENSG00000272858.1	CTA-292E10.8	-3.81	0.000157	0.0204	-0.19	-0.17	Lymphocyte counts;	chr22:28873670	chr22:28814914~28815662:+
LUAD	cis	rs10197140	0.857	rs932076	ENSG00000235721.1	AC013268.3	-3.81	0.000157	0.0205	-0.19	-0.17	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110863663	chr2:110007675~110010783:+
LUAD	cis	rs4784934	0.879	rs9931547	ENSG00000260186.4	RP11-481J2.2	3.81	0.000157	0.0205	0.21	0.17	QT interval;	chr16:58432203	chr16:58421326~58462470:+
LUAD	cis	rs7503168	0.558	rs17670584	ENSG00000267592.1	CTC-507E2.2	3.81	0.000157	0.0205	0.37	0.17	Plateletcrit;	chr17:35671885	chr17:35596904~35597128:-
LUAD	cis	rs5771242	0.769	rs4838865	ENSG00000273253.2	RP3-402G11.26	-3.81	0.000157	0.0205	-0.17	-0.17	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);	chr22:50226183	chr22:50199090~50200837:-
LUAD	cis	rs6001482	0.679	rs5995706	ENSG00000223350.2	IGLV9-49	-3.81	0.000157	0.0205	-0.17	-0.17	Diastolic blood pressure;	chr22:22236371	chr22:22343187~22343732:+
LUAD	cis	rs6001482	0.702	rs7286018	ENSG00000223350.2	IGLV9-49	-3.81	0.000157	0.0205	-0.17	-0.17	Diastolic blood pressure;	chr22:22236464	chr22:22343187~22343732:+
LUAD	cis	rs4660214	0.671	rs72637904	ENSG00000228060.1	RP11-69E11.8	-3.81	0.000157	0.0205	-0.19	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39203010	chr1:39565160~39573203:+
LUAD	cis	rs4660214	0.671	rs17491275	ENSG00000228060.1	RP11-69E11.8	-3.81	0.000157	0.0205	-0.19	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39206873	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.583	rs61779328	ENSG00000182109.6	RP11-69E11.4	3.81	0.000157	0.0205	0.23	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39487795	chr1:39522280~39546187:-
LUAD	cis	rs62244186	0.545	rs7640654	ENSG00000233509.2	ZNF197-AS1	3.81	0.000157	0.0205	0.19	0.17	Depressive symptoms;	chr3:44721545	chr3:44617128~44624797:-
LUAD	cis	rs7760535	0.794	rs463860	ENSG00000230177.1	RP5-1112D6.4	-3.81	0.000157	0.0205	-0.15	-0.17	Metabolic traits;	chr6:111370518	chr6:111277932~111278742:+
LUAD	cis	rs481331	0.866	rs12259795	ENSG00000185904.10	LINC00839	3.81	0.000157	0.0205	0.29	0.17	Systemic juvenile idiopathic arthritis;	chr10:42488627	chr10:42475543~42495336:+
LUAD	cis	rs7215564	0.818	rs7214465	ENSG00000232083.3	RPL31P7	3.81	0.000157	0.0205	0.31	0.17	Myopia (pathological);	chr17:80592992	chr17:80602549~80602926:-
LUAD	cis	rs6964587	1	rs7789492	ENSG00000188693.7	CYP51A1-AS1	-3.81	0.000157	0.0205	-0.2	-0.17	Breast cancer;	chr7:92039540	chr7:92134604~92180725:+
LUAD	cis	rs12073359	1	rs10888569	ENSG00000223945.2	RP11-458I7.1	3.81	0.000157	0.0205	0.23	0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150053690	chr1:150053864~150055034:+
LUAD	cis	rs9400467	0.528	rs240954	ENSG00000230177.1	RP5-1112D6.4	-3.81	0.000157	0.0205	-0.15	-0.17	Amino acid levels;Blood metabolite levels;	chr6:111338619	chr6:111277932~111278742:+
LUAD	cis	rs1005277	0.54	rs289638	ENSG00000273019.1	RP11-508N22.13	-3.81	0.000157	0.0205	-0.2	-0.17	Extrinsic epigenetic age acceleration;	chr10:37634803	chr10:38149968~38150293:+
LUAD	cis	rs7178424	0.742	rs1981917	ENSG00000259251.2	RP11-643M14.1	-3.81	0.000157	0.0205	-0.17	-0.17	Height;	chr15:61879707	chr15:62060503~62062434:+
LUAD	cis	rs8040855	0.627	rs4842863	ENSG00000259774.1	RP11-182J1.13	3.81	0.000157	0.0205	0.22	0.17	Bulimia nervosa;	chr15:85098974	chr15:84422618~84425882:+
LUAD	cis	rs858239	0.539	rs4295546	ENSG00000226816.2	AC005082.12	3.81	0.000157	0.0205	0.23	0.17	Cerebrospinal fluid biomarker levels;	chr7:23151402	chr7:23206013~23208045:+
LUAD	cis	rs338389	0.786	rs338344	ENSG00000260657.2	RP11-315D16.4	-3.81	0.000157	0.0205	-0.19	-0.17	Survival in rectal cancer;	chr15:67978042	chr15:68267792~68277994:-
LUAD	cis	rs3126085	0.515	rs6668321	ENSG00000237975.5	FLG-AS1	3.81	0.000157	0.0205	0.27	0.17	Atopic dermatitis;	chr1:152381464	chr1:152168125~152445456:+
LUAD	cis	rs6496044	0.547	rs8039929	ENSG00000259407.1	RP11-158M2.3	-3.81	0.000157	0.0205	-0.16	-0.17	Interstitial lung disease;	chr15:85537731	chr15:85744109~85750281:-
LUAD	cis	rs6500602	0.964	rs62039173	ENSG00000280063.1	RP11-295D4.3	3.81	0.000157	0.0205	0.11	0.17	Schizophrenia;	chr16:4413845	chr16:4346694~4348648:-
LUAD	cis	rs6121246	0.954	rs6089093	ENSG00000230613.1	HM13-AS1	3.81	0.000157	0.0205	0.25	0.17	Mean corpuscular hemoglobin;	chr20:31833656	chr20:31567707~31573263:-
LUAD	cis	rs7515577	0.898	rs3122320	ENSG00000223787.2	RP4-593M8.1	-3.81	0.000157	0.0205	-0.26	-0.17	Cholesterol, total;	chr1:92240081	chr1:92580476~92580821:-
LUAD	cis	rs7515577	0.898	rs1386585	ENSG00000223787.2	RP4-593M8.1	-3.81	0.000157	0.0205	-0.26	-0.17	Cholesterol, total;	chr1:92249650	chr1:92580476~92580821:-
LUAD	cis	rs9549260	0.816	rs7324090	ENSG00000229456.1	RLIMP1	3.81	0.000157	0.0205	0.18	0.17	Red blood cell count;	chr13:40679821	chr13:40618738~40621348:+
LUAD	cis	rs683250	0.598	rs494791	ENSG00000246067.6	RAB30-AS1	3.81	0.000157	0.0205	0.18	0.17	Subcortical brain region volumes;	chr11:83285943	chr11:83072066~83106719:+
LUAD	cis	rs10483809	0.659	rs9989153	ENSG00000259648.1	RP11-643G16.4	-3.81	0.000157	0.0205	-0.34	-0.17	Circulating chromogranin peptide levels;	chr14:68329475	chr14:67614929~67616626:+
LUAD	cis	rs853679	0.517	rs2281588	ENSG00000280107.1	AL022393.9	-3.81	0.000157	0.0205	-0.23	-0.17	Depression;	chr6:28104824	chr6:28170845~28172521:+
LUAD	cis	rs7777677	0.925	rs6969951	ENSG00000276953.1	TRBV12-4	-3.81	0.000157	0.0205	-0.16	-0.17	Alcoholic chronic pancreatitis;	chr7:142661753	chr7:142563740~142564245:+
LUAD	cis	rs6840360	0.55	rs62327267	ENSG00000270265.1	RP11-731D1.4	-3.81	0.000157	0.0205	-0.19	-0.17	Intelligence (multi-trait analysis);	chr4:151597601	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.571	rs28454076	ENSG00000270265.1	RP11-731D1.4	-3.81	0.000157	0.0205	-0.19	-0.17	Intelligence (multi-trait analysis);	chr4:151598931	chr4:151333775~151353224:-
LUAD	cis	rs4268898	0.61	rs34216622	ENSG00000242628.4	AC009228.1	3.81	0.000157	0.0205	0.25	0.17	Asthma;	chr2:24240576	chr2:24214381~24221516:+
LUAD	cis	rs2153535	0.518	rs9328473	ENSG00000230939.1	RP11-314C16.1	-3.81	0.000157	0.0205	-0.2	-0.17	Motion sickness;	chr6:8487092	chr6:8784178~8785445:+
LUAD	cis	rs6088580	0.634	rs6142159	ENSG00000276073.1	RP5-1125A11.7	3.81	0.000157	0.0205	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34405229	chr20:33985617~33988989:-
LUAD	cis	rs2253762	0.54	rs11200351	ENSG00000276742.1	RP11-500G22.4	3.81	0.000157	0.0205	0.27	0.17	Breast cancer;	chr10:122029957	chr10:121956782~121957098:+
LUAD	cis	rs9894429	0.621	rs7502337	ENSG00000263853.1	AC139530.1	-3.81	0.000157	0.0205	-0.18	-0.17	Eye color traits;	chr17:81621444	chr17:81676001~81676086:+
LUAD	cis	rs6088580	0.634	rs6141465	ENSG00000276073.1	RP5-1125A11.7	3.81	0.000158	0.0205	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34379508	chr20:33985617~33988989:-
LUAD	cis	rs2115630	0.754	rs12595321	ENSG00000229212.6	RP11-561C5.4	3.81	0.000158	0.0205	0.2	0.17	P wave terminal force;	chr15:84788038	chr15:85205440~85234795:-
LUAD	cis	rs741668	0.641	rs4942472	ENSG00000235903.6	CPB2-AS1	-3.81	0.000158	0.0205	-0.22	-0.17	Cerebrospinal fluid clusterin levels;	chr13:46070980	chr13:46052806~46113332:+
LUAD	cis	rs10080237	0.564	rs2490230	ENSG00000260645.1	RP11-250B2.5	3.81	0.000158	0.0205	0.17	0.17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;	chr6:80102747	chr6:80466958~80469080:+
LUAD	cis	rs4727963	0.74	rs1404834	ENSG00000240499.6	RP5-1101C3.1	-3.81	0.000158	0.0205	-0.15	-0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);	chr7:123075058	chr7:122328469~122440388:+
LUAD	cis	rs4727963	0.792	rs10953968	ENSG00000240499.6	RP5-1101C3.1	-3.81	0.000158	0.0205	-0.15	-0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);	chr7:123076279	chr7:122328469~122440388:+
LUAD	cis	rs9876781	1	rs7635522	ENSG00000229759.1	MRPS18AP1	3.81	0.000158	0.0205	0.17	0.17	Longevity;	chr3:48382166	chr3:48256350~48256938:-
LUAD	cis	rs11971779	0.938	rs28477480	ENSG00000273391.1	RP11-634H22.1	-3.81	0.000158	0.0205	-0.2	-0.17	Diisocyanate-induced asthma;	chr7:139351312	chr7:139359032~139359566:-
LUAD	cis	rs3617	0.652	rs60332615	ENSG00000242142.1	SERBP1P3	-3.81	0.000158	0.0205	-0.18	-0.17	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52833579	chr3:53064283~53065091:-
LUAD	cis	rs6088580	0.634	rs6142157	ENSG00000276073.1	RP5-1125A11.7	3.81	0.000158	0.0205	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34396366	chr20:33985617~33988989:-
LUAD	cis	rs2041895	0.509	rs1035236	ENSG00000260329.1	RP11-412D9.4	-3.81	0.000158	0.0205	-0.21	-0.17	Glaucoma (low intraocular pressure);	chr12:106917019	chr12:106954029~106955497:-
LUAD	cis	rs2041895	0.509	rs10861676	ENSG00000260329.1	RP11-412D9.4	-3.81	0.000158	0.0205	-0.21	-0.17	Glaucoma (low intraocular pressure);	chr12:106917457	chr12:106954029~106955497:-
LUAD	cis	rs57221529	0.766	rs56350081	ENSG00000248925.1	CTD-2083E4.6	3.81	0.000158	0.0205	0.27	0.17	Lung disease severity in cystic fibrosis;	chr5:583083	chr5:269858~271516:-
LUAD	cis	rs57221529	0.766	rs12518859	ENSG00000248925.1	CTD-2083E4.6	3.81	0.000158	0.0205	0.27	0.17	Lung disease severity in cystic fibrosis;	chr5:587317	chr5:269858~271516:-
LUAD	cis	rs4705962	0.878	rs4705965	ENSG00000233006.5	AC034220.3	3.81	0.000158	0.0205	0.16	0.17	Atopic dermatitis;	chr5:132719435	chr5:132311285~132369916:-
LUAD	cis	rs12817211	0.524	rs10876000	ENSG00000272368.2	RP4-605O3.4	-3.81	0.000158	0.0205	-0.2	-0.17	Colorectal or endometrial cancer;	chr12:50128431	chr12:50112197~50165618:+
LUAD	cis	rs3916	0.955	rs12828810	ENSG00000277423.1	RP11-173P15.9	-3.81	0.000158	0.0205	-0.22	-0.17	Urinary metabolites (H-NMR features);	chr12:120714214	chr12:120703867~120704282:+
LUAD	cis	rs3916	0.955	rs35771722	ENSG00000277423.1	RP11-173P15.9	-3.81	0.000158	0.0205	-0.22	-0.17	Urinary metabolites (H-NMR features);	chr12:120716197	chr12:120703867~120704282:+
LUAD	cis	rs6951245	0.832	rs10266519	ENSG00000199023.2	MIR339	-3.81	0.000158	0.0205	-0.3	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1103341	chr7:1022935~1023045:-
LUAD	cis	rs8054556	0.669	rs4787491	ENSG00000214725.6	CDIPT-AS1	-3.81	0.000158	0.0205	-0.2	-0.17	Autism spectrum disorder or schizophrenia;	chr16:30004016	chr16:29863593~29868053:+
LUAD	cis	rs2024714	0.967	rs2427216	ENSG00000273812.1	WI2-87327B8.2	-3.81	0.000158	0.0205	-0.18	-0.17	Longevity;	chr20:61639158	chr20:62596732~62603115:-
LUAD	cis	rs9659323	1	rs56897173	ENSG00000226172.2	RP4-712E4.1	-3.81	0.000158	0.0205	-0.18	-0.17	Body mass index;	chr1:118973109	chr1:119000344~119001392:-
LUAD	cis	rs4713118	0.662	rs149961	ENSG00000280107.1	AL022393.9	-3.81	0.000158	0.0205	-0.22	-0.17	Parkinson's disease;	chr6:28047791	chr6:28170845~28172521:+
LUAD	cis	rs2609255	0.95	rs2464523	ENSG00000270720.1	RP11-84C13.2	-3.81	0.000158	0.0205	-0.22	-0.17	Interstitial lung disease;	chr4:88939696	chr4:89119284~89119871:+
LUAD	cis	rs17685	0.712	rs2158867	ENSG00000280388.1	RP11-229D13.3	-3.81	0.000158	0.0205	-0.16	-0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76185823	chr7:76043977~76045963:-
LUAD	cis	rs12986445	0.947	rs6738270	ENSG00000218682.1	AC010150.1	3.81	0.000158	0.0205	0.2	0.17	Multiple myeloma;Multiple myeloma and monoclonal gammopathy;	chr2:25927720	chr2:25856461~25856966:-
LUAD	cis	rs1850744	0.702	rs10939428	ENSG00000249767.1	ENPP7P10	-3.81	0.000158	0.0206	-0.43	-0.17	Economic and political preferences;	chr4:9628417	chr4:9079023~9141608:+
LUAD	cis	rs7613875	0.62	rs7634441	ENSG00000234667.1	ACTBP13	3.81	0.000158	0.0206	0.19	0.17	Body mass index;	chr3:50034244	chr3:49873347~49877980:-
LUAD	cis	rs8073060	0.586	rs6505485	ENSG00000267592.1	CTC-507E2.2	3.81	0.000158	0.0206	0.24	0.17	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35669083	chr17:35596904~35597128:-
LUAD	cis	rs6088590	0.561	rs6059918	ENSG00000276073.1	RP5-1125A11.7	-3.81	0.000158	0.0206	-0.17	-0.17	Coronary artery disease;	chr20:34562699	chr20:33985617~33988989:-
LUAD	cis	rs526231	0.578	rs34794	ENSG00000250682.4	LINC00491	3.81	0.000158	0.0206	0.21	0.17	Primary biliary cholangitis;	chr5:103087664	chr5:102609156~102671559:-
LUAD	cis	rs987044	0.726	rs4964737	ENSG00000257221.1	RP11-689B22.2	-3.81	0.000158	0.0206	-0.14	-0.17	Mean platelet volume;	chr12:108706732	chr12:108628687~108641318:+
LUAD	cis	rs7923837	0.663	rs5015480	ENSG00000236493.2	EIF2S2P3	3.81	0.000158	0.0206	0.19	0.17	Multiple sclerosis;Body mass index;	chr10:92705802	chr10:92668745~92669743:-
LUAD	cis	rs10129255	0.957	rs10140904	ENSG00000211947.2	IGHV3-21	-3.81	0.000158	0.0206	-0.11	-0.17	Kawasaki disease;	chr14:106776558	chr14:106235064~106235594:-
LUAD	cis	rs721917	0.531	rs2819105	ENSG00000230091.5	TMEM254-AS1	3.81	0.000158	0.0206	0.22	0.17	Chronic obstructive pulmonary disease;	chr10:79927101	chr10:80046860~80078912:-
LUAD	cis	rs721917	0.531	rs2256167	ENSG00000230091.5	TMEM254-AS1	3.81	0.000158	0.0206	0.22	0.17	Chronic obstructive pulmonary disease;	chr10:79928592	chr10:80046860~80078912:-
LUAD	cis	rs12680842	0.576	rs35593078	ENSG00000253704.1	RP11-267M23.4	3.81	0.000158	0.0206	0.2	0.17	Body mass index;	chr8:94614917	chr8:94553722~94569745:+
LUAD	cis	rs2062225	0.735	rs7594735	ENSG00000270190.1	RP11-803D5.4	-3.81	0.000158	0.0206	-0.26	-0.17	Monocyte count;	chr2:110989279	chr2:111266868~111267473:-
LUAD	cis	rs67981189	0.778	rs989501	ENSG00000269927.1	RP6-91H8.3	-3.81	0.000158	0.0206	-0.21	-0.17	Schizophrenia;	chr14:70894697	chr14:71141125~71143253:-
LUAD	cis	rs1862618	0.853	rs2113079	ENSG00000271828.1	CTD-2310F14.1	3.81	0.000158	0.0206	0.25	0.17	Initial pursuit acceleration;	chr5:56862124	chr5:56927874~56929573:+
LUAD	cis	rs7131987	0.65	rs6487808	ENSG00000275476.1	RP11-996F15.4	3.81	0.000158	0.0206	0.19	0.17	QT interval;	chr12:29310426	chr12:29277397~29277882:-
LUAD	cis	rs7129556	0.638	rs11604207	ENSG00000241782.1	RP11-91P24.1	3.81	0.000158	0.0206	0.26	0.17	Weight loss (gastric bypass surgery);	chr11:77656497	chr11:77868722~77869195:-
LUAD	cis	rs7015630	0.657	rs2338882	ENSG00000251136.7	RP11-37B2.1	-3.81	0.000158	0.0206	-0.22	-0.17	Inflammatory bowel disease;Crohn's disease;	chr8:89809970	chr8:89609409~89757727:-
LUAD	cis	rs4853525	0.651	rs62182473	ENSG00000235852.1	AC005540.3	3.81	0.000158	0.0206	0.21	0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190876270	chr2:190880797~190882059:-
LUAD	cis	rs875971	0.545	rs221986	ENSG00000224316.1	RP11-479O9.2	-3.81	0.000158	0.0206	-0.2	-0.17	Aortic root size;	chr7:66105323	chr7:65773620~65802067:+
LUAD	cis	rs944722	0.584	rs2297514	ENSG00000266786.1	LGALS9DP	-3.81	0.000158	0.0206	-0.19	-0.17	Fractional exhaled nitric oxide (childhood);	chr17:27766289	chr17:27746132~27754954:+
LUAD	cis	rs6688613	0.729	rs2072742	ENSG00000225171.2	DUTP6	-3.81	0.000158	0.0206	-0.22	-0.17	Refractive astigmatism;	chr1:166960436	chr1:166868748~166869209:+
LUAD	cis	rs6479901	0.895	rs7916224	ENSG00000232075.1	MRPL35P2	-3.81	0.000158	0.0206	-0.24	-0.17	Intelligence (multi-trait analysis);	chr10:63144843	chr10:63634317~63634827:-
LUAD	cis	rs10829156	0.738	rs4748502	ENSG00000240291.1	RP11-499P20.2	3.81	0.000158	0.0206	0.16	0.17	Sudden cardiac arrest;	chr10:18647032	chr10:18513115~18545651:-
LUAD	cis	rs34779708	0.966	rs35079558	ENSG00000271335.4	RP11-324I22.4	3.81	0.000158	0.0206	0.18	0.17	Inflammatory bowel disease;Crohn's disease;	chr10:35190958	chr10:35314552~35336401:-
LUAD	cis	rs11874381	1	rs35049594	ENSG00000266696.1	RP11-30L3.2	-3.81	0.000158	0.0206	-0.19	-0.17	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);	chr18:49684697	chr18:49205912~49208781:+
LUAD	cis	rs11874381	1	rs62101780	ENSG00000266696.1	RP11-30L3.2	-3.81	0.000158	0.0206	-0.19	-0.17	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);	chr18:49684974	chr18:49205912~49208781:+
LUAD	cis	rs4795519	0.778	rs1975980	ENSG00000266313.1	RP11-173M1.4	-3.81	0.000158	0.0206	-0.21	-0.17	Chronic myeloid leukemia;	chr17:27068665	chr17:27333256~27348491:+
LUAD	cis	rs2904524	0.588	rs12317962	ENSG00000257815.4	RP11-611E13.2	-3.81	0.000158	0.0206	-0.21	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70398802	chr12:69904033~70243360:-
LUAD	cis	rs17685	0.753	rs10262501	ENSG00000280388.1	RP11-229D13.3	3.81	0.000158	0.0206	0.16	0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76038854	chr7:76043977~76045963:-
LUAD	cis	rs11955398	0.502	rs34592	ENSG00000272308.1	RP11-231G3.1	-3.81	0.000158	0.0206	-0.2	-0.17	Intelligence (multi-trait analysis);	chr5:61033797	chr5:60866457~60866935:-
LUAD	cis	rs801193	0.742	rs9969300	ENSG00000237310.1	GS1-124K5.4	-3.81	0.000158	0.0206	-0.19	-0.17	Aortic root size;	chr7:66316659	chr7:66493706~66495474:+
LUAD	cis	rs7615952	0.673	rs9821905	ENSG00000241288.6	RP11-379B18.5	3.81	0.000158	0.0206	0.27	0.17	Blood pressure (smoking interaction);	chr3:125902007	chr3:125827238~125916384:-
LUAD	cis	rs2412819	0.571	rs8030536	ENSG00000166763.7	STRCP1	3.81	0.000158	0.0206	0.26	0.17	Lung cancer;	chr15:43627365	chr15:43699488~43718184:-
LUAD	cis	rs9467773	0.62	rs2504571	ENSG00000261353.1	CTA-14H9.5	-3.81	0.000158	0.0206	-0.19	-0.17	Intelligence (multi-trait analysis);	chr6:26643207	chr6:26527063~26527404:+
LUAD	cis	rs1876905	0.68	rs354528	ENSG00000271789.1	RP5-1112D6.7	-3.81	0.000158	0.0206	-0.24	-0.17	Mean corpuscular hemoglobin;	chr6:111184068	chr6:111297126~111298510:+
LUAD	cis	rs1876905	0.62	rs354525	ENSG00000271789.1	RP5-1112D6.7	-3.81	0.000158	0.0206	-0.24	-0.17	Mean corpuscular hemoglobin;	chr6:111186193	chr6:111297126~111298510:+
LUAD	cis	rs9926296	0.585	rs6500450	ENSG00000260259.1	RP11-368I7.4	-3.81	0.000158	0.0206	-0.17	-0.17	Vitiligo;	chr16:89791616	chr16:89682620~89686569:-
LUAD	cis	rs7826238	0.564	rs2921053	ENSG00000173295.6	FAM86B3P	3.81	0.000158	0.0206	0.18	0.17	Systolic blood pressure;	chr8:8462453	chr8:8228595~8244865:+
LUAD	cis	rs7809950	1	rs10234355	ENSG00000238832.1	snoU109	-3.81	0.000158	0.0206	-0.25	-0.17	Coronary artery disease;	chr7:107446072	chr7:107603363~107603507:+
LUAD	cis	rs6471393	0.83	rs57803852	ENSG00000253848.1	RP11-10N23.5	3.81	0.000158	0.0206	0.21	0.17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93761156	chr8:93741193~93744534:+
LUAD	cis	rs8014204	0.804	rs2287403	ENSG00000279594.1	RP11-950C14.10	3.81	0.000159	0.0206	0.19	0.17	Caffeine consumption;	chr14:74792437	chr14:75011269~75012851:-
LUAD	cis	rs2638953	0.924	rs61920245	ENSG00000278733.1	RP11-425D17.1	-3.81	0.000159	0.0206	-0.2	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28196081	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs7957056	ENSG00000278733.1	RP11-425D17.1	-3.81	0.000159	0.0206	-0.2	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28203382	chr12:28185625~28186190:-
LUAD	cis	rs11673344	0.704	rs1726724	ENSG00000267309.1	CTD-2630F21.1	-3.81	0.000159	0.0206	-0.21	-0.17	Obesity-related traits;	chr19:36925890	chr19:36489649~36491040:+
LUAD	cis	rs6860806	0.661	rs4705927	ENSG00000263597.1	MIR3936	3.81	0.000159	0.0206	0.18	0.17	Breast cancer;	chr5:132242915	chr5:132365490~132365599:-
LUAD	cis	rs12478296	0.786	rs28802397	ENSG00000261186.2	RP11-341N2.1	-3.81	0.000159	0.0206	-0.29	-0.17	Obesity-related traits;	chr2:242107579	chr2:242087351~242088457:-
LUAD	cis	rs9366999	0.776	rs1744404	ENSG00000235033.6	RP11-61I13.3	-3.81	0.000159	0.0206	-0.19	-0.17	Obesity-related traits;	chr6:39251542	chr6:39881804~39900071:-
LUAD	cis	rs9366999	0.771	rs1651104	ENSG00000235033.6	RP11-61I13.3	-3.81	0.000159	0.0206	-0.19	-0.17	Obesity-related traits;	chr6:39252054	chr6:39881804~39900071:-
LUAD	cis	rs17826219	0.714	rs11650821	ENSG00000280069.1	CTD-2349P21.3	-3.81	0.000159	0.0206	-0.24	-0.17	Body mass index;	chr17:30641132	chr17:30738182~30740275:+
LUAD	cis	rs57221529	0.766	rs58015612	ENSG00000248925.1	CTD-2083E4.6	3.81	0.000159	0.0206	0.27	0.17	Lung disease severity in cystic fibrosis;	chr5:580550	chr5:269858~271516:-
LUAD	cis	rs57221529	0.766	rs56216231	ENSG00000248925.1	CTD-2083E4.6	3.81	0.000159	0.0206	0.27	0.17	Lung disease severity in cystic fibrosis;	chr5:581078	chr5:269858~271516:-
LUAD	cis	rs6568686	0.53	rs76540042	ENSG00000255389.1	C6orf3	3.81	0.000159	0.0206	0.23	0.17	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111616177	chr6:111599875~111602295:+
LUAD	cis	rs734999	0.967	rs6671426	ENSG00000238164.5	RP3-395M20.8	-3.81	0.000159	0.0206	-0.15	-0.17	Ulcerative colitis;	chr1:2572795	chr1:2549920~2557031:-
LUAD	cis	rs11642862	1	rs11645367	ENSG00000239791.1	AC002310.7	3.81	0.000159	0.0206	0.31	0.17	Tonsillectomy;	chr16:30758753	chr16:30572250~30583860:+
LUAD	cis	rs11642862	1	rs112234000	ENSG00000239791.1	AC002310.7	3.81	0.000159	0.0206	0.31	0.17	Tonsillectomy;	chr16:30767487	chr16:30572250~30583860:+
LUAD	cis	rs11642862	1	rs11642466	ENSG00000239791.1	AC002310.7	3.81	0.000159	0.0206	0.31	0.17	Tonsillectomy;	chr16:30770621	chr16:30572250~30583860:+
LUAD	cis	rs11642862	1	rs75500538	ENSG00000239791.1	AC002310.7	3.81	0.000159	0.0206	0.31	0.17	Tonsillectomy;	chr16:30771128	chr16:30572250~30583860:+
LUAD	cis	rs13434995	0.513	rs17721497	ENSG00000273257.1	RP11-177J6.1	3.81	0.000159	0.0206	0.22	0.17	Adiponectin levels;	chr4:55445081	chr4:55387949~55388271:+
LUAD	cis	rs12440869	0.92	rs975944	ENSG00000270964.1	RP11-502I4.3	3.81	0.000159	0.0206	0.2	0.17	Peak velocity of the mitral A-wave;	chr15:67316352	chr15:67541072~67542604:-
LUAD	cis	rs6921919	0.583	rs7740351	ENSG00000219392.1	RP1-265C24.5	-3.81	0.000159	0.0206	-0.22	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28115628~28116551:+
LUAD	cis	rs6471393	0.798	rs62525169	ENSG00000253848.1	RP11-10N23.5	3.81	0.000159	0.0206	0.22	0.17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93804169	chr8:93741193~93744534:+
LUAD	cis	rs7191700	0.674	rs12597893	ENSG00000262636.1	CTD-3088G3.4	3.81	0.000159	0.0206	0.21	0.17	Multiple sclerosis;	chr16:11332474	chr16:11380859~11381118:-
LUAD	cis	rs2904524	0.541	rs10879133	ENSG00000257815.4	RP11-611E13.2	-3.81	0.000159	0.0206	-0.21	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70386680	chr12:69904033~70243360:-
LUAD	cis	rs755249	0.642	rs28788506	ENSG00000228060.1	RP11-69E11.8	-3.81	0.000159	0.0206	-0.16	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39611108	chr1:39565160~39573203:+
LUAD	cis	rs755249	0.669	rs4660311	ENSG00000228060.1	RP11-69E11.8	-3.81	0.000159	0.0206	-0.16	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39613442	chr1:39565160~39573203:+
LUAD	cis	rs1979679	1	rs6487672	ENSG00000278733.1	RP11-425D17.1	3.81	0.000159	0.0206	0.22	0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28270413	chr12:28185625~28186190:-
LUAD	cis	rs2657294	0.726	rs4746275	ENSG00000226051.5	ZNF503-AS1	-3.81	0.000159	0.0206	-0.23	-0.17	Pneumonia;	chr10:75214940	chr10:75269819~75373500:+
LUAD	cis	rs6832769	1	rs1522111	ENSG00000272969.1	RP11-528I4.2	3.81	0.000159	0.0206	0.18	0.17	Personality dimensions;	chr4:55463396	chr4:55547112~55547889:+
LUAD	cis	rs5771069	0.933	rs137845	ENSG00000273253.2	RP3-402G11.26	-3.81	0.000159	0.0206	-0.15	-0.17	Ulcerative colitis;	chr22:50001001	chr22:50199090~50200837:-
LUAD	cis	rs11121152	0.5	rs1107284	ENSG00000232912.4	RP5-1115A15.1	3.81	0.000159	0.0206	0.16	0.17	Inflammatory skin disease;	chr1:8312476	chr1:8424645~8434838:+
LUAD	cis	rs875971	0.862	rs6460307	ENSG00000273448.1	RP11-166O4.6	3.81	0.000159	0.0206	0.16	0.17	Aortic root size;	chr7:66595884	chr7:67333047~67334383:+
LUAD	cis	rs1334894	0.901	rs16877540	ENSG00000228559.1	RP3-340B19.3	3.81	0.000159	0.0207	0.34	0.17	Coronary artery disease;	chr6:35538954	chr6:35544632~35545669:+
LUAD	cis	rs2243480	1	rs383402	ENSG00000229886.1	RP5-1132H15.3	-3.81	0.000159	0.0207	-0.29	-0.17	Diabetic kidney disease;	chr7:66121666	chr7:66025126~66031544:-
LUAD	cis	rs7017914	0.967	rs12675271	ENSG00000246366.5	RP11-382J12.1	3.81	0.000159	0.0207	0.16	0.17	Bone mineral density;	chr8:70689774	chr8:70608577~70663279:+
LUAD	cis	rs3753275	0.568	rs6688329	ENSG00000232912.4	RP5-1115A15.1	3.81	0.000159	0.0207	0.2	0.17	Educational attainment;	chr1:8602999	chr1:8424645~8434838:+
LUAD	cis	rs3753275	0.568	rs6679948	ENSG00000232912.4	RP5-1115A15.1	3.81	0.000159	0.0207	0.2	0.17	Educational attainment;	chr1:8603037	chr1:8424645~8434838:+
LUAD	cis	rs3753275	0.568	rs1038008	ENSG00000232912.4	RP5-1115A15.1	3.81	0.000159	0.0207	0.2	0.17	Educational attainment;	chr1:8604863	chr1:8424645~8434838:+
LUAD	cis	rs1979679	0.686	rs4348940	ENSG00000278733.1	RP11-425D17.1	-3.81	0.000159	0.0207	-0.23	-0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28437804	chr12:28185625~28186190:-
LUAD	cis	rs77926410	0.685	rs2417741	ENSG00000256537.3	RP11-785H5.1	-3.81	0.000159	0.0207	-0.24	-0.17	Mean corpuscular volume;	chr12:10467606	chr12:11171181~11176020:+
LUAD	cis	rs12935418	0.672	rs1453327	ENSG00000261061.1	RP11-303E16.2	3.81	0.000159	0.0207	0.19	0.17	Mean corpuscular volume;	chr16:81014959	chr16:81030770~81031485:+
LUAD	cis	rs6688537	0.658	rs6429153	ENSG00000233355.5	CHRM3-AS2	-3.81	0.000159	0.0207	-0.13	-0.17	Lung function (FEV1/FVC);	chr1:239695425	chr1:239703381~239730465:-
LUAD	cis	rs12681366	0.839	rs2931632	ENSG00000254057.1	RP3-388N13.3	3.81	0.000159	0.0207	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94406560	chr8:93834454~93846743:-
LUAD	cis	rs7976269	0.583	rs2117997	ENSG00000275476.1	RP11-996F15.4	3.81	0.000159	0.0207	0.19	0.17	Male-pattern baldness;	chr12:29143428	chr12:29277397~29277882:-
LUAD	cis	rs5758659	0.594	rs739292	ENSG00000182057.4	OGFRP1	3.81	0.000159	0.0207	0.21	0.17	Cognitive function;	chr22:41972853	chr22:42269753~42275196:+
LUAD	cis	rs4660214	0.666	rs7553009	ENSG00000182109.6	RP11-69E11.4	-3.81	0.000159	0.0207	-0.19	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39247441	chr1:39522280~39546187:-
LUAD	cis	rs11671005	0.779	rs3794970	ENSG00000268912.1	CTD-2619J13.17	3.81	0.000159	0.0207	0.24	0.17	Mean platelet volume;	chr19:58474893	chr19:58428632~58431148:-
LUAD	cis	rs11154801	0.634	rs6941396	ENSG00000231028.7	LINC00271	-3.81	0.000159	0.0207	-0.21	-0.17	Multiple sclerosis;	chr6:135606388	chr6:135497801~135716055:+
LUAD	cis	rs11158026	0.603	rs57667631	ENSG00000258413.1	RP11-665C16.6	-3.81	0.000159	0.0207	-0.23	-0.17	Parkinson's disease;	chr14:54976349	chr14:55262767~55272075:-
LUAD	cis	rs11158026	0.603	rs56335168	ENSG00000258413.1	RP11-665C16.6	-3.81	0.000159	0.0207	-0.23	-0.17	Parkinson's disease;	chr14:54978414	chr14:55262767~55272075:-
LUAD	cis	rs10510102	0.872	rs12246728	ENSG00000276742.1	RP11-500G22.4	3.81	0.000159	0.0207	0.29	0.17	Breast cancer;	chr10:121966618	chr10:121956782~121957098:+
LUAD	cis	rs10510102	0.872	rs12261371	ENSG00000276742.1	RP11-500G22.4	3.81	0.000159	0.0207	0.29	0.17	Breast cancer;	chr10:121966686	chr10:121956782~121957098:+
LUAD	cis	rs10510102	0.872	rs11200292	ENSG00000276742.1	RP11-500G22.4	3.81	0.000159	0.0207	0.29	0.17	Breast cancer;	chr10:121967383	chr10:121956782~121957098:+
LUAD	cis	rs10510102	0.808	rs17102804	ENSG00000276742.1	RP11-500G22.4	3.81	0.000159	0.0207	0.29	0.17	Breast cancer;	chr10:121968365	chr10:121956782~121957098:+
LUAD	cis	rs10510102	0.872	rs12265369	ENSG00000276742.1	RP11-500G22.4	3.81	0.000159	0.0207	0.29	0.17	Breast cancer;	chr10:121968455	chr10:121956782~121957098:+
LUAD	cis	rs10510102	0.872	rs12265542	ENSG00000276742.1	RP11-500G22.4	3.81	0.000159	0.0207	0.29	0.17	Breast cancer;	chr10:121968740	chr10:121956782~121957098:+
LUAD	cis	rs10510102	0.872	rs11200293	ENSG00000276742.1	RP11-500G22.4	3.81	0.000159	0.0207	0.29	0.17	Breast cancer;	chr10:121969195	chr10:121956782~121957098:+
LUAD	cis	rs6964587	0.967	rs10429103	ENSG00000188693.7	CYP51A1-AS1	-3.81	0.000159	0.0207	-0.2	-0.17	Breast cancer;	chr7:91969129	chr7:92134604~92180725:+
LUAD	cis	rs9467773	0.933	rs35355150	ENSG00000124549.13	BTN2A3P	3.81	0.000159	0.0207	0.16	0.17	Intelligence (multi-trait analysis);	chr6:26525811	chr6:26421391~26432383:+
LUAD	cis	rs6479891	1	rs9414799	ENSG00000232075.1	MRPL35P2	3.81	0.000159	0.0207	0.28	0.17	Arthritis (juvenile idiopathic);	chr10:63369842	chr10:63634317~63634827:-
LUAD	cis	rs6479891	1	rs4746119	ENSG00000232075.1	MRPL35P2	3.81	0.000159	0.0207	0.28	0.17	Arthritis (juvenile idiopathic);	chr10:63370157	chr10:63634317~63634827:-
LUAD	cis	rs8180040	0.932	rs62246474	ENSG00000271161.1	BOLA2P2	-3.81	0.000159	0.0207	-0.16	-0.17	Colorectal cancer;	chr3:47356640	chr3:47499841~47500407:+
LUAD	cis	rs6933660	0.666	rs9371516	ENSG00000219395.2	HSPA8P15	-3.81	0.000159	0.0207	-0.16	-0.17	Menarche (age at onset);	chr6:151418507	chr6:151411259~151413945:-
LUAD	cis	rs6479891	1	rs9414800	ENSG00000232075.1	MRPL35P2	3.81	0.000159	0.0207	0.28	0.17	Arthritis (juvenile idiopathic);	chr10:63371522	chr10:63634317~63634827:-
LUAD	cis	rs603446	0.967	rs180340	ENSG00000254851.1	RP11-109L13.1	-3.81	0.000159	0.0207	-0.21	-0.17	Triglycerides;	chr11:116745686	chr11:117135528~117138582:+
LUAD	cis	rs14027	0.596	rs28576821	ENSG00000279347.1	RP11-85I17.2	-3.81	0.000159	0.0207	-0.14	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119752777	chr8:119838736~119840385:-
LUAD	cis	rs2834288	0.666	rs2834293	ENSG00000237945.6	LINC00649	-3.81	0.000159	0.0207	-0.23	-0.17	Gut microbiota (bacterial taxa);	chr21:33903905	chr21:33915534~33977691:+
LUAD	cis	rs7772486	0.79	rs3924498	ENSG00000235652.6	RP11-545I5.3	-3.81	0.000159	0.0207	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145912202	chr6:145799409~145886585:+
LUAD	cis	rs8031584	0.918	rs11639169	ENSG00000270015.1	RP11-540B6.6	-3.81	0.000159	0.0207	-0.13	-0.17	Huntington's disease progression;	chr15:30963235	chr15:30926514~30928407:+
LUAD	cis	rs6793245	0.801	rs41315485	ENSG00000229589.1	ACVR2B-AS1	-3.81	0.000159	0.0207	-0.22	-0.17	QT interval;	chr3:38548784	chr3:38451027~38454820:-
LUAD	cis	rs7512552	0.803	rs7513205	ENSG00000275557.1	RP11-353N4.6	3.81	0.000159	0.0207	0.19	0.17	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150500305	chr1:149607765~149612402:+
LUAD	cis	rs7512552	0.839	rs17597088	ENSG00000275557.1	RP11-353N4.6	3.81	0.000159	0.0207	0.19	0.17	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150503296	chr1:149607765~149612402:+
LUAD	cis	rs7546668	1	rs6686890	ENSG00000272510.1	RP4-680D5.8	3.81	0.000159	0.0207	0.22	0.17	Glomerular filtration rate (creatinine);	chr1:15508919	chr1:15565611~15565956:-
LUAD	cis	rs1953600	0.645	rs2819950	ENSG00000226659.1	RP11-137H2.4	3.81	0.000159	0.0207	0.22	0.17	Sarcoidosis;	chr10:80175523	chr10:80529597~80535942:-
LUAD	cis	rs1348850	0.958	rs1545364	ENSG00000213963.5	AC074286.1	3.81	0.000159	0.0207	0.2	0.17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177598154	chr2:177283508~177392691:-
LUAD	cis	rs11233413	1	rs2127361	ENSG00000246067.6	RAB30-AS1	-3.81	0.000159	0.0207	-0.18	-0.17	Economic and political preferences (feminism/equality);	chr11:83005476	chr11:83072066~83106719:+
LUAD	cis	rs2390582	0.782	rs1418783	ENSG00000233593.5	RP4-665J23.1	3.81	0.000159	0.0207	0.24	0.17	Coronary artery calcification;	chr1:90530523	chr1:90782986~90851650:-
LUAD	cis	rs6547705	0.702	rs4832049	ENSG00000231259.4	AC125232.1	3.81	0.000159	0.0207	0.24	0.17	Progressive supranuclear palsy;	chr2:86826596	chr2:87031815~87053069:-
LUAD	cis	rs1790761	0.587	rs7934075	ENSG00000184224.3	C11orf72	-3.81	0.000159	0.0207	-0.19	-0.17	Mean corpuscular volume;	chr11:67528478	chr11:67602880~67606706:-
LUAD	cis	rs7141336	1	rs8019191	ENSG00000258884.1	CTD-3035D6.2	3.81	0.000159	0.0207	0.18	0.17	Anxiety disorder;	chr14:90819163	chr14:90822365~90828128:-
LUAD	cis	rs7200543	1	rs2740	ENSG00000260735.1	RP11-72I8.1	-3.81	0.000159	0.0207	-0.19	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038251	chr16:15094411~15109197:+
LUAD	cis	rs7555523	0.83	rs6426936	ENSG00000224358.1	RP11-466F5.8	3.81	0.000159	0.0207	0.29	0.17	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165715470	chr1:165768929~165775176:+
LUAD	cis	rs7551222	0.68	rs2125855	ENSG00000240219.1	RP11-430C7.5	3.81	0.000159	0.0207	0.2	0.17	Schizophrenia;	chr1:204577819	chr1:204626775~204629712:+
LUAD	cis	rs11893307	0.507	rs1465304	ENSG00000235852.1	AC005540.3	3.81	0.000159	0.0207	0.2	0.17	Mean platelet volume;	chr2:190720672	chr2:190880797~190882059:-
LUAD	cis	rs860295	0.812	rs12131079	ENSG00000160766.13	GBAP1	3.81	0.000159	0.0207	0.18	0.17	Body mass index;	chr1:155349877	chr1:155213821~155227422:-
LUAD	cis	rs7017914	0.967	rs62508819	ENSG00000246366.5	RP11-382J12.1	3.81	0.000159	0.0207	0.16	0.17	Bone mineral density;	chr8:70805871	chr8:70608577~70663279:+
LUAD	cis	rs6504663	0.558	rs7627	ENSG00000275897.1	RP11-94C24.13	3.81	0.000159	0.0207	0.24	0.17	Visceral fat;	chr17:50474793	chr17:50475819~50478391:+
LUAD	cis	rs854765	0.893	rs712265	ENSG00000223979.2	SMCR2	3.81	0.000159	0.0207	0.19	0.17	Total body bone mineral density;	chr17:18105133	chr17:17674026~17677688:-
LUAD	cis	rs7359257	0.576	rs56038097	ENSG00000270964.1	RP11-502I4.3	-3.81	0.000159	0.0207	-0.2	-0.17	Menarche (age at onset);	chr15:67612231	chr15:67541072~67542604:-
LUAD	cis	rs1075265	0.783	rs805453	ENSG00000272156.1	RP11-477N3.1	-3.81	0.000159	0.0207	-0.2	-0.17	Chronotype;Morning vs. evening chronotype;	chr2:53955761	chr2:54082554~54085066:+
LUAD	cis	rs9549260	0.816	rs7328594	ENSG00000229456.1	RLIMP1	3.81	0.000159	0.0207	0.18	0.17	Red blood cell count;	chr13:40679627	chr13:40618738~40621348:+
LUAD	cis	rs6452524	0.534	rs7724935	ENSG00000281327.1	LINC01338	3.81	0.000159	0.0207	0.18	0.17	Hypertension (SNP x SNP interaction);	chr5:83057264	chr5:82850864~82859836:-
LUAD	cis	rs6452524	0.506	rs7707143	ENSG00000281327.1	LINC01338	3.81	0.000159	0.0207	0.18	0.17	Hypertension (SNP x SNP interaction);	chr5:83057268	chr5:82850864~82859836:-
LUAD	cis	rs9921338	0.961	rs6498185	ENSG00000262703.1	RP11-485G7.6	-3.81	0.000159	0.0207	-0.17	-0.17	Vein graft stenosis in coronary artery bypass grafting;	chr16:11350869	chr16:11348143~11349321:-
LUAD	cis	rs2273788	0.527	rs767402	ENSG00000204173.9	LRRC37A5P	3.81	0.000159	0.0207	0.18	0.17	Monocyte count;	chr9:111581503	chr9:111602831~111631289:-
LUAD	cis	rs13113518	0.812	rs2048564	ENSG00000273257.1	RP11-177J6.1	3.81	0.000159	0.0207	0.19	0.17	Height;	chr4:55407965	chr4:55387949~55388271:+
LUAD	cis	rs703842	0.963	rs2291617	ENSG00000270039.1	RP11-571M6.17	-3.81	0.00016	0.0207	-0.2	-0.17	Multiple sclerosis;	chr12:57772620	chr12:57803838~57804415:+
LUAD	cis	rs683250	0.661	rs2510473	ENSG00000246067.6	RAB30-AS1	-3.81	0.00016	0.0207	-0.17	-0.17	Subcortical brain region volumes;	chr11:83414429	chr11:83072066~83106719:+
LUAD	cis	rs4594175	0.707	rs4901096	ENSG00000258955.1	LINC00519	-3.81	0.00016	0.0207	-0.21	-0.17	Cancer;	chr14:51256108	chr14:51304416~51328386:-
LUAD	cis	rs4660214	0.666	rs2256614	ENSG00000182109.6	RP11-69E11.4	3.81	0.00016	0.0207	0.19	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39359046	chr1:39522280~39546187:-
LUAD	cis	rs9467773	1	rs9467791	ENSG00000261353.1	CTA-14H9.5	3.81	0.00016	0.0207	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26562258	chr6:26527063~26527404:+
LUAD	cis	rs2288884	0.636	rs73066154	ENSG00000269959.1	SPACA6P-AS	-3.81	0.00016	0.0207	-0.18	-0.17	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52060240	chr19:51685363~51693456:-
LUAD	cis	rs9341808	0.718	rs9448908	ENSG00000233967.5	RP11-250B2.3	3.81	0.00016	0.0207	0.17	0.17	Sitting height ratio;	chr6:80188352	chr6:80443344~80465927:+
LUAD	cis	rs8077577	0.708	rs2290504	ENSG00000273018.4	CTD-2303H24.2	3.81	0.00016	0.0207	0.25	0.17	Obesity-related traits;	chr17:18233674	chr17:18511221~18551705:-
LUAD	cis	rs73607972	0.593	rs4784321	ENSG00000275191.1	RP11-36I17.2	-3.81	0.00016	0.0207	-0.23	-0.17	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53602497	chr16:53628256~53628816:-
LUAD	cis	rs7840202	0.778	rs13250340	ENSG00000253328.2	SUMO2P19	-3.81	0.00016	0.0207	-0.21	-0.17	Rate of cognitive decline in mild cognitive impairment (time interaction);Gestational age at birth in labor-initiated deliveries (child effect);	chr8:102242161	chr8:102242040~102242619:-
LUAD	cis	rs7829975	0.606	rs6422352	ENSG00000233609.3	RP11-62H7.2	-3.81	0.00016	0.0207	-0.14	-0.17	Mood instability;	chr8:8936683	chr8:8961200~8979025:+
LUAD	cis	rs2468186	0.966	rs4870897	ENSG00000281641.1	SAMD12-AS1	3.81	0.00016	0.0208	0.23	0.17	Osteoprotegerin levels;	chr8:119204097	chr8:118621001~118858218:+
LUAD	cis	rs13434995	0.513	rs1979605	ENSG00000273257.1	RP11-177J6.1	3.81	0.00016	0.0208	0.23	0.17	Adiponectin levels;	chr4:55552706	chr4:55387949~55388271:+
LUAD	cis	rs7017914	0.934	rs17760050	ENSG00000246366.5	RP11-382J12.1	3.81	0.00016	0.0208	0.16	0.17	Bone mineral density;	chr8:70662016	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.934	rs35214141	ENSG00000246366.5	RP11-382J12.1	3.81	0.00016	0.0208	0.16	0.17	Bone mineral density;	chr8:70662329	chr8:70608577~70663279:+
LUAD	cis	rs9549260	0.564	rs4943804	ENSG00000229456.1	RLIMP1	3.81	0.00016	0.0208	0.18	0.17	Red blood cell count;	chr13:40695858	chr13:40618738~40621348:+
LUAD	cis	rs763121	0.925	rs1043312	ENSG00000273076.1	RP3-508I15.22	3.81	0.00016	0.0208	0.16	0.17	Menopause (age at onset);	chr22:38735722	chr22:38743495~38743910:+
LUAD	cis	rs8180040	0.966	rs9683033	ENSG00000271161.1	BOLA2P2	3.81	0.00016	0.0208	0.16	0.17	Colorectal cancer;	chr3:47448330	chr3:47499841~47500407:+
LUAD	cis	rs8180040	0.966	rs9683177	ENSG00000271161.1	BOLA2P2	3.81	0.00016	0.0208	0.16	0.17	Colorectal cancer;	chr3:47449003	chr3:47499841~47500407:+
LUAD	cis	rs6687758	1	rs12121134	ENSG00000238042.4	RP11-815M8.1	3.81	0.00016	0.0208	0.24	0.17	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222021538	chr1:221880981~221978523:-
LUAD	cis	rs6687758	1	rs56170536	ENSG00000238042.4	RP11-815M8.1	3.81	0.00016	0.0208	0.24	0.17	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222024527	chr1:221880981~221978523:-
LUAD	cis	rs6687758	1	rs66732677	ENSG00000238042.4	RP11-815M8.1	3.81	0.00016	0.0208	0.24	0.17	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222026325	chr1:221880981~221978523:-
LUAD	cis	rs818427	0.964	rs519397	ENSG00000279522.1	CTC-487M23.6	3.81	0.00016	0.0208	0.21	0.17	Total body bone mineral density;	chr5:112893991	chr5:112894933~112896531:+
LUAD	cis	rs17597773	0.638	rs12145674	ENSG00000272823.1	RP11-295M18.6	3.81	0.00016	0.0208	0.22	0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220826931	chr1:220828676~220829211:-
LUAD	cis	rs12291225	0.679	rs11605531	ENSG00000251991.1	RNU7-49P	3.81	0.00016	0.0208	0.2	0.17	Sense of smell;	chr11:14270048	chr11:14478892~14478953:+
LUAD	cis	rs12291225	0.639	rs61883858	ENSG00000251991.1	RNU7-49P	3.81	0.00016	0.0208	0.2	0.17	Sense of smell;	chr11:14273162	chr11:14478892~14478953:+
LUAD	cis	rs12291225	0.679	rs11023170	ENSG00000251991.1	RNU7-49P	3.81	0.00016	0.0208	0.2	0.17	Sense of smell;	chr11:14273363	chr11:14478892~14478953:+
LUAD	cis	rs11673344	0.523	rs2562607	ENSG00000276846.1	CTD-3220F14.3	3.81	0.00016	0.0208	0.19	0.17	Obesity-related traits;	chr19:37031358	chr19:37314868~37315620:-
LUAD	cis	rs11673344	0.523	rs6510584	ENSG00000276846.1	CTD-3220F14.3	3.81	0.00016	0.0208	0.19	0.17	Obesity-related traits;	chr19:37058699	chr19:37314868~37315620:-
LUAD	cis	rs4372836	0.964	rs4665431	ENSG00000226833.4	AC097724.3	-3.81	0.00016	0.0208	-0.2	-0.17	Body mass index;	chr2:28715302	chr2:28708953~28736205:-
LUAD	cis	rs11168618	0.74	rs10506281	ENSG00000240399.1	RP1-228P16.1	-3.81	0.00016	0.0208	-0.16	-0.17	Adiponectin levels;	chr12:48529991	chr12:48054813~48055591:-
LUAD	cis	rs2239547	0.522	rs2581779	ENSG00000243224.1	RP5-1157M23.2	3.81	0.00016	0.0208	0.2	0.17	Schizophrenia;	chr3:53022183	chr3:52239258~52241097:+
LUAD	cis	rs17695224	0.5	rs55899451	ENSG00000269483.1	AC006272.1	3.81	0.00016	0.0208	0.19	0.17	HDL cholesterol;HDL cholesterol levels;	chr19:51818058	chr19:51839924~51843324:-
LUAD	cis	rs17695224	0.545	rs55883913	ENSG00000269483.1	AC006272.1	3.81	0.00016	0.0208	0.19	0.17	HDL cholesterol;HDL cholesterol levels;	chr19:51818071	chr19:51839924~51843324:-
LUAD	cis	rs8031584	0.678	rs4779496	ENSG00000260128.5	ULK4P2	-3.81	0.00016	0.0208	-0.23	-0.17	Huntington's disease progression;	chr15:30858851	chr15:30572738~30600647:+
LUAD	cis	rs8031584	0.678	rs4779497	ENSG00000260128.5	ULK4P2	-3.81	0.00016	0.0208	-0.23	-0.17	Huntington's disease progression;	chr15:30859162	chr15:30572738~30600647:+
LUAD	cis	rs8031584	0.678	rs8028173	ENSG00000260128.5	ULK4P2	-3.81	0.00016	0.0208	-0.23	-0.17	Huntington's disease progression;	chr15:30863546	chr15:30572738~30600647:+
LUAD	cis	rs8031584	0.706	rs2177670	ENSG00000260128.5	ULK4P2	-3.81	0.00016	0.0208	-0.23	-0.17	Huntington's disease progression;	chr15:30865548	chr15:30572738~30600647:+
LUAD	cis	rs8031584	0.678	rs36047941	ENSG00000260128.5	ULK4P2	-3.81	0.00016	0.0208	-0.23	-0.17	Huntington's disease progression;	chr15:30867032	chr15:30572738~30600647:+
LUAD	cis	rs7017914	0.967	rs35207116	ENSG00000246366.5	RP11-382J12.1	3.81	0.00016	0.0208	0.16	0.17	Bone mineral density;	chr8:70796736	chr8:70608577~70663279:+
LUAD	cis	rs6479901	0.895	rs9629895	ENSG00000232075.1	MRPL35P2	-3.81	0.00016	0.0208	-0.23	-0.17	Intelligence (multi-trait analysis);	chr10:63363027	chr10:63634317~63634827:-
LUAD	cis	rs7760535	0.826	rs7753887	ENSG00000266032.1	AL357515.1	3.81	0.00016	0.0208	0.22	0.17	Metabolic traits;	chr6:111533904	chr6:110969773~110969872:-
LUAD	cis	rs8014252	0.803	rs74712571	ENSG00000259158.2	ADAM20P1	-3.81	0.00016	0.0208	-0.3	-0.17	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70520034	chr14:70468881~70483756:-
LUAD	cis	rs8014252	0.708	rs74062730	ENSG00000259158.2	ADAM20P1	-3.81	0.00016	0.0208	-0.3	-0.17	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70524933	chr14:70468881~70483756:-
LUAD	cis	rs6951245	0.745	rs79788515	ENSG00000224079.1	AC091729.7	-3.81	0.00016	0.0208	-0.27	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061443	chr7:1074450~1078036:+
LUAD	cis	rs6496932	1	rs34434405	ENSG00000259630.2	CTD-2262B20.1	3.81	0.00016	0.0208	0.23	0.17	Central corneal thickness;Corneal structure;	chr15:85281437	chr15:85415228~85415633:+
LUAD	cis	rs761746	0.739	rs131233	ENSG00000236132.1	CTA-440B3.1	-3.8	0.00016	0.0208	-0.25	-0.17	Intelligence;	chr22:31721114	chr22:31816379~31817491:-
LUAD	cis	rs2731006	0.64	rs2459736	ENSG00000257114.2	RP11-25I15.3	3.8	0.00016	0.0208	0.28	0.17	Panic disorder;	chr12:42776971	chr12:42692216~42717119:+
LUAD	cis	rs9847710	1	rs12488768	ENSG00000242142.1	SERBP1P3	-3.8	0.00016	0.0208	-0.18	-0.17	Ulcerative colitis;	chr3:53052218	chr3:53064283~53065091:-
LUAD	cis	rs12291225	0.679	rs4756786	ENSG00000251991.1	RNU7-49P	3.8	0.00016	0.0208	0.2	0.17	Sense of smell;	chr11:14264354	chr11:14478892~14478953:+
LUAD	cis	rs2708977	0.609	rs670498	ENSG00000237510.6	AC008268.2	-3.8	0.00016	0.0208	-0.22	-0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96424490	chr2:95789654~95800166:+
LUAD	cis	rs8180040	0.932	rs12489046	ENSG00000271161.1	BOLA2P2	3.8	0.00016	0.0208	0.16	0.17	Colorectal cancer;	chr3:47486193	chr3:47499841~47500407:+
LUAD	cis	rs8180040	0.932	rs12490058	ENSG00000271161.1	BOLA2P2	3.8	0.00016	0.0208	0.16	0.17	Colorectal cancer;	chr3:47487573	chr3:47499841~47500407:+
LUAD	cis	rs6951245	0.872	rs77569514	ENSG00000199023.2	MIR339	-3.8	0.00016	0.0208	-0.31	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1045872	chr7:1022935~1023045:-
LUAD	cis	rs858239	0.571	rs2390755	ENSG00000226816.2	AC005082.12	3.8	0.00016	0.0208	0.23	0.17	Cerebrospinal fluid biomarker levels;	chr7:23151097	chr7:23206013~23208045:+
LUAD	cis	rs858239	0.539	rs4365988	ENSG00000226816.2	AC005082.12	3.8	0.00016	0.0208	0.23	0.17	Cerebrospinal fluid biomarker levels;	chr7:23151252	chr7:23206013~23208045:+
LUAD	cis	rs7824557	0.527	rs2572369	ENSG00000255046.1	RP11-297N6.4	3.8	0.00016	0.0208	0.21	0.17	Retinal vascular caliber;	chr8:11381088	chr8:11797928~11802568:-
LUAD	cis	rs7236632	0.582	rs9958388	ENSG00000267504.1	RP11-845C23.2	-3.8	0.00016	0.0208	-0.26	-0.17	Attention deficit hyperactivity disorder and conduct disorder;	chr18:57753320	chr18:58371566~58372666:+
LUAD	cis	rs1075265	0.783	rs805450	ENSG00000272156.1	RP11-477N3.1	-3.8	0.00016	0.0208	-0.2	-0.17	Chronotype;Morning vs. evening chronotype;	chr2:53951772	chr2:54082554~54085066:+
LUAD	cis	rs2274273	0.686	rs66531545	ENSG00000258413.1	RP11-665C16.6	-3.8	0.00016	0.0208	-0.24	-0.17	Protein biomarker;	chr14:55120742	chr14:55262767~55272075:-
LUAD	cis	rs6452524	0.508	rs256795	ENSG00000271862.1	RP11-343L5.2	-3.8	0.00016	0.0208	-0.17	-0.17	Hypertension (SNP x SNP interaction);	chr5:83001543	chr5:83049376~83050964:-
LUAD	cis	rs10876993	0.749	rs703832	ENSG00000245651.2	RP11-620J15.2	-3.8	0.00016	0.0208	-0.18	-0.17	Celiac disease or Rheumatoid arthritis;	chr12:57630843	chr12:57869835~57896482:-
LUAD	cis	rs6964833	1	rs36044436	ENSG00000184616.8	AC004166.6	3.8	0.00016	0.0208	0.26	0.17	Menarche (age at onset);	chr7:74675495	chr7:74906673~74913256:-
LUAD	cis	rs8133949	1	rs75128809	ENSG00000237232.6	ZNF295-AS1	3.8	0.000161	0.0208	0.21	0.17	Hand grip strength;	chr21:41998101	chr21:42009194~42024924:+
LUAD	cis	rs2834288	0.535	rs4816469	ENSG00000237945.6	LINC00649	3.8	0.000161	0.0208	0.22	0.17	Gut microbiota (bacterial taxa);	chr21:33952321	chr21:33915534~33977691:+
LUAD	cis	rs8031584	0.652	rs2691683	ENSG00000260128.5	ULK4P2	3.8	0.000161	0.0208	0.23	0.17	Huntington's disease progression;	chr15:30842857	chr15:30572738~30600647:+
LUAD	cis	rs42490	0.664	rs39767	ENSG00000251136.7	RP11-37B2.1	-3.8	0.000161	0.0208	-0.17	-0.17	Leprosy;	chr8:89807770	chr8:89609409~89757727:-
LUAD	cis	rs10419113	0.522	rs13037	ENSG00000270804.1	CTD-2583A14.11	3.8	0.000161	0.0208	0.16	0.17	Pediatric bone mineral density (spine);	chr19:57757805	chr19:57867885~57868834:+
LUAD	cis	rs72615157	0.664	rs6953580	ENSG00000078319.8	PMS2P1	-3.8	0.000161	0.0208	-0.2	-0.17	Lung function (FEV1/FVC);	chr7:100227652	chr7:100320992~100341908:-
LUAD	cis	rs6832769	0.89	rs1522107	ENSG00000272969.1	RP11-528I4.2	3.8	0.000161	0.0208	0.18	0.17	Personality dimensions;	chr4:55514606	chr4:55547112~55547889:+
LUAD	cis	rs599083	0.53	rs491347	ENSG00000212093.1	AP000807.1	-3.8	0.000161	0.0208	-0.19	-0.17	Bone mineral density (spine);	chr11:68402220	chr11:68506083~68506166:-
LUAD	cis	rs9549260	0.564	rs8000965	ENSG00000229456.1	RLIMP1	3.8	0.000161	0.0208	0.18	0.17	Red blood cell count;	chr13:40705352	chr13:40618738~40621348:+
LUAD	cis	rs526231	0.67	rs444779	ENSG00000175749.11	EIF3KP1	3.8	0.000161	0.0208	0.22	0.17	Primary biliary cholangitis;	chr5:103288460	chr5:103032376~103033031:+
LUAD	cis	rs2832077	0.505	rs9305386	ENSG00000232855.5	AF131217.1	-3.8	0.000161	0.0208	-0.22	-0.17	Cognitive test performance;	chr21:29014430	chr21:28439346~28674848:-
LUAD	cis	rs6832769	0.643	rs11735910	ENSG00000272969.1	RP11-528I4.2	-3.8	0.000161	0.0208	-0.19	-0.17	Personality dimensions;	chr4:55652579	chr4:55547112~55547889:+
LUAD	cis	rs8062405	0.54	rs151226	ENSG00000261766.1	RP11-22P6.2	-3.8	0.000161	0.0209	-0.14	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28538502	chr16:28862166~28863340:-
LUAD	cis	rs11742741	0.87	rs4701421	ENSG00000248874.4	C5orf17	-3.8	0.000161	0.0209	-0.22	-0.17	Educational attainment;	chr5:24088888	chr5:23951348~24178263:+
LUAD	cis	rs11742741	0.805	rs12186963	ENSG00000248874.4	C5orf17	-3.8	0.000161	0.0209	-0.22	-0.17	Educational attainment;	chr5:24090136	chr5:23951348~24178263:+
LUAD	cis	rs11742741	0.87	rs2877428	ENSG00000248874.4	C5orf17	-3.8	0.000161	0.0209	-0.22	-0.17	Educational attainment;	chr5:24090575	chr5:23951348~24178263:+
LUAD	cis	rs7829975	0.623	rs10092965	ENSG00000233609.3	RP11-62H7.2	3.8	0.000161	0.0209	0.14	0.17	Mood instability;	chr8:8515975	chr8:8961200~8979025:+
LUAD	cis	rs9467773	0.935	rs4573	ENSG00000124549.13	BTN2A3P	3.8	0.000161	0.0209	0.16	0.17	Intelligence (multi-trait analysis);	chr6:26546580	chr6:26421391~26432383:+
LUAD	cis	rs5758659	0.714	rs5751216	ENSG00000273366.1	CTA-989H11.1	3.8	0.000161	0.0209	0.2	0.17	Cognitive function;	chr22:42112933	chr22:42278188~42278846:+
LUAD	cis	rs7246657	0.943	rs2279148	ENSG00000226686.6	LINC01535	-3.8	0.000161	0.0209	-0.25	-0.17	Coronary artery calcification;	chr19:37533781	chr19:37251912~37265535:+
LUAD	cis	rs6781182	0.517	rs11717932	ENSG00000236452.1	AC123023.1	3.8	0.000161	0.0209	0.19	0.17	Visceral adipose tissue adjusted for BMI;	chr3:34198855	chr3:34203244~34268811:+
LUAD	cis	rs5769707	0.521	rs6009810	ENSG00000235111.1	RP1-29C18.8	-3.8	0.000161	0.0209	-0.2	-0.17	Monocyte percentage of white cells;Monocyte count;	chr22:49665892	chr22:49612657~49615716:-
LUAD	cis	rs7017914	0.934	rs62508771	ENSG00000246366.5	RP11-382J12.1	3.8	0.000161	0.0209	0.16	0.17	Bone mineral density;	chr8:70780453	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.967	rs6998786	ENSG00000246366.5	RP11-382J12.1	3.8	0.000161	0.0209	0.16	0.17	Bone mineral density;	chr8:70782395	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.967	rs12680988	ENSG00000246366.5	RP11-382J12.1	3.8	0.000161	0.0209	0.16	0.17	Bone mineral density;	chr8:70783655	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.967	rs1596566	ENSG00000246366.5	RP11-382J12.1	3.8	0.000161	0.0209	0.16	0.17	Bone mineral density;	chr8:70786341	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.967	rs6993115	ENSG00000246366.5	RP11-382J12.1	3.8	0.000161	0.0209	0.16	0.17	Bone mineral density;	chr8:70786948	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.934	rs6992879	ENSG00000246366.5	RP11-382J12.1	3.8	0.000161	0.0209	0.16	0.17	Bone mineral density;	chr8:70787048	chr8:70608577~70663279:+
LUAD	cis	rs11667325	0.7	rs11084120	ENSG00000268316.1	AC006272.2	3.8	0.000161	0.0209	0.22	0.17	Neutrophil percentage of granulocytes;	chr19:51795237	chr19:51839771~51840945:-
LUAD	cis	rs11667325	0.7	rs11084121	ENSG00000268316.1	AC006272.2	3.8	0.000161	0.0209	0.22	0.17	Neutrophil percentage of granulocytes;	chr19:51795259	chr19:51839771~51840945:-
LUAD	cis	rs7712401	0.818	rs13166350	ENSG00000249996.1	RP11-359P5.1	3.8	0.000161	0.0209	0.21	0.17	Mean platelet volume;	chr5:122817874	chr5:123036271~123054667:+
LUAD	cis	rs10411262	0.935	rs314661	ENSG00000211513.4	MIR320E	-3.8	0.000161	0.0209	-0.18	-0.17	Tonsillectomy;	chr19:46669216	chr19:46709271~46709382:-
LUAD	cis	rs12285276	0.536	rs4411261	ENSG00000205106.4	DKFZp779M0652	3.8	0.000161	0.0209	0.2	0.17	Visceral fat;	chr11:45785530	chr11:45771432~45772358:+
LUAD	cis	rs6071166	0.708	rs6071047	ENSG00000224635.1	RP4-564F22.5	-3.8	0.000161	0.0209	-0.2	-0.17	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38677363	chr20:38406011~38416797:-
LUAD	cis	rs6071166	0.646	rs6071050	ENSG00000224635.1	RP4-564F22.5	-3.8	0.000161	0.0209	-0.2	-0.17	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38677429	chr20:38406011~38416797:-
LUAD	cis	rs6071166	0.683	rs6027216	ENSG00000224635.1	RP4-564F22.5	-3.8	0.000161	0.0209	-0.2	-0.17	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38678271	chr20:38406011~38416797:-
LUAD	cis	rs848087	0.967	rs2764962	ENSG00000258661.1	RP11-964E11.2	-3.8	0.000161	0.0209	-0.2	-0.17	Breast cancer;	chr14:36759015	chr14:36647083~36658801:-
LUAD	cis	rs748404	0.588	rs2255410	ENSG00000166763.7	STRCP1	3.8	0.000161	0.0209	0.2	0.17	Lung cancer;	chr15:43538899	chr15:43699488~43718184:-
LUAD	cis	rs4934494	0.727	rs67827533	ENSG00000240996.1	RP11-80H5.7	-3.8	0.000161	0.0209	-0.24	-0.17	Red blood cell count;	chr10:89745626	chr10:89694295~89697928:-
LUAD	cis	rs4934494	0.768	rs1926139	ENSG00000240996.1	RP11-80H5.7	-3.8	0.000161	0.0209	-0.24	-0.17	Red blood cell count;	chr10:89753395	chr10:89694295~89697928:-
LUAD	cis	rs4934494	0.727	rs55823491	ENSG00000240996.1	RP11-80H5.7	-3.8	0.000161	0.0209	-0.24	-0.17	Red blood cell count;	chr10:89757598	chr10:89694295~89697928:-
LUAD	cis	rs4934494	0.727	rs12570750	ENSG00000240996.1	RP11-80H5.7	-3.8	0.000161	0.0209	-0.24	-0.17	Red blood cell count;	chr10:89761273	chr10:89694295~89697928:-
LUAD	cis	rs4934494	0.723	rs17127001	ENSG00000240996.1	RP11-80H5.7	-3.8	0.000161	0.0209	-0.24	-0.17	Red blood cell count;	chr10:89762932	chr10:89694295~89697928:-
LUAD	cis	rs4934494	0.727	rs36019294	ENSG00000240996.1	RP11-80H5.7	-3.8	0.000161	0.0209	-0.24	-0.17	Red blood cell count;	chr10:89777822	chr10:89694295~89697928:-
LUAD	cis	rs7017914	0.69	rs62506037	ENSG00000246366.5	RP11-382J12.1	3.8	0.000161	0.0209	0.16	0.17	Bone mineral density;	chr8:71066959	chr8:70608577~70663279:+
LUAD	cis	rs10266483	0.654	rs6962076	ENSG00000228653.2	HNRNPCP7	3.8	0.000161	0.0209	0.21	0.17	Response to statin therapy;	chr7:64559214	chr7:64500825~64501729:+
LUAD	cis	rs728616	0.717	rs111403425	ENSG00000225484.5	NUTM2B-AS1	-3.8	0.000161	0.0209	-0.36	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80060786	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.867	rs78131725	ENSG00000225484.5	NUTM2B-AS1	-3.8	0.000161	0.0209	-0.36	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80061163	chr10:79663088~79826594:-
LUAD	cis	rs2274273	0.624	rs11848575	ENSG00000258413.1	RP11-665C16.6	-3.8	0.000161	0.0209	-0.23	-0.17	Protein biomarker;	chr14:55289070	chr14:55262767~55272075:-
LUAD	cis	rs10197140	0.925	rs6542189	ENSG00000235721.1	AC013268.3	-3.8	0.000161	0.0209	-0.19	-0.17	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110880350	chr2:110007675~110010783:+
LUAD	cis	rs6121246	0.609	rs6060652	ENSG00000230613.1	HM13-AS1	3.8	0.000161	0.0209	0.21	0.17	Mean corpuscular hemoglobin;	chr20:31679042	chr20:31567707~31573263:-
LUAD	cis	rs17685	0.712	rs10235086	ENSG00000280388.1	RP11-229D13.3	-3.8	0.000161	0.0209	-0.16	-0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76203820	chr7:76043977~76045963:-
LUAD	cis	rs8050896	1	rs73586284	ENSG00000260695.1	RP11-513N24.1	-3.8	0.000161	0.0209	-0.31	-0.17	Response to antipsychotic treatment;	chr16:66121824	chr16:65861112~65863784:-
LUAD	cis	rs7267979	0.509	rs6115218	ENSG00000230772.1	VN1R108P	3.8	0.000161	0.0209	0.22	0.17	Liver enzyme levels (alkaline phosphatase);	chr20:25585849	chr20:25734264~25735093:+
LUAD	cis	rs6460942	1	rs17274870	ENSG00000226690.5	AC005281.1	3.8	0.000161	0.0209	0.31	0.17	Coronary artery disease;	chr7:12366595	chr7:12496429~12541910:+
LUAD	cis	rs2412819	0.571	rs2729494	ENSG00000166763.7	STRCP1	-3.8	0.000161	0.0209	-0.24	-0.17	Lung cancer;	chr15:43837395	chr15:43699488~43718184:-
LUAD	cis	rs2412819	0.571	rs528764	ENSG00000166763.7	STRCP1	-3.8	0.000161	0.0209	-0.24	-0.17	Lung cancer;	chr15:43838650	chr15:43699488~43718184:-
LUAD	cis	rs9467773	0.967	rs7753565	ENSG00000241549.7	GUSBP2	3.8	0.000161	0.0209	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26559784	chr6:26871484~26956554:-
LUAD	cis	rs4787951	0.56	rs3916997	ENSG00000259940.2	CTD-3203P2.1	-3.8	0.000161	0.0209	-0.19	-0.17	Eosinophil percentage of white cells;	chr16:27333793	chr16:27213308~27214993:-
LUAD	cis	rs3845817	0.868	rs702942	ENSG00000281920.1	RP11-418H16.1	-3.8	0.000161	0.0209	-0.21	-0.17	Bipolar disorder;	chr2:65529831	chr2:65623272~65628424:+
LUAD	cis	rs6942407	0.64	rs4728690	ENSG00000224046.1	AC005076.5	-3.8	0.000161	0.0209	-0.22	-0.17	Food allergy;	chr7:87224688	chr7:87151423~87152420:-
LUAD	cis	rs34421088	0.576	rs2572437	ENSG00000255046.1	RP11-297N6.4	3.8	0.000161	0.0209	0.22	0.17	Neuroticism;	chr8:11240932	chr8:11797928~11802568:-
LUAD	cis	rs6479901	0.895	rs7092139	ENSG00000232075.1	MRPL35P2	-3.8	0.000161	0.0209	-0.24	-0.17	Intelligence (multi-trait analysis);	chr10:63306540	chr10:63634317~63634827:-
LUAD	cis	rs6479901	1	rs7092539	ENSG00000232075.1	MRPL35P2	-3.8	0.000161	0.0209	-0.24	-0.17	Intelligence (multi-trait analysis);	chr10:63306749	chr10:63634317~63634827:-
LUAD	cis	rs141322890	1	rs141322890	ENSG00000224138.1	AC000123.4	3.8	0.000161	0.0209	0.16	0.17	Intelligence (multi-trait analysis);	chr7:127489947	chr7:127350128~127351523:+
LUAD	cis	rs600231	0.542	rs10896008	ENSG00000245532.5	NEAT1	3.8	0.000161	0.0209	0.16	0.17	Bone mineral density;	chr11:65478433	chr11:65422774~65445540:+
LUAD	cis	rs7584330	0.868	rs58057291	ENSG00000222032.1	AC112721.2	3.8	0.000161	0.0209	0.2	0.17	Prostate cancer;	chr2:237486836	chr2:237428920~237434822:-
LUAD	cis	rs10129255	0.872	rs8015406	ENSG00000274576.2	IGHV2-70	3.8	0.000161	0.0209	0.15	0.17	Kawasaki disease;	chr14:106670611	chr14:106770577~106771020:-
LUAD	cis	rs17189298	0.935	rs7558446	ENSG00000231013.1	AC013275.2	3.8	0.000161	0.0209	0.17	0.17	Cerebrospinal T-tau levels;	chr2:119088390	chr2:119476448~119487346:+
LUAD	cis	rs10752881	1	rs10911185	ENSG00000224468.3	RP11-181K3.4	-3.8	0.000161	0.0209	-0.15	-0.17	Colorectal cancer;	chr1:183002612	chr1:183138402~183141282:-
LUAD	cis	rs10752881	1	rs10737235	ENSG00000224468.3	RP11-181K3.4	-3.8	0.000161	0.0209	-0.15	-0.17	Colorectal cancer;	chr1:183002681	chr1:183138402~183141282:-
LUAD	cis	rs7178424	0.806	rs4775453	ENSG00000259251.2	RP11-643M14.1	3.8	0.000161	0.0209	0.17	0.17	Height;	chr15:61925192	chr15:62060503~62062434:+
LUAD	cis	rs13434995	0.842	rs9790448	ENSG00000249700.7	SRD5A3-AS1	-3.8	0.000161	0.0209	-0.25	-0.17	Adiponectin levels;	chr4:55592918	chr4:55363971~55395847:-
LUAD	cis	rs442309	0.749	rs224109	ENSG00000238280.1	RP11-436D10.3	-3.8	0.000161	0.0209	-0.2	-0.17	Vogt-Koyanagi-Harada syndrome;	chr10:62790311	chr10:62793562~62805887:-
LUAD	cis	rs9366309	0.501	rs7774228	ENSG00000228412.5	RP4-625H18.2	-3.8	0.000161	0.0209	-0.21	-0.17	Pulmonary function in asthmatics;	chr6:19684392	chr6:19802164~19804752:-
LUAD	cis	rs9366309	0.501	rs7739541	ENSG00000228412.5	RP4-625H18.2	-3.8	0.000161	0.0209	-0.21	-0.17	Pulmonary function in asthmatics;	chr6:19684563	chr6:19802164~19804752:-
LUAD	cis	rs7937890	0.559	rs2597208	ENSG00000254418.1	RP11-21L19.1	3.8	0.000161	0.0209	0.2	0.17	Mitochondrial DNA levels;	chr11:14450783	chr11:14262846~14273691:-
LUAD	cis	rs7107174	1	rs10899483	ENSG00000251323.2	RP11-452H21.4	3.8	0.000161	0.0209	0.21	0.17	Testicular germ cell tumor;	chr11:78350011	chr11:78423982~78429836:-
LUAD	cis	rs324126	0.78	rs4802926	ENSG00000277977.1	CTD-3018O17.5	-3.8	0.000161	0.0209	-0.18	-0.17	Colonoscopy-negative controls vs population controls;	chr19:52377012	chr19:52392659~52392755:+
LUAD	cis	rs755249	0.567	rs112672438	ENSG00000182109.6	RP11-69E11.4	3.8	0.000161	0.0209	0.21	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39181115	chr1:39522280~39546187:-
LUAD	cis	rs755249	0.567	rs16825921	ENSG00000182109.6	RP11-69E11.4	3.8	0.000161	0.0209	0.21	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39183526	chr1:39522280~39546187:-
LUAD	cis	rs2638953	0.924	rs11049392	ENSG00000278733.1	RP11-425D17.1	-3.8	0.000161	0.0209	-0.21	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28170256	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs11049394	ENSG00000278733.1	RP11-425D17.1	-3.8	0.000161	0.0209	-0.21	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28170947	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.886	rs11049395	ENSG00000278733.1	RP11-425D17.1	-3.8	0.000161	0.0209	-0.21	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28171087	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.886	rs11049397	ENSG00000278733.1	RP11-425D17.1	-3.8	0.000161	0.0209	-0.21	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28171909	chr12:28185625~28186190:-
LUAD	cis	rs4423214	0.879	rs1790330	ENSG00000226627.1	SHANK2-AS1	3.8	0.000161	0.0209	0.21	0.17	Vitamin D levels;	chr11:71436779	chr11:70631094~70635490:+
LUAD	cis	rs4423214	0.84	rs1790328	ENSG00000226627.1	SHANK2-AS1	3.8	0.000161	0.0209	0.21	0.17	Vitamin D levels;	chr11:71436992	chr11:70631094~70635490:+
LUAD	cis	rs77633900	0.892	rs2456067	ENSG00000196274.5	Metazoa_SRP	3.8	0.000161	0.0209	0.23	0.17	Glioma;Non-glioblastoma glioma;	chr15:76289077	chr15:76230048~76230390:-
LUAD	cis	rs780096	0.527	rs11127044	ENSG00000234072.1	AC074117.10	-3.8	0.000162	0.0209	-0.13	-0.17	Total body bone mineral density;	chr2:27517537	chr2:27356246~27367622:+
LUAD	cis	rs3617	0.625	rs11719137	ENSG00000242142.1	SERBP1P3	-3.8	0.000162	0.0209	-0.18	-0.17	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52842373	chr3:53064283~53065091:-
LUAD	cis	rs3617	0.598	rs56214994	ENSG00000242142.1	SERBP1P3	-3.8	0.000162	0.0209	-0.18	-0.17	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52844584	chr3:53064283~53065091:-
LUAD	cis	rs858239	0.536	rs6961109	ENSG00000230042.1	AK3P3	-3.8	0.000162	0.0209	-0.22	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23212794	chr7:23129178~23129841:+
LUAD	cis	rs643506	1	rs4936675	ENSG00000230911.1	PPIHP1	-3.8	0.000162	0.0209	-0.22	-0.17	Breast cancer;	chr11:111752364	chr11:112029858~112030367:-
LUAD	cis	rs7141336	1	rs7141336	ENSG00000258884.1	CTD-3035D6.2	-3.8	0.000162	0.0209	-0.17	-0.17	Anxiety disorder;	chr14:90819884	chr14:90822365~90828128:-
LUAD	cis	rs910316	0.967	rs4899549	ENSG00000279594.1	RP11-950C14.10	-3.8	0.000162	0.0209	-0.2	-0.17	Height;	chr14:75180791	chr14:75011269~75012851:-
LUAD	cis	rs910316	0.967	rs4899550	ENSG00000279594.1	RP11-950C14.10	-3.8	0.000162	0.0209	-0.2	-0.17	Height;	chr14:75180963	chr14:75011269~75012851:-
LUAD	cis	rs250518	0.926	rs13157511	ENSG00000226544.4	RPL7P22	3.8	0.000162	0.0209	0.18	0.17	Mean corpuscular hemoglobin concentration;	chr5:72775976	chr5:72725419~72726151:+
LUAD	cis	rs13113518	0.812	rs13140590	ENSG00000273257.1	RP11-177J6.1	3.8	0.000162	0.0209	0.19	0.17	Height;	chr4:55548666	chr4:55387949~55388271:+
LUAD	cis	rs8073060	0.586	rs17638867	ENSG00000267592.1	CTC-507E2.2	-3.8	0.000162	0.0209	-0.24	-0.17	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35725494	chr17:35596904~35597128:-
LUAD	cis	rs12149074	0.55	rs7192753	ENSG00000261390.4	RP11-345M22.2	3.8	0.000162	0.0209	0.22	0.17	Bipolar disorder and eating disorder;Eating disorder in bipolar disorder;	chr16:80064352	chr16:79715232~79770563:-
LUAD	cis	rs10829156	0.699	rs6482516	ENSG00000240291.1	RP11-499P20.2	3.8	0.000162	0.021	0.15	0.17	Sudden cardiac arrest;	chr10:18550421	chr10:18513115~18545651:-
LUAD	cis	rs763121	0.853	rs4821808	ENSG00000225450.1	RP3-508I15.14	-3.8	0.000162	0.021	-0.17	-0.17	Menopause (age at onset);	chr22:38669734	chr22:38739003~38749041:+
LUAD	cis	rs763121	0.853	rs4821809	ENSG00000225450.1	RP3-508I15.14	-3.8	0.000162	0.021	-0.17	-0.17	Menopause (age at onset);	chr22:38669738	chr22:38739003~38749041:+
LUAD	cis	rs321358	0.79	rs73015129	ENSG00000271390.1	RP11-89C3.3	3.8	0.000162	0.021	0.28	0.17	Body mass index;	chr11:111076157	chr11:111089870~111090368:-
LUAD	cis	rs321358	0.79	rs73015134	ENSG00000271390.1	RP11-89C3.3	3.8	0.000162	0.021	0.28	0.17	Body mass index;	chr11:111076520	chr11:111089870~111090368:-
LUAD	cis	rs6471393	0.798	rs55680024	ENSG00000253848.1	RP11-10N23.5	3.8	0.000162	0.021	0.22	0.17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93836533	chr8:93741193~93744534:+
LUAD	cis	rs1783925	0.529	rs11220072	ENSG00000254671.2	STT3A-AS1	-3.8	0.000162	0.021	-0.19	-0.17	Formal thought disorder in schizophrenia;	chr11:125436560	chr11:125570284~125592568:-
LUAD	cis	rs9633740	0.545	rs2343306	ENSG00000226659.1	RP11-137H2.4	3.8	0.000162	0.021	0.28	0.17	Post bronchodilator FEV1;	chr10:80470390	chr10:80529597~80535942:-
LUAD	cis	rs4268898	0.636	rs76172309	ENSG00000242628.4	AC009228.1	3.8	0.000162	0.021	0.25	0.17	Asthma;	chr2:24236042	chr2:24214381~24221516:+
LUAD	cis	rs7624766	0.903	rs12638557	ENSG00000184100.6	BRD7P2	3.8	0.000162	0.021	0.17	0.17	Response to methotrexate in rheumatoid arthritis;	chr3:160705940	chr3:160100850~160102793:+
LUAD	cis	rs2041895	0.509	rs2072559	ENSG00000260329.1	RP11-412D9.4	-3.8	0.000162	0.021	-0.22	-0.17	Glaucoma (low intraocular pressure);	chr12:106913509	chr12:106954029~106955497:-
LUAD	cis	rs683250	0.566	rs610062	ENSG00000246067.6	RAB30-AS1	3.8	0.000162	0.021	0.18	0.17	Subcortical brain region volumes;	chr11:83292247	chr11:83072066~83106719:+
LUAD	cis	rs1979679	0.842	rs7138497	ENSG00000278733.1	RP11-425D17.1	3.8	0.000162	0.021	0.21	0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28242918	chr12:28185625~28186190:-
LUAD	cis	rs287982	0.611	rs80238678	ENSG00000269973.1	RP11-95D17.1	-3.8	0.000162	0.021	-0.24	-0.17	Nonsyndromic cleft lip with cleft palate;	chr2:9836053	chr2:9936360~9939590:+
LUAD	cis	rs27434	0.602	rs2927620	ENSG00000272109.1	CTD-2260A17.3	-3.8	0.000162	0.021	-0.25	-0.17	Ankylosing spondylitis;	chr5:96845594	chr5:96804353~96806105:+
LUAD	cis	rs2239547	0.522	rs2336669	ENSG00000243224.1	RP5-1157M23.2	3.8	0.000162	0.021	0.19	0.17	Schizophrenia;	chr3:52960122	chr3:52239258~52241097:+
LUAD	cis	rs12565755	0.556	rs34386369	ENSG00000226476.2	RP11-776H12.1	3.8	0.000162	0.021	0.27	0.17	Response to tocilizumab in rheumatoid arthritis;	chr1:60487930	chr1:60540249~60640491:-
LUAD	cis	rs755249	1	rs2293476	ENSG00000182109.6	RP11-69E11.4	-3.8	0.000162	0.021	-0.2	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39571175	chr1:39522280~39546187:-
LUAD	cis	rs7247513	1	rs2042947	ENSG00000230310.1	CTD-2192J16.11	-3.8	0.000162	0.021	-0.19	-0.17	Bipolar disorder;	chr19:12582289	chr19:12552597~12553644:+
LUAD	cis	rs67478160	0.619	rs12885018	ENSG00000272533.1	SNORA28	3.8	0.000162	0.021	0.17	0.17	Schizophrenia;	chr14:103807475	chr14:103337849~103337974:+
LUAD	cis	rs67478160	0.643	rs12891175	ENSG00000272533.1	SNORA28	3.8	0.000162	0.021	0.17	0.17	Schizophrenia;	chr14:103807829	chr14:103337849~103337974:+
LUAD	cis	rs4594175	0.707	rs4606635	ENSG00000258955.1	LINC00519	-3.8	0.000162	0.021	-0.21	-0.17	Cancer;	chr14:51245374	chr14:51304416~51328386:-
LUAD	cis	rs2015599	0.517	rs7295212	ENSG00000257176.2	RP11-996F15.2	3.8	0.000162	0.021	0.18	0.17	Platelet count;Mean platelet volume;	chr12:29278432	chr12:29280418~29317848:-
LUAD	cis	rs17596685	1	rs1022926	ENSG00000271216.1	LINC01050	3.8	0.000162	0.021	0.24	0.17	C-reactive protein levels;	chr13:42584598	chr13:42810366~42812562:-
LUAD	cis	rs9309473	1	rs6753344	ENSG00000230002.2	ALMS1-IT1	-3.8	0.000162	0.021	-0.22	-0.17	Metabolite levels;	chr2:73426010	chr2:73456764~73459484:+
LUAD	cis	rs875971	0.66	rs3764903	ENSG00000273142.1	RP11-458F8.4	3.8	0.000162	0.021	0.12	0.17	Aortic root size;	chr7:66633495	chr7:66902857~66906297:+
LUAD	cis	rs148406912	1	rs148406912	ENSG00000280143.1	AP000892.6	-3.8	0.000162	0.021	-0.29	-0.17	Lobe attachment (rater-scored or self-reported);	chr11:116967001	chr11:117204967~117210292:+
LUAD	cis	rs9302635	0.513	rs8044555	ENSG00000260886.1	TAT-AS1	3.8	0.000162	0.021	0.22	0.17	Blood protein levels;	chr16:72118856	chr16:71565789~71578187:+
LUAD	cis	rs12754538	0.739	rs2131679	ENSG00000232912.4	RP5-1115A15.1	3.8	0.000162	0.021	0.18	0.17	Subjective well-being;	chr1:8751709	chr1:8424645~8434838:+
LUAD	cis	rs7246657	0.943	rs7252325	ENSG00000226686.6	LINC01535	-3.8	0.000162	0.021	-0.25	-0.17	Coronary artery calcification;	chr19:37439743	chr19:37251912~37265535:+
LUAD	cis	rs4819052	0.788	rs35323494	ENSG00000184274.3	LINC00315	-3.8	0.000162	0.021	-0.25	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45283824	chr21:45300245~45305257:-
LUAD	cis	rs4591358	1	rs7571836	ENSG00000223466.1	AC064834.2	-3.8	0.000162	0.021	-0.21	-0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195475768	chr2:195533035~195538681:+
LUAD	cis	rs8058578	0.887	rs28421305	ENSG00000232748.3	RP11-196G11.6	-3.8	0.000162	0.021	-0.22	-0.17	Multiple myeloma;	chr16:30826807	chr16:31056460~31062803:+
LUAD	cis	rs12596233	0.706	rs11859824	ENSG00000279129.1	RP11-264L1.2	3.8	0.000162	0.021	0.24	0.17	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr16:78626819	chr16:78550739~78553296:-
LUAD	cis	rs710865	0.527	rs2275403	ENSG00000270728.1	RP4-657E11.10	3.8	0.000162	0.021	0.16	0.17	Brain structure;	chr1:19231219	chr1:19297080~19297903:+
LUAD	cis	rs2274273	0.87	rs10147434	ENSG00000259318.1	RP11-454L9.2	3.8	0.000162	0.021	0.15	0.17	Protein biomarker;	chr14:55208129	chr14:55394940~55395233:-
LUAD	cis	rs7584330	0.91	rs6757376	ENSG00000222032.1	AC112721.2	3.8	0.000162	0.021	0.19	0.17	Prostate cancer;	chr2:237491393	chr2:237428920~237434822:-
LUAD	cis	rs2731006	0.64	rs975540	ENSG00000257114.2	RP11-25I15.3	3.8	0.000162	0.021	0.28	0.17	Panic disorder;	chr12:42784505	chr12:42692216~42717119:+
LUAD	cis	rs5758511	0.68	rs5758692	ENSG00000233903.2	Z83851.4	3.8	0.000162	0.021	0.25	0.17	Birth weight;	chr22:42273023	chr22:42276355~42277052:+
LUAD	cis	rs4713118	0.955	rs9468206	ENSG00000280107.1	AL022393.9	-3.8	0.000162	0.021	-0.22	-0.17	Parkinson's disease;	chr6:27722674	chr6:28170845~28172521:+
LUAD	cis	rs3748682	0.821	rs71642605	ENSG00000212541.1	RNU6-510P	-3.8	0.000162	0.021	-0.23	-0.17	Hypothyroidism;	chr1:37790755	chr1:37991462~37991569:+
LUAD	cis	rs837841	0.538	rs11681435	ENSG00000233428.1	AC019050.1	-3.8	0.000162	0.021	-0.2	-0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);	chr2:129266068	chr2:129496297~129496788:+
LUAD	cis	rs17818399	0.547	rs7607633	ENSG00000279254.1	RP11-536C12.1	-3.8	0.000162	0.021	-0.2	-0.17	Height;	chr2:46532288	chr2:46668870~46670778:+
LUAD	cis	rs10178409	1	rs10178409	ENSG00000273245.1	RP11-434P11.2	3.8	0.000162	0.021	0.21	0.17	Urinary metabolites;	chr2:73628380	chr2:73750256~73750786:-
LUAD	cis	rs5015933	0.815	rs3126227	ENSG00000232630.1	PRPS1P2	-3.8	0.000162	0.021	-0.16	-0.17	Body mass index;	chr9:125319157	chr9:125150653~125151589:+
LUAD	cis	rs2731006	0.64	rs2678102	ENSG00000257114.2	RP11-25I15.3	3.8	0.000162	0.021	0.28	0.17	Panic disorder;	chr12:42775130	chr12:42692216~42717119:+
LUAD	cis	rs10971721	0.822	rs307673	ENSG00000260947.1	RP11-384P7.7	3.8	0.000162	0.021	0.35	0.17	Body mass index;	chr9:33968821	chr9:33697459~33700986:+
LUAD	cis	rs2732480	0.538	rs2732462	ENSG00000240399.1	RP1-228P16.1	3.8	0.000162	0.021	0.18	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48302601	chr12:48054813~48055591:-
LUAD	cis	rs7142881	0.844	rs6571433	ENSG00000258525.1	RP11-829H16.3	3.8	0.000162	0.021	0.2	0.17	Response to iloperidone treatment (QT prolongation);	chr14:31567138	chr14:30876179~30889808:-
LUAD	cis	rs7142881	0.844	rs6571434	ENSG00000258525.1	RP11-829H16.3	3.8	0.000162	0.021	0.2	0.17	Response to iloperidone treatment (QT prolongation);	chr14:31567139	chr14:30876179~30889808:-
LUAD	cis	rs17428076	0.536	rs62182438	ENSG00000228389.1	AC068039.4	-3.8	0.000162	0.021	-0.21	-0.17	Myopia;	chr2:171940254	chr2:171773482~171775844:+
LUAD	cis	rs10127852	0.541	rs12062585	ENSG00000122432.15	SPATA1	3.8	0.000163	0.021	0.32	0.17	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:84795013	chr1:84506291~84566194:+
LUAD	cis	rs950881	0.601	rs11465705	ENSG00000234389.1	AC007278.3	3.8	0.000163	0.021	0.19	0.17	Allergy;	chr2:102442350	chr2:102438713~102440475:+
LUAD	cis	rs7142881	0.626	rs7141900	ENSG00000250365.5	CTD-2213F21.2	3.8	0.000163	0.021	0.2	0.17	Response to iloperidone treatment (QT prolongation);	chr14:31801928	chr14:31420286~31452883:+
LUAD	cis	rs1881797	0.932	rs4551631	ENSG00000221953.5	C1orf229	3.8	0.000163	0.021	0.23	0.17	Acute lymphoblastic leukemia (childhood);	chr1:247504361	chr1:247110160~247112417:-
LUAD	cis	rs13434995	0.589	rs62305202	ENSG00000273257.1	RP11-177J6.1	-3.8	0.000163	0.021	-0.23	-0.17	Adiponectin levels;	chr4:55386861	chr4:55387949~55388271:+
LUAD	cis	rs8028182	0.636	rs7166737	ENSG00000246877.1	DNM1P35	3.8	0.000163	0.021	0.22	0.17	Sudden cardiac arrest;	chr15:75390172	chr15:75727670~75738623:-
LUAD	cis	rs875971	0.619	rs12533585	ENSG00000222364.1	RNU6-96P	-3.8	0.000163	0.0211	-0.19	-0.17	Aortic root size;	chr7:66519618	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.66	rs12698534	ENSG00000222364.1	RNU6-96P	-3.8	0.000163	0.0211	-0.19	-0.17	Aortic root size;	chr7:66521858	chr7:66395191~66395286:+
LUAD	cis	rs1790761	0.559	rs10896190	ENSG00000184224.3	C11orf72	3.8	0.000163	0.0211	0.2	0.17	Mean corpuscular volume;	chr11:67638652	chr11:67602880~67606706:-
LUAD	cis	rs2333021	0.727	rs1986616	ENSG00000259015.1	RP11-109N23.6	-3.8	0.000163	0.0211	-0.16	-0.17	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73074228	chr14:72960595~72961993:+
LUAD	cis	rs12579720	0.695	rs11045018	ENSG00000255910.1	RP11-405A12.2	3.8	0.000163	0.0211	0.22	0.17	Diastolic blood pressure;	chr12:20073947	chr12:19775451~20009937:+
LUAD	cis	rs240993	0.812	rs9481160	ENSG00000271789.1	RP5-1112D6.7	3.8	0.000163	0.0211	0.21	0.17	Inflammatory skin disease;Psoriasis;	chr6:111517317	chr6:111297126~111298510:+
LUAD	cis	rs2348418	0.966	rs11049698	ENSG00000244712.1	RP11-874G11.1	3.8	0.000163	0.0211	0.2	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28535354	chr12:28564678~28565141:-
LUAD	cis	rs9467773	0.62	rs2504567	ENSG00000241549.7	GUSBP2	3.8	0.000163	0.0211	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26662692	chr6:26871484~26956554:-
LUAD	cis	rs1355223	0.934	rs11602669	ENSG00000271369.1	RP11-350D17.3	-3.8	0.000163	0.0211	-0.2	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34673567	chr11:34709600~34710161:+
LUAD	cis	rs2749592	0.55	rs7081464	ENSG00000263064.2	RP11-291L22.7	-3.8	0.000163	0.0211	-0.18	-0.17	Age-related hearing impairment (SNP x SNP interaction);	chr10:37595009	chr10:38448689~38448949:+
LUAD	cis	rs7005380	0.58	rs4073560	ENSG00000279347.1	RP11-85I17.2	-3.8	0.000163	0.0211	-0.14	-0.17	Interstitial lung disease;	chr8:119905148	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.62	rs7002839	ENSG00000279347.1	RP11-85I17.2	-3.8	0.000163	0.0211	-0.14	-0.17	Interstitial lung disease;	chr8:119906508	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.62	rs7006905	ENSG00000279347.1	RP11-85I17.2	-3.8	0.000163	0.0211	-0.14	-0.17	Interstitial lung disease;	chr8:119906683	chr8:119838736~119840385:-
LUAD	cis	rs2836974	0.965	rs2836965	ENSG00000232608.1	TIMM9P2	3.8	0.000163	0.0211	0.2	0.17	Cognitive function;	chr21:39261705	chr21:39216624~39217506:+
LUAD	cis	rs6840360	0.642	rs1372977	ENSG00000270265.1	RP11-731D1.4	-3.8	0.000163	0.0211	-0.17	-0.17	Intelligence (multi-trait analysis);	chr4:151531246	chr4:151333775~151353224:-
LUAD	cis	rs9860428	0.844	rs13063847	ENSG00000242770.2	RP11-180K7.1	3.8	0.000163	0.0211	0.19	0.17	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112850701	chr3:112802478~112812819:+
LUAD	cis	rs2354432	0.607	rs2297752	ENSG00000237188.3	RP11-337C18.8	3.8	0.000163	0.0211	0.26	0.17	Mitochondrial DNA levels;	chr1:147293770	chr1:147172771~147211568:+
LUAD	cis	rs4523957	0.819	rs12450354	ENSG00000262333.1	HNRNPA1P16	-3.8	0.000163	0.0211	-0.14	-0.17	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2256688	chr17:2306761~2307715:+
LUAD	cis	rs4523957	0.928	rs12453323	ENSG00000262333.1	HNRNPA1P16	-3.8	0.000163	0.0211	-0.14	-0.17	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2256920	chr17:2306761~2307715:+
LUAD	cis	rs11673344	0.704	rs1726719	ENSG00000267309.1	CTD-2630F21.1	-3.8	0.000163	0.0211	-0.21	-0.17	Obesity-related traits;	chr19:36927130	chr19:36489649~36491040:+
LUAD	cis	rs875971	0.66	rs1860470	ENSG00000273142.1	RP11-458F8.4	3.8	0.000163	0.0211	0.12	0.17	Aortic root size;	chr7:66638707	chr7:66902857~66906297:+
LUAD	cis	rs4072980	0.524	rs28477803	ENSG00000212541.1	RNU6-510P	-3.8	0.000163	0.0211	-0.22	-0.17	Coronary artery disease;	chr1:37933022	chr1:37991462~37991569:+
LUAD	cis	rs8058578	1	rs56656810	ENSG00000232748.3	RP11-196G11.6	-3.8	0.000163	0.0211	-0.22	-0.17	Multiple myeloma;	chr16:30777438	chr16:31056460~31062803:+
LUAD	cis	rs990171	0.538	rs12987295	ENSG00000234389.1	AC007278.3	3.8	0.000163	0.0211	0.17	0.17	Lymphocyte counts;	chr2:102499379	chr2:102438713~102440475:+
LUAD	cis	rs6071166	0.683	rs7262449	ENSG00000224635.1	RP4-564F22.5	-3.8	0.000163	0.0211	-0.19	-0.17	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38680668	chr20:38406011~38416797:-
LUAD	cis	rs321358	0.732	rs17535419	ENSG00000271390.1	RP11-89C3.3	3.8	0.000163	0.0211	0.28	0.17	Body mass index;	chr11:111075357	chr11:111089870~111090368:-
LUAD	cis	rs321358	0.79	rs77820525	ENSG00000271390.1	RP11-89C3.3	3.8	0.000163	0.0211	0.28	0.17	Body mass index;	chr11:111076697	chr11:111089870~111090368:-
LUAD	cis	rs321358	0.848	rs73015141	ENSG00000271390.1	RP11-89C3.3	3.8	0.000163	0.0211	0.28	0.17	Body mass index;	chr11:111077556	chr11:111089870~111090368:-
LUAD	cis	rs321358	0.848	rs73015142	ENSG00000271390.1	RP11-89C3.3	3.8	0.000163	0.0211	0.28	0.17	Body mass index;	chr11:111078647	chr11:111089870~111090368:-
LUAD	cis	rs8180040	1	rs11130127	ENSG00000271161.1	BOLA2P2	-3.8	0.000163	0.0211	-0.16	-0.17	Colorectal cancer;	chr3:47357303	chr3:47499841~47500407:+
LUAD	cis	rs4474465	0.79	rs4944206	ENSG00000251323.2	RP11-452H21.4	-3.8	0.000163	0.0211	-0.21	-0.17	Alzheimer's disease (survival time);	chr11:78552081	chr11:78423982~78429836:-
LUAD	cis	rs210152	0.588	rs210131	ENSG00000224557.6	HLA-DPB2	3.8	0.000163	0.0211	0.46	0.17	Schizophrenia;	chr6:33567689	chr6:33112451~33129084:+
LUAD	cis	rs4683346	0.652	rs339671	ENSG00000173811.9	CCDC13-AS1	-3.8	0.000163	0.0211	-0.19	-0.17	Granulocyte percentage of myeloid white cells;	chr3:42760420	chr3:42732575~42746768:+
LUAD	cis	rs7937890	0.559	rs2575837	ENSG00000254418.1	RP11-21L19.1	3.8	0.000163	0.0211	0.2	0.17	Mitochondrial DNA levels;	chr11:14476455	chr11:14262846~14273691:-
LUAD	cis	rs7937890	0.559	rs2575838	ENSG00000254418.1	RP11-21L19.1	3.8	0.000163	0.0211	0.2	0.17	Mitochondrial DNA levels;	chr11:14476675	chr11:14262846~14273691:-
LUAD	cis	rs7937890	0.559	rs2167160	ENSG00000254418.1	RP11-21L19.1	3.8	0.000163	0.0211	0.2	0.17	Mitochondrial DNA levels;	chr11:14485903	chr11:14262846~14273691:-
LUAD	cis	rs7937890	0.559	rs2597217	ENSG00000254418.1	RP11-21L19.1	3.8	0.000163	0.0211	0.2	0.17	Mitochondrial DNA levels;	chr11:14511337	chr11:14262846~14273691:-
LUAD	cis	rs3096299	0.934	rs9927904	ENSG00000182376.2	RP5-1142A6.8	3.8	0.000163	0.0211	0.18	0.17	Multiple myeloma (IgH translocation);	chr16:89396439	chr16:88742767~88745748:+
LUAD	cis	rs7760535	0.735	rs240974	ENSG00000230177.1	RP5-1112D6.4	-3.8	0.000163	0.0211	-0.15	-0.17	Metabolic traits;	chr6:111328113	chr6:111277932~111278742:+
LUAD	cis	rs7852296	0.636	rs9696009	ENSG00000236643.1	RP11-175D17.3	-3.8	0.000163	0.0211	-0.35	-0.17	Personality dimensions;	chr9:123856954	chr9:124770123~124772927:+
LUAD	cis	rs10463554	0.927	rs34831	ENSG00000250682.4	LINC00491	3.8	0.000163	0.0211	0.21	0.17	Parkinson's disease;	chr5:103108385	chr5:102609156~102671559:-
LUAD	cis	rs2380205	0.967	rs2203196	ENSG00000232807.2	RP11-536K7.3	3.8	0.000163	0.0211	0.18	0.17	Breast cancer;	chr10:5866246	chr10:5934270~5945900:-
LUAD	cis	rs11642862	1	rs75231191	ENSG00000239791.1	AC002310.7	3.8	0.000163	0.0211	0.31	0.17	Tonsillectomy;	chr16:30777280	chr16:30572250~30583860:+
LUAD	cis	rs638893	0.588	rs2156755	ENSG00000255422.1	AP002954.4	-3.8	0.000163	0.0211	-0.24	-0.17	Vitiligo;	chr11:118855521	chr11:118704607~118750263:+
LUAD	cis	rs7560272	0.538	rs17434655	ENSG00000163016.8	ALMS1P	3.8	0.000163	0.0211	0.18	0.17	Schizophrenia;	chr2:73695962	chr2:73644919~73685576:+
LUAD	cis	rs11886999	0.68	rs6576968	ENSG00000237510.6	AC008268.2	-3.8	0.000163	0.0211	-0.3	-0.17	Cardiac Troponin-T levels;	chr2:96238389	chr2:95789654~95800166:+
LUAD	cis	rs13108904	0.87	rs3733338	ENSG00000196810.4	CTBP1-AS2	3.8	0.000163	0.0211	0.21	0.17	Obesity-related traits;	chr4:1247684	chr4:1249300~1288291:+
LUAD	cis	rs7829975	0.714	rs59046059	ENSG00000233609.3	RP11-62H7.2	3.8	0.000163	0.0211	0.14	0.17	Mood instability;	chr8:8813226	chr8:8961200~8979025:+
LUAD	cis	rs3743162	0.553	rs4842994	ENSG00000259295.5	CSPG4P12	-3.8	0.000163	0.0211	-0.25	-0.17	Alzheimer's disease (age of onset);	chr15:84872568	chr15:85191438~85213905:+
LUAD	cis	rs11096990	0.634	rs3733287	ENSG00000249685.1	RP11-360F5.3	3.8	0.000163	0.0211	0.2	0.17	Cognitive function;	chr4:39215732	chr4:39133913~39135608:+
LUAD	cis	rs7824557	0.527	rs2572376	ENSG00000255046.1	RP11-297N6.4	3.8	0.000163	0.0211	0.21	0.17	Retinal vascular caliber;	chr8:11380247	chr8:11797928~11802568:-
LUAD	cis	rs12935418	0.583	rs2549837	ENSG00000261061.1	RP11-303E16.2	3.8	0.000163	0.0212	0.18	0.17	Mean corpuscular volume;	chr16:80989510	chr16:81030770~81031485:+
LUAD	cis	rs12935418	0.552	rs2549838	ENSG00000261061.1	RP11-303E16.2	3.8	0.000163	0.0212	0.18	0.17	Mean corpuscular volume;	chr16:80989605	chr16:81030770~81031485:+
LUAD	cis	rs12935418	0.583	rs2549839	ENSG00000261061.1	RP11-303E16.2	3.8	0.000163	0.0212	0.18	0.17	Mean corpuscular volume;	chr16:80989630	chr16:81030770~81031485:+
LUAD	cis	rs77633900	0.892	rs2456066	ENSG00000196274.5	Metazoa_SRP	3.8	0.000163	0.0212	0.23	0.17	Glioma;Non-glioblastoma glioma;	chr15:76295030	chr15:76230048~76230390:-
LUAD	cis	rs6121246	0.821	rs115585940	ENSG00000230613.1	HM13-AS1	3.8	0.000164	0.0212	0.26	0.17	Mean corpuscular hemoglobin;	chr20:31730099	chr20:31567707~31573263:-
LUAD	cis	rs5742933	0.744	rs13002216	ENSG00000253559.1	OSGEPL1-AS1	3.8	0.000164	0.0212	0.21	0.17	Ferritin levels;	chr2:189746358	chr2:189762704~189765556:+
LUAD	cis	rs9309473	0.948	rs2421550	ENSG00000230002.2	ALMS1-IT1	3.8	0.000164	0.0212	0.21	0.17	Metabolite levels;	chr2:73431558	chr2:73456764~73459484:+
LUAD	cis	rs2638953	0.853	rs10843179	ENSG00000278733.1	RP11-425D17.1	3.8	0.000164	0.0212	0.21	0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28462125	chr12:28185625~28186190:-
LUAD	cis	rs2348418	0.832	rs11049587	ENSG00000247934.4	RP11-967K21.1	3.8	0.000164	0.0212	0.19	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28418090	chr12:28163298~28190738:-
LUAD	cis	rs875971	0.964	rs60193905	ENSG00000273142.1	RP11-458F8.4	-3.8	0.000164	0.0212	-0.12	-0.17	Aortic root size;	chr7:66506273	chr7:66902857~66906297:+
LUAD	cis	rs1044826	1	rs964227	ENSG00000214280.3	RP11-553K23.2	-3.8	0.000164	0.0212	-0.21	-0.17	Obesity-related traits;	chr3:139437251	chr3:139582928~139583593:-
LUAD	cis	rs13434995	0.513	rs62303681	ENSG00000273257.1	RP11-177J6.1	-3.8	0.000164	0.0212	-0.23	-0.17	Adiponectin levels;	chr4:55403812	chr4:55387949~55388271:+
LUAD	cis	rs8012947	1	rs7154212	ENSG00000279636.2	LINC00216	-3.8	0.000164	0.0212	-0.19	-0.17	Alcohol consumption in current drinkers;	chr14:58295491	chr14:58288033~58289158:+
LUAD	cis	rs748404	0.666	rs34178146	ENSG00000249839.1	AC011330.5	-3.8	0.000164	0.0212	-0.27	-0.17	Lung cancer;	chr15:43384406	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.626	rs62021176	ENSG00000249839.1	AC011330.5	-3.8	0.000164	0.0212	-0.27	-0.17	Lung cancer;	chr15:43388014	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.666	rs16957680	ENSG00000249839.1	AC011330.5	-3.8	0.000164	0.0212	-0.27	-0.17	Lung cancer;	chr15:43396207	chr15:43663654~43684339:-
LUAD	cis	rs2735413	0.563	rs117731654	ENSG00000276007.1	RP11-358L22.3	3.8	0.000164	0.0212	0.24	0.17	Systolic blood pressure (alcohol consumption interaction);	chr16:78013450	chr16:78123243~78124332:+
LUAD	cis	rs858239	0.73	rs10255155	ENSG00000230042.1	AK3P3	3.8	0.000164	0.0212	0.22	0.17	Cerebrospinal fluid biomarker levels;	chr7:23362528	chr7:23129178~23129841:+
LUAD	cis	rs12440869	1	rs8029963	ENSG00000270964.1	RP11-502I4.3	-3.8	0.000164	0.0212	-0.2	-0.17	Peak velocity of the mitral A-wave;	chr15:67356317	chr15:67541072~67542604:-
LUAD	cis	rs7246967	0.673	rs16999580	ENSG00000236312.3	RPL34P34	3.8	0.000164	0.0212	0.24	0.17	Bronchopulmonary dysplasia;	chr19:22740685	chr19:22368599~22368952:-
LUAD	cis	rs7246967	0.673	rs55684269	ENSG00000236312.3	RPL34P34	3.8	0.000164	0.0212	0.24	0.17	Bronchopulmonary dysplasia;	chr19:22741745	chr19:22368599~22368952:-
LUAD	cis	rs7246967	0.673	rs34003335	ENSG00000236312.3	RPL34P34	3.8	0.000164	0.0212	0.24	0.17	Bronchopulmonary dysplasia;	chr19:22742800	chr19:22368599~22368952:-
LUAD	cis	rs7246967	0.673	rs12974988	ENSG00000236312.3	RPL34P34	3.8	0.000164	0.0212	0.24	0.17	Bronchopulmonary dysplasia;	chr19:22743163	chr19:22368599~22368952:-
LUAD	cis	rs7246967	0.673	rs2194112	ENSG00000236312.3	RPL34P34	3.8	0.000164	0.0212	0.24	0.17	Bronchopulmonary dysplasia;	chr19:22743387	chr19:22368599~22368952:-
LUAD	cis	rs7246967	0.551	rs34907478	ENSG00000236312.3	RPL34P34	3.8	0.000164	0.0212	0.24	0.17	Bronchopulmonary dysplasia;	chr19:22746029	chr19:22368599~22368952:-
LUAD	cis	rs7246967	0.673	rs12985495	ENSG00000236312.3	RPL34P34	3.8	0.000164	0.0212	0.24	0.17	Bronchopulmonary dysplasia;	chr19:22747576	chr19:22368599~22368952:-
LUAD	cis	rs7246967	0.673	rs8103430	ENSG00000236312.3	RPL34P34	3.8	0.000164	0.0212	0.24	0.17	Bronchopulmonary dysplasia;	chr19:22748696	chr19:22368599~22368952:-
LUAD	cis	rs7246967	0.673	rs34174596	ENSG00000236312.3	RPL34P34	3.8	0.000164	0.0212	0.24	0.17	Bronchopulmonary dysplasia;	chr19:22750717	chr19:22368599~22368952:-
LUAD	cis	rs801193	1	rs10234018	ENSG00000232546.1	RP11-458F8.1	3.8	0.000164	0.0212	0.15	0.17	Aortic root size;	chr7:66681297	chr7:66848496~66858136:+
LUAD	cis	rs12935418	0.583	rs2549852	ENSG00000261061.1	RP11-303E16.2	3.8	0.000164	0.0212	0.18	0.17	Mean corpuscular volume;	chr16:80992410	chr16:81030770~81031485:+
LUAD	cis	rs801193	1	rs3778909	ENSG00000222364.1	RNU6-96P	-3.8	0.000164	0.0212	-0.19	-0.17	Aortic root size;	chr7:66790659	chr7:66395191~66395286:+
LUAD	cis	rs7829975	0.564	rs2976855	ENSG00000233609.3	RP11-62H7.2	3.8	0.000164	0.0212	0.14	0.17	Mood instability;	chr8:8444284	chr8:8961200~8979025:+
LUAD	cis	rs7613051	1	rs7613051	ENSG00000223899.1	SEC13P1	3.8	0.000164	0.0212	0.21	0.17	Atopic dermatitis;	chr3:33023847	chr3:33033863~33034810:+
LUAD	cis	rs728616	0.867	rs28365998	ENSG00000234382.2	RP11-40F6.1	-3.8	0.000164	0.0212	-0.44	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80205680	chr10:80233664~80245367:+
LUAD	cis	rs7116495	0.867	rs529567	ENSG00000254682.1	RP11-660L16.2	-3.8	0.000164	0.0212	-0.36	-0.17	Severe influenza A (H1N1) infection;	chr11:71869491	chr11:71448674~71452157:+
LUAD	cis	rs7985	0.563	rs1018834	ENSG00000244625.4	MIATNB	3.8	0.000164	0.0212	0.19	0.17	Electroencephalogram traits;	chr22:26673944	chr22:26672767~26780207:+
LUAD	cis	rs2657294	0.965	rs9299525	ENSG00000233313.2	HMGA1P5	-3.8	0.000164	0.0212	-0.21	-0.17	Pneumonia;	chr10:75118267	chr10:75276376~75276646:-
LUAD	cis	rs2276498	0.54	rs6097745	ENSG00000236352.1	AC005220.3	3.8	0.000164	0.0212	0.22	0.17	Bipolar disorder and schizophrenia;	chr20:54051587	chr20:53940160~53942508:+
LUAD	cis	rs838147	0.76	rs12979144	ENSG00000232871.7	SEC1P	-3.8	0.000164	0.0212	-0.19	-0.17	Dietary macronutrient intake;	chr19:48734290	chr19:48638071~48682245:+
LUAD	cis	rs838147	0.733	rs12978499	ENSG00000232871.7	SEC1P	-3.8	0.000164	0.0212	-0.19	-0.17	Dietary macronutrient intake;	chr19:48734295	chr19:48638071~48682245:+
LUAD	cis	rs2904524	0.541	rs77082716	ENSG00000257815.4	RP11-611E13.2	-3.8	0.000164	0.0212	-0.21	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70385171	chr12:69904033~70243360:-
LUAD	cis	rs17711722	0.522	rs6957759	ENSG00000273024.4	INTS4P2	-3.8	0.000164	0.0212	-0.18	-0.17	Calcium levels;	chr7:65806798	chr7:65647864~65715661:+
LUAD	cis	rs2295359	1	rs2295359	ENSG00000275678.1	RP4-547N15.3	-3.8	0.000164	0.0212	-0.18	-0.17	Psoriasis;	chr1:67170267	chr1:67121605~67123956:-
LUAD	cis	rs753307	0.676	rs753308	ENSG00000268655.1	CTB-60B18.10	-3.8	0.000164	0.0212	-0.21	-0.17	Blood protein levels;	chr19:49015318	chr19:49018247~49019484:-
LUAD	cis	rs17507216	0.591	rs7163848	ENSG00000276710.3	CSPG4P8	-3.8	0.000164	0.0212	-0.2	-0.17	Excessive daytime sleepiness;	chr15:82729563	chr15:82459472~82477258:+
LUAD	cis	rs449789	1	rs7760427	ENSG00000235086.1	FNDC1-IT1	3.8	0.000164	0.0212	0.27	0.17	Pulse pressure;	chr6:159298207	chr6:159240786~159243329:+
LUAD	cis	rs11673344	0.526	rs17305193	ENSG00000267254.4	ZNF790-AS1	-3.8	0.000164	0.0212	-0.22	-0.17	Obesity-related traits;	chr19:37598764	chr19:36797518~36828115:+
LUAD	cis	rs7017914	0.967	rs59992214	ENSG00000246366.5	RP11-382J12.1	3.8	0.000164	0.0212	0.16	0.17	Bone mineral density;	chr8:70687310	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.935	rs35564237	ENSG00000246366.5	RP11-382J12.1	3.8	0.000164	0.0212	0.16	0.17	Bone mineral density;	chr8:70688239	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.934	rs62530772	ENSG00000246366.5	RP11-382J12.1	3.8	0.000164	0.0212	0.16	0.17	Bone mineral density;	chr8:70689306	chr8:70608577~70663279:+
LUAD	cis	rs12413361	0.967	rs2994655	ENSG00000272914.1	RP11-330O11.3	3.8	0.000164	0.0212	0.2	0.17	Height;	chr10:30836579	chr10:30831828~30833387:-
LUAD	cis	rs911186	0.68	rs34783558	ENSG00000219392.1	RP1-265C24.5	-3.8	0.000164	0.0212	-0.27	-0.17	Autism spectrum disorder or schizophrenia;	chr6:27203921	chr6:28115628~28116551:+
LUAD	cis	rs73198271	0.813	rs17697237	ENSG00000233609.3	RP11-62H7.2	3.8	0.000164	0.0212	0.14	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8758364	chr8:8961200~8979025:+
LUAD	cis	rs6763848	0.962	rs35942005	ENSG00000214073.2	RPL21P17	-3.8	0.000164	0.0212	-0.17	-0.17	Prostate cancer (SNP x SNP interaction);	chr3:1467586	chr3:1905651~1906125:+
LUAD	cis	rs6539288	0.691	rs10746071	ENSG00000260329.1	RP11-412D9.4	3.8	0.000164	0.0212	0.17	0.17	Total body bone mineral density;	chr12:106959817	chr12:106954029~106955497:-
LUAD	cis	rs9309473	0.66	rs56131703	ENSG00000230002.2	ALMS1-IT1	3.8	0.000164	0.0212	0.26	0.17	Metabolite levels;	chr2:73620133	chr2:73456764~73459484:+
LUAD	cis	rs6787172	0.837	rs1656373	ENSG00000272087.1	RP11-379F4.7	3.8	0.000164	0.0212	0.18	0.17	Subjective well-being;	chr3:158555732	chr3:158693120~158693768:-
LUAD	cis	rs4934494	0.573	rs67157720	ENSG00000240996.1	RP11-80H5.7	-3.8	0.000164	0.0212	-0.25	-0.17	Red blood cell count;	chr10:89820415	chr10:89694295~89697928:-
LUAD	cis	rs1476587	0.92	rs10480553	ENSG00000224046.1	AC005076.5	3.8	0.000164	0.0212	0.23	0.17	Brachial circumference;	chr7:87111616	chr7:87151423~87152420:-
LUAD	cis	rs1476587	0.92	rs2214351	ENSG00000224046.1	AC005076.5	3.8	0.000164	0.0212	0.23	0.17	Brachial circumference;	chr7:87111723	chr7:87151423~87152420:-
LUAD	cis	rs442309	0.841	rs224079	ENSG00000238280.1	RP11-436D10.3	-3.8	0.000164	0.0212	-0.2	-0.17	Vogt-Koyanagi-Harada syndrome;	chr10:62753470	chr10:62793562~62805887:-
LUAD	cis	rs7017914	0.967	rs6987007	ENSG00000246366.5	RP11-382J12.1	3.8	0.000164	0.0212	0.16	0.17	Bone mineral density;	chr8:70688707	chr8:70608577~70663279:+
LUAD	cis	rs3096299	0.967	rs16965692	ENSG00000182376.2	RP5-1142A6.8	3.8	0.000164	0.0213	0.18	0.17	Multiple myeloma (IgH translocation);	chr16:89405074	chr16:88742767~88745748:+
LUAD	cis	rs6471393	0.792	rs7839522	ENSG00000253848.1	RP11-10N23.5	-3.8	0.000164	0.0213	-0.22	-0.17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93827906	chr8:93741193~93744534:+
LUAD	cis	rs1056107	0.731	rs10114892	ENSG00000225513.1	RP11-165N19.2	-3.8	0.000164	0.0213	-0.19	-0.17	Colorectal cancer;	chr9:112173696	chr9:112173522~112173971:-
LUAD	cis	rs145729347	1	rs145729347	ENSG00000254731.1	CTD-2005H7.1	-3.8	0.000165	0.0213	-0.32	-0.17	Lung function (FEV1);	chr11:86731691	chr11:86703099~86714092:+
LUAD	cis	rs72827839	0.744	rs16955463	ENSG00000266601.1	RP11-6N17.3	3.8	0.000165	0.0213	0.23	0.17	Ease of getting up in the morning;	chr17:48322135	chr17:47929682~47933106:-
LUAD	cis	rs7845219	0.597	rs7002058	ENSG00000253528.2	RP11-347C18.4	3.8	0.000165	0.0213	0.17	0.17	Type 2 diabetes;	chr8:94861765	chr8:94974573~94974853:-
LUAD	cis	rs12195826	0.533	rs1680857	ENSG00000232654.1	FAM136BP	-3.8	0.000165	0.0213	-0.21	-0.17	Obesity-related traits;	chr6:2524158	chr6:3045384~3045800:+
LUAD	cis	rs7829975	0.84	rs572366	ENSG00000173295.6	FAM86B3P	3.8	0.000165	0.0213	0.18	0.17	Mood instability;	chr8:8721284	chr8:8228595~8244865:+
LUAD	cis	rs8058578	0.775	rs8046391	ENSG00000232748.3	RP11-196G11.6	-3.8	0.000165	0.0213	-0.22	-0.17	Multiple myeloma;	chr16:30825327	chr16:31056460~31062803:+
LUAD	cis	rs6088580	0.668	rs1205340	ENSG00000276073.1	RP5-1125A11.7	3.8	0.000165	0.0213	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34336065	chr20:33985617~33988989:-
LUAD	cis	rs2836974	0.545	rs3167757	ENSG00000232608.1	TIMM9P2	-3.8	0.000165	0.0213	-0.19	-0.17	Cognitive function;	chr21:39342552	chr21:39216624~39217506:+
LUAD	cis	rs7017914	0.934	rs1993862	ENSG00000246366.5	RP11-382J12.1	3.8	0.000165	0.0213	0.16	0.17	Bone mineral density;	chr8:70667127	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.87	rs34282253	ENSG00000246366.5	RP11-382J12.1	3.8	0.000165	0.0213	0.16	0.17	Bone mineral density;	chr8:70670131	chr8:70608577~70663279:+
LUAD	cis	rs6088580	0.66	rs6059893	ENSG00000276073.1	RP5-1125A11.7	-3.8	0.000165	0.0213	-0.17	-0.17	Glomerular filtration rate (creatinine);	chr20:34518092	chr20:33985617~33988989:-
LUAD	cis	rs875971	0.862	rs801195	ENSG00000273448.1	RP11-166O4.6	-3.8	0.000165	0.0213	-0.16	-0.17	Aortic root size;	chr7:66561128	chr7:67333047~67334383:+
LUAD	cis	rs6472235	0.681	rs58881093	ENSG00000200714.1	Y_RNA	-3.8	0.000165	0.0213	-0.22	-0.17	Plateletcrit;Myopia (pathological);	chr8:65952396	chr8:65592731~65592820:+
LUAD	cis	rs6840360	0.55	rs6535806	ENSG00000270265.1	RP11-731D1.4	-3.8	0.000165	0.0213	-0.19	-0.17	Intelligence (multi-trait analysis);	chr4:151562754	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.53	rs6839802	ENSG00000270265.1	RP11-731D1.4	-3.8	0.000165	0.0213	-0.19	-0.17	Intelligence (multi-trait analysis);	chr4:151564682	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.571	rs7674244	ENSG00000270265.1	RP11-731D1.4	-3.8	0.000165	0.0213	-0.19	-0.17	Intelligence (multi-trait analysis);	chr4:151567150	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.55	rs6836343	ENSG00000270265.1	RP11-731D1.4	-3.8	0.000165	0.0213	-0.19	-0.17	Intelligence (multi-trait analysis);	chr4:151576412	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.593	rs28602726	ENSG00000270265.1	RP11-731D1.4	-3.8	0.000165	0.0213	-0.19	-0.17	Intelligence (multi-trait analysis);	chr4:151578636	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.571	rs28608620	ENSG00000270265.1	RP11-731D1.4	-3.8	0.000165	0.0213	-0.19	-0.17	Intelligence (multi-trait analysis);	chr4:151583639	chr4:151333775~151353224:-
LUAD	cis	rs6121246	1	rs6121246	ENSG00000230613.1	HM13-AS1	3.8	0.000165	0.0213	0.24	0.17	Mean corpuscular hemoglobin;	chr20:31845549	chr20:31567707~31573263:-
LUAD	cis	rs6964587	1	rs58965837	ENSG00000188693.7	CYP51A1-AS1	-3.8	0.000165	0.0213	-0.2	-0.17	Breast cancer;	chr7:91955944	chr7:92134604~92180725:+
LUAD	cis	rs7512898	0.5	rs10920046	ENSG00000260088.1	RP11-92G12.3	-3.8	0.000165	0.0213	-0.23	-0.17	Electrocardiographic conduction measures;	chr1:200840100	chr1:200669507~200694250:+
LUAD	cis	rs451417	1	rs236120	ENSG00000275632.1	RP5-967N21.11	3.8	0.000165	0.0213	0.22	0.17	Menopause (age at onset);	chr20:5959003	chr20:6000418~6000941:+
LUAD	cis	rs9341808	0.519	rs4446525	ENSG00000260645.1	RP11-250B2.5	-3.8	0.000165	0.0213	-0.17	-0.17	Sitting height ratio;	chr6:80314336	chr6:80466958~80469080:+
LUAD	cis	rs3794924	1	rs7233484	ENSG00000266521.1	RP11-650P15.1	3.8	0.000165	0.0213	0.32	0.17	Survival in colon cancer;	chr18:31474869	chr18:31496645~31497195:-
LUAD	cis	rs7968440	1	rs2731434	ENSG00000272368.2	RP4-605O3.4	3.8	0.000165	0.0213	0.2	0.17	Fibrinogen;	chr12:50716092	chr12:50112197~50165618:+
LUAD	cis	rs2274273	0.837	rs6573017	ENSG00000259318.1	RP11-454L9.2	3.8	0.000165	0.0213	0.15	0.17	Protein biomarker;	chr14:55335525	chr14:55394940~55395233:-
LUAD	cis	rs12413361	0.967	rs2994653	ENSG00000272914.1	RP11-330O11.3	-3.8	0.000165	0.0213	-0.2	-0.17	Height;	chr10:30835310	chr10:30831828~30833387:-
LUAD	cis	rs16978956	0.592	rs16990336	ENSG00000236474.1	GCNT1P1	3.8	0.000165	0.0213	0.26	0.17	Body mass index;	chr20:18348968	chr20:18420160~18421454:-
LUAD	cis	rs13068223	1	rs13068223	ENSG00000243926.1	TIPARP-AS1	3.8	0.000165	0.0213	0.18	0.17	Age-related hearing impairment (SNP x SNP interaction);	chr3:156753166	chr3:156671862~156674378:-
LUAD	cis	rs73108077	0.92	rs10084487	ENSG00000281376.1	ABALON	-3.8	0.000165	0.0213	-0.26	-0.17	Red blood cell density in sickle cell anemia;	chr20:31425330	chr20:31721507~31723409:+
LUAD	cis	rs73108077	1	rs10084488	ENSG00000281376.1	ABALON	-3.8	0.000165	0.0213	-0.26	-0.17	Red blood cell density in sickle cell anemia;	chr20:31425366	chr20:31721507~31723409:+
LUAD	cis	rs8031584	0.918	rs1425292	ENSG00000259845.1	HERC2P10	3.8	0.000165	0.0213	0.2	0.17	Huntington's disease progression;	chr15:30993219	chr15:30815271~30844153:+
LUAD	cis	rs4144027	0.967	rs56126771	ENSG00000258914.1	CTD-2134A5.3	-3.8	0.000165	0.0213	-0.2	-0.17	Blood metabolite levels;	chr14:103894806	chr14:103875055~103877478:+
LUAD	cis	rs6964587	1	rs2188155	ENSG00000188693.7	CYP51A1-AS1	-3.8	0.000165	0.0213	-0.2	-0.17	Breast cancer;	chr7:91970511	chr7:92134604~92180725:+
LUAD	cis	rs6964587	0.967	rs28615927	ENSG00000188693.7	CYP51A1-AS1	-3.8	0.000165	0.0213	-0.2	-0.17	Breast cancer;	chr7:91971334	chr7:92134604~92180725:+
LUAD	cis	rs6964587	1	rs10228800	ENSG00000188693.7	CYP51A1-AS1	-3.8	0.000165	0.0213	-0.2	-0.17	Breast cancer;	chr7:91980797	chr7:92134604~92180725:+
LUAD	cis	rs6964587	1	rs6976122	ENSG00000188693.7	CYP51A1-AS1	-3.8	0.000165	0.0213	-0.2	-0.17	Breast cancer;	chr7:91981648	chr7:92134604~92180725:+
LUAD	cis	rs6964587	1	rs13230588	ENSG00000188693.7	CYP51A1-AS1	-3.8	0.000165	0.0213	-0.2	-0.17	Breast cancer;	chr7:91986113	chr7:92134604~92180725:+
LUAD	cis	rs7246657	0.943	rs1035479	ENSG00000226686.6	LINC01535	3.8	0.000165	0.0213	0.25	0.17	Coronary artery calcification;	chr19:37402398	chr19:37251912~37265535:+
LUAD	cis	rs6661961	0.714	rs10888488	ENSG00000237975.5	FLG-AS1	-3.8	0.000165	0.0213	-0.23	-0.17	Atopic dermatitis;	chr1:152438614	chr1:152168125~152445456:+
LUAD	cis	rs507080	0.769	rs11603616	ENSG00000278376.1	RP11-158I9.8	-3.8	0.000165	0.0213	-0.19	-0.17	Serum metabolite levels;	chr11:118625350	chr11:118791254~118793137:+
LUAD	cis	rs567508	0.534	rs521035	ENSG00000254905.1	RP11-712L6.7	-3.8	0.000165	0.0213	-0.29	-0.17	Lung function (FEV1);	chr11:126155094	chr11:126292922~126294254:-
LUAD	cis	rs5758659	0.714	rs5758589	ENSG00000273366.1	CTA-989H11.1	3.8	0.000165	0.0213	0.2	0.17	Cognitive function;	chr22:42122378	chr22:42278188~42278846:+
LUAD	cis	rs7772486	0.738	rs75288066	ENSG00000235652.6	RP11-545I5.3	3.8	0.000165	0.0213	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145998250	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.713	rs79248977	ENSG00000235652.6	RP11-545I5.3	3.8	0.000165	0.0213	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145998252	chr6:145799409~145886585:+
LUAD	cis	rs10946940	0.897	rs6456801	ENSG00000219392.1	RP1-265C24.5	-3.8	0.000165	0.0213	-0.21	-0.17	Systemic lupus erythematosus;	chr6:27657753	chr6:28115628~28116551:+
LUAD	cis	rs932287	0.858	rs7109896	ENSG00000254860.4	TMEM9B-AS1	-3.8	0.000165	0.0213	-0.2	-0.17	Colonoscopy-negative controls vs population controls;	chr11:9032975	chr11:8964675~8977527:+
LUAD	cis	rs7503168	0.558	rs34874930	ENSG00000267592.1	CTC-507E2.2	3.8	0.000165	0.0213	0.37	0.17	Plateletcrit;	chr17:35667961	chr17:35596904~35597128:-
LUAD	cis	rs11089937	1	rs11089937	ENSG00000211640.3	IGLV6-57	3.8	0.000165	0.0213	0.11	0.17	Periodontitis (PAL4Q3);	chr22:22152176	chr22:22195713~22196460:+
LUAD	cis	rs11240074	0.57	rs7535821	ENSG00000244371.2	PFN1P8	-3.8	0.000165	0.0213	-0.28	-0.17	Type 2 diabetes;	chr1:147481700	chr1:146957117~146957659:-
LUAD	cis	rs365302	0.868	rs381639	ENSG00000235086.1	FNDC1-IT1	-3.8	0.000165	0.0213	-0.23	-0.17	Coronary heart disease;	chr6:159232603	chr6:159240786~159243329:+
LUAD	cis	rs17036023	1	rs17036023	ENSG00000203865.8	ATP1A1-AS1	3.8	0.000165	0.0213	0.37	0.17	Asthma (childhood onset);	chr1:116587089	chr1:116392247~116418622:-
LUAD	cis	rs38055	0.881	rs370753	ENSG00000247796.2	CTD-2366F13.1	-3.8	0.000165	0.0213	-0.19	-0.17	Acne (severe);	chr5:53324826	chr5:53109842~53115126:+
LUAD	cis	rs9549260	0.755	rs17061503	ENSG00000229456.1	RLIMP1	-3.8	0.000165	0.0213	-0.18	-0.17	Red blood cell count;	chr13:40672621	chr13:40618738~40621348:+
LUAD	cis	rs896854	0.573	rs11996455	ENSG00000253528.2	RP11-347C18.4	3.8	0.000165	0.0213	0.17	0.17	Type 2 diabetes;	chr8:94841480	chr8:94974573~94974853:-
LUAD	cis	rs7615952	0.932	rs13065725	ENSG00000241288.6	RP11-379B18.5	-3.8	0.000165	0.0213	-0.23	-0.17	Blood pressure (smoking interaction);	chr3:125913446	chr3:125827238~125916384:-
LUAD	cis	rs1160985	0.967	rs741780	ENSG00000214855.8	APOC1P1	-3.8	0.000165	0.0213	-0.2	-0.17	C-reactive protein;LDL cholesterol;Lipid traits;Gut microbiota (functional units);LDL cholesterol levels;	chr19:44901174	chr19:44926804~44931386:+
LUAD	cis	rs2880765	0.835	rs4360875	ENSG00000259407.1	RP11-158M2.3	-3.8	0.000165	0.0213	-0.15	-0.17	Coronary artery disease;	chr15:85497163	chr15:85744109~85750281:-
LUAD	cis	rs2333021	0.745	rs12323848	ENSG00000259015.1	RP11-109N23.6	3.8	0.000165	0.0213	0.16	0.17	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72986502	chr14:72960595~72961993:+
LUAD	cis	rs748404	0.736	rs542036	ENSG00000205771.5	CATSPER2P1	3.8	0.000165	0.0213	0.23	0.17	Lung cancer;	chr15:43248941	chr15:43726918~43747094:-
LUAD	cis	rs12681963	0.545	rs4383929	ENSG00000271869.1	RP11-51J9.5	-3.8	0.000165	0.0213	-0.22	-0.17	Migraine;	chr8:30041288	chr8:30155830~30156232:-
LUAD	cis	rs6688613	0.729	rs7545806	ENSG00000225171.2	DUTP6	-3.8	0.000165	0.0213	-0.22	-0.17	Refractive astigmatism;	chr1:166969318	chr1:166868748~166869209:+
LUAD	cis	rs4118325	0.69	rs1730871	ENSG00000224550.1	RP11-270C12.3	3.8	0.000165	0.0213	0.2	0.17	AIDS;	chr1:107094223	chr1:107505203~107505448:+
LUAD	cis	rs7200543	0.961	rs3803573	ENSG00000260735.1	RP11-72I8.1	-3.8	0.000165	0.0213	-0.19	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15044556	chr16:15094411~15109197:+
LUAD	cis	rs7560272	0.538	rs4852976	ENSG00000163016.8	ALMS1P	-3.8	0.000165	0.0213	-0.18	-0.17	Schizophrenia;	chr2:73709195	chr2:73644919~73685576:+
LUAD	cis	rs13113518	1	rs11133388	ENSG00000273257.1	RP11-177J6.1	-3.8	0.000165	0.0213	-0.18	-0.17	Height;	chr4:55477866	chr4:55387949~55388271:+
LUAD	cis	rs4561483	0.583	rs1029285	ENSG00000261216.1	RP11-166B2.5	3.8	0.000165	0.0214	0.17	0.17	Testicular germ cell tumor;	chr16:11893261	chr16:11908208~11908916:+
LUAD	cis	rs2836950	0.52	rs2836966	ENSG00000232608.1	TIMM9P2	3.8	0.000165	0.0214	0.19	0.17	Menarche (age at onset);	chr21:39265595	chr21:39216624~39217506:+
LUAD	cis	rs7727544	0.557	rs2897096	ENSG00000233006.5	AC034220.3	3.8	0.000165	0.0214	0.15	0.17	Blood metabolite levels;	chr5:132150591	chr5:132311285~132369916:-
LUAD	cis	rs7428	0.527	rs1053560	ENSG00000246575.2	AC093162.5	3.8	0.000165	0.0214	0.16	0.17	Ear protrusion;	chr2:85319069	chr2:85315041~85316529:+
LUAD	cis	rs12724450	0.793	rs11799813	ENSG00000228126.1	FALEC	3.8	0.000165	0.0214	0.31	0.17	Blood protein levels;	chr1:150363264	chr1:150515757~150518032:+
LUAD	cis	rs1823913	0.637	rs4853578	ENSG00000230611.1	HMGB1P27	-3.8	0.000165	0.0214	-0.19	-0.17	Obesity-related traits;	chr2:191297215	chr2:191174233~191174835:+
LUAD	cis	rs4372836	1	rs2169748	ENSG00000226833.4	AC097724.3	-3.8	0.000165	0.0214	-0.2	-0.17	Body mass index;	chr2:28734887	chr2:28708953~28736205:-
LUAD	cis	rs2823962	0.892	rs2823940	ENSG00000270093.1	AP000473.8	-3.8	0.000165	0.0214	-0.17	-0.17	Amyotrophic lateral sclerosis;	chr21:16654319	chr21:16643529~16645065:+
LUAD	cis	rs8133949	0.638	rs57383000	ENSG00000237232.6	ZNF295-AS1	3.8	0.000165	0.0214	0.24	0.17	Hand grip strength;	chr21:41980127	chr21:42009194~42024924:+
LUAD	cis	rs8133949	0.638	rs2839428	ENSG00000237232.6	ZNF295-AS1	3.8	0.000165	0.0214	0.24	0.17	Hand grip strength;	chr21:41980452	chr21:42009194~42024924:+
LUAD	cis	rs755249	0.876	rs61781391	ENSG00000237624.1	OXCT2P1	3.8	0.000165	0.0214	0.27	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39611865	chr1:39514956~39516490:+
LUAD	cis	rs526231	0.543	rs34808	ENSG00000250682.4	LINC00491	3.8	0.000166	0.0214	0.21	0.17	Primary biliary cholangitis;	chr5:103093484	chr5:102609156~102671559:-
LUAD	cis	rs526231	0.543	rs34809	ENSG00000250682.4	LINC00491	3.8	0.000166	0.0214	0.21	0.17	Primary biliary cholangitis;	chr5:103094413	chr5:102609156~102671559:-
LUAD	cis	rs28714278	0.762	rs12050884	ENSG00000248508.5	SRP14-AS1	-3.8	0.000166	0.0214	-0.18	-0.17	Mean corpuscular hemoglobin;	chr15:40014133	chr15:40039311~40067290:+
LUAD	cis	rs6688613	0.729	rs10918603	ENSG00000225171.2	DUTP6	-3.8	0.000166	0.0214	-0.22	-0.17	Refractive astigmatism;	chr1:166967266	chr1:166868748~166869209:+
LUAD	cis	rs736408	0.609	rs2336545	ENSG00000243224.1	RP5-1157M23.2	3.8	0.000166	0.0214	0.17	0.17	Bipolar disorder;	chr3:52753587	chr3:52239258~52241097:+
LUAD	cis	rs2069426	1	rs17756311	ENSG00000265194.1	RP11-70L8.4	-3.8	0.000166	0.0214	-0.25	-0.17	Acute lymphoblastic leukemia (childhood);	chr9:22053896	chr9:21858910~21861926:-
LUAD	cis	rs7560272	0.502	rs4513320	ENSG00000163016.8	ALMS1P	-3.8	0.000166	0.0214	-0.18	-0.17	Schizophrenia;	chr2:73693614	chr2:73644919~73685576:+
LUAD	cis	rs858239	0.6	rs7341483	ENSG00000226816.2	AC005082.12	-3.8	0.000166	0.0214	-0.22	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23206013~23208045:+
LUAD	cis	rs6088580	0.634	rs2378134	ENSG00000276073.1	RP5-1125A11.7	3.8	0.000166	0.0214	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34350279	chr20:33985617~33988989:-
LUAD	cis	rs3893377	1	rs28608142	ENSG00000214846.4	RP11-115L11.1	3.8	0.000166	0.0214	0.29	0.17	Current cigarettes per day in chronic obstructive pulmonary disease;	chr4:15742366	chr4:15730962~15731627:-
LUAD	cis	rs7762018	0.607	rs7759404	ENSG00000231690.2	LINC00574	-3.8	0.000166	0.0214	-0.32	-0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169735632	chr6:169790321~169802873:+
LUAD	cis	rs2836974	0.897	rs2836973	ENSG00000232608.1	TIMM9P2	-3.8	0.000166	0.0214	-0.2	-0.17	Cognitive function;	chr21:39283002	chr21:39216624~39217506:+
LUAD	cis	rs8014252	1	rs8014338	ENSG00000274818.1	RP1-292L20.3	3.8	0.000166	0.0214	0.28	0.17	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70461465	chr14:70906657~70907111:-
LUAD	cis	rs2253762	0.507	rs4752630	ENSG00000276742.1	RP11-500G22.4	3.8	0.000166	0.0214	0.25	0.17	Breast cancer;	chr10:121991440	chr10:121956782~121957098:+
LUAD	cis	rs911555	0.723	rs6575982	ENSG00000259775.1	RP11-45P15.4	3.8	0.000166	0.0214	0.22	0.17	Intelligence (multi-trait analysis);	chr14:103396344	chr14:103331674~103332367:-
LUAD	cis	rs12073359	1	rs12060027	ENSG00000223945.2	RP11-458I7.1	-3.8	0.000166	0.0214	-0.24	-0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150043510	chr1:150053864~150055034:+
LUAD	cis	rs12073359	1	rs28660389	ENSG00000223945.2	RP11-458I7.1	-3.8	0.000166	0.0214	-0.24	-0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150047352	chr1:150053864~150055034:+
LUAD	cis	rs42490	0.576	rs388866	ENSG00000251136.7	RP11-37B2.1	-3.8	0.000166	0.0214	-0.19	-0.17	Leprosy;	chr8:89856604	chr8:89609409~89757727:-
LUAD	cis	rs2731006	0.591	rs2678146	ENSG00000257114.2	RP11-25I15.3	3.8	0.000166	0.0214	0.27	0.17	Panic disorder;	chr12:42783878	chr12:42692216~42717119:+
LUAD	cis	rs4865762	0.514	rs30088	ENSG00000272416.1	CTD-2081C10.7	-3.8	0.000166	0.0214	-0.18	-0.17	Intraocular pressure;	chr5:53130011	chr5:53880293~53881051:-
LUAD	cis	rs4713118	0.662	rs4713120	ENSG00000280107.1	AL022393.9	-3.8	0.000166	0.0214	-0.2	-0.17	Parkinson's disease;	chr6:27754056	chr6:28170845~28172521:+
LUAD	cis	rs7202877	0.706	rs37605	ENSG00000280152.1	RP11-331F4.5	-3.8	0.000166	0.0214	-0.2	-0.17	Type 1 diabetes;Type 2 diabetes;	chr16:75472674	chr16:75245994~75250077:-
LUAD	cis	rs11673344	0.523	rs2562605	ENSG00000276846.1	CTD-3220F14.3	3.8	0.000166	0.0214	0.19	0.17	Obesity-related traits;	chr19:37029302	chr19:37314868~37315620:-
LUAD	cis	rs748404	0.723	rs11853991	ENSG00000249839.1	AC011330.5	-3.8	0.000166	0.0214	-0.22	-0.17	Lung cancer;	chr15:43265351	chr15:43663654~43684339:-
LUAD	cis	rs321358	0.895	rs17535942	ENSG00000271390.1	RP11-89C3.3	3.8	0.000166	0.0214	0.27	0.17	Body mass index;	chr11:111085233	chr11:111089870~111090368:-
LUAD	cis	rs9952991	0.599	rs12968719	ENSG00000260302.1	RP11-973H7.1	3.8	0.000166	0.0214	0.36	0.17	Inflammatory skin disease;	chr18:12879467	chr18:12774651~12775923:-
LUAD	cis	rs67981189	0.519	rs2526853	ENSG00000269927.1	RP6-91H8.3	-3.8	0.000166	0.0214	-0.23	-0.17	Schizophrenia;	chr14:70949235	chr14:71141125~71143253:-
LUAD	cis	rs2253762	0.54	rs75670246	ENSG00000276742.1	RP11-500G22.4	3.8	0.000166	0.0214	0.27	0.17	Breast cancer;	chr10:122032687	chr10:121956782~121957098:+
LUAD	cis	rs860295	0.871	rs12724079	ENSG00000160766.13	GBAP1	3.8	0.000166	0.0214	0.18	0.17	Body mass index;	chr1:155464151	chr1:155213821~155227422:-
LUAD	cis	rs9649213	0.593	rs6465672	ENSG00000272950.1	RP11-307C18.1	-3.8	0.000166	0.0214	-0.21	-0.17	Prostate cancer (SNP x SNP interaction);	chr7:98334405	chr7:98322853~98323430:+
LUAD	cis	rs10829156	0.625	rs7082235	ENSG00000240291.1	RP11-499P20.2	3.8	0.000166	0.0214	0.15	0.17	Sudden cardiac arrest;	chr10:18536765	chr10:18513115~18545651:-
LUAD	cis	rs13108904	0.935	rs3755920	ENSG00000196810.4	CTBP1-AS2	3.8	0.000166	0.0214	0.2	0.17	Obesity-related traits;	chr4:1249829	chr4:1249300~1288291:+
LUAD	cis	rs6496932	0.503	rs4564526	ENSG00000259630.2	CTD-2262B20.1	-3.8	0.000166	0.0214	-0.22	-0.17	Central corneal thickness;Corneal structure;	chr15:85455914	chr15:85415228~85415633:+
LUAD	cis	rs11018904	0.906	rs17227345	ENSG00000280367.1	RP11-121L10.2	-3.8	0.000166	0.0214	-0.22	-0.17	Intelligence (multi-trait analysis);	chr11:90221517	chr11:90223153~90226538:+
LUAD	cis	rs2911132	0.621	rs17480169	ENSG00000272109.1	CTD-2260A17.3	-3.8	0.000166	0.0214	-0.19	-0.17	Urate levels (BMI interaction);	chr5:96753363	chr5:96804353~96806105:+
LUAD	cis	rs4423214	0.879	rs1790345	ENSG00000226627.1	SHANK2-AS1	3.8	0.000166	0.0214	0.21	0.17	Vitamin D levels;	chr11:71434895	chr11:70631094~70635490:+
LUAD	cis	rs13113518	0.812	rs12648271	ENSG00000272969.1	RP11-528I4.2	3.8	0.000166	0.0214	0.19	0.17	Height;	chr4:55501955	chr4:55547112~55547889:+
LUAD	cis	rs1167832	0.645	rs1167829	ENSG00000278416.1	PMS2L2	-3.8	0.000166	0.0214	-0.25	-0.17	Ankle injury;	chr7:75535697	chr7:75344015~75359550:-
LUAD	cis	rs7870753	0.578	rs7851198	ENSG00000188801.9	ZNF322P1	3.8	0.000166	0.0214	0.25	0.17	Height;	chr9:96370093	chr9:97198303~97199511:-
LUAD	cis	rs10876993	0.89	rs2619441	ENSG00000270039.1	RP11-571M6.17	3.8	0.000166	0.0214	0.2	0.17	Celiac disease or Rheumatoid arthritis;	chr12:57689232	chr12:57803838~57804415:+
LUAD	cis	rs210152	0.531	rs4713634	ENSG00000224557.6	HLA-DPB2	3.8	0.000166	0.0214	0.46	0.17	Schizophrenia;	chr6:33546931	chr6:33112451~33129084:+
LUAD	cis	rs6088580	0.634	rs3746455	ENSG00000276073.1	RP5-1125A11.7	3.8	0.000166	0.0214	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34369410	chr20:33985617~33988989:-
LUAD	cis	rs7560272	0.538	rs6732812	ENSG00000163016.8	ALMS1P	-3.8	0.000166	0.0214	-0.18	-0.17	Schizophrenia;	chr2:73695348	chr2:73644919~73685576:+
LUAD	cis	rs13113518	0.966	rs13144598	ENSG00000273257.1	RP11-177J6.1	3.8	0.000166	0.0214	0.19	0.17	Height;	chr4:55570311	chr4:55387949~55388271:+
LUAD	cis	rs9341808	0.5	rs806851	ENSG00000279022.1	RP11-250B2.4	-3.8	0.000166	0.0214	-0.21	-0.17	Sitting height ratio;	chr6:80321114	chr6:80440730~80441172:+
LUAD	cis	rs987710	0.568	rs4287862	ENSG00000211639.2	IGLV4-60	-3.8	0.000166	0.0214	-0.22	-0.17	Iron status biomarkers;Iron deficiency;	chr22:22132342	chr22:22162199~22162681:+
LUAD	cis	rs1979679	0.842	rs4931727	ENSG00000278733.1	RP11-425D17.1	3.8	0.000166	0.0215	0.21	0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28146186	chr12:28185625~28186190:-
LUAD	cis	rs13113518	0.812	rs13107810	ENSG00000273257.1	RP11-177J6.1	3.8	0.000166	0.0215	0.19	0.17	Height;	chr4:55542243	chr4:55387949~55388271:+
LUAD	cis	rs11148252	0.774	rs7334583	ENSG00000273784.3	RP11-78J21.7	3.8	0.000166	0.0215	0.2	0.17	Lewy body disease;	chr13:52356217	chr13:52600042~52642542:+
LUAD	cis	rs651907	0.557	rs11712748	ENSG00000244119.1	PDCL3P4	3.8	0.000166	0.0215	0.17	0.17	Colorectal cancer;	chr3:101664718	chr3:101712472~101713191:+
LUAD	cis	rs9928842	0.824	rs889515	ENSG00000261476.1	RP11-77K12.3	-3.8	0.000166	0.0215	-0.23	-0.17	Alcoholic chronic pancreatitis;	chr16:75217401	chr16:75458252~75460017:-
LUAD	cis	rs4591358	0.871	rs6434780	ENSG00000223466.1	AC064834.2	3.79	0.000167	0.0215	0.2	0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195470558	chr2:195533035~195538681:+
LUAD	cis	rs6751744	0.772	rs11901769	ENSG00000230783.1	AC009961.2	-3.79	0.000167	0.0215	-0.23	-0.17	Dysphagia;	chr2:159489746	chr2:159689217~159690291:-
LUAD	cis	rs8180040	0.726	rs2385867	ENSG00000271161.1	BOLA2P2	3.79	0.000167	0.0215	0.16	0.17	Colorectal cancer;	chr3:47017833	chr3:47499841~47500407:+
LUAD	cis	rs524281	0.773	rs11227447	ENSG00000255320.1	RP11-755F10.1	3.79	0.000167	0.0215	0.27	0.17	Electroencephalogram traits;	chr11:66280809	chr11:66244840~66246239:-
LUAD	cis	rs524281	0.773	rs2282568	ENSG00000255320.1	RP11-755F10.1	3.79	0.000167	0.0215	0.27	0.17	Electroencephalogram traits;	chr11:66285361	chr11:66244840~66246239:-
LUAD	cis	rs4561483	0.583	rs11075027	ENSG00000261216.1	RP11-166B2.5	3.79	0.000167	0.0215	0.17	0.17	Testicular germ cell tumor;	chr16:11855038	chr16:11908208~11908916:+
LUAD	cis	rs6001482	0.523	rs5757595	ENSG00000253818.1	IGLV1-41	-3.79	0.000167	0.0215	-0.18	-0.17	Diastolic blood pressure;	chr22:22235017	chr22:22404207~22404721:+
LUAD	cis	rs987710	0.568	rs5750570	ENSG00000211639.2	IGLV4-60	3.79	0.000167	0.0215	0.23	0.17	Iron status biomarkers;Iron deficiency;	chr22:22130908	chr22:22162199~22162681:+
LUAD	cis	rs7604827	0.722	rs59524479	ENSG00000230076.1	AC016708.2	3.79	0.000167	0.0215	0.25	0.17	PR interval;	chr2:214417516	chr2:214847128~214847445:+
LUAD	cis	rs12908161	1	rs35960805	ENSG00000254414.1	RP11-182J1.1	3.79	0.000167	0.0215	0.22	0.17	Schizophrenia;	chr15:84800749	chr15:84631898~84633987:-
LUAD	cis	rs12908161	1	rs12912388	ENSG00000254414.1	RP11-182J1.1	3.79	0.000167	0.0215	0.22	0.17	Schizophrenia;	chr15:84801319	chr15:84631898~84633987:-
LUAD	cis	rs703842	0.616	rs10877024	ENSG00000245651.2	RP11-620J15.2	3.79	0.000167	0.0215	0.18	0.17	Multiple sclerosis;	chr12:57832926	chr12:57869835~57896482:-
LUAD	cis	rs9951698	0.678	rs576963	ENSG00000266969.1	RP11-773H22.4	-3.79	0.000167	0.0215	-0.22	-0.17	Intelligence (multi-trait analysis);	chr18:13145265	chr18:12984694~12991173:-
LUAD	cis	rs13287066	0.692	rs10992723	ENSG00000227603.1	RP11-165J3.6	3.79	0.000167	0.0215	0.19	0.17	Intelligence (multi-trait analysis);	chr9:93407016	chr9:93435332~93437121:-
LUAD	cis	rs950169	0.519	rs7237	ENSG00000254414.1	RP11-182J1.1	3.79	0.000167	0.0215	0.22	0.17	Schizophrenia;	chr15:84643346	chr15:84631898~84633987:-
LUAD	cis	rs34286592	1	rs34286592	ENSG00000214725.6	CDIPT-AS1	-3.79	0.000167	0.0215	-0.29	-0.17	Multiple sclerosis;	chr16:29809159	chr16:29863593~29868053:+
LUAD	cis	rs10463554	0.963	rs6596530	ENSG00000250682.4	LINC00491	3.79	0.000167	0.0215	0.2	0.17	Parkinson's disease;	chr5:103035736	chr5:102609156~102671559:-
LUAD	cis	rs206548	0.561	rs7235125	ENSG00000252680.1	RNA5SP449	-3.79	0.000167	0.0215	-0.21	-0.17	Serum protein levels (sST2);	chr18:10381169	chr18:9844717~9844846:-
LUAD	cis	rs853679	0.55	rs6901017	ENSG00000226314.6	ZNF192P1	-3.79	0.000167	0.0215	-0.22	-0.17	Depression;	chr6:28184805	chr6:28161781~28169594:+
LUAD	cis	rs9896933	0.832	rs77512810	ENSG00000262663.1	RP11-497H17.1	3.79	0.000167	0.0215	0.21	0.17	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr17:82846713	chr17:82918282~82918785:+
LUAD	cis	rs238295	0.805	rs6116855	ENSG00000230563.2	RP5-828H9.1	3.79	0.000167	0.0215	0.22	0.17	Occipital cortical area (total cortical area interaction);	chr20:5574671	chr20:5471207~5475182:+
LUAD	cis	rs12898370	0.561	rs11630770	ENSG00000259362.2	RP11-307C19.1	3.79	0.000167	0.0215	0.28	0.17	Risky sexual behaviors (alcohol dependence interaction);	chr15:77177301	chr15:77525540~77534110:+
LUAD	cis	rs7119038	0.615	rs10892274	ENSG00000255422.1	AP002954.4	3.79	0.000167	0.0215	0.24	0.17	Sjögren's syndrome;	chr11:118734754	chr11:118704607~118750263:+
LUAD	cis	rs1075265	0.547	rs7587217	ENSG00000272156.1	RP11-477N3.1	-3.79	0.000167	0.0215	-0.21	-0.17	Chronotype;Morning vs. evening chronotype;	chr2:53675029	chr2:54082554~54085066:+
LUAD	cis	rs16944613	0.588	rs8024734	ENSG00000259212.1	CTD-3065B20.2	3.79	0.000167	0.0215	0.28	0.17	Colorectal cancer;	chr15:90563835	chr15:90595840~90596447:-
LUAD	cis	rs7688540	0.723	rs9684973	ENSG00000211553.1	AC253576.2	-3.79	0.000167	0.0215	-0.22	-0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245032	chr4:136461~136568:+
LUAD	cis	rs9646944	1	rs6719123	ENSG00000234389.1	AC007278.3	3.79	0.000167	0.0215	0.19	0.17	Blood protein levels;	chr2:102259080	chr2:102438713~102440475:+
LUAD	cis	rs7942368	1	rs7107409	ENSG00000254632.1	RP11-21L23.4	3.79	0.000167	0.0215	0.18	0.17	Endometriosis;	chr11:76781151	chr11:76759916~76768223:-
LUAD	cis	rs34929064	1	rs6942567	ENSG00000230658.1	KLHL7-AS1	3.79	0.000167	0.0215	0.23	0.17	Major depression and alcohol dependence;	chr7:22685024	chr7:23101228~23105703:-
LUAD	cis	rs7178909	0.872	rs7174330	ENSG00000259677.1	RP11-493E3.1	-3.79	0.000167	0.0215	-0.19	-0.17	Common traits (Other);	chr15:89891347	chr15:89876540~89877285:+
LUAD	cis	rs11673344	0.704	rs1667384	ENSG00000267309.1	CTD-2630F21.1	-3.79	0.000167	0.0215	-0.21	-0.17	Obesity-related traits;	chr19:36925852	chr19:36489649~36491040:+
LUAD	cis	rs7762018	0.76	rs28660085	ENSG00000231690.2	LINC00574	-3.79	0.000167	0.0215	-0.24	-0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169701900	chr6:169790321~169802873:+
LUAD	cis	rs4795519	1	rs1993926	ENSG00000266313.1	RP11-173M1.4	3.79	0.000167	0.0215	0.21	0.17	Chronic myeloid leukemia;	chr17:27078969	chr17:27333256~27348491:+
LUAD	cis	rs4795519	0.961	rs1993927	ENSG00000266313.1	RP11-173M1.4	3.79	0.000167	0.0215	0.21	0.17	Chronic myeloid leukemia;	chr17:27078995	chr17:27333256~27348491:+
LUAD	cis	rs7515577	0.898	rs7547429	ENSG00000223787.2	RP4-593M8.1	-3.79	0.000167	0.0215	-0.26	-0.17	Cholesterol, total;	chr1:92222881	chr1:92580476~92580821:-
LUAD	cis	rs7119038	0.774	rs874621	ENSG00000255239.1	AP002954.6	-3.79	0.000167	0.0215	-0.26	-0.17	Sjögren's syndrome;	chr11:118784936	chr11:118688039~118690600:-
LUAD	cis	rs4130344	0.874	rs11933662	ENSG00000271817.2	U3	-3.79	0.000167	0.0215	-0.18	-0.17	Intelligence (multi-trait analysis);	chr4:158784688	chr4:158700691~158700909:+
LUAD	cis	rs11637445	0.603	rs1478941	ENSG00000270964.1	RP11-502I4.3	3.79	0.000167	0.0215	0.18	0.17	Posterior cortical atrophy and Alzheimer's disease;	chr15:67834803	chr15:67541072~67542604:-
LUAD	cis	rs7200543	1	rs55727637	ENSG00000260735.1	RP11-72I8.1	-3.79	0.000167	0.0215	-0.19	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15051395	chr16:15094411~15109197:+
LUAD	cis	rs7200543	1	rs1121	ENSG00000260735.1	RP11-72I8.1	-3.79	0.000167	0.0215	-0.19	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15037219	chr16:15094411~15109197:+
LUAD	cis	rs7200543	1	rs4985154	ENSG00000260735.1	RP11-72I8.1	-3.79	0.000167	0.0215	-0.19	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15037785	chr16:15094411~15109197:+
LUAD	cis	rs7200543	1	rs1135999	ENSG00000260735.1	RP11-72I8.1	-3.79	0.000167	0.0215	-0.19	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038105	chr16:15094411~15109197:+
LUAD	cis	rs7200543	1	rs1136001	ENSG00000260735.1	RP11-72I8.1	-3.79	0.000167	0.0215	-0.19	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038117	chr16:15094411~15109197:+
LUAD	cis	rs524281	0.773	rs7951079	ENSG00000255320.1	RP11-755F10.1	3.79	0.000167	0.0215	0.27	0.17	Electroencephalogram traits;	chr11:66213079	chr11:66244840~66246239:-
LUAD	cis	rs321358	0.895	rs7950087	ENSG00000271390.1	RP11-89C3.3	-3.79	0.000167	0.0215	-0.28	-0.17	Body mass index;	chr11:111082536	chr11:111089870~111090368:-
LUAD	cis	rs7819412	0.505	rs17782536	ENSG00000255046.1	RP11-297N6.4	3.79	0.000167	0.0215	0.21	0.17	Triglycerides;	chr8:11164172	chr8:11797928~11802568:-
LUAD	cis	rs9896933	0.832	rs75552659	ENSG00000262663.1	RP11-497H17.1	3.79	0.000167	0.0215	0.2	0.17	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr17:82846754	chr17:82918282~82918785:+
LUAD	cis	rs4474465	0.85	rs4597089	ENSG00000251323.2	RP11-452H21.4	-3.79	0.000167	0.0215	-0.21	-0.17	Alzheimer's disease (survival time);	chr11:78551198	chr11:78423982~78429836:-
LUAD	cis	rs7617773	0.743	rs6804986	ENSG00000199476.1	Y_RNA	-3.79	0.000167	0.0215	-0.22	-0.17	Coronary artery disease;	chr3:48322105	chr3:48288587~48288694:+
LUAD	cis	rs7824557	0.564	rs12550129	ENSG00000255046.1	RP11-297N6.4	3.79	0.000167	0.0215	0.21	0.17	Retinal vascular caliber;	chr8:11376408	chr8:11797928~11802568:-
LUAD	cis	rs7824557	0.564	rs13274106	ENSG00000255046.1	RP11-297N6.4	3.79	0.000167	0.0215	0.21	0.17	Retinal vascular caliber;	chr8:11376449	chr8:11797928~11802568:-
LUAD	cis	rs4731367	0.931	rs1419429	ENSG00000224138.1	AC000123.4	3.79	0.000167	0.0215	0.16	0.17	Parental longevity (mother's age at death);	chr7:127555184	chr7:127350128~127351523:+
LUAD	cis	rs7512552	0.839	rs11581351	ENSG00000275557.1	RP11-353N4.6	3.79	0.000167	0.0215	0.19	0.17	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150467724	chr1:149607765~149612402:+
LUAD	cis	rs78472555	0.633	rs2123930	ENSG00000259381.2	RP11-192M23.1	-3.79	0.000167	0.0215	-0.18	-0.17	Post bronchodilator FEV1/FVC ratio in COPD;	chr15:99690828	chr15:100645434~100646655:-
LUAD	cis	rs853679	0.55	rs9295762	ENSG00000226314.6	ZNF192P1	3.79	0.000167	0.0215	0.21	0.17	Depression;	chr6:28187640	chr6:28161781~28169594:+
LUAD	cis	rs2273788	0.527	rs2273786	ENSG00000204173.9	LRRC37A5P	3.79	0.000167	0.0215	0.18	0.17	Monocyte count;	chr9:111586233	chr9:111602831~111631289:-
LUAD	cis	rs9341808	0.667	rs3828753	ENSG00000272129.1	RP11-250B2.6	3.79	0.000167	0.0215	0.21	0.17	Sitting height ratio;	chr6:80203029	chr6:80355424~80356859:+
LUAD	cis	rs4499344	0.556	rs259217	ENSG00000201388.1	SNORA68	3.79	0.000167	0.0215	0.2	0.17	Mean platelet volume;	chr19:32647462	chr19:32608337~32608469:-
LUAD	cis	rs2337406	1	rs10459466	ENSG00000280411.1	IGHV1-69-2	-3.79	0.000167	0.0215	-0.18	-0.17	Alzheimer's disease (late onset);	chr14:106689255	chr14:106762092~106762588:-
LUAD	cis	rs2638953	0.924	rs7307078	ENSG00000278733.1	RP11-425D17.1	-3.79	0.000167	0.0216	-0.2	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28184645	chr12:28185625~28186190:-
LUAD	cis	rs28530618	0.87	rs6057612	ENSG00000175730.8	BAK1P1	3.79	0.000167	0.0216	0.21	0.17	Birth weight;	chr20:32660723	chr20:32690180~32690815:-
LUAD	cis	rs6502050	0.835	rs8079389	ENSG00000266654.1	RP11-1376P16.1	-3.79	0.000167	0.0216	-0.18	-0.17	Life satisfaction;	chr17:82200780	chr17:82160056~82160452:+
LUAD	cis	rs8050896	1	rs28547342	ENSG00000260695.1	RP11-513N24.1	-3.79	0.000167	0.0216	-0.3	-0.17	Response to antipsychotic treatment;	chr16:66121107	chr16:65861112~65863784:-
LUAD	cis	rs10080237	0.564	rs2490232	ENSG00000260645.1	RP11-250B2.5	-3.79	0.000167	0.0216	-0.16	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;	chr6:80105085	chr6:80466958~80469080:+
LUAD	cis	rs12935418	0.672	rs12448656	ENSG00000261061.1	RP11-303E16.2	-3.79	0.000167	0.0216	-0.19	-0.17	Mean corpuscular volume;	chr16:81008876	chr16:81030770~81031485:+
LUAD	cis	rs7829975	0.514	rs2945873	ENSG00000233609.3	RP11-62H7.2	3.79	0.000167	0.0216	0.14	0.17	Mood instability;	chr8:8402935	chr8:8961200~8979025:+
LUAD	cis	rs2461451	0.541	rs72841736	ENSG00000273950.1	Metazoa_SRP	3.79	0.000167	0.0216	0.35	0.17	Antipsychotic drug-induced QTc interval change in schizophrenia;	chr2:128039241	chr2:127856890~127857147:+
LUAD	cis	rs6061231	0.755	rs11699160	ENSG00000275437.1	RP5-908M14.10	3.79	0.000167	0.0216	0.16	0.17	Colorectal cancer;	chr20:62383595	chr20:62402236~62405935:-
LUAD	cis	rs324126	0.78	rs34425941	ENSG00000277977.1	CTD-3018O17.5	3.79	0.000167	0.0216	0.18	0.17	Colonoscopy-negative controls vs population controls;	chr19:52377359	chr19:52392659~52392755:+
LUAD	cis	rs858239	0.57	rs6968242	ENSG00000226816.2	AC005082.12	3.79	0.000167	0.0216	0.22	0.17	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23206013~23208045:+
LUAD	cis	rs11210359	0.528	rs1551392	ENSG00000272864.1	RP11-17E13.2	3.79	0.000167	0.0216	0.2	0.17	Bipolar disorder and schizophrenia;	chr1:73879910	chr1:74698769~74699333:-
LUAD	cis	rs4660214	0.627	rs16837533	ENSG00000228060.1	RP11-69E11.8	-3.79	0.000167	0.0216	-0.19	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39238175	chr1:39565160~39573203:+
LUAD	cis	rs12898370	0.504	rs12904882	ENSG00000259362.2	RP11-307C19.1	-3.79	0.000167	0.0216	-0.29	-0.17	Risky sexual behaviors (alcohol dependence interaction);	chr15:77108801	chr15:77525540~77534110:+
LUAD	cis	rs2638953	0.924	rs1551987	ENSG00000278733.1	RP11-425D17.1	-3.79	0.000167	0.0216	-0.2	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28178761	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs1551986	ENSG00000278733.1	RP11-425D17.1	-3.79	0.000167	0.0216	-0.2	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28178778	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs2078017	ENSG00000278733.1	RP11-425D17.1	-3.79	0.000167	0.0216	-0.2	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28180175	chr12:28185625~28186190:-
LUAD	cis	rs1979679	0.918	rs10843176	ENSG00000278733.1	RP11-425D17.1	-3.79	0.000167	0.0216	-0.22	-0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28454984	chr12:28185625~28186190:-
LUAD	cis	rs950880	1	rs12470864	ENSG00000234389.1	AC007278.3	-3.79	0.000167	0.0216	-0.16	-0.17	Serum protein levels (sST2);	chr2:102309902	chr2:102438713~102440475:+
LUAD	cis	rs7809950	0.954	rs62482543	ENSG00000238832.1	snoU109	-3.79	0.000167	0.0216	-0.25	-0.17	Coronary artery disease;	chr7:107440211	chr7:107603363~107603507:+
LUAD	cis	rs12216545	0.765	rs7785909	ENSG00000177590.7	GIMAP3P	-3.79	0.000167	0.0216	-0.17	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150525142	chr7:150746893~150747728:-
LUAD	cis	rs34779708	0.897	rs7897827	ENSG00000271335.4	RP11-324I22.4	3.79	0.000167	0.0216	0.18	0.17	Inflammatory bowel disease;Crohn's disease;	chr10:35097309	chr10:35314552~35336401:-
LUAD	cis	rs6498169	0.873	rs27836	ENSG00000274038.1	RP11-66H6.4	-3.79	0.000167	0.0216	-0.22	-0.17	Multiple sclerosis;	chr16:11163262	chr16:11056556~11057034:+
LUAD	cis	rs4666002	0.789	rs6727388	ENSG00000223522.1	AC093690.1	3.79	0.000168	0.0216	0.2	0.17	Phospholipid levels (plasma);	chr2:27709720	chr2:28307691~28310459:-
LUAD	cis	rs6964587	0.934	rs6973792	ENSG00000188693.7	CYP51A1-AS1	-3.79	0.000168	0.0216	-0.2	-0.17	Breast cancer;	chr7:92120484	chr7:92134604~92180725:+
LUAD	cis	rs28510890	0.789	rs17704141	ENSG00000260337.3	RP11-386M24.6	-3.79	0.000168	0.0216	-0.21	-0.17	Lung cancer in ever smokers;	chr15:92593271	chr15:92592574~92596462:-
LUAD	cis	rs524281	0.731	rs11227439	ENSG00000255320.1	RP11-755F10.1	3.79	0.000168	0.0216	0.27	0.17	Electroencephalogram traits;	chr11:66258208	chr11:66244840~66246239:-
LUAD	cis	rs7339483	0.702	rs10411891	ENSG00000268058.1	BNIP3P40	-3.79	0.000168	0.0216	-0.3	-0.17	Discordance in emotional problems in monozygotic twins;	chr19:24185732	chr19:24098425~24098980:-
LUAD	cis	rs8002861	0.935	rs9533678	ENSG00000274001.1	RP11-5G9.5	3.79	0.000168	0.0216	0.18	0.17	Leprosy;	chr13:43889273	chr13:43877715~43878163:-
LUAD	cis	rs6467136	0.521	rs62468944	ENSG00000224138.1	AC000123.4	3.79	0.000168	0.0216	0.16	0.17	Type 2 diabetes;	chr7:127446453	chr7:127350128~127351523:+
LUAD	cis	rs73193808	0.851	rs66903141	ENSG00000215533.7	LINC00189	-3.79	0.000168	0.0216	-0.25	-0.17	Coronary artery disease;	chr21:29229214	chr21:29193480~29288205:+
LUAD	cis	rs8064024	0.599	rs3185547	ENSG00000267077.1	RP11-127I20.5	3.79	0.000168	0.0216	0.2	0.17	Cancer;	chr16:4881099	chr16:4795265~4796532:-
LUAD	cis	rs67478160	0.643	rs34813623	ENSG00000272533.1	SNORA28	3.79	0.000168	0.0216	0.17	0.17	Schizophrenia;	chr14:103796957	chr14:103337849~103337974:+
LUAD	cis	rs67478160	0.608	rs34066659	ENSG00000272533.1	SNORA28	3.79	0.000168	0.0216	0.17	0.17	Schizophrenia;	chr14:103797090	chr14:103337849~103337974:+
LUAD	cis	rs8009147	1	rs8009147	ENSG00000272533.1	SNORA28	3.79	0.000168	0.0216	0.17	0.17	Autism spectrum disorder or schizophrenia;	chr14:103798325	chr14:103337849~103337974:+
LUAD	cis	rs67478160	0.643	rs7147171	ENSG00000272533.1	SNORA28	3.79	0.000168	0.0216	0.17	0.17	Schizophrenia;	chr14:103798520	chr14:103337849~103337974:+
LUAD	cis	rs67478160	0.529	rs12880413	ENSG00000272533.1	SNORA28	3.79	0.000168	0.0216	0.17	0.17	Schizophrenia;	chr14:103801070	chr14:103337849~103337974:+
LUAD	cis	rs67478160	0.619	rs11623546	ENSG00000272533.1	SNORA28	3.79	0.000168	0.0216	0.17	0.17	Schizophrenia;	chr14:103802761	chr14:103337849~103337974:+
LUAD	cis	rs67478160	0.619	rs55824307	ENSG00000272533.1	SNORA28	3.79	0.000168	0.0216	0.17	0.17	Schizophrenia;	chr14:103804870	chr14:103337849~103337974:+
LUAD	cis	rs67478160	0.595	rs12879501	ENSG00000272533.1	SNORA28	3.79	0.000168	0.0216	0.17	0.17	Schizophrenia;	chr14:103806297	chr14:103337849~103337974:+
LUAD	cis	rs7557067	1	rs11902417	ENSG00000233005.1	AC067959.1	3.79	0.000168	0.0216	0.19	0.17	Triglycerides;	chr2:20976028	chr2:21221175~21970959:+
LUAD	cis	rs11673344	0.566	rs256733	ENSG00000267254.4	ZNF790-AS1	-3.79	0.000168	0.0216	-0.21	-0.17	Obesity-related traits;	chr19:37384729	chr19:36797518~36828115:+
LUAD	cis	rs10197140	0.89	rs12470827	ENSG00000235721.1	AC013268.3	-3.79	0.000168	0.0216	-0.19	-0.17	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110883961	chr2:110007675~110010783:+
LUAD	cis	rs6472235	0.586	rs2357567	ENSG00000200714.1	Y_RNA	3.79	0.000168	0.0216	0.23	0.17	Plateletcrit;Myopia (pathological);	chr8:66003718	chr8:65592731~65592820:+
LUAD	cis	rs10492201	0.529	rs7313068	ENSG00000255733.4	IFNG-AS1	-3.79	0.000168	0.0216	-0.18	-0.17	Itch intensity from mosquito bite adjusted by bite size;	chr12:68011805	chr12:67989445~68234686:+
LUAD	cis	rs6071166	0.869	rs6027422	ENSG00000224635.1	RP4-564F22.5	3.79	0.000168	0.0216	0.18	0.17	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38703838	chr20:38406011~38416797:-
LUAD	cis	rs7503168	0.643	rs71381467	ENSG00000267592.1	CTC-507E2.2	3.79	0.000168	0.0216	0.36	0.17	Plateletcrit;	chr17:35693030	chr17:35596904~35597128:-
LUAD	cis	rs7503168	0.643	rs17608253	ENSG00000267592.1	CTC-507E2.2	3.79	0.000168	0.0216	0.36	0.17	Plateletcrit;	chr17:35699451	chr17:35596904~35597128:-
LUAD	cis	rs73990293	0.737	rs11657558	ENSG00000267592.1	CTC-507E2.2	3.79	0.000168	0.0216	0.36	0.17	Clopidogrel active metabolite levels;	chr17:35702305	chr17:35596904~35597128:-
LUAD	cis	rs10829156	0.786	rs7077786	ENSG00000240291.1	RP11-499P20.2	3.79	0.000168	0.0216	0.16	0.17	Sudden cardiac arrest;	chr10:18603453	chr10:18513115~18545651:-
LUAD	cis	rs12440869	1	rs4597266	ENSG00000270964.1	RP11-502I4.3	-3.79	0.000168	0.0216	-0.2	-0.17	Peak velocity of the mitral A-wave;	chr15:67287643	chr15:67541072~67542604:-
LUAD	cis	rs7487075	0.78	rs10785624	ENSG00000274723.1	RP11-618L22.1	3.79	0.000168	0.0216	0.21	0.17	Itch intensity from mosquito bite;	chr12:46373004	chr12:46970504~46972155:+
LUAD	cis	rs7487075	0.78	rs2279559	ENSG00000274723.1	RP11-618L22.1	3.79	0.000168	0.0216	0.21	0.17	Itch intensity from mosquito bite;	chr12:46373392	chr12:46970504~46972155:+
LUAD	cis	rs67981189	0.865	rs2810115	ENSG00000269927.1	RP6-91H8.3	-3.79	0.000168	0.0216	-0.21	-0.17	Schizophrenia;	chr14:70928070	chr14:71141125~71143253:-
LUAD	cis	rs67981189	0.896	rs917065	ENSG00000269927.1	RP6-91H8.3	-3.79	0.000168	0.0216	-0.21	-0.17	Schizophrenia;	chr14:70931129	chr14:71141125~71143253:-
LUAD	cis	rs67981189	0.896	rs1018977	ENSG00000269927.1	RP6-91H8.3	-3.79	0.000168	0.0216	-0.21	-0.17	Schizophrenia;	chr14:70933936	chr14:71141125~71143253:-
LUAD	cis	rs67981189	0.752	rs2332477	ENSG00000269927.1	RP6-91H8.3	-3.79	0.000168	0.0216	-0.21	-0.17	Schizophrenia;	chr14:70936594	chr14:71141125~71143253:-
LUAD	cis	rs911119	0.955	rs59059917	ENSG00000270001.1	RP11-218C14.8	-3.79	0.000168	0.0216	-0.26	-0.17	Chronic kidney disease;	chr20:23615038	chr20:23631826~23632316:-
LUAD	cis	rs6479901	0.895	rs67963837	ENSG00000232075.1	MRPL35P2	-3.79	0.000168	0.0216	-0.23	-0.17	Intelligence (multi-trait analysis);	chr10:63247111	chr10:63634317~63634827:-
LUAD	cis	rs8049040	0.524	rs891125	ENSG00000260886.1	TAT-AS1	3.79	0.000168	0.0216	0.2	0.17	Blood protein levels;	chr16:71397718	chr16:71565789~71578187:+
LUAD	cis	rs1124609	1	rs78224090	ENSG00000244879.4	GABPB1-AS1	3.79	0.000168	0.0216	0.27	0.17	Subjective well-being;	chr15:50182032	chr15:50354959~50372202:+
LUAD	cis	rs10899021	0.512	rs2186955	ENSG00000279353.1	RP11-864N7.4	-3.79	0.000168	0.0216	-0.25	-0.17	Response to metformin (IC50);	chr11:74664430	chr11:74698231~74699658:-
LUAD	cis	rs7017914	0.69	rs10504492	ENSG00000246366.5	RP11-382J12.1	3.79	0.000168	0.0216	0.16	0.17	Bone mineral density;	chr8:71065724	chr8:70608577~70663279:+
LUAD	cis	rs801193	0.569	rs2659893	ENSG00000273448.1	RP11-166O4.6	3.79	0.000168	0.0216	0.16	0.17	Aortic root size;	chr7:66735006	chr7:67333047~67334383:+
LUAD	cis	rs801193	0.569	rs2659892	ENSG00000273448.1	RP11-166O4.6	3.79	0.000168	0.0216	0.16	0.17	Aortic root size;	chr7:66735318	chr7:67333047~67334383:+
LUAD	cis	rs801193	0.548	rs2659891	ENSG00000273448.1	RP11-166O4.6	3.79	0.000168	0.0216	0.16	0.17	Aortic root size;	chr7:66736127	chr7:67333047~67334383:+
LUAD	cis	rs801193	0.569	rs2707847	ENSG00000273448.1	RP11-166O4.6	3.79	0.000168	0.0216	0.16	0.17	Aortic root size;	chr7:66737884	chr7:67333047~67334383:+
LUAD	cis	rs801193	0.548	rs7805152	ENSG00000273448.1	RP11-166O4.6	3.79	0.000168	0.0216	0.16	0.17	Aortic root size;	chr7:66744266	chr7:67333047~67334383:+
LUAD	cis	rs9291683	0.595	rs35501905	ENSG00000250413.1	RP11-448G15.1	-3.79	0.000168	0.0216	-0.22	-0.17	Bone mineral density;	chr4:10051807	chr4:10006482~10009725:+
LUAD	cis	rs2731006	0.901	rs2678114	ENSG00000257114.2	RP11-25I15.3	3.79	0.000168	0.0216	0.26	0.17	Panic disorder;	chr12:42766681	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.901	rs2731005	ENSG00000257114.2	RP11-25I15.3	3.79	0.000168	0.0216	0.26	0.17	Panic disorder;	chr12:42766988	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.901	rs2731008	ENSG00000257114.2	RP11-25I15.3	3.79	0.000168	0.0216	0.26	0.17	Panic disorder;	chr12:42767221	chr12:42692216~42717119:+
LUAD	cis	rs1219407	0.708	rs664146	ENSG00000255090.4	MIR100HG	3.79	0.000168	0.0216	0.34	0.17	Mood disorder in prion disease;	chr11:121818606	chr11:122155422~122422871:-
LUAD	cis	rs1219407	0.708	rs545862	ENSG00000255090.4	MIR100HG	3.79	0.000168	0.0216	0.34	0.17	Mood disorder in prion disease;	chr11:121819117	chr11:122155422~122422871:-
LUAD	cis	rs13434995	0.513	rs972446	ENSG00000273257.1	RP11-177J6.1	3.79	0.000168	0.0216	0.23	0.17	Adiponectin levels;	chr4:55569581	chr4:55387949~55388271:+
LUAD	cis	rs13434995	0.513	rs11732481	ENSG00000273257.1	RP11-177J6.1	3.79	0.000168	0.0216	0.23	0.17	Adiponectin levels;	chr4:55570212	chr4:55387949~55388271:+
LUAD	cis	rs7005380	0.62	rs9649947	ENSG00000279347.1	RP11-85I17.2	-3.79	0.000168	0.0216	-0.14	-0.17	Interstitial lung disease;	chr8:119901117	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.62	rs13279398	ENSG00000279347.1	RP11-85I17.2	-3.79	0.000168	0.0216	-0.14	-0.17	Interstitial lung disease;	chr8:119902030	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.62	rs13277947	ENSG00000279347.1	RP11-85I17.2	-3.79	0.000168	0.0216	-0.14	-0.17	Interstitial lung disease;	chr8:119902192	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.6	rs13277992	ENSG00000279347.1	RP11-85I17.2	-3.79	0.000168	0.0216	-0.14	-0.17	Interstitial lung disease;	chr8:119902287	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.62	rs13253140	ENSG00000279347.1	RP11-85I17.2	-3.79	0.000168	0.0216	-0.14	-0.17	Interstitial lung disease;	chr8:119902668	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.6	rs11777705	ENSG00000279347.1	RP11-85I17.2	-3.79	0.000168	0.0216	-0.14	-0.17	Interstitial lung disease;	chr8:119902992	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.62	rs12681402	ENSG00000279347.1	RP11-85I17.2	-3.79	0.000168	0.0216	-0.14	-0.17	Interstitial lung disease;	chr8:119903622	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.62	rs7461290	ENSG00000279347.1	RP11-85I17.2	-3.79	0.000168	0.0216	-0.14	-0.17	Interstitial lung disease;	chr8:119904154	chr8:119838736~119840385:-
LUAD	cis	rs9291683	0.595	rs13150928	ENSG00000250413.1	RP11-448G15.1	-3.79	0.000168	0.0216	-0.22	-0.17	Bone mineral density;	chr4:10051337	chr4:10006482~10009725:+
LUAD	cis	rs9467773	0.62	rs2504599	ENSG00000241549.7	GUSBP2	3.79	0.000168	0.0216	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26640832	chr6:26871484~26956554:-
LUAD	cis	rs2348418	0.966	rs7136139	ENSG00000244712.1	RP11-874G11.1	3.79	0.000168	0.0217	0.2	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28531087	chr12:28564678~28565141:-
LUAD	cis	rs2348418	0.966	rs4144964	ENSG00000244712.1	RP11-874G11.1	3.79	0.000168	0.0217	0.2	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28531249	chr12:28564678~28565141:-
LUAD	cis	rs6088580	0.634	rs4911152	ENSG00000276073.1	RP5-1125A11.7	3.79	0.000168	0.0217	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34367218	chr20:33985617~33988989:-
LUAD	cis	rs6088580	0.634	rs9789792	ENSG00000276073.1	RP5-1125A11.7	3.79	0.000168	0.0217	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34369903	chr20:33985617~33988989:-
LUAD	cis	rs11512640	0.826	rs76118307	ENSG00000254671.2	STT3A-AS1	3.79	0.000168	0.0217	0.41	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125573106	chr11:125570284~125592568:-
LUAD	cis	rs67981189	0.896	rs34731365	ENSG00000269927.1	RP6-91H8.3	3.79	0.000168	0.0217	0.21	0.17	Schizophrenia;	chr14:70982877	chr14:71141125~71143253:-
LUAD	cis	rs2348418	0.798	rs11049486	ENSG00000247934.4	RP11-967K21.1	-3.79	0.000168	0.0217	-0.19	-0.17	Lung function (FEV1);Lung function (FVC);	chr12:28253224	chr12:28163298~28190738:-
LUAD	cis	rs860295	0.836	rs6684889	ENSG00000160766.13	GBAP1	3.79	0.000168	0.0217	0.18	0.17	Body mass index;	chr1:155457271	chr1:155213821~155227422:-
LUAD	cis	rs287982	0.611	rs77095920	ENSG00000269973.1	RP11-95D17.1	-3.79	0.000168	0.0217	-0.24	-0.17	Nonsyndromic cleft lip with cleft palate;	chr2:9833092	chr2:9936360~9939590:+
LUAD	cis	rs7812879	0.636	rs2618455	ENSG00000255046.1	RP11-297N6.4	3.79	0.000168	0.0217	0.29	0.17	Systemic lupus erythematosus;	chr8:11513369	chr8:11797928~11802568:-
LUAD	cis	rs4660214	0.666	rs10493087	ENSG00000182109.6	RP11-69E11.4	-3.79	0.000168	0.0217	-0.18	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39251584	chr1:39522280~39546187:-
LUAD	cis	rs4660214	0.666	rs11205828	ENSG00000182109.6	RP11-69E11.4	-3.79	0.000168	0.0217	-0.18	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39253674	chr1:39522280~39546187:-
LUAD	cis	rs1075265	0.749	rs2692518	ENSG00000272156.1	RP11-477N3.1	-3.79	0.000168	0.0217	-0.2	-0.17	Chronotype;Morning vs. evening chronotype;	chr2:53804746	chr2:54082554~54085066:+
LUAD	cis	rs11673344	0.523	rs2562594	ENSG00000276846.1	CTD-3220F14.3	3.79	0.000168	0.0217	0.19	0.17	Obesity-related traits;	chr19:37023783	chr19:37314868~37315620:-
LUAD	cis	rs9467773	0.62	rs2451732	ENSG00000261353.1	CTA-14H9.5	3.79	0.000168	0.0217	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26622676	chr6:26527063~26527404:+
LUAD	cis	rs7178424	0.742	rs12916268	ENSG00000259251.2	RP11-643M14.1	-3.79	0.000169	0.0217	-0.17	-0.17	Height;	chr15:61883443	chr15:62060503~62062434:+
LUAD	cis	rs9467773	1	rs6922824	ENSG00000241549.7	GUSBP2	-3.79	0.000169	0.0217	-0.19	-0.17	Intelligence (multi-trait analysis);	chr6:26553587	chr6:26871484~26956554:-
LUAD	cis	rs4142110	0.628	rs347385	ENSG00000271216.1	LINC01050	-3.79	0.000169	0.0217	-0.2	-0.17	Nephrolithiasis;	chr13:42221960	chr13:42810366~42812562:-
LUAD	cis	rs7215564	0.73	rs34806161	ENSG00000232083.3	RPL31P7	3.79	0.000169	0.0217	0.31	0.17	Myopia (pathological);	chr17:80600039	chr17:80602549~80602926:-
LUAD	cis	rs1559040	1	rs56374740	ENSG00000272156.1	RP11-477N3.1	-3.79	0.000169	0.0217	-0.29	-0.17	Sudden cardiac arrest;	chr2:54092380	chr2:54082554~54085066:+
LUAD	cis	rs877819	0.519	rs2671711	ENSG00000228403.1	RP11-563N6.6	3.79	0.000169	0.0217	0.17	0.17	Systemic lupus erythematosus;	chr10:48886741	chr10:48878022~48878649:+
LUAD	cis	rs6460942	1	rs6460938	ENSG00000226690.5	AC005281.1	3.79	0.000169	0.0217	0.31	0.17	Coronary artery disease;	chr7:12367182	chr7:12496429~12541910:+
LUAD	cis	rs6460942	1	rs62448568	ENSG00000226690.5	AC005281.1	3.79	0.000169	0.0217	0.31	0.17	Coronary artery disease;	chr7:12367819	chr7:12496429~12541910:+
LUAD	cis	rs2239547	0.657	rs12496077	ENSG00000243224.1	RP5-1157M23.2	-3.79	0.000169	0.0217	-0.19	-0.17	Schizophrenia;	chr3:52852225	chr3:52239258~52241097:+
LUAD	cis	rs2731006	0.64	rs1554251	ENSG00000257114.2	RP11-25I15.3	3.79	0.000169	0.0217	0.28	0.17	Panic disorder;	chr12:42775903	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.64	rs1554250	ENSG00000257114.2	RP11-25I15.3	3.79	0.000169	0.0217	0.28	0.17	Panic disorder;	chr12:42775924	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.64	rs1554249	ENSG00000257114.2	RP11-25I15.3	3.79	0.000169	0.0217	0.28	0.17	Panic disorder;	chr12:42775949	chr12:42692216~42717119:+
LUAD	cis	rs117623576	0.941	rs17230152	ENSG00000234335.1	RPS4XP11	-3.79	0.000169	0.0217	-0.26	-0.17	Anti-saccade response;	chr10:32143041	chr10:32102522~32103293:-
LUAD	cis	rs17275866	1	rs17354466	ENSG00000251584.1	RP11-440I14.3	3.79	0.000169	0.0217	0.22	0.17	Chin dimples;	chr4:174150380	chr4:174536640~174540784:+
LUAD	cis	rs9900280	1	rs559972	ENSG00000264808.1	RP11-802D6.1	3.79	0.000169	0.0217	0.19	0.17	Mean platelet volume;	chr17:29487478	chr17:29369717~29390777:-
LUAD	cis	rs4713118	0.629	rs149899	ENSG00000280107.1	AL022393.9	-3.79	0.000169	0.0217	-0.22	-0.17	Parkinson's disease;	chr6:28052201	chr6:28170845~28172521:+
LUAD	cis	rs4713118	0.629	rs172165	ENSG00000280107.1	AL022393.9	-3.79	0.000169	0.0217	-0.22	-0.17	Parkinson's disease;	chr6:28053036	chr6:28170845~28172521:+
LUAD	cis	rs4713118	0.597	rs172166	ENSG00000280107.1	AL022393.9	-3.79	0.000169	0.0217	-0.22	-0.17	Parkinson's disease;	chr6:28053042	chr6:28170845~28172521:+
LUAD	cis	rs12887734	0.569	rs66953418	ENSG00000258914.1	CTD-2134A5.3	-3.79	0.000169	0.0217	-0.2	-0.17	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103805133	chr14:103875055~103877478:+
LUAD	cis	rs987044	0.834	rs4964759	ENSG00000257221.1	RP11-689B22.2	-3.79	0.000169	0.0217	-0.14	-0.17	Mean platelet volume;	chr12:108810035	chr12:108628687~108641318:+
LUAD	cis	rs7178424	0.742	rs12906423	ENSG00000259251.2	RP11-643M14.1	-3.79	0.000169	0.0217	-0.17	-0.17	Height;	chr15:61911685	chr15:62060503~62062434:+
LUAD	cis	rs853679	0.517	rs9295761	ENSG00000280107.1	AL022393.9	-3.79	0.000169	0.0217	-0.23	-0.17	Depression;	chr6:28180209	chr6:28170845~28172521:+
LUAD	cis	rs1005277	0.522	rs7072977	ENSG00000263064.2	RP11-291L22.7	3.79	0.000169	0.0217	0.18	0.17	Extrinsic epigenetic age acceleration;	chr10:37651512	chr10:38448689~38448949:+
LUAD	cis	rs13260300	0.533	rs933831	ENSG00000249395.2	CASC9	3.79	0.000169	0.0217	0.2	0.17	Breast cancer-free interval (treatment with aromatase inhibitor);	chr8:74581431	chr8:75223404~75324741:-
LUAD	cis	rs595244	1	rs636178	ENSG00000259705.1	RP11-227D13.1	3.79	0.000169	0.0217	0.35	0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48605085	chr15:48645951~48652016:+
LUAD	cis	rs595244	0.901	rs2466790	ENSG00000259705.1	RP11-227D13.1	3.79	0.000169	0.0217	0.35	0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48607202	chr15:48645951~48652016:+
LUAD	cis	rs4907240	0.961	rs11682934	ENSG00000237510.6	AC008268.2	-3.79	0.000169	0.0217	-0.24	-0.17	Event-related brain oscillations;	chr2:96571416	chr2:95789654~95800166:+
LUAD	cis	rs10214930	0.697	rs757397	ENSG00000235574.1	AC073150.6	-3.79	0.000169	0.0217	-0.21	-0.17	Hypospadias;	chr7:27868922	chr7:27491682~27492765:-
LUAD	cis	rs7061710	0.871	rs6608452	ENSG00000271811.1	RP1-79C4.4	-3.79	0.000169	0.0217	-0.24	-0.17	Blood metabolite levels;	chr1:171147974	chr1:170667381~170669425:+
LUAD	cis	rs2836754	0.841	rs8133137	ENSG00000205622.8	AF064858.6	-3.79	0.000169	0.0217	-0.19	-0.17	Body mass index;Crohn's disease;	chr21:38918579	chr21:38863676~38956467:-
LUAD	cis	rs6071166	0.683	rs6064886	ENSG00000224635.1	RP4-564F22.5	-3.79	0.000169	0.0217	-0.19	-0.17	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38692725	chr20:38406011~38416797:-
LUAD	cis	rs6071166	0.683	rs6071119	ENSG00000224635.1	RP4-564F22.5	-3.79	0.000169	0.0217	-0.19	-0.17	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38693380	chr20:38406011~38416797:-
LUAD	cis	rs6071166	0.683	rs6071126	ENSG00000224635.1	RP4-564F22.5	-3.79	0.000169	0.0217	-0.19	-0.17	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38693582	chr20:38406011~38416797:-
LUAD	cis	rs6071166	0.683	rs722077	ENSG00000224635.1	RP4-564F22.5	-3.79	0.000169	0.0217	-0.19	-0.17	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38694105	chr20:38406011~38416797:-
LUAD	cis	rs6071166	0.683	rs1358900	ENSG00000224635.1	RP4-564F22.5	-3.79	0.000169	0.0217	-0.19	-0.17	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38695327	chr20:38406011~38416797:-
LUAD	cis	rs6071166	0.683	rs1885456	ENSG00000224635.1	RP4-564F22.5	-3.79	0.000169	0.0217	-0.19	-0.17	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38695853	chr20:38406011~38416797:-
LUAD	cis	rs6071166	0.683	rs6015665	ENSG00000224635.1	RP4-564F22.5	-3.79	0.000169	0.0217	-0.19	-0.17	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38695969	chr20:38406011~38416797:-
LUAD	cis	rs6071166	0.683	rs6015666	ENSG00000224635.1	RP4-564F22.5	-3.79	0.000169	0.0217	-0.19	-0.17	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38695984	chr20:38406011~38416797:-
LUAD	cis	rs6071166	0.683	rs6027369	ENSG00000224635.1	RP4-564F22.5	-3.79	0.000169	0.0217	-0.19	-0.17	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38697441	chr20:38406011~38416797:-
LUAD	cis	rs6071166	0.683	rs6071139	ENSG00000224635.1	RP4-564F22.5	-3.79	0.000169	0.0217	-0.19	-0.17	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38697906	chr20:38406011~38416797:-
LUAD	cis	rs12681366	1	rs66787185	ENSG00000253704.1	RP11-267M23.4	3.79	0.000169	0.0217	0.2	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94365254	chr8:94553722~94569745:+
LUAD	cis	rs897984	0.553	rs2125293	ENSG00000232748.3	RP11-196G11.6	3.79	0.000169	0.0218	0.23	0.17	Dementia with Lewy bodies;	chr16:30852554	chr16:31056460~31062803:+
LUAD	cis	rs2980439	0.818	rs2945249	ENSG00000233609.3	RP11-62H7.2	3.79	0.000169	0.0218	0.14	0.17	Neuroticism;	chr8:8237204	chr8:8961200~8979025:+
LUAD	cis	rs739496	0.653	rs11613713	ENSG00000234608.6	MAPKAPK5-AS1	3.79	0.000169	0.0218	0.2	0.17	Platelet count;	chr12:111779334	chr12:111839764~111842902:-
LUAD	cis	rs4321325	0.536	rs10198483	ENSG00000236682.1	AC068282.3	-3.79	0.000169	0.0218	-0.26	-0.17	Protein C levels;	chr2:127176526	chr2:127389130~127400580:+
LUAD	cis	rs11064837	0.504	rs7310148	ENSG00000248636.5	RP11-768F21.1	3.79	0.000169	0.0218	0.2	0.17	Schizophrenia;	chr12:119615925	chr12:119387987~119668079:-
LUAD	cis	rs9659323	0.931	rs113197996	ENSG00000226172.2	RP4-712E4.1	-3.79	0.000169	0.0218	-0.18	-0.17	Body mass index;	chr1:118979803	chr1:119000344~119001392:-
LUAD	cis	rs12285276	0.636	rs7114337	ENSG00000205106.4	DKFZp779M0652	3.79	0.000169	0.0218	0.24	0.17	Visceral fat;	chr11:45779608	chr11:45771432~45772358:+
LUAD	cis	rs2342371	1	rs2342371	ENSG00000273013.1	CTD-2002J20.1	3.79	0.000169	0.0218	0.21	0.17	Fat distribution (HIV);	chr3:196460737	chr3:196474801~196475394:+
LUAD	cis	rs71520386	0.846	rs13243243	ENSG00000228649.7	AC005682.5	3.79	0.000169	0.0218	0.26	0.17	Fibrinogen levels;	chr7:22781400	chr7:22854178~22861579:+
LUAD	cis	rs34783982	0.96	rs12439475	ENSG00000261441.1	RP11-217B1.2	-3.79	0.000169	0.0218	-0.23	-0.17	Squamous cell lung carcinoma;	chr15:88964092	chr15:89335053~89336161:+
LUAD	cis	rs7551222	0.752	rs12032733	ENSG00000240219.1	RP11-430C7.5	3.79	0.000169	0.0218	0.18	0.17	Schizophrenia;	chr1:204512081	chr1:204626775~204629712:+
LUAD	cis	rs7578361	0.959	rs4072901	ENSG00000231969.1	AC144449.1	-3.79	0.000169	0.0218	-0.25	-0.17	Acute lymphoblastic leukemia (childhood);	chr2:149590446	chr2:149587196~149848233:+
LUAD	cis	rs7578361	0.959	rs4129903	ENSG00000231969.1	AC144449.1	-3.79	0.000169	0.0218	-0.25	-0.17	Acute lymphoblastic leukemia (childhood);	chr2:149591162	chr2:149587196~149848233:+
LUAD	cis	rs7578361	0.959	rs4129904	ENSG00000231969.1	AC144449.1	-3.79	0.000169	0.0218	-0.25	-0.17	Acute lymphoblastic leukemia (childhood);	chr2:149591227	chr2:149587196~149848233:+
LUAD	cis	rs2050203	0.614	rs6515500	ENSG00000230725.4	RP4-738P15.1	-3.79	0.000169	0.0218	-0.32	-0.17	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;	chr20:24448262	chr20:25140789~25149258:-
LUAD	cis	rs34792	0.678	rs153787	ENSG00000275910.1	RP11-680G24.6	3.79	0.000169	0.0218	0.17	0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15499916	chr16:15015828~15016390:-
LUAD	cis	rs875971	1	rs6958271	ENSG00000273142.1	RP11-458F8.4	-3.79	0.00017	0.0218	-0.12	-0.17	Aortic root size;	chr7:66514344	chr7:66902857~66906297:+
LUAD	cis	rs875971	1	rs6958277	ENSG00000273142.1	RP11-458F8.4	-3.79	0.00017	0.0218	-0.12	-0.17	Aortic root size;	chr7:66514362	chr7:66902857~66906297:+
LUAD	cis	rs911555	0.574	rs34251103	ENSG00000259775.1	RP11-45P15.4	3.79	0.00017	0.0218	0.22	0.17	Intelligence (multi-trait analysis);	chr14:103393726	chr14:103331674~103332367:-
LUAD	cis	rs17711722	0.528	rs73138179	ENSG00000273024.4	INTS4P2	-3.79	0.00017	0.0218	-0.19	-0.17	Calcium levels;	chr7:65829495	chr7:65647864~65715661:+
LUAD	cis	rs7246657	0.598	rs28660259	ENSG00000267309.1	CTD-2630F21.1	3.79	0.00017	0.0218	0.29	0.17	Coronary artery calcification;	chr19:37167779	chr19:36489649~36491040:+
LUAD	cis	rs7017914	0.902	rs10504481	ENSG00000246366.5	RP11-382J12.1	3.79	0.00017	0.0218	0.16	0.17	Bone mineral density;	chr8:70787282	chr8:70608577~70663279:+
LUAD	cis	rs6438234	0.778	rs6767071	ENSG00000242767.1	ZBTB20-AS4	3.79	0.00017	0.0218	0.22	0.17	Type 2 diabetes;	chr3:115248033	chr3:115100423~115103061:+
LUAD	cis	rs6438234	0.778	rs6802984	ENSG00000242767.1	ZBTB20-AS4	3.79	0.00017	0.0218	0.22	0.17	Type 2 diabetes;	chr3:115248261	chr3:115100423~115103061:+
LUAD	cis	rs2024714	0.967	rs2427203	ENSG00000273812.1	WI2-87327B8.2	-3.79	0.00017	0.0218	-0.18	-0.17	Longevity;	chr20:61632016	chr20:62596732~62603115:-
LUAD	cis	rs8067545	0.641	rs203462	ENSG00000270091.1	RP11-78O7.2	-3.79	0.00017	0.0218	-0.14	-0.17	Schizophrenia;	chr17:19909228	chr17:19896590~19897287:-
LUAD	cis	rs8067545	0.641	rs203460	ENSG00000270091.1	RP11-78O7.2	-3.79	0.00017	0.0218	-0.14	-0.17	Schizophrenia;	chr17:19911973	chr17:19896590~19897287:-
LUAD	cis	rs2731006	0.64	rs2731003	ENSG00000257114.2	RP11-25I15.3	3.79	0.00017	0.0218	0.27	0.17	Panic disorder;	chr12:42790527	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.64	rs1400814	ENSG00000257114.2	RP11-25I15.3	3.79	0.00017	0.0218	0.27	0.17	Panic disorder;	chr12:42790753	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.64	rs1517666	ENSG00000257114.2	RP11-25I15.3	3.79	0.00017	0.0218	0.27	0.17	Panic disorder;	chr12:42791526	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.64	rs2037238	ENSG00000257114.2	RP11-25I15.3	3.79	0.00017	0.0218	0.27	0.17	Panic disorder;	chr12:42791547	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.64	rs2678134	ENSG00000257114.2	RP11-25I15.3	3.79	0.00017	0.0218	0.27	0.17	Panic disorder;	chr12:42792190	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.64	rs2731004	ENSG00000257114.2	RP11-25I15.3	3.79	0.00017	0.0218	0.27	0.17	Panic disorder;	chr12:42792304	chr12:42692216~42717119:+
LUAD	cis	rs62246343	0.605	rs4328788	ENSG00000254485.4	RP11-380O24.1	3.79	0.00017	0.0218	0.22	0.17	Fibrinogen levels;	chr3:9415577	chr3:9292588~9363303:-
LUAD	cis	rs62246343	0.605	rs4308263	ENSG00000254485.4	RP11-380O24.1	3.79	0.00017	0.0218	0.22	0.17	Fibrinogen levels;	chr3:9415674	chr3:9292588~9363303:-
LUAD	cis	rs78487399	0.71	rs75330033	ENSG00000234936.1	AC010883.5	3.79	0.00017	0.0218	0.25	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43470584	chr2:43229573~43233394:+
LUAD	cis	rs78487399	0.71	rs80147536	ENSG00000234936.1	AC010883.5	3.79	0.00017	0.0218	0.25	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43470889	chr2:43229573~43233394:+
LUAD	cis	rs78487399	0.808	rs75135247	ENSG00000234936.1	AC010883.5	3.79	0.00017	0.0218	0.25	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43472260	chr2:43229573~43233394:+
LUAD	cis	rs7976269	0.609	rs10771470	ENSG00000257176.2	RP11-996F15.2	-3.79	0.00017	0.0218	-0.18	-0.17	Male-pattern baldness;	chr12:29050620	chr12:29280418~29317848:-
LUAD	cis	rs6793245	0.843	rs6771881	ENSG00000229589.1	ACVR2B-AS1	-3.79	0.00017	0.0218	-0.21	-0.17	QT interval;	chr3:38536773	chr3:38451027~38454820:-
LUAD	cis	rs10129255	0.5	rs11628999	ENSG00000253209.1	IGHV3-65	3.79	0.00017	0.0218	0.13	0.17	Kawasaki disease;	chr14:106800208	chr14:106666092~106666532:-
LUAD	cis	rs270601	0.721	rs162894	ENSG00000263597.1	MIR3936	3.79	0.00017	0.0218	0.19	0.17	Acylcarnitine levels;	chr5:132276179	chr5:132365490~132365599:-
LUAD	cis	rs62025270	0.688	rs62022939	ENSG00000259416.2	RP11-158M2.5	-3.79	0.00017	0.0218	-0.23	-0.17	Idiopathic pulmonary fibrosis;	chr15:85707651	chr15:85754941~85756237:-
LUAD	cis	rs17772222	1	rs12433464	ENSG00000258789.1	RP11-507K2.3	-3.79	0.00017	0.0218	-0.23	-0.17	Coronary artery calcification;	chr14:88357671	chr14:88551597~88552493:+
LUAD	cis	rs11159086	0.793	rs1029703	ENSG00000270000.1	RP3-449M8.9	3.79	0.00017	0.0218	0.24	0.17	Advanced glycation end-product levels;	chr14:74473899	chr14:74471930~74472360:-
LUAD	cis	rs9907295	0.818	rs7211393	ENSG00000270977.1	AC015849.16	-3.79	0.00017	0.0218	-0.23	-0.17	Fibroblast growth factor basic levels;	chr17:35885124	chr17:35893707~35911023:-
LUAD	cis	rs7017914	0.967	rs2100908	ENSG00000246366.5	RP11-382J12.1	3.79	0.00017	0.0218	0.16	0.17	Bone mineral density;	chr8:70671075	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.967	rs34558600	ENSG00000246366.5	RP11-382J12.1	3.79	0.00017	0.0218	0.16	0.17	Bone mineral density;	chr8:70673917	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.967	rs6472538	ENSG00000246366.5	RP11-382J12.1	3.79	0.00017	0.0218	0.16	0.17	Bone mineral density;	chr8:70674736	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.967	rs7001162	ENSG00000246366.5	RP11-382J12.1	3.79	0.00017	0.0218	0.16	0.17	Bone mineral density;	chr8:70675235	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.967	rs56112621	ENSG00000246366.5	RP11-382J12.1	3.79	0.00017	0.0218	0.16	0.17	Bone mineral density;	chr8:70676159	chr8:70608577~70663279:+
LUAD	cis	rs12148488	0.966	rs1867148	ENSG00000260269.4	CTD-2323K18.1	3.79	0.00017	0.0218	0.21	0.17	Caffeine consumption;	chr15:75047644	chr15:75527150~75601205:-
LUAD	cis	rs12148488	0.966	rs1867149	ENSG00000260269.4	CTD-2323K18.1	3.79	0.00017	0.0218	0.21	0.17	Caffeine consumption;	chr15:75047652	chr15:75527150~75601205:-
LUAD	cis	rs4595586	0.967	rs1400280	ENSG00000257718.1	RP11-396F22.1	-3.79	0.00017	0.0218	-0.2	-0.17	Morning vs. evening chronotype;	chr12:38847438	chr12:38906451~38909592:+
LUAD	cis	rs2921073	0.51	rs2976945	ENSG00000253981.4	ALG1L13P	3.79	0.00017	0.0218	0.2	0.17	Parkinson's disease;	chr8:8413361	chr8:8236003~8244667:-
LUAD	cis	rs57104699	0.668	rs11763665	ENSG00000225541.1	AC002480.5	3.79	0.00017	0.0218	0.19	0.17	Multiple myeloma and monoclonal gammopathy;Multiple myeloma;	chr7:21886368	chr7:22571607~22661792:-
LUAD	cis	rs8012947	0.916	rs11851552	ENSG00000279636.2	LINC00216	3.79	0.00017	0.0218	0.19	0.17	Alcohol consumption in current drinkers;	chr14:58240032	chr14:58288033~58289158:+
LUAD	cis	rs4865762	0.687	rs153120	ENSG00000247796.2	CTD-2366F13.1	3.79	0.00017	0.0218	0.17	0.17	Intraocular pressure;	chr5:53231957	chr5:53109842~53115126:+
LUAD	cis	rs8073060	0.586	rs117573546	ENSG00000267592.1	CTC-507E2.2	-3.79	0.00017	0.0218	-0.25	-0.17	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35582569	chr17:35596904~35597128:-
LUAD	cis	rs12291225	0.645	rs3763950	ENSG00000251991.1	RNU7-49P	3.79	0.00017	0.0218	0.2	0.17	Sense of smell;	chr11:14256503	chr11:14478892~14478953:+
LUAD	cis	rs1431005	0.964	rs112852905	ENSG00000250658.1	RP11-138B4.1	3.79	0.00017	0.0218	0.21	0.17	Response to statin therapy;	chr4:187427031	chr4:187304083~187309682:-
LUAD	cis	rs11159086	0.941	rs12434836	ENSG00000270000.1	RP3-449M8.9	3.79	0.00017	0.0218	0.25	0.17	Advanced glycation end-product levels;	chr14:74468887	chr14:74471930~74472360:-
LUAD	cis	rs9309473	1	rs7564890	ENSG00000230002.2	ALMS1-IT1	3.79	0.00017	0.0218	0.22	0.17	Metabolite levels;	chr2:73414725	chr2:73456764~73459484:+
LUAD	cis	rs7572733	0.935	rs771010	ENSG00000222017.1	AC011997.1	-3.79	0.00017	0.0218	-0.21	-0.17	Dermatomyositis;	chr2:197826282	chr2:197693106~197774823:+
LUAD	cis	rs6964587	0.843	rs56075286	ENSG00000188693.7	CYP51A1-AS1	-3.79	0.00017	0.0218	-0.2	-0.17	Breast cancer;	chr7:92102204	chr7:92134604~92180725:+
LUAD	cis	rs10129255	0.5	rs2027902	ENSG00000274576.2	IGHV2-70	-3.79	0.00017	0.0218	-0.14	-0.17	Kawasaki disease;	chr14:106807157	chr14:106770577~106771020:-
LUAD	cis	rs442309	0.807	rs224073	ENSG00000238280.1	RP11-436D10.3	-3.79	0.00017	0.0219	-0.2	-0.17	Vogt-Koyanagi-Harada syndrome;	chr10:62750344	chr10:62793562~62805887:-
LUAD	cis	rs442309	0.841	rs224074	ENSG00000238280.1	RP11-436D10.3	-3.79	0.00017	0.0219	-0.2	-0.17	Vogt-Koyanagi-Harada syndrome;	chr10:62750627	chr10:62793562~62805887:-
LUAD	cis	rs442309	0.841	rs224076	ENSG00000238280.1	RP11-436D10.3	-3.79	0.00017	0.0219	-0.2	-0.17	Vogt-Koyanagi-Harada syndrome;	chr10:62751881	chr10:62793562~62805887:-
LUAD	cis	rs442309	0.841	rs224078	ENSG00000238280.1	RP11-436D10.3	-3.79	0.00017	0.0219	-0.2	-0.17	Vogt-Koyanagi-Harada syndrome;	chr10:62752000	chr10:62793562~62805887:-
LUAD	cis	rs442309	0.775	rs7893375	ENSG00000238280.1	RP11-436D10.3	-3.79	0.00017	0.0219	-0.2	-0.17	Vogt-Koyanagi-Harada syndrome;	chr10:62757846	chr10:62793562~62805887:-
LUAD	cis	rs67478160	0.608	rs11628787	ENSG00000272533.1	SNORA28	-3.79	0.00017	0.0219	-0.18	-0.17	Schizophrenia;	chr14:103857647	chr14:103337849~103337974:+
LUAD	cis	rs2337406	0.866	rs79901786	ENSG00000280411.1	IGHV1-69-2	-3.79	0.00017	0.0219	-0.16	-0.17	Alzheimer's disease (late onset);	chr14:106777623	chr14:106762092~106762588:-
LUAD	cis	rs911555	0.547	rs8006994	ENSG00000244691.1	RPL10AP1	-3.79	0.00017	0.0219	-0.22	-0.17	Intelligence (multi-trait analysis);	chr14:103374959	chr14:103412119~103412761:-
LUAD	cis	rs451417	1	rs451417	ENSG00000275632.1	RP5-967N21.11	3.79	0.00017	0.0219	0.22	0.17	Menopause (age at onset);	chr20:5961353	chr20:6000418~6000941:+
LUAD	cis	rs526231	0.543	rs34807	ENSG00000250682.4	LINC00491	3.79	0.00017	0.0219	0.21	0.17	Primary biliary cholangitis;	chr5:103092818	chr5:102609156~102671559:-
LUAD	cis	rs17406451	0.788	rs11124937	ENSG00000279873.2	LINC01126	3.79	0.00017	0.0219	0.14	0.17	Mitochondrial DNA levels;	chr2:43469076	chr2:43227210~43228855:+
LUAD	cis	rs67478160	0.643	rs12880167	ENSG00000272533.1	SNORA28	3.79	0.00017	0.0219	0.18	0.17	Schizophrenia;	chr14:103834492	chr14:103337849~103337974:+
LUAD	cis	rs13113518	0.966	rs1474271	ENSG00000273257.1	RP11-177J6.1	3.79	0.00017	0.0219	0.19	0.17	Height;	chr4:55435912	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs11937487	ENSG00000273257.1	RP11-177J6.1	3.79	0.00017	0.0219	0.19	0.17	Height;	chr4:55436576	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs3805146	ENSG00000273257.1	RP11-177J6.1	3.79	0.00017	0.0219	0.19	0.17	Height;	chr4:55436985	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs11133378	ENSG00000273257.1	RP11-177J6.1	3.79	0.00017	0.0219	0.19	0.17	Height;	chr4:55439472	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs11942279	ENSG00000273257.1	RP11-177J6.1	3.79	0.00017	0.0219	0.19	0.17	Height;	chr4:55439652	chr4:55387949~55388271:+
LUAD	cis	rs2625529	0.652	rs2929525	ENSG00000260173.1	RP11-2I17.4	3.79	0.00017	0.0219	0.21	0.17	Red blood cell count;	chr15:71995515	chr15:72140504~72155459:-
LUAD	cis	rs7829975	0.536	rs2980439	ENSG00000233609.3	RP11-62H7.2	3.79	0.00017	0.0219	0.14	0.17	Mood instability;	chr8:8237348	chr8:8961200~8979025:+
LUAD	cis	rs4853525	0.859	rs6434425	ENSG00000235852.1	AC005540.3	-3.79	0.00017	0.0219	-0.19	-0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190857590	chr2:190880797~190882059:-
LUAD	cis	rs17596685	1	rs6561061	ENSG00000271216.1	LINC01050	3.79	0.00017	0.0219	0.24	0.17	C-reactive protein levels;	chr13:42584451	chr13:42810366~42812562:-
LUAD	cis	rs7727544	0.584	rs7714191	ENSG00000233006.5	AC034220.3	3.79	0.00017	0.0219	0.15	0.17	Blood metabolite levels;	chr5:132005848	chr5:132311285~132369916:-
LUAD	cis	rs911119	0.908	rs12624424	ENSG00000270001.1	RP11-218C14.8	-3.79	0.00017	0.0219	-0.26	-0.17	Chronic kidney disease;	chr20:23621241	chr20:23631826~23632316:-
LUAD	cis	rs256438	0.93	rs2438634	ENSG00000251050.1	RP11-168A11.4	-3.79	0.00017	0.0219	-0.18	-0.17	Serum thyroid-stimulating hormone levels;	chr5:80095807	chr5:80019609~80019920:+
LUAD	cis	rs256438	0.894	rs2434286	ENSG00000251050.1	RP11-168A11.4	-3.79	0.00017	0.0219	-0.18	-0.17	Serum thyroid-stimulating hormone levels;	chr5:80096154	chr5:80019609~80019920:+
LUAD	cis	rs4843747	0.671	rs9933794	ENSG00000205037.2	RP11-863P13.4	3.79	0.000171	0.0219	0.24	0.17	Menopause (age at onset);	chr16:88083375	chr16:88088041~88100985:-
LUAD	cis	rs6471393	0.964	rs16916186	ENSG00000253848.1	RP11-10N23.5	3.79	0.000171	0.0219	0.21	0.17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93733158	chr8:93741193~93744534:+
LUAD	cis	rs7560272	0.538	rs17434634	ENSG00000163016.8	ALMS1P	-3.79	0.000171	0.0219	-0.18	-0.17	Schizophrenia;	chr2:73695799	chr2:73644919~73685576:+
LUAD	cis	rs1979679	0.879	rs1581630	ENSG00000278733.1	RP11-425D17.1	-3.79	0.000171	0.0219	-0.21	-0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28466378	chr12:28185625~28186190:-
LUAD	cis	rs321358	0.895	rs73015175	ENSG00000271390.1	RP11-89C3.3	3.79	0.000171	0.0219	0.28	0.17	Body mass index;	chr11:111088593	chr11:111089870~111090368:-
LUAD	cis	rs321358	0.895	rs17536143	ENSG00000271390.1	RP11-89C3.3	3.79	0.000171	0.0219	0.28	0.17	Body mass index;	chr11:111088619	chr11:111089870~111090368:-
LUAD	cis	rs10165862	0.537	rs17009372	ENSG00000163016.8	ALMS1P	-3.79	0.000171	0.0219	-0.22	-0.17	Intelligence (multi-trait analysis);	chr2:73728444	chr2:73644919~73685576:+
LUAD	cis	rs71520386	0.898	rs12536144	ENSG00000228649.7	AC005682.5	-3.79	0.000171	0.0219	-0.27	-0.17	Fibrinogen levels;	chr7:22782890	chr7:22854178~22861579:+
LUAD	cis	rs2032366	0.583	rs1452594	ENSG00000266920.1	ACTBP9	3.79	0.000171	0.0219	0.18	0.17	Obesity-related traits;	chr18:61590689	chr18:62442028~62443126:+
LUAD	cis	rs4965272	0.83	rs922671	ENSG00000272808.2	RP11-66B24.7	3.79	0.000171	0.0219	0.22	0.17	Gastroesophageal reflux disease;	chr15:100054633	chr15:100849831~100865457:+
LUAD	cis	rs7819412	0.659	rs4073948	ENSG00000255046.1	RP11-297N6.4	3.79	0.000171	0.0219	0.22	0.17	Triglycerides;	chr8:10915134	chr8:11797928~11802568:-
LUAD	cis	rs7615952	0.641	rs61048217	ENSG00000241288.6	RP11-379B18.5	-3.79	0.000171	0.0219	-0.23	-0.17	Blood pressure (smoking interaction);	chr3:126089062	chr3:125827238~125916384:-
LUAD	cis	rs7615952	0.641	rs60839048	ENSG00000241288.6	RP11-379B18.5	-3.79	0.000171	0.0219	-0.23	-0.17	Blood pressure (smoking interaction);	chr3:126089095	chr3:125827238~125916384:-
LUAD	cis	rs7615952	0.641	rs7640158	ENSG00000241288.6	RP11-379B18.5	-3.79	0.000171	0.0219	-0.23	-0.17	Blood pressure (smoking interaction);	chr3:126089168	chr3:125827238~125916384:-
LUAD	cis	rs7615952	0.641	rs2365019	ENSG00000241288.6	RP11-379B18.5	-3.79	0.000171	0.0219	-0.23	-0.17	Blood pressure (smoking interaction);	chr3:126089292	chr3:125827238~125916384:-
LUAD	cis	rs4237845	0.804	rs11172372	ENSG00000245651.2	RP11-620J15.2	3.79	0.000171	0.0219	0.16	0.17	Intelligence (multi-trait analysis);	chr12:57892490	chr12:57869835~57896482:-
LUAD	cis	rs9341808	0.591	rs7741013	ENSG00000272129.1	RP11-250B2.6	3.79	0.000171	0.0219	0.21	0.17	Sitting height ratio;	chr6:80206613	chr6:80355424~80356859:+
LUAD	cis	rs7246657	0.653	rs10401525	ENSG00000267309.1	CTD-2630F21.1	3.79	0.000171	0.0219	0.29	0.17	Coronary artery calcification;	chr19:37168077	chr19:36489649~36491040:+
LUAD	cis	rs7072268	0.791	rs6480403	ENSG00000236154.1	RP11-343J3.2	3.79	0.000171	0.0219	0.19	0.17	Glycated hemoglobin levels;	chr10:69340230	chr10:69575807~69577154:+
LUAD	cis	rs13113518	0.783	rs11133389	ENSG00000273257.1	RP11-177J6.1	3.79	0.000171	0.0219	0.19	0.17	Height;	chr4:55486718	chr4:55387949~55388271:+
LUAD	cis	rs13113518	0.812	rs4864543	ENSG00000273257.1	RP11-177J6.1	3.79	0.000171	0.0219	0.19	0.17	Height;	chr4:55490228	chr4:55387949~55388271:+
LUAD	cis	rs3916	0.911	rs7313271	ENSG00000277423.1	RP11-173P15.9	-3.79	0.000171	0.0219	-0.22	-0.17	Urinary metabolites (H-NMR features);	chr12:120714864	chr12:120703867~120704282:+
LUAD	cis	rs7017914	0.967	rs13271442	ENSG00000246366.5	RP11-382J12.1	3.79	0.000171	0.0219	0.16	0.17	Bone mineral density;	chr8:70672934	chr8:70608577~70663279:+
LUAD	cis	rs6754311	0.638	rs1011361	ENSG00000226806.1	AC011893.3	-3.79	0.000171	0.0219	-0.21	-0.17	Mosquito bite size;	chr2:135796069	chr2:135820191~135823087:+
LUAD	cis	rs2297363	1	rs13207901	ENSG00000213073.4	RP11-288H12.3	-3.79	0.000171	0.0219	-0.2	-0.17	Total cholesterol levels;Blood protein levels;	chr6:160081428	chr6:160093082~160096212:+
LUAD	cis	rs9468199	0.505	rs72847381	ENSG00000280107.1	AL022393.9	-3.79	0.000171	0.0219	-0.46	-0.17	Parkinson's disease;	chr6:27906153	chr6:28170845~28172521:+
LUAD	cis	rs7976269	0.609	rs10771475	ENSG00000275476.1	RP11-996F15.4	-3.79	0.000171	0.0219	-0.19	-0.17	Male-pattern baldness;	chr12:29071077	chr12:29277397~29277882:-
LUAD	cis	rs7976269	0.609	rs10843305	ENSG00000275476.1	RP11-996F15.4	-3.79	0.000171	0.0219	-0.19	-0.17	Male-pattern baldness;	chr12:29073147	chr12:29277397~29277882:-
LUAD	cis	rs7976269	0.609	rs10843306	ENSG00000275476.1	RP11-996F15.4	-3.79	0.000171	0.0219	-0.19	-0.17	Male-pattern baldness;	chr12:29073417	chr12:29277397~29277882:-
LUAD	cis	rs4474465	0.92	rs7113559	ENSG00000251323.2	RP11-452H21.4	-3.79	0.000171	0.0219	-0.21	-0.17	Alzheimer's disease (survival time);	chr11:78494657	chr11:78423982~78429836:-
LUAD	cis	rs36093844	0.654	rs7106460	ENSG00000279742.1	RP11-700A24.1	-3.79	0.000171	0.0219	-0.2	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85904506	chr11:85852557~85854943:-
LUAD	cis	rs17092148	0.848	rs6060030	ENSG00000250917.1	RP4-785G19.5	3.79	0.000171	0.0219	0.24	0.17	Neuroticism;	chr20:34752510	chr20:34234840~34281173:-
LUAD	cis	rs9860428	0.591	rs11705758	ENSG00000242770.2	RP11-180K7.1	3.79	0.000171	0.0219	0.19	0.17	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112932362	chr3:112802478~112812819:+
LUAD	cis	rs9860428	0.591	rs2133946	ENSG00000242770.2	RP11-180K7.1	3.79	0.000171	0.0219	0.19	0.17	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112948012	chr3:112802478~112812819:+
LUAD	cis	rs8048589	0.898	rs3851011	ENSG00000175604.2	RP11-276H1.3	-3.79	0.000171	0.0219	-0.24	-0.17	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12098615	chr16:12086746~12090302:-
LUAD	cis	rs17767294	0.612	rs9461424	ENSG00000219392.1	RP1-265C24.5	-3.79	0.000171	0.0219	-0.33	-0.17	Parkinson's disease;	chr6:27951623	chr6:28115628~28116551:+
LUAD	cis	rs6452524	0.618	rs6452503	ENSG00000281327.1	LINC01338	3.79	0.000171	0.0219	0.18	0.17	Hypertension (SNP x SNP interaction);	chr5:83074596	chr5:82850864~82859836:-
LUAD	cis	rs7727544	0.582	rs6896703	ENSG00000233006.5	AC034220.3	-3.79	0.000171	0.0219	-0.15	-0.17	Blood metabolite levels;	chr5:132185602	chr5:132311285~132369916:-
LUAD	cis	rs1401999	0.674	rs562	ENSG00000223882.1	ABCC5-AS1	-3.79	0.000171	0.0219	-0.17	-0.17	Anterior chamber depth;	chr3:183920057	chr3:184006338~184011419:+
LUAD	cis	rs2239557	0.508	rs12587320	ENSG00000259065.1	RP5-1021I20.1	3.79	0.000171	0.0219	0.22	0.17	Common traits (Other);	chr14:73901591	chr14:73787360~73803270:+
LUAD	cis	rs75920871	0.502	rs10790166	ENSG00000254851.1	RP11-109L13.1	3.79	0.000171	0.0219	0.24	0.17	Subjective well-being;	chr11:116908783	chr11:117135528~117138582:+
LUAD	cis	rs11239930	0.517	rs556976	ENSG00000225603.3	RP11-325P15.1	3.79	0.000171	0.022	0.22	0.17	AIDS progression;	chr1:147073643	chr1:147050817~147052481:+
LUAD	cis	rs683250	0.598	rs4943872	ENSG00000246067.6	RAB30-AS1	-3.79	0.000171	0.022	-0.18	-0.17	Subcortical brain region volumes;	chr11:83310509	chr11:83072066~83106719:+
LUAD	cis	rs853679	0.567	rs2232427	ENSG00000219392.1	RP1-265C24.5	-3.79	0.000171	0.022	-0.23	-0.17	Depression;	chr6:28391932	chr6:28115628~28116551:+
LUAD	cis	rs7107174	0.892	rs10431155	ENSG00000251323.2	RP11-452H21.4	3.79	0.000171	0.022	0.22	0.17	Testicular germ cell tumor;	chr11:78410932	chr11:78423982~78429836:-
LUAD	cis	rs2288073	1	rs2288073	ENSG00000223754.1	AC008073.9	-3.79	0.000171	0.022	-0.21	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr2:24190429	chr2:24199839~24201698:-
LUAD	cis	rs896854	0.573	rs13271375	ENSG00000253528.2	RP11-347C18.4	3.79	0.000171	0.022	0.17	0.17	Type 2 diabetes;	chr8:94841679	chr8:94974573~94974853:-
LUAD	cis	rs11051970	0.877	rs2651360	ENSG00000274964.1	RP11-817I4.1	-3.79	0.000171	0.022	-0.18	-0.17	Response to tocilizumab in rheumatoid arthritis;	chr12:32435986	chr12:32339368~32340724:+
LUAD	cis	rs1577917	0.655	rs12203963	ENSG00000220563.1	PKMP3	3.79	0.000171	0.022	0.16	0.17	Response to antipsychotic treatment;	chr6:85513598	chr6:85659892~85660606:-
LUAD	cis	rs6121246	0.954	rs7266148	ENSG00000230613.1	HM13-AS1	3.79	0.000171	0.022	0.24	0.17	Mean corpuscular hemoglobin;	chr20:31843267	chr20:31567707~31573263:-
LUAD	cis	rs6964587	1	rs9690778	ENSG00000188693.7	CYP51A1-AS1	-3.79	0.000171	0.022	-0.2	-0.17	Breast cancer;	chr7:92105985	chr7:92134604~92180725:+
LUAD	cis	rs6964587	1	rs12704635	ENSG00000188693.7	CYP51A1-AS1	-3.79	0.000171	0.022	-0.2	-0.17	Breast cancer;	chr7:92108010	chr7:92134604~92180725:+
LUAD	cis	rs950027	0.787	rs1547487	ENSG00000259479.5	SORD2P	3.79	0.000171	0.022	0.21	0.17	Response to fenofibrate (adiponectin levels);	chr15:45431785	chr15:44826371~44884694:-
LUAD	cis	rs4683346	0.731	rs11129983	ENSG00000173811.9	CCDC13-AS1	-3.79	0.000171	0.022	-0.2	-0.17	Granulocyte percentage of myeloid white cells;	chr3:42883191	chr3:42732575~42746768:+
LUAD	cis	rs6095360	1	rs6019602	ENSG00000222365.1	SNORD12B	-3.79	0.000171	0.022	-0.17	-0.17	Intelligence (multi-trait analysis);	chr20:49034955	chr20:49280319~49280409:+
LUAD	cis	rs11064837	0.504	rs2393522	ENSG00000248636.5	RP11-768F21.1	3.79	0.000171	0.022	0.2	0.17	Schizophrenia;	chr12:119617552	chr12:119387987~119668079:-
LUAD	cis	rs62244186	0.52	rs2372828	ENSG00000233509.2	ZNF197-AS1	-3.79	0.000171	0.022	-0.19	-0.17	Depressive symptoms;	chr3:44743457	chr3:44617128~44624797:-
LUAD	cis	rs7005380	0.581	rs7813430	ENSG00000279347.1	RP11-85I17.2	3.79	0.000171	0.022	0.16	0.17	Interstitial lung disease;	chr8:119926834	chr8:119838736~119840385:-
LUAD	cis	rs7829975	0.514	rs2976926	ENSG00000253981.4	ALG1L13P	3.79	0.000171	0.022	0.2	0.17	Mood instability;	chr8:8404114	chr8:8236003~8244667:-
LUAD	cis	rs34779708	0.658	rs4934715	ENSG00000271335.4	RP11-324I22.4	3.79	0.000171	0.022	0.18	0.17	Inflammatory bowel disease;Crohn's disease;	chr10:35076064	chr10:35314552~35336401:-
LUAD	cis	rs6951245	1	rs74652290	ENSG00000199023.2	MIR339	-3.79	0.000172	0.022	-0.3	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1050473	chr7:1022935~1023045:-
LUAD	cis	rs587080	0.559	rs12364730	ENSG00000245532.5	NEAT1	3.79	0.000172	0.022	0.16	0.17	Plateletcrit;	chr11:65460807	chr11:65422774~65445540:+
LUAD	cis	rs8062405	0.755	rs17707300	ENSG00000251417.2	RP11-1348G14.4	-3.79	0.000172	0.022	-0.17	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28802743~28817828:+
LUAD	cis	rs2274273	0.87	rs11625423	ENSG00000258413.1	RP11-665C16.6	-3.79	0.000172	0.022	-0.22	-0.17	Protein biomarker;	chr14:55329195	chr14:55262767~55272075:-
LUAD	cis	rs9549260	0.564	rs12184871	ENSG00000229456.1	RLIMP1	3.79	0.000172	0.022	0.18	0.17	Red blood cell count;	chr13:40717792	chr13:40618738~40621348:+
LUAD	cis	rs7578361	0.959	rs4547502	ENSG00000231969.1	AC144449.1	-3.79	0.000172	0.022	-0.25	-0.17	Acute lymphoblastic leukemia (childhood);	chr2:149589569	chr2:149587196~149848233:+
LUAD	cis	rs4908768	0.871	rs11121221	ENSG00000232912.4	RP5-1115A15.1	-3.79	0.000172	0.022	-0.18	-0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8707470	chr1:8424645~8434838:+
LUAD	cis	rs12744310	1	rs34190295	ENSG00000235358.1	RP11-399E6.1	3.79	0.000172	0.022	0.22	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41300207	chr1:41242373~41284861:+
LUAD	cis	rs12744310	0.945	rs34961305	ENSG00000235358.1	RP11-399E6.1	3.79	0.000172	0.022	0.22	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41300272	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs35812095	ENSG00000235358.1	RP11-399E6.1	3.79	0.000172	0.022	0.22	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41300402	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs12034357	ENSG00000235358.1	RP11-399E6.1	3.79	0.000172	0.022	0.22	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41302557	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs7553908	ENSG00000235358.1	RP11-399E6.1	3.79	0.000172	0.022	0.22	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41302569	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs12041533	ENSG00000235358.1	RP11-399E6.1	3.79	0.000172	0.022	0.22	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41302599	chr1:41242373~41284861:+
LUAD	cis	rs12744310	0.943	rs34862272	ENSG00000235358.1	RP11-399E6.1	3.79	0.000172	0.022	0.22	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41302981	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs34796305	ENSG00000235358.1	RP11-399E6.1	3.79	0.000172	0.022	0.22	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303373	chr1:41242373~41284861:+
LUAD	cis	rs12744310	0.943	rs35972058	ENSG00000235358.1	RP11-399E6.1	3.79	0.000172	0.022	0.22	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303474	chr1:41242373~41284861:+
LUAD	cis	rs12744310	0.943	rs12032906	ENSG00000235358.1	RP11-399E6.1	3.79	0.000172	0.022	0.22	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303486	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs34315814	ENSG00000235358.1	RP11-399E6.1	3.79	0.000172	0.022	0.22	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303500	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs12032191	ENSG00000235358.1	RP11-399E6.1	3.79	0.000172	0.022	0.22	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303546	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs12032215	ENSG00000235358.1	RP11-399E6.1	3.79	0.000172	0.022	0.22	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303662	chr1:41242373~41284861:+
LUAD	cis	rs12744310	1	rs12035353	ENSG00000235358.1	RP11-399E6.1	3.79	0.000172	0.022	0.22	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41303665	chr1:41242373~41284861:+
LUAD	cis	rs12935418	0.552	rs2113196	ENSG00000261061.1	RP11-303E16.2	3.79	0.000172	0.022	0.18	0.17	Mean corpuscular volume;	chr16:80991885	chr16:81030770~81031485:+
LUAD	cis	rs7618915	0.547	rs62255371	ENSG00000243224.1	RP5-1157M23.2	-3.79	0.000172	0.022	-0.17	-0.17	Bipolar disorder;	chr3:52713305	chr3:52239258~52241097:+
LUAD	cis	rs7618915	0.57	rs11714088	ENSG00000243224.1	RP5-1157M23.2	-3.79	0.000172	0.022	-0.17	-0.17	Bipolar disorder;	chr3:52724926	chr3:52239258~52241097:+
LUAD	cis	rs7618915	0.547	rs34610878	ENSG00000243224.1	RP5-1157M23.2	-3.79	0.000172	0.022	-0.17	-0.17	Bipolar disorder;	chr3:52725153	chr3:52239258~52241097:+
LUAD	cis	rs4374383	0.886	rs6711146	ENSG00000207383.1	Y_RNA	-3.79	0.000172	0.022	-0.21	-0.17	Hepatitis C induced liver fibrosis;	chr2:112016257	chr2:112579484~112579584:-
LUAD	cis	rs7474896	0.537	rs2749589	ENSG00000226578.1	RP11-258F22.1	3.79	0.000172	0.022	0.24	0.17	Obesity (extreme);	chr10:37977942	chr10:37775371~37784131:-
LUAD	cis	rs763121	0.925	rs1056661	ENSG00000225450.1	RP3-508I15.14	-3.79	0.000172	0.022	-0.16	-0.17	Menopause (age at onset);	chr22:38684240	chr22:38739003~38749041:+
LUAD	cis	rs858239	0.867	rs10250602	ENSG00000230042.1	AK3P3	-3.79	0.000172	0.022	-0.22	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23264082	chr7:23129178~23129841:+
LUAD	cis	rs17711722	0.528	rs73138179	ENSG00000237310.1	GS1-124K5.4	3.79	0.000172	0.022	0.18	0.17	Calcium levels;	chr7:65829495	chr7:66493706~66495474:+
LUAD	cis	rs2688608	0.905	rs2633300	ENSG00000271816.1	BMS1P4	3.79	0.000172	0.022	0.14	0.17	Inflammatory bowel disease;	chr10:73896889	chr10:73699151~73730487:-
LUAD	cis	rs2688608	0.967	rs2633299	ENSG00000271816.1	BMS1P4	3.79	0.000172	0.022	0.14	0.17	Inflammatory bowel disease;	chr10:73896996	chr10:73699151~73730487:-
LUAD	cis	rs9341808	0.667	rs2505929	ENSG00000260645.1	RP11-250B2.5	3.79	0.000172	0.022	0.16	0.17	Sitting height ratio;	chr6:80124491	chr6:80466958~80469080:+
LUAD	cis	rs4594175	0.707	rs28587653	ENSG00000258955.1	LINC00519	-3.79	0.000172	0.022	-0.22	-0.17	Cancer;	chr14:51242338	chr14:51304416~51328386:-
LUAD	cis	rs3845817	0.832	rs702950	ENSG00000281920.1	RP11-418H16.1	-3.79	0.000172	0.022	-0.21	-0.17	Bipolar disorder;	chr2:65537776	chr2:65623272~65628424:+
LUAD	cis	rs13434995	0.513	rs7665846	ENSG00000273257.1	RP11-177J6.1	3.79	0.000172	0.022	0.23	0.17	Adiponectin levels;	chr4:55573078	chr4:55387949~55388271:+
LUAD	cis	rs2143950	0.512	rs62625038	ENSG00000226677.3	IGBP1P1	-3.79	0.000172	0.022	-0.21	-0.17	Atopic dermatitis;	chr14:35047811	chr14:34939324~34940332:+
LUAD	cis	rs7129556	0.701	rs10899399	ENSG00000241782.1	RP11-91P24.1	3.79	0.000172	0.022	0.24	0.17	Weight loss (gastric bypass surgery);	chr11:77698787	chr11:77868722~77869195:-
LUAD	cis	rs7176527	0.848	rs72630461	ENSG00000259570.1	RP11-671M22.4	-3.79	0.000172	0.022	-0.26	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84696913	chr15:84394512~84395514:+
LUAD	cis	rs8062405	1	rs62037364	ENSG00000261419.1	RP11-57A19.4	-3.79	0.000172	0.022	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28659696~28740781:-
LUAD	cis	rs13113518	1	rs1047354	ENSG00000273257.1	RP11-177J6.1	3.79	0.000172	0.022	0.19	0.17	Height;	chr4:55429416	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs1056547	ENSG00000273257.1	RP11-177J6.1	3.79	0.000172	0.022	0.19	0.17	Height;	chr4:55430596	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs1056545	ENSG00000273257.1	RP11-177J6.1	3.79	0.000172	0.022	0.19	0.17	Height;	chr4:55430730	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs5863	ENSG00000273257.1	RP11-177J6.1	3.79	0.000172	0.022	0.19	0.17	Height;	chr4:55430740	chr4:55387949~55388271:+
LUAD	cis	rs13113518	0.966	rs6828570	ENSG00000273257.1	RP11-177J6.1	3.79	0.000172	0.022	0.19	0.17	Height;	chr4:55431595	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs3749474	ENSG00000273257.1	RP11-177J6.1	3.79	0.000172	0.022	0.19	0.17	Height;	chr4:55434518	chr4:55387949~55388271:+
LUAD	cis	rs8062405	0.679	rs72793818	ENSG00000261419.1	RP11-57A19.4	-3.79	0.000172	0.022	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28659696~28740781:-
LUAD	cis	rs10971721	0.73	rs72725361	ENSG00000260947.1	RP11-384P7.7	3.79	0.000172	0.022	0.36	0.17	Body mass index;	chr9:33806615	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs12376664	ENSG00000260947.1	RP11-384P7.7	3.79	0.000172	0.022	0.36	0.17	Body mass index;	chr9:33808705	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs72725368	ENSG00000260947.1	RP11-384P7.7	3.79	0.000172	0.022	0.36	0.17	Body mass index;	chr9:33815457	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.822	rs72725370	ENSG00000260947.1	RP11-384P7.7	3.79	0.000172	0.022	0.36	0.17	Body mass index;	chr9:33818459	chr9:33697459~33700986:+
LUAD	cis	rs10971721	0.554	rs10971712	ENSG00000260947.1	RP11-384P7.7	3.79	0.000172	0.022	0.36	0.17	Body mass index;	chr9:33820940	chr9:33697459~33700986:+
LUAD	cis	rs897984	0.684	rs6950	ENSG00000232748.3	RP11-196G11.6	3.79	0.000172	0.022	0.21	0.17	Dementia with Lewy bodies;	chr16:30984348	chr16:31056460~31062803:+
LUAD	cis	rs897984	0.645	rs9938550	ENSG00000232748.3	RP11-196G11.6	3.79	0.000172	0.022	0.21	0.17	Dementia with Lewy bodies;	chr16:30987821	chr16:31056460~31062803:+
LUAD	cis	rs897984	0.762	rs2305880	ENSG00000232748.3	RP11-196G11.6	3.79	0.000172	0.022	0.21	0.17	Dementia with Lewy bodies;	chr16:30988141	chr16:31056460~31062803:+
LUAD	cis	rs6095360	1	rs6019601	ENSG00000222365.1	SNORD12B	-3.79	0.000172	0.022	-0.17	-0.17	Intelligence (multi-trait analysis);	chr20:49031125	chr20:49280319~49280409:+
LUAD	cis	rs12935418	0.583	rs2549836	ENSG00000261061.1	RP11-303E16.2	3.79	0.000172	0.022	0.18	0.17	Mean corpuscular volume;	chr16:80989476	chr16:81030770~81031485:+
LUAD	cis	rs7572733	0.935	rs1369512	ENSG00000222017.1	AC011997.1	3.79	0.000172	0.022	0.21	0.17	Dermatomyositis;	chr2:197902408	chr2:197693106~197774823:+
LUAD	cis	rs990171	0.513	rs7573566	ENSG00000234389.1	AC007278.3	3.79	0.000172	0.022	0.17	0.17	Lymphocyte counts;	chr2:102498746	chr2:102438713~102440475:+
LUAD	cis	rs4934494	0.727	rs2418929	ENSG00000240996.1	RP11-80H5.7	-3.79	0.000172	0.022	-0.24	-0.17	Red blood cell count;	chr10:89741720	chr10:89694295~89697928:-
LUAD	cis	rs13113518	0.812	rs12500456	ENSG00000273257.1	RP11-177J6.1	3.79	0.000172	0.022	0.19	0.17	Height;	chr4:55561053	chr4:55387949~55388271:+
LUAD	cis	rs12280210	0.557	rs11216225	ENSG00000280143.1	AP000892.6	-3.79	0.000172	0.022	-0.29	-0.17	Lobe attachment (rater-scored or self-reported);	chr11:117007298	chr11:117204967~117210292:+
LUAD	cis	rs12280210	0.557	rs7112937	ENSG00000280143.1	AP000892.6	-3.79	0.000172	0.022	-0.29	-0.17	Lobe attachment (rater-scored or self-reported);	chr11:117009740	chr11:117204967~117210292:+
LUAD	cis	rs2461451	0.541	rs72841734	ENSG00000273950.1	Metazoa_SRP	3.79	0.000172	0.022	0.35	0.17	Antipsychotic drug-induced QTc interval change in schizophrenia;	chr2:128039120	chr2:127856890~127857147:+
LUAD	cis	rs1009647	0.656	rs10147254	ENSG00000258413.1	RP11-665C16.6	-3.79	0.000172	0.022	-0.23	-0.17	Testicular germ cell tumor;	chr14:55383597	chr14:55262767~55272075:-
LUAD	cis	rs761746	0.739	rs140078	ENSG00000236132.1	CTA-440B3.1	3.79	0.000172	0.022	0.24	0.17	Intelligence;	chr22:31714177	chr22:31816379~31817491:-
LUAD	cis	rs2616407	1	rs2616407	ENSG00000272650.1	RP11-571I18.4	3.79	0.000172	0.0221	0.21	0.17	Coronary artery disease;	chr4:53725232	chr4:53997415~53997712:-
LUAD	cis	rs2616407	1	rs2616408	ENSG00000272650.1	RP11-571I18.4	3.79	0.000172	0.0221	0.21	0.17	Coronary artery disease;	chr4:53725233	chr4:53997415~53997712:-
LUAD	cis	rs4474465	0.85	rs4565922	ENSG00000251323.2	RP11-452H21.4	-3.79	0.000172	0.0221	-0.21	-0.17	Alzheimer's disease (survival time);	chr11:78549653	chr11:78423982~78429836:-
LUAD	cis	rs9309473	0.95	rs6726694	ENSG00000230002.2	ALMS1-IT1	3.79	0.000172	0.0221	0.21	0.17	Metabolite levels;	chr2:73620103	chr2:73456764~73459484:+
LUAD	cis	rs12817211	0.524	rs2204683	ENSG00000272368.2	RP4-605O3.4	-3.79	0.000172	0.0221	-0.2	-0.17	Colorectal or endometrial cancer;	chr12:50128593	chr12:50112197~50165618:+
LUAD	cis	rs2031365	0.727	rs7748510	ENSG00000216990.2	HSPD1P10	3.79	0.000172	0.0221	0.23	0.17	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);	chr6:87074593	chr6:87298772~87300447:+
LUAD	cis	rs8113308	0.81	rs11880193	ENSG00000269483.1	AC006272.1	3.79	0.000172	0.0221	0.28	0.17	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51945416	chr19:51839924~51843324:-
LUAD	cis	rs1908814	0.516	rs7825529	ENSG00000255046.1	RP11-297N6.4	-3.79	0.000172	0.0221	-0.21	-0.17	Neuroticism;	chr8:11936935	chr8:11797928~11802568:-
LUAD	cis	rs7560272	0.588	rs4852959	ENSG00000163016.8	ALMS1P	-3.79	0.000172	0.0221	-0.19	-0.17	Schizophrenia;	chr2:73653474	chr2:73644919~73685576:+
LUAD	cis	rs2613514	1	rs16970811	ENSG00000204282.4	TNRC6C-AS1	-3.79	0.000172	0.0221	-0.27	-0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr17:78095099	chr17:78107398~78111799:-
LUAD	cis	rs77633900	0.892	rs2469538	ENSG00000196274.5	Metazoa_SRP	3.79	0.000172	0.0221	0.23	0.17	Glioma;Non-glioblastoma glioma;	chr15:76277802	chr15:76230048~76230390:-
LUAD	cis	rs8031584	0.578	rs1088473	ENSG00000260128.5	ULK4P2	3.79	0.000172	0.0221	0.23	0.17	Huntington's disease progression;	chr15:30847095	chr15:30572738~30600647:+
LUAD	cis	rs848490	0.889	rs55688853	ENSG00000214293.7	APTR	3.79	0.000172	0.0221	0.22	0.17	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77594304	chr7:77657660~77696265:-
LUAD	cis	rs159572	0.829	rs150913	ENSG00000250853.1	RNF138P1	3.79	0.000172	0.0221	0.2	0.17	Post-traumatic stress disorder;	chr5:56228281	chr5:55530156~55530701:-
LUAD	cis	rs2292864	0.764	rs3785872	ENSG00000278765.1	RP5-890E16.5	3.79	0.000172	0.0221	0.32	0.17	Left atrial antero-posterior diameter;	chr17:47294709	chr17:48066704~48067293:-
LUAD	cis	rs2638953	0.924	rs11049399	ENSG00000278733.1	RP11-425D17.1	-3.79	0.000172	0.0221	-0.2	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28174213	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs61920227	ENSG00000278733.1	RP11-425D17.1	-3.79	0.000172	0.0221	-0.2	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28174584	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs11049400	ENSG00000278733.1	RP11-425D17.1	-3.79	0.000172	0.0221	-0.2	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28175051	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs11049401	ENSG00000278733.1	RP11-425D17.1	-3.79	0.000172	0.0221	-0.2	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28175218	chr12:28185625~28186190:-
LUAD	cis	rs4657482	0.962	rs10800164	ENSG00000236364.3	RP11-525G13.2	3.79	0.000172	0.0221	0.17	0.17	Testicular germ cell tumor;	chr1:165889117	chr1:165890795~165900683:-
LUAD	cis	rs1005277	0.522	rs9418276	ENSG00000263064.2	RP11-291L22.7	3.79	0.000172	0.0221	0.18	0.17	Extrinsic epigenetic age acceleration;	chr10:37651188	chr10:38448689~38448949:+
LUAD	cis	rs2243480	1	rs958550	ENSG00000222364.1	RNU6-96P	3.79	0.000172	0.0221	0.26	0.17	Diabetic kidney disease;	chr7:66170692	chr7:66395191~66395286:+
LUAD	cis	rs647161	0.616	rs17716310	ENSG00000247627.2	MTND4P12	-3.79	0.000172	0.0221	-0.2	-0.17	Colorectal cancer;	chr5:135141069	chr5:134926660~134928036:-
LUAD	cis	rs1023500	0.573	rs133377	ENSG00000273366.1	CTA-989H11.1	-3.79	0.000173	0.0221	-0.2	-0.17	Schizophrenia;	chr22:42070946	chr22:42278188~42278846:+
LUAD	cis	rs858239	0.539	rs2178140	ENSG00000226816.2	AC005082.12	3.79	0.000173	0.0221	0.23	0.17	Cerebrospinal fluid biomarker levels;	chr7:23152006	chr7:23206013~23208045:+
LUAD	cis	rs9517320	1	rs9645890	ENSG00000231194.1	FARP1-AS1	3.79	0.000173	0.0221	0.19	0.17	Longevity;	chr13:98474383	chr13:98435405~98435840:-
LUAD	cis	rs8040855	0.894	rs4843023	ENSG00000259774.1	RP11-182J1.13	-3.79	0.000173	0.0221	-0.2	-0.17	Bulimia nervosa;	chr15:85162641	chr15:84422618~84425882:+
LUAD	cis	rs116095464	0.558	rs10043002	ENSG00000248925.1	CTD-2083E4.6	3.79	0.000173	0.0221	0.29	0.17	Breast cancer;	chr5:226638	chr5:269858~271516:-
LUAD	cis	rs17711722	0.565	rs4717276	ENSG00000228409.4	CCT6P1	-3.79	0.000173	0.0221	-0.14	-0.17	Calcium levels;	chr7:65829754	chr7:65751142~65763354:+
LUAD	cis	rs17122278	1	rs11216914	ENSG00000243431.1	RPL5P30	3.79	0.000173	0.0221	0.21	0.17	Total cholesterol levels;	chr11:118585699	chr11:118560690~118561580:+
LUAD	cis	rs591584	0.59	rs7107559	ENSG00000255893.1	RP11-685N10.1	3.79	0.000173	0.0221	0.21	0.17	Macrophage Migration Inhibitory Factor levels;	chr11:94590508	chr11:94472908~94473570:-
LUAD	cis	rs7178424	0.875	rs28411984	ENSG00000259251.2	RP11-643M14.1	3.79	0.000173	0.0221	0.18	0.17	Height;	chr15:61929393	chr15:62060503~62062434:+
LUAD	cis	rs4819052	0.808	rs2838825	ENSG00000237664.1	LINC00316	-3.79	0.000173	0.0221	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235736	chr21:45338590~45341990:-
LUAD	cis	rs783540	0.5	rs1313494	ENSG00000255769.6	GOLGA2P10	3.79	0.000173	0.0221	0.2	0.17	Schizophrenia;	chr15:82605530	chr15:82472993~82513950:-
LUAD	cis	rs6687758	0.687	rs12123928	ENSG00000238042.4	RP11-815M8.1	3.79	0.000173	0.0221	0.23	0.17	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221948533	chr1:221880981~221978523:-
LUAD	cis	rs6496932	0.503	rs7170085	ENSG00000259630.2	CTD-2262B20.1	-3.79	0.000173	0.0221	-0.23	-0.17	Central corneal thickness;Corneal structure;	chr15:85403879	chr15:85415228~85415633:+
LUAD	cis	rs7615952	0.599	rs2270986	ENSG00000250012.1	RP11-124N2.1	-3.79	0.000173	0.0221	-0.24	-0.17	Blood pressure (smoking interaction);	chr3:125982256	chr3:126084220~126095349:+
LUAD	cis	rs7615952	0.599	rs12496921	ENSG00000250012.1	RP11-124N2.1	-3.79	0.000173	0.0221	-0.24	-0.17	Blood pressure (smoking interaction);	chr3:125983105	chr3:126084220~126095349:+
LUAD	cis	rs7584330	0.666	rs7600317	ENSG00000222032.1	AC112721.2	3.79	0.000173	0.0221	0.21	0.17	Prostate cancer;	chr2:237444870	chr2:237428920~237434822:-
LUAD	cis	rs7005380	0.62	rs7387264	ENSG00000279347.1	RP11-85I17.2	-3.79	0.000173	0.0221	-0.14	-0.17	Interstitial lung disease;	chr8:119913758	chr8:119838736~119840385:-
LUAD	cis	rs9467773	0.583	rs2498380	ENSG00000261353.1	CTA-14H9.5	3.79	0.000173	0.0221	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26643768	chr6:26527063~26527404:+
LUAD	cis	rs73198271	0.74	rs10109886	ENSG00000233609.3	RP11-62H7.2	-3.79	0.000173	0.0221	-0.14	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8823048	chr8:8961200~8979025:+
LUAD	cis	rs8180040	0.966	rs34634681	ENSG00000271161.1	BOLA2P2	-3.79	0.000173	0.0221	-0.16	-0.17	Colorectal cancer;	chr3:47537612	chr3:47499841~47500407:+
LUAD	cis	rs6088580	0.713	rs1884669	ENSG00000276073.1	RP5-1125A11.7	-3.79	0.000173	0.0221	-0.16	-0.17	Glomerular filtration rate (creatinine);	chr20:34583483	chr20:33985617~33988989:-
LUAD	cis	rs6088590	0.561	rs2295444	ENSG00000276073.1	RP5-1125A11.7	-3.79	0.000173	0.0221	-0.16	-0.17	Coronary artery disease;	chr20:34586079	chr20:33985617~33988989:-
LUAD	cis	rs6087771	0.714	rs6058259	ENSG00000230613.1	HM13-AS1	3.79	0.000173	0.0221	0.22	0.17	Putamen volume;Subcortical brain region volumes;	chr20:31647499	chr20:31567707~31573263:-
LUAD	cis	rs6087771	0.747	rs6058261	ENSG00000230613.1	HM13-AS1	3.79	0.000173	0.0221	0.22	0.17	Putamen volume;Subcortical brain region volumes;	chr20:31647667	chr20:31567707~31573263:-
LUAD	cis	rs897984	0.542	rs11864839	ENSG00000232748.3	RP11-196G11.6	-3.79	0.000173	0.0221	-0.21	-0.17	Dementia with Lewy bodies;	chr16:31083930	chr16:31056460~31062803:+
LUAD	cis	rs11073619	0.892	rs12442117	ENSG00000230373.7	GOLGA6L5P	-3.79	0.000173	0.0221	-0.25	-0.17	Positive affect;	chr15:84634667	chr15:84507885~84516814:-
LUAD	cis	rs1355223	1	rs12792532	ENSG00000271369.1	RP11-350D17.3	-3.79	0.000173	0.0221	-0.2	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34744235	chr11:34709600~34710161:+
LUAD	cis	rs1355223	1	rs35365094	ENSG00000271369.1	RP11-350D17.3	-3.79	0.000173	0.0221	-0.2	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34746243	chr11:34709600~34710161:+
LUAD	cis	rs6088590	1	rs2378256	ENSG00000275784.1	RP5-1125A11.6	-3.79	0.000173	0.0221	-0.18	-0.17	Coronary artery disease;	chr20:34704323	chr20:33989480~33991818:-
LUAD	cis	rs6088590	0.965	rs910869	ENSG00000275784.1	RP5-1125A11.6	-3.79	0.000173	0.0221	-0.18	-0.17	Coronary artery disease;	chr20:34704973	chr20:33989480~33991818:-
LUAD	cis	rs35740288	0.571	rs11631009	ENSG00000202081.1	RNU6-1280P	3.79	0.000173	0.0221	0.24	0.17	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85775422	chr15:85651522~85651628:-
LUAD	cis	rs7005380	0.62	rs6993375	ENSG00000279347.1	RP11-85I17.2	-3.79	0.000173	0.0221	-0.14	-0.17	Interstitial lung disease;	chr8:119899390	chr8:119838736~119840385:-
LUAD	cis	rs4819052	0.959	rs8130866	ENSG00000223768.1	LINC00205	-3.79	0.000173	0.0221	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252197	chr21:45293285~45297354:+
LUAD	cis	rs1908814	0.516	rs11250178	ENSG00000255046.1	RP11-297N6.4	-3.79	0.000173	0.0221	-0.21	-0.17	Neuroticism;	chr8:11942725	chr8:11797928~11802568:-
LUAD	cis	rs2834288	0.535	rs881229	ENSG00000237945.6	LINC00649	3.79	0.000173	0.0221	0.22	0.17	Gut microbiota (bacterial taxa);	chr21:33950417	chr21:33915534~33977691:+
LUAD	cis	rs4819052	1	rs13053002	ENSG00000223768.1	LINC00205	-3.79	0.000173	0.0221	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45257939	chr21:45293285~45297354:+
LUAD	cis	rs7617773	0.779	rs77957078	ENSG00000199476.1	Y_RNA	-3.79	0.000173	0.0221	-0.23	-0.17	Coronary artery disease;	chr3:48289796	chr3:48288587~48288694:+
LUAD	cis	rs1862618	0.853	rs832553	ENSG00000271828.1	CTD-2310F14.1	3.79	0.000173	0.0221	0.24	0.17	Initial pursuit acceleration;	chr5:56818959	chr5:56927874~56929573:+
LUAD	cis	rs12073359	1	rs72692901	ENSG00000223945.2	RP11-458I7.1	-3.79	0.000173	0.0221	-0.24	-0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150084424	chr1:150053864~150055034:+
LUAD	cis	rs1853665	0.58	rs6557201	ENSG00000231760.4	RP11-350J20.5	3.79	0.000173	0.0221	0.27	0.17	Radiation response;	chr6:149951431	chr6:149796151~149826294:-
LUAD	cis	rs6687758	1	rs17442058	ENSG00000238042.4	RP11-815M8.1	3.79	0.000173	0.0221	0.24	0.17	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222006808	chr1:221880981~221978523:-
LUAD	cis	rs12073359	1	rs12058502	ENSG00000223945.2	RP11-458I7.1	-3.79	0.000173	0.0221	-0.24	-0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150037869	chr1:150053864~150055034:+
LUAD	cis	rs5758511	0.68	rs5758699	ENSG00000233903.2	Z83851.4	3.79	0.000173	0.0221	0.25	0.17	Birth weight;	chr22:42292028	chr22:42276355~42277052:+
LUAD	cis	rs13113518	0.783	rs11943206	ENSG00000273257.1	RP11-177J6.1	3.79	0.000173	0.0222	0.19	0.17	Height;	chr4:55570843	chr4:55387949~55388271:+
LUAD	cis	rs9952991	0.654	rs12964314	ENSG00000260302.1	RP11-973H7.1	3.79	0.000173	0.0222	0.36	0.17	Inflammatory skin disease;	chr18:12871973	chr18:12774651~12775923:-
LUAD	cis	rs9952991	0.599	rs71353227	ENSG00000260302.1	RP11-973H7.1	3.79	0.000173	0.0222	0.36	0.17	Inflammatory skin disease;	chr18:12872425	chr18:12774651~12775923:-
LUAD	cis	rs34779708	0.931	rs55724039	ENSG00000271335.4	RP11-324I22.4	3.79	0.000173	0.0222	0.18	0.17	Inflammatory bowel disease;Crohn's disease;	chr10:35176469	chr10:35314552~35336401:-
LUAD	cis	rs763121	0.853	rs5750621	ENSG00000225450.1	RP3-508I15.14	-3.79	0.000173	0.0222	-0.17	-0.17	Menopause (age at onset);	chr22:38560161	chr22:38739003~38749041:+
LUAD	cis	rs763121	0.744	rs5757140	ENSG00000225450.1	RP3-508I15.14	-3.79	0.000173	0.0222	-0.17	-0.17	Menopause (age at onset);	chr22:38561008	chr22:38739003~38749041:+
LUAD	cis	rs7560272	0.538	rs2012574	ENSG00000163016.8	ALMS1P	-3.79	0.000173	0.0222	-0.18	-0.17	Schizophrenia;	chr2:73701239	chr2:73644919~73685576:+
LUAD	cis	rs1124769	0.525	rs11070812	ENSG00000259378.1	DCAF13P3	3.79	0.000173	0.0222	0.24	0.17	Cognitive performance;	chr15:50770295	chr15:50944663~50945996:+
LUAD	cis	rs1124769	0.502	rs12911207	ENSG00000259378.1	DCAF13P3	3.79	0.000173	0.0222	0.24	0.17	Cognitive performance;	chr15:50777099	chr15:50944663~50945996:+
LUAD	cis	rs214785	0.932	rs214762	ENSG00000234684.5	SDCBP2-AS1	3.78	0.000173	0.0222	0.21	0.17	Basal cell carcinoma;	chr20:2297246	chr20:1325405~1378734:+
LUAD	cis	rs214785	1	rs214763	ENSG00000234684.5	SDCBP2-AS1	3.78	0.000173	0.0222	0.21	0.17	Basal cell carcinoma;	chr20:2297382	chr20:1325405~1378734:+
LUAD	cis	rs214785	1	rs214768	ENSG00000234684.5	SDCBP2-AS1	3.78	0.000173	0.0222	0.21	0.17	Basal cell carcinoma;	chr20:2298346	chr20:1325405~1378734:+
LUAD	cis	rs214785	1	rs214769	ENSG00000234684.5	SDCBP2-AS1	3.78	0.000173	0.0222	0.21	0.17	Basal cell carcinoma;	chr20:2298435	chr20:1325405~1378734:+
LUAD	cis	rs7809950	0.954	rs2520241	ENSG00000238832.1	snoU109	-3.78	0.000173	0.0222	-0.25	-0.17	Coronary artery disease;	chr7:107494998	chr7:107603363~107603507:+
LUAD	cis	rs2904524	1	rs78509050	ENSG00000257815.4	RP11-611E13.2	-3.78	0.000173	0.0222	-0.25	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70359589	chr12:69904033~70243360:-
LUAD	cis	rs2904524	1	rs75899653	ENSG00000257815.4	RP11-611E13.2	-3.78	0.000173	0.0222	-0.25	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70359894	chr12:69904033~70243360:-
LUAD	cis	rs7005380	0.581	rs2176750	ENSG00000279347.1	RP11-85I17.2	3.78	0.000173	0.0222	0.16	0.17	Interstitial lung disease;	chr8:119925460	chr8:119838736~119840385:-
LUAD	cis	rs8012947	1	rs10147580	ENSG00000279636.2	LINC00216	-3.78	0.000173	0.0222	-0.19	-0.17	Alcohol consumption in current drinkers;	chr14:58247422	chr14:58288033~58289158:+
LUAD	cis	rs8012947	0.958	rs7158746	ENSG00000279636.2	LINC00216	-3.78	0.000173	0.0222	-0.19	-0.17	Alcohol consumption in current drinkers;	chr14:58254081	chr14:58288033~58289158:+
LUAD	cis	rs703842	1	rs3782130	ENSG00000270039.1	RP11-571M6.17	-3.78	0.000173	0.0222	-0.2	-0.17	Multiple sclerosis;	chr12:57768115	chr12:57803838~57804415:+
LUAD	cis	rs2688608	0.967	rs72814394	ENSG00000271816.1	BMS1P4	3.78	0.000173	0.0222	0.14	0.17	Inflammatory bowel disease;	chr10:73896567	chr10:73699151~73730487:-
LUAD	cis	rs78905543	1	rs4872049	ENSG00000253616.4	RP11-875O11.3	-3.78	0.000173	0.0222	-0.2	-0.17	Mean corpuscular volume;	chr8:23074266	chr8:23071377~23074488:-
LUAD	cis	rs8067545	0.641	rs397969	ENSG00000270091.1	RP11-78O7.2	-3.78	0.000173	0.0222	-0.14	-0.17	Schizophrenia;	chr17:19900934	chr17:19896590~19897287:-
LUAD	cis	rs3126085	0.515	rs12032854	ENSG00000237975.5	FLG-AS1	3.78	0.000173	0.0222	0.27	0.17	Atopic dermatitis;	chr1:152374885	chr1:152168125~152445456:+
LUAD	cis	rs9907295	0.584	rs7215845	ENSG00000270977.1	AC015849.16	-3.78	0.000173	0.0222	-0.23	-0.17	Fibroblast growth factor basic levels;	chr17:35894698	chr17:35893707~35911023:-
LUAD	cis	rs240993	0.516	rs173286	ENSG00000266032.1	AL357515.1	3.78	0.000173	0.0222	0.27	0.17	Inflammatory skin disease;Psoriasis;	chr6:111292391	chr6:110969773~110969872:-
LUAD	cis	rs8062405	0.964	rs11860513	ENSG00000261419.1	RP11-57A19.4	-3.78	0.000173	0.0222	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28659696~28740781:-
LUAD	cis	rs506597	0.92	rs221803	ENSG00000281827.1	AC005071.4	3.78	0.000173	0.0222	0.29	0.17	Pursuit maintenance gain in psychotic disorders;	chr7:100693577	chr7:100344375~100344475:-
LUAD	cis	rs6687758	1	rs12731064	ENSG00000238042.4	RP11-815M8.1	3.78	0.000173	0.0222	0.24	0.17	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222016779	chr1:221880981~221978523:-
LUAD	cis	rs9291683	0.552	rs3796832	ENSG00000250413.1	RP11-448G15.1	-3.78	0.000173	0.0222	-0.22	-0.17	Bone mineral density;	chr4:10014241	chr4:10006482~10009725:+
LUAD	cis	rs2154319	0.836	rs804660	ENSG00000235358.1	RP11-399E6.1	3.78	0.000173	0.0222	0.23	0.17	Height;	chr1:41106492	chr1:41242373~41284861:+
LUAD	cis	rs6496932	0.874	rs2003294	ENSG00000259630.2	CTD-2262B20.1	3.78	0.000173	0.0222	0.23	0.17	Central corneal thickness;Corneal structure;	chr15:85274141	chr15:85415228~85415633:+
LUAD	cis	rs11742741	0.748	rs1428195	ENSG00000248874.4	C5orf17	-3.78	0.000173	0.0222	-0.21	-0.17	Educational attainment;	chr5:24128739	chr5:23951348~24178263:+
LUAD	cis	rs721917	0.531	rs2758554	ENSG00000230091.5	TMEM254-AS1	-3.78	0.000174	0.0222	-0.22	-0.17	Chronic obstructive pulmonary disease;	chr10:79931324	chr10:80046860~80078912:-
LUAD	cis	rs4718428	1	rs12534637	ENSG00000272831.1	RP11-792A8.4	3.78	0.000174	0.0222	0.16	0.17	Corneal structure;	chr7:66862667	chr7:66739829~66740385:-
LUAD	cis	rs6781182	0.517	rs11712920	ENSG00000236452.1	AC123023.1	-3.78	0.000174	0.0222	-0.19	-0.17	Visceral adipose tissue adjusted for BMI;	chr3:34189441	chr3:34203244~34268811:+
LUAD	cis	rs4845570	1	rs4845570	ENSG00000203288.3	RP11-98D18.9	3.78	0.000174	0.0222	0.25	0.17	Coronary artery disease;	chr1:151786628	chr1:151790804~151794402:+
LUAD	cis	rs7976269	0.559	rs10771477	ENSG00000275476.1	RP11-996F15.4	-3.78	0.000174	0.0222	-0.19	-0.17	Male-pattern baldness;	chr12:29074137	chr12:29277397~29277882:-
LUAD	cis	rs7976269	0.559	rs10843307	ENSG00000275476.1	RP11-996F15.4	-3.78	0.000174	0.0222	-0.19	-0.17	Male-pattern baldness;	chr12:29074710	chr12:29277397~29277882:-
LUAD	cis	rs875971	0.545	rs67775320	ENSG00000222364.1	RNU6-96P	-3.78	0.000174	0.0222	-0.22	-0.17	Aortic root size;	chr7:66193792	chr7:66395191~66395286:+
LUAD	cis	rs6494488	0.5	rs72741386	ENSG00000239465.1	RP11-330L19.2	3.78	0.000174	0.0222	0.36	0.17	Coronary artery disease;	chr15:64519884	chr15:64631109~64631914:-
LUAD	cis	rs7613875	0.58	rs3774745	ENSG00000280382.1	RP11-804H8.7	3.78	0.000174	0.0222	0.19	0.17	Body mass index;	chr3:50167312	chr3:50599879~50601148:-
LUAD	cis	rs7017914	0.967	rs1477944	ENSG00000246366.5	RP11-382J12.1	3.78	0.000174	0.0222	0.16	0.17	Bone mineral density;	chr8:70703365	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.967	rs17760497	ENSG00000246366.5	RP11-382J12.1	3.78	0.000174	0.0222	0.16	0.17	Bone mineral density;	chr8:70704810	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.967	rs34677078	ENSG00000246366.5	RP11-382J12.1	3.78	0.000174	0.0222	0.16	0.17	Bone mineral density;	chr8:70705480	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.967	rs62530792	ENSG00000246366.5	RP11-382J12.1	3.78	0.000174	0.0222	0.16	0.17	Bone mineral density;	chr8:70706532	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.902	rs35893260	ENSG00000246366.5	RP11-382J12.1	3.78	0.000174	0.0222	0.16	0.17	Bone mineral density;	chr8:70707838	chr8:70608577~70663279:+
LUAD	cis	rs7017914	1	rs13253842	ENSG00000246366.5	RP11-382J12.1	3.78	0.000174	0.0222	0.16	0.17	Bone mineral density;	chr8:70713268	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.967	rs13254908	ENSG00000246366.5	RP11-382J12.1	3.78	0.000174	0.0222	0.16	0.17	Bone mineral density;	chr8:70713863	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.967	rs13264669	ENSG00000246366.5	RP11-382J12.1	3.78	0.000174	0.0222	0.16	0.17	Bone mineral density;	chr8:70714537	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.967	rs34508469	ENSG00000246366.5	RP11-382J12.1	3.78	0.000174	0.0222	0.16	0.17	Bone mineral density;	chr8:70716228	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.967	rs6472539	ENSG00000246366.5	RP11-382J12.1	3.78	0.000174	0.0222	0.16	0.17	Bone mineral density;	chr8:70717575	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.934	rs56043721	ENSG00000246366.5	RP11-382J12.1	3.78	0.000174	0.0222	0.16	0.17	Bone mineral density;	chr8:70718192	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.967	rs3954897	ENSG00000246366.5	RP11-382J12.1	3.78	0.000174	0.0222	0.16	0.17	Bone mineral density;	chr8:70723720	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.811	rs4272413	ENSG00000246366.5	RP11-382J12.1	3.78	0.000174	0.0222	0.16	0.17	Bone mineral density;	chr8:70723952	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.935	rs6981435	ENSG00000246366.5	RP11-382J12.1	3.78	0.000174	0.0222	0.16	0.17	Bone mineral density;	chr8:70724913	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.967	rs6999739	ENSG00000246366.5	RP11-382J12.1	3.78	0.000174	0.0222	0.16	0.17	Bone mineral density;	chr8:70724977	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.967	rs7013657	ENSG00000246366.5	RP11-382J12.1	3.78	0.000174	0.0222	0.16	0.17	Bone mineral density;	chr8:70725324	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.934	rs7006615	ENSG00000246366.5	RP11-382J12.1	3.78	0.000174	0.0222	0.16	0.17	Bone mineral density;	chr8:70727572	chr8:70608577~70663279:+
LUAD	cis	rs7017914	1	rs7007450	ENSG00000246366.5	RP11-382J12.1	3.78	0.000174	0.0222	0.16	0.17	Bone mineral density;	chr8:70728034	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.967	rs11989553	ENSG00000246366.5	RP11-382J12.1	3.78	0.000174	0.0222	0.16	0.17	Bone mineral density;	chr8:70728664	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.967	rs13272523	ENSG00000246366.5	RP11-382J12.1	3.78	0.000174	0.0222	0.16	0.17	Bone mineral density;	chr8:70729237	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.934	rs62530826	ENSG00000246366.5	RP11-382J12.1	3.78	0.000174	0.0222	0.16	0.17	Bone mineral density;	chr8:70729408	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.967	rs35295900	ENSG00000246366.5	RP11-382J12.1	3.78	0.000174	0.0222	0.16	0.17	Bone mineral density;	chr8:70729826	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.967	rs35115527	ENSG00000246366.5	RP11-382J12.1	3.78	0.000174	0.0222	0.16	0.17	Bone mineral density;	chr8:70730774	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.902	rs11991273	ENSG00000246366.5	RP11-382J12.1	3.78	0.000174	0.0222	0.16	0.17	Bone mineral density;	chr8:70733625	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.869	rs11987511	ENSG00000246366.5	RP11-382J12.1	3.78	0.000174	0.0222	0.16	0.17	Bone mineral density;	chr8:70733636	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.967	rs6991329	ENSG00000246366.5	RP11-382J12.1	3.78	0.000174	0.0222	0.16	0.17	Bone mineral density;	chr8:70681190	chr8:70608577~70663279:+
LUAD	cis	rs4561483	0.549	rs154149	ENSG00000261560.1	RP11-166B2.3	-3.78	0.000174	0.0222	-0.16	-0.17	Testicular germ cell tumor;	chr16:11862261	chr16:11881075~11882569:-
LUAD	cis	rs7189233	1	rs16952251	ENSG00000279344.1	RP11-44F14.7	3.78	0.000174	0.0222	0.15	0.17	Intelligence (multi-trait analysis);	chr16:53449226	chr16:53478957~53481550:-
LUAD	cis	rs7246657	0.943	rs2291004	ENSG00000226686.6	LINC01535	-3.78	0.000174	0.0222	-0.25	-0.17	Coronary artery calcification;	chr19:37507050	chr19:37251912~37265535:+
LUAD	cis	rs8133949	0.904	rs11701177	ENSG00000237232.6	ZNF295-AS1	3.78	0.000174	0.0222	0.22	0.17	Hand grip strength;	chr21:42012779	chr21:42009194~42024924:+
LUAD	cis	rs7809950	1	rs10267907	ENSG00000238832.1	snoU109	-3.78	0.000174	0.0222	-0.25	-0.17	Coronary artery disease;	chr7:107544021	chr7:107603363~107603507:+
LUAD	cis	rs9973361	0.659	rs962503	ENSG00000232411.1	AC009495.3	-3.78	0.000174	0.0222	-0.23	-0.17	Total body bone mineral density;	chr2:165864374	chr2:165833048~165839098:-
LUAD	cis	rs10197140	0.857	rs10197135	ENSG00000235721.1	AC013268.3	-3.78	0.000174	0.0222	-0.19	-0.17	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110883031	chr2:110007675~110010783:+
LUAD	cis	rs2836950	0.565	rs8130320	ENSG00000232608.1	TIMM9P2	3.78	0.000174	0.0222	0.19	0.17	Menarche (age at onset);	chr21:39208332	chr21:39216624~39217506:+
LUAD	cis	rs9549260	0.522	rs4245401	ENSG00000168852.11	TPTE2P5	3.78	0.000174	0.0222	0.17	0.17	Red blood cell count;	chr13:40703600	chr13:40822296~40921749:-
LUAD	cis	rs6563842	0.563	rs4575411	ENSG00000168852.11	TPTE2P5	3.78	0.000174	0.0222	0.17	0.17	Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr13:40703658	chr13:40822296~40921749:-
LUAD	cis	rs5758659	0.652	rs133313	ENSG00000270083.1	RP1-257I20.14	3.78	0.000174	0.0222	0.16	0.17	Cognitive function;	chr22:42005745	chr22:42089630~42090028:-
LUAD	cis	rs5758659	0.652	rs133314	ENSG00000270083.1	RP1-257I20.14	3.78	0.000174	0.0222	0.16	0.17	Cognitive function;	chr22:42005837	chr22:42089630~42090028:-
LUAD	cis	rs7560272	0.538	rs13006448	ENSG00000163016.8	ALMS1P	-3.78	0.000174	0.0222	-0.18	-0.17	Schizophrenia;	chr2:73697297	chr2:73644919~73685576:+
LUAD	cis	rs7772486	0.875	rs9403768	ENSG00000235652.6	RP11-545I5.3	3.78	0.000174	0.0222	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:146085322	chr6:145799409~145886585:+
LUAD	cis	rs66823261	0.778	rs2906332	ENSG00000223508.5	RPL23AP53	3.78	0.000174	0.0222	0.27	0.17	Breast cancer (estrogen-receptor negative);Breast cancer;	chr8:244943	chr8:213186~232231:-
LUAD	cis	rs6071166	0.683	rs6027331	ENSG00000224635.1	RP4-564F22.5	-3.78	0.000174	0.0222	-0.19	-0.17	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38694540	chr20:38406011~38416797:-
LUAD	cis	rs11874381	1	rs36089715	ENSG00000266696.1	RP11-30L3.2	-3.78	0.000174	0.0222	-0.19	-0.17	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);	chr18:49686652	chr18:49205912~49208781:+
LUAD	cis	rs5742933	0.817	rs5742938	ENSG00000253559.1	OSGEPL1-AS1	3.78	0.000174	0.0222	0.2	0.17	Ferritin levels;	chr2:189785232	chr2:189762704~189765556:+
LUAD	cis	rs3018712	0.532	rs2510399	ENSG00000212093.1	AP000807.1	-3.78	0.000174	0.0222	-0.23	-0.17	Total body bone mineral density;	chr11:68653990	chr11:68506083~68506166:-
LUAD	cis	rs6763848	0.962	rs17039886	ENSG00000214073.2	RPL21P17	-3.78	0.000174	0.0222	-0.17	-0.17	Prostate cancer (SNP x SNP interaction);	chr3:1473548	chr3:1905651~1906125:+
LUAD	cis	rs6964587	1	rs57816416	ENSG00000188693.7	CYP51A1-AS1	-3.78	0.000174	0.0222	-0.2	-0.17	Breast cancer;	chr7:92106764	chr7:92134604~92180725:+
LUAD	cis	rs10129255	0.912	rs67410411	ENSG00000274576.2	IGHV2-70	3.78	0.000174	0.0223	0.15	0.17	Kawasaki disease;	chr14:106680324	chr14:106770577~106771020:-
LUAD	cis	rs2832191	0.967	rs1999321	ENSG00000215533.7	LINC00189	-3.78	0.000174	0.0223	-0.2	-0.17	Dental caries;	chr21:29157912	chr21:29193480~29288205:+
LUAD	cis	rs2832191	0.967	rs2251377	ENSG00000215533.7	LINC00189	-3.78	0.000174	0.0223	-0.2	-0.17	Dental caries;	chr21:29158278	chr21:29193480~29288205:+
LUAD	cis	rs7017914	0.967	rs7814648	ENSG00000246366.5	RP11-382J12.1	3.78	0.000174	0.0223	0.16	0.17	Bone mineral density;	chr8:70691749	chr8:70608577~70663279:+
LUAD	cis	rs7584330	0.74	rs10184904	ENSG00000222032.1	AC112721.2	3.78	0.000174	0.0223	0.19	0.17	Prostate cancer;	chr2:237519543	chr2:237428920~237434822:-
LUAD	cis	rs34421088	0.576	rs2572436	ENSG00000255046.1	RP11-297N6.4	3.78	0.000174	0.0223	0.22	0.17	Neuroticism;	chr8:11241700	chr8:11797928~11802568:-
LUAD	cis	rs6087771	0.781	rs6089067	ENSG00000230613.1	HM13-AS1	3.78	0.000174	0.0223	0.21	0.17	Putamen volume;Subcortical brain region volumes;	chr20:31771091	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.559	rs6058462	ENSG00000230613.1	HM13-AS1	3.78	0.000174	0.0223	0.21	0.17	Mean corpuscular hemoglobin;	chr20:31779871	chr20:31567707~31573263:-
LUAD	cis	rs10392	0.543	rs4300896	ENSG00000274825.1	RP4-616B8.5	-3.78	0.000174	0.0223	-0.21	-0.17	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;	chr20:38951487	chr20:38955910~38956547:+
LUAD	cis	rs4130344	0.874	rs11723981	ENSG00000271817.2	U3	-3.78	0.000174	0.0223	-0.18	-0.17	Intelligence (multi-trait analysis);	chr4:158778524	chr4:158700691~158700909:+
LUAD	cis	rs4130344	0.874	rs72695428	ENSG00000271817.2	U3	-3.78	0.000174	0.0223	-0.18	-0.17	Intelligence (multi-trait analysis);	chr4:158781154	chr4:158700691~158700909:+
LUAD	cis	rs4130344	0.874	rs6829398	ENSG00000271817.2	U3	-3.78	0.000174	0.0223	-0.18	-0.17	Intelligence (multi-trait analysis);	chr4:158782073	chr4:158700691~158700909:+
LUAD	cis	rs11673344	0.633	rs519606	ENSG00000267309.1	CTD-2630F21.1	-3.78	0.000174	0.0223	-0.21	-0.17	Obesity-related traits;	chr19:36942327	chr19:36489649~36491040:+
LUAD	cis	rs12744310	0.83	rs12028010	ENSG00000235358.1	RP11-399E6.1	3.78	0.000174	0.0223	0.23	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41298799	chr1:41242373~41284861:+
LUAD	cis	rs7772486	0.686	rs4895684	ENSG00000235652.6	RP11-545I5.3	-3.78	0.000174	0.0223	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145792887	chr6:145799409~145886585:+
LUAD	cis	rs1816752	0.875	rs59531061	ENSG00000273628.1	RP11-756A22.7	3.78	0.000174	0.0223	0.2	0.17	Obesity-related traits;	chr13:24507297	chr13:24933006~24936796:+
LUAD	cis	rs6787172	0.87	rs1714524	ENSG00000272087.1	RP11-379F4.7	3.78	0.000174	0.0223	0.18	0.17	Subjective well-being;	chr3:158555307	chr3:158693120~158693768:-
LUAD	cis	rs9659323	1	rs6700415	ENSG00000226172.2	RP4-712E4.1	-3.78	0.000174	0.0223	-0.18	-0.17	Body mass index;	chr1:118973551	chr1:119000344~119001392:-
LUAD	cis	rs13014235	0.846	rs10454127	ENSG00000234842.1	AC007163.8	-3.78	0.000174	0.0223	-0.2	-0.17	Basal cell carcinoma;	chr2:201347651	chr2:201549631~201550307:+
LUAD	cis	rs78572108	0.858	rs75660123	ENSG00000214691.7	AC104654.1	3.78	0.000174	0.0223	0.31	0.17	Total body bone mineral density;	chr2:42020012	chr2:41877074~41894046:+
LUAD	cis	rs638893	0.636	rs2186781	ENSG00000255239.1	AP002954.6	3.78	0.000174	0.0223	0.28	0.17	Vitiligo;	chr11:118734738	chr11:118688039~118690600:-
LUAD	cis	rs7246657	0.943	rs10420722	ENSG00000267470.4	ZNF571-AS1	3.78	0.000174	0.0223	0.24	0.17	Coronary artery calcification;	chr19:37482872	chr19:37548914~37587348:+
LUAD	cis	rs27434	0.51	rs27038	ENSG00000272109.1	CTD-2260A17.3	-3.78	0.000174	0.0223	-0.23	-0.17	Ankylosing spondylitis;	chr5:96777250	chr5:96804353~96806105:+
LUAD	cis	rs7829975	0.606	rs891570	ENSG00000253981.4	ALG1L13P	-3.78	0.000174	0.0223	-0.19	-0.17	Mood instability;	chr8:8936944	chr8:8236003~8244667:-
LUAD	cis	rs7829975	0.688	rs7837587	ENSG00000233609.3	RP11-62H7.2	3.78	0.000174	0.0223	0.14	0.17	Mood instability;	chr8:8521482	chr8:8961200~8979025:+
LUAD	cis	rs2354432	0.607	rs3820130	ENSG00000237188.3	RP11-337C18.8	3.78	0.000174	0.0223	0.29	0.17	Mitochondrial DNA levels;	chr1:147252348	chr1:147172771~147211568:+
LUAD	cis	rs5015933	0.788	rs521308	ENSG00000232630.1	PRPS1P2	-3.78	0.000174	0.0223	-0.16	-0.17	Body mass index;	chr9:125308475	chr9:125150653~125151589:+
LUAD	cis	rs8028182	0.636	rs4886716	ENSG00000246877.1	DNM1P35	3.78	0.000174	0.0223	0.22	0.17	Sudden cardiac arrest;	chr15:75563681	chr15:75727670~75738623:-
LUAD	cis	rs7178424	0.87	rs8034914	ENSG00000259251.2	RP11-643M14.1	3.78	0.000174	0.0223	0.17	0.17	Height;	chr15:61958231	chr15:62060503~62062434:+
LUAD	cis	rs3788317	0.535	rs5993856	ENSG00000232926.1	AC000078.5	-3.78	0.000174	0.0223	-0.18	-0.17	Glaucoma (primary angle closure);	chr22:19895107	chr22:19887289~19887970:+
LUAD	cis	rs12724450	0.793	rs12735903	ENSG00000228126.1	FALEC	3.78	0.000175	0.0223	0.31	0.17	Blood protein levels;	chr1:150386609	chr1:150515757~150518032:+
LUAD	cis	rs4767841	0.537	rs11064919	ENSG00000248636.5	RP11-768F21.1	-3.78	0.000175	0.0223	-0.2	-0.17	Urgency urinary incontinence;	chr12:119819078	chr12:119387987~119668079:-
LUAD	cis	rs11089937	0.825	rs5757012	ENSG00000211638.2	IGLV8-61	-3.78	0.000175	0.0223	-0.17	-0.17	Periodontitis (PAL4Q3);	chr22:22135515	chr22:22098700~22099212:+
LUAD	cis	rs12073359	1	rs56125600	ENSG00000223945.2	RP11-458I7.1	-3.78	0.000175	0.0223	-0.24	-0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150040941	chr1:150053864~150055034:+
LUAD	cis	rs454217	0.765	rs392929	ENSG00000277851.1	RP11-756G20.1	3.78	0.000175	0.0223	0.17	0.17	Smoking quantity;	chr12:92338016	chr12:92247756~92363832:-
LUAD	cis	rs448720	0.811	rs383041	ENSG00000259673.4	IQCH-AS1	3.78	0.000175	0.0223	0.18	0.17	Cognitive performance;	chr15:67892143	chr15:67403619~67521844:-
LUAD	cis	rs526231	0.764	rs365975	ENSG00000175749.11	EIF3KP1	3.78	0.000175	0.0223	0.22	0.17	Primary biliary cholangitis;	chr5:103297657	chr5:103032376~103033031:+
LUAD	cis	rs77204473	0.655	rs11216183	ENSG00000280143.1	AP000892.6	-3.78	0.000175	0.0223	-0.32	-0.17	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116910829	chr11:117204967~117210292:+
LUAD	cis	rs761746	0.739	rs5998072	ENSG00000236132.1	CTA-440B3.1	-3.78	0.000175	0.0223	-0.24	-0.17	Intelligence;	chr22:31652388	chr22:31816379~31817491:-
LUAD	cis	rs897984	0.762	rs897986	ENSG00000232748.3	RP11-196G11.6	3.78	0.000175	0.0223	0.21	0.17	Dementia with Lewy bodies;	chr16:30969581	chr16:31056460~31062803:+
LUAD	cis	rs897984	0.721	rs28360557	ENSG00000232748.3	RP11-196G11.6	3.78	0.000175	0.0223	0.21	0.17	Dementia with Lewy bodies;	chr16:30971939	chr16:31056460~31062803:+
LUAD	cis	rs897984	0.721	rs4889525	ENSG00000232748.3	RP11-196G11.6	3.78	0.000175	0.0223	0.21	0.17	Dementia with Lewy bodies;	chr16:30978537	chr16:31056460~31062803:+
LUAD	cis	rs8012947	1	rs7155580	ENSG00000279636.2	LINC00216	-3.78	0.000175	0.0223	-0.19	-0.17	Alcohol consumption in current drinkers;	chr14:58304914	chr14:58288033~58289158:+
LUAD	cis	rs2731006	0.64	rs2459741	ENSG00000257114.2	RP11-25I15.3	3.78	0.000175	0.0223	0.26	0.17	Panic disorder;	chr12:42797900	chr12:42692216~42717119:+
LUAD	cis	rs858239	0.899	rs2268745	ENSG00000230042.1	AK3P3	-3.78	0.000175	0.0223	-0.22	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23277981	chr7:23129178~23129841:+
LUAD	cis	rs6910061	0.913	rs35199324	ENSG00000247925.2	RP3-510L9.1	-3.78	0.000175	0.0223	-0.24	-0.17	Diabetic kidney disease;	chr6:11112630	chr6:11173452~11259099:+
LUAD	cis	rs9309473	0.519	rs13009035	ENSG00000163016.8	ALMS1P	-3.78	0.000175	0.0223	-0.18	-0.17	Metabolite levels;	chr2:73618582	chr2:73644919~73685576:+
LUAD	cis	rs2032366	0.63	rs1894094	ENSG00000266920.1	ACTBP9	3.78	0.000175	0.0223	0.18	0.17	Obesity-related traits;	chr18:61606390	chr18:62442028~62443126:+
LUAD	cis	rs2354432	0.607	rs6683243	ENSG00000237188.3	RP11-337C18.8	3.78	0.000175	0.0223	0.33	0.17	Mitochondrial DNA levels;	chr1:147261765	chr1:147172771~147211568:+
LUAD	cis	rs12921479	0.962	rs12596491	ENSG00000259881.1	RP11-830F9.5	-3.78	0.000175	0.0223	-0.18	-0.17	Parkinson disease and lewy body pathology;	chr16:88862009	chr16:88881038~88887136:+
LUAD	cis	rs6964587	0.967	rs10280620	ENSG00000188693.7	CYP51A1-AS1	3.78	0.000175	0.0223	0.2	0.17	Breast cancer;	chr7:91952869	chr7:92134604~92180725:+
LUAD	cis	rs6964587	1	rs10280927	ENSG00000188693.7	CYP51A1-AS1	3.78	0.000175	0.0223	0.2	0.17	Breast cancer;	chr7:91952891	chr7:92134604~92180725:+
LUAD	cis	rs703842	1	rs10877015	ENSG00000270039.1	RP11-571M6.17	-3.78	0.000175	0.0223	-0.2	-0.17	Multiple sclerosis;	chr12:57774005	chr12:57803838~57804415:+
LUAD	cis	rs8048589	0.948	rs11648228	ENSG00000175604.2	RP11-276H1.3	-3.78	0.000175	0.0224	-0.23	-0.17	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12087845	chr16:12086746~12090302:-
LUAD	cis	rs4268898	0.571	rs1986478	ENSG00000242628.4	AC009228.1	3.78	0.000175	0.0224	0.25	0.17	Asthma;	chr2:24245676	chr2:24214381~24221516:+
LUAD	cis	rs748404	0.589	rs3862138	ENSG00000249839.1	AC011330.5	-3.78	0.000175	0.0224	-0.27	-0.17	Lung cancer;	chr15:43523801	chr15:43663654~43684339:-
LUAD	cis	rs11250098	0.574	rs7015168	ENSG00000255046.1	RP11-297N6.4	3.78	0.000175	0.0224	0.21	0.17	Morning vs. evening chronotype;	chr8:10914700	chr8:11797928~11802568:-
LUAD	cis	rs875971	0.545	rs1547529	ENSG00000224316.1	RP11-479O9.2	3.78	0.000175	0.0224	0.2	0.17	Aortic root size;	chr7:66258859	chr7:65773620~65802067:+
LUAD	cis	rs12887734	0.546	rs12885509	ENSG00000258914.1	CTD-2134A5.3	-3.78	0.000175	0.0224	-0.21	-0.17	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103806988	chr14:103875055~103877478:+
LUAD	cis	rs2283792	0.73	rs2329884	ENSG00000211640.3	IGLV6-57	-3.78	0.000175	0.0224	-0.11	-0.17	Multiple sclerosis;	chr22:21927890	chr22:22195713~22196460:+
LUAD	cis	rs1075265	0.704	rs13417926	ENSG00000272156.1	RP11-477N3.1	-3.78	0.000175	0.0224	-0.2	-0.17	Chronotype;Morning vs. evening chronotype;	chr2:53825520	chr2:54082554~54085066:+
LUAD	cis	rs9896933	0.83	rs12450046	ENSG00000262663.1	RP11-497H17.1	3.78	0.000175	0.0224	0.19	0.17	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr17:82832512	chr17:82918282~82918785:+
LUAD	cis	rs6687758	1	rs17442323	ENSG00000238042.4	RP11-815M8.1	3.78	0.000175	0.0224	0.24	0.17	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222019622	chr1:221880981~221978523:-
LUAD	cis	rs957448	1	rs12543207	ENSG00000253175.1	RP11-267M23.6	3.78	0.000175	0.0224	0.21	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94485202	chr8:94565036~94565715:+
LUAD	cis	rs9513627	0.512	rs9517759	ENSG00000280710.1	RP11-214F16.8	3.78	0.000175	0.0224	0.25	0.17	Obesity-related traits;	chr13:99527854	chr13:99498524~99501315:+
LUAD	cis	rs10129255	0.5	rs7157975	ENSG00000253209.1	IGHV3-65	3.78	0.000175	0.0224	0.13	0.17	Kawasaki disease;	chr14:106804049	chr14:106666092~106666532:-
LUAD	cis	rs77972916	0.609	rs72790903	ENSG00000234936.1	AC010883.5	3.78	0.000175	0.0224	0.24	0.17	Granulocyte percentage of myeloid white cells;	chr2:43334846	chr2:43229573~43233394:+
LUAD	cis	rs2732480	0.577	rs2732479	ENSG00000273765.1	RP11-370I10.11	3.78	0.000175	0.0224	0.19	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342477	chr12:48360920~48361377:+
LUAD	cis	rs2732480	0.537	rs1061986	ENSG00000273765.1	RP11-370I10.11	3.78	0.000175	0.0224	0.19	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342656	chr12:48360920~48361377:+
LUAD	cis	rs7829975	0.686	rs907180	ENSG00000253893.2	FAM85B	-3.78	0.000175	0.0224	-0.2	-0.17	Mood instability;	chr8:8845317	chr8:8167819~8226614:-
LUAD	cis	rs9813712	0.571	rs9866568	ENSG00000228252.7	COL6A4P2	-3.78	0.000175	0.0224	-0.16	-0.17	Response to amphetamines;	chr3:130297539	chr3:130212823~130273806:+
LUAD	cis	rs3812049	0.784	rs2617617	ENSG00000245937.6	LINC01184	3.78	0.000175	0.0224	0.25	0.17	Lymphocyte counts;Red cell distribution width;	chr5:128119316	chr5:127940426~128083172:-
LUAD	cis	rs1023500	0.506	rs6002625	ENSG00000273366.1	CTA-989H11.1	3.78	0.000175	0.0224	0.21	0.17	Schizophrenia;	chr22:42121685	chr22:42278188~42278846:+
LUAD	cis	rs2664588	0.613	rs6125186	ENSG00000255438.2	CTD-2653D5.1	-3.78	0.000175	0.0224	-0.2	-0.17	Cerebrospinal fluid AB1-42 levels;	chr20:47953547	chr20:47677901~47686297:+
LUAD	cis	rs7215564	0.908	rs115148337	ENSG00000232083.3	RPL31P7	3.78	0.000175	0.0224	0.28	0.17	Myopia (pathological);	chr17:80714745	chr17:80602549~80602926:-
LUAD	cis	rs11673344	0.536	rs7259272	ENSG00000226686.6	LINC01535	3.78	0.000176	0.0224	0.2	0.17	Obesity-related traits;	chr19:37692214	chr19:37251912~37265535:+
LUAD	cis	rs9650657	0.537	rs4841457	ENSG00000255046.1	RP11-297N6.4	3.78	0.000176	0.0224	0.21	0.17	Neuroticism;	chr8:10916001	chr8:11797928~11802568:-
LUAD	cis	rs3018712	0.59	rs10750834	ENSG00000227620.4	ALG1L8P	-3.78	0.000176	0.0224	-0.23	-0.17	Total body bone mineral density;	chr11:68737907	chr11:67785273~67792335:+
LUAD	cis	rs7274811	0.744	rs6120309	ENSG00000231795.1	ITCH-IT1	3.78	0.000176	0.0224	0.19	0.17	Height;	chr20:33581794	chr20:34450930~34454552:+
LUAD	cis	rs6479901	0.895	rs907	ENSG00000232075.1	MRPL35P2	-3.78	0.000176	0.0224	-0.23	-0.17	Intelligence (multi-trait analysis);	chr10:63176919	chr10:63634317~63634827:-
LUAD	cis	rs2688608	0.839	rs2633311	ENSG00000271816.1	BMS1P4	-3.78	0.000176	0.0224	-0.14	-0.17	Inflammatory bowel disease;	chr10:73838341	chr10:73699151~73730487:-
LUAD	cis	rs67981189	0.896	rs7157250	ENSG00000269927.1	RP6-91H8.3	3.78	0.000176	0.0224	0.21	0.17	Schizophrenia;	chr14:70991112	chr14:71141125~71143253:-
LUAD	cis	rs1046491	0.523	rs11876120	ENSG00000264964.1	RP11-888D10.3	3.78	0.000176	0.0224	0.37	0.17	Scarlet fever;	chr18:9303513	chr18:9315194~9334441:-
LUAD	cis	rs8180040	0.966	rs11710322	ENSG00000271161.1	BOLA2P2	-3.78	0.000176	0.0224	-0.16	-0.17	Colorectal cancer;	chr3:47289646	chr3:47499841~47500407:+
LUAD	cis	rs12754538	0.777	rs1000184	ENSG00000232912.4	RP5-1115A15.1	3.78	0.000176	0.0224	0.18	0.17	Subjective well-being;	chr1:8580772	chr1:8424645~8434838:+
LUAD	cis	rs2803122	0.807	rs10757035	ENSG00000273226.1	RP11-513M16.8	-3.78	0.000176	0.0224	-0.18	-0.17	Pulse pressure;	chr9:19230274	chr9:19375451~19375996:+
LUAD	cis	rs7870753	0.628	rs2406005	ENSG00000188801.9	ZNF322P1	3.78	0.000176	0.0224	0.26	0.17	Height;	chr9:96435373	chr9:97198303~97199511:-
LUAD	cis	rs2187895	1	rs2187895	ENSG00000271811.1	RP1-79C4.4	3.78	0.000176	0.0224	0.25	0.17	Tonsillectomy;	chr1:170715290	chr1:170667381~170669425:+
LUAD	cis	rs2554380	0.55	rs62025854	ENSG00000259570.1	RP11-671M22.4	-3.78	0.000176	0.0224	-0.23	-0.17	Height;	chr15:83883763	chr15:84394512~84395514:+
LUAD	cis	rs13113518	1	rs4864546	ENSG00000223305.1	RN7SKP30	3.78	0.000176	0.0224	0.19	0.17	Height;	chr4:55537960	chr4:55540502~55540835:-
LUAD	cis	rs2554380	0.8	rs1544876	ENSG00000259570.1	RP11-671M22.4	3.78	0.000176	0.0224	0.25	0.17	Height;	chr15:83707049	chr15:84394512~84395514:+
LUAD	cis	rs17711722	0.585	rs6942660	ENSG00000222364.1	RNU6-96P	-3.78	0.000176	0.0224	-0.19	-0.17	Calcium levels;	chr7:65837419	chr7:66395191~66395286:+
LUAD	cis	rs17711722	0.64	rs13237956	ENSG00000222364.1	RNU6-96P	-3.78	0.000176	0.0224	-0.19	-0.17	Calcium levels;	chr7:65853042	chr7:66395191~66395286:+
LUAD	cis	rs10090774	0.71	rs13268718	ENSG00000280303.2	ERICD	-3.78	0.000176	0.0224	-0.18	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140677101	chr8:140636281~140638283:+
LUAD	cis	rs38055	0.837	rs574790	ENSG00000247796.2	CTD-2366F13.1	-3.78	0.000176	0.0224	-0.19	-0.17	Acne (severe);	chr5:53330469	chr5:53109842~53115126:+
LUAD	cis	rs57221529	0.766	rs4081846	ENSG00000248925.1	CTD-2083E4.6	3.78	0.000176	0.0224	0.27	0.17	Lung disease severity in cystic fibrosis;	chr5:573904	chr5:269858~271516:-
LUAD	cis	rs2281558	0.754	rs73597824	ENSG00000125804.12	FAM182A	-3.78	0.000176	0.0224	-0.23	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25610841	chr20:26054655~26086917:+
LUAD	cis	rs2708977	0.637	rs676007	ENSG00000237510.6	AC008268.2	-3.78	0.000176	0.0224	-0.22	-0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96409314	chr2:95789654~95800166:+
LUAD	cis	rs6840360	0.557	rs1143036	ENSG00000270265.1	RP11-731D1.4	-3.78	0.000176	0.0224	-0.17	-0.17	Intelligence (multi-trait analysis);	chr4:151408252	chr4:151333775~151353224:-
LUAD	cis	rs481331	0.866	rs11499095	ENSG00000185904.10	LINC00839	3.78	0.000176	0.0224	0.28	0.17	Systemic juvenile idiopathic arthritis;	chr10:42488077	chr10:42475543~42495336:+
LUAD	cis	rs481331	0.866	rs1855450	ENSG00000185904.10	LINC00839	3.78	0.000176	0.0224	0.28	0.17	Systemic juvenile idiopathic arthritis;	chr10:42488259	chr10:42475543~42495336:+
LUAD	cis	rs3845817	0.798	rs702952	ENSG00000281920.1	RP11-418H16.1	-3.78	0.000176	0.0224	-0.21	-0.17	Bipolar disorder;	chr2:65537915	chr2:65623272~65628424:+
LUAD	cis	rs13434995	0.513	rs58476959	ENSG00000273257.1	RP11-177J6.1	-3.78	0.000176	0.0224	-0.22	-0.17	Adiponectin levels;	chr4:55496234	chr4:55387949~55388271:+
LUAD	cis	rs957448	0.554	rs72674877	ENSG00000253175.1	RP11-267M23.6	3.78	0.000176	0.0225	0.19	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94580479	chr8:94565036~94565715:+
LUAD	cis	rs9876781	1	rs2279077	ENSG00000229759.1	MRPS18AP1	3.78	0.000176	0.0225	0.16	0.17	Longevity;	chr3:48432839	chr3:48256350~48256938:-
LUAD	cis	rs9876781	1	rs1109227	ENSG00000229759.1	MRPS18AP1	3.78	0.000176	0.0225	0.16	0.17	Longevity;	chr3:48437797	chr3:48256350~48256938:-
LUAD	cis	rs9876781	1	rs3774808	ENSG00000229759.1	MRPS18AP1	3.78	0.000176	0.0225	0.16	0.17	Longevity;	chr3:48440237	chr3:48256350~48256938:-
LUAD	cis	rs10197140	0.857	rs62159473	ENSG00000235721.1	AC013268.3	-3.78	0.000176	0.0225	-0.18	-0.17	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110877386	chr2:110007675~110010783:+
LUAD	cis	rs10197140	0.857	rs13384044	ENSG00000235721.1	AC013268.3	-3.78	0.000176	0.0225	-0.18	-0.17	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110877819	chr2:110007675~110010783:+
LUAD	cis	rs7017914	0.902	rs6472562	ENSG00000246366.5	RP11-382J12.1	3.78	0.000176	0.0225	0.16	0.17	Bone mineral density;	chr8:71057643	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.902	rs6472563	ENSG00000246366.5	RP11-382J12.1	3.78	0.000176	0.0225	0.16	0.17	Bone mineral density;	chr8:71057672	chr8:70608577~70663279:+
LUAD	cis	rs7192380	1	rs11075726	ENSG00000226232.7	RP11-419C5.2	-3.78	0.000176	0.0225	-0.15	-0.17	Sjögren's syndrome;	chr16:69550620	chr16:69976388~69996188:-
LUAD	cis	rs7824557	0.527	rs11785394	ENSG00000255046.1	RP11-297N6.4	3.78	0.000176	0.0225	0.21	0.17	Retinal vascular caliber;	chr8:11380520	chr8:11797928~11802568:-
LUAD	cis	rs1150668	0.799	rs1150707	ENSG00000176933.5	TOB2P1	-3.78	0.000176	0.0225	-0.19	-0.17	Pubertal anthropometrics;	chr6:28229827	chr6:28217643~28218634:-
LUAD	cis	rs7560272	0.538	rs2421575	ENSG00000163016.8	ALMS1P	-3.78	0.000176	0.0225	-0.18	-0.17	Schizophrenia;	chr2:73692395	chr2:73644919~73685576:+
LUAD	cis	rs3805389	0.504	rs10018932	ENSG00000273257.1	RP11-177J6.1	-3.78	0.000176	0.0225	-0.27	-0.17	Waist-to-hip ratio adjusted for body mass index;	chr4:55601699	chr4:55387949~55388271:+
LUAD	cis	rs3805389	0.504	rs28756087	ENSG00000273257.1	RP11-177J6.1	-3.78	0.000176	0.0225	-0.27	-0.17	Waist-to-hip ratio adjusted for body mass index;	chr4:55601940	chr4:55387949~55388271:+
LUAD	cis	rs3805389	0.504	rs28713371	ENSG00000273257.1	RP11-177J6.1	-3.78	0.000176	0.0225	-0.27	-0.17	Waist-to-hip ratio adjusted for body mass index;	chr4:55602255	chr4:55387949~55388271:+
LUAD	cis	rs3805389	0.504	rs10011801	ENSG00000273257.1	RP11-177J6.1	-3.78	0.000176	0.0225	-0.27	-0.17	Waist-to-hip ratio adjusted for body mass index;	chr4:55602567	chr4:55387949~55388271:+
LUAD	cis	rs3805389	0.504	rs10000512	ENSG00000273257.1	RP11-177J6.1	-3.78	0.000176	0.0225	-0.27	-0.17	Waist-to-hip ratio adjusted for body mass index;	chr4:55602855	chr4:55387949~55388271:+
LUAD	cis	rs9847710	1	rs13088455	ENSG00000242142.1	SERBP1P3	-3.78	0.000176	0.0225	-0.18	-0.17	Ulcerative colitis;	chr3:53053466	chr3:53064283~53065091:-
LUAD	cis	rs6095360	1	rs6512554	ENSG00000222365.1	SNORD12B	-3.78	0.000176	0.0225	-0.17	-0.17	Intelligence (multi-trait analysis);	chr20:48916213	chr20:49280319~49280409:+
LUAD	cis	rs9628987	0.5	rs301788	ENSG00000232912.4	RP5-1115A15.1	3.78	0.000176	0.0225	0.2	0.17	Breast cancer;	chr1:8412104	chr1:8424645~8434838:+
LUAD	cis	rs8180040	0.764	rs4682852	ENSG00000271161.1	BOLA2P2	3.78	0.000176	0.0225	0.16	0.17	Colorectal cancer;	chr3:47136282	chr3:47499841~47500407:+
LUAD	cis	rs6095360	1	rs7270848	ENSG00000222365.1	SNORD12B	-3.78	0.000176	0.0225	-0.17	-0.17	Intelligence (multi-trait analysis);	chr20:49023200	chr20:49280319~49280409:+
LUAD	cis	rs6095360	1	rs6019591	ENSG00000222365.1	SNORD12B	-3.78	0.000176	0.0225	-0.17	-0.17	Intelligence (multi-trait analysis);	chr20:49023492	chr20:49280319~49280409:+
LUAD	cis	rs6095360	1	rs66970580	ENSG00000222365.1	SNORD12B	-3.78	0.000176	0.0225	-0.17	-0.17	Intelligence (multi-trait analysis);	chr20:49024802	chr20:49280319~49280409:+
LUAD	cis	rs6095360	1	rs7262379	ENSG00000222365.1	SNORD12B	-3.78	0.000176	0.0225	-0.17	-0.17	Intelligence (multi-trait analysis);	chr20:49026042	chr20:49280319~49280409:+
LUAD	cis	rs6095360	0.933	rs6019594	ENSG00000222365.1	SNORD12B	-3.78	0.000176	0.0225	-0.17	-0.17	Intelligence (multi-trait analysis);	chr20:49027017	chr20:49280319~49280409:+
LUAD	cis	rs6095360	1	rs6019595	ENSG00000222365.1	SNORD12B	-3.78	0.000176	0.0225	-0.17	-0.17	Intelligence (multi-trait analysis);	chr20:49027495	chr20:49280319~49280409:+
LUAD	cis	rs6095360	1	rs6095400	ENSG00000222365.1	SNORD12B	-3.78	0.000176	0.0225	-0.17	-0.17	Intelligence (multi-trait analysis);	chr20:49029452	chr20:49280319~49280409:+
LUAD	cis	rs6095360	0.87	rs6095401	ENSG00000222365.1	SNORD12B	-3.78	0.000176	0.0225	-0.17	-0.17	Intelligence (multi-trait analysis);	chr20:49030084	chr20:49280319~49280409:+
LUAD	cis	rs6095360	1	rs13042947	ENSG00000222365.1	SNORD12B	-3.78	0.000176	0.0225	-0.17	-0.17	Intelligence (multi-trait analysis);	chr20:49031339	chr20:49280319~49280409:+
LUAD	cis	rs2548724	0.796	rs12055218	ENSG00000250682.4	LINC00491	3.78	0.000176	0.0225	0.22	0.17	Type 2 diabetes;	chr5:102378049	chr5:102609156~102671559:-
LUAD	cis	rs2235642	0.821	rs8051895	ENSG00000280231.1	LA16c-380F5.3	-3.78	0.000176	0.0225	-0.23	-0.17	Coronary artery disease;	chr16:1552810	chr16:1553655~1554130:-
LUAD	cis	rs2235642	0.821	rs2281234	ENSG00000280231.1	LA16c-380F5.3	-3.78	0.000176	0.0225	-0.23	-0.17	Coronary artery disease;	chr16:1552937	chr16:1553655~1554130:-
LUAD	cis	rs1876905	0.68	rs783085	ENSG00000271789.1	RP5-1112D6.7	-3.78	0.000176	0.0225	-0.24	-0.17	Mean corpuscular hemoglobin;	chr6:111155482	chr6:111297126~111298510:+
LUAD	cis	rs11637445	0.677	rs3784716	ENSG00000270964.1	RP11-502I4.3	3.78	0.000176	0.0225	0.19	0.17	Posterior cortical atrophy and Alzheimer's disease;	chr15:67792112	chr15:67541072~67542604:-
LUAD	cis	rs67981189	0.896	rs17108822	ENSG00000269927.1	RP6-91H8.3	3.78	0.000176	0.0225	0.21	0.17	Schizophrenia;	chr14:70979189	chr14:71141125~71143253:-
LUAD	cis	rs67981189	0.896	rs8012728	ENSG00000269927.1	RP6-91H8.3	3.78	0.000176	0.0225	0.21	0.17	Schizophrenia;	chr14:70981231	chr14:71141125~71143253:-
LUAD	cis	rs442309	0.875	rs224064	ENSG00000238280.1	RP11-436D10.3	-3.78	0.000176	0.0225	-0.21	-0.17	Vogt-Koyanagi-Harada syndrome;	chr10:62744452	chr10:62793562~62805887:-
LUAD	cis	rs28530618	0.87	rs6058790	ENSG00000175730.8	BAK1P1	3.78	0.000176	0.0225	0.21	0.17	Birth weight;	chr20:32659515	chr20:32690180~32690815:-
LUAD	cis	rs13113518	1	rs10462032	ENSG00000273257.1	RP11-177J6.1	3.78	0.000176	0.0225	0.19	0.17	Height;	chr4:55479069	chr4:55387949~55388271:+
LUAD	cis	rs227275	0.526	rs223497	ENSG00000251288.2	RP11-10L12.2	-3.78	0.000176	0.0225	-0.21	-0.17	Allergic disease (asthma, hay fever or eczema);	chr4:102732819	chr4:102751401~102752641:+
LUAD	cis	rs6504663	0.558	rs11871603	ENSG00000275897.1	RP11-94C24.13	3.78	0.000176	0.0225	0.24	0.17	Visceral fat;	chr17:50481676	chr17:50475819~50478391:+
LUAD	cis	rs848490	0.851	rs62473661	ENSG00000214293.7	APTR	3.78	0.000176	0.0225	0.22	0.17	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77576197	chr7:77657660~77696265:-
LUAD	cis	rs750134	0.515	rs79400537	ENSG00000257221.1	RP11-689B22.2	-3.78	0.000176	0.0225	-0.19	-0.17	Low high density lipoprotein cholesterol levels;	chr12:108776630	chr12:108628687~108641318:+
LUAD	cis	rs728616	1	rs728616	ENSG00000225484.5	NUTM2B-AS1	-3.78	0.000176	0.0225	-0.37	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80088158	chr10:79663088~79826594:-
LUAD	cis	rs7646881	0.544	rs73024783	ENSG00000240207.5	RP11-379F4.4	-3.78	0.000176	0.0225	-0.23	-0.17	Tetralogy of Fallot;	chr3:158604426	chr3:158732263~158784070:+
LUAD	cis	rs10197140	0.816	rs10165663	ENSG00000235721.1	AC013268.3	-3.78	0.000177	0.0225	-0.19	-0.17	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110874990	chr2:110007675~110010783:+
LUAD	cis	rs67478160	0.619	rs1040813	ENSG00000272533.1	SNORA28	3.78	0.000177	0.0225	0.17	0.17	Schizophrenia;	chr14:103840359	chr14:103337849~103337974:+
LUAD	cis	rs67478160	0.619	rs1187416	ENSG00000272533.1	SNORA28	3.78	0.000177	0.0225	0.17	0.17	Schizophrenia;	chr14:103845128	chr14:103337849~103337974:+
LUAD	cis	rs2147959	0.7	rs12725863	ENSG00000269934.1	RP5-1139B12.3	-3.78	0.000177	0.0225	-0.23	-0.17	Adult asthma;	chr1:228443285	chr1:228274584~228276066:-
LUAD	cis	rs13113518	0.812	rs6825774	ENSG00000273257.1	RP11-177J6.1	3.78	0.000177	0.0225	0.19	0.17	Height;	chr4:55491150	chr4:55387949~55388271:+
LUAD	cis	rs13113518	0.812	rs3805153	ENSG00000273257.1	RP11-177J6.1	3.78	0.000177	0.0225	0.19	0.17	Height;	chr4:55493557	chr4:55387949~55388271:+
LUAD	cis	rs7772486	0.686	rs9497395	ENSG00000235652.6	RP11-545I5.3	-3.78	0.000177	0.0225	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145692456	chr6:145799409~145886585:+
LUAD	cis	rs2242116	0.727	rs7635480	ENSG00000271161.1	BOLA2P2	3.78	0.000177	0.0225	0.16	0.17	Birth weight;	chr3:46926737	chr3:47499841~47500407:+
LUAD	cis	rs6964587	1	rs2299240	ENSG00000188693.7	CYP51A1-AS1	-3.78	0.000177	0.0225	-0.2	-0.17	Breast cancer;	chr7:92025304	chr7:92134604~92180725:+
LUAD	cis	rs4237845	0.537	rs12426201	ENSG00000245651.2	RP11-620J15.2	3.78	0.000177	0.0225	0.18	0.17	Intelligence (multi-trait analysis);	chr12:57865969	chr12:57869835~57896482:-
LUAD	cis	rs17711722	0.583	rs10085415	ENSG00000213640.3	EEF1DP4	3.78	0.000177	0.0225	0.21	0.17	Calcium levels;	chr7:65628655	chr7:64862999~64864370:+
LUAD	cis	rs4130344	0.874	rs6853442	ENSG00000271817.2	U3	-3.78	0.000177	0.0225	-0.18	-0.17	Intelligence (multi-trait analysis);	chr4:158776407	chr4:158700691~158700909:+
LUAD	cis	rs4130344	0.874	rs4493489	ENSG00000271817.2	U3	-3.78	0.000177	0.0225	-0.18	-0.17	Intelligence (multi-trait analysis);	chr4:158776874	chr4:158700691~158700909:+
LUAD	cis	rs4130344	0.839	rs12171338	ENSG00000271817.2	U3	-3.78	0.000177	0.0225	-0.18	-0.17	Intelligence (multi-trait analysis);	chr4:158777633	chr4:158700691~158700909:+
LUAD	cis	rs2731006	0.64	rs2678135	ENSG00000257114.2	RP11-25I15.3	3.78	0.000177	0.0225	0.27	0.17	Panic disorder;	chr12:42794158	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.64	rs2678136	ENSG00000257114.2	RP11-25I15.3	3.78	0.000177	0.0225	0.27	0.17	Panic disorder;	chr12:42794230	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.592	rs2678137	ENSG00000257114.2	RP11-25I15.3	3.78	0.000177	0.0225	0.27	0.17	Panic disorder;	chr12:42795453	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.64	rs2730968	ENSG00000257114.2	RP11-25I15.3	3.78	0.000177	0.0225	0.27	0.17	Panic disorder;	chr12:42795866	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.592	rs2678144	ENSG00000257114.2	RP11-25I15.3	3.78	0.000177	0.0225	0.27	0.17	Panic disorder;	chr12:42796621	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.64	rs2678143	ENSG00000257114.2	RP11-25I15.3	3.78	0.000177	0.0225	0.27	0.17	Panic disorder;	chr12:42796757	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.64	rs1517667	ENSG00000257114.2	RP11-25I15.3	3.78	0.000177	0.0225	0.27	0.17	Panic disorder;	chr12:42797115	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.64	rs7314719	ENSG00000257114.2	RP11-25I15.3	3.78	0.000177	0.0225	0.27	0.17	Panic disorder;	chr12:42797832	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.64	rs2468322	ENSG00000257114.2	RP11-25I15.3	3.78	0.000177	0.0225	0.27	0.17	Panic disorder;	chr12:42800781	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.64	rs1607249	ENSG00000257114.2	RP11-25I15.3	3.78	0.000177	0.0225	0.27	0.17	Panic disorder;	chr12:42801577	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.64	rs2730980	ENSG00000257114.2	RP11-25I15.3	3.78	0.000177	0.0225	0.27	0.17	Panic disorder;	chr12:42801771	chr12:42692216~42717119:+
LUAD	cis	rs11951515	0.7	rs12519554	ENSG00000249779.1	RP11-447H19.3	3.78	0.000177	0.0225	0.19	0.17	Metabolite levels  (X-11787);	chr5:43283241	chr5:43206709~43207811:+
LUAD	cis	rs703842	1	rs10877012	ENSG00000270039.1	RP11-571M6.17	-3.78	0.000177	0.0225	-0.2	-0.17	Multiple sclerosis;	chr12:57768302	chr12:57803838~57804415:+
LUAD	cis	rs7772486	0.686	rs9497380	ENSG00000235652.6	RP11-545I5.3	3.78	0.000177	0.0225	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145634169	chr6:145799409~145886585:+
LUAD	cis	rs7976269	0.515	rs11049999	ENSG00000257176.2	RP11-996F15.2	-3.78	0.000177	0.0225	-0.18	-0.17	Male-pattern baldness;	chr12:29042854	chr12:29280418~29317848:-
LUAD	cis	rs8064024	0.87	rs930854	ENSG00000267077.1	RP11-127I20.5	3.78	0.000177	0.0225	0.19	0.17	Cancer;	chr16:4814100	chr16:4795265~4796532:-
LUAD	cis	rs116095464	0.558	rs7725227	ENSG00000248925.1	CTD-2083E4.6	3.78	0.000177	0.0225	0.29	0.17	Breast cancer;	chr5:233402	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs7710005	ENSG00000248925.1	CTD-2083E4.6	3.78	0.000177	0.0225	0.29	0.17	Breast cancer;	chr5:233457	chr5:269858~271516:-
LUAD	cis	rs10129255	0.536	rs17113249	ENSG00000253209.1	IGHV3-65	3.78	0.000177	0.0225	0.13	0.17	Kawasaki disease;	chr14:106678273	chr14:106666092~106666532:-
LUAD	cis	rs6121246	0.657	rs74392247	ENSG00000230613.1	HM13-AS1	3.78	0.000177	0.0225	0.28	0.17	Mean corpuscular hemoglobin;	chr20:31653934	chr20:31567707~31573263:-
LUAD	cis	rs10129255	0.5	rs2027902	ENSG00000253209.1	IGHV3-65	3.78	0.000177	0.0226	0.13	0.17	Kawasaki disease;	chr14:106807157	chr14:106666092~106666532:-
LUAD	cis	rs740698	0.522	rs1024653	ENSG00000265702.1	RP11-156L14.1	-3.78	0.000177	0.0226	-0.21	-0.17	Pulse pressure;	chr17:62714457	chr17:62699244~62737922:+
LUAD	cis	rs10946940	0.93	rs10807029	ENSG00000219392.1	RP1-265C24.5	3.78	0.000177	0.0226	0.21	0.17	Systemic lupus erythematosus;	chr6:27605684	chr6:28115628~28116551:+
LUAD	cis	rs4795519	0.778	rs2313068	ENSG00000266313.1	RP11-173M1.4	3.78	0.000177	0.0226	0.22	0.17	Chronic myeloid leukemia;	chr17:27108965	chr17:27333256~27348491:+
LUAD	cis	rs9925964	0.933	rs4889530	ENSG00000232748.3	RP11-196G11.6	3.78	0.000177	0.0226	0.2	0.17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31054597	chr16:31056460~31062803:+
LUAD	cis	rs35851103	0.627	rs6601644	ENSG00000255046.1	RP11-297N6.4	-3.78	0.000177	0.0226	-0.21	-0.17	Neuroticism;	chr8:11989569	chr8:11797928~11802568:-
LUAD	cis	rs910316	0.663	rs175034	ENSG00000279594.1	RP11-950C14.10	-3.78	0.000177	0.0226	-0.19	-0.17	Height;	chr14:74996984	chr14:75011269~75012851:-
LUAD	cis	rs2732480	0.517	rs2634676	ENSG00000273765.1	RP11-370I10.11	3.78	0.000177	0.0226	0.19	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344453	chr12:48360920~48361377:+
LUAD	cis	rs638893	1	rs73005500	ENSG00000255422.1	AP002954.4	3.78	0.000177	0.0226	0.3	0.17	Vitiligo;	chr11:118826666	chr11:118704607~118750263:+
LUAD	cis	rs7976269	0.609	rs10771474	ENSG00000257176.2	RP11-996F15.2	3.78	0.000177	0.0226	0.18	0.17	Male-pattern baldness;	chr12:29068776	chr12:29280418~29317848:-
LUAD	cis	rs12440869	1	rs8038166	ENSG00000270964.1	RP11-502I4.3	-3.78	0.000177	0.0226	-0.19	-0.17	Peak velocity of the mitral A-wave;	chr15:67310676	chr15:67541072~67542604:-
LUAD	cis	rs2836974	0.666	rs2836975	ENSG00000232608.1	TIMM9P2	3.78	0.000177	0.0226	0.2	0.17	Cognitive function;	chr21:39291694	chr21:39216624~39217506:+
LUAD	cis	rs11240074	0.516	rs7525162	ENSG00000244371.2	PFN1P8	-3.78	0.000177	0.0226	-0.27	-0.17	Type 2 diabetes;	chr1:147458508	chr1:146957117~146957659:-
LUAD	cis	rs2408955	0.522	rs3997	ENSG00000257763.1	OR5BK1P	-3.78	0.000177	0.0226	-0.18	-0.17	Glycated hemoglobin levels;	chr12:48087804	chr12:48355792~48356614:-
LUAD	cis	rs1979679	0.573	rs2348417	ENSG00000278733.1	RP11-425D17.1	-3.78	0.000177	0.0226	-0.21	-0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28582663	chr12:28185625~28186190:-
LUAD	cis	rs2147959	0.739	rs11587839	ENSG00000269934.1	RP5-1139B12.3	-3.78	0.000177	0.0226	-0.23	-0.17	Adult asthma;	chr1:228443278	chr1:228274584~228276066:-
LUAD	cis	rs1667255	0.83	rs1667254	ENSG00000264859.4	DSG2-AS1	-3.78	0.000177	0.0226	-0.22	-0.17	Retinol levels;	chr18:31606165	chr18:31542146~31556911:-
LUAD	cis	rs3916	0.91	rs7306541	ENSG00000277423.1	RP11-173P15.9	-3.78	0.000177	0.0226	-0.21	-0.17	Urinary metabolites (H-NMR features);	chr12:120692243	chr12:120703867~120704282:+
LUAD	cis	rs6479901	0.895	rs7902187	ENSG00000232075.1	MRPL35P2	-3.78	0.000177	0.0226	-0.24	-0.17	Intelligence (multi-trait analysis);	chr10:63333375	chr10:63634317~63634827:-
LUAD	cis	rs703842	0.616	rs10877023	ENSG00000270039.1	RP11-571M6.17	-3.78	0.000177	0.0226	-0.2	-0.17	Multiple sclerosis;	chr12:57830416	chr12:57803838~57804415:+
LUAD	cis	rs8180040	0.966	rs57346147	ENSG00000271161.1	BOLA2P2	-3.78	0.000177	0.0226	-0.16	-0.17	Colorectal cancer;	chr3:47369074	chr3:47499841~47500407:+
LUAD	cis	rs6687821	0.605	rs263458	ENSG00000267734.1	RP4-604K5.3	3.78	0.000177	0.0226	0.21	0.17	Yeast infection;	chr1:86774394	chr1:86932199~86934891:-
LUAD	cis	rs9287719	0.837	rs4233882	ENSG00000243819.4	RN7SL832P	3.78	0.000177	0.0226	0.18	0.17	Prostate cancer;	chr2:10615438	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.837	rs4331474	ENSG00000243819.4	RN7SL832P	3.78	0.000177	0.0226	0.18	0.17	Prostate cancer;	chr2:10615457	chr2:10690344~10692099:+
LUAD	cis	rs4819052	0.851	rs28616694	ENSG00000215447.6	BX322557.10	-3.78	0.000177	0.0226	-0.2	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254871	chr21:45288052~45291738:+
LUAD	cis	rs6494488	0.5	rs72741357	ENSG00000239465.1	RP11-330L19.2	3.78	0.000177	0.0226	0.35	0.17	Coronary artery disease;	chr15:64491253	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs116857608	ENSG00000239465.1	RP11-330L19.2	3.78	0.000177	0.0226	0.35	0.17	Coronary artery disease;	chr15:64505969	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs72741373	ENSG00000239465.1	RP11-330L19.2	3.78	0.000177	0.0226	0.35	0.17	Coronary artery disease;	chr15:64508662	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs72741379	ENSG00000239465.1	RP11-330L19.2	3.78	0.000177	0.0226	0.35	0.17	Coronary artery disease;	chr15:64512564	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs72741381	ENSG00000239465.1	RP11-330L19.2	3.78	0.000177	0.0226	0.35	0.17	Coronary artery disease;	chr15:64514362	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs72741385	ENSG00000239465.1	RP11-330L19.2	3.78	0.000177	0.0226	0.35	0.17	Coronary artery disease;	chr15:64517112	chr15:64631109~64631914:-
LUAD	cis	rs6674176	0.597	rs12127737	ENSG00000237950.1	RP11-7O11.3	3.78	0.000177	0.0226	0.21	0.17	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43936893	chr1:43944370~43946551:-
LUAD	cis	rs875971	0.505	rs1167386	ENSG00000273142.1	RP11-458F8.4	3.78	0.000177	0.0226	0.12	0.17	Aortic root size;	chr7:66048109	chr7:66902857~66906297:+
LUAD	cis	rs875971	0.505	rs1167385	ENSG00000273142.1	RP11-458F8.4	3.78	0.000177	0.0226	0.12	0.17	Aortic root size;	chr7:66048321	chr7:66902857~66906297:+
LUAD	cis	rs7512552	0.839	rs12040949	ENSG00000275557.1	RP11-353N4.6	3.78	0.000177	0.0226	0.19	0.17	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150474986	chr1:149607765~149612402:+
LUAD	cis	rs6479901	0.894	rs10761732	ENSG00000232075.1	MRPL35P2	-3.78	0.000177	0.0226	-0.24	-0.17	Intelligence (multi-trait analysis);	chr10:63268497	chr10:63634317~63634827:-
LUAD	cis	rs62025270	0.688	rs56388190	ENSG00000259416.2	RP11-158M2.5	-3.78	0.000177	0.0226	-0.22	-0.17	Idiopathic pulmonary fibrosis;	chr15:85771665	chr15:85754941~85756237:-
LUAD	cis	rs4763879	0.739	rs12582584	ENSG00000278635.1	CTD-2318O12.1	3.78	0.000177	0.0226	0.16	0.17	Type 1 diabetes;	chr12:9671542	chr12:9415641~9416718:+
LUAD	cis	rs6121246	0.909	rs6060870	ENSG00000230613.1	HM13-AS1	3.78	0.000178	0.0226	0.24	0.17	Mean corpuscular hemoglobin;	chr20:31715496	chr20:31567707~31573263:-
LUAD	cis	rs2154319	0.887	rs9439035	ENSG00000235358.1	RP11-399E6.1	3.78	0.000178	0.0226	0.23	0.17	Height;	chr1:41074593	chr1:41242373~41284861:+
LUAD	cis	rs2154319	0.673	rs2011981	ENSG00000235358.1	RP11-399E6.1	3.78	0.000178	0.0226	0.23	0.17	Height;	chr1:41075181	chr1:41242373~41284861:+
LUAD	cis	rs2154319	0.673	rs2011982	ENSG00000235358.1	RP11-399E6.1	3.78	0.000178	0.0226	0.23	0.17	Height;	chr1:41075189	chr1:41242373~41284861:+
LUAD	cis	rs2154319	0.836	rs2749419	ENSG00000235358.1	RP11-399E6.1	3.78	0.000178	0.0226	0.23	0.17	Height;	chr1:41085769	chr1:41242373~41284861:+
LUAD	cis	rs2154319	0.836	rs6674290	ENSG00000235358.1	RP11-399E6.1	3.78	0.000178	0.0226	0.23	0.17	Height;	chr1:41095560	chr1:41242373~41284861:+
LUAD	cis	rs2154319	0.887	rs2024860	ENSG00000235358.1	RP11-399E6.1	3.78	0.000178	0.0226	0.23	0.17	Height;	chr1:41096571	chr1:41242373~41284861:+
LUAD	cis	rs2154319	0.887	rs2024859	ENSG00000235358.1	RP11-399E6.1	3.78	0.000178	0.0226	0.23	0.17	Height;	chr1:41096613	chr1:41242373~41284861:+
LUAD	cis	rs6088580	0.634	rs6059866	ENSG00000276073.1	RP5-1125A11.7	-3.78	0.000178	0.0226	-0.17	-0.17	Glomerular filtration rate (creatinine);	chr20:34488005	chr20:33985617~33988989:-
LUAD	cis	rs12449964	0.515	rs7225141	ENSG00000223979.2	SMCR2	3.78	0.000178	0.0226	0.2	0.17	Coronary artery disease or ischemic stroke;	chr17:17667513	chr17:17674026~17677688:-
LUAD	cis	rs11651753	0.805	rs55822955	ENSG00000264920.1	RP11-6N17.4	-3.78	0.000178	0.0226	-0.19	-0.17	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47884447	chr17:47891255~47895812:-
LUAD	cis	rs7005380	0.581	rs9987139	ENSG00000279347.1	RP11-85I17.2	3.78	0.000178	0.0226	0.16	0.17	Interstitial lung disease;	chr8:119924619	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.581	rs9987135	ENSG00000279347.1	RP11-85I17.2	3.78	0.000178	0.0226	0.16	0.17	Interstitial lung disease;	chr8:119924655	chr8:119838736~119840385:-
LUAD	cis	rs7560272	0.723	rs1083919	ENSG00000163016.8	ALMS1P	-3.78	0.000178	0.0226	-0.18	-0.17	Schizophrenia;	chr2:73486736	chr2:73644919~73685576:+
LUAD	cis	rs683250	0.629	rs682713	ENSG00000246067.6	RAB30-AS1	-3.78	0.000178	0.0226	-0.18	-0.17	Subcortical brain region volumes;	chr11:83223343	chr11:83072066~83106719:+
LUAD	cis	rs8031584	0.678	rs798086	ENSG00000260128.5	ULK4P2	3.78	0.000178	0.0226	0.23	0.17	Huntington's disease progression;	chr15:30837008	chr15:30572738~30600647:+
LUAD	cis	rs710913	0.618	rs12030495	ENSG00000237624.1	OXCT2P1	3.78	0.000178	0.0226	0.22	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39623923	chr1:39514956~39516490:+
LUAD	cis	rs9652601	0.719	rs2867880	ENSG00000274038.1	RP11-66H6.4	-3.78	0.000178	0.0226	-0.21	-0.17	Systemic lupus erythematosus;	chr16:11138000	chr16:11056556~11057034:+
LUAD	cis	rs159572	0.784	rs161213	ENSG00000250853.1	RNF138P1	3.78	0.000178	0.0226	0.2	0.17	Post-traumatic stress disorder;	chr5:56236124	chr5:55530156~55530701:-
LUAD	cis	rs394563	0.591	rs237018	ENSG00000216906.2	RP11-350J20.9	3.78	0.000178	0.0226	0.2	0.17	Dupuytren's disease;	chr6:149422794	chr6:149904243~149906418:+
LUAD	cis	rs73108077	1	rs73116233	ENSG00000281376.1	ABALON	-3.78	0.000178	0.0226	-0.29	-0.17	Red blood cell density in sickle cell anemia;	chr20:31448538	chr20:31721507~31723409:+
LUAD	cis	rs73108077	1	rs73116235	ENSG00000281376.1	ABALON	-3.78	0.000178	0.0226	-0.29	-0.17	Red blood cell density in sickle cell anemia;	chr20:31449052	chr20:31721507~31723409:+
LUAD	cis	rs73108077	1	rs75231340	ENSG00000281376.1	ABALON	-3.78	0.000178	0.0226	-0.29	-0.17	Red blood cell density in sickle cell anemia;	chr20:31449114	chr20:31721507~31723409:+
LUAD	cis	rs73108077	0.92	rs45520534	ENSG00000281376.1	ABALON	-3.78	0.000178	0.0226	-0.29	-0.17	Red blood cell density in sickle cell anemia;	chr20:31450235	chr20:31721507~31723409:+
LUAD	cis	rs818427	0.963	rs153545	ENSG00000279522.1	CTC-487M23.6	3.78	0.000178	0.0226	0.21	0.17	Total body bone mineral density;	chr5:112903185	chr5:112894933~112896531:+
LUAD	cis	rs6498169	0.932	rs171593	ENSG00000274038.1	RP11-66H6.4	3.78	0.000178	0.0226	0.21	0.17	Multiple sclerosis;	chr16:11154514	chr16:11056556~11057034:+
LUAD	cis	rs6467136	0.56	rs10435404	ENSG00000224138.1	AC000123.4	3.78	0.000178	0.0226	0.16	0.17	Type 2 diabetes;	chr7:127450498	chr7:127350128~127351523:+
LUAD	cis	rs7829975	0.557	rs7816427	ENSG00000253893.2	FAM85B	3.78	0.000178	0.0226	0.21	0.17	Mood instability;	chr8:8688374	chr8:8167819~8226614:-
LUAD	cis	rs7200543	1	rs34614532	ENSG00000260735.1	RP11-72I8.1	-3.78	0.000178	0.0226	-0.19	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15039051	chr16:15094411~15109197:+
LUAD	cis	rs567508	0.534	rs515271	ENSG00000254905.1	RP11-712L6.7	-3.78	0.000178	0.0226	-0.28	-0.17	Lung function (FEV1);	chr11:126157041	chr11:126292922~126294254:-
LUAD	cis	rs1007190	0.881	rs3744470	ENSG00000267505.1	CTC-296K1.3	3.78	0.000178	0.0226	0.29	0.17	DNA methylation (variation);	chr17:44906533	chr17:44793199~44794474:+
LUAD	cis	rs7119	0.604	rs2682924	ENSG00000259362.2	RP11-307C19.1	-3.78	0.000178	0.0226	-0.21	-0.17	Type 2 diabetes;	chr15:77571378	chr15:77525540~77534110:+
LUAD	cis	rs67478160	0.644	rs7159810	ENSG00000272533.1	SNORA28	3.78	0.000178	0.0226	0.18	0.17	Schizophrenia;	chr14:103827780	chr14:103337849~103337974:+
LUAD	cis	rs2274273	0.84	rs10467798	ENSG00000259318.1	RP11-454L9.2	3.78	0.000178	0.0227	0.15	0.17	Protein biomarker;	chr14:55258209	chr14:55394940~55395233:-
LUAD	cis	rs2274273	0.934	rs2341621	ENSG00000259318.1	RP11-454L9.2	3.78	0.000178	0.0227	0.15	0.17	Protein biomarker;	chr14:55259707	chr14:55394940~55395233:-
LUAD	cis	rs638893	0.617	rs2156750	ENSG00000255422.1	AP002954.4	-3.78	0.000178	0.0227	-0.23	-0.17	Vitiligo;	chr11:118848545	chr11:118704607~118750263:+
LUAD	cis	rs638893	0.561	rs2156749	ENSG00000255422.1	AP002954.4	-3.78	0.000178	0.0227	-0.23	-0.17	Vitiligo;	chr11:118848696	chr11:118704607~118750263:+
LUAD	cis	rs34929064	1	rs6969856	ENSG00000230658.1	KLHL7-AS1	3.78	0.000178	0.0227	0.23	0.17	Major depression and alcohol dependence;	chr7:22682918	chr7:23101228~23105703:-
LUAD	cis	rs7584330	0.638	rs13429533	ENSG00000222032.1	AC112721.2	3.78	0.000178	0.0227	0.19	0.17	Prostate cancer;	chr2:237540069	chr2:237428920~237434822:-
LUAD	cis	rs1542829	0.516	rs2132826	ENSG00000253540.4	FAM86HP	3.78	0.000178	0.0227	0.21	0.17	Body mass index;	chr3:130396508	chr3:130099092~130111472:-
LUAD	cis	rs4295623	0.585	rs34421088	ENSG00000255046.1	RP11-297N6.4	3.78	0.000178	0.0227	0.21	0.17	Morning vs. evening chronotype;	chr8:11731533	chr8:11797928~11802568:-
LUAD	cis	rs7618501	0.519	rs3774750	ENSG00000280382.1	RP11-804H8.7	3.78	0.000178	0.0227	0.19	0.17	Intelligence (multi-trait analysis);	chr3:50170973	chr3:50599879~50601148:-
LUAD	cis	rs875971	0.516	rs6945322	ENSG00000222364.1	RNU6-96P	-3.78	0.000178	0.0227	-0.19	-0.17	Aortic root size;	chr7:65871069	chr7:66395191~66395286:+
LUAD	cis	rs17711722	0.701	rs55773927	ENSG00000222364.1	RNU6-96P	-3.78	0.000178	0.0227	-0.19	-0.17	Calcium levels;	chr7:65872915	chr7:66395191~66395286:+
LUAD	cis	rs17711722	0.727	rs35850374	ENSG00000222364.1	RNU6-96P	-3.78	0.000178	0.0227	-0.19	-0.17	Calcium levels;	chr7:65892789	chr7:66395191~66395286:+
LUAD	cis	rs7100689	0.646	rs7092237	ENSG00000226659.1	RP11-137H2.4	-3.78	0.000178	0.0227	-0.23	-0.17	Post bronchodilator FEV1;	chr10:80405884	chr10:80529597~80535942:-
LUAD	cis	rs9287719	0.901	rs55861579	ENSG00000243819.4	RN7SL832P	3.78	0.000178	0.0227	0.18	0.17	Prostate cancer;	chr2:10623214	chr2:10690344~10692099:+
LUAD	cis	rs755249	0.761	rs61781390	ENSG00000182109.6	RP11-69E11.4	3.78	0.000178	0.0227	0.22	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39610222	chr1:39522280~39546187:-
LUAD	cis	rs1056107	0.831	rs7856158	ENSG00000225513.1	RP11-165N19.2	3.78	0.000178	0.0227	0.18	0.17	Colorectal cancer;	chr9:112188892	chr9:112173522~112173971:-
LUAD	cis	rs2836974	0.965	rs6517538	ENSG00000232608.1	TIMM9P2	-3.78	0.000178	0.0227	-0.2	-0.17	Cognitive function;	chr21:39284316	chr21:39216624~39217506:+
LUAD	cis	rs786425	0.932	rs786443	ENSG00000278112.1	RP11-972P1.11	-3.78	0.000178	0.0227	-0.15	-0.17	Pubertal anthropometrics;	chr12:123579344	chr12:123519390~123519856:-
LUAD	cis	rs12440869	1	rs2289788	ENSG00000270964.1	RP11-502I4.3	3.78	0.000178	0.0227	0.19	0.17	Peak velocity of the mitral A-wave;	chr15:67240036	chr15:67541072~67542604:-
LUAD	cis	rs703842	1	rs2069502	ENSG00000245651.2	RP11-620J15.2	-3.78	0.000178	0.0227	-0.18	-0.17	Multiple sclerosis;	chr12:57750882	chr12:57869835~57896482:-
LUAD	cis	rs4474465	0.85	rs10899538	ENSG00000251323.2	RP11-452H21.4	-3.78	0.000178	0.0227	-0.21	-0.17	Alzheimer's disease (survival time);	chr11:78526703	chr11:78423982~78429836:-
LUAD	cis	rs6840360	0.573	rs4696250	ENSG00000270265.1	RP11-731D1.4	-3.78	0.000178	0.0227	-0.18	-0.17	Intelligence (multi-trait analysis);	chr4:151345169	chr4:151333775~151353224:-
LUAD	cis	rs12440869	1	rs8031586	ENSG00000270964.1	RP11-502I4.3	-3.78	0.000178	0.0227	-0.2	-0.17	Peak velocity of the mitral A-wave;	chr15:67328315	chr15:67541072~67542604:-
LUAD	cis	rs12440869	0.959	rs4374116	ENSG00000270964.1	RP11-502I4.3	-3.78	0.000178	0.0227	-0.2	-0.17	Peak velocity of the mitral A-wave;	chr15:67330799	chr15:67541072~67542604:-
LUAD	cis	rs801193	0.935	rs2659916	ENSG00000222364.1	RNU6-96P	-3.78	0.000178	0.0227	-0.19	-0.17	Aortic root size;	chr7:66686365	chr7:66395191~66395286:+
LUAD	cis	rs801193	1	rs6958520	ENSG00000222364.1	RNU6-96P	-3.78	0.000178	0.0227	-0.19	-0.17	Aortic root size;	chr7:66686466	chr7:66395191~66395286:+
LUAD	cis	rs801193	0.967	rs2707849	ENSG00000222364.1	RNU6-96P	-3.78	0.000178	0.0227	-0.19	-0.17	Aortic root size;	chr7:66687725	chr7:66395191~66395286:+
LUAD	cis	rs801193	1	rs7788576	ENSG00000222364.1	RNU6-96P	3.78	0.000178	0.0227	0.19	0.17	Aortic root size;	chr7:66683315	chr7:66395191~66395286:+
LUAD	cis	rs950169	0.545	rs4354897	ENSG00000259570.1	RP11-671M22.4	3.78	0.000178	0.0227	0.25	0.17	Schizophrenia;	chr15:83976219	chr15:84394512~84395514:+
LUAD	cis	rs7772486	0.686	rs2092263	ENSG00000235652.6	RP11-545I5.3	-3.78	0.000178	0.0227	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145708551	chr6:145799409~145886585:+
LUAD	cis	rs6467136	0.582	rs10954157	ENSG00000224138.1	AC000123.4	3.78	0.000178	0.0227	0.16	0.17	Type 2 diabetes;	chr7:127464180	chr7:127350128~127351523:+
LUAD	cis	rs7107174	1	rs2511182	ENSG00000251323.2	RP11-452H21.4	3.78	0.000178	0.0227	0.23	0.17	Testicular germ cell tumor;	chr11:78271084	chr11:78423982~78429836:-
LUAD	cis	rs2662776	0.967	rs10753606	ENSG00000232995.6	RGS5	3.78	0.000178	0.0227	0.15	0.17	Lead levels in blood;	chr1:163186734	chr1:163244505~163321894:-
LUAD	cis	rs9549260	0.564	rs6563844	ENSG00000168852.11	TPTE2P5	3.78	0.000178	0.0227	0.17	0.17	Red blood cell count;	chr13:40724054	chr13:40822296~40921749:-
LUAD	cis	rs523522	1	rs1563333	ENSG00000278344.1	RP11-18C24.8	3.78	0.000178	0.0227	0.23	0.17	High light scatter reticulocyte count;	chr12:120496604	chr12:120500735~120501090:-
LUAD	cis	rs8073060	0.586	rs225307	ENSG00000267592.1	CTC-507E2.2	-3.78	0.000178	0.0227	-0.24	-0.17	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35591292	chr17:35596904~35597128:-
LUAD	cis	rs2562784	0.597	rs2562785	ENSG00000259728.4	LINC00933	3.78	0.000178	0.0227	0.29	0.17	Height;	chr15:83617269	chr15:84570649~84580175:+
LUAD	cis	rs7246967	0.611	rs62118770	ENSG00000236312.3	RPL34P34	3.78	0.000178	0.0227	0.25	0.17	Bronchopulmonary dysplasia;	chr19:22641227	chr19:22368599~22368952:-
LUAD	cis	rs7246967	0.611	rs62118771	ENSG00000236312.3	RPL34P34	3.78	0.000178	0.0227	0.25	0.17	Bronchopulmonary dysplasia;	chr19:22641496	chr19:22368599~22368952:-
LUAD	cis	rs7636293	0.592	rs6439167	ENSG00000270773.1	RP13-685P2.7	-3.78	0.000178	0.0227	-0.24	-0.17	Height;	chr3:129331913	chr3:129345411~129346164:+
LUAD	cis	rs7100689	0.599	rs7077847	ENSG00000226659.1	RP11-137H2.4	-3.78	0.000179	0.0227	-0.24	-0.17	Post bronchodilator FEV1;	chr10:80375196	chr10:80529597~80535942:-
LUAD	cis	rs7100689	0.622	rs7082093	ENSG00000226659.1	RP11-137H2.4	-3.78	0.000179	0.0227	-0.24	-0.17	Post bronchodilator FEV1;	chr10:80375198	chr10:80529597~80535942:-
LUAD	cis	rs76878669	0.561	rs1039594	ENSG00000213409.4	RP11-658F2.3	3.78	0.000179	0.0227	0.2	0.17	Educational attainment (years of education);	chr11:66363678	chr11:66761575~66762399:-
LUAD	cis	rs7017914	0.902	rs34856835	ENSG00000246366.5	RP11-382J12.1	3.78	0.000179	0.0227	0.16	0.17	Bone mineral density;	chr8:71058376	chr8:70608577~70663279:+
LUAD	cis	rs5742933	0.817	rs6738042	ENSG00000253559.1	OSGEPL1-AS1	3.78	0.000179	0.0227	0.21	0.17	Ferritin levels;	chr2:189776958	chr2:189762704~189765556:+
LUAD	cis	rs7107174	1	rs7116698	ENSG00000251323.2	RP11-452H21.4	3.78	0.000179	0.0227	0.23	0.17	Testicular germ cell tumor;	chr11:78284145	chr11:78423982~78429836:-
LUAD	cis	rs8002861	0.87	rs2875541	ENSG00000274001.1	RP11-5G9.5	3.78	0.000179	0.0227	0.18	0.17	Leprosy;	chr13:43843305	chr13:43877715~43878163:-
LUAD	cis	rs6687758	1	rs12125368	ENSG00000238042.4	RP11-815M8.1	3.78	0.000179	0.0227	0.24	0.17	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222025330	chr1:221880981~221978523:-
LUAD	cis	rs13113518	0.812	rs12648271	ENSG00000273257.1	RP11-177J6.1	3.78	0.000179	0.0227	0.2	0.17	Height;	chr4:55501955	chr4:55387949~55388271:+
LUAD	cis	rs7017914	0.934	rs10504479	ENSG00000246366.5	RP11-382J12.1	3.78	0.000179	0.0227	0.16	0.17	Bone mineral density;	chr8:70665280	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.934	rs35109143	ENSG00000246366.5	RP11-382J12.1	3.78	0.000179	0.0227	0.16	0.17	Bone mineral density;	chr8:70665665	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.902	rs13269513	ENSG00000246366.5	RP11-382J12.1	3.78	0.000179	0.0227	0.16	0.17	Bone mineral density;	chr8:70665844	chr8:70608577~70663279:+
LUAD	cis	rs9341808	0.538	rs667097	ENSG00000260645.1	RP11-250B2.5	-3.78	0.000179	0.0227	-0.17	-0.17	Sitting height ratio;	chr6:80269226	chr6:80466958~80469080:+
LUAD	cis	rs7302981	0.746	rs646782	ENSG00000272368.2	RP4-605O3.4	3.78	0.000179	0.0227	0.19	0.17	Systolic blood pressure;	chr12:50088428	chr12:50112197~50165618:+
LUAD	cis	rs73198271	0.74	rs3827807	ENSG00000233609.3	RP11-62H7.2	-3.78	0.000179	0.0227	-0.14	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8821875	chr8:8961200~8979025:+
LUAD	cis	rs6095360	1	rs34984028	ENSG00000222365.1	SNORD12B	-3.78	0.000179	0.0227	-0.17	-0.17	Intelligence (multi-trait analysis);	chr20:48932510	chr20:49280319~49280409:+
LUAD	cis	rs7660883	0.897	rs342466	ENSG00000251411.1	RP11-397E7.4	-3.78	0.000179	0.0227	-0.18	-0.17	HDL cholesterol levels;	chr4:87131933	chr4:86913266~86914817:-
LUAD	cis	rs10946940	0.965	rs6456799	ENSG00000219392.1	RP1-265C24.5	3.78	0.000179	0.0227	0.21	0.17	Systemic lupus erythematosus;	chr6:27605757	chr6:28115628~28116551:+
LUAD	cis	rs6736093	0.7	rs4848958	ENSG00000207383.1	Y_RNA	-3.78	0.000179	0.0227	-0.22	-0.17	Coronary artery disease;	chr2:112028198	chr2:112579484~112579584:-
LUAD	cis	rs28386778	0.897	rs6504177	ENSG00000240280.5	TCAM1P	-3.78	0.000179	0.0227	-0.19	-0.17	Prudent dietary pattern;	chr17:63735295	chr17:63849292~63864379:+
LUAD	cis	rs12440869	1	rs12440869	ENSG00000270964.1	RP11-502I4.3	-3.78	0.000179	0.0227	-0.19	-0.17	Peak velocity of the mitral A-wave;	chr15:67318613	chr15:67541072~67542604:-
LUAD	cis	rs937213	0.676	rs2412456	ENSG00000275636.1	RP11-521C20.5	3.78	0.000179	0.0228	0.22	0.17	Endometrial cancer;Endometrial endometrioid carcinoma;	chr15:39997826	chr15:40078892~40079347:+
LUAD	cis	rs8067545	0.641	rs860335	ENSG00000270091.1	RP11-78O7.2	-3.78	0.000179	0.0228	-0.14	-0.17	Schizophrenia;	chr17:19934366	chr17:19896590~19897287:-
LUAD	cis	rs8031584	0.678	rs4779790	ENSG00000260128.5	ULK4P2	-3.78	0.000179	0.0228	-0.22	-0.17	Huntington's disease progression;	chr15:30872392	chr15:30572738~30600647:+
LUAD	cis	rs795484	0.683	rs514826	ENSG00000275409.1	RP11-131L12.4	3.78	0.000179	0.0228	0.18	0.17	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118371498	chr12:118430147~118430699:+
LUAD	cis	rs78572108	0.858	rs4952588	ENSG00000214691.7	AC104654.1	3.78	0.000179	0.0228	0.28	0.17	Total body bone mineral density;	chr2:42044683	chr2:41877074~41894046:+
LUAD	cis	rs7208859	0.623	rs609063	ENSG00000280069.1	CTD-2349P21.3	-3.78	0.000179	0.0228	-0.24	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs383436	ENSG00000280069.1	CTD-2349P21.3	-3.78	0.000179	0.0228	-0.24	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30632161	chr17:30738182~30740275:+
LUAD	cis	rs2731006	0.901	rs2678118	ENSG00000257114.2	RP11-25I15.3	3.78	0.000179	0.0228	0.26	0.17	Panic disorder;	chr12:42764365	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.901	rs2678116	ENSG00000257114.2	RP11-25I15.3	3.78	0.000179	0.0228	0.26	0.17	Panic disorder;	chr12:42764824	chr12:42692216~42717119:+
LUAD	cis	rs6502050	0.835	rs34960918	ENSG00000275966.1	RP11-1055B8.9	-3.78	0.000179	0.0228	-0.18	-0.17	Life satisfaction;	chr17:82156049	chr17:81345476~81345966:-
LUAD	cis	rs875971	0.545	rs1267814	ENSG00000224316.1	RP11-479O9.2	-3.78	0.000179	0.0228	-0.19	-0.17	Aortic root size;	chr7:66579422	chr7:65773620~65802067:+
LUAD	cis	rs910316	0.934	rs8006587	ENSG00000279594.1	RP11-950C14.10	3.78	0.000179	0.0228	0.19	0.17	Height;	chr14:75198236	chr14:75011269~75012851:-
LUAD	cis	rs17711722	0.503	rs453835	ENSG00000273024.4	INTS4P2	3.78	0.000179	0.0228	0.18	0.17	Calcium levels;	chr7:66046172	chr7:65647864~65715661:+
LUAD	cis	rs2905347	0.656	rs2051723	ENSG00000232949.1	AC002480.4	-3.78	0.000179	0.0228	-0.21	-0.17	Major depression and alcohol dependence;	chr7:22626224	chr7:22589705~22591622:+
LUAD	cis	rs8141529	0.732	rs11556025	ENSG00000272858.1	CTA-292E10.8	-3.78	0.000179	0.0228	-0.19	-0.17	Lymphocyte counts;	chr22:28772767	chr22:28814914~28815662:+
LUAD	cis	rs6502050	0.637	rs74765203	ENSG00000275966.1	RP11-1055B8.9	-3.78	0.000179	0.0228	-0.17	-0.17	Life satisfaction;	chr17:82160347	chr17:81345476~81345966:-
LUAD	cis	rs2554380	0.55	rs62025825	ENSG00000259570.1	RP11-671M22.4	-3.78	0.000179	0.0228	-0.22	-0.17	Height;	chr15:83872285	chr15:84394512~84395514:+
LUAD	cis	rs17189298	0.842	rs10193777	ENSG00000231013.1	AC013275.2	3.78	0.000179	0.0228	0.17	0.17	Cerebrospinal T-tau levels;	chr2:119093509	chr2:119476448~119487346:+
LUAD	cis	rs4489787	1	rs2705154	ENSG00000240399.1	RP1-228P16.1	3.78	0.000179	0.0228	0.26	0.17	Prostate cancer (SNP x SNP interaction);	chr12:48514010	chr12:48054813~48055591:-
LUAD	cis	rs3783637	0.5	rs17128077	ENSG00000259318.1	RP11-454L9.2	3.78	0.000179	0.0228	0.19	0.17	Rheumatoid arthritis;Obesity-related traits;	chr14:54919316	chr14:55394940~55395233:-
LUAD	cis	rs957448	0.561	rs12679785	ENSG00000253175.1	RP11-267M23.6	3.78	0.000179	0.0228	0.19	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94593349	chr8:94565036~94565715:+
LUAD	cis	rs957448	0.529	rs9642928	ENSG00000253175.1	RP11-267M23.6	3.78	0.000179	0.0228	0.19	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94601698	chr8:94565036~94565715:+
LUAD	cis	rs7829975	0.688	rs13270194	ENSG00000233609.3	RP11-62H7.2	3.78	0.000179	0.0228	0.14	0.17	Mood instability;	chr8:8520592	chr8:8961200~8979025:+
LUAD	cis	rs7260598	0.605	rs67492250	ENSG00000269421.1	ZNF92P3	-3.78	0.000179	0.0228	-0.26	-0.17	Response to taxane treatment (placlitaxel);	chr19:23924293	chr19:23935220~23936173:+
LUAD	cis	rs8031584	0.679	rs34017474	ENSG00000259845.1	HERC2P10	3.78	0.000179	0.0228	0.18	0.17	Huntington's disease progression;	chr15:30938408	chr15:30815271~30844153:+
LUAD	cis	rs10492201	0.529	rs11177004	ENSG00000255733.4	IFNG-AS1	-3.78	0.000179	0.0228	-0.18	-0.17	Itch intensity from mosquito bite adjusted by bite size;	chr12:68015229	chr12:67989445~68234686:+
LUAD	cis	rs2408955	0.501	rs8716	ENSG00000257763.1	OR5BK1P	3.78	0.000179	0.0228	0.17	0.17	Glycated hemoglobin levels;	chr12:48145699	chr12:48355792~48356614:-
LUAD	cis	rs6957923	0.655	rs10232644	ENSG00000234286.1	AC006026.13	-3.78	0.000179	0.0228	-0.22	-0.17	Height;	chr7:23552301	chr7:23680195~23680786:-
LUAD	cis	rs17685	0.672	rs6465011	ENSG00000280388.1	RP11-229D13.3	-3.78	0.000179	0.0228	-0.16	-0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76181979	chr7:76043977~76045963:-
LUAD	cis	rs755249	0.509	rs11206378	ENSG00000182109.6	RP11-69E11.4	-3.78	0.000179	0.0228	-0.18	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39583512	chr1:39522280~39546187:-
LUAD	cis	rs7138803	0.562	rs7978693	ENSG00000257464.1	RP11-161H23.8	-3.78	0.000179	0.0228	-0.18	-0.17	Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index;	chr12:49803725	chr12:49442424~49442652:-
LUAD	cis	rs1383484	0.64	rs12101685	ENSG00000259728.4	LINC00933	-3.78	0.000179	0.0228	-0.22	-0.17	Height;	chr15:83974905	chr15:84570649~84580175:+
LUAD	cis	rs5758659	0.714	rs5758574	ENSG00000273366.1	CTA-989H11.1	3.78	0.000179	0.0228	0.19	0.17	Cognitive function;	chr22:42085396	chr22:42278188~42278846:+
LUAD	cis	rs6438234	0.778	rs9846688	ENSG00000242767.1	ZBTB20-AS4	3.78	0.000179	0.0228	0.22	0.17	Type 2 diabetes;	chr3:115234118	chr3:115100423~115103061:+
LUAD	cis	rs10129255	0.536	rs17113249	ENSG00000274576.2	IGHV2-70	-3.78	0.000179	0.0228	-0.14	-0.17	Kawasaki disease;	chr14:106678273	chr14:106770577~106771020:-
LUAD	cis	rs7809950	0.784	rs7803102	ENSG00000238832.1	snoU109	3.78	0.000179	0.0228	0.25	0.17	Coronary artery disease;	chr7:107608484	chr7:107603363~107603507:+
LUAD	cis	rs7618915	0.547	rs2268026	ENSG00000243224.1	RP5-1157M23.2	-3.78	0.000179	0.0228	-0.17	-0.17	Bipolar disorder;	chr3:52744331	chr3:52239258~52241097:+
LUAD	cis	rs1322639	0.614	rs9294967	ENSG00000261039.2	RP11-417E7.2	3.78	0.00018	0.0228	0.28	0.17	Pulse pressure;	chr6:169165311	chr6:169175304~169182740:-
LUAD	cis	rs6540731	0.967	rs4951581	ENSG00000229983.1	RP11-15I11.2	3.78	0.00018	0.0228	0.21	0.17	Intelligence (childhood);	chr1:212228770	chr1:212168207~212190259:+
LUAD	cis	rs2625529	0.652	rs2034879	ENSG00000260173.1	RP11-2I17.4	-3.78	0.00018	0.0228	-0.2	-0.17	Red blood cell count;	chr15:72137648	chr15:72140504~72155459:-
LUAD	cis	rs11048434	0.518	rs7136274	ENSG00000256937.1	KRT17P8	3.78	0.00018	0.0228	0.18	0.17	Sjögren's syndrome;	chr12:9022360	chr12:9127783~9128645:+
LUAD	cis	rs9341808	0.519	rs3805878	ENSG00000260645.1	RP11-250B2.5	3.78	0.00018	0.0228	0.16	0.17	Sitting height ratio;	chr6:80304138	chr6:80466958~80469080:+
LUAD	cis	rs7208859	0.673	rs28588622	ENSG00000266490.1	CTD-2349P21.9	3.78	0.00018	0.0228	0.26	0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30918681	chr17:30792372~30792833:+
LUAD	cis	rs6001482	0.507	rs62234784	ENSG00000223350.2	IGLV9-49	-3.78	0.00018	0.0228	-0.2	-0.17	Diastolic blood pressure;	chr22:22234610	chr22:22343187~22343732:+
LUAD	cis	rs12908161	1	rs36033486	ENSG00000254414.1	RP11-182J1.1	3.78	0.00018	0.0228	0.22	0.17	Schizophrenia;	chr15:84776461	chr15:84631898~84633987:-
LUAD	cis	rs12908161	1	rs12908549	ENSG00000254414.1	RP11-182J1.1	3.78	0.00018	0.0228	0.22	0.17	Schizophrenia;	chr15:84779120	chr15:84631898~84633987:-
LUAD	cis	rs2274273	0.87	rs10139000	ENSG00000259318.1	RP11-454L9.2	3.78	0.00018	0.0228	0.15	0.17	Protein biomarker;	chr14:55383158	chr14:55394940~55395233:-
LUAD	cis	rs10090774	0.71	rs13262271	ENSG00000280303.2	ERICD	-3.78	0.00018	0.0228	-0.19	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140677795	chr8:140636281~140638283:+
LUAD	cis	rs56875752	1	rs72811277	ENSG00000263648.1	RP11-471L13.3	3.78	0.00018	0.0228	0.35	0.17	Fear of pain;Fear of severe pain;	chr17:12691758	chr17:12115547~12115885:+
LUAD	cis	rs9925964	0.967	rs2032915	ENSG00000232748.3	RP11-196G11.6	3.78	0.00018	0.0228	0.21	0.17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31106092	chr16:31056460~31062803:+
LUAD	cis	rs67981189	0.896	rs4132849	ENSG00000269927.1	RP6-91H8.3	3.78	0.00018	0.0228	0.21	0.17	Schizophrenia;	chr14:70992806	chr14:71141125~71143253:-
LUAD	cis	rs67981189	0.821	rs56021283	ENSG00000269927.1	RP6-91H8.3	3.78	0.00018	0.0228	0.21	0.17	Schizophrenia;	chr14:70996042	chr14:71141125~71143253:-
LUAD	cis	rs9532580	0.614	rs61963261	ENSG00000215483.7	LINC00598	-3.78	0.00018	0.0228	-0.26	-0.17	Mean corpuscular hemoglobin;	chr13:40568158	chr13:40450934~40535807:-
LUAD	cis	rs1023500	0.551	rs133371	ENSG00000273366.1	CTA-989H11.1	-3.78	0.00018	0.0228	-0.2	-0.17	Schizophrenia;	chr22:42069570	chr22:42278188~42278846:+
LUAD	cis	rs1023500	0.573	rs133374	ENSG00000273366.1	CTA-989H11.1	-3.78	0.00018	0.0228	-0.2	-0.17	Schizophrenia;	chr22:42069937	chr22:42278188~42278846:+
LUAD	cis	rs8073060	0.963	rs11080354	ENSG00000267592.1	CTC-507E2.2	3.78	0.00018	0.0228	0.21	0.17	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35545388	chr17:35596904~35597128:-
LUAD	cis	rs10461617	0.541	rs860581	ENSG00000271828.1	CTD-2310F14.1	3.78	0.00018	0.0228	0.28	0.17	Type 2 diabetes;	chr5:56854710	chr5:56927874~56929573:+
LUAD	cis	rs34779708	0.966	rs12775548	ENSG00000271335.4	RP11-324I22.4	3.78	0.00018	0.0229	0.18	0.17	Inflammatory bowel disease;Crohn's disease;	chr10:35190576	chr10:35314552~35336401:-
LUAD	cis	rs9291683	0.609	rs55959894	ENSG00000250413.1	RP11-448G15.1	-3.78	0.00018	0.0229	-0.22	-0.17	Bone mineral density;	chr4:10024956	chr4:10006482~10009725:+
LUAD	cis	rs8031584	0.958	rs61997079	ENSG00000260128.5	ULK4P2	-3.78	0.00018	0.0229	-0.22	-0.17	Huntington's disease progression;	chr15:30946068	chr15:30572738~30600647:+
LUAD	cis	rs8031584	0.958	rs11637469	ENSG00000260128.5	ULK4P2	-3.78	0.00018	0.0229	-0.22	-0.17	Huntington's disease progression;	chr15:30946580	chr15:30572738~30600647:+
LUAD	cis	rs6494488	0.5	rs72758946	ENSG00000239465.1	RP11-330L19.2	3.78	0.00018	0.0229	0.36	0.17	Coronary artery disease;	chr15:64387164	chr15:64631109~64631914:-
LUAD	cis	rs2274273	0.87	rs1109170	ENSG00000258413.1	RP11-665C16.6	-3.78	0.00018	0.0229	-0.22	-0.17	Protein biomarker;	chr14:55319070	chr14:55262767~55272075:-
LUAD	cis	rs2274273	0.837	rs10141483	ENSG00000258413.1	RP11-665C16.6	-3.78	0.00018	0.0229	-0.22	-0.17	Protein biomarker;	chr14:55320153	chr14:55262767~55272075:-
LUAD	cis	rs2274273	0.837	rs10131913	ENSG00000258413.1	RP11-665C16.6	-3.78	0.00018	0.0229	-0.22	-0.17	Protein biomarker;	chr14:55320702	chr14:55262767~55272075:-
LUAD	cis	rs2732480	0.577	rs2732481	ENSG00000273765.1	RP11-370I10.11	3.78	0.00018	0.0229	0.19	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343202	chr12:48360920~48361377:+
LUAD	cis	rs2732480	0.557	rs2732484	ENSG00000273765.1	RP11-370I10.11	3.78	0.00018	0.0229	0.19	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343462	chr12:48360920~48361377:+
LUAD	cis	rs638893	1	rs113641235	ENSG00000255422.1	AP002954.4	3.78	0.00018	0.0229	0.3	0.17	Vitiligo;	chr11:118829555	chr11:118704607~118750263:+
LUAD	cis	rs7615952	0.641	rs4490307	ENSG00000241288.6	RP11-379B18.5	-3.78	0.00018	0.0229	-0.21	-0.17	Blood pressure (smoking interaction);	chr3:125993833	chr3:125827238~125916384:-
LUAD	cis	rs2283792	0.73	rs2027790	ENSG00000211640.3	IGLV6-57	-3.78	0.00018	0.0229	-0.11	-0.17	Multiple sclerosis;	chr22:21933592	chr22:22195713~22196460:+
LUAD	cis	rs2688608	0.901	rs2664282	ENSG00000271816.1	BMS1P4	3.78	0.00018	0.0229	0.14	0.17	Inflammatory bowel disease;	chr10:73860999	chr10:73699151~73730487:-
LUAD	cis	rs8062405	1	rs80275162	ENSG00000261419.1	RP11-57A19.4	-3.78	0.00018	0.0229	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28659696~28740781:-
LUAD	cis	rs6860806	0.507	rs272872	ENSG00000263597.1	MIR3936	-3.78	0.00018	0.0229	-0.19	-0.17	Breast cancer;	chr5:132340171	chr5:132365490~132365599:-
LUAD	cis	rs12724450	0.793	rs58853199	ENSG00000228126.1	FALEC	3.77	0.00018	0.0229	0.31	0.17	Blood protein levels;	chr1:150405736	chr1:150515757~150518032:+
LUAD	cis	rs7772486	0.817	rs9322047	ENSG00000235652.6	RP11-545I5.3	3.77	0.00018	0.0229	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:146079258	chr6:145799409~145886585:+
LUAD	cis	rs321358	1	rs321368	ENSG00000271390.1	RP11-89C3.3	3.77	0.00018	0.0229	0.28	0.17	Body mass index;	chr11:111129033	chr11:111089870~111090368:-
LUAD	cis	rs321358	1	rs321369	ENSG00000271390.1	RP11-89C3.3	3.77	0.00018	0.0229	0.28	0.17	Body mass index;	chr11:111129797	chr11:111089870~111090368:-
LUAD	cis	rs321358	1	rs321370	ENSG00000271390.1	RP11-89C3.3	3.77	0.00018	0.0229	0.28	0.17	Body mass index;	chr11:111129959	chr11:111089870~111090368:-
LUAD	cis	rs8054556	0.74	rs12716975	ENSG00000183604.13	SMG1P5	-3.77	0.00018	0.0229	-0.17	-0.17	Autism spectrum disorder or schizophrenia;	chr16:29939508	chr16:30267553~30335374:-
LUAD	cis	rs755249	0.567	rs72661927	ENSG00000182109.6	RP11-69E11.4	3.77	0.00018	0.0229	0.21	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39209650	chr1:39522280~39546187:-
LUAD	cis	rs3741404	0.574	rs616563	ENSG00000256789.1	RP11-697H9.2	-3.77	0.00018	0.0229	-0.19	-0.17	Platelet count;	chr11:64110029	chr11:63637677~63658962:+
LUAD	cis	rs5015933	0.788	rs416340	ENSG00000232630.1	PRPS1P2	-3.77	0.00018	0.0229	-0.16	-0.17	Body mass index;	chr9:125339363	chr9:125150653~125151589:+
LUAD	cis	rs6496932	0.503	rs8037726	ENSG00000259630.2	CTD-2262B20.1	-3.77	0.00018	0.0229	-0.22	-0.17	Central corneal thickness;Corneal structure;	chr15:85408154	chr15:85415228~85415633:+
LUAD	cis	rs9341808	0.628	rs1892475	ENSG00000260645.1	RP11-250B2.5	3.77	0.00018	0.0229	0.16	0.17	Sitting height ratio;	chr6:80152496	chr6:80466958~80469080:+
LUAD	cis	rs2732480	0.577	rs2634680	ENSG00000273765.1	RP11-370I10.11	3.77	0.00018	0.0229	0.19	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48340781	chr12:48360920~48361377:+
LUAD	cis	rs2732480	0.577	rs2634678	ENSG00000273765.1	RP11-370I10.11	3.77	0.00018	0.0229	0.19	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48341755	chr12:48360920~48361377:+
LUAD	cis	rs2274273	0.529	rs10131562	ENSG00000258413.1	RP11-665C16.6	-3.77	0.00018	0.0229	-0.23	-0.17	Protein biomarker;	chr14:55380297	chr14:55262767~55272075:-
LUAD	cis	rs3864277	0.51	rs31478	ENSG00000263597.1	MIR3936	3.77	0.00018	0.0229	0.18	0.17	Itch intensity from mosquito bite adjusted by bite size;	chr5:132087782	chr5:132365490~132365599:-
LUAD	cis	rs10129255	0.912	rs61997792	ENSG00000211947.2	IGHV3-21	-3.77	0.00018	0.0229	-0.11	-0.17	Kawasaki disease;	chr14:106799304	chr14:106235064~106235594:-
LUAD	cis	rs10392	0.543	rs59777567	ENSG00000274825.1	RP4-616B8.5	-3.77	0.00018	0.0229	-0.22	-0.17	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;	chr20:38928905	chr20:38955910~38956547:+
LUAD	cis	rs10392	0.543	rs57569873	ENSG00000274825.1	RP4-616B8.5	-3.77	0.00018	0.0229	-0.22	-0.17	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;	chr20:38929650	chr20:38955910~38956547:+
LUAD	cis	rs7829975	0.688	rs7826654	ENSG00000233609.3	RP11-62H7.2	3.77	0.00018	0.0229	0.14	0.17	Mood instability;	chr8:8521596	chr8:8961200~8979025:+
LUAD	cis	rs7829975	0.688	rs7826660	ENSG00000233609.3	RP11-62H7.2	3.77	0.00018	0.0229	0.14	0.17	Mood instability;	chr8:8521597	chr8:8961200~8979025:+
LUAD	cis	rs7578361	0.959	rs6713737	ENSG00000231969.1	AC144449.1	-3.77	0.00018	0.0229	-0.25	-0.17	Acute lymphoblastic leukemia (childhood);	chr2:149592462	chr2:149587196~149848233:+
LUAD	cis	rs7578361	0.842	rs10932584	ENSG00000231969.1	AC144449.1	-3.77	0.00018	0.0229	-0.25	-0.17	Acute lymphoblastic leukemia (childhood);	chr2:149594273	chr2:149587196~149848233:+
LUAD	cis	rs7578361	0.959	rs12463479	ENSG00000231969.1	AC144449.1	-3.77	0.00018	0.0229	-0.25	-0.17	Acute lymphoblastic leukemia (childhood);	chr2:149595735	chr2:149587196~149848233:+
LUAD	cis	rs7674212	0.541	rs2045746	ENSG00000251288.2	RP11-10L12.2	3.77	0.00018	0.0229	0.21	0.17	Type 2 diabetes;	chr4:103162421	chr4:102751401~102752641:+
LUAD	cis	rs4795519	1	rs953768	ENSG00000266313.1	RP11-173M1.4	3.77	0.00018	0.0229	0.21	0.17	Chronic myeloid leukemia;	chr17:27115672	chr17:27333256~27348491:+
LUAD	cis	rs763121	0.819	rs5757237	ENSG00000225450.1	RP3-508I15.14	-3.77	0.00018	0.0229	-0.17	-0.17	Menopause (age at onset);	chr22:38677830	chr22:38739003~38749041:+
LUAD	cis	rs763121	0.853	rs11704021	ENSG00000225450.1	RP3-508I15.14	-3.77	0.00018	0.0229	-0.17	-0.17	Menopause (age at onset);	chr22:38678711	chr22:38739003~38749041:+
LUAD	cis	rs17102884	0.506	rs4899540	ENSG00000279594.1	RP11-950C14.10	-3.77	0.00018	0.0229	-0.19	-0.17	Neuroticism;	chr14:74936705	chr14:75011269~75012851:-
LUAD	cis	rs12579720	1	rs10770595	ENSG00000255910.1	RP11-405A12.2	3.77	0.00018	0.0229	0.21	0.17	Diastolic blood pressure;	chr12:20011129	chr12:19775451~20009937:+
LUAD	cis	rs12579720	1	rs7972957	ENSG00000255910.1	RP11-405A12.2	3.77	0.00018	0.0229	0.21	0.17	Diastolic blood pressure;	chr12:20011269	chr12:19775451~20009937:+
LUAD	cis	rs875971	0.545	rs1638724	ENSG00000222364.1	RNU6-96P	3.77	0.00018	0.0229	0.21	0.17	Aortic root size;	chr7:66575494	chr7:66395191~66395286:+
LUAD	cis	rs13113518	0.812	rs56055342	ENSG00000249700.7	SRD5A3-AS1	3.77	0.00018	0.0229	0.18	0.17	Height;	chr4:55540928	chr4:55363971~55395847:-
LUAD	cis	rs7809950	1	rs2066735	ENSG00000238832.1	snoU109	-3.77	0.00018	0.0229	-0.25	-0.17	Coronary artery disease;	chr7:107548274	chr7:107603363~107603507:+
LUAD	cis	rs7772486	0.875	rs7739371	ENSG00000235652.6	RP11-545I5.3	3.77	0.00018	0.0229	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:146103217	chr6:145799409~145886585:+
LUAD	cis	rs3617	0.625	rs11715347	ENSG00000242142.1	SERBP1P3	-3.77	0.00018	0.0229	-0.18	-0.17	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52849054	chr3:53064283~53065091:-
LUAD	cis	rs451417	1	rs379418	ENSG00000275632.1	RP5-967N21.11	3.77	0.000181	0.0229	0.22	0.17	Menopause (age at onset);	chr20:5961561	chr20:6000418~6000941:+
LUAD	cis	rs1790761	0.587	rs4930430	ENSG00000184224.3	C11orf72	3.77	0.000181	0.0229	0.19	0.17	Mean corpuscular volume;	chr11:67526727	chr11:67602880~67606706:-
LUAD	cis	rs172166	0.61	rs276369	ENSG00000219392.1	RP1-265C24.5	-3.77	0.000181	0.0229	-0.21	-0.17	Cardiac Troponin-T levels;	chr6:27951465	chr6:28115628~28116551:+
LUAD	cis	rs2274273	0.967	rs1009978	ENSG00000258413.1	RP11-665C16.6	-3.77	0.000181	0.0229	-0.21	-0.17	Protein biomarker;	chr14:55136343	chr14:55262767~55272075:-
LUAD	cis	rs818427	0.927	rs153546	ENSG00000279522.1	CTC-487M23.6	3.77	0.000181	0.0229	0.2	0.17	Total body bone mineral density;	chr5:112902342	chr5:112894933~112896531:+
LUAD	cis	rs4972806	0.739	rs10834	ENSG00000272729.1	RP11-387A1.5	-3.77	0.000181	0.0229	-0.18	-0.17	IgG glycosylation;	chr2:176177359	chr2:176164164~176165716:-
LUAD	cis	rs6988636	0.534	rs62521778	ENSG00000204949.7	FAM83A-AS1	-3.77	0.000181	0.0229	-0.29	-0.17	Urinary uromodulin levels;	chr8:123110554	chr8:123201172~123202743:-
LUAD	cis	rs8062405	0.824	rs240702	ENSG00000261419.1	RP11-57A19.4	-3.77	0.000181	0.0229	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520032	chr16:28659696~28740781:-
LUAD	cis	rs12681963	0.686	rs78536546	ENSG00000272375.1	RP11-51J9.6	3.77	0.000181	0.0229	0.35	0.17	Migraine;	chr8:30110387	chr8:30197404~30198048:+
LUAD	cis	rs6549438	0.602	rs4677092	ENSG00000241163.6	LINC00877	-3.77	0.000181	0.0229	-0.16	-0.17	Migraine - clinic-based;	chr3:72114797	chr3:72035300~72279503:-
LUAD	cis	rs6460942	0.908	rs77894875	ENSG00000226690.5	AC005281.1	3.77	0.000181	0.023	0.33	0.17	Coronary artery disease;	chr7:12208631	chr7:12496429~12541910:+
LUAD	cis	rs17711722	0.565	rs4717276	ENSG00000273024.4	INTS4P2	-3.77	0.000181	0.023	-0.18	-0.17	Calcium levels;	chr7:65829754	chr7:65647864~65715661:+
LUAD	cis	rs1862618	0.853	rs252916	ENSG00000271828.1	CTD-2310F14.1	3.77	0.000181	0.023	0.24	0.17	Initial pursuit acceleration;	chr5:56825961	chr5:56927874~56929573:+
LUAD	cis	rs6951245	0.706	rs28483034	ENSG00000229043.2	AC091729.9	-3.77	0.000181	0.023	-0.25	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1130535	chr7:1160374~1165267:+
LUAD	cis	rs755249	0.761	rs61781390	ENSG00000237624.1	OXCT2P1	3.77	0.000181	0.023	0.27	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39610222	chr1:39514956~39516490:+
LUAD	cis	rs782590	0.764	rs2586969	ENSG00000272606.1	RP11-554J4.1	-3.77	0.000181	0.023	-0.17	-0.17	Metabolic syndrome;	chr2:55602256	chr2:55617909~55618373:+
LUAD	cis	rs782590	0.764	rs2586970	ENSG00000272606.1	RP11-554J4.1	-3.77	0.000181	0.023	-0.17	-0.17	Metabolic syndrome;	chr2:55602831	chr2:55617909~55618373:+
LUAD	cis	rs7824557	0.564	rs7839307	ENSG00000255046.1	RP11-297N6.4	-3.77	0.000181	0.023	-0.21	-0.17	Retinal vascular caliber;	chr8:11341283	chr8:11797928~11802568:-
LUAD	cis	rs7772486	0.686	rs2179323	ENSG00000235652.6	RP11-545I5.3	-3.77	0.000181	0.023	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145661650	chr6:145799409~145886585:+
LUAD	cis	rs1559040	0.932	rs10208690	ENSG00000272156.1	RP11-477N3.1	3.77	0.000181	0.023	0.27	0.17	Sudden cardiac arrest;	chr2:54066783	chr2:54082554~54085066:+
LUAD	cis	rs9815354	1	rs1717020	ENSG00000273328.4	RP11-141M3.6	-3.77	0.000181	0.023	-0.25	-0.17	Pulse pressure;Diastolic blood pressure;	chr3:41939998	chr3:42809414~42908105:+
LUAD	cis	rs10463554	0.824	rs34818	ENSG00000250682.4	LINC00491	3.77	0.000181	0.023	0.21	0.17	Parkinson's disease;	chr5:103100407	chr5:102609156~102671559:-
LUAD	cis	rs7246967	0.551	rs8103204	ENSG00000236312.3	RPL34P34	3.77	0.000181	0.023	0.23	0.17	Bronchopulmonary dysplasia;	chr19:22753715	chr19:22368599~22368952:-
LUAD	cis	rs4718428	0.672	rs36038499	ENSG00000230295.1	RP11-458F8.2	-3.77	0.000181	0.023	-0.15	-0.17	Corneal structure;	chr7:66824628	chr7:66880708~66882981:+
LUAD	cis	rs683250	0.568	rs671991	ENSG00000246067.6	RAB30-AS1	3.77	0.000181	0.023	0.18	0.17	Subcortical brain region volumes;	chr11:83295577	chr11:83072066~83106719:+
LUAD	cis	rs17098356	1	rs4902057	ENSG00000258926.1	RP11-47I22.1	-3.77	0.000181	0.023	-0.16	-0.17	Reading and spelling;	chr14:61427226	chr14:61537508~61545287:-
LUAD	cis	rs7005380	0.62	rs13282901	ENSG00000279347.1	RP11-85I17.2	-3.77	0.000181	0.023	-0.14	-0.17	Interstitial lung disease;	chr8:119881561	chr8:119838736~119840385:-
LUAD	cis	rs7119038	0.818	rs57494551	ENSG00000255239.1	AP002954.6	-3.77	0.000181	0.023	-0.26	-0.17	Sjögren's syndrome;	chr11:118790689	chr11:118688039~118690600:-
LUAD	cis	rs7903456	0.608	rs7922981	ENSG00000200253.1	RNU6-529P	3.77	0.000181	0.023	0.21	0.17	Gout;Renal underexcretion gout;	chr10:87044190	chr10:87041238~87041341:-
LUAD	cis	rs7903456	0.648	rs9421566	ENSG00000200253.1	RNU6-529P	3.77	0.000181	0.023	0.21	0.17	Gout;Renal underexcretion gout;	chr10:87045789	chr10:87041238~87041341:-
LUAD	cis	rs67478160	0.643	rs8005594	ENSG00000272533.1	SNORA28	3.77	0.000181	0.023	0.17	0.17	Schizophrenia;	chr14:103813552	chr14:103337849~103337974:+
LUAD	cis	rs8031584	0.56	rs1056118	ENSG00000259845.1	HERC2P10	-3.77	0.000181	0.023	-0.19	-0.17	Huntington's disease progression;	chr15:30911583	chr15:30815271~30844153:+
LUAD	cis	rs1346081	0.839	rs6834618	ENSG00000250075.4	RP11-584P21.2	3.77	0.000181	0.023	0.18	0.17	Intelligence (multi-trait analysis);	chr4:67070912	chr4:67417305~67468251:-
LUAD	cis	rs6479891	1	rs4133250	ENSG00000232075.1	MRPL35P2	-3.77	0.000181	0.023	-0.28	-0.17	Arthritis (juvenile idiopathic);	chr10:63332645	chr10:63634317~63634827:-
LUAD	cis	rs6479891	1	rs10995506	ENSG00000232075.1	MRPL35P2	-3.77	0.000181	0.023	-0.28	-0.17	Arthritis (juvenile idiopathic);	chr10:63334706	chr10:63634317~63634827:-
LUAD	cis	rs6479891	1	rs10740117	ENSG00000232075.1	MRPL35P2	-3.77	0.000181	0.023	-0.28	-0.17	Arthritis (juvenile idiopathic);	chr10:63338517	chr10:63634317~63634827:-
LUAD	cis	rs6479891	1	rs6479894	ENSG00000232075.1	MRPL35P2	-3.77	0.000181	0.023	-0.28	-0.17	Arthritis (juvenile idiopathic);	chr10:63338981	chr10:63634317~63634827:-
LUAD	cis	rs151234	0.741	rs11644791	ENSG00000259982.1	CDC37P1	-3.77	0.000181	0.023	-0.31	-0.17	Platelet distribution width;	chr16:28589865	chr16:28700294~28701540:-
LUAD	cis	rs151234	0.741	rs3194168	ENSG00000259982.1	CDC37P1	-3.77	0.000181	0.023	-0.31	-0.17	Platelet distribution width;	chr16:28591691	chr16:28700294~28701540:-
LUAD	cis	rs13113518	0.776	rs13124436	ENSG00000273257.1	RP11-177J6.1	3.77	0.000181	0.023	0.19	0.17	Height;	chr4:55502504	chr4:55387949~55388271:+
LUAD	cis	rs2731006	0.64	rs2731017	ENSG00000257114.2	RP11-25I15.3	3.77	0.000181	0.023	0.27	0.17	Panic disorder;	chr12:42769196	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.64	rs2678109	ENSG00000257114.2	RP11-25I15.3	3.77	0.000181	0.023	0.27	0.17	Panic disorder;	chr12:42769320	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.64	rs2678108	ENSG00000257114.2	RP11-25I15.3	3.77	0.000181	0.023	0.27	0.17	Panic disorder;	chr12:42769775	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.64	rs2407112	ENSG00000257114.2	RP11-25I15.3	3.77	0.000181	0.023	0.27	0.17	Panic disorder;	chr12:42769893	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.64	rs1878580	ENSG00000257114.2	RP11-25I15.3	3.77	0.000181	0.023	0.27	0.17	Panic disorder;	chr12:42770039	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.64	rs1878579	ENSG00000257114.2	RP11-25I15.3	3.77	0.000181	0.023	0.27	0.17	Panic disorder;	chr12:42770246	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.64	rs2678105	ENSG00000257114.2	RP11-25I15.3	3.77	0.000181	0.023	0.27	0.17	Panic disorder;	chr12:42770547	chr12:42692216~42717119:+
LUAD	cis	rs2731006	0.64	rs1878577	ENSG00000257114.2	RP11-25I15.3	-3.77	0.000181	0.023	-0.27	-0.17	Panic disorder;	chr12:42770327	chr12:42692216~42717119:+
LUAD	cis	rs12908161	0.92	rs35758837	ENSG00000254414.1	RP11-182J1.1	3.77	0.000181	0.023	0.22	0.17	Schizophrenia;	chr15:84768151	chr15:84631898~84633987:-
LUAD	cis	rs1005277	0.522	rs289649	ENSG00000273019.1	RP11-508N22.13	-3.77	0.000181	0.023	-0.19	-0.17	Extrinsic epigenetic age acceleration;	chr10:37686456	chr10:38149968~38150293:+
LUAD	cis	rs7772486	0.686	rs4896827	ENSG00000235652.6	RP11-545I5.3	3.77	0.000181	0.023	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145632202	chr6:145799409~145886585:+
LUAD	cis	rs4474465	1	rs2063727	ENSG00000251323.2	RP11-452H21.4	3.77	0.000181	0.023	0.22	0.17	Alzheimer's disease (survival time);	chr11:78472836	chr11:78423982~78429836:-
LUAD	cis	rs2732480	0.577	rs2732486	ENSG00000273765.1	RP11-370I10.11	3.77	0.000181	0.023	0.19	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344051	chr12:48360920~48361377:+
LUAD	cis	rs10129255	0.5	rs1974468	ENSG00000232216.1	IGHV3-43	3.77	0.000181	0.023	0.14	0.17	Kawasaki disease;	chr14:106686149	chr14:106470264~106470800:-
LUAD	cis	rs75583333	0.655	rs73309345	ENSG00000253522.3	CTC-231O11.1	3.77	0.000181	0.023	0.29	0.17	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr5:160033281	chr5:160468268~160487426:+
LUAD	cis	rs75583333	0.655	rs4921250	ENSG00000253522.3	CTC-231O11.1	3.77	0.000181	0.023	0.29	0.17	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr5:160035953	chr5:160468268~160487426:+
LUAD	cis	rs75583333	0.536	rs60783658	ENSG00000253522.3	CTC-231O11.1	3.77	0.000181	0.023	0.29	0.17	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr5:160037666	chr5:160468268~160487426:+
LUAD	cis	rs10463554	0.926	rs5855	ENSG00000250682.4	LINC00491	-3.77	0.000181	0.023	-0.2	-0.17	Parkinson's disease;	chr5:103029482	chr5:102609156~102671559:-
LUAD	cis	rs7971	0.743	rs55714084	ENSG00000225541.1	AC002480.5	3.77	0.000181	0.023	0.19	0.17	Breast cancer;	chr7:21899471	chr7:22571607~22661792:-
LUAD	cis	rs9467773	1	rs9467791	ENSG00000241549.7	GUSBP2	-3.77	0.000181	0.023	-0.19	-0.17	Intelligence (multi-trait analysis);	chr6:26562258	chr6:26871484~26956554:-
LUAD	cis	rs9309473	0.95	rs7567585	ENSG00000230002.2	ALMS1-IT1	3.77	0.000181	0.023	0.21	0.17	Metabolite levels;	chr2:73524839	chr2:73456764~73459484:+
LUAD	cis	rs3764400	0.567	rs208012	ENSG00000278765.1	RP5-890E16.5	-3.77	0.000181	0.023	-0.3	-0.17	Body mass index;	chr17:48180655	chr17:48066704~48067293:-
LUAD	cis	rs3764400	0.567	rs208011	ENSG00000278765.1	RP5-890E16.5	-3.77	0.000181	0.023	-0.3	-0.17	Body mass index;	chr17:48180983	chr17:48066704~48067293:-
LUAD	cis	rs6502050	0.835	rs6502068	ENSG00000275966.1	RP11-1055B8.9	-3.77	0.000181	0.023	-0.18	-0.17	Life satisfaction;	chr17:82154347	chr17:81345476~81345966:-
LUAD	cis	rs11121246	0.518	rs6684644	ENSG00000270282.1	RP5-1115A15.2	3.77	0.000181	0.023	0.19	0.17	Plateletcrit;	chr1:8850519	chr1:8512653~8513021:+
LUAD	cis	rs684232	0.8	rs865702	ENSG00000236618.2	PITPNA-AS1	3.77	0.000181	0.023	0.16	0.17	Prostate cancer;	chr17:664913	chr17:1516931~1518096:+
LUAD	cis	rs7870753	0.578	rs10820507	ENSG00000188801.9	ZNF322P1	3.77	0.000181	0.023	0.28	0.17	Height;	chr9:96385870	chr9:97198303~97199511:-
LUAD	cis	rs2836974	0.544	rs8128919	ENSG00000232608.1	TIMM9P2	-3.77	0.000181	0.023	-0.19	-0.17	Cognitive function;	chr21:39339936	chr21:39216624~39217506:+
LUAD	cis	rs2239547	0.522	rs2581805	ENSG00000243224.1	RP5-1157M23.2	3.77	0.000181	0.023	0.19	0.17	Schizophrenia;	chr3:52945034	chr3:52239258~52241097:+
LUAD	cis	rs9475752	0.552	rs6925518	ENSG00000231441.1	RP11-472M19.2	3.77	0.000181	0.023	0.24	0.17	Menarche (age at onset);	chr6:56876405	chr6:56844002~56864078:+
LUAD	cis	rs9475752	0.552	rs6905658	ENSG00000231441.1	RP11-472M19.2	3.77	0.000181	0.023	0.24	0.17	Menarche (age at onset);	chr6:56876523	chr6:56844002~56864078:+
LUAD	cis	rs67478160	0.679	rs8011109	ENSG00000272533.1	SNORA28	3.77	0.000181	0.023	0.17	0.17	Schizophrenia;	chr14:103813637	chr14:103337849~103337974:+
LUAD	cis	rs67478160	0.655	rs4900598	ENSG00000272533.1	SNORA28	3.77	0.000181	0.023	0.17	0.17	Schizophrenia;	chr14:103815204	chr14:103337849~103337974:+
LUAD	cis	rs4819052	0.851	rs28442024	ENSG00000215447.6	BX322557.10	-3.77	0.000181	0.023	-0.2	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254560	chr21:45288052~45291738:+
LUAD	cis	rs448720	1	rs7172137	ENSG00000260657.2	RP11-315D16.4	-3.77	0.000181	0.023	-0.18	-0.17	Cognitive performance;	chr15:67912019	chr15:68267792~68277994:-
LUAD	cis	rs739496	0.615	rs609230	ENSG00000234608.6	MAPKAPK5-AS1	-3.77	0.000181	0.023	-0.2	-0.17	Platelet count;	chr12:111709107	chr12:111839764~111842902:-
LUAD	cis	rs4499344	0.589	rs259218	ENSG00000201388.1	SNORA68	3.77	0.000181	0.023	0.19	0.17	Mean platelet volume;	chr19:32647219	chr19:32608337~32608469:-
LUAD	cis	rs2274273	0.837	rs7146748	ENSG00000259318.1	RP11-454L9.2	3.77	0.000181	0.023	0.15	0.17	Protein biomarker;	chr14:55280368	chr14:55394940~55395233:-
LUAD	cis	rs2702164	1	rs1716840	ENSG00000240661.1	RP11-174O3.3	-3.77	0.000181	0.023	-0.2	-0.17	Gut microbiome composition (winter);	chr3:120384513	chr3:120349510~120367998:+
LUAD	cis	rs6604026	0.589	rs34250288	ENSG00000223787.2	RP4-593M8.1	3.77	0.000181	0.023	0.24	0.17	Multiple sclerosis;	chr1:92792062	chr1:92580476~92580821:-
LUAD	cis	rs9876781	1	rs9883759	ENSG00000229759.1	MRPS18AP1	3.77	0.000181	0.023	0.16	0.17	Longevity;	chr3:48422209	chr3:48256350~48256938:-
LUAD	cis	rs9876781	1	rs6442120	ENSG00000229759.1	MRPS18AP1	3.77	0.000181	0.023	0.16	0.17	Longevity;	chr3:48423094	chr3:48256350~48256938:-
LUAD	cis	rs9876781	0.9	rs1037773	ENSG00000229759.1	MRPS18AP1	3.77	0.000181	0.023	0.16	0.17	Longevity;	chr3:48426493	chr3:48256350~48256938:-
LUAD	cis	rs7578361	1	rs12992696	ENSG00000231969.1	AC144449.1	-3.77	0.000181	0.023	-0.24	-0.17	Acute lymphoblastic leukemia (childhood);	chr2:149565423	chr2:149587196~149848233:+
LUAD	cis	rs13113518	0.812	rs12500686	ENSG00000272969.1	RP11-528I4.2	3.77	0.000181	0.023	0.19	0.17	Height;	chr4:55457922	chr4:55547112~55547889:+
LUAD	cis	rs7394190	0.935	rs12570126	ENSG00000271848.1	RP11-464F9.21	3.77	0.000181	0.023	0.23	0.17	Incident atrial fibrillation;	chr10:73657031	chr10:73654039~73674719:+
LUAD	cis	rs11642862	1	rs11645175	ENSG00000239791.1	AC002310.7	3.77	0.000181	0.023	0.31	0.17	Tonsillectomy;	chr16:30791978	chr16:30572250~30583860:+
LUAD	cis	rs6964587	0.869	rs55811257	ENSG00000188693.7	CYP51A1-AS1	3.77	0.000181	0.023	0.2	0.17	Breast cancer;	chr7:91855485	chr7:92134604~92180725:+
LUAD	cis	rs820077	0.736	rs2762336	ENSG00000232909.1	RP3-510O8.4	-3.77	0.000181	0.023	-0.25	-0.17	Systemic lupus erythematosus;	chr6:35070439	chr6:35733867~35736947:-
LUAD	cis	rs6688613	0.765	rs56229522	ENSG00000225171.2	DUTP6	-3.77	0.000181	0.023	-0.21	-0.17	Refractive astigmatism;	chr1:166846871	chr1:166868748~166869209:+
LUAD	cis	rs7061710	0.871	rs7051747	ENSG00000271811.1	RP1-79C4.4	-3.77	0.000182	0.023	-0.24	-0.17	Blood metabolite levels;	chr1:171147411	chr1:170667381~170669425:+
LUAD	cis	rs7061710	0.871	rs7066454	ENSG00000271811.1	RP1-79C4.4	-3.77	0.000182	0.023	-0.24	-0.17	Blood metabolite levels;	chr1:171147464	chr1:170667381~170669425:+
LUAD	cis	rs6088580	0.634	rs1205338	ENSG00000276073.1	RP5-1125A11.7	3.77	0.000182	0.023	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34337819	chr20:33985617~33988989:-
LUAD	cis	rs4795519	1	rs1851267	ENSG00000266313.1	RP11-173M1.4	3.77	0.000182	0.023	0.21	0.17	Chronic myeloid leukemia;	chr17:27070282	chr17:27333256~27348491:+
LUAD	cis	rs3219474	0.502	rs41343546	ENSG00000234329.1	RP11-767N6.2	3.77	0.000182	0.023	0.27	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:45442591	chr1:45651039~45651826:-
LUAD	cis	rs4660214	0.614	rs1537815	ENSG00000182109.6	RP11-69E11.4	-3.77	0.000182	0.023	-0.18	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39278946	chr1:39522280~39546187:-
LUAD	cis	rs6540731	1	rs4362041	ENSG00000229983.1	RP11-15I11.2	3.77	0.000182	0.023	0.21	0.17	Intelligence (childhood);	chr1:212227127	chr1:212168207~212190259:+
LUAD	cis	rs7131987	0.65	rs7954871	ENSG00000275476.1	RP11-996F15.4	-3.77	0.000182	0.023	-0.19	-0.17	QT interval;	chr12:29306799	chr12:29277397~29277882:-
LUAD	cis	rs2348418	0.966	rs11049699	ENSG00000244712.1	RP11-874G11.1	3.77	0.000182	0.023	0.2	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28535487	chr12:28564678~28565141:-
LUAD	cis	rs28735056	0.66	rs12454454	ENSG00000261126.6	RP11-795F19.1	-3.77	0.000182	0.023	-0.17	-0.17	Schizophrenia;	chr18:79914634	chr18:80046900~80095482:+
LUAD	cis	rs6558530	0.64	rs4875889	ENSG00000253982.1	CTD-2336O2.1	3.77	0.000182	0.023	0.22	0.17	Systolic blood pressure;	chr8:1747125	chr8:1761990~1764502:-
LUAD	cis	rs9549260	0.755	rs55920113	ENSG00000229456.1	RLIMP1	3.77	0.000182	0.023	0.19	0.17	Red blood cell count;	chr13:40647975	chr13:40618738~40621348:+
LUAD	cis	rs9287719	0.967	rs6432121	ENSG00000243819.4	RN7SL832P	3.77	0.000182	0.023	0.18	0.17	Prostate cancer;	chr2:10613678	chr2:10690344~10692099:+
LUAD	cis	rs74346567	0.522	rs1551971	ENSG00000259416.2	RP11-158M2.5	-3.77	0.000182	0.023	-0.25	-0.17	Mean corpuscular volume;	chr15:85600273	chr15:85754941~85756237:-
LUAD	cis	rs6467136	0.539	rs4731365	ENSG00000224138.1	AC000123.4	-3.77	0.000182	0.023	-0.16	-0.17	Type 2 diabetes;	chr7:127442443	chr7:127350128~127351523:+
LUAD	cis	rs7772486	0.686	rs9485019	ENSG00000235652.6	RP11-545I5.3	-3.77	0.000182	0.023	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145725245	chr6:145799409~145886585:+
LUAD	cis	rs6500602	0.727	rs11076837	ENSG00000280063.1	RP11-295D4.3	3.77	0.000182	0.0231	0.11	0.17	Schizophrenia;	chr16:4519439	chr16:4346694~4348648:-
LUAD	cis	rs9584850	0.54	rs17574536	ENSG00000231194.1	FARP1-AS1	3.77	0.000182	0.0231	0.23	0.17	Neuroticism;	chr13:98518786	chr13:98435405~98435840:-
LUAD	cis	rs7429990	0.932	rs936428	ENSG00000228638.1	FCF1P2	3.77	0.000182	0.0231	0.19	0.17	Educational attainment (years of education);	chr3:48125791	chr3:48290793~48291375:-
LUAD	cis	rs911555	0.504	rs8021368	ENSG00000269940.1	RP11-73M18.7	3.77	0.000182	0.0231	0.17	0.17	Intelligence (multi-trait analysis);	chr14:103608473	chr14:103694560~103695170:+
LUAD	cis	rs4489787	0.764	rs2705162	ENSG00000240399.1	RP1-228P16.1	3.77	0.000182	0.0231	0.26	0.17	Prostate cancer (SNP x SNP interaction);	chr12:48504734	chr12:48054813~48055591:-
LUAD	cis	rs76382185	0.61	rs7533697	ENSG00000233184.5	RP11-421L21.3	3.77	0.000182	0.0231	0.31	0.17	Lymphocyte counts;	chr1:101099679	chr1:101025878~101087268:+
LUAD	cis	rs76382185	0.61	rs7531958	ENSG00000233184.5	RP11-421L21.3	3.77	0.000182	0.0231	0.31	0.17	Lymphocyte counts;	chr1:101103876	chr1:101025878~101087268:+
LUAD	cis	rs7577696	0.888	rs494569	ENSG00000276334.1	AL133243.1	3.77	0.000182	0.0231	0.2	0.17	Inflammatory biomarkers;	chr2:32244553	chr2:32521927~32523547:+
LUAD	cis	rs7976269	0.609	rs1344854	ENSG00000257176.2	RP11-996F15.2	3.77	0.000182	0.0231	0.18	0.17	Male-pattern baldness;	chr12:29065440	chr12:29280418~29317848:-
LUAD	cis	rs4819052	0.851	rs58644915	ENSG00000215447.6	BX322557.10	-3.77	0.000182	0.0231	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249997	chr21:45288052~45291738:+
LUAD	cis	rs12413361	0.967	rs1538951	ENSG00000272914.1	RP11-330O11.3	-3.77	0.000182	0.0231	-0.2	-0.17	Height;	chr10:30840556	chr10:30831828~30833387:-
LUAD	cis	rs76878669	0.561	rs12794121	ENSG00000213409.4	RP11-658F2.3	3.77	0.000182	0.0231	0.2	0.17	Educational attainment (years of education);	chr11:66358698	chr11:66761575~66762399:-
LUAD	cis	rs76878669	0.561	rs4930178	ENSG00000213409.4	RP11-658F2.3	3.77	0.000182	0.0231	0.2	0.17	Educational attainment (years of education);	chr11:66361971	chr11:66761575~66762399:-
LUAD	cis	rs76878669	0.561	rs4244813	ENSG00000213409.4	RP11-658F2.3	3.77	0.000182	0.0231	0.2	0.17	Educational attainment (years of education);	chr11:66362017	chr11:66761575~66762399:-
LUAD	cis	rs76878669	0.515	rs12576299	ENSG00000213409.4	RP11-658F2.3	3.77	0.000182	0.0231	0.2	0.17	Educational attainment (years of education);	chr11:66364815	chr11:66761575~66762399:-
LUAD	cis	rs76878669	0.561	rs7107191	ENSG00000213409.4	RP11-658F2.3	3.77	0.000182	0.0231	0.2	0.17	Educational attainment (years of education);	chr11:66372926	chr11:66761575~66762399:-
LUAD	cis	rs2354432	0.607	rs57078845	ENSG00000237188.3	RP11-337C18.8	3.77	0.000182	0.0231	0.32	0.17	Mitochondrial DNA levels;	chr1:147250567	chr1:147172771~147211568:+
LUAD	cis	rs2664588	0.561	rs4638853	ENSG00000224565.1	RP1-148H17.1	-3.77	0.000182	0.0231	-0.18	-0.17	Cerebrospinal fluid AB1-42 levels;	chr20:47962927	chr20:47391929~47412327:-
LUAD	cis	rs2664588	0.561	rs2869318	ENSG00000224565.1	RP1-148H17.1	-3.77	0.000182	0.0231	-0.18	-0.17	Cerebrospinal fluid AB1-42 levels;	chr20:47962987	chr20:47391929~47412327:-
LUAD	cis	rs12681963	0.591	rs71506505	ENSG00000271869.1	RP11-51J9.5	-3.77	0.000182	0.0231	-0.22	-0.17	Migraine;	chr8:30043385	chr8:30155830~30156232:-
LUAD	cis	rs11673344	0.67	rs505717	ENSG00000267309.1	CTD-2630F21.1	-3.77	0.000182	0.0231	-0.21	-0.17	Obesity-related traits;	chr19:36939414	chr19:36489649~36491040:+
LUAD	cis	rs11673344	0.704	rs544543	ENSG00000267309.1	CTD-2630F21.1	-3.77	0.000182	0.0231	-0.21	-0.17	Obesity-related traits;	chr19:36939921	chr19:36489649~36491040:+
LUAD	cis	rs11673344	0.67	rs568654	ENSG00000267309.1	CTD-2630F21.1	-3.77	0.000182	0.0231	-0.21	-0.17	Obesity-related traits;	chr19:36940285	chr19:36489649~36491040:+
LUAD	cis	rs5742933	1	rs5743061	ENSG00000253559.1	OSGEPL1-AS1	3.77	0.000182	0.0231	0.22	0.17	Ferritin levels;	chr2:189829540	chr2:189762704~189765556:+
LUAD	cis	rs8031584	1	rs35811129	ENSG00000260128.5	ULK4P2	-3.77	0.000182	0.0231	-0.24	-0.17	Huntington's disease progression;	chr15:30949143	chr15:30572738~30600647:+
LUAD	cis	rs1023500	0.573	rs133382	ENSG00000273366.1	CTA-989H11.1	-3.77	0.000182	0.0231	-0.2	-0.17	Schizophrenia;	chr22:42075770	chr22:42278188~42278846:+
LUAD	cis	rs755249	0.567	rs4660546	ENSG00000182109.6	RP11-69E11.4	3.77	0.000182	0.0231	0.21	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39213730	chr1:39522280~39546187:-
LUAD	cis	rs755249	0.567	rs2036463	ENSG00000182109.6	RP11-69E11.4	3.77	0.000182	0.0231	0.21	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222403	chr1:39522280~39546187:-
LUAD	cis	rs755249	0.567	rs2036464	ENSG00000182109.6	RP11-69E11.4	3.77	0.000182	0.0231	0.21	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222570	chr1:39522280~39546187:-
LUAD	cis	rs755249	0.567	rs905381	ENSG00000182109.6	RP11-69E11.4	3.77	0.000182	0.0231	0.21	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39222880	chr1:39522280~39546187:-
LUAD	cis	rs76419734	1	rs75092650	ENSG00000251175.4	RP11-45L9.1	-3.77	0.000182	0.0231	-0.4	-0.17	Post bronchodilator FEV1;	chr4:105602279	chr4:105746245~105827172:-
LUAD	cis	rs76419734	1	rs72669980	ENSG00000251175.4	RP11-45L9.1	-3.77	0.000182	0.0231	-0.4	-0.17	Post bronchodilator FEV1;	chr4:105602406	chr4:105746245~105827172:-
LUAD	cis	rs76419734	0.557	rs72669981	ENSG00000251175.4	RP11-45L9.1	-3.77	0.000182	0.0231	-0.4	-0.17	Post bronchodilator FEV1;	chr4:105603573	chr4:105746245~105827172:-
LUAD	cis	rs34929064	1	rs12700385	ENSG00000230658.1	KLHL7-AS1	3.77	0.000182	0.0231	0.23	0.17	Major depression and alcohol dependence;	chr7:22692419	chr7:23101228~23105703:-
LUAD	cis	rs913672	0.637	rs2274950	ENSG00000229222.1	KRT18P4	3.77	0.000182	0.0231	0.2	0.17	Monocyte count;	chr20:50277887	chr20:49956745~49958032:+
LUAD	cis	rs12073359	1	rs7553622	ENSG00000223945.2	RP11-458I7.1	3.77	0.000182	0.0231	0.23	0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150092668	chr1:150053864~150055034:+
LUAD	cis	rs12073359	1	rs3850838	ENSG00000223945.2	RP11-458I7.1	3.77	0.000182	0.0231	0.23	0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150093282	chr1:150053864~150055034:+
LUAD	cis	rs10090774	0.71	rs13273096	ENSG00000280303.2	ERICD	-3.77	0.000182	0.0231	-0.19	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140665832	chr8:140636281~140638283:+
LUAD	cis	rs116095464	0.558	rs10058428	ENSG00000248925.1	CTD-2083E4.6	3.77	0.000182	0.0231	0.29	0.17	Breast cancer;	chr5:235493	chr5:269858~271516:-
LUAD	cis	rs7142881	0.626	rs7145823	ENSG00000250365.5	CTD-2213F21.2	-3.77	0.000182	0.0231	-0.19	-0.17	Response to iloperidone treatment (QT prolongation);	chr14:31806012	chr14:31420286~31452883:+
LUAD	cis	rs73108077	1	rs5022146	ENSG00000281376.1	ABALON	-3.77	0.000182	0.0231	-0.29	-0.17	Red blood cell density in sickle cell anemia;	chr20:31454603	chr20:31721507~31723409:+
LUAD	cis	rs4523957	0.928	rs12938295	ENSG00000262333.1	HNRNPA1P16	-3.77	0.000182	0.0231	-0.14	-0.17	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2257560	chr17:2306761~2307715:+
LUAD	cis	rs4523957	0.893	rs9909895	ENSG00000262333.1	HNRNPA1P16	3.77	0.000182	0.0231	0.14	0.17	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2258339	chr17:2306761~2307715:+
LUAD	cis	rs4523957	0.928	rs422632	ENSG00000262333.1	HNRNPA1P16	-3.77	0.000182	0.0231	-0.14	-0.17	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2258755	chr17:2306761~2307715:+
LUAD	cis	rs4523957	0.893	rs11078018	ENSG00000262333.1	HNRNPA1P16	3.77	0.000182	0.0231	0.14	0.17	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2258825	chr17:2306761~2307715:+
LUAD	cis	rs4523957	0.893	rs11078019	ENSG00000262333.1	HNRNPA1P16	3.77	0.000182	0.0231	0.14	0.17	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2258827	chr17:2306761~2307715:+
LUAD	cis	rs4523957	0.859	rs9891227	ENSG00000262333.1	HNRNPA1P16	3.77	0.000182	0.0231	0.14	0.17	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2261017	chr17:2306761~2307715:+
LUAD	cis	rs56309584	0.596	rs117854193	ENSG00000226871.1	AC135178.7	3.77	0.000182	0.0231	0.24	0.17	Initial pursuit acceleration;	chr17:8275149	chr17:8318088~8318712:-
LUAD	cis	rs4908769	0.66	rs10779702	ENSG00000232912.4	RP5-1115A15.1	-3.77	0.000182	0.0231	-0.16	-0.17	Allergy;	chr1:8363450	chr1:8424645~8434838:+
LUAD	cis	rs2348418	0.832	rs10506031	ENSG00000247934.4	RP11-967K21.1	-3.77	0.000182	0.0231	-0.19	-0.17	Lung function (FEV1);Lung function (FVC);	chr12:28379061	chr12:28163298~28190738:-
LUAD	cis	rs4386084	1	rs12904014	ENSG00000242737.1	RP11-562A8.1	-3.77	0.000182	0.0231	-0.22	-0.17	Basophil percentage of granulocytes;Basophil percentage of white cells;	chr15:49939548	chr15:50466738~50467096:+
LUAD	cis	rs9467773	0.873	rs9295698	ENSG00000241549.7	GUSBP2	3.77	0.000182	0.0231	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26565871	chr6:26871484~26956554:-
LUAD	cis	rs7809615	0.515	rs6961634	ENSG00000244219.5	GS1-259H13.2	-3.77	0.000182	0.0231	-0.28	-0.17	Blood metabolite ratios;	chr7:99584216	chr7:99598066~99610813:+
LUAD	cis	rs1198872	0.892	rs10427170	ENSG00000272275.1	RP11-791G15.2	3.77	0.000182	0.0231	0.21	0.17	Cardiac Troponin-T levels;	chr2:10762044	chr2:10767875~10770058:-
LUAD	cis	rs17407555	0.741	rs12509713	ENSG00000250413.1	RP11-448G15.1	3.77	0.000182	0.0231	0.24	0.17	Schizophrenia (age at onset);	chr4:10105445	chr4:10006482~10009725:+
LUAD	cis	rs6502050	0.835	rs9911379	ENSG00000266654.1	RP11-1376P16.1	-3.77	0.000182	0.0231	-0.18	-0.17	Life satisfaction;	chr17:82156653	chr17:82160056~82160452:+
LUAD	cis	rs10508774	0.81	rs72795559	ENSG00000231245.2	C1DP1	-3.77	0.000182	0.0231	-0.4	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32584043	chr10:32511336~32511737:-
LUAD	cis	rs6840360	0.571	rs1822346	ENSG00000270265.1	RP11-731D1.4	-3.77	0.000182	0.0231	-0.19	-0.17	Intelligence (multi-trait analysis);	chr4:151604151	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.571	rs1822347	ENSG00000270265.1	RP11-731D1.4	-3.77	0.000182	0.0231	-0.19	-0.17	Intelligence (multi-trait analysis);	chr4:151604167	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.571	rs4696272	ENSG00000270265.1	RP11-731D1.4	-3.77	0.000182	0.0231	-0.19	-0.17	Intelligence (multi-trait analysis);	chr4:151607077	chr4:151333775~151353224:-
LUAD	cis	rs74233809	0.636	rs284851	ENSG00000213277.3	MARCKSL1P1	3.77	0.000183	0.0231	0.23	0.17	Birth weight;	chr10:102818774	chr10:103175554~103176094:+
LUAD	cis	rs782590	0.818	rs2627782	ENSG00000272606.1	RP11-554J4.1	-3.77	0.000183	0.0231	-0.17	-0.17	Metabolic syndrome;	chr2:55598216	chr2:55617909~55618373:+
LUAD	cis	rs782590	0.764	rs935177	ENSG00000272606.1	RP11-554J4.1	-3.77	0.000183	0.0231	-0.17	-0.17	Metabolic syndrome;	chr2:55599625	chr2:55617909~55618373:+
LUAD	cis	rs9467773	1	rs12665431	ENSG00000241549.7	GUSBP2	3.77	0.000183	0.0231	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26577080	chr6:26871484~26956554:-
LUAD	cis	rs10129255	0.5	rs2105991	ENSG00000253209.1	IGHV3-65	3.77	0.000183	0.0231	0.13	0.17	Kawasaki disease;	chr14:106682022	chr14:106666092~106666532:-
LUAD	cis	rs2147959	0.941	rs6426503	ENSG00000269934.1	RP5-1139B12.3	-3.77	0.000183	0.0231	-0.22	-0.17	Adult asthma;	chr1:228463310	chr1:228274584~228276066:-
LUAD	cis	rs6502050	0.835	rs8073645	ENSG00000275966.1	RP11-1055B8.9	-3.77	0.000183	0.0231	-0.17	-0.17	Life satisfaction;	chr17:82153081	chr17:81345476~81345966:-
LUAD	cis	rs1991651	0.507	rs17778581	ENSG00000255046.1	RP11-297N6.4	3.77	0.000183	0.0231	0.21	0.17	Sum neutrophil eosinophil counts;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;	chr8:10885911	chr8:11797928~11802568:-
LUAD	cis	rs8092503	1	rs12959833	ENSG00000267325.1	LINC01415	3.77	0.000183	0.0232	0.22	0.17	Childhood body mass index;	chr18:54825348	chr18:55776727~55781721:-
LUAD	cis	rs12681366	1	rs7825731	ENSG00000253704.1	RP11-267M23.4	3.77	0.000183	0.0232	0.2	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94362147	chr8:94553722~94569745:+
LUAD	cis	rs12468226	0.689	rs73989731	ENSG00000226261.1	AC064836.3	3.77	0.000183	0.0232	0.26	0.17	Urate levels;	chr2:202109309	chr2:202336024~202336727:-
LUAD	cis	rs11685222	0.504	rs13004936	ENSG00000229326.3	AC069154.4	-3.77	0.000183	0.0232	-0.21	-0.17	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr2:119643851	chr2:119698623~119700151:+
LUAD	cis	rs6762477	0.748	rs9831967	ENSG00000234667.1	ACTBP13	3.77	0.000183	0.0232	0.19	0.17	Menarche (age at onset);	chr3:50179801	chr3:49873347~49877980:-
LUAD	cis	rs2299587	0.56	rs3913556	ENSG00000253671.1	RP11-806O11.1	-3.77	0.000183	0.0232	-0.2	-0.17	Economic and political preferences;	chr8:17923892	chr8:17808941~17820868:+
LUAD	cis	rs858239	0.899	rs1881203	ENSG00000230042.1	AK3P3	-3.77	0.000183	0.0232	-0.22	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23253189	chr7:23129178~23129841:+
LUAD	cis	rs2735413	0.563	rs72800907	ENSG00000276007.1	RP11-358L22.3	3.77	0.000183	0.0232	0.24	0.17	Systolic blood pressure (alcohol consumption interaction);	chr16:78012475	chr16:78123243~78124332:+
LUAD	cis	rs2735413	0.563	rs72800908	ENSG00000276007.1	RP11-358L22.3	3.77	0.000183	0.0232	0.24	0.17	Systolic blood pressure (alcohol consumption interaction);	chr16:78012621	chr16:78123243~78124332:+
LUAD	cis	rs8073060	0.544	rs225258	ENSG00000267592.1	CTC-507E2.2	3.77	0.000183	0.0232	0.25	0.17	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35629864	chr17:35596904~35597128:-
LUAD	cis	rs1044826	0.913	rs9849039	ENSG00000214280.3	RP11-553K23.2	-3.77	0.000183	0.0232	-0.2	-0.17	Obesity-related traits;	chr3:139428264	chr3:139582928~139583593:-
LUAD	cis	rs7429990	0.965	rs319689	ENSG00000228638.1	FCF1P2	-3.77	0.000183	0.0232	-0.19	-0.17	Educational attainment (years of education);	chr3:47886677	chr3:48290793~48291375:-
LUAD	cis	rs4865762	0.514	rs152944	ENSG00000272416.1	CTD-2081C10.7	-3.77	0.000183	0.0232	-0.18	-0.17	Intraocular pressure;	chr5:53135013	chr5:53880293~53881051:-
LUAD	cis	rs277939	0.967	rs277986	ENSG00000251634.2	RP11-1280N14.3	3.77	0.000183	0.0232	0.18	0.17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr5:71622068	chr5:71102898~71128753:-
LUAD	cis	rs10392	0.543	rs16987679	ENSG00000274825.1	RP4-616B8.5	-3.77	0.000183	0.0232	-0.22	-0.17	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;	chr20:38928542	chr20:38955910~38956547:+
LUAD	cis	rs11886999	0.68	rs997547	ENSG00000237510.6	AC008268.2	-3.77	0.000183	0.0232	-0.3	-0.17	Cardiac Troponin-T levels;	chr2:96193296	chr2:95789654~95800166:+
LUAD	cis	rs7178424	1	rs28542204	ENSG00000259251.2	RP11-643M14.1	-3.77	0.000183	0.0232	-0.17	-0.17	Height;	chr15:62073850	chr15:62060503~62062434:+
LUAD	cis	rs9815354	1	rs6599179	ENSG00000273328.4	RP11-141M3.6	-3.77	0.000183	0.0232	-0.24	-0.17	Pulse pressure;Diastolic blood pressure;	chr3:41813792	chr3:42809414~42908105:+
LUAD	cis	rs7107174	1	rs2511178	ENSG00000251323.2	RP11-452H21.4	3.77	0.000183	0.0232	0.23	0.17	Testicular germ cell tumor;	chr11:78212174	chr11:78423982~78429836:-
LUAD	cis	rs7107174	0.892	rs2510042	ENSG00000251323.2	RP11-452H21.4	3.77	0.000183	0.0232	0.23	0.17	Testicular germ cell tumor;	chr11:78212619	chr11:78423982~78429836:-
LUAD	cis	rs6460942	0.908	rs73677573	ENSG00000226690.5	AC005281.1	3.77	0.000183	0.0232	0.3	0.17	Coronary artery disease;	chr7:12243972	chr7:12496429~12541910:+
LUAD	cis	rs5769707	0.749	rs7286706	ENSG00000235111.1	RP1-29C18.8	-3.77	0.000183	0.0232	-0.18	-0.17	Monocyte percentage of white cells;Monocyte count;	chr22:49664698	chr22:49612657~49615716:-
LUAD	cis	rs7727544	0.508	rs11739935	ENSG00000233006.5	AC034220.3	3.77	0.000183	0.0232	0.17	0.17	Blood metabolite levels;	chr5:132044965	chr5:132311285~132369916:-
LUAD	cis	rs5758659	0.652	rs133321	ENSG00000270083.1	RP1-257I20.14	3.77	0.000183	0.0232	0.16	0.17	Cognitive function;	chr22:42009318	chr22:42089630~42090028:-
LUAD	cis	rs5758659	0.652	rs133324	ENSG00000270083.1	RP1-257I20.14	3.77	0.000183	0.0232	0.16	0.17	Cognitive function;	chr22:42010367	chr22:42089630~42090028:-
LUAD	cis	rs5758659	0.652	rs133330	ENSG00000270083.1	RP1-257I20.14	3.77	0.000183	0.0232	0.16	0.17	Cognitive function;	chr22:42013452	chr22:42089630~42090028:-
LUAD	cis	rs7138803	0.572	rs7953534	ENSG00000257464.1	RP11-161H23.8	-3.77	0.000183	0.0232	-0.18	-0.17	Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index;	chr12:49804097	chr12:49442424~49442652:-
LUAD	cis	rs875971	0.66	rs28698552	ENSG00000222364.1	RNU6-96P	-3.77	0.000183	0.0232	-0.19	-0.17	Aortic root size;	chr7:66540031	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.66	rs62465434	ENSG00000222364.1	RNU6-96P	-3.77	0.000183	0.0232	-0.19	-0.17	Aortic root size;	chr7:66540165	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.66	rs13224319	ENSG00000222364.1	RNU6-96P	-3.77	0.000183	0.0232	-0.19	-0.17	Aortic root size;	chr7:66542376	chr7:66395191~66395286:+
LUAD	cis	rs10129255	0.913	rs28861466	ENSG00000211947.2	IGHV3-21	-3.77	0.000183	0.0232	-0.12	-0.17	Kawasaki disease;	chr14:106718572	chr14:106235064~106235594:-
LUAD	cis	rs17102884	0.506	rs4899541	ENSG00000279594.1	RP11-950C14.10	-3.77	0.000183	0.0232	-0.19	-0.17	Neuroticism;	chr14:74936734	chr14:75011269~75012851:-
LUAD	cis	rs6689263	0.656	rs3767235	ENSG00000117242.7	PINK1-AS	3.77	0.000183	0.0232	0.35	0.17	Intelligence (multi-trait analysis);	chr1:20484691	chr1:20642657~20652193:-
LUAD	cis	rs13113518	0.966	rs7677952	ENSG00000273257.1	RP11-177J6.1	3.77	0.000183	0.0232	0.19	0.17	Height;	chr4:55425312	chr4:55387949~55388271:+
LUAD	cis	rs189798	0.807	rs330909	ENSG00000253893.2	FAM85B	-3.77	0.000183	0.0232	-0.23	-0.17	Myopia (pathological);	chr8:9137877	chr8:8167819~8226614:-
LUAD	cis	rs4784934	0.959	rs2042401	ENSG00000260186.4	RP11-481J2.2	3.77	0.000183	0.0232	0.21	0.17	QT interval;	chr16:58430171	chr16:58421326~58462470:+
LUAD	cis	rs910316	0.934	rs8016330	ENSG00000279594.1	RP11-950C14.10	-3.77	0.000183	0.0232	-0.2	-0.17	Height;	chr14:75190804	chr14:75011269~75012851:-
LUAD	cis	rs910316	0.967	rs11624893	ENSG00000279594.1	RP11-950C14.10	-3.77	0.000183	0.0232	-0.2	-0.17	Height;	chr14:75193421	chr14:75011269~75012851:-
LUAD	cis	rs9309473	0.607	rs7604588	ENSG00000230002.2	ALMS1-IT1	3.77	0.000183	0.0232	0.19	0.17	Metabolite levels;	chr2:73344289	chr2:73456764~73459484:+
LUAD	cis	rs2905347	0.726	rs2905320	ENSG00000179428.2	AC073072.5	3.77	0.000183	0.0232	0.2	0.17	Major depression and alcohol dependence;	chr7:22664624	chr7:22725395~22727620:-
LUAD	cis	rs321358	0.895	rs17457430	ENSG00000271390.1	RP11-89C3.3	3.77	0.000183	0.0232	0.27	0.17	Body mass index;	chr11:111085279	chr11:111089870~111090368:-
LUAD	cis	rs801193	1	rs2707836	ENSG00000222364.1	RNU6-96P	-3.77	0.000183	0.0232	-0.19	-0.17	Aortic root size;	chr7:66695448	chr7:66395191~66395286:+
LUAD	cis	rs801193	0.844	rs7779971	ENSG00000222364.1	RNU6-96P	-3.77	0.000183	0.0232	-0.19	-0.17	Aortic root size;	chr7:66696803	chr7:66395191~66395286:+
LUAD	cis	rs12149074	0.55	rs1842023	ENSG00000261390.4	RP11-345M22.2	-3.77	0.000183	0.0232	-0.22	-0.17	Bipolar disorder and eating disorder;Eating disorder in bipolar disorder;	chr16:80068876	chr16:79715232~79770563:-
LUAD	cis	rs5758511	0.68	rs739147	ENSG00000233903.2	Z83851.4	3.77	0.000183	0.0232	0.25	0.17	Birth weight;	chr22:42275060	chr22:42276355~42277052:+
LUAD	cis	rs12073359	1	rs77391665	ENSG00000223945.2	RP11-458I7.1	-3.77	0.000183	0.0232	-0.24	-0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150036614	chr1:150053864~150055034:+
LUAD	cis	rs853679	0.55	rs1233701	ENSG00000280107.1	AL022393.9	3.77	0.000183	0.0232	0.22	0.17	Depression;	chr6:28200948	chr6:28170845~28172521:+
LUAD	cis	rs7100689	0.646	rs1815650	ENSG00000226659.1	RP11-137H2.4	-3.77	0.000183	0.0232	-0.23	-0.17	Post bronchodilator FEV1;	chr10:80397708	chr10:80529597~80535942:-
LUAD	cis	rs7100689	0.646	rs12253992	ENSG00000226659.1	RP11-137H2.4	-3.77	0.000183	0.0232	-0.23	-0.17	Post bronchodilator FEV1;	chr10:80398954	chr10:80529597~80535942:-
LUAD	cis	rs62025270	0.632	rs62023935	ENSG00000259416.2	RP11-158M2.5	-3.77	0.000183	0.0232	-0.23	-0.17	Idiopathic pulmonary fibrosis;	chr15:85605604	chr15:85754941~85756237:-
LUAD	cis	rs10197140	1	rs62159471	ENSG00000235721.1	AC013268.3	-3.77	0.000183	0.0232	-0.19	-0.17	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110857844	chr2:110007675~110010783:+
LUAD	cis	rs7940646	0.812	rs2052691	ENSG00000177112.6	MRVI1-AS1	-3.77	0.000183	0.0232	-0.22	-0.17	Platelet aggregation;	chr11:10642874	chr11:10541272~10599932:+
LUAD	cis	rs4927850	1	rs7614767	ENSG00000278820.1	AC024937.1	3.77	0.000183	0.0232	0.15	0.17	Pancreatic cancer;	chr3:196026580	chr3:195960500~195960612:-
LUAD	cis	rs2904524	0.881	rs12316184	ENSG00000257815.4	RP11-611E13.2	-3.77	0.000183	0.0232	-0.22	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70348121	chr12:69904033~70243360:-
LUAD	cis	rs11955398	0.502	rs169700	ENSG00000272308.1	RP11-231G3.1	-3.77	0.000183	0.0232	-0.2	-0.17	Intelligence (multi-trait analysis);	chr5:60969281	chr5:60866457~60866935:-
LUAD	cis	rs8014204	0.901	rs4899536	ENSG00000279594.1	RP11-950C14.10	-3.77	0.000183	0.0232	-0.19	-0.17	Caffeine consumption;	chr14:74849911	chr14:75011269~75012851:-
LUAD	cis	rs7260598	0.642	rs10425299	ENSG00000269421.1	ZNF92P3	-3.77	0.000183	0.0232	-0.26	-0.17	Response to taxane treatment (placlitaxel);	chr19:23995757	chr19:23935220~23936173:+
LUAD	cis	rs10045504	0.502	rs72746038	ENSG00000251189.1	CTD-2196P11.2	3.77	0.000183	0.0232	0.3	0.17	Night sleep phenotypes;	chr5:38753897	chr5:38682070~38685126:+
LUAD	cis	rs2239547	0.563	rs4687699	ENSG00000243224.1	RP5-1157M23.2	-3.77	0.000183	0.0232	-0.19	-0.17	Schizophrenia;	chr3:53067208	chr3:52239258~52241097:+
LUAD	cis	rs7829975	0.514	rs2920991	ENSG00000173295.6	FAM86B3P	3.77	0.000183	0.0232	0.18	0.17	Mood instability;	chr8:8401607	chr8:8228595~8244865:+
LUAD	cis	rs3742264	1	rs9534302	ENSG00000235903.6	CPB2-AS1	-3.77	0.000183	0.0232	-0.22	-0.17	Blood protein levels;	chr13:46065920	chr13:46052806~46113332:+
LUAD	cis	rs3742264	1	rs9534303	ENSG00000235903.6	CPB2-AS1	-3.77	0.000183	0.0232	-0.22	-0.17	Blood protein levels;	chr13:46066007	chr13:46052806~46113332:+
LUAD	cis	rs3742264	0.961	rs9534304	ENSG00000235903.6	CPB2-AS1	-3.77	0.000183	0.0232	-0.22	-0.17	Blood protein levels;	chr13:46066467	chr13:46052806~46113332:+
LUAD	cis	rs3742264	0.922	rs7336360	ENSG00000235903.6	CPB2-AS1	-3.77	0.000183	0.0232	-0.22	-0.17	Blood protein levels;	chr13:46066946	chr13:46052806~46113332:+
LUAD	cis	rs3742264	1	rs9526136	ENSG00000235903.6	CPB2-AS1	-3.77	0.000183	0.0232	-0.22	-0.17	Blood protein levels;	chr13:46067012	chr13:46052806~46113332:+
LUAD	cis	rs8002861	0.935	rs9533672	ENSG00000274001.1	RP11-5G9.5	3.77	0.000183	0.0232	0.18	0.17	Leprosy;	chr13:43877044	chr13:43877715~43878163:-
LUAD	cis	rs897984	0.762	rs4889599	ENSG00000232748.3	RP11-196G11.6	3.77	0.000183	0.0232	0.21	0.17	Dementia with Lewy bodies;	chr16:30957268	chr16:31056460~31062803:+
LUAD	cis	rs897984	0.721	rs2305884	ENSG00000232748.3	RP11-196G11.6	3.77	0.000183	0.0232	0.21	0.17	Dementia with Lewy bodies;	chr16:30959420	chr16:31056460~31062803:+
LUAD	cis	rs858239	0.57	rs10271613	ENSG00000226816.2	AC005082.12	3.77	0.000183	0.0232	0.22	0.17	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23206013~23208045:+
LUAD	cis	rs858239	0.57	rs10242166	ENSG00000226816.2	AC005082.12	3.77	0.000183	0.0232	0.22	0.17	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23206013~23208045:+
LUAD	cis	rs17122278	0.932	rs45505501	ENSG00000243431.1	RPL5P30	3.77	0.000183	0.0232	0.21	0.17	Total cholesterol levels;	chr11:118534590	chr11:118560690~118561580:+
LUAD	cis	rs6493487	0.512	rs9806247	ENSG00000273674.3	CTD-2378E12.1	3.77	0.000184	0.0232	0.24	0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50824521	chr15:50839875~50908599:-
LUAD	cis	rs9549260	0.709	rs9549247	ENSG00000229456.1	RLIMP1	3.77	0.000184	0.0232	0.19	0.17	Red blood cell count;	chr13:40646640	chr13:40618738~40621348:+
LUAD	cis	rs1198430	1	rs1198431	ENSG00000232482.2	RP4-654C18.1	3.77	0.000184	0.0232	0.27	0.17	Total cholesterol levels;	chr1:23429223	chr1:23410832~23412146:+
LUAD	cis	rs2333021	0.62	rs2002033	ENSG00000259015.1	RP11-109N23.6	-3.77	0.000184	0.0232	-0.17	-0.17	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72968648	chr14:72960595~72961993:+
LUAD	cis	rs8180040	1	rs11714294	ENSG00000271161.1	BOLA2P2	-3.77	0.000184	0.0232	-0.16	-0.17	Colorectal cancer;	chr3:47298233	chr3:47499841~47500407:+
LUAD	cis	rs321358	0.945	rs10502129	ENSG00000271390.1	RP11-89C3.3	3.77	0.000184	0.0233	0.28	0.17	Body mass index;	chr11:111107405	chr11:111089870~111090368:-
LUAD	cis	rs321358	0.945	rs12420595	ENSG00000271390.1	RP11-89C3.3	3.77	0.000184	0.0233	0.28	0.17	Body mass index;	chr11:111115871	chr11:111089870~111090368:-
LUAD	cis	rs38055	0.837	rs37778	ENSG00000247796.2	CTD-2366F13.1	-3.77	0.000184	0.0233	-0.19	-0.17	Acne (severe);	chr5:53333400	chr5:53109842~53115126:+
LUAD	cis	rs875971	0.54	rs736270	ENSG00000222364.1	RNU6-96P	-3.77	0.000184	0.0233	-0.19	-0.17	Aortic root size;	chr7:65963835	chr7:66395191~66395286:+
LUAD	cis	rs67478160	0.595	rs12889993	ENSG00000272533.1	SNORA28	3.77	0.000184	0.0233	0.17	0.17	Schizophrenia;	chr14:103807957	chr14:103337849~103337974:+
LUAD	cis	rs7773456	1	rs7773456	ENSG00000228412.5	RP4-625H18.2	3.77	0.000184	0.0233	0.19	0.17	Lupus nephritis in systemic lupus erythematosus;	chr6:19823007	chr6:19802164~19804752:-
LUAD	cis	rs2378497	0.564	rs115883774	ENSG00000227925.1	RP11-191N8.2	3.77	0.000184	0.0233	0.2	0.17	Serum thyroid-stimulating hormone levels;	chr1:221986970	chr1:221827666~221840666:-
LUAD	cis	rs2098713	0.614	rs13155645	ENSG00000250155.1	CTD-2353F22.1	-3.77	0.000184	0.0233	-0.2	-0.17	Telomere length;	chr5:37476899	chr5:36666214~36725195:-
LUAD	cis	rs17596685	1	rs7996068	ENSG00000271216.1	LINC01050	3.77	0.000184	0.0233	0.25	0.17	C-reactive protein levels;	chr13:42565254	chr13:42810366~42812562:-
LUAD	cis	rs9649213	0.593	rs6465666	ENSG00000272950.1	RP11-307C18.1	-3.77	0.000184	0.0233	-0.21	-0.17	Prostate cancer (SNP x SNP interaction);	chr7:98307946	chr7:98322853~98323430:+
LUAD	cis	rs8180040	0.966	rs17784882	ENSG00000271161.1	BOLA2P2	-3.77	0.000184	0.0233	-0.16	-0.17	Colorectal cancer;	chr3:47502513	chr3:47499841~47500407:+
LUAD	cis	rs12478296	1	rs12474070	ENSG00000261186.2	RP11-341N2.1	-3.77	0.000184	0.0233	-0.29	-0.17	Obesity-related traits;	chr2:242097587	chr2:242087351~242088457:-
LUAD	cis	rs12478296	1	rs56102931	ENSG00000261186.2	RP11-341N2.1	-3.77	0.000184	0.0233	-0.29	-0.17	Obesity-related traits;	chr2:242097785	chr2:242087351~242088457:-
LUAD	cis	rs12478296	1	rs55732177	ENSG00000261186.2	RP11-341N2.1	-3.77	0.000184	0.0233	-0.29	-0.17	Obesity-related traits;	chr2:242097855	chr2:242087351~242088457:-
LUAD	cis	rs12478296	1	rs55758933	ENSG00000261186.2	RP11-341N2.1	-3.77	0.000184	0.0233	-0.29	-0.17	Obesity-related traits;	chr2:242098138	chr2:242087351~242088457:-
LUAD	cis	rs12478296	1	rs55814222	ENSG00000261186.2	RP11-341N2.1	-3.77	0.000184	0.0233	-0.29	-0.17	Obesity-related traits;	chr2:242099015	chr2:242087351~242088457:-
LUAD	cis	rs6568490	0.507	rs4945794	ENSG00000203801.7	LINC00222	-3.77	0.000184	0.0233	-0.3	-0.17	Lymphocyte counts;	chr6:107815673	chr6:108751654~108769942:+
LUAD	cis	rs2638953	0.924	rs11049471	ENSG00000278733.1	RP11-425D17.1	-3.77	0.000184	0.0233	-0.2	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28228259	chr12:28185625~28186190:-
LUAD	cis	rs74024059	0.661	rs1503955	ENSG00000260269.4	CTD-2323K18.1	-3.77	0.000184	0.0233	-0.36	-0.17	Red blood cell count;Hematocrit;	chr15:75950277	chr15:75527150~75601205:-
LUAD	cis	rs17711722	0.701	rs781145	ENSG00000222364.1	RNU6-96P	-3.77	0.000184	0.0233	-0.19	-0.17	Calcium levels;	chr7:65975383	chr7:66395191~66395286:+
LUAD	cis	rs520525	0.963	rs663887	ENSG00000271811.1	RP1-79C4.4	3.77	0.000184	0.0233	0.22	0.17	Atrial fibrillation;	chr1:170657812	chr1:170667381~170669425:+
LUAD	cis	rs7202877	0.656	rs4888374	ENSG00000280152.1	RP11-331F4.5	3.77	0.000184	0.0233	0.2	0.17	Type 1 diabetes;Type 2 diabetes;	chr16:75288330	chr16:75245994~75250077:-
LUAD	cis	rs7968440	1	rs7305655	ENSG00000272368.2	RP4-605O3.4	-3.77	0.000184	0.0233	-0.2	-0.17	Fibrinogen;	chr12:50611506	chr12:50112197~50165618:+
LUAD	cis	rs6088580	0.634	rs1205345	ENSG00000276073.1	RP5-1125A11.7	3.77	0.000184	0.0233	0.17	0.17	Glomerular filtration rate (creatinine);	chr20:34326893	chr20:33985617~33988989:-
LUAD	cis	rs2412819	0.571	rs678084	ENSG00000166763.7	STRCP1	-3.77	0.000184	0.0233	-0.24	-0.17	Lung cancer;	chr15:43828361	chr15:43699488~43718184:-
LUAD	cis	rs7613875	0.62	rs3774734	ENSG00000234667.1	ACTBP13	3.77	0.000184	0.0233	0.19	0.17	Body mass index;	chr3:50071359	chr3:49873347~49877980:-
LUAD	cis	rs11089937	0.864	rs5757041	ENSG00000211640.3	IGLV6-57	3.77	0.000184	0.0233	0.11	0.17	Periodontitis (PAL4Q3);	chr22:22140538	chr22:22195713~22196460:+
LUAD	cis	rs2506028	0.619	rs788267	ENSG00000234944.1	RP11-124O11.1	3.77	0.000184	0.0233	0.18	0.17	Blood protein levels;	chr10:42939990	chr10:42871521~42874060:+
LUAD	cis	rs911119	0.955	rs6048933	ENSG00000270001.1	RP11-218C14.8	-3.77	0.000184	0.0233	-0.26	-0.17	Chronic kidney disease;	chr20:23615000	chr20:23631826~23632316:-
LUAD	cis	rs11624221	0.896	rs7143439	ENSG00000199436.1	SNORD9	-3.77	0.000184	0.0233	-0.19	-0.17	Blood protein levels;	chr14:20668832	chr14:21392150~21392253:-
LUAD	cis	rs13260300	0.533	rs890216	ENSG00000249395.2	CASC9	-3.77	0.000184	0.0233	-0.2	-0.17	Breast cancer-free interval (treatment with aromatase inhibitor);	chr8:74581948	chr8:75223404~75324741:-
LUAD	cis	rs13260300	0.533	rs4385449	ENSG00000249395.2	CASC9	-3.77	0.000184	0.0233	-0.2	-0.17	Breast cancer-free interval (treatment with aromatase inhibitor);	chr8:74582027	chr8:75223404~75324741:-
LUAD	cis	rs13260300	0.533	rs4557676	ENSG00000249395.2	CASC9	-3.77	0.000184	0.0233	-0.2	-0.17	Breast cancer-free interval (treatment with aromatase inhibitor);	chr8:74582120	chr8:75223404~75324741:-
LUAD	cis	rs13260300	0.533	rs4557677	ENSG00000249395.2	CASC9	-3.77	0.000184	0.0233	-0.2	-0.17	Breast cancer-free interval (treatment with aromatase inhibitor);	chr8:74582171	chr8:75223404~75324741:-
LUAD	cis	rs62246343	0.504	rs3915844	ENSG00000206573.7	THUMPD3-AS1	-3.77	0.000184	0.0233	-0.18	-0.17	Fibrinogen levels;	chr3:9473172	chr3:9349689~9398579:-
LUAD	cis	rs911555	0.692	rs7140647	ENSG00000259775.1	RP11-45P15.4	3.77	0.000184	0.0233	0.22	0.17	Intelligence (multi-trait analysis);	chr14:103427128	chr14:103331674~103332367:-
LUAD	cis	rs9608946	1	rs7289828	ENSG00000279699.1	RP1-102K2.9	3.77	0.000184	0.0233	0.25	0.17	Red cell distribution width;	chr22:30525262	chr22:30275215~30276951:-
LUAD	cis	rs875971	0.505	rs2462573	ENSG00000273142.1	RP11-458F8.4	3.77	0.000184	0.0233	0.12	0.17	Aortic root size;	chr7:66042405	chr7:66902857~66906297:+
LUAD	cis	rs9951698	0.703	rs28619103	ENSG00000267480.1	RP11-703I16.1	-3.77	0.000184	0.0233	-0.21	-0.17	Intelligence (multi-trait analysis);	chr18:12993196	chr18:12031178~12032181:-
LUAD	cis	rs2486288	0.656	rs2413774	ENSG00000259479.5	SORD2P	-3.77	0.000184	0.0233	-0.2	-0.17	Glomerular filtration rate;	chr15:45257225	chr15:44826371~44884694:-
LUAD	cis	rs2015599	0.549	rs7311081	ENSG00000257176.2	RP11-996F15.2	3.77	0.000184	0.0233	0.17	0.17	Platelet count;Mean platelet volume;	chr12:29278235	chr12:29280418~29317848:-
LUAD	cis	rs875971	0.545	rs1547529	ENSG00000222364.1	RNU6-96P	-3.77	0.000184	0.0233	-0.22	-0.17	Aortic root size;	chr7:66258859	chr7:66395191~66395286:+
LUAD	cis	rs957448	0.554	rs12541408	ENSG00000253175.1	RP11-267M23.6	3.77	0.000184	0.0233	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94573579	chr8:94565036~94565715:+
LUAD	cis	rs7134599	1	rs34902013	ENSG00000240087.3	RP11-254B13.1	3.77	0.000184	0.0233	0.15	0.17	Inflammatory bowel disease;Ulcerative colitis;	chr12:68105174	chr12:68552995~68553882:-
LUAD	cis	rs7134599	1	rs7134472	ENSG00000240087.3	RP11-254B13.1	3.77	0.000184	0.0233	0.15	0.17	Inflammatory bowel disease;Ulcerative colitis;	chr12:68106206	chr12:68552995~68553882:-
LUAD	cis	rs7134599	1	rs7134599	ENSG00000240087.3	RP11-254B13.1	3.77	0.000184	0.0233	0.15	0.17	Inflammatory bowel disease;Ulcerative colitis;	chr12:68106295	chr12:68552995~68553882:-
LUAD	cis	rs62244186	0.593	rs9814298	ENSG00000233509.2	ZNF197-AS1	3.77	0.000184	0.0233	0.19	0.17	Depressive symptoms;	chr3:44830407	chr3:44617128~44624797:-
LUAD	cis	rs780096	0.565	rs11681351	ENSG00000234072.1	AC074117.10	-3.77	0.000184	0.0233	-0.13	-0.17	Total body bone mineral density;	chr2:27520556	chr2:27356246~27367622:+
LUAD	cis	rs848490	0.889	rs4291201	ENSG00000214293.7	APTR	-3.77	0.000184	0.0233	-0.22	-0.17	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77867238	chr7:77657660~77696265:-
LUAD	cis	rs11096990	0.593	rs4580660	ENSG00000249685.1	RP11-360F5.3	3.77	0.000184	0.0233	0.2	0.17	Cognitive function;	chr4:39152216	chr4:39133913~39135608:+
LUAD	cis	rs9894429	0.646	rs12603868	ENSG00000263853.1	AC139530.1	-3.77	0.000184	0.0233	-0.18	-0.17	Eye color traits;	chr17:81651804	chr17:81676001~81676086:+
LUAD	cis	rs848490	0.962	rs17807736	ENSG00000214293.7	APTR	3.77	0.000184	0.0233	0.23	0.17	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77838142	chr7:77657660~77696265:-
LUAD	cis	rs3617	0.591	rs2276823	ENSG00000242142.1	SERBP1P3	-3.77	0.000184	0.0233	-0.18	-0.17	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52835247	chr3:53064283~53065091:-
LUAD	cis	rs6754311	0.597	rs2082729	ENSG00000226806.1	AC011893.3	-3.77	0.000184	0.0233	-0.21	-0.17	Mosquito bite size;	chr2:135792539	chr2:135820191~135823087:+
LUAD	cis	rs7005380	0.733	rs6469878	ENSG00000279347.1	RP11-85I17.2	3.77	0.000185	0.0233	0.14	0.17	Interstitial lung disease;	chr8:119926208	chr8:119838736~119840385:-
LUAD	cis	rs12049351	0.774	rs12750869	ENSG00000229367.1	HMGN2P19	3.77	0.000185	0.0233	0.27	0.17	Circulating myeloperoxidase levels (plasma);	chr1:229570467	chr1:229570532~229570796:+
LUAD	cis	rs761746	0.584	rs62238892	ENSG00000236132.1	CTA-440B3.1	-3.77	0.000185	0.0233	-0.23	-0.17	Intelligence;	chr22:31765563	chr22:31816379~31817491:-
LUAD	cis	rs858239	0.899	rs5850	ENSG00000230042.1	AK3P3	-3.77	0.000185	0.0233	-0.22	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23274928	chr7:23129178~23129841:+
LUAD	cis	rs6964587	0.967	rs6465340	ENSG00000188693.7	CYP51A1-AS1	-3.77	0.000185	0.0233	-0.2	-0.17	Breast cancer;	chr7:91959350	chr7:92134604~92180725:+
LUAD	cis	rs858239	0.601	rs1981665	ENSG00000226816.2	AC005082.12	3.77	0.000185	0.0234	0.22	0.17	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23206013~23208045:+
LUAD	cis	rs77633900	0.892	rs2456042	ENSG00000196274.5	Metazoa_SRP	3.77	0.000185	0.0234	0.23	0.17	Glioma;Non-glioblastoma glioma;	chr15:76206878	chr15:76230048~76230390:-
LUAD	cis	rs238295	0.805	rs1983694	ENSG00000230563.2	RP5-828H9.1	3.77	0.000185	0.0234	0.22	0.17	Occipital cortical area (total cortical area interaction);	chr20:5593488	chr20:5471207~5475182:+
LUAD	cis	rs2346177	0.967	rs4953374	ENSG00000279254.1	RP11-536C12.1	-3.77	0.000185	0.0234	-0.18	-0.17	HDL cholesterol;	chr2:46427262	chr2:46668870~46670778:+
LUAD	cis	rs10129255	0.5	rs10143242	ENSG00000232216.1	IGHV3-43	3.77	0.000185	0.0234	0.14	0.17	Kawasaki disease;	chr14:106681814	chr14:106470264~106470800:-
LUAD	cis	rs6494488	0.5	rs72742930	ENSG00000239465.1	RP11-330L19.2	3.77	0.000185	0.0234	0.36	0.17	Coronary artery disease;	chr15:64578145	chr15:64631109~64631914:-
LUAD	cis	rs17228178	0.961	rs10152953	ENSG00000270055.1	CTD-3092A11.2	-3.77	0.000185	0.0234	-0.17	-0.17	Facial depth;Facial morphology (factor 1, breadth of lateral portion of upper face);	chr15:31175740	chr15:30487963~30490313:+
LUAD	cis	rs76878669	0.561	rs1892940	ENSG00000213409.4	RP11-658F2.3	-3.77	0.000185	0.0234	-0.2	-0.17	Educational attainment (years of education);	chr11:66343780	chr11:66761575~66762399:-
LUAD	cis	rs703842	1	rs10877015	ENSG00000245651.2	RP11-620J15.2	3.77	0.000185	0.0234	0.18	0.17	Multiple sclerosis;	chr12:57774005	chr12:57869835~57896482:-
LUAD	cis	rs73193808	0.901	rs67463471	ENSG00000215533.7	LINC00189	-3.77	0.000185	0.0234	-0.25	-0.17	Coronary artery disease;	chr21:29195488	chr21:29193480~29288205:+
LUAD	cis	rs797680	0.754	rs4847419	ENSG00000223745.6	RP4-717I23.3	3.77	0.000185	0.0234	0.13	0.17	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93380098	chr1:93262186~93346025:-
LUAD	cis	rs797680	0.664	rs4847420	ENSG00000223745.6	RP4-717I23.3	3.77	0.000185	0.0234	0.13	0.17	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93380117	chr1:93262186~93346025:-
LUAD	cis	rs67478160	0.643	rs8005225	ENSG00000272533.1	SNORA28	-3.77	0.000185	0.0234	-0.17	-0.17	Schizophrenia;	chr14:103833814	chr14:103337849~103337974:+
LUAD	cis	rs853679	0.517	rs4713150	ENSG00000280107.1	AL022393.9	-3.77	0.000185	0.0234	-0.23	-0.17	Depression;	chr6:28168434	chr6:28170845~28172521:+
LUAD	cis	rs755249	1	rs755249	ENSG00000237624.1	OXCT2P1	3.77	0.000185	0.0234	0.25	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39529402	chr1:39514956~39516490:+
LUAD	cis	rs7772486	0.79	rs9390365	ENSG00000235652.6	RP11-545I5.3	-3.77	0.000185	0.0234	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145914490	chr6:145799409~145886585:+
LUAD	cis	rs6568686	0.786	rs4145457	ENSG00000255389.1	C6orf3	-3.77	0.000185	0.0234	-0.24	-0.17	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111499979	chr6:111599875~111602295:+
LUAD	cis	rs10129255	0.518	rs10150460	ENSG00000232216.1	IGHV3-43	-3.77	0.000185	0.0234	-0.14	-0.17	Kawasaki disease;	chr14:106677179	chr14:106470264~106470800:-
LUAD	cis	rs10129255	0.518	rs7143784	ENSG00000274576.2	IGHV2-70	-3.77	0.000185	0.0234	-0.14	-0.17	Kawasaki disease;	chr14:106687277	chr14:106770577~106771020:-
LUAD	cis	rs7578361	0.959	rs11674815	ENSG00000231969.1	AC144449.1	-3.77	0.000185	0.0234	-0.25	-0.17	Acute lymphoblastic leukemia (childhood);	chr2:149597680	chr2:149587196~149848233:+
LUAD	cis	rs7119038	0.774	rs10892290	ENSG00000255239.1	AP002954.6	-3.77	0.000185	0.0234	-0.26	-0.17	Sjögren's syndrome;	chr11:118782794	chr11:118688039~118690600:-
LUAD	cis	rs13113518	1	rs12501636	ENSG00000273257.1	RP11-177J6.1	3.77	0.000185	0.0234	0.18	0.17	Height;	chr4:55482317	chr4:55387949~55388271:+
LUAD	cis	rs2348418	0.765	rs6487665	ENSG00000244712.1	RP11-874G11.1	3.77	0.000185	0.0234	0.2	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28177726	chr12:28564678~28565141:-
LUAD	cis	rs4462272	0.605	rs3818411	ENSG00000227492.1	RP11-316M21.6	3.77	0.000185	0.0234	0.17	0.17	Age-related hearing impairment (SNP x SNP interaction);	chr10:100201209	chr10:100229667~100234000:+
LUAD	cis	rs786425	0.833	rs7313628	ENSG00000278112.1	RP11-972P1.11	3.77	0.000185	0.0234	0.15	0.17	Pubertal anthropometrics;	chr12:123622468	chr12:123519390~123519856:-
LUAD	cis	rs131777	0.547	rs131753	ENSG00000272666.1	CTA-384D8.35	3.77	0.000185	0.0234	0.2	0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50584433	chr22:50542305~50542906:-
LUAD	cis	rs8028182	0.636	rs4486847	ENSG00000260269.4	CTD-2323K18.1	-3.77	0.000185	0.0234	-0.23	-0.17	Sudden cardiac arrest;	chr15:75436190	chr15:75527150~75601205:-
LUAD	cis	rs6502050	0.835	rs7503189	ENSG00000275966.1	RP11-1055B8.9	-3.77	0.000185	0.0234	-0.17	-0.17	Life satisfaction;	chr17:82141610	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs7503225	ENSG00000275966.1	RP11-1055B8.9	-3.77	0.000185	0.0234	-0.17	-0.17	Life satisfaction;	chr17:82141763	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs9904520	ENSG00000275966.1	RP11-1055B8.9	-3.77	0.000185	0.0234	-0.17	-0.17	Life satisfaction;	chr17:82142241	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.769	rs9898292	ENSG00000275966.1	RP11-1055B8.9	-3.77	0.000185	0.0234	-0.17	-0.17	Life satisfaction;	chr17:82142469	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.799	rs4789681	ENSG00000275966.1	RP11-1055B8.9	-3.77	0.000185	0.0234	-0.17	-0.17	Life satisfaction;	chr17:82142670	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.799	rs4789680	ENSG00000275966.1	RP11-1055B8.9	-3.77	0.000185	0.0234	-0.17	-0.17	Life satisfaction;	chr17:82142671	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs4789744	ENSG00000275966.1	RP11-1055B8.9	-3.77	0.000185	0.0234	-0.17	-0.17	Life satisfaction;	chr17:82143630	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs7503111	ENSG00000275966.1	RP11-1055B8.9	-3.77	0.000185	0.0234	-0.17	-0.17	Life satisfaction;	chr17:82143711	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.799	rs8066370	ENSG00000275966.1	RP11-1055B8.9	-3.77	0.000185	0.0234	-0.17	-0.17	Life satisfaction;	chr17:82144229	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs8080423	ENSG00000275966.1	RP11-1055B8.9	-3.77	0.000185	0.0234	-0.17	-0.17	Life satisfaction;	chr17:82144403	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.799	rs6502066	ENSG00000275966.1	RP11-1055B8.9	-3.77	0.000185	0.0234	-0.17	-0.17	Life satisfaction;	chr17:82145861	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.799	rs28376857	ENSG00000275966.1	RP11-1055B8.9	-3.77	0.000185	0.0234	-0.17	-0.17	Life satisfaction;	chr17:82146475	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs12600852	ENSG00000275966.1	RP11-1055B8.9	-3.77	0.000185	0.0234	-0.17	-0.17	Life satisfaction;	chr17:82146717	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.799	rs12603050	ENSG00000275966.1	RP11-1055B8.9	-3.77	0.000185	0.0234	-0.17	-0.17	Life satisfaction;	chr17:82146755	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.764	rs28676462	ENSG00000275966.1	RP11-1055B8.9	-3.77	0.000185	0.0234	-0.17	-0.17	Life satisfaction;	chr17:82147224	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs28640920	ENSG00000275966.1	RP11-1055B8.9	-3.77	0.000185	0.0234	-0.17	-0.17	Life satisfaction;	chr17:82147275	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs28481866	ENSG00000275966.1	RP11-1055B8.9	-3.77	0.000185	0.0234	-0.17	-0.17	Life satisfaction;	chr17:82147284	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.805	rs56020943	ENSG00000275966.1	RP11-1055B8.9	-3.77	0.000185	0.0234	-0.17	-0.17	Life satisfaction;	chr17:82147372	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.799	rs7502524	ENSG00000275966.1	RP11-1055B8.9	-3.77	0.000185	0.0234	-0.17	-0.17	Life satisfaction;	chr17:82149385	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.799	rs7502533	ENSG00000275966.1	RP11-1055B8.9	-3.77	0.000185	0.0234	-0.17	-0.17	Life satisfaction;	chr17:82151902	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.799	rs7501461	ENSG00000275966.1	RP11-1055B8.9	-3.77	0.000185	0.0234	-0.17	-0.17	Life satisfaction;	chr17:82151930	chr17:81345476~81345966:-
LUAD	cis	rs8012947	0.916	rs8004077	ENSG00000279636.2	LINC00216	3.77	0.000185	0.0234	0.19	0.17	Alcohol consumption in current drinkers;	chr14:58380013	chr14:58288033~58289158:+
LUAD	cis	rs683250	0.515	rs481321	ENSG00000246067.6	RAB30-AS1	3.77	0.000185	0.0234	0.18	0.17	Subcortical brain region volumes;	chr11:83246291	chr11:83072066~83106719:+
LUAD	cis	rs987044	0.726	rs1344512	ENSG00000257221.1	RP11-689B22.2	-3.77	0.000185	0.0234	-0.14	-0.17	Mean platelet volume;	chr12:108696263	chr12:108628687~108641318:+
LUAD	cis	rs2735413	0.875	rs8053987	ENSG00000276007.1	RP11-358L22.3	3.77	0.000185	0.0234	0.17	0.17	Systolic blood pressure (alcohol consumption interaction);	chr16:78050937	chr16:78123243~78124332:+
LUAD	cis	rs77633900	0.772	rs284904	ENSG00000196274.5	Metazoa_SRP	-3.77	0.000185	0.0234	-0.29	-0.17	Glioma;Non-glioblastoma glioma;	chr15:76451961	chr15:76230048~76230390:-
LUAD	cis	rs2235642	0.785	rs1057983	ENSG00000280231.1	LA16c-380F5.3	-3.77	0.000185	0.0234	-0.22	-0.17	Coronary artery disease;	chr16:1610273	chr16:1553655~1554130:-
LUAD	cis	rs1555322	0.53	rs2250205	ENSG00000269202.1	RP4-614O4.12	-3.77	0.000185	0.0234	-0.21	-0.17	Attention deficit hyperactivity disorder;	chr20:35280121	chr20:35201747~35203288:-
LUAD	cis	rs2906856	0.848	rs3015001	ENSG00000236946.2	HNRNPA1P70	3.77	0.000185	0.0234	0.14	0.17	Mosquito bite size;	chr12:68003593	chr12:68035767~68036853:+
LUAD	cis	rs507080	0.769	rs570836	ENSG00000278376.1	RP11-158I9.8	-3.77	0.000185	0.0234	-0.19	-0.17	Serum metabolite levels;	chr11:118641444	chr11:118791254~118793137:+
LUAD	cis	rs6502050	0.835	rs10163482	ENSG00000275966.1	RP11-1055B8.9	-3.77	0.000186	0.0234	-0.17	-0.17	Life satisfaction;	chr17:82152518	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs10163483	ENSG00000275966.1	RP11-1055B8.9	-3.77	0.000186	0.0234	-0.17	-0.17	Life satisfaction;	chr17:82152520	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs10163485	ENSG00000275966.1	RP11-1055B8.9	-3.77	0.000186	0.0234	-0.17	-0.17	Life satisfaction;	chr17:82152874	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs10163496	ENSG00000275966.1	RP11-1055B8.9	-3.77	0.000186	0.0234	-0.17	-0.17	Life satisfaction;	chr17:82152991	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs8067138	ENSG00000275966.1	RP11-1055B8.9	-3.77	0.000186	0.0234	-0.17	-0.17	Life satisfaction;	chr17:82153150	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs6502067	ENSG00000275966.1	RP11-1055B8.9	-3.77	0.000186	0.0234	-0.17	-0.17	Life satisfaction;	chr17:82153329	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.799	rs6416859	ENSG00000275966.1	RP11-1055B8.9	-3.77	0.000186	0.0234	-0.17	-0.17	Life satisfaction;	chr17:82153566	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs6502069	ENSG00000275966.1	RP11-1055B8.9	-3.77	0.000186	0.0234	-0.17	-0.17	Life satisfaction;	chr17:82154723	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs3924780	ENSG00000275966.1	RP11-1055B8.9	-3.77	0.000186	0.0234	-0.17	-0.17	Life satisfaction;	chr17:82155102	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs8078087	ENSG00000275966.1	RP11-1055B8.9	-3.77	0.000186	0.0234	-0.17	-0.17	Life satisfaction;	chr17:82155446	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs3935128	ENSG00000275966.1	RP11-1055B8.9	-3.77	0.000186	0.0234	-0.17	-0.17	Life satisfaction;	chr17:82155538	chr17:81345476~81345966:-
LUAD	cis	rs9517320	1	rs9517320	ENSG00000231194.1	FARP1-AS1	-3.77	0.000186	0.0234	-0.19	-0.17	Longevity;	chr13:98474049	chr13:98435405~98435840:-
LUAD	cis	rs7829975	0.714	rs7823757	ENSG00000233609.3	RP11-62H7.2	3.77	0.000186	0.0234	0.14	0.17	Mood instability;	chr8:8812667	chr8:8961200~8979025:+
LUAD	cis	rs12073359	1	rs1545762	ENSG00000223945.2	RP11-458I7.1	3.77	0.000186	0.0235	0.23	0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150156231	chr1:150053864~150055034:+
LUAD	cis	rs591584	0.621	rs593690	ENSG00000255893.1	RP11-685N10.1	-3.77	0.000186	0.0235	-0.19	-0.17	Macrophage Migration Inhibitory Factor levels;	chr11:94604054	chr11:94472908~94473570:-
LUAD	cis	rs321358	0.945	rs17458235	ENSG00000271390.1	RP11-89C3.3	-3.77	0.000186	0.0235	-0.27	-0.17	Body mass index;	chr11:111106114	chr11:111089870~111090368:-
LUAD	cis	rs7189233	0.91	rs3809634	ENSG00000279344.1	RP11-44F14.7	3.77	0.000186	0.0235	0.14	0.17	Intelligence (multi-trait analysis);	chr16:53504245	chr16:53478957~53481550:-
LUAD	cis	rs1198430	0.683	rs534417	ENSG00000232482.2	RP4-654C18.1	-3.77	0.000186	0.0235	-0.25	-0.17	Total cholesterol levels;	chr1:23458472	chr1:23410832~23412146:+
LUAD	cis	rs4819052	0.851	rs2838843	ENSG00000215447.6	BX322557.10	-3.77	0.000186	0.0235	-0.2	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249369	chr21:45288052~45291738:+
LUAD	cis	rs1555322	0.53	rs6060347	ENSG00000279253.1	RP4-614O4.13	-3.77	0.000186	0.0235	-0.21	-0.17	Attention deficit hyperactivity disorder;	chr20:35286348	chr20:35262727~35264187:-
LUAD	cis	rs1023500	0.551	rs2859438	ENSG00000273366.1	CTA-989H11.1	-3.77	0.000186	0.0235	-0.2	-0.17	Schizophrenia;	chr22:42070976	chr22:42278188~42278846:+
LUAD	cis	rs6715284	0.502	rs55759607	ENSG00000201499.1	RNU6-312P	-3.77	0.000186	0.0235	-0.32	-0.17	Rheumatoid arthritis;	chr2:201522423	chr2:200881715~200881821:-
LUAD	cis	rs6715284	0.502	rs55841134	ENSG00000201499.1	RNU6-312P	-3.77	0.000186	0.0235	-0.32	-0.17	Rheumatoid arthritis;	chr2:201522595	chr2:200881715~200881821:-
LUAD	cis	rs6715284	0.502	rs78982960	ENSG00000201499.1	RNU6-312P	-3.77	0.000186	0.0235	-0.32	-0.17	Rheumatoid arthritis;	chr2:201530590	chr2:200881715~200881821:-
LUAD	cis	rs17275866	1	rs17275866	ENSG00000251584.1	RP11-440I14.3	3.77	0.000186	0.0235	0.22	0.17	Chin dimples;	chr4:174150335	chr4:174536640~174540784:+
LUAD	cis	rs11853189	1	rs11856774	ENSG00000259562.2	RP11-762H8.2	3.77	0.000186	0.0235	0.19	0.17	Red cell distribution width;	chr15:78273697	chr15:78290527~78291221:-
LUAD	cis	rs2823962	0.927	rs2211992	ENSG00000270093.1	AP000473.8	-3.77	0.000186	0.0235	-0.17	-0.17	Amyotrophic lateral sclerosis;	chr21:16652325	chr21:16643529~16645065:+
LUAD	cis	rs7302981	0.746	rs646782	ENSG00000200428.1	Y_RNA	-3.77	0.000186	0.0235	-0.2	-0.17	Systolic blood pressure;	chr12:50088428	chr12:50743568~50743684:+
LUAD	cis	rs13260300	0.533	rs890217	ENSG00000249395.2	CASC9	-3.77	0.000186	0.0235	-0.2	-0.17	Breast cancer-free interval (treatment with aromatase inhibitor);	chr8:74581782	chr8:75223404~75324741:-
LUAD	cis	rs12935418	0.579	rs2123627	ENSG00000261061.1	RP11-303E16.2	3.77	0.000186	0.0235	0.18	0.17	Mean corpuscular volume;	chr16:80988211	chr16:81030770~81031485:+
LUAD	cis	rs7107174	1	rs2450122	ENSG00000251323.2	RP11-452H21.4	3.77	0.000186	0.0235	0.23	0.17	Testicular germ cell tumor;	chr11:78219299	chr11:78423982~78429836:-
LUAD	cis	rs56046484	0.871	rs12900736	ENSG00000259630.2	CTD-2262B20.1	-3.77	0.000186	0.0235	-0.25	-0.17	Testicular germ cell tumor;	chr15:85014909	chr15:85415228~85415633:+
LUAD	cis	rs56046484	0.871	rs12904958	ENSG00000259630.2	CTD-2262B20.1	-3.77	0.000186	0.0235	-0.25	-0.17	Testicular germ cell tumor;	chr15:85014956	chr15:85415228~85415633:+
LUAD	cis	rs56046484	0.871	rs34493704	ENSG00000259630.2	CTD-2262B20.1	-3.77	0.000186	0.0235	-0.25	-0.17	Testicular germ cell tumor;	chr15:85015539	chr15:85415228~85415633:+
LUAD	cis	rs56046484	0.871	rs71397837	ENSG00000259630.2	CTD-2262B20.1	-3.77	0.000186	0.0235	-0.25	-0.17	Testicular germ cell tumor;	chr15:85020330	chr15:85415228~85415633:+
LUAD	cis	rs56046484	0.871	rs62021203	ENSG00000259630.2	CTD-2262B20.1	-3.77	0.000186	0.0235	-0.25	-0.17	Testicular germ cell tumor;	chr15:85020846	chr15:85415228~85415633:+
LUAD	cis	rs858239	1	rs199357	ENSG00000230042.1	AK3P3	3.77	0.000186	0.0235	0.2	0.17	Cerebrospinal fluid biomarker levels;	chr7:23248690	chr7:23129178~23129841:+
LUAD	cis	rs875971	0.505	rs6955582	ENSG00000222364.1	RNU6-96P	-3.77	0.000186	0.0235	-0.19	-0.17	Aortic root size;	chr7:65966699	chr7:66395191~66395286:+
LUAD	cis	rs1823913	0.614	rs1947457	ENSG00000280083.1	RP11-317J9.1	-3.77	0.000186	0.0235	-0.36	-0.17	Obesity-related traits;	chr2:191298970	chr2:191154118~191156070:-
LUAD	cis	rs13113518	0.812	rs4865001	ENSG00000273257.1	RP11-177J6.1	3.77	0.000186	0.0235	0.19	0.17	Height;	chr4:55490176	chr4:55387949~55388271:+
LUAD	cis	rs10197140	1	rs17465162	ENSG00000235721.1	AC013268.3	-3.77	0.000186	0.0235	-0.19	-0.17	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110855568	chr2:110007675~110010783:+
LUAD	cis	rs17596685	1	rs8000846	ENSG00000271216.1	LINC01050	3.77	0.000186	0.0235	0.25	0.17	C-reactive protein levels;	chr13:42565450	chr13:42810366~42812562:-
LUAD	cis	rs2190016	0.673	rs62446190	ENSG00000236078.1	LINC01447	-3.77	0.000186	0.0235	-0.2	-0.17	Mammographic density (non-dense area);	chr7:46848055	chr7:47621939~47629893:+
LUAD	cis	rs683250	0.629	rs656515	ENSG00000246067.6	RAB30-AS1	3.77	0.000186	0.0235	0.18	0.17	Subcortical brain region volumes;	chr11:83257666	chr11:83072066~83106719:+
LUAD	cis	rs6988985	0.678	rs7011889	ENSG00000247317.3	RP11-273G15.2	-3.77	0.000186	0.0235	-0.21	-0.17	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142923844	chr8:142981738~143018437:-
LUAD	cis	rs12935418	0.523	rs2549845	ENSG00000261061.1	RP11-303E16.2	3.77	0.000186	0.0235	0.18	0.17	Mean corpuscular volume;	chr16:80990520	chr16:81030770~81031485:+
LUAD	cis	rs12935418	0.523	rs2549846	ENSG00000261061.1	RP11-303E16.2	3.77	0.000186	0.0235	0.18	0.17	Mean corpuscular volume;	chr16:80990522	chr16:81030770~81031485:+
LUAD	cis	rs2625529	0.586	rs59975112	ENSG00000260173.1	RP11-2I17.4	3.77	0.000186	0.0235	0.2	0.17	Red blood cell count;	chr15:72131369	chr15:72140504~72155459:-
LUAD	cis	rs4713118	0.869	rs9461405	ENSG00000280107.1	AL022393.9	-3.77	0.000186	0.0235	-0.21	-0.17	Parkinson's disease;	chr6:27751596	chr6:28170845~28172521:+
LUAD	cis	rs2014572	0.933	rs8109882	ENSG00000268379.1	CTC-360J11.4	3.77	0.000186	0.0235	0.2	0.17	Hyperactive-impulsive symptoms;	chr19:57244250	chr19:57175233~57177921:+
LUAD	cis	rs2014572	0.901	rs35658377	ENSG00000268379.1	CTC-360J11.4	3.77	0.000186	0.0235	0.2	0.17	Hyperactive-impulsive symptoms;	chr19:57244259	chr19:57175233~57177921:+
LUAD	cis	rs2014572	0.967	rs11084492	ENSG00000268379.1	CTC-360J11.4	3.77	0.000186	0.0235	0.2	0.17	Hyperactive-impulsive symptoms;	chr19:57244658	chr19:57175233~57177921:+
LUAD	cis	rs2014572	0.967	rs10426174	ENSG00000268379.1	CTC-360J11.4	3.77	0.000186	0.0235	0.2	0.17	Hyperactive-impulsive symptoms;	chr19:57244687	chr19:57175233~57177921:+
LUAD	cis	rs2014572	0.967	rs7259978	ENSG00000268379.1	CTC-360J11.4	3.77	0.000186	0.0235	0.2	0.17	Hyperactive-impulsive symptoms;	chr19:57244761	chr19:57175233~57177921:+
LUAD	cis	rs7976269	0.583	rs7955393	ENSG00000257176.2	RP11-996F15.2	-3.77	0.000186	0.0235	-0.18	-0.17	Male-pattern baldness;	chr12:29065773	chr12:29280418~29317848:-
LUAD	cis	rs7580658	0.613	rs6754999	ENSG00000236682.1	AC068282.3	-3.77	0.000186	0.0235	-0.22	-0.17	Protein C levels;	chr2:127437811	chr2:127389130~127400580:+
LUAD	cis	rs17711722	0.701	rs781143	ENSG00000222364.1	RNU6-96P	-3.77	0.000186	0.0235	-0.19	-0.17	Calcium levels;	chr7:65974892	chr7:66395191~66395286:+
LUAD	cis	rs2281636	0.823	rs11190225	ENSG00000233690.1	EBAG9P1	3.77	0.000186	0.0235	0.16	0.17	Obesity-related traits;	chr10:99657156	chr10:99697407~99697949:-
LUAD	cis	rs9925964	0.933	rs9929899	ENSG00000232748.3	RP11-196G11.6	3.77	0.000186	0.0235	0.2	0.17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31051380	chr16:31056460~31062803:+
LUAD	cis	rs1346081	0.874	rs10434249	ENSG00000250075.4	RP11-584P21.2	-3.77	0.000186	0.0235	-0.18	-0.17	Intelligence (multi-trait analysis);	chr4:67191913	chr4:67417305~67468251:-
LUAD	cis	rs6071166	0.683	rs6071092	ENSG00000224635.1	RP4-564F22.5	-3.77	0.000186	0.0235	-0.19	-0.17	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38685479	chr20:38406011~38416797:-
LUAD	cis	rs7824557	0.603	rs2250028	ENSG00000255046.1	RP11-297N6.4	-3.77	0.000186	0.0235	-0.21	-0.17	Retinal vascular caliber;	chr8:11356080	chr8:11797928~11802568:-
LUAD	cis	rs703842	0.56	rs11533604	ENSG00000270039.1	RP11-571M6.17	-3.77	0.000186	0.0235	-0.22	-0.17	Multiple sclerosis;	chr12:57653930	chr12:57803838~57804415:+
LUAD	cis	rs7578361	0.959	rs4667422	ENSG00000231969.1	AC144449.1	3.77	0.000186	0.0235	0.25	0.17	Acute lymphoblastic leukemia (childhood);	chr2:149564274	chr2:149587196~149848233:+
LUAD	cis	rs5758511	0.68	rs5758688	ENSG00000233903.2	Z83851.4	3.77	0.000186	0.0235	0.25	0.17	Birth weight;	chr22:42266495	chr22:42276355~42277052:+
LUAD	cis	rs1348850	0.872	rs12991272	ENSG00000271825.1	RP11-337N6.2	3.77	0.000186	0.0235	0.22	0.17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177592611	chr2:177300600~177302006:+
LUAD	cis	rs116095464	0.558	rs6869925	ENSG00000248925.1	CTD-2083E4.6	3.77	0.000186	0.0235	0.29	0.17	Breast cancer;	chr5:263921	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs6875291	ENSG00000248925.1	CTD-2083E4.6	3.77	0.000186	0.0235	0.29	0.17	Breast cancer;	chr5:264077	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs6866776	ENSG00000248925.1	CTD-2083E4.6	3.77	0.000186	0.0235	0.29	0.17	Breast cancer;	chr5:264380	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs6874745	ENSG00000248925.1	CTD-2083E4.6	3.77	0.000186	0.0235	0.29	0.17	Breast cancer;	chr5:264412	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs7715108	ENSG00000248925.1	CTD-2083E4.6	3.77	0.000186	0.0235	0.29	0.17	Breast cancer;	chr5:264546	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs7730700	ENSG00000248925.1	CTD-2083E4.6	3.77	0.000186	0.0235	0.29	0.17	Breast cancer;	chr5:264598	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs10057674	ENSG00000248925.1	CTD-2083E4.6	3.77	0.000186	0.0235	0.29	0.17	Breast cancer;	chr5:266698	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs1812843	ENSG00000248925.1	CTD-2083E4.6	3.77	0.000186	0.0235	0.29	0.17	Breast cancer;	chr5:267543	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs1971229	ENSG00000248925.1	CTD-2083E4.6	3.77	0.000186	0.0235	0.29	0.17	Breast cancer;	chr5:268072	chr5:269858~271516:-
LUAD	cis	rs2179367	0.919	rs577001	ENSG00000216906.2	RP11-350J20.9	3.77	0.000186	0.0235	0.21	0.17	Dupuytren's disease;	chr6:149325172	chr6:149904243~149906418:+
LUAD	cis	rs2239547	0.618	rs1573815	ENSG00000243224.1	RP5-1157M23.2	3.77	0.000186	0.0235	0.19	0.17	Schizophrenia;	chr3:52836116	chr3:52239258~52241097:+
LUAD	cis	rs728616	0.867	rs61860039	ENSG00000225484.5	NUTM2B-AS1	-3.77	0.000186	0.0235	-0.44	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80180150	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.867	rs61860041	ENSG00000225484.5	NUTM2B-AS1	-3.77	0.000186	0.0235	-0.44	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80184575	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.867	rs61860042	ENSG00000225484.5	NUTM2B-AS1	-3.77	0.000186	0.0235	-0.44	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80186482	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.867	rs61860043	ENSG00000225484.5	NUTM2B-AS1	-3.77	0.000186	0.0235	-0.44	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80186642	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.867	rs12415870	ENSG00000225484.5	NUTM2B-AS1	-3.77	0.000186	0.0235	-0.44	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80189714	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.867	rs12414521	ENSG00000225484.5	NUTM2B-AS1	-3.77	0.000186	0.0235	-0.44	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80189778	chr10:79663088~79826594:-
LUAD	cis	rs703842	0.616	rs1875125	ENSG00000245651.2	RP11-620J15.2	3.77	0.000186	0.0235	0.18	0.17	Multiple sclerosis;	chr12:57833458	chr12:57869835~57896482:-
LUAD	cis	rs7637701	0.901	rs4680312	ENSG00000240875.4	LINC00886	-3.77	0.000186	0.0235	-0.18	-0.17	Breast cancer;	chr3:156888140	chr3:156747346~156817062:-
LUAD	cis	rs7637701	0.967	rs11712111	ENSG00000240875.4	LINC00886	-3.77	0.000186	0.0235	-0.18	-0.17	Breast cancer;	chr3:156891151	chr3:156747346~156817062:-
LUAD	cis	rs3733418	0.929	rs2280325	ENSG00000248632.1	RP11-366M4.11	3.77	0.000186	0.0235	0.27	0.17	Obesity-related traits;	chr4:165007102	chr4:164968587~164970002:-
LUAD	cis	rs13113518	1	rs4864995	ENSG00000273257.1	RP11-177J6.1	3.77	0.000186	0.0235	0.18	0.17	Height;	chr4:55452853	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs12651640	ENSG00000273257.1	RP11-177J6.1	3.77	0.000186	0.0235	0.18	0.17	Height;	chr4:55454154	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs1554483	ENSG00000273257.1	RP11-177J6.1	3.77	0.000186	0.0235	0.18	0.17	Height;	chr4:55455650	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs1464490	ENSG00000273257.1	RP11-177J6.1	3.77	0.000186	0.0235	0.18	0.17	Height;	chr4:55456620	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs10517346	ENSG00000273257.1	RP11-177J6.1	3.77	0.000186	0.0235	0.18	0.17	Height;	chr4:55457027	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs11133384	ENSG00000273257.1	RP11-177J6.1	3.77	0.000186	0.0235	0.18	0.17	Height;	chr4:55457086	chr4:55387949~55388271:+
LUAD	cis	rs13113518	0.967	rs4340844	ENSG00000273257.1	RP11-177J6.1	3.77	0.000186	0.0235	0.19	0.17	Height;	chr4:55462689	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs1522112	ENSG00000273257.1	RP11-177J6.1	3.77	0.000186	0.0235	0.19	0.17	Height;	chr4:55463606	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs4864997	ENSG00000273257.1	RP11-177J6.1	3.77	0.000186	0.0235	0.19	0.17	Height;	chr4:55466010	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs960152	ENSG00000273257.1	RP11-177J6.1	3.77	0.000186	0.0235	0.19	0.17	Height;	chr4:55467308	chr4:55387949~55388271:+
LUAD	cis	rs13113518	0.967	rs12644948	ENSG00000273257.1	RP11-177J6.1	3.77	0.000186	0.0235	0.19	0.17	Height;	chr4:55470266	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs3805151	ENSG00000273257.1	RP11-177J6.1	3.77	0.000186	0.0235	0.19	0.17	Height;	chr4:55470874	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs13118237	ENSG00000273257.1	RP11-177J6.1	3.77	0.000186	0.0235	0.19	0.17	Height;	chr4:55474259	chr4:55387949~55388271:+
LUAD	cis	rs853679	0.527	rs213228	ENSG00000219392.1	RP1-265C24.5	-3.77	0.000186	0.0235	-0.22	-0.17	Depression;	chr6:28363475	chr6:28115628~28116551:+
LUAD	cis	rs17711722	0.522	rs62469933	ENSG00000228409.4	CCT6P1	-3.77	0.000186	0.0235	-0.14	-0.17	Calcium levels;	chr7:65800652	chr7:65751142~65763354:+
LUAD	cis	rs7824557	0.527	rs4634600	ENSG00000255046.1	RP11-297N6.4	3.77	0.000186	0.0235	0.21	0.17	Retinal vascular caliber;	chr8:11381508	chr8:11797928~11802568:-
LUAD	cis	rs7824557	0.527	rs4631425	ENSG00000255046.1	RP11-297N6.4	3.77	0.000186	0.0235	0.21	0.17	Retinal vascular caliber;	chr8:11381545	chr8:11797928~11802568:-
LUAD	cis	rs3808502	0.585	rs4549730	ENSG00000255046.1	RP11-297N6.4	3.77	0.000186	0.0235	0.21	0.17	Neuroticism;	chr8:11381569	chr8:11797928~11802568:-
LUAD	cis	rs8062405	1	rs12446589	ENSG00000261419.1	RP11-57A19.4	-3.77	0.000186	0.0235	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28659696~28740781:-
LUAD	cis	rs9659323	0.632	rs10923743	ENSG00000231365.4	RP11-418J17.1	-3.77	0.000187	0.0235	-0.2	-0.17	Body mass index;	chr1:119070009	chr1:119140396~119275973:+
LUAD	cis	rs9659323	0.632	rs10923744	ENSG00000231365.4	RP11-418J17.1	-3.77	0.000187	0.0235	-0.2	-0.17	Body mass index;	chr1:119071318	chr1:119140396~119275973:+
LUAD	cis	rs7035284	1	rs6475544	ENSG00000229298.1	TUBB8P1	3.77	0.000187	0.0235	0.22	0.17	Pediatric bone mineral content (radius);	chr9:21679153	chr9:21811621~21812347:-
LUAD	cis	rs2253762	0.54	rs12249581	ENSG00000276742.1	RP11-500G22.4	3.77	0.000187	0.0235	0.26	0.17	Breast cancer;	chr10:122013486	chr10:121956782~121957098:+
LUAD	cis	rs9860250	1	rs17398137	ENSG00000256628.3	ZBTB11-AS1	3.77	0.000187	0.0235	0.29	0.17	Optic disc area;	chr3:100906859	chr3:101676475~101679217:+
LUAD	cis	rs7572733	0.935	rs6734561	ENSG00000222017.1	AC011997.1	3.77	0.000187	0.0236	0.21	0.17	Dermatomyositis;	chr2:197860352	chr2:197693106~197774823:+
LUAD	cis	rs7572733	0.901	rs700689	ENSG00000222017.1	AC011997.1	3.77	0.000187	0.0236	0.21	0.17	Dermatomyositis;	chr2:197861925	chr2:197693106~197774823:+
LUAD	cis	rs7572733	0.935	rs700691	ENSG00000222017.1	AC011997.1	3.77	0.000187	0.0236	0.21	0.17	Dermatomyositis;	chr2:197863128	chr2:197693106~197774823:+
LUAD	cis	rs7572733	0.905	rs700693	ENSG00000222017.1	AC011997.1	3.77	0.000187	0.0236	0.21	0.17	Dermatomyositis;	chr2:197865291	chr2:197693106~197774823:+
LUAD	cis	rs4474465	0.85	rs10751294	ENSG00000251323.2	RP11-452H21.4	-3.77	0.000187	0.0236	-0.2	-0.17	Alzheimer's disease (survival time);	chr11:78542257	chr11:78423982~78429836:-
LUAD	cis	rs7005380	0.62	rs6989741	ENSG00000279347.1	RP11-85I17.2	-3.77	0.000187	0.0236	-0.14	-0.17	Interstitial lung disease;	chr8:119899914	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.6	rs13257252	ENSG00000279347.1	RP11-85I17.2	-3.77	0.000187	0.0236	-0.14	-0.17	Interstitial lung disease;	chr8:119899993	chr8:119838736~119840385:-
LUAD	cis	rs6691170	1	rs6659311	ENSG00000228437.4	RP11-400N13.2	3.77	0.000187	0.0236	0.2	0.17	Colorectal cancer;	chr1:221876788	chr1:221966341~221984964:+
LUAD	cis	rs11018904	0.861	rs61903723	ENSG00000280367.1	RP11-121L10.2	3.77	0.000187	0.0236	0.22	0.17	Intelligence (multi-trait analysis);	chr11:90235078	chr11:90223153~90226538:+
LUAD	cis	rs2014572	0.967	rs10413037	ENSG00000268379.1	CTC-360J11.4	3.77	0.000187	0.0236	0.2	0.17	Hyperactive-impulsive symptoms;	chr19:57260515	chr19:57175233~57177921:+
LUAD	cis	rs683250	0.63	rs2512659	ENSG00000246067.6	RAB30-AS1	-3.77	0.000187	0.0236	-0.18	-0.17	Subcortical brain region volumes;	chr11:83423845	chr11:83072066~83106719:+
LUAD	cis	rs7809950	1	rs67982599	ENSG00000238832.1	snoU109	-3.77	0.000187	0.0236	-0.25	-0.17	Coronary artery disease;	chr7:107459659	chr7:107603363~107603507:+
LUAD	cis	rs7809950	1	rs987391	ENSG00000238832.1	snoU109	-3.77	0.000187	0.0236	-0.25	-0.17	Coronary artery disease;	chr7:107460349	chr7:107603363~107603507:+
LUAD	cis	rs4767841	0.805	rs10849696	ENSG00000248636.5	RP11-768F21.1	-3.77	0.000187	0.0236	-0.2	-0.17	Urgency urinary incontinence;	chr12:119771207	chr12:119387987~119668079:-
LUAD	cis	rs35934224	0.769	rs78190485	ENSG00000232926.1	AC000078.5	3.77	0.000187	0.0236	0.23	0.17	Glaucoma (primary open-angle);	chr22:19870652	chr22:19887289~19887970:+
LUAD	cis	rs3805389	0.504	rs28416150	ENSG00000273257.1	RP11-177J6.1	-3.77	0.000187	0.0236	-0.27	-0.17	Waist-to-hip ratio adjusted for body mass index;	chr4:55608211	chr4:55387949~55388271:+
LUAD	cis	rs12908161	0.853	rs11633788	ENSG00000275120.1	RP11-182J1.17	3.77	0.000187	0.0236	0.23	0.17	Schizophrenia;	chr15:84761911	chr15:84599434~84606463:-
LUAD	cis	rs877356	1	rs35520957	ENSG00000250167.1	CTC-321K16.1	-3.77	0.000187	0.0236	-0.31	-0.17	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (dichotomous);	chr5:135827618	chr5:135559577~135634874:+
LUAD	cis	rs8180040	0.966	rs3736177	ENSG00000271161.1	BOLA2P2	-3.77	0.000187	0.0236	-0.16	-0.17	Colorectal cancer;	chr3:47409921	chr3:47499841~47500407:+
LUAD	cis	rs11089937	0.929	rs5757155	ENSG00000211640.3	IGLV6-57	3.77	0.000187	0.0236	0.11	0.17	Periodontitis (PAL4Q3);	chr22:22165378	chr22:22195713~22196460:+
LUAD	cis	rs7923609	0.54	rs10995455	ENSG00000232075.1	MRPL35P2	-3.77	0.000187	0.0236	-0.23	-0.17	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63176601	chr10:63634317~63634827:-
LUAD	cis	rs6964587	0.869	rs10276682	ENSG00000188693.7	CYP51A1-AS1	3.77	0.000187	0.0236	0.2	0.17	Breast cancer;	chr7:91856756	chr7:92134604~92180725:+
LUAD	cis	rs6964587	0.869	rs4729010	ENSG00000188693.7	CYP51A1-AS1	3.77	0.000187	0.0236	0.2	0.17	Breast cancer;	chr7:91857437	chr7:92134604~92180725:+
LUAD	cis	rs11051970	0.879	rs1500874	ENSG00000274964.1	RP11-817I4.1	-3.77	0.000187	0.0236	-0.18	-0.17	Response to tocilizumab in rheumatoid arthritis;	chr12:32436473	chr12:32339368~32340724:+
LUAD	cis	rs9549260	0.755	rs4943800	ENSG00000229456.1	RLIMP1	3.77	0.000187	0.0236	0.19	0.17	Red blood cell count;	chr13:40642694	chr13:40618738~40621348:+
LUAD	cis	rs71520386	0.846	rs61997069	ENSG00000228649.7	AC005682.5	-3.77	0.000187	0.0236	-0.27	-0.17	Fibrinogen levels;	chr7:22773966	chr7:22854178~22861579:+
LUAD	cis	rs5022636	0.507	rs4971035	ENSG00000232671.4	RP11-126K1.2	3.77	0.000187	0.0236	0.21	0.17	Gut microbiota (functional units);	chr1:151351582	chr1:151280024~151281929:-
LUAD	cis	rs1023500	0.573	rs2413666	ENSG00000205702.9	CYP2D7	3.77	0.000187	0.0236	0.14	0.17	Schizophrenia;	chr22:42063618	chr22:42140203~42144577:-
LUAD	cis	rs7572733	0.935	rs700679	ENSG00000222017.1	AC011997.1	3.77	0.000187	0.0236	0.21	0.17	Dermatomyositis;	chr2:197842192	chr2:197693106~197774823:+
LUAD	cis	rs8012947	1	rs1984549	ENSG00000279636.2	LINC00216	-3.77	0.000187	0.0236	-0.18	-0.17	Alcohol consumption in current drinkers;	chr14:58322121	chr14:58288033~58289158:+
LUAD	cis	rs6121246	0.559	rs6121038	ENSG00000230613.1	HM13-AS1	3.77	0.000187	0.0236	0.21	0.17	Mean corpuscular hemoglobin;	chr20:31666970	chr20:31567707~31573263:-
LUAD	cis	rs6910061	1	rs2327335	ENSG00000247925.2	RP3-510L9.1	3.77	0.000187	0.0236	0.24	0.17	Diabetic kidney disease;	chr6:11118814	chr6:11173452~11259099:+
LUAD	cis	rs9876781	1	rs9311423	ENSG00000229759.1	MRPS18AP1	3.77	0.000187	0.0236	0.16	0.17	Longevity;	chr3:48378818	chr3:48256350~48256938:-
LUAD	cis	rs9876781	1	rs7634377	ENSG00000229759.1	MRPS18AP1	3.77	0.000187	0.0236	0.16	0.17	Longevity;	chr3:48379768	chr3:48256350~48256938:-
LUAD	cis	rs8028182	0.583	rs4886722	ENSG00000260269.4	CTD-2323K18.1	-3.77	0.000187	0.0236	-0.23	-0.17	Sudden cardiac arrest;	chr15:75629295	chr15:75527150~75601205:-
LUAD	cis	rs748404	0.666	rs72709871	ENSG00000249839.1	AC011330.5	-3.77	0.000187	0.0236	-0.26	-0.17	Lung cancer;	chr15:43499025	chr15:43663654~43684339:-
LUAD	cis	rs2412819	0.571	rs495880	ENSG00000166763.7	STRCP1	-3.77	0.000187	0.0236	-0.24	-0.17	Lung cancer;	chr15:43855067	chr15:43699488~43718184:-
LUAD	cis	rs9302635	0.513	rs3902135	ENSG00000260886.1	TAT-AS1	3.77	0.000187	0.0236	0.22	0.17	Blood protein levels;	chr16:72141921	chr16:71565789~71578187:+
LUAD	cis	rs9302635	0.513	rs35460163	ENSG00000260886.1	TAT-AS1	3.77	0.000187	0.0236	0.22	0.17	Blood protein levels;	chr16:72143161	chr16:71565789~71578187:+
LUAD	cis	rs7186908	0.761	rs34714490	ENSG00000260886.1	TAT-AS1	3.77	0.000187	0.0236	0.22	0.17	Liver enzyme levels (alkaline phosphatase);	chr16:72143200	chr16:71565789~71578187:+
LUAD	cis	rs7005380	0.62	rs6988011	ENSG00000279347.1	RP11-85I17.2	-3.77	0.000187	0.0236	-0.14	-0.17	Interstitial lung disease;	chr8:119898298	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.6	rs35272074	ENSG00000279347.1	RP11-85I17.2	-3.77	0.000187	0.0236	-0.14	-0.17	Interstitial lung disease;	chr8:119898543	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.6	rs10103660	ENSG00000279347.1	RP11-85I17.2	-3.77	0.000187	0.0236	-0.14	-0.17	Interstitial lung disease;	chr8:119898547	chr8:119838736~119840385:-
LUAD	cis	rs8040855	0.52	rs11629963	ENSG00000259774.1	RP11-182J1.13	-3.77	0.000187	0.0236	-0.22	-0.17	Bulimia nervosa;	chr15:84986808	chr15:84422618~84425882:+
LUAD	cis	rs8098244	0.708	rs1154244	ENSG00000264745.1	TTC39C-AS1	3.77	0.000187	0.0236	0.21	0.17	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23964052	chr18:23994213~24015339:-
LUAD	cis	rs877819	0.583	rs2170133	ENSG00000228403.1	RP11-563N6.6	-3.77	0.000187	0.0236	-0.17	-0.17	Systemic lupus erythematosus;	chr10:48848166	chr10:48878022~48878649:+
LUAD	cis	rs10129255	0.957	rs11847726	ENSG00000211947.2	IGHV3-21	-3.77	0.000187	0.0236	-0.11	-0.17	Kawasaki disease;	chr14:106779116	chr14:106235064~106235594:-
LUAD	cis	rs9402682	0.77	rs2210366	ENSG00000232876.1	CTA-212D2.2	3.76	0.000187	0.0236	0.21	0.17	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr6:135094070	chr6:135055033~135060550:+
LUAD	cis	rs7208859	0.673	rs999798	ENSG00000263603.1	CTD-2349P21.5	-3.76	0.000187	0.0236	-0.25	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831822	chr17:30729469~30731202:+
LUAD	cis	rs11955398	0.502	rs158922	ENSG00000272308.1	RP11-231G3.1	-3.76	0.000187	0.0236	-0.2	-0.17	Intelligence (multi-trait analysis);	chr5:60945159	chr5:60866457~60866935:-
LUAD	cis	rs6071166	1	rs6071166	ENSG00000224635.1	RP4-564F22.5	-3.76	0.000187	0.0236	-0.19	-0.17	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38704369	chr20:38406011~38416797:-
LUAD	cis	rs9393777	0.778	rs4452638	ENSG00000219392.1	RP1-265C24.5	3.76	0.000187	0.0236	0.32	0.17	Intelligence (multi-trait analysis);	chr6:27261486	chr6:28115628~28116551:+
LUAD	cis	rs1908814	0.516	rs10113042	ENSG00000255046.1	RP11-297N6.4	-3.76	0.000187	0.0236	-0.21	-0.17	Neuroticism;	chr8:11935669	chr8:11797928~11802568:-
LUAD	cis	rs6781182	0.517	rs11708781	ENSG00000236452.1	AC123023.1	3.76	0.000187	0.0236	0.19	0.17	Visceral adipose tissue adjusted for BMI;	chr3:34171124	chr3:34203244~34268811:+
LUAD	cis	rs6903823	0.508	rs1150726	ENSG00000219392.1	RP1-265C24.5	-3.76	0.000187	0.0236	-0.21	-0.17	Pulmonary function;	chr6:28275265	chr6:28115628~28116551:+
LUAD	cis	rs17695224	0.545	rs11666614	ENSG00000269483.1	AC006272.1	3.76	0.000187	0.0236	0.18	0.17	HDL cholesterol;HDL cholesterol levels;	chr19:51842833	chr19:51839924~51843324:-
LUAD	cis	rs5015933	0.902	rs1874943	ENSG00000232630.1	PRPS1P2	-3.76	0.000187	0.0236	-0.16	-0.17	Body mass index;	chr9:125361055	chr9:125150653~125151589:+
LUAD	cis	rs7107174	1	rs2450129	ENSG00000251323.2	RP11-452H21.4	3.76	0.000187	0.0236	0.23	0.17	Testicular germ cell tumor;	chr11:78229339	chr11:78423982~78429836:-
LUAD	cis	rs6121246	0.559	rs6119650	ENSG00000230613.1	HM13-AS1	3.76	0.000187	0.0236	0.21	0.17	Mean corpuscular hemoglobin;	chr20:31670677	chr20:31567707~31573263:-
LUAD	cis	rs494562	0.892	rs683218	ENSG00000234155.1	RP11-30P6.6	-3.76	0.000188	0.0236	-0.33	-0.17	Metabolic traits;Blood metabolite levels;	chr6:85408866	chr6:85387219~85390186:-
LUAD	cis	rs3845817	0.67	rs840787	ENSG00000281920.1	RP11-418H16.1	-3.76	0.000188	0.0236	-0.21	-0.17	Bipolar disorder;	chr2:65548756	chr2:65623272~65628424:+
LUAD	cis	rs520525	0.963	rs552277	ENSG00000271811.1	RP1-79C4.4	3.76	0.000188	0.0236	0.22	0.17	Atrial fibrillation;	chr1:170658653	chr1:170667381~170669425:+
LUAD	cis	rs801193	0.967	rs2707841	ENSG00000222364.1	RNU6-96P	-3.76	0.000188	0.0236	-0.19	-0.17	Aortic root size;	chr7:66692033	chr7:66395191~66395286:+
LUAD	cis	rs8141529	0.732	rs6005881	ENSG00000272858.1	CTA-292E10.8	-3.76	0.000188	0.0236	-0.19	-0.17	Lymphocyte counts;	chr22:28787145	chr22:28814914~28815662:+
LUAD	cis	rs35934224	0.769	rs76916615	ENSG00000232926.1	AC000078.5	3.76	0.000188	0.0236	0.23	0.17	Glaucoma (primary open-angle);	chr22:19870373	chr22:19887289~19887970:+
LUAD	cis	rs6121246	0.609	rs6089075	ENSG00000230613.1	HM13-AS1	3.76	0.000188	0.0236	0.21	0.17	Mean corpuscular hemoglobin;	chr20:31805081	chr20:31567707~31573263:-
LUAD	cis	rs28472312	0.762	rs62037423	ENSG00000246465.1	RP11-57A19.2	3.76	0.000188	0.0236	0.2	0.17	Intelligence (multi-trait analysis);	chr16:28953395	chr16:28284885~28292064:-
LUAD	cis	rs12148488	0.816	rs11854975	ENSG00000260269.4	CTD-2323K18.1	-3.76	0.000188	0.0237	-0.21	-0.17	Caffeine consumption;	chr15:75071535	chr15:75527150~75601205:-
LUAD	cis	rs13113518	1	rs4864999	ENSG00000273257.1	RP11-177J6.1	3.76	0.000188	0.0237	0.19	0.17	Height;	chr4:55476736	chr4:55387949~55388271:+
LUAD	cis	rs13113518	0.966	rs12506788	ENSG00000273257.1	RP11-177J6.1	3.76	0.000188	0.0237	0.19	0.17	Height;	chr4:55477426	chr4:55387949~55388271:+
LUAD	cis	rs13113518	0.966	rs10517344	ENSG00000273257.1	RP11-177J6.1	3.76	0.000188	0.0237	0.19	0.17	Height;	chr4:55477545	chr4:55387949~55388271:+
LUAD	cis	rs6964587	0.967	rs7788092	ENSG00000188693.7	CYP51A1-AS1	-3.76	0.000188	0.0237	-0.2	-0.17	Breast cancer;	chr7:92016884	chr7:92134604~92180725:+
LUAD	cis	rs10644111	1	rs10644111	ENSG00000188693.7	CYP51A1-AS1	-3.76	0.000188	0.0237	-0.2	-0.17	Breast cancer;	chr7:92022864	chr7:92134604~92180725:+
LUAD	cis	rs2554380	0.943	rs1477593	ENSG00000230373.7	GOLGA6L5P	-3.76	0.000188	0.0237	-0.21	-0.17	Height;	chr15:83694293	chr15:84507885~84516814:-
LUAD	cis	rs8177876	0.822	rs8056972	ENSG00000261061.1	RP11-303E16.2	-3.76	0.000188	0.0237	-0.28	-0.17	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078817	chr16:81030770~81031485:+
LUAD	cis	rs12519773	0.526	rs4869415	ENSG00000251361.1	CTD-2091N23.1	-3.76	0.000188	0.0237	-0.18	-0.17	Migraine;	chr5:93187058	chr5:93019663~93068669:-
LUAD	cis	rs9532580	0.614	rs61963261	ENSG00000229456.1	RLIMP1	3.76	0.000188	0.0237	0.26	0.17	Mean corpuscular hemoglobin;	chr13:40568158	chr13:40618738~40621348:+
LUAD	cis	rs4662750	0.58	rs4662745	ENSG00000236682.1	AC068282.3	3.76	0.000188	0.0237	0.21	0.17	Renal cell carcinoma;	chr2:127595288	chr2:127389130~127400580:+
LUAD	cis	rs3805389	0.504	rs56288855	ENSG00000273257.1	RP11-177J6.1	-3.76	0.000188	0.0237	-0.28	-0.17	Waist-to-hip ratio adjusted for body mass index;	chr4:55603178	chr4:55387949~55388271:+
LUAD	cis	rs5015933	0.815	rs359597	ENSG00000232630.1	PRPS1P2	-3.76	0.000188	0.0237	-0.16	-0.17	Body mass index;	chr9:125274312	chr9:125150653~125151589:+
LUAD	cis	rs2179367	0.959	rs536203	ENSG00000216906.2	RP11-350J20.9	3.76	0.000188	0.0237	0.21	0.17	Dupuytren's disease;	chr6:149330128	chr6:149904243~149906418:+
LUAD	cis	rs2333021	0.689	rs10142131	ENSG00000259015.1	RP11-109N23.6	3.76	0.000188	0.0237	0.16	0.17	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73000966	chr14:72960595~72961993:+
LUAD	cis	rs911119	0.913	rs3004145	ENSG00000270001.1	RP11-218C14.8	3.76	0.000188	0.0237	0.25	0.17	Chronic kidney disease;	chr20:23602239	chr20:23631826~23632316:-
LUAD	cis	rs34929064	0.718	rs35345753	ENSG00000230658.1	KLHL7-AS1	3.76	0.000188	0.0237	0.26	0.17	Major depression and alcohol dependence;	chr7:22700894	chr7:23101228~23105703:-
LUAD	cis	rs12413361	0.967	rs947100	ENSG00000272914.1	RP11-330O11.3	-3.76	0.000188	0.0237	-0.2	-0.17	Height;	chr10:30840980	chr10:30831828~30833387:-
LUAD	cis	rs2239620	0.655	rs3945943	ENSG00000216775.2	RP1-152L7.5	-3.76	0.000188	0.0237	-0.18	-0.17	LDL cholesterol levels;	chr6:52592354	chr6:52665148~52669155:+
LUAD	cis	rs9392556	0.533	rs619439	ENSG00000230648.1	RP3-406P24.3	3.76	0.000188	0.0237	0.18	0.17	Blood metabolite levels;	chr6:4113695	chr6:4018843~4021215:-
LUAD	cis	rs739496	0.563	rs61547643	ENSG00000234608.6	MAPKAPK5-AS1	3.76	0.000188	0.0237	0.2	0.17	Platelet count;	chr12:111828820	chr12:111839764~111842902:-
LUAD	cis	rs739496	0.512	rs73422315	ENSG00000234608.6	MAPKAPK5-AS1	3.76	0.000188	0.0237	0.2	0.17	Platelet count;	chr12:111830495	chr12:111839764~111842902:-
LUAD	cis	rs137603	0.644	rs137620	ENSG00000225450.1	RP3-508I15.14	-3.76	0.000188	0.0237	-0.15	-0.17	Primary biliary cholangitis;	chr22:39313771	chr22:38739003~38749041:+
LUAD	cis	rs137603	0.644	rs137621	ENSG00000225450.1	RP3-508I15.14	-3.76	0.000188	0.0237	-0.15	-0.17	Primary biliary cholangitis;	chr22:39314239	chr22:38739003~38749041:+
LUAD	cis	rs4865762	0.514	rs251337	ENSG00000272416.1	CTD-2081C10.7	-3.76	0.000188	0.0237	-0.18	-0.17	Intraocular pressure;	chr5:53134576	chr5:53880293~53881051:-
LUAD	cis	rs2075824	0.715	rs1787989	ENSG00000267079.1	RP11-820I16.1	-3.76	0.000188	0.0237	-0.22	-0.17	Obsessive-compulsive disorder or autism spectrum disorder;	chr18:11974689	chr18:11910634~11914344:-
LUAD	cis	rs2247856	0.545	rs1533570	ENSG00000267546.2	RP11-666A8.8	3.76	0.000188	0.0237	0.15	0.17	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:76425895	chr17:76545668~76557683:-
LUAD	cis	rs6951245	0.678	rs28600085	ENSG00000229043.2	AC091729.9	-3.76	0.000188	0.0237	-0.25	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1130000	chr7:1160374~1165267:+
LUAD	cis	rs529866	0.5	rs918739	ENSG00000262703.1	RP11-485G7.6	-3.76	0.000188	0.0237	-0.16	-0.17	Inflammatory bowel disease;Crohn's disease;	chr16:11345876	chr16:11348143~11349321:-
LUAD	cis	rs7551222	0.752	rs4245737	ENSG00000240219.1	RP11-430C7.5	3.76	0.000188	0.0237	0.18	0.17	Schizophrenia;	chr1:204517114	chr1:204626775~204629712:+
LUAD	cis	rs6438234	0.778	rs9875625	ENSG00000242767.1	ZBTB20-AS4	3.76	0.000188	0.0237	0.22	0.17	Type 2 diabetes;	chr3:115250111	chr3:115100423~115103061:+
LUAD	cis	rs6438234	0.778	rs1459517	ENSG00000242767.1	ZBTB20-AS4	3.76	0.000188	0.0237	0.22	0.17	Type 2 diabetes;	chr3:115250309	chr3:115100423~115103061:+
LUAD	cis	rs9517320	0.935	rs9645891	ENSG00000231194.1	FARP1-AS1	3.76	0.000188	0.0237	0.19	0.17	Longevity;	chr13:98474546	chr13:98435405~98435840:-
LUAD	cis	rs763121	0.962	rs1980455	ENSG00000225450.1	RP3-508I15.14	-3.76	0.000188	0.0237	-0.16	-0.17	Menopause (age at onset);	chr22:38529714	chr22:38739003~38749041:+
LUAD	cis	rs12935418	0.552	rs2549847	ENSG00000261061.1	RP11-303E16.2	3.76	0.000188	0.0237	0.18	0.17	Mean corpuscular volume;	chr16:80990617	chr16:81030770~81031485:+
LUAD	cis	rs12935418	0.583	rs2602449	ENSG00000261061.1	RP11-303E16.2	3.76	0.000188	0.0237	0.18	0.17	Mean corpuscular volume;	chr16:80990668	chr16:81030770~81031485:+
LUAD	cis	rs12935418	0.583	rs2549848	ENSG00000261061.1	RP11-303E16.2	3.76	0.000188	0.0237	0.18	0.17	Mean corpuscular volume;	chr16:80990693	chr16:81030770~81031485:+
LUAD	cis	rs12935418	0.583	rs2316923	ENSG00000261061.1	RP11-303E16.2	3.76	0.000188	0.0237	0.18	0.17	Mean corpuscular volume;	chr16:80991216	chr16:81030770~81031485:+
LUAD	cis	rs12935418	0.583	rs2098726	ENSG00000261061.1	RP11-303E16.2	3.76	0.000188	0.0237	0.18	0.17	Mean corpuscular volume;	chr16:80991670	chr16:81030770~81031485:+
LUAD	cis	rs12935418	0.583	rs2113197	ENSG00000261061.1	RP11-303E16.2	3.76	0.000188	0.0237	0.18	0.17	Mean corpuscular volume;	chr16:80991901	chr16:81030770~81031485:+
LUAD	cis	rs9435732	0.594	rs2647166	ENSG00000235241.1	RP11-108M9.5	-3.76	0.000188	0.0237	-0.21	-0.17	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);	chr1:17016240	chr1:16889095~16889602:+
LUAD	cis	rs11838267	0.527	rs7311672	ENSG00000205885.6	C1RL-AS1	-3.76	0.000188	0.0237	-0.16	-0.17	Coronary artery disease;	chr12:7057810	chr12:7108052~7122501:+
LUAD	cis	rs10129255	0.5	rs8004923	ENSG00000253209.1	IGHV3-65	3.76	0.000188	0.0237	0.13	0.17	Kawasaki disease;	chr14:106785926	chr14:106666092~106666532:-
LUAD	cis	rs6871536	1	rs58760622	ENSG00000233006.5	AC034220.3	-3.76	0.000188	0.0237	-0.19	-0.17	Asthma (childhood onset);	chr5:132572420	chr5:132311285~132369916:-
LUAD	cis	rs9907295	0.591	rs2107538	ENSG00000270977.1	AC015849.16	-3.76	0.000188	0.0237	-0.22	-0.17	Fibroblast growth factor basic levels;	chr17:35880776	chr17:35893707~35911023:-
LUAD	cis	rs524281	0.773	rs10791863	ENSG00000255320.1	RP11-755F10.1	3.76	0.000188	0.0237	0.27	0.17	Electroencephalogram traits;	chr11:66259887	chr11:66244840~66246239:-
LUAD	cis	rs524281	0.773	rs10750781	ENSG00000255320.1	RP11-755F10.1	3.76	0.000188	0.0237	0.27	0.17	Electroencephalogram traits;	chr11:66269799	chr11:66244840~66246239:-
LUAD	cis	rs524281	0.773	rs2017969	ENSG00000255320.1	RP11-755F10.1	3.76	0.000188	0.0237	0.27	0.17	Electroencephalogram traits;	chr11:66271561	chr11:66244840~66246239:-
LUAD	cis	rs438034	0.764	rs6682571	ENSG00000230461.7	PROX1-AS1	3.76	0.000188	0.0237	0.22	0.17	Response to antineoplastic agents;	chr1:214699060	chr1:213817751~213988508:-
LUAD	cis	rs526231	0.726	rs35800	ENSG00000175749.11	EIF3KP1	3.76	0.000188	0.0237	0.23	0.17	Primary biliary cholangitis;	chr5:103272980	chr5:103032376~103033031:+
LUAD	cis	rs71520386	0.752	rs34015725	ENSG00000228649.7	AC005682.5	-3.76	0.000188	0.0237	-0.27	-0.17	Fibrinogen levels;	chr7:22773665	chr7:22854178~22861579:+
LUAD	cis	rs7615952	0.641	rs6438951	ENSG00000241288.6	RP11-379B18.5	-3.76	0.000188	0.0237	-0.21	-0.17	Blood pressure (smoking interaction);	chr3:125978156	chr3:125827238~125916384:-
LUAD	cis	rs2274273	0.934	rs8021940	ENSG00000258413.1	RP11-665C16.6	-3.76	0.000188	0.0237	-0.22	-0.17	Protein biomarker;	chr14:55252997	chr14:55262767~55272075:-
LUAD	cis	rs2665103	0.687	rs11633000	ENSG00000255769.6	GOLGA2P10	-3.76	0.000189	0.0237	-0.18	-0.17	Intelligence (multi-trait analysis);	chr15:82269320	chr15:82472993~82513950:-
LUAD	cis	rs13113518	1	rs4864549	ENSG00000273257.1	RP11-177J6.1	3.76	0.000189	0.0237	0.19	0.17	Height;	chr4:55554380	chr4:55387949~55388271:+
LUAD	cis	rs1383484	0.545	rs9329363	ENSG00000259728.4	LINC00933	-3.76	0.000189	0.0238	-0.22	-0.17	Height;	chr15:83974382	chr15:84570649~84580175:+
LUAD	cis	rs2625529	0.617	rs13858	ENSG00000260173.1	RP11-2I17.4	-3.76	0.000189	0.0238	-0.2	-0.17	Red blood cell count;	chr15:72140803	chr15:72140504~72155459:-
LUAD	cis	rs6663390	0.51	rs12566127	ENSG00000203709.8	C1orf132	3.76	0.000189	0.0238	0.25	0.17	Facial morphology (factor 18);	chr1:207897301	chr1:207801518~207869150:-
LUAD	cis	rs6531209	0.851	rs973129	ENSG00000234378.1	AC098828.2	3.76	0.000189	0.0238	0.26	0.17	Amyotrophic lateral sclerosis (sporadic);	chr2:20133181	chr2:20063856~20106829:-
LUAD	cis	rs34286592	0.929	rs1045968	ENSG00000214725.6	CDIPT-AS1	-3.76	0.000189	0.0238	-0.27	-0.17	Multiple sclerosis;	chr16:29815044	chr16:29863593~29868053:+
LUAD	cis	rs910316	0.737	rs175080	ENSG00000259138.1	RP11-950C14.7	-3.76	0.000189	0.0238	-0.18	-0.17	Height;	chr14:75047125	chr14:75127153~75136930:+
LUAD	cis	rs1023500	0.552	rs5758566	ENSG00000273366.1	CTA-989H11.1	-3.76	0.000189	0.0238	-0.2	-0.17	Schizophrenia;	chr22:42058350	chr22:42278188~42278846:+
LUAD	cis	rs16866061	0.926	rs17479770	ENSG00000228446.2	AC073052.1	-3.76	0.000189	0.0238	-0.18	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr2:224471097	chr2:224499387~224500100:-
LUAD	cis	rs12744310	0.895	rs1892417	ENSG00000235358.1	RP11-399E6.1	3.76	0.000189	0.0238	0.22	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41314001	chr1:41242373~41284861:+
LUAD	cis	rs7200543	0.961	rs1741	ENSG00000260735.1	RP11-72I8.1	-3.76	0.000189	0.0238	-0.19	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036494	chr16:15094411~15109197:+
LUAD	cis	rs4474465	0.92	rs10899532	ENSG00000251323.2	RP11-452H21.4	-3.76	0.000189	0.0238	-0.21	-0.17	Alzheimer's disease (survival time);	chr11:78497424	chr11:78423982~78429836:-
LUAD	cis	rs4474465	0.92	rs7947852	ENSG00000251323.2	RP11-452H21.4	3.76	0.000189	0.0238	0.21	0.17	Alzheimer's disease (survival time);	chr11:78486984	chr11:78423982~78429836:-
LUAD	cis	rs28386778	1	rs2955241	ENSG00000240280.5	TCAM1P	-3.76	0.000189	0.0238	-0.19	-0.17	Prudent dietary pattern;	chr17:63890753	chr17:63849292~63864379:+
LUAD	cis	rs10045504	0.502	rs72746054	ENSG00000251189.1	CTD-2196P11.2	3.76	0.000189	0.0238	0.32	0.17	Night sleep phenotypes;	chr5:38762249	chr5:38682070~38685126:+
LUAD	cis	rs1979679	0.842	rs4931729	ENSG00000278733.1	RP11-425D17.1	3.76	0.000189	0.0238	0.21	0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28146306	chr12:28185625~28186190:-
LUAD	cis	rs1853665	0.669	rs4368824	ENSG00000231760.4	RP11-350J20.5	3.76	0.000189	0.0238	0.32	0.17	Radiation response;	chr6:149948163	chr6:149796151~149826294:-
LUAD	cis	rs12660691	1	rs11154491	ENSG00000233351.1	RP1-69D17.3	-3.76	0.000189	0.0238	-0.3	-0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);	chr6:129690521	chr6:129479615~129481410:-
LUAD	cis	rs67478160	0.572	rs8015603	ENSG00000272533.1	SNORA28	3.76	0.000189	0.0238	0.17	0.17	Schizophrenia;	chr14:103827341	chr14:103337849~103337974:+
LUAD	cis	rs2625529	0.503	rs7162299	ENSG00000260173.1	RP11-2I17.4	3.76	0.000189	0.0238	0.2	0.17	Red blood cell count;	chr15:72121724	chr15:72140504~72155459:-
LUAD	cis	rs12744310	1	rs72665698	ENSG00000235358.1	RP11-399E6.1	3.76	0.000189	0.0238	0.22	0.17	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41309917	chr1:41242373~41284861:+
LUAD	cis	rs10863681	0.738	rs12561821	ENSG00000227925.1	RP11-191N8.2	3.76	0.000189	0.0238	0.2	0.17	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222087887	chr1:221827666~221840666:-
LUAD	cis	rs11700536	0.656	rs9978825	ENSG00000236663.1	AP001631.9	3.76	0.000189	0.0238	0.19	0.17	Interleukin-18 levels;	chr21:43149043	chr21:43140523~43141092:-
LUAD	cis	rs1910358	0.621	rs2055140	ENSG00000248874.4	C5orf17	-3.76	0.000189	0.0238	-0.23	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr5:23859035	chr5:23951348~24178263:+
LUAD	cis	rs10466239	0.73	rs2245413	ENSG00000230555.2	RP11-517P14.2	-3.76	0.000189	0.0238	-0.26	-0.17	Telomere length;	chr10:43355120	chr10:43420738~43422100:+
LUAD	cis	rs62246343	0.541	rs2596937	ENSG00000254485.4	RP11-380O24.1	3.76	0.000189	0.0238	0.22	0.17	Fibrinogen levels;	chr3:9439222	chr3:9292588~9363303:-
LUAD	cis	rs755249	0.917	rs72663503	ENSG00000237624.1	OXCT2P1	3.76	0.000189	0.0238	0.25	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39503387	chr1:39514956~39516490:+
LUAD	cis	rs2274273	0.837	rs10141552	ENSG00000258413.1	RP11-665C16.6	3.76	0.000189	0.0238	0.22	0.17	Protein biomarker;	chr14:55279373	chr14:55262767~55272075:-
LUAD	cis	rs2057178	0.546	rs12361455	ENSG00000183242.10	WT1-AS	3.76	0.000189	0.0238	0.22	0.17	Tuberculosis;	chr11:32312554	chr11:32435518~32458769:+
LUAD	cis	rs4561483	0.549	rs6498251	ENSG00000261560.1	RP11-166B2.3	3.76	0.000189	0.0238	0.16	0.17	Testicular germ cell tumor;	chr16:11858433	chr16:11881075~11882569:-
LUAD	cis	rs9341808	0.754	rs3812126	ENSG00000233967.5	RP11-250B2.3	-3.76	0.000189	0.0238	-0.16	-0.17	Sitting height ratio;	chr6:80242984	chr6:80443344~80465927:+
LUAD	cis	rs2239547	0.603	rs12489490	ENSG00000243224.1	RP5-1157M23.2	-3.76	0.000189	0.0238	-0.2	-0.17	Schizophrenia;	chr3:53030006	chr3:52239258~52241097:+
LUAD	cis	rs1908814	0.516	rs10113062	ENSG00000255046.1	RP11-297N6.4	-3.76	0.000189	0.0238	-0.21	-0.17	Neuroticism;	chr8:11935740	chr8:11797928~11802568:-
LUAD	cis	rs1908814	0.516	rs10113145	ENSG00000255046.1	RP11-297N6.4	-3.76	0.000189	0.0238	-0.21	-0.17	Neuroticism;	chr8:11935786	chr8:11797928~11802568:-
LUAD	cis	rs1908814	0.516	rs7812563	ENSG00000255046.1	RP11-297N6.4	-3.76	0.000189	0.0238	-0.21	-0.17	Neuroticism;	chr8:11936979	chr8:11797928~11802568:-
LUAD	cis	rs4865762	0.687	rs27324	ENSG00000247796.2	CTD-2366F13.1	3.76	0.000189	0.0238	0.17	0.17	Intraocular pressure;	chr5:53254750	chr5:53109842~53115126:+
LUAD	cis	rs854765	0.964	rs854762	ENSG00000223979.2	SMCR2	3.76	0.000189	0.0238	0.19	0.17	Total body bone mineral density;	chr17:18105788	chr17:17674026~17677688:-
LUAD	cis	rs7142881	0.74	rs12586434	ENSG00000250365.5	CTD-2213F21.2	3.76	0.000189	0.0238	0.19	0.17	Response to iloperidone treatment (QT prolongation);	chr14:31802565	chr14:31420286~31452883:+
LUAD	cis	rs6095360	1	rs6019535	ENSG00000222365.1	SNORD12B	-3.76	0.000189	0.0238	-0.17	-0.17	Intelligence (multi-trait analysis);	chr20:48924980	chr20:49280319~49280409:+
LUAD	cis	rs6832769	0.961	rs6824955	ENSG00000272969.1	RP11-528I4.2	3.76	0.000189	0.0238	0.18	0.17	Personality dimensions;	chr4:55450969	chr4:55547112~55547889:+
LUAD	cis	rs6928977	0.5	rs11154810	ENSG00000231028.7	LINC00271	3.76	0.000189	0.0238	0.2	0.17	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135629234	chr6:135497801~135716055:+
LUAD	cis	rs9549260	0.534	rs4943809	ENSG00000168852.11	TPTE2P5	3.76	0.000189	0.0238	0.21	0.17	Red blood cell count;	chr13:40723268	chr13:40822296~40921749:-
LUAD	cis	rs9549260	0.534	rs4943810	ENSG00000168852.11	TPTE2P5	3.76	0.000189	0.0238	0.21	0.17	Red blood cell count;	chr13:40723269	chr13:40822296~40921749:-
LUAD	cis	rs7674212	0.57	rs6841136	ENSG00000246560.2	RP11-10L12.4	3.76	0.000189	0.0238	0.22	0.17	Type 2 diabetes;	chr4:103182352	chr4:102828055~102844075:+
LUAD	cis	rs5015933	0.788	rs487228	ENSG00000232630.1	PRPS1P2	-3.76	0.000189	0.0238	-0.16	-0.17	Body mass index;	chr9:125340327	chr9:125150653~125151589:+
LUAD	cis	rs763121	0.962	rs6001159	ENSG00000225450.1	RP3-508I15.14	-3.76	0.000189	0.0238	-0.16	-0.17	Menopause (age at onset);	chr22:38570482	chr22:38739003~38749041:+
LUAD	cis	rs7777677	0.925	rs4726542	ENSG00000276953.1	TRBV12-4	3.76	0.000189	0.0238	0.16	0.17	Alcoholic chronic pancreatitis;	chr7:142659516	chr7:142563740~142564245:+
LUAD	cis	rs794185	0.625	rs2259801	ENSG00000231249.1	ITPR1-AS1	-3.76	0.000189	0.0238	-0.19	-0.17	Multiple sclerosis--Brain Glutamate Levels;	chr3:4471859	chr3:4490891~4493163:-
LUAD	cis	rs911555	0.755	rs11627446	ENSG00000259775.1	RP11-45P15.4	-3.76	0.000189	0.0238	-0.22	-0.17	Intelligence (multi-trait analysis);	chr14:103480113	chr14:103331674~103332367:-
LUAD	cis	rs6088590	1	rs6087632	ENSG00000275784.1	RP5-1125A11.6	-3.76	0.000189	0.0238	-0.19	-0.17	Coronary artery disease;	chr20:34819901	chr20:33989480~33991818:-
LUAD	cis	rs6088590	0.931	rs6088617	ENSG00000275784.1	RP5-1125A11.6	-3.76	0.000189	0.0238	-0.19	-0.17	Coronary artery disease;	chr20:34820233	chr20:33989480~33991818:-
LUAD	cis	rs1862618	0.853	rs832565	ENSG00000271828.1	CTD-2310F14.1	3.76	0.000189	0.0238	0.25	0.17	Initial pursuit acceleration;	chr5:56854976	chr5:56927874~56929573:+
LUAD	cis	rs1862618	0.853	rs832568	ENSG00000271828.1	CTD-2310F14.1	3.76	0.000189	0.0238	0.25	0.17	Initial pursuit acceleration;	chr5:56857949	chr5:56927874~56929573:+
LUAD	cis	rs1862618	0.853	rs832569	ENSG00000271828.1	CTD-2310F14.1	3.76	0.000189	0.0238	0.25	0.17	Initial pursuit acceleration;	chr5:56858757	chr5:56927874~56929573:+
LUAD	cis	rs2836974	0.545	rs8128901	ENSG00000232608.1	TIMM9P2	-3.76	0.000189	0.0238	-0.19	-0.17	Cognitive function;	chr21:39338493	chr21:39216624~39217506:+
LUAD	cis	rs7829975	0.564	rs2921057	ENSG00000233609.3	RP11-62H7.2	3.76	0.000189	0.0238	0.14	0.17	Mood instability;	chr8:8461157	chr8:8961200~8979025:+
LUAD	cis	rs11159086	1	rs58384818	ENSG00000270000.1	RP3-449M8.9	3.76	0.000189	0.0238	0.25	0.17	Advanced glycation end-product levels;	chr14:74487045	chr14:74471930~74472360:-
LUAD	cis	rs11159086	1	rs17100588	ENSG00000270000.1	RP3-449M8.9	3.76	0.000189	0.0238	0.25	0.17	Advanced glycation end-product levels;	chr14:74487624	chr14:74471930~74472360:-
LUAD	cis	rs7017914	0.69	rs17699710	ENSG00000246366.5	RP11-382J12.1	3.76	0.000189	0.0238	0.16	0.17	Bone mineral density;	chr8:71067975	chr8:70608577~70663279:+
LUAD	cis	rs4523957	0.928	rs7406247	ENSG00000262333.1	HNRNPA1P16	-3.76	0.000189	0.0238	-0.14	-0.17	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2254631	chr17:2306761~2307715:+
LUAD	cis	rs2235573	0.551	rs84770	ENSG00000235237.1	RP1-151B14.6	-3.76	0.000189	0.0238	-0.17	-0.17	Glioma;Glioblastoma;	chr22:37994121	chr22:37166757~37182850:+
LUAD	cis	rs987044	0.726	rs56364122	ENSG00000257221.1	RP11-689B22.2	-3.76	0.000189	0.0238	-0.14	-0.17	Mean platelet volume;	chr12:108666850	chr12:108628687~108641318:+
LUAD	cis	rs1993709	0.617	rs2630399	ENSG00000227207.2	RPL31P12	3.76	0.000189	0.0238	0.2	0.17	Obesity (early onset extreme);	chr1:72116871	chr1:72301472~72301829:+
LUAD	cis	rs7824557	0.713	rs6601575	ENSG00000255046.1	RP11-297N6.4	-3.76	0.000189	0.0238	-0.21	-0.17	Retinal vascular caliber;	chr8:11240295	chr8:11797928~11802568:-
LUAD	cis	rs911555	0.755	rs11620897	ENSG00000259775.1	RP11-45P15.4	-3.76	0.00019	0.0238	-0.22	-0.17	Intelligence (multi-trait analysis);	chr14:103478524	chr14:103331674~103332367:-
LUAD	cis	rs7189233	0.955	rs7189726	ENSG00000279344.1	RP11-44F14.7	3.76	0.00019	0.0238	0.15	0.17	Intelligence (multi-trait analysis);	chr16:53463862	chr16:53478957~53481550:-
LUAD	cis	rs7017914	0.967	rs6993170	ENSG00000246366.5	RP11-382J12.1	3.76	0.00019	0.0239	0.16	0.17	Bone mineral density;	chr8:70781284	chr8:70608577~70663279:+
LUAD	cis	rs7477	0.818	rs714285	ENSG00000275413.1	CTC-529I10.1	3.76	0.00019	0.0239	0.14	0.17	Amyotrophic lateral sclerosis;	chr17:16341070	chr17:16023323~16023653:-
LUAD	cis	rs7477	0.818	rs3112521	ENSG00000275413.1	CTC-529I10.1	3.76	0.00019	0.0239	0.14	0.17	Amyotrophic lateral sclerosis;	chr17:16341343	chr17:16023323~16023653:-
LUAD	cis	rs526231	0.819	rs2569018	ENSG00000175749.11	EIF3KP1	3.76	0.00019	0.0239	0.23	0.17	Primary biliary cholangitis;	chr5:103262042	chr5:103032376~103033031:+
LUAD	cis	rs7512552	0.809	rs2794679	ENSG00000275557.1	RP11-353N4.6	3.76	0.00019	0.0239	0.19	0.17	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150352381	chr1:149607765~149612402:+
LUAD	cis	rs7512552	0.646	rs1694367	ENSG00000275557.1	RP11-353N4.6	3.76	0.00019	0.0239	0.19	0.17	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150356993	chr1:149607765~149612402:+
LUAD	cis	rs7512552	0.839	rs1103115	ENSG00000275557.1	RP11-353N4.6	3.76	0.00019	0.0239	0.19	0.17	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150359828	chr1:149607765~149612402:+
LUAD	cis	rs7512552	0.839	rs1097070	ENSG00000275557.1	RP11-353N4.6	3.76	0.00019	0.0239	0.19	0.17	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150360479	chr1:149607765~149612402:+
LUAD	cis	rs8141529	0.719	rs5762880	ENSG00000272858.1	CTA-292E10.8	-3.76	0.00019	0.0239	-0.19	-0.17	Lymphocyte counts;	chr22:28891828	chr22:28814914~28815662:+
LUAD	cis	rs8141529	0.748	rs5762882	ENSG00000272858.1	CTA-292E10.8	-3.76	0.00019	0.0239	-0.19	-0.17	Lymphocyte counts;	chr22:28894692	chr22:28814914~28815662:+
LUAD	cis	rs5758511	0.689	rs5758691	ENSG00000233903.2	Z83851.4	3.76	0.00019	0.0239	0.25	0.17	Birth weight;	chr22:42272498	chr22:42276355~42277052:+
LUAD	cis	rs5758511	0.68	rs1001586	ENSG00000233903.2	Z83851.4	3.76	0.00019	0.0239	0.25	0.17	Birth weight;	chr22:42274287	chr22:42276355~42277052:+
LUAD	cis	rs2836950	0.501	rs13047518	ENSG00000232608.1	TIMM9P2	3.76	0.00019	0.0239	0.19	0.17	Menarche (age at onset);	chr21:39335381	chr21:39216624~39217506:+
LUAD	cis	rs2486288	0.656	rs11632419	ENSG00000259479.5	SORD2P	-3.76	0.00019	0.0239	-0.2	-0.17	Glomerular filtration rate;	chr15:45265258	chr15:44826371~44884694:-
LUAD	cis	rs2486288	0.656	rs2271438	ENSG00000259479.5	SORD2P	-3.76	0.00019	0.0239	-0.2	-0.17	Glomerular filtration rate;	chr15:45265270	chr15:44826371~44884694:-
LUAD	cis	rs2486288	0.656	rs11854365	ENSG00000259479.5	SORD2P	-3.76	0.00019	0.0239	-0.2	-0.17	Glomerular filtration rate;	chr15:45265885	chr15:44826371~44884694:-
LUAD	cis	rs12548874	0.607	rs12543492	ENSG00000253528.2	RP11-347C18.4	3.76	0.00019	0.0239	0.17	0.17	Hemoglobin concentration;	chr8:94879615	chr8:94974573~94974853:-
LUAD	cis	rs2645424	0.762	rs2294139	ENSG00000255046.1	RP11-297N6.4	3.76	0.00019	0.0239	0.21	0.17	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11847933	chr8:11797928~11802568:-
LUAD	cis	rs763121	0.657	rs5995603	ENSG00000228274.3	RP3-508I15.9	-3.76	0.00019	0.0239	-0.18	-0.17	Menopause (age at onset);	chr22:38644728	chr22:38667585~38681820:-
LUAD	cis	rs9341808	0.667	rs1575541	ENSG00000272129.1	RP11-250B2.6	3.76	0.00019	0.0239	0.21	0.17	Sitting height ratio;	chr6:80207768	chr6:80355424~80356859:+
LUAD	cis	rs7824557	0.527	rs2572447	ENSG00000255046.1	RP11-297N6.4	3.76	0.00019	0.0239	0.21	0.17	Retinal vascular caliber;	chr8:11382001	chr8:11797928~11802568:-
LUAD	cis	rs7824557	0.527	rs2572446	ENSG00000255046.1	RP11-297N6.4	3.76	0.00019	0.0239	0.21	0.17	Retinal vascular caliber;	chr8:11382056	chr8:11797928~11802568:-
LUAD	cis	rs1476587	0.92	rs2106952	ENSG00000224046.1	AC005076.5	3.76	0.00019	0.0239	0.23	0.17	Brachial circumference;	chr7:87110707	chr7:87151423~87152420:-
LUAD	cis	rs10463554	0.926	rs34778	ENSG00000250682.4	LINC00491	3.76	0.00019	0.0239	0.2	0.17	Parkinson's disease;	chr5:103116852	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.963	rs26524	ENSG00000250682.4	LINC00491	3.76	0.00019	0.0239	0.2	0.17	Parkinson's disease;	chr5:103120600	chr5:102609156~102671559:-
LUAD	cis	rs6088590	0.561	rs6088527	ENSG00000276073.1	RP5-1125A11.7	-3.76	0.00019	0.0239	-0.16	-0.17	Coronary artery disease;	chr20:34568037	chr20:33985617~33988989:-
LUAD	cis	rs6088590	0.561	rs6088528	ENSG00000276073.1	RP5-1125A11.7	-3.76	0.00019	0.0239	-0.16	-0.17	Coronary artery disease;	chr20:34568938	chr20:33985617~33988989:-
LUAD	cis	rs6088590	0.561	rs6087600	ENSG00000276073.1	RP5-1125A11.7	-3.76	0.00019	0.0239	-0.16	-0.17	Coronary artery disease;	chr20:34569413	chr20:33985617~33988989:-
LUAD	cis	rs6088590	0.561	rs6059926	ENSG00000276073.1	RP5-1125A11.7	-3.76	0.00019	0.0239	-0.16	-0.17	Coronary artery disease;	chr20:34577000	chr20:33985617~33988989:-
LUAD	cis	rs4374383	0.962	rs4525705	ENSG00000207383.1	Y_RNA	-3.76	0.00019	0.0239	-0.21	-0.17	Hepatitis C induced liver fibrosis;	chr2:112015217	chr2:112579484~112579584:-
LUAD	cis	rs4374383	0.926	rs4627569	ENSG00000207383.1	Y_RNA	-3.76	0.00019	0.0239	-0.21	-0.17	Hepatitis C induced liver fibrosis;	chr2:112015576	chr2:112579484~112579584:-
LUAD	cis	rs957448	1	rs957447	ENSG00000254057.1	RP3-388N13.3	3.76	0.00019	0.0239	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94528995	chr8:93834454~93846743:-
LUAD	cis	rs957448	1	rs72674852	ENSG00000254057.1	RP3-388N13.3	3.76	0.00019	0.0239	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94536523	chr8:93834454~93846743:-
LUAD	cis	rs7119038	0.818	rs6421571	ENSG00000255239.1	AP002954.6	3.76	0.00019	0.0239	0.25	0.17	Sjögren's syndrome;	chr11:118873063	chr11:118688039~118690600:-
LUAD	cis	rs5758511	0.596	rs55644935	ENSG00000233903.2	Z83851.4	3.76	0.00019	0.0239	0.24	0.17	Birth weight;	chr22:42270063	chr22:42276355~42277052:+
LUAD	cis	rs202072	0.72	rs454563	ENSG00000272379.1	RP1-257A7.5	3.76	0.00019	0.0239	0.29	0.17	HIV-1 viral setpoint;	chr6:13295304	chr6:13290018~13290490:-
LUAD	cis	rs7274811	0.744	rs209677	ENSG00000231795.1	ITCH-IT1	-3.76	0.00019	0.0239	-0.19	-0.17	Height;	chr20:33552481	chr20:34450930~34454552:+
LUAD	cis	rs62025270	0.632	rs7163838	ENSG00000259416.2	RP11-158M2.5	-3.76	0.00019	0.0239	-0.23	-0.17	Idiopathic pulmonary fibrosis;	chr15:85664390	chr15:85754941~85756237:-
LUAD	cis	rs7005380	0.6	rs6993797	ENSG00000279347.1	RP11-85I17.2	-3.76	0.00019	0.0239	-0.14	-0.17	Interstitial lung disease;	chr8:119899405	chr8:119838736~119840385:-
LUAD	cis	rs7537765	0.696	rs72640267	ENSG00000242349.4	NPPA-AS1	3.76	0.00019	0.0239	0.32	0.17	QRS complex (12-leadsum);	chr1:11837229	chr1:11841017~11848079:+
LUAD	cis	rs7537765	0.696	rs55788159	ENSG00000242349.4	NPPA-AS1	3.76	0.00019	0.0239	0.32	0.17	QRS complex (12-leadsum);	chr1:11837869	chr1:11841017~11848079:+
LUAD	cis	rs7200543	1	rs16966952	ENSG00000260735.1	RP11-72I8.1	-3.76	0.00019	0.0239	-0.19	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15042086	chr16:15094411~15109197:+
LUAD	cis	rs7107174	1	rs901103	ENSG00000251323.2	RP11-452H21.4	3.76	0.00019	0.0239	0.24	0.17	Testicular germ cell tumor;	chr11:78220300	chr11:78423982~78429836:-
LUAD	cis	rs4474465	0.92	rs7947824	ENSG00000251323.2	RP11-452H21.4	-3.76	0.00019	0.0239	-0.22	-0.17	Alzheimer's disease (survival time);	chr11:78512685	chr11:78423982~78429836:-
LUAD	cis	rs4662750	0.674	rs777437	ENSG00000272789.1	RP11-286H15.1	-3.76	0.00019	0.0239	-0.17	-0.17	Renal cell carcinoma;	chr2:127600072	chr2:127625997~127626848:-
LUAD	cis	rs6493487	0.512	rs7162631	ENSG00000273674.3	CTD-2378E12.1	3.76	0.00019	0.0239	0.24	0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50820930	chr15:50839875~50908599:-
LUAD	cis	rs6493487	0.512	rs16963910	ENSG00000273674.3	CTD-2378E12.1	3.76	0.00019	0.0239	0.24	0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50821706	chr15:50839875~50908599:-
LUAD	cis	rs6493487	0.512	rs34297767	ENSG00000273674.3	CTD-2378E12.1	3.76	0.00019	0.0239	0.24	0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50821781	chr15:50839875~50908599:-
LUAD	cis	rs6493487	0.512	rs34581168	ENSG00000273674.3	CTD-2378E12.1	3.76	0.00019	0.0239	0.24	0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50821934	chr15:50839875~50908599:-
LUAD	cis	rs6493487	0.512	rs3896066	ENSG00000273674.3	CTD-2378E12.1	3.76	0.00019	0.0239	0.24	0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50822120	chr15:50839875~50908599:-
LUAD	cis	rs2348418	0.832	rs7294553	ENSG00000247934.4	RP11-967K21.1	3.76	0.00019	0.0239	0.2	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28334832	chr12:28163298~28190738:-
LUAD	cis	rs4604732	0.642	rs10925048	ENSG00000227135.1	GCSAML-AS1	-3.76	0.00019	0.0239	-0.23	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247477434	chr1:247524679~247526752:-
LUAD	cis	rs12517906	1	rs11249745	ENSG00000280161.1	CTC-205M6.1	-3.76	0.00019	0.0239	-0.22	-0.17	Weight;Body mass index;	chr5:180744399	chr5:180810401~180811384:+
LUAD	cis	rs7976269	0.537	rs10843308	ENSG00000275476.1	RP11-996F15.4	-3.76	0.00019	0.0239	-0.19	-0.17	Male-pattern baldness;	chr12:29075172	chr12:29277397~29277882:-
LUAD	cis	rs11671005	0.735	rs3826684	ENSG00000268543.1	CTD-2619J13.16	-3.76	0.00019	0.0239	-0.24	-0.17	Mean platelet volume;	chr19:58407338	chr19:58418560~58419310:+
LUAD	cis	rs11671005	0.735	rs3826683	ENSG00000268543.1	CTD-2619J13.16	-3.76	0.00019	0.0239	-0.24	-0.17	Mean platelet volume;	chr19:58407366	chr19:58418560~58419310:+
LUAD	cis	rs11671005	0.735	rs3826681	ENSG00000268543.1	CTD-2619J13.16	-3.76	0.00019	0.0239	-0.24	-0.17	Mean platelet volume;	chr19:58407397	chr19:58418560~58419310:+
LUAD	cis	rs2732480	0.577	rs2634684	ENSG00000273765.1	RP11-370I10.11	-3.76	0.00019	0.0239	-0.18	-0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48337092	chr12:48360920~48361377:+
LUAD	cis	rs7430456	0.967	rs6780021	ENSG00000231574.4	RP11-91K9.1	-3.76	0.00019	0.0239	-0.19	-0.17	Breast cancer;	chr3:177739677	chr3:177816865~177899224:+
LUAD	cis	rs7429990	0.965	rs800762	ENSG00000228638.1	FCF1P2	-3.76	0.00019	0.0239	-0.2	-0.17	Educational attainment (years of education);	chr3:47864080	chr3:48290793~48291375:-
LUAD	cis	rs2834288	0.7	rs2834299	ENSG00000237945.6	LINC00649	-3.76	0.00019	0.0239	-0.23	-0.17	Gut microbiota (bacterial taxa);	chr21:33912198	chr21:33915534~33977691:+
LUAD	cis	rs1023500	0.596	rs133369	ENSG00000273366.1	CTA-989H11.1	-3.76	0.00019	0.0239	-0.2	-0.17	Schizophrenia;	chr22:42067810	chr22:42278188~42278846:+
LUAD	cis	rs12499086	0.568	rs4508886	ENSG00000249635.1	RP11-710F7.3	-3.76	0.00019	0.0239	-0.18	-0.17	Economic and political preferences (time);	chr4:105487539	chr4:106003317~106022478:-
LUAD	cis	rs12499086	0.642	rs12646618	ENSG00000249635.1	RP11-710F7.3	-3.76	0.00019	0.0239	-0.18	-0.17	Economic and political preferences (time);	chr4:105487789	chr4:106003317~106022478:-
LUAD	cis	rs7208859	0.673	rs78799101	ENSG00000266490.1	CTD-2349P21.9	3.76	0.00019	0.0239	0.25	0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888142	chr17:30792372~30792833:+
LUAD	cis	rs7976269	0.609	rs7135891	ENSG00000275476.1	RP11-996F15.4	-3.76	0.00019	0.0239	-0.18	-0.17	Male-pattern baldness;	chr12:29053944	chr12:29277397~29277882:-
LUAD	cis	rs41369048	0.858	rs10495155	ENSG00000238078.1	LINC01352	-3.76	0.00019	0.0239	-0.25	-0.17	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220902527	chr1:220829255~220832429:+
LUAD	cis	rs11118883	0.961	rs12738322	ENSG00000228437.4	RP11-400N13.2	-3.76	0.00019	0.0239	-0.21	-0.17	Colorectal cancer;	chr1:221896824	chr1:221966341~221984964:+
LUAD	cis	rs2380205	0.967	rs2203197	ENSG00000232807.2	RP11-536K7.3	-3.76	0.00019	0.0239	-0.18	-0.17	Breast cancer;	chr10:5862955	chr10:5934270~5945900:-
LUAD	cis	rs4388249	0.687	rs2416217	ENSG00000271849.1	CTC-332L22.1	-3.76	0.00019	0.0239	-0.24	-0.17	Schizophrenia;	chr5:109736510	chr5:109687802~109688329:-
LUAD	cis	rs9467773	0.62	rs2504540	ENSG00000241549.7	GUSBP2	3.76	0.00019	0.0239	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26641398	chr6:26871484~26956554:-
LUAD	cis	rs253959	0.545	rs10072350	ENSG00000272265.1	CTD-2287O16.4	3.76	0.00019	0.0239	0.2	0.17	Bipolar disorder and schizophrenia;	chr5:116097829	chr5:116078110~116078570:-
LUAD	cis	rs11018904	0.817	rs11601793	ENSG00000280367.1	RP11-121L10.2	3.76	0.00019	0.0239	0.22	0.17	Intelligence (multi-trait analysis);	chr11:90213186	chr11:90223153~90226538:+
LUAD	cis	rs8062405	1	rs9972693	ENSG00000261419.1	RP11-57A19.4	-3.76	0.00019	0.0239	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28659696~28740781:-
LUAD	cis	rs8062405	0.964	rs9972768	ENSG00000261419.1	RP11-57A19.4	-3.76	0.00019	0.0239	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28659696~28740781:-
LUAD	cis	rs8062405	0.965	rs56040780	ENSG00000261419.1	RP11-57A19.4	-3.76	0.00019	0.0239	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28659696~28740781:-
LUAD	cis	rs8062405	0.965	rs62037363	ENSG00000261419.1	RP11-57A19.4	-3.76	0.00019	0.0239	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28659696~28740781:-
LUAD	cis	rs8062405	1	rs7205323	ENSG00000261419.1	RP11-57A19.4	-3.76	0.00019	0.0239	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28659696~28740781:-
LUAD	cis	rs8062405	1	rs4788101	ENSG00000261419.1	RP11-57A19.4	-3.76	0.00019	0.0239	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28659696~28740781:-
LUAD	cis	rs8062405	1	rs62037365	ENSG00000261419.1	RP11-57A19.4	-3.76	0.00019	0.0239	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28659696~28740781:-
LUAD	cis	rs8062405	0.929	rs11150609	ENSG00000261419.1	RP11-57A19.4	-3.76	0.00019	0.0239	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28659696~28740781:-
LUAD	cis	rs2333021	0.934	rs4903092	ENSG00000259015.1	RP11-109N23.6	3.76	0.00019	0.0239	0.16	0.17	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73013017	chr14:72960595~72961993:+
LUAD	cis	rs4853525	0.59	rs13414554	ENSG00000235852.1	AC005540.3	3.76	0.00019	0.0239	0.21	0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190929215	chr2:190880797~190882059:-
LUAD	cis	rs600231	0.508	rs11227201	ENSG00000245532.5	NEAT1	3.76	0.00019	0.0239	0.15	0.17	Bone mineral density;	chr11:65475077	chr11:65422774~65445540:+
LUAD	cis	rs600231	0.542	rs10896010	ENSG00000245532.5	NEAT1	3.76	0.00019	0.0239	0.15	0.17	Bone mineral density;	chr11:65478749	chr11:65422774~65445540:+
LUAD	cis	rs7617773	0.817	rs3937	ENSG00000199476.1	Y_RNA	-3.76	0.000191	0.0239	-0.22	-0.17	Coronary artery disease;	chr3:48270912	chr3:48288587~48288694:+
LUAD	cis	rs7618501	0.521	rs2352984	ENSG00000234667.1	ACTBP13	-3.76	0.000191	0.0239	-0.19	-0.17	Intelligence (multi-trait analysis);	chr3:49911295	chr3:49873347~49877980:-
LUAD	cis	rs9467773	1	rs6940188	ENSG00000241549.7	GUSBP2	3.76	0.000191	0.024	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26561801	chr6:26871484~26956554:-
LUAD	cis	rs6964587	0.967	rs10953063	ENSG00000188693.7	CYP51A1-AS1	3.76	0.000191	0.024	0.2	0.17	Breast cancer;	chr7:91947644	chr7:92134604~92180725:+
LUAD	cis	rs2147959	0.882	rs4653552	ENSG00000269934.1	RP5-1139B12.3	-3.76	0.000191	0.024	-0.22	-0.17	Adult asthma;	chr1:228440437	chr1:228274584~228276066:-
LUAD	cis	rs253959	0.672	rs4921056	ENSG00000272265.1	CTD-2287O16.4	3.76	0.000191	0.024	0.18	0.17	Bipolar disorder and schizophrenia;	chr5:116087237	chr5:116078110~116078570:-
LUAD	cis	rs875971	0.522	rs1880556	ENSG00000273142.1	RP11-458F8.4	-3.76	0.000191	0.024	-0.12	-0.17	Aortic root size;	chr7:65967557	chr7:66902857~66906297:+
LUAD	cis	rs2732480	0.538	rs1387259	ENSG00000240399.1	RP1-228P16.1	-3.76	0.000191	0.024	-0.17	-0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309739	chr12:48054813~48055591:-
LUAD	cis	rs6964587	0.869	rs10250014	ENSG00000188693.7	CYP51A1-AS1	3.76	0.000191	0.024	0.2	0.17	Breast cancer;	chr7:91860894	chr7:92134604~92180725:+
LUAD	cis	rs6921919	0.583	rs1054372	ENSG00000219392.1	RP1-265C24.5	-3.76	0.000191	0.024	-0.22	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28115628~28116551:+
LUAD	cis	rs6921919	0.583	rs9468354	ENSG00000219392.1	RP1-265C24.5	-3.76	0.000191	0.024	-0.22	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28115628~28116551:+
LUAD	cis	rs6921919	0.583	rs7773051	ENSG00000219392.1	RP1-265C24.5	-3.76	0.000191	0.024	-0.22	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28115628~28116551:+
LUAD	cis	rs6921919	0.583	rs12697938	ENSG00000219392.1	RP1-265C24.5	-3.76	0.000191	0.024	-0.22	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28115628~28116551:+
LUAD	cis	rs6921919	0.583	rs13437294	ENSG00000219392.1	RP1-265C24.5	-3.76	0.000191	0.024	-0.22	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28115628~28116551:+
LUAD	cis	rs6921919	0.609	rs9468357	ENSG00000219392.1	RP1-265C24.5	-3.76	0.000191	0.024	-0.22	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28115628~28116551:+
LUAD	cis	rs6001482	0.656	rs1894237	ENSG00000211642.2	IGLV10-54	3.76	0.000191	0.024	0.19	0.17	Diastolic blood pressure;	chr22:22235546	chr22:22214794~22215270:+
LUAD	cis	rs7937	0.693	rs12973666	ENSG00000279108.1	CTC-490E21.11	3.76	0.000191	0.024	0.15	0.17	Chronic obstructive pulmonary disease;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;	chr19:40783492	chr19:40840159~40842039:+
LUAD	cis	rs757110	0.745	rs10734252	ENSG00000260196.1	RP1-239B22.5	3.76	0.000191	0.024	0.2	0.17	Type 2 diabetes;	chr11:17383292	chr11:17380649~17383531:+
LUAD	cis	rs4908760	0.827	rs2401138	ENSG00000270282.1	RP5-1115A15.2	-3.76	0.000191	0.024	-0.19	-0.17	Vitiligo;	chr1:8644000	chr1:8512653~8513021:+
LUAD	cis	rs9549260	0.785	rs10507484	ENSG00000229456.1	RLIMP1	3.76	0.000191	0.024	0.18	0.17	Red blood cell count;	chr13:40643997	chr13:40618738~40621348:+
LUAD	cis	rs6754311	0.55	rs10173394	ENSG00000226806.1	AC011893.3	-3.76	0.000191	0.024	-0.21	-0.17	Mosquito bite size;	chr2:135765105	chr2:135820191~135823087:+
LUAD	cis	rs227584	0.663	rs2040810	ENSG00000267080.4	ASB16-AS1	3.76	0.000191	0.024	0.15	0.17	Bone mineral density;Bone mineral density (hip);	chr17:44166403	chr17:44175973~44186717:-
LUAD	cis	rs6781182	0.5	rs13065915	ENSG00000236452.1	AC123023.1	3.76	0.000191	0.024	0.19	0.17	Visceral adipose tissue adjusted for BMI;	chr3:34196599	chr3:34203244~34268811:+
LUAD	cis	rs11761441	0.669	rs13241486	ENSG00000261795.1	RP11-90P13.1	-3.76	0.000191	0.024	-0.22	-0.17	Alzheimer's disease in APOE e4- carriers;	chr7:79536	chr7:161765~164972:-
LUAD	cis	rs12478296	0.892	rs60042638	ENSG00000261186.2	RP11-341N2.1	-3.76	0.000191	0.024	-0.29	-0.17	Obesity-related traits;	chr2:242096556	chr2:242087351~242088457:-
LUAD	cis	rs2836950	0.565	rs7279497	ENSG00000232608.1	TIMM9P2	-3.76	0.000191	0.024	-0.19	-0.17	Menarche (age at onset);	chr21:39159380	chr21:39216624~39217506:+
LUAD	cis	rs412050	0.547	rs112153746	ENSG00000224086.5	LL22NC03-86G7.1	-3.76	0.000191	0.024	-0.22	-0.17	Attention deficit hyperactivity disorder;	chr22:21784402	chr22:21938293~21977632:+
LUAD	cis	rs38055	0.801	rs629725	ENSG00000247796.2	CTD-2366F13.1	-3.76	0.000191	0.024	-0.19	-0.17	Acne (severe);	chr5:53335237	chr5:53109842~53115126:+
LUAD	cis	rs7809950	1	rs2250414	ENSG00000238832.1	snoU109	-3.76	0.000191	0.024	-0.25	-0.17	Coronary artery disease;	chr7:107500542	chr7:107603363~107603507:+
LUAD	cis	rs4578769	0.55	rs12958492	ENSG00000266850.1	RP11-370A5.1	3.76	0.000191	0.024	0.21	0.17	Eosinophil percentage of white cells;	chr18:22988974	chr18:22723491~22907721:-
LUAD	cis	rs2074409	0.572	rs4074605	ENSG00000276054.1	RP11-378E13.3	-3.76	0.000191	0.024	-0.26	-0.17	Response to angiotensin II receptor blocker therapy;	chr17:37562341	chr17:37386886~37387926:+
LUAD	cis	rs755249	0.917	rs61781392	ENSG00000182109.6	RP11-69E11.4	3.76	0.000191	0.024	0.21	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39617969	chr1:39522280~39546187:-
LUAD	cis	rs7726839	0.54	rs4957080	ENSG00000248925.1	CTD-2083E4.6	-3.76	0.000191	0.024	-0.26	-0.17	Obesity-related traits;	chr5:644437	chr5:269858~271516:-
LUAD	cis	rs703842	0.616	rs10783850	ENSG00000270039.1	RP11-571M6.17	-3.76	0.000191	0.024	-0.21	-0.17	Multiple sclerosis;	chr12:57835594	chr12:57803838~57804415:+
LUAD	cis	rs8046148	0.724	rs7190890	ENSG00000279356.1	RP11-429P3.8	3.76	0.000191	0.024	0.17	0.17	Testicular germ cell tumor;	chr16:50091945	chr16:50072862~50074986:+
LUAD	cis	rs7017914	0.967	rs12680166	ENSG00000246366.5	RP11-382J12.1	3.76	0.000191	0.024	0.16	0.17	Bone mineral density;	chr8:70766403	chr8:70608577~70663279:+
LUAD	cis	rs1023500	0.505	rs134901	ENSG00000205702.9	CYP2D7	3.76	0.000191	0.024	0.14	0.17	Schizophrenia;	chr22:42287514	chr22:42140203~42144577:-
LUAD	cis	rs34779708	0.931	rs11010101	ENSG00000271335.4	RP11-324I22.4	3.76	0.000191	0.024	0.18	0.17	Inflammatory bowel disease;Crohn's disease;	chr10:35122117	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.966	rs11010102	ENSG00000271335.4	RP11-324I22.4	3.76	0.000191	0.024	0.18	0.17	Inflammatory bowel disease;Crohn's disease;	chr10:35122138	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.966	rs12765038	ENSG00000271335.4	RP11-324I22.4	3.76	0.000191	0.024	0.18	0.17	Inflammatory bowel disease;Crohn's disease;	chr10:35127585	chr10:35314552~35336401:-
LUAD	cis	rs11168618	0.567	rs56354789	ENSG00000239617.1	RP11-302B13.1	3.76	0.000191	0.024	0.23	0.17	Adiponectin levels;	chr12:48410160	chr12:48903418~48903813:-
LUAD	cis	rs6494488	0.5	rs72744739	ENSG00000239465.1	RP11-330L19.2	3.76	0.000191	0.024	0.35	0.17	Coronary artery disease;	chr15:64757727	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs72744741	ENSG00000239465.1	RP11-330L19.2	3.76	0.000191	0.024	0.35	0.17	Coronary artery disease;	chr15:64758315	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs111858590	ENSG00000239465.1	RP11-330L19.2	3.76	0.000191	0.024	0.35	0.17	Coronary artery disease;	chr15:64771423	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs72744751	ENSG00000239465.1	RP11-330L19.2	3.76	0.000191	0.024	0.35	0.17	Coronary artery disease;	chr15:64772458	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs77463022	ENSG00000239465.1	RP11-330L19.2	3.76	0.000191	0.024	0.35	0.17	Coronary artery disease;	chr15:64772642	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs72744764	ENSG00000239465.1	RP11-330L19.2	3.76	0.000191	0.024	0.35	0.17	Coronary artery disease;	chr15:64784688	chr15:64631109~64631914:-
LUAD	cis	rs6490294	0.808	rs7137270	ENSG00000234608.6	MAPKAPK5-AS1	3.76	0.000191	0.024	0.19	0.17	Mean platelet volume;	chr12:111825598	chr12:111839764~111842902:-
LUAD	cis	rs739496	0.652	rs10849974	ENSG00000234608.6	MAPKAPK5-AS1	3.76	0.000191	0.024	0.19	0.17	Platelet count;	chr12:111826354	chr12:111839764~111842902:-
LUAD	cis	rs739496	0.615	rs57303367	ENSG00000234608.6	MAPKAPK5-AS1	3.76	0.000191	0.024	0.19	0.17	Platelet count;	chr12:111827279	chr12:111839764~111842902:-
LUAD	cis	rs7714584	1	rs7736554	ENSG00000197083.10	ZNF300P1	3.76	0.000191	0.024	0.31	0.17	Crohn's disease;	chr5:150878746	chr5:150930645~150946289:-
LUAD	cis	rs7714584	1	rs7736873	ENSG00000197083.10	ZNF300P1	3.76	0.000191	0.024	0.31	0.17	Crohn's disease;	chr5:150878920	chr5:150930645~150946289:-
LUAD	cis	rs7714584	1	rs7716903	ENSG00000197083.10	ZNF300P1	3.76	0.000191	0.024	0.31	0.17	Crohn's disease;	chr5:150879012	chr5:150930645~150946289:-
LUAD	cis	rs7714584	1	rs11167518	ENSG00000197083.10	ZNF300P1	3.76	0.000191	0.024	0.31	0.17	Crohn's disease;	chr5:150879358	chr5:150930645~150946289:-
LUAD	cis	rs7714584	1	rs10463310	ENSG00000197083.10	ZNF300P1	3.76	0.000191	0.024	0.31	0.17	Crohn's disease;	chr5:150881343	chr5:150930645~150946289:-
LUAD	cis	rs7714584	1	rs73284126	ENSG00000197083.10	ZNF300P1	3.76	0.000191	0.024	0.31	0.17	Crohn's disease;	chr5:150881745	chr5:150930645~150946289:-
LUAD	cis	rs7714584	1	rs7732643	ENSG00000197083.10	ZNF300P1	3.76	0.000191	0.024	0.31	0.17	Crohn's disease;	chr5:150881874	chr5:150930645~150946289:-
LUAD	cis	rs7714584	1	rs7732945	ENSG00000197083.10	ZNF300P1	3.76	0.000191	0.024	0.31	0.17	Crohn's disease;	chr5:150882039	chr5:150930645~150946289:-
LUAD	cis	rs7714584	1	rs1820682	ENSG00000197083.10	ZNF300P1	3.76	0.000191	0.024	0.31	0.17	Crohn's disease;	chr5:150882580	chr5:150930645~150946289:-
LUAD	cis	rs7714584	1	rs2344181	ENSG00000197083.10	ZNF300P1	3.76	0.000191	0.024	0.31	0.17	Crohn's disease;	chr5:150883012	chr5:150930645~150946289:-
LUAD	cis	rs7714584	1	rs4560537	ENSG00000197083.10	ZNF300P1	3.76	0.000191	0.024	0.31	0.17	Crohn's disease;	chr5:150883024	chr5:150930645~150946289:-
LUAD	cis	rs7714584	1	rs11746108	ENSG00000197083.10	ZNF300P1	3.76	0.000191	0.024	0.31	0.17	Crohn's disease;	chr5:150885060	chr5:150930645~150946289:-
LUAD	cis	rs7714584	1	rs11739619	ENSG00000197083.10	ZNF300P1	3.76	0.000191	0.024	0.31	0.17	Crohn's disease;	chr5:150885100	chr5:150930645~150946289:-
LUAD	cis	rs7714584	1	rs11167519	ENSG00000197083.10	ZNF300P1	3.76	0.000191	0.024	0.31	0.17	Crohn's disease;	chr5:150885845	chr5:150930645~150946289:-
LUAD	cis	rs7714584	1	rs11167520	ENSG00000197083.10	ZNF300P1	3.76	0.000191	0.024	0.31	0.17	Crohn's disease;	chr5:150886077	chr5:150930645~150946289:-
LUAD	cis	rs7714584	1	rs73284141	ENSG00000197083.10	ZNF300P1	3.76	0.000191	0.024	0.31	0.17	Crohn's disease;	chr5:150886524	chr5:150930645~150946289:-
LUAD	cis	rs7714584	1	rs3906527	ENSG00000197083.10	ZNF300P1	3.76	0.000191	0.024	0.31	0.17	Crohn's disease;	chr5:150886830	chr5:150930645~150946289:-
LUAD	cis	rs7714584	1	rs2345001	ENSG00000197083.10	ZNF300P1	3.76	0.000191	0.024	0.31	0.17	Crohn's disease;	chr5:150886956	chr5:150930645~150946289:-
LUAD	cis	rs7714584	1	rs3906528	ENSG00000197083.10	ZNF300P1	3.76	0.000191	0.024	0.31	0.17	Crohn's disease;	chr5:150887156	chr5:150930645~150946289:-
LUAD	cis	rs7714584	1	rs2344180	ENSG00000197083.10	ZNF300P1	3.76	0.000191	0.024	0.31	0.17	Crohn's disease;	chr5:150887795	chr5:150930645~150946289:-
LUAD	cis	rs7714584	1	rs2880791	ENSG00000197083.10	ZNF300P1	3.76	0.000191	0.024	0.31	0.17	Crohn's disease;	chr5:150887814	chr5:150930645~150946289:-
LUAD	cis	rs7714584	1	rs3857422	ENSG00000197083.10	ZNF300P1	3.76	0.000191	0.024	0.31	0.17	Crohn's disease;	chr5:150889047	chr5:150930645~150946289:-
LUAD	cis	rs7714584	0.59	rs4352593	ENSG00000197083.10	ZNF300P1	3.76	0.000191	0.024	0.31	0.17	Crohn's disease;	chr5:150889770	chr5:150930645~150946289:-
LUAD	cis	rs7714584	1	rs7709464	ENSG00000197083.10	ZNF300P1	3.76	0.000191	0.024	0.31	0.17	Crohn's disease;	chr5:150889879	chr5:150930645~150946289:-
LUAD	cis	rs7714584	1	rs10053750	ENSG00000197083.10	ZNF300P1	3.76	0.000191	0.024	0.31	0.17	Crohn's disease;	chr5:150890489	chr5:150930645~150946289:-
LUAD	cis	rs5758659	0.652	rs6519301	ENSG00000270083.1	RP1-257I20.14	3.76	0.000191	0.024	0.16	0.17	Cognitive function;	chr22:41989963	chr22:42089630~42090028:-
LUAD	cis	rs9900062	1	rs2521879	ENSG00000214174.7	AMZ2P1	3.76	0.000191	0.024	0.26	0.17	QT interval;	chr17:64746560	chr17:64966550~64975576:-
LUAD	cis	rs524281	0.731	rs6591201	ENSG00000255320.1	RP11-755F10.1	-3.76	0.000191	0.024	-0.27	-0.17	Electroencephalogram traits;	chr11:66038499	chr11:66244840~66246239:-
LUAD	cis	rs7107174	0.792	rs12291726	ENSG00000251323.2	RP11-452H21.4	3.76	0.000191	0.024	0.22	0.17	Testicular germ cell tumor;	chr11:78377164	chr11:78423982~78429836:-
LUAD	cis	rs12681366	0.801	rs72674819	ENSG00000254057.1	RP3-388N13.3	3.76	0.000191	0.024	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94468072	chr8:93834454~93846743:-
LUAD	cis	rs7215564	0.73	rs34588273	ENSG00000232083.3	RPL31P7	3.76	0.000191	0.024	0.31	0.17	Myopia (pathological);	chr17:80597665	chr17:80602549~80602926:-
LUAD	cis	rs17122278	0.544	rs499189	ENSG00000243431.1	RPL5P30	-3.76	0.000191	0.024	-0.21	-0.17	Total cholesterol levels;	chr11:118486899	chr11:118560690~118561580:+
LUAD	cis	rs6964587	0.967	rs28594877	ENSG00000188693.7	CYP51A1-AS1	-3.76	0.000191	0.024	-0.2	-0.17	Breast cancer;	chr7:92014756	chr7:92134604~92180725:+
LUAD	cis	rs7590268	0.806	rs7596480	ENSG00000279873.2	LINC01126	-3.76	0.000191	0.024	-0.16	-0.17	Orofacial clefts;	chr2:43394023	chr2:43227210~43228855:+
LUAD	cis	rs7005380	0.785	rs7814294	ENSG00000279347.1	RP11-85I17.2	3.76	0.000191	0.024	0.14	0.17	Interstitial lung disease;	chr8:119927196	chr8:119838736~119840385:-
LUAD	cis	rs897984	0.568	rs11862962	ENSG00000232748.3	RP11-196G11.6	-3.76	0.000191	0.024	-0.23	-0.17	Dementia with Lewy bodies;	chr16:30898385	chr16:31056460~31062803:+
LUAD	cis	rs9308731	0.591	rs938095	ENSG00000227992.1	AC108463.2	3.76	0.000191	0.024	0.2	0.17	Chronic lymphocytic leukemia;	chr2:111191232	chr2:111203964~111206215:-
LUAD	cis	rs875971	0.502	rs2946580	ENSG00000226002.1	RP11-460N20.5	-3.76	0.000191	0.024	-0.23	-0.17	Aortic root size;	chr7:66066855	chr7:65084103~65100232:+
LUAD	cis	rs11637445	0.677	rs3784713	ENSG00000270964.1	RP11-502I4.3	3.76	0.000191	0.024	0.19	0.17	Posterior cortical atrophy and Alzheimer's disease;	chr15:67780675	chr15:67541072~67542604:-
LUAD	cis	rs10484885	0.618	rs292241	ENSG00000217653.1	RP11-63K6.1	-3.76	0.000191	0.024	-0.22	-0.17	QRS interval (sulfonylurea treatment interaction);	chr6:89893786	chr6:89814709~89815463:+
LUAD	cis	rs10435719	0.744	rs11250175	ENSG00000255046.1	RP11-297N6.4	-3.76	0.000191	0.024	-0.21	-0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11935249	chr8:11797928~11802568:-
LUAD	cis	rs1908814	0.516	rs13252853	ENSG00000255046.1	RP11-297N6.4	-3.76	0.000191	0.024	-0.21	-0.17	Neuroticism;	chr8:11935465	chr8:11797928~11802568:-
LUAD	cis	rs1908814	0.516	rs13252854	ENSG00000255046.1	RP11-297N6.4	-3.76	0.000191	0.024	-0.21	-0.17	Neuroticism;	chr8:11935469	chr8:11797928~11802568:-
LUAD	cis	rs1908814	0.516	rs13279577	ENSG00000255046.1	RP11-297N6.4	-3.76	0.000191	0.024	-0.21	-0.17	Neuroticism;	chr8:11935587	chr8:11797928~11802568:-
LUAD	cis	rs1908814	0.516	rs10112958	ENSG00000255046.1	RP11-297N6.4	-3.76	0.000191	0.024	-0.21	-0.17	Neuroticism;	chr8:11935631	chr8:11797928~11802568:-
LUAD	cis	rs748404	0.589	rs62020612	ENSG00000249839.1	AC011330.5	-3.76	0.000191	0.024	-0.27	-0.17	Lung cancer;	chr15:43525881	chr15:43663654~43684339:-
LUAD	cis	rs6452524	0.618	rs6452506	ENSG00000281327.1	LINC01338	3.76	0.000191	0.024	0.18	0.17	Hypertension (SNP x SNP interaction);	chr5:83075844	chr5:82850864~82859836:-
LUAD	cis	rs42490	0.664	rs40457	ENSG00000251136.7	RP11-37B2.1	-3.76	0.000191	0.024	-0.17	-0.17	Leprosy;	chr8:89811459	chr8:89609409~89757727:-
LUAD	cis	rs7809615	0.515	rs3843540	ENSG00000244219.5	GS1-259H13.2	-3.76	0.000191	0.024	-0.28	-0.17	Blood metabolite ratios;	chr7:99529017	chr7:99598066~99610813:+
LUAD	cis	rs10129255	0.5	rs6576232	ENSG00000253209.1	IGHV3-65	3.76	0.000191	0.024	0.13	0.17	Kawasaki disease;	chr14:106787090	chr14:106666092~106666532:-
LUAD	cis	rs10463554	0.927	rs34820	ENSG00000250682.4	LINC00491	3.76	0.000191	0.024	0.2	0.17	Parkinson's disease;	chr5:103101164	chr5:102609156~102671559:-
LUAD	cis	rs1401999	0.836	rs34571027	ENSG00000223882.1	ABCC5-AS1	-3.76	0.000191	0.024	-0.18	-0.17	Anterior chamber depth;	chr3:184008856	chr3:184006338~184011419:+
LUAD	cis	rs5015933	0.788	rs662637	ENSG00000232630.1	PRPS1P2	-3.76	0.000192	0.024	-0.16	-0.17	Body mass index;	chr9:125258887	chr9:125150653~125151589:+
LUAD	cis	rs238295	0.805	rs1056244	ENSG00000230563.2	RP5-828H9.1	3.76	0.000192	0.024	0.22	0.17	Occipital cortical area (total cortical area interaction);	chr20:5570388	chr20:5471207~5475182:+
LUAD	cis	rs13113518	0.812	rs12500601	ENSG00000273257.1	RP11-177J6.1	3.76	0.000192	0.0241	0.19	0.17	Height;	chr4:55451489	chr4:55387949~55388271:+
LUAD	cis	rs2310173	0.966	rs7588933	ENSG00000281162.1	LINC01127	-3.76	0.000192	0.0241	-0.19	-0.17	Ulcerative colitis;Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr2:102046190	chr2:101962056~101987167:+
LUAD	cis	rs9925964	0.967	rs9936329	ENSG00000232748.3	RP11-196G11.6	3.76	0.000192	0.0241	0.21	0.17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31129478	chr16:31056460~31062803:+
LUAD	cis	rs875971	0.545	rs13311962	ENSG00000222364.1	RNU6-96P	3.76	0.000192	0.0241	0.21	0.17	Aortic root size;	chr7:66603142	chr7:66395191~66395286:+
LUAD	cis	rs56309584	0.597	rs78296773	ENSG00000269947.1	RP11-849F2.9	-3.76	0.000192	0.0241	-0.25	-0.17	Initial pursuit acceleration;	chr17:8264644	chr17:8277763~8278436:+
LUAD	cis	rs6452524	0.618	rs1993948	ENSG00000281327.1	LINC01338	3.76	0.000192	0.0241	0.18	0.17	Hypertension (SNP x SNP interaction);	chr5:83076461	chr5:82850864~82859836:-
LUAD	cis	rs10270805	0.892	rs1921831	ENSG00000229108.1	MEOX2-AS1	-3.76	0.000192	0.0241	-0.32	-0.17	Response to statin therapy;	chr7:16447634	chr7:15688378~15695491:+
LUAD	cis	rs6502050	0.835	rs6502070	ENSG00000275966.1	RP11-1055B8.9	-3.76	0.000192	0.0241	-0.17	-0.17	Life satisfaction;	chr17:82154758	chr17:81345476~81345966:-
LUAD	cis	rs6910061	1	rs13214666	ENSG00000247925.2	RP3-510L9.1	-3.76	0.000192	0.0241	-0.24	-0.17	Diabetic kidney disease;	chr6:11103304	chr6:11173452~11259099:+
LUAD	cis	rs6095360	1	rs2869694	ENSG00000222365.1	SNORD12B	-3.76	0.000192	0.0241	-0.17	-0.17	Intelligence (multi-trait analysis);	chr20:49051846	chr20:49280319~49280409:+
LUAD	cis	rs6095360	1	rs6019618	ENSG00000222365.1	SNORD12B	-3.76	0.000192	0.0241	-0.17	-0.17	Intelligence (multi-trait analysis);	chr20:49055001	chr20:49280319~49280409:+
LUAD	cis	rs6095360	0.933	rs6019620	ENSG00000222365.1	SNORD12B	-3.76	0.000192	0.0241	-0.17	-0.17	Intelligence (multi-trait analysis);	chr20:49062763	chr20:49280319~49280409:+
LUAD	cis	rs6095360	1	rs6019621	ENSG00000222365.1	SNORD12B	-3.76	0.000192	0.0241	-0.17	-0.17	Intelligence (multi-trait analysis);	chr20:49063426	chr20:49280319~49280409:+
LUAD	cis	rs6095360	1	rs2075675	ENSG00000222365.1	SNORD12B	-3.76	0.000192	0.0241	-0.17	-0.17	Intelligence (multi-trait analysis);	chr20:49068956	chr20:49280319~49280409:+
LUAD	cis	rs6964587	1	rs10488510	ENSG00000188693.7	CYP51A1-AS1	-3.76	0.000192	0.0241	-0.2	-0.17	Breast cancer;	chr7:92030911	chr7:92134604~92180725:+
LUAD	cis	rs683250	0.66	rs509144	ENSG00000246067.6	RAB30-AS1	3.76	0.000192	0.0241	0.18	0.17	Subcortical brain region volumes;	chr11:83275553	chr11:83072066~83106719:+
LUAD	cis	rs714052	0.518	rs13234378	ENSG00000274080.1	CTA-315H11.2	3.76	0.000192	0.0241	0.31	0.17	Hypertriglyceridemia;Triglycerides;	chr7:73611821	chr7:73609262~73611502:-
LUAD	cis	rs2242116	0.932	rs1531137	ENSG00000271161.1	BOLA2P2	3.76	0.000192	0.0241	0.16	0.17	Birth weight;	chr3:46901538	chr3:47499841~47500407:+
LUAD	cis	rs13113518	0.783	rs12508367	ENSG00000273257.1	RP11-177J6.1	3.76	0.000192	0.0241	0.19	0.17	Height;	chr4:55509442	chr4:55387949~55388271:+
LUAD	cis	rs13113518	0.812	rs2272073	ENSG00000273257.1	RP11-177J6.1	3.76	0.000192	0.0241	0.19	0.17	Height;	chr4:55510177	chr4:55387949~55388271:+
LUAD	cis	rs4403732	1	rs4237333	ENSG00000230526.1	RP11-472G21.2	3.76	0.000192	0.0241	0.28	0.17	Coronary artery disease;	chr10:71877468	chr10:71878356~71879107:+
LUAD	cis	rs4646450	0.838	rs10229569	ENSG00000244219.5	GS1-259H13.2	-3.76	0.000192	0.0241	-0.28	-0.17	Blood metabolite levels;	chr7:99586081	chr7:99598066~99610813:+
LUAD	cis	rs7829975	0.509	rs7838674	ENSG00000233609.3	RP11-62H7.2	-3.76	0.000192	0.0241	-0.14	-0.17	Mood instability;	chr8:8939563	chr8:8961200~8979025:+
LUAD	cis	rs76419734	1	rs72669978	ENSG00000251175.4	RP11-45L9.1	-3.76	0.000192	0.0241	-0.4	-0.17	Post bronchodilator FEV1;	chr4:105599695	chr4:105746245~105827172:-
LUAD	cis	rs523522	0.962	rs4766966	ENSG00000278344.1	RP11-18C24.8	3.76	0.000192	0.0241	0.23	0.17	High light scatter reticulocyte count;	chr12:120505108	chr12:120500735~120501090:-
LUAD	cis	rs7637701	0.78	rs9858158	ENSG00000240875.4	LINC00886	-3.76	0.000192	0.0241	-0.18	-0.17	Breast cancer;	chr3:156845538	chr3:156747346~156817062:-
LUAD	cis	rs442309	0.807	rs224069	ENSG00000238280.1	RP11-436D10.3	-3.76	0.000192	0.0241	-0.21	-0.17	Vogt-Koyanagi-Harada syndrome;	chr10:62748366	chr10:62793562~62805887:-
LUAD	cis	rs12935418	0.616	rs2549854	ENSG00000261061.1	RP11-303E16.2	-3.76	0.000192	0.0241	-0.18	-0.17	Mean corpuscular volume;	chr16:80993034	chr16:81030770~81031485:+
LUAD	cis	rs728616	0.867	rs61860039	ENSG00000234382.2	RP11-40F6.1	-3.76	0.000192	0.0241	-0.43	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80180150	chr10:80233664~80245367:+
LUAD	cis	rs728616	0.867	rs61860041	ENSG00000234382.2	RP11-40F6.1	-3.76	0.000192	0.0241	-0.43	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80184575	chr10:80233664~80245367:+
LUAD	cis	rs728616	0.867	rs61860042	ENSG00000234382.2	RP11-40F6.1	-3.76	0.000192	0.0241	-0.43	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80186482	chr10:80233664~80245367:+
LUAD	cis	rs728616	0.867	rs61860043	ENSG00000234382.2	RP11-40F6.1	-3.76	0.000192	0.0241	-0.43	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80186642	chr10:80233664~80245367:+
LUAD	cis	rs728616	0.867	rs12415870	ENSG00000234382.2	RP11-40F6.1	-3.76	0.000192	0.0241	-0.43	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80189714	chr10:80233664~80245367:+
LUAD	cis	rs728616	0.867	rs12414521	ENSG00000234382.2	RP11-40F6.1	-3.76	0.000192	0.0241	-0.43	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80189778	chr10:80233664~80245367:+
LUAD	cis	rs12682352	0.652	rs1567398	ENSG00000253893.2	FAM85B	3.76	0.000192	0.0241	0.21	0.17	Neuroticism;	chr8:8869294	chr8:8167819~8226614:-
LUAD	cis	rs13113518	0.902	rs3805150	ENSG00000273257.1	RP11-177J6.1	3.76	0.000192	0.0241	0.18	0.17	Height;	chr4:55446869	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs4864990	ENSG00000273257.1	RP11-177J6.1	3.76	0.000192	0.0241	0.18	0.17	Height;	chr4:55447523	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs11133381	ENSG00000273257.1	RP11-177J6.1	3.76	0.000192	0.0241	0.18	0.17	Height;	chr4:55450812	chr4:55387949~55388271:+
LUAD	cis	rs13113518	0.756	rs7658446	ENSG00000273257.1	RP11-177J6.1	3.76	0.000192	0.0241	0.19	0.17	Height;	chr4:55495262	chr4:55387949~55388271:+
LUAD	cis	rs6095360	1	rs707533	ENSG00000222365.1	SNORD12B	-3.76	0.000192	0.0241	-0.17	-0.17	Intelligence (multi-trait analysis);	chr20:49035717	chr20:49280319~49280409:+
LUAD	cis	rs6095360	1	rs707534	ENSG00000222365.1	SNORD12B	-3.76	0.000192	0.0241	-0.17	-0.17	Intelligence (multi-trait analysis);	chr20:49035801	chr20:49280319~49280409:+
LUAD	cis	rs6095360	0.901	rs16994347	ENSG00000222365.1	SNORD12B	-3.76	0.000192	0.0241	-0.17	-0.17	Intelligence (multi-trait analysis);	chr20:49036824	chr20:49280319~49280409:+
LUAD	cis	rs6095360	1	rs6019603	ENSG00000222365.1	SNORD12B	-3.76	0.000192	0.0241	-0.17	-0.17	Intelligence (multi-trait analysis);	chr20:49036869	chr20:49280319~49280409:+
LUAD	cis	rs6095360	0.966	rs927160	ENSG00000222365.1	SNORD12B	-3.76	0.000192	0.0241	-0.17	-0.17	Intelligence (multi-trait analysis);	chr20:49038027	chr20:49280319~49280409:+
LUAD	cis	rs6095360	0.933	rs3817652	ENSG00000222365.1	SNORD12B	-3.76	0.000192	0.0241	-0.17	-0.17	Intelligence (multi-trait analysis);	chr20:49046831	chr20:49280319~49280409:+
LUAD	cis	rs6095360	1	rs6090939	ENSG00000222365.1	SNORD12B	-3.76	0.000192	0.0241	-0.17	-0.17	Intelligence (multi-trait analysis);	chr20:49049288	chr20:49280319~49280409:+
LUAD	cis	rs6095360	1	rs6012590	ENSG00000222365.1	SNORD12B	-3.76	0.000192	0.0241	-0.17	-0.17	Intelligence (multi-trait analysis);	chr20:49050700	chr20:49280319~49280409:+
LUAD	cis	rs6095360	0.901	rs6012591	ENSG00000222365.1	SNORD12B	-3.76	0.000192	0.0241	-0.17	-0.17	Intelligence (multi-trait analysis);	chr20:49050805	chr20:49280319~49280409:+
LUAD	cis	rs6095360	1	rs7509369	ENSG00000222365.1	SNORD12B	-3.76	0.000192	0.0241	-0.17	-0.17	Intelligence (multi-trait analysis);	chr20:49051500	chr20:49280319~49280409:+
LUAD	cis	rs6840360	0.642	rs2724577	ENSG00000278978.1	RP11-164P12.5	-3.76	0.000192	0.0241	-0.18	-0.17	Intelligence (multi-trait analysis);	chr4:151433753	chr4:151669786~151670503:+
LUAD	cis	rs2638953	0.924	rs12368652	ENSG00000278733.1	RP11-425D17.1	-3.76	0.000192	0.0241	-0.2	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28170046	chr12:28185625~28186190:-
LUAD	cis	rs273259	0.583	rs3820092	ENSG00000235400.1	RP4-641G12.4	3.76	0.000192	0.0241	0.25	0.17	Febrile seizures (MMR vaccine-related);Febrile seizures;	chr1:78630851	chr1:78749073~78750659:+
LUAD	cis	rs9467773	1	rs1321479	ENSG00000261353.1	CTA-14H9.5	3.76	0.000192	0.0241	0.19	0.17	Intelligence (multi-trait analysis);	chr6:26501669	chr6:26527063~26527404:+
LUAD	cis	rs8098244	0.628	rs8083184	ENSG00000264745.1	TTC39C-AS1	3.76	0.000192	0.0241	0.18	0.17	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23683708	chr18:23994213~24015339:-
LUAD	cis	rs10129255	0.5	rs4774189	ENSG00000253209.1	IGHV3-65	3.76	0.000192	0.0241	0.13	0.17	Kawasaki disease;	chr14:106768275	chr14:106666092~106666532:-
LUAD	cis	rs6687821	0.515	rs1407132	ENSG00000261737.1	RP4-612B15.3	-3.76	0.000192	0.0241	-0.23	-0.17	Yeast infection;	chr1:86928231	chr1:86703502~86704462:-
LUAD	cis	rs1348850	0.793	rs6736390	ENSG00000213963.5	AC074286.1	3.76	0.000192	0.0241	0.2	0.17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177615586	chr2:177283508~177392691:-
LUAD	cis	rs9517320	1	rs9513430	ENSG00000231194.1	FARP1-AS1	3.76	0.000192	0.0241	0.19	0.17	Longevity;	chr13:98474998	chr13:98435405~98435840:-
LUAD	cis	rs10129255	0.872	rs1858683	ENSG00000274576.2	IGHV2-70	3.76	0.000192	0.0241	0.15	0.17	Kawasaki disease;	chr14:106670217	chr14:106770577~106771020:-
LUAD	cis	rs4660214	0.627	rs61779282	ENSG00000182109.6	RP11-69E11.4	3.76	0.000192	0.0241	0.23	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39374632	chr1:39522280~39546187:-
LUAD	cis	rs8046148	0.789	rs6500288	ENSG00000279356.1	RP11-429P3.8	-3.76	0.000192	0.0241	-0.18	-0.17	Testicular germ cell tumor;	chr16:50114497	chr16:50072862~50074986:+
LUAD	cis	rs7107174	1	rs2511175	ENSG00000251323.2	RP11-452H21.4	3.76	0.000192	0.0241	0.23	0.17	Testicular germ cell tumor;	chr11:78264035	chr11:78423982~78429836:-
LUAD	cis	rs41369048	0.858	rs11578466	ENSG00000272823.1	RP11-295M18.6	-3.76	0.000192	0.0241	-0.27	-0.17	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220884397	chr1:220828676~220829211:-
LUAD	cis	rs2904524	1	rs17107935	ENSG00000257815.4	RP11-611E13.2	-3.76	0.000192	0.0241	-0.25	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70286084	chr12:69904033~70243360:-
LUAD	cis	rs2836974	0.526	rs1888488	ENSG00000232608.1	TIMM9P2	3.76	0.000192	0.0241	0.2	0.17	Cognitive function;	chr21:39314595	chr21:39216624~39217506:+
LUAD	cis	rs12188164	0.93	rs72717436	ENSG00000221990.4	EXOC3-AS1	3.76	0.000192	0.0241	0.17	0.17	Cystic fibrosis severity;	chr5:448176	chr5:441498~443160:-
LUAD	cis	rs12188164	0.965	rs72717438	ENSG00000221990.4	EXOC3-AS1	3.76	0.000192	0.0241	0.17	0.17	Cystic fibrosis severity;	chr5:448548	chr5:441498~443160:-
LUAD	cis	rs12188164	0.93	rs72717440	ENSG00000221990.4	EXOC3-AS1	3.76	0.000192	0.0241	0.17	0.17	Cystic fibrosis severity;	chr5:449586	chr5:441498~443160:-
LUAD	cis	rs12188164	0.965	rs11743639	ENSG00000221990.4	EXOC3-AS1	3.76	0.000192	0.0241	0.17	0.17	Cystic fibrosis severity;	chr5:450595	chr5:441498~443160:-
LUAD	cis	rs12188164	0.965	rs11745789	ENSG00000221990.4	EXOC3-AS1	3.76	0.000192	0.0241	0.17	0.17	Cystic fibrosis severity;	chr5:450662	chr5:441498~443160:-
LUAD	cis	rs12188164	0.965	rs11744539	ENSG00000221990.4	EXOC3-AS1	3.76	0.000192	0.0241	0.17	0.17	Cystic fibrosis severity;	chr5:451310	chr5:441498~443160:-
LUAD	cis	rs801193	1	rs4717310	ENSG00000222364.1	RNU6-96P	-3.76	0.000192	0.0241	-0.19	-0.17	Aortic root size;	chr7:66696020	chr7:66395191~66395286:+
LUAD	cis	rs35123781	0.654	rs356443	ENSG00000250635.1	CTD-3224K15.2	-3.76	0.000193	0.0241	-0.19	-0.17	Schizophrenia;	chr5:139698244	chr5:139648999~139649728:-
LUAD	cis	rs7200543	1	rs16966953	ENSG00000260735.1	RP11-72I8.1	-3.76	0.000193	0.0241	-0.19	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15041997	chr16:15094411~15109197:+
LUAD	cis	rs9595908	0.709	rs916289	ENSG00000281026.1	N4BP2L2-IT2	-3.76	0.000193	0.0241	-0.11	-0.17	Body mass index;	chr13:32792110	chr13:32504506~32509395:-
LUAD	cis	rs10908557	0.758	rs6701341	ENSG00000223599.1	RP11-216N14.7	3.76	0.000193	0.0241	0.2	0.17	Age at first birth;	chr1:154002145	chr1:153852106~153853414:-
LUAD	cis	rs7017914	0.967	rs34042354	ENSG00000246366.5	RP11-382J12.1	3.76	0.000193	0.0242	0.16	0.17	Bone mineral density;	chr8:70818726	chr8:70608577~70663279:+
LUAD	cis	rs9313772	0.775	rs13163917	ENSG00000276778.1	RP11-524N5.1	3.76	0.000193	0.0242	0.17	0.17	Blood pressure;	chr5:158405292	chr5:158320683~158409773:-
LUAD	cis	rs9549260	0.816	rs7334318	ENSG00000229456.1	RLIMP1	3.76	0.000193	0.0242	0.18	0.17	Red blood cell count;	chr13:40643273	chr13:40618738~40621348:+
LUAD	cis	rs858239	0.6	rs10256359	ENSG00000226816.2	AC005082.12	3.76	0.000193	0.0242	0.22	0.17	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23206013~23208045:+
LUAD	cis	rs8180040	0.966	rs2062278	ENSG00000260236.1	RP11-708J19.1	3.76	0.000193	0.0242	0.15	0.17	Colorectal cancer;	chr3:47375271	chr3:47379089~47380999:-
LUAD	cis	rs13113518	0.966	rs11133387	ENSG00000273257.1	RP11-177J6.1	3.76	0.000193	0.0242	0.18	0.17	Height;	chr4:55475130	chr4:55387949~55388271:+
LUAD	cis	rs6933660	0.8	rs6930557	ENSG00000219395.2	HSPA8P15	-3.76	0.000193	0.0242	-0.16	-0.17	Menarche (age at onset);	chr6:151434671	chr6:151411259~151413945:-
LUAD	cis	rs34421088	0.56	rs2248325	ENSG00000255046.1	RP11-297N6.4	3.76	0.000193	0.0242	0.21	0.17	Neuroticism;	chr8:11539365	chr8:11797928~11802568:-
LUAD	cis	rs34421088	0.56	rs2248316	ENSG00000255046.1	RP11-297N6.4	3.76	0.000193	0.0242	0.21	0.17	Neuroticism;	chr8:11539564	chr8:11797928~11802568:-
LUAD	cis	rs10510102	0.872	rs11200277	ENSG00000276742.1	RP11-500G22.4	3.76	0.000193	0.0242	0.29	0.17	Breast cancer;	chr10:121944295	chr10:121956782~121957098:+
LUAD	cis	rs2299587	0.623	rs12718384	ENSG00000253671.1	RP11-806O11.1	-3.76	0.000193	0.0242	-0.18	-0.17	Economic and political preferences;	chr8:17923603	chr8:17808941~17820868:+
LUAD	cis	rs36093844	0.526	rs7926846	ENSG00000279742.1	RP11-700A24.1	-3.76	0.000193	0.0242	-0.18	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85900770	chr11:85852557~85854943:-
LUAD	cis	rs17772222	0.71	rs1028455	ENSG00000258789.1	RP11-507K2.3	-3.76	0.000193	0.0242	-0.21	-0.17	Coronary artery calcification;	chr14:88363631	chr14:88551597~88552493:+
LUAD	cis	rs9517320	1	rs912337	ENSG00000228889.5	UBAC2-AS1	3.76	0.000193	0.0242	0.18	0.17	Longevity;	chr13:98489018	chr13:99196377~99200710:-
LUAD	cis	rs6547741	1	rs11127071	ENSG00000223522.1	AC093690.1	3.76	0.000193	0.0242	0.16	0.17	Oral cavity cancer;	chr2:27615191	chr2:28307691~28310459:-
LUAD	cis	rs5742933	0.681	rs4525728	ENSG00000253559.1	OSGEPL1-AS1	3.76	0.000193	0.0242	0.2	0.17	Ferritin levels;	chr2:189780324	chr2:189762704~189765556:+
LUAD	cis	rs763121	0.889	rs1837988	ENSG00000225450.1	RP3-508I15.14	-3.76	0.000193	0.0242	-0.17	-0.17	Menopause (age at onset);	chr22:38505089	chr22:38739003~38749041:+
LUAD	cis	rs8073060	0.544	rs225244	ENSG00000267592.1	CTC-507E2.2	-3.76	0.000193	0.0242	-0.25	-0.17	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35619562	chr17:35596904~35597128:-
LUAD	cis	rs854765	0.964	rs854813	ENSG00000223979.2	SMCR2	3.76	0.000193	0.0242	0.19	0.17	Total body bone mineral density;	chr17:18100531	chr17:17674026~17677688:-
LUAD	cis	rs854765	0.964	rs854810	ENSG00000223979.2	SMCR2	3.76	0.000193	0.0242	0.19	0.17	Total body bone mineral density;	chr17:18103107	chr17:17674026~17677688:-
LUAD	cis	rs2154319	0.887	rs1015091	ENSG00000235358.1	RP11-399E6.1	3.76	0.000193	0.0242	0.23	0.17	Height;	chr1:41052369	chr1:41242373~41284861:+
LUAD	cis	rs8031584	0.541	rs2959037	ENSG00000259845.1	HERC2P10	-3.76	0.000193	0.0242	-0.19	-0.17	Huntington's disease progression;	chr15:30925961	chr15:30815271~30844153:+
LUAD	cis	rs1400816	0.85	rs312917	ENSG00000228389.1	AC068039.4	3.76	0.000193	0.0242	0.28	0.17	Amyotrophic lateral sclerosis (sporadic);	chr2:171714648	chr2:171773482~171775844:+
LUAD	cis	rs1400816	0.543	rs10185633	ENSG00000228389.1	AC068039.4	3.76	0.000193	0.0242	0.28	0.17	Amyotrophic lateral sclerosis (sporadic);	chr2:171721351	chr2:171773482~171775844:+
LUAD	cis	rs11779988	0.545	rs431961	ENSG00000253671.1	RP11-806O11.1	-3.76	0.000193	0.0242	-0.21	-0.17	Breast cancer;	chr8:17928695	chr8:17808941~17820868:+
LUAD	cis	rs7017914	0.967	rs13261712	ENSG00000246366.5	RP11-382J12.1	3.76	0.000193	0.0242	0.16	0.17	Bone mineral density;	chr8:70820029	chr8:70608577~70663279:+
LUAD	cis	rs2274273	0.542	rs3783642	ENSG00000258413.1	RP11-665C16.6	-3.76	0.000193	0.0242	-0.21	-0.17	Protein biomarker;	chr14:54893485	chr14:55262767~55272075:-
LUAD	cis	rs1908814	0.541	rs7824267	ENSG00000255046.1	RP11-297N6.4	-3.76	0.000193	0.0242	-0.21	-0.17	Neuroticism;	chr8:11936770	chr8:11797928~11802568:-
LUAD	cis	rs897200	0.689	rs1031508	ENSG00000280083.1	RP11-317J9.1	-3.76	0.000193	0.0242	-0.23	-0.17	Behcet's disease;	chr2:191145485	chr2:191154118~191156070:-
LUAD	cis	rs10463554	0.963	rs61418746	ENSG00000250682.4	LINC00491	3.76	0.000193	0.0242	0.2	0.17	Parkinson's disease;	chr5:103043914	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.963	rs62364875	ENSG00000250682.4	LINC00491	3.76	0.000193	0.0242	0.2	0.17	Parkinson's disease;	chr5:103056486	chr5:102609156~102671559:-
LUAD	cis	rs6951245	1	rs2363286	ENSG00000229043.2	AC091729.9	-3.76	0.000193	0.0242	-0.25	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1051989	chr7:1160374~1165267:+
LUAD	cis	rs13113518	0.812	rs4864996	ENSG00000273257.1	RP11-177J6.1	3.76	0.000193	0.0242	0.19	0.17	Height;	chr4:55452921	chr4:55387949~55388271:+
LUAD	cis	rs1816752	0.875	rs3783076	ENSG00000273628.1	RP11-756A22.7	3.76	0.000193	0.0242	0.2	0.17	Obesity-related traits;	chr13:24490319	chr13:24933006~24936796:+
LUAD	cis	rs7829975	0.577	rs7816329	ENSG00000253893.2	FAM85B	3.76	0.000193	0.0242	0.21	0.17	Mood instability;	chr8:8686333	chr8:8167819~8226614:-
LUAD	cis	rs7200786	0.528	rs41367	ENSG00000274038.1	RP11-66H6.4	-3.76	0.000193	0.0242	-0.22	-0.17	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11160474	chr16:11056556~11057034:+
LUAD	cis	rs6674176	0.935	rs4314918	ENSG00000237950.1	RP11-7O11.3	3.76	0.000193	0.0242	0.22	0.17	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43911831	chr1:43944370~43946551:-
LUAD	cis	rs6674176	1	rs6674176	ENSG00000237950.1	RP11-7O11.3	3.76	0.000193	0.0242	0.22	0.17	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43914285	chr1:43944370~43946551:-
LUAD	cis	rs2154319	0.79	rs213731	ENSG00000235358.1	RP11-399E6.1	3.76	0.000193	0.0242	0.23	0.17	Height;	chr1:41112526	chr1:41242373~41284861:+
LUAD	cis	rs1908814	0.516	rs13281077	ENSG00000255046.1	RP11-297N6.4	-3.76	0.000193	0.0242	-0.21	-0.17	Neuroticism;	chr8:11937305	chr8:11797928~11802568:-
LUAD	cis	rs1908814	0.516	rs13281315	ENSG00000255046.1	RP11-297N6.4	-3.76	0.000193	0.0242	-0.21	-0.17	Neuroticism;	chr8:11937346	chr8:11797928~11802568:-
LUAD	cis	rs1908814	0.516	rs4840597	ENSG00000255046.1	RP11-297N6.4	-3.76	0.000193	0.0242	-0.21	-0.17	Neuroticism;	chr8:11938559	chr8:11797928~11802568:-
LUAD	cis	rs875971	0.54	rs781152	ENSG00000234585.5	CCT6P3	3.76	0.000193	0.0242	0.16	0.17	Aortic root size;	chr7:66014585	chr7:65038354~65074713:+
LUAD	cis	rs17711722	0.727	rs781151	ENSG00000234585.5	CCT6P3	3.76	0.000193	0.0242	0.16	0.17	Calcium levels;	chr7:66014891	chr7:65038354~65074713:+
LUAD	cis	rs2333021	0.78	rs12886469	ENSG00000259015.1	RP11-109N23.6	3.76	0.000193	0.0242	0.16	0.17	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72985979	chr14:72960595~72961993:+
LUAD	cis	rs440932	0.565	rs19334	ENSG00000254340.1	RP11-10A14.3	3.76	0.000193	0.0242	0.21	0.17	High light scatter reticulocyte percentage of red cells;	chr8:9152396	chr8:9141424~9145435:+
LUAD	cis	rs11096990	0.572	rs35040563	ENSG00000249685.1	RP11-360F5.3	3.76	0.000193	0.0242	0.2	0.17	Cognitive function;	chr4:39154262	chr4:39133913~39135608:+
LUAD	cis	rs10435719	0.834	rs11250176	ENSG00000255046.1	RP11-297N6.4	-3.76	0.000193	0.0242	-0.21	-0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11935307	chr8:11797928~11802568:-
LUAD	cis	rs1908814	0.516	rs4367597	ENSG00000255046.1	RP11-297N6.4	-3.76	0.000193	0.0242	-0.21	-0.17	Neuroticism;	chr8:11936020	chr8:11797928~11802568:-
LUAD	cis	rs10435719	0.899	rs9329251	ENSG00000255046.1	RP11-297N6.4	-3.76	0.000193	0.0242	-0.21	-0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11936097	chr8:11797928~11802568:-
LUAD	cis	rs10435719	0.773	rs7842810	ENSG00000255046.1	RP11-297N6.4	-3.76	0.000193	0.0242	-0.21	-0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11936654	chr8:11797928~11802568:-
LUAD	cis	rs2732480	0.577	rs2450994	ENSG00000257763.1	OR5BK1P	3.76	0.000193	0.0242	0.18	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48328049	chr12:48355792~48356614:-
LUAD	cis	rs2348418	0.966	rs11049694	ENSG00000244712.1	RP11-874G11.1	3.76	0.000193	0.0242	0.2	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28527925	chr12:28564678~28565141:-
LUAD	cis	rs11064837	0.504	rs34500179	ENSG00000248636.5	RP11-768F21.1	3.76	0.000193	0.0242	0.2	0.17	Schizophrenia;	chr12:119631047	chr12:119387987~119668079:-
LUAD	cis	rs7429990	0.932	rs11130155	ENSG00000228638.1	FCF1P2	3.76	0.000193	0.0242	0.19	0.17	Educational attainment (years of education);	chr3:48098938	chr3:48290793~48291375:-
LUAD	cis	rs7937890	0.559	rs2597201	ENSG00000254418.1	RP11-21L19.1	3.76	0.000194	0.0242	0.2	0.17	Mitochondrial DNA levels;	chr11:14463858	chr11:14262846~14273691:-
LUAD	cis	rs7937890	0.532	rs2575832	ENSG00000254418.1	RP11-21L19.1	3.76	0.000194	0.0242	0.2	0.17	Mitochondrial DNA levels;	chr11:14467264	chr11:14262846~14273691:-
LUAD	cis	rs8018967	0.622	rs2041073	ENSG00000258695.2	RP3-414A15.2	3.76	0.000194	0.0242	0.19	0.17	Blood metabolite ratios;	chr14:73505831	chr14:73522878~73530610:+
LUAD	cis	rs7829975	0.871	rs7829826	ENSG00000173295.6	FAM86B3P	-3.76	0.000194	0.0242	-0.18	-0.17	Mood instability;	chr8:8720610	chr8:8228595~8244865:+
LUAD	cis	rs67340775	0.541	rs169287	ENSG00000280107.1	AL022393.9	-3.76	0.000194	0.0242	-0.26	-0.17	Lung cancer in ever smokers;	chr6:27886982	chr6:28170845~28172521:+
LUAD	cis	rs4819052	0.54	rs7282639	ENSG00000215447.6	BX322557.10	3.76	0.000194	0.0242	0.21	0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45071240	chr21:45288052~45291738:+
LUAD	cis	rs4727963	0.792	rs1525469	ENSG00000240499.6	RP5-1101C3.1	-3.76	0.000194	0.0243	-0.15	-0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);	chr7:123077984	chr7:122328469~122440388:+
LUAD	cis	rs526231	0.819	rs366437	ENSG00000175749.11	EIF3KP1	3.76	0.000194	0.0243	0.23	0.17	Primary biliary cholangitis;	chr5:103269900	chr5:103032376~103033031:+
LUAD	cis	rs607541	1	rs675413	ENSG00000259520.4	CTD-2651B20.3	-3.76	0.000194	0.0243	-0.23	-0.17	Obesity-related traits;	chr15:45644547	chr15:45251580~45279251:-
LUAD	cis	rs13113518	0.729	rs12641881	ENSG00000272969.1	RP11-528I4.2	3.76	0.000194	0.0243	0.19	0.17	Height;	chr4:55401306	chr4:55547112~55547889:+
LUAD	cis	rs5015933	0.788	rs828290	ENSG00000232630.1	PRPS1P2	-3.76	0.000194	0.0243	-0.16	-0.17	Body mass index;	chr9:125341826	chr9:125150653~125151589:+
LUAD	cis	rs1667284	0.846	rs1026123	ENSG00000266521.1	RP11-650P15.1	3.76	0.000194	0.0243	0.2	0.17	Problematic alcohol use in trauma-exposed individuals;	chr18:31627192	chr18:31496645~31497195:-
LUAD	cis	rs9925964	0.967	rs4889620	ENSG00000232748.3	RP11-196G11.6	3.76	0.000194	0.0243	0.21	0.17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31119853	chr16:31056460~31062803:+
LUAD	cis	rs57709857	0.915	rs12681196	ENSG00000272092.1	RP11-350N15.5	-3.76	0.000194	0.0243	-0.23	-0.17	Autism spectrum disorder or schizophrenia;	chr8:38379076	chr8:38382364~38383461:+
LUAD	cis	rs1876905	1	rs1876905	ENSG00000230177.1	RP5-1112D6.4	-3.76	0.000194	0.0243	-0.2	-0.17	Mean corpuscular hemoglobin;	chr6:111096756	chr6:111277932~111278742:+
LUAD	cis	rs7429990	0.901	rs7433678	ENSG00000228638.1	FCF1P2	3.76	0.000194	0.0243	0.2	0.17	Educational attainment (years of education);	chr3:47995588	chr3:48290793~48291375:-
LUAD	cis	rs7107174	1	rs10899465	ENSG00000251323.2	RP11-452H21.4	3.76	0.000194	0.0243	0.23	0.17	Testicular germ cell tumor;	chr11:78302542	chr11:78423982~78429836:-
LUAD	cis	rs2041840	1	rs6730503	ENSG00000272054.1	RP11-423P10.2	3.76	0.000194	0.0243	0.13	0.17	Chronic lymphocytic leukemia;	chr2:37301335	chr2:37208875~37212677:+
LUAD	cis	rs957448	1	rs16916874	ENSG00000254057.1	RP3-388N13.3	3.76	0.000194	0.0243	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94537749	chr8:93834454~93846743:-
LUAD	cis	rs12941828	0.737	rs17804008	ENSG00000261996.1	CTC-281F24.1	-3.76	0.000194	0.0243	-0.2	-0.17	Colonoscopy-negative controls vs population controls;	chr17:6530339	chr17:6653464~6655009:-
LUAD	cis	rs8028182	0.636	rs12909863	ENSG00000246877.1	DNM1P35	3.76	0.000194	0.0243	0.21	0.17	Sudden cardiac arrest;	chr15:75533481	chr15:75727670~75738623:-
LUAD	cis	rs6951245	0.554	rs10246354	ENSG00000226291.1	AC091729.8	-3.76	0.000194	0.0243	-0.26	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1092820	chr7:1080863~1082178:+
LUAD	cis	rs9467773	0.62	rs2504565	ENSG00000261353.1	CTA-14H9.5	-3.76	0.000194	0.0243	-0.19	-0.17	Intelligence (multi-trait analysis);	chr6:26656662	chr6:26527063~26527404:+
LUAD	cis	rs10129255	0.5	rs1024350	ENSG00000274576.2	IGHV2-70	-3.76	0.000194	0.0243	-0.14	-0.17	Kawasaki disease;	chr14:106685105	chr14:106770577~106771020:-
LUAD	cis	rs10492201	0.529	rs4913269	ENSG00000255733.4	IFNG-AS1	-3.76	0.000194	0.0243	-0.18	-0.17	Itch intensity from mosquito bite adjusted by bite size;	chr12:68014065	chr12:67989445~68234686:+
LUAD	cis	rs7246657	0.551	rs10419174	ENSG00000267309.1	CTD-2630F21.1	3.76	0.000194	0.0243	0.27	0.17	Coronary artery calcification;	chr19:37114439	chr19:36489649~36491040:+
LUAD	cis	rs7985	0.523	rs4822768	ENSG00000244625.4	MIATNB	3.76	0.000194	0.0243	0.18	0.17	Electroencephalogram traits;	chr22:26674786	chr22:26672767~26780207:+
LUAD	cis	rs7985	0.523	rs1045362	ENSG00000244625.4	MIATNB	3.76	0.000194	0.0243	0.18	0.17	Electroencephalogram traits;	chr22:26676177	chr22:26672767~26780207:+
LUAD	cis	rs6499129	1	rs9933206	ENSG00000280214.1	CTD-2012K14.5	3.76	0.000194	0.0243	0.2	0.17	Waist-to-hip ratio adjusted for body mass index;	chr16:67505119	chr16:67550815~67552935:-
LUAD	cis	rs7061710	0.826	rs17623477	ENSG00000271811.1	RP1-79C4.4	-3.76	0.000194	0.0243	-0.24	-0.17	Blood metabolite levels;	chr1:171147165	chr1:170667381~170669425:+
LUAD	cis	rs1383484	1	rs4465575	ENSG00000259728.4	LINC00933	-3.76	0.000194	0.0243	-0.22	-0.17	Height;	chr15:83844160	chr15:84570649~84580175:+
LUAD	cis	rs8028182	0.636	rs4451914	ENSG00000246877.1	DNM1P35	3.76	0.000194	0.0243	0.22	0.17	Sudden cardiac arrest;	chr15:75447483	chr15:75727670~75738623:-
LUAD	cis	rs321358	1	rs321352	ENSG00000271390.1	RP11-89C3.3	3.76	0.000194	0.0243	0.28	0.17	Body mass index;	chr11:111123001	chr11:111089870~111090368:-
LUAD	cis	rs321358	1	rs167683	ENSG00000271390.1	RP11-89C3.3	3.76	0.000194	0.0243	0.28	0.17	Body mass index;	chr11:111123131	chr11:111089870~111090368:-
LUAD	cis	rs10419113	0.641	rs12611312	ENSG00000269867.1	CTD-2583A14.8	-3.76	0.000194	0.0243	-0.15	-0.17	Pediatric bone mineral density (spine);	chr19:57764436	chr19:57867038~57868172:-
LUAD	cis	rs1910358	0.778	rs6871150	ENSG00000248874.4	C5orf17	-3.76	0.000194	0.0243	-0.22	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr5:23992945	chr5:23951348~24178263:+
LUAD	cis	rs77505915	0.512	rs12921808	ENSG00000280152.1	RP11-331F4.5	3.76	0.000194	0.0243	0.15	0.17	Migraine;	chr16:75350086	chr16:75245994~75250077:-
LUAD	cis	rs8014204	0.836	rs12588415	ENSG00000279594.1	RP11-950C14.10	3.76	0.000194	0.0243	0.19	0.17	Caffeine consumption;	chr14:74811508	chr14:75011269~75012851:-
LUAD	cis	rs7131987	0.565	rs6487797	ENSG00000257176.2	RP11-996F15.2	3.76	0.000194	0.0243	0.17	0.17	QT interval;	chr12:29270063	chr12:29280418~29317848:-
LUAD	cis	rs13113518	0.812	rs11133385	ENSG00000273257.1	RP11-177J6.1	3.76	0.000194	0.0243	0.19	0.17	Height;	chr4:55460485	chr4:55387949~55388271:+
LUAD	cis	rs9549260	0.709	rs4943795	ENSG00000229456.1	RLIMP1	-3.76	0.000194	0.0243	-0.18	-0.17	Red blood cell count;	chr13:40599296	chr13:40618738~40621348:+
LUAD	cis	rs5751168	0.646	rs362139	ENSG00000211654.2	IGLV5-37	3.76	0.000194	0.0243	0.22	0.17	Prostate cancer (SNP x SNP interaction);	chr22:22507208	chr22:22427540~22428035:+
LUAD	cis	rs11159086	1	rs12433848	ENSG00000270000.1	RP3-449M8.9	3.76	0.000194	0.0243	0.25	0.17	Advanced glycation end-product levels;	chr14:74497570	chr14:74471930~74472360:-
LUAD	cis	rs13108904	0.652	rs2878539	ENSG00000196810.4	CTBP1-AS2	3.76	0.000194	0.0243	0.2	0.17	Obesity-related traits;	chr4:1250089	chr4:1249300~1288291:+
LUAD	cis	rs875971	0.545	rs313828	ENSG00000224316.1	RP11-479O9.2	-3.76	0.000194	0.0243	-0.2	-0.17	Aortic root size;	chr7:66087627	chr7:65773620~65802067:+
LUAD	cis	rs4666002	0.789	rs12998770	ENSG00000223522.1	AC093690.1	3.76	0.000194	0.0243	0.19	0.17	Phospholipid levels (plasma);	chr2:27690321	chr2:28307691~28310459:-
LUAD	cis	rs987724	0.515	rs6762708	ENSG00000240875.4	LINC00886	3.76	0.000194	0.0243	0.23	0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156973815	chr3:156747346~156817062:-
LUAD	cis	rs7005380	0.733	rs10808505	ENSG00000279347.1	RP11-85I17.2	3.76	0.000194	0.0243	0.14	0.17	Interstitial lung disease;	chr8:119927966	chr8:119838736~119840385:-
LUAD	cis	rs6088580	0.634	rs7271970	ENSG00000276073.1	RP5-1125A11.7	3.76	0.000194	0.0243	0.16	0.17	Glomerular filtration rate (creatinine);	chr20:34399860	chr20:33985617~33988989:-
LUAD	cis	rs4971059	0.629	rs12904	ENSG00000160766.13	GBAP1	-3.76	0.000194	0.0243	-0.17	-0.17	Breast cancer;	chr1:155134221	chr1:155213821~155227422:-
LUAD	cis	rs7512552	0.839	rs7523428	ENSG00000275557.1	RP11-353N4.6	3.76	0.000194	0.0243	0.19	0.17	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150457996	chr1:149607765~149612402:+
LUAD	cis	rs7512552	0.839	rs17596326	ENSG00000275557.1	RP11-353N4.6	3.76	0.000194	0.0243	0.19	0.17	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150461343	chr1:149607765~149612402:+
LUAD	cis	rs2274273	0.84	rs2341622	ENSG00000259318.1	RP11-454L9.2	3.76	0.000194	0.0243	0.15	0.17	Protein biomarker;	chr14:55270525	chr14:55394940~55395233:-
LUAD	cis	rs34779708	0.966	rs34630580	ENSG00000271335.4	RP11-324I22.4	3.76	0.000194	0.0243	0.18	0.17	Inflammatory bowel disease;Crohn's disease;	chr10:35160300	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.931	rs35126129	ENSG00000271335.4	RP11-324I22.4	3.76	0.000194	0.0243	0.18	0.17	Inflammatory bowel disease;Crohn's disease;	chr10:35163213	chr10:35314552~35336401:-
LUAD	cis	rs2731006	0.64	rs2730969	ENSG00000257114.2	RP11-25I15.3	3.76	0.000194	0.0243	0.27	0.17	Panic disorder;	chr12:42794918	chr12:42692216~42717119:+
LUAD	cis	rs801193	1	rs4717319	ENSG00000222364.1	RNU6-96P	-3.76	0.000194	0.0243	-0.19	-0.17	Aortic root size;	chr7:66777606	chr7:66395191~66395286:+
LUAD	cis	rs801193	0.904	rs4718403	ENSG00000222364.1	RNU6-96P	-3.76	0.000194	0.0243	-0.19	-0.17	Aortic root size;	chr7:66777742	chr7:66395191~66395286:+
LUAD	cis	rs1023500	0.551	rs2301521	ENSG00000205702.9	CYP2D7	3.76	0.000194	0.0243	0.14	0.17	Schizophrenia;	chr22:42027106	chr22:42140203~42144577:-
LUAD	cis	rs56309584	0.673	rs11658322	ENSG00000226871.1	AC135178.7	3.76	0.000195	0.0243	0.25	0.17	Initial pursuit acceleration;	chr17:8268011	chr17:8318088~8318712:-
LUAD	cis	rs2486288	0.656	rs9921025	ENSG00000259479.5	SORD2P	-3.76	0.000195	0.0243	-0.2	-0.17	Glomerular filtration rate;	chr15:45254404	chr15:44826371~44884694:-
LUAD	cis	rs7584330	0.78	rs10176842	ENSG00000222032.1	AC112721.2	3.76	0.000195	0.0243	0.19	0.17	Prostate cancer;	chr2:237519613	chr2:237428920~237434822:-
LUAD	cis	rs797680	0.856	rs12118262	ENSG00000223745.6	RP4-717I23.3	-3.76	0.000195	0.0243	-0.13	-0.17	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93185990	chr1:93262186~93346025:-
LUAD	cis	rs755249	0.642	rs11206430	ENSG00000228060.1	RP11-69E11.8	-3.75	0.000195	0.0244	-0.15	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39609695	chr1:39565160~39573203:+
LUAD	cis	rs4407350	0.761	rs11702972	ENSG00000273243.1	CTA-217C2.2	3.75	0.000195	0.0244	0.17	0.17	Intelligence (multi-trait analysis);	chr22:44528514	chr22:45155539~45156011:-
LUAD	cis	rs2412819	0.597	rs2412821	ENSG00000166763.7	STRCP1	3.75	0.000195	0.0244	0.24	0.17	Lung cancer;	chr15:43864966	chr15:43699488~43718184:-
LUAD	cis	rs12935418	0.616	rs9937731	ENSG00000278985.1	RP11-303E16.9	3.75	0.000195	0.0244	0.16	0.17	Mean corpuscular volume;	chr16:80978406	chr16:80982319~80984094:-
LUAD	cis	rs8180040	0.932	rs11712445	ENSG00000271161.1	BOLA2P2	3.75	0.000195	0.0244	0.16	0.17	Colorectal cancer;	chr3:47393062	chr3:47499841~47500407:+
LUAD	cis	rs4474465	0.79	rs4945292	ENSG00000251323.2	RP11-452H21.4	-3.75	0.000195	0.0244	-0.21	-0.17	Alzheimer's disease (survival time);	chr11:78543378	chr11:78423982~78429836:-
LUAD	cis	rs10463554	0.746	rs6876072	ENSG00000250682.4	LINC00491	3.75	0.000195	0.0244	0.2	0.17	Parkinson's disease;	chr5:103251872	chr5:102609156~102671559:-
LUAD	cis	rs62355901	0.505	rs3733951	ENSG00000271828.1	CTD-2310F14.1	-3.75	0.000195	0.0244	-0.34	-0.17	Breast cancer;	chr5:56833976	chr5:56927874~56929573:+
LUAD	cis	rs1046491	1	rs62085927	ENSG00000264964.1	RP11-888D10.3	3.75	0.000195	0.0244	0.35	0.17	Scarlet fever;	chr18:9232564	chr18:9315194~9334441:-
LUAD	cis	rs10214930	0.647	rs7791369	ENSG00000235574.1	AC073150.6	-3.75	0.000195	0.0244	-0.2	-0.17	Hypospadias;	chr7:27872461	chr7:27491682~27492765:-
LUAD	cis	rs9860428	0.526	rs12497951	ENSG00000242770.2	RP11-180K7.1	3.75	0.000195	0.0244	0.18	0.17	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112937216	chr3:112802478~112812819:+
LUAD	cis	rs11073619	0.616	rs116665699	ENSG00000230373.7	GOLGA6L5P	-3.75	0.000195	0.0244	-0.27	-0.17	Positive affect;	chr15:84554498	chr15:84507885~84516814:-
LUAD	cis	rs12149074	0.55	rs4889090	ENSG00000261390.4	RP11-345M22.2	-3.75	0.000195	0.0244	-0.22	-0.17	Bipolar disorder and eating disorder;Eating disorder in bipolar disorder;	chr16:80065342	chr16:79715232~79770563:-
LUAD	cis	rs11637445	0.677	rs1564278	ENSG00000270964.1	RP11-502I4.3	3.75	0.000195	0.0244	0.18	0.17	Posterior cortical atrophy and Alzheimer's disease;	chr15:67815050	chr15:67541072~67542604:-
LUAD	cis	rs853679	0.517	rs9357065	ENSG00000280107.1	AL022393.9	-3.75	0.000195	0.0244	-0.23	-0.17	Depression;	chr6:28161802	chr6:28170845~28172521:+
LUAD	cis	rs7674212	0.507	rs223471	ENSG00000230069.3	LRRC37A15P	-3.75	0.000195	0.0244	-0.18	-0.17	Type 2 diabetes;	chr4:102777629	chr4:102727274~102730721:-
LUAD	cis	rs3845817	0.808	rs702895	ENSG00000281920.1	RP11-418H16.1	-3.75	0.000195	0.0244	-0.21	-0.17	Bipolar disorder;	chr2:65534933	chr2:65623272~65628424:+
LUAD	cis	rs3845817	0.868	rs702896	ENSG00000281920.1	RP11-418H16.1	-3.75	0.000195	0.0244	-0.21	-0.17	Bipolar disorder;	chr2:65535089	chr2:65623272~65628424:+
LUAD	cis	rs858239	0.896	rs1637193	ENSG00000230042.1	AK3P3	-3.75	0.000195	0.0244	-0.21	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23129178~23129841:+
LUAD	cis	rs8062405	0.69	rs6498089	ENSG00000261766.1	RP11-22P6.2	3.75	0.000195	0.0244	0.15	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28617979	chr16:28862166~28863340:-
LUAD	cis	rs8098244	0.541	rs1711445	ENSG00000264745.1	TTC39C-AS1	3.75	0.000195	0.0244	0.18	0.17	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23673901	chr18:23994213~24015339:-
LUAD	cis	rs34779708	0.931	rs7079498	ENSG00000271335.4	RP11-324I22.4	3.75	0.000195	0.0244	0.18	0.17	Inflammatory bowel disease;Crohn's disease;	chr10:35086416	chr10:35314552~35336401:-
LUAD	cis	rs4443100	0.837	rs6003490	ENSG00000207832.1	AC245028.1	3.75	0.000195	0.0244	0.16	0.17	Serum parathyroid hormone levels;	chr22:23046267	chr22:22856545~22856638:+
LUAD	cis	rs8031584	0.958	rs35256769	ENSG00000260128.5	ULK4P2	-3.75	0.000195	0.0244	-0.21	-0.17	Huntington's disease progression;	chr15:30945573	chr15:30572738~30600647:+
LUAD	cis	rs8031584	0.958	rs11629793	ENSG00000260128.5	ULK4P2	-3.75	0.000195	0.0244	-0.21	-0.17	Huntington's disease progression;	chr15:30946220	chr15:30572738~30600647:+
LUAD	cis	rs4763879	0.739	rs7310460	ENSG00000257027.1	RP11-705C15.3	3.75	0.000195	0.0244	0.21	0.17	Type 1 diabetes;	chr12:9688177	chr12:9658567~9662085:+
LUAD	cis	rs737008	0.922	rs1559394	ENSG00000262703.1	RP11-485G7.6	-3.75	0.000195	0.0244	-0.16	-0.17	Obesity-related traits;	chr16:11275348	chr16:11348143~11349321:-
LUAD	cis	rs9543976	0.623	rs7317250	ENSG00000261105.4	LMO7-AS1	3.75	0.000195	0.0244	0.24	0.17	Diabetic retinopathy;	chr13:75593005	chr13:75604700~75635994:-
LUAD	cis	rs1783925	0.6	rs672945	ENSG00000254833.1	RP11-50B3.2	3.75	0.000195	0.0244	0.2	0.17	Formal thought disorder in schizophrenia;	chr11:125425610	chr11:126160714~126176035:+
LUAD	cis	rs2348418	0.798	rs7310297	ENSG00000244712.1	RP11-874G11.1	3.75	0.000195	0.0244	0.2	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28313638	chr12:28564678~28565141:-
LUAD	cis	rs12439619	0.508	rs11856561	ENSG00000259429.4	UBE2Q2P2	-3.75	0.000195	0.0244	-0.14	-0.17	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82355142~82420075:+
LUAD	cis	rs6928977	0.5	rs12211833	ENSG00000231028.7	LINC00271	-3.75	0.000195	0.0244	-0.2	-0.17	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135629066	chr6:135497801~135716055:+
LUAD	cis	rs11955398	0.522	rs12522154	ENSG00000272308.1	RP11-231G3.1	3.75	0.000195	0.0244	0.2	0.17	Intelligence (multi-trait analysis);	chr5:60885673	chr5:60866457~60866935:-
LUAD	cis	rs9813712	0.571	rs6795143	ENSG00000253540.4	FAM86HP	-3.75	0.000195	0.0244	-0.17	-0.17	Response to amphetamines;	chr3:130224355	chr3:130099092~130111472:-
LUAD	cis	rs9813712	0.571	rs9289366	ENSG00000253540.4	FAM86HP	-3.75	0.000195	0.0244	-0.17	-0.17	Response to amphetamines;	chr3:130225267	chr3:130099092~130111472:-
LUAD	cis	rs9813712	0.571	rs9289367	ENSG00000253540.4	FAM86HP	-3.75	0.000195	0.0244	-0.17	-0.17	Response to amphetamines;	chr3:130225286	chr3:130099092~130111472:-
LUAD	cis	rs9813712	0.571	rs9289368	ENSG00000253540.4	FAM86HP	-3.75	0.000195	0.0244	-0.17	-0.17	Response to amphetamines;	chr3:130225562	chr3:130099092~130111472:-
LUAD	cis	rs9813712	0.571	rs6774141	ENSG00000253540.4	FAM86HP	-3.75	0.000195	0.0244	-0.17	-0.17	Response to amphetamines;	chr3:130225599	chr3:130099092~130111472:-
LUAD	cis	rs6095360	1	rs6019624	ENSG00000222365.1	SNORD12B	-3.75	0.000195	0.0244	-0.17	-0.17	Intelligence (multi-trait analysis);	chr20:49069278	chr20:49280319~49280409:+
LUAD	cis	rs2836950	0.509	rs4816618	ENSG00000232608.1	TIMM9P2	3.75	0.000195	0.0244	0.19	0.17	Menarche (age at onset);	chr21:39227603	chr21:39216624~39217506:+
LUAD	cis	rs2836950	0.527	rs2836948	ENSG00000232608.1	TIMM9P2	3.75	0.000195	0.0244	0.19	0.17	Menarche (age at onset);	chr21:39227751	chr21:39216624~39217506:+
LUAD	cis	rs9376098	0.825	rs6569999	ENSG00000232876.1	CTA-212D2.2	3.75	0.000195	0.0244	0.2	0.17	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135161428	chr6:135055033~135060550:+
LUAD	cis	rs6674970	0.518	rs6587552	ENSG00000261168.1	RP11-68I18.10	3.75	0.000195	0.0244	0.22	0.17	Childhood ear infection;	chr1:151046385	chr1:151130075~151131610:-
LUAD	cis	rs6728642	0.908	rs13400545	ENSG00000230606.9	AC159540.1	3.75	0.000195	0.0244	0.29	0.17	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97205889	chr2:97416165~97433527:-
LUAD	cis	rs10463554	0.667	rs57714862	ENSG00000250682.4	LINC00491	3.75	0.000195	0.0244	0.2	0.17	Parkinson's disease;	chr5:103047025	chr5:102609156~102671559:-
LUAD	cis	rs10197140	0.925	rs2880192	ENSG00000235721.1	AC013268.3	-3.75	0.000195	0.0244	-0.19	-0.17	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110923241	chr2:110007675~110010783:+
LUAD	cis	rs6001482	0.686	rs9623125	ENSG00000253818.1	IGLV1-41	-3.75	0.000195	0.0244	-0.18	-0.17	Diastolic blood pressure;	chr22:22234600	chr22:22404207~22404721:+
LUAD	cis	rs6001482	0.702	rs9623126	ENSG00000253818.1	IGLV1-41	-3.75	0.000195	0.0244	-0.18	-0.17	Diastolic blood pressure;	chr22:22234624	chr22:22404207~22404721:+
LUAD	cis	rs7208859	0.673	rs11654331	ENSG00000263603.1	CTD-2349P21.5	-3.75	0.000195	0.0244	-0.29	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837999	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs73277964	ENSG00000263603.1	CTD-2349P21.5	-3.75	0.000195	0.0244	-0.29	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30852183	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs11652409	ENSG00000263603.1	CTD-2349P21.5	-3.75	0.000195	0.0244	-0.29	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855689	chr17:30729469~30731202:+
LUAD	cis	rs7809950	0.954	rs2520242	ENSG00000238832.1	snoU109	3.75	0.000195	0.0244	0.25	0.17	Coronary artery disease;	chr7:107495875	chr7:107603363~107603507:+
LUAD	cis	rs467650	0.853	rs154205	ENSG00000248489.1	CTD-2007H13.3	3.75	0.000195	0.0244	0.18	0.17	Venous thromboembolism (SNP x SNP interaction);	chr5:98649598	chr5:98929171~98995013:+
LUAD	cis	rs4835473	0.932	rs1375986	ENSG00000249741.2	RP11-673E1.3	3.75	0.000195	0.0244	0.2	0.17	Immature fraction of reticulocytes;	chr4:143746048	chr4:143911514~143912053:-
LUAD	cis	rs4835473	0.868	rs35420625	ENSG00000249741.2	RP11-673E1.3	3.75	0.000195	0.0244	0.2	0.17	Immature fraction of reticulocytes;	chr4:143746089	chr4:143911514~143912053:-
LUAD	cis	rs4835473	0.9	rs4835009	ENSG00000249741.2	RP11-673E1.3	3.75	0.000195	0.0244	0.2	0.17	Immature fraction of reticulocytes;	chr4:143746130	chr4:143911514~143912053:-
LUAD	cis	rs7107174	1	rs2511187	ENSG00000251323.2	RP11-452H21.4	3.75	0.000195	0.0244	0.22	0.17	Testicular germ cell tumor;	chr11:78274803	chr11:78423982~78429836:-
LUAD	cis	rs7107174	1	rs2511190	ENSG00000251323.2	RP11-452H21.4	3.75	0.000195	0.0244	0.22	0.17	Testicular germ cell tumor;	chr11:78277264	chr11:78423982~78429836:-
LUAD	cis	rs7107174	0.892	rs3018313	ENSG00000251323.2	RP11-452H21.4	3.75	0.000195	0.0244	0.22	0.17	Testicular germ cell tumor;	chr11:78278598	chr11:78423982~78429836:-
LUAD	cis	rs7976269	0.609	rs4141946	ENSG00000257176.2	RP11-996F15.2	-3.75	0.000195	0.0244	-0.19	-0.17	Male-pattern baldness;	chr12:29066432	chr12:29280418~29317848:-
LUAD	cis	rs1124609	1	rs111705530	ENSG00000244879.4	GABPB1-AS1	3.75	0.000195	0.0244	0.26	0.17	Subjective well-being;	chr15:50186235	chr15:50354959~50372202:+
LUAD	cis	rs4268898	0.662	rs9784114	ENSG00000242628.4	AC009228.1	3.75	0.000195	0.0244	0.25	0.17	Asthma;	chr2:24214648	chr2:24214381~24221516:+
LUAD	cis	rs4268898	0.662	rs74470633	ENSG00000242628.4	AC009228.1	3.75	0.000195	0.0244	0.25	0.17	Asthma;	chr2:24215843	chr2:24214381~24221516:+
LUAD	cis	rs2408955	0.522	rs4760612	ENSG00000257763.1	OR5BK1P	-3.75	0.000195	0.0244	-0.17	-0.17	Glycated hemoglobin levels;	chr12:48028073	chr12:48355792~48356614:-
LUAD	cis	rs11073619	0.558	rs12440039	ENSG00000230373.7	GOLGA6L5P	-3.75	0.000196	0.0244	-0.27	-0.17	Positive affect;	chr15:84144748	chr15:84507885~84516814:-
LUAD	cis	rs2985684	0.894	rs4900928	ENSG00000278009.1	RP11-649E7.8	3.75	0.000196	0.0244	0.22	0.17	Carotid intima media thickness;	chr14:49554099	chr14:49601011~49601124:-
LUAD	cis	rs3764021	0.87	rs7970116	ENSG00000256582.1	RP11-75L1.1	-3.75	0.000196	0.0244	-0.17	-0.17	Type 1 diabetes;	chr12:9727518	chr12:9704077~9709350:+
LUAD	cis	rs2253762	0.507	rs10159998	ENSG00000276742.1	RP11-500G22.4	3.75	0.000196	0.0245	0.26	0.17	Breast cancer;	chr10:121994550	chr10:121956782~121957098:+
LUAD	cis	rs10463554	0.895	rs3733939	ENSG00000250682.4	LINC00491	3.75	0.000196	0.0245	0.2	0.17	Parkinson's disease;	chr5:102974462	chr5:102609156~102671559:-
LUAD	cis	rs2919009	0.509	rs12255639	ENSG00000271670.1	RP11-95I16.4	3.75	0.000196	0.0245	0.21	0.17	Obesity-related traits;	chr10:120784075	chr10:120879256~120880667:-
LUAD	cis	rs2235642	0.787	rs2235646	ENSG00000280231.1	LA16c-380F5.3	-3.75	0.000196	0.0245	-0.23	-0.17	Coronary artery disease;	chr16:1551286	chr16:1553655~1554130:-
LUAD	cis	rs4853525	0.561	rs7597768	ENSG00000235852.1	AC005540.3	3.75	0.000196	0.0245	0.22	0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190977153	chr2:190880797~190882059:-
LUAD	cis	rs62244186	0.545	rs9284880	ENSG00000233509.2	ZNF197-AS1	3.75	0.000196	0.0245	0.19	0.17	Depressive symptoms;	chr3:44717897	chr3:44617128~44624797:-
LUAD	cis	rs9309473	0.519	rs13017182	ENSG00000163016.8	ALMS1P	-3.75	0.000196	0.0245	-0.18	-0.17	Metabolite levels;	chr2:73663877	chr2:73644919~73685576:+
LUAD	cis	rs453301	0.624	rs2288671	ENSG00000253893.2	FAM85B	-3.75	0.000196	0.0245	-0.22	-0.17	Joint mobility (Beighton score);	chr8:9003384	chr8:8167819~8226614:-
LUAD	cis	rs6708413	0.52	rs6543151	ENSG00000234389.1	AC007278.3	3.75	0.000196	0.0245	0.17	0.17	Crohn's disease;Inflammatory bowel disease;	chr2:102497582	chr2:102438713~102440475:+
LUAD	cis	rs17122278	0.858	rs12289253	ENSG00000243431.1	RPL5P30	3.75	0.000196	0.0245	0.21	0.17	Total cholesterol levels;	chr11:118534353	chr11:118560690~118561580:+
LUAD	cis	rs6502050	0.835	rs4641801	ENSG00000266654.1	RP11-1376P16.1	-3.75	0.000196	0.0245	-0.18	-0.17	Life satisfaction;	chr17:82196145	chr17:82160056~82160452:+
LUAD	cis	rs6502050	0.799	rs4132775	ENSG00000266654.1	RP11-1376P16.1	-3.75	0.000196	0.0245	-0.18	-0.17	Life satisfaction;	chr17:82197536	chr17:82160056~82160452:+
LUAD	cis	rs12468226	0.689	rs60584169	ENSG00000226261.1	AC064836.3	3.75	0.000196	0.0245	0.26	0.17	Urate levels;	chr2:202111695	chr2:202336024~202336727:-
LUAD	cis	rs1431005	0.893	rs7676864	ENSG00000250658.1	RP11-138B4.1	3.75	0.000196	0.0245	0.21	0.17	Response to statin therapy;	chr4:187400331	chr4:187304083~187309682:-
LUAD	cis	rs1979679	0.918	rs7314502	ENSG00000278733.1	RP11-425D17.1	-3.75	0.000196	0.0245	-0.2	-0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28462300	chr12:28185625~28186190:-
LUAD	cis	rs10132760	0.568	rs11851168	ENSG00000211778.2	TRAV4	-3.75	0.000196	0.0245	-0.14	-0.17	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr14:21756085	chr14:21736152~21736982:+
LUAD	cis	rs2735413	0.875	rs8055298	ENSG00000276007.1	RP11-358L22.3	3.75	0.000196	0.0245	0.17	0.17	Systolic blood pressure (alcohol consumption interaction);	chr16:78050971	chr16:78123243~78124332:+
LUAD	cis	rs916888	0.773	rs199534	ENSG00000260075.1	NSFP1	-3.75	0.000196	0.0245	-0.28	-0.17	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46372855~46487141:+
LUAD	cis	rs1334894	0.901	rs12529688	ENSG00000228559.1	RP3-340B19.3	-3.75	0.000196	0.0245	-0.35	-0.17	Coronary artery disease;	chr6:35545148	chr6:35544632~35545669:+
LUAD	cis	rs8028182	0.636	rs8028277	ENSG00000246877.1	DNM1P35	3.75	0.000196	0.0245	0.22	0.17	Sudden cardiac arrest;	chr15:75391744	chr15:75727670~75738623:-
LUAD	cis	rs10859871	0.536	rs10745721	ENSG00000216306.3	KRT19P2	3.75	0.000196	0.0245	0.22	0.17	Endometriosis;	chr12:95313985	chr12:94834147~94835158:+
LUAD	cis	rs1150668	0.796	rs2247002	ENSG00000176933.5	TOB2P1	-3.75	0.000196	0.0245	-0.19	-0.17	Pubertal anthropometrics;	chr6:28430174	chr6:28217643~28218634:-
LUAD	cis	rs2024714	0.837	rs944240	ENSG00000273812.1	WI2-87327B8.2	-3.75	0.000196	0.0245	-0.18	-0.17	Longevity;	chr20:61624035	chr20:62596732~62603115:-
LUAD	cis	rs7762018	0.769	rs4716385	ENSG00000231690.2	LINC00574	-3.75	0.000196	0.0245	-0.34	-0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169727512	chr6:169790321~169802873:+
LUAD	cis	rs7107174	1	rs2510035	ENSG00000251323.2	RP11-452H21.4	3.75	0.000196	0.0245	0.23	0.17	Testicular germ cell tumor;	chr11:78242129	chr11:78423982~78429836:-
LUAD	cis	rs737008	0.922	rs376374	ENSG00000262703.1	RP11-485G7.6	-3.75	0.000196	0.0245	-0.16	-0.17	Obesity-related traits;	chr16:11276759	chr16:11348143~11349321:-
LUAD	cis	rs987044	0.726	rs10746128	ENSG00000257221.1	RP11-689B22.2	-3.75	0.000196	0.0245	-0.14	-0.17	Mean platelet volume;	chr12:108663255	chr12:108628687~108641318:+
LUAD	cis	rs8002861	0.967	rs7994883	ENSG00000274001.1	RP11-5G9.5	-3.75	0.000196	0.0245	-0.17	-0.17	Leprosy;	chr13:43904669	chr13:43877715~43878163:-
LUAD	cis	rs7131987	0.621	rs3782506	ENSG00000275476.1	RP11-996F15.4	3.75	0.000196	0.0245	0.19	0.17	QT interval;	chr12:29292489	chr12:29277397~29277882:-
LUAD	cis	rs7107174	1	rs2510036	ENSG00000251323.2	RP11-452H21.4	3.75	0.000196	0.0245	0.23	0.17	Testicular germ cell tumor;	chr11:78255742	chr11:78423982~78429836:-
LUAD	cis	rs7772486	0.686	rs9497396	ENSG00000235652.6	RP11-545I5.3	-3.75	0.000196	0.0245	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145693827	chr6:145799409~145886585:+
LUAD	cis	rs1790761	0.505	rs34721562	ENSG00000184224.3	C11orf72	-3.75	0.000196	0.0245	-0.19	-0.17	Mean corpuscular volume;	chr11:67545237	chr11:67602880~67606706:-
LUAD	cis	rs5742933	0.857	rs1233282	ENSG00000253559.1	OSGEPL1-AS1	-3.75	0.000196	0.0245	-0.2	-0.17	Ferritin levels;	chr2:189823518	chr2:189762704~189765556:+
LUAD	cis	rs9900280	1	rs4056946	ENSG00000264808.1	RP11-802D6.1	3.75	0.000196	0.0245	0.2	0.17	Mean platelet volume;	chr17:29378445	chr17:29369717~29390777:-
LUAD	cis	rs9951698	0.703	rs12605638	ENSG00000267480.1	RP11-703I16.1	-3.75	0.000196	0.0245	-0.21	-0.17	Intelligence (multi-trait analysis);	chr18:12993544	chr18:12031178~12032181:-
LUAD	cis	rs73230612	0.858	rs9868417	ENSG00000242767.1	ZBTB20-AS4	3.75	0.000196	0.0245	0.27	0.17	Type 2 diabetes;	chr3:115379124	chr3:115100423~115103061:+
LUAD	cis	rs1009077	0.627	rs35526209	ENSG00000245958.5	RP11-33B1.1	3.75	0.000196	0.0245	0.18	0.17	Endometriosis;	chr4:119675251	chr4:119454791~119552025:+
LUAD	cis	rs1023500	0.551	rs133355	ENSG00000273366.1	CTA-989H11.1	-3.75	0.000196	0.0245	-0.2	-0.17	Schizophrenia;	chr22:42044281	chr22:42278188~42278846:+
LUAD	cis	rs2348418	0.715	rs1581076	ENSG00000244712.1	RP11-874G11.1	3.75	0.000196	0.0245	0.2	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28570724	chr12:28564678~28565141:-
LUAD	cis	rs2295359	1	rs4655683	ENSG00000275678.1	RP4-547N15.3	-3.75	0.000196	0.0245	-0.17	-0.17	Psoriasis;	chr1:67145930	chr1:67121605~67123956:-
LUAD	cis	rs38055	0.837	rs584593	ENSG00000247796.2	CTD-2366F13.1	-3.75	0.000196	0.0245	-0.19	-0.17	Acne (severe);	chr5:53330398	chr5:53109842~53115126:+
LUAD	cis	rs78572108	0.858	rs12470984	ENSG00000214691.7	AC104654.1	3.75	0.000196	0.0245	0.28	0.17	Total body bone mineral density;	chr2:42005354	chr2:41877074~41894046:+
LUAD	cis	rs11960314	0.603	rs2339094	ENSG00000253348.1	CTC-455F18.1	-3.75	0.000196	0.0245	-0.19	-0.17	Age-related hearing impairment (SNP x SNP interaction);	chr5:170646390	chr5:170747047~170788650:-
LUAD	cis	rs11960314	0.643	rs2879338	ENSG00000253348.1	CTC-455F18.1	-3.75	0.000196	0.0245	-0.19	-0.17	Age-related hearing impairment (SNP x SNP interaction);	chr5:170648494	chr5:170747047~170788650:-
LUAD	cis	rs67478160	0.643	rs4900600	ENSG00000272533.1	SNORA28	3.75	0.000197	0.0246	0.17	0.17	Schizophrenia;	chr14:103825502	chr14:103337849~103337974:+
LUAD	cis	rs4907240	0.961	rs6759099	ENSG00000237510.6	AC008268.2	-3.75	0.000197	0.0246	-0.24	-0.17	Event-related brain oscillations;	chr2:96601523	chr2:95789654~95800166:+
LUAD	cis	rs4907240	0.961	rs6749159	ENSG00000237510.6	AC008268.2	-3.75	0.000197	0.0246	-0.24	-0.17	Event-related brain oscillations;	chr2:96601556	chr2:95789654~95800166:+
LUAD	cis	rs4907240	0.961	rs62154845	ENSG00000237510.6	AC008268.2	-3.75	0.000197	0.0246	-0.24	-0.17	Event-related brain oscillations;	chr2:96601907	chr2:95789654~95800166:+
LUAD	cis	rs13113518	1	rs4864993	ENSG00000273257.1	RP11-177J6.1	3.75	0.000197	0.0246	0.18	0.17	Height;	chr4:55450662	chr4:55387949~55388271:+
LUAD	cis	rs6951245	1	rs77868187	ENSG00000224079.1	AC091729.7	-3.75	0.000197	0.0246	-0.27	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054332	chr7:1074450~1078036:+
LUAD	cis	rs6951245	1	rs75016635	ENSG00000224079.1	AC091729.7	-3.75	0.000197	0.0246	-0.27	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054485	chr7:1074450~1078036:+
LUAD	cis	rs6951245	1	rs113066613	ENSG00000224079.1	AC091729.7	-3.75	0.000197	0.0246	-0.27	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054492	chr7:1074450~1078036:+
LUAD	cis	rs9549260	0.753	rs9532563	ENSG00000229456.1	RLIMP1	3.75	0.000197	0.0246	0.21	0.17	Red blood cell count;	chr13:40586133	chr13:40618738~40621348:+
LUAD	cis	rs8098244	0.603	rs1711455	ENSG00000264745.1	TTC39C-AS1	3.75	0.000197	0.0246	0.18	0.17	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23695207	chr18:23994213~24015339:-
LUAD	cis	rs748404	0.666	rs12913977	ENSG00000249839.1	AC011330.5	-3.75	0.000197	0.0246	-0.26	-0.17	Lung cancer;	chr15:43438913	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.666	rs12914122	ENSG00000249839.1	AC011330.5	-3.75	0.000197	0.0246	-0.26	-0.17	Lung cancer;	chr15:43438956	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.666	rs34697113	ENSG00000249839.1	AC011330.5	-3.75	0.000197	0.0246	-0.26	-0.17	Lung cancer;	chr15:43442041	chr15:43663654~43684339:-
LUAD	cis	rs9467773	0.583	rs2498380	ENSG00000241549.7	GUSBP2	-3.75	0.000197	0.0246	-0.19	-0.17	Intelligence (multi-trait analysis);	chr6:26643768	chr6:26871484~26956554:-
LUAD	cis	rs683250	0.661	rs2507861	ENSG00000246067.6	RAB30-AS1	-3.75	0.000197	0.0246	-0.18	-0.17	Subcortical brain region volumes;	chr11:83420821	chr11:83072066~83106719:+
LUAD	cis	rs8031584	0.541	rs1983459	ENSG00000259845.1	HERC2P10	3.75	0.000197	0.0246	0.18	0.17	Huntington's disease progression;	chr15:30916546	chr15:30815271~30844153:+
LUAD	cis	rs3213758	0.541	rs1344504	ENSG00000275191.1	RP11-36I17.2	-3.75	0.000197	0.0246	-0.26	-0.17	Vitiligo (non-segmental);	chr16:53627958	chr16:53628256~53628816:-
LUAD	cis	rs7660883	1	rs3775217	ENSG00000251411.1	RP11-397E7.4	3.75	0.000197	0.0246	0.19	0.17	HDL cholesterol levels;	chr4:87098315	chr4:86913266~86914817:-
LUAD	cis	rs7772486	0.875	rs9322043	ENSG00000235652.6	RP11-545I5.3	3.75	0.000197	0.0246	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:146031554	chr6:145799409~145886585:+
LUAD	cis	rs7178424	0.811	rs12899801	ENSG00000259251.2	RP11-643M14.1	3.75	0.000197	0.0246	0.17	0.17	Height;	chr15:61954665	chr15:62060503~62062434:+
LUAD	cis	rs2348418	0.832	rs1552761	ENSG00000247934.4	RP11-967K21.1	3.75	0.000197	0.0246	0.19	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28383406	chr12:28163298~28190738:-
LUAD	cis	rs13113518	0.902	rs12642716	ENSG00000273257.1	RP11-177J6.1	3.75	0.000197	0.0246	0.18	0.17	Height;	chr4:55479996	chr4:55387949~55388271:+
LUAD	cis	rs3087591	0.521	rs1013948	ENSG00000263531.1	RP13-753N3.1	-3.75	0.000197	0.0246	-0.28	-0.17	Hip circumference;	chr17:31203691	chr17:30863921~30864940:-
LUAD	cis	rs4716602	0.898	rs10242177	ENSG00000235029.1	MNX1-AS2	-3.75	0.000197	0.0246	-0.21	-0.17	Anti-saccade response;	chr7:156369656	chr7:157006307~157007132:+
LUAD	cis	rs11921451	0.924	rs10934801	ENSG00000244215.1	RP11-88I21.2	-3.75	0.000197	0.0246	-0.21	-0.17	Amyotrophic lateral sclerosis (sporadic);	chr3:127082270	chr3:127322307~127390670:-
LUAD	cis	rs2985684	0.948	rs12886130	ENSG00000278009.1	RP11-649E7.8	3.75	0.000197	0.0246	0.23	0.17	Carotid intima media thickness;	chr14:49616035	chr14:49601011~49601124:-
LUAD	cis	rs6496932	1	rs35796484	ENSG00000259630.2	CTD-2262B20.1	3.75	0.000197	0.0246	0.23	0.17	Central corneal thickness;Corneal structure;	chr15:85282019	chr15:85415228~85415633:+
LUAD	cis	rs12537284	0.542	rs17340646	ENSG00000275106.1	RP11-309L24.10	-3.75	0.000197	0.0246	-0.25	-0.17	Systemic lupus erythematosus;	chr7:129082460	chr7:128952527~128953316:-
LUAD	cis	rs1850744	0.702	rs7434744	ENSG00000163612.10	FAM86KP	-3.75	0.000197	0.0246	-0.46	-0.17	Economic and political preferences;	chr4:9671064	chr4:9153296~9165451:+
LUAD	cis	rs8002861	0.935	rs7318147	ENSG00000274001.1	RP11-5G9.5	-3.75	0.000197	0.0246	-0.19	-0.17	Leprosy;	chr13:43871017	chr13:43877715~43878163:-
LUAD	cis	rs2638953	0.853	rs11049679	ENSG00000278733.1	RP11-425D17.1	-3.75	0.000197	0.0246	-0.21	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28508161	chr12:28185625~28186190:-
LUAD	cis	rs6467136	0.56	rs10954158	ENSG00000224138.1	AC000123.4	-3.75	0.000197	0.0246	-0.16	-0.17	Type 2 diabetes;	chr7:127474085	chr7:127350128~127351523:+
LUAD	cis	rs41369048	0.582	rs2484709	ENSG00000221571.3	RNU6ATAC35P	-3.75	0.000197	0.0246	-0.22	-0.17	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220937297	chr1:220825620~220826063:+
LUAD	cis	rs1355223	0.833	rs11032804	ENSG00000271369.1	RP11-350D17.3	-3.75	0.000197	0.0246	-0.2	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34659051	chr11:34709600~34710161:+
LUAD	cis	rs10510102	0.516	rs10887034	ENSG00000276742.1	RP11-500G22.4	3.75	0.000197	0.0246	0.29	0.17	Breast cancer;	chr10:121973996	chr10:121956782~121957098:+
LUAD	cis	rs3812762	1	rs3812762	ENSG00000254860.4	TMEM9B-AS1	3.75	0.000197	0.0246	0.2	0.17	Hypospadias;	chr11:8730093	chr11:8964675~8977527:+
LUAD	cis	rs6493487	0.512	rs76449077	ENSG00000273674.3	CTD-2378E12.1	3.75	0.000197	0.0246	0.24	0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50827138	chr15:50839875~50908599:-
LUAD	cis	rs6502050	0.835	rs7501527	ENSG00000275966.1	RP11-1055B8.9	-3.75	0.000197	0.0246	-0.17	-0.17	Life satisfaction;	chr17:82141479	chr17:81345476~81345966:-
LUAD	cis	rs2281558	0.793	rs6115227	ENSG00000125804.12	FAM182A	-3.75	0.000197	0.0246	-0.23	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25610741	chr20:26054655~26086917:+
LUAD	cis	rs7242404	0.57	rs11664306	ENSG00000267654.1	RP11-973H7.4	3.75	0.000197	0.0246	0.2	0.17	Interleukin-9 levels;Macrophage inflammatory protein 1a levels;	chr18:12753487	chr18:12739490~12749421:-
LUAD	cis	rs7242404	0.57	rs12964137	ENSG00000267654.1	RP11-973H7.4	3.75	0.000197	0.0246	0.2	0.17	Interleukin-9 levels;Macrophage inflammatory protein 1a levels;	chr18:12753638	chr18:12739490~12749421:-
LUAD	cis	rs812925	0.855	rs6545851	ENSG00000271889.1	RP11-493E12.1	-3.75	0.000197	0.0246	-0.21	-0.17	Immature fraction of reticulocytes;	chr2:61271222	chr2:61151433~61162105:-
LUAD	cis	rs14027	0.577	rs12707876	ENSG00000279347.1	RP11-85I17.2	-3.75	0.000197	0.0246	-0.14	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119730143	chr8:119838736~119840385:-
LUAD	cis	rs2239547	0.603	rs7644973	ENSG00000243224.1	RP5-1157M23.2	-3.75	0.000197	0.0246	-0.19	-0.17	Schizophrenia;	chr3:53048921	chr3:52239258~52241097:+
LUAD	cis	rs2239547	0.603	rs71301807	ENSG00000243224.1	RP5-1157M23.2	-3.75	0.000197	0.0246	-0.19	-0.17	Schizophrenia;	chr3:53051459	chr3:52239258~52241097:+
LUAD	cis	rs1075265	0.73	rs2111868	ENSG00000272156.1	RP11-477N3.1	-3.75	0.000197	0.0246	-0.2	-0.17	Chronotype;Morning vs. evening chronotype;	chr2:53958916	chr2:54082554~54085066:+
LUAD	cis	rs9926296	0.568	rs1230	ENSG00000260259.1	RP11-368I7.4	3.75	0.000197	0.0246	0.16	0.17	Vitiligo;	chr16:89738447	chr16:89682620~89686569:-
LUAD	cis	rs7202877	0.706	rs37599	ENSG00000280152.1	RP11-331F4.5	-3.75	0.000197	0.0247	-0.19	-0.17	Type 1 diabetes;Type 2 diabetes;	chr16:75468234	chr16:75245994~75250077:-
LUAD	cis	rs1075265	0.522	rs7584474	ENSG00000272156.1	RP11-477N3.1	-3.75	0.000197	0.0247	-0.2	-0.17	Chronotype;Morning vs. evening chronotype;	chr2:53674874	chr2:54082554~54085066:+
LUAD	cis	rs412050	0.547	rs78907487	ENSG00000224086.5	LL22NC03-86G7.1	-3.75	0.000198	0.0247	-0.21	-0.17	Attention deficit hyperactivity disorder;	chr22:21797650	chr22:21938293~21977632:+
LUAD	cis	rs412050	0.547	rs17821500	ENSG00000224086.5	LL22NC03-86G7.1	-3.75	0.000198	0.0247	-0.21	-0.17	Attention deficit hyperactivity disorder;	chr22:21798191	chr22:21938293~21977632:+
LUAD	cis	rs412050	0.547	rs76200689	ENSG00000224086.5	LL22NC03-86G7.1	-3.75	0.000198	0.0247	-0.21	-0.17	Attention deficit hyperactivity disorder;	chr22:21800355	chr22:21938293~21977632:+
LUAD	cis	rs10027350	0.927	rs1035091	ENSG00000281501.1	SEPSECS-AS1	3.75	0.000198	0.0247	0.2	0.17	Childhood ear infection;	chr4:25150252	chr4:25160641~25201440:+
LUAD	cis	rs451417	1	rs236124	ENSG00000275632.1	RP5-967N21.11	3.75	0.000198	0.0247	0.21	0.17	Menopause (age at onset);	chr20:5995333	chr20:6000418~6000941:+
LUAD	cis	rs451417	1	rs236125	ENSG00000275632.1	RP5-967N21.11	3.75	0.000198	0.0247	0.21	0.17	Menopause (age at onset);	chr20:5996328	chr20:6000418~6000941:+
LUAD	cis	rs4443100	0.917	rs5996460	ENSG00000207832.1	AC245028.1	3.75	0.000198	0.0247	0.16	0.17	Serum parathyroid hormone levels;	chr22:23050912	chr22:22856545~22856638:+
LUAD	cis	rs11154801	0.696	rs4432992	ENSG00000231028.7	LINC00271	-3.75	0.000198	0.0247	-0.2	-0.17	Multiple sclerosis;	chr6:135612356	chr6:135497801~135716055:+
LUAD	cis	rs9545047	0.604	rs9545076	ENSG00000227354.5	RBM26-AS1	-3.75	0.000198	0.0247	-0.17	-0.17	Schizophrenia;	chr13:79335983	chr13:79406309~79424328:+
LUAD	cis	rs5742933	1	rs12619808	ENSG00000253559.1	OSGEPL1-AS1	-3.75	0.000198	0.0247	-0.23	-0.17	Ferritin levels;	chr2:189776458	chr2:189762704~189765556:+
LUAD	cis	rs67340775	0.541	rs200966	ENSG00000280107.1	AL022393.9	-3.75	0.000198	0.0247	-0.26	-0.17	Lung cancer in ever smokers;	chr6:27894374	chr6:28170845~28172521:+
LUAD	cis	rs1443267	1	rs1443267	ENSG00000229590.3	MSX2P1	3.75	0.000198	0.0247	0.24	0.17	Obstetric antiphospholipid syndrome;	chr17:57834081	chr17:58157028~58157800:+
LUAD	cis	rs7208859	0.573	rs73267829	ENSG00000280069.1	CTD-2349P21.3	-3.75	0.000198	0.0247	-0.24	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30676921	chr17:30738182~30740275:+
LUAD	cis	rs853679	0.55	rs1233704	ENSG00000280107.1	AL022393.9	3.75	0.000198	0.0247	0.22	0.17	Depression;	chr6:28199145	chr6:28170845~28172521:+
LUAD	cis	rs7824557	0.527	rs10109537	ENSG00000255046.1	RP11-297N6.4	3.75	0.000198	0.0247	0.21	0.17	Retinal vascular caliber;	chr8:11382131	chr8:11797928~11802568:-
LUAD	cis	rs3761847	0.5	rs10760132	ENSG00000226752.6	PSMD5-AS1	-3.75	0.000198	0.0247	-0.18	-0.17	Rheumatoid arthritis;	chr9:120977715	chr9:120824828~120854385:+
LUAD	cis	rs404005	0.572	rs62148765	ENSG00000227028.5	SLC8A1-AS1	-3.75	0.000198	0.0247	-0.21	-0.17	HIV-associated dementia;	chr2:40189973	chr2:39786453~40255209:+
LUAD	cis	rs9963862	1	rs9963862	ENSG00000265943.1	RP11-739L10.1	3.75	0.000198	0.0247	0.22	0.17	Late-onset myasthenia gravis;	chr18:23007948	chr18:22699481~22933764:-
LUAD	cis	rs858239	0.6	rs2003555	ENSG00000226816.2	AC005082.12	3.75	0.000198	0.0247	0.22	0.17	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23206013~23208045:+
LUAD	cis	rs858239	0.6	rs7784929	ENSG00000226816.2	AC005082.12	3.75	0.000198	0.0247	0.22	0.17	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23206013~23208045:+
LUAD	cis	rs73108077	0.92	rs73108088	ENSG00000281376.1	ABALON	-3.75	0.000198	0.0247	-0.29	-0.17	Red blood cell density in sickle cell anemia;	chr20:31424444	chr20:31721507~31723409:+
LUAD	cis	rs73108077	1	rs73110016	ENSG00000281376.1	ABALON	-3.75	0.000198	0.0247	-0.29	-0.17	Red blood cell density in sickle cell anemia;	chr20:31432402	chr20:31721507~31723409:+
LUAD	cis	rs73108077	0.915	rs17328705	ENSG00000281376.1	ABALON	-3.75	0.000198	0.0247	-0.29	-0.17	Red blood cell density in sickle cell anemia;	chr20:31438570	chr20:31721507~31723409:+
LUAD	cis	rs35934224	0.769	rs76204326	ENSG00000232926.1	AC000078.5	3.75	0.000198	0.0247	0.23	0.17	Glaucoma (primary open-angle);	chr22:19854779	chr22:19887289~19887970:+
LUAD	cis	rs6499244	0.508	rs11642008	ENSG00000226232.7	RP11-419C5.2	-3.75	0.000198	0.0247	-0.14	-0.17	Menarche (age at onset);	chr16:69894736	chr16:69976388~69996188:-
LUAD	cis	rs748404	0.666	rs16957730	ENSG00000249839.1	AC011330.5	-3.75	0.000198	0.0247	-0.26	-0.17	Lung cancer;	chr15:43438288	chr15:43663654~43684339:-
LUAD	cis	rs6502050	0.835	rs4789670	ENSG00000266654.1	RP11-1376P16.1	-3.75	0.000198	0.0247	-0.18	-0.17	Life satisfaction;	chr17:82193929	chr17:82160056~82160452:+
LUAD	cis	rs6502050	0.835	rs4789722	ENSG00000266654.1	RP11-1376P16.1	-3.75	0.000198	0.0247	-0.18	-0.17	Life satisfaction;	chr17:82194005	chr17:82160056~82160452:+
LUAD	cis	rs6502050	0.799	rs4482345	ENSG00000266654.1	RP11-1376P16.1	-3.75	0.000198	0.0247	-0.18	-0.17	Life satisfaction;	chr17:82195043	chr17:82160056~82160452:+
LUAD	cis	rs7208859	0.528	rs3764416	ENSG00000266490.1	CTD-2349P21.9	-3.75	0.000198	0.0247	-0.23	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30573690	chr17:30792372~30792833:+
LUAD	cis	rs7208859	0.673	rs11650305	ENSG00000263603.1	CTD-2349P21.5	-3.75	0.000198	0.0247	-0.29	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902343	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs11654914	ENSG00000263603.1	CTD-2349P21.5	-3.75	0.000198	0.0247	-0.29	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902406	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs9914271	ENSG00000263603.1	CTD-2349P21.5	-3.75	0.000198	0.0247	-0.29	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905607	chr17:30729469~30731202:+
LUAD	cis	rs12822507	0.868	rs12830917	ENSG00000275963.1	RP11-180M15.6	-3.75	0.000198	0.0247	-0.19	-0.17	Systemic lupus erythematosus;	chr12:12639582	chr12:12648939~12649713:+
LUAD	cis	rs8028182	0.636	rs7175852	ENSG00000260269.4	CTD-2323K18.1	-3.75	0.000198	0.0247	-0.24	-0.17	Sudden cardiac arrest;	chr15:75402194	chr15:75527150~75601205:-
LUAD	cis	rs5758659	1	rs5758659	ENSG00000273366.1	CTA-989H11.1	-3.75	0.000198	0.0247	-0.19	-0.17	Cognitive function;	chr22:42225997	chr22:42278188~42278846:+
LUAD	cis	rs889398	0.617	rs4985450	ENSG00000226232.7	RP11-419C5.2	3.75	0.000198	0.0247	0.14	0.17	Body mass index;	chr16:69867203	chr16:69976388~69996188:-
LUAD	cis	rs4423214	0.798	rs1894100	ENSG00000226627.1	SHANK2-AS1	3.75	0.000198	0.0247	0.2	0.17	Vitamin D levels;	chr11:71419297	chr11:70631094~70635490:+
LUAD	cis	rs1476587	0.92	rs2106953	ENSG00000224046.1	AC005076.5	3.75	0.000198	0.0247	0.23	0.17	Brachial circumference;	chr7:87110776	chr7:87151423~87152420:-
LUAD	cis	rs7826238	0.526	rs876955	ENSG00000253981.4	ALG1L13P	3.75	0.000198	0.0247	0.21	0.17	Systolic blood pressure;	chr8:8453374	chr8:8236003~8244667:-
LUAD	cis	rs6951245	0.872	rs76713558	ENSG00000224079.1	AC091729.7	-3.75	0.000198	0.0247	-0.27	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056230	chr7:1074450~1078036:+
LUAD	cis	rs6951245	0.748	rs79658522	ENSG00000224079.1	AC091729.7	-3.75	0.000198	0.0247	-0.27	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056241	chr7:1074450~1078036:+
LUAD	cis	rs6951245	0.935	rs76525951	ENSG00000224079.1	AC091729.7	-3.75	0.000198	0.0247	-0.27	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056377	chr7:1074450~1078036:+
LUAD	cis	rs6951245	1	rs79683221	ENSG00000224079.1	AC091729.7	-3.75	0.000198	0.0247	-0.27	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056503	chr7:1074450~1078036:+
LUAD	cis	rs6951245	1	rs78185801	ENSG00000224079.1	AC091729.7	-3.75	0.000198	0.0247	-0.27	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056731	chr7:1074450~1078036:+
LUAD	cis	rs11134654	1	rs11134654	ENSG00000253966.1	CTC-455F18.3	-3.75	0.000198	0.0247	-0.27	-0.17	Smooth-surface caries;	chr5:170813419	chr5:170896929~170904461:+
LUAD	cis	rs1950326	0.515	rs12884221	ENSG00000258526.4	RP11-111A21.1	-3.75	0.000198	0.0247	-0.2	-0.17	Verbal memory performance (residualized delayed recall level);	chr14:39571372	chr14:39474840~39513780:+
LUAD	cis	rs449789	0.524	rs4709306	ENSG00000235086.1	FNDC1-IT1	-3.75	0.000198	0.0247	-0.24	-0.17	Pulse pressure;	chr6:159354898	chr6:159240786~159243329:+
LUAD	cis	rs2115630	0.936	rs11073663	ENSG00000259295.5	CSPG4P12	-3.75	0.000198	0.0247	-0.2	-0.17	P wave terminal force;	chr15:84717037	chr15:85191438~85213905:+
LUAD	cis	rs17596685	1	rs7324200	ENSG00000271216.1	LINC01050	3.75	0.000198	0.0247	0.25	0.17	C-reactive protein levels;	chr13:42563388	chr13:42810366~42812562:-
LUAD	cis	rs13113518	1	rs4865007	ENSG00000273257.1	RP11-177J6.1	-3.75	0.000198	0.0247	-0.18	-0.17	Height;	chr4:55537550	chr4:55387949~55388271:+
LUAD	cis	rs2235642	0.691	rs2281235	ENSG00000280231.1	LA16c-380F5.3	-3.75	0.000198	0.0247	-0.23	-0.17	Coronary artery disease;	chr16:1553534	chr16:1553655~1554130:-
LUAD	cis	rs17695224	0.5	rs56083320	ENSG00000269483.1	AC006272.1	3.75	0.000198	0.0247	0.18	0.17	HDL cholesterol;HDL cholesterol levels;	chr19:51818005	chr19:51839924~51843324:-
LUAD	cis	rs28386778	0.787	rs2665827	ENSG00000240280.5	TCAM1P	-3.75	0.000198	0.0247	-0.2	-0.17	Prudent dietary pattern;	chr17:63883990	chr17:63849292~63864379:+
LUAD	cis	rs7852296	0.636	rs12237146	ENSG00000236643.1	RP11-175D17.3	-3.75	0.000198	0.0247	-0.35	-0.17	Personality dimensions;	chr9:123858278	chr9:124770123~124772927:+
LUAD	cis	rs7852296	0.588	rs16926913	ENSG00000236643.1	RP11-175D17.3	-3.75	0.000198	0.0247	-0.35	-0.17	Personality dimensions;	chr9:123858553	chr9:124770123~124772927:+
LUAD	cis	rs12073359	0.788	rs4926388	ENSG00000223945.2	RP11-458I7.1	3.75	0.000198	0.0247	0.22	0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150044686	chr1:150053864~150055034:+
LUAD	cis	rs6687821	1	rs6687821	ENSG00000261737.1	RP4-612B15.3	3.75	0.000198	0.0247	0.23	0.17	Yeast infection;	chr1:86741033	chr1:86703502~86704462:-
LUAD	cis	rs875971	0.545	rs2707851	ENSG00000222364.1	RNU6-96P	3.75	0.000198	0.0247	0.21	0.17	Aortic root size;	chr7:66624178	chr7:66395191~66395286:+
LUAD	cis	rs591584	0.59	rs7120587	ENSG00000255893.1	RP11-685N10.1	-3.75	0.000198	0.0247	-0.21	-0.17	Macrophage Migration Inhibitory Factor levels;	chr11:94586307	chr11:94472908~94473570:-
LUAD	cis	rs10864907	0.806	rs10188765	ENSG00000227368.1	AC079753.5	3.75	0.000198	0.0247	0.18	0.17	Pulmonary function;	chr2:112958099	chr2:112932625~112933171:+
LUAD	cis	rs638893	1	rs28827279	ENSG00000255239.1	AP002954.6	3.75	0.000198	0.0247	0.27	0.17	Vitiligo;	chr11:118830054	chr11:118688039~118690600:-
LUAD	cis	rs75422866	0.764	rs73104177	ENSG00000276691.1	RP5-1057I20.5	3.75	0.000198	0.0247	0.32	0.17	Pneumonia;	chr12:47713550	chr12:47788426~47788971:+
LUAD	cis	rs75422866	0.764	rs73104184	ENSG00000276691.1	RP5-1057I20.5	3.75	0.000198	0.0247	0.32	0.17	Pneumonia;	chr12:47715623	chr12:47788426~47788971:+
LUAD	cis	rs75422866	0.764	rs73104188	ENSG00000276691.1	RP5-1057I20.5	3.75	0.000198	0.0247	0.32	0.17	Pneumonia;	chr12:47715885	chr12:47788426~47788971:+
LUAD	cis	rs9487094	1	rs9480933	ENSG00000260273.1	RP11-425D10.10	3.75	0.000198	0.0247	0.22	0.17	Height;	chr6:109350188	chr6:109382795~109383666:+
LUAD	cis	rs3733418	0.929	rs13134940	ENSG00000248632.1	RP11-366M4.11	3.75	0.000198	0.0247	0.27	0.17	Obesity-related traits;	chr4:164968460	chr4:164968587~164970002:-
LUAD	cis	rs3733418	0.929	rs13110309	ENSG00000248632.1	RP11-366M4.11	3.75	0.000198	0.0247	0.27	0.17	Obesity-related traits;	chr4:164968520	chr4:164968587~164970002:-
LUAD	cis	rs910316	0.503	rs4903273	ENSG00000259138.1	RP11-950C14.7	-3.75	0.000198	0.0247	-0.18	-0.17	Height;	chr14:74975092	chr14:75127153~75136930:+
LUAD	cis	rs7613875	0.6	rs2856238	ENSG00000234667.1	ACTBP13	-3.75	0.000198	0.0247	-0.19	-0.17	Body mass index;	chr3:50120758	chr3:49873347~49877980:-
LUAD	cis	rs7202877	0.706	rs247438	ENSG00000280152.1	RP11-331F4.5	-3.75	0.000198	0.0247	-0.2	-0.17	Type 1 diabetes;Type 2 diabetes;	chr16:75398751	chr16:75245994~75250077:-
LUAD	cis	rs7119038	0.818	rs11217042	ENSG00000255239.1	AP002954.6	-3.75	0.000198	0.0247	-0.24	-0.17	Sjögren's syndrome;	chr11:118811819	chr11:118688039~118690600:-
LUAD	cis	rs7119038	0.818	rs17122453	ENSG00000255239.1	AP002954.6	-3.75	0.000198	0.0247	-0.24	-0.17	Sjögren's syndrome;	chr11:118812855	chr11:118688039~118690600:-
LUAD	cis	rs4462272	0.628	rs10786583	ENSG00000227492.1	RP11-316M21.6	3.75	0.000198	0.0247	0.17	0.17	Age-related hearing impairment (SNP x SNP interaction);	chr10:100186257	chr10:100229667~100234000:+
LUAD	cis	rs763121	0.853	rs3788545	ENSG00000225450.1	RP3-508I15.14	-3.75	0.000198	0.0247	-0.17	-0.17	Menopause (age at onset);	chr22:38669167	chr22:38739003~38749041:+
LUAD	cis	rs11018904	0.906	rs35129016	ENSG00000280367.1	RP11-121L10.2	3.75	0.000198	0.0247	0.22	0.17	Intelligence (multi-trait analysis);	chr11:90215521	chr11:90223153~90226538:+
LUAD	cis	rs6840360	0.571	rs11736116	ENSG00000270265.1	RP11-731D1.4	-3.75	0.000198	0.0247	-0.19	-0.17	Intelligence (multi-trait analysis);	chr4:151610664	chr4:151333775~151353224:-
LUAD	cis	rs13113518	0.783	rs34534635	ENSG00000273257.1	RP11-177J6.1	3.75	0.000198	0.0247	0.19	0.17	Height;	chr4:55573424	chr4:55387949~55388271:+
LUAD	cis	rs2041895	0.527	rs10861681	ENSG00000260329.1	RP11-412D9.4	-3.75	0.000198	0.0247	-0.2	-0.17	Glaucoma (low intraocular pressure);	chr12:106940484	chr12:106954029~106955497:-
LUAD	cis	rs4795519	0.778	rs10459955	ENSG00000266313.1	RP11-173M1.4	3.75	0.000198	0.0247	0.21	0.17	Chronic myeloid leukemia;	chr17:27080612	chr17:27333256~27348491:+
LUAD	cis	rs2253762	0.54	rs11200311	ENSG00000276742.1	RP11-500G22.4	3.75	0.000198	0.0248	0.26	0.17	Breast cancer;	chr10:121995094	chr10:121956782~121957098:+
LUAD	cis	rs2253762	0.54	rs79069897	ENSG00000276742.1	RP11-500G22.4	3.75	0.000198	0.0248	0.26	0.17	Breast cancer;	chr10:121995680	chr10:121956782~121957098:+
LUAD	cis	rs2253762	0.54	rs4752631	ENSG00000276742.1	RP11-500G22.4	3.75	0.000198	0.0248	0.26	0.17	Breast cancer;	chr10:121996442	chr10:121956782~121957098:+
LUAD	cis	rs2253762	0.54	rs10887036	ENSG00000276742.1	RP11-500G22.4	3.75	0.000198	0.0248	0.26	0.17	Breast cancer;	chr10:121997570	chr10:121956782~121957098:+
LUAD	cis	rs2253762	0.54	rs10887037	ENSG00000276742.1	RP11-500G22.4	3.75	0.000198	0.0248	0.26	0.17	Breast cancer;	chr10:121997572	chr10:121956782~121957098:+
LUAD	cis	rs2664588	0.538	rs6018827	ENSG00000224565.1	RP1-148H17.1	-3.75	0.000199	0.0248	-0.18	-0.17	Cerebrospinal fluid AB1-42 levels;	chr20:47969555	chr20:47391929~47412327:-
LUAD	cis	rs9921338	0.887	rs7189044	ENSG00000262703.1	RP11-485G7.6	-3.75	0.000199	0.0248	-0.17	-0.17	Vein graft stenosis in coronary artery bypass grafting;	chr16:11348339	chr16:11348143~11349321:-
LUAD	cis	rs2179367	0.959	rs9322178	ENSG00000216906.2	RP11-350J20.9	3.75	0.000199	0.0248	0.21	0.17	Dupuytren's disease;	chr6:149372131	chr6:149904243~149906418:+
LUAD	cis	rs9341808	0.527	rs2505946	ENSG00000272129.1	RP11-250B2.6	3.75	0.000199	0.0248	0.2	0.17	Sitting height ratio;	chr6:80100966	chr6:80355424~80356859:+
LUAD	cis	rs7772486	0.817	rs2144477	ENSG00000235652.6	RP11-545I5.3	3.75	0.000199	0.0248	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:146085112	chr6:145799409~145886585:+
LUAD	cis	rs987044	0.726	rs2111211	ENSG00000257221.1	RP11-689B22.2	-3.75	0.000199	0.0248	-0.14	-0.17	Mean platelet volume;	chr12:108646093	chr12:108628687~108641318:+
LUAD	cis	rs7580658	0.68	rs2069931	ENSG00000236682.1	AC068282.3	-3.75	0.000199	0.0248	-0.23	-0.17	Protein C levels;	chr2:127427993	chr2:127389130~127400580:+
LUAD	cis	rs7116495	0.867	rs601865	ENSG00000254682.1	RP11-660L16.2	-3.75	0.000199	0.0248	-0.36	-0.17	Severe influenza A (H1N1) infection;	chr11:71870892	chr11:71448674~71452157:+
LUAD	cis	rs6708413	0.521	rs6543153	ENSG00000234389.1	AC007278.3	3.75	0.000199	0.0248	0.17	0.17	Crohn's disease;Inflammatory bowel disease;	chr2:102497744	chr2:102438713~102440475:+
LUAD	cis	rs412050	0.696	rs76843711	ENSG00000224086.5	LL22NC03-86G7.1	-3.75	0.000199	0.0248	-0.22	-0.17	Attention deficit hyperactivity disorder;	chr22:21907753	chr22:21938293~21977632:+
LUAD	cis	rs2154319	0.895	rs1892425	ENSG00000235358.1	RP11-399E6.1	-3.75	0.000199	0.0248	-0.23	-0.17	Height;	chr1:41279149	chr1:41242373~41284861:+
LUAD	cis	rs2486288	0.656	rs10519018	ENSG00000259479.5	SORD2P	-3.75	0.000199	0.0248	-0.2	-0.17	Glomerular filtration rate;	chr15:45257067	chr15:44826371~44884694:-
LUAD	cis	rs801193	1	rs6975195	ENSG00000222364.1	RNU6-96P	3.75	0.000199	0.0248	0.19	0.17	Aortic root size;	chr7:66659787	chr7:66395191~66395286:+
LUAD	cis	rs801193	1	rs3857688	ENSG00000222364.1	RNU6-96P	3.75	0.000199	0.0248	0.19	0.17	Aortic root size;	chr7:66662819	chr7:66395191~66395286:+
LUAD	cis	rs801193	1	rs2286684	ENSG00000222364.1	RNU6-96P	3.75	0.000199	0.0248	0.19	0.17	Aortic root size;	chr7:66664843	chr7:66395191~66395286:+
LUAD	cis	rs801193	0.935	rs2286683	ENSG00000222364.1	RNU6-96P	3.75	0.000199	0.0248	0.19	0.17	Aortic root size;	chr7:66664856	chr7:66395191~66395286:+
LUAD	cis	rs801193	1	rs10274773	ENSG00000222364.1	RNU6-96P	3.75	0.000199	0.0248	0.19	0.17	Aortic root size;	chr7:66668591	chr7:66395191~66395286:+
LUAD	cis	rs957448	1	rs2381885	ENSG00000254057.1	RP3-388N13.3	3.75	0.000199	0.0248	0.19	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94499974	chr8:93834454~93846743:-
LUAD	cis	rs8031584	0.958	rs7168641	ENSG00000260128.5	ULK4P2	-3.75	0.000199	0.0248	-0.21	-0.17	Huntington's disease progression;	chr15:30943249	chr15:30572738~30600647:+
LUAD	cis	rs763121	0.853	rs2413545	ENSG00000225450.1	RP3-508I15.14	-3.75	0.000199	0.0248	-0.18	-0.17	Menopause (age at onset);	chr22:38696519	chr22:38739003~38749041:+
LUAD	cis	rs17685	0.712	rs28456330	ENSG00000280388.1	RP11-229D13.3	-3.75	0.000199	0.0248	-0.16	-0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:76181224	chr7:76043977~76045963:-
LUAD	cis	rs4130344	0.845	rs9884355	ENSG00000271817.2	U3	-3.75	0.000199	0.0248	-0.18	-0.17	Intelligence (multi-trait analysis);	chr4:158784834	chr4:158700691~158700909:+
LUAD	cis	rs875971	0.862	rs11773628	ENSG00000273448.1	RP11-166O4.6	-3.75	0.000199	0.0248	-0.16	-0.17	Aortic root size;	chr7:66517644	chr7:67333047~67334383:+
LUAD	cis	rs7714584	1	rs12054923	ENSG00000197083.10	ZNF300P1	3.75	0.000199	0.0248	0.32	0.17	Crohn's disease;	chr5:150869497	chr5:150930645~150946289:-
LUAD	cis	rs62244186	0.52	rs9311361	ENSG00000233509.2	ZNF197-AS1	3.75	0.000199	0.0248	0.18	0.17	Depressive symptoms;	chr3:44754640	chr3:44617128~44624797:-
LUAD	cis	rs1862618	0.853	rs33322	ENSG00000271828.1	CTD-2310F14.1	3.75	0.000199	0.0248	0.24	0.17	Initial pursuit acceleration;	chr5:56879399	chr5:56927874~56929573:+
LUAD	cis	rs12712135	0.709	rs10201184	ENSG00000234389.1	AC007278.3	3.75	0.000199	0.0248	0.15	0.17	Blood protein levels;	chr2:102472618	chr2:102438713~102440475:+
LUAD	cis	rs804280	0.509	rs13276433	ENSG00000255046.1	RP11-297N6.4	-3.75	0.000199	0.0248	-0.2	-0.17	Myopia (pathological);	chr8:11925527	chr8:11797928~11802568:-
LUAD	cis	rs6871536	1	rs115911400	ENSG00000233006.5	AC034220.3	-3.75	0.000199	0.0248	-0.19	-0.17	Asthma (childhood onset);	chr5:132610043	chr5:132311285~132369916:-
LUAD	cis	rs57221529	0.766	rs4957053	ENSG00000248925.1	CTD-2083E4.6	3.75	0.000199	0.0248	0.27	0.17	Lung disease severity in cystic fibrosis;	chr5:575812	chr5:269858~271516:-
LUAD	cis	rs57221529	0.709	rs111352378	ENSG00000248925.1	CTD-2083E4.6	3.75	0.000199	0.0248	0.27	0.17	Lung disease severity in cystic fibrosis;	chr5:576964	chr5:269858~271516:-
LUAD	cis	rs57221529	0.709	rs72703034	ENSG00000248925.1	CTD-2083E4.6	3.75	0.000199	0.0248	0.27	0.17	Lung disease severity in cystic fibrosis;	chr5:576986	chr5:269858~271516:-
LUAD	cis	rs57221529	0.825	rs7443550	ENSG00000248925.1	CTD-2083E4.6	3.75	0.000199	0.0248	0.27	0.17	Lung disease severity in cystic fibrosis;	chr5:578289	chr5:269858~271516:-
LUAD	cis	rs57221529	0.766	rs4245972	ENSG00000248925.1	CTD-2083E4.6	3.75	0.000199	0.0248	0.27	0.17	Lung disease severity in cystic fibrosis;	chr5:578457	chr5:269858~271516:-
LUAD	cis	rs57221529	0.766	rs72703042	ENSG00000248925.1	CTD-2083E4.6	3.75	0.000199	0.0248	0.27	0.17	Lung disease severity in cystic fibrosis;	chr5:579154	chr5:269858~271516:-
LUAD	cis	rs4561483	0.743	rs28653099	ENSG00000261216.1	RP11-166B2.5	3.75	0.000199	0.0248	0.17	0.17	Testicular germ cell tumor;	chr16:11915293	chr16:11908208~11908916:+
LUAD	cis	rs7772486	0.686	rs1004752	ENSG00000235652.6	RP11-545I5.3	-3.75	0.000199	0.0248	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145716686	chr6:145799409~145886585:+
LUAD	cis	rs1400816	0.85	rs11903123	ENSG00000228389.1	AC068039.4	3.75	0.000199	0.0248	0.28	0.17	Amyotrophic lateral sclerosis (sporadic);	chr2:171821309	chr2:171773482~171775844:+
LUAD	cis	rs1559040	0.932	rs10205315	ENSG00000272156.1	RP11-477N3.1	-3.75	0.000199	0.0248	-0.27	-0.17	Sudden cardiac arrest;	chr2:54086864	chr2:54082554~54085066:+
LUAD	cis	rs1023500	0.505	rs134874	ENSG00000205702.9	CYP2D7	3.75	0.000199	0.0248	0.13	0.17	Schizophrenia;	chr22:42265138	chr22:42140203~42144577:-
LUAD	cis	rs3849150	0.898	rs12780156	ENSG00000235939.1	RP11-123B3.2	-3.75	0.000199	0.0248	-0.26	-0.17	Subclinical atherosclerosis traits (other);	chr10:48864656	chr10:49419277~49472903:+
LUAD	cis	rs4144027	0.791	rs66473563	ENSG00000258914.1	CTD-2134A5.3	-3.75	0.000199	0.0248	-0.2	-0.17	Blood metabolite levels;	chr14:103895534	chr14:103875055~103877478:+
LUAD	cis	rs35740288	0.77	rs11631660	ENSG00000259407.1	RP11-158M2.3	3.75	0.000199	0.0248	0.16	0.17	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85672181	chr15:85744109~85750281:-
LUAD	cis	rs8091660	0.624	rs907547	ENSG00000278983.1	RP11-426J5.3	3.75	0.000199	0.0248	0.21	0.17	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48549725	chr18:48564795~48568342:+
LUAD	cis	rs8180040	0.966	rs12632132	ENSG00000271161.1	BOLA2P2	3.75	0.000199	0.0248	0.16	0.17	Colorectal cancer;	chr3:47435529	chr3:47499841~47500407:+
LUAD	cis	rs442309	0.812	rs448355	ENSG00000238280.1	RP11-436D10.3	-3.75	0.000199	0.0248	-0.2	-0.17	Vogt-Koyanagi-Harada syndrome;	chr10:62772835	chr10:62793562~62805887:-
LUAD	cis	rs3764400	0.567	rs8071199	ENSG00000278765.1	RP5-890E16.5	-3.75	0.000199	0.0248	-0.29	-0.17	Body mass index;	chr17:48117973	chr17:48066704~48067293:-
LUAD	cis	rs10129255	0.5	rs9324092	ENSG00000232216.1	IGHV3-43	-3.75	0.000199	0.0248	-0.13	-0.17	Kawasaki disease;	chr14:106683806	chr14:106470264~106470800:-
LUAD	cis	rs6479901	0.895	rs1904296	ENSG00000232075.1	MRPL35P2	-3.75	0.000199	0.0248	-0.24	-0.17	Intelligence (multi-trait analysis);	chr10:63173019	chr10:63634317~63634827:-
LUAD	cis	rs4718428	0.672	rs13241598	ENSG00000230295.1	RP11-458F8.2	-3.75	0.000199	0.0248	-0.15	-0.17	Corneal structure;	chr7:66835665	chr7:66880708~66882981:+
LUAD	cis	rs6546537	1	rs17036866	ENSG00000231024.1	AC092431.3	3.75	0.000199	0.0248	0.22	0.17	Serum thyroid-stimulating hormone levels;	chr2:69630579	chr2:69700192~69713847:-
LUAD	cis	rs1355223	0.902	rs34751755	ENSG00000271369.1	RP11-350D17.3	-3.75	0.000199	0.0248	-0.2	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34672696	chr11:34709600~34710161:+
LUAD	cis	rs4763879	0.634	rs11052582	ENSG00000278635.1	CTD-2318O12.1	3.75	0.000199	0.0248	0.15	0.17	Type 1 diabetes;	chr12:9706714	chr12:9415641~9416718:+
LUAD	cis	rs2380205	0.875	rs10795593	ENSG00000232807.2	RP11-536K7.3	3.75	0.000199	0.0248	0.18	0.17	Breast cancer;	chr10:5853793	chr10:5934270~5945900:-
LUAD	cis	rs910316	0.763	rs6574205	ENSG00000279594.1	RP11-950C14.10	3.75	0.000199	0.0248	0.19	0.17	Height;	chr14:74986336	chr14:75011269~75012851:-
LUAD	cis	rs7017914	0.87	rs2639953	ENSG00000246366.5	RP11-382J12.1	3.75	0.000199	0.0248	0.15	0.17	Bone mineral density;	chr8:71013425	chr8:70608577~70663279:+
LUAD	cis	rs8031584	1	rs35239376	ENSG00000260128.5	ULK4P2	-3.75	0.000199	0.0248	-0.23	-0.17	Huntington's disease progression;	chr15:30998335	chr15:30572738~30600647:+
LUAD	cis	rs2154319	0.79	rs710248	ENSG00000235358.1	RP11-399E6.1	3.75	0.000199	0.0248	0.23	0.17	Height;	chr1:41108950	chr1:41242373~41284861:+
LUAD	cis	rs7605235	0.959	rs36028066	ENSG00000224165.4	DNAJC27-AS1	3.75	0.000199	0.0248	0.19	0.17	Response to platinum-based chemotherapy (cisplatin);	chr2:25425795	chr2:24971390~25039694:+
LUAD	cis	rs7605235	0.959	rs13025966	ENSG00000224165.4	DNAJC27-AS1	3.75	0.000199	0.0248	0.19	0.17	Response to platinum-based chemotherapy (cisplatin);	chr2:25426307	chr2:24971390~25039694:+
LUAD	cis	rs7674212	0.531	rs4698875	ENSG00000230069.3	LRRC37A15P	-3.75	0.000199	0.0248	-0.18	-0.17	Type 2 diabetes;	chr4:103012211	chr4:102727274~102730721:-
LUAD	cis	rs2836950	0.501	rs35994303	ENSG00000232608.1	TIMM9P2	3.75	0.000199	0.0248	0.19	0.17	Menarche (age at onset);	chr21:39314094	chr21:39216624~39217506:+
LUAD	cis	rs2735413	0.563	rs72800906	ENSG00000276007.1	RP11-358L22.3	3.75	0.000199	0.0248	0.24	0.17	Systolic blood pressure (alcohol consumption interaction);	chr16:78012430	chr16:78123243~78124332:+
LUAD	cis	rs365302	1	rs371023	ENSG00000235086.1	FNDC1-IT1	3.75	0.000199	0.0248	0.23	0.17	Coronary heart disease;	chr6:159197365	chr6:159240786~159243329:+
LUAD	cis	rs365302	1	rs411523	ENSG00000235086.1	FNDC1-IT1	3.75	0.000199	0.0248	0.23	0.17	Coronary heart disease;	chr6:159197758	chr6:159240786~159243329:+
LUAD	cis	rs7189233	0.956	rs62048486	ENSG00000279344.1	RP11-44F14.7	3.75	0.000199	0.0248	0.15	0.17	Intelligence (multi-trait analysis);	chr16:53414427	chr16:53478957~53481550:-
LUAD	cis	rs4474465	0.85	rs10793322	ENSG00000251323.2	RP11-452H21.4	-3.75	0.000199	0.0248	-0.21	-0.17	Alzheimer's disease (survival time);	chr11:78531569	chr11:78423982~78429836:-
LUAD	cis	rs3805389	0.504	rs2412666	ENSG00000273257.1	RP11-177J6.1	-3.75	0.000199	0.0248	-0.28	-0.17	Waist-to-hip ratio adjusted for body mass index;	chr4:55607192	chr4:55387949~55388271:+
LUAD	cis	rs1023500	0.573	rs4822088	ENSG00000273366.1	CTA-989H11.1	-3.75	0.000199	0.0248	-0.2	-0.17	Schizophrenia;	chr22:42074585	chr22:42278188~42278846:+
LUAD	cis	rs2274273	0.624	rs7157308	ENSG00000258413.1	RP11-665C16.6	-3.75	0.000199	0.0248	-0.23	-0.17	Protein biomarker;	chr14:55315325	chr14:55262767~55272075:-
LUAD	cis	rs1387259	0.723	rs2732488	ENSG00000257763.1	OR5BK1P	3.75	0.000199	0.0248	0.18	0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48377661	chr12:48355792~48356614:-
LUAD	cis	rs1387259	0.758	rs2634670	ENSG00000257763.1	OR5BK1P	3.75	0.000199	0.0248	0.18	0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48378094	chr12:48355792~48356614:-
LUAD	cis	rs6723226	1	rs6723226	ENSG00000276334.1	AL133243.1	3.75	0.000199	0.0248	0.2	0.17	Intelligence (multi-trait analysis);	chr2:32624140	chr2:32521927~32523547:+
LUAD	cis	rs451417	1	rs236110	ENSG00000275632.1	RP5-967N21.11	3.75	0.000199	0.0248	0.22	0.17	Menopause (age at onset);	chr20:5952462	chr20:6000418~6000941:+
LUAD	cis	rs10483853	0.806	rs10141031	ENSG00000258695.2	RP3-414A15.2	-3.75	0.000199	0.0248	-0.21	-0.17	Coronary artery calcification;	chr14:73306901	chr14:73522878~73530610:+
LUAD	cis	rs7714584	1	rs3900064	ENSG00000197083.10	ZNF300P1	-3.75	0.000199	0.0248	-0.32	-0.17	Crohn's disease;	chr5:150884852	chr5:150930645~150946289:-
LUAD	cis	rs13230714	1	rs13230714	ENSG00000170356.8	OR2A20P	3.75	0.000199	0.0248	0.23	0.17	Breast cancer;	chr7:144477198	chr7:144250045~144252957:-
LUAD	cis	rs6688537	0.622	rs6661345	ENSG00000233355.5	CHRM3-AS2	-3.75	0.000199	0.0249	-0.13	-0.17	Lung function (FEV1/FVC);	chr1:239673686	chr1:239703381~239730465:-
LUAD	cis	rs67539049	1	rs66934548	ENSG00000255046.1	RP11-297N6.4	3.75	2e-04	0.0249	0.25	0.17	Itch intensity from mosquito bite;	chr8:11446541	chr8:11797928~11802568:-
LUAD	cis	rs9595908	0.785	rs7331393	ENSG00000281026.1	N4BP2L2-IT2	3.75	2e-04	0.0249	0.11	0.17	Body mass index;	chr13:32647065	chr13:32504506~32509395:-
LUAD	cis	rs8062405	0.789	rs240704	ENSG00000261419.1	RP11-57A19.4	-3.75	2e-04	0.0249	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28518628	chr16:28659696~28740781:-
LUAD	cis	rs4865762	0.514	rs251335	ENSG00000272416.1	CTD-2081C10.7	-3.75	2e-04	0.0249	-0.18	-0.17	Intraocular pressure;	chr5:53135806	chr5:53880293~53881051:-
LUAD	cis	rs2062225	0.735	rs2062223	ENSG00000270190.1	RP11-803D5.4	-3.75	2e-04	0.0249	-0.26	-0.17	Monocyte count;	chr2:110992992	chr2:111266868~111267473:-
LUAD	cis	rs4718428	1	rs4718421	ENSG00000272831.1	RP11-792A8.4	3.75	2e-04	0.0249	0.16	0.17	Corneal structure;	chr7:66885313	chr7:66739829~66740385:-
LUAD	cis	rs338389	0.516	rs6416484	ENSG00000260657.2	RP11-315D16.4	-3.75	2e-04	0.0249	-0.19	-0.17	Survival in rectal cancer;	chr15:68020438	chr15:68267792~68277994:-
LUAD	cis	rs7674212	0.51	rs2720468	ENSG00000251288.2	RP11-10L12.2	-3.75	2e-04	0.0249	-0.21	-0.17	Type 2 diabetes;	chr4:103163996	chr4:102751401~102752641:+
LUAD	cis	rs987044	0.807	rs7303331	ENSG00000257221.1	RP11-689B22.2	-3.75	2e-04	0.0249	-0.14	-0.17	Mean platelet volume;	chr12:108757619	chr12:108628687~108641318:+
LUAD	cis	rs2243480	0.522	rs778717	ENSG00000229886.1	RP5-1132H15.3	3.75	2e-04	0.0249	0.34	0.17	Diabetic kidney disease;	chr7:66383164	chr7:66025126~66031544:-
LUAD	cis	rs1823913	0.637	rs11688994	ENSG00000230611.1	HMGB1P27	-3.75	2e-04	0.0249	-0.19	-0.17	Obesity-related traits;	chr2:191266242	chr2:191174233~191174835:+
LUAD	cis	rs750134	0.901	rs77866012	ENSG00000257221.1	RP11-689B22.2	-3.75	2e-04	0.0249	-0.24	-0.17	Low high density lipoprotein cholesterol levels;	chr12:108721979	chr12:108628687~108641318:+
LUAD	cis	rs853679	0.55	rs1233704	ENSG00000226314.6	ZNF192P1	3.75	2e-04	0.0249	0.22	0.17	Depression;	chr6:28199145	chr6:28161781~28169594:+
LUAD	cis	rs875971	0.558	rs4433015	ENSG00000232546.1	RP11-458F8.1	3.75	2e-04	0.0249	0.15	0.17	Aortic root size;	chr7:66174736	chr7:66848496~66858136:+
LUAD	cis	rs2018683	0.523	rs886834	ENSG00000228421.2	AC005013.5	3.75	2e-04	0.0249	0.19	0.17	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28981720	chr7:28957667~28959345:+
LUAD	cis	rs321358	0.895	rs7101466	ENSG00000271390.1	RP11-89C3.3	3.75	2e-04	0.0249	0.27	0.17	Body mass index;	chr11:111085729	chr11:111089870~111090368:-
LUAD	cis	rs321358	0.895	rs7101576	ENSG00000271390.1	RP11-89C3.3	3.75	2e-04	0.0249	0.27	0.17	Body mass index;	chr11:111085795	chr11:111089870~111090368:-
LUAD	cis	rs4727963	0.755	rs6943941	ENSG00000240499.6	RP5-1101C3.1	3.75	2e-04	0.0249	0.15	0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);	chr7:123065597	chr7:122328469~122440388:+
LUAD	cis	rs4759375	1	rs11057224	ENSG00000235423.7	RP11-282O18.3	3.75	2e-04	0.0249	0.3	0.17	HDL cholesterol;	chr12:123270632	chr12:123252030~123261483:-
LUAD	cis	rs875971	0.545	rs6460281	ENSG00000224316.1	RP11-479O9.2	3.75	2e-04	0.0249	0.2	0.17	Aortic root size;	chr7:66216128	chr7:65773620~65802067:+
LUAD	cis	rs1559040	0.858	rs10192403	ENSG00000272156.1	RP11-477N3.1	-3.75	2e-04	0.0249	-0.27	-0.17	Sudden cardiac arrest;	chr2:54086370	chr2:54082554~54085066:+
LUAD	cis	rs7760535	1	rs7760535	ENSG00000271789.1	RP5-1112D6.7	3.75	2e-04	0.0249	0.18	0.17	Metabolic traits;	chr6:111425880	chr6:111297126~111298510:+
LUAD	cis	rs877356	0.831	rs2288833	ENSG00000250167.1	CTC-321K16.1	-3.75	2e-04	0.0249	-0.33	-0.17	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (dichotomous);	chr5:135834982	chr5:135559577~135634874:+
LUAD	cis	rs4561483	0.603	rs11544193	ENSG00000261216.1	RP11-166B2.5	3.75	2e-04	0.0249	0.17	0.17	Testicular germ cell tumor;	chr16:11915447	chr16:11908208~11908916:+
LUAD	cis	rs10761482	0.6	rs72807911	ENSG00000254271.1	RP11-131N11.4	-3.75	2e-04	0.0249	-0.21	-0.17	Schizophrenia;	chr10:60468530	chr10:60734342~60741828:+
LUAD	cis	rs7586085	1	rs12185748	ENSG00000232411.1	AC009495.3	3.75	2e-04	0.0249	0.17	0.17	Total body bone mineral density;	chr2:165720446	chr2:165833048~165839098:-
LUAD	cis	rs11893307	0.537	rs61345672	ENSG00000235852.1	AC005540.3	3.75	2e-04	0.0249	0.21	0.17	Mean platelet volume;	chr2:190642288	chr2:190880797~190882059:-
LUAD	cis	rs2836950	0.502	rs2150411	ENSG00000232608.1	TIMM9P2	3.75	2e-04	0.0249	0.19	0.17	Menarche (age at onset);	chr21:39202626	chr21:39216624~39217506:+
LUAD	cis	rs1862618	0.853	rs832582	ENSG00000271828.1	CTD-2310F14.1	3.75	2e-04	0.0249	0.24	0.17	Initial pursuit acceleration;	chr5:56881916	chr5:56927874~56929573:+
LUAD	cis	rs7178424	0.875	rs17271193	ENSG00000259251.2	RP11-643M14.1	-3.75	2e-04	0.0249	-0.18	-0.17	Height;	chr15:61872969	chr15:62060503~62062434:+
LUAD	cis	rs17597773	0.674	rs984676	ENSG00000272823.1	RP11-295M18.6	3.75	2e-04	0.0249	0.22	0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220835080	chr1:220828676~220829211:-
LUAD	cis	rs17767294	0.708	rs17693877	ENSG00000280107.1	AL022393.9	-3.75	2e-04	0.0249	-0.45	-0.17	Parkinson's disease;	chr6:27739267	chr6:28170845~28172521:+
LUAD	cis	rs2154319	0.887	rs6600366	ENSG00000235358.1	RP11-399E6.1	3.75	2e-04	0.0249	0.23	0.17	Height;	chr1:41093940	chr1:41242373~41284861:+
LUAD	cis	rs13253073	0.556	rs13279371	ENSG00000263842.1	AC104986.1	-3.75	2e-04	0.0249	-0.34	-0.17	Glucose homeostasis traits;	chr8:99407006	chr8:98999284~98999401:+
LUAD	cis	rs2239547	0.525	rs2246556	ENSG00000243224.1	RP5-1157M23.2	3.75	2e-04	0.0249	0.18	0.17	Schizophrenia;	chr3:52993967	chr3:52239258~52241097:+
LUAD	cis	rs62244186	0.535	rs59726036	ENSG00000214820.3	MPRIPP1	3.75	2e-04	0.0249	0.18	0.17	Depressive symptoms;	chr3:44808582	chr3:44579938~44581026:-
LUAD	cis	rs728616	0.867	rs55690691	ENSG00000225484.5	NUTM2B-AS1	-3.75	2e-04	0.0249	-0.43	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79899186	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.867	rs1983775	ENSG00000225484.5	NUTM2B-AS1	-3.75	2e-04	0.0249	-0.43	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79903819	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.867	rs1983776	ENSG00000225484.5	NUTM2B-AS1	-3.75	2e-04	0.0249	-0.43	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79903939	chr10:79663088~79826594:-
LUAD	cis	rs7208859	0.673	rs9896095	ENSG00000263603.1	CTD-2349P21.5	-3.75	2e-04	0.0249	-0.29	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30860479	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.573	rs58920731	ENSG00000263603.1	CTD-2349P21.5	-3.75	2e-04	0.0249	-0.29	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864728	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs73277984	ENSG00000263603.1	CTD-2349P21.5	-3.75	2e-04	0.0249	-0.29	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869115	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs73277986	ENSG00000263603.1	CTD-2349P21.5	-3.75	2e-04	0.0249	-0.29	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869179	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs12103588	ENSG00000263603.1	CTD-2349P21.5	-3.75	2e-04	0.0249	-0.29	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30870442	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs4131618	ENSG00000263603.1	CTD-2349P21.5	-3.75	2e-04	0.0249	-0.29	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30877783	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs11658344	ENSG00000263603.1	CTD-2349P21.5	-3.75	2e-04	0.0249	-0.29	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30880727	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs9900144	ENSG00000263603.1	CTD-2349P21.5	-3.75	2e-04	0.0249	-0.29	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881371	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.573	rs11656121	ENSG00000263603.1	CTD-2349P21.5	-3.75	2e-04	0.0249	-0.29	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887025	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.623	rs11650973	ENSG00000263603.1	CTD-2349P21.5	-3.75	2e-04	0.0249	-0.29	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887027	chr17:30729469~30731202:+
LUAD	cis	rs7208859	0.673	rs56085216	ENSG00000263603.1	CTD-2349P21.5	-3.75	2e-04	0.0249	-0.29	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30890216	chr17:30729469~30731202:+
LUAD	cis	rs2638953	0.64	rs11049729	ENSG00000244712.1	RP11-874G11.1	3.75	2e-04	0.0249	0.24	0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28586694	chr12:28564678~28565141:-
LUAD	cis	rs412050	0.502	rs75034650	ENSG00000224086.5	LL22NC03-86G7.1	-3.75	2e-04	0.0249	-0.23	-0.17	Attention deficit hyperactivity disorder;	chr22:21823660	chr22:21938293~21977632:+
LUAD	cis	rs10463554	0.963	rs40322	ENSG00000250682.4	LINC00491	3.75	2e-04	0.0249	0.2	0.17	Parkinson's disease;	chr5:103111253	chr5:102609156~102671559:-
LUAD	cis	rs9860428	0.526	rs4682125	ENSG00000242770.2	RP11-180K7.1	3.75	2e-04	0.0249	0.18	0.17	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112943772	chr3:112802478~112812819:+
LUAD	cis	rs9860428	0.526	rs6769091	ENSG00000242770.2	RP11-180K7.1	3.75	2e-04	0.0249	0.18	0.17	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112943929	chr3:112802478~112812819:+
LUAD	cis	rs8014252	0.667	rs2877657	ENSG00000274818.1	RP1-292L20.3	3.75	2e-04	0.0249	0.25	0.17	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70357215	chr14:70906657~70907111:-
LUAD	cis	rs9549260	0.564	rs9549271	ENSG00000168852.11	TPTE2P5	3.75	2e-04	0.0249	0.17	0.17	Red blood cell count;	chr13:40721341	chr13:40822296~40921749:-
LUAD	cis	rs9803723	0.682	rs4649065	ENSG00000261349.1	RP3-465N24.5	-3.75	2e-04	0.0249	-0.2	-0.17	Male-pattern baldness;	chr1:25105234	chr1:25266102~25267136:-
LUAD	cis	rs7202877	0.61	rs3851735	ENSG00000280152.1	RP11-331F4.5	3.75	2e-04	0.0249	0.19	0.17	Type 1 diabetes;Type 2 diabetes;	chr16:75338194	chr16:75245994~75250077:-
LUAD	cis	rs3742264	1	rs9526137	ENSG00000235903.6	CPB2-AS1	-3.75	2e-04	0.0249	-0.21	-0.17	Blood protein levels;	chr13:46067114	chr13:46052806~46113332:+
LUAD	cis	rs2836974	0.555	rs35909862	ENSG00000232608.1	TIMM9P2	3.75	2e-04	0.0249	0.2	0.17	Cognitive function;	chr21:39249232	chr21:39216624~39217506:+
LUAD	cis	rs4666002	0.789	rs4616435	ENSG00000223522.1	AC093690.1	3.75	2e-04	0.0249	0.19	0.17	Phospholipid levels (plasma);	chr2:27710775	chr2:28307691~28310459:-
LUAD	cis	rs4666002	0.789	rs6727215	ENSG00000223522.1	AC093690.1	3.75	2e-04	0.0249	0.19	0.17	Phospholipid levels (plasma);	chr2:27711864	chr2:28307691~28310459:-
LUAD	cis	rs6921919	0.583	rs34513104	ENSG00000219392.1	RP1-265C24.5	-3.75	2e-04	0.0249	-0.22	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28115628~28116551:+
LUAD	cis	rs6921919	0.583	rs9461456	ENSG00000219392.1	RP1-265C24.5	-3.75	2e-04	0.0249	-0.22	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28115628~28116551:+
LUAD	cis	rs6921919	0.525	rs9468360	ENSG00000219392.1	RP1-265C24.5	-3.75	2e-04	0.0249	-0.22	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28115628~28116551:+
LUAD	cis	rs6921919	0.583	rs16894021	ENSG00000219392.1	RP1-265C24.5	-3.75	2e-04	0.0249	-0.22	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28115628~28116551:+
LUAD	cis	rs6921919	0.583	rs11751693	ENSG00000219392.1	RP1-265C24.5	-3.75	2e-04	0.0249	-0.22	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28115628~28116551:+
LUAD	cis	rs6921919	0.583	rs7749736	ENSG00000219392.1	RP1-265C24.5	-3.75	2e-04	0.0249	-0.22	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28115628~28116551:+
LUAD	cis	rs6921919	0.525	rs9468361	ENSG00000219392.1	RP1-265C24.5	-3.75	2e-04	0.0249	-0.22	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28115628~28116551:+
LUAD	cis	rs6921919	0.583	rs7775132	ENSG00000219392.1	RP1-265C24.5	-3.75	2e-04	0.0249	-0.22	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28115628~28116551:+
LUAD	cis	rs365302	1	rs2782552	ENSG00000235086.1	FNDC1-IT1	3.75	2e-04	0.0249	0.22	0.17	Coronary heart disease;	chr6:159222664	chr6:159240786~159243329:+
LUAD	cis	rs4227	0.565	rs2270341	ENSG00000233223.2	AC113189.5	3.75	2e-04	0.0249	0.18	0.17	IgA nephropathy;	chr17:7577229	chr17:7581964~7584072:-
LUAD	cis	rs9500256	0.655	rs12208465	ENSG00000239650.4	GUSBP4	3.75	0.000201	0.025	0.2	0.17	Eosinophilic esophagitis (pediatric);	chr6:58004603	chr6:57919784~57930291:-
LUAD	cis	rs9393777	0.668	rs7746199	ENSG00000219392.1	RP1-265C24.5	3.75	0.000201	0.025	0.24	0.17	Intelligence (multi-trait analysis);	chr6:27293545	chr6:28115628~28116551:+
LUAD	cis	rs73108077	0.736	rs73104088	ENSG00000281376.1	ABALON	-3.75	0.000201	0.025	-0.29	-0.17	Red blood cell density in sickle cell anemia;	chr20:31311110	chr20:31721507~31723409:+
LUAD	cis	rs858239	0.6	rs6961406	ENSG00000226816.2	AC005082.12	3.75	0.000201	0.025	0.22	0.17	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23206013~23208045:+
LUAD	cis	rs858239	0.6	rs6461690	ENSG00000226816.2	AC005082.12	3.75	0.000201	0.025	0.22	0.17	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23206013~23208045:+
LUAD	cis	rs858239	0.6	rs6967419	ENSG00000226816.2	AC005082.12	3.75	0.000201	0.025	0.22	0.17	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23206013~23208045:+
LUAD	cis	rs8062405	1	rs55991577	ENSG00000261419.1	RP11-57A19.4	-3.75	0.000201	0.025	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28659696~28740781:-
LUAD	cis	rs8062405	1	rs56358680	ENSG00000261419.1	RP11-57A19.4	-3.75	0.000201	0.025	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28659696~28740781:-
LUAD	cis	rs8062405	1	rs62036626	ENSG00000261419.1	RP11-57A19.4	-3.75	0.000201	0.025	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28659696~28740781:-
LUAD	cis	rs8062405	1	rs62036657	ENSG00000261419.1	RP11-57A19.4	-3.75	0.000201	0.025	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28659696~28740781:-
LUAD	cis	rs8062405	1	rs12444171	ENSG00000261419.1	RP11-57A19.4	-3.75	0.000201	0.025	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28659696~28740781:-
LUAD	cis	rs8062405	1	rs56404918	ENSG00000261419.1	RP11-57A19.4	-3.75	0.000201	0.025	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28659696~28740781:-
LUAD	cis	rs8062405	1	rs55719896	ENSG00000261419.1	RP11-57A19.4	-3.75	0.000201	0.025	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28659696~28740781:-
LUAD	cis	rs8062405	1	rs55830740	ENSG00000261419.1	RP11-57A19.4	-3.75	0.000201	0.025	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28659696~28740781:-
LUAD	cis	rs8073060	0.559	rs17550632	ENSG00000267592.1	CTC-507E2.2	-3.75	0.000201	0.025	-0.25	-0.17	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35563864	chr17:35596904~35597128:-
LUAD	cis	rs10863681	0.875	rs10863685	ENSG00000228437.4	RP11-400N13.2	3.75	0.000201	0.025	0.2	0.17	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222082581	chr1:221966341~221984964:+
LUAD	cis	rs10863681	0.875	rs1591912	ENSG00000228437.4	RP11-400N13.2	3.75	0.000201	0.025	0.2	0.17	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222082798	chr1:221966341~221984964:+
LUAD	cis	rs4144027	0.904	rs10438242	ENSG00000258534.1	CTD-2134A5.4	3.75	0.000201	0.025	0.19	0.17	Blood metabolite levels;	chr14:103878738	chr14:103854366~103880111:-
LUAD	cis	rs853679	0.506	rs1150693	ENSG00000280107.1	AL022393.9	-3.75	0.000201	0.025	-0.22	-0.17	Depression;	chr6:28206812	chr6:28170845~28172521:+
LUAD	cis	rs2625529	0.652	rs2957750	ENSG00000260173.1	RP11-2I17.4	3.75	0.000201	0.025	0.2	0.17	Red blood cell count;	chr15:72039917	chr15:72140504~72155459:-
LUAD	cis	rs794185	0.564	rs304026	ENSG00000231249.1	ITPR1-AS1	-3.75	0.000201	0.025	-0.18	-0.17	Multiple sclerosis--Brain Glutamate Levels;	chr3:4503589	chr3:4490891~4493163:-
LUAD	cis	rs755249	0.876	rs61781391	ENSG00000182109.6	RP11-69E11.4	3.75	0.000201	0.025	0.21	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39611865	chr1:39522280~39546187:-
LUAD	cis	rs6001482	0.702	rs5757586	ENSG00000223350.2	IGLV9-49	-3.75	0.000201	0.025	-0.16	-0.17	Diastolic blood pressure;	chr22:22234458	chr22:22343187~22343732:+
LUAD	cis	rs7017914	0.905	rs1389206	ENSG00000246366.5	RP11-382J12.1	3.75	0.000201	0.025	0.15	0.17	Bone mineral density;	chr8:71012627	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.905	rs2639955	ENSG00000246366.5	RP11-382J12.1	3.75	0.000201	0.025	0.15	0.17	Bone mineral density;	chr8:71013107	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.869	rs2639954	ENSG00000246366.5	RP11-382J12.1	3.75	0.000201	0.025	0.15	0.17	Bone mineral density;	chr8:71013340	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.837	rs2639952	ENSG00000246366.5	RP11-382J12.1	3.75	0.000201	0.025	0.15	0.17	Bone mineral density;	chr8:71013495	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.905	rs2732108	ENSG00000246366.5	RP11-382J12.1	3.75	0.000201	0.025	0.15	0.17	Bone mineral density;	chr8:71013864	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.905	rs2732109	ENSG00000246366.5	RP11-382J12.1	3.75	0.000201	0.025	0.15	0.17	Bone mineral density;	chr8:71013988	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.905	rs1493203	ENSG00000246366.5	RP11-382J12.1	3.75	0.000201	0.025	0.15	0.17	Bone mineral density;	chr8:71014272	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.905	rs2732110	ENSG00000246366.5	RP11-382J12.1	3.75	0.000201	0.025	0.15	0.17	Bone mineral density;	chr8:71014576	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.905	rs2639951	ENSG00000246366.5	RP11-382J12.1	3.75	0.000201	0.025	0.15	0.17	Bone mineral density;	chr8:71014990	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.905	rs2732112	ENSG00000246366.5	RP11-382J12.1	3.75	0.000201	0.025	0.15	0.17	Bone mineral density;	chr8:71015606	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.811	rs1389204	ENSG00000246366.5	RP11-382J12.1	3.75	0.000201	0.025	0.15	0.17	Bone mineral density;	chr8:71016063	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.905	rs2732113	ENSG00000246366.5	RP11-382J12.1	3.75	0.000201	0.025	0.15	0.17	Bone mineral density;	chr8:71016314	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.905	rs2732114	ENSG00000246366.5	RP11-382J12.1	3.75	0.000201	0.025	0.15	0.17	Bone mineral density;	chr8:71016477	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.905	rs2732116	ENSG00000246366.5	RP11-382J12.1	3.75	0.000201	0.025	0.15	0.17	Bone mineral density;	chr8:71017092	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.905	rs2956610	ENSG00000246366.5	RP11-382J12.1	3.75	0.000201	0.025	0.15	0.17	Bone mineral density;	chr8:71017298	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.905	rs3098868	ENSG00000246366.5	RP11-382J12.1	3.75	0.000201	0.025	0.15	0.17	Bone mineral density;	chr8:71017457	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.905	rs3098870	ENSG00000246366.5	RP11-382J12.1	3.75	0.000201	0.025	0.15	0.17	Bone mineral density;	chr8:71017700	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.905	rs3110240	ENSG00000246366.5	RP11-382J12.1	3.75	0.000201	0.025	0.15	0.17	Bone mineral density;	chr8:71017869	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.875	rs3098871	ENSG00000246366.5	RP11-382J12.1	3.75	0.000201	0.025	0.15	0.17	Bone mineral density;	chr8:71018180	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.905	rs3098873	ENSG00000246366.5	RP11-382J12.1	3.75	0.000201	0.025	0.15	0.17	Bone mineral density;	chr8:71020351	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.905	rs3110241	ENSG00000246366.5	RP11-382J12.1	3.75	0.000201	0.025	0.15	0.17	Bone mineral density;	chr8:71020729	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.905	rs3110242	ENSG00000246366.5	RP11-382J12.1	3.75	0.000201	0.025	0.15	0.17	Bone mineral density;	chr8:71020732	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.905	rs3110243	ENSG00000246366.5	RP11-382J12.1	3.75	0.000201	0.025	0.15	0.17	Bone mineral density;	chr8:71020834	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.87	rs3098874	ENSG00000246366.5	RP11-382J12.1	3.75	0.000201	0.025	0.15	0.17	Bone mineral density;	chr8:71022103	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.905	rs3110247	ENSG00000246366.5	RP11-382J12.1	3.75	0.000201	0.025	0.15	0.17	Bone mineral density;	chr8:71022652	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.905	rs3110248	ENSG00000246366.5	RP11-382J12.1	3.75	0.000201	0.025	0.15	0.17	Bone mineral density;	chr8:71022700	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.905	rs3110249	ENSG00000246366.5	RP11-382J12.1	3.75	0.000201	0.025	0.15	0.17	Bone mineral density;	chr8:71023310	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.905	rs3098876	ENSG00000246366.5	RP11-382J12.1	3.75	0.000201	0.025	0.15	0.17	Bone mineral density;	chr8:71024009	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.87	rs3098877	ENSG00000246366.5	RP11-382J12.1	3.75	0.000201	0.025	0.15	0.17	Bone mineral density;	chr8:71024211	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.875	rs3110251	ENSG00000246366.5	RP11-382J12.1	3.75	0.000201	0.025	0.15	0.17	Bone mineral density;	chr8:71024739	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.905	rs3110252	ENSG00000246366.5	RP11-382J12.1	3.75	0.000201	0.025	0.15	0.17	Bone mineral density;	chr8:71024985	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.905	rs3110253	ENSG00000246366.5	RP11-382J12.1	3.75	0.000201	0.025	0.15	0.17	Bone mineral density;	chr8:71025318	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.905	rs3110254	ENSG00000246366.5	RP11-382J12.1	3.75	0.000201	0.025	0.15	0.17	Bone mineral density;	chr8:71025627	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.87	rs3110256	ENSG00000246366.5	RP11-382J12.1	3.75	0.000201	0.025	0.15	0.17	Bone mineral density;	chr8:71025901	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.905	rs3110257	ENSG00000246366.5	RP11-382J12.1	3.75	0.000201	0.025	0.15	0.17	Bone mineral density;	chr8:71025916	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.905	rs3098879	ENSG00000246366.5	RP11-382J12.1	3.75	0.000201	0.025	0.15	0.17	Bone mineral density;	chr8:71026225	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.935	rs3110258	ENSG00000246366.5	RP11-382J12.1	3.75	0.000201	0.025	0.15	0.17	Bone mineral density;	chr8:71026297	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.87	rs3098880	ENSG00000246366.5	RP11-382J12.1	3.75	0.000201	0.025	0.15	0.17	Bone mineral density;	chr8:71026686	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.905	rs3098881	ENSG00000246366.5	RP11-382J12.1	3.75	0.000201	0.025	0.15	0.17	Bone mineral density;	chr8:71027455	chr8:70608577~70663279:+
LUAD	cis	rs1707322	0.638	rs9429095	ENSG00000280836.1	AL355480.1	3.75	0.000201	0.025	0.21	0.17	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46137676	chr1:45581219~45581321:-
LUAD	cis	rs7772486	0.686	rs702314	ENSG00000235652.6	RP11-545I5.3	-3.75	0.000201	0.025	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145682374	chr6:145799409~145886585:+
LUAD	cis	rs1355223	0.867	rs1869360	ENSG00000271369.1	RP11-350D17.3	-3.75	0.000201	0.025	-0.2	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34677043	chr11:34709600~34710161:+
LUAD	cis	rs7903456	0.648	rs9421573	ENSG00000200253.1	RNU6-529P	3.75	0.000201	0.025	0.2	0.17	Gout;Renal underexcretion gout;	chr10:87061945	chr10:87041238~87041341:-
LUAD	cis	rs7031325	0.819	rs10758801	ENSG00000229611.1	RP11-390F4.10	3.75	0.000201	0.025	0.2	0.17	Systemic lupus erythematosus;	chr9:6657192	chr9:6704471~6707780:+
LUAD	cis	rs2836950	0.545	rs4818001	ENSG00000232608.1	TIMM9P2	3.75	0.000201	0.025	0.19	0.17	Menarche (age at onset);	chr21:39203162	chr21:39216624~39217506:+
LUAD	cis	rs11893307	0.509	rs12618075	ENSG00000235852.1	AC005540.3	3.75	0.000201	0.025	0.21	0.17	Mean platelet volume;	chr2:190681095	chr2:190880797~190882059:-
LUAD	cis	rs3126085	0.515	rs10788835	ENSG00000237975.5	FLG-AS1	3.75	0.000201	0.025	0.26	0.17	Atopic dermatitis;	chr1:152358469	chr1:152168125~152445456:+
LUAD	cis	rs3126085	0.515	rs2275264	ENSG00000237975.5	FLG-AS1	3.75	0.000201	0.025	0.26	0.17	Atopic dermatitis;	chr1:152359057	chr1:152168125~152445456:+
LUAD	cis	rs3126085	0.515	rs11204984	ENSG00000237975.5	FLG-AS1	3.75	0.000201	0.025	0.26	0.17	Atopic dermatitis;	chr1:152359511	chr1:152168125~152445456:+
LUAD	cis	rs214785	0.932	rs214795	ENSG00000234684.5	SDCBP2-AS1	3.75	0.000201	0.025	0.21	0.17	Basal cell carcinoma;	chr20:2305545	chr20:1325405~1378734:+
LUAD	cis	rs8056893	0.885	rs4381598	ENSG00000274698.1	RP11-71L14.4	3.75	0.000201	0.025	0.19	0.17	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68319761	chr16:68450283~68452318:+
LUAD	cis	rs9322193	0.566	rs6912330	ENSG00000268592.3	RAET1E-AS1	-3.75	0.000201	0.025	-0.25	-0.17	Lung cancer;	chr6:149908811	chr6:149863494~149919507:+
LUAD	cis	rs6586111	0.647	rs76120037	ENSG00000226659.1	RP11-137H2.4	-3.75	0.000201	0.025	-0.24	-0.17	Capecitabine sensitivity;	chr10:80612174	chr10:80529597~80535942:-
LUAD	cis	rs6452524	0.537	rs1583	ENSG00000281327.1	LINC01338	3.75	0.000201	0.025	0.18	0.17	Hypertension (SNP x SNP interaction);	chr5:83052403	chr5:82850864~82859836:-
LUAD	cis	rs10829156	0.773	rs7909552	ENSG00000240291.1	RP11-499P20.2	3.75	0.000201	0.025	0.15	0.17	Sudden cardiac arrest;	chr10:18620407	chr10:18513115~18545651:-
LUAD	cis	rs4499344	0.623	rs259278	ENSG00000201388.1	SNORA68	3.75	0.000201	0.025	0.18	0.17	Mean platelet volume;	chr19:32670220	chr19:32608337~32608469:-
LUAD	cis	rs4706831	0.647	rs627240	ENSG00000233967.5	RP11-250B2.3	-3.75	0.000201	0.025	-0.17	-0.17	Joint mobility (Beighton score);	chr6:80276168	chr6:80443344~80465927:+
LUAD	cis	rs2548724	0.617	rs2123136	ENSG00000250682.4	LINC00491	3.75	0.000201	0.025	0.2	0.17	Type 2 diabetes;	chr5:102372284	chr5:102609156~102671559:-
LUAD	cis	rs2548724	0.617	rs57415604	ENSG00000250682.4	LINC00491	3.75	0.000201	0.025	0.2	0.17	Type 2 diabetes;	chr5:102375957	chr5:102609156~102671559:-
LUAD	cis	rs2278702	0.943	rs78285258	ENSG00000259495.2	RP11-210M15.2	-3.75	0.000201	0.025	-0.27	-0.17	Bipolar disorder;	chr15:80392771	chr15:80344853~80403575:-
LUAD	cis	rs2032366	0.606	rs713485	ENSG00000266920.1	ACTBP9	3.75	0.000201	0.025	0.18	0.17	Obesity-related traits;	chr18:61603692	chr18:62442028~62443126:+
LUAD	cis	rs12822507	0.732	rs4555	ENSG00000275963.1	RP11-180M15.6	3.75	0.000201	0.025	0.19	0.17	Systemic lupus erythematosus;	chr12:12643938	chr12:12648939~12649713:+
LUAD	cis	rs13113518	1	rs9312661	ENSG00000273257.1	RP11-177J6.1	3.75	0.000201	0.025	0.18	0.17	Height;	chr4:55476159	chr4:55387949~55388271:+
LUAD	cis	rs7208859	0.673	rs9889755	ENSG00000280069.1	CTD-2349P21.3	3.75	0.000201	0.025	0.21	0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30907487	chr17:30738182~30740275:+
LUAD	cis	rs7221059	1	rs7221059	ENSG00000267506.4	RP11-13K12.1	3.75	0.000201	0.025	0.24	0.17	Pulmonary emphysema;	chr17:76992362	chr17:77546940~77563243:+
LUAD	cis	rs12122100	0.651	rs12127461	ENSG00000244371.2	PFN1P8	3.75	0.000201	0.025	0.21	0.17	HIV-1 control;	chr1:147080339	chr1:146957117~146957659:-
LUAD	cis	rs910316	0.699	rs175039	ENSG00000279594.1	RP11-950C14.10	-3.75	0.000201	0.025	-0.19	-0.17	Height;	chr14:75002247	chr14:75011269~75012851:-
LUAD	cis	rs9925964	0.804	rs4889606	ENSG00000232748.3	RP11-196G11.6	-3.75	0.000201	0.025	-0.2	-0.17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:30999862	chr16:31056460~31062803:+
LUAD	cis	rs2278702	0.622	rs77924420	ENSG00000259495.2	RP11-210M15.2	-3.75	0.000201	0.025	-0.29	-0.17	Bipolar disorder;	chr15:80380626	chr15:80344853~80403575:-
LUAD	cis	rs932287	0.651	rs1111010	ENSG00000254860.4	TMEM9B-AS1	-3.75	0.000201	0.025	-0.19	-0.17	Colonoscopy-negative controls vs population controls;	chr11:9028388	chr11:8964675~8977527:+
LUAD	cis	rs8002861	0.905	rs80209017	ENSG00000274001.1	RP11-5G9.5	3.75	0.000201	0.025	0.18	0.17	Leprosy;	chr13:43899046	chr13:43877715~43878163:-
LUAD	cis	rs12440869	1	rs12439028	ENSG00000270964.1	RP11-502I4.3	3.75	0.000201	0.025	0.19	0.17	Peak velocity of the mitral A-wave;	chr15:67286617	chr15:67541072~67542604:-
LUAD	cis	rs11673344	0.711	rs112857724	ENSG00000267309.1	CTD-2630F21.1	-3.75	0.000201	0.025	-0.21	-0.17	Obesity-related traits;	chr19:37030176	chr19:36489649~36491040:+
LUAD	cis	rs2446066	0.728	rs10876444	ENSG00000257379.1	RP11-793H13.8	3.75	0.000201	0.025	0.29	0.17	Red blood cell count;	chr12:53358697	chr12:53441741~53467528:+
LUAD	cis	rs763121	0.853	rs138705	ENSG00000228274.3	RP3-508I15.9	-3.75	0.000201	0.025	-0.17	-0.17	Menopause (age at onset);	chr22:38737798	chr22:38667585~38681820:-
LUAD	cis	rs6479901	0.557	rs12773283	ENSG00000232075.1	MRPL35P2	-3.75	0.000201	0.025	-0.26	-0.17	Intelligence (multi-trait analysis);	chr10:63298464	chr10:63634317~63634827:-
LUAD	cis	rs10863681	0.764	rs10495184	ENSG00000227925.1	RP11-191N8.2	3.75	0.000201	0.025	0.2	0.17	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222086335	chr1:221827666~221840666:-
LUAD	cis	rs6787172	0.811	rs11714869	ENSG00000272087.1	RP11-379F4.7	-3.75	0.000201	0.025	-0.18	-0.17	Subjective well-being;	chr3:158476931	chr3:158693120~158693768:-
LUAD	cis	rs944722	0.511	rs2297520	ENSG00000263266.2	RPS7P1	3.75	0.000201	0.025	0.12	0.17	Fractional exhaled nitric oxide (childhood);	chr17:27781014	chr17:28467822~28468406:+
LUAD	cis	rs6095360	1	rs2295027	ENSG00000222365.1	SNORD12B	-3.75	0.000201	0.025	-0.17	-0.17	Intelligence (multi-trait analysis);	chr20:48966347	chr20:49280319~49280409:+
LUAD	cis	rs7005380	0.6	rs13267896	ENSG00000279347.1	RP11-85I17.2	-3.75	0.000201	0.025	-0.14	-0.17	Interstitial lung disease;	chr8:119908414	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.62	rs13275524	ENSG00000279347.1	RP11-85I17.2	-3.75	0.000201	0.025	-0.14	-0.17	Interstitial lung disease;	chr8:119908701	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.6	rs6469867	ENSG00000279347.1	RP11-85I17.2	-3.75	0.000201	0.025	-0.14	-0.17	Interstitial lung disease;	chr8:119909172	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.58	rs6469868	ENSG00000279347.1	RP11-85I17.2	-3.75	0.000201	0.025	-0.14	-0.17	Interstitial lung disease;	chr8:119909601	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.606	rs6469869	ENSG00000279347.1	RP11-85I17.2	-3.75	0.000201	0.025	-0.14	-0.17	Interstitial lung disease;	chr8:119909696	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.62	rs6469870	ENSG00000279347.1	RP11-85I17.2	-3.75	0.000201	0.025	-0.14	-0.17	Interstitial lung disease;	chr8:119909773	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.62	rs6469871	ENSG00000279347.1	RP11-85I17.2	-3.75	0.000201	0.025	-0.14	-0.17	Interstitial lung disease;	chr8:119909839	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.6	rs6469872	ENSG00000279347.1	RP11-85I17.2	-3.75	0.000201	0.025	-0.14	-0.17	Interstitial lung disease;	chr8:119910007	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.6	rs7015470	ENSG00000279347.1	RP11-85I17.2	-3.75	0.000201	0.025	-0.14	-0.17	Interstitial lung disease;	chr8:119910101	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.62	rs6995139	ENSG00000279347.1	RP11-85I17.2	-3.75	0.000201	0.025	-0.14	-0.17	Interstitial lung disease;	chr8:119910157	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.62	rs10217077	ENSG00000279347.1	RP11-85I17.2	-3.75	0.000201	0.025	-0.14	-0.17	Interstitial lung disease;	chr8:119910943	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.62	rs939242	ENSG00000279347.1	RP11-85I17.2	-3.75	0.000201	0.025	-0.14	-0.17	Interstitial lung disease;	chr8:119912030	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.6	rs939241	ENSG00000279347.1	RP11-85I17.2	-3.75	0.000201	0.025	-0.14	-0.17	Interstitial lung disease;	chr8:119912297	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.62	rs10216503	ENSG00000279347.1	RP11-85I17.2	-3.75	0.000201	0.025	-0.14	-0.17	Interstitial lung disease;	chr8:119912843	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.62	rs7824545	ENSG00000279347.1	RP11-85I17.2	-3.75	0.000201	0.025	-0.14	-0.17	Interstitial lung disease;	chr8:119913381	chr8:119838736~119840385:-
LUAD	cis	rs526231	0.511	rs158402	ENSG00000250682.4	LINC00491	3.75	0.000201	0.025	0.2	0.17	Primary biliary cholangitis;	chr5:103079821	chr5:102609156~102671559:-
LUAD	cis	rs1009115	0.528	rs4725086	ENSG00000229970.3	AC007128.1	-3.75	0.000201	0.025	-0.22	-0.17	Post bronchodilator FEV1;	chr7:8358937	chr7:8262264~8344516:+
LUAD	cis	rs13113518	1	rs6858803	ENSG00000273257.1	RP11-177J6.1	3.75	0.000201	0.025	0.18	0.17	Height;	chr4:55484534	chr4:55387949~55388271:+
LUAD	cis	rs763121	0.853	rs8142098	ENSG00000225450.1	RP3-508I15.14	-3.75	0.000202	0.0251	-0.17	-0.17	Menopause (age at onset);	chr22:38662752	chr22:38739003~38749041:+
LUAD	cis	rs7674212	0.541	rs4699050	ENSG00000251288.2	RP11-10L12.2	-3.75	0.000202	0.0251	-0.21	-0.17	Type 2 diabetes;	chr4:103193140	chr4:102751401~102752641:+
LUAD	cis	rs7674212	0.541	rs17217473	ENSG00000251288.2	RP11-10L12.2	-3.75	0.000202	0.0251	-0.21	-0.17	Type 2 diabetes;	chr4:103193585	chr4:102751401~102752641:+
LUAD	cis	rs703842	1	rs2072052	ENSG00000245651.2	RP11-620J15.2	3.75	0.000202	0.0251	0.18	0.17	Multiple sclerosis;	chr12:57752936	chr12:57869835~57896482:-
LUAD	cis	rs10080237	0.564	rs2490224	ENSG00000272129.1	RP11-250B2.6	3.75	0.000202	0.0251	0.21	0.17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;	chr6:80100116	chr6:80355424~80356859:+
LUAD	cis	rs6964587	1	rs416	ENSG00000188693.7	CYP51A1-AS1	3.75	0.000202	0.0251	0.2	0.17	Breast cancer;	chr7:91951257	chr7:92134604~92180725:+
LUAD	cis	rs6142102	0.961	rs4911390	ENSG00000275784.1	RP5-1125A11.6	-3.75	0.000202	0.0251	-0.19	-0.17	Skin pigmentation;	chr20:33977401	chr20:33989480~33991818:-
LUAD	cis	rs77633900	0.803	rs2469215	ENSG00000196274.5	Metazoa_SRP	3.75	0.000202	0.0251	0.22	0.17	Glioma;Non-glioblastoma glioma;	chr15:76319592	chr15:76230048~76230390:-
LUAD	cis	rs77633900	0.892	rs2469216	ENSG00000196274.5	Metazoa_SRP	3.75	0.000202	0.0251	0.22	0.17	Glioma;Non-glioblastoma glioma;	chr15:76321136	chr15:76230048~76230390:-
LUAD	cis	rs8062405	0.824	rs28698667	ENSG00000261419.1	RP11-57A19.4	-3.75	0.000202	0.0251	-0.18	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28659696~28740781:-
LUAD	cis	rs6438234	0.961	rs952384	ENSG00000242767.1	ZBTB20-AS4	3.75	0.000202	0.0251	0.21	0.17	Type 2 diabetes;	chr3:115186394	chr3:115100423~115103061:+
LUAD	cis	rs6088590	0.687	rs13044899	ENSG00000276073.1	RP5-1125A11.7	-3.75	0.000202	0.0251	-0.16	-0.17	Coronary artery disease;	chr20:34699274	chr20:33985617~33988989:-
LUAD	cis	rs11673344	0.642	rs11083420	ENSG00000267254.4	ZNF790-AS1	-3.75	0.000202	0.0251	-0.22	-0.17	Obesity-related traits;	chr19:37317901	chr19:36797518~36828115:+
LUAD	cis	rs2502731	0.539	rs3003615	ENSG00000280758.1	RP11-216B9.9	-3.75	0.000202	0.0251	-0.15	-0.17	Attention deficit hyperactivity disorder;	chr9:128235613	chr9:128630328~128631685:-
LUAD	cis	rs11673344	0.555	rs502546	ENSG00000267254.4	ZNF790-AS1	3.75	0.000202	0.0251	0.23	0.17	Obesity-related traits;	chr19:37361788	chr19:36797518~36828115:+
LUAD	cis	rs8141529	0.702	rs8137262	ENSG00000272858.1	CTA-292E10.8	-3.75	0.000202	0.0251	-0.19	-0.17	Lymphocyte counts;	chr22:28896147	chr22:28814914~28815662:+
LUAD	cis	rs10774547	0.965	rs11065109	ENSG00000278344.1	RP11-18C24.8	3.75	0.000202	0.0251	0.23	0.17	Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);Reading disability or specific language impairment (pleiotropy);	chr12:120426111	chr12:120500735~120501090:-
LUAD	cis	rs765899	0.7	rs737387	ENSG00000240210.3	RP11-204K16.1	-3.75	0.000202	0.0251	-0.18	-0.17	Breast cancer;	chr14:68500665	chr14:68338728~68339528:-
LUAD	cis	rs6951245	0.554	rs118191017	ENSG00000226291.1	AC091729.8	-3.75	0.000202	0.0251	-0.23	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1116210	chr7:1080863~1082178:+
LUAD	cis	rs7578361	0.959	rs12999502	ENSG00000231969.1	AC144449.1	-3.75	0.000202	0.0251	-0.24	-0.17	Acute lymphoblastic leukemia (childhood);	chr2:149573523	chr2:149587196~149848233:+
LUAD	cis	rs9921338	0.961	rs11545336	ENSG00000263080.1	RP11-485G7.5	3.75	0.000202	0.0251	0.23	0.17	Vein graft stenosis in coronary artery bypass grafting;	chr16:11345639	chr16:11341809~11345211:-
LUAD	cis	rs757081	0.634	rs17472942	ENSG00000260196.1	RP1-239B22.5	-3.75	0.000202	0.0251	-0.22	-0.17	Systolic blood pressure;	chr11:17073155	chr11:17380649~17383531:+
LUAD	cis	rs683250	0.66	rs520291	ENSG00000246067.6	RAB30-AS1	3.75	0.000202	0.0251	0.18	0.17	Subcortical brain region volumes;	chr11:83246990	chr11:83072066~83106719:+
LUAD	cis	rs6493487	0.512	rs3848135	ENSG00000273674.3	CTD-2378E12.1	3.75	0.000202	0.0251	0.24	0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50822453	chr15:50839875~50908599:-
LUAD	cis	rs6493487	0.512	rs11854559	ENSG00000273674.3	CTD-2378E12.1	3.75	0.000202	0.0251	0.24	0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50822530	chr15:50839875~50908599:-
LUAD	cis	rs6493487	0.512	rs10153007	ENSG00000273674.3	CTD-2378E12.1	3.75	0.000202	0.0251	0.24	0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50823364	chr15:50839875~50908599:-
LUAD	cis	rs6493487	0.512	rs12899528	ENSG00000273674.3	CTD-2378E12.1	3.75	0.000202	0.0251	0.24	0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50824006	chr15:50839875~50908599:-
LUAD	cis	rs6493487	0.512	rs12898402	ENSG00000273674.3	CTD-2378E12.1	3.75	0.000202	0.0251	0.24	0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50824093	chr15:50839875~50908599:-
LUAD	cis	rs6493487	0.512	rs7170937	ENSG00000273674.3	CTD-2378E12.1	3.75	0.000202	0.0251	0.24	0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50825327	chr15:50839875~50908599:-
LUAD	cis	rs6493487	0.512	rs7172667	ENSG00000273674.3	CTD-2378E12.1	3.75	0.000202	0.0251	0.24	0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50825497	chr15:50839875~50908599:-
LUAD	cis	rs6493487	0.512	rs16963947	ENSG00000273674.3	CTD-2378E12.1	3.75	0.000202	0.0251	0.24	0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50826093	chr15:50839875~50908599:-
LUAD	cis	rs5758511	0.68	rs5758684	ENSG00000233903.2	Z83851.4	3.75	0.000202	0.0251	0.25	0.17	Birth weight;	chr22:42253503	chr22:42276355~42277052:+
LUAD	cis	rs6661961	0.752	rs6694145	ENSG00000237975.5	FLG-AS1	3.75	0.000202	0.0251	0.22	0.17	Atopic dermatitis;	chr1:152452349	chr1:152168125~152445456:+
LUAD	cis	rs755249	0.917	rs61781392	ENSG00000237624.1	OXCT2P1	3.75	0.000202	0.0251	0.26	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39617969	chr1:39514956~39516490:+
LUAD	cis	rs8067545	0.641	rs203458	ENSG00000270091.1	RP11-78O7.2	-3.75	0.000202	0.0251	-0.14	-0.17	Schizophrenia;	chr17:19913585	chr17:19896590~19897287:-
LUAD	cis	rs2274273	0.624	rs78205412	ENSG00000258413.1	RP11-665C16.6	-3.75	0.000202	0.0251	-0.23	-0.17	Protein biomarker;	chr14:55314532	chr14:55262767~55272075:-
LUAD	cis	rs6001482	0.638	rs5757574	ENSG00000211642.2	IGLV10-54	3.75	0.000202	0.0251	0.19	0.17	Diastolic blood pressure;	chr22:22231597	chr22:22214794~22215270:+
LUAD	cis	rs6095360	0.966	rs6019557	ENSG00000222365.1	SNORD12B	-3.75	0.000202	0.0251	-0.17	-0.17	Intelligence (multi-trait analysis);	chr20:48966835	chr20:49280319~49280409:+
LUAD	cis	rs6095360	1	rs6019558	ENSG00000222365.1	SNORD12B	-3.75	0.000202	0.0251	-0.17	-0.17	Intelligence (multi-trait analysis);	chr20:48966943	chr20:49280319~49280409:+
LUAD	cis	rs763121	0.853	rs5757141	ENSG00000225450.1	RP3-508I15.14	-3.75	0.000202	0.0251	-0.17	-0.17	Menopause (age at onset);	chr22:38561478	chr22:38739003~38749041:+
LUAD	cis	rs1735151	0.915	rs744568	ENSG00000255568.3	BRWD1-AS2	3.75	0.000202	0.0251	0.23	0.17	Hypertension;	chr21:39762063	chr21:39313935~39314962:+
LUAD	cis	rs13113518	1	rs939823	ENSG00000273257.1	RP11-177J6.1	3.75	0.000202	0.0251	0.18	0.17	Height;	chr4:55487368	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs6838882	ENSG00000273257.1	RP11-177J6.1	3.75	0.000202	0.0251	0.18	0.17	Height;	chr4:55489310	chr4:55387949~55388271:+
LUAD	cis	rs2904524	1	rs79224766	ENSG00000257815.4	RP11-611E13.2	-3.75	0.000202	0.0251	-0.25	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70292399	chr12:69904033~70243360:-
LUAD	cis	rs9309473	0.607	rs7560272	ENSG00000230002.2	ALMS1-IT1	3.75	0.000202	0.0251	0.19	0.17	Metabolite levels;	chr2:73334357	chr2:73456764~73459484:+
LUAD	cis	rs763121	0.853	rs35565791	ENSG00000225450.1	RP3-508I15.14	-3.75	0.000202	0.0251	-0.17	-0.17	Menopause (age at onset);	chr22:38667006	chr22:38739003~38749041:+
LUAD	cis	rs763121	0.853	rs35522482	ENSG00000225450.1	RP3-508I15.14	-3.75	0.000202	0.0251	-0.17	-0.17	Menopause (age at onset);	chr22:38667010	chr22:38739003~38749041:+
LUAD	cis	rs6063399	0.79	rs6067084	ENSG00000203999.7	LINC01270	-3.75	0.000202	0.0251	-0.17	-0.17	Obesity-related traits;	chr20:49406457	chr20:50292720~50314922:+
LUAD	cis	rs801193	0.935	rs3800820	ENSG00000222364.1	RNU6-96P	3.75	0.000202	0.0251	0.19	0.17	Aortic root size;	chr7:66682191	chr7:66395191~66395286:+
LUAD	cis	rs4699052	0.507	rs10005997	ENSG00000246560.2	RP11-10L12.4	3.75	0.000202	0.0251	0.24	0.17	Testicular germ cell tumor;	chr4:103380554	chr4:102828055~102844075:+
LUAD	cis	rs8028182	0.636	rs4486847	ENSG00000246877.1	DNM1P35	3.75	0.000202	0.0251	0.22	0.17	Sudden cardiac arrest;	chr15:75436190	chr15:75727670~75738623:-
LUAD	cis	rs9376307	0.92	rs9373202	ENSG00000226004.1	RP11-10J5.1	-3.75	0.000202	0.0251	-0.18	-0.17	Cancer;	chr6:137964325	chr6:137943079~137945802:-
LUAD	cis	rs17711722	0.522	rs62469933	ENSG00000273024.4	INTS4P2	-3.75	0.000202	0.0251	-0.18	-0.17	Calcium levels;	chr7:65800652	chr7:65647864~65715661:+
LUAD	cis	rs7557067	1	rs6728178	ENSG00000233005.1	AC067959.1	-3.75	0.000202	0.0251	-0.19	-0.17	Triglycerides;	chr2:20971074	chr2:21221175~21970959:+
LUAD	cis	rs80033912	0.64	rs6785832	ENSG00000229759.1	MRPS18AP1	3.75	0.000202	0.0251	0.18	0.17	Intelligence (multi-trait analysis);	chr3:49186883	chr3:48256350~48256938:-
LUAD	cis	rs2904524	0.881	rs77987335	ENSG00000257815.4	RP11-611E13.2	-3.75	0.000202	0.0251	-0.25	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70348180	chr12:69904033~70243360:-
LUAD	cis	rs854765	0.964	rs72827413	ENSG00000223979.2	SMCR2	3.75	0.000202	0.0251	0.19	0.17	Total body bone mineral density;	chr17:18084985	chr17:17674026~17677688:-
LUAD	cis	rs854765	0.624	rs11657423	ENSG00000264177.1	RP1-37N7.1	3.75	0.000202	0.0251	0.17	0.17	Total body bone mineral density;	chr17:17825260	chr17:18379855~18388984:-
LUAD	cis	rs9309473	0.615	rs62151562	ENSG00000230002.2	ALMS1-IT1	3.74	0.000202	0.0251	0.26	0.17	Metabolite levels;	chr2:73376412	chr2:73456764~73459484:+
LUAD	cis	rs8028182	0.636	rs11636199	ENSG00000246877.1	DNM1P35	3.74	0.000202	0.0251	0.21	0.17	Sudden cardiac arrest;	chr15:75532996	chr15:75727670~75738623:-
LUAD	cis	rs6957923	0.655	rs7781714	ENSG00000234286.1	AC006026.13	-3.74	0.000202	0.0251	-0.21	-0.17	Height;	chr7:23553860	chr7:23680195~23680786:-
LUAD	cis	rs12493885	0.654	rs11925207	ENSG00000243069.6	ARHGEF26-AS1	-3.74	0.000202	0.0251	-0.28	-0.17	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:153982097	chr3:154024401~154121332:-
LUAD	cis	rs28472312	0.685	rs11642638	ENSG00000246465.1	RP11-57A19.2	3.74	0.000202	0.0251	0.19	0.17	Intelligence (multi-trait analysis);	chr16:28973624	chr16:28284885~28292064:-
LUAD	cis	rs7829975	0.577	rs940032	ENSG00000253893.2	FAM85B	3.74	0.000202	0.0251	0.21	0.17	Mood instability;	chr8:8688833	chr8:8167819~8226614:-
LUAD	cis	rs9633740	0.773	rs7080009	ENSG00000226659.1	RP11-137H2.4	-3.74	0.000202	0.0251	-0.28	-0.17	Post bronchodilator FEV1;	chr10:80509705	chr10:80529597~80535942:-
LUAD	cis	rs9633740	1	rs1870137	ENSG00000226659.1	RP11-137H2.4	-3.74	0.000202	0.0251	-0.28	-0.17	Post bronchodilator FEV1;	chr10:80510092	chr10:80529597~80535942:-
LUAD	cis	rs247929	1	rs2408435	ENSG00000272369.1	RP11-446N19.1	3.74	0.000202	0.0251	0.18	0.17	Educational attainment;	chr12:45798574	chr12:46537502~46652550:+
LUAD	cis	rs2657294	0.965	rs4746270	ENSG00000233313.2	HMGA1P5	-3.74	0.000202	0.0251	-0.21	-0.17	Pneumonia;	chr10:75185189	chr10:75276376~75276646:-
LUAD	cis	rs513088	0.681	rs503961	ENSG00000225171.2	DUTP6	3.74	0.000202	0.0251	0.22	0.17	Schizophrenia;	chr1:166694494	chr1:166868748~166869209:+
LUAD	cis	rs513088	0.681	rs34900988	ENSG00000225171.2	DUTP6	-3.74	0.000202	0.0251	-0.22	-0.17	Schizophrenia;	chr1:166695161	chr1:166868748~166869209:+
LUAD	cis	rs214785	1	rs214784	ENSG00000234684.5	SDCBP2-AS1	3.74	0.000202	0.0251	0.21	0.17	Basal cell carcinoma;	chr20:2302019	chr20:1325405~1378734:+
LUAD	cis	rs214785	1	rs214785	ENSG00000234684.5	SDCBP2-AS1	3.74	0.000202	0.0251	0.21	0.17	Basal cell carcinoma;	chr20:2302811	chr20:1325405~1378734:+
LUAD	cis	rs9549260	0.755	rs9549244	ENSG00000229456.1	RLIMP1	3.74	0.000202	0.0251	0.18	0.17	Red blood cell count;	chr13:40644548	chr13:40618738~40621348:+
LUAD	cis	rs6121246	0.559	rs10439607	ENSG00000230613.1	HM13-AS1	3.74	0.000202	0.0251	0.21	0.17	Mean corpuscular hemoglobin;	chr20:31670738	chr20:31567707~31573263:-
LUAD	cis	rs4845570	1	rs11586946	ENSG00000203288.3	RP11-98D18.9	-3.74	0.000202	0.0251	-0.26	-0.17	Coronary artery disease;	chr1:151797330	chr1:151790804~151794402:+
LUAD	cis	rs12822507	0.899	rs4763859	ENSG00000275963.1	RP11-180M15.6	-3.74	0.000202	0.0251	-0.19	-0.17	Systemic lupus erythematosus;	chr12:12634071	chr12:12648939~12649713:+
LUAD	cis	rs16944613	0.541	rs4288973	ENSG00000259212.1	CTD-3065B20.2	3.74	0.000202	0.0251	0.27	0.17	Colorectal cancer;	chr15:90550444	chr15:90595840~90596447:-
LUAD	cis	rs28453840	1	rs28453840	ENSG00000226806.1	AC011893.3	-3.74	0.000202	0.0251	-0.21	-0.17	Cholesterol, total;	chr2:135765371	chr2:135820191~135823087:+
LUAD	cis	rs4713118	0.911	rs9295746	ENSG00000280107.1	AL022393.9	-3.74	0.000202	0.0251	-0.22	-0.17	Parkinson's disease;	chr6:27762285	chr6:28170845~28172521:+
LUAD	cis	rs13434995	0.513	rs6851971	ENSG00000273257.1	RP11-177J6.1	3.74	0.000202	0.0251	0.22	0.17	Adiponectin levels;	chr4:55561897	chr4:55387949~55388271:+
LUAD	cis	rs454217	0.875	rs7958204	ENSG00000277851.1	RP11-756G20.1	3.74	0.000203	0.0252	0.17	0.17	Smoking quantity;	chr12:92323167	chr12:92247756~92363832:-
LUAD	cis	rs2154319	0.887	rs2064740	ENSG00000235358.1	RP11-399E6.1	3.74	0.000203	0.0252	0.23	0.17	Height;	chr1:41048478	chr1:41242373~41284861:+
LUAD	cis	rs2154319	0.79	rs2363096	ENSG00000235358.1	RP11-399E6.1	3.74	0.000203	0.0252	0.23	0.17	Height;	chr1:41049277	chr1:41242373~41284861:+
LUAD	cis	rs2154319	0.887	rs7525193	ENSG00000235358.1	RP11-399E6.1	3.74	0.000203	0.0252	0.23	0.17	Height;	chr1:41055040	chr1:41242373~41284861:+
LUAD	cis	rs5769707	0.521	rs5769719	ENSG00000235111.1	RP1-29C18.8	-3.74	0.000203	0.0252	-0.2	-0.17	Monocyte percentage of white cells;Monocyte count;	chr22:49668453	chr22:49612657~49615716:-
LUAD	cis	rs5769707	0.521	rs5769720	ENSG00000235111.1	RP1-29C18.8	-3.74	0.000203	0.0252	-0.2	-0.17	Monocyte percentage of white cells;Monocyte count;	chr22:49668485	chr22:49612657~49615716:-
LUAD	cis	rs5769707	0.521	rs5770633	ENSG00000235111.1	RP1-29C18.8	-3.74	0.000203	0.0252	-0.2	-0.17	Monocyte percentage of white cells;Monocyte count;	chr22:49668779	chr22:49612657~49615716:-
LUAD	cis	rs6674176	0.597	rs4660262	ENSG00000237950.1	RP11-7O11.3	3.74	0.000203	0.0252	0.21	0.17	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43916852	chr1:43944370~43946551:-
LUAD	cis	rs7246657	0.943	rs2126977	ENSG00000226686.6	LINC01535	3.74	0.000203	0.0252	0.24	0.17	Coronary artery calcification;	chr19:37504845	chr19:37251912~37265535:+
LUAD	cis	rs2337406	0.641	rs10133227	ENSG00000211946.3	IGHV3-20	-3.74	0.000203	0.0252	-0.18	-0.17	Alzheimer's disease (late onset);	chr14:106814260	chr14:106210936~106211453:-
LUAD	cis	rs77633900	0.892	rs2456070	ENSG00000196274.5	Metazoa_SRP	3.74	0.000203	0.0252	0.23	0.17	Glioma;Non-glioblastoma glioma;	chr15:76243402	chr15:76230048~76230390:-
LUAD	cis	rs8067545	0.616	rs203470	ENSG00000270091.1	RP11-78O7.2	-3.74	0.000203	0.0252	-0.14	-0.17	Schizophrenia;	chr17:19955313	chr17:19896590~19897287:-
LUAD	cis	rs7772486	0.875	rs6938972	ENSG00000235652.6	RP11-545I5.3	3.74	0.000203	0.0252	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:146089472	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.875	rs12194437	ENSG00000235652.6	RP11-545I5.3	3.74	0.000203	0.0252	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:146090304	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.875	rs9403770	ENSG00000235652.6	RP11-545I5.3	3.74	0.000203	0.0252	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:146102198	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.875	rs11155452	ENSG00000235652.6	RP11-545I5.3	3.74	0.000203	0.0252	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:146103495	chr6:145799409~145886585:+
LUAD	cis	rs35740288	0.58	rs34526042	ENSG00000259407.1	RP11-158M2.3	-3.74	0.000203	0.0252	-0.18	-0.17	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85796725	chr15:85744109~85750281:-
LUAD	cis	rs35740288	0.58	rs34635893	ENSG00000259407.1	RP11-158M2.3	-3.74	0.000203	0.0252	-0.18	-0.17	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85797017	chr15:85744109~85750281:-
LUAD	cis	rs6763848	0.962	rs6778771	ENSG00000214073.2	RPL21P17	-3.74	0.000203	0.0252	-0.17	-0.17	Prostate cancer (SNP x SNP interaction);	chr3:1470731	chr3:1905651~1906125:+
LUAD	cis	rs11673344	0.864	rs2562587	ENSG00000267309.1	CTD-2630F21.1	-3.74	0.000203	0.0252	-0.21	-0.17	Obesity-related traits;	chr19:37019357	chr19:36489649~36491040:+
LUAD	cis	rs7819412	0.522	rs11776603	ENSG00000255046.1	RP11-297N6.4	3.74	0.000203	0.0252	0.21	0.17	Triglycerides;	chr8:11162803	chr8:11797928~11802568:-
LUAD	cis	rs7512552	0.809	rs696618	ENSG00000275557.1	RP11-353N4.6	3.74	0.000203	0.0252	0.19	0.17	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150403663	chr1:149607765~149612402:+
LUAD	cis	rs910316	0.763	rs175042	ENSG00000279594.1	RP11-950C14.10	-3.74	0.000203	0.0252	-0.19	-0.17	Height;	chr14:75004130	chr14:75011269~75012851:-
LUAD	cis	rs4664293	0.867	rs2059698	ENSG00000227055.1	AC009961.5	-3.74	0.000203	0.0252	-0.19	-0.17	Monocyte percentage of white cells;	chr2:159785905	chr2:159812234~159814009:-
LUAD	cis	rs7674212	0.54	rs2720469	ENSG00000246560.2	RP11-10L12.4	3.74	0.000203	0.0252	0.22	0.17	Type 2 diabetes;	chr4:103165327	chr4:102828055~102844075:+
LUAD	cis	rs7674212	0.57	rs6810571	ENSG00000246560.2	RP11-10L12.4	3.74	0.000203	0.0252	0.22	0.17	Type 2 diabetes;	chr4:103165630	chr4:102828055~102844075:+
LUAD	cis	rs12440869	1	rs15974	ENSG00000270964.1	RP11-502I4.3	3.74	0.000203	0.0252	0.19	0.17	Peak velocity of the mitral A-wave;	chr15:67201248	chr15:67541072~67542604:-
LUAD	cis	rs703842	1	rs11172333	ENSG00000270039.1	RP11-571M6.17	-3.74	0.000203	0.0252	-0.2	-0.17	Multiple sclerosis;	chr12:57776552	chr12:57803838~57804415:+
LUAD	cis	rs875971	0.571	rs160647	ENSG00000224316.1	RP11-479O9.2	-3.74	0.000203	0.0252	-0.2	-0.17	Aortic root size;	chr7:66089365	chr7:65773620~65802067:+
LUAD	cis	rs739496	0.546	rs11066055	ENSG00000234608.6	MAPKAPK5-AS1	3.74	0.000203	0.0252	0.19	0.17	Platelet count;	chr12:111875412	chr12:111839764~111842902:-
LUAD	cis	rs7615952	0.599	rs66532274	ENSG00000241288.6	RP11-379B18.5	-3.74	0.000203	0.0252	-0.2	-0.17	Blood pressure (smoking interaction);	chr3:126013002	chr3:125827238~125916384:-
LUAD	cis	rs7098100	0.641	rs2807979	ENSG00000279631.1	RP11-573G6.4	3.74	0.000203	0.0252	0.19	0.17	Breast cancer;	chr10:21924175	chr10:22252072~22254589:+
LUAD	cis	rs13108904	0.87	rs1564508	ENSG00000196810.4	CTBP1-AS2	3.74	0.000203	0.0252	0.2	0.17	Obesity-related traits;	chr4:1251091	chr4:1249300~1288291:+
LUAD	cis	rs41369048	0.66	rs2484710	ENSG00000221571.3	RNU6ATAC35P	-3.74	0.000203	0.0252	-0.22	-0.17	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220937151	chr1:220825620~220826063:+
LUAD	cis	rs4499344	0.921	rs2277927	ENSG00000267475.1	CTD-2538C1.2	3.74	0.000203	0.0252	0.22	0.17	Mean platelet volume;	chr19:32597460	chr19:32687089~32691750:-
LUAD	cis	rs7142881	0.787	rs35647158	ENSG00000258525.1	RP11-829H16.3	-3.74	0.000203	0.0252	-0.19	-0.17	Response to iloperidone treatment (QT prolongation);	chr14:31718365	chr14:30876179~30889808:-
LUAD	cis	rs9910055	0.529	rs850851	ENSG00000267080.4	ASB16-AS1	3.74	0.000203	0.0252	0.16	0.17	Total body bone mineral density;	chr17:44100306	chr17:44175973~44186717:-
LUAD	cis	rs4595586	1	rs4768388	ENSG00000257718.1	RP11-396F22.1	-3.74	0.000203	0.0252	-0.2	-0.17	Morning vs. evening chronotype;	chr12:38830122	chr12:38906451~38909592:+
LUAD	cis	rs6964587	1	rs4727266	ENSG00000188693.7	CYP51A1-AS1	3.74	0.000203	0.0252	0.2	0.17	Breast cancer;	chr7:91940815	chr7:92134604~92180725:+
LUAD	cis	rs6964587	1	rs4727267	ENSG00000188693.7	CYP51A1-AS1	3.74	0.000203	0.0252	0.2	0.17	Breast cancer;	chr7:91940976	chr7:92134604~92180725:+
LUAD	cis	rs6964587	1	rs7797369	ENSG00000188693.7	CYP51A1-AS1	3.74	0.000203	0.0252	0.2	0.17	Breast cancer;	chr7:91941301	chr7:92134604~92180725:+
LUAD	cis	rs8180040	0.739	rs12488225	ENSG00000271161.1	BOLA2P2	3.74	0.000203	0.0252	0.16	0.17	Colorectal cancer;	chr3:47193617	chr3:47499841~47500407:+
LUAD	cis	rs972578	0.837	rs4822228	ENSG00000230319.1	AL022476.2	3.74	0.000203	0.0252	0.17	0.17	Mean platelet volume;	chr22:42924210	chr22:43038585~43052366:+
LUAD	cis	rs7208859	0.673	rs1347360	ENSG00000265443.1	CTD-2349P21.6	-3.74	0.000203	0.0252	-0.26	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587514	chr17:30726305~30727564:-
LUAD	cis	rs6496932	1	rs2002642	ENSG00000218052.5	ADAMTS7P4	3.74	0.000203	0.0252	0.21	0.17	Central corneal thickness;Corneal structure;	chr15:85284513	chr15:85255369~85330334:-
LUAD	cis	rs6496932	1	rs4842872	ENSG00000218052.5	ADAMTS7P4	3.74	0.000203	0.0252	0.21	0.17	Central corneal thickness;Corneal structure;	chr15:85284825	chr15:85255369~85330334:-
LUAD	cis	rs6540731	0.782	rs12038888	ENSG00000229983.1	RP11-15I11.2	3.74	0.000203	0.0252	0.21	0.17	Intelligence (childhood);	chr1:212192711	chr1:212168207~212190259:+
LUAD	cis	rs6570726	0.846	rs6570700	ENSG00000235652.6	RP11-545I5.3	3.74	0.000203	0.0252	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145610416	chr6:145799409~145886585:+
LUAD	cis	rs7178424	0.742	rs12911564	ENSG00000259251.2	RP11-643M14.1	3.74	0.000203	0.0252	0.17	0.17	Height;	chr15:61919777	chr15:62060503~62062434:+
LUAD	cis	rs11159086	0.793	rs1029702	ENSG00000270000.1	RP3-449M8.9	3.74	0.000203	0.0252	0.23	0.17	Advanced glycation end-product levels;	chr14:74473909	chr14:74471930~74472360:-
LUAD	cis	rs7618501	0.501	rs35275715	ENSG00000234667.1	ACTBP13	-3.74	0.000203	0.0252	-0.19	-0.17	Intelligence (multi-trait analysis);	chr3:49921715	chr3:49873347~49877980:-
LUAD	cis	rs9659323	1	rs6680737	ENSG00000226172.2	RP4-712E4.1	-3.74	0.000203	0.0252	-0.18	-0.17	Body mass index;	chr1:118979008	chr1:119000344~119001392:-
LUAD	cis	rs9325144	0.723	rs11169518	ENSG00000257718.1	RP11-396F22.1	-3.74	0.000203	0.0252	-0.2	-0.17	Morning vs. evening chronotype;	chr12:38783435	chr12:38906451~38909592:+
LUAD	cis	rs4795519	0.778	rs1521560	ENSG00000266313.1	RP11-173M1.4	3.74	0.000203	0.0252	0.21	0.17	Chronic myeloid leukemia;	chr17:27073671	chr17:27333256~27348491:+
LUAD	cis	rs7138803	0.616	rs4075681	ENSG00000257464.1	RP11-161H23.8	3.74	0.000203	0.0252	0.17	0.17	Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index;	chr12:49820854	chr12:49442424~49442652:-
LUAD	cis	rs619865	0.614	rs4911466	ENSG00000250917.1	RP4-785G19.5	3.74	0.000203	0.0252	0.45	0.17	Freckling;	chr20:35102207	chr20:34234840~34281173:-
LUAD	cis	rs6494488	0.5	rs72742987	ENSG00000239465.1	RP11-330L19.2	3.74	0.000203	0.0252	0.36	0.17	Coronary artery disease;	chr15:64701558	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs72742989	ENSG00000239465.1	RP11-330L19.2	3.74	0.000203	0.0252	0.36	0.17	Coronary artery disease;	chr15:64702265	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs80142506	ENSG00000239465.1	RP11-330L19.2	3.74	0.000203	0.0252	0.36	0.17	Coronary artery disease;	chr15:64702948	chr15:64631109~64631914:-
LUAD	cis	rs16948098	1	rs16948098	ENSG00000205771.5	CATSPER2P1	-3.74	0.000203	0.0252	-0.4	-0.17	Serum albumin level;	chr15:43927409	chr15:43726918~43747094:-
LUAD	cis	rs4474465	0.79	rs4492845	ENSG00000251323.2	RP11-452H21.4	-3.74	0.000203	0.0252	-0.21	-0.17	Alzheimer's disease (survival time);	chr11:78549115	chr11:78423982~78429836:-
LUAD	cis	rs875971	0.545	rs2420456	ENSG00000222364.1	RNU6-96P	-3.74	0.000203	0.0252	-0.21	-0.17	Aortic root size;	chr7:66280619	chr7:66395191~66395286:+
LUAD	cis	rs2041895	0.509	rs12368448	ENSG00000260329.1	RP11-412D9.4	3.74	0.000204	0.0253	0.21	0.17	Glaucoma (low intraocular pressure);	chr12:106923018	chr12:106954029~106955497:-
LUAD	cis	rs238295	0.805	rs6038214	ENSG00000230563.2	RP5-828H9.1	-3.74	0.000204	0.0253	-0.22	-0.17	Occipital cortical area (total cortical area interaction);	chr20:5589176	chr20:5471207~5475182:+
LUAD	cis	rs9341808	0.667	rs2322632	ENSG00000260645.1	RP11-250B2.5	3.74	0.000204	0.0253	0.16	0.17	Sitting height ratio;	chr6:80135891	chr6:80466958~80469080:+
LUAD	cis	rs72647484	0.554	rs2807343	ENSG00000234397.3	RP11-415K20.1	-3.74	0.000204	0.0253	-0.33	-0.17	Colorectal cancer;	chr1:22221186	chr1:22322840~22323331:-
LUAD	cis	rs72647484	0.554	rs2744730	ENSG00000234397.3	RP11-415K20.1	-3.74	0.000204	0.0253	-0.33	-0.17	Colorectal cancer;	chr1:22221192	chr1:22322840~22323331:-
LUAD	cis	rs4795519	0.66	rs1479363	ENSG00000266313.1	RP11-173M1.4	3.74	0.000204	0.0253	0.2	0.17	Chronic myeloid leukemia;	chr17:27056478	chr17:27333256~27348491:+
LUAD	cis	rs9381040	0.655	rs2268188	ENSG00000161912.16	ADCY10P1	3.74	0.000204	0.0253	0.15	0.17	Alzheimer's disease (late onset);	chr6:41074851	chr6:41101022~41140835:+
LUAD	cis	rs2708977	0.671	rs582014	ENSG00000237510.6	AC008268.2	-3.74	0.000204	0.0253	-0.22	-0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96410089	chr2:95789654~95800166:+
LUAD	cis	rs911555	0.755	rs12436729	ENSG00000259775.1	RP11-45P15.4	3.74	0.000204	0.0253	0.22	0.17	Intelligence (multi-trait analysis);	chr14:103463552	chr14:103331674~103332367:-
LUAD	cis	rs73036520	0.646	rs11667235	ENSG00000242675.1	RPS16P9	3.74	0.000204	0.0253	0.19	0.17	Monocyte percentage of white cells;	chr19:45301106	chr19:45332698~45333124:-
LUAD	cis	rs9309473	0.861	rs6546857	ENSG00000230002.2	ALMS1-IT1	3.74	0.000204	0.0253	0.22	0.17	Metabolite levels;	chr2:73610828	chr2:73456764~73459484:+
LUAD	cis	rs12440869	1	rs4776919	ENSG00000270964.1	RP11-502I4.3	-3.74	0.000204	0.0253	-0.19	-0.17	Peak velocity of the mitral A-wave;	chr15:67312728	chr15:67541072~67542604:-
LUAD	cis	rs1476587	0.573	rs6948837	ENSG00000224046.1	AC005076.5	3.74	0.000204	0.0253	0.21	0.17	Brachial circumference;	chr7:87077602	chr7:87151423~87152420:-
LUAD	cis	rs2288073	0.965	rs10469924	ENSG00000223754.1	AC008073.9	3.74	0.000204	0.0253	0.22	0.17	Venous thromboembolism (SNP x SNP interaction);	chr2:24193361	chr2:24199839~24201698:-
LUAD	cis	rs321358	0.943	rs17537987	ENSG00000271390.1	RP11-89C3.3	3.74	0.000204	0.0253	0.28	0.17	Body mass index;	chr11:111134144	chr11:111089870~111090368:-
LUAD	cis	rs321358	1	rs73019218	ENSG00000271390.1	RP11-89C3.3	3.74	0.000204	0.0253	0.28	0.17	Body mass index;	chr11:111134521	chr11:111089870~111090368:-
LUAD	cis	rs1065852	0.526	rs739296	ENSG00000226450.2	CYP2D8P	-3.74	0.000204	0.0253	-0.14	-0.17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41993944	chr22:42149886~42155001:-
LUAD	cis	rs11168618	0.967	rs1895996	ENSG00000240399.1	RP1-228P16.1	3.74	0.000204	0.0253	0.17	0.17	Adiponectin levels;	chr12:48561788	chr12:48054813~48055591:-
LUAD	cis	rs586688	0.625	rs672696	ENSG00000249007.1	RP11-510N19.5	3.74	0.000204	0.0253	0.2	0.17	Obesity-related traits;	chr1:201709952	chr1:202011370~202015657:+
LUAD	cis	rs4852324	0.536	rs71418714	ENSG00000257800.1	FNBP1P1	3.74	0.000204	0.0253	0.33	0.17	Systemic lupus erythematosus;	chr2:73992759	chr2:74120680~74123218:+
LUAD	cis	rs11893307	0.509	rs17465200	ENSG00000235852.1	AC005540.3	3.74	0.000204	0.0253	0.21	0.17	Mean platelet volume;	chr2:190684910	chr2:190880797~190882059:-
LUAD	cis	rs2898290	0.617	rs13278965	ENSG00000255046.1	RP11-297N6.4	-3.74	0.000204	0.0253	-0.2	-0.17	Systolic blood pressure;	chr8:11609236	chr8:11797928~11802568:-
LUAD	cis	rs10129255	0.828	rs10140989	ENSG00000211967.3	IGHV3-53	-3.74	0.000204	0.0253	-0.13	-0.17	Kawasaki disease;	chr14:106668657	chr14:106592676~106593347:-
LUAD	cis	rs9650657	0.504	rs6601566	ENSG00000255046.1	RP11-297N6.4	3.74	0.000204	0.0253	0.21	0.17	Neuroticism;	chr8:11185465	chr8:11797928~11802568:-
LUAD	cis	rs11018874	0.597	rs4268468	ENSG00000280367.1	RP11-121L10.2	3.74	0.000204	0.0253	0.22	0.17	White blood cell types;	chr11:90153116	chr11:90223153~90226538:+
LUAD	cis	rs801193	0.569	rs11761542	ENSG00000106610.13	STAG3L4	-3.74	0.000204	0.0253	-0.22	-0.17	Aortic root size;	chr7:66753209	chr7:67302621~67321526:+
LUAD	cis	rs10266483	0.921	rs687547	ENSG00000227986.1	TRIM60P18	-3.74	0.000204	0.0253	-0.19	-0.17	Response to statin therapy;	chr7:64284551	chr7:64355078~64356199:+
LUAD	cis	rs2717559	0.522	rs10956987	ENSG00000253741.1	CTD-2292P10.4	3.74	0.000204	0.0253	0.2	0.17	Urinary tract infection frequency;	chr8:142805197	chr8:142702252~142726973:-
LUAD	cis	rs13253073	0.556	rs35194538	ENSG00000263842.1	AC104986.1	-3.74	0.000204	0.0253	-0.34	-0.17	Glucose homeostasis traits;	chr8:99397627	chr8:98999284~98999401:+
LUAD	cis	rs17596685	1	rs346588	ENSG00000271216.1	LINC01050	3.74	0.000204	0.0253	0.25	0.17	C-reactive protein levels;	chr13:42591332	chr13:42810366~42812562:-
LUAD	cis	rs8012947	1	rs56208804	ENSG00000279636.2	LINC00216	-3.74	0.000204	0.0253	-0.19	-0.17	Alcohol consumption in current drinkers;	chr14:58313408	chr14:58288033~58289158:+
LUAD	cis	rs8012947	0.959	rs3945957	ENSG00000279636.2	LINC00216	-3.74	0.000204	0.0253	-0.19	-0.17	Alcohol consumption in current drinkers;	chr14:58316335	chr14:58288033~58289158:+
LUAD	cis	rs8012947	1	rs6573199	ENSG00000279636.2	LINC00216	-3.74	0.000204	0.0253	-0.19	-0.17	Alcohol consumption in current drinkers;	chr14:58318063	chr14:58288033~58289158:+
LUAD	cis	rs4578769	0.505	rs4405649	ENSG00000265943.1	RP11-739L10.1	3.74	0.000204	0.0253	0.22	0.17	Eosinophil percentage of white cells;	chr18:23007590	chr18:22699481~22933764:-
LUAD	cis	rs5752773	0.543	rs134522	ENSG00000272858.1	CTA-292E10.8	3.74	0.000204	0.0253	0.19	0.17	Vertical cup-disc ratio;	chr22:28374594	chr22:28814914~28815662:+
LUAD	cis	rs3617	0.625	rs56019197	ENSG00000242142.1	SERBP1P3	-3.74	0.000204	0.0253	-0.18	-0.17	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52840737	chr3:53064283~53065091:-
LUAD	cis	rs7200543	0.848	rs62039480	ENSG00000260735.1	RP11-72I8.1	-3.74	0.000204	0.0253	-0.19	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15043593	chr16:15094411~15109197:+
LUAD	cis	rs8028182	0.636	rs6495182	ENSG00000246877.1	DNM1P35	3.74	0.000204	0.0253	0.22	0.17	Sudden cardiac arrest;	chr15:75522047	chr15:75727670~75738623:-
LUAD	cis	rs3020736	0.5	rs6002597	ENSG00000273366.1	CTA-989H11.1	3.74	0.000204	0.0253	0.2	0.17	Autism spectrum disorder or schizophrenia;	chr22:42092156	chr22:42278188~42278846:+
LUAD	cis	rs12534093	0.67	rs11764404	ENSG00000234286.1	AC006026.13	-3.74	0.000204	0.0253	-0.24	-0.17	Infant length;Height;	chr7:23547541	chr7:23680195~23680786:-
LUAD	cis	rs6661961	0.644	rs11205002	ENSG00000237975.5	FLG-AS1	-3.74	0.000204	0.0253	-0.23	-0.17	Atopic dermatitis;	chr1:152430863	chr1:152168125~152445456:+
LUAD	cis	rs9467773	1	rs9986382	ENSG00000241549.7	GUSBP2	3.74	0.000204	0.0253	0.18	0.17	Intelligence (multi-trait analysis);	chr6:26550391	chr6:26871484~26956554:-
LUAD	cis	rs792448	0.501	rs2307128	ENSG00000229983.1	RP11-15I11.2	3.74	0.000204	0.0253	0.21	0.17	White blood cell count (basophil);	chr1:212226474	chr1:212168207~212190259:+
LUAD	cis	rs6095360	0.966	rs3795082	ENSG00000222365.1	SNORD12B	-3.74	0.000204	0.0253	-0.17	-0.17	Intelligence (multi-trait analysis);	chr20:49056465	chr20:49280319~49280409:+
LUAD	cis	rs2836950	0.509	rs11088466	ENSG00000232608.1	TIMM9P2	3.74	0.000204	0.0253	0.19	0.17	Menarche (age at onset);	chr21:39208091	chr21:39216624~39217506:+
LUAD	cis	rs7477	0.818	rs3112518	ENSG00000275413.1	CTC-529I10.1	3.74	0.000204	0.0253	0.14	0.17	Amyotrophic lateral sclerosis;	chr17:16340194	chr17:16023323~16023653:-
LUAD	cis	rs6540731	0.782	rs10436976	ENSG00000229983.1	RP11-15I11.2	3.74	0.000204	0.0253	0.21	0.17	Intelligence (childhood);	chr1:212187066	chr1:212168207~212190259:+
LUAD	cis	rs6688613	0.694	rs1476347	ENSG00000225171.2	DUTP6	-3.74	0.000204	0.0253	-0.21	-0.17	Refractive astigmatism;	chr1:166846350	chr1:166868748~166869209:+
LUAD	cis	rs1061377	0.501	rs62308278	ENSG00000249685.1	RP11-360F5.3	3.74	0.000204	0.0253	0.2	0.17	Uric acid levels;	chr4:39161038	chr4:39133913~39135608:+
LUAD	cis	rs7131987	0.718	rs7976961	ENSG00000275476.1	RP11-996F15.4	-3.74	0.000204	0.0253	-0.19	-0.17	QT interval;	chr12:29310155	chr12:29277397~29277882:-
LUAD	cis	rs703842	0.642	rs10876994	ENSG00000270039.1	RP11-571M6.17	-3.74	0.000204	0.0253	-0.22	-0.17	Multiple sclerosis;	chr12:57670954	chr12:57803838~57804415:+
LUAD	cis	rs7617773	0.817	rs9311421	ENSG00000199476.1	Y_RNA	-3.74	0.000204	0.0253	-0.21	-0.17	Coronary artery disease;	chr3:48251588	chr3:48288587~48288694:+
LUAD	cis	rs1007190	0.881	rs12937256	ENSG00000267505.1	CTC-296K1.3	3.74	0.000204	0.0253	0.29	0.17	DNA methylation (variation);	chr17:44904131	chr17:44793199~44794474:+
LUAD	cis	rs9921338	0.887	rs6498183	ENSG00000263080.1	RP11-485G7.5	3.74	0.000204	0.0253	0.23	0.17	Vein graft stenosis in coronary artery bypass grafting;	chr16:11337051	chr16:11341809~11345211:-
LUAD	cis	rs4561483	0.603	rs62038777	ENSG00000261216.1	RP11-166B2.5	3.74	0.000204	0.0253	0.17	0.17	Testicular germ cell tumor;	chr16:11840319	chr16:11908208~11908916:+
LUAD	cis	rs3847687	1	rs3847687	ENSG00000279128.1	RP11-76C10.4	3.74	0.000204	0.0253	0.18	0.17	Longevity;	chr12:131040508	chr12:131022769~131024741:-
LUAD	cis	rs755249	0.959	rs72663520	ENSG00000182109.6	RP11-69E11.4	3.74	0.000204	0.0253	0.2	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39537738	chr1:39522280~39546187:-
LUAD	cis	rs7186908	0.711	rs9923344	ENSG00000260886.1	TAT-AS1	3.74	0.000204	0.0253	0.22	0.17	Liver enzyme levels (alkaline phosphatase);	chr16:72156754	chr16:71565789~71578187:+
LUAD	cis	rs3018712	0.59	rs4930236	ENSG00000212093.1	AP000807.1	-3.74	0.000205	0.0253	-0.22	-0.17	Total body bone mineral density;	chr11:68646532	chr11:68506083~68506166:-
LUAD	cis	rs4660214	0.666	rs1180383	ENSG00000182109.6	RP11-69E11.4	3.74	0.000205	0.0253	0.18	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39380595	chr1:39522280~39546187:-
LUAD	cis	rs11096990	0.593	rs35552004	ENSG00000249685.1	RP11-360F5.3	3.74	0.000205	0.0253	0.2	0.17	Cognitive function;	chr4:39170914	chr4:39133913~39135608:+
LUAD	cis	rs11096990	0.552	rs7655170	ENSG00000249685.1	RP11-360F5.3	3.74	0.000205	0.0253	0.2	0.17	Cognitive function;	chr4:39171984	chr4:39133913~39135608:+
LUAD	cis	rs875971	0.545	rs6460276	ENSG00000222364.1	RNU6-96P	-3.74	0.000205	0.0254	-0.22	-0.17	Aortic root size;	chr7:66182290	chr7:66395191~66395286:+
LUAD	cis	rs2665103	0.61	rs1972460	ENSG00000276710.3	CSPG4P8	-3.74	0.000205	0.0254	-0.15	-0.17	Intelligence (multi-trait analysis);	chr15:82238289	chr15:82459472~82477258:+
LUAD	cis	rs2777491	0.507	rs11854081	ENSG00000247556.5	OIP5-AS1	3.74	0.000205	0.0254	0.21	0.17	Ulcerative colitis;	chr15:41354200	chr15:41283990~41309737:+
LUAD	cis	rs6910061	1	rs9468446	ENSG00000247925.2	RP3-510L9.1	-3.74	0.000205	0.0254	-0.24	-0.17	Diabetic kidney disease;	chr6:11118485	chr6:11173452~11259099:+
LUAD	cis	rs1044826	0.913	rs9831108	ENSG00000214280.3	RP11-553K23.2	-3.74	0.000205	0.0254	-0.2	-0.17	Obesity-related traits;	chr3:139379515	chr3:139582928~139583593:-
LUAD	cis	rs6840360	0.571	rs2407069	ENSG00000270265.1	RP11-731D1.4	-3.74	0.000205	0.0254	-0.19	-0.17	Intelligence (multi-trait analysis);	chr4:151612049	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.571	rs10026670	ENSG00000270265.1	RP11-731D1.4	-3.74	0.000205	0.0254	-0.19	-0.17	Intelligence (multi-trait analysis);	chr4:151618060	chr4:151333775~151353224:-
LUAD	cis	rs6840360	0.571	rs2406976	ENSG00000270265.1	RP11-731D1.4	-3.74	0.000205	0.0254	-0.19	-0.17	Intelligence (multi-trait analysis);	chr4:151619904	chr4:151333775~151353224:-
LUAD	cis	rs2904524	1	rs17107926	ENSG00000257815.4	RP11-611E13.2	-3.74	0.000205	0.0254	-0.25	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70282250	chr12:69904033~70243360:-
LUAD	cis	rs6460942	0.908	rs78682952	ENSG00000226690.5	AC005281.1	3.74	0.000205	0.0254	0.3	0.17	Coronary artery disease;	chr7:12245260	chr7:12496429~12541910:+
LUAD	cis	rs6951245	1	rs2363286	ENSG00000224079.1	AC091729.7	-3.74	0.000205	0.0254	-0.25	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1051989	chr7:1074450~1078036:+
LUAD	cis	rs4683346	0.616	rs6779561	ENSG00000173811.9	CCDC13-AS1	3.74	0.000205	0.0254	0.18	0.17	Granulocyte percentage of myeloid white cells;	chr3:42808326	chr3:42732575~42746768:+
LUAD	cis	rs10876993	0.784	rs1871417	ENSG00000245651.2	RP11-620J15.2	3.74	0.000205	0.0254	0.17	0.17	Celiac disease or Rheumatoid arthritis;	chr12:57625196	chr12:57869835~57896482:-
LUAD	cis	rs6496667	0.865	rs8043146	ENSG00000214433.4	GOLGA2P8	3.74	0.000205	0.0254	0.29	0.17	Rheumatoid arthritis;	chr15:90307141	chr15:90291962~90295683:+
LUAD	cis	rs454217	0.846	rs2119575	ENSG00000277851.1	RP11-756G20.1	3.74	0.000205	0.0254	0.17	0.17	Smoking quantity;	chr12:92309812	chr12:92247756~92363832:-
LUAD	cis	rs4819052	0.851	rs35560973	ENSG00000215447.6	BX322557.10	-3.74	0.000205	0.0254	-0.2	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242658	chr21:45288052~45291738:+
LUAD	cis	rs6121246	0.542	rs6059761	ENSG00000230613.1	HM13-AS1	3.74	0.000205	0.0254	0.26	0.17	Mean corpuscular hemoglobin;	chr20:31522719	chr20:31567707~31573263:-
LUAD	cis	rs4474465	0.85	rs11237546	ENSG00000251323.2	RP11-452H21.4	-3.74	0.000205	0.0254	-0.21	-0.17	Alzheimer's disease (survival time);	chr11:78555878	chr11:78423982~78429836:-
LUAD	cis	rs2243480	1	rs316327	ENSG00000229886.1	RP5-1132H15.3	-3.74	0.000205	0.0254	-0.29	-0.17	Diabetic kidney disease;	chr7:66144214	chr7:66025126~66031544:-
LUAD	cis	rs6460942	0.818	rs116613169	ENSG00000226690.5	AC005281.1	3.74	0.000205	0.0254	0.33	0.17	Coronary artery disease;	chr7:12195043	chr7:12496429~12541910:+
LUAD	cis	rs2836974	0.59	rs9974757	ENSG00000232608.1	TIMM9P2	3.74	0.000205	0.0254	0.2	0.17	Cognitive function;	chr21:39245318	chr21:39216624~39217506:+
LUAD	cis	rs6494488	0.5	rs56239505	ENSG00000239465.1	RP11-330L19.2	3.74	0.000205	0.0254	0.36	0.17	Coronary artery disease;	chr15:64383223	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs72758943	ENSG00000239465.1	RP11-330L19.2	3.74	0.000205	0.0254	0.36	0.17	Coronary artery disease;	chr15:64386502	chr15:64631109~64631914:-
LUAD	cis	rs2274273	0.588	rs9323285	ENSG00000258413.1	RP11-665C16.6	3.74	0.000205	0.0254	0.23	0.17	Protein biomarker;	chr14:55397111	chr14:55262767~55272075:-
LUAD	cis	rs7204230	1	rs8048169	ENSG00000261291.1	RP11-295M3.2	3.74	0.000205	0.0254	0.2	0.17	Fibrinogen;	chr16:53317871	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs16952168	ENSG00000261291.1	RP11-295M3.2	3.74	0.000205	0.0254	0.2	0.17	Fibrinogen;	chr16:53318417	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs16952170	ENSG00000261291.1	RP11-295M3.2	3.74	0.000205	0.0254	0.2	0.17	Fibrinogen;	chr16:53319577	chr16:53168522~53169450:+
LUAD	cis	rs1387259	0.69	rs1601985	ENSG00000257763.1	OR5BK1P	3.74	0.000205	0.0254	0.18	0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48368131	chr12:48355792~48356614:-
LUAD	cis	rs2904524	1	rs2904524	ENSG00000257815.4	RP11-611E13.2	-3.74	0.000205	0.0254	-0.25	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70296305	chr12:69904033~70243360:-
LUAD	cis	rs2904524	0.867	rs77337632	ENSG00000257815.4	RP11-611E13.2	-3.74	0.000205	0.0254	-0.25	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70297167	chr12:69904033~70243360:-
LUAD	cis	rs28510890	0.828	rs56874300	ENSG00000260337.3	RP11-386M24.6	3.74	0.000205	0.0254	0.21	0.17	Lung cancer in ever smokers;	chr15:92583525	chr15:92592574~92596462:-
LUAD	cis	rs2242663	0.705	rs551708	ENSG00000213409.4	RP11-658F2.3	3.74	0.000205	0.0254	0.21	0.17	Bipolar disorder;	chr11:66718672	chr11:66761575~66762399:-
LUAD	cis	rs2242663	0.603	rs610293	ENSG00000213409.4	RP11-658F2.3	-3.74	0.000205	0.0254	-0.2	-0.17	Bipolar disorder;	chr11:66542909	chr11:66761575~66762399:-
LUAD	cis	rs6504108	0.58	rs2924251	ENSG00000264920.1	RP11-6N17.4	3.74	0.000205	0.0254	0.2	0.17	Body mass index;	chr17:48261315	chr17:47891255~47895812:-
LUAD	cis	rs911555	0.755	rs12432803	ENSG00000259775.1	RP11-45P15.4	3.74	0.000205	0.0254	0.22	0.17	Intelligence (multi-trait analysis);	chr14:103463695	chr14:103331674~103332367:-
LUAD	cis	rs4523957	0.893	rs12950555	ENSG00000262333.1	HNRNPA1P16	-3.74	0.000205	0.0254	-0.14	-0.17	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2253616	chr17:2306761~2307715:+
LUAD	cis	rs4523957	0.928	rs9899193	ENSG00000262333.1	HNRNPA1P16	-3.74	0.000205	0.0254	-0.14	-0.17	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2253623	chr17:2306761~2307715:+
LUAD	cis	rs6061231	0.597	rs624313	ENSG00000275437.1	RP5-908M14.10	-3.74	0.000205	0.0254	-0.15	-0.17	Colorectal cancer;	chr20:62352356	chr20:62402236~62405935:-
LUAD	cis	rs7578361	1	rs10469768	ENSG00000231969.1	AC144449.1	-3.74	0.000205	0.0254	-0.24	-0.17	Acute lymphoblastic leukemia (childhood);	chr2:149570678	chr2:149587196~149848233:+
LUAD	cis	rs7578361	0.851	rs4500908	ENSG00000231969.1	AC144449.1	-3.74	0.000205	0.0254	-0.24	-0.17	Acute lymphoblastic leukemia (childhood);	chr2:149571002	chr2:149587196~149848233:+
LUAD	cis	rs703842	0.616	rs10783850	ENSG00000245651.2	RP11-620J15.2	3.74	0.000205	0.0254	0.18	0.17	Multiple sclerosis;	chr12:57835594	chr12:57869835~57896482:-
LUAD	cis	rs1348850	0.75	rs13031008	ENSG00000213963.5	AC074286.1	3.74	0.000205	0.0254	0.2	0.17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177612386	chr2:177283508~177392691:-
LUAD	cis	rs7512552	0.78	rs1260411	ENSG00000275557.1	RP11-353N4.6	3.74	0.000205	0.0254	0.19	0.17	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150409612	chr1:149607765~149612402:+
LUAD	cis	rs4266290	0.818	rs10008644	ENSG00000214846.4	RP11-115L11.1	3.74	0.000205	0.0254	0.25	0.17	Parkinson's disease;	chr4:15718347	chr4:15730962~15731627:-
LUAD	cis	rs4835473	0.9	rs12503074	ENSG00000249741.2	RP11-673E1.3	3.74	0.000205	0.0254	0.2	0.17	Immature fraction of reticulocytes;	chr4:143812560	chr4:143911514~143912053:-
LUAD	cis	rs2243480	1	rs383402	ENSG00000232559.3	GS1-124K5.12	-3.74	0.000205	0.0254	-0.28	-0.17	Diabetic kidney disease;	chr7:66121666	chr7:66554588~66576923:-
LUAD	cis	rs2179367	0.959	rs540538	ENSG00000216906.2	RP11-350J20.9	3.74	0.000205	0.0254	0.21	0.17	Dupuytren's disease;	chr6:149326808	chr6:149904243~149906418:+
LUAD	cis	rs7615952	0.641	rs12488180	ENSG00000250012.1	RP11-124N2.1	-3.74	0.000205	0.0254	-0.23	-0.17	Blood pressure (smoking interaction);	chr3:126063393	chr3:126084220~126095349:+
LUAD	cis	rs763121	0.853	rs2281019	ENSG00000225450.1	RP3-508I15.14	-3.74	0.000205	0.0254	-0.17	-0.17	Menopause (age at onset);	chr22:38668373	chr22:38739003~38749041:+
LUAD	cis	rs763121	0.853	rs2281020	ENSG00000225450.1	RP3-508I15.14	-3.74	0.000205	0.0254	-0.17	-0.17	Menopause (age at onset);	chr22:38668401	chr22:38739003~38749041:+
LUAD	cis	rs763121	0.853	rs2281021	ENSG00000225450.1	RP3-508I15.14	-3.74	0.000205	0.0254	-0.17	-0.17	Menopause (age at onset);	chr22:38668662	chr22:38739003~38749041:+
LUAD	cis	rs763121	0.853	rs5995610	ENSG00000225450.1	RP3-508I15.14	-3.74	0.000205	0.0254	-0.17	-0.17	Menopause (age at onset);	chr22:38668676	chr22:38739003~38749041:+
LUAD	cis	rs728616	0.867	rs1537835	ENSG00000225484.5	NUTM2B-AS1	-3.74	0.000205	0.0254	-0.33	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80070396	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.867	rs7906286	ENSG00000225484.5	NUTM2B-AS1	-3.74	0.000205	0.0254	-0.33	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80074279	chr10:79663088~79826594:-
LUAD	cis	rs498872	0.507	rs10892247	ENSG00000255422.1	AP002954.4	3.74	0.000205	0.0254	0.26	0.17	Glioma;	chr11:118619361	chr11:118704607~118750263:+
LUAD	cis	rs12550612	0.561	rs11784599	ENSG00000253930.1	RP11-1149O23.2	-3.74	0.000205	0.0254	-0.27	-0.17	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23074609	chr8:23189279~23190675:+
LUAD	cis	rs9840812	0.623	rs1145106	ENSG00000239213.4	NCK1-AS1	3.74	0.000205	0.0254	0.21	0.17	Fibrinogen levels;	chr3:136393075	chr3:136841726~136862054:-
LUAD	cis	rs875971	0.789	rs28815324	ENSG00000224316.1	RP11-479O9.2	-3.74	0.000205	0.0254	-0.2	-0.17	Aortic root size;	chr7:66100789	chr7:65773620~65802067:+
LUAD	cis	rs6088590	0.561	rs764597	ENSG00000276073.1	RP5-1125A11.7	-3.74	0.000205	0.0254	-0.16	-0.17	Coronary artery disease;	chr20:34573421	chr20:33985617~33988989:-
LUAD	cis	rs12935418	0.616	rs2602446	ENSG00000278985.1	RP11-303E16.9	-3.74	0.000206	0.0254	-0.16	-0.17	Mean corpuscular volume;	chr16:80984310	chr16:80982319~80984094:-
LUAD	cis	rs5771069	0.933	rs137848	ENSG00000273253.2	RP3-402G11.26	-3.74	0.000206	0.0254	-0.15	-0.17	Ulcerative colitis;	chr22:50001867	chr22:50199090~50200837:-
LUAD	cis	rs5751168	0.834	rs361676	ENSG00000211654.2	IGLV5-37	3.74	0.000206	0.0255	0.25	0.17	Prostate cancer (SNP x SNP interaction);	chr22:22507724	chr22:22427540~22428035:+
LUAD	cis	rs5751168	0.834	rs362184	ENSG00000211654.2	IGLV5-37	3.74	0.000206	0.0255	0.25	0.17	Prostate cancer (SNP x SNP interaction);	chr22:22507744	chr22:22427540~22428035:+
LUAD	cis	rs1823913	0.637	rs2356354	ENSG00000230611.1	HMGB1P27	3.74	0.000206	0.0255	0.19	0.17	Obesity-related traits;	chr2:191270970	chr2:191174233~191174835:+
LUAD	cis	rs34929064	1	rs6980465	ENSG00000230658.1	KLHL7-AS1	3.74	0.000206	0.0255	0.22	0.17	Major depression and alcohol dependence;	chr7:22684914	chr7:23101228~23105703:-
LUAD	cis	rs131777	0.575	rs963980	ENSG00000272666.1	CTA-384D8.35	3.74	0.000206	0.0255	0.2	0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50583688	chr22:50542305~50542906:-
LUAD	cis	rs801193	1	rs2659912	ENSG00000222364.1	RNU6-96P	-3.74	0.000206	0.0255	-0.19	-0.17	Aortic root size;	chr7:66693012	chr7:66395191~66395286:+
LUAD	cis	rs763121	0.853	rs5750668	ENSG00000225450.1	RP3-508I15.14	-3.74	0.000206	0.0255	-0.17	-0.17	Menopause (age at onset);	chr22:38683959	chr22:38739003~38749041:+
LUAD	cis	rs6502050	0.765	rs6502074	ENSG00000275966.1	RP11-1055B8.9	-3.74	0.000206	0.0255	-0.17	-0.17	Life satisfaction;	chr17:82163900	chr17:81345476~81345966:-
LUAD	cis	rs6964587	1	rs7797834	ENSG00000188693.7	CYP51A1-AS1	3.74	0.000206	0.0255	0.2	0.17	Breast cancer;	chr7:92113836	chr7:92134604~92180725:+
LUAD	cis	rs1910358	0.778	rs6452178	ENSG00000248874.4	C5orf17	-3.74	0.000206	0.0255	-0.22	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr5:23986034	chr5:23951348~24178263:+
LUAD	cis	rs17418283	0.686	rs255339	ENSG00000251544.1	MTND5P12	3.74	0.000206	0.0255	0.19	0.17	Bipolar disorder;	chr5:94801110	chr5:94567461~94568909:+
LUAD	cis	rs9925964	0.869	rs2288004	ENSG00000232748.3	RP11-196G11.6	3.74	0.000206	0.0255	0.2	0.17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31042719	chr16:31056460~31062803:+
LUAD	cis	rs9291683	0.609	rs3796836	ENSG00000250413.1	RP11-448G15.1	-3.74	0.000206	0.0255	-0.22	-0.17	Bone mineral density;	chr4:10009721	chr4:10006482~10009725:+
LUAD	cis	rs6568686	0.786	rs3851227	ENSG00000255389.1	C6orf3	-3.74	0.000206	0.0255	-0.23	-0.17	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111505098	chr6:111599875~111602295:+
LUAD	cis	rs794185	0.532	rs304072	ENSG00000231249.1	ITPR1-AS1	-3.74	0.000206	0.0255	-0.18	-0.17	Multiple sclerosis--Brain Glutamate Levels;	chr3:4496134	chr3:4490891~4493163:-
LUAD	cis	rs794185	0.504	rs304071	ENSG00000231249.1	ITPR1-AS1	3.74	0.000206	0.0255	0.18	0.17	Multiple sclerosis--Brain Glutamate Levels;	chr3:4496283	chr3:4490891~4493163:-
LUAD	cis	rs17711722	1	rs17711722	ENSG00000222364.1	RNU6-96P	3.74	0.000206	0.0255	0.19	0.17	Calcium levels;	chr7:65806210	chr7:66395191~66395286:+
LUAD	cis	rs17711722	0.675	rs6947132	ENSG00000222364.1	RNU6-96P	3.74	0.000206	0.0255	0.19	0.17	Calcium levels;	chr7:65808508	chr7:66395191~66395286:+
LUAD	cis	rs6951245	1	rs11763793	ENSG00000224079.1	AC091729.7	-3.74	0.000206	0.0255	-0.27	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054706	chr7:1074450~1078036:+
LUAD	cis	rs6951245	1	rs11763835	ENSG00000224079.1	AC091729.7	-3.74	0.000206	0.0255	-0.27	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054877	chr7:1074450~1078036:+
LUAD	cis	rs6951245	1	rs78861357	ENSG00000224079.1	AC091729.7	-3.74	0.000206	0.0255	-0.27	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1055782	chr7:1074450~1078036:+
LUAD	cis	rs984222	0.501	rs1325941	ENSG00000226172.2	RP4-712E4.1	-3.74	0.000206	0.0255	-0.19	-0.17	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118941193	chr1:119000344~119001392:-
LUAD	cis	rs984222	0.501	rs1750333	ENSG00000226172.2	RP4-712E4.1	-3.74	0.000206	0.0255	-0.19	-0.17	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118941315	chr1:119000344~119001392:-
LUAD	cis	rs9860428	1	rs11714354	ENSG00000242770.2	RP11-180K7.1	-3.74	0.000206	0.0255	-0.18	-0.17	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112871706	chr3:112802478~112812819:+
LUAD	cis	rs2007126	0.706	rs75530048	ENSG00000224797.1	RP11-57C19.6	3.74	0.000206	0.0255	0.27	0.17	LDL peak particle diameter (total fat intake interaction);	chr9:129989077	chr9:130724786~130725050:-
LUAD	cis	rs10029851	0.56	rs3910459	ENSG00000234492.4	RPL34-AS1	3.74	0.000206	0.0255	0.22	0.17	Amyotrophic lateral sclerosis (sporadic);	chr4:108691132	chr4:108538190~108620460:-
LUAD	cis	rs67478160	0.643	rs4900594	ENSG00000272533.1	SNORA28	3.74	0.000206	0.0255	0.17	0.17	Schizophrenia;	chr14:103784669	chr14:103337849~103337974:+
LUAD	cis	rs67478160	0.643	rs3742369	ENSG00000272533.1	SNORA28	3.74	0.000206	0.0255	0.17	0.17	Schizophrenia;	chr14:103784939	chr14:103337849~103337974:+
LUAD	cis	rs41411047	0.826	rs73157025	ENSG00000271711.1	RP11-392O18.2	3.74	0.000206	0.0255	0.34	0.17	Myocardial infarction;	chr3:149931921	chr3:150611262~150611877:-
LUAD	cis	rs11089937	0.667	rs10483107	ENSG00000211640.3	IGLV6-57	3.74	0.000206	0.0255	0.13	0.17	Periodontitis (PAL4Q3);	chr22:22151036	chr22:22195713~22196460:+
LUAD	cis	rs6460942	0.908	rs79175014	ENSG00000226690.5	AC005281.1	3.74	0.000206	0.0255	0.32	0.17	Coronary artery disease;	chr7:12205752	chr7:12496429~12541910:+
LUAD	cis	rs796825	0.597	rs6438576	ENSG00000240661.1	RP11-174O3.3	-3.74	0.000206	0.0255	-0.22	-0.17	HIV-1 susceptibility;	chr3:120338749	chr3:120349510~120367998:+
LUAD	cis	rs3858704	0.517	rs7297186	ENSG00000257539.2	HSPA8P14	-3.74	0.000206	0.0255	-0.22	-0.17	Idiopathic osteonecrosis of the femoral head;	chr12:111340374	chr12:111381867~111385638:+
LUAD	cis	rs4072705	1	rs4836988	ENSG00000236643.1	RP11-175D17.3	-3.74	0.000206	0.0255	-0.19	-0.17	Menarche (age at onset);	chr9:124735294	chr9:124770123~124772927:+
LUAD	cis	rs9900280	1	rs2681178	ENSG00000264808.1	RP11-802D6.1	-3.74	0.000206	0.0255	-0.2	-0.17	Mean platelet volume;	chr17:29494074	chr17:29369717~29390777:-
LUAD	cis	rs9900280	1	rs526664	ENSG00000264808.1	RP11-802D6.1	-3.74	0.000206	0.0255	-0.2	-0.17	Mean platelet volume;	chr17:29497126	chr17:29369717~29390777:-
LUAD	cis	rs9900280	0.967	rs533949	ENSG00000264808.1	RP11-802D6.1	-3.74	0.000206	0.0255	-0.2	-0.17	Mean platelet volume;	chr17:29497882	chr17:29369717~29390777:-
LUAD	cis	rs9900280	1	rs12936923	ENSG00000264808.1	RP11-802D6.1	-3.74	0.000206	0.0255	-0.2	-0.17	Mean platelet volume;	chr17:29499524	chr17:29369717~29390777:-
LUAD	cis	rs9900280	1	rs591433	ENSG00000264808.1	RP11-802D6.1	-3.74	0.000206	0.0255	-0.2	-0.17	Mean platelet volume;	chr17:29505972	chr17:29369717~29390777:-
LUAD	cis	rs7674212	0.507	rs223413	ENSG00000230069.3	LRRC37A15P	3.74	0.000206	0.0255	0.18	0.17	Type 2 diabetes;	chr4:102811709	chr4:102727274~102730721:-
LUAD	cis	rs2408955	0.504	rs11168441	ENSG00000257763.1	OR5BK1P	3.74	0.000206	0.0255	0.17	0.17	Glycated hemoglobin levels;	chr12:48182271	chr12:48355792~48356614:-
LUAD	cis	rs6432852	0.516	rs12477613	ENSG00000232411.1	AC009495.3	3.74	0.000206	0.0255	0.17	0.17	Diabetic kidney disease;	chr2:165860674	chr2:165833048~165839098:-
LUAD	cis	rs7178424	1	rs62008532	ENSG00000259251.2	RP11-643M14.1	-3.74	0.000206	0.0255	-0.18	-0.17	Height;	chr15:62073678	chr15:62060503~62062434:+
LUAD	cis	rs11673344	0.734	rs2551047	ENSG00000267309.1	CTD-2630F21.1	-3.74	0.000206	0.0255	-0.21	-0.17	Obesity-related traits;	chr19:36935174	chr19:36489649~36491040:+
LUAD	cis	rs11673344	0.704	rs551717	ENSG00000267309.1	CTD-2630F21.1	-3.74	0.000206	0.0255	-0.21	-0.17	Obesity-related traits;	chr19:36936977	chr19:36489649~36491040:+
LUAD	cis	rs11673344	0.704	rs826290	ENSG00000267309.1	CTD-2630F21.1	-3.74	0.000206	0.0255	-0.21	-0.17	Obesity-related traits;	chr19:36937543	chr19:36489649~36491040:+
LUAD	cis	rs11673344	0.67	rs35011739	ENSG00000267309.1	CTD-2630F21.1	-3.74	0.000206	0.0255	-0.21	-0.17	Obesity-related traits;	chr19:36943328	chr19:36489649~36491040:+
LUAD	cis	rs11673344	0.704	rs540451	ENSG00000267309.1	CTD-2630F21.1	-3.74	0.000206	0.0255	-0.21	-0.17	Obesity-related traits;	chr19:36944619	chr19:36489649~36491040:+
LUAD	cis	rs7590268	0.789	rs35071299	ENSG00000279873.2	LINC01126	3.74	0.000206	0.0255	0.17	0.17	Orofacial clefts;	chr2:43415898	chr2:43227210~43228855:+
LUAD	cis	rs853679	0.55	rs1225598	ENSG00000280107.1	AL022393.9	-3.74	0.000206	0.0255	-0.22	-0.17	Depression;	chr6:28193021	chr6:28170845~28172521:+
LUAD	cis	rs703842	1	rs10877014	ENSG00000245651.2	RP11-620J15.2	3.74	0.000206	0.0255	0.17	0.17	Multiple sclerosis;	chr12:57773878	chr12:57869835~57896482:-
LUAD	cis	rs526231	0.543	rs246906	ENSG00000250682.4	LINC00491	3.74	0.000206	0.0255	0.21	0.17	Primary biliary cholangitis;	chr5:103230770	chr5:102609156~102671559:-
LUAD	cis	rs2836950	0.565	rs7276046	ENSG00000232608.1	TIMM9P2	3.74	0.000206	0.0255	0.19	0.17	Menarche (age at onset);	chr21:39209367	chr21:39216624~39217506:+
LUAD	cis	rs2836950	0.545	rs8132143	ENSG00000232608.1	TIMM9P2	3.74	0.000206	0.0255	0.19	0.17	Menarche (age at onset);	chr21:39212332	chr21:39216624~39217506:+
LUAD	cis	rs801193	1	rs11773829	ENSG00000222364.1	RNU6-96P	3.74	0.000206	0.0255	0.19	0.17	Aortic root size;	chr7:66676087	chr7:66395191~66395286:+
LUAD	cis	rs1198872	0.892	rs1198868	ENSG00000272275.1	RP11-791G15.2	-3.74	0.000206	0.0255	-0.21	-0.17	Cardiac Troponin-T levels;	chr2:10762287	chr2:10767875~10770058:-
LUAD	cis	rs911555	0.723	rs12894652	ENSG00000259775.1	RP11-45P15.4	3.74	0.000206	0.0255	0.22	0.17	Intelligence (multi-trait analysis);	chr14:103459687	chr14:103331674~103332367:-
LUAD	cis	rs76904798	0.584	rs2263418	ENSG00000260943.1	RP11-476D10.1	-3.74	0.000206	0.0255	-0.29	-0.17	Parkinson's disease;	chr12:40189191	chr12:40140926~40142876:-
LUAD	cis	rs10129255	1	rs10137758	ENSG00000211967.3	IGHV3-53	-3.74	0.000206	0.0255	-0.13	-0.17	Kawasaki disease;	chr14:106697673	chr14:106592676~106593347:-
LUAD	cis	rs7674212	0.507	rs223331	ENSG00000230069.3	LRRC37A15P	-3.74	0.000206	0.0255	-0.18	-0.17	Type 2 diabetes;	chr4:102872408	chr4:102727274~102730721:-
LUAD	cis	rs2281636	1	rs10786569	ENSG00000233690.1	EBAG9P1	3.74	0.000206	0.0255	0.16	0.17	Obesity-related traits;	chr10:99753828	chr10:99697407~99697949:-
LUAD	cis	rs9467773	1	rs9467783	ENSG00000241549.7	GUSBP2	3.74	0.000206	0.0255	0.18	0.17	Intelligence (multi-trait analysis);	chr6:26542666	chr6:26871484~26956554:-
LUAD	cis	rs13113518	1	rs4864548	ENSG00000249700.7	SRD5A3-AS1	-3.74	0.000206	0.0255	-0.17	-0.17	Height;	chr4:55547636	chr4:55363971~55395847:-
LUAD	cis	rs67981189	0.896	rs4391999	ENSG00000269927.1	RP6-91H8.3	3.74	0.000206	0.0255	0.21	0.17	Schizophrenia;	chr14:70978696	chr14:71141125~71143253:-
LUAD	cis	rs4934494	0.727	rs12572012	ENSG00000240996.1	RP11-80H5.7	-3.74	0.000206	0.0255	-0.23	-0.17	Red blood cell count;	chr10:89727892	chr10:89694295~89697928:-
LUAD	cis	rs4934494	0.727	rs3758388	ENSG00000240996.1	RP11-80H5.7	-3.74	0.000206	0.0255	-0.23	-0.17	Red blood cell count;	chr10:89729222	chr10:89694295~89697928:-
LUAD	cis	rs4934494	0.727	rs12783582	ENSG00000240996.1	RP11-80H5.7	-3.74	0.000206	0.0255	-0.23	-0.17	Red blood cell count;	chr10:89735210	chr10:89694295~89697928:-
LUAD	cis	rs910316	0.763	rs175057	ENSG00000279594.1	RP11-950C14.10	-3.74	0.000206	0.0255	-0.19	-0.17	Height;	chr14:75022929	chr14:75011269~75012851:-
LUAD	cis	rs7968440	0.902	rs2684901	ENSG00000272368.2	RP4-605O3.4	3.74	0.000206	0.0255	0.2	0.17	Fibrinogen;	chr12:50657985	chr12:50112197~50165618:+
LUAD	cis	rs7829975	0.514	rs2976926	ENSG00000173295.6	FAM86B3P	3.74	0.000207	0.0255	0.18	0.17	Mood instability;	chr8:8404114	chr8:8228595~8244865:+
LUAD	cis	rs9393777	0.778	rs13219354	ENSG00000219392.1	RP1-265C24.5	-3.74	0.000207	0.0255	-0.33	-0.17	Intelligence (multi-trait analysis);	chr6:27217885	chr6:28115628~28116551:+
LUAD	cis	rs9633740	0.947	rs1878036	ENSG00000226659.1	RP11-137H2.4	-3.74	0.000207	0.0255	-0.28	-0.17	Post bronchodilator FEV1;	chr10:80520381	chr10:80529597~80535942:-
LUAD	cis	rs683250	0.629	rs685398	ENSG00000246067.6	RAB30-AS1	3.74	0.000207	0.0255	0.18	0.17	Subcortical brain region volumes;	chr11:83249233	chr11:83072066~83106719:+
LUAD	cis	rs13113518	0.812	rs1522114	ENSG00000273257.1	RP11-177J6.1	3.74	0.000207	0.0255	0.19	0.17	Height;	chr4:55489895	chr4:55387949~55388271:+
LUAD	cis	rs6544311	0.51	rs1641455	ENSG00000227028.5	SLC8A1-AS1	-3.74	0.000207	0.0255	-0.22	-0.17	QT interval;	chr2:40219119	chr2:39786453~40255209:+
LUAD	cis	rs4947962	0.564	rs11764130	ENSG00000224057.1	EGFR-AS1	3.74	0.000207	0.0255	0.26	0.17	Subjective response to lithium treatment;	chr7:55011098	chr7:55179750~55188934:-
LUAD	cis	rs4947962	0.564	rs2330948	ENSG00000224057.1	EGFR-AS1	3.74	0.000207	0.0255	0.26	0.17	Subjective response to lithium treatment;	chr7:55012663	chr7:55179750~55188934:-
LUAD	cis	rs6496932	0.866	rs4842870	ENSG00000259630.2	CTD-2262B20.1	3.74	0.000207	0.0255	0.23	0.17	Central corneal thickness;Corneal structure;	chr15:85277568	chr15:85415228~85415633:+
LUAD	cis	rs987044	0.834	rs2375013	ENSG00000257221.1	RP11-689B22.2	-3.74	0.000207	0.0255	-0.14	-0.17	Mean platelet volume;	chr12:108801209	chr12:108628687~108641318:+
LUAD	cis	rs6964587	1	rs11772102	ENSG00000188693.7	CYP51A1-AS1	3.74	0.000207	0.0255	0.2	0.17	Breast cancer;	chr7:91929012	chr7:92134604~92180725:+
LUAD	cis	rs6964587	1	rs9969198	ENSG00000188693.7	CYP51A1-AS1	3.74	0.000207	0.0255	0.2	0.17	Breast cancer;	chr7:91938178	chr7:92134604~92180725:+
LUAD	cis	rs11671005	0.735	rs3826682	ENSG00000268543.1	CTD-2619J13.16	-3.74	0.000207	0.0255	-0.24	-0.17	Mean platelet volume;	chr19:58407381	chr19:58418560~58419310:+
LUAD	cis	rs2235573	0.527	rs139885	ENSG00000235237.1	RP1-151B14.6	-3.74	0.000207	0.0255	-0.17	-0.17	Glioma;Glioblastoma;	chr22:37975032	chr22:37166757~37182850:+
LUAD	cis	rs7061710	0.871	rs17565793	ENSG00000271811.1	RP1-79C4.4	-3.74	0.000207	0.0256	-0.24	-0.17	Blood metabolite levels;	chr1:171147128	chr1:170667381~170669425:+
LUAD	cis	rs7976269	0.583	rs4931131	ENSG00000257176.2	RP11-996F15.2	-3.74	0.000207	0.0256	-0.18	-0.17	Male-pattern baldness;	chr12:29015898	chr12:29280418~29317848:-
LUAD	cis	rs911555	0.755	rs975892	ENSG00000259775.1	RP11-45P15.4	-3.74	0.000207	0.0256	-0.22	-0.17	Intelligence (multi-trait analysis);	chr14:103417012	chr14:103331674~103332367:-
LUAD	cis	rs4853525	0.561	rs17746911	ENSG00000235852.1	AC005540.3	3.74	0.000207	0.0256	0.21	0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190854640	chr2:190880797~190882059:-
LUAD	cis	rs4853525	0.59	rs12614693	ENSG00000235852.1	AC005540.3	3.74	0.000207	0.0256	0.21	0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190854882	chr2:190880797~190882059:-
LUAD	cis	rs61884328	0.852	rs17790390	ENSG00000254780.1	RP11-793I11.1	-3.74	0.000207	0.0256	-0.31	-0.17	Total body bone mineral density (age over 60);	chr11:47130346	chr11:47905323~47905607:-
LUAD	cis	rs651907	0.557	rs59596156	ENSG00000244119.1	PDCL3P4	3.74	0.000207	0.0256	0.17	0.17	Colorectal cancer;	chr3:101675373	chr3:101712472~101713191:+
LUAD	cis	rs3805389	0.504	rs10026315	ENSG00000273257.1	RP11-177J6.1	-3.74	0.000207	0.0256	-0.26	-0.17	Waist-to-hip ratio adjusted for body mass index;	chr4:55612195	chr4:55387949~55388271:+
LUAD	cis	rs17098356	1	rs2352088	ENSG00000258926.1	RP11-47I22.1	-3.74	0.000207	0.0256	-0.16	-0.17	Reading and spelling;	chr14:61431238	chr14:61537508~61545287:-
LUAD	cis	rs1023500	0.505	rs134889	ENSG00000226450.2	CYP2D8P	3.74	0.000207	0.0256	0.13	0.17	Schizophrenia;	chr22:42278344	chr22:42149886~42155001:-
LUAD	cis	rs7955901	0.904	rs7956274	ENSG00000258053.1	CTD-2021H9.3	-3.74	0.000207	0.0256	-0.19	-0.17	Type 2 diabetes;	chr12:71030622	chr12:71047402~71118247:-
LUAD	cis	rs7955901	0.904	rs7959965	ENSG00000258053.1	CTD-2021H9.3	-3.74	0.000207	0.0256	-0.19	-0.17	Type 2 diabetes;	chr12:71031384	chr12:71047402~71118247:-
LUAD	cis	rs394563	0.625	rs394526	ENSG00000216906.2	RP11-350J20.9	3.74	0.000207	0.0256	0.21	0.17	Dupuytren's disease;	chr6:149475839	chr6:149904243~149906418:+
LUAD	cis	rs6540731	1	rs6540733	ENSG00000229983.1	RP11-15I11.2	3.74	0.000207	0.0256	0.2	0.17	Intelligence (childhood);	chr1:212219611	chr1:212168207~212190259:+
LUAD	cis	rs1334894	0.818	rs56313753	ENSG00000228559.1	RP3-340B19.3	-3.74	0.000207	0.0256	-0.32	-0.17	Coronary artery disease;	chr6:35540882	chr6:35544632~35545669:+
LUAD	cis	rs11216126	1	rs11216129	ENSG00000280143.1	AP000892.6	-3.74	0.000207	0.0256	-0.28	-0.17	HDL cholesterol;	chr11:116749540	chr11:117204967~117210292:+
LUAD	cis	rs11671005	0.737	rs11671033	ENSG00000268543.1	CTD-2619J13.16	-3.74	0.000207	0.0256	-0.25	-0.17	Mean platelet volume;	chr19:58452302	chr19:58418560~58419310:+
LUAD	cis	rs4971059	0.629	rs9297	ENSG00000160766.13	GBAP1	-3.74	0.000207	0.0256	-0.17	-0.17	Breast cancer;	chr1:155134074	chr1:155213821~155227422:-
LUAD	cis	rs73242632	0.867	rs73242636	ENSG00000269949.1	RP11-738E22.3	3.74	0.000207	0.0256	0.46	0.17	Congenital heart disease (maternal effect);	chr4:57072861	chr4:56960927~56961373:-
LUAD	cis	rs11671005	0.735	rs34873624	ENSG00000268543.1	CTD-2619J13.16	-3.74	0.000207	0.0256	-0.24	-0.17	Mean platelet volume;	chr19:58432035	chr19:58418560~58419310:+
LUAD	cis	rs11671005	0.693	rs34230465	ENSG00000268543.1	CTD-2619J13.16	-3.74	0.000207	0.0256	-0.24	-0.17	Mean platelet volume;	chr19:58432209	chr19:58418560~58419310:+
LUAD	cis	rs11671005	0.735	rs3764529	ENSG00000268543.1	CTD-2619J13.16	-3.74	0.000207	0.0256	-0.24	-0.17	Mean platelet volume;	chr19:58433722	chr19:58418560~58419310:+
LUAD	cis	rs4784934	0.921	rs4784938	ENSG00000260186.4	RP11-481J2.2	3.74	0.000207	0.0256	0.2	0.17	QT interval;	chr16:58433949	chr16:58421326~58462470:+
LUAD	cis	rs6728642	1	rs17037402	ENSG00000230606.9	AC159540.1	3.74	0.000207	0.0256	0.34	0.17	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97358816	chr2:97416165~97433527:-
LUAD	cis	rs11673344	0.523	rs8101392	ENSG00000276846.1	CTD-3220F14.3	3.74	0.000207	0.0256	0.18	0.17	Obesity-related traits;	chr19:37024416	chr19:37314868~37315620:-
LUAD	cis	rs7829975	0.533	rs13274028	ENSG00000253893.2	FAM85B	-3.74	0.000207	0.0256	-0.22	-0.17	Mood instability;	chr8:8871683	chr8:8167819~8226614:-
LUAD	cis	rs8180040	0.934	rs12630641	ENSG00000271161.1	BOLA2P2	3.74	0.000207	0.0256	0.16	0.17	Colorectal cancer;	chr3:47493346	chr3:47499841~47500407:+
LUAD	cis	rs1830074	1	rs1830074	ENSG00000187953.9	PMS2CL	-3.74	0.000207	0.0256	-0.17	-0.17	Body mass index;	chr7:6679043	chr7:6710128~6753862:+
LUAD	cis	rs3805389	0.504	rs1873091	ENSG00000273257.1	RP11-177J6.1	-3.74	0.000207	0.0256	-0.28	-0.17	Waist-to-hip ratio adjusted for body mass index;	chr4:55605266	chr4:55387949~55388271:+
LUAD	cis	rs3805389	0.504	rs17725110	ENSG00000273257.1	RP11-177J6.1	-3.74	0.000207	0.0256	-0.28	-0.17	Waist-to-hip ratio adjusted for body mass index;	chr4:55605855	chr4:55387949~55388271:+
LUAD	cis	rs9313772	0.706	rs6876925	ENSG00000276778.1	RP11-524N5.1	3.74	0.000207	0.0256	0.17	0.17	Blood pressure;	chr5:158400509	chr5:158320683~158409773:-
LUAD	cis	rs62025270	0.848	rs2554	ENSG00000259416.2	RP11-158M2.5	-3.74	0.000207	0.0256	-0.22	-0.17	Idiopathic pulmonary fibrosis;	chr15:85759412	chr15:85754941~85756237:-
LUAD	cis	rs4237845	0.837	rs7954591	ENSG00000257159.1	RP11-58A17.3	3.74	0.000207	0.0256	0.2	0.17	Intelligence (multi-trait analysis);	chr12:57905254	chr12:57967058~57968399:+
LUAD	cis	rs2494663	0.61	rs12048137	ENSG00000223599.1	RP11-216N14.7	3.74	0.000207	0.0256	0.2	0.17	Mean platelet volume;	chr1:154020258	chr1:153852106~153853414:-
LUAD	cis	rs4819052	0.851	rs2838845	ENSG00000215447.6	BX322557.10	-3.74	0.000207	0.0256	-0.2	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250897	chr21:45288052~45291738:+
LUAD	cis	rs6701713	0.919	rs6661489	ENSG00000274245.1	RP11-357P18.2	-3.74	0.000207	0.0256	-0.25	-0.17	Alzheimer's disease (late onset);	chr1:207524699	chr1:207372559~207373252:+
LUAD	cis	rs897984	0.542	rs11865038	ENSG00000232748.3	RP11-196G11.6	-3.74	0.000207	0.0256	-0.21	-0.17	Dementia with Lewy bodies;	chr16:31083850	chr16:31056460~31062803:+
LUAD	cis	rs897984	0.542	rs11864806	ENSG00000232748.3	RP11-196G11.6	-3.74	0.000207	0.0256	-0.21	-0.17	Dementia with Lewy bodies;	chr16:31083883	chr16:31056460~31062803:+
LUAD	cis	rs897984	0.542	rs7199949	ENSG00000232748.3	RP11-196G11.6	-3.74	0.000207	0.0256	-0.21	-0.17	Dementia with Lewy bodies;	chr16:31084843	chr16:31056460~31062803:+
LUAD	cis	rs79149102	0.522	rs1030888	ENSG00000259264.4	RP11-60L3.1	3.74	0.000207	0.0256	0.31	0.17	Lung cancer;	chr15:74550982	chr15:74202705~74221557:+
LUAD	cis	rs13113518	0.841	rs7699867	ENSG00000273257.1	RP11-177J6.1	3.74	0.000207	0.0256	0.19	0.17	Height;	chr4:55483718	chr4:55387949~55388271:+
LUAD	cis	rs4795519	0.778	rs2086265	ENSG00000266313.1	RP11-173M1.4	3.74	0.000207	0.0256	0.21	0.17	Chronic myeloid leukemia;	chr17:27139335	chr17:27333256~27348491:+
LUAD	cis	rs4795519	0.778	rs2046020	ENSG00000266313.1	RP11-173M1.4	3.74	0.000207	0.0256	0.21	0.17	Chronic myeloid leukemia;	chr17:27139988	chr17:27333256~27348491:+
LUAD	cis	rs10876993	0.784	rs10083154	ENSG00000245651.2	RP11-620J15.2	3.74	0.000207	0.0256	0.18	0.17	Celiac disease or Rheumatoid arthritis;	chr12:57627150	chr12:57869835~57896482:-
LUAD	cis	rs6452524	0.534	rs9293328	ENSG00000281327.1	LINC01338	3.74	0.000207	0.0256	0.18	0.17	Hypertension (SNP x SNP interaction);	chr5:83066855	chr5:82850864~82859836:-
LUAD	cis	rs7560272	0.538	rs4852972	ENSG00000163016.8	ALMS1P	-3.74	0.000207	0.0256	-0.18	-0.17	Schizophrenia;	chr2:73689545	chr2:73644919~73685576:+
LUAD	cis	rs987044	0.7	rs56366996	ENSG00000257221.1	RP11-689B22.2	-3.74	0.000207	0.0256	-0.14	-0.17	Mean platelet volume;	chr12:108691080	chr12:108628687~108641318:+
LUAD	cis	rs34779708	0.966	rs10827487	ENSG00000271335.4	RP11-324I22.4	3.74	0.000207	0.0256	0.18	0.17	Inflammatory bowel disease;Crohn's disease;	chr10:35117950	chr10:35314552~35336401:-
LUAD	cis	rs67478160	0.572	rs8016014	ENSG00000272533.1	SNORA28	3.74	0.000207	0.0256	0.17	0.17	Schizophrenia;	chr14:103827461	chr14:103337849~103337974:+
LUAD	cis	rs7017914	0.935	rs56289931	ENSG00000246366.5	RP11-382J12.1	3.74	0.000207	0.0256	0.15	0.17	Bone mineral density;	chr8:70925519	chr8:70608577~70663279:+
LUAD	cis	rs8085804	0.597	rs3910102	ENSG00000276174.1	RP11-687E1.2	-3.74	0.000207	0.0256	-0.23	-0.17	Cognitive performance;	chr18:42639919	chr18:42052705~42053030:+
LUAD	cis	rs17164851	0.569	rs12706927	ENSG00000226380.6	AC058791.1	3.74	0.000208	0.0256	0.3	0.17	Age-related hearing impairment (SNP x SNP interaction);	chr7:130383698	chr7:130876809~130913310:-
LUAD	cis	rs8180040	0.966	rs11705957	ENSG00000271161.1	BOLA2P2	-3.74	0.000208	0.0256	-0.16	-0.17	Colorectal cancer;	chr3:47401772	chr3:47499841~47500407:+
LUAD	cis	rs7017914	0.69	rs11987409	ENSG00000246366.5	RP11-382J12.1	3.74	0.000208	0.0256	0.16	0.17	Bone mineral density;	chr8:71067825	chr8:70608577~70663279:+
LUAD	cis	rs2412819	0.571	rs28410121	ENSG00000166763.7	STRCP1	-3.74	0.000208	0.0256	-0.24	-0.17	Lung cancer;	chr15:43777831	chr15:43699488~43718184:-
LUAD	cis	rs1044826	1	rs13092935	ENSG00000214280.3	RP11-553K23.2	-3.74	0.000208	0.0257	-0.2	-0.17	Obesity-related traits;	chr3:139456622	chr3:139582928~139583593:-
LUAD	cis	rs6494488	0.5	rs72741332	ENSG00000239465.1	RP11-330L19.2	3.74	0.000208	0.0257	0.36	0.17	Coronary artery disease;	chr15:64452591	chr15:64631109~64631914:-
LUAD	cis	rs10752881	1	rs6673559	ENSG00000224468.3	RP11-181K3.4	-3.74	0.000208	0.0257	-0.15	-0.17	Colorectal cancer;	chr1:183014062	chr1:183138402~183141282:-
LUAD	cis	rs10752881	1	rs6697739	ENSG00000224468.3	RP11-181K3.4	-3.74	0.000208	0.0257	-0.15	-0.17	Colorectal cancer;	chr1:183014198	chr1:183138402~183141282:-
LUAD	cis	rs10752881	1	rs12403189	ENSG00000224468.3	RP11-181K3.4	-3.74	0.000208	0.0257	-0.15	-0.17	Colorectal cancer;	chr1:183014697	chr1:183138402~183141282:-
LUAD	cis	rs877819	0.697	rs7094742	ENSG00000228403.1	RP11-563N6.6	-3.74	0.000208	0.0257	-0.18	-0.17	Systemic lupus erythematosus;	chr10:48849280	chr10:48878022~48878649:+
LUAD	cis	rs7172677	0.96	rs11072526	ENSG00000260269.4	CTD-2323K18.1	-3.74	0.000208	0.0257	-0.23	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75140176	chr15:75527150~75601205:-
LUAD	cis	rs6001482	0.638	rs5757569	ENSG00000253818.1	IGLV1-41	-3.74	0.000208	0.0257	-0.17	-0.17	Diastolic blood pressure;	chr22:22230282	chr22:22404207~22404721:+
LUAD	cis	rs4925386	0.84	rs8124907	ENSG00000273619.1	RP5-908M14.9	-3.74	0.000208	0.0257	-0.17	-0.17	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62338071	chr20:62386303~62386970:-
LUAD	cis	rs1862618	0.853	rs10461617	ENSG00000271828.1	CTD-2310F14.1	3.74	0.000208	0.0257	0.24	0.17	Initial pursuit acceleration;	chr5:56808481	chr5:56927874~56929573:+
LUAD	cis	rs2239547	0.563	rs4687560	ENSG00000243224.1	RP5-1157M23.2	-3.74	0.000208	0.0257	-0.19	-0.17	Schizophrenia;	chr3:52864105	chr3:52239258~52241097:+
LUAD	cis	rs1160985	1	rs1160985	ENSG00000214855.8	APOC1P1	-3.74	0.000208	0.0257	-0.19	-0.17	C-reactive protein;LDL cholesterol;Lipid traits;Gut microbiota (functional units);LDL cholesterol levels;	chr19:44900155	chr19:44926804~44931386:+
LUAD	cis	rs9549260	0.564	rs9577107	ENSG00000168852.11	TPTE2P5	3.74	0.000208	0.0257	0.16	0.17	Red blood cell count;	chr13:40697540	chr13:40822296~40921749:-
LUAD	cis	rs800160	0.925	rs800163	ENSG00000236264.4	RPL26P30	-3.74	0.000208	0.0257	-0.23	-0.17	Bacteremia;	chr11:2361739	chr11:2335132~2335776:-
LUAD	cis	rs10129255	0.83	rs61997609	ENSG00000211947.2	IGHV3-21	-3.74	0.000208	0.0257	-0.11	-0.17	Kawasaki disease;	chr14:106692376	chr14:106235064~106235594:-
LUAD	cis	rs2997457	0.527	rs7553840	ENSG00000241188.3	RN7SL165P	-3.74	0.000208	0.0257	-0.26	-0.17	Facial morphology (factor 16);	chr1:26054314	chr1:26814822~26815112:+
LUAD	cis	rs9517320	1	rs12864890	ENSG00000231194.1	FARP1-AS1	3.74	0.000208	0.0257	0.19	0.17	Longevity;	chr13:98474203	chr13:98435405~98435840:-
LUAD	cis	rs12025262	0.546	rs10754539	ENSG00000225300.1	RP11-1086F11.1	-3.74	0.000208	0.0257	-0.17	-0.17	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr1:247202128	chr1:246605873~246608102:+
LUAD	cis	rs7577696	0.889	rs212731	ENSG00000276334.1	AL133243.1	3.74	0.000208	0.0257	0.2	0.17	Inflammatory biomarkers;	chr2:32247081	chr2:32521927~32523547:+
LUAD	cis	rs36093844	0.626	rs12281958	ENSG00000279742.1	RP11-700A24.1	-3.74	0.000208	0.0257	-0.2	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85998907	chr11:85852557~85854943:-
LUAD	cis	rs599083	0.53	rs546803	ENSG00000212093.1	AP000807.1	-3.74	0.000208	0.0257	-0.19	-0.17	Bone mineral density (spine);	chr11:68418924	chr11:68506083~68506166:-
LUAD	cis	rs9308731	0.568	rs28723045	ENSG00000227992.1	AC108463.2	-3.74	0.000208	0.0257	-0.2	-0.17	Chronic lymphocytic leukemia;	chr2:111178121	chr2:111203964~111206215:-
LUAD	cis	rs7017914	0.905	rs3110246	ENSG00000246366.5	RP11-382J12.1	3.74	0.000208	0.0257	0.15	0.17	Bone mineral density;	chr8:71022378	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.905	rs3110250	ENSG00000246366.5	RP11-382J12.1	3.74	0.000208	0.0257	0.15	0.17	Bone mineral density;	chr8:71024149	chr8:70608577~70663279:+
LUAD	cis	rs2390582	0.722	rs1361009	ENSG00000233593.5	RP4-665J23.1	3.74	0.000208	0.0257	0.24	0.17	Coronary artery calcification;	chr1:90535500	chr1:90782986~90851650:-
LUAD	cis	rs4237845	0.537	rs7969844	ENSG00000245651.2	RP11-620J15.2	3.74	0.000208	0.0257	0.18	0.17	Intelligence (multi-trait analysis);	chr12:57884488	chr12:57869835~57896482:-
LUAD	cis	rs4474465	0.85	rs7938816	ENSG00000251323.2	RP11-452H21.4	-3.74	0.000208	0.0257	-0.22	-0.17	Alzheimer's disease (survival time);	chr11:78555181	chr11:78423982~78429836:-
LUAD	cis	rs987044	0.867	rs7980055	ENSG00000257221.1	RP11-689B22.2	-3.74	0.000208	0.0257	-0.14	-0.17	Mean platelet volume;	chr12:108799565	chr12:108628687~108641318:+
LUAD	cis	rs9951698	0.66	rs7229870	ENSG00000267480.1	RP11-703I16.1	-3.74	0.000208	0.0257	-0.2	-0.17	Intelligence (multi-trait analysis);	chr18:12994469	chr18:12031178~12032181:-
LUAD	cis	rs9951698	0.667	rs28641764	ENSG00000267480.1	RP11-703I16.1	-3.74	0.000208	0.0257	-0.2	-0.17	Intelligence (multi-trait analysis);	chr18:12994784	chr18:12031178~12032181:-
LUAD	cis	rs9438901	0.614	rs2375278	ENSG00000224183.1	SDHDP6	3.74	0.000208	0.0257	0.31	0.17	Red cell distribution width;	chr1:25202547	chr1:25294164~25294643:-
LUAD	cis	rs724950	0.624	rs4833376	ENSG00000248394.1	FOSL1P1	3.74	0.000208	0.0257	0.21	0.17	Obesity-related traits;	chr4:127422607	chr4:128155389~128156204:+
LUAD	cis	rs4237845	0.837	rs7954957	ENSG00000257159.1	RP11-58A17.3	3.74	0.000208	0.0257	0.2	0.17	Intelligence (multi-trait analysis);	chr12:57905467	chr12:57967058~57968399:+
LUAD	cis	rs5758511	0.68	rs739146	ENSG00000233903.2	Z83851.4	3.74	0.000208	0.0257	0.24	0.17	Birth weight;	chr22:42264408	chr22:42276355~42277052:+
LUAD	cis	rs875971	0.862	rs778720	ENSG00000273448.1	RP11-166O4.6	-3.74	0.000208	0.0257	-0.16	-0.17	Aortic root size;	chr7:66381288	chr7:67333047~67334383:+
LUAD	cis	rs7660883	1	rs2045592	ENSG00000251411.1	RP11-397E7.4	-3.74	0.000208	0.0257	-0.19	-0.17	HDL cholesterol levels;	chr4:87093194	chr4:86913266~86914817:-
LUAD	cis	rs7772486	0.624	rs9485018	ENSG00000235652.6	RP11-545I5.3	-3.74	0.000208	0.0257	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145704595	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.846	rs1935616	ENSG00000235652.6	RP11-545I5.3	3.74	0.000208	0.0257	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145622376	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.846	rs9376954	ENSG00000235652.6	RP11-545I5.3	3.74	0.000208	0.0257	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145622601	chr6:145799409~145886585:+
LUAD	cis	rs6570726	0.846	rs9399559	ENSG00000235652.6	RP11-545I5.3	3.74	0.000208	0.0257	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145624642	chr6:145799409~145886585:+
LUAD	cis	rs412050	0.547	rs61763401	ENSG00000224086.5	LL22NC03-86G7.1	-3.74	0.000208	0.0257	-0.22	-0.17	Attention deficit hyperactivity disorder;	chr22:21785558	chr22:21938293~21977632:+
LUAD	cis	rs9595908	0.785	rs9596058	ENSG00000281026.1	N4BP2L2-IT2	-3.74	0.000208	0.0257	-0.1	-0.17	Body mass index;	chr13:32669938	chr13:32504506~32509395:-
LUAD	cis	rs910316	0.726	rs175040	ENSG00000259138.1	RP11-950C14.7	-3.74	0.000208	0.0257	-0.18	-0.17	Height;	chr14:75002852	chr14:75127153~75136930:+
LUAD	cis	rs526231	0.819	rs26234	ENSG00000175749.11	EIF3KP1	3.74	0.000208	0.0257	0.22	0.17	Primary biliary cholangitis;	chr5:103261455	chr5:103032376~103033031:+
LUAD	cis	rs7968440	0.966	rs1521516	ENSG00000272368.2	RP4-605O3.4	3.74	0.000208	0.0257	0.2	0.17	Fibrinogen;	chr12:50661925	chr12:50112197~50165618:+
LUAD	cis	rs853679	0.55	rs1233699	ENSG00000280107.1	AL022393.9	-3.74	0.000208	0.0257	-0.21	-0.17	Depression;	chr6:28201380	chr6:28170845~28172521:+
LUAD	cis	rs1979679	0.842	rs1841964	ENSG00000278733.1	RP11-425D17.1	-3.74	0.000208	0.0257	-0.21	-0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28190100	chr12:28185625~28186190:-
LUAD	cis	rs7264396	0.561	rs6060741	ENSG00000260032.1	LINC00657	3.74	0.000208	0.0257	0.22	0.17	Total cholesterol levels;	chr20:35983562	chr20:36045622~36050960:-
LUAD	cis	rs2880765	0.546	rs11639291	ENSG00000202081.1	RNU6-1280P	3.74	0.000208	0.0257	0.2	0.17	Coronary artery disease;	chr15:85520899	chr15:85651522~85651628:-
LUAD	cis	rs9896933	0.667	rs2253131	ENSG00000262663.1	RP11-497H17.1	3.74	0.000208	0.0257	0.2	0.17	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr17:82738671	chr17:82918282~82918785:+
LUAD	cis	rs9309473	0.583	rs6718864	ENSG00000230002.2	ALMS1-IT1	3.74	0.000208	0.0257	0.19	0.17	Metabolite levels;	chr2:73347463	chr2:73456764~73459484:+
LUAD	cis	rs7246657	0.882	rs4803539	ENSG00000226686.6	LINC01535	-3.74	0.000208	0.0257	-0.24	-0.17	Coronary artery calcification;	chr19:37406620	chr19:37251912~37265535:+
LUAD	cis	rs7477	0.818	rs917609	ENSG00000275413.1	CTC-529I10.1	3.74	0.000208	0.0257	0.14	0.17	Amyotrophic lateral sclerosis;	chr17:16343294	chr17:16023323~16023653:-
LUAD	cis	rs7477	0.818	rs3112525	ENSG00000275413.1	CTC-529I10.1	3.74	0.000208	0.0257	0.14	0.17	Amyotrophic lateral sclerosis;	chr17:16343560	chr17:16023323~16023653:-
LUAD	cis	rs7477	0.818	rs3112527	ENSG00000275413.1	CTC-529I10.1	3.74	0.000208	0.0257	0.14	0.17	Amyotrophic lateral sclerosis;	chr17:16345592	chr17:16023323~16023653:-
LUAD	cis	rs6471393	0.862	rs11994625	ENSG00000253848.1	RP11-10N23.5	3.74	0.000209	0.0257	0.21	0.17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93760149	chr8:93741193~93744534:+
LUAD	cis	rs6471393	0.83	rs6981752	ENSG00000253848.1	RP11-10N23.5	3.74	0.000209	0.0257	0.21	0.17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93761046	chr8:93741193~93744534:+
LUAD	cis	rs12440869	1	rs7183186	ENSG00000270964.1	RP11-502I4.3	3.74	0.000209	0.0257	0.19	0.17	Peak velocity of the mitral A-wave;	chr15:67321754	chr15:67541072~67542604:-
LUAD	cis	rs516805	0.847	rs520046	ENSG00000279114.1	RP3-425C14.5	-3.74	0.000209	0.0257	-0.18	-0.17	Lymphocyte counts;	chr6:122446048	chr6:122471923~122484161:+
LUAD	cis	rs9593057	0.786	rs73487637	ENSG00000234835.1	PHBP13	-3.74	0.000209	0.0257	-0.32	-0.17	Lobe attachment (rater-scored or self-reported);	chr13:35006786	chr13:35251070~35251829:+
LUAD	cis	rs13113518	0.783	rs6843997	ENSG00000273257.1	RP11-177J6.1	3.74	0.000209	0.0258	0.19	0.17	Height;	chr4:55508982	chr4:55387949~55388271:+
LUAD	cis	rs703842	0.928	rs724834	ENSG00000245651.2	RP11-620J15.2	3.74	0.000209	0.0258	0.18	0.17	Multiple sclerosis;	chr12:57786633	chr12:57869835~57896482:-
LUAD	cis	rs6088590	0.561	rs6059932	ENSG00000276073.1	RP5-1125A11.7	-3.74	0.000209	0.0258	-0.16	-0.17	Coronary artery disease;	chr20:34587662	chr20:33985617~33988989:-
LUAD	cis	rs6088590	0.561	rs6087605	ENSG00000276073.1	RP5-1125A11.7	-3.74	0.000209	0.0258	-0.16	-0.17	Coronary artery disease;	chr20:34592820	chr20:33985617~33988989:-
LUAD	cis	rs2274273	0.624	rs11158034	ENSG00000258413.1	RP11-665C16.6	-3.74	0.000209	0.0258	-0.23	-0.17	Protein biomarker;	chr14:55286842	chr14:55262767~55272075:-
LUAD	cis	rs748404	0.589	rs62020616	ENSG00000249839.1	AC011330.5	-3.74	0.000209	0.0258	-0.27	-0.17	Lung cancer;	chr15:43558554	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.626	rs60367691	ENSG00000249839.1	AC011330.5	-3.74	0.000209	0.0258	-0.27	-0.17	Lung cancer;	chr15:43559201	chr15:43663654~43684339:-
LUAD	cis	rs73186030	0.764	rs4491840	ENSG00000272758.4	RP11-299J3.8	3.74	0.000209	0.0258	0.22	0.17	Serum parathyroid hormone levels;	chr3:122361900	chr3:122416207~122443180:+
LUAD	cis	rs763121	0.962	rs6001193	ENSG00000225450.1	RP3-508I15.14	-3.74	0.000209	0.0258	-0.16	-0.17	Menopause (age at onset);	chr22:38678732	chr22:38739003~38749041:+
LUAD	cis	rs12073359	1	rs7519918	ENSG00000223945.2	RP11-458I7.1	3.74	0.000209	0.0258	0.22	0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150041043	chr1:150053864~150055034:+
LUAD	cis	rs12413361	1	rs12413361	ENSG00000272914.1	RP11-330O11.3	-3.74	0.000209	0.0258	-0.2	-0.17	Height;	chr10:30838237	chr10:30831828~30833387:-
LUAD	cis	rs76878669	0.561	rs56321771	ENSG00000213409.4	RP11-658F2.3	3.74	0.000209	0.0258	0.2	0.17	Educational attainment (years of education);	chr11:66393601	chr11:66761575~66762399:-
LUAD	cis	rs76878669	0.561	rs4630308	ENSG00000213409.4	RP11-658F2.3	3.74	0.000209	0.0258	0.2	0.17	Educational attainment (years of education);	chr11:66395116	chr11:66761575~66762399:-
LUAD	cis	rs76878669	0.561	rs12420203	ENSG00000213409.4	RP11-658F2.3	3.74	0.000209	0.0258	0.2	0.17	Educational attainment (years of education);	chr11:66396323	chr11:66761575~66762399:-
LUAD	cis	rs3738443	0.594	rs6664697	ENSG00000225300.1	RP11-1086F11.1	3.74	0.000209	0.0258	0.18	0.17	Alcohol dependence;	chr1:247217308	chr1:246605873~246608102:+
LUAD	cis	rs7893279	0.505	rs12780652	ENSG00000225527.1	RP11-383B4.4	3.74	0.000209	0.0258	0.25	0.17	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18652685	chr10:18531849~18533336:-
LUAD	cis	rs4713118	0.662	rs9393881	ENSG00000280107.1	AL022393.9	-3.74	0.000209	0.0258	-0.21	-0.17	Parkinson's disease;	chr6:28055973	chr6:28170845~28172521:+
LUAD	cis	rs6964587	0.934	rs7793861	ENSG00000188693.7	CYP51A1-AS1	-3.74	0.000209	0.0258	-0.2	-0.17	Breast cancer;	chr7:92113414	chr7:92134604~92180725:+
LUAD	cis	rs13434995	0.589	rs62306207	ENSG00000273257.1	RP11-177J6.1	-3.74	0.000209	0.0258	-0.23	-0.17	Adiponectin levels;	chr4:55384548	chr4:55387949~55388271:+
LUAD	cis	rs72843166	0.812	rs8071332	ENSG00000226797.1	AC015923.1	-3.74	0.000209	0.0258	-0.2	-0.17	Intelligence (multi-trait analysis);	chr17:63064592	chr17:63381231~63414312:-
LUAD	cis	rs7727544	0.582	rs10075459	ENSG00000233006.5	AC034220.3	3.74	0.000209	0.0258	0.15	0.17	Blood metabolite levels;	chr5:132205670	chr5:132311285~132369916:-
LUAD	cis	rs6496932	0.503	rs11074205	ENSG00000259630.2	CTD-2262B20.1	-3.74	0.000209	0.0258	-0.22	-0.17	Central corneal thickness;Corneal structure;	chr15:85401381	chr15:85415228~85415633:+
LUAD	cis	rs7772486	0.623	rs735535	ENSG00000235652.6	RP11-545I5.3	-3.74	0.000209	0.0258	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145715693	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.566	rs735536	ENSG00000235652.6	RP11-545I5.3	-3.74	0.000209	0.0258	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145715696	chr6:145799409~145886585:+
LUAD	cis	rs7017914	0.967	rs1471114	ENSG00000246366.5	RP11-382J12.1	3.74	0.000209	0.0258	0.15	0.17	Bone mineral density;	chr8:70763312	chr8:70608577~70663279:+
LUAD	cis	rs577676	0.586	rs2022373	ENSG00000271811.1	RP1-79C4.4	3.74	0.000209	0.0258	0.21	0.17	Prevalent atrial fibrillation;	chr1:170619453	chr1:170667381~170669425:+
LUAD	cis	rs13113518	1	rs13146987	ENSG00000273257.1	RP11-177J6.1	3.74	0.000209	0.0258	0.18	0.17	Height;	chr4:55491628	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs7677085	ENSG00000273257.1	RP11-177J6.1	3.74	0.000209	0.0258	0.18	0.17	Height;	chr4:55495801	chr4:55387949~55388271:+
LUAD	cis	rs13113518	0.966	rs12510681	ENSG00000273257.1	RP11-177J6.1	3.74	0.000209	0.0258	0.18	0.17	Height;	chr4:55496737	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs12500162	ENSG00000273257.1	RP11-177J6.1	3.74	0.000209	0.0258	0.18	0.17	Height;	chr4:55496933	chr4:55387949~55388271:+
LUAD	cis	rs13108904	0.901	rs2293634	ENSG00000196810.4	CTBP1-AS2	3.74	0.000209	0.0258	0.19	0.17	Obesity-related traits;	chr4:1297923	chr4:1249300~1288291:+
LUAD	cis	rs6763848	0.923	rs6786404	ENSG00000214073.2	RPL21P17	-3.74	0.000209	0.0258	-0.17	-0.17	Prostate cancer (SNP x SNP interaction);	chr3:1473590	chr3:1905651~1906125:+
LUAD	cis	rs761746	0.739	rs9621317	ENSG00000236132.1	CTA-440B3.1	-3.74	0.000209	0.0258	-0.24	-0.17	Intelligence;	chr22:31698060	chr22:31816379~31817491:-
LUAD	cis	rs6832769	0.925	rs6829182	ENSG00000272969.1	RP11-528I4.2	3.74	0.000209	0.0258	0.17	0.17	Personality dimensions;	chr4:55587989	chr4:55547112~55547889:+
LUAD	cis	rs12122100	0.651	rs12743228	ENSG00000244371.2	PFN1P8	3.74	0.000209	0.0258	0.22	0.17	HIV-1 control;	chr1:147076727	chr1:146957117~146957659:-
LUAD	cis	rs8014252	1	rs114864695	ENSG00000274818.1	RP1-292L20.3	3.74	0.000209	0.0258	0.28	0.17	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70458238	chr14:70906657~70907111:-
LUAD	cis	rs11216126	1	rs12421652	ENSG00000254851.1	RP11-109L13.1	3.74	0.000209	0.0258	0.32	0.17	HDL cholesterol;	chr11:116755159	chr11:117135528~117138582:+
LUAD	cis	rs11216126	1	rs4938309	ENSG00000254851.1	RP11-109L13.1	3.74	0.000209	0.0258	0.32	0.17	HDL cholesterol;	chr11:116756339	chr11:117135528~117138582:+
LUAD	cis	rs853679	0.607	rs68188794	ENSG00000219392.1	RP1-265C24.5	-3.74	0.000209	0.0258	-0.39	-0.17	Depression;	chr6:28112999	chr6:28115628~28116551:+
LUAD	cis	rs13113518	1	rs3805148	ENSG00000273257.1	RP11-177J6.1	3.74	0.000209	0.0258	0.18	0.17	Height;	chr4:55440643	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs11133380	ENSG00000273257.1	RP11-177J6.1	3.74	0.000209	0.0258	0.18	0.17	Height;	chr4:55441110	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs12510110	ENSG00000273257.1	RP11-177J6.1	3.74	0.000209	0.0258	0.18	0.17	Height;	chr4:55441567	chr4:55387949~55388271:+
LUAD	cis	rs13113518	0.966	rs12510990	ENSG00000273257.1	RP11-177J6.1	3.74	0.000209	0.0258	0.18	0.17	Height;	chr4:55441907	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs3805149	ENSG00000273257.1	RP11-177J6.1	3.74	0.000209	0.0258	0.18	0.17	Height;	chr4:55442184	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs11945370	ENSG00000273257.1	RP11-177J6.1	3.74	0.000209	0.0258	0.18	0.17	Height;	chr4:55442875	chr4:55387949~55388271:+
LUAD	cis	rs13113518	0.966	rs12647677	ENSG00000273257.1	RP11-177J6.1	3.74	0.000209	0.0258	0.18	0.17	Height;	chr4:55444253	chr4:55387949~55388271:+
LUAD	cis	rs17507216	0.588	rs28864981	ENSG00000276710.3	CSPG4P8	-3.74	0.000209	0.0258	-0.19	-0.17	Excessive daytime sleepiness;	chr15:82695420	chr15:82459472~82477258:+
LUAD	cis	rs17507216	0.628	rs8032321	ENSG00000276710.3	CSPG4P8	-3.74	0.000209	0.0258	-0.19	-0.17	Excessive daytime sleepiness;	chr15:82698956	chr15:82459472~82477258:+
LUAD	cis	rs17507216	0.628	rs8040488	ENSG00000276710.3	CSPG4P8	-3.74	0.000209	0.0258	-0.19	-0.17	Excessive daytime sleepiness;	chr15:82699081	chr15:82459472~82477258:+
LUAD	cis	rs7937127	0.744	rs72900904	ENSG00000254907.1	RP11-484D2.2	3.74	0.000209	0.0258	0.28	0.17	Fibrinogen levels;	chr11:43371534	chr11:43328748~43359296:-
LUAD	cis	rs7937127	0.744	rs17508556	ENSG00000254907.1	RP11-484D2.2	3.74	0.000209	0.0258	0.28	0.17	Fibrinogen levels;	chr11:43375340	chr11:43328748~43359296:-
LUAD	cis	rs9549260	0.816	rs964901	ENSG00000229456.1	RLIMP1	3.74	0.000209	0.0258	0.18	0.17	Red blood cell count;	chr13:40674561	chr13:40618738~40621348:+
LUAD	cis	rs6687758	0.945	rs12033415	ENSG00000238042.4	RP11-815M8.1	3.74	0.000209	0.0258	0.23	0.17	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221981726	chr1:221880981~221978523:-
LUAD	cis	rs6951245	0.554	rs10246354	ENSG00000229043.2	AC091729.9	-3.74	0.000209	0.0258	-0.23	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1092820	chr7:1160374~1165267:+
LUAD	cis	rs2836950	0.84	rs12482317	ENSG00000255568.3	BRWD1-AS2	-3.74	0.000209	0.0258	-0.17	-0.17	Menarche (age at onset);	chr21:39216315	chr21:39313935~39314962:+
LUAD	cis	rs2274273	0.624	rs8015211	ENSG00000258413.1	RP11-665C16.6	-3.74	0.000209	0.0258	-0.23	-0.17	Protein biomarker;	chr14:55374729	chr14:55262767~55272075:-
LUAD	cis	rs56050415	1	rs28690720	ENSG00000277144.1	RP11-59H7.4	3.74	0.000209	0.0258	0.29	0.17	Metabolite levels (lipoprotein measures);	chr15:58281634	chr15:59115547~59116089:-
LUAD	cis	rs755249	0.917	rs61232586	ENSG00000237624.1	OXCT2P1	3.74	0.00021	0.0258	0.26	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39620685	chr1:39514956~39516490:+
LUAD	cis	rs7430456	0.81	rs6443489	ENSG00000231574.4	RP11-91K9.1	-3.74	0.00021	0.0258	-0.19	-0.17	Breast cancer;	chr3:177737489	chr3:177816865~177899224:+
LUAD	cis	rs6121246	0.559	rs6060599	ENSG00000230613.1	HM13-AS1	3.74	0.00021	0.0258	0.21	0.17	Mean corpuscular hemoglobin;	chr20:31669951	chr20:31567707~31573263:-
LUAD	cis	rs1075265	0.68	rs805396	ENSG00000272156.1	RP11-477N3.1	-3.74	0.00021	0.0258	-0.2	-0.17	Chronotype;Morning vs. evening chronotype;	chr2:53882314	chr2:54082554~54085066:+
LUAD	cis	rs750134	1	rs12582815	ENSG00000257221.1	RP11-689B22.2	-3.74	0.00021	0.0258	-0.23	-0.17	Low high density lipoprotein cholesterol levels;	chr12:108723602	chr12:108628687~108641318:+
LUAD	cis	rs13113518	0.966	rs11942472	ENSG00000223305.1	RN7SKP30	3.74	0.00021	0.0258	0.19	0.17	Height;	chr4:55574959	chr4:55540502~55540835:-
LUAD	cis	rs2253762	0.54	rs77032313	ENSG00000276742.1	RP11-500G22.4	3.74	0.00021	0.0258	0.25	0.17	Breast cancer;	chr10:121995687	chr10:121956782~121957098:+
LUAD	cis	rs2274273	0.905	rs2075601	ENSG00000258413.1	RP11-665C16.6	-3.74	0.00021	0.0258	-0.21	-0.17	Protein biomarker;	chr14:55142516	chr14:55262767~55272075:-
LUAD	cis	rs877819	0.697	rs10776651	ENSG00000228403.1	RP11-563N6.6	-3.74	0.00021	0.0258	-0.18	-0.17	Systemic lupus erythematosus;	chr10:48876481	chr10:48878022~48878649:+
LUAD	cis	rs6479527	0.625	rs1933667	ENSG00000227666.1	CYCSP24	3.74	0.00021	0.0258	0.26	0.17	Esophageal adenocarcinoma;	chr9:93981827	chr9:94038030~94038345:+
LUAD	cis	rs11673344	0.526	rs17244713	ENSG00000267254.4	ZNF790-AS1	-3.74	0.00021	0.0259	-0.21	-0.17	Obesity-related traits;	chr19:37559938	chr19:36797518~36828115:+
LUAD	cis	rs11673344	0.526	rs8111790	ENSG00000267254.4	ZNF790-AS1	-3.74	0.00021	0.0259	-0.21	-0.17	Obesity-related traits;	chr19:37565861	chr19:36797518~36828115:+
LUAD	cis	rs2274273	0.87	rs6573009	ENSG00000258413.1	RP11-665C16.6	-3.74	0.00021	0.0259	-0.21	-0.17	Protein biomarker;	chr14:55215606	chr14:55262767~55272075:-
LUAD	cis	rs60695258	1	rs60695258	ENSG00000251411.1	RP11-397E7.4	-3.74	0.00021	0.0259	-0.18	-0.17	Hematocrit;	chr4:87101557	chr4:86913266~86914817:-
LUAD	cis	rs8180040	0.966	rs13059519	ENSG00000271161.1	BOLA2P2	3.74	0.00021	0.0259	0.16	0.17	Colorectal cancer;	chr3:47498479	chr3:47499841~47500407:+
LUAD	cis	rs7142881	0.815	rs11620846	ENSG00000258525.1	RP11-829H16.3	-3.74	0.00021	0.0259	-0.19	-0.17	Response to iloperidone treatment (QT prolongation);	chr14:31724716	chr14:30876179~30889808:-
LUAD	cis	rs728616	0.867	rs17883671	ENSG00000234382.2	RP11-40F6.1	-3.74	0.00021	0.0259	-0.41	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79935437	chr10:80233664~80245367:+
LUAD	cis	rs728616	0.867	rs17885031	ENSG00000234382.2	RP11-40F6.1	-3.74	0.00021	0.0259	-0.41	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79936335	chr10:80233664~80245367:+
LUAD	cis	rs2342371	0.848	rs5016648	ENSG00000273013.1	CTD-2002J20.1	3.74	0.00021	0.0259	0.21	0.17	Fat distribution (HIV);	chr3:196481118	chr3:196474801~196475394:+
LUAD	cis	rs9894429	0.608	rs8477	ENSG00000263853.1	AC139530.1	-3.74	0.00021	0.0259	-0.18	-0.17	Eye color traits;	chr17:81651029	chr17:81676001~81676086:+
LUAD	cis	rs2281636	0.894	rs10883396	ENSG00000233690.1	EBAG9P1	3.74	0.00021	0.0259	0.16	0.17	Obesity-related traits;	chr10:99647135	chr10:99697407~99697949:-
LUAD	cis	rs2281636	0.894	rs12771048	ENSG00000233690.1	EBAG9P1	3.74	0.00021	0.0259	0.16	0.17	Obesity-related traits;	chr10:99649691	chr10:99697407~99697949:-
LUAD	cis	rs7617773	0.784	rs9850672	ENSG00000199476.1	Y_RNA	-3.74	0.00021	0.0259	-0.22	-0.17	Coronary artery disease;	chr3:48259682	chr3:48288587~48288694:+
LUAD	cis	rs911119	0.913	rs6036463	ENSG00000270001.1	RP11-218C14.8	3.74	0.00021	0.0259	0.25	0.17	Chronic kidney disease;	chr20:23598303	chr20:23631826~23632316:-
LUAD	cis	rs3758785	0.586	rs481597	ENSG00000255893.1	RP11-685N10.1	3.74	0.00021	0.0259	0.19	0.17	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94336850	chr11:94472908~94473570:-
LUAD	cis	rs523522	0.923	rs1048830	ENSG00000278344.1	RP11-18C24.8	3.74	0.00021	0.0259	0.23	0.17	High light scatter reticulocyte count;	chr12:120444414	chr12:120500735~120501090:-
LUAD	cis	rs404005	0.542	rs410912	ENSG00000227028.5	SLC8A1-AS1	-3.74	0.00021	0.0259	-0.23	-0.17	HIV-associated dementia;	chr2:40184026	chr2:39786453~40255209:+
LUAD	cis	rs2380205	1	rs7098372	ENSG00000232807.2	RP11-536K7.3	3.74	0.00021	0.0259	0.17	0.17	Breast cancer;	chr10:5844186	chr10:5934270~5945900:-
LUAD	cis	rs11893307	0.537	rs57780226	ENSG00000235852.1	AC005540.3	3.74	0.00021	0.0259	0.21	0.17	Mean platelet volume;	chr2:190683139	chr2:190880797~190882059:-
LUAD	cis	rs1219407	0.708	rs478903	ENSG00000255090.4	MIR100HG	3.74	0.00021	0.0259	0.33	0.17	Mood disorder in prion disease;	chr11:121815057	chr11:122155422~122422871:-
LUAD	cis	rs72647484	0.642	rs2744758	ENSG00000234397.3	RP11-415K20.1	-3.74	0.00021	0.0259	-0.35	-0.17	Colorectal cancer;	chr1:22252126	chr1:22322840~22323331:-
LUAD	cis	rs7215564	0.908	rs35103651	ENSG00000232083.3	RPL31P7	3.74	0.00021	0.0259	0.28	0.17	Myopia (pathological);	chr17:80692932	chr17:80602549~80602926:-
LUAD	cis	rs2390582	0.782	rs35314527	ENSG00000233593.5	RP4-665J23.1	3.74	0.00021	0.0259	0.24	0.17	Coronary artery calcification;	chr1:90514132	chr1:90782986~90851650:-
LUAD	cis	rs910316	0.687	rs175059	ENSG00000259138.1	RP11-950C14.7	-3.74	0.00021	0.0259	-0.18	-0.17	Height;	chr14:75023964	chr14:75127153~75136930:+
LUAD	cis	rs11096990	0.551	rs2060005	ENSG00000249685.1	RP11-360F5.3	3.74	0.00021	0.0259	0.2	0.17	Cognitive function;	chr4:39160901	chr4:39133913~39135608:+
LUAD	cis	rs2732480	0.557	rs2409004	ENSG00000257763.1	OR5BK1P	3.74	0.00021	0.0259	0.18	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48327668	chr12:48355792~48356614:-
LUAD	cis	rs2333021	0.624	rs56282258	ENSG00000259015.1	RP11-109N23.6	3.74	0.00021	0.0259	0.17	0.17	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72992221	chr14:72960595~72961993:+
LUAD	cis	rs12190007	0.934	rs10945427	ENSG00000224999.1	VTA1P1	3.74	0.00021	0.0259	0.16	0.17	Obesity-related traits;	chr6:169343769	chr6:169296471~169297959:-
LUAD	cis	rs708547	0.647	rs1718878	ENSG00000269949.1	RP11-738E22.3	3.74	0.00021	0.0259	0.22	0.17	Response to bleomycin (chromatid breaks);	chr4:57010789	chr4:56960927~56961373:-
LUAD	cis	rs708547	0.647	rs4864609	ENSG00000269949.1	RP11-738E22.3	3.74	0.00021	0.0259	0.22	0.17	Response to bleomycin (chromatid breaks);	chr4:57011975	chr4:56960927~56961373:-
LUAD	cis	rs708547	0.647	rs1626594	ENSG00000269949.1	RP11-738E22.3	3.74	0.00021	0.0259	0.22	0.17	Response to bleomycin (chromatid breaks);	chr4:57012088	chr4:56960927~56961373:-
LUAD	cis	rs708547	0.697	rs67479587	ENSG00000269949.1	RP11-738E22.3	3.74	0.00021	0.0259	0.22	0.17	Response to bleomycin (chromatid breaks);	chr4:57012718	chr4:56960927~56961373:-
LUAD	cis	rs708547	0.647	rs1713982	ENSG00000269949.1	RP11-738E22.3	3.74	0.00021	0.0259	0.22	0.17	Response to bleomycin (chromatid breaks);	chr4:57015549	chr4:56960927~56961373:-
LUAD	cis	rs708547	0.647	rs1718831	ENSG00000269949.1	RP11-738E22.3	3.74	0.00021	0.0259	0.22	0.17	Response to bleomycin (chromatid breaks);	chr4:57020780	chr4:56960927~56961373:-
LUAD	cis	rs708547	0.599	rs1718864	ENSG00000269949.1	RP11-738E22.3	3.74	0.00021	0.0259	0.22	0.17	Response to bleomycin (chromatid breaks);	chr4:57021305	chr4:56960927~56961373:-
LUAD	cis	rs708547	0.671	rs1718863	ENSG00000269949.1	RP11-738E22.3	3.74	0.00021	0.0259	0.22	0.17	Response to bleomycin (chromatid breaks);	chr4:57021420	chr4:56960927~56961373:-
LUAD	cis	rs708547	0.647	rs1718830	ENSG00000269949.1	RP11-738E22.3	3.74	0.00021	0.0259	0.22	0.17	Response to bleomycin (chromatid breaks);	chr4:57022344	chr4:56960927~56961373:-
LUAD	cis	rs4699052	0.662	rs1400363	ENSG00000246560.2	RP11-10L12.4	3.74	0.00021	0.0259	0.21	0.17	Testicular germ cell tumor;	chr4:103329565	chr4:102828055~102844075:+
LUAD	cis	rs9894429	0.646	rs7406825	ENSG00000263853.1	AC139530.1	-3.74	0.00021	0.0259	-0.18	-0.17	Eye color traits;	chr17:81652158	chr17:81676001~81676086:+
LUAD	cis	rs1150668	0.699	rs2394049	ENSG00000168126.3	OR2W6P	3.74	0.00021	0.0259	0.19	0.17	Pubertal anthropometrics;	chr6:28271903	chr6:27937465~27938403:+
LUAD	cis	rs4423214	0.879	rs1790353	ENSG00000226627.1	SHANK2-AS1	3.74	0.00021	0.0259	0.2	0.17	Vitamin D levels;	chr11:71425684	chr11:70631094~70635490:+
LUAD	cis	rs577676	0.586	rs10489231	ENSG00000271811.1	RP1-79C4.4	-3.74	0.00021	0.0259	-0.21	-0.17	Prevalent atrial fibrillation;	chr1:170620296	chr1:170667381~170669425:+
LUAD	cis	rs757110	0.526	rs757081	ENSG00000260196.1	RP1-239B22.5	-3.74	0.00021	0.0259	-0.21	-0.17	Type 2 diabetes;	chr11:17330136	chr11:17380649~17383531:+
LUAD	cis	rs820077	0.736	rs820099	ENSG00000232909.1	RP3-510O8.4	-3.73	0.00021	0.0259	-0.25	-0.17	Systemic lupus erythematosus;	chr6:35078058	chr6:35733867~35736947:-
LUAD	cis	rs9309473	1	rs7598419	ENSG00000230002.2	ALMS1-IT1	3.73	0.00021	0.0259	0.21	0.17	Metabolite levels;	chr2:73571096	chr2:73456764~73459484:+
LUAD	cis	rs6558530	0.64	rs7844748	ENSG00000253982.1	CTD-2336O2.1	-3.73	0.00021	0.0259	-0.22	-0.17	Systolic blood pressure;	chr8:1754177	chr8:1761990~1764502:-
LUAD	cis	rs78572108	0.858	rs4952587	ENSG00000214691.7	AC104654.1	3.73	0.00021	0.0259	0.27	0.17	Total body bone mineral density;	chr2:42042991	chr2:41877074~41894046:+
LUAD	cis	rs2717559	0.542	rs11777634	ENSG00000253741.1	CTD-2292P10.4	3.73	0.00021	0.0259	0.2	0.17	Urinary tract infection frequency;	chr8:142806541	chr8:142702252~142726973:-
LUAD	cis	rs4711350	0.678	rs680608	ENSG00000224557.6	HLA-DPB2	-3.73	0.00021	0.0259	-0.3	-0.17	Schizophrenia;	chr6:33745392	chr6:33112451~33129084:+
LUAD	cis	rs5015933	0.762	rs359587	ENSG00000232630.1	PRPS1P2	-3.73	0.00021	0.0259	-0.16	-0.17	Body mass index;	chr9:125296098	chr9:125150653~125151589:+
LUAD	cis	rs6706648	0.582	rs17402905	ENSG00000234624.2	AC016894.1	-3.73	0.00021	0.0259	-0.2	-0.17	F-cell distribution;	chr2:60433173	chr2:61416887~61417197:-
LUAD	cis	rs12073359	1	rs11585955	ENSG00000223945.2	RP11-458I7.1	3.73	0.00021	0.0259	0.24	0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150071479	chr1:150053864~150055034:+
LUAD	cis	rs9473147	0.798	rs4711895	ENSG00000270761.1	RP11-385F7.1	3.73	0.00021	0.0259	0.19	0.17	Platelet distribution width;Mean platelet volume;	chr6:47659291	chr6:47477243~47477572:-
LUAD	cis	rs12935418	0.616	rs1127390	ENSG00000261061.1	RP11-303E16.2	-3.73	0.00021	0.0259	-0.18	-0.17	Mean corpuscular volume;	chr16:80976176	chr16:81030770~81031485:+
LUAD	cis	rs12935418	0.579	rs1477381	ENSG00000261061.1	RP11-303E16.2	3.73	0.00021	0.0259	0.18	0.17	Mean corpuscular volume;	chr16:80981095	chr16:81030770~81031485:+
LUAD	cis	rs4795519	0.922	rs1824899	ENSG00000266313.1	RP11-173M1.4	3.73	0.00021	0.0259	0.21	0.17	Chronic myeloid leukemia;	chr17:27140612	chr17:27333256~27348491:+
LUAD	cis	rs4795519	0.883	rs4795483	ENSG00000266313.1	RP11-173M1.4	3.73	0.00021	0.0259	0.21	0.17	Chronic myeloid leukemia;	chr17:27141560	chr17:27333256~27348491:+
LUAD	cis	rs4795519	1	rs4795484	ENSG00000266313.1	RP11-173M1.4	3.73	0.00021	0.0259	0.21	0.17	Chronic myeloid leukemia;	chr17:27141792	chr17:27333256~27348491:+
LUAD	cis	rs4938303	0.633	rs1960036	ENSG00000254851.1	RP11-109L13.1	3.73	0.00021	0.0259	0.26	0.17	Triglycerides;	chr11:116676692	chr11:117135528~117138582:+
LUAD	cis	rs4938303	0.633	rs12801136	ENSG00000254851.1	RP11-109L13.1	3.73	0.00021	0.0259	0.26	0.17	Triglycerides;	chr11:116677632	chr11:117135528~117138582:+
LUAD	cis	rs4938303	0.633	rs35963862	ENSG00000254851.1	RP11-109L13.1	3.73	0.00021	0.0259	0.26	0.17	Triglycerides;	chr11:116679180	chr11:117135528~117138582:+
LUAD	cis	rs4938303	0.633	rs61906104	ENSG00000254851.1	RP11-109L13.1	3.73	0.00021	0.0259	0.26	0.17	Triglycerides;	chr11:116679398	chr11:117135528~117138582:+
LUAD	cis	rs8050896	1	rs13333888	ENSG00000260695.1	RP11-513N24.1	3.73	0.00021	0.0259	0.29	0.17	Response to antipsychotic treatment;	chr16:66121850	chr16:65861112~65863784:-
LUAD	cis	rs8014252	1	rs8020009	ENSG00000274818.1	RP1-292L20.3	3.73	0.00021	0.0259	0.28	0.17	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70441564	chr14:70906657~70907111:-
LUAD	cis	rs804280	0.517	rs7815179	ENSG00000255046.1	RP11-297N6.4	-3.73	0.00021	0.0259	-0.21	-0.17	Myopia (pathological);	chr8:11934539	chr8:11797928~11802568:-
LUAD	cis	rs10435719	0.871	rs7815186	ENSG00000255046.1	RP11-297N6.4	-3.73	0.00021	0.0259	-0.21	-0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934553	chr8:11797928~11802568:-
LUAD	cis	rs1908814	0.516	rs7833079	ENSG00000255046.1	RP11-297N6.4	-3.73	0.00021	0.0259	-0.21	-0.17	Neuroticism;	chr8:11934620	chr8:11797928~11802568:-
LUAD	cis	rs10435719	0.899	rs7815595	ENSG00000255046.1	RP11-297N6.4	-3.73	0.00021	0.0259	-0.21	-0.17	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934842	chr8:11797928~11802568:-
LUAD	cis	rs6787172	0.905	rs1714507	ENSG00000272087.1	RP11-379F4.7	3.73	0.000211	0.0259	0.18	0.17	Subjective well-being;	chr3:158533643	chr3:158693120~158693768:-
LUAD	cis	rs9646944	1	rs9646944	ENSG00000234389.1	AC007278.3	3.73	0.000211	0.0259	0.19	0.17	Blood protein levels;	chr2:102249415	chr2:102438713~102440475:+
LUAD	cis	rs1861050	0.793	rs10004540	ENSG00000248360.6	LINC00504	3.73	0.000211	0.0259	0.5	0.17	Conduct disorder;	chr4:15420913	chr4:14470465~14888169:-
LUAD	cis	rs6674176	0.561	rs4660263	ENSG00000237950.1	RP11-7O11.3	3.73	0.000211	0.0259	0.21	0.17	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43955761	chr1:43944370~43946551:-
LUAD	cis	rs5742933	0.857	rs12471217	ENSG00000253559.1	OSGEPL1-AS1	3.73	0.000211	0.0259	0.2	0.17	Ferritin levels;	chr2:189707337	chr2:189762704~189765556:+
LUAD	cis	rs2299587	0.642	rs2073570	ENSG00000253671.1	RP11-806O11.1	-3.73	0.000211	0.0259	-0.19	-0.17	Economic and political preferences;	chr8:17925118	chr8:17808941~17820868:+
LUAD	cis	rs2412819	0.545	rs17795279	ENSG00000166763.7	STRCP1	-3.73	0.000211	0.0259	-0.25	-0.17	Lung cancer;	chr15:43637180	chr15:43699488~43718184:-
LUAD	cis	rs7615952	0.599	rs2270986	ENSG00000241288.6	RP11-379B18.5	-3.73	0.000211	0.0259	-0.22	-0.17	Blood pressure (smoking interaction);	chr3:125982256	chr3:125827238~125916384:-
LUAD	cis	rs7615952	0.599	rs12496921	ENSG00000241288.6	RP11-379B18.5	-3.73	0.000211	0.0259	-0.22	-0.17	Blood pressure (smoking interaction);	chr3:125983105	chr3:125827238~125916384:-
LUAD	cis	rs4699052	0.626	rs10017383	ENSG00000246560.2	RP11-10L12.4	3.73	0.000211	0.0259	0.21	0.17	Testicular germ cell tumor;	chr4:103328800	chr4:102828055~102844075:+
LUAD	cis	rs4699052	0.662	rs6848091	ENSG00000246560.2	RP11-10L12.4	3.73	0.000211	0.0259	0.21	0.17	Testicular germ cell tumor;	chr4:103328944	chr4:102828055~102844075:+
LUAD	cis	rs4699052	0.662	rs6848593	ENSG00000246560.2	RP11-10L12.4	3.73	0.000211	0.0259	0.21	0.17	Testicular germ cell tumor;	chr4:103328956	chr4:102828055~102844075:+
LUAD	cis	rs4776997	0.559	rs11071960	ENSG00000259673.4	IQCH-AS1	3.73	0.000211	0.0259	0.2	0.17	Verbal declarative memory;	chr15:67784784	chr15:67403619~67521844:-
LUAD	cis	rs4474465	0.79	rs10751293	ENSG00000251323.2	RP11-452H21.4	-3.73	0.000211	0.0259	-0.2	-0.17	Alzheimer's disease (survival time);	chr11:78539910	chr11:78423982~78429836:-
LUAD	cis	rs2346177	0.638	rs34186951	ENSG00000279254.1	RP11-536C12.1	-3.73	0.000211	0.0259	-0.18	-0.17	HDL cholesterol;	chr2:46430520	chr2:46668870~46670778:+
LUAD	cis	rs10129255	0.913	rs10140943	ENSG00000253209.1	IGHV3-65	3.73	0.000211	0.0259	0.15	0.17	Kawasaki disease;	chr14:106767441	chr14:106666092~106666532:-
LUAD	cis	rs875971	0.502	rs2946580	ENSG00000224316.1	RP11-479O9.2	-3.73	0.000211	0.0259	-0.2	-0.17	Aortic root size;	chr7:66066855	chr7:65773620~65802067:+
LUAD	cis	rs8028182	0.549	rs7402844	ENSG00000246877.1	DNM1P35	-3.73	0.000211	0.0259	-0.22	-0.17	Sudden cardiac arrest;	chr15:75345055	chr15:75727670~75738623:-
LUAD	cis	rs2274273	0.837	rs7142857	ENSG00000259318.1	RP11-454L9.2	3.73	0.000211	0.0259	0.15	0.17	Protein biomarker;	chr14:55237410	chr14:55394940~55395233:-
LUAD	cis	rs4561483	0.583	rs12149833	ENSG00000261216.1	RP11-166B2.5	3.73	0.000211	0.026	0.17	0.17	Testicular germ cell tumor;	chr16:11909866	chr16:11908208~11908916:+
LUAD	cis	rs5758659	0.622	rs5758527	ENSG00000270083.1	RP1-257I20.14	3.73	0.000211	0.026	0.16	0.17	Cognitive function;	chr22:41979757	chr22:42089630~42090028:-
LUAD	cis	rs4763879	0.739	rs12582584	ENSG00000257027.1	RP11-705C15.3	3.73	0.000211	0.026	0.21	0.17	Type 1 diabetes;	chr12:9671542	chr12:9658567~9662085:+
LUAD	cis	rs6988985	0.678	rs28659182	ENSG00000247317.3	RP11-273G15.2	-3.73	0.000211	0.026	-0.2	-0.17	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142918503	chr8:142981738~143018437:-
LUAD	cis	rs1346081	0.904	rs13111778	ENSG00000250075.4	RP11-584P21.2	-3.73	0.000211	0.026	-0.18	-0.17	Intelligence (multi-trait analysis);	chr4:67192265	chr4:67417305~67468251:-
LUAD	cis	rs17749155	0.58	rs957240	ENSG00000255310.2	AF131215.2	3.73	0.000211	0.026	0.2	0.17	Barrett's esophagus;Barrett's esophagus  or Esophageal adenocarcinoma;	chr8:10205998	chr8:11107788~11109726:-
LUAD	cis	rs877356	0.831	rs17169187	ENSG00000250167.1	CTC-321K16.1	-3.73	0.000211	0.026	-0.3	-0.17	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (dichotomous);	chr5:135828069	chr5:135559577~135634874:+
LUAD	cis	rs7772486	0.686	rs9403741	ENSG00000235652.6	RP11-545I5.3	-3.73	0.000211	0.026	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145709412	chr6:145799409~145886585:+
LUAD	cis	rs4561483	0.583	rs17236573	ENSG00000261216.1	RP11-166B2.5	3.73	0.000211	0.026	0.17	0.17	Testicular germ cell tumor;	chr16:11900798	chr16:11908208~11908916:+
LUAD	cis	rs4561483	0.583	rs62038798	ENSG00000261216.1	RP11-166B2.5	3.73	0.000211	0.026	0.17	0.17	Testicular germ cell tumor;	chr16:11907712	chr16:11908208~11908916:+
LUAD	cis	rs7429990	0.965	rs7619882	ENSG00000228638.1	FCF1P2	-3.73	0.000211	0.026	-0.2	-0.17	Educational attainment (years of education);	chr3:47943334	chr3:48290793~48291375:-
LUAD	cis	rs7772486	0.686	rs1337841	ENSG00000235652.6	RP11-545I5.3	-3.73	0.000211	0.026	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145738351	chr6:145799409~145886585:+
LUAD	cis	rs11671005	0.779	rs55875034	ENSG00000268912.1	CTD-2619J13.17	-3.73	0.000211	0.026	-0.24	-0.17	Mean platelet volume;	chr19:58472191	chr19:58428632~58431148:-
LUAD	cis	rs2179367	0.959	rs489551	ENSG00000216906.2	RP11-350J20.9	3.73	0.000211	0.026	0.21	0.17	Dupuytren's disease;	chr6:149368321	chr6:149904243~149906418:+
LUAD	cis	rs73230612	0.858	rs13324198	ENSG00000242767.1	ZBTB20-AS4	3.73	0.000211	0.026	0.27	0.17	Type 2 diabetes;	chr3:115378761	chr3:115100423~115103061:+
LUAD	cis	rs13006833	0.739	rs172366	ENSG00000227542.1	AC092614.2	-3.73	0.000211	0.026	-0.2	-0.17	Urinary metabolites;	chr2:190326507	chr2:191229165~191246172:-
LUAD	cis	rs4474465	0.79	rs4945293	ENSG00000251323.2	RP11-452H21.4	-3.73	0.000211	0.026	-0.2	-0.17	Alzheimer's disease (survival time);	chr11:78543508	chr11:78423982~78429836:-
LUAD	cis	rs4727963	0.792	rs1525468	ENSG00000240499.6	RP5-1101C3.1	-3.73	0.000211	0.026	-0.15	-0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);	chr7:123076857	chr7:122328469~122440388:+
LUAD	cis	rs7772486	0.686	rs9376956	ENSG00000235652.6	RP11-545I5.3	3.73	0.000211	0.026	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145628708	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.658	rs6570706	ENSG00000235652.6	RP11-545I5.3	3.73	0.000211	0.026	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145641786	chr6:145799409~145886585:+
LUAD	cis	rs8141529	0.687	rs6005867	ENSG00000272858.1	CTA-292E10.8	-3.73	0.000211	0.026	-0.19	-0.17	Lymphocyte counts;	chr22:28769132	chr22:28814914~28815662:+
LUAD	cis	rs7976269	0.609	rs10843300	ENSG00000275476.1	RP11-996F15.4	-3.73	0.000211	0.026	-0.18	-0.17	Male-pattern baldness;	chr12:29060934	chr12:29277397~29277882:-
LUAD	cis	rs820077	0.736	rs820067	ENSG00000232909.1	RP3-510O8.4	-3.73	0.000211	0.026	-0.25	-0.17	Systemic lupus erythematosus;	chr6:35072437	chr6:35733867~35736947:-
LUAD	cis	rs820077	0.736	rs820066	ENSG00000232909.1	RP3-510O8.4	-3.73	0.000211	0.026	-0.25	-0.17	Systemic lupus erythematosus;	chr6:35072483	chr6:35733867~35736947:-
LUAD	cis	rs820077	0.668	rs820065	ENSG00000232909.1	RP3-510O8.4	-3.73	0.000211	0.026	-0.25	-0.17	Systemic lupus erythematosus;	chr6:35072643	chr6:35733867~35736947:-
LUAD	cis	rs2380205	0.967	rs713588	ENSG00000232807.2	RP11-536K7.3	3.73	0.000211	0.026	0.17	0.17	Breast cancer;	chr10:5844999	chr10:5934270~5945900:-
LUAD	cis	rs10197140	0.857	rs12476386	ENSG00000235721.1	AC013268.3	-3.73	0.000211	0.026	-0.18	-0.17	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110889961	chr2:110007675~110010783:+
LUAD	cis	rs7178424	0.811	rs12910541	ENSG00000259251.2	RP11-643M14.1	3.73	0.000211	0.026	0.17	0.17	Height;	chr15:61956712	chr15:62060503~62062434:+
LUAD	cis	rs237743	1	rs237743	ENSG00000177410.11	ZFAS1	-3.73	0.000211	0.026	-0.19	-0.17	Height;	chr20:49286482	chr20:49278178~49295738:+
LUAD	cis	rs3758785	0.641	rs10831207	ENSG00000255893.1	RP11-685N10.1	3.73	0.000211	0.026	0.19	0.17	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94356197	chr11:94472908~94473570:-
LUAD	cis	rs7809950	1	rs2520269	ENSG00000238832.1	snoU109	-3.73	0.000211	0.026	-0.25	-0.17	Coronary artery disease;	chr7:107550882	chr7:107603363~107603507:+
LUAD	cis	rs7141336	1	rs8005254	ENSG00000258884.1	CTD-3035D6.2	3.73	0.000211	0.026	0.17	0.17	Anxiety disorder;	chr14:90820265	chr14:90822365~90828128:-
LUAD	cis	rs7831492	0.517	rs11995974	ENSG00000253133.1	RP11-360L9.4	-3.73	0.000211	0.026	-0.22	-0.17	Colorectal cancer;	chr8:41789165	chr8:41534155~41578368:-
LUAD	cis	rs763121	0.853	rs2072796	ENSG00000225450.1	RP3-508I15.14	-3.73	0.000211	0.026	-0.17	-0.17	Menopause (age at onset);	chr22:38668225	chr22:38739003~38749041:+
LUAD	cis	rs2024714	0.967	rs2427214	ENSG00000273812.1	WI2-87327B8.2	-3.73	0.000211	0.026	-0.18	-0.17	Longevity;	chr20:61638974	chr20:62596732~62603115:-
LUAD	cis	rs2274273	0.84	rs6573014	ENSG00000259318.1	RP11-454L9.2	-3.73	0.000211	0.026	-0.15	-0.17	Protein biomarker;	chr14:55269174	chr14:55394940~55395233:-
LUAD	cis	rs9595908	0.931	rs9595630	ENSG00000281026.1	N4BP2L2-IT2	3.73	0.000211	0.026	0.11	0.17	Body mass index;	chr13:32491306	chr13:32504506~32509395:-
LUAD	cis	rs11673344	0.58	rs320881	ENSG00000267254.4	ZNF790-AS1	-3.73	0.000211	0.026	-0.22	-0.17	Obesity-related traits;	chr19:37246948	chr19:36797518~36828115:+
LUAD	cis	rs3177980	0.521	rs527261	ENSG00000239494.2	RN7SL333P	3.73	0.000211	0.026	0.16	0.17	Amyotrophic lateral sclerosis;	chr1:169976022	chr1:169859756~169860052:+
LUAD	cis	rs2991971	0.776	rs12139364	ENSG00000234329.1	RP11-767N6.2	-3.73	0.000211	0.026	-0.16	-0.17	High light scatter reticulocyte count;	chr1:45424483	chr1:45651039~45651826:-
LUAD	cis	rs10829156	0.898	rs7923072	ENSG00000240291.1	RP11-499P20.2	3.73	0.000211	0.026	0.15	0.17	Sudden cardiac arrest;	chr10:18649305	chr10:18513115~18545651:-
LUAD	cis	rs1322639	0.614	rs9689800	ENSG00000226445.1	XXyac-YX65C7_A.2	3.73	0.000211	0.026	0.19	0.17	Pulse pressure;	chr6:169172850	chr6:169213254~169239565:+
LUAD	cis	rs8050896	0.793	rs8061412	ENSG00000260695.1	RP11-513N24.1	-3.73	0.000211	0.026	-0.35	-0.17	Response to antipsychotic treatment;	chr16:66117656	chr16:65861112~65863784:-
LUAD	cis	rs2274273	0.624	rs11848456	ENSG00000258413.1	RP11-665C16.6	-3.73	0.000211	0.026	-0.23	-0.17	Protein biomarker;	chr14:55288674	chr14:55262767~55272075:-
LUAD	cis	rs7615952	0.546	rs2979333	ENSG00000243429.1	OR7E29P	3.73	0.000211	0.026	0.23	0.17	Blood pressure (smoking interaction);	chr3:125641499	chr3:125712139~125713045:+
LUAD	cis	rs7615952	0.546	rs111812401	ENSG00000243429.1	OR7E29P	3.73	0.000211	0.026	0.23	0.17	Blood pressure (smoking interaction);	chr3:125642651	chr3:125712139~125713045:+
LUAD	cis	rs7615952	0.546	rs2979350	ENSG00000243429.1	OR7E29P	3.73	0.000211	0.026	0.23	0.17	Blood pressure (smoking interaction);	chr3:125643371	chr3:125712139~125713045:+
LUAD	cis	rs12048904	0.505	rs4517368	ENSG00000207750.1	MIR553	-3.73	0.000211	0.026	-0.18	-0.17	Multiple sclerosis;	chr1:100789496	chr1:100281241~100281308:+
LUAD	cis	rs7615952	0.576	rs6780025	ENSG00000241288.6	RP11-379B18.5	-3.73	0.000211	0.026	-0.22	-0.17	Blood pressure (smoking interaction);	chr3:126096781	chr3:125827238~125916384:-
LUAD	cis	rs7615952	0.576	rs6804482	ENSG00000241288.6	RP11-379B18.5	-3.73	0.000211	0.026	-0.22	-0.17	Blood pressure (smoking interaction);	chr3:126096919	chr3:125827238~125916384:-
LUAD	cis	rs916888	0.773	rs9896243	ENSG00000232300.1	FAM215B	3.73	0.000211	0.026	0.25	0.17	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46558830~46562795:-
LUAD	cis	rs2274273	0.875	rs2075602	ENSG00000258413.1	RP11-665C16.6	-3.73	0.000211	0.026	-0.21	-0.17	Protein biomarker;	chr14:55143056	chr14:55262767~55272075:-
LUAD	cis	rs6763848	0.892	rs12493849	ENSG00000214073.2	RPL21P17	3.73	0.000211	0.026	0.17	0.17	Prostate cancer (SNP x SNP interaction);	chr3:1461491	chr3:1905651~1906125:+
LUAD	cis	rs8141529	0.748	rs715531	ENSG00000272858.1	CTA-292E10.8	-3.73	0.000211	0.026	-0.19	-0.17	Lymphocyte counts;	chr22:28886691	chr22:28814914~28815662:+
LUAD	cis	rs1850744	0.702	rs10939428	ENSG00000163612.10	FAM86KP	-3.73	0.000211	0.026	-0.47	-0.17	Economic and political preferences;	chr4:9628417	chr4:9153296~9165451:+
LUAD	cis	rs5742933	1	rs12052909	ENSG00000253559.1	OSGEPL1-AS1	-3.73	0.000211	0.026	-0.23	-0.17	Ferritin levels;	chr2:189742484	chr2:189762704~189765556:+
LUAD	cis	rs5742933	1	rs16831955	ENSG00000253559.1	OSGEPL1-AS1	-3.73	0.000211	0.026	-0.23	-0.17	Ferritin levels;	chr2:189745811	chr2:189762704~189765556:+
LUAD	cis	rs11159086	0.793	rs11621693	ENSG00000270000.1	RP3-449M8.9	3.73	0.000211	0.026	0.23	0.17	Advanced glycation end-product levels;	chr14:74472631	chr14:74471930~74472360:-
LUAD	cis	rs6496932	1	rs35796484	ENSG00000218052.5	ADAMTS7P4	3.73	0.000212	0.026	0.21	0.17	Central corneal thickness;Corneal structure;	chr15:85282019	chr15:85255369~85330334:-
LUAD	cis	rs6088590	0.523	rs6058084	ENSG00000276073.1	RP5-1125A11.7	-3.73	0.000212	0.026	-0.16	-0.17	Coronary artery disease;	chr20:34596000	chr20:33985617~33988989:-
LUAD	cis	rs683250	0.598	rs7106790	ENSG00000246067.6	RAB30-AS1	-3.73	0.000212	0.026	-0.18	-0.17	Subcortical brain region volumes;	chr11:83306871	chr11:83072066~83106719:+
LUAD	cis	rs7017914	0.69	rs17699685	ENSG00000246366.5	RP11-382J12.1	3.73	0.000212	0.026	0.16	0.17	Bone mineral density;	chr8:71066769	chr8:70608577~70663279:+
LUAD	cis	rs2281603	1	rs2281603	ENSG00000259116.1	RP11-973N13.4	-3.73	0.000212	0.026	-0.15	-0.17	Lymphocyte counts;	chr14:64459379	chr14:64514154~64540368:-
LUAD	cis	rs237743	1	rs381262	ENSG00000177410.11	ZFAS1	3.73	0.000212	0.026	0.18	0.17	Height;	chr20:49316942	chr20:49278178~49295738:+
LUAD	cis	rs6494488	0.5	rs56078804	ENSG00000239465.1	RP11-330L19.2	3.73	0.000212	0.0261	0.36	0.17	Coronary artery disease;	chr15:64809298	chr15:64631109~64631914:-
LUAD	cis	rs638893	0.617	rs4938564	ENSG00000255422.1	AP002954.4	-3.73	0.000212	0.0261	-0.23	-0.17	Vitiligo;	chr11:118849881	chr11:118704607~118750263:+
LUAD	cis	rs638893	0.588	rs4936440	ENSG00000255422.1	AP002954.4	-3.73	0.000212	0.0261	-0.23	-0.17	Vitiligo;	chr11:118849975	chr11:118704607~118750263:+
LUAD	cis	rs638893	0.588	rs4938566	ENSG00000255422.1	AP002954.4	-3.73	0.000212	0.0261	-0.23	-0.17	Vitiligo;	chr11:118850480	chr11:118704607~118750263:+
LUAD	cis	rs638893	0.617	rs4938567	ENSG00000255422.1	AP002954.4	-3.73	0.000212	0.0261	-0.23	-0.17	Vitiligo;	chr11:118850540	chr11:118704607~118750263:+
LUAD	cis	rs638893	0.617	rs11217059	ENSG00000255422.1	AP002954.4	-3.73	0.000212	0.0261	-0.23	-0.17	Vitiligo;	chr11:118852378	chr11:118704607~118750263:+
LUAD	cis	rs8002861	0.935	rs9525865	ENSG00000274001.1	RP11-5G9.5	3.73	0.000212	0.0261	0.18	0.17	Leprosy;	chr13:43885511	chr13:43877715~43878163:-
LUAD	cis	rs2274273	0.905	rs4652	ENSG00000258413.1	RP11-665C16.6	-3.73	0.000212	0.0261	-0.21	-0.17	Protein biomarker;	chr14:55138318	chr14:55262767~55272075:-
LUAD	cis	rs6081541	1	rs3827976	ENSG00000179447.2	RP5-1027G4.3	-3.73	0.000212	0.0261	-0.21	-0.17	Psychosis (atypical);	chr20:19244211	chr20:19242302~19284596:-
LUAD	cis	rs4538475	0.745	rs73224662	ENSG00000249234.1	RP11-452J21.2	3.73	0.000212	0.0261	0.24	0.17	Parkinson's disease;	chr4:15714466	chr4:16178939~16183120:+
LUAD	cis	rs7515577	0.853	rs3103180	ENSG00000223787.2	RP4-593M8.1	-3.73	0.000212	0.0261	-0.26	-0.17	Cholesterol, total;	chr1:92269455	chr1:92580476~92580821:-
LUAD	cis	rs7515577	0.898	rs3131831	ENSG00000223787.2	RP4-593M8.1	-3.73	0.000212	0.0261	-0.26	-0.17	Cholesterol, total;	chr1:92280202	chr1:92580476~92580821:-
LUAD	cis	rs7515577	0.898	rs3103177	ENSG00000223787.2	RP4-593M8.1	-3.73	0.000212	0.0261	-0.26	-0.17	Cholesterol, total;	chr1:92290950	chr1:92580476~92580821:-
LUAD	cis	rs7515577	0.853	rs6604089	ENSG00000223787.2	RP4-593M8.1	-3.73	0.000212	0.0261	-0.26	-0.17	Cholesterol, total;	chr1:92301735	chr1:92580476~92580821:-
LUAD	cis	rs7870753	0.578	rs10990621	ENSG00000188801.9	ZNF322P1	3.73	0.000212	0.0261	0.29	0.17	Height;	chr9:96339012	chr9:97198303~97199511:-
LUAD	cis	rs12146727	0.881	rs12371227	ENSG00000247853.2	RP5-940J5.6	-3.73	0.000212	0.0261	-0.26	-0.17	Blood protein levels;	chr12:7069674	chr12:6578622~6584739:+
LUAD	cis	rs17695224	0.565	rs7253182	ENSG00000269483.1	AC006272.1	3.73	0.000212	0.0261	0.18	0.17	HDL cholesterol;HDL cholesterol levels;	chr19:51808838	chr19:51839924~51843324:-
LUAD	cis	rs778371	0.676	rs11688166	ENSG00000259793.1	RP11-400N9.1	3.73	0.000212	0.0261	0.18	0.17	Schizophrenia;	chr2:232701500	chr2:233351132~233353416:-
LUAD	cis	rs897984	0.542	rs3751855	ENSG00000232748.3	RP11-196G11.6	-3.73	0.000212	0.0261	-0.21	-0.17	Dementia with Lewy bodies;	chr16:31079888	chr16:31056460~31062803:+
LUAD	cis	rs11252926	0.565	rs60553947	ENSG00000232656.6	IDI2-AS1	-3.73	0.000212	0.0261	-0.19	-0.17	Psychosis in Alzheimer's disease;	chr10:428344	chr10:1022666~1044201:+
LUAD	cis	rs8046148	0.724	rs11642695	ENSG00000279356.1	RP11-429P3.8	3.73	0.000212	0.0261	0.17	0.17	Testicular germ cell tumor;	chr16:50093209	chr16:50072862~50074986:+
LUAD	cis	rs11210359	0.51	rs1160782	ENSG00000272864.1	RP11-17E13.2	3.73	0.000212	0.0261	0.2	0.17	Bipolar disorder and schizophrenia;	chr1:73876717	chr1:74698769~74699333:-
LUAD	cis	rs12537284	0.518	rs12540468	ENSG00000275106.1	RP11-309L24.10	-3.73	0.000212	0.0261	-0.25	-0.17	Systemic lupus erythematosus;	chr7:129082746	chr7:128952527~128953316:-
LUAD	cis	rs12073359	0.955	rs1824848	ENSG00000223945.2	RP11-458I7.1	3.73	0.000212	0.0261	0.23	0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150167382	chr1:150053864~150055034:+
LUAD	cis	rs2834288	0.7	rs6517196	ENSG00000237945.6	LINC00649	-3.73	0.000212	0.0261	-0.23	-0.17	Gut microbiota (bacterial taxa);	chr21:33905116	chr21:33915534~33977691:+
LUAD	cis	rs2274273	0.662	rs2147970	ENSG00000258413.1	RP11-665C16.6	-3.73	0.000212	0.0261	-0.24	-0.17	Protein biomarker;	chr14:55193499	chr14:55262767~55272075:-
LUAD	cis	rs2274273	0.662	rs66476033	ENSG00000258413.1	RP11-665C16.6	-3.73	0.000212	0.0261	-0.24	-0.17	Protein biomarker;	chr14:55194145	chr14:55262767~55272075:-
LUAD	cis	rs2274273	0.662	rs2094436	ENSG00000258413.1	RP11-665C16.6	-3.73	0.000212	0.0261	-0.24	-0.17	Protein biomarker;	chr14:55194777	chr14:55262767~55272075:-
LUAD	cis	rs6504663	0.596	rs7208018	ENSG00000275897.1	RP11-94C24.13	-3.73	0.000212	0.0261	-0.23	-0.17	Visceral fat;	chr17:50480502	chr17:50475819~50478391:+
LUAD	cis	rs1348850	1	rs3927978	ENSG00000213963.5	AC074286.1	-3.73	0.000212	0.0261	-0.2	-0.17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177579126	chr2:177283508~177392691:-
LUAD	cis	rs2834288	0.734	rs1557269	ENSG00000237945.6	LINC00649	-3.73	0.000212	0.0261	-0.23	-0.17	Gut microbiota (bacterial taxa);	chr21:33894091	chr21:33915534~33977691:+
LUAD	cis	rs6493487	0.512	rs8024423	ENSG00000273674.3	CTD-2378E12.1	3.73	0.000212	0.0261	0.24	0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50827616	chr15:50839875~50908599:-
LUAD	cis	rs7584330	0.541	rs10202181	ENSG00000222032.1	AC112721.2	3.73	0.000212	0.0261	0.2	0.17	Prostate cancer;	chr2:237443456	chr2:237428920~237434822:-
LUAD	cis	rs7584330	0.657	rs10202292	ENSG00000222032.1	AC112721.2	3.73	0.000212	0.0261	0.2	0.17	Prostate cancer;	chr2:237443542	chr2:237428920~237434822:-
LUAD	cis	rs12073359	1	rs55918911	ENSG00000223945.2	RP11-458I7.1	-3.73	0.000212	0.0261	-0.24	-0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150040194	chr1:150053864~150055034:+
LUAD	cis	rs3126085	0.935	rs11586114	ENSG00000237975.5	FLG-AS1	3.73	0.000212	0.0261	0.28	0.17	Atopic dermatitis;	chr1:152327291	chr1:152168125~152445456:+
LUAD	cis	rs6754311	0.593	rs55825471	ENSG00000226806.1	AC011893.3	-3.73	0.000212	0.0261	-0.21	-0.17	Mosquito bite size;	chr2:135769411	chr2:135820191~135823087:+
LUAD	cis	rs4842666	0.915	rs2681472	ENSG00000258302.2	RP11-981P6.1	3.73	0.000212	0.0261	0.25	0.17	Blood pressure;	chr12:89615182	chr12:89561129~89594878:+
LUAD	cis	rs9876781	0.967	rs9876891	ENSG00000229759.1	MRPS18AP1	3.73	0.000212	0.0261	0.16	0.17	Longevity;	chr3:48440024	chr3:48256350~48256938:-
LUAD	cis	rs17596685	1	rs168312	ENSG00000271216.1	LINC01050	3.73	0.000212	0.0261	0.24	0.17	C-reactive protein levels;	chr13:42547624	chr13:42810366~42812562:-
LUAD	cis	rs5758659	0.652	rs133335	ENSG00000182057.4	OGFRP1	-3.73	0.000212	0.0261	-0.2	-0.17	Cognitive function;	chr22:42020052	chr22:42269753~42275196:+
LUAD	cis	rs5742933	0.762	rs2033746	ENSG00000253559.1	OSGEPL1-AS1	3.73	0.000212	0.0261	0.2	0.17	Ferritin levels;	chr2:189734726	chr2:189762704~189765556:+
LUAD	cis	rs6951245	1	rs11770909	ENSG00000199023.2	MIR339	-3.73	0.000212	0.0261	-0.3	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1047080	chr7:1022935~1023045:-
LUAD	cis	rs6951245	1	rs74785791	ENSG00000199023.2	MIR339	-3.73	0.000212	0.0261	-0.3	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1048858	chr7:1022935~1023045:-
LUAD	cis	rs6951245	1	rs74366004	ENSG00000199023.2	MIR339	-3.73	0.000212	0.0261	-0.3	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1048994	chr7:1022935~1023045:-
LUAD	cis	rs6951245	1	rs77702926	ENSG00000199023.2	MIR339	-3.73	0.000212	0.0261	-0.3	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1049202	chr7:1022935~1023045:-
LUAD	cis	rs7107174	0.901	rs10899498	ENSG00000251323.2	RP11-452H21.4	3.73	0.000212	0.0261	0.2	0.17	Testicular germ cell tumor;	chr11:78413529	chr11:78423982~78429836:-
LUAD	cis	rs4666002	0.789	rs13030973	ENSG00000223522.1	AC093690.1	3.73	0.000212	0.0261	0.19	0.17	Phospholipid levels (plasma);	chr2:27705930	chr2:28307691~28310459:-
LUAD	cis	rs11250097	0.535	rs11250086	ENSG00000255310.2	AF131215.2	-3.73	0.000212	0.0261	-0.17	-0.17	Neuroticism;	chr8:10912273	chr8:11107788~11109726:-
LUAD	cis	rs12754538	0.813	rs11121175	ENSG00000232912.4	RP5-1115A15.1	3.73	0.000212	0.0261	0.18	0.17	Subjective well-being;	chr1:8374986	chr1:8424645~8434838:+
LUAD	cis	rs6988985	0.678	rs10087214	ENSG00000247317.3	RP11-273G15.2	-3.73	0.000213	0.0261	-0.2	-0.17	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142918310	chr8:142981738~143018437:-
LUAD	cis	rs6502050	0.731	rs76421195	ENSG00000275966.1	RP11-1055B8.9	-3.73	0.000213	0.0261	-0.17	-0.17	Life satisfaction;	chr17:82151450	chr17:81345476~81345966:-
LUAD	cis	rs911555	0.504	rs4444269	ENSG00000269940.1	RP11-73M18.7	3.73	0.000213	0.0261	0.17	0.17	Intelligence (multi-trait analysis);	chr14:103606387	chr14:103694560~103695170:+
LUAD	cis	rs9400467	0.528	rs17539197	ENSG00000230177.1	RP5-1112D6.4	-3.73	0.000213	0.0261	-0.15	-0.17	Amino acid levels;Blood metabolite levels;	chr6:111447968	chr6:111277932~111278742:+
LUAD	cis	rs867371	0.614	rs7183805	ENSG00000259429.4	UBE2Q2P2	-3.73	0.000213	0.0261	-0.17	-0.17	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82247090	chr15:82355142~82420075:+
LUAD	cis	rs3748682	0.821	rs12022363	ENSG00000212541.1	RNU6-510P	-3.73	0.000213	0.0261	-0.23	-0.17	Hypothyroidism;	chr1:37786937	chr1:37991462~37991569:+
LUAD	cis	rs3748682	0.821	rs12025519	ENSG00000212541.1	RNU6-510P	-3.73	0.000213	0.0261	-0.23	-0.17	Hypothyroidism;	chr1:37786981	chr1:37991462~37991569:+
LUAD	cis	rs4727963	0.846	rs2402626	ENSG00000240499.6	RP5-1101C3.1	-3.73	0.000213	0.0261	-0.15	-0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);	chr7:123072304	chr7:122328469~122440388:+
LUAD	cis	rs4727963	0.846	rs12670195	ENSG00000240499.6	RP5-1101C3.1	-3.73	0.000213	0.0261	-0.15	-0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);	chr7:123072871	chr7:122328469~122440388:+
LUAD	cis	rs5742933	1	rs16831939	ENSG00000253559.1	OSGEPL1-AS1	-3.73	0.000213	0.0261	-0.23	-0.17	Ferritin levels;	chr2:189739282	chr2:189762704~189765556:+
LUAD	cis	rs3020736	0.5	rs6002614	ENSG00000273366.1	CTA-989H11.1	3.73	0.000213	0.0261	0.2	0.17	Autism spectrum disorder or schizophrenia;	chr22:42105798	chr22:42278188~42278846:+
LUAD	cis	rs3020736	0.5	rs2413669	ENSG00000273366.1	CTA-989H11.1	3.73	0.000213	0.0261	0.2	0.17	Autism spectrum disorder or schizophrenia;	chr22:42111744	chr22:42278188~42278846:+
LUAD	cis	rs3020736	0.5	rs6002618	ENSG00000273366.1	CTA-989H11.1	3.73	0.000213	0.0261	0.2	0.17	Autism spectrum disorder or schizophrenia;	chr22:42111855	chr22:42278188~42278846:+
LUAD	cis	rs1023500	0.551	rs61665536	ENSG00000273366.1	CTA-989H11.1	3.73	0.000213	0.0261	0.2	0.17	Schizophrenia;	chr22:42116609	chr22:42278188~42278846:+
LUAD	cis	rs3020736	0.5	rs2413672	ENSG00000273366.1	CTA-989H11.1	3.73	0.000213	0.0261	0.2	0.17	Autism spectrum disorder or schizophrenia;	chr22:42117257	chr22:42278188~42278846:+
LUAD	cis	rs3020736	0.5	rs6002623	ENSG00000273366.1	CTA-989H11.1	3.73	0.000213	0.0261	0.2	0.17	Autism spectrum disorder or schizophrenia;	chr22:42117757	chr22:42278188~42278846:+
LUAD	cis	rs3020736	0.5	rs11090076	ENSG00000273366.1	CTA-989H11.1	3.73	0.000213	0.0261	0.2	0.17	Autism spectrum disorder or schizophrenia;	chr22:42118186	chr22:42278188~42278846:+
LUAD	cis	rs3020736	0.519	rs5996116	ENSG00000273366.1	CTA-989H11.1	3.73	0.000213	0.0261	0.2	0.17	Autism spectrum disorder or schizophrenia;	chr22:42121488	chr22:42278188~42278846:+
LUAD	cis	rs3020736	0.5	rs764481	ENSG00000273366.1	CTA-989H11.1	3.73	0.000213	0.0261	0.2	0.17	Autism spectrum disorder or schizophrenia;	chr22:42122422	chr22:42278188~42278846:+
LUAD	cis	rs897984	0.806	rs1046276	ENSG00000275263.1	RP11-1072A3.4	3.73	0.000213	0.0261	0.22	0.17	Dementia with Lewy bodies;	chr16:30903305	chr16:30956872~30957199:-
LUAD	cis	rs8028182	0.666	rs4886708	ENSG00000260269.4	CTD-2323K18.1	-3.73	0.000213	0.0261	-0.24	-0.17	Sudden cardiac arrest;	chr15:75470267	chr15:75527150~75601205:-
LUAD	cis	rs853679	0.567	rs3799499	ENSG00000219392.1	RP1-265C24.5	-3.73	0.000213	0.0261	-0.22	-0.17	Depression;	chr6:28386473	chr6:28115628~28116551:+
LUAD	cis	rs6921919	0.583	rs3734563	ENSG00000219392.1	RP1-265C24.5	-3.73	0.000213	0.0261	-0.21	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28115628~28116551:+
LUAD	cis	rs6921919	0.583	rs1591913	ENSG00000219392.1	RP1-265C24.5	-3.73	0.000213	0.0261	-0.21	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28115628~28116551:+
LUAD	cis	rs7942368	1	rs1440979	ENSG00000254632.1	RP11-21L23.4	3.73	0.000213	0.0262	0.18	0.17	Endometriosis;	chr11:76784085	chr11:76759916~76768223:-
LUAD	cis	rs831574	0.614	rs6806547	ENSG00000239653.1	PSMD6-AS2	3.73	0.000213	0.0262	0.15	0.17	Metabolite levels (Dihydroxy docosatrienoic acid);	chr3:63907801	chr3:64004022~64012148:+
LUAD	cis	rs683250	0.661	rs2507857	ENSG00000246067.6	RAB30-AS1	-3.73	0.000213	0.0262	-0.18	-0.17	Subcortical brain region volumes;	chr11:83417909	chr11:83072066~83106719:+
LUAD	cis	rs683250	0.661	rs2507858	ENSG00000246067.6	RAB30-AS1	-3.73	0.000213	0.0262	-0.18	-0.17	Subcortical brain region volumes;	chr11:83417929	chr11:83072066~83106719:+
LUAD	cis	rs683250	0.662	rs2512678	ENSG00000246067.6	RAB30-AS1	-3.73	0.000213	0.0262	-0.18	-0.17	Subcortical brain region volumes;	chr11:83418126	chr11:83072066~83106719:+
LUAD	cis	rs683250	0.599	rs10898104	ENSG00000246067.6	RAB30-AS1	-3.73	0.000213	0.0262	-0.18	-0.17	Subcortical brain region volumes;	chr11:83359485	chr11:83072066~83106719:+
LUAD	cis	rs875971	0.638	rs35986979	ENSG00000273142.1	RP11-458F8.4	3.73	0.000213	0.0262	0.12	0.17	Aortic root size;	chr7:66624003	chr7:66902857~66906297:+
LUAD	cis	rs13113518	0.934	rs3805155	ENSG00000273257.1	RP11-177J6.1	3.73	0.000213	0.0262	0.18	0.17	Height;	chr4:55497842	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs7686261	ENSG00000273257.1	RP11-177J6.1	3.73	0.000213	0.0262	0.18	0.17	Height;	chr4:55500224	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs11729220	ENSG00000273257.1	RP11-177J6.1	3.73	0.000213	0.0262	0.18	0.17	Height;	chr4:55501629	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs11133390	ENSG00000273257.1	RP11-177J6.1	3.73	0.000213	0.0262	0.18	0.17	Height;	chr4:55501726	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs11133391	ENSG00000273257.1	RP11-177J6.1	3.73	0.000213	0.0262	0.18	0.17	Height;	chr4:55501788	chr4:55387949~55388271:+
LUAD	cis	rs13113518	0.966	rs13133484	ENSG00000273257.1	RP11-177J6.1	3.73	0.000213	0.0262	0.18	0.17	Height;	chr4:55504176	chr4:55387949~55388271:+
LUAD	cis	rs13113518	0.934	rs13127906	ENSG00000273257.1	RP11-177J6.1	3.73	0.000213	0.0262	0.18	0.17	Height;	chr4:55504201	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs6849433	ENSG00000273257.1	RP11-177J6.1	3.73	0.000213	0.0262	0.18	0.17	Height;	chr4:55506498	chr4:55387949~55388271:+
LUAD	cis	rs7200543	1	rs4985124	ENSG00000260735.1	RP11-72I8.1	-3.73	0.000213	0.0262	-0.18	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15031584	chr16:15094411~15109197:+
LUAD	cis	rs7212590	0.618	rs56142307	ENSG00000263422.1	AC005702.1	3.73	0.000213	0.0262	0.38	0.17	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59800788	chr17:60042361~60042442:-
LUAD	cis	rs117526668	0.737	rs59108105	ENSG00000252652.1	Y_RNA	3.73	0.000213	0.0262	0.3	0.17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);Response to abacavir-containing treatment in HIV-1 infection (virologic failure);	chr11:44255055	chr11:43331261~43331356:+
LUAD	cis	rs801193	1	rs7785213	ENSG00000222364.1	RNU6-96P	3.73	0.000213	0.0262	0.19	0.17	Aortic root size;	chr7:66673991	chr7:66395191~66395286:+
LUAD	cis	rs42490	0.716	rs42346	ENSG00000251136.7	RP11-37B2.1	3.73	0.000213	0.0262	0.17	0.17	Leprosy;	chr8:89816829	chr8:89609409~89757727:-
LUAD	cis	rs6964587	1	rs35653487	ENSG00000188693.7	CYP51A1-AS1	-3.73	0.000213	0.0262	-0.2	-0.17	Breast cancer;	chr7:92116127	chr7:92134604~92180725:+
LUAD	cis	rs6964587	1	rs2301559	ENSG00000188693.7	CYP51A1-AS1	-3.73	0.000213	0.0262	-0.2	-0.17	Breast cancer;	chr7:92117413	chr7:92134604~92180725:+
LUAD	cis	rs10102546	1	rs4870833	ENSG00000244642.3	RN7SL396P	3.73	0.000213	0.0262	0.19	0.17	Smoking cessation;	chr8:119537544	chr8:119862662~119862956:+
LUAD	cis	rs4795519	1	rs1521561	ENSG00000266313.1	RP11-173M1.4	3.73	0.000213	0.0262	0.21	0.17	Chronic myeloid leukemia;	chr17:27073708	chr17:27333256~27348491:+
LUAD	cis	rs7429990	0.965	rs1060407	ENSG00000228638.1	FCF1P2	-3.73	0.000213	0.0262	-0.2	-0.17	Educational attainment (years of education);	chr3:47916547	chr3:48290793~48291375:-
LUAD	cis	rs2115630	0.936	rs8033459	ENSG00000259728.4	LINC00933	-3.73	0.000213	0.0262	-0.2	-0.17	P wave terminal force;	chr15:84710027	chr15:84570649~84580175:+
LUAD	cis	rs3002142	0.554	rs77763135	ENSG00000272750.1	RP11-378J18.8	3.73	0.000213	0.0262	0.26	0.17	LDL peak particle diameter (total fat intake interaction);	chr1:222684075	chr1:222658867~222661512:-
LUAD	cis	rs3002142	0.554	rs17163431	ENSG00000272750.1	RP11-378J18.8	3.73	0.000213	0.0262	0.26	0.17	LDL peak particle diameter (total fat intake interaction);	chr1:222685056	chr1:222658867~222661512:-
LUAD	cis	rs8002861	0.935	rs4942256	ENSG00000274001.1	RP11-5G9.5	3.73	0.000213	0.0262	0.18	0.17	Leprosy;	chr13:43881784	chr13:43877715~43878163:-
LUAD	cis	rs8002861	0.935	rs9567299	ENSG00000274001.1	RP11-5G9.5	3.73	0.000213	0.0262	0.18	0.17	Leprosy;	chr13:43882833	chr13:43877715~43878163:-
LUAD	cis	rs5758511	0.68	rs34107327	ENSG00000233903.2	Z83851.4	3.73	0.000213	0.0262	0.25	0.17	Birth weight;	chr22:42252347	chr22:42276355~42277052:+
LUAD	cis	rs4853525	0.561	rs11898764	ENSG00000235852.1	AC005540.3	-3.73	0.000213	0.0262	-0.21	-0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190847844	chr2:190880797~190882059:-
LUAD	cis	rs6502050	0.769	rs9916231	ENSG00000266654.1	RP11-1376P16.1	-3.73	0.000213	0.0262	-0.18	-0.17	Life satisfaction;	chr17:82161769	chr17:82160056~82160452:+
LUAD	cis	rs6951245	1	rs80031817	ENSG00000224079.1	AC091729.7	-3.73	0.000213	0.0262	-0.27	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057157	chr7:1074450~1078036:+
LUAD	cis	rs6951245	1	rs78143408	ENSG00000224079.1	AC091729.7	-3.73	0.000213	0.0262	-0.27	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057210	chr7:1074450~1078036:+
LUAD	cis	rs6951245	0.938	rs78351779	ENSG00000224079.1	AC091729.7	-3.73	0.000213	0.0262	-0.27	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057387	chr7:1074450~1078036:+
LUAD	cis	rs6951245	1	rs11761941	ENSG00000224079.1	AC091729.7	-3.73	0.000213	0.0262	-0.27	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057547	chr7:1074450~1078036:+
LUAD	cis	rs6951245	1	rs11767527	ENSG00000224079.1	AC091729.7	-3.73	0.000213	0.0262	-0.27	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057758	chr7:1074450~1078036:+
LUAD	cis	rs7131987	0.565	rs2882294	ENSG00000257176.2	RP11-996F15.2	3.73	0.000213	0.0262	0.17	0.17	QT interval;	chr12:29245019	chr12:29280418~29317848:-
LUAD	cis	rs9925964	0.967	rs2855475	ENSG00000232748.3	RP11-196G11.6	-3.73	0.000213	0.0262	-0.21	-0.17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31136227	chr16:31056460~31062803:+
LUAD	cis	rs2274273	0.686	rs28631821	ENSG00000258413.1	RP11-665C16.6	-3.73	0.000213	0.0262	-0.21	-0.17	Protein biomarker;	chr14:55379269	chr14:55262767~55272075:-
LUAD	cis	rs2274273	0.87	rs946059	ENSG00000258413.1	RP11-665C16.6	-3.73	0.000213	0.0262	-0.21	-0.17	Protein biomarker;	chr14:55380748	chr14:55262767~55272075:-
LUAD	cis	rs7512552	0.839	rs1260367	ENSG00000275557.1	RP11-353N4.6	3.73	0.000213	0.0262	0.19	0.17	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150372038	chr1:149607765~149612402:+
LUAD	cis	rs77972916	0.561	rs72788900	ENSG00000234936.1	AC010883.5	3.73	0.000213	0.0262	0.24	0.17	Granulocyte percentage of myeloid white cells;	chr2:43331948	chr2:43229573~43233394:+
LUAD	cis	rs7712401	0.655	rs6884312	ENSG00000249996.1	RP11-359P5.1	3.73	0.000213	0.0262	0.2	0.17	Mean platelet volume;	chr5:122768282	chr5:123036271~123054667:+
LUAD	cis	rs9928842	0.765	rs4479268	ENSG00000261476.1	RP11-77K12.3	3.73	0.000213	0.0262	0.22	0.17	Alcoholic chronic pancreatitis;	chr16:75190835	chr16:75458252~75460017:-
LUAD	cis	rs9549260	0.564	rs8000965	ENSG00000168852.11	TPTE2P5	3.73	0.000213	0.0262	0.16	0.17	Red blood cell count;	chr13:40705352	chr13:40822296~40921749:-
LUAD	cis	rs8058578	0.943	rs35629860	ENSG00000232748.3	RP11-196G11.6	-3.73	0.000213	0.0262	-0.22	-0.17	Multiple myeloma;	chr16:30660211	chr16:31056460~31062803:+
LUAD	cis	rs8058578	1	rs67128646	ENSG00000232748.3	RP11-196G11.6	-3.73	0.000213	0.0262	-0.22	-0.17	Multiple myeloma;	chr16:30660776	chr16:31056460~31062803:+
LUAD	cis	rs9467773	1	rs9467783	ENSG00000228223.2	HCG11	-3.73	0.000213	0.0262	-0.18	-0.17	Intelligence (multi-trait analysis);	chr6:26542666	chr6:26523450~26526579:+
LUAD	cis	rs847577	0.54	rs3847055	ENSG00000272950.1	RP11-307C18.1	-3.73	0.000213	0.0262	-0.24	-0.17	Breast cancer;	chr7:98051333	chr7:98322853~98323430:+
LUAD	cis	rs875971	0.929	rs34406470	ENSG00000273142.1	RP11-458F8.4	-3.73	0.000213	0.0262	-0.12	-0.17	Aortic root size;	chr7:66464969	chr7:66902857~66906297:+
LUAD	cis	rs12216545	0.695	rs10276888	ENSG00000177590.7	GIMAP3P	-3.73	0.000213	0.0262	-0.17	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150533238	chr7:150746893~150747728:-
LUAD	cis	rs34779708	0.966	rs12773647	ENSG00000271335.4	RP11-324I22.4	3.73	0.000214	0.0262	0.18	0.17	Inflammatory bowel disease;Crohn's disease;	chr10:35151399	chr10:35314552~35336401:-
LUAD	cis	rs4795519	0.778	rs1851268	ENSG00000266313.1	RP11-173M1.4	3.73	0.000214	0.0262	0.21	0.17	Chronic myeloid leukemia;	chr17:27070342	chr17:27333256~27348491:+
LUAD	cis	rs11018904	0.861	rs12786959	ENSG00000280367.1	RP11-121L10.2	3.73	0.000214	0.0262	0.22	0.17	Intelligence (multi-trait analysis);	chr11:90210508	chr11:90223153~90226538:+
LUAD	cis	rs11018904	0.861	rs12787117	ENSG00000280367.1	RP11-121L10.2	3.73	0.000214	0.0262	0.22	0.17	Intelligence (multi-trait analysis);	chr11:90210513	chr11:90223153~90226538:+
LUAD	cis	rs6737205	0.579	rs937813	ENSG00000223522.1	AC093690.1	3.73	0.000214	0.0262	0.25	0.17	RR interval (tricyclic/tetracyclic antidepressant use interaction);	chr2:28078673	chr2:28307691~28310459:-
LUAD	cis	rs4716602	0.596	rs10244786	ENSG00000236018.2	RP4-814D15.1	-3.73	0.000214	0.0262	-0.18	-0.17	Anti-saccade response;	chr7:156365295	chr7:157197600~157198511:-
LUAD	cis	rs6460942	0.63	rs1866650	ENSG00000226690.5	AC005281.1	3.73	0.000214	0.0262	0.29	0.17	Coronary artery disease;	chr7:12357271	chr7:12496429~12541910:+
LUAD	cis	rs11240074	0.57	rs17160256	ENSG00000244371.2	PFN1P8	-3.73	0.000214	0.0262	-0.29	-0.17	Type 2 diabetes;	chr1:147495392	chr1:146957117~146957659:-
LUAD	cis	rs9303542	0.959	rs6504172	ENSG00000264920.1	RP11-6N17.4	-3.73	0.000214	0.0262	-0.22	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48330072	chr17:47891255~47895812:-
LUAD	cis	rs2976388	0.556	rs4736323	ENSG00000253741.1	CTD-2292P10.4	3.73	0.000214	0.0262	0.2	0.17	Urinary tract infection frequency;	chr8:142748941	chr8:142702252~142726973:-
LUAD	cis	rs9549260	0.816	rs7337995	ENSG00000168852.11	TPTE2P5	3.73	0.000214	0.0262	0.16	0.17	Red blood cell count;	chr13:40674903	chr13:40822296~40921749:-
LUAD	cis	rs11134654	1	rs1895409	ENSG00000253966.1	CTC-455F18.3	-3.73	0.000214	0.0263	-0.27	-0.17	Smooth-surface caries;	chr5:170814245	chr5:170896929~170904461:+
LUAD	cis	rs11134654	0.935	rs1895410	ENSG00000253966.1	CTC-455F18.3	-3.73	0.000214	0.0263	-0.27	-0.17	Smooth-surface caries;	chr5:170814302	chr5:170896929~170904461:+
LUAD	cis	rs13068223	0.792	rs344034	ENSG00000243926.1	TIPARP-AS1	-3.73	0.000214	0.0263	-0.17	-0.17	Age-related hearing impairment (SNP x SNP interaction);	chr3:156745215	chr3:156671862~156674378:-
LUAD	cis	rs911555	0.755	rs7147664	ENSG00000244691.1	RPL10AP1	-3.73	0.000214	0.0263	-0.22	-0.17	Intelligence (multi-trait analysis);	chr14:103497083	chr14:103412119~103412761:-
LUAD	cis	rs9813712	0.571	rs9836814	ENSG00000253540.4	FAM86HP	3.73	0.000214	0.0263	0.17	0.17	Response to amphetamines;	chr3:130216054	chr3:130099092~130111472:-
LUAD	cis	rs7584330	0.617	rs10202195	ENSG00000222032.1	AC112721.2	3.73	0.000214	0.0263	0.2	0.17	Prostate cancer;	chr2:237443485	chr2:237428920~237434822:-
LUAD	cis	rs950776	0.518	rs4887063	ENSG00000261762.1	RP11-650L12.2	-3.73	0.000214	0.0263	-0.19	-0.17	Sudden cardiac arrest;	chr15:78547373	chr15:78589123~78591276:-
LUAD	cis	rs73193808	0.901	rs67137684	ENSG00000215533.7	LINC00189	-3.73	0.000214	0.0263	-0.24	-0.17	Coronary artery disease;	chr21:29195373	chr21:29193480~29288205:+
LUAD	cis	rs2115630	0.791	rs2008262	ENSG00000229212.6	RP11-561C5.4	3.73	0.000214	0.0263	0.19	0.17	P wave terminal force;	chr15:84762039	chr15:85205440~85234795:-
LUAD	cis	rs321358	0.945	rs17458885	ENSG00000271390.1	RP11-89C3.3	3.73	0.000214	0.0263	0.28	0.17	Body mass index;	chr11:111117222	chr11:111089870~111090368:-
LUAD	cis	rs6674176	0.66	rs11210936	ENSG00000237950.1	RP11-7O11.3	3.73	0.000214	0.0263	0.21	0.17	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43925766	chr1:43944370~43946551:-
LUAD	cis	rs7107174	1	rs10899492	ENSG00000251323.2	RP11-452H21.4	3.73	0.000214	0.0263	0.21	0.17	Testicular germ cell tumor;	chr11:78398764	chr11:78423982~78429836:-
LUAD	cis	rs6988985	0.589	rs6471580	ENSG00000247317.3	RP11-273G15.2	-3.73	0.000214	0.0263	-0.19	-0.17	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142905285	chr8:142981738~143018437:-
LUAD	cis	rs6988985	0.589	rs6987382	ENSG00000247317.3	RP11-273G15.2	-3.73	0.000214	0.0263	-0.19	-0.17	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142905775	chr8:142981738~143018437:-
LUAD	cis	rs1799949	1	rs4793229	ENSG00000267340.1	RP11-242D8.3	-3.73	0.000214	0.0263	-0.17	-0.17	Menopause (age at onset);	chr17:43340966	chr17:43169880~43170077:-
LUAD	cis	rs6137287	0.667	rs753049	ENSG00000227063.5	RPL41P1	-3.73	0.000214	0.0263	-0.22	-0.17	Height;	chr20:21289427	chr20:21755270~21755350:+
LUAD	cis	rs526231	0.819	rs26232	ENSG00000175749.11	EIF3KP1	3.73	0.000214	0.0263	0.22	0.17	Primary biliary cholangitis;	chr5:103261019	chr5:103032376~103033031:+
LUAD	cis	rs9313772	1	rs7715501	ENSG00000276778.1	RP11-524N5.1	3.73	0.000214	0.0263	0.18	0.17	Blood pressure;	chr5:158375262	chr5:158320683~158409773:-
LUAD	cis	rs858239	0.669	rs6461688	ENSG00000230042.1	AK3P3	-3.73	0.000214	0.0263	-0.21	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23076996	chr7:23129178~23129841:+
LUAD	cis	rs3849150	0.95	rs12248178	ENSG00000235939.1	RP11-123B3.2	-3.73	0.000214	0.0263	-0.24	-0.17	Subclinical atherosclerosis traits (other);	chr10:48887374	chr10:49419277~49472903:+
LUAD	cis	rs67478160	0.583	rs12879612	ENSG00000272533.1	SNORA28	3.73	0.000214	0.0263	0.17	0.17	Schizophrenia;	chr14:103767281	chr14:103337849~103337974:+
LUAD	cis	rs2494663	0.61	rs11264875	ENSG00000223599.1	RP11-216N14.7	3.73	0.000214	0.0263	0.2	0.17	Mean platelet volume;	chr1:154022171	chr1:153852106~153853414:-
LUAD	cis	rs6471393	0.964	rs2914941	ENSG00000253848.1	RP11-10N23.5	3.73	0.000214	0.0263	0.21	0.17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93716983	chr8:93741193~93744534:+
LUAD	cis	rs4934494	0.813	rs12775783	ENSG00000240996.1	RP11-80H5.7	-3.73	0.000214	0.0263	-0.23	-0.17	Red blood cell count;	chr10:89646494	chr10:89694295~89697928:-
LUAD	cis	rs4474465	1	rs11602360	ENSG00000251323.2	RP11-452H21.4	-3.73	0.000214	0.0263	-0.21	-0.17	Alzheimer's disease (survival time);	chr11:78468290	chr11:78423982~78429836:-
LUAD	cis	rs375066	0.901	rs438517	ENSG00000278917.1	RP11-15A1.4	-3.73	0.000214	0.0263	-0.18	-0.17	Breast cancer;	chr19:43915506	chr19:43891233~43895411:+
LUAD	cis	rs375066	0.935	rs446674	ENSG00000278917.1	RP11-15A1.4	-3.73	0.000214	0.0263	-0.18	-0.17	Breast cancer;	chr19:43916855	chr19:43891233~43895411:+
LUAD	cis	rs1150668	0.768	rs1150709	ENSG00000219392.1	RP1-265C24.5	3.73	0.000214	0.0263	0.2	0.17	Pubertal anthropometrics;	chr6:28239585	chr6:28115628~28116551:+
LUAD	cis	rs4664293	0.867	rs7579206	ENSG00000230783.1	AC009961.2	-3.73	0.000214	0.0263	-0.2	-0.17	Monocyte percentage of white cells;	chr2:159715992	chr2:159689217~159690291:-
LUAD	cis	rs4842666	0.915	rs11105352	ENSG00000258302.2	RP11-981P6.1	3.73	0.000214	0.0263	0.25	0.17	Blood pressure;	chr12:89632685	chr12:89561129~89594878:+
LUAD	cis	rs4842666	0.915	rs11105353	ENSG00000258302.2	RP11-981P6.1	3.73	0.000214	0.0263	0.25	0.17	Blood pressure;	chr12:89632686	chr12:89561129~89594878:+
LUAD	cis	rs4842666	0.915	rs11105354	ENSG00000258302.2	RP11-981P6.1	3.73	0.000214	0.0263	0.25	0.17	Blood pressure;	chr12:89632746	chr12:89561129~89594878:+
LUAD	cis	rs6570726	0.935	rs398060	ENSG00000235652.6	RP11-545I5.3	-3.73	0.000214	0.0263	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145520379	chr6:145799409~145886585:+
LUAD	cis	rs957448	0.554	rs12680855	ENSG00000253175.1	RP11-267M23.6	3.73	0.000214	0.0263	0.19	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94570427	chr8:94565036~94565715:+
LUAD	cis	rs6088590	0.523	rs6088536	ENSG00000276073.1	RP5-1125A11.7	-3.73	0.000214	0.0263	-0.16	-0.17	Coronary artery disease;	chr20:34601302	chr20:33985617~33988989:-
LUAD	cis	rs6494488	0.5	rs72741328	ENSG00000239465.1	RP11-330L19.2	3.73	0.000214	0.0263	0.36	0.17	Coronary artery disease;	chr15:64442140	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs72741329	ENSG00000239465.1	RP11-330L19.2	3.73	0.000214	0.0263	0.36	0.17	Coronary artery disease;	chr15:64443892	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs112640485	ENSG00000239465.1	RP11-330L19.2	3.73	0.000214	0.0263	0.36	0.17	Coronary artery disease;	chr15:64448611	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs72741336	ENSG00000239465.1	RP11-330L19.2	3.73	0.000214	0.0263	0.36	0.17	Coronary artery disease;	chr15:64465718	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs112190405	ENSG00000239465.1	RP11-330L19.2	3.73	0.000214	0.0263	0.36	0.17	Coronary artery disease;	chr15:64473826	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs72741344	ENSG00000239465.1	RP11-330L19.2	3.73	0.000214	0.0263	0.36	0.17	Coronary artery disease;	chr15:64475332	chr15:64631109~64631914:-
LUAD	cis	rs8028182	0.636	rs11634863	ENSG00000246877.1	DNM1P35	3.73	0.000214	0.0263	0.22	0.17	Sudden cardiac arrest;	chr15:75474331	chr15:75727670~75738623:-
LUAD	cis	rs34421088	0.56	rs2245357	ENSG00000255046.1	RP11-297N6.4	3.73	0.000214	0.0263	0.21	0.17	Neuroticism;	chr8:11541975	chr8:11797928~11802568:-
LUAD	cis	rs728616	0.867	rs17886286	ENSG00000225484.5	NUTM2B-AS1	-3.73	0.000214	0.0263	-0.42	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79944096	chr10:79663088~79826594:-
LUAD	cis	rs4713118	0.513	rs149897	ENSG00000216901.1	AL022393.7	3.73	0.000214	0.0263	0.2	0.17	Parkinson's disease;	chr6:28038872	chr6:28176188~28176674:+
LUAD	cis	rs4713118	0.513	rs156734	ENSG00000216901.1	AL022393.7	3.73	0.000214	0.0263	0.2	0.17	Parkinson's disease;	chr6:28039579	chr6:28176188~28176674:+
LUAD	cis	rs6540731	0.935	rs903120	ENSG00000229983.1	RP11-15I11.2	3.73	0.000214	0.0263	0.2	0.17	Intelligence (childhood);	chr1:212231830	chr1:212168207~212190259:+
LUAD	cis	rs6540731	1	rs2087946	ENSG00000229983.1	RP11-15I11.2	3.73	0.000214	0.0263	0.2	0.17	Intelligence (childhood);	chr1:212232054	chr1:212168207~212190259:+
LUAD	cis	rs6540731	1	rs903121	ENSG00000229983.1	RP11-15I11.2	3.73	0.000214	0.0263	0.2	0.17	Intelligence (childhood);	chr1:212232113	chr1:212168207~212190259:+
LUAD	cis	rs3020736	0.5	rs1801311	ENSG00000273366.1	CTA-989H11.1	3.73	0.000214	0.0263	0.2	0.17	Autism spectrum disorder or schizophrenia;	chr22:42090719	chr22:42278188~42278846:+
LUAD	cis	rs1044826	1	rs1586863	ENSG00000214280.3	RP11-553K23.2	-3.73	0.000214	0.0263	-0.2	-0.17	Obesity-related traits;	chr3:139419400	chr3:139582928~139583593:-
LUAD	cis	rs2190016	0.673	rs62446187	ENSG00000236078.1	LINC01447	-3.73	0.000214	0.0263	-0.2	-0.17	Mammographic density (non-dense area);	chr7:46846894	chr7:47621939~47629893:+
LUAD	cis	rs2190016	0.673	rs62446188	ENSG00000236078.1	LINC01447	-3.73	0.000214	0.0263	-0.2	-0.17	Mammographic density (non-dense area);	chr7:46847135	chr7:47621939~47629893:+
LUAD	cis	rs2190016	0.673	rs73091727	ENSG00000236078.1	LINC01447	-3.73	0.000214	0.0263	-0.2	-0.17	Mammographic density (non-dense area);	chr7:46847456	chr7:47621939~47629893:+
LUAD	cis	rs2190016	0.673	rs62446189	ENSG00000236078.1	LINC01447	-3.73	0.000214	0.0263	-0.2	-0.17	Mammographic density (non-dense area);	chr7:46847637	chr7:47621939~47629893:+
LUAD	cis	rs7121538	0.673	rs11023165	ENSG00000254418.1	RP11-21L19.1	3.73	0.000214	0.0263	0.28	0.17	HDL cholesterol;	chr11:14263750	chr11:14262846~14273691:-
LUAD	cis	rs2898681	0.739	rs1047959	ENSG00000248375.1	RP11-177B4.1	-3.73	0.000214	0.0263	-0.24	-0.17	Optic nerve measurement (cup area);	chr4:52873689	chr4:52720081~52720831:-
LUAD	cis	rs801193	1	rs2003301	ENSG00000222364.1	RNU6-96P	3.73	0.000214	0.0263	0.19	0.17	Aortic root size;	chr7:66682669	chr7:66395191~66395286:+
LUAD	cis	rs61542988	0.57	rs62448268	ENSG00000226329.2	AC005682.6	3.73	0.000215	0.0263	0.25	0.17	Fibrinogen levels;	chr7:22789845	chr7:22863874~22881350:-
LUAD	cis	rs67981189	0.896	rs12100737	ENSG00000269927.1	RP6-91H8.3	-3.73	0.000215	0.0263	-0.21	-0.17	Schizophrenia;	chr14:71004383	chr14:71141125~71143253:-
LUAD	cis	rs4474465	0.703	rs10899547	ENSG00000251323.2	RP11-452H21.4	-3.73	0.000215	0.0263	-0.2	-0.17	Alzheimer's disease (survival time);	chr11:78543674	chr11:78423982~78429836:-
LUAD	cis	rs2904524	1	rs2091131	ENSG00000257815.4	RP11-611E13.2	-3.73	0.000215	0.0263	-0.25	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70294834	chr12:69904033~70243360:-
LUAD	cis	rs2904524	1	rs17107947	ENSG00000257815.4	RP11-611E13.2	-3.73	0.000215	0.0263	-0.25	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70295689	chr12:69904033~70243360:-
LUAD	cis	rs2904524	1	rs75796761	ENSG00000257815.4	RP11-611E13.2	-3.73	0.000215	0.0263	-0.25	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70298071	chr12:69904033~70243360:-
LUAD	cis	rs2904524	1	rs77397439	ENSG00000257815.4	RP11-611E13.2	-3.73	0.000215	0.0263	-0.25	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70313566	chr12:69904033~70243360:-
LUAD	cis	rs4144027	0.967	rs56126771	ENSG00000258534.1	CTD-2134A5.4	-3.73	0.000215	0.0263	-0.19	-0.17	Blood metabolite levels;	chr14:103894806	chr14:103854366~103880111:-
LUAD	cis	rs17275866	0.963	rs4342175	ENSG00000251584.1	RP11-440I14.3	3.73	0.000215	0.0263	0.23	0.17	Chin dimples;	chr4:174144905	chr4:174536640~174540784:+
LUAD	cis	rs8028182	0.549	rs10775209	ENSG00000246877.1	DNM1P35	-3.73	0.000215	0.0263	-0.22	-0.17	Sudden cardiac arrest;	chr15:75342418	chr15:75727670~75738623:-
LUAD	cis	rs8046148	0.789	rs6500287	ENSG00000279356.1	RP11-429P3.8	-3.73	0.000215	0.0263	-0.17	-0.17	Testicular germ cell tumor;	chr16:50114422	chr16:50072862~50074986:+
LUAD	cis	rs34929064	1	rs2097677	ENSG00000230658.1	KLHL7-AS1	3.73	0.000215	0.0264	0.23	0.17	Major depression and alcohol dependence;	chr7:22693220	chr7:23101228~23105703:-
LUAD	cis	rs1908814	0.516	rs13275143	ENSG00000255046.1	RP11-297N6.4	-3.73	0.000215	0.0264	-0.21	-0.17	Neuroticism;	chr8:11939481	chr8:11797928~11802568:-
LUAD	cis	rs3617	0.625	rs6769789	ENSG00000242142.1	SERBP1P3	-3.73	0.000215	0.0264	-0.18	-0.17	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52840430	chr3:53064283~53065091:-
LUAD	cis	rs7829975	0.871	rs777709	ENSG00000173295.6	FAM86B3P	-3.73	0.000215	0.0264	-0.18	-0.17	Mood instability;	chr8:8726362	chr8:8228595~8244865:+
LUAD	cis	rs7242404	0.57	rs12457255	ENSG00000267654.1	RP11-973H7.4	3.73	0.000215	0.0264	0.2	0.17	Interleukin-9 levels;Macrophage inflammatory protein 1a levels;	chr18:12759977	chr18:12739490~12749421:-
LUAD	cis	rs7578361	0.959	rs12329354	ENSG00000231969.1	AC144449.1	-3.73	0.000215	0.0264	-0.24	-0.17	Acute lymphoblastic leukemia (childhood);	chr2:149596205	chr2:149587196~149848233:+
LUAD	cis	rs17711722	0.701	rs781143	ENSG00000273142.1	RP11-458F8.4	-3.73	0.000215	0.0264	-0.12	-0.17	Calcium levels;	chr7:65974892	chr7:66902857~66906297:+
LUAD	cis	rs2832191	0.935	rs11910475	ENSG00000215533.7	LINC00189	3.73	0.000215	0.0264	0.19	0.17	Dental caries;	chr21:29147381	chr21:29193480~29288205:+
LUAD	cis	rs2836974	0.899	rs35774464	ENSG00000232608.1	TIMM9P2	-3.73	0.000215	0.0264	-0.21	-0.17	Cognitive function;	chr21:39208243	chr21:39216624~39217506:+
LUAD	cis	rs8028182	0.636	rs28623700	ENSG00000246877.1	DNM1P35	3.73	0.000215	0.0264	0.22	0.17	Sudden cardiac arrest;	chr15:75557373	chr15:75727670~75738623:-
LUAD	cis	rs8028182	0.577	rs28693593	ENSG00000246877.1	DNM1P35	3.73	0.000215	0.0264	0.22	0.17	Sudden cardiac arrest;	chr15:75557435	chr15:75727670~75738623:-
LUAD	cis	rs8050896	1	rs75283386	ENSG00000260695.1	RP11-513N24.1	-3.73	0.000215	0.0264	-0.29	-0.17	Response to antipsychotic treatment;	chr16:66122008	chr16:65861112~65863784:-
LUAD	cis	rs7940866	0.838	rs1118137	ENSG00000255262.3	TCEB2P2	3.73	0.000215	0.0264	0.19	0.17	Schizophrenia;	chr11:131021075	chr11:130032866~130033220:-
LUAD	cis	rs2548724	0.796	rs62369304	ENSG00000250682.4	LINC00491	3.73	0.000215	0.0264	0.22	0.17	Type 2 diabetes;	chr5:102375694	chr5:102609156~102671559:-
LUAD	cis	rs858239	0.6	rs6967475	ENSG00000226816.2	AC005082.12	3.73	0.000215	0.0264	0.22	0.17	Cerebrospinal fluid biomarker levels;	chr7:23089363	chr7:23206013~23208045:+
LUAD	cis	rs6493487	0.512	rs16963912	ENSG00000273674.3	CTD-2378E12.1	3.73	0.000215	0.0264	0.24	0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50821975	chr15:50839875~50908599:-
LUAD	cis	rs7809950	0.911	rs1015411	ENSG00000238832.1	snoU109	-3.73	0.000215	0.0264	-0.25	-0.17	Coronary artery disease;	chr7:107495167	chr7:107603363~107603507:+
LUAD	cis	rs73230612	0.858	rs7629668	ENSG00000242767.1	ZBTB20-AS4	-3.73	0.000215	0.0264	-0.24	-0.17	Type 2 diabetes;	chr3:115380170	chr3:115100423~115103061:+
LUAD	cis	rs7584330	0.868	rs67071074	ENSG00000222032.1	AC112721.2	3.73	0.000215	0.0264	0.2	0.17	Prostate cancer;	chr2:237486786	chr2:237428920~237434822:-
LUAD	cis	rs11096990	0.551	rs11724855	ENSG00000249685.1	RP11-360F5.3	3.73	0.000215	0.0264	0.2	0.17	Cognitive function;	chr4:39163379	chr4:39133913~39135608:+
LUAD	cis	rs4819052	0.851	rs8126930	ENSG00000215447.6	BX322557.10	-3.73	0.000215	0.0264	-0.19	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251800	chr21:45288052~45291738:+
LUAD	cis	rs6903823	0.508	rs1150726	ENSG00000176933.5	TOB2P1	-3.73	0.000215	0.0264	-0.19	-0.17	Pulmonary function;	chr6:28275265	chr6:28217643~28218634:-
LUAD	cis	rs5742933	0.857	rs11685425	ENSG00000253559.1	OSGEPL1-AS1	3.73	0.000215	0.0264	0.2	0.17	Ferritin levels;	chr2:189747977	chr2:189762704~189765556:+
LUAD	cis	rs875971	1	rs709595	ENSG00000273142.1	RP11-458F8.4	-3.73	0.000215	0.0264	-0.12	-0.17	Aortic root size;	chr7:66352346	chr7:66902857~66906297:+
LUAD	cis	rs875971	1	rs811880	ENSG00000273142.1	RP11-458F8.4	-3.73	0.000215	0.0264	-0.12	-0.17	Aortic root size;	chr7:66353659	chr7:66902857~66906297:+
LUAD	cis	rs911555	0.511	rs8007489	ENSG00000258851.1	RP11-894P9.2	3.73	0.000215	0.0264	0.2	0.17	Intelligence (multi-trait analysis);	chr14:103588235	chr14:103553421~103561877:+
LUAD	cis	rs9308731	0.591	rs10439396	ENSG00000227992.1	AC108463.2	-3.73	0.000215	0.0264	-0.2	-0.17	Chronic lymphocytic leukemia;	chr2:111178399	chr2:111203964~111206215:-
LUAD	cis	rs3916	0.911	rs2239758	ENSG00000277423.1	RP11-173P15.9	-3.73	0.000215	0.0264	-0.21	-0.17	Urinary metabolites (H-NMR features);	chr12:120724834	chr12:120703867~120704282:+
LUAD	cis	rs10102546	1	rs1446071	ENSG00000244642.3	RN7SL396P	3.73	0.000215	0.0264	0.19	0.17	Smoking cessation;	chr8:119538120	chr8:119862662~119862956:+
LUAD	cis	rs10129255	0.956	rs10137268	ENSG00000211967.3	IGHV3-53	-3.73	0.000215	0.0264	-0.13	-0.17	Kawasaki disease;	chr14:106697402	chr14:106592676~106593347:-
LUAD	cis	rs806321	0.587	rs2703088	ENSG00000237152.3	DLEU7-AS1	-3.73	0.000215	0.0264	-0.21	-0.17	Multiple sclerosis;	chr13:50188808	chr13:50807856~50849905:+
LUAD	cis	rs897984	0.513	rs17839568	ENSG00000232748.3	RP11-196G11.6	-3.73	0.000215	0.0264	-0.21	-0.17	Dementia with Lewy bodies;	chr16:31088462	chr16:31056460~31062803:+
LUAD	cis	rs7176527	1	rs7176527	ENSG00000259570.1	RP11-671M22.4	-3.73	0.000215	0.0264	-0.25	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84597563	chr15:84394512~84395514:+
LUAD	cis	rs755249	0.529	rs3768299	ENSG00000182109.6	RP11-69E11.4	3.73	0.000215	0.0264	0.21	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39391520	chr1:39522280~39546187:-
LUAD	cis	rs7107174	1	rs114142124	ENSG00000251323.2	RP11-452H21.4	3.73	0.000215	0.0264	0.22	0.17	Testicular germ cell tumor;	chr11:78336491	chr11:78423982~78429836:-
LUAD	cis	rs7615952	0.673	rs34209763	ENSG00000241288.6	RP11-379B18.5	-3.73	0.000215	0.0264	-0.25	-0.17	Blood pressure (smoking interaction);	chr3:125880752	chr3:125827238~125916384:-
LUAD	cis	rs7615952	0.8	rs35390120	ENSG00000241288.6	RP11-379B18.5	-3.73	0.000215	0.0264	-0.25	-0.17	Blood pressure (smoking interaction);	chr3:125880966	chr3:125827238~125916384:-
LUAD	cis	rs9309473	0.5	rs12997018	ENSG00000163016.8	ALMS1P	-3.73	0.000215	0.0264	-0.18	-0.17	Metabolite levels;	chr2:73685772	chr2:73644919~73685576:+
LUAD	cis	rs9309473	0.5	rs7608328	ENSG00000163016.8	ALMS1P	-3.73	0.000215	0.0264	-0.18	-0.17	Metabolite levels;	chr2:73686892	chr2:73644919~73685576:+
LUAD	cis	rs6933660	0.745	rs9397405	ENSG00000219395.2	HSPA8P15	-3.73	0.000215	0.0264	-0.16	-0.17	Menarche (age at onset);	chr6:151414949	chr6:151411259~151413945:-
LUAD	cis	rs238295	0.766	rs6038204	ENSG00000230563.2	RP5-828H9.1	3.73	0.000215	0.0264	0.22	0.17	Occipital cortical area (total cortical area interaction);	chr20:5568425	chr20:5471207~5475182:+
LUAD	cis	rs238295	0.631	rs6038205	ENSG00000230563.2	RP5-828H9.1	3.73	0.000215	0.0264	0.22	0.17	Occipital cortical area (total cortical area interaction);	chr20:5568427	chr20:5471207~5475182:+
LUAD	cis	rs238295	0.805	rs6085211	ENSG00000230563.2	RP5-828H9.1	3.73	0.000215	0.0264	0.22	0.17	Occipital cortical area (total cortical area interaction);	chr20:5572201	chr20:5471207~5475182:+
LUAD	cis	rs4795519	0.778	rs1402726	ENSG00000266313.1	RP11-173M1.4	3.73	0.000215	0.0264	0.21	0.17	Chronic myeloid leukemia;	chr17:27068744	chr17:27333256~27348491:+
LUAD	cis	rs875971	0.545	rs1638724	ENSG00000224316.1	RP11-479O9.2	-3.73	0.000215	0.0264	-0.19	-0.17	Aortic root size;	chr7:66575494	chr7:65773620~65802067:+
LUAD	cis	rs7242404	0.527	rs34946503	ENSG00000267654.1	RP11-973H7.4	3.73	0.000215	0.0264	0.19	0.17	Interleukin-9 levels;Macrophage inflammatory protein 1a levels;	chr18:12756232	chr18:12739490~12749421:-
LUAD	cis	rs4795519	1	rs4795481	ENSG00000266313.1	RP11-173M1.4	3.73	0.000215	0.0264	0.21	0.17	Chronic myeloid leukemia;	chr17:27141201	chr17:27333256~27348491:+
LUAD	cis	rs6061231	0.518	rs639836	ENSG00000275437.1	RP5-908M14.10	-3.73	0.000216	0.0264	-0.15	-0.17	Colorectal cancer;	chr20:62351167	chr20:62402236~62405935:-
LUAD	cis	rs11960314	0.643	rs2036559	ENSG00000253348.1	CTC-455F18.1	3.73	0.000216	0.0264	0.19	0.17	Age-related hearing impairment (SNP x SNP interaction);	chr5:170653180	chr5:170747047~170788650:-
LUAD	cis	rs5015933	0.788	rs359594	ENSG00000232630.1	PRPS1P2	-3.73	0.000216	0.0264	-0.16	-0.17	Body mass index;	chr9:125273062	chr9:125150653~125151589:+
LUAD	cis	rs6964587	1	rs7806157	ENSG00000188693.7	CYP51A1-AS1	-3.73	0.000216	0.0264	-0.2	-0.17	Breast cancer;	chr7:91972616	chr7:92134604~92180725:+
LUAD	cis	rs7727544	0.57	rs7701237	ENSG00000233006.5	AC034220.3	3.73	0.000216	0.0264	0.15	0.17	Blood metabolite levels;	chr5:132198688	chr5:132311285~132369916:-
LUAD	cis	rs8012947	0.916	rs28411823	ENSG00000279636.2	LINC00216	-3.73	0.000216	0.0264	-0.19	-0.17	Alcohol consumption in current drinkers;	chr14:58239891	chr14:58288033~58289158:+
LUAD	cis	rs7578361	0.959	rs4530332	ENSG00000231969.1	AC144449.1	-3.73	0.000216	0.0264	-0.24	-0.17	Acute lymphoblastic leukemia (childhood);	chr2:149588707	chr2:149587196~149848233:+
LUAD	cis	rs7578361	0.879	rs12463472	ENSG00000231969.1	AC144449.1	-3.73	0.000216	0.0264	-0.24	-0.17	Acute lymphoblastic leukemia (childhood);	chr2:149589131	chr2:149587196~149848233:+
LUAD	cis	rs860818	1	rs858234	ENSG00000226816.2	AC005082.12	-3.73	0.000216	0.0265	-0.4	-0.17	Initial pursuit acceleration;	chr7:23201196	chr7:23206013~23208045:+
LUAD	cis	rs7107174	0.688	rs869202	ENSG00000251323.2	RP11-452H21.4	3.73	0.000216	0.0265	0.22	0.17	Testicular germ cell tumor;	chr11:78416868	chr11:78423982~78429836:-
LUAD	cis	rs7107174	0.688	rs881361	ENSG00000251323.2	RP11-452H21.4	3.73	0.000216	0.0265	0.22	0.17	Testicular germ cell tumor;	chr11:78417001	chr11:78423982~78429836:-
LUAD	cis	rs7107174	0.681	rs881337	ENSG00000251323.2	RP11-452H21.4	3.73	0.000216	0.0265	0.22	0.17	Testicular germ cell tumor;	chr11:78417289	chr11:78423982~78429836:-
LUAD	cis	rs7107174	0.688	rs11237489	ENSG00000251323.2	RP11-452H21.4	3.73	0.000216	0.0265	0.22	0.17	Testicular germ cell tumor;	chr11:78419279	chr11:78423982~78429836:-
LUAD	cis	rs875971	0.642	rs35526611	ENSG00000273142.1	RP11-458F8.4	3.73	0.000216	0.0265	0.12	0.17	Aortic root size;	chr7:66629021	chr7:66902857~66906297:+
LUAD	cis	rs4767841	0.935	rs3213625	ENSG00000248636.5	RP11-768F21.1	-3.73	0.000216	0.0265	-0.19	-0.17	Urgency urinary incontinence;	chr12:119720724	chr12:119387987~119668079:-
LUAD	cis	rs4767841	0.935	rs3213626	ENSG00000248636.5	RP11-768F21.1	-3.73	0.000216	0.0265	-0.19	-0.17	Urgency urinary incontinence;	chr12:119720736	chr12:119387987~119668079:-
LUAD	cis	rs7077256	0.542	rs72831023	ENSG00000272767.1	JMJD1C-AS1	3.73	0.000216	0.0265	0.25	0.17	Intelligence (multi-trait analysis);	chr10:63296860	chr10:63465229~63466563:+
LUAD	cis	rs1124769	0.502	rs35088194	ENSG00000259378.1	DCAF13P3	3.73	0.000216	0.0265	0.24	0.17	Cognitive performance;	chr15:50773717	chr15:50944663~50945996:+
LUAD	cis	rs9341808	0.935	rs1535825	ENSG00000233967.5	RP11-250B2.3	-3.73	0.000216	0.0265	-0.16	-0.17	Sitting height ratio;	chr6:80228869	chr6:80443344~80465927:+
LUAD	cis	rs73230612	0.858	rs9289015	ENSG00000242767.1	ZBTB20-AS4	3.73	0.000216	0.0265	0.27	0.17	Type 2 diabetes;	chr3:115379747	chr3:115100423~115103061:+
LUAD	cis	rs2390582	0.679	rs10922884	ENSG00000233593.5	RP4-665J23.1	3.73	0.000216	0.0265	0.25	0.17	Coronary artery calcification;	chr1:90606628	chr1:90782986~90851650:-
LUAD	cis	rs12190007	0.934	rs10455745	ENSG00000224999.1	VTA1P1	-3.73	0.000216	0.0265	-0.16	-0.17	Obesity-related traits;	chr6:169343402	chr6:169296471~169297959:-
LUAD	cis	rs7772486	0.754	rs702323	ENSG00000235652.6	RP11-545I5.3	-3.73	0.000216	0.0265	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145687138	chr6:145799409~145886585:+
LUAD	cis	rs7428	0.527	rs6547612	ENSG00000246575.2	AC093162.5	3.73	0.000216	0.0265	0.16	0.17	Ear protrusion;	chr2:85324061	chr2:85315041~85316529:+
LUAD	cis	rs8058578	1	rs2289442	ENSG00000232748.3	RP11-196G11.6	-3.73	0.000216	0.0265	-0.21	-0.17	Multiple myeloma;	chr16:30728598	chr16:31056460~31062803:+
LUAD	cis	rs6933660	0.745	rs6557138	ENSG00000219395.2	HSPA8P15	-3.73	0.000216	0.0265	-0.16	-0.17	Menarche (age at onset);	chr6:151410882	chr6:151411259~151413945:-
LUAD	cis	rs6933660	0.665	rs6921042	ENSG00000219395.2	HSPA8P15	-3.73	0.000216	0.0265	-0.16	-0.17	Menarche (age at onset);	chr6:151411250	chr6:151411259~151413945:-
LUAD	cis	rs4927850	0.501	rs9881504	ENSG00000207650.1	MIR570	3.73	0.000216	0.0265	0.18	0.17	Pancreatic cancer;	chr3:195929743	chr3:195699401~195699497:+
LUAD	cis	rs56050415	1	rs11071371	ENSG00000277144.1	RP11-59H7.4	3.73	0.000216	0.0265	0.29	0.17	Metabolite levels (lipoprotein measures);	chr15:58284027	chr15:59115547~59116089:-
LUAD	cis	rs14027	0.559	rs9297603	ENSG00000279347.1	RP11-85I17.2	-3.73	0.000216	0.0265	-0.14	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119707078	chr8:119838736~119840385:-
LUAD	cis	rs16944613	0.541	rs6496690	ENSG00000259212.1	CTD-3065B20.2	3.73	0.000216	0.0265	0.27	0.17	Colorectal cancer;	chr15:90554169	chr15:90595840~90596447:-
LUAD	cis	rs62355901	0.552	rs16886128	ENSG00000271828.1	CTD-2310F14.1	3.73	0.000216	0.0265	0.32	0.17	Breast cancer;	chr5:56702258	chr5:56927874~56929573:+
LUAD	cis	rs1023500	0.596	rs5751209	ENSG00000273366.1	CTA-989H11.1	-3.73	0.000216	0.0265	-0.2	-0.17	Schizophrenia;	chr22:42055599	chr22:42278188~42278846:+
LUAD	cis	rs595244	1	rs682737	ENSG00000259705.1	RP11-227D13.1	3.73	0.000216	0.0265	0.34	0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48599574	chr15:48645951~48652016:+
LUAD	cis	rs6570726	0.967	rs6903252	ENSG00000235652.6	RP11-545I5.3	3.73	0.000216	0.0265	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145601641	chr6:145799409~145886585:+
LUAD	cis	rs4716602	0.596	rs10949585	ENSG00000235029.1	MNX1-AS2	-3.73	0.000216	0.0265	-0.21	-0.17	Anti-saccade response;	chr7:156372564	chr7:157006307~157007132:+
LUAD	cis	rs6743068	0.521	rs2349074	ENSG00000234842.1	AC007163.8	-3.73	0.000216	0.0265	-0.19	-0.17	Lymphocyte percentage of white cells;	chr2:201357784	chr2:201549631~201550307:+
LUAD	cis	rs7617773	0.78	rs34523942	ENSG00000199476.1	Y_RNA	-3.73	0.000216	0.0265	-0.22	-0.17	Coronary artery disease;	chr3:48301179	chr3:48288587~48288694:+
LUAD	cis	rs6502050	0.835	rs8081949	ENSG00000275966.1	RP11-1055B8.9	-3.73	0.000216	0.0265	-0.17	-0.17	Life satisfaction;	chr17:82159614	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs8071737	ENSG00000275966.1	RP11-1055B8.9	-3.73	0.000216	0.0265	-0.17	-0.17	Life satisfaction;	chr17:82159661	chr17:81345476~81345966:-
LUAD	cis	rs2274273	0.87	rs6573009	ENSG00000259318.1	RP11-454L9.2	3.73	0.000216	0.0265	0.15	0.17	Protein biomarker;	chr14:55215606	chr14:55394940~55395233:-
LUAD	cis	rs6467136	0.56	rs12666432	ENSG00000224138.1	AC000123.4	3.73	0.000216	0.0265	0.16	0.17	Type 2 diabetes;	chr7:127442898	chr7:127350128~127351523:+
LUAD	cis	rs3120667	0.72	rs12029431	ENSG00000237975.5	FLG-AS1	3.73	0.000216	0.0265	0.29	0.17	Eating disorders;	chr1:152419071	chr1:152168125~152445456:+
LUAD	cis	rs13434995	0.562	rs10529258	ENSG00000273257.1	RP11-177J6.1	-3.73	0.000216	0.0265	-0.23	-0.17	Adiponectin levels;	chr4:55546702	chr4:55387949~55388271:+
LUAD	cis	rs13434995	0.512	rs115635692	ENSG00000273257.1	RP11-177J6.1	-3.73	0.000216	0.0265	-0.23	-0.17	Adiponectin levels;	chr4:55546706	chr4:55387949~55388271:+
LUAD	cis	rs13434995	0.626	rs116135676	ENSG00000273257.1	RP11-177J6.1	-3.73	0.000216	0.0265	-0.23	-0.17	Adiponectin levels;	chr4:55546707	chr4:55387949~55388271:+
LUAD	cis	rs10463554	0.963	rs34829	ENSG00000250682.4	LINC00491	3.73	0.000216	0.0265	0.2	0.17	Parkinson's disease;	chr5:103108260	chr5:102609156~102671559:-
LUAD	cis	rs7512552	0.839	rs834231	ENSG00000275557.1	RP11-353N4.6	-3.73	0.000216	0.0265	-0.19	-0.17	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150416916	chr1:149607765~149612402:+
LUAD	cis	rs7551222	0.714	rs930947	ENSG00000240219.1	RP11-430C7.5	3.73	0.000216	0.0265	0.19	0.17	Schizophrenia;	chr1:204572069	chr1:204626775~204629712:+
LUAD	cis	rs7551222	0.714	rs4951404	ENSG00000240219.1	RP11-430C7.5	3.73	0.000216	0.0265	0.19	0.17	Schizophrenia;	chr1:204572214	chr1:204626775~204629712:+
LUAD	cis	rs9549260	0.604	rs9532587	ENSG00000168852.11	TPTE2P5	3.73	0.000216	0.0265	0.21	0.17	Red blood cell count;	chr13:40728558	chr13:40822296~40921749:-
LUAD	cis	rs13113518	0.812	rs11932712	ENSG00000273257.1	RP11-177J6.1	3.73	0.000216	0.0265	0.19	0.17	Height;	chr4:55436423	chr4:55387949~55388271:+
LUAD	cis	rs13113518	0.812	rs12501746	ENSG00000273257.1	RP11-177J6.1	3.73	0.000216	0.0265	0.19	0.17	Height;	chr4:55437438	chr4:55387949~55388271:+
LUAD	cis	rs10208649	0.908	rs7556936	ENSG00000233266.1	HMGB1P31	3.73	0.000216	0.0265	0.43	0.17	Body mass index;	chr2:54028594	chr2:54051334~54051760:+
LUAD	cis	rs10208649	0.908	rs7583508	ENSG00000233266.1	HMGB1P31	3.73	0.000216	0.0265	0.43	0.17	Body mass index;	chr2:54028648	chr2:54051334~54051760:+
LUAD	cis	rs9876781	1	rs898225	ENSG00000229759.1	MRPS18AP1	-3.73	0.000216	0.0265	-0.16	-0.17	Longevity;	chr3:48371689	chr3:48256350~48256938:-
LUAD	cis	rs72647484	0.643	rs2744737	ENSG00000234397.3	RP11-415K20.1	-3.73	0.000216	0.0265	-0.33	-0.17	Colorectal cancer;	chr1:22225089	chr1:22322840~22323331:-
LUAD	cis	rs6964587	0.867	rs12704637	ENSG00000188693.7	CYP51A1-AS1	-3.73	0.000216	0.0265	-0.2	-0.17	Breast cancer;	chr7:92245372	chr7:92134604~92180725:+
LUAD	cis	rs1075265	0.875	rs12616212	ENSG00000272156.1	RP11-477N3.1	-3.73	0.000216	0.0265	-0.2	-0.17	Chronotype;Morning vs. evening chronotype;	chr2:54039109	chr2:54082554~54085066:+
LUAD	cis	rs3845817	0.832	rs702945	ENSG00000281920.1	RP11-418H16.1	-3.73	0.000216	0.0265	-0.21	-0.17	Bipolar disorder;	chr2:65534098	chr2:65623272~65628424:+
LUAD	cis	rs4423214	0.879	rs736894	ENSG00000226627.1	SHANK2-AS1	-3.73	0.000216	0.0265	-0.2	-0.17	Vitamin D levels;	chr11:71441212	chr11:70631094~70635490:+
LUAD	cis	rs858239	0.6	rs1115941	ENSG00000226816.2	AC005082.12	3.73	0.000217	0.0265	0.22	0.17	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23206013~23208045:+
LUAD	cis	rs1850744	0.702	rs6836184	ENSG00000163612.10	FAM86KP	-3.73	0.000217	0.0265	-0.47	-0.17	Economic and political preferences;	chr4:9632087	chr4:9153296~9165451:+
LUAD	cis	rs9921338	0.509	rs7199847	ENSG00000263080.1	RP11-485G7.5	-3.73	0.000217	0.0265	-0.19	-0.17	Vein graft stenosis in coronary artery bypass grafting;	chr16:11353415	chr16:11341809~11345211:-
LUAD	cis	rs1350171	1	rs1350171	ENSG00000255471.1	RP11-736K20.5	3.73	0.000217	0.0265	0.28	0.17	Hepatocellular carcinoma in hepatitis B infection;	chr11:86933347	chr11:86892214~86925037:-
LUAD	cis	rs1876905	0.539	rs62420362	ENSG00000230177.1	RP5-1112D6.4	-3.73	0.000217	0.0265	-0.21	-0.17	Mean corpuscular hemoglobin;	chr6:111224167	chr6:111277932~111278742:+
LUAD	cis	rs7107174	1	rs2510039	ENSG00000251323.2	RP11-452H21.4	3.73	0.000217	0.0265	0.23	0.17	Testicular germ cell tumor;	chr11:78233434	chr11:78423982~78429836:-
LUAD	cis	rs7107174	1	rs2373009	ENSG00000251323.2	RP11-452H21.4	3.73	0.000217	0.0265	0.23	0.17	Testicular germ cell tumor;	chr11:78234769	chr11:78423982~78429836:-
LUAD	cis	rs7119038	0.818	rs6589684	ENSG00000255422.1	AP002954.4	-3.73	0.000217	0.0265	-0.25	-0.17	Sjögren's syndrome;	chr11:118740248	chr11:118704607~118750263:+
LUAD	cis	rs10197140	0.777	rs62159554	ENSG00000235721.1	AC013268.3	-3.73	0.000217	0.0265	-0.18	-0.17	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110906184	chr2:110007675~110010783:+
LUAD	cis	rs7809950	1	rs10243340	ENSG00000238832.1	snoU109	-3.73	0.000217	0.0265	-0.24	-0.17	Coronary artery disease;	chr7:107450510	chr7:107603363~107603507:+
LUAD	cis	rs901683	0.85	rs76491632	ENSG00000230869.1	CTGLF10P	-3.73	0.000217	0.0265	-0.4	-0.17	Mean corpuscular volume;Red blood cell traits;	chr10:45471150	chr10:45678692~45700532:+
LUAD	cis	rs901683	0.702	rs77676696	ENSG00000230869.1	CTGLF10P	-3.73	0.000217	0.0265	-0.4	-0.17	Mean corpuscular volume;Red blood cell traits;	chr10:45471810	chr10:45678692~45700532:+
LUAD	cis	rs6570726	1	rs386678	ENSG00000235652.6	RP11-545I5.3	3.73	0.000217	0.0265	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145547874	chr6:145799409~145886585:+
LUAD	cis	rs7142881	0.729	rs1430425	ENSG00000250365.5	CTD-2213F21.2	3.73	0.000217	0.0265	0.19	0.17	Response to iloperidone treatment (QT prolongation);	chr14:31784767	chr14:31420286~31452883:+
LUAD	cis	rs5758659	0.714	rs5758578	ENSG00000273366.1	CTA-989H11.1	3.73	0.000217	0.0266	0.19	0.17	Cognitive function;	chr22:42094288	chr22:42278188~42278846:+
LUAD	cis	rs773506	0.551	rs7856089	ENSG00000230537.1	RP11-305L7.1	3.73	0.000217	0.0266	0.21	0.17	Type 2 diabetes nephropathy;	chr9:91343175	chr9:91104957~91107304:-
LUAD	cis	rs2346160	1	rs4709159	ENSG00000231720.1	RP11-568A7.3	3.73	0.000217	0.0266	0.16	0.17	Parental extreme longevity (95 years and older);	chr6:167251430	chr6:167237508~167240480:-
LUAD	cis	rs5758511	0.68	rs56111723	ENSG00000233903.2	Z83851.4	3.73	0.000217	0.0266	0.24	0.17	Birth weight;	chr22:42268877	chr22:42276355~42277052:+
LUAD	cis	rs6547741	1	rs10205364	ENSG00000223522.1	AC093690.1	3.73	0.000217	0.0266	0.16	0.17	Oral cavity cancer;	chr2:27571366	chr2:28307691~28310459:-
LUAD	cis	rs3020736	0.5	rs6002603	ENSG00000273366.1	CTA-989H11.1	3.73	0.000217	0.0266	0.2	0.17	Autism spectrum disorder or schizophrenia;	chr22:42096358	chr22:42278188~42278846:+
LUAD	cis	rs11154801	0.589	rs6924066	ENSG00000231028.7	LINC00271	-3.73	0.000217	0.0266	-0.19	-0.17	Multiple sclerosis;	chr6:135598006	chr6:135497801~135716055:+
LUAD	cis	rs1046491	0.901	rs8090297	ENSG00000264964.1	RP11-888D10.3	3.73	0.000217	0.0266	0.35	0.17	Scarlet fever;	chr18:9117290	chr18:9315194~9334441:-
LUAD	cis	rs1046491	0.901	rs41274300	ENSG00000264964.1	RP11-888D10.3	3.73	0.000217	0.0266	0.35	0.17	Scarlet fever;	chr18:9119491	chr18:9315194~9334441:-
LUAD	cis	rs1046491	0.901	rs12454025	ENSG00000264964.1	RP11-888D10.3	3.73	0.000217	0.0266	0.35	0.17	Scarlet fever;	chr18:9123494	chr18:9315194~9334441:-
LUAD	cis	rs1046491	0.901	rs12966444	ENSG00000264964.1	RP11-888D10.3	3.73	0.000217	0.0266	0.35	0.17	Scarlet fever;	chr18:9123634	chr18:9315194~9334441:-
LUAD	cis	rs1046491	0.901	rs12966775	ENSG00000264964.1	RP11-888D10.3	3.73	0.000217	0.0266	0.35	0.17	Scarlet fever;	chr18:9123862	chr18:9315194~9334441:-
LUAD	cis	rs1046491	0.901	rs12968060	ENSG00000264964.1	RP11-888D10.3	3.73	0.000217	0.0266	0.35	0.17	Scarlet fever;	chr18:9123947	chr18:9315194~9334441:-
LUAD	cis	rs1046491	0.901	rs36125741	ENSG00000264964.1	RP11-888D10.3	3.73	0.000217	0.0266	0.35	0.17	Scarlet fever;	chr18:9125539	chr18:9315194~9334441:-
LUAD	cis	rs1046491	0.901	rs12457429	ENSG00000264964.1	RP11-888D10.3	3.73	0.000217	0.0266	0.35	0.17	Scarlet fever;	chr18:9125848	chr18:9315194~9334441:-
LUAD	cis	rs1046491	0.901	rs12457266	ENSG00000264964.1	RP11-888D10.3	3.73	0.000217	0.0266	0.35	0.17	Scarlet fever;	chr18:9125853	chr18:9315194~9334441:-
LUAD	cis	rs1046491	0.901	rs35849084	ENSG00000264964.1	RP11-888D10.3	3.73	0.000217	0.0266	0.35	0.17	Scarlet fever;	chr18:9127798	chr18:9315194~9334441:-
LUAD	cis	rs1046491	0.803	rs11872481	ENSG00000264964.1	RP11-888D10.3	3.73	0.000217	0.0266	0.35	0.17	Scarlet fever;	chr18:9128455	chr18:9315194~9334441:-
LUAD	cis	rs7512552	0.839	rs2264418	ENSG00000275557.1	RP11-353N4.6	3.73	0.000217	0.0266	0.19	0.17	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150396103	chr1:149607765~149612402:+
LUAD	cis	rs7512552	0.839	rs1260386	ENSG00000275557.1	RP11-353N4.6	3.73	0.000217	0.0266	0.19	0.17	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150397146	chr1:149607765~149612402:+
LUAD	cis	rs7131987	0.65	rs11050208	ENSG00000275476.1	RP11-996F15.4	-3.73	0.000217	0.0266	-0.2	-0.17	QT interval;	chr12:29357436	chr12:29277397~29277882:-
LUAD	cis	rs6832769	0.961	rs10009593	ENSG00000272969.1	RP11-528I4.2	-3.73	0.000217	0.0266	-0.17	-0.17	Personality dimensions;	chr4:55570514	chr4:55547112~55547889:+
LUAD	cis	rs72647484	0.554	rs2807340	ENSG00000234397.3	RP11-415K20.1	-3.73	0.000217	0.0266	-0.35	-0.17	Colorectal cancer;	chr1:22253980	chr1:22322840~22323331:-
LUAD	cis	rs72647484	0.558	rs2744697	ENSG00000234397.3	RP11-415K20.1	-3.73	0.000217	0.0266	-0.35	-0.17	Colorectal cancer;	chr1:22257162	chr1:22322840~22323331:-
LUAD	cis	rs72647484	0.642	rs72647481	ENSG00000234397.3	RP11-415K20.1	-3.73	0.000217	0.0266	-0.35	-0.17	Colorectal cancer;	chr1:22258225	chr1:22322840~22323331:-
LUAD	cis	rs3213758	0.541	rs8056869	ENSG00000275191.1	RP11-36I17.2	-3.73	0.000217	0.0266	-0.25	-0.17	Vitiligo (non-segmental);	chr16:53653467	chr16:53628256~53628816:-
LUAD	cis	rs12440869	1	rs12708493	ENSG00000270964.1	RP11-502I4.3	3.73	0.000217	0.0266	0.19	0.17	Peak velocity of the mitral A-wave;	chr15:67293473	chr15:67541072~67542604:-
LUAD	cis	rs10946940	0.632	rs9366698	ENSG00000219392.1	RP1-265C24.5	-3.73	0.000217	0.0266	-0.22	-0.17	Systemic lupus erythematosus;	chr6:27704256	chr6:28115628~28116551:+
LUAD	cis	rs7692995	1	rs7673321	ENSG00000235413.3	KRT18P63	3.73	0.000217	0.0266	0.28	0.17	Height;	chr4:17956065	chr4:17911674~17912976:+
LUAD	cis	rs13434995	0.589	rs496055	ENSG00000273257.1	RP11-177J6.1	-3.73	0.000217	0.0266	-0.23	-0.17	Adiponectin levels;	chr4:55383670	chr4:55387949~55388271:+
LUAD	cis	rs804280	0.638	rs36038176	ENSG00000255046.1	RP11-297N6.4	3.73	0.000217	0.0266	0.24	0.17	Myopia (pathological);	chr8:11752486	chr8:11797928~11802568:-
LUAD	cis	rs38055	0.837	rs626726	ENSG00000247796.2	CTD-2366F13.1	-3.73	0.000217	0.0266	-0.19	-0.17	Acne (severe);	chr5:53327934	chr5:53109842~53115126:+
LUAD	cis	rs12216545	0.765	rs10254007	ENSG00000177590.7	GIMAP3P	-3.73	0.000217	0.0266	-0.17	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150556293	chr7:150746893~150747728:-
LUAD	cis	rs5742933	0.857	rs1233284	ENSG00000253559.1	OSGEPL1-AS1	-3.73	0.000217	0.0266	-0.2	-0.17	Ferritin levels;	chr2:189825045	chr2:189762704~189765556:+
LUAD	cis	rs5742933	0.817	rs1233288	ENSG00000253559.1	OSGEPL1-AS1	-3.73	0.000217	0.0266	-0.2	-0.17	Ferritin levels;	chr2:189825999	chr2:189762704~189765556:+
LUAD	cis	rs5742933	1	rs4667306	ENSG00000253559.1	OSGEPL1-AS1	-3.73	0.000217	0.0266	-0.23	-0.17	Ferritin levels;	chr2:189725630	chr2:189762704~189765556:+
LUAD	cis	rs7134599	1	rs7138407	ENSG00000240087.3	RP11-254B13.1	3.73	0.000217	0.0266	0.15	0.17	Inflammatory bowel disease;Ulcerative colitis;	chr12:68107082	chr12:68552995~68553882:-
LUAD	cis	rs338389	0.542	rs62002423	ENSG00000260657.2	RP11-315D16.4	3.73	0.000217	0.0266	0.21	0.17	Survival in rectal cancer;	chr15:67976709	chr15:68267792~68277994:-
LUAD	cis	rs7551222	0.714	rs4951401	ENSG00000240219.1	RP11-430C7.5	3.73	0.000217	0.0266	0.19	0.17	Schizophrenia;	chr1:204568520	chr1:204626775~204629712:+
LUAD	cis	rs642803	0.933	rs644740	ENSG00000254510.1	RP11-867G23.10	-3.73	0.000217	0.0266	-0.2	-0.17	Urate levels;	chr11:65793997	chr11:66409158~66417137:+
LUAD	cis	rs591584	0.666	rs1939139	ENSG00000255893.1	RP11-685N10.1	-3.73	0.000217	0.0266	-0.21	-0.17	Macrophage Migration Inhibitory Factor levels;	chr11:94573836	chr11:94472908~94473570:-
LUAD	cis	rs4907240	0.961	rs11691670	ENSG00000237510.6	AC008268.2	-3.73	0.000217	0.0266	-0.24	-0.17	Event-related brain oscillations;	chr2:96573033	chr2:95789654~95800166:+
LUAD	cis	rs6479891	0.822	rs6479892	ENSG00000232075.1	MRPL35P2	-3.73	0.000217	0.0266	-0.27	-0.17	Arthritis (juvenile idiopathic);	chr10:63292472	chr10:63634317~63634827:-
LUAD	cis	rs7246657	0.943	rs28373708	ENSG00000226686.6	LINC01535	-3.73	0.000217	0.0266	-0.25	-0.17	Coronary artery calcification;	chr19:37485757	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.943	rs1382357	ENSG00000226686.6	LINC01535	-3.73	0.000217	0.0266	-0.25	-0.17	Coronary artery calcification;	chr19:37486707	chr19:37251912~37265535:+
LUAD	cis	rs9650657	0.562	rs10090444	ENSG00000255046.1	RP11-297N6.4	-3.73	0.000217	0.0266	-0.2	-0.17	Neuroticism;	chr8:10887959	chr8:11797928~11802568:-
LUAD	cis	rs7712401	0.72	rs12109791	ENSG00000249996.1	RP11-359P5.1	3.73	0.000217	0.0266	0.2	0.17	Mean platelet volume;	chr5:122811136	chr5:123036271~123054667:+
LUAD	cis	rs3136739	0.764	rs7018383	ENSG00000254131.1	RP11-1007J8.1	-3.73	0.000217	0.0266	-0.36	-0.17	Plasma plasminogen activator levels;	chr8:42207017	chr8:42484600~42485019:+
LUAD	cis	rs8067545	0.641	rs203482	ENSG00000270091.1	RP11-78O7.2	-3.73	0.000217	0.0266	-0.14	-0.17	Schizophrenia;	chr17:19923897	chr17:19896590~19897287:-
LUAD	cis	rs12681366	0.839	rs3019278	ENSG00000254057.1	RP3-388N13.3	3.73	0.000217	0.0266	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94434339	chr8:93834454~93846743:-
LUAD	cis	rs12681366	0.839	rs2930964	ENSG00000254057.1	RP3-388N13.3	3.73	0.000217	0.0266	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94435906	chr8:93834454~93846743:-
LUAD	cis	rs6687758	0.945	rs17011182	ENSG00000238042.4	RP11-815M8.1	3.73	0.000217	0.0266	0.23	0.17	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221990985	chr1:221880981~221978523:-
LUAD	cis	rs8141529	0.584	rs58004020	ENSG00000272858.1	CTA-292E10.8	-3.73	0.000217	0.0266	-0.19	-0.17	Lymphocyte counts;	chr22:28861062	chr22:28814914~28815662:+
LUAD	cis	rs6121246	0.609	rs6060948	ENSG00000230613.1	HM13-AS1	3.73	0.000217	0.0266	0.21	0.17	Mean corpuscular hemoglobin;	chr20:31788590	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.559	rs6060952	ENSG00000230613.1	HM13-AS1	3.73	0.000217	0.0266	0.21	0.17	Mean corpuscular hemoglobin;	chr20:31794305	chr20:31567707~31573263:-
LUAD	cis	rs2904524	1	rs17107924	ENSG00000257815.4	RP11-611E13.2	3.73	0.000217	0.0266	0.25	0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70280875	chr12:69904033~70243360:-
LUAD	cis	rs12817211	0.502	rs11169282	ENSG00000272368.2	RP4-605O3.4	3.73	0.000217	0.0266	0.19	0.17	Colorectal or endometrial cancer;	chr12:50136188	chr12:50112197~50165618:+
LUAD	cis	rs7580658	0.613	rs12463538	ENSG00000236682.1	AC068282.3	-3.73	0.000217	0.0266	-0.22	-0.17	Protein C levels;	chr2:127439278	chr2:127389130~127400580:+
LUAD	cis	rs62355901	0.599	rs12655060	ENSG00000271828.1	CTD-2310F14.1	3.73	0.000217	0.0266	0.32	0.17	Breast cancer;	chr5:56720808	chr5:56927874~56929573:+
LUAD	cis	rs6866614	0.608	rs17132288	ENSG00000233006.5	AC034220.3	3.73	0.000217	0.0266	0.15	0.17	Perceived unattractiveness to mosquitoes;	chr5:132000412	chr5:132311285~132369916:-
LUAD	cis	rs1799949	0.602	rs8176199	ENSG00000267340.1	RP11-242D8.3	3.73	0.000217	0.0266	0.2	0.17	Menopause (age at onset);	chr17:43078507	chr17:43169880~43170077:-
LUAD	cis	rs6840360	0.606	rs2709814	ENSG00000270265.1	RP11-731D1.4	-3.73	0.000217	0.0266	-0.17	-0.17	Intelligence (multi-trait analysis);	chr4:151439718	chr4:151333775~151353224:-
LUAD	cis	rs11159086	1	rs11626856	ENSG00000270000.1	RP3-449M8.9	3.73	0.000217	0.0266	0.25	0.17	Advanced glycation end-product levels;	chr14:74469665	chr14:74471930~74472360:-
LUAD	cis	rs11089937	0.864	rs5757041	ENSG00000211638.2	IGLV8-61	-3.73	0.000218	0.0266	-0.16	-0.17	Periodontitis (PAL4Q3);	chr22:22140538	chr22:22098700~22099212:+
LUAD	cis	rs117623576	0.941	rs7924082	ENSG00000234335.1	RPS4XP11	3.73	0.000218	0.0266	0.25	0.17	Anti-saccade response;	chr10:32140198	chr10:32102522~32103293:-
LUAD	cis	rs2933343	0.679	rs1091938	ENSG00000231305.3	RP11-723O4.2	3.73	0.000218	0.0266	0.18	0.17	IgG glycosylation;	chr3:128918182	chr3:128861313~128871540:-
LUAD	cis	rs7131987	0.65	rs3782509	ENSG00000275476.1	RP11-996F15.4	-3.73	0.000218	0.0266	-0.19	-0.17	QT interval;	chr12:29300845	chr12:29277397~29277882:-
LUAD	cis	rs9549260	0.755	rs2721067	ENSG00000229456.1	RLIMP1	3.73	0.000218	0.0266	0.18	0.17	Red blood cell count;	chr13:40582571	chr13:40618738~40621348:+
LUAD	cis	rs9549260	0.755	rs2701869	ENSG00000229456.1	RLIMP1	3.73	0.000218	0.0266	0.18	0.17	Red blood cell count;	chr13:40583235	chr13:40618738~40621348:+
LUAD	cis	rs6502050	0.731	rs9891378	ENSG00000275966.1	RP11-1055B8.9	-3.73	0.000218	0.0266	-0.17	-0.17	Life satisfaction;	chr17:82158159	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs66932937	ENSG00000275966.1	RP11-1055B8.9	-3.73	0.000218	0.0266	-0.17	-0.17	Life satisfaction;	chr17:82158927	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs67106357	ENSG00000275966.1	RP11-1055B8.9	-3.73	0.000218	0.0266	-0.17	-0.17	Life satisfaction;	chr17:82158950	chr17:81345476~81345966:-
LUAD	cis	rs12754538	0.734	rs12568634	ENSG00000232912.4	RP5-1115A15.1	3.73	0.000218	0.0266	0.17	0.17	Subjective well-being;	chr1:8755876	chr1:8424645~8434838:+
LUAD	cis	rs10149470	0.549	rs9652403	ENSG00000258851.1	RP11-894P9.2	-3.73	0.000218	0.0266	-0.2	-0.17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;	chr14:103569687	chr14:103553421~103561877:+
LUAD	cis	rs6763848	0.962	rs11707049	ENSG00000214073.2	RPL21P17	-3.73	0.000218	0.0266	-0.17	-0.17	Prostate cancer (SNP x SNP interaction);	chr3:1473251	chr3:1905651~1906125:+
LUAD	cis	rs17507216	0.628	rs28737193	ENSG00000276710.3	CSPG4P8	-3.73	0.000218	0.0266	-0.19	-0.17	Excessive daytime sleepiness;	chr15:82701318	chr15:82459472~82477258:+
LUAD	cis	rs721917	0.811	rs2256461	ENSG00000230091.5	TMEM254-AS1	3.73	0.000218	0.0266	0.2	0.17	Chronic obstructive pulmonary disease;	chr10:79925838	chr10:80046860~80078912:-
LUAD	cis	rs889398	0.51	rs11646575	ENSG00000226232.7	RP11-419C5.2	-3.73	0.000218	0.0266	-0.14	-0.17	Body mass index;	chr16:69533878	chr16:69976388~69996188:-
LUAD	cis	rs4927850	0.957	rs4927851	ENSG00000278820.1	AC024937.1	3.73	0.000218	0.0266	0.15	0.17	Pancreatic cancer;	chr3:196024982	chr3:195960500~195960612:-
LUAD	cis	rs2243480	1	rs34815098	ENSG00000189316.3	RP11-797H7.5	3.73	0.000218	0.0266	0.28	0.17	Diabetic kidney disease;	chr7:65827267	chr7:64888527~64890100:-
LUAD	cis	rs2243480	1	rs4548056	ENSG00000189316.3	RP11-797H7.5	3.73	0.000218	0.0266	0.28	0.17	Diabetic kidney disease;	chr7:65833886	chr7:64888527~64890100:-
LUAD	cis	rs2243480	1	rs7456042	ENSG00000189316.3	RP11-797H7.5	3.73	0.000218	0.0266	0.28	0.17	Diabetic kidney disease;	chr7:65834791	chr7:64888527~64890100:-
LUAD	cis	rs2243480	1	rs35735127	ENSG00000189316.3	RP11-797H7.5	3.73	0.000218	0.0266	0.28	0.17	Diabetic kidney disease;	chr7:65835436	chr7:64888527~64890100:-
LUAD	cis	rs2243480	0.901	rs35256305	ENSG00000189316.3	RP11-797H7.5	3.73	0.000218	0.0266	0.28	0.17	Diabetic kidney disease;	chr7:65841418	chr7:64888527~64890100:-
LUAD	cis	rs2243480	1	rs73142121	ENSG00000189316.3	RP11-797H7.5	3.73	0.000218	0.0266	0.28	0.17	Diabetic kidney disease;	chr7:65846219	chr7:64888527~64890100:-
LUAD	cis	rs2243480	0.803	rs34004500	ENSG00000189316.3	RP11-797H7.5	3.73	0.000218	0.0266	0.28	0.17	Diabetic kidney disease;	chr7:65847191	chr7:64888527~64890100:-
LUAD	cis	rs2243480	1	rs35825738	ENSG00000189316.3	RP11-797H7.5	3.73	0.000218	0.0266	0.28	0.17	Diabetic kidney disease;	chr7:65853040	chr7:64888527~64890100:-
LUAD	cis	rs875971	0.638	rs6460305	ENSG00000222364.1	RNU6-96P	3.73	0.000218	0.0266	0.19	0.17	Aortic root size;	chr7:66595421	chr7:66395191~66395286:+
LUAD	cis	rs9900280	0.935	rs2559629	ENSG00000264808.1	RP11-802D6.1	-3.73	0.000218	0.0266	-0.19	-0.17	Mean platelet volume;	chr17:29519548	chr17:29369717~29390777:-
LUAD	cis	rs62025270	1	rs62025270	ENSG00000259416.2	RP11-158M2.5	-3.73	0.000218	0.0266	-0.23	-0.17	Idiopathic pulmonary fibrosis;	chr15:85756967	chr15:85754941~85756237:-
LUAD	cis	rs911555	0.723	rs6575986	ENSG00000244691.1	RPL10AP1	-3.73	0.000218	0.0266	-0.22	-0.17	Intelligence (multi-trait analysis);	chr14:103420334	chr14:103412119~103412761:-
LUAD	cis	rs4716602	0.542	rs10261485	ENSG00000235029.1	MNX1-AS2	-3.73	0.000218	0.0266	-0.2	-0.17	Anti-saccade response;	chr7:156367081	chr7:157006307~157007132:+
LUAD	cis	rs4716602	0.542	rs10249935	ENSG00000235029.1	MNX1-AS2	-3.73	0.000218	0.0266	-0.2	-0.17	Anti-saccade response;	chr7:156367087	chr7:157006307~157007132:+
LUAD	cis	rs7017914	0.702	rs13258368	ENSG00000223220.1	Y_RNA	3.73	0.000218	0.0266	0.19	0.17	Bone mineral density;	chr8:70636516	chr8:70780914~70781008:-
LUAD	cis	rs7116495	1	rs12291678	ENSG00000254682.1	RP11-660L16.2	-3.73	0.000218	0.0266	-0.34	-0.17	Severe influenza A (H1N1) infection;	chr11:71859931	chr11:71448674~71452157:+
LUAD	cis	rs7116495	1	rs635442	ENSG00000254682.1	RP11-660L16.2	-3.73	0.000218	0.0266	-0.34	-0.17	Severe influenza A (H1N1) infection;	chr11:71859936	chr11:71448674~71452157:+
LUAD	cis	rs7116495	0.737	rs1791451	ENSG00000254682.1	RP11-660L16.2	-3.73	0.000218	0.0266	-0.34	-0.17	Severe influenza A (H1N1) infection;	chr11:71859947	chr11:71448674~71452157:+
LUAD	cis	rs494562	0.73	rs9450270	ENSG00000234155.1	RP11-30P6.6	-3.73	0.000218	0.0266	-0.3	-0.17	Metabolic traits;Blood metabolite levels;	chr6:85405048	chr6:85387219~85390186:-
LUAD	cis	rs516805	0.961	rs527978	ENSG00000279114.1	RP3-425C14.5	-3.73	0.000218	0.0267	-0.18	-0.17	Lymphocyte counts;	chr6:122475225	chr6:122471923~122484161:+
LUAD	cis	rs1501138	0.871	rs4698483	ENSG00000263327.5	TAPT1-AS1	3.73	0.000218	0.0267	0.22	0.17	Systemic juvenile idiopathic arthritis;	chr4:16409358	chr4:16226685~16320140:+
LUAD	cis	rs10129255	0.957	rs2013423	ENSG00000211947.2	IGHV3-21	-3.73	0.000218	0.0267	-0.11	-0.17	Kawasaki disease;	chr14:106690675	chr14:106235064~106235594:-
LUAD	cis	rs8031584	0.958	rs7176569	ENSG00000260128.5	ULK4P2	3.73	0.000218	0.0267	0.21	0.17	Huntington's disease progression;	chr15:30952292	chr15:30572738~30600647:+
LUAD	cis	rs10129255	0.5	rs2027903	ENSG00000232216.1	IGHV3-43	3.73	0.000218	0.0267	0.14	0.17	Kawasaki disease;	chr14:106807047	chr14:106470264~106470800:-
LUAD	cis	rs10129255	0.518	rs28378320	ENSG00000232216.1	IGHV3-43	3.73	0.000218	0.0267	0.14	0.17	Kawasaki disease;	chr14:106808609	chr14:106470264~106470800:-
LUAD	cis	rs2638953	0.924	rs10492368	ENSG00000278733.1	RP11-425D17.1	-3.73	0.000218	0.0267	-0.2	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28173941	chr12:28185625~28186190:-
LUAD	cis	rs67478160	0.571	rs1155751	ENSG00000272533.1	SNORA28	3.73	0.000218	0.0267	0.17	0.17	Schizophrenia;	chr14:103820210	chr14:103337849~103337974:+
LUAD	cis	rs7829975	0.501	rs2980769	ENSG00000173295.6	FAM86B3P	3.73	0.000218	0.0267	0.17	0.17	Mood instability;	chr8:8462781	chr8:8228595~8244865:+
LUAD	cis	rs2279168	0.737	rs74024844	ENSG00000259416.2	RP11-158M2.5	-3.73	0.000218	0.0267	-0.29	-0.17	Response to platinum-based chemotherapy (carboplatin);	chr15:85440126	chr15:85754941~85756237:-
LUAD	cis	rs12188164	0.931	rs115554641	ENSG00000221990.4	EXOC3-AS1	3.73	0.000218	0.0267	0.17	0.17	Cystic fibrosis severity;	chr5:443121	chr5:441498~443160:-
LUAD	cis	rs12188164	0.965	rs11739543	ENSG00000221990.4	EXOC3-AS1	3.73	0.000218	0.0267	0.17	0.17	Cystic fibrosis severity;	chr5:443561	chr5:441498~443160:-
LUAD	cis	rs12188164	0.965	rs72717430	ENSG00000221990.4	EXOC3-AS1	3.73	0.000218	0.0267	0.17	0.17	Cystic fibrosis severity;	chr5:444387	chr5:441498~443160:-
LUAD	cis	rs7246657	0.509	rs10426093	ENSG00000267309.1	CTD-2630F21.1	3.73	0.000218	0.0267	0.27	0.17	Coronary artery calcification;	chr19:37124727	chr19:36489649~36491040:+
LUAD	cis	rs6547741	1	rs1972669	ENSG00000223522.1	AC093690.1	3.73	0.000218	0.0267	0.16	0.17	Oral cavity cancer;	chr2:27544240	chr2:28307691~28310459:-
LUAD	cis	rs338389	0.814	rs338397	ENSG00000260657.2	RP11-315D16.4	-3.73	0.000218	0.0267	-0.19	-0.17	Survival in rectal cancer;	chr15:67962774	chr15:68267792~68277994:-
LUAD	cis	rs4268898	0.662	rs72793213	ENSG00000242628.4	AC009228.1	3.73	0.000218	0.0267	0.25	0.17	Asthma;	chr2:24301856	chr2:24214381~24221516:+
LUAD	cis	rs4268898	0.662	rs2891380	ENSG00000242628.4	AC009228.1	3.73	0.000218	0.0267	0.25	0.17	Asthma;	chr2:24302961	chr2:24214381~24221516:+
LUAD	cis	rs4591358	1	rs4850619	ENSG00000223466.1	AC064834.2	-3.73	0.000218	0.0267	-0.21	-0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195468634	chr2:195533035~195538681:+
LUAD	cis	rs2390582	0.782	rs12032305	ENSG00000233593.5	RP4-665J23.1	3.73	0.000218	0.0267	0.24	0.17	Coronary artery calcification;	chr1:90507820	chr1:90782986~90851650:-
LUAD	cis	rs12049351	0.591	rs10916508	ENSG00000229367.1	HMGN2P19	3.73	0.000218	0.0267	0.21	0.17	Circulating myeloperoxidase levels (plasma);	chr1:229524044	chr1:229570532~229570796:+
LUAD	cis	rs7142881	0.787	rs34170106	ENSG00000258525.1	RP11-829H16.3	-3.73	0.000218	0.0267	-0.19	-0.17	Response to iloperidone treatment (QT prolongation);	chr14:31710583	chr14:30876179~30889808:-
LUAD	cis	rs4499344	0.556	rs865659	ENSG00000201388.1	SNORA68	3.73	0.000218	0.0267	0.19	0.17	Mean platelet volume;	chr19:32649061	chr19:32608337~32608469:-
LUAD	cis	rs7201929	0.959	rs35725751	ENSG00000261419.1	RP11-57A19.4	3.73	0.000218	0.0267	0.22	0.17	QT interval;	chr16:28834263	chr16:28659696~28740781:-
LUAD	cis	rs9894429	0.646	rs7405870	ENSG00000263853.1	AC139530.1	-3.73	0.000218	0.0267	-0.17	-0.17	Eye color traits;	chr17:81650254	chr17:81676001~81676086:+
LUAD	cis	rs6493858	0.61	rs2718957	ENSG00000277548.1	RP11-139H15.6	3.73	0.000218	0.0267	0.18	0.17	Relative hand skill in reading disability;	chr15:56298635	chr15:55346347~55346752:-
LUAD	cis	rs7617773	0.817	rs9818937	ENSG00000199476.1	Y_RNA	-3.73	0.000218	0.0267	-0.22	-0.17	Coronary artery disease;	chr3:48283791	chr3:48288587~48288694:+
LUAD	cis	rs9860428	0.526	rs9833991	ENSG00000242770.2	RP11-180K7.1	3.73	0.000218	0.0267	0.18	0.17	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112933151	chr3:112802478~112812819:+
LUAD	cis	rs9860428	0.526	rs7615462	ENSG00000242770.2	RP11-180K7.1	3.73	0.000218	0.0267	0.18	0.17	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112934306	chr3:112802478~112812819:+
LUAD	cis	rs9860428	0.526	rs7615572	ENSG00000242770.2	RP11-180K7.1	3.73	0.000218	0.0267	0.18	0.17	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112934486	chr3:112802478~112812819:+
LUAD	cis	rs9860428	0.526	rs9877631	ENSG00000242770.2	RP11-180K7.1	3.73	0.000218	0.0267	0.18	0.17	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112936287	chr3:112802478~112812819:+
LUAD	cis	rs9860428	0.526	rs9823363	ENSG00000242770.2	RP11-180K7.1	3.73	0.000218	0.0267	0.18	0.17	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112940231	chr3:112802478~112812819:+
LUAD	cis	rs4512344	0.509	rs2409784	ENSG00000255046.1	RP11-297N6.4	3.73	0.000218	0.0267	0.2	0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:11539347	chr8:11797928~11802568:-
LUAD	cis	rs797680	0.786	rs6694508	ENSG00000223745.6	RP4-717I23.3	3.73	0.000218	0.0267	0.13	0.17	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93376466	chr1:93262186~93346025:-
LUAD	cis	rs1979679	0.842	rs10459090	ENSG00000278733.1	RP11-425D17.1	3.73	0.000218	0.0267	0.21	0.17	Ossification of the posterior longitudinal ligament of the spine;	chr12:28188207	chr12:28185625~28186190:-
LUAD	cis	rs42490	0.625	rs39519	ENSG00000251136.7	RP11-37B2.1	3.73	0.000218	0.0267	0.18	0.17	Leprosy;	chr8:89833814	chr8:89609409~89757727:-
LUAD	cis	rs2154319	0.887	rs1740615	ENSG00000235358.1	RP11-399E6.1	3.73	0.000218	0.0267	0.23	0.17	Height;	chr1:41072844	chr1:41242373~41284861:+
LUAD	cis	rs9309473	1	rs13398956	ENSG00000230002.2	ALMS1-IT1	3.73	0.000218	0.0267	0.21	0.17	Metabolite levels;	chr2:73493131	chr2:73456764~73459484:+
LUAD	cis	rs9309473	1	rs56154726	ENSG00000230002.2	ALMS1-IT1	3.73	0.000218	0.0267	0.21	0.17	Metabolite levels;	chr2:73494640	chr2:73456764~73459484:+
LUAD	cis	rs3018712	0.532	rs61889616	ENSG00000212093.1	AP000807.1	-3.73	0.000218	0.0267	-0.22	-0.17	Total body bone mineral density;	chr11:68644538	chr11:68506083~68506166:-
LUAD	cis	rs4811196	1	rs10854188	ENSG00000226144.2	RPS27AP3	3.73	0.000218	0.0267	0.21	0.17	Bone mineral density;	chr20:37855187	chr20:37049254~37049707:+
LUAD	cis	rs7772486	0.875	rs6570736	ENSG00000235652.6	RP11-545I5.3	3.73	0.000218	0.0267	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:146067184	chr6:145799409~145886585:+
LUAD	cis	rs6502050	0.835	rs8077926	ENSG00000275966.1	RP11-1055B8.9	-3.73	0.000218	0.0267	-0.17	-0.17	Life satisfaction;	chr17:82159439	chr17:81345476~81345966:-
LUAD	cis	rs17275866	0.862	rs11935491	ENSG00000250596.1	RP11-440I14.2	3.73	0.000218	0.0267	0.22	0.17	Chin dimples;	chr4:174137859	chr4:174523701~174540344:-
LUAD	cis	rs2239547	0.522	rs6445550	ENSG00000243224.1	RP5-1157M23.2	-3.73	0.000218	0.0267	-0.19	-0.17	Schizophrenia;	chr3:52949418	chr3:52239258~52241097:+
LUAD	cis	rs4795519	0.778	rs7217537	ENSG00000266313.1	RP11-173M1.4	3.73	0.000218	0.0267	0.21	0.17	Chronic myeloid leukemia;	chr17:27084920	chr17:27333256~27348491:+
LUAD	cis	rs4795519	0.778	rs4794829	ENSG00000266313.1	RP11-173M1.4	3.73	0.000218	0.0267	0.21	0.17	Chronic myeloid leukemia;	chr17:27086657	chr17:27333256~27348491:+
LUAD	cis	rs4795519	0.744	rs4794830	ENSG00000266313.1	RP11-173M1.4	3.73	0.000218	0.0267	0.21	0.17	Chronic myeloid leukemia;	chr17:27086929	chr17:27333256~27348491:+
LUAD	cis	rs4795519	0.645	rs939729	ENSG00000266313.1	RP11-173M1.4	3.73	0.000218	0.0267	0.21	0.17	Chronic myeloid leukemia;	chr17:27090024	chr17:27333256~27348491:+
LUAD	cis	rs55728055	0.661	rs5753700	ENSG00000250318.1	CTA-963H5.5	-3.73	0.000218	0.0267	-0.32	-0.17	Age-related hearing impairment;	chr22:31575272	chr22:30653877~30654814:-
LUAD	cis	rs8062405	0.737	rs11861132	ENSG00000261419.1	RP11-57A19.4	-3.73	0.000218	0.0267	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28659696~28740781:-
LUAD	cis	rs9341808	0.519	rs676311	ENSG00000260645.1	RP11-250B2.5	-3.73	0.000218	0.0267	-0.16	-0.17	Sitting height ratio;	chr6:80280033	chr6:80466958~80469080:+
LUAD	cis	rs6951245	1	rs78185558	ENSG00000224079.1	AC091729.7	-3.73	0.000218	0.0267	-0.26	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1050547	chr7:1074450~1078036:+
LUAD	cis	rs78572108	0.858	rs79551951	ENSG00000214691.7	AC104654.1	3.73	0.000218	0.0267	0.27	0.17	Total body bone mineral density;	chr2:42043619	chr2:41877074~41894046:+
LUAD	cis	rs7005380	0.62	rs10217083	ENSG00000279347.1	RP11-85I17.2	-3.72	0.000218	0.0267	-0.14	-0.17	Interstitial lung disease;	chr8:119911045	chr8:119838736~119840385:-
LUAD	cis	rs6502050	0.835	rs8081783	ENSG00000275966.1	RP11-1055B8.9	-3.72	0.000218	0.0267	-0.17	-0.17	Life satisfaction;	chr17:82159512	chr17:81345476~81345966:-
LUAD	cis	rs6539288	0.63	rs3759316	ENSG00000260329.1	RP11-412D9.4	-3.72	0.000219	0.0267	-0.17	-0.17	Total body bone mineral density;	chr12:106976432	chr12:106954029~106955497:-
LUAD	cis	rs8014252	0.901	rs80045026	ENSG00000274818.1	RP1-292L20.3	3.72	0.000219	0.0267	0.28	0.17	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70428366	chr14:70906657~70907111:-
LUAD	cis	rs8014252	1	rs8014252	ENSG00000274818.1	RP1-292L20.3	3.72	0.000219	0.0267	0.28	0.17	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70452982	chr14:70906657~70907111:-
LUAD	cis	rs6547741	1	rs6756238	ENSG00000223522.1	AC093690.1	3.72	0.000219	0.0267	0.16	0.17	Oral cavity cancer;	chr2:27618438	chr2:28307691~28310459:-
LUAD	cis	rs9611198	0.846	rs5757731	ENSG00000227188.1	MGAT3-AS1	3.72	0.000219	0.0267	0.18	0.17	Schizophrenia;	chr22:39571780	chr22:39475807~39476822:-
LUAD	cis	rs6661961	0.698	rs4845433	ENSG00000237975.5	FLG-AS1	-3.72	0.000219	0.0267	-0.23	-0.17	Atopic dermatitis;	chr1:152441963	chr1:152168125~152445456:+
LUAD	cis	rs8180040	0.871	rs11716661	ENSG00000271161.1	BOLA2P2	-3.72	0.000219	0.0267	-0.16	-0.17	Colorectal cancer;	chr3:47476283	chr3:47499841~47500407:+
LUAD	cis	rs7107174	1	rs1318241	ENSG00000251323.2	RP11-452H21.4	3.72	0.000219	0.0267	0.23	0.17	Testicular germ cell tumor;	chr11:78219746	chr11:78423982~78429836:-
LUAD	cis	rs7107174	1	rs2511171	ENSG00000251323.2	RP11-452H21.4	3.72	0.000219	0.0267	0.23	0.17	Testicular germ cell tumor;	chr11:78219889	chr11:78423982~78429836:-
LUAD	cis	rs4819052	0.851	rs2236443	ENSG00000215447.6	BX322557.10	-3.72	0.000219	0.0267	-0.2	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258259	chr21:45288052~45291738:+
LUAD	cis	rs7212590	0.881	rs7214032	ENSG00000263422.1	AC005702.1	3.72	0.000219	0.0267	0.38	0.17	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59808467	chr17:60042361~60042442:-
LUAD	cis	rs2243480	1	rs34703416	ENSG00000189316.3	RP11-797H7.5	3.72	0.000219	0.0267	0.28	0.17	Diabetic kidney disease;	chr7:65835655	chr7:64888527~64890100:-
LUAD	cis	rs7107174	1	rs6592772	ENSG00000251323.2	RP11-452H21.4	3.72	0.000219	0.0267	0.23	0.17	Testicular germ cell tumor;	chr11:78304517	chr11:78423982~78429836:-
LUAD	cis	rs957448	0.554	rs4735297	ENSG00000253175.1	RP11-267M23.6	3.72	0.000219	0.0267	0.19	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94577112	chr8:94565036~94565715:+
LUAD	cis	rs5758659	0.714	rs2284087	ENSG00000273366.1	CTA-989H11.1	3.72	0.000219	0.0267	0.19	0.17	Cognitive function;	chr22:42089667	chr22:42278188~42278846:+
LUAD	cis	rs2024714	0.967	rs2427212	ENSG00000273812.1	WI2-87327B8.2	-3.72	0.000219	0.0267	-0.18	-0.17	Longevity;	chr20:61638142	chr20:62596732~62603115:-
LUAD	cis	rs2024714	0.967	rs6061298	ENSG00000273812.1	WI2-87327B8.2	-3.72	0.000219	0.0267	-0.18	-0.17	Longevity;	chr20:61638492	chr20:62596732~62603115:-
LUAD	cis	rs1577917	0.681	rs4707211	ENSG00000220563.1	PKMP3	3.72	0.000219	0.0268	0.15	0.17	Response to antipsychotic treatment;	chr6:85522992	chr6:85659892~85660606:-
LUAD	cis	rs4646404	0.509	rs746900	ENSG00000188933.13	USP32P1	3.72	0.000219	0.0268	0.21	0.17	Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;	chr17:17522813	chr17:16786489~16804455:+
LUAD	cis	rs2803122	0.745	rs10811143	ENSG00000273226.1	RP11-513M16.8	-3.72	0.000219	0.0268	-0.18	-0.17	Pulse pressure;	chr9:19240221	chr9:19375451~19375996:+
LUAD	cis	rs35934224	0.783	rs12106549	ENSG00000237347.2	AC004461.4	3.72	0.000219	0.0268	0.24	0.17	Glaucoma (primary open-angle);	chr22:19859464	chr22:19055801~19056512:+
LUAD	cis	rs7204230	0.96	rs12596238	ENSG00000261291.1	RP11-295M3.2	3.72	0.000219	0.0268	0.2	0.17	Fibrinogen;	chr16:53320819	chr16:53168522~53169450:+
LUAD	cis	rs786425	0.899	rs1515814	ENSG00000278112.1	RP11-972P1.11	3.72	0.000219	0.0268	0.15	0.17	Pubertal anthropometrics;	chr12:123624152	chr12:123519390~123519856:-
LUAD	cis	rs442309	0.841	rs224030	ENSG00000238280.1	RP11-436D10.3	-3.72	0.000219	0.0268	-0.2	-0.17	Vogt-Koyanagi-Harada syndrome;	chr10:62760375	chr10:62793562~62805887:-
LUAD	cis	rs1023500	0.596	rs5751204	ENSG00000273366.1	CTA-989H11.1	-3.72	0.000219	0.0268	-0.2	-0.17	Schizophrenia;	chr22:42037797	chr22:42278188~42278846:+
LUAD	cis	rs62458065	0.85	rs62458066	ENSG00000226468.2	AC018641.7	3.72	0.000219	0.0268	0.28	0.17	Metabolite levels (HVA/MHPG ratio);	chr7:32424872	chr7:32456963~32457758:-
LUAD	cis	rs6502050	0.835	rs9900128	ENSG00000275966.1	RP11-1055B8.9	-3.72	0.000219	0.0268	-0.17	-0.17	Life satisfaction;	chr17:82130044	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.731	rs11867299	ENSG00000275966.1	RP11-1055B8.9	-3.72	0.000219	0.0268	-0.17	-0.17	Life satisfaction;	chr17:82130799	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.799	rs8069827	ENSG00000275966.1	RP11-1055B8.9	-3.72	0.000219	0.0268	-0.17	-0.17	Life satisfaction;	chr17:82131292	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.799	rs7406257	ENSG00000275966.1	RP11-1055B8.9	-3.72	0.000219	0.0268	-0.17	-0.17	Life satisfaction;	chr17:82131464	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs8065210	ENSG00000275966.1	RP11-1055B8.9	-3.72	0.000219	0.0268	-0.17	-0.17	Life satisfaction;	chr17:82133084	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs8065556	ENSG00000275966.1	RP11-1055B8.9	-3.72	0.000219	0.0268	-0.17	-0.17	Life satisfaction;	chr17:82133300	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs8065981	ENSG00000275966.1	RP11-1055B8.9	-3.72	0.000219	0.0268	-0.17	-0.17	Life satisfaction;	chr17:82133517	chr17:81345476~81345966:-
LUAD	cis	rs12188164	0.582	rs80273890	ENSG00000188242.4	PP7080	3.72	0.000219	0.0268	0.22	0.17	Cystic fibrosis severity;	chr5:482942	chr5:466124~473098:-
LUAD	cis	rs2243480	0.522	rs12698511	ENSG00000232559.3	GS1-124K5.12	3.72	0.000219	0.0268	0.33	0.17	Diabetic kidney disease;	chr7:66009932	chr7:66554588~66576923:-
LUAD	cis	rs8014252	0.667	rs8014459	ENSG00000259158.2	ADAM20P1	-3.72	0.000219	0.0268	-0.23	-0.17	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70315497	chr14:70468881~70483756:-
LUAD	cis	rs8014252	1	rs1953798	ENSG00000274818.1	RP1-292L20.3	-3.72	0.000219	0.0268	-0.27	-0.17	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70487432	chr14:70906657~70907111:-
LUAD	cis	rs5751168	0.527	rs408785	ENSG00000211654.2	IGLV5-37	3.72	0.000219	0.0268	0.22	0.17	Prostate cancer (SNP x SNP interaction);	chr22:22485213	chr22:22427540~22428035:+
LUAD	cis	rs4660214	0.666	rs636083	ENSG00000182109.6	RP11-69E11.4	3.72	0.000219	0.0268	0.18	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39356009	chr1:39522280~39546187:-
LUAD	cis	rs9811423	0.625	rs12695286	ENSG00000243795.1	RP11-572M11.3	3.72	0.000219	0.0268	0.2	0.17	Psychosis and Alzheimer's disease;	chr3:113097899	chr3:113142350~113167819:-
LUAD	cis	rs4879677	1	rs9695197	ENSG00000215441.3	CTAGE12P	-3.72	0.000219	0.0268	-0.2	-0.17	Gut microbiome composition (summer and winter);	chr9:27672340	chr9:27608382~27610745:-
LUAD	cis	rs875971	0.862	rs6971059	ENSG00000273448.1	RP11-166O4.6	-3.72	0.000219	0.0268	-0.16	-0.17	Aortic root size;	chr7:66602045	chr7:67333047~67334383:+
LUAD	cis	rs7247513	0.866	rs2861405	ENSG00000230310.1	CTD-2192J16.11	-3.72	0.000219	0.0268	-0.19	-0.17	Bipolar disorder;	chr19:12611518	chr19:12552597~12553644:+
LUAD	cis	rs11651753	1	rs11651753	ENSG00000264920.1	RP11-6N17.4	-3.72	0.000219	0.0268	-0.19	-0.17	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47951723	chr17:47891255~47895812:-
LUAD	cis	rs2836974	0.932	rs13048178	ENSG00000232608.1	TIMM9P2	-3.72	0.000219	0.0268	-0.2	-0.17	Cognitive function;	chr21:39189086	chr21:39216624~39217506:+
LUAD	cis	rs10463554	0.927	rs11952361	ENSG00000250682.4	LINC00491	3.72	0.000219	0.0268	0.2	0.17	Parkinson's disease;	chr5:102952216	chr5:102609156~102671559:-
LUAD	cis	rs71520386	0.796	rs71530697	ENSG00000228649.7	AC005682.5	-3.72	0.000219	0.0268	-0.27	-0.17	Fibrinogen levels;	chr7:22799134	chr7:22854178~22861579:+
LUAD	cis	rs7762018	0.882	rs4716342	ENSG00000231690.2	LINC00574	-3.72	0.000219	0.0268	-0.31	-0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169737863	chr6:169790321~169802873:+
LUAD	cis	rs477895	0.568	rs12418035	ENSG00000236935.1	AP003774.1	-3.72	0.000219	0.0268	-0.2	-0.17	Mean platelet volume;	chr11:64104086	chr11:64325050~64329504:-
LUAD	cis	rs365302	1	rs294918	ENSG00000235086.1	FNDC1-IT1	3.72	0.000219	0.0268	0.23	0.17	Coronary heart disease;	chr6:159205040	chr6:159240786~159243329:+
LUAD	cis	rs7674212	0.537	rs2623060	ENSG00000246560.2	RP11-10L12.4	3.72	0.00022	0.0268	0.21	0.17	Type 2 diabetes;	chr4:103126347	chr4:102828055~102844075:+
LUAD	cis	rs454510	0.826	rs347903	ENSG00000226172.2	RP4-712E4.1	-3.72	0.00022	0.0268	-0.2	-0.17	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;	chr1:119649808	chr1:119000344~119001392:-
LUAD	cis	rs6496932	0.663	rs2062238	ENSG00000218052.5	ADAMTS7P4	-3.72	0.00022	0.0268	-0.19	-0.17	Central corneal thickness;Corneal structure;	chr15:85376002	chr15:85255369~85330334:-
LUAD	cis	rs6066835	0.572	rs6066809	ENSG00000230758.1	SNAP23P	-3.72	0.00022	0.0268	-0.35	-0.17	Multiple myeloma;	chr20:48656581	chr20:49038357~49038602:-
LUAD	cis	rs6763848	0.892	rs1961451	ENSG00000214073.2	RPL21P17	3.72	0.00022	0.0268	0.17	0.17	Prostate cancer (SNP x SNP interaction);	chr3:1461791	chr3:1905651~1906125:+
LUAD	cis	rs12935418	0.552	rs2549835	ENSG00000261061.1	RP11-303E16.2	3.72	0.00022	0.0268	0.18	0.17	Mean corpuscular volume;	chr16:80989005	chr16:81030770~81031485:+
LUAD	cis	rs1454469	0.526	rs73465743	ENSG00000260645.1	RP11-250B2.5	3.72	0.00022	0.0268	0.26	0.17	Prudent dietary pattern;	chr6:80755394	chr6:80466958~80469080:+
LUAD	cis	rs911555	0.511	rs2296483	ENSG00000269940.1	RP11-73M18.7	3.72	0.00022	0.0268	0.17	0.17	Intelligence (multi-trait analysis);	chr14:103563455	chr14:103694560~103695170:+
LUAD	cis	rs7560272	0.538	rs7370393	ENSG00000163016.8	ALMS1P	-3.72	0.00022	0.0268	-0.18	-0.17	Schizophrenia;	chr2:73698509	chr2:73644919~73685576:+
LUAD	cis	rs1334894	0.71	rs45493300	ENSG00000228559.1	RP3-340B19.3	-3.72	0.00022	0.0268	-0.33	-0.17	Coronary artery disease;	chr6:35497803	chr6:35544632~35545669:+
LUAD	cis	rs4819052	0.851	rs2838831	ENSG00000215447.6	BX322557.10	-3.72	0.00022	0.0268	-0.2	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244860	chr21:45288052~45291738:+
LUAD	cis	rs11673344	0.502	rs62108306	ENSG00000226686.6	LINC01535	3.72	0.00022	0.0268	0.2	0.17	Obesity-related traits;	chr19:37691789	chr19:37251912~37265535:+
LUAD	cis	rs4795519	0.778	rs67290727	ENSG00000266313.1	RP11-173M1.4	3.72	0.00022	0.0268	0.21	0.17	Chronic myeloid leukemia;	chr17:27084217	chr17:27333256~27348491:+
LUAD	cis	rs4795519	0.778	rs2872212	ENSG00000266313.1	RP11-173M1.4	3.72	0.00022	0.0268	0.21	0.17	Chronic myeloid leukemia;	chr17:27097212	chr17:27333256~27348491:+
LUAD	cis	rs4795519	0.778	rs1829657	ENSG00000266313.1	RP11-173M1.4	3.72	0.00022	0.0268	0.21	0.17	Chronic myeloid leukemia;	chr17:27098000	chr17:27333256~27348491:+
LUAD	cis	rs357618	1	rs165351	ENSG00000272112.1	CTB-113P19.5	-3.72	0.00022	0.0268	-0.16	-0.17	Basophil percentage of white cells;	chr5:151475320	chr5:151724831~151725356:-
LUAD	cis	rs9303029	0.551	rs72859131	ENSG00000265458.1	RP13-20L14.6	3.72	0.00022	0.0268	0.35	0.17	Protein quantitative trait loci;	chr17:82471977	chr17:82454273~82458521:-
LUAD	cis	rs6785206	0.803	rs6774512	ENSG00000242551.2	POU5F1P6	-3.72	0.00022	0.0268	-0.32	-0.17	Lymphocyte percentage of white cells;	chr3:128697025	chr3:128674735~128677005:-
LUAD	cis	rs7903456	0.648	rs7069764	ENSG00000200253.1	RNU6-529P	3.72	0.00022	0.0268	0.2	0.17	Gout;Renal underexcretion gout;	chr10:87057507	chr10:87041238~87041341:-
LUAD	cis	rs4664293	0.867	rs7594329	ENSG00000230783.1	AC009961.2	-3.72	0.00022	0.0268	-0.2	-0.17	Monocyte percentage of white cells;	chr2:159716207	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs7582124	ENSG00000230783.1	AC009961.2	-3.72	0.00022	0.0268	-0.2	-0.17	Monocyte percentage of white cells;	chr2:159716326	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.802	rs13025347	ENSG00000230783.1	AC009961.2	-3.72	0.00022	0.0268	-0.2	-0.17	Monocyte percentage of white cells;	chr2:159721056	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs6432554	ENSG00000230783.1	AC009961.2	-3.72	0.00022	0.0268	-0.2	-0.17	Monocyte percentage of white cells;	chr2:159722573	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs6760485	ENSG00000230783.1	AC009961.2	-3.72	0.00022	0.0268	-0.2	-0.17	Monocyte percentage of white cells;	chr2:159723179	chr2:159689217~159690291:-
LUAD	cis	rs7829975	0.902	rs777707	ENSG00000173295.6	FAM86B3P	3.72	0.00022	0.0268	0.17	0.17	Mood instability;	chr8:8726834	chr8:8228595~8244865:+
LUAD	cis	rs338389	0.814	rs438118	ENSG00000260657.2	RP11-315D16.4	-3.72	0.00022	0.0268	-0.19	-0.17	Survival in rectal cancer;	chr15:67973613	chr15:68267792~68277994:-
LUAD	cis	rs9517320	0.967	rs6491430	ENSG00000231194.1	FARP1-AS1	3.72	0.00022	0.0268	0.19	0.17	Longevity;	chr13:98526022	chr13:98435405~98435840:-
LUAD	cis	rs6754311	0.55	rs12994270	ENSG00000226806.1	AC011893.3	-3.72	0.00022	0.0268	-0.21	-0.17	Mosquito bite size;	chr2:135760533	chr2:135820191~135823087:+
LUAD	cis	rs6969780	0.632	rs11762730	ENSG00000233429.8	HOTAIRM1	-3.72	0.00022	0.0269	-0.25	-0.17	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27150779	chr7:27095647~27100265:+
LUAD	cis	rs6500602	0.964	rs2896893	ENSG00000280063.1	RP11-295D4.3	3.72	0.00022	0.0269	0.11	0.17	Schizophrenia;	chr16:4428558	chr16:4346694~4348648:-
LUAD	cis	rs858239	1	rs156421	ENSG00000230042.1	AK3P3	-3.72	0.00022	0.0269	-0.21	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23129178~23129841:+
LUAD	cis	rs6427528	0.546	rs10908790	ENSG00000232879.2	RP11-544M22.3	-3.72	0.00022	0.0269	-0.26	-0.17	Response to anti-TNF therapy in rheumatoid arthritis;	chr1:160587679	chr1:161034834~161035006:+
LUAD	cis	rs6427528	0.546	rs1604784	ENSG00000232879.2	RP11-544M22.3	-3.72	0.00022	0.0269	-0.26	-0.17	Response to anti-TNF therapy in rheumatoid arthritis;	chr1:160598782	chr1:161034834~161035006:+
LUAD	cis	rs4835473	0.864	rs5015762	ENSG00000249741.2	RP11-673E1.3	3.72	0.00022	0.0269	0.2	0.17	Immature fraction of reticulocytes;	chr4:143737773	chr4:143911514~143912053:-
LUAD	cis	rs4835473	0.864	rs5015761	ENSG00000249741.2	RP11-673E1.3	3.72	0.00022	0.0269	0.2	0.17	Immature fraction of reticulocytes;	chr4:143737791	chr4:143911514~143912053:-
LUAD	cis	rs77633900	0.892	rs2456074	ENSG00000196274.5	Metazoa_SRP	3.72	0.00022	0.0269	0.23	0.17	Glioma;Non-glioblastoma glioma;	chr15:76263258	chr15:76230048~76230390:-
LUAD	cis	rs12935418	0.616	rs9931292	ENSG00000278985.1	RP11-303E16.9	3.72	0.00022	0.0269	0.16	0.17	Mean corpuscular volume;	chr16:80975671	chr16:80982319~80984094:-
LUAD	cis	rs2613964	0.504	rs2399465	ENSG00000244144.1	RP11-757F18.3	3.72	0.00022	0.0269	0.2	0.17	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113129145	chr3:112185480~112185998:-
LUAD	cis	rs2613964	0.504	rs2399466	ENSG00000244144.1	RP11-757F18.3	3.72	0.00022	0.0269	0.2	0.17	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113129190	chr3:112185480~112185998:-
LUAD	cis	rs151234	0.741	rs11074908	ENSG00000259982.1	CDC37P1	-3.72	0.00022	0.0269	-0.32	-0.17	Platelet distribution width;	chr16:28597035	chr16:28700294~28701540:-
LUAD	cis	rs2613964	0.504	rs7617193	ENSG00000244144.1	RP11-757F18.3	3.72	0.00022	0.0269	0.2	0.17	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113130004	chr3:112185480~112185998:-
LUAD	cis	rs17772222	1	rs12589467	ENSG00000258789.1	RP11-507K2.3	-3.72	0.00022	0.0269	-0.22	-0.17	Coronary artery calcification;	chr14:88357239	chr14:88551597~88552493:+
LUAD	cis	rs7976269	0.609	rs4931142	ENSG00000275476.1	RP11-996F15.4	-3.72	0.00022	0.0269	-0.18	-0.17	Male-pattern baldness;	chr12:29057877	chr12:29277397~29277882:-
LUAD	cis	rs7976269	0.609	rs2117993	ENSG00000275476.1	RP11-996F15.4	-3.72	0.00022	0.0269	-0.18	-0.17	Male-pattern baldness;	chr12:29060041	chr12:29277397~29277882:-
LUAD	cis	rs1065852	0.526	rs1062753	ENSG00000226450.2	CYP2D8P	3.72	0.00022	0.0269	0.14	0.17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41996807	chr22:42149886~42155001:-
LUAD	cis	rs2749097	0.609	rs3790858	ENSG00000244256.3	RN7SL130P	-3.72	0.00022	0.0269	-0.23	-0.17	Alcohol consumption (transferrin glycosylation);	chr1:63645877	chr1:63655743~63656047:+
LUAD	cis	rs67539049	1	rs77865852	ENSG00000255046.1	RP11-297N6.4	3.72	0.00022	0.0269	0.25	0.17	Itch intensity from mosquito bite;	chr8:11445827	chr8:11797928~11802568:-
LUAD	cis	rs911555	0.723	rs12436956	ENSG00000259775.1	RP11-45P15.4	3.72	0.00022	0.0269	0.22	0.17	Intelligence (multi-trait analysis);	chr14:103386270	chr14:103331674~103332367:-
LUAD	cis	rs324126	0.78	rs10445583	ENSG00000277977.1	CTD-3018O17.5	3.72	0.00022	0.0269	0.17	0.17	Colonoscopy-negative controls vs population controls;	chr19:52379480	chr19:52392659~52392755:+
LUAD	cis	rs324126	0.752	rs10445584	ENSG00000277977.1	CTD-3018O17.5	3.72	0.00022	0.0269	0.17	0.17	Colonoscopy-negative controls vs population controls;	chr19:52379552	chr19:52392659~52392755:+
LUAD	cis	rs324126	0.78	rs10445585	ENSG00000277977.1	CTD-3018O17.5	3.72	0.00022	0.0269	0.17	0.17	Colonoscopy-negative controls vs population controls;	chr19:52379571	chr19:52392659~52392755:+
LUAD	cis	rs7512552	0.839	rs698916	ENSG00000275557.1	RP11-353N4.6	3.72	0.00022	0.0269	0.19	0.17	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150415909	chr1:149607765~149612402:+
LUAD	cis	rs9876781	1	rs13069724	ENSG00000229759.1	MRPS18AP1	3.72	0.00022	0.0269	0.16	0.17	Longevity;	chr3:48436629	chr3:48256350~48256938:-
LUAD	cis	rs9341808	0.754	rs3805885	ENSG00000279022.1	RP11-250B2.4	-3.72	0.00022	0.0269	-0.19	-0.17	Sitting height ratio;	chr6:80287034	chr6:80440730~80441172:+
LUAD	cis	rs13113518	0.966	rs11942472	ENSG00000273257.1	RP11-177J6.1	3.72	0.00022	0.0269	0.18	0.17	Height;	chr4:55574959	chr4:55387949~55388271:+
LUAD	cis	rs11159086	0.793	rs10136668	ENSG00000270000.1	RP3-449M8.9	3.72	0.00022	0.0269	0.23	0.17	Advanced glycation end-product levels;	chr14:74492183	chr14:74471930~74472360:-
LUAD	cis	rs5015933	0.902	rs7872015	ENSG00000232630.1	PRPS1P2	-3.72	0.00022	0.0269	-0.16	-0.17	Body mass index;	chr9:125368854	chr9:125150653~125151589:+
LUAD	cis	rs4716602	0.596	rs10261230	ENSG00000235029.1	MNX1-AS2	-3.72	0.00022	0.0269	-0.2	-0.17	Anti-saccade response;	chr7:156366938	chr7:157006307~157007132:+
LUAD	cis	rs4716602	0.596	rs10267031	ENSG00000235029.1	MNX1-AS2	-3.72	0.00022	0.0269	-0.2	-0.17	Anti-saccade response;	chr7:156366955	chr7:157006307~157007132:+
LUAD	cis	rs9910055	0.529	rs228749	ENSG00000267080.4	ASB16-AS1	3.72	0.00022	0.0269	0.16	0.17	Total body bone mineral density;	chr17:44097202	chr17:44175973~44186717:-
LUAD	cis	rs2505998	0.843	rs2435344	ENSG00000273008.1	RP11-351D16.3	-3.72	0.00022	0.0269	-0.17	-0.17	Hirschsprung disease;	chr10:43090426	chr10:43136824~43138334:-
LUAD	cis	rs6502050	0.805	rs4789740	ENSG00000275966.1	RP11-1055B8.9	-3.72	0.00022	0.0269	-0.17	-0.17	Life satisfaction;	chr17:82161326	chr17:81345476~81345966:-
LUAD	cis	rs277939	0.905	rs277954	ENSG00000251634.2	RP11-1280N14.3	3.72	0.00022	0.0269	0.17	0.17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr5:71618081	chr5:71102898~71128753:-
LUAD	cis	rs4716602	0.596	rs10270517	ENSG00000235029.1	MNX1-AS2	-3.72	0.00022	0.0269	-0.2	-0.17	Anti-saccade response;	chr7:156367316	chr7:157006307~157007132:+
LUAD	cis	rs6496932	0.874	rs11074061	ENSG00000259630.2	CTD-2262B20.1	3.72	0.00022	0.0269	0.23	0.17	Central corneal thickness;Corneal structure;	chr15:85274962	chr15:85415228~85415633:+
LUAD	cis	rs17711722	0.565	rs73372653	ENSG00000229886.1	RP5-1132H15.3	-3.72	0.00022	0.0269	-0.19	-0.17	Calcium levels;	chr7:65977808	chr7:66025126~66031544:-
LUAD	cis	rs875971	0.522	rs1968127	ENSG00000222364.1	RNU6-96P	3.72	0.00022	0.0269	0.19	0.17	Aortic root size;	chr7:66591816	chr7:66395191~66395286:+
LUAD	cis	rs5758511	0.633	rs5751258	ENSG00000233903.2	Z83851.4	3.72	0.000221	0.0269	0.25	0.17	Birth weight;	chr22:42267865	chr22:42276355~42277052:+
LUAD	cis	rs1007190	0.881	rs9900293	ENSG00000267505.1	CTC-296K1.3	3.72	0.000221	0.0269	0.29	0.17	DNA methylation (variation);	chr17:44858635	chr17:44793199~44794474:+
LUAD	cis	rs35740288	0.52	rs56183577	ENSG00000202081.1	RNU6-1280P	3.72	0.000221	0.0269	0.24	0.17	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85776475	chr15:85651522~85651628:-
LUAD	cis	rs4237845	0.837	rs7954957	ENSG00000245651.2	RP11-620J15.2	3.72	0.000221	0.0269	0.16	0.17	Intelligence (multi-trait analysis);	chr12:57905467	chr12:57869835~57896482:-
LUAD	cis	rs6137287	0.589	rs6047355	ENSG00000227063.5	RPL41P1	-3.72	0.000221	0.0269	-0.22	-0.17	Height;	chr20:21285952	chr20:21755270~21755350:+
LUAD	cis	rs7246657	0.943	rs2045908	ENSG00000226686.6	LINC01535	-3.72	0.000221	0.0269	-0.24	-0.17	Coronary artery calcification;	chr19:37488866	chr19:37251912~37265535:+
LUAD	cis	rs2732480	0.557	rs923397	ENSG00000257763.1	OR5BK1P	3.72	0.000221	0.0269	0.18	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48326609	chr12:48355792~48356614:-
LUAD	cis	rs800160	0.925	rs708153	ENSG00000236264.4	RPL26P30	-3.72	0.000221	0.0269	-0.22	-0.17	Bacteremia;	chr11:2363262	chr11:2335132~2335776:-
LUAD	cis	rs8058578	0.832	rs3812999	ENSG00000232748.3	RP11-196G11.6	-3.72	0.000221	0.0269	-0.21	-0.17	Multiple myeloma;	chr16:30762284	chr16:31056460~31062803:+
LUAD	cis	rs11064768	0.633	rs7306221	ENSG00000275759.1	RP11-131L12.3	3.72	0.000221	0.0269	0.28	0.17	Schizophrenia;	chr12:119403472	chr12:118428281~118428870:+
LUAD	cis	rs4474465	0.915	rs10128737	ENSG00000251323.2	RP11-452H21.4	3.72	0.000221	0.0269	0.21	0.17	Alzheimer's disease (survival time);	chr11:78475641	chr11:78423982~78429836:-
LUAD	cis	rs7937127	0.649	rs56109100	ENSG00000254907.1	RP11-484D2.2	3.72	0.000221	0.0269	0.3	0.17	Fibrinogen levels;	chr11:43325490	chr11:43328748~43359296:-
LUAD	cis	rs7017914	0.87	rs3098883	ENSG00000246366.5	RP11-382J12.1	3.72	0.000221	0.0269	0.15	0.17	Bone mineral density;	chr8:71031332	chr8:70608577~70663279:+
LUAD	cis	rs6988985	0.678	rs1799998	ENSG00000247317.3	RP11-273G15.2	-3.72	0.000221	0.027	-0.2	-0.17	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142918184	chr8:142981738~143018437:-
LUAD	cis	rs11096990	0.593	rs35937374	ENSG00000249685.1	RP11-360F5.3	3.72	0.000221	0.027	0.2	0.17	Cognitive function;	chr4:39184735	chr4:39133913~39135608:+
LUAD	cis	rs11096990	0.574	rs34070258	ENSG00000249685.1	RP11-360F5.3	3.72	0.000221	0.027	0.2	0.17	Cognitive function;	chr4:39188132	chr4:39133913~39135608:+
LUAD	cis	rs7107174	1	rs2450131	ENSG00000251323.2	RP11-452H21.4	3.72	0.000221	0.027	0.23	0.17	Testicular germ cell tumor;	chr11:78233522	chr11:78423982~78429836:-
LUAD	cis	rs9652601	0.622	rs2286974	ENSG00000280153.1	RP11-876N24.3	-3.72	0.000221	0.027	-0.12	-0.17	Systemic lupus erythematosus;	chr16:11020655	chr16:10933903~10936280:+
LUAD	cis	rs7017914	0.905	rs3110255	ENSG00000246366.5	RP11-382J12.1	3.72	0.000221	0.027	0.15	0.17	Bone mineral density;	chr8:71025815	chr8:70608577~70663279:+
LUAD	cis	rs6964587	0.934	rs6465344	ENSG00000188693.7	CYP51A1-AS1	-3.72	0.000221	0.027	-0.19	-0.17	Breast cancer;	chr7:92010959	chr7:92134604~92180725:+
LUAD	cis	rs2803122	0.775	rs10118150	ENSG00000273226.1	RP11-513M16.8	-3.72	0.000221	0.027	-0.18	-0.17	Pulse pressure;	chr9:19235482	chr9:19375451~19375996:+
LUAD	cis	rs8127691	0.504	rs2329714	ENSG00000237604.1	AP001056.1	3.72	0.000221	0.027	0.2	0.17	Inflammatory bowel disease;	chr21:44222272	chr21:44175489~44176453:+
LUAD	cis	rs62355901	0.505	rs62355910	ENSG00000271828.1	CTD-2310F14.1	3.72	0.000221	0.027	0.37	0.17	Breast cancer;	chr5:56784810	chr5:56927874~56929573:+
LUAD	cis	rs6964587	0.967	rs6970743	ENSG00000188693.7	CYP51A1-AS1	-3.72	0.000221	0.027	-0.2	-0.17	Breast cancer;	chr7:92114997	chr7:92134604~92180725:+
LUAD	cis	rs6496667	0.609	rs7183707	ENSG00000214433.4	GOLGA2P8	3.72	0.000221	0.027	0.22	0.17	Rheumatoid arthritis;	chr15:90340501	chr15:90291962~90295683:+
LUAD	cis	rs4462272	0.675	rs7893985	ENSG00000227492.1	RP11-316M21.6	3.72	0.000221	0.027	0.16	0.17	Age-related hearing impairment (SNP x SNP interaction);	chr10:100133661	chr10:100229667~100234000:+
LUAD	cis	rs12289961	0.681	rs73479886	ENSG00000280010.1	AP001350.4	3.72	0.000221	0.027	0.28	0.17	Lymphoma;	chr11:58273736	chr11:58627435~58628528:+
LUAD	cis	rs4474465	1	rs11604969	ENSG00000251323.2	RP11-452H21.4	-3.72	0.000221	0.027	-0.21	-0.17	Alzheimer's disease (survival time);	chr11:78468247	chr11:78423982~78429836:-
LUAD	cis	rs13108904	0.87	rs2279281	ENSG00000196810.4	CTBP1-AS2	3.72	0.000221	0.027	0.2	0.17	Obesity-related traits;	chr4:1251489	chr4:1249300~1288291:+
LUAD	cis	rs9549260	0.591	rs9577115	ENSG00000168852.11	TPTE2P5	3.72	0.000221	0.027	0.16	0.17	Red blood cell count;	chr13:40702417	chr13:40822296~40921749:-
LUAD	cis	rs2380205	1	rs12253826	ENSG00000232807.2	RP11-536K7.3	3.72	0.000221	0.027	0.17	0.17	Breast cancer;	chr10:5844418	chr10:5934270~5945900:-
LUAD	cis	rs7824557	0.843	rs2572418	ENSG00000255046.1	RP11-297N6.4	3.72	0.000221	0.027	0.21	0.17	Retinal vascular caliber;	chr8:11255580	chr8:11797928~11802568:-
LUAD	cis	rs867371	0.614	rs1814739	ENSG00000255769.6	GOLGA2P10	-3.72	0.000221	0.027	-0.21	-0.17	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82234283	chr15:82472993~82513950:-
LUAD	cis	rs2412819	0.597	rs514311	ENSG00000166763.7	STRCP1	3.72	0.000221	0.027	0.24	0.17	Lung cancer;	chr15:43869376	chr15:43699488~43718184:-
LUAD	cis	rs36093844	0.527	rs4944550	ENSG00000279742.1	RP11-700A24.1	-3.72	0.000221	0.027	-0.2	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85974531	chr11:85852557~85854943:-
LUAD	cis	rs9309473	0.583	rs6546822	ENSG00000230002.2	ALMS1-IT1	3.72	0.000221	0.027	0.19	0.17	Metabolite levels;	chr2:73347970	chr2:73456764~73459484:+
LUAD	cis	rs7617773	0.925	rs34513961	ENSG00000199476.1	Y_RNA	-3.72	0.000221	0.027	-0.23	-0.17	Coronary artery disease;	chr3:48132163	chr3:48288587~48288694:+
LUAD	cis	rs2613964	0.504	rs1903431	ENSG00000244144.1	RP11-757F18.3	3.72	0.000221	0.027	0.2	0.17	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113133810	chr3:112185480~112185998:-
LUAD	cis	rs6691170	0.772	rs4308986	ENSG00000228437.4	RP11-400N13.2	3.72	0.000221	0.027	0.21	0.17	Colorectal cancer;	chr1:221841912	chr1:221966341~221984964:+
LUAD	cis	rs6460942	1	rs2033871	ENSG00000226690.5	AC005281.1	3.72	0.000222	0.027	0.3	0.17	Coronary artery disease;	chr7:12365472	chr7:12496429~12541910:+
LUAD	cis	rs4268898	0.662	rs2288074	ENSG00000242628.4	AC009228.1	3.72	0.000222	0.027	0.25	0.17	Asthma;	chr2:24190726	chr2:24214381~24221516:+
LUAD	cis	rs858239	0.899	rs2268747	ENSG00000230042.1	AK3P3	-3.72	0.000222	0.027	-0.22	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23273843	chr7:23129178~23129841:+
LUAD	cis	rs1355223	1	rs1355223	ENSG00000271369.1	RP11-350D17.3	-3.72	0.000222	0.027	-0.2	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34742932	chr11:34709600~34710161:+
LUAD	cis	rs3020736	0.5	rs4147641	ENSG00000273366.1	CTA-989H11.1	3.72	0.000222	0.027	0.2	0.17	Autism spectrum disorder or schizophrenia;	chr22:42086498	chr22:42278188~42278846:+
LUAD	cis	rs1023500	0.507	rs6002600	ENSG00000273366.1	CTA-989H11.1	3.72	0.000222	0.027	0.2	0.17	Schizophrenia;	chr22:42092902	chr22:42278188~42278846:+
LUAD	cis	rs2288073	0.965	rs6545335	ENSG00000223754.1	AC008073.9	3.72	0.000222	0.027	0.21	0.17	Venous thromboembolism (SNP x SNP interaction);	chr2:24199142	chr2:24199839~24201698:-
LUAD	cis	rs2288073	0.965	rs6545338	ENSG00000223754.1	AC008073.9	3.72	0.000222	0.027	0.21	0.17	Venous thromboembolism (SNP x SNP interaction);	chr2:24199287	chr2:24199839~24201698:-
LUAD	cis	rs2288073	0.965	rs6545340	ENSG00000223754.1	AC008073.9	3.72	0.000222	0.027	0.21	0.17	Venous thromboembolism (SNP x SNP interaction);	chr2:24199400	chr2:24199839~24201698:-
LUAD	cis	rs7428	0.527	rs7608892	ENSG00000246575.2	AC093162.5	3.72	0.000222	0.027	0.16	0.17	Ear protrusion;	chr2:85315595	chr2:85315041~85316529:+
LUAD	cis	rs13006833	0.668	rs2136566	ENSG00000227542.1	AC092614.2	-3.72	0.000222	0.027	-0.2	-0.17	Urinary metabolites;	chr2:190276557	chr2:191229165~191246172:-
LUAD	cis	rs2494663	0.585	rs7531051	ENSG00000223599.1	RP11-216N14.7	3.72	0.000222	0.027	0.2	0.17	Mean platelet volume;	chr1:154047541	chr1:153852106~153853414:-
LUAD	cis	rs8014252	1	rs12436902	ENSG00000259158.2	ADAM20P1	-3.72	0.000222	0.027	-0.25	-0.17	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70462379	chr14:70468881~70483756:-
LUAD	cis	rs8180040	0.966	rs2291298	ENSG00000271161.1	BOLA2P2	3.72	0.000222	0.027	0.16	0.17	Colorectal cancer;	chr3:47513652	chr3:47499841~47500407:+
LUAD	cis	rs62355901	0.505	rs56309635	ENSG00000271828.1	CTD-2310F14.1	3.72	0.000222	0.027	0.37	0.17	Breast cancer;	chr5:56789589	chr5:56927874~56929573:+
LUAD	cis	rs2216164	0.933	rs2193047	ENSG00000256325.1	RP11-611O2.1	3.72	0.000222	0.027	0.19	0.17	Alopecia areata;	chr12:68142848	chr12:68828118~68828553:+
LUAD	cis	rs1023500	0.552	rs133368	ENSG00000273366.1	CTA-989H11.1	-3.72	0.000222	0.0271	-0.2	-0.17	Schizophrenia;	chr22:42067685	chr22:42278188~42278846:+
LUAD	cis	rs1876905	0.68	rs9400468	ENSG00000230177.1	RP5-1112D6.4	-3.72	0.000222	0.0271	-0.2	-0.17	Mean corpuscular hemoglobin;	chr6:111138766	chr6:111277932~111278742:+
LUAD	cis	rs7141336	1	rs7141114	ENSG00000258884.1	CTD-3035D6.2	3.72	0.000222	0.0271	0.17	0.17	Anxiety disorder;	chr14:90819690	chr14:90822365~90828128:-
LUAD	cis	rs2904524	1	rs75846246	ENSG00000257815.4	RP11-611E13.2	-3.72	0.000222	0.0271	-0.25	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70305146	chr12:69904033~70243360:-
LUAD	cis	rs2904524	1	rs79903423	ENSG00000257815.4	RP11-611E13.2	-3.72	0.000222	0.0271	-0.25	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70308032	chr12:69904033~70243360:-
LUAD	cis	rs2904524	1	rs58828627	ENSG00000257815.4	RP11-611E13.2	-3.72	0.000222	0.0271	-0.25	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70317513	chr12:69904033~70243360:-
LUAD	cis	rs516805	0.923	rs487487	ENSG00000279114.1	RP3-425C14.5	-3.72	0.000222	0.0271	-0.18	-0.17	Lymphocyte counts;	chr6:122422357	chr6:122471923~122484161:+
LUAD	cis	rs516805	0.961	rs556439	ENSG00000279114.1	RP3-425C14.5	-3.72	0.000222	0.0271	-0.18	-0.17	Lymphocyte counts;	chr6:122423864	chr6:122471923~122484161:+
LUAD	cis	rs73108077	0.915	rs73116254	ENSG00000281376.1	ABALON	-3.72	0.000222	0.0271	-0.29	-0.17	Red blood cell density in sickle cell anemia;	chr20:31453983	chr20:31721507~31723409:+
LUAD	cis	rs651907	0.557	rs2303474	ENSG00000244119.1	PDCL3P4	3.72	0.000222	0.0271	0.17	0.17	Colorectal cancer;	chr3:101653055	chr3:101712472~101713191:+
LUAD	cis	rs755249	0.874	rs61779310	ENSG00000182109.6	RP11-69E11.4	3.72	0.000222	0.0271	0.2	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39476625	chr1:39522280~39546187:-
LUAD	cis	rs526231	0.783	rs28158	ENSG00000175749.11	EIF3KP1	3.72	0.000222	0.0271	0.22	0.17	Primary biliary cholangitis;	chr5:103260191	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.747	rs39984	ENSG00000175749.11	EIF3KP1	3.72	0.000222	0.0271	0.22	0.17	Primary biliary cholangitis;	chr5:103261591	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.819	rs2561482	ENSG00000175749.11	EIF3KP1	3.72	0.000222	0.0271	0.22	0.17	Primary biliary cholangitis;	chr5:103262097	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.747	rs375637	ENSG00000175749.11	EIF3KP1	3.72	0.000222	0.0271	0.22	0.17	Primary biliary cholangitis;	chr5:103263877	chr5:103032376~103033031:+
LUAD	cis	rs526231	0.747	rs434294	ENSG00000175749.11	EIF3KP1	3.72	0.000222	0.0271	0.22	0.17	Primary biliary cholangitis;	chr5:103263925	chr5:103032376~103033031:+
LUAD	cis	rs4713118	0.866	rs9468217	ENSG00000280107.1	AL022393.9	-3.72	0.000222	0.0271	-0.22	-0.17	Parkinson's disease;	chr6:27758688	chr6:28170845~28172521:+
LUAD	cis	rs13434995	0.796	rs2412664	ENSG00000249700.7	SRD5A3-AS1	3.72	0.000222	0.0271	0.25	0.17	Adiponectin levels;	chr4:55591220	chr4:55363971~55395847:-
LUAD	cis	rs8180040	0.966	rs4858868	ENSG00000271161.1	BOLA2P2	3.72	0.000222	0.0271	0.16	0.17	Colorectal cancer;	chr3:47413596	chr3:47499841~47500407:+
LUAD	cis	rs10131894	0.635	rs174997	ENSG00000259138.1	RP11-950C14.7	-3.72	0.000222	0.0271	-0.18	-0.17	Coronary artery disease;	chr14:74968103	chr14:75127153~75136930:+
LUAD	cis	rs4907240	0.925	rs4907242	ENSG00000237510.6	AC008268.2	-3.72	0.000222	0.0271	-0.24	-0.17	Event-related brain oscillations;	chr2:96607376	chr2:95789654~95800166:+
LUAD	cis	rs4907240	0.925	rs7575254	ENSG00000237510.6	AC008268.2	-3.72	0.000222	0.0271	-0.24	-0.17	Event-related brain oscillations;	chr2:96610023	chr2:95789654~95800166:+
LUAD	cis	rs442309	0.875	rs224062	ENSG00000238280.1	RP11-436D10.3	-3.72	0.000222	0.0271	-0.2	-0.17	Vogt-Koyanagi-Harada syndrome;	chr10:62743036	chr10:62793562~62805887:-
LUAD	cis	rs6763848	0.962	rs9869487	ENSG00000214073.2	RPL21P17	-3.72	0.000222	0.0271	-0.17	-0.17	Prostate cancer (SNP x SNP interaction);	chr3:1467164	chr3:1905651~1906125:+
LUAD	cis	rs755249	0.51	rs613511	ENSG00000182109.6	RP11-69E11.4	3.72	0.000222	0.0271	0.18	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39367801	chr1:39522280~39546187:-
LUAD	cis	rs4660214	0.666	rs629093	ENSG00000182109.6	RP11-69E11.4	3.72	0.000222	0.0271	0.18	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39367831	chr1:39522280~39546187:-
LUAD	cis	rs4660214	0.666	rs663449	ENSG00000182109.6	RP11-69E11.4	3.72	0.000222	0.0271	0.18	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39378286	chr1:39522280~39546187:-
LUAD	cis	rs3002142	0.643	rs3748629	ENSG00000272750.1	RP11-378J18.8	3.72	0.000222	0.0271	0.28	0.17	LDL peak particle diameter (total fat intake interaction);	chr1:222630489	chr1:222658867~222661512:-
LUAD	cis	rs8009420	0.609	rs55867246	ENSG00000224004.2	ATP5C1P1	-3.72	0.000222	0.0271	-0.33	-0.17	Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis;	chr14:53769494	chr14:53991101~53991995:-
LUAD	cis	rs1020064	0.636	rs2576726	ENSG00000235319.1	AC012360.4	-3.72	0.000222	0.0271	-0.2	-0.17	AIDS;	chr2:105319955	chr2:105324210~105330529:+
LUAD	cis	rs11673344	0.526	rs17303902	ENSG00000267254.4	ZNF790-AS1	-3.72	0.000222	0.0271	-0.21	-0.17	Obesity-related traits;	chr19:37551912	chr19:36797518~36828115:+
LUAD	cis	rs11673344	0.526	rs55754546	ENSG00000267254.4	ZNF790-AS1	-3.72	0.000222	0.0271	-0.21	-0.17	Obesity-related traits;	chr19:37552860	chr19:36797518~36828115:+
LUAD	cis	rs10896135	0.526	rs12795774	ENSG00000213409.4	RP11-658F2.3	3.72	0.000222	0.0271	0.23	0.17	Bipolar disorder;	chr11:66614046	chr11:66761575~66762399:-
LUAD	cis	rs6723108	1	rs1942055	ENSG00000224043.6	CCNT2-AS1	3.72	0.000222	0.0271	0.21	0.17	Type 2 diabetes;	chr2:134741354	chr2:134735464~134918710:-
LUAD	cis	rs9308731	0.644	rs1837369	ENSG00000227992.1	AC108463.2	-3.72	0.000222	0.0271	-0.19	-0.17	Chronic lymphocytic leukemia;	chr2:111116699	chr2:111203964~111206215:-
LUAD	cis	rs9309473	0.5	rs10189578	ENSG00000163016.8	ALMS1P	3.72	0.000222	0.0271	0.18	0.17	Metabolite levels;	chr2:73501482	chr2:73644919~73685576:+
LUAD	cis	rs4759375	1	rs61953394	ENSG00000235423.7	RP11-282O18.3	3.72	0.000222	0.0271	0.3	0.17	HDL cholesterol;	chr12:123268825	chr12:123252030~123261483:-
LUAD	cis	rs10214930	0.553	rs6943712	ENSG00000235574.1	AC073150.6	-3.72	0.000222	0.0271	-0.24	-0.17	Hypospadias;	chr7:27878265	chr7:27491682~27492765:-
LUAD	cis	rs1023500	0.551	rs133379	ENSG00000273366.1	CTA-989H11.1	-3.72	0.000222	0.0271	-0.2	-0.17	Schizophrenia;	chr22:42072531	chr22:42278188~42278846:+
LUAD	cis	rs17597773	0.638	rs11118615	ENSG00000272823.1	RP11-295M18.6	-3.72	0.000222	0.0271	-0.22	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220823271	chr1:220828676~220829211:-
LUAD	cis	rs12935418	0.616	rs2549828	ENSG00000278985.1	RP11-303E16.9	-3.72	0.000222	0.0271	-0.16	-0.17	Mean corpuscular volume;	chr16:80985378	chr16:80982319~80984094:-
LUAD	cis	rs9556958	0.527	rs9517313	ENSG00000231194.1	FARP1-AS1	3.72	0.000222	0.0271	0.2	0.17	Educational attainment (years of education);	chr13:98453638	chr13:98435405~98435840:-
LUAD	cis	rs8141529	0.702	rs5762870	ENSG00000272858.1	CTA-292E10.8	-3.72	0.000222	0.0271	-0.18	-0.17	Lymphocyte counts;	chr22:28865171	chr22:28814914~28815662:+
LUAD	cis	rs8040855	0.627	rs12909971	ENSG00000259774.1	RP11-182J1.13	3.72	0.000222	0.0271	0.21	0.17	Bulimia nervosa;	chr15:85045767	chr15:84422618~84425882:+
LUAD	cis	rs10943724	1	rs6915595	ENSG00000218582.2	GAPDHP63	3.72	0.000222	0.0271	0.16	0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:80585414	chr6:79953005~79954011:-
LUAD	cis	rs214785	1	rs214799	ENSG00000234684.5	SDCBP2-AS1	3.72	0.000222	0.0271	0.21	0.17	Basal cell carcinoma;	chr20:2306058	chr20:1325405~1378734:+
LUAD	cis	rs11250098	0.574	rs7015168	ENSG00000255310.2	AF131215.2	-3.72	0.000222	0.0271	-0.17	-0.17	Morning vs. evening chronotype;	chr8:10914700	chr8:11107788~11109726:-
LUAD	cis	rs67478160	0.643	rs2223937	ENSG00000272533.1	SNORA28	3.72	0.000222	0.0271	0.17	0.17	Schizophrenia;	chr14:103820043	chr14:103337849~103337974:+
LUAD	cis	rs9341808	0.622	rs684283	ENSG00000272129.1	RP11-250B2.6	-3.72	0.000222	0.0271	-0.2	-0.17	Sitting height ratio;	chr6:80257600	chr6:80355424~80356859:+
LUAD	cis	rs2720460	0.502	rs223374	ENSG00000230069.3	LRRC37A15P	-3.72	0.000223	0.0271	-0.18	-0.17	Testicular germ cell tumor;	chr4:102837144	chr4:102727274~102730721:-
LUAD	cis	rs875971	0.522	rs4502988	ENSG00000222364.1	RNU6-96P	-3.72	0.000223	0.0271	-0.19	-0.17	Aortic root size;	chr7:65832759	chr7:66395191~66395286:+
LUAD	cis	rs159572	0.784	rs159066	ENSG00000250853.1	RNF138P1	3.72	0.000223	0.0271	0.2	0.17	Post-traumatic stress disorder;	chr5:56228094	chr5:55530156~55530701:-
LUAD	cis	rs6479901	0.895	rs3211105	ENSG00000232075.1	MRPL35P2	-3.72	0.000223	0.0271	-0.23	-0.17	Intelligence (multi-trait analysis);	chr10:63185604	chr10:63634317~63634827:-
LUAD	cis	rs6121246	0.609	rs6060955	ENSG00000230613.1	HM13-AS1	3.72	0.000223	0.0271	0.21	0.17	Mean corpuscular hemoglobin;	chr20:31797268	chr20:31567707~31573263:-
LUAD	cis	rs72647484	0.554	rs2807316	ENSG00000234397.3	RP11-415K20.1	-3.72	0.000223	0.0271	-0.33	-0.17	Colorectal cancer;	chr1:22227085	chr1:22322840~22323331:-
LUAD	cis	rs36093844	0.527	rs72963092	ENSG00000279742.1	RP11-700A24.1	-3.72	0.000223	0.0271	-0.2	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86033584	chr11:85852557~85854943:-
LUAD	cis	rs13108904	0.901	rs12641735	ENSG00000196810.4	CTBP1-AS2	3.72	0.000223	0.0271	0.19	0.17	Obesity-related traits;	chr4:1310646	chr4:1249300~1288291:+
LUAD	cis	rs1150668	0.796	rs728122	ENSG00000176933.5	TOB2P1	-3.72	0.000223	0.0271	-0.19	-0.17	Pubertal anthropometrics;	chr6:28431347	chr6:28217643~28218634:-
LUAD	cis	rs3849150	0.95	rs17772255	ENSG00000235939.1	RP11-123B3.2	-3.72	0.000223	0.0271	-0.26	-0.17	Subclinical atherosclerosis traits (other);	chr10:48879037	chr10:49419277~49472903:+
LUAD	cis	rs2836974	0.831	rs4375956	ENSG00000232608.1	TIMM9P2	-3.72	0.000223	0.0271	-0.21	-0.17	Cognitive function;	chr21:39149862	chr21:39216624~39217506:+
LUAD	cis	rs4118325	0.734	rs1762497	ENSG00000224550.1	RP11-270C12.3	-3.72	0.000223	0.0271	-0.2	-0.17	AIDS;	chr1:107091820	chr1:107505203~107505448:+
LUAD	cis	rs67340775	0.541	rs200975	ENSG00000280107.1	AL022393.9	-3.72	0.000223	0.0271	-0.26	-0.17	Lung cancer in ever smokers;	chr6:27887847	chr6:28170845~28172521:+
LUAD	cis	rs67340775	0.541	rs200974	ENSG00000280107.1	AL022393.9	-3.72	0.000223	0.0271	-0.26	-0.17	Lung cancer in ever smokers;	chr6:27888067	chr6:28170845~28172521:+
LUAD	cis	rs180730	0.95	rs2198032	ENSG00000251609.2	SETP12	3.72	0.000223	0.0271	0.25	0.17	Fasting plasma glucose;	chr4:120918993	chr4:120895494~120897083:-
LUAD	cis	rs4763879	0.634	rs917913	ENSG00000278635.1	CTD-2318O12.1	3.72	0.000223	0.0271	0.15	0.17	Type 1 diabetes;	chr12:9707040	chr12:9415641~9416718:+
LUAD	cis	rs1400816	0.85	rs3770444	ENSG00000228389.1	AC068039.4	3.72	0.000223	0.0271	0.28	0.17	Amyotrophic lateral sclerosis (sporadic);	chr2:171852705	chr2:171773482~171775844:+
LUAD	cis	rs889398	0.617	rs11075742	ENSG00000226232.7	RP11-419C5.2	-3.72	0.000223	0.0271	-0.14	-0.17	Body mass index;	chr16:69865031	chr16:69976388~69996188:-
LUAD	cis	rs4388249	0.687	rs2300995	ENSG00000271849.1	CTC-332L22.1	-3.72	0.000223	0.0271	-0.23	-0.17	Schizophrenia;	chr5:109746724	chr5:109687802~109688329:-
LUAD	cis	rs7017914	0.902	rs1373480	ENSG00000246366.5	RP11-382J12.1	3.72	0.000223	0.0271	0.15	0.17	Bone mineral density;	chr8:70774732	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.967	rs10448014	ENSG00000246366.5	RP11-382J12.1	3.72	0.000223	0.0271	0.15	0.17	Bone mineral density;	chr8:70775930	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.967	rs7000647	ENSG00000246366.5	RP11-382J12.1	3.72	0.000223	0.0271	0.15	0.17	Bone mineral density;	chr8:70776173	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.967	rs13254801	ENSG00000246366.5	RP11-382J12.1	3.72	0.000223	0.0271	0.15	0.17	Bone mineral density;	chr8:70776749	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.783	rs13252584	ENSG00000246366.5	RP11-382J12.1	3.72	0.000223	0.0271	0.15	0.17	Bone mineral density;	chr8:70776796	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.84	rs13254851	ENSG00000246366.5	RP11-382J12.1	3.72	0.000223	0.0271	0.15	0.17	Bone mineral density;	chr8:70776799	chr8:70608577~70663279:+
LUAD	cis	rs72647484	0.642	rs2744752	ENSG00000234397.3	RP11-415K20.1	-3.72	0.000223	0.0271	-0.35	-0.17	Colorectal cancer;	chr1:22248813	chr1:22322840~22323331:-
LUAD	cis	rs10463554	0.926	rs26429	ENSG00000250682.4	LINC00491	-3.72	0.000223	0.0271	-0.2	-0.17	Parkinson's disease;	chr5:103030349	chr5:102609156~102671559:-
LUAD	cis	rs8040855	1	rs6496768	ENSG00000259774.1	RP11-182J1.13	-3.72	0.000223	0.0271	-0.2	-0.17	Bulimia nervosa;	chr15:85159701	chr15:84422618~84425882:+
LUAD	cis	rs9659323	1	rs11584380	ENSG00000226172.2	RP4-712E4.1	-3.72	0.000223	0.0271	-0.18	-0.17	Body mass index;	chr1:118974797	chr1:119000344~119001392:-
LUAD	cis	rs7246657	0.551	rs12972146	ENSG00000267309.1	CTD-2630F21.1	3.72	0.000223	0.0271	0.27	0.17	Coronary artery calcification;	chr19:37135193	chr19:36489649~36491040:+
LUAD	cis	rs4474465	0.85	rs7112872	ENSG00000251323.2	RP11-452H21.4	-3.72	0.000223	0.0271	-0.2	-0.17	Alzheimer's disease (survival time);	chr11:78516350	chr11:78423982~78429836:-
LUAD	cis	rs4474465	0.85	rs4944205	ENSG00000251323.2	RP11-452H21.4	-3.72	0.000223	0.0271	-0.2	-0.17	Alzheimer's disease (survival time);	chr11:78516744	chr11:78423982~78429836:-
LUAD	cis	rs1355223	1	rs1396879	ENSG00000271369.1	RP11-350D17.3	-3.72	0.000223	0.0272	-0.2	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34745106	chr11:34709600~34710161:+
LUAD	cis	rs2380205	0.875	rs4282898	ENSG00000232807.2	RP11-536K7.3	3.72	0.000223	0.0272	0.17	0.17	Breast cancer;	chr10:5857324	chr10:5934270~5945900:-
LUAD	cis	rs4908769	0.624	rs2708630	ENSG00000232912.4	RP5-1115A15.1	-3.72	0.000223	0.0272	-0.16	-0.17	Allergy;	chr1:8387344	chr1:8424645~8434838:+
LUAD	cis	rs7512898	0.5	rs10733063	ENSG00000260088.1	RP11-92G12.3	-3.72	0.000223	0.0272	-0.22	-0.17	Electrocardiographic conduction measures;	chr1:200821181	chr1:200669507~200694250:+
LUAD	cis	rs806321	0.587	rs2765756	ENSG00000237152.3	DLEU7-AS1	-3.72	0.000223	0.0272	-0.21	-0.17	Multiple sclerosis;	chr13:50199350	chr13:50807856~50849905:+
LUAD	cis	rs9393777	0.778	rs67457459	ENSG00000219392.1	RP1-265C24.5	-3.72	0.000223	0.0272	-0.32	-0.17	Intelligence (multi-trait analysis);	chr6:27230564	chr6:28115628~28116551:+
LUAD	cis	rs6928977	0.897	rs2246852	ENSG00000231028.7	LINC00271	3.72	0.000223	0.0272	0.2	0.17	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135370654	chr6:135497801~135716055:+
LUAD	cis	rs7909670	0.508	rs12779328	ENSG00000228330.1	RP11-730A19.5	3.72	0.000223	0.0272	0.22	0.17	Height;	chr10:12901973	chr10:13142185~13142977:-
LUAD	cis	rs7107174	0.688	rs2063725	ENSG00000251323.2	RP11-452H21.4	3.72	0.000223	0.0272	0.21	0.17	Testicular germ cell tumor;	chr11:78422406	chr11:78423982~78429836:-
LUAD	cis	rs7937890	0.631	rs7118886	ENSG00000255040.1	RP11-677N16.1	3.72	0.000223	0.0272	0.18	0.17	Mitochondrial DNA levels;	chr11:14405971	chr11:14673606~14674555:-
LUAD	cis	rs11168351	1	rs11168351	ENSG00000257763.1	OR5BK1P	3.72	0.000223	0.0272	0.17	0.17	Bipolar disorder and schizophrenia;	chr12:48009982	chr12:48355792~48356614:-
LUAD	cis	rs6793245	0.843	rs12490047	ENSG00000229589.1	ACVR2B-AS1	-3.72	0.000223	0.0272	-0.21	-0.17	QT interval;	chr3:38544924	chr3:38451027~38454820:-
LUAD	cis	rs6793245	0.843	rs56283404	ENSG00000229589.1	ACVR2B-AS1	-3.72	0.000223	0.0272	-0.21	-0.17	QT interval;	chr3:38545215	chr3:38451027~38454820:-
LUAD	cis	rs4321386	0.502	rs2871444	ENSG00000281162.1	LINC01127	-3.72	0.000223	0.0272	-0.22	-0.17	Hormone measurements;	chr2:101996388	chr2:101962056~101987167:+
LUAD	cis	rs8177876	0.686	rs2602402	ENSG00000261061.1	RP11-303E16.2	-3.72	0.000223	0.0272	-0.23	-0.17	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81052725	chr16:81030770~81031485:+
LUAD	cis	rs7772486	0.651	rs1292338	ENSG00000235652.6	RP11-545I5.3	-3.72	0.000223	0.0272	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145646335	chr6:145799409~145886585:+
LUAD	cis	rs7474896	0.537	rs1208591	ENSG00000226578.1	RP11-258F22.1	-3.72	0.000223	0.0272	-0.23	-0.17	Obesity (extreme);	chr10:37923574	chr10:37775371~37784131:-
LUAD	cis	rs6088580	0.542	rs6059882	ENSG00000276073.1	RP5-1125A11.7	-3.72	0.000223	0.0272	-0.16	-0.17	Glomerular filtration rate (creatinine);	chr20:34502362	chr20:33985617~33988989:-
LUAD	cis	rs1075265	0.836	rs10208233	ENSG00000272156.1	RP11-477N3.1	-3.72	0.000223	0.0272	-0.2	-0.17	Chronotype;Morning vs. evening chronotype;	chr2:54066433	chr2:54082554~54085066:+
LUAD	cis	rs891378	1	rs10864231	ENSG00000274245.1	RP11-357P18.2	-3.72	0.000223	0.0272	-0.21	-0.17	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207332984	chr1:207372559~207373252:+
LUAD	cis	rs9900280	1	rs9910334	ENSG00000264808.1	RP11-802D6.1	3.72	0.000223	0.0272	0.2	0.17	Mean platelet volume;	chr17:29473588	chr17:29369717~29390777:-
LUAD	cis	rs812925	0.892	rs1186699	ENSG00000271889.1	RP11-493E12.1	3.72	0.000223	0.0272	0.21	0.17	Immature fraction of reticulocytes;	chr2:61435420	chr2:61151433~61162105:-
LUAD	cis	rs7107174	1	rs901104	ENSG00000251323.2	RP11-452H21.4	3.72	0.000223	0.0272	0.23	0.17	Testicular germ cell tumor;	chr11:78219453	chr11:78423982~78429836:-
LUAD	cis	rs1150668	0.796	rs213237	ENSG00000176933.5	TOB2P1	-3.72	0.000223	0.0272	-0.19	-0.17	Pubertal anthropometrics;	chr6:28356161	chr6:28217643~28218634:-
LUAD	cis	rs911555	0.755	rs9671414	ENSG00000244691.1	RPL10AP1	3.72	0.000223	0.0272	0.22	0.17	Intelligence (multi-trait analysis);	chr14:103500962	chr14:103412119~103412761:-
LUAD	cis	rs804280	0.56	rs10503426	ENSG00000255046.1	RP11-297N6.4	-3.72	0.000223	0.0272	-0.21	-0.17	Myopia (pathological);	chr8:11731874	chr8:11797928~11802568:-
LUAD	cis	rs1075265	0.597	rs10490471	ENSG00000272156.1	RP11-477N3.1	-3.72	0.000223	0.0272	-0.2	-0.17	Chronotype;Morning vs. evening chronotype;	chr2:53769446	chr2:54082554~54085066:+
LUAD	cis	rs524281	0.773	rs79770412	ENSG00000255320.1	RP11-755F10.1	3.72	0.000223	0.0272	0.26	0.17	Electroencephalogram traits;	chr11:66277873	chr11:66244840~66246239:-
LUAD	cis	rs7712401	0.755	rs3756362	ENSG00000249996.1	RP11-359P5.1	3.72	0.000224	0.0272	0.2	0.17	Mean platelet volume;	chr5:122773195	chr5:123036271~123054667:+
LUAD	cis	rs5771225	0.505	rs2341111	ENSG00000273253.2	RP3-402G11.26	-3.72	0.000224	0.0272	-0.17	-0.17	Late-onset Alzheimer's disease;	chr22:50251893	chr22:50199090~50200837:-
LUAD	cis	rs7017914	0.967	rs7825446	ENSG00000246366.5	RP11-382J12.1	3.72	0.000224	0.0272	0.15	0.17	Bone mineral density;	chr8:70751939	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.967	rs6472543	ENSG00000246366.5	RP11-382J12.1	3.72	0.000224	0.0272	0.15	0.17	Bone mineral density;	chr8:70752173	chr8:70608577~70663279:+
LUAD	cis	rs889398	0.617	rs6499265	ENSG00000226232.7	RP11-419C5.2	-3.72	0.000224	0.0272	-0.14	-0.17	Body mass index;	chr16:69864095	chr16:69976388~69996188:-
LUAD	cis	rs7202877	0.706	rs37602	ENSG00000280152.1	RP11-331F4.5	-3.72	0.000224	0.0272	-0.19	-0.17	Type 1 diabetes;Type 2 diabetes;	chr16:75471148	chr16:75245994~75250077:-
LUAD	cis	rs9309473	1	rs6710438	ENSG00000230002.2	ALMS1-IT1	-3.72	0.000224	0.0272	-0.21	-0.17	Metabolite levels;	chr2:73592981	chr2:73456764~73459484:+
LUAD	cis	rs10080237	0.564	rs2490230	ENSG00000272129.1	RP11-250B2.6	3.72	0.000224	0.0272	0.21	0.17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;	chr6:80102747	chr6:80355424~80356859:+
LUAD	cis	rs13108904	0.87	rs4974541	ENSG00000196810.4	CTBP1-AS2	3.72	0.000224	0.0272	0.2	0.17	Obesity-related traits;	chr4:1250249	chr4:1249300~1288291:+
LUAD	cis	rs16940212	0.618	rs261301	ENSG00000242747.1	RP11-30K9.1	3.72	0.000224	0.0272	0.24	0.17	HDL cholesterol;HDL cholesterol levels;	chr15:58394740	chr15:58869659~58870134:+
LUAD	cis	rs1075265	0.783	rs805359	ENSG00000272156.1	RP11-477N3.1	-3.72	0.000224	0.0272	-0.2	-0.17	Chronotype;Morning vs. evening chronotype;	chr2:53935317	chr2:54082554~54085066:+
LUAD	cis	rs9646944	0.891	rs13027294	ENSG00000234389.1	AC007278.3	3.72	0.000224	0.0272	0.19	0.17	Blood protein levels;	chr2:102243614	chr2:102438713~102440475:+
LUAD	cis	rs67478160	0.619	rs8018062	ENSG00000272533.1	SNORA28	3.72	0.000224	0.0272	0.17	0.17	Schizophrenia;	chr14:103815617	chr14:103337849~103337974:+
LUAD	cis	rs3849150	0.95	rs12766490	ENSG00000235939.1	RP11-123B3.2	-3.72	0.000224	0.0272	-0.24	-0.17	Subclinical atherosclerosis traits (other);	chr10:48886956	chr10:49419277~49472903:+
LUAD	cis	rs3753275	0.519	rs3850465	ENSG00000232912.4	RP5-1115A15.1	3.72	0.000224	0.0272	0.2	0.17	Educational attainment;	chr1:8611720	chr1:8424645~8434838:+
LUAD	cis	rs910873	0.656	rs62213589	ENSG00000250917.1	RP4-785G19.5	-3.72	0.000224	0.0272	-0.36	-0.17	Melanoma;	chr20:34632031	chr20:34234840~34281173:-
LUAD	cis	rs56050415	1	rs58038553	ENSG00000277144.1	RP11-59H7.4	3.72	0.000224	0.0272	0.3	0.17	Metabolite levels (lipoprotein measures);	chr15:58282125	chr15:59115547~59116089:-
LUAD	cis	rs6951245	0.58	rs77101766	ENSG00000229043.2	AC091729.9	-3.72	0.000224	0.0272	-0.22	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1082802	chr7:1160374~1165267:+
LUAD	cis	rs7942368	0.715	rs12788118	ENSG00000254632.1	RP11-21L23.4	3.72	0.000224	0.0272	0.17	0.17	Endometriosis;	chr11:76783176	chr11:76759916~76768223:-
LUAD	cis	rs6071166	0.683	rs6027218	ENSG00000224635.1	RP4-564F22.5	-3.72	0.000224	0.0272	-0.19	-0.17	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38678619	chr20:38406011~38416797:-
LUAD	cis	rs116095464	0.558	rs10036253	ENSG00000248925.1	CTD-2083E4.6	3.72	0.000224	0.0272	0.28	0.17	Breast cancer;	chr5:238404	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs10075018	ENSG00000248925.1	CTD-2083E4.6	3.72	0.000224	0.0272	0.28	0.17	Breast cancer;	chr5:239060	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs10076655	ENSG00000248925.1	CTD-2083E4.6	3.72	0.000224	0.0272	0.28	0.17	Breast cancer;	chr5:239349	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs10057492	ENSG00000248925.1	CTD-2083E4.6	3.72	0.000224	0.0272	0.28	0.17	Breast cancer;	chr5:239388	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs28418643	ENSG00000248925.1	CTD-2083E4.6	3.72	0.000224	0.0272	0.28	0.17	Breast cancer;	chr5:240744	chr5:269858~271516:-
LUAD	cis	rs12188164	0.965	rs56146525	ENSG00000221990.4	EXOC3-AS1	3.72	0.000224	0.0272	0.17	0.17	Cystic fibrosis severity;	chr5:442456	chr5:441498~443160:-
LUAD	cis	rs804280	1	rs804281	ENSG00000255046.1	RP11-297N6.4	-3.72	0.000224	0.0272	-0.22	-0.17	Myopia (pathological);	chr8:11754356	chr8:11797928~11802568:-
LUAD	cis	rs7017914	0.967	rs7819332	ENSG00000246366.5	RP11-382J12.1	3.72	0.000224	0.0272	0.15	0.17	Bone mineral density;	chr8:70756030	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.967	rs7012404	ENSG00000246366.5	RP11-382J12.1	3.72	0.000224	0.0272	0.15	0.17	Bone mineral density;	chr8:70756463	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.967	rs7018381	ENSG00000246366.5	RP11-382J12.1	3.72	0.000224	0.0272	0.15	0.17	Bone mineral density;	chr8:70757882	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.967	rs13258584	ENSG00000246366.5	RP11-382J12.1	3.72	0.000224	0.0272	0.15	0.17	Bone mineral density;	chr8:70759344	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.934	rs7009297	ENSG00000246366.5	RP11-382J12.1	3.72	0.000224	0.0272	0.15	0.17	Bone mineral density;	chr8:70760131	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.967	rs7014012	ENSG00000246366.5	RP11-382J12.1	3.72	0.000224	0.0272	0.15	0.17	Bone mineral density;	chr8:70760508	chr8:70608577~70663279:+
LUAD	cis	rs2032366	0.606	rs1377171	ENSG00000266920.1	ACTBP9	3.72	0.000224	0.0273	0.18	0.17	Obesity-related traits;	chr18:61606810	chr18:62442028~62443126:+
LUAD	cis	rs9393777	0.528	rs7745603	ENSG00000219392.1	RP1-265C24.5	-3.72	0.000224	0.0273	-0.22	-0.17	Intelligence (multi-trait analysis);	chr6:27122625	chr6:28115628~28116551:+
LUAD	cis	rs7119038	0.607	rs12365699	ENSG00000255422.1	AP002954.4	3.72	0.000224	0.0273	0.29	0.17	Sjögren's syndrome;	chr11:118872577	chr11:118704607~118750263:+
LUAD	cis	rs240993	0.812	rs4945881	ENSG00000271789.1	RP5-1112D6.7	3.72	0.000224	0.0273	0.2	0.17	Inflammatory skin disease;Psoriasis;	chr6:111470260	chr6:111297126~111298510:+
LUAD	cis	rs4130344	0.874	rs13123982	ENSG00000271817.2	U3	-3.72	0.000224	0.0273	-0.18	-0.17	Intelligence (multi-trait analysis);	chr4:158778908	chr4:158700691~158700909:+
LUAD	cis	rs13434995	0.513	rs62310862	ENSG00000273257.1	RP11-177J6.1	-3.72	0.000224	0.0273	-0.23	-0.17	Adiponectin levels;	chr4:55572594	chr4:55387949~55388271:+
LUAD	cis	rs9894429	0.646	rs7406828	ENSG00000263853.1	AC139530.1	3.72	0.000224	0.0273	0.18	0.17	Eye color traits;	chr17:81652196	chr17:81676001~81676086:+
LUAD	cis	rs78572108	0.858	rs75186502	ENSG00000214691.7	AC104654.1	3.72	0.000224	0.0273	0.29	0.17	Total body bone mineral density;	chr2:42006718	chr2:41877074~41894046:+
LUAD	cis	rs2274273	0.87	rs3783652	ENSG00000259318.1	RP11-454L9.2	3.72	0.000224	0.0273	0.15	0.17	Protein biomarker;	chr14:55387490	chr14:55394940~55395233:-
LUAD	cis	rs321358	0.945	rs17537367	ENSG00000271390.1	RP11-89C3.3	3.72	0.000224	0.0273	0.28	0.17	Body mass index;	chr11:111117008	chr11:111089870~111090368:-
LUAD	cis	rs7107174	1	rs9651769	ENSG00000251323.2	RP11-452H21.4	3.72	0.000224	0.0273	0.22	0.17	Testicular germ cell tumor;	chr11:78285120	chr11:78423982~78429836:-
LUAD	cis	rs2279168	1	rs2279168	ENSG00000202081.1	RNU6-1280P	-3.72	0.000224	0.0273	-0.27	-0.17	Response to platinum-based chemotherapy (carboplatin);	chr15:85533958	chr15:85651522~85651628:-
LUAD	cis	rs8056893	0.807	rs7203220	ENSG00000260441.4	RP11-96D1.7	-3.72	0.000224	0.0273	-0.19	-0.17	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68322284	chr16:68256162~68260443:-
LUAD	cis	rs8056893	0.807	rs7194378	ENSG00000260441.4	RP11-96D1.7	-3.72	0.000224	0.0273	-0.19	-0.17	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68325831	chr16:68256162~68260443:-
LUAD	cis	rs8056893	0.807	rs7200049	ENSG00000260441.4	RP11-96D1.7	-3.72	0.000224	0.0273	-0.19	-0.17	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68326551	chr16:68256162~68260443:-
LUAD	cis	rs11089937	0.667	rs11704024	ENSG00000211640.3	IGLV6-57	3.72	0.000224	0.0273	0.13	0.17	Periodontitis (PAL4Q3);	chr22:22151195	chr22:22195713~22196460:+
LUAD	cis	rs8062405	1	rs12443881	ENSG00000261419.1	RP11-57A19.4	-3.72	0.000224	0.0273	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28659696~28740781:-
LUAD	cis	rs4767841	0.935	rs2285595	ENSG00000248636.5	RP11-768F21.1	3.72	0.000224	0.0273	0.19	0.17	Urgency urinary incontinence;	chr12:119718603	chr12:119387987~119668079:-
LUAD	cis	rs6493487	0.512	rs28566562	ENSG00000273674.3	CTD-2378E12.1	3.72	0.000224	0.0273	0.24	0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50821847	chr15:50839875~50908599:-
LUAD	cis	rs42490	0.789	rs383592	ENSG00000251136.7	RP11-37B2.1	-3.72	0.000224	0.0273	-0.17	-0.17	Leprosy;	chr8:89792100	chr8:89609409~89757727:-
LUAD	cis	rs2348418	0.966	rs11049695	ENSG00000244712.1	RP11-874G11.1	3.72	0.000224	0.0273	0.2	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28527934	chr12:28564678~28565141:-
LUAD	cis	rs9549260	0.727	rs4603422	ENSG00000229456.1	RLIMP1	3.72	0.000224	0.0273	0.18	0.17	Red blood cell count;	chr13:40574216	chr13:40618738~40621348:+
LUAD	cis	rs12682352	0.602	rs4841044	ENSG00000253893.2	FAM85B	3.72	0.000224	0.0273	0.21	0.17	Neuroticism;	chr8:8807430	chr8:8167819~8226614:-
LUAD	cis	rs12602901	0.846	rs238229	ENSG00000262678.1	RP5-1050D4.4	3.72	0.000224	0.0273	0.19	0.17	Blood metabolite levels;	chr17:4973825	chr17:4986466~4987324:+
LUAD	cis	rs2115630	0.645	rs4842978	ENSG00000259728.4	LINC00933	-3.72	0.000224	0.0273	-0.21	-0.17	P wave terminal force;	chr15:84654022	chr15:84570649~84580175:+
LUAD	cis	rs1862618	0.853	rs252904	ENSG00000271828.1	CTD-2310F14.1	3.72	0.000224	0.0273	0.23	0.17	Initial pursuit acceleration;	chr5:56822906	chr5:56927874~56929573:+
LUAD	cis	rs2732480	0.557	rs2732454	ENSG00000273765.1	RP11-370I10.11	3.72	0.000225	0.0273	0.18	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48325894	chr12:48360920~48361377:+
LUAD	cis	rs757110	0.77	rs1557765	ENSG00000260196.1	RP1-239B22.5	3.72	0.000225	0.0273	0.2	0.17	Type 2 diabetes;	chr11:17382092	chr11:17380649~17383531:+
LUAD	cis	rs11673344	0.562	rs7257320	ENSG00000276846.1	CTD-3220F14.3	3.72	0.000225	0.0273	0.18	0.17	Obesity-related traits;	chr19:37080933	chr19:37314868~37315620:-
LUAD	cis	rs451417	0.818	rs236117	ENSG00000275632.1	RP5-967N21.11	3.72	0.000225	0.0273	0.23	0.17	Menopause (age at onset);	chr20:5956529	chr20:6000418~6000941:+
LUAD	cis	rs2333021	0.649	rs2333016	ENSG00000259015.1	RP11-109N23.6	3.72	0.000225	0.0273	0.17	0.17	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72993209	chr14:72960595~72961993:+
LUAD	cis	rs2333021	0.649	rs12881153	ENSG00000259015.1	RP11-109N23.6	3.72	0.000225	0.0273	0.17	0.17	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72993647	chr14:72960595~72961993:+
LUAD	cis	rs1551277	1	rs1551277	ENSG00000146666.5	LINC00525	-3.72	0.000225	0.0273	-0.19	-0.17	Anxiety disorder;	chr7:47789719	chr7:47761476~47766772:+
LUAD	cis	rs911555	0.755	rs8018400	ENSG00000259775.1	RP11-45P15.4	3.72	0.000225	0.0273	0.22	0.17	Intelligence (multi-trait analysis);	chr14:103434748	chr14:103331674~103332367:-
LUAD	cis	rs7129556	0.701	rs72947668	ENSG00000241782.1	RP11-91P24.1	3.72	0.000225	0.0273	0.24	0.17	Weight loss (gastric bypass surgery);	chr11:77717888	chr11:77868722~77869195:-
LUAD	cis	rs875971	0.83	rs12673450	ENSG00000273448.1	RP11-166O4.6	3.72	0.000225	0.0273	0.16	0.17	Aortic root size;	chr7:66544233	chr7:67333047~67334383:+
LUAD	cis	rs8012947	1	rs4595719	ENSG00000279636.2	LINC00216	-3.72	0.000225	0.0273	-0.18	-0.17	Alcohol consumption in current drinkers;	chr14:58302084	chr14:58288033~58289158:+
LUAD	cis	rs864537	0.646	rs2995091	ENSG00000233411.1	RP11-104L21.2	3.72	0.000225	0.0273	0.22	0.17	Celiac disease or Rheumatoid arthritis;Celiac disease;	chr1:167465040	chr1:167457383~167458661:-
LUAD	cis	rs8028182	0.636	rs11638974	ENSG00000260269.4	CTD-2323K18.1	-3.72	0.000225	0.0273	-0.24	-0.17	Sudden cardiac arrest;	chr15:75506965	chr15:75527150~75601205:-
LUAD	cis	rs7515577	0.898	rs3131824	ENSG00000223787.2	RP4-593M8.1	-3.72	0.000225	0.0273	-0.26	-0.17	Cholesterol, total;	chr1:92224379	chr1:92580476~92580821:-
LUAD	cis	rs7674212	0.507	rs223322	ENSG00000230069.3	LRRC37A15P	-3.72	0.000225	0.0273	-0.18	-0.17	Type 2 diabetes;	chr4:102879037	chr4:102727274~102730721:-
LUAD	cis	rs12188164	0.965	rs1056465	ENSG00000221990.4	EXOC3-AS1	3.72	0.000225	0.0273	0.17	0.17	Cystic fibrosis severity;	chr5:442323	chr5:441498~443160:-
LUAD	cis	rs9309473	0.519	rs7598901	ENSG00000163016.8	ALMS1P	-3.72	0.000225	0.0273	-0.18	-0.17	Metabolite levels;	chr2:73448717	chr2:73644919~73685576:+
LUAD	cis	rs238295	0.805	rs6053525	ENSG00000230563.2	RP5-828H9.1	3.72	0.000225	0.0273	0.22	0.17	Occipital cortical area (total cortical area interaction);	chr20:5596354	chr20:5471207~5475182:+
LUAD	cis	rs7215564	0.818	rs34756632	ENSG00000232083.3	RPL31P7	3.72	0.000225	0.0273	0.32	0.17	Myopia (pathological);	chr17:80645059	chr17:80602549~80602926:-
LUAD	cis	rs6081541	1	rs6106043	ENSG00000179447.2	RP5-1027G4.3	-3.72	0.000225	0.0273	-0.21	-0.17	Psychosis (atypical);	chr20:19241607	chr20:19242302~19284596:-
LUAD	cis	rs6001482	0.679	rs5995706	ENSG00000253818.1	IGLV1-41	-3.72	0.000225	0.0273	-0.18	-0.17	Diastolic blood pressure;	chr22:22236371	chr22:22404207~22404721:+
LUAD	cis	rs6001482	0.702	rs7286018	ENSG00000253818.1	IGLV1-41	-3.72	0.000225	0.0273	-0.18	-0.17	Diastolic blood pressure;	chr22:22236464	chr22:22404207~22404721:+
LUAD	cis	rs7189233	0.955	rs60420081	ENSG00000279344.1	RP11-44F14.7	3.72	0.000225	0.0273	0.15	0.17	Intelligence (multi-trait analysis);	chr16:53486892	chr16:53478957~53481550:-
LUAD	cis	rs2904524	1	rs74993103	ENSG00000257613.1	LINC01481	-3.72	0.000225	0.0273	-0.3	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70259786	chr12:70219132~70221862:-
LUAD	cis	rs67340775	0.541	rs200968	ENSG00000280107.1	AL022393.9	-3.72	0.000225	0.0273	-0.26	-0.17	Lung cancer in ever smokers;	chr6:27891790	chr6:28170845~28172521:+
LUAD	cis	rs5758511	0.634	rs1001587	ENSG00000233903.2	Z83851.4	3.72	0.000225	0.0274	0.25	0.17	Birth weight;	chr22:42274105	chr22:42276355~42277052:+
LUAD	cis	rs10129255	0.957	rs10138532	ENSG00000211947.2	IGHV3-21	-3.72	0.000225	0.0274	-0.11	-0.17	Kawasaki disease;	chr14:106803901	chr14:106235064~106235594:-
LUAD	cis	rs9341808	0.652	rs2505940	ENSG00000260645.1	RP11-250B2.5	3.72	0.000225	0.0274	0.16	0.17	Sitting height ratio;	chr6:80141474	chr6:80466958~80469080:+
LUAD	cis	rs5742933	1	rs6717922	ENSG00000253559.1	OSGEPL1-AS1	-3.72	0.000225	0.0274	-0.23	-0.17	Ferritin levels;	chr2:189721497	chr2:189762704~189765556:+
LUAD	cis	rs4268898	0.686	rs2042468	ENSG00000223754.1	AC008073.9	-3.72	0.000225	0.0274	-0.2	-0.17	Asthma;	chr2:24175577	chr2:24199839~24201698:-
LUAD	cis	rs2904524	0.541	rs10784840	ENSG00000257815.4	RP11-611E13.2	-3.72	0.000225	0.0274	-0.21	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70388944	chr12:69904033~70243360:-
LUAD	cis	rs2904524	0.5	rs11178214	ENSG00000257815.4	RP11-611E13.2	-3.72	0.000225	0.0274	-0.21	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70389327	chr12:69904033~70243360:-
LUAD	cis	rs1005277	0.54	rs289638	ENSG00000263064.2	RP11-291L22.7	3.72	0.000225	0.0274	0.18	0.17	Extrinsic epigenetic age acceleration;	chr10:37634803	chr10:38448689~38448949:+
LUAD	cis	rs10463554	0.892	rs34830	ENSG00000250682.4	LINC00491	3.72	0.000225	0.0274	0.2	0.17	Parkinson's disease;	chr5:103108349	chr5:102609156~102671559:-
LUAD	cis	rs889398	0.594	rs1466863	ENSG00000226232.7	RP11-419C5.2	3.72	0.000225	0.0274	0.14	0.17	Body mass index;	chr16:69870235	chr16:69976388~69996188:-
LUAD	cis	rs9341808	0.519	rs660888	ENSG00000279022.1	RP11-250B2.4	3.72	0.000225	0.0274	0.2	0.17	Sitting height ratio;	chr6:80273495	chr6:80440730~80441172:+
LUAD	cis	rs62355901	0.505	rs62356568	ENSG00000271828.1	CTD-2310F14.1	3.72	0.000225	0.0274	0.39	0.17	Breast cancer;	chr5:56955617	chr5:56927874~56929573:+
LUAD	cis	rs334353	0.798	rs868	ENSG00000255145.2	STX17-AS1	3.72	0.000225	0.0274	0.22	0.17	Age-related macular degeneration;	chr9:99149374	chr9:99886322~99906601:-
LUAD	cis	rs10129255	0.957	rs8005468	ENSG00000274576.2	IGHV2-70	3.72	0.000225	0.0274	0.15	0.17	Kawasaki disease;	chr14:106686431	chr14:106770577~106771020:-
LUAD	cis	rs12681366	0.881	rs3019145	ENSG00000254057.1	RP3-388N13.3	3.72	0.000225	0.0274	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94401324	chr8:93834454~93846743:-
LUAD	cis	rs1853665	1	rs9383993	ENSG00000231760.4	RP11-350J20.5	-3.72	0.000225	0.0274	-0.26	-0.17	Radiation response;	chr6:149978163	chr6:149796151~149826294:-
LUAD	cis	rs8012947	1	rs6573197	ENSG00000279636.2	LINC00216	-3.72	0.000225	0.0274	-0.19	-0.17	Alcohol consumption in current drinkers;	chr14:58257490	chr14:58288033~58289158:+
LUAD	cis	rs797680	0.822	rs2297707	ENSG00000223745.6	RP4-717I23.3	3.72	0.000225	0.0274	0.13	0.17	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93180650	chr1:93262186~93346025:-
LUAD	cis	rs67478160	0.643	rs6575997	ENSG00000272533.1	SNORA28	-3.72	0.000225	0.0274	-0.17	-0.17	Schizophrenia;	chr14:103762209	chr14:103337849~103337974:+
LUAD	cis	rs334353	0.837	rs334358	ENSG00000255145.2	STX17-AS1	-3.72	0.000225	0.0274	-0.22	-0.17	Age-related macular degeneration;	chr9:99148331	chr9:99886322~99906601:-
LUAD	cis	rs2279168	1	rs28397760	ENSG00000202081.1	RNU6-1280P	-3.72	0.000225	0.0274	-0.27	-0.17	Response to platinum-based chemotherapy (carboplatin);	chr15:85534321	chr15:85651522~85651628:-
LUAD	cis	rs240993	0.516	rs1002481	ENSG00000230177.1	RP5-1112D6.4	-3.72	0.000225	0.0274	-0.2	-0.17	Inflammatory skin disease;Psoriasis;	chr6:111390819	chr6:111277932~111278742:+
LUAD	cis	rs12122100	0.955	rs12142005	ENSG00000227242.3	NBPF13P	-3.72	0.000225	0.0274	-0.22	-0.17	HIV-1 control;	chr1:147035137	chr1:147021320~147124525:-
LUAD	cis	rs321358	1	rs321361	ENSG00000271390.1	RP11-89C3.3	3.72	0.000225	0.0274	0.28	0.17	Body mass index;	chr11:111125495	chr11:111089870~111090368:-
LUAD	cis	rs321358	1	rs321362	ENSG00000271390.1	RP11-89C3.3	3.72	0.000225	0.0274	0.28	0.17	Body mass index;	chr11:111125754	chr11:111089870~111090368:-
LUAD	cis	rs321358	1	rs321363	ENSG00000271390.1	RP11-89C3.3	3.72	0.000225	0.0274	0.28	0.17	Body mass index;	chr11:111125929	chr11:111089870~111090368:-
LUAD	cis	rs1355223	0.867	rs7925421	ENSG00000271369.1	RP11-350D17.3	-3.72	0.000225	0.0274	-0.2	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34660130	chr11:34709600~34710161:+
LUAD	cis	rs11779988	0.545	rs398806	ENSG00000253671.1	RP11-806O11.1	-3.72	0.000225	0.0274	-0.21	-0.17	Breast cancer;	chr8:17928717	chr8:17808941~17820868:+
LUAD	cis	rs11048434	0.518	rs2377679	ENSG00000256937.1	KRT17P8	-3.72	0.000225	0.0274	-0.19	-0.17	Sjögren's syndrome;	chr12:9023874	chr12:9127783~9128645:+
LUAD	cis	rs11018904	0.906	rs10501713	ENSG00000280367.1	RP11-121L10.2	3.72	0.000225	0.0274	0.21	0.17	Intelligence (multi-trait analysis);	chr11:90219845	chr11:90223153~90226538:+
LUAD	cis	rs7512552	0.839	rs2867894	ENSG00000275557.1	RP11-353N4.6	3.72	0.000225	0.0274	0.19	0.17	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150480436	chr1:149607765~149612402:+
LUAD	cis	rs9473147	0.843	rs12202615	ENSG00000270761.1	RP11-385F7.1	-3.72	0.000226	0.0274	-0.19	-0.17	Platelet distribution width;Mean platelet volume;	chr6:47650435	chr6:47477243~47477572:-
LUAD	cis	rs5742933	0.696	rs6748102	ENSG00000253559.1	OSGEPL1-AS1	-3.72	0.000226	0.0274	-0.28	-0.17	Ferritin levels;	chr2:189760786	chr2:189762704~189765556:+
LUAD	cis	rs6832769	0.961	rs2412647	ENSG00000272969.1	RP11-528I4.2	3.72	0.000226	0.0274	0.17	0.17	Personality dimensions;	chr4:55452938	chr4:55547112~55547889:+
LUAD	cis	rs4132509	0.603	rs12408951	ENSG00000236031.1	RP11-269F20.1	3.72	0.000226	0.0274	0.26	0.17	RR interval (heart rate);	chr1:243516062	chr1:243545532~243548329:+
LUAD	cis	rs987044	0.726	rs7300726	ENSG00000257221.1	RP11-689B22.2	-3.72	0.000226	0.0274	-0.14	-0.17	Mean platelet volume;	chr12:108660086	chr12:108628687~108641318:+
LUAD	cis	rs10129255	0.557	rs4043727	ENSG00000211955.2	IGHV3-33	-3.72	0.000226	0.0274	-0.13	-0.17	Kawasaki disease;	chr14:106649820	chr14:106359793~106360324:-
LUAD	cis	rs12822507	0.868	rs12580006	ENSG00000275963.1	RP11-180M15.6	-3.72	0.000226	0.0274	-0.19	-0.17	Systemic lupus erythematosus;	chr12:12636712	chr12:12648939~12649713:+
LUAD	cis	rs10463554	0.963	rs257318	ENSG00000250682.4	LINC00491	3.72	0.000226	0.0274	0.2	0.17	Parkinson's disease;	chr5:103109766	chr5:102609156~102671559:-
LUAD	cis	rs3764400	0.508	rs55696440	ENSG00000278765.1	RP5-890E16.5	3.72	0.000226	0.0274	0.31	0.17	Body mass index;	chr17:48193784	chr17:48066704~48067293:-
LUAD	cis	rs9322193	0.566	rs12528243	ENSG00000268592.3	RAET1E-AS1	3.72	0.000226	0.0274	0.25	0.17	Lung cancer;	chr6:149898491	chr6:149863494~149919507:+
LUAD	cis	rs12440869	1	rs8991	ENSG00000270964.1	RP11-502I4.3	3.72	0.000226	0.0274	0.19	0.17	Peak velocity of the mitral A-wave;	chr15:67201966	chr15:67541072~67542604:-
LUAD	cis	rs8046148	0.756	rs8047742	ENSG00000279356.1	RP11-429P3.8	3.72	0.000226	0.0274	0.17	0.17	Testicular germ cell tumor;	chr16:50083405	chr16:50072862~50074986:+
LUAD	cis	rs8046148	0.724	rs2080504	ENSG00000279356.1	RP11-429P3.8	3.72	0.000226	0.0274	0.17	0.17	Testicular germ cell tumor;	chr16:50085259	chr16:50072862~50074986:+
LUAD	cis	rs8046148	0.666	rs2287196	ENSG00000279356.1	RP11-429P3.8	3.72	0.000226	0.0274	0.17	0.17	Testicular germ cell tumor;	chr16:50086211	chr16:50072862~50074986:+
LUAD	cis	rs8046148	0.789	rs2005402	ENSG00000279356.1	RP11-429P3.8	3.72	0.000226	0.0274	0.17	0.17	Testicular germ cell tumor;	chr16:50086757	chr16:50072862~50074986:+
LUAD	cis	rs8046148	0.724	rs2356835	ENSG00000279356.1	RP11-429P3.8	3.72	0.000226	0.0274	0.17	0.17	Testicular germ cell tumor;	chr16:50086956	chr16:50072862~50074986:+
LUAD	cis	rs10852606	0.685	rs2356838	ENSG00000279356.1	RP11-429P3.8	3.72	0.000226	0.0274	0.17	0.17	Glioma;Glioblastoma;	chr16:50087072	chr16:50072862~50074986:+
LUAD	cis	rs8046148	0.724	rs8057524	ENSG00000279356.1	RP11-429P3.8	3.72	0.000226	0.0274	0.17	0.17	Testicular germ cell tumor;	chr16:50089035	chr16:50072862~50074986:+
LUAD	cis	rs728616	0.867	rs41298231	ENSG00000234382.2	RP11-40F6.1	-3.72	0.000226	0.0274	-0.41	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79922705	chr10:80233664~80245367:+
LUAD	cis	rs8056893	0.775	rs6499172	ENSG00000260441.4	RP11-96D1.7	-3.72	0.000226	0.0274	-0.2	-0.17	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68342667	chr16:68256162~68260443:-
LUAD	cis	rs4423214	0.879	rs1630498	ENSG00000226627.1	SHANK2-AS1	3.72	0.000226	0.0274	0.2	0.17	Vitamin D levels;	chr11:71439739	chr11:70631094~70635490:+
LUAD	cis	rs7077256	0.504	rs35693916	ENSG00000272767.1	JMJD1C-AS1	3.72	0.000226	0.0274	0.25	0.17	Intelligence (multi-trait analysis);	chr10:63374522	chr10:63465229~63466563:+
LUAD	cis	rs7178424	1	rs17271431	ENSG00000259251.2	RP11-643M14.1	-3.72	0.000226	0.0274	-0.17	-0.17	Height;	chr15:62088817	chr15:62060503~62062434:+
LUAD	cis	rs73242632	0.5	rs1718883	ENSG00000269949.1	RP11-738E22.3	-3.72	0.000226	0.0274	-0.32	-0.17	Congenital heart disease (maternal effect);	chr4:57055895	chr4:56960927~56961373:-
LUAD	cis	rs832187	0.629	rs59971314	ENSG00000280620.1	SCAANT1	3.72	0.000226	0.0274	0.19	0.17	Schizophrenia;	chr3:63928942	chr3:63911518~63911772:-
LUAD	cis	rs875971	1	rs7781698	ENSG00000273142.1	RP11-458F8.4	-3.72	0.000226	0.0274	-0.12	-0.17	Aortic root size;	chr7:66431325	chr7:66902857~66906297:+
LUAD	cis	rs448720	0.811	rs1996120	ENSG00000259673.4	IQCH-AS1	3.72	0.000226	0.0274	0.18	0.17	Cognitive performance;	chr15:67889196	chr15:67403619~67521844:-
LUAD	cis	rs4907240	0.961	rs4907241	ENSG00000237510.6	AC008268.2	3.72	0.000226	0.0274	0.24	0.17	Event-related brain oscillations;	chr2:96576191	chr2:95789654~95800166:+
LUAD	cis	rs324126	0.78	rs10445586	ENSG00000277977.1	CTD-3018O17.5	3.72	0.000226	0.0274	0.17	0.17	Colonoscopy-negative controls vs population controls;	chr19:52379870	chr19:52392659~52392755:+
LUAD	cis	rs324126	0.78	rs62108317	ENSG00000277977.1	CTD-3018O17.5	3.72	0.000226	0.0274	0.17	0.17	Colonoscopy-negative controls vs population controls;	chr19:52380230	chr19:52392659~52392755:+
LUAD	cis	rs62246343	0.605	rs7650141	ENSG00000254485.4	RP11-380O24.1	3.72	0.000226	0.0274	0.22	0.17	Fibrinogen levels;	chr3:9407726	chr3:9292588~9363303:-
LUAD	cis	rs913672	0.609	rs8116154	ENSG00000229222.1	KRT18P4	-3.72	0.000226	0.0274	-0.21	-0.17	Monocyte count;	chr20:50276198	chr20:49956745~49958032:+
LUAD	cis	rs10129255	0.5	rs10142931	ENSG00000253209.1	IGHV3-65	3.72	0.000226	0.0274	0.13	0.17	Kawasaki disease;	chr14:106782288	chr14:106666092~106666532:-
LUAD	cis	rs78487399	0.808	rs77972916	ENSG00000234936.1	AC010883.5	3.72	0.000226	0.0274	0.28	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43534973	chr2:43229573~43233394:+
LUAD	cis	rs1346081	0.805	rs10035088	ENSG00000250075.4	RP11-584P21.2	-3.72	0.000226	0.0274	-0.18	-0.17	Intelligence (multi-trait analysis);	chr4:67075417	chr4:67417305~67468251:-
LUAD	cis	rs1346081	0.805	rs9990621	ENSG00000250075.4	RP11-584P21.2	-3.72	0.000226	0.0274	-0.18	-0.17	Intelligence (multi-trait analysis);	chr4:67075652	chr4:67417305~67468251:-
LUAD	cis	rs7215564	0.908	rs35542453	ENSG00000232083.3	RPL31P7	3.72	0.000226	0.0274	0.28	0.17	Myopia (pathological);	chr17:80713442	chr17:80602549~80602926:-
LUAD	cis	rs10129255	0.5	rs8021941	ENSG00000253209.1	IGHV3-65	3.72	0.000226	0.0274	0.13	0.17	Kawasaki disease;	chr14:106781490	chr14:106666092~106666532:-
LUAD	cis	rs9426935	0.505	rs12032914	ENSG00000223599.1	RP11-216N14.7	-3.72	0.000226	0.0275	-0.2	-0.17	Lentiform nucleus volume;	chr1:153914286	chr1:153852106~153853414:-
LUAD	cis	rs1850744	0.536	rs6843869	ENSG00000249767.1	ENPP7P10	-3.72	0.000226	0.0275	-0.42	-0.17	Economic and political preferences;	chr4:9632827	chr4:9079023~9141608:+
LUAD	cis	rs12908161	0.853	rs11633788	ENSG00000230373.7	GOLGA6L5P	-3.72	0.000226	0.0275	-0.17	-0.17	Schizophrenia;	chr15:84761911	chr15:84507885~84516814:-
LUAD	cis	rs10971721	0.631	rs10971945	ENSG00000260947.1	RP11-384P7.7	3.72	0.000226	0.0275	0.33	0.17	Body mass index;	chr9:34129397	chr9:33697459~33700986:+
LUAD	cis	rs4795519	1	rs9303617	ENSG00000266313.1	RP11-173M1.4	3.72	0.000226	0.0275	0.21	0.17	Chronic myeloid leukemia;	chr17:27109646	chr17:27333256~27348491:+
LUAD	cis	rs6496932	0.663	rs12915663	ENSG00000202081.1	RNU6-1280P	-3.72	0.000226	0.0275	-0.21	-0.17	Central corneal thickness;Corneal structure;	chr15:85362249	chr15:85651522~85651628:-
LUAD	cis	rs13113518	0.966	rs12501327	ENSG00000273257.1	RP11-177J6.1	3.72	0.000226	0.0275	0.18	0.17	Height;	chr4:55507248	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs11133392	ENSG00000273257.1	RP11-177J6.1	3.72	0.000226	0.0275	0.18	0.17	Height;	chr4:55507729	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs6838305	ENSG00000273257.1	RP11-177J6.1	3.72	0.000226	0.0275	0.18	0.17	Height;	chr4:55508587	chr4:55387949~55388271:+
LUAD	cis	rs13113518	0.902	rs12503578	ENSG00000273257.1	RP11-177J6.1	3.72	0.000226	0.0275	0.18	0.17	Height;	chr4:55509367	chr4:55387949~55388271:+
LUAD	cis	rs13113518	0.966	rs3828480	ENSG00000273257.1	RP11-177J6.1	3.72	0.000226	0.0275	0.18	0.17	Height;	chr4:55510352	chr4:55387949~55388271:+
LUAD	cis	rs2115630	0.936	rs6496318	ENSG00000259728.4	LINC00933	-3.72	0.000226	0.0275	-0.2	-0.17	P wave terminal force;	chr15:84671998	chr15:84570649~84580175:+
LUAD	cis	rs2115630	0.902	rs8023276	ENSG00000259728.4	LINC00933	-3.72	0.000226	0.0275	-0.2	-0.17	P wave terminal force;	chr15:84676407	chr15:84570649~84580175:+
LUAD	cis	rs7727544	0.582	rs3749756	ENSG00000233006.5	AC034220.3	3.72	0.000226	0.0275	0.15	0.17	Blood metabolite levels;	chr5:132198806	chr5:132311285~132369916:-
LUAD	cis	rs7100689	0.516	rs10887711	ENSG00000226659.1	RP11-137H2.4	-3.72	0.000226	0.0275	-0.22	-0.17	Post bronchodilator FEV1;	chr10:80275086	chr10:80529597~80535942:-
LUAD	cis	rs7100689	0.516	rs10788546	ENSG00000226659.1	RP11-137H2.4	-3.72	0.000226	0.0275	-0.22	-0.17	Post bronchodilator FEV1;	chr10:80275098	chr10:80529597~80535942:-
LUAD	cis	rs4639966	0.836	rs4499035	ENSG00000255422.1	AP002954.4	3.72	0.000226	0.0275	0.23	0.17	Systemic lupus erythematosus;	chr11:118739754	chr11:118704607~118750263:+
LUAD	cis	rs4639966	0.836	rs1893029	ENSG00000255422.1	AP002954.4	3.72	0.000226	0.0275	0.23	0.17	Systemic lupus erythematosus;	chr11:118740117	chr11:118704607~118750263:+
LUAD	cis	rs13113518	0.966	rs13144598	ENSG00000223305.1	RN7SKP30	3.72	0.000227	0.0275	0.19	0.17	Height;	chr4:55570311	chr4:55540502~55540835:-
LUAD	cis	rs10752881	1	rs10797802	ENSG00000224468.3	RP11-181K3.4	3.72	0.000227	0.0275	0.15	0.17	Colorectal cancer;	chr1:183004023	chr1:183138402~183141282:-
LUAD	cis	rs13006833	0.668	rs291453	ENSG00000227542.1	AC092614.2	-3.72	0.000227	0.0275	-0.2	-0.17	Urinary metabolites;	chr2:190295470	chr2:191229165~191246172:-
LUAD	cis	rs763121	0.853	rs2284073	ENSG00000228274.3	RP3-508I15.9	-3.72	0.000227	0.0275	-0.16	-0.17	Menopause (age at onset);	chr22:38709943	chr22:38667585~38681820:-
LUAD	cis	rs7727544	0.582	rs2278398	ENSG00000233006.5	AC034220.3	-3.72	0.000227	0.0275	-0.15	-0.17	Blood metabolite levels;	chr5:132194748	chr5:132311285~132369916:-
LUAD	cis	rs11951515	0.508	rs11958046	ENSG00000249286.1	CTD-2210P15.2	3.72	0.000227	0.0275	0.2	0.17	Metabolite levels  (X-11787);	chr5:43583287	chr5:43586918~43588223:-
LUAD	cis	rs7246657	0.943	rs4802766	ENSG00000267470.4	ZNF571-AS1	3.72	0.000227	0.0275	0.24	0.17	Coronary artery calcification;	chr19:37491031	chr19:37548914~37587348:+
LUAD	cis	rs3020736	0.5	rs8138678	ENSG00000273366.1	CTA-989H11.1	3.72	0.000227	0.0275	0.2	0.17	Autism spectrum disorder or schizophrenia;	chr22:42120225	chr22:42278188~42278846:+
LUAD	cis	rs11112613	0.609	rs11112585	ENSG00000258355.1	RP11-651L5.2	3.72	0.000227	0.0275	0.27	0.17	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;	chr12:105539664	chr12:106245613~106246956:-
LUAD	cis	rs8092503	1	rs12456731	ENSG00000267325.1	LINC01415	-3.72	0.000227	0.0275	-0.22	-0.17	Childhood body mass index;	chr18:54833061	chr18:55776727~55781721:-
LUAD	cis	rs13113518	0.756	rs12510275	ENSG00000273257.1	RP11-177J6.1	3.72	0.000227	0.0275	0.19	0.17	Height;	chr4:55516548	chr4:55387949~55388271:+
LUAD	cis	rs13113518	0.812	rs12510327	ENSG00000273257.1	RP11-177J6.1	3.72	0.000227	0.0275	0.19	0.17	Height;	chr4:55516744	chr4:55387949~55388271:+
LUAD	cis	rs6496044	0.568	rs11636764	ENSG00000259407.1	RP11-158M2.3	-3.72	0.000227	0.0275	-0.15	-0.17	Interstitial lung disease;	chr15:85536520	chr15:85744109~85750281:-
LUAD	cis	rs2024714	0.902	rs6089449	ENSG00000273812.1	WI2-87327B8.2	-3.72	0.000227	0.0275	-0.18	-0.17	Longevity;	chr20:61641004	chr20:62596732~62603115:-
LUAD	cis	rs2024714	0.902	rs6061690	ENSG00000273812.1	WI2-87327B8.2	-3.72	0.000227	0.0275	-0.18	-0.17	Longevity;	chr20:61641011	chr20:62596732~62603115:-
LUAD	cis	rs864537	0.676	rs1773560	ENSG00000233411.1	RP11-104L21.2	3.72	0.000227	0.0275	0.21	0.17	Celiac disease or Rheumatoid arthritis;Celiac disease;	chr1:167452526	chr1:167457383~167458661:-
LUAD	cis	rs6674176	0.628	rs12145999	ENSG00000237950.1	RP11-7O11.3	3.72	0.000227	0.0275	0.21	0.17	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43962960	chr1:43944370~43946551:-
LUAD	cis	rs590820	0.684	rs10864728	ENSG00000227934.1	RP11-423F24.3	-3.72	0.000227	0.0275	-0.19	-0.17	Metabolite levels (lipoprotein measures);	chr1:230169168	chr1:231021611~231022183:+
LUAD	cis	rs6832769	0.643	rs10003211	ENSG00000272969.1	RP11-528I4.2	-3.72	0.000227	0.0275	-0.18	-0.17	Personality dimensions;	chr4:55651165	chr4:55547112~55547889:+
LUAD	cis	rs7605235	0.959	rs34104763	ENSG00000224165.4	DNAJC27-AS1	3.72	0.000227	0.0275	0.19	0.17	Response to platinum-based chemotherapy (cisplatin);	chr2:25421330	chr2:24971390~25039694:+
LUAD	cis	rs10466239	0.892	rs4648316	ENSG00000230555.2	RP11-517P14.2	3.72	0.000227	0.0275	0.32	0.17	Telomere length;	chr10:43364487	chr10:43420738~43422100:+
LUAD	cis	rs10466239	0.892	rs10899791	ENSG00000230555.2	RP11-517P14.2	3.72	0.000227	0.0275	0.32	0.17	Telomere length;	chr10:43364606	chr10:43420738~43422100:+
LUAD	cis	rs10466239	0.803	rs10899793	ENSG00000230555.2	RP11-517P14.2	3.72	0.000227	0.0275	0.32	0.17	Telomere length;	chr10:43364754	chr10:43420738~43422100:+
LUAD	cis	rs10463554	0.927	rs34821	ENSG00000250682.4	LINC00491	3.72	0.000227	0.0275	0.2	0.17	Parkinson's disease;	chr5:103101913	chr5:102609156~102671559:-
LUAD	cis	rs9341808	0.667	rs2490241	ENSG00000260645.1	RP11-250B2.5	3.72	0.000227	0.0275	0.16	0.17	Sitting height ratio;	chr6:80136625	chr6:80466958~80469080:+
LUAD	cis	rs10392	0.543	rs62204117	ENSG00000274825.1	RP4-616B8.5	-3.72	0.000227	0.0275	-0.21	-0.17	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;	chr20:38936692	chr20:38955910~38956547:+
LUAD	cis	rs13113518	0.812	rs13107810	ENSG00000249700.7	SRD5A3-AS1	3.72	0.000227	0.0275	0.17	0.17	Height;	chr4:55542243	chr4:55363971~55395847:-
LUAD	cis	rs11174650	0.71	rs11615499	ENSG00000249753.2	RP11-415I12.3	3.72	0.000227	0.0275	0.36	0.17	Sense of smell;	chr12:62806341	chr12:63623788~63795718:-
LUAD	cis	rs17507216	0.667	rs72753916	ENSG00000255769.6	GOLGA2P10	-3.72	0.000227	0.0275	-0.2	-0.17	Excessive daytime sleepiness;	chr15:82684001	chr15:82472993~82513950:-
LUAD	cis	rs6661961	0.714	rs12125681	ENSG00000237975.5	FLG-AS1	-3.72	0.000227	0.0275	-0.23	-0.17	Atopic dermatitis;	chr1:152445737	chr1:152168125~152445456:+
LUAD	cis	rs806321	0.531	rs2066625	ENSG00000237152.3	DLEU7-AS1	-3.72	0.000227	0.0275	-0.21	-0.17	Multiple sclerosis;	chr13:50180064	chr13:50807856~50849905:+
LUAD	cis	rs4639966	0.836	rs7943039	ENSG00000255422.1	AP002954.4	3.72	0.000227	0.0275	0.23	0.17	Systemic lupus erythematosus;	chr11:118732321	chr11:118704607~118750263:+
LUAD	cis	rs7646881	0.544	rs59973861	ENSG00000240207.5	RP11-379F4.4	-3.72	0.000227	0.0275	-0.22	-0.17	Tetralogy of Fallot;	chr3:158570314	chr3:158732263~158784070:+
LUAD	cis	rs7870753	0.578	rs7044391	ENSG00000188801.9	ZNF322P1	3.72	0.000227	0.0275	0.26	0.17	Height;	chr9:96397509	chr9:97198303~97199511:-
LUAD	cis	rs4474465	0.562	rs10793318	ENSG00000251323.2	RP11-452H21.4	-3.72	0.000227	0.0275	-0.21	-0.17	Alzheimer's disease (survival time);	chr11:78504852	chr11:78423982~78429836:-
LUAD	cis	rs8056893	0.714	rs6499173	ENSG00000260441.4	RP11-96D1.7	-3.72	0.000227	0.0275	-0.19	-0.17	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68354212	chr16:68256162~68260443:-
LUAD	cis	rs6687758	0.735	rs12032653	ENSG00000238042.4	RP11-815M8.1	3.72	0.000227	0.0275	0.22	0.17	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221975457	chr1:221880981~221978523:-
LUAD	cis	rs6687758	0.679	rs12029332	ENSG00000238042.4	RP11-815M8.1	3.72	0.000227	0.0275	0.22	0.17	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221975480	chr1:221880981~221978523:-
LUAD	cis	rs13113518	0.966	rs7668429	ENSG00000273257.1	RP11-177J6.1	3.71	0.000227	0.0275	0.18	0.17	Height;	chr4:55531811	chr4:55387949~55388271:+
LUAD	cis	rs2638953	0.821	rs7964793	ENSG00000278733.1	RP11-425D17.1	3.71	0.000227	0.0276	0.2	0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28298776	chr12:28185625~28186190:-
LUAD	cis	rs10840133	1	rs10840133	ENSG00000254860.4	TMEM9B-AS1	-3.71	0.000227	0.0276	-0.19	-0.17	Reticulocyte fraction of red cells;	chr11:8824822	chr11:8964675~8977527:+
LUAD	cis	rs38055	0.793	rs37776	ENSG00000247796.2	CTD-2366F13.1	-3.71	0.000227	0.0276	-0.19	-0.17	Acne (severe);	chr5:53332300	chr5:53109842~53115126:+
LUAD	cis	rs763121	0.962	rs6001193	ENSG00000273076.1	RP3-508I15.22	3.71	0.000227	0.0276	0.16	0.17	Menopause (age at onset);	chr22:38678732	chr22:38743495~38743910:+
LUAD	cis	rs2098713	0.569	rs7715951	ENSG00000250155.1	CTD-2353F22.1	3.71	0.000227	0.0276	0.18	0.17	Telomere length;	chr5:37492108	chr5:36666214~36725195:-
LUAD	cis	rs6496044	0.568	rs11855789	ENSG00000259416.2	RP11-158M2.5	3.71	0.000227	0.0276	0.17	0.17	Interstitial lung disease;	chr15:85523172	chr15:85754941~85756237:-
LUAD	cis	rs12817211	0.536	rs9364	ENSG00000272368.2	RP4-605O3.4	3.71	0.000227	0.0276	0.2	0.17	Colorectal or endometrial cancer;	chr12:50176736	chr12:50112197~50165618:+
LUAD	cis	rs6460942	0.841	rs17443848	ENSG00000226690.5	AC005281.1	3.71	0.000227	0.0276	0.27	0.17	Coronary artery disease;	chr7:12404062	chr7:12496429~12541910:+
LUAD	cis	rs590820	0.684	rs11122455	ENSG00000227934.1	RP11-423F24.3	-3.71	0.000227	0.0276	-0.19	-0.17	Metabolite levels (lipoprotein measures);	chr1:230169184	chr1:231021611~231022183:+
LUAD	cis	rs763121	0.853	rs4820345	ENSG00000225450.1	RP3-508I15.14	-3.71	0.000227	0.0276	-0.17	-0.17	Menopause (age at onset);	chr22:38695146	chr22:38739003~38749041:+
LUAD	cis	rs7134599	0.965	rs7302327	ENSG00000240087.3	RP11-254B13.1	3.71	0.000227	0.0276	0.14	0.17	Inflammatory bowel disease;Ulcerative colitis;	chr12:68109372	chr12:68552995~68553882:-
LUAD	cis	rs6479891	1	rs9415692	ENSG00000232075.1	MRPL35P2	3.71	0.000227	0.0276	0.27	0.17	Arthritis (juvenile idiopathic);	chr10:63355392	chr10:63634317~63634827:-
LUAD	cis	rs6088580	0.634	rs1205344	ENSG00000276073.1	RP5-1125A11.7	3.71	0.000227	0.0276	0.16	0.17	Glomerular filtration rate (creatinine);	chr20:34330492	chr20:33985617~33988989:-
LUAD	cis	rs9341808	0.644	rs62408577	ENSG00000272129.1	RP11-250B2.6	-3.71	0.000227	0.0276	-0.2	-0.17	Sitting height ratio;	chr6:80232307	chr6:80355424~80356859:+
LUAD	cis	rs9341808	0.644	rs76102095	ENSG00000272129.1	RP11-250B2.6	-3.71	0.000227	0.0276	-0.2	-0.17	Sitting height ratio;	chr6:80232309	chr6:80355424~80356859:+
LUAD	cis	rs9341808	0.644	rs59371711	ENSG00000272129.1	RP11-250B2.6	-3.71	0.000227	0.0276	-0.2	-0.17	Sitting height ratio;	chr6:80232310	chr6:80355424~80356859:+
LUAD	cis	rs16944613	0.541	rs7183319	ENSG00000259212.1	CTD-3065B20.2	3.71	0.000227	0.0276	0.27	0.17	Colorectal cancer;	chr15:90551800	chr15:90595840~90596447:-
LUAD	cis	rs950173	1	rs950173	ENSG00000228389.1	AC068039.4	3.71	0.000227	0.0276	0.31	0.17	Hippocampal volume;	chr2:171713909	chr2:171773482~171775844:+
LUAD	cis	rs7119038	0.731	rs28409215	ENSG00000255239.1	AP002954.6	-3.71	0.000228	0.0276	-0.25	-0.17	Sjögren's syndrome;	chr11:118808595	chr11:118688039~118690600:-
LUAD	cis	rs2702164	0.849	rs1259327	ENSG00000240661.1	RP11-174O3.3	-3.71	0.000228	0.0276	-0.21	-0.17	Gut microbiome composition (winter);	chr3:120398075	chr3:120349510~120367998:+
LUAD	cis	rs3020736	0.5	rs6002604	ENSG00000273366.1	CTA-989H11.1	3.71	0.000228	0.0276	0.2	0.17	Autism spectrum disorder or schizophrenia;	chr22:42097077	chr22:42278188~42278846:+
LUAD	cis	rs3020736	0.5	rs5996109	ENSG00000273366.1	CTA-989H11.1	3.71	0.000228	0.0276	0.2	0.17	Autism spectrum disorder or schizophrenia;	chr22:42097094	chr22:42278188~42278846:+
LUAD	cis	rs3020736	0.5	rs5996110	ENSG00000273366.1	CTA-989H11.1	3.71	0.000228	0.0276	0.2	0.17	Autism spectrum disorder or schizophrenia;	chr22:42097763	chr22:42278188~42278846:+
LUAD	cis	rs3020736	0.5	rs9620026	ENSG00000273366.1	CTA-989H11.1	3.71	0.000228	0.0276	0.2	0.17	Autism spectrum disorder or schizophrenia;	chr22:42102574	chr22:42278188~42278846:+
LUAD	cis	rs3020736	0.5	rs28791586	ENSG00000273366.1	CTA-989H11.1	3.71	0.000228	0.0276	0.2	0.17	Autism spectrum disorder or schizophrenia;	chr22:42104479	chr22:42278188~42278846:+
LUAD	cis	rs3020736	0.5	rs2839708	ENSG00000273366.1	CTA-989H11.1	3.71	0.000228	0.0276	0.2	0.17	Autism spectrum disorder or schizophrenia;	chr22:42104741	chr22:42278188~42278846:+
LUAD	cis	rs3020736	0.5	rs6519306	ENSG00000273366.1	CTA-989H11.1	3.71	0.000228	0.0276	0.2	0.17	Autism spectrum disorder or schizophrenia;	chr22:42105213	chr22:42278188~42278846:+
LUAD	cis	rs6743068	0.521	rs6710974	ENSG00000234842.1	AC007163.8	-3.71	0.000228	0.0276	-0.19	-0.17	Lymphocyte percentage of white cells;	chr2:201348659	chr2:201549631~201550307:+
LUAD	cis	rs36093844	0.527	rs17817690	ENSG00000279742.1	RP11-700A24.1	-3.71	0.000228	0.0276	-0.2	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85981018	chr11:85852557~85854943:-
LUAD	cis	rs7584330	0.744	rs10929234	ENSG00000222032.1	AC112721.2	-3.71	0.000228	0.0276	-0.21	-0.17	Prostate cancer;	chr2:237471391	chr2:237428920~237434822:-
LUAD	cis	rs911555	0.546	rs28798508	ENSG00000269940.1	RP11-73M18.7	3.71	0.000228	0.0276	0.17	0.17	Intelligence (multi-trait analysis);	chr14:103602633	chr14:103694560~103695170:+
LUAD	cis	rs9309473	0.519	rs1815027	ENSG00000163016.8	ALMS1P	-3.71	0.000228	0.0276	-0.18	-0.17	Metabolite levels;	chr2:73604713	chr2:73644919~73685576:+
LUAD	cis	rs6942407	0.592	rs1859125	ENSG00000224046.1	AC005076.5	-3.71	0.000228	0.0276	-0.21	-0.17	Food allergy;	chr7:87122758	chr7:87151423~87152420:-
LUAD	cis	rs1476587	0.527	rs1859126	ENSG00000224046.1	AC005076.5	-3.71	0.000228	0.0276	-0.21	-0.17	Brachial circumference;	chr7:87122818	chr7:87151423~87152420:-
LUAD	cis	rs6942407	0.592	rs1859128	ENSG00000224046.1	AC005076.5	-3.71	0.000228	0.0276	-0.21	-0.17	Food allergy;	chr7:87122855	chr7:87151423~87152420:-
LUAD	cis	rs7086627	0.507	rs7077907	ENSG00000226659.1	RP11-137H2.4	-3.71	0.000228	0.0276	-0.21	-0.17	Post bronchodilator FEV1;	chr10:80257326	chr10:80529597~80535942:-
LUAD	cis	rs62012628	0.527	rs12438008	ENSG00000261143.1	ADAMTS7P3	-3.71	0.000228	0.0276	-0.18	-0.17	Diastolic blood pressure;	chr15:78792338	chr15:77976042~77993057:+
LUAD	cis	rs7017914	0.967	rs1493198	ENSG00000246366.5	RP11-382J12.1	3.71	0.000228	0.0276	0.15	0.17	Bone mineral density;	chr8:70939722	chr8:70608577~70663279:+
LUAD	cis	rs7061710	0.871	rs17565766	ENSG00000271811.1	RP1-79C4.4	3.71	0.000228	0.0276	0.23	0.17	Blood metabolite levels;	chr1:171146991	chr1:170667381~170669425:+
LUAD	cis	rs7178424	1	rs7178540	ENSG00000259251.2	RP11-643M14.1	3.71	0.000228	0.0276	0.17	0.17	Height;	chr15:62087933	chr15:62060503~62062434:+
LUAD	cis	rs1529102	0.899	rs1358624	ENSG00000225889.6	AC074289.1	3.71	0.000228	0.0276	0.17	0.17	Breast size;	chr2:64259365	chr2:64143239~64252859:+
LUAD	cis	rs6547741	1	rs10165098	ENSG00000223522.1	AC093690.1	3.71	0.000228	0.0276	0.16	0.17	Oral cavity cancer;	chr2:27573659	chr2:28307691~28310459:-
LUAD	cis	rs877819	0.552	rs2943255	ENSG00000228403.1	RP11-563N6.6	3.71	0.000228	0.0276	0.17	0.17	Systemic lupus erythematosus;	chr10:48884349	chr10:48878022~48878649:+
LUAD	cis	rs877819	0.552	rs2671710	ENSG00000228403.1	RP11-563N6.6	3.71	0.000228	0.0276	0.17	0.17	Systemic lupus erythematosus;	chr10:48886672	chr10:48878022~48878649:+
LUAD	cis	rs7005380	0.581	rs4871793	ENSG00000279347.1	RP11-85I17.2	-3.71	0.000228	0.0276	-0.16	-0.17	Interstitial lung disease;	chr8:119929288	chr8:119838736~119840385:-
LUAD	cis	rs2227564	1	rs2227564	ENSG00000271816.1	BMS1P4	-3.71	0.000228	0.0276	-0.16	-0.17	Crohn's disease;Inflammatory bowel disease;	chr10:73913343	chr10:73699151~73730487:-
LUAD	cis	rs3743162	1	rs3743161	ENSG00000225151.9	GOLGA2P7	-3.71	0.000228	0.0276	-0.26	-0.17	Alzheimer's disease (age of onset);	chr15:84887607	chr15:84199311~84230136:-
LUAD	cis	rs7429990	0.932	rs9862913	ENSG00000228638.1	FCF1P2	-3.71	0.000228	0.0276	-0.19	-0.17	Educational attainment (years of education);	chr3:47974682	chr3:48290793~48291375:-
LUAD	cis	rs1055129	0.655	rs7223416	ENSG00000267801.1	RP11-552F3.9	3.71	0.000228	0.0276	0.17	0.17	White matter hyperintensity burden;	chr17:75840081	chr17:75876372~75879546:+
LUAD	cis	rs9366999	0.809	rs1744403	ENSG00000235033.6	RP11-61I13.3	3.71	0.000228	0.0276	0.18	0.17	Obesity-related traits;	chr6:39250875	chr6:39881804~39900071:-
LUAD	cis	rs7940866	0.845	rs1433976	ENSG00000255262.3	TCEB2P2	-3.71	0.000228	0.0276	-0.19	-0.17	Schizophrenia;	chr11:131005228	chr11:130032866~130033220:-
LUAD	cis	rs12188164	0.62	rs56070387	ENSG00000188242.4	PP7080	3.71	0.000228	0.0276	0.22	0.17	Cystic fibrosis severity;	chr5:482416	chr5:466124~473098:-
LUAD	cis	rs2179367	0.959	rs585022	ENSG00000216906.2	RP11-350J20.9	3.71	0.000228	0.0276	0.21	0.17	Dupuytren's disease;	chr6:149432168	chr6:149904243~149906418:+
LUAD	cis	rs17695224	0.606	rs10411054	ENSG00000269483.1	AC006272.1	3.71	0.000228	0.0276	0.18	0.17	HDL cholesterol;HDL cholesterol levels;	chr19:51831208	chr19:51839924~51843324:-
LUAD	cis	rs12613372	0.953	rs10469990	ENSG00000278908.1	RP11-523J2.1	-3.71	0.000228	0.0276	-0.24	-0.17	Type 2 diabetes;	chr2:30863178	chr2:30677762~30679895:+
LUAD	cis	rs2613514	0.881	rs2253277	ENSG00000204282.4	TNRC6C-AS1	-3.71	0.000228	0.0276	-0.31	-0.17	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr17:78112992	chr17:78107398~78111799:-
LUAD	cis	rs4561483	0.583	rs9925010	ENSG00000261216.1	RP11-166B2.5	3.71	0.000228	0.0276	0.17	0.17	Testicular germ cell tumor;	chr16:11862811	chr16:11908208~11908916:+
LUAD	cis	rs4561483	0.545	rs9927446	ENSG00000261216.1	RP11-166B2.5	3.71	0.000228	0.0276	0.17	0.17	Testicular germ cell tumor;	chr16:11863307	chr16:11908208~11908916:+
LUAD	cis	rs6502050	0.765	rs55905076	ENSG00000275966.1	RP11-1055B8.9	-3.71	0.000228	0.0276	-0.17	-0.17	Life satisfaction;	chr17:82147565	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs55679819	ENSG00000275966.1	RP11-1055B8.9	-3.71	0.000228	0.0276	-0.17	-0.17	Life satisfaction;	chr17:82147574	chr17:81345476~81345966:-
LUAD	cis	rs2837828	1	rs2091899	ENSG00000226496.2	LINC00323	3.71	0.000228	0.0276	0.21	0.17	Neutrophil count;	chr21:40802774	chr21:41141493~41148133:-
LUAD	cis	rs2354432	0.556	rs885305	ENSG00000237188.3	RP11-337C18.8	3.71	0.000228	0.0277	0.3	0.17	Mitochondrial DNA levels;	chr1:147314360	chr1:147172771~147211568:+
LUAD	cis	rs2348418	0.864	rs7957495	ENSG00000247934.4	RP11-967K21.1	-3.71	0.000228	0.0277	-0.19	-0.17	Lung function (FEV1);Lung function (FVC);	chr12:28564522	chr12:28163298~28190738:-
LUAD	cis	rs1423688	0.857	rs1239339	ENSG00000249740.1	OSMR-AS1	3.71	0.000228	0.0277	0.21	0.17	Antipsychotic drug-induced QTc interval change in schizophrenia;	chr5:38905883	chr5:38736055~38845829:-
LUAD	cis	rs7976269	0.515	rs9300183	ENSG00000257176.2	RP11-996F15.2	-3.71	0.000228	0.0277	-0.18	-0.17	Male-pattern baldness;	chr12:29002316	chr12:29280418~29317848:-
LUAD	cis	rs4664293	0.836	rs10190704	ENSG00000230783.1	AC009961.2	-3.71	0.000228	0.0277	-0.2	-0.17	Monocyte percentage of white cells;	chr2:159738451	chr2:159689217~159690291:-
LUAD	cis	rs678347	0.63	rs554232	ENSG00000261087.1	KB-1460A1.5	3.71	0.000228	0.0277	0.24	0.17	Rheumatoid arthritis;	chr8:101452356	chr8:101166805~101169629:-
LUAD	cis	rs13113518	0.812	rs13140173	ENSG00000273257.1	RP11-177J6.1	3.71	0.000228	0.0277	0.19	0.17	Height;	chr4:55527164	chr4:55387949~55388271:+
LUAD	cis	rs155076	1	rs195570	ENSG00000224429.6	LINC00539	3.71	0.000228	0.0277	0.2	0.17	White matter hyperintensity burden;	chr13:21293441	chr13:21303515~21348721:-
LUAD	cis	rs2274273	0.837	rs8011329	ENSG00000258413.1	RP11-665C16.6	-3.71	0.000228	0.0277	-0.21	-0.17	Protein biomarker;	chr14:55210537	chr14:55262767~55272075:-
LUAD	cis	rs416603	0.967	rs11640138	ENSG00000262703.1	RP11-485G7.6	3.71	0.000228	0.0277	0.15	0.17	Type 1 diabetes;	chr16:11268872	chr16:11348143~11349321:-
LUAD	cis	rs1549118	0.669	rs11625414	ENSG00000239272.1	RPL21P10	3.71	0.000228	0.0277	0.18	0.17	Resting heart rate;	chr14:77909001	chr14:77683202~77683989:-
LUAD	cis	rs6787172	0.806	rs1435641	ENSG00000272087.1	RP11-379F4.7	3.71	0.000228	0.0277	0.18	0.17	Subjective well-being;	chr3:158558132	chr3:158693120~158693768:-
LUAD	cis	rs8046148	0.666	rs10852606	ENSG00000279356.1	RP11-429P3.8	3.71	0.000228	0.0277	0.17	0.17	Testicular germ cell tumor;	chr16:50094961	chr16:50072862~50074986:+
LUAD	cis	rs12446632	0.771	rs72769575	ENSG00000261195.1	CTD-2380F24.1	-3.71	0.000228	0.0277	-0.26	-0.17	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Menarche (age at onset);Obesity;Childhood body mass index;Waist circumference;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr16:19832195	chr16:19761172~19766099:-
LUAD	cis	rs2657294	0.796	rs4746272	ENSG00000226051.5	ZNF503-AS1	-3.71	0.000228	0.0277	-0.22	-0.17	Pneumonia;	chr10:75203869	chr10:75269819~75373500:+
LUAD	cis	rs8046148	0.789	rs1362634	ENSG00000279356.1	RP11-429P3.8	3.71	0.000228	0.0277	0.17	0.17	Testicular germ cell tumor;	chr16:50114863	chr16:50072862~50074986:+
LUAD	cis	rs6121246	0.909	rs1994251	ENSG00000230613.1	HM13-AS1	3.71	0.000229	0.0277	0.24	0.17	Mean corpuscular hemoglobin;	chr20:31699525	chr20:31567707~31573263:-
LUAD	cis	rs6723226	0.598	rs2710629	ENSG00000276334.1	AL133243.1	3.71	0.000229	0.0277	0.19	0.17	Intelligence (multi-trait analysis);	chr2:32540777	chr2:32521927~32523547:+
LUAD	cis	rs854765	0.547	rs9913277	ENSG00000223979.2	SMCR2	-3.71	0.000229	0.0277	-0.2	-0.17	Total body bone mineral density;	chr17:18016435	chr17:17674026~17677688:-
LUAD	cis	rs647161	0.588	rs6878443	ENSG00000247627.2	MTND4P12	3.71	0.000229	0.0277	0.2	0.17	Colorectal cancer;	chr5:135155753	chr5:134926660~134928036:-
LUAD	cis	rs683250	0.629	rs669290	ENSG00000246067.6	RAB30-AS1	3.71	0.000229	0.0277	0.18	0.17	Subcortical brain region volumes;	chr11:83238015	chr11:83072066~83106719:+
LUAD	cis	rs11089937	0.963	rs2073454	ENSG00000211640.3	IGLV6-57	3.71	0.000229	0.0277	0.11	0.17	Periodontitis (PAL4Q3);	chr22:22163086	chr22:22195713~22196460:+
LUAD	cis	rs2880765	0.566	rs55899824	ENSG00000259407.1	RP11-158M2.3	-3.71	0.000229	0.0277	-0.16	-0.17	Coronary artery disease;	chr15:85460860	chr15:85744109~85750281:-
LUAD	cis	rs2880765	0.631	rs55767890	ENSG00000259407.1	RP11-158M2.3	-3.71	0.000229	0.0277	-0.16	-0.17	Coronary artery disease;	chr15:85460911	chr15:85744109~85750281:-
LUAD	cis	rs8073060	0.963	rs11080353	ENSG00000267592.1	CTC-507E2.2	-3.71	0.000229	0.0277	-0.21	-0.17	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35544262	chr17:35596904~35597128:-
LUAD	cis	rs8014252	0.803	rs73282126	ENSG00000259158.2	ADAM20P1	-3.71	0.000229	0.0277	-0.28	-0.17	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70519324	chr14:70468881~70483756:-
LUAD	cis	rs8014252	0.803	rs74062726	ENSG00000259158.2	ADAM20P1	-3.71	0.000229	0.0277	-0.28	-0.17	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70519462	chr14:70468881~70483756:-
LUAD	cis	rs8014252	0.803	rs73282127	ENSG00000259158.2	ADAM20P1	-3.71	0.000229	0.0277	-0.28	-0.17	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70519696	chr14:70468881~70483756:-
LUAD	cis	rs2380205	0.967	rs7894083	ENSG00000232807.2	RP11-536K7.3	3.71	0.000229	0.0277	0.17	0.17	Breast cancer;	chr10:5851305	chr10:5934270~5945900:-
LUAD	cis	rs2380205	0.967	rs7898042	ENSG00000232807.2	RP11-536K7.3	3.71	0.000229	0.0277	0.17	0.17	Breast cancer;	chr10:5851439	chr10:5934270~5945900:-
LUAD	cis	rs7551222	0.752	rs4951075	ENSG00000240219.1	RP11-430C7.5	3.71	0.000229	0.0277	0.17	0.17	Schizophrenia;	chr1:204495318	chr1:204626775~204629712:+
LUAD	cis	rs9549260	0.592	rs9532588	ENSG00000168852.11	TPTE2P5	3.71	0.000229	0.0277	0.16	0.17	Red blood cell count;	chr13:40728777	chr13:40822296~40921749:-
LUAD	cis	rs2274273	1	rs61508494	ENSG00000259318.1	RP11-454L9.2	3.71	0.000229	0.0277	0.14	0.17	Protein biomarker;	chr14:55120579	chr14:55394940~55395233:-
LUAD	cis	rs7772486	0.875	rs2814877	ENSG00000235652.6	RP11-545I5.3	3.71	0.000229	0.0277	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:145978627	chr6:145799409~145886585:+
LUAD	cis	rs4971059	0.654	rs12028043	ENSG00000160766.13	GBAP1	-3.71	0.000229	0.0277	-0.17	-0.17	Breast cancer;	chr1:155160360	chr1:155213821~155227422:-
LUAD	cis	rs4713118	0.629	rs203889	ENSG00000280107.1	AL022393.9	-3.71	0.000229	0.0277	-0.21	-0.17	Parkinson's disease;	chr6:28053997	chr6:28170845~28172521:+
LUAD	cis	rs2346160	1	rs7753298	ENSG00000231720.1	RP11-568A7.3	-3.71	0.000229	0.0277	-0.16	-0.17	Parental extreme longevity (95 years and older);	chr6:167250705	chr6:167237508~167240480:-
LUAD	cis	rs11089937	0.616	rs5995616	ENSG00000211638.2	IGLV8-61	3.71	0.000229	0.0277	0.17	0.17	Periodontitis (PAL4Q3);	chr22:22186667	chr22:22098700~22099212:+
LUAD	cis	rs8028182	0.636	rs4886699	ENSG00000246877.1	DNM1P35	3.71	0.000229	0.0277	0.21	0.17	Sudden cardiac arrest;	chr15:75399962	chr15:75727670~75738623:-
LUAD	cis	rs7107174	1	rs2511180	ENSG00000251323.2	RP11-452H21.4	3.71	0.000229	0.0277	0.23	0.17	Testicular germ cell tumor;	chr11:78226209	chr11:78423982~78429836:-
LUAD	cis	rs4795519	1	rs1842166	ENSG00000266313.1	RP11-173M1.4	3.71	0.000229	0.0277	0.2	0.17	Chronic myeloid leukemia;	chr17:27137231	chr17:27333256~27348491:+
LUAD	cis	rs638893	0.636	rs61901411	ENSG00000255422.1	AP002954.4	3.71	0.000229	0.0277	0.31	0.17	Vitiligo;	chr11:118794615	chr11:118704607~118750263:+
LUAD	cis	rs11777747	0.545	rs11167062	ENSG00000271959.1	CTD-3064M3.7	3.71	0.000229	0.0277	0.16	0.17	Coronary artery calcification;	chr8:141448932	chr8:141434545~141437954:+
LUAD	cis	rs11777747	0.545	rs11986561	ENSG00000271959.1	CTD-3064M3.7	3.71	0.000229	0.0277	0.16	0.17	Coronary artery calcification;	chr8:141448955	chr8:141434545~141437954:+
LUAD	cis	rs36093844	0.851	rs1445499	ENSG00000279742.1	RP11-700A24.1	-3.71	0.000229	0.0277	-0.19	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85826145	chr11:85852557~85854943:-
LUAD	cis	rs10180282	0.903	rs7573683	ENSG00000228590.1	AC007381.3	3.71	0.000229	0.0277	0.19	0.17	Mosquito bite size;	chr2:60353959	chr2:60350595~60353016:-
LUAD	cis	rs9847710	0.791	rs6808387	ENSG00000242142.1	SERBP1P3	-3.71	0.000229	0.0277	-0.18	-0.17	Ulcerative colitis;	chr3:53045716	chr3:53064283~53065091:-
LUAD	cis	rs13113518	0.902	rs11133386	ENSG00000273257.1	RP11-177J6.1	3.71	0.000229	0.0277	0.18	0.17	Height;	chr4:55461320	chr4:55387949~55388271:+
LUAD	cis	rs4819052	0.851	rs13047104	ENSG00000215447.6	BX322557.10	-3.71	0.000229	0.0277	-0.2	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253647	chr21:45288052~45291738:+
LUAD	cis	rs4819052	0.885	rs28576202	ENSG00000215447.6	BX322557.10	-3.71	0.000229	0.0277	-0.2	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254769	chr21:45288052~45291738:+
LUAD	cis	rs4819052	0.851	rs35871601	ENSG00000215447.6	BX322557.10	-3.71	0.000229	0.0277	-0.2	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45255299	chr21:45288052~45291738:+
LUAD	cis	rs4819052	0.851	rs28622522	ENSG00000215447.6	BX322557.10	-3.71	0.000229	0.0277	-0.2	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256684	chr21:45288052~45291738:+
LUAD	cis	rs34779708	0.966	rs11010135	ENSG00000271335.4	RP11-324I22.4	3.71	0.000229	0.0277	0.18	0.17	Inflammatory bowel disease;Crohn's disease;	chr10:35229135	chr10:35314552~35336401:-
LUAD	cis	rs10876993	0.784	rs7314152	ENSG00000245651.2	RP11-620J15.2	3.71	0.000229	0.0277	0.17	0.17	Celiac disease or Rheumatoid arthritis;	chr12:57623918	chr12:57869835~57896482:-
LUAD	cis	rs8113308	1	rs8105440	ENSG00000269483.1	AC006272.1	3.71	0.000229	0.0277	0.24	0.17	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51948647	chr19:51839924~51843324:-
LUAD	cis	rs643506	0.967	rs2850248	ENSG00000230911.1	PPIHP1	-3.71	0.000229	0.0277	-0.22	-0.17	Breast cancer;	chr11:111774100	chr11:112029858~112030367:-
LUAD	cis	rs1015362	0.504	rs6059552	ENSG00000275784.1	RP5-1125A11.6	-3.71	0.000229	0.0278	-0.22	-0.17	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33923820	chr20:33989480~33991818:-
LUAD	cis	rs950027	0.62	rs1719245	ENSG00000259479.5	SORD2P	3.71	0.000229	0.0278	0.21	0.17	Response to fenofibrate (adiponectin levels);	chr15:45331584	chr15:44826371~44884694:-
LUAD	cis	rs142472947	1	rs142472947	ENSG00000232912.4	RP5-1115A15.1	-3.71	0.000229	0.0278	-0.2	-0.17	White blood cell count;	chr1:8460430	chr1:8424645~8434838:+
LUAD	cis	rs12908161	1	rs35808647	ENSG00000254414.1	RP11-182J1.1	3.71	0.000229	0.0278	0.22	0.17	Schizophrenia;	chr15:84834210	chr15:84631898~84633987:-
LUAD	cis	rs1023500	0.505	rs134886	ENSG00000226450.2	CYP2D8P	-3.71	0.000229	0.0278	-0.13	-0.17	Schizophrenia;	chr22:42277850	chr22:42149886~42155001:-
LUAD	cis	rs10197140	0.857	rs11123229	ENSG00000235721.1	AC013268.3	-3.71	0.000229	0.0278	-0.18	-0.17	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110891030	chr2:110007675~110010783:+
LUAD	cis	rs10197140	0.857	rs12328918	ENSG00000235721.1	AC013268.3	-3.71	0.000229	0.0278	-0.18	-0.17	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110892011	chr2:110007675~110010783:+
LUAD	cis	rs2274273	0.967	rs10147667	ENSG00000259318.1	RP11-454L9.2	-3.71	0.000229	0.0278	-0.15	-0.17	Protein biomarker;	chr14:55104131	chr14:55394940~55395233:-
LUAD	cis	rs12928939	0.518	rs12445564	ENSG00000260886.1	TAT-AS1	3.71	0.000229	0.0278	0.22	0.17	Post bronchodilator FEV1;	chr16:71909406	chr16:71565789~71578187:+
LUAD	cis	rs1075265	0.656	rs2542574	ENSG00000272156.1	RP11-477N3.1	-3.71	0.000229	0.0278	-0.2	-0.17	Chronotype;Morning vs. evening chronotype;	chr2:53820295	chr2:54082554~54085066:+
LUAD	cis	rs4237845	0.837	rs7954591	ENSG00000245651.2	RP11-620J15.2	3.71	0.000229	0.0278	0.16	0.17	Intelligence (multi-trait analysis);	chr12:57905254	chr12:57869835~57896482:-
LUAD	cis	rs8092503	1	rs1833282	ENSG00000267325.1	LINC01415	-3.71	0.000229	0.0278	-0.22	-0.17	Childhood body mass index;	chr18:54833781	chr18:55776727~55781721:-
LUAD	cis	rs7903456	0.648	rs7080134	ENSG00000200253.1	RNU6-529P	3.71	0.000229	0.0278	0.2	0.17	Gout;Renal underexcretion gout;	chr10:87067276	chr10:87041238~87041341:-
LUAD	cis	rs6964587	1	rs3753108	ENSG00000188693.7	CYP51A1-AS1	-3.71	0.000229	0.0278	-0.19	-0.17	Breast cancer;	chr7:92000670	chr7:92134604~92180725:+
LUAD	cis	rs6502050	0.835	rs3935816	ENSG00000266654.1	RP11-1376P16.1	-3.71	0.000229	0.0278	-0.18	-0.17	Life satisfaction;	chr17:82179297	chr17:82160056~82160452:+
LUAD	cis	rs7824557	0.545	rs2572450	ENSG00000255046.1	RP11-297N6.4	3.71	0.000229	0.0278	0.21	0.17	Retinal vascular caliber;	chr8:11372129	chr8:11797928~11802568:-
LUAD	cis	rs4873772	0.873	rs10109984	ENSG00000253330.1	RP11-697N18.3	3.71	0.000229	0.0278	0.18	0.17	Lobe attachment (rater-scored or self-reported);	chr8:47891114	chr8:47511034~47512141:-
LUAD	cis	rs12073359	1	rs55647342	ENSG00000223945.2	RP11-458I7.1	-3.71	0.00023	0.0278	-0.24	-0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150057947	chr1:150053864~150055034:+
LUAD	cis	rs6942407	0.592	rs1024457	ENSG00000224046.1	AC005076.5	-3.71	0.00023	0.0278	-0.25	-0.17	Food allergy;	chr7:87134826	chr7:87151423~87152420:-
LUAD	cis	rs7976269	0.559	rs4930848	ENSG00000275476.1	RP11-996F15.4	-3.71	0.00023	0.0278	-0.18	-0.17	Male-pattern baldness;	chr12:29068441	chr12:29277397~29277882:-
LUAD	cis	rs10197140	0.857	rs12470872	ENSG00000235721.1	AC013268.3	-3.71	0.00023	0.0278	-0.18	-0.17	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110884013	chr2:110007675~110010783:+
LUAD	cis	rs10197140	0.857	rs4849170	ENSG00000235721.1	AC013268.3	-3.71	0.00023	0.0278	-0.18	-0.17	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110884313	chr2:110007675~110010783:+
LUAD	cis	rs62103177	0.561	rs891488	ENSG00000278000.1	AC139100.4	-3.71	0.00023	0.0278	-0.2	-0.17	Opioid sensitivity;	chr18:79877424	chr18:80161752~80162413:+
LUAD	cis	rs7577696	0.889	rs212726	ENSG00000276334.1	AL133243.1	3.71	0.00023	0.0278	0.19	0.17	Inflammatory biomarkers;	chr2:32244316	chr2:32521927~32523547:+
LUAD	cis	rs7577696	0.889	rs212727	ENSG00000276334.1	AL133243.1	3.71	0.00023	0.0278	0.19	0.17	Inflammatory biomarkers;	chr2:32244659	chr2:32521927~32523547:+
LUAD	cis	rs6502050	0.835	rs3935403	ENSG00000275966.1	RP11-1055B8.9	-3.71	0.00023	0.0278	-0.17	-0.17	Life satisfaction;	chr17:82156269	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs9900072	ENSG00000275966.1	RP11-1055B8.9	-3.71	0.00023	0.0278	-0.17	-0.17	Life satisfaction;	chr17:82156484	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs8070014	ENSG00000275966.1	RP11-1055B8.9	-3.71	0.00023	0.0278	-0.17	-0.17	Life satisfaction;	chr17:82157371	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs8065565	ENSG00000275966.1	RP11-1055B8.9	-3.71	0.00023	0.0278	-0.17	-0.17	Life satisfaction;	chr17:82157523	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs8080625	ENSG00000275966.1	RP11-1055B8.9	-3.71	0.00023	0.0278	-0.17	-0.17	Life satisfaction;	chr17:82157571	chr17:81345476~81345966:-
LUAD	cis	rs6121246	0.909	rs1994250	ENSG00000230613.1	HM13-AS1	3.71	0.00023	0.0278	0.24	0.17	Mean corpuscular hemoglobin;	chr20:31699691	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.909	rs1994249	ENSG00000230613.1	HM13-AS1	3.71	0.00023	0.0278	0.24	0.17	Mean corpuscular hemoglobin;	chr20:31699790	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.909	rs6060812	ENSG00000230613.1	HM13-AS1	3.71	0.00023	0.0278	0.24	0.17	Mean corpuscular hemoglobin;	chr20:31705000	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.865	rs6058421	ENSG00000230613.1	HM13-AS1	3.71	0.00023	0.0278	0.24	0.17	Mean corpuscular hemoglobin;	chr20:31707210	chr20:31567707~31573263:-
LUAD	cis	rs9310995	0.542	rs3750280	ENSG00000271020.1	RP11-10C24.1	3.71	0.00023	0.0278	0.23	0.17	Pulmonary function;	chr3:32898081	chr3:33797149~33797681:-
LUAD	cis	rs7429990	0.965	rs4392441	ENSG00000228638.1	FCF1P2	3.71	0.00023	0.0278	0.19	0.17	Educational attainment (years of education);	chr3:48036211	chr3:48290793~48291375:-
LUAD	cis	rs12122100	0.955	rs12141289	ENSG00000227242.3	NBPF13P	-3.71	0.00023	0.0278	-0.21	-0.17	HIV-1 control;	chr1:147037912	chr1:147021320~147124525:-
LUAD	cis	rs13113518	0.812	rs4865003	ENSG00000273257.1	RP11-177J6.1	3.71	0.00023	0.0278	0.19	0.17	Height;	chr4:55514802	chr4:55387949~55388271:+
LUAD	cis	rs1023500	0.573	rs13057094	ENSG00000205702.9	CYP2D7	3.71	0.00023	0.0278	0.14	0.17	Schizophrenia;	chr22:42074313	chr22:42140203~42144577:-
LUAD	cis	rs7726839	0.54	rs12517638	ENSG00000248925.1	CTD-2083E4.6	3.71	0.00023	0.0278	0.26	0.17	Obesity-related traits;	chr5:645369	chr5:269858~271516:-
LUAD	cis	rs1046491	0.901	rs12454908	ENSG00000264964.1	RP11-888D10.3	3.71	0.00023	0.0278	0.35	0.17	Scarlet fever;	chr18:9134356	chr18:9315194~9334441:-
LUAD	cis	rs1046491	0.901	rs12454936	ENSG00000264964.1	RP11-888D10.3	3.71	0.00023	0.0278	0.35	0.17	Scarlet fever;	chr18:9134440	chr18:9315194~9334441:-
LUAD	cis	rs494453	0.538	rs2789544	ENSG00000227811.2	FAM212B-AS1	3.71	0.00023	0.0278	0.26	0.17	Osteoporosis-related phenotypes;	chr1:111639341	chr1:111739841~111747798:+
LUAD	cis	rs2901790	0.73	rs6808332	ENSG00000223387.5	RP11-408H1.3	-3.71	0.00023	0.0278	-0.22	-0.17	Gait speed in old age;	chr3:172499730	chr3:172560888~172595607:-
LUAD	cis	rs897984	0.806	rs12924903	ENSG00000232748.3	RP11-196G11.6	-3.71	0.00023	0.0278	-0.2	-0.17	Dementia with Lewy bodies;	chr16:30917649	chr16:31056460~31062803:+
LUAD	cis	rs7613051	0.58	rs11720449	ENSG00000223899.1	SEC13P1	3.71	0.00023	0.0278	0.22	0.17	Atopic dermatitis;	chr3:33024975	chr3:33033863~33034810:+
LUAD	cis	rs1046491	0.901	rs8095601	ENSG00000264964.1	RP11-888D10.3	3.71	0.00023	0.0278	0.35	0.17	Scarlet fever;	chr18:9136157	chr18:9315194~9334441:-
LUAD	cis	rs957448	1	rs1992370	ENSG00000254057.1	RP3-388N13.3	3.71	0.00023	0.0278	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94546466	chr8:93834454~93846743:-
LUAD	cis	rs12049351	0.774	rs1053512	ENSG00000229367.1	HMGN2P19	3.71	0.00023	0.0278	0.25	0.17	Circulating myeloperoxidase levels (plasma);	chr1:229516951	chr1:229570532~229570796:+
LUAD	cis	rs12049351	0.774	rs12138176	ENSG00000229367.1	HMGN2P19	3.71	0.00023	0.0278	0.25	0.17	Circulating myeloperoxidase levels (plasma);	chr1:229522155	chr1:229570532~229570796:+
LUAD	cis	rs12049351	0.774	rs12022203	ENSG00000229367.1	HMGN2P19	3.71	0.00023	0.0278	0.25	0.17	Circulating myeloperoxidase levels (plasma);	chr1:229523050	chr1:229570532~229570796:+
LUAD	cis	rs7246657	0.943	rs8109038	ENSG00000226686.6	LINC01535	3.71	0.00023	0.0278	0.24	0.17	Coronary artery calcification;	chr19:37524807	chr19:37251912~37265535:+
LUAD	cis	rs797680	0.822	rs1057257	ENSG00000223745.6	RP4-717I23.3	3.71	0.00023	0.0279	0.13	0.17	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93155926	chr1:93262186~93346025:-
LUAD	cis	rs13113518	0.812	rs6830409	ENSG00000273257.1	RP11-177J6.1	3.71	0.00023	0.0279	0.19	0.17	Height;	chr4:55522229	chr4:55387949~55388271:+
LUAD	cis	rs7003550	0.951	rs10110381	ENSG00000253433.1	NCRNA00250	-3.71	0.00023	0.0279	-0.22	-0.17	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr8:134853940	chr8:134838069~134842637:+
LUAD	cis	rs858239	0.6	rs10256361	ENSG00000226816.2	AC005082.12	3.71	0.00023	0.0279	0.22	0.17	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23206013~23208045:+
LUAD	cis	rs7017914	0.905	rs2732115	ENSG00000246366.5	RP11-382J12.1	3.71	0.00023	0.0279	0.15	0.17	Bone mineral density;	chr8:71016619	chr8:70608577~70663279:+
LUAD	cis	rs4971059	0.654	rs4276913	ENSG00000160766.13	GBAP1	-3.71	0.00023	0.0279	-0.17	-0.17	Breast cancer;	chr1:155159197	chr1:155213821~155227422:-
LUAD	cis	rs2657294	0.796	rs2804535	ENSG00000226051.5	ZNF503-AS1	3.71	0.00023	0.0279	0.22	0.17	Pneumonia;	chr10:75212086	chr10:75269819~75373500:+
LUAD	cis	rs2439831	0.867	rs935901	ENSG00000249839.1	AC011330.5	-3.71	0.00023	0.0279	-0.36	-0.17	Lung cancer in ever smokers;	chr15:43359058	chr15:43663654~43684339:-
LUAD	cis	rs528808	1	rs528808	ENSG00000228439.4	TSTD3	-3.71	0.00023	0.0279	-0.26	-0.17	Age-related hearing impairment;	chr6:99656413	chr6:99520693~99531918:+
LUAD	cis	rs987724	0.574	rs2321292	ENSG00000240875.4	LINC00886	-3.71	0.00023	0.0279	-0.19	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156925970	chr3:156747346~156817062:-
LUAD	cis	rs2239557	0.539	rs2302117	ENSG00000259065.1	RP5-1021I20.1	-3.71	0.00023	0.0279	-0.23	-0.17	Common traits (Other);	chr14:73988110	chr14:73787360~73803270:+
LUAD	cis	rs2239557	0.539	rs62005063	ENSG00000259065.1	RP5-1021I20.1	-3.71	0.00023	0.0279	-0.23	-0.17	Common traits (Other);	chr14:73989276	chr14:73787360~73803270:+
LUAD	cis	rs7851726	1	rs356131	ENSG00000231806.2	PCAT7	3.71	0.00023	0.0279	0.22	0.17	Urinary albumin-to-creatinine ratio;	chr9:94805045	chr9:94555069~94568127:+
LUAD	cis	rs7045881	0.674	rs3429	ENSG00000254396.1	RP11-56F10.3	3.71	0.00023	0.0279	0.27	0.17	Schizophrenia;	chr9:27062723	chr9:27102630~27104728:+
LUAD	cis	rs9894429	0.55	rs6565617	ENSG00000263853.1	AC139530.1	-3.71	0.000231	0.0279	-0.17	-0.17	Eye color traits;	chr17:81645307	chr17:81676001~81676086:+
LUAD	cis	rs9894429	0.646	rs7210026	ENSG00000263853.1	AC139530.1	-3.71	0.000231	0.0279	-0.17	-0.17	Eye color traits;	chr17:81645356	chr17:81676001~81676086:+
LUAD	cis	rs858239	0.6	rs6960001	ENSG00000226816.2	AC005082.12	3.71	0.000231	0.0279	0.22	0.17	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23206013~23208045:+
LUAD	cis	rs858239	0.6	rs10237755	ENSG00000226816.2	AC005082.12	3.71	0.000231	0.0279	0.22	0.17	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23206013~23208045:+
LUAD	cis	rs858239	0.6	rs6961131	ENSG00000226816.2	AC005082.12	3.71	0.000231	0.0279	0.22	0.17	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23206013~23208045:+
LUAD	cis	rs6871536	1	rs2240032	ENSG00000233006.5	AC034220.3	-3.71	0.000231	0.0279	-0.18	-0.17	Asthma (childhood onset);	chr5:132641435	chr5:132311285~132369916:-
LUAD	cis	rs2239547	0.657	rs4687672	ENSG00000243224.1	RP5-1157M23.2	-3.71	0.000231	0.0279	-0.19	-0.17	Schizophrenia;	chr3:52846527	chr3:52239258~52241097:+
LUAD	cis	rs4699052	0.625	rs7695593	ENSG00000246560.2	RP11-10L12.4	3.71	0.000231	0.0279	0.21	0.17	Testicular germ cell tumor;	chr4:103342626	chr4:102828055~102844075:+
LUAD	cis	rs9628987	0.5	rs56812469	ENSG00000232912.4	RP5-1115A15.1	-3.71	0.000231	0.0279	-0.19	-0.17	Breast cancer;	chr1:8384170	chr1:8424645~8434838:+
LUAD	cis	rs7102710	1	rs11023139	ENSG00000254418.1	RP11-21L19.1	3.71	0.000231	0.0279	0.4	0.17	Glucagon levels in response to oral glucose tolerance test (fasting);	chr11:14202800	chr11:14262846~14273691:-
LUAD	cis	rs12822507	0.732	rs10845586	ENSG00000180861.8	LINC01559	-3.71	0.000231	0.0279	-0.18	-0.17	Systemic lupus erythematosus;	chr12:12598728	chr12:13371089~13387167:-
LUAD	cis	rs11051970	0.559	rs11051991	ENSG00000274964.1	RP11-817I4.1	3.71	0.000231	0.0279	0.21	0.17	Response to tocilizumab in rheumatoid arthritis;	chr12:32410998	chr12:32339368~32340724:+
LUAD	cis	rs4474465	1	rs11237522	ENSG00000251323.2	RP11-452H21.4	3.71	0.000231	0.0279	0.2	0.17	Alzheimer's disease (survival time);	chr11:78498833	chr11:78423982~78429836:-
LUAD	cis	rs9303542	1	rs9894812	ENSG00000264920.1	RP11-6N17.4	3.71	0.000231	0.0279	0.21	0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48312591	chr17:47891255~47895812:-
LUAD	cis	rs2024714	0.902	rs11204437	ENSG00000273812.1	WI2-87327B8.2	-3.71	0.000231	0.0279	-0.18	-0.17	Longevity;	chr20:61642199	chr20:62596732~62603115:-
LUAD	cis	rs2024714	0.902	rs2427217	ENSG00000273812.1	WI2-87327B8.2	-3.71	0.000231	0.0279	-0.18	-0.17	Longevity;	chr20:61642550	chr20:62596732~62603115:-
LUAD	cis	rs2024714	0.902	rs2427219	ENSG00000273812.1	WI2-87327B8.2	-3.71	0.000231	0.0279	-0.18	-0.17	Longevity;	chr20:61642586	chr20:62596732~62603115:-
LUAD	cis	rs3020736	0.5	rs8143153	ENSG00000273366.1	CTA-989H11.1	3.71	0.000231	0.0279	0.2	0.17	Autism spectrum disorder or schizophrenia;	chr22:42119633	chr22:42278188~42278846:+
LUAD	cis	rs7512552	0.803	rs2454286	ENSG00000275557.1	RP11-353N4.6	3.71	0.000231	0.0279	0.19	0.17	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150383062	chr1:149607765~149612402:+
LUAD	cis	rs6988985	0.728	rs7003782	ENSG00000247317.3	RP11-273G15.2	-3.71	0.000231	0.0279	-0.19	-0.17	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142893412	chr8:142981738~143018437:-
LUAD	cis	rs2243480	1	rs6964530	ENSG00000229886.1	RP5-1132H15.3	-3.71	0.000231	0.0279	-0.29	-0.17	Diabetic kidney disease;	chr7:66253864	chr7:66025126~66031544:-
LUAD	cis	rs875971	0.545	rs7783889	ENSG00000224316.1	RP11-479O9.2	3.71	0.000231	0.0279	0.19	0.17	Aortic root size;	chr7:66283366	chr7:65773620~65802067:+
LUAD	cis	rs9951698	0.703	rs7234960	ENSG00000267480.1	RP11-703I16.1	-3.71	0.000231	0.0279	-0.21	-0.17	Intelligence (multi-trait analysis);	chr18:13018072	chr18:12031178~12032181:-
LUAD	cis	rs9889262	0.582	rs11655466	ENSG00000248714.5	RP11-1079K10.3	3.71	0.000231	0.0279	0.17	0.17	Eosinophil percentage of granulocytes;Allergic disease (asthma, hay fever or eczema);Eosinophil counts;	chr17:49267168	chr17:49361165~49369998:+
LUAD	cis	rs875971	0.54	rs4717275	ENSG00000234585.5	CCT6P3	-3.71	0.000231	0.0279	-0.16	-0.17	Aortic root size;	chr7:65800193	chr7:65038354~65074713:+
LUAD	cis	rs13113518	0.812	rs2412648	ENSG00000273257.1	RP11-177J6.1	3.71	0.000231	0.0279	0.19	0.17	Height;	chr4:55454900	chr4:55387949~55388271:+
LUAD	cis	rs13113518	0.812	rs12512737	ENSG00000273257.1	RP11-177J6.1	3.71	0.000231	0.0279	0.19	0.17	Height;	chr4:55454938	chr4:55387949~55388271:+
LUAD	cis	rs13113518	0.812	rs13125984	ENSG00000273257.1	RP11-177J6.1	3.71	0.000231	0.0279	0.19	0.17	Height;	chr4:55455102	chr4:55387949~55388271:+
LUAD	cis	rs9813712	0.571	rs9855426	ENSG00000253540.4	FAM86HP	3.71	0.000231	0.0279	0.17	0.17	Response to amphetamines;	chr3:130214475	chr3:130099092~130111472:-
LUAD	cis	rs4716602	0.596	rs10258969	ENSG00000235029.1	MNX1-AS2	-3.71	0.000231	0.0279	-0.2	-0.17	Anti-saccade response;	chr7:156365059	chr7:157006307~157007132:+
LUAD	cis	rs683250	0.598	rs7933220	ENSG00000246067.6	RAB30-AS1	3.71	0.000231	0.0279	0.18	0.17	Subcortical brain region volumes;	chr11:83307732	chr11:83072066~83106719:+
LUAD	cis	rs1502844	0.517	rs1502851	ENSG00000250682.4	LINC00491	3.71	0.000231	0.0279	0.21	0.17	Schizophrenia;	chr5:102528330	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.824	rs3776868	ENSG00000250682.4	LINC00491	3.71	0.000231	0.0279	0.2	0.17	Parkinson's disease;	chr5:102963012	chr5:102609156~102671559:-
LUAD	cis	rs6951245	1	rs74887741	ENSG00000224079.1	AC091729.7	-3.71	0.000231	0.0279	-0.26	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1071022	chr7:1074450~1078036:+
LUAD	cis	rs6951245	1	rs79617366	ENSG00000224079.1	AC091729.7	-3.71	0.000231	0.0279	-0.26	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1072322	chr7:1074450~1078036:+
LUAD	cis	rs6951245	1	rs111899361	ENSG00000224079.1	AC091729.7	-3.71	0.000231	0.0279	-0.26	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1072712	chr7:1074450~1078036:+
LUAD	cis	rs3126085	0.515	rs7515448	ENSG00000237975.5	FLG-AS1	3.71	0.000231	0.0279	0.25	0.17	Atopic dermatitis;	chr1:152399559	chr1:152168125~152445456:+
LUAD	cis	rs17597773	0.674	rs903319	ENSG00000272823.1	RP11-295M18.6	-3.71	0.000231	0.0279	-0.22	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220812469	chr1:220828676~220829211:-
LUAD	cis	rs875971	0.545	rs1909508	ENSG00000224316.1	RP11-479O9.2	3.71	0.000231	0.0279	0.19	0.17	Aortic root size;	chr7:66301366	chr7:65773620~65802067:+
LUAD	cis	rs4227	0.545	rs2302661	ENSG00000233223.2	AC113189.5	3.71	0.000231	0.0279	0.18	0.17	IgA nephropathy;	chr17:7587061	chr17:7581964~7584072:-
LUAD	cis	rs6496932	0.865	rs4842874	ENSG00000218052.5	ADAMTS7P4	3.71	0.000231	0.0279	0.22	0.17	Central corneal thickness;Corneal structure;	chr15:85323464	chr15:85255369~85330334:-
LUAD	cis	rs6496932	0.865	rs4843049	ENSG00000218052.5	ADAMTS7P4	3.71	0.000231	0.0279	0.22	0.17	Central corneal thickness;Corneal structure;	chr15:85331141	chr15:85255369~85330334:-
LUAD	cis	rs853679	0.55	rs1150689	ENSG00000280107.1	AL022393.9	-3.71	0.000231	0.0279	-0.22	-0.17	Depression;	chr6:28197321	chr6:28170845~28172521:+
LUAD	cis	rs4927850	0.918	rs4361313	ENSG00000278820.1	AC024937.1	3.71	0.000231	0.0279	0.15	0.17	Pancreatic cancer;	chr3:196025389	chr3:195960500~195960612:-
LUAD	cis	rs9549260	0.755	rs2721071	ENSG00000229456.1	RLIMP1	3.71	0.000231	0.0279	0.18	0.17	Red blood cell count;	chr13:40570370	chr13:40618738~40621348:+
LUAD	cis	rs7911264	0.765	rs7092522	ENSG00000236493.2	EIF2S2P3	3.71	0.000231	0.0279	0.2	0.17	Inflammatory bowel disease;	chr10:92583226	chr10:92668745~92669743:-
LUAD	cis	rs7911264	0.765	rs2421941	ENSG00000236493.2	EIF2S2P3	3.71	0.000231	0.0279	0.2	0.17	Inflammatory bowel disease;	chr10:92586152	chr10:92668745~92669743:-
LUAD	cis	rs34286592	0.929	rs35901559	ENSG00000214725.6	CDIPT-AS1	-3.71	0.000231	0.0279	-0.27	-0.17	Multiple sclerosis;	chr16:29818294	chr16:29863593~29868053:+
LUAD	cis	rs34286592	0.929	rs11864180	ENSG00000214725.6	CDIPT-AS1	-3.71	0.000231	0.0279	-0.27	-0.17	Multiple sclerosis;	chr16:29819508	chr16:29863593~29868053:+
LUAD	cis	rs34286592	0.929	rs9923649	ENSG00000214725.6	CDIPT-AS1	-3.71	0.000231	0.0279	-0.27	-0.17	Multiple sclerosis;	chr16:29820817	chr16:29863593~29868053:+
LUAD	cis	rs360798	0.779	rs7590973	ENSG00000231609.4	AC009501.4	3.71	0.000231	0.028	0.19	0.17	Coronary artery disease;	chr2:62678204	chr2:63043922~63048640:-
LUAD	cis	rs3764021	1	rs3764021	ENSG00000278635.1	CTD-2318O12.1	-3.71	0.000231	0.028	-0.15	-0.17	Type 1 diabetes;	chr12:9681032	chr12:9415641~9416718:+
LUAD	cis	rs8180040	0.966	rs11925823	ENSG00000271161.1	BOLA2P2	3.71	0.000231	0.028	0.16	0.17	Colorectal cancer;	chr3:47401575	chr3:47499841~47500407:+
LUAD	cis	rs26232	0.521	rs3776856	ENSG00000250682.4	LINC00491	3.71	0.000231	0.028	0.21	0.17	Rheumatoid arthritis;	chr5:103023102	chr5:102609156~102671559:-
LUAD	cis	rs2074409	0.509	rs2680720	ENSG00000276054.1	RP11-378E13.3	3.71	0.000231	0.028	0.2	0.17	Response to angiotensin II receptor blocker therapy;	chr17:37458360	chr17:37386886~37387926:+
LUAD	cis	rs11096990	0.613	rs1451821	ENSG00000249685.1	RP11-360F5.3	-3.71	0.000231	0.028	-0.2	-0.17	Cognitive function;	chr4:39178797	chr4:39133913~39135608:+
LUAD	cis	rs763121	0.853	rs4821810	ENSG00000228274.3	RP3-508I15.9	-3.71	0.000232	0.028	-0.16	-0.17	Menopause (age at onset);	chr22:38676093	chr22:38667585~38681820:-
LUAD	cis	rs2905347	0.56	rs2961291	ENSG00000179428.2	AC073072.5	3.71	0.000232	0.028	0.2	0.17	Major depression and alcohol dependence;	chr7:22641885	chr7:22725395~22727620:-
LUAD	cis	rs3788317	0.526	rs5993855	ENSG00000232926.1	AC000078.5	-3.71	0.000232	0.028	-0.18	-0.17	Glaucoma (primary angle closure);	chr22:19894592	chr22:19887289~19887970:+
LUAD	cis	rs957448	1	rs10956915	ENSG00000254057.1	RP3-388N13.3	3.71	0.000232	0.028	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94502362	chr8:93834454~93846743:-
LUAD	cis	rs17711722	0.583	rs10085415	ENSG00000224316.1	RP11-479O9.2	-3.71	0.000232	0.028	-0.17	-0.17	Calcium levels;	chr7:65628655	chr7:65773620~65802067:+
LUAD	cis	rs1858037	0.867	rs6727013	ENSG00000237979.1	AC007389.1	3.71	0.000232	0.028	0.21	0.17	Rheumatoid arthritis;	chr2:65331241	chr2:65500993~65502138:-
LUAD	cis	rs2664588	0.538	rs6063188	ENSG00000224565.1	RP1-148H17.1	-3.71	0.000232	0.028	-0.18	-0.17	Cerebrospinal fluid AB1-42 levels;	chr20:47964211	chr20:47391929~47412327:-
LUAD	cis	rs755249	1	rs12037222	ENSG00000182109.6	RP11-69E11.4	3.71	0.000232	0.028	0.21	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39599289	chr1:39522280~39546187:-
LUAD	cis	rs2239547	0.522	rs4519686	ENSG00000243224.1	RP5-1157M23.2	-3.71	0.000232	0.028	-0.18	-0.17	Schizophrenia;	chr3:52963855	chr3:52239258~52241097:+
LUAD	cis	rs638893	0.636	rs61901410	ENSG00000255422.1	AP002954.4	3.71	0.000232	0.028	0.31	0.17	Vitiligo;	chr11:118790488	chr11:118704607~118750263:+
LUAD	cis	rs911555	0.755	rs4143998	ENSG00000244691.1	RPL10AP1	-3.71	0.000232	0.028	-0.22	-0.17	Intelligence (multi-trait analysis);	chr14:103488910	chr14:103412119~103412761:-
LUAD	cis	rs34783982	0.665	rs907782	ENSG00000261441.1	RP11-217B1.2	-3.71	0.000232	0.028	-0.21	-0.17	Squamous cell lung carcinoma;	chr15:88950860	chr15:89335053~89336161:+
LUAD	cis	rs10129255	0.957	rs2007467	ENSG00000211947.2	IGHV3-21	3.71	0.000232	0.028	0.11	0.17	Kawasaki disease;	chr14:106771605	chr14:106235064~106235594:-
LUAD	cis	rs324126	0.78	rs62108320	ENSG00000277977.1	CTD-3018O17.5	3.71	0.000232	0.028	0.17	0.17	Colonoscopy-negative controls vs population controls;	chr19:52380770	chr19:52392659~52392755:+
LUAD	cis	rs324126	0.752	rs62108321	ENSG00000277977.1	CTD-3018O17.5	3.71	0.000232	0.028	0.17	0.17	Colonoscopy-negative controls vs population controls;	chr19:52380825	chr19:52392659~52392755:+
LUAD	cis	rs7937890	0.559	rs2575829	ENSG00000254418.1	RP11-21L19.1	3.71	0.000232	0.028	0.2	0.17	Mitochondrial DNA levels;	chr11:14463475	chr11:14262846~14273691:-
LUAD	cis	rs7937890	0.559	rs2597200	ENSG00000254418.1	RP11-21L19.1	3.71	0.000232	0.028	0.2	0.17	Mitochondrial DNA levels;	chr11:14464054	chr11:14262846~14273691:-
LUAD	cis	rs7937890	0.559	rs2575830	ENSG00000254418.1	RP11-21L19.1	3.71	0.000232	0.028	0.2	0.17	Mitochondrial DNA levels;	chr11:14464056	chr11:14262846~14273691:-
LUAD	cis	rs7937890	0.559	rs2575831	ENSG00000254418.1	RP11-21L19.1	3.71	0.000232	0.028	0.2	0.17	Mitochondrial DNA levels;	chr11:14464648	chr11:14262846~14273691:-
LUAD	cis	rs7937890	0.559	rs2597197	ENSG00000254418.1	RP11-21L19.1	3.71	0.000232	0.028	0.2	0.17	Mitochondrial DNA levels;	chr11:14468286	chr11:14262846~14273691:-
LUAD	cis	rs755249	0.509	rs11206378	ENSG00000228060.1	RP11-69E11.8	3.71	0.000232	0.028	0.14	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39583512	chr1:39565160~39573203:+
LUAD	cis	rs3916	0.955	rs34030695	ENSG00000277423.1	RP11-173P15.9	-3.71	0.000232	0.028	-0.21	-0.17	Urinary metabolites (H-NMR features);	chr12:120718693	chr12:120703867~120704282:+
LUAD	cis	rs7260598	0.685	rs73021420	ENSG00000268442.1	CTD-2027I19.2	3.71	0.000232	0.028	0.26	0.17	Response to taxane treatment (placlitaxel);	chr19:24082833	chr19:24162370~24163425:-
LUAD	cis	rs987044	0.726	rs4964272	ENSG00000257221.1	RP11-689B22.2	-3.71	0.000232	0.028	-0.14	-0.17	Mean platelet volume;	chr12:108709839	chr12:108628687~108641318:+
LUAD	cis	rs8141529	0.748	rs5762881	ENSG00000272858.1	CTA-292E10.8	-3.71	0.000232	0.028	-0.19	-0.17	Lymphocyte counts;	chr22:28893358	chr22:28814914~28815662:+
LUAD	cis	rs8141529	0.748	rs9620841	ENSG00000272858.1	CTA-292E10.8	-3.71	0.000232	0.028	-0.19	-0.17	Lymphocyte counts;	chr22:28894993	chr22:28814914~28815662:+
LUAD	cis	rs3198697	0.617	rs11075253	ENSG00000188599.16	NPIPP1	-3.71	0.000232	0.028	-0.15	-0.17	Triglycerides;	chr16:15054789	chr16:15104312~15123498:-
LUAD	cis	rs4713118	0.699	rs200978	ENSG00000226314.6	ZNF192P1	-3.71	0.000232	0.028	-0.22	-0.17	Parkinson's disease;	chr6:27885390	chr6:28161781~28169594:+
LUAD	cis	rs516805	0.923	rs491171	ENSG00000279114.1	RP3-425C14.5	-3.71	0.000232	0.028	-0.18	-0.17	Lymphocyte counts;	chr6:122408021	chr6:122471923~122484161:+
LUAD	cis	rs516805	0.923	rs556675	ENSG00000279114.1	RP3-425C14.5	-3.71	0.000232	0.028	-0.18	-0.17	Lymphocyte counts;	chr6:122408083	chr6:122471923~122484161:+
LUAD	cis	rs2554380	0.943	rs4843152	ENSG00000230373.7	GOLGA6L5P	-3.71	0.000232	0.028	-0.21	-0.17	Height;	chr15:83694790	chr15:84507885~84516814:-
LUAD	cis	rs6964587	1	rs6967256	ENSG00000188693.7	CYP51A1-AS1	-3.71	0.000232	0.028	-0.19	-0.17	Breast cancer;	chr7:92013905	chr7:92134604~92180725:+
LUAD	cis	rs2494663	0.61	rs7521303	ENSG00000223599.1	RP11-216N14.7	3.71	0.000232	0.028	0.2	0.17	Mean platelet volume;	chr1:154039129	chr1:153852106~153853414:-
LUAD	cis	rs2057178	0.929	rs11031716	ENSG00000183242.10	WT1-AS	-3.71	0.000232	0.028	-0.24	-0.17	Tuberculosis;	chr11:32325288	chr11:32435518~32458769:+
LUAD	cis	rs748404	0.666	rs35158584	ENSG00000249839.1	AC011330.5	-3.71	0.000232	0.0281	-0.26	-0.17	Lung cancer;	chr15:43392876	chr15:43663654~43684339:-
LUAD	cis	rs911555	0.673	rs7144271	ENSG00000244691.1	RPL10AP1	-3.71	0.000232	0.0281	-0.22	-0.17	Intelligence (multi-trait analysis);	chr14:103424337	chr14:103412119~103412761:-
LUAD	cis	rs14027	0.64	rs28421406	ENSG00000279347.1	RP11-85I17.2	-3.71	0.000232	0.0281	-0.14	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119752249	chr8:119838736~119840385:-
LUAD	cis	rs14027	0.64	rs16893104	ENSG00000279347.1	RP11-85I17.2	-3.71	0.000232	0.0281	-0.14	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119754778	chr8:119838736~119840385:-
LUAD	cis	rs9860428	0.526	rs9871985	ENSG00000242770.2	RP11-180K7.1	3.71	0.000232	0.0281	0.18	0.17	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112942507	chr3:112802478~112812819:+
LUAD	cis	rs9860428	0.526	rs9854885	ENSG00000242770.2	RP11-180K7.1	3.71	0.000232	0.0281	0.18	0.17	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112942871	chr3:112802478~112812819:+
LUAD	cis	rs2274273	0.6	rs10131730	ENSG00000258413.1	RP11-665C16.6	-3.71	0.000232	0.0281	-0.23	-0.17	Protein biomarker;	chr14:55373374	chr14:55262767~55272075:-
LUAD	cis	rs2274273	0.624	rs12050123	ENSG00000258413.1	RP11-665C16.6	-3.71	0.000232	0.0281	-0.23	-0.17	Protein biomarker;	chr14:55373668	chr14:55262767~55272075:-
LUAD	cis	rs2274273	0.624	rs10132453	ENSG00000258413.1	RP11-665C16.6	-3.71	0.000232	0.0281	-0.23	-0.17	Protein biomarker;	chr14:55374133	chr14:55262767~55272075:-
LUAD	cis	rs78487399	0.808	rs17030946	ENSG00000234936.1	AC010883.5	3.71	0.000232	0.0281	0.23	0.17	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43506370	chr2:43229573~43233394:+
LUAD	cis	rs9366999	0.809	rs1744416	ENSG00000235033.6	RP11-61I13.3	3.71	0.000232	0.0281	0.18	0.17	Obesity-related traits;	chr6:39254027	chr6:39881804~39900071:-
LUAD	cis	rs801193	0.569	rs13226966	ENSG00000106610.13	STAG3L4	-3.71	0.000232	0.0281	-0.21	-0.17	Aortic root size;	chr7:66768636	chr7:67302621~67321526:+
LUAD	cis	rs2057178	0.697	rs10488685	ENSG00000183242.10	WT1-AS	3.71	0.000232	0.0281	0.24	0.17	Tuberculosis;	chr11:32307380	chr11:32435518~32458769:+
LUAD	cis	rs6460942	1	rs62448563	ENSG00000226690.5	AC005281.1	3.71	0.000232	0.0281	0.3	0.17	Coronary artery disease;	chr7:12360414	chr7:12496429~12541910:+
LUAD	cis	rs6460942	1	rs62448565	ENSG00000226690.5	AC005281.1	3.71	0.000232	0.0281	0.3	0.17	Coronary artery disease;	chr7:12360832	chr7:12496429~12541910:+
LUAD	cis	rs6460942	1	rs2053381	ENSG00000226690.5	AC005281.1	3.71	0.000232	0.0281	0.3	0.17	Coronary artery disease;	chr7:12361084	chr7:12496429~12541910:+
LUAD	cis	rs6460942	1	rs6460935	ENSG00000226690.5	AC005281.1	3.71	0.000232	0.0281	0.3	0.17	Coronary artery disease;	chr7:12361691	chr7:12496429~12541910:+
LUAD	cis	rs6460942	1	rs7791634	ENSG00000226690.5	AC005281.1	3.71	0.000232	0.0281	0.3	0.17	Coronary artery disease;	chr7:12361856	chr7:12496429~12541910:+
LUAD	cis	rs6460942	1	rs62448566	ENSG00000226690.5	AC005281.1	3.71	0.000232	0.0281	0.3	0.17	Coronary artery disease;	chr7:12364036	chr7:12496429~12541910:+
LUAD	cis	rs875971	0.522	rs7784623	ENSG00000222364.1	RNU6-96P	-3.71	0.000232	0.0281	-0.18	-0.17	Aortic root size;	chr7:65930047	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.522	rs34973832	ENSG00000222364.1	RNU6-96P	-3.71	0.000232	0.0281	-0.18	-0.17	Aortic root size;	chr7:65931217	chr7:66395191~66395286:+
LUAD	cis	rs7584330	0.78	rs937395	ENSG00000222032.1	AC112721.2	3.71	0.000232	0.0281	0.21	0.17	Prostate cancer;	chr2:237470106	chr2:237428920~237434822:-
LUAD	cis	rs4664293	0.707	rs7563956	ENSG00000230783.1	AC009961.2	3.71	0.000233	0.0281	0.2	0.17	Monocyte percentage of white cells;	chr2:159815943	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.74	rs12464577	ENSG00000230783.1	AC009961.2	3.71	0.000233	0.0281	0.2	0.17	Monocyte percentage of white cells;	chr2:159816321	chr2:159689217~159690291:-
LUAD	cis	rs7772486	0.686	rs1292336	ENSG00000235652.6	RP11-545I5.3	-3.71	0.000233	0.0281	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145646682	chr6:145799409~145886585:+
LUAD	cis	rs1805008	0.535	rs7196459	ENSG00000261172.1	RP11-356C4.5	-3.71	0.000233	0.0281	-0.35	-0.17	Skin colour saturation;	chr16:90075069	chr16:90110574~90168225:-
LUAD	cis	rs6715284	0.681	rs79053638	ENSG00000201499.1	RNU6-312P	-3.71	0.000233	0.0281	-0.36	-0.17	Rheumatoid arthritis;	chr2:201520222	chr2:200881715~200881821:-
LUAD	cis	rs6715284	0.579	rs78392000	ENSG00000201499.1	RNU6-312P	-3.71	0.000233	0.0281	-0.36	-0.17	Rheumatoid arthritis;	chr2:201520828	chr2:200881715~200881821:-
LUAD	cis	rs6715284	0.681	rs76524758	ENSG00000201499.1	RNU6-312P	-3.71	0.000233	0.0281	-0.36	-0.17	Rheumatoid arthritis;	chr2:201522146	chr2:200881715~200881821:-
LUAD	cis	rs703842	0.642	rs11536137	ENSG00000270039.1	RP11-571M6.17	-3.71	0.000233	0.0281	-0.21	-0.17	Multiple sclerosis;	chr12:57662643	chr12:57803838~57804415:+
LUAD	cis	rs13187289	1	rs13187289	ENSG00000222266.1	RNU6-757P	3.71	0.000233	0.0281	0.22	0.17	Menarche (age at onset);	chr5:134513486	chr5:134715483~134715582:+
LUAD	cis	rs28386778	0.901	rs2665855	ENSG00000240280.5	TCAM1P	-3.71	0.000233	0.0281	-0.19	-0.17	Prudent dietary pattern;	chr17:63887783	chr17:63849292~63864379:+
LUAD	cis	rs703842	0.575	rs701006	ENSG00000270039.1	RP11-571M6.17	-3.71	0.000233	0.0281	-0.19	-0.17	Multiple sclerosis;	chr12:57713053	chr12:57803838~57804415:+
LUAD	cis	rs5758659	0.569	rs133294	ENSG00000227370.1	RP4-669P10.19	-3.71	0.000233	0.0281	-0.15	-0.17	Cognitive function;	chr22:41986801	chr22:42132543~42132998:+
LUAD	cis	rs763121	0.853	rs6001188	ENSG00000225450.1	RP3-508I15.14	-3.71	0.000233	0.0281	-0.17	-0.17	Menopause (age at onset);	chr22:38666189	chr22:38739003~38749041:+
LUAD	cis	rs4660214	0.666	rs2490946	ENSG00000182109.6	RP11-69E11.4	3.71	0.000233	0.0281	0.18	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39371955	chr1:39522280~39546187:-
LUAD	cis	rs524281	0.773	rs2155030	ENSG00000255320.1	RP11-755F10.1	3.71	0.000233	0.0281	0.26	0.17	Electroencephalogram traits;	chr11:66263216	chr11:66244840~66246239:-
LUAD	cis	rs524281	0.773	rs2155031	ENSG00000255320.1	RP11-755F10.1	3.71	0.000233	0.0281	0.26	0.17	Electroencephalogram traits;	chr11:66263456	chr11:66244840~66246239:-
LUAD	cis	rs524281	0.731	rs2276036	ENSG00000255320.1	RP11-755F10.1	3.71	0.000233	0.0281	0.26	0.17	Electroencephalogram traits;	chr11:66265959	chr11:66244840~66246239:-
LUAD	cis	rs7646881	0.544	rs12638363	ENSG00000240207.5	RP11-379F4.4	-3.71	0.000233	0.0281	-0.23	-0.17	Tetralogy of Fallot;	chr3:158686969	chr3:158732263~158784070:+
LUAD	cis	rs4474465	0.85	rs10793326	ENSG00000251323.2	RP11-452H21.4	-3.71	0.000233	0.0281	-0.21	-0.17	Alzheimer's disease (survival time);	chr11:78544376	chr11:78423982~78429836:-
LUAD	cis	rs7192380	0.964	rs6499231	ENSG00000226232.7	RP11-419C5.2	-3.71	0.000233	0.0281	-0.14	-0.17	Sjögren's syndrome;	chr16:69554113	chr16:69976388~69996188:-
LUAD	cis	rs7202877	0.61	rs10871307	ENSG00000261783.1	RP11-252K23.2	-3.71	0.000233	0.0281	-0.32	-0.17	Type 1 diabetes;Type 2 diabetes;	chr16:75301216	chr16:75379818~75381260:-
LUAD	cis	rs7202877	0.519	rs3743606	ENSG00000261783.1	RP11-252K23.2	-3.71	0.000233	0.0281	-0.32	-0.17	Type 1 diabetes;Type 2 diabetes;	chr16:75301576	chr16:75379818~75381260:-
LUAD	cis	rs73193808	1	rs2832227	ENSG00000215533.7	LINC00189	-3.71	0.000233	0.0281	-0.25	-0.17	Coronary artery disease;	chr21:29160755	chr21:29193480~29288205:+
LUAD	cis	rs8014204	0.935	rs8010840	ENSG00000279594.1	RP11-950C14.10	-3.71	0.000233	0.0281	-0.19	-0.17	Caffeine consumption;	chr14:74888500	chr14:75011269~75012851:-
LUAD	cis	rs10463554	0.927	rs34824	ENSG00000250682.4	LINC00491	3.71	0.000233	0.0281	0.2	0.17	Parkinson's disease;	chr5:103103227	chr5:102609156~102671559:-
LUAD	cis	rs7142881	0.815	rs12431783	ENSG00000258525.1	RP11-829H16.3	-3.71	0.000233	0.0281	-0.19	-0.17	Response to iloperidone treatment (QT prolongation);	chr14:31719678	chr14:30876179~30889808:-
LUAD	cis	rs7428	0.527	rs4459734	ENSG00000246575.2	AC093162.5	3.71	0.000233	0.0281	0.16	0.17	Ear protrusion;	chr2:85320306	chr2:85315041~85316529:+
LUAD	cis	rs875971	0.545	rs67775320	ENSG00000224316.1	RP11-479O9.2	3.71	0.000233	0.0281	0.19	0.17	Aortic root size;	chr7:66193792	chr7:65773620~65802067:+
LUAD	cis	rs5742933	1	rs16831925	ENSG00000253559.1	OSGEPL1-AS1	-3.71	0.000233	0.0281	-0.23	-0.17	Ferritin levels;	chr2:189731178	chr2:189762704~189765556:+
LUAD	cis	rs9532580	0.778	rs34373380	ENSG00000229456.1	RLIMP1	3.71	0.000233	0.0281	0.18	0.17	Mean corpuscular hemoglobin;	chr13:40670080	chr13:40618738~40621348:+
LUAD	cis	rs9532580	0.778	rs61963319	ENSG00000229456.1	RLIMP1	3.71	0.000233	0.0281	0.18	0.17	Mean corpuscular hemoglobin;	chr13:40670083	chr13:40618738~40621348:+
LUAD	cis	rs9549260	0.599	rs12870023	ENSG00000229456.1	RLIMP1	3.71	0.000233	0.0281	0.18	0.17	Red blood cell count;	chr13:40670085	chr13:40618738~40621348:+
LUAD	cis	rs7772486	0.875	rs13204280	ENSG00000235652.6	RP11-545I5.3	3.71	0.000233	0.0281	0.17	0.17	Lobe attachment (rater-scored or self-reported);	chr6:146094232	chr6:145799409~145886585:+
LUAD	cis	rs4879656	0.872	rs10813930	ENSG00000225693.1	LAGE3P1	-3.71	0.000233	0.0281	-0.18	-0.17	Menopause (age at onset);	chr9:33064338	chr9:33019682~33020165:-
LUAD	cis	rs11960314	0.603	rs883849	ENSG00000253348.1	CTC-455F18.1	-3.71	0.000233	0.0281	-0.19	-0.17	Age-related hearing impairment (SNP x SNP interaction);	chr5:170644098	chr5:170747047~170788650:-
LUAD	cis	rs4934494	0.768	rs58163515	ENSG00000240996.1	RP11-80H5.7	-3.71	0.000233	0.0281	-0.23	-0.17	Red blood cell count;	chr10:89637807	chr10:89694295~89697928:-
LUAD	cis	rs4819052	0.684	rs914216	ENSG00000223768.1	LINC00205	-3.71	0.000233	0.0281	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278383	chr21:45293285~45297354:+
LUAD	cis	rs12220238	0.722	rs11001087	ENSG00000233313.2	HMGA1P5	3.71	0.000233	0.0281	0.29	0.17	Soluble interleukin-2 receptor subunit alpha;	chr10:74624844	chr10:75276376~75276646:-
LUAD	cis	rs2179367	0.959	rs579789	ENSG00000216906.2	RP11-350J20.9	3.71	0.000233	0.0281	0.21	0.17	Dupuytren's disease;	chr6:149358235	chr6:149904243~149906418:+
LUAD	cis	rs9467773	0.62	rs2504592	ENSG00000241549.7	GUSBP2	3.71	0.000233	0.0281	0.18	0.17	Intelligence (multi-trait analysis);	chr6:26640723	chr6:26871484~26956554:-
LUAD	cis	rs2154319	0.887	rs213767	ENSG00000235358.1	RP11-399E6.1	3.71	0.000233	0.0281	0.23	0.17	Height;	chr1:41115640	chr1:41242373~41284861:+
LUAD	cis	rs2154319	0.887	rs213766	ENSG00000235358.1	RP11-399E6.1	3.71	0.000233	0.0281	0.23	0.17	Height;	chr1:41116291	chr1:41242373~41284861:+
LUAD	cis	rs2154319	0.636	rs213762	ENSG00000235358.1	RP11-399E6.1	3.71	0.000233	0.0281	0.23	0.17	Height;	chr1:41117938	chr1:41242373~41284861:+
LUAD	cis	rs4819052	0.851	rs1999335	ENSG00000215447.6	BX322557.10	-3.71	0.000233	0.0281	-0.2	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250698	chr21:45288052~45291738:+
LUAD	cis	rs4819052	0.851	rs2838844	ENSG00000215447.6	BX322557.10	-3.71	0.000233	0.0281	-0.2	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250818	chr21:45288052~45291738:+
LUAD	cis	rs4664293	0.833	rs3764969	ENSG00000230783.1	AC009961.2	-3.71	0.000233	0.0281	-0.2	-0.17	Monocyte percentage of white cells;	chr2:159764337	chr2:159689217~159690291:-
LUAD	cis	rs7515577	0.898	rs2025607	ENSG00000223787.2	RP4-593M8.1	3.71	0.000233	0.0281	0.25	0.17	Cholesterol, total;	chr1:92424787	chr1:92580476~92580821:-
LUAD	cis	rs2239620	0.838	rs9370135	ENSG00000216775.2	RP1-152L7.5	-3.71	0.000233	0.0281	-0.18	-0.17	LDL cholesterol levels;	chr6:52589187	chr6:52665148~52669155:+
LUAD	cis	rs683250	0.629	rs12365258	ENSG00000246067.6	RAB30-AS1	-3.71	0.000233	0.0281	-0.18	-0.17	Subcortical brain region volumes;	chr11:83324782	chr11:83072066~83106719:+
LUAD	cis	rs5758511	0.68	rs1107554	ENSG00000233903.2	Z83851.4	3.71	0.000233	0.0281	0.25	0.17	Birth weight;	chr22:42271588	chr22:42276355~42277052:+
LUAD	cis	rs875971	0.545	rs73152714	ENSG00000222364.1	RNU6-96P	-3.71	0.000233	0.0281	-0.21	-0.17	Aortic root size;	chr7:66534641	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.545	rs4718364	ENSG00000222364.1	RNU6-96P	-3.71	0.000233	0.0281	-0.21	-0.17	Aortic root size;	chr7:66536353	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.545	rs6961853	ENSG00000222364.1	RNU6-96P	-3.71	0.000233	0.0281	-0.21	-0.17	Aortic root size;	chr7:66537035	chr7:66395191~66395286:+
LUAD	cis	rs2688608	0.869	rs2633308	ENSG00000271816.1	BMS1P4	3.71	0.000233	0.0281	0.14	0.17	Inflammatory bowel disease;	chr10:73894146	chr10:73699151~73730487:-
LUAD	cis	rs4500972	1	rs4500972	ENSG00000230002.2	ALMS1-IT1	3.71	0.000233	0.0281	0.21	0.17	Glomerular filtration rate (creatinine);	chr2:73540770	chr2:73456764~73459484:+
LUAD	cis	rs10463554	0.892	rs1898673	ENSG00000250682.4	LINC00491	3.71	0.000233	0.0281	0.2	0.17	Parkinson's disease;	chr5:102957676	chr5:102609156~102671559:-
LUAD	cis	rs4763879	0.778	rs1044771	ENSG00000214776.8	RP11-726G1.1	-3.71	0.000233	0.0282	-0.2	-0.17	Type 1 diabetes;	chr12:9699333	chr12:9467552~9576275:+
LUAD	cis	rs1267303	0.682	rs1998545	ENSG00000280836.1	AL355480.1	-3.71	0.000233	0.0282	-0.21	-0.17	Monobrow;	chr1:46488915	chr1:45581219~45581321:-
LUAD	cis	rs11679640	0.544	rs12612692	ENSG00000226491.1	FTOP1	-3.71	0.000233	0.0282	-0.17	-0.17	White matter hyperintensity burden;	chr2:42877948	chr2:42797225~42798712:-
LUAD	cis	rs6496044	0.568	rs6496040	ENSG00000259416.2	RP11-158M2.5	3.71	0.000233	0.0282	0.17	0.17	Interstitial lung disease;	chr15:85520898	chr15:85754941~85756237:-
LUAD	cis	rs5742933	0.948	rs5743063	ENSG00000253559.1	OSGEPL1-AS1	3.71	0.000233	0.0282	0.22	0.17	Ferritin levels;	chr2:189829723	chr2:189762704~189765556:+
LUAD	cis	rs7665090	0.528	rs3774968	ENSG00000246560.2	RP11-10L12.4	3.71	0.000233	0.0282	0.22	0.17	Primary biliary cholangitis;	chr4:102609955	chr4:102828055~102844075:+
LUAD	cis	rs1635	0.655	rs723475	ENSG00000216901.1	AL022393.7	-3.71	0.000234	0.0282	-0.33	-0.17	Schizophrenia;	chr6:28337064	chr6:28176188~28176674:+
LUAD	cis	rs875971	0.545	rs6950988	ENSG00000222364.1	RNU6-96P	-3.71	0.000234	0.0282	-0.21	-0.17	Aortic root size;	chr7:66511428	chr7:66395191~66395286:+
LUAD	cis	rs3845817	0.703	rs1673457	ENSG00000281920.1	RP11-418H16.1	-3.71	0.000234	0.0282	-0.2	-0.17	Bipolar disorder;	chr2:65544511	chr2:65623272~65628424:+
LUAD	cis	rs6479891	1	rs6479899	ENSG00000232075.1	MRPL35P2	-3.71	0.000234	0.0282	-0.27	-0.17	Arthritis (juvenile idiopathic);	chr10:63379287	chr10:63634317~63634827:-
LUAD	cis	rs13113518	1	rs7660980	ENSG00000249700.7	SRD5A3-AS1	-3.71	0.000234	0.0282	-0.17	-0.17	Height;	chr4:55542948	chr4:55363971~55395847:-
LUAD	cis	rs3096299	0.642	rs12934829	ENSG00000261574.1	RP1-168P16.2	3.71	0.000234	0.0282	0.19	0.17	Multiple myeloma (IgH translocation);	chr16:89456941	chr16:89392375~89412564:-
LUAD	cis	rs2239547	0.618	rs2071041	ENSG00000243224.1	RP5-1157M23.2	-3.71	0.000234	0.0282	-0.19	-0.17	Schizophrenia;	chr3:52830677	chr3:52239258~52241097:+
LUAD	cis	rs12291225	0.637	rs8570	ENSG00000251991.1	RNU7-49P	3.71	0.000234	0.0282	0.19	0.17	Sense of smell;	chr11:14279213	chr11:14478892~14478953:+
LUAD	cis	rs7131987	0.621	rs6487805	ENSG00000275476.1	RP11-996F15.4	3.71	0.000234	0.0282	0.19	0.17	QT interval;	chr12:29304617	chr12:29277397~29277882:-
LUAD	cis	rs7918232	0.83	rs10764672	ENSG00000262412.1	RP11-85G18.6	-3.71	0.000234	0.0282	-0.24	-0.17	Breast cancer;	chr10:27103612	chr10:27243130~27250804:+
LUAD	cis	rs481331	0.866	rs210222	ENSG00000185904.10	LINC00839	3.71	0.000234	0.0282	0.28	0.17	Systemic juvenile idiopathic arthritis;	chr10:42561628	chr10:42475543~42495336:+
LUAD	cis	rs449789	0.524	rs4345420	ENSG00000235086.1	FNDC1-IT1	-3.71	0.000234	0.0282	-0.23	-0.17	Pulse pressure;	chr6:159324005	chr6:159240786~159243329:+
LUAD	cis	rs9860428	0.844	rs9829184	ENSG00000242770.2	RP11-180K7.1	3.71	0.000234	0.0282	0.18	0.17	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112853837	chr3:112802478~112812819:+
LUAD	cis	rs877819	0.583	rs2620887	ENSG00000228403.1	RP11-563N6.6	-3.71	0.000234	0.0282	-0.17	-0.17	Systemic lupus erythematosus;	chr10:48852457	chr10:48878022~48878649:+
LUAD	cis	rs7107174	1	rs10899468	ENSG00000251323.2	RP11-452H21.4	3.71	0.000234	0.0282	0.23	0.17	Testicular germ cell tumor;	chr11:78305604	chr11:78423982~78429836:-
LUAD	cis	rs10463554	0.856	rs26427	ENSG00000250682.4	LINC00491	-3.71	0.000234	0.0282	-0.19	-0.17	Parkinson's disease;	chr5:103031079	chr5:102609156~102671559:-
LUAD	cis	rs7005380	0.62	rs10094455	ENSG00000279347.1	RP11-85I17.2	-3.71	0.000234	0.0282	-0.14	-0.17	Interstitial lung disease;	chr8:119892436	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.62	rs10094458	ENSG00000279347.1	RP11-85I17.2	-3.71	0.000234	0.0282	-0.14	-0.17	Interstitial lung disease;	chr8:119892448	chr8:119838736~119840385:-
LUAD	cis	rs8040855	0.576	rs62022527	ENSG00000259774.1	RP11-182J1.13	3.71	0.000234	0.0282	0.22	0.17	Bulimia nervosa;	chr15:84988022	chr15:84422618~84425882:+
LUAD	cis	rs7819412	0.522	rs13276708	ENSG00000255046.1	RP11-297N6.4	3.71	0.000234	0.0282	0.21	0.17	Triglycerides;	chr8:11131696	chr8:11797928~11802568:-
LUAD	cis	rs7819412	0.522	rs13266785	ENSG00000255046.1	RP11-297N6.4	3.71	0.000234	0.0282	0.21	0.17	Triglycerides;	chr8:11132011	chr8:11797928~11802568:-
LUAD	cis	rs17767294	0.708	rs9380018	ENSG00000280107.1	AL022393.9	-3.71	0.000234	0.0282	-0.44	-0.17	Parkinson's disease;	chr6:27772867	chr6:28170845~28172521:+
LUAD	cis	rs1023500	0.573	rs133370	ENSG00000273366.1	CTA-989H11.1	-3.71	0.000234	0.0282	-0.2	-0.17	Schizophrenia;	chr22:42069256	chr22:42278188~42278846:+
LUAD	cis	rs2179367	0.887	rs6570965	ENSG00000216906.2	RP11-350J20.9	3.71	0.000234	0.0282	0.2	0.17	Dupuytren's disease;	chr6:149396340	chr6:149904243~149906418:+
LUAD	cis	rs2836974	0.899	rs34978594	ENSG00000232608.1	TIMM9P2	-3.71	0.000234	0.0282	-0.2	-0.17	Cognitive function;	chr21:39208077	chr21:39216624~39217506:+
LUAD	cis	rs2836974	0.932	rs6517526	ENSG00000232608.1	TIMM9P2	-3.71	0.000234	0.0282	-0.2	-0.17	Cognitive function;	chr21:39209604	chr21:39216624~39217506:+
LUAD	cis	rs2836974	0.932	rs6517527	ENSG00000232608.1	TIMM9P2	-3.71	0.000234	0.0282	-0.2	-0.17	Cognitive function;	chr21:39209825	chr21:39216624~39217506:+
LUAD	cis	rs595244	1	rs2456475	ENSG00000259705.1	RP11-227D13.1	3.71	0.000234	0.0282	0.33	0.17	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48593680	chr15:48645951~48652016:+
LUAD	cis	rs6661961	0.65	rs726865	ENSG00000237975.5	FLG-AS1	-3.71	0.000234	0.0282	-0.22	-0.17	Atopic dermatitis;	chr1:152427579	chr1:152168125~152445456:+
LUAD	cis	rs4474465	0.85	rs10899549	ENSG00000251323.2	RP11-452H21.4	-3.71	0.000234	0.0282	-0.2	-0.17	Alzheimer's disease (survival time);	chr11:78544343	chr11:78423982~78429836:-
LUAD	cis	rs4718428	0.705	rs12536410	ENSG00000230295.1	RP11-458F8.2	-3.71	0.000234	0.0282	-0.15	-0.17	Corneal structure;	chr7:66789303	chr7:66880708~66882981:+
LUAD	cis	rs2638953	0.85	rs11049402	ENSG00000278733.1	RP11-425D17.1	-3.71	0.000234	0.0282	-0.2	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28175974	chr12:28185625~28186190:-
LUAD	cis	rs2411233	0.967	rs11856829	ENSG00000259278.1	RP11-62C7.2	3.71	0.000234	0.0282	0.25	0.17	Platelet count;	chr15:38985580	chr15:39019233~39024918:+
LUAD	cis	rs9928842	0.771	rs2870471	ENSG00000261476.1	RP11-77K12.3	3.71	0.000234	0.0282	0.2	0.17	Alcoholic chronic pancreatitis;	chr16:75240384	chr16:75458252~75460017:-
LUAD	cis	rs2253762	0.54	rs11200313	ENSG00000276742.1	RP11-500G22.4	3.71	0.000234	0.0282	0.25	0.17	Breast cancer;	chr10:121996523	chr10:121956782~121957098:+
LUAD	cis	rs957448	0.554	rs12540967	ENSG00000253175.1	RP11-267M23.6	3.71	0.000234	0.0282	0.19	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94576862	chr8:94565036~94565715:+
LUAD	cis	rs8067545	0.641	rs4925060	ENSG00000270091.1	RP11-78O7.2	-3.71	0.000234	0.0282	-0.14	-0.17	Schizophrenia;	chr17:19959945	chr17:19896590~19897287:-
LUAD	cis	rs8180040	0.966	rs7651762	ENSG00000271161.1	BOLA2P2	-3.71	0.000234	0.0282	-0.16	-0.17	Colorectal cancer;	chr3:47428994	chr3:47499841~47500407:+
LUAD	cis	rs4561483	0.583	rs11647580	ENSG00000261216.1	RP11-166B2.5	3.71	0.000234	0.0282	0.17	0.17	Testicular germ cell tumor;	chr16:11863752	chr16:11908208~11908916:+
LUAD	cis	rs8054556	0.967	rs12918652	ENSG00000214725.6	CDIPT-AS1	-3.71	0.000234	0.0282	-0.19	-0.17	Autism spectrum disorder or schizophrenia;	chr16:29953036	chr16:29863593~29868053:+
LUAD	cis	rs7512552	0.809	rs9436108	ENSG00000275557.1	RP11-353N4.6	3.71	0.000234	0.0282	0.19	0.17	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150388454	chr1:149607765~149612402:+
LUAD	cis	rs7512552	0.839	rs834236	ENSG00000275557.1	RP11-353N4.6	3.71	0.000234	0.0282	0.19	0.17	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150390492	chr1:149607765~149612402:+
LUAD	cis	rs6460942	0.908	rs77034890	ENSG00000226690.5	AC005281.1	3.71	0.000234	0.0282	0.32	0.17	Coronary artery disease;	chr7:12204880	chr7:12496429~12541910:+
LUAD	cis	rs755249	0.565	rs7539261	ENSG00000182109.6	RP11-69E11.4	-3.71	0.000234	0.0282	-0.18	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39584831	chr1:39522280~39546187:-
LUAD	cis	rs9309711	0.772	rs9309715	ENSG00000271868.1	RP11-1293J14.1	3.71	0.000234	0.0282	0.2	0.17	Neurofibrillary tangles;	chr2:3488547	chr2:3496956~3497428:+
LUAD	cis	rs875971	0.522	rs7784623	ENSG00000273142.1	RP11-458F8.4	-3.71	0.000234	0.0283	-0.11	-0.17	Aortic root size;	chr7:65930047	chr7:66902857~66906297:+
LUAD	cis	rs875971	0.522	rs34973832	ENSG00000273142.1	RP11-458F8.4	-3.71	0.000234	0.0283	-0.11	-0.17	Aortic root size;	chr7:65931217	chr7:66902857~66906297:+
LUAD	cis	rs858239	0.6	rs28483572	ENSG00000226816.2	AC005082.12	3.71	0.000234	0.0283	0.22	0.17	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23206013~23208045:+
LUAD	cis	rs9921338	0.961	rs7187870	ENSG00000263080.1	RP11-485G7.5	3.71	0.000234	0.0283	0.23	0.17	Vein graft stenosis in coronary artery bypass grafting;	chr16:11338062	chr16:11341809~11345211:-
LUAD	cis	rs7017914	0.644	rs55970604	ENSG00000246366.5	RP11-382J12.1	3.71	0.000234	0.0283	0.16	0.17	Bone mineral density;	chr8:71065538	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.644	rs6472564	ENSG00000246366.5	RP11-382J12.1	3.71	0.000234	0.0283	0.16	0.17	Bone mineral density;	chr8:71066165	chr8:70608577~70663279:+
LUAD	cis	rs4819052	0.851	rs9974628	ENSG00000215447.6	BX322557.10	-3.71	0.000234	0.0283	-0.2	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252732	chr21:45288052~45291738:+
LUAD	cis	rs9309473	1	rs11899740	ENSG00000230002.2	ALMS1-IT1	3.71	0.000234	0.0283	0.21	0.17	Metabolite levels;	chr2:73404084	chr2:73456764~73459484:+
LUAD	cis	rs11064837	0.504	rs7972445	ENSG00000248636.5	RP11-768F21.1	3.71	0.000234	0.0283	0.19	0.17	Schizophrenia;	chr12:119617604	chr12:119387987~119668079:-
LUAD	cis	rs9308731	0.591	rs6732491	ENSG00000227992.1	AC108463.2	-3.71	0.000235	0.0283	-0.2	-0.17	Chronic lymphocytic leukemia;	chr2:111181143	chr2:111203964~111206215:-
LUAD	cis	rs67478160	0.619	rs2368560	ENSG00000272533.1	SNORA28	3.71	0.000235	0.0283	0.17	0.17	Schizophrenia;	chr14:103806974	chr14:103337849~103337974:+
LUAD	cis	rs854765	0.547	rs4459604	ENSG00000223979.2	SMCR2	-3.71	0.000235	0.0283	-0.2	-0.17	Total body bone mineral density;	chr17:17985235	chr17:17674026~17677688:-
LUAD	cis	rs9925964	1	rs9925964	ENSG00000232748.3	RP11-196G11.6	3.71	0.000235	0.0283	0.21	0.17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31118574	chr16:31056460~31062803:+
LUAD	cis	rs8062405	0.698	rs7188071	ENSG00000261766.1	RP11-22P6.2	3.71	0.000235	0.0283	0.15	0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28906323	chr16:28862166~28863340:-
LUAD	cis	rs7829975	0.606	rs10112585	ENSG00000253981.4	ALG1L13P	-3.71	0.000235	0.0283	-0.19	-0.17	Mood instability;	chr8:8937520	chr8:8236003~8244667:-
LUAD	cis	rs8058578	1	rs8048448	ENSG00000232748.3	RP11-196G11.6	-3.71	0.000235	0.0283	-0.21	-0.17	Multiple myeloma;	chr16:30680887	chr16:31056460~31062803:+
LUAD	cis	rs10859871	0.536	rs10777684	ENSG00000216306.3	KRT19P2	3.71	0.000235	0.0283	0.22	0.17	Endometriosis;	chr12:95315539	chr12:94834147~94835158:+
LUAD	cis	rs12549025	0.516	rs13257250	ENSG00000253390.1	CTC-756D1.2	-3.71	0.000235	0.0283	-0.25	-0.17	Reticulocyte fraction of red cells;	chr8:23485446	chr8:23458601~23484971:+
LUAD	cis	rs11893307	0.566	rs62179714	ENSG00000235852.1	AC005540.3	3.71	0.000235	0.0283	0.21	0.17	Mean platelet volume;	chr2:190702815	chr2:190880797~190882059:-
LUAD	cis	rs9900280	0.967	rs9909204	ENSG00000264808.1	RP11-802D6.1	3.71	0.000235	0.0283	0.2	0.17	Mean platelet volume;	chr17:29356153	chr17:29369717~29390777:-
LUAD	cis	rs8028182	0.636	rs7495610	ENSG00000246877.1	DNM1P35	3.71	0.000235	0.0283	0.22	0.17	Sudden cardiac arrest;	chr15:75492100	chr15:75727670~75738623:-
LUAD	cis	rs8002861	0.935	rs7320988	ENSG00000274001.1	RP11-5G9.5	3.71	0.000235	0.0283	0.18	0.17	Leprosy;	chr13:43839387	chr13:43877715~43878163:-
LUAD	cis	rs7976269	0.609	rs2349574	ENSG00000257176.2	RP11-996F15.2	-3.71	0.000235	0.0283	-0.18	-0.17	Male-pattern baldness;	chr12:29053805	chr12:29280418~29317848:-
LUAD	cis	rs7772486	0.624	rs6930154	ENSG00000235652.6	RP11-545I5.3	-3.71	0.000235	0.0283	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145704526	chr6:145799409~145886585:+
LUAD	cis	rs116095464	1	rs6873902	ENSG00000277812.1	AC021087.1	3.71	0.000235	0.0283	0.36	0.17	Breast cancer;	chr5:313222	chr5:262769~262881:+
LUAD	cis	rs944289	0.502	rs1958612	ENSG00000257826.1	RP11-116N8.4	-3.71	0.000235	0.0283	-0.18	-0.17	Thyroid cancer;	chr14:36204669	chr14:36061026~36067190:-
LUAD	cis	rs4841134	0.625	rs12235038	ENSG00000270966.1	RP11-62H7.3	-3.71	0.000235	0.0283	-0.18	-0.17	Age-related disease endophenotypes;	chr8:9379893	chr8:8933721~8934006:-
LUAD	cis	rs858239	0.899	rs1881203	ENSG00000226816.2	AC005082.12	3.71	0.000235	0.0283	0.22	0.17	Cerebrospinal fluid biomarker levels;	chr7:23253189	chr7:23206013~23208045:+
LUAD	cis	rs507080	0.697	rs653008	ENSG00000278376.1	RP11-158I9.8	-3.71	0.000235	0.0283	-0.18	-0.17	Serum metabolite levels;	chr11:118649775	chr11:118791254~118793137:+
LUAD	cis	rs1476587	0.573	rs6944949	ENSG00000224046.1	AC005076.5	3.71	0.000235	0.0283	0.21	0.17	Brachial circumference;	chr7:87077430	chr7:87151423~87152420:-
LUAD	cis	rs1476587	0.573	rs60760249	ENSG00000224046.1	AC005076.5	3.71	0.000235	0.0283	0.21	0.17	Brachial circumference;	chr7:87077664	chr7:87151423~87152420:-
LUAD	cis	rs1476587	0.573	rs61458956	ENSG00000224046.1	AC005076.5	3.71	0.000235	0.0283	0.21	0.17	Brachial circumference;	chr7:87077733	chr7:87151423~87152420:-
LUAD	cis	rs1476587	0.573	rs58105963	ENSG00000224046.1	AC005076.5	3.71	0.000235	0.0283	0.21	0.17	Brachial circumference;	chr7:87077743	chr7:87151423~87152420:-
LUAD	cis	rs1476587	0.607	rs35116955	ENSG00000224046.1	AC005076.5	3.71	0.000235	0.0283	0.21	0.17	Brachial circumference;	chr7:87078900	chr7:87151423~87152420:-
LUAD	cis	rs1476587	0.541	rs36035378	ENSG00000224046.1	AC005076.5	3.71	0.000235	0.0283	0.21	0.17	Brachial circumference;	chr7:87081144	chr7:87151423~87152420:-
LUAD	cis	rs13113518	0.557	rs13142096	ENSG00000272969.1	RP11-528I4.2	3.71	0.000235	0.0283	0.19	0.17	Height;	chr4:55566291	chr4:55547112~55547889:+
LUAD	cis	rs6496932	1	rs35156762	ENSG00000259630.2	CTD-2262B20.1	3.71	0.000235	0.0283	0.23	0.17	Central corneal thickness;Corneal structure;	chr15:85281243	chr15:85415228~85415633:+
LUAD	cis	rs8114671	0.967	rs6060285	ENSG00000269202.1	RP4-614O4.12	-3.71	0.000235	0.0283	-0.16	-0.17	Height;	chr20:35182684	chr20:35201747~35203288:-
LUAD	cis	rs8114671	0.967	rs2378337	ENSG00000269202.1	RP4-614O4.12	-3.71	0.000235	0.0283	-0.16	-0.17	Height;	chr20:35183632	chr20:35201747~35203288:-
LUAD	cis	rs7005380	0.62	rs13260088	ENSG00000279347.1	RP11-85I17.2	-3.71	0.000235	0.0283	-0.14	-0.17	Interstitial lung disease;	chr8:119886525	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.6	rs10955940	ENSG00000279347.1	RP11-85I17.2	-3.71	0.000235	0.0283	-0.14	-0.17	Interstitial lung disease;	chr8:119890246	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.62	rs10103058	ENSG00000279347.1	RP11-85I17.2	-3.71	0.000235	0.0283	-0.14	-0.17	Interstitial lung disease;	chr8:119890830	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.62	rs10955941	ENSG00000279347.1	RP11-85I17.2	-3.71	0.000235	0.0283	-0.14	-0.17	Interstitial lung disease;	chr8:119891271	chr8:119838736~119840385:-
LUAD	cis	rs7605235	0.874	rs34648410	ENSG00000224165.4	DNAJC27-AS1	3.71	0.000235	0.0283	0.2	0.17	Response to platinum-based chemotherapy (cisplatin);	chr2:25427762	chr2:24971390~25039694:+
LUAD	cis	rs5015933	0.788	rs430184	ENSG00000232630.1	PRPS1P2	-3.71	0.000235	0.0283	-0.16	-0.17	Body mass index;	chr9:125340911	chr9:125150653~125151589:+
LUAD	cis	rs4948102	0.667	rs7811270	ENSG00000226278.1	PSPHP1	-3.71	0.000235	0.0283	-0.2	-0.17	Plasma homocysteine levels (post-methionine load test);	chr7:56072297	chr7:55764797~55773288:+
LUAD	cis	rs4787951	0.56	rs2382720	ENSG00000259940.2	CTD-3203P2.1	-3.71	0.000235	0.0283	-0.18	-0.17	Eosinophil percentage of white cells;	chr16:27338691	chr16:27213308~27214993:-
LUAD	cis	rs1023500	0.596	rs5758562	ENSG00000273366.1	CTA-989H11.1	-3.71	0.000235	0.0283	-0.2	-0.17	Schizophrenia;	chr22:42052234	chr22:42278188~42278846:+
LUAD	cis	rs42490	0.625	rs43229	ENSG00000251136.7	RP11-37B2.1	-3.71	0.000235	0.0283	-0.18	-0.17	Leprosy;	chr8:89826558	chr8:89609409~89757727:-
LUAD	cis	rs412050	0.501	rs78329092	ENSG00000224086.5	LL22NC03-86G7.1	-3.71	0.000235	0.0283	-0.21	-0.17	Attention deficit hyperactivity disorder;	chr22:21771914	chr22:21938293~21977632:+
LUAD	cis	rs9889262	0.625	rs4794031	ENSG00000248714.5	RP11-1079K10.3	3.71	0.000235	0.0283	0.17	0.17	Eosinophil percentage of granulocytes;Allergic disease (asthma, hay fever or eczema);Eosinophil counts;	chr17:49264791	chr17:49361165~49369998:+
LUAD	cis	rs7246657	0.943	rs7248733	ENSG00000226686.6	LINC01535	-3.71	0.000235	0.0283	-0.24	-0.17	Coronary artery calcification;	chr19:37505459	chr19:37251912~37265535:+
LUAD	cis	rs3120667	0.72	rs72698974	ENSG00000237975.5	FLG-AS1	3.71	0.000235	0.0283	0.3	0.17	Eating disorders;	chr1:152456371	chr1:152168125~152445456:+
LUAD	cis	rs71636778	0.722	rs17162315	ENSG00000260063.1	RP5-968P14.2	-3.71	0.000235	0.0284	-0.22	-0.17	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26849940	chr1:26692132~26694131:-
LUAD	cis	rs763121	0.853	rs5750669	ENSG00000225450.1	RP3-508I15.14	-3.71	0.000235	0.0284	-0.17	-0.17	Menopause (age at onset);	chr22:38684633	chr22:38739003~38749041:+
LUAD	cis	rs8028182	0.636	rs62027181	ENSG00000246877.1	DNM1P35	3.71	0.000235	0.0284	0.21	0.17	Sudden cardiac arrest;	chr15:75547611	chr15:75727670~75738623:-
LUAD	cis	rs6453278	0.559	rs13168613	ENSG00000250802.5	ZBED3-AS1	-3.71	0.000235	0.0284	-0.21	-0.17	Autism;	chr5:77098757	chr5:77086740~77166909:+
LUAD	cis	rs13113518	1	rs13133579	ENSG00000273257.1	RP11-177J6.1	3.71	0.000236	0.0284	0.18	0.17	Height;	chr4:55459921	chr4:55387949~55388271:+
LUAD	cis	rs10752881	1	rs10737237	ENSG00000224468.3	RP11-181K3.4	-3.71	0.000236	0.0284	-0.15	-0.17	Colorectal cancer;	chr1:183020134	chr1:183138402~183141282:-
LUAD	cis	rs10752881	1	rs10797813	ENSG00000224468.3	RP11-181K3.4	-3.71	0.000236	0.0284	-0.15	-0.17	Colorectal cancer;	chr1:183020231	chr1:183138402~183141282:-
LUAD	cis	rs10752881	0.905	rs12132262	ENSG00000224468.3	RP11-181K3.4	-3.71	0.000236	0.0284	-0.15	-0.17	Colorectal cancer;	chr1:183020814	chr1:183138402~183141282:-
LUAD	cis	rs10752881	1	rs10752887	ENSG00000224468.3	RP11-181K3.4	-3.71	0.000236	0.0284	-0.15	-0.17	Colorectal cancer;	chr1:183021699	chr1:183138402~183141282:-
LUAD	cis	rs10752881	0.967	rs6695746	ENSG00000224468.3	RP11-181K3.4	-3.71	0.000236	0.0284	-0.15	-0.17	Colorectal cancer;	chr1:183022220	chr1:183138402~183141282:-
LUAD	cis	rs10752881	0.967	rs6695837	ENSG00000224468.3	RP11-181K3.4	-3.71	0.000236	0.0284	-0.15	-0.17	Colorectal cancer;	chr1:183022327	chr1:183138402~183141282:-
LUAD	cis	rs6754311	0.55	rs3213889	ENSG00000226806.1	AC011893.3	-3.71	0.000236	0.0284	-0.21	-0.17	Mosquito bite size;	chr2:135754005	chr2:135820191~135823087:+
LUAD	cis	rs12935418	0.616	rs9921448	ENSG00000261061.1	RP11-303E16.2	-3.71	0.000236	0.0284	-0.18	-0.17	Mean corpuscular volume;	chr16:80975593	chr16:81030770~81031485:+
LUAD	cis	rs9341808	0.527	rs2505946	ENSG00000260645.1	RP11-250B2.5	3.71	0.000236	0.0284	0.16	0.17	Sitting height ratio;	chr6:80100966	chr6:80466958~80469080:+
LUAD	cis	rs10129255	0.957	rs10132367	ENSG00000211947.2	IGHV3-21	-3.71	0.000236	0.0284	-0.11	-0.17	Kawasaki disease;	chr14:106690981	chr14:106235064~106235594:-
LUAD	cis	rs11638352	1	rs12324261	ENSG00000205771.5	CATSPER2P1	3.71	0.000236	0.0284	0.4	0.17	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44026273	chr15:43726918~43747094:-
LUAD	cis	rs2733201	1	rs8036541	ENSG00000205771.5	CATSPER2P1	3.71	0.000236	0.0284	0.4	0.17	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44027179	chr15:43726918~43747094:-
LUAD	cis	rs8028182	0.725	rs74422833	ENSG00000246877.1	DNM1P35	3.71	0.000236	0.0284	0.27	0.17	Sudden cardiac arrest;	chr15:75579180	chr15:75727670~75738623:-
LUAD	cis	rs2016266	0.502	rs7398676	ENSG00000257605.2	RP11-680A11.5	-3.71	0.000236	0.0284	-0.15	-0.17	Bone mineral density;Bone mineral density (spine);	chr12:53236774	chr12:53298655~53300314:-
LUAD	cis	rs9366999	0.809	rs1651108	ENSG00000235033.6	RP11-61I13.3	-3.71	0.000236	0.0284	-0.18	-0.17	Obesity-related traits;	chr6:39250742	chr6:39881804~39900071:-
LUAD	cis	rs2440129	0.611	rs1042356	ENSG00000262089.1	RP11-589P10.5	3.71	0.000236	0.0284	0.17	0.17	Tonsillectomy;	chr17:6999424	chr17:6994642~6995189:-
LUAD	cis	rs6472827	0.645	rs7009750	ENSG00000253983.2	RP1-16A9.1	3.71	0.000236	0.0284	0.24	0.17	Uterine fibroids;	chr8:74199894	chr8:74199396~74208441:+
LUAD	cis	rs875971	0.638	rs801205	ENSG00000222364.1	RNU6-96P	3.71	0.000236	0.0284	0.18	0.17	Aortic root size;	chr7:66557157	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.617	rs810400	ENSG00000222364.1	RNU6-96P	3.71	0.000236	0.0284	0.18	0.17	Aortic root size;	chr7:66557902	chr7:66395191~66395286:+
LUAD	cis	rs2239547	0.562	rs35380116	ENSG00000243224.1	RP5-1157M23.2	3.71	0.000236	0.0284	0.18	0.17	Schizophrenia;	chr3:52945162	chr3:52239258~52241097:+
LUAD	cis	rs950027	0.549	rs9920634	ENSG00000259479.5	SORD2P	-3.71	0.000236	0.0284	-0.21	-0.17	Response to fenofibrate (adiponectin levels);	chr15:45304348	chr15:44826371~44884694:-
LUAD	cis	rs792448	0.545	rs6679796	ENSG00000229983.1	RP11-15I11.2	3.71	0.000236	0.0284	0.21	0.17	White blood cell count (basophil);	chr1:212229182	chr1:212168207~212190259:+
LUAD	cis	rs4908769	0.624	rs301791	ENSG00000232912.4	RP5-1115A15.1	-3.71	0.000236	0.0284	-0.16	-0.17	Allergy;	chr1:8408312	chr1:8424645~8434838:+
LUAD	cis	rs7200543	0.884	rs72789542	ENSG00000260735.1	RP11-72I8.1	-3.71	0.000236	0.0284	-0.19	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15033678	chr16:15094411~15109197:+
LUAD	cis	rs11089937	0.597	rs4145535	ENSG00000211640.3	IGLV6-57	3.7	0.000236	0.0284	0.13	0.17	Periodontitis (PAL4Q3);	chr22:22143981	chr22:22195713~22196460:+
LUAD	cis	rs34929064	1	rs35610974	ENSG00000230658.1	KLHL7-AS1	3.7	0.000236	0.0284	0.22	0.17	Major depression and alcohol dependence;	chr7:22684341	chr7:23101228~23105703:-
LUAD	cis	rs4795519	0.778	rs11654544	ENSG00000266313.1	RP11-173M1.4	3.7	0.000236	0.0284	0.21	0.17	Chronic myeloid leukemia;	chr17:27138742	chr17:27333256~27348491:+
LUAD	cis	rs6964587	0.621	rs38799	ENSG00000188693.7	CYP51A1-AS1	3.7	0.000236	0.0284	0.19	0.17	Breast cancer;	chr7:92415825	chr7:92134604~92180725:+
LUAD	cis	rs6921919	0.525	rs1361386	ENSG00000219392.1	RP1-265C24.5	-3.7	0.000236	0.0284	-0.21	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28337827	chr6:28115628~28116551:+
LUAD	cis	rs6921919	0.638	rs6456815	ENSG00000219392.1	RP1-265C24.5	-3.7	0.000236	0.0284	-0.21	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28338360	chr6:28115628~28116551:+
LUAD	cis	rs453301	0.686	rs7017868	ENSG00000233609.3	RP11-62H7.2	-3.7	0.000236	0.0284	-0.14	-0.17	Joint mobility (Beighton score);	chr8:9015783	chr8:8961200~8979025:+
LUAD	cis	rs453301	0.686	rs3895823	ENSG00000233609.3	RP11-62H7.2	-3.7	0.000236	0.0284	-0.14	-0.17	Joint mobility (Beighton score);	chr8:9016136	chr8:8961200~8979025:+
LUAD	cis	rs2749097	0.609	rs1911109	ENSG00000244256.3	RN7SL130P	-3.7	0.000236	0.0284	-0.22	-0.17	Alcohol consumption (transferrin glycosylation);	chr1:63648989	chr1:63655743~63656047:+
LUAD	cis	rs6438234	0.778	rs9289012	ENSG00000242767.1	ZBTB20-AS4	3.7	0.000236	0.0284	0.21	0.17	Type 2 diabetes;	chr3:115228357	chr3:115100423~115103061:+
LUAD	cis	rs1823913	0.599	rs13035132	ENSG00000230611.1	HMGB1P27	-3.7	0.000236	0.0284	-0.19	-0.17	Obesity-related traits;	chr2:191265275	chr2:191174233~191174835:+
LUAD	cis	rs6502050	0.835	rs9891962	ENSG00000266654.1	RP11-1376P16.1	-3.7	0.000236	0.0284	-0.18	-0.17	Life satisfaction;	chr17:82195718	chr17:82160056~82160452:+
LUAD	cis	rs897200	0.689	rs1031509	ENSG00000280083.1	RP11-317J9.1	3.7	0.000236	0.0284	0.23	0.17	Behcet's disease;	chr2:191145463	chr2:191154118~191156070:-
LUAD	cis	rs7246657	0.943	rs2303131	ENSG00000226686.6	LINC01535	-3.7	0.000236	0.0284	-0.25	-0.17	Coronary artery calcification;	chr19:37445123	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.882	rs10422667	ENSG00000226686.6	LINC01535	-3.7	0.000236	0.0284	-0.25	-0.17	Coronary artery calcification;	chr19:37446974	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.943	rs1015848	ENSG00000226686.6	LINC01535	-3.7	0.000236	0.0284	-0.25	-0.17	Coronary artery calcification;	chr19:37454372	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.943	rs4801759	ENSG00000226686.6	LINC01535	-3.7	0.000236	0.0284	-0.25	-0.17	Coronary artery calcification;	chr19:37464083	chr19:37251912~37265535:+
LUAD	cis	rs858239	0.6	rs7799422	ENSG00000226816.2	AC005082.12	3.7	0.000236	0.0284	0.22	0.17	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23206013~23208045:+
LUAD	cis	rs858239	0.6	rs2014768	ENSG00000226816.2	AC005082.12	3.7	0.000236	0.0284	0.22	0.17	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23206013~23208045:+
LUAD	cis	rs858239	0.6	rs6978827	ENSG00000226816.2	AC005082.12	3.7	0.000236	0.0284	0.22	0.17	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23206013~23208045:+
LUAD	cis	rs858239	0.6	rs7790157	ENSG00000226816.2	AC005082.12	3.7	0.000236	0.0284	0.22	0.17	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23206013~23208045:+
LUAD	cis	rs7824557	0.564	rs11781637	ENSG00000255046.1	RP11-297N6.4	3.7	0.000236	0.0284	0.21	0.17	Retinal vascular caliber;	chr8:11357463	chr8:11797928~11802568:-
LUAD	cis	rs8014204	0.819	rs2003490	ENSG00000279594.1	RP11-950C14.10	3.7	0.000236	0.0285	0.2	0.17	Caffeine consumption;	chr14:74910852	chr14:75011269~75012851:-
LUAD	cis	rs7772486	0.659	rs9376957	ENSG00000235652.6	RP11-545I5.3	-3.7	0.000237	0.0285	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145689928	chr6:145799409~145886585:+
LUAD	cis	rs11779988	0.629	rs11780813	ENSG00000253671.1	RP11-806O11.1	-3.7	0.000237	0.0285	-0.19	-0.17	Breast cancer;	chr8:17998505	chr8:17808941~17820868:+
LUAD	cis	rs1044826	1	rs13060697	ENSG00000214280.3	RP11-553K23.2	-3.7	0.000237	0.0285	-0.2	-0.17	Obesity-related traits;	chr3:139382935	chr3:139582928~139583593:-
LUAD	cis	rs9309711	0.922	rs13385119	ENSG00000271868.1	RP11-1293J14.1	-3.7	0.000237	0.0285	-0.2	-0.17	Neurofibrillary tangles;	chr2:3480750	chr2:3496956~3497428:+
LUAD	cis	rs9595908	0.746	rs9596076	ENSG00000281026.1	N4BP2L2-IT2	-3.7	0.000237	0.0285	-0.1	-0.17	Body mass index;	chr13:32693515	chr13:32504506~32509395:-
LUAD	cis	rs3772130	1	rs11719458	ENSG00000243544.3	RN7SL172P	3.7	0.000237	0.0285	0.2	0.17	Cognitive performance;	chr3:121663158	chr3:121653994~121654296:-
LUAD	cis	rs4268898	0.697	rs10445892	ENSG00000223754.1	AC008073.9	-3.7	0.000237	0.0285	-0.2	-0.17	Asthma;	chr2:24184089	chr2:24199839~24201698:-
LUAD	cis	rs4948102	0.642	rs4948104	ENSG00000226278.1	PSPHP1	-3.7	0.000237	0.0285	-0.2	-0.17	Plasma homocysteine levels (post-methionine load test);	chr7:56074826	chr7:55764797~55773288:+
LUAD	cis	rs3002142	0.554	rs17163373	ENSG00000272750.1	RP11-378J18.8	3.7	0.000237	0.0285	0.26	0.17	LDL peak particle diameter (total fat intake interaction);	chr1:222657020	chr1:222658867~222661512:-
LUAD	cis	rs159572	0.829	rs159067	ENSG00000250853.1	RNF138P1	-3.7	0.000237	0.0285	-0.2	-0.17	Post-traumatic stress disorder;	chr5:56228156	chr5:55530156~55530701:-
LUAD	cis	rs10090774	0.664	rs10282830	ENSG00000280303.2	ERICD	-3.7	0.000237	0.0285	-0.18	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140661435	chr8:140636281~140638283:+
LUAD	cis	rs10090774	0.71	rs10283164	ENSG00000280303.2	ERICD	-3.7	0.000237	0.0285	-0.18	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140661530	chr8:140636281~140638283:+
LUAD	cis	rs7945705	0.905	rs7947631	ENSG00000254860.4	TMEM9B-AS1	3.7	0.000237	0.0285	0.19	0.17	Hemoglobin concentration;	chr11:8823362	chr11:8964675~8977527:+
LUAD	cis	rs6472235	0.586	rs17306183	ENSG00000200714.1	Y_RNA	-3.7	0.000237	0.0285	-0.22	-0.17	Plateletcrit;Myopia (pathological);	chr8:65992140	chr8:65592731~65592820:+
LUAD	cis	rs77972916	0.561	rs17406174	ENSG00000234936.1	AC010883.5	3.7	0.000237	0.0285	0.23	0.17	Granulocyte percentage of myeloid white cells;	chr2:43330345	chr2:43229573~43233394:+
LUAD	cis	rs77972916	0.518	rs55877805	ENSG00000234936.1	AC010883.5	3.7	0.000237	0.0285	0.23	0.17	Granulocyte percentage of myeloid white cells;	chr2:43330458	chr2:43229573~43233394:+
LUAD	cis	rs4667682	0.646	rs72625232	ENSG00000228389.1	AC068039.4	-3.7	0.000237	0.0285	-0.28	-0.17	Hippocampal atrophy;Body mass index;	chr2:171277257	chr2:171773482~171775844:+
LUAD	cis	rs6988985	0.728	rs10093618	ENSG00000247317.3	RP11-273G15.2	3.7	0.000237	0.0285	0.19	0.17	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142870798	chr8:142981738~143018437:-
LUAD	cis	rs11649653	0.502	rs4889490	ENSG00000232748.3	RP11-196G11.6	-3.7	0.000237	0.0285	-0.2	-0.17	Triglycerides;	chr16:30811726	chr16:31056460~31062803:+
LUAD	cis	rs6472235	0.681	rs34174890	ENSG00000200714.1	Y_RNA	-3.7	0.000237	0.0285	-0.22	-0.17	Plateletcrit;Myopia (pathological);	chr8:65954892	chr8:65592731~65592820:+
LUAD	cis	rs7727544	0.604	rs2069803	ENSG00000233006.5	AC034220.3	3.7	0.000237	0.0285	0.15	0.17	Blood metabolite levels;	chr5:132064740	chr5:132311285~132369916:-
LUAD	cis	rs2015599	0.549	rs3782508	ENSG00000257176.2	RP11-996F15.2	3.7	0.000237	0.0285	0.17	0.17	Platelet count;Mean platelet volume;	chr12:29298446	chr12:29280418~29317848:-
LUAD	cis	rs2015599	0.516	rs10450679	ENSG00000257176.2	RP11-996F15.2	3.7	0.000237	0.0285	0.17	0.17	Platelet count;Mean platelet volume;	chr12:29298823	chr12:29280418~29317848:-
LUAD	cis	rs1023500	0.573	rs1807494	ENSG00000273366.1	CTA-989H11.1	3.7	0.000237	0.0285	0.2	0.17	Schizophrenia;	chr22:42078134	chr22:42278188~42278846:+
LUAD	cis	rs1023500	0.573	rs8135801	ENSG00000273366.1	CTA-989H11.1	3.7	0.000237	0.0285	0.2	0.17	Schizophrenia;	chr22:42079564	chr22:42278188~42278846:+
LUAD	cis	rs17653445	0.929	rs72789806	ENSG00000151963.4	RP11-775A3.1	3.7	0.000237	0.0285	0.28	0.17	Hirschsprung disease;	chr10:37556177	chr10:37883594~37884109:+
LUAD	cis	rs877356	0.667	rs35114832	ENSG00000250167.1	CTC-321K16.1	-3.7	0.000237	0.0285	-0.3	-0.17	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (dichotomous);	chr5:135821799	chr5:135559577~135634874:+
LUAD	cis	rs11638352	1	rs2412853	ENSG00000205771.5	CATSPER2P1	3.7	0.000237	0.0285	0.39	0.17	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44003059	chr15:43726918~43747094:-
LUAD	cis	rs6661961	0.714	rs11205004	ENSG00000237975.5	FLG-AS1	-3.7	0.000237	0.0285	-0.23	-0.17	Atopic dermatitis;	chr1:152446586	chr1:152168125~152445456:+
LUAD	cis	rs6661961	0.752	rs1885529	ENSG00000237975.5	FLG-AS1	-3.7	0.000237	0.0285	-0.23	-0.17	Atopic dermatitis;	chr1:152448570	chr1:152168125~152445456:+
LUAD	cis	rs6467136	0.56	rs12673058	ENSG00000224138.1	AC000123.4	3.7	0.000237	0.0285	0.16	0.17	Type 2 diabetes;	chr7:127443075	chr7:127350128~127351523:+
LUAD	cis	rs12822507	0.868	rs61915599	ENSG00000275963.1	RP11-180M15.6	-3.7	0.000237	0.0285	-0.19	-0.17	Systemic lupus erythematosus;	chr12:12615475	chr12:12648939~12649713:+
LUAD	cis	rs1910358	0.621	rs6871540	ENSG00000248874.4	C5orf17	-3.7	0.000237	0.0285	-0.23	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr5:23860955	chr5:23951348~24178263:+
LUAD	cis	rs7870753	0.578	rs73654887	ENSG00000188801.9	ZNF322P1	3.7	0.000237	0.0285	0.26	0.17	Height;	chr9:96383995	chr9:97198303~97199511:-
LUAD	cis	rs3772130	1	rs11714406	ENSG00000243544.3	RN7SL172P	3.7	0.000237	0.0285	0.2	0.17	Cognitive performance;	chr3:121653666	chr3:121653994~121654296:-
LUAD	cis	rs11992162	0.551	rs35010200	ENSG00000255046.1	RP11-297N6.4	3.7	0.000237	0.0285	0.21	0.17	Monocyte count;	chr8:11928146	chr8:11797928~11802568:-
LUAD	cis	rs473518	0.891	rs554133	ENSG00000223023.1	Y_RNA	3.7	0.000237	0.0285	0.25	0.17	Migraine - clinic-based;	chr18:22523791	chr18:23024596~23024703:+
LUAD	cis	rs1044826	0.957	rs4544576	ENSG00000214280.3	RP11-553K23.2	-3.7	0.000237	0.0285	-0.2	-0.17	Obesity-related traits;	chr3:139424354	chr3:139582928~139583593:-
LUAD	cis	rs6479901	0.557	rs4746125	ENSG00000232075.1	MRPL35P2	3.7	0.000237	0.0285	0.26	0.17	Intelligence (multi-trait analysis);	chr10:63393125	chr10:63634317~63634827:-
LUAD	cis	rs7605235	1	rs7605235	ENSG00000224165.4	DNAJC27-AS1	3.7	0.000237	0.0285	0.19	0.17	Response to platinum-based chemotherapy (cisplatin);	chr2:25431180	chr2:24971390~25039694:+
LUAD	cis	rs4578769	0.513	rs9953640	ENSG00000266850.1	RP11-370A5.1	3.7	0.000237	0.0285	0.21	0.17	Eosinophil percentage of white cells;	chr18:22947856	chr18:22723491~22907721:-
LUAD	cis	rs7215564	0.908	rs8074870	ENSG00000232083.3	RPL31P7	3.7	0.000237	0.0285	0.27	0.17	Myopia (pathological);	chr17:80710332	chr17:80602549~80602926:-
LUAD	cis	rs9376098	1	rs1320960	ENSG00000232876.1	CTA-212D2.2	-3.7	0.000237	0.0286	-0.2	-0.17	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;	chr6:135177063	chr6:135055033~135060550:+
LUAD	cis	rs1879248	0.519	rs6802529	ENSG00000242808.6	SOX2-OT	-3.7	0.000237	0.0286	-0.18	-0.17	Schizophrenia;	chr3:180879545	chr3:180989770~181836880:+
LUAD	cis	rs238295	0.805	rs6053500	ENSG00000230563.2	RP5-828H9.1	3.7	0.000237	0.0286	0.22	0.17	Occipital cortical area (total cortical area interaction);	chr20:5562037	chr20:5471207~5475182:+
LUAD	cis	rs7955901	0.837	rs10748169	ENSG00000258053.1	CTD-2021H9.3	-3.7	0.000237	0.0286	-0.19	-0.17	Type 2 diabetes;	chr12:71023076	chr12:71047402~71118247:-
LUAD	cis	rs6479901	0.947	rs7083356	ENSG00000232075.1	MRPL35P2	-3.7	0.000237	0.0286	-0.23	-0.17	Intelligence (multi-trait analysis);	chr10:63356028	chr10:63634317~63634827:-
LUAD	cis	rs13113518	1	rs4864546	ENSG00000273257.1	RP11-177J6.1	3.7	0.000237	0.0286	0.18	0.17	Height;	chr4:55537960	chr4:55387949~55388271:+
LUAD	cis	rs3741404	0.574	rs638227	ENSG00000256789.1	RP11-697H9.2	-3.7	0.000237	0.0286	-0.18	-0.17	Platelet count;	chr11:64104077	chr11:63637677~63658962:+
LUAD	cis	rs3741404	0.609	rs592271	ENSG00000256789.1	RP11-697H9.2	-3.7	0.000237	0.0286	-0.18	-0.17	Platelet count;	chr11:64104557	chr11:63637677~63658962:+
LUAD	cis	rs3741404	0.609	rs635139	ENSG00000256789.1	RP11-697H9.2	-3.7	0.000237	0.0286	-0.18	-0.17	Platelet count;	chr11:64104738	chr11:63637677~63658962:+
LUAD	cis	rs10463554	0.963	rs26817	ENSG00000250682.4	LINC00491	-3.7	0.000238	0.0286	-0.2	-0.17	Parkinson's disease;	chr5:103204665	chr5:102609156~102671559:-
LUAD	cis	rs12681366	0.801	rs1372048	ENSG00000254057.1	RP3-388N13.3	3.7	0.000238	0.0286	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94455013	chr8:93834454~93846743:-
LUAD	cis	rs6691170	0.932	rs11579490	ENSG00000228437.4	RP11-400N13.2	3.7	0.000238	0.0286	0.19	0.17	Colorectal cancer;	chr1:221877125	chr1:221966341~221984964:+
LUAD	cis	rs10270805	0.892	rs1921831	ENSG00000272361.2	GS1-166A23.2	3.7	0.000238	0.0286	0.33	0.17	Response to statin therapy;	chr7:16447634	chr7:16593626~16594224:-
LUAD	cis	rs6496044	0.568	rs6496039	ENSG00000259416.2	RP11-158M2.5	3.7	0.000238	0.0286	0.17	0.17	Interstitial lung disease;	chr15:85518732	chr15:85754941~85756237:-
LUAD	cis	rs12935418	0.672	rs2549883	ENSG00000261061.1	RP11-303E16.2	3.7	0.000238	0.0286	0.18	0.17	Mean corpuscular volume;	chr16:81022273	chr16:81030770~81031485:+
LUAD	cis	rs2836974	0.653	rs8130556	ENSG00000232608.1	TIMM9P2	-3.7	0.000238	0.0286	-0.21	-0.17	Cognitive function;	chr21:39144946	chr21:39216624~39217506:+
LUAD	cis	rs116095464	0.558	rs1541822	ENSG00000248925.1	CTD-2083E4.6	-3.7	0.000238	0.0286	-0.29	-0.17	Breast cancer;	chr5:269119	chr5:269858~271516:-
LUAD	cis	rs61160187	0.582	rs7713481	ENSG00000215032.2	GNL3LP1	3.7	0.000238	0.0286	0.2	0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:61093038	chr5:60891935~60893577:-
LUAD	cis	rs61160187	0.582	rs7737276	ENSG00000215032.2	GNL3LP1	3.7	0.000238	0.0286	0.2	0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:61102467	chr5:60891935~60893577:-
LUAD	cis	rs4948102	0.642	rs766333	ENSG00000275875.1	RP11-613E4.5	-3.7	0.000238	0.0286	-0.18	-0.17	Plasma homocysteine levels (post-methionine load test);	chr7:56059011	chr7:55741525~55741869:+
LUAD	cis	rs8060686	0.623	rs2418736	ENSG00000280214.1	CTD-2012K14.5	3.7	0.000238	0.0286	0.16	0.17	HDL cholesterol;Metabolic syndrome;	chr16:68120959	chr16:67550815~67552935:-
LUAD	cis	rs9532669	0.511	rs3783164	ENSG00000229473.2	RGS17P1	-3.7	0.000238	0.0286	-0.21	-0.17	Cervical cancer;	chr13:40806227	chr13:40992779~40993331:-
LUAD	cis	rs7200786	0.647	rs794428	ENSG00000274038.1	RP11-66H6.4	-3.7	0.000238	0.0286	-0.21	-0.17	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11174574	chr16:11056556~11057034:+
LUAD	cis	rs7824557	0.527	rs2572448	ENSG00000255046.1	RP11-297N6.4	3.7	0.000238	0.0286	0.21	0.17	Retinal vascular caliber;	chr8:11381843	chr8:11797928~11802568:-
LUAD	cis	rs7246657	0.943	rs3803895	ENSG00000226686.6	LINC01535	-3.7	0.000238	0.0286	-0.24	-0.17	Coronary artery calcification;	chr19:37407767	chr19:37251912~37265535:+
LUAD	cis	rs6502050	0.835	rs66531647	ENSG00000275966.1	RP11-1055B8.9	-3.7	0.000238	0.0286	-0.17	-0.17	Life satisfaction;	chr17:82131146	chr17:81345476~81345966:-
LUAD	cis	rs506597	0.92	rs221786	ENSG00000281827.1	AC005071.4	3.7	0.000238	0.0286	0.29	0.17	Pursuit maintenance gain in psychotic disorders;	chr7:100668458	chr7:100344375~100344475:-
LUAD	cis	rs8141529	0.778	rs763073	ENSG00000272858.1	CTA-292E10.8	-3.7	0.000238	0.0286	-0.19	-0.17	Lymphocyte counts;	chr22:28819554	chr22:28814914~28815662:+
LUAD	cis	rs9896933	0.778	rs80243549	ENSG00000262663.1	RP11-497H17.1	3.7	0.000238	0.0286	0.2	0.17	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr17:82863609	chr17:82918282~82918785:+
LUAD	cis	rs2117029	0.727	rs10875910	ENSG00000269514.1	RP11-370I10.12	3.7	0.000238	0.0286	0.15	0.17	Intelligence (multi-trait analysis);	chr12:49008610	chr12:48198387~48202031:+
LUAD	cis	rs5742933	0.948	rs6434363	ENSG00000253559.1	OSGEPL1-AS1	-3.7	0.000238	0.0286	-0.23	-0.17	Ferritin levels;	chr2:189707565	chr2:189762704~189765556:+
LUAD	cis	rs7674212	0.57	rs2126470	ENSG00000246560.2	RP11-10L12.4	3.7	0.000238	0.0286	0.21	0.17	Type 2 diabetes;	chr4:103140605	chr4:102828055~102844075:+
LUAD	cis	rs73193808	0.901	rs8131103	ENSG00000215533.7	LINC00189	-3.7	0.000238	0.0286	-0.23	-0.17	Coronary artery disease;	chr21:29193427	chr21:29193480~29288205:+
LUAD	cis	rs214785	0.932	rs214793	ENSG00000234684.5	SDCBP2-AS1	3.7	0.000238	0.0286	0.21	0.17	Basal cell carcinoma;	chr20:2305059	chr20:1325405~1378734:+
LUAD	cis	rs2057178	0.524	rs2900666	ENSG00000183242.10	WT1-AS	3.7	0.000238	0.0286	0.27	0.17	Tuberculosis;	chr11:32282749	chr11:32435518~32458769:+
LUAD	cis	rs2057178	0.524	rs4603277	ENSG00000183242.10	WT1-AS	3.7	0.000238	0.0286	0.27	0.17	Tuberculosis;	chr11:32285780	chr11:32435518~32458769:+
LUAD	cis	rs2153535	0.539	rs4960436	ENSG00000230939.1	RP11-314C16.1	-3.7	0.000238	0.0286	-0.19	-0.17	Motion sickness;	chr6:8532237	chr6:8784178~8785445:+
LUAD	cis	rs16869652	1	rs16869652	ENSG00000224796.1	RPL32P1	3.7	0.000238	0.0286	0.23	0.17	Schizophrenia;	chr6:33883396	chr6:33079451~33079860:+
LUAD	cis	rs9467773	0.595	rs12525810	ENSG00000261353.1	CTA-14H9.5	-3.7	0.000238	0.0286	-0.19	-0.17	Intelligence (multi-trait analysis);	chr6:26623283	chr6:26527063~26527404:+
LUAD	cis	rs10090774	0.71	rs11166991	ENSG00000280303.2	ERICD	-3.7	0.000238	0.0286	-0.18	-0.17	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140656314	chr8:140636281~140638283:+
LUAD	cis	rs7560272	0.723	rs1083923	ENSG00000163016.8	ALMS1P	-3.7	0.000238	0.0286	-0.18	-0.17	Schizophrenia;	chr2:73476247	chr2:73644919~73685576:+
LUAD	cis	rs2535633	0.602	rs6801235	ENSG00000243224.1	RP5-1157M23.2	-3.7	0.000238	0.0286	-0.18	-0.17	Body mass index;	chr3:52975579	chr3:52239258~52241097:+
LUAD	cis	rs6964587	0.81	rs408	ENSG00000188693.7	CYP51A1-AS1	3.7	0.000238	0.0286	0.2	0.17	Breast cancer;	chr7:91926970	chr7:92134604~92180725:+
LUAD	cis	rs2239547	0.603	rs4687698	ENSG00000243224.1	RP5-1157M23.2	-3.7	0.000238	0.0286	-0.19	-0.17	Schizophrenia;	chr3:53063092	chr3:52239258~52241097:+
LUAD	cis	rs34792	0.688	rs13339072	ENSG00000275910.1	RP11-680G24.6	-3.7	0.000238	0.0286	-0.16	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15504090	chr16:15015828~15016390:-
LUAD	cis	rs2354432	0.714	rs7531962	ENSG00000237188.3	RP11-337C18.8	3.7	0.000238	0.0286	0.26	0.17	Mitochondrial DNA levels;	chr1:147274360	chr1:147172771~147211568:+
LUAD	cis	rs2412819	0.571	rs66903736	ENSG00000166763.7	STRCP1	3.7	0.000238	0.0286	0.26	0.17	Lung cancer;	chr15:43619435	chr15:43699488~43718184:-
LUAD	cis	rs2412819	0.571	rs66749753	ENSG00000166763.7	STRCP1	3.7	0.000238	0.0286	0.26	0.17	Lung cancer;	chr15:43619601	chr15:43699488~43718184:-
LUAD	cis	rs13006833	0.739	rs291428	ENSG00000227542.1	AC092614.2	-3.7	0.000238	0.0286	-0.2	-0.17	Urinary metabolites;	chr2:190332500	chr2:191229165~191246172:-
LUAD	cis	rs7577696	0.889	rs212735	ENSG00000276334.1	AL133243.1	3.7	0.000238	0.0286	0.19	0.17	Inflammatory biomarkers;	chr2:32248019	chr2:32521927~32523547:+
LUAD	cis	rs2494663	0.52	rs11264873	ENSG00000223599.1	RP11-216N14.7	3.7	0.000238	0.0286	0.21	0.17	Mean platelet volume;	chr1:154018470	chr1:153852106~153853414:-
LUAD	cis	rs1876905	0.597	rs1150076	ENSG00000230177.1	RP5-1112D6.4	-3.7	0.000238	0.0286	-0.2	-0.17	Mean corpuscular hemoglobin;	chr6:111227227	chr6:111277932~111278742:+
LUAD	cis	rs11742741	0.616	rs17501795	ENSG00000248874.4	C5orf17	-3.7	0.000238	0.0286	-0.21	-0.17	Educational attainment;	chr5:24066127	chr5:23951348~24178263:+
LUAD	cis	rs728616	0.867	rs4633405	ENSG00000225484.5	NUTM2B-AS1	-3.7	0.000238	0.0286	-0.43	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80167690	chr10:79663088~79826594:-
LUAD	cis	rs6500602	0.702	rs11076835	ENSG00000280063.1	RP11-295D4.3	3.7	0.000238	0.0286	0.11	0.17	Schizophrenia;	chr16:4499617	chr16:4346694~4348648:-
LUAD	cis	rs2980439	0.818	rs2945249	ENSG00000254340.1	RP11-10A14.3	3.7	0.000238	0.0286	0.2	0.17	Neuroticism;	chr8:8237204	chr8:9141424~9145435:+
LUAD	cis	rs1075265	0.73	rs805392	ENSG00000272156.1	RP11-477N3.1	-3.7	0.000238	0.0286	-0.2	-0.17	Chronotype;Morning vs. evening chronotype;	chr2:53877594	chr2:54082554~54085066:+
LUAD	cis	rs11158026	0.603	rs68065548	ENSG00000258413.1	RP11-665C16.6	-3.7	0.000238	0.0286	-0.22	-0.17	Parkinson's disease;	chr14:54979835	chr14:55262767~55272075:-
LUAD	cis	rs8046148	0.724	rs12930079	ENSG00000279356.1	RP11-429P3.8	3.7	0.000238	0.0286	0.17	0.17	Testicular germ cell tumor;	chr16:50092780	chr16:50072862~50074986:+
LUAD	cis	rs3845817	0.703	rs702919	ENSG00000281920.1	RP11-418H16.1	-3.7	0.000238	0.0286	-0.2	-0.17	Bipolar disorder;	chr2:65545157	chr2:65623272~65628424:+
LUAD	cis	rs11073619	0.572	rs35984335	ENSG00000230373.7	GOLGA6L5P	-3.7	0.000238	0.0287	-0.27	-0.17	Positive affect;	chr15:84393638	chr15:84507885~84516814:-
LUAD	cis	rs858239	0.669	rs6461687	ENSG00000230042.1	AK3P3	-3.7	0.000238	0.0287	-0.21	-0.17	Cerebrospinal fluid biomarker levels;	chr7:23076961	chr7:23129178~23129841:+
LUAD	cis	rs1862618	0.802	rs986049	ENSG00000271828.1	CTD-2310F14.1	3.7	0.000238	0.0287	0.24	0.17	Initial pursuit acceleration;	chr5:56814406	chr5:56927874~56929573:+
LUAD	cis	rs14027	0.64	rs2043431	ENSG00000279347.1	RP11-85I17.2	-3.7	0.000238	0.0287	-0.14	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119736214	chr8:119838736~119840385:-
LUAD	cis	rs755249	0.761	rs3768321	ENSG00000182109.6	RP11-69E11.4	3.7	0.000238	0.0287	0.22	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39570256	chr1:39522280~39546187:-
LUAD	cis	rs1007190	0.881	rs75199539	ENSG00000267505.1	CTC-296K1.3	3.7	0.000238	0.0287	0.29	0.17	DNA methylation (variation);	chr17:44852878	chr17:44793199~44794474:+
LUAD	cis	rs2834288	0.7	rs2409502	ENSG00000237945.6	LINC00649	-3.7	0.000238	0.0287	-0.22	-0.17	Gut microbiota (bacterial taxa);	chr21:33902431	chr21:33915534~33977691:+
LUAD	cis	rs76878669	0.561	rs2279862	ENSG00000213409.4	RP11-658F2.3	3.7	0.000238	0.0287	0.2	0.17	Educational attainment (years of education);	chr11:66367708	chr11:66761575~66762399:-
LUAD	cis	rs76878669	0.561	rs12416747	ENSG00000213409.4	RP11-658F2.3	3.7	0.000238	0.0287	0.2	0.17	Educational attainment (years of education);	chr11:66368143	chr11:66761575~66762399:-
LUAD	cis	rs3020736	0.5	rs4147638	ENSG00000273366.1	CTA-989H11.1	3.7	0.000238	0.0287	0.2	0.17	Autism spectrum disorder or schizophrenia;	chr22:42091896	chr22:42278188~42278846:+
LUAD	cis	rs36093844	0.527	rs17817588	ENSG00000279742.1	RP11-700A24.1	-3.7	0.000239	0.0287	-0.19	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85965788	chr11:85852557~85854943:-
LUAD	cis	rs13006833	0.668	rs2582735	ENSG00000227542.1	AC092614.2	-3.7	0.000239	0.0287	-0.2	-0.17	Urinary metabolites;	chr2:190279072	chr2:191229165~191246172:-
LUAD	cis	rs7215564	0.908	rs35884143	ENSG00000232083.3	RPL31P7	3.7	0.000239	0.0287	0.27	0.17	Myopia (pathological);	chr17:80682243	chr17:80602549~80602926:-
LUAD	cis	rs7870753	0.578	rs16910750	ENSG00000188801.9	ZNF322P1	3.7	0.000239	0.0287	0.25	0.17	Height;	chr9:96322189	chr9:97198303~97199511:-
LUAD	cis	rs6095360	1	rs6019604	ENSG00000222365.1	SNORD12B	-3.7	0.000239	0.0287	-0.17	-0.17	Intelligence (multi-trait analysis);	chr20:49036961	chr20:49280319~49280409:+
LUAD	cis	rs6933660	0.8	rs9383893	ENSG00000219395.2	HSPA8P15	-3.7	0.000239	0.0287	-0.16	-0.17	Menarche (age at onset);	chr6:151436192	chr6:151411259~151413945:-
LUAD	cis	rs4713118	0.699	rs200969	ENSG00000226314.6	ZNF192P1	-3.7	0.000239	0.0287	-0.22	-0.17	Parkinson's disease;	chr6:27891675	chr6:28161781~28169594:+
LUAD	cis	rs7829975	0.902	rs485107	ENSG00000233609.3	RP11-62H7.2	-3.7	0.000239	0.0287	-0.14	-0.17	Mood instability;	chr8:8723898	chr8:8961200~8979025:+
LUAD	cis	rs590820	0.684	rs10489615	ENSG00000227934.1	RP11-423F24.3	-3.7	0.000239	0.0287	-0.19	-0.17	Metabolite levels (lipoprotein measures);	chr1:230169242	chr1:231021611~231022183:+
LUAD	cis	rs7617773	0.817	rs745116	ENSG00000199476.1	Y_RNA	-3.7	0.000239	0.0287	-0.21	-0.17	Coronary artery disease;	chr3:48231046	chr3:48288587~48288694:+
LUAD	cis	rs4474465	0.915	rs12794810	ENSG00000251323.2	RP11-452H21.4	-3.7	0.000239	0.0287	-0.21	-0.17	Alzheimer's disease (survival time);	chr11:78501697	chr11:78423982~78429836:-
LUAD	cis	rs7660883	0.808	rs1408	ENSG00000251411.1	RP11-397E7.4	-3.7	0.000239	0.0287	-0.18	-0.17	HDL cholesterol levels;	chr4:87136201	chr4:86913266~86914817:-
LUAD	cis	rs2841233	0.692	rs2028416	ENSG00000258701.1	LINC00638	3.7	0.000239	0.0287	0.19	0.17	IgG glycosylation;	chr14:104882215	chr14:104821201~104823718:+
LUAD	cis	rs6095360	1	rs1048590	ENSG00000222365.1	SNORD12B	-3.7	0.000239	0.0287	-0.17	-0.17	Intelligence (multi-trait analysis);	chr20:48993760	chr20:49280319~49280409:+
LUAD	cis	rs6095360	1	rs2295033	ENSG00000222365.1	SNORD12B	-3.7	0.000239	0.0287	-0.17	-0.17	Intelligence (multi-trait analysis);	chr20:48994359	chr20:49280319~49280409:+
LUAD	cis	rs1953600	0.521	rs7067644	ENSG00000226659.1	RP11-137H2.4	-3.7	0.000239	0.0287	-0.21	-0.17	Sarcoidosis;	chr10:80164489	chr10:80529597~80535942:-
LUAD	cis	rs10392	0.543	rs1733	ENSG00000274825.1	RP4-616B8.5	-3.7	0.000239	0.0287	-0.21	-0.17	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;	chr20:38952863	chr20:38955910~38956547:+
LUAD	cis	rs755249	0.567	rs72637906	ENSG00000182109.6	RP11-69E11.4	3.7	0.000239	0.0287	0.21	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39242630	chr1:39522280~39546187:-
LUAD	cis	rs755249	0.567	rs67886352	ENSG00000182109.6	RP11-69E11.4	3.7	0.000239	0.0287	0.21	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39243031	chr1:39522280~39546187:-
LUAD	cis	rs755249	0.567	rs60323161	ENSG00000182109.6	RP11-69E11.4	3.7	0.000239	0.0287	0.21	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39244787	chr1:39522280~39546187:-
LUAD	cis	rs755249	0.567	rs66727439	ENSG00000182109.6	RP11-69E11.4	3.7	0.000239	0.0287	0.21	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39246258	chr1:39522280~39546187:-
LUAD	cis	rs6921919	0.638	rs1416920	ENSG00000219392.1	RP1-265C24.5	-3.7	0.000239	0.0287	-0.21	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28335007	chr6:28115628~28116551:+
LUAD	cis	rs701145	0.537	rs1713842	ENSG00000243069.6	ARHGEF26-AS1	-3.7	0.000239	0.0287	-0.27	-0.17	Coronary artery disease;	chr3:154068454	chr3:154024401~154121332:-
LUAD	cis	rs786425	0.966	rs786444	ENSG00000278112.1	RP11-972P1.11	3.7	0.000239	0.0287	0.15	0.17	Pubertal anthropometrics;	chr12:123580869	chr12:123519390~123519856:-
LUAD	cis	rs797680	0.856	rs10874762	ENSG00000223745.6	RP4-717I23.3	3.7	0.000239	0.0287	0.13	0.17	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93173544	chr1:93262186~93346025:-
LUAD	cis	rs797680	0.856	rs6688230	ENSG00000223745.6	RP4-717I23.3	3.7	0.000239	0.0287	0.13	0.17	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93175567	chr1:93262186~93346025:-
LUAD	cis	rs797680	0.856	rs7553465	ENSG00000223745.6	RP4-717I23.3	3.7	0.000239	0.0287	0.13	0.17	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93178853	chr1:93262186~93346025:-
LUAD	cis	rs3126085	0.932	rs11204949	ENSG00000237975.5	FLG-AS1	3.7	0.000239	0.0287	0.28	0.17	Atopic dermatitis;	chr1:152247321	chr1:152168125~152445456:+
LUAD	cis	rs6496044	0.568	rs7166642	ENSG00000259416.2	RP11-158M2.5	3.7	0.000239	0.0287	0.17	0.17	Interstitial lung disease;	chr15:85518040	chr15:85754941~85756237:-
LUAD	cis	rs7429990	0.965	rs7426976	ENSG00000228638.1	FCF1P2	3.7	0.000239	0.0287	0.19	0.17	Educational attainment (years of education);	chr3:47981083	chr3:48290793~48291375:-
LUAD	cis	rs7429990	0.965	rs1013431	ENSG00000228638.1	FCF1P2	3.7	0.000239	0.0287	0.19	0.17	Educational attainment (years of education);	chr3:47987628	chr3:48290793~48291375:-
LUAD	cis	rs6688613	0.721	rs2312675	ENSG00000225171.2	DUTP6	-3.7	0.000239	0.0287	-0.2	-0.17	Refractive astigmatism;	chr1:166953296	chr1:166868748~166869209:+
LUAD	cis	rs6736093	0.67	rs72829613	ENSG00000207383.1	Y_RNA	-3.7	0.000239	0.0287	-0.22	-0.17	Coronary artery disease;	chr2:112037055	chr2:112579484~112579584:-
LUAD	cis	rs3811273	0.568	rs4981417	ENSG00000211816.2	TRAV38-1	-3.7	0.000239	0.0287	-0.23	-0.17	Periodontal disease-related phenotypes;	chr14:22261486	chr14:22271968~22272563:+
LUAD	cis	rs7824557	0.583	rs2736292	ENSG00000255046.1	RP11-297N6.4	-3.7	0.000239	0.0287	-0.2	-0.17	Retinal vascular caliber;	chr8:11376991	chr8:11797928~11802568:-
LUAD	cis	rs1383484	0.506	rs899927	ENSG00000225151.9	GOLGA2P7	3.7	0.000239	0.0287	0.19	0.17	Height;	chr15:83893127	chr15:84199311~84230136:-
LUAD	cis	rs7829975	0.514	rs2945873	ENSG00000253981.4	ALG1L13P	3.7	0.000239	0.0287	0.19	0.17	Mood instability;	chr8:8402935	chr8:8236003~8244667:-
LUAD	cis	rs2688608	0.904	rs2675669	ENSG00000271816.1	BMS1P4	3.7	0.000239	0.0287	0.14	0.17	Inflammatory bowel disease;	chr10:73894114	chr10:73699151~73730487:-
LUAD	cis	rs4819052	0.851	rs2838840	ENSG00000215447.6	BX322557.10	-3.7	0.000239	0.0287	-0.2	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45248579	chr21:45288052~45291738:+
LUAD	cis	rs708547	0.647	rs2293175	ENSG00000269949.1	RP11-738E22.3	3.7	0.000239	0.0287	0.21	0.17	Response to bleomycin (chromatid breaks);	chr4:56995192	chr4:56960927~56961373:-
LUAD	cis	rs4731367	0.931	rs10276671	ENSG00000224138.1	AC000123.4	3.7	0.000239	0.0287	0.16	0.17	Parental longevity (mother's age at death);	chr7:127570965	chr7:127350128~127351523:+
LUAD	cis	rs516805	0.961	rs1267942	ENSG00000279114.1	RP3-425C14.5	-3.7	0.000239	0.0287	-0.18	-0.17	Lymphocyte counts;	chr6:122472375	chr6:122471923~122484161:+
LUAD	cis	rs516805	0.961	rs471620	ENSG00000279114.1	RP3-425C14.5	-3.7	0.000239	0.0287	-0.18	-0.17	Lymphocyte counts;	chr6:122473532	chr6:122471923~122484161:+
LUAD	cis	rs9392556	0.6	rs2326408	ENSG00000230648.1	RP3-406P24.3	3.7	0.000239	0.0287	0.18	0.17	Blood metabolite levels;	chr6:4119282	chr6:4018843~4021215:-
LUAD	cis	rs875971	0.66	rs801192	ENSG00000222364.1	RNU6-96P	3.7	0.000239	0.0287	0.18	0.17	Aortic root size;	chr7:66566965	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.66	rs801190	ENSG00000222364.1	RNU6-96P	3.7	0.000239	0.0287	0.18	0.17	Aortic root size;	chr7:66568046	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.66	rs3857686	ENSG00000222364.1	RNU6-96P	3.7	0.000239	0.0287	0.18	0.17	Aortic root size;	chr7:66571204	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.638	rs3898855	ENSG00000222364.1	RNU6-96P	3.7	0.000239	0.0287	0.18	0.17	Aortic root size;	chr7:66571411	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.638	rs10278816	ENSG00000222364.1	RNU6-96P	3.7	0.000239	0.0287	0.18	0.17	Aortic root size;	chr7:66572000	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.66	rs10281080	ENSG00000222364.1	RNU6-96P	3.7	0.000239	0.0287	0.18	0.17	Aortic root size;	chr7:66577454	chr7:66395191~66395286:+
LUAD	cis	rs6452524	0.534	rs72765386	ENSG00000281327.1	LINC01338	3.7	0.000239	0.0287	0.18	0.17	Hypertension (SNP x SNP interaction);	chr5:83061502	chr5:82850864~82859836:-
LUAD	cis	rs7688540	0.771	rs11737268	ENSG00000211553.1	AC253576.2	-3.7	0.000239	0.0287	-0.23	-0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:230663	chr4:136461~136568:+
LUAD	cis	rs7688540	0.771	rs11726829	ENSG00000211553.1	AC253576.2	-3.7	0.000239	0.0287	-0.23	-0.17	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231159	chr4:136461~136568:+
LUAD	cis	rs7017914	0.934	rs7830550	ENSG00000246366.5	RP11-382J12.1	3.7	0.000239	0.0287	0.15	0.17	Bone mineral density;	chr8:70658196	chr8:70608577~70663279:+
LUAD	cis	rs1124609	1	rs1124609	ENSG00000244879.4	GABPB1-AS1	3.7	0.000239	0.0287	0.26	0.17	Subjective well-being;	chr15:50193820	chr15:50354959~50372202:+
LUAD	cis	rs4819052	1	rs13052356	ENSG00000223768.1	LINC00205	-3.7	0.000239	0.0287	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243673	chr21:45293285~45297354:+
LUAD	cis	rs4819052	1	rs28628220	ENSG00000223768.1	LINC00205	-3.7	0.000239	0.0287	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243826	chr21:45293285~45297354:+
LUAD	cis	rs4423214	0.625	rs78685409	ENSG00000226627.1	SHANK2-AS1	3.7	0.000239	0.0287	0.2	0.17	Vitamin D levels;	chr11:71426337	chr11:70631094~70635490:+
LUAD	cis	rs4423214	0.879	rs1792277	ENSG00000226627.1	SHANK2-AS1	3.7	0.000239	0.0287	0.2	0.17	Vitamin D levels;	chr11:71427872	chr11:70631094~70635490:+
LUAD	cis	rs73242632	1	rs41344750	ENSG00000269949.1	RP11-738E22.3	3.7	0.000239	0.0287	0.39	0.17	Congenital heart disease (maternal effect);	chr4:56964047	chr4:56960927~56961373:-
LUAD	cis	rs8058578	1	rs7198250	ENSG00000232748.3	RP11-196G11.6	-3.7	0.000239	0.0287	-0.21	-0.17	Multiple myeloma;	chr16:30735501	chr16:31056460~31062803:+
LUAD	cis	rs11018904	0.817	rs11606060	ENSG00000280367.1	RP11-121L10.2	3.7	0.000239	0.0287	0.22	0.17	Intelligence (multi-trait analysis);	chr11:90195429	chr11:90223153~90226538:+
LUAD	cis	rs11018904	0.906	rs11603498	ENSG00000280367.1	RP11-121L10.2	3.7	0.000239	0.0287	0.22	0.17	Intelligence (multi-trait analysis);	chr11:90195615	chr11:90223153~90226538:+
LUAD	cis	rs4706831	0.625	rs638056	ENSG00000279022.1	RP11-250B2.4	-3.7	0.000239	0.0287	-0.19	-0.17	Joint mobility (Beighton score);	chr6:80271091	chr6:80440730~80441172:+
LUAD	cis	rs36093844	0.527	rs4943935	ENSG00000279742.1	RP11-700A24.1	-3.7	0.000239	0.0287	-0.2	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86040813	chr11:85852557~85854943:-
LUAD	cis	rs7611694	0.81	rs13092681	ENSG00000242770.2	RP11-180K7.1	-3.7	0.000239	0.0287	-0.16	-0.17	Prostate cancer;	chr3:113571603	chr3:112802478~112812819:+
LUAD	cis	rs1055129	0.681	rs7221792	ENSG00000267801.1	RP11-552F3.9	3.7	0.000239	0.0287	0.17	0.17	White matter hyperintensity burden;	chr17:75838609	chr17:75876372~75879546:+
LUAD	cis	rs67981189	0.896	rs17108925	ENSG00000269927.1	RP6-91H8.3	3.7	0.000239	0.0287	0.21	0.17	Schizophrenia;	chr14:71033010	chr14:71141125~71143253:-
LUAD	cis	rs67981189	0.896	rs28374308	ENSG00000269927.1	RP6-91H8.3	3.7	0.000239	0.0287	0.21	0.17	Schizophrenia;	chr14:71035040	chr14:71141125~71143253:-
LUAD	cis	rs13006833	0.635	rs2664251	ENSG00000227542.1	AC092614.2	-3.7	0.000239	0.0287	-0.2	-0.17	Urinary metabolites;	chr2:190282941	chr2:191229165~191246172:-
LUAD	cis	rs2274273	0.837	rs7142857	ENSG00000258413.1	RP11-665C16.6	-3.7	0.000239	0.0288	-0.21	-0.17	Protein biomarker;	chr14:55237410	chr14:55262767~55272075:-
LUAD	cis	rs6479901	0.895	rs7920159	ENSG00000232075.1	MRPL35P2	-3.7	0.000239	0.0288	-0.23	-0.17	Intelligence (multi-trait analysis);	chr10:63212416	chr10:63634317~63634827:-
LUAD	cis	rs6502050	0.865	rs74480314	ENSG00000275966.1	RP11-1055B8.9	-3.7	0.000239	0.0288	-0.17	-0.17	Life satisfaction;	chr17:82159840	chr17:81345476~81345966:-
LUAD	cis	rs1075265	0.73	rs805391	ENSG00000272156.1	RP11-477N3.1	3.7	0.000239	0.0288	0.2	0.17	Chronotype;Morning vs. evening chronotype;	chr2:53877181	chr2:54082554~54085066:+
LUAD	cis	rs12440869	1	rs17295739	ENSG00000270964.1	RP11-502I4.3	3.7	0.000239	0.0288	0.19	0.17	Peak velocity of the mitral A-wave;	chr15:67243093	chr15:67541072~67542604:-
LUAD	cis	rs9487094	1	rs9480955	ENSG00000260273.1	RP11-425D10.10	3.7	0.000239	0.0288	0.22	0.17	Height;	chr6:109423330	chr6:109382795~109383666:+
LUAD	cis	rs9487094	1	rs9320287	ENSG00000260273.1	RP11-425D10.10	3.7	0.000239	0.0288	0.22	0.17	Height;	chr6:109423487	chr6:109382795~109383666:+
LUAD	cis	rs911119	0.913	rs12710327	ENSG00000270001.1	RP11-218C14.8	-3.7	0.00024	0.0288	-0.24	-0.17	Chronic kidney disease;	chr20:23589052	chr20:23631826~23632316:-
LUAD	cis	rs7560272	0.538	rs35767294	ENSG00000163016.8	ALMS1P	-3.7	0.00024	0.0288	-0.18	-0.17	Schizophrenia;	chr2:73695707	chr2:73644919~73685576:+
LUAD	cis	rs7560272	0.502	rs13013228	ENSG00000163016.8	ALMS1P	-3.7	0.00024	0.0288	-0.18	-0.17	Schizophrenia;	chr2:73698089	chr2:73644919~73685576:+
LUAD	cis	rs7178424	1	rs7177276	ENSG00000259251.2	RP11-643M14.1	-3.7	0.00024	0.0288	-0.17	-0.17	Height;	chr15:62087469	chr15:62060503~62062434:+
LUAD	cis	rs7178424	1	rs7178945	ENSG00000259251.2	RP11-643M14.1	-3.7	0.00024	0.0288	-0.17	-0.17	Height;	chr15:62087615	chr15:62060503~62062434:+
LUAD	cis	rs7178424	1	rs7178424	ENSG00000259251.2	RP11-643M14.1	-3.7	0.00024	0.0288	-0.17	-0.17	Height;	chr15:62088060	chr15:62060503~62062434:+
LUAD	cis	rs6088580	0.634	rs1890002	ENSG00000276073.1	RP5-1125A11.7	3.7	0.00024	0.0288	0.16	0.17	Glomerular filtration rate (creatinine);	chr20:34331413	chr20:33985617~33988989:-
LUAD	cis	rs7077256	0.504	rs35506078	ENSG00000272767.1	JMJD1C-AS1	3.7	0.00024	0.0288	0.24	0.17	Intelligence (multi-trait analysis);	chr10:63450792	chr10:63465229~63466563:+
LUAD	cis	rs10760158	0.51	rs7020643	ENSG00000226752.6	PSMD5-AS1	-3.7	0.00024	0.0288	-0.18	-0.17	Pulse pressure;	chr9:121099578	chr9:120824828~120854385:+
LUAD	cis	rs7772486	0.686	rs1292337	ENSG00000235652.6	RP11-545I5.3	-3.7	0.00024	0.0288	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145646671	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.686	rs857879	ENSG00000235652.6	RP11-545I5.3	-3.7	0.00024	0.0288	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145652907	chr6:145799409~145886585:+
LUAD	cis	rs61542988	0.797	rs4329182	ENSG00000221740.1	SNORD93	3.7	0.00024	0.0288	0.22	0.17	Fibrinogen levels;	chr7:22843002	chr7:22856613~22856686:+
LUAD	cis	rs10911232	0.507	rs6668980	ENSG00000224468.3	RP11-181K3.4	-3.7	0.00024	0.0288	-0.15	-0.17	Hypertriglyceridemia;	chr1:183049722	chr1:183138402~183141282:-
LUAD	cis	rs10911232	0.507	rs4422969	ENSG00000224468.3	RP11-181K3.4	-3.7	0.00024	0.0288	-0.15	-0.17	Hypertriglyceridemia;	chr1:183051627	chr1:183138402~183141282:-
LUAD	cis	rs10911232	0.507	rs10752891	ENSG00000224468.3	RP11-181K3.4	-3.7	0.00024	0.0288	-0.15	-0.17	Hypertriglyceridemia;	chr1:183054148	chr1:183138402~183141282:-
LUAD	cis	rs10752881	0.935	rs4652771	ENSG00000224468.3	RP11-181K3.4	-3.7	0.00024	0.0288	-0.15	-0.17	Colorectal cancer;	chr1:183054368	chr1:183138402~183141282:-
LUAD	cis	rs10752881	0.875	rs10797825	ENSG00000224468.3	RP11-181K3.4	-3.7	0.00024	0.0288	-0.15	-0.17	Colorectal cancer;	chr1:183055446	chr1:183138402~183141282:-
LUAD	cis	rs9467773	0.549	rs9467805	ENSG00000241549.7	GUSBP2	3.7	0.00024	0.0288	0.18	0.17	Intelligence (multi-trait analysis);	chr6:26583138	chr6:26871484~26956554:-
LUAD	cis	rs4907240	0.922	rs4907246	ENSG00000237510.6	AC008268.2	-3.7	0.00024	0.0288	-0.24	-0.17	Event-related brain oscillations;	chr2:96660549	chr2:95789654~95800166:+
LUAD	cis	rs7017914	0.702	rs62531711	ENSG00000223220.1	Y_RNA	3.7	0.00024	0.0288	0.19	0.17	Bone mineral density;	chr8:70618265	chr8:70780914~70781008:-
LUAD	cis	rs160451	0.966	rs160427	ENSG00000251136.7	RP11-37B2.1	3.7	0.00024	0.0288	0.17	0.17	Leprosy;	chr8:89659156	chr8:89609409~89757727:-
LUAD	cis	rs7942368	0.941	rs10793195	ENSG00000254632.1	RP11-21L23.4	3.7	0.00024	0.0288	0.18	0.17	Endometriosis;	chr11:76793688	chr11:76759916~76768223:-
LUAD	cis	rs2702164	1	rs1733331	ENSG00000240661.1	RP11-174O3.3	-3.7	0.00024	0.0288	-0.2	-0.17	Gut microbiome composition (winter);	chr3:120390322	chr3:120349510~120367998:+
LUAD	cis	rs683250	0.629	rs584242	ENSG00000246067.6	RAB30-AS1	3.7	0.00024	0.0288	0.18	0.17	Subcortical brain region volumes;	chr11:83230878	chr11:83072066~83106719:+
LUAD	cis	rs703842	0.963	rs2069506	ENSG00000245651.2	RP11-620J15.2	3.7	0.00024	0.0288	0.18	0.17	Multiple sclerosis;	chr12:57749071	chr12:57869835~57896482:-
LUAD	cis	rs9392556	0.6	rs611500	ENSG00000230648.1	RP3-406P24.3	3.7	0.00024	0.0288	0.18	0.17	Blood metabolite levels;	chr6:4126529	chr6:4018843~4021215:-
LUAD	cis	rs7674212	0.541	rs11727498	ENSG00000251288.2	RP11-10L12.2	-3.7	0.00024	0.0288	-0.21	-0.17	Type 2 diabetes;	chr4:103179830	chr4:102751401~102752641:+
LUAD	cis	rs62355901	0.505	rs72759725	ENSG00000271828.1	CTD-2310F14.1	3.7	0.00024	0.0288	0.39	0.17	Breast cancer;	chr5:56941932	chr5:56927874~56929573:+
LUAD	cis	rs12822507	0.811	rs34946234	ENSG00000275963.1	RP11-180M15.6	-3.7	0.00024	0.0288	-0.19	-0.17	Systemic lupus erythematosus;	chr12:12628878	chr12:12648939~12649713:+
LUAD	cis	rs10911232	0.507	rs28477876	ENSG00000224468.3	RP11-181K3.4	-3.7	0.00024	0.0288	-0.15	-0.17	Hypertriglyceridemia;	chr1:183050747	chr1:183138402~183141282:-
LUAD	cis	rs6471393	0.964	rs11549490	ENSG00000253848.1	RP11-10N23.5	-3.7	0.00024	0.0288	-0.2	-0.17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93732822	chr8:93741193~93744534:+
LUAD	cis	rs9366999	0.809	rs1744409	ENSG00000235033.6	RP11-61I13.3	-3.7	0.00024	0.0288	-0.18	-0.17	Obesity-related traits;	chr6:39252963	chr6:39881804~39900071:-
LUAD	cis	rs9366999	0.809	rs1744410	ENSG00000235033.6	RP11-61I13.3	-3.7	0.00024	0.0288	-0.18	-0.17	Obesity-related traits;	chr6:39253299	chr6:39881804~39900071:-
LUAD	cis	rs78572108	0.858	rs735868	ENSG00000214691.7	AC104654.1	3.7	0.00024	0.0288	0.27	0.17	Total body bone mineral density;	chr2:42045249	chr2:41877074~41894046:+
LUAD	cis	rs7429990	0.965	rs2631721	ENSG00000228638.1	FCF1P2	-3.7	0.00024	0.0288	-0.2	-0.17	Educational attainment (years of education);	chr3:47881807	chr3:48290793~48291375:-
LUAD	cis	rs10911232	0.507	rs10797819	ENSG00000224468.3	RP11-181K3.4	-3.7	0.00024	0.0288	-0.15	-0.17	Hypertriglyceridemia;	chr1:183037776	chr1:183138402~183141282:-
LUAD	cis	rs10911232	0.507	rs4652769	ENSG00000224468.3	RP11-181K3.4	-3.7	0.00024	0.0288	-0.15	-0.17	Hypertriglyceridemia;	chr1:183040061	chr1:183138402~183141282:-
LUAD	cis	rs10911232	0.507	rs10797820	ENSG00000224468.3	RP11-181K3.4	-3.7	0.00024	0.0288	-0.15	-0.17	Hypertriglyceridemia;	chr1:183042231	chr1:183138402~183141282:-
LUAD	cis	rs10911232	0.507	rs10911206	ENSG00000224468.3	RP11-181K3.4	-3.7	0.00024	0.0288	-0.15	-0.17	Hypertriglyceridemia;	chr1:183043288	chr1:183138402~183141282:-
LUAD	cis	rs10911232	0.507	rs10797821	ENSG00000224468.3	RP11-181K3.4	-3.7	0.00024	0.0288	-0.15	-0.17	Hypertriglyceridemia;	chr1:183043424	chr1:183138402~183141282:-
LUAD	cis	rs10911232	0.524	rs10911209	ENSG00000224468.3	RP11-181K3.4	-3.7	0.00024	0.0288	-0.15	-0.17	Hypertriglyceridemia;	chr1:183044853	chr1:183138402~183141282:-
LUAD	cis	rs10911232	0.507	rs6664995	ENSG00000224468.3	RP11-181K3.4	-3.7	0.00024	0.0288	-0.15	-0.17	Hypertriglyceridemia;	chr1:183048210	chr1:183138402~183141282:-
LUAD	cis	rs10911232	0.507	rs10797822	ENSG00000224468.3	RP11-181K3.4	-3.7	0.00024	0.0288	-0.15	-0.17	Hypertriglyceridemia;	chr1:183048634	chr1:183138402~183141282:-
LUAD	cis	rs8046148	0.671	rs2160571	ENSG00000279356.1	RP11-429P3.8	3.7	0.00024	0.0288	0.17	0.17	Testicular germ cell tumor;	chr16:50080644	chr16:50072862~50074986:+
LUAD	cis	rs10911232	0.507	rs10752890	ENSG00000224468.3	RP11-181K3.4	-3.7	0.00024	0.0288	-0.15	-0.17	Hypertriglyceridemia;	chr1:183052775	chr1:183138402~183141282:-
LUAD	cis	rs2274273	0.837	rs56949365	ENSG00000258413.1	RP11-665C16.6	-3.7	0.00024	0.0288	-0.22	-0.17	Protein biomarker;	chr14:55323360	chr14:55262767~55272075:-
LUAD	cis	rs2274273	0.87	rs4496026	ENSG00000258413.1	RP11-665C16.6	-3.7	0.00024	0.0288	-0.22	-0.17	Protein biomarker;	chr14:55323794	chr14:55262767~55272075:-
LUAD	cis	rs2274273	0.87	rs4366639	ENSG00000258413.1	RP11-665C16.6	-3.7	0.00024	0.0288	-0.22	-0.17	Protein biomarker;	chr14:55323798	chr14:55262767~55272075:-
LUAD	cis	rs12285276	0.75	rs11038658	ENSG00000205106.4	DKFZp779M0652	-3.7	0.00024	0.0288	-0.21	-0.17	Visceral fat;	chr11:45791762	chr11:45771432~45772358:+
LUAD	cis	rs4578769	0.55	rs12954377	ENSG00000266850.1	RP11-370A5.1	3.7	0.00024	0.0288	0.21	0.17	Eosinophil percentage of white cells;	chr18:22940862	chr18:22723491~22907721:-
LUAD	cis	rs4578769	0.55	rs9957690	ENSG00000266850.1	RP11-370A5.1	3.7	0.00024	0.0288	0.21	0.17	Eosinophil percentage of white cells;	chr18:22942697	chr18:22723491~22907721:-
LUAD	cis	rs4578769	0.55	rs12956837	ENSG00000266850.1	RP11-370A5.1	3.7	0.00024	0.0288	0.21	0.17	Eosinophil percentage of white cells;	chr18:22946865	chr18:22723491~22907721:-
LUAD	cis	rs4578769	0.55	rs9953479	ENSG00000266850.1	RP11-370A5.1	3.7	0.00024	0.0288	0.21	0.17	Eosinophil percentage of white cells;	chr18:22962644	chr18:22723491~22907721:-
LUAD	cis	rs4578769	0.55	rs12971230	ENSG00000266850.1	RP11-370A5.1	3.7	0.00024	0.0288	0.21	0.17	Eosinophil percentage of white cells;	chr18:22962987	chr18:22723491~22907721:-
LUAD	cis	rs11637445	0.627	rs72751453	ENSG00000270964.1	RP11-502I4.3	-3.7	0.00024	0.0288	-0.18	-0.17	Posterior cortical atrophy and Alzheimer's disease;	chr15:67832327	chr15:67541072~67542604:-
LUAD	cis	rs9303542	1	rs7210445	ENSG00000264920.1	RP11-6N17.4	-3.7	0.00024	0.0288	-0.22	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48323956	chr17:47891255~47895812:-
LUAD	cis	rs2015599	0.549	rs6487802	ENSG00000257176.2	RP11-996F15.2	3.7	0.00024	0.0288	0.17	0.17	Platelet count;Mean platelet volume;	chr12:29299480	chr12:29280418~29317848:-
LUAD	cis	rs2015599	0.549	rs6487803	ENSG00000257176.2	RP11-996F15.2	3.7	0.00024	0.0288	0.17	0.17	Platelet count;Mean platelet volume;	chr12:29299760	chr12:29280418~29317848:-
LUAD	cis	rs2015599	0.549	rs7954990	ENSG00000257176.2	RP11-996F15.2	3.7	0.00024	0.0288	0.17	0.17	Platelet count;Mean platelet volume;	chr12:29299841	chr12:29280418~29317848:-
LUAD	cis	rs7200543	1	rs14347	ENSG00000260735.1	RP11-72I8.1	-3.7	0.00024	0.0288	-0.19	-0.17	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15040032	chr16:15094411~15109197:+
LUAD	cis	rs3771317	0.941	rs10931468	ENSG00000235852.1	AC005540.3	-3.7	0.00024	0.0288	-0.27	-0.17	Primary biliary cholangitis;	chr2:190673836	chr2:190880797~190882059:-
LUAD	cis	rs324126	0.78	rs62108319	ENSG00000277977.1	CTD-3018O17.5	3.7	0.00024	0.0288	0.17	0.17	Colonoscopy-negative controls vs population controls;	chr19:52380577	chr19:52392659~52392755:+
LUAD	cis	rs76382185	0.61	rs4409674	ENSG00000233184.5	RP11-421L21.3	3.7	0.00024	0.0288	0.32	0.17	Lymphocyte counts;	chr1:101077833	chr1:101025878~101087268:+
LUAD	cis	rs10510102	0.808	rs11200296	ENSG00000276742.1	RP11-500G22.4	3.7	0.00024	0.0288	0.29	0.17	Breast cancer;	chr10:121971956	chr10:121956782~121957098:+
LUAD	cis	rs7777677	0.925	rs6960743	ENSG00000276953.1	TRBV12-4	3.7	0.00024	0.0288	0.16	0.17	Alcoholic chronic pancreatitis;	chr7:142661768	chr7:142563740~142564245:+
LUAD	cis	rs7618915	0.547	rs3755806	ENSG00000243224.1	RP5-1157M23.2	3.7	0.00024	0.0288	0.17	0.17	Bipolar disorder;	chr3:52609669	chr3:52239258~52241097:+
LUAD	cis	rs7829975	0.514	rs2976926	ENSG00000233609.3	RP11-62H7.2	3.7	0.00024	0.0289	0.14	0.17	Mood instability;	chr8:8404114	chr8:8961200~8979025:+
LUAD	cis	rs61160187	0.556	rs10939881	ENSG00000215032.2	GNL3LP1	3.7	0.000241	0.0289	0.2	0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:61087146	chr5:60891935~60893577:-
LUAD	cis	rs73242632	0.737	rs73242637	ENSG00000269949.1	RP11-738E22.3	3.7	0.000241	0.0289	0.46	0.17	Congenital heart disease (maternal effect);	chr4:57078661	chr4:56960927~56961373:-
LUAD	cis	rs7829975	0.514	rs2979139	ENSG00000173295.6	FAM86B3P	3.7	0.000241	0.0289	0.17	0.17	Mood instability;	chr8:8410803	chr8:8228595~8244865:+
LUAD	cis	rs8192282	0.739	rs56047170	ENSG00000272030.1	RP1-178F15.4	3.7	0.000241	0.0289	0.21	0.17	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);	chr1:154555577	chr1:153631438~153634397:-
LUAD	cis	rs12565755	0.556	rs12408850	ENSG00000226476.2	RP11-776H12.1	3.7	0.000241	0.0289	0.27	0.17	Response to tocilizumab in rheumatoid arthritis;	chr1:60496595	chr1:60540249~60640491:-
LUAD	cis	rs11621969	0.647	rs55637037	ENSG00000258454.1	RP11-361H10.3	3.7	0.000241	0.0289	0.27	0.17	Periodontal microbiota;	chr14:75370213	chr14:76235817~76263474:+
LUAD	cis	rs889398	0.617	rs1566456	ENSG00000226232.7	RP11-419C5.2	-3.7	0.000241	0.0289	-0.14	-0.17	Body mass index;	chr16:69866323	chr16:69976388~69996188:-
LUAD	cis	rs7615952	0.932	rs7629977	ENSG00000241288.6	RP11-379B18.5	-3.7	0.000241	0.0289	-0.21	-0.17	Blood pressure (smoking interaction);	chr3:125930730	chr3:125827238~125916384:-
LUAD	cis	rs818427	0.528	rs153552	ENSG00000279522.1	CTC-487M23.6	3.7	0.000241	0.0289	0.19	0.17	Total body bone mineral density;	chr5:112898053	chr5:112894933~112896531:+
LUAD	cis	rs7809950	1	rs1544336	ENSG00000238832.1	snoU109	-3.7	0.000241	0.0289	-0.25	-0.17	Coronary artery disease;	chr7:107441970	chr7:107603363~107603507:+
LUAD	cis	rs7503168	0.558	rs11650621	ENSG00000267592.1	CTC-507E2.2	3.7	0.000241	0.0289	0.35	0.17	Plateletcrit;	chr17:35631827	chr17:35596904~35597128:-
LUAD	cis	rs7503168	0.558	rs12947274	ENSG00000267592.1	CTC-507E2.2	3.7	0.000241	0.0289	0.35	0.17	Plateletcrit;	chr17:35635146	chr17:35596904~35597128:-
LUAD	cis	rs7503168	0.558	rs12936693	ENSG00000267592.1	CTC-507E2.2	3.7	0.000241	0.0289	0.35	0.17	Plateletcrit;	chr17:35639391	chr17:35596904~35597128:-
LUAD	cis	rs7503168	0.558	rs71381465	ENSG00000267592.1	CTC-507E2.2	3.7	0.000241	0.0289	0.35	0.17	Plateletcrit;	chr17:35647713	chr17:35596904~35597128:-
LUAD	cis	rs7503168	0.558	rs12943224	ENSG00000267592.1	CTC-507E2.2	3.7	0.000241	0.0289	0.35	0.17	Plateletcrit;	chr17:35650519	chr17:35596904~35597128:-
LUAD	cis	rs12200782	0.505	rs7765920	ENSG00000241549.7	GUSBP2	3.7	0.000241	0.0289	0.22	0.17	Small cell lung carcinoma;	chr6:26514543	chr6:26871484~26956554:-
LUAD	cis	rs67981189	0.896	rs12883437	ENSG00000269927.1	RP6-91H8.3	3.7	0.000241	0.0289	0.21	0.17	Schizophrenia;	chr14:70998064	chr14:71141125~71143253:-
LUAD	cis	rs2702164	1	rs7639127	ENSG00000240661.1	RP11-174O3.3	-3.7	0.000241	0.0289	-0.2	-0.17	Gut microbiome composition (winter);	chr3:120389805	chr3:120349510~120367998:+
LUAD	cis	rs2702164	1	rs7639144	ENSG00000240661.1	RP11-174O3.3	-3.7	0.000241	0.0289	-0.2	-0.17	Gut microbiome composition (winter);	chr3:120389856	chr3:120349510~120367998:+
LUAD	cis	rs7605235	0.959	rs12470950	ENSG00000224165.4	DNAJC27-AS1	3.7	0.000241	0.0289	0.19	0.17	Response to platinum-based chemotherapy (cisplatin);	chr2:25423821	chr2:24971390~25039694:+
LUAD	cis	rs7605235	0.874	rs6722782	ENSG00000224165.4	DNAJC27-AS1	3.7	0.000241	0.0289	0.19	0.17	Response to platinum-based chemotherapy (cisplatin);	chr2:25424808	chr2:24971390~25039694:+
LUAD	cis	rs8114671	0.967	rs2069948	ENSG00000269202.1	RP4-614O4.12	-3.7	0.000241	0.0289	-0.16	-0.17	Height;	chr20:35174686	chr20:35201747~35203288:-
LUAD	cis	rs599083	0.53	rs667126	ENSG00000212093.1	AP000807.1	-3.7	0.000241	0.0289	-0.18	-0.17	Bone mineral density (spine);	chr11:68410260	chr11:68506083~68506166:-
LUAD	cis	rs7829975	0.567	rs6601273	ENSG00000233609.3	RP11-62H7.2	-3.7	0.000241	0.0289	-0.14	-0.17	Mood instability;	chr8:8939009	chr8:8961200~8979025:+
LUAD	cis	rs9659323	0.689	rs10923716	ENSG00000231365.4	RP11-418J17.1	-3.7	0.000241	0.0289	-0.21	-0.17	Body mass index;	chr1:118993496	chr1:119140396~119275973:+
LUAD	cis	rs1910358	0.718	rs12188224	ENSG00000248874.4	C5orf17	-3.7	0.000241	0.0289	-0.22	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr5:23986918	chr5:23951348~24178263:+
LUAD	cis	rs1910358	0.778	rs28386991	ENSG00000248874.4	C5orf17	-3.7	0.000241	0.0289	-0.22	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr5:23991262	chr5:23951348~24178263:+
LUAD	cis	rs6907340	0.513	rs6938418	ENSG00000228412.5	RP4-625H18.2	-3.7	0.000241	0.0289	-0.22	-0.17	Endometriosis;	chr6:19808802	chr6:19802164~19804752:-
LUAD	cis	rs7142881	0.844	rs1972925	ENSG00000258525.1	RP11-829H16.3	-3.7	0.000241	0.0289	-0.19	-0.17	Response to iloperidone treatment (QT prolongation);	chr14:31566913	chr14:30876179~30889808:-
LUAD	cis	rs1876905	0.597	rs191631	ENSG00000230177.1	RP5-1112D6.4	-3.7	0.000241	0.0289	-0.21	-0.17	Mean corpuscular hemoglobin;	chr6:111226862	chr6:111277932~111278742:+
LUAD	cis	rs9608946	1	rs1001409	ENSG00000279699.1	RP1-102K2.9	3.7	0.000241	0.0289	0.24	0.17	Red cell distribution width;	chr22:30522838	chr22:30275215~30276951:-
LUAD	cis	rs11216126	0.554	rs11601168	ENSG00000280143.1	AP000892.6	-3.7	0.000241	0.0289	-0.29	-0.17	HDL cholesterol;	chr11:116700422	chr11:117204967~117210292:+
LUAD	cis	rs7918232	0.83	rs7087033	ENSG00000262412.1	RP11-85G18.6	3.7	0.000241	0.0289	0.25	0.17	Breast cancer;	chr10:27103593	chr10:27243130~27250804:+
LUAD	cis	rs1023500	0.596	rs133352	ENSG00000273366.1	CTA-989H11.1	-3.7	0.000241	0.0289	-0.2	-0.17	Schizophrenia;	chr22:42038018	chr22:42278188~42278846:+
LUAD	cis	rs860295	0.529	rs1475766	ENSG00000203761.5	MSTO2P	3.7	0.000241	0.0289	0.12	0.17	Body mass index;	chr1:156011698	chr1:155745829~155750137:+
LUAD	cis	rs494562	0.892	rs567686	ENSG00000234155.1	RP11-30P6.6	-3.7	0.000241	0.0289	-0.32	-0.17	Metabolic traits;Blood metabolite levels;	chr6:85414446	chr6:85387219~85390186:-
LUAD	cis	rs494562	0.892	rs7767626	ENSG00000234155.1	RP11-30P6.6	-3.7	0.000241	0.0289	-0.32	-0.17	Metabolic traits;Blood metabolite levels;	chr6:85414676	chr6:85387219~85390186:-
LUAD	cis	rs7131987	0.65	rs67146951	ENSG00000275476.1	RP11-996F15.4	-3.7	0.000241	0.0289	-0.19	-0.17	QT interval;	chr12:29297620	chr12:29277397~29277882:-
LUAD	cis	rs7131987	0.65	rs10843382	ENSG00000275476.1	RP11-996F15.4	-3.7	0.000241	0.0289	-0.19	-0.17	QT interval;	chr12:29298788	chr12:29277397~29277882:-
LUAD	cis	rs13108904	0.901	rs7695691	ENSG00000196810.4	CTBP1-AS2	3.7	0.000241	0.0289	0.19	0.17	Obesity-related traits;	chr4:1310844	chr4:1249300~1288291:+
LUAD	cis	rs5015933	0.872	rs491283	ENSG00000232630.1	PRPS1P2	-3.7	0.000241	0.0289	-0.16	-0.17	Body mass index;	chr9:125255437	chr9:125150653~125151589:+
LUAD	cis	rs8014252	0.901	rs61671382	ENSG00000274818.1	RP1-292L20.3	3.7	0.000241	0.0289	0.27	0.17	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70483097	chr14:70906657~70907111:-
LUAD	cis	rs8002861	0.935	rs4101376	ENSG00000274001.1	RP11-5G9.5	-3.7	0.000241	0.0289	-0.17	-0.17	Leprosy;	chr13:43895699	chr13:43877715~43878163:-
LUAD	cis	rs2494663	0.61	rs11264886	ENSG00000223599.1	RP11-216N14.7	-3.7	0.000241	0.0289	-0.2	-0.17	Mean platelet volume;	chr1:154024870	chr1:153852106~153853414:-
LUAD	cis	rs9951698	0.667	rs7234094	ENSG00000267480.1	RP11-703I16.1	-3.7	0.000241	0.0289	-0.2	-0.17	Intelligence (multi-trait analysis);	chr18:13007481	chr18:12031178~12032181:-
LUAD	cis	rs454217	0.846	rs1948656	ENSG00000277851.1	RP11-756G20.1	3.7	0.000241	0.0289	0.17	0.17	Smoking quantity;	chr12:92337508	chr12:92247756~92363832:-
LUAD	cis	rs11642862	1	rs113454775	ENSG00000239791.1	AC002310.7	3.7	0.000241	0.0289	0.3	0.17	Tonsillectomy;	chr16:30798213	chr16:30572250~30583860:+
LUAD	cis	rs6687758	0.687	rs7520544	ENSG00000238042.4	RP11-815M8.1	3.7	0.000241	0.0289	0.23	0.17	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221943856	chr1:221880981~221978523:-
LUAD	cis	rs7215564	0.73	rs34405143	ENSG00000232083.3	RPL31P7	3.7	0.000241	0.0289	0.31	0.17	Myopia (pathological);	chr17:80611881	chr17:80602549~80602926:-
LUAD	cis	rs7215564	0.818	rs4890054	ENSG00000232083.3	RPL31P7	3.7	0.000241	0.0289	0.31	0.17	Myopia (pathological);	chr17:80613395	chr17:80602549~80602926:-
LUAD	cis	rs2468186	0.789	rs13252588	ENSG00000281641.1	SAMD12-AS1	-3.7	0.000241	0.0289	-0.22	-0.17	Osteoprotegerin levels;	chr8:119204313	chr8:118621001~118858218:+
LUAD	cis	rs4554975	0.516	rs10881011	ENSG00000274723.1	RP11-618L22.1	-3.7	0.000241	0.0289	-0.2	-0.17	Metabolite levels (small molecules and protein measures);	chr12:46932122	chr12:46970504~46972155:+
LUAD	cis	rs7077256	0.564	rs12772006	ENSG00000272767.1	JMJD1C-AS1	3.7	0.000241	0.0289	0.25	0.17	Intelligence (multi-trait analysis);	chr10:63358085	chr10:63465229~63466563:+
LUAD	cis	rs4907240	0.806	rs4907237	ENSG00000237510.6	AC008268.2	-3.7	0.000241	0.0289	-0.24	-0.17	Event-related brain oscillations;	chr2:96524760	chr2:95789654~95800166:+
LUAD	cis	rs655720	1	rs655720	ENSG00000239213.4	NCK1-AS1	3.7	0.000241	0.0289	0.2	0.17	Coronary artery disease;	chr3:136384425	chr3:136841726~136862054:-
LUAD	cis	rs7178375	1	rs9806159	ENSG00000270015.1	RP11-540B6.6	3.7	0.000241	0.0289	0.14	0.17	Hypertriglyceridemia;	chr15:30917451	chr15:30926514~30928407:+
LUAD	cis	rs6764363	0.674	rs17271940	ENSG00000224318.4	CHL1-AS2	3.7	0.000241	0.0289	0.24	0.17	Sudden cardiac arrest;	chr3:242064	chr3:195758~197341:-
LUAD	cis	rs6460942	0.841	rs6968277	ENSG00000226690.5	AC005281.1	3.7	0.000241	0.0289	0.27	0.17	Coronary artery disease;	chr7:12404169	chr7:12496429~12541910:+
LUAD	cis	rs911555	0.755	rs1138400	ENSG00000244691.1	RPL10AP1	-3.7	0.000242	0.029	-0.22	-0.17	Intelligence (multi-trait analysis);	chr14:103490496	chr14:103412119~103412761:-
LUAD	cis	rs7968440	0.933	rs2700480	ENSG00000272368.2	RP4-605O3.4	3.7	0.000242	0.029	0.19	0.17	Fibrinogen;	chr12:50628648	chr12:50112197~50165618:+
LUAD	cis	rs10829156	0.699	rs7911922	ENSG00000240291.1	RP11-499P20.2	3.7	0.000242	0.029	0.15	0.17	Sudden cardiac arrest;	chr10:18542768	chr10:18513115~18545651:-
LUAD	cis	rs6121246	0.909	rs6060793	ENSG00000230613.1	HM13-AS1	3.7	0.000242	0.029	0.24	0.17	Mean corpuscular hemoglobin;	chr20:31701027	chr20:31567707~31573263:-
LUAD	cis	rs2708977	0.637	rs583705	ENSG00000237510.6	AC008268.2	-3.7	0.000242	0.029	-0.21	-0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96403016	chr2:95789654~95800166:+
LUAD	cis	rs2717559	0.542	rs10956986	ENSG00000253741.1	CTD-2292P10.4	3.7	0.000242	0.029	0.19	0.17	Urinary tract infection frequency;	chr8:142805185	chr8:142702252~142726973:-
LUAD	cis	rs10065813	1	rs77286766	ENSG00000253119.1	HNRNPA3P7	3.7	0.000242	0.029	0.26	0.17	Obesity-related traits;	chr5:153525523	chr5:154337471~154338452:-
LUAD	cis	rs3198697	0.617	rs11075253	ENSG00000207425.1	Y_RNA	3.7	0.000242	0.029	0.21	0.17	Triglycerides;	chr16:15054789	chr16:14915457~14915556:-
LUAD	cis	rs7976269	0.559	rs10771471	ENSG00000275476.1	RP11-996F15.4	-3.7	0.000242	0.029	-0.18	-0.17	Male-pattern baldness;	chr12:29050894	chr12:29277397~29277882:-
LUAD	cis	rs7178424	0.967	rs11635980	ENSG00000259251.2	RP11-643M14.1	-3.7	0.000242	0.029	-0.17	-0.17	Height;	chr15:62078317	chr15:62060503~62062434:+
LUAD	cis	rs3743162	1	rs3743162	ENSG00000225151.9	GOLGA2P7	-3.7	0.000242	0.029	-0.25	-0.17	Alzheimer's disease (age of onset);	chr15:84887738	chr15:84199311~84230136:-
LUAD	cis	rs412050	0.547	rs79111189	ENSG00000224086.5	LL22NC03-86G7.1	-3.7	0.000242	0.029	-0.21	-0.17	Attention deficit hyperactivity disorder;	chr22:21810308	chr22:21938293~21977632:+
LUAD	cis	rs9309473	0.948	rs10170849	ENSG00000230002.2	ALMS1-IT1	3.7	0.000242	0.029	0.21	0.17	Metabolite levels;	chr2:73520805	chr2:73456764~73459484:+
LUAD	cis	rs2348418	0.864	rs7295120	ENSG00000244712.1	RP11-874G11.1	3.7	0.000242	0.029	0.2	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28565175	chr12:28564678~28565141:-
LUAD	cis	rs507080	0.733	rs601318	ENSG00000278376.1	RP11-158I9.8	-3.7	0.000242	0.029	-0.18	-0.17	Serum metabolite levels;	chr11:118648845	chr11:118791254~118793137:+
LUAD	cis	rs2295359	1	rs4655524	ENSG00000275678.1	RP4-547N15.3	-3.7	0.000242	0.029	-0.17	-0.17	Psoriasis;	chr1:67163786	chr1:67121605~67123956:-
LUAD	cis	rs4676049	1	rs4676228	ENSG00000204588.5	LINC01123	-3.7	0.000242	0.029	-0.26	-0.17	Alzheimer's disease (late onset);	chr2:109018765	chr2:109987063~109996140:+
LUAD	cis	rs7246657	0.943	rs7253091	ENSG00000226686.6	LINC01535	-3.7	0.000242	0.029	-0.24	-0.17	Coronary artery calcification;	chr19:37476312	chr19:37251912~37265535:+
LUAD	cis	rs8073060	0.586	rs6505487	ENSG00000267592.1	CTC-507E2.2	3.7	0.000242	0.029	0.24	0.17	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35669831	chr17:35596904~35597128:-
LUAD	cis	rs757081	0.667	rs34724588	ENSG00000260196.1	RP1-239B22.5	-3.7	0.000242	0.029	-0.22	-0.17	Systolic blood pressure;	chr11:17116034	chr11:17380649~17383531:+
LUAD	cis	rs757081	0.667	rs3950680	ENSG00000260196.1	RP1-239B22.5	-3.7	0.000242	0.029	-0.22	-0.17	Systolic blood pressure;	chr11:17117119	chr11:17380649~17383531:+
LUAD	cis	rs4716602	0.596	rs10266659	ENSG00000235029.1	MNX1-AS2	-3.7	0.000242	0.029	-0.2	-0.17	Anti-saccade response;	chr7:156366584	chr7:157006307~157007132:+
LUAD	cis	rs2348418	0.798	rs10843161	ENSG00000247934.4	RP11-967K21.1	3.7	0.000242	0.029	0.19	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28367688	chr12:28163298~28190738:-
LUAD	cis	rs7840202	0.961	rs3018507	ENSG00000253328.2	SUMO2P19	3.7	0.000242	0.029	0.18	0.17	Rate of cognitive decline in mild cognitive impairment (time interaction);Gestational age at birth in labor-initiated deliveries (child effect);	chr8:102266460	chr8:102242040~102242619:-
LUAD	cis	rs6438234	0.778	rs747988	ENSG00000242767.1	ZBTB20-AS4	3.7	0.000242	0.029	0.21	0.17	Type 2 diabetes;	chr3:115220663	chr3:115100423~115103061:+
LUAD	cis	rs763121	0.853	rs1569716	ENSG00000228274.3	RP3-508I15.9	-3.7	0.000242	0.029	-0.16	-0.17	Menopause (age at onset);	chr22:38602514	chr22:38667585~38681820:-
LUAD	cis	rs7826238	0.517	rs35144760	ENSG00000173295.6	FAM86B3P	-3.7	0.000242	0.029	-0.18	-0.17	Systolic blood pressure;	chr8:8504213	chr8:8228595~8244865:+
LUAD	cis	rs703842	1	rs11172351	ENSG00000245651.2	RP11-620J15.2	3.7	0.000242	0.029	0.18	0.17	Multiple sclerosis;	chr12:57819702	chr12:57869835~57896482:-
LUAD	cis	rs9951698	0.678	rs557846	ENSG00000266969.1	RP11-773H22.4	3.7	0.000242	0.029	0.22	0.17	Intelligence (multi-trait analysis);	chr18:13133775	chr18:12984694~12991173:-
LUAD	cis	rs2179367	0.959	rs562428	ENSG00000216906.2	RP11-350J20.9	3.7	0.000242	0.029	0.21	0.17	Dupuytren's disease;	chr6:149326389	chr6:149904243~149906418:+
LUAD	cis	rs1551277	1	rs1551276	ENSG00000146666.5	LINC00525	-3.7	0.000242	0.029	-0.19	-0.17	Anxiety disorder;	chr7:47789664	chr7:47761476~47766772:+
LUAD	cis	rs7546668	1	rs4233534	ENSG00000272510.1	RP4-680D5.8	3.7	0.000242	0.029	0.21	0.17	Glomerular filtration rate (creatinine);	chr1:15515834	chr1:15565611~15565956:-
LUAD	cis	rs36093844	0.527	rs4944554	ENSG00000279742.1	RP11-700A24.1	-3.7	0.000242	0.029	-0.2	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86046850	chr11:85852557~85854943:-
LUAD	cis	rs17406451	1	rs34175409	ENSG00000279873.2	LINC01126	3.7	0.000242	0.029	0.14	0.17	Mitochondrial DNA levels;	chr2:43416175	chr2:43227210~43228855:+
LUAD	cis	rs6502050	0.835	rs67682841	ENSG00000275966.1	RP11-1055B8.9	-3.7	0.000242	0.029	-0.17	-0.17	Life satisfaction;	chr17:82159869	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.698	rs67143649	ENSG00000275966.1	RP11-1055B8.9	-3.7	0.000242	0.029	-0.17	-0.17	Life satisfaction;	chr17:82159896	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.698	rs36043222	ENSG00000275966.1	RP11-1055B8.9	-3.7	0.000242	0.029	-0.17	-0.17	Life satisfaction;	chr17:82159946	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.799	rs34795957	ENSG00000275966.1	RP11-1055B8.9	-3.7	0.000242	0.029	-0.17	-0.17	Life satisfaction;	chr17:82160137	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs12950475	ENSG00000275966.1	RP11-1055B8.9	-3.7	0.000242	0.029	-0.17	-0.17	Life satisfaction;	chr17:82161048	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.764	rs35416122	ENSG00000275966.1	RP11-1055B8.9	-3.7	0.000242	0.029	-0.17	-0.17	Life satisfaction;	chr17:82161130	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.764	rs35713597	ENSG00000275966.1	RP11-1055B8.9	-3.7	0.000242	0.029	-0.17	-0.17	Life satisfaction;	chr17:82161140	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs35192339	ENSG00000275966.1	RP11-1055B8.9	-3.7	0.000242	0.029	-0.17	-0.17	Life satisfaction;	chr17:82161230	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.805	rs9915071	ENSG00000275966.1	RP11-1055B8.9	-3.7	0.000242	0.029	-0.17	-0.17	Life satisfaction;	chr17:82161262	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.769	rs4789741	ENSG00000275966.1	RP11-1055B8.9	-3.7	0.000242	0.029	-0.17	-0.17	Life satisfaction;	chr17:82161308	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.769	rs8068708	ENSG00000275966.1	RP11-1055B8.9	-3.7	0.000242	0.029	-0.17	-0.17	Life satisfaction;	chr17:82162548	chr17:81345476~81345966:-
LUAD	cis	rs2147959	0.831	rs7555386	ENSG00000269934.1	RP5-1139B12.3	-3.7	0.000242	0.029	-0.22	-0.17	Adult asthma;	chr1:228442888	chr1:228274584~228276066:-
LUAD	cis	rs2348418	0.864	rs7960369	ENSG00000247934.4	RP11-967K21.1	3.7	0.000242	0.029	0.19	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28561569	chr12:28163298~28190738:-
LUAD	cis	rs6661961	0.752	rs4845768	ENSG00000237975.5	FLG-AS1	-3.7	0.000242	0.029	-0.23	-0.17	Atopic dermatitis;	chr1:152442997	chr1:152168125~152445456:+
LUAD	cis	rs34286592	0.929	rs11863748	ENSG00000214725.6	CDIPT-AS1	-3.7	0.000242	0.029	-0.27	-0.17	Multiple sclerosis;	chr16:29824267	chr16:29863593~29868053:+
LUAD	cis	rs7242404	0.57	rs2096863	ENSG00000267654.1	RP11-973H7.4	3.7	0.000242	0.029	0.19	0.17	Interleukin-9 levels;Macrophage inflammatory protein 1a levels;	chr18:12762351	chr18:12739490~12749421:-
LUAD	cis	rs451417	1	rs236102	ENSG00000275632.1	RP5-967N21.11	3.7	0.000242	0.029	0.21	0.17	Menopause (age at onset);	chr20:5971320	chr20:6000418~6000941:+
LUAD	cis	rs8014204	0.836	rs7153700	ENSG00000279594.1	RP11-950C14.10	3.7	0.000242	0.029	0.19	0.17	Caffeine consumption;	chr14:74801841	chr14:75011269~75012851:-
LUAD	cis	rs10129255	0.957	rs1024349	ENSG00000211947.2	IGHV3-21	-3.7	0.000242	0.029	-0.11	-0.17	Kawasaki disease;	chr14:106689997	chr14:106235064~106235594:-
LUAD	cis	rs638893	0.853	rs4938549	ENSG00000255239.1	AP002954.6	3.7	0.000242	0.029	0.27	0.17	Vitiligo;	chr11:118830888	chr11:118688039~118690600:-
LUAD	cis	rs638893	0.898	rs530646	ENSG00000255239.1	AP002954.6	3.7	0.000242	0.029	0.27	0.17	Vitiligo;	chr11:118830959	chr11:118688039~118690600:-
LUAD	cis	rs7617773	0.817	rs6800492	ENSG00000199476.1	Y_RNA	-3.7	0.000242	0.029	-0.22	-0.17	Coronary artery disease;	chr3:48282400	chr3:48288587~48288694:+
LUAD	cis	rs35520189	0.625	rs12614316	ENSG00000227368.1	AC079753.5	3.7	0.000243	0.029	0.21	0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112947826	chr2:112932625~112933171:+
LUAD	cis	rs7005380	0.6	rs13257316	ENSG00000279347.1	RP11-85I17.2	-3.7	0.000243	0.029	-0.14	-0.17	Interstitial lung disease;	chr8:119891494	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.58	rs12681623	ENSG00000279347.1	RP11-85I17.2	-3.7	0.000243	0.029	-0.14	-0.17	Interstitial lung disease;	chr8:119891616	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.62	rs13265367	ENSG00000279347.1	RP11-85I17.2	-3.7	0.000243	0.029	-0.14	-0.17	Interstitial lung disease;	chr8:119891769	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.62	rs10107251	ENSG00000279347.1	RP11-85I17.2	-3.7	0.000243	0.029	-0.14	-0.17	Interstitial lung disease;	chr8:119892108	chr8:119838736~119840385:-
LUAD	cis	rs7005380	0.62	rs10094587	ENSG00000279347.1	RP11-85I17.2	-3.7	0.000243	0.029	-0.14	-0.17	Interstitial lung disease;	chr8:119892560	chr8:119838736~119840385:-
LUAD	cis	rs7824557	0.564	rs6601584	ENSG00000255046.1	RP11-297N6.4	3.7	0.000243	0.0291	0.2	0.17	Retinal vascular caliber;	chr8:11374834	chr8:11797928~11802568:-
LUAD	cis	rs4838594	0.563	rs730509	ENSG00000265018.5	CTGLF12P	-3.7	0.000243	0.0291	-0.2	-0.17	Daytime sleep phenotypes;	chr10:48471110	chr10:48009873~48031640:-
LUAD	cis	rs7945705	0.791	rs7944560	ENSG00000254860.4	TMEM9B-AS1	-3.7	0.000243	0.0291	-0.19	-0.17	Hemoglobin concentration;	chr11:8795729	chr11:8964675~8977527:+
LUAD	cis	rs7674212	0.57	rs12501621	ENSG00000251288.2	RP11-10L12.2	-3.7	0.000243	0.0291	-0.21	-0.17	Type 2 diabetes;	chr4:103174348	chr4:102751401~102752641:+
LUAD	cis	rs4474465	0.833	rs7934912	ENSG00000251323.2	RP11-452H21.4	-3.7	0.000243	0.0291	-0.21	-0.17	Alzheimer's disease (survival time);	chr11:78507510	chr11:78423982~78429836:-
LUAD	cis	rs7831492	0.548	rs10089438	ENSG00000253133.1	RP11-360L9.4	-3.7	0.000243	0.0291	-0.23	-0.17	Colorectal cancer;	chr8:41806628	chr8:41534155~41578368:-
LUAD	cis	rs1501138	0.597	rs203442	ENSG00000263327.5	TAPT1-AS1	-3.7	0.000243	0.0291	-0.24	-0.17	Systemic juvenile idiopathic arthritis;	chr4:16245045	chr4:16226685~16320140:+
LUAD	cis	rs6071166	0.873	rs2864948	ENSG00000224635.1	RP4-564F22.5	-3.7	0.000243	0.0291	-0.18	-0.17	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38694171	chr20:38406011~38416797:-
LUAD	cis	rs5995756	0.627	rs3788568	ENSG00000227188.1	MGAT3-AS1	-3.7	0.000243	0.0291	-0.18	-0.17	Autism spectrum disorder or schizophrenia;	chr22:39615268	chr22:39475807~39476822:-
LUAD	cis	rs7129556	0.728	rs34130561	ENSG00000241782.1	RP11-91P24.1	3.7	0.000243	0.0291	0.24	0.17	Weight loss (gastric bypass surgery);	chr11:77785645	chr11:77868722~77869195:-
LUAD	cis	rs7129556	0.737	rs623173	ENSG00000241782.1	RP11-91P24.1	-3.7	0.000243	0.0291	-0.24	-0.17	Weight loss (gastric bypass surgery);	chr11:77818482	chr11:77868722~77869195:-
LUAD	cis	rs214785	1	rs214783	ENSG00000234684.5	SDCBP2-AS1	3.7	0.000243	0.0291	0.2	0.17	Basal cell carcinoma;	chr20:2301403	chr20:1325405~1378734:+
LUAD	cis	rs2380205	0.601	rs4293039	ENSG00000232807.2	RP11-536K7.3	3.7	0.000243	0.0291	0.18	0.17	Breast cancer;	chr10:5856261	chr10:5934270~5945900:-
LUAD	cis	rs12446632	0.941	rs8055543	ENSG00000261195.1	CTD-2380F24.1	-3.7	0.000243	0.0291	-0.24	-0.17	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Menarche (age at onset);Obesity;Childhood body mass index;Waist circumference;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr16:19914869	chr16:19761172~19766099:-
LUAD	cis	rs12446632	0.941	rs72771041	ENSG00000261195.1	CTD-2380F24.1	-3.7	0.000243	0.0291	-0.24	-0.17	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Menarche (age at onset);Obesity;Childhood body mass index;Waist circumference;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr16:19916385	chr16:19761172~19766099:-
LUAD	cis	rs12446632	0.882	rs7190603	ENSG00000261195.1	CTD-2380F24.1	-3.7	0.000243	0.0291	-0.24	-0.17	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Menarche (age at onset);Obesity;Childhood body mass index;Waist circumference;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr16:19917340	chr16:19761172~19766099:-
LUAD	cis	rs481331	0.866	rs11239614	ENSG00000185904.10	LINC00839	3.7	0.000243	0.0291	0.28	0.17	Systemic juvenile idiopathic arthritis;	chr10:42487070	chr10:42475543~42495336:+
LUAD	cis	rs7551222	0.68	rs2169137	ENSG00000240219.1	RP11-430C7.5	3.7	0.000243	0.0291	0.19	0.17	Schizophrenia;	chr1:204528785	chr1:204626775~204629712:+
LUAD	cis	rs2033711	0.654	rs734380	ENSG00000269054.1	CTD-2619J13.3	-3.7	0.000243	0.0291	-0.16	-0.17	Uric acid clearance;	chr19:58387596	chr19:58362585~58366591:+
LUAD	cis	rs1023500	0.505	rs134891	ENSG00000273366.1	CTA-989H11.1	-3.7	0.000243	0.0291	-0.19	-0.17	Schizophrenia;	chr22:42279876	chr22:42278188~42278846:+
LUAD	cis	rs13113518	0.729	rs13120134	ENSG00000273257.1	RP11-177J6.1	3.7	0.000243	0.0291	0.2	0.17	Height;	chr4:55415153	chr4:55387949~55388271:+
LUAD	cis	rs7017914	1	rs13252719	ENSG00000246366.5	RP11-382J12.1	3.7	0.000243	0.0291	0.15	0.17	Bone mineral density;	chr8:70822334	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.934	rs13274062	ENSG00000246366.5	RP11-382J12.1	3.7	0.000243	0.0291	0.15	0.17	Bone mineral density;	chr8:70824852	chr8:70608577~70663279:+
LUAD	cis	rs7005380	0.581	rs28461628	ENSG00000279347.1	RP11-85I17.2	3.7	0.000243	0.0291	0.16	0.17	Interstitial lung disease;	chr8:119928627	chr8:119838736~119840385:-
LUAD	cis	rs6479901	0.894	rs7098614	ENSG00000232075.1	MRPL35P2	-3.7	0.000243	0.0291	-0.22	-0.17	Intelligence (multi-trait analysis);	chr10:63355667	chr10:63634317~63634827:-
LUAD	cis	rs6540731	1	rs7518329	ENSG00000229983.1	RP11-15I11.2	3.7	0.000243	0.0291	0.2	0.17	Intelligence (childhood);	chr1:212225191	chr1:212168207~212190259:+
LUAD	cis	rs9309473	0.95	rs13408433	ENSG00000273245.1	RP11-434P11.2	3.7	0.000243	0.0291	0.21	0.17	Metabolite levels;	chr2:73655945	chr2:73750256~73750786:-
LUAD	cis	rs7107174	1	rs10899479	ENSG00000251323.2	RP11-452H21.4	3.7	0.000243	0.0291	0.21	0.17	Testicular germ cell tumor;	chr11:78341493	chr11:78423982~78429836:-
LUAD	cis	rs7107174	1	rs11237462	ENSG00000251323.2	RP11-452H21.4	3.7	0.000243	0.0291	0.21	0.17	Testicular germ cell tumor;	chr11:78347766	chr11:78423982~78429836:-
LUAD	cis	rs4938303	0.671	rs35352977	ENSG00000254851.1	RP11-109L13.1	3.7	0.000243	0.0291	0.26	0.17	Triglycerides;	chr11:116681756	chr11:117135528~117138582:+
LUAD	cis	rs13395090	0.967	rs12105179	ENSG00000242282.5	AC108488.4	3.7	0.000243	0.0291	0.18	0.17	Response to inhaled corticosteroid treatment in asthma (change in FEV1);	chr2:3674139	chr2:3531813~3536873:-
LUAD	cis	rs6661961	0.752	rs4845767	ENSG00000237975.5	FLG-AS1	-3.7	0.000243	0.0291	-0.23	-0.17	Atopic dermatitis;	chr1:152442832	chr1:152168125~152445456:+
LUAD	cis	rs9925964	0.967	rs1549293	ENSG00000232748.3	RP11-196G11.6	3.7	0.000243	0.0291	0.21	0.17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31130672	chr16:31056460~31062803:+
LUAD	cis	rs8046148	0.724	rs2356836	ENSG00000279356.1	RP11-429P3.8	3.7	0.000243	0.0291	0.17	0.17	Testicular germ cell tumor;	chr16:50086958	chr16:50072862~50074986:+
LUAD	cis	rs11673344	0.932	rs76350084	ENSG00000267309.1	CTD-2630F21.1	-3.7	0.000243	0.0291	-0.21	-0.17	Obesity-related traits;	chr19:37187917	chr19:36489649~36491040:+
LUAD	cis	rs10197140	0.857	rs17545286	ENSG00000235721.1	AC013268.3	-3.7	0.000243	0.0291	-0.18	-0.17	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110908204	chr2:110007675~110010783:+
LUAD	cis	rs4578769	0.55	rs9951410	ENSG00000266850.1	RP11-370A5.1	3.7	0.000243	0.0291	0.21	0.17	Eosinophil percentage of white cells;	chr18:22964944	chr18:22723491~22907721:-
LUAD	cis	rs4578769	0.505	rs9951982	ENSG00000266850.1	RP11-370A5.1	3.7	0.000243	0.0291	0.21	0.17	Eosinophil percentage of white cells;	chr18:22965607	chr18:22723491~22907721:-
LUAD	cis	rs4819052	1	rs2838847	ENSG00000223768.1	LINC00205	-3.7	0.000243	0.0291	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251043	chr21:45293285~45297354:+
LUAD	cis	rs1023500	0.573	rs13057094	ENSG00000273366.1	CTA-989H11.1	-3.7	0.000243	0.0291	-0.2	-0.17	Schizophrenia;	chr22:42074313	chr22:42278188~42278846:+
LUAD	cis	rs4474465	0.688	rs10899553	ENSG00000251323.2	RP11-452H21.4	-3.7	0.000243	0.0291	-0.21	-0.17	Alzheimer's disease (survival time);	chr11:78554164	chr11:78423982~78429836:-
LUAD	cis	rs4474465	0.85	rs7936232	ENSG00000251323.2	RP11-452H21.4	-3.7	0.000243	0.0291	-0.21	-0.17	Alzheimer's disease (survival time);	chr11:78555556	chr11:78423982~78429836:-
LUAD	cis	rs6951245	1	rs78158942	ENSG00000199023.2	MIR339	-3.7	0.000243	0.0291	-0.3	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1050804	chr7:1022935~1023045:-
LUAD	cis	rs875971	0.895	rs1974769	ENSG00000273142.1	RP11-458F8.4	-3.7	0.000243	0.0291	-0.12	-0.17	Aortic root size;	chr7:66485627	chr7:66902857~66906297:+
LUAD	cis	rs875971	0.895	rs6460300	ENSG00000273142.1	RP11-458F8.4	-3.7	0.000243	0.0291	-0.12	-0.17	Aortic root size;	chr7:66487937	chr7:66902857~66906297:+
LUAD	cis	rs875971	0.862	rs7803416	ENSG00000273142.1	RP11-458F8.4	-3.7	0.000243	0.0291	-0.12	-0.17	Aortic root size;	chr7:66489212	chr7:66902857~66906297:+
LUAD	cis	rs875971	0.862	rs1981799	ENSG00000273142.1	RP11-458F8.4	-3.7	0.000243	0.0291	-0.12	-0.17	Aortic root size;	chr7:66490572	chr7:66902857~66906297:+
LUAD	cis	rs875971	0.964	rs2277911	ENSG00000273142.1	RP11-458F8.4	-3.7	0.000243	0.0291	-0.12	-0.17	Aortic root size;	chr7:66493638	chr7:66902857~66906297:+
LUAD	cis	rs875971	0.964	rs6978429	ENSG00000273142.1	RP11-458F8.4	-3.7	0.000243	0.0291	-0.12	-0.17	Aortic root size;	chr7:66494889	chr7:66902857~66906297:+
LUAD	cis	rs875971	1	rs4718357	ENSG00000273142.1	RP11-458F8.4	-3.7	0.000243	0.0291	-0.12	-0.17	Aortic root size;	chr7:66495891	chr7:66902857~66906297:+
LUAD	cis	rs875971	0.929	rs12535036	ENSG00000273142.1	RP11-458F8.4	-3.7	0.000243	0.0291	-0.12	-0.17	Aortic root size;	chr7:66499076	chr7:66902857~66906297:+
LUAD	cis	rs875971	1	rs12533997	ENSG00000273142.1	RP11-458F8.4	-3.7	0.000243	0.0291	-0.12	-0.17	Aortic root size;	chr7:66500390	chr7:66902857~66906297:+
LUAD	cis	rs875971	1	rs12698523	ENSG00000273142.1	RP11-458F8.4	-3.7	0.000243	0.0291	-0.12	-0.17	Aortic root size;	chr7:66503126	chr7:66902857~66906297:+
LUAD	cis	rs875971	1	rs6970030	ENSG00000273142.1	RP11-458F8.4	-3.7	0.000243	0.0291	-0.12	-0.17	Aortic root size;	chr7:66503692	chr7:66902857~66906297:+
LUAD	cis	rs875971	0.928	rs6970357	ENSG00000273142.1	RP11-458F8.4	-3.7	0.000243	0.0291	-0.12	-0.17	Aortic root size;	chr7:66503891	chr7:66902857~66906297:+
LUAD	cis	rs13006833	0.739	rs291470	ENSG00000227542.1	AC092614.2	-3.7	0.000243	0.0291	-0.2	-0.17	Urinary metabolites;	chr2:190324832	chr2:191229165~191246172:-
LUAD	cis	rs6121246	0.821	rs3181073	ENSG00000230613.1	HM13-AS1	-3.7	0.000243	0.0291	-0.24	-0.17	Mean corpuscular hemoglobin;	chr20:31719396	chr20:31567707~31573263:-
LUAD	cis	rs4763879	0.594	rs12427310	ENSG00000278635.1	CTD-2318O12.1	3.7	0.000243	0.0291	0.15	0.17	Type 1 diabetes;	chr12:9707539	chr12:9415641~9416718:+
LUAD	cis	rs6781182	0.517	rs968102	ENSG00000236452.1	AC123023.1	3.7	0.000243	0.0291	0.18	0.17	Visceral adipose tissue adjusted for BMI;	chr3:34192971	chr3:34203244~34268811:+
LUAD	cis	rs2506028	1	rs788261	ENSG00000234944.1	RP11-124O11.1	3.7	0.000243	0.0291	0.18	0.17	Blood protein levels;	chr10:42942522	chr10:42871521~42874060:+
LUAD	cis	rs4819052	0.851	rs2236444	ENSG00000215447.6	BX322557.10	-3.7	0.000244	0.0291	-0.2	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258311	chr21:45288052~45291738:+
LUAD	cis	rs4815191	0.887	rs6048678	ENSG00000259974.2	LINC00261	3.7	0.000244	0.0291	0.19	0.17	Obesity-related traits;	chr20:23285260	chr20:22547671~22578642:-
LUAD	cis	rs728616	0.867	rs2152548	ENSG00000225484.5	NUTM2B-AS1	-3.7	0.000244	0.0291	-0.37	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80042911	chr10:79663088~79826594:-
LUAD	cis	rs3126085	0.935	rs6681457	ENSG00000237975.5	FLG-AS1	3.7	0.000244	0.0291	0.27	0.17	Atopic dermatitis;	chr1:152324641	chr1:152168125~152445456:+
LUAD	cis	rs2664588	0.538	rs6018825	ENSG00000224565.1	RP1-148H17.1	-3.7	0.000244	0.0291	-0.18	-0.17	Cerebrospinal fluid AB1-42 levels;	chr20:47965916	chr20:47391929~47412327:-
LUAD	cis	rs1044826	0.956	rs7374385	ENSG00000214280.3	RP11-553K23.2	-3.7	0.000244	0.0292	-0.2	-0.17	Obesity-related traits;	chr3:139399702	chr3:139582928~139583593:-
LUAD	cis	rs2625529	0.652	rs8036307	ENSG00000260173.1	RP11-2I17.4	3.7	0.000244	0.0292	0.2	0.17	Red blood cell count;	chr15:71882779	chr15:72140504~72155459:-
LUAD	cis	rs9467773	0.62	rs2451738	ENSG00000261353.1	CTA-14H9.5	3.7	0.000244	0.0292	0.18	0.17	Intelligence (multi-trait analysis);	chr6:26618231	chr6:26527063~26527404:+
LUAD	cis	rs2554380	0.891	rs2244838	ENSG00000230373.7	GOLGA6L5P	-3.7	0.000244	0.0292	-0.2	-0.17	Height;	chr15:83629846	chr15:84507885~84516814:-
LUAD	cis	rs8014204	0.868	rs2230237	ENSG00000279594.1	RP11-950C14.10	-3.7	0.000244	0.0292	-0.19	-0.17	Caffeine consumption;	chr14:74892967	chr14:75011269~75012851:-
LUAD	cis	rs8014204	0.935	rs4903267	ENSG00000279594.1	RP11-950C14.10	-3.7	0.000244	0.0292	-0.19	-0.17	Caffeine consumption;	chr14:74893716	chr14:75011269~75012851:-
LUAD	cis	rs911555	0.692	rs60235428	ENSG00000259775.1	RP11-45P15.4	3.7	0.000244	0.0292	0.22	0.17	Intelligence (multi-trait analysis);	chr14:103438013	chr14:103331674~103332367:-
LUAD	cis	rs911555	0.755	rs8016676	ENSG00000259775.1	RP11-45P15.4	3.7	0.000244	0.0292	0.22	0.17	Intelligence (multi-trait analysis);	chr14:103438505	chr14:103331674~103332367:-
LUAD	cis	rs9549260	0.564	rs7998086	ENSG00000168852.11	TPTE2P5	3.7	0.000244	0.0292	0.16	0.17	Red blood cell count;	chr13:40694788	chr13:40822296~40921749:-
LUAD	cis	rs1023500	0.551	rs133379	ENSG00000205702.9	CYP2D7	3.7	0.000244	0.0292	0.14	0.17	Schizophrenia;	chr22:42072531	chr22:42140203~42144577:-
LUAD	cis	rs755249	0.565	rs4660846	ENSG00000182109.6	RP11-69E11.4	-3.7	0.000244	0.0292	-0.18	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39583839	chr1:39522280~39546187:-
LUAD	cis	rs755249	0.565	rs7539279	ENSG00000182109.6	RP11-69E11.4	-3.7	0.000244	0.0292	-0.18	-0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39584896	chr1:39522280~39546187:-
LUAD	cis	rs2348418	0.966	rs7315631	ENSG00000244712.1	RP11-874G11.1	3.7	0.000244	0.0292	0.2	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28545311	chr12:28564678~28565141:-
LUAD	cis	rs11673344	0.526	rs17305823	ENSG00000267254.4	ZNF790-AS1	3.7	0.000244	0.0292	0.21	0.17	Obesity-related traits;	chr19:37644145	chr19:36797518~36828115:+
LUAD	cis	rs8031584	0.958	rs8034856	ENSG00000260128.5	ULK4P2	-3.7	0.000244	0.0292	-0.21	-0.17	Huntington's disease progression;	chr15:30948754	chr15:30572738~30600647:+
LUAD	cis	rs910873	0.656	rs4911442	ENSG00000250917.1	RP4-785G19.5	3.7	0.000244	0.0292	0.35	0.17	Melanoma;	chr20:34767243	chr20:34234840~34281173:-
LUAD	cis	rs75920871	0.64	rs4938357	ENSG00000280143.1	AP000892.6	3.7	0.000244	0.0292	0.26	0.17	Subjective well-being;	chr11:117213324	chr11:117204967~117210292:+
LUAD	cis	rs10878674	1	rs10878674	ENSG00000255772.4	LINC01479	3.7	0.000244	0.0292	0.18	0.17	Daytime sleep phenotypes;	chr12:67837461	chr12:67929235~67970017:+
LUAD	cis	rs7942368	1	rs1440980	ENSG00000254632.1	RP11-21L23.4	3.7	0.000244	0.0292	0.18	0.17	Endometriosis;	chr11:76784032	chr11:76759916~76768223:-
LUAD	cis	rs2616407	1	rs2616406	ENSG00000272650.1	RP11-571I18.4	3.7	0.000244	0.0292	0.21	0.17	Coronary artery disease;	chr4:53724556	chr4:53997415~53997712:-
LUAD	cis	rs2616407	1	rs2590831	ENSG00000272650.1	RP11-571I18.4	3.7	0.000244	0.0292	0.21	0.17	Coronary artery disease;	chr4:53724721	chr4:53997415~53997712:-
LUAD	cis	rs2616407	1	rs2590832	ENSG00000272650.1	RP11-571I18.4	3.7	0.000244	0.0292	0.21	0.17	Coronary artery disease;	chr4:53724769	chr4:53997415~53997712:-
LUAD	cis	rs2616407	1	rs2245157	ENSG00000272650.1	RP11-571I18.4	-3.7	0.000244	0.0292	-0.21	-0.17	Coronary artery disease;	chr4:53730299	chr4:53997415~53997712:-
LUAD	cis	rs2616407	1	rs1382083	ENSG00000272650.1	RP11-571I18.4	3.7	0.000244	0.0292	0.21	0.17	Coronary artery disease;	chr4:53730710	chr4:53997415~53997712:-
LUAD	cis	rs2616407	0.945	rs2590776	ENSG00000272650.1	RP11-571I18.4	3.7	0.000244	0.0292	0.21	0.17	Coronary artery disease;	chr4:53730873	chr4:53997415~53997712:-
LUAD	cis	rs2616407	1	rs2616413	ENSG00000272650.1	RP11-571I18.4	3.7	0.000244	0.0292	0.21	0.17	Coronary artery disease;	chr4:53732112	chr4:53997415~53997712:-
LUAD	cis	rs2616407	1	rs2616414	ENSG00000272650.1	RP11-571I18.4	3.7	0.000244	0.0292	0.21	0.17	Coronary artery disease;	chr4:53732814	chr4:53997415~53997712:-
LUAD	cis	rs9341808	0.6	rs2505930	ENSG00000260645.1	RP11-250B2.5	3.7	0.000244	0.0292	0.16	0.17	Sitting height ratio;	chr6:80127341	chr6:80466958~80469080:+
LUAD	cis	rs2348418	0.868	rs12302861	ENSG00000244712.1	RP11-874G11.1	3.7	0.000244	0.0292	0.2	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28516269	chr12:28564678~28565141:-
LUAD	cis	rs7772486	0.686	rs2328708	ENSG00000235652.6	RP11-545I5.3	-3.7	0.000244	0.0292	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145774603	chr6:145799409~145886585:+
LUAD	cis	rs8012947	1	rs8011191	ENSG00000279636.2	LINC00216	-3.7	0.000244	0.0292	-0.18	-0.17	Alcohol consumption in current drinkers;	chr14:58250295	chr14:58288033~58289158:+
LUAD	cis	rs526231	0.853	rs35802	ENSG00000175749.11	EIF3KP1	3.7	0.000244	0.0292	0.22	0.17	Primary biliary cholangitis;	chr5:103271884	chr5:103032376~103033031:+
LUAD	cis	rs987044	0.639	rs10861956	ENSG00000257221.1	RP11-689B22.2	-3.7	0.000244	0.0292	-0.14	-0.17	Mean platelet volume;	chr12:108660699	chr12:108628687~108641318:+
LUAD	cis	rs7200786	0.546	rs1364254	ENSG00000274038.1	RP11-66H6.4	-3.7	0.000244	0.0292	-0.21	-0.17	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11162219	chr16:11056556~11057034:+
LUAD	cis	rs11250098	0.503	rs13270870	ENSG00000255310.2	AF131215.2	-3.7	0.000244	0.0292	-0.16	-0.17	Morning vs. evening chronotype;	chr8:10913272	chr8:11107788~11109726:-
LUAD	cis	rs4578769	0.55	rs4800442	ENSG00000266850.1	RP11-370A5.1	3.7	0.000244	0.0292	0.21	0.17	Eosinophil percentage of white cells;	chr18:22958337	chr18:22723491~22907721:-
LUAD	cis	rs7176527	0.706	rs35641144	ENSG00000259570.1	RP11-671M22.4	-3.7	0.000244	0.0292	-0.25	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84723543	chr15:84394512~84395514:+
LUAD	cis	rs17597773	0.638	rs17008806	ENSG00000272823.1	RP11-295M18.6	-3.7	0.000244	0.0292	-0.21	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220802915	chr1:220828676~220829211:-
LUAD	cis	rs2904524	0.867	rs10879121	ENSG00000257613.1	LINC01481	-3.7	0.000244	0.0292	-0.29	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70277447	chr12:70219132~70221862:-
LUAD	cis	rs412050	0.793	rs238782	ENSG00000224086.5	LL22NC03-86G7.1	-3.7	0.000244	0.0292	-0.21	-0.17	Attention deficit hyperactivity disorder;	chr22:21987595	chr22:21938293~21977632:+
LUAD	cis	rs7429990	0.965	rs9854454	ENSG00000228638.1	FCF1P2	3.7	0.000244	0.0292	0.2	0.17	Educational attainment (years of education);	chr3:47971307	chr3:48290793~48291375:-
LUAD	cis	rs8014252	1	rs7159432	ENSG00000274818.1	RP1-292L20.3	3.7	0.000244	0.0292	0.27	0.17	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70494977	chr14:70906657~70907111:-
LUAD	cis	rs2664588	0.561	rs4629214	ENSG00000224565.1	RP1-148H17.1	-3.7	0.000244	0.0292	-0.18	-0.17	Cerebrospinal fluid AB1-42 levels;	chr20:47963104	chr20:47391929~47412327:-
LUAD	cis	rs950880	0.796	rs12987977	ENSG00000234389.1	AC007278.3	-3.7	0.000244	0.0292	-0.16	-0.17	Serum protein levels (sST2);	chr2:102358876	chr2:102438713~102440475:+
LUAD	cis	rs4795519	0.961	rs11657415	ENSG00000266313.1	RP11-173M1.4	3.7	0.000245	0.0292	0.21	0.17	Chronic myeloid leukemia;	chr17:27175511	chr17:27333256~27348491:+
LUAD	cis	rs6540731	0.521	rs10779572	ENSG00000226251.4	RP11-15I11.3	3.7	0.000245	0.0292	0.2	0.17	Intelligence (childhood);	chr1:212181070	chr1:212225278~212238977:-
LUAD	cis	rs2274273	0.588	rs7155054	ENSG00000258413.1	RP11-665C16.6	-3.7	0.000245	0.0292	-0.22	-0.17	Protein biomarker;	chr14:55283944	chr14:55262767~55272075:-
LUAD	cis	rs2505998	0.868	rs7092603	ENSG00000273008.1	RP11-351D16.3	-3.7	0.000245	0.0292	-0.18	-0.17	Hirschsprung disease;	chr10:43057483	chr10:43136824~43138334:-
LUAD	cis	rs3126085	0.935	rs4845750	ENSG00000237975.5	FLG-AS1	-3.7	0.000245	0.0292	-0.25	-0.17	Atopic dermatitis;	chr1:152228741	chr1:152168125~152445456:+
LUAD	cis	rs8002861	0.905	rs9525869	ENSG00000274001.1	RP11-5G9.5	3.7	0.000245	0.0293	0.17	0.17	Leprosy;	chr13:43893074	chr13:43877715~43878163:-
LUAD	cis	rs7937890	0.559	rs1116739	ENSG00000254418.1	RP11-21L19.1	3.7	0.000245	0.0293	0.19	0.17	Mitochondrial DNA levels;	chr11:14467636	chr11:14262846~14273691:-
LUAD	cis	rs7017914	0.905	rs2732094	ENSG00000246366.5	RP11-382J12.1	3.7	0.000245	0.0293	0.15	0.17	Bone mineral density;	chr8:71007683	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.905	rs2732095	ENSG00000246366.5	RP11-382J12.1	3.7	0.000245	0.0293	0.15	0.17	Bone mineral density;	chr8:71007711	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.87	rs2732096	ENSG00000246366.5	RP11-382J12.1	3.7	0.000245	0.0293	0.15	0.17	Bone mineral density;	chr8:71007745	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.935	rs2732097	ENSG00000246366.5	RP11-382J12.1	3.7	0.000245	0.0293	0.15	0.17	Bone mineral density;	chr8:71007778	chr8:70608577~70663279:+
LUAD	cis	rs524281	0.861	rs6591207	ENSG00000255320.1	RP11-755F10.1	3.7	0.000245	0.0293	0.24	0.17	Electroencephalogram traits;	chr11:66182203	chr11:66244840~66246239:-
LUAD	cis	rs6001482	0.679	rs1475928	ENSG00000211642.2	IGLV10-54	3.7	0.000245	0.0293	0.19	0.17	Diastolic blood pressure;	chr22:22236137	chr22:22214794~22215270:+
LUAD	cis	rs4727963	0.846	rs1554703	ENSG00000240499.6	RP5-1101C3.1	3.7	0.000245	0.0293	0.15	0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);	chr7:123062008	chr7:122328469~122440388:+
LUAD	cis	rs728616	0.867	rs12411407	ENSG00000225484.5	NUTM2B-AS1	-3.7	0.000245	0.0293	-0.35	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80068475	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.867	rs61859008	ENSG00000225484.5	NUTM2B-AS1	-3.7	0.000245	0.0293	-0.35	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80071955	chr10:79663088~79826594:-
LUAD	cis	rs523522	0.673	rs643372	ENSG00000278344.1	RP11-18C24.8	3.7	0.000245	0.0293	0.23	0.17	High light scatter reticulocyte count;	chr12:120584837	chr12:120500735~120501090:-
LUAD	cis	rs6743068	0.541	rs6761514	ENSG00000234842.1	AC007163.8	-3.7	0.000245	0.0293	-0.19	-0.17	Lymphocyte percentage of white cells;	chr2:201362826	chr2:201549631~201550307:+
LUAD	cis	rs9400467	0.508	rs61269242	ENSG00000266032.1	AL357515.1	3.7	0.000245	0.0293	0.22	0.17	Amino acid levels;Blood metabolite levels;	chr6:111481856	chr6:110969773~110969872:-
LUAD	cis	rs72681920	0.881	rs2156731	ENSG00000246090.5	RP11-696N14.1	-3.7	0.000245	0.0293	-0.29	-0.17	Alcohol dependence;	chr4:99151410	chr4:99088857~99301356:+
LUAD	cis	rs2836974	0.932	rs56306759	ENSG00000232608.1	TIMM9P2	-3.7	0.000245	0.0293	-0.2	-0.17	Cognitive function;	chr21:39236180	chr21:39216624~39217506:+
LUAD	cis	rs67981189	0.896	rs3814869	ENSG00000269927.1	RP6-91H8.3	3.7	0.000245	0.0293	0.21	0.17	Schizophrenia;	chr14:71028982	chr14:71141125~71143253:-
LUAD	cis	rs9549260	0.591	rs9577108	ENSG00000168852.11	TPTE2P5	3.7	0.000245	0.0293	0.16	0.17	Red blood cell count;	chr13:40697628	chr13:40822296~40921749:-
LUAD	cis	rs7242404	0.549	rs2105665	ENSG00000267654.1	RP11-973H7.4	3.7	0.000245	0.0293	0.19	0.17	Interleukin-9 levels;Macrophage inflammatory protein 1a levels;	chr18:12762046	chr18:12739490~12749421:-
LUAD	cis	rs453301	0.631	rs28572014	ENSG00000233609.3	RP11-62H7.2	-3.7	0.000245	0.0293	-0.14	-0.17	Joint mobility (Beighton score);	chr8:8936097	chr8:8961200~8979025:+
LUAD	cis	rs7202877	0.561	rs9933956	ENSG00000280152.1	RP11-331F4.5	3.7	0.000245	0.0293	0.19	0.17	Type 1 diabetes;Type 2 diabetes;	chr16:75328915	chr16:75245994~75250077:-
LUAD	cis	rs11920570	0.959	rs9821819	ENSG00000272758.4	RP11-299J3.8	3.7	0.000245	0.0293	0.17	0.17	Resting heart rate;	chr3:122350791	chr3:122416207~122443180:+
LUAD	cis	rs75920871	0.688	rs7109876	ENSG00000254851.1	RP11-109L13.1	-3.7	0.000245	0.0293	-0.32	-0.17	Subjective well-being;	chr11:116977932	chr11:117135528~117138582:+
LUAD	cis	rs9900280	0.967	rs6505119	ENSG00000264808.1	RP11-802D6.1	3.7	0.000245	0.0293	0.2	0.17	Mean platelet volume;	chr17:29378000	chr17:29369717~29390777:-
LUAD	cis	rs1552244	0.882	rs17050672	ENSG00000180385.7	EMC3-AS1	3.7	0.000245	0.0293	0.21	0.17	Alzheimer's disease;	chr3:9983779	chr3:9986893~10006990:+
LUAD	cis	rs801193	0.66	rs1962050	ENSG00000232559.3	GS1-124K5.12	-3.69	0.000245	0.0293	-0.19	-0.17	Aortic root size;	chr7:66775021	chr7:66554588~66576923:-
LUAD	cis	rs7829975	0.755	rs3789849	ENSG00000233609.3	RP11-62H7.2	3.69	0.000245	0.0293	0.14	0.17	Mood instability;	chr8:8829544	chr8:8961200~8979025:+
LUAD	cis	rs1559040	1	rs67951010	ENSG00000272156.1	RP11-477N3.1	-3.69	0.000245	0.0293	-0.27	-0.17	Sudden cardiac arrest;	chr2:54102818	chr2:54082554~54085066:+
LUAD	cis	rs6001482	0.662	rs6001526	ENSG00000211642.2	IGLV10-54	3.69	0.000245	0.0293	0.19	0.17	Diastolic blood pressure;	chr22:22234518	chr22:22214794~22215270:+
LUAD	cis	rs4591358	0.587	rs7604146	ENSG00000223466.1	AC064834.2	3.69	0.000245	0.0293	0.19	0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195522900	chr2:195533035~195538681:+
LUAD	cis	rs1150668	0.799	rs1150705	ENSG00000176933.5	TOB2P1	-3.69	0.000245	0.0293	-0.19	-0.17	Pubertal anthropometrics;	chr6:28226008	chr6:28217643~28218634:-
LUAD	cis	rs3096299	0.967	rs2965937	ENSG00000261574.1	RP1-168P16.2	3.69	0.000245	0.0293	0.19	0.17	Multiple myeloma (IgH translocation);	chr16:89422371	chr16:89392375~89412564:-
LUAD	cis	rs818427	0.964	rs434090	ENSG00000279522.1	CTC-487M23.6	3.69	0.000245	0.0293	0.2	0.17	Total body bone mineral density;	chr5:112893826	chr5:112894933~112896531:+
LUAD	cis	rs2554380	0.943	rs11636516	ENSG00000230373.7	GOLGA6L5P	-3.69	0.000245	0.0293	-0.21	-0.17	Height;	chr15:83693021	chr15:84507885~84516814:-
LUAD	cis	rs7942368	0.941	rs12290350	ENSG00000254632.1	RP11-21L23.4	-3.69	0.000245	0.0293	-0.18	-0.17	Endometriosis;	chr11:76769211	chr11:76759916~76768223:-
LUAD	cis	rs62246343	0.504	rs7652415	ENSG00000206573.7	THUMPD3-AS1	-3.69	0.000245	0.0293	-0.18	-0.17	Fibrinogen levels;	chr3:9463554	chr3:9349689~9398579:-
LUAD	cis	rs6496932	0.865	rs10520600	ENSG00000259630.2	CTD-2262B20.1	3.69	0.000246	0.0293	0.25	0.17	Central corneal thickness;Corneal structure;	chr15:85365171	chr15:85415228~85415633:+
LUAD	cis	rs7142881	0.844	rs10144137	ENSG00000258525.1	RP11-829H16.3	3.69	0.000246	0.0293	0.19	0.17	Response to iloperidone treatment (QT prolongation);	chr14:31563008	chr14:30876179~30889808:-
LUAD	cis	rs7512552	0.839	rs1260459	ENSG00000275557.1	RP11-353N4.6	3.69	0.000246	0.0293	0.19	0.17	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150375777	chr1:149607765~149612402:+
LUAD	cis	rs7512552	0.839	rs834232	ENSG00000275557.1	RP11-353N4.6	3.69	0.000246	0.0293	0.19	0.17	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150382206	chr1:149607765~149612402:+
LUAD	cis	rs8012947	0.877	rs10136481	ENSG00000279636.2	LINC00216	-3.69	0.000246	0.0293	-0.18	-0.17	Alcohol consumption in current drinkers;	chr14:58302690	chr14:58288033~58289158:+
LUAD	cis	rs1563304	1	rs1563304	ENSG00000260075.1	NSFP1	-3.69	0.000246	0.0293	-0.3	-0.17	Neuroticism;	chr17:46797087	chr17:46372855~46487141:+
LUAD	cis	rs7617773	0.744	rs2125482	ENSG00000199476.1	Y_RNA	-3.69	0.000246	0.0293	-0.22	-0.17	Coronary artery disease;	chr3:48281643	chr3:48288587~48288694:+
LUAD	cis	rs8177876	0.658	rs2316730	ENSG00000261061.1	RP11-303E16.2	-3.69	0.000246	0.0293	-0.28	-0.17	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81106035	chr16:81030770~81031485:+
LUAD	cis	rs159572	0.701	rs149175	ENSG00000250853.1	RNF138P1	3.69	0.000246	0.0293	0.2	0.17	Post-traumatic stress disorder;	chr5:56229757	chr5:55530156~55530701:-
LUAD	cis	rs35740288	0.77	rs12898597	ENSG00000259407.1	RP11-158M2.3	-3.69	0.000246	0.0293	-0.16	-0.17	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85646688	chr15:85744109~85750281:-
LUAD	cis	rs35740288	0.77	rs11631386	ENSG00000259407.1	RP11-158M2.3	-3.69	0.000246	0.0293	-0.16	-0.17	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85648764	chr15:85744109~85750281:-
LUAD	cis	rs507080	0.769	rs527290	ENSG00000278376.1	RP11-158I9.8	-3.69	0.000246	0.0293	-0.18	-0.17	Serum metabolite levels;	chr11:118644898	chr11:118791254~118793137:+
LUAD	cis	rs1065852	0.526	rs56234624	ENSG00000226450.2	CYP2D8P	3.69	0.000246	0.0294	0.14	0.17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41992822	chr22:42149886~42155001:-
LUAD	cis	rs4948102	0.642	rs6593297	ENSG00000275875.1	RP11-613E4.5	3.69	0.000246	0.0294	0.18	0.17	Plasma homocysteine levels (post-methionine load test);	chr7:56054365	chr7:55741525~55741869:+
LUAD	cis	rs1348850	0.793	rs13027299	ENSG00000271825.1	RP11-337N6.2	3.69	0.000246	0.0294	0.22	0.17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177590773	chr2:177300600~177302006:+
LUAD	cis	rs9907295	0.591	rs9908928	ENSG00000270977.1	AC015849.16	-3.69	0.000246	0.0294	-0.22	-0.17	Fibroblast growth factor basic levels;	chr17:35862013	chr17:35893707~35911023:-
LUAD	cis	rs17318866	0.529	rs9392523	ENSG00000218472.2	RP1-140K8.2	-3.69	0.000246	0.0294	-0.19	-0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin);	chr6:3805239	chr6:3913922~3914292:-
LUAD	cis	rs10197140	0.857	rs9308692	ENSG00000227992.1	AC108463.2	-3.69	0.000246	0.0294	-0.2	-0.17	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110883686	chr2:111203964~111206215:-
LUAD	cis	rs7801037	0.606	rs2028015	ENSG00000279048.1	RP11-511H23.2	3.69	0.000246	0.0294	0.15	0.17	Male-pattern baldness;	chr7:18871438	chr7:17940503~17942922:+
LUAD	cis	rs11148252	0.512	rs9526950	ENSG00000273784.3	RP11-78J21.7	-3.69	0.000246	0.0294	-0.2	-0.17	Lewy body disease;	chr13:52600328	chr13:52600042~52642542:+
LUAD	cis	rs8028182	0.636	rs4886703	ENSG00000246877.1	DNM1P35	3.69	0.000246	0.0294	0.21	0.17	Sudden cardiac arrest;	chr15:75438025	chr15:75727670~75738623:-
LUAD	cis	rs237743	1	rs35506374	ENSG00000177410.11	ZFAS1	3.69	0.000246	0.0294	0.19	0.17	Height;	chr20:49311346	chr20:49278178~49295738:+
LUAD	cis	rs11250098	0.574	rs4554431	ENSG00000255310.2	AF131215.2	-3.69	0.000246	0.0294	-0.16	-0.17	Morning vs. evening chronotype;	chr8:10914128	chr8:11107788~11109726:-
LUAD	cis	rs6502050	0.799	rs9911129	ENSG00000275966.1	RP11-1055B8.9	-3.69	0.000246	0.0294	-0.17	-0.17	Life satisfaction;	chr17:82129943	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.635	rs9889327	ENSG00000275966.1	RP11-1055B8.9	-3.69	0.000246	0.0294	-0.17	-0.17	Life satisfaction;	chr17:82129963	chr17:81345476~81345966:-
LUAD	cis	rs2274273	0.87	rs7158768	ENSG00000258413.1	RP11-665C16.6	-3.69	0.000246	0.0294	-0.21	-0.17	Protein biomarker;	chr14:55296894	chr14:55262767~55272075:-
LUAD	cis	rs2274273	0.87	rs10142547	ENSG00000258413.1	RP11-665C16.6	-3.69	0.000246	0.0294	-0.21	-0.17	Protein biomarker;	chr14:55297245	chr14:55262767~55272075:-
LUAD	cis	rs6781182	0.535	rs13063086	ENSG00000236452.1	AC123023.1	3.69	0.000246	0.0294	0.19	0.17	Visceral adipose tissue adjusted for BMI;	chr3:34198994	chr3:34203244~34268811:+
LUAD	cis	rs13113518	1	rs34648901	ENSG00000273257.1	RP11-177J6.1	3.69	0.000246	0.0294	0.18	0.17	Height;	chr4:55541259	chr4:55387949~55388271:+
LUAD	cis	rs4474465	0.85	rs10899536	ENSG00000251323.2	RP11-452H21.4	-3.69	0.000246	0.0294	-0.21	-0.17	Alzheimer's disease (survival time);	chr11:78505946	chr11:78423982~78429836:-
LUAD	cis	rs1198430	0.5	rs968280	ENSG00000232482.2	RP4-654C18.1	-3.69	0.000246	0.0294	-0.22	-0.17	Total cholesterol levels;	chr1:23475472	chr1:23410832~23412146:+
LUAD	cis	rs1198430	0.562	rs10917388	ENSG00000232482.2	RP4-654C18.1	-3.69	0.000246	0.0294	-0.22	-0.17	Total cholesterol levels;	chr1:23476645	chr1:23410832~23412146:+
LUAD	cis	rs9659323	0.539	rs1750331	ENSG00000231365.4	RP11-418J17.1	-3.69	0.000246	0.0294	-0.2	-0.17	Body mass index;	chr1:118952350	chr1:119140396~119275973:+
LUAD	cis	rs2717559	0.542	rs34147336	ENSG00000253741.1	CTD-2292P10.4	3.69	0.000246	0.0294	0.2	0.17	Urinary tract infection frequency;	chr8:142803453	chr8:142702252~142726973:-
LUAD	cis	rs9545047	0.716	rs9318638	ENSG00000227354.5	RBM26-AS1	-3.69	0.000246	0.0294	-0.18	-0.17	Schizophrenia;	chr13:79412018	chr13:79406309~79424328:+
LUAD	cis	rs13113518	0.812	rs11939580	ENSG00000273257.1	RP11-177J6.1	3.69	0.000246	0.0294	0.19	0.17	Height;	chr4:55517185	chr4:55387949~55388271:+
LUAD	cis	rs7429990	0.965	rs319682	ENSG00000228638.1	FCF1P2	-3.69	0.000246	0.0294	-0.2	-0.17	Educational attainment (years of education);	chr3:47873628	chr3:48290793~48291375:-
LUAD	cis	rs7937890	0.967	rs963212	ENSG00000251991.1	RNU7-49P	-3.69	0.000246	0.0294	-0.17	-0.17	Mitochondrial DNA levels;	chr11:14303186	chr11:14478892~14478953:+
LUAD	cis	rs2795502	1	rs3121279	ENSG00000234944.1	RP11-124O11.1	-3.69	0.000246	0.0294	-0.26	-0.17	Blood protein levels;	chr10:42883001	chr10:42871521~42874060:+
LUAD	cis	rs198389	0.617	rs503040	ENSG00000242349.4	NPPA-AS1	-3.69	0.000246	0.0294	-0.17	-0.17	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11830638	chr1:11841017~11848079:+
LUAD	cis	rs2190016	0.673	rs4236383	ENSG00000236078.1	LINC01447	-3.69	0.000246	0.0294	-0.2	-0.17	Mammographic density (non-dense area);	chr7:46849893	chr7:47621939~47629893:+
LUAD	cis	rs10129255	0.957	rs61997760	ENSG00000253209.1	IGHV3-65	3.69	0.000246	0.0294	0.15	0.17	Kawasaki disease;	chr14:106716993	chr14:106666092~106666532:-
LUAD	cis	rs7551222	0.752	rs10900593	ENSG00000240219.1	RP11-430C7.5	3.69	0.000246	0.0294	0.17	0.17	Schizophrenia;	chr1:204500968	chr1:204626775~204629712:+
LUAD	cis	rs10466239	0.892	rs7921001	ENSG00000230555.2	RP11-517P14.2	3.69	0.000246	0.0294	0.3	0.17	Telomere length;	chr10:43367980	chr10:43420738~43422100:+
LUAD	cis	rs2348418	0.798	rs7309905	ENSG00000247934.4	RP11-967K21.1	3.69	0.000246	0.0294	0.19	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28373473	chr12:28163298~28190738:-
LUAD	cis	rs7674212	0.507	rs10516495	ENSG00000230069.3	LRRC37A15P	-3.69	0.000246	0.0294	-0.19	-0.17	Type 2 diabetes;	chr4:102978933	chr4:102727274~102730721:-
LUAD	cis	rs6754311	0.731	rs12615624	ENSG00000226806.1	AC011893.3	3.69	0.000246	0.0294	0.21	0.17	Mosquito bite size;	chr2:135964033	chr2:135820191~135823087:+
LUAD	cis	rs9840812	0.598	rs1145101	ENSG00000239213.4	NCK1-AS1	3.69	0.000246	0.0294	0.24	0.17	Fibrinogen levels;	chr3:136350444	chr3:136841726~136862054:-
LUAD	cis	rs9309473	0.95	rs10206899	ENSG00000230002.2	ALMS1-IT1	3.69	0.000246	0.0294	0.21	0.17	Metabolite levels;	chr2:73673773	chr2:73456764~73459484:+
LUAD	cis	rs950169	0.614	rs765524	ENSG00000259570.1	RP11-671M22.4	3.69	0.000247	0.0294	0.24	0.17	Schizophrenia;	chr15:84013030	chr15:84394512~84395514:+
LUAD	cis	rs6793245	0.843	rs6762565	ENSG00000229589.1	ACVR2B-AS1	-3.69	0.000247	0.0294	-0.21	-0.17	QT interval;	chr3:38540700	chr3:38451027~38454820:-
LUAD	cis	rs911119	0.913	rs3004139	ENSG00000270001.1	RP11-218C14.8	3.69	0.000247	0.0294	0.24	0.17	Chronic kidney disease;	chr20:23598037	chr20:23631826~23632316:-
LUAD	cis	rs11673344	0.523	rs2385415	ENSG00000276846.1	CTD-3220F14.3	3.69	0.000247	0.0294	0.18	0.17	Obesity-related traits;	chr19:37035291	chr19:37314868~37315620:-
LUAD	cis	rs11673344	0.562	rs6510580	ENSG00000276846.1	CTD-3220F14.3	3.69	0.000247	0.0294	0.18	0.17	Obesity-related traits;	chr19:37038452	chr19:37314868~37315620:-
LUAD	cis	rs11673344	0.523	rs2082009	ENSG00000276846.1	CTD-3220F14.3	3.69	0.000247	0.0294	0.18	0.17	Obesity-related traits;	chr19:37039834	chr19:37314868~37315620:-
LUAD	cis	rs11673344	0.523	rs7246739	ENSG00000276846.1	CTD-3220F14.3	3.69	0.000247	0.0294	0.18	0.17	Obesity-related traits;	chr19:37040829	chr19:37314868~37315620:-
LUAD	cis	rs11673344	0.523	rs7260488	ENSG00000276846.1	CTD-3220F14.3	3.69	0.000247	0.0294	0.18	0.17	Obesity-related traits;	chr19:37058883	chr19:37314868~37315620:-
LUAD	cis	rs7789940	0.904	rs7459185	ENSG00000230305.2	AC004980.9	-3.69	0.000247	0.0294	-0.21	-0.17	Multiple sclerosis;	chr7:76305323	chr7:76524515~76532692:+
LUAD	cis	rs875971	0.545	rs17138156	ENSG00000222364.1	RNU6-96P	-3.69	0.000247	0.0294	-0.21	-0.17	Aortic root size;	chr7:66249708	chr7:66395191~66395286:+
LUAD	cis	rs6951245	1	rs113146460	ENSG00000224079.1	AC091729.7	-3.69	0.000247	0.0295	-0.26	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1065528	chr7:1074450~1078036:+
LUAD	cis	rs6951245	0.935	rs61753396	ENSG00000224079.1	AC091729.7	-3.69	0.000247	0.0295	-0.26	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1065736	chr7:1074450~1078036:+
LUAD	cis	rs6951245	1	rs79327308	ENSG00000224079.1	AC091729.7	-3.69	0.000247	0.0295	-0.26	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1068505	chr7:1074450~1078036:+
LUAD	cis	rs6951245	0.938	rs117729148	ENSG00000224079.1	AC091729.7	-3.69	0.000247	0.0295	-0.26	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1068895	chr7:1074450~1078036:+
LUAD	cis	rs6095360	0.87	rs1569749	ENSG00000222365.1	SNORD12B	-3.69	0.000247	0.0295	-0.17	-0.17	Intelligence (multi-trait analysis);	chr20:48984972	chr20:49280319~49280409:+
LUAD	cis	rs1055129	0.655	rs8067076	ENSG00000267801.1	RP11-552F3.9	-3.69	0.000247	0.0295	-0.17	-0.17	White matter hyperintensity burden;	chr17:75841061	chr17:75876372~75879546:+
LUAD	cis	rs854765	0.619	rs6502636	ENSG00000223979.2	SMCR2	-3.69	0.000247	0.0295	-0.2	-0.17	Total body bone mineral density;	chr17:18080503	chr17:17674026~17677688:-
LUAD	cis	rs8049040	0.609	rs4258624	ENSG00000260886.1	TAT-AS1	-3.69	0.000247	0.0295	-0.2	-0.17	Blood protein levels;	chr16:71434048	chr16:71565789~71578187:+
LUAD	cis	rs3764021	0.87	rs11052710	ENSG00000256582.1	RP11-75L1.1	3.69	0.000247	0.0295	0.17	0.17	Type 1 diabetes;	chr12:9723754	chr12:9704077~9709350:+
LUAD	cis	rs950881	0.932	rs10189154	ENSG00000234389.1	AC007278.3	3.69	0.000247	0.0295	0.2	0.17	Allergy;	chr2:102321084	chr2:102438713~102440475:+
LUAD	cis	rs950881	0.932	rs10189526	ENSG00000234389.1	AC007278.3	3.69	0.000247	0.0295	0.2	0.17	Allergy;	chr2:102321423	chr2:102438713~102440475:+
LUAD	cis	rs10865050	1	rs10865050	ENSG00000234389.1	AC007278.3	3.69	0.000247	0.0295	0.2	0.17	Allergic disease (asthma, hay fever or eczema);	chr2:102324851	chr2:102438713~102440475:+
LUAD	cis	rs526231	0.578	rs6860588	ENSG00000250682.4	LINC00491	-3.69	0.000247	0.0295	-0.2	-0.17	Primary biliary cholangitis;	chr5:102944598	chr5:102609156~102671559:-
LUAD	cis	rs231513	0.906	rs11657450	ENSG00000267595.1	RP11-242D8.2	-3.69	0.000247	0.0295	-0.22	-0.17	Cognitive function;	chr17:43925096	chr17:43168170~43168249:-
LUAD	cis	rs4237845	0.715	rs4760340	ENSG00000245651.2	RP11-620J15.2	3.69	0.000247	0.0295	0.16	0.17	Intelligence (multi-trait analysis);	chr12:57881393	chr12:57869835~57896482:-
LUAD	cis	rs6661961	0.78	rs11803629	ENSG00000237975.5	FLG-AS1	-3.69	0.000247	0.0295	-0.23	-0.17	Atopic dermatitis;	chr1:152445670	chr1:152168125~152445456:+
LUAD	cis	rs1598856	0.932	rs230530	ENSG00000246560.2	RP11-10L12.4	-3.69	0.000247	0.0295	-0.21	-0.17	Primary biliary cholangitis;	chr4:102532823	chr4:102828055~102844075:+
LUAD	cis	rs7142881	0.815	rs55701649	ENSG00000258525.1	RP11-829H16.3	-3.69	0.000247	0.0295	-0.19	-0.17	Response to iloperidone treatment (QT prolongation);	chr14:31689083	chr14:30876179~30889808:-
LUAD	cis	rs7142881	0.815	rs17098061	ENSG00000258525.1	RP11-829H16.3	-3.69	0.000247	0.0295	-0.19	-0.17	Response to iloperidone treatment (QT prolongation);	chr14:31693577	chr14:30876179~30889808:-
LUAD	cis	rs4144027	0.875	rs6576010	ENSG00000258534.1	CTD-2134A5.4	3.69	0.000247	0.0295	0.19	0.17	Blood metabolite levels;	chr14:103883265	chr14:103854366~103880111:-
LUAD	cis	rs6061231	0.74	rs11698650	ENSG00000275437.1	RP5-908M14.10	3.69	0.000247	0.0295	0.15	0.17	Colorectal cancer;	chr20:62383318	chr20:62402236~62405935:-
LUAD	cis	rs911555	0.755	rs1138400	ENSG00000259775.1	RP11-45P15.4	-3.69	0.000247	0.0295	-0.22	-0.17	Intelligence (multi-trait analysis);	chr14:103490496	chr14:103331674~103332367:-
LUAD	cis	rs7129556	0.737	rs484363	ENSG00000241782.1	RP11-91P24.1	3.69	0.000247	0.0295	0.24	0.17	Weight loss (gastric bypass surgery);	chr11:77781548	chr11:77868722~77869195:-
LUAD	cis	rs7560272	0.538	rs13014700	ENSG00000163016.8	ALMS1P	-3.69	0.000247	0.0295	-0.18	-0.17	Schizophrenia;	chr2:73692994	chr2:73644919~73685576:+
LUAD	cis	rs4683346	0.616	rs11129976	ENSG00000173811.9	CCDC13-AS1	-3.69	0.000247	0.0295	-0.18	-0.17	Granulocyte percentage of myeloid white cells;	chr3:42808873	chr3:42732575~42746768:+
LUAD	cis	rs763121	0.853	rs5750633	ENSG00000228274.3	RP3-508I15.9	-3.69	0.000247	0.0295	-0.16	-0.17	Menopause (age at onset);	chr22:38597462	chr22:38667585~38681820:-
LUAD	cis	rs17695224	0.545	rs7252805	ENSG00000269483.1	AC006272.1	3.69	0.000247	0.0295	0.18	0.17	HDL cholesterol;HDL cholesterol levels;	chr19:51840169	chr19:51839924~51843324:-
LUAD	cis	rs516805	0.961	rs572632	ENSG00000279114.1	RP3-425C14.5	-3.69	0.000247	0.0295	-0.18	-0.17	Lymphocyte counts;	chr6:122437753	chr6:122471923~122484161:+
LUAD	cis	rs10752881	1	rs12133714	ENSG00000224468.3	RP11-181K3.4	-3.69	0.000247	0.0295	-0.15	-0.17	Colorectal cancer;	chr1:183019117	chr1:183138402~183141282:-
LUAD	cis	rs10911232	0.507	rs4483371	ENSG00000224468.3	RP11-181K3.4	-3.69	0.000247	0.0295	-0.15	-0.17	Hypertriglyceridemia;	chr1:183019217	chr1:183138402~183141282:-
LUAD	cis	rs8028182	0.636	rs7163451	ENSG00000246877.1	DNM1P35	3.69	0.000247	0.0295	0.21	0.17	Sudden cardiac arrest;	chr15:75568735	chr15:75727670~75738623:-
LUAD	cis	rs8028182	0.636	rs8036884	ENSG00000246877.1	DNM1P35	3.69	0.000247	0.0295	0.21	0.17	Sudden cardiac arrest;	chr15:75570552	chr15:75727670~75738623:-
LUAD	cis	rs8028182	0.636	rs4075522	ENSG00000246877.1	DNM1P35	3.69	0.000247	0.0295	0.21	0.17	Sudden cardiac arrest;	chr15:75571994	chr15:75727670~75738623:-
LUAD	cis	rs4819052	0.851	rs875621	ENSG00000215447.6	BX322557.10	-3.69	0.000247	0.0295	-0.2	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45262380	chr21:45288052~45291738:+
LUAD	cis	rs875971	1	rs3735148	ENSG00000273142.1	RP11-458F8.4	-3.69	0.000247	0.0295	-0.12	-0.17	Aortic root size;	chr7:66506022	chr7:66902857~66906297:+
LUAD	cis	rs3126085	0.935	rs4511111	ENSG00000237975.5	FLG-AS1	3.69	0.000247	0.0295	0.28	0.17	Atopic dermatitis;	chr1:152239148	chr1:152168125~152445456:+
LUAD	cis	rs2274273	0.87	rs7160523	ENSG00000258413.1	RP11-665C16.6	-3.69	0.000247	0.0295	-0.21	-0.17	Protein biomarker;	chr14:55127842	chr14:55262767~55272075:-
LUAD	cis	rs11971779	1	rs11971779	ENSG00000273391.1	RP11-634H22.1	-3.69	0.000247	0.0295	-0.2	-0.17	Diisocyanate-induced asthma;	chr7:139355512	chr7:139359032~139359566:-
LUAD	cis	rs10752881	1	rs4454510	ENSG00000224468.3	RP11-181K3.4	3.69	0.000247	0.0295	0.15	0.17	Colorectal cancer;	chr1:183013168	chr1:183138402~183141282:-
LUAD	cis	rs7605235	0.958	rs34736805	ENSG00000224165.4	DNAJC27-AS1	3.69	0.000247	0.0295	0.19	0.17	Response to platinum-based chemotherapy (cisplatin);	chr2:25428004	chr2:24971390~25039694:+
LUAD	cis	rs6951245	1	rs74652290	ENSG00000224079.1	AC091729.7	-3.69	0.000247	0.0295	-0.25	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1050473	chr7:1074450~1078036:+
LUAD	cis	rs6694672	1	rs1170881	ENSG00000235582.2	RP11-448G4.2	3.69	0.000247	0.0295	0.24	0.17	Asthma;	chr1:196980141	chr1:197735636~197736107:+
LUAD	cis	rs4835473	0.932	rs13130345	ENSG00000249741.2	RP11-673E1.3	-3.69	0.000247	0.0295	-0.19	-0.17	Immature fraction of reticulocytes;	chr4:143920939	chr4:143911514~143912053:-
LUAD	cis	rs214785	1	rs214772	ENSG00000234684.5	SDCBP2-AS1	3.69	0.000247	0.0295	0.2	0.17	Basal cell carcinoma;	chr20:2299248	chr20:1325405~1378734:+
LUAD	cis	rs214785	0.872	rs214773	ENSG00000234684.5	SDCBP2-AS1	3.69	0.000247	0.0295	0.2	0.17	Basal cell carcinoma;	chr20:2299263	chr20:1325405~1378734:+
LUAD	cis	rs2274273	0.662	rs67588230	ENSG00000258413.1	RP11-665C16.6	-3.69	0.000247	0.0295	-0.23	-0.17	Protein biomarker;	chr14:55200312	chr14:55262767~55272075:-
LUAD	cis	rs17596685	1	rs7999416	ENSG00000271216.1	LINC01050	3.69	0.000247	0.0295	0.25	0.17	C-reactive protein levels;	chr13:42562210	chr13:42810366~42812562:-
LUAD	cis	rs10129255	0.957	rs8009073	ENSG00000211947.2	IGHV3-21	-3.69	0.000247	0.0295	-0.11	-0.17	Kawasaki disease;	chr14:106777278	chr14:106235064~106235594:-
LUAD	cis	rs9309473	0.583	rs6709853	ENSG00000230002.2	ALMS1-IT1	3.69	0.000247	0.0295	0.19	0.17	Metabolite levels;	chr2:73348937	chr2:73456764~73459484:+
LUAD	cis	rs13126694	0.744	rs7657303	ENSG00000280140.1	RP11-597D13.2	3.69	0.000247	0.0295	0.2	0.17	Blood osmolality (transformed sodium);	chr4:157992992	chr4:158111361~158111931:-
LUAD	cis	rs2274273	0.837	rs7148171	ENSG00000258413.1	RP11-665C16.6	-3.69	0.000247	0.0295	-0.21	-0.17	Protein biomarker;	chr14:55304026	chr14:55262767~55272075:-
LUAD	cis	rs8062405	1	rs4451951	ENSG00000261419.1	RP11-57A19.4	-3.69	0.000248	0.0295	-0.18	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28659696~28740781:-
LUAD	cis	rs6840360	0.571	rs4696270	ENSG00000270265.1	RP11-731D1.4	-3.69	0.000248	0.0295	-0.19	-0.17	Intelligence (multi-trait analysis);	chr4:151577137	chr4:151333775~151353224:-
LUAD	cis	rs1198430	0.562	rs7546989	ENSG00000232482.2	RP4-654C18.1	-3.69	0.000248	0.0295	-0.21	-0.17	Total cholesterol levels;	chr1:23463205	chr1:23410832~23412146:+
LUAD	cis	rs7200786	0.528	rs27838	ENSG00000274038.1	RP11-66H6.4	-3.69	0.000248	0.0295	-0.21	-0.17	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11159626	chr16:11056556~11057034:+
LUAD	cis	rs4716602	0.596	rs10258969	ENSG00000236018.2	RP4-814D15.1	-3.69	0.000248	0.0295	-0.18	-0.17	Anti-saccade response;	chr7:156365059	chr7:157197600~157198511:-
LUAD	cis	rs7824557	0.872	rs2572417	ENSG00000255046.1	RP11-297N6.4	3.69	0.000248	0.0296	0.2	0.17	Retinal vascular caliber;	chr8:11253953	chr8:11797928~11802568:-
LUAD	cis	rs13113518	0.812	rs13116035	ENSG00000249700.7	SRD5A3-AS1	3.69	0.000248	0.0296	0.17	0.17	Height;	chr4:55561218	chr4:55363971~55395847:-
LUAD	cis	rs59901009	0.516	rs7925889	ENSG00000246273.5	SBF2-AS1	3.69	0.000248	0.0296	0.22	0.17	Hematocrit;Hemoglobin concentration;	chr11:10026772	chr11:9758292~9811319:+
LUAD	cis	rs2708977	0.73	rs596069	ENSG00000237510.6	AC008268.2	3.69	0.000248	0.0296	0.22	0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96410905	chr2:95789654~95800166:+
LUAD	cis	rs858239	0.831	rs7796541	ENSG00000226816.2	AC005082.12	3.69	0.000248	0.0296	0.21	0.17	Cerebrospinal fluid biomarker levels;	chr7:23349454	chr7:23206013~23208045:+
LUAD	cis	rs448720	0.811	rs4776382	ENSG00000259673.4	IQCH-AS1	3.69	0.000248	0.0296	0.18	0.17	Cognitive performance;	chr15:67887313	chr15:67403619~67521844:-
LUAD	cis	rs7246657	0.943	rs713256	ENSG00000226686.6	LINC01535	-3.69	0.000248	0.0296	-0.25	-0.17	Coronary artery calcification;	chr19:37374463	chr19:37251912~37265535:+
LUAD	cis	rs2880765	0.546	rs35316253	ENSG00000202081.1	RNU6-1280P	3.69	0.000248	0.0296	0.2	0.17	Coronary artery disease;	chr15:85522329	chr15:85651522~85651628:-
LUAD	cis	rs3096299	0.838	rs3096319	ENSG00000261574.1	RP1-168P16.2	3.69	0.000248	0.0296	0.18	0.17	Multiple myeloma (IgH translocation);	chr16:89336226	chr16:89392375~89412564:-
LUAD	cis	rs2664588	0.538	rs6018821	ENSG00000224565.1	RP1-148H17.1	-3.69	0.000248	0.0296	-0.18	-0.17	Cerebrospinal fluid AB1-42 levels;	chr20:47964482	chr20:47391929~47412327:-
LUAD	cis	rs10946940	0.965	rs62401383	ENSG00000219392.1	RP1-265C24.5	3.69	0.000248	0.0296	0.2	0.17	Systemic lupus erythematosus;	chr6:27596768	chr6:28115628~28116551:+
LUAD	cis	rs3741404	0.609	rs641378	ENSG00000256789.1	RP11-697H9.2	-3.69	0.000248	0.0296	-0.18	-0.17	Platelet count;	chr11:64102021	chr11:63637677~63658962:+
LUAD	cis	rs3741404	0.609	rs666497	ENSG00000256789.1	RP11-697H9.2	-3.69	0.000248	0.0296	-0.18	-0.17	Platelet count;	chr11:64102349	chr11:63637677~63658962:+
LUAD	cis	rs3741404	0.609	rs669913	ENSG00000256789.1	RP11-697H9.2	-3.69	0.000248	0.0296	-0.18	-0.17	Platelet count;	chr11:64102407	chr11:63637677~63658962:+
LUAD	cis	rs10129255	0.957	rs12589190	ENSG00000211947.2	IGHV3-21	-3.69	0.000248	0.0296	-0.11	-0.17	Kawasaki disease;	chr14:106783079	chr14:106235064~106235594:-
LUAD	cis	rs10129255	0.957	rs7493713	ENSG00000211947.2	IGHV3-21	-3.69	0.000248	0.0296	-0.11	-0.17	Kawasaki disease;	chr14:106783685	chr14:106235064~106235594:-
LUAD	cis	rs10129255	0.912	rs35468694	ENSG00000211947.2	IGHV3-21	-3.69	0.000248	0.0296	-0.11	-0.17	Kawasaki disease;	chr14:106784199	chr14:106235064~106235594:-
LUAD	cis	rs10129255	0.957	rs8019272	ENSG00000211947.2	IGHV3-21	-3.69	0.000248	0.0296	-0.11	-0.17	Kawasaki disease;	chr14:106784709	chr14:106235064~106235594:-
LUAD	cis	rs4591358	0.834	rs4850621	ENSG00000223466.1	AC064834.2	-3.69	0.000248	0.0296	-0.2	-0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195484850	chr2:195533035~195538681:+
LUAD	cis	rs2154319	0.836	rs2013925	ENSG00000235358.1	RP11-399E6.1	3.69	0.000248	0.0296	0.23	0.17	Height;	chr1:41094619	chr1:41242373~41284861:+
LUAD	cis	rs11154801	0.732	rs13202115	ENSG00000231028.7	LINC00271	-3.69	0.000248	0.0296	-0.19	-0.17	Multiple sclerosis;	chr6:135604386	chr6:135497801~135716055:+
LUAD	cis	rs7246967	0.611	rs8102927	ENSG00000236312.3	RPL34P34	3.69	0.000248	0.0296	0.25	0.17	Bronchopulmonary dysplasia;	chr19:22696554	chr19:22368599~22368952:-
LUAD	cis	rs1502337	0.532	rs1106724	ENSG00000278993.1	RP3-424M6.4	-3.69	0.000248	0.0296	-0.2	-0.17	Body mass index;	chr12:110636898	chr12:110501614~110503441:+
LUAD	cis	rs2274273	1	rs1009977	ENSG00000259318.1	RP11-454L9.2	3.69	0.000248	0.0296	0.14	0.17	Protein biomarker;	chr14:55136284	chr14:55394940~55395233:-
LUAD	cis	rs7617773	0.779	rs11718329	ENSG00000199476.1	Y_RNA	-3.69	0.000248	0.0296	-0.21	-0.17	Coronary artery disease;	chr3:48268338	chr3:48288587~48288694:+
LUAD	cis	rs13113518	1	rs4864547	ENSG00000273257.1	RP11-177J6.1	3.69	0.000248	0.0296	0.18	0.17	Height;	chr4:55538228	chr4:55387949~55388271:+
LUAD	cis	rs12440869	0.959	rs17296465	ENSG00000270964.1	RP11-502I4.3	3.69	0.000248	0.0296	0.19	0.17	Peak velocity of the mitral A-wave;	chr15:67310278	chr15:67541072~67542604:-
LUAD	cis	rs1056107	0.7	rs10981293	ENSG00000225513.1	RP11-165N19.2	-3.69	0.000248	0.0296	-0.18	-0.17	Colorectal cancer;	chr9:112169467	chr9:112173522~112173971:-
LUAD	cis	rs6964587	1	rs34043009	ENSG00000188693.7	CYP51A1-AS1	3.69	0.000248	0.0296	0.19	0.17	Breast cancer;	chr7:91949133	chr7:92134604~92180725:+
LUAD	cis	rs11673344	0.566	rs8109103	ENSG00000226686.6	LINC01535	3.69	0.000248	0.0296	0.2	0.17	Obesity-related traits;	chr19:37503209	chr19:37251912~37265535:+
LUAD	cis	rs7045881	0.674	rs62542706	ENSG00000254396.1	RP11-56F10.3	3.69	0.000248	0.0296	0.27	0.17	Schizophrenia;	chr9:27054959	chr9:27102630~27104728:+
LUAD	cis	rs2253762	0.54	rs11200357	ENSG00000276742.1	RP11-500G22.4	3.69	0.000248	0.0296	0.26	0.17	Breast cancer;	chr10:122034390	chr10:121956782~121957098:+
LUAD	cis	rs2024714	0.967	rs2427204	ENSG00000273812.1	WI2-87327B8.2	-3.69	0.000248	0.0296	-0.18	-0.17	Longevity;	chr20:61632345	chr20:62596732~62603115:-
LUAD	cis	rs2024714	0.933	rs2427205	ENSG00000273812.1	WI2-87327B8.2	-3.69	0.000248	0.0296	-0.18	-0.17	Longevity;	chr20:61632464	chr20:62596732~62603115:-
LUAD	cis	rs2024714	0.933	rs2427206	ENSG00000273812.1	WI2-87327B8.2	-3.69	0.000248	0.0296	-0.18	-0.17	Longevity;	chr20:61632467	chr20:62596732~62603115:-
LUAD	cis	rs12497850	0.931	rs11705888	ENSG00000225399.4	RP11-3B7.1	3.69	0.000248	0.0296	0.22	0.17	Parkinson's disease;	chr3:48779856	chr3:49260085~49261316:+
LUAD	cis	rs8012947	0.959	rs6573196	ENSG00000279636.2	LINC00216	-3.69	0.000248	0.0296	-0.19	-0.17	Alcohol consumption in current drinkers;	chr14:58255821	chr14:58288033~58289158:+
LUAD	cis	rs2281603	0.674	rs74883409	ENSG00000259116.1	RP11-973N13.4	-3.69	0.000248	0.0296	-0.15	-0.17	Lymphocyte counts;	chr14:64594361	chr14:64514154~64540368:-
LUAD	cis	rs61160187	0.582	rs12653132	ENSG00000215032.2	GNL3LP1	3.69	0.000248	0.0296	0.2	0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:61062881	chr5:60891935~60893577:-
LUAD	cis	rs61160187	0.582	rs56284222	ENSG00000215032.2	GNL3LP1	3.69	0.000248	0.0296	0.2	0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:61065723	chr5:60891935~60893577:-
LUAD	cis	rs2242116	0.592	rs2290545	ENSG00000271161.1	BOLA2P2	3.69	0.000248	0.0296	0.18	0.17	Birth weight;	chr3:46925550	chr3:47499841~47500407:+
LUAD	cis	rs8098244	0.737	rs1258137	ENSG00000264745.1	TTC39C-AS1	-3.69	0.000248	0.0296	-0.21	-0.17	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23980147	chr18:23994213~24015339:-
LUAD	cis	rs13006833	0.739	rs291468	ENSG00000227542.1	AC092614.2	-3.69	0.000248	0.0296	-0.2	-0.17	Urinary metabolites;	chr2:190323393	chr2:191229165~191246172:-
LUAD	cis	rs2625529	0.652	rs2899776	ENSG00000260173.1	RP11-2I17.4	3.69	0.000249	0.0296	0.2	0.17	Red blood cell count;	chr15:71976024	chr15:72140504~72155459:-
LUAD	cis	rs6452524	0.563	rs10473863	ENSG00000281327.1	LINC01338	3.69	0.000249	0.0296	0.18	0.17	Hypertension (SNP x SNP interaction);	chr5:83057500	chr5:82850864~82859836:-
LUAD	cis	rs7215564	0.908	rs34135683	ENSG00000232083.3	RPL31P7	3.69	0.000249	0.0296	0.27	0.17	Myopia (pathological);	chr17:80679103	chr17:80602549~80602926:-
LUAD	cis	rs7215564	0.908	rs35128297	ENSG00000232083.3	RPL31P7	3.69	0.000249	0.0296	0.27	0.17	Myopia (pathological);	chr17:80679109	chr17:80602549~80602926:-
LUAD	cis	rs7215564	0.908	rs80183474	ENSG00000232083.3	RPL31P7	3.69	0.000249	0.0296	0.27	0.17	Myopia (pathological);	chr17:80681270	chr17:80602549~80602926:-
LUAD	cis	rs4795519	0.922	rs1842167	ENSG00000266313.1	RP11-173M1.4	3.69	0.000249	0.0296	0.2	0.17	Chronic myeloid leukemia;	chr17:27137274	chr17:27333256~27348491:+
LUAD	cis	rs6460942	1	rs2053382	ENSG00000226690.5	AC005281.1	3.69	0.000249	0.0296	0.3	0.17	Coronary artery disease;	chr7:12360961	chr7:12496429~12541910:+
LUAD	cis	rs13113518	0.729	rs11133377	ENSG00000273257.1	RP11-177J6.1	3.69	0.000249	0.0297	0.2	0.17	Height;	chr4:55413708	chr4:55387949~55388271:+
LUAD	cis	rs2765539	0.701	rs10754391	ENSG00000231365.4	RP11-418J17.1	-3.69	0.000249	0.0297	-0.22	-0.17	Waist-hip ratio;	chr1:119087081	chr1:119140396~119275973:+
LUAD	cis	rs875971	0.545	rs1796217	ENSG00000222364.1	RNU6-96P	3.69	0.000249	0.0297	0.21	0.17	Aortic root size;	chr7:66620931	chr7:66395191~66395286:+
LUAD	cis	rs9921338	0.961	rs7200667	ENSG00000262703.1	RP11-485G7.6	-3.69	0.000249	0.0297	-0.17	-0.17	Vein graft stenosis in coronary artery bypass grafting;	chr16:11346547	chr16:11348143~11349321:-
LUAD	cis	rs9921338	0.924	rs7202024	ENSG00000262703.1	RP11-485G7.6	-3.69	0.000249	0.0297	-0.17	-0.17	Vein graft stenosis in coronary artery bypass grafting;	chr16:11346901	chr16:11348143~11349321:-
LUAD	cis	rs9921338	0.961	rs7206017	ENSG00000262703.1	RP11-485G7.6	-3.69	0.000249	0.0297	-0.17	-0.17	Vein graft stenosis in coronary artery bypass grafting;	chr16:11347004	chr16:11348143~11349321:-
LUAD	cis	rs67478160	0.643	rs12880821	ENSG00000272533.1	SNORA28	3.69	0.000249	0.0297	0.17	0.17	Schizophrenia;	chr14:103809712	chr14:103337849~103337974:+
LUAD	cis	rs2834288	0.535	rs7278341	ENSG00000273102.1	AP000569.9	3.69	0.000249	0.0297	0.21	0.17	Gut microbiota (bacterial taxa);	chr21:33961692	chr21:33967101~33968573:-
LUAD	cis	rs2834288	0.535	rs7279183	ENSG00000273102.1	AP000569.9	3.69	0.000249	0.0297	0.21	0.17	Gut microbiota (bacterial taxa);	chr21:33961701	chr21:33967101~33968573:-
LUAD	cis	rs12214131	0.526	rs4946690	ENSG00000219088.1	RP3-359N14.1	-3.69	0.000249	0.0297	-0.18	-0.17	Male-pattern baldness;	chr6:105753929	chr6:105666326~105667998:+
LUAD	cis	rs7617773	0.746	rs11713476	ENSG00000199476.1	Y_RNA	-3.69	0.000249	0.0297	-0.22	-0.17	Coronary artery disease;	chr3:48333944	chr3:48288587~48288694:+
LUAD	cis	rs10127852	0.541	rs9724727	ENSG00000122432.15	SPATA1	3.69	0.000249	0.0297	0.3	0.17	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:84794497	chr1:84506291~84566194:+
LUAD	cis	rs4838594	0.563	rs9794032	ENSG00000265018.5	CTGLF12P	-3.69	0.000249	0.0297	-0.21	-0.17	Daytime sleep phenotypes;	chr10:48473243	chr10:48009873~48031640:-
LUAD	cis	rs875971	0.929	rs10950041	ENSG00000273142.1	RP11-458F8.4	-3.69	0.000249	0.0297	-0.12	-0.17	Aortic root size;	chr7:66508888	chr7:66902857~66906297:+
LUAD	cis	rs875971	0.929	rs6970860	ENSG00000273142.1	RP11-458F8.4	-3.69	0.000249	0.0297	-0.12	-0.17	Aortic root size;	chr7:66511647	chr7:66902857~66906297:+
LUAD	cis	rs703842	0.616	rs871871	ENSG00000245651.2	RP11-620J15.2	3.69	0.000249	0.0297	0.18	0.17	Multiple sclerosis;	chr12:57825898	chr12:57869835~57896482:-
LUAD	cis	rs13113518	0.812	rs7667741	ENSG00000249700.7	SRD5A3-AS1	3.69	0.000249	0.0297	0.17	0.17	Height;	chr4:55544621	chr4:55363971~55395847:-
LUAD	cis	rs10829156	0.732	rs10741086	ENSG00000240291.1	RP11-499P20.2	3.69	0.000249	0.0297	0.16	0.17	Sudden cardiac arrest;	chr10:18505027	chr10:18513115~18545651:-
LUAD	cis	rs11673344	0.667	rs504549	ENSG00000267309.1	CTD-2630F21.1	-3.69	0.000249	0.0297	-0.21	-0.17	Obesity-related traits;	chr19:36946299	chr19:36489649~36491040:+
LUAD	cis	rs72634501	0.716	rs4660165	ENSG00000182109.6	RP11-69E11.4	-3.69	0.000249	0.0297	-0.21	-0.17	HDL cholesterol;	chr1:39112860	chr1:39522280~39546187:-
LUAD	cis	rs1993709	0.617	rs1486095	ENSG00000227207.2	RPL31P12	3.69	0.000249	0.0297	0.2	0.17	Obesity (early onset extreme);	chr1:72114828	chr1:72301472~72301829:+
LUAD	cis	rs3096299	0.586	rs4572400	ENSG00000182376.2	RP5-1142A6.8	3.69	0.000249	0.0297	0.17	0.17	Multiple myeloma (IgH translocation);	chr16:89467108	chr16:88742767~88745748:+
LUAD	cis	rs73230612	1	rs16823578	ENSG00000242767.1	ZBTB20-AS4	3.69	0.000249	0.0297	0.27	0.17	Type 2 diabetes;	chr3:115222262	chr3:115100423~115103061:+
LUAD	cis	rs4763879	0.634	rs2098298	ENSG00000278635.1	CTD-2318O12.1	3.69	0.000249	0.0297	0.15	0.17	Type 1 diabetes;	chr12:9707473	chr12:9415641~9416718:+
LUAD	cis	rs7937890	0.504	rs2575847	ENSG00000254418.1	RP11-21L19.1	3.69	0.000249	0.0297	0.2	0.17	Mitochondrial DNA levels;	chr11:14449626	chr11:14262846~14273691:-
LUAD	cis	rs7937890	0.559	rs2575825	ENSG00000254418.1	RP11-21L19.1	3.69	0.000249	0.0297	0.2	0.17	Mitochondrial DNA levels;	chr11:14450550	chr11:14262846~14273691:-
LUAD	cis	rs4908769	0.624	rs6678140	ENSG00000232912.4	RP5-1115A15.1	-3.69	0.000249	0.0297	-0.16	-0.17	Allergy;	chr1:8376742	chr1:8424645~8434838:+
LUAD	cis	rs11658311	0.85	rs11078396	ENSG00000273018.4	CTD-2303H24.2	-3.69	0.000249	0.0297	-0.38	-0.17	Obsessive-compulsive symptoms;	chr17:17744082	chr17:18511221~18551705:-
LUAD	cis	rs321358	0.79	rs10502128	ENSG00000271390.1	RP11-89C3.3	3.69	0.000249	0.0297	0.26	0.17	Body mass index;	chr11:111076827	chr11:111089870~111090368:-
LUAD	cis	rs321358	0.848	rs57168185	ENSG00000271390.1	RP11-89C3.3	3.69	0.000249	0.0297	0.26	0.17	Body mass index;	chr11:111078120	chr11:111089870~111090368:-
LUAD	cis	rs4716602	0.862	rs10257343	ENSG00000235029.1	MNX1-AS2	-3.69	0.000249	0.0297	-0.21	-0.17	Anti-saccade response;	chr7:156369684	chr7:157006307~157007132:+
LUAD	cis	rs8114671	0.935	rs945960	ENSG00000269202.1	RP4-614O4.12	-3.69	0.000249	0.0297	-0.16	-0.17	Height;	chr20:35175051	chr20:35201747~35203288:-
LUAD	cis	rs8114671	0.967	rs2069952	ENSG00000269202.1	RP4-614O4.12	-3.69	0.000249	0.0297	-0.16	-0.17	Height;	chr20:35176148	chr20:35201747~35203288:-
LUAD	cis	rs1005277	0.522	rs9418276	ENSG00000273019.1	RP11-508N22.13	-3.69	0.000249	0.0297	-0.19	-0.17	Extrinsic epigenetic age acceleration;	chr10:37651188	chr10:38149968~38150293:+
LUAD	cis	rs4713118	0.523	rs2179096	ENSG00000280107.1	AL022393.9	-3.69	0.000249	0.0297	-0.19	-0.17	Parkinson's disease;	chr6:27698141	chr6:28170845~28172521:+
LUAD	cis	rs6547741	1	rs76784350	ENSG00000223522.1	AC093690.1	3.69	0.00025	0.0297	0.16	0.17	Oral cavity cancer;	chr2:27541411	chr2:28307691~28310459:-
LUAD	cis	rs812925	0.859	rs778138	ENSG00000271889.1	RP11-493E12.1	3.69	0.00025	0.0297	0.21	0.17	Immature fraction of reticulocytes;	chr2:61460079	chr2:61151433~61162105:-
LUAD	cis	rs10510102	0.935	rs11200257	ENSG00000276742.1	RP11-500G22.4	3.69	0.00025	0.0297	0.27	0.17	Breast cancer;	chr10:121917232	chr10:121956782~121957098:+
LUAD	cis	rs755249	1	rs61779359	ENSG00000182109.6	RP11-69E11.4	3.69	0.00025	0.0297	0.2	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39544563	chr1:39522280~39546187:-
LUAD	cis	rs755249	0.959	rs61781363	ENSG00000182109.6	RP11-69E11.4	3.69	0.00025	0.0297	0.2	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39546761	chr1:39522280~39546187:-
LUAD	cis	rs755249	1	rs4660808	ENSG00000182109.6	RP11-69E11.4	3.69	0.00025	0.0297	0.2	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39552837	chr1:39522280~39546187:-
LUAD	cis	rs755249	1	rs61781364	ENSG00000182109.6	RP11-69E11.4	3.69	0.00025	0.0297	0.2	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39553919	chr1:39522280~39546187:-
LUAD	cis	rs17711722	0.522	rs6957759	ENSG00000228409.4	CCT6P1	-3.69	0.00025	0.0297	-0.14	-0.17	Calcium levels;	chr7:65806798	chr7:65751142~65763354:+
LUAD	cis	rs61160187	0.582	rs12516995	ENSG00000215032.2	GNL3LP1	3.69	0.00025	0.0297	0.2	0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:61012447	chr5:60891935~60893577:-
LUAD	cis	rs7302981	0.719	rs844347	ENSG00000200428.1	Y_RNA	-3.69	0.00025	0.0297	-0.2	-0.17	Systolic blood pressure;	chr12:50067893	chr12:50743568~50743684:+
LUAD	cis	rs9467773	0.62	rs2504592	ENSG00000261353.1	CTA-14H9.5	-3.69	0.00025	0.0297	-0.19	-0.17	Intelligence (multi-trait analysis);	chr6:26640723	chr6:26527063~26527404:+
LUAD	cis	rs4908769	0.624	rs2708632	ENSG00000232912.4	RP5-1115A15.1	-3.69	0.00025	0.0298	-0.16	-0.17	Allergy;	chr1:8404449	chr1:8424645~8434838:+
LUAD	cis	rs4865762	0.687	rs774234	ENSG00000247796.2	CTD-2366F13.1	3.69	0.00025	0.0298	0.17	0.17	Intraocular pressure;	chr5:53198906	chr5:53109842~53115126:+
LUAD	cis	rs7077256	0.526	rs72837033	ENSG00000272767.1	JMJD1C-AS1	3.69	0.00025	0.0298	0.24	0.17	Intelligence (multi-trait analysis);	chr10:63448892	chr10:63465229~63466563:+
LUAD	cis	rs28374715	0.635	rs28557159	ENSG00000247556.5	OIP5-AS1	3.69	0.00025	0.0298	0.2	0.17	Ulcerative colitis;	chr15:41365155	chr15:41283990~41309737:+
LUAD	cis	rs8180040	0.966	rs6765990	ENSG00000271161.1	BOLA2P2	3.69	0.00025	0.0298	0.16	0.17	Colorectal cancer;	chr3:47501404	chr3:47499841~47500407:+
LUAD	cis	rs7968440	1	rs2731440	ENSG00000272368.2	RP4-605O3.4	3.69	0.00025	0.0298	0.19	0.17	Fibrinogen;	chr12:50663844	chr12:50112197~50165618:+
LUAD	cis	rs7968440	1	rs2731439	ENSG00000272368.2	RP4-605O3.4	3.69	0.00025	0.0298	0.19	0.17	Fibrinogen;	chr12:50666567	chr12:50112197~50165618:+
LUAD	cis	rs858239	1	rs156425	ENSG00000230042.1	AK3P3	3.69	0.00025	0.0298	0.21	0.17	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23129178~23129841:+
LUAD	cis	rs794185	0.592	rs304079	ENSG00000231249.1	ITPR1-AS1	3.69	0.00025	0.0298	0.18	0.17	Multiple sclerosis--Brain Glutamate Levels;	chr3:4490785	chr3:4490891~4493163:-
LUAD	cis	rs10859871	0.536	rs1873052	ENSG00000216306.3	KRT19P2	3.69	0.00025	0.0298	0.22	0.17	Endometriosis;	chr12:95243458	chr12:94834147~94835158:+
LUAD	cis	rs7584330	0.868	rs13386290	ENSG00000222032.1	AC112721.2	3.69	0.00025	0.0298	0.19	0.17	Prostate cancer;	chr2:237484493	chr2:237428920~237434822:-
LUAD	cis	rs62621207	0.541	rs41444045	ENSG00000272572.1	RP11-179B2.2	3.69	0.00025	0.0298	0.42	0.17	Lung cancer;	chr10:100985749	chr10:100911103~100912739:-
LUAD	cis	rs1502844	0.516	rs35506458	ENSG00000250682.4	LINC00491	-3.69	0.00025	0.0298	-0.21	-0.17	Schizophrenia;	chr5:102535118	chr5:102609156~102671559:-
LUAD	cis	rs2836950	0.805	rs2836961	ENSG00000255568.3	BRWD1-AS2	-3.69	0.00025	0.0298	-0.16	-0.17	Menarche (age at onset);	chr21:39255094	chr21:39313935~39314962:+
LUAD	cis	rs7826238	0.601	rs2976907	ENSG00000233609.3	RP11-62H7.2	3.69	0.00025	0.0298	0.14	0.17	Systolic blood pressure;	chr8:8487658	chr8:8961200~8979025:+
LUAD	cis	rs2342371	0.848	rs4244200	ENSG00000273013.1	CTD-2002J20.1	-3.69	0.00025	0.0298	-0.22	-0.17	Fat distribution (HIV);	chr3:196499188	chr3:196474801~196475394:+
LUAD	cis	rs6001482	0.679	rs8142710	ENSG00000223350.2	IGLV9-49	-3.69	0.00025	0.0298	-0.16	-0.17	Diastolic blood pressure;	chr22:22233044	chr22:22343187~22343732:+
LUAD	cis	rs7674212	0.54	rs2720469	ENSG00000251288.2	RP11-10L12.2	-3.69	0.00025	0.0298	-0.21	-0.17	Type 2 diabetes;	chr4:103165327	chr4:102751401~102752641:+
LUAD	cis	rs7674212	0.57	rs6810571	ENSG00000251288.2	RP11-10L12.2	-3.69	0.00025	0.0298	-0.21	-0.17	Type 2 diabetes;	chr4:103165630	chr4:102751401~102752641:+
LUAD	cis	rs6460942	1	rs111761262	ENSG00000226690.5	AC005281.1	3.69	0.00025	0.0298	0.3	0.17	Coronary artery disease;	chr7:12376290	chr7:12496429~12541910:+
LUAD	cis	rs2380205	0.967	rs4009521	ENSG00000232807.2	RP11-536K7.3	3.69	0.00025	0.0298	0.17	0.17	Breast cancer;	chr10:5846127	chr10:5934270~5945900:-
LUAD	cis	rs2348418	0.966	rs7316351	ENSG00000244712.1	RP11-874G11.1	3.69	0.00025	0.0298	0.2	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28545595	chr12:28564678~28565141:-
LUAD	cis	rs7979673	1	rs7953554	ENSG00000239335.4	LLPH-AS1	-3.69	0.00025	0.0298	-0.44	-0.17	Height;	chr12:65806998	chr12:66130751~66134449:+
LUAD	cis	rs5769707	0.777	rs739243	ENSG00000235111.1	RP1-29C18.8	-3.69	0.000251	0.0298	-0.18	-0.17	Monocyte percentage of white cells;Monocyte count;	chr22:49663563	chr22:49612657~49615716:-
LUAD	cis	rs2390582	0.891	rs17131073	ENSG00000233593.5	RP4-665J23.1	3.69	0.000251	0.0298	0.23	0.17	Coronary artery calcification;	chr1:90496814	chr1:90782986~90851650:-
LUAD	cis	rs6479891	1	rs7099425	ENSG00000232075.1	MRPL35P2	-3.69	0.000251	0.0298	-0.27	-0.17	Arthritis (juvenile idiopathic);	chr10:63200957	chr10:63634317~63634827:-
LUAD	cis	rs7772486	0.686	rs9390349	ENSG00000235652.6	RP11-545I5.3	-3.69	0.000251	0.0298	-0.16	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145733294	chr6:145799409~145886585:+
LUAD	cis	rs7976269	0.609	rs2117994	ENSG00000275476.1	RP11-996F15.4	-3.69	0.000251	0.0298	-0.18	-0.17	Male-pattern baldness;	chr12:29054666	chr12:29277397~29277882:-
LUAD	cis	rs7976269	0.583	rs6487753	ENSG00000275476.1	RP11-996F15.4	-3.69	0.000251	0.0298	-0.18	-0.17	Male-pattern baldness;	chr12:29056103	chr12:29277397~29277882:-
LUAD	cis	rs7976269	0.583	rs6487754	ENSG00000275476.1	RP11-996F15.4	-3.69	0.000251	0.0298	-0.18	-0.17	Male-pattern baldness;	chr12:29056104	chr12:29277397~29277882:-
LUAD	cis	rs7976269	0.609	rs6487755	ENSG00000275476.1	RP11-996F15.4	-3.69	0.000251	0.0298	-0.18	-0.17	Male-pattern baldness;	chr12:29056156	chr12:29277397~29277882:-
LUAD	cis	rs6715284	0.579	rs56974892	ENSG00000201499.1	RNU6-312P	-3.69	0.000251	0.0298	-0.36	-0.17	Rheumatoid arthritis;	chr2:201548015	chr2:200881715~200881821:-
LUAD	cis	rs6715284	0.579	rs56394080	ENSG00000201499.1	RNU6-312P	-3.69	0.000251	0.0298	-0.36	-0.17	Rheumatoid arthritis;	chr2:201549474	chr2:200881715~200881821:-
LUAD	cis	rs6715284	0.579	rs76042247	ENSG00000201499.1	RNU6-312P	-3.69	0.000251	0.0298	-0.36	-0.17	Rheumatoid arthritis;	chr2:201552065	chr2:200881715~200881821:-
LUAD	cis	rs7216064	0.953	rs75231441	ENSG00000266717.1	RP11-855A2.3	3.69	0.000251	0.0298	0.2	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67889369	chr17:67950885~67951746:-
LUAD	cis	rs4819052	0.765	rs2838852	ENSG00000215447.6	BX322557.10	-3.69	0.000251	0.0298	-0.2	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45257122	chr21:45288052~45291738:+
LUAD	cis	rs10752881	1	rs12126434	ENSG00000224468.3	RP11-181K3.4	3.69	0.000251	0.0298	0.15	0.17	Colorectal cancer;	chr1:183019279	chr1:183138402~183141282:-
LUAD	cis	rs6763848	0.923	rs9854789	ENSG00000214073.2	RPL21P17	-3.69	0.000251	0.0298	-0.17	-0.17	Prostate cancer (SNP x SNP interaction);	chr3:1468408	chr3:1905651~1906125:+
LUAD	cis	rs4443100	0.792	rs9612223	ENSG00000207832.1	AC245028.1	3.69	0.000251	0.0298	0.15	0.17	Serum parathyroid hormone levels;	chr22:23046964	chr22:22856545~22856638:+
LUAD	cis	rs1923539	0.549	rs2250360	ENSG00000230091.5	TMEM254-AS1	3.69	0.000251	0.0298	0.22	0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79905258	chr10:80046860~80078912:-
LUAD	cis	rs1208	0.965	rs13270462	ENSG00000253384.1	CTD-2547L16.3	3.69	0.000251	0.0298	0.19	0.17	Insulin resistance/response;	chr8:18408027	chr8:18088569~18089687:-
LUAD	cis	rs62481355	0.68	rs9640842	ENSG00000224138.1	AC000123.4	3.69	0.000251	0.0298	0.16	0.17	Type 2 diabetes;	chr7:127431409	chr7:127350128~127351523:+
LUAD	cis	rs2115630	1	rs55646601	ENSG00000259728.4	LINC00933	-3.69	0.000251	0.0298	-0.2	-0.17	P wave terminal force;	chr15:84780337	chr15:84570649~84580175:+
LUAD	cis	rs11159086	1	rs17100451	ENSG00000270000.1	RP3-449M8.9	3.69	0.000251	0.0298	0.24	0.17	Advanced glycation end-product levels;	chr14:74476210	chr14:74471930~74472360:-
LUAD	cis	rs7646881	0.544	rs17630785	ENSG00000240207.5	RP11-379F4.4	-3.69	0.000251	0.0298	-0.23	-0.17	Tetralogy of Fallot;	chr3:158674437	chr3:158732263~158784070:+
LUAD	cis	rs34421088	0.56	rs2618434	ENSG00000255046.1	RP11-297N6.4	3.69	0.000251	0.0299	0.2	0.17	Neuroticism;	chr8:11541356	chr8:11797928~11802568:-
LUAD	cis	rs13113518	1	rs4864542	ENSG00000223305.1	RN7SKP30	-3.69	0.000251	0.0299	-0.19	-0.17	Height;	chr4:55487920	chr4:55540502~55540835:-
LUAD	cis	rs10934524	0.715	rs35826627	ENSG00000243547.1	HNRNPKP4	3.69	0.000251	0.0299	0.12	0.17	Longevity;	chr3:96422356	chr3:96349554~96350939:+
LUAD	cis	rs6832769	0.579	rs1118271	ENSG00000272969.1	RP11-528I4.2	-3.69	0.000251	0.0299	-0.18	-0.17	Personality dimensions;	chr4:55646973	chr4:55547112~55547889:+
LUAD	cis	rs6832769	0.579	rs1948189	ENSG00000272969.1	RP11-528I4.2	-3.69	0.000251	0.0299	-0.18	-0.17	Personality dimensions;	chr4:55646975	chr4:55547112~55547889:+
LUAD	cis	rs6832769	0.598	rs1118272	ENSG00000272969.1	RP11-528I4.2	-3.69	0.000251	0.0299	-0.18	-0.17	Personality dimensions;	chr4:55647055	chr4:55547112~55547889:+
LUAD	cis	rs6723108	0.603	rs62168897	ENSG00000224043.6	CCNT2-AS1	-3.69	0.000251	0.0299	-0.21	-0.17	Type 2 diabetes;	chr2:134960427	chr2:134735464~134918710:-
LUAD	cis	rs801193	0.569	rs6978178	ENSG00000273448.1	RP11-166O4.6	-3.69	0.000251	0.0299	-0.16	-0.17	Aortic root size;	chr7:66658097	chr7:67333047~67334383:+
LUAD	cis	rs7615952	0.599	rs6779141	ENSG00000241288.6	RP11-379B18.5	-3.69	0.000251	0.0299	-0.22	-0.17	Blood pressure (smoking interaction);	chr3:125991152	chr3:125827238~125916384:-
LUAD	cis	rs6471393	0.964	rs2914959	ENSG00000253848.1	RP11-10N23.5	3.69	0.000251	0.0299	0.22	0.17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93727117	chr8:93741193~93744534:+
LUAD	cis	rs797680	0.856	rs1335679	ENSG00000223745.6	RP4-717I23.3	3.69	0.000251	0.0299	0.13	0.17	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93179625	chr1:93262186~93346025:-
LUAD	cis	rs217727	0.524	rs7483477	ENSG00000226416.1	MRPL23-AS1	-3.69	0.000251	0.0299	-0.21	-0.17	Breast cancer;	chr11:1899025	chr11:1983237~1989920:-
LUAD	cis	rs9291683	0.53	rs998675	ENSG00000250413.1	RP11-448G15.1	-3.69	0.000251	0.0299	-0.21	-0.17	Bone mineral density;	chr4:9947205	chr4:10006482~10009725:+
LUAD	cis	rs4386084	1	rs12905434	ENSG00000242737.1	RP11-562A8.1	3.69	0.000251	0.0299	0.21	0.17	Basophil percentage of granulocytes;Basophil percentage of white cells;	chr15:49939630	chr15:50466738~50467096:+
LUAD	cis	rs7714584	1	rs77698001	ENSG00000197083.10	ZNF300P1	3.69	0.000251	0.0299	0.32	0.17	Crohn's disease;	chr5:150870805	chr5:150930645~150946289:-
LUAD	cis	rs3758785	0.597	rs615465	ENSG00000255893.1	RP11-685N10.1	3.69	0.000251	0.0299	0.19	0.17	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94353088	chr11:94472908~94473570:-
LUAD	cis	rs17596685	0.932	rs9533158	ENSG00000271216.1	LINC01050	3.69	0.000251	0.0299	0.24	0.17	C-reactive protein levels;	chr13:42579022	chr13:42810366~42812562:-
LUAD	cis	rs448720	0.692	rs4777011	ENSG00000260657.2	RP11-315D16.4	-3.69	0.000251	0.0299	-0.2	-0.17	Cognitive performance;	chr15:67928836	chr15:68267792~68277994:-
LUAD	cis	rs28374715	0.635	rs8023530	ENSG00000247556.5	OIP5-AS1	3.69	0.000251	0.0299	0.2	0.17	Ulcerative colitis;	chr15:41355577	chr15:41283990~41309737:+
LUAD	cis	rs2342371	0.848	rs9864836	ENSG00000273013.1	CTD-2002J20.1	-3.69	0.000251	0.0299	-0.2	-0.17	Fat distribution (HIV);	chr3:196473866	chr3:196474801~196475394:+
LUAD	cis	rs6840360	0.558	rs2709821	ENSG00000270265.1	RP11-731D1.4	-3.69	0.000251	0.0299	-0.17	-0.17	Intelligence (multi-trait analysis);	chr4:151421038	chr4:151333775~151353224:-
LUAD	cis	rs13113518	0.966	rs13108409	ENSG00000273257.1	RP11-177J6.1	3.69	0.000251	0.0299	0.18	0.17	Height;	chr4:55520278	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs11726198	ENSG00000273257.1	RP11-177J6.1	3.69	0.000251	0.0299	0.18	0.17	Height;	chr4:55523835	chr4:55387949~55388271:+
LUAD	cis	rs13113518	0.966	rs11133396	ENSG00000273257.1	RP11-177J6.1	3.69	0.000251	0.0299	0.18	0.17	Height;	chr4:55524246	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs7675109	ENSG00000273257.1	RP11-177J6.1	3.69	0.000251	0.0299	0.18	0.17	Height;	chr4:55525589	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs4865005	ENSG00000273257.1	RP11-177J6.1	3.69	0.000251	0.0299	0.18	0.17	Height;	chr4:55525781	chr4:55387949~55388271:+
LUAD	cis	rs6471393	0.964	rs56282609	ENSG00000253848.1	RP11-10N23.5	3.69	0.000251	0.0299	0.21	0.17	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93737852	chr8:93741193~93744534:+
LUAD	cis	rs3617	0.625	rs2336558	ENSG00000242142.1	SERBP1P3	-3.69	0.000251	0.0299	-0.18	-0.17	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52852224	chr3:53064283~53065091:-
LUAD	cis	rs2299587	0.61	rs7001974	ENSG00000253671.1	RP11-806O11.1	-3.69	0.000251	0.0299	-0.19	-0.17	Economic and political preferences;	chr8:17915786	chr8:17808941~17820868:+
LUAD	cis	rs2299587	0.61	rs6987474	ENSG00000253671.1	RP11-806O11.1	-3.69	0.000251	0.0299	-0.19	-0.17	Economic and political preferences;	chr8:17915789	chr8:17808941~17820868:+
LUAD	cis	rs412050	0.547	rs61757982	ENSG00000224086.5	LL22NC03-86G7.1	-3.69	0.000251	0.0299	-0.21	-0.17	Attention deficit hyperactivity disorder;	chr22:21759451	chr22:21938293~21977632:+
LUAD	cis	rs7578361	0.885	rs7571890	ENSG00000231969.1	AC144449.1	-3.69	0.000251	0.0299	-0.24	-0.17	Acute lymphoblastic leukemia (childhood);	chr2:149563379	chr2:149587196~149848233:+
LUAD	cis	rs6479901	0.895	rs10822162	ENSG00000232075.1	MRPL35P2	-3.69	0.000251	0.0299	-0.23	-0.17	Intelligence (multi-trait analysis);	chr10:63364320	chr10:63634317~63634827:-
LUAD	cis	rs638893	0.947	rs12808822	ENSG00000255239.1	AP002954.6	3.69	0.000251	0.0299	0.27	0.17	Vitiligo;	chr11:118831560	chr11:118688039~118690600:-
LUAD	cis	rs17711722	0.565	rs73372653	ENSG00000228409.4	CCT6P1	-3.69	0.000251	0.0299	-0.14	-0.17	Calcium levels;	chr7:65977808	chr7:65751142~65763354:+
LUAD	cis	rs4474465	1	rs2063726	ENSG00000251323.2	RP11-452H21.4	3.69	0.000251	0.0299	0.21	0.17	Alzheimer's disease (survival time);	chr11:78472487	chr11:78423982~78429836:-
LUAD	cis	rs7893279	0.505	rs12766314	ENSG00000225527.1	RP11-383B4.4	3.69	0.000251	0.0299	0.25	0.17	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18584361	chr10:18531849~18533336:-
LUAD	cis	rs9860428	0.533	rs28394328	ENSG00000242770.2	RP11-180K7.1	3.69	0.000251	0.0299	0.18	0.17	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112960219	chr3:112802478~112812819:+
LUAD	cis	rs1023500	0.573	rs133381	ENSG00000273366.1	CTA-989H11.1	-3.69	0.000251	0.0299	-0.2	-0.17	Schizophrenia;	chr22:42074604	chr22:42278188~42278846:+
LUAD	cis	rs894638	0.519	rs9985640	ENSG00000263327.5	TAPT1-AS1	3.69	0.000251	0.0299	0.21	0.17	Glomerular filtration rate in chronic kidney disease;	chr4:16128047	chr4:16226685~16320140:+
LUAD	cis	rs6832769	1	rs7667849	ENSG00000272969.1	RP11-528I4.2	-3.69	0.000252	0.0299	-0.17	-0.17	Personality dimensions;	chr4:55522032	chr4:55547112~55547889:+
LUAD	cis	rs11724804	0.532	rs62295557	ENSG00000254094.1	AC078852.1	3.69	0.000252	0.0299	0.2	0.17	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;	chr4:861920	chr4:1356581~1358075:+
LUAD	cis	rs4713118	0.868	rs742047	ENSG00000280107.1	AL022393.9	-3.69	0.000252	0.0299	-0.22	-0.17	Parkinson's disease;	chr6:27771601	chr6:28170845~28172521:+
LUAD	cis	rs9659323	0.632	rs12045138	ENSG00000231365.4	RP11-418J17.1	-3.69	0.000252	0.0299	-0.19	-0.17	Body mass index;	chr1:119076825	chr1:119140396~119275973:+
LUAD	cis	rs1005277	0.522	rs7072977	ENSG00000273019.1	RP11-508N22.13	-3.69	0.000252	0.0299	-0.19	-0.17	Extrinsic epigenetic age acceleration;	chr10:37651512	chr10:38149968~38150293:+
LUAD	cis	rs683250	0.599	rs7110564	ENSG00000246067.6	RAB30-AS1	-3.69	0.000252	0.0299	-0.18	-0.17	Subcortical brain region volumes;	chr11:83367576	chr11:83072066~83106719:+
LUAD	cis	rs7208859	0.562	rs11650923	ENSG00000280069.1	CTD-2349P21.3	-3.69	0.000252	0.0299	-0.23	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30681149	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs56378576	ENSG00000280069.1	CTD-2349P21.3	-3.69	0.000252	0.0299	-0.23	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30683102	chr17:30738182~30740275:+
LUAD	cis	rs7208859	0.623	rs35916850	ENSG00000280069.1	CTD-2349P21.3	-3.69	0.000252	0.0299	-0.23	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30684155	chr17:30738182~30740275:+
LUAD	cis	rs219780	0.799	rs2850109	ENSG00000233818.1	AP000695.4	3.69	0.000252	0.0299	0.2	0.17	Kidney stones;	chr21:36445653	chr21:36445731~36532408:+
LUAD	cis	rs6871536	1	rs62383714	ENSG00000233006.5	AC034220.3	-3.69	0.000252	0.0299	-0.19	-0.17	Asthma (childhood onset);	chr5:132574103	chr5:132311285~132369916:-
LUAD	cis	rs9860428	0.967	rs9842637	ENSG00000242770.2	RP11-180K7.1	3.69	0.000252	0.0299	0.18	0.17	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112861222	chr3:112802478~112812819:+
LUAD	cis	rs7119038	0.774	rs7945144	ENSG00000255422.1	AP002954.4	3.69	0.000252	0.0299	0.25	0.17	Sjögren's syndrome;	chr11:118738007	chr11:118704607~118750263:+
LUAD	cis	rs6502050	0.731	rs34796376	ENSG00000275966.1	RP11-1055B8.9	-3.69	0.000252	0.0299	-0.17	-0.17	Life satisfaction;	chr17:82158759	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.528	rs12942561	ENSG00000275966.1	RP11-1055B8.9	-3.69	0.000252	0.0299	-0.17	-0.17	Life satisfaction;	chr17:82158763	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.529	rs35585236	ENSG00000275966.1	RP11-1055B8.9	-3.69	0.000252	0.0299	-0.17	-0.17	Life satisfaction;	chr17:82158765	chr17:81345476~81345966:-
LUAD	cis	rs4072705	1	rs2416949	ENSG00000236643.1	RP11-175D17.3	-3.69	0.000252	0.0299	-0.19	-0.17	Menarche (age at onset);	chr9:124712832	chr9:124770123~124772927:+
LUAD	cis	rs2153904	0.793	rs12118655	ENSG00000261000.1	RP11-534L20.5	3.69	0.000252	0.0299	0.27	0.17	Prostate-specific antigen levels;	chr1:205694350	chr1:206503948~206504456:+
LUAD	cis	rs12681963	0.614	rs74600875	ENSG00000272375.1	RP11-51J9.6	3.69	0.000252	0.0299	0.34	0.17	Migraine;	chr8:30039317	chr8:30197404~30198048:+
LUAD	cis	rs6427528	0.557	rs10737177	ENSG00000232879.2	RP11-544M22.3	-3.69	0.000252	0.0299	-0.23	-0.17	Response to anti-TNF therapy in rheumatoid arthritis;	chr1:160590226	chr1:161034834~161035006:+
LUAD	cis	rs6427528	0.546	rs10797081	ENSG00000232879.2	RP11-544M22.3	-3.69	0.000252	0.0299	-0.23	-0.17	Response to anti-TNF therapy in rheumatoid arthritis;	chr1:160591981	chr1:161034834~161035006:+
LUAD	cis	rs6427528	0.546	rs4565710	ENSG00000232879.2	RP11-544M22.3	-3.69	0.000252	0.0299	-0.23	-0.17	Response to anti-TNF therapy in rheumatoid arthritis;	chr1:160594684	chr1:161034834~161035006:+
LUAD	cis	rs115769866	0.609	rs974334	ENSG00000216901.1	AL022393.7	3.69	0.000252	0.0299	0.22	0.17	Bipolar disorder;	chr6:28506441	chr6:28176188~28176674:+
LUAD	cis	rs8056893	0.714	rs1530643	ENSG00000260441.4	RP11-96D1.7	-3.69	0.000252	0.0299	-0.19	-0.17	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68362189	chr16:68256162~68260443:-
LUAD	cis	rs3753275	0.519	rs4908771	ENSG00000232912.4	RP5-1115A15.1	3.69	0.000252	0.0299	0.19	0.17	Educational attainment;	chr1:8662448	chr1:8424645~8434838:+
LUAD	cis	rs9325144	0.723	rs11169519	ENSG00000257718.1	RP11-396F22.1	-3.69	0.000252	0.0299	-0.2	-0.17	Morning vs. evening chronotype;	chr12:38783639	chr12:38906451~38909592:+
LUAD	cis	rs638893	1	rs649338	ENSG00000255239.1	AP002954.6	3.69	0.000252	0.0299	0.27	0.17	Vitiligo;	chr11:118834945	chr11:118688039~118690600:-
LUAD	cis	rs2412819	0.571	rs4923964	ENSG00000166763.7	STRCP1	-3.69	0.000252	0.0299	-0.24	-0.17	Lung cancer;	chr15:43722882	chr15:43699488~43718184:-
LUAD	cis	rs1910358	0.959	rs966297	ENSG00000248874.4	C5orf17	-3.69	0.000252	0.0299	-0.24	-0.17	Venous thromboembolism (SNP x SNP interaction);	chr5:23878098	chr5:23951348~24178263:+
LUAD	cis	rs360798	0.711	rs11900596	ENSG00000231609.4	AC009501.4	3.69	0.000252	0.0299	0.19	0.17	Coronary artery disease;	chr2:62677534	chr2:63043922~63048640:-
LUAD	cis	rs454217	1	rs454217	ENSG00000277851.1	RP11-756G20.1	3.69	0.000252	0.03	0.17	0.17	Smoking quantity;	chr12:92324782	chr12:92247756~92363832:-
LUAD	cis	rs6001482	0.647	rs8140302	ENSG00000253818.1	IGLV1-41	-3.69	0.000252	0.03	-0.18	-0.17	Diastolic blood pressure;	chr22:22234843	chr22:22404207~22404721:+
LUAD	cis	rs6540731	0.905	rs12073206	ENSG00000229983.1	RP11-15I11.2	3.69	0.000252	0.03	0.19	0.17	Intelligence (childhood);	chr1:212214294	chr1:212168207~212190259:+
LUAD	cis	rs7605235	0.959	rs34845373	ENSG00000224165.4	DNAJC27-AS1	3.69	0.000252	0.03	0.19	0.17	Response to platinum-based chemotherapy (cisplatin);	chr2:25412902	chr2:24971390~25039694:+
LUAD	cis	rs683250	0.629	rs645954	ENSG00000246067.6	RAB30-AS1	3.69	0.000252	0.03	0.18	0.17	Subcortical brain region volumes;	chr11:83262003	chr11:83072066~83106719:+
LUAD	cis	rs7551222	0.752	rs16853958	ENSG00000240219.1	RP11-430C7.5	3.69	0.000252	0.03	0.18	0.17	Schizophrenia;	chr1:204559216	chr1:204626775~204629712:+
LUAD	cis	rs11064768	0.633	rs11064778	ENSG00000275759.1	RP11-131L12.3	3.69	0.000252	0.03	0.28	0.17	Schizophrenia;	chr12:119404346	chr12:118428281~118428870:+
LUAD	cis	rs11064768	0.633	rs11064782	ENSG00000275759.1	RP11-131L12.3	3.69	0.000252	0.03	0.28	0.17	Schizophrenia;	chr12:119407783	chr12:118428281~118428870:+
LUAD	cis	rs7005380	0.733	rs2037346	ENSG00000279347.1	RP11-85I17.2	-3.69	0.000252	0.03	-0.14	-0.17	Interstitial lung disease;	chr8:119923212	chr8:119838736~119840385:-
LUAD	cis	rs2274273	1	rs8011834	ENSG00000259318.1	RP11-454L9.2	3.69	0.000252	0.03	0.14	0.17	Protein biomarker;	chr14:55159259	chr14:55394940~55395233:-
LUAD	cis	rs858239	0.6	rs7776644	ENSG00000226816.2	AC005082.12	3.69	0.000252	0.03	0.22	0.17	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23206013~23208045:+
LUAD	cis	rs7665939	1	rs11942826	ENSG00000251297.1	TUBB7P	3.69	0.000252	0.03	0.32	0.17	Amyotrophic lateral sclerosis;	chr4:189188208	chr4:189982523~189984871:-
LUAD	cis	rs11089937	0.626	rs5757051	ENSG00000211640.3	IGLV6-57	-3.69	0.000252	0.03	-0.12	-0.17	Periodontitis (PAL4Q3);	chr22:22141753	chr22:22195713~22196460:+
LUAD	cis	rs12049351	0.613	rs3738185	ENSG00000229367.1	HMGN2P19	3.69	0.000252	0.03	0.25	0.17	Circulating myeloperoxidase levels (plasma);	chr1:229499520	chr1:229570532~229570796:+
LUAD	cis	rs12049351	0.774	rs12033713	ENSG00000229367.1	HMGN2P19	3.69	0.000252	0.03	0.25	0.17	Circulating myeloperoxidase levels (plasma);	chr1:229502693	chr1:229570532~229570796:+
LUAD	cis	rs7818688	0.546	rs13250762	ENSG00000253528.2	RP11-347C18.4	-3.69	0.000252	0.03	-0.22	-0.17	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;	chr8:94975342	chr8:94974573~94974853:-
LUAD	cis	rs67539049	1	rs67932868	ENSG00000255046.1	RP11-297N6.4	3.69	0.000252	0.03	0.24	0.17	Itch intensity from mosquito bite;	chr8:11445936	chr8:11797928~11802568:-
LUAD	cis	rs4713118	0.824	rs2179095	ENSG00000280107.1	AL022393.9	3.69	0.000252	0.03	0.21	0.17	Parkinson's disease;	chr6:27783079	chr6:28170845~28172521:+
LUAD	cis	rs984222	0.508	rs2645303	ENSG00000226172.2	RP4-712E4.1	-3.69	0.000252	0.03	-0.18	-0.17	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119012523	chr1:119000344~119001392:-
LUAD	cis	rs12413361	0.967	rs4749617	ENSG00000272914.1	RP11-330O11.3	-3.69	0.000252	0.03	-0.2	-0.17	Height;	chr10:30824794	chr10:30831828~30833387:-
LUAD	cis	rs76419734	0.85	rs17036142	ENSG00000251175.4	RP11-45L9.1	3.69	0.000252	0.03	0.32	0.17	Post bronchodilator FEV1;	chr4:105713579	chr4:105746245~105827172:-
LUAD	cis	rs11051970	0.879	rs2088807	ENSG00000274964.1	RP11-817I4.1	-3.69	0.000252	0.03	-0.18	-0.17	Response to tocilizumab in rheumatoid arthritis;	chr12:32439167	chr12:32339368~32340724:+
LUAD	cis	rs56163509	1	rs56163509	ENSG00000261419.1	RP11-57A19.4	-3.69	0.000252	0.03	-0.19	-0.17	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28659696~28740781:-
LUAD	cis	rs8062405	0.964	rs7187333	ENSG00000261419.1	RP11-57A19.4	-3.69	0.000252	0.03	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28659696~28740781:-
LUAD	cis	rs8062405	1	rs62037369	ENSG00000261419.1	RP11-57A19.4	-3.69	0.000252	0.03	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28659696~28740781:-
LUAD	cis	rs8062405	0.965	rs7359397	ENSG00000261419.1	RP11-57A19.4	-3.69	0.000252	0.03	-0.19	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28659696~28740781:-
LUAD	cis	rs6910061	1	rs9468436	ENSG00000247925.2	RP3-510L9.1	-3.69	0.000252	0.03	-0.23	-0.17	Diabetic kidney disease;	chr6:11112393	chr6:11173452~11259099:+
LUAD	cis	rs910316	0.763	rs175014	ENSG00000279594.1	RP11-950C14.10	-3.69	0.000252	0.03	-0.19	-0.17	Height;	chr14:74990224	chr14:75011269~75012851:-
LUAD	cis	rs4474465	0.85	rs7938257	ENSG00000251323.2	RP11-452H21.4	-3.69	0.000252	0.03	-0.22	-0.17	Alzheimer's disease (survival time);	chr11:78513862	chr11:78423982~78429836:-
LUAD	cis	rs7618915	0.547	rs2878726	ENSG00000243224.1	RP5-1157M23.2	-3.69	0.000252	0.03	-0.17	-0.17	Bipolar disorder;	chr3:52714255	chr3:52239258~52241097:+
LUAD	cis	rs7618915	0.547	rs10780035	ENSG00000243224.1	RP5-1157M23.2	-3.69	0.000252	0.03	-0.17	-0.17	Bipolar disorder;	chr3:52730608	chr3:52239258~52241097:+
LUAD	cis	rs7618915	0.547	rs2268027	ENSG00000243224.1	RP5-1157M23.2	-3.69	0.000252	0.03	-0.17	-0.17	Bipolar disorder;	chr3:52732590	chr3:52239258~52241097:+
LUAD	cis	rs2216164	0.623	rs4913404	ENSG00000256325.1	RP11-611O2.1	3.69	0.000252	0.03	0.19	0.17	Alopecia areata;	chr12:68116805	chr12:68828118~68828553:+
LUAD	cis	rs9309473	0.847	rs13538	ENSG00000230002.2	ALMS1-IT1	3.69	0.000252	0.03	0.21	0.17	Metabolite levels;	chr2:73641201	chr2:73456764~73459484:+
LUAD	cis	rs7077256	0.564	rs34205815	ENSG00000272767.1	JMJD1C-AS1	3.69	0.000252	0.03	0.24	0.17	Intelligence (multi-trait analysis);	chr10:63530144	chr10:63465229~63466563:+
LUAD	cis	rs10463554	0.889	rs34822	ENSG00000250682.4	LINC00491	3.69	0.000253	0.03	0.2	0.17	Parkinson's disease;	chr5:103102007	chr5:102609156~102671559:-
LUAD	cis	rs9392556	0.6	rs664299	ENSG00000230648.1	RP3-406P24.3	3.69	0.000253	0.03	0.18	0.17	Blood metabolite levels;	chr6:4112007	chr6:4018843~4021215:-
LUAD	cis	rs2279168	0.867	rs76807446	ENSG00000202081.1	RNU6-1280P	-3.69	0.000253	0.03	-0.3	-0.17	Response to platinum-based chemotherapy (carboplatin);	chr15:85421025	chr15:85651522~85651628:-
LUAD	cis	rs360798	0.711	rs6760804	ENSG00000231609.4	AC009501.4	3.69	0.000253	0.03	0.19	0.17	Coronary artery disease;	chr2:62678949	chr2:63043922~63048640:-
LUAD	cis	rs360798	0.817	rs6745862	ENSG00000231609.4	AC009501.4	3.69	0.000253	0.03	0.19	0.17	Coronary artery disease;	chr2:62679062	chr2:63043922~63048640:-
LUAD	cis	rs4489787	0.892	rs2731101	ENSG00000240399.1	RP1-228P16.1	3.69	0.000253	0.03	0.25	0.17	Prostate cancer (SNP x SNP interaction);	chr12:48510456	chr12:48054813~48055591:-
LUAD	cis	rs9309473	1	rs6736866	ENSG00000230002.2	ALMS1-IT1	3.69	0.000253	0.03	0.21	0.17	Metabolite levels;	chr2:73434858	chr2:73456764~73459484:+
LUAD	cis	rs4666002	0.75	rs13021208	ENSG00000223522.1	AC093690.1	3.69	0.000253	0.03	0.19	0.17	Phospholipid levels (plasma);	chr2:27678861	chr2:28307691~28310459:-
LUAD	cis	rs11064768	0.633	rs12371440	ENSG00000275759.1	RP11-131L12.3	3.69	0.000253	0.03	0.28	0.17	Schizophrenia;	chr12:119408865	chr12:118428281~118428870:+
LUAD	cis	rs11064768	0.633	rs11064785	ENSG00000275759.1	RP11-131L12.3	3.69	0.000253	0.03	0.28	0.17	Schizophrenia;	chr12:119412143	chr12:118428281~118428870:+
LUAD	cis	rs11064768	0.633	rs80158076	ENSG00000275759.1	RP11-131L12.3	3.69	0.000253	0.03	0.28	0.17	Schizophrenia;	chr12:119414741	chr12:118428281~118428870:+
LUAD	cis	rs7308116	0.53	rs11113578	ENSG00000257951.1	RP11-554D14.4	3.69	0.000253	0.03	0.18	0.17	Pelvic organ prolapse (moderate/severe);	chr12:107906609	chr12:107881242~107883382:+
LUAD	cis	rs4474465	1	rs10899517	ENSG00000251323.2	RP11-452H21.4	3.69	0.000253	0.03	0.21	0.17	Alzheimer's disease (survival time);	chr11:78469461	chr11:78423982~78429836:-
LUAD	cis	rs4474465	1	rs10899518	ENSG00000251323.2	RP11-452H21.4	3.69	0.000253	0.03	0.21	0.17	Alzheimer's disease (survival time);	chr11:78469462	chr11:78423982~78429836:-
LUAD	cis	rs4474465	1	rs10899520	ENSG00000251323.2	RP11-452H21.4	3.69	0.000253	0.03	0.21	0.17	Alzheimer's disease (survival time);	chr11:78472324	chr11:78423982~78429836:-
LUAD	cis	rs6088590	0.965	rs13040449	ENSG00000275784.1	RP5-1125A11.6	-3.69	0.000253	0.03	-0.18	-0.17	Coronary artery disease;	chr20:34771098	chr20:33989480~33991818:-
LUAD	cis	rs6088590	0.582	rs6059909	ENSG00000276073.1	RP5-1125A11.7	-3.69	0.000253	0.03	-0.16	-0.17	Coronary artery disease;	chr20:34551887	chr20:33985617~33988989:-
LUAD	cis	rs6088590	0.561	rs11167239	ENSG00000276073.1	RP5-1125A11.7	-3.69	0.000253	0.03	-0.16	-0.17	Coronary artery disease;	chr20:34552668	chr20:33985617~33988989:-
LUAD	cis	rs6088590	0.523	rs6059913	ENSG00000276073.1	RP5-1125A11.7	-3.69	0.000253	0.03	-0.16	-0.17	Coronary artery disease;	chr20:34555484	chr20:33985617~33988989:-
LUAD	cis	rs9608946	0.515	rs3804078	ENSG00000279699.1	RP1-102K2.9	-3.69	0.000253	0.03	-0.22	-0.17	Red cell distribution width;	chr22:30457895	chr22:30275215~30276951:-
LUAD	cis	rs2243480	1	rs4718317	ENSG00000232559.3	GS1-124K5.12	-3.69	0.000253	0.03	-0.28	-0.17	Diabetic kidney disease;	chr7:66183914	chr7:66554588~66576923:-
LUAD	cis	rs12908161	1	rs60957376	ENSG00000254414.1	RP11-182J1.1	3.69	0.000253	0.03	0.21	0.17	Schizophrenia;	chr15:84737561	chr15:84631898~84633987:-
LUAD	cis	rs7131987	0.565	rs7976667	ENSG00000257176.2	RP11-996F15.2	3.69	0.000253	0.03	0.17	0.17	QT interval;	chr12:29273098	chr12:29280418~29317848:-
LUAD	cis	rs987044	0.726	rs9783411	ENSG00000257221.1	RP11-689B22.2	-3.69	0.000253	0.03	-0.14	-0.17	Mean platelet volume;	chr12:108712761	chr12:108628687~108641318:+
LUAD	cis	rs11874381	1	rs62101776	ENSG00000266696.1	RP11-30L3.2	-3.69	0.000253	0.03	-0.19	-0.17	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);	chr18:49683704	chr18:49205912~49208781:+
LUAD	cis	rs7428	0.527	rs4832164	ENSG00000246575.2	AC093162.5	3.69	0.000253	0.03	0.16	0.17	Ear protrusion;	chr2:85319809	chr2:85315041~85316529:+
LUAD	cis	rs7777677	0.925	rs2156964	ENSG00000276953.1	TRBV12-4	3.69	0.000253	0.03	0.16	0.17	Alcoholic chronic pancreatitis;	chr7:142664755	chr7:142563740~142564245:+
LUAD	cis	rs728616	0.867	rs1054054	ENSG00000234382.2	RP11-40F6.1	-3.69	0.000253	0.03	-0.41	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79922972	chr10:80233664~80245367:+
LUAD	cis	rs728616	0.867	rs61859766	ENSG00000234382.2	RP11-40F6.1	-3.69	0.000253	0.03	-0.41	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79923284	chr10:80233664~80245367:+
LUAD	cis	rs603446	0.84	rs180329	ENSG00000254851.1	RP11-109L13.1	-3.69	0.000253	0.03	-0.2	-0.17	Triglycerides;	chr11:116752242	chr11:117135528~117138582:+
LUAD	cis	rs1346081	0.904	rs1946344	ENSG00000250075.4	RP11-584P21.2	-3.69	0.000253	0.03	-0.18	-0.17	Intelligence (multi-trait analysis);	chr4:67125207	chr4:67417305~67468251:-
LUAD	cis	rs12908161	0.96	rs17599989	ENSG00000254414.1	RP11-182J1.1	3.69	0.000253	0.03	0.21	0.17	Schizophrenia;	chr15:84742305	chr15:84631898~84633987:-
LUAD	cis	rs10739663	0.52	rs3122937	ENSG00000232630.1	PRPS1P2	-3.69	0.000253	0.03	-0.16	-0.17	Resting heart rate;	chr9:125392529	chr9:125150653~125151589:+
LUAD	cis	rs17685	0.849	rs3815455	ENSG00000205485.12	AC004980.7	-3.69	0.000253	0.03	-0.18	-0.17	Coffee consumption (cups per day);Coffee consumption;	chr7:75982438	chr7:76549360~76627982:+
LUAD	cis	rs9907295	0.591	rs4325615	ENSG00000270977.1	AC015849.16	-3.69	0.000253	0.03	-0.22	-0.17	Fibroblast growth factor basic levels;	chr17:35826379	chr17:35893707~35911023:-
LUAD	cis	rs9907295	0.551	rs28595279	ENSG00000270977.1	AC015849.16	-3.69	0.000253	0.03	-0.22	-0.17	Fibroblast growth factor basic levels;	chr17:35826416	chr17:35893707~35911023:-
LUAD	cis	rs2486288	0.656	rs2413768	ENSG00000259479.5	SORD2P	-3.69	0.000253	0.03	-0.2	-0.17	Glomerular filtration rate;	chr15:45269786	chr15:44826371~44884694:-
LUAD	cis	rs6540731	1	rs1389369	ENSG00000229983.1	RP11-15I11.2	3.69	0.000253	0.03	0.2	0.17	Intelligence (childhood);	chr1:212227194	chr1:212168207~212190259:+
LUAD	cis	rs6540731	1	rs1389370	ENSG00000229983.1	RP11-15I11.2	3.69	0.000253	0.03	0.2	0.17	Intelligence (childhood);	chr1:212227275	chr1:212168207~212190259:+
LUAD	cis	rs6540731	1	rs6540735	ENSG00000229983.1	RP11-15I11.2	3.69	0.000253	0.03	0.2	0.17	Intelligence (childhood);	chr1:212227418	chr1:212168207~212190259:+
LUAD	cis	rs6540731	1	rs6657900	ENSG00000229983.1	RP11-15I11.2	3.69	0.000253	0.03	0.2	0.17	Intelligence (childhood);	chr1:212227524	chr1:212168207~212190259:+
LUAD	cis	rs6540731	1	rs35209719	ENSG00000229983.1	RP11-15I11.2	3.69	0.000253	0.03	0.2	0.17	Intelligence (childhood);	chr1:212228335	chr1:212168207~212190259:+
LUAD	cis	rs4308124	0.708	rs10179596	ENSG00000230499.1	AC108463.1	-3.69	0.000253	0.03	-0.23	-0.17	Vitiligo;	chr2:111212803	chr2:111195963~111206494:+
LUAD	cis	rs4308124	0.708	rs6727313	ENSG00000230499.1	AC108463.1	-3.69	0.000253	0.03	-0.23	-0.17	Vitiligo;	chr2:111213963	chr2:111195963~111206494:+
LUAD	cis	rs4308124	0.708	rs10178095	ENSG00000230499.1	AC108463.1	-3.69	0.000253	0.03	-0.23	-0.17	Vitiligo;	chr2:111214939	chr2:111195963~111206494:+
LUAD	cis	rs1923539	0.549	rs2250135	ENSG00000230091.5	TMEM254-AS1	3.69	0.000253	0.0301	0.22	0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79907567	chr10:80046860~80078912:-
LUAD	cis	rs2731006	0.64	rs2731002	ENSG00000257114.2	RP11-25I15.3	-3.69	0.000253	0.0301	-0.27	-0.17	Panic disorder;	chr12:42790472	chr12:42692216~42717119:+
LUAD	cis	rs1015362	0.503	rs1883708	ENSG00000275784.1	RP5-1125A11.6	-3.69	0.000253	0.0301	-0.22	-0.17	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33924107	chr20:33989480~33991818:-
LUAD	cis	rs804280	0.544	rs804276	ENSG00000255046.1	RP11-297N6.4	-3.69	0.000253	0.0301	-0.21	-0.17	Myopia (pathological);	chr8:11767499	chr8:11797928~11802568:-
LUAD	cis	rs6687758	1	rs12135286	ENSG00000238042.4	RP11-815M8.1	3.69	0.000253	0.0301	0.23	0.17	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222045419	chr1:221880981~221978523:-
LUAD	cis	rs3020736	0.5	rs4147640	ENSG00000273366.1	CTA-989H11.1	3.69	0.000253	0.0301	0.2	0.17	Autism spectrum disorder or schizophrenia;	chr22:42089288	chr22:42278188~42278846:+
LUAD	cis	rs734999	1	rs734999	ENSG00000238164.5	RP3-395M20.8	-3.69	0.000253	0.0301	-0.14	-0.17	Ulcerative colitis;	chr1:2581777	chr1:2549920~2557031:-
LUAD	cis	rs734999	1	rs2016366	ENSG00000238164.5	RP3-395M20.8	-3.69	0.000253	0.0301	-0.14	-0.17	Ulcerative colitis;	chr1:2582239	chr1:2549920~2557031:-
LUAD	cis	rs13113518	1	rs6822740	ENSG00000273257.1	RP11-177J6.1	3.69	0.000253	0.0301	0.18	0.17	Height;	chr4:55518922	chr4:55387949~55388271:+
LUAD	cis	rs10129255	0.557	rs4043727	ENSG00000253209.1	IGHV3-65	3.69	0.000253	0.0301	0.14	0.17	Kawasaki disease;	chr14:106649820	chr14:106666092~106666532:-
LUAD	cis	rs9309473	0.847	rs13538	ENSG00000273245.1	RP11-434P11.2	3.69	0.000253	0.0301	0.21	0.17	Metabolite levels;	chr2:73641201	chr2:73750256~73750786:-
LUAD	cis	rs2999052	0.602	rs1625296	ENSG00000244932.2	RP11-529F4.1	3.69	0.000253	0.0301	0.12	0.17	Hypospadias;	chr3:128389139	chr3:129381298~129394149:+
LUAD	cis	rs10463554	0.856	rs257293	ENSG00000250682.4	LINC00491	3.69	0.000253	0.0301	0.2	0.17	Parkinson's disease;	chr5:103159824	chr5:102609156~102671559:-
LUAD	cis	rs11671005	0.779	rs3752112	ENSG00000268912.1	CTD-2619J13.17	-3.69	0.000253	0.0301	-0.23	-0.17	Mean platelet volume;	chr19:58480853	chr19:58428632~58431148:-
LUAD	cis	rs13113518	1	rs13152173	ENSG00000273257.1	RP11-177J6.1	3.69	0.000253	0.0301	0.18	0.17	Height;	chr4:55534788	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs13141049	ENSG00000273257.1	RP11-177J6.1	3.69	0.000253	0.0301	0.18	0.17	Height;	chr4:55535489	chr4:55387949~55388271:+
LUAD	cis	rs13113518	0.967	rs12507722	ENSG00000273257.1	RP11-177J6.1	3.69	0.000253	0.0301	0.18	0.17	Height;	chr4:55536421	chr4:55387949~55388271:+
LUAD	cis	rs13113518	0.967	rs7696832	ENSG00000273257.1	RP11-177J6.1	3.69	0.000253	0.0301	0.18	0.17	Height;	chr4:55537080	chr4:55387949~55388271:+
LUAD	cis	rs1148114	0.518	rs1148117	ENSG00000254667.2	AP000783.1	3.69	0.000253	0.0301	0.27	0.17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Delta-6 desaturase activity;	chr11:123622353	chr11:123430737~123435710:+
LUAD	cis	rs12049351	0.774	rs1020353	ENSG00000229367.1	HMGN2P19	3.69	0.000253	0.0301	0.25	0.17	Circulating myeloperoxidase levels (plasma);	chr1:229561571	chr1:229570532~229570796:+
LUAD	cis	rs2652834	0.718	rs2652836	ENSG00000259498.1	RP11-244F12.3	-3.69	0.000253	0.0301	-0.23	-0.17	HDL cholesterol;	chr15:63104102	chr15:63046034~63049387:-
LUAD	cis	rs12681963	0.925	rs13263107	ENSG00000272375.1	RP11-51J9.6	-3.69	0.000253	0.0301	-0.22	-0.17	Migraine;	chr8:30111988	chr8:30197404~30198048:+
LUAD	cis	rs924712	0.545	rs12216049	ENSG00000261116.1	RP3-523K23.2	3.69	0.000253	0.0301	0.18	0.17	Breast cancer;	chr6:54845171	chr6:54943167~54945099:+
LUAD	cis	rs2280018	0.526	rs2941257	ENSG00000183458.12	RP11-958N24.1	-3.69	0.000253	0.0301	-0.13	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072588	chr16:14911551~14935708:+
LUAD	cis	rs10129255	0.833	rs7156689	ENSG00000211974.3	IGHV2-70	3.69	0.000253	0.0301	0.17	0.17	Kawasaki disease;	chr14:106816039	chr14:106723574~106724093:-
LUAD	cis	rs16940212	0.618	rs7497636	ENSG00000242747.1	RP11-30K9.1	-3.69	0.000253	0.0301	-0.25	-0.17	HDL cholesterol;HDL cholesterol levels;	chr15:58393432	chr15:58869659~58870134:+
LUAD	cis	rs7546668	1	rs4646093	ENSG00000272510.1	RP4-680D5.8	3.69	0.000254	0.0301	0.21	0.17	Glomerular filtration rate (creatinine);	chr1:15494905	chr1:15565611~15565956:-
LUAD	cis	rs7665090	0.528	rs4235405	ENSG00000246560.2	RP11-10L12.4	3.69	0.000254	0.0301	0.22	0.17	Primary biliary cholangitis;	chr4:102595654	chr4:102828055~102844075:+
LUAD	cis	rs231513	0.906	rs75508812	ENSG00000267595.1	RP11-242D8.2	-3.69	0.000254	0.0301	-0.22	-0.17	Cognitive function;	chr17:43926029	chr17:43168170~43168249:-
LUAD	cis	rs987044	0.726	rs7358571	ENSG00000257221.1	RP11-689B22.2	-3.69	0.000254	0.0301	-0.14	-0.17	Mean platelet volume;	chr12:108675924	chr12:108628687~108641318:+
LUAD	cis	rs9921338	0.961	rs11074958	ENSG00000263080.1	RP11-485G7.5	3.69	0.000254	0.0301	0.23	0.17	Vein graft stenosis in coronary artery bypass grafting;	chr16:11303222	chr16:11341809~11345211:-
LUAD	cis	rs11158026	0.603	rs4335711	ENSG00000258413.1	RP11-665C16.6	-3.69	0.000254	0.0301	-0.22	-0.17	Parkinson's disease;	chr14:55004145	chr14:55262767~55272075:-
LUAD	cis	rs12712135	0.525	rs11123917	ENSG00000234389.1	AC007278.3	-3.69	0.000254	0.0301	-0.15	-0.17	Blood protein levels;	chr2:102275189	chr2:102438713~102440475:+
LUAD	cis	rs67981189	0.896	rs2810098	ENSG00000269927.1	RP6-91H8.3	-3.69	0.000254	0.0301	-0.21	-0.17	Schizophrenia;	chr14:70967194	chr14:71141125~71143253:-
LUAD	cis	rs9532563	0.55	rs61963699	ENSG00000215483.7	LINC00598	-3.69	0.000254	0.0301	-0.27	-0.17	Mean corpuscular volume;	chr13:40566345	chr13:40450934~40535807:-
LUAD	cis	rs61160187	0.582	rs55814394	ENSG00000215032.2	GNL3LP1	3.69	0.000254	0.0301	0.2	0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:61014107	chr5:60891935~60893577:-
LUAD	cis	rs61160187	0.582	rs10939879	ENSG00000215032.2	GNL3LP1	3.69	0.000254	0.0301	0.2	0.17	Educational attainment (years of education);Educational attainment (college completion);	chr5:61019996	chr5:60891935~60893577:-
LUAD	cis	rs9309473	0.95	rs6546847	ENSG00000230002.2	ALMS1-IT1	3.69	0.000254	0.0301	0.2	0.17	Metabolite levels;	chr2:73558231	chr2:73456764~73459484:+
LUAD	cis	rs9309473	0.898	rs7580750	ENSG00000230002.2	ALMS1-IT1	3.69	0.000254	0.0301	0.2	0.17	Metabolite levels;	chr2:73560999	chr2:73456764~73459484:+
LUAD	cis	rs7017914	0.902	rs34882924	ENSG00000246366.5	RP11-382J12.1	3.69	0.000254	0.0301	0.15	0.17	Bone mineral density;	chr8:70654073	chr8:70608577~70663279:+
LUAD	cis	rs57221529	0.545	rs55955015	ENSG00000248925.1	CTD-2083E4.6	3.69	0.000254	0.0301	0.26	0.17	Lung disease severity in cystic fibrosis;	chr5:575067	chr5:269858~271516:-
LUAD	cis	rs7973683	0.541	rs6488910	ENSG00000251497.2	RP11-197N18.7	-3.69	0.000254	0.0301	-0.19	-0.17	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr12:123909150	chr12:123081384~123084744:+
LUAD	cis	rs7395662	0.853	rs4882062	ENSG00000254879.1	PTPRJ-AS1	3.69	0.000254	0.0301	0.18	0.17	HDL cholesterol;	chr11:48431719	chr11:48014406~48015855:-
LUAD	cis	rs6088590	0.93	rs6087618	ENSG00000275784.1	RP5-1125A11.6	-3.69	0.000254	0.0301	-0.18	-0.17	Coronary artery disease;	chr20:34700603	chr20:33989480~33991818:-
LUAD	cis	rs7809950	0.954	rs2894466	ENSG00000238832.1	snoU109	3.69	0.000254	0.0301	0.25	0.17	Coronary artery disease;	chr7:107602464	chr7:107603363~107603507:+
LUAD	cis	rs7809950	0.834	rs3801946	ENSG00000238832.1	snoU109	3.69	0.000254	0.0301	0.25	0.17	Coronary artery disease;	chr7:107602550	chr7:107603363~107603507:+
LUAD	cis	rs62244186	0.541	rs9859879	ENSG00000233509.2	ZNF197-AS1	3.69	0.000254	0.0301	0.18	0.17	Depressive symptoms;	chr3:44798674	chr3:44617128~44624797:-
LUAD	cis	rs6661961	0.752	rs1885528	ENSG00000237975.5	FLG-AS1	-3.69	0.000254	0.0301	-0.23	-0.17	Atopic dermatitis;	chr1:152448978	chr1:152168125~152445456:+
LUAD	cis	rs6661961	0.752	rs1885527	ENSG00000237975.5	FLG-AS1	-3.69	0.000254	0.0301	-0.23	-0.17	Atopic dermatitis;	chr1:152449069	chr1:152168125~152445456:+
LUAD	cis	rs6661961	0.752	rs4991216	ENSG00000237975.5	FLG-AS1	-3.69	0.000254	0.0301	-0.23	-0.17	Atopic dermatitis;	chr1:152449124	chr1:152168125~152445456:+
LUAD	cis	rs2281636	0.823	rs4917877	ENSG00000233690.1	EBAG9P1	3.69	0.000254	0.0301	0.16	0.17	Obesity-related traits;	chr10:99670281	chr10:99697407~99697949:-
LUAD	cis	rs854765	0.647	rs6502637	ENSG00000223979.2	SMCR2	-3.69	0.000254	0.0301	-0.2	-0.17	Total body bone mineral density;	chr17:18082784	chr17:17674026~17677688:-
LUAD	cis	rs854765	0.647	rs7212447	ENSG00000223979.2	SMCR2	-3.69	0.000254	0.0301	-0.2	-0.17	Total body bone mineral density;	chr17:18083753	chr17:17674026~17677688:-
LUAD	cis	rs4268898	0.862	rs11125549	ENSG00000223754.1	AC008073.9	-3.69	0.000254	0.0301	-0.2	-0.17	Asthma;	chr2:24353371	chr2:24199839~24201698:-
LUAD	cis	rs451417	1	rs236107	ENSG00000275632.1	RP5-967N21.11	3.69	0.000254	0.0301	0.21	0.17	Menopause (age at onset);	chr20:5985085	chr20:6000418~6000941:+
LUAD	cis	rs4718428	0.705	rs4717328	ENSG00000230295.1	RP11-458F8.2	-3.69	0.000254	0.0301	-0.15	-0.17	Corneal structure;	chr7:66887678	chr7:66880708~66882981:+
LUAD	cis	rs875971	0.545	rs73148639	ENSG00000222364.1	RNU6-96P	-3.69	0.000254	0.0301	-0.21	-0.17	Aortic root size;	chr7:66390342	chr7:66395191~66395286:+
LUAD	cis	rs7017914	0.902	rs7831792	ENSG00000246366.5	RP11-382J12.1	3.69	0.000254	0.0301	0.15	0.17	Bone mineral density;	chr8:70653121	chr8:70608577~70663279:+
LUAD	cis	rs875971	0.522	rs709604	ENSG00000273142.1	RP11-458F8.4	3.69	0.000254	0.0301	0.11	0.17	Aortic root size;	chr7:66032447	chr7:66902857~66906297:+
LUAD	cis	rs4699052	0.739	rs11936824	ENSG00000251288.2	RP11-10L12.2	-3.69	0.000254	0.0301	-0.2	-0.17	Testicular germ cell tumor;	chr4:103316846	chr4:102751401~102752641:+
LUAD	cis	rs4648739	0.57	rs4388640	ENSG00000268575.1	RP1-283E3.8	3.69	0.000254	0.0302	0.17	0.17	Severe influenza A (H1N1) infection;	chr1:1976600	chr1:1702736~1737688:-
LUAD	cis	rs2921036	0.545	rs4840975	ENSG00000233609.3	RP11-62H7.2	-3.69	0.000254	0.0302	-0.14	-0.17	Neuroticism;	chr8:8505748	chr8:8961200~8979025:+
LUAD	cis	rs7714584	1	rs1896708	ENSG00000197083.10	ZNF300P1	3.69	0.000254	0.0302	0.32	0.17	Crohn's disease;	chr5:150865514	chr5:150930645~150946289:-
LUAD	cis	rs13108904	0.775	rs2279282	ENSG00000196810.4	CTBP1-AS2	3.69	0.000254	0.0302	0.19	0.17	Obesity-related traits;	chr4:1222245	chr4:1249300~1288291:+
LUAD	cis	rs7712401	0.791	rs9327279	ENSG00000249996.1	RP11-359P5.1	3.69	0.000254	0.0302	0.2	0.17	Mean platelet volume;	chr5:122786465	chr5:123036271~123054667:+
LUAD	cis	rs1023500	0.573	rs2269524	ENSG00000273366.1	CTA-989H11.1	3.69	0.000254	0.0302	0.2	0.17	Schizophrenia;	chr22:42079699	chr22:42278188~42278846:+
LUAD	cis	rs1023500	0.573	rs6002592	ENSG00000273366.1	CTA-989H11.1	3.69	0.000254	0.0302	0.2	0.17	Schizophrenia;	chr22:42080750	chr22:42278188~42278846:+
LUAD	cis	rs6942407	0.546	rs6465093	ENSG00000224046.1	AC005076.5	-3.69	0.000254	0.0302	-0.25	-0.17	Food allergy;	chr7:87135561	chr7:87151423~87152420:-
LUAD	cis	rs1346081	0.904	rs7659917	ENSG00000250075.4	RP11-584P21.2	-3.69	0.000254	0.0302	-0.18	-0.17	Intelligence (multi-trait analysis);	chr4:67125808	chr4:67417305~67468251:-
LUAD	cis	rs1346081	0.904	rs13128397	ENSG00000250075.4	RP11-584P21.2	-3.69	0.000254	0.0302	-0.18	-0.17	Intelligence (multi-trait analysis);	chr4:67127881	chr4:67417305~67468251:-
LUAD	cis	rs877819	0.583	rs2940729	ENSG00000228403.1	RP11-563N6.6	-3.69	0.000254	0.0302	-0.17	-0.17	Systemic lupus erythematosus;	chr10:48866159	chr10:48878022~48878649:+
LUAD	cis	rs877819	0.583	rs2663019	ENSG00000228403.1	RP11-563N6.6	-3.69	0.000254	0.0302	-0.17	-0.17	Systemic lupus erythematosus;	chr10:48867416	chr10:48878022~48878649:+
LUAD	cis	rs877819	0.583	rs2663020	ENSG00000228403.1	RP11-563N6.6	-3.69	0.000254	0.0302	-0.17	-0.17	Systemic lupus erythematosus;	chr10:48868229	chr10:48878022~48878649:+
LUAD	cis	rs249625	1	rs249625	ENSG00000245017.2	RP11-181C3.1	3.69	0.000254	0.0302	0.19	0.17	Iris color (L* coordinate);	chr12:97791470	chr12:98485544~98503855:-
LUAD	cis	rs6661961	0.686	rs6587671	ENSG00000237975.5	FLG-AS1	3.69	0.000254	0.0302	0.21	0.17	Atopic dermatitis;	chr1:152428801	chr1:152168125~152445456:+
LUAD	cis	rs10875976	0.525	rs7954572	ENSG00000257464.1	RP11-161H23.8	-3.69	0.000254	0.0302	-0.17	-0.17	Obesity;	chr12:49859132	chr12:49442424~49442652:-
LUAD	cis	rs7674212	0.556	rs6533039	ENSG00000230069.3	LRRC37A15P	-3.69	0.000254	0.0302	-0.17	-0.17	Type 2 diabetes;	chr4:102938381	chr4:102727274~102730721:-
LUAD	cis	rs7515577	0.898	rs77111349	ENSG00000223787.2	RP4-593M8.1	3.69	0.000254	0.0302	0.25	0.17	Cholesterol, total;	chr1:92439794	chr1:92580476~92580821:-
LUAD	cis	rs7515577	0.898	rs78220437	ENSG00000223787.2	RP4-593M8.1	3.69	0.000254	0.0302	0.25	0.17	Cholesterol, total;	chr1:92449400	chr1:92580476~92580821:-
LUAD	cis	rs6942407	0.546	rs10952896	ENSG00000224046.1	AC005076.5	-3.69	0.000254	0.0302	-0.25	-0.17	Food allergy;	chr7:87136447	chr7:87151423~87152420:-
LUAD	cis	rs2836974	0.836	rs1041440	ENSG00000232608.1	TIMM9P2	-3.69	0.000254	0.0302	-0.2	-0.17	Cognitive function;	chr21:39255399	chr21:39216624~39217506:+
LUAD	cis	rs7170668	0.93	rs12899367	ENSG00000259134.4	LINC00924	3.69	0.000254	0.0302	0.2	0.17	Motion sickness;	chr15:95469794	chr15:95433095~95507847:+
LUAD	cis	rs2348418	0.831	rs2348416	ENSG00000244712.1	RP11-874G11.1	3.69	0.000254	0.0302	0.2	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28556283	chr12:28564678~28565141:-
LUAD	cis	rs1065852	0.526	rs9607869	ENSG00000226450.2	CYP2D8P	3.69	0.000254	0.0302	0.14	0.17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42022106	chr22:42149886~42155001:-
LUAD	cis	rs9309473	0.847	rs4547554	ENSG00000273245.1	RP11-434P11.2	3.69	0.000254	0.0302	0.21	0.17	Metabolite levels;	chr2:73640735	chr2:73750256~73750786:-
LUAD	cis	rs6496932	0.755	rs12905673	ENSG00000259630.2	CTD-2262B20.1	-3.69	0.000254	0.0302	-0.2	-0.17	Central corneal thickness;Corneal structure;	chr15:85346540	chr15:85415228~85415633:+
LUAD	cis	rs11073619	0.616	rs34602083	ENSG00000230373.7	GOLGA6L5P	-3.69	0.000254	0.0302	-0.26	-0.17	Positive affect;	chr15:84397156	chr15:84507885~84516814:-
LUAD	cis	rs2243480	1	rs34702770	ENSG00000189316.3	RP11-797H7.5	3.69	0.000255	0.0302	0.28	0.17	Diabetic kidney disease;	chr7:65879836	chr7:64888527~64890100:-
LUAD	cis	rs6964587	0.869	rs6964050	ENSG00000188693.7	CYP51A1-AS1	3.69	0.000255	0.0302	0.2	0.17	Breast cancer;	chr7:91853104	chr7:92134604~92180725:+
LUAD	cis	rs6500602	0.702	rs6500606	ENSG00000280063.1	RP11-295D4.3	-3.69	0.000255	0.0302	-0.11	-0.17	Schizophrenia;	chr16:4452513	chr16:4346694~4348648:-
LUAD	cis	rs8031584	0.958	rs1043742	ENSG00000260128.5	ULK4P2	-3.69	0.000255	0.0302	-0.21	-0.17	Huntington's disease progression;	chr15:30940378	chr15:30572738~30600647:+
LUAD	cis	rs586688	0.625	rs606114	ENSG00000249007.1	RP11-510N19.5	3.69	0.000255	0.0302	0.2	0.17	Obesity-related traits;	chr1:201694973	chr1:202011370~202015657:+
LUAD	cis	rs7560272	0.723	rs780395	ENSG00000163016.8	ALMS1P	-3.69	0.000255	0.0302	-0.18	-0.17	Schizophrenia;	chr2:73473726	chr2:73644919~73685576:+
LUAD	cis	rs7560272	0.695	rs780394	ENSG00000163016.8	ALMS1P	-3.69	0.000255	0.0302	-0.18	-0.17	Schizophrenia;	chr2:73473803	chr2:73644919~73685576:+
LUAD	cis	rs4227	0.565	rs1641550	ENSG00000233223.2	AC113189.5	3.69	0.000255	0.0302	0.18	0.17	IgA nephropathy;	chr17:7600470	chr17:7581964~7584072:-
LUAD	cis	rs591584	0.621	rs489591	ENSG00000255893.1	RP11-685N10.1	-3.69	0.000255	0.0302	-0.19	-0.17	Macrophage Migration Inhibitory Factor levels;	chr11:94603265	chr11:94472908~94473570:-
LUAD	cis	rs526231	0.644	rs386352	ENSG00000175749.11	EIF3KP1	3.69	0.000255	0.0302	0.21	0.17	Primary biliary cholangitis;	chr5:103280006	chr5:103032376~103033031:+
LUAD	cis	rs2280018	0.526	rs1510148	ENSG00000183458.12	RP11-958N24.1	-3.69	0.000255	0.0302	-0.13	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15073522	chr16:14911551~14935708:+
LUAD	cis	rs6586111	0.967	rs6586106	ENSG00000226659.1	RP11-137H2.4	-3.68	0.000255	0.0302	-0.21	-0.17	Capecitabine sensitivity;	chr10:80612544	chr10:80529597~80535942:-
LUAD	cis	rs137603	0.644	rs137620	ENSG00000230149.2	RP3-508I15.19	-3.68	0.000255	0.0302	-0.13	-0.17	Primary biliary cholangitis;	chr22:39313771	chr22:38734730~38738990:+
LUAD	cis	rs137603	0.644	rs137621	ENSG00000230149.2	RP3-508I15.19	-3.68	0.000255	0.0302	-0.13	-0.17	Primary biliary cholangitis;	chr22:39314239	chr22:38734730~38738990:+
LUAD	cis	rs6088580	0.634	rs6059897	ENSG00000276073.1	RP5-1125A11.7	-3.68	0.000255	0.0302	-0.16	-0.17	Glomerular filtration rate (creatinine);	chr20:34525419	chr20:33985617~33988989:-
LUAD	cis	rs2115630	0.645	rs1107179	ENSG00000275120.1	RP11-182J1.17	3.68	0.000255	0.0302	0.21	0.17	P wave terminal force;	chr15:84655131	chr15:84599434~84606463:-
LUAD	cis	rs1046491	1	rs6506647	ENSG00000264964.1	RP11-888D10.3	3.68	0.000255	0.0302	0.34	0.17	Scarlet fever;	chr18:9240901	chr18:9315194~9334441:-
LUAD	cis	rs1046491	1	rs8086362	ENSG00000264964.1	RP11-888D10.3	3.68	0.000255	0.0302	0.34	0.17	Scarlet fever;	chr18:9243963	chr18:9315194~9334441:-
LUAD	cis	rs1046491	1	rs11661901	ENSG00000264964.1	RP11-888D10.3	3.68	0.000255	0.0302	0.34	0.17	Scarlet fever;	chr18:9250377	chr18:9315194~9334441:-
LUAD	cis	rs1046491	1	rs11664929	ENSG00000264964.1	RP11-888D10.3	3.68	0.000255	0.0302	0.34	0.17	Scarlet fever;	chr18:9250538	chr18:9315194~9334441:-
LUAD	cis	rs10752881	0.967	rs10911186	ENSG00000224468.3	RP11-181K3.4	-3.68	0.000255	0.0302	-0.15	-0.17	Colorectal cancer;	chr1:183003407	chr1:183138402~183141282:-
LUAD	cis	rs3120667	0.72	rs11581711	ENSG00000237975.5	FLG-AS1	3.68	0.000255	0.0302	0.3	0.17	Eating disorders;	chr1:152452003	chr1:152168125~152445456:+
LUAD	cis	rs7615952	0.932	rs13321217	ENSG00000241288.6	RP11-379B18.5	-3.68	0.000255	0.0302	-0.21	-0.17	Blood pressure (smoking interaction);	chr3:125912928	chr3:125827238~125916384:-
LUAD	cis	rs454217	0.846	rs337661	ENSG00000277851.1	RP11-756G20.1	3.68	0.000255	0.0302	0.17	0.17	Smoking quantity;	chr12:92310960	chr12:92247756~92363832:-
LUAD	cis	rs7819412	0.505	rs17726209	ENSG00000255046.1	RP11-297N6.4	-3.68	0.000255	0.0302	-0.21	-0.17	Triglycerides;	chr8:11164675	chr8:11797928~11802568:-
LUAD	cis	rs3095008	0.902	rs3114473	ENSG00000243004.4	AC005062.2	3.68	0.000255	0.0302	0.19	0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide);	chr7:20203413	chr7:19918981~20140453:-
LUAD	cis	rs3794924	1	rs35585743	ENSG00000266521.1	RP11-650P15.1	3.68	0.000255	0.0302	0.32	0.17	Survival in colon cancer;	chr18:31470398	chr18:31496645~31497195:-
LUAD	cis	rs453301	0.658	rs9329175	ENSG00000253981.4	ALG1L13P	-3.68	0.000255	0.0302	-0.2	-0.17	Joint mobility (Beighton score);	chr8:9009151	chr8:8236003~8244667:-
LUAD	cis	rs2652834	0.718	rs2729834	ENSG00000259498.1	RP11-244F12.3	3.68	0.000255	0.0302	0.24	0.17	HDL cholesterol;	chr15:63104848	chr15:63046034~63049387:-
LUAD	cis	rs2652834	0.718	rs8034620	ENSG00000259498.1	RP11-244F12.3	3.68	0.000255	0.0302	0.24	0.17	HDL cholesterol;	chr15:63104956	chr15:63046034~63049387:-
LUAD	cis	rs10483853	0.747	rs17126867	ENSG00000258695.2	RP3-414A15.2	-3.68	0.000255	0.0302	-0.21	-0.17	Coronary artery calcification;	chr14:73324563	chr14:73522878~73530610:+
LUAD	cis	rs6502050	0.799	rs8082355	ENSG00000275966.1	RP11-1055B8.9	-3.68	0.000255	0.0302	-0.17	-0.17	Life satisfaction;	chr17:82162440	chr17:81345476~81345966:-
LUAD	cis	rs7131987	0.65	rs11050187	ENSG00000275476.1	RP11-996F15.4	-3.68	0.000255	0.0302	-0.19	-0.17	QT interval;	chr12:29319943	chr12:29277397~29277882:-
LUAD	cis	rs5751168	0.834	rs11109	ENSG00000211654.2	IGLV5-37	3.68	0.000255	0.0302	0.24	0.17	Prostate cancer (SNP x SNP interaction);	chr22:22487881	chr22:22427540~22428035:+
LUAD	cis	rs10995505	0.589	rs10822140	ENSG00000232075.1	MRPL35P2	-3.68	0.000255	0.0303	-0.23	-0.17	Intelligence (multi-trait analysis);	chr10:63123267	chr10:63634317~63634827:-
LUAD	cis	rs10995505	0.589	rs2896496	ENSG00000232075.1	MRPL35P2	-3.68	0.000255	0.0303	-0.23	-0.17	Intelligence (multi-trait analysis);	chr10:63123622	chr10:63634317~63634827:-
LUAD	cis	rs3893377	1	rs10019008	ENSG00000214846.4	RP11-115L11.1	3.68	0.000255	0.0303	0.27	0.17	Current cigarettes per day in chronic obstructive pulmonary disease;	chr4:15741950	chr4:15730962~15731627:-
LUAD	cis	rs4237845	0.773	rs6650217	ENSG00000245651.2	RP11-620J15.2	3.68	0.000255	0.0303	0.16	0.17	Intelligence (multi-trait analysis);	chr12:57895289	chr12:57869835~57896482:-
LUAD	cis	rs4237845	0.773	rs6650218	ENSG00000245651.2	RP11-620J15.2	3.68	0.000255	0.0303	0.16	0.17	Intelligence (multi-trait analysis);	chr12:57895295	chr12:57869835~57896482:-
LUAD	cis	rs10911232	0.507	rs6660111	ENSG00000224468.3	RP11-181K3.4	-3.68	0.000255	0.0303	-0.15	-0.17	Hypertriglyceridemia;	chr1:183045154	chr1:183138402~183141282:-
LUAD	cis	rs9309473	1	rs10187416	ENSG00000230002.2	ALMS1-IT1	3.68	0.000255	0.0303	0.21	0.17	Metabolite levels;	chr2:73486614	chr2:73456764~73459484:+
LUAD	cis	rs9309473	0.95	rs10207264	ENSG00000230002.2	ALMS1-IT1	3.68	0.000255	0.0303	0.21	0.17	Metabolite levels;	chr2:73486970	chr2:73456764~73459484:+
LUAD	cis	rs1065852	0.526	rs2097561	ENSG00000226450.2	CYP2D8P	3.68	0.000255	0.0303	0.14	0.17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41993427	chr22:42149886~42155001:-
LUAD	cis	rs1065852	0.526	rs2097562	ENSG00000226450.2	CYP2D8P	3.68	0.000255	0.0303	0.14	0.17	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41993496	chr22:42149886~42155001:-
LUAD	cis	rs62025270	0.688	rs17638180	ENSG00000259416.2	RP11-158M2.5	-3.68	0.000255	0.0303	-0.21	-0.17	Idiopathic pulmonary fibrosis;	chr15:85735164	chr15:85754941~85756237:-
LUAD	cis	rs7181230	1	rs11638521	ENSG00000278621.1	CTD-2033D15.3	-3.68	0.000255	0.0303	-0.19	-0.17	Dehydroepiandrosterone sulphate levels;	chr15:40068113	chr15:39588357~39588882:-
LUAD	cis	rs2390582	0.782	rs12032399	ENSG00000233593.5	RP4-665J23.1	3.68	0.000255	0.0303	0.24	0.17	Coronary artery calcification;	chr1:90521288	chr1:90782986~90851650:-
LUAD	cis	rs10751667	0.58	rs7396041	ENSG00000255284.1	AP006621.5	3.68	0.000255	0.0303	0.14	0.17	Alzheimer's disease (late onset);	chr11:1001607	chr11:777578~784297:+
LUAD	cis	rs2625529	0.586	rs7170456	ENSG00000260173.1	RP11-2I17.4	3.68	0.000255	0.0303	0.2	0.17	Red blood cell count;	chr15:72177605	chr15:72140504~72155459:-
LUAD	cis	rs2348418	0.864	rs6487687	ENSG00000247934.4	RP11-967K21.1	3.68	0.000255	0.0303	0.19	0.17	Lung function (FEV1);Lung function (FVC);	chr12:28558230	chr12:28163298~28190738:-
LUAD	cis	rs7017914	0.934	rs6987313	ENSG00000246366.5	RP11-382J12.1	3.68	0.000255	0.0303	0.15	0.17	Bone mineral density;	chr8:70658754	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.902	rs35580034	ENSG00000246366.5	RP11-382J12.1	3.68	0.000255	0.0303	0.15	0.17	Bone mineral density;	chr8:70659838	chr8:70608577~70663279:+
LUAD	cis	rs301901	1	rs210540	ENSG00000250155.1	CTD-2353F22.1	-3.68	0.000255	0.0303	-0.17	-0.17	Height;	chr5:36804263	chr5:36666214~36725195:-
LUAD	cis	rs3120667	0.72	rs72698963	ENSG00000237975.5	FLG-AS1	3.68	0.000255	0.0303	0.3	0.17	Eating disorders;	chr1:152444006	chr1:152168125~152445456:+
LUAD	cis	rs3738443	0.645	rs11811599	ENSG00000225300.1	RP11-1086F11.1	-3.68	0.000255	0.0303	-0.18	-0.17	Alcohol dependence;	chr1:247203133	chr1:246605873~246608102:+
LUAD	cis	rs321358	0.945	rs10502130	ENSG00000271390.1	RP11-89C3.3	3.68	0.000255	0.0303	0.27	0.17	Body mass index;	chr11:111107437	chr11:111089870~111090368:-
LUAD	cis	rs321358	0.945	rs73017109	ENSG00000271390.1	RP11-89C3.3	3.68	0.000255	0.0303	0.27	0.17	Body mass index;	chr11:111108484	chr11:111089870~111090368:-
LUAD	cis	rs321358	0.887	rs1470537	ENSG00000271390.1	RP11-89C3.3	3.68	0.000255	0.0303	0.27	0.17	Body mass index;	chr11:111109328	chr11:111089870~111090368:-
LUAD	cis	rs321358	0.945	rs12421769	ENSG00000271390.1	RP11-89C3.3	3.68	0.000255	0.0303	0.27	0.17	Body mass index;	chr11:111109500	chr11:111089870~111090368:-
LUAD	cis	rs321358	0.945	rs73017114	ENSG00000271390.1	RP11-89C3.3	3.68	0.000255	0.0303	0.27	0.17	Body mass index;	chr11:111111582	chr11:111089870~111090368:-
LUAD	cis	rs321358	0.945	rs17458493	ENSG00000271390.1	RP11-89C3.3	3.68	0.000255	0.0303	0.27	0.17	Body mass index;	chr11:111112156	chr11:111089870~111090368:-
LUAD	cis	rs321358	0.945	rs17458541	ENSG00000271390.1	RP11-89C3.3	3.68	0.000255	0.0303	0.27	0.17	Body mass index;	chr11:111113182	chr11:111089870~111090368:-
LUAD	cis	rs321358	0.836	rs17458597	ENSG00000271390.1	RP11-89C3.3	3.68	0.000255	0.0303	0.27	0.17	Body mass index;	chr11:111113599	chr11:111089870~111090368:-
LUAD	cis	rs321358	0.945	rs73017176	ENSG00000271390.1	RP11-89C3.3	3.68	0.000255	0.0303	0.27	0.17	Body mass index;	chr11:111113879	chr11:111089870~111090368:-
LUAD	cis	rs321358	0.887	rs80221187	ENSG00000271390.1	RP11-89C3.3	3.68	0.000255	0.0303	0.27	0.17	Body mass index;	chr11:111113977	chr11:111089870~111090368:-
LUAD	cis	rs321358	0.945	rs73017177	ENSG00000271390.1	RP11-89C3.3	3.68	0.000255	0.0303	0.27	0.17	Body mass index;	chr11:111114034	chr11:111089870~111090368:-
LUAD	cis	rs321358	0.895	rs73017179	ENSG00000271390.1	RP11-89C3.3	3.68	0.000255	0.0303	0.27	0.17	Body mass index;	chr11:111114037	chr11:111089870~111090368:-
LUAD	cis	rs321358	0.945	rs1356411	ENSG00000271390.1	RP11-89C3.3	3.68	0.000255	0.0303	0.27	0.17	Body mass index;	chr11:111115371	chr11:111089870~111090368:-
LUAD	cis	rs321358	0.945	rs17537360	ENSG00000271390.1	RP11-89C3.3	3.68	0.000255	0.0303	0.27	0.17	Body mass index;	chr11:111116921	chr11:111089870~111090368:-
LUAD	cis	rs7560272	0.501	rs10191988	ENSG00000163016.8	ALMS1P	-3.68	0.000255	0.0303	-0.18	-0.17	Schizophrenia;	chr2:73720660	chr2:73644919~73685576:+
LUAD	cis	rs4819052	0.851	rs2838866	ENSG00000223768.1	LINC00205	-3.68	0.000256	0.0303	-0.21	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45293099	chr21:45293285~45297354:+
LUAD	cis	rs1958023	0.637	rs66728351	ENSG00000259045.1	RP11-320M16.1	-3.68	0.000256	0.0303	-0.18	-0.17	Mitochondrial DNA levels;	chr14:33170982	chr14:32484098~32484800:-
LUAD	cis	rs7176527	0.848	rs3748374	ENSG00000259570.1	RP11-671M22.4	-3.68	0.000256	0.0303	-0.25	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84641012	chr15:84394512~84395514:+
LUAD	cis	rs736408	0.609	rs62255396	ENSG00000243224.1	RP5-1157M23.2	-3.68	0.000256	0.0303	-0.17	-0.17	Bipolar disorder;	chr3:52748823	chr3:52239258~52241097:+
LUAD	cis	rs911555	0.617	rs7156036	ENSG00000259775.1	RP11-45P15.4	3.68	0.000256	0.0303	0.22	0.17	Intelligence (multi-trait analysis);	chr14:103441805	chr14:103331674~103332367:-
LUAD	cis	rs911555	0.723	rs6575991	ENSG00000259775.1	RP11-45P15.4	3.68	0.000256	0.0303	0.22	0.17	Intelligence (multi-trait analysis);	chr14:103442096	chr14:103331674~103332367:-
LUAD	cis	rs12928939	0.517	rs71384782	ENSG00000260886.1	TAT-AS1	3.68	0.000256	0.0303	0.23	0.17	Post bronchodilator FEV1;	chr16:71944688	chr16:71565789~71578187:+
LUAD	cis	rs513088	0.718	rs562914	ENSG00000225171.2	DUTP6	3.68	0.000256	0.0303	0.22	0.17	Schizophrenia;	chr1:166702692	chr1:166868748~166869209:+
LUAD	cis	rs2281636	0.894	rs1332103	ENSG00000233690.1	EBAG9P1	3.68	0.000256	0.0303	0.16	0.17	Obesity-related traits;	chr10:99616139	chr10:99697407~99697949:-
LUAD	cis	rs8048589	0.612	rs2869808	ENSG00000175604.2	RP11-276H1.3	-3.68	0.000256	0.0303	-0.22	-0.17	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12083007	chr16:12086746~12090302:-
LUAD	cis	rs8048589	0.642	rs8062015	ENSG00000175604.2	RP11-276H1.3	-3.68	0.000256	0.0303	-0.22	-0.17	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12083022	chr16:12086746~12090302:-
LUAD	cis	rs1790761	0.587	rs4930431	ENSG00000184224.3	C11orf72	-3.68	0.000256	0.0303	-0.19	-0.17	Mean corpuscular volume;	chr11:67526837	chr11:67602880~67606706:-
LUAD	cis	rs10214930	0.561	rs6961731	ENSG00000235574.1	AC073150.6	3.68	0.000256	0.0303	0.22	0.17	Hypospadias;	chr7:27885539	chr7:27491682~27492765:-
LUAD	cis	rs116095464	0.614	rs62344339	ENSG00000248925.1	CTD-2083E4.6	3.68	0.000256	0.0303	0.28	0.17	Breast cancer;	chr5:252880	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs9687898	ENSG00000248925.1	CTD-2083E4.6	3.68	0.000256	0.0303	0.28	0.17	Breast cancer;	chr5:253837	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs9688045	ENSG00000248925.1	CTD-2083E4.6	3.68	0.000256	0.0303	0.28	0.17	Breast cancer;	chr5:253920	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs112343653	ENSG00000248925.1	CTD-2083E4.6	3.68	0.000256	0.0303	0.28	0.17	Breast cancer;	chr5:257059	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs73024831	ENSG00000248925.1	CTD-2083E4.6	3.68	0.000256	0.0303	0.28	0.17	Breast cancer;	chr5:257077	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs62344345	ENSG00000248925.1	CTD-2083E4.6	3.68	0.000256	0.0303	0.28	0.17	Breast cancer;	chr5:257305	chr5:269858~271516:-
LUAD	cis	rs911555	0.755	rs34411783	ENSG00000259775.1	RP11-45P15.4	3.68	0.000256	0.0303	0.22	0.17	Intelligence (multi-trait analysis);	chr14:103434302	chr14:103331674~103332367:-
LUAD	cis	rs61542988	0.57	rs10950919	ENSG00000226816.2	AC005082.12	-3.68	0.000256	0.0303	-0.24	-0.17	Fibrinogen levels;	chr7:22794202	chr7:23206013~23208045:+
LUAD	cis	rs10129255	0.518	rs10150460	ENSG00000274576.2	IGHV2-70	3.68	0.000256	0.0303	0.13	0.17	Kawasaki disease;	chr14:106677179	chr14:106770577~106771020:-
LUAD	cis	rs6688613	0.694	rs11576455	ENSG00000225171.2	DUTP6	-3.68	0.000256	0.0303	-0.21	-0.17	Refractive astigmatism;	chr1:166842733	chr1:166868748~166869209:+
LUAD	cis	rs728616	0.614	rs3934643	ENSG00000234382.2	RP11-40F6.1	-3.68	0.000256	0.0303	-0.29	-0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79977061	chr10:80233664~80245367:+
LUAD	cis	rs71520386	0.846	rs76474740	ENSG00000228649.7	AC005682.5	-3.68	0.000256	0.0303	-0.26	-0.17	Fibrinogen levels;	chr7:22775741	chr7:22854178~22861579:+
LUAD	cis	rs71520386	0.846	rs77741999	ENSG00000228649.7	AC005682.5	-3.68	0.000256	0.0303	-0.26	-0.17	Fibrinogen levels;	chr7:22775785	chr7:22854178~22861579:+
LUAD	cis	rs71520386	0.796	rs71520381	ENSG00000228649.7	AC005682.5	-3.68	0.000256	0.0303	-0.26	-0.17	Fibrinogen levels;	chr7:22776388	chr7:22854178~22861579:+
LUAD	cis	rs4865762	0.687	rs166129	ENSG00000247796.2	CTD-2366F13.1	3.68	0.000256	0.0303	0.17	0.17	Intraocular pressure;	chr5:53202943	chr5:53109842~53115126:+
LUAD	cis	rs590820	0.684	rs1321257	ENSG00000227934.1	RP11-423F24.3	-3.68	0.000256	0.0304	-0.18	-0.17	Metabolite levels (lipoprotein measures);	chr1:230169566	chr1:231021611~231022183:+
LUAD	cis	rs9549260	0.569	rs73174811	ENSG00000168852.11	TPTE2P5	3.68	0.000256	0.0304	0.21	0.17	Red blood cell count;	chr13:40741862	chr13:40822296~40921749:-
LUAD	cis	rs4578769	0.55	rs12964830	ENSG00000266850.1	RP11-370A5.1	3.68	0.000256	0.0304	0.21	0.17	Eosinophil percentage of white cells;	chr18:22938970	chr18:22723491~22907721:-
LUAD	cis	rs189798	0.807	rs330905	ENSG00000173295.6	FAM86B3P	3.68	0.000256	0.0304	0.19	0.17	Myopia (pathological);	chr8:9136041	chr8:8228595~8244865:+
LUAD	cis	rs1858037	0.867	rs953312	ENSG00000237979.1	AC007389.1	3.68	0.000256	0.0304	0.21	0.17	Rheumatoid arthritis;	chr2:65340556	chr2:65500993~65502138:-
LUAD	cis	rs9659323	0.632	rs6658479	ENSG00000231365.4	RP11-418J17.1	-3.68	0.000256	0.0304	-0.19	-0.17	Body mass index;	chr1:119085233	chr1:119140396~119275973:+
LUAD	cis	rs7208859	0.614	rs9914534	ENSG00000263603.1	CTD-2349P21.5	-3.68	0.000256	0.0304	-0.29	-0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30875646	chr17:30729469~30731202:+
LUAD	cis	rs2333021	0.649	rs12893375	ENSG00000259015.1	RP11-109N23.6	3.68	0.000256	0.0304	0.17	0.17	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72990559	chr14:72960595~72961993:+
LUAD	cis	rs1577917	0.654	rs9450284	ENSG00000220563.1	PKMP3	3.68	0.000256	0.0304	0.15	0.17	Response to antipsychotic treatment;	chr6:85489611	chr6:85659892~85660606:-
LUAD	cis	rs3136739	0.764	rs58134732	ENSG00000254131.1	RP11-1007J8.1	-3.68	0.000256	0.0304	-0.36	-0.17	Plasma plasminogen activator levels;	chr8:42218643	chr8:42484600~42485019:+
LUAD	cis	rs7215564	0.908	rs34914062	ENSG00000232083.3	RPL31P7	3.68	0.000256	0.0304	0.3	0.17	Myopia (pathological);	chr17:80682109	chr17:80602549~80602926:-
LUAD	cis	rs6502050	0.835	rs8075086	ENSG00000275966.1	RP11-1055B8.9	-3.68	0.000256	0.0304	-0.17	-0.17	Life satisfaction;	chr17:82134773	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs9902485	ENSG00000275966.1	RP11-1055B8.9	-3.68	0.000256	0.0304	-0.17	-0.17	Life satisfaction;	chr17:82135825	chr17:81345476~81345966:-
LUAD	cis	rs6964587	0.692	rs2374550	ENSG00000188693.7	CYP51A1-AS1	-3.68	0.000256	0.0304	-0.19	-0.17	Breast cancer;	chr7:92191673	chr7:92134604~92180725:+
LUAD	cis	rs11603023	0.874	rs613243	ENSG00000278376.1	RP11-158I9.8	-3.68	0.000256	0.0304	-0.17	-0.17	Cholesterol, total;	chr11:118643304	chr11:118791254~118793137:+
LUAD	cis	rs6494488	0.5	rs72741325	ENSG00000239465.1	RP11-330L19.2	3.68	0.000257	0.0304	0.35	0.17	Coronary artery disease;	chr15:64438185	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs72741327	ENSG00000239465.1	RP11-330L19.2	3.68	0.000257	0.0304	0.35	0.17	Coronary artery disease;	chr15:64438623	chr15:64631109~64631914:-
LUAD	cis	rs2098086	1	rs2098086	ENSG00000223878.1	AC005517.3	3.68	0.000257	0.0304	0.17	0.17	Facial morphology (factor 16);	chr17:15033793	chr17:15506866~15507354:+
LUAD	cis	rs17772222	0.582	rs12050316	ENSG00000258789.1	RP11-507K2.3	-3.68	0.000257	0.0304	-0.2	-0.17	Coronary artery calcification;	chr14:88522097	chr14:88551597~88552493:+
LUAD	cis	rs8014252	1	rs34512695	ENSG00000274818.1	RP1-292L20.3	3.68	0.000257	0.0304	0.28	0.17	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70490958	chr14:70906657~70907111:-
LUAD	cis	rs4683346	0.616	rs4683332	ENSG00000173811.9	CCDC13-AS1	-3.68	0.000257	0.0304	-0.18	-0.17	Granulocyte percentage of myeloid white cells;	chr3:42785945	chr3:42732575~42746768:+
LUAD	cis	rs7976269	0.609	rs10771474	ENSG00000275476.1	RP11-996F15.4	3.68	0.000257	0.0304	0.18	0.17	Male-pattern baldness;	chr12:29068776	chr12:29277397~29277882:-
LUAD	cis	rs448720	1	rs379281	ENSG00000260657.2	RP11-315D16.4	-3.68	0.000257	0.0304	-0.18	-0.17	Cognitive performance;	chr15:67918362	chr15:68267792~68277994:-
LUAD	cis	rs7061710	0.703	rs72712640	ENSG00000271811.1	RP1-79C4.4	-3.68	0.000257	0.0304	-0.26	-0.17	Blood metabolite levels;	chr1:171078110	chr1:170667381~170669425:+
LUAD	cis	rs11051970	0.569	rs7298319	ENSG00000274964.1	RP11-817I4.1	3.68	0.000257	0.0304	0.17	0.17	Response to tocilizumab in rheumatoid arthritis;	chr12:32377451	chr12:32339368~32340724:+
LUAD	cis	rs6964587	1	rs2106171	ENSG00000188693.7	CYP51A1-AS1	-3.68	0.000257	0.0304	-0.2	-0.17	Breast cancer;	chr7:92121136	chr7:92134604~92180725:+
LUAD	cis	rs6452524	0.534	rs11746747	ENSG00000281327.1	LINC01338	3.68	0.000257	0.0304	0.18	0.17	Hypertension (SNP x SNP interaction);	chr5:83067666	chr5:82850864~82859836:-
LUAD	cis	rs1561288	0.954	rs7577562	ENSG00000235072.2	AC012074.2	-3.68	0.000257	0.0304	-0.19	-0.17	Body mass index;	chr2:25125623	chr2:25369136~25375845:-
LUAD	cis	rs7615952	0.611	rs2971298	ENSG00000241288.6	RP11-379B18.5	-3.68	0.000257	0.0304	-0.24	-0.17	Blood pressure (smoking interaction);	chr3:125883870	chr3:125827238~125916384:-
LUAD	cis	rs42490	0.59	rs39771	ENSG00000251136.7	RP11-37B2.1	-3.68	0.000257	0.0304	-0.18	-0.17	Leprosy;	chr8:89826378	chr8:89609409~89757727:-
LUAD	cis	rs2427308	0.643	rs477859	ENSG00000273619.1	RP5-908M14.9	3.68	0.000257	0.0304	0.18	0.17	Colorectal cancer;	chr20:62362541	chr20:62386303~62386970:-
LUAD	cis	rs6964833	1	rs34324835	ENSG00000184616.8	AC004166.6	3.68	0.000257	0.0304	0.25	0.17	Menarche (age at onset);	chr7:74717986	chr7:74906673~74913256:-
LUAD	cis	rs7017914	0.967	rs7842851	ENSG00000246366.5	RP11-382J12.1	3.68	0.000257	0.0304	0.15	0.17	Bone mineral density;	chr8:70751570	chr8:70608577~70663279:+
LUAD	cis	rs2274273	0.905	rs8007620	ENSG00000259318.1	RP11-454L9.2	3.68	0.000257	0.0304	0.14	0.17	Protein biomarker;	chr14:55119869	chr14:55394940~55395233:-
LUAD	cis	rs6687758	1	rs12140604	ENSG00000238042.4	RP11-815M8.1	3.68	0.000257	0.0304	0.23	0.17	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221985808	chr1:221880981~221978523:-
LUAD	cis	rs2039553	0.935	rs9574460	ENSG00000227676.3	LINC01068	-3.68	0.000257	0.0304	-0.21	-0.17	Pancreatic cancer;	chr13:79729287	chr13:79566727~79571436:+
LUAD	cis	rs2905347	0.52	rs2905309	ENSG00000232949.1	AC002480.4	-3.68	0.000257	0.0304	-0.2	-0.17	Major depression and alcohol dependence;	chr7:22608923	chr7:22589705~22591622:+
LUAD	cis	rs4474465	0.85	rs4387376	ENSG00000251323.2	RP11-452H21.4	-3.68	0.000257	0.0304	-0.2	-0.17	Alzheimer's disease (survival time);	chr11:78546616	chr11:78423982~78429836:-
LUAD	cis	rs6496044	0.611	rs6496055	ENSG00000259416.2	RP11-158M2.5	3.68	0.000257	0.0304	0.17	0.17	Interstitial lung disease;	chr15:85527457	chr15:85754941~85756237:-
LUAD	cis	rs3811273	0.614	rs7155927	ENSG00000211816.2	TRAV38-1	3.68	0.000257	0.0304	0.23	0.17	Periodontal disease-related phenotypes;	chr14:22263097	chr14:22271968~22272563:+
LUAD	cis	rs12908161	1	rs11632465	ENSG00000254414.1	RP11-182J1.1	3.68	0.000257	0.0305	0.21	0.17	Schizophrenia;	chr15:84738814	chr15:84631898~84633987:-
LUAD	cis	rs7246657	0.943	rs35540940	ENSG00000267470.4	ZNF571-AS1	3.68	0.000257	0.0305	0.23	0.17	Coronary artery calcification;	chr19:37517333	chr19:37548914~37587348:+
LUAD	cis	rs2904524	1	rs1404124	ENSG00000257815.4	RP11-611E13.2	-3.68	0.000257	0.0305	-0.25	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70319519	chr12:69904033~70243360:-
LUAD	cis	rs2904524	1	rs74768022	ENSG00000257815.4	RP11-611E13.2	-3.68	0.000257	0.0305	-0.25	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70333874	chr12:69904033~70243360:-
LUAD	cis	rs2904524	1	rs17107996	ENSG00000257815.4	RP11-611E13.2	-3.68	0.000257	0.0305	-0.25	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70334297	chr12:69904033~70243360:-
LUAD	cis	rs2904524	1	rs74823021	ENSG00000257815.4	RP11-611E13.2	-3.68	0.000257	0.0305	-0.25	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70334627	chr12:69904033~70243360:-
LUAD	cis	rs7829975	0.742	rs7832968	ENSG00000233609.3	RP11-62H7.2	3.68	0.000257	0.0305	0.14	0.17	Mood instability;	chr8:8795379	chr8:8961200~8979025:+
LUAD	cis	rs61542988	0.57	rs10950919	ENSG00000226329.2	AC005682.6	3.68	0.000257	0.0305	0.25	0.17	Fibrinogen levels;	chr7:22794202	chr7:22863874~22881350:-
LUAD	cis	rs1816752	0.679	rs8181826	ENSG00000273628.1	RP11-756A22.7	-3.68	0.000257	0.0305	-0.19	-0.17	Obesity-related traits;	chr13:24396570	chr13:24933006~24936796:+
LUAD	cis	rs957448	1	rs2381882	ENSG00000254057.1	RP3-388N13.3	3.68	0.000257	0.0305	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94535496	chr8:93834454~93846743:-
LUAD	cis	rs7712401	0.755	rs10900759	ENSG00000249996.1	RP11-359P5.1	3.68	0.000257	0.0305	0.2	0.17	Mean platelet volume;	chr5:122769385	chr5:123036271~123054667:+
LUAD	cis	rs9341808	0.538	rs9343980	ENSG00000233967.5	RP11-250B2.3	-3.68	0.000257	0.0305	-0.17	-0.17	Sitting height ratio;	chr6:80313715	chr6:80443344~80465927:+
LUAD	cis	rs600231	0.508	rs34582634	ENSG00000245532.5	NEAT1	3.68	0.000257	0.0305	0.15	0.17	Bone mineral density;	chr11:65452735	chr11:65422774~65445540:+
LUAD	cis	rs875971	0.522	rs6960048	ENSG00000273142.1	RP11-458F8.4	-3.68	0.000257	0.0305	-0.11	-0.17	Aortic root size;	chr7:65943052	chr7:66902857~66906297:+
LUAD	cis	rs6754311	0.731	rs218174	ENSG00000226806.1	AC011893.3	-3.68	0.000257	0.0305	-0.2	-0.17	Mosquito bite size;	chr2:135900775	chr2:135820191~135823087:+
LUAD	cis	rs4699052	0.625	rs11097808	ENSG00000246560.2	RP11-10L12.4	3.68	0.000257	0.0305	0.21	0.17	Testicular germ cell tumor;	chr4:103341973	chr4:102828055~102844075:+
LUAD	cis	rs7107174	0.901	rs2450139	ENSG00000251323.2	RP11-452H21.4	3.68	0.000257	0.0305	0.21	0.17	Testicular germ cell tumor;	chr11:78213498	chr11:78423982~78429836:-
LUAD	cis	rs9300255	0.596	rs10734900	ENSG00000256092.2	RP13-942N8.1	3.68	0.000257	0.0305	0.15	0.17	Neutrophil percentage of white cells;	chr12:123258898	chr12:123363868~123366113:+
LUAD	cis	rs9300255	0.596	rs10734901	ENSG00000256092.2	RP13-942N8.1	3.68	0.000257	0.0305	0.15	0.17	Neutrophil percentage of white cells;	chr12:123258900	chr12:123363868~123366113:+
LUAD	cis	rs4727963	0.792	rs10247666	ENSG00000240499.6	RP5-1101C3.1	3.68	0.000257	0.0305	0.15	0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);	chr7:123077144	chr7:122328469~122440388:+
LUAD	cis	rs897200	0.689	rs7561832	ENSG00000280083.1	RP11-317J9.1	3.68	0.000258	0.0305	0.23	0.17	Behcet's disease;	chr2:191145863	chr2:191154118~191156070:-
LUAD	cis	rs1876905	0.68	rs1215848	ENSG00000271789.1	RP5-1112D6.7	-3.68	0.000258	0.0305	-0.23	-0.17	Mean corpuscular hemoglobin;	chr6:111204333	chr6:111297126~111298510:+
LUAD	cis	rs1876905	0.68	rs402940	ENSG00000271789.1	RP5-1112D6.7	-3.68	0.000258	0.0305	-0.23	-0.17	Mean corpuscular hemoglobin;	chr6:111206785	chr6:111297126~111298510:+
LUAD	cis	rs1234598	1	rs1234598	ENSG00000271789.1	RP5-1112D6.7	-3.68	0.000258	0.0305	-0.23	-0.17	Mean corpuscular volume;	chr6:111208250	chr6:111297126~111298510:+
LUAD	cis	rs1876905	0.68	rs354543	ENSG00000271789.1	RP5-1112D6.7	-3.68	0.000258	0.0305	-0.23	-0.17	Mean corpuscular hemoglobin;	chr6:111209050	chr6:111297126~111298510:+
LUAD	cis	rs12285276	0.673	rs12283175	ENSG00000205106.4	DKFZp779M0652	3.68	0.000258	0.0305	0.22	0.17	Visceral fat;	chr11:45781619	chr11:45771432~45772358:+
LUAD	cis	rs12285276	0.75	rs7116816	ENSG00000205106.4	DKFZp779M0652	3.68	0.000258	0.0305	0.22	0.17	Visceral fat;	chr11:45783444	chr11:45771432~45772358:+
LUAD	cis	rs12285276	0.711	rs12274152	ENSG00000205106.4	DKFZp779M0652	3.68	0.000258	0.0305	0.22	0.17	Visceral fat;	chr11:45786272	chr11:45771432~45772358:+
LUAD	cis	rs12285276	0.75	rs4756024	ENSG00000205106.4	DKFZp779M0652	3.68	0.000258	0.0305	0.22	0.17	Visceral fat;	chr11:45789727	chr11:45771432~45772358:+
LUAD	cis	rs34286592	0.929	rs8058824	ENSG00000214725.6	CDIPT-AS1	-3.68	0.000258	0.0305	-0.27	-0.17	Multiple sclerosis;	chr16:29817389	chr16:29863593~29868053:+
LUAD	cis	rs6793245	0.801	rs62239356	ENSG00000229589.1	ACVR2B-AS1	-3.68	0.000258	0.0305	-0.21	-0.17	QT interval;	chr3:38545602	chr3:38451027~38454820:-
LUAD	cis	rs7937890	0.531	rs2575828	ENSG00000254418.1	RP11-21L19.1	3.68	0.000258	0.0305	0.19	0.17	Mitochondrial DNA levels;	chr11:14462646	chr11:14262846~14273691:-
LUAD	cis	rs12368653	0.525	rs1564374	ENSG00000245651.2	RP11-620J15.2	-3.68	0.000258	0.0305	-0.16	-0.17	Multiple sclerosis;	chr12:57616380	chr12:57869835~57896482:-
LUAD	cis	rs6832769	1	rs9684708	ENSG00000272969.1	RP11-528I4.2	-3.68	0.000258	0.0305	-0.17	-0.17	Personality dimensions;	chr4:55564214	chr4:55547112~55547889:+
LUAD	cis	rs7077256	0.505	rs17814528	ENSG00000272767.1	JMJD1C-AS1	3.68	0.000258	0.0305	0.24	0.17	Intelligence (multi-trait analysis);	chr10:63474752	chr10:63465229~63466563:+
LUAD	cis	rs9309473	0.95	rs11689588	ENSG00000230002.2	ALMS1-IT1	3.68	0.000258	0.0305	0.21	0.17	Metabolite levels;	chr2:73546564	chr2:73456764~73459484:+
LUAD	cis	rs42490	0.664	rs376110	ENSG00000251136.7	RP11-37B2.1	-3.68	0.000258	0.0305	-0.17	-0.17	Leprosy;	chr8:89819362	chr8:89609409~89757727:-
LUAD	cis	rs17507216	1	rs17507216	ENSG00000276710.3	CSPG4P8	3.68	0.000258	0.0305	0.18	0.17	Excessive daytime sleepiness;	chr15:82558175	chr15:82459472~82477258:+
LUAD	cis	rs4937076	0.51	rs13424	ENSG00000254671.2	STT3A-AS1	3.68	0.000258	0.0305	0.19	0.17	Primary tooth development (time to first tooth eruption);	chr11:125957058	chr11:125570284~125592568:-
LUAD	cis	rs13006833	0.668	rs291449	ENSG00000227542.1	AC092614.2	3.68	0.000258	0.0305	0.2	0.17	Urinary metabolites;	chr2:190312741	chr2:191229165~191246172:-
LUAD	cis	rs797680	0.786	rs12133576	ENSG00000223745.6	RP4-717I23.3	-3.68	0.000258	0.0305	-0.13	-0.17	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93350843	chr1:93262186~93346025:-
LUAD	cis	rs9467773	0.62	rs2451711	ENSG00000261353.1	CTA-14H9.5	-3.68	0.000258	0.0305	-0.19	-0.17	Intelligence (multi-trait analysis);	chr6:26662882	chr6:26527063~26527404:+
LUAD	cis	rs2980439	0.807	rs2980438	ENSG00000233609.3	RP11-62H7.2	3.68	0.000258	0.0305	0.14	0.17	Neuroticism;	chr8:8237303	chr8:8961200~8979025:+
LUAD	cis	rs9896933	0.723	rs7224189	ENSG00000262663.1	RP11-497H17.1	3.68	0.000258	0.0305	0.19	0.17	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr17:82824351	chr17:82918282~82918785:+
LUAD	cis	rs34286592	1	rs4788188	ENSG00000214725.6	CDIPT-AS1	-3.68	0.000258	0.0305	-0.26	-0.17	Multiple sclerosis;	chr16:29849542	chr16:29863593~29868053:+
LUAD	cis	rs782590	0.764	rs2054728	ENSG00000272606.1	RP11-554J4.1	-3.68	0.000258	0.0305	-0.17	-0.17	Metabolic syndrome;	chr2:55591283	chr2:55617909~55618373:+
LUAD	cis	rs3845817	0.703	rs702909	ENSG00000281920.1	RP11-418H16.1	3.68	0.000258	0.0305	0.2	0.17	Bipolar disorder;	chr2:65540113	chr2:65623272~65628424:+
LUAD	cis	rs12291225	0.679	rs11023178	ENSG00000251991.1	RNU7-49P	3.68	0.000258	0.0305	0.19	0.17	Sense of smell;	chr11:14288736	chr11:14478892~14478953:+
LUAD	cis	rs7580658	0.963	rs62160261	ENSG00000236682.1	AC068282.3	-3.68	0.000258	0.0305	-0.23	-0.17	Protein C levels;	chr2:127395085	chr2:127389130~127400580:+
LUAD	cis	rs897876	0.817	rs840795	ENSG00000281920.1	RP11-418H16.1	3.68	0.000258	0.0305	0.22	0.17	Pulse pressure in young-onset hypertension;	chr2:65551256	chr2:65623272~65628424:+
LUAD	cis	rs7829975	0.84	rs572366	ENSG00000253981.4	ALG1L13P	3.68	0.000258	0.0305	0.19	0.17	Mood instability;	chr8:8721284	chr8:8236003~8244667:-
LUAD	cis	rs13113518	1	rs13108499	ENSG00000273257.1	RP11-177J6.1	3.68	0.000258	0.0305	0.18	0.17	Height;	chr4:55526514	chr4:55387949~55388271:+
LUAD	cis	rs2014572	0.904	rs10412465	ENSG00000268379.1	CTC-360J11.4	3.68	0.000258	0.0305	0.19	0.17	Hyperactive-impulsive symptoms;	chr19:57242563	chr19:57175233~57177921:+
LUAD	cis	rs8040855	0.576	rs62022528	ENSG00000259774.1	RP11-182J1.13	3.68	0.000258	0.0305	0.22	0.17	Bulimia nervosa;	chr15:84992030	chr15:84422618~84425882:+
LUAD	cis	rs7560272	0.723	rs6729468	ENSG00000163016.8	ALMS1P	3.68	0.000258	0.0305	0.18	0.17	Schizophrenia;	chr2:73538126	chr2:73644919~73685576:+
LUAD	cis	rs10934524	0.691	rs9829940	ENSG00000243547.1	HNRNPKP4	-3.68	0.000258	0.0305	-0.12	-0.17	Longevity;	chr3:96448805	chr3:96349554~96350939:+
LUAD	cis	rs8073060	0.927	rs7502331	ENSG00000267592.1	CTC-507E2.2	-3.68	0.000258	0.0305	-0.21	-0.17	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35541839	chr17:35596904~35597128:-
LUAD	cis	rs990171	0.538	rs2075191	ENSG00000234389.1	AC007278.3	3.68	0.000258	0.0305	0.16	0.17	Lymphocyte counts;	chr2:102501840	chr2:102438713~102440475:+
LUAD	cis	rs683250	0.629	rs612008	ENSG00000246067.6	RAB30-AS1	3.68	0.000258	0.0305	0.18	0.17	Subcortical brain region volumes;	chr11:83232441	chr11:83072066~83106719:+
LUAD	cis	rs683250	0.629	rs613790	ENSG00000246067.6	RAB30-AS1	3.68	0.000258	0.0305	0.18	0.17	Subcortical brain region volumes;	chr11:83232853	chr11:83072066~83106719:+
LUAD	cis	rs6942407	0.592	rs739711	ENSG00000224046.1	AC005076.5	-3.68	0.000258	0.0305	-0.21	-0.17	Food allergy;	chr7:87117425	chr7:87151423~87152420:-
LUAD	cis	rs6942407	0.543	rs739712	ENSG00000224046.1	AC005076.5	-3.68	0.000258	0.0305	-0.21	-0.17	Food allergy;	chr7:87117482	chr7:87151423~87152420:-
LUAD	cis	rs6942407	0.542	rs744136	ENSG00000224046.1	AC005076.5	-3.68	0.000258	0.0305	-0.21	-0.17	Food allergy;	chr7:87117765	chr7:87151423~87152420:-
LUAD	cis	rs6942407	0.542	rs1981535	ENSG00000224046.1	AC005076.5	-3.68	0.000258	0.0305	-0.21	-0.17	Food allergy;	chr7:87118059	chr7:87151423~87152420:-
LUAD	cis	rs6942407	0.592	rs1981536	ENSG00000224046.1	AC005076.5	-3.68	0.000258	0.0305	-0.21	-0.17	Food allergy;	chr7:87118573	chr7:87151423~87152420:-
LUAD	cis	rs8012947	1	rs9743908	ENSG00000279636.2	LINC00216	-3.68	0.000258	0.0305	-0.19	-0.17	Alcohol consumption in current drinkers;	chr14:58256828	chr14:58288033~58289158:+
LUAD	cis	rs9987353	0.522	rs2929466	ENSG00000253893.2	FAM85B	3.68	0.000258	0.0305	0.21	0.17	Recombination measurement;	chr8:9206389	chr8:8167819~8226614:-
LUAD	cis	rs7017914	0.905	rs3110244	ENSG00000246366.5	RP11-382J12.1	-3.68	0.000258	0.0305	-0.15	-0.17	Bone mineral density;	chr8:71020962	chr8:70608577~70663279:+
LUAD	cis	rs453301	0.653	rs1562211	ENSG00000233609.3	RP11-62H7.2	-3.68	0.000258	0.0305	-0.13	-0.17	Joint mobility (Beighton score);	chr8:9044914	chr8:8961200~8979025:+
LUAD	cis	rs950881	0.932	rs10173081	ENSG00000234389.1	AC007278.3	3.68	0.000258	0.0305	0.21	0.17	Allergy;	chr2:102340888	chr2:102438713~102440475:+
LUAD	cis	rs11250098	0.547	rs2409764	ENSG00000255046.1	RP11-297N6.4	-3.68	0.000258	0.0305	-0.2	-0.17	Morning vs. evening chronotype;	chr8:11423764	chr8:11797928~11802568:-
LUAD	cis	rs9303542	1	rs9891073	ENSG00000264920.1	RP11-6N17.4	-3.68	0.000258	0.0305	-0.22	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48360887	chr17:47891255~47895812:-
LUAD	cis	rs9303542	1	rs1553749	ENSG00000264920.1	RP11-6N17.4	-3.68	0.000258	0.0305	-0.22	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48364079	chr17:47891255~47895812:-
LUAD	cis	rs9303542	1	rs1912153	ENSG00000264920.1	RP11-6N17.4	-3.68	0.000258	0.0305	-0.22	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48365377	chr17:47891255~47895812:-
LUAD	cis	rs9303542	1	rs1912154	ENSG00000264920.1	RP11-6N17.4	-3.68	0.000258	0.0305	-0.22	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48366232	chr17:47891255~47895812:-
LUAD	cis	rs9303542	1	rs7210708	ENSG00000264920.1	RP11-6N17.4	-3.68	0.000258	0.0305	-0.22	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48367248	chr17:47891255~47895812:-
LUAD	cis	rs9303542	1	rs7217025	ENSG00000264920.1	RP11-6N17.4	-3.68	0.000258	0.0305	-0.22	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48370028	chr17:47891255~47895812:-
LUAD	cis	rs9303542	0.959	rs8074212	ENSG00000264920.1	RP11-6N17.4	-3.68	0.000258	0.0305	-0.22	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48370760	chr17:47891255~47895812:-
LUAD	cis	rs12468226	0.689	rs73989733	ENSG00000272966.1	RP11-686O6.1	3.68	0.000258	0.0305	0.26	0.17	Urate levels;	chr2:202115241	chr2:202336739~202337200:+
LUAD	cis	rs10129255	0.957	rs56134540	ENSG00000211947.2	IGHV3-21	-3.68	0.000258	0.0305	-0.11	-0.17	Kawasaki disease;	chr14:106691290	chr14:106235064~106235594:-
LUAD	cis	rs990171	0.538	rs4851012	ENSG00000234389.1	AC007278.3	-3.68	0.000258	0.0305	-0.16	-0.17	Lymphocyte counts;	chr2:102499456	chr2:102438713~102440475:+
LUAD	cis	rs7119038	0.818	rs11217032	ENSG00000255239.1	AP002954.6	-3.68	0.000258	0.0305	-0.25	-0.17	Sjögren's syndrome;	chr11:118798896	chr11:118688039~118690600:-
LUAD	cis	rs4835473	0.808	rs6831401	ENSG00000249741.2	RP11-673E1.3	3.68	0.000258	0.0305	0.2	0.17	Immature fraction of reticulocytes;	chr4:143801038	chr4:143911514~143912053:-
LUAD	cis	rs4835473	0.778	rs6853798	ENSG00000249741.2	RP11-673E1.3	3.68	0.000258	0.0305	0.2	0.17	Immature fraction of reticulocytes;	chr4:143801153	chr4:143911514~143912053:-
LUAD	cis	rs4835473	0.9	rs12502940	ENSG00000249741.2	RP11-673E1.3	3.68	0.000258	0.0305	0.2	0.17	Immature fraction of reticulocytes;	chr4:143812117	chr4:143911514~143912053:-
LUAD	cis	rs6081541	1	rs6081541	ENSG00000179447.2	RP5-1027G4.3	3.68	0.000258	0.0305	0.21	0.17	Psychosis (atypical);	chr20:19232246	chr20:19242302~19284596:-
LUAD	cis	rs3764400	0.567	rs9890691	ENSG00000278765.1	RP5-890E16.5	-3.68	0.000258	0.0305	-0.28	-0.17	Body mass index;	chr17:48115574	chr17:48066704~48067293:-
LUAD	cis	rs7937890	0.505	rs1403248	ENSG00000251991.1	RNU7-49P	3.68	0.000258	0.0305	0.18	0.17	Mitochondrial DNA levels;	chr11:14657471	chr11:14478892~14478953:+
LUAD	cis	rs58123204	1	rs58123204	ENSG00000257379.1	RP11-793H13.8	3.68	0.000258	0.0305	0.29	0.17	Mean corpuscular hemoglobin;	chr12:53366378	chr12:53441741~53467528:+
LUAD	cis	rs7829975	0.514	rs2920991	ENSG00000233609.3	RP11-62H7.2	3.68	0.000258	0.0306	0.14	0.17	Mood instability;	chr8:8401607	chr8:8961200~8979025:+
LUAD	cis	rs703842	0.616	rs7489290	ENSG00000245651.2	RP11-620J15.2	3.68	0.000258	0.0306	0.17	0.17	Multiple sclerosis;	chr12:57834805	chr12:57869835~57896482:-
LUAD	cis	rs10129255	1	rs10141557	ENSG00000211947.2	IGHV3-21	-3.68	0.000258	0.0306	-0.11	-0.17	Kawasaki disease;	chr14:106767990	chr14:106235064~106235594:-
LUAD	cis	rs2274273	0.84	rs6573020	ENSG00000258413.1	RP11-665C16.6	-3.68	0.000258	0.0306	-0.21	-0.17	Protein biomarker;	chr14:55404734	chr14:55262767~55272075:-
LUAD	cis	rs12701220	0.542	rs6957866	ENSG00000229043.2	AC091729.9	-3.68	0.000258	0.0306	-0.24	-0.17	Bronchopulmonary dysplasia;	chr7:1072038	chr7:1160374~1165267:+
LUAD	cis	rs12701220	0.689	rs6973645	ENSG00000229043.2	AC091729.9	-3.68	0.000258	0.0306	-0.24	-0.17	Bronchopulmonary dysplasia;	chr7:1072610	chr7:1160374~1165267:+
LUAD	cis	rs36093844	0.626	rs11234513	ENSG00000279742.1	RP11-700A24.1	-3.68	0.000258	0.0306	-0.19	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86012084	chr11:85852557~85854943:-
LUAD	cis	rs7760535	0.826	rs3777905	ENSG00000266032.1	AL357515.1	3.68	0.000258	0.0306	0.21	0.17	Metabolic traits;	chr6:111549385	chr6:110969773~110969872:-
LUAD	cis	rs9532580	0.614	rs2180961	ENSG00000215483.7	LINC00598	-3.68	0.000258	0.0306	-0.26	-0.17	Mean corpuscular hemoglobin;	chr13:40565907	chr13:40450934~40535807:-
LUAD	cis	rs4835473	0.9	rs13137885	ENSG00000249741.2	RP11-673E1.3	3.68	0.000259	0.0306	0.2	0.17	Immature fraction of reticulocytes;	chr4:143734212	chr4:143911514~143912053:-
LUAD	cis	rs4835473	0.9	rs13105550	ENSG00000249741.2	RP11-673E1.3	3.68	0.000259	0.0306	0.2	0.17	Immature fraction of reticulocytes;	chr4:143734220	chr4:143911514~143912053:-
LUAD	cis	rs4835473	0.9	rs13105571	ENSG00000249741.2	RP11-673E1.3	3.68	0.000259	0.0306	0.2	0.17	Immature fraction of reticulocytes;	chr4:143734241	chr4:143911514~143912053:-
LUAD	cis	rs4835473	0.9	rs36083417	ENSG00000249741.2	RP11-673E1.3	3.68	0.000259	0.0306	0.2	0.17	Immature fraction of reticulocytes;	chr4:143734253	chr4:143911514~143912053:-
LUAD	cis	rs17597773	0.638	rs17596850	ENSG00000272823.1	RP11-295M18.6	-3.68	0.000259	0.0306	-0.22	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220819001	chr1:220828676~220829211:-
LUAD	cis	rs831571	0.649	rs831556	ENSG00000280620.1	SCAANT1	-3.68	0.000259	0.0306	-0.22	-0.17	Type 2 diabetes;	chr3:64036017	chr3:63911518~63911772:-
LUAD	cis	rs2348418	0.715	rs4931083	ENSG00000247934.4	RP11-967K21.1	-3.68	0.000259	0.0306	-0.19	-0.17	Lung function (FEV1);Lung function (FVC);	chr12:28568952	chr12:28163298~28190738:-
LUAD	cis	rs4718428	0.705	rs3800817	ENSG00000230295.1	RP11-458F8.2	-3.68	0.000259	0.0306	-0.15	-0.17	Corneal structure;	chr7:66798563	chr7:66880708~66882981:+
LUAD	cis	rs1577917	0.655	rs7766485	ENSG00000220563.1	PKMP3	3.68	0.000259	0.0306	0.15	0.17	Response to antipsychotic treatment;	chr6:85553837	chr6:85659892~85660606:-
LUAD	cis	rs6687821	0.515	rs10489917	ENSG00000261737.1	RP4-612B15.3	-3.68	0.000259	0.0306	-0.23	-0.17	Yeast infection;	chr1:86932105	chr1:86703502~86704462:-
LUAD	cis	rs6687821	0.515	rs12072434	ENSG00000261737.1	RP4-612B15.3	-3.68	0.000259	0.0306	-0.23	-0.17	Yeast infection;	chr1:86935026	chr1:86703502~86704462:-
LUAD	cis	rs6687821	0.515	rs1923144	ENSG00000261737.1	RP4-612B15.3	-3.68	0.000259	0.0306	-0.23	-0.17	Yeast infection;	chr1:86938548	chr1:86703502~86704462:-
LUAD	cis	rs36093844	0.626	rs72961111	ENSG00000279742.1	RP11-700A24.1	-3.68	0.000259	0.0306	-0.19	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86008770	chr11:85852557~85854943:-
LUAD	cis	rs763121	0.853	rs5757253	ENSG00000228274.3	RP3-508I15.9	-3.68	0.000259	0.0306	-0.16	-0.17	Menopause (age at onset);	chr22:38708315	chr22:38667585~38681820:-
LUAD	cis	rs7176527	0.747	rs28363946	ENSG00000259570.1	RP11-671M22.4	-3.68	0.000259	0.0306	-0.26	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84829244	chr15:84394512~84395514:+
LUAD	cis	rs72843166	0.812	rs17682747	ENSG00000226797.1	AC015923.1	-3.68	0.000259	0.0306	-0.2	-0.17	Intelligence (multi-trait analysis);	chr17:63103751	chr17:63381231~63414312:-
LUAD	cis	rs875971	1	rs6957199	ENSG00000273142.1	RP11-458F8.4	-3.68	0.000259	0.0306	-0.12	-0.17	Aortic root size;	chr7:66513532	chr7:66902857~66906297:+
LUAD	cis	rs7605235	0.959	rs35065219	ENSG00000224165.4	DNAJC27-AS1	3.68	0.000259	0.0306	0.19	0.17	Response to platinum-based chemotherapy (cisplatin);	chr2:25412589	chr2:24971390~25039694:+
LUAD	cis	rs7605235	0.959	rs12987881	ENSG00000224165.4	DNAJC27-AS1	3.68	0.000259	0.0306	0.19	0.17	Response to platinum-based chemotherapy (cisplatin);	chr2:25415539	chr2:24971390~25039694:+
LUAD	cis	rs452036	0.524	rs2277474	ENSG00000259054.1	AE000662.93	-3.68	0.000259	0.0306	-0.22	-0.17	P wave duration;Resting heart rate;	chr14:23405314	chr14:22556311~22557062:-
LUAD	cis	rs2933343	0.63	rs75824035	ENSG00000231305.3	RP11-723O4.2	3.68	0.000259	0.0306	0.18	0.17	IgG glycosylation;	chr3:128934142	chr3:128861313~128871540:-
LUAD	cis	rs4268898	0.662	rs72795832	ENSG00000242628.4	AC009228.1	3.68	0.000259	0.0306	0.24	0.17	Asthma;	chr2:24218986	chr2:24214381~24221516:+
LUAD	cis	rs4811196	1	rs4809859	ENSG00000226144.2	RPS27AP3	-3.68	0.000259	0.0306	-0.2	-0.17	Bone mineral density;	chr20:37849826	chr20:37049254~37049707:+
LUAD	cis	rs4664293	0.836	rs4516379	ENSG00000230783.1	AC009961.2	-3.68	0.000259	0.0306	-0.2	-0.17	Monocyte percentage of white cells;	chr2:159808892	chr2:159689217~159690291:-
LUAD	cis	rs449789	0.524	rs6912475	ENSG00000235086.1	FNDC1-IT1	3.68	0.000259	0.0306	0.23	0.17	Pulse pressure;	chr6:159326441	chr6:159240786~159243329:+
LUAD	cis	rs763121	0.853	rs5757234	ENSG00000228274.3	RP3-508I15.9	-3.68	0.000259	0.0306	-0.16	-0.17	Menopause (age at onset);	chr22:38676681	chr22:38667585~38681820:-
LUAD	cis	rs3213758	0.541	rs9935278	ENSG00000275191.1	RP11-36I17.2	-3.68	0.000259	0.0306	-0.25	-0.17	Vitiligo (non-segmental);	chr16:53627670	chr16:53628256~53628816:-
LUAD	cis	rs6502050	0.805	rs4356529	ENSG00000266654.1	RP11-1376P16.1	3.68	0.000259	0.0306	0.18	0.17	Life satisfaction;	chr17:82199921	chr17:82160056~82160452:+
LUAD	cis	rs7824557	0.815	rs958648	ENSG00000255046.1	RP11-297N6.4	3.68	0.000259	0.0306	0.2	0.17	Retinal vascular caliber;	chr8:11246386	chr8:11797928~11802568:-
LUAD	cis	rs6001482	0.679	rs5750786	ENSG00000253818.1	IGLV1-41	-3.68	0.000259	0.0306	-0.18	-0.17	Diastolic blood pressure;	chr22:22235358	chr22:22404207~22404721:+
LUAD	cis	rs6951245	0.935	rs61910751	ENSG00000224079.1	AC091729.7	-3.68	0.000259	0.0306	-0.26	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1058259	chr7:1074450~1078036:+
LUAD	cis	rs6951245	0.872	rs77434655	ENSG00000224079.1	AC091729.7	-3.68	0.000259	0.0306	-0.26	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1058769	chr7:1074450~1078036:+
LUAD	cis	rs6951245	0.872	rs75398423	ENSG00000224079.1	AC091729.7	-3.68	0.000259	0.0306	-0.26	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1058778	chr7:1074450~1078036:+
LUAD	cis	rs6951245	0.872	rs112309216	ENSG00000224079.1	AC091729.7	-3.68	0.000259	0.0306	-0.26	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1060660	chr7:1074450~1078036:+
LUAD	cis	rs6951245	0.872	rs76161580	ENSG00000224079.1	AC091729.7	-3.68	0.000259	0.0306	-0.26	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1060671	chr7:1074450~1078036:+
LUAD	cis	rs6951245	1	rs76388414	ENSG00000224079.1	AC091729.7	-3.68	0.000259	0.0306	-0.26	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061058	chr7:1074450~1078036:+
LUAD	cis	rs6951245	1	rs77305932	ENSG00000224079.1	AC091729.7	-3.68	0.000259	0.0306	-0.26	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061225	chr7:1074450~1078036:+
LUAD	cis	rs6951245	0.872	rs11768486	ENSG00000224079.1	AC091729.7	-3.68	0.000259	0.0306	-0.26	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061654	chr7:1074450~1078036:+
LUAD	cis	rs6951245	1	rs11766526	ENSG00000224079.1	AC091729.7	-3.68	0.000259	0.0306	-0.26	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061797	chr7:1074450~1078036:+
LUAD	cis	rs6951245	1	rs76214082	ENSG00000224079.1	AC091729.7	-3.68	0.000259	0.0306	-0.26	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1062461	chr7:1074450~1078036:+
LUAD	cis	rs6951245	1	rs80094748	ENSG00000224079.1	AC091729.7	-3.68	0.000259	0.0306	-0.26	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1064322	chr7:1074450~1078036:+
LUAD	cis	rs6951245	0.938	rs113642700	ENSG00000224079.1	AC091729.7	-3.68	0.000259	0.0306	-0.26	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1066018	chr7:1074450~1078036:+
LUAD	cis	rs3764021	0.933	rs10492165	ENSG00000278635.1	CTD-2318O12.1	-3.68	0.000259	0.0306	-0.14	-0.17	Type 1 diabetes;	chr12:9733365	chr12:9415641~9416718:+
LUAD	cis	rs2836974	0.932	rs8128734	ENSG00000232608.1	TIMM9P2	-3.68	0.000259	0.0306	-0.2	-0.17	Cognitive function;	chr21:39197585	chr21:39216624~39217506:+
LUAD	cis	rs2836974	0.932	rs2234543	ENSG00000232608.1	TIMM9P2	-3.68	0.000259	0.0306	-0.2	-0.17	Cognitive function;	chr21:39200146	chr21:39216624~39217506:+
LUAD	cis	rs2836974	0.899	rs2836938	ENSG00000232608.1	TIMM9P2	-3.68	0.000259	0.0306	-0.2	-0.17	Cognitive function;	chr21:39202265	chr21:39216624~39217506:+
LUAD	cis	rs7430456	1	rs7430456	ENSG00000231574.4	RP11-91K9.1	3.68	0.000259	0.0306	0.19	0.17	Breast cancer;	chr3:177768082	chr3:177816865~177899224:+
LUAD	cis	rs7760535	0.826	rs3851229	ENSG00000230177.1	RP5-1112D6.4	-3.68	0.000259	0.0306	-0.15	-0.17	Metabolic traits;	chr6:111533457	chr6:111277932~111278742:+
LUAD	cis	rs11673344	0.523	rs8110158	ENSG00000276846.1	CTD-3220F14.3	3.68	0.000259	0.0306	0.18	0.17	Obesity-related traits;	chr19:37063491	chr19:37314868~37315620:-
LUAD	cis	rs6496932	0.909	rs74024818	ENSG00000218052.5	ADAMTS7P4	3.68	0.000259	0.0306	0.22	0.17	Central corneal thickness;Corneal structure;	chr15:85339299	chr15:85255369~85330334:-
LUAD	cis	rs3733418	0.929	rs72697952	ENSG00000248632.1	RP11-366M4.11	3.68	0.000259	0.0306	0.26	0.17	Obesity-related traits;	chr4:164979776	chr4:164968587~164970002:-
LUAD	cis	rs60695258	1	rs17605615	ENSG00000251411.1	RP11-397E7.4	-3.68	0.000259	0.0306	-0.18	-0.17	Hematocrit;	chr4:87075593	chr4:86913266~86914817:-
LUAD	cis	rs4713118	0.513	rs149972	ENSG00000216901.1	AL022393.7	3.68	0.000259	0.0306	0.2	0.17	Parkinson's disease;	chr6:28015449	chr6:28176188~28176674:+
LUAD	cis	rs4713118	0.513	rs149975	ENSG00000216901.1	AL022393.7	3.68	0.000259	0.0306	0.2	0.17	Parkinson's disease;	chr6:28018562	chr6:28176188~28176674:+
LUAD	cis	rs8012947	0.877	rs12879675	ENSG00000279636.2	LINC00216	-3.68	0.000259	0.0306	-0.18	-0.17	Alcohol consumption in current drinkers;	chr14:58240535	chr14:58288033~58289158:+
LUAD	cis	rs3617	0.573	rs4687682	ENSG00000242142.1	SERBP1P3	-3.68	0.000259	0.0306	-0.18	-0.17	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52882923	chr3:53064283~53065091:-
LUAD	cis	rs1577917	0.655	rs2758849	ENSG00000220563.1	PKMP3	-3.68	0.000259	0.0306	-0.15	-0.17	Response to antipsychotic treatment;	chr6:85634578	chr6:85659892~85660606:-
LUAD	cis	rs36093844	0.527	rs72949443	ENSG00000279742.1	RP11-700A24.1	-3.68	0.000259	0.0306	-0.2	-0.17	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85944402	chr11:85852557~85854943:-
LUAD	cis	rs11089937	0.963	rs2226943	ENSG00000211640.3	IGLV6-57	3.68	0.000259	0.0306	0.11	0.17	Periodontitis (PAL4Q3);	chr22:22143100	chr22:22195713~22196460:+
LUAD	cis	rs2041895	0.509	rs7976343	ENSG00000260329.1	RP11-412D9.4	-3.68	0.000259	0.0306	-0.2	-0.17	Glaucoma (low intraocular pressure);	chr12:106902250	chr12:106954029~106955497:-
LUAD	cis	rs6964587	0.934	rs4512319	ENSG00000188693.7	CYP51A1-AS1	-3.68	0.000259	0.0306	-0.2	-0.17	Breast cancer;	chr7:92104515	chr7:92134604~92180725:+
LUAD	cis	rs1790761	0.505	rs4320958	ENSG00000184224.3	C11orf72	-3.68	0.000259	0.0306	-0.19	-0.17	Mean corpuscular volume;	chr11:67542863	chr11:67602880~67606706:-
LUAD	cis	rs1005277	0.577	rs4934906	ENSG00000273019.1	RP11-508N22.13	-3.68	0.000259	0.0306	-0.19	-0.17	Extrinsic epigenetic age acceleration;	chr10:37726100	chr10:38149968~38150293:+
LUAD	cis	rs7893279	0.505	rs12767923	ENSG00000225527.1	RP11-383B4.4	3.68	0.000259	0.0307	0.24	0.17	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18618822	chr10:18531849~18533336:-
LUAD	cis	rs2243480	1	rs160634	ENSG00000228409.4	CCT6P1	-3.68	0.000259	0.0307	-0.2	-0.17	Diabetic kidney disease;	chr7:66063677	chr7:65751142~65763354:+
LUAD	cis	rs6496932	0.663	rs7183764	ENSG00000202081.1	RNU6-1280P	-3.68	0.000259	0.0307	-0.21	-0.17	Central corneal thickness;Corneal structure;	chr15:85359820	chr15:85651522~85651628:-
LUAD	cis	rs6496932	0.663	rs4842878	ENSG00000202081.1	RNU6-1280P	-3.68	0.000259	0.0307	-0.21	-0.17	Central corneal thickness;Corneal structure;	chr15:85361001	chr15:85651522~85651628:-
LUAD	cis	rs5758659	0.569	rs133293	ENSG00000270083.1	RP1-257I20.14	3.68	0.000259	0.0307	0.16	0.17	Cognitive function;	chr22:41986793	chr22:42089630~42090028:-
LUAD	cis	rs12742923	0.534	rs323962	ENSG00000236268.4	LINC01361	-3.68	0.000259	0.0307	-0.21	-0.17	HIV-associated dementia;	chr1:83152534	chr1:82973882~82986208:-
LUAD	cis	rs2985684	0.948	rs11623263	ENSG00000278009.1	RP11-649E7.8	3.68	0.000259	0.0307	0.22	0.17	Carotid intima media thickness;	chr14:49616577	chr14:49601011~49601124:-
LUAD	cis	rs34929064	0.536	rs2905306	ENSG00000232949.1	AC002480.4	3.68	0.000259	0.0307	0.19	0.17	Major depression and alcohol dependence;	chr7:22599199	chr7:22589705~22591622:+
LUAD	cis	rs6502050	0.667	rs9892469	ENSG00000275966.1	RP11-1055B8.9	-3.68	0.000259	0.0307	-0.17	-0.17	Life satisfaction;	chr17:82135781	chr17:81345476~81345966:-
LUAD	cis	rs7200786	0.528	rs27868	ENSG00000274038.1	RP11-66H6.4	-3.68	0.000259	0.0307	-0.21	-0.17	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11158660	chr16:11056556~11057034:+
LUAD	cis	rs703842	0.616	rs870392	ENSG00000270039.1	RP11-571M6.17	-3.68	0.00026	0.0307	-0.2	-0.17	Multiple sclerosis;	chr12:57825390	chr12:57803838~57804415:+
LUAD	cis	rs3753275	0.519	rs7533442	ENSG00000232912.4	RP5-1115A15.1	3.68	0.00026	0.0307	0.19	0.17	Educational attainment;	chr1:8690532	chr1:8424645~8434838:+
LUAD	cis	rs155076	1	rs261369	ENSG00000224429.6	LINC00539	3.68	0.00026	0.0307	0.2	0.17	White matter hyperintensity burden;	chr13:21294281	chr13:21303515~21348721:-
LUAD	cis	rs12122100	0.651	rs12728300	ENSG00000244371.2	PFN1P8	3.68	0.00026	0.0307	0.21	0.17	HIV-1 control;	chr1:147070640	chr1:146957117~146957659:-
LUAD	cis	rs28374715	0.578	rs7169543	ENSG00000247556.5	OIP5-AS1	3.68	0.00026	0.0307	0.21	0.17	Ulcerative colitis;	chr15:41328207	chr15:41283990~41309737:+
LUAD	cis	rs28374715	0.528	rs7181982	ENSG00000247556.5	OIP5-AS1	3.68	0.00026	0.0307	0.21	0.17	Ulcerative colitis;	chr15:41330822	chr15:41283990~41309737:+
LUAD	cis	rs28374715	0.528	rs28492932	ENSG00000247556.5	OIP5-AS1	3.68	0.00026	0.0307	0.21	0.17	Ulcerative colitis;	chr15:41332199	chr15:41283990~41309737:+
LUAD	cis	rs2836950	0.565	rs2836942	ENSG00000232608.1	TIMM9P2	3.68	0.00026	0.0307	0.19	0.17	Menarche (age at onset);	chr21:39219455	chr21:39216624~39217506:+
LUAD	cis	rs12368653	1	rs12368653	ENSG00000245651.2	RP11-620J15.2	3.68	0.00026	0.0307	0.16	0.17	Multiple sclerosis;	chr12:57739473	chr12:57869835~57896482:-
LUAD	cis	rs9951698	0.601	rs1973779	ENSG00000267480.1	RP11-703I16.1	-3.68	0.00026	0.0307	-0.2	-0.17	Intelligence (multi-trait analysis);	chr18:12997774	chr18:12031178~12032181:-
LUAD	cis	rs9309473	0.898	rs10201159	ENSG00000273245.1	RP11-434P11.2	3.68	0.00026	0.0307	0.21	0.17	Metabolite levels;	chr2:73631838	chr2:73750256~73750786:-
LUAD	cis	rs13108904	0.901	rs66987549	ENSG00000196810.4	CTBP1-AS2	3.68	0.00026	0.0307	0.2	0.17	Obesity-related traits;	chr4:1278829	chr4:1249300~1288291:+
LUAD	cis	rs7829975	0.606	rs7819827	ENSG00000233609.3	RP11-62H7.2	-3.68	0.00026	0.0307	-0.14	-0.17	Mood instability;	chr8:8939545	chr8:8961200~8979025:+
LUAD	cis	rs7829975	0.573	rs7842359	ENSG00000233609.3	RP11-62H7.2	-3.68	0.00026	0.0307	-0.14	-0.17	Mood instability;	chr8:8939568	chr8:8961200~8979025:+
LUAD	cis	rs7809950	1	rs17154104	ENSG00000238832.1	snoU109	-3.68	0.00026	0.0307	-0.24	-0.17	Coronary artery disease;	chr7:107450253	chr7:107603363~107603507:+
LUAD	cis	rs4388249	0.687	rs2416218	ENSG00000271849.1	CTC-332L22.1	-3.68	0.00026	0.0307	-0.23	-0.17	Schizophrenia;	chr5:109736511	chr5:109687802~109688329:-
LUAD	cis	rs7829975	0.567	rs6601273	ENSG00000253981.4	ALG1L13P	-3.68	0.00026	0.0307	-0.19	-0.17	Mood instability;	chr8:8939009	chr8:8236003~8244667:-
LUAD	cis	rs3096299	0.559	rs9931073	ENSG00000261118.1	RP11-104N10.1	3.68	0.00026	0.0307	0.17	0.17	Multiple myeloma (IgH translocation);	chr16:89502105	chr16:89492017~89504460:-
LUAD	cis	rs7772486	0.686	rs2072911	ENSG00000235652.6	RP11-545I5.3	-3.68	0.00026	0.0307	-0.17	-0.17	Lobe attachment (rater-scored or self-reported);	chr6:145735665	chr6:145799409~145886585:+
LUAD	cis	rs7521902	0.614	rs3820282	ENSG00000234397.3	RP11-415K20.1	3.68	0.00026	0.0307	0.27	0.17	Endometriosis;Ovarian cancer;Bone mineral density;Hip circumference adjusted for BMI;	chr1:22141722	chr1:22322840~22323331:-
LUAD	cis	rs7017914	0.934	rs13255886	ENSG00000246366.5	RP11-382J12.1	3.68	0.00026	0.0307	0.15	0.17	Bone mineral density;	chr8:70653719	chr8:70608577~70663279:+
LUAD	cis	rs987724	0.593	rs13316183	ENSG00000240875.4	LINC00886	-3.68	0.00026	0.0307	-0.18	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156942983	chr3:156747346~156817062:-
LUAD	cis	rs9595908	0.827	rs9595885	ENSG00000281026.1	N4BP2L2-IT2	-3.68	0.00026	0.0307	-0.11	-0.17	Body mass index;	chr13:32593913	chr13:32504506~32509395:-
LUAD	cis	rs9549260	0.755	rs2755214	ENSG00000229456.1	RLIMP1	3.68	0.00026	0.0307	0.18	0.17	Red blood cell count;	chr13:40575208	chr13:40618738~40621348:+
LUAD	cis	rs10946940	1	rs10946940	ENSG00000219392.1	RP1-265C24.5	3.68	0.00026	0.0307	0.2	0.17	Systemic lupus erythematosus;	chr6:27592808	chr6:28115628~28116551:+
LUAD	cis	rs1502337	0.532	rs4766430	ENSG00000278993.1	RP3-424M6.4	-3.68	0.00026	0.0307	-0.21	-0.17	Body mass index;	chr12:110569474	chr12:110501614~110503441:+
LUAD	cis	rs2346177	0.816	rs74179078	ENSG00000279254.1	RP11-536C12.1	-3.68	0.00026	0.0307	-0.18	-0.17	HDL cholesterol;	chr2:46427512	chr2:46668870~46670778:+
LUAD	cis	rs910316	0.712	rs175015	ENSG00000259138.1	RP11-950C14.7	-3.68	0.00026	0.0307	-0.17	-0.17	Height;	chr14:74990372	chr14:75127153~75136930:+
LUAD	cis	rs755249	0.51	rs1184716	ENSG00000182109.6	RP11-69E11.4	3.68	0.00026	0.0307	0.18	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39380817	chr1:39522280~39546187:-
LUAD	cis	rs9467773	1	rs12665431	ENSG00000261353.1	CTA-14H9.5	-3.68	0.00026	0.0307	-0.19	-0.17	Intelligence (multi-trait analysis);	chr6:26577080	chr6:26527063~26527404:+
LUAD	cis	rs3738443	0.868	rs17269923	ENSG00000215795.2	RP11-488L18.3	-3.68	0.00026	0.0307	-0.24	-0.17	Alcohol dependence;	chr1:247208861	chr1:247183813~247185482:-
LUAD	cis	rs7189233	1	rs7194519	ENSG00000279344.1	RP11-44F14.7	3.68	0.00026	0.0307	0.14	0.17	Intelligence (multi-trait analysis);	chr16:53501364	chr16:53478957~53481550:-
LUAD	cis	rs2554380	0.943	rs2033071	ENSG00000230373.7	GOLGA6L5P	-3.68	0.00026	0.0307	-0.2	-0.17	Height;	chr15:83696682	chr15:84507885~84516814:-
LUAD	cis	rs12146727	0.881	rs11838267	ENSG00000247853.2	RP5-940J5.6	3.68	0.00026	0.0307	0.27	0.17	Blood protein levels;	chr12:7068568	chr12:6578622~6584739:+
LUAD	cis	rs3849150	0.898	rs12777007	ENSG00000235939.1	RP11-123B3.2	-3.68	0.00026	0.0307	-0.26	-0.17	Subclinical atherosclerosis traits (other);	chr10:48874063	chr10:49419277~49472903:+
LUAD	cis	rs3849150	0.898	rs35193987	ENSG00000235939.1	RP11-123B3.2	-3.68	0.00026	0.0307	-0.26	-0.17	Subclinical atherosclerosis traits (other);	chr10:48876224	chr10:49419277~49472903:+
LUAD	cis	rs17431357	1	rs16950287	ENSG00000241030.1	RPL29P24	3.68	0.00026	0.0307	0.35	0.17	Insulin resistance/response;	chr12:120576264	chr12:120522664~120523443:-
LUAD	cis	rs7537765	1	rs6669371	ENSG00000230337.1	RP4-635E18.6	3.68	0.00026	0.0307	0.3	0.17	QRS complex (12-leadsum);	chr1:11822085	chr1:11099675~11102100:+
LUAD	cis	rs6661961	0.752	rs4845770	ENSG00000237975.5	FLG-AS1	-3.68	0.00026	0.0307	-0.22	-0.17	Atopic dermatitis;	chr1:152451191	chr1:152168125~152445456:+
LUAD	cis	rs748404	0.666	rs7183708	ENSG00000249839.1	AC011330.5	-3.68	0.00026	0.0307	-0.26	-0.17	Lung cancer;	chr15:43355226	chr15:43663654~43684339:-
LUAD	cis	rs9381040	0.701	rs722442	ENSG00000161912.16	ADCY10P1	3.68	0.00026	0.0307	0.15	0.17	Alzheimer's disease (late onset);	chr6:41121942	chr6:41101022~41140835:+
LUAD	cis	rs17772222	0.651	rs1950280	ENSG00000258789.1	RP11-507K2.3	3.68	0.00026	0.0307	0.2	0.17	Coronary artery calcification;	chr14:88366259	chr14:88551597~88552493:+
LUAD	cis	rs12122100	0.913	rs61838896	ENSG00000227242.3	NBPF13P	-3.68	0.00026	0.0308	-0.22	-0.17	HIV-1 control;	chr1:147041583	chr1:147021320~147124525:-
LUAD	cis	rs3847687	1	rs78233646	ENSG00000279128.1	RP11-76C10.4	3.68	0.00026	0.0308	0.17	0.17	Longevity;	chr12:131035625	chr12:131022769~131024741:-
LUAD	cis	rs4763879	0.634	rs2012643	ENSG00000278635.1	CTD-2318O12.1	3.68	0.00026	0.0308	0.14	0.17	Type 1 diabetes;	chr12:9707128	chr12:9415641~9416718:+
LUAD	cis	rs6479901	0.793	rs10761733	ENSG00000232075.1	MRPL35P2	-3.68	0.000261	0.0308	-0.23	-0.17	Intelligence (multi-trait analysis);	chr10:63275024	chr10:63634317~63634827:-
LUAD	cis	rs7107174	1	rs10899454	ENSG00000251323.2	RP11-452H21.4	3.68	0.000261	0.0308	0.22	0.17	Testicular germ cell tumor;	chr11:78286467	chr11:78423982~78429836:-
LUAD	cis	rs7107174	1	rs11237438	ENSG00000251323.2	RP11-452H21.4	3.68	0.000261	0.0308	0.22	0.17	Testicular germ cell tumor;	chr11:78287442	chr11:78423982~78429836:-
LUAD	cis	rs116095464	1	rs10054850	ENSG00000250848.1	CTD-2083E4.5	-3.68	0.000261	0.0308	-0.36	-0.17	Breast cancer;	chr5:335712	chr5:288833~290321:-
LUAD	cis	rs116095464	0.85	rs10057272	ENSG00000250848.1	CTD-2083E4.5	-3.68	0.000261	0.0308	-0.36	-0.17	Breast cancer;	chr5:340073	chr5:288833~290321:-
LUAD	cis	rs116095464	0.85	rs62330058	ENSG00000250848.1	CTD-2083E4.5	-3.68	0.000261	0.0308	-0.36	-0.17	Breast cancer;	chr5:343449	chr5:288833~290321:-
LUAD	cis	rs909685	0.59	rs3747177	ENSG00000280216.1	RP3-333H23.9	3.68	0.000261	0.0308	0.2	0.17	Rheumatoid arthritis;	chr22:39350163	chr22:39379610~39380015:+
LUAD	cis	rs73230612	1	rs11712587	ENSG00000242767.1	ZBTB20-AS4	-3.68	0.000261	0.0308	-0.27	-0.17	Type 2 diabetes;	chr3:115233557	chr3:115100423~115103061:+
LUAD	cis	rs12285276	0.636	rs7120031	ENSG00000205106.4	DKFZp779M0652	3.68	0.000261	0.0308	0.23	0.17	Visceral fat;	chr11:45794469	chr11:45771432~45772358:+
LUAD	cis	rs4130344	0.845	rs4434197	ENSG00000271817.2	U3	-3.68	0.000261	0.0308	-0.18	-0.17	Intelligence (multi-trait analysis);	chr4:158787008	chr4:158700691~158700909:+
LUAD	cis	rs7428	0.527	rs7607284	ENSG00000246575.2	AC093162.5	3.68	0.000261	0.0308	0.15	0.17	Ear protrusion;	chr2:85320253	chr2:85315041~85316529:+
LUAD	cis	rs7428	0.527	rs1554110	ENSG00000246575.2	AC093162.5	3.68	0.000261	0.0308	0.15	0.17	Ear protrusion;	chr2:85320840	chr2:85315041~85316529:+
LUAD	cis	rs4776997	0.559	rs12902904	ENSG00000259673.4	IQCH-AS1	3.68	0.000261	0.0308	0.2	0.17	Verbal declarative memory;	chr15:67784195	chr15:67403619~67521844:-
LUAD	cis	rs683250	0.661	rs2510474	ENSG00000246067.6	RAB30-AS1	-3.68	0.000261	0.0308	-0.18	-0.17	Subcortical brain region volumes;	chr11:83412686	chr11:83072066~83106719:+
LUAD	cis	rs3020736	0.5	rs6002616	ENSG00000273366.1	CTA-989H11.1	3.68	0.000261	0.0308	0.2	0.17	Autism spectrum disorder or schizophrenia;	chr22:42108675	chr22:42278188~42278846:+
LUAD	cis	rs3020736	0.5	rs7364293	ENSG00000273366.1	CTA-989H11.1	3.68	0.000261	0.0308	0.2	0.17	Autism spectrum disorder or schizophrenia;	chr22:42110366	chr22:42278188~42278846:+
LUAD	cis	rs2832270	1	rs73342417	ENSG00000174680.8	GRIK1-AS1	3.68	0.000261	0.0308	0.29	0.17	Response to mTOR inhibitor (everolimus);	chr21:29214306	chr21:29748175~29764002:+
LUAD	cis	rs2832270	0.915	rs9917509	ENSG00000174680.8	GRIK1-AS1	3.68	0.000261	0.0308	0.29	0.17	Response to mTOR inhibitor (everolimus);	chr21:29217641	chr21:29748175~29764002:+
LUAD	cis	rs564309	0.681	rs6426501	ENSG00000269934.1	RP5-1139B12.3	-3.68	0.000261	0.0308	-0.27	-0.17	Hip circumference (psychosocial stress interaction);	chr1:228435542	chr1:228274584~228276066:-
LUAD	cis	rs17508449	0.547	rs3195954	ENSG00000232450.1	RP4-730K3.3	-3.68	0.000261	0.0308	-0.24	-0.17	Leprosy;	chr1:113812032	chr1:113698884~113699631:-
LUAD	cis	rs2617170	0.922	rs2617160	ENSG00000245648.1	RP11-277P12.20	3.68	0.000261	0.0308	0.2	0.17	Behcet's disease;	chr12:10392998	chr12:10363769~10398506:+
LUAD	cis	rs28374715	0.578	rs17730888	ENSG00000247556.5	OIP5-AS1	3.68	0.000261	0.0308	0.21	0.17	Ulcerative colitis;	chr15:41345349	chr15:41283990~41309737:+
LUAD	cis	rs13401620	0.871	rs66532914	ENSG00000227788.1	AC012363.8	-3.68	0.000261	0.0308	-0.2	-0.17	Breast size;	chr2:119925053	chr2:120211727~120212862:+
LUAD	cis	rs12304921	0.639	rs2018022	ENSG00000277201.1	AC087884.1	3.68	0.000261	0.0308	0.17	0.17	Type 2 diabetes;	chr12:51081570	chr12:51049921~51050025:+
LUAD	cis	rs11779988	0.545	rs438873	ENSG00000253671.1	RP11-806O11.1	-3.68	0.000261	0.0308	-0.2	-0.17	Breast cancer;	chr8:17929007	chr8:17808941~17820868:+
LUAD	cis	rs6496932	0.503	rs7164354	ENSG00000259630.2	CTD-2262B20.1	-3.68	0.000261	0.0308	-0.22	-0.17	Central corneal thickness;Corneal structure;	chr15:85405217	chr15:85415228~85415633:+
LUAD	cis	rs7142881	0.787	rs11623835	ENSG00000258525.1	RP11-829H16.3	-3.68	0.000261	0.0308	-0.19	-0.17	Response to iloperidone treatment (QT prolongation);	chr14:31714642	chr14:30876179~30889808:-
LUAD	cis	rs7142881	0.815	rs11624772	ENSG00000258525.1	RP11-829H16.3	-3.68	0.000261	0.0308	-0.19	-0.17	Response to iloperidone treatment (QT prolongation);	chr14:31714764	chr14:30876179~30889808:-
LUAD	cis	rs2880765	0.546	rs11639291	ENSG00000259407.1	RP11-158M2.3	-3.68	0.000261	0.0308	-0.16	-0.17	Coronary artery disease;	chr15:85520899	chr15:85744109~85750281:-
LUAD	cis	rs61542988	0.535	rs10807813	ENSG00000226329.2	AC005682.6	3.68	0.000261	0.0308	0.25	0.17	Fibrinogen levels;	chr7:22790342	chr7:22863874~22881350:-
LUAD	cis	rs1044826	0.642	rs4683464	ENSG00000214280.3	RP11-553K23.2	-3.68	0.000261	0.0308	-0.18	-0.17	Obesity-related traits;	chr3:139478119	chr3:139582928~139583593:-
LUAD	cis	rs7674212	0.507	rs223317	ENSG00000230069.3	LRRC37A15P	-3.68	0.000261	0.0308	-0.18	-0.17	Type 2 diabetes;	chr4:102881667	chr4:102727274~102730721:-
LUAD	cis	rs9341808	0.727	rs9352809	ENSG00000279022.1	RP11-250B2.4	3.68	0.000261	0.0308	0.2	0.17	Sitting height ratio;	chr6:80289599	chr6:80440730~80441172:+
LUAD	cis	rs6910061	1	rs6910061	ENSG00000247925.2	RP3-510L9.1	3.68	0.000261	0.0308	0.23	0.17	Diabetic kidney disease;	chr6:11101685	chr6:11173452~11259099:+
LUAD	cis	rs11064768	0.633	rs11064776	ENSG00000275759.1	RP11-131L12.3	3.68	0.000261	0.0308	0.28	0.17	Schizophrenia;	chr12:119402895	chr12:118428281~118428870:+
LUAD	cis	rs11064768	0.633	rs4471499	ENSG00000275759.1	RP11-131L12.3	3.68	0.000261	0.0308	0.28	0.17	Schizophrenia;	chr12:119403883	chr12:118428281~118428870:+
LUAD	cis	rs11064768	0.633	rs11064779	ENSG00000275759.1	RP11-131L12.3	3.68	0.000261	0.0308	0.28	0.17	Schizophrenia;	chr12:119404889	chr12:118428281~118428870:+
LUAD	cis	rs11064768	0.633	rs7312409	ENSG00000275759.1	RP11-131L12.3	3.68	0.000261	0.0308	0.28	0.17	Schizophrenia;	chr12:119405222	chr12:118428281~118428870:+
LUAD	cis	rs11064768	0.633	rs7308840	ENSG00000275759.1	RP11-131L12.3	3.68	0.000261	0.0308	0.28	0.17	Schizophrenia;	chr12:119405629	chr12:118428281~118428870:+
LUAD	cis	rs11064768	0.633	rs7959781	ENSG00000275759.1	RP11-131L12.3	3.68	0.000261	0.0308	0.28	0.17	Schizophrenia;	chr12:119406253	chr12:118428281~118428870:+
LUAD	cis	rs11064768	0.633	rs7980254	ENSG00000275759.1	RP11-131L12.3	3.68	0.000261	0.0308	0.28	0.17	Schizophrenia;	chr12:119406318	chr12:118428281~118428870:+
LUAD	cis	rs2239547	0.603	rs59989280	ENSG00000243224.1	RP5-1157M23.2	-3.68	0.000261	0.0308	-0.19	-0.17	Schizophrenia;	chr3:53064859	chr3:52239258~52241097:+
LUAD	cis	rs2239547	0.603	rs6789219	ENSG00000243224.1	RP5-1157M23.2	-3.68	0.000261	0.0308	-0.19	-0.17	Schizophrenia;	chr3:53064922	chr3:52239258~52241097:+
LUAD	cis	rs6819013	0.555	rs17761516	ENSG00000249234.1	RP11-452J21.2	3.68	0.000261	0.0308	0.19	0.17	QT interval;	chr4:16916291	chr4:16178939~16183120:+
LUAD	cis	rs2274273	1	rs7142704	ENSG00000259318.1	RP11-454L9.2	3.68	0.000261	0.0308	0.14	0.17	Protein biomarker;	chr14:55163885	chr14:55394940~55395233:-
LUAD	cis	rs3925075	0.5	rs10438639	ENSG00000260911.2	RP11-196G11.2	-3.68	0.000261	0.0308	-0.16	-0.17	IgA nephropathy;	chr16:31256377	chr16:31043150~31049868:+
LUAD	cis	rs6438234	0.744	rs2219521	ENSG00000242767.1	ZBTB20-AS4	3.68	0.000261	0.0308	0.21	0.17	Type 2 diabetes;	chr3:115223678	chr3:115100423~115103061:+
LUAD	cis	rs1198872	0.892	rs1198866	ENSG00000272275.1	RP11-791G15.2	-3.68	0.000261	0.0308	-0.21	-0.17	Cardiac Troponin-T levels;	chr2:10761664	chr2:10767875~10770058:-
LUAD	cis	rs12073359	0.913	rs4926406	ENSG00000223945.2	RP11-458I7.1	3.68	0.000261	0.0308	0.22	0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150074899	chr1:150053864~150055034:+
LUAD	cis	rs7870753	0.578	rs10820378	ENSG00000188801.9	ZNF322P1	-3.68	0.000261	0.0308	-0.25	-0.17	Height;	chr9:96330467	chr9:97198303~97199511:-
LUAD	cis	rs6502050	0.805	rs9898326	ENSG00000275966.1	RP11-1055B8.9	-3.68	0.000261	0.0308	-0.17	-0.17	Life satisfaction;	chr17:82161706	chr17:81345476~81345966:-
LUAD	cis	rs12304921	0.639	rs7722	ENSG00000277201.1	AC087884.1	3.68	0.000262	0.0308	0.16	0.17	Type 2 diabetes;	chr12:51061621	chr12:51049921~51050025:+
LUAD	cis	rs4819052	0.851	rs13050359	ENSG00000215447.6	BX322557.10	-3.68	0.000262	0.0309	-0.2	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252756	chr21:45288052~45291738:+
LUAD	cis	rs4819052	0.851	rs13052344	ENSG00000215447.6	BX322557.10	-3.68	0.000262	0.0309	-0.2	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256186	chr21:45288052~45291738:+
LUAD	cis	rs4819052	0.808	rs11909411	ENSG00000215447.6	BX322557.10	-3.68	0.000262	0.0309	-0.2	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256641	chr21:45288052~45291738:+
LUAD	cis	rs4819052	0.851	rs28676615	ENSG00000215447.6	BX322557.10	-3.68	0.000262	0.0309	-0.2	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256661	chr21:45288052~45291738:+
LUAD	cis	rs4819052	0.851	rs28501512	ENSG00000215447.6	BX322557.10	-3.68	0.000262	0.0309	-0.2	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256787	chr21:45288052~45291738:+
LUAD	cis	rs230529	0.51	rs1120986	ENSG00000246560.2	RP11-10L12.4	3.68	0.000262	0.0309	0.21	0.17	Schizophrenia (treatment resistant);	chr4:102515484	chr4:102828055~102844075:+
LUAD	cis	rs38055	0.881	rs384866	ENSG00000247796.2	CTD-2366F13.1	-3.68	0.000262	0.0309	-0.18	-0.17	Acne (severe);	chr5:53317694	chr5:53109842~53115126:+
LUAD	cis	rs4803480	0.786	rs4803479	ENSG00000270164.1	LINC01480	-3.68	0.000262	0.0309	-0.14	-0.17	Schizophrenia;	chr19:41551234	chr19:41535183~41536904:+
LUAD	cis	rs3213758	0.588	rs78389273	ENSG00000261630.1	RP11-357N13.3	-3.68	0.000262	0.0309	-0.28	-0.17	Vitiligo (non-segmental);	chr16:53529901	chr16:53981229~53981912:-
LUAD	cis	rs57502260	0.573	rs12291008	ENSG00000212093.1	AP000807.1	3.68	0.000262	0.0309	0.19	0.17	Total body bone mineral density (age 45-60);	chr11:68621604	chr11:68506083~68506166:-
LUAD	cis	rs6539288	0.674	rs4964494	ENSG00000260329.1	RP11-412D9.4	-3.68	0.000262	0.0309	-0.17	-0.17	Total body bone mineral density;	chr12:106890682	chr12:106954029~106955497:-
LUAD	cis	rs247929	1	rs2193749	ENSG00000272369.1	RP11-446N19.1	-3.68	0.000262	0.0309	-0.18	-0.17	Educational attainment;	chr12:45741029	chr12:46537502~46652550:+
LUAD	cis	rs6502050	0.835	rs7221544	ENSG00000275966.1	RP11-1055B8.9	3.68	0.000262	0.0309	0.17	0.17	Life satisfaction;	chr17:82129461	chr17:81345476~81345966:-
LUAD	cis	rs2836950	0.502	rs12627205	ENSG00000232608.1	TIMM9P2	3.68	0.000262	0.0309	0.18	0.17	Menarche (age at onset);	chr21:39258101	chr21:39216624~39217506:+
LUAD	cis	rs12073359	0.909	rs7554367	ENSG00000223945.2	RP11-458I7.1	3.68	0.000262	0.0309	0.23	0.17	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150047605	chr1:150053864~150055034:+
LUAD	cis	rs7674212	0.57	rs2069274	ENSG00000246560.2	RP11-10L12.4	3.68	0.000262	0.0309	0.21	0.17	Type 2 diabetes;	chr4:103099624	chr4:102828055~102844075:+
LUAD	cis	rs34421088	0.585	rs10101661	ENSG00000255046.1	RP11-297N6.4	3.68	0.000262	0.0309	0.21	0.17	Neuroticism;	chr8:11735995	chr8:11797928~11802568:-
LUAD	cis	rs643506	0.934	rs4936690	ENSG00000230911.1	PPIHP1	-3.68	0.000262	0.0309	-0.21	-0.17	Breast cancer;	chr11:111776191	chr11:112029858~112030367:-
LUAD	cis	rs62246343	0.605	rs7650141	ENSG00000186162.9	CIDECP	-3.68	0.000262	0.0309	-0.23	-0.17	Fibrinogen levels;	chr3:9407726	chr3:10014238~10026365:-
LUAD	cis	rs10463554	0.895	rs3756583	ENSG00000250682.4	LINC00491	3.68	0.000262	0.0309	0.19	0.17	Parkinson's disease;	chr5:102998340	chr5:102609156~102671559:-
LUAD	cis	rs786425	0.707	rs1051793	ENSG00000278112.1	RP11-972P1.11	3.68	0.000262	0.0309	0.16	0.17	Pubertal anthropometrics;	chr12:123659848	chr12:123519390~123519856:-
LUAD	cis	rs2657294	0.796	rs6480770	ENSG00000226051.5	ZNF503-AS1	-3.68	0.000262	0.0309	-0.22	-0.17	Pneumonia;	chr10:75098799	chr10:75269819~75373500:+
LUAD	cis	rs9308731	0.568	rs6754736	ENSG00000227992.1	AC108463.2	-3.68	0.000262	0.0309	-0.2	-0.17	Chronic lymphocytic leukemia;	chr2:111190964	chr2:111203964~111206215:-
LUAD	cis	rs62359376	1	rs62359376	ENSG00000247796.2	CTD-2366F13.1	3.68	0.000262	0.0309	0.31	0.17	Systemic juvenile idiopathic arthritis;	chr5:53115498	chr5:53109842~53115126:+
LUAD	cis	rs801193	1	rs13239306	ENSG00000222364.1	RNU6-96P	3.68	0.000262	0.0309	0.19	0.17	Aortic root size;	chr7:66671030	chr7:66395191~66395286:+
LUAD	cis	rs516805	0.961	rs510283	ENSG00000279114.1	RP3-425C14.5	-3.68	0.000262	0.0309	-0.18	-0.17	Lymphocyte counts;	chr6:122451547	chr6:122471923~122484161:+
LUAD	cis	rs57709857	0.957	rs11985168	ENSG00000272092.1	RP11-350N15.5	-3.68	0.000262	0.0309	-0.21	-0.17	Autism spectrum disorder or schizophrenia;	chr8:38302525	chr8:38382364~38383461:+
LUAD	cis	rs9341808	0.935	rs2322633	ENSG00000233967.5	RP11-250B2.3	-3.68	0.000262	0.0309	-0.16	-0.17	Sitting height ratio;	chr6:80136272	chr6:80443344~80465927:+
LUAD	cis	rs2652834	0.718	rs2729832	ENSG00000259498.1	RP11-244F12.3	3.68	0.000262	0.0309	0.23	0.17	HDL cholesterol;	chr15:63104202	chr15:63046034~63049387:-
LUAD	cis	rs3750965	0.575	rs7131509	ENSG00000260895.1	RP11-554A11.7	-3.68	0.000262	0.0309	-0.19	-0.17	Hair color;	chr11:69116088	chr11:69103493~69109094:+
LUAD	cis	rs858239	0.899	rs28458177	ENSG00000226816.2	AC005082.12	3.68	0.000262	0.0309	0.22	0.17	Cerebrospinal fluid biomarker levels;	chr7:23255253	chr7:23206013~23208045:+
LUAD	cis	rs6691170	1	rs12118052	ENSG00000228437.4	RP11-400N13.2	3.68	0.000262	0.0309	0.2	0.17	Colorectal cancer;	chr1:221872940	chr1:221966341~221984964:+
LUAD	cis	rs1044826	1	rs13089007	ENSG00000214280.3	RP11-553K23.2	-3.68	0.000262	0.0309	-0.2	-0.17	Obesity-related traits;	chr3:139376745	chr3:139582928~139583593:-
LUAD	cis	rs10129255	0.701	rs2005643	ENSG00000211947.2	IGHV3-21	-3.68	0.000262	0.0309	-0.11	-0.17	Kawasaki disease;	chr14:106676288	chr14:106235064~106235594:-
LUAD	cis	rs16940212	0.618	rs1444942	ENSG00000242747.1	RP11-30K9.1	-3.68	0.000262	0.0309	-0.25	-0.17	HDL cholesterol;HDL cholesterol levels;	chr15:58393614	chr15:58869659~58870134:+
LUAD	cis	rs7017914	0.905	rs2732102	ENSG00000246366.5	RP11-382J12.1	-3.68	0.000262	0.0309	-0.15	-0.17	Bone mineral density;	chr8:71010637	chr8:70608577~70663279:+
LUAD	cis	rs71520386	0.846	rs17778126	ENSG00000228649.7	AC005682.5	-3.68	0.000262	0.0309	-0.26	-0.17	Fibrinogen levels;	chr7:22779340	chr7:22854178~22861579:+
LUAD	cis	rs9400467	0.528	rs9689727	ENSG00000266032.1	AL357515.1	3.68	0.000262	0.0309	0.21	0.17	Amino acid levels;Blood metabolite levels;	chr6:111475360	chr6:110969773~110969872:-
LUAD	cis	rs9400467	0.528	rs12214380	ENSG00000266032.1	AL357515.1	3.68	0.000262	0.0309	0.21	0.17	Amino acid levels;Blood metabolite levels;	chr6:111475734	chr6:110969773~110969872:-
LUAD	cis	rs12122100	1	rs12122100	ENSG00000227242.3	NBPF13P	-3.68	0.000263	0.0309	-0.21	-0.17	HIV-1 control;	chr1:147037378	chr1:147021320~147124525:-
LUAD	cis	rs13398147	0.879	rs72971048	ENSG00000267034.1	RP11-384O8.1	3.68	0.000263	0.031	0.23	0.17	Adolescent idiopathic scoliosis;	chr2:221866170	chr2:222317242~222318653:-
LUAD	cis	rs7665939	1	rs72727637	ENSG00000251297.1	TUBB7P	3.68	0.000263	0.031	0.35	0.17	Amyotrophic lateral sclerosis;	chr4:189185524	chr4:189982523~189984871:-
LUAD	cis	rs7665939	1	rs72727639	ENSG00000251297.1	TUBB7P	3.68	0.000263	0.031	0.35	0.17	Amyotrophic lateral sclerosis;	chr4:189186838	chr4:189982523~189984871:-
LUAD	cis	rs950881	0.932	rs72823619	ENSG00000234389.1	AC007278.3	3.68	0.000263	0.031	0.2	0.17	Allergy;	chr2:102308155	chr2:102438713~102440475:+
LUAD	cis	rs17098356	1	rs12589412	ENSG00000258926.1	RP11-47I22.1	-3.68	0.000263	0.031	-0.16	-0.17	Reading and spelling;	chr14:61430808	chr14:61537508~61545287:-
LUAD	cis	rs42490	0.664	rs453266	ENSG00000251136.7	RP11-37B2.1	-3.68	0.000263	0.031	-0.17	-0.17	Leprosy;	chr8:89823789	chr8:89609409~89757727:-
LUAD	cis	rs42490	0.638	rs369771	ENSG00000251136.7	RP11-37B2.1	-3.68	0.000263	0.031	-0.17	-0.17	Leprosy;	chr8:89823884	chr8:89609409~89757727:-
LUAD	cis	rs1876905	0.569	rs354542	ENSG00000271789.1	RP5-1112D6.7	-3.68	0.000263	0.031	-0.23	-0.17	Mean corpuscular hemoglobin;	chr6:111193483	chr6:111297126~111298510:+
LUAD	cis	rs1876905	0.68	rs1216020	ENSG00000271789.1	RP5-1112D6.7	-3.68	0.000263	0.031	-0.23	-0.17	Mean corpuscular hemoglobin;	chr6:111194004	chr6:111297126~111298510:+
LUAD	cis	rs1876905	0.569	rs354541	ENSG00000271789.1	RP5-1112D6.7	-3.68	0.000263	0.031	-0.23	-0.17	Mean corpuscular hemoglobin;	chr6:111195262	chr6:111297126~111298510:+
LUAD	cis	rs1876905	0.68	rs354537	ENSG00000271789.1	RP5-1112D6.7	-3.68	0.000263	0.031	-0.23	-0.17	Mean corpuscular hemoglobin;	chr6:111197097	chr6:111297126~111298510:+
LUAD	cis	rs1876905	0.68	rs354536	ENSG00000271789.1	RP5-1112D6.7	-3.68	0.000263	0.031	-0.23	-0.17	Mean corpuscular hemoglobin;	chr6:111197808	chr6:111297126~111298510:+
LUAD	cis	rs1876905	0.68	rs557028	ENSG00000271789.1	RP5-1112D6.7	-3.68	0.000263	0.031	-0.23	-0.17	Mean corpuscular hemoglobin;	chr6:111201606	chr6:111297126~111298510:+
LUAD	cis	rs2243480	0.706	rs34466769	ENSG00000232559.3	GS1-124K5.12	3.68	0.000263	0.031	0.25	0.17	Diabetic kidney disease;	chr7:65988305	chr7:66554588~66576923:-
LUAD	cis	rs911555	0.755	rs4143998	ENSG00000259775.1	RP11-45P15.4	-3.68	0.000263	0.031	-0.22	-0.17	Intelligence (multi-trait analysis);	chr14:103488910	chr14:103331674~103332367:-
LUAD	cis	rs7017914	0.702	rs13278019	ENSG00000223220.1	Y_RNA	3.68	0.000263	0.031	0.19	0.17	Bone mineral density;	chr8:70621109	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.702	rs12678320	ENSG00000223220.1	Y_RNA	3.68	0.000263	0.031	0.19	0.17	Bone mineral density;	chr8:70624957	chr8:70780914~70781008:-
LUAD	cis	rs7017914	0.652	rs6988053	ENSG00000223220.1	Y_RNA	3.68	0.000263	0.031	0.19	0.17	Bone mineral density;	chr8:70634728	chr8:70780914~70781008:-
LUAD	cis	rs763121	0.853	rs5757193	ENSG00000225450.1	RP3-508I15.14	3.68	0.000263	0.031	0.17	0.17	Menopause (age at onset);	chr22:38638862	chr22:38739003~38749041:+
LUAD	cis	rs1923539	0.549	rs1923542	ENSG00000230091.5	TMEM254-AS1	3.68	0.000263	0.031	0.22	0.17	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79909470	chr10:80046860~80078912:-
LUAD	cis	rs7824557	0.591	rs2736283	ENSG00000255046.1	RP11-297N6.4	3.68	0.000263	0.031	0.21	0.17	Retinal vascular caliber;	chr8:11368401	chr8:11797928~11802568:-
LUAD	cis	rs7259376	0.807	rs11669254	ENSG00000269345.1	VN1R85P	3.68	0.000263	0.031	0.19	0.17	Menopause (age at onset);	chr19:22362003	chr19:22174766~22175191:-
LUAD	cis	rs4664293	0.867	rs7565297	ENSG00000230783.1	AC009961.2	-3.68	0.000263	0.031	-0.2	-0.17	Monocyte percentage of white cells;	chr2:159716008	chr2:159689217~159690291:-
LUAD	cis	rs7142881	0.815	rs8007984	ENSG00000258525.1	RP11-829H16.3	-3.68	0.000263	0.031	-0.19	-0.17	Response to iloperidone treatment (QT prolongation);	chr14:31716175	chr14:30876179~30889808:-
LUAD	cis	rs2281603	0.598	rs10151656	ENSG00000259116.1	RP11-973N13.4	-3.68	0.000263	0.031	-0.15	-0.17	Lymphocyte counts;	chr14:64594970	chr14:64514154~64540368:-
LUAD	cis	rs6793245	0.801	rs12497866	ENSG00000229589.1	ACVR2B-AS1	-3.68	0.000263	0.031	-0.21	-0.17	QT interval;	chr3:38534374	chr3:38451027~38454820:-
LUAD	cis	rs75920871	0.513	rs76904522	ENSG00000280143.1	AP000892.6	3.68	0.000263	0.031	0.25	0.17	Subjective well-being;	chr11:117144147	chr11:117204967~117210292:+
LUAD	cis	rs75920871	0.513	rs113560866	ENSG00000280143.1	AP000892.6	3.68	0.000263	0.031	0.25	0.17	Subjective well-being;	chr11:117144473	chr11:117204967~117210292:+
LUAD	cis	rs2408955	0.561	rs11168365	ENSG00000257763.1	OR5BK1P	-3.68	0.000263	0.031	-0.17	-0.17	Glycated hemoglobin levels;	chr12:48027989	chr12:48355792~48356614:-
LUAD	cis	rs11992162	0.55	rs61426048	ENSG00000255046.1	RP11-297N6.4	3.68	0.000263	0.031	0.21	0.17	Monocyte count;	chr8:11927447	chr8:11797928~11802568:-
LUAD	cis	rs4683346	0.616	rs7641046	ENSG00000173811.9	CCDC13-AS1	-3.68	0.000263	0.031	-0.18	-0.17	Granulocyte percentage of myeloid white cells;	chr3:42789838	chr3:42732575~42746768:+
LUAD	cis	rs4683346	0.585	rs11129975	ENSG00000173811.9	CCDC13-AS1	-3.68	0.000263	0.031	-0.18	-0.17	Granulocyte percentage of myeloid white cells;	chr3:42794493	chr3:42732575~42746768:+
LUAD	cis	rs4683346	0.616	rs13096498	ENSG00000173811.9	CCDC13-AS1	-3.68	0.000263	0.031	-0.18	-0.17	Granulocyte percentage of myeloid white cells;	chr3:42795494	chr3:42732575~42746768:+
LUAD	cis	rs9309473	1	rs6705489	ENSG00000230002.2	ALMS1-IT1	3.68	0.000263	0.031	0.21	0.17	Metabolite levels;	chr2:73421683	chr2:73456764~73459484:+
LUAD	cis	rs642743	0.517	rs157077	ENSG00000228261.1	RP11-127L20.3	3.68	0.000263	0.031	0.19	0.17	Left ventricular obstructive tract defect (maternal effect);	chr10:104278136	chr10:104323369~104327004:+
LUAD	cis	rs4716602	0.542	rs13224561	ENSG00000235029.1	MNX1-AS2	-3.68	0.000263	0.031	-0.2	-0.17	Anti-saccade response;	chr7:156368369	chr7:157006307~157007132:+
LUAD	cis	rs4716602	0.542	rs35137250	ENSG00000235029.1	MNX1-AS2	-3.68	0.000263	0.031	-0.2	-0.17	Anti-saccade response;	chr7:156368372	chr7:157006307~157007132:+
LUAD	cis	rs875971	0.545	rs11767262	ENSG00000224316.1	RP11-479O9.2	3.68	0.000263	0.031	0.19	0.17	Aortic root size;	chr7:66302237	chr7:65773620~65802067:+
LUAD	cis	rs6921919	0.583	rs16894060	ENSG00000219392.1	RP1-265C24.5	-3.68	0.000263	0.031	-0.21	-0.17	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28115628~28116551:+
LUAD	cis	rs2708977	0.637	rs687950	ENSG00000237510.6	AC008268.2	3.68	0.000263	0.031	0.21	0.17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96403874	chr2:95789654~95800166:+
LUAD	cis	rs9914544	0.628	rs4924924	ENSG00000154874.13	CCDC144B	-3.68	0.000263	0.031	-0.18	-0.17	Educational attainment (years of education);	chr17:18774461	chr17:18537800~18625617:-
LUAD	cis	rs1417205	1	rs9591032	ENSG00000276968.1	RP11-90M2.5	-3.68	0.000263	0.031	-0.36	-0.17	Cannabis use (initiation);	chr13:47326285	chr13:48041751~48042184:-
LUAD	cis	rs453301	0.522	rs2929309	ENSG00000173295.6	FAM86B3P	-3.68	0.000263	0.031	-0.18	-0.17	Joint mobility (Beighton score);	chr8:9226261	chr8:8228595~8244865:+
LUAD	cis	rs3764400	0.508	rs757353	ENSG00000278765.1	RP5-890E16.5	3.68	0.000263	0.031	0.3	0.17	Body mass index;	chr17:48044908	chr17:48066704~48067293:-
LUAD	cis	rs792448	0.527	rs11119887	ENSG00000229983.1	RP11-15I11.2	3.68	0.000263	0.031	0.21	0.17	White blood cell count (basophil);	chr1:212234220	chr1:212168207~212190259:+
LUAD	cis	rs7200786	0.528	rs27867	ENSG00000274038.1	RP11-66H6.4	-3.68	0.000263	0.031	-0.21	-0.17	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11153920	chr16:11056556~11057034:+
LUAD	cis	rs600231	0.542	rs11227205	ENSG00000245532.5	NEAT1	3.68	0.000263	0.031	0.16	0.17	Bone mineral density;	chr11:65488693	chr11:65422774~65445540:+
LUAD	cis	rs6951245	0.935	rs113365567	ENSG00000224079.1	AC091729.7	-3.68	0.000263	0.031	-0.26	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1069149	chr7:1074450~1078036:+
LUAD	cis	rs7674212	0.507	rs6843738	ENSG00000230069.3	LRRC37A15P	-3.68	0.000263	0.031	-0.18	-0.17	Type 2 diabetes;	chr4:103014844	chr4:102727274~102730721:-
LUAD	cis	rs9308731	0.605	rs6754738	ENSG00000227992.1	AC108463.2	-3.68	0.000263	0.031	-0.2	-0.17	Chronic lymphocytic leukemia;	chr2:111190966	chr2:111203964~111206215:-
LUAD	cis	rs638893	0.617	rs4938565	ENSG00000255422.1	AP002954.4	3.68	0.000263	0.031	0.23	0.17	Vitiligo;	chr11:118850289	chr11:118704607~118750263:+
LUAD	cis	rs2239547	0.523	rs6803486	ENSG00000243224.1	RP5-1157M23.2	-3.68	0.000263	0.031	-0.19	-0.17	Schizophrenia;	chr3:53064193	chr3:52239258~52241097:+
LUAD	cis	rs4938303	0.633	rs61906081	ENSG00000254851.1	RP11-109L13.1	3.68	0.000263	0.031	0.26	0.17	Triglycerides;	chr11:116666342	chr11:117135528~117138582:+
LUAD	cis	rs8049040	0.547	rs12929335	ENSG00000260886.1	TAT-AS1	3.68	0.000263	0.031	0.2	0.17	Blood protein levels;	chr16:71401849	chr16:71565789~71578187:+
LUAD	cis	rs7339483	0.618	rs7247209	ENSG00000268058.1	BNIP3P40	-3.68	0.000263	0.031	-0.27	-0.17	Discordance in emotional problems in monozygotic twins;	chr19:24166959	chr19:24098425~24098980:-
LUAD	cis	rs7339483	0.618	rs10424642	ENSG00000268058.1	BNIP3P40	-3.68	0.000263	0.031	-0.27	-0.17	Discordance in emotional problems in monozygotic twins;	chr19:24169784	chr19:24098425~24098980:-
LUAD	cis	rs75920871	0.589	rs56081989	ENSG00000280143.1	AP000892.6	3.68	0.000264	0.031	0.25	0.17	Subjective well-being;	chr11:117214589	chr11:117204967~117210292:+
LUAD	cis	rs253959	0.564	rs4921064	ENSG00000272265.1	CTD-2287O16.4	3.68	0.000264	0.031	0.2	0.17	Bipolar disorder and schizophrenia;	chr5:116111637	chr5:116078110~116078570:-
LUAD	cis	rs763121	0.925	rs1056661	ENSG00000273076.1	RP3-508I15.22	3.68	0.000264	0.031	0.15	0.17	Menopause (age at onset);	chr22:38684240	chr22:38743495~38743910:+
LUAD	cis	rs2380205	0.967	rs10905303	ENSG00000232807.2	RP11-536K7.3	3.68	0.000264	0.031	0.17	0.17	Breast cancer;	chr10:5852217	chr10:5934270~5945900:-
LUAD	cis	rs2380205	0.967	rs10905307	ENSG00000232807.2	RP11-536K7.3	3.68	0.000264	0.031	0.17	0.17	Breast cancer;	chr10:5852537	chr10:5934270~5945900:-
LUAD	cis	rs2380205	0.935	rs2380200	ENSG00000232807.2	RP11-536K7.3	3.68	0.000264	0.031	0.17	0.17	Breast cancer;	chr10:5852976	chr10:5934270~5945900:-
LUAD	cis	rs2380205	0.967	rs9732607	ENSG00000232807.2	RP11-536K7.3	3.68	0.000264	0.031	0.17	0.17	Breast cancer;	chr10:5853138	chr10:5934270~5945900:-
LUAD	cis	rs2380205	0.967	rs11255555	ENSG00000232807.2	RP11-536K7.3	3.68	0.000264	0.031	0.17	0.17	Breast cancer;	chr10:5853398	chr10:5934270~5945900:-
LUAD	cis	rs2380205	0.875	rs10795592	ENSG00000232807.2	RP11-536K7.3	3.68	0.000264	0.031	0.17	0.17	Breast cancer;	chr10:5853792	chr10:5934270~5945900:-
LUAD	cis	rs2380205	0.967	rs11255558	ENSG00000232807.2	RP11-536K7.3	3.68	0.000264	0.031	0.17	0.17	Breast cancer;	chr10:5854429	chr10:5934270~5945900:-
LUAD	cis	rs2380205	0.935	rs7901964	ENSG00000232807.2	RP11-536K7.3	3.68	0.000264	0.031	0.17	0.17	Breast cancer;	chr10:5854938	chr10:5934270~5945900:-
LUAD	cis	rs7428	0.545	rs7572750	ENSG00000246575.2	AC093162.5	3.68	0.000264	0.031	0.15	0.17	Ear protrusion;	chr2:85325063	chr2:85315041~85316529:+
LUAD	cis	rs957448	1	rs56716157	ENSG00000254057.1	RP3-388N13.3	3.68	0.000264	0.0311	0.19	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94530644	chr8:93834454~93846743:-
LUAD	cis	rs2904524	1	rs17108038	ENSG00000257815.4	RP11-611E13.2	-3.68	0.000264	0.0311	-0.24	-0.17	Amyotrophic lateral sclerosis (age of onset);	chr12:70347828	chr12:69904033~70243360:-
LUAD	cis	rs6547741	0.935	rs6761095	ENSG00000223522.1	AC093690.1	3.68	0.000264	0.0311	0.16	0.17	Oral cavity cancer;	chr2:27555143	chr2:28307691~28310459:-
LUAD	cis	rs4835473	0.932	rs13147386	ENSG00000249741.2	RP11-673E1.3	-3.68	0.000264	0.0311	-0.19	-0.17	Immature fraction of reticulocytes;	chr4:143736586	chr4:143911514~143912053:-
LUAD	cis	rs9341808	0.935	rs2298307	ENSG00000233967.5	RP11-250B2.3	3.68	0.000264	0.0311	0.16	0.17	Sitting height ratio;	chr6:80106579	chr6:80443344~80465927:+
LUAD	cis	rs9517320	1	rs7338549	ENSG00000231194.1	FARP1-AS1	3.68	0.000264	0.0311	0.19	0.17	Longevity;	chr13:98490491	chr13:98435405~98435840:-
LUAD	cis	rs10951138	0.786	rs34041259	ENSG00000214870.7	AC004540.5	-3.68	0.000264	0.0311	-0.28	-0.17	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr7:26442517	chr7:26398593~26494256:+
LUAD	cis	rs739496	0.579	rs7488629	ENSG00000234608.6	MAPKAPK5-AS1	3.68	0.000264	0.0311	0.19	0.17	Platelet count;	chr12:111835696	chr12:111839764~111842902:-
LUAD	cis	rs6490294	0.748	rs73422316	ENSG00000234608.6	MAPKAPK5-AS1	3.68	0.000264	0.0311	0.19	0.17	Mean platelet volume;	chr12:111835870	chr12:111839764~111842902:-
LUAD	cis	rs38055	0.837	rs252034	ENSG00000247796.2	CTD-2366F13.1	-3.68	0.000264	0.0311	-0.18	-0.17	Acne (severe);	chr5:53318961	chr5:53109842~53115126:+
LUAD	cis	rs2554380	0.55	rs62025822	ENSG00000259570.1	RP11-671M22.4	-3.68	0.000264	0.0311	-0.22	-0.17	Height;	chr15:83870162	chr15:84394512~84395514:+
LUAD	cis	rs2554380	0.55	rs56159777	ENSG00000259570.1	RP11-671M22.4	-3.68	0.000264	0.0311	-0.22	-0.17	Height;	chr15:83870527	chr15:84394512~84395514:+
LUAD	cis	rs2554380	0.55	rs4842919	ENSG00000259570.1	RP11-671M22.4	-3.68	0.000264	0.0311	-0.22	-0.17	Height;	chr15:83870668	chr15:84394512~84395514:+
LUAD	cis	rs9973361	0.51	rs3815993	ENSG00000232411.1	AC009495.3	-3.68	0.000264	0.0311	-0.23	-0.17	Total body bone mineral density;	chr2:165875827	chr2:165833048~165839098:-
LUAD	cis	rs4683346	0.616	rs13070029	ENSG00000173811.9	CCDC13-AS1	-3.68	0.000264	0.0311	-0.19	-0.17	Granulocyte percentage of myeloid white cells;	chr3:42810715	chr3:42732575~42746768:+
LUAD	cis	rs1046491	0.901	rs10853373	ENSG00000264964.1	RP11-888D10.3	3.68	0.000264	0.0311	0.34	0.17	Scarlet fever;	chr18:9149417	chr18:9315194~9334441:-
LUAD	cis	rs8028182	0.636	rs4299117	ENSG00000246877.1	DNM1P35	3.68	0.000264	0.0311	0.22	0.17	Sudden cardiac arrest;	chr15:75497103	chr15:75727670~75738623:-
LUAD	cis	rs8028182	0.636	rs11637586	ENSG00000246877.1	DNM1P35	3.68	0.000264	0.0311	0.22	0.17	Sudden cardiac arrest;	chr15:75498771	chr15:75727670~75738623:-
LUAD	cis	rs189798	0.807	rs12785	ENSG00000253893.2	FAM85B	-3.68	0.000264	0.0311	-0.23	-0.17	Myopia (pathological);	chr8:9137426	chr8:8167819~8226614:-
LUAD	cis	rs2736345	0.747	rs1478901	ENSG00000270154.1	RP11-419I17.1	3.68	0.000264	0.0311	0.22	0.17	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11490324	chr8:12476462~12477122:+
LUAD	cis	rs2732480	0.5	rs2932093	ENSG00000273765.1	RP11-370I10.11	3.68	0.000264	0.0311	0.18	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48254488	chr12:48360920~48361377:+
LUAD	cis	rs7618915	0.547	rs2286800	ENSG00000243224.1	RP5-1157M23.2	-3.68	0.000264	0.0311	-0.17	-0.17	Bipolar disorder;	chr3:52744035	chr3:52239258~52241097:+
LUAD	cis	rs970797	0.522	rs2103108	ENSG00000237260.1	AC073069.2	3.68	0.000264	0.0311	0.2	0.17	Monobrow;Lobe attachment (rater-scored or self-reported);	chr2:176331817	chr2:176338637~176339077:+
LUAD	cis	rs4727963	0.846	rs1608829	ENSG00000240499.6	RP5-1101C3.1	-3.68	0.000264	0.0311	-0.15	-0.17	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);	chr7:123067559	chr7:122328469~122440388:+
LUAD	cis	rs12049351	0.774	rs36021190	ENSG00000229367.1	HMGN2P19	3.68	0.000264	0.0311	0.24	0.17	Circulating myeloperoxidase levels (plasma);	chr1:229562116	chr1:229570532~229570796:+
LUAD	cis	rs1552244	1	rs17032299	ENSG00000180385.7	EMC3-AS1	3.68	0.000264	0.0311	0.19	0.17	Alzheimer's disease;	chr3:10045954	chr3:9986893~10006990:+
LUAD	cis	rs116095464	1	rs62330028	ENSG00000250848.1	CTD-2083E4.5	-3.68	0.000264	0.0311	-0.36	-0.17	Breast cancer;	chr5:319042	chr5:288833~290321:-
LUAD	cis	rs7192380	1	rs11647110	ENSG00000226232.7	RP11-419C5.2	-3.68	0.000264	0.0311	-0.14	-0.17	Sjögren's syndrome;	chr16:69555460	chr16:69976388~69996188:-
LUAD	cis	rs9309473	1	rs10179134	ENSG00000230002.2	ALMS1-IT1	3.68	0.000264	0.0311	0.21	0.17	Metabolite levels;	chr2:73410391	chr2:73456764~73459484:+
LUAD	cis	rs7260598	0.585	rs8112076	ENSG00000269421.1	ZNF92P3	-3.68	0.000264	0.0311	-0.25	-0.17	Response to taxane treatment (placlitaxel);	chr19:23956561	chr19:23935220~23936173:+
LUAD	cis	rs3617	0.625	rs11922961	ENSG00000242142.1	SERBP1P3	-3.68	0.000264	0.0311	-0.18	-0.17	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52834594	chr3:53064283~53065091:-
LUAD	cis	rs6088580	0.567	rs6088520	ENSG00000276073.1	RP5-1125A11.7	3.68	0.000264	0.0311	0.16	0.17	Glomerular filtration rate (creatinine);	chr20:34544560	chr20:33985617~33988989:-
LUAD	cis	rs2274273	0.87	rs3825616	ENSG00000258413.1	RP11-665C16.6	-3.68	0.000264	0.0311	-0.21	-0.17	Protein biomarker;	chr14:55386570	chr14:55262767~55272075:-
LUAD	cis	rs13113518	1	rs13113518	ENSG00000249700.7	SRD5A3-AS1	3.68	0.000264	0.0311	0.16	0.17	Height;	chr4:55533481	chr4:55363971~55395847:-
LUAD	cis	rs4268898	0.662	rs9917315	ENSG00000242628.4	AC009228.1	3.68	0.000264	0.0311	0.24	0.17	Asthma;	chr2:24208632	chr2:24214381~24221516:+
LUAD	cis	rs4268898	0.662	rs2303292	ENSG00000242628.4	AC009228.1	3.68	0.000264	0.0311	0.24	0.17	Asthma;	chr2:24209269	chr2:24214381~24221516:+
LUAD	cis	rs4268898	0.662	rs2303296	ENSG00000242628.4	AC009228.1	3.68	0.000264	0.0311	0.24	0.17	Asthma;	chr2:24209970	chr2:24214381~24221516:+
LUAD	cis	rs4268898	0.662	rs2303297	ENSG00000242628.4	AC009228.1	3.68	0.000264	0.0311	0.24	0.17	Asthma;	chr2:24210068	chr2:24214381~24221516:+
LUAD	cis	rs4268898	0.662	rs9917355	ENSG00000242628.4	AC009228.1	3.68	0.000264	0.0311	0.24	0.17	Asthma;	chr2:24210531	chr2:24214381~24221516:+
LUAD	cis	rs4268898	0.662	rs72795824	ENSG00000242628.4	AC009228.1	3.68	0.000264	0.0311	0.24	0.17	Asthma;	chr2:24212968	chr2:24214381~24221516:+
LUAD	cis	rs7208859	0.623	rs9914242	ENSG00000266490.1	CTD-2349P21.9	3.68	0.000264	0.0311	0.26	0.17	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889227	chr17:30792372~30792833:+
LUAD	cis	rs1387259	0.839	rs7486941	ENSG00000257763.1	OR5BK1P	-3.68	0.000264	0.0311	-0.16	-0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48184848	chr12:48355792~48356614:-
LUAD	cis	rs2041840	1	rs6544065	ENSG00000272054.1	RP11-423P10.2	-3.68	0.000264	0.0311	-0.13	-0.17	Chronic lymphocytic leukemia;	chr2:37270274	chr2:37208875~37212677:+
LUAD	cis	rs911186	0.74	rs6938200	ENSG00000219392.1	RP1-265C24.5	-3.68	0.000264	0.0311	-0.23	-0.17	Autism spectrum disorder or schizophrenia;	chr6:27263371	chr6:28115628~28116551:+
LUAD	cis	rs1383484	0.958	rs5006997	ENSG00000259728.4	LINC00933	-3.68	0.000264	0.0311	-0.21	-0.17	Height;	chr15:83849268	chr15:84570649~84580175:+
LUAD	cis	rs526231	0.819	rs2561476	ENSG00000175749.11	EIF3KP1	3.68	0.000264	0.0311	0.22	0.17	Primary biliary cholangitis;	chr5:103273133	chr5:103032376~103033031:+
LUAD	cis	rs7976269	0.609	rs1344855	ENSG00000275476.1	RP11-996F15.4	3.68	0.000264	0.0311	0.18	0.17	Male-pattern baldness;	chr12:29065605	chr12:29277397~29277882:-
LUAD	cis	rs2905347	0.757	rs2961295	ENSG00000179428.2	AC073072.5	-3.68	0.000264	0.0311	-0.19	-0.17	Major depression and alcohol dependence;	chr7:22656653	chr7:22725395~22727620:-
LUAD	cis	rs6903823	0.508	rs1150724	ENSG00000176933.5	TOB2P1	-3.68	0.000264	0.0311	-0.18	-0.17	Pulmonary function;	chr6:28282459	chr6:28217643~28218634:-
LUAD	cis	rs11673344	0.562	rs256740	ENSG00000267309.1	CTD-2630F21.1	3.68	0.000264	0.0311	0.21	0.17	Obesity-related traits;	chr19:37365451	chr19:36489649~36491040:+
LUAD	cis	rs9889262	0.561	rs1124881	ENSG00000248714.5	RP11-1079K10.3	3.68	0.000265	0.0311	0.16	0.17	Eosinophil percentage of granulocytes;Allergic disease (asthma, hay fever or eczema);Eosinophil counts;	chr17:49276125	chr17:49361165~49369998:+
LUAD	cis	rs9309473	0.898	rs10201159	ENSG00000230002.2	ALMS1-IT1	3.68	0.000265	0.0311	0.21	0.17	Metabolite levels;	chr2:73631838	chr2:73456764~73459484:+
LUAD	cis	rs6502050	0.731	rs9892653	ENSG00000275966.1	RP11-1055B8.9	-3.68	0.000265	0.0311	-0.17	-0.17	Life satisfaction;	chr17:82142315	chr17:81345476~81345966:-
LUAD	cis	rs2732480	0.5	rs7966829	ENSG00000257763.1	OR5BK1P	3.68	0.000265	0.0311	0.17	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48221820	chr12:48355792~48356614:-
LUAD	cis	rs9951698	0.703	rs6505777	ENSG00000267480.1	RP11-703I16.1	-3.68	0.000265	0.0311	-0.2	-0.17	Intelligence (multi-trait analysis);	chr18:13008370	chr18:12031178~12032181:-
LUAD	cis	rs2074409	0.54	rs853202	ENSG00000276054.1	RP11-378E13.3	3.68	0.000265	0.0311	0.2	0.17	Response to angiotensin II receptor blocker therapy;	chr17:37445289	chr17:37386886~37387926:+
LUAD	cis	rs6743068	0.521	rs9288318	ENSG00000234842.1	AC007163.8	-3.68	0.000265	0.0311	-0.19	-0.17	Lymphocyte percentage of white cells;	chr2:201331340	chr2:201549631~201550307:+
LUAD	cis	rs4713118	0.911	rs9461406	ENSG00000280107.1	AL022393.9	3.67	0.000265	0.0311	0.21	0.17	Parkinson's disease;	chr6:27751985	chr6:28170845~28172521:+
LUAD	cis	rs2625529	0.652	rs2957724	ENSG00000260173.1	RP11-2I17.4	3.67	0.000265	0.0311	0.2	0.17	Red blood cell count;	chr15:71956133	chr15:72140504~72155459:-
LUAD	cis	rs4363385	0.693	rs10788849	ENSG00000223599.1	RP11-216N14.7	-3.67	0.000265	0.0312	-0.19	-0.17	Inflammatory skin disease;	chr1:152929764	chr1:153852106~153853414:-
LUAD	cis	rs13006833	0.668	rs2582736	ENSG00000227542.1	AC092614.2	-3.67	0.000265	0.0312	-0.2	-0.17	Urinary metabolites;	chr2:190280166	chr2:191229165~191246172:-
LUAD	cis	rs13006833	0.634	rs1876877	ENSG00000227542.1	AC092614.2	-3.67	0.000265	0.0312	-0.2	-0.17	Urinary metabolites;	chr2:190280548	chr2:191229165~191246172:-
LUAD	cis	rs7246657	0.55	rs10411176	ENSG00000267309.1	CTD-2630F21.1	3.67	0.000265	0.0312	0.29	0.17	Coronary artery calcification;	chr19:37196051	chr19:36489649~36491040:+
LUAD	cis	rs2732480	0.557	rs2732454	ENSG00000257763.1	OR5BK1P	3.67	0.000265	0.0312	0.17	0.17	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48325894	chr12:48355792~48356614:-
LUAD	cis	rs2291447	0.618	rs7207047	ENSG00000214425.5	LRRC37A4P	-3.67	0.000265	0.0312	-0.2	-0.17	Economic and political preferences;	chr17:45121631	chr17:45506741~45550335:-
LUAD	cis	rs180730	1	rs1530799	ENSG00000251609.2	SETP12	3.67	0.000265	0.0312	0.25	0.17	Fasting plasma glucose;	chr4:120923267	chr4:120895494~120897083:-
LUAD	cis	rs10908557	0.709	rs72694300	ENSG00000223599.1	RP11-216N14.7	3.67	0.000265	0.0312	0.2	0.17	Age at first birth;	chr1:154084358	chr1:153852106~153853414:-
LUAD	cis	rs9341808	0.667	rs583426	ENSG00000272129.1	RP11-250B2.6	-3.67	0.000265	0.0312	-0.2	-0.17	Sitting height ratio;	chr6:80236970	chr6:80355424~80356859:+
LUAD	cis	rs7580658	0.613	rs12478656	ENSG00000236682.1	AC068282.3	-3.67	0.000265	0.0312	-0.22	-0.17	Protein C levels;	chr2:127438944	chr2:127389130~127400580:+
LUAD	cis	rs867186	1	rs11906148	ENSG00000222460.1	RN7SKP271	-3.67	0.000265	0.0312	-0.29	-0.17	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35196218	chr20:35643143~35643462:+
LUAD	cis	rs867186	1	rs117802529	ENSG00000222460.1	RN7SKP271	-3.67	0.000265	0.0312	-0.29	-0.17	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35198874	chr20:35643143~35643462:+
LUAD	cis	rs7107174	1	rs7127187	ENSG00000251323.2	RP11-452H21.4	3.67	0.000265	0.0312	0.22	0.17	Testicular germ cell tumor;	chr11:78284142	chr11:78423982~78429836:-
LUAD	cis	rs6438234	0.778	rs1072686	ENSG00000242767.1	ZBTB20-AS4	3.67	0.000265	0.0312	0.21	0.17	Type 2 diabetes;	chr3:115228686	chr3:115100423~115103061:+
LUAD	cis	rs10463554	0.927	rs34825	ENSG00000250682.4	LINC00491	3.67	0.000265	0.0312	0.2	0.17	Parkinson's disease;	chr5:103103614	chr5:102609156~102671559:-
LUAD	cis	rs10463554	0.963	rs34826	ENSG00000250682.4	LINC00491	3.67	0.000265	0.0312	0.2	0.17	Parkinson's disease;	chr5:103106044	chr5:102609156~102671559:-
LUAD	cis	rs7578361	0.959	rs7587837	ENSG00000231969.1	AC144449.1	-3.67	0.000265	0.0312	-0.24	-0.17	Acute lymphoblastic leukemia (childhood);	chr2:149598881	chr2:149587196~149848233:+
LUAD	cis	rs8031584	0.958	rs11293	ENSG00000259845.1	HERC2P10	3.67	0.000265	0.0312	0.19	0.17	Huntington's disease progression;	chr15:30942778	chr15:30815271~30844153:+
LUAD	cis	rs7246657	0.551	rs4806413	ENSG00000267309.1	CTD-2630F21.1	3.67	0.000265	0.0312	0.27	0.17	Coronary artery calcification;	chr19:37126814	chr19:36489649~36491040:+
LUAD	cis	rs1555322	0.53	rs2425049	ENSG00000261582.1	RP4-614O4.11	-3.67	0.000265	0.0312	-0.2	-0.17	Attention deficit hyperactivity disorder;	chr20:35286917	chr20:35267885~35280043:-
LUAD	cis	rs513088	0.681	rs494467	ENSG00000225171.2	DUTP6	3.67	0.000265	0.0312	0.22	0.17	Schizophrenia;	chr1:166692954	chr1:166868748~166869209:+
LUAD	cis	rs2274273	0.87	rs4597235	ENSG00000258413.1	RP11-665C16.6	-3.67	0.000265	0.0312	-0.21	-0.17	Protein biomarker;	chr14:55385269	chr14:55262767~55272075:-
LUAD	cis	rs526231	0.67	rs421946	ENSG00000175749.11	EIF3KP1	3.67	0.000265	0.0312	0.21	0.17	Primary biliary cholangitis;	chr5:103286340	chr5:103032376~103033031:+
LUAD	cis	rs1876905	0.62	rs354530	ENSG00000255389.1	C6orf3	3.67	0.000265	0.0312	0.22	0.17	Mean corpuscular hemoglobin;	chr6:111183286	chr6:111599875~111602295:+
LUAD	cis	rs5015933	0.902	rs10819047	ENSG00000232630.1	PRPS1P2	-3.67	0.000265	0.0312	-0.15	-0.17	Body mass index;	chr9:125365133	chr9:125150653~125151589:+
LUAD	cis	rs5015933	0.902	rs2291858	ENSG00000232630.1	PRPS1P2	-3.67	0.000265	0.0312	-0.15	-0.17	Body mass index;	chr9:125366503	chr9:125150653~125151589:+
LUAD	cis	rs763121	0.853	rs6519120	ENSG00000225450.1	RP3-508I15.14	3.67	0.000265	0.0312	0.17	0.17	Menopause (age at onset);	chr22:38595388	chr22:38739003~38749041:+
LUAD	cis	rs10129255	0.872	rs8015406	ENSG00000211967.3	IGHV3-53	-3.67	0.000265	0.0312	-0.13	-0.17	Kawasaki disease;	chr14:106670611	chr14:106592676~106593347:-
LUAD	cis	rs6001482	0.679	rs6001528	ENSG00000211642.2	IGLV10-54	3.67	0.000265	0.0312	0.19	0.17	Diastolic blood pressure;	chr22:22236511	chr22:22214794~22215270:+
LUAD	cis	rs911555	0.755	rs7147664	ENSG00000259775.1	RP11-45P15.4	-3.67	0.000265	0.0312	-0.22	-0.17	Intelligence (multi-trait analysis);	chr14:103497083	chr14:103331674~103332367:-
LUAD	cis	rs10504390	0.656	rs17395190	ENSG00000200714.1	Y_RNA	-3.67	0.000266	0.0312	-0.43	-0.17	IgG glycosylation;	chr8:65668823	chr8:65592731~65592820:+
LUAD	cis	rs2880765	0.506	rs719138	ENSG00000259407.1	RP11-158M2.3	-3.67	0.000266	0.0312	-0.16	-0.17	Coronary artery disease;	chr15:85511831	chr15:85744109~85750281:-
LUAD	cis	rs957448	0.607	rs12680842	ENSG00000253175.1	RP11-267M23.6	3.67	0.000266	0.0312	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94570378	chr8:94565036~94565715:+
LUAD	cis	rs874460	0.709	rs313839	ENSG00000211513.4	MIR320E	3.67	0.000266	0.0312	0.27	0.17	Chronic lymphocytic leukemia;	chr19:46718300	chr19:46709271~46709382:-
LUAD	cis	rs1044826	1	rs13092507	ENSG00000214280.3	RP11-553K23.2	-3.67	0.000266	0.0312	-0.2	-0.17	Obesity-related traits;	chr3:139433638	chr3:139582928~139583593:-
LUAD	cis	rs10129255	0.957	rs10136781	ENSG00000211947.2	IGHV3-21	-3.67	0.000266	0.0312	-0.11	-0.17	Kawasaki disease;	chr14:106780451	chr14:106235064~106235594:-
LUAD	cis	rs10129255	0.957	rs8022165	ENSG00000211947.2	IGHV3-21	-3.67	0.000266	0.0312	-0.11	-0.17	Kawasaki disease;	chr14:106781682	chr14:106235064~106235594:-
LUAD	cis	rs10129255	0.917	rs8022493	ENSG00000211947.2	IGHV3-21	-3.67	0.000266	0.0312	-0.11	-0.17	Kawasaki disease;	chr14:106781820	chr14:106235064~106235594:-
LUAD	cis	rs14027	0.512	rs7010808	ENSG00000279347.1	RP11-85I17.2	-3.67	0.000266	0.0312	-0.14	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119712216	chr8:119838736~119840385:-
LUAD	cis	rs7236632	0.582	rs9958388	ENSG00000267226.2	RP11-126O1.5	-3.67	0.000266	0.0312	-0.28	-0.17	Attention deficit hyperactivity disorder and conduct disorder;	chr18:57753320	chr18:58670009~58671877:-
LUAD	cis	rs13113518	0.966	rs4864544	ENSG00000273257.1	RP11-177J6.1	3.67	0.000266	0.0312	0.18	0.17	Height;	chr4:55515292	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs6847529	ENSG00000273257.1	RP11-177J6.1	3.67	0.000266	0.0312	0.18	0.17	Height;	chr4:55518776	chr4:55387949~55388271:+
LUAD	cis	rs9876781	1	rs6784322	ENSG00000229759.1	MRPS18AP1	3.67	0.000266	0.0312	0.16	0.17	Longevity;	chr3:48380745	chr3:48256350~48256938:-
LUAD	cis	rs7945705	0.837	rs10769966	ENSG00000254860.4	TMEM9B-AS1	-3.67	0.000266	0.0312	-0.19	-0.17	Hemoglobin concentration;	chr11:8825494	chr11:8964675~8977527:+
LUAD	cis	rs26232	0.52	rs26432	ENSG00000250682.4	LINC00491	-3.67	0.000266	0.0312	-0.2	-0.17	Rheumatoid arthritis;	chr5:103030006	chr5:102609156~102671559:-
LUAD	cis	rs4819052	0.851	rs4819049	ENSG00000215447.6	BX322557.10	-3.67	0.000266	0.0312	-0.2	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253171	chr21:45288052~45291738:+
LUAD	cis	rs2239547	0.657	rs6445539	ENSG00000243224.1	RP5-1157M23.2	-3.67	0.000266	0.0312	-0.18	-0.17	Schizophrenia;	chr3:52840280	chr3:52239258~52241097:+
LUAD	cis	rs2239547	0.657	rs7638524	ENSG00000243224.1	RP5-1157M23.2	-3.67	0.000266	0.0312	-0.18	-0.17	Schizophrenia;	chr3:52840845	chr3:52239258~52241097:+
LUAD	cis	rs4664293	0.867	rs13022404	ENSG00000230783.1	AC009961.2	-3.67	0.000266	0.0312	-0.21	-0.17	Monocyte percentage of white cells;	chr2:159732981	chr2:159689217~159690291:-
LUAD	cis	rs7119038	0.818	rs2155433	ENSG00000255239.1	AP002954.6	-3.67	0.000266	0.0312	-0.24	-0.17	Sjögren's syndrome;	chr11:118742212	chr11:118688039~118690600:-
LUAD	cis	rs4716602	0.586	rs13224457	ENSG00000235029.1	MNX1-AS2	-3.67	0.000266	0.0313	-0.2	-0.17	Anti-saccade response;	chr7:156368311	chr7:157006307~157007132:+
LUAD	cis	rs7216064	0.817	rs28609796	ENSG00000266717.1	RP11-855A2.3	3.67	0.000266	0.0313	0.2	0.17	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67858988	chr17:67950885~67951746:-
LUAD	cis	rs7015630	0.657	rs13278954	ENSG00000251136.7	RP11-37B2.1	-3.67	0.000266	0.0313	-0.22	-0.17	Inflammatory bowel disease;Crohn's disease;	chr8:89839830	chr8:89609409~89757727:-
LUAD	cis	rs7015630	0.697	rs34699769	ENSG00000251136.7	RP11-37B2.1	-3.67	0.000266	0.0313	-0.22	-0.17	Inflammatory bowel disease;Crohn's disease;	chr8:89841119	chr8:89609409~89757727:-
LUAD	cis	rs6951245	0.744	rs10265736	ENSG00000226291.1	AC091729.8	-3.67	0.000266	0.0313	-0.27	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1132829	chr7:1080863~1082178:+
LUAD	cis	rs11089937	0.597	rs5757027	ENSG00000211640.3	IGLV6-57	3.67	0.000266	0.0313	0.12	0.17	Periodontitis (PAL4Q3);	chr22:22137683	chr22:22195713~22196460:+
LUAD	cis	rs6951245	0.935	rs79143504	ENSG00000199023.2	MIR339	-3.67	0.000266	0.0313	-0.3	-0.17	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1070576	chr7:1022935~1023045:-
LUAD	cis	rs8062405	0.755	rs62031607	ENSG00000261766.1	RP11-22P6.2	-3.67	0.000266	0.0313	-0.15	-0.17	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620209	chr16:28862166~28863340:-
LUAD	cis	rs9309473	0.95	rs7596773	ENSG00000230002.2	ALMS1-IT1	3.67	0.000266	0.0313	0.21	0.17	Metabolite levels;	chr2:73618873	chr2:73456764~73459484:+
LUAD	cis	rs7015630	0.657	rs12155807	ENSG00000251136.7	RP11-37B2.1	-3.67	0.000266	0.0313	-0.22	-0.17	Inflammatory bowel disease;Crohn's disease;	chr8:89835484	chr8:89609409~89757727:-
LUAD	cis	rs35542019	1	rs35542019	ENSG00000237945.6	LINC00649	3.67	0.000266	0.0313	0.2	0.17	Hemoglobin concentration;Hematocrit;Red blood cell count;	chr21:33974555	chr21:33915534~33977691:+
LUAD	cis	rs2030114	1	rs7197626	ENSG00000224578.4	HNRNPA1P48	3.67	0.000266	0.0313	0.15	0.17	Blood pressure measurement (high sodium and potassium intervention);	chr16:51576874	chr16:51645756~51647132:+
LUAD	cis	rs6001482	0.573	rs4990163	ENSG00000211642.2	IGLV10-54	3.67	0.000266	0.0313	0.19	0.17	Diastolic blood pressure;	chr22:22233778	chr22:22214794~22215270:+
LUAD	cis	rs6494488	0.5	rs72744726	ENSG00000239465.1	RP11-330L19.2	3.67	0.000266	0.0313	0.35	0.17	Coronary artery disease;	chr15:64738796	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs72744729	ENSG00000239465.1	RP11-330L19.2	3.67	0.000266	0.0313	0.35	0.17	Coronary artery disease;	chr15:64746285	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs72744730	ENSG00000239465.1	RP11-330L19.2	3.67	0.000266	0.0313	0.35	0.17	Coronary artery disease;	chr15:64747866	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs72744734	ENSG00000239465.1	RP11-330L19.2	3.67	0.000266	0.0313	0.35	0.17	Coronary artery disease;	chr15:64750113	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs951721	ENSG00000239465.1	RP11-330L19.2	3.67	0.000266	0.0313	0.35	0.17	Coronary artery disease;	chr15:64752236	chr15:64631109~64631914:-
LUAD	cis	rs2837828	0.966	rs2205097	ENSG00000226496.2	LINC00323	3.67	0.000266	0.0313	0.21	0.17	Neutrophil count;	chr21:40800422	chr21:41141493~41148133:-
LUAD	cis	rs6088580	0.634	rs62212172	ENSG00000276073.1	RP5-1125A11.7	3.67	0.000266	0.0313	0.16	0.17	Glomerular filtration rate (creatinine);	chr20:34399899	chr20:33985617~33988989:-
LUAD	cis	rs6088580	0.634	rs4142007	ENSG00000276073.1	RP5-1125A11.7	3.67	0.000266	0.0313	0.16	0.17	Glomerular filtration rate (creatinine);	chr20:34402244	chr20:33985617~33988989:-
LUAD	cis	rs9381040	0.61	rs4140580	ENSG00000161912.16	ADCY10P1	3.67	0.000266	0.0313	0.14	0.17	Alzheimer's disease (late onset);	chr6:41074003	chr6:41101022~41140835:+
LUAD	cis	rs9381040	0.61	rs4140579	ENSG00000161912.16	ADCY10P1	3.67	0.000266	0.0313	0.14	0.17	Alzheimer's disease (late onset);	chr6:41074013	chr6:41101022~41140835:+
LUAD	cis	rs4908768	0.871	rs4908508	ENSG00000232912.4	RP5-1115A15.1	-3.67	0.000266	0.0313	-0.18	-0.17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8740721	chr1:8424645~8434838:+
LUAD	cis	rs3617	0.625	rs7617468	ENSG00000242142.1	SERBP1P3	3.67	0.000266	0.0313	0.18	0.17	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52815533	chr3:53064283~53065091:-
LUAD	cis	rs7077256	0.564	rs7915339	ENSG00000272767.1	JMJD1C-AS1	3.67	0.000266	0.0313	0.24	0.17	Intelligence (multi-trait analysis);	chr10:63407010	chr10:63465229~63466563:+
LUAD	cis	rs1348850	0.958	rs4243390	ENSG00000213963.5	AC074286.1	3.67	0.000266	0.0313	0.2	0.17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177603280	chr2:177283508~177392691:-
LUAD	cis	rs8014252	1	rs12586328	ENSG00000259158.2	ADAM20P1	-3.67	0.000266	0.0313	-0.26	-0.17	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70472288	chr14:70468881~70483756:-
LUAD	cis	rs1722141	0.633	rs903889	ENSG00000229628.1	AC073115.7	-3.67	0.000267	0.0313	-0.25	-0.17	Sitting height ratio;	chr7:45925396	chr7:45990905~46000898:+
LUAD	cis	rs9532563	0.55	rs61963699	ENSG00000229456.1	RLIMP1	3.67	0.000267	0.0313	0.26	0.17	Mean corpuscular volume;	chr13:40566345	chr13:40618738~40621348:+
LUAD	cis	rs763121	1	rs86796	ENSG00000225450.1	RP3-508I15.14	3.67	0.000267	0.0313	0.15	0.17	Menopause (age at onset);	chr22:38485449	chr22:38739003~38749041:+
LUAD	cis	rs2738459	0.569	rs2738456	ENSG00000267174.4	CTC-510F12.4	3.67	0.000267	0.0313	0.21	0.17	LDL cholesterol;	chr19:11126128	chr19:11300777~11324441:-
LUAD	cis	rs11992162	0.613	rs6601634	ENSG00000255046.1	RP11-297N6.4	3.67	0.000267	0.0313	0.2	0.17	Monocyte count;	chr8:11948947	chr8:11797928~11802568:-
LUAD	cis	rs1417205	1	rs1417202	ENSG00000276968.1	RP11-90M2.5	-3.67	0.000267	0.0313	-0.36	-0.17	Cannabis use (initiation);	chr13:47322292	chr13:48041751~48042184:-
LUAD	cis	rs950169	0.92	rs34672825	ENSG00000259570.1	RP11-671M22.4	3.67	0.000267	0.0313	0.25	0.17	Schizophrenia;	chr15:84034718	chr15:84394512~84395514:+
LUAD	cis	rs6081541	1	rs6081548	ENSG00000179447.2	RP5-1027G4.3	-3.67	0.000267	0.0314	-0.21	-0.17	Psychosis (atypical);	chr20:19249683	chr20:19242302~19284596:-
LUAD	cis	rs4683346	0.691	rs12488474	ENSG00000173811.9	CCDC13-AS1	-3.67	0.000267	0.0314	-0.2	-0.17	Granulocyte percentage of myeloid white cells;	chr3:42896185	chr3:42732575~42746768:+
LUAD	cis	rs3864277	0.51	rs31478	ENSG00000233006.5	AC034220.3	3.67	0.000267	0.0314	0.15	0.17	Itch intensity from mosquito bite adjusted by bite size;	chr5:132087782	chr5:132311285~132369916:-
LUAD	cis	rs2024714	0.902	rs28671463	ENSG00000273812.1	WI2-87327B8.2	-3.67	0.000267	0.0314	-0.18	-0.17	Longevity;	chr20:61641203	chr20:62596732~62603115:-
LUAD	cis	rs2024714	0.902	rs28698108	ENSG00000273812.1	WI2-87327B8.2	-3.67	0.000267	0.0314	-0.18	-0.17	Longevity;	chr20:61641213	chr20:62596732~62603115:-
LUAD	cis	rs1023500	0.596	rs133350	ENSG00000273366.1	CTA-989H11.1	-3.67	0.000267	0.0314	-0.2	-0.17	Schizophrenia;	chr22:42033045	chr22:42278188~42278846:+
LUAD	cis	rs6121246	0.567	rs6060295	ENSG00000230613.1	HM13-AS1	3.67	0.000267	0.0314	0.26	0.17	Mean corpuscular hemoglobin;	chr20:31610670	chr20:31567707~31573263:-
LUAD	cis	rs11955398	0.502	rs34591	ENSG00000272308.1	RP11-231G3.1	-3.67	0.000267	0.0314	-0.19	-0.17	Intelligence (multi-trait analysis);	chr5:61034039	chr5:60866457~60866935:-
LUAD	cis	rs4699052	0.59	rs1356293	ENSG00000246560.2	RP11-10L12.4	3.67	0.000267	0.0314	0.21	0.17	Testicular germ cell tumor;	chr4:103367043	chr4:102828055~102844075:+
LUAD	cis	rs4713118	0.513	rs149941	ENSG00000216901.1	AL022393.7	3.67	0.000267	0.0314	0.2	0.17	Parkinson's disease;	chr6:28033255	chr6:28176188~28176674:+
LUAD	cis	rs9309711	0.961	rs11692184	ENSG00000271868.1	RP11-1293J14.1	-3.67	0.000267	0.0314	-0.19	-0.17	Neurofibrillary tangles;	chr2:3476939	chr2:3496956~3497428:+
LUAD	cis	rs4705962	0.837	rs10062446	ENSG00000233006.5	AC034220.3	3.67	0.000267	0.0314	0.16	0.17	Atopic dermatitis;	chr5:132704682	chr5:132311285~132369916:-
LUAD	cis	rs12216545	0.765	rs7787639	ENSG00000241134.3	BET1P1	-3.67	0.000267	0.0314	-0.17	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150529528	chr7:150749736~150750094:+
LUAD	cis	rs12216545	0.737	rs7788962	ENSG00000241134.3	BET1P1	-3.67	0.000267	0.0314	-0.17	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150530139	chr7:150749736~150750094:+
LUAD	cis	rs138229	0.506	rs9628282	ENSG00000279182.1	XX-C00717C00720L.1	-3.67	0.000267	0.0314	-0.13	-0.17	Behavioural disinhibition (generation interaction);	chr22:50096523	chr22:50316035~50317025:+
LUAD	cis	rs8012947	1	rs12878264	ENSG00000279636.2	LINC00216	-3.67	0.000267	0.0314	-0.18	-0.17	Alcohol consumption in current drinkers;	chr14:58254250	chr14:58288033~58289158:+
LUAD	cis	rs6071166	0.513	rs6123987	ENSG00000224635.1	RP4-564F22.5	3.67	0.000267	0.0314	0.18	0.17	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38711002	chr20:38406011~38416797:-
LUAD	cis	rs7429990	0.93	rs11130152	ENSG00000228638.1	FCF1P2	3.67	0.000267	0.0314	0.2	0.17	Educational attainment (years of education);	chr3:48014919	chr3:48290793~48291375:-
LUAD	cis	rs1972460	0.506	rs62012050	ENSG00000259429.4	UBE2Q2P2	-3.67	0.000267	0.0314	-0.16	-0.17	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82355142~82420075:+
LUAD	cis	rs6910061	1	rs9468452	ENSG00000247925.2	RP3-510L9.1	-3.67	0.000267	0.0314	-0.23	-0.17	Diabetic kidney disease;	chr6:11121760	chr6:11173452~11259099:+
LUAD	cis	rs7937890	0.532	rs2575833	ENSG00000254418.1	RP11-21L19.1	3.67	0.000267	0.0314	0.19	0.17	Mitochondrial DNA levels;	chr11:14470959	chr11:14262846~14273691:-
LUAD	cis	rs17695224	0.545	rs8099997	ENSG00000269483.1	AC006272.1	3.67	0.000267	0.0314	0.18	0.17	HDL cholesterol;HDL cholesterol levels;	chr19:51842216	chr19:51839924~51843324:-
LUAD	cis	rs11159086	1	rs8006909	ENSG00000270000.1	RP3-449M8.9	3.67	0.000267	0.0314	0.24	0.17	Advanced glycation end-product levels;	chr14:74478085	chr14:74471930~74472360:-
LUAD	cis	rs11159086	1	rs8006958	ENSG00000270000.1	RP3-449M8.9	3.67	0.000267	0.0314	0.24	0.17	Advanced glycation end-product levels;	chr14:74478148	chr14:74471930~74472360:-
LUAD	cis	rs6005807	0.764	rs9620817	ENSG00000272858.1	CTA-292E10.8	-3.67	0.000267	0.0314	-0.3	-0.17	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28712568	chr22:28814914~28815662:+
LUAD	cis	rs7829975	0.593	rs2921061	ENSG00000233609.3	RP11-62H7.2	3.67	0.000267	0.0314	0.14	0.17	Mood instability;	chr8:8460105	chr8:8961200~8979025:+
LUAD	cis	rs2548724	1	rs2263376	ENSG00000250682.4	LINC00491	-3.67	0.000267	0.0314	-0.23	-0.17	Type 2 diabetes;	chr5:102269476	chr5:102609156~102671559:-
LUAD	cis	rs2548724	1	rs2600834	ENSG00000250682.4	LINC00491	-3.67	0.000267	0.0314	-0.23	-0.17	Type 2 diabetes;	chr5:102269937	chr5:102609156~102671559:-
LUAD	cis	rs6568686	0.786	rs9481155	ENSG00000255389.1	C6orf3	-3.67	0.000267	0.0314	-0.23	-0.17	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111508036	chr6:111599875~111602295:+
LUAD	cis	rs1075265	0.84	rs2884254	ENSG00000272156.1	RP11-477N3.1	-3.67	0.000268	0.0314	-0.2	-0.17	Chronotype;Morning vs. evening chronotype;	chr2:53979326	chr2:54082554~54085066:+
LUAD	cis	rs9925964	0.935	rs12597511	ENSG00000232748.3	RP11-196G11.6	3.67	0.000268	0.0314	0.21	0.17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31133898	chr16:31056460~31062803:+
LUAD	cis	rs78572108	0.858	rs746580	ENSG00000214691.7	AC104654.1	3.67	0.000268	0.0314	0.27	0.17	Total body bone mineral density;	chr2:42045522	chr2:41877074~41894046:+
LUAD	cis	rs7809950	0.773	rs62483722	ENSG00000238832.1	snoU109	-3.67	0.000268	0.0314	-0.24	-0.17	Coronary artery disease;	chr7:107545904	chr7:107603363~107603507:+
LUAD	cis	rs7809950	0.906	rs62483723	ENSG00000238832.1	snoU109	-3.67	0.000268	0.0314	-0.24	-0.17	Coronary artery disease;	chr7:107545913	chr7:107603363~107603507:+
LUAD	cis	rs7809950	0.953	rs2520267	ENSG00000238832.1	snoU109	-3.67	0.000268	0.0314	-0.24	-0.17	Coronary artery disease;	chr7:107547052	chr7:107603363~107603507:+
LUAD	cis	rs9409565	0.826	rs4744338	ENSG00000231806.2	PCAT7	3.67	0.000268	0.0314	0.23	0.17	Colorectal cancer (alcohol consumption interaction);	chr9:94396683	chr9:94555069~94568127:+
LUAD	cis	rs2229238	0.911	rs7551873	ENSG00000264384.2	RN7SL431P	-3.67	0.000268	0.0314	-0.18	-0.17	Coronary heart disease;	chr1:154533381	chr1:154166245~154166549:-
LUAD	cis	rs55704346	0.572	rs3822217	ENSG00000242640.1	RP11-302F12.1	-3.67	0.000268	0.0314	-0.15	-0.17	Tonsillectomy;	chr4:25377097	chr4:25678850~25679020:+
LUAD	cis	rs8056893	1	rs8056893	ENSG00000274698.1	RP11-71L14.4	3.67	0.000268	0.0314	0.19	0.17	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68270489	chr16:68450283~68452318:+
LUAD	cis	rs9287719	0.967	rs6432113	ENSG00000243819.4	RN7SL832P	-3.67	0.000268	0.0314	-0.17	-0.17	Prostate cancer;	chr2:10604763	chr2:10690344~10692099:+
LUAD	cis	rs9549260	0.564	rs4943808	ENSG00000168852.11	TPTE2P5	3.67	0.000268	0.0314	0.16	0.17	Red blood cell count;	chr13:40719814	chr13:40822296~40921749:-
LUAD	cis	rs9549260	0.564	rs4941989	ENSG00000168852.11	TPTE2P5	3.67	0.000268	0.0314	0.16	0.17	Red blood cell count;	chr13:40725551	chr13:40822296~40921749:-
LUAD	cis	rs9549260	0.564	rs4941990	ENSG00000168852.11	TPTE2P5	3.67	0.000268	0.0314	0.16	0.17	Red blood cell count;	chr13:40725721	chr13:40822296~40921749:-
LUAD	cis	rs1823913	0.637	rs979967	ENSG00000230611.1	HMGB1P27	-3.67	0.000268	0.0315	-0.19	-0.17	Obesity-related traits;	chr2:191304695	chr2:191174233~191174835:+
LUAD	cis	rs8002861	0.967	rs7321596	ENSG00000274001.1	RP11-5G9.5	3.67	0.000268	0.0315	0.17	0.17	Leprosy;	chr13:43898119	chr13:43877715~43878163:-
LUAD	cis	rs8002861	0.967	rs2166301	ENSG00000274001.1	RP11-5G9.5	3.67	0.000268	0.0315	0.17	0.17	Leprosy;	chr13:43899819	chr13:43877715~43878163:-
LUAD	cis	rs7107174	1	rs10793308	ENSG00000251323.2	RP11-452H21.4	3.67	0.000268	0.0315	0.2	0.17	Testicular germ cell tumor;	chr11:78374959	chr11:78423982~78429836:-
LUAD	cis	rs1023500	0.551	rs2301521	ENSG00000273366.1	CTA-989H11.1	-3.67	0.000268	0.0315	-0.2	-0.17	Schizophrenia;	chr22:42027106	chr22:42278188~42278846:+
LUAD	cis	rs6840360	0.571	rs10007653	ENSG00000270265.1	RP11-731D1.4	-3.67	0.000268	0.0315	-0.18	-0.17	Intelligence (multi-trait analysis);	chr4:151602903	chr4:151333775~151353224:-
LUAD	cis	rs12681963	0.858	rs62499790	ENSG00000272375.1	RP11-51J9.6	-3.67	0.000268	0.0315	-0.22	-0.17	Migraine;	chr8:30094955	chr8:30197404~30198048:+
LUAD	cis	rs1443267	1	rs3785489	ENSG00000229590.3	MSX2P1	-3.67	0.000268	0.0315	-0.23	-0.17	Obstetric antiphospholipid syndrome;	chr17:57839210	chr17:58157028~58157800:+
LUAD	cis	rs6661961	0.752	rs7529997	ENSG00000237975.5	FLG-AS1	-3.67	0.000268	0.0315	-0.22	-0.17	Atopic dermatitis;	chr1:152458670	chr1:152168125~152445456:+
LUAD	cis	rs11159086	0.793	rs28612392	ENSG00000270000.1	RP3-449M8.9	3.67	0.000268	0.0315	0.23	0.17	Advanced glycation end-product levels;	chr14:74467894	chr14:74471930~74472360:-
LUAD	cis	rs6479901	0.895	rs7918743	ENSG00000232075.1	MRPL35P2	-3.67	0.000268	0.0315	-0.23	-0.17	Intelligence (multi-trait analysis);	chr10:63333302	chr10:63634317~63634827:-
LUAD	cis	rs7845219	0.555	rs1129152	ENSG00000253528.2	RP11-347C18.4	3.67	0.000268	0.0315	0.16	0.17	Type 2 diabetes;	chr8:94876079	chr8:94974573~94974853:-
LUAD	cis	rs1431005	1	rs60320548	ENSG00000250658.1	RP11-138B4.1	3.67	0.000268	0.0315	0.2	0.17	Response to statin therapy;	chr4:187436265	chr4:187304083~187309682:-
LUAD	cis	rs987044	0.725	rs4964731	ENSG00000257221.1	RP11-689B22.2	-3.67	0.000268	0.0315	-0.14	-0.17	Mean platelet volume;	chr12:108664033	chr12:108628687~108641318:+
LUAD	cis	rs4795519	0.922	rs10163511	ENSG00000266313.1	RP11-173M1.4	3.67	0.000268	0.0315	0.2	0.17	Chronic myeloid leukemia;	chr17:27123761	chr17:27333256~27348491:+
LUAD	cis	rs6493858	0.61	rs2725840	ENSG00000277548.1	RP11-139H15.6	3.67	0.000268	0.0315	0.17	0.17	Relative hand skill in reading disability;	chr15:56296021	chr15:55346347~55346752:-
LUAD	cis	rs6496044	0.568	rs12708554	ENSG00000259416.2	RP11-158M2.5	3.67	0.000268	0.0315	0.17	0.17	Interstitial lung disease;	chr15:85531066	chr15:85754941~85756237:-
LUAD	cis	rs4561483	0.603	rs17235629	ENSG00000261560.1	RP11-166B2.3	-3.67	0.000268	0.0315	-0.15	-0.17	Testicular germ cell tumor;	chr16:11838564	chr16:11881075~11882569:-
LUAD	cis	rs910316	0.763	rs175450	ENSG00000259138.1	RP11-950C14.7	-3.67	0.000268	0.0315	-0.17	-0.17	Height;	chr14:75123637	chr14:75127153~75136930:+
LUAD	cis	rs898097	0.625	rs7406464	ENSG00000263063.1	RP11-388C12.1	-3.67	0.000268	0.0315	-0.17	-0.17	Breast cancer;	chr17:82933584	chr17:82713908~82716255:-
LUAD	cis	rs3002142	0.554	rs75711036	ENSG00000272750.1	RP11-378J18.8	3.67	0.000268	0.0315	0.27	0.17	LDL peak particle diameter (total fat intake interaction);	chr1:222666811	chr1:222658867~222661512:-
LUAD	cis	rs8114671	0.933	rs2103971	ENSG00000269202.1	RP4-614O4.12	3.67	0.000268	0.0315	0.16	0.17	Height;	chr20:35198453	chr20:35201747~35203288:-
LUAD	cis	rs2274273	0.648	rs58553156	ENSG00000258413.1	RP11-665C16.6	-3.67	0.000268	0.0315	-0.22	-0.17	Protein biomarker;	chr14:55115976	chr14:55262767~55272075:-
LUAD	cis	rs321358	1	rs321353	ENSG00000271390.1	RP11-89C3.3	-3.67	0.000268	0.0315	-0.27	-0.17	Body mass index;	chr11:111123841	chr11:111089870~111090368:-
LUAD	cis	rs2288073	0.619	rs6713263	ENSG00000242628.4	AC009228.1	3.67	0.000268	0.0315	0.21	0.17	Venous thromboembolism (SNP x SNP interaction);	chr2:24152593	chr2:24214381~24221516:+
LUAD	cis	rs9810888	0.63	rs1401494	ENSG00000271916.1	RP11-884K10.6	-3.67	0.000268	0.0315	-0.16	-0.17	Hypertension;Diastolic blood pressure;Systolic blood pressure;	chr3:53662928	chr3:53797764~53798019:-
LUAD	cis	rs8002861	0.935	rs1822969	ENSG00000274001.1	RP11-5G9.5	3.67	0.000268	0.0315	0.17	0.17	Leprosy;	chr13:43844028	chr13:43877715~43878163:-
LUAD	cis	rs259282	0.56	rs4805786	ENSG00000201388.1	SNORA68	3.67	0.000268	0.0315	0.17	0.17	Schizophrenia;	chr19:32629359	chr19:32608337~32608469:-
LUAD	cis	rs7949566	0.652	rs4937128	ENSG00000254671.2	STT3A-AS1	3.67	0.000269	0.0315	0.19	0.17	Platelet distribution width;Mean platelet volume;	chr11:126422701	chr11:125570284~125592568:-
LUAD	cis	rs524281	0.773	rs2298468	ENSG00000255320.1	RP11-755F10.1	3.67	0.000269	0.0315	0.26	0.17	Electroencephalogram traits;	chr11:66275491	chr11:66244840~66246239:-
LUAD	cis	rs7017914	0.837	rs2732105	ENSG00000246366.5	RP11-382J12.1	3.67	0.000269	0.0315	0.15	0.17	Bone mineral density;	chr8:71011410	chr8:70608577~70663279:+
LUAD	cis	rs11159086	1	rs11159086	ENSG00000270000.1	RP3-449M8.9	3.67	0.000269	0.0315	0.23	0.17	Advanced glycation end-product levels;	chr14:74495572	chr14:74471930~74472360:-
LUAD	cis	rs4723738	1	rs10282407	ENSG00000211699.2	TRGV3	-3.67	0.000269	0.0315	-0.17	-0.17	Treatment response for severe sepsis;	chr7:38193791	chr7:38358512~38359162:-
LUAD	cis	rs4853525	0.818	rs4853520	ENSG00000235852.1	AC005540.3	3.67	0.000269	0.0315	0.18	0.17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190854772	chr2:190880797~190882059:-
LUAD	cis	rs7017914	0.905	rs1908033	ENSG00000246366.5	RP11-382J12.1	3.67	0.000269	0.0315	0.15	0.17	Bone mineral density;	chr8:71010564	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.905	rs2732103	ENSG00000246366.5	RP11-382J12.1	3.67	0.000269	0.0315	0.15	0.17	Bone mineral density;	chr8:71011261	chr8:70608577~70663279:+
LUAD	cis	rs10752881	1	rs4593781	ENSG00000224468.3	RP11-181K3.4	-3.67	0.000269	0.0315	-0.15	-0.17	Colorectal cancer;	chr1:183015848	chr1:183138402~183141282:-
LUAD	cis	rs10752881	1	rs12028732	ENSG00000224468.3	RP11-181K3.4	-3.67	0.000269	0.0315	-0.15	-0.17	Colorectal cancer;	chr1:183016390	chr1:183138402~183141282:-
LUAD	cis	rs10752881	1	rs12028740	ENSG00000224468.3	RP11-181K3.4	-3.67	0.000269	0.0315	-0.15	-0.17	Colorectal cancer;	chr1:183016446	chr1:183138402~183141282:-
LUAD	cis	rs10752881	1	rs12035773	ENSG00000224468.3	RP11-181K3.4	-3.67	0.000269	0.0315	-0.15	-0.17	Colorectal cancer;	chr1:183016581	chr1:183138402~183141282:-
LUAD	cis	rs10752881	1	rs4402094	ENSG00000224468.3	RP11-181K3.4	-3.67	0.000269	0.0315	-0.15	-0.17	Colorectal cancer;	chr1:183017306	chr1:183138402~183141282:-
LUAD	cis	rs10752881	1	rs6424879	ENSG00000224468.3	RP11-181K3.4	-3.67	0.000269	0.0315	-0.15	-0.17	Colorectal cancer;	chr1:183017457	chr1:183138402~183141282:-
LUAD	cis	rs10752881	1	rs6424880	ENSG00000224468.3	RP11-181K3.4	-3.67	0.000269	0.0315	-0.15	-0.17	Colorectal cancer;	chr1:183017544	chr1:183138402~183141282:-
LUAD	cis	rs10752881	1	rs10752886	ENSG00000224468.3	RP11-181K3.4	-3.67	0.000269	0.0315	-0.15	-0.17	Colorectal cancer;	chr1:183018113	chr1:183138402~183141282:-
LUAD	cis	rs10170310	1	rs12691947	ENSG00000228043.4	AC097721.2	3.67	0.000269	0.0315	0.23	0.17	Response to antipsychotic treatment;	chr2:138506901	chr2:138418284~138501698:-
LUAD	cis	rs4118325	0.629	rs1762496	ENSG00000224550.1	RP11-270C12.3	-3.67	0.000269	0.0315	-0.2	-0.17	AIDS;	chr1:107091606	chr1:107505203~107505448:+
LUAD	cis	rs4474465	0.85	rs4945287	ENSG00000251323.2	RP11-452H21.4	-3.67	0.000269	0.0315	-0.21	-0.17	Alzheimer's disease (survival time);	chr11:78515475	chr11:78423982~78429836:-
LUAD	cis	rs2274273	0.87	rs1952087	ENSG00000259318.1	RP11-454L9.2	3.67	0.000269	0.0315	0.14	0.17	Protein biomarker;	chr14:55216493	chr14:55394940~55395233:-
LUAD	cis	rs875971	0.522	rs2008188	ENSG00000273142.1	RP11-458F8.4	-3.67	0.000269	0.0315	-0.11	-0.17	Aortic root size;	chr7:65964026	chr7:66902857~66906297:+
LUAD	cis	rs7246657	0.943	rs2303131	ENSG00000267470.4	ZNF571-AS1	3.67	0.000269	0.0315	0.24	0.17	Coronary artery calcification;	chr19:37445123	chr19:37548914~37587348:+
LUAD	cis	rs7246657	0.882	rs10422667	ENSG00000267470.4	ZNF571-AS1	3.67	0.000269	0.0315	0.24	0.17	Coronary artery calcification;	chr19:37446974	chr19:37548914~37587348:+
LUAD	cis	rs7246657	0.943	rs1015848	ENSG00000267470.4	ZNF571-AS1	3.67	0.000269	0.0315	0.24	0.17	Coronary artery calcification;	chr19:37454372	chr19:37548914~37587348:+
LUAD	cis	rs7246657	0.943	rs4801759	ENSG00000267470.4	ZNF571-AS1	3.67	0.000269	0.0315	0.24	0.17	Coronary artery calcification;	chr19:37464083	chr19:37548914~37587348:+
LUAD	cis	rs9840812	0.728	rs12635723	ENSG00000239213.4	NCK1-AS1	3.67	0.000269	0.0315	0.2	0.17	Fibrinogen levels;	chr3:136581890	chr3:136841726~136862054:-
LUAD	cis	rs763121	0.889	rs4820335	ENSG00000273076.1	RP3-508I15.22	-3.67	0.000269	0.0316	-0.15	-0.17	Menopause (age at onset);	chr22:38539922	chr22:38743495~38743910:+
LUAD	cis	rs7141336	1	rs6575154	ENSG00000258884.1	CTD-3035D6.2	3.67	0.000269	0.0316	0.17	0.17	Anxiety disorder;	chr14:90818361	chr14:90822365~90828128:-
LUAD	cis	rs4819052	0.851	rs2838842	ENSG00000215447.6	BX322557.10	-3.67	0.000269	0.0316	-0.19	-0.17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249302	chr21:45288052~45291738:+
LUAD	cis	rs79040073	0.53	rs1055254	ENSG00000259531.2	RP11-295H24.3	3.67	0.000269	0.0316	0.22	0.17	Lung cancer in ever smokers;	chr15:49328003	chr15:49365124~49366685:-
LUAD	cis	rs79040073	0.53	rs2078024	ENSG00000259531.2	RP11-295H24.3	3.67	0.000269	0.0316	0.22	0.17	Lung cancer in ever smokers;	chr15:49329413	chr15:49365124~49366685:-
LUAD	cis	rs10752881	1	rs10797811	ENSG00000224468.3	RP11-181K3.4	-3.67	0.000269	0.0316	-0.15	-0.17	Colorectal cancer;	chr1:183015297	chr1:183138402~183141282:-
LUAD	cis	rs67981189	0.542	rs1012725	ENSG00000269927.1	RP6-91H8.3	-3.67	0.000269	0.0316	-0.23	-0.17	Schizophrenia;	chr14:71138994	chr14:71141125~71143253:-
LUAD	cis	rs2380205	0.967	rs907685	ENSG00000232807.2	RP11-536K7.3	3.67	0.000269	0.0316	0.17	0.17	Breast cancer;	chr10:5858369	chr10:5934270~5945900:-
LUAD	cis	rs9894429	0.646	rs12948797	ENSG00000263853.1	AC139530.1	-3.67	0.000269	0.0316	-0.17	-0.17	Eye color traits;	chr17:81650354	chr17:81676001~81676086:+
LUAD	cis	rs7942368	1	rs4309181	ENSG00000254632.1	RP11-21L23.4	3.67	0.000269	0.0316	0.18	0.17	Endometriosis;	chr11:76790661	chr11:76759916~76768223:-
LUAD	cis	rs7584330	0.657	rs10211024	ENSG00000222032.1	AC112721.2	3.67	0.000269	0.0316	0.19	0.17	Prostate cancer;	chr2:237445133	chr2:237428920~237434822:-
LUAD	cis	rs2625529	0.652	rs2957734	ENSG00000260173.1	RP11-2I17.4	3.67	0.000269	0.0316	0.2	0.17	Red blood cell count;	chr15:71969044	chr15:72140504~72155459:-
LUAD	cis	rs1198430	0.925	rs2510072	ENSG00000232482.2	RP4-654C18.1	-3.67	0.000269	0.0316	-0.28	-0.17	Total cholesterol levels;	chr1:23443181	chr1:23410832~23412146:+
LUAD	cis	rs9928842	1	rs9928842	ENSG00000261476.1	RP11-77K12.3	-3.67	0.000269	0.0316	-0.22	-0.17	Alcoholic chronic pancreatitis;	chr16:75208969	chr16:75458252~75460017:-
LUAD	cis	rs7942368	1	rs10899280	ENSG00000254632.1	RP11-21L23.4	3.67	0.000269	0.0316	0.18	0.17	Endometriosis;	chr11:76785693	chr11:76759916~76768223:-
LUAD	cis	rs6540731	1	rs11119885	ENSG00000229983.1	RP11-15I11.2	3.67	0.000269	0.0316	0.2	0.17	Intelligence (childhood);	chr1:212227656	chr1:212168207~212190259:+
LUAD	cis	rs2880765	0.546	rs11637726	ENSG00000259407.1	RP11-158M2.3	3.67	0.000269	0.0316	0.16	0.17	Coronary artery disease;	chr15:85516040	chr15:85744109~85750281:-
LUAD	cis	rs6928977	0.675	rs6908428	ENSG00000231028.7	LINC00271	-3.67	0.000269	0.0316	-0.19	-0.17	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135472568	chr6:135497801~135716055:+
LUAD	cis	rs1056107	0.7	rs10817274	ENSG00000225513.1	RP11-165N19.2	-3.67	0.000269	0.0316	-0.18	-0.17	Colorectal cancer;	chr9:112167691	chr9:112173522~112173971:-
LUAD	cis	rs6137287	0.667	rs6047338	ENSG00000227063.5	RPL41P1	-3.67	0.000269	0.0316	-0.22	-0.17	Height;	chr20:21265351	chr20:21755270~21755350:+
LUAD	cis	rs7512552	0.839	rs1694385	ENSG00000275557.1	RP11-353N4.6	3.67	0.000269	0.0316	0.19	0.17	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150405484	chr1:149607765~149612402:+
LUAD	cis	rs76878669	0.561	rs2279861	ENSG00000213409.4	RP11-658F2.3	3.67	0.000269	0.0316	0.2	0.17	Educational attainment (years of education);	chr11:66365865	chr11:66761575~66762399:-
LUAD	cis	rs7604827	0.778	rs10932535	ENSG00000230076.1	AC016708.2	3.67	0.000269	0.0316	0.24	0.17	PR interval;	chr2:214407245	chr2:214847128~214847445:+
LUAD	cis	rs2880765	0.546	rs8042776	ENSG00000259295.5	CSPG4P12	3.67	0.000269	0.0316	0.2	0.17	Coronary artery disease;	chr15:85512398	chr15:85191438~85213905:+
LUAD	cis	rs9907295	0.591	rs8080959	ENSG00000270977.1	AC015849.16	-3.67	0.00027	0.0316	-0.22	-0.17	Fibroblast growth factor basic levels;	chr17:35813450	chr17:35893707~35911023:-
LUAD	cis	rs957448	1	rs12679345	ENSG00000254057.1	RP3-388N13.3	3.67	0.00027	0.0316	0.18	0.17	Nonsyndromic cleft lip with cleft palate;	chr8:94552305	chr8:93834454~93846743:-
LUAD	cis	rs3770081	1	rs6750765	ENSG00000273080.1	RP11-301O19.1	-3.67	0.00027	0.0316	-0.4	-0.17	Facial emotion recognition (sad faces);	chr2:86073185	chr2:86195590~86196049:+
LUAD	cis	rs73198271	0.71	rs11779561	ENSG00000233609.3	RP11-62H7.2	-3.67	0.00027	0.0316	-0.14	-0.17	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8822478	chr8:8961200~8979025:+
LUAD	cis	rs453301	0.522	rs2929455	ENSG00000173295.6	FAM86B3P	-3.67	0.00027	0.0316	-0.18	-0.17	Joint mobility (Beighton score);	chr8:9225923	chr8:8228595~8244865:+
LUAD	cis	rs748404	0.626	rs57938858	ENSG00000249839.1	AC011330.5	-3.67	0.00027	0.0316	-0.26	-0.17	Lung cancer;	chr15:43520259	chr15:43663654~43684339:-
LUAD	cis	rs9951698	0.703	rs475139	ENSG00000266969.1	RP11-773H22.4	3.67	0.00027	0.0316	0.22	0.17	Intelligence (multi-trait analysis);	chr18:13141397	chr18:12984694~12991173:-
LUAD	cis	rs2638953	0.861	rs11049685	ENSG00000278733.1	RP11-425D17.1	-3.67	0.00027	0.0316	-0.19	-0.17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28512775	chr12:28185625~28186190:-
LUAD	cis	rs6928977	0.675	rs11154803	ENSG00000231028.7	LINC00271	-3.67	0.00027	0.0316	-0.19	-0.17	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135477707	chr6:135497801~135716055:+
LUAD	cis	rs35520189	0.591	rs12465526	ENSG00000227368.1	AC079753.5	3.67	0.00027	0.0316	0.2	0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112942404	chr2:112932625~112933171:+
LUAD	cis	rs35520189	0.591	rs67995749	ENSG00000227368.1	AC079753.5	3.67	0.00027	0.0316	0.2	0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112943315	chr2:112932625~112933171:+
LUAD	cis	rs35520189	0.591	rs12466653	ENSG00000227368.1	AC079753.5	3.67	0.00027	0.0316	0.2	0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112943411	chr2:112932625~112933171:+
LUAD	cis	rs35520189	0.556	rs12470439	ENSG00000227368.1	AC079753.5	3.67	0.00027	0.0316	0.2	0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112943587	chr2:112932625~112933171:+
LUAD	cis	rs35520189	0.591	rs6722962	ENSG00000227368.1	AC079753.5	3.67	0.00027	0.0316	0.2	0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112943806	chr2:112932625~112933171:+
LUAD	cis	rs35520189	0.591	rs6733001	ENSG00000227368.1	AC079753.5	3.67	0.00027	0.0316	0.2	0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112943870	chr2:112932625~112933171:+
LUAD	cis	rs35520189	0.591	rs6733003	ENSG00000227368.1	AC079753.5	3.67	0.00027	0.0316	0.2	0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112943875	chr2:112932625~112933171:+
LUAD	cis	rs35520189	0.591	rs6723197	ENSG00000227368.1	AC079753.5	3.67	0.00027	0.0316	0.2	0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112944021	chr2:112932625~112933171:+
LUAD	cis	rs35520189	0.591	rs6705432	ENSG00000227368.1	AC079753.5	3.67	0.00027	0.0316	0.2	0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112944247	chr2:112932625~112933171:+
LUAD	cis	rs35520189	0.591	rs12614988	ENSG00000227368.1	AC079753.5	3.67	0.00027	0.0316	0.2	0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112944601	chr2:112932625~112933171:+
LUAD	cis	rs35520189	0.591	rs12466604	ENSG00000227368.1	AC079753.5	3.67	0.00027	0.0316	0.2	0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112945487	chr2:112932625~112933171:+
LUAD	cis	rs35520189	0.591	rs12464758	ENSG00000227368.1	AC079753.5	3.67	0.00027	0.0316	0.2	0.17	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112945704	chr2:112932625~112933171:+
LUAD	cis	rs6438234	0.778	rs9289011	ENSG00000242767.1	ZBTB20-AS4	3.67	0.00027	0.0316	0.21	0.17	Type 2 diabetes;	chr3:115211989	chr3:115100423~115103061:+
LUAD	cis	rs987724	0.593	rs2874494	ENSG00000240875.4	LINC00886	-3.67	0.00027	0.0316	-0.18	-0.17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156964340	chr3:156747346~156817062:-
LUAD	cis	rs7809950	1	rs10251808	ENSG00000238832.1	snoU109	-3.67	0.00027	0.0316	-0.24	-0.17	Coronary artery disease;	chr7:107480008	chr7:107603363~107603507:+
LUAD	cis	rs755249	0.917	rs61779331	ENSG00000182109.6	RP11-69E11.4	3.67	0.00027	0.0316	0.2	0.17	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39505256	chr1:39522280~39546187:-
LUAD	cis	rs9595908	0.746	rs3848087	ENSG00000281026.1	N4BP2L2-IT2	-3.67	0.00027	0.0316	-0.1	-0.17	Body mass index;	chr13:32697637	chr13:32504506~32509395:-
LUAD	cis	rs76734026	0.515	rs10149000	ENSG00000255002.1	CTD-2509G16.2	-3.67	0.00027	0.0316	-0.29	-0.17	Pediatric areal bone mineral density (radius);	chr14:65248675	chr14:65212893~65222347:-
LUAD	cis	rs76734026	0.515	rs12436594	ENSG00000255002.1	CTD-2509G16.2	-3.67	0.00027	0.0316	-0.29	-0.17	Pediatric areal bone mineral density (radius);	chr14:65248822	chr14:65212893~65222347:-
LUAD	cis	rs76734026	0.551	rs28850312	ENSG00000255002.1	CTD-2509G16.2	-3.67	0.00027	0.0316	-0.29	-0.17	Pediatric areal bone mineral density (radius);	chr14:65249330	chr14:65212893~65222347:-
LUAD	cis	rs76734026	0.515	rs12100912	ENSG00000255002.1	CTD-2509G16.2	-3.67	0.00027	0.0316	-0.29	-0.17	Pediatric areal bone mineral density (radius);	chr14:65249920	chr14:65212893~65222347:-
LUAD	cis	rs2911280	0.764	rs7196069	ENSG00000259867.4	RP11-525K10.3	3.67	0.00027	0.0317	0.38	0.17	Dehydroepiandrosterone sulphate levels;	chr16:81527851	chr16:80155053~80563135:-
LUAD	cis	rs7107174	1	rs2511157	ENSG00000251323.2	RP11-452H21.4	3.67	0.00027	0.0317	0.23	0.17	Testicular germ cell tumor;	chr11:78261586	chr11:78423982~78429836:-
LUAD	cis	rs6095360	0.934	rs6095395	ENSG00000222365.1	SNORD12B	-3.67	0.00027	0.0317	-0.17	-0.17	Intelligence (multi-trait analysis);	chr20:49010558	chr20:49280319~49280409:+
LUAD	cis	rs1850744	0.609	rs6448959	ENSG00000249767.1	ENPP7P10	-3.67	0.00027	0.0317	-0.41	-0.17	Economic and political preferences;	chr4:9682303	chr4:9079023~9141608:+
LUAD	cis	rs1850744	0.702	rs13104360	ENSG00000249767.1	ENPP7P10	-3.67	0.00027	0.0317	-0.41	-0.17	Economic and political preferences;	chr4:9683180	chr4:9079023~9141608:+
LUAD	cis	rs2548724	0.812	rs434771	ENSG00000250682.4	LINC00491	-3.67	0.00027	0.0317	-0.21	-0.17	Type 2 diabetes;	chr5:102261084	chr5:102609156~102671559:-
LUAD	cis	rs1075265	0.756	rs3821081	ENSG00000272156.1	RP11-477N3.1	3.67	0.00027	0.0317	0.19	0.17	Chronotype;Morning vs. evening chronotype;	chr2:53738252	chr2:54082554~54085066:+
LUAD	cis	rs797680	0.786	rs7525248	ENSG00000223745.6	RP4-717I23.3	3.67	0.00027	0.0317	0.13	0.17	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93362966	chr1:93262186~93346025:-
LUAD	cis	rs797680	0.786	rs4847412	ENSG00000223745.6	RP4-717I23.3	3.67	0.00027	0.0317	0.13	0.17	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93363691	chr1:93262186~93346025:-
LUAD	cis	rs651907	0.557	rs34376498	ENSG00000244119.1	PDCL3P4	3.67	0.00027	0.0317	0.16	0.17	Colorectal cancer;	chr3:101761312	chr3:101712472~101713191:+
LUAD	cis	rs4907240	0.961	rs12469420	ENSG00000237510.6	AC008268.2	3.67	0.00027	0.0317	0.23	0.17	Event-related brain oscillations;	chr2:96577568	chr2:95789654~95800166:+
LUAD	cis	rs11233413	0.829	rs11233422	ENSG00000246067.6	RAB30-AS1	-3.67	0.00027	0.0317	-0.18	-0.17	Economic and political preferences (feminism/equality);	chr11:83019480	chr11:83072066~83106719:+
LUAD	cis	rs1858037	0.867	rs67817304	ENSG00000237979.1	AC007389.1	3.67	0.00027	0.0317	0.21	0.17	Rheumatoid arthritis;	chr2:65346982	chr2:65500993~65502138:-
LUAD	cis	rs62244186	0.566	rs55901755	ENSG00000233509.2	ZNF197-AS1	3.67	0.00027	0.0317	0.18	0.17	Depressive symptoms;	chr3:44793215	chr3:44617128~44624797:-
LUAD	cis	rs9889262	0.602	rs57345398	ENSG00000248714.5	RP11-1079K10.3	3.67	0.00027	0.0317	0.16	0.17	Eosinophil percentage of granulocytes;Allergic disease (asthma, hay fever or eczema);Eosinophil counts;	chr17:49280088	chr17:49361165~49369998:+
LUAD	cis	rs9889262	0.602	rs11079868	ENSG00000248714.5	RP11-1079K10.3	3.67	0.00027	0.0317	0.16	0.17	Eosinophil percentage of granulocytes;Allergic disease (asthma, hay fever or eczema);Eosinophil counts;	chr17:49280607	chr17:49361165~49369998:+
LUAD	cis	rs9889262	0.602	rs4794034	ENSG00000248714.5	RP11-1079K10.3	3.67	0.00027	0.0317	0.16	0.17	Eosinophil percentage of granulocytes;Allergic disease (asthma, hay fever or eczema);Eosinophil counts;	chr17:49281198	chr17:49361165~49369998:+
LUAD	cis	rs9467773	1	rs9467779	ENSG00000228223.2	HCG11	3.67	0.00027	0.0317	0.18	0.17	Intelligence (multi-trait analysis);	chr6:26536459	chr6:26523450~26526579:+
LUAD	cis	rs6726292	0.539	rs34928331	ENSG00000272156.1	RP11-477N3.1	-3.67	0.00027	0.0317	-0.25	-0.17	Obesity (extreme);	chr2:55000247	chr2:54082554~54085066:+
LUAD	cis	rs4578769	0.513	rs34623893	ENSG00000266850.1	RP11-370A5.1	3.67	0.00027	0.0317	0.21	0.17	Eosinophil percentage of white cells;	chr18:22967224	chr18:22723491~22907721:-
LUAD	cis	rs4578769	0.55	rs8087501	ENSG00000266850.1	RP11-370A5.1	3.67	0.00027	0.0317	0.21	0.17	Eosinophil percentage of white cells;	chr18:22970711	chr18:22723491~22907721:-
LUAD	cis	rs7200786	0.528	rs8045630	ENSG00000274038.1	RP11-66H6.4	-3.67	0.00027	0.0317	-0.21	-0.17	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11137483	chr16:11056556~11057034:+
LUAD	cis	rs6121246	0.529	rs6060291	ENSG00000230613.1	HM13-AS1	3.67	0.00027	0.0317	0.26	0.17	Mean corpuscular hemoglobin;	chr20:31610240	chr20:31567707~31573263:-
LUAD	cis	rs2535633	0.602	rs2581816	ENSG00000243224.1	RP5-1157M23.2	-3.67	0.000271	0.0317	-0.18	-0.17	Body mass index;	chr3:52980641	chr3:52239258~52241097:+
LUAD	cis	rs11250098	0.503	rs7821826	ENSG00000255310.2	AF131215.2	-3.67	0.000271	0.0317	-0.16	-0.17	Morning vs. evening chronotype;	chr8:10911929	chr8:11107788~11109726:-
LUAD	cis	rs11159086	0.793	rs8015894	ENSG00000270000.1	RP3-449M8.9	3.67	0.000271	0.0317	0.23	0.17	Advanced glycation end-product levels;	chr14:74491917	chr14:74471930~74472360:-
LUAD	cis	rs2235642	0.821	rs2281236	ENSG00000280231.1	LA16c-380F5.3	-3.67	0.000271	0.0317	-0.22	-0.17	Coronary artery disease;	chr16:1553575	chr16:1553655~1554130:-
LUAD	cis	rs17711722	0.701	rs781145	ENSG00000273142.1	RP11-458F8.4	-3.67	0.000271	0.0317	-0.12	-0.17	Calcium levels;	chr7:65975383	chr7:66902857~66906297:+
LUAD	cis	rs4268898	1	rs4268898	ENSG00000242628.4	AC009228.1	-3.67	0.000271	0.0317	-0.22	-0.17	Asthma;	chr2:24267544	chr2:24214381~24221516:+
LUAD	cis	rs9308731	0.563	rs6760053	ENSG00000227992.1	AC108463.2	-3.67	0.000271	0.0317	-0.19	-0.16	Chronic lymphocytic leukemia;	chr2:111175420	chr2:111203964~111206215:-
LUAD	cis	rs442309	0.812	rs224092	ENSG00000238280.1	RP11-436D10.3	-3.67	0.000271	0.0317	-0.2	-0.16	Vogt-Koyanagi-Harada syndrome;	chr10:62781644	chr10:62793562~62805887:-
LUAD	cis	rs12122100	0.696	rs12733095	ENSG00000244371.2	PFN1P8	3.67	0.000271	0.0317	0.21	0.16	HIV-1 control;	chr1:147074193	chr1:146957117~146957659:-
LUAD	cis	rs7017914	0.905	rs2639898	ENSG00000246366.5	RP11-382J12.1	3.67	0.000271	0.0317	0.15	0.16	Bone mineral density;	chr8:71008075	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.84	rs2732099	ENSG00000246366.5	RP11-382J12.1	3.67	0.000271	0.0317	0.15	0.16	Bone mineral density;	chr8:71008815	chr8:70608577~70663279:+
LUAD	cis	rs10761482	0.566	rs7092863	ENSG00000254271.1	RP11-131N11.4	3.67	0.000271	0.0317	0.2	0.16	Schizophrenia;	chr10:60421124	chr10:60734342~60741828:+
LUAD	cis	rs72799341	1	rs7185007	ENSG00000232748.3	RP11-196G11.6	-3.67	0.000271	0.0318	-0.23	-0.16	Diastolic blood pressure;	chr16:30916188	chr16:31056460~31062803:+
LUAD	cis	rs7615952	0.546	rs11718647	ENSG00000243429.1	OR7E29P	3.67	0.000271	0.0318	0.22	0.16	Blood pressure (smoking interaction);	chr3:125633178	chr3:125712139~125713045:+
LUAD	cis	rs721917	0.531	rs2758553	ENSG00000230091.5	TMEM254-AS1	3.67	0.000271	0.0318	0.21	0.16	Chronic obstructive pulmonary disease;	chr10:79931624	chr10:80046860~80078912:-
LUAD	cis	rs6088580	0.634	rs945673	ENSG00000276073.1	RP5-1125A11.7	3.67	0.000271	0.0318	0.16	0.16	Glomerular filtration rate (creatinine);	chr20:34376459	chr20:33985617~33988989:-
LUAD	cis	rs9341808	0.754	rs3805907	ENSG00000260645.1	RP11-250B2.5	-3.67	0.000271	0.0318	-0.15	-0.16	Sitting height ratio;	chr6:80263948	chr6:80466958~80469080:+
LUAD	cis	rs4473651	0.551	rs12644506	ENSG00000214846.4	RP11-115L11.1	3.67	0.000271	0.0318	0.44	0.16	Blood protein levels;	chr4:15798255	chr4:15730962~15731627:-
LUAD	cis	rs2074409	0.509	rs853219	ENSG00000276054.1	RP11-378E13.3	-3.67	0.000271	0.0318	-0.2	-0.16	Response to angiotensin II receptor blocker therapy;	chr17:37427296	chr17:37386886~37387926:+
LUAD	cis	rs7829975	0.606	rs7819827	ENSG00000253981.4	ALG1L13P	-3.67	0.000271	0.0318	-0.19	-0.16	Mood instability;	chr8:8939545	chr8:8236003~8244667:-
LUAD	cis	rs7829975	0.573	rs7842359	ENSG00000253981.4	ALG1L13P	-3.67	0.000271	0.0318	-0.19	-0.16	Mood instability;	chr8:8939568	chr8:8236003~8244667:-
LUAD	cis	rs67981189	0.865	rs34488204	ENSG00000269927.1	RP6-91H8.3	3.67	0.000271	0.0318	0.21	0.16	Schizophrenia;	chr14:71028571	chr14:71141125~71143253:-
LUAD	cis	rs3096299	0.504	rs4785574	ENSG00000182376.2	RP5-1142A6.8	3.67	0.000271	0.0318	0.17	0.16	Multiple myeloma (IgH translocation);	chr16:89502467	chr16:88742767~88745748:+
LUAD	cis	rs9309473	0.847	rs4547554	ENSG00000230002.2	ALMS1-IT1	3.67	0.000271	0.0318	0.21	0.16	Metabolite levels;	chr2:73640735	chr2:73456764~73459484:+
LUAD	cis	rs6453278	0.559	rs3934500	ENSG00000250802.5	ZBED3-AS1	-3.67	0.000271	0.0318	-0.2	-0.16	Autism;	chr5:77098071	chr5:77086740~77166909:+
LUAD	cis	rs4763879	0.778	rs1056151	ENSG00000214776.8	RP11-726G1.1	-3.67	0.000271	0.0318	-0.19	-0.16	Type 1 diabetes;	chr12:9698427	chr12:9467552~9576275:+
LUAD	cis	rs6502050	0.835	rs35555954	ENSG00000275966.1	RP11-1055B8.9	-3.67	0.000271	0.0318	-0.17	-0.16	Life satisfaction;	chr17:82164562	chr17:81345476~81345966:-
LUAD	cis	rs4795519	1	rs12449779	ENSG00000266313.1	RP11-173M1.4	3.67	0.000271	0.0318	0.2	0.16	Chronic myeloid leukemia;	chr17:27083289	chr17:27333256~27348491:+
LUAD	cis	rs9322193	0.607	rs9383941	ENSG00000268592.3	RAET1E-AS1	-3.67	0.000271	0.0318	-0.24	-0.16	Lung cancer;	chr6:149912100	chr6:149863494~149919507:+
LUAD	cis	rs4595586	1	rs1523118	ENSG00000257718.1	RP11-396F22.1	-3.67	0.000271	0.0318	-0.2	-0.16	Morning vs. evening chronotype;	chr12:38835897	chr12:38906451~38909592:+
LUAD	cis	rs8098244	0.737	rs1258147	ENSG00000264745.1	TTC39C-AS1	-3.67	0.000271	0.0318	-0.2	-0.16	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23939672	chr18:23994213~24015339:-
LUAD	cis	rs12122100	0.837	rs12742539	ENSG00000227242.3	NBPF13P	-3.67	0.000271	0.0318	-0.21	-0.16	HIV-1 control;	chr1:147036289	chr1:147021320~147124525:-
LUAD	cis	rs11992162	0.507	rs60902764	ENSG00000255046.1	RP11-297N6.4	3.67	0.000271	0.0318	0.21	0.16	Monocyte count;	chr8:11927482	chr8:11797928~11802568:-
LUAD	cis	rs62355901	0.505	rs17661089	ENSG00000271828.1	CTD-2310F14.1	3.67	0.000271	0.0318	0.35	0.16	Breast cancer;	chr5:56810169	chr5:56927874~56929573:+
LUAD	cis	rs748404	0.666	rs7180812	ENSG00000249839.1	AC011330.5	-3.67	0.000271	0.0318	-0.26	-0.16	Lung cancer;	chr15:43403033	chr15:43663654~43684339:-
LUAD	cis	rs7829975	0.514	rs2976929	ENSG00000233609.3	RP11-62H7.2	3.67	0.000271	0.0318	0.14	0.16	Mood instability;	chr8:8401202	chr8:8961200~8979025:+
LUAD	cis	rs2154319	0.887	rs6698511	ENSG00000235358.1	RP11-399E6.1	3.67	0.000271	0.0318	0.23	0.16	Height;	chr1:41079478	chr1:41242373~41284861:+
LUAD	cis	rs2057178	0.627	rs10835883	ENSG00000183242.10	WT1-AS	3.67	0.000271	0.0318	0.24	0.16	Tuberculosis;	chr11:32307019	chr11:32435518~32458769:+
LUAD	cis	rs2274273	0.638	rs58269011	ENSG00000258413.1	RP11-665C16.6	-3.67	0.000271	0.0318	-0.23	-0.16	Protein biomarker;	chr14:55217670	chr14:55262767~55272075:-
LUAD	cis	rs2274273	0.638	rs9919921	ENSG00000258413.1	RP11-665C16.6	-3.67	0.000271	0.0318	-0.23	-0.16	Protein biomarker;	chr14:55228787	chr14:55262767~55272075:-
LUAD	cis	rs26232	0.583	rs26430	ENSG00000250682.4	LINC00491	-3.67	0.000271	0.0318	-0.2	-0.16	Rheumatoid arthritis;	chr5:103030228	chr5:102609156~102671559:-
LUAD	cis	rs34929064	0.881	rs7802442	ENSG00000232949.1	AC002480.4	3.67	0.000271	0.0318	0.2	0.16	Major depression and alcohol dependence;	chr7:22696827	chr7:22589705~22591622:+
LUAD	cis	rs2274273	0.624	rs3783651	ENSG00000258413.1	RP11-665C16.6	-3.67	0.000272	0.0318	-0.22	-0.16	Protein biomarker;	chr14:55384255	chr14:55262767~55272075:-
LUAD	cis	rs13113518	1	rs13114841	ENSG00000273257.1	RP11-177J6.1	3.67	0.000272	0.0318	0.18	0.16	Height;	chr4:55485974	chr4:55387949~55388271:+
LUAD	cis	rs4118325	0.734	rs1762490	ENSG00000224550.1	RP11-270C12.3	-3.67	0.000272	0.0318	-0.2	-0.16	AIDS;	chr1:107089919	chr1:107505203~107505448:+
LUAD	cis	rs4118325	0.697	rs1762491	ENSG00000224550.1	RP11-270C12.3	-3.67	0.000272	0.0318	-0.2	-0.16	AIDS;	chr1:107090309	chr1:107505203~107505448:+
LUAD	cis	rs797680	0.786	rs1593512	ENSG00000223745.6	RP4-717I23.3	3.67	0.000272	0.0318	0.13	0.16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93392817	chr1:93262186~93346025:-
LUAD	cis	rs2274273	0.805	rs10131926	ENSG00000259318.1	RP11-454L9.2	3.67	0.000272	0.0318	0.15	0.16	Protein biomarker;	chr14:55246528	chr14:55394940~55395233:-
LUAD	cis	rs2548724	1	rs2600825	ENSG00000250682.4	LINC00491	-3.67	0.000272	0.0318	-0.22	-0.16	Type 2 diabetes;	chr5:102284760	chr5:102609156~102671559:-
LUAD	cis	rs7142881	0.815	rs7149572	ENSG00000258525.1	RP11-829H16.3	-3.67	0.000272	0.0318	-0.19	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31581682	chr14:30876179~30889808:-
LUAD	cis	rs7142881	0.815	rs7154174	ENSG00000258525.1	RP11-829H16.3	-3.67	0.000272	0.0318	-0.19	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31581916	chr14:30876179~30889808:-
LUAD	cis	rs4853525	0.923	rs7578618	ENSG00000235852.1	AC005540.3	3.67	0.000272	0.0318	0.19	0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190868631	chr2:190880797~190882059:-
LUAD	cis	rs2905347	0.895	rs2905308	ENSG00000232949.1	AC002480.4	-3.67	0.000272	0.0318	-0.19	-0.16	Major depression and alcohol dependence;	chr7:22608575	chr7:22589705~22591622:+
LUAD	cis	rs14027	0.64	rs16893071	ENSG00000279347.1	RP11-85I17.2	-3.67	0.000272	0.0318	-0.14	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119738183	chr8:119838736~119840385:-
LUAD	cis	rs7107174	1	rs10899467	ENSG00000251323.2	RP11-452H21.4	3.67	0.000272	0.0318	0.22	0.16	Testicular germ cell tumor;	chr11:78303011	chr11:78423982~78429836:-
LUAD	cis	rs6738440	0.51	rs10490071	ENSG00000234624.2	AC016894.1	3.67	0.000272	0.0318	0.2	0.16	F-cell distribution;	chr2:60441755	chr2:61416887~61417197:-
LUAD	cis	rs987044	0.596	rs12579105	ENSG00000257221.1	RP11-689B22.2	-3.67	0.000272	0.0318	-0.14	-0.16	Mean platelet volume;	chr12:108693078	chr12:108628687~108641318:+
LUAD	cis	rs1075265	0.87	rs6724389	ENSG00000272156.1	RP11-477N3.1	-3.67	0.000272	0.0318	-0.2	-0.16	Chronotype;Morning vs. evening chronotype;	chr2:53985698	chr2:54082554~54085066:+
LUAD	cis	rs72799341	1	rs35675346	ENSG00000232748.3	RP11-196G11.6	-3.67	0.000272	0.0318	-0.22	-0.16	Diastolic blood pressure;	chr16:30924760	chr16:31056460~31062803:+
LUAD	cis	rs61884328	0.85	rs79232684	ENSG00000254780.1	RP11-793I11.1	3.67	0.000272	0.0318	0.37	0.16	Total body bone mineral density (age over 60);	chr11:47150163	chr11:47905323~47905607:-
LUAD	cis	rs7210990	0.575	rs1045599	ENSG00000276855.1	CTD-3157E16.2	-3.67	0.000272	0.0318	-0.2	-0.16	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr17:15976596	chr17:15789016~15789705:+
LUAD	cis	rs10435719	0.805	rs13269417	ENSG00000255046.1	RP11-297N6.4	-3.67	0.000272	0.0319	-0.21	-0.16	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11934453	chr8:11797928~11802568:-
LUAD	cis	rs4718428	0.705	rs4718422	ENSG00000230295.1	RP11-458F8.2	-3.67	0.000272	0.0319	-0.15	-0.16	Corneal structure;	chr7:66894282	chr7:66880708~66882981:+
LUAD	cis	rs4718428	0.705	rs13231140	ENSG00000230295.1	RP11-458F8.2	-3.67	0.000272	0.0319	-0.15	-0.16	Corneal structure;	chr7:66896631	chr7:66880708~66882981:+
LUAD	cis	rs2749097	0.609	rs12122838	ENSG00000244256.3	RN7SL130P	-3.67	0.000272	0.0319	-0.22	-0.16	Alcohol consumption (transferrin glycosylation);	chr1:63646498	chr1:63655743~63656047:+
LUAD	cis	rs7512552	0.839	rs698919	ENSG00000275557.1	RP11-353N4.6	3.67	0.000272	0.0319	0.19	0.16	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150414524	chr1:149607765~149612402:+
LUAD	cis	rs6502050	0.835	rs12051747	ENSG00000275966.1	RP11-1055B8.9	-3.67	0.000272	0.0319	-0.17	-0.16	Life satisfaction;	chr17:82156938	chr17:81345476~81345966:-
LUAD	cis	rs7515577	0.853	rs76600721	ENSG00000223787.2	RP4-593M8.1	3.67	0.000272	0.0319	0.25	0.16	Cholesterol, total;	chr1:92411460	chr1:92580476~92580821:-
LUAD	cis	rs1005224	0.895	rs11624114	ENSG00000242952.1	RP11-187O7.1	-3.67	0.000272	0.0319	-0.16	-0.16	Large artery stroke;	chr14:75665457	chr14:76634775~76635661:-
LUAD	cis	rs564309	0.867	rs12082349	ENSG00000231563.1	RP11-245P10.4	-3.67	0.000272	0.0319	-0.3	-0.16	Hip circumference (psychosocial stress interaction);	chr1:228383884	chr1:228407381~228409694:+
LUAD	cis	rs2613964	0.504	rs4682466	ENSG00000244144.1	RP11-757F18.3	-3.67	0.000272	0.0319	-0.19	-0.16	Pediatric bone mineral content (spine);Pediatric bone mineral density (spine);	chr3:113130841	chr3:112185480~112185998:-
LUAD	cis	rs240993	0.812	rs10214442	ENSG00000271789.1	RP5-1112D6.7	-3.67	0.000272	0.0319	-0.2	-0.16	Inflammatory skin disease;Psoriasis;	chr6:111431857	chr6:111297126~111298510:+
LUAD	cis	rs10463554	0.75	rs26257	ENSG00000250682.4	LINC00491	3.67	0.000272	0.0319	0.21	0.16	Parkinson's disease;	chr5:103214830	chr5:102609156~102671559:-
LUAD	cis	rs2002133	0.741	rs17014410	ENSG00000236682.1	AC068282.3	3.67	0.000272	0.0319	0.25	0.16	Initial pursuit acceleration;	chr2:126768654	chr2:127389130~127400580:+
LUAD	cis	rs990171	0.538	rs4851014	ENSG00000234389.1	AC007278.3	3.67	0.000272	0.0319	0.16	0.16	Lymphocyte counts;	chr2:102499817	chr2:102438713~102440475:+
LUAD	cis	rs7605235	0.874	rs17802463	ENSG00000224165.4	DNAJC27-AS1	3.67	0.000272	0.0319	0.19	0.16	Response to platinum-based chemotherapy (cisplatin);	chr2:25420352	chr2:24971390~25039694:+
LUAD	cis	rs3026445	0.855	rs6606686	ENSG00000278993.1	RP3-424M6.4	-3.67	0.000272	0.0319	-0.18	-0.16	QT interval;	chr12:110465575	chr12:110501614~110503441:+
LUAD	cis	rs225245	0.61	rs321607	ENSG00000267592.1	CTC-507E2.2	3.67	0.000272	0.0319	0.18	0.16	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr17:35553565	chr17:35596904~35597128:-
LUAD	cis	rs225245	0.61	rs321608	ENSG00000267592.1	CTC-507E2.2	3.67	0.000272	0.0319	0.18	0.16	High light scatter reticulocyte count;Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr17:35553617	chr17:35596904~35597128:-
LUAD	cis	rs10861342	0.786	rs12303948	ENSG00000257999.1	RP11-61E11.2	-3.67	0.000272	0.0319	-0.42	-0.16	IgG glycosylation;	chr12:105197791	chr12:105102472~105107179:-
LUAD	cis	rs9303542	1	rs9890488	ENSG00000264920.1	RP11-6N17.4	-3.67	0.000272	0.0319	-0.21	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48309587	chr17:47891255~47895812:-
LUAD	cis	rs9303542	1	rs9916227	ENSG00000264920.1	RP11-6N17.4	-3.67	0.000272	0.0319	-0.21	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48312550	chr17:47891255~47895812:-
LUAD	cis	rs6496932	0.663	rs11074169	ENSG00000218052.5	ADAMTS7P4	-3.67	0.000272	0.0319	-0.19	-0.16	Central corneal thickness;Corneal structure;	chr15:85375721	chr15:85255369~85330334:-
LUAD	cis	rs2731006	0.592	rs2255231	ENSG00000257114.2	RP11-25I15.3	-3.67	0.000272	0.0319	-0.26	-0.16	Panic disorder;	chr12:42775101	chr12:42692216~42717119:+
LUAD	cis	rs1910358	0.591	rs12659609	ENSG00000248874.4	C5orf17	-3.67	0.000272	0.0319	-0.21	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23974976	chr5:23951348~24178263:+
LUAD	cis	rs2115630	0.645	rs6496284	ENSG00000275120.1	RP11-182J1.17	-3.67	0.000272	0.0319	-0.21	-0.16	P wave terminal force;	chr15:84635039	chr15:84599434~84606463:-
LUAD	cis	rs76878669	0.515	rs947978	ENSG00000213409.4	RP11-658F2.3	3.67	0.000272	0.0319	0.2	0.16	Educational attainment (years of education);	chr11:66341189	chr11:66761575~66762399:-
LUAD	cis	rs1348850	0.757	rs2166554	ENSG00000213963.5	AC074286.1	3.67	0.000272	0.0319	0.2	0.16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177591096	chr2:177283508~177392691:-
LUAD	cis	rs2836950	0.545	rs2836940	ENSG00000232608.1	TIMM9P2	3.67	0.000273	0.0319	0.19	0.16	Menarche (age at onset);	chr21:39216770	chr21:39216624~39217506:+
LUAD	cis	rs7077256	0.564	rs17740722	ENSG00000272767.1	JMJD1C-AS1	3.67	0.000273	0.0319	0.25	0.16	Intelligence (multi-trait analysis);	chr10:63378839	chr10:63465229~63466563:+
LUAD	cis	rs10829156	0.699	rs1917209	ENSG00000240291.1	RP11-499P20.2	3.67	0.000273	0.0319	0.15	0.16	Sudden cardiac arrest;	chr10:18543631	chr10:18513115~18545651:-
LUAD	cis	rs12681366	0.511	rs2919670	ENSG00000253704.1	RP11-267M23.4	3.67	0.000273	0.0319	0.2	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94444390	chr8:94553722~94569745:+
LUAD	cis	rs12681366	0.537	rs2197004	ENSG00000253704.1	RP11-267M23.4	3.67	0.000273	0.0319	0.2	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94444748	chr8:94553722~94569745:+
LUAD	cis	rs7829975	0.509	rs7838674	ENSG00000253981.4	ALG1L13P	-3.67	0.000273	0.0319	-0.19	-0.16	Mood instability;	chr8:8939563	chr8:8236003~8244667:-
LUAD	cis	rs13113518	1	rs12501636	ENSG00000223305.1	RN7SKP30	3.67	0.000273	0.0319	0.19	0.16	Height;	chr4:55482317	chr4:55540502~55540835:-
LUAD	cis	rs404005	0.643	rs388470	ENSG00000227028.5	SLC8A1-AS1	-3.67	0.000273	0.0319	-0.22	-0.16	HIV-associated dementia;	chr2:40184716	chr2:39786453~40255209:+
LUAD	cis	rs8072100	0.837	rs8070463	ENSG00000228782.6	CTD-2026D20.3	3.67	0.000273	0.0319	0.17	0.16	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47691470	chr17:47450568~47492492:-
LUAD	cis	rs7017914	0.967	rs13274381	ENSG00000246366.5	RP11-382J12.1	3.67	0.000273	0.0319	0.15	0.16	Bone mineral density;	chr8:70852859	chr8:70608577~70663279:+
LUAD	cis	rs73607972	0.569	rs34115013	ENSG00000275191.1	RP11-36I17.2	-3.67	0.000273	0.0319	-0.21	-0.16	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53534324	chr16:53628256~53628816:-
LUAD	cis	rs7107174	1	rs2511158	ENSG00000251323.2	RP11-452H21.4	3.67	0.000273	0.0319	0.23	0.16	Testicular germ cell tumor;	chr11:78262934	chr11:78423982~78429836:-
LUAD	cis	rs801193	0.569	rs7782587	ENSG00000273448.1	RP11-166O4.6	3.67	0.000273	0.0319	0.16	0.16	Aortic root size;	chr7:66701485	chr7:67333047~67334383:+
LUAD	cis	rs801193	0.569	rs4717315	ENSG00000273448.1	RP11-166O4.6	3.67	0.000273	0.0319	0.16	0.16	Aortic root size;	chr7:66713338	chr7:67333047~67334383:+
LUAD	cis	rs801193	0.527	rs2707837	ENSG00000273448.1	RP11-166O4.6	3.67	0.000273	0.0319	0.16	0.16	Aortic root size;	chr7:66716086	chr7:67333047~67334383:+
LUAD	cis	rs17772222	0.682	rs2274736	ENSG00000258983.2	RP11-507K2.2	3.67	0.000273	0.0319	0.18	0.16	Coronary artery calcification;	chr14:88472308	chr14:88499334~88515502:+
LUAD	cis	rs9860428	0.526	rs6784838	ENSG00000242770.2	RP11-180K7.1	3.67	0.000273	0.0319	0.17	0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112944432	chr3:112802478~112812819:+
LUAD	cis	rs1032726	0.753	rs9870335	ENSG00000242770.2	RP11-180K7.1	3.67	0.000273	0.0319	0.17	0.16	Sum eosinophil basophil counts;Eosinophil counts;	chr3:112945570	chr3:112802478~112812819:+
LUAD	cis	rs35934224	0.769	rs77611691	ENSG00000232926.1	AC000078.5	3.67	0.000273	0.0319	0.23	0.16	Glaucoma (primary open-angle);	chr22:19858734	chr22:19887289~19887970:+
LUAD	cis	rs2548724	0.773	rs432190	ENSG00000250682.4	LINC00491	-3.67	0.000273	0.0319	-0.21	-0.16	Type 2 diabetes;	chr5:102252254	chr5:102609156~102671559:-
LUAD	cis	rs2548724	0.812	rs431778	ENSG00000250682.4	LINC00491	-3.67	0.000273	0.0319	-0.21	-0.16	Type 2 diabetes;	chr5:102255718	chr5:102609156~102671559:-
LUAD	cis	rs2548724	0.773	rs261102	ENSG00000250682.4	LINC00491	-3.67	0.000273	0.0319	-0.21	-0.16	Type 2 diabetes;	chr5:102256197	chr5:102609156~102671559:-
LUAD	cis	rs2548724	0.812	rs402846	ENSG00000250682.4	LINC00491	-3.67	0.000273	0.0319	-0.21	-0.16	Type 2 diabetes;	chr5:102256781	chr5:102609156~102671559:-
LUAD	cis	rs2708977	0.637	rs597420	ENSG00000237510.6	AC008268.2	-3.67	0.000273	0.0319	-0.21	-0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96404615	chr2:95789654~95800166:+
LUAD	cis	rs17711722	0.727	rs2658585	ENSG00000222364.1	RNU6-96P	-3.67	0.000273	0.032	-0.18	-0.16	Calcium levels;	chr7:65996954	chr7:66395191~66395286:+
LUAD	cis	rs7578361	1	rs6724414	ENSG00000231969.1	AC144449.1	-3.67	0.000273	0.032	-0.24	-0.16	Acute lymphoblastic leukemia (childhood);	chr2:149574840	chr2:149587196~149848233:+
LUAD	cis	rs7578361	1	rs12232959	ENSG00000231969.1	AC144449.1	-3.67	0.000273	0.032	-0.24	-0.16	Acute lymphoblastic leukemia (childhood);	chr2:149575863	chr2:149587196~149848233:+
LUAD	cis	rs17597773	0.638	rs6541161	ENSG00000272823.1	RP11-295M18.6	-3.67	0.000273	0.032	-0.21	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220820922	chr1:220828676~220829211:-
LUAD	cis	rs7811142	1	rs73161762	ENSG00000078319.8	PMS2P1	-3.67	0.000273	0.032	-0.21	-0.16	Platelet count;	chr7:100417223	chr7:100320992~100341908:-
LUAD	cis	rs2253017	0.767	rs4770070	ENSG00000275485.1	RP11-261P13.6	-3.67	0.000273	0.032	-0.22	-0.16	PR segment;	chr13:20756637	chr13:20768876~20769375:-
LUAD	cis	rs72799341	0.706	rs889555	ENSG00000273724.1	RP11-347C12.12	-3.67	0.000273	0.032	-0.18	-0.16	Diastolic blood pressure;	chr16:31111250	chr16:30336400~30343336:+
LUAD	cis	rs9381040	0.61	rs2268196	ENSG00000161912.16	ADCY10P1	-3.67	0.000273	0.032	-0.14	-0.16	Alzheimer's disease (late onset);	chr6:41054211	chr6:41101022~41140835:+
LUAD	cis	rs35123781	0.696	rs356429	ENSG00000250635.1	CTD-3224K15.2	-3.67	0.000273	0.032	-0.19	-0.16	Schizophrenia;	chr5:139693558	chr5:139648999~139649728:-
LUAD	cis	rs72634501	0.642	rs67452844	ENSG00000182109.6	RP11-69E11.4	3.67	0.000273	0.032	0.19	0.16	HDL cholesterol;	chr1:39150610	chr1:39522280~39546187:-
LUAD	cis	rs6964587	1	rs4644173	ENSG00000188693.7	CYP51A1-AS1	-3.67	0.000273	0.032	-0.19	-0.16	Breast cancer;	chr7:92130283	chr7:92134604~92180725:+
LUAD	cis	rs56875752	1	rs72811281	ENSG00000263648.1	RP11-471L13.3	3.67	0.000273	0.032	0.34	0.16	Fear of pain;Fear of severe pain;	chr17:12696763	chr17:12115547~12115885:+
LUAD	cis	rs944990	0.538	rs10821166	ENSG00000227603.1	RP11-165J3.6	3.67	0.000273	0.032	0.19	0.16	Body mass index;	chr9:93589641	chr9:93435332~93437121:-
LUAD	cis	rs1575891	1	rs1853988	ENSG00000276968.1	RP11-90M2.5	-3.67	0.000273	0.032	-0.19	-0.16	Cardiac hypertrophy;	chr13:47629853	chr13:48041751~48042184:-
LUAD	cis	rs11886999	0.68	rs62152972	ENSG00000237510.6	AC008268.2	-3.67	0.000273	0.032	-0.29	-0.16	Cardiac Troponin-T levels;	chr2:96176915	chr2:95789654~95800166:+
LUAD	cis	rs11886999	0.638	rs73958180	ENSG00000237510.6	AC008268.2	-3.67	0.000273	0.032	-0.29	-0.16	Cardiac Troponin-T levels;	chr2:96178365	chr2:95789654~95800166:+
LUAD	cis	rs2274273	0.624	rs10146637	ENSG00000258413.1	RP11-665C16.6	-3.67	0.000273	0.032	-0.22	-0.16	Protein biomarker;	chr14:55278092	chr14:55262767~55272075:-
LUAD	cis	rs2736345	0.535	rs4366049	ENSG00000270154.1	RP11-419I17.1	3.67	0.000273	0.032	0.19	0.16	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11540995	chr8:12476462~12477122:+
LUAD	cis	rs9951698	0.678	rs71353243	ENSG00000266969.1	RP11-773H22.4	3.67	0.000273	0.032	0.21	0.16	Intelligence (multi-trait analysis);	chr18:13134998	chr18:12984694~12991173:-
LUAD	cis	rs56309584	0.596	rs8075078	ENSG00000226871.1	AC135178.7	3.67	0.000273	0.032	0.23	0.16	Initial pursuit acceleration;	chr17:8282778	chr17:8318088~8318712:-
LUAD	cis	rs683250	0.598	rs625102	ENSG00000246067.6	RAB30-AS1	3.67	0.000273	0.032	0.18	0.16	Subcortical brain region volumes;	chr11:83241066	chr11:83072066~83106719:+
LUAD	cis	rs11158345	1	rs11158345	ENSG00000258926.1	RP11-47I22.1	3.67	0.000274	0.032	0.18	0.16	Word reading;	chr14:61428327	chr14:61537508~61545287:-
LUAD	cis	rs12724450	0.793	rs11809332	ENSG00000228126.1	FALEC	3.67	0.000274	0.032	0.3	0.16	Blood protein levels;	chr1:150345342	chr1:150515757~150518032:+
LUAD	cis	rs6951245	1	rs78158942	ENSG00000224079.1	AC091729.7	-3.67	0.000274	0.032	-0.26	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1050804	chr7:1074450~1078036:+
LUAD	cis	rs1577917	0.655	rs9444352	ENSG00000220563.1	PKMP3	3.67	0.000274	0.032	0.15	0.16	Response to antipsychotic treatment;	chr6:85547817	chr6:85659892~85660606:-
LUAD	cis	rs12935418	0.616	rs55776427	ENSG00000278985.1	RP11-303E16.9	3.67	0.000274	0.032	0.15	0.16	Mean corpuscular volume;	chr16:80971999	chr16:80982319~80984094:-
LUAD	cis	rs17065868	1	rs9533938	ENSG00000214455.4	RCN1P2	-3.67	0.000274	0.032	-0.34	-0.16	Antineutrophil cytoplasmic antibody-associated vasculitis;	chr13:44648660	chr13:45390353~45391267:-
LUAD	cis	rs8046148	0.724	rs8052492	ENSG00000279356.1	RP11-429P3.8	-3.67	0.000274	0.032	-0.16	-0.16	Testicular germ cell tumor;	chr16:50065836	chr16:50072862~50074986:+
LUAD	cis	rs1598856	0.873	rs230510	ENSG00000246560.2	RP11-10L12.4	-3.67	0.000274	0.032	-0.21	-0.16	Primary biliary cholangitis;	chr4:102555009	chr4:102828055~102844075:+
LUAD	cis	rs4664293	0.867	rs6761145	ENSG00000230783.1	AC009961.2	-3.67	0.000274	0.032	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159725673	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs6732987	ENSG00000230783.1	AC009961.2	-3.67	0.000274	0.032	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159725918	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs7589941	ENSG00000230783.1	AC009961.2	-3.67	0.000274	0.032	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159727589	chr2:159689217~159690291:-
LUAD	cis	rs2154319	0.887	rs2144788	ENSG00000235358.1	RP11-399E6.1	3.67	0.000274	0.032	0.23	0.16	Height;	chr1:41066772	chr1:41242373~41284861:+
LUAD	cis	rs745109	0.504	rs74432925	ENSG00000273080.1	RP11-301O19.1	3.67	0.000274	0.032	0.27	0.16	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86386592	chr2:86195590~86196049:+
LUAD	cis	rs935334	1	rs2121077	ENSG00000258454.1	RP11-361H10.3	-3.67	0.000274	0.032	-0.24	-0.16	Blood pressure;	chr14:76210012	chr14:76235817~76263474:+
LUAD	cis	rs1993709	0.617	rs2630397	ENSG00000227207.2	RPL31P12	3.67	0.000274	0.032	0.2	0.16	Obesity (early onset extreme);	chr1:72116283	chr1:72301472~72301829:+
LUAD	cis	rs2921073	0.604	rs2979140	ENSG00000253981.4	ALG1L13P	3.67	0.000274	0.032	0.19	0.16	Parkinson's disease;	chr8:8409692	chr8:8236003~8244667:-
LUAD	cis	rs935334	1	rs2121075	ENSG00000258454.1	RP11-361H10.3	3.67	0.000274	0.032	0.24	0.16	Blood pressure;	chr14:76209197	chr14:76235817~76263474:+
LUAD	cis	rs7015630	0.657	rs6984540	ENSG00000251136.7	RP11-37B2.1	-3.67	0.000274	0.032	-0.22	-0.16	Inflammatory bowel disease;Crohn's disease;	chr8:89835724	chr8:89609409~89757727:-
LUAD	cis	rs7870753	0.838	rs2181071	ENSG00000188801.9	ZNF322P1	3.67	0.000274	0.032	0.24	0.16	Height;	chr9:96497462	chr9:97198303~97199511:-
LUAD	cis	rs1979679	0.918	rs10843187	ENSG00000278733.1	RP11-425D17.1	-3.67	0.000274	0.032	-0.21	-0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28483586	chr12:28185625~28186190:-
LUAD	cis	rs7242404	0.57	rs11662231	ENSG00000267654.1	RP11-973H7.4	3.67	0.000274	0.032	0.19	0.16	Interleukin-9 levels;Macrophage inflammatory protein 1a levels;	chr18:12758033	chr18:12739490~12749421:-
LUAD	cis	rs6500602	0.727	rs4786509	ENSG00000280063.1	RP11-295D4.3	-3.67	0.000274	0.032	-0.11	-0.16	Schizophrenia;	chr16:4518768	chr16:4346694~4348648:-
LUAD	cis	rs8141529	0.732	rs2239815	ENSG00000272858.1	CTA-292E10.8	3.67	0.000274	0.032	0.18	0.16	Lymphocyte counts;	chr22:28796682	chr22:28814914~28815662:+
LUAD	cis	rs703842	1	rs11172349	ENSG00000245651.2	RP11-620J15.2	3.67	0.000274	0.032	0.17	0.16	Multiple sclerosis;	chr12:57818745	chr12:57869835~57896482:-
LUAD	cis	rs17608059	0.545	rs9944522	ENSG00000236088.8	COX10-AS1	-3.67	0.000274	0.032	-0.18	-0.16	Temperament;	chr17:14015466	chr17:13756478~14069495:-
LUAD	cis	rs13113518	0.934	rs11133397	ENSG00000273257.1	RP11-177J6.1	3.67	0.000274	0.032	0.18	0.16	Height;	chr4:55534166	chr4:55387949~55388271:+
LUAD	cis	rs13113518	0.934	rs11133398	ENSG00000273257.1	RP11-177J6.1	3.67	0.000274	0.032	0.18	0.16	Height;	chr4:55534180	chr4:55387949~55388271:+
LUAD	cis	rs6832769	1	rs10002541	ENSG00000272969.1	RP11-528I4.2	-3.67	0.000274	0.032	-0.17	-0.16	Personality dimensions;	chr4:55528844	chr4:55547112~55547889:+
LUAD	cis	rs16866061	1	rs11694987	ENSG00000228446.2	AC073052.1	-3.67	0.000274	0.032	-0.19	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr2:224532692	chr2:224499387~224500100:-
LUAD	cis	rs728616	0.867	rs61860412	ENSG00000234382.2	RP11-40F6.1	-3.67	0.000274	0.0321	-0.4	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79968730	chr10:80233664~80245367:+
LUAD	cis	rs4474465	0.92	rs10899526	ENSG00000251323.2	RP11-452H21.4	-3.67	0.000274	0.0321	-0.2	-0.16	Alzheimer's disease (survival time);	chr11:78495111	chr11:78423982~78429836:-
LUAD	cis	rs9652601	0.622	rs1003603	ENSG00000280153.1	RP11-876N24.3	-3.67	0.000274	0.0321	-0.11	-0.16	Systemic lupus erythematosus;	chr16:11020766	chr16:10933903~10936280:+
LUAD	cis	rs75804782	0.557	rs10178728	ENSG00000229915.1	AC016999.2	3.67	0.000274	0.0321	0.27	0.16	Chronotype;Morning vs. evening chronotype;	chr2:238451480	chr2:238427077~238427729:-
LUAD	cis	rs854765	0.964	rs854764	ENSG00000223979.2	SMCR2	3.67	0.000274	0.0321	0.19	0.16	Total body bone mineral density;	chr17:18108436	chr17:17674026~17677688:-
LUAD	cis	rs9860428	0.583	rs1466872	ENSG00000242770.2	RP11-180K7.1	3.67	0.000274	0.0321	0.17	0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112928766	chr3:112802478~112812819:+
LUAD	cis	rs875971	0.638	rs6960778	ENSG00000222364.1	RNU6-96P	3.67	0.000274	0.0321	0.18	0.16	Aortic root size;	chr7:66606610	chr7:66395191~66395286:+
LUAD	cis	rs3733585	0.683	rs3796839	ENSG00000250413.1	RP11-448G15.1	-3.67	0.000274	0.0321	-0.21	-0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:10008293	chr4:10006482~10009725:+
LUAD	cis	rs4908769	0.627	rs2252865	ENSG00000232912.4	RP5-1115A15.1	-3.67	0.000274	0.0321	-0.16	-0.16	Allergy;	chr1:8362616	chr1:8424645~8434838:+
LUAD	cis	rs5758659	0.623	rs133328	ENSG00000227370.1	RP4-669P10.19	-3.67	0.000274	0.0321	-0.15	-0.16	Cognitive function;	chr22:42012075	chr22:42132543~42132998:+
LUAD	cis	rs11158026	0.574	rs58055971	ENSG00000258413.1	RP11-665C16.6	-3.67	0.000274	0.0321	-0.22	-0.16	Parkinson's disease;	chr14:54969606	chr14:55262767~55272075:-
LUAD	cis	rs13113518	1	rs10462032	ENSG00000223305.1	RN7SKP30	3.67	0.000274	0.0321	0.19	0.16	Height;	chr4:55479069	chr4:55540502~55540835:-
LUAD	cis	rs11742741	0.967	rs72747803	ENSG00000248874.4	C5orf17	-3.67	0.000274	0.0321	-0.2	-0.16	Educational attainment;	chr5:24202777	chr5:23951348~24178263:+
LUAD	cis	rs6502050	0.769	rs9916231	ENSG00000275966.1	RP11-1055B8.9	-3.67	0.000274	0.0321	-0.17	-0.16	Life satisfaction;	chr17:82161769	chr17:81345476~81345966:-
LUAD	cis	rs8056893	0.714	rs4783554	ENSG00000260441.4	RP11-96D1.7	-3.67	0.000275	0.0321	-0.19	-0.16	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68350107	chr16:68256162~68260443:-
LUAD	cis	rs727479	0.626	rs17703883	ENSG00000259306.2	RP11-108K3.2	3.67	0.000275	0.0321	0.19	0.16	Estradiol levels;	chr15:51237900	chr15:51315841~51321996:+
LUAD	cis	rs3741404	0.665	rs594461	ENSG00000256789.1	RP11-697H9.2	-3.67	0.000275	0.0321	-0.18	-0.16	Platelet count;	chr11:64105071	chr11:63637677~63658962:+
LUAD	cis	rs11051970	0.659	rs950082	ENSG00000275854.1	RP11-278C7.5	-3.67	0.000275	0.0321	-0.17	-0.16	Response to tocilizumab in rheumatoid arthritis;	chr12:32435480	chr12:32736930~32737660:-
LUAD	cis	rs11051970	0.659	rs950081	ENSG00000275854.1	RP11-278C7.5	-3.67	0.000275	0.0321	-0.17	-0.16	Response to tocilizumab in rheumatoid arthritis;	chr12:32435554	chr12:32736930~32737660:-
LUAD	cis	rs11121246	0.518	rs12135416	ENSG00000270282.1	RP5-1115A15.2	-3.67	0.000275	0.0321	-0.18	-0.16	Plateletcrit;	chr1:8850288	chr1:8512653~8513021:+
LUAD	cis	rs7584330	0.657	rs10190310	ENSG00000222032.1	AC112721.2	3.67	0.000275	0.0321	0.2	0.16	Prostate cancer;	chr2:237443639	chr2:237428920~237434822:-
LUAD	cis	rs77972916	0.614	rs80323638	ENSG00000234936.1	AC010883.5	3.67	0.000275	0.0321	0.26	0.16	Granulocyte percentage of myeloid white cells;	chr2:43242476	chr2:43229573~43233394:+
LUAD	cis	rs4727963	0.765	rs6971635	ENSG00000240499.6	RP5-1101C3.1	-3.67	0.000275	0.0321	-0.15	-0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);	chr7:123064134	chr7:122328469~122440388:+
LUAD	cis	rs7674212	0.57	rs12501621	ENSG00000246560.2	RP11-10L12.4	3.67	0.000275	0.0321	0.21	0.16	Type 2 diabetes;	chr4:103174348	chr4:102828055~102844075:+
LUAD	cis	rs6496932	0.503	rs10520588	ENSG00000259630.2	CTD-2262B20.1	-3.67	0.000275	0.0321	-0.22	-0.16	Central corneal thickness;Corneal structure;	chr15:85419479	chr15:85415228~85415633:+
LUAD	cis	rs7933887	0.574	rs35600242	ENSG00000254671.2	STT3A-AS1	-3.67	0.000275	0.0321	-0.25	-0.16	Coronary artery disease;	chr11:126418413	chr11:125570284~125592568:-
LUAD	cis	rs2274273	0.837	rs6573010	ENSG00000259318.1	RP11-454L9.2	3.67	0.000275	0.0321	0.14	0.16	Protein biomarker;	chr14:55254874	chr14:55394940~55395233:-
LUAD	cis	rs7870753	0.628	rs7860871	ENSG00000188801.9	ZNF322P1	3.67	0.000275	0.0321	0.24	0.16	Height;	chr9:96425121	chr9:97198303~97199511:-
LUAD	cis	rs7829975	0.582	rs6982832	ENSG00000253981.4	ALG1L13P	-3.67	0.000275	0.0321	-0.19	-0.16	Mood instability;	chr8:8934707	chr8:8236003~8244667:-
LUAD	cis	rs1020064	0.636	rs1529975	ENSG00000235319.1	AC012360.4	-3.67	0.000275	0.0321	-0.19	-0.16	AIDS;	chr2:105313444	chr2:105324210~105330529:+
LUAD	cis	rs6479901	0.895	rs10822157	ENSG00000232075.1	MRPL35P2	-3.67	0.000275	0.0321	-0.23	-0.16	Intelligence (multi-trait analysis);	chr10:63329720	chr10:63634317~63634827:-
LUAD	cis	rs6952407	1	rs6952407	ENSG00000222364.1	RNU6-96P	3.67	0.000275	0.0321	0.18	0.16	Cotinine glucuronidation;	chr7:66580525	chr7:66395191~66395286:+
LUAD	cis	rs8133949	1	rs2839434	ENSG00000237232.6	ZNF295-AS1	3.67	0.000275	0.0321	0.21	0.16	Hand grip strength;	chr21:41998796	chr21:42009194~42024924:+
LUAD	cis	rs219780	0.699	rs2244237	ENSG00000233818.1	AP000695.4	3.67	0.000275	0.0321	0.2	0.16	Kidney stones;	chr21:36445843	chr21:36445731~36532408:+
LUAD	cis	rs6479891	0.915	rs10740110	ENSG00000232075.1	MRPL35P2	-3.66	0.000275	0.0321	-0.27	-0.16	Arthritis (juvenile idiopathic);	chr10:63283461	chr10:63634317~63634827:-
LUAD	cis	rs79040073	0.53	rs17476940	ENSG00000259531.2	RP11-295H24.3	-3.66	0.000275	0.0321	-0.22	-0.16	Lung cancer in ever smokers;	chr15:49332587	chr15:49365124~49366685:-
LUAD	cis	rs8046148	0.694	rs877639	ENSG00000279356.1	RP11-429P3.8	-3.66	0.000275	0.0321	-0.16	-0.16	Testicular germ cell tumor;	chr16:50084334	chr16:50072862~50074986:+
LUAD	cis	rs2144940	0.506	rs844880	ENSG00000233746.1	LINC00656	3.66	0.000275	0.0321	0.36	0.16	Venous thromboembolism;	chr20:23122115	chr20:23125068~23132621:-
LUAD	cis	rs736408	0.609	rs13087772	ENSG00000243224.1	RP5-1157M23.2	-3.66	0.000275	0.0321	-0.17	-0.16	Bipolar disorder;	chr3:52748258	chr3:52239258~52241097:+
LUAD	cis	rs10752881	1	rs8179262	ENSG00000224468.3	RP11-181K3.4	-3.66	0.000275	0.0321	-0.15	-0.16	Colorectal cancer;	chr1:183004051	chr1:183138402~183141282:-
LUAD	cis	rs10752881	0.967	rs8179361	ENSG00000224468.3	RP11-181K3.4	-3.66	0.000275	0.0321	-0.15	-0.16	Colorectal cancer;	chr1:183005437	chr1:183138402~183141282:-
LUAD	cis	rs10752881	1	rs8179282	ENSG00000224468.3	RP11-181K3.4	-3.66	0.000275	0.0321	-0.15	-0.16	Colorectal cancer;	chr1:183005463	chr1:183138402~183141282:-
LUAD	cis	rs10752881	1	rs8179283	ENSG00000224468.3	RP11-181K3.4	-3.66	0.000275	0.0321	-0.15	-0.16	Colorectal cancer;	chr1:183005467	chr1:183138402~183141282:-
LUAD	cis	rs10752881	0.967	rs8179284	ENSG00000224468.3	RP11-181K3.4	-3.66	0.000275	0.0321	-0.15	-0.16	Colorectal cancer;	chr1:183005572	chr1:183138402~183141282:-
LUAD	cis	rs10752881	0.967	rs4652757	ENSG00000224468.3	RP11-181K3.4	-3.66	0.000275	0.0321	-0.15	-0.16	Colorectal cancer;	chr1:183005615	chr1:183138402~183141282:-
LUAD	cis	rs10752881	0.967	rs4652758	ENSG00000224468.3	RP11-181K3.4	-3.66	0.000275	0.0321	-0.15	-0.16	Colorectal cancer;	chr1:183005965	chr1:183138402~183141282:-
LUAD	cis	rs10911232	0.507	rs4575047	ENSG00000224468.3	RP11-181K3.4	-3.66	0.000275	0.0321	-0.15	-0.16	Hypertriglyceridemia;	chr1:183006893	chr1:183138402~183141282:-
LUAD	cis	rs10911232	0.507	rs4596846	ENSG00000224468.3	RP11-181K3.4	-3.66	0.000275	0.0321	-0.15	-0.16	Hypertriglyceridemia;	chr1:183006899	chr1:183138402~183141282:-
LUAD	cis	rs10752881	1	rs4420053	ENSG00000224468.3	RP11-181K3.4	-3.66	0.000275	0.0321	-0.15	-0.16	Colorectal cancer;	chr1:183006998	chr1:183138402~183141282:-
LUAD	cis	rs10752881	1	rs6701400	ENSG00000224468.3	RP11-181K3.4	-3.66	0.000275	0.0321	-0.15	-0.16	Colorectal cancer;	chr1:183008062	chr1:183138402~183141282:-
LUAD	cis	rs10911232	0.507	rs9787327	ENSG00000224468.3	RP11-181K3.4	-3.66	0.000275	0.0321	-0.15	-0.16	Hypertriglyceridemia;	chr1:183009324	chr1:183138402~183141282:-
LUAD	cis	rs10752881	1	rs10797807	ENSG00000224468.3	RP11-181K3.4	-3.66	0.000275	0.0321	-0.15	-0.16	Colorectal cancer;	chr1:183009738	chr1:183138402~183141282:-
LUAD	cis	rs10752881	1	rs10911190	ENSG00000224468.3	RP11-181K3.4	-3.66	0.000275	0.0321	-0.15	-0.16	Colorectal cancer;	chr1:183009945	chr1:183138402~183141282:-
LUAD	cis	rs10752881	1	rs10797808	ENSG00000224468.3	RP11-181K3.4	-3.66	0.000275	0.0321	-0.15	-0.16	Colorectal cancer;	chr1:183010488	chr1:183138402~183141282:-
LUAD	cis	rs10911232	0.524	rs4487994	ENSG00000224468.3	RP11-181K3.4	-3.66	0.000275	0.0321	-0.15	-0.16	Hypertriglyceridemia;	chr1:183013038	chr1:183138402~183141282:-
LUAD	cis	rs10911232	0.507	rs4442336	ENSG00000224468.3	RP11-181K3.4	-3.66	0.000275	0.0321	-0.15	-0.16	Hypertriglyceridemia;	chr1:183013403	chr1:183138402~183141282:-
LUAD	cis	rs6743068	0.541	rs1966423	ENSG00000234842.1	AC007163.8	-3.66	0.000275	0.0321	-0.19	-0.16	Lymphocyte percentage of white cells;	chr2:201351938	chr2:201549631~201550307:+
LUAD	cis	rs6743068	0.521	rs6705845	ENSG00000234842.1	AC007163.8	-3.66	0.000275	0.0321	-0.19	-0.16	Lymphocyte percentage of white cells;	chr2:201354316	chr2:201549631~201550307:+
LUAD	cis	rs736408	0.609	rs13082960	ENSG00000243224.1	RP5-1157M23.2	-3.66	0.000275	0.0321	-0.17	-0.16	Bipolar disorder;	chr3:52751152	chr3:52239258~52241097:+
LUAD	cis	rs7503168	0.558	rs12945102	ENSG00000267592.1	CTC-507E2.2	3.66	0.000275	0.0321	0.35	0.16	Plateletcrit;	chr17:35601894	chr17:35596904~35597128:-
LUAD	cis	rs12712135	0.677	rs6705385	ENSG00000234389.1	AC007278.3	-3.66	0.000275	0.0321	-0.15	-0.16	Blood protein levels;	chr2:102460109	chr2:102438713~102440475:+
LUAD	cis	rs9923856	0.519	rs9923455	ENSG00000280153.1	RP11-876N24.3	-3.66	0.000275	0.0321	-0.12	-0.16	Atopic dermatitis;Adult asthma;	chr16:11038007	chr16:10933903~10936280:+
LUAD	cis	rs42490	0.664	rs43227	ENSG00000251136.7	RP11-37B2.1	-3.66	0.000275	0.0321	-0.17	-0.16	Leprosy;	chr8:89809351	chr8:89609409~89757727:-
LUAD	cis	rs11886999	0.812	rs2276650	ENSG00000237510.6	AC008268.2	-3.66	0.000275	0.0321	-0.29	-0.16	Cardiac Troponin-T levels;	chr2:96195421	chr2:95789654~95800166:+
LUAD	cis	rs7727544	0.548	rs35696821	ENSG00000233006.5	AC034220.3	3.66	0.000275	0.0322	0.15	0.16	Blood metabolite levels;	chr5:132172324	chr5:132311285~132369916:-
LUAD	cis	rs10752881	1	rs10797810	ENSG00000224468.3	RP11-181K3.4	-3.66	0.000275	0.0322	-0.15	-0.16	Colorectal cancer;	chr1:183011815	chr1:183138402~183141282:-
LUAD	cis	rs10752881	1	rs10752883	ENSG00000224468.3	RP11-181K3.4	-3.66	0.000275	0.0322	-0.15	-0.16	Colorectal cancer;	chr1:183011828	chr1:183138402~183141282:-
LUAD	cis	rs8141529	0.748	rs132533	ENSG00000272858.1	CTA-292E10.8	3.66	0.000275	0.0322	0.18	0.16	Lymphocyte counts;	chr22:28903583	chr22:28814914~28815662:+
LUAD	cis	rs9392556	0.6	rs661404	ENSG00000230648.1	RP3-406P24.3	3.66	0.000275	0.0322	0.18	0.16	Blood metabolite levels;	chr6:4125863	chr6:4018843~4021215:-
LUAD	cis	rs38055	0.881	rs408393	ENSG00000247796.2	CTD-2366F13.1	-3.66	0.000275	0.0322	-0.18	-0.16	Acne (severe);	chr5:53317725	chr5:53109842~53115126:+
LUAD	cis	rs2274273	1	rs6573006	ENSG00000259318.1	RP11-454L9.2	3.66	0.000275	0.0322	0.14	0.16	Protein biomarker;	chr14:55143714	chr14:55394940~55395233:-
LUAD	cis	rs2024714	0.9	rs1535142	ENSG00000273812.1	WI2-87327B8.2	-3.66	0.000275	0.0322	-0.17	-0.16	Longevity;	chr20:61627700	chr20:62596732~62603115:-
LUAD	cis	rs6472827	0.645	rs2936683	ENSG00000253983.2	RP1-16A9.1	3.66	0.000275	0.0322	0.24	0.16	Uterine fibroids;	chr8:74201004	chr8:74199396~74208441:+
LUAD	cis	rs6472827	0.645	rs16836	ENSG00000253983.2	RP1-16A9.1	3.66	0.000275	0.0322	0.24	0.16	Uterine fibroids;	chr8:74201827	chr8:74199396~74208441:+
LUAD	cis	rs3738443	0.817	rs61840052	ENSG00000215795.2	RP11-488L18.3	-3.66	0.000276	0.0322	-0.24	-0.16	Alcohol dependence;	chr1:247204036	chr1:247183813~247185482:-
LUAD	cis	rs6787172	0.644	rs55705928	ENSG00000272087.1	RP11-379F4.7	3.66	0.000276	0.0322	0.19	0.16	Subjective well-being;	chr3:158463730	chr3:158693120~158693768:-
LUAD	cis	rs7667	0.919	rs12026907	ENSG00000270728.1	RP4-657E11.10	-3.66	0.000276	0.0322	-0.16	-0.16	Crohn's disease and psoriasis;	chr1:19412024	chr1:19297080~19297903:+
LUAD	cis	rs2288884	0.636	rs6509620	ENSG00000269959.1	SPACA6P-AS	-3.66	0.000276	0.0322	-0.17	-0.16	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52077543	chr19:51685363~51693456:-
LUAD	cis	rs4268898	0.662	rs56006260	ENSG00000242628.4	AC009228.1	3.66	0.000276	0.0322	0.24	0.16	Asthma;	chr2:24187034	chr2:24214381~24221516:+
LUAD	cis	rs9894429	0.646	rs9904137	ENSG00000263853.1	AC139530.1	-3.66	0.000276	0.0322	-0.17	-0.16	Eye color traits;	chr17:81646899	chr17:81676001~81676086:+
LUAD	cis	rs4266144	0.562	rs2086667	ENSG00000244515.1	KRT18P34	-3.66	0.000276	0.0322	-0.23	-0.16	Coronary artery disease;	chr3:157118728	chr3:157162663~157163932:-
LUAD	cis	rs6547741	1	rs4665381	ENSG00000223522.1	AC093690.1	3.66	0.000276	0.0322	0.16	0.16	Oral cavity cancer;	chr2:27534283	chr2:28307691~28310459:-
LUAD	cis	rs2074409	0.509	rs2411157	ENSG00000276054.1	RP11-378E13.3	3.66	0.000276	0.0322	0.2	0.16	Response to angiotensin II receptor blocker therapy;	chr17:37424298	chr17:37386886~37387926:+
LUAD	cis	rs875971	0.638	rs7793569	ENSG00000222364.1	RNU6-96P	3.66	0.000276	0.0322	0.18	0.16	Aortic root size;	chr7:66651646	chr7:66395191~66395286:+
LUAD	cis	rs763121	0.853	rs2267393	ENSG00000225450.1	RP3-508I15.14	-3.66	0.000276	0.0322	-0.16	-0.16	Menopause (age at onset);	chr22:38705614	chr22:38739003~38749041:+
LUAD	cis	rs763121	0.853	rs2267394	ENSG00000225450.1	RP3-508I15.14	-3.66	0.000276	0.0322	-0.16	-0.16	Menopause (age at onset);	chr22:38705628	chr22:38739003~38749041:+
LUAD	cis	rs7061710	0.58	rs2103351	ENSG00000271811.1	RP1-79C4.4	3.66	0.000276	0.0322	0.24	0.16	Blood metabolite levels;	chr1:171076324	chr1:170667381~170669425:+
LUAD	cis	rs2274273	0.87	rs10145203	ENSG00000258413.1	RP11-665C16.6	-3.66	0.000276	0.0322	-0.21	-0.16	Protein biomarker;	chr14:55317740	chr14:55262767~55272075:-
LUAD	cis	rs8062405	0.757	rs2411453	ENSG00000261766.1	RP11-22P6.2	3.66	0.000276	0.0322	0.15	0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620700	chr16:28862166~28863340:-
LUAD	cis	rs12822507	0.732	rs873218	ENSG00000180861.8	LINC01559	3.66	0.000276	0.0322	0.18	0.16	Systemic lupus erythematosus;	chr12:12612669	chr12:13371089~13387167:-
LUAD	cis	rs4700393	0.517	rs13183561	ENSG00000272308.1	RP11-231G3.1	3.66	0.000276	0.0322	0.21	0.16	Intelligence (multi-trait analysis);	chr5:60803976	chr5:60866457~60866935:-
LUAD	cis	rs2025345	0.619	rs10905656	ENSG00000229664.1	RP11-536K7.5	-3.66	0.000276	0.0322	-0.18	-0.16	Self-reported allergy;	chr10:6044130	chr10:6025978~6036427:+
LUAD	cis	rs7968440	1	rs11832315	ENSG00000272368.2	RP4-605O3.4	3.66	0.000276	0.0322	0.19	0.16	Fibrinogen;	chr12:50550149	chr12:50112197~50165618:+
LUAD	cis	rs1348850	0.747	rs1047884	ENSG00000213963.5	AC074286.1	3.66	0.000276	0.0322	0.19	0.16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177623553	chr2:177283508~177392691:-
LUAD	cis	rs17418283	0.509	rs255371	ENSG00000251544.1	MTND5P12	-3.66	0.000276	0.0322	-0.17	-0.16	Bipolar disorder;	chr5:94782393	chr5:94567461~94568909:+
LUAD	cis	rs78572108	0.858	rs58541628	ENSG00000214691.7	AC104654.1	3.66	0.000276	0.0322	0.27	0.16	Total body bone mineral density;	chr2:42003676	chr2:41877074~41894046:+
LUAD	cis	rs11051970	0.879	rs2088806	ENSG00000274964.1	RP11-817I4.1	-3.66	0.000276	0.0322	-0.18	-0.16	Response to tocilizumab in rheumatoid arthritis;	chr12:32439191	chr12:32339368~32340724:+
LUAD	cis	rs2239557	0.508	rs1974582	ENSG00000259065.1	RP5-1021I20.1	-3.66	0.000276	0.0322	-0.22	-0.16	Common traits (Other);	chr14:73900601	chr14:73787360~73803270:+
LUAD	cis	rs6871536	0.951	rs2706401	ENSG00000233006.5	AC034220.3	-3.66	0.000276	0.0322	-0.18	-0.16	Asthma (childhood onset);	chr5:132545913	chr5:132311285~132369916:-
LUAD	cis	rs8014204	0.836	rs12888998	ENSG00000279594.1	RP11-950C14.10	3.66	0.000276	0.0322	0.19	0.16	Caffeine consumption;	chr14:74825959	chr14:75011269~75012851:-
LUAD	cis	rs9500256	0.683	rs10458024	ENSG00000266579.1	RP1-71H19.2	-3.66	0.000276	0.0323	-0.22	-0.16	Eosinophilic esophagitis (pediatric);	chr6:57997811	chr6:57493855~57497691:+
LUAD	cis	rs10102546	1	rs6999626	ENSG00000244642.3	RN7SL396P	3.66	0.000276	0.0323	0.19	0.16	Smoking cessation;	chr8:119534167	chr8:119862662~119862956:+
LUAD	cis	rs728616	0.867	rs56271768	ENSG00000225484.5	NUTM2B-AS1	-3.66	0.000276	0.0323	-0.34	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80077295	chr10:79663088~79826594:-
LUAD	cis	rs801193	1	rs2659915	ENSG00000272831.1	RP11-792A8.4	3.66	0.000276	0.0323	0.16	0.16	Aortic root size;	chr7:66688114	chr7:66739829~66740385:-
LUAD	cis	rs755249	0.508	rs12023553	ENSG00000182109.6	RP11-69E11.4	-3.66	0.000276	0.0323	-0.18	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39205820	chr1:39522280~39546187:-
LUAD	cis	rs2274273	0.624	rs7150763	ENSG00000258413.1	RP11-665C16.6	-3.66	0.000276	0.0323	-0.22	-0.16	Protein biomarker;	chr14:55373083	chr14:55262767~55272075:-
LUAD	cis	rs3018712	0.517	rs10791994	ENSG00000227620.4	ALG1L8P	-3.66	0.000276	0.0323	-0.23	-0.16	Total body bone mineral density;	chr11:68745778	chr11:67785273~67792335:+
LUAD	cis	rs7208859	0.673	rs11651802	ENSG00000265443.1	CTD-2349P21.6	-3.66	0.000277	0.0323	-0.28	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832642	chr17:30726305~30727564:-
LUAD	cis	rs11667325	0.92	rs12610825	ENSG00000268316.1	AC006272.2	3.66	0.000277	0.0323	0.19	0.16	Neutrophil percentage of granulocytes;	chr19:51795323	chr19:51839771~51840945:-
LUAD	cis	rs2242663	0.798	rs1791679	ENSG00000213409.4	RP11-658F2.3	-3.66	0.000277	0.0323	-0.2	-0.16	Bipolar disorder;	chr11:66570403	chr11:66761575~66762399:-
LUAD	cis	rs4934494	0.677	rs1409360	ENSG00000232936.4	RP11-80H5.2	3.66	0.000277	0.0323	0.22	0.16	Red blood cell count;	chr10:89625547	chr10:89645282~89650667:+
LUAD	cis	rs4474465	0.79	rs7106931	ENSG00000251323.2	RP11-452H21.4	-3.66	0.000277	0.0323	-0.21	-0.16	Alzheimer's disease (survival time);	chr11:78518566	chr11:78423982~78429836:-
LUAD	cis	rs1431005	0.927	rs12651176	ENSG00000250658.1	RP11-138B4.1	3.66	0.000277	0.0323	0.21	0.16	Response to statin therapy;	chr4:187439724	chr4:187304083~187309682:-
LUAD	cis	rs875971	1	rs12532998	ENSG00000273142.1	RP11-458F8.4	-3.66	0.000277	0.0323	-0.12	-0.16	Aortic root size;	chr7:66502472	chr7:66902857~66906297:+
LUAD	cis	rs4639966	0.836	rs7124498	ENSG00000255422.1	AP002954.4	3.66	0.000277	0.0323	0.23	0.16	Systemic lupus erythematosus;	chr11:118745544	chr11:118704607~118750263:+
LUAD	cis	rs2483519	0.54	rs11196855	ENSG00000275024.1	CTB-1144G6.6	3.66	0.000277	0.0323	0.19	0.16	Paclitaxel disposition in epithelial ovarian cancer;	chr10:114670807	chr10:114280725~114281258:-
LUAD	cis	rs2115630	0.967	rs7171167	ENSG00000259728.4	LINC00933	-3.66	0.000277	0.0323	-0.2	-0.16	P wave terminal force;	chr15:84695892	chr15:84570649~84580175:+
LUAD	cis	rs9900280	1	rs35763383	ENSG00000264808.1	RP11-802D6.1	-3.66	0.000277	0.0323	-0.19	-0.16	Mean platelet volume;	chr17:29526267	chr17:29369717~29390777:-
LUAD	cis	rs9900280	1	rs592862	ENSG00000264808.1	RP11-802D6.1	-3.66	0.000277	0.0323	-0.19	-0.16	Mean platelet volume;	chr17:29527984	chr17:29369717~29390777:-
LUAD	cis	rs10262624	0.504	rs4722255	ENSG00000232818.2	RPS2P32	-3.66	0.000277	0.0323	-0.18	-0.16	Schizophrenia;	chr7:23706453	chr7:23490473~23491364:+
LUAD	cis	rs2024714	0.803	rs6061679	ENSG00000273812.1	WI2-87327B8.2	-3.66	0.000277	0.0323	-0.17	-0.16	Longevity;	chr20:61625619	chr20:62596732~62603115:-
LUAD	cis	rs5742933	0.948	rs6434365	ENSG00000253559.1	OSGEPL1-AS1	-3.66	0.000277	0.0323	-0.23	-0.16	Ferritin levels;	chr2:189707695	chr2:189762704~189765556:+
LUAD	cis	rs338389	0.807	rs8035426	ENSG00000260657.2	RP11-315D16.4	-3.66	0.000277	0.0323	-0.19	-0.16	Survival in rectal cancer;	chr15:67991744	chr15:68267792~68277994:-
LUAD	cis	rs755249	0.567	rs4660603	ENSG00000182109.6	RP11-69E11.4	-3.66	0.000277	0.0323	-0.21	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39270662	chr1:39522280~39546187:-
LUAD	cis	rs62025270	0.632	rs6496109	ENSG00000259416.2	RP11-158M2.5	-3.66	0.000277	0.0323	-0.23	-0.16	Idiopathic pulmonary fibrosis;	chr15:85588777	chr15:85754941~85756237:-
LUAD	cis	rs11118883	0.884	rs11577023	ENSG00000228437.4	RP11-400N13.2	3.66	0.000277	0.0323	0.21	0.16	Colorectal cancer;	chr1:221888631	chr1:221966341~221984964:+
LUAD	cis	rs8114671	0.967	rs6142320	ENSG00000269202.1	RP4-614O4.12	3.66	0.000277	0.0323	0.16	0.16	Height;	chr20:35200390	chr20:35201747~35203288:-
LUAD	cis	rs8114671	0.967	rs6142321	ENSG00000269202.1	RP4-614O4.12	3.66	0.000277	0.0323	0.16	0.16	Height;	chr20:35200671	chr20:35201747~35203288:-
LUAD	cis	rs334353	0.798	rs10819638	ENSG00000255145.2	STX17-AS1	-3.66	0.000277	0.0323	-0.21	-0.16	Age-related macular degeneration;	chr9:99112032	chr9:99886322~99906601:-
LUAD	cis	rs6563842	0.572	rs9549263	ENSG00000168852.11	TPTE2P5	3.66	0.000277	0.0323	0.16	0.16	Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr13:40690648	chr13:40822296~40921749:-
LUAD	cis	rs911555	0.755	rs10148970	ENSG00000244691.1	RPL10AP1	-3.66	0.000277	0.0323	-0.21	-0.16	Intelligence (multi-trait analysis);	chr14:103425663	chr14:103412119~103412761:-
LUAD	cis	rs7772486	0.846	rs7755440	ENSG00000235652.6	RP11-545I5.3	3.66	0.000277	0.0323	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:146054770	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.817	rs12198065	ENSG00000235652.6	RP11-545I5.3	3.66	0.000277	0.0323	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:146064150	chr6:145799409~145886585:+
LUAD	cis	rs875971	0.522	rs1701760	ENSG00000234585.5	CCT6P3	3.66	0.000277	0.0323	0.15	0.16	Aortic root size;	chr7:66008701	chr7:65038354~65074713:+
LUAD	cis	rs9921338	0.961	rs4780358	ENSG00000263080.1	RP11-485G7.5	3.66	0.000277	0.0323	0.22	0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11280355	chr16:11341809~11345211:-
LUAD	cis	rs4716602	0.596	rs10244786	ENSG00000235029.1	MNX1-AS2	-3.66	0.000277	0.0323	-0.2	-0.16	Anti-saccade response;	chr7:156365295	chr7:157006307~157007132:+
LUAD	cis	rs12440869	1	rs8042340	ENSG00000270964.1	RP11-502I4.3	-3.66	0.000277	0.0323	-0.19	-0.16	Peak velocity of the mitral A-wave;	chr15:67251384	chr15:67541072~67542604:-
LUAD	cis	rs1858037	0.765	rs67404371	ENSG00000237979.1	AC007389.1	3.66	0.000277	0.0323	0.21	0.16	Rheumatoid arthritis;	chr2:65370137	chr2:65500993~65502138:-
LUAD	cis	rs10483853	0.806	rs66498577	ENSG00000258695.2	RP3-414A15.2	-3.66	0.000277	0.0323	-0.21	-0.16	Coronary artery calcification;	chr14:73292012	chr14:73522878~73530610:+
LUAD	cis	rs2333021	1	rs2333021	ENSG00000259015.1	RP11-109N23.6	3.66	0.000277	0.0323	0.16	0.16	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73017676	chr14:72960595~72961993:+
LUAD	cis	rs1678542	0.679	rs775251	ENSG00000270039.1	RP11-571M6.17	-3.66	0.000277	0.0323	-0.2	-0.16	Rheumatoid arthritis;	chr12:57584957	chr12:57803838~57804415:+
LUAD	cis	rs9900280	0.967	rs511093	ENSG00000264808.1	RP11-802D6.1	-3.66	0.000277	0.0323	-0.19	-0.16	Mean platelet volume;	chr17:29485413	chr17:29369717~29390777:-
LUAD	cis	rs10911232	0.52	rs10797831	ENSG00000224468.3	RP11-181K3.4	-3.66	0.000277	0.0323	-0.15	-0.16	Hypertriglyceridemia;	chr1:183067681	chr1:183138402~183141282:-
LUAD	cis	rs9500256	0.655	rs12210275	ENSG00000239650.4	GUSBP4	3.66	0.000277	0.0323	0.19	0.16	Eosinophilic esophagitis (pediatric);	chr6:58005481	chr6:57919784~57930291:-
LUAD	cis	rs67539049	1	rs67526040	ENSG00000255046.1	RP11-297N6.4	3.66	0.000277	0.0323	0.24	0.16	Itch intensity from mosquito bite;	chr8:11445487	chr8:11797928~11802568:-
LUAD	cis	rs6754311	0.731	rs1470457	ENSG00000226806.1	AC011893.3	3.66	0.000277	0.0324	0.21	0.16	Mosquito bite size;	chr2:135824278	chr2:135820191~135823087:+
LUAD	cis	rs858239	0.899	rs10085838	ENSG00000226816.2	AC005082.12	3.66	0.000277	0.0324	0.22	0.16	Cerebrospinal fluid biomarker levels;	chr7:23258796	chr7:23206013~23208045:+
LUAD	cis	rs1075265	0.756	rs809280	ENSG00000272156.1	RP11-477N3.1	-3.66	0.000277	0.0324	-0.2	-0.16	Chronotype;Morning vs. evening chronotype;	chr2:53921270	chr2:54082554~54085066:+
LUAD	cis	rs6479901	0.557	rs1009984	ENSG00000232075.1	MRPL35P2	-3.66	0.000277	0.0324	-0.24	-0.16	Intelligence (multi-trait analysis);	chr10:63156709	chr10:63634317~63634827:-
LUAD	cis	rs595244	1	rs77360718	ENSG00000259705.1	RP11-227D13.1	3.66	0.000277	0.0324	0.33	0.16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48501418	chr15:48645951~48652016:+
LUAD	cis	rs8058578	1	rs13338946	ENSG00000232748.3	RP11-196G11.6	-3.66	0.000277	0.0324	-0.21	-0.16	Multiple myeloma;	chr16:30689537	chr16:31056460~31062803:+
LUAD	cis	rs7772486	0.875	rs9390377	ENSG00000235652.6	RP11-545I5.3	3.66	0.000277	0.0324	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:146065796	chr6:145799409~145886585:+
LUAD	cis	rs2749097	0.735	rs10493349	ENSG00000244256.3	RN7SL130P	-3.66	0.000277	0.0324	-0.22	-0.16	Alcohol consumption (transferrin glycosylation);	chr1:63690237	chr1:63655743~63656047:+
LUAD	cis	rs2295359	1	rs11465754	ENSG00000275678.1	RP4-547N15.3	-3.66	0.000278	0.0324	-0.17	-0.16	Psoriasis;	chr1:67165748	chr1:67121605~67123956:-
LUAD	cis	rs2239547	0.657	rs4687554	ENSG00000243224.1	RP5-1157M23.2	-3.66	0.000278	0.0324	-0.19	-0.16	Schizophrenia;	chr3:52830119	chr3:52239258~52241097:+
LUAD	cis	rs1075265	0.704	rs805405	ENSG00000272156.1	RP11-477N3.1	-3.66	0.000278	0.0324	-0.2	-0.16	Chronotype;Morning vs. evening chronotype;	chr2:53891014	chr2:54082554~54085066:+
LUAD	cis	rs6088590	0.965	rs6088620	ENSG00000275784.1	RP5-1125A11.6	-3.66	0.000278	0.0324	-0.18	-0.16	Coronary artery disease;	chr20:34824219	chr20:33989480~33991818:-
LUAD	cis	rs7829975	0.871	rs572307	ENSG00000233609.3	RP11-62H7.2	-3.66	0.000278	0.0324	-0.13	-0.16	Mood instability;	chr8:8721301	chr8:8961200~8979025:+
LUAD	cis	rs2153535	0.553	rs2984099	ENSG00000230939.1	RP11-314C16.1	3.66	0.000278	0.0324	0.24	0.16	Motion sickness;	chr6:8637041	chr6:8784178~8785445:+
LUAD	cis	rs10129255	0.912	rs8009135	ENSG00000211947.2	IGHV3-21	-3.66	0.000278	0.0324	-0.11	-0.16	Kawasaki disease;	chr14:106777528	chr14:106235064~106235594:-
LUAD	cis	rs6547741	0.717	rs2178197	ENSG00000234072.1	AC074117.10	3.66	0.000278	0.0324	0.13	0.16	Oral cavity cancer;	chr2:27637684	chr2:27356246~27367622:+
LUAD	cis	rs910316	0.726	rs12882664	ENSG00000279594.1	RP11-950C14.10	3.66	0.000278	0.0324	0.19	0.16	Height;	chr14:74980075	chr14:75011269~75012851:-
LUAD	cis	rs12146727	0.609	rs113747960	ENSG00000247853.2	RP5-940J5.6	3.66	0.000278	0.0324	0.26	0.16	Blood protein levels;	chr12:7074644	chr12:6578622~6584739:+
LUAD	cis	rs7615952	0.576	rs66671308	ENSG00000250012.1	RP11-124N2.1	-3.66	0.000278	0.0324	-0.23	-0.16	Blood pressure (smoking interaction);	chr3:126074683	chr3:126084220~126095349:+
LUAD	cis	rs4470077	1	rs12879078	ENSG00000259318.1	RP11-454L9.2	3.66	0.000278	0.0324	0.17	0.16	Platelet count;	chr14:55432697	chr14:55394940~55395233:-
LUAD	cis	rs7709377	1	rs1541655	ENSG00000248445.4	SEMA6A-AS1	3.66	0.000278	0.0324	0.13	0.16	Metabolite levels  (X-11787);	chr5:116205580	chr5:116447547~116508276:+
LUAD	cis	rs10946940	0.632	rs9366698	ENSG00000280107.1	AL022393.9	-3.66	0.000278	0.0324	-0.2	-0.16	Systemic lupus erythematosus;	chr6:27704256	chr6:28170845~28172521:+
LUAD	cis	rs4865762	0.874	rs2548321	ENSG00000247796.2	CTD-2366F13.1	-3.66	0.000278	0.0324	-0.17	-0.16	Intraocular pressure;	chr5:53206696	chr5:53109842~53115126:+
LUAD	cis	rs7131987	0.621	rs57803026	ENSG00000275476.1	RP11-996F15.4	-3.66	0.000278	0.0324	-0.19	-0.16	QT interval;	chr12:29344573	chr12:29277397~29277882:-
LUAD	cis	rs17711722	0.727	rs1880555	ENSG00000222364.1	RNU6-96P	-3.66	0.000278	0.0324	-0.18	-0.16	Calcium levels;	chr7:65967580	chr7:66395191~66395286:+
LUAD	cis	rs8062405	1	rs11861174	ENSG00000261419.1	RP11-57A19.4	-3.66	0.000278	0.0324	-0.18	-0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28659696~28740781:-
LUAD	cis	rs8062405	1	rs4788102	ENSG00000261419.1	RP11-57A19.4	-3.66	0.000278	0.0324	-0.18	-0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28659696~28740781:-
LUAD	cis	rs8062405	1	rs62037367	ENSG00000261419.1	RP11-57A19.4	-3.66	0.000278	0.0324	-0.18	-0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28659696~28740781:-
LUAD	cis	rs8062405	1	rs7198606	ENSG00000261419.1	RP11-57A19.4	-3.66	0.000278	0.0324	-0.18	-0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28659696~28740781:-
LUAD	cis	rs8062405	0.929	rs11864750	ENSG00000261419.1	RP11-57A19.4	-3.66	0.000278	0.0324	-0.18	-0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28659696~28740781:-
LUAD	cis	rs8062405	0.964	rs7193733	ENSG00000261419.1	RP11-57A19.4	-3.66	0.000278	0.0324	-0.18	-0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28659696~28740781:-
LUAD	cis	rs8062405	1	rs8055982	ENSG00000261419.1	RP11-57A19.4	-3.66	0.000278	0.0324	-0.18	-0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28659696~28740781:-
LUAD	cis	rs8062405	1	rs7498665	ENSG00000261419.1	RP11-57A19.4	-3.66	0.000278	0.0324	-0.18	-0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28659696~28740781:-
LUAD	cis	rs8062405	0.964	rs11864107	ENSG00000261419.1	RP11-57A19.4	-3.66	0.000278	0.0324	-0.18	-0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28659696~28740781:-
LUAD	cis	rs8062405	1	rs62037371	ENSG00000261419.1	RP11-57A19.4	-3.66	0.000278	0.0324	-0.18	-0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28659696~28740781:-
LUAD	cis	rs72634501	0.622	rs4660416	ENSG00000182109.6	RP11-69E11.4	3.66	0.000278	0.0324	0.2	0.16	HDL cholesterol;	chr1:39113314	chr1:39522280~39546187:-
LUAD	cis	rs1576263	0.504	rs1854411	ENSG00000230939.1	RP11-314C16.1	-3.66	0.000278	0.0324	-0.19	-0.16	Photic sneeze reflex;	chr6:8545771	chr6:8784178~8785445:+
LUAD	cis	rs13113518	0.902	rs11133386	ENSG00000223305.1	RN7SKP30	3.66	0.000278	0.0324	0.19	0.16	Height;	chr4:55461320	chr4:55540502~55540835:-
LUAD	cis	rs763121	0.819	rs5757160	ENSG00000228274.3	RP3-508I15.9	-3.66	0.000278	0.0324	-0.16	-0.16	Menopause (age at onset);	chr22:38593641	chr22:38667585~38681820:-
LUAD	cis	rs763121	0.853	rs5757166	ENSG00000228274.3	RP3-508I15.9	-3.66	0.000278	0.0324	-0.16	-0.16	Menopause (age at onset);	chr22:38599380	chr22:38667585~38681820:-
LUAD	cis	rs763121	0.819	rs5757169	ENSG00000228274.3	RP3-508I15.9	-3.66	0.000278	0.0324	-0.16	-0.16	Menopause (age at onset);	chr22:38607490	chr22:38667585~38681820:-
LUAD	cis	rs2239547	0.657	rs3755803	ENSG00000243224.1	RP5-1157M23.2	-3.66	0.000278	0.0324	-0.19	-0.16	Schizophrenia;	chr3:52832141	chr3:52239258~52241097:+
LUAD	cis	rs2098713	0.569	rs12523333	ENSG00000250155.1	CTD-2353F22.1	3.66	0.000278	0.0324	0.18	0.16	Telomere length;	chr5:37498871	chr5:36666214~36725195:-
LUAD	cis	rs8002861	0.935	rs1373903	ENSG00000274001.1	RP11-5G9.5	3.66	0.000278	0.0324	0.17	0.16	Leprosy;	chr13:43901378	chr13:43877715~43878163:-
LUAD	cis	rs910316	0.789	rs12894419	ENSG00000279594.1	RP11-950C14.10	3.66	0.000278	0.0324	0.19	0.16	Height;	chr14:75005099	chr14:75011269~75012851:-
LUAD	cis	rs2278702	0.622	rs77656838	ENSG00000259495.2	RP11-210M15.2	-3.66	0.000278	0.0324	-0.28	-0.16	Bipolar disorder;	chr15:80370249	chr15:80344853~80403575:-
LUAD	cis	rs6981992	1	rs6981992	ENSG00000272010.1	CTD-3025N20.3	3.66	0.000278	0.0324	0.19	0.16	Obesity-related traits;	chr8:65551243	chr8:65591850~65592472:-
LUAD	cis	rs7674212	0.581	rs10516496	ENSG00000230069.3	LRRC37A15P	-3.66	0.000278	0.0324	-0.18	-0.16	Type 2 diabetes;	chr4:103021008	chr4:102727274~102730721:-
LUAD	cis	rs854765	0.547	rs2955384	ENSG00000223979.2	SMCR2	-3.66	0.000278	0.0324	-0.19	-0.16	Total body bone mineral density;	chr17:18036259	chr17:17674026~17677688:-
LUAD	cis	rs6547741	0.935	rs4665384	ENSG00000223522.1	AC093690.1	3.66	0.000278	0.0324	0.16	0.16	Oral cavity cancer;	chr2:27625530	chr2:28307691~28310459:-
LUAD	cis	rs797680	0.786	rs4847240	ENSG00000223745.6	RP4-717I23.3	3.66	0.000278	0.0324	0.13	0.16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93352389	chr1:93262186~93346025:-
LUAD	cis	rs683250	0.629	rs588016	ENSG00000246067.6	RAB30-AS1	3.66	0.000278	0.0324	0.17	0.16	Subcortical brain region volumes;	chr11:83236701	chr11:83072066~83106719:+
LUAD	cis	rs683250	0.629	rs573053	ENSG00000246067.6	RAB30-AS1	3.66	0.000278	0.0324	0.17	0.16	Subcortical brain region volumes;	chr11:83239931	chr11:83072066~83106719:+
LUAD	cis	rs5742933	0.762	rs12992061	ENSG00000253559.1	OSGEPL1-AS1	3.66	0.000278	0.0324	0.2	0.16	Ferritin levels;	chr2:189736026	chr2:189762704~189765556:+
LUAD	cis	rs3741404	0.609	rs651855	ENSG00000256789.1	RP11-697H9.2	-3.66	0.000278	0.0324	-0.18	-0.16	Platelet count;	chr11:64103338	chr11:63637677~63658962:+
LUAD	cis	rs7017914	0.905	rs2732106	ENSG00000246366.5	RP11-382J12.1	3.66	0.000278	0.0324	0.15	0.16	Bone mineral density;	chr8:71011604	chr8:70608577~70663279:+
LUAD	cis	rs8028182	0.636	rs8036758	ENSG00000246877.1	DNM1P35	3.66	0.000278	0.0324	0.21	0.16	Sudden cardiac arrest;	chr15:75525221	chr15:75727670~75738623:-
LUAD	cis	rs7829975	0.514	rs2976929	ENSG00000173295.6	FAM86B3P	3.66	0.000278	0.0324	0.17	0.16	Mood instability;	chr8:8401202	chr8:8228595~8244865:+
LUAD	cis	rs16869652	0.614	rs16869650	ENSG00000229596.3	MYL8P	3.66	0.000278	0.0324	0.29	0.16	Schizophrenia;	chr6:33883356	chr6:33338978~33339495:+
LUAD	cis	rs6568490	0.556	rs6939731	ENSG00000203801.7	LINC00222	3.66	0.000278	0.0324	0.24	0.16	Lymphocyte counts;	chr6:107774206	chr6:108751654~108769942:+
LUAD	cis	rs73108077	1	rs115577082	ENSG00000281376.1	ABALON	-3.66	0.000278	0.0325	-0.29	-0.16	Red blood cell density in sickle cell anemia;	chr20:31433893	chr20:31721507~31723409:+
LUAD	cis	rs2018683	0.624	rs1006521	ENSG00000272568.4	CTB-113D17.1	3.66	0.000278	0.0325	0.19	0.16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28956604	chr7:28979967~29013367:+
LUAD	cis	rs76382185	0.61	rs35918661	ENSG00000233184.5	RP11-421L21.3	3.66	0.000278	0.0325	0.32	0.16	Lymphocyte counts;	chr1:101099280	chr1:101025878~101087268:+
LUAD	cis	rs116175783	0.793	rs3769956	ENSG00000227403.1	AC009299.3	-3.66	0.000278	0.0325	-0.34	-0.16	Intelligence (multi-trait analysis);	chr2:161420790	chr2:161244739~161249050:+
LUAD	cis	rs2342371	0.883	rs11185542	ENSG00000273013.1	CTD-2002J20.1	3.66	0.000279	0.0325	0.21	0.16	Fat distribution (HIV);	chr3:196461056	chr3:196474801~196475394:+
LUAD	cis	rs9951011	0.714	rs4267427	ENSG00000260578.1	CTD-2541J13.1	-3.66	0.000279	0.0325	-0.27	-0.16	Non-response to selective serotonin reuptake inhibitors and depression;	chr18:67383287	chr18:67481791~67484966:-
LUAD	cis	rs12073359	1	rs11583720	ENSG00000223945.2	RP11-458I7.1	-3.66	0.000279	0.0325	-0.23	-0.16	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150071406	chr1:150053864~150055034:+
LUAD	cis	rs2880765	0.805	rs34598679	ENSG00000259407.1	RP11-158M2.3	-3.66	0.000279	0.0325	-0.15	-0.16	Coronary artery disease;	chr15:85498974	chr15:85744109~85750281:-
LUAD	cis	rs2880765	0.835	rs4344688	ENSG00000259407.1	RP11-158M2.3	-3.66	0.000279	0.0325	-0.15	-0.16	Coronary artery disease;	chr15:85499776	chr15:85744109~85750281:-
LUAD	cis	rs2880765	0.835	rs4280192	ENSG00000259407.1	RP11-158M2.3	-3.66	0.000279	0.0325	-0.15	-0.16	Coronary artery disease;	chr15:85499789	chr15:85744109~85750281:-
LUAD	cis	rs2880765	0.835	rs7162502	ENSG00000259407.1	RP11-158M2.3	-3.66	0.000279	0.0325	-0.15	-0.16	Coronary artery disease;	chr15:85501242	chr15:85744109~85750281:-
LUAD	cis	rs2880765	0.835	rs7169632	ENSG00000259407.1	RP11-158M2.3	-3.66	0.000279	0.0325	-0.15	-0.16	Coronary artery disease;	chr15:85501436	chr15:85744109~85750281:-
LUAD	cis	rs2880765	0.835	rs7163958	ENSG00000259407.1	RP11-158M2.3	-3.66	0.000279	0.0325	-0.15	-0.16	Coronary artery disease;	chr15:85501984	chr15:85744109~85750281:-
LUAD	cis	rs2880765	0.835	rs12910373	ENSG00000259407.1	RP11-158M2.3	-3.66	0.000279	0.0325	-0.15	-0.16	Coronary artery disease;	chr15:85503571	chr15:85744109~85750281:-
LUAD	cis	rs11637445	0.677	rs4386088	ENSG00000270964.1	RP11-502I4.3	3.66	0.000279	0.0325	0.18	0.16	Posterior cortical atrophy and Alzheimer's disease;	chr15:67816575	chr15:67541072~67542604:-
LUAD	cis	rs11637445	0.64	rs4508380	ENSG00000270964.1	RP11-502I4.3	3.66	0.000279	0.0325	0.18	0.16	Posterior cortical atrophy and Alzheimer's disease;	chr15:67816711	chr15:67541072~67542604:-
LUAD	cis	rs3017493	0.581	rs2015997	ENSG00000254682.1	RP11-660L16.2	3.66	0.000279	0.0325	0.27	0.16	Renal transplant outcome;	chr11:70818113	chr11:71448674~71452157:+
LUAD	cis	rs4252435	0.52	rs7797896	ENSG00000211716.2	TRBV9	-3.66	0.000279	0.0325	-0.31	-0.16	Cancer;	chr7:142944102	chr7:142391891~142392412:+
LUAD	cis	rs7045881	0.558	rs62542707	ENSG00000254396.1	RP11-56F10.3	3.66	0.000279	0.0325	0.27	0.16	Schizophrenia;	chr9:27066936	chr9:27102630~27104728:+
LUAD	cis	rs7772486	0.875	rs932522	ENSG00000235652.6	RP11-545I5.3	-3.66	0.000279	0.0325	-0.16	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:146052890	chr6:145799409~145886585:+
LUAD	cis	rs2486288	0.656	rs2413772	ENSG00000259479.5	SORD2P	-3.66	0.000279	0.0325	-0.2	-0.16	Glomerular filtration rate;	chr15:45257664	chr15:44826371~44884694:-
LUAD	cis	rs4374383	1	rs4374383	ENSG00000207383.1	Y_RNA	-3.66	0.000279	0.0325	-0.2	-0.16	Hepatitis C induced liver fibrosis;	chr2:112013193	chr2:112579484~112579584:-
LUAD	cis	rs4908768	1	rs11121203	ENSG00000232912.4	RP5-1115A15.1	-3.66	0.000279	0.0325	-0.2	-0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8588181	chr1:8424645~8434838:+
LUAD	cis	rs854765	0.647	rs854763	ENSG00000223979.2	SMCR2	-3.66	0.000279	0.0325	-0.2	-0.16	Total body bone mineral density;	chr17:18106781	chr17:17674026~17677688:-
LUAD	cis	rs6568686	0.786	rs3851226	ENSG00000255389.1	C6orf3	-3.66	0.000279	0.0325	-0.23	-0.16	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111505092	chr6:111599875~111602295:+
LUAD	cis	rs4819052	0.851	rs2838855	ENSG00000223768.1	LINC00205	3.66	0.000279	0.0325	0.2	0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260651	chr21:45293285~45297354:+
LUAD	cis	rs7584330	0.91	rs880930	ENSG00000222032.1	AC112721.2	3.66	0.000279	0.0325	0.19	0.16	Prostate cancer;	chr2:237488229	chr2:237428920~237434822:-
LUAD	cis	rs7584330	0.91	rs72620830	ENSG00000222032.1	AC112721.2	3.66	0.000279	0.0325	0.19	0.16	Prostate cancer;	chr2:237488342	chr2:237428920~237434822:-
LUAD	cis	rs8062405	1	rs1987472	ENSG00000261419.1	RP11-57A19.4	-3.66	0.000279	0.0325	-0.18	-0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28659696~28740781:-
LUAD	cis	rs8062405	0.895	rs56186137	ENSG00000261419.1	RP11-57A19.4	-3.66	0.000279	0.0325	-0.18	-0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28659696~28740781:-
LUAD	cis	rs9900280	1	rs4289056	ENSG00000264808.1	RP11-802D6.1	3.66	0.000279	0.0325	0.19	0.16	Mean platelet volume;	chr17:29439134	chr17:29369717~29390777:-
LUAD	cis	rs7667	0.959	rs12561981	ENSG00000270728.1	RP4-657E11.10	-3.66	0.000279	0.0325	-0.16	-0.16	Crohn's disease and psoriasis;	chr1:19404787	chr1:19297080~19297903:+
LUAD	cis	rs950881	0.932	rs3771180	ENSG00000234389.1	AC007278.3	3.66	0.000279	0.0325	0.2	0.16	Allergy;	chr2:102337157	chr2:102438713~102440475:+
LUAD	cis	rs950881	0.932	rs72823646	ENSG00000234389.1	AC007278.3	3.66	0.000279	0.0325	0.2	0.16	Allergy;	chr2:102337753	chr2:102438713~102440475:+
LUAD	cis	rs950881	0.932	rs13431828	ENSG00000234389.1	AC007278.3	3.66	0.000279	0.0325	0.2	0.16	Allergy;	chr2:102338193	chr2:102438713~102440475:+
LUAD	cis	rs950881	0.932	rs13408569	ENSG00000234389.1	AC007278.3	3.66	0.000279	0.0325	0.2	0.16	Allergy;	chr2:102338596	chr2:102438713~102440475:+
LUAD	cis	rs950881	0.932	rs13408661	ENSG00000234389.1	AC007278.3	3.66	0.000279	0.0325	0.2	0.16	Allergy;	chr2:102338622	chr2:102438713~102440475:+
LUAD	cis	rs9341808	0.754	rs6907729	ENSG00000279022.1	RP11-250B2.4	-3.66	0.000279	0.0325	-0.19	-0.16	Sitting height ratio;	chr6:80295205	chr6:80440730~80441172:+
LUAD	cis	rs11089937	0.626	rs5757017	ENSG00000211640.3	IGLV6-57	3.66	0.000279	0.0325	0.12	0.16	Periodontitis (PAL4Q3);	chr22:22135947	chr22:22195713~22196460:+
LUAD	cis	rs11089937	0.568	rs59356111	ENSG00000211640.3	IGLV6-57	3.66	0.000279	0.0325	0.12	0.16	Periodontitis (PAL4Q3);	chr22:22136175	chr22:22195713~22196460:+
LUAD	cis	rs11089937	0.626	rs5757019	ENSG00000211640.3	IGLV6-57	3.66	0.000279	0.0325	0.12	0.16	Periodontitis (PAL4Q3);	chr22:22136286	chr22:22195713~22196460:+
LUAD	cis	rs11089937	0.597	rs5750579	ENSG00000211640.3	IGLV6-57	3.66	0.000279	0.0325	0.12	0.16	Periodontitis (PAL4Q3);	chr22:22136581	chr22:22195713~22196460:+
LUAD	cis	rs11089937	0.597	rs11089925	ENSG00000211640.3	IGLV6-57	3.66	0.000279	0.0325	0.12	0.16	Periodontitis (PAL4Q3);	chr22:22137267	chr22:22195713~22196460:+
LUAD	cis	rs11089937	0.597	rs5757024	ENSG00000211640.3	IGLV6-57	3.66	0.000279	0.0325	0.12	0.16	Periodontitis (PAL4Q3);	chr22:22137415	chr22:22195713~22196460:+
LUAD	cis	rs11089937	0.597	rs5757026	ENSG00000211640.3	IGLV6-57	3.66	0.000279	0.0325	0.12	0.16	Periodontitis (PAL4Q3);	chr22:22137556	chr22:22195713~22196460:+
LUAD	cis	rs11089937	0.597	rs2213156	ENSG00000211640.3	IGLV6-57	3.66	0.000279	0.0325	0.12	0.16	Periodontitis (PAL4Q3);	chr22:22137852	chr22:22195713~22196460:+
LUAD	cis	rs11089937	0.626	rs9622955	ENSG00000211640.3	IGLV6-57	3.66	0.000279	0.0325	0.12	0.16	Periodontitis (PAL4Q3);	chr22:22138343	chr22:22195713~22196460:+
LUAD	cis	rs11089937	0.626	rs4821781	ENSG00000211640.3	IGLV6-57	3.66	0.000279	0.0325	0.12	0.16	Periodontitis (PAL4Q3);	chr22:22138845	chr22:22195713~22196460:+
LUAD	cis	rs11089937	0.626	rs5750589	ENSG00000211640.3	IGLV6-57	3.66	0.000279	0.0325	0.12	0.16	Periodontitis (PAL4Q3);	chr22:22139655	chr22:22195713~22196460:+
LUAD	cis	rs11089937	0.626	rs5757038	ENSG00000211640.3	IGLV6-57	3.66	0.000279	0.0325	0.12	0.16	Periodontitis (PAL4Q3);	chr22:22140149	chr22:22195713~22196460:+
LUAD	cis	rs12908161	0.959	rs12906348	ENSG00000254414.1	RP11-182J1.1	3.66	0.000279	0.0325	0.21	0.16	Schizophrenia;	chr15:84786190	chr15:84631898~84633987:-
LUAD	cis	rs1417205	1	rs1538803	ENSG00000276968.1	RP11-90M2.5	-3.66	0.000279	0.0325	-0.36	-0.16	Cannabis use (initiation);	chr13:47322760	chr13:48041751~48042184:-
LUAD	cis	rs4595586	1	rs3803020	ENSG00000257718.1	RP11-396F22.1	-3.66	0.000279	0.0325	-0.2	-0.16	Morning vs. evening chronotype;	chr12:38839969	chr12:38906451~38909592:+
LUAD	cis	rs6547741	0.935	rs6749426	ENSG00000223522.1	AC093690.1	3.66	0.000279	0.0325	0.16	0.16	Oral cavity cancer;	chr2:27624739	chr2:28307691~28310459:-
LUAD	cis	rs3805389	0.504	rs17725163	ENSG00000273257.1	RP11-177J6.1	3.66	0.000279	0.0325	0.27	0.16	Waist-to-hip ratio adjusted for body mass index;	chr4:55609280	chr4:55387949~55388271:+
LUAD	cis	rs321358	0.895	rs17457658	ENSG00000271390.1	RP11-89C3.3	3.66	0.000279	0.0326	0.26	0.16	Body mass index;	chr11:111089448	chr11:111089870~111090368:-
LUAD	cis	rs3020736	0.5	rs6002605	ENSG00000273366.1	CTA-989H11.1	3.66	0.000279	0.0326	0.2	0.16	Autism spectrum disorder or schizophrenia;	chr22:42098331	chr22:42278188~42278846:+
LUAD	cis	rs7829975	0.582	rs6983150	ENSG00000253981.4	ALG1L13P	-3.66	0.000279	0.0326	-0.19	-0.16	Mood instability;	chr8:8934916	chr8:8236003~8244667:-
LUAD	cis	rs523522	0.892	rs4767916	ENSG00000278344.1	RP11-18C24.8	3.66	0.000279	0.0326	0.23	0.16	High light scatter reticulocyte count;	chr12:120586229	chr12:120500735~120501090:-
LUAD	cis	rs36093844	0.626	rs11234502	ENSG00000279742.1	RP11-700A24.1	-3.66	0.00028	0.0326	-0.19	-0.16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85985767	chr11:85852557~85854943:-
LUAD	cis	rs4965272	1	rs6598289	ENSG00000259706.1	HSP90B2P	-3.66	0.00028	0.0326	-0.17	-0.16	Gastroesophageal reflux disease;	chr15:100047119	chr15:99257632~99260015:+
LUAD	cis	rs13014235	0.562	rs2080325	ENSG00000213090.2	AC007256.5	-3.66	0.00028	0.0326	-0.19	-0.16	Basal cell carcinoma;	chr2:201513640	chr2:201410544~201413308:-
LUAD	cis	rs877819	0.519	rs7088194	ENSG00000228403.1	RP11-563N6.6	-3.66	0.00028	0.0326	-0.16	-0.16	Systemic lupus erythematosus;	chr10:48887887	chr10:48878022~48878649:+
LUAD	cis	rs6903823	0.508	rs1778484	ENSG00000176933.5	TOB2P1	-3.66	0.00028	0.0326	-0.18	-0.16	Pulmonary function;	chr6:28273021	chr6:28217643~28218634:-
LUAD	cis	rs10911232	0.507	rs10911212	ENSG00000224468.3	RP11-181K3.4	-3.66	0.00028	0.0326	-0.15	-0.16	Hypertriglyceridemia;	chr1:183055334	chr1:183138402~183141282:-
LUAD	cis	rs5015933	0.832	rs2841332	ENSG00000232630.1	PRPS1P2	-3.66	0.00028	0.0326	-0.15	-0.16	Body mass index;	chr9:125367578	chr9:125150653~125151589:+
LUAD	cis	rs7138803	0.616	rs73114136	ENSG00000257464.1	RP11-161H23.8	-3.66	0.00028	0.0326	-0.17	-0.16	Obesity;Menarche (age at onset);Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Hip circumference;Body mass index in physically inactive individuals;Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference;Weight;Childhood body mass index;	chr12:49817623	chr12:49442424~49442652:-
LUAD	cis	rs4648739	0.657	rs28588807	ENSG00000268575.1	RP1-283E3.8	3.66	0.00028	0.0326	0.17	0.16	Severe influenza A (H1N1) infection;	chr1:1976573	chr1:1702736~1737688:-
LUAD	cis	rs2657294	0.796	rs1259501	ENSG00000226051.5	ZNF503-AS1	-3.66	0.00028	0.0326	-0.22	-0.16	Pneumonia;	chr10:75230427	chr10:75269819~75373500:+
LUAD	cis	rs10752881	1	rs6658501	ENSG00000224468.3	RP11-181K3.4	3.66	0.00028	0.0326	0.14	0.16	Colorectal cancer;	chr1:183022282	chr1:183138402~183141282:-
LUAD	cis	rs7674212	0.541	rs4699051	ENSG00000251288.2	RP11-10L12.2	-3.66	0.00028	0.0326	-0.21	-0.16	Type 2 diabetes;	chr4:103193237	chr4:102751401~102752641:+
LUAD	cis	rs2702164	1	rs1733325	ENSG00000240661.1	RP11-174O3.3	-3.66	0.00028	0.0326	-0.2	-0.16	Gut microbiome composition (winter);	chr3:120384214	chr3:120349510~120367998:+
LUAD	cis	rs2702164	1	rs1733327	ENSG00000240661.1	RP11-174O3.3	-3.66	0.00028	0.0326	-0.2	-0.16	Gut microbiome composition (winter);	chr3:120385825	chr3:120349510~120367998:+
LUAD	cis	rs2702164	0.962	rs2702156	ENSG00000240661.1	RP11-174O3.3	-3.66	0.00028	0.0326	-0.2	-0.16	Gut microbiome composition (winter);	chr3:120386200	chr3:120349510~120367998:+
LUAD	cis	rs2281636	0.755	rs2111324	ENSG00000233690.1	EBAG9P1	3.66	0.00028	0.0326	0.16	0.16	Obesity-related traits;	chr10:99636807	chr10:99697407~99697949:-
LUAD	cis	rs2832191	0.935	rs67287920	ENSG00000215533.7	LINC00189	3.66	0.00028	0.0326	0.19	0.16	Dental caries;	chr21:29151198	chr21:29193480~29288205:+
LUAD	cis	rs853679	0.517	rs9283884	ENSG00000226314.6	ZNF192P1	3.66	0.00028	0.0326	0.22	0.16	Depression;	chr6:28167882	chr6:28161781~28169594:+
LUAD	cis	rs4795519	0.826	rs35633882	ENSG00000266313.1	RP11-173M1.4	3.66	0.00028	0.0326	0.2	0.16	Chronic myeloid leukemia;	chr17:27065159	chr17:27333256~27348491:+
LUAD	cis	rs9313772	0.775	rs7724820	ENSG00000276778.1	RP11-524N5.1	3.66	0.00028	0.0326	0.16	0.16	Blood pressure;	chr5:158399245	chr5:158320683~158409773:-
LUAD	cis	rs9313772	0.775	rs9313774	ENSG00000276778.1	RP11-524N5.1	3.66	0.00028	0.0326	0.16	0.16	Blood pressure;	chr5:158400233	chr5:158320683~158409773:-
LUAD	cis	rs9313772	0.775	rs6891063	ENSG00000276778.1	RP11-524N5.1	3.66	0.00028	0.0326	0.16	0.16	Blood pressure;	chr5:158400378	chr5:158320683~158409773:-
LUAD	cis	rs9925964	0.935	rs4527034	ENSG00000232748.3	RP11-196G11.6	-3.66	0.00028	0.0326	-0.2	-0.16	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31120293	chr16:31056460~31062803:+
LUAD	cis	rs4474465	0.85	rs10899551	ENSG00000251323.2	RP11-452H21.4	3.66	0.00028	0.0326	0.2	0.16	Alzheimer's disease (survival time);	chr11:78545952	chr11:78423982~78429836:-
LUAD	cis	rs10127852	0.717	rs9729198	ENSG00000122432.15	SPATA1	3.66	0.00028	0.0326	0.3	0.16	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:84794436	chr1:84506291~84566194:+
LUAD	cis	rs10911232	0.507	rs10911222	ENSG00000224468.3	RP11-181K3.4	-3.66	0.00028	0.0326	-0.15	-0.16	Hypertriglyceridemia;	chr1:183078228	chr1:183138402~183141282:-
LUAD	cis	rs10057188	0.742	rs9293756	ENSG00000213757.3	CTC-451P13.1	3.66	0.00028	0.0326	0.14	0.16	Pulse pressure;	chr5:78622313	chr5:79284132~79284918:-
LUAD	cis	rs11583043	0.957	rs6667932	ENSG00000233184.5	RP11-421L21.3	3.66	0.00028	0.0326	0.22	0.16	Inflammatory bowel disease;Ulcerative colitis;	chr1:101038199	chr1:101025878~101087268:+
LUAD	cis	rs4237845	0.844	rs7306124	ENSG00000245651.2	RP11-620J15.2	3.66	0.00028	0.0326	0.17	0.16	Intelligence (multi-trait analysis);	chr12:57909566	chr12:57869835~57896482:-
LUAD	cis	rs73193808	0.901	rs8128235	ENSG00000215533.7	LINC00189	-3.66	0.00028	0.0326	-0.23	-0.16	Coronary artery disease;	chr21:29193197	chr21:29193480~29288205:+
LUAD	cis	rs9813712	0.571	rs9824426	ENSG00000253540.4	FAM86HP	-3.66	0.00028	0.0326	-0.17	-0.16	Response to amphetamines;	chr3:130226115	chr3:130099092~130111472:-
LUAD	cis	rs2274273	0.624	rs67386901	ENSG00000258413.1	RP11-665C16.6	-3.66	0.00028	0.0326	-0.22	-0.16	Protein biomarker;	chr14:55290646	chr14:55262767~55272075:-
LUAD	cis	rs2274273	0.624	rs7140628	ENSG00000258413.1	RP11-665C16.6	-3.66	0.00028	0.0326	-0.22	-0.16	Protein biomarker;	chr14:55293963	chr14:55262767~55272075:-
LUAD	cis	rs2274273	0.624	rs7154796	ENSG00000258413.1	RP11-665C16.6	-3.66	0.00028	0.0326	-0.22	-0.16	Protein biomarker;	chr14:55304740	chr14:55262767~55272075:-
LUAD	cis	rs2274273	0.624	rs10129505	ENSG00000258413.1	RP11-665C16.6	-3.66	0.00028	0.0326	-0.22	-0.16	Protein biomarker;	chr14:55309657	chr14:55262767~55272075:-
LUAD	cis	rs2274273	0.624	rs68138420	ENSG00000258413.1	RP11-665C16.6	-3.66	0.00028	0.0326	-0.22	-0.16	Protein biomarker;	chr14:55311249	chr14:55262767~55272075:-
LUAD	cis	rs858239	0.601	rs12539331	ENSG00000226816.2	AC005082.12	3.66	0.00028	0.0326	0.22	0.16	Cerebrospinal fluid biomarker levels;	chr7:23111711	chr7:23206013~23208045:+
LUAD	cis	rs12440869	0.96	rs8034421	ENSG00000270964.1	RP11-502I4.3	3.66	0.00028	0.0326	0.19	0.16	Peak velocity of the mitral A-wave;	chr15:67210234	chr15:67541072~67542604:-
LUAD	cis	rs11673344	0.518	rs73033134	ENSG00000267254.4	ZNF790-AS1	-3.66	0.00028	0.0326	-0.21	-0.16	Obesity-related traits;	chr19:37596046	chr19:36797518~36828115:+
LUAD	cis	rs62103177	0.513	rs9945153	ENSG00000261126.6	RP11-795F19.1	3.66	0.00028	0.0326	0.23	0.16	Opioid sensitivity;	chr18:79838450	chr18:80046900~80095482:+
LUAD	cis	rs7246657	0.653	rs28701616	ENSG00000267309.1	CTD-2630F21.1	3.66	0.00028	0.0326	0.28	0.16	Coronary artery calcification;	chr19:37190196	chr19:36489649~36491040:+
LUAD	cis	rs4072705	1	rs4240487	ENSG00000236643.1	RP11-175D17.3	-3.66	0.00028	0.0326	-0.19	-0.16	Menarche (age at onset);	chr9:124608028	chr9:124770123~124772927:+
LUAD	cis	rs1348850	0.918	rs4893966	ENSG00000213963.5	AC074286.1	3.66	0.00028	0.0326	0.2	0.16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177605410	chr2:177283508~177392691:-
LUAD	cis	rs13113518	1	rs7660980	ENSG00000223305.1	RN7SKP30	-3.66	0.00028	0.0326	-0.19	-0.16	Height;	chr4:55542948	chr4:55540502~55540835:-
LUAD	cis	rs9487094	0.614	rs11968978	ENSG00000260273.1	RP11-425D10.10	3.66	0.00028	0.0326	0.24	0.16	Height;	chr6:109775693	chr6:109382795~109383666:+
LUAD	cis	rs56205728	0.606	rs3784397	ENSG00000176753.5	C15orf56	-3.66	0.00028	0.0326	-0.17	-0.16	Schizophrenia;	chr15:40304643	chr15:40250664~40252969:-
LUAD	cis	rs9951698	0.608	rs692833	ENSG00000266969.1	RP11-773H22.4	3.66	0.00028	0.0326	0.21	0.16	Intelligence (multi-trait analysis);	chr18:13135434	chr18:12984694~12991173:-
LUAD	cis	rs2688608	0.901	rs2664280	ENSG00000271816.1	BMS1P4	-3.66	0.000281	0.0327	-0.14	-0.16	Inflammatory bowel disease;	chr10:73857586	chr10:73699151~73730487:-
LUAD	cis	rs10752881	0.905	rs10797830	ENSG00000224468.3	RP11-181K3.4	-3.66	0.000281	0.0327	-0.15	-0.16	Colorectal cancer;	chr1:183067139	chr1:183138402~183141282:-
LUAD	cis	rs7003550	0.951	rs10110381	ENSG00000254028.1	AC083843.2	-3.66	0.000281	0.0327	-0.21	-0.16	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr8:134853940	chr8:134832747~134834482:+
LUAD	cis	rs990171	0.538	rs4851599	ENSG00000234389.1	AC007278.3	3.66	0.000281	0.0327	0.16	0.16	Lymphocyte counts;	chr2:102499561	chr2:102438713~102440475:+
LUAD	cis	rs4713118	0.513	rs149989	ENSG00000216901.1	AL022393.7	3.66	0.000281	0.0327	0.2	0.16	Parkinson's disease;	chr6:28030406	chr6:28176188~28176674:+
LUAD	cis	rs6547741	1	rs6750943	ENSG00000223522.1	AC093690.1	3.66	0.000281	0.0327	0.16	0.16	Oral cavity cancer;	chr2:27555037	chr2:28307691~28310459:-
LUAD	cis	rs73198271	0.96	rs11776546	ENSG00000253893.2	FAM85B	3.66	0.000281	0.0327	0.23	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751671	chr8:8167819~8226614:-
LUAD	cis	rs2494663	0.56	rs55696120	ENSG00000223599.1	RP11-216N14.7	3.66	0.000281	0.0327	0.2	0.16	Mean platelet volume;	chr1:154077123	chr1:153852106~153853414:-
LUAD	cis	rs3764021	0.87	rs7956831	ENSG00000278635.1	CTD-2318O12.1	3.66	0.000281	0.0327	0.14	0.16	Type 1 diabetes;	chr12:9736561	chr12:9415641~9416718:+
LUAD	cis	rs11624221	0.896	rs7144257	ENSG00000199436.1	SNORD9	-3.66	0.000281	0.0327	-0.18	-0.16	Blood protein levels;	chr14:20669846	chr14:21392150~21392253:-
LUAD	cis	rs801193	0.569	rs2707824	ENSG00000273448.1	RP11-166O4.6	3.66	0.000281	0.0327	0.16	0.16	Aortic root size;	chr7:66724256	chr7:67333047~67334383:+
LUAD	cis	rs13021401	1	rs342069	ENSG00000228950.1	AC023137.2	3.66	0.000281	0.0327	0.19	0.16	Systemic sclerosis;	chr2:20485834	chr2:20451042~20452947:+
LUAD	cis	rs7960884	0.655	rs7960330	ENSG00000177359.16	RP11-551L14.1	3.66	0.000281	0.0327	0.18	0.16	Systolic blood pressure response to hydrochlorothiazide in hypertension;	chr12:31230346	chr12:31111652~31206154:-
LUAD	cis	rs3916	0.955	rs35525135	ENSG00000277423.1	RP11-173P15.9	-3.66	0.000281	0.0327	-0.21	-0.16	Urinary metabolites (H-NMR features);	chr12:120702261	chr12:120703867~120704282:+
LUAD	cis	rs10917151	1	rs10917151	ENSG00000234397.3	RP11-415K20.1	3.66	0.000281	0.0327	0.26	0.16	Endometriosis;	chr1:22096228	chr1:22322840~22323331:-
LUAD	cis	rs10510102	0.935	rs7907871	ENSG00000276742.1	RP11-500G22.4	3.66	0.000281	0.0327	0.26	0.16	Breast cancer;	chr10:121878185	chr10:121956782~121957098:+
LUAD	cis	rs6951245	0.744	rs10265736	ENSG00000229043.2	AC091729.9	-3.66	0.000281	0.0327	-0.24	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1132829	chr7:1160374~1165267:+
LUAD	cis	rs683250	0.599	rs5003308	ENSG00000246067.6	RAB30-AS1	-3.66	0.000281	0.0327	-0.18	-0.16	Subcortical brain region volumes;	chr11:83358762	chr11:83072066~83106719:+
LUAD	cis	rs11673344	0.503	rs7246720	ENSG00000276846.1	CTD-3220F14.3	3.66	0.000281	0.0327	0.18	0.16	Obesity-related traits;	chr19:37073726	chr19:37314868~37315620:-
LUAD	cis	rs9303029	0.611	rs12449726	ENSG00000265458.1	RP13-20L14.6	3.66	0.000281	0.0327	0.35	0.16	Protein quantitative trait loci;	chr17:82450007	chr17:82454273~82458521:-
LUAD	cis	rs7937127	0.744	rs72898983	ENSG00000254907.1	RP11-484D2.2	3.66	0.000281	0.0327	0.28	0.16	Fibrinogen levels;	chr11:43338864	chr11:43328748~43359296:-
LUAD	cis	rs7937127	0.696	rs72898993	ENSG00000254907.1	RP11-484D2.2	3.66	0.000281	0.0327	0.28	0.16	Fibrinogen levels;	chr11:43352649	chr11:43328748~43359296:-
LUAD	cis	rs7937127	0.744	rs72898994	ENSG00000254907.1	RP11-484D2.2	3.66	0.000281	0.0327	0.28	0.16	Fibrinogen levels;	chr11:43357020	chr11:43328748~43359296:-
LUAD	cis	rs7937127	0.696	rs72898996	ENSG00000254907.1	RP11-484D2.2	3.66	0.000281	0.0327	0.28	0.16	Fibrinogen levels;	chr11:43359775	chr11:43328748~43359296:-
LUAD	cis	rs875971	0.545	rs6460276	ENSG00000224316.1	RP11-479O9.2	3.66	0.000281	0.0327	0.19	0.16	Aortic root size;	chr7:66182290	chr7:65773620~65802067:+
LUAD	cis	rs5751168	0.598	rs7290828	ENSG00000211654.2	IGLV5-37	3.66	0.000281	0.0327	0.24	0.16	Prostate cancer (SNP x SNP interaction);	chr22:22509461	chr22:22427540~22428035:+
LUAD	cis	rs2074409	0.509	rs853231	ENSG00000276054.1	RP11-378E13.3	3.66	0.000281	0.0327	0.2	0.16	Response to angiotensin II receptor blocker therapy;	chr17:37454281	chr17:37386886~37387926:+
LUAD	cis	rs745109	0.504	rs75610186	ENSG00000273080.1	RP11-301O19.1	3.66	0.000281	0.0327	0.27	0.16	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86372933	chr2:86195590~86196049:+
LUAD	cis	rs987724	0.593	rs12634915	ENSG00000240875.4	LINC00886	-3.66	0.000281	0.0327	-0.18	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156974446	chr3:156747346~156817062:-
LUAD	cis	rs875971	0.619	rs10278371	ENSG00000222364.1	RNU6-96P	3.66	0.000281	0.0327	0.18	0.16	Aortic root size;	chr7:66586553	chr7:66395191~66395286:+
LUAD	cis	rs5742933	0.948	rs7592066	ENSG00000253559.1	OSGEPL1-AS1	3.66	0.000281	0.0327	0.2	0.16	Ferritin levels;	chr2:189778792	chr2:189762704~189765556:+
LUAD	cis	rs5742933	0.779	rs7595020	ENSG00000253559.1	OSGEPL1-AS1	3.66	0.000281	0.0327	0.2	0.16	Ferritin levels;	chr2:189778950	chr2:189762704~189765556:+
LUAD	cis	rs2554380	0.55	rs12904106	ENSG00000230373.7	GOLGA6L5P	-3.66	0.000281	0.0327	-0.19	-0.16	Height;	chr15:83842571	chr15:84507885~84516814:-
LUAD	cis	rs7772486	0.625	rs9390355	ENSG00000235652.6	RP11-545I5.3	-3.66	0.000281	0.0327	-0.16	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145791806	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.658	rs4895683	ENSG00000235652.6	RP11-545I5.3	-3.66	0.000281	0.0327	-0.16	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145792518	chr6:145799409~145886585:+
LUAD	cis	rs7189233	1	rs7189233	ENSG00000279344.1	RP11-44F14.7	3.66	0.000281	0.0327	0.14	0.16	Intelligence (multi-trait analysis);	chr16:53421471	chr16:53478957~53481550:-
LUAD	cis	rs288326	0.561	rs75466155	ENSG00000213958.2	KRT18P29	-3.66	0.000281	0.0327	-0.35	-0.16	Blood protein levels;	chr2:182842076	chr2:181961212~181962478:-
LUAD	cis	rs763121	0.626	rs5750643	ENSG00000228274.3	RP3-508I15.9	-3.66	0.000281	0.0327	-0.16	-0.16	Menopause (age at onset);	chr22:38613012	chr22:38667585~38681820:-
LUAD	cis	rs2638953	0.924	rs2272361	ENSG00000278733.1	RP11-425D17.1	-3.66	0.000281	0.0327	-0.19	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28450037	chr12:28185625~28186190:-
LUAD	cis	rs6951245	1	rs75488469	ENSG00000224079.1	AC091729.7	-3.66	0.000281	0.0327	-0.26	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1062486	chr7:1074450~1078036:+
LUAD	cis	rs6120849	0.951	rs6120848	ENSG00000202150.1	RNU6-407P	3.66	0.000281	0.0327	0.23	0.16	Protein C levels;	chr20:35140875	chr20:35030317~35030420:-
LUAD	cis	rs1823913	0.599	rs1823912	ENSG00000230611.1	HMGB1P27	-3.66	0.000281	0.0327	-0.19	-0.16	Obesity-related traits;	chr2:191266388	chr2:191174233~191174835:+
LUAD	cis	rs338389	0.516	rs7359201	ENSG00000270964.1	RP11-502I4.3	-3.66	0.000281	0.0327	-0.17	-0.16	Survival in rectal cancer;	chr15:68021411	chr15:67541072~67542604:-
LUAD	cis	rs3805389	0.504	rs13434995	ENSG00000249700.7	SRD5A3-AS1	-3.66	0.000281	0.0327	-0.24	-0.16	Waist-to-hip ratio adjusted for body mass index;	chr4:55601047	chr4:55363971~55395847:-
LUAD	cis	rs7429990	1	rs1684942	ENSG00000228638.1	FCF1P2	-3.66	0.000281	0.0327	-0.19	-0.16	Educational attainment (years of education);	chr3:47859213	chr3:48290793~48291375:-
LUAD	cis	rs270601	0.77	rs10463891	ENSG00000263597.1	MIR3936	-3.66	0.000281	0.0327	-0.17	-0.16	Acylcarnitine levels;	chr5:132261699	chr5:132365490~132365599:-
LUAD	cis	rs8056893	0.885	rs7199750	ENSG00000260441.4	RP11-96D1.7	-3.66	0.000281	0.0327	-0.19	-0.16	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68317956	chr16:68256162~68260443:-
LUAD	cis	rs6460942	1	rs6970095	ENSG00000226690.5	AC005281.1	3.66	0.000281	0.0327	0.3	0.16	Coronary artery disease;	chr7:12364214	chr7:12496429~12541910:+
LUAD	cis	rs2803122	0.871	rs10481512	ENSG00000273226.1	RP11-513M16.8	-3.66	0.000281	0.0327	-0.17	-0.16	Pulse pressure;	chr9:19230741	chr9:19375451~19375996:+
LUAD	cis	rs9595908	0.708	rs12429740	ENSG00000281026.1	N4BP2L2-IT2	-3.66	0.000281	0.0327	-0.1	-0.16	Body mass index;	chr13:32684928	chr13:32504506~32509395:-
LUAD	cis	rs3753275	0.519	rs6702457	ENSG00000232912.4	RP5-1115A15.1	3.66	0.000281	0.0327	0.19	0.16	Educational attainment;	chr1:8685652	chr1:8424645~8434838:+
LUAD	cis	rs7949566	0.647	rs4502008	ENSG00000254671.2	STT3A-AS1	-3.66	0.000281	0.0327	-0.19	-0.16	Platelet distribution width;Mean platelet volume;	chr11:126417859	chr11:125570284~125592568:-
LUAD	cis	rs237743	1	rs237711	ENSG00000177410.11	ZFAS1	3.66	0.000282	0.0327	0.18	0.16	Height;	chr20:49310319	chr20:49278178~49295738:+
LUAD	cis	rs7550648	1	rs7541917	ENSG00000236773.1	RP11-365O16.1	3.66	0.000282	0.0328	0.2	0.16	Cancer;	chr1:224519399	chr1:224175476~224175706:-
LUAD	cis	rs67478160	0.619	rs12886363	ENSG00000272533.1	SNORA28	3.66	0.000282	0.0328	0.17	0.16	Schizophrenia;	chr14:103807449	chr14:103337849~103337974:+
LUAD	cis	rs4713118	0.615	rs9348772	ENSG00000280107.1	AL022393.9	-3.66	0.000282	0.0328	-0.19	-0.16	Parkinson's disease;	chr6:27688311	chr6:28170845~28172521:+
LUAD	cis	rs13113518	0.783	rs7690837	ENSG00000273257.1	RP11-177J6.1	3.66	0.000282	0.0328	0.19	0.16	Height;	chr4:55575856	chr4:55387949~55388271:+
LUAD	cis	rs6496044	0.568	rs10468112	ENSG00000259416.2	RP11-158M2.5	3.66	0.000282	0.0328	0.17	0.16	Interstitial lung disease;	chr15:85530193	chr15:85754941~85756237:-
LUAD	cis	rs7077256	0.564	rs12762639	ENSG00000272767.1	JMJD1C-AS1	3.66	0.000282	0.0328	0.25	0.16	Intelligence (multi-trait analysis);	chr10:63353093	chr10:63465229~63466563:+
LUAD	cis	rs1124769	0.525	rs8033807	ENSG00000259378.1	DCAF13P3	3.66	0.000282	0.0328	0.22	0.16	Cognitive performance;	chr15:50778531	chr15:50944663~50945996:+
LUAD	cis	rs34929064	0.958	rs4722167	ENSG00000230658.1	KLHL7-AS1	3.66	0.000282	0.0328	0.23	0.16	Major depression and alcohol dependence;	chr7:22700693	chr7:23101228~23105703:-
LUAD	cis	rs10504130	0.932	rs77831588	ENSG00000253475.1	RP11-110G21.2	-3.66	0.000282	0.0328	-0.28	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr8:51946419	chr8:51895957~51896374:-
LUAD	cis	rs11790994	0.524	rs12352803	ENSG00000271155.1	RP11-435O5.5	3.66	0.000282	0.0328	0.3	0.16	Inattentive symptoms;	chr9:95721614	chr9:95506235~95507636:+
LUAD	cis	rs9595908	0.709	rs4942892	ENSG00000281026.1	N4BP2L2-IT2	3.66	0.000282	0.0328	0.1	0.16	Body mass index;	chr13:32754269	chr13:32504506~32509395:-
LUAD	cis	rs812925	0.537	rs778139	ENSG00000271889.1	RP11-493E12.1	-3.66	0.000282	0.0328	-0.19	-0.16	Immature fraction of reticulocytes;	chr2:61457429	chr2:61151433~61162105:-
LUAD	cis	rs2346177	0.806	rs56048837	ENSG00000279254.1	RP11-536C12.1	-3.66	0.000282	0.0328	-0.18	-0.16	HDL cholesterol;	chr2:46429508	chr2:46668870~46670778:+
LUAD	cis	rs990171	0.511	rs2072509	ENSG00000234389.1	AC007278.3	3.66	0.000282	0.0328	0.16	0.16	Lymphocyte counts;	chr2:102501878	chr2:102438713~102440475:+
LUAD	cis	rs782590	0.607	rs2061032	ENSG00000272606.1	RP11-554J4.1	-3.66	0.000282	0.0328	-0.17	-0.16	Metabolic syndrome;	chr2:55452354	chr2:55617909~55618373:+
LUAD	cis	rs950173	1	rs6716901	ENSG00000228389.1	AC068039.4	3.66	0.000282	0.0328	0.27	0.16	Hippocampal volume;	chr2:171816943	chr2:171773482~171775844:+
LUAD	cis	rs1876905	0.569	rs354523	ENSG00000271789.1	RP5-1112D6.7	-3.66	0.000282	0.0328	-0.23	-0.16	Mean corpuscular hemoglobin;	chr6:111188122	chr6:111297126~111298510:+
LUAD	cis	rs6661961	0.714	rs12069640	ENSG00000237975.5	FLG-AS1	-3.66	0.000282	0.0328	-0.23	-0.16	Atopic dermatitis;	chr1:152444300	chr1:152168125~152445456:+
LUAD	cis	rs755249	1	rs61779359	ENSG00000237624.1	OXCT2P1	3.66	0.000282	0.0328	0.24	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39544563	chr1:39514956~39516490:+
LUAD	cis	rs755249	0.959	rs61781363	ENSG00000237624.1	OXCT2P1	3.66	0.000282	0.0328	0.24	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39546761	chr1:39514956~39516490:+
LUAD	cis	rs755249	1	rs4660808	ENSG00000237624.1	OXCT2P1	3.66	0.000282	0.0328	0.24	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39552837	chr1:39514956~39516490:+
LUAD	cis	rs755249	1	rs61781364	ENSG00000237624.1	OXCT2P1	3.66	0.000282	0.0328	0.24	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39553919	chr1:39514956~39516490:+
LUAD	cis	rs8180040	0.966	rs11130137	ENSG00000271161.1	BOLA2P2	3.66	0.000282	0.0328	0.16	0.16	Colorectal cancer;	chr3:47537348	chr3:47499841~47500407:+
LUAD	cis	rs4716602	0.572	rs10271030	ENSG00000235029.1	MNX1-AS2	-3.66	0.000282	0.0328	-0.2	-0.16	Anti-saccade response;	chr7:156367102	chr7:157006307~157007132:+
LUAD	cis	rs481331	0.932	rs210228	ENSG00000185904.10	LINC00839	-3.66	0.000282	0.0328	-0.27	-0.16	Systemic juvenile idiopathic arthritis;	chr10:42507610	chr10:42475543~42495336:+
LUAD	cis	rs116095464	0.558	rs13357299	ENSG00000248925.1	CTD-2083E4.6	3.66	0.000282	0.0328	0.28	0.16	Breast cancer;	chr5:242096	chr5:269858~271516:-
LUAD	cis	rs1075265	0.783	rs698858	ENSG00000272156.1	RP11-477N3.1	-3.66	0.000282	0.0328	-0.2	-0.16	Chronotype;Morning vs. evening chronotype;	chr2:53943333	chr2:54082554~54085066:+
LUAD	cis	rs3213958	0.574	rs73138004	ENSG00000249274.1	PDLIM1P4	-3.66	0.000282	0.0328	-0.26	-0.16	Blood protein levels;	chr3:98825460	chr3:98782188~98783193:+
LUAD	cis	rs12073359	1	rs2318763	ENSG00000223945.2	RP11-458I7.1	-3.66	0.000282	0.0328	-0.24	-0.16	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150143798	chr1:150053864~150055034:+
LUAD	cis	rs12073359	0.954	rs72694950	ENSG00000223945.2	RP11-458I7.1	-3.66	0.000282	0.0328	-0.24	-0.16	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150146961	chr1:150053864~150055034:+
LUAD	cis	rs4648739	0.613	rs7528894	ENSG00000268575.1	RP1-283E3.8	3.66	0.000282	0.0328	0.16	0.16	Severe influenza A (H1N1) infection;	chr1:1976473	chr1:1702736~1737688:-
LUAD	cis	rs911555	0.723	rs11160751	ENSG00000259775.1	RP11-45P15.4	-3.66	0.000282	0.0328	-0.21	-0.16	Intelligence (multi-trait analysis);	chr14:103459403	chr14:103331674~103332367:-
LUAD	cis	rs867371	0.614	rs7183805	ENSG00000255769.6	GOLGA2P10	-3.66	0.000282	0.0328	-0.21	-0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82247090	chr15:82472993~82513950:-
LUAD	cis	rs8048589	0.75	rs12926900	ENSG00000175604.2	RP11-276H1.3	-3.66	0.000282	0.0328	-0.2	-0.16	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12090227	chr16:12086746~12090302:-
LUAD	cis	rs6866614	0.605	rs5029422	ENSG00000233006.5	AC034220.3	3.66	0.000282	0.0328	0.16	0.16	Perceived unattractiveness to mosquitoes;	chr5:132054921	chr5:132311285~132369916:-
LUAD	cis	rs137603	0.932	rs137602	ENSG00000235209.1	CTA-150C2.13	-3.66	0.000282	0.0328	-0.19	-0.16	Primary biliary cholangitis;	chr22:39297403	chr22:38921227~38924708:+
LUAD	cis	rs7017914	0.935	rs2732093	ENSG00000246366.5	RP11-382J12.1	3.66	0.000282	0.0328	0.15	0.16	Bone mineral density;	chr8:71006844	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.905	rs2639899	ENSG00000246366.5	RP11-382J12.1	3.66	0.000282	0.0328	0.15	0.16	Bone mineral density;	chr8:71007227	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.875	rs2639897	ENSG00000246366.5	RP11-382J12.1	3.66	0.000282	0.0328	0.15	0.16	Bone mineral density;	chr8:71008441	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.905	rs2639896	ENSG00000246366.5	RP11-382J12.1	3.66	0.000282	0.0328	0.15	0.16	Bone mineral density;	chr8:71008548	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.87	rs1353057	ENSG00000246366.5	RP11-382J12.1	3.66	0.000282	0.0328	0.15	0.16	Bone mineral density;	chr8:71009862	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.905	rs2639960	ENSG00000246366.5	RP11-382J12.1	3.66	0.000282	0.0328	0.15	0.16	Bone mineral density;	chr8:71009904	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.905	rs2639958	ENSG00000246366.5	RP11-382J12.1	3.66	0.000282	0.0328	0.15	0.16	Bone mineral density;	chr8:71009915	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.905	rs1908036	ENSG00000246366.5	RP11-382J12.1	3.66	0.000282	0.0328	0.15	0.16	Bone mineral density;	chr8:71010089	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.905	rs1908035	ENSG00000246366.5	RP11-382J12.1	3.66	0.000282	0.0328	0.15	0.16	Bone mineral density;	chr8:71010173	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.905	rs1908034	ENSG00000246366.5	RP11-382J12.1	3.66	0.000282	0.0328	0.15	0.16	Bone mineral density;	chr8:71010319	chr8:70608577~70663279:+
LUAD	cis	rs6728642	0.831	rs10496325	ENSG00000230606.9	AC159540.1	-3.66	0.000283	0.0328	-0.24	-0.16	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97017592	chr2:97416165~97433527:-
LUAD	cis	rs1044826	1	rs10935323	ENSG00000214280.3	RP11-553K23.2	-3.66	0.000283	0.0328	-0.2	-0.16	Obesity-related traits;	chr3:139391293	chr3:139582928~139583593:-
LUAD	cis	rs2274273	0.638	rs67416413	ENSG00000258413.1	RP11-665C16.6	-3.66	0.000283	0.0328	-0.23	-0.16	Protein biomarker;	chr14:55235545	chr14:55262767~55272075:-
LUAD	cis	rs2274273	0.615	rs67008693	ENSG00000258413.1	RP11-665C16.6	-3.66	0.000283	0.0328	-0.23	-0.16	Protein biomarker;	chr14:55235975	chr14:55262767~55272075:-
LUAD	cis	rs17275866	0.862	rs17275084	ENSG00000250596.1	RP11-440I14.2	3.66	0.000283	0.0328	0.22	0.16	Chin dimples;	chr4:174140407	chr4:174523701~174540344:-
LUAD	cis	rs10751667	0.6	rs7394783	ENSG00000255284.1	AP006621.5	-3.66	0.000283	0.0329	-0.14	-0.16	Alzheimer's disease (late onset);	chr11:1005108	chr11:777578~784297:+
LUAD	cis	rs2625529	0.73	rs6494975	ENSG00000260173.1	RP11-2I17.4	3.66	0.000283	0.0329	0.2	0.16	Red blood cell count;	chr15:71885484	chr15:72140504~72155459:-
LUAD	cis	rs11159086	0.793	rs1860108	ENSG00000270000.1	RP3-449M8.9	3.66	0.000283	0.0329	0.23	0.16	Advanced glycation end-product levels;	chr14:74478562	chr14:74471930~74472360:-
LUAD	cis	rs11159086	0.793	rs3784035	ENSG00000270000.1	RP3-449M8.9	3.66	0.000283	0.0329	0.23	0.16	Advanced glycation end-product levels;	chr14:74482221	chr14:74471930~74472360:-
LUAD	cis	rs11159086	0.793	rs12433382	ENSG00000270000.1	RP3-449M8.9	3.66	0.000283	0.0329	0.23	0.16	Advanced glycation end-product levels;	chr14:74482940	chr14:74471930~74472360:-
LUAD	cis	rs11159086	0.793	rs10148268	ENSG00000270000.1	RP3-449M8.9	3.66	0.000283	0.0329	0.23	0.16	Advanced glycation end-product levels;	chr14:74484261	chr14:74471930~74472360:-
LUAD	cis	rs2823962	0.927	rs1119223	ENSG00000270093.1	AP000473.8	3.66	0.000283	0.0329	0.17	0.16	Amyotrophic lateral sclerosis;	chr21:16658584	chr21:16643529~16645065:+
LUAD	cis	rs2553026	0.758	rs1863186	ENSG00000229754.1	CXCR2P1	-3.66	0.000283	0.0329	-0.18	-0.16	Height;	chr2:217288749	chr2:218059155~218065729:-
LUAD	cis	rs526231	0.543	rs72785717	ENSG00000250682.4	LINC00491	3.66	0.000283	0.0329	0.22	0.16	Primary biliary cholangitis;	chr5:102997401	chr5:102609156~102671559:-
LUAD	cis	rs11018904	0.906	rs7925507	ENSG00000280367.1	RP11-121L10.2	3.66	0.000283	0.0329	0.22	0.16	Intelligence (multi-trait analysis);	chr11:90206978	chr11:90223153~90226538:+
LUAD	cis	rs4363385	0.693	rs4845497	ENSG00000223599.1	RP11-216N14.7	-3.66	0.000283	0.0329	-0.19	-0.16	Inflammatory skin disease;	chr1:152931686	chr1:153852106~153853414:-
LUAD	cis	rs8031584	0.958	rs61997079	ENSG00000259845.1	HERC2P10	3.66	0.000283	0.0329	0.19	0.16	Huntington's disease progression;	chr15:30946068	chr15:30815271~30844153:+
LUAD	cis	rs8031584	0.958	rs11637469	ENSG00000259845.1	HERC2P10	3.66	0.000283	0.0329	0.19	0.16	Huntington's disease progression;	chr15:30946580	chr15:30815271~30844153:+
LUAD	cis	rs911555	0.723	rs4906320	ENSG00000259775.1	RP11-45P15.4	3.66	0.000283	0.0329	0.22	0.16	Intelligence (multi-trait analysis);	chr14:103410588	chr14:103331674~103332367:-
LUAD	cis	rs2348418	0.715	rs4931083	ENSG00000244712.1	RP11-874G11.1	-3.66	0.000283	0.0329	-0.2	-0.16	Lung function (FEV1);Lung function (FVC);	chr12:28568952	chr12:28564678~28565141:-
LUAD	cis	rs910316	0.737	rs175055	ENSG00000279594.1	RP11-950C14.10	-3.66	0.000283	0.0329	-0.19	-0.16	Height;	chr14:75022243	chr14:75011269~75012851:-
LUAD	cis	rs10419113	0.522	rs6510102	ENSG00000270804.1	CTD-2583A14.11	3.66	0.000283	0.0329	0.16	0.16	Pediatric bone mineral density (spine);	chr19:57797273	chr19:57867885~57868834:+
LUAD	cis	rs4561483	0.583	rs1019814	ENSG00000261216.1	RP11-166B2.5	3.66	0.000283	0.0329	0.17	0.16	Testicular germ cell tumor;	chr16:11846907	chr16:11908208~11908916:+
LUAD	cis	rs4561483	0.583	rs1019813	ENSG00000261216.1	RP11-166B2.5	3.66	0.000283	0.0329	0.17	0.16	Testicular germ cell tumor;	chr16:11846972	chr16:11908208~11908916:+
LUAD	cis	rs4713118	0.568	rs9468213	ENSG00000280107.1	AL022393.9	-3.66	0.000283	0.0329	-0.19	-0.16	Parkinson's disease;	chr6:27738401	chr6:28170845~28172521:+
LUAD	cis	rs8114671	0.967	rs6142323	ENSG00000269202.1	RP4-614O4.12	3.66	0.000283	0.0329	0.16	0.16	Height;	chr20:35201180	chr20:35201747~35203288:-
LUAD	cis	rs9467773	0.62	rs2451741	ENSG00000261353.1	CTA-14H9.5	-3.66	0.000283	0.0329	-0.19	-0.16	Intelligence (multi-trait analysis);	chr6:26629176	chr6:26527063~26527404:+
LUAD	cis	rs10829156	0.66	rs7910506	ENSG00000240291.1	RP11-499P20.2	-3.66	0.000283	0.0329	-0.14	-0.16	Sudden cardiac arrest;	chr10:18518128	chr10:18513115~18545651:-
LUAD	cis	rs9303029	0.611	rs9909476	ENSG00000265458.1	RP13-20L14.6	-3.66	0.000283	0.0329	-0.34	-0.16	Protein quantitative trait loci;	chr17:82481857	chr17:82454273~82458521:-
LUAD	cis	rs9900280	1	rs605898	ENSG00000264808.1	RP11-802D6.1	-3.66	0.000283	0.0329	-0.19	-0.16	Mean platelet volume;	chr17:29529478	chr17:29369717~29390777:-
LUAD	cis	rs9900280	0.967	rs514334	ENSG00000264808.1	RP11-802D6.1	-3.66	0.000283	0.0329	-0.19	-0.16	Mean platelet volume;	chr17:29529559	chr17:29369717~29390777:-
LUAD	cis	rs9900280	0.967	rs508694	ENSG00000264808.1	RP11-802D6.1	-3.66	0.000283	0.0329	-0.19	-0.16	Mean platelet volume;	chr17:29529905	chr17:29369717~29390777:-
LUAD	cis	rs6493487	0.512	rs12324214	ENSG00000273674.3	CTD-2378E12.1	-3.66	0.000283	0.0329	-0.23	-0.16	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50827284	chr15:50839875~50908599:-
LUAD	cis	rs950169	0.763	rs35372971	ENSG00000188388.10	GOLGA6L3	3.66	0.000283	0.0329	0.22	0.16	Schizophrenia;	chr15:84387097	chr15:85240472~85247170:+
LUAD	cis	rs2239547	0.525	rs2246556	ENSG00000242142.1	SERBP1P3	-3.66	0.000283	0.0329	-0.18	-0.16	Schizophrenia;	chr3:52993967	chr3:53064283~53065091:-
LUAD	cis	rs8046148	0.724	rs7203348	ENSG00000279356.1	RP11-429P3.8	3.66	0.000283	0.0329	0.17	0.16	Testicular germ cell tumor;	chr16:50078356	chr16:50072862~50074986:+
LUAD	cis	rs4819052	0.851	rs9979545	ENSG00000223768.1	LINC00205	-3.66	0.000283	0.0329	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259890	chr21:45293285~45297354:+
LUAD	cis	rs4819052	0.851	rs7276591	ENSG00000223768.1	LINC00205	-3.66	0.000283	0.0329	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260241	chr21:45293285~45297354:+
LUAD	cis	rs7129556	0.815	rs72947625	ENSG00000241782.1	RP11-91P24.1	3.66	0.000283	0.0329	0.24	0.16	Weight loss (gastric bypass surgery);	chr11:77688557	chr11:77868722~77869195:-
LUAD	cis	rs2274273	0.87	rs10139083	ENSG00000258413.1	RP11-665C16.6	-3.66	0.000283	0.0329	-0.21	-0.16	Protein biomarker;	chr14:55316017	chr14:55262767~55272075:-
LUAD	cis	rs4865762	0.512	rs62357423	ENSG00000247796.2	CTD-2366F13.1	3.66	0.000283	0.0329	0.18	0.16	Intraocular pressure;	chr5:53209626	chr5:53109842~53115126:+
LUAD	cis	rs4865762	0.512	rs62357424	ENSG00000247796.2	CTD-2366F13.1	3.66	0.000283	0.0329	0.18	0.16	Intraocular pressure;	chr5:53209861	chr5:53109842~53115126:+
LUAD	cis	rs4865762	0.512	rs56686182	ENSG00000247796.2	CTD-2366F13.1	3.66	0.000283	0.0329	0.18	0.16	Intraocular pressure;	chr5:53211721	chr5:53109842~53115126:+
LUAD	cis	rs6467136	0.901	rs10954161	ENSG00000224138.1	AC000123.4	3.66	0.000283	0.0329	0.16	0.16	Type 2 diabetes;	chr7:127571421	chr7:127350128~127351523:+
LUAD	cis	rs6502050	0.835	rs4789677	ENSG00000275966.1	RP11-1055B8.9	-3.66	0.000283	0.0329	-0.17	-0.16	Life satisfaction;	chr17:82161966	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.799	rs12940433	ENSG00000275966.1	RP11-1055B8.9	-3.66	0.000283	0.0329	-0.17	-0.16	Life satisfaction;	chr17:82162950	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.799	rs34448080	ENSG00000275966.1	RP11-1055B8.9	-3.66	0.000283	0.0329	-0.17	-0.16	Life satisfaction;	chr17:82163399	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs34867501	ENSG00000275966.1	RP11-1055B8.9	-3.66	0.000283	0.0329	-0.17	-0.16	Life satisfaction;	chr17:82163482	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.765	rs6502075	ENSG00000275966.1	RP11-1055B8.9	-3.66	0.000283	0.0329	-0.17	-0.16	Life satisfaction;	chr17:82163937	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.698	rs6502076	ENSG00000275966.1	RP11-1055B8.9	-3.66	0.000283	0.0329	-0.17	-0.16	Life satisfaction;	chr17:82164102	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs8078950	ENSG00000275966.1	RP11-1055B8.9	-3.66	0.000283	0.0329	-0.17	-0.16	Life satisfaction;	chr17:82164451	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs6502077	ENSG00000275966.1	RP11-1055B8.9	-3.66	0.000283	0.0329	-0.17	-0.16	Life satisfaction;	chr17:82165090	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs4789738	ENSG00000275966.1	RP11-1055B8.9	-3.66	0.000283	0.0329	-0.17	-0.16	Life satisfaction;	chr17:82165177	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs4789676	ENSG00000275966.1	RP11-1055B8.9	-3.66	0.000283	0.0329	-0.17	-0.16	Life satisfaction;	chr17:82165202	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs4789675	ENSG00000275966.1	RP11-1055B8.9	-3.66	0.000283	0.0329	-0.17	-0.16	Life satisfaction;	chr17:82165268	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.799	rs4789674	ENSG00000275966.1	RP11-1055B8.9	-3.66	0.000283	0.0329	-0.17	-0.16	Life satisfaction;	chr17:82165324	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.799	rs4789673	ENSG00000275966.1	RP11-1055B8.9	-3.66	0.000283	0.0329	-0.17	-0.16	Life satisfaction;	chr17:82165342	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs4789737	ENSG00000275966.1	RP11-1055B8.9	-3.66	0.000283	0.0329	-0.17	-0.16	Life satisfaction;	chr17:82165393	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.799	rs6502078	ENSG00000275966.1	RP11-1055B8.9	-3.66	0.000283	0.0329	-0.17	-0.16	Life satisfaction;	chr17:82166488	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs6502079	ENSG00000275966.1	RP11-1055B8.9	-3.66	0.000283	0.0329	-0.17	-0.16	Life satisfaction;	chr17:82166578	chr17:81345476~81345966:-
LUAD	cis	rs4474465	0.833	rs10793320	ENSG00000251323.2	RP11-452H21.4	-3.66	0.000283	0.0329	-0.2	-0.16	Alzheimer's disease (survival time);	chr11:78506414	chr11:78423982~78429836:-
LUAD	cis	rs526231	0.511	rs17154965	ENSG00000250682.4	LINC00491	3.66	0.000283	0.0329	0.2	0.16	Primary biliary cholangitis;	chr5:103023862	chr5:102609156~102671559:-
LUAD	cis	rs78572108	1	rs78572108	ENSG00000214691.7	AC104654.1	3.66	0.000283	0.0329	0.29	0.16	Total body bone mineral density;	chr2:42052926	chr2:41877074~41894046:+
LUAD	cis	rs838147	0.537	rs503279	ENSG00000232871.7	SEC1P	-3.66	0.000283	0.0329	-0.18	-0.16	Dietary macronutrient intake;	chr19:48705753	chr19:48638071~48682245:+
LUAD	cis	rs7107174	1	rs4944195	ENSG00000251323.2	RP11-452H21.4	3.66	0.000283	0.0329	0.23	0.16	Testicular germ cell tumor;	chr11:78292453	chr11:78423982~78429836:-
LUAD	cis	rs7107174	1	rs10899458	ENSG00000251323.2	RP11-452H21.4	3.66	0.000283	0.0329	0.23	0.16	Testicular germ cell tumor;	chr11:78296405	chr11:78423982~78429836:-
LUAD	cis	rs7107174	1	rs4627115	ENSG00000251323.2	RP11-452H21.4	3.66	0.000283	0.0329	0.23	0.16	Testicular germ cell tumor;	chr11:78296827	chr11:78423982~78429836:-
LUAD	cis	rs7107174	0.892	rs4944196	ENSG00000251323.2	RP11-452H21.4	3.66	0.000283	0.0329	0.23	0.16	Testicular germ cell tumor;	chr11:78297685	chr11:78423982~78429836:-
LUAD	cis	rs5742933	1	rs55792400	ENSG00000253559.1	OSGEPL1-AS1	-3.66	0.000283	0.0329	-0.23	-0.16	Ferritin levels;	chr2:189686708	chr2:189762704~189765556:+
LUAD	cis	rs5742933	0.947	rs62185871	ENSG00000253559.1	OSGEPL1-AS1	-3.66	0.000283	0.0329	-0.23	-0.16	Ferritin levels;	chr2:189686980	chr2:189762704~189765556:+
LUAD	cis	rs728616	0.867	rs12412257	ENSG00000234382.2	RP11-40F6.1	-3.66	0.000283	0.0329	-0.4	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79969847	chr10:80233664~80245367:+
LUAD	cis	rs4713118	0.588	rs200994	ENSG00000226314.6	ZNF192P1	3.66	0.000283	0.0329	0.22	0.16	Parkinson's disease;	chr6:27846035	chr6:28161781~28169594:+
LUAD	cis	rs875971	0.545	rs12670811	ENSG00000222364.1	RNU6-96P	-3.66	0.000283	0.0329	-0.21	-0.16	Aortic root size;	chr7:66358032	chr7:66395191~66395286:+
LUAD	cis	rs683250	0.567	rs11233582	ENSG00000246067.6	RAB30-AS1	-3.66	0.000283	0.0329	-0.18	-0.16	Subcortical brain region volumes;	chr11:83359384	chr11:83072066~83106719:+
LUAD	cis	rs11239930	0.538	rs604716	ENSG00000225603.3	RP11-325P15.1	3.66	0.000284	0.0329	0.21	0.16	AIDS progression;	chr1:147073173	chr1:147050817~147052481:+
LUAD	cis	rs4474465	0.85	rs10793327	ENSG00000251323.2	RP11-452H21.4	-3.66	0.000284	0.0329	-0.2	-0.16	Alzheimer's disease (survival time);	chr11:78545795	chr11:78423982~78429836:-
LUAD	cis	rs11158026	0.603	rs4325453	ENSG00000258413.1	RP11-665C16.6	-3.66	0.000284	0.0329	-0.21	-0.16	Parkinson's disease;	chr14:54972600	chr14:55262767~55272075:-
LUAD	cis	rs748404	0.56	rs570933	ENSG00000166763.7	STRCP1	3.66	0.000284	0.033	0.2	0.16	Lung cancer;	chr15:43531832	chr15:43699488~43718184:-
LUAD	cis	rs4853525	0.62	rs2066804	ENSG00000235852.1	AC005540.3	3.66	0.000284	0.033	0.21	0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190977033	chr2:190880797~190882059:-
LUAD	cis	rs2726040	0.902	rs33957528	ENSG00000251417.2	RP11-1348G14.4	3.66	0.000284	0.033	0.16	0.16	Hip circumference;	chr16:28296619	chr16:28802743~28817828:+
LUAD	cis	rs17275866	0.862	rs11934791	ENSG00000250596.1	RP11-440I14.2	3.66	0.000284	0.033	0.22	0.16	Chin dimples;	chr4:174139571	chr4:174523701~174540344:-
LUAD	cis	rs7503168	0.558	rs71381460	ENSG00000267592.1	CTC-507E2.2	3.66	0.000284	0.033	0.35	0.16	Plateletcrit;	chr17:35564602	chr17:35596904~35597128:-
LUAD	cis	rs7503168	0.558	rs11655098	ENSG00000267592.1	CTC-507E2.2	3.66	0.000284	0.033	0.35	0.16	Plateletcrit;	chr17:35567831	chr17:35596904~35597128:-
LUAD	cis	rs7503168	0.558	rs17638076	ENSG00000267592.1	CTC-507E2.2	3.66	0.000284	0.033	0.35	0.16	Plateletcrit;	chr17:35569254	chr17:35596904~35597128:-
LUAD	cis	rs12073359	1	rs3925724	ENSG00000223945.2	RP11-458I7.1	3.66	0.000284	0.033	0.22	0.16	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150108151	chr1:150053864~150055034:+
LUAD	cis	rs11064837	0.504	rs7310536	ENSG00000248636.5	RP11-768F21.1	3.66	0.000284	0.033	0.19	0.16	Schizophrenia;	chr12:119616268	chr12:119387987~119668079:-
LUAD	cis	rs7216064	1	rs62084238	ENSG00000266717.1	RP11-855A2.3	3.66	0.000284	0.033	0.2	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67860457	chr17:67950885~67951746:-
LUAD	cis	rs7712401	0.791	rs1870559	ENSG00000249996.1	RP11-359P5.1	3.66	0.000284	0.033	0.2	0.16	Mean platelet volume;	chr5:122781011	chr5:123036271~123054667:+
LUAD	cis	rs7712401	0.791	rs10059964	ENSG00000249996.1	RP11-359P5.1	3.66	0.000284	0.033	0.2	0.16	Mean platelet volume;	chr5:122782598	chr5:123036271~123054667:+
LUAD	cis	rs2460905	1	rs2460346	ENSG00000251468.2	RP11-369K16.1	-3.66	0.000284	0.033	-0.38	-0.16	Post-traumatic stress disorder;	chr8:12978477	chr8:12958387~12962200:+
LUAD	cis	rs4218	0.681	rs58335303	ENSG00000277144.1	RP11-59H7.4	-3.66	0.000284	0.033	-0.21	-0.16	Social communication problems;	chr15:59073206	chr15:59115547~59116089:-
LUAD	cis	rs4767841	0.935	rs7299963	ENSG00000248636.5	RP11-768F21.1	-3.66	0.000284	0.033	-0.19	-0.16	Urgency urinary incontinence;	chr12:119720398	chr12:119387987~119668079:-
LUAD	cis	rs1894292	0.715	rs6446944	ENSG00000221639.1	SNORA3	-3.66	0.000284	0.033	-0.17	-0.16	Prostate cancer;	chr4:73600415	chr4:73263960~73264084:+
LUAD	cis	rs4795519	0.922	rs939730	ENSG00000266313.1	RP11-173M1.4	3.66	0.000284	0.033	0.2	0.16	Chronic myeloid leukemia;	chr17:27090553	chr17:27333256~27348491:+
LUAD	cis	rs4664293	0.802	rs7563417	ENSG00000230783.1	AC009961.2	-3.66	0.000284	0.033	-0.21	-0.16	Monocyte percentage of white cells;	chr2:159727762	chr2:159689217~159690291:-
LUAD	cis	rs987044	0.802	rs11114041	ENSG00000257221.1	RP11-689B22.2	-3.66	0.000284	0.033	-0.14	-0.16	Mean platelet volume;	chr12:108730353	chr12:108628687~108641318:+
LUAD	cis	rs875971	0.619	rs12533585	ENSG00000273142.1	RP11-458F8.4	-3.66	0.000284	0.033	-0.11	-0.16	Aortic root size;	chr7:66519618	chr7:66902857~66906297:+
LUAD	cis	rs875971	0.66	rs12698534	ENSG00000273142.1	RP11-458F8.4	-3.66	0.000284	0.033	-0.11	-0.16	Aortic root size;	chr7:66521858	chr7:66902857~66906297:+
LUAD	cis	rs67340775	0.541	rs200973	ENSG00000280107.1	AL022393.9	-3.66	0.000284	0.033	-0.25	-0.16	Lung cancer in ever smokers;	chr6:27890643	chr6:28170845~28172521:+
LUAD	cis	rs5742933	1	rs5742933	ENSG00000253559.1	OSGEPL1-AS1	-3.66	0.000284	0.033	-0.23	-0.16	Ferritin levels;	chr2:189784590	chr2:189762704~189765556:+
LUAD	cis	rs2024714	0.967	rs2427200	ENSG00000273812.1	WI2-87327B8.2	-3.66	0.000284	0.033	-0.17	-0.16	Longevity;	chr20:61630019	chr20:62596732~62603115:-
LUAD	cis	rs159572	0.784	rs167623	ENSG00000250853.1	RNF138P1	3.66	0.000284	0.033	0.19	0.16	Post-traumatic stress disorder;	chr5:56243515	chr5:55530156~55530701:-
LUAD	cis	rs55966801	0.853	rs505404	ENSG00000277290.1	RP11-326C3.16	-3.66	0.000284	0.033	-0.17	-0.16	Plateletcrit;	chr11:243268	chr11:243099~243483:-
LUAD	cis	rs62246343	0.564	rs17050383	ENSG00000206573.7	THUMPD3-AS1	-3.66	0.000284	0.033	-0.17	-0.16	Fibrinogen levels;	chr3:9472896	chr3:9349689~9398579:-
LUAD	cis	rs708547	0.624	rs1718886	ENSG00000269949.1	RP11-738E22.3	3.66	0.000284	0.033	0.21	0.16	Response to bleomycin (chromatid breaks);	chr4:56983085	chr4:56960927~56961373:-
LUAD	cis	rs4523957	0.928	rs216176	ENSG00000262333.1	HNRNPA1P16	-3.66	0.000284	0.033	-0.14	-0.16	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2265215	chr17:2306761~2307715:+
LUAD	cis	rs412050	0.502	rs17759796	ENSG00000224086.5	LL22NC03-86G7.1	3.66	0.000284	0.033	0.21	0.16	Attention deficit hyperactivity disorder;	chr22:21835874	chr22:21938293~21977632:+
LUAD	cis	rs3764021	0.743	rs7973535	ENSG00000256582.1	RP11-75L1.1	3.66	0.000284	0.033	0.17	0.16	Type 1 diabetes;	chr12:9727801	chr12:9704077~9709350:+
LUAD	cis	rs3764021	0.87	rs7973638	ENSG00000256582.1	RP11-75L1.1	3.66	0.000284	0.033	0.17	0.16	Type 1 diabetes;	chr12:9727845	chr12:9704077~9709350:+
LUAD	cis	rs11073619	0.616	rs3994408	ENSG00000230373.7	GOLGA6L5P	-3.66	0.000284	0.033	-0.26	-0.16	Positive affect;	chr15:84390854	chr15:84507885~84516814:-
LUAD	cis	rs38055	0.589	rs7711335	ENSG00000247796.2	CTD-2366F13.1	3.66	0.000284	0.033	0.18	0.16	Acne (severe);	chr5:53209183	chr5:53109842~53115126:+
LUAD	cis	rs7578361	1	rs4536618	ENSG00000231969.1	AC144449.1	-3.66	0.000284	0.033	-0.24	-0.16	Acute lymphoblastic leukemia (childhood);	chr2:149590162	chr2:149587196~149848233:+
LUAD	cis	rs9951698	0.703	rs9964466	ENSG00000267480.1	RP11-703I16.1	-3.66	0.000284	0.033	-0.2	-0.16	Intelligence (multi-trait analysis);	chr18:13030384	chr18:12031178~12032181:-
LUAD	cis	rs6502050	0.835	rs4789754	ENSG00000275966.1	RP11-1055B8.9	-3.66	0.000284	0.033	-0.17	-0.16	Life satisfaction;	chr17:82134065	chr17:81345476~81345966:-
LUAD	cis	rs4489787	1	rs61995742	ENSG00000240399.1	RP1-228P16.1	-3.66	0.000284	0.033	-0.28	-0.16	Prostate cancer (SNP x SNP interaction);	chr12:48560247	chr12:48054813~48055591:-
LUAD	cis	rs2243480	0.522	rs73150635	ENSG00000229886.1	RP5-1132H15.3	3.66	0.000284	0.033	0.33	0.16	Diabetic kidney disease;	chr7:66507503	chr7:66025126~66031544:-
LUAD	cis	rs875971	0.545	rs6970498	ENSG00000224316.1	RP11-479O9.2	3.66	0.000284	0.033	0.19	0.16	Aortic root size;	chr7:66275908	chr7:65773620~65802067:+
LUAD	cis	rs950169	0.84	rs12905223	ENSG00000188388.10	GOLGA6L3	3.66	0.000285	0.033	0.22	0.16	Schizophrenia;	chr15:84571037	chr15:85240472~85247170:+
LUAD	cis	rs2834288	0.7	rs731059	ENSG00000237945.6	LINC00649	-3.66	0.000285	0.033	-0.22	-0.16	Gut microbiota (bacterial taxa);	chr21:33902813	chr21:33915534~33977691:+
LUAD	cis	rs2834288	0.7	rs731061	ENSG00000237945.6	LINC00649	-3.66	0.000285	0.033	-0.22	-0.16	Gut microbiota (bacterial taxa);	chr21:33902937	chr21:33915534~33977691:+
LUAD	cis	rs11159086	0.729	rs8015872	ENSG00000270000.1	RP3-449M8.9	3.66	0.000285	0.033	0.22	0.16	Advanced glycation end-product levels;	chr14:74475529	chr14:74471930~74472360:-
LUAD	cis	rs7107174	1	rs11601196	ENSG00000251323.2	RP11-452H21.4	3.66	0.000285	0.033	0.21	0.16	Testicular germ cell tumor;	chr11:78332385	chr11:78423982~78429836:-
LUAD	cis	rs1198430	0.925	rs1207124	ENSG00000232482.2	RP4-654C18.1	-3.66	0.000285	0.033	-0.27	-0.16	Total cholesterol levels;	chr1:23433915	chr1:23410832~23412146:+
LUAD	cis	rs35320143	0.5	rs11075640	ENSG00000258122.1	RP11-61A14.1	-3.66	0.000285	0.033	-0.2	-0.16	Number of children (6+ vs. 0 or 1);	chr16:66714709	chr16:66841433~66853448:-
LUAD	cis	rs11096990	0.613	rs35391082	ENSG00000249685.1	RP11-360F5.3	3.66	0.000285	0.033	0.19	0.16	Cognitive function;	chr4:39191033	chr4:39133913~39135608:+
LUAD	cis	rs11096990	0.613	rs4974990	ENSG00000249685.1	RP11-360F5.3	3.66	0.000285	0.033	0.19	0.16	Cognitive function;	chr4:39191645	chr4:39133913~39135608:+
LUAD	cis	rs11096990	0.613	rs6840578	ENSG00000249685.1	RP11-360F5.3	3.66	0.000285	0.033	0.19	0.16	Cognitive function;	chr4:39206996	chr4:39133913~39135608:+
LUAD	cis	rs11096990	0.613	rs7690414	ENSG00000249685.1	RP11-360F5.3	3.66	0.000285	0.033	0.19	0.16	Cognitive function;	chr4:39210669	chr4:39133913~39135608:+
LUAD	cis	rs11096990	0.593	rs7685619	ENSG00000249685.1	RP11-360F5.3	3.66	0.000285	0.033	0.19	0.16	Cognitive function;	chr4:39211779	chr4:39133913~39135608:+
LUAD	cis	rs73242632	1	rs3755901	ENSG00000269949.1	RP11-738E22.3	3.66	0.000285	0.033	0.41	0.16	Congenital heart disease (maternal effect);	chr4:56909830	chr4:56960927~56961373:-
LUAD	cis	rs4713118	0.662	rs149900	ENSG00000280107.1	AL022393.9	-3.66	0.000285	0.033	-0.21	-0.16	Parkinson's disease;	chr6:28046819	chr6:28170845~28172521:+
LUAD	cis	rs6866614	0.639	rs1858074	ENSG00000233006.5	AC034220.3	3.66	0.000285	0.033	0.16	0.16	Perceived unattractiveness to mosquitoes;	chr5:132036306	chr5:132311285~132369916:-
LUAD	cis	rs728616	0.867	rs61859022	ENSG00000225484.5	NUTM2B-AS1	-3.66	0.000285	0.033	-0.36	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80101043	chr10:79663088~79826594:-
LUAD	cis	rs10102546	1	rs6987543	ENSG00000244642.3	RN7SL396P	3.66	0.000285	0.0331	0.19	0.16	Smoking cessation;	chr8:119535442	chr8:119862662~119862956:+
LUAD	cis	rs12908161	1	rs17600551	ENSG00000259654.1	RP11-245C17.2	-3.66	0.000285	0.0331	-0.23	-0.16	Schizophrenia;	chr15:84776027	chr15:84685884~84686946:+
LUAD	cis	rs12908161	1	rs62019469	ENSG00000259654.1	RP11-245C17.2	-3.66	0.000285	0.0331	-0.23	-0.16	Schizophrenia;	chr15:84777989	chr15:84685884~84686946:+
LUAD	cis	rs7660883	0.897	rs342469	ENSG00000251411.1	RP11-397E7.4	-3.66	0.000285	0.0331	-0.18	-0.16	HDL cholesterol levels;	chr4:87129402	chr4:86913266~86914817:-
LUAD	cis	rs743757	0.762	rs391620	ENSG00000273356.1	RP11-804H8.6	3.66	0.000285	0.0331	0.22	0.16	Diastolic blood pressure;	chr3:50543817	chr3:50669989~50672048:+
LUAD	cis	rs41369048	0.66	rs1335928	ENSG00000221571.3	RNU6ATAC35P	-3.66	0.000285	0.0331	-0.21	-0.16	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220922257	chr1:220825620~220826063:+
LUAD	cis	rs115056730	0.52	rs114113305	ENSG00000230606.9	AC159540.1	3.66	0.000285	0.0331	0.35	0.16	Monocyte chemoattractant protein-3 levels;	chr2:97572746	chr2:97416165~97433527:-
LUAD	cis	rs860295	0.812	rs2297775	ENSG00000225855.5	RUSC1-AS1	-3.66	0.000285	0.0331	-0.11	-0.16	Body mass index;	chr1:155765221	chr1:155316863~155324176:-
LUAD	cis	rs12549058	0.792	rs12548349	ENSG00000223220.1	Y_RNA	-3.66	0.000285	0.0331	-0.32	-0.16	Waist-hip ratio;	chr8:71618169	chr8:70780914~70781008:-
LUAD	cis	rs2904524	1	rs2053102	ENSG00000257613.1	LINC01481	-3.66	0.000285	0.0331	-0.28	-0.16	Amyotrophic lateral sclerosis (age of onset);	chr12:70375628	chr12:70219132~70221862:-
LUAD	cis	rs9308731	0.583	rs10211562	ENSG00000227992.1	AC108463.2	-3.66	0.000285	0.0331	-0.19	-0.16	Chronic lymphocytic leukemia;	chr2:111173219	chr2:111203964~111206215:-
LUAD	cis	rs3213958	0.509	rs56322058	ENSG00000249274.1	PDLIM1P4	-3.66	0.000285	0.0331	-0.26	-0.16	Blood protein levels;	chr3:98900445	chr3:98782188~98783193:+
LUAD	cis	rs643506	1	rs612345	ENSG00000230911.1	PPIHP1	-3.66	0.000285	0.0331	-0.21	-0.16	Breast cancer;	chr11:111768398	chr11:112029858~112030367:-
LUAD	cis	rs786425	0.53	rs7295552	ENSG00000280300.1	RP11-338K17.10	-3.66	0.000285	0.0331	-0.14	-0.16	Pubertal anthropometrics;	chr12:123739297	chr12:123754246~123754794:-
LUAD	cis	rs1020064	0.636	rs2679883	ENSG00000235319.1	AC012360.4	-3.66	0.000285	0.0331	-0.19	-0.16	AIDS;	chr2:105333211	chr2:105324210~105330529:+
LUAD	cis	rs875971	0.54	rs781152	ENSG00000273142.1	RP11-458F8.4	-3.66	0.000285	0.0331	-0.12	-0.16	Aortic root size;	chr7:66014585	chr7:66902857~66906297:+
LUAD	cis	rs17711722	0.727	rs781151	ENSG00000273142.1	RP11-458F8.4	-3.66	0.000285	0.0331	-0.12	-0.16	Calcium levels;	chr7:66014891	chr7:66902857~66906297:+
LUAD	cis	rs2717559	0.522	rs35816096	ENSG00000253741.1	CTD-2292P10.4	3.66	0.000285	0.0331	0.2	0.16	Urinary tract infection frequency;	chr8:142803522	chr8:142702252~142726973:-
LUAD	cis	rs6661961	0.752	rs4845771	ENSG00000237975.5	FLG-AS1	-3.66	0.000285	0.0331	-0.22	-0.16	Atopic dermatitis;	chr1:152458204	chr1:152168125~152445456:+
LUAD	cis	rs4907240	0.925	rs11164109	ENSG00000237510.6	AC008268.2	-3.66	0.000285	0.0331	-0.23	-0.16	Event-related brain oscillations;	chr2:96635096	chr2:95789654~95800166:+
LUAD	cis	rs577676	0.586	rs12031871	ENSG00000271811.1	RP1-79C4.4	3.66	0.000285	0.0331	0.21	0.16	Prevalent atrial fibrillation;	chr1:170621426	chr1:170667381~170669425:+
LUAD	cis	rs651386	0.505	rs10753817	ENSG00000271811.1	RP1-79C4.4	3.66	0.000285	0.0331	0.21	0.16	Atrial fibrillation;	chr1:170622667	chr1:170667381~170669425:+
LUAD	cis	rs944990	0.538	rs10821165	ENSG00000227603.1	RP11-165J3.6	3.66	0.000285	0.0331	0.19	0.16	Body mass index;	chr9:93589352	chr9:93435332~93437121:-
LUAD	cis	rs301800	0.56	rs2895941	ENSG00000232912.4	RP5-1115A15.1	3.66	0.000285	0.0331	0.19	0.16	Educational attainment (years of education);	chr1:8686105	chr1:8424645~8434838:+
LUAD	cis	rs12724450	0.793	rs35762205	ENSG00000228126.1	FALEC	3.66	0.000285	0.0331	0.3	0.16	Blood protein levels;	chr1:150325460	chr1:150515757~150518032:+
LUAD	cis	rs12724450	0.793	rs71515775	ENSG00000228126.1	FALEC	3.66	0.000285	0.0331	0.3	0.16	Blood protein levels;	chr1:150331925	chr1:150515757~150518032:+
LUAD	cis	rs12724450	0.793	rs35347210	ENSG00000228126.1	FALEC	3.66	0.000285	0.0331	0.3	0.16	Blood protein levels;	chr1:150347501	chr1:150515757~150518032:+
LUAD	cis	rs9889262	0.58	rs2906095	ENSG00000248714.5	RP11-1079K10.3	3.66	0.000285	0.0331	0.16	0.16	Eosinophil percentage of granulocytes;Allergic disease (asthma, hay fever or eczema);Eosinophil counts;	chr17:49304906	chr17:49361165~49369998:+
LUAD	cis	rs9889262	0.625	rs1010322	ENSG00000248714.5	RP11-1079K10.3	3.66	0.000285	0.0331	0.16	0.16	Eosinophil percentage of granulocytes;Allergic disease (asthma, hay fever or eczema);Eosinophil counts;	chr17:49260721	chr17:49361165~49369998:+
LUAD	cis	rs6787172	0.84	rs1656374	ENSG00000272087.1	RP11-379F4.7	3.66	0.000285	0.0331	0.17	0.16	Subjective well-being;	chr3:158565271	chr3:158693120~158693768:-
LUAD	cis	rs911119	0.866	rs2405393	ENSG00000270001.1	RP11-218C14.8	-3.66	0.000285	0.0331	-0.24	-0.16	Chronic kidney disease;	chr20:23588755	chr20:23631826~23632316:-
LUAD	cis	rs911119	0.866	rs4346460	ENSG00000270001.1	RP11-218C14.8	-3.66	0.000285	0.0331	-0.24	-0.16	Chronic kidney disease;	chr20:23588763	chr20:23631826~23632316:-
LUAD	cis	rs4835473	0.932	rs13134327	ENSG00000249741.2	RP11-673E1.3	-3.66	0.000285	0.0331	-0.19	-0.16	Immature fraction of reticulocytes;	chr4:143738642	chr4:143911514~143912053:-
LUAD	cis	rs4908768	0.906	rs12410336	ENSG00000232912.4	RP5-1115A15.1	-3.65	0.000286	0.0331	-0.19	-0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8563605	chr1:8424645~8434838:+
LUAD	cis	rs8046148	0.724	rs12933325	ENSG00000279356.1	RP11-429P3.8	-3.65	0.000286	0.0331	-0.16	-0.16	Testicular germ cell tumor;	chr16:50063533	chr16:50072862~50074986:+
LUAD	cis	rs7646881	0.544	rs3817373	ENSG00000240207.5	RP11-379F4.4	-3.65	0.000286	0.0331	-0.22	-0.16	Tetralogy of Fallot;	chr3:158571246	chr3:158732263~158784070:+
LUAD	cis	rs8046148	0.614	rs8047504	ENSG00000279356.1	RP11-429P3.8	3.65	0.000286	0.0331	0.17	0.16	Testicular germ cell tumor;	chr16:50073724	chr16:50072862~50074986:+
LUAD	cis	rs8046148	0.54	rs59059423	ENSG00000279356.1	RP11-429P3.8	3.65	0.000286	0.0331	0.17	0.16	Testicular germ cell tumor;	chr16:50074191	chr16:50072862~50074986:+
LUAD	cis	rs7077256	0.564	rs34204266	ENSG00000272767.1	JMJD1C-AS1	3.65	0.000286	0.0331	0.25	0.16	Intelligence (multi-trait analysis);	chr10:63350280	chr10:63465229~63466563:+
LUAD	cis	rs763121	0.853	rs5750672	ENSG00000225450.1	RP3-508I15.14	3.65	0.000286	0.0331	0.16	0.16	Menopause (age at onset);	chr22:38708163	chr22:38739003~38749041:+
LUAD	cis	rs683250	0.599	rs12789325	ENSG00000246067.6	RAB30-AS1	-3.65	0.000286	0.0331	-0.17	-0.16	Subcortical brain region volumes;	chr11:83366880	chr11:83072066~83106719:+
LUAD	cis	rs7615952	0.641	rs6438951	ENSG00000250012.1	RP11-124N2.1	-3.65	0.000286	0.0331	-0.22	-0.16	Blood pressure (smoking interaction);	chr3:125978156	chr3:126084220~126095349:+
LUAD	cis	rs17123764	1	rs11833411	ENSG00000257464.1	RP11-161H23.8	-3.65	0.000286	0.0331	-0.24	-0.16	Intelligence (multi-trait analysis);	chr12:49606604	chr12:49442424~49442652:-
LUAD	cis	rs17123764	0.818	rs11169092	ENSG00000257464.1	RP11-161H23.8	-3.65	0.000286	0.0331	-0.24	-0.16	Intelligence (multi-trait analysis);	chr12:49614819	chr12:49442424~49442652:-
LUAD	cis	rs13113518	0.812	rs2035691	ENSG00000273257.1	RP11-177J6.1	3.65	0.000286	0.0331	0.19	0.16	Height;	chr4:55529786	chr4:55387949~55388271:+
LUAD	cis	rs12195826	0.533	rs7766538	ENSG00000232654.1	FAM136BP	-3.65	0.000286	0.0331	-0.21	-0.16	Obesity-related traits;	chr6:2522961	chr6:3045384~3045800:+
LUAD	cis	rs10435719	0.902	rs6601633	ENSG00000255046.1	RP11-297N6.4	3.65	0.000286	0.0332	0.2	0.16	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947664	chr8:11797928~11802568:-
LUAD	cis	rs11159086	0.793	rs10139029	ENSG00000270000.1	RP3-449M8.9	3.65	0.000286	0.0332	0.23	0.16	Advanced glycation end-product levels;	chr14:74492284	chr14:74471930~74472360:-
LUAD	cis	rs3617	0.625	rs6445541	ENSG00000242142.1	SERBP1P3	3.65	0.000286	0.0332	0.17	0.16	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52846112	chr3:53064283~53065091:-
LUAD	cis	rs2795502	0.766	rs947549	ENSG00000185904.10	LINC00839	-3.65	0.000286	0.0332	-0.33	-0.16	Blood protein levels;	chr10:42770432	chr10:42475543~42495336:+
LUAD	cis	rs9467773	1	rs1001687	ENSG00000261353.1	CTA-14H9.5	-3.65	0.000286	0.0332	-0.19	-0.16	Intelligence (multi-trait analysis);	chr6:26572990	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs1570060	ENSG00000261353.1	CTA-14H9.5	-3.65	0.000286	0.0332	-0.19	-0.16	Intelligence (multi-trait analysis);	chr6:26573334	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs1977201	ENSG00000261353.1	CTA-14H9.5	-3.65	0.000286	0.0332	-0.19	-0.16	Intelligence (multi-trait analysis);	chr6:26573446	chr6:26527063~26527404:+
LUAD	cis	rs9467773	0.967	rs1321482	ENSG00000261353.1	CTA-14H9.5	-3.65	0.000286	0.0332	-0.19	-0.16	Intelligence (multi-trait analysis);	chr6:26574926	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs9467798	ENSG00000261353.1	CTA-14H9.5	-3.65	0.000286	0.0332	-0.19	-0.16	Intelligence (multi-trait analysis);	chr6:26575469	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs1570061	ENSG00000261353.1	CTA-14H9.5	-3.65	0.000286	0.0332	-0.19	-0.16	Intelligence (multi-trait analysis);	chr6:26575758	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs6913462	ENSG00000261353.1	CTA-14H9.5	-3.65	0.000286	0.0332	-0.19	-0.16	Intelligence (multi-trait analysis);	chr6:26577302	chr6:26527063~26527404:+
LUAD	cis	rs1790761	0.505	rs7106423	ENSG00000184224.3	C11orf72	-3.65	0.000286	0.0332	-0.19	-0.16	Mean corpuscular volume;	chr11:67546673	chr11:67602880~67606706:-
LUAD	cis	rs2904524	0.588	rs968122	ENSG00000257815.4	RP11-611E13.2	3.65	0.000286	0.0332	0.2	0.16	Amyotrophic lateral sclerosis (age of onset);	chr12:70397835	chr12:69904033~70243360:-
LUAD	cis	rs7617773	0.963	rs6800730	ENSG00000199476.1	Y_RNA	-3.65	0.000286	0.0332	-0.21	-0.16	Coronary artery disease;	chr3:48132720	chr3:48288587~48288694:+
LUAD	cis	rs2348418	0.932	rs7968515	ENSG00000244712.1	RP11-874G11.1	3.65	0.000286	0.0332	0.2	0.16	Lung function (FEV1);Lung function (FVC);	chr12:28542914	chr12:28564678~28565141:-
LUAD	cis	rs7584330	0.695	rs6709497	ENSG00000222032.1	AC112721.2	3.65	0.000286	0.0332	0.19	0.16	Prostate cancer;	chr2:237460282	chr2:237428920~237434822:-
LUAD	cis	rs4819052	0.788	rs2236449	ENSG00000184274.3	LINC00315	-3.65	0.000286	0.0332	-0.24	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45282591	chr21:45300245~45305257:-
LUAD	cis	rs11853189	0.938	rs2280364	ENSG00000259562.2	RP11-762H8.2	3.65	0.000286	0.0332	0.19	0.16	Red cell distribution width;	chr15:78292764	chr15:78290527~78291221:-
LUAD	cis	rs2985684	0.948	rs6572592	ENSG00000278009.1	RP11-649E7.8	3.65	0.000286	0.0332	0.22	0.16	Carotid intima media thickness;	chr14:49614153	chr14:49601011~49601124:-
LUAD	cis	rs329122	0.528	rs329113	ENSG00000280420.1	AC005355.3	3.65	0.000286	0.0332	0.18	0.16	Body mass index;Type 2 diabetes;	chr5:134520717	chr5:134522613~134523096:-
LUAD	cis	rs6430585	0.583	rs2304371	ENSG00000231890.6	DARS-AS1	-3.65	0.000286	0.0332	-0.25	-0.16	Corneal structure;	chr2:135803987	chr2:135985176~136022593:+
LUAD	cis	rs1334894	0.792	rs2103680	ENSG00000228559.1	RP3-340B19.3	-3.65	0.000286	0.0332	-0.39	-0.16	Coronary artery disease;	chr6:35507387	chr6:35544632~35545669:+
LUAD	cis	rs4853525	0.859	rs1882397	ENSG00000235852.1	AC005540.3	3.65	0.000286	0.0332	0.18	0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190855406	chr2:190880797~190882059:-
LUAD	cis	rs116988415	0.636	rs4899147	ENSG00000255002.1	CTD-2509G16.2	3.65	0.000286	0.0332	0.27	0.16	Daytime sleep phenotypes;	chr14:64829236	chr14:65212893~65222347:-
LUAD	cis	rs7660883	1	rs4693156	ENSG00000251411.1	RP11-397E7.4	3.65	0.000286	0.0332	0.18	0.16	HDL cholesterol levels;	chr4:87086075	chr4:86913266~86914817:-
LUAD	cis	rs3617	0.652	rs7630552	ENSG00000242142.1	SERBP1P3	-3.65	0.000286	0.0332	-0.18	-0.16	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52857554	chr3:53064283~53065091:-
LUAD	cis	rs3617	0.625	rs7620690	ENSG00000242142.1	SERBP1P3	-3.65	0.000286	0.0332	-0.18	-0.16	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52857691	chr3:53064283~53065091:-
LUAD	cis	rs116095464	0.558	rs62347677	ENSG00000248925.1	CTD-2083E4.6	3.65	0.000286	0.0332	0.28	0.16	Breast cancer;	chr5:227338	chr5:269858~271516:-
LUAD	cis	rs910873	0.505	rs7261964	ENSG00000250917.1	RP4-785G19.5	3.65	0.000286	0.0332	0.28	0.16	Melanoma;	chr20:34617207	chr20:34234840~34281173:-
LUAD	cis	rs10392	0.543	rs6028208	ENSG00000274825.1	RP4-616B8.5	-3.65	0.000286	0.0332	-0.21	-0.16	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;	chr20:38927432	chr20:38955910~38956547:+
LUAD	cis	rs17711722	0.74	rs7809991	ENSG00000222364.1	RNU6-96P	-3.65	0.000287	0.0332	-0.18	-0.16	Calcium levels;	chr7:65941231	chr7:66395191~66395286:+
LUAD	cis	rs6452524	0.534	rs7727691	ENSG00000281327.1	LINC01338	3.65	0.000287	0.0332	0.18	0.16	Hypertension (SNP x SNP interaction);	chr5:83075876	chr5:82850864~82859836:-
LUAD	cis	rs10463554	0.963	rs32840	ENSG00000250682.4	LINC00491	3.65	0.000287	0.0332	0.2	0.16	Parkinson's disease;	chr5:103143446	chr5:102609156~102671559:-
LUAD	cis	rs2281603	0.57	rs1470851	ENSG00000259116.1	RP11-973N13.4	-3.65	0.000287	0.0332	-0.14	-0.16	Lymphocyte counts;	chr14:64509402	chr14:64514154~64540368:-
LUAD	cis	rs10761256	0.59	rs61453782	ENSG00000269929.1	RP11-2B6.2	-3.65	0.000287	0.0332	-0.2	-0.16	Itch intensity from mosquito bite adjusted by bite size;	chr9:93624478	chr9:94176458~94177892:+
LUAD	cis	rs755249	0.959	rs72663520	ENSG00000237624.1	OXCT2P1	3.65	0.000287	0.0332	0.24	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39537738	chr1:39514956~39516490:+
LUAD	cis	rs7131987	0.65	rs16934135	ENSG00000275476.1	RP11-996F15.4	-3.65	0.000287	0.0332	-0.19	-0.16	QT interval;	chr12:29331030	chr12:29277397~29277882:-
LUAD	cis	rs8028182	0.636	rs7175852	ENSG00000246877.1	DNM1P35	3.65	0.000287	0.0332	0.21	0.16	Sudden cardiac arrest;	chr15:75402194	chr15:75727670~75738623:-
LUAD	cis	rs6502050	0.835	rs12450189	ENSG00000275966.1	RP11-1055B8.9	-3.65	0.000287	0.0332	-0.17	-0.16	Life satisfaction;	chr17:82137252	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.634	rs11077973	ENSG00000275966.1	RP11-1055B8.9	-3.65	0.000287	0.0332	-0.17	-0.16	Life satisfaction;	chr17:82137315	chr17:81345476~81345966:-
LUAD	cis	rs4625783	0.583	rs11077974	ENSG00000275966.1	RP11-1055B8.9	-3.65	0.000287	0.0332	-0.17	-0.16	Blood metabolite levels;	chr17:82137317	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs6502065	ENSG00000275966.1	RP11-1055B8.9	-3.65	0.000287	0.0332	-0.17	-0.16	Life satisfaction;	chr17:82137766	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.731	rs35156322	ENSG00000275966.1	RP11-1055B8.9	-3.65	0.000287	0.0332	-0.17	-0.16	Life satisfaction;	chr17:82138447	chr17:81345476~81345966:-
LUAD	cis	rs7613875	0.6	rs2856237	ENSG00000234667.1	ACTBP13	3.65	0.000287	0.0332	0.19	0.16	Body mass index;	chr3:50121341	chr3:49873347~49877980:-
LUAD	cis	rs818427	0.964	rs818425	ENSG00000279522.1	CTC-487M23.6	3.65	0.000287	0.0332	0.2	0.16	Total body bone mineral density;	chr5:112890958	chr5:112894933~112896531:+
LUAD	cis	rs214785	1	rs214758	ENSG00000234684.5	SDCBP2-AS1	-3.65	0.000287	0.0332	-0.2	-0.16	Basal cell carcinoma;	chr20:2294882	chr20:1325405~1378734:+
LUAD	cis	rs3733418	0.929	rs12507869	ENSG00000248632.1	RP11-366M4.11	3.65	0.000287	0.0332	0.26	0.16	Obesity-related traits;	chr4:164974522	chr4:164968587~164970002:-
LUAD	cis	rs137603	0.644	rs137619	ENSG00000225450.1	RP3-508I15.14	-3.65	0.000287	0.0332	-0.15	-0.16	Primary biliary cholangitis;	chr22:39310355	chr22:38739003~38749041:+
LUAD	cis	rs11252926	0.589	rs12359901	ENSG00000232656.6	IDI2-AS1	-3.65	0.000287	0.0332	-0.18	-0.16	Psychosis in Alzheimer's disease;	chr10:429128	chr10:1022666~1044201:+
LUAD	cis	rs1552244	0.832	rs61056817	ENSG00000180385.7	EMC3-AS1	3.65	0.000287	0.0332	0.21	0.16	Alzheimer's disease;	chr3:9985957	chr3:9986893~10006990:+
LUAD	cis	rs41369048	0.66	rs1414517	ENSG00000221571.3	RNU6ATAC35P	-3.65	0.000287	0.0332	-0.21	-0.16	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220919496	chr1:220825620~220826063:+
LUAD	cis	rs7246657	0.551	rs28462002	ENSG00000267309.1	CTD-2630F21.1	3.65	0.000287	0.0332	0.27	0.16	Coronary artery calcification;	chr19:37143560	chr19:36489649~36491040:+
LUAD	cis	rs10129255	0.957	rs17113284	ENSG00000211947.2	IGHV3-21	3.65	0.000287	0.0332	0.11	0.16	Kawasaki disease;	chr14:106684476	chr14:106235064~106235594:-
LUAD	cis	rs9876781	1	rs7636782	ENSG00000229759.1	MRPS18AP1	3.65	0.000287	0.0332	0.16	0.16	Longevity;	chr3:48379897	chr3:48256350~48256938:-
LUAD	cis	rs7017914	0.905	rs10091471	ENSG00000246366.5	RP11-382J12.1	3.65	0.000287	0.0333	0.15	0.16	Bone mineral density;	chr8:71041520	chr8:70608577~70663279:+
LUAD	cis	rs2041895	0.565	rs10861679	ENSG00000260329.1	RP11-412D9.4	-3.65	0.000287	0.0333	-0.19	-0.16	Glaucoma (low intraocular pressure);	chr12:106929137	chr12:106954029~106955497:-
LUAD	cis	rs4873772	0.714	rs1231201	ENSG00000253330.1	RP11-697N18.3	3.65	0.000287	0.0333	0.18	0.16	Lobe attachment (rater-scored or self-reported);	chr8:47933603	chr8:47511034~47512141:-
LUAD	cis	rs7077256	0.564	rs12767847	ENSG00000272767.1	JMJD1C-AS1	3.65	0.000287	0.0333	0.25	0.16	Intelligence (multi-trait analysis);	chr10:63232413	chr10:63465229~63466563:+
LUAD	cis	rs12701220	0.689	rs12536282	ENSG00000229043.2	AC091729.9	-3.65	0.000287	0.0333	-0.24	-0.16	Bronchopulmonary dysplasia;	chr7:1076014	chr7:1160374~1165267:+
LUAD	cis	rs9921338	0.924	rs7204628	ENSG00000262703.1	RP11-485G7.6	-3.65	0.000287	0.0333	-0.17	-0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11350715	chr16:11348143~11349321:-
LUAD	cis	rs10992211	0.874	rs6479401	ENSG00000228216.1	RP11-367F23.1	3.65	0.000287	0.0333	0.2	0.16	Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis;	chr9:90129357	chr9:90957260~90965393:-
LUAD	cis	rs877356	0.748	rs7703565	ENSG00000250167.1	CTC-321K16.1	-3.65	0.000287	0.0333	-0.29	-0.16	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (dichotomous);	chr5:135832851	chr5:135559577~135634874:+
LUAD	cis	rs10876993	0.89	rs1585781	ENSG00000270039.1	RP11-571M6.17	3.65	0.000287	0.0333	0.19	0.16	Celiac disease or Rheumatoid arthritis;	chr12:57662918	chr12:57803838~57804415:+
LUAD	cis	rs10876993	0.928	rs1689594	ENSG00000270039.1	RP11-571M6.17	3.65	0.000287	0.0333	0.19	0.16	Celiac disease or Rheumatoid arthritis;	chr12:57663373	chr12:57803838~57804415:+
LUAD	cis	rs10508774	0.81	rs12244832	ENSG00000231245.2	C1DP1	-3.65	0.000287	0.0333	-0.38	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32583192	chr10:32511336~32511737:-
LUAD	cis	rs7142881	0.815	rs8022163	ENSG00000258525.1	RP11-829H16.3	-3.65	0.000287	0.0333	-0.19	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31611267	chr14:30876179~30889808:-
LUAD	cis	rs12440869	1	rs9920957	ENSG00000270964.1	RP11-502I4.3	3.65	0.000287	0.0333	0.19	0.16	Peak velocity of the mitral A-wave;	chr15:67297231	chr15:67541072~67542604:-
LUAD	cis	rs12440869	1	rs28429363	ENSG00000270964.1	RP11-502I4.3	3.65	0.000287	0.0333	0.19	0.16	Peak velocity of the mitral A-wave;	chr15:67313317	chr15:67541072~67542604:-
LUAD	cis	rs12440869	1	rs4776920	ENSG00000270964.1	RP11-502I4.3	3.65	0.000287	0.0333	0.19	0.16	Peak velocity of the mitral A-wave;	chr15:67316778	chr15:67541072~67542604:-
LUAD	cis	rs6736093	0.966	rs11681063	ENSG00000207383.1	Y_RNA	-3.65	0.000287	0.0333	-0.21	-0.16	Coronary artery disease;	chr2:111985765	chr2:112579484~112579584:-
LUAD	cis	rs1823913	0.637	rs10931497	ENSG00000230611.1	HMGB1P27	3.65	0.000287	0.0333	0.19	0.16	Obesity-related traits;	chr2:191306254	chr2:191174233~191174835:+
LUAD	cis	rs1023500	0.596	rs133350	ENSG00000205702.9	CYP2D7	3.65	0.000287	0.0333	0.14	0.16	Schizophrenia;	chr22:42033045	chr22:42140203~42144577:-
LUAD	cis	rs1198430	1	rs1198439	ENSG00000232482.2	RP4-654C18.1	-3.65	0.000287	0.0333	-0.25	-0.16	Total cholesterol levels;	chr1:23423100	chr1:23410832~23412146:+
LUAD	cis	rs9889262	0.93	rs16948048	ENSG00000251179.1	TMEM92-AS1	3.65	0.000287	0.0333	0.17	0.16	Eosinophil percentage of granulocytes;Allergic disease (asthma, hay fever or eczema);Eosinophil counts;	chr17:49363104	chr17:50281577~50287855:-
LUAD	cis	rs111612372	1	rs111612372	ENSG00000234378.1	AC098828.2	-3.65	0.000287	0.0333	-0.21	-0.16	Body mass index;	chr2:20233457	chr2:20063856~20106829:-
LUAD	cis	rs117623576	0.941	rs111864818	ENSG00000234335.1	RPS4XP11	-3.65	0.000287	0.0333	-0.25	-0.16	Anti-saccade response;	chr10:32137685	chr10:32102522~32103293:-
LUAD	cis	rs897984	0.574	rs11647284	ENSG00000232748.3	RP11-196G11.6	-3.65	0.000287	0.0333	-0.21	-0.16	Dementia with Lewy bodies;	chr16:31066014	chr16:31056460~31062803:+
LUAD	cis	rs4835473	0.808	rs13134564	ENSG00000249741.2	RP11-673E1.3	3.65	0.000287	0.0333	0.19	0.16	Immature fraction of reticulocytes;	chr4:143738763	chr4:143911514~143912053:-
LUAD	cis	rs4835473	0.932	rs13139738	ENSG00000249741.2	RP11-673E1.3	3.65	0.000287	0.0333	0.19	0.16	Immature fraction of reticulocytes;	chr4:143738828	chr4:143911514~143912053:-
LUAD	cis	rs4835473	0.932	rs17018165	ENSG00000249741.2	RP11-673E1.3	3.65	0.000287	0.0333	0.19	0.16	Immature fraction of reticulocytes;	chr4:143738849	chr4:143911514~143912053:-
LUAD	cis	rs12680842	0.883	rs13265241	ENSG00000253175.1	RP11-267M23.6	3.65	0.000287	0.0333	0.18	0.16	Body mass index;	chr8:94575129	chr8:94565036~94565715:+
LUAD	cis	rs7557067	1	rs7557067	ENSG00000233005.1	AC067959.1	-3.65	0.000287	0.0333	-0.2	-0.16	Triglycerides;	chr2:20985339	chr2:21221175~21970959:+
LUAD	cis	rs3020736	0.5	rs6002601	ENSG00000273366.1	CTA-989H11.1	3.65	0.000287	0.0333	0.19	0.16	Autism spectrum disorder or schizophrenia;	chr22:42093054	chr22:42278188~42278846:+
LUAD	cis	rs11159086	0.793	rs12432412	ENSG00000270000.1	RP3-449M8.9	3.65	0.000287	0.0333	0.23	0.16	Advanced glycation end-product levels;	chr14:74474294	chr14:74471930~74472360:-
LUAD	cis	rs11159086	0.793	rs1029700	ENSG00000270000.1	RP3-449M8.9	3.65	0.000287	0.0333	0.23	0.16	Advanced glycation end-product levels;	chr14:74474309	chr14:74471930~74472360:-
LUAD	cis	rs11159086	0.793	rs1029699	ENSG00000270000.1	RP3-449M8.9	3.65	0.000287	0.0333	0.23	0.16	Advanced glycation end-product levels;	chr14:74474790	chr14:74471930~74472360:-
LUAD	cis	rs4578769	0.55	rs4517887	ENSG00000266850.1	RP11-370A5.1	-3.65	0.000288	0.0333	-0.21	-0.16	Eosinophil percentage of white cells;	chr18:22994715	chr18:22723491~22907721:-
LUAD	cis	rs7918232	1	rs6482595	ENSG00000262412.1	RP11-85G18.6	-3.65	0.000288	0.0333	-0.22	-0.16	Breast cancer;	chr10:27091332	chr10:27243130~27250804:+
LUAD	cis	rs11726248	0.718	rs17629735	ENSG00000250266.1	RP11-789C1.1	3.65	0.000288	0.0333	0.27	0.16	Thyroid hormone levels;	chr4:170258789	chr4:170273919~170283079:+
LUAD	cis	rs2115630	0.936	rs8033459	ENSG00000259295.5	CSPG4P12	-3.65	0.000288	0.0333	-0.19	-0.16	P wave terminal force;	chr15:84710027	chr15:85191438~85213905:+
LUAD	cis	rs4888378	0.6	rs729109	ENSG00000280152.1	RP11-331F4.5	3.65	0.000288	0.0333	0.15	0.16	Coronary artery disease;	chr16:75282176	chr16:75245994~75250077:-
LUAD	cis	rs7142881	0.815	rs8003788	ENSG00000258525.1	RP11-829H16.3	-3.65	0.000288	0.0333	-0.19	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31569474	chr14:30876179~30889808:-
LUAD	cis	rs7003550	0.951	rs10111648	ENSG00000253433.1	NCRNA00250	-3.65	0.000288	0.0333	-0.22	-0.16	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr8:134843787	chr8:134838069~134842637:+
LUAD	cis	rs7968440	1	rs67701624	ENSG00000272368.2	RP4-605O3.4	3.65	0.000288	0.0333	0.19	0.16	Fibrinogen;	chr12:50535155	chr12:50112197~50165618:+
LUAD	cis	rs7968440	0.966	rs68171620	ENSG00000272368.2	RP4-605O3.4	3.65	0.000288	0.0333	0.19	0.16	Fibrinogen;	chr12:50543755	chr12:50112197~50165618:+
LUAD	cis	rs338389	0.872	rs1913303	ENSG00000270964.1	RP11-502I4.3	3.65	0.000288	0.0333	0.17	0.16	Survival in rectal cancer;	chr15:67996718	chr15:67541072~67542604:-
LUAD	cis	rs5015933	0.788	rs461961	ENSG00000232630.1	PRPS1P2	-3.65	0.000288	0.0333	-0.15	-0.16	Body mass index;	chr9:125290977	chr9:125150653~125151589:+
LUAD	cis	rs875971	0.895	rs12698520	ENSG00000273142.1	RP11-458F8.4	-3.65	0.000288	0.0333	-0.11	-0.16	Aortic root size;	chr7:66453720	chr7:66902857~66906297:+
LUAD	cis	rs8062405	0.964	rs78613234	ENSG00000261419.1	RP11-57A19.4	-3.65	0.000288	0.0333	-0.18	-0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28659696~28740781:-
LUAD	cis	rs8062405	1	rs62036624	ENSG00000261419.1	RP11-57A19.4	-3.65	0.000288	0.0333	-0.18	-0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28659696~28740781:-
LUAD	cis	rs61160187	0.582	rs1479645	ENSG00000215032.2	GNL3LP1	3.65	0.000288	0.0333	0.2	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:61023904	chr5:60891935~60893577:-
LUAD	cis	rs35520189	0.556	rs11893071	ENSG00000227368.1	AC079753.5	3.65	0.000288	0.0333	0.2	0.16	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112951213	chr2:112932625~112933171:+
LUAD	cis	rs8180040	0.739	rs4683320	ENSG00000271161.1	BOLA2P2	3.65	0.000288	0.0333	0.16	0.16	Colorectal cancer;	chr3:47111502	chr3:47499841~47500407:+
LUAD	cis	rs1198430	1	rs1198434	ENSG00000232482.2	RP4-654C18.1	-3.65	0.000288	0.0333	-0.26	-0.16	Total cholesterol levels;	chr1:23431641	chr1:23410832~23412146:+
LUAD	cis	rs2273156	1	rs17102967	ENSG00000226677.3	IGBP1P1	-3.65	0.000288	0.0333	-0.25	-0.16	Immunoglobulin light chain (AL) amyloidosis;	chr14:35011182	chr14:34939324~34940332:+
LUAD	cis	rs7210990	0.699	rs4792718	ENSG00000275413.1	CTC-529I10.1	-3.65	0.000288	0.0333	-0.14	-0.16	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr17:16051378	chr17:16023323~16023653:-
LUAD	cis	rs2274273	0.87	rs10144345	ENSG00000258413.1	RP11-665C16.6	-3.65	0.000288	0.0333	-0.21	-0.16	Protein biomarker;	chr14:55381019	chr14:55262767~55272075:-
LUAD	cis	rs76878669	0.561	rs3177514	ENSG00000213409.4	RP11-658F2.3	3.65	0.000288	0.0333	0.2	0.16	Educational attainment (years of education);	chr11:66362887	chr11:66761575~66762399:-
LUAD	cis	rs763121	0.962	rs5757135	ENSG00000273076.1	RP3-508I15.22	3.65	0.000288	0.0333	0.15	0.16	Menopause (age at onset);	chr22:38556568	chr22:38743495~38743910:+
LUAD	cis	rs1478898	0.526	rs1478897	ENSG00000270154.1	RP11-419I17.1	3.65	0.000288	0.0333	0.19	0.16	Morning vs. evening chronotype;	chr8:11537723	chr8:12476462~12477122:+
LUAD	cis	rs1150668	0.799	rs7206	ENSG00000176933.5	TOB2P1	-3.65	0.000288	0.0334	-0.19	-0.16	Pubertal anthropometrics;	chr6:28233360	chr6:28217643~28218634:-
LUAD	cis	rs8062405	1	rs12325113	ENSG00000261419.1	RP11-57A19.4	-3.65	0.000288	0.0334	-0.18	-0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28659696~28740781:-
LUAD	cis	rs12754538	0.665	rs12037534	ENSG00000232912.4	RP5-1115A15.1	3.65	0.000288	0.0334	0.18	0.16	Subjective well-being;	chr1:8589865	chr1:8424645~8434838:+
LUAD	cis	rs7762018	1	rs17860606	ENSG00000231690.2	LINC00574	-3.65	0.000288	0.0334	-0.3	-0.16	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr6:169699465	chr6:169790321~169802873:+
LUAD	cis	rs2239557	0.508	rs11159044	ENSG00000259065.1	RP5-1021I20.1	-3.65	0.000288	0.0334	-0.22	-0.16	Common traits (Other);	chr14:73901158	chr14:73787360~73803270:+
LUAD	cis	rs10090774	0.67	rs13273943	ENSG00000280303.2	ERICD	-3.65	0.000288	0.0334	-0.19	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140724786	chr8:140636281~140638283:+
LUAD	cis	rs7215564	0.908	rs35878324	ENSG00000232083.3	RPL31P7	3.65	0.000288	0.0334	0.33	0.16	Myopia (pathological);	chr17:80703730	chr17:80602549~80602926:-
LUAD	cis	rs6088590	1	rs2076668	ENSG00000275784.1	RP5-1125A11.6	-3.65	0.000288	0.0334	-0.18	-0.16	Coronary artery disease;	chr20:34849818	chr20:33989480~33991818:-
LUAD	cis	rs1040393	0.903	rs4657611	ENSG00000225171.2	DUTP6	3.65	0.000288	0.0334	0.21	0.16	Schizophrenia;	chr1:166880307	chr1:166868748~166869209:+
LUAD	cis	rs3096299	0.838	rs3102376	ENSG00000261574.1	RP1-168P16.2	3.65	0.000288	0.0334	0.18	0.16	Multiple myeloma (IgH translocation);	chr16:89336065	chr16:89392375~89412564:-
LUAD	cis	rs9303542	1	rs4451990	ENSG00000264920.1	RP11-6N17.4	-3.65	0.000288	0.0334	-0.21	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48323291	chr17:47891255~47895812:-
LUAD	cis	rs4795519	0.826	rs2313051	ENSG00000266313.1	RP11-173M1.4	3.65	0.000288	0.0334	0.2	0.16	Chronic myeloid leukemia;	chr17:27039258	chr17:27333256~27348491:+
LUAD	cis	rs4795519	0.704	rs11080049	ENSG00000266313.1	RP11-173M1.4	3.65	0.000288	0.0334	0.2	0.16	Chronic myeloid leukemia;	chr17:27047846	chr17:27333256~27348491:+
LUAD	cis	rs3096299	0.754	rs2965816	ENSG00000261574.1	RP1-168P16.2	-3.65	0.000288	0.0334	-0.18	-0.16	Multiple myeloma (IgH translocation);	chr16:89447775	chr16:89392375~89412564:-
LUAD	cis	rs7847445	0.536	rs2104546	ENSG00000231459.1	LINC00032	3.65	0.000288	0.0334	0.2	0.16	Loneliness;	chr9:26567702	chr9:27245684~27282793:-
LUAD	cis	rs9813712	0.526	rs13065659	ENSG00000253540.4	FAM86HP	-3.65	0.000288	0.0334	-0.17	-0.16	Response to amphetamines;	chr3:130231945	chr3:130099092~130111472:-
LUAD	cis	rs27434	0.605	rs12659825	ENSG00000272109.1	CTD-2260A17.3	3.65	0.000288	0.0334	0.24	0.16	Ankylosing spondylitis;	chr5:96852380	chr5:96804353~96806105:+
LUAD	cis	rs7107174	0.688	rs10899501	ENSG00000251323.2	RP11-452H21.4	3.65	0.000288	0.0334	0.22	0.16	Testicular germ cell tumor;	chr11:78420362	chr11:78423982~78429836:-
LUAD	cis	rs1862618	0.802	rs7733041	ENSG00000271828.1	CTD-2310F14.1	3.65	0.000288	0.0334	0.23	0.16	Initial pursuit acceleration;	chr5:56811550	chr5:56927874~56929573:+
LUAD	cis	rs365302	1	rs365302	ENSG00000235086.1	FNDC1-IT1	-3.65	0.000288	0.0334	-0.22	-0.16	Coronary heart disease;	chr6:159225301	chr6:159240786~159243329:+
LUAD	cis	rs10129255	1	rs10129255	ENSG00000211947.2	IGHV3-21	3.65	0.000288	0.0334	0.11	0.16	Kawasaki disease;	chr14:106767970	chr14:106235064~106235594:-
LUAD	cis	rs7824557	0.603	rs2736278	ENSG00000255046.1	RP11-297N6.4	-3.65	0.000288	0.0334	-0.2	-0.16	Retinal vascular caliber;	chr8:11362272	chr8:11797928~11802568:-
LUAD	cis	rs728616	0.571	rs113030473	ENSG00000225484.5	NUTM2B-AS1	-3.65	0.000288	0.0334	-0.43	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79889275	chr10:79663088~79826594:-
LUAD	cis	rs944990	0.557	rs10761237	ENSG00000227603.1	RP11-165J3.6	3.65	0.000288	0.0334	0.19	0.16	Body mass index;	chr9:93578535	chr9:93435332~93437121:-
LUAD	cis	rs6496044	0.568	rs12899946	ENSG00000259416.2	RP11-158M2.5	3.65	0.000288	0.0334	0.17	0.16	Interstitial lung disease;	chr15:85522851	chr15:85754941~85756237:-
LUAD	cis	rs6496044	0.568	rs12898783	ENSG00000259416.2	RP11-158M2.5	3.65	0.000288	0.0334	0.17	0.16	Interstitial lung disease;	chr15:85522869	chr15:85754941~85756237:-
LUAD	cis	rs4268898	0.56	rs78711174	ENSG00000242628.4	AC009228.1	3.65	0.000289	0.0334	0.25	0.16	Asthma;	chr2:24273662	chr2:24214381~24221516:+
LUAD	cis	rs2554380	0.8	rs8034055	ENSG00000230373.7	GOLGA6L5P	-3.65	0.000289	0.0334	-0.2	-0.16	Height;	chr15:83743143	chr15:84507885~84516814:-
LUAD	cis	rs2625529	0.526	rs10851850	ENSG00000260173.1	RP11-2I17.4	3.65	0.000289	0.0334	0.2	0.16	Red blood cell count;	chr15:72194168	chr15:72140504~72155459:-
LUAD	cis	rs7142881	0.844	rs34872357	ENSG00000258525.1	RP11-829H16.3	3.65	0.000289	0.0334	0.19	0.16	Response to iloperidone treatment (QT prolongation);	chr14:31564607	chr14:30876179~30889808:-
LUAD	cis	rs9983113	0.783	rs4817972	ENSG00000205622.8	AF064858.6	3.65	0.000289	0.0334	0.19	0.16	Body mass index;	chr21:38937667	chr21:38863676~38956467:-
LUAD	cis	rs9983113	0.783	rs4817973	ENSG00000205622.8	AF064858.6	3.65	0.000289	0.0334	0.19	0.16	Body mass index;	chr21:38937668	chr21:38863676~38956467:-
LUAD	cis	rs8014252	1	rs4550388	ENSG00000274818.1	RP1-292L20.3	3.65	0.000289	0.0334	0.27	0.16	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70434105	chr14:70906657~70907111:-
LUAD	cis	rs8014252	0.908	rs12586481	ENSG00000274818.1	RP1-292L20.3	3.65	0.000289	0.0334	0.27	0.16	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70435571	chr14:70906657~70907111:-
LUAD	cis	rs4845570	1	rs6673002	ENSG00000203288.3	RP11-98D18.9	3.65	0.000289	0.0334	0.25	0.16	Coronary artery disease;	chr1:151770799	chr1:151790804~151794402:+
LUAD	cis	rs1046491	1	rs12454497	ENSG00000264964.1	RP11-888D10.3	3.65	0.000289	0.0334	0.34	0.16	Scarlet fever;	chr18:9224441	chr18:9315194~9334441:-
LUAD	cis	rs753955	0.554	rs2031587	ENSG00000205861.10	C1QTNF9B-AS1	3.65	0.000289	0.0334	0.2	0.16	Lung cancer;	chr13:23843196	chr13:23888889~23897263:+
LUAD	cis	rs9889262	0.602	rs4794032	ENSG00000248714.5	RP11-1079K10.3	3.65	0.000289	0.0334	0.16	0.16	Eosinophil percentage of granulocytes;Allergic disease (asthma, hay fever or eczema);Eosinophil counts;	chr17:49270517	chr17:49361165~49369998:+
LUAD	cis	rs3764021	0.87	rs10844597	ENSG00000256582.1	RP11-75L1.1	3.65	0.000289	0.0334	0.17	0.16	Type 1 diabetes;	chr12:9722303	chr12:9704077~9709350:+
LUAD	cis	rs6088580	0.634	rs1890000	ENSG00000276073.1	RP5-1125A11.7	3.65	0.000289	0.0334	0.16	0.16	Glomerular filtration rate (creatinine);	chr20:34380506	chr20:33985617~33988989:-
LUAD	cis	rs8113308	0.515	rs68124997	ENSG00000269483.1	AC006272.1	3.65	0.000289	0.0334	0.3	0.16	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51949276	chr19:51839924~51843324:-
LUAD	cis	rs763121	0.719	rs9610995	ENSG00000225450.1	RP3-508I15.14	-3.65	0.000289	0.0334	-0.16	-0.16	Menopause (age at onset);	chr22:38661758	chr22:38739003~38749041:+
LUAD	cis	rs763121	0.853	rs2413544	ENSG00000225450.1	RP3-508I15.14	-3.65	0.000289	0.0334	-0.16	-0.16	Menopause (age at onset);	chr22:38663399	chr22:38739003~38749041:+
LUAD	cis	rs763121	0.752	rs5757222	ENSG00000225450.1	RP3-508I15.14	-3.65	0.000289	0.0334	-0.16	-0.16	Menopause (age at onset);	chr22:38664468	chr22:38739003~38749041:+
LUAD	cis	rs763121	0.819	rs5750658	ENSG00000225450.1	RP3-508I15.14	-3.65	0.000289	0.0334	-0.16	-0.16	Menopause (age at onset);	chr22:38664912	chr22:38739003~38749041:+
LUAD	cis	rs763121	0.819	rs8137829	ENSG00000225450.1	RP3-508I15.14	-3.65	0.000289	0.0334	-0.16	-0.16	Menopause (age at onset);	chr22:38665025	chr22:38739003~38749041:+
LUAD	cis	rs12586722	1	rs12586722	ENSG00000274818.1	RP1-292L20.3	3.65	0.000289	0.0334	0.27	0.16	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70423423	chr14:70906657~70907111:-
LUAD	cis	rs8014252	1	rs75971975	ENSG00000274818.1	RP1-292L20.3	3.65	0.000289	0.0334	0.27	0.16	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70436281	chr14:70906657~70907111:-
LUAD	cis	rs8014252	1	rs12436808	ENSG00000274818.1	RP1-292L20.3	3.65	0.000289	0.0334	0.27	0.16	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70437890	chr14:70906657~70907111:-
LUAD	cis	rs8014252	1	rs73291972	ENSG00000274818.1	RP1-292L20.3	3.65	0.000289	0.0334	0.27	0.16	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70452813	chr14:70906657~70907111:-
LUAD	cis	rs2153535	0.518	rs2183113	ENSG00000230939.1	RP11-314C16.1	-3.65	0.000289	0.0334	-0.19	-0.16	Motion sickness;	chr6:8528305	chr6:8784178~8785445:+
LUAD	cis	rs2153535	0.518	rs6597336	ENSG00000230939.1	RP11-314C16.1	-3.65	0.000289	0.0334	-0.19	-0.16	Motion sickness;	chr6:8530663	chr6:8784178~8785445:+
LUAD	cis	rs6689263	0.584	rs76992245	ENSG00000117242.7	PINK1-AS	3.65	0.000289	0.0334	0.38	0.16	Intelligence (multi-trait analysis);	chr1:20588252	chr1:20642657~20652193:-
LUAD	cis	rs159572	0.695	rs149573	ENSG00000250853.1	RNF138P1	3.65	0.000289	0.0334	0.19	0.16	Post-traumatic stress disorder;	chr5:56229036	chr5:55530156~55530701:-
LUAD	cis	rs875971	0.867	rs1002053	ENSG00000273142.1	RP11-458F8.4	3.65	0.000289	0.0334	0.12	0.16	Aortic root size;	chr7:66333558	chr7:66902857~66906297:+
LUAD	cis	rs2279168	1	rs16940964	ENSG00000202081.1	RNU6-1280P	-3.65	0.000289	0.0334	-0.26	-0.16	Response to platinum-based chemotherapy (carboplatin);	chr15:85527566	chr15:85651522~85651628:-
LUAD	cis	rs4664293	0.836	rs2556102	ENSG00000230783.1	AC009961.2	-3.65	0.000289	0.0334	-0.21	-0.16	Monocyte percentage of white cells;	chr2:159798611	chr2:159689217~159690291:-
LUAD	cis	rs67478160	0.643	rs2295145	ENSG00000272533.1	SNORA28	3.65	0.000289	0.0334	0.17	0.16	Schizophrenia;	chr14:103735967	chr14:103337849~103337974:+
LUAD	cis	rs417065	0.516	rs11121131	ENSG00000227634.1	RP11-431K24.3	-3.65	0.000289	0.0334	-0.23	-0.16	Psoriasis;	chr1:8212171	chr1:8208672~8215210:+
LUAD	cis	rs9341808	0.622	rs682482	ENSG00000272129.1	RP11-250B2.6	-3.65	0.000289	0.0334	-0.2	-0.16	Sitting height ratio;	chr6:80251422	chr6:80355424~80356859:+
LUAD	cis	rs2278702	1	rs2278702	ENSG00000259495.2	RP11-210M15.2	-3.65	0.000289	0.0334	-0.24	-0.16	Bipolar disorder;	chr15:80402580	chr15:80344853~80403575:-
LUAD	cis	rs1044826	1	rs9868544	ENSG00000214280.3	RP11-553K23.2	-3.65	0.000289	0.0334	-0.2	-0.16	Obesity-related traits;	chr3:139444312	chr3:139582928~139583593:-
LUAD	cis	rs2554380	0.55	rs17296856	ENSG00000259570.1	RP11-671M22.4	-3.65	0.000289	0.0335	-0.22	-0.16	Height;	chr15:83888698	chr15:84394512~84395514:+
LUAD	cis	rs60695258	0.963	rs3775228	ENSG00000251411.1	RP11-397E7.4	-3.65	0.000289	0.0335	-0.18	-0.16	Hematocrit;	chr4:87064014	chr4:86913266~86914817:-
LUAD	cis	rs1878931	0.624	rs39728	ENSG00000262370.4	RP11-473M20.9	3.65	0.000289	0.0335	0.13	0.16	Body mass index (adult);	chr16:3403076	chr16:3076911~3087100:-
LUAD	cis	rs2348418	0.864	rs7977817	ENSG00000247934.4	RP11-967K21.1	3.65	0.000289	0.0335	0.19	0.16	Lung function (FEV1);Lung function (FVC);	chr12:28562549	chr12:28163298~28190738:-
LUAD	cis	rs2348418	0.831	rs7977525	ENSG00000247934.4	RP11-967K21.1	3.65	0.000289	0.0335	0.19	0.16	Lung function (FEV1);Lung function (FVC);	chr12:28562584	chr12:28163298~28190738:-
LUAD	cis	rs2348418	0.864	rs7977850	ENSG00000247934.4	RP11-967K21.1	3.65	0.000289	0.0335	0.19	0.16	Lung function (FEV1);Lung function (FVC);	chr12:28562715	chr12:28163298~28190738:-
LUAD	cis	rs2348418	0.864	rs7978086	ENSG00000247934.4	RP11-967K21.1	3.65	0.000289	0.0335	0.19	0.16	Lung function (FEV1);Lung function (FVC);	chr12:28562761	chr12:28163298~28190738:-
LUAD	cis	rs2348418	0.864	rs11609924	ENSG00000247934.4	RP11-967K21.1	3.65	0.000289	0.0335	0.19	0.16	Lung function (FEV1);Lung function (FVC);	chr12:28563197	chr12:28163298~28190738:-
LUAD	cis	rs2348418	0.864	rs7968563	ENSG00000247934.4	RP11-967K21.1	3.65	0.000289	0.0335	0.19	0.16	Lung function (FEV1);Lung function (FVC);	chr12:28563844	chr12:28163298~28190738:-
LUAD	cis	rs2348418	0.864	rs2137072	ENSG00000247934.4	RP11-967K21.1	3.65	0.000289	0.0335	0.19	0.16	Lung function (FEV1);Lung function (FVC);	chr12:28563872	chr12:28163298~28190738:-
LUAD	cis	rs6496932	0.865	rs4842874	ENSG00000259630.2	CTD-2262B20.1	3.65	0.000289	0.0335	0.23	0.16	Central corneal thickness;Corneal structure;	chr15:85323464	chr15:85415228~85415633:+
LUAD	cis	rs6496932	0.865	rs4843049	ENSG00000259630.2	CTD-2262B20.1	3.65	0.000289	0.0335	0.23	0.16	Central corneal thickness;Corneal structure;	chr15:85331141	chr15:85415228~85415633:+
LUAD	cis	rs6500602	0.964	rs2304633	ENSG00000280063.1	RP11-295D4.3	3.65	0.000289	0.0335	0.11	0.16	Schizophrenia;	chr16:4446972	chr16:4346694~4348648:-
LUAD	cis	rs2832077	0.506	rs10222093	ENSG00000215533.7	LINC00189	3.65	0.000289	0.0335	0.21	0.16	Cognitive test performance;	chr21:28791196	chr21:29193480~29288205:+
LUAD	cis	rs2412819	0.597	rs541871	ENSG00000166763.7	STRCP1	3.65	0.000289	0.0335	0.23	0.16	Lung cancer;	chr15:43868656	chr15:43699488~43718184:-
LUAD	cis	rs889398	0.617	rs3790082	ENSG00000226232.7	RP11-419C5.2	-3.65	0.000289	0.0335	-0.14	-0.16	Body mass index;	chr16:69862851	chr16:69976388~69996188:-
LUAD	cis	rs9921338	0.961	rs8048768	ENSG00000263080.1	RP11-485G7.5	3.65	0.000289	0.0335	0.22	0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11302983	chr16:11341809~11345211:-
LUAD	cis	rs7212590	0.618	rs59767604	ENSG00000263422.1	AC005702.1	3.65	0.000289	0.0335	0.37	0.16	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59963978	chr17:60042361~60042442:-
LUAD	cis	rs875971	0.66	rs10950044	ENSG00000222364.1	RNU6-96P	3.65	0.000289	0.0335	0.18	0.16	Aortic root size;	chr7:66577989	chr7:66395191~66395286:+
LUAD	cis	rs11853189	0.938	rs16969707	ENSG00000259562.2	RP11-762H8.2	3.65	0.000289	0.0335	0.18	0.16	Red cell distribution width;	chr15:78301763	chr15:78290527~78291221:-
LUAD	cis	rs2548724	0.716	rs62371033	ENSG00000250682.4	LINC00491	3.65	0.000289	0.0335	0.21	0.16	Type 2 diabetes;	chr5:102477424	chr5:102609156~102671559:-
LUAD	cis	rs7617773	0.817	rs9837228	ENSG00000199476.1	Y_RNA	3.65	0.000289	0.0335	0.21	0.16	Coronary artery disease;	chr3:48282976	chr3:48288587~48288694:+
LUAD	cis	rs12908161	0.959	rs1051168	ENSG00000254414.1	RP11-182J1.1	3.65	0.000289	0.0335	0.21	0.16	Schizophrenia;	chr15:84657289	chr15:84631898~84633987:-
LUAD	cis	rs34421088	0.548	rs2618443	ENSG00000270154.1	RP11-419I17.1	-3.65	0.000289	0.0335	-0.19	-0.16	Neuroticism;	chr8:11527047	chr8:12476462~12477122:+
LUAD	cis	rs3764400	0.508	rs74412170	ENSG00000278765.1	RP5-890E16.5	3.65	0.000289	0.0335	0.3	0.16	Body mass index;	chr17:48040147	chr17:48066704~48067293:-
LUAD	cis	rs3764400	0.508	rs12601350	ENSG00000278765.1	RP5-890E16.5	3.65	0.000289	0.0335	0.3	0.16	Body mass index;	chr17:48043057	chr17:48066704~48067293:-
LUAD	cis	rs2274273	0.87	rs3783650	ENSG00000258413.1	RP11-665C16.6	-3.65	0.000289	0.0335	-0.21	-0.16	Protein biomarker;	chr14:55382254	chr14:55262767~55272075:-
LUAD	cis	rs10800713	0.779	rs2815289	ENSG00000260088.1	RP11-92G12.3	3.65	0.000289	0.0335	0.25	0.16	Tandem gait;	chr1:200610628	chr1:200669507~200694250:+
LUAD	cis	rs13300663	0.697	rs13284412	ENSG00000214195.4	HMGN2P31	-3.65	0.00029	0.0335	-0.23	-0.16	Platelet count;	chr9:4778777	chr9:5311444~5311716:+
LUAD	cis	rs1198430	0.639	rs2297841	ENSG00000232482.2	RP4-654C18.1	-3.65	0.00029	0.0335	-0.23	-0.16	Total cholesterol levels;	chr1:23437656	chr1:23410832~23412146:+
LUAD	cis	rs7100689	0.646	rs7081889	ENSG00000226659.1	RP11-137H2.4	-3.65	0.00029	0.0335	-0.22	-0.16	Post bronchodilator FEV1;	chr10:80405671	chr10:80529597~80535942:-
LUAD	cis	rs2479106	0.791	rs2536951	ENSG00000236901.4	MIR600HG	3.65	0.00029	0.0335	0.12	0.16	Polycystic ovary syndrome;	chr9:123884240	chr9:123109494~123115477:-
LUAD	cis	rs116095464	1	rs10475185	ENSG00000250848.1	CTD-2083E4.5	-3.65	0.00029	0.0335	-0.34	-0.16	Breast cancer;	chr5:306866	chr5:288833~290321:-
LUAD	cis	rs7560272	0.723	rs6744697	ENSG00000163016.8	ALMS1P	3.65	0.00029	0.0335	0.18	0.16	Schizophrenia;	chr2:73538311	chr2:73644919~73685576:+
LUAD	cis	rs2832270	1	rs2832270	ENSG00000174680.8	GRIK1-AS1	3.65	0.00029	0.0335	0.29	0.16	Response to mTOR inhibitor (everolimus);	chr21:29222211	chr21:29748175~29764002:+
LUAD	cis	rs12440869	1	rs12708494	ENSG00000270964.1	RP11-502I4.3	3.65	0.00029	0.0335	0.19	0.16	Peak velocity of the mitral A-wave;	chr15:67355230	chr15:67541072~67542604:-
LUAD	cis	rs9341808	0.5	rs806851	ENSG00000260645.1	RP11-250B2.5	-3.65	0.00029	0.0335	-0.16	-0.16	Sitting height ratio;	chr6:80321114	chr6:80466958~80469080:+
LUAD	cis	rs10392	0.543	rs3752290	ENSG00000274825.1	RP4-616B8.5	-3.65	0.00029	0.0335	-0.21	-0.16	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;	chr20:38926473	chr20:38955910~38956547:+
LUAD	cis	rs34779708	0.931	rs4007289	ENSG00000271335.4	RP11-324I22.4	3.65	0.00029	0.0335	0.17	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:34980862	chr10:35314552~35336401:-
LUAD	cis	rs12928939	0.517	rs9940234	ENSG00000260886.1	TAT-AS1	3.65	0.00029	0.0335	0.21	0.16	Post bronchodilator FEV1;	chr16:71930902	chr16:71565789~71578187:+
LUAD	cis	rs12928939	0.517	rs11865456	ENSG00000260886.1	TAT-AS1	3.65	0.00029	0.0335	0.21	0.16	Post bronchodilator FEV1;	chr16:71935594	chr16:71565789~71578187:+
LUAD	cis	rs7610301	1	rs60911065	ENSG00000276925.1	RP11-708J19.3	3.65	0.00029	0.0335	0.2	0.16	Blood protein levels;	chr3:46600747	chr3:47469777~47469987:+
LUAD	cis	rs9549260	0.816	rs964901	ENSG00000168852.11	TPTE2P5	3.65	0.00029	0.0335	0.16	0.16	Red blood cell count;	chr13:40674561	chr13:40822296~40921749:-
LUAD	cis	rs7560272	0.501	rs2006997	ENSG00000163016.8	ALMS1P	-3.65	0.00029	0.0335	-0.18	-0.16	Schizophrenia;	chr2:73720719	chr2:73644919~73685576:+
LUAD	cis	rs7560272	0.512	rs13015885	ENSG00000163016.8	ALMS1P	-3.65	0.00029	0.0335	-0.18	-0.16	Schizophrenia;	chr2:73693355	chr2:73644919~73685576:+
LUAD	cis	rs11673344	0.864	rs2562595	ENSG00000267309.1	CTD-2630F21.1	-3.65	0.00029	0.0335	-0.21	-0.16	Obesity-related traits;	chr19:37023964	chr19:36489649~36491040:+
LUAD	cis	rs11673344	0.832	rs8101407	ENSG00000267309.1	CTD-2630F21.1	-3.65	0.00029	0.0335	-0.21	-0.16	Obesity-related traits;	chr19:37024444	chr19:36489649~36491040:+
LUAD	cis	rs2239547	0.618	rs4687658	ENSG00000243224.1	RP5-1157M23.2	-3.65	0.00029	0.0335	-0.19	-0.16	Schizophrenia;	chr3:52826350	chr3:52239258~52241097:+
LUAD	cis	rs2239547	0.657	rs2276817	ENSG00000243224.1	RP5-1157M23.2	-3.65	0.00029	0.0335	-0.19	-0.16	Schizophrenia;	chr3:52826920	chr3:52239258~52241097:+
LUAD	cis	rs2239547	0.657	rs13072536	ENSG00000243224.1	RP5-1157M23.2	-3.65	0.00029	0.0335	-0.19	-0.16	Schizophrenia;	chr3:52827195	chr3:52239258~52241097:+
LUAD	cis	rs2239547	0.657	rs12488303	ENSG00000243224.1	RP5-1157M23.2	-3.65	0.00029	0.0335	-0.19	-0.16	Schizophrenia;	chr3:52827987	chr3:52239258~52241097:+
LUAD	cis	rs2239547	0.657	rs2072391	ENSG00000243224.1	RP5-1157M23.2	-3.65	0.00029	0.0335	-0.19	-0.16	Schizophrenia;	chr3:52828184	chr3:52239258~52241097:+
LUAD	cis	rs9921338	0.961	rs8043692	ENSG00000262703.1	RP11-485G7.6	-3.65	0.00029	0.0335	-0.17	-0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11333100	chr16:11348143~11349321:-
LUAD	cis	rs9921338	0.923	rs6498181	ENSG00000262703.1	RP11-485G7.6	-3.65	0.00029	0.0335	-0.17	-0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11333336	chr16:11348143~11349321:-
LUAD	cis	rs11921451	0.924	rs11705767	ENSG00000244215.1	RP11-88I21.2	-3.65	0.00029	0.0335	-0.21	-0.16	Amyotrophic lateral sclerosis (sporadic);	chr3:127081212	chr3:127322307~127390670:-
LUAD	cis	rs9926296	0.533	rs12102290	ENSG00000260259.1	RP11-368I7.4	-3.65	0.00029	0.0335	-0.16	-0.16	Vitiligo;	chr16:89746209	chr16:89682620~89686569:-
LUAD	cis	rs9926296	0.533	rs12102297	ENSG00000260259.1	RP11-368I7.4	-3.65	0.00029	0.0335	-0.16	-0.16	Vitiligo;	chr16:89746354	chr16:89682620~89686569:-
LUAD	cis	rs7551222	0.716	rs6679311	ENSG00000236779.1	RP11-430C7.2	-3.65	0.00029	0.0335	-0.22	-0.16	Schizophrenia;	chr1:204590548	chr1:204528845~204529692:-
LUAD	cis	rs73071352	0.577	rs73075228	ENSG00000273328.4	RP11-141M3.6	-3.65	0.00029	0.0335	-0.3	-0.16	Multiple myeloma and monoclonal gammopathy;Multiple myeloma;	chr3:42008137	chr3:42809414~42908105:+
LUAD	cis	rs198389	0.589	rs198391	ENSG00000242349.4	NPPA-AS1	3.65	0.00029	0.0335	0.17	0.16	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11816360	chr1:11841017~11848079:+
LUAD	cis	rs4819052	0.851	rs8130285	ENSG00000215447.6	BX322557.10	-3.65	0.00029	0.0335	-0.19	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251786	chr21:45288052~45291738:+
LUAD	cis	rs2745572	0.688	rs2317961	ENSG00000272279.1	RP11-157J24.2	3.65	0.00029	0.0335	0.2	0.16	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1532881	chr6:1528364~1528911:-
LUAD	cis	rs7712401	0.755	rs13172043	ENSG00000249996.1	RP11-359P5.1	3.65	0.00029	0.0335	0.2	0.16	Mean platelet volume;	chr5:122849064	chr5:123036271~123054667:+
LUAD	cis	rs7572733	0.773	rs7603839	ENSG00000222017.1	AC011997.1	3.65	0.00029	0.0335	0.2	0.16	Dermatomyositis;	chr2:197669984	chr2:197693106~197774823:+
LUAD	cis	rs3760982	1	rs10421887	ENSG00000267058.1	RP11-15A1.3	3.65	0.00029	0.0335	0.19	0.16	Breast cancer (estrogen-receptor negative);Breast cancer;	chr19:43790697	chr19:43891804~43901805:-
LUAD	cis	rs763121	0.853	rs1056610	ENSG00000225450.1	RP3-508I15.14	3.65	0.00029	0.0335	0.16	0.16	Menopause (age at onset);	chr22:38684073	chr22:38739003~38749041:+
LUAD	cis	rs9341808	0.667	rs2476826	ENSG00000272129.1	RP11-250B2.6	3.65	0.00029	0.0335	0.2	0.16	Sitting height ratio;	chr6:80166347	chr6:80355424~80356859:+
LUAD	cis	rs2354432	0.607	rs12402309	ENSG00000237188.3	RP11-337C18.8	3.65	0.00029	0.0335	0.29	0.16	Mitochondrial DNA levels;	chr1:147250328	chr1:147172771~147211568:+
LUAD	cis	rs9921338	0.961	rs9302459	ENSG00000263080.1	RP11-485G7.5	-3.65	0.00029	0.0335	-0.22	-0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11326482	chr16:11341809~11345211:-
LUAD	cis	rs9309473	1	rs10496193	ENSG00000230002.2	ALMS1-IT1	3.65	0.00029	0.0336	0.2	0.16	Metabolite levels;	chr2:73546376	chr2:73456764~73459484:+
LUAD	cis	rs6095360	0.727	rs111235329	ENSG00000222365.1	SNORD12B	-3.65	0.00029	0.0336	-0.19	-0.16	Intelligence (multi-trait analysis);	chr20:48891540	chr20:49280319~49280409:+
LUAD	cis	rs1020064	0.636	rs1529974	ENSG00000235319.1	AC012360.4	-3.65	0.00029	0.0336	-0.19	-0.16	AIDS;	chr2:105311539	chr2:105324210~105330529:+
LUAD	cis	rs1020064	0.636	rs2679876	ENSG00000235319.1	AC012360.4	-3.65	0.00029	0.0336	-0.19	-0.16	AIDS;	chr2:105321650	chr2:105324210~105330529:+
LUAD	cis	rs2179367	0.959	rs4895788	ENSG00000216906.2	RP11-350J20.9	3.65	0.00029	0.0336	0.2	0.16	Dupuytren's disease;	chr6:149426955	chr6:149904243~149906418:+
LUAD	cis	rs17407555	0.738	rs55731306	ENSG00000250413.1	RP11-448G15.1	3.65	0.00029	0.0336	0.26	0.16	Schizophrenia (age at onset);	chr4:10066261	chr4:10006482~10009725:+
LUAD	cis	rs3120667	0.72	rs72698953	ENSG00000237975.5	FLG-AS1	3.65	0.00029	0.0336	0.3	0.16	Eating disorders;	chr1:152437918	chr1:152168125~152445456:+
LUAD	cis	rs6439153	0.524	rs7642885	ENSG00000248916.1	NUP210P3	-3.65	0.00029	0.0336	-0.16	-0.16	Pneumococcal bacteremia;	chr3:129028526	chr3:129323046~129325426:-
LUAD	cis	rs6439153	0.524	rs1531807	ENSG00000248916.1	NUP210P3	-3.65	0.00029	0.0336	-0.16	-0.16	Pneumococcal bacteremia;	chr3:129029305	chr3:129323046~129325426:-
LUAD	cis	rs1555322	0.53	rs2275275	ENSG00000261582.1	RP4-614O4.11	-3.65	0.00029	0.0336	-0.21	-0.16	Attention deficit hyperactivity disorder;	chr20:35284508	chr20:35267885~35280043:-
LUAD	cis	rs61160187	0.582	rs12652830	ENSG00000215032.2	GNL3LP1	3.65	0.00029	0.0336	0.2	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60956655	chr5:60891935~60893577:-
LUAD	cis	rs3811273	0.614	rs7150591	ENSG00000211816.2	TRAV38-1	-3.65	0.00029	0.0336	-0.23	-0.16	Periodontal disease-related phenotypes;	chr14:22262926	chr14:22271968~22272563:+
LUAD	cis	rs9840812	0.591	rs1291921	ENSG00000239213.4	NCK1-AS1	3.65	0.00029	0.0336	0.2	0.16	Fibrinogen levels;	chr3:136317384	chr3:136841726~136862054:-
LUAD	cis	rs4218	0.528	rs57557135	ENSG00000277144.1	RP11-59H7.4	-3.65	0.00029	0.0336	-0.2	-0.16	Social communication problems;	chr15:59054018	chr15:59115547~59116089:-
LUAD	cis	rs853679	0.55	rs1150692	ENSG00000280107.1	AL022393.9	-3.65	0.00029	0.0336	-0.21	-0.16	Depression;	chr6:28206179	chr6:28170845~28172521:+
LUAD	cis	rs8062405	0.721	rs151181	ENSG00000261419.1	RP11-57A19.4	-3.65	0.000291	0.0336	-0.18	-0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28659696~28740781:-
LUAD	cis	rs61884328	0.733	rs61897843	ENSG00000254780.1	RP11-793I11.1	3.65	0.000291	0.0336	0.33	0.16	Total body bone mineral density (age over 60);	chr11:47165998	chr11:47905323~47905607:-
LUAD	cis	rs6088580	0.634	rs6087579	ENSG00000276073.1	RP5-1125A11.7	3.65	0.000291	0.0336	0.16	0.16	Glomerular filtration rate (creatinine);	chr20:34397349	chr20:33985617~33988989:-
LUAD	cis	rs17711722	0.583	rs10085415	ENSG00000189316.3	RP11-797H7.5	3.65	0.000291	0.0336	0.18	0.16	Calcium levels;	chr7:65628655	chr7:64888527~64890100:-
LUAD	cis	rs36052053	0.908	rs932222	ENSG00000260273.1	RP11-425D10.10	-3.65	0.000291	0.0336	-0.28	-0.16	Red cell distribution width;	chr6:109265475	chr6:109382795~109383666:+
LUAD	cis	rs12216545	0.765	rs6464082	ENSG00000177590.7	GIMAP3P	-3.65	0.000291	0.0336	-0.17	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150563519	chr7:150746893~150747728:-
LUAD	cis	rs6732426	0.55	rs6544647	ENSG00000279873.2	LINC01126	3.65	0.000291	0.0336	0.14	0.16	Hair morphology;	chr2:43351280	chr2:43227210~43228855:+
LUAD	cis	rs338389	0.748	rs12912013	ENSG00000260657.2	RP11-315D16.4	-3.65	0.000291	0.0336	-0.18	-0.16	Survival in rectal cancer;	chr15:67983141	chr15:68267792~68277994:-
LUAD	cis	rs2281558	1	rs2281558	ENSG00000125804.12	FAM182A	-3.65	0.000291	0.0336	-0.23	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25259553	chr20:26054655~26086917:+
LUAD	cis	rs13113518	0.729	rs12641881	ENSG00000273257.1	RP11-177J6.1	3.65	0.000291	0.0336	0.2	0.16	Height;	chr4:55401306	chr4:55387949~55388271:+
LUAD	cis	rs875971	0.66	rs10215132	ENSG00000222364.1	RNU6-96P	3.65	0.000291	0.0336	0.18	0.16	Aortic root size;	chr7:66589419	chr7:66395191~66395286:+
LUAD	cis	rs13006833	0.739	rs291429	ENSG00000227542.1	AC092614.2	-3.65	0.000291	0.0336	-0.2	-0.16	Urinary metabolites;	chr2:190333215	chr2:191229165~191246172:-
LUAD	cis	rs600231	0.508	rs35292734	ENSG00000245532.5	NEAT1	3.65	0.000291	0.0336	0.15	0.16	Bone mineral density;	chr11:65460229	chr11:65422774~65445540:+
LUAD	cis	rs7840202	1	rs2168689	ENSG00000253328.2	SUMO2P19	-3.65	0.000291	0.0336	-0.19	-0.16	Rate of cognitive decline in mild cognitive impairment (time interaction);Gestational age at birth in labor-initiated deliveries (child effect);	chr8:102289327	chr8:102242040~102242619:-
LUAD	cis	rs7840202	1	rs7840202	ENSG00000253328.2	SUMO2P19	-3.65	0.000291	0.0336	-0.19	-0.16	Rate of cognitive decline in mild cognitive impairment (time interaction);Gestational age at birth in labor-initiated deliveries (child effect);	chr8:102296172	chr8:102242040~102242619:-
LUAD	cis	rs7840202	0.961	rs2925783	ENSG00000253328.2	SUMO2P19	-3.65	0.000291	0.0336	-0.19	-0.16	Rate of cognitive decline in mild cognitive impairment (time interaction);Gestational age at birth in labor-initiated deliveries (child effect);	chr8:102296210	chr8:102242040~102242619:-
LUAD	cis	rs7840202	0.71	rs2925784	ENSG00000253328.2	SUMO2P19	-3.65	0.000291	0.0336	-0.19	-0.16	Rate of cognitive decline in mild cognitive impairment (time interaction);Gestational age at birth in labor-initiated deliveries (child effect);	chr8:102296567	chr8:102242040~102242619:-
LUAD	cis	rs797680	0.786	rs1426318	ENSG00000223745.6	RP4-717I23.3	3.65	0.000291	0.0336	0.13	0.16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93381863	chr1:93262186~93346025:-
LUAD	cis	rs797680	0.786	rs59417472	ENSG00000223745.6	RP4-717I23.3	3.65	0.000291	0.0336	0.13	0.16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93382956	chr1:93262186~93346025:-
LUAD	cis	rs797680	0.786	rs12406245	ENSG00000223745.6	RP4-717I23.3	3.65	0.000291	0.0336	0.13	0.16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93395068	chr1:93262186~93346025:-
LUAD	cis	rs79478560	0.552	rs10773041	ENSG00000251497.2	RP11-197N18.7	-3.65	0.000291	0.0336	-0.18	-0.16	Lymphocyte counts;	chr12:123857634	chr12:123081384~123084744:+
LUAD	cis	rs12519773	0.526	rs4285204	ENSG00000251361.1	CTD-2091N23.1	-3.65	0.000291	0.0336	-0.18	-0.16	Migraine;	chr5:93192566	chr5:93019663~93068669:-
LUAD	cis	rs12519773	0.526	rs4632783	ENSG00000251361.1	CTD-2091N23.1	-3.65	0.000291	0.0336	-0.18	-0.16	Migraine;	chr5:93192603	chr5:93019663~93068669:-
LUAD	cis	rs17639215	0.55	rs4851003	ENSG00000234389.1	AC007278.3	3.65	0.000291	0.0336	0.17	0.16	Serum protein levels (sST2);	chr2:102292817	chr2:102438713~102440475:+
LUAD	cis	rs9467773	1	rs1570059	ENSG00000261353.1	CTA-14H9.5	-3.65	0.000291	0.0336	-0.19	-0.16	Intelligence (multi-trait analysis);	chr6:26573097	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs6456735	ENSG00000261353.1	CTA-14H9.5	-3.65	0.000291	0.0336	-0.19	-0.16	Intelligence (multi-trait analysis);	chr6:26573921	chr6:26527063~26527404:+
LUAD	cis	rs6964587	0.935	rs28412174	ENSG00000188693.7	CYP51A1-AS1	3.65	0.000291	0.0336	0.19	0.16	Breast cancer;	chr7:91947931	chr7:92134604~92180725:+
LUAD	cis	rs7142881	0.61	rs17463975	ENSG00000250365.5	CTD-2213F21.2	3.65	0.000291	0.0336	0.19	0.16	Response to iloperidone treatment (QT prolongation);	chr14:31828720	chr14:31420286~31452883:+
LUAD	cis	rs12073359	1	rs2027349	ENSG00000223945.2	RP11-458I7.1	3.65	0.000291	0.0336	0.22	0.16	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150067621	chr1:150053864~150055034:+
LUAD	cis	rs9894429	0.646	rs7406522	ENSG00000263853.1	AC139530.1	-3.65	0.000291	0.0336	-0.17	-0.16	Eye color traits;	chr17:81648366	chr17:81676001~81676086:+
LUAD	cis	rs4378999	0.8	rs6772197	ENSG00000273356.1	RP11-804H8.6	3.65	0.000291	0.0336	0.21	0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;	chr3:51114368	chr3:50669989~50672048:+
LUAD	cis	rs2281603	0.762	rs10132794	ENSG00000259116.1	RP11-973N13.4	-3.65	0.000291	0.0336	-0.16	-0.16	Lymphocyte counts;	chr14:64581793	chr14:64514154~64540368:-
LUAD	cis	rs1046491	1	rs34322928	ENSG00000264964.1	RP11-888D10.3	3.65	0.000291	0.0336	0.34	0.16	Scarlet fever;	chr18:9259396	chr18:9315194~9334441:-
LUAD	cis	rs76878669	0.538	rs1785633	ENSG00000213409.4	RP11-658F2.3	3.65	0.000291	0.0336	0.2	0.16	Educational attainment (years of education);	chr11:66340056	chr11:66761575~66762399:-
LUAD	cis	rs722599	0.651	rs7159354	ENSG00000279594.1	RP11-950C14.10	3.65	0.000291	0.0337	0.2	0.16	IgG glycosylation;	chr14:74787144	chr14:75011269~75012851:-
LUAD	cis	rs1454469	0.526	rs13197173	ENSG00000260645.1	RP11-250B2.5	3.65	0.000291	0.0337	0.25	0.16	Prudent dietary pattern;	chr6:80762379	chr6:80466958~80469080:+
LUAD	cis	rs6781182	0.5	rs11717786	ENSG00000236452.1	AC123023.1	3.65	0.000291	0.0337	0.19	0.16	Visceral adipose tissue adjusted for BMI;	chr3:34195309	chr3:34203244~34268811:+
LUAD	cis	rs2664588	0.561	rs11086233	ENSG00000224565.1	RP1-148H17.1	3.65	0.000291	0.0337	0.18	0.16	Cerebrospinal fluid AB1-42 levels;	chr20:47963748	chr20:47391929~47412327:-
LUAD	cis	rs7077256	0.564	rs72835387	ENSG00000272767.1	JMJD1C-AS1	3.65	0.000291	0.0337	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63360098	chr10:63465229~63466563:+
LUAD	cis	rs7077256	0.564	rs35732435	ENSG00000272767.1	JMJD1C-AS1	3.65	0.000291	0.0337	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63361202	chr10:63465229~63466563:+
LUAD	cis	rs116095464	0.558	rs10055993	ENSG00000250848.1	CTD-2083E4.5	-3.65	0.000291	0.0337	-0.24	-0.16	Breast cancer;	chr5:264181	chr5:288833~290321:-
LUAD	cis	rs4795519	0.826	rs4794819	ENSG00000266313.1	RP11-173M1.4	3.65	0.000291	0.0337	0.2	0.16	Chronic myeloid leukemia;	chr17:27063914	chr17:27333256~27348491:+
LUAD	cis	rs12817211	0.502	rs34167640	ENSG00000272368.2	RP4-605O3.4	-3.65	0.000291	0.0337	-0.19	-0.16	Colorectal or endometrial cancer;	chr12:50123208	chr12:50112197~50165618:+
LUAD	cis	rs7463659	1	rs7836944	ENSG00000259820.1	AC083843.1	3.65	0.000291	0.0337	0.15	0.16	Colonoscopy-negative controls vs population controls;	chr8:134423959	chr8:134792020~134798272:-
LUAD	cis	rs238295	0.846	rs6053528	ENSG00000230563.2	RP5-828H9.1	3.65	0.000292	0.0337	0.22	0.16	Occipital cortical area (total cortical area interaction);	chr20:5601952	chr20:5471207~5475182:+
LUAD	cis	rs17092148	0.697	rs13037664	ENSG00000250917.1	RP4-785G19.5	3.65	0.000292	0.0337	0.24	0.16	Neuroticism;	chr20:34709184	chr20:34234840~34281173:-
LUAD	cis	rs10129255	0.5	rs10143242	ENSG00000278473.1	IGHV3-41	3.65	0.000292	0.0337	0.11	0.16	Kawasaki disease;	chr14:106681814	chr14:106443133~106443583:-
LUAD	cis	rs651907	0.557	rs7629753	ENSG00000244119.1	PDCL3P4	-3.65	0.000292	0.0337	-0.16	-0.16	Colorectal cancer;	chr3:101653078	chr3:101712472~101713191:+
LUAD	cis	rs6071166	0.683	rs6071145	ENSG00000224635.1	RP4-564F22.5	-3.65	0.000292	0.0337	-0.19	-0.16	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38699933	chr20:38406011~38416797:-
LUAD	cis	rs6993244	1	rs6993244	ENSG00000253893.2	FAM85B	-3.65	0.000292	0.0337	-0.21	-0.16	Mean corpuscular hemoglobin;	chr8:9005549	chr8:8167819~8226614:-
LUAD	cis	rs7246657	0.943	rs12981532	ENSG00000267470.4	ZNF571-AS1	3.65	0.000292	0.0337	0.23	0.16	Coronary artery calcification;	chr19:37398378	chr19:37548914~37587348:+
LUAD	cis	rs7246657	0.943	rs7246993	ENSG00000267470.4	ZNF571-AS1	3.65	0.000292	0.0337	0.23	0.16	Coronary artery calcification;	chr19:37399252	chr19:37548914~37587348:+
LUAD	cis	rs7246657	0.943	rs10413602	ENSG00000267470.4	ZNF571-AS1	3.65	0.000292	0.0337	0.23	0.16	Coronary artery calcification;	chr19:37400590	chr19:37548914~37587348:+
LUAD	cis	rs10863681	0.764	rs10495184	ENSG00000200033.1	RNU6-403P	3.65	0.000292	0.0337	0.19	0.16	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222086335	chr1:221837334~221837437:-
LUAD	cis	rs7477	0.555	rs1476810	ENSG00000226145.6	KRT16P6	-3.65	0.000292	0.0337	-0.18	-0.16	Amyotrophic lateral sclerosis;	chr17:16329903	chr17:16817983~16822579:-
LUAD	cis	rs10411161	1	rs10411161	ENSG00000269483.1	AC006272.1	3.65	0.000292	0.0337	0.25	0.16	Breast cancer;	chr19:51869723	chr19:51839924~51843324:-
LUAD	cis	rs2274273	0.934	rs8021940	ENSG00000259318.1	RP11-454L9.2	3.65	0.000292	0.0337	0.14	0.16	Protein biomarker;	chr14:55252997	chr14:55394940~55395233:-
LUAD	cis	rs875971	1	rs1981798	ENSG00000273142.1	RP11-458F8.4	-3.65	0.000292	0.0337	-0.12	-0.16	Aortic root size;	chr7:66489916	chr7:66902857~66906297:+
LUAD	cis	rs34929064	1	rs34775303	ENSG00000230658.1	KLHL7-AS1	3.65	0.000292	0.0337	0.22	0.16	Major depression and alcohol dependence;	chr7:22680470	chr7:23101228~23105703:-
LUAD	cis	rs10435719	0.867	rs6999030	ENSG00000255046.1	RP11-297N6.4	-3.65	0.000292	0.0337	-0.2	-0.16	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937799	chr8:11797928~11802568:-
LUAD	cis	rs6001482	0.638	rs5757569	ENSG00000211642.2	IGLV10-54	3.65	0.000292	0.0337	0.18	0.16	Diastolic blood pressure;	chr22:22230282	chr22:22214794~22215270:+
LUAD	cis	rs763121	0.853	rs6001173	ENSG00000225450.1	RP3-508I15.14	-3.65	0.000292	0.0337	-0.16	-0.16	Menopause (age at onset);	chr22:38619297	chr22:38739003~38749041:+
LUAD	cis	rs9900280	0.967	rs9914752	ENSG00000264808.1	RP11-802D6.1	3.65	0.000292	0.0337	0.19	0.16	Mean platelet volume;	chr17:29440569	chr17:29369717~29390777:-
LUAD	cis	rs9900280	1	rs4795510	ENSG00000264808.1	RP11-802D6.1	3.65	0.000292	0.0337	0.19	0.16	Mean platelet volume;	chr17:29451816	chr17:29369717~29390777:-
LUAD	cis	rs116095464	0.558	rs57335027	ENSG00000248925.1	CTD-2083E4.6	3.65	0.000292	0.0337	0.28	0.16	Breast cancer;	chr5:262792	chr5:269858~271516:-
LUAD	cis	rs3758785	0.641	rs4753600	ENSG00000255893.1	RP11-685N10.1	3.65	0.000292	0.0337	0.18	0.16	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94368179	chr11:94472908~94473570:-
LUAD	cis	rs7215564	0.749	rs7217825	ENSG00000262979.1	CTD-2047H16.2	3.65	0.000292	0.0337	0.22	0.16	Myopia (pathological);	chr17:80760101	chr17:80315651~80316633:+
LUAD	cis	rs4795519	1	rs2061900	ENSG00000266313.1	RP11-173M1.4	3.65	0.000292	0.0337	0.2	0.16	Chronic myeloid leukemia;	chr17:27121540	chr17:27333256~27348491:+
LUAD	cis	rs2548724	0.716	rs78857908	ENSG00000250682.4	LINC00491	3.65	0.000292	0.0337	0.22	0.16	Type 2 diabetes;	chr5:102364919	chr5:102609156~102671559:-
LUAD	cis	rs73193808	0.901	rs12626758	ENSG00000215533.7	LINC00189	-3.65	0.000292	0.0337	-0.23	-0.16	Coronary artery disease;	chr21:29194430	chr21:29193480~29288205:+
LUAD	cis	rs73193808	0.901	rs67211015	ENSG00000215533.7	LINC00189	-3.65	0.000292	0.0337	-0.23	-0.16	Coronary artery disease;	chr21:29194901	chr21:29193480~29288205:+
LUAD	cis	rs73193808	0.802	rs66691348	ENSG00000215533.7	LINC00189	-3.65	0.000292	0.0337	-0.23	-0.16	Coronary artery disease;	chr21:29195220	chr21:29193480~29288205:+
LUAD	cis	rs2179367	0.959	rs9377212	ENSG00000216906.2	RP11-350J20.9	3.65	0.000292	0.0337	0.2	0.16	Dupuytren's disease;	chr6:149383765	chr6:149904243~149906418:+
LUAD	cis	rs505151	0.793	rs17111652	ENSG00000198711.5	SSBP3-AS1	-3.65	0.000292	0.0337	-0.29	-0.16	LDL cholesterol levels;Total cholesterol levels;	chr1:55124792	chr1:54236440~54239063:+
LUAD	cis	rs7712401	0.791	rs6887101	ENSG00000249996.1	RP11-359P5.1	-3.65	0.000292	0.0337	-0.2	-0.16	Mean platelet volume;	chr5:122773512	chr5:123036271~123054667:+
LUAD	cis	rs875971	0.545	rs12671152	ENSG00000222364.1	RNU6-96P	-3.65	0.000292	0.0337	-0.22	-0.16	Aortic root size;	chr7:66311140	chr7:66395191~66395286:+
LUAD	cis	rs10876993	0.89	rs1689584	ENSG00000270039.1	RP11-571M6.17	3.65	0.000292	0.0338	0.2	0.16	Celiac disease or Rheumatoid arthritis;	chr12:57687695	chr12:57803838~57804415:+
LUAD	cis	rs2242663	0.798	rs607736	ENSG00000213409.4	RP11-658F2.3	-3.65	0.000292	0.0338	-0.2	-0.16	Bipolar disorder;	chr11:66561406	chr11:66761575~66762399:-
LUAD	cis	rs74544699	1	rs61412577	ENSG00000269559.2	RP11-629B11.5	-3.65	0.000293	0.0338	-0.34	-0.16	Growth-regulated protein alpha levels;	chr4:73876344	chr4:74156511~74158373:-
LUAD	cis	rs34779708	0.931	rs12776390	ENSG00000271335.4	RP11-324I22.4	3.65	0.000293	0.0338	0.17	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35102607	chr10:35314552~35336401:-
LUAD	cis	rs9467773	0.935	rs4573	ENSG00000261353.1	CTA-14H9.5	-3.65	0.000293	0.0338	-0.18	-0.16	Intelligence (multi-trait analysis);	chr6:26546580	chr6:26527063~26527404:+
LUAD	cis	rs12534093	0.67	rs11773115	ENSG00000234286.1	AC006026.13	-3.65	0.000293	0.0338	-0.24	-0.16	Infant length;Height;	chr7:23549423	chr7:23680195~23680786:-
LUAD	cis	rs875971	1	rs6460296	ENSG00000273142.1	RP11-458F8.4	-3.65	0.000293	0.0338	-0.11	-0.16	Aortic root size;	chr7:66430152	chr7:66902857~66906297:+
LUAD	cis	rs875971	1	rs4717292	ENSG00000273142.1	RP11-458F8.4	-3.65	0.000293	0.0338	-0.11	-0.16	Aortic root size;	chr7:66430611	chr7:66902857~66906297:+
LUAD	cis	rs875971	0.895	rs4718349	ENSG00000273142.1	RP11-458F8.4	-3.65	0.000293	0.0338	-0.11	-0.16	Aortic root size;	chr7:66444024	chr7:66902857~66906297:+
LUAD	cis	rs875971	1	rs2420591	ENSG00000273142.1	RP11-458F8.4	-3.65	0.000293	0.0338	-0.11	-0.16	Aortic root size;	chr7:66447394	chr7:66902857~66906297:+
LUAD	cis	rs875971	0.895	rs10755833	ENSG00000273142.1	RP11-458F8.4	-3.65	0.000293	0.0338	-0.11	-0.16	Aortic root size;	chr7:66448930	chr7:66902857~66906297:+
LUAD	cis	rs875971	0.964	rs12668936	ENSG00000273142.1	RP11-458F8.4	-3.65	0.000293	0.0338	-0.11	-0.16	Aortic root size;	chr7:66449417	chr7:66902857~66906297:+
LUAD	cis	rs875971	0.895	rs1833495	ENSG00000273142.1	RP11-458F8.4	-3.65	0.000293	0.0338	-0.11	-0.16	Aortic root size;	chr7:66456608	chr7:66902857~66906297:+
LUAD	cis	rs875971	0.964	rs6945032	ENSG00000273142.1	RP11-458F8.4	-3.65	0.000293	0.0338	-0.11	-0.16	Aortic root size;	chr7:66457499	chr7:66902857~66906297:+
LUAD	cis	rs875971	0.929	rs12673810	ENSG00000273142.1	RP11-458F8.4	-3.65	0.000293	0.0338	-0.11	-0.16	Aortic root size;	chr7:66458866	chr7:66902857~66906297:+
LUAD	cis	rs875971	1	rs2042133	ENSG00000273142.1	RP11-458F8.4	-3.65	0.000293	0.0338	-0.11	-0.16	Aortic root size;	chr7:66466935	chr7:66902857~66906297:+
LUAD	cis	rs875971	0.964	rs2161065	ENSG00000273142.1	RP11-458F8.4	-3.65	0.000293	0.0338	-0.11	-0.16	Aortic root size;	chr7:66467918	chr7:66902857~66906297:+
LUAD	cis	rs875971	1	rs6961155	ENSG00000273142.1	RP11-458F8.4	-3.65	0.000293	0.0338	-0.11	-0.16	Aortic root size;	chr7:66468308	chr7:66902857~66906297:+
LUAD	cis	rs875971	0.895	rs3857684	ENSG00000273142.1	RP11-458F8.4	-3.65	0.000293	0.0338	-0.11	-0.16	Aortic root size;	chr7:66473171	chr7:66902857~66906297:+
LUAD	cis	rs875971	1	rs7789768	ENSG00000273142.1	RP11-458F8.4	-3.65	0.000293	0.0338	-0.11	-0.16	Aortic root size;	chr7:66473993	chr7:66902857~66906297:+
LUAD	cis	rs875971	0.862	rs12698521	ENSG00000273142.1	RP11-458F8.4	-3.65	0.000293	0.0338	-0.11	-0.16	Aortic root size;	chr7:66474502	chr7:66902857~66906297:+
LUAD	cis	rs13113518	0.783	rs6843722	ENSG00000249700.7	SRD5A3-AS1	3.65	0.000293	0.0338	0.17	0.16	Height;	chr4:55465165	chr4:55363971~55395847:-
LUAD	cis	rs10411262	0.935	rs314666	ENSG00000211513.4	MIR320E	-3.65	0.000293	0.0338	-0.18	-0.16	Tonsillectomy;	chr19:46673568	chr19:46709271~46709382:-
LUAD	cis	rs11603023	0.874	rs577396	ENSG00000278376.1	RP11-158I9.8	-3.65	0.000293	0.0338	-0.17	-0.16	Cholesterol, total;	chr11:118628753	chr11:118791254~118793137:+
LUAD	cis	rs11603023	0.874	rs11216934	ENSG00000278376.1	RP11-158I9.8	-3.65	0.000293	0.0338	-0.17	-0.16	Cholesterol, total;	chr11:118630742	chr11:118791254~118793137:+
LUAD	cis	rs10266483	0.921	rs687547	ENSG00000228653.2	HNRNPCP7	-3.65	0.000293	0.0338	-0.19	-0.16	Response to statin therapy;	chr7:64284551	chr7:64500825~64501729:+
LUAD	cis	rs180730	0.847	rs1450459	ENSG00000251609.2	SETP12	3.65	0.000293	0.0338	0.24	0.16	Fasting plasma glucose;	chr4:120925312	chr4:120895494~120897083:-
LUAD	cis	rs13098911	0.54	rs6785091	ENSG00000226933.1	NRBF2P2	3.65	0.000293	0.0338	0.24	0.16	Celiac disease;	chr3:45943855	chr3:46023296~46024156:+
LUAD	cis	rs240993	0.516	rs465646	ENSG00000271789.1	RP5-1112D6.7	-3.65	0.000293	0.0338	-0.22	-0.16	Inflammatory skin disease;Psoriasis;	chr6:111299555	chr6:111297126~111298510:+
LUAD	cis	rs4784934	1	rs4784934	ENSG00000260186.4	RP11-481J2.2	3.65	0.000293	0.0338	0.2	0.16	QT interval;	chr16:58426022	chr16:58421326~58462470:+
LUAD	cis	rs9341808	0.538	rs7747327	ENSG00000260645.1	RP11-250B2.5	-3.65	0.000293	0.0338	-0.16	-0.16	Sitting height ratio;	chr6:80326057	chr6:80466958~80469080:+
LUAD	cis	rs3096299	0.719	rs2911262	ENSG00000182376.2	RP5-1142A6.8	3.65	0.000293	0.0338	0.17	0.16	Multiple myeloma (IgH translocation);	chr16:89448633	chr16:88742767~88745748:+
LUAD	cis	rs1910358	0.508	rs68152875	ENSG00000248874.4	C5orf17	-3.65	0.000293	0.0338	-0.21	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23883275	chr5:23951348~24178263:+
LUAD	cis	rs4713118	0.826	rs2893929	ENSG00000280107.1	AL022393.9	-3.65	0.000293	0.0338	-0.22	-0.16	Parkinson's disease;	chr6:27770953	chr6:28170845~28172521:+
LUAD	cis	rs4713118	0.666	rs4140646	ENSG00000280107.1	AL022393.9	-3.65	0.000293	0.0338	-0.22	-0.16	Parkinson's disease;	chr6:27771022	chr6:28170845~28172521:+
LUAD	cis	rs4713118	0.666	rs2893930	ENSG00000280107.1	AL022393.9	-3.65	0.000293	0.0338	-0.22	-0.16	Parkinson's disease;	chr6:27771027	chr6:28170845~28172521:+
LUAD	cis	rs7107174	0.892	rs11237450	ENSG00000251323.2	RP11-452H21.4	3.65	0.000293	0.0338	0.23	0.16	Testicular germ cell tumor;	chr11:78312310	chr11:78423982~78429836:-
LUAD	cis	rs198389	0.589	rs535107	ENSG00000242349.4	NPPA-AS1	3.65	0.000293	0.0338	0.17	0.16	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11829411	chr1:11841017~11848079:+
LUAD	cis	rs12149074	0.55	rs4889084	ENSG00000261390.4	RP11-345M22.2	-3.65	0.000293	0.0338	-0.22	-0.16	Bipolar disorder and eating disorder;Eating disorder in bipolar disorder;	chr16:80064808	chr16:79715232~79770563:-
LUAD	cis	rs35058679	0.526	rs4540944	ENSG00000247400.3	DNAJC3-AS1	3.65	0.000293	0.0338	0.2	0.16	Schizophrenia;	chr13:95529871	chr13:95648733~95676925:-
LUAD	cis	rs10502219	0.634	rs7110879	ENSG00000246100.3	LINC00900	-3.65	0.000293	0.0338	-0.24	-0.16	Mitochondrial DNA levels;	chr11:116570421	chr11:115754248~115760627:-
LUAD	cis	rs3213958	0.574	rs73136038	ENSG00000249274.1	PDLIM1P4	-3.65	0.000293	0.0338	-0.26	-0.16	Blood protein levels;	chr3:98782993	chr3:98782188~98783193:+
LUAD	cis	rs4660214	0.694	rs16866216	ENSG00000182109.6	RP11-69E11.4	-3.65	0.000293	0.0338	-0.18	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39208916	chr1:39522280~39546187:-
LUAD	cis	rs7515577	0.898	rs80215994	ENSG00000223787.2	RP4-593M8.1	3.65	0.000293	0.0338	0.25	0.16	Cholesterol, total;	chr1:92416050	chr1:92580476~92580821:-
LUAD	cis	rs7515577	0.898	rs74959960	ENSG00000223787.2	RP4-593M8.1	3.65	0.000293	0.0338	0.25	0.16	Cholesterol, total;	chr1:92422161	chr1:92580476~92580821:-
LUAD	cis	rs10102546	0.932	rs4871333	ENSG00000244642.3	RN7SL396P	3.65	0.000293	0.0338	0.19	0.16	Smoking cessation;	chr8:119540623	chr8:119862662~119862956:+
LUAD	cis	rs6471393	0.964	rs16916191	ENSG00000253848.1	RP11-10N23.5	3.65	0.000293	0.0338	0.19	0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93737337	chr8:93741193~93744534:+
LUAD	cis	rs6547741	1	rs6706610	ENSG00000223522.1	AC093690.1	3.65	0.000293	0.0338	0.16	0.16	Oral cavity cancer;	chr2:27555224	chr2:28307691~28310459:-
LUAD	cis	rs9921338	0.561	rs78831935	ENSG00000280153.1	RP11-876N24.3	3.65	0.000293	0.0338	0.19	0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11374417	chr16:10933903~10936280:+
LUAD	cis	rs8002861	0.87	rs4942254	ENSG00000274001.1	RP11-5G9.5	3.65	0.000293	0.0338	0.17	0.16	Leprosy;	chr13:43877684	chr13:43877715~43878163:-
LUAD	cis	rs8077577	0.708	rs2290502	ENSG00000273018.4	CTD-2303H24.2	3.65	0.000293	0.0338	0.24	0.16	Obesity-related traits;	chr17:18230181	chr17:18511221~18551705:-
LUAD	cis	rs8077577	0.708	rs3862147	ENSG00000273018.4	CTD-2303H24.2	3.65	0.000293	0.0338	0.24	0.16	Obesity-related traits;	chr17:18230399	chr17:18511221~18551705:-
LUAD	cis	rs8077577	0.708	rs3889544	ENSG00000273018.4	CTD-2303H24.2	3.65	0.000293	0.0338	0.24	0.16	Obesity-related traits;	chr17:18230474	chr17:18511221~18551705:-
LUAD	cis	rs8077577	0.708	rs3829590	ENSG00000273018.4	CTD-2303H24.2	3.65	0.000293	0.0338	0.24	0.16	Obesity-related traits;	chr17:18230951	chr17:18511221~18551705:-
LUAD	cis	rs8077577	0.708	rs3829589	ENSG00000273018.4	CTD-2303H24.2	3.65	0.000293	0.0338	0.24	0.16	Obesity-related traits;	chr17:18230952	chr17:18511221~18551705:-
LUAD	cis	rs8077577	0.708	rs4556848	ENSG00000273018.4	CTD-2303H24.2	3.65	0.000293	0.0338	0.24	0.16	Obesity-related traits;	chr17:18231553	chr17:18511221~18551705:-
LUAD	cis	rs763121	0.853	rs6001173	ENSG00000228274.3	RP3-508I15.9	-3.65	0.000293	0.0338	-0.16	-0.16	Menopause (age at onset);	chr22:38619297	chr22:38667585~38681820:-
LUAD	cis	rs9815354	0.857	rs7652369	ENSG00000273328.4	RP11-141M3.6	-3.65	0.000293	0.0338	-0.27	-0.16	Pulse pressure;Diastolic blood pressure;	chr3:41979481	chr3:42809414~42908105:+
LUAD	cis	rs6568686	0.786	rs9387014	ENSG00000255389.1	C6orf3	-3.65	0.000293	0.0338	-0.23	-0.16	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111529338	chr6:111599875~111602295:+
LUAD	cis	rs8023401	0.938	rs12907167	ENSG00000274654.1	CTD-3247H4.2	3.65	0.000293	0.0338	0.33	0.16	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48471071	chr15:48528980~48529728:-
LUAD	cis	rs189798	0.738	rs330908	ENSG00000253981.4	ALG1L13P	3.65	0.000293	0.0338	0.2	0.16	Myopia (pathological);	chr8:9137656	chr8:8236003~8244667:-
LUAD	cis	rs4700393	0.967	rs4700394	ENSG00000272308.1	RP11-231G3.1	3.65	0.000293	0.0338	0.17	0.16	Intelligence (multi-trait analysis);	chr5:60821375	chr5:60866457~60866935:-
LUAD	cis	rs875971	0.505	rs1723275	ENSG00000273142.1	RP11-458F8.4	3.65	0.000293	0.0338	0.11	0.16	Aortic root size;	chr7:66039646	chr7:66902857~66906297:+
LUAD	cis	rs4378999	0.66	rs4572801	ENSG00000273356.1	RP11-804H8.6	3.65	0.000293	0.0338	0.21	0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;	chr3:51065702	chr3:50669989~50672048:+
LUAD	cis	rs2980439	0.846	rs2980437	ENSG00000233609.3	RP11-62H7.2	-3.65	0.000293	0.0338	-0.13	-0.16	Neuroticism;	chr8:8237241	chr8:8961200~8979025:+
LUAD	cis	rs2274273	0.624	rs7155954	ENSG00000258413.1	RP11-665C16.6	-3.65	0.000293	0.0338	-0.22	-0.16	Protein biomarker;	chr14:55284225	chr14:55262767~55272075:-
LUAD	cis	rs6883311	0.961	rs10866663	ENSG00000254211.4	LINC01485	3.65	0.000293	0.0338	0.15	0.16	Immunoglobulin A vasculitis;	chr5:173374555	chr5:173786790~173809039:-
LUAD	cis	rs7971	1	rs7971	ENSG00000225541.1	AC002480.5	3.65	0.000294	0.0339	0.18	0.16	Breast cancer;	chr7:21901342	chr7:22571607~22661792:-
LUAD	cis	rs13113518	1	rs6858803	ENSG00000223305.1	RN7SKP30	3.65	0.000294	0.0339	0.18	0.16	Height;	chr4:55484534	chr4:55540502~55540835:-
LUAD	cis	rs4819052	0.851	rs7276103	ENSG00000215447.6	BX322557.10	-3.65	0.000294	0.0339	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246163	chr21:45288052~45291738:+
LUAD	cis	rs9322193	0.607	rs4870078	ENSG00000223701.3	RAET1E-AS1	-3.65	0.000294	0.0339	-0.22	-0.16	Lung cancer;	chr6:149880676	chr6:149884431~149919508:+
LUAD	cis	rs897984	0.571	rs7184567	ENSG00000232748.3	RP11-196G11.6	-3.65	0.000294	0.0339	-0.21	-0.16	Dementia with Lewy bodies;	chr16:31009757	chr16:31056460~31062803:+
LUAD	cis	rs651907	0.557	rs62284199	ENSG00000244119.1	PDCL3P4	3.65	0.000294	0.0339	0.16	0.16	Colorectal cancer;	chr3:101759687	chr3:101712472~101713191:+
LUAD	cis	rs4835473	0.932	rs7356305	ENSG00000249741.2	RP11-673E1.3	-3.65	0.000294	0.0339	-0.2	-0.16	Immature fraction of reticulocytes;	chr4:143737850	chr4:143911514~143912053:-
LUAD	cis	rs875971	0.545	rs4441996	ENSG00000224316.1	RP11-479O9.2	-3.65	0.000294	0.0339	-0.19	-0.16	Aortic root size;	chr7:66123233	chr7:65773620~65802067:+
LUAD	cis	rs12908161	0.96	rs11633450	ENSG00000254414.1	RP11-182J1.1	3.65	0.000294	0.0339	0.21	0.16	Schizophrenia;	chr15:84764056	chr15:84631898~84633987:-
LUAD	cis	rs3764400	0.507	rs16954324	ENSG00000278765.1	RP5-890E16.5	3.65	0.000294	0.0339	0.3	0.16	Body mass index;	chr17:48247222	chr17:48066704~48067293:-
LUAD	cis	rs7142881	0.791	rs11847399	ENSG00000250365.5	CTD-2213F21.2	-3.65	0.000294	0.0339	-0.19	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31783610	chr14:31420286~31452883:+
LUAD	cis	rs6942407	0.542	rs6958797	ENSG00000224046.1	AC005076.5	-3.65	0.000294	0.0339	-0.21	-0.16	Food allergy;	chr7:87122352	chr7:87151423~87152420:-
LUAD	cis	rs6942407	0.592	rs2373389	ENSG00000224046.1	AC005076.5	-3.65	0.000294	0.0339	-0.21	-0.16	Food allergy;	chr7:87122461	chr7:87151423~87152420:-
LUAD	cis	rs9467773	0.596	rs2451750	ENSG00000261353.1	CTA-14H9.5	-3.65	0.000294	0.0339	-0.18	-0.16	Intelligence (multi-trait analysis);	chr6:26646351	chr6:26527063~26527404:+
LUAD	cis	rs9467773	0.596	rs2451751	ENSG00000261353.1	CTA-14H9.5	-3.65	0.000294	0.0339	-0.18	-0.16	Intelligence (multi-trait analysis);	chr6:26646486	chr6:26527063~26527404:+
LUAD	cis	rs9467773	0.62	rs2504600	ENSG00000261353.1	CTA-14H9.5	-3.65	0.000294	0.0339	-0.18	-0.16	Intelligence (multi-trait analysis);	chr6:26648106	chr6:26527063~26527404:+
LUAD	cis	rs9467773	0.62	rs2130657	ENSG00000261353.1	CTA-14H9.5	-3.65	0.000294	0.0339	-0.18	-0.16	Intelligence (multi-trait analysis);	chr6:26650598	chr6:26527063~26527404:+
LUAD	cis	rs9467773	0.62	rs2498351	ENSG00000261353.1	CTA-14H9.5	-3.65	0.000294	0.0339	-0.18	-0.16	Intelligence (multi-trait analysis);	chr6:26659414	chr6:26527063~26527404:+
LUAD	cis	rs9467773	0.62	rs2504566	ENSG00000261353.1	CTA-14H9.5	-3.65	0.000294	0.0339	-0.18	-0.16	Intelligence (multi-trait analysis);	chr6:26660260	chr6:26527063~26527404:+
LUAD	cis	rs9467773	0.62	rs2494716	ENSG00000261353.1	CTA-14H9.5	-3.65	0.000294	0.0339	-0.18	-0.16	Intelligence (multi-trait analysis);	chr6:26662508	chr6:26527063~26527404:+
LUAD	cis	rs12986445	0.947	rs2072695	ENSG00000218682.1	AC010150.1	3.65	0.000294	0.0339	0.19	0.16	Multiple myeloma;Multiple myeloma and monoclonal gammopathy;	chr2:25928774	chr2:25856461~25856966:-
LUAD	cis	rs858239	0.6	rs1468592	ENSG00000226816.2	AC005082.12	-3.65	0.000294	0.0339	-0.21	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23206013~23208045:+
LUAD	cis	rs116095464	1	rs111646826	ENSG00000250848.1	CTD-2083E4.5	-3.65	0.000294	0.0339	-0.36	-0.16	Breast cancer;	chr5:328237	chr5:288833~290321:-
LUAD	cis	rs4462272	0.675	rs10883446	ENSG00000227492.1	RP11-316M21.6	3.65	0.000294	0.0339	0.16	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr10:100134849	chr10:100229667~100234000:+
LUAD	cis	rs3814244	0.788	rs3741649	ENSG00000247363.2	RP11-637A17.2	3.65	0.000294	0.0339	0.19	0.16	Itch intensity from mosquito bite adjusted by bite size;	chr12:68028351	chr12:68674371~68687755:-
LUAD	cis	rs9309473	0.95	rs6546854	ENSG00000230002.2	ALMS1-IT1	3.65	0.000294	0.0339	0.21	0.16	Metabolite levels;	chr2:73606907	chr2:73456764~73459484:+
LUAD	cis	rs910316	0.763	rs6574205	ENSG00000259138.1	RP11-950C14.7	3.65	0.000294	0.0339	0.17	0.16	Height;	chr14:74986336	chr14:75127153~75136930:+
LUAD	cis	rs875971	0.545	rs6460298	ENSG00000222364.1	RNU6-96P	-3.65	0.000294	0.0339	-0.21	-0.16	Aortic root size;	chr7:66442783	chr7:66395191~66395286:+
LUAD	cis	rs12681366	0.801	rs2011246	ENSG00000254057.1	RP3-388N13.3	3.65	0.000294	0.0339	0.17	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94450846	chr8:93834454~93846743:-
LUAD	cis	rs12681366	0.801	rs55963151	ENSG00000254057.1	RP3-388N13.3	3.65	0.000294	0.0339	0.17	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94466198	chr8:93834454~93846743:-
LUAD	cis	rs365302	0.723	rs391046	ENSG00000235086.1	FNDC1-IT1	3.65	0.000294	0.0339	0.22	0.16	Coronary heart disease;	chr6:159225200	chr6:159240786~159243329:+
LUAD	cis	rs10463554	0.963	rs11955683	ENSG00000250682.4	LINC00491	3.65	0.000294	0.0339	0.2	0.16	Parkinson's disease;	chr5:102990992	chr5:102609156~102671559:-
LUAD	cis	rs6964587	1	rs6961928	ENSG00000188693.7	CYP51A1-AS1	-3.65	0.000294	0.0339	-0.19	-0.16	Breast cancer;	chr7:92040494	chr7:92134604~92180725:+
LUAD	cis	rs11673344	0.864	rs7256213	ENSG00000267309.1	CTD-2630F21.1	-3.65	0.000294	0.0339	-0.21	-0.16	Obesity-related traits;	chr19:37020589	chr19:36489649~36491040:+
LUAD	cis	rs9467773	0.62	rs9467810	ENSG00000261353.1	CTA-14H9.5	-3.65	0.000294	0.0339	-0.18	-0.16	Intelligence (multi-trait analysis);	chr6:26608033	chr6:26527063~26527404:+
LUAD	cis	rs4908768	0.906	rs751790	ENSG00000232912.4	RP5-1115A15.1	3.65	0.000294	0.0339	0.19	0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8469081	chr1:8424645~8434838:+
LUAD	cis	rs3753275	0.69	rs301809	ENSG00000232912.4	RP5-1115A15.1	3.65	0.000294	0.0339	0.19	0.16	Educational attainment;	chr1:8459010	chr1:8424645~8434838:+
LUAD	cis	rs4819052	0.851	rs2330011	ENSG00000215447.6	BX322557.10	-3.65	0.000294	0.0339	-0.19	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238583	chr21:45288052~45291738:+
LUAD	cis	rs6687821	0.515	rs2390224	ENSG00000267272.4	LINC01140	3.65	0.000294	0.0339	0.2	0.16	Yeast infection;	chr1:86991201	chr1:87129765~87169198:+
LUAD	cis	rs5758511	0.573	rs5996074	ENSG00000227370.1	RP4-669P10.19	-3.65	0.000294	0.0339	-0.16	-0.16	Birth weight;	chr22:41840333	chr22:42132543~42132998:+
LUAD	cis	rs9308731	0.583	rs7596789	ENSG00000227992.1	AC108463.2	-3.65	0.000294	0.0339	-0.2	-0.16	Chronic lymphocytic leukemia;	chr2:111175039	chr2:111203964~111206215:-
LUAD	cis	rs9308731	0.563	rs11899831	ENSG00000227992.1	AC108463.2	-3.65	0.000294	0.0339	-0.2	-0.16	Chronic lymphocytic leukemia;	chr2:111175117	chr2:111203964~111206215:-
LUAD	cis	rs7204230	0.88	rs62049787	ENSG00000261291.1	RP11-295M3.2	3.65	0.000294	0.0339	0.21	0.16	Fibrinogen;	chr16:53284351	chr16:53168522~53169450:+
LUAD	cis	rs4705962	0.918	rs11242122	ENSG00000233006.5	AC034220.3	-3.65	0.000294	0.0339	-0.16	-0.16	Atopic dermatitis;	chr5:132689016	chr5:132311285~132369916:-
LUAD	cis	rs3824488	0.6	rs16909865	ENSG00000237857.2	RP11-435O5.2	3.65	0.000294	0.0339	0.31	0.16	Neuroticism;	chr9:95445020	chr9:95414834~95426796:-
LUAD	cis	rs564309	0.867	rs12094956	ENSG00000231563.1	RP11-245P10.4	3.65	0.000294	0.0339	0.3	0.16	Hip circumference (psychosocial stress interaction);	chr1:228382881	chr1:228407381~228409694:+
LUAD	cis	rs875971	0.895	rs7788984	ENSG00000273142.1	RP11-458F8.4	-3.65	0.000294	0.0339	-0.11	-0.16	Aortic root size;	chr7:66450629	chr7:66902857~66906297:+
LUAD	cis	rs4853525	0.561	rs13414648	ENSG00000235852.1	AC005540.3	3.65	0.000294	0.0339	0.21	0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190929310	chr2:190880797~190882059:-
LUAD	cis	rs6472235	0.681	rs4129057	ENSG00000200714.1	Y_RNA	-3.65	0.000295	0.0339	-0.21	-0.16	Plateletcrit;Myopia (pathological);	chr8:65943911	chr8:65592731~65592820:+
LUAD	cis	rs6460942	0.597	rs4719315	ENSG00000226690.5	AC005281.1	3.65	0.000295	0.0339	0.31	0.16	Coronary artery disease;	chr7:12489008	chr7:12496429~12541910:+
LUAD	cis	rs990171	0.511	rs4851013	ENSG00000234389.1	AC007278.3	3.65	0.000295	0.0339	0.16	0.16	Lymphocyte counts;	chr2:102499676	chr2:102438713~102440475:+
LUAD	cis	rs7772486	0.686	rs1337839	ENSG00000235652.6	RP11-545I5.3	-3.65	0.000295	0.0339	-0.17	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145689103	chr6:145799409~145886585:+
LUAD	cis	rs2281636	0.894	rs12782208	ENSG00000233690.1	EBAG9P1	3.65	0.000295	0.0339	0.16	0.16	Obesity-related traits;	chr10:99617219	chr10:99697407~99697949:-
LUAD	cis	rs818427	0.964	rs456313	ENSG00000279522.1	CTC-487M23.6	3.65	0.000295	0.034	0.2	0.16	Total body bone mineral density;	chr5:112889255	chr5:112894933~112896531:+
LUAD	cis	rs4713118	0.629	rs203890	ENSG00000280107.1	AL022393.9	-3.65	0.000295	0.034	-0.21	-0.16	Parkinson's disease;	chr6:28054470	chr6:28170845~28172521:+
LUAD	cis	rs12908161	1	rs58416181	ENSG00000254414.1	RP11-182J1.1	3.65	0.000295	0.034	0.21	0.16	Schizophrenia;	chr15:84721230	chr15:84631898~84633987:-
LUAD	cis	rs12440869	1	rs971868	ENSG00000270964.1	RP11-502I4.3	3.65	0.000295	0.034	0.19	0.16	Peak velocity of the mitral A-wave;	chr15:67283158	chr15:67541072~67542604:-
LUAD	cis	rs1876905	0.68	rs354528	ENSG00000255389.1	C6orf3	3.65	0.000295	0.034	0.22	0.16	Mean corpuscular hemoglobin;	chr6:111184068	chr6:111599875~111602295:+
LUAD	cis	rs1876905	0.62	rs354525	ENSG00000255389.1	C6orf3	3.65	0.000295	0.034	0.22	0.16	Mean corpuscular hemoglobin;	chr6:111186193	chr6:111599875~111602295:+
LUAD	cis	rs7129556	0.775	rs72945598	ENSG00000241782.1	RP11-91P24.1	3.65	0.000295	0.034	0.24	0.16	Weight loss (gastric bypass surgery);	chr11:77656693	chr11:77868722~77869195:-
LUAD	cis	rs4561483	0.583	rs11645213	ENSG00000261216.1	RP11-166B2.5	3.65	0.000295	0.034	0.16	0.16	Testicular germ cell tumor;	chr16:11849067	chr16:11908208~11908916:+
LUAD	cis	rs6001482	0.679	rs8142710	ENSG00000211642.2	IGLV10-54	3.65	0.000295	0.034	0.19	0.16	Diastolic blood pressure;	chr22:22233044	chr22:22214794~22215270:+
LUAD	cis	rs8046148	1	rs4785382	ENSG00000279356.1	RP11-429P3.8	3.65	0.000295	0.034	0.19	0.16	Testicular germ cell tumor;	chr16:50108309	chr16:50072862~50074986:+
LUAD	cis	rs11134654	1	rs1422160	ENSG00000253966.1	CTC-455F18.3	-3.65	0.000295	0.034	-0.26	-0.16	Smooth-surface caries;	chr5:170816429	chr5:170896929~170904461:+
LUAD	cis	rs10129255	0.5	rs4774189	ENSG00000232216.1	IGHV3-43	3.65	0.000295	0.034	0.13	0.16	Kawasaki disease;	chr14:106768275	chr14:106470264~106470800:-
LUAD	cis	rs6001482	0.573	rs4990163	ENSG00000253818.1	IGLV1-41	-3.65	0.000295	0.034	-0.17	-0.16	Diastolic blood pressure;	chr22:22233778	chr22:22404207~22404721:+
LUAD	cis	rs3002131	0.562	rs2173401	ENSG00000272750.1	RP11-378J18.8	3.65	0.000295	0.034	0.23	0.16	Interleukin-10 levels;	chr1:222575992	chr1:222658867~222661512:-
LUAD	cis	rs4591358	0.871	rs1500608	ENSG00000223466.1	AC064834.2	-3.65	0.000295	0.034	-0.19	-0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195482075	chr2:195533035~195538681:+
LUAD	cis	rs13113518	0.783	rs12504300	ENSG00000272969.1	RP11-528I4.2	3.65	0.000295	0.034	0.18	0.16	Height;	chr4:55482360	chr4:55547112~55547889:+
LUAD	cis	rs2239547	0.522	rs2336162	ENSG00000243224.1	RP5-1157M23.2	3.65	0.000295	0.034	0.19	0.16	Schizophrenia;	chr3:52917503	chr3:52239258~52241097:+
LUAD	cis	rs13113518	0.812	rs4507426	ENSG00000273257.1	RP11-177J6.1	3.65	0.000295	0.034	0.19	0.16	Height;	chr4:55529387	chr4:55387949~55388271:+
LUAD	cis	rs6543140	0.601	rs78178597	ENSG00000234389.1	AC007278.3	3.65	0.000295	0.034	0.19	0.16	Blood protein levels;	chr2:102407136	chr2:102438713~102440475:+
LUAD	cis	rs12822507	0.732	rs7132530	ENSG00000180861.8	LINC01559	3.65	0.000295	0.034	0.18	0.16	Systemic lupus erythematosus;	chr12:12601016	chr12:13371089~13387167:-
LUAD	cis	rs1850744	1	rs2867388	ENSG00000163612.10	FAM86KP	-3.65	0.000295	0.034	-0.5	-0.16	Economic and political preferences;	chr4:9794871	chr4:9153296~9165451:+
LUAD	cis	rs8014204	0.836	rs8021280	ENSG00000279594.1	RP11-950C14.10	3.65	0.000295	0.034	0.18	0.16	Caffeine consumption;	chr14:74823315	chr14:75011269~75012851:-
LUAD	cis	rs7615952	0.736	rs13063122	ENSG00000241288.6	RP11-379B18.5	-3.65	0.000295	0.034	-0.21	-0.16	Blood pressure (smoking interaction);	chr3:125925017	chr3:125827238~125916384:-
LUAD	cis	rs7801037	0.619	rs13242358	ENSG00000279048.1	RP11-511H23.2	3.65	0.000295	0.034	0.15	0.16	Male-pattern baldness;	chr7:18866198	chr7:17940503~17942922:+
LUAD	cis	rs10829156	0.898	rs6482565	ENSG00000240291.1	RP11-499P20.2	3.65	0.000295	0.034	0.15	0.16	Sudden cardiac arrest;	chr10:18611664	chr10:18513115~18545651:-
LUAD	cis	rs7772486	0.754	rs6570703	ENSG00000235652.6	RP11-545I5.3	3.65	0.000295	0.034	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145635916	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.686	rs6570705	ENSG00000235652.6	RP11-545I5.3	3.65	0.000295	0.034	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145640065	chr6:145799409~145886585:+
LUAD	cis	rs36093844	0.626	rs11234517	ENSG00000279742.1	RP11-700A24.1	3.65	0.000295	0.034	0.19	0.16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86020533	chr11:85852557~85854943:-
LUAD	cis	rs10946940	0.965	rs6921256	ENSG00000219392.1	RP1-265C24.5	-3.65	0.000295	0.034	-0.2	-0.16	Systemic lupus erythematosus;	chr6:27619739	chr6:28115628~28116551:+
LUAD	cis	rs7615952	0.576	rs2276726	ENSG00000241288.6	RP11-379B18.5	-3.65	0.000295	0.034	-0.2	-0.16	Blood pressure (smoking interaction);	chr3:126107444	chr3:125827238~125916384:-
LUAD	cis	rs6951245	0.938	rs11764937	ENSG00000224079.1	AC091729.7	-3.65	0.000295	0.034	-0.24	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1052438	chr7:1074450~1078036:+
LUAD	cis	rs1923539	0.549	rs2246698	ENSG00000230091.5	TMEM254-AS1	3.65	0.000295	0.034	0.22	0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79912831	chr10:80046860~80078912:-
LUAD	cis	rs375066	0.935	rs388685	ENSG00000278917.1	RP11-15A1.4	-3.65	0.000295	0.034	-0.17	-0.16	Breast cancer;	chr19:43914528	chr19:43891233~43895411:+
LUAD	cis	rs1154275	0.713	rs9827082	ENSG00000242770.2	RP11-180K7.1	3.65	0.000296	0.034	0.17	0.16	Takotsubo syndrome;	chr3:112782993	chr3:112802478~112812819:+
LUAD	cis	rs13006833	0.703	rs291427	ENSG00000227542.1	AC092614.2	-3.65	0.000296	0.034	-0.2	-0.16	Urinary metabolites;	chr2:190329333	chr2:191229165~191246172:-
LUAD	cis	rs3738443	0.817	rs61840053	ENSG00000215795.2	RP11-488L18.3	-3.65	0.000296	0.034	-0.24	-0.16	Alcohol dependence;	chr1:247204038	chr1:247183813~247185482:-
LUAD	cis	rs875971	0.545	rs6460281	ENSG00000222364.1	RNU6-96P	-3.65	0.000296	0.034	-0.21	-0.16	Aortic root size;	chr7:66216128	chr7:66395191~66395286:+
LUAD	cis	rs321358	0.79	rs4635115	ENSG00000271390.1	RP11-89C3.3	3.65	0.000296	0.034	0.26	0.16	Body mass index;	chr11:111076352	chr11:111089870~111090368:-
LUAD	cis	rs7247513	0.964	rs8100964	ENSG00000230310.1	CTD-2192J16.11	-3.65	0.000296	0.034	-0.19	-0.16	Bipolar disorder;	chr19:12609817	chr19:12552597~12553644:+
LUAD	cis	rs2616407	1	rs2590828	ENSG00000272650.1	RP11-571I18.4	3.65	0.000296	0.034	0.21	0.16	Coronary artery disease;	chr4:53723488	chr4:53997415~53997712:-
LUAD	cis	rs6928977	0.514	rs2757635	ENSG00000231028.7	LINC00271	3.65	0.000296	0.034	0.19	0.16	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135413172	chr6:135497801~135716055:+
LUAD	cis	rs12519773	0.717	rs6557063	ENSG00000251361.1	CTD-2091N23.1	-3.65	0.000296	0.0341	-0.18	-0.16	Migraine;	chr5:93157612	chr5:93019663~93068669:-
LUAD	cis	rs17711722	0.727	rs2658585	ENSG00000234585.5	CCT6P3	3.65	0.000296	0.0341	0.15	0.16	Calcium levels;	chr7:65996954	chr7:65038354~65074713:+
LUAD	cis	rs6452524	0.506	rs7891	ENSG00000281327.1	LINC01338	3.65	0.000296	0.0341	0.18	0.16	Hypertension (SNP x SNP interaction);	chr5:83053558	chr5:82850864~82859836:-
LUAD	cis	rs12724450	0.793	rs34696422	ENSG00000228126.1	FALEC	3.65	0.000296	0.0341	0.3	0.16	Blood protein levels;	chr1:150407916	chr1:150515757~150518032:+
LUAD	cis	rs12724450	0.793	rs12747619	ENSG00000228126.1	FALEC	3.65	0.000296	0.0341	0.3	0.16	Blood protein levels;	chr1:150414667	chr1:150515757~150518032:+
LUAD	cis	rs12724450	0.793	rs12759551	ENSG00000228126.1	FALEC	3.65	0.000296	0.0341	0.3	0.16	Blood protein levels;	chr1:150423187	chr1:150515757~150518032:+
LUAD	cis	rs12724450	0.793	rs71622698	ENSG00000228126.1	FALEC	3.65	0.000296	0.0341	0.3	0.16	Blood protein levels;	chr1:150432497	chr1:150515757~150518032:+
LUAD	cis	rs7189233	0.955	rs72801821	ENSG00000279344.1	RP11-44F14.7	3.65	0.000296	0.0341	0.14	0.16	Intelligence (multi-trait analysis);	chr16:53445740	chr16:53478957~53481550:-
LUAD	cis	rs6120849	0.707	rs6088703	ENSG00000202150.1	RNU6-407P	3.65	0.000296	0.0341	0.24	0.16	Protein C levels;	chr20:35088246	chr20:35030317~35030420:-
LUAD	cis	rs12900463	0.813	rs186266	ENSG00000259728.4	LINC00933	3.65	0.000296	0.0341	0.23	0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine);	chr15:84859564	chr15:84570649~84580175:+
LUAD	cis	rs28374715	0.532	rs28703570	ENSG00000247556.5	OIP5-AS1	3.65	0.000296	0.0341	0.2	0.16	Ulcerative colitis;	chr15:41387294	chr15:41283990~41309737:+
LUAD	cis	rs4718428	0.96	rs6460317	ENSG00000232546.1	RP11-458F8.1	-3.65	0.000296	0.0341	-0.15	-0.16	Corneal structure;	chr7:66925268	chr7:66848496~66858136:+
LUAD	cis	rs13126694	0.744	rs10049927	ENSG00000280140.1	RP11-597D13.2	-3.65	0.000296	0.0341	-0.2	-0.16	Blood osmolality (transformed sodium);	chr4:157998056	chr4:158111361~158111931:-
LUAD	cis	rs2274273	0.662	rs67958555	ENSG00000258413.1	RP11-665C16.6	-3.65	0.000296	0.0341	-0.23	-0.16	Protein biomarker;	chr14:55204148	chr14:55262767~55272075:-
LUAD	cis	rs2274273	0.662	rs67092614	ENSG00000258413.1	RP11-665C16.6	-3.65	0.000296	0.0341	-0.23	-0.16	Protein biomarker;	chr14:55205337	chr14:55262767~55272075:-
LUAD	cis	rs2274273	0.615	rs17672058	ENSG00000258413.1	RP11-665C16.6	-3.65	0.000296	0.0341	-0.23	-0.16	Protein biomarker;	chr14:55206676	chr14:55262767~55272075:-
LUAD	cis	rs2274273	0.662	rs67215571	ENSG00000258413.1	RP11-665C16.6	-3.65	0.000296	0.0341	-0.23	-0.16	Protein biomarker;	chr14:55207005	chr14:55262767~55272075:-
LUAD	cis	rs7940646	0.812	rs4910165	ENSG00000246308.1	RP11-685M7.3	-3.65	0.000296	0.0341	-0.2	-0.16	Platelet aggregation;	chr11:10652497	chr11:10809297~10822931:+
LUAD	cis	rs8056893	0.885	rs56372488	ENSG00000260441.4	RP11-96D1.7	-3.65	0.000296	0.0341	-0.19	-0.16	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68305831	chr16:68256162~68260443:-
LUAD	cis	rs73990293	0.737	rs12951703	ENSG00000267592.1	CTC-507E2.2	3.65	0.000296	0.0341	0.35	0.16	Clopidogrel active metabolite levels;	chr17:35586035	chr17:35596904~35597128:-
LUAD	cis	rs7503168	0.558	rs79468963	ENSG00000267592.1	CTC-507E2.2	3.65	0.000296	0.0341	0.35	0.16	Plateletcrit;	chr17:35590408	chr17:35596904~35597128:-
LUAD	cis	rs7503168	0.558	rs71381461	ENSG00000267592.1	CTC-507E2.2	3.65	0.000296	0.0341	0.35	0.16	Plateletcrit;	chr17:35593601	chr17:35596904~35597128:-
LUAD	cis	rs7503168	0.558	rs34937989	ENSG00000267592.1	CTC-507E2.2	3.65	0.000296	0.0341	0.35	0.16	Plateletcrit;	chr17:35594744	chr17:35596904~35597128:-
LUAD	cis	rs2227564	0.645	rs2633309	ENSG00000271816.1	BMS1P4	3.65	0.000296	0.0341	0.15	0.16	Crohn's disease;Inflammatory bowel disease;	chr10:73894328	chr10:73699151~73730487:-
LUAD	cis	rs700641	1	rs700641	ENSG00000222017.1	AC011997.1	3.65	0.000296	0.0341	0.21	0.16	Morning vs. evening chronotype;	chr2:197734509	chr2:197693106~197774823:+
LUAD	cis	rs2836974	0.568	rs4816620	ENSG00000232608.1	TIMM9P2	3.65	0.000296	0.0341	0.19	0.16	Cognitive function;	chr21:39241860	chr21:39216624~39217506:+
LUAD	cis	rs360798	0.598	rs2129508	ENSG00000231609.4	AC009501.4	3.65	0.000296	0.0341	0.18	0.16	Coronary artery disease;	chr2:62632996	chr2:63043922~63048640:-
LUAD	cis	rs360798	0.656	rs2421712	ENSG00000231609.4	AC009501.4	3.65	0.000296	0.0341	0.18	0.16	Coronary artery disease;	chr2:62637514	chr2:63043922~63048640:-
LUAD	cis	rs360798	0.656	rs4671446	ENSG00000231609.4	AC009501.4	3.65	0.000296	0.0341	0.18	0.16	Coronary artery disease;	chr2:62638353	chr2:63043922~63048640:-
LUAD	cis	rs7512552	0.839	rs12045304	ENSG00000275557.1	RP11-353N4.6	3.65	0.000296	0.0341	0.19	0.16	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150427342	chr1:149607765~149612402:+
LUAD	cis	rs4845570	0.92	rs10788809	ENSG00000203288.3	RP11-98D18.9	3.65	0.000296	0.0341	0.25	0.16	Coronary artery disease;	chr1:151788316	chr1:151790804~151794402:+
LUAD	cis	rs3794924	1	rs3794924	ENSG00000266521.1	RP11-650P15.1	-3.65	0.000296	0.0341	-0.29	-0.16	Survival in colon cancer;	chr18:31461771	chr18:31496645~31497195:-
LUAD	cis	rs2408955	0.521	rs11168437	ENSG00000257763.1	OR5BK1P	3.65	0.000296	0.0341	0.17	0.16	Glycated hemoglobin levels;	chr12:48172373	chr12:48355792~48356614:-
LUAD	cis	rs2880765	0.835	rs4281668	ENSG00000259407.1	RP11-158M2.3	-3.65	0.000296	0.0341	-0.15	-0.16	Coronary artery disease;	chr15:85504055	chr15:85744109~85750281:-
LUAD	cis	rs481331	0.866	rs34920187	ENSG00000185904.10	LINC00839	3.65	0.000296	0.0341	0.27	0.16	Systemic juvenile idiopathic arthritis;	chr10:42497070	chr10:42475543~42495336:+
LUAD	cis	rs875971	0.545	rs73148639	ENSG00000224316.1	RP11-479O9.2	3.65	0.000296	0.0341	0.19	0.16	Aortic root size;	chr7:66390342	chr7:65773620~65802067:+
LUAD	cis	rs7955901	0.904	rs1913201	ENSG00000258053.1	CTD-2021H9.3	-3.65	0.000296	0.0341	-0.19	-0.16	Type 2 diabetes;	chr12:71046045	chr12:71047402~71118247:-
LUAD	cis	rs1552244	0.882	rs28366039	ENSG00000180385.7	EMC3-AS1	3.65	0.000296	0.0341	0.21	0.16	Alzheimer's disease;	chr3:9987304	chr3:9986893~10006990:+
LUAD	cis	rs75920871	0.764	rs4938326	ENSG00000254851.1	RP11-109L13.1	-3.65	0.000296	0.0341	-0.33	-0.16	Subjective well-being;	chr11:117034748	chr11:117135528~117138582:+
LUAD	cis	rs8056893	0.714	rs1110570	ENSG00000260441.4	RP11-96D1.7	-3.65	0.000296	0.0341	-0.19	-0.16	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68374216	chr16:68256162~68260443:-
LUAD	cis	rs8056893	0.714	rs3760002	ENSG00000260441.4	RP11-96D1.7	-3.65	0.000296	0.0341	-0.19	-0.16	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68374933	chr16:68256162~68260443:-
LUAD	cis	rs4072980	0.524	rs16824514	ENSG00000212541.1	RNU6-510P	-3.65	0.000296	0.0341	-0.21	-0.16	Coronary artery disease;	chr1:37930275	chr1:37991462~37991569:+
LUAD	cis	rs6121246	0.567	rs6060260	ENSG00000230613.1	HM13-AS1	3.65	0.000296	0.0341	0.26	0.16	Mean corpuscular hemoglobin;	chr20:31605104	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.567	rs6060261	ENSG00000230613.1	HM13-AS1	3.65	0.000296	0.0341	0.26	0.16	Mean corpuscular hemoglobin;	chr20:31605145	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.567	rs6060263	ENSG00000230613.1	HM13-AS1	3.65	0.000296	0.0341	0.26	0.16	Mean corpuscular hemoglobin;	chr20:31605307	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.567	rs2811	ENSG00000230613.1	HM13-AS1	3.65	0.000296	0.0341	0.26	0.16	Mean corpuscular hemoglobin;	chr20:31606445	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.529	rs6058196	ENSG00000230613.1	HM13-AS1	3.65	0.000296	0.0341	0.26	0.16	Mean corpuscular hemoglobin;	chr20:31606911	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.567	rs6058197	ENSG00000230613.1	HM13-AS1	3.65	0.000296	0.0341	0.26	0.16	Mean corpuscular hemoglobin;	chr20:31607096	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.522	rs6088736	ENSG00000230613.1	HM13-AS1	3.65	0.000296	0.0341	0.26	0.16	Mean corpuscular hemoglobin;	chr20:31607363	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.523	rs6060286	ENSG00000230613.1	HM13-AS1	3.65	0.000296	0.0341	0.26	0.16	Mean corpuscular hemoglobin;	chr20:31609860	chr20:31567707~31573263:-
LUAD	cis	rs2837828	0.967	rs2222984	ENSG00000226496.2	LINC00323	3.65	0.000296	0.0341	0.21	0.16	Neutrophil count;	chr21:40800235	chr21:41141493~41148133:-
LUAD	cis	rs6781182	0.573	rs1960959	ENSG00000236452.1	AC123023.1	3.65	0.000296	0.0341	0.18	0.16	Visceral adipose tissue adjusted for BMI;	chr3:34174900	chr3:34203244~34268811:+
LUAD	cis	rs6781182	0.593	rs7612155	ENSG00000236452.1	AC123023.1	3.65	0.000296	0.0341	0.18	0.16	Visceral adipose tissue adjusted for BMI;	chr3:34175335	chr3:34203244~34268811:+
LUAD	cis	rs2625529	0.652	rs2957736	ENSG00000260173.1	RP11-2I17.4	3.65	0.000296	0.0341	0.2	0.16	Red blood cell count;	chr15:71973003	chr15:72140504~72155459:-
LUAD	cis	rs11159086	0.793	rs10147316	ENSG00000270000.1	RP3-449M8.9	3.65	0.000296	0.0341	0.23	0.16	Advanced glycation end-product levels;	chr14:74475688	chr14:74471930~74472360:-
LUAD	cis	rs11159086	0.793	rs8021664	ENSG00000270000.1	RP3-449M8.9	3.65	0.000296	0.0341	0.23	0.16	Advanced glycation end-product levels;	chr14:74476592	chr14:74471930~74472360:-
LUAD	cis	rs2834288	0.666	rs762188	ENSG00000237945.6	LINC00649	-3.65	0.000296	0.0341	-0.22	-0.16	Gut microbiota (bacterial taxa);	chr21:33902206	chr21:33915534~33977691:+
LUAD	cis	rs1910358	0.664	rs7708664	ENSG00000248874.4	C5orf17	-3.65	0.000296	0.0341	-0.21	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23885088	chr5:23951348~24178263:+
LUAD	cis	rs910316	0.737	rs175043	ENSG00000279594.1	RP11-950C14.10	-3.65	0.000296	0.0341	-0.19	-0.16	Height;	chr14:75005100	chr14:75011269~75012851:-
LUAD	cis	rs34783982	0.659	rs8025139	ENSG00000261441.1	RP11-217B1.2	-3.65	0.000296	0.0341	-0.21	-0.16	Squamous cell lung carcinoma;	chr15:88969050	chr15:89335053~89336161:+
LUAD	cis	rs116095464	0.558	rs13354585	ENSG00000248925.1	CTD-2083E4.6	3.65	0.000296	0.0341	0.28	0.16	Breast cancer;	chr5:242148	chr5:269858~271516:-
LUAD	cis	rs6942407	0.546	rs4140847	ENSG00000224046.1	AC005076.5	-3.64	0.000297	0.0341	-0.24	-0.16	Food allergy;	chr7:87153947	chr7:87151423~87152420:-
LUAD	cis	rs6942407	0.546	rs3789251	ENSG00000224046.1	AC005076.5	-3.64	0.000297	0.0341	-0.24	-0.16	Food allergy;	chr7:87163987	chr7:87151423~87152420:-
LUAD	cis	rs6942407	0.546	rs3789252	ENSG00000224046.1	AC005076.5	-3.64	0.000297	0.0341	-0.24	-0.16	Food allergy;	chr7:87164046	chr7:87151423~87152420:-
LUAD	cis	rs6942407	0.546	rs2074757	ENSG00000224046.1	AC005076.5	-3.64	0.000297	0.0341	-0.24	-0.16	Food allergy;	chr7:87164805	chr7:87151423~87152420:-
LUAD	cis	rs6942407	0.546	rs765968	ENSG00000224046.1	AC005076.5	-3.64	0.000297	0.0341	-0.24	-0.16	Food allergy;	chr7:87165408	chr7:87151423~87152420:-
LUAD	cis	rs7637701	0.517	rs3851992	ENSG00000243926.1	TIPARP-AS1	3.64	0.000297	0.0341	0.17	0.16	Breast cancer;	chr3:156681391	chr3:156671862~156674378:-
LUAD	cis	rs62025270	0.632	rs74025655	ENSG00000259416.2	RP11-158M2.5	-3.64	0.000297	0.0341	-0.21	-0.16	Idiopathic pulmonary fibrosis;	chr15:85674319	chr15:85754941~85756237:-
LUAD	cis	rs5015933	0.966	rs7870475	ENSG00000232630.1	PRPS1P2	-3.64	0.000297	0.0341	-0.16	-0.16	Body mass index;	chr9:125371755	chr9:125150653~125151589:+
LUAD	cis	rs7141336	1	rs6575155	ENSG00000258884.1	CTD-3035D6.2	3.64	0.000297	0.0341	0.17	0.16	Anxiety disorder;	chr14:90818596	chr14:90822365~90828128:-
LUAD	cis	rs12579764	1	rs12579764	ENSG00000275409.1	RP11-131L12.4	-3.64	0.000297	0.0341	-0.31	-0.16	Loneliness;Loneliness (linear analysis);	chr12:118435624	chr12:118430147~118430699:+
LUAD	cis	rs17092148	0.614	rs62212173	ENSG00000250917.1	RP4-785G19.5	-3.64	0.000297	0.0341	-0.35	-0.16	Neuroticism;	chr20:34406823	chr20:34234840~34281173:-
LUAD	cis	rs10510102	0.872	rs11200261	ENSG00000276742.1	RP11-500G22.4	3.64	0.000297	0.0341	0.27	0.16	Breast cancer;	chr10:121921133	chr10:121956782~121957098:+
LUAD	cis	rs7246657	0.653	rs10414983	ENSG00000226686.6	LINC01535	-3.64	0.000297	0.0341	-0.27	-0.16	Coronary artery calcification;	chr19:37174830	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.598	rs10405372	ENSG00000226686.6	LINC01535	-3.64	0.000297	0.0341	-0.27	-0.16	Coronary artery calcification;	chr19:37177873	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.653	rs10425441	ENSG00000226686.6	LINC01535	-3.64	0.000297	0.0341	-0.27	-0.16	Coronary artery calcification;	chr19:37179746	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.653	rs4805207	ENSG00000226686.6	LINC01535	-3.64	0.000297	0.0341	-0.27	-0.16	Coronary artery calcification;	chr19:37182831	chr19:37251912~37265535:+
LUAD	cis	rs41411047	0.826	rs73157068	ENSG00000271711.1	RP11-392O18.2	3.64	0.000297	0.0341	0.3	0.16	Myocardial infarction;	chr3:150018571	chr3:150611262~150611877:-
LUAD	cis	rs41411047	0.826	rs76324883	ENSG00000271711.1	RP11-392O18.2	3.64	0.000297	0.0341	0.3	0.16	Myocardial infarction;	chr3:150031640	chr3:150611262~150611877:-
LUAD	cis	rs2625529	0.652	rs2278987	ENSG00000260173.1	RP11-2I17.4	3.64	0.000297	0.0341	0.2	0.16	Red blood cell count;	chr15:72117428	chr15:72140504~72155459:-
LUAD	cis	rs7660883	1	rs3775221	ENSG00000251411.1	RP11-397E7.4	3.64	0.000297	0.0342	0.18	0.16	HDL cholesterol levels;	chr4:87090641	chr4:86913266~86914817:-
LUAD	cis	rs710913	0.587	rs6690413	ENSG00000237624.1	OXCT2P1	3.64	0.000297	0.0342	0.21	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39620620	chr1:39514956~39516490:+
LUAD	cis	rs9457247	0.905	rs444210	ENSG00000227598.1	RP1-167A14.2	-3.64	0.000297	0.0342	-0.18	-0.16	Crohn's disease;	chr6:166976754	chr6:166969626~166999065:-
LUAD	cis	rs3805389	0.504	rs1873090	ENSG00000273257.1	RP11-177J6.1	-3.64	0.000297	0.0342	-0.26	-0.16	Waist-to-hip ratio adjusted for body mass index;	chr4:55605237	chr4:55387949~55388271:+
LUAD	cis	rs8062405	1	rs8055138	ENSG00000261419.1	RP11-57A19.4	-3.64	0.000297	0.0342	-0.18	-0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28659696~28740781:-
LUAD	cis	rs28374715	0.578	rs8036026	ENSG00000247556.5	OIP5-AS1	3.64	0.000297	0.0342	0.21	0.16	Ulcerative colitis;	chr15:41338301	chr15:41283990~41309737:+
LUAD	cis	rs28374715	0.528	rs7178360	ENSG00000247556.5	OIP5-AS1	3.64	0.000297	0.0342	0.21	0.16	Ulcerative colitis;	chr15:41338977	chr15:41283990~41309737:+
LUAD	cis	rs28374715	0.578	rs7165914	ENSG00000247556.5	OIP5-AS1	3.64	0.000297	0.0342	0.21	0.16	Ulcerative colitis;	chr15:41340253	chr15:41283990~41309737:+
LUAD	cis	rs17826219	0.789	rs4794873	ENSG00000266490.1	CTD-2349P21.9	3.64	0.000297	0.0342	0.24	0.16	Body mass index;	chr17:30421334	chr17:30792372~30792833:+
LUAD	cis	rs12935418	0.83	rs7195459	ENSG00000261838.4	RP11-303E16.6	3.64	0.000297	0.0342	0.28	0.16	Mean corpuscular volume;	chr16:81016376	chr16:81069854~81076598:+
LUAD	cis	rs76382185	0.756	rs34749125	ENSG00000233184.5	RP11-421L21.3	3.64	0.000297	0.0342	0.29	0.16	Lymphocyte counts;	chr1:101122823	chr1:101025878~101087268:+
LUAD	cis	rs7246657	0.943	rs10422074	ENSG00000267470.4	ZNF571-AS1	3.64	0.000297	0.0342	0.24	0.16	Coronary artery calcification;	chr19:37403334	chr19:37548914~37587348:+
LUAD	cis	rs9322193	0.566	rs3922947	ENSG00000268592.3	RAET1E-AS1	-3.64	0.000297	0.0342	-0.24	-0.16	Lung cancer;	chr6:149924856	chr6:149863494~149919507:+
LUAD	cis	rs4072705	0.967	rs2148787	ENSG00000236643.1	RP11-175D17.3	-3.64	0.000297	0.0342	-0.19	-0.16	Menarche (age at onset);	chr9:124705925	chr9:124770123~124772927:+
LUAD	cis	rs3849150	0.95	rs12777759	ENSG00000235939.1	RP11-123B3.2	-3.64	0.000297	0.0342	-0.25	-0.16	Subclinical atherosclerosis traits (other);	chr10:48882867	chr10:49419277~49472903:+
LUAD	cis	rs10463554	0.963	rs40093	ENSG00000250682.4	LINC00491	3.64	0.000297	0.0342	0.2	0.16	Parkinson's disease;	chr5:103104121	chr5:102609156~102671559:-
LUAD	cis	rs858239	0.539	rs10279194	ENSG00000226816.2	AC005082.12	3.64	0.000297	0.0342	0.22	0.16	Cerebrospinal fluid biomarker levels;	chr7:23151464	chr7:23206013~23208045:+
LUAD	cis	rs858239	0.539	rs3950345	ENSG00000226816.2	AC005082.12	3.64	0.000297	0.0342	0.22	0.16	Cerebrospinal fluid biomarker levels;	chr7:23151495	chr7:23206013~23208045:+
LUAD	cis	rs321358	1	rs321355	ENSG00000271390.1	RP11-89C3.3	3.64	0.000297	0.0342	0.27	0.16	Body mass index;	chr11:111124273	chr11:111089870~111090368:-
LUAD	cis	rs14027	0.64	rs2326378	ENSG00000279347.1	RP11-85I17.2	-3.64	0.000297	0.0342	-0.14	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119764355	chr8:119838736~119840385:-
LUAD	cis	rs7976269	0.609	rs4402335	ENSG00000275476.1	RP11-996F15.4	-3.64	0.000297	0.0342	-0.18	-0.16	Male-pattern baldness;	chr12:29052836	chr12:29277397~29277882:-
LUAD	cis	rs357618	1	rs165352	ENSG00000272112.1	CTB-113P19.5	-3.64	0.000297	0.0342	-0.15	-0.16	Basophil percentage of white cells;	chr5:151476546	chr5:151724831~151725356:-
LUAD	cis	rs357618	1	rs165353	ENSG00000272112.1	CTB-113P19.5	-3.64	0.000297	0.0342	-0.15	-0.16	Basophil percentage of white cells;	chr5:151477196	chr5:151724831~151725356:-
LUAD	cis	rs34034104	0.501	rs16970660	ENSG00000223313.1	RNU6-516P	3.64	0.000297	0.0342	0.3	0.16	Itch intensity from mosquito bite;Itch intensity from mosquito bite adjusted by bite size;	chr15:40408568	chr15:40529570~40529673:+
LUAD	cis	rs9902453	0.817	rs59420007	ENSG00000263531.1	RP13-753N3.1	-3.64	0.000297	0.0342	-0.2	-0.16	Coffee consumption (cups per day);	chr17:29869096	chr17:30863921~30864940:-
LUAD	cis	rs2880765	0.546	rs35316253	ENSG00000259407.1	RP11-158M2.3	-3.64	0.000297	0.0342	-0.16	-0.16	Coronary artery disease;	chr15:85522329	chr15:85744109~85750281:-
LUAD	cis	rs6602398	0.656	rs11256457	ENSG00000229664.1	RP11-536K7.5	3.64	0.000297	0.0342	0.19	0.16	Emotional dysregulation;	chr10:6038831	chr10:6025978~6036427:+
LUAD	cis	rs9921338	0.961	rs9936328	ENSG00000262703.1	RP11-485G7.6	-3.64	0.000297	0.0342	-0.17	-0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11344364	chr16:11348143~11349321:-
LUAD	cis	rs2274273	0.967	rs2094102	ENSG00000259318.1	RP11-454L9.2	3.64	0.000297	0.0342	0.14	0.16	Protein biomarker;	chr14:55124380	chr14:55394940~55395233:-
LUAD	cis	rs7246657	0.943	rs13343502	ENSG00000267470.4	ZNF571-AS1	3.64	0.000297	0.0342	0.24	0.16	Coronary artery calcification;	chr19:37471390	chr19:37548914~37587348:+
LUAD	cis	rs2242663	0.581	rs2511224	ENSG00000213409.4	RP11-658F2.3	3.64	0.000297	0.0342	0.19	0.16	Bipolar disorder;	chr11:66495135	chr11:66761575~66762399:-
LUAD	cis	rs2354432	0.556	rs59180647	ENSG00000237188.3	RP11-337C18.8	3.64	0.000297	0.0342	0.29	0.16	Mitochondrial DNA levels;	chr1:147300364	chr1:147172771~147211568:+
LUAD	cis	rs2354432	0.607	rs11239980	ENSG00000237188.3	RP11-337C18.8	3.64	0.000297	0.0342	0.29	0.16	Mitochondrial DNA levels;	chr1:147310982	chr1:147172771~147211568:+
LUAD	cis	rs2354432	0.607	rs58941651	ENSG00000237188.3	RP11-337C18.8	3.64	0.000297	0.0342	0.29	0.16	Mitochondrial DNA levels;	chr1:147313199	chr1:147172771~147211568:+
LUAD	cis	rs6787172	0.644	rs67286798	ENSG00000272087.1	RP11-379F4.7	3.64	0.000297	0.0342	0.18	0.16	Subjective well-being;	chr3:158496414	chr3:158693120~158693768:-
LUAD	cis	rs8067545	0.641	rs175922	ENSG00000270091.1	RP11-78O7.2	-3.64	0.000297	0.0342	-0.14	-0.16	Schizophrenia;	chr17:19922266	chr17:19896590~19897287:-
LUAD	cis	rs8012947	1	rs8009579	ENSG00000279636.2	LINC00216	-3.64	0.000298	0.0342	-0.18	-0.16	Alcohol consumption in current drinkers;	chr14:58246841	chr14:58288033~58289158:+
LUAD	cis	rs11174650	0.818	rs11174656	ENSG00000249753.2	RP11-415I12.3	3.64	0.000298	0.0342	0.37	0.16	Sense of smell;	chr12:62805670	chr12:63623788~63795718:-
LUAD	cis	rs6453278	0.52	rs13182877	ENSG00000250802.5	ZBED3-AS1	-3.64	0.000298	0.0342	-0.2	-0.16	Autism;	chr5:77098755	chr5:77086740~77166909:+
LUAD	cis	rs897984	0.609	rs57576577	ENSG00000232748.3	RP11-196G11.6	-3.64	0.000298	0.0342	-0.21	-0.16	Dementia with Lewy bodies;	chr16:31025046	chr16:31056460~31062803:+
LUAD	cis	rs987044	0.664	rs2111212	ENSG00000257221.1	RP11-689B22.2	3.64	0.000298	0.0342	0.14	0.16	Mean platelet volume;	chr12:108646018	chr12:108628687~108641318:+
LUAD	cis	rs755249	0.917	rs72663503	ENSG00000182109.6	RP11-69E11.4	3.64	0.000298	0.0342	0.2	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39503387	chr1:39522280~39546187:-
LUAD	cis	rs8002861	0.934	rs9533685	ENSG00000274001.1	RP11-5G9.5	3.64	0.000298	0.0342	0.17	0.16	Leprosy;	chr13:43894195	chr13:43877715~43878163:-
LUAD	cis	rs875971	0.706	rs1643374	ENSG00000232546.1	RP11-458F8.1	-3.64	0.000298	0.0342	-0.15	-0.16	Aortic root size;	chr7:66407695	chr7:66848496~66858136:+
LUAD	cis	rs6832769	1	rs28448438	ENSG00000272969.1	RP11-528I4.2	-3.64	0.000298	0.0342	-0.17	-0.16	Personality dimensions;	chr4:55550498	chr4:55547112~55547889:+
LUAD	cis	rs62025270	0.522	rs338519	ENSG00000259416.2	RP11-158M2.5	-3.64	0.000298	0.0342	-0.18	-0.16	Idiopathic pulmonary fibrosis;	chr15:85671648	chr15:85754941~85756237:-
LUAD	cis	rs7535752	0.52	rs301800	ENSG00000232912.4	RP5-1115A15.1	-3.64	0.000298	0.0342	-0.19	-0.16	Breast cancer;	chr1:8430543	chr1:8424645~8434838:+
LUAD	cis	rs13113518	0.812	rs6849474	ENSG00000273257.1	RP11-177J6.1	3.64	0.000298	0.0342	0.19	0.16	Height;	chr4:55452295	chr4:55387949~55388271:+
LUAD	cis	rs7590268	0.707	rs35805220	ENSG00000279873.2	LINC01126	3.64	0.000298	0.0342	0.16	0.16	Orofacial clefts;	chr2:43335660	chr2:43227210~43228855:+
LUAD	cis	rs7077256	0.542	rs34188653	ENSG00000272767.1	JMJD1C-AS1	3.64	0.000298	0.0342	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63165897	chr10:63465229~63466563:+
LUAD	cis	rs7077256	0.564	rs56378743	ENSG00000272767.1	JMJD1C-AS1	3.64	0.000298	0.0342	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63166776	chr10:63465229~63466563:+
LUAD	cis	rs2395128	0.519	rs79935100	ENSG00000213731.2	RAB5CP1	3.64	0.000298	0.0342	0.32	0.16	Ulcerative colitis;Inflammatory bowel disease;	chr10:75066184	chr10:74423435~74424014:-
LUAD	cis	rs9309473	1	rs6546836	ENSG00000230002.2	ALMS1-IT1	3.64	0.000298	0.0342	0.2	0.16	Metabolite levels;	chr2:73450706	chr2:73456764~73459484:+
LUAD	cis	rs6500602	0.929	rs6500603	ENSG00000280063.1	RP11-295D4.3	3.64	0.000298	0.0342	0.11	0.16	Schizophrenia;	chr16:4447536	chr16:4346694~4348648:-
LUAD	cis	rs2625529	0.878	rs2929511	ENSG00000260173.1	RP11-2I17.4	3.64	0.000298	0.0342	0.2	0.16	Red blood cell count;	chr15:71939341	chr15:72140504~72155459:-
LUAD	cis	rs794185	0.504	rs184233	ENSG00000231249.1	ITPR1-AS1	-3.64	0.000298	0.0342	-0.18	-0.16	Multiple sclerosis--Brain Glutamate Levels;	chr3:4495754	chr3:4490891~4493163:-
LUAD	cis	rs6467136	0.577	rs10487490	ENSG00000224138.1	AC000123.4	3.64	0.000298	0.0342	0.16	0.16	Type 2 diabetes;	chr7:127515485	chr7:127350128~127351523:+
LUAD	cis	rs875971	1	rs35149210	ENSG00000273142.1	RP11-458F8.4	-3.64	0.000298	0.0342	-0.11	-0.16	Aortic root size;	chr7:66464938	chr7:66902857~66906297:+
LUAD	cis	rs7142881	0.844	rs7152506	ENSG00000258525.1	RP11-829H16.3	3.64	0.000298	0.0342	0.19	0.16	Response to iloperidone treatment (QT prolongation);	chr14:31563887	chr14:30876179~30889808:-
LUAD	cis	rs1267303	0.682	rs1886117	ENSG00000280836.1	AL355480.1	3.64	0.000298	0.0342	0.21	0.16	Monobrow;	chr1:46499237	chr1:45581219~45581321:-
LUAD	cis	rs9983113	0.783	rs13047416	ENSG00000205622.8	AF064858.6	3.64	0.000298	0.0343	0.19	0.16	Body mass index;	chr21:38937512	chr21:38863676~38956467:-
LUAD	cis	rs8024893	0.764	rs7178760	ENSG00000270055.1	CTD-3092A11.2	3.64	0.000298	0.0343	0.22	0.16	Red cell distribution width;	chr15:31239170	chr15:30487963~30490313:+
LUAD	cis	rs875971	1	rs1363055	ENSG00000273142.1	RP11-458F8.4	-3.64	0.000298	0.0343	-0.11	-0.16	Aortic root size;	chr7:66478288	chr7:66902857~66906297:+
LUAD	cis	rs875971	0.964	rs9691480	ENSG00000273142.1	RP11-458F8.4	-3.64	0.000298	0.0343	-0.11	-0.16	Aortic root size;	chr7:66479319	chr7:66902857~66906297:+
LUAD	cis	rs875971	1	rs7789554	ENSG00000273142.1	RP11-458F8.4	-3.64	0.000298	0.0343	-0.11	-0.16	Aortic root size;	chr7:66481051	chr7:66902857~66906297:+
LUAD	cis	rs875971	1	rs4717300	ENSG00000273142.1	RP11-458F8.4	-3.64	0.000298	0.0343	-0.11	-0.16	Aortic root size;	chr7:66482393	chr7:66902857~66906297:+
LUAD	cis	rs6951245	0.744	rs1133122	ENSG00000249574.1	AC226118.1	-3.64	0.000298	0.0343	-0.25	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1152936	chr7:379359~382712:+
LUAD	cis	rs2625529	0.529	rs1552133	ENSG00000260173.1	RP11-2I17.4	3.64	0.000298	0.0343	0.2	0.16	Red blood cell count;	chr15:71940556	chr15:72140504~72155459:-
LUAD	cis	rs2625529	0.556	rs1552134	ENSG00000260173.1	RP11-2I17.4	3.64	0.000298	0.0343	0.2	0.16	Red blood cell count;	chr15:71940557	chr15:72140504~72155459:-
LUAD	cis	rs6502050	0.835	rs4789668	ENSG00000266654.1	RP11-1376P16.1	-3.64	0.000298	0.0343	-0.18	-0.16	Life satisfaction;	chr17:82204114	chr17:82160056~82160452:+
LUAD	cis	rs2554380	0.891	rs2562782	ENSG00000230373.7	GOLGA6L5P	-3.64	0.000298	0.0343	-0.2	-0.16	Height;	chr15:83631329	chr15:84507885~84516814:-
LUAD	cis	rs2708977	0.698	rs772159	ENSG00000237510.6	AC008268.2	-3.64	0.000298	0.0343	-0.22	-0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96370701	chr2:95789654~95800166:+
LUAD	cis	rs2548724	1	rs1098806	ENSG00000250682.4	LINC00491	-3.64	0.000298	0.0343	-0.23	-0.16	Type 2 diabetes;	chr5:102278952	chr5:102609156~102671559:-
LUAD	cis	rs7131987	0.65	rs7973786	ENSG00000275476.1	RP11-996F15.4	-3.64	0.000298	0.0343	-0.19	-0.16	QT interval;	chr12:29309811	chr12:29277397~29277882:-
LUAD	cis	rs875971	0.767	rs12668005	ENSG00000273448.1	RP11-166O4.6	3.64	0.000298	0.0343	0.16	0.16	Aortic root size;	chr7:66444034	chr7:67333047~67334383:+
LUAD	cis	rs875971	0.862	rs11765791	ENSG00000273448.1	RP11-166O4.6	3.64	0.000298	0.0343	0.16	0.16	Aortic root size;	chr7:66471587	chr7:67333047~67334383:+
LUAD	cis	rs2281636	0.894	rs7077070	ENSG00000233690.1	EBAG9P1	3.64	0.000298	0.0343	0.16	0.16	Obesity-related traits;	chr10:99692220	chr10:99697407~99697949:-
LUAD	cis	rs2836974	0.897	rs13339986	ENSG00000232608.1	TIMM9P2	-3.64	0.000298	0.0343	-0.2	-0.16	Cognitive function;	chr21:39234056	chr21:39216624~39217506:+
LUAD	cis	rs2380205	0.967	rs4256891	ENSG00000232807.2	RP11-536K7.3	3.64	0.000298	0.0343	0.17	0.16	Breast cancer;	chr10:5846095	chr10:5934270~5945900:-
LUAD	cis	rs2380205	0.935	rs3954757	ENSG00000232807.2	RP11-536K7.3	3.64	0.000298	0.0343	0.17	0.16	Breast cancer;	chr10:5846103	chr10:5934270~5945900:-
LUAD	cis	rs2717559	0.542	rs2717586	ENSG00000253741.1	CTD-2292P10.4	-3.64	0.000298	0.0343	-0.2	-0.16	Urinary tract infection frequency;	chr8:142816466	chr8:142702252~142726973:-
LUAD	cis	rs638893	1	rs636736	ENSG00000255239.1	AP002954.6	3.64	0.000299	0.0343	0.26	0.16	Vitiligo;	chr11:118834436	chr11:118688039~118690600:-
LUAD	cis	rs465969	0.793	rs34288099	ENSG00000229276.1	REV3L-IT1	3.64	0.000299	0.0343	0.31	0.16	Psoriasis;	chr6:111424034	chr6:111360641~111361607:-
LUAD	cis	rs6964587	1	rs7802788	ENSG00000188693.7	CYP51A1-AS1	-3.64	0.000299	0.0343	-0.19	-0.16	Breast cancer;	chr7:92107560	chr7:92134604~92180725:+
LUAD	cis	rs10863681	0.764	rs6678715	ENSG00000200033.1	RNU6-403P	3.64	0.000299	0.0343	0.19	0.16	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222103941	chr1:221837334~221837437:-
LUAD	cis	rs8073060	0.586	rs72828038	ENSG00000267592.1	CTC-507E2.2	-3.64	0.000299	0.0343	-0.24	-0.16	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35566889	chr17:35596904~35597128:-
LUAD	cis	rs10129255	1	rs10129319	ENSG00000211947.2	IGHV3-21	-3.64	0.000299	0.0343	-0.11	-0.16	Kawasaki disease;	chr14:106767996	chr14:106235064~106235594:-
LUAD	cis	rs12190007	0.776	rs2981940	ENSG00000224999.1	VTA1P1	3.64	0.000299	0.0343	0.16	0.16	Obesity-related traits;	chr6:169385406	chr6:169296471~169297959:-
LUAD	cis	rs1198430	0.929	rs1210852	ENSG00000232482.2	RP4-654C18.1	-3.64	0.000299	0.0343	-0.26	-0.16	Total cholesterol levels;	chr1:23427040	chr1:23410832~23412146:+
LUAD	cis	rs2058382	1	rs2058382	ENSG00000234215.2	RP5-942I16.1	3.64	0.000299	0.0343	0.18	0.16	Subjective well-being;	chr7:70114038	chr7:69595958~69597448:-
LUAD	cis	rs10102546	0.966	rs10090542	ENSG00000244642.3	RN7SL396P	3.64	0.000299	0.0343	0.19	0.16	Smoking cessation;	chr8:119532177	chr8:119862662~119862956:+
LUAD	cis	rs7613875	0.62	rs17657688	ENSG00000234667.1	ACTBP13	3.64	0.000299	0.0343	0.18	0.16	Body mass index;	chr3:49995795	chr3:49873347~49877980:-
LUAD	cis	rs12681366	0.537	rs9297939	ENSG00000253704.1	RP11-267M23.4	3.64	0.000299	0.0343	0.2	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94467961	chr8:94553722~94569745:+
LUAD	cis	rs8028182	0.609	rs8038760	ENSG00000246877.1	DNM1P35	3.64	0.000299	0.0343	0.21	0.16	Sudden cardiac arrest;	chr15:75449754	chr15:75727670~75738623:-
LUAD	cis	rs8012947	1	rs10142973	ENSG00000279636.2	LINC00216	-3.64	0.000299	0.0343	-0.18	-0.16	Alcohol consumption in current drinkers;	chr14:58332400	chr14:58288033~58289158:+
LUAD	cis	rs8073060	0.586	rs225305	ENSG00000267592.1	CTC-507E2.2	3.64	0.000299	0.0343	0.24	0.16	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35594141	chr17:35596904~35597128:-
LUAD	cis	rs2834288	0.535	rs13049489	ENSG00000273102.1	AP000569.9	3.64	0.000299	0.0343	0.2	0.16	Gut microbiota (bacterial taxa);	chr21:33961054	chr21:33967101~33968573:-
LUAD	cis	rs6928977	0.538	rs17064702	ENSG00000231028.7	LINC00271	-3.64	0.000299	0.0343	-0.2	-0.16	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135607114	chr6:135497801~135716055:+
LUAD	cis	rs9637599	0.967	rs7661312	ENSG00000246375.2	RP11-10L7.1	3.64	0.000299	0.0343	0.21	0.16	Metabolite levels (small molecules and protein measures);	chr4:88279855	chr4:88284942~88331421:+
LUAD	cis	rs12681366	0.564	rs10808669	ENSG00000253704.1	RP11-267M23.4	3.64	0.000299	0.0343	0.2	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94468833	chr8:94553722~94569745:+
LUAD	cis	rs73108077	1	rs73116268	ENSG00000281376.1	ABALON	-3.64	0.000299	0.0343	-0.28	-0.16	Red blood cell density in sickle cell anemia;	chr20:31461103	chr20:31721507~31723409:+
LUAD	cis	rs728616	0.867	rs7080405	ENSG00000225484.5	NUTM2B-AS1	-3.64	0.000299	0.0343	-0.41	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80142187	chr10:79663088~79826594:-
LUAD	cis	rs10936632	0.565	rs9865021	ENSG00000242578.1	RP11-469J4.3	-3.64	0.000299	0.0344	-0.18	-0.16	Prostate cancer;	chr3:170429093	chr3:170410512~170418615:+
LUAD	cis	rs6723108	0.603	rs6708336	ENSG00000224043.6	CCNT2-AS1	-3.64	0.000299	0.0344	-0.2	-0.16	Type 2 diabetes;	chr2:134961562	chr2:134735464~134918710:-
LUAD	cis	rs6723108	0.603	rs56271357	ENSG00000224043.6	CCNT2-AS1	-3.64	0.000299	0.0344	-0.2	-0.16	Type 2 diabetes;	chr2:134963145	chr2:134735464~134918710:-
LUAD	cis	rs11853189	0.938	rs77056929	ENSG00000259562.2	RP11-762H8.2	3.64	0.000299	0.0344	0.18	0.16	Red cell distribution width;	chr15:78296175	chr15:78290527~78291221:-
LUAD	cis	rs1355223	1	rs11607300	ENSG00000271369.1	RP11-350D17.3	-3.64	0.000299	0.0344	-0.2	-0.16	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34737772	chr11:34709600~34710161:+
LUAD	cis	rs9308731	0.583	rs6726007	ENSG00000227992.1	AC108463.2	-3.64	0.000299	0.0344	-0.19	-0.16	Chronic lymphocytic leukemia;	chr2:111174545	chr2:111203964~111206215:-
LUAD	cis	rs854765	0.583	rs4925129	ENSG00000264177.1	RP1-37N7.1	-3.64	0.000299	0.0344	-0.16	-0.16	Total body bone mineral density;	chr17:17903872	chr17:18379855~18388984:-
LUAD	cis	rs13021401	1	rs342093	ENSG00000228950.1	AC023137.2	3.64	0.000299	0.0344	0.19	0.16	Systemic sclerosis;	chr2:20497984	chr2:20451042~20452947:+
LUAD	cis	rs8028182	0.636	rs12708520	ENSG00000246877.1	DNM1P35	3.64	0.000299	0.0344	0.21	0.16	Sudden cardiac arrest;	chr15:75538198	chr15:75727670~75738623:-
LUAD	cis	rs189798	0.807	rs330905	ENSG00000253981.4	ALG1L13P	3.64	0.000299	0.0344	0.21	0.16	Myopia (pathological);	chr8:9136041	chr8:8236003~8244667:-
LUAD	cis	rs7937890	0.532	rs2575827	ENSG00000254418.1	RP11-21L19.1	3.64	0.000299	0.0344	0.19	0.16	Mitochondrial DNA levels;	chr11:14453969	chr11:14262846~14273691:-
LUAD	cis	rs7937890	0.532	rs2256884	ENSG00000254418.1	RP11-21L19.1	3.64	0.000299	0.0344	0.19	0.16	Mitochondrial DNA levels;	chr11:14454856	chr11:14262846~14273691:-
LUAD	cis	rs6452524	0.618	rs6452504	ENSG00000281327.1	LINC01338	3.64	0.000299	0.0344	0.17	0.16	Hypertension (SNP x SNP interaction);	chr5:83074625	chr5:82850864~82859836:-
LUAD	cis	rs750134	0.901	rs12423733	ENSG00000257221.1	RP11-689B22.2	-3.64	0.000299	0.0344	-0.23	-0.16	Low high density lipoprotein cholesterol levels;	chr12:108724213	chr12:108628687~108641318:+
LUAD	cis	rs11673344	0.864	rs1879497	ENSG00000267309.1	CTD-2630F21.1	-3.64	0.000299	0.0344	-0.21	-0.16	Obesity-related traits;	chr19:37141975	chr19:36489649~36491040:+
LUAD	cis	rs10129255	0.518	rs10150460	ENSG00000253209.1	IGHV3-65	-3.64	0.000299	0.0344	-0.13	-0.16	Kawasaki disease;	chr14:106677179	chr14:106666092~106666532:-
LUAD	cis	rs7200543	1	rs3803575	ENSG00000260735.1	RP11-72I8.1	-3.64	0.000299	0.0344	-0.18	-0.16	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15044590	chr16:15094411~15109197:+
LUAD	cis	rs6095360	0.966	rs6090940	ENSG00000222365.1	SNORD12B	-3.64	0.000299	0.0344	-0.17	-0.16	Intelligence (multi-trait analysis);	chr20:49049490	chr20:49280319~49280409:+
LUAD	cis	rs950027	0.549	rs12909409	ENSG00000259479.5	SORD2P	-3.64	0.000299	0.0344	-0.2	-0.16	Response to fenofibrate (adiponectin levels);	chr15:45316384	chr15:44826371~44884694:-
LUAD	cis	rs78572108	0.858	rs971915	ENSG00000214691.7	AC104654.1	3.64	3e-04	0.0344	0.28	0.16	Total body bone mineral density;	chr2:42025798	chr2:41877074~41894046:+
LUAD	cis	rs7098414	0.531	rs3844126	ENSG00000226659.1	RP11-137H2.4	-3.64	3e-04	0.0344	-0.21	-0.16	Post bronchodilator FEV1;	chr10:80260241	chr10:80529597~80535942:-
LUAD	cis	rs7660883	0.897	rs1037814	ENSG00000251411.1	RP11-397E7.4	-3.64	3e-04	0.0344	-0.18	-0.16	HDL cholesterol levels;	chr4:87128698	chr4:86913266~86914817:-
LUAD	cis	rs3096299	0.606	rs2965946	ENSG00000182376.2	RP5-1142A6.8	3.64	3e-04	0.0344	0.19	0.16	Multiple myeloma (IgH translocation);	chr16:89450204	chr16:88742767~88745748:+
LUAD	cis	rs34779708	0.931	rs35886556	ENSG00000271335.4	RP11-324I22.4	3.64	3e-04	0.0344	0.17	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35046057	chr10:35314552~35336401:-
LUAD	cis	rs9926296	0.533	rs7190823	ENSG00000260259.1	RP11-368I7.4	-3.64	3e-04	0.0344	-0.16	-0.16	Vitiligo;	chr16:89799635	chr16:89682620~89686569:-
LUAD	cis	rs67981189	0.789	rs2810073	ENSG00000269927.1	RP6-91H8.3	-3.64	3e-04	0.0344	-0.21	-0.16	Schizophrenia;	chr14:70917131	chr14:71141125~71143253:-
LUAD	cis	rs4664293	0.867	rs7566584	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159728284	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs7566802	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159728480	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs3732289	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159728887	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs3821299	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159729229	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs13415100	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159729716	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs13415025	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159729799	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs13389662	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159729926	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs7562060	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159730618	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs4665110	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159731014	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs34893664	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159732266	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs34795915	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159732420	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs10204867	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159732674	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs35196716	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159733266	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs6432557	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159735699	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs7603274	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159736179	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.836	rs13403371	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159736603	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs13428679	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159736687	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs12623283	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159736959	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs2098976	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159737264	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs2081723	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159737649	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs2081722	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159737697	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs10166694	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159738380	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs2357529	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159738922	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs12692562	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159739199	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs12998291	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159739392	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs2357532	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159740916	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs16844269	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159742569	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.836	rs4664300	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159743927	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs16822556	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159744392	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs16822558	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159744496	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs1834761	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159745278	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs6432558	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159745397	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.836	rs7567818	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159746186	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs12692563	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159746300	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs12620924	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159746452	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.836	rs13397597	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159747084	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.805	rs7593273	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159749349	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.805	rs6432559	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159750649	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs6432560	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159750758	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs3863924	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159758247	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs11681565	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159760362	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.836	rs11687502	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159760464	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.836	rs13401087	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159760957	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs12692564	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159761326	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs1427328	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159762064	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.613	rs9784044	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159765854	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs4664301	ENSG00000230783.1	AC009961.2	-3.64	3e-04	0.0344	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159766855	chr2:159689217~159690291:-
LUAD	cis	rs1910358	0.636	rs7717072	ENSG00000248874.4	C5orf17	-3.64	3e-04	0.0344	-0.21	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23949421	chr5:23951348~24178263:+
LUAD	cis	rs513088	0.681	rs517224	ENSG00000225171.2	DUTP6	-3.64	3e-04	0.0344	-0.2	-0.16	Schizophrenia;	chr1:166677709	chr1:166868748~166869209:+
LUAD	cis	rs6502050	0.835	rs8067875	ENSG00000275966.1	RP11-1055B8.9	-3.64	3e-04	0.0344	-0.17	-0.16	Life satisfaction;	chr17:82134902	chr17:81345476~81345966:-
LUAD	cis	rs2836974	0.863	rs1065242	ENSG00000232608.1	TIMM9P2	-3.64	3e-04	0.0344	-0.2	-0.16	Cognitive function;	chr21:39195790	chr21:39216624~39217506:+
LUAD	cis	rs875971	0.66	rs801193	ENSG00000273142.1	RP11-458F8.4	3.64	3e-04	0.0344	0.11	0.16	Aortic root size;	chr7:66565625	chr7:66902857~66906297:+
LUAD	cis	rs867371	0.502	rs7176926	ENSG00000259429.4	UBE2Q2P2	-3.64	3e-04	0.0344	-0.14	-0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82245753	chr15:82355142~82420075:+
LUAD	cis	rs2269241	0.636	rs61765292	ENSG00000244256.3	RN7SL130P	-3.64	3e-04	0.0344	-0.22	-0.16	Type 1 diabetes;	chr1:63647788	chr1:63655743~63656047:+
LUAD	cis	rs4727963	0.846	rs4727961	ENSG00000240499.6	RP5-1101C3.1	3.64	3e-04	0.0344	0.15	0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);	chr7:123076289	chr7:122328469~122440388:+
LUAD	cis	rs875971	0.862	rs778736	ENSG00000273448.1	RP11-166O4.6	3.64	3e-04	0.0344	0.16	0.16	Aortic root size;	chr7:66348861	chr7:67333047~67334383:+
LUAD	cis	rs875971	0.862	rs2088653	ENSG00000273448.1	RP11-166O4.6	-3.64	3e-04	0.0344	-0.16	-0.16	Aortic root size;	chr7:66343621	chr7:67333047~67334383:+
LUAD	cis	rs16893526	0.649	rs1931626	ENSG00000224995.1	LINC01526	-3.64	3e-04	0.0344	-0.29	-0.16	Coronary heart disease;	chr6:81813624	chr6:81813286~81814157:-
LUAD	cis	rs7204230	1	rs8055218	ENSG00000261291.1	RP11-295M3.2	3.64	3e-04	0.0344	0.19	0.16	Fibrinogen;	chr16:53314295	chr16:53168522~53169450:+
LUAD	cis	rs10876993	0.928	rs1689586	ENSG00000270039.1	RP11-571M6.17	3.64	3e-04	0.0344	0.19	0.16	Celiac disease or Rheumatoid arthritis;	chr12:57685803	chr12:57803838~57804415:+
LUAD	cis	rs1050288	0.525	rs2113882	ENSG00000256377.4	RP11-1060J15.4	-3.64	3e-04	0.0344	-0.24	-0.16	Pulse pressure;Resting heart rate;	chr12:27787987	chr12:27696388~27710770:-
LUAD	cis	rs73990293	0.737	rs4531775	ENSG00000267592.1	CTC-507E2.2	3.64	3e-04	0.0344	0.35	0.16	Clopidogrel active metabolite levels;	chr17:35559919	chr17:35596904~35597128:-
LUAD	cis	rs13113518	0.557	rs13142096	ENSG00000249700.7	SRD5A3-AS1	3.64	3e-04	0.0344	0.18	0.16	Height;	chr4:55566291	chr4:55363971~55395847:-
LUAD	cis	rs4667682	0.646	rs6433287	ENSG00000228507.1	DAP3P2	-3.64	3e-04	0.0344	-0.34	-0.16	Hippocampal atrophy;Body mass index;	chr2:171277866	chr2:171491422~171491931:+
LUAD	cis	rs6430585	0.697	rs1050115	ENSG00000226806.1	AC011893.3	3.64	3e-04	0.0344	0.25	0.16	Corneal structure;	chr2:135754247	chr2:135820191~135823087:+
LUAD	cis	rs1799955	0.935	rs9567623	ENSG00000215515.2	IFIT1P1	-3.64	3e-04	0.0344	-0.24	-0.16	LDL cholesterol levels;	chr13:32377317	chr13:32384660~32386108:+
LUAD	cis	rs3864261	0.515	rs55769858	ENSG00000272081.1	CTD-2376I4.2	3.64	3e-04	0.0344	0.22	0.16	Discordance in emotional problems in monozygotic twins;	chr5:72984937	chr5:72955206~72955699:-
LUAD	cis	rs4388249	0.687	rs2300998	ENSG00000271849.1	CTC-332L22.1	-3.64	3e-04	0.0344	-0.23	-0.16	Schizophrenia;	chr5:109747421	chr5:109687802~109688329:-
LUAD	cis	rs4622329	0.615	rs6539019	ENSG00000258230.2	RP11-511H9.3	3.64	3e-04	0.0344	0.15	0.16	Systemic lupus erythematosus;	chr12:101909308	chr12:101773114~101773755:-
LUAD	cis	rs4130344	0.874	rs13152601	ENSG00000271817.2	U3	3.64	3e-04	0.0345	0.17	0.16	Intelligence (multi-trait analysis);	chr4:158811622	chr4:158700691~158700909:+
LUAD	cis	rs3096299	0.967	rs2911255	ENSG00000261574.1	RP1-168P16.2	3.64	3e-04	0.0345	0.18	0.16	Multiple myeloma (IgH translocation);	chr16:89420729	chr16:89392375~89412564:-
LUAD	cis	rs13113518	0.812	rs12649507	ENSG00000273257.1	RP11-177J6.1	-3.64	3e-04	0.0345	-0.18	-0.16	Height;	chr4:55514317	chr4:55387949~55388271:+
LUAD	cis	rs78572108	0.858	rs12472434	ENSG00000214691.7	AC104654.1	3.64	3e-04	0.0345	0.27	0.16	Total body bone mineral density;	chr2:42003318	chr2:41877074~41894046:+
LUAD	cis	rs78572108	0.858	rs58379580	ENSG00000214691.7	AC104654.1	3.64	3e-04	0.0345	0.27	0.16	Total body bone mineral density;	chr2:42003571	chr2:41877074~41894046:+
LUAD	cis	rs4731367	0.931	rs10280804	ENSG00000224138.1	AC000123.4	-3.64	3e-04	0.0345	-0.15	-0.16	Parental longevity (mother's age at death);	chr7:127564584	chr7:127350128~127351523:+
LUAD	cis	rs1476587	0.527	rs1859127	ENSG00000224046.1	AC005076.5	-3.64	3e-04	0.0345	-0.21	-0.16	Brachial circumference;	chr7:87122826	chr7:87151423~87152420:-
LUAD	cis	rs7208859	0.673	rs79541516	ENSG00000265443.1	CTD-2349P21.6	-3.64	3e-04	0.0345	-0.28	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913565	chr17:30726305~30727564:-
LUAD	cis	rs7208859	0.673	rs9895684	ENSG00000265443.1	CTD-2349P21.6	-3.64	3e-04	0.0345	-0.28	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30915582	chr17:30726305~30727564:-
LUAD	cis	rs7615916	1	rs10865710	ENSG00000225026.1	AC091492.2	3.64	3e-04	0.0345	0.23	0.16	Eosinophil percentage of white cells;	chr3:12311699	chr3:12328003~12328274:+
LUAD	cis	rs6883311	0.922	rs10866662	ENSG00000254211.4	LINC01485	3.64	3e-04	0.0345	0.15	0.16	Immunoglobulin A vasculitis;	chr5:173374442	chr5:173786790~173809039:-
LUAD	cis	rs7829975	0.624	rs7823056	ENSG00000233609.3	RP11-62H7.2	3.64	3e-04	0.0345	0.14	0.16	Mood instability;	chr8:8525195	chr8:8961200~8979025:+
LUAD	cis	rs3227	0.55	rs545787	ENSG00000197251.3	LINC00336	-3.64	3e-04	0.0345	-0.22	-0.16	Educational attainment;	chr6:33735453	chr6:33586106~33593338:-
LUAD	cis	rs12499086	0.541	rs2074396	ENSG00000249635.1	RP11-710F7.3	-3.64	3e-04	0.0345	-0.17	-0.16	Economic and political preferences (time);	chr4:105473223	chr4:106003317~106022478:-
LUAD	cis	rs35320143	0.5	rs12920542	ENSG00000258122.1	RP11-61A14.1	-3.64	3e-04	0.0345	-0.2	-0.16	Number of children (6+ vs. 0 or 1);	chr16:66712648	chr16:66841433~66853448:-
LUAD	cis	rs1555322	0.53	rs2297789	ENSG00000261582.1	RP4-614O4.11	-3.64	0.000301	0.0345	-0.21	-0.16	Attention deficit hyperactivity disorder;	chr20:35279445	chr20:35267885~35280043:-
LUAD	cis	rs860295	0.702	rs1325908	ENSG00000160766.13	GBAP1	-3.64	0.000301	0.0345	-0.17	-0.16	Body mass index;	chr1:155443513	chr1:155213821~155227422:-
LUAD	cis	rs1075265	0.783	rs805438	ENSG00000272156.1	RP11-477N3.1	-3.64	0.000301	0.0345	-0.19	-0.16	Chronotype;Morning vs. evening chronotype;	chr2:53829051	chr2:54082554~54085066:+
LUAD	cis	rs911555	0.755	rs10144051	ENSG00000244691.1	RPL10AP1	-3.64	0.000301	0.0345	-0.21	-0.16	Intelligence (multi-trait analysis);	chr14:103419594	chr14:103412119~103412761:-
LUAD	cis	rs4718428	1	rs4718428	ENSG00000272831.1	RP11-792A8.4	3.64	0.000301	0.0345	0.16	0.16	Corneal structure;	chr7:66956459	chr7:66739829~66740385:-
LUAD	cis	rs7107174	0.688	rs11237490	ENSG00000251323.2	RP11-452H21.4	3.64	0.000301	0.0345	0.22	0.16	Testicular germ cell tumor;	chr11:78424183	chr11:78423982~78429836:-
LUAD	cis	rs9652601	0.622	rs9935174	ENSG00000280153.1	RP11-876N24.3	-3.64	0.000301	0.0345	-0.11	-0.16	Systemic lupus erythematosus;	chr16:11017490	chr16:10933903~10936280:+
LUAD	cis	rs7727544	0.545	rs10074490	ENSG00000233006.5	AC034220.3	3.64	0.000301	0.0345	0.15	0.16	Blood metabolite levels;	chr5:132004339	chr5:132311285~132369916:-
LUAD	cis	rs6547741	1	rs1080060	ENSG00000223522.1	AC093690.1	3.64	0.000301	0.0345	0.16	0.16	Oral cavity cancer;	chr2:27545941	chr2:28307691~28310459:-
LUAD	cis	rs9951698	0.703	rs7226616	ENSG00000267480.1	RP11-703I16.1	-3.64	0.000301	0.0345	-0.2	-0.16	Intelligence (multi-trait analysis);	chr18:13009906	chr18:12031178~12032181:-
LUAD	cis	rs9951698	0.703	rs7237236	ENSG00000267480.1	RP11-703I16.1	-3.64	0.000301	0.0345	-0.2	-0.16	Intelligence (multi-trait analysis);	chr18:13011432	chr18:12031178~12032181:-
LUAD	cis	rs6430585	0.702	rs73958637	ENSG00000226806.1	AC011893.3	3.64	0.000301	0.0345	0.25	0.16	Corneal structure;	chr2:135789357	chr2:135820191~135823087:+
LUAD	cis	rs7615952	0.515	rs4267608	ENSG00000241288.6	RP11-379B18.5	-3.64	0.000301	0.0345	-0.2	-0.16	Blood pressure (smoking interaction);	chr3:125961657	chr3:125827238~125916384:-
LUAD	cis	rs972578	0.533	rs6002998	ENSG00000230319.1	AL022476.2	3.64	0.000301	0.0345	0.18	0.16	Mean platelet volume;	chr22:43024660	chr22:43038585~43052366:+
LUAD	cis	rs6125597	0.904	rs2273146	ENSG00000230758.1	SNAP23P	3.64	0.000301	0.0345	0.17	0.16	Intelligence (multi-trait analysis);	chr20:49223116	chr20:49038357~49038602:-
LUAD	cis	rs6125597	1	rs6125597	ENSG00000230758.1	SNAP23P	3.64	0.000301	0.0345	0.17	0.16	Intelligence (multi-trait analysis);	chr20:49224235	chr20:49038357~49038602:-
LUAD	cis	rs7402982	0.647	rs34038360	ENSG00000278022.1	RP11-35O15.2	-3.64	0.000301	0.0345	-0.18	-0.16	Birth weight;	chr15:98658344	chr15:98660210~98660668:+
LUAD	cis	rs7584330	0.695	rs7570882	ENSG00000222032.1	AC112721.2	3.64	0.000301	0.0345	0.18	0.16	Prostate cancer;	chr2:237526443	chr2:237428920~237434822:-
LUAD	cis	rs838147	0.76	rs281408	ENSG00000232871.7	SEC1P	3.64	0.000301	0.0345	0.18	0.16	Dietary macronutrient intake;	chr19:48730149	chr19:48638071~48682245:+
LUAD	cis	rs12928939	0.815	rs61753635	ENSG00000262140.1	RP11-417N10.3	-3.64	0.000301	0.0345	-0.19	-0.16	Post bronchodilator FEV1;	chr16:71626501	chr16:71833787~71835932:+
LUAD	cis	rs1155848	0.892	rs9565509	ENSG00000227676.3	LINC01068	-3.64	0.000301	0.0345	-0.41	-0.16	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79483696	chr13:79566727~79571436:+
LUAD	cis	rs9457247	1	rs429083	ENSG00000227598.1	RP1-167A14.2	-3.64	0.000301	0.0345	-0.18	-0.16	Crohn's disease;	chr6:166970484	chr6:166969626~166999065:-
LUAD	cis	rs6921919	0.583	rs9461459	ENSG00000219392.1	RP1-265C24.5	-3.64	0.000301	0.0345	-0.21	-0.16	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28115628~28116551:+
LUAD	cis	rs6921919	0.583	rs28360638	ENSG00000219392.1	RP1-265C24.5	-3.64	0.000301	0.0345	-0.21	-0.16	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28115628~28116551:+
LUAD	cis	rs6988985	0.678	rs4072020	ENSG00000247317.3	RP11-273G15.2	-3.64	0.000301	0.0345	-0.19	-0.16	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142915999	chr8:142981738~143018437:-
LUAD	cis	rs9341808	0.6	rs668329	ENSG00000272129.1	RP11-250B2.6	-3.64	0.000301	0.0345	-0.2	-0.16	Sitting height ratio;	chr6:80258861	chr6:80355424~80356859:+
LUAD	cis	rs8046148	0.724	rs9939688	ENSG00000279356.1	RP11-429P3.8	3.64	0.000301	0.0345	0.17	0.16	Testicular germ cell tumor;	chr16:50075189	chr16:50072862~50074986:+
LUAD	cis	rs8046148	0.724	rs12931497	ENSG00000279356.1	RP11-429P3.8	3.64	0.000301	0.0345	0.17	0.16	Testicular germ cell tumor;	chr16:50075567	chr16:50072862~50074986:+
LUAD	cis	rs9813712	0.548	rs9880123	ENSG00000253540.4	FAM86HP	-3.64	0.000301	0.0345	-0.17	-0.16	Response to amphetamines;	chr3:130215275	chr3:130099092~130111472:-
LUAD	cis	rs2904524	1	rs17108018	ENSG00000257815.4	RP11-611E13.2	-3.64	0.000301	0.0345	-0.23	-0.16	Amyotrophic lateral sclerosis (age of onset);	chr12:70343166	chr12:69904033~70243360:-
LUAD	cis	rs7560272	0.512	rs2421677	ENSG00000163016.8	ALMS1P	-3.64	0.000301	0.0345	-0.18	-0.16	Schizophrenia;	chr2:73738790	chr2:73644919~73685576:+
LUAD	cis	rs2554380	0.843	rs7182216	ENSG00000230373.7	GOLGA6L5P	3.64	0.000301	0.0345	0.19	0.16	Height;	chr15:83753754	chr15:84507885~84516814:-
LUAD	cis	rs394563	0.591	rs237035	ENSG00000216906.2	RP11-350J20.9	3.64	0.000301	0.0345	0.19	0.16	Dupuytren's disease;	chr6:149389712	chr6:149904243~149906418:+
LUAD	cis	rs17597773	0.638	rs7544735	ENSG00000272823.1	RP11-295M18.6	3.64	0.000301	0.0345	0.21	0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220825571	chr1:220828676~220829211:-
LUAD	cis	rs137603	0.562	rs137644	ENSG00000235209.1	CTA-150C2.13	-3.64	0.000301	0.0346	-0.17	-0.16	Primary biliary cholangitis;	chr22:39332134	chr22:38921227~38924708:+
LUAD	cis	rs10463554	0.963	rs26821	ENSG00000250682.4	LINC00491	3.64	0.000301	0.0346	0.2	0.16	Parkinson's disease;	chr5:103184699	chr5:102609156~102671559:-
LUAD	cis	rs6472235	0.524	rs11985050	ENSG00000200714.1	Y_RNA	-3.64	0.000301	0.0346	-0.22	-0.16	Plateletcrit;Myopia (pathological);	chr8:65992811	chr8:65592731~65592820:+
LUAD	cis	rs7432375	0.578	rs17366234	ENSG00000239213.4	NCK1-AS1	3.64	0.000301	0.0346	0.18	0.16	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136858243	chr3:136841726~136862054:-
LUAD	cis	rs10876993	0.928	rs10877008	ENSG00000270039.1	RP11-571M6.17	3.64	0.000301	0.0346	0.2	0.16	Celiac disease or Rheumatoid arthritis;	chr12:57709809	chr12:57803838~57804415:+
LUAD	cis	rs8192282	0.739	rs9427415	ENSG00000272030.1	RP1-178F15.4	3.64	0.000301	0.0346	0.23	0.16	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);	chr1:154535961	chr1:153631438~153634397:-
LUAD	cis	rs4699052	0.739	rs6836157	ENSG00000251288.2	RP11-10L12.2	-3.64	0.000301	0.0346	-0.2	-0.16	Testicular germ cell tumor;	chr4:103321833	chr4:102751401~102752641:+
LUAD	cis	rs911555	0.713	rs10162425	ENSG00000259775.1	RP11-45P15.4	-3.64	0.000301	0.0346	-0.21	-0.16	Intelligence (multi-trait analysis);	chr14:103465284	chr14:103331674~103332367:-
LUAD	cis	rs7610301	1	rs4683249	ENSG00000276925.1	RP11-708J19.3	3.64	0.000301	0.0346	0.2	0.16	Blood protein levels;	chr3:46601651	chr3:47469777~47469987:+
LUAD	cis	rs11018904	0.608	rs35700249	ENSG00000280367.1	RP11-121L10.2	3.64	0.000301	0.0346	0.25	0.16	Intelligence (multi-trait analysis);	chr11:90198759	chr11:90223153~90226538:+
LUAD	cis	rs910316	0.763	rs175036	ENSG00000279594.1	RP11-950C14.10	-3.64	0.000301	0.0346	-0.19	-0.16	Height;	chr14:74997592	chr14:75011269~75012851:-
LUAD	cis	rs763121	0.819	rs5750629	ENSG00000228274.3	RP3-508I15.9	-3.64	0.000302	0.0346	-0.15	-0.16	Menopause (age at onset);	chr22:38589060	chr22:38667585~38681820:-
LUAD	cis	rs7546668	1	rs6695562	ENSG00000272510.1	RP4-680D5.8	3.64	0.000302	0.0346	0.21	0.16	Glomerular filtration rate (creatinine);	chr1:15516347	chr1:15565611~15565956:-
LUAD	cis	rs6460942	0.63	rs17671056	ENSG00000226690.5	AC005281.1	3.64	0.000302	0.0346	0.28	0.16	Coronary artery disease;	chr7:12351335	chr7:12496429~12541910:+
LUAD	cis	rs28588043	0.618	rs28448365	ENSG00000271811.1	RP1-79C4.4	3.64	0.000302	0.0346	0.23	0.16	Number of children (6+ vs. 0 or 1);	chr1:170991842	chr1:170667381~170669425:+
LUAD	cis	rs4660214	0.666	rs2275187	ENSG00000182109.6	RP11-69E11.4	-3.64	0.000302	0.0346	-0.18	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39297570	chr1:39522280~39546187:-
LUAD	cis	rs11822910	0.645	rs7122734	ENSG00000265566.2	RN7SL605P	-3.64	0.000302	0.0346	-0.22	-0.16	Platelet distribution width;	chr11:57422947	chr11:57528085~57528365:-
LUAD	cis	rs4683346	0.731	rs7623543	ENSG00000173811.9	CCDC13-AS1	-3.64	0.000302	0.0346	-0.19	-0.16	Granulocyte percentage of myeloid white cells;	chr3:42880135	chr3:42732575~42746768:+
LUAD	cis	rs2179367	0.92	rs638407	ENSG00000216906.2	RP11-350J20.9	3.64	0.000302	0.0346	0.2	0.16	Dupuytren's disease;	chr6:149417214	chr6:149904243~149906418:+
LUAD	cis	rs4268898	0.795	rs12470303	ENSG00000242628.4	AC009228.1	3.64	0.000302	0.0346	0.21	0.16	Asthma;	chr2:24397014	chr2:24214381~24221516:+
LUAD	cis	rs10463554	1	rs6879788	ENSG00000250682.4	LINC00491	3.64	0.000302	0.0346	0.19	0.16	Parkinson's disease;	chr5:102978353	chr5:102609156~102671559:-
LUAD	cis	rs3096299	0.967	rs2965830	ENSG00000182376.2	RP5-1142A6.8	3.64	0.000302	0.0346	0.17	0.16	Multiple myeloma (IgH translocation);	chr16:89393882	chr16:88742767~88745748:+
LUAD	cis	rs910316	0.763	rs1548807	ENSG00000279594.1	RP11-950C14.10	3.64	0.000302	0.0346	0.19	0.16	Height;	chr14:75012879	chr14:75011269~75012851:-
LUAD	cis	rs2273156	0.57	rs28399702	ENSG00000226677.3	IGBP1P1	-3.64	0.000302	0.0346	-0.24	-0.16	Immunoglobulin light chain (AL) amyloidosis;	chr14:35156011	chr14:34939324~34940332:+
LUAD	cis	rs8073060	0.671	rs9894813	ENSG00000255987.1	TOMM20P2	3.64	0.000302	0.0346	0.17	0.16	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35546829	chr17:35514766~35515186:-
LUAD	cis	rs911555	0.692	rs7146215	ENSG00000259775.1	RP11-45P15.4	3.64	0.000302	0.0346	0.22	0.16	Intelligence (multi-trait analysis);	chr14:103449571	chr14:103331674~103332367:-
LUAD	cis	rs7809950	1	rs2520249	ENSG00000238832.1	snoU109	-3.64	0.000302	0.0346	-0.24	-0.16	Coronary artery disease;	chr7:107506303	chr7:107603363~107603507:+
LUAD	cis	rs7512552	0.839	rs11577600	ENSG00000275557.1	RP11-353N4.6	3.64	0.000302	0.0346	0.18	0.16	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150434967	chr1:149607765~149612402:+
LUAD	cis	rs2412819	0.545	rs3862143	ENSG00000166763.7	STRCP1	-3.64	0.000302	0.0346	-0.24	-0.16	Lung cancer;	chr15:43779282	chr15:43699488~43718184:-
LUAD	cis	rs8056893	0.842	rs3785114	ENSG00000260441.4	RP11-96D1.7	-3.64	0.000302	0.0346	-0.19	-0.16	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68338420	chr16:68256162~68260443:-
LUAD	cis	rs797680	0.822	rs1572343	ENSG00000223745.6	RP4-717I23.3	3.64	0.000302	0.0346	0.13	0.16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93150645	chr1:93262186~93346025:-
LUAD	cis	rs13021401	1	rs342070	ENSG00000228950.1	AC023137.2	3.64	0.000302	0.0346	0.19	0.16	Systemic sclerosis;	chr2:20485710	chr2:20451042~20452947:+
LUAD	cis	rs2288073	0.965	rs13395596	ENSG00000223754.1	AC008073.9	3.64	0.000302	0.0346	0.21	0.16	Venous thromboembolism (SNP x SNP interaction);	chr2:24187869	chr2:24199839~24201698:-
LUAD	cis	rs2288073	0.896	rs13404513	ENSG00000223754.1	AC008073.9	3.64	0.000302	0.0346	0.21	0.16	Venous thromboembolism (SNP x SNP interaction);	chr2:24187911	chr2:24199839~24201698:-
LUAD	cis	rs7829975	0.667	rs1877119	ENSG00000233609.3	RP11-62H7.2	3.64	0.000302	0.0346	0.13	0.16	Mood instability;	chr8:8849687	chr8:8961200~8979025:+
LUAD	cis	rs7712401	0.755	rs27740	ENSG00000249996.1	RP11-359P5.1	-3.64	0.000302	0.0346	-0.2	-0.16	Mean platelet volume;	chr5:122869077	chr5:123036271~123054667:+
LUAD	cis	rs10875976	0.545	rs7309919	ENSG00000257464.1	RP11-161H23.8	-3.64	0.000302	0.0346	-0.17	-0.16	Obesity;	chr12:49857032	chr12:49442424~49442652:-
LUAD	cis	rs10208649	0.808	rs11886366	ENSG00000233266.1	HMGB1P31	3.64	0.000302	0.0346	0.44	0.16	Body mass index;	chr2:53997126	chr2:54051334~54051760:+
LUAD	cis	rs875971	0.789	rs7808013	ENSG00000273448.1	RP11-166O4.6	-3.64	0.000302	0.0346	-0.16	-0.16	Aortic root size;	chr7:66606209	chr7:67333047~67334383:+
LUAD	cis	rs875971	0.825	rs7384021	ENSG00000273448.1	RP11-166O4.6	-3.64	0.000302	0.0346	-0.16	-0.16	Aortic root size;	chr7:66612917	chr7:67333047~67334383:+
LUAD	cis	rs875971	0.825	rs66981195	ENSG00000273448.1	RP11-166O4.6	-3.64	0.000302	0.0346	-0.16	-0.16	Aortic root size;	chr7:66614048	chr7:67333047~67334383:+
LUAD	cis	rs875971	0.862	rs3926380	ENSG00000273448.1	RP11-166O4.6	-3.64	0.000302	0.0346	-0.16	-0.16	Aortic root size;	chr7:66615658	chr7:67333047~67334383:+
LUAD	cis	rs2060793	0.55	rs1037378	ENSG00000251991.1	RNU7-49P	3.64	0.000302	0.0346	0.17	0.16	Vitamin D levels;	chr11:14830944	chr11:14478892~14478953:+
LUAD	cis	rs6001482	0.523	rs5757595	ENSG00000211642.2	IGLV10-54	3.64	0.000302	0.0346	0.19	0.16	Diastolic blood pressure;	chr22:22235017	chr22:22214794~22215270:+
LUAD	cis	rs4759375	1	rs2271976	ENSG00000235423.7	RP11-282O18.3	3.64	0.000302	0.0346	0.29	0.16	HDL cholesterol;	chr12:123267179	chr12:123252030~123261483:-
LUAD	cis	rs73036520	0.646	rs12460848	ENSG00000242675.1	RPS16P9	3.64	0.000302	0.0346	0.19	0.16	Monocyte percentage of white cells;	chr19:45290449	chr19:45332698~45333124:-
LUAD	cis	rs7204230	1	rs8049550	ENSG00000261291.1	RP11-295M3.2	3.64	0.000302	0.0346	0.19	0.16	Fibrinogen;	chr16:53290527	chr16:53168522~53169450:+
LUAD	cis	rs12887734	0.524	rs4900599	ENSG00000258914.1	CTD-2134A5.3	-3.64	0.000302	0.0346	-0.2	-0.16	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103817107	chr14:103875055~103877478:+
LUAD	cis	rs6708413	0.528	rs7567885	ENSG00000234389.1	AC007278.3	-3.64	0.000302	0.0346	-0.16	-0.16	Crohn's disease;Inflammatory bowel disease;	chr2:102492393	chr2:102438713~102440475:+
LUAD	cis	rs11649653	0.502	rs62057232	ENSG00000232748.3	RP11-196G11.6	3.64	0.000302	0.0346	0.2	0.16	Triglycerides;	chr16:30809545	chr16:31056460~31062803:+
LUAD	cis	rs56145559	1	rs56145559	ENSG00000230002.2	ALMS1-IT1	3.64	0.000302	0.0346	0.21	0.16	Schizophrenia;	chr2:73396311	chr2:73456764~73459484:+
LUAD	cis	rs4795519	0.922	rs2061897	ENSG00000266313.1	RP11-173M1.4	3.64	0.000302	0.0346	0.2	0.16	Chronic myeloid leukemia;	chr17:27081913	chr17:27333256~27348491:+
LUAD	cis	rs11018904	0.906	rs36177012	ENSG00000280367.1	RP11-121L10.2	3.64	0.000302	0.0346	0.21	0.16	Intelligence (multi-trait analysis);	chr11:90200151	chr11:90223153~90226538:+
LUAD	cis	rs17685	0.89	rs76021834	ENSG00000205485.12	AC004980.7	-3.64	0.000302	0.0346	-0.18	-0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:75977837	chr7:76549360~76627982:+
LUAD	cis	rs875971	0.619	rs2302918	ENSG00000222364.1	RNU6-96P	-3.64	0.000302	0.0346	-0.18	-0.16	Aortic root size;	chr7:66535945	chr7:66395191~66395286:+
LUAD	cis	rs2702164	0.962	rs1615793	ENSG00000240661.1	RP11-174O3.3	-3.64	0.000302	0.0346	-0.2	-0.16	Gut microbiome composition (winter);	chr3:120387415	chr3:120349510~120367998:+
LUAD	cis	rs6547741	1	rs1528404	ENSG00000223522.1	AC093690.1	-3.64	0.000302	0.0346	-0.16	-0.16	Oral cavity cancer;	chr2:27623736	chr2:28307691~28310459:-
LUAD	cis	rs4948102	0.642	rs4948104	ENSG00000275875.1	RP11-613E4.5	-3.64	0.000302	0.0346	-0.18	-0.16	Plasma homocysteine levels (post-methionine load test);	chr7:56074826	chr7:55741525~55741869:+
LUAD	cis	rs262150	1	rs262154	ENSG00000231419.5	LINC00689	-3.64	0.000302	0.0346	-0.2	-0.16	Facial morphology (factor 20);	chr7:158981245	chr7:159006522~159030195:+
LUAD	cis	rs806321	0.72	rs2580184	ENSG00000237152.3	DLEU7-AS1	-3.64	0.000302	0.0346	-0.21	-0.16	Multiple sclerosis;	chr13:50218455	chr13:50807856~50849905:+
LUAD	cis	rs1879248	0.5	rs7616419	ENSG00000242808.6	SOX2-OT	3.64	0.000302	0.0346	0.18	0.16	Schizophrenia;	chr3:181007067	chr3:180989770~181836880:+
LUAD	cis	rs8035452	0.964	rs7182865	ENSG00000259240.1	RP11-108K3.1	-3.64	0.000302	0.0346	-0.19	-0.16	Alzheimer's disease (late onset);	chr15:50745095	chr15:51037488~51293912:+
LUAD	cis	rs950881	1	rs950881	ENSG00000234389.1	AC007278.3	3.64	0.000302	0.0346	0.2	0.16	Allergy;	chr2:102316052	chr2:102438713~102440475:+
LUAD	cis	rs4268898	0.662	rs35624938	ENSG00000242628.4	AC009228.1	3.64	0.000303	0.0347	0.24	0.16	Asthma;	chr2:24353782	chr2:24214381~24221516:+
LUAD	cis	rs6738440	0.675	rs35507444	ENSG00000234624.2	AC016894.1	3.64	0.000303	0.0347	0.22	0.16	F-cell distribution;	chr2:60454619	chr2:61416887~61417197:-
LUAD	cis	rs34198350	0.639	rs6714441	ENSG00000233845.1	AC093732.1	-3.64	0.000303	0.0347	-0.24	-0.16	QT interval in Tripanosoma cruzi seropositivity;	chr2:47876905	chr2:47035279~47040524:-
LUAD	cis	rs7772486	0.622	rs1292333	ENSG00000235652.6	RP11-545I5.3	-3.64	0.000303	0.0347	-0.16	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145661208	chr6:145799409~145886585:+
LUAD	cis	rs2281558	0.917	rs3787080	ENSG00000125804.12	FAM182A	-3.64	0.000303	0.0347	-0.23	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25251968	chr20:26054655~26086917:+
LUAD	cis	rs1355223	0.623	rs286878	ENSG00000271369.1	RP11-350D17.3	-3.64	0.000303	0.0347	-0.2	-0.16	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34673309	chr11:34709600~34710161:+
LUAD	cis	rs11976180	1	rs2961134	ENSG00000273234.1	OR2A13P	-3.64	0.000303	0.0347	-0.2	-0.16	Obesity-related traits;	chr7:144073969	chr7:144142009~144142938:+
LUAD	cis	rs11971779	0.793	rs9632774	ENSG00000273391.1	RP11-634H22.1	3.64	0.000303	0.0347	0.18	0.16	Diisocyanate-induced asthma;	chr7:139452816	chr7:139359032~139359566:-
LUAD	cis	rs7208859	0.673	rs28588622	ENSG00000265443.1	CTD-2349P21.6	-3.64	0.000303	0.0347	-0.27	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30918681	chr17:30726305~30727564:-
LUAD	cis	rs10908458	0.808	rs10908456	ENSG00000160766.13	GBAP1	3.64	0.000303	0.0347	0.17	0.16	Liver enzyme levels (gamma-glutamyl transferase);	chr1:155113672	chr1:155213821~155227422:-
LUAD	cis	rs7615952	0.599	rs12485717	ENSG00000250012.1	RP11-124N2.1	3.64	0.000303	0.0347	0.23	0.16	Blood pressure (smoking interaction);	chr3:125988232	chr3:126084220~126095349:+
LUAD	cis	rs17189298	0.904	rs13025848	ENSG00000231013.1	AC013275.2	3.64	0.000303	0.0347	0.16	0.16	Cerebrospinal T-tau levels;	chr2:119080314	chr2:119476448~119487346:+
LUAD	cis	rs17189298	0.967	rs12993491	ENSG00000231013.1	AC013275.2	3.64	0.000303	0.0347	0.16	0.16	Cerebrospinal T-tau levels;	chr2:119080361	chr2:119476448~119487346:+
LUAD	cis	rs13113518	0.934	rs10866425	ENSG00000223305.1	RN7SKP30	3.64	0.000303	0.0347	0.19	0.16	Height;	chr4:55582068	chr4:55540502~55540835:-
LUAD	cis	rs3213758	0.588	rs10521295	ENSG00000261630.1	RP11-357N13.3	-3.64	0.000303	0.0347	-0.27	-0.16	Vitiligo (non-segmental);	chr16:53529064	chr16:53981229~53981912:-
LUAD	cis	rs838147	0.76	rs412712	ENSG00000232871.7	SEC1P	-3.64	0.000303	0.0347	-0.18	-0.16	Dietary macronutrient intake;	chr19:48731042	chr19:48638071~48682245:+
LUAD	cis	rs13113518	1	rs13116194	ENSG00000273257.1	RP11-177J6.1	3.64	0.000303	0.0347	0.18	0.16	Height;	chr4:55531150	chr4:55387949~55388271:+
LUAD	cis	rs13113518	1	rs13117836	ENSG00000273257.1	RP11-177J6.1	3.64	0.000303	0.0347	0.18	0.16	Height;	chr4:55531218	chr4:55387949~55388271:+
LUAD	cis	rs773506	0.655	rs4744037	ENSG00000237422.1	RP11-305L7.3	3.64	0.000303	0.0347	0.21	0.16	Type 2 diabetes nephropathy;	chr9:91170206	chr9:91119138~91163087:-
LUAD	cis	rs42490	0.625	rs438485	ENSG00000251136.7	RP11-37B2.1	-3.64	0.000303	0.0347	-0.17	-0.16	Leprosy;	chr8:89831190	chr8:89609409~89757727:-
LUAD	cis	rs7819412	0.595	rs4841500	ENSG00000255046.1	RP11-297N6.4	3.64	0.000303	0.0347	0.2	0.16	Triglycerides;	chr8:11130765	chr8:11797928~11802568:-
LUAD	cis	rs8031584	0.736	rs11635775	ENSG00000260128.5	ULK4P2	-3.64	0.000303	0.0347	-0.22	-0.16	Huntington's disease progression;	chr15:30868437	chr15:30572738~30600647:+
LUAD	cis	rs8058578	1	rs3747481	ENSG00000232748.3	RP11-196G11.6	-3.64	0.000303	0.0347	-0.21	-0.16	Multiple myeloma;	chr16:30655046	chr16:31056460~31062803:+
LUAD	cis	rs7142881	0.815	rs7154830	ENSG00000258525.1	RP11-829H16.3	-3.64	0.000303	0.0347	-0.19	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31694791	chr14:30876179~30889808:-
LUAD	cis	rs7615916	0.955	rs6785890	ENSG00000225026.1	AC091492.2	-3.64	0.000303	0.0347	-0.22	-0.16	Eosinophil percentage of white cells;	chr3:12294317	chr3:12328003~12328274:+
LUAD	cis	rs6121246	0.567	rs6058187	ENSG00000230613.1	HM13-AS1	3.64	0.000303	0.0347	0.25	0.16	Mean corpuscular hemoglobin;	chr20:31603120	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.567	rs6060249	ENSG00000230613.1	HM13-AS1	3.64	0.000303	0.0347	0.25	0.16	Mean corpuscular hemoglobin;	chr20:31603141	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.528	rs6060252	ENSG00000230613.1	HM13-AS1	3.64	0.000303	0.0347	0.25	0.16	Mean corpuscular hemoglobin;	chr20:31603281	chr20:31567707~31573263:-
LUAD	cis	rs683250	0.63	rs11233593	ENSG00000246067.6	RAB30-AS1	-3.64	0.000303	0.0347	-0.18	-0.16	Subcortical brain region volumes;	chr11:83393687	chr11:83072066~83106719:+
LUAD	cis	rs683250	0.63	rs11233594	ENSG00000246067.6	RAB30-AS1	-3.64	0.000303	0.0347	-0.18	-0.16	Subcortical brain region volumes;	chr11:83393935	chr11:83072066~83106719:+
LUAD	cis	rs683250	0.63	rs4944438	ENSG00000246067.6	RAB30-AS1	-3.64	0.000303	0.0347	-0.18	-0.16	Subcortical brain region volumes;	chr11:83397981	chr11:83072066~83106719:+
LUAD	cis	rs683250	0.54	rs56284741	ENSG00000246067.6	RAB30-AS1	-3.64	0.000303	0.0347	-0.18	-0.16	Subcortical brain region volumes;	chr11:83399791	chr11:83072066~83106719:+
LUAD	cis	rs683250	0.63	rs11233603	ENSG00000246067.6	RAB30-AS1	-3.64	0.000303	0.0347	-0.18	-0.16	Subcortical brain region volumes;	chr11:83401953	chr11:83072066~83106719:+
LUAD	cis	rs683250	0.599	rs35446705	ENSG00000246067.6	RAB30-AS1	-3.64	0.000303	0.0347	-0.18	-0.16	Subcortical brain region volumes;	chr11:83402414	chr11:83072066~83106719:+
LUAD	cis	rs683250	0.63	rs2226416	ENSG00000246067.6	RAB30-AS1	-3.64	0.000303	0.0347	-0.18	-0.16	Subcortical brain region volumes;	chr11:83405000	chr11:83072066~83106719:+
LUAD	cis	rs728616	0.867	rs1923534	ENSG00000234382.2	RP11-40F6.1	-3.64	0.000303	0.0347	-0.39	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79950729	chr10:80233664~80245367:+
LUAD	cis	rs728616	0.557	rs17107449	ENSG00000234382.2	RP11-40F6.1	-3.64	0.000303	0.0347	-0.39	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955940	chr10:80233664~80245367:+
LUAD	cis	rs728616	0.867	rs76239460	ENSG00000234382.2	RP11-40F6.1	-3.64	0.000303	0.0347	-0.39	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79963471	chr10:80233664~80245367:+
LUAD	cis	rs9810888	0.738	rs2680656	ENSG00000271916.1	RP11-884K10.6	-3.64	0.000303	0.0347	-0.17	-0.16	Hypertension;Diastolic blood pressure;Systolic blood pressure;	chr3:53645552	chr3:53797764~53798019:-
LUAD	cis	rs1065852	0.526	rs7290907	ENSG00000226450.2	CYP2D8P	3.64	0.000303	0.0347	0.14	0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41994205	chr22:42149886~42155001:-
LUAD	cis	rs1065852	0.526	rs7290655	ENSG00000226450.2	CYP2D8P	3.64	0.000303	0.0347	0.14	0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:41994221	chr22:42149886~42155001:-
LUAD	cis	rs950027	0.549	rs2899375	ENSG00000259479.5	SORD2P	-3.64	0.000303	0.0347	-0.2	-0.16	Response to fenofibrate (adiponectin levels);	chr15:45306137	chr15:44826371~44884694:-
LUAD	cis	rs6496932	0.909	rs74024818	ENSG00000259630.2	CTD-2262B20.1	3.64	0.000303	0.0347	0.23	0.16	Central corneal thickness;Corneal structure;	chr15:85339299	chr15:85415228~85415633:+
LUAD	cis	rs6496932	0.563	rs2344083	ENSG00000202081.1	RNU6-1280P	-3.64	0.000303	0.0347	-0.19	-0.16	Central corneal thickness;Corneal structure;	chr15:85354201	chr15:85651522~85651628:-
LUAD	cis	rs10129255	0.913	rs28861466	ENSG00000253209.1	IGHV3-65	3.64	0.000303	0.0347	0.14	0.16	Kawasaki disease;	chr14:106718572	chr14:106666092~106666532:-
LUAD	cis	rs7660883	0.897	rs342467	ENSG00000251411.1	RP11-397E7.4	-3.64	0.000303	0.0347	-0.18	-0.16	HDL cholesterol levels;	chr4:87131067	chr4:86913266~86914817:-
LUAD	cis	rs13068223	0.74	rs344003	ENSG00000243926.1	TIPARP-AS1	-3.64	0.000303	0.0347	-0.17	-0.16	Age-related hearing impairment (SNP x SNP interaction);	chr3:156739931	chr3:156671862~156674378:-
LUAD	cis	rs984222	0.648	rs6428801	ENSG00000226172.2	RP4-712E4.1	-3.64	0.000303	0.0347	-0.18	-0.16	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119145867	chr1:119000344~119001392:-
LUAD	cis	rs72759215	1	rs72759215	ENSG00000215032.2	GNL3LP1	3.64	0.000303	0.0347	0.2	0.16	Intelligence (multi-trait analysis);	chr5:61056756	chr5:60891935~60893577:-
LUAD	cis	rs875971	0.545	rs66594357	ENSG00000224316.1	RP11-479O9.2	3.64	0.000304	0.0347	0.19	0.16	Aortic root size;	chr7:66327797	chr7:65773620~65802067:+
LUAD	cis	rs7824557	0.872	rs2572431	ENSG00000255046.1	RP11-297N6.4	3.64	0.000304	0.0348	0.2	0.16	Retinal vascular caliber;	chr8:11247568	chr8:11797928~11802568:-
LUAD	cis	rs3764400	0.567	rs2229369	ENSG00000278765.1	RP5-890E16.5	3.64	0.000304	0.0348	0.3	0.16	Body mass index;	chr17:48058771	chr17:48066704~48067293:-
LUAD	cis	rs755249	1	rs76841360	ENSG00000182109.6	RP11-69E11.4	3.64	0.000304	0.0348	0.2	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39594353	chr1:39522280~39546187:-
LUAD	cis	rs11076805	0.51	rs365010	ENSG00000275056.1	RP11-127I20.8	3.64	0.000304	0.0348	0.16	0.16	Breast cancer (estrogen-receptor negative);Breast cancer;	chr16:4102189	chr16:4839244~4840334:-
LUAD	cis	rs1866758	0.726	rs12563071	ENSG00000234917.2	RP5-994D16.3	3.64	0.000304	0.0348	0.19	0.16	Intraocular pressure;	chr1:41807982	chr1:42678735~42681659:+
LUAD	cis	rs1577917	0.681	rs4348284	ENSG00000220563.1	PKMP3	-3.64	0.000304	0.0348	-0.15	-0.16	Response to antipsychotic treatment;	chr6:85640676	chr6:85659892~85660606:-
LUAD	cis	rs3738443	1	rs74152976	ENSG00000215795.2	RP11-488L18.3	-3.64	0.000304	0.0348	-0.25	-0.16	Alcohol dependence;	chr1:247183504	chr1:247183813~247185482:-
LUAD	cis	rs4811196	0.536	rs238300	ENSG00000226144.2	RPS27AP3	3.64	0.000304	0.0348	0.16	0.16	Bone mineral density;	chr20:37776305	chr20:37049254~37049707:+
LUAD	cis	rs875971	0.522	rs10807697	ENSG00000222364.1	RNU6-96P	-3.64	0.000304	0.0348	-0.18	-0.16	Aortic root size;	chr7:65951183	chr7:66395191~66395286:+
LUAD	cis	rs379123	0.528	rs225215	ENSG00000266777.1	SH3GL1P1	3.64	0.000304	0.0348	0.12	0.16	Local histogram emphysema pattern;	chr17:32569892	chr17:32039974~32042828:+
LUAD	cis	rs9311474	0.581	rs13621	ENSG00000243224.1	RP5-1157M23.2	-3.64	0.000304	0.0348	-0.16	-0.16	Electroencephalogram traits;	chr3:52524117	chr3:52239258~52241097:+
LUAD	cis	rs2288884	0.559	rs12611043	ENSG00000269959.1	SPACA6P-AS	-3.64	0.000304	0.0348	-0.17	-0.16	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52084372	chr19:51685363~51693456:-
LUAD	cis	rs7017914	0.967	rs17689955	ENSG00000246366.5	RP11-382J12.1	3.64	0.000304	0.0348	0.15	0.16	Bone mineral density;	chr8:70936629	chr8:70608577~70663279:+
LUAD	cis	rs9467773	0.967	rs1056347	ENSG00000241549.7	GUSBP2	3.64	0.000304	0.0348	0.18	0.16	Intelligence (multi-trait analysis);	chr6:26527296	chr6:26871484~26956554:-
LUAD	cis	rs4716602	0.596	rs10265909	ENSG00000235029.1	MNX1-AS2	-3.64	0.000304	0.0348	-0.2	-0.16	Anti-saccade response;	chr7:156365401	chr7:157006307~157007132:+
LUAD	cis	rs4716602	0.596	rs12386632	ENSG00000235029.1	MNX1-AS2	-3.64	0.000304	0.0348	-0.2	-0.16	Anti-saccade response;	chr7:156365527	chr7:157006307~157007132:+
LUAD	cis	rs4716602	0.609	rs12386633	ENSG00000235029.1	MNX1-AS2	-3.64	0.000304	0.0348	-0.2	-0.16	Anti-saccade response;	chr7:156365538	chr7:157006307~157007132:+
LUAD	cis	rs4716602	0.596	rs12386682	ENSG00000235029.1	MNX1-AS2	-3.64	0.000304	0.0348	-0.2	-0.16	Anti-saccade response;	chr7:156365571	chr7:157006307~157007132:+
LUAD	cis	rs4716602	0.596	rs12386634	ENSG00000235029.1	MNX1-AS2	-3.64	0.000304	0.0348	-0.2	-0.16	Anti-saccade response;	chr7:156365679	chr7:157006307~157007132:+
LUAD	cis	rs2712475	0.585	rs80081532	ENSG00000241218.1	RP11-446H18.1	3.64	0.000304	0.0348	0.25	0.16	Colonoscopy-negative controls vs population controls;	chr3:106481137	chr3:107327830~107329197:-
LUAD	cis	rs12446632	0.771	rs72769573	ENSG00000261195.1	CTD-2380F24.1	-3.64	0.000304	0.0348	-0.26	-0.16	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Menarche (age at onset);Obesity;Childhood body mass index;Waist circumference;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr16:19830554	chr16:19761172~19766099:-
LUAD	cis	rs12446632	0.713	rs11641786	ENSG00000261195.1	CTD-2380F24.1	-3.64	0.000304	0.0348	-0.26	-0.16	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Menarche (age at onset);Obesity;Childhood body mass index;Waist circumference;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr16:19833543	chr16:19761172~19766099:-
LUAD	cis	rs8031584	0.958	rs3512	ENSG00000259845.1	HERC2P10	3.64	0.000304	0.0348	0.19	0.16	Huntington's disease progression;	chr15:30942802	chr15:30815271~30844153:+
LUAD	cis	rs17620991	1	rs17620991	ENSG00000259826.1	RP11-467D6.1	-3.64	0.000304	0.0348	-0.21	-0.16	Alcohol dependence;	chr7:40796922	chr7:39947522~39949755:-
LUAD	cis	rs4268898	0.527	rs72789910	ENSG00000242628.4	AC009228.1	3.64	0.000304	0.0348	0.24	0.16	Asthma;	chr2:24165740	chr2:24214381~24221516:+
LUAD	cis	rs820077	0.668	rs820063	ENSG00000232909.1	RP3-510O8.4	-3.64	0.000304	0.0348	-0.24	-0.16	Systemic lupus erythematosus;	chr6:35074624	chr6:35733867~35736947:-
LUAD	cis	rs820077	0.736	rs820062	ENSG00000232909.1	RP3-510O8.4	-3.64	0.000304	0.0348	-0.24	-0.16	Systemic lupus erythematosus;	chr6:35075282	chr6:35733867~35736947:-
LUAD	cis	rs2242116	0.796	rs7645278	ENSG00000271161.1	BOLA2P2	3.64	0.000304	0.0348	0.16	0.16	Birth weight;	chr3:46932610	chr3:47499841~47500407:+
LUAD	cis	rs10129255	0.872	rs1858683	ENSG00000211967.3	IGHV3-53	-3.64	0.000304	0.0348	-0.13	-0.16	Kawasaki disease;	chr14:106670217	chr14:106592676~106593347:-
LUAD	cis	rs2904524	1	rs4761195	ENSG00000257815.4	RP11-611E13.2	-3.64	0.000304	0.0348	-0.24	-0.16	Amyotrophic lateral sclerosis (age of onset);	chr12:70306967	chr12:69904033~70243360:-
LUAD	cis	rs2904524	1	rs7487329	ENSG00000257815.4	RP11-611E13.2	-3.64	0.000304	0.0348	-0.24	-0.16	Amyotrophic lateral sclerosis (age of onset);	chr12:70310025	chr12:69904033~70243360:-
LUAD	cis	rs3087591	0.6	rs2905808	ENSG00000263531.1	RP13-753N3.1	-3.64	0.000304	0.0348	-0.28	-0.16	Hip circumference;	chr17:31166975	chr17:30863921~30864940:-
LUAD	cis	rs4795519	1	rs2061896	ENSG00000266313.1	RP11-173M1.4	3.64	0.000304	0.0348	0.2	0.16	Chronic myeloid leukemia;	chr17:27081804	chr17:27333256~27348491:+
LUAD	cis	rs4578769	0.55	rs4635434	ENSG00000266850.1	RP11-370A5.1	-3.64	0.000304	0.0348	-0.21	-0.16	Eosinophil percentage of white cells;	chr18:22996032	chr18:22723491~22907721:-
LUAD	cis	rs4578769	0.55	rs4471804	ENSG00000266850.1	RP11-370A5.1	-3.64	0.000304	0.0348	-0.21	-0.16	Eosinophil percentage of white cells;	chr18:22996218	chr18:22723491~22907721:-
LUAD	cis	rs9517320	1	rs912337	ENSG00000231194.1	FARP1-AS1	-3.64	0.000304	0.0348	-0.18	-0.16	Longevity;	chr13:98489018	chr13:98435405~98435840:-
LUAD	cis	rs62103177	0.733	rs62103232	ENSG00000261126.6	RP11-795F19.1	3.64	0.000304	0.0348	0.24	0.16	Opioid sensitivity;	chr18:79875553	chr18:80046900~80095482:+
LUAD	cis	rs7572733	0.935	rs771015	ENSG00000222017.1	AC011997.1	3.64	0.000304	0.0348	0.21	0.16	Dermatomyositis;	chr2:197803570	chr2:197693106~197774823:+
LUAD	cis	rs2625529	0.73	rs12912771	ENSG00000260173.1	RP11-2I17.4	-3.64	0.000304	0.0348	-0.19	-0.16	Red blood cell count;	chr15:71870587	chr15:72140504~72155459:-
LUAD	cis	rs897984	0.609	rs4889609	ENSG00000232748.3	RP11-196G11.6	-3.64	0.000304	0.0348	-0.2	-0.16	Dementia with Lewy bodies;	chr16:31015106	chr16:31056460~31062803:+
LUAD	cis	rs1426063	0.614	rs17000262	ENSG00000260265.1	RP11-44F21.5	3.64	0.000305	0.0348	0.37	0.16	QT interval;	chr4:75108836	chr4:75081702~75084717:-
LUAD	cis	rs3741404	0.56	rs2875748	ENSG00000256789.1	RP11-697H9.2	3.64	0.000305	0.0348	0.18	0.16	Platelet count;	chr11:64148065	chr11:63637677~63658962:+
LUAD	cis	rs13113518	1	rs55699500	ENSG00000249700.7	SRD5A3-AS1	3.64	0.000305	0.0348	0.17	0.16	Height;	chr4:55540912	chr4:55363971~55395847:-
LUAD	cis	rs13113518	1	rs56362210	ENSG00000249700.7	SRD5A3-AS1	3.64	0.000305	0.0348	0.17	0.16	Height;	chr4:55540972	chr4:55363971~55395847:-
LUAD	cis	rs137603	0.623	rs137657	ENSG00000230149.2	RP3-508I15.19	-3.64	0.000305	0.0348	-0.13	-0.16	Primary biliary cholangitis;	chr22:39337237	chr22:38734730~38738990:+
LUAD	cis	rs7210990	0.612	rs2286795	ENSG00000276855.1	CTD-3157E16.2	-3.64	0.000305	0.0348	-0.2	-0.16	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr17:15980495	chr17:15789016~15789705:+
LUAD	cis	rs6687821	0.515	rs4656133	ENSG00000267272.4	LINC01140	3.64	0.000305	0.0348	0.19	0.16	Yeast infection;	chr1:87000140	chr1:87129765~87169198:+
LUAD	cis	rs7107174	0.901	rs11237487	ENSG00000251323.2	RP11-452H21.4	3.64	0.000305	0.0348	0.22	0.16	Testicular germ cell tumor;	chr11:78415708	chr11:78423982~78429836:-
LUAD	cis	rs7560272	0.538	rs4852977	ENSG00000163016.8	ALMS1P	-3.64	0.000305	0.0349	-0.18	-0.16	Schizophrenia;	chr2:73711168	chr2:73644919~73685576:+
LUAD	cis	rs11672691	0.871	rs2191139	ENSG00000267107.5	PCAT19	3.64	0.000305	0.0349	0.2	0.16	Prostate cancer;	chr19:41495302	chr19:41454169~41500649:-
LUAD	cis	rs9308731	0.591	rs6542350	ENSG00000227992.1	AC108463.2	-3.64	0.000305	0.0349	-0.2	-0.16	Chronic lymphocytic leukemia;	chr2:111187163	chr2:111203964~111206215:-
LUAD	cis	rs761746	0.577	rs131245	ENSG00000236132.1	CTA-440B3.1	-3.64	0.000305	0.0349	-0.22	-0.16	Intelligence;	chr22:31730777	chr22:31816379~31817491:-
LUAD	cis	rs6490294	0.747	rs659964	ENSG00000234608.6	MAPKAPK5-AS1	3.64	0.000305	0.0349	0.19	0.16	Mean platelet volume;	chr12:111692395	chr12:111839764~111842902:-
LUAD	cis	rs7615952	0.641	rs12487875	ENSG00000241288.6	RP11-379B18.5	-3.64	0.000305	0.0349	-0.21	-0.16	Blood pressure (smoking interaction);	chr3:126068381	chr3:125827238~125916384:-
LUAD	cis	rs7949566	0.652	rs7927916	ENSG00000254671.2	STT3A-AS1	-3.64	0.000305	0.0349	-0.19	-0.16	Platelet distribution width;Mean platelet volume;	chr11:126422367	chr11:125570284~125592568:-
LUAD	cis	rs2239547	0.618	rs4687663	ENSG00000243224.1	RP5-1157M23.2	-3.64	0.000305	0.0349	-0.19	-0.16	Schizophrenia;	chr3:52836602	chr3:52239258~52241097:+
LUAD	cis	rs6951245	0.935	rs79067319	ENSG00000199023.2	MIR339	-3.64	0.000305	0.0349	-0.29	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1025912	chr7:1022935~1023045:-
LUAD	cis	rs6832769	0.961	rs6817663	ENSG00000272969.1	RP11-528I4.2	-3.64	0.000305	0.0349	-0.17	-0.16	Personality dimensions;	chr4:55581048	chr4:55547112~55547889:+
LUAD	cis	rs12936587	0.536	rs8075153	ENSG00000223979.2	SMCR2	3.64	0.000305	0.0349	0.19	0.16	Coronary heart disease;Coronary artery disease or large artery stroke;Coronary artery disease;Hip circumference;	chr17:17719352	chr17:17674026~17677688:-
LUAD	cis	rs910316	0.712	rs175037	ENSG00000279594.1	RP11-950C14.10	-3.64	0.000305	0.0349	-0.19	-0.16	Height;	chr14:74998335	chr14:75011269~75012851:-
LUAD	cis	rs12216545	0.695	rs10276888	ENSG00000241134.3	BET1P1	-3.64	0.000305	0.0349	-0.17	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150533238	chr7:150749736~150750094:+
LUAD	cis	rs35740288	0.77	rs11630286	ENSG00000259407.1	RP11-158M2.3	-3.64	0.000305	0.0349	-0.16	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85659298	chr15:85744109~85750281:-
LUAD	cis	rs9309473	0.95	rs73947808	ENSG00000230002.2	ALMS1-IT1	3.64	0.000305	0.0349	0.21	0.16	Metabolite levels;	chr2:73494123	chr2:73456764~73459484:+
LUAD	cis	rs4664293	0.867	rs3771719	ENSG00000227055.1	AC009961.5	-3.64	0.000305	0.0349	-0.16	-0.16	Monocyte percentage of white cells;	chr2:159774453	chr2:159812234~159814009:-
LUAD	cis	rs11673344	0.704	rs1644710	ENSG00000267309.1	CTD-2630F21.1	-3.64	0.000305	0.0349	-0.2	-0.16	Obesity-related traits;	chr19:36926160	chr19:36489649~36491040:+
LUAD	cis	rs8014252	1	rs73291944	ENSG00000274818.1	RP1-292L20.3	3.64	0.000305	0.0349	0.27	0.16	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70438599	chr14:70906657~70907111:-
LUAD	cis	rs7017914	0.905	rs4571761	ENSG00000246366.5	RP11-382J12.1	-3.64	0.000305	0.0349	-0.15	-0.16	Bone mineral density;	chr8:71044938	chr8:70608577~70663279:+
LUAD	cis	rs9457247	1	rs364283	ENSG00000227598.1	RP1-167A14.2	-3.64	0.000305	0.0349	-0.18	-0.16	Crohn's disease;	chr6:166970262	chr6:166969626~166999065:-
LUAD	cis	rs1198872	0.892	rs1198865	ENSG00000272275.1	RP11-791G15.2	-3.64	0.000305	0.0349	-0.2	-0.16	Cardiac Troponin-T levels;	chr2:10760936	chr2:10767875~10770058:-
LUAD	cis	rs6502050	0.805	rs9898507	ENSG00000275966.1	RP11-1055B8.9	-3.64	0.000305	0.0349	-0.17	-0.16	Life satisfaction;	chr17:82161752	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.769	rs9904237	ENSG00000275966.1	RP11-1055B8.9	-3.64	0.000305	0.0349	-0.17	-0.16	Life satisfaction;	chr17:82161788	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.769	rs9898542	ENSG00000275966.1	RP11-1055B8.9	-3.64	0.000305	0.0349	-0.17	-0.16	Life satisfaction;	chr17:82161806	chr17:81345476~81345966:-
LUAD	cis	rs797680	0.856	rs6682670	ENSG00000223745.6	RP4-717I23.3	3.64	0.000305	0.0349	0.13	0.16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93184175	chr1:93262186~93346025:-
LUAD	cis	rs797680	0.754	rs12118230	ENSG00000223745.6	RP4-717I23.3	3.64	0.000305	0.0349	0.13	0.16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93185904	chr1:93262186~93346025:-
LUAD	cis	rs12822507	0.732	rs10492241	ENSG00000275963.1	RP11-180M15.6	3.64	0.000305	0.0349	0.19	0.16	Systemic lupus erythematosus;	chr12:12597575	chr12:12648939~12649713:+
LUAD	cis	rs6088590	1	rs6119512	ENSG00000275784.1	RP5-1125A11.6	-3.64	0.000305	0.0349	-0.18	-0.16	Coronary artery disease;	chr20:34719100	chr20:33989480~33991818:-
LUAD	cis	rs877356	0.588	rs12719478	ENSG00000250378.1	RP11-119J18.1	-3.64	0.000305	0.0349	-0.32	-0.16	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (dichotomous);	chr5:135820218	chr5:135812667~135826582:+
LUAD	cis	rs7551222	0.681	rs2045623	ENSG00000240219.1	RP11-430C7.5	3.64	0.000305	0.0349	0.17	0.16	Schizophrenia;	chr1:204528285	chr1:204626775~204629712:+
LUAD	cis	rs7551222	0.716	rs4245738	ENSG00000240219.1	RP11-430C7.5	3.64	0.000305	0.0349	0.17	0.16	Schizophrenia;	chr1:204536979	chr1:204626775~204629712:+
LUAD	cis	rs2625529	0.73	rs2957725	ENSG00000260173.1	RP11-2I17.4	3.64	0.000305	0.0349	0.2	0.16	Red blood cell count;	chr15:71955864	chr15:72140504~72155459:-
LUAD	cis	rs1322639	0.614	rs4708414	ENSG00000226445.1	XXyac-YX65C7_A.2	-3.64	0.000305	0.0349	-0.19	-0.16	Pulse pressure;	chr6:169174049	chr6:169213254~169239565:+
LUAD	cis	rs4374383	0.962	rs4524124	ENSG00000207383.1	Y_RNA	-3.64	0.000305	0.0349	-0.2	-0.16	Hepatitis C induced liver fibrosis;	chr2:112014626	chr2:112579484~112579584:-
LUAD	cis	rs11853189	0.938	rs11854322	ENSG00000259562.2	RP11-762H8.2	3.64	0.000306	0.0349	0.18	0.16	Red cell distribution width;	chr15:78298072	chr15:78290527~78291221:-
LUAD	cis	rs1150668	0.796	rs213236	ENSG00000176933.5	TOB2P1	-3.64	0.000306	0.0349	-0.18	-0.16	Pubertal anthropometrics;	chr6:28356620	chr6:28217643~28218634:-
LUAD	cis	rs7142881	0.815	rs35157202	ENSG00000258525.1	RP11-829H16.3	-3.64	0.000306	0.0349	-0.18	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31699712	chr14:30876179~30889808:-
LUAD	cis	rs3749855	0.679	rs13203422	ENSG00000220920.1	RP3-525L6.2	-3.64	0.000306	0.035	-0.34	-0.16	Glucose homeostasis traits;	chr6:17260456	chr6:17953572~17953930:+
LUAD	cis	rs7208859	0.673	rs999796	ENSG00000263603.1	CTD-2349P21.5	-3.64	0.000306	0.035	-0.25	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832386	chr17:30729469~30731202:+
LUAD	cis	rs4938303	0.633	rs528806	ENSG00000280143.1	AP000892.6	-3.64	0.000306	0.035	-0.23	-0.16	Triglycerides;	chr11:116659197	chr11:117204967~117210292:+
LUAD	cis	rs911555	0.755	rs7148567	ENSG00000244691.1	RPL10AP1	-3.64	0.000306	0.035	-0.21	-0.16	Intelligence (multi-trait analysis);	chr14:103415897	chr14:103412119~103412761:-
LUAD	cis	rs73198271	0.562	rs17698256	ENSG00000233609.3	RP11-62H7.2	-3.64	0.000306	0.035	-0.16	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8802103	chr8:8961200~8979025:+
LUAD	cis	rs2506028	0.507	rs11239813	ENSG00000234944.1	RP11-124O11.1	3.64	0.000306	0.035	0.21	0.16	Blood protein levels;	chr10:42890594	chr10:42871521~42874060:+
LUAD	cis	rs467650	0.549	rs162676	ENSG00000248489.1	CTD-2007H13.3	-3.64	0.000306	0.035	-0.17	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:98655799	chr5:98929171~98995013:+
LUAD	cis	rs832187	0.665	rs7627690	ENSG00000280620.1	SCAANT1	3.64	0.000306	0.035	0.18	0.16	Schizophrenia;	chr3:63914801	chr3:63911518~63911772:-
LUAD	cis	rs17653445	0.929	rs72789805	ENSG00000151963.4	RP11-775A3.1	3.64	0.000306	0.035	0.28	0.16	Hirschsprung disease;	chr10:37554043	chr10:37883594~37884109:+
LUAD	cis	rs2625529	0.73	rs1481860	ENSG00000260173.1	RP11-2I17.4	3.64	0.000306	0.035	0.21	0.16	Red blood cell count;	chr15:71949516	chr15:72140504~72155459:-
LUAD	cis	rs12236219	0.579	rs10993178	ENSG00000232063.1	RP11-307E17.8	3.64	0.000306	0.035	0.38	0.16	Body mass index;	chr9:94366722	chr9:94332476~94360948:+
LUAD	cis	rs295490	0.688	rs184156	ENSG00000272656.1	RP11-219D15.3	-3.64	0.000306	0.035	-0.24	-0.16	PR interval in Tripanosoma cruzi seropositivity;	chr3:139519526	chr3:139349024~139349371:-
LUAD	cis	rs2239557	0.539	rs7161037	ENSG00000259065.1	RP5-1021I20.1	-3.64	0.000306	0.035	-0.22	-0.16	Common traits (Other);	chr14:73966426	chr14:73787360~73803270:+
LUAD	cis	rs7142881	0.815	rs11626320	ENSG00000258525.1	RP11-829H16.3	-3.64	0.000306	0.035	-0.18	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31570255	chr14:30876179~30889808:-
LUAD	cis	rs7003550	1	rs7003550	ENSG00000253433.1	NCRNA00250	3.64	0.000306	0.035	0.22	0.16	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr8:134838655	chr8:134838069~134842637:+
LUAD	cis	rs11955398	0.502	rs34610	ENSG00000272308.1	RP11-231G3.1	-3.64	0.000306	0.035	-0.19	-0.16	Intelligence (multi-trait analysis);	chr5:61183854	chr5:60866457~60866935:-
LUAD	cis	rs3126085	0.877	rs4415568	ENSG00000237975.5	FLG-AS1	-3.64	0.000306	0.035	-0.25	-0.16	Atopic dermatitis;	chr1:152208731	chr1:152168125~152445456:+
LUAD	cis	rs73108077	1	rs75774213	ENSG00000281376.1	ABALON	-3.64	0.000306	0.035	-0.28	-0.16	Red blood cell density in sickle cell anemia;	chr20:31462439	chr20:31721507~31723409:+
LUAD	cis	rs7429990	0.965	rs777015	ENSG00000228638.1	FCF1P2	-3.64	0.000306	0.035	-0.19	-0.16	Educational attainment (years of education);	chr3:47895582	chr3:48290793~48291375:-
LUAD	cis	rs5015933	0.788	rs2945039	ENSG00000232630.1	PRPS1P2	-3.64	0.000306	0.035	-0.15	-0.16	Body mass index;	chr9:125281525	chr9:125150653~125151589:+
LUAD	cis	rs686320	0.666	rs11605125	ENSG00000254614.2	AP003068.23	3.64	0.000306	0.035	0.34	0.16	Hip circumference adjusted for BMI;	chr11:65443548	chr11:65177606~65181834:-
LUAD	cis	rs11893307	0.537	rs1558473	ENSG00000235852.1	AC005540.3	3.64	0.000306	0.035	0.2	0.16	Mean platelet volume;	chr2:190639338	chr2:190880797~190882059:-
LUAD	cis	rs7017914	0.846	rs6472561	ENSG00000246366.5	RP11-382J12.1	-3.64	0.000306	0.035	-0.15	-0.16	Bone mineral density;	chr8:71042948	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.905	rs4074909	ENSG00000246366.5	RP11-382J12.1	-3.64	0.000306	0.035	-0.15	-0.16	Bone mineral density;	chr8:71043592	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.905	rs4078067	ENSG00000246366.5	RP11-382J12.1	-3.64	0.000306	0.035	-0.15	-0.16	Bone mineral density;	chr8:71044236	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.905	rs4504667	ENSG00000246366.5	RP11-382J12.1	-3.64	0.000306	0.035	-0.15	-0.16	Bone mineral density;	chr8:71044557	chr8:70608577~70663279:+
LUAD	cis	rs4474465	0.85	rs4579956	ENSG00000251323.2	RP11-452H21.4	-3.64	0.000306	0.035	-0.21	-0.16	Alzheimer's disease (survival time);	chr11:78521399	chr11:78423982~78429836:-
LUAD	cis	rs62025270	0.632	rs55981798	ENSG00000259416.2	RP11-158M2.5	-3.64	0.000306	0.035	-0.22	-0.16	Idiopathic pulmonary fibrosis;	chr15:85600869	chr15:85754941~85756237:-
LUAD	cis	rs62025270	0.576	rs17633959	ENSG00000259416.2	RP11-158M2.5	-3.64	0.000306	0.035	-0.22	-0.16	Idiopathic pulmonary fibrosis;	chr15:85600950	chr15:85754941~85756237:-
LUAD	cis	rs17772222	0.917	rs1950806	ENSG00000258789.1	RP11-507K2.3	-3.64	0.000306	0.035	-0.23	-0.16	Coronary artery calcification;	chr14:88774412	chr14:88551597~88552493:+
LUAD	cis	rs4716602	0.596	rs4490714	ENSG00000235029.1	MNX1-AS2	-3.64	0.000306	0.035	-0.2	-0.16	Anti-saccade response;	chr7:156369816	chr7:157006307~157007132:+
LUAD	cis	rs9325144	0.624	rs7979541	ENSG00000257718.1	RP11-396F22.1	-3.64	0.000306	0.035	-0.19	-0.16	Morning vs. evening chronotype;	chr12:38735877	chr12:38906451~38909592:+
LUAD	cis	rs9325144	0.532	rs1352121	ENSG00000257718.1	RP11-396F22.1	-3.64	0.000306	0.035	-0.19	-0.16	Morning vs. evening chronotype;	chr12:38736894	chr12:38906451~38909592:+
LUAD	cis	rs6502050	0.734	rs9674631	ENSG00000275966.1	RP11-1055B8.9	-3.64	0.000306	0.035	-0.17	-0.16	Life satisfaction;	chr17:82138649	chr17:81345476~81345966:-
LUAD	cis	rs875971	0.862	rs6460290	ENSG00000273448.1	RP11-166O4.6	-3.64	0.000306	0.035	-0.16	-0.16	Aortic root size;	chr7:66344119	chr7:67333047~67334383:+
LUAD	cis	rs9309473	0.95	rs13431529	ENSG00000273245.1	RP11-434P11.2	3.64	0.000306	0.035	0.2	0.16	Metabolite levels;	chr2:73648914	chr2:73750256~73750786:-
LUAD	cis	rs1040393	0.769	rs1543314	ENSG00000225171.2	DUTP6	3.64	0.000306	0.035	0.21	0.16	Schizophrenia;	chr1:166874787	chr1:166868748~166869209:+
LUAD	cis	rs891378	1	rs1507760	ENSG00000274245.1	RP11-357P18.2	3.64	0.000306	0.035	0.2	0.16	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207336020	chr1:207372559~207373252:+
LUAD	cis	rs7119038	0.818	rs73003215	ENSG00000255239.1	AP002954.6	-3.64	0.000306	0.035	-0.24	-0.16	Sjögren's syndrome;	chr11:118778803	chr11:118688039~118690600:-
LUAD	cis	rs7560272	0.501	rs12992607	ENSG00000163016.8	ALMS1P	-3.64	0.000307	0.035	-0.17	-0.16	Schizophrenia;	chr2:73732833	chr2:73644919~73685576:+
LUAD	cis	rs9983113	0.783	rs4817974	ENSG00000205622.8	AF064858.6	3.64	0.000307	0.035	0.19	0.16	Body mass index;	chr21:38937835	chr21:38863676~38956467:-
LUAD	cis	rs12146727	0.881	rs12367198	ENSG00000247853.2	RP5-940J5.6	3.64	0.000307	0.035	0.26	0.16	Blood protein levels;	chr12:7071407	chr12:6578622~6584739:+
LUAD	cis	rs6921919	0.583	rs35560946	ENSG00000219392.1	RP1-265C24.5	-3.64	0.000307	0.035	-0.21	-0.16	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28115628~28116551:+
LUAD	cis	rs74461473	0.567	rs55852549	ENSG00000228008.1	CTD-2330K9.3	3.64	0.000307	0.035	0.28	0.16	Conotruncal heart defects (maternal effects);	chr3:50632224	chr3:49903845~49916937:+
LUAD	cis	rs9595908	0.869	rs7337687	ENSG00000281026.1	N4BP2L2-IT2	3.64	0.000307	0.035	0.1	0.16	Body mass index;	chr13:32595560	chr13:32504506~32509395:-
LUAD	cis	rs17826219	0.568	rs11658027	ENSG00000265443.1	CTD-2349P21.6	3.64	0.000307	0.035	0.26	0.16	Body mass index;	chr17:30767864	chr17:30726305~30727564:-
LUAD	cis	rs73230612	0.858	rs9289014	ENSG00000242767.1	ZBTB20-AS4	3.64	0.000307	0.035	0.26	0.16	Type 2 diabetes;	chr3:115358896	chr3:115100423~115103061:+
LUAD	cis	rs73230612	0.722	rs11715303	ENSG00000242767.1	ZBTB20-AS4	3.64	0.000307	0.035	0.26	0.16	Type 2 diabetes;	chr3:115362981	chr3:115100423~115103061:+
LUAD	cis	rs5015933	0.966	rs1965342	ENSG00000232630.1	PRPS1P2	-3.64	0.000307	0.035	-0.15	-0.16	Body mass index;	chr9:125371382	chr9:125150653~125151589:+
LUAD	cis	rs4795519	0.614	rs2086267	ENSG00000266313.1	RP11-173M1.4	3.64	0.000307	0.035	0.22	0.16	Chronic myeloid leukemia;	chr17:27197301	chr17:27333256~27348491:+
LUAD	cis	rs6964587	0.621	rs39744	ENSG00000188693.7	CYP51A1-AS1	-3.64	0.000307	0.035	-0.19	-0.16	Breast cancer;	chr7:92413702	chr7:92134604~92180725:+
LUAD	cis	rs6951245	0.935	rs78573577	ENSG00000199023.2	MIR339	-3.64	0.000307	0.035	-0.29	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1049451	chr7:1022935~1023045:-
LUAD	cis	rs6951245	1	rs76129108	ENSG00000199023.2	MIR339	-3.64	0.000307	0.035	-0.29	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1049523	chr7:1022935~1023045:-
LUAD	cis	rs72634501	0.531	rs67758468	ENSG00000182109.6	RP11-69E11.4	3.64	0.000307	0.035	0.19	0.16	HDL cholesterol;	chr1:39156916	chr1:39522280~39546187:-
LUAD	cis	rs794185	0.652	rs2633844	ENSG00000231249.1	ITPR1-AS1	-3.64	0.000307	0.0351	-0.18	-0.16	Multiple sclerosis--Brain Glutamate Levels;	chr3:4470207	chr3:4490891~4493163:-
LUAD	cis	rs2837828	1	rs2091879	ENSG00000226496.2	LINC00323	3.64	0.000307	0.0351	0.21	0.16	Neutrophil count;	chr21:40802754	chr21:41141493~41148133:-
LUAD	cis	rs11158026	0.603	rs66769866	ENSG00000258413.1	RP11-665C16.6	-3.64	0.000307	0.0351	-0.21	-0.16	Parkinson's disease;	chr14:54979435	chr14:55262767~55272075:-
LUAD	cis	rs11158026	0.603	rs7151670	ENSG00000258413.1	RP11-665C16.6	-3.64	0.000307	0.0351	-0.21	-0.16	Parkinson's disease;	chr14:54986041	chr14:55262767~55272075:-
LUAD	cis	rs910316	0.789	rs175457	ENSG00000259138.1	RP11-950C14.7	-3.64	0.000307	0.0351	-0.17	-0.16	Height;	chr14:75117804	chr14:75127153~75136930:+
LUAD	cis	rs13113518	1	rs13133579	ENSG00000223305.1	RN7SKP30	3.64	0.000307	0.0351	0.18	0.16	Height;	chr4:55459921	chr4:55540502~55540835:-
LUAD	cis	rs3026445	0.791	rs7306072	ENSG00000278993.1	RP3-424M6.4	3.64	0.000307	0.0351	0.17	0.16	QT interval;	chr12:110118907	chr12:110501614~110503441:+
LUAD	cis	rs10508774	0.81	rs13377150	ENSG00000231245.2	C1DP1	-3.64	0.000307	0.0351	-0.38	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32566929	chr10:32511336~32511737:-
LUAD	cis	rs10508774	0.733	rs12254344	ENSG00000231245.2	C1DP1	-3.64	0.000307	0.0351	-0.38	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32568301	chr10:32511336~32511737:-
LUAD	cis	rs10508774	0.81	rs11008979	ENSG00000231245.2	C1DP1	-3.64	0.000307	0.0351	-0.38	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32571339	chr10:32511336~32511737:-
LUAD	cis	rs7937127	0.744	rs11607970	ENSG00000254907.1	RP11-484D2.2	3.64	0.000307	0.0351	0.28	0.16	Fibrinogen levels;	chr11:43383832	chr11:43328748~43359296:-
LUAD	cis	rs7937127	0.744	rs72900916	ENSG00000254907.1	RP11-484D2.2	3.64	0.000307	0.0351	0.28	0.16	Fibrinogen levels;	chr11:43386781	chr11:43328748~43359296:-
LUAD	cis	rs7937127	0.696	rs11601684	ENSG00000254907.1	RP11-484D2.2	3.64	0.000307	0.0351	0.28	0.16	Fibrinogen levels;	chr11:43389017	chr11:43328748~43359296:-
LUAD	cis	rs2836974	0.897	rs2026265	ENSG00000232608.1	TIMM9P2	-3.64	0.000307	0.0351	-0.2	-0.16	Cognitive function;	chr21:39223591	chr21:39216624~39217506:+
LUAD	cis	rs2836974	0.897	rs1984022	ENSG00000232608.1	TIMM9P2	-3.64	0.000307	0.0351	-0.2	-0.16	Cognitive function;	chr21:39224159	chr21:39216624~39217506:+
LUAD	cis	rs9921338	0.961	rs11545336	ENSG00000262703.1	RP11-485G7.6	-3.64	0.000307	0.0351	-0.17	-0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11345639	chr16:11348143~11349321:-
LUAD	cis	rs2494663	0.61	rs6427457	ENSG00000223599.1	RP11-216N14.7	3.64	0.000307	0.0351	0.2	0.16	Mean platelet volume;	chr1:154106815	chr1:153852106~153853414:-
LUAD	cis	rs8049040	0.586	rs13333985	ENSG00000260886.1	TAT-AS1	3.64	0.000307	0.0351	0.2	0.16	Blood protein levels;	chr16:71516950	chr16:71565789~71578187:+
LUAD	cis	rs12122100	0.837	rs6681167	ENSG00000227242.3	NBPF13P	3.64	0.000307	0.0351	0.21	0.16	HIV-1 control;	chr1:147035308	chr1:147021320~147124525:-
LUAD	cis	rs2074409	0.509	rs853193	ENSG00000276054.1	RP11-378E13.3	3.64	0.000307	0.0351	0.2	0.16	Response to angiotensin II receptor blocker therapy;	chr17:37463009	chr17:37386886~37387926:+
LUAD	cis	rs2074409	0.509	rs853205	ENSG00000276054.1	RP11-378E13.3	3.64	0.000307	0.0351	0.2	0.16	Response to angiotensin II receptor blocker therapy;	chr17:37464292	chr17:37386886~37387926:+
LUAD	cis	rs2074409	0.509	rs2074412	ENSG00000276054.1	RP11-378E13.3	3.64	0.000307	0.0351	0.2	0.16	Response to angiotensin II receptor blocker therapy;	chr17:37478961	chr17:37386886~37387926:+
LUAD	cis	rs8050896	0.793	rs11864858	ENSG00000260695.1	RP11-513N24.1	-3.64	0.000307	0.0351	-0.34	-0.16	Response to antipsychotic treatment;	chr16:66116703	chr16:65861112~65863784:-
LUAD	cis	rs2836974	0.897	rs34035316	ENSG00000232608.1	TIMM9P2	-3.64	0.000307	0.0351	-0.2	-0.16	Cognitive function;	chr21:39222097	chr21:39216624~39217506:+
LUAD	cis	rs7142881	0.815	rs12882018	ENSG00000258525.1	RP11-829H16.3	-3.64	0.000307	0.0351	-0.18	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31605125	chr14:30876179~30889808:-
LUAD	cis	rs12908161	1	rs12910012	ENSG00000254414.1	RP11-182J1.1	3.64	0.000307	0.0351	0.21	0.16	Schizophrenia;	chr15:84755431	chr15:84631898~84633987:-
LUAD	cis	rs12908161	1	rs12899981	ENSG00000254414.1	RP11-182J1.1	3.64	0.000307	0.0351	0.21	0.16	Schizophrenia;	chr15:84759142	chr15:84631898~84633987:-
LUAD	cis	rs7617773	0.817	rs6801801	ENSG00000199476.1	Y_RNA	-3.64	0.000307	0.0351	-0.21	-0.16	Coronary artery disease;	chr3:48284943	chr3:48288587~48288694:+
LUAD	cis	rs9863	0.896	rs34854841	ENSG00000270061.1	RP11-214K3.19	-3.64	0.000307	0.0351	-0.17	-0.16	White blood cell count;	chr12:123966957	chr12:123969990~123970344:-
LUAD	cis	rs7617773	0.78	rs6442111	ENSG00000199476.1	Y_RNA	-3.64	0.000307	0.0351	-0.21	-0.16	Coronary artery disease;	chr3:48270570	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.851	rs6775179	ENSG00000199476.1	Y_RNA	-3.64	0.000307	0.0351	-0.21	-0.16	Coronary artery disease;	chr3:48271928	chr3:48288587~48288694:+
LUAD	cis	rs701145	0.585	rs357482	ENSG00000243069.6	ARHGEF26-AS1	3.64	0.000307	0.0351	0.27	0.16	Coronary artery disease;	chr3:154172066	chr3:154024401~154121332:-
LUAD	cis	rs5758659	0.652	rs133322	ENSG00000227370.1	RP4-669P10.19	-3.64	0.000307	0.0351	-0.15	-0.16	Cognitive function;	chr22:42009655	chr22:42132543~42132998:+
LUAD	cis	rs9863	0.931	rs11057407	ENSG00000270061.1	RP11-214K3.19	-3.64	0.000307	0.0351	-0.17	-0.16	White blood cell count;	chr12:123965282	chr12:123969990~123970344:-
LUAD	cis	rs11159086	0.938	rs11623040	ENSG00000259005.1	RP3-449M8.6	3.64	0.000307	0.0351	0.25	0.16	Advanced glycation end-product levels;	chr14:74496743	chr14:74474007~74474864:-
LUAD	cis	rs2460905	0.717	rs62487523	ENSG00000251468.2	RP11-369K16.1	-3.64	0.000307	0.0351	-0.37	-0.16	Post-traumatic stress disorder;	chr8:12925625	chr8:12958387~12962200:+
LUAD	cis	rs7176527	0.848	rs17600128	ENSG00000259570.1	RP11-671M22.4	-3.64	0.000307	0.0351	-0.25	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84744141	chr15:84394512~84395514:+
LUAD	cis	rs950169	0.8	rs34302901	ENSG00000188388.10	GOLGA6L3	3.64	0.000307	0.0351	0.22	0.16	Schizophrenia;	chr15:84567712	chr15:85240472~85247170:+
LUAD	cis	rs9341808	0.754	rs9352808	ENSG00000279022.1	RP11-250B2.4	3.64	0.000307	0.0351	0.19	0.16	Sitting height ratio;	chr6:80287625	chr6:80440730~80441172:+
LUAD	cis	rs6688613	0.685	rs6427047	ENSG00000225171.2	DUTP6	-3.64	0.000307	0.0351	-0.2	-0.16	Refractive astigmatism;	chr1:166945021	chr1:166868748~166869209:+
LUAD	cis	rs12237653	0.929	rs10966874	ENSG00000236199.1	RP11-264I13.2	-3.64	0.000307	0.0351	-0.25	-0.16	Gambling;	chr9:2545581	chr9:2041900~2046023:-
LUAD	cis	rs7332672	0.62	rs2015342	ENSG00000228889.5	UBAC2-AS1	3.64	0.000307	0.0351	0.21	0.16	Eosinophil counts;	chr13:99408243	chr13:99196377~99200710:-
LUAD	cis	rs6502050	0.835	rs8071425	ENSG00000275966.1	RP11-1055B8.9	3.64	0.000307	0.0351	0.17	0.16	Life satisfaction;	chr17:82159459	chr17:81345476~81345966:-
LUAD	cis	rs1075265	0.744	rs2909460	ENSG00000272156.1	RP11-477N3.1	-3.64	0.000307	0.0351	-0.2	-0.16	Chronotype;Morning vs. evening chronotype;	chr2:53967611	chr2:54082554~54085066:+
LUAD	cis	rs1075265	0.811	rs805308	ENSG00000272156.1	RP11-477N3.1	-3.64	0.000307	0.0351	-0.2	-0.16	Chronotype;Morning vs. evening chronotype;	chr2:53967797	chr2:54082554~54085066:+
LUAD	cis	rs5015933	0.788	rs359592	ENSG00000232630.1	PRPS1P2	-3.64	0.000307	0.0351	-0.15	-0.16	Body mass index;	chr9:125285007	chr9:125150653~125151589:+
LUAD	cis	rs10911232	0.507	rs7547953	ENSG00000224468.3	RP11-181K3.4	-3.64	0.000307	0.0351	-0.15	-0.16	Hypertriglyceridemia;	chr1:183062506	chr1:183138402~183141282:-
LUAD	cis	rs1858037	0.867	rs1553675	ENSG00000237979.1	AC007389.1	-3.64	0.000307	0.0351	-0.2	-0.16	Rheumatoid arthritis;	chr2:65343173	chr2:65500993~65502138:-
LUAD	cis	rs2657294	0.674	rs10824268	ENSG00000233313.2	HMGA1P5	-3.64	0.000308	0.0351	-0.21	-0.16	Pneumonia;	chr10:75085937	chr10:75276376~75276646:-
LUAD	cis	rs10435719	0.638	rs67146188	ENSG00000255046.1	RP11-297N6.4	3.64	0.000308	0.0351	0.2	0.16	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11924924	chr8:11797928~11802568:-
LUAD	cis	rs9921338	0.961	rs66555362	ENSG00000263080.1	RP11-485G7.5	3.64	0.000308	0.0351	0.22	0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11294976	chr16:11341809~11345211:-
LUAD	cis	rs206548	0.561	rs7237976	ENSG00000252680.1	RNA5SP449	3.64	0.000308	0.0351	0.21	0.16	Serum protein levels (sST2);	chr18:10385523	chr18:9844717~9844846:-
LUAD	cis	rs2348418	0.864	rs11049716	ENSG00000247934.4	RP11-967K21.1	3.64	0.000308	0.0351	0.19	0.16	Lung function (FEV1);Lung function (FVC);	chr12:28564713	chr12:28163298~28190738:-
LUAD	cis	rs2348418	0.864	rs7136843	ENSG00000247934.4	RP11-967K21.1	3.64	0.000308	0.0351	0.19	0.16	Lung function (FEV1);Lung function (FVC);	chr12:28564875	chr12:28163298~28190738:-
LUAD	cis	rs9921338	0.561	rs11859280	ENSG00000280153.1	RP11-876N24.3	3.64	0.000308	0.0351	0.18	0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11376515	chr16:10933903~10936280:+
LUAD	cis	rs8028182	0.636	rs62027209	ENSG00000260274.1	RP11-817O13.8	3.64	0.000308	0.0351	0.18	0.16	Sudden cardiac arrest;	chr15:75579285	chr15:75368155~75369584:+
LUAD	cis	rs448720	1	rs448720	ENSG00000260657.2	RP11-315D16.4	-3.64	0.000308	0.0351	-0.18	-0.16	Cognitive performance;	chr15:67906573	chr15:68267792~68277994:-
LUAD	cis	rs3733418	0.929	rs13149738	ENSG00000248632.1	RP11-366M4.11	3.64	0.000308	0.0351	0.26	0.16	Obesity-related traits;	chr4:164984545	chr4:164968587~164970002:-
LUAD	cis	rs6001482	0.638	rs5757569	ENSG00000223350.2	IGLV9-49	-3.64	0.000308	0.0351	-0.16	-0.16	Diastolic blood pressure;	chr22:22230282	chr22:22343187~22343732:+
LUAD	cis	rs6840360	0.615	rs12641433	ENSG00000270265.1	RP11-731D1.4	-3.64	0.000308	0.0351	-0.18	-0.16	Intelligence (multi-trait analysis);	chr4:151686396	chr4:151333775~151353224:-
LUAD	cis	rs3126085	0.935	rs12726613	ENSG00000237975.5	FLG-AS1	3.64	0.000308	0.0351	0.25	0.16	Atopic dermatitis;	chr1:152213024	chr1:152168125~152445456:+
LUAD	cis	rs10785571	0.595	rs1986427	ENSG00000275481.1	RP11-474P2.6	3.64	0.000308	0.0351	0.14	0.16	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr12:45447550	chr12:46388856~46392126:+
LUAD	cis	rs2836974	0.829	rs34227163	ENSG00000232608.1	TIMM9P2	-3.64	0.000308	0.0351	-0.19	-0.16	Cognitive function;	chr21:39180017	chr21:39216624~39217506:+
LUAD	cis	rs330048	0.525	rs10112237	ENSG00000253893.2	FAM85B	3.64	0.000308	0.0351	0.2	0.16	Systemic lupus erythematosus;	chr8:9215219	chr8:8167819~8226614:-
LUAD	cis	rs11886999	0.812	rs12613263	ENSG00000237510.6	AC008268.2	-3.64	0.000308	0.0352	-0.28	-0.16	Cardiac Troponin-T levels;	chr2:96197939	chr2:95789654~95800166:+
LUAD	cis	rs8133949	0.768	rs7280167	ENSG00000237232.6	ZNF295-AS1	3.64	0.000308	0.0352	0.2	0.16	Hand grip strength;	chr21:42012188	chr21:42009194~42024924:+
LUAD	cis	rs357618	1	rs357627	ENSG00000272112.1	CTB-113P19.5	-3.64	0.000308	0.0352	-0.15	-0.16	Basophil percentage of white cells;	chr5:151470699	chr5:151724831~151725356:-
LUAD	cis	rs357618	1	rs357628	ENSG00000272112.1	CTB-113P19.5	-3.64	0.000308	0.0352	-0.15	-0.16	Basophil percentage of white cells;	chr5:151470791	chr5:151724831~151725356:-
LUAD	cis	rs7107174	1	rs55825352	ENSG00000251323.2	RP11-452H21.4	3.63	0.000308	0.0352	0.21	0.16	Testicular germ cell tumor;	chr11:78323378	chr11:78423982~78429836:-
LUAD	cis	rs10875976	0.525	rs7969178	ENSG00000257464.1	RP11-161H23.8	-3.63	0.000308	0.0352	-0.17	-0.16	Obesity;	chr12:49859019	chr12:49442424~49442652:-
LUAD	cis	rs2239547	0.618	rs13083728	ENSG00000243224.1	RP5-1157M23.2	-3.63	0.000308	0.0352	-0.19	-0.16	Schizophrenia;	chr3:52834429	chr3:52239258~52241097:+
LUAD	cis	rs590820	0.684	rs10864727	ENSG00000227934.1	RP11-423F24.3	-3.63	0.000308	0.0352	-0.19	-0.16	Metabolite levels (lipoprotein measures);	chr1:230162193	chr1:231021611~231022183:+
LUAD	cis	rs360798	0.656	rs11125934	ENSG00000231609.4	AC009501.4	3.63	0.000308	0.0352	0.18	0.16	Coronary artery disease;	chr2:62628964	chr2:63043922~63048640:-
LUAD	cis	rs12724450	0.793	rs71622694	ENSG00000228126.1	FALEC	3.63	0.000308	0.0352	0.3	0.16	Blood protein levels;	chr1:150323754	chr1:150515757~150518032:+
LUAD	cis	rs12724450	0.793	rs35437473	ENSG00000228126.1	FALEC	3.63	0.000308	0.0352	0.3	0.16	Blood protein levels;	chr1:150324779	chr1:150515757~150518032:+
LUAD	cis	rs7809950	0.817	rs10224503	ENSG00000238832.1	snoU109	-3.63	0.000308	0.0352	-0.26	-0.16	Coronary artery disease;	chr7:107435124	chr7:107603363~107603507:+
LUAD	cis	rs12712135	0.709	rs11465729	ENSG00000234389.1	AC007278.3	-3.63	0.000308	0.0352	-0.15	-0.16	Blood protein levels;	chr2:102448052	chr2:102438713~102440475:+
LUAD	cis	rs7656342	0.964	rs13141706	ENSG00000186234.7	FAM86MP	3.63	0.000308	0.0352	0.2	0.16	Gut microbiota (bacterial taxa);	chr4:9816721	chr4:9692495~9702954:+
LUAD	cis	rs8056893	0.842	rs4783553	ENSG00000260441.4	RP11-96D1.7	3.63	0.000308	0.0352	0.19	0.16	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68332052	chr16:68256162~68260443:-
LUAD	cis	rs9926296	0.529	rs7195906	ENSG00000260259.1	RP11-368I7.4	-3.63	0.000308	0.0352	-0.16	-0.16	Vitiligo;	chr16:89739939	chr16:89682620~89686569:-
LUAD	cis	rs875971	0.66	rs10272357	ENSG00000273142.1	RP11-458F8.4	3.63	0.000308	0.0352	0.11	0.16	Aortic root size;	chr7:66598087	chr7:66902857~66906297:+
LUAD	cis	rs4699052	0.59	rs1156669	ENSG00000246560.2	RP11-10L12.4	3.63	0.000308	0.0352	0.21	0.16	Testicular germ cell tumor;	chr4:103367047	chr4:102828055~102844075:+
LUAD	cis	rs7954584	0.56	rs745327	ENSG00000212694.7	LINC01089	3.63	0.000308	0.0352	0.1	0.16	Mean corpuscular volume;	chr12:122018618	chr12:121795267~121803906:-
LUAD	cis	rs7077256	0.564	rs72829157	ENSG00000272767.1	JMJD1C-AS1	3.63	0.000308	0.0352	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63173017	chr10:63465229~63466563:+
LUAD	cis	rs7077256	0.564	rs35854283	ENSG00000272767.1	JMJD1C-AS1	3.63	0.000308	0.0352	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63177554	chr10:63465229~63466563:+
LUAD	cis	rs7077256	0.526	rs34069123	ENSG00000272767.1	JMJD1C-AS1	3.63	0.000308	0.0352	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63178951	chr10:63465229~63466563:+
LUAD	cis	rs9309473	0.95	rs13408433	ENSG00000230002.2	ALMS1-IT1	3.63	0.000308	0.0352	0.21	0.16	Metabolite levels;	chr2:73655945	chr2:73456764~73459484:+
LUAD	cis	rs792448	0.545	rs7519168	ENSG00000229983.1	RP11-15I11.2	-3.63	0.000308	0.0352	-0.2	-0.16	White blood cell count (basophil);	chr1:212220043	chr1:212168207~212190259:+
LUAD	cis	rs448720	0.544	rs392285	ENSG00000260657.2	RP11-315D16.4	-3.63	0.000309	0.0352	-0.19	-0.16	Cognitive performance;	chr15:67940161	chr15:68267792~68277994:-
LUAD	cis	rs17597773	0.638	rs6668666	ENSG00000272823.1	RP11-295M18.6	-3.63	0.000309	0.0352	-0.21	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220826069	chr1:220828676~220829211:-
LUAD	cis	rs4561483	0.831	rs33648	ENSG00000261216.1	RP11-166B2.5	-3.63	0.000309	0.0352	-0.17	-0.16	Testicular germ cell tumor;	chr16:11885765	chr16:11908208~11908916:+
LUAD	cis	rs7216064	1	rs2128792	ENSG00000266717.1	RP11-855A2.3	3.63	0.000309	0.0352	0.2	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67861061	chr17:67950885~67951746:-
LUAD	cis	rs7216064	1	rs2365764	ENSG00000266717.1	RP11-855A2.3	3.63	0.000309	0.0352	0.2	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67861598	chr17:67950885~67951746:-
LUAD	cis	rs7216064	1	rs59950564	ENSG00000266717.1	RP11-855A2.3	3.63	0.000309	0.0352	0.2	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67864743	chr17:67950885~67951746:-
LUAD	cis	rs7216064	1	rs34872586	ENSG00000266717.1	RP11-855A2.3	3.63	0.000309	0.0352	0.2	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67867350	chr17:67950885~67951746:-
LUAD	cis	rs7216064	0.953	rs58141639	ENSG00000266717.1	RP11-855A2.3	3.63	0.000309	0.0352	0.2	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67868786	chr17:67950885~67951746:-
LUAD	cis	rs7216064	1	rs62084246	ENSG00000266717.1	RP11-855A2.3	3.63	0.000309	0.0352	0.2	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67871795	chr17:67950885~67951746:-
LUAD	cis	rs7216064	1	rs11869819	ENSG00000266717.1	RP11-855A2.3	3.63	0.000309	0.0352	0.2	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67872553	chr17:67950885~67951746:-
LUAD	cis	rs7216064	1	rs55939964	ENSG00000266717.1	RP11-855A2.3	3.63	0.000309	0.0352	0.2	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67873181	chr17:67950885~67951746:-
LUAD	cis	rs7216064	1	rs12602912	ENSG00000266717.1	RP11-855A2.3	3.63	0.000309	0.0352	0.2	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67873957	chr17:67950885~67951746:-
LUAD	cis	rs7216064	0.953	rs12450907	ENSG00000266717.1	RP11-855A2.3	3.63	0.000309	0.0352	0.2	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67874528	chr17:67950885~67951746:-
LUAD	cis	rs7216064	1	rs4569324	ENSG00000266717.1	RP11-855A2.3	3.63	0.000309	0.0352	0.2	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67876634	chr17:67950885~67951746:-
LUAD	cis	rs7216064	1	rs62084248	ENSG00000266717.1	RP11-855A2.3	3.63	0.000309	0.0352	0.2	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67878425	chr17:67950885~67951746:-
LUAD	cis	rs7216064	1	rs12451511	ENSG00000266717.1	RP11-855A2.3	3.63	0.000309	0.0352	0.2	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67878745	chr17:67950885~67951746:-
LUAD	cis	rs7216064	1	rs62084249	ENSG00000266717.1	RP11-855A2.3	3.63	0.000309	0.0352	0.2	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67878882	chr17:67950885~67951746:-
LUAD	cis	rs7216064	1	rs35243555	ENSG00000266717.1	RP11-855A2.3	3.63	0.000309	0.0352	0.2	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67880361	chr17:67950885~67951746:-
LUAD	cis	rs7216064	1	rs58122682	ENSG00000266717.1	RP11-855A2.3	3.63	0.000309	0.0352	0.2	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67880799	chr17:67950885~67951746:-
LUAD	cis	rs7216064	1	rs62084251	ENSG00000266717.1	RP11-855A2.3	3.63	0.000309	0.0352	0.2	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67882620	chr17:67950885~67951746:-
LUAD	cis	rs7216064	1	rs4318247	ENSG00000266717.1	RP11-855A2.3	3.63	0.000309	0.0352	0.2	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67886056	chr17:67950885~67951746:-
LUAD	cis	rs7216064	0.954	rs8079291	ENSG00000266717.1	RP11-855A2.3	3.63	0.000309	0.0352	0.2	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67891506	chr17:67950885~67951746:-
LUAD	cis	rs412050	0.793	rs74576380	ENSG00000224086.5	LL22NC03-86G7.1	-3.63	0.000309	0.0352	-0.2	-0.16	Attention deficit hyperactivity disorder;	chr22:21928908	chr22:21938293~21977632:+
LUAD	cis	rs9311474	0.659	rs7638808	ENSG00000243224.1	RP5-1157M23.2	3.63	0.000309	0.0352	0.16	0.16	Electroencephalogram traits;	chr3:52538040	chr3:52239258~52241097:+
LUAD	cis	rs73230612	0.858	rs6768463	ENSG00000242767.1	ZBTB20-AS4	3.63	0.000309	0.0352	0.26	0.16	Type 2 diabetes;	chr3:115245417	chr3:115100423~115103061:+
LUAD	cis	rs73230612	1	rs13326167	ENSG00000242767.1	ZBTB20-AS4	3.63	0.000309	0.0352	0.26	0.16	Type 2 diabetes;	chr3:115246544	chr3:115100423~115103061:+
LUAD	cis	rs1544167	1	rs1544167	ENSG00000237927.1	RP3-393E18.2	-3.63	0.000309	0.0352	-0.22	-0.16	Lipoprotein (a) - cholesterol levels;	chr6:159379992	chr6:159586955~159589169:-
LUAD	cis	rs2985684	0.894	rs2281837	ENSG00000278009.1	RP11-649E7.8	3.63	0.000309	0.0352	0.22	0.16	Carotid intima media thickness;	chr14:49598641	chr14:49601011~49601124:-
LUAD	cis	rs11089937	0.929	rs5750624	ENSG00000211640.3	IGLV6-57	3.63	0.000309	0.0352	0.1	0.16	Periodontitis (PAL4Q3);	chr22:22165354	chr22:22195713~22196460:+
LUAD	cis	rs17345786	0.52	rs1476123	ENSG00000244119.1	PDCL3P4	3.63	0.000309	0.0352	0.15	0.16	Colonoscopy-negative controls vs population controls;	chr3:101594569	chr3:101712472~101713191:+
LUAD	cis	rs10938353	0.689	rs17462266	ENSG00000273369.1	RP11-700J17.1	3.63	0.000309	0.0352	0.24	0.16	Body mass index;	chr4:44614886	chr4:44693946~44694386:-
LUAD	cis	rs7772486	0.623	rs9485021	ENSG00000235652.6	RP11-545I5.3	-3.63	0.000309	0.0352	-0.16	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145747661	chr6:145799409~145886585:+
LUAD	cis	rs7107174	1	rs10899469	ENSG00000251323.2	RP11-452H21.4	3.63	0.000309	0.0352	0.23	0.16	Testicular germ cell tumor;	chr11:78307267	chr11:78423982~78429836:-
LUAD	cis	rs7107174	0.579	rs10793299	ENSG00000251323.2	RP11-452H21.4	3.63	0.000309	0.0352	0.23	0.16	Testicular germ cell tumor;	chr11:78307908	chr11:78423982~78429836:-
LUAD	cis	rs7107174	1	rs10793300	ENSG00000251323.2	RP11-452H21.4	3.63	0.000309	0.0352	0.23	0.16	Testicular germ cell tumor;	chr11:78308536	chr11:78423982~78429836:-
LUAD	cis	rs7107174	1	rs10899470	ENSG00000251323.2	RP11-452H21.4	3.63	0.000309	0.0352	0.23	0.16	Testicular germ cell tumor;	chr11:78309006	chr11:78423982~78429836:-
LUAD	cis	rs7107174	0.681	rs10793301	ENSG00000251323.2	RP11-452H21.4	3.63	0.000309	0.0352	0.23	0.16	Testicular germ cell tumor;	chr11:78309867	chr11:78423982~78429836:-
LUAD	cis	rs2243480	0.522	rs1638736	ENSG00000229886.1	RP5-1132H15.3	3.63	0.000309	0.0352	0.32	0.16	Diabetic kidney disease;	chr7:66627321	chr7:66025126~66031544:-
LUAD	cis	rs4474465	0.736	rs4945291	ENSG00000251323.2	RP11-452H21.4	-3.63	0.000309	0.0353	-0.2	-0.16	Alzheimer's disease (survival time);	chr11:78543367	chr11:78423982~78429836:-
LUAD	cis	rs4718428	0.607	rs66954441	ENSG00000230295.1	RP11-458F8.2	-3.63	0.000309	0.0353	-0.14	-0.16	Corneal structure;	chr7:66904222	chr7:66880708~66882981:+
LUAD	cis	rs7162943	0.887	rs11858280	ENSG00000260123.1	RP11-326A19.4	-3.63	0.000309	0.0353	-0.2	-0.16	Mean platelet volume;	chr15:89069059	chr15:89041223~89082819:+
LUAD	cis	rs4664293	0.867	rs12617546	ENSG00000230783.1	AC009961.2	-3.63	0.000309	0.0353	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159767079	chr2:159689217~159690291:-
LUAD	cis	rs3213758	1	rs2024473	ENSG00000261630.1	RP11-357N13.3	-3.63	0.000309	0.0353	-0.33	-0.16	Vitiligo (non-segmental);	chr16:53546083	chr16:53981229~53981912:-
LUAD	cis	rs3213758	1	rs12445553	ENSG00000261630.1	RP11-357N13.3	-3.63	0.000309	0.0353	-0.33	-0.16	Vitiligo (non-segmental);	chr16:53546830	chr16:53981229~53981912:-
LUAD	cis	rs1823913	0.637	rs12992372	ENSG00000230611.1	HMGB1P27	-3.63	0.000309	0.0353	-0.18	-0.16	Obesity-related traits;	chr2:191289251	chr2:191174233~191174835:+
LUAD	cis	rs34929064	1	rs13225099	ENSG00000230658.1	KLHL7-AS1	3.63	0.000309	0.0353	0.22	0.16	Major depression and alcohol dependence;	chr7:22683306	chr7:23101228~23105703:-
LUAD	cis	rs7584330	0.697	rs60278044	ENSG00000222032.1	AC112721.2	3.63	0.000309	0.0353	0.2	0.16	Prostate cancer;	chr2:237448475	chr2:237428920~237434822:-
LUAD	cis	rs7246657	0.943	rs8106839	ENSG00000226686.6	LINC01535	-3.63	0.000309	0.0353	-0.24	-0.16	Coronary artery calcification;	chr19:37467573	chr19:37251912~37265535:+
LUAD	cis	rs4865762	0.512	rs16774	ENSG00000247796.2	CTD-2366F13.1	3.63	0.000309	0.0353	0.18	0.16	Intraocular pressure;	chr5:53195963	chr5:53109842~53115126:+
LUAD	cis	rs4865762	0.512	rs62357406	ENSG00000247796.2	CTD-2366F13.1	3.63	0.000309	0.0353	0.18	0.16	Intraocular pressure;	chr5:53199219	chr5:53109842~53115126:+
LUAD	cis	rs11216126	0.554	rs1942478	ENSG00000235910.1	APOA1-AS	3.63	0.000309	0.0353	0.29	0.16	HDL cholesterol;	chr11:116780747	chr11:116836117~116855729:+
LUAD	cis	rs7215564	0.818	rs36034584	ENSG00000232083.3	RPL31P7	3.63	0.000309	0.0353	0.27	0.16	Myopia (pathological);	chr17:80697678	chr17:80602549~80602926:-
LUAD	cis	rs2255336	0.578	rs7965744	ENSG00000245648.1	RP11-277P12.20	-3.63	0.000309	0.0353	-0.24	-0.16	Blood protein levels;	chr12:10367580	chr12:10363769~10398506:+
LUAD	cis	rs720475	1	rs720475	ENSG00000244198.4	RP4-545C24.1	-3.63	0.000309	0.0353	-0.22	-0.16	Breast cancer;	chr7:144377836	chr7:144194858~144280547:+
LUAD	cis	rs7142881	0.815	rs11156690	ENSG00000258525.1	RP11-829H16.3	-3.63	0.000309	0.0353	-0.18	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31570721	chr14:30876179~30889808:-
LUAD	cis	rs10463554	0.963	rs154355	ENSG00000250682.4	LINC00491	3.63	0.000309	0.0353	0.2	0.16	Parkinson's disease;	chr5:103163177	chr5:102609156~102671559:-
LUAD	cis	rs26232	0.517	rs154356	ENSG00000250682.4	LINC00491	3.63	0.000309	0.0353	0.2	0.16	Rheumatoid arthritis;	chr5:103163440	chr5:102609156~102671559:-
LUAD	cis	rs238295	0.805	rs6053527	ENSG00000230563.2	RP5-828H9.1	3.63	0.00031	0.0353	0.22	0.16	Occipital cortical area (total cortical area interaction);	chr20:5601811	chr20:5471207~5475182:+
LUAD	cis	rs12034598	0.945	rs12567990	ENSG00000234219.1	CDCA4P4	3.63	0.00031	0.0353	0.25	0.16	Inflammatory biomarkers;	chr1:207508340	chr1:207762584~207763263:+
LUAD	cis	rs417065	0.516	rs6661746	ENSG00000227634.1	RP11-431K24.3	-3.63	0.00031	0.0353	-0.22	-0.16	Psoriasis;	chr1:8208560	chr1:8208672~8215210:+
LUAD	cis	rs473518	0.945	rs585954	ENSG00000223023.1	Y_RNA	-3.63	0.00031	0.0353	-0.25	-0.16	Migraine - clinic-based;	chr18:22508336	chr18:23024596~23024703:+
LUAD	cis	rs473518	0.891	rs480637	ENSG00000223023.1	Y_RNA	-3.63	0.00031	0.0353	-0.25	-0.16	Migraine - clinic-based;	chr18:22508341	chr18:23024596~23024703:+
LUAD	cis	rs4605213	0.605	rs41524846	ENSG00000250107.1	CACNA1G-AS1	-3.63	0.00031	0.0353	-0.23	-0.16	Height;	chr17:51174877	chr17:50556207~50562108:-
LUAD	cis	rs911555	0.576	rs8015723	ENSG00000244691.1	RPL10AP1	3.63	0.00031	0.0353	0.22	0.16	Intelligence (multi-trait analysis);	chr14:103429572	chr14:103412119~103412761:-
LUAD	cis	rs5771225	0.544	rs13055135	ENSG00000273253.2	RP3-402G11.26	-3.63	0.00031	0.0353	-0.16	-0.16	Late-onset Alzheimer's disease;	chr22:50234050	chr22:50199090~50200837:-
LUAD	cis	rs526231	0.781	rs2569015	ENSG00000175749.11	EIF3KP1	3.63	0.00031	0.0353	0.22	0.16	Primary biliary cholangitis;	chr5:103273146	chr5:103032376~103033031:+
LUAD	cis	rs9341808	0.718	rs9343971	ENSG00000233967.5	RP11-250B2.3	3.63	0.00031	0.0353	0.16	0.16	Sitting height ratio;	chr6:80172339	chr6:80443344~80465927:+
LUAD	cis	rs4664293	0.867	rs3771721	ENSG00000230783.1	AC009961.2	-3.63	0.00031	0.0353	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159771644	chr2:159689217~159690291:-
LUAD	cis	rs2281636	0.824	rs2160620	ENSG00000233690.1	EBAG9P1	3.63	0.00031	0.0353	0.16	0.16	Obesity-related traits;	chr10:99627261	chr10:99697407~99697949:-
LUAD	cis	rs7615952	0.641	rs66520539	ENSG00000241288.6	RP11-379B18.5	-3.63	0.00031	0.0353	-0.21	-0.16	Blood pressure (smoking interaction);	chr3:126061531	chr3:125827238~125916384:-
LUAD	cis	rs8035452	0.964	rs12915708	ENSG00000259240.1	RP11-108K3.1	-3.63	0.00031	0.0353	-0.19	-0.16	Alzheimer's disease (late onset);	chr15:50756405	chr15:51037488~51293912:+
LUAD	cis	rs8035452	0.964	rs12916038	ENSG00000259240.1	RP11-108K3.1	-3.63	0.00031	0.0353	-0.19	-0.16	Alzheimer's disease (late onset);	chr15:50756603	chr15:51037488~51293912:+
LUAD	cis	rs10863681	0.738	rs12561821	ENSG00000200033.1	RNU6-403P	3.63	0.00031	0.0353	0.19	0.16	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222087887	chr1:221837334~221837437:-
LUAD	cis	rs2408955	0.521	rs10875749	ENSG00000257763.1	OR5BK1P	-3.63	0.00031	0.0353	-0.17	-0.16	Glycated hemoglobin levels;	chr12:48138134	chr12:48355792~48356614:-
LUAD	cis	rs877819	0.583	rs1904600	ENSG00000228403.1	RP11-563N6.6	-3.63	0.00031	0.0353	-0.17	-0.16	Systemic lupus erythematosus;	chr10:48859171	chr10:48878022~48878649:+
LUAD	cis	rs6088590	0.965	rs6120730	ENSG00000275784.1	RP5-1125A11.6	-3.63	0.00031	0.0353	-0.18	-0.16	Coronary artery disease;	chr20:34797299	chr20:33989480~33991818:-
LUAD	cis	rs11853189	0.938	rs78151008	ENSG00000259562.2	RP11-762H8.2	3.63	0.00031	0.0353	0.18	0.16	Red cell distribution width;	chr15:78300364	chr15:78290527~78291221:-
LUAD	cis	rs2991971	0.81	rs998199	ENSG00000234329.1	RP11-767N6.2	3.63	0.00031	0.0354	0.15	0.16	High light scatter reticulocyte count;	chr1:45447226	chr1:45651039~45651826:-
LUAD	cis	rs7615952	0.641	rs7632497	ENSG00000241288.6	RP11-379B18.5	-3.63	0.00031	0.0354	-0.21	-0.16	Blood pressure (smoking interaction);	chr3:126064243	chr3:125827238~125916384:-
LUAD	cis	rs7688540	0.8	rs28429717	ENSG00000211553.1	AC253576.2	-3.63	0.00031	0.0354	-0.21	-0.16	Facial morphology (factor 6, height of vermillion lower lip);	chr4:266384	chr4:136461~136568:+
LUAD	cis	rs7968440	1	rs11609231	ENSG00000272368.2	RP4-605O3.4	3.63	0.00031	0.0354	0.19	0.16	Fibrinogen;	chr12:50538647	chr12:50112197~50165618:+
LUAD	cis	rs957448	1	rs72674866	ENSG00000254057.1	RP3-388N13.3	3.63	0.00031	0.0354	0.18	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94564619	chr8:93834454~93846743:-
LUAD	cis	rs957448	1	rs55897841	ENSG00000254057.1	RP3-388N13.3	3.63	0.00031	0.0354	0.18	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94565042	chr8:93834454~93846743:-
LUAD	cis	rs957448	0.948	rs72674867	ENSG00000254057.1	RP3-388N13.3	3.63	0.00031	0.0354	0.18	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94565973	chr8:93834454~93846743:-
LUAD	cis	rs875971	0.66	rs7807930	ENSG00000222364.1	RNU6-96P	3.63	0.00031	0.0354	0.18	0.16	Aortic root size;	chr7:66622178	chr7:66395191~66395286:+
LUAD	cis	rs875971	0.66	rs7807944	ENSG00000222364.1	RNU6-96P	3.63	0.00031	0.0354	0.18	0.16	Aortic root size;	chr7:66622208	chr7:66395191~66395286:+
LUAD	cis	rs11121246	0.518	rs6673587	ENSG00000270282.1	RP5-1115A15.2	-3.63	0.00031	0.0354	-0.18	-0.16	Plateletcrit;	chr1:8850646	chr1:8512653~8513021:+
LUAD	cis	rs8062405	0.754	rs28410083	ENSG00000261766.1	RP11-22P6.2	3.63	0.00031	0.0354	0.14	0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620039	chr16:28862166~28863340:-
LUAD	cis	rs8062405	0.789	rs1968751	ENSG00000261766.1	RP11-22P6.2	3.63	0.00031	0.0354	0.14	0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620438	chr16:28862166~28863340:-
LUAD	cis	rs7615952	0.515	rs4441610	ENSG00000241288.6	RP11-379B18.5	-3.63	0.00031	0.0354	-0.19	-0.16	Blood pressure (smoking interaction);	chr3:125962464	chr3:125827238~125916384:-
LUAD	cis	rs4268898	0.636	rs72787383	ENSG00000242628.4	AC009228.1	3.63	0.00031	0.0354	0.24	0.16	Asthma;	chr2:24360992	chr2:24214381~24221516:+
LUAD	cis	rs17711722	0.565	rs4275112	ENSG00000228409.4	CCT6P1	3.63	0.00031	0.0354	0.14	0.16	Calcium levels;	chr7:65733651	chr7:65751142~65763354:+
LUAD	cis	rs7246657	0.943	rs10420430	ENSG00000267470.4	ZNF571-AS1	3.63	0.00031	0.0354	0.24	0.16	Coronary artery calcification;	chr19:37403292	chr19:37548914~37587348:+
LUAD	cis	rs1876905	0.68	rs1150082	ENSG00000271789.1	RP5-1112D6.7	-3.63	0.00031	0.0354	-0.22	-0.16	Mean corpuscular hemoglobin;	chr6:111189519	chr6:111297126~111298510:+
LUAD	cis	rs4759375	1	rs1109560	ENSG00000235423.7	RP11-282O18.3	3.63	0.00031	0.0354	0.29	0.16	HDL cholesterol;	chr12:123273358	chr12:123252030~123261483:-
LUAD	cis	rs9549260	0.816	rs7324090	ENSG00000168852.11	TPTE2P5	3.63	0.00031	0.0354	0.16	0.16	Red blood cell count;	chr13:40679821	chr13:40822296~40921749:-
LUAD	cis	rs8046148	1	rs8046148	ENSG00000279356.1	RP11-429P3.8	3.63	0.00031	0.0354	0.19	0.16	Testicular germ cell tumor;	chr16:50109033	chr16:50072862~50074986:+
LUAD	cis	rs8046148	0.951	rs9933767	ENSG00000279356.1	RP11-429P3.8	3.63	0.00031	0.0354	0.19	0.16	Testicular germ cell tumor;	chr16:50109293	chr16:50072862~50074986:+
LUAD	cis	rs34656763	0.666	rs12063502	ENSG00000198468.6	FLVCR1-AS1	-3.63	0.00031	0.0354	-0.23	-0.16	Loneliness;Loneliness (multivariate analysis);Loneliness (linear analysis);	chr1:212521193	chr1:212852108~212858088:-
LUAD	cis	rs10102546	0.966	rs4871324	ENSG00000244642.3	RN7SL396P	3.63	0.00031	0.0354	0.19	0.16	Smoking cessation;	chr8:119531119	chr8:119862662~119862956:+
LUAD	cis	rs987044	0.7	rs7136703	ENSG00000257221.1	RP11-689B22.2	-3.63	0.00031	0.0354	-0.14	-0.16	Mean platelet volume;	chr12:108728679	chr12:108628687~108641318:+
LUAD	cis	rs4718428	0.705	rs28648401	ENSG00000230295.1	RP11-458F8.2	-3.63	0.00031	0.0354	-0.14	-0.16	Corneal structure;	chr7:66902145	chr7:66880708~66882981:+
LUAD	cis	rs17507216	0.718	rs4779034	ENSG00000276710.3	CSPG4P8	-3.63	0.000311	0.0354	-0.18	-0.16	Excessive daytime sleepiness;	chr15:82576799	chr15:82459472~82477258:+
LUAD	cis	rs10510102	0.935	rs12264495	ENSG00000276742.1	RP11-500G22.4	3.63	0.000311	0.0354	0.27	0.16	Breast cancer;	chr10:121919967	chr10:121956782~121957098:+
LUAD	cis	rs4835473	0.932	rs13152443	ENSG00000249741.2	RP11-673E1.3	3.63	0.000311	0.0354	0.2	0.16	Immature fraction of reticulocytes;	chr4:143742492	chr4:143911514~143912053:-
LUAD	cis	rs12908161	1	rs11632465	ENSG00000259654.1	RP11-245C17.2	-3.63	0.000311	0.0354	-0.23	-0.16	Schizophrenia;	chr15:84738814	chr15:84685884~84686946:+
LUAD	cis	rs1023500	0.505	rs134886	ENSG00000273366.1	CTA-989H11.1	3.63	0.000311	0.0354	0.19	0.16	Schizophrenia;	chr22:42277850	chr22:42278188~42278846:+
LUAD	cis	rs7572733	0.84	rs700640	ENSG00000222017.1	AC011997.1	3.63	0.000311	0.0354	0.21	0.16	Dermatomyositis;	chr2:197726162	chr2:197693106~197774823:+
LUAD	cis	rs9291683	0.679	rs3756225	ENSG00000250413.1	RP11-448G15.1	3.63	0.000311	0.0354	0.2	0.16	Bone mineral density;	chr4:10092509	chr4:10006482~10009725:+
LUAD	cis	rs7617773	0.817	rs9847953	ENSG00000199476.1	Y_RNA	-3.63	0.000311	0.0354	-0.21	-0.16	Coronary artery disease;	chr3:48241205	chr3:48288587~48288694:+
LUAD	cis	rs10129255	0.957	rs8009638	ENSG00000211947.2	IGHV3-21	-3.63	0.000311	0.0354	-0.11	-0.16	Kawasaki disease;	chr14:106777570	chr14:106235064~106235594:-
LUAD	cis	rs617791	0.53	rs735942	ENSG00000255320.1	RP11-755F10.1	3.63	0.000311	0.0354	0.21	0.16	Breast cancer;	chr11:65981866	chr11:66244840~66246239:-
LUAD	cis	rs77633900	0.892	rs2456040	ENSG00000196274.5	Metazoa_SRP	3.63	0.000311	0.0354	0.22	0.16	Glioma;Non-glioblastoma glioma;	chr15:76213506	chr15:76230048~76230390:-
LUAD	cis	rs12440869	1	rs28418884	ENSG00000270964.1	RP11-502I4.3	3.63	0.000311	0.0354	0.19	0.16	Peak velocity of the mitral A-wave;	chr15:67209639	chr15:67541072~67542604:-
LUAD	cis	rs10170310	1	rs6720716	ENSG00000228043.4	AC097721.2	3.63	0.000311	0.0354	0.23	0.16	Response to antipsychotic treatment;	chr2:138511232	chr2:138418284~138501698:-
LUAD	cis	rs4865762	0.512	rs16881069	ENSG00000247796.2	CTD-2366F13.1	3.63	0.000311	0.0354	0.18	0.16	Intraocular pressure;	chr5:53213746	chr5:53109842~53115126:+
LUAD	cis	rs12519773	0.717	rs67779882	ENSG00000251361.1	CTD-2091N23.1	-3.63	0.000311	0.0354	-0.18	-0.16	Migraine;	chr5:93152303	chr5:93019663~93068669:-
LUAD	cis	rs12519773	0.717	rs66496757	ENSG00000251361.1	CTD-2091N23.1	-3.63	0.000311	0.0354	-0.18	-0.16	Migraine;	chr5:93152356	chr5:93019663~93068669:-
LUAD	cis	rs12519773	0.611	rs6873704	ENSG00000251361.1	CTD-2091N23.1	-3.63	0.000311	0.0354	-0.18	-0.16	Migraine;	chr5:93155158	chr5:93019663~93068669:-
LUAD	cis	rs12519773	0.662	rs6883741	ENSG00000251361.1	CTD-2091N23.1	-3.63	0.000311	0.0354	-0.18	-0.16	Migraine;	chr5:93155775	chr5:93019663~93068669:-
LUAD	cis	rs4767841	0.565	rs4462403	ENSG00000248636.5	RP11-768F21.1	-3.63	0.000311	0.0354	-0.19	-0.16	Urgency urinary incontinence;	chr12:119773788	chr12:119387987~119668079:-
LUAD	cis	rs7772486	0.654	rs6928007	ENSG00000235652.6	RP11-545I5.3	-3.63	0.000311	0.0354	-0.16	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145753805	chr6:145799409~145886585:+
LUAD	cis	rs17711722	0.701	rs781143	ENSG00000234585.5	CCT6P3	3.63	0.000311	0.0354	0.15	0.16	Calcium levels;	chr7:65974892	chr7:65038354~65074713:+
LUAD	cis	rs6793245	0.801	rs55880069	ENSG00000229589.1	ACVR2B-AS1	-3.63	0.000311	0.0354	-0.21	-0.16	QT interval;	chr3:38541550	chr3:38451027~38454820:-
LUAD	cis	rs4819052	0.808	rs2246697	ENSG00000223768.1	LINC00205	-3.63	0.000311	0.0354	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270084	chr21:45293285~45297354:+
LUAD	cis	rs4819052	0.819	rs7279136	ENSG00000223768.1	LINC00205	-3.63	0.000311	0.0354	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45272372	chr21:45293285~45297354:+
LUAD	cis	rs4819052	0.788	rs4819051	ENSG00000223768.1	LINC00205	-3.63	0.000311	0.0354	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273213	chr21:45293285~45297354:+
LUAD	cis	rs4819052	0.819	rs8134084	ENSG00000223768.1	LINC00205	-3.63	0.000311	0.0354	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273380	chr21:45293285~45297354:+
LUAD	cis	rs3126085	0.515	rs11204994	ENSG00000237975.5	FLG-AS1	3.63	0.000311	0.0354	0.25	0.16	Atopic dermatitis;	chr1:152386164	chr1:152168125~152445456:+
LUAD	cis	rs1862618	0.511	rs2591952	ENSG00000271828.1	CTD-2310F14.1	3.63	0.000311	0.0355	0.24	0.16	Initial pursuit acceleration;	chr5:56824942	chr5:56927874~56929573:+
LUAD	cis	rs9400467	0.506	rs78344470	ENSG00000255389.1	C6orf3	3.63	0.000311	0.0355	0.22	0.16	Amino acid levels;Blood metabolite levels;	chr6:111440580	chr6:111599875~111602295:+
LUAD	cis	rs3805389	0.884	rs62310884	ENSG00000273257.1	RP11-177J6.1	-3.63	0.000311	0.0355	-0.22	-0.16	Waist-to-hip ratio adjusted for body mass index;	chr4:55592233	chr4:55387949~55388271:+
LUAD	cis	rs9910055	0.529	rs228757	ENSG00000267080.4	ASB16-AS1	3.63	0.000311	0.0355	0.16	0.16	Total body bone mineral density;	chr17:44087517	chr17:44175973~44186717:-
LUAD	cis	rs9860428	0.526	rs7646849	ENSG00000242770.2	RP11-180K7.1	3.63	0.000311	0.0355	0.17	0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112946451	chr3:112802478~112812819:+
LUAD	cis	rs9860428	0.526	rs6438120	ENSG00000242770.2	RP11-180K7.1	3.63	0.000311	0.0355	0.17	0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112947121	chr3:112802478~112812819:+
LUAD	cis	rs6763768	0.719	rs3755815	ENSG00000274967.1	Y_RNA	-3.63	0.000311	0.0355	-0.21	-0.16	Bacterial meningitis;	chr3:53493266	chr3:53290640~53290751:+
LUAD	cis	rs8180040	1	rs2159400	ENSG00000271161.1	BOLA2P2	-3.63	0.000311	0.0355	-0.15	-0.16	Colorectal cancer;	chr3:47334400	chr3:47499841~47500407:+
LUAD	cis	rs7605235	0.916	rs35602018	ENSG00000224165.4	DNAJC27-AS1	3.63	0.000311	0.0355	0.19	0.16	Response to platinum-based chemotherapy (cisplatin);	chr2:25412395	chr2:24971390~25039694:+
LUAD	cis	rs7260598	0.642	rs67799720	ENSG00000269421.1	ZNF92P3	-3.63	0.000311	0.0355	-0.25	-0.16	Response to taxane treatment (placlitaxel);	chr19:23981347	chr19:23935220~23936173:+
LUAD	cis	rs2664588	0.566	rs6012307	ENSG00000224565.1	RP1-148H17.1	-3.63	0.000311	0.0355	-0.17	-0.16	Cerebrospinal fluid AB1-42 levels;	chr20:47963425	chr20:47391929~47412327:-
LUAD	cis	rs2446066	0.659	rs2272002	ENSG00000257379.1	RP11-793H13.8	3.63	0.000311	0.0355	0.3	0.16	Red blood cell count;	chr12:53424132	chr12:53441741~53467528:+
LUAD	cis	rs1075265	0.783	rs805424	ENSG00000272156.1	RP11-477N3.1	-3.63	0.000311	0.0355	-0.19	-0.16	Chronotype;Morning vs. evening chronotype;	chr2:53901098	chr2:54082554~54085066:+
LUAD	cis	rs12908161	1	rs17600551	ENSG00000254414.1	RP11-182J1.1	3.63	0.000311	0.0355	0.21	0.16	Schizophrenia;	chr15:84776027	chr15:84631898~84633987:-
LUAD	cis	rs12908161	1	rs62019469	ENSG00000254414.1	RP11-182J1.1	3.63	0.000311	0.0355	0.21	0.16	Schizophrenia;	chr15:84777989	chr15:84631898~84633987:-
LUAD	cis	rs67539049	1	rs68063127	ENSG00000255046.1	RP11-297N6.4	3.63	0.000311	0.0355	0.24	0.16	Itch intensity from mosquito bite;	chr8:11446217	chr8:11797928~11802568:-
LUAD	cis	rs757081	0.667	rs12420958	ENSG00000260196.1	RP1-239B22.5	-3.63	0.000311	0.0355	-0.21	-0.16	Systolic blood pressure;	chr11:17078885	chr11:17380649~17383531:+
LUAD	cis	rs757081	0.667	rs12577388	ENSG00000260196.1	RP1-239B22.5	-3.63	0.000311	0.0355	-0.21	-0.16	Systolic blood pressure;	chr11:17079608	chr11:17380649~17383531:+
LUAD	cis	rs757081	0.667	rs1987694	ENSG00000260196.1	RP1-239B22.5	-3.63	0.000311	0.0355	-0.21	-0.16	Systolic blood pressure;	chr11:17086101	chr11:17380649~17383531:+
LUAD	cis	rs1355223	0.867	rs11821793	ENSG00000271369.1	RP11-350D17.3	-3.63	0.000311	0.0355	-0.19	-0.16	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34659915	chr11:34709600~34710161:+
LUAD	cis	rs7714584	1	rs2115069	ENSG00000197083.10	ZNF300P1	3.63	0.000312	0.0355	0.32	0.16	Crohn's disease;	chr5:150872803	chr5:150930645~150946289:-
LUAD	cis	rs794728	0.564	rs2913534	ENSG00000249031.1	SUMO2P6	3.63	0.000312	0.0355	0.18	0.16	Depressive symptoms (SSRI exposure interaction);	chr5:174432654	chr5:174561776~174562063:+
LUAD	cis	rs4819052	0.885	rs9980676	ENSG00000215447.6	BX322557.10	-3.63	0.000312	0.0355	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245515	chr21:45288052~45291738:+
LUAD	cis	rs735539	0.521	rs1348370	ENSG00000275485.1	RP11-261P13.6	-3.63	0.000312	0.0355	-0.2	-0.16	Dental caries;	chr13:20830519	chr13:20768876~20769375:-
LUAD	cis	rs748404	0.666	rs7177146	ENSG00000249839.1	AC011330.5	-3.63	0.000312	0.0355	-0.26	-0.16	Lung cancer;	chr15:43506110	chr15:43663654~43684339:-
LUAD	cis	rs797680	0.856	rs12124011	ENSG00000223745.6	RP4-717I23.3	3.63	0.000312	0.0355	0.13	0.16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93186987	chr1:93262186~93346025:-
LUAD	cis	rs7809950	1	rs10274041	ENSG00000238832.1	snoU109	3.63	0.000312	0.0355	0.24	0.16	Coronary artery disease;	chr7:107621111	chr7:107603363~107603507:+
LUAD	cis	rs7129556	0.954	rs6592738	ENSG00000241782.1	RP11-91P24.1	3.63	0.000312	0.0355	0.21	0.16	Weight loss (gastric bypass surgery);	chr11:77612081	chr11:77868722~77869195:-
LUAD	cis	rs590820	0.649	rs2281718	ENSG00000227934.1	RP11-423F24.3	-3.63	0.000312	0.0355	-0.19	-0.16	Metabolite levels (lipoprotein measures);	chr1:230162032	chr1:231021611~231022183:+
LUAD	cis	rs4818048	1	rs4818048	ENSG00000255568.3	BRWD1-AS2	3.63	0.000312	0.0355	0.31	0.16	Obsessive-compulsive symptoms;	chr21:39537025	chr21:39313935~39314962:+
LUAD	cis	rs2274273	0.662	rs4040064	ENSG00000258413.1	RP11-665C16.6	-3.63	0.000312	0.0355	-0.23	-0.16	Protein biomarker;	chr14:55211370	chr14:55262767~55272075:-
LUAD	cis	rs74233809	0.636	rs284861	ENSG00000213277.3	MARCKSL1P1	-3.63	0.000312	0.0355	-0.23	-0.16	Birth weight;	chr10:102812519	chr10:103175554~103176094:+
LUAD	cis	rs3772130	1	rs34086988	ENSG00000243544.3	RN7SL172P	3.63	0.000312	0.0355	0.2	0.16	Cognitive performance;	chr3:121633898	chr3:121653994~121654296:-
LUAD	cis	rs6687821	0.515	rs2390219	ENSG00000267272.4	LINC01140	3.63	0.000312	0.0355	0.19	0.16	Yeast infection;	chr1:86988738	chr1:87129765~87169198:+
LUAD	cis	rs13068223	0.617	rs13061457	ENSG00000243926.1	TIPARP-AS1	3.63	0.000312	0.0355	0.17	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr3:156725596	chr3:156671862~156674378:-
LUAD	cis	rs8056893	0.842	rs4783553	ENSG00000274698.1	RP11-71L14.4	-3.63	0.000312	0.0355	-0.18	-0.16	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68332052	chr16:68450283~68452318:+
LUAD	cis	rs2024714	0.967	rs2427196	ENSG00000273812.1	WI2-87327B8.2	-3.63	0.000312	0.0355	-0.17	-0.16	Longevity;	chr20:61629248	chr20:62596732~62603115:-
LUAD	cis	rs643506	1	rs1788955	ENSG00000230911.1	PPIHP1	-3.63	0.000312	0.0355	-0.21	-0.16	Breast cancer;	chr11:111760274	chr11:112029858~112030367:-
LUAD	cis	rs6883311	0.922	rs10866661	ENSG00000254211.4	LINC01485	3.63	0.000312	0.0355	0.15	0.16	Immunoglobulin A vasculitis;	chr5:173374410	chr5:173786790~173809039:-
LUAD	cis	rs7772486	0.686	rs1415744	ENSG00000235652.6	RP11-545I5.3	3.63	0.000312	0.0355	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145701395	chr6:145799409~145886585:+
LUAD	cis	rs6928977	0.675	rs7759971	ENSG00000231028.7	LINC00271	-3.63	0.000312	0.0355	-0.2	-0.16	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135425746	chr6:135497801~135716055:+
LUAD	cis	rs2535633	0.631	rs2465101	ENSG00000243224.1	RP5-1157M23.2	3.63	0.000312	0.0355	0.18	0.16	Body mass index;	chr3:52957291	chr3:52239258~52241097:+
LUAD	cis	rs9650657	0.571	rs4240673	ENSG00000255310.2	AF131215.2	-3.63	0.000312	0.0355	-0.17	-0.16	Neuroticism;	chr8:10930102	chr8:11107788~11109726:-
LUAD	cis	rs417065	0.516	rs6687168	ENSG00000227634.1	RP11-431K24.3	-3.63	0.000312	0.0355	-0.22	-0.16	Psoriasis;	chr1:8208853	chr1:8208672~8215210:+
LUAD	cis	rs2985684	0.894	rs10147029	ENSG00000278009.1	RP11-649E7.8	-3.63	0.000312	0.0356	-0.21	-0.16	Carotid intima media thickness;	chr14:49553514	chr14:49601011~49601124:-
LUAD	cis	rs7829975	0.714	rs4841040	ENSG00000233609.3	RP11-62H7.2	3.63	0.000312	0.0356	0.13	0.16	Mood instability;	chr8:8797017	chr8:8961200~8979025:+
LUAD	cis	rs7615952	0.8	rs2062773	ENSG00000241288.6	RP11-379B18.5	-3.63	0.000312	0.0356	-0.21	-0.16	Blood pressure (smoking interaction);	chr3:125920805	chr3:125827238~125916384:-
LUAD	cis	rs55702914	0.712	rs12619296	ENSG00000222017.1	AC011997.1	-3.63	0.000312	0.0356	-0.2	-0.16	Major depression and alcohol dependence;	chr2:197284043	chr2:197693106~197774823:+
LUAD	cis	rs76382185	0.61	rs6658449	ENSG00000233184.5	RP11-421L21.3	3.63	0.000312	0.0356	0.3	0.16	Lymphocyte counts;	chr1:101108353	chr1:101025878~101087268:+
LUAD	cis	rs7515577	0.898	rs59679370	ENSG00000223787.2	RP4-593M8.1	3.63	0.000312	0.0356	0.25	0.16	Cholesterol, total;	chr1:92456933	chr1:92580476~92580821:-
LUAD	cis	rs12073837	0.784	rs6673877	ENSG00000272823.1	RP11-295M18.6	-3.63	0.000312	0.0356	-0.21	-0.16	F-cell distribution;	chr1:220817642	chr1:220828676~220829211:-
LUAD	cis	rs1577917	0.655	rs9342045	ENSG00000220563.1	PKMP3	3.63	0.000312	0.0356	0.15	0.16	Response to antipsychotic treatment;	chr6:85715430	chr6:85659892~85660606:-
LUAD	cis	rs9467773	0.595	rs12525810	ENSG00000241549.7	GUSBP2	3.63	0.000312	0.0356	0.19	0.16	Intelligence (multi-trait analysis);	chr6:26623283	chr6:26871484~26956554:-
LUAD	cis	rs7537765	0.649	rs2066470	ENSG00000242349.4	NPPA-AS1	3.63	0.000312	0.0356	0.32	0.16	QRS complex (12-leadsum);	chr1:11803000	chr1:11841017~11848079:+
LUAD	cis	rs11960314	0.643	rs924876	ENSG00000253348.1	CTC-455F18.1	3.63	0.000312	0.0356	0.19	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr5:170651295	chr5:170747047~170788650:-
LUAD	cis	rs6496932	0.503	rs2086756	ENSG00000259630.2	CTD-2262B20.1	-3.63	0.000312	0.0356	-0.21	-0.16	Central corneal thickness;Corneal structure;	chr15:85424322	chr15:85415228~85415633:+
LUAD	cis	rs7937127	0.649	rs4132524	ENSG00000254907.1	RP11-484D2.2	3.63	0.000312	0.0356	0.28	0.16	Fibrinogen levels;	chr11:43366611	chr11:43328748~43359296:-
LUAD	cis	rs7937127	0.744	rs72900934	ENSG00000254907.1	RP11-484D2.2	3.63	0.000312	0.0356	0.28	0.16	Fibrinogen levels;	chr11:43410740	chr11:43328748~43359296:-
LUAD	cis	rs7937127	0.744	rs11602575	ENSG00000254907.1	RP11-484D2.2	3.63	0.000312	0.0356	0.28	0.16	Fibrinogen levels;	chr11:43411957	chr11:43328748~43359296:-
LUAD	cis	rs10045504	0.502	rs17456198	ENSG00000251189.1	CTD-2196P11.2	3.63	0.000312	0.0356	0.28	0.16	Night sleep phenotypes;	chr5:38731903	chr5:38682070~38685126:+
LUAD	cis	rs12908161	0.96	rs62019463	ENSG00000254414.1	RP11-182J1.1	3.63	0.000312	0.0356	0.21	0.16	Schizophrenia;	chr15:84744856	chr15:84631898~84633987:-
LUAD	cis	rs875971	0.522	rs10807697	ENSG00000273142.1	RP11-458F8.4	-3.63	0.000313	0.0356	-0.11	-0.16	Aortic root size;	chr7:65951183	chr7:66902857~66906297:+
LUAD	cis	rs3213758	1	rs2024474	ENSG00000261630.1	RP11-357N13.3	-3.63	0.000313	0.0356	-0.33	-0.16	Vitiligo (non-segmental);	chr16:53546370	chr16:53981229~53981912:-
LUAD	cis	rs6736093	0.704	rs11897014	ENSG00000207383.1	Y_RNA	-3.63	0.000313	0.0356	-0.21	-0.16	Coronary artery disease;	chr2:112038331	chr2:112579484~112579584:-
LUAD	cis	rs3126085	0.935	rs11204943	ENSG00000237975.5	FLG-AS1	-3.63	0.000313	0.0356	-0.25	-0.16	Atopic dermatitis;	chr1:152231430	chr1:152168125~152445456:+
LUAD	cis	rs3126085	0.935	rs4845751	ENSG00000237975.5	FLG-AS1	-3.63	0.000313	0.0356	-0.25	-0.16	Atopic dermatitis;	chr1:152236521	chr1:152168125~152445456:+
LUAD	cis	rs8002861	0.935	rs1819595	ENSG00000274001.1	RP11-5G9.5	3.63	0.000313	0.0356	0.17	0.16	Leprosy;	chr13:43855580	chr13:43877715~43878163:-
LUAD	cis	rs12216545	0.737	rs6464075	ENSG00000241134.3	BET1P1	-3.63	0.000313	0.0356	-0.17	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150537453	chr7:150749736~150750094:+
LUAD	cis	rs1635	0.655	rs1416919	ENSG00000216901.1	AL022393.7	3.63	0.000313	0.0356	0.33	0.16	Schizophrenia;	chr6:28335107	chr6:28176188~28176674:+
LUAD	cis	rs1635	0.655	rs73742535	ENSG00000216901.1	AL022393.7	3.63	0.000313	0.0356	0.33	0.16	Schizophrenia;	chr6:28335148	chr6:28176188~28176674:+
LUAD	cis	rs1635	0.655	rs73742536	ENSG00000216901.1	AL022393.7	3.63	0.000313	0.0356	0.33	0.16	Schizophrenia;	chr6:28335466	chr6:28176188~28176674:+
LUAD	cis	rs1635	0.655	rs59598126	ENSG00000216901.1	AL022393.7	3.63	0.000313	0.0356	0.33	0.16	Schizophrenia;	chr6:28335823	chr6:28176188~28176674:+
LUAD	cis	rs1635	0.655	rs2281041	ENSG00000216901.1	AL022393.7	3.63	0.000313	0.0356	0.33	0.16	Schizophrenia;	chr6:28336068	chr6:28176188~28176674:+
LUAD	cis	rs1635	0.655	rs58019071	ENSG00000216901.1	AL022393.7	3.63	0.000313	0.0356	0.33	0.16	Schizophrenia;	chr6:28336239	chr6:28176188~28176674:+
LUAD	cis	rs6781182	0.517	rs11129588	ENSG00000236452.1	AC123023.1	-3.63	0.000313	0.0356	-0.18	-0.16	Visceral adipose tissue adjusted for BMI;	chr3:34182513	chr3:34203244~34268811:+
LUAD	cis	rs4819052	0.851	rs914214	ENSG00000223768.1	LINC00205	-3.63	0.000313	0.0356	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45277905	chr21:45293285~45297354:+
LUAD	cis	rs7074356	0.522	rs1591958	ENSG00000226659.1	RP11-137H2.4	3.63	0.000313	0.0356	0.26	0.16	Borderline personality disorder;	chr10:80302905	chr10:80529597~80535942:-
LUAD	cis	rs520525	0.963	rs501680	ENSG00000271811.1	RP1-79C4.4	3.63	0.000313	0.0356	0.2	0.16	Atrial fibrillation;	chr1:170656726	chr1:170667381~170669425:+
LUAD	cis	rs9313772	0.775	rs7708926	ENSG00000276778.1	RP11-524N5.1	3.63	0.000313	0.0356	0.16	0.16	Blood pressure;	chr5:158410759	chr5:158320683~158409773:-
LUAD	cis	rs9595908	0.709	rs7318563	ENSG00000281026.1	N4BP2L2-IT2	-3.63	0.000313	0.0356	-0.1	-0.16	Body mass index;	chr13:32749348	chr13:32504506~32509395:-
LUAD	cis	rs2007126	0.636	rs4837443	ENSG00000224797.1	RP11-57C19.6	3.63	0.000313	0.0356	0.29	0.16	LDL peak particle diameter (total fat intake interaction);	chr9:129993491	chr9:130724786~130725050:-
LUAD	cis	rs77972916	0.561	rs13411485	ENSG00000234936.1	AC010883.5	-3.63	0.000313	0.0356	-0.22	-0.16	Granulocyte percentage of myeloid white cells;	chr2:43348845	chr2:43229573~43233394:+
LUAD	cis	rs17122278	1	rs17122278	ENSG00000243431.1	RPL5P30	-3.63	0.000313	0.0356	-0.21	-0.16	Total cholesterol levels;	chr11:118578655	chr11:118560690~118561580:+
LUAD	cis	rs7107174	1	rs4944198	ENSG00000251323.2	RP11-452H21.4	3.63	0.000313	0.0356	0.21	0.16	Testicular germ cell tumor;	chr11:78321559	chr11:78423982~78429836:-
LUAD	cis	rs73198271	0.96	rs17154702	ENSG00000253893.2	FAM85B	3.63	0.000313	0.0356	0.22	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8752370	chr8:8167819~8226614:-
LUAD	cis	rs526231	0.819	rs35801	ENSG00000175749.11	EIF3KP1	3.63	0.000313	0.0356	0.22	0.16	Primary biliary cholangitis;	chr5:103272512	chr5:103032376~103033031:+
LUAD	cis	rs13113518	0.812	rs12505880	ENSG00000273257.1	RP11-177J6.1	3.63	0.000313	0.0356	0.18	0.16	Height;	chr4:55440988	chr4:55387949~55388271:+
LUAD	cis	rs2348418	0.831	rs7296538	ENSG00000247934.4	RP11-967K21.1	-3.63	0.000313	0.0356	-0.19	-0.16	Lung function (FEV1);Lung function (FVC);	chr12:28558850	chr12:28163298~28190738:-
LUAD	cis	rs7674212	0.541	rs2251322	ENSG00000246560.2	RP11-10L12.4	3.63	0.000313	0.0356	0.21	0.16	Type 2 diabetes;	chr4:103158267	chr4:102828055~102844075:+
LUAD	cis	rs2638953	0.924	rs11049403	ENSG00000278733.1	RP11-425D17.1	-3.63	0.000313	0.0356	-0.2	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28177105	chr12:28185625~28186190:-
LUAD	cis	rs6438234	0.744	rs6762228	ENSG00000242767.1	ZBTB20-AS4	3.63	0.000313	0.0356	0.21	0.16	Type 2 diabetes;	chr3:115220954	chr3:115100423~115103061:+
LUAD	cis	rs11064837	0.504	rs11064850	ENSG00000248636.5	RP11-768F21.1	3.63	0.000313	0.0356	0.19	0.16	Schizophrenia;	chr12:119617981	chr12:119387987~119668079:-
LUAD	cis	rs7572733	0.935	rs771016	ENSG00000222017.1	AC011997.1	3.63	0.000313	0.0356	0.21	0.16	Dermatomyositis;	chr2:197800796	chr2:197693106~197774823:+
LUAD	cis	rs683250	0.569	rs11233577	ENSG00000246067.6	RAB30-AS1	-3.63	0.000313	0.0356	-0.18	-0.16	Subcortical brain region volumes;	chr11:83356345	chr11:83072066~83106719:+
LUAD	cis	rs683250	0.569	rs4617618	ENSG00000246067.6	RAB30-AS1	-3.63	0.000313	0.0356	-0.18	-0.16	Subcortical brain region volumes;	chr11:83356502	chr11:83072066~83106719:+
LUAD	cis	rs683250	0.599	rs4590895	ENSG00000246067.6	RAB30-AS1	-3.63	0.000313	0.0356	-0.18	-0.16	Subcortical brain region volumes;	chr11:83356617	chr11:83072066~83106719:+
LUAD	cis	rs9303542	1	rs12944592	ENSG00000264920.1	RP11-6N17.4	-3.63	0.000313	0.0357	-0.21	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48353043	chr17:47891255~47895812:-
LUAD	cis	rs7560272	0.538	rs3980695	ENSG00000163016.8	ALMS1P	-3.63	0.000313	0.0357	-0.17	-0.16	Schizophrenia;	chr2:73712425	chr2:73644919~73685576:+
LUAD	cis	rs3764021	0.87	rs10772085	ENSG00000256582.1	RP11-75L1.1	3.63	0.000313	0.0357	0.17	0.16	Type 1 diabetes;	chr12:9724281	chr12:9704077~9709350:+
LUAD	cis	rs2795502	0.935	rs2744060	ENSG00000185904.10	LINC00839	-3.63	0.000313	0.0357	-0.32	-0.16	Blood protein levels;	chr10:42767168	chr10:42475543~42495336:+
LUAD	cis	rs7077256	0.564	rs12775231	ENSG00000272767.1	JMJD1C-AS1	3.63	0.000313	0.0357	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63258493	chr10:63465229~63466563:+
LUAD	cis	rs4819052	0.851	rs10470246	ENSG00000215447.6	BX322557.10	-3.63	0.000313	0.0357	-0.19	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239102	chr21:45288052~45291738:+
LUAD	cis	rs4819052	0.851	rs10470247	ENSG00000215447.6	BX322557.10	-3.63	0.000313	0.0357	-0.19	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239103	chr21:45288052~45291738:+
LUAD	cis	rs4819052	0.851	rs4819043	ENSG00000215447.6	BX322557.10	-3.63	0.000313	0.0357	-0.19	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240163	chr21:45288052~45291738:+
LUAD	cis	rs4819052	0.851	rs4819044	ENSG00000215447.6	BX322557.10	-3.63	0.000313	0.0357	-0.19	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240203	chr21:45288052~45291738:+
LUAD	cis	rs12554020	0.681	rs75519210	ENSG00000227603.1	RP11-165J3.6	3.63	0.000313	0.0357	0.34	0.16	Schizophrenia;	chr9:93661448	chr9:93435332~93437121:-
LUAD	cis	rs12554020	0.504	rs74369348	ENSG00000227603.1	RP11-165J3.6	3.63	0.000313	0.0357	0.34	0.16	Schizophrenia;	chr9:93664902	chr9:93435332~93437121:-
LUAD	cis	rs7339483	0.541	rs1433128	ENSG00000268058.1	BNIP3P40	-3.63	0.000313	0.0357	-0.27	-0.16	Discordance in emotional problems in monozygotic twins;	chr19:24157827	chr19:24098425~24098980:-
LUAD	cis	rs1075265	0.783	rs805439	ENSG00000272156.1	RP11-477N3.1	-3.63	0.000313	0.0357	-0.19	-0.16	Chronotype;Morning vs. evening chronotype;	chr2:53829437	chr2:54082554~54085066:+
LUAD	cis	rs2295359	1	rs12043240	ENSG00000275678.1	RP4-547N15.3	-3.63	0.000314	0.0357	-0.17	-0.16	Psoriasis;	chr1:67158621	chr1:67121605~67123956:-
LUAD	cis	rs9543976	0.858	rs9530447	ENSG00000261105.4	LMO7-AS1	3.63	0.000314	0.0357	0.26	0.16	Diabetic retinopathy;	chr13:75592666	chr13:75604700~75635994:-
LUAD	cis	rs875971	0.862	rs4718383	ENSG00000273448.1	RP11-166O4.6	-3.63	0.000314	0.0357	-0.16	-0.16	Aortic root size;	chr7:66643422	chr7:67333047~67334383:+
LUAD	cis	rs7617773	0.709	rs4404473	ENSG00000199476.1	Y_RNA	-3.63	0.000314	0.0357	-0.22	-0.16	Coronary artery disease;	chr3:48312136	chr3:48288587~48288694:+
LUAD	cis	rs4144027	0.904	rs10438243	ENSG00000258534.1	CTD-2134A5.4	3.63	0.000314	0.0357	0.18	0.16	Blood metabolite levels;	chr14:103879485	chr14:103854366~103880111:-
LUAD	cis	rs1910358	0.566	rs320572	ENSG00000248874.4	C5orf17	-3.63	0.000314	0.0357	-0.25	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23848157	chr5:23951348~24178263:+
LUAD	cis	rs926392	0.896	rs1569538	ENSG00000274825.1	RP4-616B8.5	3.63	0.000314	0.0357	0.2	0.16	Dialysis-related mortality;	chr20:39056573	chr20:38955910~38956547:+
LUAD	cis	rs9341808	0.935	rs2298307	ENSG00000272129.1	RP11-250B2.6	3.63	0.000314	0.0357	0.19	0.16	Sitting height ratio;	chr6:80106579	chr6:80355424~80356859:+
LUAD	cis	rs2333021	1	rs4899453	ENSG00000259015.1	RP11-109N23.6	-3.63	0.000314	0.0357	-0.15	-0.16	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73021883	chr14:72960595~72961993:+
LUAD	cis	rs8031584	0.781	rs4779498	ENSG00000260128.5	ULK4P2	-3.63	0.000314	0.0357	-0.21	-0.16	Huntington's disease progression;	chr15:30885273	chr15:30572738~30600647:+
LUAD	cis	rs4388249	0.687	rs10041575	ENSG00000271849.1	CTC-332L22.1	-3.63	0.000314	0.0357	-0.23	-0.16	Schizophrenia;	chr5:109768576	chr5:109687802~109688329:-
LUAD	cis	rs858239	0.632	rs7811903	ENSG00000226816.2	AC005082.12	3.63	0.000314	0.0357	0.22	0.16	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23206013~23208045:+
LUAD	cis	rs7107174	1	rs10899456	ENSG00000251323.2	RP11-452H21.4	3.63	0.000314	0.0357	0.21	0.16	Testicular germ cell tumor;	chr11:78289109	chr11:78423982~78429836:-
LUAD	cis	rs35740288	0.694	rs17618909	ENSG00000259295.5	CSPG4P12	3.63	0.000314	0.0357	0.2	0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85552231	chr15:85191438~85213905:+
LUAD	cis	rs42490	0.638	rs40637	ENSG00000251136.7	RP11-37B2.1	-3.63	0.000314	0.0357	-0.16	-0.16	Leprosy;	chr8:89811082	chr8:89609409~89757727:-
LUAD	cis	rs214785	1	rs214790	ENSG00000234684.5	SDCBP2-AS1	3.63	0.000314	0.0357	0.2	0.16	Basal cell carcinoma;	chr20:2304260	chr20:1325405~1378734:+
LUAD	cis	rs214785	1	rs214791	ENSG00000234684.5	SDCBP2-AS1	3.63	0.000314	0.0357	0.2	0.16	Basal cell carcinoma;	chr20:2304328	chr20:1325405~1378734:+
LUAD	cis	rs214785	1	rs214792	ENSG00000234684.5	SDCBP2-AS1	3.63	0.000314	0.0357	0.2	0.16	Basal cell carcinoma;	chr20:2304389	chr20:1325405~1378734:+
LUAD	cis	rs7077256	0.564	rs871689	ENSG00000272767.1	JMJD1C-AS1	3.63	0.000314	0.0357	0.25	0.16	Intelligence (multi-trait analysis);	chr10:63134287	chr10:63465229~63466563:+
LUAD	cis	rs3769124	0.513	rs6755460	ENSG00000234949.2	AC104667.3	3.63	0.000314	0.0357	0.26	0.16	Pulmonary function;	chr2:238582119	chr2:237591020~237595981:+
LUAD	cis	rs13113518	0.756	rs11939652	ENSG00000273257.1	RP11-177J6.1	3.63	0.000314	0.0357	0.18	0.16	Height;	chr4:55532542	chr4:55387949~55388271:+
LUAD	cis	rs4865762	0.512	rs1445992	ENSG00000247796.2	CTD-2366F13.1	3.63	0.000314	0.0357	0.18	0.16	Intraocular pressure;	chr5:53212451	chr5:53109842~53115126:+
LUAD	cis	rs877819	0.583	rs2663049	ENSG00000228403.1	RP11-563N6.6	-3.63	0.000314	0.0357	-0.17	-0.16	Systemic lupus erythematosus;	chr10:48858716	chr10:48878022~48878649:+
LUAD	cis	rs76419734	1	rs75904349	ENSG00000251175.4	RP11-45L9.1	-3.63	0.000314	0.0357	-0.38	-0.16	Post bronchodilator FEV1;	chr4:105605537	chr4:105746245~105827172:-
LUAD	cis	rs6921919	0.583	rs740621	ENSG00000219392.1	RP1-265C24.5	-3.63	0.000314	0.0357	-0.21	-0.16	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28115628~28116551:+
LUAD	cis	rs6921919	0.583	rs740622	ENSG00000219392.1	RP1-265C24.5	-3.63	0.000314	0.0357	-0.21	-0.16	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28115628~28116551:+
LUAD	cis	rs11159086	1	rs4899514	ENSG00000270000.1	RP3-449M8.9	-3.63	0.000314	0.0357	-0.23	-0.16	Advanced glycation end-product levels;	chr14:74473467	chr14:74471930~74472360:-
LUAD	cis	rs7772486	0.686	rs1045820	ENSG00000235652.6	RP11-545I5.3	3.63	0.000314	0.0357	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145625944	chr6:145799409~145886585:+
LUAD	cis	rs3126085	0.935	rs1496045	ENSG00000237975.5	FLG-AS1	-3.63	0.000314	0.0357	-0.25	-0.16	Atopic dermatitis;	chr1:152212228	chr1:152168125~152445456:+
LUAD	cis	rs3126085	0.735	rs4845744	ENSG00000237975.5	FLG-AS1	-3.63	0.000314	0.0357	-0.25	-0.16	Atopic dermatitis;	chr1:152212619	chr1:152168125~152445456:+
LUAD	cis	rs3126085	0.935	rs4845745	ENSG00000237975.5	FLG-AS1	-3.63	0.000314	0.0357	-0.25	-0.16	Atopic dermatitis;	chr1:152212708	chr1:152168125~152445456:+
LUAD	cis	rs4727963	0.811	rs7458859	ENSG00000240499.6	RP5-1101C3.1	-3.63	0.000314	0.0357	-0.15	-0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);	chr7:123071304	chr7:122328469~122440388:+
LUAD	cis	rs7826238	0.509	rs2948288	ENSG00000233609.3	RP11-62H7.2	3.63	0.000314	0.0357	0.14	0.16	Systolic blood pressure;	chr8:8257782	chr8:8961200~8979025:+
LUAD	cis	rs7613875	0.663	rs6762477	ENSG00000234667.1	ACTBP13	3.63	0.000314	0.0357	0.18	0.16	Body mass index;	chr3:50055776	chr3:49873347~49877980:-
LUAD	cis	rs11846409	0.932	rs28378201	ENSG00000211972.2	IGHV3-66	3.63	0.000314	0.0357	0.17	0.16	Rheumatic heart disease;	chr14:106637262	chr14:106675017~106675544:-
LUAD	cis	rs11846409	0.86	rs74091720	ENSG00000211972.2	IGHV3-66	3.63	0.000314	0.0357	0.17	0.16	Rheumatic heart disease;	chr14:106638192	chr14:106675017~106675544:-
LUAD	cis	rs11089937	0.626	rs5757011	ENSG00000211640.3	IGLV6-57	3.63	0.000314	0.0358	0.12	0.16	Periodontitis (PAL4Q3);	chr22:22135336	chr22:22195713~22196460:+
LUAD	cis	rs72843166	0.853	rs75514394	ENSG00000265282.1	RP11-269G24.4	3.63	0.000314	0.0358	0.25	0.16	Intelligence (multi-trait analysis);	chr17:63277411	chr17:63430468~63432211:-
LUAD	cis	rs72843166	0.853	rs74909212	ENSG00000265282.1	RP11-269G24.4	3.63	0.000314	0.0358	0.25	0.16	Intelligence (multi-trait analysis);	chr17:63277422	chr17:63430468~63432211:-
LUAD	cis	rs4795519	0.885	rs11867203	ENSG00000266313.1	RP11-173M1.4	3.63	0.000314	0.0358	0.2	0.16	Chronic myeloid leukemia;	chr17:27089292	chr17:27333256~27348491:+
LUAD	cis	rs4795519	0.667	rs7211637	ENSG00000266313.1	RP11-173M1.4	3.63	0.000314	0.0358	0.2	0.16	Chronic myeloid leukemia;	chr17:27091492	chr17:27333256~27348491:+
LUAD	cis	rs4795519	0.645	rs7211651	ENSG00000266313.1	RP11-173M1.4	3.63	0.000314	0.0358	0.2	0.16	Chronic myeloid leukemia;	chr17:27091520	chr17:27333256~27348491:+
LUAD	cis	rs9291683	0.53	rs10939620	ENSG00000250413.1	RP11-448G15.1	3.63	0.000314	0.0358	0.21	0.16	Bone mineral density;	chr4:9944508	chr4:10006482~10009725:+
LUAD	cis	rs7512552	0.839	rs832622	ENSG00000275557.1	RP11-353N4.6	3.63	0.000315	0.0358	0.18	0.16	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150420354	chr1:149607765~149612402:+
LUAD	cis	rs7512552	0.839	rs11577843	ENSG00000275557.1	RP11-353N4.6	3.63	0.000315	0.0358	0.18	0.16	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150425782	chr1:149607765~149612402:+
LUAD	cis	rs7512552	0.839	rs11590787	ENSG00000275557.1	RP11-353N4.6	3.63	0.000315	0.0358	0.18	0.16	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150426055	chr1:149607765~149612402:+
LUAD	cis	rs3740713	1	rs35593189	ENSG00000256464.1	YWHABP2	3.63	0.000315	0.0358	0.31	0.16	Amyotrophic lateral sclerosis (sporadic);	chr11:18446831	chr11:18490243~18490955:-
LUAD	cis	rs7202877	0.611	rs56092808	ENSG00000280152.1	RP11-331F4.5	3.63	0.000315	0.0358	0.2	0.16	Type 1 diabetes;Type 2 diabetes;	chr16:75278818	chr16:75245994~75250077:-
LUAD	cis	rs1722141	0.67	rs2965073	ENSG00000237471.1	AC073115.6	3.63	0.000315	0.0358	0.26	0.16	Sitting height ratio;	chr7:45941524	chr7:45969657~45980191:+
LUAD	cis	rs1722141	0.6	rs1525819	ENSG00000237471.1	AC073115.6	3.63	0.000315	0.0358	0.26	0.16	Sitting height ratio;	chr7:45945301	chr7:45969657~45980191:+
LUAD	cis	rs4853525	0.859	rs1882396	ENSG00000235852.1	AC005540.3	3.63	0.000315	0.0358	0.18	0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190851286	chr2:190880797~190882059:-
LUAD	cis	rs4853525	0.859	rs1894775	ENSG00000235852.1	AC005540.3	3.63	0.000315	0.0358	0.18	0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190851980	chr2:190880797~190882059:-
LUAD	cis	rs6479901	0.846	rs7082926	ENSG00000232075.1	MRPL35P2	-3.63	0.000315	0.0358	-0.23	-0.16	Intelligence (multi-trait analysis);	chr10:63355771	chr10:63634317~63634827:-
LUAD	cis	rs7551222	0.646	rs1398148	ENSG00000240219.1	RP11-430C7.5	3.63	0.000315	0.0358	0.17	0.16	Schizophrenia;	chr1:204489200	chr1:204626775~204629712:+
LUAD	cis	rs755249	1	rs17513135	ENSG00000182109.6	RP11-69E11.4	3.63	0.000315	0.0358	0.2	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39570014	chr1:39522280~39546187:-
LUAD	cis	rs2380205	0.967	rs11255581	ENSG00000232807.2	RP11-536K7.3	3.63	0.000315	0.0358	0.17	0.16	Breast cancer;	chr10:5856919	chr10:5934270~5945900:-
LUAD	cis	rs10510102	0.872	rs11814703	ENSG00000276742.1	RP11-500G22.4	3.63	0.000315	0.0358	0.28	0.16	Breast cancer;	chr10:121964774	chr10:121956782~121957098:+
LUAD	cis	rs10510102	0.872	rs12259144	ENSG00000276742.1	RP11-500G22.4	3.63	0.000315	0.0358	0.28	0.16	Breast cancer;	chr10:121965433	chr10:121956782~121957098:+
LUAD	cis	rs721917	0.569	rs2247820	ENSG00000244733.5	RP11-506M13.3	-3.63	0.000315	0.0358	-0.17	-0.16	Chronic obstructive pulmonary disease;	chr10:79963123	chr10:79660891~79677996:+
LUAD	cis	rs6964587	1	rs2075881	ENSG00000188693.7	CYP51A1-AS1	-3.63	0.000315	0.0358	-0.19	-0.16	Breast cancer;	chr7:92105238	chr7:92134604~92180725:+
LUAD	cis	rs6964587	1	rs7785971	ENSG00000188693.7	CYP51A1-AS1	-3.63	0.000315	0.0358	-0.19	-0.16	Breast cancer;	chr7:92107480	chr7:92134604~92180725:+
LUAD	cis	rs6964587	0.967	rs10231496	ENSG00000188693.7	CYP51A1-AS1	-3.63	0.000315	0.0358	-0.19	-0.16	Breast cancer;	chr7:92111818	chr7:92134604~92180725:+
LUAD	cis	rs11239930	0.517	rs590286	ENSG00000225603.3	RP11-325P15.1	3.63	0.000315	0.0358	0.2	0.16	AIDS progression;	chr1:147074056	chr1:147050817~147052481:+
LUAD	cis	rs6120849	1	rs6120849	ENSG00000202150.1	RNU6-407P	3.63	0.000315	0.0358	0.22	0.16	Protein C levels;	chr20:35142584	chr20:35030317~35030420:-
LUAD	cis	rs7976269	0.609	rs10771478	ENSG00000275476.1	RP11-996F15.4	3.63	0.000315	0.0358	0.18	0.16	Male-pattern baldness;	chr12:29075351	chr12:29277397~29277882:-
LUAD	cis	rs910316	0.737	rs2098251	ENSG00000259138.1	RP11-950C14.7	3.63	0.000315	0.0358	0.17	0.16	Height;	chr14:75025993	chr14:75127153~75136930:+
LUAD	cis	rs910316	0.664	rs2098252	ENSG00000259138.1	RP11-950C14.7	3.63	0.000315	0.0358	0.17	0.16	Height;	chr14:75026029	chr14:75127153~75136930:+
LUAD	cis	rs924712	0.545	rs12216039	ENSG00000261116.1	RP3-523K23.2	3.63	0.000315	0.0358	0.17	0.16	Breast cancer;	chr6:54845124	chr6:54943167~54945099:+
LUAD	cis	rs4795519	1	rs2061899	ENSG00000266313.1	RP11-173M1.4	3.63	0.000315	0.0358	0.2	0.16	Chronic myeloid leukemia;	chr17:27082786	chr17:27333256~27348491:+
LUAD	cis	rs4795519	1	rs11652017	ENSG00000266313.1	RP11-173M1.4	3.63	0.000315	0.0358	0.2	0.16	Chronic myeloid leukemia;	chr17:27083613	chr17:27333256~27348491:+
LUAD	cis	rs4795519	1	rs11650889	ENSG00000266313.1	RP11-173M1.4	3.63	0.000315	0.0358	0.2	0.16	Chronic myeloid leukemia;	chr17:27083708	chr17:27333256~27348491:+
LUAD	cis	rs4795519	1	rs11653183	ENSG00000266313.1	RP11-173M1.4	3.63	0.000315	0.0358	0.2	0.16	Chronic myeloid leukemia;	chr17:27084115	chr17:27333256~27348491:+
LUAD	cis	rs4795519	1	rs7216530	ENSG00000266313.1	RP11-173M1.4	3.63	0.000315	0.0358	0.2	0.16	Chronic myeloid leukemia;	chr17:27084303	chr17:27333256~27348491:+
LUAD	cis	rs763121	0.853	rs1013338	ENSG00000225450.1	RP3-508I15.14	-3.63	0.000315	0.0358	-0.15	-0.16	Menopause (age at onset);	chr22:38578149	chr22:38739003~38749041:+
LUAD	cis	rs324126	0.78	rs62108318	ENSG00000277977.1	CTD-3018O17.5	3.63	0.000315	0.0358	0.17	0.16	Colonoscopy-negative controls vs population controls;	chr19:52380322	chr19:52392659~52392755:+
LUAD	cis	rs9900280	1	rs7208675	ENSG00000264808.1	RP11-802D6.1	3.63	0.000315	0.0358	0.19	0.16	Mean platelet volume;	chr17:29410130	chr17:29369717~29390777:-
LUAD	cis	rs67478160	0.654	rs11628240	ENSG00000272533.1	SNORA28	3.63	0.000315	0.0358	0.17	0.16	Schizophrenia;	chr14:103751798	chr14:103337849~103337974:+
LUAD	cis	rs67478160	0.643	rs11847468	ENSG00000272533.1	SNORA28	3.63	0.000315	0.0358	0.17	0.16	Schizophrenia;	chr14:103753958	chr14:103337849~103337974:+
LUAD	cis	rs4795519	0.826	rs16972670	ENSG00000266313.1	RP11-173M1.4	3.63	0.000315	0.0358	0.2	0.16	Chronic myeloid leukemia;	chr17:27065272	chr17:27333256~27348491:+
LUAD	cis	rs4716602	0.573	rs34810003	ENSG00000235029.1	MNX1-AS2	-3.63	0.000315	0.0358	-0.2	-0.16	Anti-saccade response;	chr7:156368189	chr7:157006307~157007132:+
LUAD	cis	rs4716602	0.548	rs34245976	ENSG00000235029.1	MNX1-AS2	-3.63	0.000315	0.0358	-0.2	-0.16	Anti-saccade response;	chr7:156368203	chr7:157006307~157007132:+
LUAD	cis	rs7937890	0.559	rs2597206	ENSG00000254418.1	RP11-21L19.1	3.63	0.000315	0.0358	0.19	0.16	Mitochondrial DNA levels;	chr11:14455992	chr11:14262846~14273691:-
LUAD	cis	rs561341	0.709	rs11542477	ENSG00000265798.5	RP11-271K11.5	-3.63	0.000315	0.0358	-0.27	-0.16	Hip circumference adjusted for BMI;	chr17:31858873	chr17:31038575~31059121:-
LUAD	cis	rs10197140	0.857	rs6542188	ENSG00000235721.1	AC013268.3	-3.63	0.000315	0.0358	-0.18	-0.16	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110880294	chr2:110007675~110010783:+
LUAD	cis	rs7260598	0.642	rs11667910	ENSG00000269421.1	ZNF92P3	-3.63	0.000316	0.0359	-0.25	-0.16	Response to taxane treatment (placlitaxel);	chr19:23976911	chr19:23935220~23936173:+
LUAD	cis	rs7260598	0.642	rs10424894	ENSG00000269421.1	ZNF92P3	-3.63	0.000316	0.0359	-0.25	-0.16	Response to taxane treatment (placlitaxel);	chr19:23978053	chr19:23935220~23936173:+
LUAD	cis	rs7260598	0.642	rs10423626	ENSG00000269421.1	ZNF92P3	-3.63	0.000316	0.0359	-0.25	-0.16	Response to taxane treatment (placlitaxel);	chr19:23978229	chr19:23935220~23936173:+
LUAD	cis	rs8046148	0.724	rs2287197	ENSG00000279356.1	RP11-429P3.8	3.63	0.000316	0.0359	0.16	0.16	Testicular germ cell tumor;	chr16:50072683	chr16:50072862~50074986:+
LUAD	cis	rs9475752	0.947	rs748996	ENSG00000231441.1	RP11-472M19.2	3.63	0.000316	0.0359	0.25	0.16	Menarche (age at onset);	chr6:56933223	chr6:56844002~56864078:+
LUAD	cis	rs9897596	1	rs9897596	ENSG00000223979.2	SMCR2	3.63	0.000316	0.0359	0.18	0.16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr17:17690139	chr17:17674026~17677688:-
LUAD	cis	rs12549058	0.792	rs12548347	ENSG00000223220.1	Y_RNA	3.63	0.000316	0.0359	0.32	0.16	Waist-hip ratio;	chr8:71618140	chr8:70780914~70781008:-
LUAD	cis	rs526231	0.578	rs2112886	ENSG00000250682.4	LINC00491	-3.63	0.000316	0.0359	-0.2	-0.16	Primary biliary cholangitis;	chr5:102915678	chr5:102609156~102671559:-
LUAD	cis	rs1421334	0.781	rs11778607	ENSG00000279041.1	CTD-2373N4.3	3.63	0.000316	0.0359	0.16	0.16	Intelligence (multi-trait analysis);	chr8:30982052	chr8:30552345~30553766:+
LUAD	cis	rs412050	0.696	rs79103791	ENSG00000224086.5	LL22NC03-86G7.1	-3.63	0.000316	0.0359	-0.21	-0.16	Attention deficit hyperactivity disorder;	chr22:21890558	chr22:21938293~21977632:+
LUAD	cis	rs412050	0.649	rs117808805	ENSG00000224086.5	LL22NC03-86G7.1	-3.63	0.000316	0.0359	-0.21	-0.16	Attention deficit hyperactivity disorder;	chr22:21892296	chr22:21938293~21977632:+
LUAD	cis	rs7077256	0.542	rs67586772	ENSG00000272767.1	JMJD1C-AS1	3.63	0.000316	0.0359	0.25	0.16	Intelligence (multi-trait analysis);	chr10:63307243	chr10:63465229~63466563:+
LUAD	cis	rs7512552	0.809	rs9436112	ENSG00000275557.1	RP11-353N4.6	3.63	0.000316	0.0359	0.18	0.16	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150433973	chr1:149607765~149612402:+
LUAD	cis	rs1062753	0.922	rs9611712	ENSG00000226450.2	CYP2D8P	3.63	0.000316	0.0359	0.14	0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42014989	chr22:42149886~42155001:-
LUAD	cis	rs6860806	0.661	rs6890009	ENSG00000263597.1	MIR3936	3.63	0.000316	0.0359	0.16	0.16	Breast cancer;	chr5:132244340	chr5:132365490~132365599:-
LUAD	cis	rs6951245	0.706	rs28522260	ENSG00000226291.1	AC091729.8	-3.63	0.000316	0.0359	-0.27	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1144328	chr7:1080863~1082178:+
LUAD	cis	rs10197140	1	rs17465210	ENSG00000235721.1	AC013268.3	-3.63	0.000316	0.0359	-0.18	-0.16	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110858410	chr2:110007675~110010783:+
LUAD	cis	rs12216545	0.765	rs7792574	ENSG00000241134.3	BET1P1	-3.63	0.000316	0.0359	-0.17	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150527118	chr7:150749736~150750094:+
LUAD	cis	rs4699052	0.662	rs1516732	ENSG00000246560.2	RP11-10L12.4	3.63	0.000316	0.0359	0.21	0.16	Testicular germ cell tumor;	chr4:103329997	chr4:102828055~102844075:+
LUAD	cis	rs7976269	0.609	rs2196480	ENSG00000275476.1	RP11-996F15.4	-3.63	0.000316	0.0359	-0.18	-0.16	Male-pattern baldness;	chr12:29062850	chr12:29277397~29277882:-
LUAD	cis	rs7976269	0.537	rs10743642	ENSG00000275476.1	RP11-996F15.4	-3.63	0.000316	0.0359	-0.18	-0.16	Male-pattern baldness;	chr12:29063557	chr12:29277397~29277882:-
LUAD	cis	rs7976269	0.609	rs10771472	ENSG00000275476.1	RP11-996F15.4	-3.63	0.000316	0.0359	-0.18	-0.16	Male-pattern baldness;	chr12:29063930	chr12:29277397~29277882:-
LUAD	cis	rs875971	0.545	rs73142245	ENSG00000224316.1	RP11-479O9.2	3.63	0.000316	0.0359	0.19	0.16	Aortic root size;	chr7:66226662	chr7:65773620~65802067:+
LUAD	cis	rs11250098	0.567	rs4326350	ENSG00000255310.2	AF131215.2	3.63	0.000316	0.0359	0.16	0.16	Morning vs. evening chronotype;	chr8:10906145	chr8:11107788~11109726:-
LUAD	cis	rs2281636	0.894	rs2297446	ENSG00000233690.1	EBAG9P1	3.63	0.000316	0.0359	0.16	0.16	Obesity-related traits;	chr10:99610258	chr10:99697407~99697949:-
LUAD	cis	rs67981189	0.865	rs2810117	ENSG00000269927.1	RP6-91H8.3	-3.63	0.000316	0.0359	-0.2	-0.16	Schizophrenia;	chr14:70924308	chr14:71141125~71143253:-
LUAD	cis	rs7535752	0.519	rs11583012	ENSG00000232912.4	RP5-1115A15.1	-3.63	0.000316	0.0359	-0.19	-0.16	Breast cancer;	chr1:8380072	chr1:8424645~8434838:+
LUAD	cis	rs4835473	0.932	rs7356157	ENSG00000249741.2	RP11-673E1.3	-3.63	0.000316	0.0359	-0.2	-0.16	Immature fraction of reticulocytes;	chr4:143739233	chr4:143911514~143912053:-
LUAD	cis	rs4716602	0.596	rs13221649	ENSG00000235029.1	MNX1-AS2	-3.63	0.000316	0.0359	-0.2	-0.16	Anti-saccade response;	chr7:156368099	chr7:157006307~157007132:+
LUAD	cis	rs4716602	0.596	rs34977094	ENSG00000235029.1	MNX1-AS2	-3.63	0.000316	0.0359	-0.2	-0.16	Anti-saccade response;	chr7:156368170	chr7:157006307~157007132:+
LUAD	cis	rs73108077	1	rs73108061	ENSG00000281376.1	ABALON	-3.63	0.000316	0.0359	-0.29	-0.16	Red blood cell density in sickle cell anemia;	chr20:31413650	chr20:31721507~31723409:+
LUAD	cis	rs4622329	0.615	rs7306175	ENSG00000258230.2	RP11-511H9.3	3.63	0.000316	0.0359	0.15	0.16	Systemic lupus erythematosus;	chr12:101900840	chr12:101773114~101773755:-
LUAD	cis	rs7772486	0.806	rs4075696	ENSG00000235652.6	RP11-545I5.3	-3.63	0.000316	0.0359	-0.16	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145929811	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.806	rs4075695	ENSG00000235652.6	RP11-545I5.3	-3.63	0.000316	0.0359	-0.16	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145929823	chr6:145799409~145886585:+
LUAD	cis	rs7477	0.766	rs3112526	ENSG00000275413.1	CTC-529I10.1	3.63	0.000316	0.0359	0.14	0.16	Amyotrophic lateral sclerosis;	chr17:16343786	chr17:16023323~16023653:-
LUAD	cis	rs10129255	0.5	rs10143242	ENSG00000253209.1	IGHV3-65	3.63	0.000316	0.0359	0.13	0.16	Kawasaki disease;	chr14:106681814	chr14:106666092~106666532:-
LUAD	cis	rs9860428	0.526	rs9834840	ENSG00000242770.2	RP11-180K7.1	3.63	0.000316	0.0359	0.17	0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112942669	chr3:112802478~112812819:+
LUAD	cis	rs11621975	0.57	rs61994022	ENSG00000258512.1	LINC00239	-3.63	0.000316	0.0359	-0.34	-0.16	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;	chr14:101789505	chr14:101730437~101732522:+
LUAD	cis	rs4716602	0.596	rs36013171	ENSG00000235029.1	MNX1-AS2	-3.63	0.000316	0.0359	-0.2	-0.16	Anti-saccade response;	chr7:156367817	chr7:157006307~157007132:+
LUAD	cis	rs4716602	0.596	rs10265482	ENSG00000235029.1	MNX1-AS2	-3.63	0.000316	0.0359	-0.2	-0.16	Anti-saccade response;	chr7:156367961	chr7:157006307~157007132:+
LUAD	cis	rs10129255	0.509	rs756583	ENSG00000211955.2	IGHV3-33	-3.63	0.000316	0.0359	-0.12	-0.16	Kawasaki disease;	chr14:106680002	chr14:106359793~106360324:-
LUAD	cis	rs13113518	0.902	rs12642716	ENSG00000223305.1	RN7SKP30	3.63	0.000316	0.0359	0.18	0.16	Height;	chr4:55479996	chr4:55540502~55540835:-
LUAD	cis	rs11853189	0.938	rs74894101	ENSG00000259562.2	RP11-762H8.2	3.63	0.000316	0.0359	0.18	0.16	Red cell distribution width;	chr15:78305063	chr15:78290527~78291221:-
LUAD	cis	rs11853189	0.938	rs75886457	ENSG00000259562.2	RP11-762H8.2	3.63	0.000316	0.0359	0.18	0.16	Red cell distribution width;	chr15:78305359	chr15:78290527~78291221:-
LUAD	cis	rs4664293	0.867	rs2357531	ENSG00000230783.1	AC009961.2	-3.63	0.000316	0.0359	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159740907	chr2:159689217~159690291:-
LUAD	cis	rs4819052	0.851	rs2838848	ENSG00000215447.6	BX322557.10	-3.63	0.000316	0.0359	-0.19	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251102	chr21:45288052~45291738:+
LUAD	cis	rs4819052	0.851	rs2838849	ENSG00000215447.6	BX322557.10	-3.63	0.000316	0.0359	-0.19	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251112	chr21:45288052~45291738:+
LUAD	cis	rs6095360	0.901	rs2426120	ENSG00000222365.1	SNORD12B	-3.63	0.000316	0.0359	-0.17	-0.16	Intelligence (multi-trait analysis);	chr20:49080716	chr20:49280319~49280409:+
LUAD	cis	rs6095360	0.933	rs2426122	ENSG00000222365.1	SNORD12B	-3.63	0.000316	0.0359	-0.17	-0.16	Intelligence (multi-trait analysis);	chr20:49081402	chr20:49280319~49280409:+
LUAD	cis	rs6661961	0.752	rs11579085	ENSG00000237975.5	FLG-AS1	-3.63	0.000317	0.0359	-0.22	-0.16	Atopic dermatitis;	chr1:152447965	chr1:152168125~152445456:+
LUAD	cis	rs732716	0.504	rs9352	ENSG00000267769.1	CTB-50L17.9	-3.63	0.000317	0.0359	-0.14	-0.16	Mean corpuscular volume;	chr19:4442339	chr19:4454014~4455286:+
LUAD	cis	rs9291683	0.509	rs6849717	ENSG00000250413.1	RP11-448G15.1	3.63	0.000317	0.0359	0.21	0.16	Bone mineral density;	chr4:9957095	chr4:10006482~10009725:+
LUAD	cis	rs4795519	1	rs4794835	ENSG00000266313.1	RP11-173M1.4	3.63	0.000317	0.0359	0.2	0.16	Chronic myeloid leukemia;	chr17:27116350	chr17:27333256~27348491:+
LUAD	cis	rs4795519	1	rs2199750	ENSG00000266313.1	RP11-173M1.4	3.63	0.000317	0.0359	0.2	0.16	Chronic myeloid leukemia;	chr17:27117803	chr17:27333256~27348491:+
LUAD	cis	rs6479891	1	rs12416113	ENSG00000232075.1	MRPL35P2	3.63	0.000317	0.0359	0.26	0.16	Arthritis (juvenile idiopathic);	chr10:63136717	chr10:63634317~63634827:-
LUAD	cis	rs7674212	0.57	rs1031804	ENSG00000246560.2	RP11-10L12.4	3.63	0.000317	0.036	0.21	0.16	Type 2 diabetes;	chr4:103144892	chr4:102828055~102844075:+
LUAD	cis	rs6951245	1	rs80212261	ENSG00000224079.1	AC091729.7	-3.63	0.000317	0.036	-0.26	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1074376	chr7:1074450~1078036:+
LUAD	cis	rs6736093	0.966	rs74182850	ENSG00000207383.1	Y_RNA	-3.63	0.000317	0.036	-0.22	-0.16	Coronary artery disease;	chr2:111923760	chr2:112579484~112579584:-
LUAD	cis	rs6736093	0.931	rs34974369	ENSG00000207383.1	Y_RNA	-3.63	0.000317	0.036	-0.22	-0.16	Coronary artery disease;	chr2:111925813	chr2:112579484~112579584:-
LUAD	cis	rs6736093	0.966	rs11686647	ENSG00000207383.1	Y_RNA	-3.63	0.000317	0.036	-0.22	-0.16	Coronary artery disease;	chr2:111926820	chr2:112579484~112579584:-
LUAD	cis	rs6736093	0.966	rs13027171	ENSG00000207383.1	Y_RNA	-3.63	0.000317	0.036	-0.22	-0.16	Coronary artery disease;	chr2:111929411	chr2:112579484~112579584:-
LUAD	cis	rs875971	0.54	rs4717275	ENSG00000222364.1	RNU6-96P	3.63	0.000317	0.036	0.18	0.16	Aortic root size;	chr7:65800193	chr7:66395191~66395286:+
LUAD	cis	rs801193	0.569	rs2659908	ENSG00000273448.1	RP11-166O4.6	3.63	0.000317	0.036	0.15	0.16	Aortic root size;	chr7:66695835	chr7:67333047~67334383:+
LUAD	cis	rs3849150	0.95	rs35968275	ENSG00000235939.1	RP11-123B3.2	-3.63	0.000317	0.036	-0.25	-0.16	Subclinical atherosclerosis traits (other);	chr10:48888553	chr10:49419277~49472903:+
LUAD	cis	rs357618	0.897	rs165362	ENSG00000272112.1	CTB-113P19.5	-3.63	0.000317	0.036	-0.15	-0.16	Basophil percentage of white cells;	chr5:151483526	chr5:151724831~151725356:-
LUAD	cis	rs2274273	1	rs7160110	ENSG00000259318.1	RP11-454L9.2	3.63	0.000317	0.036	0.14	0.16	Protein biomarker;	chr14:55127917	chr14:55394940~55395233:-
LUAD	cis	rs9287719	0.639	rs2357649	ENSG00000234818.1	AC092687.5	-3.63	0.000317	0.036	-0.2	-0.16	Prostate cancer;	chr2:10556662	chr2:10589166~10604830:+
LUAD	cis	rs916888	0.773	rs199448	ENSG00000260075.1	NSFP1	-3.63	0.000317	0.036	-0.27	-0.16	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46372855~46487141:+
LUAD	cis	rs2735413	0.794	rs55951868	ENSG00000276007.1	RP11-358L22.3	-3.63	0.000317	0.036	-0.16	-0.16	Systolic blood pressure (alcohol consumption interaction);	chr16:78044907	chr16:78123243~78124332:+
LUAD	cis	rs683250	0.63	rs4944439	ENSG00000246067.6	RAB30-AS1	-3.63	0.000317	0.036	-0.18	-0.16	Subcortical brain region volumes;	chr11:83398330	chr11:83072066~83106719:+
LUAD	cis	rs13113518	1	rs4864999	ENSG00000223305.1	RN7SKP30	3.63	0.000317	0.036	0.18	0.16	Height;	chr4:55476736	chr4:55540502~55540835:-
LUAD	cis	rs13113518	0.966	rs12506788	ENSG00000223305.1	RN7SKP30	3.63	0.000317	0.036	0.18	0.16	Height;	chr4:55477426	chr4:55540502~55540835:-
LUAD	cis	rs13113518	0.966	rs10517344	ENSG00000223305.1	RN7SKP30	3.63	0.000317	0.036	0.18	0.16	Height;	chr4:55477545	chr4:55540502~55540835:-
LUAD	cis	rs853679	0.55	rs1225599	ENSG00000280107.1	AL022393.9	-3.63	0.000317	0.036	-0.21	-0.16	Depression;	chr6:28197412	chr6:28170845~28172521:+
LUAD	cis	rs853679	0.574	rs1233705	ENSG00000280107.1	AL022393.9	-3.63	0.000317	0.036	-0.21	-0.16	Depression;	chr6:28198669	chr6:28170845~28172521:+
LUAD	cis	rs6121246	0.909	rs6119651	ENSG00000230613.1	HM13-AS1	3.63	0.000317	0.036	0.23	0.16	Mean corpuscular hemoglobin;	chr20:31671443	chr20:31567707~31573263:-
LUAD	cis	rs9309711	0.623	rs4641971	ENSG00000271868.1	RP11-1293J14.1	3.63	0.000317	0.036	0.18	0.16	Neurofibrillary tangles;	chr2:3478086	chr2:3496956~3497428:+
LUAD	cis	rs2834288	0.7	rs731060	ENSG00000237945.6	LINC00649	-3.63	0.000317	0.036	-0.22	-0.16	Gut microbiota (bacterial taxa);	chr21:33902624	chr21:33915534~33977691:+
LUAD	cis	rs7937890	0.559	rs6486193	ENSG00000254418.1	RP11-21L19.1	3.63	0.000317	0.036	0.19	0.16	Mitochondrial DNA levels;	chr11:14416061	chr11:14262846~14273691:-
LUAD	cis	rs6066835	1	rs6063314	ENSG00000230758.1	SNAP23P	-3.63	0.000317	0.036	-0.31	-0.16	Multiple myeloma;	chr20:48736569	chr20:49038357~49038602:-
LUAD	cis	rs6066835	1	rs6066830	ENSG00000230758.1	SNAP23P	-3.63	0.000317	0.036	-0.31	-0.16	Multiple myeloma;	chr20:48737360	chr20:49038357~49038602:-
LUAD	cis	rs6066835	1	rs6066831	ENSG00000230758.1	SNAP23P	-3.63	0.000317	0.036	-0.31	-0.16	Multiple myeloma;	chr20:48737594	chr20:49038357~49038602:-
LUAD	cis	rs6066835	1	rs6066832	ENSG00000230758.1	SNAP23P	-3.63	0.000317	0.036	-0.31	-0.16	Multiple myeloma;	chr20:48737595	chr20:49038357~49038602:-
LUAD	cis	rs6066835	1	rs6066833	ENSG00000230758.1	SNAP23P	-3.63	0.000317	0.036	-0.31	-0.16	Multiple myeloma;	chr20:48737957	chr20:49038357~49038602:-
LUAD	cis	rs9366999	0.776	rs1651105	ENSG00000235033.6	RP11-61I13.3	-3.63	0.000317	0.036	-0.18	-0.16	Obesity-related traits;	chr6:39251827	chr6:39881804~39900071:-
LUAD	cis	rs14027	0.512	rs13253139	ENSG00000279347.1	RP11-85I17.2	3.63	0.000317	0.036	0.14	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119718225	chr8:119838736~119840385:-
LUAD	cis	rs2016266	0.502	rs9971671	ENSG00000257605.2	RP11-680A11.5	3.63	0.000317	0.036	0.15	0.16	Bone mineral density;Bone mineral density (spine);	chr12:53240454	chr12:53298655~53300314:-
LUAD	cis	rs4865762	0.514	rs251336	ENSG00000272416.1	CTD-2081C10.7	-3.63	0.000317	0.036	-0.18	-0.16	Intraocular pressure;	chr5:53135558	chr5:53880293~53881051:-
LUAD	cis	rs7246657	0.943	rs10409204	ENSG00000226686.6	LINC01535	-3.63	0.000317	0.036	-0.25	-0.16	Coronary artery calcification;	chr19:37426790	chr19:37251912~37265535:+
LUAD	cis	rs7572733	0.773	rs13396312	ENSG00000222017.1	AC011997.1	-3.63	0.000317	0.036	-0.2	-0.16	Dermatomyositis;	chr2:197628979	chr2:197693106~197774823:+
LUAD	cis	rs2836974	0.563	rs6517522	ENSG00000232608.1	TIMM9P2	-3.63	0.000317	0.036	-0.18	-0.16	Cognitive function;	chr21:39181919	chr21:39216624~39217506:+
LUAD	cis	rs1400816	0.85	rs6433315	ENSG00000228389.1	AC068039.4	3.63	0.000317	0.036	0.27	0.16	Amyotrophic lateral sclerosis (sporadic);	chr2:171829780	chr2:171773482~171775844:+
LUAD	cis	rs78572108	0.858	rs971913	ENSG00000214691.7	AC104654.1	3.63	0.000318	0.036	0.28	0.16	Total body bone mineral density;	chr2:42025563	chr2:41877074~41894046:+
LUAD	cis	rs2239547	0.657	rs6445538	ENSG00000243224.1	RP5-1157M23.2	-3.63	0.000318	0.036	-0.18	-0.16	Schizophrenia;	chr3:52840272	chr3:52239258~52241097:+
LUAD	cis	rs11779988	0.545	rs439374	ENSG00000253671.1	RP11-806O11.1	-3.63	0.000318	0.036	-0.2	-0.16	Breast cancer;	chr8:17929309	chr8:17808941~17820868:+
LUAD	cis	rs7216064	0.953	rs2086744	ENSG00000266717.1	RP11-855A2.3	3.63	0.000318	0.036	0.2	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67853159	chr17:67950885~67951746:-
LUAD	cis	rs7216064	1	rs2046323	ENSG00000266717.1	RP11-855A2.3	3.63	0.000318	0.036	0.2	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67853811	chr17:67950885~67951746:-
LUAD	cis	rs10752881	0.74	rs1889307	ENSG00000224468.3	RP11-181K3.4	-3.63	0.000318	0.036	-0.15	-0.16	Colorectal cancer;	chr1:183080254	chr1:183138402~183141282:-
LUAD	cis	rs12724450	0.546	rs11801255	ENSG00000228126.1	FALEC	3.63	0.000318	0.036	0.3	0.16	Blood protein levels;	chr1:150451824	chr1:150515757~150518032:+
LUAD	cis	rs12724450	0.546	rs34448981	ENSG00000228126.1	FALEC	3.63	0.000318	0.036	0.3	0.16	Blood protein levels;	chr1:150463101	chr1:150515757~150518032:+
LUAD	cis	rs651907	0.557	rs35850993	ENSG00000244119.1	PDCL3P4	3.63	0.000318	0.036	0.16	0.16	Colorectal cancer;	chr3:101718589	chr3:101712472~101713191:+
LUAD	cis	rs4763879	0.634	rs61915473	ENSG00000278635.1	CTD-2318O12.1	3.63	0.000318	0.036	0.14	0.16	Type 1 diabetes;	chr12:9705282	chr12:9415641~9416718:+
LUAD	cis	rs6471393	1	rs6471393	ENSG00000253848.1	RP11-10N23.5	-3.63	0.000318	0.036	-0.21	-0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93703063	chr8:93741193~93744534:+
LUAD	cis	rs9313772	0.775	rs7724836	ENSG00000276778.1	RP11-524N5.1	3.63	0.000318	0.036	0.16	0.16	Blood pressure;	chr5:158399273	chr5:158320683~158409773:-
LUAD	cis	rs577676	0.586	rs12068805	ENSG00000271811.1	RP1-79C4.4	3.63	0.000318	0.036	0.21	0.16	Prevalent atrial fibrillation;	chr1:170632172	chr1:170667381~170669425:+
LUAD	cis	rs9549260	0.564	rs7997896	ENSG00000168852.11	TPTE2P5	3.63	0.000318	0.036	0.16	0.16	Red blood cell count;	chr13:40694687	chr13:40822296~40921749:-
LUAD	cis	rs875971	0.825	rs1860472	ENSG00000273448.1	RP11-166O4.6	-3.63	0.000318	0.036	-0.15	-0.16	Aortic root size;	chr7:66617736	chr7:67333047~67334383:+
LUAD	cis	rs736408	0.609	rs13095332	ENSG00000243224.1	RP5-1157M23.2	-3.63	0.000318	0.036	-0.17	-0.16	Bipolar disorder;	chr3:52753226	chr3:52239258~52241097:+
LUAD	cis	rs647161	0.588	rs6872104	ENSG00000247627.2	MTND4P12	-3.63	0.000318	0.0361	-0.2	-0.16	Colorectal cancer;	chr5:135154384	chr5:134926660~134928036:-
LUAD	cis	rs2041840	0.53	rs3845783	ENSG00000272054.1	RP11-423P10.2	3.63	0.000318	0.0361	0.13	0.16	Chronic lymphocytic leukemia;	chr2:37174881	chr2:37208875~37212677:+
LUAD	cis	rs6832769	0.925	rs2412663	ENSG00000272969.1	RP11-528I4.2	-3.63	0.000318	0.0361	-0.17	-0.16	Personality dimensions;	chr4:55589649	chr4:55547112~55547889:+
LUAD	cis	rs10496166	0.761	rs2311419	ENSG00000236259.1	AC017083.2	-3.63	0.000318	0.0361	-0.2	-0.16	RR interval (heart rate);	chr2:68816932	chr2:68125265~68125747:+
LUAD	cis	rs13113518	1	rs4865004	ENSG00000223305.1	RN7SKP30	3.63	0.000318	0.0361	0.18	0.16	Height;	chr4:55515118	chr4:55540502~55540835:-
LUAD	cis	rs739496	0.579	rs3177647	ENSG00000234608.6	MAPKAPK5-AS1	3.63	0.000318	0.0361	0.19	0.16	Platelet count;	chr12:111839772	chr12:111839764~111842902:-
LUAD	cis	rs7004769	0.578	rs10091799	ENSG00000233609.3	RP11-62H7.2	3.63	0.000318	0.0361	0.15	0.16	Fibrinogen levels;	chr8:9368362	chr8:8961200~8979025:+
LUAD	cis	rs6573604	1	rs6573604	ENSG00000258878.1	CTD-2509G16.3	3.63	0.000318	0.0361	0.21	0.16	N-glycan levels;	chr14:65321223	chr14:65234515~65235101:-
LUAD	cis	rs6573604	1	rs57071950	ENSG00000258878.1	CTD-2509G16.3	3.63	0.000318	0.0361	0.21	0.16	N-glycan levels;	chr14:65321719	chr14:65234515~65235101:-
LUAD	cis	rs12681366	0.959	rs58826082	ENSG00000253704.1	RP11-267M23.4	3.63	0.000318	0.0361	0.2	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94351487	chr8:94553722~94569745:+
LUAD	cis	rs67539049	1	rs73207496	ENSG00000255046.1	RP11-297N6.4	3.63	0.000318	0.0361	0.26	0.16	Itch intensity from mosquito bite;	chr8:11430976	chr8:11797928~11802568:-
LUAD	cis	rs6942407	0.592	rs6465092	ENSG00000224046.1	AC005076.5	-3.63	0.000318	0.0361	-0.21	-0.16	Food allergy;	chr7:87121609	chr7:87151423~87152420:-
LUAD	cis	rs6942407	0.592	rs6958626	ENSG00000224046.1	AC005076.5	-3.63	0.000318	0.0361	-0.21	-0.16	Food allergy;	chr7:87122209	chr7:87151423~87152420:-
LUAD	cis	rs6942407	0.592	rs6959152	ENSG00000224046.1	AC005076.5	-3.63	0.000318	0.0361	-0.21	-0.16	Food allergy;	chr7:87122291	chr7:87151423~87152420:-
LUAD	cis	rs7503168	0.558	rs12939138	ENSG00000267592.1	CTC-507E2.2	3.63	0.000318	0.0361	0.34	0.16	Plateletcrit;	chr17:35574559	chr17:35596904~35597128:-
LUAD	cis	rs7172809	0.897	rs869302	ENSG00000259362.2	RP11-307C19.1	3.63	0.000318	0.0361	0.2	0.16	Glucose homeostasis traits;	chr15:77538088	chr15:77525540~77534110:+
LUAD	cis	rs12579720	0.505	rs2728632	ENSG00000255910.1	RP11-405A12.2	-3.63	0.000318	0.0361	-0.22	-0.16	Diastolic blood pressure;	chr12:19993593	chr12:19775451~20009937:+
LUAD	cis	rs321358	0.895	rs6589210	ENSG00000271390.1	RP11-89C3.3	3.63	0.000318	0.0361	0.25	0.16	Body mass index;	chr11:111088408	chr11:111089870~111090368:-
LUAD	cis	rs1559040	1	rs10166363	ENSG00000272156.1	RP11-477N3.1	-3.63	0.000318	0.0361	-0.27	-0.16	Sudden cardiac arrest;	chr2:54103105	chr2:54082554~54085066:+
LUAD	cis	rs1559040	1	rs10169648	ENSG00000272156.1	RP11-477N3.1	-3.63	0.000318	0.0361	-0.27	-0.16	Sudden cardiac arrest;	chr2:54103980	chr2:54082554~54085066:+
LUAD	cis	rs990171	0.538	rs4851600	ENSG00000234389.1	AC007278.3	-3.63	0.000318	0.0361	-0.16	-0.16	Lymphocyte counts;	chr2:102499764	chr2:102438713~102440475:+
LUAD	cis	rs2554380	0.943	rs2585049	ENSG00000230373.7	GOLGA6L5P	3.63	0.000318	0.0361	0.2	0.16	Height;	chr15:83684121	chr15:84507885~84516814:-
LUAD	cis	rs2795502	0.873	rs2795527	ENSG00000185904.10	LINC00839	-3.63	0.000318	0.0361	-0.32	-0.16	Blood protein levels;	chr10:42774792	chr10:42475543~42495336:+
LUAD	cis	rs321358	0.945	rs7111445	ENSG00000271390.1	RP11-89C3.3	-3.63	0.000318	0.0361	-0.27	-0.16	Body mass index;	chr11:111105787	chr11:111089870~111090368:-
LUAD	cis	rs736408	0.609	rs13061423	ENSG00000243224.1	RP5-1157M23.2	-3.63	0.000318	0.0361	-0.17	-0.16	Bipolar disorder;	chr3:52756197	chr3:52239258~52241097:+
LUAD	cis	rs2235642	0.859	rs12599207	ENSG00000280231.1	LA16c-380F5.3	-3.63	0.000318	0.0361	-0.22	-0.16	Coronary artery disease;	chr16:1556444	chr16:1553655~1554130:-
LUAD	cis	rs16940212	0.58	rs74019425	ENSG00000242747.1	RP11-30K9.1	-3.63	0.000318	0.0361	-0.24	-0.16	HDL cholesterol;HDL cholesterol levels;	chr15:58395266	chr15:58869659~58870134:+
LUAD	cis	rs763121	0.853	rs5750649	ENSG00000228274.3	RP3-508I15.9	-3.63	0.000318	0.0361	-0.15	-0.16	Menopause (age at onset);	chr22:38640764	chr22:38667585~38681820:-
LUAD	cis	rs763121	0.853	rs6519124	ENSG00000228274.3	RP3-508I15.9	-3.63	0.000318	0.0361	-0.15	-0.16	Menopause (age at onset);	chr22:38649094	chr22:38667585~38681820:-
LUAD	cis	rs763121	0.853	rs5750652	ENSG00000228274.3	RP3-508I15.9	-3.63	0.000318	0.0361	-0.15	-0.16	Menopause (age at onset);	chr22:38652311	chr22:38667585~38681820:-
LUAD	cis	rs7611694	0.904	rs11921816	ENSG00000242770.2	RP11-180K7.1	-3.63	0.000318	0.0361	-0.16	-0.16	Prostate cancer;	chr3:113569382	chr3:112802478~112812819:+
LUAD	cis	rs2348418	0.864	rs2137071	ENSG00000247934.4	RP11-967K21.1	3.63	0.000318	0.0361	0.19	0.16	Lung function (FEV1);Lung function (FVC);	chr12:28563797	chr12:28163298~28190738:-
LUAD	cis	rs9467773	1	rs12663883	ENSG00000261353.1	CTA-14H9.5	-3.63	0.000318	0.0361	-0.19	-0.16	Intelligence (multi-trait analysis);	chr6:26577098	chr6:26527063~26527404:+
LUAD	cis	rs9467773	0.967	rs6913877	ENSG00000261353.1	CTA-14H9.5	-3.63	0.000318	0.0361	-0.19	-0.16	Intelligence (multi-trait analysis);	chr6:26577260	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs6918506	ENSG00000261353.1	CTA-14H9.5	-3.63	0.000318	0.0361	-0.19	-0.16	Intelligence (multi-trait analysis);	chr6:26577629	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs6918360	ENSG00000261353.1	CTA-14H9.5	-3.63	0.000318	0.0361	-0.19	-0.16	Intelligence (multi-trait analysis);	chr6:26577639	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs6918854	ENSG00000261353.1	CTA-14H9.5	-3.63	0.000318	0.0361	-0.19	-0.16	Intelligence (multi-trait analysis);	chr6:26577696	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs9467800	ENSG00000261353.1	CTA-14H9.5	-3.63	0.000318	0.0361	-0.19	-0.16	Intelligence (multi-trait analysis);	chr6:26578297	chr6:26527063~26527404:+
LUAD	cis	rs9467773	0.901	rs10223789	ENSG00000261353.1	CTA-14H9.5	-3.63	0.000318	0.0361	-0.19	-0.16	Intelligence (multi-trait analysis);	chr6:26579381	chr6:26527063~26527404:+
LUAD	cis	rs9467773	1	rs9467802	ENSG00000261353.1	CTA-14H9.5	-3.63	0.000318	0.0361	-0.19	-0.16	Intelligence (multi-trait analysis);	chr6:26580940	chr6:26527063~26527404:+
LUAD	cis	rs34929064	0.536	rs2961278	ENSG00000232949.1	AC002480.4	-3.63	0.000318	0.0361	-0.21	-0.16	Major depression and alcohol dependence;	chr7:22595160	chr7:22589705~22591622:+
LUAD	cis	rs7674212	0.541	rs2615539	ENSG00000246560.2	RP11-10L12.4	3.63	0.000318	0.0361	0.21	0.16	Type 2 diabetes;	chr4:103159949	chr4:102828055~102844075:+
LUAD	cis	rs7674212	0.57	rs2251634	ENSG00000246560.2	RP11-10L12.4	3.63	0.000318	0.0361	0.21	0.16	Type 2 diabetes;	chr4:103161192	chr4:102828055~102844075:+
LUAD	cis	rs683250	0.599	rs7123856	ENSG00000246067.6	RAB30-AS1	-3.63	0.000318	0.0361	-0.17	-0.16	Subcortical brain region volumes;	chr11:83363669	chr11:83072066~83106719:+
LUAD	cis	rs875971	0.862	rs6460293	ENSG00000273448.1	RP11-166O4.6	-3.63	0.000318	0.0361	-0.16	-0.16	Aortic root size;	chr7:66345205	chr7:67333047~67334383:+
LUAD	cis	rs1910358	0.638	rs7702367	ENSG00000248874.4	C5orf17	-3.63	0.000318	0.0361	-0.21	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23881016	chr5:23951348~24178263:+
LUAD	cis	rs1910358	0.664	rs10473666	ENSG00000248874.4	C5orf17	-3.63	0.000318	0.0361	-0.21	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23884120	chr5:23951348~24178263:+
LUAD	cis	rs1910358	0.614	rs1602373	ENSG00000248874.4	C5orf17	-3.63	0.000318	0.0361	-0.21	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23889548	chr5:23951348~24178263:+
LUAD	cis	rs1910358	0.664	rs35319374	ENSG00000248874.4	C5orf17	-3.63	0.000318	0.0361	-0.21	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23896969	chr5:23951348~24178263:+
LUAD	cis	rs1910358	0.664	rs35603833	ENSG00000248874.4	C5orf17	-3.63	0.000318	0.0361	-0.21	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23897087	chr5:23951348~24178263:+
LUAD	cis	rs2041840	1	rs11124575	ENSG00000272054.1	RP11-423P10.2	-3.63	0.000318	0.0361	-0.12	-0.16	Chronic lymphocytic leukemia;	chr2:37273292	chr2:37208875~37212677:+
LUAD	cis	rs1569175	0.655	rs4261699	ENSG00000252759.1	Y_RNA	3.63	0.000319	0.0361	0.31	0.16	Response to treatment for acute lymphoblastic leukemia;	chr2:200168318	chr2:200863152~200863247:-
LUAD	cis	rs67383717	0.777	rs591486	ENSG00000224848.1	RP11-535M15.1	-3.63	0.000319	0.0361	-0.19	-0.16	Parkinson's disease (pesticide exposure interaction);	chr9:95887764	chr9:96687056~96721121:+
LUAD	cis	rs11159086	0.793	rs11625502	ENSG00000270000.1	RP3-449M8.9	3.63	0.000319	0.0361	0.23	0.16	Advanced glycation end-product levels;	chr14:74468309	chr14:74471930~74472360:-
LUAD	cis	rs8054556	1	rs7190185	ENSG00000214725.6	CDIPT-AS1	-3.63	0.000319	0.0361	-0.19	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29951031	chr16:29863593~29868053:+
LUAD	cis	rs16978956	0.592	rs16990329	ENSG00000236474.1	GCNT1P1	3.63	0.000319	0.0361	0.26	0.16	Body mass index;	chr20:18345414	chr20:18420160~18421454:-
LUAD	cis	rs4683346	0.621	rs704898	ENSG00000173811.9	CCDC13-AS1	-3.63	0.000319	0.0361	-0.19	-0.16	Granulocyte percentage of myeloid white cells;	chr3:42976202	chr3:42732575~42746768:+
LUAD	cis	rs9907295	0.591	rs11650668	ENSG00000270977.1	AC015849.16	-3.63	0.000319	0.0361	-0.22	-0.16	Fibroblast growth factor basic levels;	chr17:35822045	chr17:35893707~35911023:-
LUAD	cis	rs9907295	0.591	rs4251749	ENSG00000270977.1	AC015849.16	-3.63	0.000319	0.0361	-0.22	-0.16	Fibroblast growth factor basic levels;	chr17:35823421	chr17:35893707~35911023:-
LUAD	cis	rs6453278	1	rs6453279	ENSG00000238961.1	SNORA47	-3.63	0.000319	0.0361	-0.17	-0.16	Autism;	chr5:77121249	chr5:77080434~77080571:-
LUAD	cis	rs2832191	0.935	rs11910316	ENSG00000215533.7	LINC00189	3.63	0.000319	0.0361	0.19	0.16	Dental caries;	chr21:29147408	chr21:29193480~29288205:+
LUAD	cis	rs36093844	0.527	rs72951266	ENSG00000279742.1	RP11-700A24.1	-3.63	0.000319	0.0361	-0.2	-0.16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85983565	chr11:85852557~85854943:-
LUAD	cis	rs875971	1	rs2077593	ENSG00000273142.1	RP11-458F8.4	-3.63	0.000319	0.0361	-0.11	-0.16	Aortic root size;	chr7:66427543	chr7:66902857~66906297:+
LUAD	cis	rs6065777	0.961	rs13037444	ENSG00000226243.1	RPL37AP1	-3.63	0.000319	0.0361	-0.16	-0.16	Schizophrenia;	chr20:44983439	chr20:44466564~44466842:-
LUAD	cis	rs4845570	1	rs3811415	ENSG00000203288.3	RP11-98D18.9	-3.63	0.000319	0.0361	-0.25	-0.16	Coronary artery disease;	chr1:151791291	chr1:151790804~151794402:+
LUAD	cis	rs4764039	0.881	rs10845858	ENSG00000256084.1	RP11-134N1.2	-3.63	0.000319	0.0361	-0.3	-0.16	Total ventricular volume;	chr12:13892784	chr12:14216590~14221297:+
LUAD	cis	rs448720	1	rs4777009	ENSG00000260657.2	RP11-315D16.4	-3.63	0.000319	0.0361	-0.18	-0.16	Cognitive performance;	chr15:67908169	chr15:68267792~68277994:-
LUAD	cis	rs7107174	0.901	rs990706	ENSG00000251323.2	RP11-452H21.4	3.63	0.000319	0.0361	0.2	0.16	Testicular germ cell tumor;	chr11:78424658	chr11:78423982~78429836:-
LUAD	cis	rs797680	0.754	rs12044883	ENSG00000223745.6	RP4-717I23.3	3.63	0.000319	0.0361	0.13	0.16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93355018	chr1:93262186~93346025:-
LUAD	cis	rs2380205	0.58	rs907687	ENSG00000232807.2	RP11-536K7.3	-3.63	0.000319	0.0361	-0.17	-0.16	Breast cancer;	chr10:5858799	chr10:5934270~5945900:-
LUAD	cis	rs75920871	0.562	rs68137714	ENSG00000280143.1	AP000892.6	3.63	0.000319	0.0361	0.24	0.16	Subjective well-being;	chr11:117154641	chr11:117204967~117210292:+
LUAD	cis	rs2153904	0.793	rs12132270	ENSG00000261000.1	RP11-534L20.5	3.63	0.000319	0.0362	0.26	0.16	Prostate-specific antigen levels;	chr1:205691812	chr1:206503948~206504456:+
LUAD	cis	rs6502050	0.769	rs8079122	ENSG00000275966.1	RP11-1055B8.9	-3.63	0.000319	0.0362	-0.17	-0.16	Life satisfaction;	chr17:82162551	chr17:81345476~81345966:-
LUAD	cis	rs9900280	1	rs13341521	ENSG00000264808.1	RP11-802D6.1	3.63	0.000319	0.0362	0.19	0.16	Mean platelet volume;	chr17:29436224	chr17:29369717~29390777:-
LUAD	cis	rs7903456	0.648	rs1923939	ENSG00000200253.1	RNU6-529P	3.63	0.000319	0.0362	0.19	0.16	Gout;Renal underexcretion gout;	chr10:87068411	chr10:87041238~87041341:-
LUAD	cis	rs7903456	0.648	rs4275529	ENSG00000200253.1	RNU6-529P	3.63	0.000319	0.0362	0.19	0.16	Gout;Renal underexcretion gout;	chr10:87069031	chr10:87041238~87041341:-
LUAD	cis	rs9925964	0.933	rs8050894	ENSG00000232748.3	RP11-196G11.6	3.63	0.000319	0.0362	0.2	0.16	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31093188	chr16:31056460~31062803:+
LUAD	cis	rs9894429	0.621	rs9747119	ENSG00000263853.1	AC139530.1	-3.63	0.000319	0.0362	-0.17	-0.16	Eye color traits;	chr17:81639991	chr17:81676001~81676086:+
LUAD	cis	rs34779708	0.931	rs17583009	ENSG00000271335.4	RP11-324I22.4	3.63	0.000319	0.0362	0.17	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35031987	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.898	rs11595898	ENSG00000271335.4	RP11-324I22.4	3.63	0.000319	0.0362	0.17	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35037335	chr10:35314552~35336401:-
LUAD	cis	rs7131987	0.65	rs7301398	ENSG00000275476.1	RP11-996F15.4	-3.63	0.000319	0.0362	-0.19	-0.16	QT interval;	chr12:29302457	chr12:29277397~29277882:-
LUAD	cis	rs7131987	0.65	rs7301188	ENSG00000275476.1	RP11-996F15.4	-3.63	0.000319	0.0362	-0.19	-0.16	QT interval;	chr12:29302458	chr12:29277397~29277882:-
LUAD	cis	rs11853189	0.938	rs16969710	ENSG00000259562.2	RP11-762H8.2	-3.63	0.000319	0.0362	-0.17	-0.16	Red cell distribution width;	chr15:78314020	chr15:78290527~78291221:-
LUAD	cis	rs4743820	0.535	rs13289294	ENSG00000230537.1	RP11-305L7.1	3.63	0.000319	0.0362	0.21	0.16	Ulcerative colitis;Inflammatory bowel disease;	chr9:91362132	chr9:91104957~91107304:-
LUAD	cis	rs513088	0.681	rs540253	ENSG00000225171.2	DUTP6	-3.63	0.000319	0.0362	-0.21	-0.16	Schizophrenia;	chr1:166691952	chr1:166868748~166869209:+
LUAD	cis	rs17092148	0.667	rs62212171	ENSG00000250917.1	RP4-785G19.5	-3.63	0.000319	0.0362	-0.35	-0.16	Neuroticism;	chr20:34399881	chr20:34234840~34281173:-
LUAD	cis	rs8058578	1	rs6565201	ENSG00000232748.3	RP11-196G11.6	-3.63	0.000319	0.0362	-0.2	-0.16	Multiple myeloma;	chr16:30735870	chr16:31056460~31062803:+
LUAD	cis	rs2288073	0.965	rs10173949	ENSG00000223754.1	AC008073.9	3.63	0.000319	0.0362	0.21	0.16	Venous thromboembolism (SNP x SNP interaction);	chr2:24187387	chr2:24199839~24201698:-
LUAD	cis	rs2933343	0.729	rs1683816	ENSG00000231305.3	RP11-723O4.2	-3.63	0.000319	0.0362	-0.18	-0.16	IgG glycosylation;	chr3:128932352	chr3:128861313~128871540:-
LUAD	cis	rs4700393	0.517	rs13158594	ENSG00000272308.1	RP11-231G3.1	3.63	0.000319	0.0362	0.21	0.16	Intelligence (multi-trait analysis);	chr5:60794183	chr5:60866457~60866935:-
LUAD	cis	rs4700393	0.517	rs12523070	ENSG00000272308.1	RP11-231G3.1	3.63	0.000319	0.0362	0.21	0.16	Intelligence (multi-trait analysis);	chr5:60795496	chr5:60866457~60866935:-
LUAD	cis	rs321358	0.895	rs73015171	ENSG00000271390.1	RP11-89C3.3	3.63	0.000319	0.0362	0.26	0.16	Body mass index;	chr11:111087535	chr11:111089870~111090368:-
LUAD	cis	rs17620991	1	rs66651482	ENSG00000259826.1	RP11-467D6.1	-3.63	0.000319	0.0362	-0.22	-0.16	Alcohol dependence;	chr7:40811643	chr7:39947522~39949755:-
LUAD	cis	rs17620991	1	rs67648979	ENSG00000259826.1	RP11-467D6.1	-3.63	0.000319	0.0362	-0.22	-0.16	Alcohol dependence;	chr7:40812136	chr7:39947522~39949755:-
LUAD	cis	rs7809950	1	rs4727684	ENSG00000238832.1	snoU109	-3.63	0.000319	0.0362	-0.25	-0.16	Coronary artery disease;	chr7:107586025	chr7:107603363~107603507:+
LUAD	cis	rs10508774	0.759	rs11813339	ENSG00000231245.2	C1DP1	-3.63	0.000319	0.0362	-0.39	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32544138	chr10:32511336~32511737:-
LUAD	cis	rs10129255	1	rs10129407	ENSG00000211947.2	IGHV3-21	-3.63	0.000319	0.0362	-0.11	-0.16	Kawasaki disease;	chr14:106767956	chr14:106235064~106235594:-
LUAD	cis	rs4865762	0.512	rs61125444	ENSG00000247796.2	CTD-2366F13.1	3.63	0.000319	0.0362	0.18	0.16	Intraocular pressure;	chr5:53198143	chr5:53109842~53115126:+
LUAD	cis	rs786425	0.932	rs786448	ENSG00000278112.1	RP11-972P1.11	-3.63	0.000319	0.0362	-0.15	-0.16	Pubertal anthropometrics;	chr12:123585667	chr12:123519390~123519856:-
LUAD	cis	rs3733585	0.806	rs11723382	ENSG00000250413.1	RP11-448G15.1	3.63	0.000319	0.0362	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9953036	chr4:10006482~10009725:+
LUAD	cis	rs6496044	0.568	rs7176291	ENSG00000259416.2	RP11-158M2.5	3.63	0.000319	0.0362	0.17	0.16	Interstitial lung disease;	chr15:85524167	chr15:85754941~85756237:-
LUAD	cis	rs7246657	0.941	rs10418729	ENSG00000226686.6	LINC01535	-3.63	0.000319	0.0362	-0.25	-0.16	Coronary artery calcification;	chr19:37246163	chr19:37251912~37265535:+
LUAD	cis	rs8002861	0.967	rs9533689	ENSG00000274001.1	RP11-5G9.5	3.63	0.00032	0.0362	0.17	0.16	Leprosy;	chr13:43906277	chr13:43877715~43878163:-
LUAD	cis	rs8002861	0.967	rs9533690	ENSG00000274001.1	RP11-5G9.5	3.63	0.00032	0.0362	0.17	0.16	Leprosy;	chr13:43906462	chr13:43877715~43878163:-
LUAD	cis	rs8002861	0.967	rs7999434	ENSG00000274001.1	RP11-5G9.5	3.63	0.00032	0.0362	0.17	0.16	Leprosy;	chr13:43908825	chr13:43877715~43878163:-
LUAD	cis	rs5758659	0.714	rs133373	ENSG00000273366.1	CTA-989H11.1	-3.63	0.00032	0.0362	-0.19	-0.16	Cognitive function;	chr22:42069784	chr22:42278188~42278846:+
LUAD	cis	rs10419113	0.641	rs61333077	ENSG00000269867.1	CTD-2583A14.8	3.63	0.00032	0.0362	0.14	0.16	Pediatric bone mineral density (spine);	chr19:57766589	chr19:57867038~57868172:-
LUAD	cis	rs7521902	0.617	rs7412010	ENSG00000234397.3	RP11-415K20.1	3.63	0.00032	0.0362	0.26	0.16	Endometriosis;Ovarian cancer;Bone mineral density;Hip circumference adjusted for BMI;	chr1:22109953	chr1:22322840~22323331:-
LUAD	cis	rs17189298	0.842	rs1596832	ENSG00000231013.1	AC013275.2	3.62	0.00032	0.0362	0.17	0.16	Cerebrospinal T-tau levels;	chr2:119102417	chr2:119476448~119487346:+
LUAD	cis	rs13113518	0.812	rs2035692	ENSG00000273257.1	RP11-177J6.1	3.62	0.00032	0.0362	0.18	0.16	Height;	chr4:55528801	chr4:55387949~55388271:+
LUAD	cis	rs73230612	0.858	rs9813872	ENSG00000242767.1	ZBTB20-AS4	3.62	0.00032	0.0362	0.26	0.16	Type 2 diabetes;	chr3:115379728	chr3:115100423~115103061:+
LUAD	cis	rs2836974	0.897	rs13049280	ENSG00000232608.1	TIMM9P2	-3.62	0.00032	0.0362	-0.2	-0.16	Cognitive function;	chr21:39222730	chr21:39216624~39217506:+
LUAD	cis	rs11853189	0.938	rs2090679	ENSG00000259562.2	RP11-762H8.2	3.62	0.00032	0.0362	0.18	0.16	Red cell distribution width;	chr15:78304564	chr15:78290527~78291221:-
LUAD	cis	rs950027	0.549	rs11070452	ENSG00000259479.5	SORD2P	-3.62	0.00032	0.0362	-0.2	-0.16	Response to fenofibrate (adiponectin levels);	chr15:45302638	chr15:44826371~44884694:-
LUAD	cis	rs745109	0.504	rs76654460	ENSG00000273080.1	RP11-301O19.1	3.62	0.00032	0.0362	0.27	0.16	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86378757	chr2:86195590~86196049:+
LUAD	cis	rs6546537	0.824	rs55864699	ENSG00000231024.1	AC092431.3	3.62	0.00032	0.0362	0.22	0.16	Serum thyroid-stimulating hormone levels;	chr2:69576518	chr2:69700192~69713847:-
LUAD	cis	rs8058578	0.943	rs3747486	ENSG00000232748.3	RP11-196G11.6	-3.62	0.00032	0.0362	-0.21	-0.16	Multiple myeloma;	chr16:30775606	chr16:31056460~31062803:+
LUAD	cis	rs4767841	1	rs2996027	ENSG00000248636.5	RP11-768F21.1	-3.62	0.00032	0.0363	-0.19	-0.16	Urgency urinary incontinence;	chr12:119726478	chr12:119387987~119668079:-
LUAD	cis	rs818427	0.929	rs153550	ENSG00000279522.1	CTC-487M23.6	3.62	0.00032	0.0363	0.19	0.16	Total body bone mineral density;	chr5:112899260	chr5:112894933~112896531:+
LUAD	cis	rs34779708	0.966	rs7913615	ENSG00000271335.4	RP11-324I22.4	3.62	0.00032	0.0363	0.17	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35134029	chr10:35314552~35336401:-
LUAD	cis	rs9921338	0.961	rs4390613	ENSG00000263080.1	RP11-485G7.5	-3.62	0.00032	0.0363	-0.22	-0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11328979	chr16:11341809~11345211:-
LUAD	cis	rs433598	0.964	rs234279	ENSG00000180747.14	SMG1P3	3.62	0.00032	0.0363	0.16	0.16	Schizophrenia;	chr16:20677307	chr16:21446683~21520444:-
LUAD	cis	rs2115630	0.905	rs1975277	ENSG00000259295.5	CSPG4P12	-3.62	0.00032	0.0363	-0.19	-0.16	P wave terminal force;	chr15:84786327	chr15:85191438~85213905:+
LUAD	cis	rs74781061	0.932	rs11629749	ENSG00000260103.2	RP11-10O17.1	-3.62	0.00032	0.0363	-0.15	-0.16	Endometriosis;	chr15:74627252	chr15:74478070~74490286:-
LUAD	cis	rs2348418	0.832	rs12301674	ENSG00000247934.4	RP11-967K21.1	3.62	0.00032	0.0363	0.19	0.16	Lung function (FEV1);Lung function (FVC);	chr12:28357543	chr12:28163298~28190738:-
LUAD	cis	rs786425	0.966	rs6551	ENSG00000278112.1	RP11-972P1.11	-3.62	0.00032	0.0363	-0.15	-0.16	Pubertal anthropometrics;	chr12:123597693	chr12:123519390~123519856:-
LUAD	cis	rs854765	1	rs854765	ENSG00000223979.2	SMCR2	3.62	0.00032	0.0363	0.18	0.16	Total body bone mineral density;	chr17:18109416	chr17:17674026~17677688:-
LUAD	cis	rs6787172	0.644	rs55971926	ENSG00000272087.1	RP11-379F4.7	3.62	0.00032	0.0363	0.19	0.16	Subjective well-being;	chr3:158466856	chr3:158693120~158693768:-
LUAD	cis	rs683250	0.629	rs681367	ENSG00000246067.6	RAB30-AS1	-3.62	0.00032	0.0363	-0.17	-0.16	Subcortical brain region volumes;	chr11:83250082	chr11:83072066~83106719:+
LUAD	cis	rs7590268	0.836	rs6729902	ENSG00000279873.2	LINC01126	3.62	0.00032	0.0363	0.16	0.16	Orofacial clefts;	chr2:43349829	chr2:43227210~43228855:+
LUAD	cis	rs858239	0.539	rs2178139	ENSG00000226816.2	AC005082.12	3.62	0.00032	0.0363	0.22	0.16	Cerebrospinal fluid biomarker levels;	chr7:23152017	chr7:23206013~23208045:+
LUAD	cis	rs858239	0.539	rs2141306	ENSG00000226816.2	AC005082.12	3.62	0.00032	0.0363	0.22	0.16	Cerebrospinal fluid biomarker levels;	chr7:23152045	chr7:23206013~23208045:+
LUAD	cis	rs7430456	0.837	rs7651130	ENSG00000231574.4	RP11-91K9.1	-3.62	0.00032	0.0363	-0.18	-0.16	Breast cancer;	chr3:177719720	chr3:177816865~177899224:+
LUAD	cis	rs3742264	0.731	rs7318648	ENSG00000235903.6	CPB2-AS1	-3.62	0.00032	0.0363	-0.21	-0.16	Blood protein levels;	chr13:46032497	chr13:46052806~46113332:+
LUAD	cis	rs9300255	0.539	rs1969355	ENSG00000256092.2	RP13-942N8.1	3.62	0.00032	0.0363	0.15	0.16	Neutrophil percentage of white cells;	chr12:123257514	chr12:123363868~123366113:+
LUAD	cis	rs12295403	0.691	rs12808591	ENSG00000256588.1	RP11-613F22.8	3.62	0.000321	0.0363	0.2	0.16	Ovarian reserve;	chr11:18655764	chr11:18507608~18508820:-
LUAD	cis	rs12295403	0.691	rs12808592	ENSG00000256588.1	RP11-613F22.8	3.62	0.000321	0.0363	0.2	0.16	Ovarian reserve;	chr11:18655768	chr11:18507608~18508820:-
LUAD	cis	rs4664293	0.836	rs13421392	ENSG00000226266.5	AC009961.3	-3.62	0.000321	0.0363	-0.22	-0.16	Monocyte percentage of white cells;	chr2:159801785	chr2:159670708~159712435:-
LUAD	cis	rs763121	0.776	rs5757177	ENSG00000225450.1	RP3-508I15.14	-3.62	0.000321	0.0363	-0.16	-0.16	Menopause (age at onset);	chr22:38611169	chr22:38739003~38749041:+
LUAD	cis	rs7772486	0.875	rs2814876	ENSG00000235652.6	RP11-545I5.3	3.62	0.000321	0.0363	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145982894	chr6:145799409~145886585:+
LUAD	cis	rs7200786	0.692	rs8063318	ENSG00000274038.1	RP11-66H6.4	3.62	0.000321	0.0363	0.21	0.16	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11162735	chr16:11056556~11057034:+
LUAD	cis	rs7973683	0.541	rs57078519	ENSG00000251497.2	RP11-197N18.7	-3.62	0.000321	0.0363	-0.19	-0.16	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr12:123904237	chr12:123081384~123084744:+
LUAD	cis	rs4937076	1	rs1065398	ENSG00000254671.2	STT3A-AS1	3.62	0.000321	0.0363	0.18	0.16	Primary tooth development (time to first tooth eruption);	chr11:125958112	chr11:125570284~125592568:-
LUAD	cis	rs13113518	0.841	rs11133400	ENSG00000223305.1	RN7SKP30	3.62	0.000321	0.0363	0.19	0.16	Height;	chr4:55578787	chr4:55540502~55540835:-
LUAD	cis	rs7674212	0.539	rs6854709	ENSG00000251288.2	RP11-10L12.2	-3.62	0.000321	0.0363	-0.2	-0.16	Type 2 diabetes;	chr4:103208629	chr4:102751401~102752641:+
LUAD	cis	rs1009115	1	rs6463804	ENSG00000272328.1	RP4-594A5.1	-3.62	0.000321	0.0363	-0.22	-0.16	Post bronchodilator FEV1;	chr7:8408267	chr7:8303741~8341343:+
LUAD	cis	rs4268898	0.56	rs2384007	ENSG00000242628.4	AC009228.1	3.62	0.000321	0.0363	0.24	0.16	Asthma;	chr2:24291972	chr2:24214381~24221516:+
LUAD	cis	rs6460942	0.63	rs17670901	ENSG00000226690.5	AC005281.1	3.62	0.000321	0.0363	0.28	0.16	Coronary artery disease;	chr7:12346996	chr7:12496429~12541910:+
LUAD	cis	rs6460942	0.63	rs62451487	ENSG00000226690.5	AC005281.1	3.62	0.000321	0.0363	0.28	0.16	Coronary artery disease;	chr7:12350838	chr7:12496429~12541910:+
LUAD	cis	rs843451	1	rs843453	ENSG00000222020.2	AC062017.1	3.62	0.000321	0.0363	0.16	0.16	Neuritic plaque;	chr2:239411399	chr2:239401436~239402364:+
LUAD	cis	rs9325144	0.577	rs12314639	ENSG00000257718.1	RP11-396F22.1	-3.62	0.000321	0.0363	-0.19	-0.16	Morning vs. evening chronotype;	chr12:38726067	chr12:38906451~38909592:+
LUAD	cis	rs526231	0.578	rs59323174	ENSG00000250682.4	LINC00491	3.62	0.000321	0.0363	0.2	0.16	Primary biliary cholangitis;	chr5:102932165	chr5:102609156~102671559:-
LUAD	cis	rs9543976	1	rs7989568	ENSG00000261105.4	LMO7-AS1	3.62	0.000321	0.0363	0.25	0.16	Diabetic retinopathy;	chr13:75581428	chr13:75604700~75635994:-
LUAD	cis	rs11233413	1	rs4944422	ENSG00000246067.6	RAB30-AS1	3.62	0.000321	0.0363	0.17	0.16	Economic and political preferences (feminism/equality);	chr11:83004440	chr11:83072066~83106719:+
LUAD	cis	rs10129255	0.957	rs8009464	ENSG00000211947.2	IGHV3-21	-3.62	0.000321	0.0363	-0.11	-0.16	Kawasaki disease;	chr14:106777611	chr14:106235064~106235594:-
LUAD	cis	rs889122	0.765	rs16996255	ENSG00000267289.1	CTD-2623N2.11	3.62	0.000321	0.0363	0.18	0.16	Menarche (age at onset);	chr19:9872134	chr19:9834079~9835013:-
LUAD	cis	rs9381040	0.61	rs6941090	ENSG00000161912.16	ADCY10P1	3.62	0.000321	0.0363	0.14	0.16	Alzheimer's disease (late onset);	chr6:41075726	chr6:41101022~41140835:+
LUAD	cis	rs9381040	0.655	rs9381031	ENSG00000161912.16	ADCY10P1	3.62	0.000321	0.0363	0.14	0.16	Alzheimer's disease (late onset);	chr6:41077218	chr6:41101022~41140835:+
LUAD	cis	rs9381040	0.61	rs717883	ENSG00000161912.16	ADCY10P1	3.62	0.000321	0.0363	0.14	0.16	Alzheimer's disease (late onset);	chr6:41077531	chr6:41101022~41140835:+
LUAD	cis	rs6430585	0.536	rs3213892	ENSG00000226806.1	AC011893.3	3.62	0.000321	0.0363	0.25	0.16	Corneal structure;	chr2:135794947	chr2:135820191~135823087:+
LUAD	cis	rs73198271	0.74	rs3827807	ENSG00000253893.2	FAM85B	3.62	0.000321	0.0364	0.21	0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8821875	chr8:8167819~8226614:-
LUAD	cis	rs2837828	1	rs1888510	ENSG00000226496.2	LINC00323	3.62	0.000321	0.0364	0.21	0.16	Neutrophil count;	chr21:40797048	chr21:41141493~41148133:-
LUAD	cis	rs2239547	0.522	rs7652131	ENSG00000243224.1	RP5-1157M23.2	-3.62	0.000321	0.0364	-0.18	-0.16	Schizophrenia;	chr3:52963138	chr3:52239258~52241097:+
LUAD	cis	rs17123764	0.818	rs4045193	ENSG00000257464.1	RP11-161H23.8	-3.62	0.000321	0.0364	-0.24	-0.16	Intelligence (multi-trait analysis);	chr12:49610197	chr12:49442424~49442652:-
LUAD	cis	rs11671005	0.735	rs11671591	ENSG00000268543.1	CTD-2619J13.16	3.62	0.000321	0.0364	0.23	0.16	Mean platelet volume;	chr19:58406970	chr19:58418560~58419310:+
LUAD	cis	rs9381040	0.626	rs2272986	ENSG00000161912.16	ADCY10P1	3.62	0.000321	0.0364	0.14	0.16	Alzheimer's disease (late onset);	chr6:41070039	chr6:41101022~41140835:+
LUAD	cis	rs9381040	0.655	rs7738684	ENSG00000161912.16	ADCY10P1	3.62	0.000321	0.0364	0.14	0.16	Alzheimer's disease (late onset);	chr6:41070813	chr6:41101022~41140835:+
LUAD	cis	rs9381040	0.655	rs4140578	ENSG00000161912.16	ADCY10P1	3.62	0.000321	0.0364	0.14	0.16	Alzheimer's disease (late onset);	chr6:41074090	chr6:41101022~41140835:+
LUAD	cis	rs5758659	0.652	rs5758553	ENSG00000227370.1	RP4-669P10.19	-3.62	0.000321	0.0364	-0.15	-0.16	Cognitive function;	chr22:42035425	chr22:42132543~42132998:+
LUAD	cis	rs889398	0.594	rs2133799	ENSG00000226232.7	RP11-419C5.2	-3.62	0.000321	0.0364	-0.14	-0.16	Body mass index;	chr16:69879123	chr16:69976388~69996188:-
LUAD	cis	rs253959	0.532	rs10045890	ENSG00000272265.1	CTD-2287O16.4	3.62	0.000321	0.0364	0.2	0.16	Bipolar disorder and schizophrenia;	chr5:116112188	chr5:116078110~116078570:-
LUAD	cis	rs10483853	0.806	rs7141241	ENSG00000258695.2	RP3-414A15.2	-3.62	0.000321	0.0364	-0.21	-0.16	Coronary artery calcification;	chr14:73342096	chr14:73522878~73530610:+
LUAD	cis	rs6964587	0.692	rs10236483	ENSG00000188693.7	CYP51A1-AS1	-3.62	0.000321	0.0364	-0.19	-0.16	Breast cancer;	chr7:92167982	chr7:92134604~92180725:+
LUAD	cis	rs6964587	0.692	rs12536220	ENSG00000188693.7	CYP51A1-AS1	-3.62	0.000321	0.0364	-0.19	-0.16	Breast cancer;	chr7:92176281	chr7:92134604~92180725:+
LUAD	cis	rs11118883	0.559	rs35192818	ENSG00000228437.4	RP11-400N13.2	3.62	0.000321	0.0364	0.2	0.16	Colorectal cancer;	chr1:221915766	chr1:221966341~221984964:+
LUAD	cis	rs763121	0.853	rs5750671	ENSG00000225450.1	RP3-508I15.14	-3.62	0.000321	0.0364	-0.16	-0.16	Menopause (age at onset);	chr22:38698614	chr22:38739003~38749041:+
LUAD	cis	rs763121	0.853	rs926299	ENSG00000225450.1	RP3-508I15.14	-3.62	0.000321	0.0364	-0.16	-0.16	Menopause (age at onset);	chr22:38699693	chr22:38739003~38749041:+
LUAD	cis	rs763121	0.785	rs6001203	ENSG00000225450.1	RP3-508I15.14	-3.62	0.000321	0.0364	-0.16	-0.16	Menopause (age at onset);	chr22:38703597	chr22:38739003~38749041:+
LUAD	cis	rs763121	0.853	rs6001204	ENSG00000225450.1	RP3-508I15.14	-3.62	0.000321	0.0364	-0.16	-0.16	Menopause (age at onset);	chr22:38704234	chr22:38739003~38749041:+
LUAD	cis	rs910873	1	rs910873	ENSG00000250917.1	RP4-785G19.5	-3.62	0.000321	0.0364	-0.36	-0.16	Melanoma;	chr20:34583968	chr20:34234840~34281173:-
LUAD	cis	rs2348418	0.864	rs7312339	ENSG00000247934.4	RP11-967K21.1	3.62	0.000321	0.0364	0.19	0.16	Lung function (FEV1);Lung function (FVC);	chr12:28558751	chr12:28163298~28190738:-
LUAD	cis	rs860295	0.729	rs11264369	ENSG00000160766.13	GBAP1	3.62	0.000322	0.0364	0.18	0.16	Body mass index;	chr1:155390039	chr1:155213821~155227422:-
LUAD	cis	rs2179367	0.959	rs564961	ENSG00000216906.2	RP11-350J20.9	3.62	0.000322	0.0364	0.2	0.16	Dupuytren's disease;	chr6:149336091	chr6:149904243~149906418:+
LUAD	cis	rs2179367	0.959	rs504985	ENSG00000216906.2	RP11-350J20.9	3.62	0.000322	0.0364	0.2	0.16	Dupuytren's disease;	chr6:149337842	chr6:149904243~149906418:+
LUAD	cis	rs166040	0.59	rs248503	ENSG00000277795.1	AC005752.10	-3.62	0.000322	0.0364	-0.26	-0.16	Major depressive disorder;	chr5:141830135	chr5:141259235~141261364:+
LUAD	cis	rs2548724	0.738	rs398228	ENSG00000250682.4	LINC00491	-3.62	0.000322	0.0364	-0.21	-0.16	Type 2 diabetes;	chr5:102257782	chr5:102609156~102671559:-
LUAD	cis	rs2548724	0.812	rs416734	ENSG00000250682.4	LINC00491	-3.62	0.000322	0.0364	-0.21	-0.16	Type 2 diabetes;	chr5:102257783	chr5:102609156~102671559:-
LUAD	cis	rs2548724	0.773	rs261100	ENSG00000250682.4	LINC00491	-3.62	0.000322	0.0364	-0.21	-0.16	Type 2 diabetes;	chr5:102258482	chr5:102609156~102671559:-
LUAD	cis	rs7674212	0.581	rs11946020	ENSG00000230069.3	LRRC37A15P	-3.62	0.000322	0.0364	-0.17	-0.16	Type 2 diabetes;	chr4:103023585	chr4:102727274~102730721:-
LUAD	cis	rs7604827	0.543	rs3924563	ENSG00000230076.1	AC016708.2	3.62	0.000322	0.0364	0.25	0.16	PR interval;	chr2:214414880	chr2:214847128~214847445:+
LUAD	cis	rs360932	0.734	rs360928	ENSG00000251377.1	RP11-18H21.3	-3.62	0.000322	0.0364	-0.16	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr4:151986429	chr4:152207421~152225870:-
LUAD	cis	rs1577917	0.655	rs9444351	ENSG00000220563.1	PKMP3	3.62	0.000322	0.0364	0.15	0.16	Response to antipsychotic treatment;	chr6:85538081	chr6:85659892~85660606:-
LUAD	cis	rs6496932	0.635	rs11074191	ENSG00000202081.1	RNU6-1280P	-3.62	0.000322	0.0364	-0.21	-0.16	Central corneal thickness;Corneal structure;	chr15:85388794	chr15:85651522~85651628:-
LUAD	cis	rs457717	0.73	rs2937415	ENSG00000249014.2	HMGN2P4	-3.62	0.000322	0.0364	-0.18	-0.16	Hearing impairment;	chr5:76637272	chr5:76242024~76242404:-
LUAD	cis	rs5758659	0.652	rs133349	ENSG00000227370.1	RP4-669P10.19	-3.62	0.000322	0.0364	-0.15	-0.16	Cognitive function;	chr22:42032723	chr22:42132543~42132998:+
LUAD	cis	rs4578769	0.55	rs11082225	ENSG00000266850.1	RP11-370A5.1	3.62	0.000322	0.0364	0.21	0.16	Eosinophil percentage of white cells;	chr18:22963794	chr18:22723491~22907721:-
LUAD	cis	rs755249	0.517	rs56809193	ENSG00000228060.1	RP11-69E11.8	-3.62	0.000322	0.0364	-0.18	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39143626	chr1:39565160~39573203:+
LUAD	cis	rs17597773	0.638	rs7553447	ENSG00000272823.1	RP11-295M18.6	-3.62	0.000322	0.0364	-0.21	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220816192	chr1:220828676~220829211:-
LUAD	cis	rs17597773	0.638	rs10495152	ENSG00000272823.1	RP11-295M18.6	-3.62	0.000322	0.0364	-0.21	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220817013	chr1:220828676~220829211:-
LUAD	cis	rs6951245	0.882	rs10252404	ENSG00000226291.1	AC091729.8	-3.62	0.000322	0.0364	-0.28	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1169971	chr7:1080863~1082178:+
LUAD	cis	rs7209700	0.889	rs11079769	ENSG00000228782.6	CTD-2026D20.3	-3.62	0.000322	0.0364	-0.18	-0.16	IgG glycosylation;	chr17:47272365	chr17:47450568~47492492:-
LUAD	cis	rs8002861	0.967	rs2325071	ENSG00000274001.1	RP11-5G9.5	3.62	0.000322	0.0364	0.17	0.16	Leprosy;	chr13:43902657	chr13:43877715~43878163:-
LUAD	cis	rs2239547	0.522	rs2581815	ENSG00000243224.1	RP5-1157M23.2	-3.62	0.000322	0.0364	-0.18	-0.16	Schizophrenia;	chr3:52948143	chr3:52239258~52241097:+
LUAD	cis	rs1023500	0.505	rs134874	ENSG00000273366.1	CTA-989H11.1	-3.62	0.000322	0.0364	-0.19	-0.16	Schizophrenia;	chr22:42265138	chr22:42278188~42278846:+
LUAD	cis	rs5769707	0.967	rs763126	ENSG00000235111.1	RP1-29C18.8	3.62	0.000322	0.0364	0.17	0.16	Monocyte percentage of white cells;Monocyte count;	chr22:49594926	chr22:49612657~49615716:-
LUAD	cis	rs4835473	0.932	rs5016158	ENSG00000249741.2	RP11-673E1.3	3.62	0.000322	0.0364	0.19	0.16	Immature fraction of reticulocytes;	chr4:143738472	chr4:143911514~143912053:-
LUAD	cis	rs4795519	1	rs2169956	ENSG00000266313.1	RP11-173M1.4	-3.62	0.000322	0.0364	-0.2	-0.16	Chronic myeloid leukemia;	chr17:27143718	chr17:27333256~27348491:+
LUAD	cis	rs7937890	1	rs2970335	ENSG00000251991.1	RNU7-49P	3.62	0.000322	0.0364	0.17	0.16	Mitochondrial DNA levels;	chr11:14303855	chr11:14478892~14478953:+
LUAD	cis	rs2749097	0.66	rs11208273	ENSG00000244256.3	RN7SL130P	-3.62	0.000322	0.0364	-0.22	-0.16	Alcohol consumption (transferrin glycosylation);	chr1:63699074	chr1:63655743~63656047:+
LUAD	cis	rs10876993	0.928	rs2928053	ENSG00000270039.1	RP11-571M6.17	3.62	0.000322	0.0364	0.19	0.16	Celiac disease or Rheumatoid arthritis;	chr12:57669692	chr12:57803838~57804415:+
LUAD	cis	rs8064024	0.582	rs2660241	ENSG00000267077.1	RP11-127I20.5	3.62	0.000322	0.0364	0.2	0.16	Cancer;	chr16:4890022	chr16:4795265~4796532:-
LUAD	cis	rs2702164	1	rs1733354	ENSG00000240661.1	RP11-174O3.3	-3.62	0.000322	0.0365	-0.2	-0.16	Gut microbiome composition (winter);	chr3:120381207	chr3:120349510~120367998:+
LUAD	cis	rs2702164	1	rs1623323	ENSG00000240661.1	RP11-174O3.3	-3.62	0.000322	0.0365	-0.2	-0.16	Gut microbiome composition (winter);	chr3:120381803	chr3:120349510~120367998:+
LUAD	cis	rs2702164	1	rs1733353	ENSG00000240661.1	RP11-174O3.3	-3.62	0.000322	0.0365	-0.2	-0.16	Gut microbiome composition (winter);	chr3:120381957	chr3:120349510~120367998:+
LUAD	cis	rs6493487	0.512	rs3848134	ENSG00000273674.3	CTD-2378E12.1	3.62	0.000322	0.0365	0.23	0.16	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50818386	chr15:50839875~50908599:-
LUAD	cis	rs6493487	0.556	rs8033351	ENSG00000273674.3	CTD-2378E12.1	3.62	0.000322	0.0365	0.23	0.16	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50819123	chr15:50839875~50908599:-
LUAD	cis	rs4795519	0.778	rs2016467	ENSG00000266313.1	RP11-173M1.4	3.62	0.000322	0.0365	0.21	0.16	Chronic myeloid leukemia;	chr17:27124093	chr17:27333256~27348491:+
LUAD	cis	rs4268898	0.862	rs11125549	ENSG00000242628.4	AC009228.1	-3.62	0.000322	0.0365	-0.21	-0.16	Asthma;	chr2:24353371	chr2:24214381~24221516:+
LUAD	cis	rs11673344	0.526	rs17244769	ENSG00000267254.4	ZNF790-AS1	-3.62	0.000322	0.0365	-0.21	-0.16	Obesity-related traits;	chr19:37562031	chr19:36797518~36828115:+
LUAD	cis	rs970797	0.522	rs2222518	ENSG00000237260.1	AC073069.2	3.62	0.000322	0.0365	0.19	0.16	Monobrow;Lobe attachment (rater-scored or self-reported);	chr2:176320725	chr2:176338637~176339077:+
LUAD	cis	rs2836974	0.867	rs77959119	ENSG00000232608.1	TIMM9P2	-3.62	0.000322	0.0365	-0.2	-0.16	Cognitive function;	chr21:39170842	chr21:39216624~39217506:+
LUAD	cis	rs7176527	0.796	rs1057946	ENSG00000259570.1	RP11-671M22.4	-3.62	0.000322	0.0365	-0.24	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84639555	chr15:84394512~84395514:+
LUAD	cis	rs727479	0.962	rs12595627	ENSG00000259306.2	RP11-108K3.2	-3.62	0.000322	0.0365	-0.18	-0.16	Estradiol levels;	chr15:51224903	chr15:51315841~51321996:+
LUAD	cis	rs757081	0.667	rs12577418	ENSG00000260196.1	RP1-239B22.5	-3.62	0.000322	0.0365	-0.21	-0.16	Systolic blood pressure;	chr11:17080007	chr11:17380649~17383531:+
LUAD	cis	rs41411047	0.702	rs17788050	ENSG00000271711.1	RP11-392O18.2	-3.62	0.000322	0.0365	-0.31	-0.16	Myocardial infarction;	chr3:149781984	chr3:150611262~150611877:-
LUAD	cis	rs4819052	0.851	rs35064782	ENSG00000215447.6	BX322557.10	-3.62	0.000322	0.0365	-0.19	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254445	chr21:45288052~45291738:+
LUAD	cis	rs116095464	1	rs56095714	ENSG00000250848.1	CTD-2083E4.5	-3.62	0.000322	0.0365	-0.34	-0.16	Breast cancer;	chr5:311141	chr5:288833~290321:-
LUAD	cis	rs1577917	0.56	rs12193777	ENSG00000220563.1	PKMP3	3.62	0.000322	0.0365	0.15	0.16	Response to antipsychotic treatment;	chr6:85536991	chr6:85659892~85660606:-
LUAD	cis	rs12497850	0.931	rs6442130	ENSG00000225399.4	RP11-3B7.1	3.62	0.000322	0.0365	0.22	0.16	Parkinson's disease;	chr3:48740594	chr3:49260085~49261316:+
LUAD	cis	rs6871536	1	rs2299013	ENSG00000233006.5	AC034220.3	-3.62	0.000322	0.0365	-0.19	-0.16	Asthma (childhood onset);	chr5:132581226	chr5:132311285~132369916:-
LUAD	cis	rs6871536	1	rs2252775	ENSG00000233006.5	AC034220.3	-3.62	0.000322	0.0365	-0.19	-0.16	Asthma (childhood onset);	chr5:132582752	chr5:132311285~132369916:-
LUAD	cis	rs62244186	0.566	rs55852922	ENSG00000233509.2	ZNF197-AS1	3.62	0.000323	0.0365	0.18	0.16	Depressive symptoms;	chr3:44784696	chr3:44617128~44624797:-
LUAD	cis	rs34669198	1	rs3770262	ENSG00000231848.1	AC012354.8	-3.62	0.000323	0.0365	-0.27	-0.16	Type 2 diabetes;	chr2:45449986	chr2:44996413~44996873:+
LUAD	cis	rs34669198	0.932	rs13032444	ENSG00000231848.1	AC012354.8	-3.62	0.000323	0.0365	-0.27	-0.16	Type 2 diabetes;	chr2:45450399	chr2:44996413~44996873:+
LUAD	cis	rs10129255	0.5	rs4774008	ENSG00000232216.1	IGHV3-43	3.62	0.000323	0.0365	0.13	0.16	Kawasaki disease;	chr14:106681273	chr14:106470264~106470800:-
LUAD	cis	rs1155848	0.892	rs28546558	ENSG00000227676.3	LINC01068	-3.62	0.000323	0.0365	-0.41	-0.16	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79516024	chr13:79566727~79571436:+
LUAD	cis	rs911119	0.955	rs12625716	ENSG00000270001.1	RP11-218C14.8	3.62	0.000323	0.0365	0.24	0.16	Chronic kidney disease;	chr20:23626208	chr20:23631826~23632316:-
LUAD	cis	rs3126085	0.935	rs11204941	ENSG00000237975.5	FLG-AS1	-3.62	0.000323	0.0365	-0.25	-0.16	Atopic dermatitis;	chr1:152230867	chr1:152168125~152445456:+
LUAD	cis	rs4835473	0.932	rs5016157	ENSG00000249741.2	RP11-673E1.3	3.62	0.000323	0.0365	0.19	0.16	Immature fraction of reticulocytes;	chr4:143738587	chr4:143911514~143912053:-
LUAD	cis	rs6066835	1	rs4455220	ENSG00000230758.1	SNAP23P	-3.62	0.000323	0.0365	-0.3	-0.16	Multiple myeloma;	chr20:48718479	chr20:49038357~49038602:-
LUAD	cis	rs7170668	0.93	rs7170640	ENSG00000259134.4	LINC00924	3.62	0.000323	0.0365	0.2	0.16	Motion sickness;	chr15:95470867	chr15:95433095~95507847:+
LUAD	cis	rs7949566	0.614	rs948055	ENSG00000254671.2	STT3A-AS1	-3.62	0.000323	0.0365	-0.19	-0.16	Platelet distribution width;Mean platelet volume;	chr11:126422394	chr11:125570284~125592568:-
LUAD	cis	rs526231	0.819	rs35803	ENSG00000175749.11	EIF3KP1	3.62	0.000323	0.0365	0.22	0.16	Primary biliary cholangitis;	chr5:103271241	chr5:103032376~103033031:+
LUAD	cis	rs7923609	0.5	rs9804238	ENSG00000232075.1	MRPL35P2	-3.62	0.000323	0.0365	-0.22	-0.16	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63597129	chr10:63634317~63634827:-
LUAD	cis	rs748404	0.56	rs2255663	ENSG00000166763.7	STRCP1	-3.62	0.000323	0.0365	-0.19	-0.16	Lung cancer;	chr15:43536810	chr15:43699488~43718184:-
LUAD	cis	rs12908161	0.959	rs12906348	ENSG00000259654.1	RP11-245C17.2	-3.62	0.000323	0.0365	-0.23	-0.16	Schizophrenia;	chr15:84786190	chr15:84685884~84686946:+
LUAD	cis	rs7521902	0.66	rs2235529	ENSG00000228397.1	RP1-224A6.3	-3.62	0.000323	0.0365	-0.3	-0.16	Endometriosis;Ovarian cancer;Bone mineral density;Hip circumference adjusted for BMI;	chr1:22123994	chr1:22023994~22024968:-
LUAD	cis	rs1850744	1	rs2280208	ENSG00000163612.10	FAM86KP	-3.62	0.000323	0.0365	-0.5	-0.16	Economic and political preferences;	chr4:9798419	chr4:9153296~9165451:+
LUAD	cis	rs858239	0.6	rs4409314	ENSG00000226816.2	AC005082.12	3.62	0.000323	0.0365	0.22	0.16	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23206013~23208045:+
LUAD	cis	rs7512898	0.5	rs10753882	ENSG00000260088.1	RP11-92G12.3	-3.62	0.000323	0.0365	-0.22	-0.16	Electrocardiographic conduction measures;	chr1:200821492	chr1:200669507~200694250:+
LUAD	cis	rs577676	0.586	rs666419	ENSG00000271811.1	RP1-79C4.4	3.62	0.000323	0.0365	0.21	0.16	Prevalent atrial fibrillation;	chr1:170645103	chr1:170667381~170669425:+
LUAD	cis	rs4819052	0.959	rs9976074	ENSG00000215447.6	BX322557.10	-3.62	0.000323	0.0365	-0.21	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235723	chr21:45288052~45291738:+
LUAD	cis	rs5771069	0.931	rs5771222	ENSG00000273253.2	RP3-402G11.26	3.62	0.000323	0.0365	0.14	0.16	Ulcerative colitis;	chr22:50007275	chr22:50199090~50200837:-
LUAD	cis	rs10785571	0.597	rs4768615	ENSG00000275481.1	RP11-474P2.6	3.62	0.000323	0.0366	0.14	0.16	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr12:45448956	chr12:46388856~46392126:+
LUAD	cis	rs2346177	0.875	rs2881327	ENSG00000279254.1	RP11-536C12.1	-3.62	0.000323	0.0366	-0.17	-0.16	HDL cholesterol;	chr2:46414816	chr2:46668870~46670778:+
LUAD	cis	rs9584850	0.54	rs61969407	ENSG00000231194.1	FARP1-AS1	3.62	0.000323	0.0366	0.23	0.16	Neuroticism;	chr13:98466906	chr13:98435405~98435840:-
LUAD	cis	rs12216545	0.737	rs1879866	ENSG00000177590.7	GIMAP3P	-3.62	0.000323	0.0366	-0.17	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150561241	chr7:150746893~150747728:-
LUAD	cis	rs797680	0.856	rs10874759	ENSG00000223745.6	RP4-717I23.3	3.62	0.000324	0.0366	0.13	0.16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93164615	chr1:93262186~93346025:-
LUAD	cis	rs11051970	0.614	rs2728684	ENSG00000275854.1	RP11-278C7.5	-3.62	0.000324	0.0366	-0.17	-0.16	Response to tocilizumab in rheumatoid arthritis;	chr12:32422731	chr12:32736930~32737660:-
LUAD	cis	rs7083	0.716	rs574603	ENSG00000254851.1	RP11-109L13.1	3.62	0.000324	0.0366	0.22	0.16	Blood protein levels;	chr11:117307025	chr11:117135528~117138582:+
LUAD	cis	rs34783982	0.529	rs12917490	ENSG00000261441.1	RP11-217B1.2	3.62	0.000324	0.0366	0.2	0.16	Squamous cell lung carcinoma;	chr15:88930574	chr15:89335053~89336161:+
LUAD	cis	rs2823962	0.892	rs7279705	ENSG00000270093.1	AP000473.8	-3.62	0.000324	0.0366	-0.16	-0.16	Amyotrophic lateral sclerosis;	chr21:16657879	chr21:16643529~16645065:+
LUAD	cis	rs568617	0.626	rs78028320	ENSG00000255320.1	RP11-755F10.1	3.62	0.000324	0.0366	0.26	0.16	Crohn's disease;	chr11:65814544	chr11:66244840~66246239:-
LUAD	cis	rs910316	0.763	rs175016	ENSG00000279594.1	RP11-950C14.10	-3.62	0.000324	0.0366	-0.19	-0.16	Height;	chr14:74992930	chr14:75011269~75012851:-
LUAD	cis	rs4727027	0.736	rs12704084	ENSG00000244560.5	RP4-800G7.2	-3.62	0.000324	0.0366	-0.1	-0.16	Neutrophil percentage of granulocytes;Eosinophil counts;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr7:149217958	chr7:149285281~149297312:+
LUAD	cis	rs17772222	0.63	rs816069	ENSG00000258983.2	RP11-507K2.2	-3.62	0.000324	0.0366	-0.17	-0.16	Coronary artery calcification;	chr14:88500992	chr14:88499334~88515502:+
LUAD	cis	rs7061710	0.703	rs12402295	ENSG00000271811.1	RP1-79C4.4	-3.62	0.000324	0.0366	-0.25	-0.16	Blood metabolite levels;	chr1:171086904	chr1:170667381~170669425:+
LUAD	cis	rs812925	0.855	rs777592	ENSG00000271889.1	RP11-493E12.1	3.62	0.000324	0.0366	0.2	0.16	Immature fraction of reticulocytes;	chr2:61191208	chr2:61151433~61162105:-
LUAD	cis	rs4332428	1	rs4268415	ENSG00000238840.1	U8	3.62	0.000324	0.0366	0.25	0.16	Height;	chr10:4941398	chr10:4962436~4962568:-
LUAD	cis	rs6840360	0.638	rs6816002	ENSG00000270265.1	RP11-731D1.4	-3.62	0.000324	0.0366	-0.18	-0.16	Intelligence (multi-trait analysis);	chr4:151668287	chr4:151333775~151353224:-
LUAD	cis	rs7223966	1	rs9912201	ENSG00000279369.1	RP11-51F16.1	-3.62	0.000324	0.0366	-0.18	-0.16	Hip circumference adjusted for BMI;Body mass index;	chr17:63685848	chr17:63700847~63702670:+
LUAD	cis	rs3617	0.625	rs2535633	ENSG00000242142.1	SERBP1P3	-3.62	0.000324	0.0366	-0.17	-0.16	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52825614	chr3:53064283~53065091:-
LUAD	cis	rs7223966	1	rs56057198	ENSG00000279369.1	RP11-51F16.1	-3.62	0.000324	0.0366	-0.19	-0.16	Hip circumference adjusted for BMI;Body mass index;	chr17:63655972	chr17:63700847~63702670:+
LUAD	cis	rs4716602	0.596	rs12698432	ENSG00000235029.1	MNX1-AS2	3.62	0.000324	0.0366	0.19	0.16	Anti-saccade response;	chr7:156366025	chr7:157006307~157007132:+
LUAD	cis	rs7339483	0.618	rs6511686	ENSG00000268058.1	BNIP3P40	3.62	0.000324	0.0366	0.26	0.16	Discordance in emotional problems in monozygotic twins;	chr19:24159782	chr19:24098425~24098980:-
LUAD	cis	rs9467773	1	rs9467799	ENSG00000261353.1	CTA-14H9.5	-3.62	0.000324	0.0366	-0.19	-0.16	Intelligence (multi-trait analysis);	chr6:26578136	chr6:26527063~26527404:+
LUAD	cis	rs9467773	0.967	rs10223792	ENSG00000261353.1	CTA-14H9.5	-3.62	0.000324	0.0366	-0.19	-0.16	Intelligence (multi-trait analysis);	chr6:26579388	chr6:26527063~26527404:+
LUAD	cis	rs9467773	0.967	rs9461272	ENSG00000261353.1	CTA-14H9.5	-3.62	0.000324	0.0366	-0.19	-0.16	Intelligence (multi-trait analysis);	chr6:26579420	chr6:26527063~26527404:+
LUAD	cis	rs6663390	0.51	rs6540445	ENSG00000203709.8	C1orf132	-3.62	0.000324	0.0366	-0.22	-0.16	Facial morphology (factor 18);	chr1:207908122	chr1:207801518~207869150:-
LUAD	cis	rs728616	0.867	rs77376252	ENSG00000225484.5	NUTM2B-AS1	-3.62	0.000324	0.0366	-0.35	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80049626	chr10:79663088~79826594:-
LUAD	cis	rs7432375	0.523	rs12486911	ENSG00000239213.4	NCK1-AS1	3.62	0.000324	0.0366	0.18	0.16	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136840111	chr3:136841726~136862054:-
LUAD	cis	rs7432375	0.579	rs10935199	ENSG00000239213.4	NCK1-AS1	3.62	0.000324	0.0366	0.18	0.16	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136844693	chr3:136841726~136862054:-
LUAD	cis	rs11089937	0.609	rs9622980	ENSG00000211640.3	IGLV6-57	3.62	0.000324	0.0366	0.13	0.16	Periodontitis (PAL4Q3);	chr22:22149888	chr22:22195713~22196460:+
LUAD	cis	rs9303542	0.959	rs7213513	ENSG00000264920.1	RP11-6N17.4	-3.62	0.000324	0.0366	-0.21	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48314932	chr17:47891255~47895812:-
LUAD	cis	rs2933343	0.729	rs813732	ENSG00000231305.3	RP11-723O4.2	3.62	0.000324	0.0366	0.18	0.16	IgG glycosylation;	chr3:128900514	chr3:128861313~128871540:-
LUAD	cis	rs321358	1	rs321366	ENSG00000271390.1	RP11-89C3.3	3.62	0.000324	0.0366	0.27	0.16	Body mass index;	chr11:111128003	chr11:111089870~111090368:-
LUAD	cis	rs595244	1	rs11638586	ENSG00000259705.1	RP11-227D13.1	3.62	0.000324	0.0366	0.35	0.16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48480646	chr15:48645951~48652016:+
LUAD	cis	rs12565755	0.616	rs67276550	ENSG00000226476.2	RP11-776H12.1	3.62	0.000324	0.0366	0.26	0.16	Response to tocilizumab in rheumatoid arthritis;	chr1:60515254	chr1:60540249~60640491:-
LUAD	cis	rs9291683	0.509	rs998676	ENSG00000250413.1	RP11-448G15.1	3.62	0.000324	0.0366	0.21	0.16	Bone mineral density;	chr4:9946940	chr4:10006482~10009725:+
LUAD	cis	rs7712401	0.791	rs154507	ENSG00000249996.1	RP11-359P5.1	-3.62	0.000324	0.0366	-0.2	-0.16	Mean platelet volume;	chr5:122865212	chr5:123036271~123054667:+
LUAD	cis	rs7976269	0.537	rs4471475	ENSG00000257176.2	RP11-996F15.2	-3.62	0.000324	0.0366	-0.18	-0.16	Male-pattern baldness;	chr12:29022461	chr12:29280418~29317848:-
LUAD	cis	rs9291683	0.655	rs3822242	ENSG00000250413.1	RP11-448G15.1	3.62	0.000324	0.0366	0.2	0.16	Bone mineral density;	chr4:10093280	chr4:10006482~10009725:+
LUAD	cis	rs3617	0.599	rs12487379	ENSG00000242142.1	SERBP1P3	3.62	0.000324	0.0367	0.18	0.16	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52861769	chr3:53064283~53065091:-
LUAD	cis	rs12928939	0.862	rs7197104	ENSG00000262140.1	RP11-417N10.3	-3.62	0.000324	0.0367	-0.19	-0.16	Post bronchodilator FEV1;	chr16:71760158	chr16:71833787~71835932:+
LUAD	cis	rs4474465	1	rs10793319	ENSG00000251323.2	RP11-452H21.4	-3.62	0.000324	0.0367	-0.21	-0.16	Alzheimer's disease (survival time);	chr11:78506191	chr11:78423982~78429836:-
LUAD	cis	rs1009077	0.868	rs62321186	ENSG00000245958.5	RP11-33B1.1	3.62	0.000324	0.0367	0.17	0.16	Endometriosis;	chr4:119681707	chr4:119454791~119552025:+
LUAD	cis	rs1009077	0.909	rs13103531	ENSG00000245958.5	RP11-33B1.1	3.62	0.000324	0.0367	0.17	0.16	Endometriosis;	chr4:119684289	chr4:119454791~119552025:+
LUAD	cis	rs2274273	0.87	rs67514154	ENSG00000259318.1	RP11-454L9.2	3.62	0.000324	0.0367	0.14	0.16	Protein biomarker;	chr14:55300664	chr14:55394940~55395233:-
LUAD	cis	rs2832077	0.506	rs2832088	ENSG00000215533.7	LINC00189	3.62	0.000324	0.0367	0.2	0.16	Cognitive test performance;	chr21:28786298	chr21:29193480~29288205:+
LUAD	cis	rs6502050	0.835	rs8077772	ENSG00000266654.1	RP11-1376P16.1	3.62	0.000325	0.0367	0.17	0.16	Life satisfaction;	chr17:82159344	chr17:82160056~82160452:+
LUAD	cis	rs11779988	0.545	rs421290	ENSG00000253671.1	RP11-806O11.1	-3.62	0.000325	0.0367	-0.2	-0.16	Breast cancer;	chr8:17908907	chr8:17808941~17820868:+
LUAD	cis	rs12681963	1	rs1355412	ENSG00000253708.1	RP11-51J9.4	3.62	0.000325	0.0367	0.22	0.16	Migraine;	chr8:30128167	chr8:30176554~30180888:-
LUAD	cis	rs6951245	1	rs77346188	ENSG00000224079.1	AC091729.7	-3.62	0.000325	0.0367	-0.26	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1074387	chr7:1074450~1078036:+
LUAD	cis	rs7555523	0.832	rs7524755	ENSG00000224358.1	RP11-466F5.8	-3.62	0.000325	0.0367	-0.25	-0.16	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165725660	chr1:165768929~165775176:+
LUAD	cis	rs513088	0.681	rs523900	ENSG00000225171.2	DUTP6	3.62	0.000325	0.0367	0.21	0.16	Schizophrenia;	chr1:166680370	chr1:166868748~166869209:+
LUAD	cis	rs2041895	0.527	rs10861678	ENSG00000260329.1	RP11-412D9.4	-3.62	0.000325	0.0367	-0.2	-0.16	Glaucoma (low intraocular pressure);	chr12:106925883	chr12:106954029~106955497:-
LUAD	cis	rs67478160	0.654	rs1997913	ENSG00000272533.1	SNORA28	3.62	0.000325	0.0367	0.17	0.16	Schizophrenia;	chr14:103747623	chr14:103337849~103337974:+
LUAD	cis	rs9309473	1	rs3813227	ENSG00000230002.2	ALMS1-IT1	-3.62	0.000325	0.0367	-0.2	-0.16	Metabolite levels;	chr2:73424839	chr2:73456764~73459484:+
LUAD	cis	rs453301	0.631	rs13250781	ENSG00000233609.3	RP11-62H7.2	-3.62	0.000325	0.0367	-0.14	-0.16	Joint mobility (Beighton score);	chr8:8935833	chr8:8961200~8979025:+
LUAD	cis	rs10129255	0.83	rs61997609	ENSG00000274576.2	IGHV2-70	3.62	0.000325	0.0367	0.15	0.16	Kawasaki disease;	chr14:106692376	chr14:106770577~106771020:-
LUAD	cis	rs3733585	0.674	rs7375643	ENSG00000250413.1	RP11-448G15.1	3.62	0.000325	0.0367	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9953615	chr4:10006482~10009725:+
LUAD	cis	rs6088590	0.542	rs6059956	ENSG00000276073.1	RP5-1125A11.7	-3.62	0.000325	0.0367	-0.15	-0.16	Coronary artery disease;	chr20:34632266	chr20:33985617~33988989:-
LUAD	cis	rs8180040	0.8	rs11920354	ENSG00000260236.1	RP11-708J19.1	-3.62	0.000325	0.0367	-0.15	-0.16	Colorectal cancer;	chr3:47220756	chr3:47379089~47380999:-
LUAD	cis	rs7208859	0.573	rs73277960	ENSG00000263603.1	CTD-2349P21.5	-3.62	0.000325	0.0367	-0.28	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30850423	chr17:30729469~30731202:+
LUAD	cis	rs4591358	0.677	rs7562869	ENSG00000223466.1	AC064834.2	3.62	0.000325	0.0367	0.19	0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195425224	chr2:195533035~195538681:+
LUAD	cis	rs2286720	0.932	rs73071756	ENSG00000225611.1	RP11-70C1.1	3.62	0.000325	0.0367	0.32	0.16	Response to antipsychotic treatment in schizophrenia (reasoning);	chr3:42406618	chr3:42770612~42773635:+
LUAD	cis	rs12468226	0.689	rs73989733	ENSG00000226261.1	AC064836.3	3.62	0.000325	0.0367	0.25	0.16	Urate levels;	chr2:202115241	chr2:202336024~202336727:-
LUAD	cis	rs3743162	0.553	rs4842994	ENSG00000259728.4	LINC00933	-3.62	0.000325	0.0367	-0.24	-0.16	Alzheimer's disease (age of onset);	chr15:84872568	chr15:84570649~84580175:+
LUAD	cis	rs10502219	0.597	rs7110823	ENSG00000246100.3	LINC00900	-3.62	0.000325	0.0367	-0.24	-0.16	Mitochondrial DNA levels;	chr11:116570560	chr11:115754248~115760627:-
LUAD	cis	rs2274273	0.638	rs17672364	ENSG00000258413.1	RP11-665C16.6	-3.62	0.000325	0.0367	-0.23	-0.16	Protein biomarker;	chr14:55239186	chr14:55262767~55272075:-
LUAD	cis	rs6438234	0.778	rs2085699	ENSG00000242767.1	ZBTB20-AS4	3.62	0.000325	0.0367	0.21	0.16	Type 2 diabetes;	chr3:115215506	chr3:115100423~115103061:+
LUAD	cis	rs3770081	0.59	rs57367442	ENSG00000273080.1	RP11-301O19.1	-3.62	0.000325	0.0367	-0.38	-0.16	Facial emotion recognition (sad faces);	chr2:86226275	chr2:86195590~86196049:+
LUAD	cis	rs11122895	1	rs11685349	ENSG00000236307.2	EEF1E1P1	3.62	0.000325	0.0367	0.18	0.16	Allergic sensitization;	chr2:111705548	chr2:111887914~111888741:+
LUAD	cis	rs2880765	0.835	rs7161880	ENSG00000259407.1	RP11-158M2.3	-3.62	0.000325	0.0367	-0.15	-0.16	Coronary artery disease;	chr15:85475515	chr15:85744109~85750281:-
LUAD	cis	rs1551277	0.959	rs4724644	ENSG00000146666.5	LINC00525	-3.62	0.000325	0.0367	-0.18	-0.16	Anxiety disorder;	chr7:47789469	chr7:47761476~47766772:+
LUAD	cis	rs6871536	1	rs56183820	ENSG00000233006.5	AC034220.3	-3.62	0.000325	0.0367	-0.18	-0.16	Asthma (childhood onset);	chr5:132629914	chr5:132311285~132369916:-
LUAD	cis	rs4474465	0.79	rs10899554	ENSG00000251323.2	RP11-452H21.4	-3.62	0.000325	0.0367	-0.2	-0.16	Alzheimer's disease (survival time);	chr11:78554621	chr11:78423982~78429836:-
LUAD	cis	rs12822507	0.732	rs4763855	ENSG00000180861.8	LINC01559	3.62	0.000325	0.0367	0.18	0.16	Systemic lupus erythematosus;	chr12:12614824	chr12:13371089~13387167:-
LUAD	cis	rs7584330	0.868	rs2325839	ENSG00000222032.1	AC112721.2	3.62	0.000325	0.0367	0.19	0.16	Prostate cancer;	chr2:237477643	chr2:237428920~237434822:-
LUAD	cis	rs812925	0.893	rs1186705	ENSG00000271889.1	RP11-493E12.1	3.62	0.000325	0.0367	0.2	0.16	Immature fraction of reticulocytes;	chr2:61446143	chr2:61151433~61162105:-
LUAD	cis	rs2834288	0.536	rs762357	ENSG00000237945.6	LINC00649	3.62	0.000325	0.0367	0.21	0.16	Gut microbiota (bacterial taxa);	chr21:33964695	chr21:33915534~33977691:+
LUAD	cis	rs6472235	0.656	rs62506593	ENSG00000200714.1	Y_RNA	-3.62	0.000325	0.0367	-0.21	-0.16	Plateletcrit;Myopia (pathological);	chr8:65966114	chr8:65592731~65592820:+
LUAD	cis	rs5749696	1	rs5749696	ENSG00000224086.5	LL22NC03-86G7.1	-3.62	0.000325	0.0367	-0.15	-0.16	Schizophrenia;	chr22:21709048	chr22:21938293~21977632:+
LUAD	cis	rs8012947	1	rs941752	ENSG00000279636.2	LINC00216	-3.62	0.000325	0.0367	-0.18	-0.16	Alcohol consumption in current drinkers;	chr14:58332643	chr14:58288033~58289158:+
LUAD	cis	rs950027	0.572	rs12910764	ENSG00000259479.5	SORD2P	-3.62	0.000325	0.0367	-0.2	-0.16	Response to fenofibrate (adiponectin levels);	chr15:45317162	chr15:44826371~44884694:-
LUAD	cis	rs72615157	0.716	rs75779608	ENSG00000078319.8	PMS2P1	-3.62	0.000325	0.0367	-0.2	-0.16	Lung function (FEV1/FVC);	chr7:100171334	chr7:100320992~100341908:-
LUAD	cis	rs11621975	0.57	rs45482193	ENSG00000258512.1	LINC00239	-3.62	0.000325	0.0367	-0.33	-0.16	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;	chr14:101785993	chr14:101730437~101732522:+
LUAD	cis	rs7546668	1	rs4661640	ENSG00000272510.1	RP4-680D5.8	3.62	0.000326	0.0368	0.21	0.16	Glomerular filtration rate (creatinine);	chr1:15528387	chr1:15565611~15565956:-
LUAD	cis	rs7546668	1	rs7546668	ENSG00000272510.1	RP4-680D5.8	3.62	0.000326	0.0368	0.21	0.16	Glomerular filtration rate (creatinine);	chr1:15528628	chr1:15565611~15565956:-
LUAD	cis	rs2348418	0.864	rs2203088	ENSG00000247934.4	RP11-967K21.1	3.62	0.000326	0.0368	0.19	0.16	Lung function (FEV1);Lung function (FVC);	chr12:28556767	chr12:28163298~28190738:-
LUAD	cis	rs62025270	0.632	rs3169119	ENSG00000202081.1	RNU6-1280P	-3.62	0.000326	0.0368	-0.24	-0.16	Idiopathic pulmonary fibrosis;	chr15:85748038	chr15:85651522~85651628:-
LUAD	cis	rs7077256	0.564	rs34730656	ENSG00000272767.1	JMJD1C-AS1	3.62	0.000326	0.0368	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63397205	chr10:63465229~63466563:+
LUAD	cis	rs7077256	0.542	rs67453614	ENSG00000272767.1	JMJD1C-AS1	3.62	0.000326	0.0368	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63397948	chr10:63465229~63466563:+
LUAD	cis	rs10129255	0.53	rs11624912	ENSG00000253209.1	IGHV3-65	3.62	0.000326	0.0368	0.13	0.16	Kawasaki disease;	chr14:106673891	chr14:106666092~106666532:-
LUAD	cis	rs5751614	0.557	rs928781	ENSG00000230701.2	FBXW4P1	-3.62	0.000326	0.0368	-0.19	-0.16	Height;	chr22:23257826	chr22:23262767~23265005:+
LUAD	cis	rs875971	0.862	rs6460302	ENSG00000273448.1	RP11-166O4.6	3.62	0.000326	0.0368	0.16	0.16	Aortic root size;	chr7:66495270	chr7:67333047~67334383:+
LUAD	cis	rs67478160	0.595	rs67768834	ENSG00000272533.1	SNORA28	3.62	0.000326	0.0368	0.17	0.16	Schizophrenia;	chr14:103754748	chr14:103337849~103337974:+
LUAD	cis	rs1953600	0.87	rs2236557	ENSG00000272447.1	RP11-182L21.6	-3.62	0.000326	0.0368	-0.18	-0.16	Sarcoidosis;	chr10:80164205	chr10:79825902~79827602:+
LUAD	cis	rs6430585	0.697	rs6724569	ENSG00000226806.1	AC011893.3	3.62	0.000326	0.0368	0.26	0.16	Corneal structure;	chr2:135759400	chr2:135820191~135823087:+
LUAD	cis	rs6921919	0.583	rs9468367	ENSG00000219392.1	RP1-265C24.5	-3.62	0.000326	0.0368	-0.21	-0.16	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28115628~28116551:+
LUAD	cis	rs4947019	1	rs11153170	ENSG00000260273.1	RP11-425D10.10	-3.62	0.000326	0.0368	-0.32	-0.16	Hematological parameters;	chr6:109331325	chr6:109382795~109383666:+
LUAD	cis	rs10214930	0.671	rs7799957	ENSG00000235574.1	AC073150.6	-3.62	0.000326	0.0368	-0.2	-0.16	Hypospadias;	chr7:27842641	chr7:27491682~27492765:-
LUAD	cis	rs6687758	1	rs66666316	ENSG00000238042.4	RP11-815M8.1	3.62	0.000326	0.0368	0.23	0.16	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:222018592	chr1:221880981~221978523:-
LUAD	cis	rs4934494	0.689	rs17127588	ENSG00000240996.1	RP11-80H5.7	-3.62	0.000326	0.0368	-0.22	-0.16	Red blood cell count;	chr10:89815887	chr10:89694295~89697928:-
LUAD	cis	rs9834975	0.544	rs6780181	ENSG00000272758.4	RP11-299J3.8	3.62	0.000326	0.0368	0.16	0.16	Diastolic blood pressure;	chr3:122545772	chr3:122416207~122443180:+
LUAD	cis	rs56309584	0.673	rs11658322	ENSG00000269947.1	RP11-849F2.9	-3.62	0.000326	0.0368	-0.24	-0.16	Initial pursuit acceleration;	chr17:8268011	chr17:8277763~8278436:+
LUAD	cis	rs2281636	0.894	rs11190196	ENSG00000233690.1	EBAG9P1	3.62	0.000326	0.0368	0.15	0.16	Obesity-related traits;	chr10:99626757	chr10:99697407~99697949:-
LUAD	cis	rs4378999	0.66	rs35356497	ENSG00000273356.1	RP11-804H8.6	3.62	0.000326	0.0368	0.21	0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;	chr3:51082271	chr3:50669989~50672048:+
LUAD	cis	rs13401620	0.871	rs4480992	ENSG00000227788.1	AC012363.8	3.62	0.000326	0.0368	0.19	0.16	Breast size;	chr2:119951741	chr2:120211727~120212862:+
LUAD	cis	rs2905347	0.755	rs2961288	ENSG00000232949.1	AC002480.4	-3.62	0.000326	0.0368	-0.19	-0.16	Major depression and alcohol dependence;	chr7:22625510	chr7:22589705~22591622:+
LUAD	cis	rs6445967	0.545	rs2271635	ENSG00000273493.1	RP11-80H18.4	-3.62	0.000326	0.0368	-0.23	-0.16	Platelet count;	chr3:58274433	chr3:58329965~58330118:+
LUAD	cis	rs5751168	0.57	rs7288160	ENSG00000211654.2	IGLV5-37	-3.62	0.000326	0.0368	-0.23	-0.16	Prostate cancer (SNP x SNP interaction);	chr22:22512137	chr22:22427540~22428035:+
LUAD	cis	rs11089937	0.857	rs5750578	ENSG00000211638.2	IGLV8-61	-3.62	0.000326	0.0368	-0.16	-0.16	Periodontitis (PAL4Q3);	chr22:22136444	chr22:22098700~22099212:+
LUAD	cis	rs1208	0.965	rs1495737	ENSG00000253384.1	CTD-2547L16.3	3.62	0.000327	0.0368	0.19	0.16	Insulin resistance/response;	chr8:18407327	chr8:18088569~18089687:-
LUAD	cis	rs10908458	0.584	rs10908454	ENSG00000160766.13	GBAP1	-3.62	0.000327	0.0368	-0.17	-0.16	Liver enzyme levels (gamma-glutamyl transferase);	chr1:155093940	chr1:155213821~155227422:-
LUAD	cis	rs513088	0.681	rs506349	ENSG00000225171.2	DUTP6	3.62	0.000327	0.0369	0.21	0.16	Schizophrenia;	chr1:166673214	chr1:166868748~166869209:+
LUAD	cis	rs2836974	0.666	rs12626405	ENSG00000232608.1	TIMM9P2	3.62	0.000327	0.0369	0.19	0.16	Cognitive function;	chr21:39291195	chr21:39216624~39217506:+
LUAD	cis	rs8014252	1	rs7159432	ENSG00000259158.2	ADAM20P1	-3.62	0.000327	0.0369	-0.23	-0.16	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70494977	chr14:70468881~70483756:-
LUAD	cis	rs6496932	0.635	rs2200214	ENSG00000202081.1	RNU6-1280P	-3.62	0.000327	0.0369	-0.21	-0.16	Central corneal thickness;Corneal structure;	chr15:85383745	chr15:85651522~85651628:-
LUAD	cis	rs7611694	0.775	rs7613082	ENSG00000242770.2	RP11-180K7.1	-3.62	0.000327	0.0369	-0.16	-0.16	Prostate cancer;	chr3:113565898	chr3:112802478~112812819:+
LUAD	cis	rs9467773	1	rs9467782	ENSG00000241549.7	GUSBP2	3.62	0.000327	0.0369	0.18	0.16	Intelligence (multi-trait analysis);	chr6:26542545	chr6:26871484~26956554:-
LUAD	cis	rs9467773	0.935	rs9461270	ENSG00000241549.7	GUSBP2	3.62	0.000327	0.0369	0.18	0.16	Intelligence (multi-trait analysis);	chr6:26543882	chr6:26871484~26956554:-
LUAD	cis	rs9467773	1	rs1884946	ENSG00000241549.7	GUSBP2	3.62	0.000327	0.0369	0.18	0.16	Intelligence (multi-trait analysis);	chr6:26545080	chr6:26871484~26956554:-
LUAD	cis	rs9467773	1	rs4871	ENSG00000241549.7	GUSBP2	3.62	0.000327	0.0369	0.18	0.16	Intelligence (multi-trait analysis);	chr6:26545404	chr6:26871484~26956554:-
LUAD	cis	rs12908161	0.92	rs35738019	ENSG00000254414.1	RP11-182J1.1	3.62	0.000327	0.0369	0.21	0.16	Schizophrenia;	chr15:84736979	chr15:84631898~84633987:-
LUAD	cis	rs12908161	1	rs34570071	ENSG00000254414.1	RP11-182J1.1	3.62	0.000327	0.0369	0.21	0.16	Schizophrenia;	chr15:84736981	chr15:84631898~84633987:-
LUAD	cis	rs2286720	1	rs2286720	ENSG00000225611.1	RP11-70C1.1	-3.62	0.000327	0.0369	-0.3	-0.16	Response to antipsychotic treatment in schizophrenia (reasoning);	chr3:42406979	chr3:42770612~42773635:+
LUAD	cis	rs7107174	1	rs7116611	ENSG00000251323.2	RP11-452H21.4	3.62	0.000327	0.0369	0.22	0.16	Testicular germ cell tumor;	chr11:78319000	chr11:78423982~78429836:-
LUAD	cis	rs42490	0.638	rs28144	ENSG00000251136.7	RP11-37B2.1	-3.62	0.000327	0.0369	-0.16	-0.16	Leprosy;	chr8:89810531	chr8:89609409~89757727:-
LUAD	cis	rs4423214	0.84	rs1792233	ENSG00000226627.1	SHANK2-AS1	3.62	0.000327	0.0369	0.2	0.16	Vitamin D levels;	chr11:71471133	chr11:70631094~70635490:+
LUAD	cis	rs748404	0.56	rs1060939	ENSG00000166763.7	STRCP1	3.62	0.000327	0.0369	0.19	0.16	Lung cancer;	chr15:43524719	chr15:43699488~43718184:-
LUAD	cis	rs80226907	0.634	rs76052518	ENSG00000239686.1	RP11-665C16.1	3.62	0.000327	0.0369	0.31	0.16	Mean platelet volume;	chr14:55423367	chr14:55282296~55282643:-
LUAD	cis	rs80226907	0.634	rs78297851	ENSG00000239686.1	RP11-665C16.1	3.62	0.000327	0.0369	0.31	0.16	Mean platelet volume;	chr14:55423737	chr14:55282296~55282643:-
LUAD	cis	rs4561483	0.583	rs33636	ENSG00000261216.1	RP11-166B2.5	-3.62	0.000327	0.0369	-0.16	-0.16	Testicular germ cell tumor;	chr16:11896466	chr16:11908208~11908916:+
LUAD	cis	rs703842	0.616	rs10783851	ENSG00000245651.2	RP11-620J15.2	-3.62	0.000327	0.0369	-0.17	-0.16	Multiple sclerosis;	chr12:57837372	chr12:57869835~57896482:-
LUAD	cis	rs6452524	0.935	rs7718284	ENSG00000271862.1	RP11-343L5.2	-3.62	0.000327	0.0369	-0.16	-0.16	Hypertension (SNP x SNP interaction);	chr5:83082488	chr5:83049376~83050964:-
LUAD	cis	rs875971	1	rs6460292	ENSG00000273142.1	RP11-458F8.4	3.62	0.000327	0.0369	0.11	0.16	Aortic root size;	chr7:66345088	chr7:66902857~66906297:+
LUAD	cis	rs987044	0.69	rs10778655	ENSG00000257221.1	RP11-689B22.2	-3.62	0.000327	0.0369	-0.14	-0.16	Mean platelet volume;	chr12:108721912	chr12:108628687~108641318:+
LUAD	cis	rs3096299	0.719	rs2911262	ENSG00000261574.1	RP1-168P16.2	3.62	0.000327	0.0369	0.18	0.16	Multiple myeloma (IgH translocation);	chr16:89448633	chr16:89392375~89412564:-
LUAD	cis	rs2834288	0.535	rs2834306	ENSG00000273102.1	AP000569.9	-3.62	0.000327	0.0369	-0.2	-0.16	Gut microbiota (bacterial taxa);	chr21:33957563	chr21:33967101~33968573:-
LUAD	cis	rs7829975	0.514	rs2979139	ENSG00000233609.3	RP11-62H7.2	3.62	0.000327	0.0369	0.13	0.16	Mood instability;	chr8:8410803	chr8:8961200~8979025:+
LUAD	cis	rs4423214	0.879	rs1792281	ENSG00000226627.1	SHANK2-AS1	3.62	0.000327	0.0369	0.2	0.16	Vitamin D levels;	chr11:71424450	chr11:70631094~70635490:+
LUAD	cis	rs9309473	0.948	rs6719753	ENSG00000230002.2	ALMS1-IT1	3.62	0.000327	0.0369	0.2	0.16	Metabolite levels;	chr2:73521927	chr2:73456764~73459484:+
LUAD	cis	rs4667682	0.646	rs6433287	ENSG00000234061.1	AC007969.4	-3.62	0.000327	0.0369	-0.33	-0.16	Hippocampal atrophy;Body mass index;	chr2:171277866	chr2:171492905~171493095:+
LUAD	cis	rs7618915	0.547	rs4130905	ENSG00000243224.1	RP5-1157M23.2	-3.62	0.000327	0.0369	-0.17	-0.16	Bipolar disorder;	chr3:52675815	chr3:52239258~52241097:+
LUAD	cis	rs9341808	0.935	rs942381	ENSG00000233967.5	RP11-250B2.3	3.62	0.000328	0.0369	0.16	0.16	Sitting height ratio;	chr6:80170433	chr6:80443344~80465927:+
LUAD	cis	rs6496932	0.663	rs8040940	ENSG00000202081.1	RNU6-1280P	-3.62	0.000328	0.0369	-0.2	-0.16	Central corneal thickness;Corneal structure;	chr15:85361817	chr15:85651522~85651628:-
LUAD	cis	rs115575488	0.641	rs12725462	ENSG00000231365.4	RP11-418J17.1	3.62	0.000328	0.0369	0.33	0.16	Lobe attachment (rater-scored or self-reported);	chr1:119229935	chr1:119140396~119275973:+
LUAD	cis	rs786425	0.838	rs1543075	ENSG00000278112.1	RP11-972P1.11	-3.62	0.000328	0.0369	-0.15	-0.16	Pubertal anthropometrics;	chr12:123601901	chr12:123519390~123519856:-
LUAD	cis	rs683250	0.599	rs1943737	ENSG00000246067.6	RAB30-AS1	-3.62	0.000328	0.037	-0.17	-0.16	Subcortical brain region volumes;	chr11:83365985	chr11:83072066~83106719:+
LUAD	cis	rs683250	0.599	rs12788709	ENSG00000246067.6	RAB30-AS1	-3.62	0.000328	0.037	-0.17	-0.16	Subcortical brain region volumes;	chr11:83366511	chr11:83072066~83106719:+
LUAD	cis	rs683250	0.599	rs35615759	ENSG00000246067.6	RAB30-AS1	-3.62	0.000328	0.037	-0.17	-0.16	Subcortical brain region volumes;	chr11:83367021	chr11:83072066~83106719:+
LUAD	cis	rs683250	0.599	rs7110308	ENSG00000246067.6	RAB30-AS1	-3.62	0.000328	0.037	-0.17	-0.16	Subcortical brain region volumes;	chr11:83367410	chr11:83072066~83106719:+
LUAD	cis	rs683250	0.63	rs1943739	ENSG00000246067.6	RAB30-AS1	-3.62	0.000328	0.037	-0.17	-0.16	Subcortical brain region volumes;	chr11:83368709	chr11:83072066~83106719:+
LUAD	cis	rs683250	0.599	rs1943740	ENSG00000246067.6	RAB30-AS1	-3.62	0.000328	0.037	-0.17	-0.16	Subcortical brain region volumes;	chr11:83368932	chr11:83072066~83106719:+
LUAD	cis	rs875971	0.545	rs73142265	ENSG00000224316.1	RP11-479O9.2	3.62	0.000328	0.037	0.19	0.16	Aortic root size;	chr7:66234510	chr7:65773620~65802067:+
LUAD	cis	rs7760535	0.764	rs2343614	ENSG00000230177.1	RP5-1112D6.4	-3.62	0.000328	0.037	-0.14	-0.16	Metabolic traits;	chr6:111383955	chr6:111277932~111278742:+
LUAD	cis	rs7474896	0.515	rs594594	ENSG00000226578.1	RP11-258F22.1	3.62	0.000328	0.037	0.23	0.16	Obesity (extreme);	chr10:38018795	chr10:37775371~37784131:-
LUAD	cis	rs9381040	0.655	rs6939989	ENSG00000161912.16	ADCY10P1	3.62	0.000328	0.037	0.14	0.16	Alzheimer's disease (late onset);	chr6:41052466	chr6:41101022~41140835:+
LUAD	cis	rs990171	0.538	rs11682754	ENSG00000234389.1	AC007278.3	3.62	0.000328	0.037	0.16	0.16	Lymphocyte counts;	chr2:102500636	chr2:102438713~102440475:+
LUAD	cis	rs990171	0.538	rs6728288	ENSG00000234389.1	AC007278.3	3.62	0.000328	0.037	0.16	0.16	Lymphocyte counts;	chr2:102500809	chr2:102438713~102440475:+
LUAD	cis	rs990171	0.538	rs6741235	ENSG00000234389.1	AC007278.3	3.62	0.000328	0.037	0.16	0.16	Lymphocyte counts;	chr2:102500824	chr2:102438713~102440475:+
LUAD	cis	rs4713118	0.539	rs200951	ENSG00000216901.1	AL022393.7	3.62	0.000328	0.037	0.2	0.16	Parkinson's disease;	chr6:27868152	chr6:28176188~28176674:+
LUAD	cis	rs9902453	1	rs62070270	ENSG00000263531.1	RP13-753N3.1	-3.62	0.000328	0.037	-0.2	-0.16	Coffee consumption (cups per day);	chr17:29936962	chr17:30863921~30864940:-
LUAD	cis	rs11009175	0.556	rs1815241	ENSG00000273038.2	RP11-479G22.8	-3.62	0.000328	0.037	-0.2	-0.16	Depression (quantitative trait);	chr10:33018096	chr10:32887255~32889311:-
LUAD	cis	rs8014204	0.806	rs11159105	ENSG00000279594.1	RP11-950C14.10	3.62	0.000328	0.037	0.18	0.16	Caffeine consumption;	chr14:74831349	chr14:75011269~75012851:-
LUAD	cis	rs8014204	0.836	rs7150254	ENSG00000279594.1	RP11-950C14.10	3.62	0.000328	0.037	0.18	0.16	Caffeine consumption;	chr14:74832398	chr14:75011269~75012851:-
LUAD	cis	rs7216064	1	rs12452511	ENSG00000266717.1	RP11-855A2.3	3.62	0.000328	0.037	0.2	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67836460	chr17:67950885~67951746:-
LUAD	cis	rs12681366	0.537	rs2919667	ENSG00000253704.1	RP11-267M23.4	3.62	0.000328	0.037	0.2	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94452974	chr8:94553722~94569745:+
LUAD	cis	rs12681366	0.537	rs2381886	ENSG00000253704.1	RP11-267M23.4	3.62	0.000328	0.037	0.2	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94464825	chr8:94553722~94569745:+
LUAD	cis	rs338389	0.516	rs11855801	ENSG00000270964.1	RP11-502I4.3	3.62	0.000328	0.037	0.17	0.16	Survival in rectal cancer;	chr15:68020994	chr15:67541072~67542604:-
LUAD	cis	rs6964587	1	rs2282971	ENSG00000188693.7	CYP51A1-AS1	-3.62	0.000328	0.037	-0.19	-0.16	Breast cancer;	chr7:91955042	chr7:92134604~92180725:+
LUAD	cis	rs8056893	0.842	rs1111571	ENSG00000260441.4	RP11-96D1.7	3.62	0.000328	0.037	0.19	0.16	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68329278	chr16:68256162~68260443:-
LUAD	cis	rs9926296	0.533	rs10852623	ENSG00000260259.1	RP11-368I7.4	-3.62	0.000328	0.037	-0.16	-0.16	Vitiligo;	chr16:89798834	chr16:89682620~89686569:-
LUAD	cis	rs4795519	0.922	rs2313737	ENSG00000266313.1	RP11-173M1.4	3.62	0.000328	0.037	0.2	0.16	Chronic myeloid leukemia;	chr17:27120496	chr17:27333256~27348491:+
LUAD	cis	rs4795519	0.71	rs8071054	ENSG00000266313.1	RP11-173M1.4	3.62	0.000328	0.037	0.2	0.16	Chronic myeloid leukemia;	chr17:27129633	chr17:27333256~27348491:+
LUAD	cis	rs2154319	0.887	rs9439033	ENSG00000235358.1	RP11-399E6.1	-3.62	0.000328	0.037	-0.22	-0.16	Height;	chr1:41060351	chr1:41242373~41284861:+
LUAD	cis	rs10885396	0.967	rs7094871	ENSG00000233547.1	RP11-57H14.2	-3.62	0.000328	0.037	-0.16	-0.16	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr10:112952395	chr10:112950646~112951875:-
LUAD	cis	rs2288073	0.965	rs10192600	ENSG00000223754.1	AC008073.9	3.62	0.000328	0.037	0.21	0.16	Venous thromboembolism (SNP x SNP interaction);	chr2:24173811	chr2:24199839~24201698:-
LUAD	cis	rs4578769	0.55	rs9945620	ENSG00000266850.1	RP11-370A5.1	3.62	0.000328	0.037	0.21	0.16	Eosinophil percentage of white cells;	chr18:22997367	chr18:22723491~22907721:-
LUAD	cis	rs4578769	0.55	rs2305886	ENSG00000266850.1	RP11-370A5.1	3.62	0.000328	0.037	0.21	0.16	Eosinophil percentage of white cells;	chr18:22997493	chr18:22723491~22907721:-
LUAD	cis	rs11153306	0.552	rs12196381	ENSG00000266032.1	AL357515.1	-3.62	0.000328	0.037	-0.2	-0.16	Tonsillectomy;	chr6:111618197	chr6:110969773~110969872:-
LUAD	cis	rs12149074	0.55	rs10445060	ENSG00000261390.4	RP11-345M22.2	-3.62	0.000328	0.037	-0.21	-0.16	Bipolar disorder and eating disorder;Eating disorder in bipolar disorder;	chr16:80070862	chr16:79715232~79770563:-
LUAD	cis	rs4716602	1	rs4716602	ENSG00000235029.1	MNX1-AS2	-3.62	0.000328	0.037	-0.21	-0.16	Anti-saccade response;	chr7:156373855	chr7:157006307~157007132:+
LUAD	cis	rs34638952	0.507	rs797960	ENSG00000264808.1	RP11-802D6.1	-3.62	0.000328	0.037	-0.19	-0.16	Sitting height ratio;	chr17:29287819	chr17:29369717~29390777:-
LUAD	cis	rs11673344	0.526	rs57654288	ENSG00000267254.4	ZNF790-AS1	-3.62	0.000328	0.037	-0.2	-0.16	Obesity-related traits;	chr19:37587870	chr19:36797518~36828115:+
LUAD	cis	rs7077256	0.542	rs12773235	ENSG00000272767.1	JMJD1C-AS1	3.62	0.000328	0.037	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63254915	chr10:63465229~63466563:+
LUAD	cis	rs334353	0.798	rs10283455	ENSG00000255145.2	STX17-AS1	-3.62	0.000328	0.037	-0.22	-0.16	Age-related macular degeneration;	chr9:99143361	chr9:99886322~99906601:-
LUAD	cis	rs7404928	0.592	rs11644907	ENSG00000261528.2	AC002400.1	-3.62	0.000328	0.037	-0.17	-0.16	Rheumatoid arthritis;Primary biliary cholangitis;	chr16:23898664	chr16:23500905~23501630:+
LUAD	cis	rs2154319	0.831	rs213761	ENSG00000235358.1	RP11-399E6.1	3.62	0.000329	0.037	0.23	0.16	Height;	chr1:41125462	chr1:41242373~41284861:+
LUAD	cis	rs2243480	1	rs2243480	ENSG00000229886.1	RP5-1132H15.3	3.62	0.000329	0.037	0.28	0.16	Diabetic kidney disease;	chr7:66134209	chr7:66025126~66031544:-
LUAD	cis	rs7772486	0.686	rs4896833	ENSG00000235652.6	RP11-545I5.3	3.62	0.000329	0.037	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145644537	chr6:145799409~145886585:+
LUAD	cis	rs647161	0.616	rs10074380	ENSG00000247627.2	MTND4P12	-3.62	0.000329	0.037	-0.2	-0.16	Colorectal cancer;	chr5:135153385	chr5:134926660~134928036:-
LUAD	cis	rs6951245	0.872	rs77569514	ENSG00000224079.1	AC091729.7	-3.62	0.000329	0.037	-0.25	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1045872	chr7:1074450~1078036:+
LUAD	cis	rs6871536	1	rs60490216	ENSG00000233006.5	AC034220.3	-3.62	0.000329	0.037	-0.18	-0.16	Asthma (childhood onset);	chr5:132586193	chr5:132311285~132369916:-
LUAD	cis	rs4795519	0.778	rs1402724	ENSG00000266313.1	RP11-173M1.4	-3.62	0.000329	0.037	-0.21	-0.16	Chronic myeloid leukemia;	chr17:27082500	chr17:27333256~27348491:+
LUAD	cis	rs6081541	1	rs3790167	ENSG00000179447.2	RP5-1027G4.3	-3.62	0.000329	0.037	-0.2	-0.16	Psychosis (atypical);	chr20:19240267	chr20:19242302~19284596:-
LUAD	cis	rs4908768	0.906	rs12405049	ENSG00000232912.4	RP5-1115A15.1	-3.62	0.000329	0.037	-0.19	-0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8566058	chr1:8424645~8434838:+
LUAD	cis	rs2554380	0.943	rs2562777	ENSG00000230373.7	GOLGA6L5P	-3.62	0.000329	0.037	-0.21	-0.16	Height;	chr15:83697314	chr15:84507885~84516814:-
LUAD	cis	rs1862618	0.756	rs13356762	ENSG00000271828.1	CTD-2310F14.1	3.62	0.000329	0.037	0.23	0.16	Initial pursuit acceleration;	chr5:56815165	chr5:56927874~56929573:+
LUAD	cis	rs2408955	0.521	rs7301003	ENSG00000257763.1	OR5BK1P	3.62	0.000329	0.0371	0.17	0.16	Glycated hemoglobin levels;	chr12:48156444	chr12:48355792~48356614:-
LUAD	cis	rs701145	0.537	rs1713819	ENSG00000243069.6	ARHGEF26-AS1	3.62	0.000329	0.0371	0.25	0.16	Coronary artery disease;	chr3:154146685	chr3:154024401~154121332:-
LUAD	cis	rs701145	0.585	rs4680125	ENSG00000243069.6	ARHGEF26-AS1	-3.62	0.000329	0.0371	-0.28	-0.16	Coronary artery disease;	chr3:154066909	chr3:154024401~154121332:-
LUAD	cis	rs11642862	1	rs74483355	ENSG00000239791.1	AC002310.7	3.62	0.000329	0.0371	0.29	0.16	Tonsillectomy;	chr16:30825109	chr16:30572250~30583860:+
LUAD	cis	rs78572108	0.8	rs74261249	ENSG00000214691.7	AC104654.1	3.62	0.000329	0.0371	0.27	0.16	Total body bone mineral density;	chr2:42008155	chr2:41877074~41894046:+
LUAD	cis	rs78572108	0.858	rs79431280	ENSG00000214691.7	AC104654.1	3.62	0.000329	0.0371	0.27	0.16	Total body bone mineral density;	chr2:42008570	chr2:41877074~41894046:+
LUAD	cis	rs2257011	0.733	rs1896796	ENSG00000230373.7	GOLGA6L5P	-3.62	0.000329	0.0371	-0.15	-0.16	Height;	chr15:83606228	chr15:84507885~84516814:-
LUAD	cis	rs7142881	0.815	rs7156670	ENSG00000258525.1	RP11-829H16.3	-3.62	0.000329	0.0371	-0.18	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31704385	chr14:30876179~30889808:-
LUAD	cis	rs911555	0.511	rs2296483	ENSG00000258851.1	RP11-894P9.2	-3.62	0.000329	0.0371	-0.19	-0.16	Intelligence (multi-trait analysis);	chr14:103563455	chr14:103553421~103561877:+
LUAD	cis	rs7208859	0.673	rs12949860	ENSG00000263603.1	CTD-2349P21.5	-3.62	0.000329	0.0371	-0.28	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896014	chr17:30729469~30731202:+
LUAD	cis	rs9309473	1	rs9309473	ENSG00000230002.2	ALMS1-IT1	3.62	0.000329	0.0371	0.21	0.16	Metabolite levels;	chr2:73516855	chr2:73456764~73459484:+
LUAD	cis	rs6088590	1	rs6058111	ENSG00000275784.1	RP5-1125A11.6	-3.62	0.000329	0.0371	-0.18	-0.16	Coronary artery disease;	chr20:34723195	chr20:33989480~33991818:-
LUAD	cis	rs6546537	0.955	rs35947226	ENSG00000231024.1	AC092431.3	3.62	0.000329	0.0371	0.21	0.16	Serum thyroid-stimulating hormone levels;	chr2:69618697	chr2:69700192~69713847:-
LUAD	cis	rs6942407	0.592	rs56327053	ENSG00000224046.1	AC005076.5	-3.62	0.000329	0.0371	-0.2	-0.16	Food allergy;	chr7:87119223	chr7:87151423~87152420:-
LUAD	cis	rs6942407	0.592	rs17766011	ENSG00000224046.1	AC005076.5	-3.62	0.000329	0.0371	-0.2	-0.16	Food allergy;	chr7:87119853	chr7:87151423~87152420:-
LUAD	cis	rs6942407	0.64	rs17698411	ENSG00000224046.1	AC005076.5	-3.62	0.000329	0.0371	-0.2	-0.16	Food allergy;	chr7:87119881	chr7:87151423~87152420:-
LUAD	cis	rs897984	0.52	rs4889536	ENSG00000232748.3	RP11-196G11.6	3.62	0.000329	0.0371	0.22	0.16	Dementia with Lewy bodies;	chr16:30860434	chr16:31056460~31062803:+
LUAD	cis	rs7824557	0.614	rs7816606	ENSG00000255046.1	RP11-297N6.4	-3.62	0.000329	0.0371	-0.21	-0.16	Retinal vascular caliber;	chr8:11348093	chr8:11797928~11802568:-
LUAD	cis	rs6951245	0.706	rs28522260	ENSG00000249574.1	AC226118.1	-3.62	0.000329	0.0371	-0.25	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1144328	chr7:379359~382712:+
LUAD	cis	rs3020736	0.5	rs5996111	ENSG00000273366.1	CTA-989H11.1	3.62	0.000329	0.0371	0.2	0.16	Autism spectrum disorder or schizophrenia;	chr22:42097898	chr22:42278188~42278846:+
LUAD	cis	rs763121	0.853	rs5757253	ENSG00000225450.1	RP3-508I15.14	-3.62	0.000329	0.0371	-0.15	-0.16	Menopause (age at onset);	chr22:38708315	chr22:38739003~38749041:+
LUAD	cis	rs11838267	0.527	rs1990477	ENSG00000256967.1	RP11-273B20.1	-3.62	0.000329	0.0371	-0.16	-0.16	Coronary artery disease;	chr12:7056109	chr12:7129079~7131198:-
LUAD	cis	rs4835473	0.932	rs9685306	ENSG00000249741.2	RP11-673E1.3	3.62	0.000329	0.0371	0.2	0.16	Immature fraction of reticulocytes;	chr4:143748843	chr4:143911514~143912053:-
LUAD	cis	rs17189298	0.869	rs4364032	ENSG00000231013.1	AC013275.2	3.62	0.000329	0.0371	0.16	0.16	Cerebrospinal T-tau levels;	chr2:119081078	chr2:119476448~119487346:+
LUAD	cis	rs2024714	0.967	rs6089444	ENSG00000273812.1	WI2-87327B8.2	-3.62	0.000329	0.0371	-0.17	-0.16	Longevity;	chr20:61631696	chr20:62596732~62603115:-
LUAD	cis	rs16866061	0.926	rs1523919	ENSG00000228446.2	AC073052.1	-3.62	0.00033	0.0371	-0.18	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr2:224538898	chr2:224499387~224500100:-
LUAD	cis	rs4795519	0.922	rs12942290	ENSG00000266313.1	RP11-173M1.4	3.62	0.00033	0.0371	0.2	0.16	Chronic myeloid leukemia;	chr17:27089673	chr17:27333256~27348491:+
LUAD	cis	rs4795519	0.744	rs12942522	ENSG00000266313.1	RP11-173M1.4	3.62	0.00033	0.0371	0.2	0.16	Chronic myeloid leukemia;	chr17:27089710	chr17:27333256~27348491:+
LUAD	cis	rs4683346	0.653	rs834580	ENSG00000173811.9	CCDC13-AS1	-3.62	0.00033	0.0371	-0.19	-0.16	Granulocyte percentage of myeloid white cells;	chr3:42928100	chr3:42732575~42746768:+
LUAD	cis	rs11893307	0.566	rs10203824	ENSG00000235852.1	AC005540.3	3.62	0.00033	0.0371	0.21	0.16	Mean platelet volume;	chr2:190731124	chr2:190880797~190882059:-
LUAD	cis	rs7615952	0.546	rs16836896	ENSG00000241288.6	RP11-379B18.5	-3.62	0.00033	0.0371	-0.21	-0.16	Blood pressure (smoking interaction);	chr3:125592418	chr3:125827238~125916384:-
LUAD	cis	rs1129187	0.818	rs9462858	ENSG00000261068.2	RP11-7K24.3	-3.62	0.00033	0.0371	-0.17	-0.16	Alzheimer's disease in APOE e4+ carriers;	chr6:42978752	chr6:42092233~42094259:-
LUAD	cis	rs6928977	0.66	rs2757647	ENSG00000231028.7	LINC00271	3.62	0.00033	0.0371	0.19	0.16	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135446416	chr6:135497801~135716055:+
LUAD	cis	rs12073359	0.955	rs4926391	ENSG00000223945.2	RP11-458I7.1	3.62	0.00033	0.0371	0.23	0.16	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150168687	chr1:150053864~150055034:+
LUAD	cis	rs1150668	0.799	rs1736891	ENSG00000176933.5	TOB2P1	-3.62	0.00033	0.0371	-0.18	-0.16	Pubertal anthropometrics;	chr6:28219323	chr6:28217643~28218634:-
LUAD	cis	rs8012947	1	rs1951202	ENSG00000279636.2	LINC00216	3.62	0.00033	0.0371	0.18	0.16	Alcohol consumption in current drinkers;	chr14:58312699	chr14:58288033~58289158:+
LUAD	cis	rs875971	0.798	rs12698522	ENSG00000273448.1	RP11-166O4.6	3.62	0.00033	0.0371	0.16	0.16	Aortic root size;	chr7:66502354	chr7:67333047~67334383:+
LUAD	cis	rs875971	0.83	rs28714531	ENSG00000273448.1	RP11-166O4.6	3.62	0.00033	0.0371	0.16	0.16	Aortic root size;	chr7:66503250	chr7:67333047~67334383:+
LUAD	cis	rs875971	0.862	rs12698526	ENSG00000273448.1	RP11-166O4.6	3.62	0.00033	0.0371	0.16	0.16	Aortic root size;	chr7:66504118	chr7:67333047~67334383:+
LUAD	cis	rs9549260	0.564	rs4245402	ENSG00000168852.11	TPTE2P5	3.62	0.00033	0.0371	0.16	0.16	Red blood cell count;	chr13:40713404	chr13:40822296~40921749:-
LUAD	cis	rs1346081	0.869	rs12504877	ENSG00000250075.4	RP11-584P21.2	-3.62	0.00033	0.0371	-0.18	-0.16	Intelligence (multi-trait analysis);	chr4:67192963	chr4:67417305~67468251:-
LUAD	cis	rs7178424	0.967	rs17271403	ENSG00000259251.2	RP11-643M14.1	-3.62	0.00033	0.0371	-0.16	-0.16	Height;	chr15:62083190	chr15:62060503~62062434:+
LUAD	cis	rs2273156	1	rs2273156	ENSG00000226677.3	IGBP1P1	-3.62	0.00033	0.0371	-0.24	-0.16	Immunoglobulin light chain (AL) amyloidosis;	chr14:34969593	chr14:34939324~34940332:+
LUAD	cis	rs74346567	0.649	rs2467097	ENSG00000259416.2	RP11-158M2.5	-3.62	0.00033	0.0371	-0.24	-0.16	Mean corpuscular volume;	chr15:85667367	chr15:85754941~85756237:-
LUAD	cis	rs7911264	0.628	rs6583833	ENSG00000236493.2	EIF2S2P3	3.62	0.00033	0.0371	0.18	0.16	Inflammatory bowel disease;	chr10:92650043	chr10:92668745~92669743:-
LUAD	cis	rs7506045	1	rs16976887	ENSG00000267079.1	RP11-820I16.1	-3.62	0.00033	0.0372	-0.31	-0.16	Stroke;	chr18:11986657	chr18:11910634~11914344:-
LUAD	cis	rs7200543	0.583	rs4985149	ENSG00000260735.1	RP11-72I8.1	-3.62	0.00033	0.0372	-0.19	-0.16	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15053481	chr16:15094411~15109197:+
LUAD	cis	rs1044826	1	rs9848241	ENSG00000214280.3	RP11-553K23.2	-3.62	0.00033	0.0372	-0.2	-0.16	Obesity-related traits;	chr3:139410789	chr3:139582928~139583593:-
LUAD	cis	rs1853665	0.58	rs4242282	ENSG00000231760.4	RP11-350J20.5	3.62	0.00033	0.0372	0.26	0.16	Radiation response;	chr6:149952210	chr6:149796151~149826294:-
LUAD	cis	rs2115630	0.818	rs7176522	ENSG00000225151.9	GOLGA2P7	3.62	0.00033	0.0372	0.19	0.16	P wave terminal force;	chr15:84672152	chr15:84199311~84230136:-
LUAD	cis	rs6460942	0.915	rs62447641	ENSG00000226690.5	AC005281.1	3.62	0.00033	0.0372	0.29	0.16	Coronary artery disease;	chr7:12449138	chr7:12496429~12541910:+
LUAD	cis	rs4246307	0.935	rs4246308	ENSG00000254744.3	CTD-3076O17.1	3.62	0.00033	0.0372	0.2	0.16	Hip circumference adjusted for BMI;	chr15:100224997	chr15:99970215~99974010:+
LUAD	cis	rs2974760	0.606	rs6600143	ENSG00000260803.1	Z84812.4	3.62	0.00033	0.0372	0.2	0.16	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr16:151390	chr16:17514~35195:-
LUAD	cis	rs818427	0.656	rs818426	ENSG00000279522.1	CTC-487M23.6	3.62	0.00033	0.0372	0.19	0.16	Total body bone mineral density;	chr5:112890495	chr5:112894933~112896531:+
LUAD	cis	rs1383484	1	rs28612730	ENSG00000259728.4	LINC00933	-3.62	0.00033	0.0372	-0.21	-0.16	Height;	chr15:83842454	chr15:84570649~84580175:+
LUAD	cis	rs116095464	0.681	rs10060016	ENSG00000248925.1	CTD-2083E4.6	3.62	0.00033	0.0372	0.28	0.16	Breast cancer;	chr5:240985	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs10057299	ENSG00000248925.1	CTD-2083E4.6	3.62	0.00033	0.0372	0.28	0.16	Breast cancer;	chr5:242020	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs13356367	ENSG00000248925.1	CTD-2083E4.6	3.62	0.00033	0.0372	0.28	0.16	Breast cancer;	chr5:242280	chr5:269858~271516:-
LUAD	cis	rs116095464	0.85	rs10055295	ENSG00000248925.1	CTD-2083E4.6	3.62	0.00033	0.0372	0.28	0.16	Breast cancer;	chr5:243634	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs10055354	ENSG00000248925.1	CTD-2083E4.6	3.62	0.00033	0.0372	0.28	0.16	Breast cancer;	chr5:243679	chr5:269858~271516:-
LUAD	cis	rs116095464	0.614	rs62344292	ENSG00000248925.1	CTD-2083E4.6	3.62	0.00033	0.0372	0.28	0.16	Breast cancer;	chr5:244515	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs60251075	ENSG00000248925.1	CTD-2083E4.6	3.62	0.00033	0.0372	0.28	0.16	Breast cancer;	chr5:245177	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs10462754	ENSG00000248925.1	CTD-2083E4.6	3.62	0.00033	0.0372	0.28	0.16	Breast cancer;	chr5:246554	chr5:269858~271516:-
LUAD	cis	rs116095464	0.558	rs10462755	ENSG00000248925.1	CTD-2083E4.6	3.62	0.00033	0.0372	0.28	0.16	Breast cancer;	chr5:246633	chr5:269858~271516:-
LUAD	cis	rs2274273	0.624	rs4580079	ENSG00000258413.1	RP11-665C16.6	-3.62	0.00033	0.0372	-0.22	-0.16	Protein biomarker;	chr14:55313648	chr14:55262767~55272075:-
LUAD	cis	rs2274273	0.6	rs35112084	ENSG00000258413.1	RP11-665C16.6	-3.62	0.00033	0.0372	-0.22	-0.16	Protein biomarker;	chr14:55314382	chr14:55262767~55272075:-
LUAD	cis	rs6832769	0.643	rs1488939	ENSG00000272969.1	RP11-528I4.2	-3.62	0.00033	0.0372	-0.18	-0.16	Personality dimensions;	chr4:55652977	chr4:55547112~55547889:+
LUAD	cis	rs699371	0.533	rs12893163	ENSG00000270000.1	RP3-449M8.9	3.62	0.00033	0.0372	0.18	0.16	Height;	chr14:74428292	chr14:74471930~74472360:-
LUAD	cis	rs12214131	0.509	rs10871994	ENSG00000219088.1	RP3-359N14.1	-3.62	0.00033	0.0372	-0.17	-0.16	Male-pattern baldness;	chr6:105751778	chr6:105666326~105667998:+
LUAD	cis	rs2288073	0.965	rs13387930	ENSG00000223754.1	AC008073.9	3.62	0.00033	0.0372	0.21	0.16	Venous thromboembolism (SNP x SNP interaction);	chr2:24191531	chr2:24199839~24201698:-
LUAD	cis	rs7107174	0.901	rs4944199	ENSG00000251323.2	RP11-452H21.4	3.62	0.00033	0.0372	0.2	0.16	Testicular germ cell tumor;	chr11:78411733	chr11:78423982~78429836:-
LUAD	cis	rs797680	0.82	rs11164879	ENSG00000223745.6	RP4-717I23.3	3.62	0.00033	0.0372	0.13	0.16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93189965	chr1:93262186~93346025:-
LUAD	cis	rs797680	0.856	rs7541687	ENSG00000223745.6	RP4-717I23.3	3.62	0.00033	0.0372	0.13	0.16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93191031	chr1:93262186~93346025:-
LUAD	cis	rs797680	0.753	rs11164881	ENSG00000223745.6	RP4-717I23.3	3.62	0.00033	0.0372	0.13	0.16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93193432	chr1:93262186~93346025:-
LUAD	cis	rs797680	0.856	rs10874764	ENSG00000223745.6	RP4-717I23.3	3.62	0.00033	0.0372	0.13	0.16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93195785	chr1:93262186~93346025:-
LUAD	cis	rs11779988	0.545	rs454692	ENSG00000253671.1	RP11-806O11.1	-3.62	0.00033	0.0372	-0.2	-0.16	Breast cancer;	chr8:17931789	chr8:17808941~17820868:+
LUAD	cis	rs42490	0.589	rs39772	ENSG00000251136.7	RP11-37B2.1	-3.62	0.00033	0.0372	-0.17	-0.16	Leprosy;	chr8:89831636	chr8:89609409~89757727:-
LUAD	cis	rs2274273	0.624	rs67412516	ENSG00000258413.1	RP11-665C16.6	-3.62	0.00033	0.0372	-0.22	-0.16	Protein biomarker;	chr14:55386519	chr14:55262767~55272075:-
LUAD	cis	rs10392	0.5	rs8118646	ENSG00000274825.1	RP4-616B8.5	-3.62	0.00033	0.0372	-0.21	-0.16	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;	chr20:38972244	chr20:38955910~38956547:+
LUAD	cis	rs683250	0.63	rs2512657	ENSG00000246067.6	RAB30-AS1	-3.62	0.00033	0.0372	-0.17	-0.16	Subcortical brain region volumes;	chr11:83424108	chr11:83072066~83106719:+
LUAD	cis	rs2494663	0.585	rs7520349	ENSG00000223599.1	RP11-216N14.7	3.62	0.00033	0.0372	0.2	0.16	Mean platelet volume;	chr1:154109173	chr1:153852106~153853414:-
LUAD	cis	rs1501138	0.573	rs10805348	ENSG00000263327.5	TAPT1-AS1	-3.62	0.00033	0.0372	-0.23	-0.16	Systemic juvenile idiopathic arthritis;	chr4:16314316	chr4:16226685~16320140:+
LUAD	cis	rs853679	0.55	rs1237875	ENSG00000280107.1	AL022393.9	3.62	0.00033	0.0372	0.21	0.16	Depression;	chr6:28205232	chr6:28170845~28172521:+
LUAD	cis	rs3772130	0.962	rs35679661	ENSG00000243544.3	RN7SL172P	3.62	0.00033	0.0372	0.2	0.16	Cognitive performance;	chr3:121765916	chr3:121653994~121654296:-
LUAD	cis	rs748404	0.666	rs72709850	ENSG00000249839.1	AC011330.5	-3.62	0.00033	0.0372	-0.25	-0.16	Lung cancer;	chr15:43462486	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.666	rs34633582	ENSG00000249839.1	AC011330.5	-3.62	0.00033	0.0372	-0.25	-0.16	Lung cancer;	chr15:43462683	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.666	rs36078097	ENSG00000249839.1	AC011330.5	-3.62	0.00033	0.0372	-0.25	-0.16	Lung cancer;	chr15:43466209	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.666	rs7181783	ENSG00000249839.1	AC011330.5	-3.62	0.00033	0.0372	-0.25	-0.16	Lung cancer;	chr15:43469723	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.666	rs35903301	ENSG00000249839.1	AC011330.5	-3.62	0.00033	0.0372	-0.25	-0.16	Lung cancer;	chr15:43472332	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.666	rs34002293	ENSG00000249839.1	AC011330.5	-3.62	0.00033	0.0372	-0.25	-0.16	Lung cancer;	chr15:43472401	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.666	rs34181131	ENSG00000249839.1	AC011330.5	-3.62	0.00033	0.0372	-0.25	-0.16	Lung cancer;	chr15:43478527	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.666	rs7173383	ENSG00000249839.1	AC011330.5	-3.62	0.00033	0.0372	-0.25	-0.16	Lung cancer;	chr15:43480838	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.666	rs55801120	ENSG00000249839.1	AC011330.5	-3.62	0.00033	0.0372	-0.25	-0.16	Lung cancer;	chr15:43495042	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.666	rs12911740	ENSG00000249839.1	AC011330.5	-3.62	0.00033	0.0372	-0.25	-0.16	Lung cancer;	chr15:43498254	chr15:43663654~43684339:-
LUAD	cis	rs138249	0.902	rs138240	ENSG00000273253.2	RP3-402G11.26	3.62	0.00033	0.0372	0.14	0.16	Gestational age at birth in labor-initiated deliveries (child effect);	chr22:50125752	chr22:50199090~50200837:-
LUAD	cis	rs683250	0.599	rs11233576	ENSG00000246067.6	RAB30-AS1	-3.62	0.00033	0.0372	-0.17	-0.16	Subcortical brain region volumes;	chr11:83356330	chr11:83072066~83106719:+
LUAD	cis	rs765787	1	rs765787	ENSG00000250130.1	RP11-616K22.1	3.62	0.000331	0.0372	0.25	0.16	Uric acid levels;	chr15:45207849	chr15:44354691~44355692:+
LUAD	cis	rs2236553	1	rs2236553	ENSG00000276317.1	RP11-93B14.10	-3.62	0.000331	0.0372	-0.19	-0.16	Menopause (age at onset);	chr20:62658391	chr20:62651272~62652186:-
LUAD	cis	rs4835473	0.932	rs12509642	ENSG00000249741.2	RP11-673E1.3	3.62	0.000331	0.0372	0.19	0.16	Immature fraction of reticulocytes;	chr4:143737080	chr4:143911514~143912053:-
LUAD	cis	rs412050	0.744	rs735244	ENSG00000224086.5	LL22NC03-86G7.1	-3.62	0.000331	0.0372	-0.2	-0.16	Attention deficit hyperactivity disorder;	chr22:21937727	chr22:21938293~21977632:+
LUAD	cis	rs10129255	0.833	rs61997797	ENSG00000211947.2	IGHV3-21	-3.62	0.000331	0.0372	-0.11	-0.16	Kawasaki disease;	chr14:106815190	chr14:106235064~106235594:-
LUAD	cis	rs3741404	0.895	rs2429455	ENSG00000256789.1	RP11-697H9.2	-3.62	0.000331	0.0372	-0.18	-0.16	Platelet count;	chr11:64227830	chr11:63637677~63658962:+
LUAD	cis	rs6095360	1	rs6019547	ENSG00000222365.1	SNORD12B	-3.62	0.000331	0.0372	-0.17	-0.16	Intelligence (multi-trait analysis);	chr20:48944554	chr20:49280319~49280409:+
LUAD	cis	rs7077256	0.564	rs72835357	ENSG00000272767.1	JMJD1C-AS1	3.62	0.000331	0.0372	0.25	0.16	Intelligence (multi-trait analysis);	chr10:63336674	chr10:63465229~63466563:+
LUAD	cis	rs7829975	0.658	rs907181	ENSG00000173295.6	FAM86B3P	3.62	0.000331	0.0372	0.17	0.16	Mood instability;	chr8:8845365	chr8:8228595~8244865:+
LUAD	cis	rs4908768	0.871	rs4908775	ENSG00000232912.4	RP5-1115A15.1	-3.62	0.000331	0.0372	-0.18	-0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8734351	chr1:8424645~8434838:+
LUAD	cis	rs5022636	0.507	rs2800953	ENSG00000232671.4	RP11-126K1.2	-3.62	0.000331	0.0372	-0.2	-0.16	Gut microbiota (functional units);	chr1:151366094	chr1:151280024~151281929:-
LUAD	cis	rs10510102	0.935	rs11200258	ENSG00000276742.1	RP11-500G22.4	3.62	0.000331	0.0372	0.27	0.16	Breast cancer;	chr10:121918392	chr10:121956782~121957098:+
LUAD	cis	rs938554	0.542	rs7678287	ENSG00000163612.10	FAM86KP	-3.62	0.000331	0.0372	-0.25	-0.16	Blood metabolite levels;	chr4:9998877	chr4:9153296~9165451:+
LUAD	cis	rs938554	0.577	rs7683856	ENSG00000163612.10	FAM86KP	-3.62	0.000331	0.0372	-0.25	-0.16	Blood metabolite levels;	chr4:9999323	chr4:9153296~9165451:+
LUAD	cis	rs2115630	0.967	rs10438428	ENSG00000259295.5	CSPG4P12	-3.62	0.000331	0.0372	-0.19	-0.16	P wave terminal force;	chr15:84787514	chr15:85191438~85213905:+
LUAD	cis	rs4699052	0.625	rs6822783	ENSG00000251288.2	RP11-10L12.2	-3.62	0.000331	0.0372	-0.2	-0.16	Testicular germ cell tumor;	chr4:103363767	chr4:102751401~102752641:+
LUAD	cis	rs277939	0.967	rs277980	ENSG00000251634.2	RP11-1280N14.3	-3.62	0.000331	0.0372	-0.16	-0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr5:71632029	chr5:71102898~71128753:-
LUAD	cis	rs10752881	1	rs10911191	ENSG00000224468.3	RP11-181K3.4	-3.62	0.000331	0.0372	-0.14	-0.16	Colorectal cancer;	chr1:183015389	chr1:183138402~183141282:-
LUAD	cis	rs11621975	0.655	rs72715638	ENSG00000258512.1	LINC00239	-3.62	0.000331	0.0372	-0.33	-0.16	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;	chr14:101784513	chr14:101730437~101732522:+
LUAD	cis	rs375066	0.935	rs425217	ENSG00000278917.1	RP11-15A1.4	-3.62	0.000331	0.0372	-0.17	-0.16	Breast cancer;	chr19:43889823	chr19:43891233~43895411:+
LUAD	cis	rs9457247	1	rs405553	ENSG00000227598.1	RP1-167A14.2	-3.62	0.000331	0.0372	-0.17	-0.16	Crohn's disease;	chr6:166981570	chr6:166969626~166999065:-
LUAD	cis	rs17695224	0.545	rs4802884	ENSG00000269483.1	AC006272.1	3.62	0.000331	0.0372	0.18	0.16	HDL cholesterol;HDL cholesterol levels;	chr19:51845202	chr19:51839924~51843324:-
LUAD	cis	rs2041840	0.961	rs6742641	ENSG00000272054.1	RP11-423P10.2	-3.62	0.000331	0.0372	-0.13	-0.16	Chronic lymphocytic leukemia;	chr2:37304380	chr2:37208875~37212677:+
LUAD	cis	rs6467136	0.577	rs17658206	ENSG00000224138.1	AC000123.4	3.62	0.000331	0.0372	0.16	0.16	Type 2 diabetes;	chr7:127534694	chr7:127350128~127351523:+
LUAD	cis	rs12291225	0.753	rs1431374	ENSG00000251991.1	RNU7-49P	3.62	0.000331	0.0372	0.19	0.16	Sense of smell;	chr11:14282429	chr11:14478892~14478953:+
LUAD	cis	rs72799341	1	rs1458201	ENSG00000232748.3	RP11-196G11.6	-3.62	0.000331	0.0372	-0.23	-0.16	Diastolic blood pressure;	chr16:30904808	chr16:31056460~31062803:+
LUAD	cis	rs6493487	0.556	rs8034718	ENSG00000273674.3	CTD-2378E12.1	3.62	0.000331	0.0372	0.23	0.16	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50815656	chr15:50839875~50908599:-
LUAD	cis	rs10911232	0.507	rs10732271	ENSG00000224468.3	RP11-181K3.4	-3.62	0.000331	0.0372	-0.15	-0.16	Hypertriglyceridemia;	chr1:183056763	chr1:183138402~183141282:-
LUAD	cis	rs10911232	0.507	rs3934578	ENSG00000224468.3	RP11-181K3.4	-3.62	0.000331	0.0372	-0.15	-0.16	Hypertriglyceridemia;	chr1:183058081	chr1:183138402~183141282:-
LUAD	cis	rs10911232	0.507	rs3934579	ENSG00000224468.3	RP11-181K3.4	-3.62	0.000331	0.0372	-0.15	-0.16	Hypertriglyceridemia;	chr1:183058297	chr1:183138402~183141282:-
LUAD	cis	rs10911232	0.507	rs3934697	ENSG00000224468.3	RP11-181K3.4	-3.62	0.000331	0.0372	-0.15	-0.16	Hypertriglyceridemia;	chr1:183058377	chr1:183138402~183141282:-
LUAD	cis	rs2243480	1	rs778679	ENSG00000222364.1	RNU6-96P	-3.62	0.000331	0.0372	-0.27	-0.16	Diabetic kidney disease;	chr7:66375924	chr7:66395191~66395286:+
LUAD	cis	rs3126085	1	rs72698906	ENSG00000237975.5	FLG-AS1	3.62	0.000331	0.0372	0.27	0.16	Atopic dermatitis;	chr1:152334708	chr1:152168125~152445456:+
LUAD	cis	rs1350171	0.79	rs12805523	ENSG00000255471.1	RP11-736K20.5	-3.62	0.000331	0.0372	-0.27	-0.16	Hepatocellular carcinoma in hepatitis B infection;	chr11:86933325	chr11:86892214~86925037:-
LUAD	cis	rs4237845	0.742	rs6650219	ENSG00000245651.2	RP11-620J15.2	3.62	0.000331	0.0373	0.16	0.16	Intelligence (multi-trait analysis);	chr12:57895317	chr12:57869835~57896482:-
LUAD	cis	rs67981189	0.896	rs7146932	ENSG00000269927.1	RP6-91H8.3	3.62	0.000331	0.0373	0.21	0.16	Schizophrenia;	chr14:71010328	chr14:71141125~71143253:-
LUAD	cis	rs1383484	0.506	rs4414460	ENSG00000225151.9	GOLGA2P7	3.62	0.000331	0.0373	0.18	0.16	Height;	chr15:83893988	chr15:84199311~84230136:-
LUAD	cis	rs8085804	0.504	rs16976532	ENSG00000276174.1	RP11-687E1.2	-3.62	0.000331	0.0373	-0.22	-0.16	Cognitive performance;	chr18:42660318	chr18:42052705~42053030:+
LUAD	cis	rs7584330	0.91	rs66509917	ENSG00000222032.1	AC112721.2	3.62	0.000331	0.0373	0.18	0.16	Prostate cancer;	chr2:237486751	chr2:237428920~237434822:-
LUAD	cis	rs4716602	0.55	rs12672151	ENSG00000235029.1	MNX1-AS2	-3.62	0.000331	0.0373	-0.2	-0.16	Anti-saccade response;	chr7:156366359	chr7:157006307~157007132:+
LUAD	cis	rs7142881	0.765	rs8010603	ENSG00000250365.5	CTD-2213F21.2	-3.62	0.000331	0.0373	-0.19	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31785529	chr14:31420286~31452883:+
LUAD	cis	rs9921338	0.886	rs4780363	ENSG00000263080.1	RP11-485G7.5	-3.62	0.000331	0.0373	-0.21	-0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11322034	chr16:11341809~11345211:-
LUAD	cis	rs2880765	0.525	rs2062234	ENSG00000259407.1	RP11-158M2.3	-3.62	0.000331	0.0373	-0.15	-0.16	Coronary artery disease;	chr15:85511259	chr15:85744109~85750281:-
LUAD	cis	rs7772486	0.79	rs1133832	ENSG00000235652.6	RP11-545I5.3	-3.62	0.000331	0.0373	-0.16	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145884468	chr6:145799409~145886585:+
LUAD	cis	rs4934494	0.768	rs34663515	ENSG00000240996.1	RP11-80H5.7	-3.62	0.000331	0.0373	-0.23	-0.16	Red blood cell count;	chr10:89632786	chr10:89694295~89697928:-
LUAD	cis	rs1015362	0.54	rs2050209	ENSG00000275784.1	RP5-1125A11.6	3.62	0.000331	0.0373	0.22	0.16	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33897730	chr20:33989480~33991818:-
LUAD	cis	rs7615952	0.609	rs13088451	ENSG00000241288.6	RP11-379B18.5	-3.62	0.000331	0.0373	-0.21	-0.16	Blood pressure (smoking interaction);	chr3:125834656	chr3:125827238~125916384:-
LUAD	cis	rs10863681	0.52	rs10863689	ENSG00000238042.4	RP11-815M8.1	-3.62	0.000331	0.0373	-0.19	-0.16	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222109143	chr1:221880981~221978523:-
LUAD	cis	rs2115630	1	rs6496441	ENSG00000259728.4	LINC00933	-3.62	0.000331	0.0373	-0.19	-0.16	P wave terminal force;	chr15:84820117	chr15:84570649~84580175:+
LUAD	cis	rs1967017	1	rs1471633	ENSG00000272150.4	NBPF25P	3.62	0.000331	0.0373	0.18	0.16	Urate levels;Urate levels in overweight individuals;	chr1:145711327	chr1:145572345~145607858:-
LUAD	cis	rs1967017	1	rs1967017	ENSG00000272150.4	NBPF25P	3.62	0.000331	0.0373	0.18	0.16	Urate levels;Urate levels in overweight individuals;	chr1:145711421	chr1:145572345~145607858:-
LUAD	cis	rs2354432	0.556	rs7520661	ENSG00000237188.3	RP11-337C18.8	3.62	0.000331	0.0373	0.28	0.16	Mitochondrial DNA levels;	chr1:147321430	chr1:147172771~147211568:+
LUAD	cis	rs10875976	0.525	rs10783323	ENSG00000257464.1	RP11-161H23.8	-3.62	0.000331	0.0373	-0.17	-0.16	Obesity;	chr12:49860365	chr12:49442424~49442652:-
LUAD	cis	rs13113518	1	rs939823	ENSG00000223305.1	RN7SKP30	3.62	0.000331	0.0373	0.18	0.16	Height;	chr4:55487368	chr4:55540502~55540835:-
LUAD	cis	rs13113518	1	rs6838882	ENSG00000223305.1	RN7SKP30	3.62	0.000331	0.0373	0.18	0.16	Height;	chr4:55489310	chr4:55540502~55540835:-
LUAD	cis	rs11637445	0.589	rs4776989	ENSG00000270964.1	RP11-502I4.3	3.62	0.000331	0.0373	0.18	0.16	Posterior cortical atrophy and Alzheimer's disease;	chr15:67838346	chr15:67541072~67542604:-
LUAD	cis	rs14027	0.512	rs4871528	ENSG00000279347.1	RP11-85I17.2	3.62	0.000331	0.0373	0.14	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119700371	chr8:119838736~119840385:-
LUAD	cis	rs6120849	0.707	rs3746448	ENSG00000202150.1	RNU6-407P	3.62	0.000332	0.0373	0.26	0.16	Protein C levels;	chr20:34985176	chr20:35030317~35030420:-
LUAD	cis	rs4908768	0.906	rs74324642	ENSG00000232912.4	RP5-1115A15.1	-3.62	0.000332	0.0373	-0.19	-0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8560113	chr1:8424645~8434838:+
LUAD	cis	rs4474465	0.92	rs7396701	ENSG00000251323.2	RP11-452H21.4	-3.62	0.000332	0.0373	-0.2	-0.16	Alzheimer's disease (survival time);	chr11:78491653	chr11:78423982~78429836:-
LUAD	cis	rs4845570	0.85	rs4504897	ENSG00000203288.3	RP11-98D18.9	3.62	0.000332	0.0373	0.22	0.16	Coronary artery disease;	chr1:151794375	chr1:151790804~151794402:+
LUAD	cis	rs2288073	0.93	rs7604097	ENSG00000223754.1	AC008073.9	3.62	0.000332	0.0373	0.21	0.16	Venous thromboembolism (SNP x SNP interaction);	chr2:24178936	chr2:24199839~24201698:-
LUAD	cis	rs34638952	0.507	rs797974	ENSG00000264808.1	RP11-802D6.1	3.62	0.000332	0.0373	0.19	0.16	Sitting height ratio;	chr17:29295500	chr17:29369717~29390777:-
LUAD	cis	rs12908161	0.92	rs35738019	ENSG00000259654.1	RP11-245C17.2	-3.62	0.000332	0.0373	-0.23	-0.16	Schizophrenia;	chr15:84736979	chr15:84685884~84686946:+
LUAD	cis	rs12908161	1	rs34570071	ENSG00000259654.1	RP11-245C17.2	-3.62	0.000332	0.0373	-0.23	-0.16	Schizophrenia;	chr15:84736981	chr15:84685884~84686946:+
LUAD	cis	rs972578	0.561	rs2413740	ENSG00000230319.1	AL022476.2	3.62	0.000332	0.0373	0.18	0.16	Mean platelet volume;	chr22:43023319	chr22:43038585~43052366:+
LUAD	cis	rs3213758	1	rs16952315	ENSG00000261630.1	RP11-357N13.3	-3.62	0.000332	0.0373	-0.4	-0.16	Vitiligo (non-segmental);	chr16:53554447	chr16:53981229~53981912:-
LUAD	cis	rs12819124	0.502	rs10875718	ENSG00000257763.1	OR5BK1P	3.62	0.000332	0.0373	0.17	0.16	Glycated hemoglobin levels;	chr12:48017319	chr12:48355792~48356614:-
LUAD	cis	rs666723	0.846	rs578169	ENSG00000235505.6	RP11-693N9.2	-3.62	0.000332	0.0373	-0.14	-0.16	Major depressive disorder;	chr11:104990916	chr11:104901549~104919073:-
LUAD	cis	rs2836974	0.897	rs2836944	ENSG00000232608.1	TIMM9P2	-3.62	0.000332	0.0373	-0.2	-0.16	Cognitive function;	chr21:39221613	chr21:39216624~39217506:+
LUAD	cis	rs7107174	1	rs7101429	ENSG00000251323.2	RP11-452H21.4	3.62	0.000332	0.0373	0.22	0.16	Testicular germ cell tumor;	chr11:78281921	chr11:78423982~78429836:-
LUAD	cis	rs12579764	0.71	rs78123962	ENSG00000275409.1	RP11-131L12.4	3.62	0.000332	0.0373	0.32	0.16	Loneliness;Loneliness (linear analysis);	chr12:118381688	chr12:118430147~118430699:+
LUAD	cis	rs7204230	1	rs12596829	ENSG00000261291.1	RP11-295M3.2	3.62	0.000332	0.0373	0.19	0.16	Fibrinogen;	chr16:53315088	chr16:53168522~53169450:+
LUAD	cis	rs9303542	1	rs12450081	ENSG00000264920.1	RP11-6N17.4	-3.61	0.000332	0.0373	-0.21	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48317881	chr17:47891255~47895812:-
LUAD	cis	rs7521902	0.522	rs12042083	ENSG00000234397.3	RP11-415K20.1	3.61	0.000332	0.0373	0.22	0.16	Endometriosis;Ovarian cancer;Bone mineral density;Hip circumference adjusted for BMI;	chr1:22146239	chr1:22322840~22323331:-
LUAD	cis	rs6754311	0.773	rs666407	ENSG00000231890.6	DARS-AS1	-3.61	0.000332	0.0373	-0.23	-0.16	Mosquito bite size;	chr2:135882663	chr2:135985176~136022593:+
LUAD	cis	rs9951011	0.714	rs4584936	ENSG00000260578.1	CTD-2541J13.1	-3.61	0.000332	0.0373	-0.27	-0.16	Non-response to selective serotonin reuptake inhibitors and depression;	chr18:67382336	chr18:67481791~67484966:-
LUAD	cis	rs7617773	0.78	rs3731550	ENSG00000199476.1	Y_RNA	-3.61	0.000332	0.0374	-0.22	-0.16	Coronary artery disease;	chr3:48165093	chr3:48288587~48288694:+
LUAD	cis	rs7829975	0.626	rs907183	ENSG00000233609.3	RP11-62H7.2	-3.61	0.000332	0.0374	-0.13	-0.16	Mood instability;	chr8:8872251	chr8:8961200~8979025:+
LUAD	cis	rs10510102	0.688	rs74570569	ENSG00000276742.1	RP11-500G22.4	3.61	0.000332	0.0374	0.28	0.16	Breast cancer;	chr10:121945347	chr10:121956782~121957098:+
LUAD	cis	rs10510102	0.872	rs7076727	ENSG00000276742.1	RP11-500G22.4	3.61	0.000332	0.0374	0.28	0.16	Breast cancer;	chr10:121947000	chr10:121956782~121957098:+
LUAD	cis	rs10510102	0.745	rs7076882	ENSG00000276742.1	RP11-500G22.4	3.61	0.000332	0.0374	0.28	0.16	Breast cancer;	chr10:121947039	chr10:121956782~121957098:+
LUAD	cis	rs10510102	0.872	rs7077035	ENSG00000276742.1	RP11-500G22.4	3.61	0.000332	0.0374	0.28	0.16	Breast cancer;	chr10:121947130	chr10:121956782~121957098:+
LUAD	cis	rs6793245	0.843	rs55872442	ENSG00000229589.1	ACVR2B-AS1	-3.61	0.000332	0.0374	-0.21	-0.16	QT interval;	chr3:38539944	chr3:38451027~38454820:-
LUAD	cis	rs62025270	0.632	rs62022943	ENSG00000259416.2	RP11-158M2.5	-3.61	0.000332	0.0374	-0.21	-0.16	Idiopathic pulmonary fibrosis;	chr15:85716239	chr15:85754941~85756237:-
LUAD	cis	rs6546537	1	rs4852892	ENSG00000231024.1	AC092431.3	3.61	0.000332	0.0374	0.21	0.16	Serum thyroid-stimulating hormone levels;	chr2:69639637	chr2:69700192~69713847:-
LUAD	cis	rs1497406	0.59	rs6676143	ENSG00000280114.1	RP5-875O13.7	-3.61	0.000332	0.0374	-0.18	-0.16	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);	chr1:16201723	chr1:16681097~16688749:-
LUAD	cis	rs10829156	0.66	rs10764587	ENSG00000240291.1	RP11-499P20.2	3.61	0.000332	0.0374	0.15	0.16	Sudden cardiac arrest;	chr10:18548901	chr10:18513115~18545651:-
LUAD	cis	rs180730	0.752	rs4639096	ENSG00000251609.2	SETP12	3.61	0.000332	0.0374	0.28	0.16	Fasting plasma glucose;	chr4:120902221	chr4:120895494~120897083:-
LUAD	cis	rs7178424	1	rs7162536	ENSG00000259251.2	RP11-643M14.1	-3.61	0.000332	0.0374	-0.16	-0.16	Height;	chr15:62081260	chr15:62060503~62062434:+
LUAD	cis	rs8048589	0.615	rs34598762	ENSG00000175604.2	RP11-276H1.3	-3.61	0.000332	0.0374	-0.25	-0.16	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12141101	chr16:12086746~12090302:-
LUAD	cis	rs2486288	0.656	rs11639420	ENSG00000259479.5	SORD2P	-3.61	0.000333	0.0374	-0.19	-0.16	Glomerular filtration rate;	chr15:45267070	chr15:44826371~44884694:-
LUAD	cis	rs11250098	0.547	rs2409764	ENSG00000255495.1	AC145124.2	3.61	0.000333	0.0374	0.2	0.16	Morning vs. evening chronotype;	chr8:11423764	chr8:12194467~12196280:+
LUAD	cis	rs6736093	0.704	rs11684476	ENSG00000207383.1	Y_RNA	-3.61	0.000333	0.0374	-0.21	-0.16	Coronary artery disease;	chr2:112036404	chr2:112579484~112579584:-
LUAD	cis	rs6687821	0.515	rs2390221	ENSG00000267272.4	LINC01140	3.61	0.000333	0.0374	0.19	0.16	Yeast infection;	chr1:86990333	chr1:87129765~87169198:+
LUAD	cis	rs7215564	0.908	rs34547024	ENSG00000232083.3	RPL31P7	3.61	0.000333	0.0374	0.26	0.16	Myopia (pathological);	chr17:80687573	chr17:80602549~80602926:-
LUAD	cis	rs2242663	0.798	rs1945302	ENSG00000213409.4	RP11-658F2.3	-3.61	0.000333	0.0374	-0.2	-0.16	Bipolar disorder;	chr11:66570027	chr11:66761575~66762399:-
LUAD	cis	rs2235642	0.893	rs2076445	ENSG00000280231.1	LA16c-380F5.3	-3.61	0.000333	0.0374	-0.22	-0.16	Coronary artery disease;	chr16:1542265	chr16:1553655~1554130:-
LUAD	cis	rs4938642	0.822	rs4148173	ENSG00000254909.1	RP11-110I1.5	-3.61	0.000333	0.0374	-0.19	-0.16	Platelet count;	chr11:119160102	chr11:119005727~119005934:-
LUAD	cis	rs9595908	0.746	rs17516171	ENSG00000281026.1	N4BP2L2-IT2	-3.61	0.000333	0.0374	-0.1	-0.16	Body mass index;	chr13:32694914	chr13:32504506~32509395:-
LUAD	cis	rs4908768	0.911	rs6693127	ENSG00000232912.4	RP5-1115A15.1	-3.61	0.000333	0.0374	-0.17	-0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8714914	chr1:8424645~8434838:+
LUAD	cis	rs867371	0.502	rs2047679	ENSG00000259429.4	UBE2Q2P2	-3.61	0.000333	0.0374	-0.14	-0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82239540	chr15:82355142~82420075:+
LUAD	cis	rs2274273	0.84	rs10150760	ENSG00000259318.1	RP11-454L9.2	-3.61	0.000333	0.0374	-0.14	-0.16	Protein biomarker;	chr14:55354830	chr14:55394940~55395233:-
LUAD	cis	rs7829975	0.577	rs940030	ENSG00000253893.2	FAM85B	3.61	0.000333	0.0374	0.2	0.16	Mood instability;	chr8:8689418	chr8:8167819~8226614:-
LUAD	cis	rs8073060	0.586	rs11080356	ENSG00000267592.1	CTC-507E2.2	-3.61	0.000333	0.0374	-0.23	-0.16	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35568290	chr17:35596904~35597128:-
LUAD	cis	rs2735413	0.875	rs8045975	ENSG00000276007.1	RP11-358L22.3	3.61	0.000333	0.0374	0.16	0.16	Systolic blood pressure (alcohol consumption interaction);	chr16:78056290	chr16:78123243~78124332:+
LUAD	cis	rs7208859	0.623	rs73263788	ENSG00000263603.1	CTD-2349P21.5	-3.61	0.000333	0.0374	-0.28	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889472	chr17:30729469~30731202:+
LUAD	cis	rs3126085	0.877	rs10888472	ENSG00000237975.5	FLG-AS1	3.61	0.000333	0.0374	0.26	0.16	Atopic dermatitis;	chr1:152234420	chr1:152168125~152445456:+
LUAD	cis	rs7246967	0.673	rs2361260	ENSG00000236312.3	RPL34P34	-3.61	0.000333	0.0374	-0.22	-0.16	Bronchopulmonary dysplasia;	chr19:22731342	chr19:22368599~22368952:-
LUAD	cis	rs4332428	0.649	rs80261559	ENSG00000151631.8	AKR1C6P	3.61	0.000333	0.0374	0.31	0.16	Height;	chr10:4940020	chr10:4871901~4891975:-
LUAD	cis	rs7660883	1	rs3775220	ENSG00000251411.1	RP11-397E7.4	-3.61	0.000333	0.0374	-0.18	-0.16	HDL cholesterol levels;	chr4:87093601	chr4:86913266~86914817:-
LUAD	cis	rs4879656	0.8	rs10971379	ENSG00000225693.1	LAGE3P1	-3.61	0.000333	0.0374	-0.18	-0.16	Menopause (age at onset);	chr9:33064932	chr9:33019682~33020165:-
LUAD	cis	rs12712135	0.709	rs12463588	ENSG00000234389.1	AC007278.3	-3.61	0.000333	0.0374	-0.15	-0.16	Blood protein levels;	chr2:102468797	chr2:102438713~102440475:+
LUAD	cis	rs12712135	0.709	rs2310302	ENSG00000234389.1	AC007278.3	-3.61	0.000333	0.0374	-0.15	-0.16	Blood protein levels;	chr2:102469589	chr2:102438713~102440475:+
LUAD	cis	rs12712135	0.709	rs12469887	ENSG00000234389.1	AC007278.3	-3.61	0.000333	0.0374	-0.15	-0.16	Blood protein levels;	chr2:102470298	chr2:102438713~102440475:+
LUAD	cis	rs41369048	0.8	rs2784252	ENSG00000238078.1	LINC01352	-3.61	0.000333	0.0374	-0.24	-0.16	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220889342	chr1:220829255~220832429:+
LUAD	cis	rs41369048	0.8	rs2784254	ENSG00000238078.1	LINC01352	-3.61	0.000333	0.0374	-0.24	-0.16	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220891002	chr1:220829255~220832429:+
LUAD	cis	rs11089937	0.626	rs5757014	ENSG00000211640.3	IGLV6-57	3.61	0.000333	0.0374	0.12	0.16	Periodontitis (PAL4Q3);	chr22:22135612	chr22:22195713~22196460:+
LUAD	cis	rs6460942	0.597	rs35317839	ENSG00000226690.5	AC005281.1	3.61	0.000333	0.0374	0.31	0.16	Coronary artery disease;	chr7:12484771	chr7:12496429~12541910:+
LUAD	cis	rs6460942	0.597	rs13227809	ENSG00000226690.5	AC005281.1	3.61	0.000333	0.0374	0.31	0.16	Coronary artery disease;	chr7:12485931	chr7:12496429~12541910:+
LUAD	cis	rs6460942	0.597	rs17448193	ENSG00000226690.5	AC005281.1	3.61	0.000333	0.0374	0.31	0.16	Coronary artery disease;	chr7:12486015	chr7:12496429~12541910:+
LUAD	cis	rs3750965	0.734	rs11604251	ENSG00000260895.1	RP11-554A11.7	-3.61	0.000333	0.0374	-0.2	-0.16	Hair color;	chr11:69052961	chr11:69103493~69109094:+
LUAD	cis	rs11722228	0.522	rs1109472	ENSG00000261490.1	RP11-448G15.3	3.61	0.000333	0.0374	0.14	0.16	Urate levels;Serum uric acid levels;Gout;	chr4:10132824	chr4:10068089~10073019:-
LUAD	cis	rs7129556	0.815	rs11607715	ENSG00000241782.1	RP11-91P24.1	3.61	0.000333	0.0374	0.21	0.16	Weight loss (gastric bypass surgery);	chr11:77527814	chr11:77868722~77869195:-
LUAD	cis	rs8002861	0.967	rs7983109	ENSG00000274001.1	RP11-5G9.5	3.61	0.000333	0.0374	0.17	0.16	Leprosy;	chr13:43910215	chr13:43877715~43878163:-
LUAD	cis	rs8002861	0.967	rs7984393	ENSG00000274001.1	RP11-5G9.5	3.61	0.000333	0.0374	0.17	0.16	Leprosy;	chr13:43910225	chr13:43877715~43878163:-
LUAD	cis	rs1348850	0.793	rs12990917	ENSG00000213963.5	AC074286.1	3.61	0.000333	0.0374	0.19	0.16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177622531	chr2:177283508~177392691:-
LUAD	cis	rs7674212	0.541	rs2720460	ENSG00000246560.2	RP11-10L12.4	-3.61	0.000333	0.0375	-0.21	-0.16	Type 2 diabetes;	chr4:103133529	chr4:102828055~102844075:+
LUAD	cis	rs877819	0.583	rs2663050	ENSG00000228403.1	RP11-563N6.6	-3.61	0.000333	0.0375	-0.17	-0.16	Systemic lupus erythematosus;	chr10:48862280	chr10:48878022~48878649:+
LUAD	cis	rs11673344	0.526	rs55909413	ENSG00000267254.4	ZNF790-AS1	-3.61	0.000333	0.0375	-0.21	-0.16	Obesity-related traits;	chr19:37578663	chr19:36797518~36828115:+
LUAD	cis	rs11673344	0.526	rs55865869	ENSG00000267254.4	ZNF790-AS1	-3.61	0.000333	0.0375	-0.21	-0.16	Obesity-related traits;	chr19:37578683	chr19:36797518~36828115:+
LUAD	cis	rs11673344	0.526	rs73033122	ENSG00000267254.4	ZNF790-AS1	-3.61	0.000333	0.0375	-0.21	-0.16	Obesity-related traits;	chr19:37586006	chr19:36797518~36828115:+
LUAD	cis	rs7247513	0.964	rs8105902	ENSG00000230310.1	CTD-2192J16.11	-3.61	0.000333	0.0375	-0.19	-0.16	Bipolar disorder;	chr19:12607537	chr19:12552597~12553644:+
LUAD	cis	rs7100689	0.556	rs6585971	ENSG00000226659.1	RP11-137H2.4	-3.61	0.000333	0.0375	-0.22	-0.16	Post bronchodilator FEV1;	chr10:80385301	chr10:80529597~80535942:-
LUAD	cis	rs7100689	0.646	rs1953971	ENSG00000226659.1	RP11-137H2.4	-3.61	0.000333	0.0375	-0.22	-0.16	Post bronchodilator FEV1;	chr10:80385891	chr10:80529597~80535942:-
LUAD	cis	rs7100689	0.646	rs1953972	ENSG00000226659.1	RP11-137H2.4	-3.61	0.000333	0.0375	-0.22	-0.16	Post bronchodilator FEV1;	chr10:80385910	chr10:80529597~80535942:-
LUAD	cis	rs10911232	0.507	rs10797814	ENSG00000224468.3	RP11-181K3.4	-3.61	0.000333	0.0375	-0.14	-0.16	Hypertriglyceridemia;	chr1:183021794	chr1:183138402~183141282:-
LUAD	cis	rs9467773	1	rs2255070	ENSG00000241549.7	GUSBP2	3.61	0.000333	0.0375	0.18	0.16	Intelligence (multi-trait analysis);	chr6:26501549	chr6:26871484~26956554:-
LUAD	cis	rs8014252	1	rs2332389	ENSG00000259158.2	ADAM20P1	-3.61	0.000334	0.0375	-0.24	-0.16	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70496302	chr14:70468881~70483756:-
LUAD	cis	rs7557067	1	rs6544366	ENSG00000233005.1	AC067959.1	3.61	0.000334	0.0375	0.19	0.16	Triglycerides;	chr2:20981153	chr2:21221175~21970959:+
LUAD	cis	rs11673344	0.566	rs1545755	ENSG00000226686.6	LINC01535	3.61	0.000334	0.0375	0.19	0.16	Obesity-related traits;	chr19:37490607	chr19:37251912~37265535:+
LUAD	cis	rs9457247	1	rs402749	ENSG00000227598.1	RP1-167A14.2	-3.61	0.000334	0.0375	-0.17	-0.16	Crohn's disease;	chr6:166972616	chr6:166969626~166999065:-
LUAD	cis	rs9457247	1	rs385863	ENSG00000227598.1	RP1-167A14.2	-3.61	0.000334	0.0375	-0.17	-0.16	Crohn's disease;	chr6:166973127	chr6:166969626~166999065:-
LUAD	cis	rs9457247	1	rs397713	ENSG00000227598.1	RP1-167A14.2	-3.61	0.000334	0.0375	-0.17	-0.16	Crohn's disease;	chr6:166973226	chr6:166969626~166999065:-
LUAD	cis	rs9457247	0.905	rs453184	ENSG00000227598.1	RP1-167A14.2	-3.61	0.000334	0.0375	-0.17	-0.16	Crohn's disease;	chr6:166973916	chr6:166969626~166999065:-
LUAD	cis	rs9457247	1	rs436707	ENSG00000227598.1	RP1-167A14.2	-3.61	0.000334	0.0375	-0.17	-0.16	Crohn's disease;	chr6:166975355	chr6:166969626~166999065:-
LUAD	cis	rs9457247	0.967	rs377753	ENSG00000227598.1	RP1-167A14.2	-3.61	0.000334	0.0375	-0.17	-0.16	Crohn's disease;	chr6:166976008	chr6:166969626~166999065:-
LUAD	cis	rs9457247	1	rs430477	ENSG00000227598.1	RP1-167A14.2	-3.61	0.000334	0.0375	-0.17	-0.16	Crohn's disease;	chr6:166976363	chr6:166969626~166999065:-
LUAD	cis	rs9457247	1	rs376574	ENSG00000227598.1	RP1-167A14.2	-3.61	0.000334	0.0375	-0.17	-0.16	Crohn's disease;	chr6:166976468	chr6:166969626~166999065:-
LUAD	cis	rs9457247	1	rs439237	ENSG00000227598.1	RP1-167A14.2	-3.61	0.000334	0.0375	-0.17	-0.16	Crohn's disease;	chr6:166977904	chr6:166969626~166999065:-
LUAD	cis	rs9457247	1	rs9457247	ENSG00000227598.1	RP1-167A14.2	-3.61	0.000334	0.0375	-0.17	-0.16	Crohn's disease;	chr6:166978686	chr6:166969626~166999065:-
LUAD	cis	rs755249	0.567	rs2018212	ENSG00000182109.6	RP11-69E11.4	3.61	0.000334	0.0375	0.2	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39439916	chr1:39522280~39546187:-
LUAD	cis	rs755249	0.567	rs4660751	ENSG00000182109.6	RP11-69E11.4	3.61	0.000334	0.0375	0.2	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39440201	chr1:39522280~39546187:-
LUAD	cis	rs747650	0.532	rs7128650	ENSG00000255197.4	RP11-750H9.5	3.61	0.000334	0.0375	0.15	0.16	Acne (severe);	chr11:47025508	chr11:47383148~47409190:-
LUAD	cis	rs875971	0.545	rs35459055	ENSG00000224316.1	RP11-479O9.2	3.61	0.000334	0.0375	0.19	0.16	Aortic root size;	chr7:66479399	chr7:65773620~65802067:+
LUAD	cis	rs2625529	0.526	rs1035744	ENSG00000260173.1	RP11-2I17.4	3.61	0.000334	0.0375	0.2	0.16	Red blood cell count;	chr15:72274274	chr15:72140504~72155459:-
LUAD	cis	rs3764021	0.87	rs7976584	ENSG00000256582.1	RP11-75L1.1	3.61	0.000334	0.0375	0.16	0.16	Type 1 diabetes;	chr12:9726059	chr12:9704077~9709350:+
LUAD	cis	rs990171	0.538	rs11690932	ENSG00000234389.1	AC007278.3	3.61	0.000334	0.0375	0.16	0.16	Lymphocyte counts;	chr2:102502570	chr2:102438713~102440475:+
LUAD	cis	rs10463554	1	rs10463554	ENSG00000250682.4	LINC00491	3.61	0.000334	0.0375	0.19	0.16	Parkinson's disease;	chr5:102983270	chr5:102609156~102671559:-
LUAD	cis	rs2731006	0.64	rs2730966	ENSG00000257114.2	RP11-25I15.3	3.61	0.000334	0.0375	0.26	0.16	Panic disorder;	chr12:42781330	chr12:42692216~42717119:+
LUAD	cis	rs9467773	1	rs9467773	ENSG00000241549.7	GUSBP2	3.61	0.000334	0.0375	0.18	0.16	Intelligence (multi-trait analysis);	chr6:26498198	chr6:26871484~26956554:-
LUAD	cis	rs9467773	1	rs6926629	ENSG00000241549.7	GUSBP2	3.61	0.000334	0.0375	0.18	0.16	Intelligence (multi-trait analysis);	chr6:26499675	chr6:26871484~26956554:-
LUAD	cis	rs9467773	1	rs6903973	ENSG00000241549.7	GUSBP2	3.61	0.000334	0.0375	0.18	0.16	Intelligence (multi-trait analysis);	chr6:26499714	chr6:26871484~26956554:-
LUAD	cis	rs10129255	0.589	rs78599641	ENSG00000253209.1	IGHV3-65	3.61	0.000334	0.0375	0.14	0.16	Kawasaki disease;	chr14:106637576	chr14:106666092~106666532:-
LUAD	cis	rs17711722	0.74	rs7809991	ENSG00000273142.1	RP11-458F8.4	-3.61	0.000334	0.0375	-0.11	-0.16	Calcium levels;	chr7:65941231	chr7:66902857~66906297:+
LUAD	cis	rs11638352	1	rs4924737	ENSG00000205771.5	CATSPER2P1	3.61	0.000334	0.0375	0.4	0.16	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44072703	chr15:43726918~43747094:-
LUAD	cis	rs11638352	1	rs1365456	ENSG00000205771.5	CATSPER2P1	3.61	0.000334	0.0375	0.4	0.16	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44086645	chr15:43726918~43747094:-
LUAD	cis	rs7586085	0.934	rs1895701	ENSG00000232411.1	AC009495.3	-3.61	0.000334	0.0375	-0.16	-0.16	Total body bone mineral density;	chr2:165746577	chr2:165833048~165839098:-
LUAD	cis	rs7131987	0.683	rs3782511	ENSG00000275476.1	RP11-996F15.4	-3.61	0.000334	0.0375	-0.19	-0.16	QT interval;	chr12:29343291	chr12:29277397~29277882:-
LUAD	cis	rs1075265	0.783	rs718872	ENSG00000272156.1	RP11-477N3.1	-3.61	0.000334	0.0375	-0.19	-0.16	Chronotype;Morning vs. evening chronotype;	chr2:53946569	chr2:54082554~54085066:+
LUAD	cis	rs6736093	0.965	rs4264571	ENSG00000207383.1	Y_RNA	-3.61	0.000334	0.0375	-0.22	-0.16	Coronary artery disease;	chr2:111916572	chr2:112579484~112579584:-
LUAD	cis	rs739496	0.579	rs73422318	ENSG00000234608.6	MAPKAPK5-AS1	3.61	0.000334	0.0375	0.19	0.16	Platelet count;	chr12:111838169	chr12:111839764~111842902:-
LUAD	cis	rs3087591	0.666	rs2953016	ENSG00000263531.1	RP13-753N3.1	-3.61	0.000334	0.0375	-0.23	-0.16	Hip circumference;	chr17:31167675	chr17:30863921~30864940:-
LUAD	cis	rs6921919	0.583	rs16894108	ENSG00000219392.1	RP1-265C24.5	-3.61	0.000334	0.0375	-0.21	-0.16	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28115628~28116551:+
LUAD	cis	rs1878931	0.501	rs28735976	ENSG00000262362.1	LA16c-380H5.2	-3.61	0.000334	0.0375	-0.17	-0.16	Body mass index (adult);	chr16:3368419	chr16:3003431~3005101:-
LUAD	cis	rs7772486	0.806	rs2265477	ENSG00000235652.6	RP11-545I5.3	3.61	0.000334	0.0375	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145891202	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.806	rs2247317	ENSG00000235652.6	RP11-545I5.3	3.61	0.000334	0.0375	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145896434	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.776	rs2265467	ENSG00000235652.6	RP11-545I5.3	3.61	0.000334	0.0375	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145897203	chr6:145799409~145886585:+
LUAD	cis	rs13113518	0.966	rs11133387	ENSG00000223305.1	RN7SKP30	3.61	0.000334	0.0375	0.18	0.16	Height;	chr4:55475130	chr4:55540502~55540835:-
LUAD	cis	rs9291683	0.609	rs12507050	ENSG00000250413.1	RP11-448G15.1	-3.61	0.000334	0.0375	-0.21	-0.16	Bone mineral density;	chr4:10005681	chr4:10006482~10009725:+
LUAD	cis	rs1355223	1	rs11604069	ENSG00000271369.1	RP11-350D17.3	-3.61	0.000334	0.0375	-0.2	-0.16	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34742704	chr11:34709600~34710161:+
LUAD	cis	rs1075265	0.756	rs805367	ENSG00000272156.1	RP11-477N3.1	-3.61	0.000334	0.0375	-0.19	-0.16	Chronotype;Morning vs. evening chronotype;	chr2:53943956	chr2:54082554~54085066:+
LUAD	cis	rs12440869	1	rs8032438	ENSG00000270964.1	RP11-502I4.3	3.61	0.000334	0.0375	0.19	0.16	Peak velocity of the mitral A-wave;	chr15:67323615	chr15:67541072~67542604:-
LUAD	cis	rs848087	0.967	rs712325	ENSG00000258661.1	RP11-964E11.2	-3.61	0.000334	0.0375	-0.19	-0.16	Breast cancer;	chr14:36765758	chr14:36647083~36658801:-
LUAD	cis	rs9549260	0.564	rs12184871	ENSG00000168852.11	TPTE2P5	3.61	0.000334	0.0375	0.16	0.16	Red blood cell count;	chr13:40717792	chr13:40822296~40921749:-
LUAD	cis	rs763121	0.853	rs4821798	ENSG00000225450.1	RP3-508I15.14	-3.61	0.000334	0.0375	-0.15	-0.16	Menopause (age at onset);	chr22:38625160	chr22:38739003~38749041:+
LUAD	cis	rs12681963	1	rs12681963	ENSG00000272375.1	RP11-51J9.6	-3.61	0.000334	0.0375	-0.24	-0.16	Migraine;	chr8:30125002	chr8:30197404~30198048:+
LUAD	cis	rs8025790	0.508	rs4776370	ENSG00000270964.1	RP11-502I4.3	-3.61	0.000334	0.0375	-0.2	-0.16	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr15:67612173	chr15:67541072~67542604:-
LUAD	cis	rs2031365	0.697	rs6909630	ENSG00000216990.2	HSPD1P10	3.61	0.000334	0.0375	0.23	0.16	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);	chr6:87104125	chr6:87298772~87300447:+
LUAD	cis	rs6787172	0.783	rs6441201	ENSG00000272087.1	RP11-379F4.7	3.61	0.000334	0.0375	0.18	0.16	Subjective well-being;	chr3:158460535	chr3:158693120~158693768:-
LUAD	cis	rs6787172	0.783	rs12496767	ENSG00000272087.1	RP11-379F4.7	3.61	0.000334	0.0375	0.18	0.16	Subjective well-being;	chr3:158461448	chr3:158693120~158693768:-
LUAD	cis	rs6493858	0.588	rs2682064	ENSG00000277548.1	RP11-139H15.6	3.61	0.000334	0.0375	0.17	0.16	Relative hand skill in reading disability;	chr15:56277935	chr15:55346347~55346752:-
LUAD	cis	rs6493858	0.588	rs2682065	ENSG00000277548.1	RP11-139H15.6	3.61	0.000334	0.0375	0.17	0.16	Relative hand skill in reading disability;	chr15:56277936	chr15:55346347~55346752:-
LUAD	cis	rs2880765	0.835	rs4843062	ENSG00000259407.1	RP11-158M2.3	-3.61	0.000334	0.0375	-0.14	-0.16	Coronary artery disease;	chr15:85496906	chr15:85744109~85750281:-
LUAD	cis	rs728616	0.867	rs12412226	ENSG00000234382.2	RP11-40F6.1	-3.61	0.000334	0.0376	-0.4	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79975532	chr10:80233664~80245367:+
LUAD	cis	rs728616	0.867	rs4387301	ENSG00000234382.2	RP11-40F6.1	-3.61	0.000334	0.0376	-0.4	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79976643	chr10:80233664~80245367:+
LUAD	cis	rs728616	0.764	rs117833443	ENSG00000234382.2	RP11-40F6.1	-3.61	0.000334	0.0376	-0.4	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79978380	chr10:80233664~80245367:+
LUAD	cis	rs728616	0.867	rs116994688	ENSG00000234382.2	RP11-40F6.1	-3.61	0.000334	0.0376	-0.4	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79978381	chr10:80233664~80245367:+
LUAD	cis	rs728616	0.867	rs61860420	ENSG00000234382.2	RP11-40F6.1	-3.61	0.000334	0.0376	-0.4	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79979623	chr10:80233664~80245367:+
LUAD	cis	rs728616	0.867	rs75447386	ENSG00000234382.2	RP11-40F6.1	-3.61	0.000334	0.0376	-0.4	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79979891	chr10:80233664~80245367:+
LUAD	cis	rs728616	0.867	rs4520539	ENSG00000234382.2	RP11-40F6.1	-3.61	0.000334	0.0376	-0.4	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79980773	chr10:80233664~80245367:+
LUAD	cis	rs728616	0.867	rs61860421	ENSG00000234382.2	RP11-40F6.1	-3.61	0.000334	0.0376	-0.4	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79983643	chr10:80233664~80245367:+
LUAD	cis	rs7546668	1	rs12741552	ENSG00000272510.1	RP4-680D5.8	3.61	0.000334	0.0376	0.21	0.16	Glomerular filtration rate (creatinine);	chr1:15526781	chr1:15565611~15565956:-
LUAD	cis	rs7546668	1	rs3795759	ENSG00000272510.1	RP4-680D5.8	3.61	0.000334	0.0376	0.21	0.16	Glomerular filtration rate (creatinine);	chr1:15527133	chr1:15565611~15565956:-
LUAD	cis	rs875971	0.862	rs1860469	ENSG00000273448.1	RP11-166O4.6	-3.61	0.000334	0.0376	-0.16	-0.16	Aortic root size;	chr7:66641888	chr7:67333047~67334383:+
LUAD	cis	rs7714584	1	rs59980321	ENSG00000197083.10	ZNF300P1	3.61	0.000334	0.0376	0.31	0.16	Crohn's disease;	chr5:150862251	chr5:150930645~150946289:-
LUAD	cis	rs1555322	0.53	rs6060341	ENSG00000261582.1	RP4-614O4.11	3.61	0.000335	0.0376	0.21	0.16	Attention deficit hyperactivity disorder;	chr20:35275830	chr20:35267885~35280043:-
LUAD	cis	rs12554020	0.582	rs76863038	ENSG00000227603.1	RP11-165J3.6	3.61	0.000335	0.0376	0.33	0.16	Schizophrenia;	chr9:93666143	chr9:93435332~93437121:-
LUAD	cis	rs12554020	0.582	rs56310424	ENSG00000227603.1	RP11-165J3.6	3.61	0.000335	0.0376	0.33	0.16	Schizophrenia;	chr9:93666313	chr9:93435332~93437121:-
LUAD	cis	rs12554020	0.504	rs12551694	ENSG00000227603.1	RP11-165J3.6	3.61	0.000335	0.0376	0.33	0.16	Schizophrenia;	chr9:93666619	chr9:93435332~93437121:-
LUAD	cis	rs4664293	0.867	rs10194483	ENSG00000230783.1	AC009961.2	-3.61	0.000335	0.0376	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159739883	chr2:159689217~159690291:-
LUAD	cis	rs449789	1	rs2102244	ENSG00000235086.1	FNDC1-IT1	-3.61	0.000335	0.0376	-0.29	-0.16	Pulse pressure;	chr6:159303265	chr6:159240786~159243329:+
LUAD	cis	rs937213	0.781	rs28893849	ENSG00000275636.1	RP11-521C20.5	3.61	0.000335	0.0376	0.22	0.16	Endometrial cancer;Endometrial endometrioid carcinoma;	chr15:40004727	chr15:40078892~40079347:+
LUAD	cis	rs818427	0.858	rs461866	ENSG00000279522.1	CTC-487M23.6	3.61	0.000335	0.0376	0.19	0.16	Total body bone mineral density;	chr5:112895753	chr5:112894933~112896531:+
LUAD	cis	rs910316	0.737	rs28687415	ENSG00000259138.1	RP11-950C14.7	3.61	0.000335	0.0376	0.17	0.16	Height;	chr14:75028779	chr14:75127153~75136930:+
LUAD	cis	rs62103177	0.789	rs7242289	ENSG00000261126.6	RP11-795F19.1	3.61	0.000335	0.0376	0.23	0.16	Opioid sensitivity;	chr18:79843291	chr18:80046900~80095482:+
LUAD	cis	rs794185	0.625	rs1844123	ENSG00000231249.1	ITPR1-AS1	-3.61	0.000335	0.0376	-0.18	-0.16	Multiple sclerosis--Brain Glutamate Levels;	chr3:4471177	chr3:4490891~4493163:-
LUAD	cis	rs4852324	0.541	rs7568898	ENSG00000217702.2	RP11-287D1.4	3.61	0.000335	0.0376	0.33	0.16	Systemic lupus erythematosus;	chr2:74044450	chr2:74130583~74135395:+
LUAD	cis	rs76734026	0.515	rs12586596	ENSG00000255002.1	CTD-2509G16.2	-3.61	0.000335	0.0376	-0.29	-0.16	Pediatric areal bone mineral density (radius);	chr14:65246596	chr14:65212893~65222347:-
LUAD	cis	rs76734026	0.515	rs12588941	ENSG00000255002.1	CTD-2509G16.2	-3.61	0.000335	0.0376	-0.29	-0.16	Pediatric areal bone mineral density (radius);	chr14:65246695	chr14:65212893~65222347:-
LUAD	cis	rs76734026	0.515	rs11158584	ENSG00000255002.1	CTD-2509G16.2	-3.61	0.000335	0.0376	-0.29	-0.16	Pediatric areal bone mineral density (radius);	chr14:65248264	chr14:65212893~65222347:-
LUAD	cis	rs7098414	0.531	rs4120852	ENSG00000226659.1	RP11-137H2.4	-3.61	0.000335	0.0376	-0.21	-0.16	Post bronchodilator FEV1;	chr10:80258838	chr10:80529597~80535942:-
LUAD	cis	rs4908768	0.911	rs12121933	ENSG00000232912.4	RP5-1115A15.1	-3.61	0.000335	0.0376	-0.17	-0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8717022	chr1:8424645~8434838:+
LUAD	cis	rs6951245	0.935	rs11766669	ENSG00000199023.2	MIR339	-3.61	0.000335	0.0376	-0.29	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1023957	chr7:1022935~1023045:-
LUAD	cis	rs3803170	0.513	rs10849943	ENSG00000257595.2	RP3-473L9.4	-3.61	0.000335	0.0376	-0.21	-0.16	Mean corpuscular hemoglobin;	chr12:111381785	chr12:111369282~111403310:+
LUAD	cis	rs78487399	0.808	rs78497923	ENSG00000234936.1	AC010883.5	3.61	0.000335	0.0376	0.23	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43495843	chr2:43229573~43233394:+
LUAD	cis	rs78487399	0.808	rs75097983	ENSG00000234936.1	AC010883.5	3.61	0.000335	0.0376	0.23	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43498485	chr2:43229573~43233394:+
LUAD	cis	rs7812879	0.543	rs2736356	ENSG00000255046.1	RP11-297N6.4	3.61	0.000335	0.0376	0.28	0.16	Systemic lupus erythematosus;	chr8:11512942	chr8:11797928~11802568:-
LUAD	cis	rs7477	0.818	rs3112524	ENSG00000275413.1	CTC-529I10.1	-3.61	0.000335	0.0376	-0.13	-0.16	Amyotrophic lateral sclerosis;	chr17:16342464	chr17:16023323~16023653:-
LUAD	cis	rs7893279	0.505	rs7075135	ENSG00000225527.1	RP11-383B4.4	3.61	0.000335	0.0376	0.24	0.16	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18595123	chr10:18531849~18533336:-
LUAD	cis	rs334353	0.798	rs789675	ENSG00000255145.2	STX17-AS1	-3.61	0.000335	0.0376	-0.22	-0.16	Age-related macular degeneration;	chr9:99159997	chr9:99886322~99906601:-
LUAD	cis	rs4784934	0.589	rs9940062	ENSG00000260186.4	RP11-481J2.2	-3.61	0.000335	0.0376	-0.19	-0.16	QT interval;	chr16:58437315	chr16:58421326~58462470:+
LUAD	cis	rs12754538	0.687	rs10864363	ENSG00000232912.4	RP5-1115A15.1	-3.61	0.000335	0.0376	-0.16	-0.16	Subjective well-being;	chr1:8707252	chr1:8424645~8434838:+
LUAD	cis	rs9894429	0.646	rs6565612	ENSG00000263853.1	AC139530.1	3.61	0.000335	0.0376	0.17	0.16	Eye color traits;	chr17:81635794	chr17:81676001~81676086:+
LUAD	cis	rs8177876	0.822	rs9923732	ENSG00000261061.1	RP11-303E16.2	-3.61	0.000335	0.0376	-0.27	-0.16	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077298	chr16:81030770~81031485:+
LUAD	cis	rs8177876	0.822	rs9933184	ENSG00000261061.1	RP11-303E16.2	-3.61	0.000335	0.0376	-0.27	-0.16	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077571	chr16:81030770~81031485:+
LUAD	cis	rs8177876	0.822	rs9926174	ENSG00000261061.1	RP11-303E16.2	-3.61	0.000335	0.0376	-0.27	-0.16	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077831	chr16:81030770~81031485:+
LUAD	cis	rs8177876	0.642	rs8052490	ENSG00000261061.1	RP11-303E16.2	-3.61	0.000335	0.0376	-0.27	-0.16	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078251	chr16:81030770~81031485:+
LUAD	cis	rs12073359	0.571	rs11584606	ENSG00000223945.2	RP11-458I7.1	-3.61	0.000335	0.0376	-0.26	-0.16	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150194971	chr1:150053864~150055034:+
LUAD	cis	rs12216545	0.765	rs2373816	ENSG00000241134.3	BET1P1	-3.61	0.000335	0.0376	-0.17	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150574041	chr7:150749736~150750094:+
LUAD	cis	rs4888378	0.576	rs8050367	ENSG00000280152.1	RP11-331F4.5	3.61	0.000335	0.0376	0.15	0.16	Coronary artery disease;	chr16:75279360	chr16:75245994~75250077:-
LUAD	cis	rs7200786	0.667	rs12448611	ENSG00000274038.1	RP11-66H6.4	3.61	0.000335	0.0376	0.19	0.16	Systemic lupus erythematosus;Multiple sclerosis;	chr16:10986594	chr16:11056556~11057034:+
LUAD	cis	rs10463554	1	rs17154893	ENSG00000250682.4	LINC00491	3.61	0.000335	0.0376	0.19	0.16	Parkinson's disease;	chr5:102980902	chr5:102609156~102671559:-
LUAD	cis	rs10463554	1	rs6596529	ENSG00000250682.4	LINC00491	3.61	0.000335	0.0376	0.19	0.16	Parkinson's disease;	chr5:102981338	chr5:102609156~102671559:-
LUAD	cis	rs4853525	0.923	rs1882398	ENSG00000235852.1	AC005540.3	3.61	0.000335	0.0376	0.18	0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190859734	chr2:190880797~190882059:-
LUAD	cis	rs12724450	1	rs12724450	ENSG00000228126.1	FALEC	3.61	0.000335	0.0376	0.29	0.16	Blood protein levels;	chr1:150508095	chr1:150515757~150518032:+
LUAD	cis	rs9457247	1	rs365189	ENSG00000227598.1	RP1-167A14.2	-3.61	0.000335	0.0376	-0.17	-0.16	Crohn's disease;	chr6:166971057	chr6:166969626~166999065:-
LUAD	cis	rs9457247	1	rs376551	ENSG00000227598.1	RP1-167A14.2	-3.61	0.000335	0.0376	-0.17	-0.16	Crohn's disease;	chr6:166971435	chr6:166969626~166999065:-
LUAD	cis	rs755249	0.53	rs4660475	ENSG00000182109.6	RP11-69E11.4	3.61	0.000335	0.0376	0.2	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39146568	chr1:39522280~39546187:-
LUAD	cis	rs755249	0.53	rs66848709	ENSG00000182109.6	RP11-69E11.4	3.61	0.000335	0.0376	0.2	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39146885	chr1:39522280~39546187:-
LUAD	cis	rs10463554	0.89	rs26428	ENSG00000250682.4	LINC00491	-3.61	0.000335	0.0376	-0.19	-0.16	Parkinson's disease;	chr5:103030780	chr5:102609156~102671559:-
LUAD	cis	rs1150668	0.83	rs2859365	ENSG00000176933.5	TOB2P1	3.61	0.000335	0.0376	0.18	0.16	Pubertal anthropometrics;	chr6:28423688	chr6:28217643~28218634:-
LUAD	cis	rs11018904	0.906	rs55685917	ENSG00000280367.1	RP11-121L10.2	3.61	0.000335	0.0376	0.21	0.16	Intelligence (multi-trait analysis);	chr11:90231197	chr11:90223153~90226538:+
LUAD	cis	rs11018904	0.906	rs35286339	ENSG00000280367.1	RP11-121L10.2	3.61	0.000335	0.0376	0.21	0.16	Intelligence (multi-trait analysis);	chr11:90232511	chr11:90223153~90226538:+
LUAD	cis	rs7302981	0.809	rs66768395	ENSG00000200428.1	Y_RNA	-3.61	0.000335	0.0376	-0.2	-0.16	Systolic blood pressure;	chr12:50174482	chr12:50743568~50743684:+
LUAD	cis	rs7302981	0.809	rs1044370	ENSG00000200428.1	Y_RNA	-3.61	0.000335	0.0376	-0.2	-0.16	Systolic blood pressure;	chr12:50176827	chr12:50743568~50743684:+
LUAD	cis	rs7246657	0.653	rs28701616	ENSG00000226686.6	LINC01535	-3.61	0.000335	0.0376	-0.27	-0.16	Coronary artery calcification;	chr19:37190196	chr19:37251912~37265535:+
LUAD	cis	rs10510102	0.935	rs11200201	ENSG00000276742.1	RP11-500G22.4	3.61	0.000335	0.0376	0.26	0.16	Breast cancer;	chr10:121864790	chr10:121956782~121957098:+
LUAD	cis	rs9638182	0.667	rs13240065	ENSG00000274080.1	CTA-315H11.2	3.61	0.000335	0.0376	0.3	0.16	Triglycerides;	chr7:73601039	chr7:73609262~73611502:-
LUAD	cis	rs9341808	0.905	rs3805903	ENSG00000233967.5	RP11-250B2.3	3.61	0.000335	0.0376	0.16	0.16	Sitting height ratio;	chr6:80266112	chr6:80443344~80465927:+
LUAD	cis	rs61160187	0.51	rs6893642	ENSG00000272308.1	RP11-231G3.1	-3.61	0.000335	0.0376	-0.17	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60821896	chr5:60866457~60866935:-
LUAD	cis	rs61160187	0.51	rs3936423	ENSG00000272308.1	RP11-231G3.1	-3.61	0.000335	0.0376	-0.17	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60823134	chr5:60866457~60866935:-
LUAD	cis	rs61160187	0.51	rs1445293	ENSG00000272308.1	RP11-231G3.1	-3.61	0.000335	0.0376	-0.17	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60823910	chr5:60866457~60866935:-
LUAD	cis	rs9467773	0.844	rs2393669	ENSG00000241549.7	GUSBP2	3.61	0.000335	0.0376	0.18	0.16	Intelligence (multi-trait analysis);	chr6:26503645	chr6:26871484~26956554:-
LUAD	cis	rs9467773	1	rs9461259	ENSG00000241549.7	GUSBP2	3.61	0.000335	0.0376	0.18	0.16	Intelligence (multi-trait analysis);	chr6:26504607	chr6:26871484~26956554:-
LUAD	cis	rs9467773	1	rs9467774	ENSG00000241549.7	GUSBP2	3.61	0.000335	0.0376	0.18	0.16	Intelligence (multi-trait analysis);	chr6:26504808	chr6:26871484~26956554:-
LUAD	cis	rs9467773	1	rs3736781	ENSG00000241549.7	GUSBP2	3.61	0.000335	0.0376	0.18	0.16	Intelligence (multi-trait analysis);	chr6:26505134	chr6:26871484~26956554:-
LUAD	cis	rs9467773	1	rs3736782	ENSG00000241549.7	GUSBP2	3.61	0.000335	0.0376	0.18	0.16	Intelligence (multi-trait analysis);	chr6:26505175	chr6:26871484~26956554:-
LUAD	cis	rs9467773	1	rs2208331	ENSG00000241549.7	GUSBP2	3.61	0.000335	0.0376	0.18	0.16	Intelligence (multi-trait analysis);	chr6:26507091	chr6:26871484~26956554:-
LUAD	cis	rs9467773	1	rs9393728	ENSG00000241549.7	GUSBP2	3.61	0.000335	0.0376	0.18	0.16	Intelligence (multi-trait analysis);	chr6:26509102	chr6:26871484~26956554:-
LUAD	cis	rs9467773	1	rs1056667	ENSG00000241549.7	GUSBP2	3.61	0.000335	0.0376	0.18	0.16	Intelligence (multi-trait analysis);	chr6:26510336	chr6:26871484~26956554:-
LUAD	cis	rs6500602	1	rs7204827	ENSG00000280063.1	RP11-295D4.3	3.61	0.000335	0.0376	0.11	0.16	Schizophrenia;	chr16:4417532	chr16:4346694~4348648:-
LUAD	cis	rs3758785	0.641	rs7949222	ENSG00000255893.1	RP11-685N10.1	3.61	0.000335	0.0376	0.18	0.16	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94365335	chr11:94472908~94473570:-
LUAD	cis	rs7017914	0.934	rs1389202	ENSG00000246366.5	RP11-382J12.1	3.61	0.000336	0.0376	0.15	0.16	Bone mineral density;	chr8:70940050	chr8:70608577~70663279:+
LUAD	cis	rs7017914	0.967	rs13255735	ENSG00000246366.5	RP11-382J12.1	3.61	0.000336	0.0376	0.15	0.16	Bone mineral density;	chr8:70947504	chr8:70608577~70663279:+
LUAD	cis	rs6493487	0.512	rs71471522	ENSG00000273674.3	CTD-2378E12.1	3.61	0.000336	0.0376	0.23	0.16	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50861600	chr15:50839875~50908599:-
LUAD	cis	rs7646881	0.544	rs58034569	ENSG00000240207.5	RP11-379F4.4	-3.61	0.000336	0.0376	-0.21	-0.16	Tetralogy of Fallot;	chr3:158569900	chr3:158732263~158784070:+
LUAD	cis	rs4142110	0.767	rs9594704	ENSG00000271216.1	LINC01050	3.61	0.000336	0.0376	0.2	0.16	Nephrolithiasis;	chr13:42206262	chr13:42810366~42812562:-
LUAD	cis	rs683250	0.598	rs657824	ENSG00000246067.6	RAB30-AS1	3.61	0.000336	0.0377	0.17	0.16	Subcortical brain region volumes;	chr11:83257376	chr11:83072066~83106719:+
LUAD	cis	rs7223966	1	rs8076717	ENSG00000279369.1	RP11-51F16.1	3.61	0.000336	0.0377	0.18	0.16	Hip circumference adjusted for BMI;Body mass index;	chr17:63772941	chr17:63700847~63702670:+
LUAD	cis	rs763121	0.853	rs2235230	ENSG00000225450.1	RP3-508I15.14	3.61	0.000336	0.0377	0.17	0.16	Menopause (age at onset);	chr22:38728462	chr22:38739003~38749041:+
LUAD	cis	rs7116495	0.737	rs613971	ENSG00000254682.1	RP11-660L16.2	-3.61	0.000336	0.0377	-0.35	-0.16	Severe influenza A (H1N1) infection;	chr11:71863864	chr11:71448674~71452157:+
LUAD	cis	rs394563	0.556	rs398159	ENSG00000231760.4	RP11-350J20.5	3.61	0.000336	0.0377	0.22	0.16	Dupuytren's disease;	chr6:149471632	chr6:149796151~149826294:-
LUAD	cis	rs8180040	0.627	rs6442059	ENSG00000260236.1	RP11-708J19.1	3.61	0.000336	0.0377	0.15	0.16	Colorectal cancer;	chr3:47145585	chr3:47379089~47380999:-
LUAD	cis	rs8180040	0.681	rs9818382	ENSG00000260236.1	RP11-708J19.1	3.61	0.000336	0.0377	0.15	0.16	Colorectal cancer;	chr3:47151544	chr3:47379089~47380999:-
LUAD	cis	rs8180040	0.654	rs6766230	ENSG00000260236.1	RP11-708J19.1	3.61	0.000336	0.0377	0.15	0.16	Colorectal cancer;	chr3:47154719	chr3:47379089~47380999:-
LUAD	cis	rs8180040	0.627	rs9821119	ENSG00000260236.1	RP11-708J19.1	3.61	0.000336	0.0377	0.15	0.16	Colorectal cancer;	chr3:47156947	chr3:47379089~47380999:-
LUAD	cis	rs7726354	0.793	rs16886113	ENSG00000271828.1	CTD-2310F14.1	-3.61	0.000336	0.0377	-0.33	-0.16	Breast cancer (early onset);	chr5:56699208	chr5:56927874~56929573:+
LUAD	cis	rs438034	0.764	rs12117398	ENSG00000230461.7	PROX1-AS1	3.61	0.000336	0.0377	0.21	0.16	Response to antineoplastic agents;	chr1:214695454	chr1:213817751~213988508:-
LUAD	cis	rs7246967	0.611	rs35355374	ENSG00000236312.3	RPL34P34	3.61	0.000336	0.0377	0.24	0.16	Bronchopulmonary dysplasia;	chr19:22654899	chr19:22368599~22368952:-
LUAD	cis	rs7142881	0.815	rs4981106	ENSG00000258525.1	RP11-829H16.3	-3.61	0.000336	0.0377	-0.18	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31602829	chr14:30876179~30889808:-
LUAD	cis	rs11159086	0.793	rs9285594	ENSG00000270000.1	RP3-449M8.9	3.61	0.000336	0.0377	0.22	0.16	Advanced glycation end-product levels;	chr14:74489253	chr14:74471930~74472360:-
LUAD	cis	rs11159086	0.793	rs4903229	ENSG00000270000.1	RP3-449M8.9	3.61	0.000336	0.0377	0.22	0.16	Advanced glycation end-product levels;	chr14:74489865	chr14:74471930~74472360:-
LUAD	cis	rs11159086	0.793	rs8016972	ENSG00000270000.1	RP3-449M8.9	3.61	0.000336	0.0377	0.22	0.16	Advanced glycation end-product levels;	chr14:74491833	chr14:74471930~74472360:-
LUAD	cis	rs4474465	0.736	rs10899550	ENSG00000251323.2	RP11-452H21.4	-3.61	0.000336	0.0377	-0.2	-0.16	Alzheimer's disease (survival time);	chr11:78545032	chr11:78423982~78429836:-
LUAD	cis	rs56309584	0.596	rs11649742	ENSG00000226871.1	AC135178.7	3.61	0.000336	0.0377	0.23	0.16	Initial pursuit acceleration;	chr17:8273097	chr17:8318088~8318712:-
LUAD	cis	rs848087	0.935	rs848121	ENSG00000258661.1	RP11-964E11.2	-3.61	0.000336	0.0377	-0.19	-0.16	Breast cancer;	chr14:36775054	chr14:36647083~36658801:-
LUAD	cis	rs9925964	0.744	rs12716979	ENSG00000232748.3	RP11-196G11.6	3.61	0.000336	0.0377	0.19	0.16	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31000500	chr16:31056460~31062803:+
LUAD	cis	rs35065479	1	rs4530197	ENSG00000278627.1	RP11-506H21.5	-3.61	0.000336	0.0377	-0.22	-0.16	Schizophrenia;	chr17:57657987	chr17:58202352~58203003:-
LUAD	cis	rs72681920	0.881	rs2226896	ENSG00000246090.5	RP11-696N14.1	-3.61	0.000336	0.0377	-0.28	-0.16	Alcohol dependence;	chr4:99146186	chr4:99088857~99301356:+
LUAD	cis	rs72681920	0.618	rs12649136	ENSG00000246090.5	RP11-696N14.1	-3.61	0.000336	0.0377	-0.28	-0.16	Alcohol dependence;	chr4:99149659	chr4:99088857~99301356:+
LUAD	cis	rs6674176	0.66	rs12726706	ENSG00000237950.1	RP11-7O11.3	3.61	0.000336	0.0377	0.21	0.16	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43934270	chr1:43944370~43946551:-
LUAD	cis	rs3020736	0.5	rs7292241	ENSG00000273366.1	CTA-989H11.1	3.61	0.000336	0.0377	0.2	0.16	Autism spectrum disorder or schizophrenia;	chr22:42096059	chr22:42278188~42278846:+
LUAD	cis	rs1862618	0.853	rs43184	ENSG00000271828.1	CTD-2310F14.1	3.61	0.000336	0.0377	0.24	0.16	Initial pursuit acceleration;	chr5:56845950	chr5:56927874~56929573:+
LUAD	cis	rs1862618	0.853	rs33326	ENSG00000271828.1	CTD-2310F14.1	3.61	0.000336	0.0377	0.24	0.16	Initial pursuit acceleration;	chr5:56846774	chr5:56927874~56929573:+
LUAD	cis	rs1862618	0.802	rs33327	ENSG00000271828.1	CTD-2310F14.1	3.61	0.000336	0.0377	0.24	0.16	Initial pursuit acceleration;	chr5:56846866	chr5:56927874~56929573:+
LUAD	cis	rs111580313	0.71	rs77733759	ENSG00000243697.1	RP11-463O9.1	3.61	0.000336	0.0377	0.35	0.16	Systemic juvenile idiopathic arthritis;	chr16:86590513	chr16:86525457~86526252:+
LUAD	cis	rs262150	1	rs262150	ENSG00000231419.5	LINC00689	-3.61	0.000336	0.0377	-0.19	-0.16	Facial morphology (factor 20);	chr7:158985243	chr7:159006522~159030195:+
LUAD	cis	rs4268898	0.636	rs72787385	ENSG00000242628.4	AC009228.1	3.61	0.000336	0.0377	0.24	0.16	Asthma;	chr2:24362951	chr2:24214381~24221516:+
LUAD	cis	rs3753275	0.519	rs7554164	ENSG00000232912.4	RP5-1115A15.1	3.61	0.000336	0.0377	0.18	0.16	Educational attainment;	chr1:8685065	chr1:8424645~8434838:+
LUAD	cis	rs2980439	0.846	rs2980437	ENSG00000254340.1	RP11-10A14.3	-3.61	0.000336	0.0377	-0.19	-0.16	Neuroticism;	chr8:8237241	chr8:9141424~9145435:+
LUAD	cis	rs12530845	0.943	rs11984203	ENSG00000223718.3	AC093107.7	-3.61	0.000336	0.0377	-0.25	-0.16	Red blood cell traits;	chr7:135641199	chr7:135660039~135660647:+
LUAD	cis	rs2289700	0.518	rs77362013	ENSG00000252061.1	RNU6-415P	-3.61	0.000336	0.0377	-0.33	-0.16	Bipolar disorder;	chr15:78874918	chr15:78898840~78898936:-
LUAD	cis	rs2288884	0.767	rs28379522	ENSG00000269959.1	SPACA6P-AS	-3.61	0.000336	0.0377	-0.19	-0.16	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52036234	chr19:51685363~51693456:-
LUAD	cis	rs1023500	0.573	rs2413666	ENSG00000273366.1	CTA-989H11.1	-3.61	0.000336	0.0377	-0.19	-0.16	Schizophrenia;	chr22:42063618	chr22:42278188~42278846:+
LUAD	cis	rs786425	0.71	rs11057326	ENSG00000278112.1	RP11-972P1.11	3.61	0.000336	0.0377	0.15	0.16	Pubertal anthropometrics;	chr12:123663931	chr12:123519390~123519856:-
LUAD	cis	rs138529210	1	rs138529210	ENSG00000259081.1	RP11-488C13.6	-3.61	0.000336	0.0377	-0.31	-0.16	Chronic sinus infection;	chr14:77767002	chr14:76774284~76781518:-
LUAD	cis	rs950881	0.932	rs72823621	ENSG00000234389.1	AC007278.3	3.61	0.000336	0.0377	0.2	0.16	Allergy;	chr2:102308975	chr2:102438713~102440475:+
LUAD	cis	rs9311474	0.713	rs352170	ENSG00000243224.1	RP5-1157M23.2	-3.61	0.000336	0.0377	-0.16	-0.16	Electroencephalogram traits;	chr3:52202061	chr3:52239258~52241097:+
LUAD	cis	rs786425	0.966	rs786449	ENSG00000278112.1	RP11-972P1.11	-3.61	0.000336	0.0377	-0.15	-0.16	Pubertal anthropometrics;	chr12:123587181	chr12:123519390~123519856:-
LUAD	cis	rs9921338	0.961	rs7199821	ENSG00000263080.1	RP11-485G7.5	3.61	0.000337	0.0377	0.22	0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11331154	chr16:11341809~11345211:-
LUAD	cis	rs9921338	0.961	rs77552156	ENSG00000263080.1	RP11-485G7.5	3.61	0.000337	0.0377	0.22	0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11332542	chr16:11341809~11345211:-
LUAD	cis	rs9921338	0.961	rs4781069	ENSG00000263080.1	RP11-485G7.5	3.61	0.000337	0.0377	0.22	0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11334905	chr16:11341809~11345211:-
LUAD	cis	rs6460942	1	rs2053378	ENSG00000226690.5	AC005281.1	3.61	0.000337	0.0377	0.3	0.16	Coronary artery disease;	chr7:12365938	chr7:12496429~12541910:+
LUAD	cis	rs6460942	1	rs7796485	ENSG00000226690.5	AC005281.1	3.61	0.000337	0.0377	0.3	0.16	Coronary artery disease;	chr7:12366050	chr7:12496429~12541910:+
LUAD	cis	rs4699052	0.787	rs2169508	ENSG00000246560.2	RP11-10L12.4	3.61	0.000337	0.0377	0.21	0.16	Testicular germ cell tumor;	chr4:103145733	chr4:102828055~102844075:+
LUAD	cis	rs10751667	0.6	rs11246376	ENSG00000255284.1	AP006621.5	3.61	0.000337	0.0377	0.14	0.16	Alzheimer's disease (late onset);	chr11:999622	chr11:777578~784297:+
LUAD	cis	rs28472312	0.855	rs12448482	ENSG00000246465.1	RP11-57A19.2	3.61	0.000337	0.0377	0.19	0.16	Intelligence (multi-trait analysis);	chr16:28826752	chr16:28284885~28292064:-
LUAD	cis	rs2524005	1	rs2524005	ENSG00000270604.4	HCG17	-3.61	0.000337	0.0377	-0.22	-0.16	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:30234039~30326134:-
LUAD	cis	rs4667682	0.583	rs1035249	ENSG00000228507.1	DAP3P2	-3.61	0.000337	0.0377	-0.36	-0.16	Hippocampal atrophy;Body mass index;	chr2:171282655	chr2:171491422~171491931:+
LUAD	cis	rs10911232	0.507	rs7515822	ENSG00000224468.3	RP11-181K3.4	-3.61	0.000337	0.0377	-0.15	-0.16	Hypertriglyceridemia;	chr1:183068668	chr1:183138402~183141282:-
LUAD	cis	rs10911232	0.507	rs10797832	ENSG00000224468.3	RP11-181K3.4	-3.61	0.000337	0.0377	-0.15	-0.16	Hypertriglyceridemia;	chr1:183074899	chr1:183138402~183141282:-
LUAD	cis	rs10911232	0.507	rs10797833	ENSG00000224468.3	RP11-181K3.4	-3.61	0.000337	0.0377	-0.15	-0.16	Hypertriglyceridemia;	chr1:183074932	chr1:183138402~183141282:-
LUAD	cis	rs137603	0.602	rs137654	ENSG00000230149.2	RP3-508I15.19	-3.61	0.000337	0.0377	-0.13	-0.16	Primary biliary cholangitis;	chr22:39336408	chr22:38734730~38738990:+
LUAD	cis	rs990171	0.538	rs12995030	ENSG00000234389.1	AC007278.3	3.61	0.000337	0.0377	0.16	0.16	Lymphocyte counts;	chr2:102500007	chr2:102438713~102440475:+
LUAD	cis	rs910316	0.726	rs175040	ENSG00000279594.1	RP11-950C14.10	-3.61	0.000337	0.0377	-0.19	-0.16	Height;	chr14:75002852	chr14:75011269~75012851:-
LUAD	cis	rs875971	0.522	rs1917563	ENSG00000234585.5	CCT6P3	-3.61	0.000337	0.0377	-0.15	-0.16	Aortic root size;	chr7:65950660	chr7:65038354~65074713:+
LUAD	cis	rs2688608	0.967	rs2688609	ENSG00000271816.1	BMS1P4	-3.61	0.000337	0.0377	-0.13	-0.16	Inflammatory bowel disease;	chr10:73898423	chr10:73699151~73730487:-
LUAD	cis	rs11893307	0.509	rs12611764	ENSG00000235852.1	AC005540.3	3.61	0.000337	0.0378	0.21	0.16	Mean platelet volume;	chr2:190672417	chr2:190880797~190882059:-
LUAD	cis	rs728616	0.764	rs12413678	ENSG00000225484.5	NUTM2B-AS1	-3.61	0.000337	0.0378	-0.38	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79927343	chr10:79663088~79826594:-
LUAD	cis	rs526231	0.511	rs11951374	ENSG00000250682.4	LINC00491	3.61	0.000337	0.0378	0.2	0.16	Primary biliary cholangitis;	chr5:103020094	chr5:102609156~102671559:-
LUAD	cis	rs1876905	0.68	rs354540	ENSG00000271789.1	RP5-1112D6.7	-3.61	0.000337	0.0378	-0.22	-0.16	Mean corpuscular hemoglobin;	chr6:111195827	chr6:111297126~111298510:+
LUAD	cis	rs12681963	0.764	rs16876504	ENSG00000272375.1	RP11-51J9.6	3.61	0.000337	0.0378	0.29	0.16	Migraine;	chr8:30117802	chr8:30197404~30198048:+
LUAD	cis	rs7968440	0.651	rs7309519	ENSG00000200428.1	Y_RNA	3.61	0.000337	0.0378	0.19	0.16	Fibrinogen;	chr12:50258497	chr12:50743568~50743684:+
LUAD	cis	rs763121	0.819	rs5750629	ENSG00000225450.1	RP3-508I15.14	-3.61	0.000337	0.0378	-0.15	-0.16	Menopause (age at onset);	chr22:38589060	chr22:38739003~38749041:+
LUAD	cis	rs683250	0.599	rs2226415	ENSG00000246067.6	RAB30-AS1	-3.61	0.000337	0.0378	-0.17	-0.16	Subcortical brain region volumes;	chr11:83369776	chr11:83072066~83106719:+
LUAD	cis	rs683250	0.599	rs1943742	ENSG00000246067.6	RAB30-AS1	3.61	0.000337	0.0378	0.17	0.16	Subcortical brain region volumes;	chr11:83369540	chr11:83072066~83106719:+
LUAD	cis	rs495337	0.509	rs8123655	ENSG00000229222.1	KRT18P4	3.61	0.000337	0.0378	0.18	0.16	Psoriasis;	chr20:49901717	chr20:49956745~49958032:+
LUAD	cis	rs8014252	0.901	rs61671382	ENSG00000259158.2	ADAM20P1	-3.61	0.000337	0.0378	-0.23	-0.16	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70483097	chr14:70468881~70483756:-
LUAD	cis	rs7613875	0.6	rs2624848	ENSG00000234667.1	ACTBP13	3.61	0.000337	0.0378	0.18	0.16	Body mass index;	chr3:50127668	chr3:49873347~49877980:-
LUAD	cis	rs3936340	1	rs3936340	ENSG00000268001.1	CARD8-AS1	3.61	0.000337	0.0378	0.2	0.16	Intelligence;	chr19:48024325	chr19:48255675~48258199:+
LUAD	cis	rs9392556	0.734	rs648900	ENSG00000230648.1	RP3-406P24.3	3.61	0.000337	0.0378	0.18	0.16	Blood metabolite levels;	chr6:4109188	chr6:4018843~4021215:-
LUAD	cis	rs2625529	0.556	rs55679065	ENSG00000260173.1	RP11-2I17.4	3.61	0.000337	0.0378	0.19	0.16	Red blood cell count;	chr15:72141054	chr15:72140504~72155459:-
LUAD	cis	rs2154319	0.887	rs213756	ENSG00000235358.1	RP11-399E6.1	3.61	0.000337	0.0378	0.23	0.16	Height;	chr1:41129409	chr1:41242373~41284861:+
LUAD	cis	rs2154319	0.836	rs213755	ENSG00000235358.1	RP11-399E6.1	3.61	0.000337	0.0378	0.23	0.16	Height;	chr1:41129493	chr1:41242373~41284861:+
LUAD	cis	rs2732480	0.577	rs2634693	ENSG00000273765.1	RP11-370I10.11	3.61	0.000337	0.0378	0.18	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48312715	chr12:48360920~48361377:+
LUAD	cis	rs4819052	0.851	rs7276828	ENSG00000223768.1	LINC00205	-3.61	0.000337	0.0378	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275124	chr21:45293285~45297354:+
LUAD	cis	rs4819052	0.851	rs7281263	ENSG00000223768.1	LINC00205	-3.61	0.000337	0.0378	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275691	chr21:45293285~45297354:+
LUAD	cis	rs10911251	0.546	rs2027085	ENSG00000224468.3	RP11-181K3.4	3.61	0.000337	0.0378	0.14	0.16	Colorectal cancer;	chr1:183139476	chr1:183138402~183141282:-
LUAD	cis	rs7192380	0.964	rs11075729	ENSG00000226232.7	RP11-419C5.2	-3.61	0.000337	0.0378	-0.14	-0.16	Sjögren's syndrome;	chr16:69586375	chr16:69976388~69996188:-
LUAD	cis	rs5758511	0.689	rs17002947	ENSG00000226450.2	CYP2D8P	-3.61	0.000337	0.0378	-0.15	-0.16	Birth weight;	chr22:42292526	chr22:42149886~42155001:-
LUAD	cis	rs28374715	0.532	rs28897479	ENSG00000247556.5	OIP5-AS1	3.61	0.000337	0.0378	0.21	0.16	Ulcerative colitis;	chr15:41398653	chr15:41283990~41309737:+
LUAD	cis	rs7829975	0.591	rs12677543	ENSG00000233609.3	RP11-62H7.2	3.61	0.000337	0.0378	0.13	0.16	Mood instability;	chr8:8786764	chr8:8961200~8979025:+
LUAD	cis	rs701145	0.585	rs959376	ENSG00000243069.6	ARHGEF26-AS1	3.61	0.000337	0.0378	0.26	0.16	Coronary artery disease;	chr3:154148918	chr3:154024401~154121332:-
LUAD	cis	rs9303542	1	rs7214589	ENSG00000264920.1	RP11-6N17.4	-3.61	0.000337	0.0378	-0.21	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48324038	chr17:47891255~47895812:-
LUAD	cis	rs10242311	0.527	rs1706911	ENSG00000272918.1	CTB-152G17.6	3.61	0.000337	0.0378	0.21	0.16	Dental caries;	chr7:105640415	chr7:105102838~105105483:-
LUAD	cis	rs9601248	0.756	rs9601252	ENSG00000227676.3	LINC01068	-3.61	0.000337	0.0378	-0.2	-0.16	Major depressive disorder;	chr13:79615607	chr13:79566727~79571436:+
LUAD	cis	rs5742933	1	rs7557519	ENSG00000253559.1	OSGEPL1-AS1	-3.61	0.000337	0.0378	-0.22	-0.16	Ferritin levels;	chr2:189718461	chr2:189762704~189765556:+
LUAD	cis	rs6460942	0.915	rs62447642	ENSG00000226690.5	AC005281.1	3.61	0.000338	0.0378	0.29	0.16	Coronary artery disease;	chr7:12449521	chr7:12496429~12541910:+
LUAD	cis	rs3026445	0.713	rs12316812	ENSG00000278993.1	RP3-424M6.4	3.61	0.000338	0.0378	0.16	0.16	QT interval;	chr12:110131291	chr12:110501614~110503441:+
LUAD	cis	rs12602901	0.716	rs238228	ENSG00000262678.1	RP5-1050D4.4	-3.61	0.000338	0.0378	-0.18	-0.16	Blood metabolite levels;	chr17:4975665	chr17:4986466~4987324:+
LUAD	cis	rs9652601	0.622	rs7194305	ENSG00000280153.1	RP11-876N24.3	-3.61	0.000338	0.0378	-0.11	-0.16	Systemic lupus erythematosus;	chr16:11005850	chr16:10933903~10936280:+
LUAD	cis	rs7560272	0.501	rs2421676	ENSG00000163016.8	ALMS1P	-3.61	0.000338	0.0378	-0.17	-0.16	Schizophrenia;	chr2:73738960	chr2:73644919~73685576:+
LUAD	cis	rs12550612	0.614	rs4268128	ENSG00000253930.1	RP11-1149O23.2	-3.61	0.000338	0.0378	-0.24	-0.16	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23080343	chr8:23189279~23190675:+
LUAD	cis	rs860295	0.966	rs821551	ENSG00000203761.5	MSTO2P	-3.61	0.000338	0.0378	-0.13	-0.16	Body mass index;	chr1:155718789	chr1:155745829~155750137:+
LUAD	cis	rs12744310	0.887	rs12724625	ENSG00000235358.1	RP11-399E6.1	3.61	0.000338	0.0378	0.21	0.16	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41316598	chr1:41242373~41284861:+
LUAD	cis	rs394563	0.726	rs366905	ENSG00000216906.2	RP11-350J20.9	3.61	0.000338	0.0378	0.2	0.16	Dupuytren's disease;	chr6:149413961	chr6:149904243~149906418:+
LUAD	cis	rs4795519	0.826	rs11868530	ENSG00000266313.1	RP11-173M1.4	3.61	0.000338	0.0378	0.19	0.16	Chronic myeloid leukemia;	chr17:27029139	chr17:27333256~27348491:+
LUAD	cis	rs4795519	0.826	rs11080048	ENSG00000266313.1	RP11-173M1.4	3.61	0.000338	0.0378	0.19	0.16	Chronic myeloid leukemia;	chr17:27045922	chr17:27333256~27348491:+
LUAD	cis	rs4795519	0.826	rs11658274	ENSG00000266313.1	RP11-173M1.4	3.61	0.000338	0.0378	0.19	0.16	Chronic myeloid leukemia;	chr17:27046022	chr17:27333256~27348491:+
LUAD	cis	rs4795519	0.826	rs11657456	ENSG00000266313.1	RP11-173M1.4	3.61	0.000338	0.0378	0.19	0.16	Chronic myeloid leukemia;	chr17:27051101	chr17:27333256~27348491:+
LUAD	cis	rs11971779	0.941	rs28395455	ENSG00000273391.1	RP11-634H22.1	3.61	0.000338	0.0378	0.19	0.16	Diisocyanate-induced asthma;	chr7:139351240	chr7:139359032~139359566:-
LUAD	cis	rs4578769	0.569	rs12957183	ENSG00000266850.1	RP11-370A5.1	3.61	0.000338	0.0378	0.21	0.16	Eosinophil percentage of white cells;	chr18:22927124	chr18:22723491~22907721:-
LUAD	cis	rs4578769	0.569	rs9948922	ENSG00000266850.1	RP11-370A5.1	3.61	0.000338	0.0378	0.21	0.16	Eosinophil percentage of white cells;	chr18:22930198	chr18:22723491~22907721:-
LUAD	cis	rs11874381	0.76	rs9949052	ENSG00000266696.1	RP11-30L3.2	-3.61	0.000338	0.0378	-0.18	-0.16	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);	chr18:49679459	chr18:49205912~49208781:+
LUAD	cis	rs875971	0.862	rs2909688	ENSG00000273448.1	RP11-166O4.6	3.61	0.000338	0.0378	0.16	0.16	Aortic root size;	chr7:66376625	chr7:67333047~67334383:+
LUAD	cis	rs2252586	0.92	rs73410447	ENSG00000226278.1	PSPHP1	-3.61	0.000338	0.0379	-0.2	-0.16	Glioma;	chr7:54902458	chr7:55764797~55773288:+
LUAD	cis	rs1075265	0.756	rs698854	ENSG00000272156.1	RP11-477N3.1	-3.61	0.000338	0.0379	-0.19	-0.16	Chronotype;Morning vs. evening chronotype;	chr2:53826784	chr2:54082554~54085066:+
LUAD	cis	rs3026445	0.851	rs4630352	ENSG00000278993.1	RP3-424M6.4	3.61	0.000338	0.0379	0.17	0.16	QT interval;	chr12:110309614	chr12:110501614~110503441:+
LUAD	cis	rs8062405	0.721	rs151303	ENSG00000261419.1	RP11-57A19.4	-3.61	0.000338	0.0379	-0.18	-0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28481189	chr16:28659696~28740781:-
LUAD	cis	rs6095360	1	rs6019600	ENSG00000222365.1	SNORD12B	-3.61	0.000338	0.0379	-0.17	-0.16	Intelligence (multi-trait analysis);	chr20:49030395	chr20:49280319~49280409:+
LUAD	cis	rs11096990	0.613	rs9997015	ENSG00000249685.1	RP11-360F5.3	-3.61	0.000338	0.0379	-0.19	-0.16	Cognitive function;	chr4:39222677	chr4:39133913~39135608:+
LUAD	cis	rs8031584	0.958	rs34294266	ENSG00000260128.5	ULK4P2	-3.61	0.000338	0.0379	-0.21	-0.16	Huntington's disease progression;	chr15:30954637	chr15:30572738~30600647:+
LUAD	cis	rs2834288	0.535	rs9982605	ENSG00000273102.1	AP000569.9	3.61	0.000338	0.0379	0.2	0.16	Gut microbiota (bacterial taxa);	chr21:33961205	chr21:33967101~33968573:-
LUAD	cis	rs11893307	0.509	rs2356126	ENSG00000235852.1	AC005540.3	3.61	0.000338	0.0379	0.2	0.16	Mean platelet volume;	chr2:190677788	chr2:190880797~190882059:-
LUAD	cis	rs7181649	0.679	rs11539008	ENSG00000259635.1	AC100830.3	-3.61	0.000338	0.0379	-0.23	-0.16	Mean corpuscular hemoglobin;	chr15:65564315	chr15:64701248~64719602:+
LUAD	cis	rs36093844	0.626	rs72951268	ENSG00000279742.1	RP11-700A24.1	-3.61	0.000338	0.0379	-0.19	-0.16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85985315	chr11:85852557~85854943:-
LUAD	cis	rs911555	0.723	rs7149767	ENSG00000259775.1	RP11-45P15.4	3.61	0.000338	0.0379	0.21	0.16	Intelligence (multi-trait analysis);	chr14:103397208	chr14:103331674~103332367:-
LUAD	cis	rs1198872	0.812	rs1198867	ENSG00000272275.1	RP11-791G15.2	-3.61	0.000338	0.0379	-0.2	-0.16	Cardiac Troponin-T levels;	chr2:10762281	chr2:10767875~10770058:-
LUAD	cis	rs1198872	0.892	rs1198869	ENSG00000272275.1	RP11-791G15.2	-3.61	0.000338	0.0379	-0.2	-0.16	Cardiac Troponin-T levels;	chr2:10762319	chr2:10767875~10770058:-
LUAD	cis	rs897984	0.572	rs4889526	ENSG00000232748.3	RP11-196G11.6	-3.61	0.000338	0.0379	-0.2	-0.16	Dementia with Lewy bodies;	chr16:31019023	chr16:31056460~31062803:+
LUAD	cis	rs3733585	0.806	rs7375599	ENSG00000250413.1	RP11-448G15.1	-3.61	0.000338	0.0379	-0.21	-0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9953294	chr4:10006482~10009725:+
LUAD	cis	rs12682352	0.652	rs1567398	ENSG00000233609.3	RP11-62H7.2	-3.61	0.000338	0.0379	-0.13	-0.16	Neuroticism;	chr8:8869294	chr8:8961200~8979025:+
LUAD	cis	rs10510102	0.872	rs7916008	ENSG00000276742.1	RP11-500G22.4	3.61	0.000338	0.0379	0.28	0.16	Breast cancer;	chr10:121943578	chr10:121956782~121957098:+
LUAD	cis	rs10510102	0.872	rs7916380	ENSG00000276742.1	RP11-500G22.4	3.61	0.000338	0.0379	0.28	0.16	Breast cancer;	chr10:121943773	chr10:121956782~121957098:+
LUAD	cis	rs10510102	0.808	rs7920024	ENSG00000276742.1	RP11-500G22.4	3.61	0.000338	0.0379	0.28	0.16	Breast cancer;	chr10:121944063	chr10:121956782~121957098:+
LUAD	cis	rs481331	0.866	rs1889310	ENSG00000185904.10	LINC00839	3.61	0.000338	0.0379	0.27	0.16	Systemic juvenile idiopathic arthritis;	chr10:42486247	chr10:42475543~42495336:+
LUAD	cis	rs10776612	0.625	rs11101365	ENSG00000276850.3	CH17-360D5.2	-3.61	0.000339	0.0379	-0.17	-0.16	Conduct disorder;	chr10:48521703	chr10:47908064~47991850:-
LUAD	cis	rs7665090	1	rs2125211	ENSG00000246560.2	RP11-10L12.4	-3.61	0.000339	0.0379	-0.2	-0.16	Primary biliary cholangitis;	chr4:102638719	chr4:102828055~102844075:+
LUAD	cis	rs910316	0.737	rs424120	ENSG00000279594.1	RP11-950C14.10	-3.61	0.000339	0.0379	-0.19	-0.16	Height;	chr14:75016125	chr14:75011269~75012851:-
LUAD	cis	rs2011013	1	rs56278218	ENSG00000259570.1	RP11-671M22.4	-3.61	0.000339	0.0379	-0.22	-0.16	Sitting height ratio;	chr15:83957942	chr15:84394512~84395514:+
LUAD	cis	rs1910358	0.614	rs7702668	ENSG00000248874.4	C5orf17	-3.61	0.000339	0.0379	-0.21	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23975226	chr5:23951348~24178263:+
LUAD	cis	rs7474896	0.515	rs675628	ENSG00000226578.1	RP11-258F22.1	3.61	0.000339	0.0379	0.23	0.16	Obesity (extreme);	chr10:38016403	chr10:37775371~37784131:-
LUAD	cis	rs7615952	0.576	rs2276729	ENSG00000250012.1	RP11-124N2.1	-3.61	0.000339	0.0379	-0.22	-0.16	Blood pressure (smoking interaction);	chr3:126107371	chr3:126084220~126095349:+
LUAD	cis	rs7107174	1	rs2510045	ENSG00000251323.2	RP11-452H21.4	3.61	0.000339	0.0379	0.23	0.16	Testicular germ cell tumor;	chr11:78209517	chr11:78423982~78429836:-
LUAD	cis	rs6878284	0.608	rs841929	ENSG00000250682.4	LINC00491	-3.61	0.000339	0.0379	-0.17	-0.16	Schizophrenia;	chr5:102291323	chr5:102609156~102671559:-
LUAD	cis	rs6878284	0.575	rs841927	ENSG00000250682.4	LINC00491	-3.61	0.000339	0.0379	-0.17	-0.16	Schizophrenia;	chr5:102291808	chr5:102609156~102671559:-
LUAD	cis	rs6878284	0.575	rs841924	ENSG00000250682.4	LINC00491	-3.61	0.000339	0.0379	-0.17	-0.16	Schizophrenia;	chr5:102292910	chr5:102609156~102671559:-
LUAD	cis	rs651907	0.557	rs34181125	ENSG00000244119.1	PDCL3P4	3.61	0.000339	0.0379	0.16	0.16	Colorectal cancer;	chr3:101771434	chr3:101712472~101713191:+
LUAD	cis	rs1075265	0.783	rs6545376	ENSG00000272156.1	RP11-477N3.1	-3.61	0.000339	0.0379	-0.19	-0.16	Chronotype;Morning vs. evening chronotype;	chr2:53987685	chr2:54082554~54085066:+
LUAD	cis	rs34779708	0.931	rs72789609	ENSG00000271335.4	RP11-324I22.4	3.61	0.000339	0.038	0.17	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35017278	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.931	rs7908573	ENSG00000271335.4	RP11-324I22.4	3.61	0.000339	0.038	0.17	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35020585	chr10:35314552~35336401:-
LUAD	cis	rs4664293	0.867	rs6432553	ENSG00000230783.1	AC009961.2	-3.61	0.000339	0.038	-0.19	-0.16	Monocyte percentage of white cells;	chr2:159720499	chr2:159689217~159690291:-
LUAD	cis	rs1910358	0.614	rs10078669	ENSG00000248874.4	C5orf17	-3.61	0.000339	0.038	-0.21	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23951099	chr5:23951348~24178263:+
LUAD	cis	rs9309473	1	rs1881245	ENSG00000230002.2	ALMS1-IT1	3.61	0.000339	0.038	0.2	0.16	Metabolite levels;	chr2:73422800	chr2:73456764~73459484:+
LUAD	cis	rs577676	0.586	rs549449	ENSG00000271811.1	RP1-79C4.4	3.61	0.000339	0.038	0.21	0.16	Prevalent atrial fibrillation;	chr1:170641569	chr1:170667381~170669425:+
LUAD	cis	rs577676	0.586	rs639720	ENSG00000271811.1	RP1-79C4.4	3.61	0.000339	0.038	0.21	0.16	Prevalent atrial fibrillation;	chr1:170643785	chr1:170667381~170669425:+
LUAD	cis	rs577676	0.586	rs593173	ENSG00000271811.1	RP1-79C4.4	3.61	0.000339	0.038	0.21	0.16	Prevalent atrial fibrillation;	chr1:170646719	chr1:170667381~170669425:+
LUAD	cis	rs8180040	0.654	rs6773521	ENSG00000260236.1	RP11-708J19.1	-3.61	0.000339	0.038	-0.15	-0.16	Colorectal cancer;	chr3:47192929	chr3:47379089~47380999:-
LUAD	cis	rs8180040	0.647	rs57756484	ENSG00000260236.1	RP11-708J19.1	-3.61	0.000339	0.038	-0.15	-0.16	Colorectal cancer;	chr3:47197843	chr3:47379089~47380999:-
LUAD	cis	rs8180040	0.654	rs1466740	ENSG00000260236.1	RP11-708J19.1	-3.61	0.000339	0.038	-0.15	-0.16	Colorectal cancer;	chr3:47204393	chr3:47379089~47380999:-
LUAD	cis	rs683250	0.629	rs513468	ENSG00000246067.6	RAB30-AS1	-3.61	0.000339	0.038	-0.17	-0.16	Subcortical brain region volumes;	chr11:83222507	chr11:83072066~83106719:+
LUAD	cis	rs10911232	0.507	rs10737239	ENSG00000224468.3	RP11-181K3.4	-3.61	0.000339	0.038	-0.15	-0.16	Hypertriglyceridemia;	chr1:183061035	chr1:183138402~183141282:-
LUAD	cis	rs848087	1	rs848087	ENSG00000258661.1	RP11-964E11.2	3.61	0.000339	0.038	0.19	0.16	Breast cancer;	chr14:36808438	chr14:36647083~36658801:-
LUAD	cis	rs4819052	0.851	rs8131143	ENSG00000215447.6	BX322557.10	3.61	0.000339	0.038	0.19	0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251731	chr21:45288052~45291738:+
LUAD	cis	rs3811273	0.614	rs7156203	ENSG00000211816.2	TRAV38-1	-3.61	0.000339	0.038	-0.23	-0.16	Periodontal disease-related phenotypes;	chr14:22263640	chr14:22271968~22272563:+
LUAD	cis	rs17572109	0.666	rs4674297	ENSG00000261338.2	RP11-378A13.1	3.61	0.000339	0.038	0.19	0.16	Platelet count;Platelet distribution width;Mean platelet volume;	chr2:218364424	chr2:218255319~218257366:+
LUAD	cis	rs8048589	0.527	rs9939383	ENSG00000175604.2	RP11-276H1.3	-3.61	0.000339	0.038	-0.22	-0.16	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12082263	chr16:12086746~12090302:-
LUAD	cis	rs9926296	0.546	rs7187436	ENSG00000260259.1	RP11-368I7.4	-3.61	0.000339	0.038	-0.16	-0.16	Vitiligo;	chr16:89778702	chr16:89682620~89686569:-
LUAD	cis	rs61542988	0.57	rs7781074	ENSG00000226329.2	AC005682.6	-3.61	0.000339	0.038	-0.24	-0.16	Fibrinogen levels;	chr7:22786741	chr7:22863874~22881350:-
LUAD	cis	rs7726354	0.655	rs16886034	ENSG00000271828.1	CTD-2310F14.1	-3.61	0.00034	0.038	-0.37	-0.16	Breast cancer (early onset);	chr5:56688029	chr5:56927874~56929573:+
LUAD	cis	rs9457247	0.967	rs1211447	ENSG00000227598.1	RP1-167A14.2	-3.61	0.00034	0.038	-0.17	-0.16	Crohn's disease;	chr6:166968491	chr6:166969626~166999065:-
LUAD	cis	rs9457247	0.967	rs1187532	ENSG00000227598.1	RP1-167A14.2	-3.61	0.00034	0.038	-0.17	-0.16	Crohn's disease;	chr6:166968532	chr6:166969626~166999065:-
LUAD	cis	rs9457247	1	rs448060	ENSG00000227598.1	RP1-167A14.2	-3.61	0.00034	0.038	-0.17	-0.16	Crohn's disease;	chr6:166969134	chr6:166969626~166999065:-
LUAD	cis	rs9457247	0.967	rs2015864	ENSG00000227598.1	RP1-167A14.2	3.61	0.00034	0.038	0.17	0.16	Crohn's disease;	chr6:166967988	chr6:166969626~166999065:-
LUAD	cis	rs61160187	0.582	rs17419290	ENSG00000215032.2	GNL3LP1	-3.61	0.00034	0.038	-0.2	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:61012077	chr5:60891935~60893577:-
LUAD	cis	rs11640436	0.584	rs12932492	ENSG00000261707.1	RP11-264M12.2	-3.61	0.00034	0.038	-0.18	-0.16	Lobe attachment (rater-scored or self-reported);	chr16:77275846	chr16:77741468~77743000:-
LUAD	cis	rs910316	0.737	rs108622	ENSG00000279594.1	RP11-950C14.10	-3.61	0.00034	0.038	-0.19	-0.16	Height;	chr14:75015205	chr14:75011269~75012851:-
LUAD	cis	rs3096299	0.719	rs2353581	ENSG00000261574.1	RP1-168P16.2	3.61	0.00034	0.038	0.18	0.16	Multiple myeloma (IgH translocation);	chr16:89452500	chr16:89392375~89412564:-
LUAD	cis	rs9549260	0.564	rs4943805	ENSG00000168852.11	TPTE2P5	3.61	0.00034	0.038	0.16	0.16	Red blood cell count;	chr13:40695944	chr13:40822296~40921749:-
LUAD	cis	rs12822507	0.719	rs10845585	ENSG00000180861.8	LINC01559	3.61	0.00034	0.038	0.18	0.16	Systemic lupus erythematosus;	chr12:12596691	chr12:13371089~13387167:-
LUAD	cis	rs12928939	0.769	rs34680964	ENSG00000262140.1	RP11-417N10.3	-3.61	0.00034	0.038	-0.19	-0.16	Post bronchodilator FEV1;	chr16:71624691	chr16:71833787~71835932:+
LUAD	cis	rs683250	0.661	rs2507865	ENSG00000246067.6	RAB30-AS1	-3.61	0.00034	0.038	-0.17	-0.16	Subcortical brain region volumes;	chr11:83424349	chr11:83072066~83106719:+
LUAD	cis	rs2115630	0.764	rs11073716	ENSG00000229212.6	RP11-561C5.4	3.61	0.00034	0.038	0.19	0.16	P wave terminal force;	chr15:84792543	chr15:85205440~85234795:-
LUAD	cis	rs11988997	0.867	rs4876855	ENSG00000281641.1	SAMD12-AS1	-3.61	0.00034	0.038	-0.35	-0.16	Pancreatitis;	chr8:118728549	chr8:118621001~118858218:+
LUAD	cis	rs7955901	0.805	rs1913196	ENSG00000258053.1	CTD-2021H9.3	-3.61	0.00034	0.038	-0.18	-0.16	Type 2 diabetes;	chr12:71024567	chr12:71047402~71118247:-
LUAD	cis	rs240993	0.812	rs28770304	ENSG00000271789.1	RP5-1112D6.7	3.61	0.00034	0.038	0.19	0.16	Inflammatory skin disease;Psoriasis;	chr6:111461586	chr6:111297126~111298510:+
LUAD	cis	rs2836950	0.565	rs2836945	ENSG00000232608.1	TIMM9P2	3.61	0.00034	0.038	0.18	0.16	Menarche (age at onset);	chr21:39224831	chr21:39216624~39217506:+
LUAD	cis	rs7572733	0.935	rs700665	ENSG00000222017.1	AC011997.1	3.61	0.00034	0.038	0.21	0.16	Dermatomyositis;	chr2:197808655	chr2:197693106~197774823:+
LUAD	cis	rs10885396	1	rs10885396	ENSG00000233547.1	RP11-57H14.2	-3.61	0.00034	0.038	-0.16	-0.16	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr10:112951996	chr10:112950646~112951875:-
LUAD	cis	rs701145	0.585	rs896013	ENSG00000243069.6	ARHGEF26-AS1	3.61	0.00034	0.038	0.26	0.16	Coronary artery disease;	chr3:154146084	chr3:154024401~154121332:-
LUAD	cis	rs701145	0.585	rs1542254	ENSG00000243069.6	ARHGEF26-AS1	3.61	0.00034	0.038	0.26	0.16	Coronary artery disease;	chr3:154146507	chr3:154024401~154121332:-
LUAD	cis	rs701145	0.585	rs1470664	ENSG00000243069.6	ARHGEF26-AS1	3.61	0.00034	0.038	0.26	0.16	Coronary artery disease;	chr3:154147404	chr3:154024401~154121332:-
LUAD	cis	rs2380205	0.967	rs907688	ENSG00000232807.2	RP11-536K7.3	-3.61	0.00034	0.038	-0.17	-0.16	Breast cancer;	chr10:5858859	chr10:5934270~5945900:-
LUAD	cis	rs4423214	0.798	rs12224205	ENSG00000226627.1	SHANK2-AS1	3.61	0.00034	0.038	0.2	0.16	Vitamin D levels;	chr11:71469946	chr11:70631094~70635490:+
LUAD	cis	rs1065852	0.526	rs12166549	ENSG00000226450.2	CYP2D8P	3.61	0.00034	0.038	0.14	0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42014415	chr22:42149886~42155001:-
LUAD	cis	rs1065852	0.526	rs9611711	ENSG00000226450.2	CYP2D8P	3.61	0.00034	0.038	0.14	0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42014691	chr22:42149886~42155001:-
LUAD	cis	rs35740288	0.571	rs11629608	ENSG00000259407.1	RP11-158M2.3	-3.61	0.00034	0.038	-0.17	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85786893	chr15:85744109~85750281:-
LUAD	cis	rs7824557	0.583	rs4448232	ENSG00000255046.1	RP11-297N6.4	-3.61	0.00034	0.038	-0.2	-0.16	Retinal vascular caliber;	chr8:11373845	chr8:11797928~11802568:-
LUAD	cis	rs12146727	0.881	rs11064501	ENSG00000247853.2	RP5-940J5.6	3.61	0.00034	0.0381	0.26	0.16	Blood protein levels;	chr12:7072518	chr12:6578622~6584739:+
LUAD	cis	rs12146727	0.881	rs12368181	ENSG00000247853.2	RP5-940J5.6	3.61	0.00034	0.0381	0.26	0.16	Blood protein levels;	chr12:7073801	chr12:6578622~6584739:+
LUAD	cis	rs12146727	0.881	rs12366520	ENSG00000247853.2	RP5-940J5.6	3.61	0.00034	0.0381	0.26	0.16	Blood protein levels;	chr12:7073858	chr12:6578622~6584739:+
LUAD	cis	rs12291225	0.679	rs10832240	ENSG00000251991.1	RNU7-49P	3.61	0.00034	0.0381	0.19	0.16	Sense of smell;	chr11:14283198	chr11:14478892~14478953:+
LUAD	cis	rs12291225	0.679	rs7934671	ENSG00000251991.1	RNU7-49P	3.61	0.00034	0.0381	0.19	0.16	Sense of smell;	chr11:14283555	chr11:14478892~14478953:+
LUAD	cis	rs6793245	0.801	rs10865879	ENSG00000229589.1	ACVR2B-AS1	-3.61	0.00034	0.0381	-0.21	-0.16	QT interval;	chr3:38535871	chr3:38451027~38454820:-
LUAD	cis	rs7819412	0.595	rs10106914	ENSG00000255046.1	RP11-297N6.4	3.61	0.00034	0.0381	0.2	0.16	Triglycerides;	chr8:11130141	chr8:11797928~11802568:-
LUAD	cis	rs7942368	1	rs1440978	ENSG00000254632.1	RP11-21L23.4	3.61	0.00034	0.0381	0.17	0.16	Endometriosis;	chr11:76765236	chr11:76759916~76768223:-
LUAD	cis	rs3120667	0.72	rs56325026	ENSG00000237975.5	FLG-AS1	3.61	0.00034	0.0381	0.29	0.16	Eating disorders;	chr1:152446103	chr1:152168125~152445456:+
LUAD	cis	rs1007190	0.881	rs6503406	ENSG00000267505.1	CTC-296K1.3	3.61	0.00034	0.0381	0.29	0.16	DNA methylation (variation);	chr17:44859737	chr17:44793199~44794474:+
LUAD	cis	rs2239547	0.562	rs6794389	ENSG00000243224.1	RP5-1157M23.2	-3.61	0.00034	0.0381	-0.19	-0.16	Schizophrenia;	chr3:53062378	chr3:52239258~52241097:+
LUAD	cis	rs10129255	0.5	rs7161740	ENSG00000232216.1	IGHV3-43	3.61	0.00034	0.0381	0.13	0.16	Kawasaki disease;	chr14:106776119	chr14:106470264~106470800:-
LUAD	cis	rs10129255	0.556	rs6576222	ENSG00000232216.1	IGHV3-43	3.61	0.00034	0.0381	0.13	0.16	Kawasaki disease;	chr14:106776442	chr14:106470264~106470800:-
LUAD	cis	rs10129255	0.536	rs6576223	ENSG00000232216.1	IGHV3-43	3.61	0.00034	0.0381	0.13	0.16	Kawasaki disease;	chr14:106776448	chr14:106470264~106470800:-
LUAD	cis	rs2803122	0.84	rs10757036	ENSG00000273226.1	RP11-513M16.8	-3.61	0.00034	0.0381	-0.17	-0.16	Pulse pressure;	chr9:19236127	chr9:19375451~19375996:+
LUAD	cis	rs11992162	0.56	rs13256329	ENSG00000255046.1	RP11-297N6.4	3.61	0.000341	0.0381	0.2	0.16	Monocyte count;	chr8:11924705	chr8:11797928~11802568:-
LUAD	cis	rs11992162	0.551	rs13268217	ENSG00000255046.1	RP11-297N6.4	3.61	0.000341	0.0381	0.2	0.16	Monocyte count;	chr8:11925100	chr8:11797928~11802568:-
LUAD	cis	rs11992162	0.573	rs61468577	ENSG00000255046.1	RP11-297N6.4	3.61	0.000341	0.0381	0.2	0.16	Monocyte count;	chr8:11927416	chr8:11797928~11802568:-
LUAD	cis	rs12216545	0.765	rs939958	ENSG00000177590.7	GIMAP3P	-3.61	0.000341	0.0381	-0.16	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150560680	chr7:150746893~150747728:-
LUAD	cis	rs12216545	0.64	rs1879867	ENSG00000177590.7	GIMAP3P	-3.61	0.000341	0.0381	-0.16	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150561018	chr7:150746893~150747728:-
LUAD	cis	rs10197140	0.857	rs11123221	ENSG00000235721.1	AC013268.3	-3.61	0.000341	0.0381	-0.18	-0.16	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110884109	chr2:110007675~110010783:+
LUAD	cis	rs6460942	0.915	rs62447639	ENSG00000226690.5	AC005281.1	3.61	0.000341	0.0381	0.29	0.16	Coronary artery disease;	chr7:12447177	chr7:12496429~12541910:+
LUAD	cis	rs9300255	0.596	rs10732573	ENSG00000256092.2	RP13-942N8.1	3.61	0.000341	0.0381	0.15	0.16	Neutrophil percentage of white cells;	chr12:123259336	chr12:123363868~123366113:+
LUAD	cis	rs970797	0.522	rs2689948	ENSG00000237260.1	AC073069.2	3.61	0.000341	0.0381	0.19	0.16	Monobrow;Lobe attachment (rater-scored or self-reported);	chr2:176334691	chr2:176338637~176339077:+
LUAD	cis	rs970797	0.522	rs818363	ENSG00000237260.1	AC073069.2	3.61	0.000341	0.0381	0.19	0.16	Monobrow;Lobe attachment (rater-scored or self-reported);	chr2:176337342	chr2:176338637~176339077:+
LUAD	cis	rs1823874	0.605	rs1840300	ENSG00000182397.13	DNM1P46	-3.61	0.000341	0.0381	-0.19	-0.16	IgG glycosylation;	chr15:99826739	chr15:99790156~99806927:-
LUAD	cis	rs17597773	0.638	rs7530176	ENSG00000272823.1	RP11-295M18.6	-3.61	0.000341	0.0381	-0.21	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220816040	chr1:220828676~220829211:-
LUAD	cis	rs17189298	0.904	rs12998633	ENSG00000231013.1	AC013275.2	3.61	0.000341	0.0381	0.16	0.16	Cerebrospinal T-tau levels;	chr2:119084144	chr2:119476448~119487346:+
LUAD	cis	rs745109	0.504	rs80252327	ENSG00000273080.1	RP11-301O19.1	3.61	0.000341	0.0381	0.26	0.16	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86385089	chr2:86195590~86196049:+
LUAD	cis	rs1055129	0.655	rs3744006	ENSG00000267801.1	RP11-552F3.9	3.61	0.000341	0.0381	0.16	0.16	White matter hyperintensity burden;	chr17:75842735	chr17:75876372~75879546:+
LUAD	cis	rs467650	0.509	rs2591443	ENSG00000248489.1	CTD-2007H13.3	-3.61	0.000341	0.0381	-0.17	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:98661785	chr5:98929171~98995013:+
LUAD	cis	rs1910358	0.718	rs17500497	ENSG00000248874.4	C5orf17	-3.61	0.000341	0.0381	-0.2	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23868046	chr5:23951348~24178263:+
LUAD	cis	rs3772130	1	rs7427165	ENSG00000243544.3	RN7SL172P	3.61	0.000341	0.0381	0.19	0.16	Cognitive performance;	chr3:121645777	chr3:121653994~121654296:-
LUAD	cis	rs2348418	0.966	rs1527578	ENSG00000244712.1	RP11-874G11.1	3.61	0.000341	0.0381	0.19	0.16	Lung function (FEV1);Lung function (FVC);	chr12:28536903	chr12:28564678~28565141:-
LUAD	cis	rs2348418	0.966	rs16932891	ENSG00000244712.1	RP11-874G11.1	3.61	0.000341	0.0381	0.19	0.16	Lung function (FEV1);Lung function (FVC);	chr12:28537055	chr12:28564678~28565141:-
LUAD	cis	rs2348418	0.966	rs2881910	ENSG00000244712.1	RP11-874G11.1	3.61	0.000341	0.0381	0.19	0.16	Lung function (FEV1);Lung function (FVC);	chr12:28544459	chr12:28564678~28565141:-
LUAD	cis	rs2071518	1	rs72684286	ENSG00000254343.2	RP11-760H22.2	-3.61	0.000341	0.0381	-0.2	-0.16	Blood pressure;Pulse pressure;	chr8:119388929	chr8:120052180~120056201:+
LUAD	cis	rs11096990	0.613	rs12505690	ENSG00000249685.1	RP11-360F5.3	3.61	0.000341	0.0381	0.19	0.16	Cognitive function;	chr4:39167425	chr4:39133913~39135608:+
LUAD	cis	rs6977955	1	rs6977955	ENSG00000234336.5	JAZF1-AS1	3.61	0.000341	0.0381	0.22	0.16	Allergic disease (asthma, hay fever or eczema);	chr7:28117268	chr7:28180322~28243917:+
LUAD	cis	rs10102546	1	rs1446070	ENSG00000244642.3	RN7SL396P	3.61	0.000341	0.0381	0.19	0.16	Smoking cessation;	chr8:119537919	chr8:119862662~119862956:+
LUAD	cis	rs4965272	1	rs6598289	ENSG00000272808.2	RP11-66B24.7	3.61	0.000341	0.0381	0.21	0.16	Gastroesophageal reflux disease;	chr15:100047119	chr15:100849831~100865457:+
LUAD	cis	rs7772486	0.875	rs9322045	ENSG00000235652.6	RP11-545I5.3	3.61	0.000341	0.0381	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:146063814	chr6:145799409~145886585:+
LUAD	cis	rs10102546	1	rs4871336	ENSG00000244642.3	RN7SL396P	3.61	0.000341	0.0381	0.19	0.16	Smoking cessation;	chr8:119542167	chr8:119862662~119862956:+
LUAD	cis	rs3018066	0.748	rs7657962	ENSG00000251259.1	AC004069.2	-3.61	0.000341	0.0381	-0.2	-0.16	Cancer;	chr4:106045558	chr4:105137280~105140619:-
LUAD	cis	rs8180040	0.654	rs11714373	ENSG00000260236.1	RP11-708J19.1	-3.61	0.000341	0.0381	-0.15	-0.16	Colorectal cancer;	chr3:47173327	chr3:47379089~47380999:-
LUAD	cis	rs7260598	0.892	rs58931976	ENSG00000268442.1	CTD-2027I19.2	3.61	0.000341	0.0381	0.25	0.16	Response to taxane treatment (placlitaxel);	chr19:24008247	chr19:24162370~24163425:-
LUAD	cis	rs7260598	0.892	rs59831281	ENSG00000268442.1	CTD-2027I19.2	3.61	0.000341	0.0381	0.25	0.16	Response to taxane treatment (placlitaxel);	chr19:24008258	chr19:24162370~24163425:-
LUAD	cis	rs16940212	0.618	rs76679589	ENSG00000242747.1	RP11-30K9.1	-3.61	0.000341	0.0381	-0.24	-0.16	HDL cholesterol;HDL cholesterol levels;	chr15:58394492	chr15:58869659~58870134:+
LUAD	cis	rs73108077	0.736	rs73104095	ENSG00000281376.1	ABALON	-3.61	0.000341	0.0381	-0.26	-0.16	Red blood cell density in sickle cell anemia;	chr20:31312074	chr20:31721507~31723409:+
LUAD	cis	rs7246657	0.943	rs4801803	ENSG00000267470.4	ZNF571-AS1	-3.61	0.000341	0.0381	-0.22	-0.16	Coronary artery calcification;	chr19:37476021	chr19:37548914~37587348:+
LUAD	cis	rs6921919	0.583	rs3800328	ENSG00000219392.1	RP1-265C24.5	-3.61	0.000341	0.0381	-0.21	-0.16	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28115628~28116551:+
LUAD	cis	rs6921919	0.609	rs67211468	ENSG00000219392.1	RP1-265C24.5	-3.61	0.000341	0.0381	-0.21	-0.16	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28115628~28116551:+
LUAD	cis	rs7615952	0.512	rs4679430	ENSG00000171084.14	FAM86JP	3.61	0.000341	0.0381	0.21	0.16	Blood pressure (smoking interaction);	chr3:125639049	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.512	rs34651730	ENSG00000171084.14	FAM86JP	3.61	0.000341	0.0381	0.21	0.16	Blood pressure (smoking interaction);	chr3:125639796	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.512	rs2979334	ENSG00000171084.14	FAM86JP	3.61	0.000341	0.0381	0.21	0.16	Blood pressure (smoking interaction);	chr3:125639980	chr3:125916620~125930024:+
LUAD	cis	rs7615952	0.512	rs11921452	ENSG00000171084.14	FAM86JP	3.61	0.000341	0.0381	0.21	0.16	Blood pressure (smoking interaction);	chr3:125640906	chr3:125916620~125930024:+
LUAD	cis	rs796825	0.553	rs939499	ENSG00000240661.1	RP11-174O3.3	-3.61	0.000341	0.0381	-0.21	-0.16	HIV-1 susceptibility;	chr3:120341555	chr3:120349510~120367998:+
LUAD	cis	rs796825	0.597	rs2138259	ENSG00000240661.1	RP11-174O3.3	-3.61	0.000341	0.0381	-0.21	-0.16	HIV-1 susceptibility;	chr3:120342387	chr3:120349510~120367998:+
LUAD	cis	rs796825	0.626	rs6438578	ENSG00000240661.1	RP11-174O3.3	-3.61	0.000341	0.0381	-0.21	-0.16	HIV-1 susceptibility;	chr3:120346322	chr3:120349510~120367998:+
LUAD	cis	rs796825	0.597	rs6438579	ENSG00000240661.1	RP11-174O3.3	-3.61	0.000341	0.0381	-0.21	-0.16	HIV-1 susceptibility;	chr3:120346362	chr3:120349510~120367998:+
LUAD	cis	rs3805389	0.504	rs17781708	ENSG00000273257.1	RP11-177J6.1	3.61	0.000341	0.0382	0.26	0.16	Waist-to-hip ratio adjusted for body mass index;	chr4:55614902	chr4:55387949~55388271:+
LUAD	cis	rs10392	0.543	rs4812336	ENSG00000274825.1	RP4-616B8.5	-3.61	0.000341	0.0382	-0.21	-0.16	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;	chr20:38918731	chr20:38955910~38956547:+
LUAD	cis	rs10129255	0.5	rs2027903	ENSG00000253209.1	IGHV3-65	3.61	0.000341	0.0382	0.13	0.16	Kawasaki disease;	chr14:106807047	chr14:106666092~106666532:-
LUAD	cis	rs10129255	0.518	rs28378320	ENSG00000253209.1	IGHV3-65	3.61	0.000341	0.0382	0.13	0.16	Kawasaki disease;	chr14:106808609	chr14:106666092~106666532:-
LUAD	cis	rs743757	0.878	rs35986136	ENSG00000273356.1	RP11-804H8.6	3.61	0.000341	0.0382	0.23	0.16	Diastolic blood pressure;	chr3:50497790	chr3:50669989~50672048:+
LUAD	cis	rs270601	0.683	rs81598	ENSG00000263597.1	MIR3936	3.61	0.000341	0.0382	0.17	0.16	Acylcarnitine levels;	chr5:132252267	chr5:132365490~132365599:-
LUAD	cis	rs3126085	0.515	rs7534951	ENSG00000237975.5	FLG-AS1	3.61	0.000341	0.0382	0.25	0.16	Atopic dermatitis;	chr1:152390496	chr1:152168125~152445456:+
LUAD	cis	rs875971	0.965	rs9969301	ENSG00000273142.1	RP11-458F8.4	3.61	0.000341	0.0382	0.11	0.16	Aortic root size;	chr7:66316668	chr7:66902857~66906297:+
LUAD	cis	rs2494663	0.61	rs11264964	ENSG00000223599.1	RP11-216N14.7	3.61	0.000341	0.0382	0.19	0.16	Mean platelet volume;	chr1:154056974	chr1:153852106~153853414:-
LUAD	cis	rs61884328	0.733	rs61897858	ENSG00000254780.1	RP11-793I11.1	3.61	0.000341	0.0382	0.32	0.16	Total body bone mineral density (age over 60);	chr11:47213712	chr11:47905323~47905607:-
LUAD	cis	rs7003550	1	rs10091775	ENSG00000254028.1	AC083843.2	-3.61	0.000341	0.0382	-0.21	-0.16	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr8:134843938	chr8:134832747~134834482:+
LUAD	cis	rs2299587	0.527	rs10112643	ENSG00000253671.1	RP11-806O11.1	-3.61	0.000341	0.0382	-0.16	-0.16	Economic and political preferences;	chr8:17868510	chr8:17808941~17820868:+
LUAD	cis	rs7246657	0.653	rs4805208	ENSG00000226686.6	LINC01535	-3.61	0.000341	0.0382	-0.27	-0.16	Coronary artery calcification;	chr19:37183357	chr19:37251912~37265535:+
LUAD	cis	rs7474896	0.515	rs2738203	ENSG00000226578.1	RP11-258F22.1	3.61	0.000341	0.0382	0.24	0.16	Obesity (extreme);	chr10:37988668	chr10:37775371~37784131:-
LUAD	cis	rs2408955	0.5	rs12816820	ENSG00000257763.1	OR5BK1P	3.61	0.000342	0.0382	0.17	0.16	Glycated hemoglobin levels;	chr12:48164542	chr12:48355792~48356614:-
LUAD	cis	rs453301	0.658	rs6986044	ENSG00000233609.3	RP11-62H7.2	-3.61	0.000342	0.0382	-0.14	-0.16	Joint mobility (Beighton score);	chr8:9017276	chr8:8961200~8979025:+
LUAD	cis	rs6493487	0.512	rs35845857	ENSG00000273674.3	CTD-2378E12.1	3.61	0.000342	0.0382	0.23	0.16	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50826694	chr15:50839875~50908599:-
LUAD	cis	rs4907240	0.961	rs7580048	ENSG00000237510.6	AC008268.2	-3.61	0.000342	0.0382	-0.23	-0.16	Event-related brain oscillations;	chr2:96638443	chr2:95789654~95800166:+
LUAD	cis	rs6088590	0.931	rs6088624	ENSG00000275784.1	RP5-1125A11.6	-3.61	0.000342	0.0382	-0.18	-0.16	Coronary artery disease;	chr20:34849049	chr20:33989480~33991818:-
LUAD	cis	rs7474896	0.806	rs1779150	ENSG00000226578.1	RP11-258F22.1	-3.61	0.000342	0.0382	-0.33	-0.16	Obesity (extreme);	chr10:37749759	chr10:37775371~37784131:-
LUAD	cis	rs875971	0.545	rs75577046	ENSG00000224316.1	RP11-479O9.2	3.61	0.000342	0.0382	0.19	0.16	Aortic root size;	chr7:66493729	chr7:65773620~65802067:+
LUAD	cis	rs8133949	0.638	rs35719508	ENSG00000237232.6	ZNF295-AS1	3.61	0.000342	0.0382	0.23	0.16	Hand grip strength;	chr21:41971289	chr21:42009194~42024924:+
LUAD	cis	rs4853525	0.59	rs1921910	ENSG00000235852.1	AC005540.3	3.61	0.000342	0.0382	0.21	0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190859206	chr2:190880797~190882059:-
LUAD	cis	rs3750965	0.575	rs3892895	ENSG00000260895.1	RP11-554A11.7	-3.61	0.000342	0.0382	-0.18	-0.16	Hair color;	chr11:69117287	chr11:69103493~69109094:+
LUAD	cis	rs7512898	0.522	rs7520287	ENSG00000260088.1	RP11-92G12.3	-3.61	0.000342	0.0382	-0.22	-0.16	Electrocardiographic conduction measures;	chr1:200781448	chr1:200669507~200694250:+
LUAD	cis	rs36093844	0.626	rs41381550	ENSG00000279742.1	RP11-700A24.1	3.61	0.000342	0.0382	0.19	0.16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85956045	chr11:85852557~85854943:-
LUAD	cis	rs4561483	0.514	rs33639	ENSG00000261560.1	RP11-166B2.3	-3.61	0.000342	0.0382	-0.15	-0.16	Testicular germ cell tumor;	chr16:11895642	chr16:11881075~11882569:-
LUAD	cis	rs4474465	1	rs10751290	ENSG00000251323.2	RP11-452H21.4	3.61	0.000342	0.0382	0.2	0.16	Alzheimer's disease (survival time);	chr11:78481661	chr11:78423982~78429836:-
LUAD	cis	rs4561483	0.583	rs11075032	ENSG00000261216.1	RP11-166B2.5	3.61	0.000342	0.0382	0.16	0.16	Testicular germ cell tumor;	chr16:11910593	chr16:11908208~11908916:+
LUAD	cis	rs533581	0.866	rs475796	ENSG00000261373.1	VPS9D1-AS1	-3.61	0.000342	0.0382	-0.19	-0.16	Social autistic-like traits;	chr16:88904368	chr16:89711856~89718165:+
LUAD	cis	rs7474896	0.515	rs688608	ENSG00000226578.1	RP11-258F22.1	3.61	0.000342	0.0382	0.24	0.16	Obesity (extreme);	chr10:38042696	chr10:37775371~37784131:-
LUAD	cis	rs115344852	0.575	rs1015811	ENSG00000216901.1	AL022393.7	3.61	0.000342	0.0382	0.2	0.16	Epithelial ovarian cancer;	chr6:28480309	chr6:28176188~28176674:+
LUAD	cis	rs7045881	0.674	rs62542705	ENSG00000254396.1	RP11-56F10.3	3.61	0.000342	0.0382	0.26	0.16	Schizophrenia;	chr9:27050025	chr9:27102630~27104728:+
LUAD	cis	rs73242632	0.749	rs11573061	ENSG00000269949.1	RP11-738E22.3	3.61	0.000342	0.0382	0.45	0.16	Congenital heart disease (maternal effect);	chr4:57076371	chr4:56960927~56961373:-
LUAD	cis	rs975752	1	rs10509741	ENSG00000227492.1	RP11-316M21.6	3.61	0.000342	0.0382	0.24	0.16	Schizophrenia;	chr10:100157609	chr10:100229667~100234000:+
LUAD	cis	rs1023500	0.596	rs5758562	ENSG00000205702.9	CYP2D7	3.61	0.000342	0.0382	0.14	0.16	Schizophrenia;	chr22:42052234	chr22:42140203~42144577:-
LUAD	cis	rs2664588	0.561	rs8119209	ENSG00000224565.1	RP1-148H17.1	-3.61	0.000342	0.0382	-0.17	-0.16	Cerebrospinal fluid AB1-42 levels;	chr20:47964834	chr20:47391929~47412327:-
LUAD	cis	rs1129187	0.967	rs3805952	ENSG00000261068.2	RP11-7K24.3	-3.61	0.000342	0.0382	-0.17	-0.16	Alzheimer's disease in APOE e4+ carriers;	chr6:42969388	chr6:42092233~42094259:-
LUAD	cis	rs1129187	0.967	rs3805951	ENSG00000261068.2	RP11-7K24.3	-3.61	0.000342	0.0382	-0.17	-0.16	Alzheimer's disease in APOE e4+ carriers;	chr6:42969438	chr6:42092233~42094259:-
LUAD	cis	rs12887734	0.524	rs4906364	ENSG00000258914.1	CTD-2134A5.3	-3.61	0.000342	0.0382	-0.19	-0.16	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103748005	chr14:103875055~103877478:+
LUAD	cis	rs867371	0.502	rs1846908	ENSG00000259429.4	UBE2Q2P2	-3.61	0.000342	0.0382	-0.14	-0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82230185	chr15:82355142~82420075:+
LUAD	cis	rs2665103	0.655	rs1501367	ENSG00000259429.4	UBE2Q2P2	-3.61	0.000342	0.0382	-0.14	-0.16	Intelligence (multi-trait analysis);	chr15:82230475	chr15:82355142~82420075:+
LUAD	cis	rs4423214	0.879	rs1792284	ENSG00000226627.1	SHANK2-AS1	-3.61	0.000342	0.0382	-0.19	-0.16	Vitamin D levels;	chr11:71423920	chr11:70631094~70635490:+
LUAD	cis	rs2625529	0.824	rs7182776	ENSG00000260173.1	RP11-2I17.4	3.61	0.000342	0.0382	0.21	0.16	Red blood cell count;	chr15:72170490	chr15:72140504~72155459:-
LUAD	cis	rs9652601	0.622	rs2286974	ENSG00000262222.1	RP11-876N24.4	-3.61	0.000342	0.0382	-0.14	-0.16	Systemic lupus erythematosus;	chr16:11020655	chr16:10940719~10943021:+
LUAD	cis	rs516805	0.561	rs9490497	ENSG00000279453.1	RP3-425C14.4	-3.61	0.000342	0.0382	-0.24	-0.16	Lymphocyte counts;	chr6:122615904	chr6:122436789~122439223:-
LUAD	cis	rs2024714	1	rs2427197	ENSG00000273812.1	WI2-87327B8.2	-3.61	0.000342	0.0382	-0.17	-0.16	Longevity;	chr20:61629274	chr20:62596732~62603115:-
LUAD	cis	rs2832191	0.967	rs3787660	ENSG00000215533.7	LINC00189	-3.61	0.000342	0.0382	-0.18	-0.16	Dental caries;	chr21:29148586	chr21:29193480~29288205:+
LUAD	cis	rs10463554	0.856	rs257292	ENSG00000250682.4	LINC00491	3.61	0.000342	0.0382	0.19	0.16	Parkinson's disease;	chr5:103159047	chr5:102609156~102671559:-
LUAD	cis	rs36093844	0.626	rs72959177	ENSG00000279742.1	RP11-700A24.1	-3.61	0.000342	0.0382	-0.19	-0.16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85988019	chr11:85852557~85854943:-
LUAD	cis	rs748404	0.666	rs72709879	ENSG00000249839.1	AC011330.5	-3.61	0.000342	0.0382	-0.25	-0.16	Lung cancer;	chr15:43507777	chr15:43663654~43684339:-
LUAD	cis	rs10859871	0.536	rs10859859	ENSG00000216306.3	KRT19P2	-3.61	0.000342	0.0383	-0.21	-0.16	Endometriosis;	chr12:95247746	chr12:94834147~94835158:+
LUAD	cis	rs987044	0.834	rs1035317	ENSG00000257221.1	RP11-689B22.2	-3.61	0.000343	0.0383	-0.14	-0.16	Mean platelet volume;	chr12:108801248	chr12:108628687~108641318:+
LUAD	cis	rs6832769	1	rs6834676	ENSG00000272969.1	RP11-528I4.2	3.61	0.000343	0.0383	0.17	0.16	Personality dimensions;	chr4:55432247	chr4:55547112~55547889:+
LUAD	cis	rs8046148	1	rs2058813	ENSG00000279356.1	RP11-429P3.8	-3.61	0.000343	0.0383	-0.18	-0.16	Testicular germ cell tumor;	chr16:50095543	chr16:50072862~50074986:+
LUAD	cis	rs697003	1	rs697003	ENSG00000231057.3	RP11-122M14.1	-3.61	0.000343	0.0383	-0.17	-0.16	Red cell distribution width;	chr1:211669734	chr1:211675762~211690103:+
LUAD	cis	rs56875752	1	rs72811279	ENSG00000263648.1	RP11-471L13.3	3.61	0.000343	0.0383	0.33	0.16	Fear of pain;Fear of severe pain;	chr17:12692895	chr17:12115547~12115885:+
LUAD	cis	rs4378999	0.623	rs6796642	ENSG00000273356.1	RP11-804H8.6	3.61	0.000343	0.0383	0.21	0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;	chr3:51053961	chr3:50669989~50672048:+
LUAD	cis	rs7940646	0.861	rs4909945	ENSG00000246308.1	RP11-685M7.3	-3.61	0.000343	0.0383	-0.19	-0.16	Platelet aggregation;	chr11:10652192	chr11:10809297~10822931:+
LUAD	cis	rs4727963	0.846	rs7805573	ENSG00000240499.6	RP5-1101C3.1	3.61	0.000343	0.0383	0.14	0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);	chr7:123059060	chr7:122328469~122440388:+
LUAD	cis	rs4727963	0.846	rs6466851	ENSG00000240499.6	RP5-1101C3.1	3.61	0.000343	0.0383	0.14	0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);	chr7:123059152	chr7:122328469~122440388:+
LUAD	cis	rs12502114	0.504	rs4069779	ENSG00000225356.3	RP11-433O3.1	3.61	0.000343	0.0383	0.17	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr4:181734019	chr4:181522666~181523001:+
LUAD	cis	rs1595014	0.508	rs7776839	ENSG00000226690.5	AC005281.1	3.61	0.000343	0.0383	0.2	0.16	Alzheimer's disease (APOE e4 interaction);	chr7:12171838	chr7:12496429~12541910:+
LUAD	cis	rs6728642	0.519	rs62152905	ENSG00000230606.9	AC159540.1	3.61	0.000343	0.0383	0.26	0.16	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96906485	chr2:97416165~97433527:-
LUAD	cis	rs6728642	0.519	rs72811651	ENSG00000230606.9	AC159540.1	3.61	0.000343	0.0383	0.26	0.16	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96906492	chr2:97416165~97433527:-
LUAD	cis	rs6728642	0.519	rs62152906	ENSG00000230606.9	AC159540.1	3.61	0.000343	0.0383	0.26	0.16	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96906533	chr2:97416165~97433527:-
LUAD	cis	rs683250	0.629	rs694566	ENSG00000246067.6	RAB30-AS1	3.61	0.000343	0.0383	0.17	0.16	Subcortical brain region volumes;	chr11:83228490	chr11:83072066~83106719:+
LUAD	cis	rs2880765	0.743	rs4551990	ENSG00000259630.2	CTD-2262B20.1	-3.61	0.000343	0.0383	-0.18	-0.16	Coronary artery disease;	chr15:85472056	chr15:85415228~85415633:+
LUAD	cis	rs8031584	0.918	rs1425292	ENSG00000260128.5	ULK4P2	-3.61	0.000343	0.0383	-0.21	-0.16	Huntington's disease progression;	chr15:30993219	chr15:30572738~30600647:+
LUAD	cis	rs9926296	0.585	rs1800337	ENSG00000260259.1	RP11-368I7.4	-3.61	0.000343	0.0383	-0.16	-0.16	Vitiligo;	chr16:89778786	chr16:89682620~89686569:-
LUAD	cis	rs10090774	0.813	rs11787221	ENSG00000280303.2	ERICD	-3.61	0.000343	0.0383	-0.18	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140708995	chr8:140636281~140638283:+
LUAD	cis	rs11955398	0.502	rs42437	ENSG00000272308.1	RP11-231G3.1	-3.61	0.000343	0.0383	-0.19	-0.16	Intelligence (multi-trait analysis);	chr5:61052219	chr5:60866457~60866935:-
LUAD	cis	rs4819052	0.851	rs914218	ENSG00000223768.1	LINC00205	-3.61	0.000343	0.0383	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278530	chr21:45293285~45297354:+
LUAD	cis	rs2625529	0.652	rs7497104	ENSG00000260173.1	RP11-2I17.4	-3.61	0.000343	0.0383	-0.19	-0.16	Red blood cell count;	chr15:71861659	chr15:72140504~72155459:-
LUAD	cis	rs3096299	0.933	rs889576	ENSG00000261574.1	RP1-168P16.2	-3.61	0.000343	0.0383	-0.18	-0.16	Multiple myeloma (IgH translocation);	chr16:89363245	chr16:89392375~89412564:-
LUAD	cis	rs1933112	1	rs1323534	ENSG00000213062.4	RP1-206D15.6	-3.61	0.000343	0.0383	-0.18	-0.16	Blood protein levels;	chr1:168534039	chr1:169486076~169486986:+
LUAD	cis	rs755249	0.567	rs67408364	ENSG00000182109.6	RP11-69E11.4	3.61	0.000343	0.0383	0.2	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39152884	chr1:39522280~39546187:-
LUAD	cis	rs3733585	0.753	rs1122141	ENSG00000250413.1	RP11-448G15.1	3.61	0.000343	0.0383	0.21	0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:9945654	chr4:10006482~10009725:+
LUAD	cis	rs78572108	0.925	rs4952585	ENSG00000214691.7	AC104654.1	3.61	0.000343	0.0383	0.26	0.16	Total body bone mineral density;	chr2:42042496	chr2:41877074~41894046:+
LUAD	cis	rs287982	0.611	rs111493633	ENSG00000269973.1	RP11-95D17.1	-3.61	0.000343	0.0383	-0.23	-0.16	Nonsyndromic cleft lip with cleft palate;	chr2:9840033	chr2:9936360~9939590:+
LUAD	cis	rs1046491	1	rs11081469	ENSG00000264964.1	RP11-888D10.3	3.61	0.000343	0.0383	0.34	0.16	Scarlet fever;	chr18:9276265	chr18:9315194~9334441:-
LUAD	cis	rs17597773	0.638	rs7530074	ENSG00000272823.1	RP11-295M18.6	-3.61	0.000343	0.0383	-0.21	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220815924	chr1:220828676~220829211:-
LUAD	cis	rs7200786	0.565	rs41369	ENSG00000274038.1	RP11-66H6.4	-3.61	0.000343	0.0383	-0.21	-0.16	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11160855	chr16:11056556~11057034:+
LUAD	cis	rs2837828	1	rs9636975	ENSG00000226496.2	LINC00323	3.61	0.000343	0.0383	0.21	0.16	Neutrophil count;	chr21:40798198	chr21:41141493~41148133:-
LUAD	cis	rs2548724	0.716	rs10515326	ENSG00000250682.4	LINC00491	3.61	0.000343	0.0383	0.2	0.16	Type 2 diabetes;	chr5:102478044	chr5:102609156~102671559:-
LUAD	cis	rs2243480	0.901	rs35823062	ENSG00000222364.1	RNU6-96P	-3.61	0.000343	0.0383	-0.27	-0.16	Diabetic kidney disease;	chr7:66500834	chr7:66395191~66395286:+
LUAD	cis	rs17507216	0.718	rs17158403	ENSG00000276710.3	CSPG4P8	-3.61	0.000343	0.0383	-0.18	-0.16	Excessive daytime sleepiness;	chr15:82572478	chr15:82459472~82477258:+
LUAD	cis	rs9309711	0.961	rs11890651	ENSG00000271868.1	RP11-1293J14.1	-3.61	0.000343	0.0383	-0.18	-0.16	Neurofibrillary tangles;	chr2:3479025	chr2:3496956~3497428:+
LUAD	cis	rs6728642	0.519	rs6718420	ENSG00000230606.9	AC159540.1	3.61	0.000343	0.0383	0.26	0.16	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96906733	chr2:97416165~97433527:-
LUAD	cis	rs763121	0.785	rs5750646	ENSG00000228274.3	RP3-508I15.9	-3.61	0.000343	0.0383	-0.15	-0.16	Menopause (age at onset);	chr22:38617825	chr22:38667585~38681820:-
LUAD	cis	rs2985684	0.894	rs7152110	ENSG00000278009.1	RP11-649E7.8	3.61	0.000343	0.0383	0.21	0.16	Carotid intima media thickness;	chr14:49551500	chr14:49601011~49601124:-
LUAD	cis	rs394563	0.591	rs237028	ENSG00000216906.2	RP11-350J20.9	3.61	0.000343	0.0383	0.19	0.16	Dupuytren's disease;	chr6:149397514	chr6:149904243~149906418:+
LUAD	cis	rs11118883	0.53	rs12126771	ENSG00000228437.4	RP11-400N13.2	3.61	0.000343	0.0383	0.2	0.16	Colorectal cancer;	chr1:221917222	chr1:221966341~221984964:+
LUAD	cis	rs3772130	1	rs62268732	ENSG00000243544.3	RN7SL172P	3.61	0.000343	0.0383	0.2	0.16	Cognitive performance;	chr3:121651608	chr3:121653994~121654296:-
LUAD	cis	rs4718428	0.705	rs4717331	ENSG00000230295.1	RP11-458F8.2	-3.61	0.000343	0.0383	-0.14	-0.16	Corneal structure;	chr7:66913899	chr7:66880708~66882981:+
LUAD	cis	rs1910358	0.638	rs6887361	ENSG00000248874.4	C5orf17	-3.61	0.000343	0.0383	-0.21	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23950889	chr5:23951348~24178263:+
LUAD	cis	rs4767841	1	rs4767839	ENSG00000248636.5	RP11-768F21.1	-3.61	0.000343	0.0383	-0.19	-0.16	Urgency urinary incontinence;	chr12:119722317	chr12:119387987~119668079:-
LUAD	cis	rs9921338	0.509	rs7190050	ENSG00000277369.1	RP11-486I11.2	-3.61	0.000343	0.0383	-0.17	-0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11348225	chr16:11797468~11798275:+
LUAD	cis	rs8062405	0.964	rs62036614	ENSG00000261419.1	RP11-57A19.4	-3.61	0.000343	0.0383	-0.18	-0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28659696~28740781:-
LUAD	cis	rs7546668	1	rs1467513	ENSG00000272510.1	RP4-680D5.8	3.61	0.000343	0.0383	0.21	0.16	Glomerular filtration rate (creatinine);	chr1:15568464	chr1:15565611~15565956:-
LUAD	cis	rs34638657	0.518	rs2288050	ENSG00000261235.1	RP11-510J16.5	-3.61	0.000343	0.0383	-0.2	-0.16	Lung adenocarcinoma;	chr16:82149798	chr16:82044336~82139631:-
LUAD	cis	rs2414856	0.51	rs72758928	ENSG00000259635.1	AC100830.3	-3.61	0.000344	0.0383	-0.4	-0.16	Pulse pressure;Systolic blood pressure;	chr15:64365485	chr15:64701248~64719602:+
LUAD	cis	rs2414856	0.51	rs72758930	ENSG00000259635.1	AC100830.3	-3.61	0.000344	0.0383	-0.4	-0.16	Pulse pressure;Systolic blood pressure;	chr15:64368654	chr15:64701248~64719602:+
LUAD	cis	rs2414856	0.51	rs72758931	ENSG00000259635.1	AC100830.3	-3.61	0.000344	0.0383	-0.4	-0.16	Pulse pressure;Systolic blood pressure;	chr15:64369025	chr15:64701248~64719602:+
LUAD	cis	rs2414856	0.51	rs72758937	ENSG00000259635.1	AC100830.3	-3.61	0.000344	0.0383	-0.4	-0.16	Pulse pressure;Systolic blood pressure;	chr15:64375731	chr15:64701248~64719602:+
LUAD	cis	rs35094601	0.704	rs13396774	ENSG00000228043.4	AC097721.2	3.61	0.000344	0.0383	0.18	0.16	Schizophrenia;	chr2:138471656	chr2:138418284~138501698:-
LUAD	cis	rs35094601	0.731	rs12468073	ENSG00000228043.4	AC097721.2	3.61	0.000344	0.0383	0.18	0.16	Schizophrenia;	chr2:138472117	chr2:138418284~138501698:-
LUAD	cis	rs35094601	0.731	rs13384399	ENSG00000228043.4	AC097721.2	3.61	0.000344	0.0383	0.18	0.16	Schizophrenia;	chr2:138472319	chr2:138418284~138501698:-
LUAD	cis	rs782590	0.582	rs2627767	ENSG00000272606.1	RP11-554J4.1	-3.61	0.000344	0.0383	-0.16	-0.16	Metabolic syndrome;	chr2:55699680	chr2:55617909~55618373:+
LUAD	cis	rs67981189	0.896	rs8016506	ENSG00000269927.1	RP6-91H8.3	3.61	0.000344	0.0383	0.2	0.16	Schizophrenia;	chr14:71039600	chr14:71141125~71143253:-
LUAD	cis	rs67981189	0.858	rs35631530	ENSG00000269927.1	RP6-91H8.3	3.61	0.000344	0.0383	0.2	0.16	Schizophrenia;	chr14:71041312	chr14:71141125~71143253:-
LUAD	cis	rs1876905	0.68	rs187130	ENSG00000271789.1	RP5-1112D6.7	-3.61	0.000344	0.0384	-0.22	-0.16	Mean corpuscular hemoglobin;	chr6:111188360	chr6:111297126~111298510:+
LUAD	cis	rs11673344	0.864	rs7247589	ENSG00000267309.1	CTD-2630F21.1	-3.61	0.000344	0.0384	-0.21	-0.16	Obesity-related traits;	chr19:37019879	chr19:36489649~36491040:+
LUAD	cis	rs216345	0.7	rs307660	ENSG00000200834.1	Y_RNA	-3.61	0.000344	0.0384	-0.16	-0.16	Bipolar disorder;	chr9:33942932	chr9:33830978~33831078:+
LUAD	cis	rs6822297	0.905	rs724624	ENSG00000240005.4	RP11-293A21.1	-3.61	0.000344	0.0384	-0.2	-0.16	Obesity-related traits;	chr4:27014099	chr4:26859806~26860599:-
LUAD	cis	rs62246343	0.605	rs17746498	ENSG00000206573.7	THUMPD3-AS1	-3.61	0.000344	0.0384	-0.16	-0.16	Fibrinogen levels;	chr3:9411976	chr3:9349689~9398579:-
LUAD	cis	rs2832270	0.915	rs2832260	ENSG00000174680.8	GRIK1-AS1	3.61	0.000344	0.0384	0.34	0.16	Response to mTOR inhibitor (everolimus);	chr21:29212486	chr21:29748175~29764002:+
LUAD	cis	rs2904524	1	rs9804870	ENSG00000257815.4	RP11-611E13.2	-3.61	0.000344	0.0384	-0.22	-0.16	Amyotrophic lateral sclerosis (age of onset);	chr12:70346955	chr12:69904033~70243360:-
LUAD	cis	rs1722141	0.634	rs2453850	ENSG00000237471.1	AC073115.6	3.61	0.000344	0.0384	0.25	0.16	Sitting height ratio;	chr7:45941135	chr7:45969657~45980191:+
LUAD	cis	rs7613875	0.641	rs6446194	ENSG00000234667.1	ACTBP13	3.61	0.000344	0.0384	0.18	0.16	Body mass index;	chr3:50029865	chr3:49873347~49877980:-
LUAD	cis	rs12681963	1	rs6468131	ENSG00000272375.1	RP11-51J9.6	-3.61	0.000344	0.0384	-0.22	-0.16	Migraine;	chr8:30123504	chr8:30197404~30198048:+
LUAD	cis	rs35123781	0.696	rs10067965	ENSG00000250635.1	CTD-3224K15.2	-3.61	0.000344	0.0384	-0.19	-0.16	Schizophrenia;	chr5:139691768	chr5:139648999~139649728:-
LUAD	cis	rs7584330	0.738	rs13398506	ENSG00000222032.1	AC112721.2	3.61	0.000344	0.0384	0.19	0.16	Prostate cancer;	chr2:237466181	chr2:237428920~237434822:-
LUAD	cis	rs7584330	0.738	rs4402703	ENSG00000222032.1	AC112721.2	3.61	0.000344	0.0384	0.19	0.16	Prostate cancer;	chr2:237466314	chr2:237428920~237434822:-
LUAD	cis	rs1040393	0.522	rs2049910	ENSG00000225171.2	DUTP6	-3.61	0.000344	0.0384	-0.23	-0.16	Schizophrenia;	chr1:166862888	chr1:166868748~166869209:+
LUAD	cis	rs1322639	0.614	rs6925201	ENSG00000261039.2	RP11-417E7.2	3.61	0.000344	0.0384	0.25	0.16	Pulse pressure;	chr6:169163262	chr6:169175304~169182740:-
LUAD	cis	rs12908161	1	rs35316992	ENSG00000254414.1	RP11-182J1.1	3.61	0.000344	0.0384	0.21	0.16	Schizophrenia;	chr15:84704902	chr15:84631898~84633987:-
LUAD	cis	rs12908161	1	rs4643294	ENSG00000254414.1	RP11-182J1.1	3.61	0.000344	0.0384	0.21	0.16	Schizophrenia;	chr15:84707022	chr15:84631898~84633987:-
LUAD	cis	rs12908161	1	rs62021219	ENSG00000254414.1	RP11-182J1.1	3.61	0.000344	0.0384	0.21	0.16	Schizophrenia;	chr15:84712928	chr15:84631898~84633987:-
LUAD	cis	rs12908161	1	rs34900908	ENSG00000254414.1	RP11-182J1.1	3.61	0.000344	0.0384	0.21	0.16	Schizophrenia;	chr15:84714368	chr15:84631898~84633987:-
LUAD	cis	rs12908161	1	rs35524990	ENSG00000254414.1	RP11-182J1.1	3.61	0.000344	0.0384	0.21	0.16	Schizophrenia;	chr15:84714972	chr15:84631898~84633987:-
LUAD	cis	rs5758659	0.652	rs133336	ENSG00000227370.1	RP4-669P10.19	-3.61	0.000344	0.0384	-0.15	-0.16	Cognitive function;	chr22:42020299	chr22:42132543~42132998:+
LUAD	cis	rs9549260	0.564	rs6563845	ENSG00000168852.11	TPTE2P5	3.61	0.000344	0.0384	0.16	0.16	Red blood cell count;	chr13:40744771	chr13:40822296~40921749:-
LUAD	cis	rs3849150	0.95	rs34546247	ENSG00000235939.1	RP11-123B3.2	-3.61	0.000344	0.0384	-0.23	-0.16	Subclinical atherosclerosis traits (other);	chr10:48882584	chr10:49419277~49472903:+
LUAD	cis	rs3126085	0.877	rs868304	ENSG00000237975.5	FLG-AS1	-3.61	0.000344	0.0384	-0.25	-0.16	Atopic dermatitis;	chr1:152206092	chr1:152168125~152445456:+
LUAD	cis	rs3126085	0.935	rs2291770	ENSG00000237975.5	FLG-AS1	-3.61	0.000344	0.0384	-0.25	-0.16	Atopic dermatitis;	chr1:152207316	chr1:152168125~152445456:+
LUAD	cis	rs3126085	0.935	rs10888468	ENSG00000237975.5	FLG-AS1	-3.61	0.000344	0.0384	-0.25	-0.16	Atopic dermatitis;	chr1:152209063	chr1:152168125~152445456:+
LUAD	cis	rs3126085	0.935	rs4421596	ENSG00000237975.5	FLG-AS1	-3.61	0.000344	0.0384	-0.25	-0.16	Atopic dermatitis;	chr1:152209197	chr1:152168125~152445456:+
LUAD	cis	rs7688540	0.8	rs11731285	ENSG00000211553.1	AC253576.2	-3.61	0.000344	0.0384	-0.21	-0.16	Facial morphology (factor 6, height of vermillion lower lip);	chr4:271152	chr4:136461~136568:+
LUAD	cis	rs116139393	0.505	rs3801033	ENSG00000187953.9	PMS2CL	3.61	0.000344	0.0384	0.18	0.16	Alzheimer's disease (APOE e4 interaction);	chr7:6694472	chr7:6710128~6753862:+
LUAD	cis	rs2736345	0.788	rs9693589	ENSG00000270154.1	RP11-419I17.1	3.61	0.000344	0.0384	0.22	0.16	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11491452	chr8:12476462~12477122:+
LUAD	cis	rs2736345	0.788	rs13277113	ENSG00000270154.1	RP11-419I17.1	3.61	0.000344	0.0384	0.22	0.16	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11491677	chr8:12476462~12477122:+
LUAD	cis	rs3749855	0.62	rs35275668	ENSG00000220920.1	RP3-525L6.2	3.61	0.000344	0.0384	0.33	0.16	Glucose homeostasis traits;	chr6:17259036	chr6:17953572~17953930:+
LUAD	cis	rs2274273	0.624	rs7159824	ENSG00000258413.1	RP11-665C16.6	-3.61	0.000344	0.0384	-0.22	-0.16	Protein biomarker;	chr14:55305818	chr14:55262767~55272075:-
LUAD	cis	rs2380205	0.967	rs12774966	ENSG00000232807.2	RP11-536K7.3	3.61	0.000344	0.0384	0.17	0.16	Breast cancer;	chr10:5856135	chr10:5934270~5945900:-
LUAD	cis	rs6001482	0.679	rs1894238	ENSG00000253818.1	IGLV1-41	-3.61	0.000344	0.0384	-0.17	-0.16	Diastolic blood pressure;	chr22:22235704	chr22:22404207~22404721:+
LUAD	cis	rs4811196	1	rs17786860	ENSG00000226144.2	RPS27AP3	-3.61	0.000344	0.0384	-0.2	-0.16	Bone mineral density;	chr20:37839237	chr20:37049254~37049707:+
LUAD	cis	rs683250	0.661	rs2510475	ENSG00000246067.6	RAB30-AS1	3.61	0.000344	0.0384	0.17	0.16	Subcortical brain region volumes;	chr11:83412261	chr11:83072066~83106719:+
LUAD	cis	rs319690	1	rs319690	ENSG00000228638.1	FCF1P2	-3.61	0.000345	0.0384	-0.19	-0.16	Diastolic blood pressure;Systolic blood pressure;Blood pressure;	chr3:47885994	chr3:48290793~48291375:-
LUAD	cis	rs6787172	0.811	rs9883657	ENSG00000272087.1	RP11-379F4.7	-3.61	0.000345	0.0384	-0.17	-0.16	Subjective well-being;	chr3:158508210	chr3:158693120~158693768:-
LUAD	cis	rs1348850	0.632	rs13009207	ENSG00000213963.5	AC074286.1	3.61	0.000345	0.0384	0.2	0.16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177636904	chr2:177283508~177392691:-
LUAD	cis	rs75920871	0.589	rs67201490	ENSG00000280143.1	AP000892.6	3.61	0.000345	0.0384	0.25	0.16	Subjective well-being;	chr11:117212288	chr11:117204967~117210292:+
LUAD	cis	rs9532669	0.926	rs9525438	ENSG00000168852.11	TPTE2P5	3.61	0.000345	0.0384	0.16	0.16	Cervical cancer;	chr13:40964123	chr13:40822296~40921749:-
LUAD	cis	rs10170310	0.938	rs11680891	ENSG00000228043.4	AC097721.2	3.61	0.000345	0.0384	0.23	0.16	Response to antipsychotic treatment;	chr2:138506884	chr2:138418284~138501698:-
LUAD	cis	rs10934524	0.715	rs10934513	ENSG00000243547.1	HNRNPKP4	-3.61	0.000345	0.0384	-0.12	-0.16	Longevity;	chr3:96425393	chr3:96349554~96350939:+
LUAD	cis	rs10510102	1	rs6585764	ENSG00000276742.1	RP11-500G22.4	3.6	0.000345	0.0385	0.25	0.16	Breast cancer;	chr10:121837308	chr10:121956782~121957098:+
LUAD	cis	rs2613514	0.527	rs2290906	ENSG00000204282.4	TNRC6C-AS1	-3.6	0.000345	0.0385	-0.2	-0.16	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr17:78097785	chr17:78107398~78111799:-
LUAD	cis	rs9475752	0.947	rs17752435	ENSG00000231441.1	RP11-472M19.2	3.6	0.000345	0.0385	0.25	0.16	Menarche (age at onset);	chr6:56926697	chr6:56844002~56864078:+
LUAD	cis	rs11118883	0.559	rs12748885	ENSG00000228437.4	RP11-400N13.2	3.6	0.000345	0.0385	0.2	0.16	Colorectal cancer;	chr1:221921501	chr1:221966341~221984964:+
LUAD	cis	rs12073837	0.784	rs61830289	ENSG00000272823.1	RP11-295M18.6	-3.6	0.000345	0.0385	-0.2	-0.16	F-cell distribution;	chr1:220815400	chr1:220828676~220829211:-
LUAD	cis	rs12073837	0.784	rs35730037	ENSG00000272823.1	RP11-295M18.6	-3.6	0.000345	0.0385	-0.2	-0.16	F-cell distribution;	chr1:220815403	chr1:220828676~220829211:-
LUAD	cis	rs11779988	0.545	rs422746	ENSG00000253671.1	RP11-806O11.1	-3.6	0.000345	0.0385	-0.2	-0.16	Breast cancer;	chr8:17926977	chr8:17808941~17820868:+
LUAD	cis	rs858239	0.539	rs6945510	ENSG00000226816.2	AC005082.12	3.6	0.000345	0.0385	0.21	0.16	Cerebrospinal fluid biomarker levels;	chr7:23152621	chr7:23206013~23208045:+
LUAD	cis	rs526231	0.543	rs42431	ENSG00000250682.4	LINC00491	-3.6	0.000345	0.0385	-0.2	-0.16	Primary biliary cholangitis;	chr5:103064359	chr5:102609156~102671559:-
LUAD	cis	rs73108077	1	rs117762506	ENSG00000281376.1	ABALON	-3.6	0.000345	0.0385	-0.28	-0.16	Red blood cell density in sickle cell anemia;	chr20:31467935	chr20:31721507~31723409:+
LUAD	cis	rs4938642	0.822	rs73564406	ENSG00000254909.1	RP11-110I1.5	3.6	0.000345	0.0385	0.21	0.16	Platelet count;	chr11:119163141	chr11:119005727~119005934:-
LUAD	cis	rs4713118	0.868	rs7756968	ENSG00000280107.1	AL022393.9	-3.6	0.000345	0.0385	-0.22	-0.16	Parkinson's disease;	chr6:27767175	chr6:28170845~28172521:+
LUAD	cis	rs6472827	0.645	rs2956058	ENSG00000253983.2	RP1-16A9.1	3.6	0.000345	0.0385	0.23	0.16	Uterine fibroids;	chr8:74197824	chr8:74199396~74208441:+
LUAD	cis	rs12146727	0.881	rs7183	ENSG00000247853.2	RP5-940J5.6	3.6	0.000345	0.0385	0.26	0.16	Blood protein levels;	chr12:7070715	chr12:6578622~6584739:+
LUAD	cis	rs8073060	0.516	rs2376177	ENSG00000267592.1	CTC-507E2.2	3.6	0.000345	0.0385	0.24	0.16	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35611070	chr17:35596904~35597128:-
LUAD	cis	rs8073060	0.586	rs225250	ENSG00000267592.1	CTC-507E2.2	3.6	0.000345	0.0385	0.24	0.16	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35614944	chr17:35596904~35597128:-
LUAD	cis	rs8073060	0.544	rs225249	ENSG00000267592.1	CTC-507E2.2	3.6	0.000345	0.0385	0.24	0.16	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35615521	chr17:35596904~35597128:-
LUAD	cis	rs7621025	0.5	rs9845460	ENSG00000273486.1	RP11-731C17.2	3.6	0.000345	0.0385	0.17	0.16	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136868275	chr3:136837338~136839021:-
LUAD	cis	rs7560272	0.501	rs13003035	ENSG00000163016.8	ALMS1P	-3.6	0.000345	0.0385	-0.17	-0.16	Schizophrenia;	chr2:73730100	chr2:73644919~73685576:+
LUAD	cis	rs7208859	0.778	rs6505219	ENSG00000263603.1	CTD-2349P21.5	-3.6	0.000345	0.0385	-0.23	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30938603	chr17:30729469~30731202:+
LUAD	cis	rs4716602	0.794	rs10242287	ENSG00000235029.1	MNX1-AS2	-3.6	0.000345	0.0385	-0.2	-0.16	Anti-saccade response;	chr7:156369716	chr7:157006307~157007132:+
LUAD	cis	rs9921338	0.961	rs9937269	ENSG00000263080.1	RP11-485G7.5	-3.6	0.000345	0.0385	-0.22	-0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11322822	chr16:11341809~11345211:-
LUAD	cis	rs6496932	1	rs11638110	ENSG00000218052.5	ADAMTS7P4	3.6	0.000345	0.0385	0.21	0.16	Central corneal thickness;Corneal structure;	chr15:85279653	chr15:85255369~85330334:-
LUAD	cis	rs1198430	0.683	rs7551124	ENSG00000232482.2	RP4-654C18.1	-3.6	0.000345	0.0385	-0.24	-0.16	Total cholesterol levels;	chr1:23459267	chr1:23410832~23412146:+
LUAD	cis	rs6661961	0.752	rs4845436	ENSG00000237975.5	FLG-AS1	-3.6	0.000345	0.0385	-0.22	-0.16	Atopic dermatitis;	chr1:152451483	chr1:152168125~152445456:+
LUAD	cis	rs12073359	1	rs7520930	ENSG00000223945.2	RP11-458I7.1	3.6	0.000345	0.0385	0.22	0.16	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150065560	chr1:150053864~150055034:+
LUAD	cis	rs11603023	0.874	rs483598	ENSG00000278376.1	RP11-158I9.8	-3.6	0.000345	0.0385	-0.17	-0.16	Cholesterol, total;	chr11:118638950	chr11:118791254~118793137:+
LUAD	cis	rs4268898	0.662	rs714531	ENSG00000242628.4	AC009228.1	3.6	0.000345	0.0385	0.24	0.16	Asthma;	chr2:24177008	chr2:24214381~24221516:+
LUAD	cis	rs1979679	0.573	rs4931087	ENSG00000278733.1	RP11-425D17.1	3.6	0.000345	0.0385	0.2	0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28582158	chr12:28185625~28186190:-
LUAD	cis	rs755249	0.917	rs61779330	ENSG00000182109.6	RP11-69E11.4	3.6	0.000345	0.0385	0.19	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39501551	chr1:39522280~39546187:-
LUAD	cis	rs755249	0.876	rs72662001	ENSG00000182109.6	RP11-69E11.4	3.6	0.000345	0.0385	0.19	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39501608	chr1:39522280~39546187:-
LUAD	cis	rs73230612	1	rs980944	ENSG00000242767.1	ZBTB20-AS4	-3.6	0.000345	0.0385	-0.25	-0.16	Type 2 diabetes;	chr3:115210665	chr3:115100423~115103061:+
LUAD	cis	rs9291683	0.588	rs12507330	ENSG00000250413.1	RP11-448G15.1	-3.6	0.000346	0.0385	-0.21	-0.16	Bone mineral density;	chr4:10000571	chr4:10006482~10009725:+
LUAD	cis	rs11853189	0.938	rs75369292	ENSG00000259562.2	RP11-762H8.2	3.6	0.000346	0.0385	0.18	0.16	Red cell distribution width;	chr15:78263015	chr15:78290527~78291221:-
LUAD	cis	rs11853189	0.938	rs77185764	ENSG00000259562.2	RP11-762H8.2	3.6	0.000346	0.0385	0.18	0.16	Red cell distribution width;	chr15:78263734	chr15:78290527~78291221:-
LUAD	cis	rs11853189	0.882	rs78827644	ENSG00000259562.2	RP11-762H8.2	3.6	0.000346	0.0385	0.18	0.16	Red cell distribution width;	chr15:78263908	chr15:78290527~78291221:-
LUAD	cis	rs11853189	0.882	rs79052265	ENSG00000259562.2	RP11-762H8.2	3.6	0.000346	0.0385	0.18	0.16	Red cell distribution width;	chr15:78263916	chr15:78290527~78291221:-
LUAD	cis	rs11853189	0.873	rs117636273	ENSG00000259562.2	RP11-762H8.2	3.6	0.000346	0.0385	0.18	0.16	Red cell distribution width;	chr15:78264553	chr15:78290527~78291221:-
LUAD	cis	rs11853189	0.938	rs113594982	ENSG00000259562.2	RP11-762H8.2	3.6	0.000346	0.0385	0.18	0.16	Red cell distribution width;	chr15:78265050	chr15:78290527~78291221:-
LUAD	cis	rs786425	0.77	rs7306549	ENSG00000278112.1	RP11-972P1.11	3.6	0.000346	0.0385	0.15	0.16	Pubertal anthropometrics;	chr12:123672350	chr12:123519390~123519856:-
LUAD	cis	rs4578769	0.531	rs768793	ENSG00000266850.1	RP11-370A5.1	3.6	0.000346	0.0385	0.21	0.16	Eosinophil percentage of white cells;	chr18:22976640	chr18:22723491~22907721:-
LUAD	cis	rs2731006	0.592	rs2678152	ENSG00000257114.2	RP11-25I15.3	3.6	0.000346	0.0385	0.27	0.16	Panic disorder;	chr12:42779257	chr12:42692216~42717119:+
LUAD	cis	rs2408955	0.522	rs6580650	ENSG00000257763.1	OR5BK1P	-3.6	0.000346	0.0385	-0.17	-0.16	Glycated hemoglobin levels;	chr12:48024773	chr12:48355792~48356614:-
LUAD	cis	rs11951515	0.508	rs6898866	ENSG00000248240.1	RP11-159F24.5	-3.6	0.000346	0.0385	-0.17	-0.16	Metabolite levels  (X-11787);	chr5:43586273	chr5:43515274~43525310:+
LUAD	cis	rs4819052	0.851	rs2255766	ENSG00000215447.6	BX322557.10	-3.6	0.000346	0.0385	-0.19	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263862	chr21:45288052~45291738:+
LUAD	cis	rs4948102	0.667	rs7811270	ENSG00000275875.1	RP11-613E4.5	-3.6	0.000346	0.0385	-0.18	-0.16	Plasma homocysteine levels (post-methionine load test);	chr7:56072297	chr7:55741525~55741869:+
LUAD	cis	rs3126085	0.825	rs10788830	ENSG00000237975.5	FLG-AS1	-3.6	0.000346	0.0385	-0.25	-0.16	Atopic dermatitis;	chr1:152234422	chr1:152168125~152445456:+
LUAD	cis	rs1150668	0.796	rs1005125	ENSG00000176933.5	TOB2P1	-3.6	0.000346	0.0385	-0.18	-0.16	Pubertal anthropometrics;	chr6:28399578	chr6:28217643~28218634:-
LUAD	cis	rs12073359	0.955	rs4926411	ENSG00000223945.2	RP11-458I7.1	3.6	0.000346	0.0385	0.23	0.16	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150165577	chr1:150053864~150055034:+
LUAD	cis	rs2749097	0.609	rs2269245	ENSG00000244256.3	RN7SL130P	-3.6	0.000346	0.0385	-0.22	-0.16	Alcohol consumption (transferrin glycosylation);	chr1:63642222	chr1:63655743~63656047:+
LUAD	cis	rs6741892	0.536	rs11688977	ENSG00000231312.5	AC007246.3	3.6	0.000346	0.0386	0.3	0.16	5-HTT brain serotonin transporter levels;	chr2:38669489	chr2:39436637~39665343:+
LUAD	cis	rs1387259	0.79	rs2732445	ENSG00000273765.1	RP11-370I10.11	3.6	0.000346	0.0386	0.18	0.16	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48251750	chr12:48360920~48361377:+
LUAD	cis	rs3096299	0.781	rs3102381	ENSG00000261574.1	RP1-168P16.2	3.6	0.000346	0.0386	0.17	0.16	Multiple myeloma (IgH translocation);	chr16:89343312	chr16:89392375~89412564:-
LUAD	cis	rs806321	0.619	rs1359613	ENSG00000237152.3	DLEU7-AS1	-3.6	0.000346	0.0386	-0.2	-0.16	Multiple sclerosis;	chr13:50192104	chr13:50807856~50849905:+
LUAD	cis	rs11100904	0.967	rs13104870	ENSG00000250673.1	RP11-6L6.2	-3.6	0.000346	0.0386	-0.17	-0.16	Dental caries;	chr4:145982337	chr4:146224557~146229056:+
LUAD	cis	rs13398147	0.879	rs4510218	ENSG00000267034.1	RP11-384O8.1	3.6	0.000346	0.0386	0.23	0.16	Adolescent idiopathic scoliosis;	chr2:221861668	chr2:222317242~222318653:-
LUAD	cis	rs7246657	0.941	rs7256130	ENSG00000226686.6	LINC01535	-3.6	0.000346	0.0386	-0.23	-0.16	Coronary artery calcification;	chr19:37443079	chr19:37251912~37265535:+
LUAD	cis	rs11233413	0.794	rs66653310	ENSG00000246067.6	RAB30-AS1	3.6	0.000346	0.0386	0.17	0.16	Economic and political preferences (feminism/equality);	chr11:83005958	chr11:83072066~83106719:+
LUAD	cis	rs3096299	0.838	rs4785561	ENSG00000182376.2	RP5-1142A6.8	3.6	0.000346	0.0386	0.16	0.16	Multiple myeloma (IgH translocation);	chr16:89362644	chr16:88742767~88745748:+
LUAD	cis	rs1023500	0.596	rs5751209	ENSG00000205702.9	CYP2D7	3.6	0.000346	0.0386	0.14	0.16	Schizophrenia;	chr22:42055599	chr22:42140203~42144577:-
LUAD	cis	rs321358	1	rs321360	ENSG00000271390.1	RP11-89C3.3	3.6	0.000346	0.0386	0.27	0.16	Body mass index;	chr11:111125346	chr11:111089870~111090368:-
LUAD	cis	rs72647484	0.554	rs2807321	ENSG00000234397.3	RP11-415K20.1	-3.6	0.000346	0.0386	-0.32	-0.16	Colorectal cancer;	chr1:22228398	chr1:22322840~22323331:-
LUAD	cis	rs17608059	0.611	rs2108591	ENSG00000236088.8	COX10-AS1	-3.6	0.000346	0.0386	-0.18	-0.16	Temperament;	chr17:14019308	chr17:13756478~14069495:-
LUAD	cis	rs4144027	0.869	rs55924227	ENSG00000258914.1	CTD-2134A5.3	-3.6	0.000346	0.0386	-0.19	-0.16	Blood metabolite levels;	chr14:103895013	chr14:103875055~103877478:+
LUAD	cis	rs1009115	0.551	rs6965848	ENSG00000229970.3	AC007128.1	-3.6	0.000346	0.0386	-0.21	-0.16	Post bronchodilator FEV1;	chr7:8373021	chr7:8262264~8344516:+
LUAD	cis	rs10863681	0.738	rs7513781	ENSG00000227925.1	RP11-191N8.2	3.6	0.000346	0.0386	0.18	0.16	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222066590	chr1:221827666~221840666:-
LUAD	cis	rs9921338	0.961	rs4781055	ENSG00000263080.1	RP11-485G7.5	3.6	0.000346	0.0386	0.22	0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11275571	chr16:11341809~11345211:-
LUAD	cis	rs4716602	0.596	rs10253193	ENSG00000236018.2	RP4-814D15.1	-3.6	0.000346	0.0386	-0.17	-0.16	Anti-saccade response;	chr7:156365107	chr7:157197600~157198511:-
LUAD	cis	rs116095464	0.51	rs73016876	ENSG00000250848.1	CTD-2083E4.5	-3.6	0.000347	0.0386	-0.21	-0.16	Breast cancer;	chr5:244360	chr5:288833~290321:-
LUAD	cis	rs7216064	1	rs12451707	ENSG00000266717.1	RP11-855A2.3	3.6	0.000347	0.0386	0.2	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67875482	chr17:67950885~67951746:-
LUAD	cis	rs11512640	0.826	rs74986931	ENSG00000254671.2	STT3A-AS1	3.6	0.000347	0.0386	0.39	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125573240	chr11:125570284~125592568:-
LUAD	cis	rs11512640	0.826	rs78682798	ENSG00000254671.2	STT3A-AS1	3.6	0.000347	0.0386	0.39	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125575621	chr11:125570284~125592568:-
LUAD	cis	rs881375	0.933	rs7028641	ENSG00000238181.2	AHCYP2	-3.6	0.000347	0.0386	-0.2	-0.16	Rheumatoid arthritis;	chr9:120928863	chr9:120720673~120721972:+
LUAD	cis	rs2664588	0.566	rs6018817	ENSG00000224565.1	RP1-148H17.1	-3.6	0.000347	0.0386	-0.17	-0.16	Cerebrospinal fluid AB1-42 levels;	chr20:47963424	chr20:47391929~47412327:-
LUAD	cis	rs858239	0.799	rs10279941	ENSG00000230042.1	AK3P3	-3.6	0.000347	0.0386	-0.21	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23330889	chr7:23129178~23129841:+
LUAD	cis	rs7829975	0.54	rs2976909	ENSG00000254340.1	RP11-10A14.3	-3.6	0.000347	0.0386	-0.19	-0.16	Mood instability;	chr8:8489180	chr8:9141424~9145435:+
LUAD	cis	rs7119038	0.818	rs76704408	ENSG00000255239.1	AP002954.6	-3.6	0.000347	0.0386	-0.23	-0.16	Sjögren's syndrome;	chr11:118812618	chr11:118688039~118690600:-
LUAD	cis	rs11064837	0.504	rs10774508	ENSG00000248636.5	RP11-768F21.1	3.6	0.000347	0.0386	0.19	0.16	Schizophrenia;	chr12:119632301	chr12:119387987~119668079:-
LUAD	cis	rs17695224	0.565	rs61681419	ENSG00000269483.1	AC006272.1	3.6	0.000347	0.0386	0.18	0.16	HDL cholesterol;HDL cholesterol levels;	chr19:51830726	chr19:51839924~51843324:-
LUAD	cis	rs17695224	0.545	rs13346095	ENSG00000269483.1	AC006272.1	3.6	0.000347	0.0386	0.18	0.16	HDL cholesterol;HDL cholesterol levels;	chr19:51831092	chr19:51839924~51843324:-
LUAD	cis	rs17695224	0.5	rs13346104	ENSG00000269483.1	AC006272.1	3.6	0.000347	0.0386	0.18	0.16	HDL cholesterol;HDL cholesterol levels;	chr19:51831173	chr19:51839924~51843324:-
LUAD	cis	rs41271951	0.518	rs12145630	ENSG00000223945.2	RP11-458I7.1	-3.6	0.000347	0.0386	-0.29	-0.16	Blood protein levels;	chr1:150291412	chr1:150053864~150055034:+
LUAD	cis	rs7017914	0.934	rs13255152	ENSG00000246366.5	RP11-382J12.1	3.6	0.000347	0.0386	0.15	0.16	Bone mineral density;	chr8:70947384	chr8:70608577~70663279:+
LUAD	cis	rs10129255	0.957	rs8009948	ENSG00000211967.3	IGHV3-53	-3.6	0.000347	0.0386	-0.13	-0.16	Kawasaki disease;	chr14:106805607	chr14:106592676~106593347:-
LUAD	cis	rs35520189	0.556	rs13026837	ENSG00000227368.1	AC079753.5	3.6	0.000347	0.0386	0.2	0.16	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112948096	chr2:112932625~112933171:+
LUAD	cis	rs35520189	0.591	rs12618418	ENSG00000227368.1	AC079753.5	3.6	0.000347	0.0386	0.2	0.16	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112950068	chr2:112932625~112933171:+
LUAD	cis	rs2975734	0.674	rs6983870	ENSG00000280294.1	RP11-177H2.1	-3.6	0.000347	0.0386	-0.2	-0.16	Chronotype;Morning vs. evening chronotype;	chr8:10253784	chr8:10856085~10859436:-
LUAD	cis	rs4662750	0.619	rs2244042	ENSG00000272789.1	RP11-286H15.1	3.6	0.000347	0.0386	0.16	0.16	Renal cell carcinoma;	chr2:127647423	chr2:127625997~127626848:-
LUAD	cis	rs7809950	1	rs7782057	ENSG00000238832.1	snoU109	-3.6	0.000347	0.0386	-0.24	-0.16	Coronary artery disease;	chr7:107458432	chr7:107603363~107603507:+
LUAD	cis	rs6736093	0.704	rs10169022	ENSG00000207383.1	Y_RNA	-3.6	0.000347	0.0386	-0.21	-0.16	Coronary artery disease;	chr2:112035079	chr2:112579484~112579584:-
LUAD	cis	rs11638352	1	rs4924729	ENSG00000205771.5	CATSPER2P1	3.6	0.000347	0.0386	0.36	0.16	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:43999046	chr15:43726918~43747094:-
LUAD	cis	rs8085804	0.597	rs8097989	ENSG00000276174.1	RP11-687E1.2	-3.6	0.000347	0.0386	-0.22	-0.16	Cognitive performance;	chr18:42638547	chr18:42052705~42053030:+
LUAD	cis	rs8085804	0.597	rs8099114	ENSG00000276174.1	RP11-687E1.2	-3.6	0.000347	0.0386	-0.22	-0.16	Cognitive performance;	chr18:42638690	chr18:42052705~42053030:+
LUAD	cis	rs4795519	0.614	rs11653883	ENSG00000266313.1	RP11-173M1.4	3.6	0.000347	0.0387	0.22	0.16	Chronic myeloid leukemia;	chr17:27160582	chr17:27333256~27348491:+
LUAD	cis	rs7260598	0.786	rs59387271	ENSG00000268442.1	CTD-2027I19.2	3.6	0.000347	0.0387	0.25	0.16	Response to taxane treatment (placlitaxel);	chr19:24009130	chr19:24162370~24163425:-
LUAD	cis	rs877819	0.583	rs2940712	ENSG00000228403.1	RP11-563N6.6	-3.6	0.000347	0.0387	-0.17	-0.16	Systemic lupus erythematosus;	chr10:48848403	chr10:48878022~48878649:+
LUAD	cis	rs9291683	0.632	rs11734786	ENSG00000250413.1	RP11-448G15.1	-3.6	0.000347	0.0387	-0.21	-0.16	Bone mineral density;	chr4:10039875	chr4:10006482~10009725:+
LUAD	cis	rs9291683	0.632	rs7679916	ENSG00000250413.1	RP11-448G15.1	-3.6	0.000347	0.0387	-0.21	-0.16	Bone mineral density;	chr4:10040536	chr4:10006482~10009725:+
LUAD	cis	rs9291683	0.632	rs13137074	ENSG00000250413.1	RP11-448G15.1	-3.6	0.000347	0.0387	-0.21	-0.16	Bone mineral density;	chr4:10041218	chr4:10006482~10009725:+
LUAD	cis	rs9291683	0.632	rs13101785	ENSG00000250413.1	RP11-448G15.1	-3.6	0.000347	0.0387	-0.21	-0.16	Bone mineral density;	chr4:10041291	chr4:10006482~10009725:+
LUAD	cis	rs875971	0.964	rs778735	ENSG00000273142.1	RP11-458F8.4	-3.6	0.000347	0.0387	-0.11	-0.16	Aortic root size;	chr7:66349822	chr7:66902857~66906297:+
LUAD	cis	rs975752	1	rs12806	ENSG00000227492.1	RP11-316M21.6	3.6	0.000347	0.0387	0.24	0.16	Schizophrenia;	chr10:100151385	chr10:100229667~100234000:+
LUAD	cis	rs8046148	0.737	rs4074655	ENSG00000279356.1	RP11-429P3.8	3.6	0.000347	0.0387	0.17	0.16	Testicular germ cell tumor;	chr16:50112333	chr16:50072862~50074986:+
LUAD	cis	rs10118776	0.677	rs13302749	ENSG00000231967.1	RP11-12D24.6	3.6	0.000347	0.0387	0.41	0.16	Small cell lung carcinoma;	chr9:6171731	chr9:5356312~5356525:-
LUAD	cis	rs9291683	0.618	rs13137343	ENSG00000250413.1	RP11-448G15.1	-3.6	0.000347	0.0387	-0.21	-0.16	Bone mineral density;	chr4:10041404	chr4:10006482~10009725:+
LUAD	cis	rs523522	0.885	rs524735	ENSG00000278344.1	RP11-18C24.8	3.6	0.000347	0.0387	0.22	0.16	High light scatter reticulocyte count;	chr12:120584296	chr12:120500735~120501090:-
LUAD	cis	rs6901004	0.605	rs2297939	ENSG00000271789.1	RP5-1112D6.7	-3.6	0.000347	0.0387	-0.18	-0.16	Blood metabolite levels;	chr6:111227959	chr6:111297126~111298510:+
LUAD	cis	rs12908161	0.92	rs35758837	ENSG00000259654.1	RP11-245C17.2	-3.6	0.000347	0.0387	-0.23	-0.16	Schizophrenia;	chr15:84768151	chr15:84685884~84686946:+
LUAD	cis	rs11773103	0.708	rs802030	ENSG00000224046.1	AC005076.5	3.6	0.000347	0.0387	0.25	0.16	Bipolar disorder or major depressive disorder (combined);	chr7:87364235	chr7:87151423~87152420:-
LUAD	cis	rs9652601	0.676	rs9926615	ENSG00000280153.1	RP11-876N24.3	-3.6	0.000347	0.0387	-0.11	-0.16	Systemic lupus erythematosus;	chr16:11009303	chr16:10933903~10936280:+
LUAD	cis	rs4227	0.565	rs1142832	ENSG00000233223.2	AC113189.5	3.6	0.000347	0.0387	0.18	0.16	IgA nephropathy;	chr17:7575897	chr17:7581964~7584072:-
LUAD	cis	rs7772486	0.79	rs2254288	ENSG00000235652.6	RP11-545I5.3	3.6	0.000347	0.0387	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145883334	chr6:145799409~145886585:+
LUAD	cis	rs67478160	0.643	rs2295141	ENSG00000272533.1	SNORA28	3.6	0.000347	0.0387	0.17	0.16	Schizophrenia;	chr14:103746612	chr14:103337849~103337974:+
LUAD	cis	rs67478160	0.643	rs3818085	ENSG00000272533.1	SNORA28	3.6	0.000347	0.0387	0.17	0.16	Schizophrenia;	chr14:103749648	chr14:103337849~103337974:+
LUAD	cis	rs67478160	0.643	rs1535098	ENSG00000272533.1	SNORA28	3.6	0.000347	0.0387	0.17	0.16	Schizophrenia;	chr14:103750176	chr14:103337849~103337974:+
LUAD	cis	rs2625529	0.529	rs7183055	ENSG00000260173.1	RP11-2I17.4	3.6	0.000348	0.0387	0.19	0.16	Red blood cell count;	chr15:72084707	chr15:72140504~72155459:-
LUAD	cis	rs7955901	0.904	rs4760785	ENSG00000258053.1	CTD-2021H9.3	-3.6	0.000348	0.0387	-0.19	-0.16	Type 2 diabetes;	chr12:71045165	chr12:71047402~71118247:-
LUAD	cis	rs17695224	0.545	rs4802875	ENSG00000269483.1	AC006272.1	3.6	0.000348	0.0387	0.17	0.16	HDL cholesterol;HDL cholesterol levels;	chr19:51827056	chr19:51839924~51843324:-
LUAD	cis	rs6493858	0.61	rs1426067	ENSG00000277548.1	RP11-139H15.6	3.6	0.000348	0.0387	0.17	0.16	Relative hand skill in reading disability;	chr15:56298920	chr15:55346347~55346752:-
LUAD	cis	rs9921338	0.961	rs7202814	ENSG00000263080.1	RP11-485G7.5	3.6	0.000348	0.0387	0.22	0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11295917	chr16:11341809~11345211:-
LUAD	cis	rs9341808	0.905	rs9343977	ENSG00000272129.1	RP11-250B2.6	3.6	0.000348	0.0387	0.19	0.16	Sitting height ratio;	chr6:80257284	chr6:80355424~80356859:+
LUAD	cis	rs12440869	1	rs28693872	ENSG00000270964.1	RP11-502I4.3	3.6	0.000348	0.0387	0.18	0.16	Peak velocity of the mitral A-wave;	chr15:67209444	chr15:67541072~67542604:-
LUAD	cis	rs28374715	0.532	rs28535540	ENSG00000247556.5	OIP5-AS1	3.6	0.000348	0.0387	0.2	0.16	Ulcerative colitis;	chr15:41367079	chr15:41283990~41309737:+
LUAD	cis	rs9549260	0.564	rs9577110	ENSG00000229456.1	RLIMP1	3.6	0.000348	0.0387	0.17	0.16	Red blood cell count;	chr13:40697742	chr13:40618738~40621348:+
LUAD	cis	rs2190016	0.645	rs4724511	ENSG00000236078.1	LINC01447	-3.6	0.000348	0.0387	-0.19	-0.16	Mammographic density (non-dense area);	chr7:46845634	chr7:47621939~47629893:+
LUAD	cis	rs683250	0.599	rs4445661	ENSG00000246067.6	RAB30-AS1	-3.6	0.000348	0.0387	-0.17	-0.16	Subcortical brain region volumes;	chr11:83356829	chr11:83072066~83106719:+
LUAD	cis	rs34421088	0.559	rs12386974	ENSG00000255046.1	RP11-297N6.4	-3.6	0.000348	0.0387	-0.2	-0.16	Neuroticism;	chr8:11543119	chr8:11797928~11802568:-
LUAD	cis	rs4072980	0.545	rs16824518	ENSG00000212541.1	RNU6-510P	3.6	0.000348	0.0387	0.21	0.16	Coronary artery disease;	chr1:37949643	chr1:37991462~37991569:+
LUAD	cis	rs1040393	0.522	rs2049909	ENSG00000225171.2	DUTP6	3.6	0.000348	0.0387	0.24	0.16	Schizophrenia;	chr1:166862708	chr1:166868748~166869209:+
LUAD	cis	rs13113518	0.841	rs11133400	ENSG00000273257.1	RP11-177J6.1	3.6	0.000348	0.0387	0.18	0.16	Height;	chr4:55578787	chr4:55387949~55388271:+
LUAD	cis	rs416603	0.901	rs149597	ENSG00000262703.1	RP11-485G7.6	-3.6	0.000348	0.0387	-0.15	-0.16	Type 1 diabetes;	chr16:11250085	chr16:11348143~11349321:-
LUAD	cis	rs8014252	1	rs1959484	ENSG00000274818.1	RP1-292L20.3	3.6	0.000348	0.0387	0.26	0.16	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70485990	chr14:70906657~70907111:-
LUAD	cis	rs3849150	0.95	rs7909543	ENSG00000235939.1	RP11-123B3.2	-3.6	0.000348	0.0387	-0.23	-0.16	Subclinical atherosclerosis traits (other);	chr10:48881824	chr10:49419277~49472903:+
LUAD	cis	rs9875589	0.628	rs62234602	ENSG00000228242.5	AC093495.4	-3.6	0.000348	0.0387	-0.11	-0.16	Ovarian reserve;	chr3:13960670	chr3:14144637~14165978:+
LUAD	cis	rs7119	0.604	rs2271398	ENSG00000259362.2	RP11-307C19.1	3.6	0.000348	0.0387	0.19	0.16	Type 2 diabetes;	chr15:77615442	chr15:77525540~77534110:+
LUAD	cis	rs867371	0.502	rs28610286	ENSG00000259429.4	UBE2Q2P2	-3.6	0.000348	0.0387	-0.14	-0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82233314	chr15:82355142~82420075:+
LUAD	cis	rs4578769	0.531	rs9957103	ENSG00000266850.1	RP11-370A5.1	3.6	0.000348	0.0387	0.21	0.16	Eosinophil percentage of white cells;	chr18:22870172	chr18:22723491~22907721:-
LUAD	cis	rs7141336	0.8	rs10136977	ENSG00000258884.1	CTD-3035D6.2	3.6	0.000348	0.0387	0.17	0.16	Anxiety disorder;	chr14:90822467	chr14:90822365~90828128:-
LUAD	cis	rs3893377	1	rs11947310	ENSG00000214846.4	RP11-115L11.1	3.6	0.000348	0.0387	0.27	0.16	Current cigarettes per day in chronic obstructive pulmonary disease;	chr4:15742953	chr4:15730962~15731627:-
LUAD	cis	rs9608946	1	rs7286807	ENSG00000279699.1	RP1-102K2.9	3.6	0.000348	0.0387	0.24	0.16	Red cell distribution width;	chr22:30529629	chr22:30275215~30276951:-
LUAD	cis	rs773506	0.565	rs773512	ENSG00000237422.1	RP11-305L7.3	3.6	0.000348	0.0387	0.21	0.16	Type 2 diabetes nephropathy;	chr9:91189751	chr9:91119138~91163087:-
LUAD	cis	rs5742933	0.857	rs1233291	ENSG00000253559.1	OSGEPL1-AS1	-3.6	0.000348	0.0387	-0.2	-0.16	Ferritin levels;	chr2:189826225	chr2:189762704~189765556:+
LUAD	cis	rs9907295	0.636	rs4251724	ENSG00000270977.1	AC015849.16	-3.6	0.000348	0.0387	-0.22	-0.16	Fibroblast growth factor basic levels;	chr17:35816641	chr17:35893707~35911023:-
LUAD	cis	rs7772486	0.875	rs865913	ENSG00000235652.6	RP11-545I5.3	3.6	0.000348	0.0387	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145987738	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.875	rs2814873	ENSG00000235652.6	RP11-545I5.3	3.6	0.000348	0.0387	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145987796	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.84	rs2777478	ENSG00000235652.6	RP11-545I5.3	3.6	0.000348	0.0387	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145987981	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.875	rs2814872	ENSG00000235652.6	RP11-545I5.3	3.6	0.000348	0.0387	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145989098	chr6:145799409~145886585:+
LUAD	cis	rs11122895	1	rs11122895	ENSG00000236307.2	EEF1E1P1	3.6	0.000348	0.0387	0.18	0.16	Allergic sensitization;	chr2:111712578	chr2:111887914~111888741:+
LUAD	cis	rs6871536	1	rs17166050	ENSG00000233006.5	AC034220.3	-3.6	0.000348	0.0388	-0.19	-0.16	Asthma (childhood onset);	chr5:132579521	chr5:132311285~132369916:-
LUAD	cis	rs7772486	0.686	rs9403746	ENSG00000235652.6	RP11-545I5.3	-3.6	0.000348	0.0388	-0.16	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145782632	chr6:145799409~145886585:+
LUAD	cis	rs4819052	1	rs2297286	ENSG00000184274.3	LINC00315	-3.6	0.000348	0.0388	-0.25	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45287982	chr21:45300245~45305257:-
LUAD	cis	rs2974760	0.606	rs2858918	ENSG00000260803.1	Z84812.4	-3.6	0.000348	0.0388	-0.21	-0.16	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr16:151184	chr16:17514~35195:-
LUAD	cis	rs911119	0.913	rs13037490	ENSG00000270001.1	RP11-218C14.8	-3.6	0.000348	0.0388	-0.25	-0.16	Chronic kidney disease;	chr20:23603088	chr20:23631826~23632316:-
LUAD	cis	rs987044	0.682	rs4964273	ENSG00000257221.1	RP11-689B22.2	-3.6	0.000348	0.0388	-0.14	-0.16	Mean platelet volume;	chr12:108709897	chr12:108628687~108641318:+
LUAD	cis	rs9815354	0.812	rs809930	ENSG00000273328.4	RP11-141M3.6	-3.6	0.000348	0.0388	-0.26	-0.16	Pulse pressure;Diastolic blood pressure;	chr3:42023513	chr3:42809414~42908105:+
LUAD	cis	rs10838687	0.673	rs10838663	ENSG00000255197.4	RP11-750H9.5	-3.6	0.000348	0.0388	-0.17	-0.16	Proinsulin levels;	chr11:47163420	chr11:47383148~47409190:-
LUAD	cis	rs4474465	0.688	rs7942527	ENSG00000251323.2	RP11-452H21.4	-3.6	0.000348	0.0388	-0.2	-0.16	Alzheimer's disease (survival time);	chr11:78569277	chr11:78423982~78429836:-
LUAD	cis	rs4474465	0.688	rs7945812	ENSG00000251323.2	RP11-452H21.4	-3.6	0.000348	0.0388	-0.2	-0.16	Alzheimer's disease (survival time);	chr11:78569464	chr11:78423982~78429836:-
LUAD	cis	rs4474465	0.688	rs7124803	ENSG00000251323.2	RP11-452H21.4	-3.6	0.000348	0.0388	-0.2	-0.16	Alzheimer's disease (survival time);	chr11:78569777	chr11:78423982~78429836:-
LUAD	cis	rs9923856	0.523	rs11642631	ENSG00000280153.1	RP11-876N24.3	-3.6	0.000349	0.0388	-0.12	-0.16	Atopic dermatitis;Adult asthma;	chr16:11104978	chr16:10933903~10936280:+
LUAD	cis	rs17122278	1	rs7932700	ENSG00000243431.1	RPL5P30	3.6	0.000349	0.0388	0.2	0.16	Total cholesterol levels;	chr11:118540998	chr11:118560690~118561580:+
LUAD	cis	rs3126085	0.515	rs7514696	ENSG00000237975.5	FLG-AS1	3.6	0.000349	0.0388	0.25	0.16	Atopic dermatitis;	chr1:152391398	chr1:152168125~152445456:+
LUAD	cis	rs10129255	0.5	rs10143242	ENSG00000274576.2	IGHV2-70	-3.6	0.000349	0.0388	-0.13	-0.16	Kawasaki disease;	chr14:106681814	chr14:106770577~106771020:-
LUAD	cis	rs2905347	0.737	rs756879	ENSG00000232949.1	AC002480.4	-3.6	0.000349	0.0388	-0.19	-0.16	Major depression and alcohol dependence;	chr7:22594386	chr7:22589705~22591622:+
LUAD	cis	rs9921338	0.961	rs7626	ENSG00000263080.1	RP11-485G7.5	3.6	0.000349	0.0388	0.22	0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11351739	chr16:11341809~11345211:-
LUAD	cis	rs7976269	0.537	rs4471475	ENSG00000275476.1	RP11-996F15.4	-3.6	0.000349	0.0388	-0.18	-0.16	Male-pattern baldness;	chr12:29022461	chr12:29277397~29277882:-
LUAD	cis	rs4853525	0.59	rs3771308	ENSG00000235852.1	AC005540.3	3.6	0.000349	0.0388	0.2	0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190936179	chr2:190880797~190882059:-
LUAD	cis	rs1678542	0.651	rs2888334	ENSG00000270039.1	RP11-571M6.17	3.6	0.000349	0.0388	0.2	0.16	Rheumatoid arthritis;	chr12:57582864	chr12:57803838~57804415:+
LUAD	cis	rs9517320	0.967	rs7997785	ENSG00000231194.1	FARP1-AS1	3.6	0.000349	0.0388	0.19	0.16	Longevity;	chr13:98475731	chr13:98435405~98435840:-
LUAD	cis	rs9517320	1	rs7996629	ENSG00000231194.1	FARP1-AS1	3.6	0.000349	0.0388	0.19	0.16	Longevity;	chr13:98475783	chr13:98435405~98435840:-
LUAD	cis	rs4386084	1	rs36025803	ENSG00000242737.1	RP11-562A8.1	-3.6	0.000349	0.0388	-0.22	-0.16	Basophil percentage of granulocytes;Basophil percentage of white cells;	chr15:49937454	chr15:50466738~50467096:+
LUAD	cis	rs7772486	0.654	rs702321	ENSG00000235652.6	RP11-545I5.3	-3.6	0.000349	0.0388	-0.16	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145685559	chr6:145799409~145886585:+
LUAD	cis	rs12935418	0.583	rs2549841	ENSG00000261061.1	RP11-303E16.2	3.6	0.000349	0.0388	0.17	0.16	Mean corpuscular volume;	chr16:80989967	chr16:81030770~81031485:+
LUAD	cis	rs10875976	0.525	rs7306374	ENSG00000257464.1	RP11-161H23.8	-3.6	0.000349	0.0388	-0.17	-0.16	Obesity;	chr12:49856606	chr12:49442424~49442652:-
LUAD	cis	rs10875976	0.525	rs7137210	ENSG00000257464.1	RP11-161H23.8	-3.6	0.000349	0.0388	-0.17	-0.16	Obesity;	chr12:49856660	chr12:49442424~49442652:-
LUAD	cis	rs8133949	0.68	rs11701415	ENSG00000237232.6	ZNF295-AS1	3.6	0.000349	0.0388	0.23	0.16	Hand grip strength;	chr21:41970573	chr21:42009194~42024924:+
LUAD	cis	rs1881797	0.932	rs10925071	ENSG00000221953.5	C1orf229	3.6	0.000349	0.0388	0.21	0.16	Acute lymphoblastic leukemia (childhood);	chr1:247523219	chr1:247110160~247112417:-
LUAD	cis	rs1858037	0.867	rs57913336	ENSG00000237979.1	AC007389.1	3.6	0.000349	0.0388	0.2	0.16	Rheumatoid arthritis;	chr2:65360485	chr2:65500993~65502138:-
LUAD	cis	rs6088590	1	rs10048849	ENSG00000275784.1	RP5-1125A11.6	-3.6	0.000349	0.0388	-0.18	-0.16	Coronary artery disease;	chr20:34831877	chr20:33989480~33991818:-
LUAD	cis	rs638893	0.842	rs480791	ENSG00000255239.1	AP002954.6	3.6	0.000349	0.0388	0.25	0.16	Vitiligo;	chr11:118833546	chr11:118688039~118690600:-
LUAD	cis	rs7546668	1	rs10803388	ENSG00000272510.1	RP4-680D5.8	3.6	0.000349	0.0388	0.21	0.16	Glomerular filtration rate (creatinine);	chr1:15523602	chr1:15565611~15565956:-
LUAD	cis	rs7546668	0.947	rs4645989	ENSG00000272510.1	RP4-680D5.8	3.6	0.000349	0.0388	0.21	0.16	Glomerular filtration rate (creatinine);	chr1:15523848	chr1:15565611~15565956:-
LUAD	cis	rs6586111	1	rs7915642	ENSG00000226659.1	RP11-137H2.4	-3.6	0.000349	0.0388	-0.21	-0.16	Capecitabine sensitivity;	chr10:80618105	chr10:80529597~80535942:-
LUAD	cis	rs17772222	0.682	rs2297129	ENSG00000258983.2	RP11-507K2.2	3.6	0.000349	0.0388	0.18	0.16	Coronary artery calcification;	chr14:88469581	chr14:88499334~88515502:+
LUAD	cis	rs17772222	0.682	rs61542857	ENSG00000258983.2	RP11-507K2.2	3.6	0.000349	0.0388	0.18	0.16	Coronary artery calcification;	chr14:88470358	chr14:88499334~88515502:+
LUAD	cis	rs17772222	0.637	rs7161660	ENSG00000258983.2	RP11-507K2.2	3.6	0.000349	0.0388	0.18	0.16	Coronary artery calcification;	chr14:88471832	chr14:88499334~88515502:+
LUAD	cis	rs17772222	0.682	rs7141363	ENSG00000258983.2	RP11-507K2.2	3.6	0.000349	0.0388	0.18	0.16	Coronary artery calcification;	chr14:88471879	chr14:88499334~88515502:+
LUAD	cis	rs4835473	0.897	rs2060654	ENSG00000249741.2	RP11-673E1.3	3.6	0.000349	0.0388	0.19	0.16	Immature fraction of reticulocytes;	chr4:143739155	chr4:143911514~143912053:-
LUAD	cis	rs4835473	0.932	rs2060655	ENSG00000249741.2	RP11-673E1.3	3.6	0.000349	0.0388	0.19	0.16	Immature fraction of reticulocytes;	chr4:143739159	chr4:143911514~143912053:-
LUAD	cis	rs10129255	0.53	rs11624912	ENSG00000274576.2	IGHV2-70	-3.6	0.000349	0.0388	-0.13	-0.16	Kawasaki disease;	chr14:106673891	chr14:106770577~106771020:-
LUAD	cis	rs338389	0.516	rs7359201	ENSG00000260657.2	RP11-315D16.4	-3.6	0.000349	0.0388	-0.18	-0.16	Survival in rectal cancer;	chr15:68021411	chr15:68267792~68277994:-
LUAD	cis	rs7618915	0.547	rs12486847	ENSG00000243224.1	RP5-1157M23.2	-3.6	0.000349	0.0388	-0.16	-0.16	Bipolar disorder;	chr3:52657096	chr3:52239258~52241097:+
LUAD	cis	rs13068223	0.503	rs34277251	ENSG00000240875.4	LINC00886	-3.6	0.000349	0.0388	-0.18	-0.16	Age-related hearing impairment (SNP x SNP interaction);	chr3:156703736	chr3:156747346~156817062:-
LUAD	cis	rs12048904	0.505	rs4517368	ENSG00000224616.1	RTCA-AS1	-3.6	0.000349	0.0388	-0.19	-0.16	Multiple sclerosis;	chr1:100789496	chr1:100264009~100266120:-
LUAD	cis	rs4763879	0.634	rs12424826	ENSG00000256582.1	RP11-75L1.1	-3.6	0.000349	0.0388	-0.17	-0.16	Type 1 diabetes;	chr12:9701981	chr12:9704077~9709350:+
LUAD	cis	rs2348418	0.832	rs2126894	ENSG00000244712.1	RP11-874G11.1	3.6	0.000349	0.0388	0.19	0.16	Lung function (FEV1);Lung function (FVC);	chr12:28323914	chr12:28564678~28565141:-
LUAD	cis	rs9863	0.804	rs80270210	ENSG00000270028.1	RP11-380L11.4	3.6	0.000349	0.0388	0.22	0.16	White blood cell count;	chr12:123962850	chr12:123925461~123926083:-
LUAD	cis	rs7208859	0.673	rs9915139	ENSG00000266490.1	CTD-2349P21.9	3.6	0.000349	0.0389	0.23	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831497	chr17:30792372~30792833:+
LUAD	cis	rs6121246	0.697	rs6060912	ENSG00000230613.1	HM13-AS1	3.6	0.000349	0.0389	0.23	0.16	Mean corpuscular hemoglobin;	chr20:31737952	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.909	rs6089058	ENSG00000230613.1	HM13-AS1	3.6	0.000349	0.0389	0.23	0.16	Mean corpuscular hemoglobin;	chr20:31738535	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.821	rs6119718	ENSG00000230613.1	HM13-AS1	3.6	0.000349	0.0389	0.23	0.16	Mean corpuscular hemoglobin;	chr20:31743271	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.821	rs6058448	ENSG00000230613.1	HM13-AS1	3.6	0.000349	0.0389	0.23	0.16	Mean corpuscular hemoglobin;	chr20:31744593	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.909	rs8126355	ENSG00000230613.1	HM13-AS1	3.6	0.000349	0.0389	0.23	0.16	Mean corpuscular hemoglobin;	chr20:31744857	chr20:31567707~31573263:-
LUAD	cis	rs11838267	0.527	rs7311672	ENSG00000256967.1	RP11-273B20.1	-3.6	0.000349	0.0389	-0.16	-0.16	Coronary artery disease;	chr12:7057810	chr12:7129079~7131198:-
LUAD	cis	rs494453	0.583	rs564807	ENSG00000227811.2	FAM212B-AS1	-3.6	0.000349	0.0389	-0.25	-0.16	Osteoporosis-related phenotypes;	chr1:111669679	chr1:111739841~111747798:+
LUAD	cis	rs494453	0.583	rs559981	ENSG00000227811.2	FAM212B-AS1	-3.6	0.000349	0.0389	-0.25	-0.16	Osteoporosis-related phenotypes;	chr1:111676716	chr1:111739841~111747798:+
LUAD	cis	rs10208649	0.808	rs6730494	ENSG00000233266.1	HMGB1P31	3.6	0.000349	0.0389	0.44	0.16	Body mass index;	chr2:53992049	chr2:54051334~54051760:+
LUAD	cis	rs6460942	0.544	rs73287153	ENSG00000226690.5	AC005281.1	3.6	0.00035	0.0389	0.31	0.16	Coronary artery disease;	chr7:12099646	chr7:12496429~12541910:+
LUAD	cis	rs4908768	0.911	rs953535	ENSG00000232912.4	RP5-1115A15.1	-3.6	0.00035	0.0389	-0.18	-0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8716660	chr1:8424645~8434838:+
LUAD	cis	rs11250098	0.574	rs4240672	ENSG00000255310.2	AF131215.2	-3.6	0.00035	0.0389	-0.16	-0.16	Morning vs. evening chronotype;	chr8:10910407	chr8:11107788~11109726:-
LUAD	cis	rs8062405	0.756	rs151182	ENSG00000261419.1	RP11-57A19.4	-3.6	0.00035	0.0389	-0.18	-0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28484431	chr16:28659696~28740781:-
LUAD	cis	rs61160187	0.582	rs1526896	ENSG00000215032.2	GNL3LP1	3.6	0.00035	0.0389	0.2	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:61063883	chr5:60891935~60893577:-
LUAD	cis	rs9393777	0.668	rs72839449	ENSG00000219392.1	RP1-265C24.5	-3.6	0.00035	0.0389	-0.25	-0.16	Intelligence (multi-trait analysis);	chr6:27293882	chr6:28115628~28116551:+
LUAD	cis	rs11874381	0.721	rs11875988	ENSG00000266696.1	RP11-30L3.2	-3.6	0.00035	0.0389	-0.17	-0.16	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);	chr18:49679062	chr18:49205912~49208781:+
LUAD	cis	rs12440869	0.92	rs8030142	ENSG00000270964.1	RP11-502I4.3	-3.6	0.00035	0.0389	-0.19	-0.16	Peak velocity of the mitral A-wave;	chr15:67357100	chr15:67541072~67542604:-
LUAD	cis	rs9303542	1	rs11655672	ENSG00000264920.1	RP11-6N17.4	-3.6	0.00035	0.0389	-0.21	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48379488	chr17:47891255~47895812:-
LUAD	cis	rs7824557	0.724	rs2572398	ENSG00000255046.1	RP11-297N6.4	-3.6	0.00035	0.0389	-0.2	-0.16	Retinal vascular caliber;	chr8:11320584	chr8:11797928~11802568:-
LUAD	cis	rs12681366	0.801	rs6981551	ENSG00000254057.1	RP3-388N13.3	3.6	0.00035	0.0389	0.17	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94466421	chr8:93834454~93846743:-
LUAD	cis	rs4130344	0.845	rs4328866	ENSG00000271817.2	U3	-3.6	0.00035	0.0389	-0.17	-0.16	Intelligence (multi-trait analysis);	chr4:158787024	chr4:158700691~158700909:+
LUAD	cis	rs11992162	0.597	rs6996342	ENSG00000255046.1	RP11-297N6.4	3.6	0.00035	0.0389	0.2	0.16	Monocyte count;	chr8:11927032	chr8:11797928~11802568:-
LUAD	cis	rs481331	0.799	rs210241	ENSG00000185904.10	LINC00839	-3.6	0.00035	0.0389	-0.27	-0.16	Systemic juvenile idiopathic arthritis;	chr10:42525810	chr10:42475543~42495336:+
LUAD	cis	rs17695224	0.5	rs4801897	ENSG00000269483.1	AC006272.1	3.6	0.00035	0.0389	0.18	0.16	HDL cholesterol;HDL cholesterol levels;	chr19:51831942	chr19:51839924~51843324:-
LUAD	cis	rs6494488	0.5	rs72744738	ENSG00000239465.1	RP11-330L19.2	3.6	0.00035	0.0389	0.34	0.16	Coronary artery disease;	chr15:64756135	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs72744740	ENSG00000239465.1	RP11-330L19.2	3.6	0.00035	0.0389	0.34	0.16	Coronary artery disease;	chr15:64758292	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs72744749	ENSG00000239465.1	RP11-330L19.2	3.6	0.00035	0.0389	0.34	0.16	Coronary artery disease;	chr15:64770620	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs72744763	ENSG00000239465.1	RP11-330L19.2	3.6	0.00035	0.0389	0.34	0.16	Coronary artery disease;	chr15:64784453	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs72744766	ENSG00000239465.1	RP11-330L19.2	3.6	0.00035	0.0389	0.34	0.16	Coronary artery disease;	chr15:64786892	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs111793398	ENSG00000239465.1	RP11-330L19.2	3.6	0.00035	0.0389	0.34	0.16	Coronary artery disease;	chr15:64787155	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs72744788	ENSG00000239465.1	RP11-330L19.2	3.6	0.00035	0.0389	0.34	0.16	Coronary artery disease;	chr15:64803036	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs72744790	ENSG00000239465.1	RP11-330L19.2	3.6	0.00035	0.0389	0.34	0.16	Coronary artery disease;	chr15:64807806	chr15:64631109~64631914:-
LUAD	cis	rs10463554	0.963	rs27970	ENSG00000250682.4	LINC00491	3.6	0.00035	0.0389	0.19	0.16	Parkinson's disease;	chr5:103151019	chr5:102609156~102671559:-
LUAD	cis	rs11105298	0.891	rs10777163	ENSG00000270344.2	RP11-734K2.4	3.6	0.00035	0.0389	0.2	0.16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89436943	chr12:89525654~89548005:+
LUAD	cis	rs728616	0.867	rs61858980	ENSG00000225484.5	NUTM2B-AS1	-3.6	0.00035	0.0389	-0.33	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80056862	chr10:79663088~79826594:-
LUAD	cis	rs728616	0.867	rs2152550	ENSG00000225484.5	NUTM2B-AS1	-3.6	0.00035	0.0389	-0.33	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80058753	chr10:79663088~79826594:-
LUAD	cis	rs763121	0.962	rs909564	ENSG00000273076.1	RP3-508I15.22	3.6	0.00035	0.0389	0.15	0.16	Menopause (age at onset);	chr22:38730503	chr22:38743495~38743910:+
LUAD	cis	rs6121246	0.909	rs7272062	ENSG00000230613.1	HM13-AS1	3.6	0.00035	0.0389	0.23	0.16	Mean corpuscular hemoglobin;	chr20:31671342	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.909	rs6060679	ENSG00000230613.1	HM13-AS1	-3.6	0.00035	0.0389	-0.23	-0.16	Mean corpuscular hemoglobin;	chr20:31682969	chr20:31567707~31573263:-
LUAD	cis	rs6502050	0.799	rs4789667	ENSG00000266654.1	RP11-1376P16.1	-3.6	0.00035	0.0389	-0.17	-0.16	Life satisfaction;	chr17:82204267	chr17:82160056~82160452:+
LUAD	cis	rs12999542	0.5	rs13001301	ENSG00000234389.1	AC007278.3	3.6	0.00035	0.0389	0.24	0.16	Serum protein levels (sST2);	chr2:102322538	chr2:102438713~102440475:+
LUAD	cis	rs12999542	0.5	rs17695648	ENSG00000234389.1	AC007278.3	3.6	0.00035	0.0389	0.24	0.16	Serum protein levels (sST2);	chr2:102331721	chr2:102438713~102440475:+
LUAD	cis	rs2904524	0.748	rs11178226	ENSG00000257613.1	LINC01481	-3.6	0.00035	0.0389	-0.29	-0.16	Amyotrophic lateral sclerosis (age of onset);	chr12:70409894	chr12:70219132~70221862:-
LUAD	cis	rs2904524	0.748	rs11178227	ENSG00000257613.1	LINC01481	-3.6	0.00035	0.0389	-0.29	-0.16	Amyotrophic lateral sclerosis (age of onset);	chr12:70409970	chr12:70219132~70221862:-
LUAD	cis	rs2904524	0.748	rs11178228	ENSG00000257613.1	LINC01481	-3.6	0.00035	0.0389	-0.29	-0.16	Amyotrophic lateral sclerosis (age of onset);	chr12:70410290	chr12:70219132~70221862:-
LUAD	cis	rs2348418	0.864	rs6487689	ENSG00000247934.4	RP11-967K21.1	3.6	0.00035	0.0389	0.19	0.16	Lung function (FEV1);Lung function (FVC);	chr12:28560101	chr12:28163298~28190738:-
LUAD	cis	rs7800244	0.848	rs62447755	ENSG00000146666.5	LINC00525	-3.6	0.00035	0.0389	-0.21	-0.16	Hepatitis C induced liver fibrosis;	chr7:47750564	chr7:47761476~47766772:+
LUAD	cis	rs8054556	0.73	rs4788190	ENSG00000183604.13	SMG1P5	-3.6	0.00035	0.0389	-0.16	-0.16	Autism spectrum disorder or schizophrenia;	chr16:29937080	chr16:30267553~30335374:-
LUAD	cis	rs11992162	0.591	rs4240678	ENSG00000255046.1	RP11-297N6.4	3.6	0.00035	0.0389	0.2	0.16	Monocyte count;	chr8:11944917	chr8:11797928~11802568:-
LUAD	cis	rs7537765	0.696	rs2076001	ENSG00000242349.4	NPPA-AS1	3.6	0.00035	0.0389	0.3	0.16	QRS complex (12-leadsum);	chr1:11819210	chr1:11841017~11848079:+
LUAD	cis	rs12908161	1	rs62019464	ENSG00000254414.1	RP11-182J1.1	3.6	0.00035	0.0389	0.21	0.16	Schizophrenia;	chr15:84751238	chr15:84631898~84633987:-
LUAD	cis	rs4561483	0.603	rs7202065	ENSG00000261560.1	RP11-166B2.3	3.6	0.00035	0.0389	0.15	0.16	Testicular germ cell tumor;	chr16:11857188	chr16:11881075~11882569:-
LUAD	cis	rs7178375	0.607	rs71474639	ENSG00000259845.1	HERC2P10	3.6	0.00035	0.0389	0.28	0.16	Hypertriglyceridemia;	chr15:30921054	chr15:30815271~30844153:+
LUAD	cis	rs11216126	0.643	rs11602073	ENSG00000235910.1	APOA1-AS	3.6	0.00035	0.0389	0.29	0.16	HDL cholesterol;	chr11:116776142	chr11:116836117~116855729:+
LUAD	cis	rs7772486	0.875	rs863820	ENSG00000235652.6	RP11-545I5.3	-3.6	0.00035	0.0389	-0.16	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:146026266	chr6:145799409~145886585:+
LUAD	cis	rs2292864	0.681	rs35735886	ENSG00000278765.1	RP5-890E16.5	3.6	0.00035	0.0389	0.3	0.16	Left atrial antero-posterior diameter;	chr17:47296911	chr17:48066704~48067293:-
LUAD	cis	rs2494663	0.585	rs12021641	ENSG00000223599.1	RP11-216N14.7	3.6	0.00035	0.0389	0.2	0.16	Mean platelet volume;	chr1:154091967	chr1:153852106~153853414:-
LUAD	cis	rs763121	0.853	rs6001175	ENSG00000228274.3	RP3-508I15.9	-3.6	0.00035	0.0389	-0.15	-0.16	Menopause (age at onset);	chr22:38622329	chr22:38667585~38681820:-
LUAD	cis	rs12817211	0.502	rs7135322	ENSG00000272368.2	RP4-605O3.4	-3.6	0.00035	0.0389	-0.19	-0.16	Colorectal or endometrial cancer;	chr12:50118065	chr12:50112197~50165618:+
LUAD	cis	rs1065852	0.51	rs5758666	ENSG00000226450.2	CYP2D8P	3.6	0.000351	0.039	0.14	0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42236827	chr22:42149886~42155001:-
LUAD	cis	rs9325144	0.723	rs10161183	ENSG00000257718.1	RP11-396F22.1	-3.6	0.000351	0.039	-0.19	-0.16	Morning vs. evening chronotype;	chr12:38788285	chr12:38906451~38909592:+
LUAD	cis	rs9325144	0.723	rs11169535	ENSG00000257718.1	RP11-396F22.1	-3.6	0.000351	0.039	-0.19	-0.16	Morning vs. evening chronotype;	chr12:38789692	chr12:38906451~38909592:+
LUAD	cis	rs9325144	0.723	rs3887436	ENSG00000257718.1	RP11-396F22.1	-3.6	0.000351	0.039	-0.19	-0.16	Morning vs. evening chronotype;	chr12:38795724	chr12:38906451~38909592:+
LUAD	cis	rs10911232	0.507	rs4652767	ENSG00000224468.3	RP11-181K3.4	-3.6	0.000351	0.039	-0.14	-0.16	Hypertriglyceridemia;	chr1:183033348	chr1:183138402~183141282:-
LUAD	cis	rs10911232	0.507	rs4129857	ENSG00000224468.3	RP11-181K3.4	-3.6	0.000351	0.039	-0.14	-0.16	Hypertriglyceridemia;	chr1:183035412	chr1:183138402~183141282:-
LUAD	cis	rs7955901	0.837	rs10748168	ENSG00000258053.1	CTD-2021H9.3	-3.6	0.000351	0.039	-0.18	-0.16	Type 2 diabetes;	chr12:71015072	chr12:71047402~71118247:-
LUAD	cis	rs9951698	0.703	rs8097125	ENSG00000267480.1	RP11-703I16.1	-3.6	0.000351	0.039	-0.2	-0.16	Intelligence (multi-trait analysis);	chr18:13005474	chr18:12031178~12032181:-
LUAD	cis	rs6964587	0.967	rs410	ENSG00000188693.7	CYP51A1-AS1	3.6	0.000351	0.039	0.19	0.16	Breast cancer;	chr7:91928111	chr7:92134604~92180725:+
LUAD	cis	rs10197140	0.925	rs10177582	ENSG00000227992.1	AC108463.2	3.6	0.000351	0.039	0.2	0.16	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110870975	chr2:111203964~111206215:-
LUAD	cis	rs3781264	0.595	rs7084988	ENSG00000273450.1	RP11-76P2.4	3.6	0.000351	0.039	0.21	0.16	Esophageal cancer and gastric cancer;	chr10:94349085	chr10:94314907~94315327:-
LUAD	cis	rs4462272	0.605	rs2270961	ENSG00000227492.1	RP11-316M21.6	3.6	0.000351	0.039	0.16	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr10:100256511	chr10:100229667~100234000:+
LUAD	cis	rs867371	0.656	rs2665103	ENSG00000259429.4	UBE2Q2P2	3.6	0.000351	0.039	0.14	0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82140374	chr15:82355142~82420075:+
LUAD	cis	rs6472235	0.656	rs11995784	ENSG00000200714.1	Y_RNA	-3.6	0.000351	0.039	-0.21	-0.16	Plateletcrit;Myopia (pathological);	chr8:65967906	chr8:65592731~65592820:+
LUAD	cis	rs10129255	1	rs9324091	ENSG00000211967.3	IGHV3-53	-3.6	0.000351	0.039	-0.13	-0.16	Kawasaki disease;	chr14:106676625	chr14:106592676~106593347:-
LUAD	cis	rs4908768	0.906	rs114812780	ENSG00000232912.4	RP5-1115A15.1	-3.6	0.000351	0.039	-0.19	-0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8468794	chr1:8424645~8434838:+
LUAD	cis	rs7142881	0.74	rs2151782	ENSG00000250365.5	CTD-2213F21.2	-3.6	0.000351	0.039	-0.19	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31831842	chr14:31420286~31452883:+
LUAD	cis	rs2279168	0.737	rs60345430	ENSG00000202081.1	RNU6-1280P	-3.6	0.000351	0.039	-0.32	-0.16	Response to platinum-based chemotherapy (carboplatin);	chr15:85416871	chr15:85651522~85651628:-
LUAD	cis	rs7474896	0.515	rs662928	ENSG00000226578.1	RP11-258F22.1	3.6	0.000351	0.039	0.23	0.16	Obesity (extreme);	chr10:38027288	chr10:37775371~37784131:-
LUAD	cis	rs2144940	0.545	rs844839	ENSG00000233746.1	LINC00656	3.6	0.000351	0.039	0.35	0.16	Venous thromboembolism;	chr20:23109455	chr20:23125068~23132621:-
LUAD	cis	rs6121246	0.909	rs6089070	ENSG00000230613.1	HM13-AS1	-3.6	0.000351	0.039	-0.25	-0.16	Mean corpuscular hemoglobin;	chr20:31789970	chr20:31567707~31573263:-
LUAD	cis	rs683250	0.599	rs4590896	ENSG00000246067.6	RAB30-AS1	-3.6	0.000351	0.039	-0.17	-0.16	Subcortical brain region volumes;	chr11:83356907	chr11:83072066~83106719:+
LUAD	cis	rs683250	0.599	rs4619176	ENSG00000246067.6	RAB30-AS1	-3.6	0.000351	0.039	-0.17	-0.16	Subcortical brain region volumes;	chr11:83356954	chr11:83072066~83106719:+
LUAD	cis	rs683250	0.599	rs11233578	ENSG00000246067.6	RAB30-AS1	-3.6	0.000351	0.039	-0.17	-0.16	Subcortical brain region volumes;	chr11:83357066	chr11:83072066~83106719:+
LUAD	cis	rs683250	0.599	rs11233579	ENSG00000246067.6	RAB30-AS1	-3.6	0.000351	0.039	-0.17	-0.16	Subcortical brain region volumes;	chr11:83357261	chr11:83072066~83106719:+
LUAD	cis	rs683250	0.599	rs11233580	ENSG00000246067.6	RAB30-AS1	-3.6	0.000351	0.039	-0.17	-0.16	Subcortical brain region volumes;	chr11:83357329	chr11:83072066~83106719:+
LUAD	cis	rs683250	0.57	rs11512910	ENSG00000246067.6	RAB30-AS1	-3.6	0.000351	0.039	-0.17	-0.16	Subcortical brain region volumes;	chr11:83357426	chr11:83072066~83106719:+
LUAD	cis	rs4842666	0.915	rs11105364	ENSG00000258302.2	RP11-981P6.1	3.6	0.000351	0.039	0.24	0.16	Blood pressure;	chr12:89675499	chr12:89561129~89594878:+
LUAD	cis	rs2625529	0.617	rs2306576	ENSG00000260173.1	RP11-2I17.4	3.6	0.000351	0.039	0.19	0.16	Red blood cell count;	chr15:71878345	chr15:72140504~72155459:-
LUAD	cis	rs9894429	0.646	rs9902264	ENSG00000263853.1	AC139530.1	-3.6	0.000351	0.039	-0.17	-0.16	Eye color traits;	chr17:81646802	chr17:81676001~81676086:+
LUAD	cis	rs7771547	0.855	rs1406945	ENSG00000232909.1	RP3-510O8.4	3.6	0.000351	0.039	0.18	0.16	Platelet distribution width;	chr6:36594664	chr6:35733867~35736947:-
LUAD	cis	rs523522	0.962	rs655530	ENSG00000278344.1	RP11-18C24.8	3.6	0.000351	0.039	0.22	0.16	High light scatter reticulocyte count;	chr12:120584472	chr12:120500735~120501090:-
LUAD	cis	rs13113518	1	rs11724094	ENSG00000273257.1	RP11-177J6.1	3.6	0.000351	0.039	0.18	0.16	Height;	chr4:55501479	chr4:55387949~55388271:+
LUAD	cis	rs6688537	0.658	rs12403980	ENSG00000233355.5	CHRM3-AS2	-3.6	0.000351	0.039	-0.12	-0.16	Lung function (FEV1/FVC);	chr1:239689643	chr1:239703381~239730465:-
LUAD	cis	rs7621025	0.5	rs71630059	ENSG00000273486.1	RP11-731C17.2	-3.6	0.000351	0.039	-0.18	-0.16	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136862769	chr3:136837338~136839021:-
LUAD	cis	rs1075265	0.749	rs2357693	ENSG00000272156.1	RP11-477N3.1	-3.6	0.000351	0.039	-0.19	-0.16	Chronotype;Morning vs. evening chronotype;	chr2:53735699	chr2:54082554~54085066:+
LUAD	cis	rs35094601	0.731	rs12463988	ENSG00000228043.4	AC097721.2	3.6	0.000351	0.039	0.18	0.16	Schizophrenia;	chr2:138471955	chr2:138418284~138501698:-
LUAD	cis	rs79040073	0.911	rs17393193	ENSG00000259531.2	RP11-295H24.3	3.6	0.000351	0.039	0.23	0.16	Lung cancer in ever smokers;	chr15:49039882	chr15:49365124~49366685:-
LUAD	cis	rs4667682	0.583	rs1035249	ENSG00000228389.1	AC068039.4	-3.6	0.000351	0.039	-0.29	-0.16	Hippocampal atrophy;Body mass index;	chr2:171282655	chr2:171773482~171775844:+
LUAD	cis	rs8141529	0.632	rs5762803	ENSG00000272858.1	CTA-292E10.8	-3.6	0.000351	0.039	-0.19	-0.16	Lymphocyte counts;	chr22:28797650	chr22:28814914~28815662:+
LUAD	cis	rs404005	0.684	rs13394655	ENSG00000227028.5	SLC8A1-AS1	-3.6	0.000351	0.039	-0.2	-0.16	HIV-associated dementia;	chr2:40168624	chr2:39786453~40255209:+
LUAD	cis	rs734999	0.967	rs10752745	ENSG00000238164.5	RP3-395M20.8	-3.6	0.000351	0.039	-0.14	-0.16	Ulcerative colitis;	chr1:2576499	chr1:2549920~2557031:-
LUAD	cis	rs7142881	0.815	rs12886765	ENSG00000258525.1	RP11-829H16.3	-3.6	0.000351	0.039	-0.18	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31713468	chr14:30876179~30889808:-
LUAD	cis	rs2288884	0.708	rs12460617	ENSG00000269959.1	SPACA6P-AS	-3.6	0.000351	0.039	-0.19	-0.16	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52032581	chr19:51685363~51693456:-
LUAD	cis	rs7107174	0.892	rs11237463	ENSG00000251323.2	RP11-452H21.4	3.6	0.000351	0.039	0.21	0.16	Testicular germ cell tumor;	chr11:78349418	chr11:78423982~78429836:-
LUAD	cis	rs570399	0.837	rs523103	ENSG00000232862.4	RP4-665N4.4	-3.6	0.000352	0.039	-0.16	-0.16	Neuroticism;	chr1:36743674	chr1:36080066~36082322:-
LUAD	cis	rs860818	1	rs858276	ENSG00000226816.2	AC005082.12	3.6	0.000352	0.039	0.41	0.16	Initial pursuit acceleration;	chr7:23212934	chr7:23206013~23208045:+
LUAD	cis	rs2638953	0.893	rs7313862	ENSG00000278733.1	RP11-425D17.1	-3.6	0.000352	0.039	-0.19	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28458846	chr12:28185625~28186190:-
LUAD	cis	rs4865762	0.512	rs56197881	ENSG00000247796.2	CTD-2366F13.1	3.6	0.000352	0.0391	0.18	0.16	Intraocular pressure;	chr5:53204165	chr5:53109842~53115126:+
LUAD	cis	rs6502050	0.835	rs9674648	ENSG00000275966.1	RP11-1055B8.9	-3.6	0.000352	0.0391	-0.16	-0.16	Life satisfaction;	chr17:82138880	chr17:81345476~81345966:-
LUAD	cis	rs4578769	0.55	rs9953702	ENSG00000266850.1	RP11-370A5.1	3.6	0.000352	0.0391	0.21	0.16	Eosinophil percentage of white cells;	chr18:22971001	chr18:22723491~22907721:-
LUAD	cis	rs4578769	0.569	rs9951157	ENSG00000266850.1	RP11-370A5.1	3.6	0.000352	0.0391	0.21	0.16	Eosinophil percentage of white cells;	chr18:22974173	chr18:22723491~22907721:-
LUAD	cis	rs2239785	0.959	rs129423	ENSG00000268818.2	CITF22-62D4.1	3.6	0.000352	0.0391	0.22	0.16	Glomerulosclerosis;	chr22:36261283	chr22:35626988~35635134:-
LUAD	cis	rs10129255	0.5	rs10143242	ENSG00000211955.2	IGHV3-33	-3.6	0.000352	0.0391	-0.12	-0.16	Kawasaki disease;	chr14:106681814	chr14:106359793~106360324:-
LUAD	cis	rs11210359	0.546	rs10789381	ENSG00000272864.1	RP11-17E13.2	3.6	0.000352	0.0391	0.2	0.16	Bipolar disorder and schizophrenia;	chr1:73870762	chr1:74698769~74699333:-
LUAD	cis	rs6494488	0.5	rs72741307	ENSG00000259635.1	AC100830.3	-3.6	0.000352	0.0391	-0.38	-0.16	Coronary artery disease;	chr15:64408024	chr15:64701248~64719602:+
LUAD	cis	rs2414856	0.51	rs77109323	ENSG00000259635.1	AC100830.3	-3.6	0.000352	0.0391	-0.38	-0.16	Pulse pressure;Systolic blood pressure;	chr15:64412742	chr15:64701248~64719602:+
LUAD	cis	rs6494488	0.5	rs34758599	ENSG00000259635.1	AC100830.3	-3.6	0.000352	0.0391	-0.38	-0.16	Coronary artery disease;	chr15:64414133	chr15:64701248~64719602:+
LUAD	cis	rs8050896	0.59	rs113959873	ENSG00000260695.1	RP11-513N24.1	-3.6	0.000352	0.0391	-0.33	-0.16	Response to antipsychotic treatment;	chr16:66182835	chr16:65861112~65863784:-
LUAD	cis	rs7955901	0.901	rs10784891	ENSG00000258053.1	CTD-2021H9.3	-3.6	0.000352	0.0391	-0.19	-0.16	Type 2 diabetes;	chr12:71036018	chr12:71047402~71118247:-
LUAD	cis	rs7955901	0.901	rs10879238	ENSG00000258053.1	CTD-2021H9.3	-3.6	0.000352	0.0391	-0.19	-0.16	Type 2 diabetes;	chr12:71036158	chr12:71047402~71118247:-
LUAD	cis	rs4853525	0.859	rs11897136	ENSG00000235852.1	AC005540.3	3.6	0.000352	0.0391	0.17	0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190846354	chr2:190880797~190882059:-
LUAD	cis	rs2505998	0.843	rs2506008	ENSG00000273008.1	RP11-351D16.3	-3.6	0.000352	0.0391	-0.17	-0.16	Hirschsprung disease;	chr10:43084776	chr10:43136824~43138334:-
LUAD	cis	rs17189298	0.935	rs330771	ENSG00000231013.1	AC013275.2	-3.6	0.000352	0.0391	-0.16	-0.16	Cerebrospinal T-tau levels;	chr2:119075935	chr2:119476448~119487346:+
LUAD	cis	rs9309473	0.5	rs1528169	ENSG00000163016.8	ALMS1P	-3.6	0.000352	0.0391	-0.17	-0.16	Metabolite levels;	chr2:73442058	chr2:73644919~73685576:+
LUAD	cis	rs9341808	0.718	rs1324123	ENSG00000233967.5	RP11-250B2.3	3.6	0.000352	0.0391	0.16	0.16	Sitting height ratio;	chr6:80223177	chr6:80443344~80465927:+
LUAD	cis	rs6921919	0.583	rs6907950	ENSG00000219392.1	RP1-265C24.5	-3.6	0.000352	0.0391	-0.21	-0.16	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28115628~28116551:+
LUAD	cis	rs1002107	0.84	rs10858665	ENSG00000257526.2	RP11-20E24.1	-3.6	0.000352	0.0391	-0.22	-0.16	Methadone dose in opioid dependence;	chr12:77304143	chr12:76562294~76615567:+
LUAD	cis	rs253959	0.672	rs4920903	ENSG00000272265.1	CTD-2287O16.4	3.6	0.000352	0.0391	0.17	0.16	Bipolar disorder and schizophrenia;	chr5:116085892	chr5:116078110~116078570:-
LUAD	cis	rs9475752	0.947	rs35961728	ENSG00000231441.1	RP11-472M19.2	3.6	0.000352	0.0391	0.26	0.16	Menarche (age at onset);	chr6:56941764	chr6:56844002~56864078:+
LUAD	cis	rs13113518	0.967	rs4340844	ENSG00000223305.1	RN7SKP30	3.6	0.000352	0.0391	0.18	0.16	Height;	chr4:55462689	chr4:55540502~55540835:-
LUAD	cis	rs13113518	1	rs1522112	ENSG00000223305.1	RN7SKP30	3.6	0.000352	0.0391	0.18	0.16	Height;	chr4:55463606	chr4:55540502~55540835:-
LUAD	cis	rs13113518	1	rs4864997	ENSG00000223305.1	RN7SKP30	3.6	0.000352	0.0391	0.18	0.16	Height;	chr4:55466010	chr4:55540502~55540835:-
LUAD	cis	rs13113518	1	rs960152	ENSG00000223305.1	RN7SKP30	3.6	0.000352	0.0391	0.18	0.16	Height;	chr4:55467308	chr4:55540502~55540835:-
LUAD	cis	rs13113518	0.967	rs12644948	ENSG00000223305.1	RN7SKP30	3.6	0.000352	0.0391	0.18	0.16	Height;	chr4:55470266	chr4:55540502~55540835:-
LUAD	cis	rs13113518	1	rs3805151	ENSG00000223305.1	RN7SKP30	3.6	0.000352	0.0391	0.18	0.16	Height;	chr4:55470874	chr4:55540502~55540835:-
LUAD	cis	rs13113518	1	rs13118237	ENSG00000223305.1	RN7SKP30	3.6	0.000352	0.0391	0.18	0.16	Height;	chr4:55474259	chr4:55540502~55540835:-
LUAD	cis	rs10946940	0.965	rs6910838	ENSG00000219392.1	RP1-265C24.5	3.6	0.000352	0.0391	0.2	0.16	Systemic lupus erythematosus;	chr6:27547740	chr6:28115628~28116551:+
LUAD	cis	rs6496044	0.568	rs2344436	ENSG00000259416.2	RP11-158M2.5	3.6	0.000352	0.0391	0.17	0.16	Interstitial lung disease;	chr15:85531675	chr15:85754941~85756237:-
LUAD	cis	rs6496044	0.568	rs6496065	ENSG00000259416.2	RP11-158M2.5	3.6	0.000352	0.0391	0.17	0.16	Interstitial lung disease;	chr15:85532141	chr15:85754941~85756237:-
LUAD	cis	rs6496044	0.568	rs6496066	ENSG00000259416.2	RP11-158M2.5	3.6	0.000352	0.0391	0.17	0.16	Interstitial lung disease;	chr15:85532231	chr15:85754941~85756237:-
LUAD	cis	rs2281558	0.876	rs2274890	ENSG00000125804.12	FAM182A	-3.6	0.000352	0.0391	-0.23	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25320386	chr20:26054655~26086917:+
LUAD	cis	rs858239	0.539	rs2141305	ENSG00000226816.2	AC005082.12	3.6	0.000352	0.0391	0.21	0.16	Cerebrospinal fluid biomarker levels;	chr7:23152280	chr7:23206013~23208045:+
LUAD	cis	rs794185	0.534	rs304063	ENSG00000231249.1	ITPR1-AS1	-3.6	0.000353	0.0391	-0.18	-0.16	Multiple sclerosis--Brain Glutamate Levels;	chr3:4499876	chr3:4490891~4493163:-
LUAD	cis	rs1376303	0.73	rs2278819	ENSG00000272905.1	RP11-265E18.1	3.6	0.000353	0.0391	0.19	0.16	Intelligence (multi-trait analysis);	chr7:32921912	chr7:32845394~32846061:+
LUAD	cis	rs1376303	0.841	rs2278820	ENSG00000272905.1	RP11-265E18.1	3.6	0.000353	0.0391	0.19	0.16	Intelligence (multi-trait analysis);	chr7:32922041	chr7:32845394~32846061:+
LUAD	cis	rs2803122	0.967	rs10811148	ENSG00000273226.1	RP11-513M16.8	-3.6	0.000353	0.0391	-0.17	-0.16	Pulse pressure;	chr9:19246469	chr9:19375451~19375996:+
LUAD	cis	rs10266483	0.774	rs11765812	ENSG00000227986.1	TRIM60P18	3.6	0.000353	0.0391	0.19	0.16	Response to statin therapy;	chr7:64385366	chr7:64355078~64356199:+
LUAD	cis	rs4763879	0.778	rs11052497	ENSG00000214776.8	RP11-726G1.1	-3.6	0.000353	0.0391	-0.19	-0.16	Type 1 diabetes;	chr12:9696679	chr12:9467552~9576275:+
LUAD	cis	rs6493487	0.512	rs7170364	ENSG00000273674.3	CTD-2378E12.1	3.6	0.000353	0.0391	0.23	0.16	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50830830	chr15:50839875~50908599:-
LUAD	cis	rs4795519	0.826	rs1851272	ENSG00000266313.1	RP11-173M1.4	3.6	0.000353	0.0392	0.19	0.16	Chronic myeloid leukemia;	chr17:27048727	chr17:27333256~27348491:+
LUAD	cis	rs13014235	0.579	rs6745435	ENSG00000234842.1	AC007163.8	-3.6	0.000353	0.0392	-0.19	-0.16	Basal cell carcinoma;	chr2:201337840	chr2:201549631~201550307:+
LUAD	cis	rs13014235	0.644	rs10201587	ENSG00000234842.1	AC007163.8	-3.6	0.000353	0.0392	-0.19	-0.16	Basal cell carcinoma;	chr2:201338068	chr2:201549631~201550307:+
LUAD	cis	rs970797	0.522	rs3754986	ENSG00000237260.1	AC073069.2	3.6	0.000353	0.0392	0.19	0.16	Monobrow;Lobe attachment (rater-scored or self-reported);	chr2:176325740	chr2:176338637~176339077:+
LUAD	cis	rs1823913	0.637	rs4853575	ENSG00000230611.1	HMGB1P27	3.6	0.000353	0.0392	0.18	0.16	Obesity-related traits;	chr2:191296149	chr2:191174233~191174835:+
LUAD	cis	rs10492201	0.529	rs12422954	ENSG00000255733.4	IFNG-AS1	3.6	0.000353	0.0392	0.17	0.16	Itch intensity from mosquito bite adjusted by bite size;	chr12:68007611	chr12:67989445~68234686:+
LUAD	cis	rs7618915	0.547	rs6976	ENSG00000243224.1	RP5-1157M23.2	-3.6	0.000353	0.0392	-0.17	-0.16	Bipolar disorder;	chr3:52694788	chr3:52239258~52241097:+
LUAD	cis	rs9921338	0.961	rs9936093	ENSG00000262703.1	RP11-485G7.6	-3.6	0.000353	0.0392	-0.17	-0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11343459	chr16:11348143~11349321:-
LUAD	cis	rs950169	0.734	rs67119537	ENSG00000230373.7	GOLGA6L5P	-3.6	0.000353	0.0392	-0.18	-0.16	Schizophrenia;	chr15:84395671	chr15:84507885~84516814:-
LUAD	cis	rs10129255	0.912	rs8011090	ENSG00000211967.3	IGHV3-53	-3.6	0.000353	0.0392	-0.13	-0.16	Kawasaki disease;	chr14:106678896	chr14:106592676~106593347:-
LUAD	cis	rs11960314	0.566	rs2292146	ENSG00000253348.1	CTC-455F18.1	-3.6	0.000353	0.0392	-0.18	-0.16	Age-related hearing impairment (SNP x SNP interaction);	chr5:170642186	chr5:170747047~170788650:-
LUAD	cis	rs6967385	0.546	rs6966667	ENSG00000226690.5	AC005281.1	3.6	0.000353	0.0392	0.22	0.16	Response to taxane treatment (placlitaxel);	chr7:12351379	chr7:12496429~12541910:+
LUAD	cis	rs3126085	0.515	rs6671146	ENSG00000237975.5	FLG-AS1	3.6	0.000353	0.0392	0.24	0.16	Atopic dermatitis;	chr1:152381996	chr1:152168125~152445456:+
LUAD	cis	rs7772486	0.774	rs2247571	ENSG00000235652.6	RP11-545I5.3	3.6	0.000353	0.0392	0.17	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145898397	chr6:145799409~145886585:+
LUAD	cis	rs6088590	0.901	rs6087631	ENSG00000275784.1	RP5-1125A11.6	-3.6	0.000353	0.0392	-0.18	-0.16	Coronary artery disease;	chr20:34815706	chr20:33989480~33991818:-
LUAD	cis	rs4938642	0.908	rs7108508	ENSG00000254909.1	RP11-110I1.5	3.6	0.000353	0.0392	0.21	0.16	Platelet count;	chr11:119155342	chr11:119005727~119005934:-
LUAD	cis	rs4938642	0.822	rs4938633	ENSG00000254909.1	RP11-110I1.5	3.6	0.000353	0.0392	0.21	0.16	Platelet count;	chr11:119155618	chr11:119005727~119005934:-
LUAD	cis	rs4938642	0.822	rs4938634	ENSG00000254909.1	RP11-110I1.5	3.6	0.000353	0.0392	0.21	0.16	Platelet count;	chr11:119155620	chr11:119005727~119005934:-
LUAD	cis	rs4938642	0.822	rs4938635	ENSG00000254909.1	RP11-110I1.5	3.6	0.000353	0.0392	0.21	0.16	Platelet count;	chr11:119155750	chr11:119005727~119005934:-
LUAD	cis	rs13437751	0.536	rs28438490	ENSG00000182722.5	SEPHS1P1	3.6	0.000353	0.0392	0.37	0.16	QT interval (drug interaction);	chr7:63871760	chr7:64852397~64853354:-
LUAD	cis	rs7617773	0.817	rs3731555	ENSG00000199476.1	Y_RNA	-3.6	0.000353	0.0392	-0.21	-0.16	Coronary artery disease;	chr3:48164612	chr3:48288587~48288694:+
LUAD	cis	rs4767841	1	rs10849691	ENSG00000248636.5	RP11-768F21.1	-3.6	0.000353	0.0392	-0.18	-0.16	Urgency urinary incontinence;	chr12:119716449	chr12:119387987~119668079:-
LUAD	cis	rs3733418	0.858	rs11100583	ENSG00000248632.1	RP11-366M4.11	3.6	0.000353	0.0392	0.27	0.16	Obesity-related traits;	chr4:164956493	chr4:164968587~164970002:-
LUAD	cis	rs797680	0.754	rs10874777	ENSG00000223745.6	RP4-717I23.3	3.6	0.000353	0.0392	0.13	0.16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93396463	chr1:93262186~93346025:-
LUAD	cis	rs7246657	0.943	rs4801803	ENSG00000226686.6	LINC01535	3.6	0.000353	0.0392	0.24	0.16	Coronary artery calcification;	chr19:37476021	chr19:37251912~37265535:+
LUAD	cis	rs7429990	1	rs319680	ENSG00000228638.1	FCF1P2	-3.6	0.000353	0.0392	-0.2	-0.16	Educational attainment (years of education);	chr3:47856817	chr3:48290793~48291375:-
LUAD	cis	rs11048434	0.518	rs2377678	ENSG00000256937.1	KRT17P8	-3.6	0.000353	0.0392	-0.18	-0.16	Sjögren's syndrome;	chr12:9021562	chr12:9127783~9128645:+
LUAD	cis	rs858239	0.965	rs156429	ENSG00000230042.1	AK3P3	-3.6	0.000353	0.0392	-0.2	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23129178~23129841:+
LUAD	cis	rs3805389	0.504	rs10017749	ENSG00000249700.7	SRD5A3-AS1	-3.6	0.000353	0.0392	-0.24	-0.16	Waist-to-hip ratio adjusted for body mass index;	chr4:55613007	chr4:55363971~55395847:-
LUAD	cis	rs3805389	0.504	rs3805385	ENSG00000249700.7	SRD5A3-AS1	-3.6	0.000353	0.0392	-0.24	-0.16	Waist-to-hip ratio adjusted for body mass index;	chr4:55613821	chr4:55363971~55395847:-
LUAD	cis	rs3805389	0.504	rs3805386	ENSG00000249700.7	SRD5A3-AS1	-3.6	0.000353	0.0392	-0.24	-0.16	Waist-to-hip ratio adjusted for body mass index;	chr4:55613838	chr4:55363971~55395847:-
LUAD	cis	rs3805389	0.504	rs3805387	ENSG00000249700.7	SRD5A3-AS1	-3.6	0.000353	0.0392	-0.24	-0.16	Waist-to-hip ratio adjusted for body mass index;	chr4:55613841	chr4:55363971~55395847:-
LUAD	cis	rs3805389	0.504	rs3805388	ENSG00000249700.7	SRD5A3-AS1	-3.6	0.000353	0.0392	-0.24	-0.16	Waist-to-hip ratio adjusted for body mass index;	chr4:55614754	chr4:55363971~55395847:-
LUAD	cis	rs442309	0.846	rs224049	ENSG00000238280.1	RP11-436D10.3	-3.6	0.000353	0.0392	-0.19	-0.16	Vogt-Koyanagi-Harada syndrome;	chr10:62732673	chr10:62793562~62805887:-
LUAD	cis	rs7326068	0.558	rs8002588	ENSG00000275485.1	RP11-261P13.6	-3.6	0.000353	0.0392	-0.22	-0.16	Schizophrenia, bipolar disorder and depression (combined);	chr13:20765247	chr13:20768876~20769375:-
LUAD	cis	rs3096299	0.781	rs2170839	ENSG00000261574.1	RP1-168P16.2	3.6	0.000353	0.0392	0.18	0.16	Multiple myeloma (IgH translocation);	chr16:89343044	chr16:89392375~89412564:-
LUAD	cis	rs763121	0.962	rs5757130	ENSG00000225450.1	RP3-508I15.14	-3.6	0.000353	0.0392	-0.15	-0.16	Menopause (age at onset);	chr22:38541789	chr22:38739003~38749041:+
LUAD	cis	rs9549260	0.755	rs7333037	ENSG00000229456.1	RLIMP1	3.6	0.000353	0.0392	0.18	0.16	Red blood cell count;	chr13:40641119	chr13:40618738~40621348:+
LUAD	cis	rs7772486	0.686	rs4896828	ENSG00000235652.6	RP11-545I5.3	3.6	0.000353	0.0392	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145632203	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.686	rs6570701	ENSG00000235652.6	RP11-545I5.3	3.6	0.000353	0.0392	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145632954	chr6:145799409~145886585:+
LUAD	cis	rs763121	0.814	rs5757212	ENSG00000228274.3	RP3-508I15.9	-3.6	0.000353	0.0392	-0.15	-0.16	Menopause (age at onset);	chr22:38657752	chr22:38667585~38681820:-
LUAD	cis	rs10463554	0.853	rs2432177	ENSG00000250682.4	LINC00491	3.6	0.000354	0.0392	0.2	0.16	Parkinson's disease;	chr5:103236172	chr5:102609156~102671559:-
LUAD	cis	rs9341808	0.718	rs9352806	ENSG00000233967.5	RP11-250B2.3	3.6	0.000354	0.0392	0.16	0.16	Sitting height ratio;	chr6:80270340	chr6:80443344~80465927:+
LUAD	cis	rs7824557	0.544	rs1865521	ENSG00000255046.1	RP11-297N6.4	-3.6	0.000354	0.0392	-0.2	-0.16	Retinal vascular caliber;	chr8:11373740	chr8:11797928~11802568:-
LUAD	cis	rs4474465	1	rs7395344	ENSG00000251323.2	RP11-452H21.4	3.6	0.000354	0.0392	0.21	0.16	Alzheimer's disease (survival time);	chr11:78491342	chr11:78423982~78429836:-
LUAD	cis	rs72799341	1	rs72799341	ENSG00000232748.3	RP11-196G11.6	-3.6	0.000354	0.0392	-0.23	-0.16	Diastolic blood pressure;	chr16:30925422	chr16:31056460~31062803:+
LUAD	cis	rs74544699	1	rs1957069	ENSG00000269559.2	RP11-629B11.5	-3.6	0.000354	0.0392	-0.35	-0.16	Growth-regulated protein alpha levels;	chr4:73874500	chr4:74156511~74158373:-
LUAD	cis	rs73108077	0.79	rs73104064	ENSG00000281376.1	ABALON	-3.6	0.000354	0.0392	-0.27	-0.16	Red blood cell density in sickle cell anemia;	chr20:31297920	chr20:31721507~31723409:+
LUAD	cis	rs73108077	0.79	rs73104067	ENSG00000281376.1	ABALON	-3.6	0.000354	0.0392	-0.27	-0.16	Red blood cell density in sickle cell anemia;	chr20:31298693	chr20:31721507~31723409:+
LUAD	cis	rs10435719	0.58	rs13260712	ENSG00000255046.1	RP11-297N6.4	3.6	0.000354	0.0392	0.2	0.16	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11925061	chr8:11797928~11802568:-
LUAD	cis	rs875971	0.545	rs10950029	ENSG00000224316.1	RP11-479O9.2	3.6	0.000354	0.0392	0.18	0.16	Aortic root size;	chr7:66169334	chr7:65773620~65802067:+
LUAD	cis	rs12149074	0.621	rs8059251	ENSG00000261390.4	RP11-345M22.2	-3.6	0.000354	0.0393	-0.22	-0.16	Bipolar disorder and eating disorder;Eating disorder in bipolar disorder;	chr16:80066415	chr16:79715232~79770563:-
LUAD	cis	rs35000415	0.873	rs13246321	ENSG00000275106.1	RP11-309L24.10	-3.6	0.000354	0.0393	-0.32	-0.16	Systemic lupus erythematosus;	chr7:129061277	chr7:128952527~128953316:-
LUAD	cis	rs72634501	0.716	rs67062906	ENSG00000182109.6	RP11-69E11.4	3.6	0.000354	0.0393	0.2	0.16	HDL cholesterol;	chr1:39151018	chr1:39522280~39546187:-
LUAD	cis	rs898097	0.625	rs898095	ENSG00000263063.1	RP11-388C12.1	3.6	0.000354	0.0393	0.16	0.16	Breast cancer;	chr17:82932762	chr17:82713908~82716255:-
LUAD	cis	rs898097	0.625	rs6502017	ENSG00000263063.1	RP11-388C12.1	3.6	0.000354	0.0393	0.16	0.16	Breast cancer;	chr17:82933259	chr17:82713908~82716255:-
LUAD	cis	rs17772222	0.682	rs3783889	ENSG00000258983.2	RP11-507K2.2	3.6	0.000354	0.0393	0.18	0.16	Coronary artery calcification;	chr14:88475637	chr14:88499334~88515502:+
LUAD	cis	rs17772222	0.637	rs879932	ENSG00000258983.2	RP11-507K2.2	3.6	0.000354	0.0393	0.18	0.16	Coronary artery calcification;	chr14:88479247	chr14:88499334~88515502:+
LUAD	cis	rs7428	0.545	rs9248	ENSG00000246575.2	AC093162.5	3.6	0.000354	0.0393	0.15	0.16	Ear protrusion;	chr2:85310189	chr2:85315041~85316529:+
LUAD	cis	rs61629263	0.618	rs851055	ENSG00000267151.3	RP11-100E5.2	-3.6	0.000354	0.0393	-0.18	-0.16	Facial morphology (factor 17, height of vermillion upper lip);	chr17:43759492	chr17:43444707~43451200:+
LUAD	cis	rs28671666	1	rs28671666	ENSG00000226690.5	AC005281.1	3.6	0.000354	0.0393	0.2	0.16	Hippocampal sclerosis;	chr7:12144804	chr7:12496429~12541910:+
LUAD	cis	rs334353	0.798	rs334350	ENSG00000255145.2	STX17-AS1	-3.6	0.000354	0.0393	-0.22	-0.16	Age-related macular degeneration;	chr9:99158317	chr9:99886322~99906601:-
LUAD	cis	rs7204230	1	rs8053033	ENSG00000261291.1	RP11-295M3.2	3.6	0.000354	0.0393	0.19	0.16	Fibrinogen;	chr16:53289001	chr16:53168522~53169450:+
LUAD	cis	rs10510102	0.935	rs11200260	ENSG00000276742.1	RP11-500G22.4	3.6	0.000354	0.0393	0.26	0.16	Breast cancer;	chr10:121920169	chr10:121956782~121957098:+
LUAD	cis	rs8014252	1	rs2332389	ENSG00000274818.1	RP1-292L20.3	3.6	0.000354	0.0393	0.27	0.16	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70496302	chr14:70906657~70907111:-
LUAD	cis	rs916888	0.773	rs199451	ENSG00000260075.1	NSFP1	-3.6	0.000354	0.0393	-0.27	-0.16	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46372855~46487141:+
LUAD	cis	rs6661961	0.752	rs556124	ENSG00000237975.5	FLG-AS1	-3.6	0.000354	0.0393	-0.23	-0.16	Atopic dermatitis;	chr1:152448127	chr1:152168125~152445456:+
LUAD	cis	rs17122278	1	rs17122269	ENSG00000243431.1	RPL5P30	3.6	0.000354	0.0393	0.21	0.16	Total cholesterol levels;	chr11:118574560	chr11:118560690~118561580:+
LUAD	cis	rs3026445	0.752	rs58792942	ENSG00000278993.1	RP3-424M6.4	3.6	0.000354	0.0393	0.16	0.16	QT interval;	chr12:110113340	chr12:110501614~110503441:+
LUAD	cis	rs3026445	0.722	rs12311063	ENSG00000278993.1	RP3-424M6.4	3.6	0.000354	0.0393	0.16	0.16	QT interval;	chr12:110119507	chr12:110501614~110503441:+
LUAD	cis	rs3026445	0.751	rs12306972	ENSG00000278993.1	RP3-424M6.4	3.6	0.000354	0.0393	0.16	0.16	QT interval;	chr12:110125805	chr12:110501614~110503441:+
LUAD	cis	rs3026445	0.791	rs12300649	ENSG00000278993.1	RP3-424M6.4	3.6	0.000354	0.0393	0.16	0.16	QT interval;	chr12:110135535	chr12:110501614~110503441:+
LUAD	cis	rs12440869	1	rs4410030	ENSG00000270964.1	RP11-502I4.3	3.6	0.000354	0.0393	0.18	0.16	Peak velocity of the mitral A-wave;	chr15:67350301	chr15:67541072~67542604:-
LUAD	cis	rs12440869	1	rs12904476	ENSG00000270964.1	RP11-502I4.3	3.6	0.000354	0.0393	0.18	0.16	Peak velocity of the mitral A-wave;	chr15:67352544	chr15:67541072~67542604:-
LUAD	cis	rs4664293	0.867	rs2303550	ENSG00000230783.1	AC009961.2	-3.6	0.000354	0.0393	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159781110	chr2:159689217~159690291:-
LUAD	cis	rs7061710	0.711	rs7886938	ENSG00000271811.1	RP1-79C4.4	3.6	0.000354	0.0393	0.24	0.16	Blood metabolite levels;	chr1:171152129	chr1:170667381~170669425:+
LUAD	cis	rs2380205	0.967	rs4287254	ENSG00000232807.2	RP11-536K7.3	3.6	0.000354	0.0393	0.17	0.16	Breast cancer;	chr10:5846178	chr10:5934270~5945900:-
LUAD	cis	rs2380205	0.967	rs7897260	ENSG00000232807.2	RP11-536K7.3	3.6	0.000354	0.0393	0.17	0.16	Breast cancer;	chr10:5846464	chr10:5934270~5945900:-
LUAD	cis	rs2380205	0.967	rs7907795	ENSG00000232807.2	RP11-536K7.3	3.6	0.000354	0.0393	0.17	0.16	Breast cancer;	chr10:5846817	chr10:5934270~5945900:-
LUAD	cis	rs2380205	0.967	rs7903875	ENSG00000232807.2	RP11-536K7.3	3.6	0.000354	0.0393	0.17	0.16	Breast cancer;	chr10:5846822	chr10:5934270~5945900:-
LUAD	cis	rs2380205	0.967	rs7898059	ENSG00000232807.2	RP11-536K7.3	3.6	0.000354	0.0393	0.17	0.16	Breast cancer;	chr10:5847075	chr10:5934270~5945900:-
LUAD	cis	rs2380205	0.967	rs10795590	ENSG00000232807.2	RP11-536K7.3	3.6	0.000354	0.0393	0.17	0.16	Breast cancer;	chr10:5847123	chr10:5934270~5945900:-
LUAD	cis	rs1023500	0.505	rs134887	ENSG00000226450.2	CYP2D8P	3.6	0.000354	0.0393	0.12	0.16	Schizophrenia;	chr22:42278233	chr22:42149886~42155001:-
LUAD	cis	rs1038094	0.929	rs28649098	ENSG00000277749.1	RP11-60L3.6	3.6	0.000354	0.0393	0.24	0.16	Bipolar disorder;	chr15:73731159	chr15:74311516~74319688:-
LUAD	cis	rs1038094	1	rs28627084	ENSG00000277749.1	RP11-60L3.6	3.6	0.000354	0.0393	0.24	0.16	Bipolar disorder;	chr15:73731297	chr15:74311516~74319688:-
LUAD	cis	rs1038094	1	rs4887036	ENSG00000277749.1	RP11-60L3.6	3.6	0.000354	0.0393	0.24	0.16	Bipolar disorder;	chr15:73731512	chr15:74311516~74319688:-
LUAD	cis	rs1038094	1	rs4887039	ENSG00000277749.1	RP11-60L3.6	3.6	0.000354	0.0393	0.24	0.16	Bipolar disorder;	chr15:73731523	chr15:74311516~74319688:-
LUAD	cis	rs34286592	1	rs34127220	ENSG00000214725.6	CDIPT-AS1	-3.6	0.000354	0.0393	-0.26	-0.16	Multiple sclerosis;	chr16:29831570	chr16:29863593~29868053:+
LUAD	cis	rs6502050	0.805	rs9898507	ENSG00000266654.1	RP11-1376P16.1	-3.6	0.000354	0.0393	-0.17	-0.16	Life satisfaction;	chr17:82161752	chr17:82160056~82160452:+
LUAD	cis	rs6502050	0.769	rs9904237	ENSG00000266654.1	RP11-1376P16.1	-3.6	0.000354	0.0393	-0.17	-0.16	Life satisfaction;	chr17:82161788	chr17:82160056~82160452:+
LUAD	cis	rs6502050	0.769	rs9898542	ENSG00000266654.1	RP11-1376P16.1	-3.6	0.000354	0.0393	-0.17	-0.16	Life satisfaction;	chr17:82161806	chr17:82160056~82160452:+
LUAD	cis	rs2024714	0.967	rs2427199	ENSG00000273812.1	WI2-87327B8.2	-3.6	0.000354	0.0393	-0.17	-0.16	Longevity;	chr20:61629837	chr20:62596732~62603115:-
LUAD	cis	rs4666002	0.636	rs2272406	ENSG00000223522.1	AC093690.1	3.6	0.000354	0.0393	0.19	0.16	Phospholipid levels (plasma);	chr2:27669156	chr2:28307691~28310459:-
LUAD	cis	rs9341808	0.718	rs2322630	ENSG00000233967.5	RP11-250B2.3	3.6	0.000354	0.0393	0.16	0.16	Sitting height ratio;	chr6:80131316	chr6:80443344~80465927:+
LUAD	cis	rs755249	0.51	rs582883	ENSG00000182109.6	RP11-69E11.4	3.6	0.000354	0.0393	0.18	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39369868	chr1:39522280~39546187:-
LUAD	cis	rs6460942	1	rs6944134	ENSG00000226690.5	AC005281.1	3.6	0.000354	0.0393	0.29	0.16	Coronary artery disease;	chr7:12378410	chr7:12496429~12541910:+
LUAD	cis	rs2836950	0.561	rs34705151	ENSG00000232608.1	TIMM9P2	3.6	0.000354	0.0393	0.18	0.16	Menarche (age at onset);	chr21:39181418	chr21:39216624~39217506:+
LUAD	cis	rs6921919	0.638	rs7772827	ENSG00000176933.5	TOB2P1	-3.6	0.000354	0.0393	-0.19	-0.16	Autism spectrum disorder or schizophrenia;	chr6:28333366	chr6:28217643~28218634:-
LUAD	cis	rs76878669	0.561	rs55998145	ENSG00000213409.4	RP11-658F2.3	3.6	0.000354	0.0393	0.19	0.16	Educational attainment (years of education);	chr11:66385115	chr11:66761575~66762399:-
LUAD	cis	rs9468186	1	rs9468186	ENSG00000219392.1	RP1-265C24.5	-3.6	0.000355	0.0393	-0.21	-0.16	Neuroticism;	chr6:27658852	chr6:28115628~28116551:+
LUAD	cis	rs17826219	0.568	rs59858012	ENSG00000266490.1	CTD-2349P21.9	3.6	0.000355	0.0393	0.27	0.16	Body mass index;	chr17:30751564	chr17:30792372~30792833:+
LUAD	cis	rs78572108	0.778	rs971914	ENSG00000214691.7	AC104654.1	3.6	0.000355	0.0393	0.28	0.16	Total body bone mineral density;	chr2:42025736	chr2:41877074~41894046:+
LUAD	cis	rs11673344	0.864	rs7259513	ENSG00000267309.1	CTD-2630F21.1	-3.6	0.000355	0.0393	-0.21	-0.16	Obesity-related traits;	chr19:37085802	chr19:36489649~36491040:+
LUAD	cis	rs2613514	0.568	rs4789535	ENSG00000204282.4	TNRC6C-AS1	-3.6	0.000355	0.0393	-0.2	-0.16	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr17:78101560	chr17:78107398~78111799:-
LUAD	cis	rs8085804	0.597	rs3861286	ENSG00000276174.1	RP11-687E1.2	-3.6	0.000355	0.0393	-0.21	-0.16	Cognitive performance;	chr18:42638103	chr18:42052705~42053030:+
LUAD	cis	rs9325144	0.723	rs1586373	ENSG00000257718.1	RP11-396F22.1	-3.6	0.000355	0.0393	-0.19	-0.16	Morning vs. evening chronotype;	chr12:38787780	chr12:38906451~38909592:+
LUAD	cis	rs4908769	0.588	rs2784737	ENSG00000232912.4	RP5-1115A15.1	-3.6	0.000355	0.0393	-0.15	-0.16	Allergy;	chr1:8403116	chr1:8424645~8434838:+
LUAD	cis	rs1555322	0.53	rs2425044	ENSG00000269202.1	RP4-614O4.12	-3.6	0.000355	0.0393	-0.2	-0.16	Attention deficit hyperactivity disorder;	chr20:35281932	chr20:35201747~35203288:-
LUAD	cis	rs6787172	0.811	rs9858318	ENSG00000272087.1	RP11-379F4.7	3.6	0.000355	0.0393	0.17	0.16	Subjective well-being;	chr3:158505502	chr3:158693120~158693768:-
LUAD	cis	rs763121	0.626	rs5750643	ENSG00000225450.1	RP3-508I15.14	-3.6	0.000355	0.0393	-0.15	-0.16	Menopause (age at onset);	chr22:38613012	chr22:38739003~38749041:+
LUAD	cis	rs6088590	1	rs6087623	ENSG00000275784.1	RP5-1125A11.6	-3.6	0.000355	0.0393	-0.17	-0.16	Coronary artery disease;	chr20:34729858	chr20:33989480~33991818:-
LUAD	cis	rs2712475	0.556	rs77849805	ENSG00000241218.1	RP11-446H18.1	3.6	0.000355	0.0393	0.25	0.16	Colonoscopy-negative controls vs population controls;	chr3:106483153	chr3:107327830~107329197:-
LUAD	cis	rs11073619	0.803	rs7180895	ENSG00000230373.7	GOLGA6L5P	3.6	0.000355	0.0393	0.24	0.16	Positive affect;	chr15:84614489	chr15:84507885~84516814:-
LUAD	cis	rs473518	0.945	rs581098	ENSG00000223023.1	Y_RNA	3.6	0.000355	0.0393	0.24	0.16	Migraine - clinic-based;	chr18:22504389	chr18:23024596~23024703:+
LUAD	cis	rs12754538	0.777	rs6675857	ENSG00000232912.4	RP5-1115A15.1	3.6	0.000355	0.0393	0.17	0.16	Subjective well-being;	chr1:8592095	chr1:8424645~8434838:+
LUAD	cis	rs250518	0.926	rs1912005	ENSG00000226544.4	RPL7P22	3.6	0.000355	0.0394	0.17	0.16	Mean corpuscular hemoglobin concentration;	chr5:72772227	chr5:72725419~72726151:+
LUAD	cis	rs6012953	0.845	rs968701	ENSG00000231715.1	COX6CP2	-3.6	0.000355	0.0394	-0.16	-0.16	Vitiligo;	chr20:50578711	chr20:50479767~50479991:+
LUAD	cis	rs987724	0.593	rs7652112	ENSG00000240875.4	LINC00886	-3.6	0.000355	0.0394	-0.18	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156854774	chr3:156747346~156817062:-
LUAD	cis	rs987724	0.593	rs2060015	ENSG00000240875.4	LINC00886	-3.6	0.000355	0.0394	-0.18	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156856141	chr3:156747346~156817062:-
LUAD	cis	rs2024714	0.933	rs2427194	ENSG00000273812.1	WI2-87327B8.2	-3.6	0.000355	0.0394	-0.17	-0.16	Longevity;	chr20:61628789	chr20:62596732~62603115:-
LUAD	cis	rs2024714	0.933	rs2427195	ENSG00000273812.1	WI2-87327B8.2	-3.6	0.000355	0.0394	-0.17	-0.16	Longevity;	chr20:61628914	chr20:62596732~62603115:-
LUAD	cis	rs7584330	0.695	rs77922291	ENSG00000222032.1	AC112721.2	3.6	0.000355	0.0394	0.19	0.16	Prostate cancer;	chr2:237457674	chr2:237428920~237434822:-
LUAD	cis	rs7584330	0.737	rs937392	ENSG00000222032.1	AC112721.2	3.6	0.000355	0.0394	0.19	0.16	Prostate cancer;	chr2:237458487	chr2:237428920~237434822:-
LUAD	cis	rs6688613	0.685	rs2142615	ENSG00000225171.2	DUTP6	-3.6	0.000355	0.0394	-0.21	-0.16	Refractive astigmatism;	chr1:166953494	chr1:166868748~166869209:+
LUAD	cis	rs1910358	0.69	rs1604454	ENSG00000248874.4	C5orf17	-3.6	0.000355	0.0394	-0.21	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23945694	chr5:23951348~24178263:+
LUAD	cis	rs7107174	0.892	rs4945265	ENSG00000251323.2	RP11-452H21.4	3.6	0.000355	0.0394	0.22	0.16	Testicular germ cell tumor;	chr11:78316412	chr11:78423982~78429836:-
LUAD	cis	rs7107174	0.786	rs4945266	ENSG00000251323.2	RP11-452H21.4	3.6	0.000355	0.0394	0.22	0.16	Testicular germ cell tumor;	chr11:78316442	chr11:78423982~78429836:-
LUAD	cis	rs970797	0.522	rs1880226	ENSG00000237260.1	AC073069.2	3.6	0.000355	0.0394	0.19	0.16	Monobrow;Lobe attachment (rater-scored or self-reported);	chr2:176331785	chr2:176338637~176339077:+
LUAD	cis	rs4927850	1	rs7630875	ENSG00000278820.1	AC024937.1	3.6	0.000355	0.0394	0.14	0.16	Pancreatic cancer;	chr3:196026895	chr3:195960500~195960612:-
LUAD	cis	rs6005807	0.543	rs12168849	ENSG00000272858.1	CTA-292E10.8	-3.6	0.000355	0.0394	-0.25	-0.16	Invasive epithelial ovarian cancer;Epithelial ovarian cancer;Cerebrospinal P-tau181p levels;Cerebrospinal T-tau levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;	chr22:28806075	chr22:28814914~28815662:+
LUAD	cis	rs7121538	0.673	rs11023164	ENSG00000254418.1	RP11-21L19.1	-3.6	0.000355	0.0394	-0.28	-0.16	HDL cholesterol;	chr11:14261908	chr11:14262846~14273691:-
LUAD	cis	rs7665090	0.517	rs1585214	ENSG00000246560.2	RP11-10L12.4	3.6	0.000356	0.0394	0.21	0.16	Primary biliary cholangitis;	chr4:102523376	chr4:102828055~102844075:+
LUAD	cis	rs1595014	0.508	rs6460886	ENSG00000226690.5	AC005281.1	3.6	0.000356	0.0394	0.2	0.16	Alzheimer's disease (APOE e4 interaction);	chr7:12163959	chr7:12496429~12541910:+
LUAD	cis	rs1552244	0.882	rs67631672	ENSG00000180385.7	EMC3-AS1	3.6	0.000356	0.0394	0.19	0.16	Alzheimer's disease;	chr3:9963084	chr3:9986893~10006990:+
LUAD	cis	rs6674176	0.597	rs2352990	ENSG00000237950.1	RP11-7O11.3	3.6	0.000356	0.0394	0.2	0.16	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43927604	chr1:43944370~43946551:-
LUAD	cis	rs75583333	0.655	rs79505993	ENSG00000253522.3	CTC-231O11.1	3.6	0.000356	0.0394	0.27	0.16	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr5:160059012	chr5:160468268~160487426:+
LUAD	cis	rs67981189	0.896	rs7153237	ENSG00000269927.1	RP6-91H8.3	3.6	0.000356	0.0394	0.2	0.16	Schizophrenia;	chr14:71021937	chr14:71141125~71143253:-
LUAD	cis	rs494562	0.892	rs521005	ENSG00000234155.1	RP11-30P6.6	-3.6	0.000356	0.0394	-0.31	-0.16	Metabolic traits;Blood metabolite levels;	chr6:85406824	chr6:85387219~85390186:-
LUAD	cis	rs9309473	1	rs7572722	ENSG00000230002.2	ALMS1-IT1	3.6	0.000356	0.0394	0.21	0.16	Metabolite levels;	chr2:73497548	chr2:73456764~73459484:+
LUAD	cis	rs1979755	0.933	rs13016349	ENSG00000214691.7	AC104654.1	3.6	0.000356	0.0394	0.19	0.16	Body mass index;	chr2:42483922	chr2:41877074~41894046:+
LUAD	cis	rs7071275	0.6	rs11200051	ENSG00000226864.1	ATE1-AS1	3.6	0.000356	0.0394	0.31	0.16	Dupuytren's disease;	chr10:121642661	chr10:121928312~121951965:+
LUAD	cis	rs76878669	0.538	rs4930360	ENSG00000213409.4	RP11-658F2.3	3.6	0.000356	0.0394	0.2	0.16	Educational attainment (years of education);	chr11:66375776	chr11:66761575~66762399:-
LUAD	cis	rs7142881	0.787	rs4981114	ENSG00000258525.1	RP11-829H16.3	-3.6	0.000356	0.0394	-0.18	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31700940	chr14:30876179~30889808:-
LUAD	cis	rs4142995	0.695	rs2723510	ENSG00000279048.1	RP11-511H23.2	-3.6	0.000356	0.0394	-0.13	-0.16	HDL cholesterol;HDL cholesterol levels;	chr7:17777015	chr7:17940503~17942922:+
LUAD	cis	rs875971	0.545	rs75840613	ENSG00000224316.1	RP11-479O9.2	3.6	0.000356	0.0394	0.19	0.16	Aortic root size;	chr7:66376399	chr7:65773620~65802067:+
LUAD	cis	rs5758659	0.652	rs133347	ENSG00000227370.1	RP4-669P10.19	-3.6	0.000356	0.0394	-0.15	-0.16	Cognitive function;	chr22:42027641	chr22:42132543~42132998:+
LUAD	cis	rs7178424	1	rs11629596	ENSG00000259251.2	RP11-643M14.1	-3.6	0.000356	0.0394	-0.16	-0.16	Height;	chr15:62077914	chr15:62060503~62062434:+
LUAD	cis	rs7017914	0.934	rs2639921	ENSG00000246366.5	RP11-382J12.1	3.6	0.000356	0.0394	0.15	0.16	Bone mineral density;	chr8:70962599	chr8:70608577~70663279:+
LUAD	cis	rs1023500	0.505	rs2143139	ENSG00000205702.9	CYP2D7	3.6	0.000356	0.0394	0.13	0.16	Schizophrenia;	chr22:42218395	chr22:42140203~42144577:-
LUAD	cis	rs9951698	0.703	rs6505776	ENSG00000266969.1	RP11-773H22.4	3.6	0.000356	0.0395	0.21	0.16	Intelligence (multi-trait analysis);	chr18:12984145	chr18:12984694~12991173:-
LUAD	cis	rs2274273	0.638	rs3759667	ENSG00000258413.1	RP11-665C16.6	-3.6	0.000356	0.0395	-0.23	-0.16	Protein biomarker;	chr14:55191703	chr14:55262767~55272075:-
LUAD	cis	rs6781182	0.5	rs7626572	ENSG00000236452.1	AC123023.1	3.6	0.000356	0.0395	0.18	0.16	Visceral adipose tissue adjusted for BMI;	chr3:34176172	chr3:34203244~34268811:+
LUAD	cis	rs10510102	0.566	rs885543	ENSG00000276742.1	RP11-500G22.4	3.6	0.000356	0.0395	0.28	0.16	Breast cancer;	chr10:121973536	chr10:121956782~121957098:+
LUAD	cis	rs513088	0.681	rs12142855	ENSG00000225171.2	DUTP6	3.6	0.000356	0.0395	0.21	0.16	Schizophrenia;	chr1:166685613	chr1:166868748~166869209:+
LUAD	cis	rs7208859	0.725	rs9910051	ENSG00000263603.1	CTD-2349P21.5	-3.6	0.000356	0.0395	-0.25	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834184	chr17:30729469~30731202:+
LUAD	cis	rs8180040	0.932	rs1531875	ENSG00000271161.1	BOLA2P2	3.6	0.000356	0.0395	0.16	0.16	Colorectal cancer;	chr3:47411296	chr3:47499841~47500407:+
LUAD	cis	rs990171	0.538	rs7593935	ENSG00000234389.1	AC007278.3	3.6	0.000356	0.0395	0.16	0.16	Lymphocyte counts;	chr2:102501669	chr2:102438713~102440475:+
LUAD	cis	rs990171	0.538	rs2075192	ENSG00000234389.1	AC007278.3	3.6	0.000356	0.0395	0.16	0.16	Lymphocyte counts;	chr2:102501769	chr2:102438713~102440475:+
LUAD	cis	rs990171	0.538	rs2075190	ENSG00000234389.1	AC007278.3	3.6	0.000356	0.0395	0.16	0.16	Lymphocyte counts;	chr2:102502100	chr2:102438713~102440475:+
LUAD	cis	rs6708413	0.501	rs2075189	ENSG00000234389.1	AC007278.3	3.6	0.000356	0.0395	0.16	0.16	Crohn's disease;Inflammatory bowel disease;	chr2:102502230	chr2:102438713~102440475:+
LUAD	cis	rs875971	0.929	rs4122249	ENSG00000273142.1	RP11-458F8.4	-3.6	0.000356	0.0395	-0.11	-0.16	Aortic root size;	chr7:66455949	chr7:66902857~66906297:+
LUAD	cis	rs7809950	1	rs4727681	ENSG00000238832.1	snoU109	-3.6	0.000356	0.0395	-0.24	-0.16	Coronary artery disease;	chr7:107455699	chr7:107603363~107603507:+
LUAD	cis	rs61160187	0.582	rs4700407	ENSG00000272308.1	RP11-231G3.1	3.6	0.000356	0.0395	0.17	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:61070701	chr5:60866457~60866935:-
LUAD	cis	rs1799949	1	rs2298862	ENSG00000267340.1	RP11-242D8.3	3.6	0.000356	0.0395	0.17	0.16	Menopause (age at onset);	chr17:43024671	chr17:43169880~43170077:-
LUAD	cis	rs1799949	0.93	rs2298861	ENSG00000267340.1	RP11-242D8.3	3.6	0.000356	0.0395	0.17	0.16	Menopause (age at onset);	chr17:43024814	chr17:43169880~43170077:-
LUAD	cis	rs13113518	1	rs4865004	ENSG00000273257.1	RP11-177J6.1	3.6	0.000356	0.0395	0.18	0.16	Height;	chr4:55515118	chr4:55387949~55388271:+
LUAD	cis	rs34783982	0.919	rs12593652	ENSG00000261441.1	RP11-217B1.2	-3.6	0.000356	0.0395	-0.22	-0.16	Squamous cell lung carcinoma;	chr15:88960496	chr15:89335053~89336161:+
LUAD	cis	rs10129255	1	rs10134517	ENSG00000211947.2	IGHV3-21	-3.6	0.000356	0.0395	-0.11	-0.16	Kawasaki disease;	chr14:106718498	chr14:106235064~106235594:-
LUAD	cis	rs7760535	0.93	rs10872069	ENSG00000271789.1	RP5-1112D6.7	-3.6	0.000356	0.0395	-0.17	-0.16	Metabolic traits;	chr6:111540523	chr6:111297126~111298510:+
LUAD	cis	rs4664293	0.867	rs11681245	ENSG00000230783.1	AC009961.2	-3.6	0.000356	0.0395	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159772882	chr2:159689217~159690291:-
LUAD	cis	rs8014252	0.803	rs17108107	ENSG00000259158.2	ADAM20P1	-3.6	0.000356	0.0395	-0.24	-0.16	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70411054	chr14:70468881~70483756:-
LUAD	cis	rs7208859	0.623	rs55811708	ENSG00000265443.1	CTD-2349P21.6	-3.6	0.000357	0.0395	-0.26	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30726305~30727564:-
LUAD	cis	rs4713118	0.824	rs742046	ENSG00000280107.1	AL022393.9	-3.6	0.000357	0.0395	-0.2	-0.16	Parkinson's disease;	chr6:27771475	chr6:28170845~28172521:+
LUAD	cis	rs516805	0.961	rs544099	ENSG00000279114.1	RP3-425C14.5	3.6	0.000357	0.0395	0.18	0.16	Lymphocyte counts;	chr6:122479837	chr6:122471923~122484161:+
LUAD	cis	rs7674212	0.541	rs4699051	ENSG00000246560.2	RP11-10L12.4	3.6	0.000357	0.0395	0.21	0.16	Type 2 diabetes;	chr4:103193237	chr4:102828055~102844075:+
LUAD	cis	rs755249	0.958	rs17264866	ENSG00000237624.1	OXCT2P1	3.6	0.000357	0.0395	0.24	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39557105	chr1:39514956~39516490:+
LUAD	cis	rs11065706	0.715	rs1265742	ENSG00000278993.1	RP3-424M6.4	-3.6	0.000357	0.0395	-0.21	-0.16	Heart rate;	chr12:110577316	chr12:110501614~110503441:+
LUAD	cis	rs12928939	0.815	rs12446005	ENSG00000262140.1	RP11-417N10.3	-3.6	0.000357	0.0395	-0.19	-0.16	Post bronchodilator FEV1;	chr16:71621132	chr16:71833787~71835932:+
LUAD	cis	rs7246657	0.943	rs10407084	ENSG00000267470.4	ZNF571-AS1	3.6	0.000357	0.0395	0.23	0.16	Coronary artery calcification;	chr19:37416890	chr19:37548914~37587348:+
LUAD	cis	rs7246657	0.943	rs7252099	ENSG00000267470.4	ZNF571-AS1	3.6	0.000357	0.0395	0.23	0.16	Coronary artery calcification;	chr19:37442878	chr19:37548914~37587348:+
LUAD	cis	rs7246657	0.943	rs7255972	ENSG00000267470.4	ZNF571-AS1	3.6	0.000357	0.0395	0.23	0.16	Coronary artery calcification;	chr19:37442939	chr19:37548914~37587348:+
LUAD	cis	rs7246657	0.943	rs1015849	ENSG00000267470.4	ZNF571-AS1	3.6	0.000357	0.0395	0.23	0.16	Coronary artery calcification;	chr19:37455278	chr19:37548914~37587348:+
LUAD	cis	rs794185	0.657	rs2633846	ENSG00000231249.1	ITPR1-AS1	-3.6	0.000357	0.0395	-0.18	-0.16	Multiple sclerosis--Brain Glutamate Levels;	chr3:4471781	chr3:4490891~4493163:-
LUAD	cis	rs2732480	0.538	rs2732462	ENSG00000257763.1	OR5BK1P	3.6	0.000357	0.0395	0.17	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48302601	chr12:48355792~48356614:-
LUAD	cis	rs7546668	1	rs4646090	ENSG00000272510.1	RP4-680D5.8	3.6	0.000357	0.0395	0.2	0.16	Glomerular filtration rate (creatinine);	chr1:15495578	chr1:15565611~15565956:-
LUAD	cis	rs7546668	1	rs6685648	ENSG00000272510.1	RP4-680D5.8	3.6	0.000357	0.0395	0.2	0.16	Glomerular filtration rate (creatinine);	chr1:15498700	chr1:15565611~15565956:-
LUAD	cis	rs7546668	1	rs4646068	ENSG00000272510.1	RP4-680D5.8	3.6	0.000357	0.0395	0.2	0.16	Glomerular filtration rate (creatinine);	chr1:15502209	chr1:15565611~15565956:-
LUAD	cis	rs10875976	0.525	rs9805137	ENSG00000257464.1	RP11-161H23.8	-3.6	0.000357	0.0395	-0.16	-0.16	Obesity;	chr12:49865279	chr12:49442424~49442652:-
LUAD	cis	rs3749855	0.596	rs35515913	ENSG00000220920.1	RP3-525L6.2	3.6	0.000357	0.0395	0.33	0.16	Glucose homeostasis traits;	chr6:17251995	chr6:17953572~17953930:+
LUAD	cis	rs3749855	0.679	rs13217920	ENSG00000220920.1	RP3-525L6.2	3.6	0.000357	0.0395	0.33	0.16	Glucose homeostasis traits;	chr6:17252111	chr6:17953572~17953930:+
LUAD	cis	rs3749855	0.679	rs13199169	ENSG00000220920.1	RP3-525L6.2	3.6	0.000357	0.0395	0.33	0.16	Glucose homeostasis traits;	chr6:17252244	chr6:17953572~17953930:+
LUAD	cis	rs3749855	0.679	rs13214895	ENSG00000220920.1	RP3-525L6.2	3.6	0.000357	0.0395	0.33	0.16	Glucose homeostasis traits;	chr6:17252311	chr6:17953572~17953930:+
LUAD	cis	rs2834288	0.535	rs8129694	ENSG00000273102.1	AP000569.9	-3.6	0.000357	0.0395	-0.2	-0.16	Gut microbiota (bacterial taxa);	chr21:33954795	chr21:33967101~33968573:-
LUAD	cis	rs16846053	0.642	rs16846107	ENSG00000227403.1	AC009299.3	3.6	0.000357	0.0395	0.29	0.16	Blood osmolality (transformed sodium);	chr2:161775746	chr2:161244739~161249050:+
LUAD	cis	rs28386778	0.897	rs2727330	ENSG00000240280.5	TCAM1P	3.6	0.000357	0.0395	0.18	0.16	Prudent dietary pattern;	chr17:63848138	chr17:63849292~63864379:+
LUAD	cis	rs763121	1	rs1946990	ENSG00000225450.1	RP3-508I15.14	3.6	0.000357	0.0395	0.15	0.16	Menopause (age at onset);	chr22:38516766	chr22:38739003~38749041:+
LUAD	cis	rs7142881	0.815	rs35827419	ENSG00000258525.1	RP11-829H16.3	-3.6	0.000357	0.0395	-0.18	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31703780	chr14:30876179~30889808:-
LUAD	cis	rs7142881	0.815	rs2185522	ENSG00000258525.1	RP11-829H16.3	-3.6	0.000357	0.0395	-0.18	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31703848	chr14:30876179~30889808:-
LUAD	cis	rs7142881	0.787	rs7156969	ENSG00000258525.1	RP11-829H16.3	-3.6	0.000357	0.0395	-0.18	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31704382	chr14:30876179~30889808:-
LUAD	cis	rs7142881	0.815	rs12435348	ENSG00000258525.1	RP11-829H16.3	-3.6	0.000357	0.0395	-0.18	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31705937	chr14:30876179~30889808:-
LUAD	cis	rs7142881	0.815	rs11621446	ENSG00000258525.1	RP11-829H16.3	-3.6	0.000357	0.0395	-0.18	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31709461	chr14:30876179~30889808:-
LUAD	cis	rs7142881	0.815	rs72674891	ENSG00000258525.1	RP11-829H16.3	-3.6	0.000357	0.0395	-0.18	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31711840	chr14:30876179~30889808:-
LUAD	cis	rs10435719	0.902	rs4840599	ENSG00000255046.1	RP11-297N6.4	3.6	0.000357	0.0395	0.2	0.16	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11947871	chr8:11797928~11802568:-
LUAD	cis	rs950169	0.922	rs11630507	ENSG00000188388.10	GOLGA6L3	3.6	0.000357	0.0395	0.22	0.16	Schizophrenia;	chr15:84552494	chr15:85240472~85247170:+
LUAD	cis	rs7142881	0.815	rs11621253	ENSG00000258525.1	RP11-829H16.3	-3.6	0.000357	0.0395	-0.18	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31701846	chr14:30876179~30889808:-
LUAD	cis	rs448720	0.684	rs338346	ENSG00000260657.2	RP11-315D16.4	-3.6	0.000357	0.0395	-0.19	-0.16	Cognitive performance;	chr15:67932831	chr15:68267792~68277994:-
LUAD	cis	rs448720	0.684	rs338347	ENSG00000260657.2	RP11-315D16.4	-3.6	0.000357	0.0395	-0.19	-0.16	Cognitive performance;	chr15:67933483	chr15:68267792~68277994:-
LUAD	cis	rs1046491	1	rs71362073	ENSG00000264964.1	RP11-888D10.3	3.6	0.000357	0.0395	0.33	0.16	Scarlet fever;	chr18:9208548	chr18:9315194~9334441:-
LUAD	cis	rs1046491	1	rs62085924	ENSG00000264964.1	RP11-888D10.3	3.6	0.000357	0.0395	0.33	0.16	Scarlet fever;	chr18:9209456	chr18:9315194~9334441:-
LUAD	cis	rs8180040	0.8	rs11921117	ENSG00000260236.1	RP11-708J19.1	-3.6	0.000357	0.0395	-0.15	-0.16	Colorectal cancer;	chr3:47252510	chr3:47379089~47380999:-
LUAD	cis	rs6502050	0.699	rs9901808	ENSG00000275966.1	RP11-1055B8.9	-3.6	0.000357	0.0395	-0.17	-0.16	Life satisfaction;	chr17:82149938	chr17:81345476~81345966:-
LUAD	cis	rs11838267	0.527	rs3919533	ENSG00000256967.1	RP11-273B20.1	-3.6	0.000357	0.0395	-0.16	-0.16	Coronary artery disease;	chr12:7055497	chr12:7129079~7131198:-
LUAD	cis	rs570399	0.899	rs478746	ENSG00000232862.4	RP4-665N4.4	-3.6	0.000357	0.0396	-0.16	-0.16	Neuroticism;	chr1:36738834	chr1:36080066~36082322:-
LUAD	cis	rs10102546	1	rs895384	ENSG00000244642.3	RN7SL396P	3.6	0.000357	0.0396	0.19	0.16	Smoking cessation;	chr8:119539267	chr8:119862662~119862956:+
LUAD	cis	rs10102546	1	rs895385	ENSG00000244642.3	RN7SL396P	3.6	0.000357	0.0396	0.19	0.16	Smoking cessation;	chr8:119539323	chr8:119862662~119862956:+
LUAD	cis	rs899997	1	rs9888691	ENSG00000261143.1	ADAMTS7P3	3.6	0.000357	0.0396	0.18	0.16	Coronary artery disease or large artery stroke;	chr15:78717704	chr15:77976042~77993057:+
LUAD	cis	rs2836950	0.565	rs3171465	ENSG00000232608.1	TIMM9P2	3.6	0.000357	0.0396	0.18	0.16	Menarche (age at onset);	chr21:39180381	chr21:39216624~39217506:+
LUAD	cis	rs2548724	1	rs841934	ENSG00000250682.4	LINC00491	-3.6	0.000357	0.0396	-0.22	-0.16	Type 2 diabetes;	chr5:102286496	chr5:102609156~102671559:-
LUAD	cis	rs13434995	0.838	rs73236165	ENSG00000249700.7	SRD5A3-AS1	-3.6	0.000357	0.0396	-0.24	-0.16	Adiponectin levels;	chr4:55617617	chr4:55363971~55395847:-
LUAD	cis	rs6832769	0.961	rs3805147	ENSG00000272969.1	RP11-528I4.2	3.6	0.000357	0.0396	0.17	0.16	Personality dimensions;	chr4:55440563	chr4:55547112~55547889:+
LUAD	cis	rs6832769	1	rs3736544	ENSG00000272969.1	RP11-528I4.2	3.6	0.000357	0.0396	0.17	0.16	Personality dimensions;	chr4:55443825	chr4:55547112~55547889:+
LUAD	cis	rs9308731	0.666	rs724710	ENSG00000227992.1	AC108463.2	3.6	0.000357	0.0396	0.2	0.16	Chronic lymphocytic leukemia;	chr2:111150114	chr2:111203964~111206215:-
LUAD	cis	rs7976269	0.609	rs2082943	ENSG00000275476.1	RP11-996F15.4	-3.6	0.000357	0.0396	-0.18	-0.16	Male-pattern baldness;	chr12:29050251	chr12:29277397~29277882:-
LUAD	cis	rs17711722	0.522	rs62469933	ENSG00000213640.3	EEF1DP4	-3.6	0.000357	0.0396	-0.19	-0.16	Calcium levels;	chr7:65800652	chr7:64862999~64864370:+
LUAD	cis	rs10178409	1	rs10178409	ENSG00000230002.2	ALMS1-IT1	3.6	0.000357	0.0396	0.21	0.16	Urinary metabolites;	chr2:73628380	chr2:73456764~73459484:+
LUAD	cis	rs7590268	0.895	rs2046916	ENSG00000279873.2	LINC01126	-3.6	0.000358	0.0396	-0.16	-0.16	Orofacial clefts;	chr2:43459068	chr2:43227210~43228855:+
LUAD	cis	rs2708977	0.698	rs772161	ENSG00000237510.6	AC008268.2	-3.6	0.000358	0.0396	-0.21	-0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96378065	chr2:95789654~95800166:+
LUAD	cis	rs4795519	0.614	rs11650830	ENSG00000266313.1	RP11-173M1.4	3.6	0.000358	0.0396	0.22	0.16	Chronic myeloid leukemia;	chr17:27160524	chr17:27333256~27348491:+
LUAD	cis	rs10090774	0.76	rs6993266	ENSG00000280303.2	ERICD	3.6	0.000358	0.0396	0.18	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140752560	chr8:140636281~140638283:+
LUAD	cis	rs6832769	0.961	rs13138697	ENSG00000272969.1	RP11-528I4.2	3.6	0.000358	0.0396	0.17	0.16	Personality dimensions;	chr4:55497142	chr4:55547112~55547889:+
LUAD	cis	rs13398147	0.879	rs62180482	ENSG00000267034.1	RP11-384O8.1	3.6	0.000358	0.0396	0.22	0.16	Adolescent idiopathic scoliosis;	chr2:221850798	chr2:222317242~222318653:-
LUAD	cis	rs13398147	0.788	rs4099414	ENSG00000267034.1	RP11-384O8.1	3.6	0.000358	0.0396	0.22	0.16	Adolescent idiopathic scoliosis;	chr2:221851517	chr2:222317242~222318653:-
LUAD	cis	rs860295	1	rs6427286	ENSG00000203761.5	MSTO2P	-3.6	0.000358	0.0396	-0.12	-0.16	Body mass index;	chr1:155753506	chr1:155745829~155750137:+
LUAD	cis	rs860295	1	rs6427287	ENSG00000203761.5	MSTO2P	-3.6	0.000358	0.0396	-0.12	-0.16	Body mass index;	chr1:155753629	chr1:155745829~155750137:+
LUAD	cis	rs860295	1	rs7541060	ENSG00000203761.5	MSTO2P	-3.6	0.000358	0.0396	-0.12	-0.16	Body mass index;	chr1:155758297	chr1:155745829~155750137:+
LUAD	cis	rs6498169	0.899	rs42469	ENSG00000274038.1	RP11-66H6.4	-3.6	0.000358	0.0396	-0.21	-0.16	Multiple sclerosis;	chr16:11151542	chr16:11056556~11057034:+
LUAD	cis	rs16949788	1	rs41315964	ENSG00000261351.2	CTD-3185P2.1	-3.6	0.000358	0.0396	-0.28	-0.16	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66487360	chr15:66488658~66492109:-
LUAD	cis	rs3002142	0.554	rs17531468	ENSG00000272750.1	RP11-378J18.8	3.59	0.000358	0.0396	0.27	0.16	LDL peak particle diameter (total fat intake interaction);	chr1:222671358	chr1:222658867~222661512:-
LUAD	cis	rs910316	0.763	rs4556	ENSG00000279594.1	RP11-950C14.10	3.59	0.000358	0.0396	0.19	0.16	Height;	chr14:75009368	chr14:75011269~75012851:-
LUAD	cis	rs17102884	0.506	rs887746	ENSG00000279594.1	RP11-950C14.10	-3.59	0.000358	0.0396	-0.18	-0.16	Neuroticism;	chr14:74937114	chr14:75011269~75012851:-
LUAD	cis	rs728616	0.867	rs118134654	ENSG00000234382.2	RP11-40F6.1	-3.59	0.000358	0.0396	-0.39	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79984625	chr10:80233664~80245367:+
LUAD	cis	rs8114671	0.967	rs1415774	ENSG00000269202.1	RP4-614O4.12	3.59	0.000358	0.0396	0.16	0.16	Height;	chr20:35177813	chr20:35201747~35203288:-
LUAD	cis	rs34779708	0.931	rs34304999	ENSG00000271335.4	RP11-324I22.4	3.59	0.000358	0.0396	0.17	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35076777	chr10:35314552~35336401:-
LUAD	cis	rs4142110	0.699	rs61959236	ENSG00000271216.1	LINC01050	3.59	0.000358	0.0396	0.2	0.16	Nephrolithiasis;	chr13:42178477	chr13:42810366~42812562:-
LUAD	cis	rs911119	0.913	rs67483168	ENSG00000270001.1	RP11-218C14.8	-3.59	0.000358	0.0396	-0.25	-0.16	Chronic kidney disease;	chr20:23600675	chr20:23631826~23632316:-
LUAD	cis	rs911119	0.913	rs34792920	ENSG00000270001.1	RP11-218C14.8	-3.59	0.000358	0.0396	-0.25	-0.16	Chronic kidney disease;	chr20:23601239	chr20:23631826~23632316:-
LUAD	cis	rs6460942	1	rs6460936	ENSG00000226690.5	AC005281.1	3.59	0.000358	0.0396	0.3	0.16	Coronary artery disease;	chr7:12365287	chr7:12496429~12541910:+
LUAD	cis	rs13434995	0.945	rs28473211	ENSG00000249700.7	SRD5A3-AS1	-3.59	0.000358	0.0396	-0.24	-0.16	Adiponectin levels;	chr4:55615808	chr4:55363971~55395847:-
LUAD	cis	rs7546668	0.895	rs10754894	ENSG00000272510.1	RP4-680D5.8	3.59	0.000358	0.0396	0.21	0.16	Glomerular filtration rate (creatinine);	chr1:15508739	chr1:15565611~15565956:-
LUAD	cis	rs763121	0.889	rs4820335	ENSG00000225450.1	RP3-508I15.14	3.59	0.000358	0.0396	0.15	0.16	Menopause (age at onset);	chr22:38539922	chr22:38739003~38749041:+
LUAD	cis	rs3743266	0.507	rs62005026	ENSG00000245534.5	RORA-AS1	-3.59	0.000358	0.0396	-0.22	-0.16	Menarche (age at onset);	chr15:60406255	chr15:60479178~60630637:+
LUAD	cis	rs8002861	0.781	rs3816311	ENSG00000274001.1	RP11-5G9.5	3.59	0.000358	0.0396	0.17	0.16	Leprosy;	chr13:43879647	chr13:43877715~43878163:-
LUAD	cis	rs2024714	0.902	rs2427208	ENSG00000273812.1	WI2-87327B8.2	-3.59	0.000358	0.0396	-0.17	-0.16	Longevity;	chr20:61633886	chr20:62596732~62603115:-
LUAD	cis	rs794185	0.686	rs2633843	ENSG00000231249.1	ITPR1-AS1	-3.59	0.000358	0.0396	-0.18	-0.16	Multiple sclerosis--Brain Glutamate Levels;	chr3:4470109	chr3:4490891~4493163:-
LUAD	cis	rs2837828	1	rs2837821	ENSG00000226496.2	LINC00323	-3.59	0.000358	0.0396	-0.2	-0.16	Neutrophil count;	chr21:40789918	chr21:41141493~41148133:-
LUAD	cis	rs62025270	0.632	rs8029034	ENSG00000259416.2	RP11-158M2.5	-3.59	0.000358	0.0396	-0.23	-0.16	Idiopathic pulmonary fibrosis;	chr15:85582497	chr15:85754941~85756237:-
LUAD	cis	rs4470077	1	rs10146736	ENSG00000259318.1	RP11-454L9.2	3.59	0.000358	0.0396	0.17	0.16	Platelet count;	chr14:55431206	chr14:55394940~55395233:-
LUAD	cis	rs4470077	0.941	rs10149166	ENSG00000259318.1	RP11-454L9.2	3.59	0.000358	0.0396	0.17	0.16	Platelet count;	chr14:55431258	chr14:55394940~55395233:-
LUAD	cis	rs375066	0.935	rs422457	ENSG00000278917.1	RP11-15A1.4	-3.59	0.000358	0.0396	-0.17	-0.16	Breast cancer;	chr19:43905259	chr19:43891233~43895411:+
LUAD	cis	rs12146727	0.881	rs77620124	ENSG00000247853.2	RP5-940J5.6	3.59	0.000358	0.0396	0.26	0.16	Blood protein levels;	chr12:7065598	chr12:6578622~6584739:+
LUAD	cis	rs3738443	0.868	rs2892054	ENSG00000215795.2	RP11-488L18.3	-3.59	0.000358	0.0396	-0.24	-0.16	Alcohol dependence;	chr1:247203803	chr1:247183813~247185482:-
LUAD	cis	rs10776612	0.625	rs11101367	ENSG00000276850.3	CH17-360D5.2	-3.59	0.000358	0.0396	-0.17	-0.16	Conduct disorder;	chr10:48522504	chr10:47908064~47991850:-
LUAD	cis	rs10751667	0.6	rs6597948	ENSG00000255284.1	AP006621.5	3.59	0.000359	0.0396	0.14	0.16	Alzheimer's disease (late onset);	chr11:1005308	chr11:777578~784297:+
LUAD	cis	rs10129255	0.917	rs7142373	ENSG00000253209.1	IGHV3-65	3.59	0.000359	0.0396	0.14	0.16	Kawasaki disease;	chr14:106708947	chr14:106666092~106666532:-
LUAD	cis	rs247929	0.934	rs7976870	ENSG00000272369.1	RP11-446N19.1	-3.59	0.000359	0.0397	-0.18	-0.16	Educational attainment;	chr12:45829991	chr12:46537502~46652550:+
LUAD	cis	rs794728	0.543	rs2964064	ENSG00000249031.1	SUMO2P6	-3.59	0.000359	0.0397	-0.18	-0.16	Depressive symptoms (SSRI exposure interaction);	chr5:174432733	chr5:174561776~174562063:+
LUAD	cis	rs12216545	0.711	rs939957	ENSG00000177590.7	GIMAP3P	-3.59	0.000359	0.0397	-0.16	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150560517	chr7:150746893~150747728:-
LUAD	cis	rs7870753	0.838	rs10991378	ENSG00000188801.9	ZNF322P1	3.59	0.000359	0.0397	0.23	0.16	Height;	chr9:96498698	chr9:97198303~97199511:-
LUAD	cis	rs7142881	0.815	rs17098014	ENSG00000258525.1	RP11-829H16.3	-3.59	0.000359	0.0397	-0.18	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31583497	chr14:30876179~30889808:-
LUAD	cis	rs7142881	0.815	rs58110472	ENSG00000258525.1	RP11-829H16.3	-3.59	0.000359	0.0397	-0.18	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31583772	chr14:30876179~30889808:-
LUAD	cis	rs6787172	0.667	rs4324501	ENSG00000272087.1	RP11-379F4.7	3.59	0.000359	0.0397	0.19	0.16	Subjective well-being;	chr3:158458200	chr3:158693120~158693768:-
LUAD	cis	rs6787172	0.667	rs12631628	ENSG00000272087.1	RP11-379F4.7	3.59	0.000359	0.0397	0.19	0.16	Subjective well-being;	chr3:158459634	chr3:158693120~158693768:-
LUAD	cis	rs6787172	0.652	rs12631675	ENSG00000272087.1	RP11-379F4.7	3.59	0.000359	0.0397	0.19	0.16	Subjective well-being;	chr3:158459793	chr3:158693120~158693768:-
LUAD	cis	rs7129556	0.859	rs11237236	ENSG00000241782.1	RP11-91P24.1	3.59	0.000359	0.0397	0.22	0.16	Weight loss (gastric bypass surgery);	chr11:77601745	chr11:77868722~77869195:-
LUAD	cis	rs7204230	0.96	rs6499536	ENSG00000261291.1	RP11-295M3.2	3.59	0.000359	0.0397	0.19	0.16	Fibrinogen;	chr16:53289968	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs8044969	ENSG00000261291.1	RP11-295M3.2	3.59	0.000359	0.0397	0.19	0.16	Fibrinogen;	chr16:53290784	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs1894904	ENSG00000261291.1	RP11-295M3.2	3.59	0.000359	0.0397	0.19	0.16	Fibrinogen;	chr16:53292013	chr16:53168522~53169450:+
LUAD	cis	rs7572733	0.935	rs4850817	ENSG00000222017.1	AC011997.1	-3.59	0.000359	0.0397	-0.21	-0.16	Dermatomyositis;	chr2:197930480	chr2:197693106~197774823:+
LUAD	cis	rs935334	1	rs8006048	ENSG00000258454.1	RP11-361H10.3	3.59	0.000359	0.0397	0.24	0.16	Blood pressure;	chr14:76217165	chr14:76235817~76263474:+
LUAD	cis	rs2002133	0.782	rs2897001	ENSG00000236682.1	AC068282.3	3.59	0.000359	0.0397	0.24	0.16	Initial pursuit acceleration;	chr2:126771435	chr2:127389130~127400580:+
LUAD	cis	rs1979679	0.918	rs1533142	ENSG00000278733.1	RP11-425D17.1	-3.59	0.000359	0.0397	-0.2	-0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28461206	chr12:28185625~28186190:-
LUAD	cis	rs7107174	0.581	rs11237485	ENSG00000251323.2	RP11-452H21.4	3.59	0.000359	0.0397	0.21	0.16	Testicular germ cell tumor;	chr11:78414965	chr11:78423982~78429836:-
LUAD	cis	rs9860428	0.591	rs11705758	ENSG00000240057.4	RP11-572M11.4	-3.59	0.000359	0.0397	-0.2	-0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112932362	chr3:113019532~113183301:+
LUAD	cis	rs9860428	0.591	rs2133946	ENSG00000240057.4	RP11-572M11.4	-3.59	0.000359	0.0397	-0.2	-0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112948012	chr3:113019532~113183301:+
LUAD	cis	rs1005224	0.963	rs2303345	ENSG00000242952.1	RP11-187O7.1	3.59	0.000359	0.0397	0.15	0.16	Large artery stroke;	chr14:75690266	chr14:76634775~76635661:-
LUAD	cis	rs778371	0.723	rs11689851	ENSG00000259793.1	RP11-400N9.1	3.59	0.000359	0.0397	0.17	0.16	Schizophrenia;	chr2:232702632	chr2:233351132~233353416:-
LUAD	cis	rs2729385	1	rs2729385	ENSG00000265566.2	RN7SL605P	-3.59	0.000359	0.0397	-0.21	-0.16	Interleukin-18 levels;	chr11:57495520	chr11:57528085~57528365:-
LUAD	cis	rs2904524	0.748	rs11178226	ENSG00000257815.4	RP11-611E13.2	-3.59	0.000359	0.0397	-0.24	-0.16	Amyotrophic lateral sclerosis (age of onset);	chr12:70409894	chr12:69904033~70243360:-
LUAD	cis	rs2904524	0.748	rs11178227	ENSG00000257815.4	RP11-611E13.2	-3.59	0.000359	0.0397	-0.24	-0.16	Amyotrophic lateral sclerosis (age of onset);	chr12:70409970	chr12:69904033~70243360:-
LUAD	cis	rs2904524	0.748	rs11178228	ENSG00000257815.4	RP11-611E13.2	-3.59	0.000359	0.0397	-0.24	-0.16	Amyotrophic lateral sclerosis (age of onset);	chr12:70410290	chr12:69904033~70243360:-
LUAD	cis	rs2279168	0.867	rs79665867	ENSG00000202081.1	RNU6-1280P	-3.59	0.000359	0.0397	-0.3	-0.16	Response to platinum-based chemotherapy (carboplatin);	chr15:85494777	chr15:85651522~85651628:-
LUAD	cis	rs1979679	0.918	rs10771427	ENSG00000278733.1	RP11-425D17.1	3.59	0.000359	0.0397	0.2	0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28452493	chr12:28185625~28186190:-
LUAD	cis	rs214785	0.932	rs214803	ENSG00000234684.5	SDCBP2-AS1	3.59	0.000359	0.0397	0.2	0.16	Basal cell carcinoma;	chr20:2309687	chr20:1325405~1378734:+
LUAD	cis	rs9652601	0.676	rs9926615	ENSG00000262222.1	RP11-876N24.4	-3.59	0.000359	0.0397	-0.14	-0.16	Systemic lupus erythematosus;	chr16:11009303	chr16:10940719~10943021:+
LUAD	cis	rs55702914	0.625	rs59757315	ENSG00000222017.1	AC011997.1	3.59	0.000359	0.0397	0.21	0.16	Major depression and alcohol dependence;	chr2:197385489	chr2:197693106~197774823:+
LUAD	cis	rs957448	1	rs12680965	ENSG00000254057.1	RP3-388N13.3	3.59	0.000359	0.0397	0.18	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94554069	chr8:93834454~93846743:-
LUAD	cis	rs453301	0.538	rs7830804	ENSG00000254367.4	RP11-211C9.1	3.59	0.000359	0.0397	0.21	0.16	Joint mobility (Beighton score);	chr8:9113252	chr8:8723693~8782479:-
LUAD	cis	rs4763879	0.634	rs11052582	ENSG00000256582.1	RP11-75L1.1	-3.59	0.000359	0.0397	-0.17	-0.16	Type 1 diabetes;	chr12:9706714	chr12:9704077~9709350:+
LUAD	cis	rs2702164	1	rs2673696	ENSG00000240661.1	RP11-174O3.3	-3.59	0.000359	0.0397	-0.19	-0.16	Gut microbiome composition (winter);	chr3:120389908	chr3:120349510~120367998:+
LUAD	cis	rs4835473	0.868	rs4350958	ENSG00000249741.2	RP11-673E1.3	-3.59	0.000359	0.0397	-0.19	-0.16	Immature fraction of reticulocytes;	chr4:143744656	chr4:143911514~143912053:-
LUAD	cis	rs6547741	0.935	rs12615690	ENSG00000223522.1	AC093690.1	3.59	0.000359	0.0397	0.15	0.16	Oral cavity cancer;	chr2:27628253	chr2:28307691~28310459:-
LUAD	cis	rs75920871	0.609	rs11216187	ENSG00000254851.1	RP11-109L13.1	-3.59	0.000359	0.0397	-0.33	-0.16	Subjective well-being;	chr11:116916432	chr11:117135528~117138582:+
LUAD	cis	rs8031584	0.678	rs8035703	ENSG00000260128.5	ULK4P2	-3.59	0.000359	0.0397	-0.21	-0.16	Huntington's disease progression;	chr15:30876269	chr15:30572738~30600647:+
LUAD	cis	rs8062405	1	rs3888190	ENSG00000261419.1	RP11-57A19.4	-3.59	0.000359	0.0397	-0.18	-0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28659696~28740781:-
LUAD	cis	rs932316	0.599	rs72838866	ENSG00000124549.13	BTN2A3P	3.59	0.000359	0.0397	0.23	0.16	Iron status biomarkers;	chr6:25673045	chr6:26421391~26432383:+
LUAD	cis	rs3845817	0.733	rs702906	ENSG00000281920.1	RP11-418H16.1	-3.59	0.000359	0.0397	-0.2	-0.16	Bipolar disorder;	chr2:65539745	chr2:65623272~65628424:+
LUAD	cis	rs321358	1	rs12419222	ENSG00000271390.1	RP11-89C3.3	3.59	0.000359	0.0397	0.27	0.16	Body mass index;	chr11:111128439	chr11:111089870~111090368:-
LUAD	cis	rs12541595	0.836	rs6980573	ENSG00000249816.5	LINC00964	3.59	0.000359	0.0397	0.2	0.16	Left ventricle diastolic internal dimension;	chr8:124840111	chr8:124848737~124954328:+
LUAD	cis	rs8141529	0.504	rs6005915	ENSG00000272858.1	CTA-292E10.8	-3.59	0.000359	0.0397	-0.2	-0.16	Lymphocyte counts;	chr22:28837274	chr22:28814914~28815662:+
LUAD	cis	rs7208859	0.673	rs11655623	ENSG00000263603.1	CTD-2349P21.5	-3.59	0.000359	0.0397	-0.28	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30835155	chr17:30729469~30731202:+
LUAD	cis	rs7617773	0.851	rs13068288	ENSG00000199476.1	Y_RNA	-3.59	0.000359	0.0397	-0.23	-0.16	Coronary artery disease;	chr3:48290261	chr3:48288587~48288694:+
LUAD	cis	rs806321	0.556	rs2066634	ENSG00000237152.3	DLEU7-AS1	-3.59	0.00036	0.0397	-0.2	-0.16	Multiple sclerosis;	chr13:50190346	chr13:50807856~50849905:+
LUAD	cis	rs7968440	0.933	rs2684889	ENSG00000272368.2	RP4-605O3.4	3.59	0.00036	0.0397	0.19	0.16	Fibrinogen;	chr12:50686091	chr12:50112197~50165618:+
LUAD	cis	rs7968440	1	rs2700482	ENSG00000272368.2	RP4-605O3.4	3.59	0.00036	0.0397	0.19	0.16	Fibrinogen;	chr12:50689482	chr12:50112197~50165618:+
LUAD	cis	rs11018874	0.597	rs10765243	ENSG00000280367.1	RP11-121L10.2	3.59	0.00036	0.0397	0.23	0.16	White blood cell types;	chr11:90121950	chr11:90223153~90226538:+
LUAD	cis	rs6494488	0.5	rs72758953	ENSG00000239465.1	RP11-330L19.2	3.59	0.00036	0.0398	0.35	0.16	Coronary artery disease;	chr15:64399953	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs72741303	ENSG00000239465.1	RP11-330L19.2	3.59	0.00036	0.0398	0.35	0.16	Coronary artery disease;	chr15:64400219	chr15:64631109~64631914:-
LUAD	cis	rs8180040	0.8	rs7632501	ENSG00000260236.1	RP11-708J19.1	-3.59	0.00036	0.0398	-0.15	-0.16	Colorectal cancer;	chr3:47226816	chr3:47379089~47380999:-
LUAD	cis	rs8180040	0.8	rs62248905	ENSG00000260236.1	RP11-708J19.1	-3.59	0.00036	0.0398	-0.15	-0.16	Colorectal cancer;	chr3:47232592	chr3:47379089~47380999:-
LUAD	cis	rs8180040	0.8	rs56250009	ENSG00000260236.1	RP11-708J19.1	-3.59	0.00036	0.0398	-0.15	-0.16	Colorectal cancer;	chr3:47238007	chr3:47379089~47380999:-
LUAD	cis	rs8180040	0.8	rs2088135	ENSG00000260236.1	RP11-708J19.1	-3.59	0.00036	0.0398	-0.15	-0.16	Colorectal cancer;	chr3:47238528	chr3:47379089~47380999:-
LUAD	cis	rs8180040	0.8	rs6768221	ENSG00000260236.1	RP11-708J19.1	-3.59	0.00036	0.0398	-0.15	-0.16	Colorectal cancer;	chr3:47255409	chr3:47379089~47380999:-
LUAD	cis	rs8180040	0.8	rs11130126	ENSG00000260236.1	RP11-708J19.1	-3.59	0.00036	0.0398	-0.15	-0.16	Colorectal cancer;	chr3:47265404	chr3:47379089~47380999:-
LUAD	cis	rs8180040	0.767	rs11920853	ENSG00000260236.1	RP11-708J19.1	-3.59	0.00036	0.0398	-0.15	-0.16	Colorectal cancer;	chr3:47266693	chr3:47379089~47380999:-
LUAD	cis	rs357618	1	rs193299	ENSG00000272112.1	CTB-113P19.5	-3.59	0.00036	0.0398	-0.15	-0.16	Basophil percentage of white cells;	chr5:151468094	chr5:151724831~151725356:-
LUAD	cis	rs357618	0.965	rs187180	ENSG00000272112.1	CTB-113P19.5	-3.59	0.00036	0.0398	-0.15	-0.16	Basophil percentage of white cells;	chr5:151468434	chr5:151724831~151725356:-
LUAD	cis	rs357618	1	rs357622	ENSG00000272112.1	CTB-113P19.5	-3.59	0.00036	0.0398	-0.15	-0.16	Basophil percentage of white cells;	chr5:151468844	chr5:151724831~151725356:-
LUAD	cis	rs357618	1	rs357623	ENSG00000272112.1	CTB-113P19.5	-3.59	0.00036	0.0398	-0.15	-0.16	Basophil percentage of white cells;	chr5:151468939	chr5:151724831~151725356:-
LUAD	cis	rs357618	1	rs357624	ENSG00000272112.1	CTB-113P19.5	-3.59	0.00036	0.0398	-0.15	-0.16	Basophil percentage of white cells;	chr5:151469140	chr5:151724831~151725356:-
LUAD	cis	rs12908161	1	rs36033486	ENSG00000259654.1	RP11-245C17.2	-3.59	0.00036	0.0398	-0.23	-0.16	Schizophrenia;	chr15:84776461	chr15:84685884~84686946:+
LUAD	cis	rs12908161	1	rs12908549	ENSG00000259654.1	RP11-245C17.2	-3.59	0.00036	0.0398	-0.23	-0.16	Schizophrenia;	chr15:84779120	chr15:84685884~84686946:+
LUAD	cis	rs7772486	0.686	rs1569540	ENSG00000235652.6	RP11-545I5.3	-3.59	0.00036	0.0398	-0.16	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145747976	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.686	rs2142983	ENSG00000235652.6	RP11-545I5.3	-3.59	0.00036	0.0398	-0.16	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145748565	chr6:145799409~145886585:+
LUAD	cis	rs739401	0.595	rs6578304	ENSG00000183562.3	CTC-343N3.1	3.59	0.00036	0.0398	0.16	0.16	Longevity;	chr11:2977049	chr11:2989863~2991344:+
LUAD	cis	rs12744310	0.887	rs12041352	ENSG00000235358.1	RP11-399E6.1	3.59	0.00036	0.0398	0.21	0.16	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41317109	chr1:41242373~41284861:+
LUAD	cis	rs12744310	0.887	rs28566545	ENSG00000235358.1	RP11-399E6.1	3.59	0.00036	0.0398	0.21	0.16	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41317561	chr1:41242373~41284861:+
LUAD	cis	rs12744310	0.887	rs16828067	ENSG00000235358.1	RP11-399E6.1	3.59	0.00036	0.0398	0.21	0.16	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41317880	chr1:41242373~41284861:+
LUAD	cis	rs12744310	0.887	rs16828071	ENSG00000235358.1	RP11-399E6.1	3.59	0.00036	0.0398	0.21	0.16	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41317931	chr1:41242373~41284861:+
LUAD	cis	rs10170310	0.872	rs62161711	ENSG00000228043.4	AC097721.2	3.59	0.00036	0.0398	0.22	0.16	Response to antipsychotic treatment;	chr2:138501652	chr2:138418284~138501698:-
LUAD	cis	rs6472235	0.656	rs11993927	ENSG00000200714.1	Y_RNA	-3.59	0.00036	0.0398	-0.21	-0.16	Plateletcrit;Myopia (pathological);	chr8:65969407	chr8:65592731~65592820:+
LUAD	cis	rs7976269	0.609	rs10743641	ENSG00000275476.1	RP11-996F15.4	-3.59	0.00036	0.0398	-0.18	-0.16	Male-pattern baldness;	chr12:29050819	chr12:29277397~29277882:-
LUAD	cis	rs7976269	0.609	rs4930846	ENSG00000275476.1	RP11-996F15.4	-3.59	0.00036	0.0398	-0.18	-0.16	Male-pattern baldness;	chr12:29051306	chr12:29277397~29277882:-
LUAD	cis	rs7003550	0.951	rs10111648	ENSG00000254028.1	AC083843.2	-3.59	0.00036	0.0398	-0.21	-0.16	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr8:134843787	chr8:134832747~134834482:+
LUAD	cis	rs7824557	0.606	rs2736270	ENSG00000255046.1	RP11-297N6.4	-3.59	0.00036	0.0398	-0.2	-0.16	Retinal vascular caliber;	chr8:11335084	chr8:11797928~11802568:-
LUAD	cis	rs9517320	1	rs9584857	ENSG00000231194.1	FARP1-AS1	3.59	0.00036	0.0398	0.19	0.16	Longevity;	chr13:98476318	chr13:98435405~98435840:-
LUAD	cis	rs3811273	0.614	rs12589726	ENSG00000211816.2	TRAV38-1	-3.59	0.00036	0.0398	-0.23	-0.16	Periodontal disease-related phenotypes;	chr14:22262396	chr14:22271968~22272563:+
LUAD	cis	rs3811273	0.614	rs12587104	ENSG00000211816.2	TRAV38-1	-3.59	0.00036	0.0398	-0.23	-0.16	Periodontal disease-related phenotypes;	chr14:22262556	chr14:22271968~22272563:+
LUAD	cis	rs8098244	0.52	rs6508073	ENSG00000264745.1	TTC39C-AS1	-3.59	0.00036	0.0398	-0.2	-0.16	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23988403	chr18:23994213~24015339:-
LUAD	cis	rs8098244	0.597	rs57266464	ENSG00000264745.1	TTC39C-AS1	-3.59	0.00036	0.0398	-0.2	-0.16	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23989811	chr18:23994213~24015339:-
LUAD	cis	rs12724450	0.793	rs34233130	ENSG00000228126.1	FALEC	3.59	0.00036	0.0398	0.3	0.16	Blood protein levels;	chr1:150477290	chr1:150515757~150518032:+
LUAD	cis	rs41313321	0.526	rs2240960	ENSG00000203286.5	Metazoa_SRP	3.59	0.00036	0.0398	0.23	0.16	Coenzyme Q10 levels;	chr9:128276971	chr9:128745857~128746138:-
LUAD	cis	rs3741404	0.583	rs640999	ENSG00000256789.1	RP11-697H9.2	-3.59	0.00036	0.0398	-0.18	-0.16	Platelet count;	chr11:64101953	chr11:63637677~63658962:+
LUAD	cis	rs848490	1	rs848490	ENSG00000214293.7	APTR	-3.59	0.00036	0.0398	-0.22	-0.16	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77925688	chr7:77657660~77696265:-
LUAD	cis	rs12819124	0.502	rs10875718	ENSG00000226413.2	OR8T1P	3.59	0.00036	0.0398	0.21	0.16	Glycated hemoglobin levels;	chr12:48017319	chr12:48442030~48442947:-
LUAD	cis	rs4561483	0.603	rs11075033	ENSG00000261216.1	RP11-166B2.5	3.59	0.00036	0.0398	0.16	0.16	Testicular germ cell tumor;	chr16:11912481	chr16:11908208~11908916:+
LUAD	cis	rs853679	0.55	rs1233707	ENSG00000280107.1	AL022393.9	-3.59	0.00036	0.0398	-0.21	-0.16	Depression;	chr6:28205175	chr6:28170845~28172521:+
LUAD	cis	rs9973361	0.531	rs62174851	ENSG00000232411.1	AC009495.3	-3.59	0.00036	0.0398	-0.18	-0.16	Total body bone mineral density;	chr2:165800811	chr2:165833048~165839098:-
LUAD	cis	rs11734570	0.581	rs4401459	ENSG00000249348.1	UGDH-AS1	-3.59	0.00036	0.0398	-0.18	-0.16	Crohn's disease;Inflammatory bowel disease;	chr4:38583647	chr4:39528019~39594707:+
LUAD	cis	rs4908768	0.906	rs10492965	ENSG00000232912.4	RP5-1115A15.1	-3.59	0.000361	0.0398	-0.19	-0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8538068	chr1:8424645~8434838:+
LUAD	cis	rs433598	0.798	rs234280	ENSG00000180747.14	SMG1P3	-3.59	0.000361	0.0398	-0.15	-0.16	Schizophrenia;	chr16:20677618	chr16:21446683~21520444:-
LUAD	cis	rs801193	1	rs2707856	ENSG00000273142.1	RP11-458F8.4	-3.59	0.000361	0.0398	-0.11	-0.16	Aortic root size;	chr7:66746023	chr7:66902857~66906297:+
LUAD	cis	rs3811273	0.614	rs7157477	ENSG00000211816.2	TRAV38-1	-3.59	0.000361	0.0398	-0.22	-0.16	Periodontal disease-related phenotypes;	chr14:22266229	chr14:22271968~22272563:+
LUAD	cis	rs3811273	0.614	rs7152167	ENSG00000211816.2	TRAV38-1	-3.59	0.000361	0.0398	-0.22	-0.16	Periodontal disease-related phenotypes;	chr14:22266254	chr14:22271968~22272563:+
LUAD	cis	rs755249	0.565	rs3768320	ENSG00000182109.6	RP11-69E11.4	-3.59	0.000361	0.0398	-0.17	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39566567	chr1:39522280~39546187:-
LUAD	cis	rs16949788	1	rs41306345	ENSG00000261351.2	CTD-3185P2.1	-3.59	0.000361	0.0398	-0.28	-0.16	Spherical equivalent (joint analysis main effects and education interaction);	chr15:66489710	chr15:66488658~66492109:-
LUAD	cis	rs2905347	0.737	rs2905349	ENSG00000232949.1	AC002480.4	3.59	0.000361	0.0398	0.19	0.16	Major depression and alcohol dependence;	chr7:22589666	chr7:22589705~22591622:+
LUAD	cis	rs875971	0.502	rs11769702	ENSG00000224316.1	RP11-479O9.2	3.59	0.000361	0.0398	0.19	0.16	Aortic root size;	chr7:66255529	chr7:65773620~65802067:+
LUAD	cis	rs10270805	0.667	rs4721503	ENSG00000272361.2	GS1-166A23.2	3.59	0.000361	0.0398	0.27	0.16	Response to statin therapy;	chr7:16454782	chr7:16593626~16594224:-
LUAD	cis	rs7976269	0.609	rs11050010	ENSG00000275476.1	RP11-996F15.4	-3.59	0.000361	0.0398	-0.18	-0.16	Male-pattern baldness;	chr12:29061952	chr12:29277397~29277882:-
LUAD	cis	rs7474896	0.559	rs1208560	ENSG00000226578.1	RP11-258F22.1	3.59	0.000361	0.0398	0.22	0.16	Obesity (extreme);	chr10:37932690	chr10:37775371~37784131:-
LUAD	cis	rs11216126	0.643	rs4417316	ENSG00000254851.1	RP11-109L13.1	3.59	0.000361	0.0398	0.34	0.16	HDL cholesterol;	chr11:116781585	chr11:117135528~117138582:+
LUAD	cis	rs8056893	0.714	rs1465468	ENSG00000260441.4	RP11-96D1.7	-3.59	0.000361	0.0398	-0.19	-0.16	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68364387	chr16:68256162~68260443:-
LUAD	cis	rs13113518	1	rs13116194	ENSG00000223305.1	RN7SKP30	3.59	0.000361	0.0398	0.18	0.16	Height;	chr4:55531150	chr4:55540502~55540835:-
LUAD	cis	rs13113518	1	rs13117836	ENSG00000223305.1	RN7SKP30	3.59	0.000361	0.0398	0.18	0.16	Height;	chr4:55531218	chr4:55540502~55540835:-
LUAD	cis	rs786425	0.77	rs7313140	ENSG00000278112.1	RP11-972P1.11	3.59	0.000361	0.0398	0.15	0.16	Pubertal anthropometrics;	chr12:123672641	chr12:123519390~123519856:-
LUAD	cis	rs786425	0.77	rs7134074	ENSG00000278112.1	RP11-972P1.11	3.59	0.000361	0.0398	0.15	0.16	Pubertal anthropometrics;	chr12:123675338	chr12:123519390~123519856:-
LUAD	cis	rs2657294	0.796	rs2657290	ENSG00000226051.5	ZNF503-AS1	-3.59	0.000361	0.0398	-0.21	-0.16	Pneumonia;	chr10:75207404	chr10:75269819~75373500:+
LUAD	cis	rs79478560	0.552	rs2341779	ENSG00000251497.2	RP11-197N18.7	-3.59	0.000361	0.0398	-0.18	-0.16	Lymphocyte counts;	chr12:123858316	chr12:123081384~123084744:+
LUAD	cis	rs79478560	0.552	rs7314335	ENSG00000251497.2	RP11-197N18.7	-3.59	0.000361	0.0398	-0.18	-0.16	Lymphocyte counts;	chr12:123858894	chr12:123081384~123084744:+
LUAD	cis	rs7560272	0.538	rs7599453	ENSG00000163016.8	ALMS1P	-3.59	0.000361	0.0399	-0.17	-0.16	Schizophrenia;	chr2:73710774	chr2:73644919~73685576:+
LUAD	cis	rs1555322	0.53	rs2425043	ENSG00000261582.1	RP4-614O4.11	-3.59	0.000361	0.0399	-0.21	-0.16	Attention deficit hyperactivity disorder;	chr20:35280899	chr20:35267885~35280043:-
LUAD	cis	rs7809950	1	rs2808	ENSG00000238832.1	snoU109	3.59	0.000361	0.0399	0.24	0.16	Coronary artery disease;	chr7:107620411	chr7:107603363~107603507:+
LUAD	cis	rs7674212	0.541	rs2720471	ENSG00000246560.2	RP11-10L12.4	3.59	0.000361	0.0399	0.21	0.16	Type 2 diabetes;	chr4:103102683	chr4:102828055~102844075:+
LUAD	cis	rs17826219	0.562	rs719600	ENSG00000263603.1	CTD-2349P21.5	3.59	0.000361	0.0399	0.28	0.16	Body mass index;	chr17:30404244	chr17:30729469~30731202:+
LUAD	cis	rs7204230	1	rs12599839	ENSG00000261291.1	RP11-295M3.2	3.59	0.000361	0.0399	0.19	0.16	Fibrinogen;	chr16:53196430	chr16:53168522~53169450:+
LUAD	cis	rs12519773	0.501	rs4321736	ENSG00000251361.1	CTD-2091N23.1	-3.59	0.000361	0.0399	-0.18	-0.16	Migraine;	chr5:93197657	chr5:93019663~93068669:-
LUAD	cis	rs12232346	1	rs12232346	ENSG00000261559.1	FSCN1P1	3.59	0.000361	0.0399	0.21	0.16	Post-traumatic stress disorder;	chr15:34768262	chr15:34494420~34495900:+
LUAD	cis	rs2018683	0.523	rs1499224	ENSG00000228421.2	AC005013.5	3.59	0.000361	0.0399	0.19	0.16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28989852	chr7:28957667~28959345:+
LUAD	cis	rs7646881	0.544	rs16829116	ENSG00000240207.5	RP11-379F4.4	-3.59	0.000361	0.0399	-0.21	-0.16	Tetralogy of Fallot;	chr3:158570012	chr3:158732263~158784070:+
LUAD	cis	rs9813712	0.818	rs11718381	ENSG00000249846.5	RP11-77P16.4	3.59	0.000361	0.0399	0.21	0.16	Response to amphetamines;	chr3:130222660	chr3:130112550~130120579:+
LUAD	cis	rs9309473	0.95	rs2947860	ENSG00000273245.1	RP11-434P11.2	3.59	0.000361	0.0399	0.2	0.16	Metabolite levels;	chr2:73628259	chr2:73750256~73750786:-
LUAD	cis	rs703842	1	rs11172335	ENSG00000245651.2	RP11-620J15.2	3.59	0.000361	0.0399	0.17	0.16	Multiple sclerosis;	chr12:57781418	chr12:57869835~57896482:-
LUAD	cis	rs703842	0.964	rs2014886	ENSG00000245651.2	RP11-620J15.2	3.59	0.000361	0.0399	0.17	0.16	Multiple sclerosis;	chr12:57783654	chr12:57869835~57896482:-
LUAD	cis	rs703842	1	rs1599932	ENSG00000245651.2	RP11-620J15.2	3.59	0.000361	0.0399	0.17	0.16	Multiple sclerosis;	chr12:57784160	chr12:57869835~57896482:-
LUAD	cis	rs703842	1	rs11172342	ENSG00000245651.2	RP11-620J15.2	3.59	0.000361	0.0399	0.17	0.16	Multiple sclerosis;	chr12:57793975	chr12:57869835~57896482:-
LUAD	cis	rs703842	1	rs11172343	ENSG00000245651.2	RP11-620J15.2	3.59	0.000361	0.0399	0.17	0.16	Multiple sclerosis;	chr12:57794374	chr12:57869835~57896482:-
LUAD	cis	rs703842	1	rs1875124	ENSG00000245651.2	RP11-620J15.2	3.59	0.000361	0.0399	0.17	0.16	Multiple sclerosis;	chr12:57803019	chr12:57869835~57896482:-
LUAD	cis	rs76419734	1	rs17035960	ENSG00000251175.4	RP11-45L9.1	-3.59	0.000361	0.0399	-0.38	-0.16	Post bronchodilator FEV1;	chr4:105610689	chr4:105746245~105827172:-
LUAD	cis	rs76419734	0.85	rs17035971	ENSG00000251175.4	RP11-45L9.1	-3.59	0.000361	0.0399	-0.38	-0.16	Post bronchodilator FEV1;	chr4:105610984	chr4:105746245~105827172:-
LUAD	cis	rs6430585	0.702	rs3213890	ENSG00000226806.1	AC011893.3	3.59	0.000361	0.0399	0.25	0.16	Corneal structure;	chr2:135794618	chr2:135820191~135823087:+
LUAD	cis	rs9341808	0.727	rs10943697	ENSG00000233967.5	RP11-250B2.3	3.59	0.000361	0.0399	0.16	0.16	Sitting height ratio;	chr6:80221789	chr6:80443344~80465927:+
LUAD	cis	rs11673344	0.583	rs7247090	ENSG00000226686.6	LINC01535	3.59	0.000361	0.0399	0.19	0.16	Obesity-related traits;	chr19:37522509	chr19:37251912~37265535:+
LUAD	cis	rs6599077	0.756	rs9867657	ENSG00000223797.4	ENTPD3-AS1	3.59	0.000361	0.0399	0.16	0.16	Sleep-related phenotypes;	chr3:40050747	chr3:40313802~40453329:-
LUAD	cis	rs7618915	0.547	rs4687548	ENSG00000243224.1	RP5-1157M23.2	-3.59	0.000361	0.0399	-0.17	-0.16	Bipolar disorder;	chr3:52632634	chr3:52239258~52241097:+
LUAD	cis	rs7618915	0.547	rs13069481	ENSG00000243224.1	RP5-1157M23.2	-3.59	0.000361	0.0399	-0.17	-0.16	Bipolar disorder;	chr3:52632850	chr3:52239258~52241097:+
LUAD	cis	rs58904263	1	rs58904263	ENSG00000230613.1	HM13-AS1	3.59	0.000361	0.0399	0.23	0.16	Monocyte count;	chr20:31813603	chr20:31567707~31573263:-
LUAD	cis	rs2638953	0.924	rs11524516	ENSG00000278733.1	RP11-425D17.1	-3.59	0.000361	0.0399	-0.21	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28209517	chr12:28185625~28186190:-
LUAD	cis	rs10496034	1	rs4672006	ENSG00000240401.7	AC012358.8	3.59	0.000361	0.0399	0.42	0.16	Refractive astigmatism;	chr2:55024375	chr2:55282350~55346049:+
LUAD	cis	rs6736093	0.966	rs2271701	ENSG00000207383.1	Y_RNA	-3.59	0.000361	0.0399	-0.21	-0.16	Coronary artery disease;	chr2:111973596	chr2:112579484~112579584:-
LUAD	cis	rs71520386	0.846	rs35247857	ENSG00000230658.1	KLHL7-AS1	3.59	0.000361	0.0399	0.24	0.16	Fibrinogen levels;	chr7:22780901	chr7:23101228~23105703:-
LUAD	cis	rs4853525	0.923	rs4853523	ENSG00000235852.1	AC005540.3	3.59	0.000361	0.0399	0.18	0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190868053	chr2:190880797~190882059:-
LUAD	cis	rs7955901	0.837	rs1317055	ENSG00000258053.1	CTD-2021H9.3	-3.59	0.000361	0.0399	-0.18	-0.16	Type 2 diabetes;	chr12:71025982	chr12:71047402~71118247:-
LUAD	cis	rs2243480	0.706	rs34466769	ENSG00000222364.1	RNU6-96P	-3.59	0.000361	0.0399	-0.24	-0.16	Diabetic kidney disease;	chr7:65988305	chr7:66395191~66395286:+
LUAD	cis	rs214785	0.858	rs6082633	ENSG00000235958.4	UBOX5-AS1	3.59	0.000362	0.0399	0.19	0.16	Basal cell carcinoma;	chr20:2290305	chr20:3106913~3150867:+
LUAD	cis	rs1979679	0.766	rs10843197	ENSG00000278733.1	RP11-425D17.1	-3.59	0.000362	0.0399	-0.2	-0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28518308	chr12:28185625~28186190:-
LUAD	cis	rs6691170	0.897	rs7550628	ENSG00000228437.4	RP11-400N13.2	3.59	0.000362	0.0399	0.2	0.16	Colorectal cancer;	chr1:221865973	chr1:221966341~221984964:+
LUAD	cis	rs1850744	0.702	rs7434744	ENSG00000249767.1	ENPP7P10	-3.59	0.000362	0.0399	-0.39	-0.16	Economic and political preferences;	chr4:9671064	chr4:9079023~9141608:+
LUAD	cis	rs6472235	0.656	rs16932382	ENSG00000200714.1	Y_RNA	-3.59	0.000362	0.0399	-0.21	-0.16	Plateletcrit;Myopia (pathological);	chr8:65966241	chr8:65592731~65592820:+
LUAD	cis	rs8035452	0.964	rs7166544	ENSG00000259240.1	RP11-108K3.1	-3.59	0.000362	0.0399	-0.19	-0.16	Alzheimer's disease (late onset);	chr15:50745197	chr15:51037488~51293912:+
LUAD	cis	rs7204230	1	rs8053429	ENSG00000261291.1	RP11-295M3.2	3.59	0.000362	0.0399	0.19	0.16	Fibrinogen;	chr16:53199308	chr16:53168522~53169450:+
LUAD	cis	rs16940212	0.618	rs16940181	ENSG00000242747.1	RP11-30K9.1	-3.59	0.000362	0.0399	-0.24	-0.16	HDL cholesterol;HDL cholesterol levels;	chr15:58395325	chr15:58869659~58870134:+
LUAD	cis	rs6071166	0.683	rs1885461	ENSG00000224635.1	RP4-564F22.5	-3.59	0.000362	0.0399	-0.18	-0.16	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38685539	chr20:38406011~38416797:-
LUAD	cis	rs755249	0.567	rs72661961	ENSG00000182109.6	RP11-69E11.4	3.59	0.000362	0.0399	0.2	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39366096	chr1:39522280~39546187:-
LUAD	cis	rs755249	0.532	rs61779277	ENSG00000182109.6	RP11-69E11.4	3.59	0.000362	0.0399	0.2	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39367863	chr1:39522280~39546187:-
LUAD	cis	rs755249	0.532	rs61779278	ENSG00000182109.6	RP11-69E11.4	3.59	0.000362	0.0399	0.2	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39368945	chr1:39522280~39546187:-
LUAD	cis	rs755249	0.567	rs2296172	ENSG00000182109.6	RP11-69E11.4	3.59	0.000362	0.0399	0.2	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39370145	chr1:39522280~39546187:-
LUAD	cis	rs755249	0.567	rs61779279	ENSG00000182109.6	RP11-69E11.4	3.59	0.000362	0.0399	0.2	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39371430	chr1:39522280~39546187:-
LUAD	cis	rs755249	0.567	rs76111861	ENSG00000182109.6	RP11-69E11.4	3.59	0.000362	0.0399	0.2	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39377018	chr1:39522280~39546187:-
LUAD	cis	rs755249	0.567	rs72661965	ENSG00000182109.6	RP11-69E11.4	3.59	0.000362	0.0399	0.2	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39380918	chr1:39522280~39546187:-
LUAD	cis	rs564309	0.867	rs12735877	ENSG00000231563.1	RP11-245P10.4	-3.59	0.000362	0.0399	-0.3	-0.16	Hip circumference (psychosocial stress interaction);	chr1:228380500	chr1:228407381~228409694:+
LUAD	cis	rs564309	0.867	rs12093491	ENSG00000231563.1	RP11-245P10.4	-3.59	0.000362	0.0399	-0.3	-0.16	Hip circumference (psychosocial stress interaction);	chr1:228381797	chr1:228407381~228409694:+
LUAD	cis	rs11089937	0.626	rs5757056	ENSG00000211640.3	IGLV6-57	3.59	0.000362	0.0399	0.12	0.16	Periodontitis (PAL4Q3);	chr22:22142491	chr22:22195713~22196460:+
LUAD	cis	rs17122278	1	rs1047079	ENSG00000243431.1	RPL5P30	3.59	0.000362	0.0399	0.21	0.16	Total cholesterol levels;	chr11:118602516	chr11:118560690~118561580:+
LUAD	cis	rs12928939	0.911	rs12919271	ENSG00000262140.1	RP11-417N10.3	-3.59	0.000362	0.0399	-0.19	-0.16	Post bronchodilator FEV1;	chr16:71758793	chr16:71833787~71835932:+
LUAD	cis	rs9341808	0.556	rs1535075	ENSG00000233967.5	RP11-250B2.3	3.59	0.000362	0.0399	0.16	0.16	Sitting height ratio;	chr6:80325089	chr6:80443344~80465927:+
LUAD	cis	rs4474465	0.79	rs7481910	ENSG00000251323.2	RP11-452H21.4	-3.59	0.000362	0.0399	-0.2	-0.16	Alzheimer's disease (survival time);	chr11:78553156	chr11:78423982~78429836:-
LUAD	cis	rs6121246	0.567	rs6060297	ENSG00000230613.1	HM13-AS1	3.59	0.000362	0.0399	0.25	0.16	Mean corpuscular hemoglobin;	chr20:31610757	chr20:31567707~31573263:-
LUAD	cis	rs2274273	0.84	rs3742569	ENSG00000258413.1	RP11-665C16.6	-3.59	0.000362	0.0399	-0.21	-0.16	Protein biomarker;	chr14:55351988	chr14:55262767~55272075:-
LUAD	cis	rs2144940	0.545	rs844835	ENSG00000233746.1	LINC00656	3.59	0.000362	0.0399	0.35	0.16	Venous thromboembolism;	chr20:23106135	chr20:23125068~23132621:-
LUAD	cis	rs357618	0.931	rs394736	ENSG00000272112.1	CTB-113P19.5	-3.59	0.000362	0.0399	-0.15	-0.16	Basophil percentage of white cells;	chr5:151467948	chr5:151724831~151725356:-
LUAD	cis	rs357618	0.965	rs357621	ENSG00000272112.1	CTB-113P19.5	-3.59	0.000362	0.0399	-0.15	-0.16	Basophil percentage of white cells;	chr5:151467993	chr5:151724831~151725356:-
LUAD	cis	rs9308731	0.64	rs10204044	ENSG00000227992.1	AC108463.2	3.59	0.000362	0.0399	0.21	0.16	Chronic lymphocytic leukemia;	chr2:111137967	chr2:111203964~111206215:-
LUAD	cis	rs6447650	0.688	rs1844996	ENSG00000248780.1	RP11-632F7.1	3.59	0.000362	0.04	0.22	0.16	Body mass index (change over time);	chr4:40371384	chr4:40786110~40786710:+
LUAD	cis	rs2905347	0.56	rs2961293	ENSG00000179428.2	AC073072.5	3.59	0.000362	0.04	0.19	0.16	Major depression and alcohol dependence;	chr7:22644465	chr7:22725395~22727620:-
LUAD	cis	rs6494488	0.5	rs72758953	ENSG00000259635.1	AC100830.3	-3.59	0.000362	0.04	-0.38	-0.16	Coronary artery disease;	chr15:64399953	chr15:64701248~64719602:+
LUAD	cis	rs6494488	0.5	rs72741303	ENSG00000259635.1	AC100830.3	-3.59	0.000362	0.04	-0.38	-0.16	Coronary artery disease;	chr15:64400219	chr15:64701248~64719602:+
LUAD	cis	rs1575891	1	rs1172417	ENSG00000276968.1	RP11-90M2.5	3.59	0.000362	0.04	0.18	0.16	Cardiac hypertrophy;	chr13:47645570	chr13:48041751~48042184:-
LUAD	cis	rs891378	0.959	rs6681853	ENSG00000274245.1	RP11-357P18.2	-3.59	0.000362	0.04	-0.2	-0.16	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207325299	chr1:207372559~207373252:+
LUAD	cis	rs3845817	0.671	rs840785	ENSG00000281920.1	RP11-418H16.1	-3.59	0.000362	0.04	-0.2	-0.16	Bipolar disorder;	chr2:65541842	chr2:65623272~65628424:+
LUAD	cis	rs3845817	0.703	rs702915	ENSG00000281920.1	RP11-418H16.1	-3.59	0.000362	0.04	-0.2	-0.16	Bipolar disorder;	chr2:65543462	chr2:65623272~65628424:+
LUAD	cis	rs3845817	0.703	rs1673458	ENSG00000281920.1	RP11-418H16.1	-3.59	0.000362	0.04	-0.2	-0.16	Bipolar disorder;	chr2:65544512	chr2:65623272~65628424:+
LUAD	cis	rs7017914	0.652	rs13264053	ENSG00000246366.5	RP11-382J12.1	3.59	0.000362	0.04	0.15	0.16	Bone mineral density;	chr8:71079101	chr8:70608577~70663279:+
LUAD	cis	rs1520724	0.663	rs10859699	ENSG00000258172.1	RP11-1105G2.4	-3.59	0.000362	0.04	-0.18	-0.16	Obesity-related traits;	chr12:94465233	chr12:94272150~94277195:-
LUAD	cis	rs1348850	0.958	rs10930800	ENSG00000213963.5	AC074286.1	3.59	0.000362	0.04	0.2	0.16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177594941	chr2:177283508~177392691:-
LUAD	cis	rs11841001	0.731	rs4884020	ENSG00000261105.4	LMO7-AS1	3.59	0.000362	0.04	0.4	0.16	Corneal astigmatism;	chr13:75805161	chr13:75604700~75635994:-
LUAD	cis	rs3749855	0.679	rs13206076	ENSG00000220920.1	RP3-525L6.2	3.59	0.000362	0.04	0.32	0.16	Glucose homeostasis traits;	chr6:17251222	chr6:17953572~17953930:+
LUAD	cis	rs7726839	0.54	rs4957081	ENSG00000248925.1	CTD-2083E4.6	3.59	0.000362	0.04	0.26	0.16	Obesity-related traits;	chr5:646303	chr5:269858~271516:-
LUAD	cis	rs3849150	1	rs12761826	ENSG00000235939.1	RP11-123B3.2	-3.59	0.000362	0.04	-0.24	-0.16	Subclinical atherosclerosis traits (other);	chr10:48890521	chr10:49419277~49472903:+
LUAD	cis	rs7119038	0.686	rs55894437	ENSG00000255422.1	AP002954.4	3.59	0.000362	0.04	0.24	0.16	Sjögren's syndrome;	chr11:118736708	chr11:118704607~118750263:+
LUAD	cis	rs694419	0.583	rs35347334	ENSG00000278017.1	RP11-120K19.4	-3.59	0.000362	0.04	-0.21	-0.16	Serum albumin level;	chr18:62520659	chr18:62525919~62526325:-
LUAD	cis	rs7937890	0.559	rs2034480	ENSG00000254418.1	RP11-21L19.1	3.59	0.000362	0.04	0.19	0.16	Mitochondrial DNA levels;	chr11:14445377	chr11:14262846~14273691:-
LUAD	cis	rs76878669	0.561	rs4930177	ENSG00000213409.4	RP11-658F2.3	3.59	0.000362	0.04	0.19	0.16	Educational attainment (years of education);	chr11:66353313	chr11:66761575~66762399:-
LUAD	cis	rs7176527	0.747	rs28363946	ENSG00000229212.6	RP11-561C5.4	3.59	0.000363	0.04	0.25	0.16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84829244	chr15:85205440~85234795:-
LUAD	cis	rs4795519	0.778	rs7213353	ENSG00000266313.1	RP11-173M1.4	3.59	0.000363	0.04	0.21	0.16	Chronic myeloid leukemia;	chr17:27110020	chr17:27333256~27348491:+
LUAD	cis	rs4795519	0.778	rs7213358	ENSG00000266313.1	RP11-173M1.4	3.59	0.000363	0.04	0.21	0.16	Chronic myeloid leukemia;	chr17:27110031	chr17:27333256~27348491:+
LUAD	cis	rs763121	0.853	rs4821810	ENSG00000225450.1	RP3-508I15.14	-3.59	0.000363	0.04	-0.15	-0.16	Menopause (age at onset);	chr22:38676093	chr22:38739003~38749041:+
LUAD	cis	rs7100689	0.646	rs10749579	ENSG00000226659.1	RP11-137H2.4	-3.59	0.000363	0.04	-0.22	-0.16	Post bronchodilator FEV1;	chr10:80381203	chr10:80529597~80535942:-
LUAD	cis	rs259282	0.669	rs731673	ENSG00000201388.1	SNORA68	3.59	0.000363	0.04	0.16	0.16	Schizophrenia;	chr19:32641389	chr19:32608337~32608469:-
LUAD	cis	rs8085804	0.597	rs988109	ENSG00000276174.1	RP11-687E1.2	3.59	0.000363	0.04	0.22	0.16	Cognitive performance;	chr18:42641569	chr18:42052705~42053030:+
LUAD	cis	rs7824557	0.688	rs2572397	ENSG00000255046.1	RP11-297N6.4	-3.59	0.000363	0.04	-0.2	-0.16	Retinal vascular caliber;	chr8:11318894	chr8:11797928~11802568:-
LUAD	cis	rs10785571	0.628	rs2408316	ENSG00000275481.1	RP11-474P2.6	3.59	0.000363	0.04	0.14	0.16	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr12:45446318	chr12:46388856~46392126:+
LUAD	cis	rs12234571	1	rs35005980	ENSG00000214293.7	APTR	-3.59	0.000363	0.04	-0.35	-0.16	Obesity-related traits;	chr7:77955678	chr7:77657660~77696265:-
LUAD	cis	rs4474465	1	rs7927722	ENSG00000251323.2	RP11-452H21.4	-3.59	0.000363	0.04	-0.21	-0.16	Alzheimer's disease (survival time);	chr11:78499847	chr11:78423982~78429836:-
LUAD	cis	rs9467773	0.62	rs2504599	ENSG00000261353.1	CTA-14H9.5	-3.59	0.000363	0.04	-0.18	-0.16	Intelligence (multi-trait analysis);	chr6:26640832	chr6:26527063~26527404:+
LUAD	cis	rs7847628	0.587	rs10760117	ENSG00000238181.2	AHCYP2	-3.59	0.000363	0.04	-0.21	-0.16	Birth weight;	chr9:120824459	chr9:120720673~120721972:+
LUAD	cis	rs375066	0.901	rs12977303	ENSG00000278917.1	RP11-15A1.4	-3.59	0.000363	0.04	-0.17	-0.16	Breast cancer;	chr19:43873517	chr19:43891233~43895411:+
LUAD	cis	rs1023500	0.505	rs134888	ENSG00000226450.2	CYP2D8P	3.59	0.000363	0.04	0.12	0.16	Schizophrenia;	chr22:42278275	chr22:42149886~42155001:-
LUAD	cis	rs801193	0.548	rs2659904	ENSG00000273142.1	RP11-458F8.4	-3.59	0.000363	0.04	-0.11	-0.16	Aortic root size;	chr7:66713615	chr7:66902857~66906297:+
LUAD	cis	rs1910358	0.69	rs7713296	ENSG00000248874.4	C5orf17	-3.59	0.000363	0.04	-0.21	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23949541	chr5:23951348~24178263:+
LUAD	cis	rs10483853	0.806	rs12586996	ENSG00000258695.2	RP3-414A15.2	3.59	0.000363	0.04	0.2	0.16	Coronary artery calcification;	chr14:73342516	chr14:73522878~73530610:+
LUAD	cis	rs4462272	0.605	rs4917889	ENSG00000227492.1	RP11-316M21.6	3.59	0.000363	0.04	0.16	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr10:100239637	chr10:100229667~100234000:+
LUAD	cis	rs2412819	0.597	rs7181912	ENSG00000166763.7	STRCP1	-3.59	0.000363	0.04	-0.23	-0.16	Lung cancer;	chr15:43770676	chr15:43699488~43718184:-
LUAD	cis	rs10752881	0.935	rs10797834	ENSG00000224468.3	RP11-181K3.4	-3.59	0.000363	0.04	-0.14	-0.16	Colorectal cancer;	chr1:183079614	chr1:183138402~183141282:-
LUAD	cis	rs10911232	0.542	rs12128323	ENSG00000224468.3	RP11-181K3.4	-3.59	0.000363	0.04	-0.14	-0.16	Hypertriglyceridemia;	chr1:183080952	chr1:183138402~183141282:-
LUAD	cis	rs10911232	0.524	rs10911229	ENSG00000224468.3	RP11-181K3.4	-3.59	0.000363	0.04	-0.14	-0.16	Hypertriglyceridemia;	chr1:183081233	chr1:183138402~183141282:-
LUAD	cis	rs10752881	0.875	rs10752894	ENSG00000224468.3	RP11-181K3.4	-3.59	0.000363	0.04	-0.14	-0.16	Colorectal cancer;	chr1:183081475	chr1:183138402~183141282:-
LUAD	cis	rs10911232	0.507	rs10911230	ENSG00000224468.3	RP11-181K3.4	-3.59	0.000363	0.04	-0.14	-0.16	Hypertriglyceridemia;	chr1:183081983	chr1:183138402~183141282:-
LUAD	cis	rs10911232	0.507	rs35782443	ENSG00000224468.3	RP11-181K3.4	-3.59	0.000363	0.04	-0.14	-0.16	Hypertriglyceridemia;	chr1:183082367	chr1:183138402~183141282:-
LUAD	cis	rs10752881	0.935	rs12082051	ENSG00000224468.3	RP11-181K3.4	-3.59	0.000363	0.04	-0.14	-0.16	Colorectal cancer;	chr1:183082479	chr1:183138402~183141282:-
LUAD	cis	rs10911232	0.507	rs10911231	ENSG00000224468.3	RP11-181K3.4	-3.59	0.000363	0.04	-0.14	-0.16	Hypertriglyceridemia;	chr1:183082610	chr1:183138402~183141282:-
LUAD	cis	rs10911232	0.507	rs10911234	ENSG00000224468.3	RP11-181K3.4	-3.59	0.000363	0.04	-0.14	-0.16	Hypertriglyceridemia;	chr1:183083866	chr1:183138402~183141282:-
LUAD	cis	rs10911232	0.507	rs4397624	ENSG00000224468.3	RP11-181K3.4	-3.59	0.000363	0.04	-0.14	-0.16	Hypertriglyceridemia;	chr1:183083996	chr1:183138402~183141282:-
LUAD	cis	rs10752881	0.935	rs10911235	ENSG00000224468.3	RP11-181K3.4	-3.59	0.000363	0.04	-0.14	-0.16	Colorectal cancer;	chr1:183084611	chr1:183138402~183141282:-
LUAD	cis	rs1155848	0.892	rs9565508	ENSG00000227676.3	LINC01068	-3.59	0.000363	0.04	-0.39	-0.16	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79482451	chr13:79566727~79571436:+
LUAD	cis	rs524281	0.773	rs2236651	ENSG00000255320.1	RP11-755F10.1	3.59	0.000363	0.04	0.25	0.16	Electroencephalogram traits;	chr11:66233947	chr11:66244840~66246239:-
LUAD	cis	rs524281	0.773	rs4393319	ENSG00000255320.1	RP11-755F10.1	3.59	0.000363	0.04	0.25	0.16	Electroencephalogram traits;	chr11:66234407	chr11:66244840~66246239:-
LUAD	cis	rs524281	0.773	rs10896105	ENSG00000255320.1	RP11-755F10.1	3.59	0.000363	0.04	0.25	0.16	Electroencephalogram traits;	chr11:66234789	chr11:66244840~66246239:-
LUAD	cis	rs524281	0.773	rs2236652	ENSG00000255320.1	RP11-755F10.1	3.59	0.000363	0.04	0.25	0.16	Electroencephalogram traits;	chr11:66235210	chr11:66244840~66246239:-
LUAD	cis	rs524281	0.731	rs11227433	ENSG00000255320.1	RP11-755F10.1	3.59	0.000363	0.04	0.25	0.16	Electroencephalogram traits;	chr11:66237222	chr11:66244840~66246239:-
LUAD	cis	rs524281	0.773	rs10791861	ENSG00000255320.1	RP11-755F10.1	3.59	0.000363	0.04	0.25	0.16	Electroencephalogram traits;	chr11:66240999	chr11:66244840~66246239:-
LUAD	cis	rs524281	0.773	rs10791862	ENSG00000255320.1	RP11-755F10.1	3.59	0.000363	0.04	0.25	0.16	Electroencephalogram traits;	chr11:66246193	chr11:66244840~66246239:-
LUAD	cis	rs524281	0.773	rs2155198	ENSG00000255320.1	RP11-755F10.1	3.59	0.000363	0.04	0.25	0.16	Electroencephalogram traits;	chr11:66246829	chr11:66244840~66246239:-
LUAD	cis	rs56309584	0.56	rs3027160	ENSG00000226871.1	AC135178.7	3.59	0.000363	0.04	0.23	0.16	Initial pursuit acceleration;	chr17:8154254	chr17:8318088~8318712:-
LUAD	cis	rs4474465	0.79	rs4544031	ENSG00000251323.2	RP11-452H21.4	-3.59	0.000363	0.04	-0.2	-0.16	Alzheimer's disease (survival time);	chr11:78554357	chr11:78423982~78429836:-
LUAD	cis	rs8141529	0.748	rs2064261	ENSG00000272858.1	CTA-292E10.8	-3.59	0.000363	0.04	-0.18	-0.16	Lymphocyte counts;	chr22:28891742	chr22:28814914~28815662:+
LUAD	cis	rs9951698	0.678	rs1786279	ENSG00000266969.1	RP11-773H22.4	3.59	0.000363	0.04	0.21	0.16	Intelligence (multi-trait analysis);	chr18:13144973	chr18:12984694~12991173:-
LUAD	cis	rs9951698	0.678	rs482577	ENSG00000266969.1	RP11-773H22.4	3.59	0.000363	0.04	0.21	0.16	Intelligence (multi-trait analysis);	chr18:13148618	chr18:12984694~12991173:-
LUAD	cis	rs8133949	0.768	rs7278794	ENSG00000237232.6	ZNF295-AS1	3.59	0.000363	0.04	0.2	0.16	Hand grip strength;	chr21:42012145	chr21:42009194~42024924:+
LUAD	cis	rs4845552	0.767	rs2339696	ENSG00000272030.1	RP1-178F15.4	3.59	0.000363	0.04	0.24	0.16	Hippocampal atrophy;	chr1:153508187	chr1:153631438~153634397:-
LUAD	cis	rs7210990	0.699	rs4792709	ENSG00000276855.1	CTD-3157E16.2	-3.59	0.000363	0.04	-0.2	-0.16	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr17:15989127	chr17:15789016~15789705:+
LUAD	cis	rs3126085	0.877	rs4845742	ENSG00000237975.5	FLG-AS1	-3.59	0.000363	0.04	-0.25	-0.16	Atopic dermatitis;	chr1:152211473	chr1:152168125~152445456:+
LUAD	cis	rs4795519	0.645	rs12938069	ENSG00000266313.1	RP11-173M1.4	3.59	0.000363	0.04	0.22	0.16	Chronic myeloid leukemia;	chr17:27163348	chr17:27333256~27348491:+
LUAD	cis	rs6502050	0.805	rs62080003	ENSG00000275966.1	RP11-1055B8.9	3.59	0.000363	0.04	0.17	0.16	Life satisfaction;	chr17:82121081	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs7406529	ENSG00000275966.1	RP11-1055B8.9	3.59	0.000363	0.04	0.17	0.16	Life satisfaction;	chr17:82123001	chr17:81345476~81345966:-
LUAD	cis	rs763121	0.819	rs5757160	ENSG00000225450.1	RP3-508I15.14	-3.59	0.000363	0.04	-0.15	-0.16	Menopause (age at onset);	chr22:38593641	chr22:38739003~38749041:+
LUAD	cis	rs763121	0.853	rs5757166	ENSG00000225450.1	RP3-508I15.14	-3.59	0.000363	0.04	-0.15	-0.16	Menopause (age at onset);	chr22:38599380	chr22:38739003~38749041:+
LUAD	cis	rs763121	0.819	rs5757169	ENSG00000225450.1	RP3-508I15.14	-3.59	0.000363	0.04	-0.15	-0.16	Menopause (age at onset);	chr22:38607490	chr22:38739003~38749041:+
LUAD	cis	rs10435719	0.834	rs6985792	ENSG00000255046.1	RP11-297N6.4	-3.59	0.000363	0.04	-0.2	-0.16	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11937826	chr8:11797928~11802568:-
LUAD	cis	rs11742741	0.744	rs72745737	ENSG00000248874.4	C5orf17	-3.59	0.000363	0.04	-0.2	-0.16	Educational attainment;	chr5:24074073	chr5:23951348~24178263:+
LUAD	cis	rs11742741	0.806	rs11745873	ENSG00000248874.4	C5orf17	-3.59	0.000363	0.04	-0.2	-0.16	Educational attainment;	chr5:24074812	chr5:23951348~24178263:+
LUAD	cis	rs2024125	1	rs2024125	ENSG00000232006.7	AC005537.2	3.59	0.000363	0.04	0.19	0.16	Obesity-related traits;	chr7:43118878	chr7:42954135~43113931:-
LUAD	cis	rs2333021	0.649	rs34158414	ENSG00000259015.1	RP11-109N23.6	3.59	0.000363	0.0401	0.16	0.16	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72995629	chr14:72960595~72961993:+
LUAD	cis	rs2333021	0.649	rs9888613	ENSG00000259015.1	RP11-109N23.6	3.59	0.000363	0.0401	0.16	0.16	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72995635	chr14:72960595~72961993:+
LUAD	cis	rs2333021	0.624	rs9888617	ENSG00000259015.1	RP11-109N23.6	3.59	0.000363	0.0401	0.16	0.16	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72996154	chr14:72960595~72961993:+
LUAD	cis	rs2625529	0.652	rs8027164	ENSG00000260173.1	RP11-2I17.4	3.59	0.000363	0.0401	0.19	0.16	Red blood cell count;	chr15:72115392	chr15:72140504~72155459:-
LUAD	cis	rs1198430	0.714	rs1198437	ENSG00000232482.2	RP4-654C18.1	-3.59	0.000364	0.0401	-0.23	-0.16	Total cholesterol levels;	chr1:23420931	chr1:23410832~23412146:+
LUAD	cis	rs12908161	0.96	rs17599989	ENSG00000259654.1	RP11-245C17.2	-3.59	0.000364	0.0401	-0.23	-0.16	Schizophrenia;	chr15:84742305	chr15:84685884~84686946:+
LUAD	cis	rs6088590	1	rs2295354	ENSG00000275784.1	RP5-1125A11.6	-3.59	0.000364	0.0401	-0.18	-0.16	Coronary artery disease;	chr20:34768738	chr20:33989480~33991818:-
LUAD	cis	rs9341808	0.5	rs806851	ENSG00000233967.5	RP11-250B2.3	-3.59	0.000364	0.0401	-0.16	-0.16	Sitting height ratio;	chr6:80321114	chr6:80443344~80465927:+
LUAD	cis	rs7617773	0.539	rs13087050	ENSG00000199476.1	Y_RNA	-3.59	0.000364	0.0401	-0.2	-0.16	Coronary artery disease;	chr3:48351310	chr3:48288587~48288694:+
LUAD	cis	rs449789	0.524	rs1875819	ENSG00000235086.1	FNDC1-IT1	-3.59	0.000364	0.0401	-0.22	-0.16	Pulse pressure;	chr6:159326711	chr6:159240786~159243329:+
LUAD	cis	rs3126085	0.935	rs10749670	ENSG00000237975.5	FLG-AS1	-3.59	0.000364	0.0401	-0.24	-0.16	Atopic dermatitis;	chr1:152247991	chr1:152168125~152445456:+
LUAD	cis	rs11955398	0.502	rs159357	ENSG00000272308.1	RP11-231G3.1	-3.59	0.000364	0.0401	-0.18	-0.16	Intelligence (multi-trait analysis);	chr5:61174363	chr5:60866457~60866935:-
LUAD	cis	rs12744310	0.887	rs35021924	ENSG00000235358.1	RP11-399E6.1	3.59	0.000364	0.0401	0.21	0.16	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41321235	chr1:41242373~41284861:+
LUAD	cis	rs12744310	0.887	rs35592291	ENSG00000235358.1	RP11-399E6.1	3.59	0.000364	0.0401	0.21	0.16	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41325599	chr1:41242373~41284861:+
LUAD	cis	rs12744310	0.887	rs2363811	ENSG00000235358.1	RP11-399E6.1	3.59	0.000364	0.0401	0.21	0.16	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41326193	chr1:41242373~41284861:+
LUAD	cis	rs12744310	0.887	rs12026778	ENSG00000235358.1	RP11-399E6.1	3.59	0.000364	0.0401	0.21	0.16	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41326602	chr1:41242373~41284861:+
LUAD	cis	rs12744310	0.887	rs4453028	ENSG00000235358.1	RP11-399E6.1	3.59	0.000364	0.0401	0.21	0.16	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41326851	chr1:41242373~41284861:+
LUAD	cis	rs12744310	0.83	rs4406620	ENSG00000235358.1	RP11-399E6.1	3.59	0.000364	0.0401	0.21	0.16	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41327093	chr1:41242373~41284861:+
LUAD	cis	rs12744310	0.887	rs35436312	ENSG00000235358.1	RP11-399E6.1	3.59	0.000364	0.0401	0.21	0.16	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41327686	chr1:41242373~41284861:+
LUAD	cis	rs12744310	0.887	rs1316274	ENSG00000235358.1	RP11-399E6.1	3.59	0.000364	0.0401	0.21	0.16	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41327986	chr1:41242373~41284861:+
LUAD	cis	rs10208649	0.908	rs10181332	ENSG00000233266.1	HMGB1P31	3.59	0.000364	0.0401	0.43	0.16	Body mass index;	chr2:54118288	chr2:54051334~54051760:+
LUAD	cis	rs755249	0.567	rs66531516	ENSG00000182109.6	RP11-69E11.4	3.59	0.000364	0.0401	0.2	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39163390	chr1:39522280~39546187:-
LUAD	cis	rs2856321	0.874	rs1009951	ENSG00000256682.2	TAS2R12	-3.59	0.000364	0.0401	-0.19	-0.16	Height;	chr12:11739962	chr12:10894943~10896952:-
LUAD	cis	rs9921338	0.961	rs7191093	ENSG00000262703.1	RP11-485G7.6	-3.59	0.000364	0.0401	-0.17	-0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11348422	chr16:11348143~11349321:-
LUAD	cis	rs13113518	0.783	rs12504300	ENSG00000249700.7	SRD5A3-AS1	3.59	0.000364	0.0401	0.17	0.16	Height;	chr4:55482360	chr4:55363971~55395847:-
LUAD	cis	rs8062405	1	rs62036622	ENSG00000261419.1	RP11-57A19.4	-3.59	0.000364	0.0401	-0.18	-0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28659696~28740781:-
LUAD	cis	rs7107174	0.901	rs10899500	ENSG00000251323.2	RP11-452H21.4	3.59	0.000364	0.0401	0.21	0.16	Testicular germ cell tumor;	chr11:78414200	chr11:78423982~78429836:-
LUAD	cis	rs12146727	0.881	rs16933078	ENSG00000247853.2	RP5-940J5.6	3.59	0.000364	0.0401	0.26	0.16	Blood protein levels;	chr12:7064034	chr12:6578622~6584739:+
LUAD	cis	rs4907240	0.961	rs66727130	ENSG00000237510.6	AC008268.2	-3.59	0.000364	0.0401	-0.23	-0.16	Event-related brain oscillations;	chr2:96659254	chr2:95789654~95800166:+
LUAD	cis	rs180730	1	rs1376109	ENSG00000251609.2	SETP12	-3.59	0.000364	0.0401	-0.24	-0.16	Fasting plasma glucose;	chr4:120917160	chr4:120895494~120897083:-
LUAD	cis	rs5742933	0.842	rs1225101	ENSG00000253559.1	OSGEPL1-AS1	-3.59	0.000364	0.0401	-0.22	-0.16	Ferritin levels;	chr2:189740695	chr2:189762704~189765556:+
LUAD	cis	rs9638182	0.778	rs3812316	ENSG00000274080.1	CTA-315H11.2	3.59	0.000364	0.0401	0.3	0.16	Triglycerides;	chr7:73606007	chr7:73609262~73611502:-
LUAD	cis	rs7572733	0.773	rs56858593	ENSG00000222017.1	AC011997.1	3.59	0.000364	0.0401	0.2	0.16	Dermatomyositis;	chr2:197629744	chr2:197693106~197774823:+
LUAD	cis	rs7572733	0.742	rs3828317	ENSG00000222017.1	AC011997.1	3.59	0.000364	0.0401	0.2	0.16	Dermatomyositis;	chr2:197630707	chr2:197693106~197774823:+
LUAD	cis	rs6496044	0.568	rs12708554	ENSG00000259407.1	RP11-158M2.3	-3.59	0.000364	0.0401	-0.15	-0.16	Interstitial lung disease;	chr15:85531066	chr15:85744109~85750281:-
LUAD	cis	rs1979679	0.573	rs7134807	ENSG00000278733.1	RP11-425D17.1	3.59	0.000364	0.0401	0.2	0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28576317	chr12:28185625~28186190:-
LUAD	cis	rs2836974	0.932	rs11910151	ENSG00000232608.1	TIMM9P2	-3.59	0.000364	0.0401	-0.19	-0.16	Cognitive function;	chr21:39188336	chr21:39216624~39217506:+
LUAD	cis	rs773506	0.551	rs7856089	ENSG00000237422.1	RP11-305L7.3	3.59	0.000364	0.0401	0.21	0.16	Type 2 diabetes nephropathy;	chr9:91343175	chr9:91119138~91163087:-
LUAD	cis	rs7141336	0.965	rs12884258	ENSG00000258884.1	CTD-3035D6.2	3.59	0.000364	0.0401	0.17	0.16	Anxiety disorder;	chr14:90817368	chr14:90822365~90828128:-
LUAD	cis	rs4835473	0.897	rs17693780	ENSG00000249741.2	RP11-673E1.3	3.59	0.000364	0.0401	0.19	0.16	Immature fraction of reticulocytes;	chr4:143737563	chr4:143911514~143912053:-
LUAD	cis	rs4835473	0.897	rs35556180	ENSG00000249741.2	RP11-673E1.3	3.59	0.000364	0.0401	0.19	0.16	Immature fraction of reticulocytes;	chr4:143737595	chr4:143911514~143912053:-
LUAD	cis	rs4835473	0.897	rs35377051	ENSG00000249741.2	RP11-673E1.3	3.59	0.000364	0.0401	0.19	0.16	Immature fraction of reticulocytes;	chr4:143737627	chr4:143911514~143912053:-
LUAD	cis	rs4835473	0.864	rs17018131	ENSG00000249741.2	RP11-673E1.3	3.59	0.000364	0.0401	0.19	0.16	Immature fraction of reticulocytes;	chr4:143737647	chr4:143911514~143912053:-
LUAD	cis	rs11159086	0.793	rs17100414	ENSG00000270000.1	RP3-449M8.9	3.59	0.000364	0.0401	0.23	0.16	Advanced glycation end-product levels;	chr14:74467918	chr14:74471930~74472360:-
LUAD	cis	rs4664293	0.867	rs34392518	ENSG00000230783.1	AC009961.2	-3.59	0.000364	0.0401	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159749367	chr2:159689217~159690291:-
LUAD	cis	rs151450	1	rs151450	ENSG00000251411.1	RP11-397E7.4	-3.59	0.000364	0.0401	-0.18	-0.16	Basophil percentage of white cells;	chr4:87095362	chr4:86913266~86914817:-
LUAD	cis	rs7557067	1	rs10184054	ENSG00000233005.1	AC067959.1	-3.59	0.000364	0.0401	-0.19	-0.16	Triglycerides;	chr2:20981005	chr2:21221175~21970959:+
LUAD	cis	rs875971	0.545	rs316324	ENSG00000224316.1	RP11-479O9.2	-3.59	0.000365	0.0402	-0.19	-0.16	Aortic root size;	chr7:66145627	chr7:65773620~65802067:+
LUAD	cis	rs875971	0.545	rs316323	ENSG00000224316.1	RP11-479O9.2	-3.59	0.000365	0.0402	-0.19	-0.16	Aortic root size;	chr7:66146002	chr7:65773620~65802067:+
LUAD	cis	rs875971	0.545	rs316316	ENSG00000224316.1	RP11-479O9.2	-3.59	0.000365	0.0402	-0.19	-0.16	Aortic root size;	chr7:66149270	chr7:65773620~65802067:+
LUAD	cis	rs875971	0.545	rs316305	ENSG00000224316.1	RP11-479O9.2	-3.59	0.000365	0.0402	-0.19	-0.16	Aortic root size;	chr7:66152984	chr7:65773620~65802067:+
LUAD	cis	rs2348418	0.639	rs10459086	ENSG00000247934.4	RP11-967K21.1	-3.59	0.000365	0.0402	-0.18	-0.16	Lung function (FEV1);Lung function (FVC);	chr12:28115511	chr12:28163298~28190738:-
LUAD	cis	rs2880765	0.835	rs12708553	ENSG00000259407.1	RP11-158M2.3	3.59	0.000365	0.0402	0.14	0.16	Coronary artery disease;	chr15:85503602	chr15:85744109~85750281:-
LUAD	cis	rs7615952	0.673	rs35955861	ENSG00000241288.6	RP11-379B18.5	-3.59	0.000365	0.0402	-0.26	-0.16	Blood pressure (smoking interaction);	chr3:125907358	chr3:125827238~125916384:-
LUAD	cis	rs7615952	0.673	rs35001498	ENSG00000241288.6	RP11-379B18.5	-3.59	0.000365	0.0402	-0.26	-0.16	Blood pressure (smoking interaction);	chr3:125909801	chr3:125827238~125916384:-
LUAD	cis	rs5769707	0.967	rs2187891	ENSG00000235111.1	RP1-29C18.8	-3.59	0.000365	0.0402	-0.17	-0.16	Monocyte percentage of white cells;Monocyte count;	chr22:49600446	chr22:49612657~49615716:-
LUAD	cis	rs9595908	0.965	rs9595877	ENSG00000281026.1	N4BP2L2-IT2	-3.59	0.000365	0.0402	-0.11	-0.16	Body mass index;	chr13:32589512	chr13:32504506~32509395:-
LUAD	cis	rs755249	0.508	rs586057	ENSG00000182109.6	RP11-69E11.4	3.59	0.000365	0.0402	0.18	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39393122	chr1:39522280~39546187:-
LUAD	cis	rs11673344	0.555	rs502546	ENSG00000267309.1	CTD-2630F21.1	3.59	0.000365	0.0402	0.21	0.16	Obesity-related traits;	chr19:37361788	chr19:36489649~36491040:+
LUAD	cis	rs1910358	0.621	rs6891863	ENSG00000248874.4	C5orf17	-3.59	0.000365	0.0402	-0.22	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23852557	chr5:23951348~24178263:+
LUAD	cis	rs61160187	0.582	rs2049579	ENSG00000215032.2	GNL3LP1	3.59	0.000365	0.0402	0.2	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:61054838	chr5:60891935~60893577:-
LUAD	cis	rs115769866	0.618	rs7759252	ENSG00000216901.1	AL022393.7	3.59	0.000365	0.0402	0.23	0.16	Bipolar disorder;	chr6:28501645	chr6:28176188~28176674:+
LUAD	cis	rs638893	0.636	rs1784295	ENSG00000255239.1	AP002954.6	3.59	0.000365	0.0402	0.27	0.16	Vitiligo;	chr11:118790223	chr11:118688039~118690600:-
LUAD	cis	rs7302981	0.746	rs836177	ENSG00000200428.1	Y_RNA	-3.59	0.000365	0.0402	-0.19	-0.16	Systolic blood pressure;	chr12:50098038	chr12:50743568~50743684:+
LUAD	cis	rs6066835	0.867	rs11696900	ENSG00000230758.1	SNAP23P	-3.59	0.000365	0.0402	-0.34	-0.16	Multiple myeloma;	chr20:48720429	chr20:49038357~49038602:-
LUAD	cis	rs864537	0.646	rs1773542	ENSG00000233411.1	RP11-104L21.2	3.59	0.000365	0.0402	0.21	0.16	Celiac disease or Rheumatoid arthritis;Celiac disease;	chr1:167463712	chr1:167457383~167458661:-
LUAD	cis	rs864537	0.646	rs1723016	ENSG00000233411.1	RP11-104L21.2	3.59	0.000365	0.0402	0.21	0.16	Celiac disease or Rheumatoid arthritis;Celiac disease;	chr1:167463819	chr1:167457383~167458661:-
LUAD	cis	rs62246343	0.541	rs2596937	ENSG00000206573.7	THUMPD3-AS1	-3.59	0.000365	0.0402	-0.15	-0.16	Fibrinogen levels;	chr3:9439222	chr3:9349689~9398579:-
LUAD	cis	rs591584	0.874	rs10831245	ENSG00000255893.1	RP11-685N10.1	-3.59	0.000365	0.0402	-0.18	-0.16	Macrophage Migration Inhibitory Factor levels;	chr11:94586722	chr11:94472908~94473570:-
LUAD	cis	rs591584	0.834	rs4543942	ENSG00000255893.1	RP11-685N10.1	-3.59	0.000365	0.0402	-0.18	-0.16	Macrophage Migration Inhibitory Factor levels;	chr11:94588727	chr11:94472908~94473570:-
LUAD	cis	rs4664293	0.747	rs7600347	ENSG00000230783.1	AC009961.2	-3.59	0.000365	0.0402	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159800981	chr2:159689217~159690291:-
LUAD	cis	rs7107174	1	rs7111986	ENSG00000251323.2	RP11-452H21.4	3.59	0.000365	0.0402	0.22	0.16	Testicular germ cell tumor;	chr11:78391220	chr11:78423982~78429836:-
LUAD	cis	rs17189298	0.9	rs330770	ENSG00000231013.1	AC013275.2	-3.59	0.000365	0.0402	-0.16	-0.16	Cerebrospinal T-tau levels;	chr2:119075720	chr2:119476448~119487346:+
LUAD	cis	rs13068223	0.503	rs34277251	ENSG00000243926.1	TIPARP-AS1	3.59	0.000365	0.0402	0.17	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr3:156703736	chr3:156671862~156674378:-
LUAD	cis	rs7613051	0.947	rs13093698	ENSG00000223899.1	SEC13P1	3.59	0.000365	0.0402	0.2	0.16	Atopic dermatitis;	chr3:33021558	chr3:33033863~33034810:+
LUAD	cis	rs786425	0.868	rs786447	ENSG00000278112.1	RP11-972P1.11	-3.59	0.000365	0.0402	-0.15	-0.16	Pubertal anthropometrics;	chr12:123585120	chr12:123519390~123519856:-
LUAD	cis	rs6493487	0.512	rs34676299	ENSG00000273674.3	CTD-2378E12.1	3.59	0.000365	0.0402	0.23	0.16	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50827018	chr15:50839875~50908599:-
LUAD	cis	rs875971	0.545	rs10261710	ENSG00000224316.1	RP11-479O9.2	3.59	0.000365	0.0402	0.19	0.16	Aortic root size;	chr7:66249202	chr7:65773620~65802067:+
LUAD	cis	rs1198430	0.636	rs2156087	ENSG00000232482.2	RP4-654C18.1	3.59	0.000365	0.0402	0.2	0.16	Total cholesterol levels;	chr1:23417088	chr1:23410832~23412146:+
LUAD	cis	rs9652601	0.622	rs1003603	ENSG00000262222.1	RP11-876N24.4	-3.59	0.000365	0.0402	-0.14	-0.16	Systemic lupus erythematosus;	chr16:11020766	chr16:10940719~10943021:+
LUAD	cis	rs3126085	0.935	rs1390485	ENSG00000237975.5	FLG-AS1	3.59	0.000365	0.0402	0.25	0.16	Atopic dermatitis;	chr1:152209692	chr1:152168125~152445456:+
LUAD	cis	rs9815354	0.723	rs12152489	ENSG00000273328.4	RP11-141M3.6	-3.59	0.000365	0.0402	-0.3	-0.16	Pulse pressure;Diastolic blood pressure;	chr3:42018910	chr3:42809414~42908105:+
LUAD	cis	rs7937890	0.81	rs10734224	ENSG00000255040.1	RP11-677N16.1	3.59	0.000365	0.0402	0.17	0.16	Mitochondrial DNA levels;	chr11:14402578	chr11:14673606~14674555:-
LUAD	cis	rs10791097	0.547	rs10791101	ENSG00000255455.2	RP11-890B15.3	-3.59	0.000365	0.0402	-0.16	-0.16	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130869238	chr11:130866254~130870247:-
LUAD	cis	rs7017914	0.967	rs2639903	ENSG00000246366.5	RP11-382J12.1	3.59	0.000365	0.0402	0.15	0.16	Bone mineral density;	chr8:71005209	chr8:70608577~70663279:+
LUAD	cis	rs7632954	0.935	rs6770049	ENSG00000227110.5	LMCD1-AS1	3.59	0.000366	0.0402	0.18	0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr3:8480702	chr3:7952805~8611924:-
LUAD	cis	rs8067545	0.641	rs203450	ENSG00000270091.1	RP11-78O7.2	-3.59	0.000366	0.0402	-0.14	-0.16	Schizophrenia;	chr17:19919757	chr17:19896590~19897287:-
LUAD	cis	rs9650657	0.513	rs7005884	ENSG00000255310.2	AF131215.2	-3.59	0.000366	0.0403	-0.16	-0.16	Neuroticism;	chr8:10938962	chr8:11107788~11109726:-
LUAD	cis	rs4664293	0.867	rs3771718	ENSG00000230783.1	AC009961.2	-3.59	0.000366	0.0403	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159780397	chr2:159689217~159690291:-
LUAD	cis	rs6751744	0.824	rs10205689	ENSG00000230783.1	AC009961.2	-3.59	0.000366	0.0403	-0.21	-0.16	Dysphagia;	chr2:159507158	chr2:159689217~159690291:-
LUAD	cis	rs2494663	0.585	rs11265076	ENSG00000223599.1	RP11-216N14.7	3.59	0.000366	0.0403	0.2	0.16	Mean platelet volume;	chr1:154101823	chr1:153852106~153853414:-
LUAD	cis	rs72681920	0.881	rs61681818	ENSG00000246090.5	RP11-696N14.1	-3.59	0.000366	0.0403	-0.28	-0.16	Alcohol dependence;	chr4:99164306	chr4:99088857~99301356:+
LUAD	cis	rs72681920	0.618	rs36139400	ENSG00000246090.5	RP11-696N14.1	-3.59	0.000366	0.0403	-0.28	-0.16	Alcohol dependence;	chr4:99173207	chr4:99088857~99301356:+
LUAD	cis	rs1198430	0.759	rs946267	ENSG00000232482.2	RP4-654C18.1	-3.59	0.000366	0.0403	-0.23	-0.16	Total cholesterol levels;	chr1:23421210	chr1:23410832~23412146:+
LUAD	cis	rs7402982	0.625	rs7179841	ENSG00000278022.1	RP11-35O15.2	-3.59	0.000366	0.0403	-0.18	-0.16	Birth weight;	chr15:98661423	chr15:98660210~98660668:+
LUAD	cis	rs273259	0.583	rs1333969	ENSG00000235400.1	RP4-641G12.4	-3.59	0.000366	0.0403	-0.23	-0.16	Febrile seizures (MMR vaccine-related);Febrile seizures;	chr1:78624969	chr1:78749073~78750659:+
LUAD	cis	rs8050896	0.59	rs13380550	ENSG00000260695.1	RP11-513N24.1	-3.59	0.000366	0.0403	-0.35	-0.16	Response to antipsychotic treatment;	chr16:66138751	chr16:65861112~65863784:-
LUAD	cis	rs2625529	0.652	rs8040216	ENSG00000260173.1	RP11-2I17.4	3.59	0.000366	0.0403	0.2	0.16	Red blood cell count;	chr15:71962908	chr15:72140504~72155459:-
LUAD	cis	rs10419113	0.641	rs12610315	ENSG00000269867.1	CTD-2583A14.8	3.59	0.000366	0.0403	0.14	0.16	Pediatric bone mineral density (spine);	chr19:57765288	chr19:57867038~57868172:-
LUAD	cis	rs950169	0.84	rs72748702	ENSG00000188388.10	GOLGA6L3	3.59	0.000366	0.0403	0.22	0.16	Schizophrenia;	chr15:84246494	chr15:85240472~85247170:+
LUAD	cis	rs7612209	0.655	rs12637552	ENSG00000277241.1	RP11-114M1.3	3.59	0.000366	0.0403	0.21	0.16	Cognitive performance;	chr3:177879979	chr3:177700346~177701072:-
LUAD	cis	rs6494488	0.5	rs55881719	ENSG00000259635.1	AC100830.3	-3.59	0.000366	0.0403	-0.38	-0.16	Coronary artery disease;	chr15:64422704	chr15:64701248~64719602:+
LUAD	cis	rs6494488	0.5	rs72741319	ENSG00000259635.1	AC100830.3	-3.59	0.000366	0.0403	-0.38	-0.16	Coronary artery disease;	chr15:64424778	chr15:64701248~64719602:+
LUAD	cis	rs6494488	0.5	rs72741320	ENSG00000259635.1	AC100830.3	-3.59	0.000366	0.0403	-0.38	-0.16	Coronary artery disease;	chr15:64429546	chr15:64701248~64719602:+
LUAD	cis	rs6494488	0.5	rs78659827	ENSG00000259635.1	AC100830.3	-3.59	0.000366	0.0403	-0.38	-0.16	Coronary artery disease;	chr15:64429728	chr15:64701248~64719602:+
LUAD	cis	rs7162943	0.887	rs12438271	ENSG00000260123.1	RP11-326A19.4	-3.59	0.000366	0.0403	-0.19	-0.16	Mean platelet volume;	chr15:89069996	chr15:89041223~89082819:+
LUAD	cis	rs17767392	0.609	rs60526802	ENSG00000266869.1	RP6-114E22.1	-3.59	0.000366	0.0403	-0.23	-0.16	Mitral valve prolapse;	chr14:71213361	chr14:71848606~71908430:+
LUAD	cis	rs17767392	0.681	rs4899390	ENSG00000266869.1	RP6-114E22.1	-3.59	0.000366	0.0403	-0.23	-0.16	Mitral valve prolapse;	chr14:71213631	chr14:71848606~71908430:+
LUAD	cis	rs739496	0.579	rs2158030	ENSG00000234608.6	MAPKAPK5-AS1	3.59	0.000366	0.0403	0.19	0.16	Platelet count;	chr12:111847787	chr12:111839764~111842902:-
LUAD	cis	rs6490294	0.799	rs7315642	ENSG00000234608.6	MAPKAPK5-AS1	3.59	0.000366	0.0403	0.19	0.16	Mean platelet volume;	chr12:111848992	chr12:111839764~111842902:-
LUAD	cis	rs739496	0.579	rs12302040	ENSG00000234608.6	MAPKAPK5-AS1	3.59	0.000366	0.0403	0.19	0.16	Platelet count;	chr12:111850375	chr12:111839764~111842902:-
LUAD	cis	rs739496	0.579	rs12322899	ENSG00000234608.6	MAPKAPK5-AS1	3.59	0.000366	0.0403	0.19	0.16	Platelet count;	chr12:111850398	chr12:111839764~111842902:-
LUAD	cis	rs739496	0.579	rs12307192	ENSG00000234608.6	MAPKAPK5-AS1	3.59	0.000366	0.0403	0.19	0.16	Platelet count;	chr12:111852542	chr12:111839764~111842902:-
LUAD	cis	rs739496	0.579	rs12307365	ENSG00000234608.6	MAPKAPK5-AS1	3.59	0.000366	0.0403	0.19	0.16	Platelet count;	chr12:111852847	chr12:111839764~111842902:-
LUAD	cis	rs739496	0.579	rs6489817	ENSG00000234608.6	MAPKAPK5-AS1	3.59	0.000366	0.0403	0.19	0.16	Platelet count;	chr12:111853438	chr12:111839764~111842902:-
LUAD	cis	rs739496	0.579	rs7296199	ENSG00000234608.6	MAPKAPK5-AS1	3.59	0.000366	0.0403	0.19	0.16	Platelet count;	chr12:111854040	chr12:111839764~111842902:-
LUAD	cis	rs739496	0.579	rs12313385	ENSG00000234608.6	MAPKAPK5-AS1	3.59	0.000366	0.0403	0.19	0.16	Platelet count;	chr12:111854343	chr12:111839764~111842902:-
LUAD	cis	rs739496	0.579	rs7310605	ENSG00000234608.6	MAPKAPK5-AS1	3.59	0.000366	0.0403	0.19	0.16	Platelet count;	chr12:111854666	chr12:111839764~111842902:-
LUAD	cis	rs739496	0.579	rs57427612	ENSG00000234608.6	MAPKAPK5-AS1	3.59	0.000366	0.0403	0.19	0.16	Platelet count;	chr12:111856192	chr12:111839764~111842902:-
LUAD	cis	rs739496	0.579	rs7294623	ENSG00000234608.6	MAPKAPK5-AS1	3.59	0.000366	0.0403	0.19	0.16	Platelet count;	chr12:111879292	chr12:111839764~111842902:-
LUAD	cis	rs739496	0.527	rs16941703	ENSG00000234608.6	MAPKAPK5-AS1	3.59	0.000366	0.0403	0.19	0.16	Platelet count;	chr12:111880930	chr12:111839764~111842902:-
LUAD	cis	rs739496	0.527	rs61440627	ENSG00000234608.6	MAPKAPK5-AS1	3.59	0.000366	0.0403	0.19	0.16	Platelet count;	chr12:111881193	chr12:111839764~111842902:-
LUAD	cis	rs4795519	0.778	rs4795458	ENSG00000266313.1	RP11-173M1.4	3.59	0.000366	0.0403	0.21	0.16	Chronic myeloid leukemia;	chr17:27120877	chr17:27333256~27348491:+
LUAD	cis	rs513088	1	rs540656	ENSG00000236364.3	RP11-525G13.2	3.59	0.000366	0.0403	0.16	0.16	Schizophrenia;	chr1:166700000	chr1:165890795~165900683:-
LUAD	cis	rs6452524	0.534	rs10037377	ENSG00000281327.1	LINC01338	3.59	0.000366	0.0403	0.17	0.16	Hypertension (SNP x SNP interaction);	chr5:83071150	chr5:82850864~82859836:-
LUAD	cis	rs7134599	1	rs4255613	ENSG00000240087.3	RP11-254B13.1	3.59	0.000366	0.0403	0.14	0.16	Inflammatory bowel disease;Ulcerative colitis;	chr12:68104890	chr12:68552995~68553882:-
LUAD	cis	rs12712135	0.652	rs11465727	ENSG00000234389.1	AC007278.3	-3.59	0.000366	0.0403	-0.15	-0.16	Blood protein levels;	chr2:102448043	chr2:102438713~102440475:+
LUAD	cis	rs9500256	0.655	rs12209098	ENSG00000239650.4	GUSBP4	-3.59	0.000366	0.0403	-0.19	-0.16	Eosinophilic esophagitis (pediatric);	chr6:58014194	chr6:57919784~57930291:-
LUAD	cis	rs11122895	1	rs11122891	ENSG00000236307.2	EEF1E1P1	3.59	0.000366	0.0403	0.18	0.16	Allergic sensitization;	chr2:111710024	chr2:111887914~111888741:+
LUAD	cis	rs17507216	0.628	rs4513065	ENSG00000276710.3	CSPG4P8	-3.59	0.000366	0.0403	-0.19	-0.16	Excessive daytime sleepiness;	chr15:82712096	chr15:82459472~82477258:+
LUAD	cis	rs6751744	0.855	rs35019796	ENSG00000230783.1	AC009961.2	-3.59	0.000366	0.0403	-0.22	-0.16	Dysphagia;	chr2:159510644	chr2:159689217~159690291:-
LUAD	cis	rs448720	0.811	rs399408	ENSG00000259673.4	IQCH-AS1	3.59	0.000366	0.0403	0.17	0.16	Cognitive performance;	chr15:67891513	chr15:67403619~67521844:-
LUAD	cis	rs1348850	0.793	rs13020788	ENSG00000213963.5	AC074286.1	3.59	0.000366	0.0403	0.19	0.16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177615986	chr2:177283508~177392691:-
LUAD	cis	rs7107174	1	rs4492844	ENSG00000251323.2	RP11-452H21.4	3.59	0.000366	0.0403	0.22	0.16	Testicular germ cell tumor;	chr11:78315470	chr11:78423982~78429836:-
LUAD	cis	rs2803122	0.774	rs10757034	ENSG00000273226.1	RP11-513M16.8	-3.59	0.000366	0.0403	-0.17	-0.16	Pulse pressure;	chr9:19227805	chr9:19375451~19375996:+
LUAD	cis	rs763121	0.853	rs5750633	ENSG00000225450.1	RP3-508I15.14	-3.59	0.000366	0.0403	-0.15	-0.16	Menopause (age at onset);	chr22:38597462	chr22:38739003~38749041:+
LUAD	cis	rs6671200	0.607	rs1927043	ENSG00000228852.5	RP11-57H12.5	-3.59	0.000366	0.0403	-0.19	-0.16	Stearic acid (18:0) levels;	chr1:95201695	chr1:95243167~95278940:-
LUAD	cis	rs2288884	0.636	rs11669439	ENSG00000269959.1	SPACA6P-AS	-3.59	0.000366	0.0403	-0.17	-0.16	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52069047	chr19:51685363~51693456:-
LUAD	cis	rs8028182	0.636	rs8034317	ENSG00000246877.1	DNM1P35	3.59	0.000366	0.0403	0.21	0.16	Sudden cardiac arrest;	chr15:75472002	chr15:75727670~75738623:-
LUAD	cis	rs8028182	0.636	rs28737338	ENSG00000246877.1	DNM1P35	3.59	0.000366	0.0403	0.21	0.16	Sudden cardiac arrest;	chr15:75476338	chr15:75727670~75738623:-
LUAD	cis	rs8042680	0.592	rs11073960	ENSG00000259746.1	HSPE1P3	3.59	0.000366	0.0403	0.17	0.16	Type 2 diabetes;	chr15:90940027	chr15:90634725~90635033:+
LUAD	cis	rs7760535	0.93	rs7742244	ENSG00000271789.1	RP5-1112D6.7	-3.59	0.000366	0.0403	-0.17	-0.16	Metabolic traits;	chr6:111531459	chr6:111297126~111298510:+
LUAD	cis	rs1046491	1	rs8089577	ENSG00000264964.1	RP11-888D10.3	3.59	0.000367	0.0403	0.33	0.16	Scarlet fever;	chr18:9217484	chr18:9315194~9334441:-
LUAD	cis	rs1046491	1	rs11872176	ENSG00000264964.1	RP11-888D10.3	3.59	0.000367	0.0403	0.33	0.16	Scarlet fever;	chr18:9218600	chr18:9315194~9334441:-
LUAD	cis	rs2638953	0.924	rs11049416	ENSG00000278733.1	RP11-425D17.1	3.59	0.000367	0.0403	0.21	0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28190305	chr12:28185625~28186190:-
LUAD	cis	rs11216126	1	rs12421652	ENSG00000280143.1	AP000892.6	-3.59	0.000367	0.0403	-0.27	-0.16	HDL cholesterol;	chr11:116755159	chr11:117204967~117210292:+
LUAD	cis	rs11216126	1	rs4938309	ENSG00000280143.1	AP000892.6	-3.59	0.000367	0.0403	-0.27	-0.16	HDL cholesterol;	chr11:116756339	chr11:117204967~117210292:+
LUAD	cis	rs42490	0.536	rs379015	ENSG00000251136.7	RP11-37B2.1	-3.59	0.000367	0.0403	-0.18	-0.16	Leprosy;	chr8:89856245	chr8:89609409~89757727:-
LUAD	cis	rs4648045	0.624	rs1609798	ENSG00000251288.2	RP11-10L12.2	-3.59	0.000367	0.0403	-0.2	-0.16	Lymphocyte percentage of white cells;	chr4:102616285	chr4:102751401~102752641:+
LUAD	cis	rs4246511	0.739	rs1925678	ENSG00000228436.2	RP5-864K19.4	-3.59	0.000367	0.0403	-0.2	-0.16	Menopause (age at onset);	chr1:38859391	chr1:38860000~38919396:+
LUAD	cis	rs6951245	0.58	rs10257426	ENSG00000224079.1	AC091729.7	-3.59	0.000367	0.0403	-0.23	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1174058	chr7:1074450~1078036:+
LUAD	cis	rs820077	0.736	rs820061	ENSG00000232909.1	RP3-510O8.4	-3.59	0.000367	0.0403	-0.24	-0.16	Systemic lupus erythematosus;	chr6:35075883	chr6:35733867~35736947:-
LUAD	cis	rs7626444	0.625	rs7648479	ENSG00000228028.2	AC069257.8	3.59	0.000367	0.0403	0.16	0.16	Monocyte count;	chr3:196750342	chr3:196250542~196251654:+
LUAD	cis	rs2712475	0.556	rs17178958	ENSG00000241218.1	RP11-446H18.1	3.59	0.000367	0.0404	0.25	0.16	Colonoscopy-negative controls vs population controls;	chr3:106483263	chr3:107327830~107329197:-
LUAD	cis	rs4474465	0.85	rs10793328	ENSG00000251323.2	RP11-452H21.4	-3.59	0.000367	0.0404	-0.21	-0.16	Alzheimer's disease (survival time);	chr11:78545822	chr11:78423982~78429836:-
LUAD	cis	rs13006833	1	rs13006833	ENSG00000227542.1	AC092614.2	-3.59	0.000367	0.0404	-0.2	-0.16	Urinary metabolites;	chr2:190340773	chr2:191229165~191246172:-
LUAD	cis	rs4795519	0.778	rs1807854	ENSG00000266313.1	RP11-173M1.4	3.59	0.000367	0.0404	0.21	0.16	Chronic myeloid leukemia;	chr17:27132035	chr17:27333256~27348491:+
LUAD	cis	rs6472235	0.656	rs72650541	ENSG00000200714.1	Y_RNA	-3.59	0.000367	0.0404	-0.21	-0.16	Plateletcrit;Myopia (pathological);	chr8:65966056	chr8:65592731~65592820:+
LUAD	cis	rs2274273	0.87	rs7153612	ENSG00000258413.1	RP11-665C16.6	-3.59	0.000367	0.0404	-0.21	-0.16	Protein biomarker;	chr14:55322044	chr14:55262767~55272075:-
LUAD	cis	rs7584330	0.652	rs7607231	ENSG00000222032.1	AC112721.2	3.59	0.000367	0.0404	0.19	0.16	Prostate cancer;	chr2:237464253	chr2:237428920~237434822:-
LUAD	cis	rs860295	1	rs860295	ENSG00000203761.5	MSTO2P	3.59	0.000367	0.0404	0.12	0.16	Body mass index;	chr1:155797917	chr1:155745829~155750137:+
LUAD	cis	rs12999542	1	rs11465597	ENSG00000234389.1	AC007278.3	3.59	0.000367	0.0404	0.23	0.16	Serum protein levels (sST2);	chr2:102370753	chr2:102438713~102440475:+
LUAD	cis	rs7017914	0.652	rs17778232	ENSG00000246366.5	RP11-382J12.1	3.59	0.000367	0.0404	0.15	0.16	Bone mineral density;	chr8:71079283	chr8:70608577~70663279:+
LUAD	cis	rs683250	0.599	rs4944435	ENSG00000246067.6	RAB30-AS1	-3.59	0.000367	0.0404	-0.17	-0.16	Subcortical brain region volumes;	chr11:83358089	chr11:83072066~83106719:+
LUAD	cis	rs2273156	0.517	rs7159324	ENSG00000258704.4	SRP54-AS1	3.59	0.000367	0.0404	0.24	0.16	Immunoglobulin light chain (AL) amyloidosis;	chr14:35157791	chr14:34920858~34982532:-
LUAD	cis	rs1876905	0.68	rs434034	ENSG00000271789.1	RP5-1112D6.7	-3.59	0.000367	0.0404	-0.23	-0.16	Mean corpuscular hemoglobin;	chr6:111204180	chr6:111297126~111298510:+
LUAD	cis	rs990171	0.538	rs4851017	ENSG00000234389.1	AC007278.3	3.59	0.000367	0.0404	0.16	0.16	Lymphocyte counts;	chr2:102504310	chr2:102438713~102440475:+
LUAD	cis	rs990171	0.52	rs4851605	ENSG00000234389.1	AC007278.3	3.59	0.000367	0.0404	0.16	0.16	Lymphocyte counts;	chr2:102504409	chr2:102438713~102440475:+
LUAD	cis	rs990171	0.538	rs4851606	ENSG00000234389.1	AC007278.3	3.59	0.000367	0.0404	0.16	0.16	Lymphocyte counts;	chr2:102504430	chr2:102438713~102440475:+
LUAD	cis	rs2274273	0.87	rs8018110	ENSG00000258413.1	RP11-665C16.6	-3.59	0.000367	0.0404	-0.21	-0.16	Protein biomarker;	chr14:55174996	chr14:55262767~55272075:-
LUAD	cis	rs4727963	0.846	rs6968535	ENSG00000240499.6	RP5-1101C3.1	3.59	0.000367	0.0404	0.14	0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);	chr7:123075384	chr7:122328469~122440388:+
LUAD	cis	rs898097	0.51	rs10445242	ENSG00000263063.1	RP11-388C12.1	3.59	0.000367	0.0404	0.16	0.16	Breast cancer;	chr17:82933790	chr17:82713908~82716255:-
LUAD	cis	rs7955901	0.774	rs7308528	ENSG00000258053.1	CTD-2021H9.3	-3.59	0.000367	0.0404	-0.18	-0.16	Type 2 diabetes;	chr12:71024220	chr12:71047402~71118247:-
LUAD	cis	rs9291683	0.632	rs12508991	ENSG00000250413.1	RP11-448G15.1	-3.59	0.000367	0.0404	-0.21	-0.16	Bone mineral density;	chr4:10039480	chr4:10006482~10009725:+
LUAD	cis	rs9341808	0.667	rs1408292	ENSG00000272129.1	RP11-250B2.6	3.59	0.000367	0.0404	0.2	0.16	Sitting height ratio;	chr6:80174189	chr6:80355424~80356859:+
LUAD	cis	rs891378	1	rs891376	ENSG00000274245.1	RP11-357P18.2	-3.59	0.000367	0.0404	-0.2	-0.16	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207318144	chr1:207372559~207373252:+
LUAD	cis	rs9810888	0.63	rs2250736	ENSG00000271916.1	RP11-884K10.6	3.59	0.000367	0.0404	0.16	0.16	Hypertension;Diastolic blood pressure;Systolic blood pressure;	chr3:53666523	chr3:53797764~53798019:-
LUAD	cis	rs4474465	0.85	rs10751292	ENSG00000251323.2	RP11-452H21.4	-3.59	0.000367	0.0404	-0.2	-0.16	Alzheimer's disease (survival time);	chr11:78531155	chr11:78423982~78429836:-
LUAD	cis	rs7809950	1	rs986994	ENSG00000238832.1	snoU109	-3.59	0.000367	0.0404	-0.24	-0.16	Coronary artery disease;	chr7:107463670	chr7:107603363~107603507:+
LUAD	cis	rs11233413	1	rs7106216	ENSG00000246067.6	RAB30-AS1	3.59	0.000367	0.0404	0.17	0.16	Economic and political preferences (feminism/equality);	chr11:83001576	chr11:83072066~83106719:+
LUAD	cis	rs1823913	0.637	rs6741454	ENSG00000230611.1	HMGB1P27	3.59	0.000368	0.0404	0.18	0.16	Obesity-related traits;	chr2:191269520	chr2:191174233~191174835:+
LUAD	cis	rs73230612	0.722	rs9790250	ENSG00000242767.1	ZBTB20-AS4	3.59	0.000368	0.0404	0.26	0.16	Type 2 diabetes;	chr3:115231831	chr3:115100423~115103061:+
LUAD	cis	rs73230612	1	rs9867281	ENSG00000242767.1	ZBTB20-AS4	3.59	0.000368	0.0404	0.26	0.16	Type 2 diabetes;	chr3:115236600	chr3:115100423~115103061:+
LUAD	cis	rs73230612	1	rs11718803	ENSG00000242767.1	ZBTB20-AS4	3.59	0.000368	0.0404	0.26	0.16	Type 2 diabetes;	chr3:115237273	chr3:115100423~115103061:+
LUAD	cis	rs73230612	1	rs13318807	ENSG00000242767.1	ZBTB20-AS4	3.59	0.000368	0.0404	0.26	0.16	Type 2 diabetes;	chr3:115237504	chr3:115100423~115103061:+
LUAD	cis	rs2732480	0.5	rs12829841	ENSG00000273765.1	RP11-370I10.11	3.59	0.000368	0.0404	0.18	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48234956	chr12:48360920~48361377:+
LUAD	cis	rs2732480	0.523	rs34286639	ENSG00000273765.1	RP11-370I10.11	3.59	0.000368	0.0404	0.18	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48235261	chr12:48360920~48361377:+
LUAD	cis	rs1387259	0.929	rs11168484	ENSG00000273765.1	RP11-370I10.11	3.59	0.000368	0.0404	0.18	0.16	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48239806	chr12:48360920~48361377:+
LUAD	cis	rs6472827	0.645	rs2956056	ENSG00000253983.2	RP1-16A9.1	3.59	0.000368	0.0404	0.23	0.16	Uterine fibroids;	chr8:74199608	chr8:74199396~74208441:+
LUAD	cis	rs7017914	0.967	rs2639919	ENSG00000246366.5	RP11-382J12.1	3.59	0.000368	0.0404	0.15	0.16	Bone mineral density;	chr8:70962893	chr8:70608577~70663279:+
LUAD	cis	rs9287719	0.774	rs4997811	ENSG00000243819.4	RN7SL832P	3.59	0.000368	0.0404	0.17	0.16	Prostate cancer;	chr2:10615412	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.745	rs4997810	ENSG00000243819.4	RN7SL832P	3.59	0.000368	0.0404	0.17	0.16	Prostate cancer;	chr2:10615414	chr2:10690344~10692099:+
LUAD	cis	rs9287719	0.745	rs4997809	ENSG00000243819.4	RN7SL832P	3.59	0.000368	0.0404	0.17	0.16	Prostate cancer;	chr2:10615416	chr2:10690344~10692099:+
LUAD	cis	rs6860806	0.661	rs2136188	ENSG00000263597.1	MIR3936	-3.59	0.000368	0.0404	-0.16	-0.16	Breast cancer;	chr5:132241821	chr5:132365490~132365599:-
LUAD	cis	rs7824557	0.603	rs2249804	ENSG00000255046.1	RP11-297N6.4	-3.59	0.000368	0.0404	-0.2	-0.16	Retinal vascular caliber;	chr8:11358108	chr8:11797928~11802568:-
LUAD	cis	rs74024059	1	rs334941	ENSG00000260269.4	CTD-2323K18.1	-3.59	0.000368	0.0404	-0.44	-0.16	Red blood cell count;Hematocrit;	chr15:76002529	chr15:75527150~75601205:-
LUAD	cis	rs7100689	0.622	rs4933378	ENSG00000226659.1	RP11-137H2.4	-3.59	0.000368	0.0405	-0.22	-0.16	Post bronchodilator FEV1;	chr10:80387301	chr10:80529597~80535942:-
LUAD	cis	rs7077256	0.564	rs72829184	ENSG00000272767.1	JMJD1C-AS1	3.59	0.000368	0.0405	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63216433	chr10:63465229~63466563:+
LUAD	cis	rs9291683	0.538	rs11727199	ENSG00000250413.1	RP11-448G15.1	-3.59	0.000368	0.0405	-0.21	-0.16	Bone mineral density;	chr4:10034566	chr4:10006482~10009725:+
LUAD	cis	rs3811273	0.614	rs7154715	ENSG00000211816.2	TRAV38-1	-3.59	0.000368	0.0405	-0.23	-0.16	Periodontal disease-related phenotypes;	chr14:22263528	chr14:22271968~22272563:+
LUAD	cis	rs6787172	0.579	rs6799272	ENSG00000272087.1	RP11-379F4.7	3.59	0.000368	0.0405	0.18	0.16	Subjective well-being;	chr3:158470614	chr3:158693120~158693768:-
LUAD	cis	rs6787172	0.667	rs7627374	ENSG00000272087.1	RP11-379F4.7	3.59	0.000368	0.0405	0.18	0.16	Subjective well-being;	chr3:158472275	chr3:158693120~158693768:-
LUAD	cis	rs9400467	0.528	rs6913769	ENSG00000266032.1	AL357515.1	3.59	0.000368	0.0405	0.21	0.16	Amino acid levels;Blood metabolite levels;	chr6:111471694	chr6:110969773~110969872:-
LUAD	cis	rs9303542	1	rs8067953	ENSG00000264920.1	RP11-6N17.4	-3.59	0.000368	0.0405	-0.21	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48352255	chr17:47891255~47895812:-
LUAD	cis	rs9303542	1	rs9907699	ENSG00000264920.1	RP11-6N17.4	-3.59	0.000368	0.0405	-0.21	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48356776	chr17:47891255~47895812:-
LUAD	cis	rs62025270	0.649	rs12148610	ENSG00000259416.2	RP11-158M2.5	-3.59	0.000368	0.0405	-0.22	-0.16	Idiopathic pulmonary fibrosis;	chr15:85702697	chr15:85754941~85756237:-
LUAD	cis	rs5751168	0.622	rs361907	ENSG00000211654.2	IGLV5-37	3.59	0.000368	0.0405	0.25	0.16	Prostate cancer (SNP x SNP interaction);	chr22:22508495	chr22:22427540~22428035:+
LUAD	cis	rs61160187	0.548	rs1983484	ENSG00000215032.2	GNL3LP1	3.59	0.000368	0.0405	0.2	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:61050998	chr5:60891935~60893577:-
LUAD	cis	rs61160187	0.582	rs56025209	ENSG00000215032.2	GNL3LP1	3.59	0.000368	0.0405	0.2	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:61053793	chr5:60891935~60893577:-
LUAD	cis	rs3733418	0.929	rs13120990	ENSG00000248632.1	RP11-366M4.11	3.59	0.000368	0.0405	0.26	0.16	Obesity-related traits;	chr4:164983966	chr4:164968587~164970002:-
LUAD	cis	rs3733418	0.929	rs13149062	ENSG00000248632.1	RP11-366M4.11	3.59	0.000368	0.0405	0.26	0.16	Obesity-related traits;	chr4:164984208	chr4:164968587~164970002:-
LUAD	cis	rs9921222	0.509	rs2301522	ENSG00000236829.8	Z97634.3	3.59	0.000368	0.0405	0.19	0.16	Bone mineral density (spine);Bone mineral density;	chr16:309953	chr16:382097~392960:+
LUAD	cis	rs6840360	0.598	rs11944921	ENSG00000270265.1	RP11-731D1.4	3.59	0.000368	0.0405	0.16	0.16	Intelligence (multi-trait analysis);	chr4:151809957	chr4:151333775~151353224:-
LUAD	cis	rs4934494	0.689	rs17127596	ENSG00000240996.1	RP11-80H5.7	3.59	0.000368	0.0405	0.21	0.16	Red blood cell count;	chr10:89816128	chr10:89694295~89697928:-
LUAD	cis	rs78254601	1	rs78254601	ENSG00000214691.7	AC104654.1	3.59	0.000368	0.0405	0.27	0.16	Total body bone mineral density;	chr2:42015477	chr2:41877074~41894046:+
LUAD	cis	rs727479	0.543	rs8023263	ENSG00000259306.2	RP11-108K3.2	-3.59	0.000368	0.0405	-0.17	-0.16	Estradiol levels;	chr15:51225400	chr15:51315841~51321996:+
LUAD	cis	rs4718428	0.924	rs6971897	ENSG00000272831.1	RP11-792A8.4	3.59	0.000368	0.0405	0.16	0.16	Corneal structure;	chr7:66947787	chr7:66739829~66740385:-
LUAD	cis	rs3126085	0.935	rs12405678	ENSG00000237975.5	FLG-AS1	3.59	0.000369	0.0405	0.27	0.16	Atopic dermatitis;	chr1:152222832	chr1:152168125~152445456:+
LUAD	cis	rs3126085	1	rs72696969	ENSG00000237975.5	FLG-AS1	3.59	0.000369	0.0405	0.27	0.16	Atopic dermatitis;	chr1:152223863	chr1:152168125~152445456:+
LUAD	cis	rs1799949	0.93	rs4584865	ENSG00000267340.1	RP11-242D8.3	3.59	0.000369	0.0405	0.17	0.16	Menopause (age at onset);	chr17:43347551	chr17:43169880~43170077:-
LUAD	cis	rs6933660	0.72	rs6936936	ENSG00000219395.2	HSPA8P15	-3.59	0.000369	0.0405	-0.16	-0.16	Menarche (age at onset);	chr6:151432260	chr6:151411259~151413945:-
LUAD	cis	rs6933660	0.72	rs6914656	ENSG00000219395.2	HSPA8P15	-3.59	0.000369	0.0405	-0.16	-0.16	Menarche (age at onset);	chr6:151432286	chr6:151411259~151413945:-
LUAD	cis	rs12908161	1	rs60957376	ENSG00000259654.1	RP11-245C17.2	-3.59	0.000369	0.0405	-0.23	-0.16	Schizophrenia;	chr15:84737561	chr15:84685884~84686946:+
LUAD	cis	rs6496932	0.663	rs4843051	ENSG00000259630.2	CTD-2262B20.1	-3.59	0.000369	0.0405	-0.2	-0.16	Central corneal thickness;Corneal structure;	chr15:85360907	chr15:85415228~85415633:+
LUAD	cis	rs2274273	0.905	rs10134800	ENSG00000258413.1	RP11-665C16.6	-3.59	0.000369	0.0405	-0.21	-0.16	Protein biomarker;	chr14:55168491	chr14:55262767~55272075:-
LUAD	cis	rs2625529	0.652	rs2930069	ENSG00000260173.1	RP11-2I17.4	3.59	0.000369	0.0405	0.19	0.16	Red blood cell count;	chr15:71934636	chr15:72140504~72155459:-
LUAD	cis	rs3764021	0.84	rs12304510	ENSG00000278635.1	CTD-2318O12.1	-3.59	0.000369	0.0405	-0.14	-0.16	Type 1 diabetes;	chr12:9732930	chr12:9415641~9416718:+
LUAD	cis	rs448720	0.811	rs420790	ENSG00000259673.4	IQCH-AS1	3.59	0.000369	0.0405	0.17	0.16	Cognitive performance;	chr15:67891702	chr15:67403619~67521844:-
LUAD	cis	rs4763879	0.778	rs1044771	ENSG00000257027.1	RP11-705C15.3	3.59	0.000369	0.0405	0.2	0.16	Type 1 diabetes;	chr12:9699333	chr12:9658567~9662085:+
LUAD	cis	rs13113518	0.812	rs11932712	ENSG00000249700.7	SRD5A3-AS1	3.59	0.000369	0.0405	0.17	0.16	Height;	chr4:55436423	chr4:55363971~55395847:-
LUAD	cis	rs13113518	0.812	rs12501746	ENSG00000249700.7	SRD5A3-AS1	3.59	0.000369	0.0405	0.17	0.16	Height;	chr4:55437438	chr4:55363971~55395847:-
LUAD	cis	rs7537765	1	rs56153133	ENSG00000230337.1	RP4-635E18.6	3.59	0.000369	0.0405	0.29	0.16	QRS complex (12-leadsum);	chr1:11825590	chr1:11099675~11102100:+
LUAD	cis	rs4595586	1	rs1403521	ENSG00000257718.1	RP11-396F22.1	3.59	0.000369	0.0405	0.19	0.16	Morning vs. evening chronotype;	chr12:38838205	chr12:38906451~38909592:+
LUAD	cis	rs6576878	0.553	rs6576879	ENSG00000267734.1	RP4-604K5.3	3.59	0.000369	0.0405	0.18	0.16	White blood cell types;	chr1:87239448	chr1:86932199~86934891:-
LUAD	cis	rs9291683	0.588	rs13121211	ENSG00000250413.1	RP11-448G15.1	-3.59	0.000369	0.0405	-0.2	-0.16	Bone mineral density;	chr4:9997915	chr4:10006482~10009725:+
LUAD	cis	rs2239547	0.522	rs6770957	ENSG00000243224.1	RP5-1157M23.2	-3.59	0.000369	0.0405	-0.18	-0.16	Schizophrenia;	chr3:52961400	chr3:52239258~52241097:+
LUAD	cis	rs9309473	0.632	rs7599076	ENSG00000230002.2	ALMS1-IT1	3.59	0.000369	0.0405	0.18	0.16	Metabolite levels;	chr2:73358391	chr2:73456764~73459484:+
LUAD	cis	rs9309473	0.583	rs11126397	ENSG00000230002.2	ALMS1-IT1	3.59	0.000369	0.0405	0.18	0.16	Metabolite levels;	chr2:73361605	chr2:73456764~73459484:+
LUAD	cis	rs773506	0.655	rs10991796	ENSG00000237422.1	RP11-305L7.3	3.59	0.000369	0.0405	0.21	0.16	Type 2 diabetes nephropathy;	chr9:91167961	chr9:91119138~91163087:-
LUAD	cis	rs2985684	0.894	rs2354439	ENSG00000278009.1	RP11-649E7.8	3.59	0.000369	0.0405	0.21	0.16	Carotid intima media thickness;	chr14:49552699	chr14:49601011~49601124:-
LUAD	cis	rs6496932	0.503	rs4842882	ENSG00000218052.5	ADAMTS7P4	-3.59	0.000369	0.0405	-0.19	-0.16	Central corneal thickness;Corneal structure;	chr15:85440952	chr15:85255369~85330334:-
LUAD	cis	rs11088226	0.581	rs2833856	ENSG00000186842.4	LINC00846	3.59	0.000369	0.0405	0.18	0.16	Gastritis;	chr21:32505381	chr21:32572238~32575881:-
LUAD	cis	rs12754538	0.66	rs7517686	ENSG00000232912.4	RP5-1115A15.1	3.59	0.000369	0.0405	0.17	0.16	Subjective well-being;	chr1:8582428	chr1:8424645~8434838:+
LUAD	cis	rs9467773	0.525	rs1535274	ENSG00000124549.13	BTN2A3P	3.59	0.000369	0.0405	0.15	0.16	Intelligence (multi-trait analysis);	chr6:26520519	chr6:26421391~26432383:+
LUAD	cis	rs9467773	0.565	rs6925047	ENSG00000124549.13	BTN2A3P	3.59	0.000369	0.0405	0.15	0.16	Intelligence (multi-trait analysis);	chr6:26521207	chr6:26421391~26432383:+
LUAD	cis	rs9467773	0.565	rs4343916	ENSG00000124549.13	BTN2A3P	3.59	0.000369	0.0405	0.15	0.16	Intelligence (multi-trait analysis);	chr6:26522447	chr6:26421391~26432383:+
LUAD	cis	rs4268898	0.965	rs13033241	ENSG00000223754.1	AC008073.9	-3.59	0.000369	0.0406	-0.2	-0.16	Asthma;	chr2:24253249	chr2:24199839~24201698:-
LUAD	cis	rs875971	0.66	rs79009421	ENSG00000273142.1	RP11-458F8.4	3.59	0.000369	0.0406	0.11	0.16	Aortic root size;	chr7:66603522	chr7:66902857~66906297:+
LUAD	cis	rs7200786	0.546	rs6498168	ENSG00000274038.1	RP11-66H6.4	-3.59	0.000369	0.0406	-0.21	-0.16	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11141273	chr16:11056556~11057034:+
LUAD	cis	rs1910358	0.614	rs1948767	ENSG00000248874.4	C5orf17	-3.59	0.000369	0.0406	-0.2	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23953017	chr5:23951348~24178263:+
LUAD	cis	rs238295	0.805	rs6076852	ENSG00000230563.2	RP5-828H9.1	-3.59	0.000369	0.0406	-0.21	-0.16	Occipital cortical area (total cortical area interaction);	chr20:5563856	chr20:5471207~5475182:+
LUAD	cis	rs238295	0.766	rs6139762	ENSG00000230563.2	RP5-828H9.1	-3.59	0.000369	0.0406	-0.21	-0.16	Occipital cortical area (total cortical area interaction);	chr20:5566048	chr20:5471207~5475182:+
LUAD	cis	rs683250	0.63	rs4943876	ENSG00000246067.6	RAB30-AS1	-3.59	0.000369	0.0406	-0.17	-0.16	Subcortical brain region volumes;	chr11:83390802	chr11:83072066~83106719:+
LUAD	cis	rs10864907	0.905	rs11695077	ENSG00000227368.1	AC079753.5	3.59	0.000369	0.0406	0.18	0.16	Pulmonary function;	chr2:112932865	chr2:112932625~112933171:+
LUAD	cis	rs9815354	0.638	rs73075241	ENSG00000273328.4	RP11-141M3.6	-3.59	0.000369	0.0406	-0.3	-0.16	Pulse pressure;Diastolic blood pressure;	chr3:42016553	chr3:42809414~42908105:+
LUAD	cis	rs7940646	0.812	rs4910165	ENSG00000177112.6	MRVI1-AS1	-3.59	0.000369	0.0406	-0.21	-0.16	Platelet aggregation;	chr11:10652497	chr11:10541272~10599932:+
LUAD	cis	rs7208859	0.673	rs9913782	ENSG00000265443.1	CTD-2349P21.6	-3.59	0.00037	0.0406	-0.27	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910366	chr17:30726305~30727564:-
LUAD	cis	rs910316	0.763	rs12588981	ENSG00000279594.1	RP11-950C14.10	3.59	0.00037	0.0406	0.19	0.16	Height;	chr14:74993858	chr14:75011269~75012851:-
LUAD	cis	rs9948	0.5	rs62152903	ENSG00000230606.9	AC159540.1	3.59	0.00037	0.0406	0.26	0.16	Erectile dysfunction and prostate cancer treatment;	chr2:96904640	chr2:97416165~97433527:-
LUAD	cis	rs6728642	0.561	rs58984980	ENSG00000230606.9	AC159540.1	3.59	0.00037	0.0406	0.26	0.16	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96905022	chr2:97416165~97433527:-
LUAD	cis	rs8085804	0.571	rs11082290	ENSG00000276174.1	RP11-687E1.2	-3.59	0.00037	0.0406	-0.22	-0.16	Cognitive performance;	chr18:42680527	chr18:42052705~42053030:+
LUAD	cis	rs9303542	0.959	rs8065385	ENSG00000264920.1	RP11-6N17.4	-3.59	0.00037	0.0406	-0.21	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48285211	chr17:47891255~47895812:-
LUAD	cis	rs9341808	0.718	rs910266	ENSG00000233967.5	RP11-250B2.3	3.59	0.00037	0.0406	0.16	0.16	Sitting height ratio;	chr6:80211453	chr6:80443344~80465927:+
LUAD	cis	rs329122	0.528	rs329117	ENSG00000280420.1	AC005355.3	3.59	0.00037	0.0406	0.18	0.16	Body mass index;Type 2 diabetes;	chr5:134524410	chr5:134522613~134523096:-
LUAD	cis	rs35065479	1	rs35065479	ENSG00000263004.1	RP11-166P13.3	-3.59	0.00037	0.0406	-0.21	-0.16	Schizophrenia;	chr17:57659374	chr17:57078298~57085024:-
LUAD	cis	rs6493487	0.512	rs7179865	ENSG00000273674.3	CTD-2378E12.1	-3.59	0.00037	0.0406	-0.23	-0.16	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50816754	chr15:50839875~50908599:-
LUAD	cis	rs73230612	1	rs9822860	ENSG00000242767.1	ZBTB20-AS4	3.59	0.00037	0.0406	0.26	0.16	Type 2 diabetes;	chr3:115224932	chr3:115100423~115103061:+
LUAD	cis	rs73230612	1	rs59774725	ENSG00000242767.1	ZBTB20-AS4	3.59	0.00037	0.0406	0.26	0.16	Type 2 diabetes;	chr3:115226475	chr3:115100423~115103061:+
LUAD	cis	rs7712401	0.791	rs6872932	ENSG00000249996.1	RP11-359P5.1	3.59	0.00037	0.0406	0.2	0.16	Mean platelet volume;	chr5:122809941	chr5:123036271~123054667:+
LUAD	cis	rs4664293	0.836	rs13016015	ENSG00000230783.1	AC009961.2	-3.59	0.00037	0.0406	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159790018	chr2:159689217~159690291:-
LUAD	cis	rs4853525	0.59	rs13399044	ENSG00000235852.1	AC005540.3	3.59	0.00037	0.0406	0.21	0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190944844	chr2:190880797~190882059:-
LUAD	cis	rs3783637	0.5	rs72715546	ENSG00000259318.1	RP11-454L9.2	3.59	0.00037	0.0406	0.2	0.16	Rheumatoid arthritis;Obesity-related traits;	chr14:54918780	chr14:55394940~55395233:-
LUAD	cis	rs8050896	0.59	rs28579037	ENSG00000260695.1	RP11-513N24.1	-3.59	0.00037	0.0406	-0.33	-0.16	Response to antipsychotic treatment;	chr16:66159843	chr16:65861112~65863784:-
LUAD	cis	rs877819	0.583	rs2620894	ENSG00000228403.1	RP11-563N6.6	-3.59	0.00037	0.0406	-0.16	-0.16	Systemic lupus erythematosus;	chr10:48858616	chr10:48878022~48878649:+
LUAD	cis	rs4835473	0.808	rs2060652	ENSG00000249741.2	RP11-673E1.3	3.59	0.00037	0.0406	0.19	0.16	Immature fraction of reticulocytes;	chr4:143739129	chr4:143911514~143912053:-
LUAD	cis	rs3811273	0.614	rs10149605	ENSG00000211816.2	TRAV38-1	-3.59	0.00037	0.0406	-0.23	-0.16	Periodontal disease-related phenotypes;	chr14:22263646	chr14:22271968~22272563:+
LUAD	cis	rs8062405	0.573	rs6565300	ENSG00000261419.1	RP11-57A19.4	-3.59	0.00037	0.0406	-0.18	-0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28981728	chr16:28659696~28740781:-
LUAD	cis	rs10876993	0.928	rs1689596	ENSG00000270039.1	RP11-571M6.17	3.59	0.00037	0.0406	0.19	0.16	Celiac disease or Rheumatoid arthritis;	chr12:57659246	chr12:57803838~57804415:+
LUAD	cis	rs10262624	0.528	rs5029444	ENSG00000232818.2	RPS2P32	3.59	0.00037	0.0406	0.18	0.16	Schizophrenia;	chr7:23698176	chr7:23490473~23491364:+
LUAD	cis	rs13021401	0.964	rs676621	ENSG00000228950.1	AC023137.2	3.59	0.00037	0.0406	0.18	0.16	Systemic sclerosis;	chr2:20484400	chr2:20451042~20452947:+
LUAD	cis	rs7223966	1	rs8080211	ENSG00000279369.1	RP11-51F16.1	-3.59	0.00037	0.0406	-0.18	-0.16	Hip circumference adjusted for BMI;Body mass index;	chr17:63652522	chr17:63700847~63702670:+
LUAD	cis	rs2906856	0.524	rs56236103	ENSG00000236946.2	HNRNPA1P70	-3.59	0.00037	0.0406	-0.16	-0.16	Mosquito bite size;	chr12:67937437	chr12:68035767~68036853:+
LUAD	cis	rs72827839	0.779	rs16955073	ENSG00000266601.1	RP11-6N17.3	3.59	0.00037	0.0406	0.22	0.16	Ease of getting up in the morning;	chr17:48304384	chr17:47929682~47933106:-
LUAD	cis	rs61160187	0.582	rs4700404	ENSG00000215032.2	GNL3LP1	3.59	0.00037	0.0406	0.2	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:61028769	chr5:60891935~60893577:-
LUAD	cis	rs2892838	1	rs2892838	ENSG00000237773.4	AC003075.4	-3.59	0.00037	0.0406	-0.2	-0.16	Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);Caffeine metabolism (plasma 1,3,7-trimethylxanthine (caffeine) level);	chr7:17285000	chr7:17279834~17299357:-
LUAD	cis	rs78572108	0.925	rs1044305	ENSG00000214691.7	AC104654.1	3.59	0.00037	0.0406	0.26	0.16	Total body bone mineral density;	chr2:42057744	chr2:41877074~41894046:+
LUAD	cis	rs2535633	0.631	rs2465101	ENSG00000242142.1	SERBP1P3	-3.59	0.00037	0.0407	-0.18	-0.16	Body mass index;	chr3:52957291	chr3:53064283~53065091:-
LUAD	cis	rs394563	0.591	rs237029	ENSG00000216906.2	RP11-350J20.9	3.59	0.00037	0.0407	0.19	0.16	Dupuytren's disease;	chr6:149396289	chr6:149904243~149906418:+
LUAD	cis	rs6547741	0.935	rs4666005	ENSG00000223522.1	AC093690.1	3.59	0.00037	0.0407	0.15	0.16	Oral cavity cancer;	chr2:27632372	chr2:28307691~28310459:-
LUAD	cis	rs4474465	0.646	rs7936011	ENSG00000251323.2	RP11-452H21.4	-3.59	0.00037	0.0407	-0.19	-0.16	Alzheimer's disease (survival time);	chr11:78564885	chr11:78423982~78429836:-
LUAD	cis	rs2834288	0.536	rs762357	ENSG00000273102.1	AP000569.9	3.59	0.00037	0.0407	0.2	0.16	Gut microbiota (bacterial taxa);	chr21:33964695	chr21:33967101~33968573:-
LUAD	cis	rs7512552	0.582	rs834233	ENSG00000275557.1	RP11-353N4.6	3.59	0.00037	0.0407	0.19	0.16	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150381800	chr1:149607765~149612402:+
LUAD	cis	rs743757	0.697	rs763030	ENSG00000271858.4	CYB561D2	-3.59	0.00037	0.0407	-0.18	-0.16	Diastolic blood pressure;	chr3:50490661	chr3:50365334~50368197:+
LUAD	cis	rs4971059	0.617	rs12127609	ENSG00000160766.13	GBAP1	-3.59	0.00037	0.0407	-0.16	-0.16	Breast cancer;	chr1:155161015	chr1:155213821~155227422:-
LUAD	cis	rs516805	0.886	rs557528	ENSG00000279114.1	RP3-425C14.5	-3.59	0.00037	0.0407	-0.18	-0.16	Lymphocyte counts;	chr6:122482793	chr6:122471923~122484161:+
LUAD	cis	rs516805	0.961	rs559721	ENSG00000279114.1	RP3-425C14.5	-3.59	0.00037	0.0407	-0.18	-0.16	Lymphocyte counts;	chr6:122482796	chr6:122471923~122484161:+
LUAD	cis	rs801193	1	rs10234018	ENSG00000224316.1	RP11-479O9.2	-3.59	0.00037	0.0407	-0.16	-0.16	Aortic root size;	chr7:66681297	chr7:65773620~65802067:+
LUAD	cis	rs8014204	0.806	rs11159104	ENSG00000279594.1	RP11-950C14.10	3.59	0.000371	0.0407	0.18	0.16	Caffeine consumption;	chr14:74826671	chr14:75011269~75012851:-
LUAD	cis	rs7119038	0.818	rs6589685	ENSG00000255239.1	AP002954.6	-3.59	0.000371	0.0407	-0.23	-0.16	Sjögren's syndrome;	chr11:118741488	chr11:118688039~118690600:-
LUAD	cis	rs4925386	0.808	rs1760073	ENSG00000275437.1	RP5-908M14.10	-3.59	0.000371	0.0407	-0.14	-0.16	Colorectal cancer (SNP x SNP interaction);Colorectal cancer;	chr20:62351050	chr20:62402236~62405935:-
LUAD	cis	rs6121246	0.56	rs6088854	ENSG00000230613.1	HM13-AS1	3.59	0.000371	0.0407	0.27	0.16	Mean corpuscular hemoglobin;	chr20:31637554	chr20:31567707~31573263:-
LUAD	cis	rs7134599	0.561	rs10784670	ENSG00000255733.4	IFNG-AS1	-3.59	0.000371	0.0407	-0.13	-0.16	Inflammatory bowel disease;Ulcerative colitis;	chr12:68080315	chr12:67989445~68234686:+
LUAD	cis	rs4811196	1	rs4809871	ENSG00000226144.2	RPS27AP3	3.59	0.000371	0.0407	0.2	0.16	Bone mineral density;	chr20:37873503	chr20:37049254~37049707:+
LUAD	cis	rs7610301	1	rs35413899	ENSG00000276925.1	RP11-708J19.3	3.59	0.000371	0.0407	0.2	0.16	Blood protein levels;	chr3:46601510	chr3:47469777~47469987:+
LUAD	cis	rs7610301	1	rs4683247	ENSG00000276925.1	RP11-708J19.3	3.59	0.000371	0.0407	0.2	0.16	Blood protein levels;	chr3:46601562	chr3:47469777~47469987:+
LUAD	cis	rs7610301	1	rs4683248	ENSG00000276925.1	RP11-708J19.3	3.59	0.000371	0.0407	0.2	0.16	Blood protein levels;	chr3:46601563	chr3:47469777~47469987:+
LUAD	cis	rs7610301	0.954	rs4683250	ENSG00000276925.1	RP11-708J19.3	3.59	0.000371	0.0407	0.2	0.16	Blood protein levels;	chr3:46601718	chr3:47469777~47469987:+
LUAD	cis	rs13113518	0.738	rs6849883	ENSG00000273257.1	RP11-177J6.1	3.59	0.000371	0.0407	0.19	0.16	Height;	chr4:55387515	chr4:55387949~55388271:+
LUAD	cis	rs6736093	0.897	rs4848874	ENSG00000207383.1	Y_RNA	-3.59	0.000371	0.0407	-0.21	-0.16	Coronary artery disease;	chr2:111923923	chr2:112579484~112579584:-
LUAD	cis	rs6736093	0.966	rs11687451	ENSG00000207383.1	Y_RNA	-3.59	0.000371	0.0407	-0.21	-0.16	Coronary artery disease;	chr2:111924984	chr2:112579484~112579584:-
LUAD	cis	rs6736093	0.933	rs4848229	ENSG00000207383.1	Y_RNA	-3.59	0.000371	0.0407	-0.21	-0.16	Coronary artery disease;	chr2:111935073	chr2:112579484~112579584:-
LUAD	cis	rs6736093	0.966	rs34087685	ENSG00000207383.1	Y_RNA	-3.59	0.000371	0.0407	-0.21	-0.16	Coronary artery disease;	chr2:111935433	chr2:112579484~112579584:-
LUAD	cis	rs34198350	0.575	rs73929251	ENSG00000230979.3	AC079250.1	-3.59	0.000371	0.0407	-0.17	-0.16	QT interval in Tripanosoma cruzi seropositivity;	chr2:47899600	chr2:47690716~47691246:-
LUAD	cis	rs6793245	0.843	rs1473805	ENSG00000229589.1	ACVR2B-AS1	-3.59	0.000371	0.0407	-0.21	-0.16	QT interval;	chr3:38536188	chr3:38451027~38454820:-
LUAD	cis	rs897984	0.511	rs7196726	ENSG00000232748.3	RP11-196G11.6	-3.59	0.000371	0.0407	-0.2	-0.16	Dementia with Lewy bodies;	chr16:31080754	chr16:31056460~31062803:+
LUAD	cis	rs41313321	0.646	rs56151688	ENSG00000203286.5	Metazoa_SRP	3.59	0.000371	0.0407	0.23	0.16	Coenzyme Q10 levels;	chr9:128281635	chr9:128745857~128746138:-
LUAD	cis	rs17772222	0.793	rs7143853	ENSG00000258789.1	RP11-507K2.3	-3.59	0.000371	0.0407	-0.22	-0.16	Coronary artery calcification;	chr14:88578477	chr14:88551597~88552493:+
LUAD	cis	rs7100689	0.599	rs6585968	ENSG00000226659.1	RP11-137H2.4	-3.59	0.000371	0.0407	-0.22	-0.16	Post bronchodilator FEV1;	chr10:80380051	chr10:80529597~80535942:-
LUAD	cis	rs1009115	0.551	rs7801567	ENSG00000229970.3	AC007128.1	-3.59	0.000371	0.0407	-0.21	-0.16	Post bronchodilator FEV1;	chr7:8350988	chr7:8262264~8344516:+
LUAD	cis	rs334353	0.798	rs10739779	ENSG00000255145.2	STX17-AS1	-3.59	0.000371	0.0407	-0.22	-0.16	Age-related macular degeneration;	chr9:99119917	chr9:99886322~99906601:-
LUAD	cis	rs9309473	1	rs6711033	ENSG00000230002.2	ALMS1-IT1	3.59	0.000371	0.0407	0.2	0.16	Metabolite levels;	chr2:73519516	chr2:73456764~73459484:+
LUAD	cis	rs9309473	1	rs7604682	ENSG00000230002.2	ALMS1-IT1	3.59	0.000371	0.0407	0.2	0.16	Metabolite levels;	chr2:73560899	chr2:73456764~73459484:+
LUAD	cis	rs6493487	0.512	rs77629026	ENSG00000273674.3	CTD-2378E12.1	3.59	0.000371	0.0407	0.23	0.16	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50830028	chr15:50839875~50908599:-
LUAD	cis	rs9308731	0.591	rs10199020	ENSG00000227992.1	AC108463.2	-3.59	0.000371	0.0407	-0.2	-0.16	Chronic lymphocytic leukemia;	chr2:111188879	chr2:111203964~111206215:-
LUAD	cis	rs2921073	0.509	rs2976931	ENSG00000233609.3	RP11-62H7.2	3.59	0.000371	0.0407	0.13	0.16	Parkinson's disease;	chr8:8399807	chr8:8961200~8979025:+
LUAD	cis	rs9549260	0.816	rs9532582	ENSG00000229456.1	RLIMP1	3.59	0.000371	0.0407	0.17	0.16	Red blood cell count;	chr13:40677070	chr13:40618738~40621348:+
LUAD	cis	rs4711350	0.723	rs684119	ENSG00000224557.6	HLA-DPB2	-3.59	0.000371	0.0407	-0.28	-0.16	Schizophrenia;	chr6:33694890	chr6:33112451~33129084:+
LUAD	cis	rs5758511	0.68	rs5758698	ENSG00000233903.2	Z83851.4	3.59	0.000371	0.0407	0.24	0.16	Birth weight;	chr22:42288812	chr22:42276355~42277052:+
LUAD	cis	rs1555322	0.53	rs2425042	ENSG00000269202.1	RP4-614O4.12	-3.59	0.000371	0.0407	-0.2	-0.16	Attention deficit hyperactivity disorder;	chr20:35278092	chr20:35201747~35203288:-
LUAD	cis	rs1555322	0.53	rs7004	ENSG00000269202.1	RP4-614O4.12	-3.59	0.000371	0.0407	-0.2	-0.16	Attention deficit hyperactivity disorder;	chr20:35278950	chr20:35201747~35203288:-
LUAD	cis	rs4787951	0.58	rs1805010	ENSG00000259940.2	CTD-3203P2.1	-3.59	0.000371	0.0407	-0.18	-0.16	Eosinophil percentage of white cells;	chr16:27344882	chr16:27213308~27214993:-
LUAD	cis	rs301901	0.581	rs292170	ENSG00000250155.1	CTD-2353F22.1	-3.59	0.000371	0.0407	-0.17	-0.16	Height;	chr5:36816559	chr5:36666214~36725195:-
LUAD	cis	rs6964587	1	rs2282970	ENSG00000188693.7	CYP51A1-AS1	-3.59	0.000371	0.0407	-0.19	-0.16	Breast cancer;	chr7:91954967	chr7:92134604~92180725:+
LUAD	cis	rs7223966	0.81	rs2665838	ENSG00000279369.1	RP11-51F16.1	-3.59	0.000371	0.0407	-0.18	-0.16	Hip circumference adjusted for BMI;Body mass index;	chr17:63889105	chr17:63700847~63702670:+
LUAD	cis	rs13126694	0.71	rs13137826	ENSG00000280140.1	RP11-597D13.2	-3.59	0.000371	0.0407	-0.19	-0.16	Blood osmolality (transformed sodium);	chr4:158001354	chr4:158111361~158111931:-
LUAD	cis	rs7618915	0.547	rs11130317	ENSG00000243224.1	RP5-1157M23.2	-3.59	0.000371	0.0407	-0.16	-0.16	Bipolar disorder;	chr3:52697467	chr3:52239258~52241097:+
LUAD	cis	rs6502050	0.835	rs62078304	ENSG00000275966.1	RP11-1055B8.9	3.59	0.000371	0.0407	0.17	0.16	Life satisfaction;	chr17:82127348	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.805	rs6502061	ENSG00000275966.1	RP11-1055B8.9	3.59	0.000371	0.0407	0.17	0.16	Life satisfaction;	chr17:82128282	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.749	rs7406163	ENSG00000275966.1	RP11-1055B8.9	3.59	0.000371	0.0407	0.17	0.16	Life satisfaction;	chr17:82128513	chr17:81345476~81345966:-
LUAD	cis	rs9549260	0.564	rs9549279	ENSG00000168852.11	TPTE2P5	-3.59	0.000371	0.0407	-0.16	-0.16	Red blood cell count;	chr13:40741446	chr13:40822296~40921749:-
LUAD	cis	rs11126435	0.641	rs6709863	ENSG00000272183.1	RP11-523H20.3	3.59	0.000371	0.0407	0.23	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr2:74518953	chr2:74501717~74502365:+
LUAD	cis	rs1910358	0.549	rs10473669	ENSG00000248874.4	C5orf17	-3.59	0.000371	0.0408	-0.2	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23969968	chr5:23951348~24178263:+
LUAD	cis	rs1910358	0.614	rs1501939	ENSG00000248874.4	C5orf17	-3.59	0.000371	0.0408	-0.2	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23971061	chr5:23951348~24178263:+
LUAD	cis	rs1910358	0.591	rs4522961	ENSG00000248874.4	C5orf17	-3.59	0.000371	0.0408	-0.2	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23973660	chr5:23951348~24178263:+
LUAD	cis	rs1910358	0.664	rs6881059	ENSG00000248874.4	C5orf17	-3.59	0.000371	0.0408	-0.21	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23882024	chr5:23951348~24178263:+
LUAD	cis	rs2904524	1	rs80024915	ENSG00000257815.4	RP11-611E13.2	-3.59	0.000371	0.0408	-0.24	-0.16	Amyotrophic lateral sclerosis (age of onset);	chr12:70353430	chr12:69904033~70243360:-
LUAD	cis	rs62025270	0.547	rs386346	ENSG00000259416.2	RP11-158M2.5	-3.59	0.000371	0.0408	-0.18	-0.16	Idiopathic pulmonary fibrosis;	chr15:85651328	chr15:85754941~85756237:-
LUAD	cis	rs2281603	0.57	rs3742606	ENSG00000259116.1	RP11-973N13.4	-3.59	0.000371	0.0408	-0.13	-0.16	Lymphocyte counts;	chr14:64478371	chr14:64514154~64540368:-
LUAD	cis	rs28374715	0.532	rs11070328	ENSG00000247556.5	OIP5-AS1	3.58	0.000372	0.0408	0.2	0.16	Ulcerative colitis;	chr15:41359371	chr15:41283990~41309737:+
LUAD	cis	rs6921919	0.638	rs2108926	ENSG00000219392.1	RP1-265C24.5	-3.58	0.000372	0.0408	-0.21	-0.16	Autism spectrum disorder or schizophrenia;	chr6:28340970	chr6:28115628~28116551:+
LUAD	cis	rs683250	0.63	rs10898108	ENSG00000246067.6	RAB30-AS1	-3.58	0.000372	0.0408	-0.17	-0.16	Subcortical brain region volumes;	chr11:83378360	chr11:83072066~83106719:+
LUAD	cis	rs11846409	0.932	rs28378201	ENSG00000211938.2	IGHV3-7	-3.58	0.000372	0.0408	-0.15	-0.16	Rheumatic heart disease;	chr14:106637262	chr14:106062151~106062683:-
LUAD	cis	rs11846409	0.86	rs74091720	ENSG00000211938.2	IGHV3-7	-3.58	0.000372	0.0408	-0.15	-0.16	Rheumatic heart disease;	chr14:106638192	chr14:106062151~106062683:-
LUAD	cis	rs755249	0.958	rs2068663	ENSG00000237624.1	OXCT2P1	3.58	0.000372	0.0408	0.24	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39572899	chr1:39514956~39516490:+
LUAD	cis	rs4374383	0.739	rs55757240	ENSG00000207383.1	Y_RNA	3.58	0.000372	0.0408	0.2	0.16	Hepatitis C induced liver fibrosis;	chr2:111911983	chr2:112579484~112579584:-
LUAD	cis	rs937213	0.712	rs2279580	ENSG00000275636.1	RP11-521C20.5	3.58	0.000372	0.0408	0.21	0.16	Endometrial cancer;Endometrial endometrioid carcinoma;	chr15:40008013	chr15:40078892~40079347:+
LUAD	cis	rs564309	0.681	rs1188488	ENSG00000231563.1	RP11-245P10.4	-3.58	0.000372	0.0408	-0.28	-0.16	Hip circumference (psychosocial stress interaction);	chr1:228433925	chr1:228407381~228409694:+
LUAD	cis	rs6573604	0.892	rs10142617	ENSG00000258878.1	CTD-2509G16.3	3.58	0.000372	0.0408	0.2	0.16	N-glycan levels;	chr14:65306953	chr14:65234515~65235101:-
LUAD	cis	rs6573604	1	rs10144975	ENSG00000258878.1	CTD-2509G16.3	3.58	0.000372	0.0408	0.2	0.16	N-glycan levels;	chr14:65307264	chr14:65234515~65235101:-
LUAD	cis	rs6573604	1	rs17102587	ENSG00000258878.1	CTD-2509G16.3	3.58	0.000372	0.0408	0.2	0.16	N-glycan levels;	chr14:65307759	chr14:65234515~65235101:-
LUAD	cis	rs6573604	1	rs8012054	ENSG00000258878.1	CTD-2509G16.3	3.58	0.000372	0.0408	0.2	0.16	N-glycan levels;	chr14:65308044	chr14:65234515~65235101:-
LUAD	cis	rs6573604	1	rs8013568	ENSG00000258878.1	CTD-2509G16.3	3.58	0.000372	0.0408	0.2	0.16	N-glycan levels;	chr14:65308157	chr14:65234515~65235101:-
LUAD	cis	rs6573604	1	rs8017974	ENSG00000258878.1	CTD-2509G16.3	3.58	0.000372	0.0408	0.2	0.16	N-glycan levels;	chr14:65308469	chr14:65234515~65235101:-
LUAD	cis	rs2414856	0.51	rs72758941	ENSG00000259635.1	AC100830.3	-3.58	0.000372	0.0408	-0.4	-0.16	Pulse pressure;Systolic blood pressure;	chr15:64379883	chr15:64701248~64719602:+
LUAD	cis	rs8058578	1	rs8051050	ENSG00000232748.3	RP11-196G11.6	-3.58	0.000372	0.0408	-0.21	-0.16	Multiple myeloma;	chr16:30676588	chr16:31056460~31062803:+
LUAD	cis	rs1910358	0.548	rs2172769	ENSG00000248874.4	C5orf17	-3.58	0.000372	0.0408	-0.21	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23872601	chr5:23951348~24178263:+
LUAD	cis	rs2562784	0.638	rs2730075	ENSG00000259728.4	LINC00933	3.58	0.000372	0.0408	0.28	0.16	Height;	chr15:83645689	chr15:84570649~84580175:+
LUAD	cis	rs9650657	0.77	rs6601529	ENSG00000255046.1	RP11-297N6.4	3.58	0.000372	0.0408	0.2	0.16	Neuroticism;	chr8:10813040	chr8:11797928~11802568:-
LUAD	cis	rs7777677	0.925	rs4726540	ENSG00000276953.1	TRBV12-4	3.58	0.000372	0.0408	0.15	0.16	Alcoholic chronic pancreatitis;	chr7:142658771	chr7:142563740~142564245:+
LUAD	cis	rs763121	0.853	rs2284073	ENSG00000225450.1	RP3-508I15.14	-3.58	0.000372	0.0408	-0.15	-0.16	Menopause (age at onset);	chr22:38709943	chr22:38739003~38749041:+
LUAD	cis	rs1443267	0.935	rs2586036	ENSG00000229590.3	MSX2P1	3.58	0.000372	0.0408	0.23	0.16	Obstetric antiphospholipid syndrome;	chr17:57838353	chr17:58157028~58157800:+
LUAD	cis	rs2390582	0.722	rs2152730	ENSG00000233593.5	RP4-665J23.1	3.58	0.000372	0.0408	0.23	0.16	Coronary artery calcification;	chr1:90551594	chr1:90782986~90851650:-
LUAD	cis	rs2390582	0.679	rs2152729	ENSG00000233593.5	RP4-665J23.1	3.58	0.000372	0.0408	0.23	0.16	Coronary artery calcification;	chr1:90551611	chr1:90782986~90851650:-
LUAD	cis	rs2390582	0.722	rs1336873	ENSG00000233593.5	RP4-665J23.1	3.58	0.000372	0.0408	0.23	0.16	Coronary artery calcification;	chr1:90552023	chr1:90782986~90851650:-
LUAD	cis	rs7107174	1	rs10899474	ENSG00000251323.2	RP11-452H21.4	3.58	0.000372	0.0408	0.21	0.16	Testicular germ cell tumor;	chr11:78332590	chr11:78423982~78429836:-
LUAD	cis	rs61160187	0.582	rs888799	ENSG00000215032.2	GNL3LP1	3.58	0.000372	0.0408	0.2	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:61049363	chr5:60891935~60893577:-
LUAD	cis	rs2765539	0.781	rs6428790	ENSG00000224238.2	WARS2-IT1	-3.58	0.000372	0.0408	-0.24	-0.16	Waist-hip ratio;	chr1:119063374	chr1:119047405~119064785:+
LUAD	cis	rs4934494	0.862	rs12246250	ENSG00000240996.1	RP11-80H5.7	-3.58	0.000372	0.0408	-0.2	-0.16	Red blood cell count;	chr10:89629540	chr10:89694295~89697928:-
LUAD	cis	rs7178424	0.742	rs2414755	ENSG00000259251.2	RP11-643M14.1	-3.58	0.000372	0.0408	-0.16	-0.16	Height;	chr15:61880230	chr15:62060503~62062434:+
LUAD	cis	rs7809950	1	rs2107713	ENSG00000238832.1	snoU109	-3.58	0.000372	0.0408	-0.24	-0.16	Coronary artery disease;	chr7:107591924	chr7:107603363~107603507:+
LUAD	cis	rs2932538	0.922	rs11102508	ENSG00000235299.2	MRPL53P1	3.58	0.000372	0.0408	0.2	0.16	Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension;	chr1:112598553	chr1:112625906~112626224:-
LUAD	cis	rs7430456	0.874	rs7428501	ENSG00000231574.4	RP11-91K9.1	-3.58	0.000372	0.0408	-0.18	-0.16	Breast cancer;	chr3:177751974	chr3:177816865~177899224:+
LUAD	cis	rs342296	0.836	rs342236	ENSG00000228742.8	RP5-884M6.1	-3.58	0.000372	0.0408	-0.19	-0.16	Mean platelet volume;	chr7:106695192	chr7:106775011~106795564:+
LUAD	cis	rs10392	0.543	rs3752292	ENSG00000274825.1	RP4-616B8.5	-3.58	0.000372	0.0408	-0.2	-0.16	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;	chr20:38941832	chr20:38955910~38956547:+
LUAD	cis	rs321358	1	rs321359	ENSG00000271390.1	RP11-89C3.3	3.58	0.000372	0.0408	0.27	0.16	Body mass index;	chr11:111125257	chr11:111089870~111090368:-
LUAD	cis	rs6599077	0.789	rs2371138	ENSG00000223797.4	ENTPD3-AS1	3.58	0.000372	0.0408	0.16	0.16	Sleep-related phenotypes;	chr3:40056772	chr3:40313802~40453329:-
LUAD	cis	rs13113518	1	rs13114841	ENSG00000223305.1	RN7SKP30	3.58	0.000372	0.0408	0.18	0.16	Height;	chr4:55485974	chr4:55540502~55540835:-
LUAD	cis	rs1499614	0.522	rs13247442	ENSG00000229886.1	RP5-1132H15.3	3.58	0.000372	0.0408	0.33	0.16	Gout;	chr7:66723871	chr7:66025126~66031544:-
LUAD	cis	rs365302	1	rs509648	ENSG00000235086.1	FNDC1-IT1	3.58	0.000372	0.0408	0.21	0.16	Coronary heart disease;	chr6:159229946	chr6:159240786~159243329:+
LUAD	cis	rs6988985	0.594	rs12543598	ENSG00000247317.3	RP11-273G15.2	-3.58	0.000372	0.0408	-0.19	-0.16	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142873902	chr8:142981738~143018437:-
LUAD	cis	rs4237845	0.844	rs4630335	ENSG00000224713.4	AC025165.8	-3.58	0.000372	0.0408	-0.17	-0.16	Intelligence (multi-trait analysis);	chr12:57908475	chr12:57612118~57619638:-
LUAD	cis	rs344364	0.511	rs1657144	ENSG00000280402.1	RP11-20I23.10	3.58	0.000373	0.0409	0.24	0.16	Glomerular filtration rate in chronic kidney disease;	chr16:1913988	chr16:2578395~2579963:+
LUAD	cis	rs858239	0.539	rs10270695	ENSG00000226816.2	AC005082.12	-3.58	0.000373	0.0409	-0.21	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23149369	chr7:23206013~23208045:+
LUAD	cis	rs820077	0.736	rs820100	ENSG00000232909.1	RP3-510O8.4	-3.58	0.000373	0.0409	-0.24	-0.16	Systemic lupus erythematosus;	chr6:35078377	chr6:35733867~35736947:-
LUAD	cis	rs4713118	0.868	rs10484401	ENSG00000280107.1	AL022393.9	3.58	0.000373	0.0409	0.21	0.16	Parkinson's disease;	chr6:27778811	chr6:28170845~28172521:+
LUAD	cis	rs3753275	0.578	rs2399143	ENSG00000232912.4	RP5-1115A15.1	3.58	0.000373	0.0409	0.19	0.16	Educational attainment;	chr1:8519390	chr1:8424645~8434838:+
LUAD	cis	rs1577917	0.655	rs2842605	ENSG00000220563.1	PKMP3	-3.58	0.000373	0.0409	-0.15	-0.16	Response to antipsychotic treatment;	chr6:85625432	chr6:85659892~85660606:-
LUAD	cis	rs1577917	0.655	rs2758848	ENSG00000220563.1	PKMP3	-3.58	0.000373	0.0409	-0.15	-0.16	Response to antipsychotic treatment;	chr6:85637887	chr6:85659892~85660606:-
LUAD	cis	rs4802666	1	rs55762838	ENSG00000171101.12	SIGLEC17P	-3.58	0.000373	0.0409	-0.18	-0.16	Disc degeneration (lumbar);	chr19:50223922	chr19:51167328~51173524:+
LUAD	cis	rs321358	0.945	rs7112932	ENSG00000271390.1	RP11-89C3.3	3.58	0.000373	0.0409	0.27	0.16	Body mass index;	chr11:111101099	chr11:111089870~111090368:-
LUAD	cis	rs11955398	0.502	rs295524	ENSG00000272308.1	RP11-231G3.1	-3.58	0.000373	0.0409	-0.18	-0.16	Intelligence (multi-trait analysis);	chr5:61177224	chr5:60866457~60866935:-
LUAD	cis	rs6088580	0.634	rs4277599	ENSG00000275784.1	RP5-1125A11.6	3.58	0.000373	0.0409	0.17	0.16	Glomerular filtration rate (creatinine);	chr20:34421099	chr20:33989480~33991818:-
LUAD	cis	rs1208	0.932	rs4540438	ENSG00000253384.1	CTD-2547L16.3	3.58	0.000373	0.0409	0.18	0.16	Insulin resistance/response;	chr8:18406093	chr8:18088569~18089687:-
LUAD	cis	rs3738443	0.599	rs1934986	ENSG00000225300.1	RP11-1086F11.1	-3.58	0.000373	0.0409	-0.21	-0.16	Alcohol dependence;	chr1:247235696	chr1:246605873~246608102:+
LUAD	cis	rs2980439	0.525	rs2945238	ENSG00000173295.6	FAM86B3P	3.58	0.000373	0.0409	0.17	0.16	Neuroticism;	chr8:8312614	chr8:8228595~8244865:+
LUAD	cis	rs3769124	0.513	rs76475671	ENSG00000234949.2	AC104667.3	3.58	0.000373	0.0409	0.25	0.16	Pulmonary function;	chr2:238583512	chr2:237591020~237595981:+
LUAD	cis	rs7142881	0.815	rs12434789	ENSG00000258525.1	RP11-829H16.3	-3.58	0.000373	0.0409	-0.18	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31587359	chr14:30876179~30889808:-
LUAD	cis	rs763121	0.853	rs5757234	ENSG00000225450.1	RP3-508I15.14	-3.58	0.000373	0.0409	-0.15	-0.16	Menopause (age at onset);	chr22:38676681	chr22:38739003~38749041:+
LUAD	cis	rs4474465	0.688	rs7937225	ENSG00000251323.2	RP11-452H21.4	-3.58	0.000373	0.0409	-0.19	-0.16	Alzheimer's disease (survival time);	chr11:78567080	chr11:78423982~78429836:-
LUAD	cis	rs3845817	0.868	rs702938	ENSG00000281920.1	RP11-418H16.1	3.58	0.000373	0.0409	0.2	0.16	Bipolar disorder;	chr2:65520308	chr2:65623272~65628424:+
LUAD	cis	rs28386778	1	rs28386778	ENSG00000240280.5	TCAM1P	-3.58	0.000373	0.0409	-0.19	-0.16	Prudent dietary pattern;	chr17:63887455	chr17:63849292~63864379:+
LUAD	cis	rs13113518	0.783	rs2171618	ENSG00000249700.7	SRD5A3-AS1	3.58	0.000373	0.0409	0.17	0.16	Height;	chr4:55564241	chr4:55363971~55395847:-
LUAD	cis	rs4662750	0.58	rs7558838	ENSG00000236682.1	AC068282.3	3.58	0.000373	0.0409	0.21	0.16	Renal cell carcinoma;	chr2:127593771	chr2:127389130~127400580:+
LUAD	cis	rs7404843	0.789	rs222909	ENSG00000183458.12	RP11-958N24.1	3.58	0.000373	0.0409	0.18	0.16	Testicular germ cell tumor;	chr16:15405432	chr16:14911551~14935708:+
LUAD	cis	rs9467773	0.62	rs2504540	ENSG00000261353.1	CTA-14H9.5	-3.58	0.000373	0.0409	-0.18	-0.16	Intelligence (multi-trait analysis);	chr6:26641398	chr6:26527063~26527404:+
LUAD	cis	rs73198271	0.562	rs55961293	ENSG00000233609.3	RP11-62H7.2	-3.58	0.000373	0.0409	-0.16	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8817968	chr8:8961200~8979025:+
LUAD	cis	rs73198271	0.562	rs55657655	ENSG00000233609.3	RP11-62H7.2	-3.58	0.000373	0.0409	-0.16	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8817981	chr8:8961200~8979025:+
LUAD	cis	rs11951515	0.738	rs10805673	ENSG00000249779.1	RP11-447H19.3	-3.58	0.000373	0.0409	-0.19	-0.16	Metabolite levels  (X-11787);	chr5:43347921	chr5:43206709~43207811:+
LUAD	cis	rs5770917	0.522	rs5770916	ENSG00000273272.1	CTA-384D8.34	-3.58	0.000373	0.0409	-0.25	-0.16	Narcolepsy;	chr22:50577669	chr22:50542650~50543011:+
LUAD	cis	rs9650657	0.77	rs9969626	ENSG00000255046.1	RP11-297N6.4	3.58	0.000373	0.0409	0.21	0.16	Neuroticism;	chr8:10813291	chr8:11797928~11802568:-
LUAD	cis	rs11118883	0.559	rs12126886	ENSG00000228437.4	RP11-400N13.2	3.58	0.000373	0.0409	0.2	0.16	Colorectal cancer;	chr1:221917550	chr1:221966341~221984964:+
LUAD	cis	rs753955	0.567	rs11617286	ENSG00000205861.10	C1QTNF9B-AS1	-3.58	0.000373	0.0409	-0.19	-0.16	Lung cancer;	chr13:23835209	chr13:23888889~23897263:+
LUAD	cis	rs7674212	0.51	rs55715738	ENSG00000246560.2	RP11-10L12.4	3.58	0.000374	0.0409	0.21	0.16	Type 2 diabetes;	chr4:103209032	chr4:102828055~102844075:+
LUAD	cis	rs3769124	0.513	rs79024584	ENSG00000234949.2	AC104667.3	3.58	0.000374	0.0409	0.25	0.16	Pulmonary function;	chr2:238580357	chr2:237591020~237595981:+
LUAD	cis	rs7674212	0.541	rs2623070	ENSG00000246560.2	RP11-10L12.4	-3.58	0.000374	0.0409	-0.21	-0.16	Type 2 diabetes;	chr4:103116231	chr4:102828055~102844075:+
LUAD	cis	rs56875752	1	rs72811284	ENSG00000263648.1	RP11-471L13.3	3.58	0.000374	0.0409	0.34	0.16	Fear of pain;Fear of severe pain;	chr17:12700729	chr17:12115547~12115885:+
LUAD	cis	rs4794202	0.609	rs4794318	ENSG00000264920.1	RP11-6N17.4	-3.58	0.000374	0.0409	-0.28	-0.16	Alzheimer's disease (cognitive decline);	chr17:47950705	chr17:47891255~47895812:-
LUAD	cis	rs12681963	0.702	rs13272074	ENSG00000271869.1	RP11-51J9.5	-3.58	0.000374	0.0409	-0.17	-0.16	Migraine;	chr8:30087471	chr8:30155830~30156232:-
LUAD	cis	rs10751667	0.6	rs10902264	ENSG00000255284.1	AP006621.5	3.58	0.000374	0.0409	0.14	0.16	Alzheimer's disease (late onset);	chr11:1003523	chr11:777578~784297:+
LUAD	cis	rs9475752	0.564	rs7744240	ENSG00000231441.1	RP11-472M19.2	3.58	0.000374	0.0409	0.24	0.16	Menarche (age at onset);	chr6:56878714	chr6:56844002~56864078:+
LUAD	cis	rs748404	0.666	rs12905220	ENSG00000249839.1	AC011330.5	-3.58	0.000374	0.0409	-0.25	-0.16	Lung cancer;	chr15:43465641	chr15:43663654~43684339:-
LUAD	cis	rs2120243	0.533	rs62278578	ENSG00000244515.1	KRT18P34	-3.58	0.000374	0.041	-0.19	-0.16	Hepatocellular carcinoma in hepatitis B infection;	chr3:157338078	chr3:157162663~157163932:-
LUAD	cis	rs8035452	0.964	rs56811013	ENSG00000259240.1	RP11-108K3.1	-3.58	0.000374	0.041	-0.18	-0.16	Alzheimer's disease (late onset);	chr15:50752399	chr15:51037488~51293912:+
LUAD	cis	rs7216064	0.773	rs74541577	ENSG00000266717.1	RP11-855A2.3	3.58	0.000374	0.041	0.2	0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67857535	chr17:67950885~67951746:-
LUAD	cis	rs6951245	1	rs1997243	ENSG00000224079.1	AC091729.7	-3.58	0.000374	0.041	-0.25	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1044141	chr7:1074450~1078036:+
LUAD	cis	rs6951245	1	rs77760339	ENSG00000224079.1	AC091729.7	-3.58	0.000374	0.041	-0.25	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1044291	chr7:1074450~1078036:+
LUAD	cis	rs6951245	1	rs113575110	ENSG00000224079.1	AC091729.7	-3.58	0.000374	0.041	-0.25	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1044758	chr7:1074450~1078036:+
LUAD	cis	rs6951245	1	rs1881123	ENSG00000224079.1	AC091729.7	-3.58	0.000374	0.041	-0.25	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1045070	chr7:1074450~1078036:+
LUAD	cis	rs2732480	0.577	rs2634691	ENSG00000273765.1	RP11-370I10.11	3.58	0.000374	0.041	0.18	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48314476	chr12:48360920~48361377:+
LUAD	cis	rs12681963	1	rs12547941	ENSG00000272375.1	RP11-51J9.6	3.58	0.000374	0.041	0.22	0.16	Migraine;	chr8:30122816	chr8:30197404~30198048:+
LUAD	cis	rs7667	0.96	rs214343	ENSG00000270728.1	RP4-657E11.10	3.58	0.000374	0.041	0.16	0.16	Crohn's disease and psoriasis;	chr1:19354964	chr1:19297080~19297903:+
LUAD	cis	rs9860428	1	rs13076130	ENSG00000242770.2	RP11-180K7.1	3.58	0.000374	0.041	0.17	0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112910842	chr3:112802478~112812819:+
LUAD	cis	rs2380205	0.967	rs4567357	ENSG00000232807.2	RP11-536K7.3	3.58	0.000374	0.041	0.17	0.16	Breast cancer;	chr10:5857320	chr10:5934270~5945900:-
LUAD	cis	rs2834288	0.7	rs2834298	ENSG00000237945.6	LINC00649	-3.58	0.000374	0.041	-0.22	-0.16	Gut microbiota (bacterial taxa);	chr21:33911251	chr21:33915534~33977691:+
LUAD	cis	rs858239	0.632	rs6952947	ENSG00000226816.2	AC005082.12	-3.58	0.000374	0.041	-0.21	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23206013~23208045:+
LUAD	cis	rs12138950	0.948	rs873095	ENSG00000270728.1	RP4-657E11.10	3.58	0.000374	0.041	0.18	0.16	Hypothyroidism;Thyroid volume;	chr1:19496835	chr1:19297080~19297903:+
LUAD	cis	rs7210086	0.948	rs72849449	ENSG00000263893.2	CTD-3010D24.3	3.58	0.000374	0.041	0.24	0.16	Ulcerative colitis;	chr17:72642366	chr17:72642731~72644490:+
LUAD	cis	rs7210086	0.948	rs72849451	ENSG00000263893.2	CTD-3010D24.3	3.58	0.000374	0.041	0.24	0.16	Ulcerative colitis;	chr17:72642426	chr17:72642731~72644490:+
LUAD	cis	rs9900280	0.967	rs6505125	ENSG00000264808.1	RP11-802D6.1	3.58	0.000374	0.041	0.19	0.16	Mean platelet volume;	chr17:29405141	chr17:29369717~29390777:-
LUAD	cis	rs2749097	0.609	rs3790857	ENSG00000244256.3	RN7SL130P	3.58	0.000374	0.041	0.21	0.16	Alcohol consumption (transferrin glycosylation);	chr1:63646195	chr1:63655743~63656047:+
LUAD	cis	rs12440869	1	rs4776921	ENSG00000270964.1	RP11-502I4.3	3.58	0.000374	0.041	0.18	0.16	Peak velocity of the mitral A-wave;	chr15:67325731	chr15:67541072~67542604:-
LUAD	cis	rs13021401	0.963	rs342094	ENSG00000228950.1	AC023137.2	3.58	0.000374	0.041	0.19	0.16	Systemic sclerosis;	chr2:20497944	chr2:20451042~20452947:+
LUAD	cis	rs1862618	0.853	rs2548665	ENSG00000271828.1	CTD-2310F14.1	3.58	0.000374	0.041	0.23	0.16	Initial pursuit acceleration;	chr5:56835978	chr5:56927874~56929573:+
LUAD	cis	rs1862618	0.802	rs2591949	ENSG00000271828.1	CTD-2310F14.1	3.58	0.000374	0.041	0.23	0.16	Initial pursuit acceleration;	chr5:56836800	chr5:56927874~56929573:+
LUAD	cis	rs1862618	0.853	rs2548664	ENSG00000271828.1	CTD-2310F14.1	3.58	0.000374	0.041	0.23	0.16	Initial pursuit acceleration;	chr5:56837728	chr5:56927874~56929573:+
LUAD	cis	rs1862618	0.853	rs3099459	ENSG00000271828.1	CTD-2310F14.1	3.58	0.000374	0.041	0.23	0.16	Initial pursuit acceleration;	chr5:56841343	chr5:56927874~56929573:+
LUAD	cis	rs2018683	0.523	rs4513881	ENSG00000228421.2	AC005013.5	-3.58	0.000374	0.041	-0.19	-0.16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28985794	chr7:28957667~28959345:+
LUAD	cis	rs10859871	0.536	rs6538620	ENSG00000216306.3	KRT19P2	3.58	0.000374	0.041	0.21	0.16	Endometriosis;	chr12:95229508	chr12:94834147~94835158:+
LUAD	cis	rs875971	0.666	rs13242072	ENSG00000232546.1	RP11-458F8.1	3.58	0.000374	0.041	0.14	0.16	Aortic root size;	chr7:66301001	chr7:66848496~66858136:+
LUAD	cis	rs4835473	0.801	rs76574827	ENSG00000249741.2	RP11-673E1.3	3.58	0.000374	0.041	0.19	0.16	Immature fraction of reticulocytes;	chr4:143737303	chr4:143911514~143912053:-
LUAD	cis	rs4835473	0.832	rs62337616	ENSG00000249741.2	RP11-673E1.3	3.58	0.000374	0.041	0.19	0.16	Immature fraction of reticulocytes;	chr4:143737307	chr4:143911514~143912053:-
LUAD	cis	rs4835473	0.832	rs66717029	ENSG00000249741.2	RP11-673E1.3	3.58	0.000374	0.041	0.19	0.16	Immature fraction of reticulocytes;	chr4:143737318	chr4:143911514~143912053:-
LUAD	cis	rs4835473	0.864	rs17750354	ENSG00000249741.2	RP11-673E1.3	3.58	0.000374	0.041	0.19	0.16	Immature fraction of reticulocytes;	chr4:143737352	chr4:143911514~143912053:-
LUAD	cis	rs12565755	0.616	rs12405611	ENSG00000226476.2	RP11-776H12.1	3.58	0.000374	0.041	0.25	0.16	Response to tocilizumab in rheumatoid arthritis;	chr1:60506983	chr1:60540249~60640491:-
LUAD	cis	rs2991971	0.81	rs2356413	ENSG00000234329.1	RP11-767N6.2	3.58	0.000374	0.041	0.15	0.16	High light scatter reticulocyte count;	chr1:45448376	chr1:45651039~45651826:-
LUAD	cis	rs2991971	0.716	rs7532573	ENSG00000234329.1	RP11-767N6.2	3.58	0.000374	0.041	0.15	0.16	High light scatter reticulocyte count;	chr1:45450220	chr1:45651039~45651826:-
LUAD	cis	rs11233413	1	rs11233415	ENSG00000246067.6	RAB30-AS1	3.58	0.000374	0.041	0.17	0.16	Economic and political preferences (feminism/equality);	chr11:83013995	chr11:83072066~83106719:+
LUAD	cis	rs3741404	0.791	rs2282491	ENSG00000256789.1	RP11-697H9.2	-3.58	0.000374	0.041	-0.19	-0.16	Platelet count;	chr11:64150901	chr11:63637677~63658962:+
LUAD	cis	rs7674212	0.581	rs13150953	ENSG00000230069.3	LRRC37A15P	-3.58	0.000374	0.041	-0.17	-0.16	Type 2 diabetes;	chr4:103021341	chr4:102727274~102730721:-
LUAD	cis	rs7674212	0.556	rs13151569	ENSG00000230069.3	LRRC37A15P	-3.58	0.000374	0.041	-0.17	-0.16	Type 2 diabetes;	chr4:103021633	chr4:102727274~102730721:-
LUAD	cis	rs910316	0.737	rs175077	ENSG00000259138.1	RP11-950C14.7	-3.58	0.000374	0.041	-0.17	-0.16	Height;	chr14:75040172	chr14:75127153~75136930:+
LUAD	cis	rs820077	0.61	rs2177382	ENSG00000232909.1	RP3-510O8.4	-3.58	0.000374	0.041	-0.25	-0.16	Systemic lupus erythematosus;	chr6:35082729	chr6:35733867~35736947:-
LUAD	cis	rs60695258	1	rs2035403	ENSG00000251411.1	RP11-397E7.4	-3.58	0.000374	0.041	-0.17	-0.16	Hematocrit;	chr4:87097839	chr4:86913266~86914817:-
LUAD	cis	rs3741404	0.56	rs12362602	ENSG00000256789.1	RP11-697H9.2	3.58	0.000374	0.041	0.17	0.16	Platelet count;	chr11:64141188	chr11:63637677~63658962:+
LUAD	cis	rs7615952	0.688	rs12638224	ENSG00000241288.6	RP11-379B18.5	-3.58	0.000374	0.041	-0.21	-0.16	Blood pressure (smoking interaction);	chr3:125822477	chr3:125827238~125916384:-
LUAD	cis	rs755249	0.532	rs2296173	ENSG00000182109.6	RP11-69E11.4	3.58	0.000374	0.041	0.2	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39447679	chr1:39522280~39546187:-
LUAD	cis	rs755249	0.567	rs3118014	ENSG00000182109.6	RP11-69E11.4	3.58	0.000374	0.041	0.2	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39448418	chr1:39522280~39546187:-
LUAD	cis	rs2836974	0.897	rs8128102	ENSG00000232608.1	TIMM9P2	-3.58	0.000374	0.041	-0.19	-0.16	Cognitive function;	chr21:39234488	chr21:39216624~39217506:+
LUAD	cis	rs41271951	0.542	rs113775984	ENSG00000223945.2	RP11-458I7.1	-3.58	0.000374	0.041	-0.3	-0.16	Blood protein levels;	chr1:150275044	chr1:150053864~150055034:+
LUAD	cis	rs6981523	0.553	rs11783045	ENSG00000255046.1	RP11-297N6.4	3.58	0.000375	0.041	0.19	0.16	Neuroticism;	chr8:11198666	chr8:11797928~11802568:-
LUAD	cis	rs854765	0.647	rs721669	ENSG00000223979.2	SMCR2	-3.58	0.000375	0.041	-0.19	-0.16	Total body bone mineral density;	chr17:18101759	chr17:17674026~17677688:-
LUAD	cis	rs438034	0.764	rs6671279	ENSG00000230461.7	PROX1-AS1	3.58	0.000375	0.041	0.2	0.16	Response to antineoplastic agents;	chr1:214698961	chr1:213817751~213988508:-
LUAD	cis	rs438034	0.764	rs6658739	ENSG00000230461.7	PROX1-AS1	3.58	0.000375	0.041	0.2	0.16	Response to antineoplastic agents;	chr1:214698975	chr1:213817751~213988508:-
LUAD	cis	rs8031584	0.918	rs61997138	ENSG00000259845.1	HERC2P10	3.58	0.000375	0.041	0.19	0.16	Huntington's disease progression;	chr15:30978573	chr15:30815271~30844153:+
LUAD	cis	rs8031584	0.918	rs61997140	ENSG00000259845.1	HERC2P10	3.58	0.000375	0.041	0.19	0.16	Huntington's disease progression;	chr15:30985109	chr15:30815271~30844153:+
LUAD	cis	rs10512488	1	rs10512488	ENSG00000108785.7	HSD17B1P1	-3.58	0.000375	0.041	-0.2	-0.16	Type 2 diabetes (age of onset);	chr17:42811886	chr17:42546764~42548706:+
LUAD	cis	rs2137920	0.945	rs2254409	ENSG00000265018.5	CTGLF12P	-3.58	0.000375	0.041	-0.24	-0.16	Migraine with aura;	chr10:49030408	chr10:48009873~48031640:-
LUAD	cis	rs897984	0.568	rs67264578	ENSG00000232748.3	RP11-196G11.6	-3.58	0.000375	0.041	-0.22	-0.16	Dementia with Lewy bodies;	chr16:30868074	chr16:31056460~31062803:+
LUAD	cis	rs763121	0.853	rs138702	ENSG00000225450.1	RP3-508I15.14	3.58	0.000375	0.041	0.16	0.16	Menopause (age at onset);	chr22:38736596	chr22:38739003~38749041:+
LUAD	cis	rs858239	0.831	rs7796541	ENSG00000230042.1	AK3P3	-3.58	0.000375	0.041	-0.2	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23349454	chr7:23129178~23129841:+
LUAD	cis	rs6446298	0.738	rs1060970	ENSG00000234667.1	ACTBP13	3.58	0.000375	0.041	0.21	0.16	Intelligence (multi-trait analysis);	chr3:49671336	chr3:49873347~49877980:-
LUAD	cis	rs6460942	1	rs62448562	ENSG00000226690.5	AC005281.1	3.58	0.000375	0.041	0.3	0.16	Coronary artery disease;	chr7:12359159	chr7:12496429~12541910:+
LUAD	cis	rs324126	0.78	rs1993530	ENSG00000277977.1	CTD-3018O17.5	-3.58	0.000375	0.041	-0.17	-0.16	Colonoscopy-negative controls vs population controls;	chr19:52381756	chr19:52392659~52392755:+
LUAD	cis	rs2708977	0.667	rs772156	ENSG00000237510.6	AC008268.2	-3.58	0.000375	0.041	-0.21	-0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96364092	chr2:95789654~95800166:+
LUAD	cis	rs9921338	0.961	rs8056282	ENSG00000263080.1	RP11-485G7.5	3.58	0.000375	0.041	0.22	0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11313379	chr16:11341809~11345211:-
LUAD	cis	rs6088590	0.561	rs6059934	ENSG00000276073.1	RP5-1125A11.7	-3.58	0.000375	0.041	-0.16	-0.16	Coronary artery disease;	chr20:34590520	chr20:33985617~33988989:-
LUAD	cis	rs9341808	0.683	rs7771449	ENSG00000233967.5	RP11-250B2.3	3.58	0.000375	0.041	0.16	0.16	Sitting height ratio;	chr6:80210260	chr6:80443344~80465927:+
LUAD	cis	rs7142881	0.787	rs1470285	ENSG00000258525.1	RP11-829H16.3	-3.58	0.000375	0.041	-0.18	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31702893	chr14:30876179~30889808:-
LUAD	cis	rs3805389	0.504	rs62308708	ENSG00000249700.7	SRD5A3-AS1	-3.58	0.000375	0.041	-0.25	-0.16	Waist-to-hip ratio adjusted for body mass index;	chr4:55626177	chr4:55363971~55395847:-
LUAD	cis	rs6546537	1	rs6712370	ENSG00000231024.1	AC092431.3	-3.58	0.000375	0.041	-0.21	-0.16	Serum thyroid-stimulating hormone levels;	chr2:69627962	chr2:69700192~69713847:-
LUAD	cis	rs6674176	0.597	rs4031031	ENSG00000237950.1	RP11-7O11.3	3.58	0.000375	0.041	0.2	0.16	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43927861	chr1:43944370~43946551:-
LUAD	cis	rs365302	1	rs294923	ENSG00000235086.1	FNDC1-IT1	3.58	0.000375	0.041	0.22	0.16	Coronary heart disease;	chr6:159199893	chr6:159240786~159243329:+
LUAD	cis	rs6502050	0.805	rs9898326	ENSG00000266654.1	RP11-1376P16.1	-3.58	0.000375	0.0411	-0.17	-0.16	Life satisfaction;	chr17:82161706	chr17:82160056~82160452:+
LUAD	cis	rs2007126	0.706	rs1393904	ENSG00000224797.1	RP11-57C19.6	3.58	0.000375	0.0411	0.24	0.16	LDL peak particle diameter (total fat intake interaction);	chr9:129996188	chr9:130724786~130725050:-
LUAD	cis	rs3126085	0.515	rs6668764	ENSG00000237975.5	FLG-AS1	-3.58	0.000375	0.0411	-0.25	-0.16	Atopic dermatitis;	chr1:152376602	chr1:152168125~152445456:+
LUAD	cis	rs4819052	0.851	rs2236445	ENSG00000223768.1	LINC00205	-3.58	0.000375	0.0411	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258538	chr21:45293285~45297354:+
LUAD	cis	rs9992667	0.829	rs337628	ENSG00000231160.8	KLF3-AS1	3.58	0.000375	0.0411	0.18	0.16	Eosinophil percentage of granulocytes;	chr4:38633523	chr4:38612701~38664883:-
LUAD	cis	rs12188164	0.965	rs72717435	ENSG00000221990.4	EXOC3-AS1	3.58	0.000375	0.0411	0.16	0.16	Cystic fibrosis severity;	chr5:448087	chr5:441498~443160:-
LUAD	cis	rs36093844	0.527	rs111552865	ENSG00000279742.1	RP11-700A24.1	-3.58	0.000375	0.0411	-0.19	-0.16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86049069	chr11:85852557~85854943:-
LUAD	cis	rs6951245	1	rs78523927	ENSG00000199023.2	MIR339	-3.58	0.000375	0.0411	-0.29	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1049822	chr7:1022935~1023045:-
LUAD	cis	rs11671005	0.695	rs8106061	ENSG00000269473.1	CTD-2619J13.19	3.58	0.000375	0.0411	0.2	0.16	Mean platelet volume;	chr19:58406623	chr19:58440448~58445849:+
LUAD	cis	rs8056893	0.842	rs3785119	ENSG00000274698.1	RP11-71L14.4	3.58	0.000375	0.0411	0.18	0.16	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68340531	chr16:68450283~68452318:+
LUAD	cis	rs683250	0.599	rs4944434	ENSG00000246067.6	RAB30-AS1	-3.58	0.000375	0.0411	-0.17	-0.16	Subcortical brain region volumes;	chr11:83357726	chr11:83072066~83106719:+
LUAD	cis	rs7546668	0.947	rs4233538	ENSG00000272510.1	RP4-680D5.8	3.58	0.000375	0.0411	0.21	0.16	Glomerular filtration rate (creatinine);	chr1:15523360	chr1:15565611~15565956:-
LUAD	cis	rs7546668	1	rs3795758	ENSG00000272510.1	RP4-680D5.8	3.58	0.000375	0.0411	0.21	0.16	Glomerular filtration rate (creatinine);	chr1:15527056	chr1:15565611~15565956:-
LUAD	cis	rs607541	1	rs675876	ENSG00000259520.4	CTD-2651B20.3	-3.58	0.000375	0.0411	-0.23	-0.16	Obesity-related traits;	chr15:45644658	chr15:45251580~45279251:-
LUAD	cis	rs607541	0.85	rs675890	ENSG00000259520.4	CTD-2651B20.3	-3.58	0.000375	0.0411	-0.23	-0.16	Obesity-related traits;	chr15:45644666	chr15:45251580~45279251:-
LUAD	cis	rs17640804	0.765	rs846315	ENSG00000224017.1	LINC01449	3.58	0.000375	0.0411	0.2	0.16	middle facial morphology traits (quantitative measurement);facial morphology traits (multivariate analysis);	chr7:42087398	chr7:41101604~41133507:+
LUAD	cis	rs6502050	0.835	rs7207947	ENSG00000266654.1	RP11-1376P16.1	-3.58	0.000376	0.0411	-0.18	-0.16	Life satisfaction;	chr17:82187415	chr17:82160056~82160452:+
LUAD	cis	rs357618	1	rs441652	ENSG00000272112.1	CTB-113P19.5	-3.58	0.000376	0.0411	-0.15	-0.16	Basophil percentage of white cells;	chr5:151467944	chr5:151724831~151725356:-
LUAD	cis	rs11742741	0.967	rs1428549	ENSG00000248874.4	C5orf17	-3.58	0.000376	0.0411	-0.2	-0.16	Educational attainment;	chr5:24188472	chr5:23951348~24178263:+
LUAD	cis	rs9549260	0.755	rs7989711	ENSG00000229456.1	RLIMP1	3.58	0.000376	0.0411	0.18	0.16	Red blood cell count;	chr13:40641559	chr13:40618738~40621348:+
LUAD	cis	rs1208	0.965	rs11776893	ENSG00000253384.1	CTD-2547L16.3	3.58	0.000376	0.0411	0.18	0.16	Insulin resistance/response;	chr8:18407900	chr8:18088569~18089687:-
LUAD	cis	rs701145	0.585	rs1727940	ENSG00000243069.6	ARHGEF26-AS1	3.58	0.000376	0.0411	0.26	0.16	Coronary artery disease;	chr3:154109468	chr3:154024401~154121332:-
LUAD	cis	rs7537765	1	rs55857306	ENSG00000230337.1	RP4-635E18.6	3.58	0.000376	0.0411	0.29	0.16	QRS complex (12-leadsum);	chr1:11835738	chr1:11099675~11102100:+
LUAD	cis	rs71636778	0.631	rs76133297	ENSG00000260063.1	RP5-968P14.2	-3.58	0.000376	0.0411	-0.22	-0.16	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26827979	chr1:26692132~26694131:-
LUAD	cis	rs56205728	0.606	rs2898991	ENSG00000176753.5	C15orf56	-3.58	0.000376	0.0411	-0.17	-0.16	Schizophrenia;	chr15:40304367	chr15:40250664~40252969:-
LUAD	cis	rs9467773	0.62	rs9461275	ENSG00000261353.1	CTA-14H9.5	-3.58	0.000376	0.0411	-0.18	-0.16	Intelligence (multi-trait analysis);	chr6:26590573	chr6:26527063~26527404:+
LUAD	cis	rs7824557	0.724	rs2251473	ENSG00000255046.1	RP11-297N6.4	-3.58	0.000376	0.0411	-0.2	-0.16	Retinal vascular caliber;	chr8:11319617	chr8:11797928~11802568:-
LUAD	cis	rs7727544	0.547	rs10076758	ENSG00000233006.5	AC034220.3	3.58	0.000376	0.0411	0.15	0.16	Blood metabolite levels;	chr5:132188606	chr5:132311285~132369916:-
LUAD	cis	rs76878669	0.561	rs905770	ENSG00000213409.4	RP11-658F2.3	3.58	0.000376	0.0411	0.19	0.16	Educational attainment (years of education);	chr11:66389294	chr11:66761575~66762399:-
LUAD	cis	rs8181477	0.764	rs11014484	ENSG00000240291.1	RP11-499P20.2	-3.58	0.000376	0.0411	-0.13	-0.16	Obesity-related traits;	chr10:18490395	chr10:18513115~18545651:-
LUAD	cis	rs76878669	0.538	rs2282530	ENSG00000213409.4	RP11-658F2.3	-3.58	0.000376	0.0411	-0.2	-0.16	Educational attainment (years of education);	chr11:66410481	chr11:66761575~66762399:-
LUAD	cis	rs3126085	0.56	rs2525	ENSG00000237975.5	FLG-AS1	3.58	0.000376	0.0411	0.26	0.16	Atopic dermatitis;	chr1:152366588	chr1:152168125~152445456:+
LUAD	cis	rs3126085	0.56	rs941935	ENSG00000237975.5	FLG-AS1	3.58	0.000376	0.0411	0.26	0.16	Atopic dermatitis;	chr1:152367012	chr1:152168125~152445456:+
LUAD	cis	rs3126085	0.56	rs11204987	ENSG00000237975.5	FLG-AS1	3.58	0.000376	0.0411	0.26	0.16	Atopic dermatitis;	chr1:152370393	chr1:152168125~152445456:+
LUAD	cis	rs9517320	0.967	rs9517337	ENSG00000231194.1	FARP1-AS1	3.58	0.000376	0.0411	0.18	0.16	Longevity;	chr13:98529393	chr13:98435405~98435840:-
LUAD	cis	rs9309473	1	rs3738848	ENSG00000230002.2	ALMS1-IT1	3.58	0.000376	0.0411	0.2	0.16	Metabolite levels;	chr2:73534754	chr2:73456764~73459484:+
LUAD	cis	rs338389	0.803	rs2037014	ENSG00000270964.1	RP11-502I4.3	-3.58	0.000376	0.0411	-0.17	-0.16	Survival in rectal cancer;	chr15:67996121	chr15:67541072~67542604:-
LUAD	cis	rs4907240	0.961	rs12471390	ENSG00000237510.6	AC008268.2	-3.58	0.000376	0.0411	-0.23	-0.16	Event-related brain oscillations;	chr2:96657221	chr2:95789654~95800166:+
LUAD	cis	rs6500602	0.702	rs11076834	ENSG00000280063.1	RP11-295D4.3	3.58	0.000376	0.0411	0.1	0.16	Schizophrenia;	chr16:4499582	chr16:4346694~4348648:-
LUAD	cis	rs6121246	0.697	rs45557936	ENSG00000230613.1	HM13-AS1	3.58	0.000376	0.0412	0.24	0.16	Mean corpuscular hemoglobin;	chr20:31638887	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.697	rs6087716	ENSG00000230613.1	HM13-AS1	3.58	0.000376	0.0412	0.24	0.16	Mean corpuscular hemoglobin;	chr20:31641237	chr20:31567707~31573263:-
LUAD	cis	rs911555	0.755	rs6575988	ENSG00000244691.1	RPL10AP1	3.58	0.000376	0.0412	0.21	0.16	Intelligence (multi-trait analysis);	chr14:103434490	chr14:103412119~103412761:-
LUAD	cis	rs62514666	1	rs75011997	ENSG00000261693.1	RP13-467H17.1	-3.58	0.000376	0.0412	-0.37	-0.16	Facial morphology (factor 19);	chr8:142142643	chr8:142403652~142407028:+
LUAD	cis	rs864537	0.676	rs3108155	ENSG00000233411.1	RP11-104L21.2	3.58	0.000376	0.0412	0.2	0.16	Celiac disease or Rheumatoid arthritis;Celiac disease;	chr1:167452820	chr1:167457383~167458661:-
LUAD	cis	rs9341808	0.667	rs2490251	ENSG00000260645.1	RP11-250B2.5	3.58	0.000376	0.0412	0.15	0.16	Sitting height ratio;	chr6:80185447	chr6:80466958~80469080:+
LUAD	cis	rs9313772	0.775	rs4704938	ENSG00000276778.1	RP11-524N5.1	3.58	0.000376	0.0412	0.16	0.16	Blood pressure;	chr5:158407623	chr5:158320683~158409773:-
LUAD	cis	rs67981189	0.865	rs2189806	ENSG00000269927.1	RP6-91H8.3	-3.58	0.000376	0.0412	-0.2	-0.16	Schizophrenia;	chr14:70921681	chr14:71141125~71143253:-
LUAD	cis	rs7772486	0.714	rs1883365	ENSG00000235652.6	RP11-545I5.3	-3.58	0.000376	0.0412	-0.16	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145755613	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.625	rs2050027	ENSG00000235652.6	RP11-545I5.3	-3.58	0.000376	0.0412	-0.16	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145794977	chr6:145799409~145886585:+
LUAD	cis	rs11673344	0.526	rs8101610	ENSG00000267254.4	ZNF790-AS1	3.58	0.000376	0.0412	0.21	0.16	Obesity-related traits;	chr19:37566604	chr19:36797518~36828115:+
LUAD	cis	rs4819052	1	rs2297285	ENSG00000184274.3	LINC00315	3.58	0.000376	0.0412	0.25	0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285706	chr21:45300245~45305257:-
LUAD	cis	rs7772486	0.686	rs6933161	ENSG00000235652.6	RP11-545I5.3	-3.58	0.000376	0.0412	-0.16	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145760233	chr6:145799409~145886585:+
LUAD	cis	rs10129255	1	rs61997605	ENSG00000211967.3	IGHV3-53	-3.58	0.000376	0.0412	-0.13	-0.16	Kawasaki disease;	chr14:106678368	chr14:106592676~106593347:-
LUAD	cis	rs10129255	1	rs8012033	ENSG00000211967.3	IGHV3-53	-3.58	0.000376	0.0412	-0.13	-0.16	Kawasaki disease;	chr14:106678854	chr14:106592676~106593347:-
LUAD	cis	rs9313772	0.775	rs13153555	ENSG00000276778.1	RP11-524N5.1	3.58	0.000376	0.0412	0.16	0.16	Blood pressure;	chr5:158406985	chr5:158320683~158409773:-
LUAD	cis	rs34779708	0.931	rs34375045	ENSG00000271335.4	RP11-324I22.4	3.58	0.000376	0.0412	0.17	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35073428	chr10:35314552~35336401:-
LUAD	cis	rs445114	0.578	rs418269	ENSG00000254166.1	CASC19	-3.58	0.000376	0.0412	-0.16	-0.16	Prostate cancer;Prostate cancer (SNP x SNP interaction);	chr8:127334113	chr8:127185635~127203222:-
LUAD	cis	rs4795519	0.677	rs34063420	ENSG00000266313.1	RP11-173M1.4	3.58	0.000376	0.0412	0.21	0.16	Chronic myeloid leukemia;	chr17:27090707	chr17:27333256~27348491:+
LUAD	cis	rs7560272	0.538	rs1806683	ENSG00000163016.8	ALMS1P	3.58	0.000376	0.0412	0.17	0.16	Schizophrenia;	chr2:73712685	chr2:73644919~73685576:+
LUAD	cis	rs3764021	0.87	rs2401394	ENSG00000214776.8	RP11-726G1.1	3.58	0.000376	0.0412	0.18	0.16	Type 1 diabetes;	chr12:9726830	chr12:9467552~9576275:+
LUAD	cis	rs897984	0.568	rs56083427	ENSG00000232748.3	RP11-196G11.6	-3.58	0.000377	0.0412	-0.22	-0.16	Dementia with Lewy bodies;	chr16:30869977	chr16:31056460~31062803:+
LUAD	cis	rs8067545	0.641	rs203455	ENSG00000270091.1	RP11-78O7.2	-3.58	0.000377	0.0412	-0.14	-0.16	Schizophrenia;	chr17:19917872	chr17:19896590~19897287:-
LUAD	cis	rs2346177	1	rs11125074	ENSG00000279254.1	RP11-536C12.1	-3.58	0.000377	0.0412	-0.17	-0.16	HDL cholesterol;	chr2:46428121	chr2:46668870~46670778:+
LUAD	cis	rs12214131	0.526	rs4946688	ENSG00000219088.1	RP3-359N14.1	-3.58	0.000377	0.0412	-0.17	-0.16	Male-pattern baldness;	chr6:105752720	chr6:105666326~105667998:+
LUAD	cis	rs4664293	0.867	rs13432	ENSG00000230783.1	AC009961.2	-3.58	0.000377	0.0412	-0.21	-0.16	Monocyte percentage of white cells;	chr2:159769216	chr2:159689217~159690291:-
LUAD	cis	rs2905347	0.696	rs2905319	ENSG00000179428.2	AC073072.5	3.58	0.000377	0.0412	0.19	0.16	Major depression and alcohol dependence;	chr7:22657522	chr7:22725395~22727620:-
LUAD	cis	rs2985684	0.802	rs8015368	ENSG00000278009.1	RP11-649E7.8	3.58	0.000377	0.0412	0.21	0.16	Carotid intima media thickness;	chr14:49553792	chr14:49601011~49601124:-
LUAD	cis	rs6472235	0.609	rs11985589	ENSG00000200714.1	Y_RNA	-3.58	0.000377	0.0412	-0.21	-0.16	Plateletcrit;Myopia (pathological);	chr8:65972076	chr8:65592731~65592820:+
LUAD	cis	rs2749097	0.545	rs2301054	ENSG00000244256.3	RN7SL130P	-3.58	0.000377	0.0412	-0.22	-0.16	Alcohol consumption (transferrin glycosylation);	chr1:63641357	chr1:63655743~63656047:+
LUAD	cis	rs11138902	0.673	rs10867682	ENSG00000222465.1	RNU2-5P	3.58	0.000377	0.0412	0.17	0.16	Intelligence (multi-trait analysis);Cognitive ability;Intelligence;	chr9:69503703	chr9:70188571~70188750:-
LUAD	cis	rs2281603	0.57	rs10134530	ENSG00000259116.1	RP11-973N13.4	3.58	0.000377	0.0412	0.13	0.16	Lymphocyte counts;	chr14:64484240	chr14:64514154~64540368:-
LUAD	cis	rs41313321	0.688	rs73672490	ENSG00000203286.5	Metazoa_SRP	3.58	0.000377	0.0412	0.22	0.16	Coenzyme Q10 levels;	chr9:128293454	chr9:128745857~128746138:-
LUAD	cis	rs2390582	0.83	rs10922866	ENSG00000233593.5	RP4-665J23.1	3.58	0.000377	0.0412	0.24	0.16	Coronary artery calcification;	chr1:90500613	chr1:90782986~90851650:-
LUAD	cis	rs7515577	0.898	rs76593661	ENSG00000223787.2	RP4-593M8.1	3.58	0.000377	0.0412	0.24	0.16	Cholesterol, total;	chr1:92464449	chr1:92580476~92580821:-
LUAD	cis	rs7515577	0.898	rs17579779	ENSG00000223787.2	RP4-593M8.1	3.58	0.000377	0.0412	0.24	0.16	Cholesterol, total;	chr1:92464918	chr1:92580476~92580821:-
LUAD	cis	rs7515577	0.898	rs79164177	ENSG00000223787.2	RP4-593M8.1	3.58	0.000377	0.0412	0.24	0.16	Cholesterol, total;	chr1:92465839	chr1:92580476~92580821:-
LUAD	cis	rs12236219	0.786	rs10821352	ENSG00000232063.1	RP11-307E17.8	3.58	0.000377	0.0412	0.34	0.16	Body mass index;	chr9:94495032	chr9:94332476~94360948:+
LUAD	cis	rs4302906	0.515	rs4744164	ENSG00000227603.1	RP11-165J3.6	-3.58	0.000377	0.0412	-0.18	-0.16	Lobe attachment (rater-scored or self-reported);	chr9:93004778	chr9:93435332~93437121:-
LUAD	cis	rs7903456	0.569	rs12572491	ENSG00000224914.2	LINC00863	-3.58	0.000377	0.0412	-0.23	-0.16	Gout;Renal underexcretion gout;	chr10:87034126	chr10:87342736~87357882:+
LUAD	cis	rs6088590	0.965	rs6087619	ENSG00000275784.1	RP5-1125A11.6	-3.58	0.000377	0.0412	-0.17	-0.16	Coronary artery disease;	chr20:34700707	chr20:33989480~33991818:-
LUAD	cis	rs739496	0.542	rs7306529	ENSG00000234608.6	MAPKAPK5-AS1	3.58	0.000377	0.0412	0.16	0.16	Platelet count;	chr12:111342840	chr12:111839764~111842902:-
LUAD	cis	rs9973361	0.531	rs17209563	ENSG00000232411.1	AC009495.3	3.58	0.000377	0.0412	0.18	0.16	Total body bone mineral density;	chr2:165836141	chr2:165833048~165839098:-
LUAD	cis	rs10874639	0.667	rs1451036	ENSG00000183298.5	RP11-556K13.1	-3.58	0.000377	0.0412	-0.25	-0.16	Protein quantitative trait loci;	chr1:102684037	chr1:101786340~101787219:-
LUAD	cis	rs11673344	0.864	rs7256876	ENSG00000267309.1	CTD-2630F21.1	-3.58	0.000377	0.0412	-0.2	-0.16	Obesity-related traits;	chr19:37088570	chr19:36489649~36491040:+
LUAD	cis	rs7618915	0.501	rs12486554	ENSG00000243224.1	RP5-1157M23.2	-3.58	0.000377	0.0412	-0.16	-0.16	Bipolar disorder;	chr3:52708521	chr3:52239258~52241097:+
LUAD	cis	rs67981189	0.896	rs1859468	ENSG00000269927.1	RP6-91H8.3	-3.58	0.000377	0.0412	-0.2	-0.16	Schizophrenia;	chr14:70935573	chr14:71141125~71143253:-
LUAD	cis	rs854765	0.603	rs4506967	ENSG00000223979.2	SMCR2	-3.58	0.000377	0.0412	-0.2	-0.16	Total body bone mineral density;	chr17:18087160	chr17:17674026~17677688:-
LUAD	cis	rs911555	0.504	rs61995761	ENSG00000269940.1	RP11-73M18.7	3.58	0.000377	0.0412	0.16	0.16	Intelligence (multi-trait analysis);	chr14:103609375	chr14:103694560~103695170:+
LUAD	cis	rs67981189	0.858	rs2526862	ENSG00000269927.1	RP6-91H8.3	-3.58	0.000377	0.0412	-0.2	-0.16	Schizophrenia;	chr14:70942897	chr14:71141125~71143253:-
LUAD	cis	rs67981189	0.788	rs2526860	ENSG00000269927.1	RP6-91H8.3	-3.58	0.000377	0.0412	-0.2	-0.16	Schizophrenia;	chr14:70945161	chr14:71141125~71143253:-
LUAD	cis	rs2613514	1	rs2748431	ENSG00000204282.4	TNRC6C-AS1	-3.58	0.000377	0.0412	-0.28	-0.16	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr17:78109673	chr17:78107398~78111799:-
LUAD	cis	rs237743	0.786	rs34078534	ENSG00000177410.11	ZFAS1	3.58	0.000377	0.0412	0.19	0.16	Height;	chr20:49208367	chr20:49278178~49295738:+
LUAD	cis	rs7215564	0.908	rs8080789	ENSG00000262979.1	CTD-2047H16.2	3.58	0.000377	0.0412	0.22	0.16	Myopia (pathological);	chr17:80761402	chr17:80315651~80316633:+
LUAD	cis	rs2898290	0.617	rs13273172	ENSG00000255046.1	RP11-297N6.4	3.58	0.000377	0.0413	0.19	0.16	Systolic blood pressure;	chr8:11603602	chr8:11797928~11802568:-
LUAD	cis	rs1348850	0.914	rs6761593	ENSG00000271825.1	RP11-337N6.2	-3.58	0.000377	0.0413	-0.21	-0.16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177586872	chr2:177300600~177302006:+
LUAD	cis	rs10510102	0.872	rs11200269	ENSG00000276742.1	RP11-500G22.4	3.58	0.000377	0.0413	0.27	0.16	Breast cancer;	chr10:121934021	chr10:121956782~121957098:+
LUAD	cis	rs10510102	0.872	rs11498944	ENSG00000276742.1	RP11-500G22.4	3.58	0.000377	0.0413	0.27	0.16	Breast cancer;	chr10:121938748	chr10:121956782~121957098:+
LUAD	cis	rs10510102	0.81	rs12267347	ENSG00000276742.1	RP11-500G22.4	3.58	0.000377	0.0413	0.27	0.16	Breast cancer;	chr10:121939110	chr10:121956782~121957098:+
LUAD	cis	rs10510102	0.808	rs12253007	ENSG00000276742.1	RP11-500G22.4	3.58	0.000377	0.0413	0.27	0.16	Breast cancer;	chr10:121939360	chr10:121956782~121957098:+
LUAD	cis	rs10510102	0.872	rs79865971	ENSG00000276742.1	RP11-500G22.4	3.58	0.000377	0.0413	0.27	0.16	Breast cancer;	chr10:121941208	chr10:121956782~121957098:+
LUAD	cis	rs10510102	0.872	rs74318512	ENSG00000276742.1	RP11-500G22.4	3.58	0.000377	0.0413	0.27	0.16	Breast cancer;	chr10:121941465	chr10:121956782~121957098:+
LUAD	cis	rs10510102	0.872	rs12257207	ENSG00000276742.1	RP11-500G22.4	3.58	0.000377	0.0413	0.27	0.16	Breast cancer;	chr10:121941737	chr10:121956782~121957098:+
LUAD	cis	rs12908161	1	rs11637142	ENSG00000259654.1	RP11-245C17.2	-3.58	0.000377	0.0413	-0.23	-0.16	Schizophrenia;	chr15:84752696	chr15:84685884~84686946:+
LUAD	cis	rs9341808	0.718	rs2322636	ENSG00000233967.5	RP11-250B2.3	3.58	0.000377	0.0413	0.16	0.16	Sitting height ratio;	chr6:80187719	chr6:80443344~80465927:+
LUAD	cis	rs6539247	0.775	rs736788	ENSG00000257890.1	RP11-114F10.2	-3.58	0.000377	0.0413	-0.18	-0.16	Attention function in attention deficit hyperactive disorder;	chr12:106077893	chr12:106050961~106058254:-
LUAD	cis	rs270601	0.71	rs371709	ENSG00000263597.1	MIR3936	3.58	0.000377	0.0413	0.17	0.16	Acylcarnitine levels;	chr5:132247547	chr5:132365490~132365599:-
LUAD	cis	rs11577318	0.626	rs11806568	ENSG00000238084.4	RP3-469D22.1	-3.58	0.000378	0.0413	-0.19	-0.16	Granulocyte percentage of myeloid white cells;	chr1:26360346	chr1:25398721~25399198:+
LUAD	cis	rs449789	0.619	rs6922094	ENSG00000235086.1	FNDC1-IT1	-3.58	0.000378	0.0413	-0.28	-0.16	Pulse pressure;	chr6:159353515	chr6:159240786~159243329:+
LUAD	cis	rs7551222	0.752	rs11240755	ENSG00000240219.1	RP11-430C7.5	3.58	0.000378	0.0413	0.17	0.16	Schizophrenia;	chr1:204509521	chr1:204626775~204629712:+
LUAD	cis	rs7551222	0.691	rs4951077	ENSG00000240219.1	RP11-430C7.5	3.58	0.000378	0.0413	0.17	0.16	Schizophrenia;	chr1:204513134	chr1:204626775~204629712:+
LUAD	cis	rs7551222	0.716	rs6679717	ENSG00000236779.1	RP11-430C7.2	-3.58	0.000378	0.0413	-0.18	-0.16	Schizophrenia;	chr1:204591549	chr1:204528845~204529692:-
LUAD	cis	rs4489787	0.881	rs12230091	ENSG00000240399.1	RP1-228P16.1	-3.58	0.000378	0.0413	-0.29	-0.16	Prostate cancer (SNP x SNP interaction);	chr12:48556769	chr12:48054813~48055591:-
LUAD	cis	rs4489787	1	rs11168632	ENSG00000240399.1	RP1-228P16.1	-3.58	0.000378	0.0413	-0.29	-0.16	Prostate cancer (SNP x SNP interaction);	chr12:48556795	chr12:48054813~48055591:-
LUAD	cis	rs12440869	1	rs6494639	ENSG00000270964.1	RP11-502I4.3	-3.58	0.000378	0.0413	-0.18	-0.16	Peak velocity of the mitral A-wave;	chr15:67238061	chr15:67541072~67542604:-
LUAD	cis	rs7584330	0.744	rs72620822	ENSG00000222032.1	AC112721.2	3.58	0.000378	0.0413	0.21	0.16	Prostate cancer;	chr2:237470939	chr2:237428920~237434822:-
LUAD	cis	rs9475752	0.947	rs17685185	ENSG00000231441.1	RP11-472M19.2	3.58	0.000378	0.0413	0.23	0.16	Menarche (age at onset);	chr6:56926807	chr6:56844002~56864078:+
LUAD	cis	rs8064024	0.599	rs2456779	ENSG00000267077.1	RP11-127I20.5	3.58	0.000378	0.0413	0.19	0.16	Cancer;	chr16:4875816	chr16:4795265~4796532:-
LUAD	cis	rs2657294	0.929	rs6480771	ENSG00000233313.2	HMGA1P5	-3.58	0.000378	0.0413	-0.2	-0.16	Pneumonia;	chr10:75101922	chr10:75276376~75276646:-
LUAD	cis	rs417065	1	rs11588420	ENSG00000227634.1	RP11-431K24.3	-3.58	0.000378	0.0413	-0.24	-0.16	Psoriasis;	chr1:8200696	chr1:8208672~8215210:+
LUAD	cis	rs12579720	0.673	rs2728565	ENSG00000255910.1	RP11-405A12.2	-3.58	0.000378	0.0413	-0.22	-0.16	Diastolic blood pressure;	chr12:20055681	chr12:19775451~20009937:+
LUAD	cis	rs1577917	0.61	rs11752795	ENSG00000220563.1	PKMP3	3.58	0.000378	0.0413	0.15	0.16	Response to antipsychotic treatment;	chr6:85577411	chr6:85659892~85660606:-
LUAD	cis	rs2144940	0.506	rs844886	ENSG00000233746.1	LINC00656	3.58	0.000378	0.0413	0.34	0.16	Venous thromboembolism;	chr20:23125207	chr20:23125068~23132621:-
LUAD	cis	rs7727544	0.506	rs10040809	ENSG00000233006.5	AC034220.3	3.58	0.000378	0.0413	0.15	0.16	Blood metabolite levels;	chr5:132007324	chr5:132311285~132369916:-
LUAD	cis	rs913672	0.637	rs6125965	ENSG00000229222.1	KRT18P4	-3.58	0.000378	0.0413	-0.2	-0.16	Monocyte count;	chr20:50282076	chr20:49956745~49958032:+
LUAD	cis	rs8035452	0.964	rs3809501	ENSG00000259240.1	RP11-108K3.1	-3.58	0.000378	0.0413	-0.18	-0.16	Alzheimer's disease (late onset);	chr15:50750617	chr15:51037488~51293912:+
LUAD	cis	rs9921338	0.961	rs7195536	ENSG00000262703.1	RP11-485G7.6	-3.58	0.000378	0.0413	-0.17	-0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11348171	chr16:11348143~11349321:-
LUAD	cis	rs638893	1	rs638893	ENSG00000255239.1	AP002954.6	3.58	0.000378	0.0413	0.26	0.16	Vitiligo;	chr11:118827828	chr11:118688039~118690600:-
LUAD	cis	rs683250	0.599	rs11233585	ENSG00000246067.6	RAB30-AS1	-3.58	0.000378	0.0413	-0.17	-0.16	Subcortical brain region volumes;	chr11:83365128	chr11:83072066~83106719:+
LUAD	cis	rs6430585	0.64	rs58301703	ENSG00000226806.1	AC011893.3	3.58	0.000378	0.0413	0.25	0.16	Corneal structure;	chr2:135774655	chr2:135820191~135823087:+
LUAD	cis	rs2625529	0.652	rs3759820	ENSG00000260173.1	RP11-2I17.4	3.58	0.000378	0.0413	0.2	0.16	Red blood cell count;	chr15:72007690	chr15:72140504~72155459:-
LUAD	cis	rs9309711	0.922	rs7561600	ENSG00000271868.1	RP11-1293J14.1	-3.58	0.000378	0.0413	-0.19	-0.16	Neurofibrillary tangles;	chr2:3482322	chr2:3496956~3497428:+
LUAD	cis	rs1208	0.965	rs4282612	ENSG00000253384.1	CTD-2547L16.3	3.58	0.000378	0.0413	0.18	0.16	Insulin resistance/response;	chr8:18406648	chr8:18088569~18089687:-
LUAD	cis	rs638893	0.617	rs7933007	ENSG00000255422.1	AP002954.4	3.58	0.000378	0.0413	0.22	0.16	Vitiligo;	chr11:118859960	chr11:118704607~118750263:+
LUAD	cis	rs330048	0.51	rs11784654	ENSG00000253981.4	ALG1L13P	-3.58	0.000378	0.0413	-0.18	-0.16	Systemic lupus erythematosus;	chr8:9112101	chr8:8236003~8244667:-
LUAD	cis	rs4474465	0.85	rs10793329	ENSG00000251323.2	RP11-452H21.4	-3.58	0.000378	0.0413	-0.2	-0.16	Alzheimer's disease (survival time);	chr11:78554609	chr11:78423982~78429836:-
LUAD	cis	rs4845570	1	rs7416415	ENSG00000203288.3	RP11-98D18.9	3.58	0.000378	0.0413	0.25	0.16	Coronary artery disease;	chr1:151785322	chr1:151790804~151794402:+
LUAD	cis	rs9467773	0.572	rs62394558	ENSG00000241549.7	GUSBP2	3.58	0.000378	0.0413	0.18	0.16	Intelligence (multi-trait analysis);	chr6:26604422	chr6:26871484~26956554:-
LUAD	cis	rs9595908	0.536	rs73452706	ENSG00000281026.1	N4BP2L2-IT2	-3.58	0.000378	0.0413	-0.1	-0.16	Body mass index;	chr13:32718155	chr13:32504506~32509395:-
LUAD	cis	rs853679	0.527	rs1997660	ENSG00000176933.5	TOB2P1	-3.58	0.000378	0.0414	-0.18	-0.16	Depression;	chr6:28301886	chr6:28217643~28218634:-
LUAD	cis	rs6044003	0.786	rs6044008	ENSG00000273998.1	RP4-777L9.2	3.58	0.000378	0.0414	0.36	0.16	Intelligence;	chr20:16484370	chr20:16576068~16579615:+
LUAD	cis	rs6044003	0.786	rs6034500	ENSG00000273998.1	RP4-777L9.2	3.58	0.000378	0.0414	0.36	0.16	Intelligence;	chr20:16484602	chr20:16576068~16579615:+
LUAD	cis	rs7116495	0.867	rs513292	ENSG00000254682.1	RP11-660L16.2	-3.58	0.000379	0.0414	-0.34	-0.16	Severe influenza A (H1N1) infection;	chr11:71862725	chr11:71448674~71452157:+
LUAD	cis	rs897984	0.52	rs4889534	ENSG00000232748.3	RP11-196G11.6	3.58	0.000379	0.0414	0.22	0.16	Dementia with Lewy bodies;	chr16:30854119	chr16:31056460~31062803:+
LUAD	cis	rs71520386	0.625	rs10265548	ENSG00000230658.1	KLHL7-AS1	3.58	0.000379	0.0414	0.2	0.16	Fibrinogen levels;	chr7:22772959	chr7:23101228~23105703:-
LUAD	cis	rs56804039	0.895	rs11776995	ENSG00000253981.4	ALG1L13P	-3.58	0.000379	0.0414	-0.21	-0.16	Cervical cancer;	chr8:8528037	chr8:8236003~8244667:-
LUAD	cis	rs11776272	0.927	rs11135789	ENSG00000253125.1	RP11-459E5.1	3.58	0.000379	0.0414	0.2	0.16	Obesity-related traits;	chr8:22021096	chr8:22690150~22798616:+
LUAD	cis	rs7487075	0.78	rs10785624	ENSG00000257261.4	RP11-96H19.1	3.58	0.000379	0.0414	0.19	0.16	Itch intensity from mosquito bite;	chr12:46373004	chr12:46383679~46876159:+
LUAD	cis	rs7487075	0.78	rs2279559	ENSG00000257261.4	RP11-96H19.1	3.58	0.000379	0.0414	0.19	0.16	Itch intensity from mosquito bite;	chr12:46373392	chr12:46383679~46876159:+
LUAD	cis	rs1400816	0.85	rs2037164	ENSG00000228389.1	AC068039.4	-3.58	0.000379	0.0414	-0.27	-0.16	Amyotrophic lateral sclerosis (sporadic);	chr2:171685728	chr2:171773482~171775844:+
LUAD	cis	rs1400816	0.702	rs1554165	ENSG00000228389.1	AC068039.4	-3.58	0.000379	0.0414	-0.27	-0.16	Amyotrophic lateral sclerosis (sporadic);	chr2:171695092	chr2:171773482~171775844:+
LUAD	cis	rs875971	0.545	rs73142233	ENSG00000224316.1	RP11-479O9.2	3.58	0.000379	0.0414	0.19	0.16	Aortic root size;	chr7:66221293	chr7:65773620~65802067:+
LUAD	cis	rs9894429	0.608	rs7406219	ENSG00000263853.1	AC139530.1	-3.58	0.000379	0.0414	-0.17	-0.16	Eye color traits;	chr17:81642384	chr17:81676001~81676086:+
LUAD	cis	rs9894429	0.505	rs35570626	ENSG00000263853.1	AC139530.1	-3.58	0.000379	0.0414	-0.17	-0.16	Eye color traits;	chr17:81644058	chr17:81676001~81676086:+
LUAD	cis	rs3740713	1	rs113036885	ENSG00000256464.1	YWHABP2	3.58	0.000379	0.0414	0.3	0.16	Amyotrophic lateral sclerosis (sporadic);	chr11:18431185	chr11:18490243~18490955:-
LUAD	cis	rs3740713	1	rs112410494	ENSG00000256464.1	YWHABP2	3.58	0.000379	0.0414	0.3	0.16	Amyotrophic lateral sclerosis (sporadic);	chr11:18431208	chr11:18490243~18490955:-
LUAD	cis	rs3740713	1	rs74741949	ENSG00000256464.1	YWHABP2	3.58	0.000379	0.0414	0.3	0.16	Amyotrophic lateral sclerosis (sporadic);	chr11:18431501	chr11:18490243~18490955:-
LUAD	cis	rs1910358	0.614	rs1501940	ENSG00000248874.4	C5orf17	-3.58	0.000379	0.0414	-0.2	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23976006	chr5:23951348~24178263:+
LUAD	cis	rs10129255	0.518	rs2006284	ENSG00000253209.1	IGHV3-65	3.58	0.000379	0.0414	0.13	0.16	Kawasaki disease;	chr14:106676185	chr14:106666092~106666532:-
LUAD	cis	rs875971	0.522	rs781144	ENSG00000234585.5	CCT6P3	3.58	0.000379	0.0414	0.15	0.16	Aortic root size;	chr7:65975357	chr7:65038354~65074713:+
LUAD	cis	rs6447650	0.688	rs1492504	ENSG00000248780.1	RP11-632F7.1	3.58	0.000379	0.0414	0.22	0.16	Body mass index (change over time);	chr4:40371285	chr4:40786110~40786710:+
LUAD	cis	rs9595908	0.669	rs9591303	ENSG00000281026.1	N4BP2L2-IT2	-3.58	0.000379	0.0414	-0.1	-0.16	Body mass index;	chr13:32748278	chr13:32504506~32509395:-
LUAD	cis	rs1816752	0.875	rs17384871	ENSG00000273628.1	RP11-756A22.7	3.58	0.000379	0.0414	0.19	0.16	Obesity-related traits;	chr13:24484959	chr13:24933006~24936796:+
LUAD	cis	rs7402982	0.625	rs4966011	ENSG00000278022.1	RP11-35O15.2	-3.58	0.000379	0.0414	-0.17	-0.16	Birth weight;	chr15:98660777	chr15:98660210~98660668:+
LUAD	cis	rs301800	0.56	rs6687239	ENSG00000232912.4	RP5-1115A15.1	3.58	0.000379	0.0414	0.18	0.16	Educational attainment (years of education);	chr1:8685417	chr1:8424645~8434838:+
LUAD	cis	rs786425	0.77	rs7133199	ENSG00000278112.1	RP11-972P1.11	3.58	0.000379	0.0414	0.15	0.16	Pubertal anthropometrics;	chr12:123674638	chr12:123519390~123519856:-
LUAD	cis	rs9889262	0.602	rs2107634	ENSG00000248714.5	RP11-1079K10.3	-3.58	0.000379	0.0414	-0.16	-0.16	Eosinophil percentage of granulocytes;Allergic disease (asthma, hay fever or eczema);Eosinophil counts;	chr17:49278738	chr17:49361165~49369998:+
LUAD	cis	rs12887734	0.524	rs12588797	ENSG00000258914.1	CTD-2134A5.3	3.58	0.000379	0.0414	0.19	0.16	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103833683	chr14:103875055~103877478:+
LUAD	cis	rs950881	0.866	rs72823628	ENSG00000234389.1	AC007278.3	3.58	0.000379	0.0414	0.2	0.16	Allergy;	chr2:102312157	chr2:102438713~102440475:+
LUAD	cis	rs7359257	0.576	rs11638507	ENSG00000270964.1	RP11-502I4.3	-3.58	0.000379	0.0414	-0.18	-0.16	Menarche (age at onset);	chr15:67581707	chr15:67541072~67542604:-
LUAD	cis	rs875971	0.862	rs11763189	ENSG00000273448.1	RP11-166O4.6	3.58	0.000379	0.0414	0.15	0.16	Aortic root size;	chr7:66518542	chr7:67333047~67334383:+
LUAD	cis	rs12724450	0.793	rs74124686	ENSG00000228126.1	FALEC	3.58	0.000379	0.0414	0.3	0.16	Blood protein levels;	chr1:150444145	chr1:150515757~150518032:+
LUAD	cis	rs12724450	0.793	rs56214117	ENSG00000228126.1	FALEC	3.58	0.000379	0.0414	0.3	0.16	Blood protein levels;	chr1:150448149	chr1:150515757~150518032:+
LUAD	cis	rs4664293	0.903	rs10185155	ENSG00000227055.1	AC009961.5	3.58	0.000379	0.0414	0.18	0.16	Monocyte percentage of white cells;	chr2:159696717	chr2:159812234~159814009:-
LUAD	cis	rs4474465	0.646	rs6592794	ENSG00000251323.2	RP11-452H21.4	-3.58	0.000379	0.0414	-0.19	-0.16	Alzheimer's disease (survival time);	chr11:78564697	chr11:78423982~78429836:-
LUAD	cis	rs6736093	0.966	rs11682629	ENSG00000207383.1	Y_RNA	-3.58	0.000379	0.0414	-0.21	-0.16	Coronary artery disease;	chr2:111986722	chr2:112579484~112579584:-
LUAD	cis	rs6736093	0.966	rs11685190	ENSG00000207383.1	Y_RNA	-3.58	0.000379	0.0414	-0.21	-0.16	Coronary artery disease;	chr2:111991127	chr2:112579484~112579584:-
LUAD	cis	rs11673344	0.566	rs11666708	ENSG00000267254.4	ZNF790-AS1	3.58	0.000379	0.0414	0.2	0.16	Obesity-related traits;	chr19:37396208	chr19:36797518~36828115:+
LUAD	cis	rs7772486	0.686	rs9399565	ENSG00000235652.6	RP11-545I5.3	-3.58	0.000379	0.0414	-0.16	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145760770	chr6:145799409~145886585:+
LUAD	cis	rs3738443	0.52	rs6699577	ENSG00000225300.1	RP11-1086F11.1	-3.58	0.000379	0.0414	-0.18	-0.16	Alcohol dependence;	chr1:247224152	chr1:246605873~246608102:+
LUAD	cis	rs990171	0.687	rs13019784	ENSG00000234389.1	AC007278.3	-3.58	0.000379	0.0414	-0.17	-0.16	Lymphocyte counts;	chr2:102506842	chr2:102438713~102440475:+
LUAD	cis	rs4908768	0.906	rs12401496	ENSG00000232912.4	RP5-1115A15.1	-3.58	0.000379	0.0414	-0.19	-0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8540342	chr1:8424645~8434838:+
LUAD	cis	rs4908768	0.906	rs12145445	ENSG00000232912.4	RP5-1115A15.1	-3.58	0.000379	0.0414	-0.19	-0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8544311	chr1:8424645~8434838:+
LUAD	cis	rs4908768	0.906	rs28422051	ENSG00000232912.4	RP5-1115A15.1	-3.58	0.000379	0.0414	-0.19	-0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8558278	chr1:8424645~8434838:+
LUAD	cis	rs5751614	0.557	rs928781	ENSG00000240160.3	RN7SL263P	-3.58	0.000379	0.0414	-0.2	-0.16	Height;	chr22:23257826	chr22:23261782~23262071:-
LUAD	cis	rs56205728	0.606	rs3784398	ENSG00000176753.5	C15orf56	-3.58	0.00038	0.0415	-0.17	-0.16	Schizophrenia;	chr15:40304665	chr15:40250664~40252969:-
LUAD	cis	rs5015933	0.815	rs3104550	ENSG00000232630.1	PRPS1P2	-3.58	0.00038	0.0415	-0.15	-0.16	Body mass index;	chr9:125348573	chr9:125150653~125151589:+
LUAD	cis	rs9341808	0.754	rs6916405	ENSG00000279022.1	RP11-250B2.4	3.58	0.00038	0.0415	0.19	0.16	Sitting height ratio;	chr6:80314471	chr6:80440730~80441172:+
LUAD	cis	rs2060793	0.526	rs10766194	ENSG00000251991.1	RNU7-49P	3.58	0.00038	0.0415	0.17	0.16	Vitamin D levels;	chr11:14842668	chr11:14478892~14478953:+
LUAD	cis	rs7131987	0.565	rs7974254	ENSG00000257176.2	RP11-996F15.2	3.58	0.00038	0.0415	0.17	0.16	QT interval;	chr12:29246592	chr12:29280418~29317848:-
LUAD	cis	rs7131987	0.565	rs6487787	ENSG00000257176.2	RP11-996F15.2	3.58	0.00038	0.0415	0.17	0.16	QT interval;	chr12:29248353	chr12:29280418~29317848:-
LUAD	cis	rs7131987	0.565	rs6487791	ENSG00000257176.2	RP11-996F15.2	3.58	0.00038	0.0415	0.17	0.16	QT interval;	chr12:29250989	chr12:29280418~29317848:-
LUAD	cis	rs7107174	1	rs2244508	ENSG00000251323.2	RP11-452H21.4	3.58	0.00038	0.0415	0.22	0.16	Testicular germ cell tumor;	chr11:78237469	chr11:78423982~78429836:-
LUAD	cis	rs4474465	0.85	rs10793324	ENSG00000251323.2	RP11-452H21.4	3.58	0.00038	0.0415	0.19	0.16	Alzheimer's disease (survival time);	chr11:78540439	chr11:78423982~78429836:-
LUAD	cis	rs467650	0.529	rs2549200	ENSG00000248489.1	CTD-2007H13.3	-3.58	0.00038	0.0415	-0.17	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:98660644	chr5:98929171~98995013:+
LUAD	cis	rs7515577	0.898	rs6668685	ENSG00000223787.2	RP4-593M8.1	-3.58	0.00038	0.0415	-0.24	-0.16	Cholesterol, total;	chr1:92326255	chr1:92580476~92580821:-
LUAD	cis	rs7515577	0.853	rs11166568	ENSG00000223787.2	RP4-593M8.1	-3.58	0.00038	0.0415	-0.24	-0.16	Cholesterol, total;	chr1:92327301	chr1:92580476~92580821:-
LUAD	cis	rs7515577	0.773	rs11166575	ENSG00000223787.2	RP4-593M8.1	-3.58	0.00038	0.0415	-0.24	-0.16	Cholesterol, total;	chr1:92329201	chr1:92580476~92580821:-
LUAD	cis	rs7515577	0.898	rs6604091	ENSG00000223787.2	RP4-593M8.1	-3.58	0.00038	0.0415	-0.24	-0.16	Cholesterol, total;	chr1:92332257	chr1:92580476~92580821:-
LUAD	cis	rs7515577	0.898	rs7542747	ENSG00000223787.2	RP4-593M8.1	-3.58	0.00038	0.0415	-0.24	-0.16	Cholesterol, total;	chr1:92332474	chr1:92580476~92580821:-
LUAD	cis	rs7515577	0.898	rs1487537	ENSG00000223787.2	RP4-593M8.1	-3.58	0.00038	0.0415	-0.24	-0.16	Cholesterol, total;	chr1:92333594	chr1:92580476~92580821:-
LUAD	cis	rs7515577	0.898	rs17519833	ENSG00000223787.2	RP4-593M8.1	3.58	0.00038	0.0415	0.24	0.16	Cholesterol, total;	chr1:92348914	chr1:92580476~92580821:-
LUAD	cis	rs7515577	0.898	rs6603963	ENSG00000223787.2	RP4-593M8.1	-3.58	0.00038	0.0415	-0.24	-0.16	Cholesterol, total;	chr1:92355817	chr1:92580476~92580821:-
LUAD	cis	rs7515577	0.617	rs56373822	ENSG00000223787.2	RP4-593M8.1	-3.58	0.00038	0.0415	-0.24	-0.16	Cholesterol, total;	chr1:92360004	chr1:92580476~92580821:-
LUAD	cis	rs7515577	0.898	rs6692060	ENSG00000223787.2	RP4-593M8.1	-3.58	0.00038	0.0415	-0.24	-0.16	Cholesterol, total;	chr1:92381124	chr1:92580476~92580821:-
LUAD	cis	rs7515577	0.853	rs111434556	ENSG00000223787.2	RP4-593M8.1	3.58	0.00038	0.0415	0.24	0.16	Cholesterol, total;	chr1:92405289	chr1:92580476~92580821:-
LUAD	cis	rs3764400	0.567	rs2325784	ENSG00000278765.1	RP5-890E16.5	-3.58	0.00038	0.0415	-0.3	-0.16	Body mass index;	chr17:48134947	chr17:48066704~48067293:-
LUAD	cis	rs3764400	0.567	rs8079616	ENSG00000278765.1	RP5-890E16.5	-3.58	0.00038	0.0415	-0.3	-0.16	Body mass index;	chr17:48136126	chr17:48066704~48067293:-
LUAD	cis	rs7326068	0.543	rs2785740	ENSG00000275485.1	RP11-261P13.6	-3.58	0.00038	0.0415	-0.21	-0.16	Schizophrenia, bipolar disorder and depression (combined);	chr13:20849386	chr13:20768876~20769375:-
LUAD	cis	rs7809950	0.906	rs2253269	ENSG00000238832.1	snoU109	-3.58	0.00038	0.0415	-0.24	-0.16	Coronary artery disease;	chr7:107560669	chr7:107603363~107603507:+
LUAD	cis	rs10508774	0.81	rs72795563	ENSG00000231245.2	C1DP1	-3.58	0.00038	0.0415	-0.38	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32591476	chr10:32511336~32511737:-
LUAD	cis	rs10508774	0.81	rs11008987	ENSG00000231245.2	C1DP1	-3.58	0.00038	0.0415	-0.38	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32592723	chr10:32511336~32511737:-
LUAD	cis	rs9900280	0.902	rs9896579	ENSG00000264808.1	RP11-802D6.1	3.58	0.00038	0.0415	0.19	0.16	Mean platelet volume;	chr17:29459442	chr17:29369717~29390777:-
LUAD	cis	rs7077256	0.564	rs34119992	ENSG00000272767.1	JMJD1C-AS1	3.58	0.00038	0.0415	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63182351	chr10:63465229~63466563:+
LUAD	cis	rs1075265	0.84	rs805309	ENSG00000272156.1	RP11-477N3.1	-3.58	0.00038	0.0415	-0.19	-0.16	Chronotype;Morning vs. evening chronotype;	chr2:53968877	chr2:54082554~54085066:+
LUAD	cis	rs2625529	0.617	rs2128112	ENSG00000260173.1	RP11-2I17.4	3.58	0.00038	0.0415	0.19	0.16	Red blood cell count;	chr15:71893945	chr15:72140504~72155459:-
LUAD	cis	rs17711722	0.727	rs1880555	ENSG00000273142.1	RP11-458F8.4	-3.58	0.00038	0.0415	-0.11	-0.16	Calcium levels;	chr7:65967580	chr7:66902857~66906297:+
LUAD	cis	rs7824557	0.628	rs11777746	ENSG00000255046.1	RP11-297N6.4	-3.58	0.00038	0.0415	-0.2	-0.16	Retinal vascular caliber;	chr8:11347246	chr8:11797928~11802568:-
LUAD	cis	rs34421088	0.678	rs35928010	ENSG00000255046.1	RP11-297N6.4	3.58	0.00038	0.0415	0.2	0.16	Neuroticism;	chr8:11734367	chr8:11797928~11802568:-
LUAD	cis	rs2070997	0.702	rs10901296	ENSG00000226987.1	RP11-544A12.5	3.58	0.00038	0.0415	0.32	0.16	Response to amphetamines;	chr9:130890269	chr9:131240687~131241724:+
LUAD	cis	rs6500602	0.727	rs7193136	ENSG00000280063.1	RP11-295D4.3	3.58	0.00038	0.0415	0.1	0.16	Schizophrenia;	chr16:4530033	chr16:4346694~4348648:-
LUAD	cis	rs12493885	0.818	rs61791543	ENSG00000243069.6	ARHGEF26-AS1	-3.58	0.00038	0.0415	-0.28	-0.16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154049008	chr3:154024401~154121332:-
LUAD	cis	rs12493885	0.725	rs73158447	ENSG00000243069.6	ARHGEF26-AS1	-3.58	0.00038	0.0415	-0.27	-0.16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154012003	chr3:154024401~154121332:-
LUAD	cis	rs12493885	0.654	rs61793488	ENSG00000243069.6	ARHGEF26-AS1	-3.58	0.00038	0.0415	-0.27	-0.16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154012762	chr3:154024401~154121332:-
LUAD	cis	rs12493885	0.725	rs61793489	ENSG00000243069.6	ARHGEF26-AS1	-3.58	0.00038	0.0415	-0.27	-0.16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154013367	chr3:154024401~154121332:-
LUAD	cis	rs12493885	0.725	rs4679728	ENSG00000243069.6	ARHGEF26-AS1	-3.58	0.00038	0.0415	-0.27	-0.16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154014972	chr3:154024401~154121332:-
LUAD	cis	rs259282	0.524	rs731674	ENSG00000201388.1	SNORA68	3.58	0.00038	0.0415	0.16	0.16	Schizophrenia;	chr19:32641489	chr19:32608337~32608469:-
LUAD	cis	rs2905347	0.591	rs12155285	ENSG00000179428.2	AC073072.5	3.58	0.00038	0.0415	0.19	0.16	Major depression and alcohol dependence;	chr7:22639018	chr7:22725395~22727620:-
LUAD	cis	rs9309473	1	rs62151652	ENSG00000230002.2	ALMS1-IT1	3.58	0.00038	0.0415	0.2	0.16	Metabolite levels;	chr2:73473004	chr2:73456764~73459484:+
LUAD	cis	rs11773103	0.881	rs28873439	ENSG00000224046.1	AC005076.5	3.58	0.000381	0.0415	0.25	0.16	Bipolar disorder or major depressive disorder (combined);	chr7:87227775	chr7:87151423~87152420:-
LUAD	cis	rs12928939	0.774	rs7205340	ENSG00000260886.1	TAT-AS1	-3.58	0.000381	0.0415	-0.19	-0.16	Post bronchodilator FEV1;	chr16:71611767	chr16:71565789~71578187:+
LUAD	cis	rs7428	0.545	rs2366404	ENSG00000246575.2	AC093162.5	3.58	0.000381	0.0415	0.15	0.16	Ear protrusion;	chr2:85324656	chr2:85315041~85316529:+
LUAD	cis	rs910316	0.763	rs175047	ENSG00000279594.1	RP11-950C14.10	-3.58	0.000381	0.0415	-0.18	-0.16	Height;	chr14:75012336	chr14:75011269~75012851:-
LUAD	cis	rs4268898	0.932	rs7577964	ENSG00000242628.4	AC009228.1	-3.58	0.000381	0.0415	-0.21	-0.16	Asthma;	chr2:24375410	chr2:24214381~24221516:+
LUAD	cis	rs9595908	0.655	rs56080053	ENSG00000281026.1	N4BP2L2-IT2	-3.58	0.000381	0.0415	-0.1	-0.16	Body mass index;	chr13:32720045	chr13:32504506~32509395:-
LUAD	cis	rs9402743	0.632	rs9389329	ENSG00000231028.7	LINC00271	3.58	0.000381	0.0415	0.19	0.16	Systemic lupus erythematosus;	chr6:135777966	chr6:135497801~135716055:+
LUAD	cis	rs2664588	0.561	rs4372968	ENSG00000224565.1	RP1-148H17.1	-3.58	0.000381	0.0415	-0.18	-0.16	Cerebrospinal fluid AB1-42 levels;	chr20:47963565	chr20:47391929~47412327:-
LUAD	cis	rs13113518	0.812	rs11945371	ENSG00000249700.7	SRD5A3-AS1	3.58	0.000381	0.0416	0.17	0.16	Height;	chr4:55409063	chr4:55363971~55395847:-
LUAD	cis	rs2880765	0.546	rs36098649	ENSG00000259407.1	RP11-158M2.3	-3.58	0.000381	0.0416	-0.15	-0.16	Coronary artery disease;	chr15:85513576	chr15:85744109~85750281:-
LUAD	cis	rs7870753	0.73	rs10122517	ENSG00000188801.9	ZNF322P1	3.58	0.000381	0.0416	0.22	0.16	Height;	chr9:96413174	chr9:97198303~97199511:-
LUAD	cis	rs67981189	0.574	rs2526848	ENSG00000269927.1	RP6-91H8.3	-3.58	0.000381	0.0416	-0.19	-0.16	Schizophrenia;	chr14:70953025	chr14:71141125~71143253:-
LUAD	cis	rs1910358	0.69	rs4461602	ENSG00000248874.4	C5orf17	-3.58	0.000381	0.0416	-0.21	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23968921	chr5:23951348~24178263:+
LUAD	cis	rs9646944	0.578	rs13418548	ENSG00000234389.1	AC007278.3	3.58	0.000381	0.0416	0.2	0.16	Blood protein levels;	chr2:102300779	chr2:102438713~102440475:+
LUAD	cis	rs8031584	0.678	rs798125	ENSG00000215302.7	CTD-3092A11.1	3.58	0.000381	0.0416	0.19	0.16	Huntington's disease progression;	chr15:30824597	chr15:30470779~30507623:+
LUAD	cis	rs10752881	0.967	rs12404594	ENSG00000224468.3	RP11-181K3.4	-3.58	0.000381	0.0416	-0.14	-0.16	Colorectal cancer;	chr1:183018892	chr1:183138402~183141282:-
LUAD	cis	rs2535633	0.631	rs2710314	ENSG00000242142.1	SERBP1P3	-3.58	0.000381	0.0416	-0.18	-0.16	Body mass index;	chr3:52935112	chr3:53064283~53065091:-
LUAD	cis	rs1858037	0.867	rs871974	ENSG00000237979.1	AC007389.1	-3.58	0.000381	0.0416	-0.2	-0.16	Rheumatoid arthritis;	chr2:65330153	chr2:65500993~65502138:-
LUAD	cis	rs4853525	0.59	rs1921911	ENSG00000235852.1	AC005540.3	3.58	0.000381	0.0416	0.2	0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190855644	chr2:190880797~190882059:-
LUAD	cis	rs7005380	0.733	rs56864850	ENSG00000279347.1	RP11-85I17.2	3.58	0.000381	0.0416	0.13	0.16	Interstitial lung disease;	chr8:119931204	chr8:119838736~119840385:-
LUAD	cis	rs1046491	1	rs62085926	ENSG00000264964.1	RP11-888D10.3	3.58	0.000381	0.0416	0.33	0.16	Scarlet fever;	chr18:9212641	chr18:9315194~9334441:-
LUAD	cis	rs1046491	1	rs11661921	ENSG00000264964.1	RP11-888D10.3	3.58	0.000381	0.0416	0.33	0.16	Scarlet fever;	chr18:9214150	chr18:9315194~9334441:-
LUAD	cis	rs2382999	0.649	rs9297702	ENSG00000253227.1	RP11-383J24.1	3.58	0.000381	0.0416	0.32	0.16	Response to paliperidone in schizophrenia (negative Marder score);	chr8:124944395	chr8:124271683~124277584:+
LUAD	cis	rs2382999	0.649	rs9297703	ENSG00000253227.1	RP11-383J24.1	3.58	0.000381	0.0416	0.32	0.16	Response to paliperidone in schizophrenia (negative Marder score);	chr8:124944397	chr8:124271683~124277584:+
LUAD	cis	rs1577917	0.566	rs2842611	ENSG00000220563.1	PKMP3	-3.58	0.000381	0.0416	-0.15	-0.16	Response to antipsychotic treatment;	chr6:85592316	chr6:85659892~85660606:-
LUAD	cis	rs8064024	0.87	rs6500635	ENSG00000267077.1	RP11-127I20.5	3.58	0.000381	0.0416	0.19	0.16	Cancer;	chr16:4817564	chr16:4795265~4796532:-
LUAD	cis	rs6589563	0.609	rs57641217	ENSG00000280143.1	AP000892.6	3.58	0.000381	0.0416	0.3	0.16	Eosinophil counts;	chr11:116762240	chr11:117204967~117210292:+
LUAD	cis	rs4664293	0.967	rs13000070	ENSG00000227055.1	AC009961.5	3.58	0.000381	0.0416	0.18	0.16	Monocyte percentage of white cells;	chr2:159669263	chr2:159812234~159814009:-
LUAD	cis	rs3740713	1	rs73440637	ENSG00000256464.1	YWHABP2	3.58	0.000381	0.0416	0.32	0.16	Amyotrophic lateral sclerosis (sporadic);	chr11:18452581	chr11:18490243~18490955:-
LUAD	cis	rs875971	0.545	rs6460298	ENSG00000224316.1	RP11-479O9.2	3.58	0.000381	0.0416	0.19	0.16	Aortic root size;	chr7:66442783	chr7:65773620~65802067:+
LUAD	cis	rs6496044	0.568	rs3743321	ENSG00000259416.2	RP11-158M2.5	3.58	0.000381	0.0416	0.17	0.16	Interstitial lung disease;	chr15:85521737	chr15:85754941~85756237:-
LUAD	cis	rs10863681	0.52	rs10863689	ENSG00000200033.1	RNU6-403P	-3.58	0.000381	0.0416	-0.19	-0.16	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222109143	chr1:221837334~221837437:-
LUAD	cis	rs860295	1	rs822490	ENSG00000203761.5	MSTO2P	-3.58	0.000381	0.0416	-0.12	-0.16	Body mass index;	chr1:155853180	chr1:155745829~155750137:+
LUAD	cis	rs7017914	0.559	rs12056347	ENSG00000246366.5	RP11-382J12.1	3.58	0.000381	0.0416	0.16	0.16	Bone mineral density;	chr8:71072374	chr8:70608577~70663279:+
LUAD	cis	rs10129255	0.957	rs1024349	ENSG00000274576.2	IGHV2-70	3.58	0.000381	0.0416	0.14	0.16	Kawasaki disease;	chr14:106689997	chr14:106770577~106771020:-
LUAD	cis	rs4727027	0.704	rs13229244	ENSG00000244560.5	RP4-800G7.2	3.58	0.000382	0.0416	0.1	0.16	Neutrophil percentage of granulocytes;Eosinophil counts;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr7:149201127	chr7:149285281~149297312:+
LUAD	cis	rs17407555	0.821	rs17198197	ENSG00000250413.1	RP11-448G15.1	-3.58	0.000382	0.0416	-0.26	-0.16	Schizophrenia (age at onset);	chr4:10137533	chr4:10006482~10009725:+
LUAD	cis	rs8031584	0.958	rs8034856	ENSG00000259845.1	HERC2P10	3.58	0.000382	0.0416	0.19	0.16	Huntington's disease progression;	chr15:30948754	chr15:30815271~30844153:+
LUAD	cis	rs797680	0.754	rs3767964	ENSG00000223745.6	RP4-717I23.3	3.58	0.000382	0.0416	0.12	0.16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93349933	chr1:93262186~93346025:-
LUAD	cis	rs10864907	0.905	rs11683383	ENSG00000227368.1	AC079753.5	3.58	0.000382	0.0416	0.18	0.16	Pulmonary function;	chr2:112932773	chr2:112932625~112933171:+
LUAD	cis	rs910316	0.737	rs175424	ENSG00000259138.1	RP11-950C14.7	-3.58	0.000382	0.0416	-0.17	-0.16	Height;	chr14:75159554	chr14:75127153~75136930:+
LUAD	cis	rs910316	0.763	rs2080201	ENSG00000259138.1	RP11-950C14.7	-3.58	0.000382	0.0416	-0.17	-0.16	Height;	chr14:75163269	chr14:75127153~75136930:+
LUAD	cis	rs12264252	0.767	rs35998463	ENSG00000226659.1	RP11-137H2.4	3.58	0.000382	0.0416	0.25	0.16	Coronary artery disease;	chr10:80485754	chr10:80529597~80535942:-
LUAD	cis	rs6951245	0.744	rs10275401	ENSG00000249574.1	AC226118.1	-3.58	0.000382	0.0416	-0.25	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1174307	chr7:379359~382712:+
LUAD	cis	rs9309473	0.519	rs7606947	ENSG00000163016.8	ALMS1P	3.58	0.000382	0.0416	0.17	0.16	Metabolite levels;	chr2:73682691	chr2:73644919~73685576:+
LUAD	cis	rs365302	1	rs294917	ENSG00000235086.1	FNDC1-IT1	3.58	0.000382	0.0416	0.22	0.16	Coronary heart disease;	chr6:159206045	chr6:159240786~159243329:+
LUAD	cis	rs2348418	0.832	rs1032391	ENSG00000244712.1	RP11-874G11.1	3.58	0.000382	0.0416	0.19	0.16	Lung function (FEV1);Lung function (FVC);	chr12:28383775	chr12:28564678~28565141:-
LUAD	cis	rs4865762	0.512	rs1838736	ENSG00000247796.2	CTD-2366F13.1	3.58	0.000382	0.0416	0.18	0.16	Intraocular pressure;	chr5:53208231	chr5:53109842~53115126:+
LUAD	cis	rs5770917	1	rs762677	ENSG00000273272.1	CTA-384D8.34	3.58	0.000382	0.0416	0.35	0.16	Narcolepsy;	chr22:50579284	chr22:50542650~50543011:+
LUAD	cis	rs2408955	0.522	rs10875721	ENSG00000257763.1	OR5BK1P	-3.58	0.000382	0.0417	-0.17	-0.16	Glycated hemoglobin levels;	chr12:48019810	chr12:48355792~48356614:-
LUAD	cis	rs1400816	0.702	rs1850031	ENSG00000228389.1	AC068039.4	-3.58	0.000382	0.0417	-0.27	-0.16	Amyotrophic lateral sclerosis (sporadic);	chr2:171701229	chr2:171773482~171775844:+
LUAD	cis	rs1400816	0.702	rs1515812	ENSG00000228389.1	AC068039.4	-3.58	0.000382	0.0417	-0.27	-0.16	Amyotrophic lateral sclerosis (sporadic);	chr2:171701537	chr2:171773482~171775844:+
LUAD	cis	rs17407555	0.738	rs56143194	ENSG00000250413.1	RP11-448G15.1	3.58	0.000382	0.0417	0.25	0.16	Schizophrenia (age at onset);	chr4:10065911	chr4:10006482~10009725:+
LUAD	cis	rs3114020	1	rs2622609	ENSG00000246375.2	RP11-10L7.1	-3.58	0.000382	0.0417	-0.21	-0.16	Gout;	chr4:88167323	chr4:88284942~88331421:+
LUAD	cis	rs7937127	0.64	rs12792780	ENSG00000254907.1	RP11-484D2.2	3.58	0.000382	0.0417	0.27	0.16	Fibrinogen levels;	chr11:43505357	chr11:43328748~43359296:-
LUAD	cis	rs13398147	0.879	rs17312518	ENSG00000267034.1	RP11-384O8.1	3.58	0.000382	0.0417	0.22	0.16	Adolescent idiopathic scoliosis;	chr2:221873321	chr2:222317242~222318653:-
LUAD	cis	rs4489787	1	rs12230448	ENSG00000240399.1	RP1-228P16.1	-3.58	0.000382	0.0417	-0.28	-0.16	Prostate cancer (SNP x SNP interaction);	chr12:48557155	chr12:48054813~48055591:-
LUAD	cis	rs4489787	1	rs12230471	ENSG00000240399.1	RP1-228P16.1	-3.58	0.000382	0.0417	-0.28	-0.16	Prostate cancer (SNP x SNP interaction);	chr12:48557406	chr12:48054813~48055591:-
LUAD	cis	rs4489787	1	rs11168633	ENSG00000240399.1	RP1-228P16.1	-3.58	0.000382	0.0417	-0.28	-0.16	Prostate cancer (SNP x SNP interaction);	chr12:48557441	chr12:48054813~48055591:-
LUAD	cis	rs4489787	1	rs11168634	ENSG00000240399.1	RP1-228P16.1	-3.58	0.000382	0.0417	-0.28	-0.16	Prostate cancer (SNP x SNP interaction);	chr12:48557810	chr12:48054813~48055591:-
LUAD	cis	rs4489787	1	rs11168636	ENSG00000240399.1	RP1-228P16.1	-3.58	0.000382	0.0417	-0.28	-0.16	Prostate cancer (SNP x SNP interaction);	chr12:48558057	chr12:48054813~48055591:-
LUAD	cis	rs9925964	0.967	rs889548	ENSG00000232748.3	RP11-196G11.6	-3.58	0.000382	0.0417	-0.2	-0.16	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31126391	chr16:31056460~31062803:+
LUAD	cis	rs2030114	0.531	rs1072858	ENSG00000224578.4	HNRNPA1P48	-3.58	0.000382	0.0417	-0.13	-0.16	Blood pressure measurement (high sodium and potassium intervention);	chr16:51559453	chr16:51645756~51647132:+
LUAD	cis	rs35740288	0.77	rs34048547	ENSG00000259407.1	RP11-158M2.3	-3.58	0.000382	0.0417	-0.15	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85637836	chr15:85744109~85750281:-
LUAD	cis	rs7646881	0.544	rs16847135	ENSG00000240207.5	RP11-379F4.4	-3.58	0.000382	0.0417	-0.22	-0.16	Tetralogy of Fallot;	chr3:158706064	chr3:158732263~158784070:+
LUAD	cis	rs755249	0.883	rs12035330	ENSG00000182109.6	RP11-69E11.4	3.58	0.000382	0.0417	0.19	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39535388	chr1:39522280~39546187:-
LUAD	cis	rs875971	0.522	rs9530	ENSG00000273142.1	RP11-458F8.4	-3.58	0.000382	0.0417	-0.11	-0.16	Aortic root size;	chr7:65960907	chr7:66902857~66906297:+
LUAD	cis	rs12446632	0.771	rs11865578	ENSG00000261195.1	CTD-2380F24.1	-3.58	0.000382	0.0417	-0.24	-0.16	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Menarche (age at onset);Obesity;Childhood body mass index;Waist circumference;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr16:19860660	chr16:19761172~19766099:-
LUAD	cis	rs3213758	1	rs16952304	ENSG00000261630.1	RP11-357N13.3	-3.58	0.000382	0.0417	-0.32	-0.16	Vitiligo (non-segmental);	chr16:53544801	chr16:53981229~53981912:-
LUAD	cis	rs10496034	1	rs80194342	ENSG00000240401.7	AC012358.8	3.58	0.000382	0.0417	0.41	0.16	Refractive astigmatism;	chr2:54995971	chr2:55282350~55346049:+
LUAD	cis	rs11673344	0.642	rs11083420	ENSG00000267309.1	CTD-2630F21.1	-3.58	0.000382	0.0417	-0.21	-0.16	Obesity-related traits;	chr19:37317901	chr19:36489649~36491040:+
LUAD	cis	rs6728642	1	rs80303184	ENSG00000230606.9	AC159540.1	3.58	0.000382	0.0417	0.33	0.16	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97349066	chr2:97416165~97433527:-
LUAD	cis	rs755249	0.508	rs624971	ENSG00000182109.6	RP11-69E11.4	3.58	0.000382	0.0417	0.17	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39393275	chr1:39522280~39546187:-
LUAD	cis	rs6787172	0.667	rs2885663	ENSG00000272087.1	RP11-379F4.7	3.58	0.000382	0.0417	0.18	0.16	Subjective well-being;	chr3:158466474	chr3:158693120~158693768:-
LUAD	cis	rs3126085	1	rs12405278	ENSG00000237975.5	FLG-AS1	3.58	0.000382	0.0417	0.28	0.16	Atopic dermatitis;	chr1:152309791	chr1:152168125~152445456:+
LUAD	cis	rs3126085	1	rs11588170	ENSG00000237975.5	FLG-AS1	3.58	0.000382	0.0417	0.28	0.16	Atopic dermatitis;	chr1:152313556	chr1:152168125~152445456:+
LUAD	cis	rs3126085	0.935	rs12407156	ENSG00000237975.5	FLG-AS1	3.58	0.000382	0.0417	0.28	0.16	Atopic dermatitis;	chr1:152323466	chr1:152168125~152445456:+
LUAD	cis	rs577676	0.586	rs12566725	ENSG00000271811.1	RP1-79C4.4	3.58	0.000382	0.0417	0.2	0.16	Prevalent atrial fibrillation;	chr1:170632794	chr1:170667381~170669425:+
LUAD	cis	rs595244	1	rs363820	ENSG00000259705.1	RP11-227D13.1	-3.58	0.000382	0.0417	-0.31	-0.16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48436833	chr15:48645951~48652016:+
LUAD	cis	rs10859871	0.536	rs6538621	ENSG00000216306.3	KRT19P2	3.58	0.000382	0.0417	0.21	0.16	Endometriosis;	chr12:95231704	chr12:94834147~94835158:+
LUAD	cis	rs748404	0.629	rs34657657	ENSG00000249839.1	AC011330.5	-3.58	0.000383	0.0417	-0.25	-0.16	Lung cancer;	chr15:43315763	chr15:43663654~43684339:-
LUAD	cis	rs6496932	1	rs35156762	ENSG00000218052.5	ADAMTS7P4	3.58	0.000383	0.0417	0.2	0.16	Central corneal thickness;Corneal structure;	chr15:85281243	chr15:85255369~85330334:-
LUAD	cis	rs62025270	0.688	rs17576534	ENSG00000259416.2	RP11-158M2.5	-3.58	0.000383	0.0417	-0.22	-0.16	Idiopathic pulmonary fibrosis;	chr15:85742509	chr15:85754941~85756237:-
LUAD	cis	rs2980439	0.818	rs2948294	ENSG00000254340.1	RP11-10A14.3	3.58	0.000383	0.0417	0.19	0.16	Neuroticism;	chr8:8237439	chr8:9141424~9145435:+
LUAD	cis	rs4268898	0.662	rs58971404	ENSG00000242628.4	AC009228.1	3.58	0.000383	0.0417	0.24	0.16	Asthma;	chr2:24180884	chr2:24214381~24221516:+
LUAD	cis	rs4268898	0.662	rs59996104	ENSG00000242628.4	AC009228.1	3.58	0.000383	0.0417	0.24	0.16	Asthma;	chr2:24181195	chr2:24214381~24221516:+
LUAD	cis	rs9308731	0.591	rs60982612	ENSG00000227992.1	AC108463.2	-3.58	0.000383	0.0417	-0.19	-0.16	Chronic lymphocytic leukemia;	chr2:111183362	chr2:111203964~111206215:-
LUAD	cis	rs72647484	0.554	rs2807345	ENSG00000234397.3	RP11-415K20.1	-3.58	0.000383	0.0417	-0.32	-0.16	Colorectal cancer;	chr1:22218645	chr1:22322840~22323331:-
LUAD	cis	rs786425	0.77	rs7960951	ENSG00000278112.1	RP11-972P1.11	3.58	0.000383	0.0417	0.15	0.16	Pubertal anthropometrics;	chr12:123681282	chr12:123519390~123519856:-
LUAD	cis	rs7210990	0.575	rs11654	ENSG00000276855.1	CTD-3157E16.2	-3.58	0.000383	0.0417	-0.2	-0.16	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr17:15977837	chr17:15789016~15789705:+
LUAD	cis	rs7210990	0.575	rs2109632	ENSG00000276855.1	CTD-3157E16.2	-3.58	0.000383	0.0417	-0.2	-0.16	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr17:15978414	chr17:15789016~15789705:+
LUAD	cis	rs9341808	0.754	rs3793000	ENSG00000279022.1	RP11-250B2.4	3.58	0.000383	0.0417	0.19	0.16	Sitting height ratio;	chr6:80285420	chr6:80440730~80441172:+
LUAD	cis	rs6921919	0.583	rs4642462	ENSG00000219392.1	RP1-265C24.5	-3.58	0.000383	0.0417	-0.21	-0.16	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28115628~28116551:+
LUAD	cis	rs8023401	0.938	rs11855195	ENSG00000274654.1	CTD-3247H4.2	3.58	0.000383	0.0417	0.32	0.16	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48468700	chr15:48528980~48529728:-
LUAD	cis	rs8023401	0.872	rs75227249	ENSG00000274654.1	CTD-3247H4.2	3.58	0.000383	0.0417	0.32	0.16	Spherical equivalent (joint analysis main effects and education interaction);	chr15:48470811	chr15:48528980~48529728:-
LUAD	cis	rs10129255	0.912	rs67410411	ENSG00000211967.3	IGHV3-53	-3.58	0.000383	0.0417	-0.13	-0.16	Kawasaki disease;	chr14:106680324	chr14:106592676~106593347:-
LUAD	cis	rs4667682	0.646	rs72625232	ENSG00000228507.1	DAP3P2	-3.58	0.000383	0.0417	-0.34	-0.16	Hippocampal atrophy;Body mass index;	chr2:171277257	chr2:171491422~171491931:+
LUAD	cis	rs7613875	0.58	rs2624819	ENSG00000234667.1	ACTBP13	-3.58	0.000383	0.0417	-0.18	-0.16	Body mass index;	chr3:49973138	chr3:49873347~49877980:-
LUAD	cis	rs7107174	1	rs10793297	ENSG00000251323.2	RP11-452H21.4	3.58	0.000383	0.0417	0.22	0.16	Testicular germ cell tumor;	chr11:78298614	chr11:78423982~78429836:-
LUAD	cis	rs7107174	1	rs10899460	ENSG00000251323.2	RP11-452H21.4	3.58	0.000383	0.0417	0.22	0.16	Testicular germ cell tumor;	chr11:78299034	chr11:78423982~78429836:-
LUAD	cis	rs7107174	0.892	rs11601866	ENSG00000251323.2	RP11-452H21.4	3.58	0.000383	0.0417	0.22	0.16	Testicular germ cell tumor;	chr11:78300107	chr11:78423982~78429836:-
LUAD	cis	rs9595908	0.746	rs7985640	ENSG00000281026.1	N4BP2L2-IT2	-3.58	0.000383	0.0417	-0.1	-0.16	Body mass index;	chr13:32698228	chr13:32504506~32509395:-
LUAD	cis	rs9595908	0.785	rs9591252	ENSG00000281026.1	N4BP2L2-IT2	-3.58	0.000383	0.0417	-0.1	-0.16	Body mass index;	chr13:32698297	chr13:32504506~32509395:-
LUAD	cis	rs9595908	0.785	rs9596083	ENSG00000281026.1	N4BP2L2-IT2	-3.58	0.000383	0.0417	-0.1	-0.16	Body mass index;	chr13:32700494	chr13:32504506~32509395:-
LUAD	cis	rs6878284	0.608	rs841928	ENSG00000250682.4	LINC00491	-3.58	0.000383	0.0417	-0.17	-0.16	Schizophrenia;	chr5:102291731	chr5:102609156~102671559:-
LUAD	cis	rs1020064	0.583	rs2576775	ENSG00000235319.1	AC012360.4	-3.58	0.000383	0.0417	-0.19	-0.16	AIDS;	chr2:105356755	chr2:105324210~105330529:+
LUAD	cis	rs12549058	0.792	rs12541041	ENSG00000223220.1	Y_RNA	-3.58	0.000383	0.0418	-0.32	-0.16	Waist-hip ratio;	chr8:71618048	chr8:70780914~70781008:-
LUAD	cis	rs9548119	0.696	rs9566273	ENSG00000223685.4	LINC00571	-3.58	0.000383	0.0418	-0.27	-0.16	Self-rated health;	chr13:37906741	chr13:38050817~38143232:-
LUAD	cis	rs7077256	0.564	rs10509188	ENSG00000272767.1	JMJD1C-AS1	3.58	0.000383	0.0418	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63459037	chr10:63465229~63466563:+
LUAD	cis	rs748404	0.56	rs689797	ENSG00000166763.7	STRCP1	3.58	0.000383	0.0418	0.19	0.16	Lung cancer;	chr15:43534359	chr15:43699488~43718184:-
LUAD	cis	rs412050	0.502	rs8136405	ENSG00000224086.5	LL22NC03-86G7.1	-3.58	0.000383	0.0418	-0.21	-0.16	Attention deficit hyperactivity disorder;	chr22:21793732	chr22:21938293~21977632:+
LUAD	cis	rs73193808	0.851	rs2223036	ENSG00000215533.7	LINC00189	3.58	0.000383	0.0418	0.24	0.16	Coronary artery disease;	chr21:29232461	chr21:29193480~29288205:+
LUAD	cis	rs12034598	0.639	rs10863358	ENSG00000234219.1	CDCA4P4	3.58	0.000383	0.0418	0.23	0.16	Inflammatory biomarkers;	chr1:207517526	chr1:207762584~207763263:+
LUAD	cis	rs2414856	0.504	rs11554310	ENSG00000259635.1	AC100830.3	-3.58	0.000383	0.0418	-0.4	-0.16	Pulse pressure;Systolic blood pressure;	chr15:64381416	chr15:64701248~64719602:+
LUAD	cis	rs4835473	0.838	rs13134571	ENSG00000249741.2	RP11-673E1.3	3.58	0.000383	0.0418	0.19	0.16	Immature fraction of reticulocytes;	chr4:143738771	chr4:143911514~143912053:-
LUAD	cis	rs7200786	0.546	rs41370	ENSG00000274038.1	RP11-66H6.4	-3.58	0.000383	0.0418	-0.21	-0.16	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11163472	chr16:11056556~11057034:+
LUAD	cis	rs224278	0.624	rs2136613	ENSG00000238280.1	RP11-436D10.3	-3.58	0.000383	0.0418	-0.19	-0.16	Ewing sarcoma;	chr10:62834404	chr10:62793562~62805887:-
LUAD	cis	rs2039553	0.777	rs1414116	ENSG00000227676.3	LINC01068	3.58	0.000383	0.0418	0.21	0.16	Pancreatic cancer;	chr13:79744500	chr13:79566727~79571436:+
LUAD	cis	rs875971	0.522	rs709604	ENSG00000234585.5	CCT6P3	-3.58	0.000383	0.0418	-0.15	-0.16	Aortic root size;	chr7:66032447	chr7:65038354~65074713:+
LUAD	cis	rs41369048	0.66	rs2210837	ENSG00000221571.3	RNU6ATAC35P	-3.58	0.000384	0.0418	-0.21	-0.16	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220916248	chr1:220825620~220826063:+
LUAD	cis	rs7512898	0.5	rs6691268	ENSG00000260088.1	RP11-92G12.3	-3.58	0.000384	0.0418	-0.22	-0.16	Electrocardiographic conduction measures;	chr1:200786938	chr1:200669507~200694250:+
LUAD	cis	rs4795519	0.614	rs8070908	ENSG00000266313.1	RP11-173M1.4	3.58	0.000384	0.0418	0.22	0.16	Chronic myeloid leukemia;	chr17:27164439	chr17:27333256~27348491:+
LUAD	cis	rs4795519	0.614	rs8077670	ENSG00000266313.1	RP11-173M1.4	3.58	0.000384	0.0418	0.22	0.16	Chronic myeloid leukemia;	chr17:27177968	chr17:27333256~27348491:+
LUAD	cis	rs4795519	0.583	rs12453923	ENSG00000266313.1	RP11-173M1.4	3.58	0.000384	0.0418	0.22	0.16	Chronic myeloid leukemia;	chr17:27192183	chr17:27333256~27348491:+
LUAD	cis	rs889122	0.765	rs889162	ENSG00000267289.1	CTD-2623N2.11	3.58	0.000384	0.0418	0.18	0.16	Menarche (age at onset);	chr19:9841240	chr19:9834079~9835013:-
LUAD	cis	rs12744310	0.887	rs67483852	ENSG00000235358.1	RP11-399E6.1	3.58	0.000384	0.0418	0.21	0.16	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41318793	chr1:41242373~41284861:+
LUAD	cis	rs12744310	0.887	rs36015391	ENSG00000235358.1	RP11-399E6.1	3.58	0.000384	0.0418	0.21	0.16	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41319133	chr1:41242373~41284861:+
LUAD	cis	rs12744310	0.887	rs28399806	ENSG00000235358.1	RP11-399E6.1	3.58	0.000384	0.0418	0.21	0.16	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41319299	chr1:41242373~41284861:+
LUAD	cis	rs12744310	0.887	rs12047875	ENSG00000235358.1	RP11-399E6.1	3.58	0.000384	0.0418	0.21	0.16	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41319504	chr1:41242373~41284861:+
LUAD	cis	rs12744310	0.887	rs35932978	ENSG00000235358.1	RP11-399E6.1	3.58	0.000384	0.0418	0.21	0.16	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41319773	chr1:41242373~41284861:+
LUAD	cis	rs8014204	0.87	rs3742790	ENSG00000279594.1	RP11-950C14.10	-3.58	0.000384	0.0418	-0.18	-0.16	Caffeine consumption;	chr14:74842055	chr14:75011269~75012851:-
LUAD	cis	rs9513627	1	rs2390279	ENSG00000280710.1	RP11-214F16.8	-3.58	0.000384	0.0418	-0.3	-0.16	Obesity-related traits;	chr13:99556451	chr13:99498524~99501315:+
LUAD	cis	rs765899	0.658	rs2525510	ENSG00000240210.3	RP11-204K16.1	-3.58	0.000384	0.0418	-0.17	-0.16	Breast cancer;	chr14:68500249	chr14:68338728~68339528:-
LUAD	cis	rs4363385	0.776	rs1415957	ENSG00000223599.1	RP11-216N14.7	-3.58	0.000384	0.0418	-0.19	-0.16	Inflammatory skin disease;	chr1:152976433	chr1:153852106~153853414:-
LUAD	cis	rs7142881	0.815	rs12896685	ENSG00000258525.1	RP11-829H16.3	-3.58	0.000384	0.0418	-0.18	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31736468	chr14:30876179~30889808:-
LUAD	cis	rs7829975	0.688	rs6995407	ENSG00000233609.3	RP11-62H7.2	3.58	0.000384	0.0418	0.13	0.16	Mood instability;	chr8:8527137	chr8:8961200~8979025:+
LUAD	cis	rs6921919	0.583	rs7759191	ENSG00000219392.1	RP1-265C24.5	-3.58	0.000384	0.0418	-0.21	-0.16	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28115628~28116551:+
LUAD	cis	rs4845875	0.513	rs198397	ENSG00000242349.4	NPPA-AS1	-3.58	0.000384	0.0418	-0.16	-0.16	Midregional pro atrial natriuretic peptide levels;	chr1:11823275	chr1:11841017~11848079:+
LUAD	cis	rs11264213	0.901	rs581459	ENSG00000239636.1	RP4-728D4.2	-3.58	0.000384	0.0418	-0.2	-0.16	Schizophrenia;	chr1:35909509	chr1:35569813~35577729:-
LUAD	cis	rs2235642	0.893	rs2143285	ENSG00000280231.1	LA16c-380F5.3	-3.58	0.000384	0.0418	-0.22	-0.16	Coronary artery disease;	chr16:1543170	chr16:1553655~1554130:-
LUAD	cis	rs801193	0.591	rs4506088	ENSG00000273448.1	RP11-166O4.6	-3.58	0.000384	0.0418	-0.15	-0.16	Aortic root size;	chr7:66670470	chr7:67333047~67334383:+
LUAD	cis	rs7909670	0.526	rs11258041	ENSG00000228330.1	RP11-730A19.5	3.58	0.000384	0.0418	0.21	0.16	Height;	chr10:12876662	chr10:13142185~13142977:-
LUAD	cis	rs564309	0.867	rs3738687	ENSG00000231563.1	RP11-245P10.4	-3.58	0.000384	0.0418	-0.31	-0.16	Hip circumference (psychosocial stress interaction);	chr1:228377744	chr1:228407381~228409694:+
LUAD	cis	rs2147959	0.941	rs1007686	ENSG00000269934.1	RP5-1139B12.3	-3.58	0.000384	0.0418	-0.21	-0.16	Adult asthma;	chr1:228463756	chr1:228274584~228276066:-
LUAD	cis	rs7208859	0.623	rs9914242	ENSG00000280069.1	CTD-2349P21.3	-3.58	0.000384	0.0418	-0.23	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889227	chr17:30738182~30740275:+
LUAD	cis	rs6661961	0.714	rs11579024	ENSG00000237975.5	FLG-AS1	-3.58	0.000384	0.0418	-0.22	-0.16	Atopic dermatitis;	chr1:152447632	chr1:152168125~152445456:+
LUAD	cis	rs2832077	0.527	rs2776210	ENSG00000232855.5	AF131217.1	-3.58	0.000384	0.0418	-0.16	-0.16	Cognitive test performance;	chr21:28896236	chr21:28439346~28674848:-
LUAD	cis	rs13398147	0.879	rs72971007	ENSG00000267034.1	RP11-384O8.1	3.58	0.000384	0.0418	0.22	0.16	Adolescent idiopathic scoliosis;	chr2:221848813	chr2:222317242~222318653:-
LUAD	cis	rs1005224	0.782	rs34882722	ENSG00000242952.1	RP11-187O7.1	-3.58	0.000384	0.0418	-0.15	-0.16	Large artery stroke;	chr14:75687553	chr14:76634775~76635661:-
LUAD	cis	rs9659323	0.622	rs11582744	ENSG00000231365.4	RP11-418J17.1	-3.58	0.000384	0.0418	-0.2	-0.16	Body mass index;	chr1:118914781	chr1:119140396~119275973:+
LUAD	cis	rs3738443	1	rs61840057	ENSG00000215795.2	RP11-488L18.3	-3.58	0.000384	0.0418	-0.24	-0.16	Alcohol dependence;	chr1:247206054	chr1:247183813~247185482:-
LUAD	cis	rs875971	0.522	rs2949690	ENSG00000273142.1	RP11-458F8.4	3.58	0.000384	0.0418	0.11	0.16	Aortic root size;	chr7:66018255	chr7:66902857~66906297:+
LUAD	cis	rs1910358	0.69	rs10076817	ENSG00000248874.4	C5orf17	-3.58	0.000384	0.0418	-0.21	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23939564	chr5:23951348~24178263:+
LUAD	cis	rs8067545	0.641	rs203479	ENSG00000270091.1	RP11-78O7.2	-3.58	0.000384	0.0418	-0.14	-0.16	Schizophrenia;	chr17:19925998	chr17:19896590~19897287:-
LUAD	cis	rs2039553	0.748	rs9565521	ENSG00000227676.3	LINC01068	3.58	0.000384	0.0418	0.2	0.16	Pancreatic cancer;	chr13:79730110	chr13:79566727~79571436:+
LUAD	cis	rs2039553	0.807	rs9530951	ENSG00000227676.3	LINC01068	3.58	0.000384	0.0418	0.2	0.16	Pancreatic cancer;	chr13:79730195	chr13:79566727~79571436:+
LUAD	cis	rs7142881	0.815	rs2153560	ENSG00000258525.1	RP11-829H16.3	-3.58	0.000384	0.0418	-0.18	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31686411	chr14:30876179~30889808:-
LUAD	cis	rs7119038	0.818	rs11217033	ENSG00000255239.1	AP002954.6	-3.58	0.000384	0.0418	-0.24	-0.16	Sjögren's syndrome;	chr11:118802997	chr11:118688039~118690600:-
LUAD	cis	rs11217036	1	rs11217036	ENSG00000255239.1	AP002954.6	-3.58	0.000384	0.0418	-0.24	-0.16	Allergy;	chr11:118805063	chr11:118688039~118690600:-
LUAD	cis	rs7119038	0.774	rs11217038	ENSG00000255239.1	AP002954.6	-3.58	0.000384	0.0418	-0.24	-0.16	Sjögren's syndrome;	chr11:118806646	chr11:118688039~118690600:-
LUAD	cis	rs7674212	0.541	rs2720464	ENSG00000246560.2	RP11-10L12.4	3.58	0.000384	0.0418	0.21	0.16	Type 2 diabetes;	chr4:103152044	chr4:102828055~102844075:+
LUAD	cis	rs445114	0.601	rs373616	ENSG00000254166.1	CASC19	-3.58	0.000384	0.0419	-0.16	-0.16	Prostate cancer;Prostate cancer (SNP x SNP interaction);	chr8:127335817	chr8:127185635~127203222:-
LUAD	cis	rs11779988	0.545	rs208058	ENSG00000253671.1	RP11-806O11.1	-3.58	0.000384	0.0419	-0.19	-0.16	Breast cancer;	chr8:17962924	chr8:17808941~17820868:+
LUAD	cis	rs6871536	1	rs2301713	ENSG00000233006.5	AC034220.3	3.58	0.000384	0.0419	0.17	0.16	Asthma (childhood onset);	chr5:132616304	chr5:132311285~132369916:-
LUAD	cis	rs755249	0.53	rs4660443	ENSG00000182109.6	RP11-69E11.4	3.58	0.000384	0.0419	0.2	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39126107	chr1:39522280~39546187:-
LUAD	cis	rs11159086	0.793	rs1029701	ENSG00000270000.1	RP3-449M8.9	3.58	0.000384	0.0419	0.22	0.16	Advanced glycation end-product levels;	chr14:74474112	chr14:74471930~74472360:-
LUAD	cis	rs9921338	0.923	rs7186455	ENSG00000262703.1	RP11-485G7.6	-3.58	0.000384	0.0419	-0.16	-0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11333891	chr16:11348143~11349321:-
LUAD	cis	rs10102546	1	rs7838891	ENSG00000244642.3	RN7SL396P	3.58	0.000384	0.0419	0.18	0.16	Smoking cessation;	chr8:119535804	chr8:119862662~119862956:+
LUAD	cis	rs17596685	1	rs2277439	ENSG00000271216.1	LINC01050	3.58	0.000385	0.0419	0.23	0.16	C-reactive protein levels;	chr13:42581307	chr13:42810366~42812562:-
LUAD	cis	rs7615952	0.866	rs13063119	ENSG00000241288.6	RP11-379B18.5	-3.58	0.000385	0.0419	-0.21	-0.16	Blood pressure (smoking interaction);	chr3:125925004	chr3:125827238~125916384:-
LUAD	cis	rs4664293	0.867	rs2059698	ENSG00000230783.1	AC009961.2	3.58	0.000385	0.0419	0.2	0.16	Monocyte percentage of white cells;	chr2:159785905	chr2:159689217~159690291:-
LUAD	cis	rs4218	1	rs4218	ENSG00000277144.1	RP11-59H7.4	-3.58	0.000385	0.0419	-0.19	-0.16	Social communication problems;	chr15:59136459	chr15:59115547~59116089:-
LUAD	cis	rs35520189	0.591	rs12995439	ENSG00000227368.1	AC079753.5	3.58	0.000385	0.0419	0.2	0.16	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112946069	chr2:112932625~112933171:+
LUAD	cis	rs4699052	0.662	rs6825489	ENSG00000246560.2	RP11-10L12.4	3.58	0.000385	0.0419	0.21	0.16	Testicular germ cell tumor;	chr4:103329027	chr4:102828055~102844075:+
LUAD	cis	rs3617	0.625	rs3774364	ENSG00000242142.1	SERBP1P3	3.58	0.000385	0.0419	0.17	0.16	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52829589	chr3:53064283~53065091:-
LUAD	cis	rs2380205	0.967	rs7099029	ENSG00000232807.2	RP11-536K7.3	3.58	0.000385	0.0419	0.17	0.16	Breast cancer;	chr10:5857225	chr10:5934270~5945900:-
LUAD	cis	rs3847687	0.966	rs3847689	ENSG00000279128.1	RP11-76C10.4	3.58	0.000385	0.0419	0.17	0.16	Longevity;	chr12:131040989	chr12:131022769~131024741:-
LUAD	cis	rs2024714	0.902	rs2427207	ENSG00000273812.1	WI2-87327B8.2	-3.58	0.000385	0.0419	-0.17	-0.16	Longevity;	chr20:61633733	chr20:62596732~62603115:-
LUAD	cis	rs4819052	0.851	rs7275870	ENSG00000215447.6	BX322557.10	-3.58	0.000385	0.0419	-0.19	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251299	chr21:45288052~45291738:+
LUAD	cis	rs4819052	0.851	rs7275874	ENSG00000215447.6	BX322557.10	-3.58	0.000385	0.0419	-0.19	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251308	chr21:45288052~45291738:+
LUAD	cis	rs2299587	0.554	rs3739404	ENSG00000253671.1	RP11-806O11.1	-3.58	0.000385	0.0419	-0.16	-0.16	Economic and political preferences;	chr8:17882334	chr8:17808941~17820868:+
LUAD	cis	rs10876993	0.928	rs1628552	ENSG00000270039.1	RP11-571M6.17	3.58	0.000385	0.0419	0.19	0.16	Celiac disease or Rheumatoid arthritis;	chr12:57688359	chr12:57803838~57804415:+
LUAD	cis	rs950027	0.62	rs872192	ENSG00000259479.5	SORD2P	3.58	0.000385	0.0419	0.2	0.16	Response to fenofibrate (adiponectin levels);	chr15:45322304	chr15:44826371~44884694:-
LUAD	cis	rs17264034	0.821	rs605126	ENSG00000250786.1	SNHG18	3.58	0.000385	0.0419	0.23	0.16	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9541754	chr5:9546200~9550609:+
LUAD	cis	rs12887734	0.546	rs4900597	ENSG00000258914.1	CTD-2134A5.3	3.58	0.000385	0.0419	0.19	0.16	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103800327	chr14:103875055~103877478:+
LUAD	cis	rs526231	0.511	rs3776861	ENSG00000250682.4	LINC00491	3.58	0.000385	0.0419	0.2	0.16	Primary biliary cholangitis;	chr5:103013958	chr5:102609156~102671559:-
LUAD	cis	rs9341808	0.667	rs2490239	ENSG00000272129.1	RP11-250B2.6	3.58	0.000385	0.0419	0.2	0.16	Sitting height ratio;	chr6:80116572	chr6:80355424~80356859:+
LUAD	cis	rs3916	0.911	rs3999408	ENSG00000277423.1	RP11-173P15.9	-3.58	0.000385	0.0419	-0.2	-0.16	Urinary metabolites (H-NMR features);	chr12:120729584	chr12:120703867~120704282:+
LUAD	cis	rs9309473	0.95	rs1918863	ENSG00000230002.2	ALMS1-IT1	3.58	0.000385	0.0419	0.2	0.16	Metabolite levels;	chr2:73417353	chr2:73456764~73459484:+
LUAD	cis	rs6988985	0.693	rs6395	ENSG00000247317.3	RP11-273G15.2	-3.58	0.000385	0.0419	-0.18	-0.16	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142875392	chr8:142981738~143018437:-
LUAD	cis	rs2144940	0.545	rs844838	ENSG00000233746.1	LINC00656	3.58	0.000385	0.0419	0.35	0.16	Venous thromboembolism;	chr20:23108239	chr20:23125068~23132621:-
LUAD	cis	rs62355901	0.505	rs62358079	ENSG00000271828.1	CTD-2310F14.1	3.58	0.000385	0.0419	0.36	0.16	Breast cancer;	chr5:56858020	chr5:56927874~56929573:+
LUAD	cis	rs442309	0.875	rs382424	ENSG00000238280.1	RP11-436D10.3	-3.58	0.000385	0.0419	-0.19	-0.16	Vogt-Koyanagi-Harada syndrome;	chr10:62730014	chr10:62793562~62805887:-
LUAD	cis	rs708547	0.647	rs1277308	ENSG00000269949.1	RP11-738E22.3	3.58	0.000385	0.0419	0.21	0.16	Response to bleomycin (chromatid breaks);	chr4:57031698	chr4:56960927~56961373:-
LUAD	cis	rs7077256	0.564	rs2306264	ENSG00000272767.1	JMJD1C-AS1	3.58	0.000385	0.0419	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63194199	chr10:63465229~63466563:+
LUAD	cis	rs2228479	0.717	rs11649210	ENSG00000222019.6	URAHP	3.58	0.000385	0.0419	0.19	0.16	Skin colour saturation;	chr16:89740825	chr16:90039761~90047773:-
LUAD	cis	rs2115630	0.846	rs8024538	ENSG00000254414.1	RP11-182J1.1	-3.58	0.000385	0.0419	-0.17	-0.16	P wave terminal force;	chr15:84825188	chr15:84631898~84633987:-
LUAD	cis	rs9309473	1	rs7594511	ENSG00000230002.2	ALMS1-IT1	3.58	0.000385	0.0419	0.2	0.16	Metabolite levels;	chr2:73454512	chr2:73456764~73459484:+
LUAD	cis	rs4811196	0.536	rs238308	ENSG00000226144.2	RPS27AP3	3.58	0.000385	0.0419	0.16	0.16	Bone mineral density;	chr20:37786624	chr20:37049254~37049707:+
LUAD	cis	rs2018683	0.803	rs12700920	ENSG00000272568.4	CTB-113D17.1	3.58	0.000385	0.0419	0.18	0.16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28945307	chr7:28979967~29013367:+
LUAD	cis	rs2018683	0.933	rs12536127	ENSG00000272568.4	CTB-113D17.1	3.58	0.000385	0.0419	0.18	0.16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28946350	chr7:28979967~29013367:+
LUAD	cis	rs453301	0.598	rs10104303	ENSG00000233609.3	RP11-62H7.2	3.58	0.000385	0.0419	0.13	0.16	Joint mobility (Beighton score);	chr8:8977018	chr8:8961200~8979025:+
LUAD	cis	rs950169	0.544	rs2036949	ENSG00000254414.1	RP11-182J1.1	3.58	0.000385	0.0419	0.21	0.16	Schizophrenia;	chr15:84620374	chr15:84631898~84633987:-
LUAD	cis	rs11640436	0.584	rs1428853	ENSG00000261707.1	RP11-264M12.2	-3.58	0.000385	0.0419	-0.17	-0.16	Lobe attachment (rater-scored or self-reported);	chr16:77274704	chr16:77741468~77743000:-
LUAD	cis	rs11951515	0.509	rs12521249	ENSG00000248240.1	RP11-159F24.5	3.58	0.000385	0.042	0.17	0.16	Metabolite levels  (X-11787);	chr5:43558527	chr5:43515274~43525310:+
LUAD	cis	rs2239547	0.563	rs9839035	ENSG00000243224.1	RP5-1157M23.2	-3.58	0.000385	0.042	-0.18	-0.16	Schizophrenia;	chr3:52875861	chr3:52239258~52241097:+
LUAD	cis	rs6452524	0.562	rs10474080	ENSG00000281327.1	LINC01338	3.58	0.000385	0.042	0.17	0.16	Hypertension (SNP x SNP interaction);	chr5:83078300	chr5:82850864~82859836:-
LUAD	cis	rs12681963	0.702	rs12547330	ENSG00000271869.1	RP11-51J9.5	-3.58	0.000385	0.042	-0.17	-0.16	Migraine;	chr8:30083637	chr8:30155830~30156232:-
LUAD	cis	rs10829156	0.57	rs7904365	ENSG00000240291.1	RP11-499P20.2	3.58	0.000386	0.042	0.15	0.16	Sudden cardiac arrest;	chr10:18542375	chr10:18513115~18545651:-
LUAD	cis	rs647161	0.616	rs647283	ENSG00000247627.2	MTND4P12	-3.58	0.000386	0.042	-0.2	-0.16	Colorectal cancer;	chr5:135151537	chr5:134926660~134928036:-
LUAD	cis	rs10510102	0.935	rs12240893	ENSG00000276742.1	RP11-500G22.4	3.57	0.000386	0.042	0.27	0.16	Breast cancer;	chr10:121870572	chr10:121956782~121957098:+
LUAD	cis	rs10510102	0.935	rs11200203	ENSG00000276742.1	RP11-500G22.4	3.57	0.000386	0.042	0.27	0.16	Breast cancer;	chr10:121874014	chr10:121956782~121957098:+
LUAD	cis	rs1431005	0.963	rs6553064	ENSG00000250658.1	RP11-138B4.1	3.57	0.000386	0.042	0.2	0.16	Response to statin therapy;	chr4:187423507	chr4:187304083~187309682:-
LUAD	cis	rs9437689	0.714	rs7537374	ENSG00000235565.1	RP11-86H7.7	-3.57	0.000386	0.042	-0.2	-0.16	Phospholipid levels (plasma);	chr1:95019868	chr1:94621151~94624184:-
LUAD	cis	rs6951245	1	rs11770909	ENSG00000224079.1	AC091729.7	-3.57	0.000386	0.042	-0.25	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1047080	chr7:1074450~1078036:+
LUAD	cis	rs6951245	1	rs74785791	ENSG00000224079.1	AC091729.7	-3.57	0.000386	0.042	-0.25	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1048858	chr7:1074450~1078036:+
LUAD	cis	rs6951245	1	rs74366004	ENSG00000224079.1	AC091729.7	-3.57	0.000386	0.042	-0.25	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1048994	chr7:1074450~1078036:+
LUAD	cis	rs6951245	1	rs77702926	ENSG00000224079.1	AC091729.7	-3.57	0.000386	0.042	-0.25	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1049202	chr7:1074450~1078036:+
LUAD	cis	rs853679	0.527	rs707907	ENSG00000176933.5	TOB2P1	-3.57	0.000386	0.042	-0.18	-0.16	Depression;	chr6:28323463	chr6:28217643~28218634:-
LUAD	cis	rs2295359	1	rs10889661	ENSG00000275678.1	RP4-547N15.3	-3.57	0.000386	0.042	-0.17	-0.16	Psoriasis;	chr1:67159626	chr1:67121605~67123956:-
LUAD	cis	rs6502050	0.835	rs66531647	ENSG00000266654.1	RP11-1376P16.1	-3.57	0.000386	0.042	-0.17	-0.16	Life satisfaction;	chr17:82131146	chr17:82160056~82160452:+
LUAD	cis	rs703842	0.963	rs2291617	ENSG00000245651.2	RP11-620J15.2	3.57	0.000386	0.042	0.17	0.16	Multiple sclerosis;	chr12:57772620	chr12:57869835~57896482:-
LUAD	cis	rs9876781	1	rs9815103	ENSG00000229759.1	MRPS18AP1	3.57	0.000386	0.042	0.16	0.16	Longevity;	chr3:48372725	chr3:48256350~48256938:-
LUAD	cis	rs9381040	0.655	rs2268187	ENSG00000161912.16	ADCY10P1	3.57	0.000386	0.042	0.14	0.16	Alzheimer's disease (late onset);	chr6:41075254	chr6:41101022~41140835:+
LUAD	cis	rs9381040	0.655	rs9381032	ENSG00000161912.16	ADCY10P1	3.57	0.000386	0.042	0.14	0.16	Alzheimer's disease (late onset);	chr6:41077247	chr6:41101022~41140835:+
LUAD	cis	rs9400467	0.506	rs10457238	ENSG00000255389.1	C6orf3	3.57	0.000386	0.042	0.21	0.16	Amino acid levels;Blood metabolite levels;	chr6:111441390	chr6:111599875~111602295:+
LUAD	cis	rs4713118	0.662	rs9357060	ENSG00000280107.1	AL022393.9	-3.57	0.000386	0.042	-0.21	-0.16	Parkinson's disease;	chr6:28056708	chr6:28170845~28172521:+
LUAD	cis	rs4713118	0.662	rs9468271	ENSG00000280107.1	AL022393.9	-3.57	0.000386	0.042	-0.21	-0.16	Parkinson's disease;	chr6:28056792	chr6:28170845~28172521:+
LUAD	cis	rs7246657	0.525	rs10401417	ENSG00000267682.1	CTD-3220F14.2	3.57	0.000386	0.042	0.21	0.16	Coronary artery calcification;	chr19:36976638	chr19:37337236~37337743:+
LUAD	cis	rs741677	0.893	rs1978963	ENSG00000231784.7	DBIL5P	3.57	0.000386	0.042	0.2	0.16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr17:580592	chr17:752660~755336:+
LUAD	cis	rs9314614	0.899	rs2977802	ENSG00000245857.2	GS1-24F4.2	-3.57	0.000386	0.042	-0.18	-0.16	White blood cell count (basophil);IgA nephropathy;	chr8:6837323	chr8:6835554~6885276:+
LUAD	cis	rs4662750	0.536	rs4662744	ENSG00000236682.1	AC068282.3	3.57	0.000386	0.042	0.2	0.16	Renal cell carcinoma;	chr2:127593390	chr2:127389130~127400580:+
LUAD	cis	rs2837828	0.899	rs998120	ENSG00000226496.2	LINC00323	3.57	0.000386	0.042	0.2	0.16	Neutrophil count;	chr21:40799325	chr21:41141493~41148133:-
LUAD	cis	rs2749097	0.609	rs10889435	ENSG00000244256.3	RN7SL130P	-3.57	0.000386	0.042	-0.21	-0.16	Alcohol consumption (transferrin glycosylation);	chr1:63648285	chr1:63655743~63656047:+
LUAD	cis	rs2408955	0.541	rs11168428	ENSG00000257763.1	OR5BK1P	-3.57	0.000386	0.042	-0.16	-0.16	Glycated hemoglobin levels;	chr12:48153345	chr12:48355792~48356614:-
LUAD	cis	rs6736093	0.966	rs13020304	ENSG00000207383.1	Y_RNA	-3.57	0.000386	0.042	-0.21	-0.16	Coronary artery disease;	chr2:111983958	chr2:112579484~112579584:-
LUAD	cis	rs4423214	0.84	rs1790339	ENSG00000226627.1	SHANK2-AS1	3.57	0.000386	0.042	0.2	0.16	Vitamin D levels;	chr11:71471715	chr11:70631094~70635490:+
LUAD	cis	rs7829975	0.774	rs1703982	ENSG00000173295.6	FAM86B3P	-3.57	0.000386	0.042	-0.17	-0.16	Mood instability;	chr8:8740878	chr8:8228595~8244865:+
LUAD	cis	rs42490	0.57	rs454561	ENSG00000251136.7	RP11-37B2.1	-3.57	0.000386	0.042	-0.16	-0.16	Leprosy;	chr8:89824387	chr8:89609409~89757727:-
LUAD	cis	rs7665090	0.967	rs228611	ENSG00000251288.2	RP11-10L12.2	3.57	0.000386	0.042	0.19	0.16	Primary biliary cholangitis;	chr4:102640552	chr4:102751401~102752641:+
LUAD	cis	rs4072705	0.934	rs4838194	ENSG00000236643.1	RP11-175D17.3	-3.57	0.000386	0.042	-0.19	-0.16	Menarche (age at onset);	chr9:124580536	chr9:124770123~124772927:+
LUAD	cis	rs2251666	0.765	rs17771656	ENSG00000276641.1	MIR6769A	3.57	0.000386	0.042	0.18	0.16	Cancer;	chr16:4878256	chr16:4671318~4671390:+
LUAD	cis	rs7142881	0.844	rs9972191	ENSG00000258525.1	RP11-829H16.3	3.57	0.000386	0.042	0.19	0.16	Response to iloperidone treatment (QT prolongation);	chr14:31560274	chr14:30876179~30889808:-
LUAD	cis	rs3087591	0.6	rs2952975	ENSG00000263531.1	RP13-753N3.1	-3.57	0.000386	0.042	-0.27	-0.16	Hip circumference;	chr17:31163974	chr17:30863921~30864940:-
LUAD	cis	rs8012947	0.959	rs10137327	ENSG00000279636.2	LINC00216	-3.57	0.000386	0.042	-0.18	-0.16	Alcohol consumption in current drinkers;	chr14:58287183	chr14:58288033~58289158:+
LUAD	cis	rs7942368	1	rs11236924	ENSG00000254632.1	RP11-21L23.4	3.57	0.000386	0.042	0.18	0.16	Endometriosis;	chr11:76756303	chr11:76759916~76768223:-
LUAD	cis	rs3126085	0.877	rs1969019	ENSG00000237975.5	FLG-AS1	-3.57	0.000387	0.042	-0.24	-0.16	Atopic dermatitis;	chr1:152239026	chr1:152168125~152445456:+
LUAD	cis	rs7584330	0.744	rs58223447	ENSG00000222032.1	AC112721.2	3.57	0.000387	0.042	0.21	0.16	Prostate cancer;	chr2:237470001	chr2:237428920~237434822:-
LUAD	cis	rs75804782	0.522	rs11889150	ENSG00000229915.1	AC016999.2	3.57	0.000387	0.0421	0.25	0.16	Chronotype;Morning vs. evening chronotype;	chr2:238415901	chr2:238427077~238427729:-
LUAD	cis	rs7572644	0.537	rs13408504	ENSG00000265706.1	SNORD53_SNORD92	-3.57	0.000387	0.0421	-0.19	-0.16	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);	chr2:28135467	chr2:28927983~28928060:+
LUAD	cis	rs17695224	0.545	rs10500309	ENSG00000269483.1	AC006272.1	3.57	0.000387	0.0421	0.18	0.16	HDL cholesterol;HDL cholesterol levels;	chr19:51829123	chr19:51839924~51843324:-
LUAD	cis	rs17695224	0.545	rs8111469	ENSG00000269483.1	AC006272.1	3.57	0.000387	0.0421	0.18	0.16	HDL cholesterol;HDL cholesterol levels;	chr19:51829272	chr19:51839924~51843324:-
LUAD	cis	rs3772130	1	rs3772128	ENSG00000243544.3	RN7SL172P	3.57	0.000387	0.0421	0.19	0.16	Cognitive performance;	chr3:121626247	chr3:121653994~121654296:-
LUAD	cis	rs73193808	0.901	rs73354869	ENSG00000215533.7	LINC00189	-3.57	0.000387	0.0421	-0.23	-0.16	Coronary artery disease;	chr21:29194964	chr21:29193480~29288205:+
LUAD	cis	rs4845552	0.767	rs17695220	ENSG00000272030.1	RP1-178F15.4	-3.57	0.000387	0.0421	-0.23	-0.16	Hippocampal atrophy;	chr1:153510467	chr1:153631438~153634397:-
LUAD	cis	rs6691170	0.513	rs12137702	ENSG00000228437.4	RP11-400N13.2	3.57	0.000387	0.0421	0.19	0.16	Colorectal cancer;	chr1:221882415	chr1:221966341~221984964:+
LUAD	cis	rs13113518	1	rs1047354	ENSG00000249700.7	SRD5A3-AS1	3.57	0.000387	0.0421	0.16	0.16	Height;	chr4:55429416	chr4:55363971~55395847:-
LUAD	cis	rs13113518	1	rs1056547	ENSG00000249700.7	SRD5A3-AS1	3.57	0.000387	0.0421	0.16	0.16	Height;	chr4:55430596	chr4:55363971~55395847:-
LUAD	cis	rs13113518	1	rs1056545	ENSG00000249700.7	SRD5A3-AS1	3.57	0.000387	0.0421	0.16	0.16	Height;	chr4:55430730	chr4:55363971~55395847:-
LUAD	cis	rs13113518	1	rs5863	ENSG00000249700.7	SRD5A3-AS1	3.57	0.000387	0.0421	0.16	0.16	Height;	chr4:55430740	chr4:55363971~55395847:-
LUAD	cis	rs13113518	0.966	rs6828570	ENSG00000249700.7	SRD5A3-AS1	3.57	0.000387	0.0421	0.16	0.16	Height;	chr4:55431595	chr4:55363971~55395847:-
LUAD	cis	rs13113518	1	rs3749474	ENSG00000249700.7	SRD5A3-AS1	3.57	0.000387	0.0421	0.16	0.16	Height;	chr4:55434518	chr4:55363971~55395847:-
LUAD	cis	rs722599	0.639	rs12882676	ENSG00000279594.1	RP11-950C14.10	3.57	0.000387	0.0421	0.19	0.16	IgG glycosylation;	chr14:74805730	chr14:75011269~75012851:-
LUAD	cis	rs9400467	0.506	rs79720667	ENSG00000255389.1	C6orf3	3.57	0.000387	0.0421	0.22	0.16	Amino acid levels;Blood metabolite levels;	chr6:111458630	chr6:111599875~111602295:+
LUAD	cis	rs2243480	1	rs3885839	ENSG00000189316.3	RP11-797H7.5	3.57	0.000387	0.0421	0.27	0.16	Diabetic kidney disease;	chr7:65825416	chr7:64888527~64890100:-
LUAD	cis	rs2243480	0.901	rs3813708	ENSG00000189316.3	RP11-797H7.5	3.57	0.000387	0.0421	0.27	0.16	Diabetic kidney disease;	chr7:65840645	chr7:64888527~64890100:-
LUAD	cis	rs2243480	1	rs73142122	ENSG00000189316.3	RP11-797H7.5	3.57	0.000387	0.0421	0.27	0.16	Diabetic kidney disease;	chr7:65846311	chr7:64888527~64890100:-
LUAD	cis	rs2243480	0.901	rs73142137	ENSG00000189316.3	RP11-797H7.5	3.57	0.000387	0.0421	0.27	0.16	Diabetic kidney disease;	chr7:65878455	chr7:64888527~64890100:-
LUAD	cis	rs7537765	0.602	rs6701960	ENSG00000242349.4	NPPA-AS1	3.57	0.000387	0.0421	0.3	0.16	QRS complex (12-leadsum);	chr1:11812338	chr1:11841017~11848079:+
LUAD	cis	rs7537765	0.696	rs6687229	ENSG00000242349.4	NPPA-AS1	3.57	0.000387	0.0421	0.3	0.16	QRS complex (12-leadsum);	chr1:11812599	chr1:11841017~11848079:+
LUAD	cis	rs7537765	0.696	rs72640249	ENSG00000242349.4	NPPA-AS1	3.57	0.000387	0.0421	0.3	0.16	QRS complex (12-leadsum);	chr1:11812927	chr1:11841017~11848079:+
LUAD	cis	rs7537765	0.696	rs72640251	ENSG00000242349.4	NPPA-AS1	3.57	0.000387	0.0421	0.3	0.16	QRS complex (12-leadsum);	chr1:11812963	chr1:11841017~11848079:+
LUAD	cis	rs7537765	0.649	rs72640252	ENSG00000242349.4	NPPA-AS1	3.57	0.000387	0.0421	0.3	0.16	QRS complex (12-leadsum);	chr1:11812995	chr1:11841017~11848079:+
LUAD	cis	rs7537765	0.696	rs72640253	ENSG00000242349.4	NPPA-AS1	3.57	0.000387	0.0421	0.3	0.16	QRS complex (12-leadsum);	chr1:11812998	chr1:11841017~11848079:+
LUAD	cis	rs7537765	0.696	rs17376286	ENSG00000242349.4	NPPA-AS1	3.57	0.000387	0.0421	0.3	0.16	QRS complex (12-leadsum);	chr1:11813928	chr1:11841017~11848079:+
LUAD	cis	rs7537765	0.696	rs17037432	ENSG00000242349.4	NPPA-AS1	3.57	0.000387	0.0421	0.3	0.16	QRS complex (12-leadsum);	chr1:11814097	chr1:11841017~11848079:+
LUAD	cis	rs7537765	0.696	rs17037434	ENSG00000242349.4	NPPA-AS1	3.57	0.000387	0.0421	0.3	0.16	QRS complex (12-leadsum);	chr1:11814121	chr1:11841017~11848079:+
LUAD	cis	rs7537765	0.696	rs17037435	ENSG00000242349.4	NPPA-AS1	3.57	0.000387	0.0421	0.3	0.16	QRS complex (12-leadsum);	chr1:11814132	chr1:11841017~11848079:+
LUAD	cis	rs7537765	0.557	rs114083374	ENSG00000242349.4	NPPA-AS1	3.57	0.000387	0.0421	0.3	0.16	QRS complex (12-leadsum);	chr1:11814374	chr1:11841017~11848079:+
LUAD	cis	rs7142881	0.815	rs11156692	ENSG00000258525.1	RP11-829H16.3	-3.57	0.000387	0.0421	-0.18	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31586343	chr14:30876179~30889808:-
LUAD	cis	rs526231	0.578	rs17154821	ENSG00000250682.4	LINC00491	3.57	0.000387	0.0421	0.19	0.16	Primary biliary cholangitis;	chr5:102905637	chr5:102609156~102671559:-
LUAD	cis	rs10129255	0.536	rs6576201	ENSG00000278473.1	IGHV3-41	-3.57	0.000387	0.0421	-0.1	-0.16	Kawasaki disease;	chr14:106683696	chr14:106443133~106443583:-
LUAD	cis	rs7246657	0.941	rs67293224	ENSG00000226686.6	LINC01535	-3.57	0.000387	0.0421	-0.25	-0.16	Coronary artery calcification;	chr19:37312346	chr19:37251912~37265535:+
LUAD	cis	rs4908768	0.906	rs12117910	ENSG00000232912.4	RP5-1115A15.1	-3.57	0.000387	0.0421	-0.19	-0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8496893	chr1:8424645~8434838:+
LUAD	cis	rs4908768	0.906	rs12403339	ENSG00000232912.4	RP5-1115A15.1	-3.57	0.000387	0.0421	-0.19	-0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8498232	chr1:8424645~8434838:+
LUAD	cis	rs4908768	0.906	rs11584261	ENSG00000232912.4	RP5-1115A15.1	-3.57	0.000387	0.0421	-0.19	-0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8500306	chr1:8424645~8434838:+
LUAD	cis	rs4727963	0.777	rs4262262	ENSG00000240499.6	RP5-1101C3.1	3.57	0.000387	0.0421	0.14	0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);	chr7:123061310	chr7:122328469~122440388:+
LUAD	cis	rs13016963	0.546	rs11898821	ENSG00000234842.1	AC007163.8	-3.57	0.000387	0.0421	-0.18	-0.16	Esophageal squamous cell carcinoma;Melanoma;	chr2:201334965	chr2:201549631~201550307:+
LUAD	cis	rs6500602	0.727	rs8051389	ENSG00000280063.1	RP11-295D4.3	3.57	0.000387	0.0421	0.1	0.16	Schizophrenia;	chr16:4520569	chr16:4346694~4348648:-
LUAD	cis	rs6500602	0.702	rs4786511	ENSG00000280063.1	RP11-295D4.3	3.57	0.000387	0.0421	0.1	0.16	Schizophrenia;	chr16:4521644	chr16:4346694~4348648:-
LUAD	cis	rs11122895	0.967	rs11677976	ENSG00000236307.2	EEF1E1P1	3.57	0.000387	0.0421	0.18	0.16	Allergic sensitization;	chr2:111710641	chr2:111887914~111888741:+
LUAD	cis	rs9467773	0.62	rs6925087	ENSG00000261353.1	CTA-14H9.5	-3.57	0.000387	0.0421	-0.18	-0.16	Intelligence (multi-trait analysis);	chr6:26592625	chr6:26527063~26527404:+
LUAD	cis	rs9921338	0.961	rs7206749	ENSG00000263080.1	RP11-485G7.5	3.57	0.000387	0.0421	0.22	0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11283065	chr16:11341809~11345211:-
LUAD	cis	rs9921338	0.961	rs55707838	ENSG00000263080.1	RP11-485G7.5	3.57	0.000387	0.0421	0.22	0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11284218	chr16:11341809~11345211:-
LUAD	cis	rs2625529	0.59	rs8023703	ENSG00000260173.1	RP11-2I17.4	3.57	0.000387	0.0421	0.21	0.16	Red blood cell count;	chr15:72211718	chr15:72140504~72155459:-
LUAD	cis	rs1799949	0.965	rs11650913	ENSG00000267340.1	RP11-242D8.3	3.57	0.000387	0.0421	0.17	0.16	Menopause (age at onset);	chr17:43179580	chr17:43169880~43170077:-
LUAD	cis	rs1799949	1	rs12936831	ENSG00000267340.1	RP11-242D8.3	3.57	0.000387	0.0421	0.17	0.16	Menopause (age at onset);	chr17:43179799	chr17:43169880~43170077:-
LUAD	cis	rs11671005	0.735	rs34188294	ENSG00000268543.1	CTD-2619J13.16	-3.57	0.000387	0.0421	-0.23	-0.16	Mean platelet volume;	chr19:58408190	chr19:58418560~58419310:+
LUAD	cis	rs2708977	0.609	rs611943	ENSG00000237510.6	AC008268.2	-3.57	0.000387	0.0421	-0.21	-0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96401336	chr2:95789654~95800166:+
LUAD	cis	rs9562987	0.671	rs2182784	ENSG00000123201.13	GUCY1B2	-3.57	0.000388	0.0421	-0.22	-0.16	Breast cancer;	chr13:50559285	chr13:50994511~51080862:-
LUAD	cis	rs1044826	0.692	rs184155	ENSG00000214280.3	RP11-553K23.2	3.57	0.000388	0.0421	0.18	0.16	Obesity-related traits;	chr3:139510930	chr3:139582928~139583593:-
LUAD	cis	rs67981189	0.896	rs58133478	ENSG00000269927.1	RP6-91H8.3	3.57	0.000388	0.0421	0.2	0.16	Schizophrenia;	chr14:71058370	chr14:71141125~71143253:-
LUAD	cis	rs67981189	0.896	rs34763296	ENSG00000269927.1	RP6-91H8.3	3.57	0.000388	0.0421	0.2	0.16	Schizophrenia;	chr14:71083458	chr14:71141125~71143253:-
LUAD	cis	rs12440869	1	rs28571147	ENSG00000270964.1	RP11-502I4.3	3.57	0.000388	0.0421	0.18	0.16	Peak velocity of the mitral A-wave;	chr15:67336311	chr15:67541072~67542604:-
LUAD	cis	rs2985684	0.894	rs2883436	ENSG00000278009.1	RP11-649E7.8	3.57	0.000388	0.0421	0.21	0.16	Carotid intima media thickness;	chr14:49547104	chr14:49601011~49601124:-
LUAD	cis	rs564343	0.583	rs571374	ENSG00000254614.2	AP003068.23	3.57	0.000388	0.0421	0.22	0.16	Obesity (early onset extreme);	chr11:66050121	chr11:65177606~65181834:-
LUAD	cis	rs394563	0.591	rs11155641	ENSG00000216906.2	RP11-350J20.9	-3.57	0.000388	0.0421	-0.19	-0.16	Dupuytren's disease;	chr6:149327459	chr6:149904243~149906418:+
LUAD	cis	rs4927850	1	rs10881563	ENSG00000278820.1	AC024937.1	3.57	0.000388	0.0421	0.15	0.16	Pancreatic cancer;	chr3:196023354	chr3:195960500~195960612:-
LUAD	cis	rs6430585	0.583	rs12475516	ENSG00000226806.1	AC011893.3	3.57	0.000388	0.0421	0.22	0.16	Corneal structure;	chr2:135803191	chr2:135820191~135823087:+
LUAD	cis	rs6430585	0.583	rs2304370	ENSG00000226806.1	AC011893.3	3.57	0.000388	0.0421	0.22	0.16	Corneal structure;	chr2:135804165	chr2:135820191~135823087:+
LUAD	cis	rs2287641	1	rs12623320	ENSG00000272156.1	RP11-477N3.1	3.57	0.000388	0.0421	0.4	0.16	Cannabis dependence symptom count;	chr2:54126417	chr2:54082554~54085066:+
LUAD	cis	rs9341808	0.718	rs3828754	ENSG00000233967.5	RP11-250B2.3	3.57	0.000388	0.0421	0.16	0.16	Sitting height ratio;	chr6:80190923	chr6:80443344~80465927:+
LUAD	cis	rs9341808	0.718	rs10943696	ENSG00000233967.5	RP11-250B2.3	3.57	0.000388	0.0421	0.16	0.16	Sitting height ratio;	chr6:80191555	chr6:80443344~80465927:+
LUAD	cis	rs9341808	0.718	rs6910201	ENSG00000233967.5	RP11-250B2.3	3.57	0.000388	0.0421	0.16	0.16	Sitting height ratio;	chr6:80195221	chr6:80443344~80465927:+
LUAD	cis	rs9341808	0.69	rs9448909	ENSG00000233967.5	RP11-250B2.3	3.57	0.000388	0.0421	0.16	0.16	Sitting height ratio;	chr6:80199314	chr6:80443344~80465927:+
LUAD	cis	rs8046148	0.666	rs8046856	ENSG00000279356.1	RP11-429P3.8	3.57	0.000388	0.0421	0.16	0.16	Testicular germ cell tumor;	chr16:50064976	chr16:50072862~50074986:+
LUAD	cis	rs7630852	0.965	rs6774504	ENSG00000272359.1	U4	3.57	0.000388	0.0422	0.17	0.16	Eosinophil counts;	chr3:196784021	chr3:196747192~196747324:-
LUAD	cis	rs2625529	0.586	rs2306489	ENSG00000260173.1	RP11-2I17.4	3.57	0.000388	0.0422	0.19	0.16	Red blood cell count;	chr15:71935130	chr15:72140504~72155459:-
LUAD	cis	rs55702914	0.712	rs12616329	ENSG00000222017.1	AC011997.1	-3.57	0.000388	0.0422	-0.2	-0.16	Major depression and alcohol dependence;	chr2:197283905	chr2:197693106~197774823:+
LUAD	cis	rs9549260	0.816	rs7328594	ENSG00000168852.11	TPTE2P5	3.57	0.000388	0.0422	0.16	0.16	Red blood cell count;	chr13:40679627	chr13:40822296~40921749:-
LUAD	cis	rs748404	0.666	rs7181634	ENSG00000249839.1	AC011330.5	-3.57	0.000388	0.0422	-0.25	-0.16	Lung cancer;	chr15:43351703	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.666	rs55748552	ENSG00000249839.1	AC011330.5	-3.57	0.000388	0.0422	-0.25	-0.16	Lung cancer;	chr15:43359428	chr15:43663654~43684339:-
LUAD	cis	rs7107174	1	rs1567890	ENSG00000251323.2	RP11-452H21.4	3.57	0.000388	0.0422	0.21	0.16	Testicular germ cell tumor;	chr11:78390654	chr11:78423982~78429836:-
LUAD	cis	rs7107174	0.892	rs1567891	ENSG00000251323.2	RP11-452H21.4	3.57	0.000388	0.0422	0.21	0.16	Testicular germ cell tumor;	chr11:78390939	chr11:78423982~78429836:-
LUAD	cis	rs7107174	1	rs7128666	ENSG00000251323.2	RP11-452H21.4	3.57	0.000388	0.0422	0.21	0.16	Testicular germ cell tumor;	chr11:78391317	chr11:78423982~78429836:-
LUAD	cis	rs7107174	0.892	rs12284390	ENSG00000251323.2	RP11-452H21.4	3.57	0.000388	0.0422	0.21	0.16	Testicular germ cell tumor;	chr11:78392856	chr11:78423982~78429836:-
LUAD	cis	rs7107174	1	rs10793311	ENSG00000251323.2	RP11-452H21.4	3.57	0.000388	0.0422	0.21	0.16	Testicular germ cell tumor;	chr11:78393353	chr11:78423982~78429836:-
LUAD	cis	rs7107174	1	rs10899491	ENSG00000251323.2	RP11-452H21.4	3.57	0.000388	0.0422	0.21	0.16	Testicular germ cell tumor;	chr11:78395259	chr11:78423982~78429836:-
LUAD	cis	rs4819052	0.819	rs34818688	ENSG00000215447.6	BX322557.10	-3.57	0.000388	0.0422	-0.19	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252501	chr21:45288052~45291738:+
LUAD	cis	rs6951245	0.744	rs1133122	ENSG00000226291.1	AC091729.8	-3.57	0.000388	0.0422	-0.27	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1152936	chr7:1080863~1082178:+
LUAD	cis	rs10214930	0.597	rs720437	ENSG00000235574.1	AC073150.6	3.57	0.000388	0.0422	0.23	0.16	Hypospadias;	chr7:27878796	chr7:27491682~27492765:-
LUAD	cis	rs984222	0.677	rs6428792	ENSG00000226172.2	RP4-712E4.1	-3.57	0.000388	0.0422	-0.18	-0.16	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119114244	chr1:119000344~119001392:-
LUAD	cis	rs2274273	0.588	rs2297816	ENSG00000258413.1	RP11-665C16.6	-3.57	0.000388	0.0422	-0.22	-0.16	Protein biomarker;	chr14:55366320	chr14:55262767~55272075:-
LUAD	cis	rs2749097	0.735	rs10889438	ENSG00000244256.3	RN7SL130P	-3.57	0.000388	0.0422	-0.22	-0.16	Alcohol consumption (transferrin glycosylation);	chr1:63695232	chr1:63655743~63656047:+
LUAD	cis	rs62246343	0.605	rs3898760	ENSG00000206573.7	THUMPD3-AS1	-3.57	0.000388	0.0422	-0.15	-0.16	Fibrinogen levels;	chr3:9453435	chr3:9349689~9398579:-
LUAD	cis	rs911555	0.755	rs2756132	ENSG00000259775.1	RP11-45P15.4	3.57	0.000388	0.0422	0.21	0.16	Intelligence (multi-trait analysis);	chr14:103501483	chr14:103331674~103332367:-
LUAD	cis	rs9381040	0.61	rs2294694	ENSG00000161912.16	ADCY10P1	3.57	0.000388	0.0422	0.14	0.16	Alzheimer's disease (late onset);	chr6:41078438	chr6:41101022~41140835:+
LUAD	cis	rs1044826	1	rs9818691	ENSG00000214280.3	RP11-553K23.2	-3.57	0.000388	0.0422	-0.19	-0.16	Obesity-related traits;	chr3:139394357	chr3:139582928~139583593:-
LUAD	cis	rs9921338	0.887	rs7189044	ENSG00000263080.1	RP11-485G7.5	3.57	0.000388	0.0422	0.21	0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11348339	chr16:11341809~11345211:-
LUAD	cis	rs935334	1	rs4903386	ENSG00000258454.1	RP11-361H10.3	3.57	0.000388	0.0422	0.23	0.16	Blood pressure;	chr14:76203315	chr14:76235817~76263474:+
LUAD	cis	rs11168351	0.926	rs10875719	ENSG00000226413.2	OR8T1P	3.57	0.000388	0.0422	0.21	0.16	Bipolar disorder and schizophrenia;	chr12:48017375	chr12:48442030~48442947:-
LUAD	cis	rs4795519	1	rs6505073	ENSG00000266313.1	RP11-173M1.4	3.57	0.000388	0.0422	0.2	0.16	Chronic myeloid leukemia;	chr17:27070943	chr17:27333256~27348491:+
LUAD	cis	rs214785	1	rs214796	ENSG00000234684.5	SDCBP2-AS1	-3.57	0.000388	0.0422	-0.19	-0.16	Basal cell carcinoma;	chr20:2305697	chr20:1325405~1378734:+
LUAD	cis	rs77633900	0.892	rs2469552	ENSG00000196274.5	Metazoa_SRP	3.57	0.000388	0.0422	0.21	0.16	Glioma;Non-glioblastoma glioma;	chr15:76323140	chr15:76230048~76230390:-
LUAD	cis	rs1799949	1	rs8074136	ENSG00000267340.1	RP11-242D8.3	3.57	0.000388	0.0422	0.17	0.16	Menopause (age at onset);	chr17:43190296	chr17:43169880~43170077:-
LUAD	cis	rs9925964	0.933	rs2303222	ENSG00000232748.3	RP11-196G11.6	3.57	0.000388	0.0422	0.19	0.16	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31074149	chr16:31056460~31062803:+
LUAD	cis	rs4965272	1	rs4965557	ENSG00000259219.1	CTD-3076O17.2	3.57	0.000388	0.0422	0.2	0.16	Gastroesophageal reflux disease;	chr15:100043512	chr15:99976481~99980774:+
LUAD	cis	rs2287641	1	rs2112126	ENSG00000272156.1	RP11-477N3.1	3.57	0.000389	0.0422	0.4	0.16	Cannabis dependence symptom count;	chr2:54117772	chr2:54082554~54085066:+
LUAD	cis	rs2702164	1	rs1606872	ENSG00000240661.1	RP11-174O3.3	-3.57	0.000389	0.0422	-0.19	-0.16	Gut microbiome composition (winter);	chr3:120371869	chr3:120349510~120367998:+
LUAD	cis	rs2702164	1	rs1606873	ENSG00000240661.1	RP11-174O3.3	-3.57	0.000389	0.0422	-0.19	-0.16	Gut microbiome composition (winter);	chr3:120371950	chr3:120349510~120367998:+
LUAD	cis	rs2902440	0.502	rs4655527	ENSG00000275678.1	RP4-547N15.3	-3.57	0.000389	0.0422	-0.16	-0.16	Crohn's disease;	chr1:67198808	chr1:67121605~67123956:-
LUAD	cis	rs6736093	0.966	rs13003919	ENSG00000207383.1	Y_RNA	3.57	0.000389	0.0422	0.21	0.16	Coronary artery disease;	chr2:111996373	chr2:112579484~112579584:-
LUAD	cis	rs7242404	0.57	rs1833325	ENSG00000267654.1	RP11-973H7.4	3.57	0.000389	0.0422	0.19	0.16	Interleukin-9 levels;Macrophage inflammatory protein 1a levels;	chr18:12755582	chr18:12739490~12749421:-
LUAD	cis	rs17680741	0.697	rs12264252	ENSG00000226659.1	RP11-137H2.4	3.57	0.000389	0.0422	0.28	0.16	Coronary artery disease;	chr10:80517585	chr10:80529597~80535942:-
LUAD	cis	rs4386084	1	rs12148767	ENSG00000242737.1	RP11-562A8.1	-3.57	0.000389	0.0422	-0.21	-0.16	Basophil percentage of granulocytes;Basophil percentage of white cells;	chr15:49932114	chr15:50466738~50467096:+
LUAD	cis	rs11992162	1	rs7460395	ENSG00000251402.3	FAM90A25P	3.57	0.000389	0.0422	0.19	0.16	Monocyte count;	chr8:11977866	chr8:12415080~12418090:-
LUAD	cis	rs2243480	0.901	rs778687	ENSG00000222364.1	RNU6-96P	-3.57	0.000389	0.0422	-0.27	-0.16	Diabetic kidney disease;	chr7:66370832	chr7:66395191~66395286:+
LUAD	cis	rs2243480	1	rs778704	ENSG00000222364.1	RNU6-96P	-3.57	0.000389	0.0422	-0.27	-0.16	Diabetic kidney disease;	chr7:66398480	chr7:66395191~66395286:+
LUAD	cis	rs2243480	0.901	rs778693	ENSG00000222364.1	RNU6-96P	-3.57	0.000389	0.0422	-0.27	-0.16	Diabetic kidney disease;	chr7:66407358	chr7:66395191~66395286:+
LUAD	cis	rs2243480	1	rs778691	ENSG00000222364.1	RNU6-96P	-3.57	0.000389	0.0422	-0.27	-0.16	Diabetic kidney disease;	chr7:66408105	chr7:66395191~66395286:+
LUAD	cis	rs2243480	1	rs13235972	ENSG00000222364.1	RNU6-96P	-3.57	0.000389	0.0422	-0.27	-0.16	Diabetic kidney disease;	chr7:66418618	chr7:66395191~66395286:+
LUAD	cis	rs2243480	1	rs34192067	ENSG00000222364.1	RNU6-96P	-3.57	0.000389	0.0422	-0.27	-0.16	Diabetic kidney disease;	chr7:66422670	chr7:66395191~66395286:+
LUAD	cis	rs6832769	1	rs6812042	ENSG00000272969.1	RP11-528I4.2	3.57	0.000389	0.0422	0.17	0.16	Personality dimensions;	chr4:55529912	chr4:55547112~55547889:+
LUAD	cis	rs2299587	0.623	rs7816738	ENSG00000253671.1	RP11-806O11.1	-3.57	0.000389	0.0422	-0.17	-0.16	Economic and political preferences;	chr8:17910973	chr8:17808941~17820868:+
LUAD	cis	rs854765	0.647	rs2974998	ENSG00000223979.2	SMCR2	-3.57	0.000389	0.0422	-0.19	-0.16	Total body bone mineral density;	chr17:18092305	chr17:17674026~17677688:-
LUAD	cis	rs748404	0.63	rs35278805	ENSG00000249839.1	AC011330.5	-3.57	0.000389	0.0422	-0.25	-0.16	Lung cancer;	chr15:43361124	chr15:43663654~43684339:-
LUAD	cis	rs748404	0.666	rs35160541	ENSG00000249839.1	AC011330.5	-3.57	0.000389	0.0422	-0.25	-0.16	Lung cancer;	chr15:43365601	chr15:43663654~43684339:-
LUAD	cis	rs7503168	0.558	rs12945980	ENSG00000267592.1	CTC-507E2.2	3.57	0.000389	0.0422	0.34	0.16	Plateletcrit;	chr17:35603002	chr17:35596904~35597128:-
LUAD	cis	rs6860806	0.507	rs272878	ENSG00000263597.1	MIR3936	-3.57	0.000389	0.0422	-0.18	-0.16	Breast cancer;	chr5:132336076	chr5:132365490~132365599:-
LUAD	cis	rs848087	0.967	rs712326	ENSG00000258661.1	RP11-964E11.2	-3.57	0.000389	0.0422	-0.19	-0.16	Breast cancer;	chr14:36769620	chr14:36647083~36658801:-
LUAD	cis	rs1876905	0.68	rs3749867	ENSG00000230177.1	RP5-1112D6.4	-3.57	0.000389	0.0422	-0.19	-0.16	Mean corpuscular hemoglobin;	chr6:111103615	chr6:111277932~111278742:+
LUAD	cis	rs6001482	0.679	rs8142710	ENSG00000253818.1	IGLV1-41	-3.57	0.000389	0.0422	-0.17	-0.16	Diastolic blood pressure;	chr22:22233044	chr22:22404207~22404721:+
LUAD	cis	rs6430585	0.583	rs12373779	ENSG00000226806.1	AC011893.3	3.57	0.000389	0.0423	0.24	0.16	Corneal structure;	chr2:135829270	chr2:135820191~135823087:+
LUAD	cis	rs3120667	0.72	rs1923501	ENSG00000237975.5	FLG-AS1	3.57	0.000389	0.0423	0.28	0.16	Eating disorders;	chr1:152438677	chr1:152168125~152445456:+
LUAD	cis	rs7613875	0.521	rs4688754	ENSG00000234667.1	ACTBP13	3.57	0.000389	0.0423	0.18	0.16	Body mass index;	chr3:50037208	chr3:49873347~49877980:-
LUAD	cis	rs1043099	0.731	rs5763923	ENSG00000279699.1	RP1-102K2.9	-3.57	0.000389	0.0423	-0.25	-0.16	Rheumatoid arthritis;	chr22:30279228	chr22:30275215~30276951:-
LUAD	cis	rs2348418	0.765	rs2078016	ENSG00000244712.1	RP11-874G11.1	-3.57	0.000389	0.0423	-0.19	-0.16	Lung function (FEV1);Lung function (FVC);	chr12:28180174	chr12:28564678~28565141:-
LUAD	cis	rs10774547	1	rs4767891	ENSG00000278344.1	RP11-18C24.8	3.57	0.000389	0.0423	0.22	0.16	Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);Reading disability or specific language impairment (pleiotropy);	chr12:120425619	chr12:120500735~120501090:-
LUAD	cis	rs4824093	0.541	rs8142132	ENSG00000278869.1	CITF22-49E9.3	3.57	0.000389	0.0423	0.35	0.16	Amyotrophic lateral sclerosis (sporadic);	chr22:49817646	chr22:49933198~49934074:-
LUAD	cis	rs60695258	0.55	rs388401	ENSG00000251411.1	RP11-397E7.4	3.57	0.000389	0.0423	0.17	0.16	Hematocrit;	chr4:87053263	chr4:86913266~86914817:-
LUAD	cis	rs8014252	1	rs1959484	ENSG00000259158.2	ADAM20P1	-3.57	0.000389	0.0423	-0.23	-0.16	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70485990	chr14:70468881~70483756:-
LUAD	cis	rs334353	0.798	rs385057	ENSG00000255145.2	STX17-AS1	-3.57	0.000389	0.0423	-0.22	-0.16	Age-related macular degeneration;	chr9:99160130	chr9:99886322~99906601:-
LUAD	cis	rs7142881	0.815	rs12882060	ENSG00000258525.1	RP11-829H16.3	-3.57	0.00039	0.0423	-0.18	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31751741	chr14:30876179~30889808:-
LUAD	cis	rs4938303	0.633	rs12799441	ENSG00000254851.1	RP11-109L13.1	3.57	0.00039	0.0423	0.25	0.16	Triglycerides;	chr11:116687799	chr11:117135528~117138582:+
LUAD	cis	rs481331	0.8	rs6593345	ENSG00000185904.10	LINC00839	3.57	0.00039	0.0423	0.27	0.16	Systemic juvenile idiopathic arthritis;	chr10:42485679	chr10:42475543~42495336:+
LUAD	cis	rs481331	0.866	rs11499092	ENSG00000185904.10	LINC00839	3.57	0.00039	0.0423	0.27	0.16	Systemic juvenile idiopathic arthritis;	chr10:42487197	chr10:42475543~42495336:+
LUAD	cis	rs481331	0.866	rs11239615	ENSG00000185904.10	LINC00839	3.57	0.00039	0.0423	0.27	0.16	Systemic juvenile idiopathic arthritis;	chr10:42487207	chr10:42475543~42495336:+
LUAD	cis	rs28735056	0.591	rs2277724	ENSG00000261126.6	RP11-795F19.1	-3.57	0.00039	0.0423	-0.16	-0.16	Schizophrenia;	chr18:79934294	chr18:80046900~80095482:+
LUAD	cis	rs7142881	0.844	rs67468105	ENSG00000258525.1	RP11-829H16.3	-3.57	0.00039	0.0423	-0.18	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31597130	chr14:30876179~30889808:-
LUAD	cis	rs5751168	0.831	rs5758484	ENSG00000211654.2	IGLV5-37	3.57	0.00039	0.0423	0.23	0.16	Prostate cancer (SNP x SNP interaction);	chr22:22490315	chr22:22427540~22428035:+
LUAD	cis	rs7572733	0.84	rs770666	ENSG00000222017.1	AC011997.1	3.57	0.00039	0.0423	0.21	0.16	Dermatomyositis;	chr2:197747173	chr2:197693106~197774823:+
LUAD	cis	rs6951245	0.935	rs11763765	ENSG00000199023.2	MIR339	-3.57	0.00039	0.0423	-0.28	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1020874	chr7:1022935~1023045:-
LUAD	cis	rs7809950	1	rs2253146	ENSG00000238832.1	snoU109	-3.57	0.00039	0.0423	-0.24	-0.16	Coronary artery disease;	chr7:107559874	chr7:107603363~107603507:+
LUAD	cis	rs4938642	0.822	rs4938636	ENSG00000254909.1	RP11-110I1.5	3.57	0.00039	0.0423	0.21	0.16	Platelet count;	chr11:119155759	chr11:119005727~119005934:-
LUAD	cis	rs7204230	1	rs16952093	ENSG00000261291.1	RP11-295M3.2	3.57	0.00039	0.0423	0.19	0.16	Fibrinogen;	chr16:53221892	chr16:53168522~53169450:+
LUAD	cis	rs7061710	0.58	rs2091657	ENSG00000271811.1	RP1-79C4.4	3.57	0.00039	0.0423	0.24	0.16	Blood metabolite levels;	chr1:171076176	chr1:170667381~170669425:+
LUAD	cis	rs7246657	0.551	rs4806414	ENSG00000226686.6	LINC01535	-3.57	0.00039	0.0423	-0.27	-0.16	Coronary artery calcification;	chr19:37147886	chr19:37251912~37265535:+
LUAD	cis	rs831571	0.876	rs56363381	ENSG00000280620.1	SCAANT1	3.57	0.00039	0.0423	0.24	0.16	Type 2 diabetes;	chr3:64071001	chr3:63911518~63911772:-
LUAD	cis	rs6121246	0.697	rs6088864	ENSG00000230613.1	HM13-AS1	3.57	0.00039	0.0423	0.24	0.16	Mean corpuscular hemoglobin;	chr20:31640354	chr20:31567707~31573263:-
LUAD	cis	rs875971	0.54	rs1723268	ENSG00000234585.5	CCT6P3	3.57	0.00039	0.0423	0.15	0.16	Aortic root size;	chr7:66008093	chr7:65038354~65074713:+
LUAD	cis	rs9926664	0.584	rs8046526	ENSG00000274134.1	MIR6774	3.57	0.00039	0.0423	0.22	0.16	Neutrophil count;Sum basophil neutrophil counts;	chr16:85918029	chr16:85918347~85918416:+
LUAD	cis	rs12368653	1	rs12371356	ENSG00000245651.2	RP11-620J15.2	-3.57	0.00039	0.0423	-0.16	-0.16	Multiple sclerosis;	chr12:57741637	chr12:57869835~57896482:-
LUAD	cis	rs11252926	0.797	rs61837235	ENSG00000232656.6	IDI2-AS1	-3.57	0.00039	0.0423	-0.19	-0.16	Psychosis in Alzheimer's disease;	chr10:443423	chr10:1022666~1044201:+
LUAD	cis	rs6504108	0.647	rs3805370	ENSG00000278765.1	RP5-890E16.5	-3.57	0.00039	0.0423	-0.18	-0.16	Body mass index;	chr17:48181731	chr17:48066704~48067293:-
LUAD	cis	rs6504108	0.647	rs3805371	ENSG00000278765.1	RP5-890E16.5	-3.57	0.00039	0.0423	-0.18	-0.16	Body mass index;	chr17:48181739	chr17:48066704~48067293:-
LUAD	cis	rs4763879	0.634	rs61915472	ENSG00000214776.8	RP11-726G1.1	-3.57	0.00039	0.0423	-0.18	-0.16	Type 1 diabetes;	chr12:9700995	chr12:9467552~9576275:+
LUAD	cis	rs2638953	0.886	rs11049393	ENSG00000278733.1	RP11-425D17.1	-3.57	0.00039	0.0423	-0.2	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28170273	chr12:28185625~28186190:-
LUAD	cis	rs452036	0.562	rs432256	ENSG00000259054.1	AE000662.93	3.57	0.00039	0.0423	0.22	0.16	P wave duration;Resting heart rate;	chr14:23401543	chr14:22556311~22557062:-
LUAD	cis	rs4378999	0.748	rs9864693	ENSG00000239557.1	RP11-168J18.6	3.57	0.00039	0.0423	0.22	0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;	chr3:51622354	chr3:52373652~52374882:+
LUAD	cis	rs77204473	1	rs35184536	ENSG00000280143.1	AP000892.6	-3.57	0.00039	0.0423	-0.38	-0.16	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116908097	chr11:117204967~117210292:+
LUAD	cis	rs73193808	0.901	rs2832271	ENSG00000215533.7	LINC00189	-3.57	0.00039	0.0423	-0.24	-0.16	Coronary artery disease;	chr21:29223865	chr21:29193480~29288205:+
LUAD	cis	rs9860428	0.591	rs11711794	ENSG00000240057.4	RP11-572M11.4	-3.57	0.00039	0.0423	-0.2	-0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112948640	chr3:113019532~113183301:+
LUAD	cis	rs9860428	0.591	rs9869203	ENSG00000240057.4	RP11-572M11.4	-3.57	0.00039	0.0423	-0.2	-0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112950820	chr3:113019532~113183301:+
LUAD	cis	rs6453278	0.66	rs13178961	ENSG00000250802.5	ZBED3-AS1	-3.57	0.00039	0.0423	-0.2	-0.16	Autism;	chr5:77100623	chr5:77086740~77166909:+
LUAD	cis	rs7824557	0.583	rs6601585	ENSG00000255046.1	RP11-297N6.4	3.57	0.00039	0.0423	0.2	0.16	Retinal vascular caliber;	chr8:11376150	chr8:11797928~11802568:-
LUAD	cis	rs7829975	0.777	rs560544	ENSG00000233609.3	RP11-62H7.2	-3.57	0.00039	0.0423	-0.13	-0.16	Mood instability;	chr8:8779919	chr8:8961200~8979025:+
LUAD	cis	rs7617773	0.817	rs3731534	ENSG00000199476.1	Y_RNA	-3.57	0.00039	0.0423	-0.21	-0.16	Coronary artery disease;	chr3:48170287	chr3:48288587~48288694:+
LUAD	cis	rs2075555	1	rs2075555	ENSG00000250107.1	CACNA1G-AS1	-3.57	0.00039	0.0424	-0.29	-0.16	Breast cancer;	chr17:50196930	chr17:50556207~50562108:-
LUAD	cis	rs5742933	0.857	rs1233272	ENSG00000253559.1	OSGEPL1-AS1	-3.57	0.00039	0.0424	-0.19	-0.16	Ferritin levels;	chr2:189814968	chr2:189762704~189765556:+
LUAD	cis	rs3788317	0.526	rs5992495	ENSG00000232926.1	AC000078.5	-3.57	0.00039	0.0424	-0.17	-0.16	Glaucoma (primary angle closure);	chr22:19895461	chr22:19887289~19887970:+
LUAD	cis	rs10791097	0.547	rs11222371	ENSG00000255455.2	RP11-890B15.3	-3.57	0.00039	0.0424	-0.16	-0.16	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130875824	chr11:130866254~130870247:-
LUAD	cis	rs7017914	0.558	rs4526394	ENSG00000246366.5	RP11-382J12.1	3.57	0.00039	0.0424	0.15	0.16	Bone mineral density;	chr8:71076092	chr8:70608577~70663279:+
LUAD	cis	rs2390582	0.83	rs10922879	ENSG00000233593.5	RP4-665J23.1	3.57	0.00039	0.0424	0.25	0.16	Coronary artery calcification;	chr1:90582953	chr1:90782986~90851650:-
LUAD	cis	rs4763879	0.778	rs11052497	ENSG00000257027.1	RP11-705C15.3	3.57	0.00039	0.0424	0.2	0.16	Type 1 diabetes;	chr12:9696679	chr12:9658567~9662085:+
LUAD	cis	rs2281603	0.57	rs11848179	ENSG00000259116.1	RP11-973N13.4	-3.57	0.00039	0.0424	-0.14	-0.16	Lymphocyte counts;	chr14:64510335	chr14:64514154~64540368:-
LUAD	cis	rs4664293	0.802	rs7563417	ENSG00000227055.1	AC009961.5	3.57	0.000391	0.0424	0.18	0.16	Monocyte percentage of white cells;	chr2:159727762	chr2:159812234~159814009:-
LUAD	cis	rs11673344	0.704	rs571340	ENSG00000267309.1	CTD-2630F21.1	-3.57	0.000391	0.0424	-0.2	-0.16	Obesity-related traits;	chr19:36933981	chr19:36489649~36491040:+
LUAD	cis	rs7824557	0.583	rs2263511	ENSG00000255046.1	RP11-297N6.4	3.57	0.000391	0.0424	0.2	0.16	Retinal vascular caliber;	chr8:11375809	chr8:11797928~11802568:-
LUAD	cis	rs7824557	0.583	rs2263512	ENSG00000255046.1	RP11-297N6.4	3.57	0.000391	0.0424	0.2	0.16	Retinal vascular caliber;	chr8:11375910	chr8:11797928~11802568:-
LUAD	cis	rs8062405	0.754	rs151179	ENSG00000261419.1	RP11-57A19.4	-3.57	0.000391	0.0424	-0.18	-0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28659696~28740781:-
LUAD	cis	rs78487399	0.71	rs75607314	ENSG00000234936.1	AC010883.5	3.57	0.000391	0.0424	0.23	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43492552	chr2:43229573~43233394:+
LUAD	cis	rs6568686	0.73	rs4947120	ENSG00000255389.1	C6orf3	-3.57	0.000391	0.0424	-0.23	-0.16	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111497841	chr6:111599875~111602295:+
LUAD	cis	rs6568686	0.786	rs6927920	ENSG00000255389.1	C6orf3	-3.57	0.000391	0.0424	-0.23	-0.16	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111499179	chr6:111599875~111602295:+
LUAD	cis	rs4938642	0.822	rs4148171	ENSG00000254909.1	RP11-110I1.5	3.57	0.000391	0.0424	0.2	0.16	Platelet count;	chr11:119157120	chr11:119005727~119005934:-
LUAD	cis	rs916888	0.821	rs70600	ENSG00000260075.1	NSFP1	-3.57	0.000391	0.0424	-0.27	-0.16	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46372855~46487141:+
LUAD	cis	rs3749855	0.679	rs13198514	ENSG00000220920.1	RP3-525L6.2	3.57	0.000391	0.0424	0.33	0.16	Glucose homeostasis traits;	chr6:17252451	chr6:17953572~17953930:+
LUAD	cis	rs7178909	0.835	rs2174292	ENSG00000259677.1	RP11-493E3.1	3.57	0.000391	0.0424	0.18	0.16	Common traits (Other);	chr15:89872349	chr15:89876540~89877285:+
LUAD	cis	rs3764021	0.87	rs2192437	ENSG00000256582.1	RP11-75L1.1	3.57	0.000391	0.0424	0.16	0.16	Type 1 diabetes;	chr12:9726639	chr12:9704077~9709350:+
LUAD	cis	rs3764021	0.87	rs10844617	ENSG00000256582.1	RP11-75L1.1	3.57	0.000391	0.0424	0.16	0.16	Type 1 diabetes;	chr12:9726772	chr12:9704077~9709350:+
LUAD	cis	rs3764021	0.87	rs2401395	ENSG00000256582.1	RP11-75L1.1	3.57	0.000391	0.0424	0.16	0.16	Type 1 diabetes;	chr12:9726944	chr12:9704077~9709350:+
LUAD	cis	rs970797	0.522	rs1524080	ENSG00000237260.1	AC073069.2	3.57	0.000391	0.0424	0.19	0.16	Monobrow;Lobe attachment (rater-scored or self-reported);	chr2:176333817	chr2:176338637~176339077:+
LUAD	cis	rs334353	0.798	rs10988714	ENSG00000255145.2	STX17-AS1	-3.57	0.000391	0.0424	-0.21	-0.16	Age-related macular degeneration;	chr9:99122598	chr9:99886322~99906601:-
LUAD	cis	rs116095464	0.51	rs60844864	ENSG00000248925.1	CTD-2083E4.6	3.57	0.000391	0.0424	0.27	0.16	Breast cancer;	chr5:266885	chr5:269858~271516:-
LUAD	cis	rs1198872	0.892	rs1198862	ENSG00000272275.1	RP11-791G15.2	-3.57	0.000391	0.0424	-0.2	-0.16	Cardiac Troponin-T levels;	chr2:10760201	chr2:10767875~10770058:-
LUAD	cis	rs13398147	0.833	rs4674617	ENSG00000267034.1	RP11-384O8.1	3.57	0.000391	0.0424	0.23	0.16	Adolescent idiopathic scoliosis;	chr2:221853226	chr2:222317242~222318653:-
LUAD	cis	rs728616	1	rs728615	ENSG00000225484.5	NUTM2B-AS1	-3.57	0.000391	0.0424	-0.35	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80088333	chr10:79663088~79826594:-
LUAD	cis	rs3753275	0.519	rs1535158	ENSG00000232912.4	RP5-1115A15.1	3.57	0.000391	0.0424	0.19	0.16	Educational attainment;	chr1:8580833	chr1:8424645~8434838:+
LUAD	cis	rs10508774	0.81	rs11008965	ENSG00000231245.2	C1DP1	-3.57	0.000391	0.0424	-0.38	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32535523	chr10:32511336~32511737:-
LUAD	cis	rs10508774	0.81	rs12259710	ENSG00000231245.2	C1DP1	-3.57	0.000391	0.0424	-0.38	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32536942	chr10:32511336~32511737:-
LUAD	cis	rs10508774	0.81	rs1987197	ENSG00000231245.2	C1DP1	-3.57	0.000391	0.0424	-0.38	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32541667	chr10:32511336~32511737:-
LUAD	cis	rs6460942	0.915	rs62447638	ENSG00000226690.5	AC005281.1	3.57	0.000391	0.0424	0.29	0.16	Coronary artery disease;	chr7:12445041	chr7:12496429~12541910:+
LUAD	cis	rs10206020	0.921	rs72778009	ENSG00000231482.2	AC141930.2	-3.57	0.000391	0.0424	-0.22	-0.16	IgG glycosylation;	chr2:1569550	chr2:1572554~1580311:-
LUAD	cis	rs526231	0.511	rs7731395	ENSG00000250682.4	LINC00491	3.57	0.000391	0.0424	0.19	0.16	Primary biliary cholangitis;	chr5:103026057	chr5:102609156~102671559:-
LUAD	cis	rs6128907	0.615	rs116490114	ENSG00000224635.1	RP4-564F22.5	3.57	0.000391	0.0424	0.24	0.16	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38779527	chr20:38406011~38416797:-
LUAD	cis	rs4474465	0.79	rs12363982	ENSG00000251323.2	RP11-452H21.4	-3.57	0.000391	0.0424	-0.19	-0.16	Alzheimer's disease (survival time);	chr11:78518121	chr11:78423982~78429836:-
LUAD	cis	rs2664588	0.613	rs6125187	ENSG00000255438.2	CTD-2653D5.1	3.57	0.000391	0.0424	0.19	0.16	Cerebrospinal fluid AB1-42 levels;	chr20:47953827	chr20:47677901~47686297:+
LUAD	cis	rs4948102	0.642	rs766333	ENSG00000226278.1	PSPHP1	-3.57	0.000391	0.0424	-0.19	-0.16	Plasma homocysteine levels (post-methionine load test);	chr7:56059011	chr7:55764797~55773288:+
LUAD	cis	rs7808935	0.789	rs2040668	ENSG00000235574.1	AC073150.6	3.57	0.000391	0.0424	0.21	0.16	Prostate cancer;	chr7:27919154	chr7:27491682~27492765:-
LUAD	cis	rs67383717	0.713	rs1369156	ENSG00000225194.2	LINC00092	3.57	0.000391	0.0424	0.17	0.16	Parkinson's disease (pesticide exposure interaction);	chr9:95794612	chr9:96019732~96027965:-
LUAD	cis	rs3764021	0.84	rs10743823	ENSG00000214776.8	RP11-726G1.1	3.57	0.000391	0.0424	0.18	0.16	Type 1 diabetes;	chr12:9728529	chr12:9467552~9576275:+
LUAD	cis	rs10208649	0.71	rs10190353	ENSG00000233266.1	HMGB1P31	3.57	0.000391	0.0424	0.42	0.16	Body mass index;	chr2:54015688	chr2:54051334~54051760:+
LUAD	cis	rs9921338	1	rs8049173	ENSG00000262703.1	RP11-485G7.6	-3.57	0.000391	0.0424	-0.17	-0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11343025	chr16:11348143~11349321:-
LUAD	cis	rs9921338	1	rs8055427	ENSG00000262703.1	RP11-485G7.6	-3.57	0.000391	0.0424	-0.17	-0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11343026	chr16:11348143~11349321:-
LUAD	cis	rs3849150	0.95	rs12774147	ENSG00000235939.1	RP11-123B3.2	-3.57	0.000391	0.0424	-0.24	-0.16	Subclinical atherosclerosis traits (other);	chr10:48885899	chr10:49419277~49472903:+
LUAD	cis	rs12823128	1	rs12823128	ENSG00000234428.2	RP11-666F17.1	-3.57	0.000391	0.0424	-0.19	-0.16	Birth weight;	chr12:26719797	chr12:26623369~26649479:+
LUAD	cis	rs6088590	1	rs6119524	ENSG00000275784.1	RP5-1125A11.6	-3.57	0.000391	0.0424	-0.17	-0.16	Coronary artery disease;	chr20:34786010	chr20:33989480~33991818:-
LUAD	cis	rs2977125	0.815	rs2956757	ENSG00000251468.2	RP11-369K16.1	-3.57	0.000391	0.0424	-0.25	-0.16	Schizophrenia;	chr8:12893022	chr8:12958387~12962200:+
LUAD	cis	rs2333021	0.934	rs7155380	ENSG00000259015.1	RP11-109N23.6	3.57	0.000391	0.0424	0.15	0.16	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:73014626	chr14:72960595~72961993:+
LUAD	cis	rs11951515	0.508	rs6860493	ENSG00000248240.1	RP11-159F24.5	-3.57	0.000391	0.0424	-0.17	-0.16	Metabolite levels  (X-11787);	chr5:43602611	chr5:43515274~43525310:+
LUAD	cis	rs9900280	1	rs771428	ENSG00000264808.1	RP11-802D6.1	3.57	0.000391	0.0424	0.19	0.16	Mean platelet volume;	chr17:29466541	chr17:29369717~29390777:-
LUAD	cis	rs11722228	0.522	rs77691548	ENSG00000261490.1	RP11-448G15.3	3.57	0.000391	0.0424	0.14	0.16	Urate levels;Serum uric acid levels;Gout;	chr4:10134491	chr4:10068089~10073019:-
LUAD	cis	rs9400467	0.508	rs12211763	ENSG00000266032.1	AL357515.1	3.57	0.000391	0.0424	0.21	0.16	Amino acid levels;Blood metabolite levels;	chr6:111465953	chr6:110969773~110969872:-
LUAD	cis	rs11240074	0.733	rs17160305	ENSG00000244371.2	PFN1P8	-3.57	0.000391	0.0425	-0.24	-0.16	Type 2 diabetes;	chr1:147509908	chr1:146957117~146957659:-
LUAD	cis	rs12681366	0.881	rs2931631	ENSG00000254057.1	RP3-388N13.3	3.57	0.000391	0.0425	0.17	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94401415	chr8:93834454~93846743:-
LUAD	cis	rs6951245	0.744	rs10275401	ENSG00000226291.1	AC091729.8	-3.57	0.000392	0.0425	-0.27	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1174307	chr7:1080863~1082178:+
LUAD	cis	rs143626010	1	rs143626010	ENSG00000261766.1	RP11-22P6.2	-3.57	0.000392	0.0425	-0.14	-0.16	Mosquito bite size;	chr16:28528081	chr16:28862166~28863340:-
LUAD	cis	rs28374715	0.662	rs522063	ENSG00000157021.9	FAM92A1P1	-3.57	0.000392	0.0425	-0.21	-0.16	Ulcerative colitis;	chr15:41184011	chr15:41163162~41164374:+
LUAD	cis	rs7546668	1	rs4233535	ENSG00000272510.1	RP4-680D5.8	3.57	0.000392	0.0425	0.21	0.16	Glomerular filtration rate (creatinine);	chr1:15518702	chr1:15565611~15565956:-
LUAD	cis	rs7546668	1	rs4233537	ENSG00000272510.1	RP4-680D5.8	3.57	0.000392	0.0425	0.21	0.16	Glomerular filtration rate (creatinine);	chr1:15523205	chr1:15565611~15565956:-
LUAD	cis	rs7216064	1	rs11079707	ENSG00000278740.1	RP11-147L13.14	-3.57	0.000392	0.0425	-0.19	-0.16	EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer;	chr17:67839501	chr17:68188547~68189165:+
LUAD	cis	rs524281	0.773	rs7925123	ENSG00000255320.1	RP11-755F10.1	3.57	0.000392	0.0425	0.25	0.16	Electroencephalogram traits;	chr11:66225742	chr11:66244840~66246239:-
LUAD	cis	rs17122278	0.929	rs45474901	ENSG00000243431.1	RPL5P30	3.57	0.000392	0.0425	0.2	0.16	Total cholesterol levels;	chr11:118534738	chr11:118560690~118561580:+
LUAD	cis	rs3749855	0.679	rs13197116	ENSG00000220920.1	RP3-525L6.2	3.57	0.000392	0.0425	0.33	0.16	Glucose homeostasis traits;	chr6:17255104	chr6:17953572~17953930:+
LUAD	cis	rs9894429	0.646	rs8079963	ENSG00000263853.1	AC139530.1	-3.57	0.000392	0.0425	-0.16	-0.16	Eye color traits;	chr17:81636259	chr17:81676001~81676086:+
LUAD	cis	rs7917772	0.636	rs2250580	ENSG00000272933.1	RP11-47A8.5	-3.57	0.000392	0.0425	-0.2	-0.16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102745930	chr10:102642792~102644140:-
LUAD	cis	rs2625529	0.73	rs2957368	ENSG00000260173.1	RP11-2I17.4	-3.57	0.000392	0.0425	-0.2	-0.16	Red blood cell count;	chr15:72037565	chr15:72140504~72155459:-
LUAD	cis	rs1541160	1	rs476269	ENSG00000239494.2	RN7SL333P	-3.57	0.000392	0.0425	-0.15	-0.16	Amyotrophic lateral sclerosis;	chr1:169974145	chr1:169859756~169860052:+
LUAD	cis	rs7208859	0.673	rs9911989	ENSG00000265443.1	CTD-2349P21.6	3.57	0.000392	0.0425	0.26	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30726305~30727564:-
LUAD	cis	rs2041840	0.961	rs2372990	ENSG00000272054.1	RP11-423P10.2	-3.57	0.000392	0.0425	-0.12	-0.16	Chronic lymphocytic leukemia;	chr2:37272924	chr2:37208875~37212677:+
LUAD	cis	rs112744032	1	rs112744032	ENSG00000240350.2	AC017002.1	-3.57	0.000392	0.0425	-0.25	-0.16	Mean corpuscular hemoglobin;	chr2:111521757	chr2:111491273~111570974:+
LUAD	cis	rs62162297	1	rs62162297	ENSG00000240350.2	AC017002.1	-3.57	0.000392	0.0425	-0.25	-0.16	Red blood cell count;	chr2:111521758	chr2:111491273~111570974:+
LUAD	cis	rs9659323	0.804	rs10923722	ENSG00000226172.2	RP4-712E4.1	-3.57	0.000392	0.0425	-0.18	-0.16	Body mass index;	chr1:119000863	chr1:119000344~119001392:-
LUAD	cis	rs9659323	0.745	rs10923723	ENSG00000226172.2	RP4-712E4.1	-3.57	0.000392	0.0425	-0.18	-0.16	Body mass index;	chr1:119001379	chr1:119000344~119001392:-
LUAD	cis	rs324126	0.78	rs1993531	ENSG00000277977.1	CTD-3018O17.5	3.57	0.000392	0.0425	0.16	0.16	Colonoscopy-negative controls vs population controls;	chr19:52381633	chr19:52392659~52392755:+
LUAD	cis	rs56050415	1	rs72739147	ENSG00000277144.1	RP11-59H7.4	3.57	0.000392	0.0425	0.29	0.16	Metabolite levels (lipoprotein measures);	chr15:58279202	chr15:59115547~59116089:-
LUAD	cis	rs8192282	0.739	rs41302545	ENSG00000272030.1	RP1-178F15.4	3.57	0.000392	0.0425	0.22	0.16	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);	chr1:154553523	chr1:153631438~153634397:-
LUAD	cis	rs35520189	0.591	rs12623837	ENSG00000227368.1	AC079753.5	3.57	0.000392	0.0425	0.2	0.16	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112944891	chr2:112932625~112933171:+
LUAD	cis	rs2625529	0.586	rs7175197	ENSG00000260173.1	RP11-2I17.4	3.57	0.000392	0.0425	0.19	0.16	Red blood cell count;	chr15:72169307	chr15:72140504~72155459:-
LUAD	cis	rs4474465	0.79	rs10751295	ENSG00000251323.2	RP11-452H21.4	-3.57	0.000392	0.0425	-0.2	-0.16	Alzheimer's disease (survival time);	chr11:78555001	chr11:78423982~78429836:-
LUAD	cis	rs2041840	0.961	rs3902740	ENSG00000272054.1	RP11-423P10.2	-3.57	0.000392	0.0425	-0.12	-0.16	Chronic lymphocytic leukemia;	chr2:37279023	chr2:37208875~37212677:+
LUAD	cis	rs62355901	0.509	rs116154674	ENSG00000271828.1	CTD-2310F14.1	3.57	0.000392	0.0425	0.31	0.16	Breast cancer;	chr5:56710833	chr5:56927874~56929573:+
LUAD	cis	rs2276498	0.751	rs6123344	ENSG00000236352.1	AC005220.3	-3.57	0.000392	0.0425	-0.21	-0.16	Bipolar disorder and schizophrenia;	chr20:54023975	chr20:53940160~53942508:+
LUAD	cis	rs4718428	0.672	rs4718412	ENSG00000230295.1	RP11-458F8.2	3.57	0.000392	0.0425	0.14	0.16	Corneal structure;	chr7:66821880	chr7:66880708~66882981:+
LUAD	cis	rs10197140	0.816	rs13429695	ENSG00000227992.1	AC108463.2	-3.57	0.000392	0.0425	-0.19	-0.16	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110867071	chr2:111203964~111206215:-
LUAD	cis	rs1910358	0.664	rs9647547	ENSG00000248874.4	C5orf17	-3.57	0.000392	0.0425	-0.2	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23901534	chr5:23951348~24178263:+
LUAD	cis	rs898097	0.585	rs9892342	ENSG00000263063.1	RP11-388C12.1	3.57	0.000392	0.0425	0.16	0.16	Breast cancer;	chr17:82935153	chr17:82713908~82716255:-
LUAD	cis	rs6583826	0.758	rs12220493	ENSG00000236493.2	EIF2S2P3	3.57	0.000392	0.0425	0.18	0.16	Type 2 diabetes;	chr10:92551152	chr10:92668745~92669743:-
LUAD	cis	rs7142881	0.815	rs2226057	ENSG00000258525.1	RP11-829H16.3	-3.57	0.000392	0.0425	-0.18	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31700006	chr14:30876179~30889808:-
LUAD	cis	rs7142881	0.815	rs2211251	ENSG00000258525.1	RP11-829H16.3	-3.57	0.000392	0.0425	-0.18	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31700240	chr14:30876179~30889808:-
LUAD	cis	rs35740288	0.618	rs11630755	ENSG00000202081.1	RNU6-1280P	3.57	0.000392	0.0425	0.18	0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85565506	chr15:85651522~85651628:-
LUAD	cis	rs17264034	0.5	rs10475468	ENSG00000250786.1	SNHG18	-3.57	0.000392	0.0425	-0.19	-0.16	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9538645	chr5:9546200~9550609:+
LUAD	cis	rs7015630	0.542	rs13280951	ENSG00000251136.7	RP11-37B2.1	-3.57	0.000392	0.0425	-0.21	-0.16	Inflammatory bowel disease;Crohn's disease;	chr8:89809746	chr8:89609409~89757727:-
LUAD	cis	rs10739663	0.52	rs2819624	ENSG00000232630.1	PRPS1P2	-3.57	0.000392	0.0425	-0.16	-0.16	Resting heart rate;	chr9:125394240	chr9:125150653~125151589:+
LUAD	cis	rs13113518	0.966	rs1474271	ENSG00000249700.7	SRD5A3-AS1	3.57	0.000392	0.0425	0.16	0.16	Height;	chr4:55435912	chr4:55363971~55395847:-
LUAD	cis	rs13113518	1	rs11937487	ENSG00000249700.7	SRD5A3-AS1	3.57	0.000392	0.0425	0.16	0.16	Height;	chr4:55436576	chr4:55363971~55395847:-
LUAD	cis	rs13113518	1	rs3805146	ENSG00000249700.7	SRD5A3-AS1	3.57	0.000392	0.0425	0.16	0.16	Height;	chr4:55436985	chr4:55363971~55395847:-
LUAD	cis	rs13113518	1	rs11133378	ENSG00000249700.7	SRD5A3-AS1	3.57	0.000392	0.0425	0.16	0.16	Height;	chr4:55439472	chr4:55363971~55395847:-
LUAD	cis	rs13113518	1	rs11942279	ENSG00000249700.7	SRD5A3-AS1	3.57	0.000392	0.0425	0.16	0.16	Height;	chr4:55439652	chr4:55363971~55395847:-
LUAD	cis	rs7521902	0.521	rs3765350	ENSG00000228397.1	RP1-224A6.3	-3.57	0.000392	0.0425	-0.25	-0.16	Endometriosis;Ovarian cancer;Bone mineral density;Hip circumference adjusted for BMI;	chr1:22120823	chr1:22023994~22024968:-
LUAD	cis	rs7204230	1	rs12599784	ENSG00000261291.1	RP11-295M3.2	3.57	0.000393	0.0425	0.19	0.16	Fibrinogen;	chr16:53226247	chr16:53168522~53169450:+
LUAD	cis	rs9308731	0.583	rs2165107	ENSG00000227992.1	AC108463.2	-3.57	0.000393	0.0425	-0.19	-0.16	Chronic lymphocytic leukemia;	chr2:111173773	chr2:111203964~111206215:-
LUAD	cis	rs12570188	1	rs12570188	ENSG00000260475.1	RP11-85A1.3	-3.57	0.000393	0.0425	-0.36	-0.16	Asthma (childhood onset);	chr10:99095945	chr10:99621055~99621918:+
LUAD	cis	rs911119	0.913	rs6048923	ENSG00000270001.1	RP11-218C14.8	-3.57	0.000393	0.0425	-0.25	-0.16	Chronic kidney disease;	chr20:23597569	chr20:23631826~23632316:-
LUAD	cis	rs12817211	0.524	rs7967979	ENSG00000272368.2	RP4-605O3.4	-3.57	0.000393	0.0425	-0.19	-0.16	Colorectal or endometrial cancer;	chr12:50126893	chr12:50112197~50165618:+
LUAD	cis	rs12817211	0.548	rs2204684	ENSG00000272368.2	RP4-605O3.4	-3.57	0.000393	0.0425	-0.19	-0.16	Colorectal or endometrial cancer;	chr12:50128689	chr12:50112197~50165618:+
LUAD	cis	rs7521902	0.617	rs12037376	ENSG00000234397.3	RP11-415K20.1	3.57	0.000393	0.0425	0.26	0.16	Endometriosis;Ovarian cancer;Bone mineral density;Hip circumference adjusted for BMI;	chr1:22135618	chr1:22322840~22323331:-
LUAD	cis	rs812925	0.762	rs74181273	ENSG00000271889.1	RP11-493E12.1	3.57	0.000393	0.0426	0.2	0.16	Immature fraction of reticulocytes;	chr2:61471028	chr2:61151433~61162105:-
LUAD	cis	rs911555	0.755	rs8014800	ENSG00000259775.1	RP11-45P15.4	3.57	0.000393	0.0426	0.21	0.16	Intelligence (multi-trait analysis);	chr14:103479965	chr14:103331674~103332367:-
LUAD	cis	rs4523957	0.928	rs7213232	ENSG00000262333.1	HNRNPA1P16	3.57	0.000393	0.0426	0.13	0.16	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2262046	chr17:2306761~2307715:+
LUAD	cis	rs6687758	0.645	rs949618	ENSG00000238042.4	RP11-815M8.1	3.57	0.000393	0.0426	0.21	0.16	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221940598	chr1:221880981~221978523:-
LUAD	cis	rs4811196	0.879	rs2235470	ENSG00000226144.2	RPS27AP3	3.57	0.000393	0.0426	0.2	0.16	Bone mineral density;	chr20:37844766	chr20:37049254~37049707:+
LUAD	cis	rs4811196	1	rs2235466	ENSG00000226144.2	RPS27AP3	3.57	0.000393	0.0426	0.2	0.16	Bone mineral density;	chr20:37845590	chr20:37049254~37049707:+
LUAD	cis	rs4811196	1	rs2235465	ENSG00000226144.2	RPS27AP3	3.57	0.000393	0.0426	0.2	0.16	Bone mineral density;	chr20:37846128	chr20:37049254~37049707:+
LUAD	cis	rs4811196	1	rs2235464	ENSG00000226144.2	RPS27AP3	3.57	0.000393	0.0426	0.2	0.16	Bone mineral density;	chr20:37846158	chr20:37049254~37049707:+
LUAD	cis	rs4811196	1	rs2064182	ENSG00000226144.2	RPS27AP3	3.57	0.000393	0.0426	0.2	0.16	Bone mineral density;	chr20:37846877	chr20:37049254~37049707:+
LUAD	cis	rs4811196	1	rs6067854	ENSG00000226144.2	RPS27AP3	3.57	0.000393	0.0426	0.2	0.16	Bone mineral density;	chr20:37848592	chr20:37049254~37049707:+
LUAD	cis	rs4811196	1	rs6512730	ENSG00000226144.2	RPS27AP3	3.57	0.000393	0.0426	0.2	0.16	Bone mineral density;	chr20:37848977	chr20:37049254~37049707:+
LUAD	cis	rs4811196	1	rs6512731	ENSG00000226144.2	RPS27AP3	3.57	0.000393	0.0426	0.2	0.16	Bone mineral density;	chr20:37849078	chr20:37049254~37049707:+
LUAD	cis	rs72681920	0.881	rs12502056	ENSG00000246090.5	RP11-696N14.1	-3.57	0.000393	0.0426	-0.28	-0.16	Alcohol dependence;	chr4:99194917	chr4:99088857~99301356:+
LUAD	cis	rs72681920	0.881	rs12499710	ENSG00000246090.5	RP11-696N14.1	-3.57	0.000393	0.0426	-0.28	-0.16	Alcohol dependence;	chr4:99199835	chr4:99088857~99301356:+
LUAD	cis	rs931127	0.502	rs1466462	ENSG00000254510.1	RP11-867G23.10	-3.57	0.000393	0.0426	-0.21	-0.16	Systemic lupus erythematosus;	chr11:65651893	chr11:66409158~66417137:+
LUAD	cis	rs8180040	0.627	rs58956475	ENSG00000260236.1	RP11-708J19.1	-3.57	0.000393	0.0426	-0.15	-0.16	Colorectal cancer;	chr3:47183125	chr3:47379089~47380999:-
LUAD	cis	rs35740288	0.742	rs2061818	ENSG00000202081.1	RNU6-1280P	3.57	0.000393	0.0426	0.18	0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85593013	chr15:85651522~85651628:-
LUAD	cis	rs9291683	0.609	rs4622999	ENSG00000250413.1	RP11-448G15.1	-3.57	0.000393	0.0426	-0.2	-0.16	Bone mineral density;	chr4:10001771	chr4:10006482~10009725:+
LUAD	cis	rs12446632	0.665	rs4780829	ENSG00000261195.1	CTD-2380F24.1	-3.57	0.000393	0.0426	-0.25	-0.16	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Menarche (age at onset);Obesity;Childhood body mass index;Waist circumference;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr16:19844663	chr16:19761172~19766099:-
LUAD	cis	rs12446632	0.771	rs4782294	ENSG00000261195.1	CTD-2380F24.1	-3.57	0.000393	0.0426	-0.25	-0.16	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Menarche (age at onset);Obesity;Childhood body mass index;Waist circumference;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr16:19855699	chr16:19761172~19766099:-
LUAD	cis	rs7615952	0.576	rs4646748	ENSG00000241288.6	RP11-379B18.5	-3.57	0.000393	0.0426	-0.21	-0.16	Blood pressure (smoking interaction);	chr3:126107486	chr3:125827238~125916384:-
LUAD	cis	rs3743162	0.955	rs12442557	ENSG00000225151.9	GOLGA2P7	-3.57	0.000393	0.0426	-0.25	-0.16	Alzheimer's disease (age of onset);	chr15:84887913	chr15:84199311~84230136:-
LUAD	cis	rs7618915	0.547	rs10865973	ENSG00000243224.1	RP5-1157M23.2	-3.57	0.000393	0.0426	-0.16	-0.16	Bipolar disorder;	chr3:52684138	chr3:52239258~52241097:+
LUAD	cis	rs7940646	0.817	rs10840457	ENSG00000177112.6	MRVI1-AS1	-3.57	0.000393	0.0426	-0.21	-0.16	Platelet aggregation;	chr11:10654191	chr11:10541272~10599932:+
LUAD	cis	rs6490294	0.799	rs11066080	ENSG00000234608.6	MAPKAPK5-AS1	3.57	0.000393	0.0426	0.18	0.16	Mean platelet volume;	chr12:111912600	chr12:111839764~111842902:-
LUAD	cis	rs2837828	1	rs2837828	ENSG00000226496.2	LINC00323	3.57	0.000393	0.0426	0.2	0.16	Neutrophil count;	chr21:40803034	chr21:41141493~41148133:-
LUAD	cis	rs2837828	1	rs2837829	ENSG00000226496.2	LINC00323	3.57	0.000393	0.0426	0.2	0.16	Neutrophil count;	chr21:40803497	chr21:41141493~41148133:-
LUAD	cis	rs7829975	0.806	rs2428	ENSG00000233609.3	RP11-62H7.2	3.57	0.000393	0.0426	0.13	0.16	Mood instability;	chr8:8783635	chr8:8961200~8979025:+
LUAD	cis	rs7955901	0.904	rs4760895	ENSG00000258053.1	CTD-2021H9.3	-3.57	0.000393	0.0426	-0.18	-0.16	Type 2 diabetes;	chr12:71045347	chr12:71047402~71118247:-
LUAD	cis	rs2243480	1	rs4718334	ENSG00000222364.1	RNU6-96P	3.57	0.000393	0.0426	0.27	0.16	Diabetic kidney disease;	chr7:66324467	chr7:66395191~66395286:+
LUAD	cis	rs11638352	0.661	rs2733209	ENSG00000205771.5	CATSPER2P1	3.57	0.000393	0.0426	0.35	0.16	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44158298	chr15:43726918~43747094:-
LUAD	cis	rs6460942	0.597	rs7798779	ENSG00000226690.5	AC005281.1	3.57	0.000393	0.0426	0.31	0.16	Coronary artery disease;	chr7:12503864	chr7:12496429~12541910:+
LUAD	cis	rs6663390	0.51	rs2300055	ENSG00000203709.8	C1orf132	3.57	0.000393	0.0426	0.23	0.16	Facial morphology (factor 18);	chr1:207892035	chr1:207801518~207869150:-
LUAD	cis	rs6951245	0.882	rs56048221	ENSG00000229043.2	AC091729.9	-3.57	0.000393	0.0426	-0.23	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1052897	chr7:1160374~1165267:+
LUAD	cis	rs4302906	0.515	rs10761187	ENSG00000227603.1	RP11-165J3.6	-3.57	0.000393	0.0426	-0.18	-0.16	Lobe attachment (rater-scored or self-reported);	chr9:93004388	chr9:93435332~93437121:-
LUAD	cis	rs2836974	0.932	rs6517523	ENSG00000232608.1	TIMM9P2	-3.57	0.000393	0.0426	-0.19	-0.16	Cognitive function;	chr21:39185406	chr21:39216624~39217506:+
LUAD	cis	rs4699052	0.662	rs6533083	ENSG00000251288.2	RP11-10L12.2	-3.57	0.000393	0.0426	-0.19	-0.16	Testicular germ cell tumor;	chr4:103320110	chr4:102751401~102752641:+
LUAD	cis	rs10510102	1	rs7923678	ENSG00000276742.1	RP11-500G22.4	3.57	0.000393	0.0426	0.25	0.16	Breast cancer;	chr10:121832546	chr10:121956782~121957098:+
LUAD	cis	rs7242404	0.509	rs11080597	ENSG00000267654.1	RP11-973H7.4	3.57	0.000393	0.0426	0.19	0.16	Interleukin-9 levels;Macrophage inflammatory protein 1a levels;	chr18:12751429	chr18:12739490~12749421:-
LUAD	cis	rs9863	0.931	rs35825716	ENSG00000270028.1	RP11-380L11.4	3.57	0.000393	0.0426	0.21	0.16	White blood cell count;	chr12:123942977	chr12:123925461~123926083:-
LUAD	cis	rs240993	0.516	rs465646	ENSG00000230177.1	RP5-1112D6.4	-3.57	0.000393	0.0426	-0.18	-0.16	Inflammatory skin disease;Psoriasis;	chr6:111299555	chr6:111277932~111278742:+
LUAD	cis	rs9400467	0.528	rs17539197	ENSG00000266032.1	AL357515.1	3.57	0.000393	0.0426	0.21	0.16	Amino acid levels;Blood metabolite levels;	chr6:111447968	chr6:110969773~110969872:-
LUAD	cis	rs763121	0.853	rs5750673	ENSG00000228274.3	RP3-508I15.9	-3.57	0.000393	0.0426	-0.16	-0.16	Menopause (age at onset);	chr22:38714119	chr22:38667585~38681820:-
LUAD	cis	rs7178572	1	rs11633054	ENSG00000259420.4	RP11-307C19.2	3.57	0.000394	0.0426	0.19	0.16	Type 2 diabetes;	chr15:77454934	chr15:77568970~77608888:+
LUAD	cis	rs4819052	0.851	rs2838850	ENSG00000215447.6	BX322557.10	-3.57	0.000394	0.0426	-0.19	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251530	chr21:45288052~45291738:+
LUAD	cis	rs7942368	1	rs12282785	ENSG00000254632.1	RP11-21L23.4	3.57	0.000394	0.0426	0.17	0.16	Endometriosis;	chr11:76764986	chr11:76759916~76768223:-
LUAD	cis	rs17711722	0.528	rs73138179	ENSG00000213640.3	EEF1DP4	-3.57	0.000394	0.0426	-0.19	-0.16	Calcium levels;	chr7:65829495	chr7:64862999~64864370:+
LUAD	cis	rs10129255	1	rs11621409	ENSG00000274576.2	IGHV2-70	3.57	0.000394	0.0426	0.15	0.16	Kawasaki disease;	chr14:106695603	chr14:106770577~106771020:-
LUAD	cis	rs7045881	0.674	rs73438223	ENSG00000254396.1	RP11-56F10.3	3.57	0.000394	0.0426	0.26	0.16	Schizophrenia;	chr9:27041663	chr9:27102630~27104728:+
LUAD	cis	rs910316	0.591	rs7157158	ENSG00000279594.1	RP11-950C14.10	3.57	0.000394	0.0426	0.18	0.16	Height;	chr14:74990535	chr14:75011269~75012851:-
LUAD	cis	rs6832769	1	rs4865010	ENSG00000272969.1	RP11-528I4.2	-3.57	0.000394	0.0426	-0.17	-0.16	Personality dimensions;	chr4:55548795	chr4:55547112~55547889:+
LUAD	cis	rs1559040	0.929	rs13418039	ENSG00000272156.1	RP11-477N3.1	-3.57	0.000394	0.0426	-0.26	-0.16	Sudden cardiac arrest;	chr2:54093114	chr2:54082554~54085066:+
LUAD	cis	rs1559040	1	rs13418839	ENSG00000272156.1	RP11-477N3.1	-3.57	0.000394	0.0426	-0.26	-0.16	Sudden cardiac arrest;	chr2:54093638	chr2:54082554~54085066:+
LUAD	cis	rs1559040	0.929	rs13418658	ENSG00000272156.1	RP11-477N3.1	-3.57	0.000394	0.0426	-0.26	-0.16	Sudden cardiac arrest;	chr2:54093662	chr2:54082554~54085066:+
LUAD	cis	rs13113518	0.966	rs7668429	ENSG00000223305.1	RN7SKP30	3.57	0.000394	0.0426	0.18	0.16	Height;	chr4:55531811	chr4:55540502~55540835:-
LUAD	cis	rs67981189	0.574	rs4467005	ENSG00000269927.1	RP6-91H8.3	3.57	0.000394	0.0426	0.19	0.16	Schizophrenia;	chr14:71031939	chr14:71141125~71143253:-
LUAD	cis	rs14027	0.64	rs7843304	ENSG00000279347.1	RP11-85I17.2	-3.57	0.000394	0.0426	-0.13	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119770796	chr8:119838736~119840385:-
LUAD	cis	rs12149074	0.55	rs6564728	ENSG00000261390.4	RP11-345M22.2	-3.57	0.000394	0.0426	-0.21	-0.16	Bipolar disorder and eating disorder;Eating disorder in bipolar disorder;	chr16:80062935	chr16:79715232~79770563:-
LUAD	cis	rs564309	0.867	rs35711644	ENSG00000231563.1	RP11-245P10.4	-3.57	0.000394	0.0426	-0.32	-0.16	Hip circumference (psychosocial stress interaction);	chr1:228368702	chr1:228407381~228409694:+
LUAD	cis	rs1910358	0.614	rs1393226	ENSG00000248874.4	C5orf17	-3.57	0.000394	0.0426	-0.2	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23956667	chr5:23951348~24178263:+
LUAD	cis	rs1910358	0.659	rs10076648	ENSG00000248874.4	C5orf17	-3.57	0.000394	0.0426	-0.2	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23958998	chr5:23951348~24178263:+
LUAD	cis	rs3213758	0.541	rs5005161	ENSG00000275191.1	RP11-36I17.2	-3.57	0.000394	0.0427	-0.24	-0.16	Vitiligo (non-segmental);	chr16:53664764	chr16:53628256~53628816:-
LUAD	cis	rs10102546	1	rs11782176	ENSG00000244642.3	RN7SL396P	3.57	0.000394	0.0427	0.18	0.16	Smoking cessation;	chr8:119536437	chr8:119862662~119862956:+
LUAD	cis	rs4268898	0.965	rs4665673	ENSG00000242628.4	AC009228.1	-3.57	0.000394	0.0427	-0.21	-0.16	Asthma;	chr2:24236868	chr2:24214381~24221516:+
LUAD	cis	rs73108077	1	rs73116272	ENSG00000281376.1	ABALON	-3.57	0.000394	0.0427	-0.28	-0.16	Red blood cell density in sickle cell anemia;	chr20:31467430	chr20:31721507~31723409:+
LUAD	cis	rs801193	0.569	rs2659893	ENSG00000106610.13	STAG3L4	-3.57	0.000394	0.0427	-0.21	-0.16	Aortic root size;	chr7:66735006	chr7:67302621~67321526:+
LUAD	cis	rs801193	0.569	rs2659892	ENSG00000106610.13	STAG3L4	-3.57	0.000394	0.0427	-0.21	-0.16	Aortic root size;	chr7:66735318	chr7:67302621~67321526:+
LUAD	cis	rs801193	0.548	rs2659891	ENSG00000106610.13	STAG3L4	-3.57	0.000394	0.0427	-0.21	-0.16	Aortic root size;	chr7:66736127	chr7:67302621~67321526:+
LUAD	cis	rs801193	0.569	rs2707847	ENSG00000106610.13	STAG3L4	-3.57	0.000394	0.0427	-0.21	-0.16	Aortic root size;	chr7:66737884	chr7:67302621~67321526:+
LUAD	cis	rs801193	0.548	rs7805152	ENSG00000106610.13	STAG3L4	-3.57	0.000394	0.0427	-0.21	-0.16	Aortic root size;	chr7:66744266	chr7:67302621~67321526:+
LUAD	cis	rs9543976	1	rs7339146	ENSG00000261105.4	LMO7-AS1	-3.57	0.000394	0.0427	-0.26	-0.16	Diabetic retinopathy;	chr13:75599583	chr13:75604700~75635994:-
LUAD	cis	rs748404	0.666	rs17780417	ENSG00000249839.1	AC011330.5	-3.57	0.000394	0.0427	-0.25	-0.16	Lung cancer;	chr15:43347264	chr15:43663654~43684339:-
LUAD	cis	rs3749855	0.539	rs13215794	ENSG00000220920.1	RP3-525L6.2	3.57	0.000394	0.0427	0.34	0.16	Glucose homeostasis traits;	chr6:17263682	chr6:17953572~17953930:+
LUAD	cis	rs12200782	0.505	rs7765920	ENSG00000124549.13	BTN2A3P	3.57	0.000394	0.0427	0.18	0.16	Small cell lung carcinoma;	chr6:26514543	chr6:26421391~26432383:+
LUAD	cis	rs11955398	0.522	rs34643	ENSG00000272308.1	RP11-231G3.1	-3.57	0.000394	0.0427	-0.19	-0.16	Intelligence (multi-trait analysis);	chr5:61048750	chr5:60866457~60866935:-
LUAD	cis	rs237743	0.896	rs2063710	ENSG00000177410.11	ZFAS1	-3.57	0.000394	0.0427	-0.18	-0.16	Height;	chr20:49215517	chr20:49278178~49295738:+
LUAD	cis	rs6120849	0.707	rs6088694	ENSG00000202150.1	RNU6-407P	3.57	0.000394	0.0427	0.23	0.16	Protein C levels;	chr20:35064568	chr20:35030317~35030420:-
LUAD	cis	rs944722	0.934	rs4796040	ENSG00000265646.2	TUFMP1	-3.57	0.000394	0.0427	-0.19	-0.16	Fractional exhaled nitric oxide (childhood);	chr17:27770454	chr17:27082690~27084036:-
LUAD	cis	rs4268898	0.636	rs72787371	ENSG00000242628.4	AC009228.1	3.57	0.000394	0.0427	0.24	0.16	Asthma;	chr2:24347204	chr2:24214381~24221516:+
LUAD	cis	rs67539049	1	rs73546312	ENSG00000255046.1	RP11-297N6.4	3.57	0.000394	0.0427	0.23	0.16	Itch intensity from mosquito bite;	chr8:11445200	chr8:11797928~11802568:-
LUAD	cis	rs9973361	0.531	rs717027	ENSG00000232411.1	AC009495.3	3.57	0.000394	0.0427	0.18	0.16	Total body bone mineral density;	chr2:165829904	chr2:165833048~165839098:-
LUAD	cis	rs7665939	1	rs72709206	ENSG00000251297.1	TUBB7P	3.57	0.000394	0.0427	0.34	0.16	Amyotrophic lateral sclerosis;	chr4:189188017	chr4:189982523~189984871:-
LUAD	cis	rs794185	0.714	rs2633861	ENSG00000231249.1	ITPR1-AS1	-3.57	0.000394	0.0427	-0.18	-0.16	Multiple sclerosis--Brain Glutamate Levels;	chr3:4457864	chr3:4490891~4493163:-
LUAD	cis	rs357618	1	rs357625	ENSG00000272112.1	CTB-113P19.5	-3.57	0.000394	0.0427	-0.15	-0.16	Basophil percentage of white cells;	chr5:151469313	chr5:151724831~151725356:-
LUAD	cis	rs2390582	0.891	rs12028695	ENSG00000233593.5	RP4-665J23.1	3.57	0.000394	0.0427	0.23	0.16	Coronary artery calcification;	chr1:90499226	chr1:90782986~90851650:-
LUAD	cis	rs2613514	1	rs2273280	ENSG00000204282.4	TNRC6C-AS1	-3.57	0.000395	0.0427	-0.26	-0.16	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr17:78107582	chr17:78107398~78111799:-
LUAD	cis	rs2014572	0.967	rs10427146	ENSG00000268379.1	CTC-360J11.4	3.57	0.000395	0.0427	0.19	0.16	Hyperactive-impulsive symptoms;	chr19:57244630	chr19:57175233~57177921:+
LUAD	cis	rs3845817	0.703	rs702904	ENSG00000281920.1	RP11-418H16.1	-3.57	0.000395	0.0427	-0.2	-0.16	Bipolar disorder;	chr2:65538960	chr2:65623272~65628424:+
LUAD	cis	rs7201929	1	rs7201929	ENSG00000251417.2	RP11-1348G14.4	-3.57	0.000395	0.0427	-0.18	-0.16	QT interval;	chr16:28860645	chr16:28802743~28817828:+
LUAD	cis	rs7246657	0.943	rs10406177	ENSG00000226686.6	LINC01535	-3.57	0.000395	0.0427	-0.23	-0.16	Coronary artery calcification;	chr19:37417045	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.882	rs28623164	ENSG00000226686.6	LINC01535	-3.57	0.000395	0.0427	-0.23	-0.16	Coronary artery calcification;	chr19:37422551	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.943	rs7252346	ENSG00000226686.6	LINC01535	-3.57	0.000395	0.0427	-0.23	-0.16	Coronary artery calcification;	chr19:37423780	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.943	rs2891699	ENSG00000226686.6	LINC01535	-3.57	0.000395	0.0427	-0.23	-0.16	Coronary artery calcification;	chr19:37429335	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.943	rs9676967	ENSG00000226686.6	LINC01535	-3.57	0.000395	0.0427	-0.23	-0.16	Coronary artery calcification;	chr19:37437187	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.943	rs8109632	ENSG00000226686.6	LINC01535	-3.57	0.000395	0.0427	-0.23	-0.16	Coronary artery calcification;	chr19:37440223	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.943	rs7255407	ENSG00000226686.6	LINC01535	-3.57	0.000395	0.0427	-0.23	-0.16	Coronary artery calcification;	chr19:37443034	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.943	rs2112923	ENSG00000226686.6	LINC01535	-3.57	0.000395	0.0427	-0.23	-0.16	Coronary artery calcification;	chr19:37449425	chr19:37251912~37265535:+
LUAD	cis	rs7246657	0.943	rs3760825	ENSG00000226686.6	LINC01535	-3.57	0.000395	0.0427	-0.23	-0.16	Coronary artery calcification;	chr19:37454699	chr19:37251912~37265535:+
LUAD	cis	rs2554380	0.628	rs6602993	ENSG00000259570.1	RP11-671M22.4	3.57	0.000395	0.0427	0.21	0.16	Height;	chr15:83813610	chr15:84394512~84395514:+
LUAD	cis	rs4937076	1	rs4937076	ENSG00000254671.2	STT3A-AS1	3.57	0.000395	0.0427	0.17	0.16	Primary tooth development (time to first tooth eruption);	chr11:125956807	chr11:125570284~125592568:-
LUAD	cis	rs5751614	0.517	rs928780	ENSG00000230701.2	FBXW4P1	3.57	0.000395	0.0427	0.19	0.16	Height;	chr22:23257682	chr22:23262767~23265005:+
LUAD	cis	rs6088590	1	rs6088607	ENSG00000275784.1	RP5-1125A11.6	-3.57	0.000395	0.0427	-0.17	-0.16	Coronary artery disease;	chr20:34790930	chr20:33989480~33991818:-
LUAD	cis	rs62158800	0.852	rs1040176	ENSG00000237223.5	SULT1C2P1	-3.57	0.000395	0.0427	-0.3	-0.16	Facial morphology (factor 22);	chr2:107691334	chr2:108322238~108353799:+
LUAD	cis	rs2883428	0.821	rs7548324	ENSG00000233355.5	CHRM3-AS2	-3.57	0.000395	0.0427	-0.13	-0.16	White matter hyperintensity burden;	chr1:239424212	chr1:239703381~239730465:-
LUAD	cis	rs6496932	0.663	rs11074169	ENSG00000202081.1	RNU6-1280P	-3.57	0.000395	0.0427	-0.21	-0.16	Central corneal thickness;Corneal structure;	chr15:85375721	chr15:85651522~85651628:-
LUAD	cis	rs6933660	0.646	rs9397051	ENSG00000219395.2	HSPA8P15	-3.57	0.000395	0.0427	-0.16	-0.16	Menarche (age at onset);	chr6:151457190	chr6:151411259~151413945:-
LUAD	cis	rs8067545	0.641	rs119672	ENSG00000270091.1	RP11-78O7.2	-3.57	0.000395	0.0427	-0.13	-0.16	Schizophrenia;	chr17:19915288	chr17:19896590~19897287:-
LUAD	cis	rs13113518	0.595	rs13120635	ENSG00000223305.1	RN7SKP30	3.57	0.000395	0.0427	0.2	0.16	Height;	chr4:55361200	chr4:55540502~55540835:-
LUAD	cis	rs10876993	0.928	rs1689587	ENSG00000270039.1	RP11-571M6.17	3.57	0.000395	0.0427	0.19	0.16	Celiac disease or Rheumatoid arthritis;	chr12:57681615	chr12:57803838~57804415:+
LUAD	cis	rs10876993	0.928	rs2640636	ENSG00000270039.1	RP11-571M6.17	3.57	0.000395	0.0427	0.19	0.16	Celiac disease or Rheumatoid arthritis;	chr12:57683761	chr12:57803838~57804415:+
LUAD	cis	rs10876993	0.928	rs2640637	ENSG00000270039.1	RP11-571M6.17	3.57	0.000395	0.0427	0.19	0.16	Celiac disease or Rheumatoid arthritis;	chr12:57683803	chr12:57803838~57804415:+
LUAD	cis	rs7512552	0.698	rs12028001	ENSG00000275557.1	RP11-353N4.6	3.57	0.000395	0.0428	0.18	0.16	Allergic disease (asthma, hay fever or eczema);Atopic dermatitis;	chr1:150435344	chr1:149607765~149612402:+
LUAD	cis	rs7142881	0.78	rs6571437	ENSG00000258525.1	RP11-829H16.3	-3.57	0.000395	0.0428	-0.18	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31610780	chr14:30876179~30889808:-
LUAD	cis	rs9303542	1	rs7219816	ENSG00000264920.1	RP11-6N17.4	-3.57	0.000395	0.0428	-0.21	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48316432	chr17:47891255~47895812:-
LUAD	cis	rs9303542	1	rs4131712	ENSG00000264920.1	RP11-6N17.4	-3.57	0.000395	0.0428	-0.21	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48316810	chr17:47891255~47895812:-
LUAD	cis	rs9303542	1	rs16955397	ENSG00000264920.1	RP11-6N17.4	-3.57	0.000395	0.0428	-0.21	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48316968	chr17:47891255~47895812:-
LUAD	cis	rs28510890	0.789	rs10852177	ENSG00000260337.3	RP11-386M24.6	3.57	0.000395	0.0428	0.21	0.16	Lung cancer in ever smokers;	chr15:92594248	chr15:92592574~92596462:-
LUAD	cis	rs950169	0.922	rs11631096	ENSG00000188388.10	GOLGA6L3	3.57	0.000395	0.0428	0.22	0.16	Schizophrenia;	chr15:84557698	chr15:85240472~85247170:+
LUAD	cis	rs11673344	0.583	rs7247090	ENSG00000267254.4	ZNF790-AS1	-3.57	0.000395	0.0428	-0.2	-0.16	Obesity-related traits;	chr19:37522509	chr19:36797518~36828115:+
LUAD	cis	rs62246343	0.605	rs17050395	ENSG00000206573.7	THUMPD3-AS1	-3.57	0.000396	0.0428	-0.14	-0.16	Fibrinogen levels;	chr3:9492290	chr3:9349689~9398579:-
LUAD	cis	rs1894292	0.715	rs1957659	ENSG00000221639.1	SNORA3	-3.57	0.000396	0.0428	-0.17	-0.16	Prostate cancer;	chr4:73606364	chr4:73263960~73264084:+
LUAD	cis	rs35740288	0.77	rs1382538	ENSG00000259407.1	RP11-158M2.3	-3.57	0.000396	0.0428	-0.16	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85622665	chr15:85744109~85750281:-
LUAD	cis	rs1387259	0.723	rs2732488	ENSG00000273765.1	RP11-370I10.11	3.57	0.000396	0.0428	0.17	0.16	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48377661	chr12:48360920~48361377:+
LUAD	cis	rs1387259	0.758	rs2634670	ENSG00000273765.1	RP11-370I10.11	3.57	0.000396	0.0428	0.17	0.16	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48378094	chr12:48360920~48361377:+
LUAD	cis	rs6460942	1	rs6948314	ENSG00000226690.5	AC005281.1	3.57	0.000396	0.0428	0.29	0.16	Coronary artery disease;	chr7:12378737	chr7:12496429~12541910:+
LUAD	cis	rs703842	1	rs11172333	ENSG00000245651.2	RP11-620J15.2	3.57	0.000396	0.0428	0.17	0.16	Multiple sclerosis;	chr12:57776552	chr12:57869835~57896482:-
LUAD	cis	rs1198872	0.892	rs1198863	ENSG00000272275.1	RP11-791G15.2	-3.57	0.000396	0.0428	-0.2	-0.16	Cardiac Troponin-T levels;	chr2:10760349	chr2:10767875~10770058:-
LUAD	cis	rs7204230	0.96	rs12149749	ENSG00000261291.1	RP11-295M3.2	3.57	0.000396	0.0428	0.19	0.16	Fibrinogen;	chr16:53302840	chr16:53168522~53169450:+
LUAD	cis	rs17597773	0.638	rs4143773	ENSG00000272823.1	RP11-295M18.6	-3.57	0.000396	0.0428	-0.21	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220814900	chr1:220828676~220829211:-
LUAD	cis	rs17680741	1	rs12260962	ENSG00000226659.1	RP11-137H2.4	3.57	0.000396	0.0428	0.24	0.16	Coronary artery disease;	chr10:80503070	chr10:80529597~80535942:-
LUAD	cis	rs7727544	0.582	rs3805683	ENSG00000233006.5	AC034220.3	3.57	0.000396	0.0428	0.14	0.16	Blood metabolite levels;	chr5:132199432	chr5:132311285~132369916:-
LUAD	cis	rs1790761	0.505	rs7938563	ENSG00000184224.3	C11orf72	-3.57	0.000396	0.0428	-0.19	-0.16	Mean corpuscular volume;	chr11:67536660	chr11:67602880~67606706:-
LUAD	cis	rs2147959	0.941	rs7524236	ENSG00000269934.1	RP5-1139B12.3	3.57	0.000396	0.0428	0.21	0.16	Adult asthma;	chr1:228442694	chr1:228274584~228276066:-
LUAD	cis	rs10863681	0.764	rs6678715	ENSG00000227925.1	RP11-191N8.2	3.57	0.000396	0.0428	0.19	0.16	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222103941	chr1:221827666~221840666:-
LUAD	cis	rs6121246	0.909	rs6060633	ENSG00000230613.1	HM13-AS1	3.57	0.000396	0.0428	0.23	0.16	Mean corpuscular hemoglobin;	chr20:31675514	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.909	rs6060644	ENSG00000230613.1	HM13-AS1	3.57	0.000396	0.0428	0.23	0.16	Mean corpuscular hemoglobin;	chr20:31677849	chr20:31567707~31573263:-
LUAD	cis	rs520525	0.963	rs627848	ENSG00000271811.1	RP1-79C4.4	3.57	0.000396	0.0428	0.21	0.16	Atrial fibrillation;	chr1:170662279	chr1:170667381~170669425:+
LUAD	cis	rs67981189	1	rs67981189	ENSG00000269927.1	RP6-91H8.3	3.57	0.000396	0.0428	0.2	0.16	Schizophrenia;	chr14:71005509	chr14:71141125~71143253:-
LUAD	cis	rs9921338	0.961	rs56136462	ENSG00000263080.1	RP11-485G7.5	3.57	0.000396	0.0428	0.22	0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11321738	chr16:11341809~11345211:-
LUAD	cis	rs4308124	0.679	rs7600458	ENSG00000230499.1	AC108463.1	-3.57	0.000396	0.0428	-0.22	-0.16	Vitiligo;	chr2:111206013	chr2:111195963~111206494:+
LUAD	cis	rs4308124	0.708	rs56693625	ENSG00000230499.1	AC108463.1	-3.57	0.000396	0.0428	-0.22	-0.16	Vitiligo;	chr2:111207578	chr2:111195963~111206494:+
LUAD	cis	rs4308124	0.708	rs61358692	ENSG00000230499.1	AC108463.1	-3.57	0.000396	0.0428	-0.22	-0.16	Vitiligo;	chr2:111207582	chr2:111195963~111206494:+
LUAD	cis	rs240993	0.516	rs173286	ENSG00000230177.1	RP5-1112D6.4	-3.57	0.000396	0.0428	-0.17	-0.16	Inflammatory skin disease;Psoriasis;	chr6:111292391	chr6:111277932~111278742:+
LUAD	cis	rs1346081	0.839	rs6820606	ENSG00000250075.4	RP11-584P21.2	-3.57	0.000396	0.0428	-0.17	-0.16	Intelligence (multi-trait analysis);	chr4:67071184	chr4:67417305~67468251:-
LUAD	cis	rs6687821	0.515	rs512912	ENSG00000261737.1	RP4-612B15.3	-3.57	0.000396	0.0428	-0.22	-0.16	Yeast infection;	chr1:86898359	chr1:86703502~86704462:-
LUAD	cis	rs877819	0.552	rs2671712	ENSG00000228403.1	RP11-563N6.6	3.57	0.000396	0.0428	0.16	0.16	Systemic lupus erythematosus;	chr10:48883000	chr10:48878022~48878649:+
LUAD	cis	rs5758511	0.773	rs10154700	ENSG00000226450.2	CYP2D8P	3.57	0.000396	0.0428	0.14	0.16	Birth weight;	chr22:41969069	chr22:42149886~42155001:-
LUAD	cis	rs1044826	1	rs9860201	ENSG00000214280.3	RP11-553K23.2	-3.57	0.000396	0.0428	-0.19	-0.16	Obesity-related traits;	chr3:139372602	chr3:139582928~139583593:-
LUAD	cis	rs2071518	0.76	rs11782995	ENSG00000254343.2	RP11-760H22.2	-3.57	0.000396	0.0428	-0.2	-0.16	Blood pressure;Pulse pressure;	chr8:119388607	chr8:120052180~120056201:+
LUAD	cis	rs2921073	0.605	rs2976933	ENSG00000253981.4	ALG1L13P	3.57	0.000396	0.0429	0.19	0.16	Parkinson's disease;	chr8:8397365	chr8:8236003~8244667:-
LUAD	cis	rs9475752	1	rs34812189	ENSG00000231441.1	RP11-472M19.2	3.57	0.000396	0.0429	0.26	0.16	Menarche (age at onset);	chr6:56941929	chr6:56844002~56864078:+
LUAD	cis	rs4268898	0.552	rs11125455	ENSG00000242628.4	AC009228.1	-3.57	0.000396	0.0429	-0.21	-0.16	Asthma;	chr2:24151687	chr2:24214381~24221516:+
LUAD	cis	rs9467773	0.869	rs1796521	ENSG00000261353.1	CTA-14H9.5	3.57	0.000396	0.0429	0.18	0.16	Intelligence (multi-trait analysis);	chr6:26421164	chr6:26527063~26527404:+
LUAD	cis	rs6921919	1	rs6922111	ENSG00000219392.1	RP1-265C24.5	-3.57	0.000396	0.0429	-0.23	-0.16	Autism spectrum disorder or schizophrenia;	chr6:28357531	chr6:28115628~28116551:+
LUAD	cis	rs13014235	0.532	rs11681592	ENSG00000213090.2	AC007256.5	3.57	0.000397	0.0429	0.18	0.16	Basal cell carcinoma;	chr2:201399178	chr2:201410544~201413308:-
LUAD	cis	rs2898290	0.506	rs2736311	ENSG00000255046.1	RP11-297N6.4	3.57	0.000397	0.0429	0.19	0.16	Systolic blood pressure;	chr8:11394661	chr8:11797928~11802568:-
LUAD	cis	rs950169	0.84	rs62019457	ENSG00000188388.10	GOLGA6L3	3.57	0.000397	0.0429	0.21	0.16	Schizophrenia;	chr15:84558911	chr15:85240472~85247170:+
LUAD	cis	rs13398147	0.879	rs62180487	ENSG00000267034.1	RP11-384O8.1	3.57	0.000397	0.0429	0.23	0.16	Adolescent idiopathic scoliosis;	chr2:221858742	chr2:222317242~222318653:-
LUAD	cis	rs4865762	0.512	rs12521034	ENSG00000247796.2	CTD-2366F13.1	3.57	0.000397	0.0429	0.18	0.16	Intraocular pressure;	chr5:53218777	chr5:53109842~53115126:+
LUAD	cis	rs4865762	0.512	rs6897187	ENSG00000247796.2	CTD-2366F13.1	3.57	0.000397	0.0429	0.18	0.16	Intraocular pressure;	chr5:53218847	chr5:53109842~53115126:+
LUAD	cis	rs38055	0.581	rs6897912	ENSG00000247796.2	CTD-2366F13.1	3.57	0.000397	0.0429	0.18	0.16	Acne (severe);	chr5:53219317	chr5:53109842~53115126:+
LUAD	cis	rs4474465	0.85	rs4590904	ENSG00000251323.2	RP11-452H21.4	-3.57	0.000397	0.0429	-0.2	-0.16	Alzheimer's disease (survival time);	chr11:78552801	chr11:78423982~78429836:-
LUAD	cis	rs763121	0.886	rs1013339	ENSG00000225450.1	RP3-508I15.14	-3.57	0.000397	0.0429	-0.15	-0.16	Menopause (age at onset);	chr22:38578675	chr22:38739003~38749041:+
LUAD	cis	rs73108077	0.736	rs73105954	ENSG00000281376.1	ABALON	-3.57	0.000397	0.0429	-0.26	-0.16	Red blood cell density in sickle cell anemia;	chr20:31355903	chr20:31721507~31723409:+
LUAD	cis	rs9549260	0.848	rs966968	ENSG00000168852.11	TPTE2P5	-3.57	0.000397	0.0429	-0.16	-0.16	Red blood cell count;	chr13:40673900	chr13:40822296~40921749:-
LUAD	cis	rs7142881	0.844	rs7152067	ENSG00000258525.1	RP11-829H16.3	3.57	0.000397	0.0429	0.19	0.16	Response to iloperidone treatment (QT prolongation);	chr14:31563847	chr14:30876179~30889808:-
LUAD	cis	rs6951245	1	rs78523927	ENSG00000224079.1	AC091729.7	-3.57	0.000397	0.0429	-0.25	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1049822	chr7:1074450~1078036:+
LUAD	cis	rs848087	0.967	rs848125	ENSG00000258661.1	RP11-964E11.2	-3.57	0.000397	0.0429	-0.19	-0.16	Breast cancer;	chr14:36778607	chr14:36647083~36658801:-
LUAD	cis	rs12049351	0.774	rs767301	ENSG00000229367.1	HMGN2P19	3.57	0.000397	0.0429	0.22	0.16	Circulating myeloperoxidase levels (plasma);	chr1:229563268	chr1:229570532~229570796:+
LUAD	cis	rs7134599	1	rs10878748	ENSG00000240087.3	RP11-254B13.1	3.57	0.000397	0.0429	0.14	0.16	Inflammatory bowel disease;Ulcerative colitis;	chr12:68113313	chr12:68552995~68553882:-
LUAD	cis	rs2281636	0.931	rs2300984	ENSG00000233690.1	EBAG9P1	3.57	0.000397	0.0429	0.16	0.16	Obesity-related traits;	chr10:99717100	chr10:99697407~99697949:-
LUAD	cis	rs2281636	0.894	rs2300985	ENSG00000233690.1	EBAG9P1	3.57	0.000397	0.0429	0.16	0.16	Obesity-related traits;	chr10:99717148	chr10:99697407~99697949:-
LUAD	cis	rs12073359	1	rs7530922	ENSG00000223945.2	RP11-458I7.1	3.57	0.000397	0.0429	0.23	0.16	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150051427	chr1:150053864~150055034:+
LUAD	cis	rs2243480	1	rs422164	ENSG00000222364.1	RNU6-96P	-3.57	0.000397	0.0429	-0.26	-0.16	Diabetic kidney disease;	chr7:66121618	chr7:66395191~66395286:+
LUAD	cis	rs2243480	0.908	rs1532573	ENSG00000222364.1	RNU6-96P	3.57	0.000397	0.0429	0.26	0.16	Diabetic kidney disease;	chr7:66333815	chr7:66395191~66395286:+
LUAD	cis	rs72827839	0.696	rs117974417	ENSG00000228782.6	CTD-2026D20.3	3.57	0.000397	0.0429	0.26	0.16	Ease of getting up in the morning;	chr17:48079148	chr17:47450568~47492492:-
LUAD	cis	rs8141529	0.956	rs469989	ENSG00000226471.5	CTA-292E10.6	3.57	0.000397	0.0429	0.2	0.16	Lymphocyte counts;	chr22:28907607	chr22:28800683~28848559:+
LUAD	cis	rs34783982	0.764	rs2351488	ENSG00000261441.1	RP11-217B1.2	-3.57	0.000397	0.0429	-0.22	-0.16	Squamous cell lung carcinoma;	chr15:88958681	chr15:89335053~89336161:+
LUAD	cis	rs2117029	0.767	rs3741622	ENSG00000258017.1	RP11-386G11.10	-3.57	0.000397	0.0429	-0.21	-0.16	Intelligence (multi-trait analysis);	chr12:49032195	chr12:49127782~49147869:+
LUAD	cis	rs7937890	1	rs6486190	ENSG00000251991.1	RNU7-49P	3.57	0.000397	0.0429	0.17	0.16	Mitochondrial DNA levels;	chr11:14379670	chr11:14478892~14478953:+
LUAD	cis	rs6933660	0.8	rs3800273	ENSG00000219395.2	HSPA8P15	-3.57	0.000397	0.0429	-0.16	-0.16	Menarche (age at onset);	chr6:151437900	chr6:151411259~151413945:-
LUAD	cis	rs2832077	0.506	rs2832093	ENSG00000215533.7	LINC00189	3.57	0.000397	0.0429	0.2	0.16	Cognitive test performance;	chr21:28792533	chr21:29193480~29288205:+
LUAD	cis	rs1910358	0.69	rs10066987	ENSG00000248874.4	C5orf17	-3.57	0.000397	0.0429	-0.21	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23970584	chr5:23951348~24178263:+
LUAD	cis	rs1910358	0.664	rs4554168	ENSG00000248874.4	C5orf17	-3.57	0.000397	0.0429	-0.21	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23973867	chr5:23951348~24178263:+
LUAD	cis	rs12908161	0.96	rs62019463	ENSG00000259654.1	RP11-245C17.2	-3.57	0.000397	0.0429	-0.23	-0.16	Schizophrenia;	chr15:84744856	chr15:84685884~84686946:+
LUAD	cis	rs7539542	0.556	rs2275734	ENSG00000234996.3	RP11-480I12.7	-3.57	0.000397	0.0429	-0.17	-0.16	Mean platelet volume;	chr1:202918167	chr1:202861754~202875241:+
LUAD	cis	rs4792901	0.918	rs1728181	ENSG00000198496.9	NBR2	-3.57	0.000397	0.0429	-0.19	-0.16	Dupuytren's disease;	chr17:43597608	chr17:43125610~43153671:+
LUAD	cis	rs2546057	1	rs2546057	ENSG00000274104.1	CTD-2553L13.10	3.57	0.000397	0.0429	0.17	0.16	Body mass index (joint analysis main effects and physical activity interaction);Major depressive disorder;Body mass index in physically active individuals;Body mass index;	chr19:33829949	chr19:34733298~34733837:-
LUAD	cis	rs329122	0.528	rs329121	ENSG00000280420.1	AC005355.3	3.57	0.000397	0.0429	0.18	0.16	Body mass index;Type 2 diabetes;	chr5:134527662	chr5:134522613~134523096:-
LUAD	cis	rs2074518	0.875	rs2339123	ENSG00000267312.1	RP11-1094M14.7	-3.57	0.000397	0.043	-0.18	-0.16	QT interval;	chr17:35055715	chr17:35459481~35460550:-
LUAD	cis	rs2074518	0.934	rs1634800	ENSG00000267312.1	RP11-1094M14.7	-3.57	0.000397	0.043	-0.18	-0.16	QT interval;	chr17:35056011	chr17:35459481~35460550:-
LUAD	cis	rs7219021	0.669	rs35584414	ENSG00000270781.1	RP11-501C14.9	-3.57	0.000398	0.043	-0.21	-0.16	Schizophrenia or bipolar disorder;	chr17:48945365	chr17:48899131~48899748:+
LUAD	cis	rs7176527	0.8	rs56747535	ENSG00000259570.1	RP11-671M22.4	-3.57	0.000398	0.043	-0.24	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84632709	chr15:84394512~84395514:+
LUAD	cis	rs910316	0.737	rs91144	ENSG00000259138.1	RP11-950C14.7	-3.57	0.000398	0.043	-0.17	-0.16	Height;	chr14:74982814	chr14:75127153~75136930:+
LUAD	cis	rs56322409	0.561	rs12778814	ENSG00000231829.2	RP11-310E22.5	-3.57	0.000398	0.043	-0.19	-0.16	Blood metabolite levels;	chr10:95607360	chr10:95141925~95168425:-
LUAD	cis	rs8033133	0.514	rs11634505	ENSG00000275529.1	SNORD116-4	3.57	0.000398	0.043	0.18	0.16	Blood osmolality (transformed sodium);	chr15:25060769	chr15:25059538~25059633:+
LUAD	cis	rs7870753	0.578	rs80024379	ENSG00000188801.9	ZNF322P1	3.57	0.000398	0.043	0.25	0.16	Height;	chr9:96337968	chr9:97198303~97199511:-
LUAD	cis	rs9595908	0.785	rs9315174	ENSG00000281026.1	N4BP2L2-IT2	-3.57	0.000398	0.043	-0.1	-0.16	Body mass index;	chr13:32645750	chr13:32504506~32509395:-
LUAD	cis	rs7760535	0.735	rs240974	ENSG00000271789.1	RP5-1112D6.7	-3.57	0.000398	0.043	-0.17	-0.16	Metabolic traits;	chr6:111328113	chr6:111297126~111298510:+
LUAD	cis	rs451417	0.818	rs236103	ENSG00000275632.1	RP5-967N21.11	3.57	0.000398	0.043	0.22	0.16	Menopause (age at onset);	chr20:5977341	chr20:6000418~6000941:+
LUAD	cis	rs9287719	0.747	rs1534400	ENSG00000243819.4	RN7SL832P	3.57	0.000398	0.043	0.17	0.16	Prostate cancer;	chr2:10556707	chr2:10690344~10692099:+
LUAD	cis	rs4595586	1	rs4384412	ENSG00000257718.1	RP11-396F22.1	-3.57	0.000398	0.043	-0.19	-0.16	Morning vs. evening chronotype;	chr12:38824311	chr12:38906451~38909592:+
LUAD	cis	rs1348850	1	rs3927978	ENSG00000271825.1	RP11-337N6.2	-3.57	0.000398	0.043	-0.2	-0.16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177579126	chr2:177300600~177302006:+
LUAD	cis	rs219780	0.796	rs2244034	ENSG00000233818.1	AP000695.4	3.57	0.000398	0.043	0.21	0.16	Kidney stones;	chr21:36444007	chr21:36445731~36532408:+
LUAD	cis	rs10496034	1	rs57737203	ENSG00000240401.7	AC012358.8	3.57	0.000398	0.043	0.41	0.16	Refractive astigmatism;	chr2:55041055	chr2:55282350~55346049:+
LUAD	cis	rs7077256	0.542	rs36089084	ENSG00000272767.1	JMJD1C-AS1	3.57	0.000398	0.043	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63478892	chr10:63465229~63466563:+
LUAD	cis	rs7077256	0.564	rs12770873	ENSG00000272767.1	JMJD1C-AS1	3.57	0.000398	0.043	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63488747	chr10:63465229~63466563:+
LUAD	cis	rs7077256	0.564	rs72837051	ENSG00000272767.1	JMJD1C-AS1	3.57	0.000398	0.043	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63494298	chr10:63465229~63466563:+
LUAD	cis	rs7077256	0.521	rs71508969	ENSG00000272767.1	JMJD1C-AS1	3.57	0.000398	0.043	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63494750	chr10:63465229~63466563:+
LUAD	cis	rs7077256	0.564	rs12785227	ENSG00000272767.1	JMJD1C-AS1	3.57	0.000398	0.043	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63502925	chr10:63465229~63466563:+
LUAD	cis	rs7274811	0.595	rs13045068	ENSG00000231795.1	ITCH-IT1	3.57	0.000398	0.043	0.19	0.16	Height;	chr20:33545678	chr20:34450930~34454552:+
LUAD	cis	rs7274811	0.554	rs35556109	ENSG00000231795.1	ITCH-IT1	3.57	0.000398	0.043	0.19	0.16	Height;	chr20:33545683	chr20:34450930~34454552:+
LUAD	cis	rs7274811	0.554	rs6120299	ENSG00000231795.1	ITCH-IT1	3.57	0.000398	0.043	0.19	0.16	Height;	chr20:33545685	chr20:34450930~34454552:+
LUAD	cis	rs3617	0.573	rs12638968	ENSG00000242142.1	SERBP1P3	-3.57	0.000398	0.043	-0.17	-0.16	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52885431	chr3:53064283~53065091:-
LUAD	cis	rs6471393	0.964	rs1051914	ENSG00000253848.1	RP11-10N23.5	3.57	0.000398	0.043	0.2	0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93728838	chr8:93741193~93744534:+
LUAD	cis	rs12368653	0.84	rs3816896	ENSG00000245651.2	RP11-620J15.2	-3.57	0.000398	0.043	-0.16	-0.16	Multiple sclerosis;	chr12:57801990	chr12:57869835~57896482:-
LUAD	cis	rs9910055	0.502	rs1684662	ENSG00000267080.4	ASB16-AS1	3.57	0.000398	0.043	0.15	0.16	Total body bone mineral density;	chr17:44103454	chr17:44175973~44186717:-
LUAD	cis	rs9341808	0.591	rs6454147	ENSG00000272129.1	RP11-250B2.6	3.57	0.000398	0.043	0.2	0.16	Sitting height ratio;	chr6:80206611	chr6:80355424~80356859:+
LUAD	cis	rs3788317	0.526	rs12168841	ENSG00000232926.1	AC000078.5	-3.57	0.000398	0.043	-0.18	-0.16	Glaucoma (primary angle closure);	chr22:19897505	chr22:19887289~19887970:+
LUAD	cis	rs67478160	0.643	rs8004408	ENSG00000272533.1	SNORA28	3.57	0.000398	0.043	0.17	0.16	Schizophrenia;	chr14:103737601	chr14:103337849~103337974:+
LUAD	cis	rs2456930	0.648	rs2261443	ENSG00000261296.1	RP11-299H22.6	3.57	0.000399	0.043	0.21	0.16	Brain structure (temporal lobe volume);	chr15:62387973	chr15:62274163~62278365:+
LUAD	cis	rs2732480	0.5	rs2450989	ENSG00000273765.1	RP11-370I10.11	-3.57	0.000399	0.043	-0.17	-0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48259625	chr12:48360920~48361377:+
LUAD	cis	rs12368653	0.84	rs10877020	ENSG00000245651.2	RP11-620J15.2	-3.57	0.000399	0.043	-0.16	-0.16	Multiple sclerosis;	chr12:57794231	chr12:57869835~57896482:-
LUAD	cis	rs4841134	0.745	rs13278594	ENSG00000233609.3	RP11-62H7.2	-3.57	0.000399	0.043	-0.13	-0.16	Age-related disease endophenotypes;	chr8:9338956	chr8:8961200~8979025:+
LUAD	cis	rs9921338	0.961	rs4315353	ENSG00000263080.1	RP11-485G7.5	-3.57	0.000399	0.043	-0.21	-0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11320303	chr16:11341809~11345211:-
LUAD	cis	rs8180040	0.62	rs1811652	ENSG00000260236.1	RP11-708J19.1	-3.57	0.000399	0.0431	-0.15	-0.16	Colorectal cancer;	chr3:47167208	chr3:47379089~47380999:-
LUAD	cis	rs8180040	0.654	rs62246451	ENSG00000260236.1	RP11-708J19.1	-3.57	0.000399	0.0431	-0.15	-0.16	Colorectal cancer;	chr3:47170142	chr3:47379089~47380999:-
LUAD	cis	rs6487679	0.543	rs4883222	ENSG00000111788.10	RP11-22B23.1	3.57	0.000399	0.0431	0.24	0.16	Non-alcoholic fatty liver disease histology (AST);	chr12:9223819	chr12:9277235~9313241:+
LUAD	cis	rs2074409	0.509	rs11655957	ENSG00000276054.1	RP11-378E13.3	3.57	0.000399	0.0431	0.2	0.16	Response to angiotensin II receptor blocker therapy;	chr17:37459133	chr17:37386886~37387926:+
LUAD	cis	rs7017914	0.69	rs7825815	ENSG00000246366.5	RP11-382J12.1	3.57	0.000399	0.0431	0.15	0.16	Bone mineral density;	chr8:71074170	chr8:70608577~70663279:+
LUAD	cis	rs910316	0.763	rs175044	ENSG00000279594.1	RP11-950C14.10	-3.57	0.000399	0.0431	-0.18	-0.16	Height;	chr14:75005406	chr14:75011269~75012851:-
LUAD	cis	rs4662986	0.535	rs11694670	ENSG00000214100.7	AC079776.2	3.57	0.000399	0.0431	0.3	0.16	Age at smoking initiation in chronic obstructive pulmonary disease;	chr2:129656488	chr2:129922863~129934317:-
LUAD	cis	rs7204230	1	rs16952141	ENSG00000261291.1	RP11-295M3.2	3.57	0.000399	0.0431	0.19	0.16	Fibrinogen;	chr16:53294875	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs12596211	ENSG00000261291.1	RP11-295M3.2	3.57	0.000399	0.0431	0.19	0.16	Fibrinogen;	chr16:53298530	chr16:53168522~53169450:+
LUAD	cis	rs3741404	0.791	rs11603192	ENSG00000256789.1	RP11-697H9.2	-3.57	0.000399	0.0431	-0.18	-0.16	Platelet count;	chr11:64160223	chr11:63637677~63658962:+
LUAD	cis	rs73242632	1	rs115267736	ENSG00000269949.1	RP11-738E22.3	3.57	0.000399	0.0431	0.4	0.16	Congenital heart disease (maternal effect);	chr4:56900757	chr4:56960927~56961373:-
LUAD	cis	rs67478160	0.619	rs2368560	ENSG00000258914.1	CTD-2134A5.3	-3.57	0.000399	0.0431	-0.18	-0.16	Schizophrenia;	chr14:103806974	chr14:103875055~103877478:+
LUAD	cis	rs7812879	0.636	rs2618456	ENSG00000255046.1	RP11-297N6.4	3.57	0.000399	0.0431	0.28	0.16	Systemic lupus erythematosus;	chr8:11513224	chr8:11797928~11802568:-
LUAD	cis	rs9900280	1	rs4419109	ENSG00000264808.1	RP11-802D6.1	3.57	0.000399	0.0431	0.19	0.16	Mean platelet volume;	chr17:29432045	chr17:29369717~29390777:-
LUAD	cis	rs28374715	0.681	rs28728213	ENSG00000247556.5	OIP5-AS1	3.57	0.000399	0.0431	0.19	0.16	Ulcerative colitis;	chr15:41361404	chr15:41283990~41309737:+
LUAD	cis	rs6701713	0.84	rs6656401	ENSG00000274245.1	RP11-357P18.2	3.57	0.000399	0.0431	0.26	0.16	Alzheimer's disease (late onset);	chr1:207518704	chr1:207372559~207373252:+
LUAD	cis	rs13113518	1	rs13132420	ENSG00000273257.1	RP11-177J6.1	-3.57	0.000399	0.0431	-0.17	-0.16	Height;	chr4:55526646	chr4:55387949~55388271:+
LUAD	cis	rs4656940	0.943	rs11265498	ENSG00000224259.4	LINC01133	-3.57	0.000399	0.0431	-0.2	-0.16	Crohn's disease;	chr1:160858495	chr1:159961218~159979061:+
LUAD	cis	rs1722141	0.67	rs1722148	ENSG00000237471.1	AC073115.6	3.57	0.000399	0.0431	0.25	0.16	Sitting height ratio;	chr7:45953897	chr7:45969657~45980191:+
LUAD	cis	rs1722141	0.67	rs788766	ENSG00000237471.1	AC073115.6	3.57	0.000399	0.0431	0.25	0.16	Sitting height ratio;	chr7:45957944	chr7:45969657~45980191:+
LUAD	cis	rs1722141	0.67	rs788768	ENSG00000237471.1	AC073115.6	3.57	0.000399	0.0431	0.25	0.16	Sitting height ratio;	chr7:45960955	chr7:45969657~45980191:+
LUAD	cis	rs1910358	0.614	rs12656465	ENSG00000248874.4	C5orf17	-3.57	0.000399	0.0431	-0.2	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23965369	chr5:23951348~24178263:+
LUAD	cis	rs7772486	0.686	rs702305	ENSG00000235652.6	RP11-545I5.3	-3.57	0.000399	0.0431	-0.16	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145652704	chr6:145799409~145886585:+
LUAD	cis	rs7170668	0.894	rs8036283	ENSG00000259134.4	LINC00924	-3.57	0.000399	0.0431	-0.19	-0.16	Motion sickness;	chr15:95480382	chr15:95433095~95507847:+
LUAD	cis	rs7615952	0.576	rs12497295	ENSG00000241288.6	RP11-379B18.5	-3.57	0.000399	0.0431	-0.22	-0.16	Blood pressure (smoking interaction);	chr3:126099807	chr3:125827238~125916384:-
LUAD	cis	rs763121	0.853	rs5750627	ENSG00000228274.3	RP3-508I15.9	-3.57	0.000399	0.0431	-0.15	-0.16	Menopause (age at onset);	chr22:38586316	chr22:38667585~38681820:-
LUAD	cis	rs860295	1	rs708611	ENSG00000203761.5	MSTO2P	3.57	0.000399	0.0431	0.12	0.16	Body mass index;	chr1:155773519	chr1:155745829~155750137:+
LUAD	cis	rs2274273	0.84	rs943590	ENSG00000259318.1	RP11-454L9.2	3.57	0.000399	0.0431	0.14	0.16	Protein biomarker;	chr14:55271878	chr14:55394940~55395233:-
LUAD	cis	rs8062405	1	rs8061590	ENSG00000261766.1	RP11-22P6.2	-3.57	0.000399	0.0431	-0.14	-0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28883809	chr16:28862166~28863340:-
LUAD	cis	rs8177876	0.822	rs9925940	ENSG00000261061.1	RP11-303E16.2	-3.57	0.000399	0.0431	-0.27	-0.16	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077379	chr16:81030770~81031485:+
LUAD	cis	rs8177876	0.822	rs9925943	ENSG00000261061.1	RP11-303E16.2	-3.57	0.000399	0.0431	-0.27	-0.16	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81077402	chr16:81030770~81031485:+
LUAD	cis	rs6496667	0.908	rs12592935	ENSG00000214433.4	GOLGA2P8	3.57	0.000399	0.0431	0.27	0.16	Rheumatoid arthritis;	chr15:90309205	chr15:90291962~90295683:+
LUAD	cis	rs7942368	1	rs1837680	ENSG00000254632.1	RP11-21L23.4	3.57	0.000399	0.0431	0.17	0.16	Endometriosis;	chr11:76790407	chr11:76759916~76768223:-
LUAD	cis	rs12440869	1	rs8025186	ENSG00000270964.1	RP11-502I4.3	-3.57	0.000399	0.0431	-0.19	-0.16	Peak velocity of the mitral A-wave;	chr15:67349216	chr15:67541072~67542604:-
LUAD	cis	rs4372836	0.964	rs56240884	ENSG00000265321.1	MIR4263	3.57	0.000399	0.0431	0.22	0.16	Body mass index;	chr2:28717288	chr2:27996367~27996449:+
LUAD	cis	rs4268898	0.896	rs2702042	ENSG00000223754.1	AC008073.9	3.57	0.000399	0.0431	0.2	0.16	Asthma;	chr2:24323673	chr2:24199839~24201698:-
LUAD	cis	rs7077256	0.521	rs1054693	ENSG00000272767.1	JMJD1C-AS1	3.57	0.000399	0.0431	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63465690	chr10:63465229~63466563:+
LUAD	cis	rs7976269	0.559	rs10843313	ENSG00000275476.1	RP11-996F15.4	-3.57	0.000399	0.0431	-0.18	-0.16	Male-pattern baldness;	chr12:29078317	chr12:29277397~29277882:-
LUAD	cis	rs7976269	0.609	rs6487744	ENSG00000275476.1	RP11-996F15.4	-3.57	0.000399	0.0431	-0.17	-0.16	Male-pattern baldness;	chr12:29030756	chr12:29277397~29277882:-
LUAD	cis	rs2115630	0.653	rs61394864	ENSG00000275120.1	RP11-182J1.17	-3.57	0.000399	0.0431	-0.21	-0.16	P wave terminal force;	chr15:84626943	chr15:84599434~84606463:-
LUAD	cis	rs2975734	0.676	rs4841299	ENSG00000280294.1	RP11-177H2.1	-3.57	4e-04	0.0431	-0.21	-0.16	Chronotype;Morning vs. evening chronotype;	chr8:10255083	chr8:10856085~10859436:-
LUAD	cis	rs2274273	0.745	rs8005399	ENSG00000259318.1	RP11-454L9.2	3.57	4e-04	0.0431	0.14	0.16	Protein biomarker;	chr14:55076127	chr14:55394940~55395233:-
LUAD	cis	rs7308116	0.645	rs10861833	ENSG00000258072.1	RP11-554D14.2	3.57	4e-04	0.0431	0.18	0.16	Pelvic organ prolapse (moderate/severe);	chr12:107902358	chr12:107903270~107903948:-
LUAD	cis	rs763121	0.925	rs5757251	ENSG00000225450.1	RP3-508I15.14	-3.57	4e-04	0.0431	-0.15	-0.16	Menopause (age at onset);	chr22:38704123	chr22:38739003~38749041:+
LUAD	cis	rs2147959	0.941	rs10916317	ENSG00000269934.1	RP5-1139B12.3	-3.57	4e-04	0.0431	-0.21	-0.16	Adult asthma;	chr1:228457362	chr1:228274584~228276066:-
LUAD	cis	rs6012953	0.845	rs718053	ENSG00000231715.1	COX6CP2	-3.57	4e-04	0.0431	-0.16	-0.16	Vitiligo;	chr20:50580065	chr20:50479767~50479991:+
LUAD	cis	rs7204230	1	rs11861565	ENSG00000261291.1	RP11-295M3.2	3.57	4e-04	0.0431	0.19	0.16	Fibrinogen;	chr16:53199751	chr16:53168522~53169450:+
LUAD	cis	rs4865762	0.512	rs6873915	ENSG00000247796.2	CTD-2366F13.1	3.57	4e-04	0.0431	0.18	0.16	Intraocular pressure;	chr5:53214634	chr5:53109842~53115126:+
LUAD	cis	rs7829975	0.582	rs448231	ENSG00000233609.3	RP11-62H7.2	-3.57	4e-04	0.0431	-0.13	-0.16	Mood instability;	chr8:8932549	chr8:8961200~8979025:+
LUAD	cis	rs2243480	1	rs1404147	ENSG00000228409.4	CCT6P1	3.57	4e-04	0.0431	0.19	0.16	Diabetic kidney disease;	chr7:65799537	chr7:65751142~65763354:+
LUAD	cis	rs6570726	0.526	rs9403699	ENSG00000235652.6	RP11-545I5.3	3.57	4e-04	0.0431	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145409549	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.686	rs857875	ENSG00000235652.6	RP11-545I5.3	-3.57	4e-04	0.0431	-0.16	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145658897	chr6:145799409~145886585:+
LUAD	cis	rs6688613	0.685	rs10918599	ENSG00000225171.2	DUTP6	-3.57	4e-04	0.0431	-0.2	-0.16	Refractive astigmatism;	chr1:166949549	chr1:166868748~166869209:+
LUAD	cis	rs2708977	0.73	rs674920	ENSG00000237510.6	AC008268.2	-3.57	4e-04	0.0431	-0.21	-0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96404418	chr2:95789654~95800166:+
LUAD	cis	rs708547	0.599	rs2948348	ENSG00000269949.1	RP11-738E22.3	3.57	4e-04	0.0432	0.21	0.16	Response to bleomycin (chromatid breaks);	chr4:56982606	chr4:56960927~56961373:-
LUAD	cis	rs8114671	0.967	rs6088753	ENSG00000269202.1	RP4-614O4.12	-3.57	4e-04	0.0432	-0.16	-0.16	Height;	chr20:35180449	chr20:35201747~35203288:-
LUAD	cis	rs9900280	1	rs2559625	ENSG00000264808.1	RP11-802D6.1	-3.57	4e-04	0.0432	-0.19	-0.16	Mean platelet volume;	chr17:29502228	chr17:29369717~29390777:-
LUAD	cis	rs9896933	0.623	rs77166830	ENSG00000262663.1	RP11-497H17.1	3.57	4e-04	0.0432	0.2	0.16	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr17:82875649	chr17:82918282~82918785:+
LUAD	cis	rs7215564	0.818	rs34929663	ENSG00000232083.3	RPL31P7	3.57	4e-04	0.0432	0.29	0.16	Myopia (pathological);	chr17:80643412	chr17:80602549~80602926:-
LUAD	cis	rs10129255	0.834	rs10139893	ENSG00000274576.2	IGHV2-70	3.57	4e-04	0.0432	0.15	0.16	Kawasaki disease;	chr14:106711377	chr14:106770577~106771020:-
LUAD	cis	rs1555322	0.872	rs2425046	ENSG00000279253.1	RP4-614O4.13	-3.56	4e-04	0.0432	-0.26	-0.16	Attention deficit hyperactivity disorder;	chr20:35283858	chr20:35262727~35264187:-
LUAD	cis	rs7537765	0.696	rs72640257	ENSG00000242349.4	NPPA-AS1	3.56	4e-04	0.0432	0.3	0.16	QRS complex (12-leadsum);	chr1:11816338	chr1:11841017~11848079:+
LUAD	cis	rs7537765	0.649	rs72640258	ENSG00000242349.4	NPPA-AS1	3.56	4e-04	0.0432	0.3	0.16	QRS complex (12-leadsum);	chr1:11817209	chr1:11841017~11848079:+
LUAD	cis	rs7537765	0.696	rs12564593	ENSG00000242349.4	NPPA-AS1	3.56	4e-04	0.0432	0.3	0.16	QRS complex (12-leadsum);	chr1:11818562	chr1:11841017~11848079:+
LUAD	cis	rs7537765	0.696	rs2076002	ENSG00000242349.4	NPPA-AS1	3.56	4e-04	0.0432	0.3	0.16	QRS complex (12-leadsum);	chr1:11819303	chr1:11841017~11848079:+
LUAD	cis	rs7537765	0.696	rs2076004	ENSG00000242349.4	NPPA-AS1	3.56	4e-04	0.0432	0.3	0.16	QRS complex (12-leadsum);	chr1:11826756	chr1:11841017~11848079:+
LUAD	cis	rs3849150	0.898	rs35495091	ENSG00000235939.1	RP11-123B3.2	-3.56	4e-04	0.0432	-0.25	-0.16	Subclinical atherosclerosis traits (other);	chr10:48873033	chr10:49419277~49472903:+
LUAD	cis	rs2625529	0.73	rs3759900	ENSG00000260173.1	RP11-2I17.4	3.56	4e-04	0.0432	0.2	0.16	Red blood cell count;	chr15:72159486	chr15:72140504~72155459:-
LUAD	cis	rs739496	0.527	rs10774639	ENSG00000234608.6	MAPKAPK5-AS1	3.56	4e-04	0.0432	0.17	0.16	Platelet count;	chr12:111820641	chr12:111839764~111842902:-
LUAD	cis	rs748404	0.626	rs35992154	ENSG00000249839.1	AC011330.5	-3.56	4e-04	0.0432	-0.25	-0.16	Lung cancer;	chr15:43345669	chr15:43663654~43684339:-
LUAD	cis	rs987044	0.807	rs7959539	ENSG00000257221.1	RP11-689B22.2	-3.56	4e-04	0.0432	-0.13	-0.16	Mean platelet volume;	chr12:108741204	chr12:108628687~108641318:+
LUAD	cis	rs2880765	0.835	rs4536419	ENSG00000259630.2	CTD-2262B20.1	-3.56	4e-04	0.0432	-0.18	-0.16	Coronary artery disease;	chr15:85496240	chr15:85415228~85415633:+
LUAD	cis	rs2071518	1	rs2279112	ENSG00000254343.2	RP11-760H22.2	-3.56	4e-04	0.0432	-0.19	-0.16	Blood pressure;Pulse pressure;	chr8:119416784	chr8:120052180~120056201:+
LUAD	cis	rs1431005	0.893	rs9684748	ENSG00000250658.1	RP11-138B4.1	3.56	0.000401	0.0432	0.2	0.16	Response to statin therapy;	chr4:187398070	chr4:187304083~187309682:-
LUAD	cis	rs755249	0.567	rs3768301	ENSG00000182109.6	RP11-69E11.4	3.56	0.000401	0.0432	0.2	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39405121	chr1:39522280~39546187:-
LUAD	cis	rs755249	0.567	rs113214136	ENSG00000182109.6	RP11-69E11.4	3.56	0.000401	0.0432	0.2	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39408867	chr1:39522280~39546187:-
LUAD	cis	rs755249	0.567	rs3768302	ENSG00000182109.6	RP11-69E11.4	3.56	0.000401	0.0432	0.2	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39414647	chr1:39522280~39546187:-
LUAD	cis	rs755249	0.532	rs17343193	ENSG00000182109.6	RP11-69E11.4	3.56	0.000401	0.0432	0.2	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39415796	chr1:39522280~39546187:-
LUAD	cis	rs755249	0.567	rs61779300	ENSG00000182109.6	RP11-69E11.4	3.56	0.000401	0.0432	0.2	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39420091	chr1:39522280~39546187:-
LUAD	cis	rs8046148	0.724	rs8051902	ENSG00000279356.1	RP11-429P3.8	3.56	0.000401	0.0432	0.16	0.16	Testicular germ cell tumor;	chr16:50065866	chr16:50072862~50074986:+
LUAD	cis	rs8046148	0.724	rs4389139	ENSG00000279356.1	RP11-429P3.8	3.56	0.000401	0.0432	0.16	0.16	Testicular germ cell tumor;	chr16:50066342	chr16:50072862~50074986:+
LUAD	cis	rs8046148	0.641	rs1547478	ENSG00000279356.1	RP11-429P3.8	3.56	0.000401	0.0432	0.16	0.16	Testicular germ cell tumor;	chr16:50067104	chr16:50072862~50074986:+
LUAD	cis	rs73108077	0.79	rs73104050	ENSG00000281376.1	ABALON	-3.56	0.000401	0.0432	-0.26	-0.16	Red blood cell density in sickle cell anemia;	chr20:31289961	chr20:31721507~31723409:+
LUAD	cis	rs73108077	0.79	rs73104055	ENSG00000281376.1	ABALON	-3.56	0.000401	0.0432	-0.26	-0.16	Red blood cell density in sickle cell anemia;	chr20:31293082	chr20:31721507~31723409:+
LUAD	cis	rs6743068	0.541	rs7578456	ENSG00000234842.1	AC007163.8	-3.56	0.000401	0.0432	-0.19	-0.16	Lymphocyte percentage of white cells;	chr2:201370625	chr2:201549631~201550307:+
LUAD	cis	rs76419734	1	rs72669995	ENSG00000251175.4	RP11-45L9.1	-3.56	0.000401	0.0432	-0.38	-0.16	Post bronchodilator FEV1;	chr4:105664099	chr4:105746245~105827172:-
LUAD	cis	rs494562	0.892	rs7767800	ENSG00000234155.1	RP11-30P6.6	-3.56	0.000401	0.0432	-0.31	-0.16	Metabolic traits;Blood metabolite levels;	chr6:85414808	chr6:85387219~85390186:-
LUAD	cis	rs494562	0.892	rs9344518	ENSG00000234155.1	RP11-30P6.6	-3.56	0.000401	0.0432	-0.31	-0.16	Metabolic traits;Blood metabolite levels;	chr6:85415426	chr6:85387219~85390186:-
LUAD	cis	rs494562	0.892	rs9294335	ENSG00000234155.1	RP11-30P6.6	-3.56	0.000401	0.0432	-0.31	-0.16	Metabolic traits;Blood metabolite levels;	chr6:85416962	chr6:85387219~85390186:-
LUAD	cis	rs494562	0.892	rs1322404	ENSG00000234155.1	RP11-30P6.6	-3.56	0.000401	0.0432	-0.31	-0.16	Metabolic traits;Blood metabolite levels;	chr6:85417194	chr6:85387219~85390186:-
LUAD	cis	rs494562	0.892	rs1322403	ENSG00000234155.1	RP11-30P6.6	-3.56	0.000401	0.0432	-0.31	-0.16	Metabolic traits;Blood metabolite levels;	chr6:85417444	chr6:85387219~85390186:-
LUAD	cis	rs3026445	0.832	rs11832936	ENSG00000278993.1	RP3-424M6.4	3.56	0.000401	0.0432	0.16	0.16	QT interval;	chr12:110111728	chr12:110501614~110503441:+
LUAD	cis	rs875971	0.545	rs75840613	ENSG00000222364.1	RNU6-96P	-3.56	0.000401	0.0432	-0.2	-0.16	Aortic root size;	chr7:66376399	chr7:66395191~66395286:+
LUAD	cis	rs2242663	0.529	rs1785640	ENSG00000213409.4	RP11-658F2.3	-3.56	0.000401	0.0432	-0.19	-0.16	Bipolar disorder;	chr11:66455687	chr11:66761575~66762399:-
LUAD	cis	rs7077256	0.564	rs35479340	ENSG00000272767.1	JMJD1C-AS1	3.56	0.000401	0.0432	0.23	0.16	Intelligence (multi-trait analysis);	chr10:63569582	chr10:63465229~63466563:+
LUAD	cis	rs7615952	0.512	rs11929125	ENSG00000171084.14	FAM86JP	3.56	0.000401	0.0432	0.2	0.16	Blood pressure (smoking interaction);	chr3:125640599	chr3:125916620~125930024:+
LUAD	cis	rs1910358	0.621	rs7734054	ENSG00000248874.4	C5orf17	-3.56	0.000401	0.0432	-0.22	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23858070	chr5:23951348~24178263:+
LUAD	cis	rs9921338	1	rs9921338	ENSG00000263080.1	RP11-485G7.5	-3.56	0.000401	0.0432	-0.21	-0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11322982	chr16:11341809~11345211:-
LUAD	cis	rs12493885	0.725	rs61791468	ENSG00000243069.6	ARHGEF26-AS1	-3.56	0.000401	0.0432	-0.26	-0.16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154021731	chr3:154024401~154121332:-
LUAD	cis	rs2837828	0.966	rs5006701	ENSG00000226496.2	LINC00323	3.56	0.000401	0.0433	0.2	0.16	Neutrophil count;	chr21:40798914	chr21:41141493~41148133:-
LUAD	cis	rs2837828	0.899	rs998121	ENSG00000226496.2	LINC00323	3.56	0.000401	0.0433	0.2	0.16	Neutrophil count;	chr21:40799326	chr21:41141493~41148133:-
LUAD	cis	rs874536	0.573	rs3786371	ENSG00000273368.1	RP11-376P6.3	3.56	0.000401	0.0433	0.2	0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr18:8355189	chr18:8154558~8155070:+
LUAD	cis	rs957448	0.561	rs4735302	ENSG00000253175.1	RP11-267M23.6	-3.56	0.000401	0.0433	-0.18	-0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94604752	chr8:94565036~94565715:+
LUAD	cis	rs2985684	0.846	rs4476096	ENSG00000278009.1	RP11-649E7.8	3.56	0.000401	0.0433	0.21	0.16	Carotid intima media thickness;	chr14:49552673	chr14:49601011~49601124:-
LUAD	cis	rs13113518	1	rs3762837	ENSG00000223305.1	RN7SKP30	3.56	0.000401	0.0433	0.18	0.16	Height;	chr4:55511198	chr4:55540502~55540835:-
LUAD	cis	rs7819412	0.505	rs17782554	ENSG00000255046.1	RP11-297N6.4	3.56	0.000401	0.0433	0.2	0.16	Triglycerides;	chr8:11164596	chr8:11797928~11802568:-
LUAD	cis	rs7430456	0.901	rs9824206	ENSG00000231574.4	RP11-91K9.1	-3.56	0.000401	0.0433	-0.18	-0.16	Breast cancer;	chr3:177742093	chr3:177816865~177899224:+
LUAD	cis	rs526231	0.511	rs3756582	ENSG00000250682.4	LINC00491	3.56	0.000401	0.0433	0.2	0.16	Primary biliary cholangitis;	chr5:103003848	chr5:102609156~102671559:-
LUAD	cis	rs526231	0.511	rs45518833	ENSG00000250682.4	LINC00491	3.56	0.000401	0.0433	0.2	0.16	Primary biliary cholangitis;	chr5:103007286	chr5:102609156~102671559:-
LUAD	cis	rs526231	0.511	rs1826673	ENSG00000250682.4	LINC00491	3.56	0.000401	0.0433	0.2	0.16	Primary biliary cholangitis;	chr5:103010212	chr5:102609156~102671559:-
LUAD	cis	rs526231	0.511	rs62362545	ENSG00000250682.4	LINC00491	3.56	0.000401	0.0433	0.2	0.16	Primary biliary cholangitis;	chr5:103011748	chr5:102609156~102671559:-
LUAD	cis	rs526231	0.511	rs3910557	ENSG00000250682.4	LINC00491	3.56	0.000401	0.0433	0.2	0.16	Primary biliary cholangitis;	chr5:103014767	chr5:102609156~102671559:-
LUAD	cis	rs526231	0.511	rs2288389	ENSG00000250682.4	LINC00491	3.56	0.000401	0.0433	0.2	0.16	Primary biliary cholangitis;	chr5:103018104	chr5:102609156~102671559:-
LUAD	cis	rs1400816	0.85	rs9287948	ENSG00000228389.1	AC068039.4	3.56	0.000401	0.0433	0.27	0.16	Amyotrophic lateral sclerosis (sporadic);	chr2:171740404	chr2:171773482~171775844:+
LUAD	cis	rs2279168	1	rs2279167	ENSG00000202081.1	RNU6-1280P	-3.56	0.000401	0.0433	-0.25	-0.16	Response to platinum-based chemotherapy (carboplatin);	chr15:85533353	chr15:85651522~85651628:-
LUAD	cis	rs10181042	0.528	rs2564118	ENSG00000228590.1	AC007381.3	-3.56	0.000401	0.0433	-0.18	-0.16	Crohn's disease;	chr2:61006154	chr2:60350595~60353016:-
LUAD	cis	rs2071518	1	rs7839760	ENSG00000254343.2	RP11-760H22.2	-3.56	0.000401	0.0433	-0.19	-0.16	Blood pressure;Pulse pressure;	chr8:119409294	chr8:120052180~120056201:+
LUAD	cis	rs6479891	1	rs9414788	ENSG00000232075.1	MRPL35P2	-3.56	0.000401	0.0433	-0.27	-0.16	Arthritis (juvenile idiopathic);	chr10:63296952	chr10:63634317~63634827:-
LUAD	cis	rs13068223	0.74	rs343999	ENSG00000243926.1	TIPARP-AS1	-3.56	0.000401	0.0433	-0.17	-0.16	Age-related hearing impairment (SNP x SNP interaction);	chr3:156734050	chr3:156671862~156674378:-
LUAD	cis	rs2274273	0.935	rs8004787	ENSG00000258413.1	RP11-665C16.6	-3.56	0.000401	0.0433	-0.21	-0.16	Protein biomarker;	chr14:55140648	chr14:55262767~55272075:-
LUAD	cis	rs1023500	0.505	rs134885	ENSG00000273366.1	CTA-989H11.1	-3.56	0.000401	0.0433	-0.19	-0.16	Schizophrenia;	chr22:42277805	chr22:42278188~42278846:+
LUAD	cis	rs9815354	0.67	rs73073238	ENSG00000273328.4	RP11-141M3.6	-3.56	0.000402	0.0433	-0.27	-0.16	Pulse pressure;Diastolic blood pressure;	chr3:41972833	chr3:42809414~42908105:+
LUAD	cis	rs7210990	0.724	rs178814	ENSG00000275413.1	CTC-529I10.1	-3.56	0.000402	0.0433	-0.14	-0.16	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr17:16190841	chr17:16023323~16023653:-
LUAD	cis	rs3753275	0.69	rs4908503	ENSG00000232912.4	RP5-1115A15.1	3.56	0.000402	0.0433	0.19	0.16	Educational attainment;	chr1:8498816	chr1:8424645~8434838:+
LUAD	cis	rs8192282	0.739	rs61811362	ENSG00000272030.1	RP1-178F15.4	3.56	0.000402	0.0433	0.22	0.16	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);	chr1:154540019	chr1:153631438~153634397:-
LUAD	cis	rs13113518	0.678	rs7663650	ENSG00000273257.1	RP11-177J6.1	-3.56	0.000402	0.0433	-0.18	-0.16	Height;	chr4:55364952	chr4:55387949~55388271:+
LUAD	cis	rs10181042	0.565	rs1177234	ENSG00000228590.1	AC007381.3	-3.56	0.000402	0.0433	-0.18	-0.16	Crohn's disease;	chr2:61032928	chr2:60350595~60353016:-
LUAD	cis	rs17508449	0.547	rs3765598	ENSG00000232450.1	RP4-730K3.3	-3.56	0.000402	0.0433	-0.23	-0.16	Leprosy;	chr1:113851841	chr1:113698884~113699631:-
LUAD	cis	rs7557067	0.671	rs78980904	ENSG00000233005.1	AC067959.1	-3.56	0.000402	0.0433	-0.2	-0.16	Triglycerides;	chr2:20921704	chr2:21221175~21970959:+
LUAD	cis	rs13113518	1	rs13146987	ENSG00000223305.1	RN7SKP30	3.56	0.000402	0.0433	0.18	0.16	Height;	chr4:55491628	chr4:55540502~55540835:-
LUAD	cis	rs13113518	1	rs7677085	ENSG00000223305.1	RN7SKP30	3.56	0.000402	0.0433	0.18	0.16	Height;	chr4:55495801	chr4:55540502~55540835:-
LUAD	cis	rs13113518	0.966	rs12510681	ENSG00000223305.1	RN7SKP30	3.56	0.000402	0.0433	0.18	0.16	Height;	chr4:55496737	chr4:55540502~55540835:-
LUAD	cis	rs13113518	1	rs12500162	ENSG00000223305.1	RN7SKP30	3.56	0.000402	0.0433	0.18	0.16	Height;	chr4:55496933	chr4:55540502~55540835:-
LUAD	cis	rs7955901	0.837	rs11178531	ENSG00000258053.1	CTD-2021H9.3	-3.56	0.000402	0.0433	-0.18	-0.16	Type 2 diabetes;	chr12:71014910	chr12:71047402~71118247:-
LUAD	cis	rs4648045	0.594	rs62327180	ENSG00000251288.2	RP11-10L12.2	-3.56	0.000402	0.0433	-0.2	-0.16	Lymphocyte percentage of white cells;	chr4:102619605	chr4:102751401~102752641:+
LUAD	cis	rs448720	0.811	rs1996121	ENSG00000259673.4	IQCH-AS1	3.56	0.000402	0.0433	0.17	0.16	Cognitive performance;	chr15:67889240	chr15:67403619~67521844:-
LUAD	cis	rs395157	0.591	rs395967	ENSG00000249911.1	LINC01265	3.56	0.000402	0.0433	0.19	0.16	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr5:38842857	chr5:38710367~38720273:-
LUAD	cis	rs74461473	0.567	rs55672941	ENSG00000228008.1	CTD-2330K9.3	3.56	0.000402	0.0433	0.27	0.16	Conotruncal heart defects (maternal effects);	chr3:50690323	chr3:49903845~49916937:+
LUAD	cis	rs74461473	0.512	rs62260127	ENSG00000228008.1	CTD-2330K9.3	3.56	0.000402	0.0433	0.27	0.16	Conotruncal heart defects (maternal effects);	chr3:50692590	chr3:49903845~49916937:+
LUAD	cis	rs577676	0.524	rs601938	ENSG00000271811.1	RP1-79C4.4	3.56	0.000402	0.0433	0.21	0.16	Prevalent atrial fibrillation;	chr1:170661118	chr1:170667381~170669425:+
LUAD	cis	rs35740288	0.77	rs56092539	ENSG00000259407.1	RP11-158M2.3	-3.56	0.000402	0.0433	-0.15	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85639281	chr15:85744109~85750281:-
LUAD	cis	rs35740288	0.77	rs11636185	ENSG00000259407.1	RP11-158M2.3	-3.56	0.000402	0.0433	-0.15	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85639887	chr15:85744109~85750281:-
LUAD	cis	rs4374383	0.962	rs10187041	ENSG00000236307.2	EEF1E1P1	-3.56	0.000402	0.0433	-0.19	-0.16	Hepatitis C induced liver fibrosis;	chr2:112018075	chr2:111887914~111888741:+
LUAD	cis	rs9287719	0.639	rs2357650	ENSG00000243819.4	RN7SL832P	3.56	0.000402	0.0433	0.18	0.16	Prostate cancer;	chr2:10556751	chr2:10690344~10692099:+
LUAD	cis	rs71636778	0.722	rs34928032	ENSG00000260063.1	RP5-968P14.2	-3.56	0.000402	0.0433	-0.22	-0.16	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26812738	chr1:26692132~26694131:-
LUAD	cis	rs8114671	0.967	rs9574	ENSG00000269202.1	RP4-614O4.12	-3.56	0.000402	0.0433	-0.16	-0.16	Height;	chr20:35176829	chr20:35201747~35203288:-
LUAD	cis	rs10197140	0.857	rs62159473	ENSG00000227992.1	AC108463.2	-3.56	0.000402	0.0434	-0.19	-0.16	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110877386	chr2:111203964~111206215:-
LUAD	cis	rs10197140	0.857	rs13384044	ENSG00000227992.1	AC108463.2	-3.56	0.000402	0.0434	-0.19	-0.16	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110877819	chr2:111203964~111206215:-
LUAD	cis	rs721917	0.506	rs927452	ENSG00000244733.5	RP11-506M13.3	-3.56	0.000402	0.0434	-0.17	-0.16	Chronic obstructive pulmonary disease;	chr10:79892510	chr10:79660891~79677996:+
LUAD	cis	rs7692995	1	rs16896074	ENSG00000235413.3	KRT18P63	3.56	0.000402	0.0434	0.25	0.16	Height;	chr4:17946250	chr4:17911674~17912976:+
LUAD	cis	rs4845570	1	rs11585294	ENSG00000203288.3	RP11-98D18.9	-3.56	0.000402	0.0434	-0.25	-0.16	Coronary artery disease;	chr1:151797411	chr1:151790804~151794402:+
LUAD	cis	rs13398147	0.879	rs4099413	ENSG00000267034.1	RP11-384O8.1	3.56	0.000402	0.0434	0.23	0.16	Adolescent idiopathic scoliosis;	chr2:221851363	chr2:222317242~222318653:-
LUAD	cis	rs6580649	0.883	rs7967762	ENSG00000257763.1	OR5BK1P	-3.56	0.000402	0.0434	-0.21	-0.16	Lung cancer;	chr12:48026431	chr12:48355792~48356614:-
LUAD	cis	rs7893279	0.505	rs4748498	ENSG00000225527.1	RP11-383B4.4	3.56	0.000402	0.0434	0.23	0.16	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18618124	chr10:18531849~18533336:-
LUAD	cis	rs10463554	0.759	rs34815	ENSG00000250682.4	LINC00491	3.56	0.000402	0.0434	0.2	0.16	Parkinson's disease;	chr5:103098561	chr5:102609156~102671559:-
LUAD	cis	rs10129255	0.913	rs10140943	ENSG00000211947.2	IGHV3-21	-3.56	0.000402	0.0434	-0.11	-0.16	Kawasaki disease;	chr14:106767441	chr14:106235064~106235594:-
LUAD	cis	rs4763879	0.634	rs61915472	ENSG00000256582.1	RP11-75L1.1	-3.56	0.000402	0.0434	-0.17	-0.16	Type 1 diabetes;	chr12:9700995	chr12:9704077~9709350:+
LUAD	cis	rs8141529	0.702	rs132536	ENSG00000272858.1	CTA-292E10.8	3.56	0.000402	0.0434	0.18	0.16	Lymphocyte counts;	chr22:28906918	chr22:28814914~28815662:+
LUAD	cis	rs6933660	0.745	rs6912830	ENSG00000219395.2	HSPA8P15	-3.56	0.000402	0.0434	-0.15	-0.16	Menarche (age at onset);	chr6:151422494	chr6:151411259~151413945:-
LUAD	cis	rs9628987	0.5	rs55823627	ENSG00000232912.4	RP5-1115A15.1	-3.56	0.000402	0.0434	-0.19	-0.16	Breast cancer;	chr1:8402019	chr1:8424645~8434838:+
LUAD	cis	rs854765	0.647	rs4365346	ENSG00000223979.2	SMCR2	-3.56	0.000402	0.0434	-0.19	-0.16	Total body bone mineral density;	chr17:18086059	chr17:17674026~17677688:-
LUAD	cis	rs12935418	0.673	rs2602426	ENSG00000278985.1	RP11-303E16.9	-3.56	0.000402	0.0434	-0.15	-0.16	Mean corpuscular volume;	chr16:81027632	chr16:80982319~80984094:-
LUAD	cis	rs76419734	0.85	rs72669992	ENSG00000251175.4	RP11-45L9.1	-3.56	0.000402	0.0434	-0.38	-0.16	Post bronchodilator FEV1;	chr4:105657997	chr4:105746245~105827172:-
LUAD	cis	rs76419734	1	rs72669993	ENSG00000251175.4	RP11-45L9.1	-3.56	0.000402	0.0434	-0.38	-0.16	Post bronchodilator FEV1;	chr4:105661987	chr4:105746245~105827172:-
LUAD	cis	rs3213958	0.574	rs73138030	ENSG00000249274.1	PDLIM1P4	-3.56	0.000402	0.0434	-0.26	-0.16	Blood protein levels;	chr3:98855209	chr3:98782188~98783193:+
LUAD	cis	rs36093844	0.527	rs17745105	ENSG00000279742.1	RP11-700A24.1	-3.56	0.000402	0.0434	-0.2	-0.16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86001394	chr11:85852557~85854943:-
LUAD	cis	rs7402982	0.934	rs8028620	ENSG00000278022.1	RP11-35O15.2	-3.56	0.000402	0.0434	-0.17	-0.16	Birth weight;	chr15:98659646	chr15:98660210~98660668:+
LUAD	cis	rs7590268	1	rs13035011	ENSG00000279873.2	LINC01126	3.56	0.000402	0.0434	0.17	0.16	Orofacial clefts;	chr2:43316978	chr2:43227210~43228855:+
LUAD	cis	rs11100904	1	rs11100904	ENSG00000250673.1	RP11-6L6.2	-3.56	0.000402	0.0434	-0.17	-0.16	Dental caries;	chr4:145983152	chr4:146224557~146229056:+
LUAD	cis	rs2024714	0.902	rs2427210	ENSG00000273812.1	WI2-87327B8.2	-3.56	0.000402	0.0434	-0.17	-0.16	Longevity;	chr20:61634610	chr20:62596732~62603115:-
LUAD	cis	rs10129255	0.53	rs11624912	ENSG00000232216.1	IGHV3-43	3.56	0.000403	0.0434	0.13	0.16	Kawasaki disease;	chr14:106673891	chr14:106470264~106470800:-
LUAD	cis	rs7142881	0.815	rs2165814	ENSG00000258525.1	RP11-829H16.3	-3.56	0.000403	0.0434	-0.18	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31624038	chr14:30876179~30889808:-
LUAD	cis	rs10496166	0.761	rs2280309	ENSG00000236259.1	AC017083.2	-3.56	0.000403	0.0434	-0.19	-0.16	RR interval (heart rate);	chr2:68813084	chr2:68125265~68125747:+
LUAD	cis	rs10496166	0.761	rs2280310	ENSG00000236259.1	AC017083.2	-3.56	0.000403	0.0434	-0.19	-0.16	RR interval (heart rate);	chr2:68813368	chr2:68125265~68125747:+
LUAD	cis	rs7824557	0.606	rs1435277	ENSG00000255046.1	RP11-297N6.4	-3.56	0.000403	0.0434	-0.2	-0.16	Retinal vascular caliber;	chr8:11339461	chr8:11797928~11802568:-
LUAD	cis	rs6121246	0.567	rs6058203	ENSG00000230613.1	HM13-AS1	3.56	0.000403	0.0434	0.25	0.16	Mean corpuscular hemoglobin;	chr20:31611176	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.529	rs6120862	ENSG00000230613.1	HM13-AS1	3.56	0.000403	0.0434	0.25	0.16	Mean corpuscular hemoglobin;	chr20:31611656	chr20:31567707~31573263:-
LUAD	cis	rs703842	1	rs3825079	ENSG00000245651.2	RP11-620J15.2	3.56	0.000403	0.0434	0.17	0.16	Multiple sclerosis;	chr12:57809571	chr12:57869835~57896482:-
LUAD	cis	rs728616	0.614	rs55768100	ENSG00000234382.2	RP11-40F6.1	-3.56	0.000403	0.0434	-0.26	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79964721	chr10:80233664~80245367:+
LUAD	cis	rs10863681	0.764	rs12038701	ENSG00000200033.1	RNU6-403P	-3.56	0.000403	0.0434	-0.18	-0.16	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222069435	chr1:221837334~221837437:-
LUAD	cis	rs1876905	0.569	rs354523	ENSG00000255389.1	C6orf3	3.56	0.000403	0.0434	0.21	0.16	Mean corpuscular hemoglobin;	chr6:111188122	chr6:111599875~111602295:+
LUAD	cis	rs7131987	0.683	rs7954278	ENSG00000275476.1	RP11-996F15.4	-3.56	0.000403	0.0434	-0.18	-0.16	QT interval;	chr12:29306357	chr12:29277397~29277882:-
LUAD	cis	rs117623576	0.816	rs72784871	ENSG00000234335.1	RPS4XP11	-3.56	0.000403	0.0434	-0.24	-0.16	Anti-saccade response;	chr10:32156241	chr10:32102522~32103293:-
LUAD	cis	rs10911232	0.507	rs11582514	ENSG00000224468.3	RP11-181K3.4	-3.56	0.000403	0.0434	-0.14	-0.16	Hypertriglyceridemia;	chr1:183023026	chr1:183138402~183141282:-
LUAD	cis	rs10911232	0.507	rs10911194	ENSG00000224468.3	RP11-181K3.4	-3.56	0.000403	0.0434	-0.14	-0.16	Hypertriglyceridemia;	chr1:183023890	chr1:183138402~183141282:-
LUAD	cis	rs10911232	0.507	rs10911195	ENSG00000224468.3	RP11-181K3.4	-3.56	0.000403	0.0434	-0.14	-0.16	Hypertriglyceridemia;	chr1:183024303	chr1:183138402~183141282:-
LUAD	cis	rs7212590	0.881	rs7216675	ENSG00000263422.1	AC005702.1	3.56	0.000403	0.0434	0.36	0.16	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59805313	chr17:60042361~60042442:-
LUAD	cis	rs7212590	1	rs73315284	ENSG00000263422.1	AC005702.1	3.56	0.000403	0.0434	0.36	0.16	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59807507	chr17:60042361~60042442:-
LUAD	cis	rs7212590	1	rs7212590	ENSG00000263422.1	AC005702.1	3.56	0.000403	0.0434	0.36	0.16	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59808348	chr17:60042361~60042442:-
LUAD	cis	rs694419	0.608	rs11663195	ENSG00000278017.1	RP11-120K19.4	-3.56	0.000403	0.0434	-0.21	-0.16	Serum albumin level;	chr18:62518997	chr18:62525919~62526325:-
LUAD	cis	rs10466239	0.73	rs2946992	ENSG00000230555.2	RP11-517P14.2	-3.56	0.000403	0.0434	-0.25	-0.16	Telomere length;	chr10:43358831	chr10:43420738~43422100:+
LUAD	cis	rs13113518	0.513	rs13147861	ENSG00000272969.1	RP11-528I4.2	3.56	0.000403	0.0434	0.17	0.16	Height;	chr4:55611014	chr4:55547112~55547889:+
LUAD	cis	rs4727963	0.846	rs4316096	ENSG00000240499.6	RP5-1101C3.1	3.56	0.000403	0.0434	0.14	0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);	chr7:123072421	chr7:122328469~122440388:+
LUAD	cis	rs4476553	0.647	rs10012526	ENSG00000247708.6	STX18-AS1	-3.56	0.000403	0.0435	-0.2	-0.16	Response to amphetamines;	chr4:4725434	chr4:4542131~4710938:+
LUAD	cis	rs9595908	0.709	rs55797910	ENSG00000281026.1	N4BP2L2-IT2	-3.56	0.000403	0.0435	-0.1	-0.16	Body mass index;	chr13:32787154	chr13:32504506~32509395:-
LUAD	cis	rs2239547	0.603	rs9870898	ENSG00000243224.1	RP5-1157M23.2	-3.56	0.000403	0.0435	-0.18	-0.16	Schizophrenia;	chr3:53058359	chr3:52239258~52241097:+
LUAD	cis	rs10911232	0.507	rs10752888	ENSG00000224468.3	RP11-181K3.4	-3.56	0.000403	0.0435	-0.14	-0.16	Hypertriglyceridemia;	chr1:183024616	chr1:183138402~183141282:-
LUAD	cis	rs8056893	1	rs8056893	ENSG00000260441.4	RP11-96D1.7	-3.56	0.000403	0.0435	-0.19	-0.16	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68270489	chr16:68256162~68260443:-
LUAD	cis	rs17164851	0.778	rs59875249	ENSG00000226380.6	AC058791.1	3.56	0.000403	0.0435	0.25	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr7:130353183	chr7:130876809~130913310:-
LUAD	cis	rs590820	0.684	rs10779835	ENSG00000227934.1	RP11-423F24.3	-3.56	0.000403	0.0435	-0.18	-0.16	Metabolite levels (lipoprotein measures);	chr1:230164203	chr1:231021611~231022183:+
LUAD	cis	rs9628987	0.569	rs11121176	ENSG00000232912.4	RP5-1115A15.1	-3.56	0.000404	0.0435	-0.19	-0.16	Breast cancer;	chr1:8376972	chr1:8424645~8434838:+
LUAD	cis	rs2348418	0.932	rs61922464	ENSG00000244712.1	RP11-874G11.1	3.56	0.000404	0.0435	0.19	0.16	Lung function (FEV1);Lung function (FVC);	chr12:28485665	chr12:28564678~28565141:-
LUAD	cis	rs2348418	0.932	rs11049661	ENSG00000244712.1	RP11-874G11.1	3.56	0.000404	0.0435	0.19	0.16	Lung function (FEV1);Lung function (FVC);	chr12:28486215	chr12:28564678~28565141:-
LUAD	cis	rs2348418	0.932	rs11049662	ENSG00000244712.1	RP11-874G11.1	3.56	0.000404	0.0435	0.19	0.16	Lung function (FEV1);Lung function (FVC);	chr12:28487344	chr12:28564678~28565141:-
LUAD	cis	rs2348418	0.932	rs7306581	ENSG00000244712.1	RP11-874G11.1	3.56	0.000404	0.0435	0.19	0.16	Lung function (FEV1);Lung function (FVC);	chr12:28488641	chr12:28564678~28565141:-
LUAD	cis	rs7826238	0.535	rs2979179	ENSG00000173295.6	FAM86B3P	3.56	0.000404	0.0435	0.17	0.16	Systolic blood pressure;	chr8:8462519	chr8:8228595~8244865:+
LUAD	cis	rs6751744	0.855	rs933794	ENSG00000227055.1	AC009961.5	3.56	0.000404	0.0435	0.19	0.16	Dysphagia;	chr2:159524380	chr2:159812234~159814009:-
LUAD	cis	rs78487399	0.71	rs114510001	ENSG00000234936.1	AC010883.5	3.56	0.000404	0.0435	0.25	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43289949	chr2:43229573~43233394:+
LUAD	cis	rs10504390	0.656	rs76852163	ENSG00000200714.1	Y_RNA	-3.56	0.000404	0.0435	-0.42	-0.16	IgG glycosylation;	chr8:65659083	chr8:65592731~65592820:+
LUAD	cis	rs67517081	1	rs67517081	ENSG00000232748.3	RP11-196G11.6	3.56	0.000404	0.0435	0.2	0.16	Mean corpuscular hemoglobin;	chr16:30976060	chr16:31056460~31062803:+
LUAD	cis	rs11673344	0.642	rs55755939	ENSG00000267254.4	ZNF790-AS1	-3.56	0.000404	0.0435	-0.21	-0.16	Obesity-related traits;	chr19:37353723	chr19:36797518~36828115:+
LUAD	cis	rs8014204	1	rs8014204	ENSG00000279594.1	RP11-950C14.10	3.56	0.000404	0.0435	0.18	0.16	Caffeine consumption;	chr14:74856091	chr14:75011269~75012851:-
LUAD	cis	rs1426063	0.614	rs74949513	ENSG00000260265.1	RP11-44F21.5	3.56	0.000404	0.0435	0.37	0.16	QT interval;	chr4:75124631	chr4:75081702~75084717:-
LUAD	cis	rs1426063	0.614	rs77982391	ENSG00000260265.1	RP11-44F21.5	3.56	0.000404	0.0435	0.37	0.16	QT interval;	chr4:75125224	chr4:75081702~75084717:-
LUAD	cis	rs1426063	0.541	rs116664844	ENSG00000260265.1	RP11-44F21.5	3.56	0.000404	0.0435	0.37	0.16	QT interval;	chr4:75125677	chr4:75081702~75084717:-
LUAD	cis	rs1426063	0.541	rs114162294	ENSG00000260265.1	RP11-44F21.5	3.56	0.000404	0.0435	0.37	0.16	QT interval;	chr4:75125682	chr4:75081702~75084717:-
LUAD	cis	rs755249	0.833	rs61779313	ENSG00000182109.6	RP11-69E11.4	3.56	0.000404	0.0435	0.19	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39478577	chr1:39522280~39546187:-
LUAD	cis	rs4763879	1	rs917911	ENSG00000214776.8	RP11-726G1.1	-3.56	0.000404	0.0435	-0.2	-0.16	Type 1 diabetes;	chr12:9753255	chr12:9467552~9576275:+
LUAD	cis	rs4423214	0.84	rs1790340	ENSG00000226627.1	SHANK2-AS1	3.56	0.000404	0.0435	0.2	0.16	Vitamin D levels;	chr11:71471543	chr11:70631094~70635490:+
LUAD	cis	rs240993	0.812	rs9487632	ENSG00000271789.1	RP5-1112D6.7	-3.56	0.000404	0.0435	-0.19	-0.16	Inflammatory skin disease;Psoriasis;	chr6:111417970	chr6:111297126~111298510:+
LUAD	cis	rs240993	0.812	rs11153295	ENSG00000271789.1	RP5-1112D6.7	-3.56	0.000404	0.0435	-0.19	-0.16	Inflammatory skin disease;Psoriasis;	chr6:111420164	chr6:111297126~111298510:+
LUAD	cis	rs240993	0.812	rs6915753	ENSG00000271789.1	RP5-1112D6.7	-3.56	0.000404	0.0435	-0.19	-0.16	Inflammatory skin disease;Psoriasis;	chr6:111420476	chr6:111297126~111298510:+
LUAD	cis	rs240993	0.812	rs4620159	ENSG00000271789.1	RP5-1112D6.7	-3.56	0.000404	0.0435	-0.19	-0.16	Inflammatory skin disease;Psoriasis;	chr6:111423532	chr6:111297126~111298510:+
LUAD	cis	rs12197554	0.556	rs7738424	ENSG00000226149.4	RP1-69D17.4	-3.56	0.000404	0.0435	-0.22	-0.16	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);Exploratory eye movement dysfunction in schizophrenia (responsive search score);Exploratory eye movement dysfunction in schizophrenia (cognitive search score);	chr6:130433072	chr6:129526626~129552587:-
LUAD	cis	rs9595908	0.758	rs7329120	ENSG00000281026.1	N4BP2L2-IT2	-3.56	0.000404	0.0435	-0.1	-0.16	Body mass index;	chr13:32646605	chr13:32504506~32509395:-
LUAD	cis	rs7017914	0.905	rs4434651	ENSG00000246366.5	RP11-382J12.1	3.56	0.000404	0.0435	0.14	0.16	Bone mineral density;	chr8:71034952	chr8:70608577~70663279:+
LUAD	cis	rs2832077	0.689	rs2832055	ENSG00000224649.1	AF124730.4	3.56	0.000404	0.0435	0.19	0.16	Cognitive test performance;	chr21:28760060	chr21:29182027~29187795:-
LUAD	cis	rs9900280	1	rs4794857	ENSG00000264808.1	RP11-802D6.1	-3.56	0.000404	0.0435	-0.19	-0.16	Mean platelet volume;	chr17:29455272	chr17:29369717~29390777:-
LUAD	cis	rs7638909	0.512	rs6804918	ENSG00000229589.1	ACVR2B-AS1	-3.56	0.000404	0.0435	-0.18	-0.16	Electrocardiographic conduction measures;	chr3:38557465	chr3:38451027~38454820:-
LUAD	cis	rs6435862	0.5	rs12477063	ENSG00000229267.2	AC072062.1	3.56	0.000404	0.0435	0.19	0.16	Neuroblastoma (high-risk);	chr2:214808940	chr2:214810229~214963274:+
LUAD	cis	rs4578769	0.55	rs12966925	ENSG00000266850.1	RP11-370A5.1	3.56	0.000404	0.0435	0.21	0.16	Eosinophil percentage of white cells;	chr18:22953734	chr18:22723491~22907721:-
LUAD	cis	rs12611088	0.571	rs7252955	ENSG00000270679.1	CTC-512J12.7	-3.56	0.000404	0.0435	-0.18	-0.16	Plasma amyloid beta peptide concentrations (ABx-42);	chr19:43517614	chr19:44290081~44290911:+
LUAD	cis	rs8028182	0.501	rs7166281	ENSG00000260274.1	RP11-817O13.8	-3.56	0.000404	0.0435	-0.17	-0.16	Sudden cardiac arrest;	chr15:75635851	chr15:75368155~75369584:+
LUAD	cis	rs62103177	0.561	rs891488	ENSG00000261126.6	RP11-795F19.1	-3.56	0.000404	0.0435	-0.19	-0.16	Opioid sensitivity;	chr18:79877424	chr18:80046900~80095482:+
LUAD	cis	rs67539049	1	rs56138616	ENSG00000255046.1	RP11-297N6.4	3.56	0.000404	0.0435	0.25	0.16	Itch intensity from mosquito bite;	chr8:11430041	chr8:11797928~11802568:-
LUAD	cis	rs2115630	0.875	rs8039472	ENSG00000259728.4	LINC00933	-3.56	0.000404	0.0435	-0.2	-0.16	P wave terminal force;	chr15:84818413	chr15:84570649~84580175:+
LUAD	cis	rs13006833	0.694	rs291444	ENSG00000227542.1	AC092614.2	-3.56	0.000404	0.0435	-0.19	-0.16	Urinary metabolites;	chr2:190311497	chr2:191229165~191246172:-
LUAD	cis	rs13006833	0.694	rs291448	ENSG00000227542.1	AC092614.2	-3.56	0.000404	0.0435	-0.19	-0.16	Urinary metabolites;	chr2:190312490	chr2:191229165~191246172:-
LUAD	cis	rs13006833	0.703	rs291459	ENSG00000227542.1	AC092614.2	-3.56	0.000404	0.0435	-0.19	-0.16	Urinary metabolites;	chr2:190316801	chr2:191229165~191246172:-
LUAD	cis	rs13006833	0.635	rs291460	ENSG00000227542.1	AC092614.2	-3.56	0.000404	0.0435	-0.19	-0.16	Urinary metabolites;	chr2:190316859	chr2:191229165~191246172:-
LUAD	cis	rs13006833	0.668	rs291461	ENSG00000227542.1	AC092614.2	-3.56	0.000404	0.0435	-0.19	-0.16	Urinary metabolites;	chr2:190316918	chr2:191229165~191246172:-
LUAD	cis	rs13006833	0.668	rs291462	ENSG00000227542.1	AC092614.2	-3.56	0.000404	0.0435	-0.19	-0.16	Urinary metabolites;	chr2:190316952	chr2:191229165~191246172:-
LUAD	cis	rs8056893	0.714	rs1465470	ENSG00000260441.4	RP11-96D1.7	-3.56	0.000404	0.0435	-0.19	-0.16	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68364006	chr16:68256162~68260443:-
LUAD	cis	rs1950326	0.515	rs1955711	ENSG00000258526.4	RP11-111A21.1	-3.56	0.000404	0.0435	-0.19	-0.16	Verbal memory performance (residualized delayed recall level);	chr14:39563985	chr14:39474840~39513780:+
LUAD	cis	rs1799949	1	rs12944458	ENSG00000267340.1	RP11-242D8.3	3.56	0.000404	0.0435	0.17	0.16	Menopause (age at onset);	chr17:43028755	chr17:43169880~43170077:-
LUAD	cis	rs1559040	1	rs61572658	ENSG00000272156.1	RP11-477N3.1	-3.56	0.000404	0.0435	-0.26	-0.16	Sudden cardiac arrest;	chr2:54097606	chr2:54082554~54085066:+
LUAD	cis	rs2836974	0.897	rs2836933	ENSG00000232608.1	TIMM9P2	-3.56	0.000404	0.0436	-0.19	-0.16	Cognitive function;	chr21:39192276	chr21:39216624~39217506:+
LUAD	cis	rs2243480	1	rs778729	ENSG00000222364.1	RNU6-96P	-3.56	0.000405	0.0436	-0.27	-0.16	Diabetic kidney disease;	chr7:66359432	chr7:66395191~66395286:+
LUAD	cis	rs7246657	0.765	rs10402455	ENSG00000267309.1	CTD-2630F21.1	3.56	0.000405	0.0436	0.26	0.16	Coronary artery calcification;	chr19:37237805	chr19:36489649~36491040:+
LUAD	cis	rs6988985	0.678	rs6651273	ENSG00000247317.3	RP11-273G15.2	-3.56	0.000405	0.0436	-0.19	-0.16	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142905084	chr8:142981738~143018437:-
LUAD	cis	rs6988985	0.765	rs6471581	ENSG00000247317.3	RP11-273G15.2	-3.56	0.000405	0.0436	-0.19	-0.16	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142905503	chr8:142981738~143018437:-
LUAD	cis	rs6988985	0.693	rs4736357	ENSG00000247317.3	RP11-273G15.2	-3.56	0.000405	0.0436	-0.19	-0.16	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142905802	chr8:142981738~143018437:-
LUAD	cis	rs6988985	0.765	rs4736359	ENSG00000247317.3	RP11-273G15.2	-3.56	0.000405	0.0436	-0.19	-0.16	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142906011	chr8:142981738~143018437:-
LUAD	cis	rs1979679	0.573	rs6487693	ENSG00000278733.1	RP11-425D17.1	-3.56	0.000405	0.0436	-0.21	-0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28574158	chr12:28185625~28186190:-
LUAD	cis	rs357618	1	rs357620	ENSG00000272112.1	CTB-113P19.5	-3.56	0.000405	0.0436	-0.15	-0.16	Basophil percentage of white cells;	chr5:151467560	chr5:151724831~151725356:-
LUAD	cis	rs4374383	0.962	rs11887259	ENSG00000236307.2	EEF1E1P1	-3.56	0.000405	0.0436	-0.19	-0.16	Hepatitis C induced liver fibrosis;	chr2:112016617	chr2:111887914~111888741:+
LUAD	cis	rs3772130	1	rs56314138	ENSG00000243544.3	RN7SL172P	3.56	0.000405	0.0436	0.19	0.16	Cognitive performance;	chr3:121637809	chr3:121653994~121654296:-
LUAD	cis	rs3772130	1	rs17691170	ENSG00000243544.3	RN7SL172P	3.56	0.000405	0.0436	0.19	0.16	Cognitive performance;	chr3:121638779	chr3:121653994~121654296:-
LUAD	cis	rs3772130	0.961	rs11716984	ENSG00000243544.3	RN7SL172P	3.56	0.000405	0.0436	0.19	0.16	Cognitive performance;	chr3:121643560	chr3:121653994~121654296:-
LUAD	cis	rs3892630	0.878	rs6510277	ENSG00000267475.1	CTD-2538C1.2	-3.56	0.000405	0.0436	-0.26	-0.16	Red blood cell traits;	chr19:32692763	chr19:32687089~32691750:-
LUAD	cis	rs451417	0.73	rs236128	ENSG00000275632.1	RP5-967N21.11	-3.56	0.000405	0.0436	-0.22	-0.16	Menopause (age at onset);	chr20:5999007	chr20:6000418~6000941:+
LUAD	cis	rs763121	0.853	rs138716	ENSG00000228274.3	RP3-508I15.9	-3.56	0.000405	0.0436	-0.16	-0.16	Menopause (age at onset);	chr22:38750522	chr22:38667585~38681820:-
LUAD	cis	rs7937682	0.889	rs2850247	ENSG00000230911.1	PPIHP1	3.56	0.000405	0.0436	0.21	0.16	Primary sclerosing cholangitis;	chr11:111766478	chr11:112029858~112030367:-
LUAD	cis	rs2239547	0.563	rs6445547	ENSG00000243224.1	RP5-1157M23.2	-3.56	0.000405	0.0436	-0.18	-0.16	Schizophrenia;	chr3:52874561	chr3:52239258~52241097:+
LUAD	cis	rs972578	0.806	rs4822225	ENSG00000230319.1	AL022476.2	3.56	0.000405	0.0436	0.17	0.16	Mean platelet volume;	chr22:42914646	chr22:43038585~43052366:+
LUAD	cis	rs4699052	0.625	rs28397882	ENSG00000246560.2	RP11-10L12.4	3.56	0.000405	0.0436	0.21	0.16	Testicular germ cell tumor;	chr4:103361679	chr4:102828055~102844075:+
LUAD	cis	rs4699052	0.59	rs28728298	ENSG00000246560.2	RP11-10L12.4	3.56	0.000405	0.0436	0.21	0.16	Testicular germ cell tumor;	chr4:103361693	chr4:102828055~102844075:+
LUAD	cis	rs2625529	0.617	rs2929509	ENSG00000260173.1	RP11-2I17.4	3.56	0.000405	0.0436	0.19	0.16	Red blood cell count;	chr15:71946931	chr15:72140504~72155459:-
LUAD	cis	rs11168351	0.75	rs11168366	ENSG00000257763.1	OR5BK1P	-3.56	0.000405	0.0436	-0.17	-0.16	Bipolar disorder and schizophrenia;	chr12:48027990	chr12:48355792~48356614:-
LUAD	cis	rs2144940	0.545	rs844867	ENSG00000233746.1	LINC00656	-3.56	0.000405	0.0436	-0.35	-0.16	Venous thromboembolism;	chr20:23119565	chr20:23125068~23132621:-
LUAD	cis	rs11048434	0.518	rs759469	ENSG00000256937.1	KRT17P8	3.56	0.000405	0.0436	0.18	0.16	Sjögren's syndrome;	chr12:9023108	chr12:9127783~9128645:+
LUAD	cis	rs2708977	0.666	rs17685664	ENSG00000237510.6	AC008268.2	3.56	0.000405	0.0436	0.22	0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96649833	chr2:95789654~95800166:+
LUAD	cis	rs7077256	0.564	rs12763038	ENSG00000272767.1	JMJD1C-AS1	3.56	0.000405	0.0436	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63196855	chr10:63465229~63466563:+
LUAD	cis	rs412050	0.696	rs113366054	ENSG00000224086.5	LL22NC03-86G7.1	-3.56	0.000405	0.0436	-0.2	-0.16	Attention deficit hyperactivity disorder;	chr22:21912844	chr22:21938293~21977632:+
LUAD	cis	rs6496932	0.913	rs34896088	ENSG00000259630.2	CTD-2262B20.1	3.56	0.000405	0.0436	0.22	0.16	Central corneal thickness;Corneal structure;	chr15:85278393	chr15:85415228~85415633:+
LUAD	cis	rs10751667	0.56	rs10902265	ENSG00000255284.1	AP006621.5	3.56	0.000405	0.0436	0.14	0.16	Alzheimer's disease (late onset);	chr11:1003642	chr11:777578~784297:+
LUAD	cis	rs3768617	0.51	rs10797842	ENSG00000224468.3	RP11-181K3.4	-3.56	0.000405	0.0436	-0.14	-0.16	Fuchs's corneal dystrophy;	chr1:183112732	chr1:183138402~183141282:-
LUAD	cis	rs3772130	1	rs3772130	ENSG00000243544.3	RN7SL172P	3.56	0.000405	0.0436	0.19	0.16	Cognitive performance;	chr3:121625293	chr3:121653994~121654296:-
LUAD	cis	rs11051970	0.611	rs56146365	ENSG00000274964.1	RP11-817I4.1	-3.56	0.000405	0.0436	-0.16	-0.16	Response to tocilizumab in rheumatoid arthritis;	chr12:32376700	chr12:32339368~32340724:+
LUAD	cis	rs651907	0.557	rs62284198	ENSG00000244119.1	PDCL3P4	3.56	0.000405	0.0436	0.16	0.16	Colorectal cancer;	chr3:101755855	chr3:101712472~101713191:+
LUAD	cis	rs651907	0.557	rs2318090	ENSG00000244119.1	PDCL3P4	3.56	0.000405	0.0436	0.16	0.16	Colorectal cancer;	chr3:101756089	chr3:101712472~101713191:+
LUAD	cis	rs6921919	0.583	rs6922169	ENSG00000219392.1	RP1-265C24.5	-3.56	0.000405	0.0436	-0.21	-0.16	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28115628~28116551:+
LUAD	cis	rs6921919	0.559	rs13210866	ENSG00000219392.1	RP1-265C24.5	-3.56	0.000405	0.0436	-0.21	-0.16	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28115628~28116551:+
LUAD	cis	rs6921919	0.583	rs13201726	ENSG00000219392.1	RP1-265C24.5	-3.56	0.000405	0.0436	-0.21	-0.16	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28115628~28116551:+
LUAD	cis	rs6921919	0.583	rs2027361	ENSG00000219392.1	RP1-265C24.5	-3.56	0.000405	0.0436	-0.21	-0.16	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28115628~28116551:+
LUAD	cis	rs5758511	0.573	rs139558	ENSG00000227370.1	RP4-669P10.19	-3.56	0.000405	0.0436	-0.16	-0.16	Birth weight;	chr22:41793547	chr22:42132543~42132998:+
LUAD	cis	rs2836950	0.565	rs2836943	ENSG00000232608.1	TIMM9P2	3.56	0.000405	0.0436	0.18	0.16	Menarche (age at onset);	chr21:39220685	chr21:39216624~39217506:+
LUAD	cis	rs12928939	0.518	rs12445564	ENSG00000262140.1	RP11-417N10.3	-3.56	0.000405	0.0436	-0.2	-0.16	Post bronchodilator FEV1;	chr16:71909406	chr16:71833787~71835932:+
LUAD	cis	rs56875752	0.901	rs8073609	ENSG00000263648.1	RP11-471L13.3	3.56	0.000405	0.0436	0.32	0.16	Fear of pain;Fear of severe pain;	chr17:12704954	chr17:12115547~12115885:+
LUAD	cis	rs3738443	0.52	rs1771932	ENSG00000225300.1	RP11-1086F11.1	-3.56	0.000405	0.0436	-0.17	-0.16	Alcohol dependence;	chr1:247218747	chr1:246605873~246608102:+
LUAD	cis	rs763567	0.869	rs629234	ENSG00000271811.1	RP1-79C4.4	3.56	0.000405	0.0436	0.19	0.16	Tonsillectomy;	chr1:170662622	chr1:170667381~170669425:+
LUAD	cis	rs7819412	0.522	rs4642600	ENSG00000255046.1	RP11-297N6.4	3.56	0.000405	0.0436	0.2	0.16	Triglycerides;	chr8:11155515	chr8:11797928~11802568:-
LUAD	cis	rs7107174	1	rs2511155	ENSG00000251323.2	RP11-452H21.4	3.56	0.000405	0.0436	0.21	0.16	Testicular germ cell tumor;	chr11:78258177	chr11:78423982~78429836:-
LUAD	cis	rs7615952	0.512	rs2979351	ENSG00000171084.14	FAM86JP	3.56	0.000405	0.0436	0.21	0.16	Blood pressure (smoking interaction);	chr3:125644755	chr3:125916620~125930024:+
LUAD	cis	rs67311347	1	rs73078169	ENSG00000280739.1	EIF1B-AS1	3.56	0.000406	0.0436	0.18	0.16	Renal cell carcinoma;	chr3:40442307	chr3:40173145~40309698:-
LUAD	cis	rs2179367	0.959	rs537354	ENSG00000216906.2	RP11-350J20.9	3.56	0.000406	0.0436	0.2	0.16	Dupuytren's disease;	chr6:149344801	chr6:149904243~149906418:+
LUAD	cis	rs9309473	0.948	rs7607892	ENSG00000230002.2	ALMS1-IT1	3.56	0.000406	0.0436	0.2	0.16	Metabolite levels;	chr2:73591580	chr2:73456764~73459484:+
LUAD	cis	rs9951698	0.678	rs529620	ENSG00000266969.1	RP11-773H22.4	3.56	0.000406	0.0436	0.21	0.16	Intelligence (multi-trait analysis);	chr18:13123877	chr18:12984694~12991173:-
LUAD	cis	rs5758659	0.716	rs86669	ENSG00000273366.1	CTA-989H11.1	-3.56	0.000406	0.0436	-0.18	-0.16	Cognitive function;	chr22:42284794	chr22:42278188~42278846:+
LUAD	cis	rs1823913	0.637	rs1947456	ENSG00000230611.1	HMGB1P27	3.56	0.000406	0.0436	0.18	0.16	Obesity-related traits;	chr2:191298759	chr2:191174233~191174835:+
LUAD	cis	rs1823913	0.614	rs11693878	ENSG00000230611.1	HMGB1P27	3.56	0.000406	0.0436	0.18	0.16	Obesity-related traits;	chr2:191299399	chr2:191174233~191174835:+
LUAD	cis	rs1823913	0.637	rs10931494	ENSG00000230611.1	HMGB1P27	3.56	0.000406	0.0436	0.18	0.16	Obesity-related traits;	chr2:191299442	chr2:191174233~191174835:+
LUAD	cis	rs1823913	0.637	rs10931495	ENSG00000230611.1	HMGB1P27	3.56	0.000406	0.0436	0.18	0.16	Obesity-related traits;	chr2:191299447	chr2:191174233~191174835:+
LUAD	cis	rs1823913	0.637	rs12623156	ENSG00000230611.1	HMGB1P27	3.56	0.000406	0.0436	0.18	0.16	Obesity-related traits;	chr2:191299661	chr2:191174233~191174835:+
LUAD	cis	rs1799949	1	rs36036395	ENSG00000267340.1	RP11-242D8.3	3.56	0.000406	0.0437	0.17	0.16	Menopause (age at onset);	chr17:43029280	chr17:43169880~43170077:-
LUAD	cis	rs1799949	1	rs72829113	ENSG00000267340.1	RP11-242D8.3	3.56	0.000406	0.0437	0.17	0.16	Menopause (age at onset);	chr17:43029818	chr17:43169880~43170077:-
LUAD	cis	rs520525	1	rs520525	ENSG00000271811.1	RP1-79C4.4	3.56	0.000406	0.0437	0.21	0.16	Atrial fibrillation;	chr1:170669192	chr1:170667381~170669425:+
LUAD	cis	rs4908769	0.624	rs2708633	ENSG00000232912.4	RP5-1115A15.1	-3.56	0.000406	0.0437	-0.15	-0.16	Allergy;	chr1:8379565	chr1:8424645~8434838:+
LUAD	cis	rs4142110	0.679	rs4942092	ENSG00000271216.1	LINC01050	3.56	0.000406	0.0437	0.2	0.16	Nephrolithiasis;	chr13:42131365	chr13:42810366~42812562:-
LUAD	cis	rs950027	0.62	rs35861938	ENSG00000259479.5	SORD2P	3.56	0.000406	0.0437	0.2	0.16	Response to fenofibrate (adiponectin levels);	chr15:45345145	chr15:44826371~44884694:-
LUAD	cis	rs9381040	0.655	rs2294696	ENSG00000161912.16	ADCY10P1	-3.56	0.000406	0.0437	-0.14	-0.16	Alzheimer's disease (late onset);	chr6:41069249	chr6:41101022~41140835:+
LUAD	cis	rs3120667	0.72	rs12067942	ENSG00000237975.5	FLG-AS1	3.56	0.000406	0.0437	0.28	0.16	Eating disorders;	chr1:152430794	chr1:152168125~152445456:+
LUAD	cis	rs4423214	0.84	rs1792231	ENSG00000226627.1	SHANK2-AS1	3.56	0.000406	0.0437	0.2	0.16	Vitamin D levels;	chr11:71471635	chr11:70631094~70635490:+
LUAD	cis	rs10170310	0.608	rs10928657	ENSG00000228043.4	AC097721.2	3.56	0.000406	0.0437	0.22	0.16	Response to antipsychotic treatment;	chr2:138534199	chr2:138418284~138501698:-
LUAD	cis	rs9400467	0.506	rs12200758	ENSG00000255389.1	C6orf3	3.56	0.000406	0.0437	0.21	0.16	Amino acid levels;Blood metabolite levels;	chr6:111389641	chr6:111599875~111602295:+
LUAD	cis	rs7142881	0.815	rs1560426	ENSG00000258525.1	RP11-829H16.3	-3.56	0.000406	0.0437	-0.18	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31696462	chr14:30876179~30889808:-
LUAD	cis	rs13068223	0.74	rs344028	ENSG00000243926.1	TIPARP-AS1	3.56	0.000406	0.0437	0.17	0.16	Age-related hearing impairment (SNP x SNP interaction);	chr3:156747980	chr3:156671862~156674378:-
LUAD	cis	rs237743	0.928	rs237714	ENSG00000177410.11	ZFAS1	3.56	0.000406	0.0437	0.18	0.16	Height;	chr20:49306363	chr20:49278178~49295738:+
LUAD	cis	rs56309584	0.521	rs11651599	ENSG00000269947.1	RP11-849F2.9	-3.56	0.000406	0.0437	-0.23	-0.16	Initial pursuit acceleration;	chr17:8276194	chr17:8277763~8278436:+
LUAD	cis	rs862034	1	rs862031	ENSG00000270000.1	RP3-449M8.9	3.56	0.000406	0.0437	0.18	0.16	Height;	chr14:74525152	chr14:74471930~74472360:-
LUAD	cis	rs651907	0.557	rs3094296	ENSG00000244119.1	PDCL3P4	3.56	0.000406	0.0437	0.16	0.16	Colorectal cancer;	chr3:101681323	chr3:101712472~101713191:+
LUAD	cis	rs4819052	0.918	rs2330013	ENSG00000223768.1	LINC00205	-3.56	0.000406	0.0437	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238747	chr21:45293285~45297354:+
LUAD	cis	rs6568686	0.627	rs12207557	ENSG00000255389.1	C6orf3	3.56	0.000406	0.0437	0.22	0.16	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111446256	chr6:111599875~111602295:+
LUAD	cis	rs10946940	0.965	rs6456799	ENSG00000280107.1	AL022393.9	3.56	0.000406	0.0437	0.18	0.16	Systemic lupus erythematosus;	chr6:27605757	chr6:28170845~28172521:+
LUAD	cis	rs17772222	0.92	rs61975260	ENSG00000258789.1	RP11-507K2.3	-3.56	0.000406	0.0437	-0.22	-0.16	Coronary artery calcification;	chr14:88429597	chr14:88551597~88552493:+
LUAD	cis	rs2281558	0.833	rs6115202	ENSG00000125804.12	FAM182A	3.56	0.000406	0.0437	0.22	0.16	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25516902	chr20:26054655~26086917:+
LUAD	cis	rs4683346	0.731	rs35807837	ENSG00000173811.9	CCDC13-AS1	-3.56	0.000407	0.0437	-0.18	-0.16	Granulocyte percentage of myeloid white cells;	chr3:42878743	chr3:42732575~42746768:+
LUAD	cis	rs12908161	0.959	rs2175567	ENSG00000254414.1	RP11-182J1.1	3.56	0.000407	0.0437	0.21	0.16	Schizophrenia;	chr15:84657715	chr15:84631898~84633987:-
LUAD	cis	rs4074961	0.527	rs10908355	ENSG00000233621.1	LINC01137	-3.56	0.000407	0.0437	-0.15	-0.16	Axial length;	chr1:37569685	chr1:37454879~37474411:-
LUAD	cis	rs2361718	0.5	rs4889818	ENSG00000279259.1	RP11-334C17.3	3.56	0.000407	0.0437	0.19	0.16	Yeast infection;	chr17:80111429	chr17:80147250~80148596:+
LUAD	cis	rs2287641	0.826	rs7558563	ENSG00000272156.1	RP11-477N3.1	3.56	0.000407	0.0437	0.4	0.16	Cannabis dependence symptom count;	chr2:54111803	chr2:54082554~54085066:+
LUAD	cis	rs2274273	0.805	rs7159808	ENSG00000258413.1	RP11-665C16.6	-3.56	0.000407	0.0437	-0.21	-0.16	Protein biomarker;	chr14:55157609	chr14:55262767~55272075:-
LUAD	cis	rs4073582	0.595	rs801739	ENSG00000197847.11	SLC22A20	-3.56	0.000407	0.0437	-0.18	-0.16	Gout;	chr11:66155118	chr11:65213840~65242757:+
LUAD	cis	rs1387259	0.69	rs1601985	ENSG00000273765.1	RP11-370I10.11	3.56	0.000407	0.0437	0.17	0.16	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48368131	chr12:48360920~48361377:+
LUAD	cis	rs1046491	0.901	rs7229685	ENSG00000264964.1	RP11-888D10.3	3.56	0.000407	0.0438	0.33	0.16	Scarlet fever;	chr18:9194172	chr18:9315194~9334441:-
LUAD	cis	rs6479901	0.895	rs10761722	ENSG00000232075.1	MRPL35P2	-3.56	0.000407	0.0438	-0.22	-0.16	Intelligence (multi-trait analysis);	chr10:63195287	chr10:63634317~63634827:-
LUAD	cis	rs11122895	1	rs34217241	ENSG00000236307.2	EEF1E1P1	3.56	0.000407	0.0438	0.19	0.16	Allergic sensitization;	chr2:111708062	chr2:111887914~111888741:+
LUAD	cis	rs11216126	1	rs11216126	ENSG00000280143.1	AP000892.6	-3.56	0.000407	0.0438	-0.27	-0.16	HDL cholesterol;	chr11:116746524	chr11:117204967~117210292:+
LUAD	cis	rs448720	1	rs410554	ENSG00000260657.2	RP11-315D16.4	-3.56	0.000407	0.0438	-0.18	-0.16	Cognitive performance;	chr15:67906161	chr15:68267792~68277994:-
LUAD	cis	rs4811196	0.956	rs4811194	ENSG00000226144.2	RPS27AP3	3.56	0.000407	0.0438	0.2	0.16	Bone mineral density;	chr20:37841112	chr20:37049254~37049707:+
LUAD	cis	rs216345	0.7	rs1760822	ENSG00000200834.1	Y_RNA	3.56	0.000407	0.0438	0.16	0.16	Bipolar disorder;	chr9:34025952	chr9:33830978~33831078:+
LUAD	cis	rs526231	0.543	rs158395	ENSG00000250682.4	LINC00491	3.56	0.000407	0.0438	0.19	0.16	Primary biliary cholangitis;	chr5:103075685	chr5:102609156~102671559:-
LUAD	cis	rs526231	0.543	rs158400	ENSG00000250682.4	LINC00491	3.56	0.000407	0.0438	0.19	0.16	Primary biliary cholangitis;	chr5:103077628	chr5:102609156~102671559:-
LUAD	cis	rs526231	0.543	rs257302	ENSG00000250682.4	LINC00491	3.56	0.000407	0.0438	0.19	0.16	Primary biliary cholangitis;	chr5:103080426	chr5:102609156~102671559:-
LUAD	cis	rs526231	0.543	rs257303	ENSG00000250682.4	LINC00491	3.56	0.000407	0.0438	0.19	0.16	Primary biliary cholangitis;	chr5:103081023	chr5:102609156~102671559:-
LUAD	cis	rs4662750	0.619	rs2244042	ENSG00000236682.1	AC068282.3	-3.56	0.000407	0.0438	-0.2	-0.16	Renal cell carcinoma;	chr2:127647423	chr2:127389130~127400580:+
LUAD	cis	rs2735413	0.709	rs8051521	ENSG00000276007.1	RP11-358L22.3	3.56	0.000407	0.0438	0.17	0.16	Systolic blood pressure (alcohol consumption interaction);	chr16:78054259	chr16:78123243~78124332:+
LUAD	cis	rs2836974	0.674	rs1011413	ENSG00000232608.1	TIMM9P2	3.56	0.000407	0.0438	0.18	0.16	Cognitive function;	chr21:39266315	chr21:39216624~39217506:+
LUAD	cis	rs12034383	0.967	rs7519119	ENSG00000274245.1	RP11-357P18.2	-3.56	0.000407	0.0438	-0.19	-0.16	Erythrocyte sedimentation rate;	chr1:207612807	chr1:207372559~207373252:+
LUAD	cis	rs12034383	0.967	rs7542544	ENSG00000274245.1	RP11-357P18.2	-3.56	0.000407	0.0438	-0.19	-0.16	Erythrocyte sedimentation rate;	chr1:207612878	chr1:207372559~207373252:+
LUAD	cis	rs957448	0.561	rs71532325	ENSG00000253175.1	RP11-267M23.6	3.56	0.000407	0.0438	0.18	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94615738	chr8:94565036~94565715:+
LUAD	cis	rs3849221	0.729	rs3849222	ENSG00000233936.1	RP11-399H11.2	-3.56	0.000407	0.0438	-0.17	-0.16	Obesity-related traits;	chr9:135140199	chr9:135245696~135252708:-
LUAD	cis	rs11233413	1	rs11233405	ENSG00000246067.6	RAB30-AS1	-3.56	0.000407	0.0438	-0.17	-0.16	Economic and political preferences (feminism/equality);	chr11:82998588	chr11:83072066~83106719:+
LUAD	cis	rs924712	0.545	rs10948862	ENSG00000261116.1	RP3-523K23.2	3.56	0.000407	0.0438	0.17	0.16	Breast cancer;	chr6:54846673	chr6:54943167~54945099:+
LUAD	cis	rs12928939	0.517	rs8050058	ENSG00000262140.1	RP11-417N10.3	-3.56	0.000407	0.0438	-0.2	-0.16	Post bronchodilator FEV1;	chr16:71947471	chr16:71833787~71835932:+
LUAD	cis	rs7674212	0.57	rs6841136	ENSG00000251288.2	RP11-10L12.2	-3.56	0.000407	0.0438	-0.2	-0.16	Type 2 diabetes;	chr4:103182352	chr4:102751401~102752641:+
LUAD	cis	rs9295536	0.651	rs6900792	ENSG00000260455.1	NBAT1	3.56	0.000407	0.0438	0.2	0.16	Neuroblastoma;	chr6:22136709	chr6:22134957~22147193:-
LUAD	cis	rs4784934	0.55	rs4784939	ENSG00000260186.4	RP11-481J2.2	3.56	0.000407	0.0438	0.2	0.16	QT interval;	chr16:58434307	chr16:58421326~58462470:+
LUAD	cis	rs4842666	0.831	rs11105378	ENSG00000258302.2	RP11-981P6.1	3.56	0.000407	0.0438	0.24	0.16	Blood pressure;	chr12:89696964	chr12:89561129~89594878:+
LUAD	cis	rs9302635	0.678	rs8054585	ENSG00000260886.1	TAT-AS1	3.56	0.000407	0.0438	0.21	0.16	Blood protein levels;	chr16:72191415	chr16:71565789~71578187:+
LUAD	cis	rs7605235	0.959	rs17745923	ENSG00000224165.4	DNAJC27-AS1	3.56	0.000407	0.0438	0.18	0.16	Response to platinum-based chemotherapy (cisplatin);	chr2:25421075	chr2:24971390~25039694:+
LUAD	cis	rs794185	0.714	rs2633860	ENSG00000231249.1	ITPR1-AS1	-3.56	0.000408	0.0438	-0.18	-0.16	Multiple sclerosis--Brain Glutamate Levels;	chr3:4457662	chr3:4490891~4493163:-
LUAD	cis	rs875971	0.83	rs4718358	ENSG00000273142.1	RP11-458F8.4	-3.56	0.000408	0.0438	-0.11	-0.16	Aortic root size;	chr7:66508681	chr7:66902857~66906297:+
LUAD	cis	rs4938303	0.633	rs17092638	ENSG00000254851.1	RP11-109L13.1	3.56	0.000408	0.0438	0.24	0.16	Triglycerides;	chr11:116685520	chr11:117135528~117138582:+
LUAD	cis	rs6453278	0.559	rs3934501	ENSG00000250802.5	ZBED3-AS1	-3.56	0.000408	0.0438	-0.2	-0.16	Autism;	chr5:77097859	chr5:77086740~77166909:+
LUAD	cis	rs6502050	0.799	rs4789667	ENSG00000275966.1	RP11-1055B8.9	-3.56	0.000408	0.0438	-0.16	-0.16	Life satisfaction;	chr17:82204267	chr17:81345476~81345966:-
LUAD	cis	rs858239	0.899	rs10262243	ENSG00000226816.2	AC005082.12	3.56	0.000408	0.0438	0.21	0.16	Cerebrospinal fluid biomarker levels;	chr7:23251368	chr7:23206013~23208045:+
LUAD	cis	rs10463554	0.963	rs6889592	ENSG00000250682.4	LINC00491	3.56	0.000408	0.0438	0.19	0.16	Parkinson's disease;	chr5:102978235	chr5:102609156~102671559:-
LUAD	cis	rs2731006	0.64	rs2730970	ENSG00000257114.2	RP11-25I15.3	-3.56	0.000408	0.0438	-0.25	-0.16	Panic disorder;	chr12:42793077	chr12:42692216~42717119:+
LUAD	cis	rs8035452	0.964	rs12906839	ENSG00000259240.1	RP11-108K3.1	-3.56	0.000408	0.0438	-0.18	-0.16	Alzheimer's disease (late onset);	chr15:50742511	chr15:51037488~51293912:+
LUAD	cis	rs76419734	0.702	rs78583682	ENSG00000251175.4	RP11-45L9.1	-3.56	0.000408	0.0438	-0.38	-0.16	Post bronchodilator FEV1;	chr4:105597041	chr4:105746245~105827172:-
LUAD	cis	rs524281	0.773	rs2155201	ENSG00000255320.1	RP11-755F10.1	3.56	0.000408	0.0438	0.25	0.16	Electroencephalogram traits;	chr11:66224873	chr11:66244840~66246239:-
LUAD	cis	rs17711722	0.701	rs781145	ENSG00000234585.5	CCT6P3	3.56	0.000408	0.0438	0.15	0.16	Calcium levels;	chr7:65975383	chr7:65038354~65074713:+
LUAD	cis	rs2137920	0.947	rs2466755	ENSG00000265018.5	CTGLF12P	-3.56	0.000408	0.0438	-0.24	-0.16	Migraine with aura;	chr10:49020871	chr10:48009873~48031640:-
LUAD	cis	rs2137920	1	rs2466754	ENSG00000265018.5	CTGLF12P	-3.56	0.000408	0.0438	-0.24	-0.16	Migraine with aura;	chr10:49020877	chr10:48009873~48031640:-
LUAD	cis	rs2808510	0.74	rs71633898	ENSG00000230623.2	RP11-469A15.2	-3.56	0.000408	0.0439	-0.21	-0.16	Myopia;	chr1:200341770	chr1:200473920~200478293:+
LUAD	cis	rs6736093	0.769	rs56361454	ENSG00000207383.1	Y_RNA	-3.56	0.000408	0.0439	-0.2	-0.16	Coronary artery disease;	chr2:112016528	chr2:112579484~112579584:-
LUAD	cis	rs797680	0.93	rs2295423	ENSG00000223745.6	RP4-717I23.3	3.56	0.000408	0.0439	0.12	0.16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93115467	chr1:93262186~93346025:-
LUAD	cis	rs7077256	0.564	rs35555565	ENSG00000272767.1	JMJD1C-AS1	3.56	0.000408	0.0439	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63201508	chr10:63465229~63466563:+
LUAD	cis	rs2731006	0.64	rs2678148	ENSG00000257114.2	RP11-25I15.3	3.56	0.000408	0.0439	0.26	0.16	Panic disorder;	chr12:42783661	chr12:42692216~42717119:+
LUAD	cis	rs6001482	0.647	rs8140302	ENSG00000211642.2	IGLV10-54	3.56	0.000408	0.0439	0.18	0.16	Diastolic blood pressure;	chr22:22234843	chr22:22214794~22215270:+
LUAD	cis	rs990171	0.538	rs2075188	ENSG00000234389.1	AC007278.3	3.56	0.000408	0.0439	0.16	0.16	Lymphocyte counts;	chr2:102503773	chr2:102438713~102440475:+
LUAD	cis	rs990171	0.538	rs4851016	ENSG00000234389.1	AC007278.3	3.56	0.000408	0.0439	0.16	0.16	Lymphocyte counts;	chr2:102503941	chr2:102438713~102440475:+
LUAD	cis	rs4591358	0.626	rs7565624	ENSG00000223466.1	AC064834.2	3.56	0.000408	0.0439	0.18	0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195431262	chr2:195533035~195538681:+
LUAD	cis	rs4591358	0.651	rs66489016	ENSG00000223466.1	AC064834.2	3.56	0.000408	0.0439	0.18	0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195431900	chr2:195533035~195538681:+
LUAD	cis	rs9662662	1	rs9662662	ENSG00000228606.1	RP11-574F21.2	-3.56	0.000408	0.0439	-0.17	-0.16	Growth-regulated protein alpha levels;	chr1:159549353	chr1:160261744~160262778:+
LUAD	cis	rs755249	0.565	rs9729677	ENSG00000182109.6	RP11-69E11.4	-3.56	0.000408	0.0439	-0.17	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39587137	chr1:39522280~39546187:-
LUAD	cis	rs6687758	1	rs6687758	ENSG00000238042.4	RP11-815M8.1	3.56	0.000408	0.0439	0.22	0.16	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221991606	chr1:221880981~221978523:-
LUAD	cis	rs6121246	0.697	rs6120970	ENSG00000230613.1	HM13-AS1	3.56	0.000408	0.0439	0.23	0.16	Mean corpuscular hemoglobin;	chr20:31644649	chr20:31567707~31573263:-
LUAD	cis	rs1185460	0.967	rs2509121	ENSG00000272186.1	RP11-110I1.13	-3.56	0.000408	0.0439	-0.19	-0.16	Coronary artery disease;	chr11:119057542	chr11:119067374~119067698:-
LUAD	cis	rs7474896	0.515	rs2749582	ENSG00000226578.1	RP11-258F22.1	3.56	0.000408	0.0439	0.22	0.16	Obesity (extreme);	chr10:37986356	chr10:37775371~37784131:-
LUAD	cis	rs2024714	0.902	rs6089445	ENSG00000273812.1	WI2-87327B8.2	-3.56	0.000408	0.0439	-0.17	-0.16	Longevity;	chr20:61635030	chr20:62596732~62603115:-
LUAD	cis	rs2548724	0.755	rs1376907	ENSG00000250682.4	LINC00491	3.56	0.000408	0.0439	0.2	0.16	Type 2 diabetes;	chr5:102443332	chr5:102609156~102671559:-
LUAD	cis	rs7515577	0.853	rs2046621	ENSG00000223787.2	RP4-593M8.1	-3.56	0.000408	0.0439	-0.24	-0.16	Cholesterol, total;	chr1:92323212	chr1:92580476~92580821:-
LUAD	cis	rs4716602	0.596	rs1996994	ENSG00000235029.1	MNX1-AS2	3.56	0.000408	0.0439	0.19	0.16	Anti-saccade response;	chr7:156367000	chr7:157006307~157007132:+
LUAD	cis	rs8064024	0.599	rs1876359	ENSG00000267077.1	RP11-127I20.5	3.56	0.000408	0.0439	0.19	0.16	Cancer;	chr16:4880099	chr16:4795265~4796532:-
LUAD	cis	rs7204230	1	rs6499550	ENSG00000261291.1	RP11-295M3.2	3.56	0.000409	0.0439	0.19	0.16	Fibrinogen;	chr16:53308542	chr16:53168522~53169450:+
LUAD	cis	rs2333021	0.649	rs997667	ENSG00000259015.1	RP11-109N23.6	3.56	0.000409	0.0439	0.16	0.16	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72998295	chr14:72960595~72961993:+
LUAD	cis	rs4388249	0.659	rs10065099	ENSG00000271849.1	CTC-332L22.1	-3.56	0.000409	0.0439	-0.23	-0.16	Schizophrenia;	chr5:109841677	chr5:109687802~109688329:-
LUAD	cis	rs4763879	0.778	rs1056151	ENSG00000257027.1	RP11-705C15.3	3.56	0.000409	0.0439	0.2	0.16	Type 1 diabetes;	chr12:9698427	chr12:9658567~9662085:+
LUAD	cis	rs1722141	0.633	rs2132570	ENSG00000229628.1	AC073115.7	3.56	0.000409	0.0439	0.24	0.16	Sitting height ratio;	chr7:45922864	chr7:45990905~46000898:+
LUAD	cis	rs6452524	0.534	rs10514246	ENSG00000281327.1	LINC01338	3.56	0.000409	0.0439	0.17	0.16	Hypertension (SNP x SNP interaction);	chr5:83069979	chr5:82850864~82859836:-
LUAD	cis	rs490234	0.841	rs829311	ENSG00000232630.1	PRPS1P2	-3.56	0.000409	0.0439	-0.15	-0.16	Mean arterial pressure;	chr9:125632344	chr9:125150653~125151589:+
LUAD	cis	rs1799949	1	rs9646412	ENSG00000267340.1	RP11-242D8.3	3.56	0.000409	0.0439	0.17	0.16	Menopause (age at onset);	chr17:43348525	chr17:43169880~43170077:-
LUAD	cis	rs4699052	0.625	rs1400365	ENSG00000251288.2	RP11-10L12.2	-3.56	0.000409	0.0439	-0.19	-0.16	Testicular germ cell tumor;	chr4:103368239	chr4:102751401~102752641:+
LUAD	cis	rs62514666	1	rs57214024	ENSG00000261693.1	RP13-467H17.1	-3.56	0.000409	0.0439	-0.36	-0.16	Facial morphology (factor 19);	chr8:142142983	chr8:142403652~142407028:+
LUAD	cis	rs6860806	0.661	rs1588263	ENSG00000263597.1	MIR3936	3.56	0.000409	0.0439	0.16	0.16	Breast cancer;	chr5:132241465	chr5:132365490~132365599:-
LUAD	cis	rs6728302	0.557	rs12467271	ENSG00000181798.2	LINC00471	3.56	0.000409	0.0439	0.38	0.16	Height;	chr2:232301414	chr2:231508426~231514339:-
LUAD	cis	rs1667284	0.935	rs1791171	ENSG00000263393.1	RP11-53I6.4	-3.56	0.000409	0.0439	-0.15	-0.16	Problematic alcohol use in trauma-exposed individuals;	chr18:31636194	chr18:32122400~32124478:-
LUAD	cis	rs12908161	1	rs62019464	ENSG00000259654.1	RP11-245C17.2	-3.56	0.000409	0.0439	-0.23	-0.16	Schizophrenia;	chr15:84751238	chr15:84685884~84686946:+
LUAD	cis	rs987724	0.574	rs7638625	ENSG00000240875.4	LINC00886	-3.56	0.000409	0.0439	-0.18	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156840267	chr3:156747346~156817062:-
LUAD	cis	rs8046148	0.865	rs11076512	ENSG00000279356.1	RP11-429P3.8	3.56	0.000409	0.0439	0.19	0.16	Testicular germ cell tumor;	chr16:50097943	chr16:50072862~50074986:+
LUAD	cis	rs8046148	0.951	rs11642579	ENSG00000279356.1	RP11-429P3.8	3.56	0.000409	0.0439	0.19	0.16	Testicular germ cell tumor;	chr16:50098169	chr16:50072862~50074986:+
LUAD	cis	rs7636293	0.592	rs6439168	ENSG00000270773.1	RP13-685P2.7	-3.56	0.000409	0.0439	-0.23	-0.16	Height;	chr3:129332100	chr3:129345411~129346164:+
LUAD	cis	rs2115630	0.645	rs2292463	ENSG00000275120.1	RP11-182J1.17	-3.56	0.000409	0.0439	-0.2	-0.16	P wave terminal force;	chr15:84632519	chr15:84599434~84606463:-
LUAD	cis	rs116095464	1	rs56700778	ENSG00000250848.1	CTD-2083E4.5	-3.56	0.000409	0.0439	-0.33	-0.16	Breast cancer;	chr5:313071	chr5:288833~290321:-
LUAD	cis	rs8031584	0.872	rs11634761	ENSG00000259845.1	HERC2P10	3.56	0.000409	0.0439	0.19	0.16	Huntington's disease progression;	chr15:30950970	chr15:30815271~30844153:+
LUAD	cis	rs6502050	0.835	rs7502676	ENSG00000266654.1	RP11-1376P16.1	-3.56	0.000409	0.0439	-0.17	-0.16	Life satisfaction;	chr17:82135557	chr17:82160056~82160452:+
LUAD	cis	rs6121246	0.567	rs6120815	ENSG00000230613.1	HM13-AS1	3.56	0.000409	0.0439	0.25	0.16	Mean corpuscular hemoglobin;	chr20:31597063	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.529	rs6060195	ENSG00000230613.1	HM13-AS1	3.56	0.000409	0.0439	0.25	0.16	Mean corpuscular hemoglobin;	chr20:31597835	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.529	rs6060210	ENSG00000230613.1	HM13-AS1	3.56	0.000409	0.0439	0.25	0.16	Mean corpuscular hemoglobin;	chr20:31599878	chr20:31567707~31573263:-
LUAD	cis	rs10090774	0.87	rs4563941	ENSG00000280303.2	ERICD	-3.56	0.000409	0.0439	-0.18	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140722653	chr8:140636281~140638283:+
LUAD	cis	rs7077256	0.5	rs72835361	ENSG00000272767.1	JMJD1C-AS1	3.56	0.000409	0.0439	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63338705	chr10:63465229~63466563:+
LUAD	cis	rs17660992	0.525	rs10421946	ENSG00000273837.1	LLNLR-470E3.1	-3.56	0.000409	0.0439	-0.18	-0.16	Blood protein levels;	chr19:51661797	chr19:51639478~51639931:-
LUAD	cis	rs12999542	1	rs13007174	ENSG00000234389.1	AC007278.3	3.56	0.000409	0.0439	0.22	0.16	Serum protein levels (sST2);	chr2:102344027	chr2:102438713~102440475:+
LUAD	cis	rs12999542	1	rs13007819	ENSG00000234389.1	AC007278.3	3.56	0.000409	0.0439	0.22	0.16	Serum protein levels (sST2);	chr2:102344359	chr2:102438713~102440475:+
LUAD	cis	rs12999542	1	rs13014044	ENSG00000234389.1	AC007278.3	3.56	0.000409	0.0439	0.22	0.16	Serum protein levels (sST2);	chr2:102344906	chr2:102438713~102440475:+
LUAD	cis	rs12999542	1	rs1054096	ENSG00000234389.1	AC007278.3	3.56	0.000409	0.0439	0.22	0.16	Serum protein levels (sST2);	chr2:102345890	chr2:102438713~102440475:+
LUAD	cis	rs12999542	1	rs12989197	ENSG00000234389.1	AC007278.3	3.56	0.000409	0.0439	0.22	0.16	Serum protein levels (sST2);	chr2:102346279	chr2:102438713~102440475:+
LUAD	cis	rs12999542	1	rs12996097	ENSG00000234389.1	AC007278.3	3.56	0.000409	0.0439	0.22	0.16	Serum protein levels (sST2);	chr2:102347168	chr2:102438713~102440475:+
LUAD	cis	rs12999542	0.925	rs13028993	ENSG00000234389.1	AC007278.3	3.56	0.000409	0.0439	0.22	0.16	Serum protein levels (sST2);	chr2:102347489	chr2:102438713~102440475:+
LUAD	cis	rs12999542	1	rs12999542	ENSG00000234389.1	AC007278.3	3.56	0.000409	0.0439	0.22	0.16	Serum protein levels (sST2);	chr2:102348932	chr2:102438713~102440475:+
LUAD	cis	rs7660883	0.866	rs342468	ENSG00000251411.1	RP11-397E7.4	-3.56	0.000409	0.0439	-0.17	-0.16	HDL cholesterol levels;	chr4:87130756	chr4:86913266~86914817:-
LUAD	cis	rs1150668	0.83	rs213240	ENSG00000176933.5	TOB2P1	-3.56	0.000409	0.0439	-0.18	-0.16	Pubertal anthropometrics;	chr6:28348098	chr6:28217643~28218634:-
LUAD	cis	rs7116495	1	rs2250866	ENSG00000254682.1	RP11-660L16.2	3.56	0.000409	0.0439	0.35	0.16	Severe influenza A (H1N1) infection;	chr11:72093467	chr11:71448674~71452157:+
LUAD	cis	rs34779708	0.733	rs11597184	ENSG00000271335.4	RP11-324I22.4	3.56	0.000409	0.0439	0.17	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35108468	chr10:35314552~35336401:-
LUAD	cis	rs4716602	0.898	rs10275754	ENSG00000235029.1	MNX1-AS2	-3.56	0.000409	0.0439	-0.21	-0.16	Anti-saccade response;	chr7:156369069	chr7:157006307~157007132:+
LUAD	cis	rs2732480	0.538	rs1387259	ENSG00000273765.1	RP11-370I10.11	-3.56	0.000409	0.0439	-0.18	-0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309739	chr12:48360920~48361377:+
LUAD	cis	rs804280	0.662	rs804283	ENSG00000255046.1	RP11-297N6.4	-3.56	0.000409	0.044	-0.23	-0.16	Myopia (pathological);	chr8:11753534	chr8:11797928~11802568:-
LUAD	cis	rs935334	1	rs12879642	ENSG00000258454.1	RP11-361H10.3	3.56	0.000409	0.044	0.24	0.16	Blood pressure;	chr14:76216624	chr14:76235817~76263474:+
LUAD	cis	rs6568686	0.627	rs12207339	ENSG00000255389.1	C6orf3	3.56	0.000409	0.044	0.22	0.16	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111445809	chr6:111599875~111602295:+
LUAD	cis	rs6568686	0.627	rs12191726	ENSG00000255389.1	C6orf3	3.56	0.000409	0.044	0.22	0.16	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111448321	chr6:111599875~111602295:+
LUAD	cis	rs9400467	0.506	rs17751426	ENSG00000255389.1	C6orf3	3.56	0.000409	0.044	0.22	0.16	Amino acid levels;Blood metabolite levels;	chr6:111451020	chr6:111599875~111602295:+
LUAD	cis	rs9400467	0.506	rs74529244	ENSG00000255389.1	C6orf3	3.56	0.000409	0.044	0.22	0.16	Amino acid levels;Blood metabolite levels;	chr6:111454155	chr6:111599875~111602295:+
LUAD	cis	rs6568686	0.627	rs113922733	ENSG00000255389.1	C6orf3	3.56	0.000409	0.044	0.22	0.16	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111458245	chr6:111599875~111602295:+
LUAD	cis	rs6754311	0.689	rs191079	ENSG00000231890.6	DARS-AS1	-3.56	0.000409	0.044	-0.22	-0.16	Mosquito bite size;	chr2:135876201	chr2:135985176~136022593:+
LUAD	cis	rs2823962	0.927	rs7276313	ENSG00000270093.1	AP000473.8	-3.56	0.000409	0.044	-0.16	-0.16	Amyotrophic lateral sclerosis;	chr21:16660288	chr21:16643529~16645065:+
LUAD	cis	rs2975734	0.709	rs4841298	ENSG00000280294.1	RP11-177H2.1	-3.56	0.000409	0.044	-0.21	-0.16	Chronotype;Morning vs. evening chronotype;	chr8:10254127	chr8:10856085~10859436:-
LUAD	cis	rs6496932	0.503	rs4564526	ENSG00000218052.5	ADAMTS7P4	-3.56	0.000409	0.044	-0.19	-0.16	Central corneal thickness;Corneal structure;	chr15:85455914	chr15:85255369~85330334:-
LUAD	cis	rs2281636	0.792	rs10883385	ENSG00000233690.1	EBAG9P1	3.56	0.000409	0.044	0.15	0.16	Obesity-related traits;	chr10:99621956	chr10:99697407~99697949:-
LUAD	cis	rs11587682	0.911	rs12120683	ENSG00000223945.2	RP11-458I7.1	-3.56	0.000409	0.044	-0.29	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150300385	chr1:150053864~150055034:+
LUAD	cis	rs11587682	0.956	rs72696807	ENSG00000223945.2	RP11-458I7.1	-3.56	0.000409	0.044	-0.29	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150302061	chr1:150053864~150055034:+
LUAD	cis	rs41271951	0.518	rs72696808	ENSG00000223945.2	RP11-458I7.1	-3.56	0.000409	0.044	-0.29	-0.16	Blood protein levels;	chr1:150302181	chr1:150053864~150055034:+
LUAD	cis	rs7208859	0.673	rs12103759	ENSG00000265443.1	CTD-2349P21.6	-3.56	0.000409	0.044	-0.27	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908669	chr17:30726305~30727564:-
LUAD	cis	rs7208859	0.623	rs59029591	ENSG00000265443.1	CTD-2349P21.6	-3.56	0.000409	0.044	-0.27	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908728	chr17:30726305~30727564:-
LUAD	cis	rs7208859	0.673	rs73265633	ENSG00000265443.1	CTD-2349P21.6	-3.56	0.000409	0.044	-0.27	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30909288	chr17:30726305~30727564:-
LUAD	cis	rs41369048	0.669	rs6660867	ENSG00000257551.1	HLX-AS1	-3.56	0.00041	0.044	-0.24	-0.16	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220864097	chr1:220832763~220880140:-
LUAD	cis	rs4578769	0.55	rs7237400	ENSG00000266850.1	RP11-370A5.1	3.56	0.00041	0.044	0.2	0.16	Eosinophil percentage of white cells;	chr18:22986533	chr18:22723491~22907721:-
LUAD	cis	rs7893279	0.543	rs7099423	ENSG00000225527.1	RP11-383B4.4	3.56	0.00041	0.044	0.23	0.16	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18623773	chr10:18531849~18533336:-
LUAD	cis	rs875971	0.638	rs6960778	ENSG00000273142.1	RP11-458F8.4	3.56	0.00041	0.044	0.11	0.16	Aortic root size;	chr7:66606610	chr7:66902857~66906297:+
LUAD	cis	rs2446066	0.872	rs11170516	ENSG00000257379.1	RP11-793H13.8	3.56	0.00041	0.044	0.26	0.16	Red blood cell count;	chr12:53358908	chr12:53441741~53467528:+
LUAD	cis	rs6472827	0.595	rs2977068	ENSG00000253983.2	RP1-16A9.1	3.56	0.00041	0.044	0.23	0.16	Uterine fibroids;	chr8:74192817	chr8:74199396~74208441:+
LUAD	cis	rs10090774	0.87	rs7834669	ENSG00000280303.2	ERICD	-3.56	0.00041	0.044	-0.18	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140724287	chr8:140636281~140638283:+
LUAD	cis	rs875971	0.522	rs1917563	ENSG00000222364.1	RNU6-96P	3.56	0.00041	0.044	0.18	0.16	Aortic root size;	chr7:65950660	chr7:66395191~66395286:+
LUAD	cis	rs9311474	0.581	rs4687626	ENSG00000243224.1	RP5-1157M23.2	-3.56	0.00041	0.044	-0.16	-0.16	Electroencephalogram traits;	chr3:52535082	chr3:52239258~52241097:+
LUAD	cis	rs2424635	1	rs2424635	ENSG00000277938.1	RP5-965G21.3	-3.56	0.00041	0.044	-0.17	-0.16	Bipolar disorder and schizophrenia;	chr20:24736449	chr20:25229150~25231933:+
LUAD	cis	rs10463554	0.963	rs10463555	ENSG00000250682.4	LINC00491	3.56	0.00041	0.044	0.19	0.16	Parkinson's disease;	chr5:102983333	chr5:102609156~102671559:-
LUAD	cis	rs3126085	0.935	rs11584427	ENSG00000237975.5	FLG-AS1	3.56	0.00041	0.044	0.27	0.16	Atopic dermatitis;	chr1:152327312	chr1:152168125~152445456:+
LUAD	cis	rs34779708	0.966	rs34605125	ENSG00000271335.4	RP11-324I22.4	3.56	0.00041	0.044	0.17	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35122318	chr10:35314552~35336401:-
LUAD	cis	rs10090774	0.71	rs11166990	ENSG00000280303.2	ERICD	3.56	0.00041	0.044	0.17	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140653873	chr8:140636281~140638283:+
LUAD	cis	rs10863681	0.875	rs1890759	ENSG00000227925.1	RP11-191N8.2	3.56	0.00041	0.044	0.18	0.16	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222081282	chr1:221827666~221840666:-
LUAD	cis	rs3845817	1	rs3911863	ENSG00000281920.1	RP11-418H16.1	3.56	0.00041	0.044	0.19	0.16	Bipolar disorder;	chr2:65532630	chr2:65623272~65628424:+
LUAD	cis	rs3845817	0.966	rs3845818	ENSG00000281920.1	RP11-418H16.1	3.56	0.00041	0.044	0.19	0.16	Bipolar disorder;	chr2:65533349	chr2:65623272~65628424:+
LUAD	cis	rs728616	0.867	rs61859763	ENSG00000225484.5	NUTM2B-AS1	-3.56	0.00041	0.044	-0.41	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79911859	chr10:79663088~79826594:-
LUAD	cis	rs7142881	0.626	rs2105275	ENSG00000250365.5	CTD-2213F21.2	3.56	0.00041	0.044	0.18	0.16	Response to iloperidone treatment (QT prolongation);	chr14:31816190	chr14:31420286~31452883:+
LUAD	cis	rs3126085	0.935	rs1466757	ENSG00000237975.5	FLG-AS1	-3.56	0.00041	0.044	-0.24	-0.16	Atopic dermatitis;	chr1:152239993	chr1:152168125~152445456:+
LUAD	cis	rs6860806	0.531	rs270607	ENSG00000263597.1	MIR3936	3.56	0.00041	0.044	0.18	0.16	Breast cancer;	chr5:132313493	chr5:132365490~132365599:-
LUAD	cis	rs1799949	1	rs11653253	ENSG00000267340.1	RP11-242D8.3	3.56	0.00041	0.044	0.17	0.16	Menopause (age at onset);	chr17:43030645	chr17:43169880~43170077:-
LUAD	cis	rs1799949	1	rs12951869	ENSG00000267340.1	RP11-242D8.3	3.56	0.00041	0.044	0.17	0.16	Menopause (age at onset);	chr17:43035550	chr17:43169880~43170077:-
LUAD	cis	rs1799949	1	rs11654452	ENSG00000267340.1	RP11-242D8.3	3.56	0.00041	0.044	0.17	0.16	Menopause (age at onset);	chr17:43037366	chr17:43169880~43170077:-
LUAD	cis	rs1423688	0.893	rs357254	ENSG00000249740.1	OSMR-AS1	3.56	0.00041	0.044	0.2	0.16	Antipsychotic drug-induced QTc interval change in schizophrenia;	chr5:38907644	chr5:38736055~38845829:-
LUAD	cis	rs1423688	0.893	rs357255	ENSG00000249740.1	OSMR-AS1	3.56	0.00041	0.044	0.2	0.16	Antipsychotic drug-induced QTc interval change in schizophrenia;	chr5:38908130	chr5:38736055~38845829:-
LUAD	cis	rs9973361	0.513	rs13399960	ENSG00000232411.1	AC009495.3	-3.56	0.00041	0.044	-0.17	-0.16	Total body bone mineral density;	chr2:165842209	chr2:165833048~165839098:-
LUAD	cis	rs9473147	0.551	rs6900120	ENSG00000270761.1	RP11-385F7.1	3.56	0.00041	0.044	0.19	0.16	Platelet distribution width;Mean platelet volume;	chr6:47684774	chr6:47477243~47477572:-
LUAD	cis	rs7667	1	rs12088915	ENSG00000270728.1	RP4-657E11.10	-3.56	0.00041	0.044	-0.16	-0.16	Crohn's disease and psoriasis;	chr1:19381869	chr1:19297080~19297903:+
LUAD	cis	rs1991651	0.507	rs17778581	ENSG00000255310.2	AF131215.2	-3.56	0.00041	0.044	-0.16	-0.16	Sum neutrophil eosinophil counts;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Granulocyte count;	chr8:10885911	chr8:11107788~11109726:-
LUAD	cis	rs1055129	0.537	rs1135640	ENSG00000267801.1	RP11-552F3.9	-3.56	0.00041	0.0441	-0.16	-0.16	White matter hyperintensity burden;	chr17:75953459	chr17:75876372~75879546:+
LUAD	cis	rs329122	0.528	rs329114	ENSG00000280420.1	AC005355.3	3.56	0.000411	0.0441	0.18	0.16	Body mass index;Type 2 diabetes;	chr5:134522017	chr5:134522613~134523096:-
LUAD	cis	rs7727544	0.557	rs715285	ENSG00000233006.5	AC034220.3	3.56	0.000411	0.0441	0.14	0.16	Blood metabolite levels;	chr5:132149690	chr5:132311285~132369916:-
LUAD	cis	rs7107174	1	rs10793303	ENSG00000251323.2	RP11-452H21.4	3.56	0.000411	0.0441	0.21	0.16	Testicular germ cell tumor;	chr11:78349704	chr11:78423982~78429836:-
LUAD	cis	rs2953174	1	rs1133353	ENSG00000229996.1	AC093585.6	3.56	0.000411	0.0441	0.24	0.16	Bipolar disorder;	chr2:240582850	chr2:241010045~241010744:-
LUAD	cis	rs9467773	0.967	rs9295694	ENSG00000241549.7	GUSBP2	3.56	0.000411	0.0441	0.17	0.16	Intelligence (multi-trait analysis);	chr6:26512766	chr6:26871484~26956554:-
LUAD	cis	rs9467773	0.967	rs9467775	ENSG00000241549.7	GUSBP2	3.56	0.000411	0.0441	0.17	0.16	Intelligence (multi-trait analysis);	chr6:26513207	chr6:26871484~26956554:-
LUAD	cis	rs9467773	1	rs9393729	ENSG00000241549.7	GUSBP2	3.56	0.000411	0.0441	0.17	0.16	Intelligence (multi-trait analysis);	chr6:26513938	chr6:26871484~26956554:-
LUAD	cis	rs7077256	0.564	rs35468796	ENSG00000272767.1	JMJD1C-AS1	3.56	0.000411	0.0441	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63403246	chr10:63465229~63466563:+
LUAD	cis	rs7077256	0.564	rs34028683	ENSG00000272767.1	JMJD1C-AS1	3.56	0.000411	0.0441	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63406002	chr10:63465229~63466563:+
LUAD	cis	rs7077256	0.564	rs2393971	ENSG00000272767.1	JMJD1C-AS1	3.56	0.000411	0.0441	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63413613	chr10:63465229~63466563:+
LUAD	cis	rs7077256	0.564	rs17813795	ENSG00000272767.1	JMJD1C-AS1	3.56	0.000411	0.0441	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63428151	chr10:63465229~63466563:+
LUAD	cis	rs7077256	0.564	rs17740989	ENSG00000272767.1	JMJD1C-AS1	3.56	0.000411	0.0441	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63428643	chr10:63465229~63466563:+
LUAD	cis	rs7077256	0.564	rs12762599	ENSG00000272767.1	JMJD1C-AS1	3.56	0.000411	0.0441	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63432779	chr10:63465229~63466563:+
LUAD	cis	rs7077256	0.564	rs34230554	ENSG00000272767.1	JMJD1C-AS1	3.56	0.000411	0.0441	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63440815	chr10:63465229~63466563:+
LUAD	cis	rs7077256	0.526	rs56206255	ENSG00000272767.1	JMJD1C-AS1	3.56	0.000411	0.0441	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63441316	chr10:63465229~63466563:+
LUAD	cis	rs7077256	0.564	rs17741131	ENSG00000272767.1	JMJD1C-AS1	3.56	0.000411	0.0441	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63442166	chr10:63465229~63466563:+
LUAD	cis	rs7077256	0.564	rs35322962	ENSG00000272767.1	JMJD1C-AS1	3.56	0.000411	0.0441	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63452020	chr10:63465229~63466563:+
LUAD	cis	rs7077256	0.564	rs34037284	ENSG00000272767.1	JMJD1C-AS1	3.56	0.000411	0.0441	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63452090	chr10:63465229~63466563:+
LUAD	cis	rs7077256	0.564	rs12761593	ENSG00000272767.1	JMJD1C-AS1	3.56	0.000411	0.0441	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63453817	chr10:63465229~63466563:+
LUAD	cis	rs7077256	0.542	rs12761965	ENSG00000272767.1	JMJD1C-AS1	3.56	0.000411	0.0441	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63453884	chr10:63465229~63466563:+
LUAD	cis	rs7077256	0.564	rs67019024	ENSG00000272767.1	JMJD1C-AS1	3.56	0.000411	0.0441	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63454811	chr10:63465229~63466563:+
LUAD	cis	rs737008	0.8	rs535998	ENSG00000262703.1	RP11-485G7.6	-3.56	0.000411	0.0441	-0.15	-0.16	Obesity-related traits;	chr16:11272146	chr16:11348143~11349321:-
LUAD	cis	rs8062405	0.691	rs11646653	ENSG00000261766.1	RP11-22P6.2	3.56	0.000411	0.0441	0.15	0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28862166~28863340:-
LUAD	cis	rs9303401	0.646	rs7217845	ENSG00000264049.1	MIR4737	-3.56	0.000411	0.0441	-0.22	-0.16	Cognitive test performance;	chr17:59159539	chr17:60043025~60043105:-
LUAD	cis	rs9303401	0.646	rs7213269	ENSG00000264049.1	MIR4737	-3.56	0.000411	0.0441	-0.22	-0.16	Cognitive test performance;	chr17:59160435	chr17:60043025~60043105:-
LUAD	cis	rs7172809	0.587	rs28375490	ENSG00000259420.4	RP11-307C19.2	3.56	0.000411	0.0441	0.2	0.16	Glucose homeostasis traits;	chr15:77556677	chr15:77568970~77608888:+
LUAD	cis	rs524281	0.682	rs4483592	ENSG00000255320.1	RP11-755F10.1	3.56	0.000411	0.0441	0.25	0.16	Electroencephalogram traits;	chr11:66222968	chr11:66244840~66246239:-
LUAD	cis	rs4561483	0.673	rs28279	ENSG00000261560.1	RP11-166B2.3	3.56	0.000411	0.0441	0.15	0.16	Testicular germ cell tumor;	chr16:11874698	chr16:11881075~11882569:-
LUAD	cis	rs9475752	1	rs35527216	ENSG00000231441.1	RP11-472M19.2	3.56	0.000411	0.0441	0.25	0.16	Menarche (age at onset);	chr6:56926480	chr6:56844002~56864078:+
LUAD	cis	rs17772222	0.636	rs77528165	ENSG00000258983.2	RP11-507K2.2	3.56	0.000411	0.0441	0.2	0.16	Coronary artery calcification;	chr14:88794249	chr14:88499334~88515502:+
LUAD	cis	rs9309473	1	rs6755241	ENSG00000230002.2	ALMS1-IT1	3.56	0.000411	0.0441	0.2	0.16	Metabolite levels;	chr2:73414236	chr2:73456764~73459484:+
LUAD	cis	rs3741404	0.757	rs2282492	ENSG00000256789.1	RP11-697H9.2	-3.56	0.000411	0.0441	-0.18	-0.16	Platelet count;	chr11:64151117	chr11:63637677~63658962:+
LUAD	cis	rs1993709	0.617	rs2630401	ENSG00000227207.2	RPL31P12	3.56	0.000411	0.0441	0.19	0.16	Obesity (early onset extreme);	chr1:72119988	chr1:72301472~72301829:+
LUAD	cis	rs4727027	0.704	rs2888600	ENSG00000244560.5	RP4-800G7.2	-3.56	0.000411	0.0441	-0.1	-0.16	Neutrophil percentage of granulocytes;Eosinophil counts;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr7:149211470	chr7:149285281~149297312:+
LUAD	cis	rs8058578	0.633	rs113448632	ENSG00000232748.3	RP11-196G11.6	-3.56	0.000411	0.0441	-0.22	-0.16	Multiple myeloma;	chr16:30886898	chr16:31056460~31062803:+
LUAD	cis	rs10129255	0.789	rs61997796	ENSG00000211947.2	IGHV3-21	-3.56	0.000411	0.0441	-0.11	-0.16	Kawasaki disease;	chr14:106813798	chr14:106235064~106235594:-
LUAD	cis	rs721917	0.525	rs2246111	ENSG00000244733.5	RP11-506M13.3	-3.56	0.000411	0.0441	-0.17	-0.16	Chronic obstructive pulmonary disease;	chr10:79929985	chr10:79660891~79677996:+
LUAD	cis	rs9467773	0.549	rs9461273	ENSG00000261353.1	CTA-14H9.5	3.56	0.000411	0.0441	0.18	0.16	Intelligence (multi-trait analysis);	chr6:26584298	chr6:26527063~26527404:+
LUAD	cis	rs7200786	0.669	rs7189563	ENSG00000274038.1	RP11-66H6.4	-3.56	0.000411	0.0441	-0.2	-0.16	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11156556	chr16:11056556~11057034:+
LUAD	cis	rs899997	1	rs11072794	ENSG00000261143.1	ADAMTS7P3	3.56	0.000411	0.0441	0.18	0.16	Coronary artery disease or large artery stroke;	chr15:78714240	chr15:77976042~77993057:+
LUAD	cis	rs357618	1	rs357629	ENSG00000272112.1	CTB-113P19.5	3.56	0.000411	0.0441	0.15	0.16	Basophil percentage of white cells;	chr5:151471385	chr5:151724831~151725356:-
LUAD	cis	rs7215564	0.73	rs76008137	ENSG00000232083.3	RPL31P7	3.56	0.000411	0.0441	0.3	0.16	Myopia (pathological);	chr17:80612413	chr17:80602549~80602926:-
LUAD	cis	rs3849150	1	rs35422654	ENSG00000235939.1	RP11-123B3.2	-3.56	0.000411	0.0441	-0.25	-0.16	Subclinical atherosclerosis traits (other);	chr10:48896915	chr10:49419277~49472903:+
LUAD	cis	rs875971	1	rs55962648	ENSG00000273142.1	RP11-458F8.4	3.56	0.000411	0.0441	0.11	0.16	Aortic root size;	chr7:66160764	chr7:66902857~66906297:+
LUAD	cis	rs875971	1	rs2420168	ENSG00000273142.1	RP11-458F8.4	3.56	0.000411	0.0441	0.11	0.16	Aortic root size;	chr7:66165644	chr7:66902857~66906297:+
LUAD	cis	rs801193	0.548	rs2109297	ENSG00000273448.1	RP11-166O4.6	-3.56	0.000411	0.0441	-0.15	-0.16	Aortic root size;	chr7:66657397	chr7:67333047~67334383:+
LUAD	cis	rs801193	0.591	rs721717	ENSG00000273448.1	RP11-166O4.6	-3.56	0.000411	0.0441	-0.15	-0.16	Aortic root size;	chr7:66665305	chr7:67333047~67334383:+
LUAD	cis	rs801193	0.569	rs6951302	ENSG00000273448.1	RP11-166O4.6	-3.56	0.000411	0.0441	-0.15	-0.16	Aortic root size;	chr7:66667525	chr7:67333047~67334383:+
LUAD	cis	rs9467773	0.967	rs6456732	ENSG00000241549.7	GUSBP2	3.56	0.000411	0.0441	0.17	0.16	Intelligence (multi-trait analysis);	chr6:26514217	chr6:26871484~26956554:-
LUAD	cis	rs10496166	0.761	rs2280308	ENSG00000236259.1	AC017083.2	-3.56	0.000411	0.0441	-0.19	-0.16	RR interval (heart rate);	chr2:68812835	chr2:68125265~68125747:+
LUAD	cis	rs9921338	0.886	rs3931015	ENSG00000263080.1	RP11-485G7.5	-3.56	0.000412	0.0442	-0.21	-0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11321782	chr16:11341809~11345211:-
LUAD	cis	rs2732480	0.538	rs2468943	ENSG00000273765.1	RP11-370I10.11	-3.56	0.000412	0.0442	-0.17	-0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48353466	chr12:48360920~48361377:+
LUAD	cis	rs13434995	0.513	rs2171617	ENSG00000273257.1	RP11-177J6.1	3.56	0.000412	0.0442	0.22	0.16	Adiponectin levels;	chr4:55591023	chr4:55387949~55388271:+
LUAD	cis	rs6500602	0.584	rs11646063	ENSG00000280063.1	RP11-295D4.3	-3.56	0.000412	0.0442	-0.1	-0.16	Schizophrenia;	chr16:4389208	chr16:4346694~4348648:-
LUAD	cis	rs11951515	0.508	rs7706431	ENSG00000248240.1	RP11-159F24.5	-3.56	0.000412	0.0442	-0.17	-0.16	Metabolite levels  (X-11787);	chr5:43582321	chr5:43515274~43525310:+
LUAD	cis	rs73191547	0.519	rs7812517	ENSG00000261451.1	RP11-981G7.1	-3.56	0.000412	0.0442	-0.18	-0.16	Schizophrenia;	chr8:10203793	chr8:10433672~10438312:+
LUAD	cis	rs288326	0.561	rs79804181	ENSG00000213958.2	KRT18P29	-3.56	0.000412	0.0442	-0.35	-0.16	Blood protein levels;	chr2:182846170	chr2:181961212~181962478:-
LUAD	cis	rs4648739	0.613	rs13303201	ENSG00000268575.1	RP1-283E3.8	3.56	0.000412	0.0442	0.16	0.16	Severe influenza A (H1N1) infection;	chr1:1972273	chr1:1702736~1737688:-
LUAD	cis	rs2235573	0.551	rs139893	ENSG00000235237.1	RP1-151B14.6	-3.56	0.000412	0.0442	-0.16	-0.16	Glioma;Glioblastoma;	chr22:37997601	chr22:37166757~37182850:+
LUAD	cis	rs4239252	0.929	rs4251787	ENSG00000270977.1	AC015849.16	-3.56	0.000412	0.0442	-0.21	-0.16	Blood protein levels;	chr17:35845577	chr17:35893707~35911023:-
LUAD	cis	rs4239252	0.929	rs4251791	ENSG00000270977.1	AC015849.16	-3.56	0.000412	0.0442	-0.21	-0.16	Blood protein levels;	chr17:35845711	chr17:35893707~35911023:-
LUAD	cis	rs9907295	0.591	rs78655848	ENSG00000270977.1	AC015849.16	-3.56	0.000412	0.0442	-0.21	-0.16	Fibroblast growth factor basic levels;	chr17:35856952	chr17:35893707~35911023:-
LUAD	cis	rs867186	1	rs78967641	ENSG00000222460.1	RN7SKP271	-3.56	0.000412	0.0442	-0.28	-0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35195250	chr20:35643143~35643462:+
LUAD	cis	rs4853525	0.522	rs62179717	ENSG00000235852.1	AC005540.3	3.56	0.000412	0.0442	0.19	0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190726087	chr2:190880797~190882059:-
LUAD	cis	rs2117029	0.767	rs11614738	ENSG00000258017.1	RP11-386G11.10	-3.56	0.000412	0.0442	-0.21	-0.16	Intelligence (multi-trait analysis);	chr12:49030833	chr12:49127782~49147869:+
LUAD	cis	rs1858037	0.867	rs67453645	ENSG00000237979.1	AC007389.1	3.56	0.000412	0.0442	0.2	0.16	Rheumatoid arthritis;	chr2:65358908	chr2:65500993~65502138:-
LUAD	cis	rs2451932	0.555	rs10064975	ENSG00000251050.1	RP11-168A11.4	-3.56	0.000412	0.0442	-0.17	-0.16	LDL peak particle diameter (total fat intake interaction);	chr5:79981392	chr5:80019609~80019920:+
LUAD	cis	rs755249	0.833	rs61779313	ENSG00000237624.1	OXCT2P1	3.56	0.000412	0.0442	0.24	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39478577	chr1:39514956~39516490:+
LUAD	cis	rs11051970	0.655	rs7298381	ENSG00000274964.1	RP11-817I4.1	-3.56	0.000412	0.0442	-0.16	-0.16	Response to tocilizumab in rheumatoid arthritis;	chr12:32377323	chr12:32339368~32340724:+
LUAD	cis	rs2243480	0.831	rs57294491	ENSG00000222364.1	RNU6-96P	3.56	0.000412	0.0442	0.27	0.16	Diabetic kidney disease;	chr7:66219914	chr7:66395191~66395286:+
LUAD	cis	rs858239	0.712	rs200717	ENSG00000230042.1	AK3P3	-3.56	0.000412	0.0442	-0.2	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23352652	chr7:23129178~23129841:+
LUAD	cis	rs7561273	0.609	rs6720226	ENSG00000242628.4	AC009228.1	3.56	0.000412	0.0442	0.2	0.16	Quantitative traits;	chr2:24072983	chr2:24214381~24221516:+
LUAD	cis	rs7561273	0.586	rs11900665	ENSG00000242628.4	AC009228.1	3.56	0.000412	0.0442	0.2	0.16	Quantitative traits;	chr2:24075328	chr2:24214381~24221516:+
LUAD	cis	rs17689437	0.914	rs55652840	ENSG00000260084.1	RP11-615I2.1	-3.56	0.000412	0.0442	-0.26	-0.16	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68528195	chr16:68573782~68589512:-
LUAD	cis	rs5742933	1	rs1317751	ENSG00000253559.1	OSGEPL1-AS1	-3.56	0.000412	0.0442	-0.22	-0.16	Ferritin levels;	chr2:189807898	chr2:189762704~189765556:+
LUAD	cis	rs4363385	0.776	rs1890284	ENSG00000223599.1	RP11-216N14.7	-3.56	0.000412	0.0442	-0.19	-0.16	Inflammatory skin disease;	chr1:152969714	chr1:153852106~153853414:-
LUAD	cis	rs7646881	0.508	rs12106885	ENSG00000240207.5	RP11-379F4.4	-3.56	0.000412	0.0442	-0.22	-0.16	Tetralogy of Fallot;	chr3:158598854	chr3:158732263~158784070:+
LUAD	cis	rs7615952	0.688	rs12485622	ENSG00000241288.6	RP11-379B18.5	-3.56	0.000412	0.0442	-0.2	-0.16	Blood pressure (smoking interaction);	chr3:125991896	chr3:125827238~125916384:-
LUAD	cis	rs240993	0.812	rs9487626	ENSG00000271789.1	RP5-1112D6.7	-3.56	0.000413	0.0442	-0.19	-0.16	Inflammatory skin disease;Psoriasis;	chr6:111395665	chr6:111297126~111298510:+
LUAD	cis	rs240993	0.715	rs9487627	ENSG00000271789.1	RP5-1112D6.7	-3.56	0.000413	0.0442	-0.19	-0.16	Inflammatory skin disease;Psoriasis;	chr6:111408846	chr6:111297126~111298510:+
LUAD	cis	rs6460942	0.597	rs17448913	ENSG00000226690.5	AC005281.1	3.56	0.000413	0.0442	0.3	0.16	Coronary artery disease;	chr7:12494358	chr7:12496429~12541910:+
LUAD	cis	rs6460942	0.597	rs4721105	ENSG00000226690.5	AC005281.1	3.56	0.000413	0.0442	0.3	0.16	Coronary artery disease;	chr7:12495255	chr7:12496429~12541910:+
LUAD	cis	rs6460942	0.597	rs4721106	ENSG00000226690.5	AC005281.1	3.56	0.000413	0.0442	0.3	0.16	Coronary artery disease;	chr7:12495427	chr7:12496429~12541910:+
LUAD	cis	rs6460942	0.597	rs4721107	ENSG00000226690.5	AC005281.1	3.56	0.000413	0.0442	0.3	0.16	Coronary artery disease;	chr7:12495479	chr7:12496429~12541910:+
LUAD	cis	rs6460942	0.597	rs6977059	ENSG00000226690.5	AC005281.1	3.56	0.000413	0.0442	0.3	0.16	Coronary artery disease;	chr7:12495531	chr7:12496429~12541910:+
LUAD	cis	rs6460942	0.597	rs4721108	ENSG00000226690.5	AC005281.1	3.56	0.000413	0.0442	0.3	0.16	Coronary artery disease;	chr7:12495621	chr7:12496429~12541910:+
LUAD	cis	rs6460942	0.597	rs6961238	ENSG00000226690.5	AC005281.1	3.56	0.000413	0.0442	0.3	0.16	Coronary artery disease;	chr7:12495802	chr7:12496429~12541910:+
LUAD	cis	rs6460942	0.597	rs35589221	ENSG00000226690.5	AC005281.1	3.56	0.000413	0.0442	0.3	0.16	Coronary artery disease;	chr7:12496215	chr7:12496429~12541910:+
LUAD	cis	rs745109	0.504	rs76526816	ENSG00000273080.1	RP11-301O19.1	3.56	0.000413	0.0442	0.26	0.16	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86370509	chr2:86195590~86196049:+
LUAD	cis	rs745109	0.504	rs77013753	ENSG00000273080.1	RP11-301O19.1	3.56	0.000413	0.0442	0.26	0.16	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86371654	chr2:86195590~86196049:+
LUAD	cis	rs8012947	0.959	rs4520767	ENSG00000279636.2	LINC00216	-3.56	0.000413	0.0442	-0.18	-0.16	Alcohol consumption in current drinkers;	chr14:58302220	chr14:58288033~58289158:+
LUAD	cis	rs11673344	0.864	rs8108727	ENSG00000267309.1	CTD-2630F21.1	-3.56	0.000413	0.0442	-0.2	-0.16	Obesity-related traits;	chr19:37090622	chr19:36489649~36491040:+
LUAD	cis	rs6688613	0.694	rs12562794	ENSG00000225171.2	DUTP6	-3.56	0.000413	0.0442	-0.2	-0.16	Refractive astigmatism;	chr1:166859720	chr1:166868748~166869209:+
LUAD	cis	rs4699052	0.662	rs1996346	ENSG00000246560.2	RP11-10L12.4	3.56	0.000413	0.0442	0.21	0.16	Testicular germ cell tumor;	chr4:103329167	chr4:102828055~102844075:+
LUAD	cis	rs4792901	0.918	rs11869927	ENSG00000198496.9	NBR2	-3.56	0.000413	0.0442	-0.19	-0.16	Dupuytren's disease;	chr17:43597143	chr17:43125610~43153671:+
LUAD	cis	rs9548119	0.696	rs4943544	ENSG00000223685.4	LINC00571	3.56	0.000413	0.0443	0.26	0.16	Self-rated health;	chr13:37900316	chr13:38050817~38143232:-
LUAD	cis	rs61542988	0.756	rs5013587	ENSG00000221740.1	SNORD93	3.56	0.000413	0.0443	0.21	0.16	Fibrinogen levels;	chr7:22843041	chr7:22856613~22856686:+
LUAD	cis	rs62246343	0.541	rs2596937	ENSG00000186162.9	CIDECP	-3.56	0.000413	0.0443	-0.22	-0.16	Fibrinogen levels;	chr3:9439222	chr3:10014238~10026365:-
LUAD	cis	rs875971	1	rs11971949	ENSG00000273142.1	RP11-458F8.4	3.56	0.000413	0.0443	0.11	0.16	Aortic root size;	chr7:66161027	chr7:66902857~66906297:+
LUAD	cis	rs12446632	0.941	rs7204864	ENSG00000261195.1	CTD-2380F24.1	-3.56	0.000413	0.0443	-0.22	-0.16	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Menarche (age at onset);Obesity;Childhood body mass index;Waist circumference;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr16:19931605	chr16:19761172~19766099:-
LUAD	cis	rs6504108	0.624	rs1002330	ENSG00000278765.1	RP5-890E16.5	-3.56	0.000413	0.0443	-0.18	-0.16	Body mass index;	chr17:48176153	chr17:48066704~48067293:-
LUAD	cis	rs453301	0.571	rs2929453	ENSG00000173295.6	FAM86B3P	-3.56	0.000413	0.0443	-0.17	-0.16	Joint mobility (Beighton score);	chr8:9226831	chr8:8228595~8244865:+
LUAD	cis	rs6942407	0.546	rs2373387	ENSG00000224046.1	AC005076.5	-3.56	0.000413	0.0443	-0.23	-0.16	Food allergy;	chr7:87116632	chr7:87151423~87152420:-
LUAD	cis	rs11158026	0.574	rs7152033	ENSG00000258413.1	RP11-665C16.6	-3.56	0.000413	0.0443	-0.22	-0.16	Parkinson's disease;	chr14:54926036	chr14:55262767~55272075:-
LUAD	cis	rs10129255	0.5	rs8011115	ENSG00000253209.1	IGHV3-65	3.56	0.000413	0.0443	0.13	0.16	Kawasaki disease;	chr14:106786292	chr14:106666092~106666532:-
LUAD	cis	rs1862618	0.756	rs9292125	ENSG00000271828.1	CTD-2310F14.1	3.56	0.000413	0.0443	0.23	0.16	Initial pursuit acceleration;	chr5:56811373	chr5:56927874~56929573:+
LUAD	cis	rs7172809	0.573	rs17384809	ENSG00000259420.4	RP11-307C19.2	-3.56	0.000413	0.0443	-0.2	-0.16	Glucose homeostasis traits;	chr15:77329664	chr15:77568970~77608888:+
LUAD	cis	rs4664293	0.867	rs6720304	ENSG00000230783.1	AC009961.2	-3.56	0.000413	0.0443	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159787321	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs3764968	ENSG00000230783.1	AC009961.2	-3.56	0.000413	0.0443	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159790579	chr2:159689217~159690291:-
LUAD	cis	rs4664293	0.867	rs6740910	ENSG00000230783.1	AC009961.2	-3.56	0.000413	0.0443	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159792709	chr2:159689217~159690291:-
LUAD	cis	rs3741404	0.825	rs11604782	ENSG00000256789.1	RP11-697H9.2	-3.56	0.000413	0.0443	-0.19	-0.16	Platelet count;	chr11:64179178	chr11:63637677~63658962:+
LUAD	cis	rs2144940	0.506	rs844872	ENSG00000233746.1	LINC00656	3.56	0.000413	0.0443	0.34	0.16	Venous thromboembolism;	chr20:23120934	chr20:23125068~23132621:-
LUAD	cis	rs2144940	0.506	rs844873	ENSG00000233746.1	LINC00656	3.56	0.000413	0.0443	0.34	0.16	Venous thromboembolism;	chr20:23121155	chr20:23125068~23132621:-
LUAD	cis	rs683250	0.662	rs2510477	ENSG00000246067.6	RAB30-AS1	-3.56	0.000413	0.0443	-0.17	-0.16	Subcortical brain region volumes;	chr11:83429948	chr11:83072066~83106719:+
LUAD	cis	rs2288073	0.801	rs10175668	ENSG00000242628.4	AC009228.1	3.56	0.000413	0.0443	0.21	0.16	Venous thromboembolism (SNP x SNP interaction);	chr2:24144405	chr2:24214381~24221516:+
LUAD	cis	rs794185	0.719	rs2633859	ENSG00000231249.1	ITPR1-AS1	-3.56	0.000413	0.0443	-0.18	-0.16	Multiple sclerosis--Brain Glutamate Levels;	chr3:4455181	chr3:4490891~4493163:-
LUAD	cis	rs7610301	1	rs6787465	ENSG00000276925.1	RP11-708J19.3	3.56	0.000413	0.0443	0.2	0.16	Blood protein levels;	chr3:46604119	chr3:47469777~47469987:+
LUAD	cis	rs7610301	1	rs35795952	ENSG00000276925.1	RP11-708J19.3	3.56	0.000413	0.0443	0.2	0.16	Blood protein levels;	chr3:46604204	chr3:47469777~47469987:+
LUAD	cis	rs61160187	0.582	rs12655209	ENSG00000215032.2	GNL3LP1	-3.56	0.000413	0.0443	-0.19	-0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:61010225	chr5:60891935~60893577:-
LUAD	cis	rs10496166	0.729	rs7592302	ENSG00000236259.1	AC017083.2	-3.56	0.000413	0.0443	-0.2	-0.16	RR interval (heart rate);	chr2:68815596	chr2:68125265~68125747:+
LUAD	cis	rs2144940	0.506	rs844832	ENSG00000233746.1	LINC00656	3.56	0.000413	0.0443	0.35	0.16	Venous thromboembolism;	chr20:23105221	chr20:23125068~23132621:-
LUAD	cis	rs2144940	0.545	rs844833	ENSG00000233746.1	LINC00656	3.56	0.000413	0.0443	0.35	0.16	Venous thromboembolism;	chr20:23105446	chr20:23125068~23132621:-
LUAD	cis	rs2144940	0.545	rs844836	ENSG00000233746.1	LINC00656	3.56	0.000413	0.0443	0.35	0.16	Venous thromboembolism;	chr20:23106523	chr20:23125068~23132621:-
LUAD	cis	rs9652601	0.622	rs6498143	ENSG00000280153.1	RP11-876N24.3	-3.56	0.000413	0.0443	-0.11	-0.16	Systemic lupus erythematosus;	chr16:11001179	chr16:10933903~10936280:+
LUAD	cis	rs11673344	0.566	rs8109103	ENSG00000267254.4	ZNF790-AS1	-3.56	0.000414	0.0443	-0.2	-0.16	Obesity-related traits;	chr19:37503209	chr19:36797518~36828115:+
LUAD	cis	rs9921338	0.961	rs7193278	ENSG00000262703.1	RP11-485G7.6	-3.56	0.000414	0.0443	-0.17	-0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11351974	chr16:11348143~11349321:-
LUAD	cis	rs4879628	0.656	rs10971211	ENSG00000231991.4	ANXA2P2	3.56	0.000414	0.0443	0.23	0.16	Amyotrophic lateral sclerosis;	chr9:32910294	chr9:33624274~33625293:+
LUAD	cis	rs6832769	0.58	rs7658532	ENSG00000272969.1	RP11-528I4.2	-3.56	0.000414	0.0443	-0.18	-0.16	Personality dimensions;	chr4:55642741	chr4:55547112~55547889:+
LUAD	cis	rs13113518	1	rs13115828	ENSG00000249700.7	SRD5A3-AS1	3.56	0.000414	0.0443	0.16	0.16	Height;	chr4:55551447	chr4:55363971~55395847:-
LUAD	cis	rs9341808	0.718	rs2143887	ENSG00000233967.5	RP11-250B2.3	3.56	0.000414	0.0443	0.16	0.16	Sitting height ratio;	chr6:80207570	chr6:80443344~80465927:+
LUAD	cis	rs8046148	0.906	rs11640627	ENSG00000279356.1	RP11-429P3.8	3.56	0.000414	0.0443	0.19	0.16	Testicular germ cell tumor;	chr16:50103990	chr16:50072862~50074986:+
LUAD	cis	rs8046148	0.826	rs1558813	ENSG00000279356.1	RP11-429P3.8	3.56	0.000414	0.0443	0.19	0.16	Testicular germ cell tumor;	chr16:50105888	chr16:50072862~50074986:+
LUAD	cis	rs6121246	0.909	rs6060923	ENSG00000230613.1	HM13-AS1	3.56	0.000414	0.0443	0.23	0.16	Mean corpuscular hemoglobin;	chr20:31748852	chr20:31567707~31573263:-
LUAD	cis	rs4718428	0.672	rs12530806	ENSG00000230295.1	RP11-458F8.2	-3.56	0.000414	0.0443	-0.14	-0.16	Corneal structure;	chr7:66925737	chr7:66880708~66882981:+
LUAD	cis	rs4718428	0.705	rs10267335	ENSG00000230295.1	RP11-458F8.2	-3.56	0.000414	0.0443	-0.14	-0.16	Corneal structure;	chr7:66938233	chr7:66880708~66882981:+
LUAD	cis	rs2836974	0.932	rs35571600	ENSG00000232608.1	TIMM9P2	-3.56	0.000414	0.0443	-0.19	-0.16	Cognitive function;	chr21:39218698	chr21:39216624~39217506:+
LUAD	cis	rs17572109	0.666	rs11696005	ENSG00000261338.2	RP11-378A13.1	-3.56	0.000414	0.0443	-0.19	-0.16	Platelet count;Platelet distribution width;Mean platelet volume;	chr2:218364918	chr2:218255319~218257366:+
LUAD	cis	rs2932538	0.922	rs6537745	ENSG00000235299.2	MRPL53P1	3.56	0.000414	0.0443	0.2	0.16	Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension;	chr1:112611458	chr1:112625906~112626224:-
LUAD	cis	rs6095360	1	rs6512567	ENSG00000222365.1	SNORD12B	-3.56	0.000414	0.0443	-0.16	-0.16	Intelligence (multi-trait analysis);	chr20:49072083	chr20:49280319~49280409:+
LUAD	cis	rs6095360	1	rs2075676	ENSG00000222365.1	SNORD12B	-3.56	0.000414	0.0443	-0.16	-0.16	Intelligence (multi-trait analysis);	chr20:49074674	chr20:49280319~49280409:+
LUAD	cis	rs17189298	0.967	rs893769	ENSG00000231013.1	AC013275.2	3.56	0.000414	0.0443	0.16	0.16	Cerebrospinal T-tau levels;	chr2:119082508	chr2:119476448~119487346:+
LUAD	cis	rs11976180	1	rs1919951	ENSG00000228960.5	OR2A9P	-3.56	0.000414	0.0443	-0.21	-0.16	Obesity-related traits;	chr7:144071798	chr7:144294480~144300934:+
LUAD	cis	rs17711722	0.522	rs6957759	ENSG00000229886.1	RP5-1132H15.3	-3.56	0.000414	0.0443	-0.18	-0.16	Calcium levels;	chr7:65806798	chr7:66025126~66031544:-
LUAD	cis	rs7200543	1	rs7200543	ENSG00000260735.1	RP11-72I8.1	3.56	0.000414	0.0443	0.18	0.16	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036113	chr16:15094411~15109197:+
LUAD	cis	rs910873	0.711	rs62212235	ENSG00000250917.1	RP4-785G19.5	-3.56	0.000414	0.0443	-0.37	-0.16	Melanoma;	chr20:34494366	chr20:34234840~34281173:-
LUAD	cis	rs9400467	0.528	rs7750792	ENSG00000266032.1	AL357515.1	3.56	0.000414	0.0443	0.21	0.16	Amino acid levels;Blood metabolite levels;	chr6:111462556	chr6:110969773~110969872:-
LUAD	cis	rs516805	0.748	rs155458	ENSG00000279453.1	RP3-425C14.4	3.56	0.000414	0.0443	0.21	0.16	Lymphocyte counts;	chr6:122493636	chr6:122436789~122439223:-
LUAD	cis	rs8002861	0.967	rs9533691	ENSG00000274001.1	RP11-5G9.5	3.56	0.000414	0.0443	0.17	0.16	Leprosy;	chr13:43908072	chr13:43877715~43878163:-
LUAD	cis	rs155076	1	rs261432	ENSG00000224429.6	LINC00539	3.56	0.000414	0.0443	0.19	0.16	White matter hyperintensity burden;	chr13:21291776	chr13:21303515~21348721:-
LUAD	cis	rs7809950	1	rs2293658	ENSG00000238832.1	snoU109	-3.56	0.000414	0.0444	-0.24	-0.16	Coronary artery disease;	chr7:107630122	chr7:107603363~107603507:+
LUAD	cis	rs2548724	0.812	rs3096196	ENSG00000250682.4	LINC00491	-3.56	0.000414	0.0444	-0.21	-0.16	Type 2 diabetes;	chr5:102268210	chr5:102609156~102671559:-
LUAD	cis	rs2548724	0.812	rs2113091	ENSG00000250682.4	LINC00491	-3.56	0.000414	0.0444	-0.21	-0.16	Type 2 diabetes;	chr5:102268835	chr5:102609156~102671559:-
LUAD	cis	rs2548724	0.812	rs2600835	ENSG00000250682.4	LINC00491	-3.56	0.000414	0.0444	-0.21	-0.16	Type 2 diabetes;	chr5:102269730	chr5:102609156~102671559:-
LUAD	cis	rs2548724	0.812	rs2600832	ENSG00000250682.4	LINC00491	-3.56	0.000414	0.0444	-0.21	-0.16	Type 2 diabetes;	chr5:102270298	chr5:102609156~102671559:-
LUAD	cis	rs2548724	0.812	rs2600827	ENSG00000250682.4	LINC00491	-3.56	0.000414	0.0444	-0.21	-0.16	Type 2 diabetes;	chr5:102272642	chr5:102609156~102671559:-
LUAD	cis	rs9400467	0.506	rs12191195	ENSG00000255389.1	C6orf3	3.56	0.000414	0.0444	0.21	0.16	Amino acid levels;Blood metabolite levels;	chr6:111391515	chr6:111599875~111602295:+
LUAD	cis	rs9400467	0.506	rs75819068	ENSG00000255389.1	C6orf3	3.56	0.000414	0.0444	0.21	0.16	Amino acid levels;Blood metabolite levels;	chr6:111401284	chr6:111599875~111602295:+
LUAD	cis	rs7760535	0.794	rs463860	ENSG00000271789.1	RP5-1112D6.7	-3.56	0.000414	0.0444	-0.17	-0.16	Metabolic traits;	chr6:111370518	chr6:111297126~111298510:+
LUAD	cis	rs72843166	0.853	rs72845245	ENSG00000265282.1	RP11-269G24.4	3.56	0.000414	0.0444	0.25	0.16	Intelligence (multi-trait analysis);	chr17:63292275	chr17:63430468~63432211:-
LUAD	cis	rs72843166	0.853	rs72845246	ENSG00000265282.1	RP11-269G24.4	3.56	0.000414	0.0444	0.25	0.16	Intelligence (multi-trait analysis);	chr17:63292640	chr17:63430468~63432211:-
LUAD	cis	rs7760535	0.764	rs240994	ENSG00000271789.1	RP5-1112D6.7	-3.56	0.000414	0.0444	-0.17	-0.16	Metabolic traits;	chr6:111354554	chr6:111297126~111298510:+
LUAD	cis	rs67478160	0.643	rs2024667	ENSG00000272533.1	SNORA28	3.56	0.000414	0.0444	0.16	0.16	Schizophrenia;	chr14:103745192	chr14:103337849~103337974:+
LUAD	cis	rs2902440	0.502	rs58621044	ENSG00000275678.1	RP4-547N15.3	-3.56	0.000414	0.0444	-0.16	-0.16	Crohn's disease;	chr1:67199157	chr1:67121605~67123956:-
LUAD	cis	rs7208859	0.623	rs426434	ENSG00000265443.1	CTD-2349P21.6	-3.56	0.000414	0.0444	-0.25	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30598335	chr17:30726305~30727564:-
LUAD	cis	rs2380205	0.967	rs9663697	ENSG00000232807.2	RP11-536K7.3	3.56	0.000414	0.0444	0.17	0.16	Breast cancer;	chr10:5855943	chr10:5934270~5945900:-
LUAD	cis	rs7246967	0.673	rs62119090	ENSG00000236312.3	RPL34P34	3.56	0.000414	0.0444	0.27	0.16	Bronchopulmonary dysplasia;	chr19:22741112	chr19:22368599~22368952:-
LUAD	cis	rs877819	0.667	rs7916558	ENSG00000228403.1	RP11-563N6.6	-3.56	0.000414	0.0444	-0.17	-0.16	Systemic lupus erythematosus;	chr10:48863564	chr10:48878022~48878649:+
LUAD	cis	rs6494488	0.5	rs72741307	ENSG00000239465.1	RP11-330L19.2	3.56	0.000414	0.0444	0.34	0.16	Coronary artery disease;	chr15:64408024	chr15:64631109~64631914:-
LUAD	cis	rs2414856	0.51	rs77109323	ENSG00000239465.1	RP11-330L19.2	3.56	0.000414	0.0444	0.34	0.16	Pulse pressure;Systolic blood pressure;	chr15:64412742	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs34758599	ENSG00000239465.1	RP11-330L19.2	3.56	0.000414	0.0444	0.34	0.16	Coronary artery disease;	chr15:64414133	chr15:64631109~64631914:-
LUAD	cis	rs1334894	0.584	rs7738975	ENSG00000228559.1	RP3-340B19.3	-3.56	0.000414	0.0444	-0.28	-0.16	Coronary artery disease;	chr6:35501946	chr6:35544632~35545669:+
LUAD	cis	rs8133949	0.768	rs11701229	ENSG00000237232.6	ZNF295-AS1	3.56	0.000414	0.0444	0.2	0.16	Hand grip strength;	chr21:42013022	chr21:42009194~42024924:+
LUAD	cis	rs7551222	0.716	rs4951078	ENSG00000240219.1	RP11-430C7.5	3.56	0.000415	0.0444	0.17	0.16	Schizophrenia;	chr1:204522674	chr1:204626775~204629712:+
LUAD	cis	rs875971	0.545	rs313830	ENSG00000224316.1	RP11-479O9.2	-3.56	0.000415	0.0444	-0.19	-0.16	Aortic root size;	chr7:66086944	chr7:65773620~65802067:+
LUAD	cis	rs334353	0.761	rs10819637	ENSG00000255145.2	STX17-AS1	-3.56	0.000415	0.0444	-0.22	-0.16	Age-related macular degeneration;	chr9:99111183	chr9:99886322~99906601:-
LUAD	cis	rs7560272	0.538	rs12619258	ENSG00000163016.8	ALMS1P	-3.56	0.000415	0.0444	-0.17	-0.16	Schizophrenia;	chr2:73708788	chr2:73644919~73685576:+
LUAD	cis	rs9400467	0.528	rs240954	ENSG00000271789.1	RP5-1112D6.7	-3.56	0.000415	0.0444	-0.17	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111338619	chr6:111297126~111298510:+
LUAD	cis	rs2274273	0.837	rs11625968	ENSG00000259318.1	RP11-454L9.2	3.56	0.000415	0.0444	0.14	0.16	Protein biomarker;	chr14:55334286	chr14:55394940~55395233:-
LUAD	cis	rs17428076	0.633	rs705870	ENSG00000228389.1	AC068039.4	-3.56	0.000415	0.0444	-0.18	-0.16	Myopia;	chr2:172067555	chr2:171773482~171775844:+
LUAD	cis	rs3845817	1	rs11126042	ENSG00000281920.1	RP11-418H16.1	3.56	0.000415	0.0444	0.19	0.16	Bipolar disorder;	chr2:65536511	chr2:65623272~65628424:+
LUAD	cis	rs67478160	0.654	rs1535097	ENSG00000272533.1	SNORA28	3.56	0.000415	0.0444	0.16	0.16	Schizophrenia;	chr14:103750312	chr14:103337849~103337974:+
LUAD	cis	rs7260598	0.792	rs73021461	ENSG00000268442.1	CTD-2027I19.2	3.56	0.000415	0.0444	0.25	0.16	Response to taxane treatment (placlitaxel);	chr19:24140154	chr19:24162370~24163425:-
LUAD	cis	rs6012953	0.874	rs2426159	ENSG00000231715.1	COX6CP2	-3.56	0.000415	0.0444	-0.16	-0.16	Vitiligo;	chr20:50556642	chr20:50479767~50479991:+
LUAD	cis	rs7819412	0.56	rs13265553	ENSG00000255046.1	RP11-297N6.4	3.56	0.000415	0.0444	0.2	0.16	Triglycerides;	chr8:11131547	chr8:11797928~11802568:-
LUAD	cis	rs13113518	0.783	rs11133389	ENSG00000249700.7	SRD5A3-AS1	3.56	0.000415	0.0444	0.17	0.16	Height;	chr4:55486718	chr4:55363971~55395847:-
LUAD	cis	rs13113518	0.812	rs4864543	ENSG00000249700.7	SRD5A3-AS1	3.56	0.000415	0.0444	0.17	0.16	Height;	chr4:55490228	chr4:55363971~55395847:-
LUAD	cis	rs6894249	1	rs6894249	ENSG00000234290.2	AC116366.6	-3.56	0.000415	0.0444	-0.09	-0.16	Asthma;	chr5:132461855	chr5:132468890~132473043:-
LUAD	cis	rs739496	0.579	rs16941759	ENSG00000234608.6	MAPKAPK5-AS1	-3.56	0.000415	0.0444	-0.18	-0.16	Platelet count;	chr12:111930117	chr12:111839764~111842902:-
LUAD	cis	rs7546668	1	rs10803390	ENSG00000272510.1	RP4-680D5.8	3.56	0.000415	0.0444	0.2	0.16	Glomerular filtration rate (creatinine);	chr1:15538923	chr1:15565611~15565956:-
LUAD	cis	rs6933660	0.745	rs9322320	ENSG00000219395.2	HSPA8P15	-3.56	0.000415	0.0444	-0.15	-0.16	Menarche (age at onset);	chr6:151430773	chr6:151411259~151413945:-
LUAD	cis	rs4246302	0.529	rs9672847	ENSG00000259706.1	HSP90B2P	-3.56	0.000415	0.0444	-0.14	-0.16	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for body mass index;	chr15:100124589	chr15:99257632~99260015:+
LUAD	cis	rs216345	0.7	rs844305	ENSG00000200834.1	Y_RNA	-3.56	0.000415	0.0444	-0.16	-0.16	Bipolar disorder;	chr9:33976579	chr9:33830978~33831078:+
LUAD	cis	rs9400467	0.528	rs6568680	ENSG00000266032.1	AL357515.1	3.56	0.000415	0.0444	0.2	0.16	Amino acid levels;Blood metabolite levels;	chr6:111454961	chr6:110969773~110969872:-
LUAD	cis	rs3018066	0.748	rs12510966	ENSG00000251259.1	AC004069.2	-3.56	0.000415	0.0444	-0.19	-0.16	Cancer;	chr4:106062447	chr4:105137280~105140619:-
LUAD	cis	rs9341808	0.718	rs3805922	ENSG00000233967.5	RP11-250B2.3	3.56	0.000415	0.0444	0.16	0.16	Sitting height ratio;	chr6:80182272	chr6:80443344~80465927:+
LUAD	cis	rs9341808	0.718	rs3805920	ENSG00000233967.5	RP11-250B2.3	3.56	0.000415	0.0444	0.16	0.16	Sitting height ratio;	chr6:80183028	chr6:80443344~80465927:+
LUAD	cis	rs13006833	0.668	rs2136569	ENSG00000227542.1	AC092614.2	3.56	0.000415	0.0444	0.19	0.16	Urinary metabolites;	chr2:190302688	chr2:191229165~191246172:-
LUAD	cis	rs2921073	0.51	rs2976945	ENSG00000173295.6	FAM86B3P	3.56	0.000415	0.0444	0.17	0.16	Parkinson's disease;	chr8:8413361	chr8:8228595~8244865:+
LUAD	cis	rs524281	0.731	rs7931167	ENSG00000255320.1	RP11-755F10.1	-3.56	0.000415	0.0444	-0.26	-0.16	Electroencephalogram traits;	chr11:66036279	chr11:66244840~66246239:-
LUAD	cis	rs8002861	0.935	rs1811464	ENSG00000274001.1	RP11-5G9.5	3.56	0.000415	0.0444	0.17	0.16	Leprosy;	chr13:43895154	chr13:43877715~43878163:-
LUAD	cis	rs796825	0.597	rs787210	ENSG00000240661.1	RP11-174O3.3	-3.56	0.000415	0.0445	-0.21	-0.16	HIV-1 susceptibility;	chr3:120321280	chr3:120349510~120367998:+
LUAD	cis	rs9467773	1	rs4713006	ENSG00000241549.7	GUSBP2	3.55	0.000415	0.0445	0.17	0.16	Intelligence (multi-trait analysis);	chr6:26519644	chr6:26871484~26956554:-
LUAD	cis	rs9467773	0.967	rs6924865	ENSG00000241549.7	GUSBP2	3.55	0.000415	0.0445	0.17	0.16	Intelligence (multi-trait analysis);	chr6:26521125	chr6:26871484~26956554:-
LUAD	cis	rs9467773	1	rs6925703	ENSG00000241549.7	GUSBP2	3.55	0.000415	0.0445	0.17	0.16	Intelligence (multi-trait analysis);	chr6:26521361	chr6:26871484~26956554:-
LUAD	cis	rs9467773	1	rs6910899	ENSG00000241549.7	GUSBP2	3.55	0.000415	0.0445	0.17	0.16	Intelligence (multi-trait analysis);	chr6:26524111	chr6:26871484~26956554:-
LUAD	cis	rs9467773	0.967	rs9461267	ENSG00000241549.7	GUSBP2	3.55	0.000415	0.0445	0.17	0.16	Intelligence (multi-trait analysis);	chr6:26525227	chr6:26871484~26956554:-
LUAD	cis	rs238295	0.805	rs6053486	ENSG00000230563.2	RP5-828H9.1	3.55	0.000415	0.0445	0.21	0.16	Occipital cortical area (total cortical area interaction);	chr20:5550121	chr20:5471207~5475182:+
LUAD	cis	rs1401999	0.714	rs13066518	ENSG00000223882.1	ABCC5-AS1	-3.55	0.000415	0.0445	-0.17	-0.16	Anterior chamber depth;	chr3:183917710	chr3:184006338~184011419:+
LUAD	cis	rs7189233	1	rs62048543	ENSG00000279344.1	RP11-44F14.7	3.55	0.000415	0.0445	0.14	0.16	Intelligence (multi-trait analysis);	chr16:53500712	chr16:53478957~53481550:-
LUAD	cis	rs6504108	0.624	rs17681336	ENSG00000278765.1	RP5-890E16.5	-3.55	0.000415	0.0445	-0.18	-0.16	Body mass index;	chr17:48172430	chr17:48066704~48067293:-
LUAD	cis	rs4795519	0.71	rs6505096	ENSG00000266313.1	RP11-173M1.4	3.55	0.000415	0.0445	0.2	0.16	Chronic myeloid leukemia;	chr17:27132430	chr17:27333256~27348491:+
LUAD	cis	rs4795519	0.778	rs11080074	ENSG00000266313.1	RP11-173M1.4	3.55	0.000415	0.0445	0.2	0.16	Chronic myeloid leukemia;	chr17:27133483	chr17:27333256~27348491:+
LUAD	cis	rs875971	0.66	rs6460308	ENSG00000273142.1	RP11-458F8.4	3.55	0.000415	0.0445	0.11	0.16	Aortic root size;	chr7:66619753	chr7:66902857~66906297:+
LUAD	cis	rs11138902	0.673	rs10511966	ENSG00000222465.1	RNU2-5P	-3.55	0.000415	0.0445	-0.17	-0.16	Intelligence (multi-trait analysis);Cognitive ability;Intelligence;	chr9:69499507	chr9:70188571~70188750:-
LUAD	cis	rs10861342	0.786	rs11112393	ENSG00000257999.1	RP11-61E11.2	-3.55	0.000415	0.0445	-0.28	-0.16	IgG glycosylation;	chr12:105154275	chr12:105102472~105107179:-
LUAD	cis	rs875971	0.545	rs4718325	ENSG00000224316.1	RP11-479O9.2	3.55	0.000416	0.0445	0.19	0.16	Aortic root size;	chr7:66215323	chr7:65773620~65802067:+
LUAD	cis	rs240993	0.502	rs240966	ENSG00000266032.1	AL357515.1	3.55	0.000416	0.0445	0.24	0.16	Inflammatory skin disease;Psoriasis;	chr6:111323462	chr6:110969773~110969872:-
LUAD	cis	rs12519773	0.502	rs67862943	ENSG00000251361.1	CTD-2091N23.1	-3.55	0.000416	0.0445	-0.18	-0.16	Migraine;	chr5:93193562	chr5:93019663~93068669:-
LUAD	cis	rs6860806	0.507	rs273912	ENSG00000263597.1	MIR3936	-3.55	0.000416	0.0445	-0.18	-0.16	Breast cancer;	chr5:132325656	chr5:132365490~132365599:-
LUAD	cis	rs7246657	0.943	rs6508733	ENSG00000226686.6	LINC01535	-3.55	0.000416	0.0445	-0.23	-0.16	Coronary artery calcification;	chr19:37509646	chr19:37251912~37265535:+
LUAD	cis	rs8014252	0.667	rs11844845	ENSG00000274818.1	RP1-292L20.3	3.55	0.000416	0.0445	0.23	0.16	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70372672	chr14:70906657~70907111:-
LUAD	cis	rs13113518	1	rs3805148	ENSG00000223305.1	RN7SKP30	3.55	0.000416	0.0445	0.18	0.16	Height;	chr4:55440643	chr4:55540502~55540835:-
LUAD	cis	rs13113518	1	rs11133380	ENSG00000223305.1	RN7SKP30	3.55	0.000416	0.0445	0.18	0.16	Height;	chr4:55441110	chr4:55540502~55540835:-
LUAD	cis	rs13113518	1	rs12510110	ENSG00000223305.1	RN7SKP30	3.55	0.000416	0.0445	0.18	0.16	Height;	chr4:55441567	chr4:55540502~55540835:-
LUAD	cis	rs13113518	0.966	rs12510990	ENSG00000223305.1	RN7SKP30	3.55	0.000416	0.0445	0.18	0.16	Height;	chr4:55441907	chr4:55540502~55540835:-
LUAD	cis	rs13113518	1	rs3805149	ENSG00000223305.1	RN7SKP30	3.55	0.000416	0.0445	0.18	0.16	Height;	chr4:55442184	chr4:55540502~55540835:-
LUAD	cis	rs13113518	1	rs11945370	ENSG00000223305.1	RN7SKP30	3.55	0.000416	0.0445	0.18	0.16	Height;	chr4:55442875	chr4:55540502~55540835:-
LUAD	cis	rs13113518	0.966	rs12647677	ENSG00000223305.1	RN7SKP30	3.55	0.000416	0.0445	0.18	0.16	Height;	chr4:55444253	chr4:55540502~55540835:-
LUAD	cis	rs899997	1	rs4887078	ENSG00000261143.1	ADAMTS7P3	3.55	0.000416	0.0445	0.18	0.16	Coronary artery disease or large artery stroke;	chr15:78718731	chr15:77976042~77993057:+
LUAD	cis	rs7617773	0.78	rs11706277	ENSG00000199476.1	Y_RNA	-3.55	0.000416	0.0445	-0.22	-0.16	Coronary artery disease;	chr3:48318943	chr3:48288587~48288694:+
LUAD	cis	rs957448	1	rs60655325	ENSG00000254057.1	RP3-388N13.3	3.55	0.000416	0.0445	0.17	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94552606	chr8:93834454~93846743:-
LUAD	cis	rs6466055	0.669	rs6950620	ENSG00000237513.1	RP11-325F22.2	-3.55	0.000416	0.0445	-0.15	-0.16	Schizophrenia;	chr7:105129939	chr7:104941063~104962334:+
LUAD	cis	rs899997	1	rs11629824	ENSG00000261143.1	ADAMTS7P3	3.55	0.000416	0.0445	0.18	0.16	Coronary artery disease or large artery stroke;	chr15:78713182	chr15:77976042~77993057:+
LUAD	cis	rs899997	1	rs11634628	ENSG00000261143.1	ADAMTS7P3	3.55	0.000416	0.0445	0.18	0.16	Coronary artery disease or large artery stroke;	chr15:78713237	chr15:77976042~77993057:+
LUAD	cis	rs9595908	0.785	rs9315177	ENSG00000281026.1	N4BP2L2-IT2	-3.55	0.000416	0.0445	-0.1	-0.16	Body mass index;	chr13:32696214	chr13:32504506~32509395:-
LUAD	cis	rs9595908	0.785	rs9596081	ENSG00000281026.1	N4BP2L2-IT2	-3.55	0.000416	0.0445	-0.1	-0.16	Body mass index;	chr13:32698405	chr13:32504506~32509395:-
LUAD	cis	rs6687821	0.515	rs523679	ENSG00000261737.1	RP4-612B15.3	-3.55	0.000416	0.0445	-0.22	-0.16	Yeast infection;	chr1:86902412	chr1:86703502~86704462:-
LUAD	cis	rs6687821	0.515	rs525519	ENSG00000261737.1	RP4-612B15.3	-3.55	0.000416	0.0445	-0.22	-0.16	Yeast infection;	chr1:86902611	chr1:86703502~86704462:-
LUAD	cis	rs394563	0.591	rs237012	ENSG00000216906.2	RP11-350J20.9	3.55	0.000416	0.0445	0.19	0.16	Dupuytren's disease;	chr6:149408062	chr6:149904243~149906418:+
LUAD	cis	rs8014204	0.935	rs10141438	ENSG00000279594.1	RP11-950C14.10	-3.55	0.000416	0.0445	-0.18	-0.16	Caffeine consumption;	chr14:74887897	chr14:75011269~75012851:-
LUAD	cis	rs12681963	0.688	rs1511167	ENSG00000272375.1	RP11-51J9.6	3.55	0.000416	0.0445	0.27	0.16	Migraine;	chr8:30123200	chr8:30197404~30198048:+
LUAD	cis	rs12986445	0.652	rs11897652	ENSG00000218682.1	AC010150.1	3.55	0.000416	0.0445	0.19	0.16	Multiple myeloma;Multiple myeloma and monoclonal gammopathy;	chr2:25767112	chr2:25856461~25856966:-
LUAD	cis	rs12440869	1	rs4312262	ENSG00000270964.1	RP11-502I4.3	-3.55	0.000416	0.0445	-0.18	-0.16	Peak velocity of the mitral A-wave;	chr15:67365172	chr15:67541072~67542604:-
LUAD	cis	rs7604827	0.658	rs73072768	ENSG00000230076.1	AC016708.2	3.55	0.000416	0.0445	0.25	0.16	PR interval;	chr2:214446865	chr2:214847128~214847445:+
LUAD	cis	rs7107174	1	rs1006441	ENSG00000251323.2	RP11-452H21.4	3.55	0.000416	0.0445	0.22	0.16	Testicular germ cell tumor;	chr11:78221080	chr11:78423982~78429836:-
LUAD	cis	rs2018683	0.523	rs1499227	ENSG00000228421.2	AC005013.5	3.55	0.000416	0.0445	0.18	0.16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28985999	chr7:28957667~28959345:+
LUAD	cis	rs67981189	0.896	rs17108967	ENSG00000269927.1	RP6-91H8.3	3.55	0.000416	0.0445	0.2	0.16	Schizophrenia;	chr14:71075451	chr14:71141125~71143253:-
LUAD	cis	rs13113518	0.812	rs12500456	ENSG00000249700.7	SRD5A3-AS1	3.55	0.000416	0.0445	0.17	0.16	Height;	chr4:55561053	chr4:55363971~55395847:-
LUAD	cis	rs10908458	0.808	rs11264322	ENSG00000160766.13	GBAP1	-3.55	0.000416	0.0445	-0.16	-0.16	Liver enzyme levels (gamma-glutamyl transferase);	chr1:155115457	chr1:155213821~155227422:-
LUAD	cis	rs2390582	0.782	rs867434	ENSG00000233593.5	RP4-665J23.1	3.55	0.000416	0.0445	0.23	0.16	Coronary artery calcification;	chr1:90548793	chr1:90782986~90851650:-
LUAD	cis	rs1401999	0.65	rs3749445	ENSG00000223882.1	ABCC5-AS1	-3.55	0.000416	0.0445	-0.17	-0.16	Anterior chamber depth;	chr3:183920718	chr3:184006338~184011419:+
LUAD	cis	rs838147	0.537	rs632111	ENSG00000232871.7	SEC1P	3.55	0.000416	0.0445	0.17	0.16	Dietary macronutrient intake;	chr19:48705721	chr19:48638071~48682245:+
LUAD	cis	rs10129255	0.5	rs1024350	ENSG00000232216.1	IGHV3-43	3.55	0.000416	0.0445	0.13	0.16	Kawasaki disease;	chr14:106685105	chr14:106470264~106470800:-
LUAD	cis	rs2378497	0.564	rs115883774	ENSG00000236230.1	RP11-400N13.1	3.55	0.000416	0.0445	0.19	0.16	Serum thyroid-stimulating hormone levels;	chr1:221986970	chr1:222089169~222387434:-
LUAD	cis	rs4268898	0.662	rs55661701	ENSG00000242628.4	AC009228.1	3.55	0.000416	0.0445	0.24	0.16	Asthma;	chr2:24177900	chr2:24214381~24221516:+
LUAD	cis	rs735539	0.521	rs2818995	ENSG00000275485.1	RP11-261P13.6	-3.55	0.000416	0.0445	-0.21	-0.16	Dental caries;	chr13:20846825	chr13:20768876~20769375:-
LUAD	cis	rs757110	0.868	rs5219	ENSG00000260196.1	RP1-239B22.5	3.55	0.000416	0.0445	0.19	0.16	Type 2 diabetes;	chr11:17388025	chr11:17380649~17383531:+
LUAD	cis	rs854765	0.647	rs2974999	ENSG00000223979.2	SMCR2	-3.55	0.000416	0.0445	-0.19	-0.16	Total body bone mineral density;	chr17:18094233	chr17:17674026~17677688:-
LUAD	cis	rs10876993	0.928	rs1689592	ENSG00000270039.1	RP11-571M6.17	3.55	0.000416	0.0445	0.19	0.16	Celiac disease or Rheumatoid arthritis;	chr12:57663990	chr12:57803838~57804415:+
LUAD	cis	rs7100689	0.622	rs10736344	ENSG00000226659.1	RP11-137H2.4	-3.55	0.000416	0.0445	-0.22	-0.16	Post bronchodilator FEV1;	chr10:80374199	chr10:80529597~80535942:-
LUAD	cis	rs7100689	0.646	rs10736345	ENSG00000226659.1	RP11-137H2.4	-3.55	0.000416	0.0445	-0.22	-0.16	Post bronchodilator FEV1;	chr10:80374384	chr10:80529597~80535942:-
LUAD	cis	rs7100689	0.646	rs10736346	ENSG00000226659.1	RP11-137H2.4	-3.55	0.000416	0.0445	-0.22	-0.16	Post bronchodilator FEV1;	chr10:80374525	chr10:80529597~80535942:-
LUAD	cis	rs7100689	0.646	rs10736347	ENSG00000226659.1	RP11-137H2.4	-3.55	0.000416	0.0445	-0.22	-0.16	Post bronchodilator FEV1;	chr10:80374709	chr10:80529597~80535942:-
LUAD	cis	rs7100689	0.646	rs9804233	ENSG00000226659.1	RP11-137H2.4	-3.55	0.000416	0.0445	-0.22	-0.16	Post bronchodilator FEV1;	chr10:80374911	chr10:80529597~80535942:-
LUAD	cis	rs7100689	0.646	rs7077712	ENSG00000226659.1	RP11-137H2.4	-3.55	0.000416	0.0445	-0.22	-0.16	Post bronchodilator FEV1;	chr10:80375138	chr10:80529597~80535942:-
LUAD	cis	rs7100689	0.646	rs9804236	ENSG00000226659.1	RP11-137H2.4	-3.55	0.000416	0.0445	-0.22	-0.16	Post bronchodilator FEV1;	chr10:80375344	chr10:80529597~80535942:-
LUAD	cis	rs7100689	0.646	rs11202721	ENSG00000226659.1	RP11-137H2.4	-3.55	0.000416	0.0445	-0.22	-0.16	Post bronchodilator FEV1;	chr10:80376006	chr10:80529597~80535942:-
LUAD	cis	rs7100689	0.646	rs11202724	ENSG00000226659.1	RP11-137H2.4	-3.55	0.000416	0.0445	-0.22	-0.16	Post bronchodilator FEV1;	chr10:80376434	chr10:80529597~80535942:-
LUAD	cis	rs7100689	0.646	rs11202725	ENSG00000226659.1	RP11-137H2.4	-3.55	0.000416	0.0445	-0.22	-0.16	Post bronchodilator FEV1;	chr10:80376520	chr10:80529597~80535942:-
LUAD	cis	rs7100689	0.646	rs10749573	ENSG00000226659.1	RP11-137H2.4	-3.55	0.000416	0.0445	-0.22	-0.16	Post bronchodilator FEV1;	chr10:80377083	chr10:80529597~80535942:-
LUAD	cis	rs3814244	0.788	rs11177014	ENSG00000247363.2	RP11-637A17.2	3.55	0.000416	0.0446	0.18	0.16	Itch intensity from mosquito bite adjusted by bite size;	chr12:68031871	chr12:68674371~68687755:-
LUAD	cis	rs17826219	0.733	rs7221691	ENSG00000263603.1	CTD-2349P21.5	3.55	0.000417	0.0446	0.28	0.16	Body mass index;	chr17:30396601	chr17:30729469~30731202:+
LUAD	cis	rs10186458	0.932	rs10174270	ENSG00000234378.1	AC098828.2	-3.55	0.000417	0.0446	-0.19	-0.16	Kidney disease (early stage) in type 1 diabetes;	chr2:20398755	chr2:20063856~20106829:-
LUAD	cis	rs2276498	0.872	rs6097731	ENSG00000236352.1	AC005220.3	-3.55	0.000417	0.0446	-0.21	-0.16	Bipolar disorder and schizophrenia;	chr20:54027973	chr20:53940160~53942508:+
LUAD	cis	rs1154275	0.682	rs9827161	ENSG00000242770.2	RP11-180K7.1	3.55	0.000417	0.0446	0.16	0.16	Takotsubo syndrome;	chr3:112782872	chr3:112802478~112812819:+
LUAD	cis	rs481331	0.734	rs35917885	ENSG00000185904.10	LINC00839	3.55	0.000417	0.0446	0.27	0.16	Systemic juvenile idiopathic arthritis;	chr10:42483589	chr10:42475543~42495336:+
LUAD	cis	rs2548724	0.796	rs62372300	ENSG00000250682.4	LINC00491	3.55	0.000417	0.0446	0.21	0.16	Type 2 diabetes;	chr5:102340441	chr5:102609156~102671559:-
LUAD	cis	rs3753275	0.519	rs6658881	ENSG00000232912.4	RP5-1115A15.1	3.55	0.000417	0.0446	0.18	0.16	Educational attainment;	chr1:8691209	chr1:8424645~8434838:+
LUAD	cis	rs11159086	0.793	rs11845370	ENSG00000270000.1	RP3-449M8.9	3.55	0.000417	0.0446	0.22	0.16	Advanced glycation end-product levels;	chr14:74481587	chr14:74471930~74472360:-
LUAD	cis	rs1075265	0.818	rs12713253	ENSG00000272156.1	RP11-477N3.1	-3.55	0.000417	0.0446	-0.19	-0.16	Chronotype;Morning vs. evening chronotype;	chr2:54037323	chr2:54082554~54085066:+
LUAD	cis	rs9341808	0.538	rs7756067	ENSG00000233967.5	RP11-250B2.3	-3.55	0.000417	0.0446	-0.16	-0.16	Sitting height ratio;	chr6:80310077	chr6:80443344~80465927:+
LUAD	cis	rs3126085	1	rs72696989	ENSG00000237975.5	FLG-AS1	3.55	0.000417	0.0446	0.27	0.16	Atopic dermatitis;	chr1:152276198	chr1:152168125~152445456:+
LUAD	cis	rs214785	0.858	rs214787	ENSG00000234684.5	SDCBP2-AS1	3.55	0.000417	0.0446	0.2	0.16	Basal cell carcinoma;	chr20:2303021	chr20:1325405~1378734:+
LUAD	cis	rs214785	0.929	rs214789	ENSG00000234684.5	SDCBP2-AS1	3.55	0.000417	0.0446	0.2	0.16	Basal cell carcinoma;	chr20:2303618	chr20:1325405~1378734:+
LUAD	cis	rs7474896	0.515	rs624359	ENSG00000226578.1	RP11-258F22.1	3.55	0.000417	0.0446	0.22	0.16	Obesity (extreme);	chr10:38010204	chr10:37775371~37784131:-
LUAD	cis	rs7474896	0.537	rs598857	ENSG00000226578.1	RP11-258F22.1	3.55	0.000417	0.0446	0.22	0.16	Obesity (extreme);	chr10:38013998	chr10:37775371~37784131:-
LUAD	cis	rs7474896	0.515	rs2738208	ENSG00000226578.1	RP11-258F22.1	3.55	0.000417	0.0446	0.22	0.16	Obesity (extreme);	chr10:38017200	chr10:37775371~37784131:-
LUAD	cis	rs2288073	0.562	rs112892911	ENSG00000242628.4	AC009228.1	3.55	0.000417	0.0446	0.24	0.16	Venous thromboembolism (SNP x SNP interaction);	chr2:24367931	chr2:24214381~24221516:+
LUAD	cis	rs1154275	0.627	rs2633968	ENSG00000242770.2	RP11-180K7.1	-3.55	0.000417	0.0446	-0.16	-0.16	Takotsubo syndrome;	chr3:112782290	chr3:112802478~112812819:+
LUAD	cis	rs1154275	0.713	rs12695269	ENSG00000242770.2	RP11-180K7.1	3.55	0.000417	0.0446	0.16	0.16	Takotsubo syndrome;	chr3:112782673	chr3:112802478~112812819:+
LUAD	cis	rs1154275	0.713	rs11922070	ENSG00000242770.2	RP11-180K7.1	3.55	0.000417	0.0446	0.16	0.16	Takotsubo syndrome;	chr3:112782751	chr3:112802478~112812819:+
LUAD	cis	rs9876781	1	rs7630741	ENSG00000229759.1	MRPS18AP1	3.55	0.000417	0.0446	0.16	0.16	Longevity;	chr3:48378233	chr3:48256350~48256938:-
LUAD	cis	rs17772222	0.606	rs1955598	ENSG00000258789.1	RP11-507K2.3	-3.55	0.000417	0.0446	-0.19	-0.16	Coronary artery calcification;	chr14:88357311	chr14:88551597~88552493:+
LUAD	cis	rs5770872	0.521	rs7511047	ENSG00000273253.2	RP3-402G11.26	3.55	0.000417	0.0446	0.15	0.16	Tonsillectomy;	chr22:50378190	chr22:50199090~50200837:-
LUAD	cis	rs6599077	0.704	rs4293655	ENSG00000223797.4	ENTPD3-AS1	3.55	0.000417	0.0446	0.17	0.16	Sleep-related phenotypes;	chr3:40063850	chr3:40313802~40453329:-
LUAD	cis	rs4667682	0.529	rs7562674	ENSG00000228507.1	DAP3P2	-3.55	0.000417	0.0446	-0.31	-0.16	Hippocampal atrophy;Body mass index;	chr2:171403177	chr2:171491422~171491931:+
LUAD	cis	rs11064768	1	rs76987839	ENSG00000275759.1	RP11-131L12.3	3.55	0.000417	0.0446	0.32	0.16	Schizophrenia;	chr12:119384606	chr12:118428281~118428870:+
LUAD	cis	rs9900280	1	rs596700	ENSG00000264808.1	RP11-802D6.1	-3.55	0.000417	0.0446	-0.18	-0.16	Mean platelet volume;	chr17:29513229	chr17:29369717~29390777:-
LUAD	cis	rs2299587	0.521	rs3739406	ENSG00000253671.1	RP11-806O11.1	-3.55	0.000417	0.0446	-0.16	-0.16	Economic and political preferences;	chr8:17882029	chr8:17808941~17820868:+
LUAD	cis	rs6988985	0.728	rs4736311	ENSG00000247317.3	RP11-273G15.2	-3.55	0.000417	0.0446	-0.18	-0.16	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142871284	chr8:142981738~143018437:-
LUAD	cis	rs2274273	0.837	rs8008119	ENSG00000258413.1	RP11-665C16.6	-3.55	0.000417	0.0446	-0.21	-0.16	Protein biomarker;	chr14:55364510	chr14:55262767~55272075:-
LUAD	cis	rs6479901	0.895	rs10740119	ENSG00000232075.1	MRPL35P2	-3.55	0.000417	0.0446	-0.22	-0.16	Intelligence (multi-trait analysis);	chr10:63365477	chr10:63634317~63634827:-
LUAD	cis	rs9952991	0.654	rs35923716	ENSG00000260302.1	RP11-973H7.1	3.55	0.000417	0.0446	0.34	0.16	Inflammatory skin disease;	chr18:12885578	chr18:12774651~12775923:-
LUAD	cis	rs55702914	0.712	rs6730590	ENSG00000222017.1	AC011997.1	-3.55	0.000418	0.0446	-0.2	-0.16	Major depression and alcohol dependence;	chr2:197283360	chr2:197693106~197774823:+
LUAD	cis	rs860295	1	rs822527	ENSG00000203761.5	MSTO2P	3.55	0.000418	0.0446	0.12	0.16	Body mass index;	chr1:155768262	chr1:155745829~155750137:+
LUAD	cis	rs591584	0.73	rs7342170	ENSG00000255893.1	RP11-685N10.1	-3.55	0.000418	0.0446	-0.2	-0.16	Macrophage Migration Inhibitory Factor levels;	chr11:94581311	chr11:94472908~94473570:-
LUAD	cis	rs6736093	0.966	rs11692445	ENSG00000207383.1	Y_RNA	-3.55	0.000418	0.0446	-0.21	-0.16	Coronary artery disease;	chr2:111946456	chr2:112579484~112579584:-
LUAD	cis	rs7142881	0.844	rs4981860	ENSG00000258525.1	RP11-829H16.3	-3.55	0.000418	0.0446	-0.18	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31594574	chr14:30876179~30889808:-
LUAD	cis	rs2390582	0.823	rs1336875	ENSG00000233593.5	RP4-665J23.1	3.55	0.000418	0.0446	0.23	0.16	Coronary artery calcification;	chr1:90542446	chr1:90782986~90851650:-
LUAD	cis	rs7223966	1	rs11658329	ENSG00000279369.1	RP11-51F16.1	3.55	0.000418	0.0446	0.17	0.16	Hip circumference adjusted for BMI;Body mass index;	chr17:63685671	chr17:63700847~63702670:+
LUAD	cis	rs9309473	0.528	rs10191517	ENSG00000230002.2	ALMS1-IT1	3.55	0.000418	0.0447	0.19	0.16	Metabolite levels;	chr2:73331275	chr2:73456764~73459484:+
LUAD	cis	rs4835473	0.932	rs7664248	ENSG00000249741.2	RP11-673E1.3	-3.55	0.000418	0.0447	-0.2	-0.16	Immature fraction of reticulocytes;	chr4:143732554	chr4:143911514~143912053:-
LUAD	cis	rs7107174	1	rs10899452	ENSG00000251323.2	RP11-452H21.4	3.55	0.000418	0.0447	0.21	0.16	Testicular germ cell tumor;	chr11:78284097	chr11:78423982~78429836:-
LUAD	cis	rs9549260	0.604	rs61963351	ENSG00000168852.11	TPTE2P5	3.55	0.000418	0.0447	0.21	0.16	Red blood cell count;	chr13:40744686	chr13:40822296~40921749:-
LUAD	cis	rs520525	0.927	rs1234282	ENSG00000271811.1	RP1-79C4.4	3.55	0.000418	0.0447	0.2	0.16	Atrial fibrillation;	chr1:170650183	chr1:170667381~170669425:+
LUAD	cis	rs3113494	0.605	rs2594279	ENSG00000251411.1	RP11-397E7.4	3.55	0.000418	0.0447	0.17	0.16	Amyotrophic lateral sclerosis;	chr4:86944235	chr4:86913266~86914817:-
LUAD	cis	rs3113494	0.55	rs13125904	ENSG00000251411.1	RP11-397E7.4	3.55	0.000418	0.0447	0.17	0.16	Amyotrophic lateral sclerosis;	chr4:86944386	chr4:86913266~86914817:-
LUAD	cis	rs2333021	0.689	rs2535897	ENSG00000259015.1	RP11-109N23.6	-3.55	0.000418	0.0447	-0.16	-0.16	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72967514	chr14:72960595~72961993:+
LUAD	cis	rs2712475	0.585	rs35969919	ENSG00000241218.1	RP11-446H18.1	3.55	0.000418	0.0447	0.24	0.16	Colonoscopy-negative controls vs population controls;	chr3:106481597	chr3:107327830~107329197:-
LUAD	cis	rs748404	0.666	rs12907870	ENSG00000249839.1	AC011330.5	-3.55	0.000418	0.0447	-0.25	-0.16	Lung cancer;	chr15:43453971	chr15:43663654~43684339:-
LUAD	cis	rs6471393	0.964	rs2914952	ENSG00000253848.1	RP11-10N23.5	3.55	0.000418	0.0447	0.2	0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93729524	chr8:93741193~93744534:+
LUAD	cis	rs9341808	0.754	rs9343973	ENSG00000233967.5	RP11-250B2.3	3.55	0.000418	0.0447	0.16	0.16	Sitting height ratio;	chr6:80203499	chr6:80443344~80465927:+
LUAD	cis	rs794185	0.564	rs304080	ENSG00000231249.1	ITPR1-AS1	-3.55	0.000418	0.0447	-0.17	-0.16	Multiple sclerosis--Brain Glutamate Levels;	chr3:4490262	chr3:4490891~4493163:-
LUAD	cis	rs4865762	0.512	rs7725098	ENSG00000247796.2	CTD-2366F13.1	3.55	0.000418	0.0447	0.18	0.16	Intraocular pressure;	chr5:53216736	chr5:53109842~53115126:+
LUAD	cis	rs4865762	0.512	rs7726216	ENSG00000247796.2	CTD-2366F13.1	3.55	0.000418	0.0447	0.18	0.16	Intraocular pressure;	chr5:53216779	chr5:53109842~53115126:+
LUAD	cis	rs4865762	0.512	rs7725380	ENSG00000247796.2	CTD-2366F13.1	3.55	0.000418	0.0447	0.18	0.16	Intraocular pressure;	chr5:53216931	chr5:53109842~53115126:+
LUAD	cis	rs4865762	0.512	rs10940294	ENSG00000247796.2	CTD-2366F13.1	3.55	0.000418	0.0447	0.18	0.16	Intraocular pressure;	chr5:53217378	chr5:53109842~53115126:+
LUAD	cis	rs548181	0.736	rs497344	ENSG00000254671.2	STT3A-AS1	-3.55	0.000418	0.0447	-0.29	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr11:125600629	chr11:125570284~125592568:-
LUAD	cis	rs9303542	1	rs11079818	ENSG00000264920.1	RP11-6N17.4	-3.55	0.000418	0.0447	-0.21	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48376815	chr17:47891255~47895812:-
LUAD	cis	rs9303542	1	rs6504203	ENSG00000264920.1	RP11-6N17.4	-3.55	0.000418	0.0447	-0.21	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48377313	chr17:47891255~47895812:-
LUAD	cis	rs449789	0.585	rs7753342	ENSG00000235086.1	FNDC1-IT1	-3.55	0.000418	0.0447	-0.28	-0.16	Pulse pressure;	chr6:159360085	chr6:159240786~159243329:+
LUAD	cis	rs1979679	0.573	rs6487694	ENSG00000278733.1	RP11-425D17.1	-3.55	0.000418	0.0447	-0.21	-0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28574801	chr12:28185625~28186190:-
LUAD	cis	rs2243480	0.615	rs34363376	ENSG00000222364.1	RNU6-96P	-3.55	0.000418	0.0447	-0.27	-0.16	Diabetic kidney disease;	chr7:66474549	chr7:66395191~66395286:+
LUAD	cis	rs753955	0.593	rs7982516	ENSG00000205861.10	C1QTNF9B-AS1	3.55	0.000418	0.0447	0.19	0.16	Lung cancer;	chr13:23836139	chr13:23888889~23897263:+
LUAD	cis	rs12681366	0.839	rs3019281	ENSG00000254057.1	RP3-388N13.3	3.55	0.000418	0.0447	0.17	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94438061	chr8:93834454~93846743:-
LUAD	cis	rs6496044	0.568	rs1351196	ENSG00000259416.2	RP11-158M2.5	3.55	0.000418	0.0447	0.17	0.16	Interstitial lung disease;	chr15:85534173	chr15:85754941~85756237:-
LUAD	cis	rs7598759	1	rs7598759	ENSG00000181798.2	LINC00471	-3.55	0.000418	0.0447	-0.18	-0.16	Noise-induced hearing loss;	chr2:231457245	chr2:231508426~231514339:-
LUAD	cis	rs2638953	0.64	rs10843204	ENSG00000244712.1	RP11-874G11.1	-3.55	0.000418	0.0447	-0.23	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28568028	chr12:28564678~28565141:-
LUAD	cis	rs2638953	0.64	rs10843205	ENSG00000244712.1	RP11-874G11.1	-3.55	0.000418	0.0447	-0.23	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28568220	chr12:28564678~28565141:-
LUAD	cis	rs4561483	0.771	rs12924398	ENSG00000261216.1	RP11-166B2.5	-3.55	0.000418	0.0447	-0.16	-0.16	Testicular germ cell tumor;	chr16:11879091	chr16:11908208~11908916:+
LUAD	cis	rs7613875	0.58	rs12634780	ENSG00000234667.1	ACTBP13	3.55	0.000418	0.0447	0.18	0.16	Body mass index;	chr3:50005908	chr3:49873347~49877980:-
LUAD	cis	rs9628987	0.5	rs11121179	ENSG00000232912.4	RP5-1115A15.1	-3.55	0.000418	0.0447	-0.19	-0.16	Breast cancer;	chr1:8395652	chr1:8424645~8434838:+
LUAD	cis	rs11009175	0.547	rs7070167	ENSG00000273038.2	RP11-479G22.8	-3.55	0.000418	0.0447	-0.21	-0.16	Depression (quantitative trait);	chr10:33109200	chr10:32887255~32889311:-
LUAD	cis	rs7100689	0.646	rs10736348	ENSG00000226659.1	RP11-137H2.4	-3.55	0.000418	0.0447	-0.22	-0.16	Post bronchodilator FEV1;	chr10:80379488	chr10:80529597~80535942:-
LUAD	cis	rs453301	0.624	rs2288673	ENSG00000253981.4	ALG1L13P	3.55	0.000418	0.0447	0.19	0.16	Joint mobility (Beighton score);	chr8:9002766	chr8:8236003~8244667:-
LUAD	cis	rs4879656	0.741	rs10758183	ENSG00000225693.1	LAGE3P1	3.55	0.000418	0.0447	0.18	0.16	Menopause (age at onset);	chr9:33055473	chr9:33019682~33020165:-
LUAD	cis	rs8056893	0.714	rs7192234	ENSG00000260441.4	RP11-96D1.7	-3.55	0.000418	0.0447	-0.19	-0.16	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68357286	chr16:68256162~68260443:-
LUAD	cis	rs1046491	0.901	rs7226632	ENSG00000264964.1	RP11-888D10.3	3.55	0.000418	0.0447	0.33	0.16	Scarlet fever;	chr18:9179151	chr18:9315194~9334441:-
LUAD	cis	rs1046491	1	rs11877843	ENSG00000264964.1	RP11-888D10.3	3.55	0.000418	0.0447	0.33	0.16	Scarlet fever;	chr18:9180217	chr18:9315194~9334441:-
LUAD	cis	rs1046491	0.901	rs11663949	ENSG00000264964.1	RP11-888D10.3	3.55	0.000418	0.0447	0.33	0.16	Scarlet fever;	chr18:9189252	chr18:9315194~9334441:-
LUAD	cis	rs12681366	0.881	rs12674614	ENSG00000254057.1	RP3-388N13.3	3.55	0.000418	0.0447	0.17	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94396605	chr8:93834454~93846743:-
LUAD	cis	rs12681366	0.881	rs3019155	ENSG00000254057.1	RP3-388N13.3	3.55	0.000418	0.0447	0.17	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94405359	chr8:93834454~93846743:-
LUAD	cis	rs9400467	0.528	rs7752361	ENSG00000266032.1	AL357515.1	3.55	0.000418	0.0447	0.21	0.16	Amino acid levels;Blood metabolite levels;	chr6:111459502	chr6:110969773~110969872:-
LUAD	cis	rs7760535	0.811	rs7764591	ENSG00000266032.1	AL357515.1	3.55	0.000418	0.0447	0.21	0.16	Metabolic traits;	chr6:111462211	chr6:110969773~110969872:-
LUAD	cis	rs6878284	0.608	rs841931	ENSG00000250682.4	LINC00491	-3.55	0.000418	0.0447	-0.17	-0.16	Schizophrenia;	chr5:102289649	chr5:102609156~102671559:-
LUAD	cis	rs10908557	0.957	rs6724	ENSG00000223599.1	RP11-216N14.7	3.55	0.000418	0.0447	0.2	0.16	Age at first birth;	chr1:153959736	chr1:153852106~153853414:-
LUAD	cis	rs2288073	0.801	rs2384008	ENSG00000242628.4	AC009228.1	3.55	0.000418	0.0447	0.21	0.16	Venous thromboembolism (SNP x SNP interaction);	chr2:24150280	chr2:24214381~24221516:+
LUAD	cis	rs61160187	0.548	rs68104763	ENSG00000215032.2	GNL3LP1	3.55	0.000419	0.0447	0.2	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:61107016	chr5:60891935~60893577:-
LUAD	cis	rs9652601	0.691	rs6498160	ENSG00000280153.1	RP11-876N24.3	-3.55	0.000419	0.0447	-0.11	-0.16	Systemic lupus erythematosus;	chr16:11105590	chr16:10933903~10936280:+
LUAD	cis	rs2985684	0.894	rs6572585	ENSG00000278009.1	RP11-649E7.8	3.55	0.000419	0.0447	0.21	0.16	Carotid intima media thickness;	chr14:49554357	chr14:49601011~49601124:-
LUAD	cis	rs12962334	0.555	rs9959556	ENSG00000266850.1	RP11-370A5.1	3.55	0.000419	0.0447	0.2	0.16	Breast cancer;	chr18:23011982	chr18:22723491~22907721:-
LUAD	cis	rs4578769	0.531	rs4800443	ENSG00000266850.1	RP11-370A5.1	3.55	0.000419	0.0447	0.2	0.16	Eosinophil percentage of white cells;	chr18:23015139	chr18:22723491~22907721:-
LUAD	cis	rs10127852	0.541	rs12065415	ENSG00000122432.15	SPATA1	3.55	0.000419	0.0447	0.31	0.16	Cerebrospinal fluid t-tau:AB1-42 ratio;	chr1:84796671	chr1:84506291~84566194:+
LUAD	cis	rs6687821	0.515	rs502404	ENSG00000261737.1	RP4-612B15.3	-3.55	0.000419	0.0447	-0.22	-0.16	Yeast infection;	chr1:86878204	chr1:86703502~86704462:-
LUAD	cis	rs35740288	0.539	rs4843101	ENSG00000202081.1	RNU6-1280P	3.55	0.000419	0.0447	0.23	0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85796430	chr15:85651522~85651628:-
LUAD	cis	rs6502050	0.835	rs9901076	ENSG00000266654.1	RP11-1376P16.1	-3.55	0.000419	0.0447	-0.17	-0.16	Life satisfaction;	chr17:82212144	chr17:82160056~82160452:+
LUAD	cis	rs7246657	0.943	rs10409204	ENSG00000267470.4	ZNF571-AS1	3.55	0.000419	0.0447	0.23	0.16	Coronary artery calcification;	chr19:37426790	chr19:37548914~37587348:+
LUAD	cis	rs10878674	1	rs11176892	ENSG00000255772.4	LINC01479	3.55	0.000419	0.0447	0.17	0.16	Daytime sleep phenotypes;	chr12:67840618	chr12:67929235~67970017:+
LUAD	cis	rs11638352	1	rs11638352	ENSG00000205771.5	CATSPER2P1	3.55	0.000419	0.0447	0.38	0.16	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44000939	chr15:43726918~43747094:-
LUAD	cis	rs2733201	1	rs12913809	ENSG00000205771.5	CATSPER2P1	3.55	0.000419	0.0447	0.38	0.16	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44001013	chr15:43726918~43747094:-
LUAD	cis	rs1023500	0.573	rs133378	ENSG00000273366.1	CTA-989H11.1	-3.55	0.000419	0.0447	-0.19	-0.16	Schizophrenia;	chr22:42071691	chr22:42278188~42278846:+
LUAD	cis	rs12499086	0.642	rs11733400	ENSG00000249635.1	RP11-710F7.3	-3.55	0.000419	0.0448	-0.17	-0.16	Economic and political preferences (time);	chr4:105490016	chr4:106003317~106022478:-
LUAD	cis	rs7210990	0.674	rs8080221	ENSG00000275413.1	CTC-529I10.1	-3.55	0.000419	0.0448	-0.14	-0.16	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr17:16038771	chr17:16023323~16023653:-
LUAD	cis	rs7976269	0.515	rs11049999	ENSG00000275476.1	RP11-996F15.4	-3.55	0.000419	0.0448	-0.17	-0.16	Male-pattern baldness;	chr12:29042854	chr12:29277397~29277882:-
LUAD	cis	rs1577917	0.655	rs2842600	ENSG00000220563.1	PKMP3	-3.55	0.000419	0.0448	-0.15	-0.16	Response to antipsychotic treatment;	chr6:85615914	chr6:85659892~85660606:-
LUAD	cis	rs7077256	0.526	rs34899893	ENSG00000272767.1	JMJD1C-AS1	3.55	0.000419	0.0448	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63222412	chr10:63465229~63466563:+
LUAD	cis	rs7077256	0.564	rs66929943	ENSG00000272767.1	JMJD1C-AS1	3.55	0.000419	0.0448	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63223230	chr10:63465229~63466563:+
LUAD	cis	rs7077256	0.564	rs35885463	ENSG00000272767.1	JMJD1C-AS1	3.55	0.000419	0.0448	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63228863	chr10:63465229~63466563:+
LUAD	cis	rs7077256	0.564	rs12770806	ENSG00000272767.1	JMJD1C-AS1	3.55	0.000419	0.0448	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63229813	chr10:63465229~63466563:+
LUAD	cis	rs12681366	0.801	rs2043988	ENSG00000254057.1	RP3-388N13.3	3.55	0.000419	0.0448	0.17	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94457327	chr8:93834454~93846743:-
LUAD	cis	rs12681366	0.801	rs2919658	ENSG00000254057.1	RP3-388N13.3	3.55	0.000419	0.0448	0.17	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94459550	chr8:93834454~93846743:-
LUAD	cis	rs12681366	0.801	rs2930956	ENSG00000254057.1	RP3-388N13.3	3.55	0.000419	0.0448	0.17	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94460840	chr8:93834454~93846743:-
LUAD	cis	rs10197140	0.925	rs932078	ENSG00000235721.1	AC013268.3	3.55	0.000419	0.0448	0.17	0.16	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110863376	chr2:110007675~110010783:+
LUAD	cis	rs116095464	1	rs62331560	ENSG00000250848.1	CTD-2083E4.5	-3.55	0.000419	0.0448	-0.33	-0.16	Breast cancer;	chr5:346670	chr5:288833~290321:-
LUAD	cis	rs11089937	0.626	rs9619800	ENSG00000211640.3	IGLV6-57	3.55	0.000419	0.0448	0.12	0.16	Periodontitis (PAL4Q3);	chr22:22141088	chr22:22195713~22196460:+
LUAD	cis	rs755249	0.567	rs16825887	ENSG00000182109.6	RP11-69E11.4	-3.55	0.000419	0.0448	-0.19	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39177710	chr1:39522280~39546187:-
LUAD	cis	rs74024059	1	rs2133409	ENSG00000260269.4	CTD-2323K18.1	3.55	0.000419	0.0448	0.41	0.16	Red blood cell count;Hematocrit;	chr15:75984088	chr15:75527150~75601205:-
LUAD	cis	rs8050896	0.59	rs112446341	ENSG00000260695.1	RP11-513N24.1	-3.55	0.000419	0.0448	-0.34	-0.16	Response to antipsychotic treatment;	chr16:66152611	chr16:65861112~65863784:-
LUAD	cis	rs2834288	0.535	rs881228	ENSG00000273102.1	AP000569.9	3.55	0.000419	0.0448	0.2	0.16	Gut microbiota (bacterial taxa);	chr21:33950387	chr21:33967101~33968573:-
LUAD	cis	rs7428	0.527	rs1061782	ENSG00000246575.2	AC093162.5	-3.55	0.000419	0.0448	-0.15	-0.16	Ear protrusion;	chr2:85319492	chr2:85315041~85316529:+
LUAD	cis	rs4934494	0.834	rs1359624	ENSG00000240996.1	RP11-80H5.7	-3.55	0.000419	0.0448	-0.2	-0.16	Red blood cell count;	chr10:89635671	chr10:89694295~89697928:-
LUAD	cis	rs12681963	0.925	rs11984896	ENSG00000272375.1	RP11-51J9.6	3.55	0.000419	0.0448	0.21	0.16	Migraine;	chr8:30111513	chr8:30197404~30198048:+
LUAD	cis	rs7204230	1	rs7189455	ENSG00000261291.1	RP11-295M3.2	3.55	0.000419	0.0448	0.19	0.16	Fibrinogen;	chr16:53237337	chr16:53168522~53169450:+
LUAD	cis	rs3018066	0.748	rs72677306	ENSG00000251259.1	AC004069.2	-3.55	0.000419	0.0448	-0.2	-0.16	Cancer;	chr4:106076521	chr4:105137280~105140619:-
LUAD	cis	rs6061231	0.571	rs482010	ENSG00000275437.1	RP5-908M14.10	-3.55	0.000419	0.0448	-0.14	-0.16	Colorectal cancer;	chr20:62352495	chr20:62402236~62405935:-
LUAD	cis	rs786425	0.966	rs6488883	ENSG00000278112.1	RP11-972P1.11	3.55	0.000419	0.0448	0.14	0.16	Pubertal anthropometrics;	chr12:123616800	chr12:123519390~123519856:-
LUAD	cis	rs4389656	0.556	rs11959367	ENSG00000248677.1	CTD-2044J15.1	-3.55	0.000419	0.0448	-0.19	-0.16	Coronary artery disease;	chr5:6795536	chr5:6686325~6707711:-
LUAD	cis	rs897984	0.553	rs2335013	ENSG00000232748.3	RP11-196G11.6	3.55	0.000419	0.0448	0.21	0.16	Dementia with Lewy bodies;	chr16:30866025	chr16:31056460~31062803:+
LUAD	cis	rs4268898	0.662	rs72793967	ENSG00000242628.4	AC009228.1	3.55	0.000419	0.0448	0.24	0.16	Asthma;	chr2:24200033	chr2:24214381~24221516:+
LUAD	cis	rs2731006	0.591	rs908658	ENSG00000257114.2	RP11-25I15.3	-3.55	0.000419	0.0448	-0.25	-0.16	Panic disorder;	chr12:42774929	chr12:42692216~42717119:+
LUAD	cis	rs854765	0.583	rs4925130	ENSG00000264177.1	RP1-37N7.1	-3.55	0.000419	0.0448	-0.16	-0.16	Total body bone mineral density;	chr17:17904544	chr17:18379855~18388984:-
LUAD	cis	rs9309473	1	rs6715819	ENSG00000230002.2	ALMS1-IT1	3.55	0.000419	0.0448	0.2	0.16	Metabolite levels;	chr2:73545182	chr2:73456764~73459484:+
LUAD	cis	rs4908769	0.66	rs13596	ENSG00000232912.4	RP5-1115A15.1	-3.55	0.000419	0.0448	-0.15	-0.16	Allergy;	chr1:8361143	chr1:8424645~8434838:+
LUAD	cis	rs6502050	0.835	rs3924781	ENSG00000275966.1	RP11-1055B8.9	-3.55	0.00042	0.0448	-0.16	-0.16	Life satisfaction;	chr17:82155254	chr17:81345476~81345966:-
LUAD	cis	rs16940212	0.618	rs8032310	ENSG00000242747.1	RP11-30K9.1	-3.55	0.00042	0.0448	-0.23	-0.16	HDL cholesterol;HDL cholesterol levels;	chr15:58395663	chr15:58869659~58870134:+
LUAD	cis	rs4664293	0.867	rs13022404	ENSG00000227055.1	AC009961.5	3.55	0.00042	0.0448	0.18	0.16	Monocyte percentage of white cells;	chr2:159732981	chr2:159812234~159814009:-
LUAD	cis	rs7404843	0.789	rs222907	ENSG00000263335.1	AF001548.5	3.55	0.00042	0.0448	0.29	0.16	Testicular germ cell tumor;	chr16:15404950	chr16:15726674~15732993:+
LUAD	cis	rs42490	0.576	rs432457	ENSG00000251136.7	RP11-37B2.1	-3.55	0.00042	0.0448	-0.18	-0.16	Leprosy;	chr8:89853680	chr8:89609409~89757727:-
LUAD	cis	rs7674212	0.57	rs2711899	ENSG00000246560.2	RP11-10L12.4	3.55	0.00042	0.0448	0.2	0.16	Type 2 diabetes;	chr4:103141257	chr4:102828055~102844075:+
LUAD	cis	rs6088590	1	rs3787222	ENSG00000275784.1	RP5-1125A11.6	-3.55	0.00042	0.0448	-0.17	-0.16	Coronary artery disease;	chr20:34745236	chr20:33989480~33991818:-
LUAD	cis	rs4130344	0.874	rs4331733	ENSG00000271817.2	U3	-3.55	0.00042	0.0448	-0.17	-0.16	Intelligence (multi-trait analysis);	chr4:158776934	chr4:158700691~158700909:+
LUAD	cis	rs78572108	0.858	rs12472780	ENSG00000214691.7	AC104654.1	3.55	0.00042	0.0448	0.26	0.16	Total body bone mineral density;	chr2:42042105	chr2:41877074~41894046:+
LUAD	cis	rs858239	0.738	rs13225593	ENSG00000230042.1	AK3P3	-3.55	0.00042	0.0448	-0.2	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23220688	chr7:23129178~23129841:+
LUAD	cis	rs4795519	0.826	rs7217913	ENSG00000266313.1	RP11-173M1.4	3.55	0.00042	0.0448	0.19	0.16	Chronic myeloid leukemia;	chr17:27036894	chr17:27333256~27348491:+
LUAD	cis	rs748404	0.666	rs12899865	ENSG00000249839.1	AC011330.5	-3.55	0.00042	0.0448	-0.24	-0.16	Lung cancer;	chr15:43448819	chr15:43663654~43684339:-
LUAD	cis	rs78572108	0.858	rs12467432	ENSG00000214691.7	AC104654.1	3.55	0.00042	0.0448	0.27	0.16	Total body bone mineral density;	chr2:42011229	chr2:41877074~41894046:+
LUAD	cis	rs13006833	0.668	rs291445	ENSG00000227542.1	AC092614.2	-3.55	0.00042	0.0449	-0.19	-0.16	Urinary metabolites;	chr2:190311753	chr2:191229165~191246172:-
LUAD	cis	rs9322193	0.607	rs4870078	ENSG00000268592.3	RAET1E-AS1	-3.55	0.00042	0.0449	-0.23	-0.16	Lung cancer;	chr6:149880676	chr6:149863494~149919507:+
LUAD	cis	rs7572733	0.773	rs16866970	ENSG00000222017.1	AC011997.1	3.55	0.00042	0.0449	0.2	0.16	Dermatomyositis;	chr2:197646362	chr2:197693106~197774823:+
LUAD	cis	rs7572733	0.773	rs11690491	ENSG00000222017.1	AC011997.1	3.55	0.00042	0.0449	0.2	0.16	Dermatomyositis;	chr2:197650200	chr2:197693106~197774823:+
LUAD	cis	rs3617	0.625	rs2240917	ENSG00000242142.1	SERBP1P3	3.55	0.00042	0.0449	0.17	0.16	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52817121	chr3:53064283~53065091:-
LUAD	cis	rs3617	0.572	rs2245538	ENSG00000242142.1	SERBP1P3	3.55	0.00042	0.0449	0.17	0.16	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52818044	chr3:53064283~53065091:-
LUAD	cis	rs14027	0.64	rs10096846	ENSG00000279347.1	RP11-85I17.2	-3.55	0.00042	0.0449	-0.13	-0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119760884	chr8:119838736~119840385:-
LUAD	cis	rs875971	0.66	rs6460308	ENSG00000222364.1	RNU6-96P	3.55	0.00042	0.0449	0.18	0.16	Aortic root size;	chr7:66619753	chr7:66395191~66395286:+
LUAD	cis	rs2921036	0.503	rs7817832	ENSG00000253981.4	ALG1L13P	3.55	0.00042	0.0449	0.2	0.16	Neuroticism;	chr8:8523311	chr8:8236003~8244667:-
LUAD	cis	rs9907295	0.591	rs2291299	ENSG00000270977.1	AC015849.16	-3.55	0.00042	0.0449	-0.21	-0.16	Fibroblast growth factor basic levels;	chr17:35864402	chr17:35893707~35911023:-
LUAD	cis	rs10784496	0.627	rs12823148	ENSG00000239335.4	LLPH-AS1	3.55	0.00042	0.0449	0.22	0.16	Cerebrospinal fluid AB1-42 levels;	chr12:65751518	chr12:66130751~66134449:+
LUAD	cis	rs1198430	0.562	rs7522616	ENSG00000232482.2	RP4-654C18.1	-3.55	0.00042	0.0449	-0.21	-0.16	Total cholesterol levels;	chr1:23468421	chr1:23410832~23412146:+
LUAD	cis	rs577676	0.586	rs578928	ENSG00000271811.1	RP1-79C4.4	3.55	0.00042	0.0449	0.2	0.16	Prevalent atrial fibrillation;	chr1:170640602	chr1:170667381~170669425:+
LUAD	cis	rs2018683	0.834	rs2012754	ENSG00000272568.4	CTB-113D17.1	3.55	0.00042	0.0449	0.18	0.16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28986641	chr7:28979967~29013367:+
LUAD	cis	rs889398	0.594	rs7202233	ENSG00000226232.7	RP11-419C5.2	-3.55	0.00042	0.0449	-0.13	-0.16	Body mass index;	chr16:69860529	chr16:69976388~69996188:-
LUAD	cis	rs7572733	0.84	rs770667	ENSG00000222017.1	AC011997.1	3.55	0.00042	0.0449	0.2	0.16	Dermatomyositis;	chr2:197748584	chr2:197693106~197774823:+
LUAD	cis	rs7572733	0.84	rs1065953	ENSG00000222017.1	AC011997.1	3.55	0.00042	0.0449	0.2	0.16	Dermatomyositis;	chr2:197749888	chr2:197693106~197774823:+
LUAD	cis	rs7572733	0.84	rs700648	ENSG00000222017.1	AC011997.1	3.55	0.00042	0.0449	0.2	0.16	Dermatomyositis;	chr2:197757912	chr2:197693106~197774823:+
LUAD	cis	rs7572733	0.84	rs700649	ENSG00000222017.1	AC011997.1	3.55	0.00042	0.0449	0.2	0.16	Dermatomyositis;	chr2:197758028	chr2:197693106~197774823:+
LUAD	cis	rs7572733	0.84	rs700650	ENSG00000222017.1	AC011997.1	3.55	0.00042	0.0449	0.2	0.16	Dermatomyositis;	chr2:197759561	chr2:197693106~197774823:+
LUAD	cis	rs7572733	0.811	rs771013	ENSG00000222017.1	AC011997.1	3.55	0.00042	0.0449	0.2	0.16	Dermatomyositis;	chr2:197760513	chr2:197693106~197774823:+
LUAD	cis	rs7572733	0.84	rs1065949	ENSG00000222017.1	AC011997.1	3.55	0.00042	0.0449	0.2	0.16	Dermatomyositis;	chr2:197762331	chr2:197693106~197774823:+
LUAD	cis	rs7572733	0.84	rs700653	ENSG00000222017.1	AC011997.1	3.55	0.00042	0.0449	0.2	0.16	Dermatomyositis;	chr2:197772709	chr2:197693106~197774823:+
LUAD	cis	rs7572733	0.84	rs700654	ENSG00000222017.1	AC011997.1	3.55	0.00042	0.0449	0.2	0.16	Dermatomyositis;	chr2:197778697	chr2:197693106~197774823:+
LUAD	cis	rs7572733	0.875	rs771018	ENSG00000222017.1	AC011997.1	3.55	0.00042	0.0449	0.2	0.16	Dermatomyositis;	chr2:197785535	chr2:197693106~197774823:+
LUAD	cis	rs2613514	0.568	rs2871764	ENSG00000204282.4	TNRC6C-AS1	-3.55	0.00042	0.0449	-0.21	-0.16	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr17:78071374	chr17:78107398~78111799:-
LUAD	cis	rs727479	0.502	rs4774583	ENSG00000259306.2	RP11-108K3.2	-3.55	0.00042	0.0449	-0.16	-0.16	Estradiol levels;	chr15:51213796	chr15:51315841~51321996:+
LUAD	cis	rs7129556	0.737	rs72949616	ENSG00000241782.1	RP11-91P24.1	3.55	0.00042	0.0449	0.23	0.16	Weight loss (gastric bypass surgery);	chr11:77753325	chr11:77868722~77869195:-
LUAD	cis	rs7129556	0.737	rs72949618	ENSG00000241782.1	RP11-91P24.1	3.55	0.00042	0.0449	0.23	0.16	Weight loss (gastric bypass surgery);	chr11:77753485	chr11:77868722~77869195:-
LUAD	cis	rs7129556	0.737	rs56218634	ENSG00000241782.1	RP11-91P24.1	3.55	0.00042	0.0449	0.23	0.16	Weight loss (gastric bypass surgery);	chr11:77753789	chr11:77868722~77869195:-
LUAD	cis	rs7129556	0.737	rs643388	ENSG00000241782.1	RP11-91P24.1	3.55	0.00042	0.0449	0.23	0.16	Weight loss (gastric bypass surgery);	chr11:77759997	chr11:77868722~77869195:-
LUAD	cis	rs7615952	0.558	rs7641353	ENSG00000171084.14	FAM86JP	3.55	0.00042	0.0449	0.21	0.16	Blood pressure (smoking interaction);	chr3:125621035	chr3:125916620~125930024:+
LUAD	cis	rs6504108	0.624	rs1316657	ENSG00000278765.1	RP5-890E16.5	-3.55	0.00042	0.0449	-0.18	-0.16	Body mass index;	chr17:48174029	chr17:48066704~48067293:-
LUAD	cis	rs1007190	0.881	rs16939676	ENSG00000267505.1	CTC-296K1.3	3.55	0.00042	0.0449	0.28	0.16	DNA methylation (variation);	chr17:44898979	chr17:44793199~44794474:+
LUAD	cis	rs17507216	0.718	rs28587782	ENSG00000276710.3	CSPG4P8	-3.55	0.00042	0.0449	-0.18	-0.16	Excessive daytime sleepiness;	chr15:82576881	chr15:82459472~82477258:+
LUAD	cis	rs6502050	0.835	rs8081949	ENSG00000266654.1	RP11-1376P16.1	-3.55	0.00042	0.0449	-0.17	-0.16	Life satisfaction;	chr17:82159614	chr17:82160056~82160452:+
LUAD	cis	rs6502050	0.835	rs8071737	ENSG00000266654.1	RP11-1376P16.1	-3.55	0.00042	0.0449	-0.17	-0.16	Life satisfaction;	chr17:82159661	chr17:82160056~82160452:+
LUAD	cis	rs9437689	0.566	rs1146465	ENSG00000228852.5	RP11-57H12.5	3.55	0.000421	0.0449	0.14	0.16	Phospholipid levels (plasma);	chr1:94936057	chr1:95243167~95278940:-
LUAD	cis	rs9437689	0.591	rs1146460	ENSG00000228852.5	RP11-57H12.5	3.55	0.000421	0.0449	0.14	0.16	Phospholipid levels (plasma);	chr1:94943364	chr1:95243167~95278940:-
LUAD	cis	rs1555322	0.53	rs932562	ENSG00000261582.1	RP4-614O4.11	-3.55	0.000421	0.0449	-0.2	-0.16	Attention deficit hyperactivity disorder;	chr20:35283507	chr20:35267885~35280043:-
LUAD	cis	rs2657294	0.796	rs1259499	ENSG00000226051.5	ZNF503-AS1	-3.55	0.000421	0.0449	-0.21	-0.16	Pneumonia;	chr10:75228308	chr10:75269819~75373500:+
LUAD	cis	rs6504108	0.577	rs2109982	ENSG00000278765.1	RP5-890E16.5	-3.55	0.000421	0.0449	-0.18	-0.16	Body mass index;	chr17:48167407	chr17:48066704~48067293:-
LUAD	cis	rs6046393	1	rs6136866	ENSG00000275142.1	RP5-999L4.2	-3.55	0.000421	0.0449	-0.25	-0.16	Verbal declarative memory;	chr20:19878037	chr20:19871891~19872284:+
LUAD	cis	rs13113518	0.812	rs13140590	ENSG00000249700.7	SRD5A3-AS1	3.55	0.000421	0.0449	0.17	0.16	Height;	chr4:55548666	chr4:55363971~55395847:-
LUAD	cis	rs647161	0.588	rs6860345	ENSG00000247627.2	MTND4P12	-3.55	0.000421	0.0449	-0.19	-0.16	Colorectal cancer;	chr5:135156218	chr5:134926660~134928036:-
LUAD	cis	rs8056893	0.686	rs10775304	ENSG00000260441.4	RP11-96D1.7	-3.55	0.000421	0.0449	-0.19	-0.16	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68377259	chr16:68256162~68260443:-
LUAD	cis	rs12190007	0.547	rs3006217	ENSG00000224999.1	VTA1P1	3.55	0.000421	0.0449	0.16	0.16	Obesity-related traits;	chr6:169462783	chr6:169296471~169297959:-
LUAD	cis	rs6964587	0.967	rs6980247	ENSG00000188693.7	CYP51A1-AS1	-3.55	0.000421	0.0449	-0.19	-0.16	Breast cancer;	chr7:91964914	chr7:92134604~92180725:+
LUAD	cis	rs6661961	0.752	rs6587674	ENSG00000237975.5	FLG-AS1	-3.55	0.000421	0.0449	-0.22	-0.16	Atopic dermatitis;	chr1:152460870	chr1:152168125~152445456:+
LUAD	cis	rs1949733	0.628	rs1543246	ENSG00000205959.3	RP11-689P11.2	-3.55	0.000421	0.0449	-0.16	-0.16	Response to antineoplastic agents;	chr4:8503182	chr4:8482270~8512610:+
LUAD	cis	rs6502050	0.865	rs74480314	ENSG00000266654.1	RP11-1376P16.1	-3.55	0.000421	0.0449	-0.17	-0.16	Life satisfaction;	chr17:82159840	chr17:82160056~82160452:+
LUAD	cis	rs11696845	0.787	rs13043441	ENSG00000276223.1	RP4-781B1.5	-3.55	0.000421	0.0449	-0.2	-0.16	Obesity-related traits;	chr20:44735667	chr20:44746642~44747201:+
LUAD	cis	rs1005277	1	rs1005277	ENSG00000263064.2	RP11-291L22.7	-3.55	0.000421	0.0449	-0.19	-0.16	Extrinsic epigenetic age acceleration;	chr10:37929331	chr10:38448689~38448949:+
LUAD	cis	rs17596685	1	rs17596685	ENSG00000271216.1	LINC01050	3.55	0.000421	0.0449	0.23	0.16	C-reactive protein levels;	chr13:42543065	chr13:42810366~42812562:-
LUAD	cis	rs2460905	1	rs2460903	ENSG00000251468.2	RP11-369K16.1	3.55	0.000421	0.0449	0.33	0.16	Post-traumatic stress disorder;	chr8:12976116	chr8:12958387~12962200:+
LUAD	cis	rs73230612	0.858	rs7609986	ENSG00000242767.1	ZBTB20-AS4	3.55	0.000421	0.0449	0.26	0.16	Type 2 diabetes;	chr3:115356110	chr3:115100423~115103061:+
LUAD	cis	rs1387259	0.57	rs12368659	ENSG00000257763.1	OR5BK1P	3.55	0.000421	0.0449	0.16	0.16	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48168516	chr12:48355792~48356614:-
LUAD	cis	rs7772486	0.875	rs2814875	ENSG00000235652.6	RP11-545I5.3	3.55	0.000421	0.045	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145984674	chr6:145799409~145886585:+
LUAD	cis	rs7772486	0.875	rs2814874	ENSG00000235652.6	RP11-545I5.3	3.55	0.000421	0.045	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145984759	chr6:145799409~145886585:+
LUAD	cis	rs38055	0.881	rs251525	ENSG00000247796.2	CTD-2366F13.1	-3.55	0.000421	0.045	-0.18	-0.16	Acne (severe);	chr5:53289681	chr5:53109842~53115126:+
LUAD	cis	rs1348850	0.958	rs11684320	ENSG00000213963.5	AC074286.1	3.55	0.000421	0.045	0.19	0.16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177591618	chr2:177283508~177392691:-
LUAD	cis	rs1348850	0.874	rs13013752	ENSG00000213963.5	AC074286.1	3.55	0.000421	0.045	0.19	0.16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177592134	chr2:177283508~177392691:-
LUAD	cis	rs62025270	0.547	rs338536	ENSG00000259416.2	RP11-158M2.5	-3.55	0.000421	0.045	-0.18	-0.16	Idiopathic pulmonary fibrosis;	chr15:85654009	chr15:85754941~85756237:-
LUAD	cis	rs4474465	0.85	rs10899552	ENSG00000251323.2	RP11-452H21.4	-3.55	0.000421	0.045	-0.2	-0.16	Alzheimer's disease (survival time);	chr11:78551216	chr11:78423982~78429836:-
LUAD	cis	rs11955398	0.62	rs6449512	ENSG00000215032.2	GNL3LP1	3.55	0.000421	0.045	0.2	0.16	Intelligence (multi-trait analysis);	chr5:60938415	chr5:60891935~60893577:-
LUAD	cis	rs11673344	0.704	rs510757	ENSG00000267309.1	CTD-2630F21.1	3.55	0.000422	0.045	0.2	0.16	Obesity-related traits;	chr19:36931900	chr19:36489649~36491040:+
LUAD	cis	rs11992162	0.613	rs56094399	ENSG00000255046.1	RP11-297N6.4	3.55	0.000422	0.045	0.2	0.16	Monocyte count;	chr8:11939961	chr8:11797928~11802568:-
LUAD	cis	rs2546057	0.933	rs442398	ENSG00000274104.1	CTD-2553L13.10	3.55	0.000422	0.045	0.17	0.16	Body mass index (joint analysis main effects and physical activity interaction);Major depressive disorder;Body mass index in physically active individuals;Body mass index;	chr19:33831087	chr19:34733298~34733837:-
LUAD	cis	rs6502050	0.777	rs11077969	ENSG00000266654.1	RP11-1376P16.1	3.55	0.000422	0.045	0.17	0.16	Life satisfaction;	chr17:82127757	chr17:82160056~82160452:+
LUAD	cis	rs6071166	0.683	rs722079	ENSG00000224635.1	RP4-564F22.5	-3.55	0.000422	0.045	-0.18	-0.16	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38694192	chr20:38406011~38416797:-
LUAD	cis	rs6071166	0.683	rs6027371	ENSG00000224635.1	RP4-564F22.5	-3.55	0.000422	0.045	-0.18	-0.16	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38697529	chr20:38406011~38416797:-
LUAD	cis	rs4865762	0.512	rs2897474	ENSG00000247796.2	CTD-2366F13.1	3.55	0.000422	0.045	0.18	0.16	Intraocular pressure;	chr5:53210280	chr5:53109842~53115126:+
LUAD	cis	rs2408955	0.5	rs12816820	ENSG00000273765.1	RP11-370I10.11	3.55	0.000422	0.045	0.17	0.16	Glycated hemoglobin levels;	chr12:48164542	chr12:48360920~48361377:+
LUAD	cis	rs67981189	0.858	rs221927	ENSG00000269927.1	RP6-91H8.3	-3.55	0.000422	0.045	-0.2	-0.16	Schizophrenia;	chr14:71112024	chr14:71141125~71143253:-
LUAD	cis	rs875971	1	rs709597	ENSG00000273142.1	RP11-458F8.4	3.55	0.000422	0.045	0.11	0.16	Aortic root size;	chr7:66360996	chr7:66902857~66906297:+
LUAD	cis	rs2836950	0.805	rs62223042	ENSG00000255568.3	BRWD1-AS2	-3.55	0.000422	0.045	-0.16	-0.16	Menarche (age at onset);	chr21:39311814	chr21:39313935~39314962:+
LUAD	cis	rs442309	0.875	rs224061	ENSG00000238280.1	RP11-436D10.3	-3.55	0.000422	0.045	-0.19	-0.16	Vogt-Koyanagi-Harada syndrome;	chr10:62742409	chr10:62793562~62805887:-
LUAD	cis	rs854765	0.693	rs35451946	ENSG00000264177.1	RP1-37N7.1	3.55	0.000422	0.045	0.16	0.16	Total body bone mineral density;	chr17:17860747	chr17:18379855~18388984:-
LUAD	cis	rs2980439	0.525	rs1850511	ENSG00000173295.6	FAM86B3P	3.55	0.000422	0.045	0.17	0.16	Neuroticism;	chr8:8312807	chr8:8228595~8244865:+
LUAD	cis	rs36093844	0.527	rs80333693	ENSG00000279742.1	RP11-700A24.1	-3.55	0.000422	0.045	-0.19	-0.16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86056863	chr11:85852557~85854943:-
LUAD	cis	rs3812762	0.843	rs34599227	ENSG00000254860.4	TMEM9B-AS1	3.55	0.000422	0.045	0.2	0.16	Hypospadias;	chr11:8760973	chr11:8964675~8977527:+
LUAD	cis	rs875971	0.522	rs6960048	ENSG00000234585.5	CCT6P3	3.55	0.000422	0.045	0.15	0.16	Aortic root size;	chr7:65943052	chr7:65038354~65074713:+
LUAD	cis	rs3772130	0.961	rs34667636	ENSG00000243544.3	RN7SL172P	3.55	0.000422	0.045	0.19	0.16	Cognitive performance;	chr3:121634444	chr3:121653994~121654296:-
LUAD	cis	rs2278702	0.568	rs3736420	ENSG00000259495.2	RP11-210M15.2	-3.55	0.000422	0.045	-0.27	-0.16	Bipolar disorder;	chr15:80373243	chr15:80344853~80403575:-
LUAD	cis	rs590820	0.684	rs11122450	ENSG00000227934.1	RP11-423F24.3	-3.55	0.000422	0.045	-0.18	-0.16	Metabolite levels (lipoprotein measures);	chr1:230166065	chr1:231021611~231022183:+
LUAD	cis	rs11118883	0.922	rs12726661	ENSG00000200033.1	RNU6-403P	3.55	0.000422	0.045	0.19	0.16	Colorectal cancer;	chr1:221894446	chr1:221837334~221837437:-
LUAD	cis	rs4713118	0.587	rs61471148	ENSG00000280107.1	AL022393.9	-3.55	0.000422	0.045	-0.21	-0.16	Parkinson's disease;	chr6:28069254	chr6:28170845~28172521:+
LUAD	cis	rs7618915	0.501	rs55678971	ENSG00000243224.1	RP5-1157M23.2	-3.55	0.000422	0.045	-0.16	-0.16	Bipolar disorder;	chr3:52683213	chr3:52239258~52241097:+
LUAD	cis	rs8085804	0.597	rs10163713	ENSG00000276174.1	RP11-687E1.2	-3.55	0.000422	0.045	-0.22	-0.16	Cognitive performance;	chr18:42642832	chr18:42052705~42053030:+
LUAD	cis	rs950881	0.867	rs56179005	ENSG00000234389.1	AC007278.3	3.55	0.000422	0.045	0.19	0.16	Allergy;	chr2:102357868	chr2:102438713~102440475:+
LUAD	cis	rs875971	0.522	rs1701760	ENSG00000273142.1	RP11-458F8.4	-3.55	0.000422	0.045	-0.11	-0.16	Aortic root size;	chr7:66008701	chr7:66902857~66906297:+
LUAD	cis	rs6785206	0.892	rs6439143	ENSG00000242551.2	POU5F1P6	-3.55	0.000422	0.0451	-0.3	-0.16	Lymphocyte percentage of white cells;	chr3:128706289	chr3:128674735~128677005:-
LUAD	cis	rs6785206	1	rs2712370	ENSG00000242551.2	POU5F1P6	-3.55	0.000422	0.0451	-0.3	-0.16	Lymphocyte percentage of white cells;	chr3:128706361	chr3:128674735~128677005:-
LUAD	cis	rs1823913	0.614	rs6755243	ENSG00000230611.1	HMGB1P27	3.55	0.000422	0.0451	0.18	0.16	Obesity-related traits;	chr2:191269810	chr2:191174233~191174835:+
LUAD	cis	rs728616	0.867	rs61860044	ENSG00000234382.2	RP11-40F6.1	-3.55	0.000422	0.0451	-0.41	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80186782	chr10:80233664~80245367:+
LUAD	cis	rs3742264	1	rs11618062	ENSG00000235903.6	CPB2-AS1	3.55	0.000422	0.0451	0.2	0.16	Blood protein levels;	chr13:46075433	chr13:46052806~46113332:+
LUAD	cis	rs7824557	0.606	rs1047950	ENSG00000255046.1	RP11-297N6.4	-3.55	0.000423	0.0451	-0.2	-0.16	Retinal vascular caliber;	chr8:11327587	chr8:11797928~11802568:-
LUAD	cis	rs9926296	0.528	rs4785721	ENSG00000260259.1	RP11-368I7.4	-3.55	0.000423	0.0451	-0.16	-0.16	Vitiligo;	chr16:89773589	chr16:89682620~89686569:-
LUAD	cis	rs7617773	0.925	rs35942721	ENSG00000199476.1	Y_RNA	-3.55	0.000423	0.0451	-0.22	-0.16	Coronary artery disease;	chr3:48131579	chr3:48288587~48288694:+
LUAD	cis	rs526231	0.853	rs1991797	ENSG00000175749.11	EIF3KP1	3.55	0.000423	0.0451	0.21	0.16	Primary biliary cholangitis;	chr5:103286752	chr5:103032376~103033031:+
LUAD	cis	rs6689263	0.929	rs74701752	ENSG00000117242.7	PINK1-AS	3.55	0.000423	0.0451	0.35	0.16	Intelligence (multi-trait analysis);	chr1:20549183	chr1:20642657~20652193:-
LUAD	cis	rs818427	0.896	rs818429	ENSG00000279522.1	CTC-487M23.6	3.55	0.000423	0.0451	0.19	0.16	Total body bone mineral density;	chr5:112884837	chr5:112894933~112896531:+
LUAD	cis	rs6933660	0.646	rs3736176	ENSG00000219395.2	HSPA8P15	-3.55	0.000423	0.0451	-0.16	-0.16	Menarche (age at onset);	chr6:151452185	chr6:151411259~151413945:-
LUAD	cis	rs6933660	0.646	rs3816778	ENSG00000219395.2	HSPA8P15	-3.55	0.000423	0.0451	-0.16	-0.16	Menarche (age at onset);	chr6:151452218	chr6:151411259~151413945:-
LUAD	cis	rs77633900	0.892	rs1810348	ENSG00000260288.3	RP11-24M17.4	-3.55	0.000423	0.0451	-0.21	-0.16	Glioma;Non-glioblastoma glioma;	chr15:76340146	chr15:75737820~75763321:+
LUAD	cis	rs11158026	0.603	rs66820631	ENSG00000258413.1	RP11-665C16.6	-3.55	0.000423	0.0451	-0.21	-0.16	Parkinson's disease;	chr14:54998835	chr14:55262767~55272075:-
LUAD	cis	rs2436845	0.627	rs2679750	ENSG00000253669.3	KB-1732A1.1	-3.55	0.000423	0.0451	-0.19	-0.16	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102848164	chr8:102805517~102809971:+
LUAD	cis	rs494562	0.892	rs617483	ENSG00000234155.1	RP11-30P6.6	-3.55	0.000423	0.0451	-0.31	-0.16	Metabolic traits;Blood metabolite levels;	chr6:85414290	chr6:85387219~85390186:-
LUAD	cis	rs6878284	0.542	rs841930	ENSG00000250682.4	LINC00491	-3.55	0.000423	0.0451	-0.17	-0.16	Schizophrenia;	chr5:102290514	chr5:102609156~102671559:-
LUAD	cis	rs741668	0.641	rs9562637	ENSG00000235903.6	CPB2-AS1	-3.55	0.000423	0.0451	-0.2	-0.16	Cerebrospinal fluid clusterin levels;	chr13:46071410	chr13:46052806~46113332:+
LUAD	cis	rs11233413	1	rs11233418	ENSG00000246067.6	RAB30-AS1	3.55	0.000423	0.0451	0.17	0.16	Economic and political preferences (feminism/equality);	chr11:83017420	chr11:83072066~83106719:+
LUAD	cis	rs3126085	0.56	rs6693160	ENSG00000237975.5	FLG-AS1	3.55	0.000423	0.0451	0.27	0.16	Atopic dermatitis;	chr1:152368845	chr1:152168125~152445456:+
LUAD	cis	rs3126085	0.56	rs11204986	ENSG00000237975.5	FLG-AS1	3.55	0.000423	0.0451	0.27	0.16	Atopic dermatitis;	chr1:152369583	chr1:152168125~152445456:+
LUAD	cis	rs3126085	0.56	rs12403031	ENSG00000237975.5	FLG-AS1	3.55	0.000423	0.0451	0.27	0.16	Atopic dermatitis;	chr1:152370918	chr1:152168125~152445456:+
LUAD	cis	rs590820	0.684	rs11122456	ENSG00000227934.1	RP11-423F24.3	-3.55	0.000423	0.0451	-0.18	-0.16	Metabolite levels (lipoprotein measures);	chr1:230170220	chr1:231021611~231022183:+
LUAD	cis	rs35520189	0.591	rs12105482	ENSG00000227368.1	AC079753.5	3.55	0.000423	0.0451	0.2	0.16	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112939658	chr2:112932625~112933171:+
LUAD	cis	rs453301	0.624	rs6987558	ENSG00000253893.2	FAM85B	-3.55	0.000423	0.0451	-0.21	-0.16	Joint mobility (Beighton score);	chr8:9005011	chr8:8167819~8226614:-
LUAD	cis	rs1799955	0.554	rs1029304	ENSG00000215515.2	IFIT1P1	-3.55	0.000423	0.0451	-0.21	-0.16	LDL cholesterol levels;	chr13:32334492	chr13:32384660~32386108:+
LUAD	cis	rs38055	0.633	rs6414820	ENSG00000247796.2	CTD-2366F13.1	3.55	0.000423	0.0451	0.18	0.16	Acne (severe);	chr5:53214329	chr5:53109842~53115126:+
LUAD	cis	rs10510102	0.872	rs12240306	ENSG00000276742.1	RP11-500G22.4	3.55	0.000423	0.0451	0.27	0.16	Breast cancer;	chr10:121963391	chr10:121956782~121957098:+
LUAD	cis	rs10510102	0.872	rs12240308	ENSG00000276742.1	RP11-500G22.4	3.55	0.000423	0.0451	0.27	0.16	Breast cancer;	chr10:121963407	chr10:121956782~121957098:+
LUAD	cis	rs708547	0.624	rs1277284	ENSG00000269949.1	RP11-738E22.3	3.55	0.000423	0.0451	0.2	0.16	Response to bleomycin (chromatid breaks);	chr4:56989195	chr4:56960927~56961373:-
LUAD	cis	rs2573652	1	rs2581343	ENSG00000182397.13	DNM1P46	3.55	0.000423	0.0451	0.19	0.16	Height;	chr15:99974213	chr15:99790156~99806927:-
LUAD	cis	rs76734026	0.591	rs10148613	ENSG00000255002.1	CTD-2509G16.2	-3.55	0.000423	0.0451	-0.28	-0.16	Pediatric areal bone mineral density (radius);	chr14:65248320	chr14:65212893~65222347:-
LUAD	cis	rs198389	0.589	rs12404124	ENSG00000242349.4	NPPA-AS1	-3.55	0.000423	0.0451	-0.16	-0.16	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11813812	chr1:11841017~11848079:+
LUAD	cis	rs6471393	1	rs6997642	ENSG00000253848.1	RP11-10N23.5	-3.55	0.000423	0.0451	-0.2	-0.16	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93703737	chr8:93741193~93744534:+
LUAD	cis	rs6871536	1	rs2897443	ENSG00000233006.5	AC034220.3	3.55	0.000423	0.0451	0.18	0.16	Asthma (childhood onset);	chr5:132593902	chr5:132311285~132369916:-
LUAD	cis	rs12681366	0.563	rs6999103	ENSG00000253704.1	RP11-267M23.4	3.55	0.000423	0.0451	0.2	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94470309	chr8:94553722~94569745:+
LUAD	cis	rs9951698	0.678	rs1786263	ENSG00000266969.1	RP11-773H22.4	3.55	0.000423	0.0451	0.21	0.16	Intelligence (multi-trait analysis);	chr18:13116433	chr18:12984694~12991173:-
LUAD	cis	rs4938303	0.633	rs77835865	ENSG00000254851.1	RP11-109L13.1	3.55	0.000423	0.0451	0.24	0.16	Triglycerides;	chr11:116684713	chr11:117135528~117138582:+
LUAD	cis	rs1799949	1	rs35956818	ENSG00000267340.1	RP11-242D8.3	3.55	0.000423	0.0451	0.17	0.16	Menopause (age at onset);	chr17:43345617	chr17:43169880~43170077:-
LUAD	cis	rs6832769	1	rs11726609	ENSG00000272969.1	RP11-528I4.2	3.55	0.000423	0.0451	0.17	0.16	Personality dimensions;	chr4:55534702	chr4:55547112~55547889:+
LUAD	cis	rs924712	0.545	rs12203709	ENSG00000261116.1	RP3-523K23.2	3.55	0.000423	0.0451	0.17	0.16	Breast cancer;	chr6:54842819	chr6:54943167~54945099:+
LUAD	cis	rs6496932	0.663	rs7183764	ENSG00000259630.2	CTD-2262B20.1	-3.55	0.000423	0.0451	-0.2	-0.16	Central corneal thickness;Corneal structure;	chr15:85359820	chr15:85415228~85415633:+
LUAD	cis	rs6496932	0.663	rs4842878	ENSG00000259630.2	CTD-2262B20.1	-3.55	0.000423	0.0451	-0.2	-0.16	Central corneal thickness;Corneal structure;	chr15:85361001	chr15:85415228~85415633:+
LUAD	cis	rs6088590	0.648	rs6059991	ENSG00000276073.1	RP5-1125A11.7	-3.55	0.000423	0.0451	-0.16	-0.16	Coronary artery disease;	chr20:34693032	chr20:33985617~33988989:-
LUAD	cis	rs2273156	0.57	rs2010648	ENSG00000258704.4	SRP54-AS1	-3.55	0.000423	0.0451	-0.24	-0.16	Immunoglobulin light chain (AL) amyloidosis;	chr14:35135686	chr14:34920858~34982532:-
LUAD	cis	rs523522	0.962	rs687873	ENSG00000278344.1	RP11-18C24.8	3.55	0.000423	0.0451	0.22	0.16	High light scatter reticulocyte count;	chr12:120581831	chr12:120500735~120501090:-
LUAD	cis	rs523522	0.962	rs670568	ENSG00000278344.1	RP11-18C24.8	3.55	0.000423	0.0451	0.22	0.16	High light scatter reticulocyte count;	chr12:120583403	chr12:120500735~120501090:-
LUAD	cis	rs910316	0.737	rs175071	ENSG00000279594.1	RP11-950C14.10	-3.55	0.000424	0.0451	-0.18	-0.16	Height;	chr14:75031474	chr14:75011269~75012851:-
LUAD	cis	rs6137287	0.667	rs2296728	ENSG00000227063.5	RPL41P1	-3.55	0.000424	0.0451	-0.21	-0.16	Height;	chr20:21326469	chr20:21755270~21755350:+
LUAD	cis	rs73198271	0.71	rs3827808	ENSG00000233609.3	RP11-62H7.2	-3.55	0.000424	0.0451	-0.13	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8821847	chr8:8961200~8979025:+
LUAD	cis	rs2702164	1	rs2943754	ENSG00000240661.1	RP11-174O3.3	-3.55	0.000424	0.0451	-0.19	-0.16	Gut microbiome composition (winter);	chr3:120370040	chr3:120349510~120367998:+
LUAD	cis	rs1799949	1	rs11659028	ENSG00000267340.1	RP11-242D8.3	3.55	0.000424	0.0451	0.17	0.16	Menopause (age at onset);	chr17:43043008	chr17:43169880~43170077:-
LUAD	cis	rs1150668	0.764	rs9368565	ENSG00000176933.5	TOB2P1	3.55	0.000424	0.0451	0.18	0.16	Pubertal anthropometrics;	chr6:28377433	chr6:28217643~28218634:-
LUAD	cis	rs1150668	0.796	rs1052215	ENSG00000176933.5	TOB2P1	3.55	0.000424	0.0451	0.18	0.16	Pubertal anthropometrics;	chr6:28380381	chr6:28217643~28218634:-
LUAD	cis	rs11773103	0.881	rs73204826	ENSG00000224046.1	AC005076.5	3.55	0.000424	0.0451	0.25	0.16	Bipolar disorder or major depressive disorder (combined);	chr7:87144942	chr7:87151423~87152420:-
LUAD	cis	rs7107174	1	rs2512532	ENSG00000251323.2	RP11-452H21.4	3.55	0.000424	0.0451	0.21	0.16	Testicular germ cell tumor;	chr11:78257595	chr11:78423982~78429836:-
LUAD	cis	rs10197140	0.857	rs932076	ENSG00000227992.1	AC108463.2	-3.55	0.000424	0.0452	-0.19	-0.16	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110863663	chr2:111203964~111206215:-
LUAD	cis	rs321358	1	rs321358	ENSG00000271390.1	RP11-89C3.3	3.55	0.000424	0.0452	0.26	0.16	Body mass index;	chr11:111125247	chr11:111089870~111090368:-
LUAD	cis	rs2024714	0.967	rs2427198	ENSG00000273812.1	WI2-87327B8.2	-3.55	0.000424	0.0452	-0.17	-0.16	Longevity;	chr20:61629624	chr20:62596732~62603115:-
LUAD	cis	rs2024714	0.967	rs6089442	ENSG00000273812.1	WI2-87327B8.2	-3.55	0.000424	0.0452	-0.17	-0.16	Longevity;	chr20:61630002	chr20:62596732~62603115:-
LUAD	cis	rs2024714	0.967	rs1002761	ENSG00000273812.1	WI2-87327B8.2	-3.55	0.000424	0.0452	-0.17	-0.16	Longevity;	chr20:61630231	chr20:62596732~62603115:-
LUAD	cis	rs757081	0.671	rs214072	ENSG00000260196.1	RP1-239B22.5	-3.55	0.000424	0.0452	-0.22	-0.16	Systolic blood pressure;	chr11:17283723	chr11:17380649~17383531:+
LUAD	cis	rs757081	0.671	rs214070	ENSG00000260196.1	RP1-239B22.5	-3.55	0.000424	0.0452	-0.22	-0.16	Systolic blood pressure;	chr11:17283770	chr11:17380649~17383531:+
LUAD	cis	rs2880765	0.566	rs17553249	ENSG00000259630.2	CTD-2262B20.1	-3.55	0.000424	0.0452	-0.18	-0.16	Coronary artery disease;	chr15:85463463	chr15:85415228~85415633:+
LUAD	cis	rs4253311	0.547	rs7377304	ENSG00000251165.4	F11-AS1	-3.55	0.000424	0.0452	-0.18	-0.16	Plasma renin activity levels;Blood metabolite levels;Circulating chromogranin peptide levels;	chr4:186208626	chr4:186286094~186500997:-
LUAD	cis	rs1979679	0.573	rs4930825	ENSG00000278733.1	RP11-425D17.1	-3.55	0.000424	0.0452	-0.21	-0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28574174	chr12:28185625~28186190:-
LUAD	cis	rs1979679	0.541	rs4931085	ENSG00000278733.1	RP11-425D17.1	-3.55	0.000424	0.0452	-0.21	-0.16	Ossification of the posterior longitudinal ligament of the spine;	chr12:28574577	chr12:28185625~28186190:-
LUAD	cis	rs2662776	1	rs10753607	ENSG00000232995.6	RGS5	3.55	0.000424	0.0452	0.14	0.16	Lead levels in blood;	chr1:163189038	chr1:163244505~163321894:-
LUAD	cis	rs2274273	0.87	rs8021583	ENSG00000258413.1	RP11-665C16.6	-3.55	0.000424	0.0452	-0.21	-0.16	Protein biomarker;	chr14:55282889	chr14:55262767~55272075:-
LUAD	cis	rs4474465	1	rs10899533	ENSG00000251323.2	RP11-452H21.4	-3.55	0.000424	0.0452	-0.2	-0.16	Alzheimer's disease (survival time);	chr11:78497434	chr11:78423982~78429836:-
LUAD	cis	rs42490	0.576	rs390536	ENSG00000251136.7	RP11-37B2.1	-3.55	0.000424	0.0452	-0.18	-0.16	Leprosy;	chr8:89857122	chr8:89609409~89757727:-
LUAD	cis	rs1005224	0.963	rs11626062	ENSG00000242952.1	RP11-187O7.1	-3.55	0.000424	0.0452	-0.15	-0.16	Large artery stroke;	chr14:75669986	chr14:76634775~76635661:-
LUAD	cis	rs8031584	0.781	rs4779498	ENSG00000259845.1	HERC2P10	3.55	0.000424	0.0452	0.19	0.16	Huntington's disease progression;	chr15:30885273	chr15:30815271~30844153:+
LUAD	cis	rs12681366	0.881	rs12682038	ENSG00000254057.1	RP3-388N13.3	3.55	0.000424	0.0452	0.17	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94393252	chr8:93834454~93846743:-
LUAD	cis	rs8028182	0.636	rs7171507	ENSG00000246877.1	DNM1P35	3.55	0.000424	0.0452	0.21	0.16	Sudden cardiac arrest;	chr15:75444946	chr15:75727670~75738623:-
LUAD	cis	rs1910358	0.69	rs1948768	ENSG00000248874.4	C5orf17	-3.55	0.000424	0.0452	-0.2	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23953216	chr5:23951348~24178263:+
LUAD	cis	rs11951515	0.508	rs11958046	ENSG00000248240.1	RP11-159F24.5	-3.55	0.000424	0.0452	-0.17	-0.16	Metabolite levels  (X-11787);	chr5:43583287	chr5:43515274~43525310:+
LUAD	cis	rs9921338	0.961	rs7193278	ENSG00000263080.1	RP11-485G7.5	3.55	0.000424	0.0452	0.21	0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11351974	chr16:11341809~11345211:-
LUAD	cis	rs797680	0.856	rs531358	ENSG00000223745.6	RP4-717I23.3	3.55	0.000424	0.0452	0.12	0.16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93210454	chr1:93262186~93346025:-
LUAD	cis	rs797680	0.786	rs555161	ENSG00000223745.6	RP4-717I23.3	3.55	0.000424	0.0452	0.12	0.16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93210757	chr1:93262186~93346025:-
LUAD	cis	rs797680	0.856	rs2765545	ENSG00000223745.6	RP4-717I23.3	3.55	0.000424	0.0452	0.12	0.16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93211712	chr1:93262186~93346025:-
LUAD	cis	rs797680	0.856	rs627779	ENSG00000223745.6	RP4-717I23.3	-3.55	0.000424	0.0452	-0.12	-0.16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93218532	chr1:93262186~93346025:-
LUAD	cis	rs797680	0.796	rs797661	ENSG00000223745.6	RP4-717I23.3	-3.55	0.000424	0.0452	-0.12	-0.16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93221534	chr1:93262186~93346025:-
LUAD	cis	rs10829156	0.898	rs4748504	ENSG00000240291.1	RP11-499P20.2	3.55	0.000424	0.0452	0.14	0.16	Sudden cardiac arrest;	chr10:18651868	chr10:18513115~18545651:-
LUAD	cis	rs7210086	0.948	rs72849448	ENSG00000263893.2	CTD-3010D24.3	3.55	0.000424	0.0452	0.24	0.16	Ulcerative colitis;	chr17:72642184	chr17:72642731~72644490:+
LUAD	cis	rs2024714	0.967	rs1002760	ENSG00000273812.1	WI2-87327B8.2	-3.55	0.000424	0.0452	-0.17	-0.16	Longevity;	chr20:61630418	chr20:62596732~62603115:-
LUAD	cis	rs4792901	0.797	rs118013810	ENSG00000198496.9	NBR2	3.55	0.000425	0.0452	0.18	0.16	Dupuytren's disease;	chr17:43548776	chr17:43125610~43153671:+
LUAD	cis	rs4792901	0.797	rs117711821	ENSG00000198496.9	NBR2	3.55	0.000425	0.0452	0.18	0.16	Dupuytren's disease;	chr17:43548777	chr17:43125610~43153671:+
LUAD	cis	rs4792901	0.959	rs72833147	ENSG00000198496.9	NBR2	3.55	0.000425	0.0452	0.18	0.16	Dupuytren's disease;	chr17:43549210	chr17:43125610~43153671:+
LUAD	cis	rs9921338	0.887	rs9926136	ENSG00000262703.1	RP11-485G7.6	-3.55	0.000425	0.0452	-0.17	-0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11343418	chr16:11348143~11349321:-
LUAD	cis	rs4727963	0.846	rs4574772	ENSG00000240499.6	RP5-1101C3.1	3.55	0.000425	0.0452	0.14	0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);	chr7:123061483	chr7:122328469~122440388:+
LUAD	cis	rs10490626	0.808	rs66492574	ENSG00000236255.1	AC009404.2	-3.55	0.000425	0.0452	-0.3	-0.16	LDL cholesterol;Cholesterol, total;	chr2:117868296	chr2:117833937~117841658:+
LUAD	cis	rs12149074	0.527	rs4500745	ENSG00000261390.4	RP11-345M22.2	-3.55	0.000425	0.0452	-0.22	-0.16	Bipolar disorder and eating disorder;Eating disorder in bipolar disorder;	chr16:80066107	chr16:79715232~79770563:-
LUAD	cis	rs6531209	0.888	rs975950	ENSG00000234378.1	AC098828.2	3.55	0.000425	0.0452	0.24	0.16	Amyotrophic lateral sclerosis (sporadic);	chr2:20131367	chr2:20063856~20106829:-
LUAD	cis	rs7772486	0.875	rs2474356	ENSG00000235652.6	RP11-545I5.3	3.55	0.000425	0.0452	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145975662	chr6:145799409~145886585:+
LUAD	cis	rs6543140	0.601	rs7558013	ENSG00000234389.1	AC007278.3	3.55	0.000425	0.0452	0.19	0.16	Blood protein levels;	chr2:102376346	chr2:102438713~102440475:+
LUAD	cis	rs2007126	0.706	rs1472686	ENSG00000224797.1	RP11-57C19.6	-3.55	0.000425	0.0452	-0.28	-0.16	LDL peak particle diameter (total fat intake interaction);	chr9:129965348	chr9:130724786~130725050:-
LUAD	cis	rs2837828	1	rs1076569	ENSG00000226496.2	LINC00323	3.55	0.000425	0.0452	0.2	0.16	Neutrophil count;	chr21:40803871	chr21:41141493~41148133:-
LUAD	cis	rs9926664	0.584	rs8058904	ENSG00000274134.1	MIR6774	3.55	0.000425	0.0452	0.22	0.16	Neutrophil count;Sum basophil neutrophil counts;	chr16:85918076	chr16:85918347~85918416:+
LUAD	cis	rs615134	0.52	rs111436404	ENSG00000234608.6	MAPKAPK5-AS1	3.55	0.000425	0.0452	0.25	0.16	Mean corpuscular volume;	chr12:111978990	chr12:111839764~111842902:-
LUAD	cis	rs911555	0.723	rs4906324	ENSG00000259775.1	RP11-45P15.4	3.55	0.000425	0.0452	0.21	0.16	Intelligence (multi-trait analysis);	chr14:103456762	chr14:103331674~103332367:-
LUAD	cis	rs911555	0.723	rs2273701	ENSG00000259775.1	RP11-45P15.4	3.55	0.000425	0.0452	0.21	0.16	Intelligence (multi-trait analysis);	chr14:103456888	chr14:103331674~103332367:-
LUAD	cis	rs6751744	0.855	rs1425045	ENSG00000230783.1	AC009961.2	-3.55	0.000425	0.0452	-0.21	-0.16	Dysphagia;	chr2:159508236	chr2:159689217~159690291:-
LUAD	cis	rs9467773	0.596	rs3001369	ENSG00000241549.7	GUSBP2	3.55	0.000425	0.0452	0.18	0.16	Intelligence (multi-trait analysis);	chr6:26670741	chr6:26871484~26956554:-
LUAD	cis	rs4667682	0.529	rs17285541	ENSG00000228507.1	DAP3P2	-3.55	0.000425	0.0452	-0.33	-0.16	Hippocampal atrophy;Body mass index;	chr2:171362887	chr2:171491422~171491931:+
LUAD	cis	rs17711722	0.727	rs2658585	ENSG00000273142.1	RP11-458F8.4	-3.55	0.000425	0.0452	-0.11	-0.16	Calcium levels;	chr7:65996954	chr7:66902857~66906297:+
LUAD	cis	rs4423214	0.84	rs4435028	ENSG00000226627.1	SHANK2-AS1	3.55	0.000425	0.0452	0.2	0.16	Vitamin D levels;	chr11:71472644	chr11:70631094~70635490:+
LUAD	cis	rs4423214	0.802	rs4616066	ENSG00000226627.1	SHANK2-AS1	3.55	0.000425	0.0452	0.2	0.16	Vitamin D levels;	chr11:71472800	chr11:70631094~70635490:+
LUAD	cis	rs4423214	0.802	rs4402322	ENSG00000226627.1	SHANK2-AS1	3.55	0.000425	0.0452	0.2	0.16	Vitamin D levels;	chr11:71472969	chr11:70631094~70635490:+
LUAD	cis	rs4423214	0.802	rs2276358	ENSG00000226627.1	SHANK2-AS1	3.55	0.000425	0.0452	0.2	0.16	Vitamin D levels;	chr11:71473452	chr11:70631094~70635490:+
LUAD	cis	rs4423214	0.84	rs3794057	ENSG00000226627.1	SHANK2-AS1	3.55	0.000425	0.0452	0.2	0.16	Vitamin D levels;	chr11:71475698	chr11:70631094~70635490:+
LUAD	cis	rs4423214	0.84	rs2017686	ENSG00000226627.1	SHANK2-AS1	3.55	0.000425	0.0452	0.2	0.16	Vitamin D levels;	chr11:71476015	chr11:70631094~70635490:+
LUAD	cis	rs4835473	0.897	rs6835827	ENSG00000249741.2	RP11-673E1.3	-3.55	0.000425	0.0452	-0.19	-0.16	Immature fraction of reticulocytes;	chr4:143712803	chr4:143911514~143912053:-
LUAD	cis	rs34779708	0.931	rs79749947	ENSG00000271335.4	RP11-324I22.4	3.55	0.000425	0.0452	0.17	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:34988153	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.931	rs9663401	ENSG00000271335.4	RP11-324I22.4	3.55	0.000425	0.0452	0.17	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:34989921	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.897	rs9787566	ENSG00000271335.4	RP11-324I22.4	3.55	0.000425	0.0452	0.17	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:34990527	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.931	rs4351760	ENSG00000271335.4	RP11-324I22.4	3.55	0.000425	0.0452	0.17	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:34991326	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.898	rs4934695	ENSG00000271335.4	RP11-324I22.4	3.55	0.000425	0.0452	0.17	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:34991677	chr10:35314552~35336401:-
LUAD	cis	rs7870753	0.73	rs2897257	ENSG00000188801.9	ZNF322P1	3.55	0.000425	0.0452	0.22	0.16	Height;	chr9:96402234	chr9:97198303~97199511:-
LUAD	cis	rs1401999	0.69	rs6768149	ENSG00000223882.1	ABCC5-AS1	-3.55	0.000425	0.0452	-0.17	-0.16	Anterior chamber depth;	chr3:183918407	chr3:184006338~184011419:+
LUAD	cis	rs17695224	0.545	rs7252508	ENSG00000269483.1	AC006272.1	3.55	0.000425	0.0452	0.17	0.16	HDL cholesterol;HDL cholesterol levels;	chr19:51831530	chr19:51839924~51843324:-
LUAD	cis	rs365302	1	rs294920	ENSG00000235086.1	FNDC1-IT1	3.55	0.000425	0.0453	0.21	0.16	Coronary heart disease;	chr6:159201770	chr6:159240786~159243329:+
LUAD	cis	rs755249	0.567	rs61779284	ENSG00000182109.6	RP11-69E11.4	3.55	0.000425	0.0453	0.2	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39389505	chr1:39522280~39546187:-
LUAD	cis	rs2354432	0.556	rs34602039	ENSG00000237188.3	RP11-337C18.8	3.55	0.000425	0.0453	0.29	0.16	Mitochondrial DNA levels;	chr1:147379251	chr1:147172771~147211568:+
LUAD	cis	rs62025270	0.688	rs17575870	ENSG00000259416.2	RP11-158M2.5	-3.55	0.000425	0.0453	-0.21	-0.16	Idiopathic pulmonary fibrosis;	chr15:85713926	chr15:85754941~85756237:-
LUAD	cis	rs2985684	1	rs8014170	ENSG00000278009.1	RP11-649E7.8	3.55	0.000425	0.0453	0.22	0.16	Carotid intima media thickness;	chr14:49604976	chr14:49601011~49601124:-
LUAD	cis	rs6951245	0.938	rs11764937	ENSG00000199023.2	MIR339	-3.55	0.000425	0.0453	-0.27	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1052438	chr7:1022935~1023045:-
LUAD	cis	rs11158026	0.567	rs61224609	ENSG00000258413.1	RP11-665C16.6	-3.55	0.000425	0.0453	-0.22	-0.16	Parkinson's disease;	chr14:54936490	chr14:55262767~55272075:-
LUAD	cis	rs683250	0.629	rs680562	ENSG00000246067.6	RAB30-AS1	3.55	0.000425	0.0453	0.17	0.16	Subcortical brain region volumes;	chr11:83237847	chr11:83072066~83106719:+
LUAD	cis	rs10896135	0.526	rs624561	ENSG00000213409.4	RP11-658F2.3	3.55	0.000425	0.0453	0.22	0.16	Bipolar disorder;	chr11:66647444	chr11:66761575~66762399:-
LUAD	cis	rs71520386	0.807	rs10263435	ENSG00000228649.7	AC005682.5	-3.55	0.000425	0.0453	-0.24	-0.16	Fibrinogen levels;	chr7:22790243	chr7:22854178~22861579:+
LUAD	cis	rs2836950	0.565	rs2836934	ENSG00000232608.1	TIMM9P2	3.55	0.000425	0.0453	0.18	0.16	Menarche (age at onset);	chr21:39192959	chr21:39216624~39217506:+
LUAD	cis	rs12073837	0.784	rs61830288	ENSG00000272823.1	RP11-295M18.6	-3.55	0.000425	0.0453	-0.2	-0.16	F-cell distribution;	chr1:220815399	chr1:220828676~220829211:-
LUAD	cis	rs4664293	0.867	rs1126842	ENSG00000230783.1	AC009961.2	-3.55	0.000425	0.0453	-0.2	-0.16	Monocyte percentage of white cells;	chr2:159770806	chr2:159689217~159690291:-
LUAD	cis	rs2299587	0.554	rs13253029	ENSG00000253671.1	RP11-806O11.1	-3.55	0.000426	0.0453	-0.16	-0.16	Economic and political preferences;	chr8:17892113	chr8:17808941~17820868:+
LUAD	cis	rs11089937	0.626	rs5757013	ENSG00000211640.3	IGLV6-57	3.55	0.000426	0.0453	0.12	0.16	Periodontitis (PAL4Q3);	chr22:22135544	chr22:22195713~22196460:+
LUAD	cis	rs2638953	0.924	rs10843139	ENSG00000278733.1	RP11-425D17.1	-3.55	0.000426	0.0453	-0.21	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28227160	chr12:28185625~28186190:-
LUAD	cis	rs2011013	1	rs2011013	ENSG00000259570.1	RP11-671M22.4	-3.55	0.000426	0.0453	-0.2	-0.16	Sitting height ratio;	chr15:83957014	chr15:84394512~84395514:+
LUAD	cis	rs875971	0.66	rs7807930	ENSG00000273142.1	RP11-458F8.4	3.55	0.000426	0.0453	0.11	0.16	Aortic root size;	chr7:66622178	chr7:66902857~66906297:+
LUAD	cis	rs875971	0.66	rs7807944	ENSG00000273142.1	RP11-458F8.4	3.55	0.000426	0.0453	0.11	0.16	Aortic root size;	chr7:66622208	chr7:66902857~66906297:+
LUAD	cis	rs7181230	0.961	rs7183977	ENSG00000278621.1	CTD-2033D15.3	-3.55	0.000426	0.0453	-0.19	-0.16	Dehydroepiandrosterone sulphate levels;	chr15:40084891	chr15:39588357~39588882:-
LUAD	cis	rs875971	0.545	rs35459055	ENSG00000222364.1	RNU6-96P	-3.55	0.000426	0.0453	-0.2	-0.16	Aortic root size;	chr7:66479399	chr7:66395191~66395286:+
LUAD	cis	rs6860806	0.631	rs6863548	ENSG00000263597.1	MIR3936	3.55	0.000426	0.0453	0.16	0.16	Breast cancer;	chr5:132240227	chr5:132365490~132365599:-
LUAD	cis	rs950881	0.932	rs72823632	ENSG00000234389.1	AC007278.3	3.55	0.000426	0.0453	0.2	0.16	Allergy;	chr2:102315074	chr2:102438713~102440475:+
LUAD	cis	rs950881	0.932	rs72823635	ENSG00000234389.1	AC007278.3	3.55	0.000426	0.0453	0.2	0.16	Allergy;	chr2:102315152	chr2:102438713~102440475:+
LUAD	cis	rs950881	0.932	rs10179458	ENSG00000234389.1	AC007278.3	3.55	0.000426	0.0453	0.2	0.16	Allergy;	chr2:102318514	chr2:102438713~102440475:+
LUAD	cis	rs6472827	0.645	rs2977067	ENSG00000253983.2	RP1-16A9.1	3.55	0.000426	0.0453	0.23	0.16	Uterine fibroids;	chr8:74190596	chr8:74199396~74208441:+
LUAD	cis	rs4290173	0.85	rs28701508	ENSG00000231345.3	BEND3P1	-3.55	0.000426	0.0453	-0.36	-0.16	Narcolepsy with cataplexy;	chr10:50900405	chr10:50655967~50660472:+
LUAD	cis	rs9549260	0.755	rs4943797	ENSG00000229456.1	RLIMP1	-3.55	0.000426	0.0453	-0.17	-0.16	Red blood cell count;	chr13:40627496	chr13:40618738~40621348:+
LUAD	cis	rs6121246	0.909	rs6119729	ENSG00000230613.1	HM13-AS1	-3.55	0.000426	0.0453	-0.23	-0.16	Mean corpuscular hemoglobin;	chr20:31825360	chr20:31567707~31573263:-
LUAD	cis	rs6921919	0.583	rs9468370	ENSG00000219392.1	RP1-265C24.5	-3.55	0.000426	0.0453	-0.2	-0.16	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28115628~28116551:+
LUAD	cis	rs8034595	0.508	rs2018118	ENSG00000275322.1	RP11-262A16.1	3.55	0.000426	0.0453	0.24	0.16	Optic disc area;	chr15:96182803	chr15:96342953~96345651:+
LUAD	cis	rs12681963	0.623	rs2340418	ENSG00000272375.1	RP11-51J9.6	-3.55	0.000426	0.0453	-0.21	-0.16	Migraine;	chr8:30040190	chr8:30197404~30198048:+
LUAD	cis	rs9900280	1	rs2586150	ENSG00000264808.1	RP11-802D6.1	-3.55	0.000426	0.0453	-0.19	-0.16	Mean platelet volume;	chr17:29501674	chr17:29369717~29390777:-
LUAD	cis	rs8014204	0.753	rs6574199	ENSG00000279594.1	RP11-950C14.10	-3.55	0.000426	0.0453	-0.18	-0.16	Caffeine consumption;	chr14:74889400	chr14:75011269~75012851:-
LUAD	cis	rs6964587	1	rs6465343	ENSG00000188693.7	CYP51A1-AS1	-3.55	0.000426	0.0453	-0.19	-0.16	Breast cancer;	chr7:91988894	chr7:92134604~92180725:+
LUAD	cis	rs4423214	0.84	rs1792235	ENSG00000226627.1	SHANK2-AS1	3.55	0.000426	0.0454	0.2	0.16	Vitamin D levels;	chr11:71470427	chr11:70631094~70635490:+
LUAD	cis	rs4423214	0.84	rs1619577	ENSG00000226627.1	SHANK2-AS1	3.55	0.000426	0.0454	0.2	0.16	Vitamin D levels;	chr11:71470439	chr11:70631094~70635490:+
LUAD	cis	rs4423214	0.84	rs1792234	ENSG00000226627.1	SHANK2-AS1	3.55	0.000426	0.0454	0.2	0.16	Vitamin D levels;	chr11:71470972	chr11:70631094~70635490:+
LUAD	cis	rs8141529	0.702	rs469990	ENSG00000272858.1	CTA-292E10.8	-3.55	0.000426	0.0454	-0.18	-0.16	Lymphocyte counts;	chr22:28908212	chr22:28814914~28815662:+
LUAD	cis	rs10483853	0.747	rs2333193	ENSG00000258695.2	RP3-414A15.2	-3.55	0.000427	0.0454	-0.2	-0.16	Coronary artery calcification;	chr14:73285359	chr14:73522878~73530610:+
LUAD	cis	rs4218	0.517	rs71480503	ENSG00000277144.1	RP11-59H7.4	-3.55	0.000427	0.0454	-0.21	-0.16	Social communication problems;	chr15:59098246	chr15:59115547~59116089:-
LUAD	cis	rs9291683	0.679	rs13137795	ENSG00000250413.1	RP11-448G15.1	-3.55	0.000427	0.0454	-0.21	-0.16	Bone mineral density;	chr4:10049882	chr4:10006482~10009725:+
LUAD	cis	rs7474896	0.559	rs11594904	ENSG00000151963.4	RP11-775A3.1	3.55	0.000427	0.0454	0.22	0.16	Obesity (extreme);	chr10:37558634	chr10:37883594~37884109:+
LUAD	cis	rs10508774	0.81	rs12251853	ENSG00000231245.2	C1DP1	-3.55	0.000427	0.0454	-0.38	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32661922	chr10:32511336~32511737:-
LUAD	cis	rs10508774	0.81	rs10218979	ENSG00000231245.2	C1DP1	-3.55	0.000427	0.0454	-0.38	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32663101	chr10:32511336~32511737:-
LUAD	cis	rs10508774	1	rs10159499	ENSG00000231245.2	C1DP1	-3.55	0.000427	0.0454	-0.38	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32664630	chr10:32511336~32511737:-
LUAD	cis	rs11148252	0.774	rs6561666	ENSG00000273784.3	RP11-78J21.7	-3.55	0.000427	0.0454	-0.18	-0.16	Lewy body disease;	chr13:52355910	chr13:52600042~52642542:+
LUAD	cis	rs4380275	0.782	rs11691064	ENSG00000231482.2	AC141930.2	-3.55	0.000427	0.0454	-0.19	-0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:755718	chr2:1572554~1580311:-
LUAD	cis	rs6502050	0.799	rs11491185	ENSG00000266654.1	RP11-1376P16.1	-3.55	0.000427	0.0454	-0.17	-0.16	Life satisfaction;	chr17:82193225	chr17:82160056~82160452:+
LUAD	cis	rs6502050	0.835	rs56095560	ENSG00000266654.1	RP11-1376P16.1	-3.55	0.000427	0.0454	-0.17	-0.16	Life satisfaction;	chr17:82193428	chr17:82160056~82160452:+
LUAD	cis	rs9595908	0.746	rs1029306	ENSG00000281026.1	N4BP2L2-IT2	-3.55	0.000427	0.0454	-0.1	-0.16	Body mass index;	chr13:32707695	chr13:32504506~32509395:-
LUAD	cis	rs858239	0.698	rs4265084	ENSG00000230042.1	AK3P3	-3.55	0.000427	0.0454	-0.2	-0.16	Cerebrospinal fluid biomarker levels;	chr7:23367621	chr7:23129178~23129841:+
LUAD	cis	rs6430585	0.591	rs75223002	ENSG00000226806.1	AC011893.3	3.55	0.000427	0.0454	0.25	0.16	Corneal structure;	chr2:135767739	chr2:135820191~135823087:+
LUAD	cis	rs6430585	0.702	rs2304601	ENSG00000226806.1	AC011893.3	3.55	0.000427	0.0454	0.25	0.16	Corneal structure;	chr2:135770464	chr2:135820191~135823087:+
LUAD	cis	rs6430585	0.759	rs12467770	ENSG00000226806.1	AC011893.3	3.55	0.000427	0.0454	0.25	0.16	Corneal structure;	chr2:135778525	chr2:135820191~135823087:+
LUAD	cis	rs34421088	0.56	rs2467520	ENSG00000255046.1	RP11-297N6.4	3.55	0.000427	0.0454	0.2	0.16	Neuroticism;	chr8:11541444	chr8:11797928~11802568:-
LUAD	cis	rs701145	0.585	rs1620712	ENSG00000243069.6	ARHGEF26-AS1	3.55	0.000427	0.0454	0.25	0.16	Coronary artery disease;	chr3:154072261	chr3:154024401~154121332:-
LUAD	cis	rs4819052	0.851	rs2838865	ENSG00000223768.1	LINC00205	-3.55	0.000427	0.0454	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45292384	chr21:45293285~45297354:+
LUAD	cis	rs4763879	0.593	rs7960328	ENSG00000214776.8	RP11-726G1.1	-3.55	0.000427	0.0454	-0.18	-0.16	Type 1 diabetes;	chr12:9699584	chr12:9467552~9576275:+
LUAD	cis	rs57996174	0.92	rs4817576	ENSG00000233956.1	BTF3P6	3.55	0.000427	0.0454	0.3	0.16	Psoriasis;	chr21:33492118	chr21:33518610~33519108:-
LUAD	cis	rs4788196	1	rs4788196	ENSG00000214725.6	CDIPT-AS1	-3.55	0.000427	0.0454	-0.18	-0.16	Pubertal anthropometrics;	chr16:29956113	chr16:29863593~29868053:+
LUAD	cis	rs9650657	0.648	rs7833945	ENSG00000255046.1	RP11-297N6.4	3.55	0.000427	0.0454	0.2	0.16	Neuroticism;	chr8:10842756	chr8:11797928~11802568:-
LUAD	cis	rs10785571	0.596	rs2408315	ENSG00000275481.1	RP11-474P2.6	3.55	0.000427	0.0454	0.14	0.16	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr12:45446156	chr12:46388856~46392126:+
LUAD	cis	rs394563	0.601	rs367133	ENSG00000216906.2	RP11-350J20.9	3.55	0.000427	0.0454	0.2	0.16	Dupuytren's disease;	chr6:149476584	chr6:149904243~149906418:+
LUAD	cis	rs964184	0.554	rs7118999	ENSG00000254851.1	RP11-109L13.1	-3.55	0.000427	0.0454	-0.21	-0.16	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116774559	chr11:117135528~117138582:+
LUAD	cis	rs3743162	1	rs12909280	ENSG00000259728.4	LINC00933	3.55	0.000427	0.0454	0.25	0.16	Alzheimer's disease (age of onset);	chr15:84886125	chr15:84570649~84580175:+
LUAD	cis	rs7615952	0.688	rs12638240	ENSG00000241288.6	RP11-379B18.5	-3.55	0.000427	0.0454	-0.2	-0.16	Blood pressure (smoking interaction);	chr3:125822395	chr3:125827238~125916384:-
LUAD	cis	rs4835473	0.932	rs13134808	ENSG00000249741.2	RP11-673E1.3	3.55	0.000427	0.0454	0.2	0.16	Immature fraction of reticulocytes;	chr4:143798339	chr4:143911514~143912053:-
LUAD	cis	rs10751667	0.6	rs11246376	ENSG00000279672.1	CMB9-55F22.1	3.55	0.000427	0.0454	0.16	0.16	Alzheimer's disease (late onset);	chr11:999622	chr11:779617~780755:+
LUAD	cis	rs8014252	1	rs4902817	ENSG00000274818.1	RP1-292L20.3	3.55	0.000427	0.0454	0.26	0.16	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70421081	chr14:70906657~70907111:-
LUAD	cis	rs17407555	0.821	rs55919137	ENSG00000250413.1	RP11-448G15.1	3.55	0.000427	0.0454	0.26	0.16	Schizophrenia (age at onset);	chr4:10132179	chr4:10006482~10009725:+
LUAD	cis	rs12446632	0.771	rs72769587	ENSG00000261195.1	CTD-2380F24.1	-3.55	0.000427	0.0454	-0.25	-0.16	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Menarche (age at onset);Obesity;Childhood body mass index;Waist circumference;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr16:19847584	chr16:19761172~19766099:-
LUAD	cis	rs12446632	0.723	rs55909205	ENSG00000261195.1	CTD-2380F24.1	-3.55	0.000427	0.0454	-0.25	-0.16	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Menarche (age at onset);Obesity;Childhood body mass index;Waist circumference;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr16:19848529	chr16:19761172~19766099:-
LUAD	cis	rs12446632	0.771	rs4780830	ENSG00000261195.1	CTD-2380F24.1	-3.55	0.000427	0.0454	-0.25	-0.16	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Menarche (age at onset);Obesity;Childhood body mass index;Waist circumference;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr16:19852999	chr16:19761172~19766099:-
LUAD	cis	rs12446632	0.771	rs72769590	ENSG00000261195.1	CTD-2380F24.1	-3.55	0.000427	0.0454	-0.25	-0.16	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Menarche (age at onset);Obesity;Childhood body mass index;Waist circumference;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr16:19853513	chr16:19761172~19766099:-
LUAD	cis	rs12232346	0.626	rs1865923	ENSG00000259751.1	RP11-83J16.3	-3.55	0.000427	0.0454	-0.2	-0.16	Post-traumatic stress disorder;	chr15:34768971	chr15:34849137~34850395:-
LUAD	cis	rs1799949	1	rs9646417	ENSG00000267340.1	RP11-242D8.3	3.55	0.000427	0.0454	0.17	0.16	Menopause (age at onset);	chr17:43346885	chr17:43169880~43170077:-
LUAD	cis	rs1799949	1	rs1545764	ENSG00000267340.1	RP11-242D8.3	3.55	0.000427	0.0454	0.17	0.16	Menopause (age at onset);	chr17:43347197	chr17:43169880~43170077:-
LUAD	cis	rs7546668	1	rs10803389	ENSG00000272510.1	RP4-680D5.8	3.55	0.000427	0.0454	0.2	0.16	Glomerular filtration rate (creatinine);	chr1:15534792	chr1:15565611~15565956:-
LUAD	cis	rs35520189	0.796	rs1143627	ENSG00000234174.1	AC016683.5	3.55	0.000427	0.0454	0.18	0.16	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112836810	chr2:113171535~113175360:-
LUAD	cis	rs6951245	0.786	rs77943789	ENSG00000229043.2	AC091729.9	-3.55	0.000427	0.0454	-0.24	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1100522	chr7:1160374~1165267:+
LUAD	cis	rs3126085	0.867	rs11204948	ENSG00000237975.5	FLG-AS1	-3.55	0.000427	0.0454	-0.24	-0.16	Atopic dermatitis;	chr1:152245997	chr1:152168125~152445456:+
LUAD	cis	rs7210990	0.699	rs8070859	ENSG00000276855.1	CTD-3157E16.2	-3.55	0.000427	0.0454	-0.19	-0.16	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr17:15984475	chr17:15789016~15789705:+
LUAD	cis	rs7210990	0.699	rs11869563	ENSG00000276855.1	CTD-3157E16.2	-3.55	0.000427	0.0454	-0.19	-0.16	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr17:15984994	chr17:15789016~15789705:+
LUAD	cis	rs12291225	0.679	rs34238445	ENSG00000251991.1	RNU7-49P	3.55	0.000427	0.0455	0.18	0.16	Sense of smell;	chr11:14294369	chr11:14478892~14478953:+
LUAD	cis	rs34779708	0.966	rs4934538	ENSG00000271335.4	RP11-324I22.4	3.55	0.000427	0.0455	0.17	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35183222	chr10:35314552~35336401:-
LUAD	cis	rs2115630	0.641	rs11073613	ENSG00000259728.4	LINC00933	-3.55	0.000427	0.0455	-0.2	-0.16	P wave terminal force;	chr15:84642662	chr15:84570649~84580175:+
LUAD	cis	rs793571	0.505	rs9920042	ENSG00000259250.1	RP11-50C13.1	-3.55	0.000428	0.0455	-0.22	-0.16	Schizophrenia;	chr15:58609197	chr15:58587507~58591676:+
LUAD	cis	rs898097	0.585	rs9893200	ENSG00000263063.1	RP11-388C12.1	3.55	0.000428	0.0455	0.16	0.16	Breast cancer;	chr17:82935152	chr17:82713908~82716255:-
LUAD	cis	rs6781182	0.553	rs7618115	ENSG00000236452.1	AC123023.1	3.55	0.000428	0.0455	0.17	0.16	Visceral adipose tissue adjusted for BMI;	chr3:34168232	chr3:34203244~34268811:+
LUAD	cis	rs56318008	0.625	rs10737462	ENSG00000228397.1	RP1-224A6.3	-3.55	0.000428	0.0455	-0.25	-0.16	Total body bone mineral density;Gestational age at birth (maternal effect);	chr1:22118482	chr1:22023994~22024968:-
LUAD	cis	rs2288884	0.636	rs1560690	ENSG00000269959.1	SPACA6P-AS	-3.55	0.000428	0.0455	-0.17	-0.16	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52075094	chr19:51685363~51693456:-
LUAD	cis	rs12122100	0.955	rs12142005	ENSG00000225603.3	RP11-325P15.1	-3.55	0.000428	0.0455	-0.2	-0.16	HIV-1 control;	chr1:147035137	chr1:147050817~147052481:+
LUAD	cis	rs72843166	0.853	rs72845231	ENSG00000265282.1	RP11-269G24.4	3.55	0.000428	0.0455	0.25	0.16	Intelligence (multi-trait analysis);	chr17:63271168	chr17:63430468~63432211:-
LUAD	cis	rs72843166	0.853	rs118099714	ENSG00000265282.1	RP11-269G24.4	3.55	0.000428	0.0455	0.25	0.16	Intelligence (multi-trait analysis);	chr17:63271317	chr17:63430468~63432211:-
LUAD	cis	rs72843166	0.853	rs17202291	ENSG00000265282.1	RP11-269G24.4	3.55	0.000428	0.0455	0.25	0.16	Intelligence (multi-trait analysis);	chr17:63280171	chr17:63430468~63432211:-
LUAD	cis	rs72843166	0.853	rs72845237	ENSG00000265282.1	RP11-269G24.4	3.55	0.000428	0.0455	0.25	0.16	Intelligence (multi-trait analysis);	chr17:63280223	chr17:63430468~63432211:-
LUAD	cis	rs8114671	0.836	rs2425006	ENSG00000276073.1	RP5-1125A11.7	3.55	0.000428	0.0455	0.15	0.16	Height;	chr20:34983425	chr20:33985617~33988989:-
LUAD	cis	rs9341808	0.69	rs3805926	ENSG00000233967.5	RP11-250B2.3	3.55	0.000428	0.0455	0.16	0.16	Sitting height ratio;	chr6:80169563	chr6:80443344~80465927:+
LUAD	cis	rs7809950	1	rs2712201	ENSG00000238832.1	snoU109	-3.55	0.000428	0.0455	-0.23	-0.16	Coronary artery disease;	chr7:107505119	chr7:107603363~107603507:+
LUAD	cis	rs13287066	0.669	rs10992728	ENSG00000227603.1	RP11-165J3.6	3.55	0.000428	0.0455	0.18	0.16	Intelligence (multi-trait analysis);	chr9:93416386	chr9:93435332~93437121:-
LUAD	cis	rs9300255	0.596	rs1568427	ENSG00000256092.2	RP13-942N8.1	3.55	0.000428	0.0455	0.14	0.16	Neutrophil percentage of white cells;	chr12:123254131	chr12:123363868~123366113:+
LUAD	cis	rs5758511	0.689	rs56906457	ENSG00000227370.1	RP4-669P10.19	3.55	0.000428	0.0455	0.19	0.16	Birth weight;	chr22:42232329	chr22:42132543~42132998:+
LUAD	cis	rs12478296	1	rs55767645	ENSG00000261186.2	RP11-341N2.1	-3.55	0.000428	0.0455	-0.32	-0.16	Obesity-related traits;	chr2:242057199	chr2:242087351~242088457:-
LUAD	cis	rs13113518	1	rs13136282	ENSG00000249700.7	SRD5A3-AS1	3.55	0.000428	0.0455	0.16	0.16	Height;	chr4:55551845	chr4:55363971~55395847:-
LUAD	cis	rs13113518	1	rs11934897	ENSG00000249700.7	SRD5A3-AS1	3.55	0.000428	0.0455	0.16	0.16	Height;	chr4:55553396	chr4:55363971~55395847:-
LUAD	cis	rs13113518	0.934	rs11932293	ENSG00000249700.7	SRD5A3-AS1	3.55	0.000428	0.0455	0.16	0.16	Height;	chr4:55554025	chr4:55363971~55395847:-
LUAD	cis	rs13113518	1	rs4865011	ENSG00000249700.7	SRD5A3-AS1	3.55	0.000428	0.0455	0.16	0.16	Height;	chr4:55554456	chr4:55363971~55395847:-
LUAD	cis	rs8180040	0.967	rs4858856	ENSG00000271161.1	BOLA2P2	3.55	0.000428	0.0455	0.15	0.16	Colorectal cancer;	chr3:47523934	chr3:47499841~47500407:+
LUAD	cis	rs11577318	0.579	rs10794532	ENSG00000238084.4	RP3-469D22.1	-3.55	0.000428	0.0455	-0.19	-0.16	Granulocyte percentage of myeloid white cells;	chr1:26367769	chr1:25398721~25399198:+
LUAD	cis	rs9341808	1	rs1359239	ENSG00000233967.5	RP11-250B2.3	3.55	0.000428	0.0455	0.15	0.16	Sitting height ratio;	chr6:80246429	chr6:80443344~80465927:+
LUAD	cis	rs782590	0.967	rs62165172	ENSG00000272606.1	RP11-554J4.1	-3.55	0.000428	0.0455	-0.16	-0.16	Metabolic syndrome;	chr2:55509101	chr2:55617909~55618373:+
LUAD	cis	rs7212590	0.655	rs62081824	ENSG00000263422.1	AC005702.1	3.55	0.000428	0.0455	0.36	0.16	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59830589	chr17:60042361~60042442:-
LUAD	cis	rs7212590	0.748	rs9904374	ENSG00000263422.1	AC005702.1	3.55	0.000428	0.0455	0.36	0.16	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59830735	chr17:60042361~60042442:-
LUAD	cis	rs1005224	0.895	rs6574252	ENSG00000242952.1	RP11-187O7.1	-3.55	0.000428	0.0455	-0.15	-0.16	Large artery stroke;	chr14:75675491	chr14:76634775~76635661:-
LUAD	cis	rs1005224	0.864	rs11625011	ENSG00000242952.1	RP11-187O7.1	-3.55	0.000428	0.0455	-0.15	-0.16	Large artery stroke;	chr14:75678485	chr14:76634775~76635661:-
LUAD	cis	rs6502050	0.799	rs11491185	ENSG00000275966.1	RP11-1055B8.9	-3.55	0.000428	0.0455	-0.16	-0.16	Life satisfaction;	chr17:82193225	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs56095560	ENSG00000275966.1	RP11-1055B8.9	-3.55	0.000428	0.0455	-0.16	-0.16	Life satisfaction;	chr17:82193428	chr17:81345476~81345966:-
LUAD	cis	rs7178909	0.872	rs7179633	ENSG00000259677.1	RP11-493E3.1	3.55	0.000428	0.0455	0.17	0.16	Common traits (Other);	chr15:89891645	chr15:89876540~89877285:+
LUAD	cis	rs7178909	0.872	rs28865973	ENSG00000259677.1	RP11-493E3.1	3.55	0.000428	0.0455	0.17	0.16	Common traits (Other);	chr15:89891946	chr15:89876540~89877285:+
LUAD	cis	rs256438	0.731	rs12332694	ENSG00000251050.1	RP11-168A11.4	-3.55	0.000428	0.0455	-0.18	-0.16	Serum thyroid-stimulating hormone levels;	chr5:80046166	chr5:80019609~80019920:+
LUAD	cis	rs4142110	0.737	rs1475327	ENSG00000271216.1	LINC01050	3.55	0.000428	0.0455	0.2	0.16	Nephrolithiasis;	chr13:42175447	chr13:42810366~42812562:-
LUAD	cis	rs4374383	0.884	rs6726639	ENSG00000236307.2	EEF1E1P1	-3.55	0.000428	0.0455	-0.18	-0.16	Hepatitis C induced liver fibrosis;	chr2:111995520	chr2:111887914~111888741:+
LUAD	cis	rs7772486	0.686	rs9403739	ENSG00000235652.6	RP11-545I5.3	-3.55	0.000428	0.0455	-0.16	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145694221	chr6:145799409~145886585:+
LUAD	cis	rs9309711	0.922	rs11679058	ENSG00000271868.1	RP11-1293J14.1	-3.55	0.000429	0.0455	-0.19	-0.16	Neurofibrillary tangles;	chr2:3480042	chr2:3496956~3497428:+
LUAD	cis	rs12822507	0.868	rs7301486	ENSG00000275963.1	RP11-180M15.6	-3.55	0.000429	0.0455	-0.18	-0.16	Systemic lupus erythematosus;	chr12:12614032	chr12:12648939~12649713:+
LUAD	cis	rs2274273	0.686	rs2182207	ENSG00000258413.1	RP11-665C16.6	-3.55	0.000429	0.0455	-0.22	-0.16	Protein biomarker;	chr14:55123085	chr14:55262767~55272075:-
LUAD	cis	rs2292864	0.764	rs36046953	ENSG00000278765.1	RP5-890E16.5	3.55	0.000429	0.0455	0.3	0.16	Left atrial antero-posterior diameter;	chr17:47304425	chr17:48066704~48067293:-
LUAD	cis	rs56309584	0.596	rs11649742	ENSG00000269947.1	RP11-849F2.9	-3.55	0.000429	0.0455	-0.23	-0.16	Initial pursuit acceleration;	chr17:8273097	chr17:8277763~8278436:+
LUAD	cis	rs3749855	0.679	rs13203498	ENSG00000220920.1	RP3-525L6.2	3.55	0.000429	0.0456	0.33	0.16	Glucose homeostasis traits;	chr6:17253305	chr6:17953572~17953930:+
LUAD	cis	rs3749855	0.679	rs13195686	ENSG00000220920.1	RP3-525L6.2	3.55	0.000429	0.0456	0.33	0.16	Glucose homeostasis traits;	chr6:17253754	chr6:17953572~17953930:+
LUAD	cis	rs3749855	0.679	rs13195960	ENSG00000220920.1	RP3-525L6.2	3.55	0.000429	0.0456	0.33	0.16	Glucose homeostasis traits;	chr6:17253935	chr6:17953572~17953930:+
LUAD	cis	rs3749855	0.679	rs12527687	ENSG00000220920.1	RP3-525L6.2	3.55	0.000429	0.0456	0.33	0.16	Glucose homeostasis traits;	chr6:17254168	chr6:17953572~17953930:+
LUAD	cis	rs3749855	0.679	rs12527728	ENSG00000220920.1	RP3-525L6.2	3.55	0.000429	0.0456	0.33	0.16	Glucose homeostasis traits;	chr6:17254695	chr6:17953572~17953930:+
LUAD	cis	rs4853525	0.923	rs2204859	ENSG00000235852.1	AC005540.3	3.55	0.000429	0.0456	0.18	0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190872147	chr2:190880797~190882059:-
LUAD	cis	rs3772130	0.962	rs11719093	ENSG00000243544.3	RN7SL172P	3.55	0.000429	0.0456	0.19	0.16	Cognitive performance;	chr3:121768839	chr3:121653994~121654296:-
LUAD	cis	rs8180040	0.966	rs6790763	ENSG00000271161.1	BOLA2P2	3.55	0.000429	0.0456	0.16	0.16	Colorectal cancer;	chr3:47531095	chr3:47499841~47500407:+
LUAD	cis	rs2348418	0.733	rs1904386	ENSG00000244712.1	RP11-874G11.1	-3.55	0.000429	0.0456	-0.19	-0.16	Lung function (FEV1);Lung function (FVC);	chr12:28202321	chr12:28564678~28565141:-
LUAD	cis	rs2348418	0.733	rs1824769	ENSG00000244712.1	RP11-874G11.1	-3.55	0.000429	0.0456	-0.19	-0.16	Lung function (FEV1);Lung function (FVC);	chr12:28202322	chr12:28564678~28565141:-
LUAD	cis	rs2348418	0.671	rs2169753	ENSG00000244712.1	RP11-874G11.1	-3.55	0.000429	0.0456	-0.19	-0.16	Lung function (FEV1);Lung function (FVC);	chr12:28203481	chr12:28564678~28565141:-
LUAD	cis	rs1009115	1	rs1009115	ENSG00000272328.1	RP4-594A5.1	-3.55	0.000429	0.0456	-0.22	-0.16	Post bronchodilator FEV1;	chr7:8395352	chr7:8303741~8341343:+
LUAD	cis	rs10510102	0.872	rs11200268	ENSG00000276742.1	RP11-500G22.4	3.55	0.000429	0.0456	0.27	0.16	Breast cancer;	chr10:121932661	chr10:121956782~121957098:+
LUAD	cis	rs8062405	0.698	rs8046545	ENSG00000261766.1	RP11-22P6.2	3.55	0.000429	0.0456	0.15	0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28903896	chr16:28862166~28863340:-
LUAD	cis	rs8062405	0.698	rs10499	ENSG00000261766.1	RP11-22P6.2	3.55	0.000429	0.0456	0.15	0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28904206	chr16:28862166~28863340:-
LUAD	cis	rs12073359	1	rs11205331	ENSG00000275557.1	RP11-353N4.6	-3.55	0.000429	0.0456	-0.22	-0.16	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150131878	chr1:149607765~149612402:+
LUAD	cis	rs11874381	1	rs35337492	ENSG00000266696.1	RP11-30L3.2	-3.55	0.000429	0.0456	-0.18	-0.16	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);	chr18:49684454	chr18:49205912~49208781:+
LUAD	cis	rs11874381	1	rs62101781	ENSG00000266696.1	RP11-30L3.2	-3.55	0.000429	0.0456	-0.18	-0.16	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);	chr18:49685490	chr18:49205912~49208781:+
LUAD	cis	rs6540731	0.905	rs12028026	ENSG00000229983.1	RP11-15I11.2	3.55	0.000429	0.0456	0.19	0.16	Intelligence (childhood);	chr1:212216793	chr1:212168207~212190259:+
LUAD	cis	rs7618915	0.547	rs11177	ENSG00000243224.1	RP5-1157M23.2	-3.55	0.000429	0.0456	-0.16	-0.16	Bipolar disorder;	chr3:52687289	chr3:52239258~52241097:+
LUAD	cis	rs7618915	0.547	rs6762813	ENSG00000243224.1	RP5-1157M23.2	-3.55	0.000429	0.0456	-0.16	-0.16	Bipolar disorder;	chr3:52692679	chr3:52239258~52241097:+
LUAD	cis	rs2736345	0.788	rs2618476	ENSG00000270154.1	RP11-419I17.1	3.55	0.000429	0.0456	0.2	0.16	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11495032	chr8:12476462~12477122:+
LUAD	cis	rs1476587	0.573	rs7459046	ENSG00000224046.1	AC005076.5	-3.55	0.000429	0.0456	-0.2	-0.16	Brachial circumference;	chr7:87083279	chr7:87151423~87152420:-
LUAD	cis	rs6754311	0.593	rs10195620	ENSG00000226806.1	AC011893.3	-3.55	0.000429	0.0456	-0.2	-0.16	Mosquito bite size;	chr2:135738049	chr2:135820191~135823087:+
LUAD	cis	rs6095360	0.934	rs3818224	ENSG00000222365.1	SNORD12B	-3.55	0.000429	0.0456	-0.16	-0.16	Intelligence (multi-trait analysis);	chr20:49011633	chr20:49280319~49280409:+
LUAD	cis	rs2731006	0.64	rs2138862	ENSG00000257114.2	RP11-25I15.3	3.55	0.000429	0.0456	0.26	0.16	Panic disorder;	chr12:42789961	chr12:42692216~42717119:+
LUAD	cis	rs11665867	0.941	rs73047100	ENSG00000269843.1	CTC-490E21.10	-3.55	0.000429	0.0456	-0.24	-0.16	Hematocrit;	chr19:40809766	chr19:40831221~40837210:-
LUAD	cis	rs13113518	0.934	rs3805155	ENSG00000223305.1	RN7SKP30	3.55	0.000429	0.0456	0.18	0.16	Height;	chr4:55497842	chr4:55540502~55540835:-
LUAD	cis	rs13113518	1	rs7686261	ENSG00000223305.1	RN7SKP30	3.55	0.000429	0.0456	0.18	0.16	Height;	chr4:55500224	chr4:55540502~55540835:-
LUAD	cis	rs13113518	1	rs11729220	ENSG00000223305.1	RN7SKP30	3.55	0.000429	0.0456	0.18	0.16	Height;	chr4:55501629	chr4:55540502~55540835:-
LUAD	cis	rs13113518	1	rs11133390	ENSG00000223305.1	RN7SKP30	3.55	0.000429	0.0456	0.18	0.16	Height;	chr4:55501726	chr4:55540502~55540835:-
LUAD	cis	rs13113518	1	rs11133391	ENSG00000223305.1	RN7SKP30	3.55	0.000429	0.0456	0.18	0.16	Height;	chr4:55501788	chr4:55540502~55540835:-
LUAD	cis	rs13113518	0.966	rs13133484	ENSG00000223305.1	RN7SKP30	3.55	0.000429	0.0456	0.18	0.16	Height;	chr4:55504176	chr4:55540502~55540835:-
LUAD	cis	rs13113518	0.934	rs13127906	ENSG00000223305.1	RN7SKP30	3.55	0.000429	0.0456	0.18	0.16	Height;	chr4:55504201	chr4:55540502~55540835:-
LUAD	cis	rs13113518	1	rs6849433	ENSG00000223305.1	RN7SKP30	3.55	0.000429	0.0456	0.18	0.16	Height;	chr4:55506498	chr4:55540502~55540835:-
LUAD	cis	rs8062405	0.655	rs7184597	ENSG00000261766.1	RP11-22P6.2	3.55	0.000429	0.0456	0.15	0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28862166~28863340:-
LUAD	cis	rs4072705	1	rs4838206	ENSG00000236643.1	RP11-175D17.3	-3.55	0.000429	0.0456	-0.18	-0.16	Menarche (age at onset);	chr9:124749645	chr9:124770123~124772927:+
LUAD	cis	rs11009175	0.512	rs7901213	ENSG00000273038.2	RP11-479G22.8	-3.55	0.000429	0.0456	-0.17	-0.16	Depression (quantitative trait);	chr10:33089044	chr10:32887255~32889311:-
LUAD	cis	rs7918232	0.882	rs10829190	ENSG00000262412.1	RP11-85G18.6	3.55	0.000429	0.0456	0.24	0.16	Breast cancer;	chr10:27120626	chr10:27243130~27250804:+
LUAD	cis	rs38055	0.881	rs252042	ENSG00000247796.2	CTD-2366F13.1	-3.55	0.00043	0.0456	-0.18	-0.16	Acne (severe);	chr5:53308971	chr5:53109842~53115126:+
LUAD	cis	rs8073060	0.586	rs225298	ENSG00000267592.1	CTC-507E2.2	3.55	0.00043	0.0456	0.23	0.16	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35596927	chr17:35596904~35597128:-
LUAD	cis	rs240993	0.812	rs9398272	ENSG00000266032.1	AL357515.1	-3.55	0.00043	0.0456	-0.23	-0.16	Inflammatory skin disease;Psoriasis;	chr6:111522345	chr6:110969773~110969872:-
LUAD	cis	rs38055	0.881	rs252038	ENSG00000247796.2	CTD-2366F13.1	-3.55	0.00043	0.0456	-0.18	-0.16	Acne (severe);	chr5:53309832	chr5:53109842~53115126:+
LUAD	cis	rs38055	0.881	rs252035	ENSG00000247796.2	CTD-2366F13.1	-3.55	0.00043	0.0456	-0.18	-0.16	Acne (severe);	chr5:53312130	chr5:53109842~53115126:+
LUAD	cis	rs2991971	0.81	rs6657237	ENSG00000234329.1	RP11-767N6.2	3.55	0.00043	0.0456	0.15	0.16	High light scatter reticulocyte count;	chr1:45454436	chr1:45651039~45651826:-
LUAD	cis	rs1858037	0.867	rs9789444	ENSG00000237979.1	AC007389.1	3.55	0.00043	0.0456	0.2	0.16	Rheumatoid arthritis;	chr2:65342093	chr2:65500993~65502138:-
LUAD	cis	rs4474465	0.85	rs4245460	ENSG00000251323.2	RP11-452H21.4	-3.55	0.00043	0.0456	-0.21	-0.16	Alzheimer's disease (survival time);	chr11:78547101	chr11:78423982~78429836:-
LUAD	cis	rs6502050	0.871	rs6502051	ENSG00000266654.1	RP11-1376P16.1	3.55	0.00043	0.0456	0.17	0.16	Life satisfaction;	chr17:82101456	chr17:82160056~82160452:+
LUAD	cis	rs7520050	0.831	rs61783169	ENSG00000234329.1	RP11-767N6.2	-3.55	0.00043	0.0456	-0.15	-0.16	Reticulocyte count;Red blood cell count;	chr1:45790655	chr1:45651039~45651826:-
LUAD	cis	rs7617773	0.779	rs9833309	ENSG00000199476.1	Y_RNA	-3.55	0.00043	0.0456	-0.21	-0.16	Coronary artery disease;	chr3:48285960	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.817	rs9853804	ENSG00000199476.1	Y_RNA	-3.55	0.00043	0.0456	-0.21	-0.16	Coronary artery disease;	chr3:48286239	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.817	rs9834095	ENSG00000199476.1	Y_RNA	-3.55	0.00043	0.0456	-0.21	-0.16	Coronary artery disease;	chr3:48286261	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.817	rs4131361	ENSG00000199476.1	Y_RNA	-3.55	0.00043	0.0456	-0.21	-0.16	Coronary artery disease;	chr3:48287322	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.817	rs6791930	ENSG00000199476.1	Y_RNA	-3.55	0.00043	0.0456	-0.21	-0.16	Coronary artery disease;	chr3:48288410	chr3:48288587~48288694:+
LUAD	cis	rs7617773	0.817	rs6794644	ENSG00000199476.1	Y_RNA	-3.55	0.00043	0.0456	-0.21	-0.16	Coronary artery disease;	chr3:48288547	chr3:48288587~48288694:+
LUAD	cis	rs2024714	0.967	rs6142811	ENSG00000273812.1	WI2-87327B8.2	-3.55	0.00043	0.0456	-0.17	-0.16	Longevity;	chr20:61632737	chr20:62596732~62603115:-
LUAD	cis	rs847649	0.842	rs4729873	ENSG00000233297.4	RASA4DP	-3.55	0.00043	0.0456	-0.21	-0.16	Morning vs. evening chronotype;	chr7:103091334	chr7:102681836~102690469:-
LUAD	cis	rs375066	0.935	rs376032	ENSG00000278917.1	RP11-15A1.4	-3.55	0.00043	0.0457	-0.17	-0.16	Breast cancer;	chr19:43903412	chr19:43891233~43895411:+
LUAD	cis	rs2929278	0.638	rs2016840	ENSG00000166763.7	STRCP1	-3.55	0.00043	0.0457	-0.18	-0.16	Schizophrenia;	chr15:43919670	chr15:43699488~43718184:-
LUAD	cis	rs6121246	0.821	rs6121209	ENSG00000230613.1	HM13-AS1	3.55	0.00043	0.0457	0.23	0.16	Mean corpuscular hemoglobin;	chr20:31723455	chr20:31567707~31573263:-
LUAD	cis	rs6121246	0.909	rs57726761	ENSG00000230613.1	HM13-AS1	3.55	0.00043	0.0457	0.23	0.16	Mean corpuscular hemoglobin;	chr20:31726243	chr20:31567707~31573263:-
LUAD	cis	rs875971	0.638	rs35986979	ENSG00000222364.1	RNU6-96P	3.55	0.00043	0.0457	0.18	0.16	Aortic root size;	chr7:66624003	chr7:66395191~66395286:+
LUAD	cis	rs867186	1	rs7263203	ENSG00000222460.1	RN7SKP271	-3.55	0.00043	0.0457	-0.27	-0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35185572	chr20:35643143~35643462:+
LUAD	cis	rs28374715	0.532	rs1899	ENSG00000247556.5	OIP5-AS1	3.55	0.00043	0.0457	0.2	0.16	Ulcerative colitis;	chr15:41397034	chr15:41283990~41309737:+
LUAD	cis	rs17290922	1	rs12924030	ENSG00000261114.1	RP11-325K4.2	-3.55	0.00043	0.0457	-0.24	-0.16	Schizophrenia;	chr16:56992918	chr16:56941028~56941726:+
LUAD	cis	rs8046148	0.724	rs12599260	ENSG00000279356.1	RP11-429P3.8	3.55	0.00043	0.0457	0.16	0.16	Testicular germ cell tumor;	chr16:50059327	chr16:50072862~50074986:+
LUAD	cis	rs8046148	0.724	rs1861661	ENSG00000279356.1	RP11-429P3.8	3.55	0.00043	0.0457	0.16	0.16	Testicular germ cell tumor;	chr16:50060293	chr16:50072862~50074986:+
LUAD	cis	rs448720	0.811	rs2458506	ENSG00000259673.4	IQCH-AS1	3.55	0.00043	0.0457	0.17	0.16	Cognitive performance;	chr15:67890272	chr15:67403619~67521844:-
LUAD	cis	rs13016963	0.506	rs11684505	ENSG00000234842.1	AC007163.8	-3.55	0.00043	0.0457	-0.19	-0.16	Esophageal squamous cell carcinoma;Melanoma;	chr2:201376440	chr2:201549631~201550307:+
LUAD	cis	rs8114671	0.967	rs2069945	ENSG00000269202.1	RP4-614O4.12	-3.55	0.00043	0.0457	-0.16	-0.16	Height;	chr20:35174034	chr20:35201747~35203288:-
LUAD	cis	rs1198430	0.639	rs16860685	ENSG00000232482.2	RP4-654C18.1	-3.55	0.00043	0.0457	-0.22	-0.16	Total cholesterol levels;	chr1:23440151	chr1:23410832~23412146:+
LUAD	cis	rs7204230	1	rs8050978	ENSG00000261291.1	RP11-295M3.2	3.55	0.00043	0.0457	0.19	0.16	Fibrinogen;	chr16:53217618	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs59490761	ENSG00000261291.1	RP11-295M3.2	3.55	0.00043	0.0457	0.19	0.16	Fibrinogen;	chr16:53218108	chr16:53168522~53169450:+
LUAD	cis	rs7204230	1	rs58474046	ENSG00000261291.1	RP11-295M3.2	3.55	0.00043	0.0457	0.19	0.16	Fibrinogen;	chr16:53219798	chr16:53168522~53169450:+
LUAD	cis	rs7246657	0.823	rs4802236	ENSG00000267470.4	ZNF571-AS1	3.55	0.00043	0.0457	0.23	0.16	Coronary artery calcification;	chr19:37428344	chr19:37548914~37587348:+
LUAD	cis	rs2765539	0.701	rs6671822	ENSG00000231365.4	RP11-418J17.1	-3.55	0.00043	0.0457	-0.22	-0.16	Waist-hip ratio;	chr1:119118898	chr1:119140396~119275973:+
LUAD	cis	rs6951245	0.554	rs11544331	ENSG00000229043.2	AC091729.9	-3.55	0.00043	0.0457	-0.21	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1091775	chr7:1160374~1165267:+
LUAD	cis	rs1044826	0.642	rs295482	ENSG00000214280.3	RP11-553K23.2	3.55	0.00043	0.0457	0.18	0.16	Obesity-related traits;	chr3:139510422	chr3:139582928~139583593:-
LUAD	cis	rs12935418	0.616	rs2549857	ENSG00000261061.1	RP11-303E16.2	-3.55	0.00043	0.0457	-0.17	-0.16	Mean corpuscular volume;	chr16:80993353	chr16:81030770~81031485:+
LUAD	cis	rs3849150	0.95	rs2137916	ENSG00000235939.1	RP11-123B3.2	-3.55	0.00043	0.0457	-0.23	-0.16	Subclinical atherosclerosis traits (other);	chr10:48885105	chr10:49419277~49472903:+
LUAD	cis	rs11673344	0.642	rs12462487	ENSG00000267254.4	ZNF790-AS1	-3.55	0.000431	0.0457	-0.21	-0.16	Obesity-related traits;	chr19:37311211	chr19:36797518~36828115:+
LUAD	cis	rs7940646	0.906	rs4442541	ENSG00000246308.1	RP11-685M7.3	3.55	0.000431	0.0457	0.19	0.16	Platelet aggregation;	chr11:10647625	chr11:10809297~10822931:+
LUAD	cis	rs12216545	0.669	rs1879871	ENSG00000241134.3	BET1P1	-3.55	0.000431	0.0457	-0.17	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150603305	chr7:150749736~150750094:+
LUAD	cis	rs12216545	0.662	rs1879872	ENSG00000241134.3	BET1P1	-3.55	0.000431	0.0457	-0.17	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150603336	chr7:150749736~150750094:+
LUAD	cis	rs12216545	0.644	rs62491782	ENSG00000241134.3	BET1P1	-3.55	0.000431	0.0457	-0.17	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150612325	chr7:150749736~150750094:+
LUAD	cis	rs6467136	0.623	rs12671806	ENSG00000224138.1	AC000123.4	3.55	0.000431	0.0457	0.15	0.16	Type 2 diabetes;	chr7:127507574	chr7:127350128~127351523:+
LUAD	cis	rs4474465	0.85	rs4285892	ENSG00000251323.2	RP11-452H21.4	-3.55	0.000431	0.0457	-0.19	-0.16	Alzheimer's disease (survival time);	chr11:78532088	chr11:78423982~78429836:-
LUAD	cis	rs9437689	0.591	rs7518326	ENSG00000228852.5	RP11-57H12.5	3.55	0.000431	0.0457	0.14	0.16	Phospholipid levels (plasma);	chr1:94957735	chr1:95243167~95278940:-
LUAD	cis	rs8141529	0.702	rs469992	ENSG00000272858.1	CTA-292E10.8	3.55	0.000431	0.0457	0.18	0.16	Lymphocyte counts;	chr22:28918911	chr22:28814914~28815662:+
LUAD	cis	rs9549260	0.564	rs9577110	ENSG00000168852.11	TPTE2P5	3.55	0.000431	0.0457	0.16	0.16	Red blood cell count;	chr13:40697742	chr13:40822296~40921749:-
LUAD	cis	rs11722228	0.521	rs12501336	ENSG00000261490.1	RP11-448G15.3	3.55	0.000431	0.0457	0.14	0.16	Urate levels;Serum uric acid levels;Gout;	chr4:10135727	chr4:10068089~10073019:-
LUAD	cis	rs10863681	0.764	rs1339875	ENSG00000227925.1	RP11-191N8.2	3.55	0.000431	0.0457	0.18	0.16	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222066980	chr1:221827666~221840666:-
LUAD	cis	rs6736093	0.901	rs34875611	ENSG00000207383.1	Y_RNA	-3.55	0.000431	0.0457	-0.2	-0.16	Coronary artery disease;	chr2:112005448	chr2:112579484~112579584:-
LUAD	cis	rs449789	0.573	rs529273	ENSG00000235086.1	FNDC1-IT1	-3.55	0.000431	0.0457	-0.27	-0.16	Pulse pressure;	chr6:159287467	chr6:159240786~159243329:+
LUAD	cis	rs6502050	0.769	rs8079122	ENSG00000266654.1	RP11-1376P16.1	-3.55	0.000431	0.0457	-0.17	-0.16	Life satisfaction;	chr17:82162551	chr17:82160056~82160452:+
LUAD	cis	rs4865762	0.512	rs34277022	ENSG00000247796.2	CTD-2366F13.1	3.55	0.000431	0.0457	0.18	0.16	Intraocular pressure;	chr5:53211714	chr5:53109842~53115126:+
LUAD	cis	rs75583333	0.655	rs80333548	ENSG00000253522.3	CTC-231O11.1	3.55	0.000431	0.0457	0.27	0.16	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr5:160047410	chr5:160468268~160487426:+
LUAD	cis	rs448720	0.776	rs1001870	ENSG00000259673.4	IQCH-AS1	3.55	0.000431	0.0457	0.17	0.16	Cognitive performance;	chr15:67859110	chr15:67403619~67521844:-
LUAD	cis	rs2932538	0.961	rs6537747	ENSG00000235299.2	MRPL53P1	-3.55	0.000431	0.0457	-0.2	-0.16	Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension;	chr1:112636975	chr1:112625906~112626224:-
LUAD	cis	rs11051970	0.879	rs2651363	ENSG00000274964.1	RP11-817I4.1	3.55	0.000431	0.0457	0.17	0.16	Response to tocilizumab in rheumatoid arthritis;	chr12:32434616	chr12:32339368~32340724:+
LUAD	cis	rs2742234	0.955	rs1272142	ENSG00000273008.1	RP11-351D16.3	-3.54	0.000431	0.0457	-0.17	-0.16	Hirschsprung disease;	chr10:43200036	chr10:43136824~43138334:-
LUAD	cis	rs4763879	0.739	rs2114871	ENSG00000278635.1	CTD-2318O12.1	3.54	0.000431	0.0457	0.15	0.16	Type 1 diabetes;	chr12:9676842	chr12:9415641~9416718:+
LUAD	cis	rs6736093	0.704	rs34593596	ENSG00000207383.1	Y_RNA	-3.54	0.000431	0.0457	-0.21	-0.16	Coronary artery disease;	chr2:112039292	chr2:112579484~112579584:-
LUAD	cis	rs12681366	0.839	rs3019280	ENSG00000254057.1	RP3-388N13.3	3.54	0.000431	0.0457	0.17	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94437804	chr8:93834454~93846743:-
LUAD	cis	rs1876905	0.68	rs395564	ENSG00000271789.1	RP5-1112D6.7	-3.54	0.000431	0.0458	-0.22	-0.16	Mean corpuscular hemoglobin;	chr6:111176176	chr6:111297126~111298510:+
LUAD	cis	rs12349081	0.614	rs9657608	ENSG00000265194.1	RP11-70L8.4	-3.54	0.000431	0.0458	-0.23	-0.16	Cancer;	chr9:21956231	chr9:21858910~21861926:-
LUAD	cis	rs67981189	0.593	rs7154437	ENSG00000269927.1	RP6-91H8.3	3.54	0.000431	0.0458	0.19	0.16	Schizophrenia;	chr14:70974668	chr14:71141125~71143253:-
LUAD	cis	rs7615952	0.799	rs13315434	ENSG00000241288.6	RP11-379B18.5	-3.54	0.000431	0.0458	-0.2	-0.16	Blood pressure (smoking interaction);	chr3:125922551	chr3:125827238~125916384:-
LUAD	cis	rs7474896	0.559	rs2738185	ENSG00000226578.1	RP11-258F22.1	3.54	0.000431	0.0458	0.22	0.16	Obesity (extreme);	chr10:37958808	chr10:37775371~37784131:-
LUAD	cis	rs3096299	0.692	rs4785565	ENSG00000261574.1	RP1-168P16.2	3.54	0.000431	0.0458	0.18	0.16	Multiple myeloma (IgH translocation);	chr16:89449351	chr16:89392375~89412564:-
LUAD	cis	rs2554380	0.6	rs6602986	ENSG00000259570.1	RP11-671M22.4	3.54	0.000431	0.0458	0.2	0.16	Height;	chr15:83778347	chr15:84394512~84395514:+
LUAD	cis	rs2554380	0.943	rs2562776	ENSG00000230373.7	GOLGA6L5P	-3.54	0.000431	0.0458	-0.2	-0.16	Height;	chr15:83699411	chr15:84507885~84516814:-
LUAD	cis	rs10197140	0.705	rs3789127	ENSG00000235721.1	AC013268.3	-3.54	0.000431	0.0458	-0.18	-0.16	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110947183	chr2:110007675~110010783:+
LUAD	cis	rs6502050	0.799	rs6502089	ENSG00000275966.1	RP11-1055B8.9	-3.54	0.000431	0.0458	-0.16	-0.16	Life satisfaction;	chr17:82211647	chr17:81345476~81345966:-
LUAD	cis	rs1430128	0.584	rs11681655	ENSG00000230580.1	AC021016.7	-3.54	0.000431	0.0458	-0.26	-0.16	Congenital heart disease (inherited effect);	chr2:217593923	chr2:218354075~218354572:+
LUAD	cis	rs448720	1	rs35768117	ENSG00000260657.2	RP11-315D16.4	-3.54	0.000432	0.0458	-0.18	-0.16	Cognitive performance;	chr15:67911903	chr15:68267792~68277994:-
LUAD	cis	rs7777677	0.925	rs6956269	ENSG00000276953.1	TRBV12-4	3.54	0.000432	0.0458	0.15	0.16	Alcoholic chronic pancreatitis;	chr7:142661303	chr7:142563740~142564245:+
LUAD	cis	rs7777677	0.925	rs4726547	ENSG00000276953.1	TRBV12-4	3.54	0.000432	0.0458	0.15	0.16	Alcoholic chronic pancreatitis;	chr7:142662750	chr7:142563740~142564245:+
LUAD	cis	rs6687821	0.515	rs1199726	ENSG00000267272.4	LINC01140	-3.54	0.000432	0.0458	-0.19	-0.16	Yeast infection;	chr1:86951691	chr1:87129765~87169198:+
LUAD	cis	rs2408955	0.521	rs11168437	ENSG00000273765.1	RP11-370I10.11	3.54	0.000432	0.0458	0.17	0.16	Glycated hemoglobin levels;	chr12:48172373	chr12:48360920~48361377:+
LUAD	cis	rs4819052	0.807	rs1075788	ENSG00000215447.6	BX322557.10	-3.54	0.000432	0.0458	-0.19	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246649	chr21:45288052~45291738:+
LUAD	cis	rs867186	1	rs11907011	ENSG00000222460.1	RN7SKP271	-3.54	0.000432	0.0458	-0.27	-0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35179967	chr20:35643143~35643462:+
LUAD	cis	rs4474465	0.688	rs7940720	ENSG00000251323.2	RP11-452H21.4	-3.54	0.000432	0.0458	-0.19	-0.16	Alzheimer's disease (survival time);	chr11:78565628	chr11:78423982~78429836:-
LUAD	cis	rs7173947	0.51	rs11631109	ENSG00000258754.6	LINC01579	3.54	0.000432	0.0458	0.19	0.16	Hematological and biochemical traits;	chr15:94734799	chr15:93718542~94070820:-
LUAD	cis	rs526231	0.578	rs3776870	ENSG00000250682.4	LINC00491	3.54	0.000432	0.0458	0.19	0.16	Primary biliary cholangitis;	chr5:102959366	chr5:102609156~102671559:-
LUAD	cis	rs2929278	0.617	rs524908	ENSG00000166763.7	STRCP1	-3.54	0.000432	0.0458	-0.18	-0.16	Schizophrenia;	chr15:43895793	chr15:43699488~43718184:-
LUAD	cis	rs2333021	0.649	rs9888558	ENSG00000259015.1	RP11-109N23.6	3.54	0.000432	0.0458	0.16	0.16	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);	chr14:72997435	chr14:72960595~72961993:+
LUAD	cis	rs638893	0.528	rs521910	ENSG00000255422.1	AP002954.4	3.54	0.000432	0.0458	0.26	0.16	Vitiligo;	chr11:118739920	chr11:118704607~118750263:+
LUAD	cis	rs13126694	0.682	rs6536288	ENSG00000280140.1	RP11-597D13.2	3.54	0.000432	0.0458	0.19	0.16	Blood osmolality (transformed sodium);	chr4:157949748	chr4:158111361~158111931:-
LUAD	cis	rs35000415	0.873	rs34748780	ENSG00000275106.1	RP11-309L24.10	-3.54	0.000432	0.0458	-0.31	-0.16	Systemic lupus erythematosus;	chr7:129060099	chr7:128952527~128953316:-
LUAD	cis	rs4723738	0.967	rs12531618	ENSG00000211698.2	TRGV4	-3.54	0.000432	0.0458	-0.17	-0.16	Treatment response for severe sepsis;	chr7:38213263	chr7:38353715~38354517:-
LUAD	cis	rs1400816	0.85	rs1996425	ENSG00000228389.1	AC068039.4	3.54	0.000432	0.0458	0.26	0.16	Amyotrophic lateral sclerosis (sporadic);	chr2:171858421	chr2:171773482~171775844:+
LUAD	cis	rs1400816	0.85	rs1105264	ENSG00000228389.1	AC068039.4	3.54	0.000432	0.0458	0.26	0.16	Amyotrophic lateral sclerosis (sporadic);	chr2:171858655	chr2:171773482~171775844:+
LUAD	cis	rs1823913	0.599	rs1378155	ENSG00000230611.1	HMGB1P27	-3.54	0.000432	0.0458	-0.18	-0.16	Obesity-related traits;	chr2:191266610	chr2:191174233~191174835:+
LUAD	cis	rs1823913	0.576	rs13011608	ENSG00000230611.1	HMGB1P27	-3.54	0.000432	0.0458	-0.18	-0.16	Obesity-related traits;	chr2:191267097	chr2:191174233~191174835:+
LUAD	cis	rs9325144	0.678	rs7315271	ENSG00000257718.1	RP11-396F22.1	-3.54	0.000432	0.0458	-0.19	-0.16	Morning vs. evening chronotype;	chr12:38770929	chr12:38906451~38909592:+
LUAD	cis	rs7760535	0.826	rs10872068	ENSG00000266032.1	AL357515.1	-3.54	0.000432	0.0458	-0.21	-0.16	Metabolic traits;	chr6:111528657	chr6:110969773~110969872:-
LUAD	cis	rs7134599	0.561	rs4913395	ENSG00000255733.4	IFNG-AS1	-3.54	0.000432	0.0458	-0.13	-0.16	Inflammatory bowel disease;Ulcerative colitis;	chr12:68076705	chr12:67989445~68234686:+
LUAD	cis	rs10118776	0.677	rs13285109	ENSG00000231967.1	RP11-12D24.6	3.54	0.000432	0.0458	0.4	0.16	Small cell lung carcinoma;	chr9:6197408	chr9:5356312~5356525:-
LUAD	cis	rs647161	0.616	rs10074434	ENSG00000247627.2	MTND4P12	-3.54	0.000432	0.0458	-0.19	-0.16	Colorectal cancer;	chr5:135153492	chr5:134926660~134928036:-
LUAD	cis	rs763567	0.869	rs680084	ENSG00000271811.1	RP1-79C4.4	3.54	0.000432	0.0458	0.18	0.16	Tonsillectomy;	chr1:170659114	chr1:170667381~170669425:+
LUAD	cis	rs2412819	0.571	rs10163069	ENSG00000166763.7	STRCP1	-3.54	0.000432	0.0458	-0.23	-0.16	Lung cancer;	chr15:43755372	chr15:43699488~43718184:-
LUAD	cis	rs2929278	0.617	rs3986209	ENSG00000166763.7	STRCP1	-3.54	0.000432	0.0458	-0.23	-0.16	Schizophrenia;	chr15:43758675	chr15:43699488~43718184:-
LUAD	cis	rs8098244	0.571	rs72876000	ENSG00000264745.1	TTC39C-AS1	-3.54	0.000432	0.0458	-0.22	-0.16	Serous borderline ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Epithelial ovarian cancer;	chr18:23989446	chr18:23994213~24015339:-
LUAD	cis	rs6736093	0.966	rs870761	ENSG00000207383.1	Y_RNA	-3.54	0.000432	0.0458	-0.2	-0.16	Coronary artery disease;	chr2:111987713	chr2:112579484~112579584:-
LUAD	cis	rs6540731	0.875	rs10863953	ENSG00000229983.1	RP11-15I11.2	3.54	0.000432	0.0458	0.19	0.16	Intelligence (childhood);	chr1:212192458	chr1:212168207~212190259:+
LUAD	cis	rs4664293	0.867	rs13432	ENSG00000227055.1	AC009961.5	3.54	0.000432	0.0458	0.18	0.16	Monocyte percentage of white cells;	chr2:159769216	chr2:159812234~159814009:-
LUAD	cis	rs4664293	0.967	rs4665103	ENSG00000227055.1	AC009961.5	3.54	0.000432	0.0458	0.18	0.16	Monocyte percentage of white cells;	chr2:159675801	chr2:159812234~159814009:-
LUAD	cis	rs6494488	0.5	rs55881719	ENSG00000239465.1	RP11-330L19.2	3.54	0.000432	0.0458	0.34	0.16	Coronary artery disease;	chr15:64422704	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs72741319	ENSG00000239465.1	RP11-330L19.2	3.54	0.000432	0.0458	0.34	0.16	Coronary artery disease;	chr15:64424778	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs72741320	ENSG00000239465.1	RP11-330L19.2	3.54	0.000432	0.0458	0.34	0.16	Coronary artery disease;	chr15:64429546	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs78659827	ENSG00000239465.1	RP11-330L19.2	3.54	0.000432	0.0458	0.34	0.16	Coronary artery disease;	chr15:64429728	chr15:64631109~64631914:-
LUAD	cis	rs6452524	0.967	rs11949474	ENSG00000281327.1	LINC01338	3.54	0.000432	0.0459	0.17	0.16	Hypertension (SNP x SNP interaction);	chr5:83179759	chr5:82850864~82859836:-
LUAD	cis	rs17695224	0.545	rs7253924	ENSG00000269483.1	AC006272.1	3.54	0.000432	0.0459	0.17	0.16	HDL cholesterol;HDL cholesterol levels;	chr19:51824960	chr19:51839924~51843324:-
LUAD	cis	rs17695224	0.545	rs8109098	ENSG00000269483.1	AC006272.1	3.54	0.000432	0.0459	0.17	0.16	HDL cholesterol;HDL cholesterol levels;	chr19:51825363	chr19:51839924~51843324:-
LUAD	cis	rs11158345	0.929	rs11621346	ENSG00000258926.1	RP11-47I22.1	3.54	0.000432	0.0459	0.17	0.16	Word reading;	chr14:61426473	chr14:61537508~61545287:-
LUAD	cis	rs1346081	0.786	rs7669686	ENSG00000250075.4	RP11-584P21.2	3.54	0.000432	0.0459	0.18	0.16	Intelligence (multi-trait analysis);	chr4:67172841	chr4:67417305~67468251:-
LUAD	cis	rs875971	0.545	rs1638735	ENSG00000224316.1	RP11-479O9.2	3.54	0.000432	0.0459	0.18	0.16	Aortic root size;	chr7:66630751	chr7:65773620~65802067:+
LUAD	cis	rs76382185	0.808	rs34864335	ENSG00000233184.5	RP11-421L21.3	3.54	0.000433	0.0459	0.28	0.16	Lymphocyte counts;	chr1:101115171	chr1:101025878~101087268:+
LUAD	cis	rs5742933	0.948	rs2264018	ENSG00000253559.1	OSGEPL1-AS1	-3.54	0.000433	0.0459	-0.21	-0.16	Ferritin levels;	chr2:189712052	chr2:189762704~189765556:+
LUAD	cis	rs2239547	0.522	rs2564947	ENSG00000243224.1	RP5-1157M23.2	3.54	0.000433	0.0459	0.17	0.16	Schizophrenia;	chr3:53012200	chr3:52239258~52241097:+
LUAD	cis	rs818427	0.929	rs469663	ENSG00000279522.1	CTC-487M23.6	3.54	0.000433	0.0459	0.19	0.16	Total body bone mineral density;	chr5:112896132	chr5:112894933~112896531:+
LUAD	cis	rs12190007	0.776	rs3006188	ENSG00000224999.1	VTA1P1	3.54	0.000433	0.0459	0.16	0.16	Obesity-related traits;	chr6:169387777	chr6:169296471~169297959:-
LUAD	cis	rs12712135	0.677	rs11678721	ENSG00000234389.1	AC007278.3	-3.54	0.000433	0.0459	-0.15	-0.16	Blood protein levels;	chr2:102456778	chr2:102438713~102440475:+
LUAD	cis	rs12712135	0.709	rs11677555	ENSG00000234389.1	AC007278.3	-3.54	0.000433	0.0459	-0.15	-0.16	Blood protein levels;	chr2:102456833	chr2:102438713~102440475:+
LUAD	cis	rs12712135	0.651	rs12712150	ENSG00000234389.1	AC007278.3	-3.54	0.000433	0.0459	-0.15	-0.16	Blood protein levels;	chr2:102458353	chr2:102438713~102440475:+
LUAD	cis	rs12712135	0.709	rs6705498	ENSG00000234389.1	AC007278.3	-3.54	0.000433	0.0459	-0.15	-0.16	Blood protein levels;	chr2:102460210	chr2:102438713~102440475:+
LUAD	cis	rs12712135	0.709	rs6719196	ENSG00000234389.1	AC007278.3	-3.54	0.000433	0.0459	-0.15	-0.16	Blood protein levels;	chr2:102460428	chr2:102438713~102440475:+
LUAD	cis	rs12712135	0.709	rs11676236	ENSG00000234389.1	AC007278.3	-3.54	0.000433	0.0459	-0.15	-0.16	Blood protein levels;	chr2:102465235	chr2:102438713~102440475:+
LUAD	cis	rs12712135	0.677	rs11687013	ENSG00000234389.1	AC007278.3	-3.54	0.000433	0.0459	-0.15	-0.16	Blood protein levels;	chr2:102465261	chr2:102438713~102440475:+
LUAD	cis	rs12712135	0.709	rs4140786	ENSG00000234389.1	AC007278.3	-3.54	0.000433	0.0459	-0.15	-0.16	Blood protein levels;	chr2:102471716	chr2:102438713~102440475:+
LUAD	cis	rs12493885	0.818	rs62276828	ENSG00000243069.6	ARHGEF26-AS1	-3.54	0.000433	0.0459	-0.27	-0.16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154058152	chr3:154024401~154121332:-
LUAD	cis	rs12493885	0.769	rs11718319	ENSG00000243069.6	ARHGEF26-AS1	-3.54	0.000433	0.0459	-0.27	-0.16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154059155	chr3:154024401~154121332:-
LUAD	cis	rs12493885	0.697	rs11710478	ENSG00000243069.6	ARHGEF26-AS1	-3.54	0.000433	0.0459	-0.27	-0.16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154059248	chr3:154024401~154121332:-
LUAD	cis	rs12493885	0.769	rs11710560	ENSG00000243069.6	ARHGEF26-AS1	-3.54	0.000433	0.0459	-0.27	-0.16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154059487	chr3:154024401~154121332:-
LUAD	cis	rs41369048	0.858	rs1572384	ENSG00000238078.1	LINC01352	-3.54	0.000433	0.0459	-0.23	-0.16	Eosinophil counts;Sum eosinophil basophil counts;	chr1:220907383	chr1:220829255~220832429:+
LUAD	cis	rs1442407	0.86	rs67844700	ENSG00000254319.4	RP11-134O21.1	-3.54	0.000433	0.0459	-0.28	-0.16	Systolic blood pressure in sickle cell anemia;	chr8:3246762	chr8:2666079~2728451:-
LUAD	cis	rs4699052	0.597	rs951598	ENSG00000246560.2	RP11-10L12.4	3.54	0.000433	0.0459	0.2	0.16	Testicular germ cell tumor;	chr4:103431408	chr4:102828055~102844075:+
LUAD	cis	rs7674212	0.531	rs10006474	ENSG00000230069.3	LRRC37A15P	-3.54	0.000433	0.0459	-0.17	-0.16	Type 2 diabetes;	chr4:103006890	chr4:102727274~102730721:-
LUAD	cis	rs4919669	0.668	rs3824756	ENSG00000213277.3	MARCKSL1P1	3.54	0.000433	0.0459	0.25	0.16	Mean arterial pressure (long-term average);Systolic blood pressure (long-term average);	chr10:102599593	chr10:103175554~103176094:+
LUAD	cis	rs6586111	0.765	rs11186273	ENSG00000226659.1	RP11-137H2.4	-3.54	0.000433	0.0459	-0.21	-0.16	Capecitabine sensitivity;	chr10:80611556	chr10:80529597~80535942:-
LUAD	cis	rs8064024	1	rs8064024	ENSG00000267077.1	RP11-127I20.5	-3.54	0.000433	0.0459	-0.18	-0.16	Cancer;	chr16:4805278	chr16:4795265~4796532:-
LUAD	cis	rs9951698	0.703	rs7233600	ENSG00000266969.1	RP11-773H22.4	3.54	0.000433	0.0459	0.21	0.16	Intelligence (multi-trait analysis);	chr18:12986001	chr18:12984694~12991173:-
LUAD	cis	rs6988985	0.765	rs4379428	ENSG00000247317.3	RP11-273G15.2	-3.54	0.000433	0.0459	-0.19	-0.16	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142906632	chr8:142981738~143018437:-
LUAD	cis	rs7246657	0.525	rs1667357	ENSG00000267309.1	CTD-2630F21.1	3.54	0.000433	0.0459	0.25	0.16	Coronary artery calcification;	chr19:36993450	chr19:36489649~36491040:+
LUAD	cis	rs7246657	0.525	rs1667359	ENSG00000267309.1	CTD-2630F21.1	3.54	0.000433	0.0459	0.25	0.16	Coronary artery calcification;	chr19:36995270	chr19:36489649~36491040:+
LUAD	cis	rs4819052	0.807	rs7283915	ENSG00000215447.6	BX322557.10	-3.54	0.000433	0.0459	-0.19	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251373	chr21:45288052~45291738:+
LUAD	cis	rs7829975	0.871	rs572307	ENSG00000253981.4	ALG1L13P	-3.54	0.000433	0.0459	-0.18	-0.16	Mood instability;	chr8:8721301	chr8:8236003~8244667:-
LUAD	cis	rs7937127	0.744	rs11602173	ENSG00000254907.1	RP11-484D2.2	-3.54	0.000433	0.0459	-0.27	-0.16	Fibrinogen levels;	chr11:43460399	chr11:43328748~43359296:-
LUAD	cis	rs9457247	1	rs2149085	ENSG00000227598.1	RP1-167A14.2	3.54	0.000433	0.0459	0.17	0.16	Crohn's disease;	chr6:166957622	chr6:166969626~166999065:-
LUAD	cis	rs3753275	0.568	rs1812457	ENSG00000232912.4	RP5-1115A15.1	3.54	0.000433	0.0459	0.18	0.16	Educational attainment;	chr1:8625461	chr1:8424645~8434838:+
LUAD	cis	rs2885805	0.794	rs6694506	ENSG00000261654.1	RP11-96K19.4	3.54	0.000433	0.0459	0.23	0.16	Cytomegalovirus antibody response;	chr1:110856346	chr1:110936369~110942353:-
LUAD	cis	rs12908161	0.959	rs17598603	ENSG00000254414.1	RP11-182J1.1	-3.54	0.000433	0.0459	-0.2	-0.16	Schizophrenia;	chr15:84656980	chr15:84631898~84633987:-
LUAD	cis	rs3733418	0.929	rs12510464	ENSG00000248632.1	RP11-366M4.11	3.54	0.000433	0.0459	0.26	0.16	Obesity-related traits;	chr4:164997888	chr4:164968587~164970002:-
LUAD	cis	rs34779708	0.931	rs1926556	ENSG00000271335.4	RP11-324I22.4	3.54	0.000433	0.0459	0.17	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35055979	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.931	rs1926554	ENSG00000271335.4	RP11-324I22.4	3.54	0.000433	0.0459	0.17	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35056041	chr10:35314552~35336401:-
LUAD	cis	rs34779708	0.931	rs4934710	ENSG00000271335.4	RP11-324I22.4	3.54	0.000433	0.0459	0.17	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35061488	chr10:35314552~35336401:-
LUAD	cis	rs7142881	0.605	rs35875023	ENSG00000250365.5	CTD-2213F21.2	3.54	0.000433	0.0459	0.18	0.16	Response to iloperidone treatment (QT prolongation);	chr14:31829768	chr14:31420286~31452883:+
LUAD	cis	rs4386084	0.963	rs56061666	ENSG00000242737.1	RP11-562A8.1	-3.54	0.000433	0.0459	-0.21	-0.16	Basophil percentage of granulocytes;Basophil percentage of white cells;	chr15:49946627	chr15:50466738~50467096:+
LUAD	cis	rs4386084	1	rs12904835	ENSG00000242737.1	RP11-562A8.1	-3.54	0.000433	0.0459	-0.21	-0.16	Basophil percentage of granulocytes;Basophil percentage of white cells;	chr15:49947160	chr15:50466738~50467096:+
LUAD	cis	rs4386084	0.963	rs9646199	ENSG00000242737.1	RP11-562A8.1	-3.54	0.000433	0.0459	-0.21	-0.16	Basophil percentage of granulocytes;Basophil percentage of white cells;	chr15:49953788	chr15:50466738~50467096:+
LUAD	cis	rs11976180	1	rs13243677	ENSG00000228960.5	OR2A9P	-3.54	0.000433	0.0459	-0.21	-0.16	Obesity-related traits;	chr7:144049479	chr7:144294480~144300934:+
LUAD	cis	rs35851103	0.6	rs4841662	ENSG00000255046.1	RP11-297N6.4	3.54	0.000433	0.0459	0.19	0.16	Neuroticism;	chr8:11986249	chr8:11797928~11802568:-
LUAD	cis	rs10456809	0.808	rs6918261	ENSG00000220920.1	RP3-525L6.2	-3.54	0.000433	0.0459	-0.2	-0.16	Prostate cancer (SNP x SNP interaction);	chr6:17815200	chr6:17953572~17953930:+
LUAD	cis	rs6088590	1	rs6119530	ENSG00000275784.1	RP5-1125A11.6	-3.54	0.000433	0.0459	-0.17	-0.16	Coronary artery disease;	chr20:34816127	chr20:33989480~33991818:-
LUAD	cis	rs6921919	0.638	rs7772827	ENSG00000219392.1	RP1-265C24.5	-3.54	0.000433	0.0459	-0.21	-0.16	Autism spectrum disorder or schizophrenia;	chr6:28333366	chr6:28115628~28116551:+
LUAD	cis	rs4835473	0.897	rs35598237	ENSG00000249741.2	RP11-673E1.3	3.54	0.000433	0.0459	0.19	0.16	Immature fraction of reticulocytes;	chr4:143735961	chr4:143911514~143912053:-
LUAD	cis	rs9611198	0.846	rs5757733	ENSG00000227188.1	MGAT3-AS1	-3.54	0.000433	0.0459	-0.18	-0.16	Schizophrenia;	chr22:39572168	chr22:39475807~39476822:-
LUAD	cis	rs7192380	0.965	rs7205551	ENSG00000226232.7	RP11-419C5.2	-3.54	0.000433	0.0459	-0.14	-0.16	Sjögren's syndrome;	chr16:69572065	chr16:69976388~69996188:-
LUAD	cis	rs2216164	0.898	rs10784681	ENSG00000256325.1	RP11-611O2.1	-3.54	0.000433	0.0459	-0.18	-0.16	Alopecia areata;	chr12:68135824	chr12:68828118~68828553:+
LUAD	cis	rs41271951	0.518	rs11580234	ENSG00000223945.2	RP11-458I7.1	-3.54	0.000433	0.0459	-0.29	-0.16	Blood protein levels;	chr1:150311867	chr1:150053864~150055034:+
LUAD	cis	rs41271951	0.518	rs114327352	ENSG00000223945.2	RP11-458I7.1	-3.54	0.000433	0.0459	-0.29	-0.16	Blood protein levels;	chr1:150313271	chr1:150053864~150055034:+
LUAD	cis	rs12743824	0.809	rs1325956	ENSG00000224616.1	RTCA-AS1	-3.54	0.000433	0.0459	-0.19	-0.16	Non-alcoholic fatty liver disease histology (other);	chr1:99326988	chr1:100264009~100266120:-
LUAD	cis	rs4763879	0.778	rs7977940	ENSG00000257027.1	RP11-705C15.3	3.54	0.000433	0.0459	0.2	0.16	Type 1 diabetes;	chr12:9686320	chr12:9658567~9662085:+
LUAD	cis	rs6467136	0.901	rs6962882	ENSG00000224138.1	AC000123.4	3.54	0.000433	0.0459	0.15	0.16	Type 2 diabetes;	chr7:127542254	chr7:127350128~127351523:+
LUAD	cis	rs2535633	0.631	rs2245424	ENSG00000243224.1	RP5-1157M23.2	3.54	0.000434	0.046	0.17	0.16	Body mass index;	chr3:52969005	chr3:52239258~52241097:+
LUAD	cis	rs67311347	1	rs2371186	ENSG00000280739.1	EIF1B-AS1	3.54	0.000434	0.046	0.18	0.16	Renal cell carcinoma;	chr3:40447222	chr3:40173145~40309698:-
LUAD	cis	rs9619254	0.92	rs16990001	ENSG00000224050.1	RP1-90G24.6	3.54	0.000434	0.046	0.25	0.16	Loneliness (multivariate analysis);	chr22:32204928	chr22:32273420~32277186:+
LUAD	cis	rs4470077	1	rs7156648	ENSG00000259318.1	RP11-454L9.2	3.54	0.000434	0.046	0.17	0.16	Platelet count;	chr14:55431681	chr14:55394940~55395233:-
LUAD	cis	rs6951245	1	rs11764748	ENSG00000224079.1	AC091729.7	-3.54	0.000434	0.046	-0.24	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054872	chr7:1074450~1078036:+
LUAD	cis	rs1346081	0.765	rs13125404	ENSG00000250075.4	RP11-584P21.2	-3.54	0.000434	0.046	-0.17	-0.16	Intelligence (multi-trait analysis);	chr4:67184094	chr4:67417305~67468251:-
LUAD	cis	rs2836974	0.897	rs14194	ENSG00000232608.1	TIMM9P2	-3.54	0.000434	0.046	-0.19	-0.16	Cognitive function;	chr21:39177540	chr21:39216624~39217506:+
LUAD	cis	rs875971	0.862	rs10274883	ENSG00000273448.1	RP11-166O4.6	-3.54	0.000434	0.046	-0.15	-0.16	Aortic root size;	chr7:66651104	chr7:67333047~67334383:+
LUAD	cis	rs801193	0.569	rs881285	ENSG00000273448.1	RP11-166O4.6	-3.54	0.000434	0.046	-0.15	-0.16	Aortic root size;	chr7:66654433	chr7:67333047~67334383:+
LUAD	cis	rs801193	0.569	rs3846973	ENSG00000273448.1	RP11-166O4.6	-3.54	0.000434	0.046	-0.15	-0.16	Aortic root size;	chr7:66655048	chr7:67333047~67334383:+
LUAD	cis	rs801193	0.569	rs2013908	ENSG00000273448.1	RP11-166O4.6	-3.54	0.000434	0.046	-0.15	-0.16	Aortic root size;	chr7:66656082	chr7:67333047~67334383:+
LUAD	cis	rs10129255	1	rs10141557	ENSG00000253209.1	IGHV3-65	3.54	0.000434	0.046	0.14	0.16	Kawasaki disease;	chr14:106767990	chr14:106666092~106666532:-
LUAD	cis	rs12744310	0.887	rs12042464	ENSG00000235358.1	RP11-399E6.1	-3.54	0.000434	0.046	-0.21	-0.16	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41321182	chr1:41242373~41284861:+
LUAD	cis	rs1577917	0.655	rs9444354	ENSG00000220563.1	PKMP3	3.54	0.000434	0.046	0.15	0.16	Response to antipsychotic treatment;	chr6:85582217	chr6:85659892~85660606:-
LUAD	cis	rs473518	0.796	rs665207	ENSG00000223023.1	Y_RNA	-3.54	0.000434	0.046	-0.25	-0.16	Migraine - clinic-based;	chr18:22514315	chr18:23024596~23024703:+
LUAD	cis	rs10129255	1	rs11627342	ENSG00000211967.3	IGHV3-53	-3.54	0.000434	0.046	-0.13	-0.16	Kawasaki disease;	chr14:106675823	chr14:106592676~106593347:-
LUAD	cis	rs2708977	0.637	rs585781	ENSG00000237510.6	AC008268.2	-3.54	0.000434	0.046	-0.21	-0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96422886	chr2:95789654~95800166:+
LUAD	cis	rs11168618	0.567	rs7314569	ENSG00000239617.1	RP11-302B13.1	3.54	0.000434	0.046	0.21	0.16	Adiponectin levels;	chr12:48423198	chr12:48903418~48903813:-
LUAD	cis	rs4819052	0.704	rs2297283	ENSG00000184274.3	LINC00315	-3.54	0.000434	0.046	-0.22	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263675	chr21:45300245~45305257:-
LUAD	cis	rs17818399	0.653	rs34050156	ENSG00000279254.1	RP11-536C12.1	-3.54	0.000434	0.046	-0.19	-0.16	Height;	chr2:46550507	chr2:46668870~46670778:+
LUAD	cis	rs7215564	0.822	rs2340771	ENSG00000232083.3	RPL31P7	-3.54	0.000434	0.046	-0.25	-0.16	Myopia (pathological);	chr17:80779147	chr17:80602549~80602926:-
LUAD	cis	rs6460942	0.659	rs6969309	ENSG00000226690.5	AC005281.1	3.54	0.000434	0.046	0.3	0.16	Coronary artery disease;	chr7:12476221	chr7:12496429~12541910:+
LUAD	cis	rs6460942	0.597	rs7811374	ENSG00000226690.5	AC005281.1	3.54	0.000434	0.046	0.3	0.16	Coronary artery disease;	chr7:12477811	chr7:12496429~12541910:+
LUAD	cis	rs4246511	0.77	rs1925679	ENSG00000228436.2	RP5-864K19.4	-3.54	0.000434	0.046	-0.2	-0.16	Menopause (age at onset);	chr1:38859187	chr1:38860000~38919396:+
LUAD	cis	rs7918232	0.943	rs6482593	ENSG00000262412.1	RP11-85G18.6	3.54	0.000434	0.046	0.23	0.16	Breast cancer;	chr10:27082508	chr10:27243130~27250804:+
LUAD	cis	rs17772222	0.597	rs17700521	ENSG00000258983.2	RP11-507K2.2	3.54	0.000434	0.046	0.19	0.16	Coronary artery calcification;	chr14:88849531	chr14:88499334~88515502:+
LUAD	cis	rs7246657	0.943	rs2081096	ENSG00000226686.6	LINC01535	-3.54	0.000434	0.046	-0.23	-0.16	Coronary artery calcification;	chr19:37473798	chr19:37251912~37265535:+
LUAD	cis	rs10510102	0.872	rs7906462	ENSG00000276742.1	RP11-500G22.4	3.54	0.000434	0.046	0.26	0.16	Breast cancer;	chr10:121948098	chr10:121956782~121957098:+
LUAD	cis	rs2071518	0.853	rs16892552	ENSG00000254343.2	RP11-760H22.2	-3.54	0.000434	0.046	-0.2	-0.16	Blood pressure;Pulse pressure;	chr8:119426033	chr8:120052180~120056201:+
LUAD	cis	rs2071518	0.853	rs58210708	ENSG00000254343.2	RP11-760H22.2	-3.54	0.000434	0.046	-0.2	-0.16	Blood pressure;Pulse pressure;	chr8:119426769	chr8:120052180~120056201:+
LUAD	cis	rs786425	0.966	rs7134896	ENSG00000278112.1	RP11-972P1.11	3.54	0.000434	0.046	0.14	0.16	Pubertal anthropometrics;	chr12:123617311	chr12:123519390~123519856:-
LUAD	cis	rs9595908	0.746	rs9591229	ENSG00000281026.1	N4BP2L2-IT2	-3.54	0.000434	0.046	-0.1	-0.16	Body mass index;	chr13:32658870	chr13:32504506~32509395:-
LUAD	cis	rs9595908	0.746	rs4942792	ENSG00000281026.1	N4BP2L2-IT2	-3.54	0.000434	0.046	-0.1	-0.16	Body mass index;	chr13:32663326	chr13:32504506~32509395:-
LUAD	cis	rs9595908	0.746	rs9596048	ENSG00000281026.1	N4BP2L2-IT2	-3.54	0.000434	0.046	-0.1	-0.16	Body mass index;	chr13:32664595	chr13:32504506~32509395:-
LUAD	cis	rs1062753	0.771	rs5751245	ENSG00000226450.2	CYP2D8P	3.54	0.000434	0.046	0.14	0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42224934	chr22:42149886~42155001:-
LUAD	cis	rs7003550	1	rs10091775	ENSG00000253433.1	NCRNA00250	-3.54	0.000434	0.046	-0.21	-0.16	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr8:134843938	chr8:134838069~134842637:+
LUAD	cis	rs17772222	0.675	rs845758	ENSG00000258789.1	RP11-507K2.3	3.54	0.000435	0.046	0.19	0.16	Coronary artery calcification;	chr14:88433746	chr14:88551597~88552493:+
LUAD	cis	rs11874381	1	rs17656948	ENSG00000266696.1	RP11-30L3.2	3.54	0.000435	0.046	0.18	0.16	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);	chr18:49683601	chr18:49205912~49208781:+
LUAD	cis	rs6137287	0.667	rs6082391	ENSG00000227063.5	RPL41P1	-3.54	0.000435	0.046	-0.2	-0.16	Height;	chr20:21343872	chr20:21755270~21755350:+
LUAD	cis	rs6137287	0.667	rs6035850	ENSG00000227063.5	RPL41P1	-3.54	0.000435	0.046	-0.2	-0.16	Height;	chr20:21345073	chr20:21755270~21755350:+
LUAD	cis	rs1075265	0.87	rs7569370	ENSG00000272156.1	RP11-477N3.1	-3.54	0.000435	0.046	-0.19	-0.16	Chronotype;Morning vs. evening chronotype;	chr2:53989212	chr2:54082554~54085066:+
LUAD	cis	rs3749855	0.679	rs13219435	ENSG00000220920.1	RP3-525L6.2	3.54	0.000435	0.046	0.33	0.16	Glucose homeostasis traits;	chr6:17253450	chr6:17953572~17953930:+
LUAD	cis	rs7940646	0.812	rs2052690	ENSG00000246308.1	RP11-685M7.3	-3.54	0.000435	0.046	-0.19	-0.16	Platelet aggregation;	chr11:10642486	chr11:10809297~10822931:+
LUAD	cis	rs763121	0.925	rs1043312	ENSG00000225450.1	RP3-508I15.14	-3.54	0.000435	0.0461	-0.15	-0.16	Menopause (age at onset);	chr22:38735722	chr22:38739003~38749041:+
LUAD	cis	rs2235642	0.533	rs2667679	ENSG00000280231.1	LA16c-380F5.3	-3.54	0.000435	0.0461	-0.22	-0.16	Coronary artery disease;	chr16:1604945	chr16:1553655~1554130:-
LUAD	cis	rs1144	0.537	rs2470949	ENSG00000237513.1	RP11-325F22.2	3.54	0.000435	0.0461	0.15	0.16	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for body mass index;	chr7:104950333	chr7:104941063~104962334:+
LUAD	cis	rs4727963	0.811	rs2140853	ENSG00000240499.6	RP5-1101C3.1	3.54	0.000435	0.0461	0.14	0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);	chr7:123073067	chr7:122328469~122440388:+
LUAD	cis	rs9400467	0.922	rs1216019	ENSG00000271789.1	RP5-1112D6.7	-3.54	0.000435	0.0461	-0.17	-0.16	Amino acid levels;Blood metabolite levels;	chr6:111181991	chr6:111297126~111298510:+
LUAD	cis	rs7208859	0.673	rs216424	ENSG00000280069.1	CTD-2349P21.3	-3.54	0.000435	0.0461	-0.19	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30616046	chr17:30738182~30740275:+
LUAD	cis	rs4763879	0.729	rs10844472	ENSG00000214776.8	RP11-726G1.1	-3.54	0.000435	0.0461	-0.19	-0.16	Type 1 diabetes;	chr12:9691137	chr12:9467552~9576275:+
LUAD	cis	rs6430585	0.583	rs3769008	ENSG00000226806.1	AC011893.3	3.54	0.000435	0.0461	0.24	0.16	Corneal structure;	chr2:135828613	chr2:135820191~135823087:+
LUAD	cis	rs2333194	0.844	rs17182286	ENSG00000258695.2	RP3-414A15.2	-3.54	0.000435	0.0461	-0.17	-0.16	Bipolar disorder with mood-incongruent psychosis;	chr14:73282200	chr14:73522878~73530610:+
LUAD	cis	rs2274273	0.967	rs10137409	ENSG00000259318.1	RP11-454L9.2	3.54	0.000435	0.0461	0.14	0.16	Protein biomarker;	chr14:55144723	chr14:55394940~55395233:-
LUAD	cis	rs950169	0.881	rs4842852	ENSG00000188388.10	GOLGA6L3	3.54	0.000435	0.0461	0.22	0.16	Schizophrenia;	chr15:84387263	chr15:85240472~85247170:+
LUAD	cis	rs950169	0.84	rs4842853	ENSG00000188388.10	GOLGA6L3	3.54	0.000435	0.0461	0.22	0.16	Schizophrenia;	chr15:84387606	chr15:85240472~85247170:+
LUAD	cis	rs950169	0.922	rs4842946	ENSG00000188388.10	GOLGA6L3	3.54	0.000435	0.0461	0.22	0.16	Schizophrenia;	chr15:84387633	chr15:85240472~85247170:+
LUAD	cis	rs950169	0.887	rs3860265	ENSG00000188388.10	GOLGA6L3	3.54	0.000435	0.0461	0.22	0.16	Schizophrenia;	chr15:84390487	chr15:85240472~85247170:+
LUAD	cis	rs293377	0.961	rs293370	ENSG00000260123.1	RP11-326A19.4	-3.54	0.000435	0.0461	-0.2	-0.16	Gut microbiota (beta diversity);	chr15:89087245	chr15:89041223~89082819:+
LUAD	cis	rs734999	1	rs10797432	ENSG00000238164.5	RP3-395M20.8	-3.54	0.000435	0.0461	-0.13	-0.16	Ulcerative colitis;	chr1:2569899	chr1:2549920~2557031:-
LUAD	cis	rs6502050	0.604	rs9897355	ENSG00000275966.1	RP11-1055B8.9	3.54	0.000435	0.0461	0.16	0.16	Life satisfaction;	chr17:82120219	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs35857672	ENSG00000275966.1	RP11-1055B8.9	3.54	0.000435	0.0461	0.16	0.16	Life satisfaction;	chr17:82120427	chr17:81345476~81345966:-
LUAD	cis	rs10496166	0.729	rs11126200	ENSG00000236259.1	AC017083.2	-3.54	0.000435	0.0461	-0.19	-0.16	RR interval (heart rate);	chr2:68814651	chr2:68125265~68125747:+
LUAD	cis	rs2337406	0.925	rs2011167	ENSG00000280411.1	IGHV1-69-2	-3.54	0.000435	0.0461	-0.15	-0.16	Alzheimer's disease (late onset);	chr14:106680831	chr14:106762092~106762588:-
LUAD	cis	rs7107174	1	rs7107174	ENSG00000251323.2	RP11-452H21.4	3.54	0.000435	0.0461	0.22	0.16	Testicular germ cell tumor;	chr11:78286890	chr11:78423982~78429836:-
LUAD	cis	rs1552244	0.882	rs13089863	ENSG00000180385.7	EMC3-AS1	-3.54	0.000435	0.0461	-0.2	-0.16	Alzheimer's disease;	chr3:9990575	chr3:9986893~10006990:+
LUAD	cis	rs9309711	0.922	rs13431788	ENSG00000271868.1	RP11-1293J14.1	-3.54	0.000435	0.0461	-0.19	-0.16	Neurofibrillary tangles;	chr2:3479141	chr2:3496956~3497428:+
LUAD	cis	rs7142881	0.787	rs11625161	ENSG00000258525.1	RP11-829H16.3	-3.54	0.000435	0.0461	-0.18	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31592177	chr14:30876179~30889808:-
LUAD	cis	rs35740288	0.77	rs35348278	ENSG00000259407.1	RP11-158M2.3	-3.54	0.000436	0.0461	-0.16	-0.16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85657109	chr15:85744109~85750281:-
LUAD	cis	rs7772486	0.764	rs2265471	ENSG00000235652.6	RP11-545I5.3	3.54	0.000436	0.0461	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145899114	chr6:145799409~145886585:+
LUAD	cis	rs9543976	0.623	rs6562915	ENSG00000261105.4	LMO7-AS1	3.54	0.000436	0.0461	0.23	0.16	Diabetic retinopathy;	chr13:75596750	chr13:75604700~75635994:-
LUAD	cis	rs7942368	1	rs10160660	ENSG00000254632.1	RP11-21L23.4	3.54	0.000436	0.0461	0.17	0.16	Endometriosis;	chr11:76763493	chr11:76759916~76768223:-
LUAD	cis	rs7660883	0.897	rs236987	ENSG00000251411.1	RP11-397E7.4	3.54	0.000436	0.0461	0.17	0.16	HDL cholesterol levels;	chr4:87088627	chr4:86913266~86914817:-
LUAD	cis	rs8092503	1	rs3764512	ENSG00000267325.1	LINC01415	-3.54	0.000436	0.0461	-0.21	-0.16	Childhood body mass index;	chr18:54828093	chr18:55776727~55781721:-
LUAD	cis	rs6001482	0.533	rs12484704	ENSG00000223350.2	IGLV9-49	-3.54	0.000436	0.0461	-0.19	-0.16	Diastolic blood pressure;	chr22:22228856	chr22:22343187~22343732:+
LUAD	cis	rs6736093	1	rs34928784	ENSG00000207383.1	Y_RNA	-3.54	0.000436	0.0461	-0.21	-0.16	Coronary artery disease;	chr2:111899485	chr2:112579484~112579584:-
LUAD	cis	rs12220238	0.722	rs11001087	ENSG00000226051.5	ZNF503-AS1	3.54	0.000436	0.0461	0.29	0.16	Soluble interleukin-2 receptor subunit alpha;	chr10:74624844	chr10:75269819~75373500:+
LUAD	cis	rs6121246	0.909	rs2376992	ENSG00000230613.1	HM13-AS1	3.54	0.000436	0.0462	0.23	0.16	Mean corpuscular hemoglobin;	chr20:31675615	chr20:31567707~31573263:-
LUAD	cis	rs9859260	0.744	rs3933	ENSG00000207650.1	MIR570	-3.54	0.000436	0.0462	-0.17	-0.16	Mean corpuscular volume;	chr3:196058126	chr3:195699401~195699497:+
LUAD	cis	rs72827839	0.779	rs72827844	ENSG00000266601.1	RP11-6N17.3	3.54	0.000436	0.0462	0.22	0.16	Ease of getting up in the morning;	chr17:48357079	chr17:47929682~47933106:-
LUAD	cis	rs10510102	0.872	rs12244199	ENSG00000276742.1	RP11-500G22.4	3.54	0.000436	0.0462	0.28	0.16	Breast cancer;	chr10:121965117	chr10:121956782~121957098:+
LUAD	cis	rs7612209	0.762	rs7643184	ENSG00000277241.1	RP11-114M1.3	3.54	0.000436	0.0462	0.21	0.16	Cognitive performance;	chr3:177880694	chr3:177700346~177701072:-
LUAD	cis	rs4763879	1	rs4763879	ENSG00000214776.8	RP11-726G1.1	3.54	0.000436	0.0462	0.19	0.16	Type 1 diabetes;	chr12:9757568	chr12:9467552~9576275:+
LUAD	cis	rs10090774	0.834	rs11997161	ENSG00000280303.2	ERICD	-3.54	0.000436	0.0462	-0.17	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140728488	chr8:140636281~140638283:+
LUAD	cis	rs4842666	0.915	rs17249754	ENSG00000258302.2	RP11-981P6.1	-3.54	0.000436	0.0462	-0.21	-0.16	Blood pressure;	chr12:89666809	chr12:89561129~89594878:+
LUAD	cis	rs4601821	1	rs3897584	ENSG00000270179.1	RP11-159N11.4	3.54	0.000436	0.0462	0.16	0.16	Alcoholic chronic pancreatitis;	chr11:113379003	chr11:113368478~113369117:+
LUAD	cis	rs12440869	1	rs17230761	ENSG00000270964.1	RP11-502I4.3	3.54	0.000436	0.0462	0.18	0.16	Peak velocity of the mitral A-wave;	chr15:67312745	chr15:67541072~67542604:-
LUAD	cis	rs7824557	0.527	rs2572449	ENSG00000255046.1	RP11-297N6.4	-3.54	0.000436	0.0462	-0.2	-0.16	Retinal vascular caliber;	chr8:11381628	chr8:11797928~11802568:-
LUAD	cis	rs10483853	0.806	rs11625692	ENSG00000258695.2	RP3-414A15.2	-3.54	0.000436	0.0462	-0.2	-0.16	Coronary artery calcification;	chr14:73329557	chr14:73522878~73530610:+
LUAD	cis	rs4845570	0.92	rs3811414	ENSG00000203288.3	RP11-98D18.9	-3.54	0.000436	0.0462	-0.22	-0.16	Coronary artery disease;	chr1:151790770	chr1:151790804~151794402:+
LUAD	cis	rs4822983	0.516	rs695797	ENSG00000272858.1	CTA-292E10.8	-3.54	0.000436	0.0462	-0.2	-0.16	Esophageal cancer (squamous cell);	chr22:28453761	chr22:28814914~28815662:+
LUAD	cis	rs4237845	0.837	rs7963992	ENSG00000245651.2	RP11-620J15.2	3.54	0.000436	0.0462	0.15	0.16	Intelligence (multi-trait analysis);	chr12:57902166	chr12:57869835~57896482:-
LUAD	cis	rs734999	0.87	rs2147905	ENSG00000238164.5	RP3-395M20.8	3.54	0.000436	0.0462	0.13	0.16	Ulcerative colitis;	chr1:2551482	chr1:2549920~2557031:-
LUAD	cis	rs11159086	0.838	rs10147963	ENSG00000270000.1	RP3-449M8.9	3.54	0.000436	0.0462	0.22	0.16	Advanced glycation end-product levels;	chr14:74476091	chr14:74471930~74472360:-
LUAD	cis	rs1555322	0.53	rs2425044	ENSG00000261582.1	RP4-614O4.11	-3.54	0.000436	0.0462	-0.21	-0.16	Attention deficit hyperactivity disorder;	chr20:35281932	chr20:35267885~35280043:-
LUAD	cis	rs950169	0.92	rs11637666	ENSG00000259570.1	RP11-671M22.4	3.54	0.000436	0.0462	0.24	0.16	Schizophrenia;	chr15:84035122	chr15:84394512~84395514:+
LUAD	cis	rs10829156	0.679	rs4747352	ENSG00000240291.1	RP11-499P20.2	3.54	0.000436	0.0462	0.15	0.16	Sudden cardiac arrest;	chr10:18539734	chr10:18513115~18545651:-
LUAD	cis	rs12438356	0.686	rs12101761	ENSG00000212766.8	EWSAT1	-3.54	0.000436	0.0462	-0.29	-0.16	CTACK levels;	chr15:69218794	chr15:69072926~69095820:+
LUAD	cis	rs8085804	0.597	rs12185391	ENSG00000276174.1	RP11-687E1.2	-3.54	0.000436	0.0462	-0.21	-0.16	Cognitive performance;	chr18:42632115	chr18:42052705~42053030:+
LUAD	cis	rs875971	1	rs778726	ENSG00000273142.1	RP11-458F8.4	-3.54	0.000436	0.0462	-0.11	-0.16	Aortic root size;	chr7:66363744	chr7:66902857~66906297:+
LUAD	cis	rs875971	0.964	rs778723	ENSG00000273142.1	RP11-458F8.4	-3.54	0.000436	0.0462	-0.11	-0.16	Aortic root size;	chr7:66364510	chr7:66902857~66906297:+
LUAD	cis	rs875971	0.767	rs1695815	ENSG00000273142.1	RP11-458F8.4	-3.54	0.000436	0.0462	-0.11	-0.16	Aortic root size;	chr7:66366357	chr7:66902857~66906297:+
LUAD	cis	rs875971	1	rs778685	ENSG00000273142.1	RP11-458F8.4	-3.54	0.000436	0.0462	-0.11	-0.16	Aortic root size;	chr7:66371189	chr7:66902857~66906297:+
LUAD	cis	rs875971	0.929	rs778682	ENSG00000273142.1	RP11-458F8.4	-3.54	0.000436	0.0462	-0.11	-0.16	Aortic root size;	chr7:66372947	chr7:66902857~66906297:+
LUAD	cis	rs875971	0.964	rs11765965	ENSG00000273142.1	RP11-458F8.4	-3.54	0.000436	0.0462	-0.11	-0.16	Aortic root size;	chr7:66377234	chr7:66902857~66906297:+
LUAD	cis	rs262150	0.704	rs2730236	ENSG00000231419.5	LINC00689	-3.54	0.000436	0.0462	-0.19	-0.16	Facial morphology (factor 20);	chr7:158972852	chr7:159006522~159030195:+
LUAD	cis	rs9834975	0.565	rs4677957	ENSG00000272758.4	RP11-299J3.8	3.54	0.000436	0.0462	0.15	0.16	Diastolic blood pressure;	chr3:122538920	chr3:122416207~122443180:+
LUAD	cis	rs11122272	0.735	rs2739513	ENSG00000233461.4	RP11-295G20.2	-3.54	0.000436	0.0462	-0.16	-0.16	Hemoglobin concentration;	chr1:231379455	chr1:231522388~231528556:-
LUAD	cis	rs797680	0.891	rs4847399	ENSG00000223745.6	RP4-717I23.3	3.54	0.000437	0.0462	0.12	0.16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93119049	chr1:93262186~93346025:-
LUAD	cis	rs7017914	0.905	rs1353058	ENSG00000246366.5	RP11-382J12.1	3.54	0.000437	0.0462	0.14	0.16	Bone mineral density;	chr8:71009783	chr8:70608577~70663279:+
LUAD	cis	rs10911232	0.507	rs4072709	ENSG00000224468.3	RP11-181K3.4	-3.54	0.000437	0.0462	-0.14	-0.16	Hypertriglyceridemia;	chr1:183059720	chr1:183138402~183141282:-
LUAD	cis	rs939960	0.618	rs1234357	ENSG00000279536.1	RP11-445N20.2	-3.54	0.000437	0.0462	-0.23	-0.16	Neutrophil percentage of white cells;	chr7:150686429	chr7:149881477~149882105:+
LUAD	cis	rs899997	1	rs12899940	ENSG00000261143.1	ADAMTS7P3	-3.54	0.000437	0.0462	-0.17	-0.16	Coronary artery disease or large artery stroke;	chr15:78709357	chr15:77976042~77993057:+
LUAD	cis	rs7223966	1	rs11079511	ENSG00000279369.1	RP11-51F16.1	-3.54	0.000437	0.0462	-0.18	-0.16	Hip circumference adjusted for BMI;Body mass index;	chr17:63781177	chr17:63700847~63702670:+
LUAD	cis	rs7942368	0.941	rs11236936	ENSG00000254632.1	RP11-21L23.4	3.54	0.000437	0.0462	0.17	0.16	Endometriosis;	chr11:76789786	chr11:76759916~76768223:-
LUAD	cis	rs2342371	0.805	rs55997345	ENSG00000273013.1	CTD-2002J20.1	-3.54	0.000437	0.0462	-0.2	-0.16	Fat distribution (HIV);	chr3:196491482	chr3:196474801~196475394:+
LUAD	cis	rs2342371	0.848	rs12632592	ENSG00000273013.1	CTD-2002J20.1	-3.54	0.000437	0.0462	-0.2	-0.16	Fat distribution (HIV);	chr3:196492494	chr3:196474801~196475394:+
LUAD	cis	rs7215564	0.73	rs7212125	ENSG00000232083.3	RPL31P7	-3.54	0.000437	0.0462	-0.26	-0.16	Myopia (pathological);	chr17:80655063	chr17:80602549~80602926:-
LUAD	cis	rs6806253	0.838	rs13094018	ENSG00000279507.1	RP11-723O4.7	-3.54	0.000437	0.0462	-0.24	-0.16	Pit-and-Fissure caries;	chr3:128560414	chr3:128914833~128915060:-
LUAD	cis	rs7772486	0.686	rs9399564	ENSG00000235652.6	RP11-545I5.3	-3.54	0.000437	0.0462	-0.16	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145757771	chr6:145799409~145886585:+
LUAD	cis	rs8028182	0.636	rs28783769	ENSG00000246877.1	DNM1P35	3.54	0.000437	0.0462	0.21	0.16	Sudden cardiac arrest;	chr15:75556668	chr15:75727670~75738623:-
LUAD	cis	rs155346	1	rs645850	ENSG00000281398.1	SNHG4	3.54	0.000437	0.0462	0.18	0.16	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;	chr5:140013832	chr5:139274102~139283244:+
LUAD	cis	rs2348418	0.715	rs12307612	ENSG00000244712.1	RP11-874G11.1	3.54	0.000437	0.0462	0.19	0.16	Lung function (FEV1);Lung function (FVC);	chr12:28566713	chr12:28564678~28565141:-
LUAD	cis	rs2348418	0.715	rs12307709	ENSG00000244712.1	RP11-874G11.1	3.54	0.000437	0.0462	0.19	0.16	Lung function (FEV1);Lung function (FVC);	chr12:28566767	chr12:28564678~28565141:-
LUAD	cis	rs2348418	0.715	rs11049719	ENSG00000244712.1	RP11-874G11.1	3.54	0.000437	0.0462	0.19	0.16	Lung function (FEV1);Lung function (FVC);	chr12:28567446	chr12:28564678~28565141:-
LUAD	cis	rs2348418	0.715	rs11049720	ENSG00000244712.1	RP11-874G11.1	3.54	0.000437	0.0462	0.19	0.16	Lung function (FEV1);Lung function (FVC);	chr12:28567477	chr12:28564678~28565141:-
LUAD	cis	rs78572108	0.858	rs4952565	ENSG00000214691.7	AC104654.1	3.54	0.000437	0.0462	0.28	0.16	Total body bone mineral density;	chr2:42016755	chr2:41877074~41894046:+
LUAD	cis	rs875971	0.642	rs35526611	ENSG00000222364.1	RNU6-96P	3.54	0.000437	0.0462	0.18	0.16	Aortic root size;	chr7:66629021	chr7:66395191~66395286:+
LUAD	cis	rs17596685	1	rs2277438	ENSG00000271216.1	LINC01050	3.54	0.000437	0.0462	0.23	0.16	C-reactive protein levels;	chr13:42581032	chr13:42810366~42812562:-
LUAD	cis	rs6452524	0.507	rs28592576	ENSG00000281327.1	LINC01338	3.54	0.000437	0.0462	0.17	0.16	Hypertension (SNP x SNP interaction);	chr5:83074772	chr5:82850864~82859836:-
LUAD	cis	rs11992162	0.573	rs13275808	ENSG00000255046.1	RP11-297N6.4	3.54	0.000437	0.0462	0.2	0.16	Monocyte count;	chr8:11925306	chr8:11797928~11802568:-
LUAD	cis	rs2803122	0.934	rs2175378	ENSG00000273226.1	RP11-513M16.8	-3.54	0.000437	0.0462	-0.17	-0.16	Pulse pressure;	chr9:19241965	chr9:19375451~19375996:+
LUAD	cis	rs11779988	0.545	rs4124900	ENSG00000253671.1	RP11-806O11.1	-3.54	0.000437	0.0462	-0.2	-0.16	Breast cancer;	chr8:17927757	chr8:17808941~17820868:+
LUAD	cis	rs4474465	0.85	rs6592789	ENSG00000251323.2	RP11-452H21.4	-3.54	0.000437	0.0462	-0.21	-0.16	Alzheimer's disease (survival time);	chr11:78535721	chr11:78423982~78429836:-
LUAD	cis	rs926392	0.965	rs6028258	ENSG00000274825.1	RP4-616B8.5	-3.54	0.000437	0.0462	-0.2	-0.16	Dialysis-related mortality;	chr20:39064201	chr20:38955910~38956547:+
LUAD	cis	rs6928977	0.66	rs2757643	ENSG00000231028.7	LINC00271	-3.54	0.000437	0.0463	-0.18	-0.16	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135440095	chr6:135497801~135716055:+
LUAD	cis	rs755249	0.53	rs1472662	ENSG00000182109.6	RP11-69E11.4	3.54	0.000437	0.0463	0.2	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39124737	chr1:39522280~39546187:-
LUAD	cis	rs4578769	0.569	rs12966840	ENSG00000266850.1	RP11-370A5.1	-3.54	0.000437	0.0463	-0.2	-0.16	Eosinophil percentage of white cells;	chr18:22856911	chr18:22723491~22907721:-
LUAD	cis	rs9457247	1	rs2769347	ENSG00000227598.1	RP1-167A14.2	3.54	0.000437	0.0463	0.17	0.16	Crohn's disease;	chr6:166958249	chr6:166969626~166999065:-
LUAD	cis	rs2239547	0.657	rs2071040	ENSG00000243224.1	RP5-1157M23.2	-3.54	0.000437	0.0463	-0.19	-0.16	Schizophrenia;	chr3:52830844	chr3:52239258~52241097:+
LUAD	cis	rs62025270	0.747	rs17639314	ENSG00000259416.2	RP11-158M2.5	-3.54	0.000437	0.0463	-0.21	-0.16	Idiopathic pulmonary fibrosis;	chr15:85766678	chr15:85754941~85756237:-
LUAD	cis	rs2302045	1	rs2240544	ENSG00000216921.6	AC131097.4	3.54	0.000437	0.0463	0.37	0.16	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio);	chr2:241127415	chr2:241893985~241902551:-
LUAD	cis	rs9973361	0.592	rs3764998	ENSG00000232411.1	AC009495.3	-3.54	0.000437	0.0463	-0.22	-0.16	Total body bone mineral density;	chr2:165876017	chr2:165833048~165839098:-
LUAD	cis	rs875971	0.638	rs801205	ENSG00000273142.1	RP11-458F8.4	3.54	0.000437	0.0463	0.11	0.16	Aortic root size;	chr7:66557157	chr7:66902857~66906297:+
LUAD	cis	rs875971	0.617	rs810400	ENSG00000273142.1	RP11-458F8.4	3.54	0.000437	0.0463	0.11	0.16	Aortic root size;	chr7:66557902	chr7:66902857~66906297:+
LUAD	cis	rs12049351	0.774	rs10799533	ENSG00000229367.1	HMGN2P19	3.54	0.000437	0.0463	0.23	0.16	Circulating myeloperoxidase levels (plasma);	chr1:229520815	chr1:229570532~229570796:+
LUAD	cis	rs12049351	0.613	rs10799535	ENSG00000229367.1	HMGN2P19	3.54	0.000437	0.0463	0.23	0.16	Circulating myeloperoxidase levels (plasma);	chr1:229522047	chr1:229570532~229570796:+
LUAD	cis	rs950169	0.922	rs67804993	ENSG00000188388.10	GOLGA6L3	3.54	0.000437	0.0463	0.21	0.16	Schizophrenia;	chr15:84560799	chr15:85240472~85247170:+
LUAD	cis	rs17157903	0.822	rs10244625	ENSG00000243352.3	RN7SL8P	3.54	0.000437	0.0463	0.22	0.16	Multiple sclerosis (age of onset);	chr7:103979358	chr7:104911928~104912193:+
LUAD	cis	rs17157903	0.822	rs10248660	ENSG00000243352.3	RN7SL8P	3.54	0.000437	0.0463	0.22	0.16	Multiple sclerosis (age of onset);	chr7:103980107	chr7:104911928~104912193:+
LUAD	cis	rs440932	0.747	rs330946	ENSG00000254340.1	RP11-10A14.3	3.54	0.000437	0.0463	0.2	0.16	High light scatter reticulocyte percentage of red cells;	chr8:9164667	chr8:9141424~9145435:+
LUAD	cis	rs9900280	1	rs12452156	ENSG00000264808.1	RP11-802D6.1	3.54	0.000438	0.0463	0.19	0.16	Mean platelet volume;	chr17:29445300	chr17:29369717~29390777:-
LUAD	cis	rs2836974	0.568	rs2836969	ENSG00000232608.1	TIMM9P2	3.54	0.000438	0.0463	0.18	0.16	Cognitive function;	chr21:39276339	chr21:39216624~39217506:+
LUAD	cis	rs2836974	0.584	rs6517535	ENSG00000232608.1	TIMM9P2	3.54	0.000438	0.0463	0.18	0.16	Cognitive function;	chr21:39281426	chr21:39216624~39217506:+
LUAD	cis	rs2836974	0.627	rs7278985	ENSG00000232608.1	TIMM9P2	3.54	0.000438	0.0463	0.18	0.16	Cognitive function;	chr21:39281841	chr21:39216624~39217506:+
LUAD	cis	rs9921338	0.961	rs4356497	ENSG00000263080.1	RP11-485G7.5	-3.54	0.000438	0.0463	-0.21	-0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11320339	chr16:11341809~11345211:-
LUAD	cis	rs2179367	0.959	rs9285519	ENSG00000216906.2	RP11-350J20.9	3.54	0.000438	0.0463	0.19	0.16	Dupuytren's disease;	chr6:149371799	chr6:149904243~149906418:+
LUAD	cis	rs448720	1	rs11853797	ENSG00000260657.2	RP11-315D16.4	3.54	0.000438	0.0463	0.18	0.16	Cognitive performance;	chr15:67908240	chr15:68267792~68277994:-
LUAD	cis	rs4835473	0.897	rs17693768	ENSG00000249741.2	RP11-673E1.3	3.54	0.000438	0.0463	0.19	0.16	Immature fraction of reticulocytes;	chr4:143737503	chr4:143911514~143912053:-
LUAD	cis	rs2455601	0.744	rs11042107	ENSG00000243964.1	RP11-16F15.1	-3.54	0.000438	0.0463	-0.18	-0.16	Schizophrenia;	chr11:8884324	chr11:9606142~9606609:+
LUAD	cis	rs6951245	0.554	rs58210047	ENSG00000229043.2	AC091729.9	-3.54	0.000438	0.0463	-0.2	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1109745	chr7:1160374~1165267:+
LUAD	cis	rs957448	1	rs56716157	ENSG00000253175.1	RP11-267M23.6	3.54	0.000438	0.0463	0.2	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94530644	chr8:94565036~94565715:+
LUAD	cis	rs6012953	0.817	rs1060402	ENSG00000231715.1	COX6CP2	-3.54	0.000438	0.0463	-0.16	-0.16	Vitiligo;	chr20:50588558	chr20:50479767~50479991:+
LUAD	cis	rs7246967	0.673	rs73022717	ENSG00000236312.3	RPL34P34	3.54	0.000438	0.0463	0.24	0.16	Bronchopulmonary dysplasia;	chr19:22694257	chr19:22368599~22368952:-
LUAD	cis	rs9900280	0.935	rs2681179	ENSG00000264808.1	RP11-802D6.1	-3.54	0.000438	0.0463	-0.18	-0.16	Mean platelet volume;	chr17:29492033	chr17:29369717~29390777:-
LUAD	cis	rs12681963	0.702	rs10090988	ENSG00000272375.1	RP11-51J9.6	-3.54	0.000438	0.0463	-0.2	-0.16	Migraine;	chr8:30079888	chr8:30197404~30198048:+
LUAD	cis	rs13113518	1	rs34648901	ENSG00000223305.1	RN7SKP30	3.54	0.000438	0.0463	0.18	0.16	Height;	chr4:55541259	chr4:55540502~55540835:-
LUAD	cis	rs8012947	1	rs1957038	ENSG00000279636.2	LINC00216	-3.54	0.000438	0.0463	-0.18	-0.16	Alcohol consumption in current drinkers;	chr14:58299899	chr14:58288033~58289158:+
LUAD	cis	rs6736093	0.704	rs10207301	ENSG00000207383.1	Y_RNA	-3.54	0.000438	0.0463	-0.21	-0.16	Coronary artery disease;	chr2:112044768	chr2:112579484~112579584:-
LUAD	cis	rs10916248	0.559	rs116083281	ENSG00000232628.4	RP11-365O16.3	3.54	0.000438	0.0463	0.23	0.16	QT interval (drug interaction);	chr1:224199365	chr1:224208747~224213279:-
LUAD	cis	rs3758911	0.964	rs7358296	ENSG00000261098.1	RP11-819C21.1	-3.54	0.000438	0.0463	-0.14	-0.16	Coronary artery disease;	chr11:107403212	chr11:107312132~107316271:-
LUAD	cis	rs5758659	0.714	rs6002607	ENSG00000273366.1	CTA-989H11.1	3.54	0.000438	0.0463	0.18	0.16	Cognitive function;	chr22:42100502	chr22:42278188~42278846:+
LUAD	cis	rs7809950	1	rs2520268	ENSG00000238832.1	snoU109	-3.54	0.000438	0.0463	-0.24	-0.16	Coronary artery disease;	chr7:107550716	chr7:107603363~107603507:+
LUAD	cis	rs9595908	0.785	rs17515873	ENSG00000281026.1	N4BP2L2-IT2	-3.54	0.000438	0.0463	-0.1	-0.16	Body mass index;	chr13:32647711	chr13:32504506~32509395:-
LUAD	cis	rs7569084	0.64	rs11126039	ENSG00000237979.1	AC007389.1	3.54	0.000438	0.0463	0.2	0.16	Sum eosinophil basophil counts;	chr2:65457953	chr2:65500993~65502138:-
LUAD	cis	rs7569084	0.687	rs11675538	ENSG00000237979.1	AC007389.1	3.54	0.000438	0.0463	0.2	0.16	Sum eosinophil basophil counts;	chr2:65459327	chr2:65500993~65502138:-
LUAD	cis	rs9457247	0.967	rs1590257	ENSG00000227598.1	RP1-167A14.2	3.54	0.000438	0.0463	0.17	0.16	Crohn's disease;	chr6:166964294	chr6:166969626~166999065:-
LUAD	cis	rs9457247	1	rs2769354	ENSG00000227598.1	RP1-167A14.2	3.54	0.000438	0.0463	0.17	0.16	Crohn's disease;	chr6:166966283	chr6:166969626~166999065:-
LUAD	cis	rs9457247	0.846	rs2757052	ENSG00000227598.1	RP1-167A14.2	3.54	0.000438	0.0463	0.17	0.16	Crohn's disease;	chr6:166966686	chr6:166969626~166999065:-
LUAD	cis	rs62244186	0.535	rs59726036	ENSG00000236869.1	RP11-944L7.4	3.54	0.000438	0.0463	0.19	0.16	Depressive symptoms;	chr3:44808582	chr3:44557357~44685653:-
LUAD	cis	rs763121	0.819	rs5757161	ENSG00000225450.1	RP3-508I15.14	-3.54	0.000438	0.0464	-0.15	-0.16	Menopause (age at onset);	chr22:38594657	chr22:38739003~38749041:+
LUAD	cis	rs6430585	0.583	rs3754689	ENSG00000226806.1	AC011893.3	3.54	0.000438	0.0464	0.22	0.16	Corneal structure;	chr2:135833176	chr2:135820191~135823087:+
LUAD	cis	rs4272382	1	rs4272382	ENSG00000248538.5	RP11-10A14.5	-3.54	0.000438	0.0464	-0.32	-0.16	Response to cytidine analogues (gemcitabine);	chr8:8575978	chr8:9189011~9202854:+
LUAD	cis	rs240993	0.909	rs240991	ENSG00000271789.1	RP5-1112D6.7	-3.54	0.000438	0.0464	-0.18	-0.16	Inflammatory skin disease;Psoriasis;	chr6:111346971	chr6:111297126~111298510:+
LUAD	cis	rs240993	1	rs240993	ENSG00000271789.1	RP5-1112D6.7	-3.54	0.000438	0.0464	-0.18	-0.16	Inflammatory skin disease;Psoriasis;	chr6:111352511	chr6:111297126~111298510:+
LUAD	cis	rs13014235	0.532	rs13029007	ENSG00000213090.2	AC007256.5	3.54	0.000438	0.0464	0.18	0.16	Basal cell carcinoma;	chr2:201400154	chr2:201410544~201413308:-
LUAD	cis	rs10819861	0.645	rs7045648	ENSG00000269907.1	RP11-330M2.4	-3.54	0.000438	0.0464	-0.18	-0.16	Electrocardiographic traits;	chr9:96092757	chr9:96910076~96910405:+
LUAD	cis	rs9341808	0.727	rs1324120	ENSG00000233967.5	RP11-250B2.3	3.54	0.000438	0.0464	0.16	0.16	Sitting height ratio;	chr6:80266408	chr6:80443344~80465927:+
LUAD	cis	rs853679	0.657	rs1778483	ENSG00000219392.1	RP1-265C24.5	-3.54	0.000438	0.0464	-0.21	-0.16	Depression;	chr6:28273214	chr6:28115628~28116551:+
LUAD	cis	rs853679	0.657	rs1778482	ENSG00000219392.1	RP1-265C24.5	-3.54	0.000438	0.0464	-0.21	-0.16	Depression;	chr6:28273215	chr6:28115628~28116551:+
LUAD	cis	rs2243480	0.706	rs34466769	ENSG00000229886.1	RP5-1132H15.3	3.54	0.000438	0.0464	0.24	0.16	Diabetic kidney disease;	chr7:65988305	chr7:66025126~66031544:-
LUAD	cis	rs4474465	0.79	rs7932315	ENSG00000251323.2	RP11-452H21.4	-3.54	0.000439	0.0464	-0.2	-0.16	Alzheimer's disease (survival time);	chr11:78503832	chr11:78423982~78429836:-
LUAD	cis	rs763121	0.815	rs4821799	ENSG00000225450.1	RP3-508I15.14	-3.54	0.000439	0.0464	-0.14	-0.16	Menopause (age at onset);	chr22:38625321	chr22:38739003~38749041:+
LUAD	cis	rs404005	0.833	rs1019781	ENSG00000227028.5	SLC8A1-AS1	-3.54	0.000439	0.0464	-0.2	-0.16	HIV-associated dementia;	chr2:40169713	chr2:39786453~40255209:+
LUAD	cis	rs13113518	0.967	rs4340844	ENSG00000249700.7	SRD5A3-AS1	3.54	0.000439	0.0464	0.16	0.16	Height;	chr4:55462689	chr4:55363971~55395847:-
LUAD	cis	rs13113518	1	rs1522112	ENSG00000249700.7	SRD5A3-AS1	3.54	0.000439	0.0464	0.16	0.16	Height;	chr4:55463606	chr4:55363971~55395847:-
LUAD	cis	rs13113518	1	rs4864997	ENSG00000249700.7	SRD5A3-AS1	3.54	0.000439	0.0464	0.16	0.16	Height;	chr4:55466010	chr4:55363971~55395847:-
LUAD	cis	rs13113518	1	rs960152	ENSG00000249700.7	SRD5A3-AS1	3.54	0.000439	0.0464	0.16	0.16	Height;	chr4:55467308	chr4:55363971~55395847:-
LUAD	cis	rs13113518	0.967	rs12644948	ENSG00000249700.7	SRD5A3-AS1	3.54	0.000439	0.0464	0.16	0.16	Height;	chr4:55470266	chr4:55363971~55395847:-
LUAD	cis	rs13113518	1	rs3805151	ENSG00000249700.7	SRD5A3-AS1	3.54	0.000439	0.0464	0.16	0.16	Height;	chr4:55470874	chr4:55363971~55395847:-
LUAD	cis	rs13113518	1	rs13118237	ENSG00000249700.7	SRD5A3-AS1	3.54	0.000439	0.0464	0.16	0.16	Height;	chr4:55474259	chr4:55363971~55395847:-
LUAD	cis	rs1862618	0.802	rs832560	ENSG00000271828.1	CTD-2310F14.1	3.54	0.000439	0.0464	0.23	0.16	Initial pursuit acceleration;	chr5:56828596	chr5:56927874~56929573:+
LUAD	cis	rs10863681	0.764	rs1856620	ENSG00000227925.1	RP11-191N8.2	3.54	0.000439	0.0464	0.18	0.16	Metabolite levels (HVA-5-HIAA Factor score);	chr1:222067037	chr1:221827666~221840666:-
LUAD	cis	rs638893	1	rs113641235	ENSG00000255239.1	AP002954.6	-3.54	0.000439	0.0464	-0.27	-0.16	Vitiligo;	chr11:118829555	chr11:118688039~118690600:-
LUAD	cis	rs10859871	0.536	rs2886933	ENSG00000216306.3	KRT19P2	3.54	0.000439	0.0464	0.21	0.16	Endometriosis;	chr12:95272136	chr12:94834147~94835158:+
LUAD	cis	rs7077256	0.564	rs34568091	ENSG00000272767.1	JMJD1C-AS1	3.54	0.000439	0.0464	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63257482	chr10:63465229~63466563:+
LUAD	cis	rs7077256	0.564	rs72829202	ENSG00000272767.1	JMJD1C-AS1	3.54	0.000439	0.0464	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63260258	chr10:63465229~63466563:+
LUAD	cis	rs7077256	0.564	rs12766208	ENSG00000272767.1	JMJD1C-AS1	3.54	0.000439	0.0464	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63262262	chr10:63465229~63466563:+
LUAD	cis	rs7077256	0.542	rs36036508	ENSG00000272767.1	JMJD1C-AS1	3.54	0.000439	0.0464	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63267848	chr10:63465229~63466563:+
LUAD	cis	rs445114	0.578	rs385278	ENSG00000254166.1	CASC19	-3.54	0.000439	0.0464	-0.16	-0.16	Prostate cancer;Prostate cancer (SNP x SNP interaction);	chr8:127334772	chr8:127185635~127203222:-
LUAD	cis	rs445114	0.601	rs382824	ENSG00000254166.1	CASC19	-3.54	0.000439	0.0464	-0.16	-0.16	Prostate cancer;Prostate cancer (SNP x SNP interaction);	chr8:127335479	chr8:127185635~127203222:-
LUAD	cis	rs445114	0.578	rs383205	ENSG00000254166.1	CASC19	-3.54	0.000439	0.0464	-0.16	-0.16	Prostate cancer;Prostate cancer (SNP x SNP interaction);	chr8:127335732	chr8:127185635~127203222:-
LUAD	cis	rs1346081	0.782	rs7668746	ENSG00000250075.4	RP11-584P21.2	-3.54	0.000439	0.0464	-0.17	-0.16	Intelligence (multi-trait analysis);	chr4:67105153	chr4:67417305~67468251:-
LUAD	cis	rs1346081	0.81	rs13138028	ENSG00000250075.4	RP11-584P21.2	-3.54	0.000439	0.0464	-0.17	-0.16	Intelligence (multi-trait analysis);	chr4:67110515	chr4:67417305~67468251:-
LUAD	cis	rs6601327	0.641	rs4840437	ENSG00000233609.3	RP11-62H7.2	-3.54	0.000439	0.0464	-0.13	-0.16	Multiple myeloma (hyperdiploidy);	chr8:9748754	chr8:8961200~8979025:+
LUAD	cis	rs4713118	0.662	rs149969	ENSG00000168126.3	OR2W6P	3.54	0.000439	0.0464	0.19	0.16	Parkinson's disease;	chr6:28009959	chr6:27937465~27938403:+
LUAD	cis	rs4763879	0.778	rs9332411	ENSG00000214776.8	RP11-726G1.1	-3.54	0.000439	0.0464	-0.18	-0.16	Type 1 diabetes;	chr12:9681749	chr12:9467552~9576275:+
LUAD	cis	rs13113518	1	rs4865013	ENSG00000223305.1	RN7SKP30	3.54	0.000439	0.0464	0.18	0.16	Height;	chr4:55559957	chr4:55540502~55540835:-
LUAD	cis	rs2548724	0.755	rs11950639	ENSG00000250682.4	LINC00491	3.54	0.000439	0.0464	0.2	0.16	Type 2 diabetes;	chr5:102442092	chr5:102609156~102671559:-
LUAD	cis	rs2548724	0.716	rs10434748	ENSG00000250682.4	LINC00491	3.54	0.000439	0.0464	0.2	0.16	Type 2 diabetes;	chr5:102455814	chr5:102609156~102671559:-
LUAD	cis	rs2548724	0.66	rs10434749	ENSG00000250682.4	LINC00491	3.54	0.000439	0.0464	0.2	0.16	Type 2 diabetes;	chr5:102456271	chr5:102609156~102671559:-
LUAD	cis	rs935334	1	rs10137323	ENSG00000258454.1	RP11-361H10.3	-3.54	0.000439	0.0464	-0.24	-0.16	Blood pressure;	chr14:76219390	chr14:76235817~76263474:+
LUAD	cis	rs17290922	1	rs7205459	ENSG00000261114.1	RP11-325K4.2	-3.54	0.000439	0.0464	-0.24	-0.16	Schizophrenia;	chr16:56991259	chr16:56941028~56941726:+
LUAD	cis	rs8048589	0.948	rs11648468	ENSG00000175604.2	RP11-276H1.3	3.54	0.000439	0.0464	0.22	0.16	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);	chr16:12087653	chr16:12086746~12090302:-
LUAD	cis	rs9926296	0.712	rs447735	ENSG00000274627.1	RP11-104N10.2	3.54	0.000439	0.0464	0.15	0.16	Vitiligo;	chr16:89667941	chr16:89516797~89522217:+
LUAD	cis	rs7100689	0.646	rs10788586	ENSG00000226659.1	RP11-137H2.4	-3.54	0.000439	0.0464	-0.22	-0.16	Post bronchodilator FEV1;	chr10:80357679	chr10:80529597~80535942:-
LUAD	cis	rs7100689	0.646	rs6585946	ENSG00000226659.1	RP11-137H2.4	-3.54	0.000439	0.0464	-0.22	-0.16	Post bronchodilator FEV1;	chr10:80358536	chr10:80529597~80535942:-
LUAD	cis	rs11658309	1	rs11658309	ENSG00000264177.1	RP1-37N7.1	3.54	0.000439	0.0464	0.16	0.16	Strep throat;	chr17:17858933	chr17:18379855~18388984:-
LUAD	cis	rs901683	0.85	rs76294334	ENSG00000230869.1	CTGLF10P	-3.54	0.000439	0.0464	-0.37	-0.16	Mean corpuscular volume;Red blood cell traits;	chr10:45468831	chr10:45678692~45700532:+
LUAD	cis	rs6502050	0.865	rs8073679	ENSG00000266654.1	RP11-1376P16.1	-3.54	0.000439	0.0464	-0.17	-0.16	Life satisfaction;	chr17:82197467	chr17:82160056~82160452:+
LUAD	cis	rs6951245	1	rs2363286	ENSG00000226291.1	AC091729.8	-3.54	0.000439	0.0464	-0.26	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1051989	chr7:1080863~1082178:+
LUAD	cis	rs6736093	0.862	rs79798002	ENSG00000207383.1	Y_RNA	-3.54	0.000439	0.0464	-0.2	-0.16	Coronary artery disease;	chr2:111976401	chr2:112579484~112579584:-
LUAD	cis	rs6540731	0.754	rs2358452	ENSG00000229983.1	RP11-15I11.2	3.54	0.000439	0.0464	0.19	0.16	Intelligence (childhood);	chr1:212185707	chr1:212168207~212190259:+
LUAD	cis	rs6751744	0.855	rs10206214	ENSG00000230783.1	AC009961.2	-3.54	0.000439	0.0464	-0.21	-0.16	Dysphagia;	chr2:159507781	chr2:159689217~159690291:-
LUAD	cis	rs11122895	1	rs12619033	ENSG00000236307.2	EEF1E1P1	-3.54	0.000439	0.0464	-0.18	-0.16	Allergic sensitization;	chr2:111706560	chr2:111887914~111888741:+
LUAD	cis	rs10938353	0.68	rs55637944	ENSG00000273369.1	RP11-700J17.1	3.54	0.000439	0.0464	0.23	0.16	Body mass index;	chr4:44622791	chr4:44693946~44694386:-
LUAD	cis	rs858239	0.72	rs10227559	ENSG00000226816.2	AC005082.12	3.54	0.000439	0.0464	0.21	0.16	Cerebrospinal fluid biomarker levels;	chr7:23232525	chr7:23206013~23208045:+
LUAD	cis	rs794185	0.747	rs2819566	ENSG00000231249.1	ITPR1-AS1	-3.54	0.000439	0.0464	-0.18	-0.16	Multiple sclerosis--Brain Glutamate Levels;	chr3:4463958	chr3:4490891~4493163:-
LUAD	cis	rs7246967	0.551	rs59127381	ENSG00000236312.3	RPL34P34	3.54	0.000439	0.0464	0.24	0.16	Bronchopulmonary dysplasia;	chr19:22702233	chr19:22368599~22368952:-
LUAD	cis	rs7246967	0.551	rs73022749	ENSG00000236312.3	RPL34P34	3.54	0.000439	0.0464	0.24	0.16	Bronchopulmonary dysplasia;	chr19:22704458	chr19:22368599~22368952:-
LUAD	cis	rs1863918	0.807	rs4701049	ENSG00000249140.1	PRDX2P3	-3.54	0.000439	0.0464	-0.18	-0.16	Depression in response to interferon-based therapy in chronic hepatitis C;	chr5:179118213	chr5:179572156~179572741:+
LUAD	cis	rs5742933	1	rs1966729	ENSG00000253559.1	OSGEPL1-AS1	-3.54	0.000439	0.0464	-0.22	-0.16	Ferritin levels;	chr2:189721105	chr2:189762704~189765556:+
LUAD	cis	rs6743068	0.541	rs2349075	ENSG00000234842.1	AC007163.8	-3.54	0.000439	0.0464	-0.18	-0.16	Lymphocyte percentage of white cells;	chr2:201358843	chr2:201549631~201550307:+
LUAD	cis	rs11158026	0.603	rs67571433	ENSG00000258413.1	RP11-665C16.6	-3.54	0.000439	0.0464	-0.21	-0.16	Parkinson's disease;	chr14:54981264	chr14:55262767~55272075:-
LUAD	cis	rs6663390	0.51	rs1932818	ENSG00000203709.8	C1orf132	3.54	0.000439	0.0464	0.22	0.16	Facial morphology (factor 18);	chr1:207904912	chr1:207801518~207869150:-
LUAD	cis	rs6736093	0.966	rs11679801	ENSG00000207383.1	Y_RNA	-3.54	0.000439	0.0464	-0.21	-0.16	Coronary artery disease;	chr2:111955258	chr2:112579484~112579584:-
LUAD	cis	rs67981189	0.865	rs2810071	ENSG00000269927.1	RP6-91H8.3	-3.54	0.000439	0.0464	-0.2	-0.16	Schizophrenia;	chr14:70920931	chr14:71141125~71143253:-
LUAD	cis	rs526231	0.543	rs171558	ENSG00000250682.4	LINC00491	3.54	0.000439	0.0464	0.2	0.16	Primary biliary cholangitis;	chr5:103242193	chr5:102609156~102671559:-
LUAD	cis	rs41357746	0.525	rs57030473	ENSG00000270964.1	RP11-502I4.3	-3.54	0.000439	0.0464	-0.17	-0.16	Total body bone mineral density;	chr15:67484340	chr15:67541072~67542604:-
LUAD	cis	rs9593057	0.892	rs17051831	ENSG00000234835.1	PHBP13	-3.54	0.000439	0.0464	-0.31	-0.16	Lobe attachment (rater-scored or self-reported);	chr13:35053720	chr13:35251070~35251829:+
LUAD	cis	rs3120667	0.72	rs36061814	ENSG00000237975.5	FLG-AS1	3.54	0.00044	0.0464	0.28	0.16	Eating disorders;	chr1:152444388	chr1:152168125~152445456:+
LUAD	cis	rs2279168	0.737	rs7178054	ENSG00000202081.1	RNU6-1280P	3.54	0.00044	0.0465	0.3	0.16	Response to platinum-based chemotherapy (carboplatin);	chr15:85440272	chr15:85651522~85651628:-
LUAD	cis	rs683250	0.661	rs2510476	ENSG00000246067.6	RAB30-AS1	-3.54	0.00044	0.0465	-0.17	-0.16	Subcortical brain region volumes;	chr11:83411630	chr11:83072066~83106719:+
LUAD	cis	rs683250	0.661	rs2512682	ENSG00000246067.6	RAB30-AS1	-3.54	0.00044	0.0465	-0.17	-0.16	Subcortical brain region volumes;	chr11:83411801	chr11:83072066~83106719:+
LUAD	cis	rs1005224	0.853	rs12898082	ENSG00000242952.1	RP11-187O7.1	3.54	0.00044	0.0465	0.15	0.16	Large artery stroke;	chr14:75840016	chr14:76634775~76635661:-
LUAD	cis	rs4899292	0.662	rs4902712	ENSG00000258520.1	RP11-363J20.2	-3.54	0.00044	0.0465	-0.19	-0.16	Neuroticism;	chr14:69288056	chr14:69239166~69260567:-
LUAD	cis	rs67981189	0.896	rs7145484	ENSG00000269927.1	RP6-91H8.3	3.54	0.00044	0.0465	0.2	0.16	Schizophrenia;	chr14:71006820	chr14:71141125~71143253:-
LUAD	cis	rs13273088	0.649	rs6472466	ENSG00000253967.1	RP11-333A23.4	3.54	0.00044	0.0465	0.22	0.16	Fasting blood insulin (BMI interaction);	chr8:69594538	chr8:70471134~70485687:+
LUAD	cis	rs7560272	0.501	rs12713793	ENSG00000163016.8	ALMS1P	-3.54	0.00044	0.0465	-0.17	-0.16	Schizophrenia;	chr2:73728987	chr2:73644919~73685576:+
LUAD	cis	rs9341808	0.935	rs4706113	ENSG00000233967.5	RP11-250B2.3	3.54	0.00044	0.0465	0.15	0.16	Sitting height ratio;	chr6:80129598	chr6:80443344~80465927:+
LUAD	cis	rs7572733	0.84	rs4286272	ENSG00000222017.1	AC011997.1	-3.54	0.00044	0.0465	-0.2	-0.16	Dermatomyositis;	chr2:197670954	chr2:197693106~197774823:+
LUAD	cis	rs2702164	0.962	rs1147682	ENSG00000240661.1	RP11-174O3.3	-3.54	0.00044	0.0465	-0.2	-0.16	Gut microbiome composition (winter);	chr3:120363948	chr3:120349510~120367998:+
LUAD	cis	rs1445898	1	rs2303137	ENSG00000279400.1	CTD-2353F22.2	3.54	0.00044	0.0465	0.15	0.16	Type 1 diabetes;	chr5:35895623	chr5:36667717~36669958:+
LUAD	cis	rs9475752	1	rs1451708	ENSG00000231441.1	RP11-472M19.2	3.54	0.00044	0.0465	0.26	0.16	Menarche (age at onset);	chr6:56937403	chr6:56844002~56864078:+
LUAD	cis	rs875971	0.545	rs3735147	ENSG00000222364.1	RNU6-96P	-3.54	0.00044	0.0465	-0.2	-0.16	Aortic root size;	chr7:66505541	chr7:66395191~66395286:+
LUAD	cis	rs897984	0.52	rs4889614	ENSG00000232748.3	RP11-196G11.6	3.54	0.00044	0.0465	0.22	0.16	Dementia with Lewy bodies;	chr16:30850814	chr16:31056460~31062803:+
LUAD	cis	rs9595908	0.785	rs7328827	ENSG00000281026.1	N4BP2L2-IT2	-3.54	0.00044	0.0465	-0.1	-0.16	Body mass index;	chr13:32686650	chr13:32504506~32509395:-
LUAD	cis	rs9595908	0.785	rs3858846	ENSG00000281026.1	N4BP2L2-IT2	-3.54	0.00044	0.0465	-0.1	-0.16	Body mass index;	chr13:32687408	chr13:32504506~32509395:-
LUAD	cis	rs728616	0.867	rs726289	ENSG00000225484.5	NUTM2B-AS1	-3.54	0.00044	0.0465	-0.38	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79947195	chr10:79663088~79826594:-
LUAD	cis	rs4699052	0.662	rs1516731	ENSG00000246560.2	RP11-10L12.4	3.54	0.00044	0.0465	0.2	0.16	Testicular germ cell tumor;	chr4:103331537	chr4:102828055~102844075:+
LUAD	cis	rs4699052	0.625	rs11734836	ENSG00000246560.2	RP11-10L12.4	3.54	0.00044	0.0465	0.2	0.16	Testicular germ cell tumor;	chr4:103332046	chr4:102828055~102844075:+
LUAD	cis	rs4699052	0.625	rs4481237	ENSG00000246560.2	RP11-10L12.4	3.54	0.00044	0.0465	0.2	0.16	Testicular germ cell tumor;	chr4:103332852	chr4:102828055~102844075:+
LUAD	cis	rs61542988	0.606	rs4722185	ENSG00000226329.2	AC005682.6	3.54	0.00044	0.0465	0.24	0.16	Fibrinogen levels;	chr7:22793092	chr7:22863874~22881350:-
LUAD	cis	rs1023500	0.505	rs134878	ENSG00000205702.9	CYP2D7	3.54	0.00044	0.0465	0.13	0.16	Schizophrenia;	chr22:42267868	chr22:42140203~42144577:-
LUAD	cis	rs227275	0.554	rs223485	ENSG00000230069.3	LRRC37A15P	-3.54	0.00044	0.0465	-0.16	-0.16	Allergic disease (asthma, hay fever or eczema);	chr4:102764018	chr4:102727274~102730721:-
LUAD	cis	rs4388249	0.687	rs11745926	ENSG00000271849.1	CTC-332L22.1	-3.54	0.00044	0.0465	-0.23	-0.16	Schizophrenia;	chr5:109809489	chr5:109687802~109688329:-
LUAD	cis	rs1075265	0.87	rs7569214	ENSG00000272156.1	RP11-477N3.1	-3.54	0.00044	0.0465	-0.19	-0.16	Chronotype;Morning vs. evening chronotype;	chr2:53989049	chr2:54082554~54085066:+
LUAD	cis	rs9309473	0.948	rs13391552	ENSG00000230002.2	ALMS1-IT1	3.54	0.00044	0.0465	0.2	0.16	Metabolite levels;	chr2:73591809	chr2:73456764~73459484:+
LUAD	cis	rs3617	0.625	rs7612624	ENSG00000242142.1	SERBP1P3	-3.54	0.00044	0.0465	-0.17	-0.16	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52859410	chr3:53064283~53065091:-
LUAD	cis	rs6547741	0.935	rs2384626	ENSG00000223522.1	AC093690.1	3.54	0.00044	0.0465	0.15	0.16	Oral cavity cancer;	chr2:27550781	chr2:28307691~28310459:-
LUAD	cis	rs17596685	0.591	rs4338693	ENSG00000271216.1	LINC01050	-3.54	0.00044	0.0465	-0.26	-0.16	C-reactive protein levels;	chr13:42609547	chr13:42810366~42812562:-
LUAD	cis	rs10875976	0.525	rs7967564	ENSG00000257464.1	RP11-161H23.8	-3.54	0.00044	0.0465	-0.16	-0.16	Obesity;	chr12:49855748	chr12:49442424~49442652:-
LUAD	cis	rs4263408	1	rs7656037	ENSG00000249064.1	KRT18P25	-3.54	0.00044	0.0465	-0.17	-0.16	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39716345	chr4:40020240~40021517:+
LUAD	cis	rs2153535	0.518	rs6926976	ENSG00000230939.1	RP11-314C16.1	3.54	0.00044	0.0465	0.18	0.16	Motion sickness;	chr6:8622045	chr6:8784178~8785445:+
LUAD	cis	rs4374383	0.962	rs4524124	ENSG00000236307.2	EEF1E1P1	-3.54	0.00044	0.0465	-0.19	-0.16	Hepatitis C induced liver fibrosis;	chr2:112014626	chr2:111887914~111888741:+
LUAD	cis	rs155346	1	rs2560711	ENSG00000281398.1	SNHG4	3.54	0.00044	0.0465	0.19	0.16	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;	chr5:140015356	chr5:139274102~139283244:+
LUAD	cis	rs910316	0.737	rs175055	ENSG00000259138.1	RP11-950C14.7	-3.54	0.00044	0.0465	-0.17	-0.16	Height;	chr14:75022243	chr14:75127153~75136930:+
LUAD	cis	rs8067545	0.641	rs203457	ENSG00000270091.1	RP11-78O7.2	3.54	0.000441	0.0465	0.13	0.16	Schizophrenia;	chr17:19915025	chr17:19896590~19897287:-
LUAD	cis	rs957448	1	rs16916881	ENSG00000254057.1	RP3-388N13.3	3.54	0.000441	0.0465	0.17	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94554042	chr8:93834454~93846743:-
LUAD	cis	rs2803122	0.967	rs10964066	ENSG00000273226.1	RP11-513M16.8	-3.54	0.000441	0.0465	-0.17	-0.16	Pulse pressure;	chr9:19250780	chr9:19375451~19375996:+
LUAD	cis	rs7829975	0.577	rs17684466	ENSG00000253893.2	FAM85B	3.54	0.000441	0.0465	0.2	0.16	Mood instability;	chr8:8687723	chr8:8167819~8226614:-
LUAD	cis	rs7916697	0.593	rs3740587	ENSG00000233590.1	RP11-153K11.3	3.54	0.000441	0.0465	0.19	0.16	Optic disc area;	chr10:68261045	chr10:68233251~68242379:-
LUAD	cis	rs2554380	1	rs2554380	ENSG00000230373.7	GOLGA6L5P	-3.54	0.000441	0.0465	-0.19	-0.16	Height;	chr15:83647132	chr15:84507885~84516814:-
LUAD	cis	rs2554380	1	rs2730076	ENSG00000230373.7	GOLGA6L5P	-3.54	0.000441	0.0465	-0.19	-0.16	Height;	chr15:83647233	chr15:84507885~84516814:-
LUAD	cis	rs4927850	1	rs7627706	ENSG00000278820.1	AC024937.1	3.54	0.000441	0.0465	0.14	0.16	Pancreatic cancer;	chr3:196026482	chr3:195960500~195960612:-
LUAD	cis	rs4819052	1	rs2838830	ENSG00000223768.1	LINC00205	-3.54	0.000441	0.0465	-0.2	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244312	chr21:45293285~45297354:+
LUAD	cis	rs7077256	0.564	rs12770187	ENSG00000272767.1	JMJD1C-AS1	3.54	0.000441	0.0465	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63148929	chr10:63465229~63466563:+
LUAD	cis	rs4764487	0.76	rs2268009	ENSG00000202318.1	Y_RNA	-3.54	0.000441	0.0466	-0.17	-0.16	Mean platelet volume;	chr12:6231222	chr12:6234345~6234455:-
LUAD	cis	rs6736093	0.966	rs13013340	ENSG00000207383.1	Y_RNA	-3.54	0.000441	0.0466	-0.21	-0.16	Coronary artery disease;	chr2:111937411	chr2:112579484~112579584:-
LUAD	cis	rs6736093	0.966	rs71414616	ENSG00000207383.1	Y_RNA	-3.54	0.000441	0.0466	-0.21	-0.16	Coronary artery disease;	chr2:111939107	chr2:112579484~112579584:-
LUAD	cis	rs6736093	0.966	rs13033393	ENSG00000207383.1	Y_RNA	-3.54	0.000441	0.0466	-0.21	-0.16	Coronary artery disease;	chr2:111940055	chr2:112579484~112579584:-
LUAD	cis	rs6736093	0.966	rs11674226	ENSG00000207383.1	Y_RNA	-3.54	0.000441	0.0466	-0.21	-0.16	Coronary artery disease;	chr2:111940811	chr2:112579484~112579584:-
LUAD	cis	rs8028182	0.636	rs4486847	ENSG00000260274.1	RP11-817O13.8	3.54	0.000441	0.0466	0.17	0.16	Sudden cardiac arrest;	chr15:75436190	chr15:75368155~75369584:+
LUAD	cis	rs6540731	1	rs2012917	ENSG00000229983.1	RP11-15I11.2	3.54	0.000441	0.0466	0.19	0.16	Intelligence (childhood);	chr1:212232429	chr1:212168207~212190259:+
LUAD	cis	rs2535633	0.631	rs2710313	ENSG00000242142.1	SERBP1P3	-3.54	0.000441	0.0466	-0.18	-0.16	Body mass index;	chr3:52935513	chr3:53064283~53065091:-
LUAD	cis	rs7615952	0.599	rs16834938	ENSG00000250012.1	RP11-124N2.1	-3.54	0.000441	0.0466	-0.21	-0.16	Blood pressure (smoking interaction);	chr3:125987203	chr3:126084220~126095349:+
LUAD	cis	rs6496932	0.503	rs4842882	ENSG00000259630.2	CTD-2262B20.1	-3.54	0.000441	0.0466	-0.21	-0.16	Central corneal thickness;Corneal structure;	chr15:85440952	chr15:85415228~85415633:+
LUAD	cis	rs11822910	1	rs4477456	ENSG00000265566.2	RN7SL605P	3.54	0.000441	0.0466	0.23	0.16	Platelet distribution width;	chr11:57430308	chr11:57528085~57528365:-
LUAD	cis	rs2348418	0.715	rs10843206	ENSG00000244712.1	RP11-874G11.1	3.54	0.000441	0.0466	0.19	0.16	Lung function (FEV1);Lung function (FVC);	chr12:28569823	chr12:28564678~28565141:-
LUAD	cis	rs2348418	0.681	rs10843207	ENSG00000244712.1	RP11-874G11.1	3.54	0.000441	0.0466	0.19	0.16	Lung function (FEV1);Lung function (FVC);	chr12:28569929	chr12:28564678~28565141:-
LUAD	cis	rs2348418	0.715	rs7971717	ENSG00000244712.1	RP11-874G11.1	3.54	0.000441	0.0466	0.19	0.16	Lung function (FEV1);Lung function (FVC);	chr12:28570087	chr12:28564678~28565141:-
LUAD	cis	rs4845570	0.92	rs1196456	ENSG00000203288.3	RP11-98D18.9	3.54	0.000441	0.0466	0.22	0.16	Coronary artery disease;	chr1:151764873	chr1:151790804~151794402:+
LUAD	cis	rs5742933	0.857	rs13021611	ENSG00000223249.1	Y_RNA	3.54	0.000441	0.0466	0.2	0.16	Ferritin levels;	chr2:189700038	chr2:189753464~189753559:+
LUAD	cis	rs7302981	0.51	rs860698	ENSG00000200428.1	Y_RNA	-3.54	0.000441	0.0466	-0.19	-0.16	Systolic blood pressure;	chr12:50092539	chr12:50743568~50743684:+
LUAD	cis	rs11742741	0.806	rs4701417	ENSG00000248874.4	C5orf17	-3.54	0.000441	0.0466	-0.2	-0.16	Educational attainment;	chr5:24013458	chr5:23951348~24178263:+
LUAD	cis	rs357894	0.802	rs357895	ENSG00000266696.1	RP11-30L3.2	3.54	0.000441	0.0466	0.17	0.16	Dental caries;	chr18:49053897	chr18:49205912~49208781:+
LUAD	cis	rs2638953	0.924	rs11049454	ENSG00000278733.1	RP11-425D17.1	-3.54	0.000441	0.0466	-0.2	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28204755	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs10843134	ENSG00000278733.1	RP11-425D17.1	-3.54	0.000441	0.0466	-0.2	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28205710	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs1824768	ENSG00000278733.1	RP11-425D17.1	-3.54	0.000441	0.0466	-0.2	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28206530	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.886	rs11049465	ENSG00000278733.1	RP11-425D17.1	-3.54	0.000441	0.0466	-0.2	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28212086	chr12:28185625~28186190:-
LUAD	cis	rs9467773	1	rs1321481	ENSG00000228223.2	HCG11	-3.54	0.000441	0.0466	-0.17	-0.16	Intelligence (multi-trait analysis);	chr6:26537982	chr6:26523450~26526579:+
LUAD	cis	rs9467773	1	rs4713008	ENSG00000228223.2	HCG11	-3.54	0.000441	0.0466	-0.17	-0.16	Intelligence (multi-trait analysis);	chr6:26538040	chr6:26523450~26526579:+
LUAD	cis	rs9467773	0.967	rs6932865	ENSG00000228223.2	HCG11	-3.54	0.000441	0.0466	-0.17	-0.16	Intelligence (multi-trait analysis);	chr6:26539938	chr6:26523450~26526579:+
LUAD	cis	rs9467773	1	rs6933176	ENSG00000228223.2	HCG11	-3.54	0.000441	0.0466	-0.17	-0.16	Intelligence (multi-trait analysis);	chr6:26539950	chr6:26523450~26526579:+
LUAD	cis	rs3126085	0.935	rs7534716	ENSG00000237975.5	FLG-AS1	-3.54	0.000441	0.0466	-0.24	-0.16	Atopic dermatitis;	chr1:152226178	chr1:152168125~152445456:+
LUAD	cis	rs3126085	0.935	rs1390488	ENSG00000237975.5	FLG-AS1	-3.54	0.000441	0.0466	-0.24	-0.16	Atopic dermatitis;	chr1:152227024	chr1:152168125~152445456:+
LUAD	cis	rs3126085	0.935	rs10888470	ENSG00000237975.5	FLG-AS1	-3.54	0.000441	0.0466	-0.24	-0.16	Atopic dermatitis;	chr1:152227996	chr1:152168125~152445456:+
LUAD	cis	rs4423214	0.84	rs1629220	ENSG00000226627.1	SHANK2-AS1	3.54	0.000441	0.0466	0.2	0.16	Vitamin D levels;	chr11:71463507	chr11:70631094~70635490:+
LUAD	cis	rs4423214	0.84	rs1792224	ENSG00000226627.1	SHANK2-AS1	3.54	0.000441	0.0466	0.2	0.16	Vitamin D levels;	chr11:71465095	chr11:70631094~70635490:+
LUAD	cis	rs4423214	0.84	rs1792226	ENSG00000226627.1	SHANK2-AS1	3.54	0.000441	0.0466	0.2	0.16	Vitamin D levels;	chr11:71465528	chr11:70631094~70635490:+
LUAD	cis	rs4423214	0.84	rs1790344	ENSG00000226627.1	SHANK2-AS1	3.54	0.000441	0.0466	0.2	0.16	Vitamin D levels;	chr11:71465851	chr11:70631094~70635490:+
LUAD	cis	rs4423214	0.84	rs1790343	ENSG00000226627.1	SHANK2-AS1	3.54	0.000441	0.0466	0.2	0.16	Vitamin D levels;	chr11:71466161	chr11:70631094~70635490:+
LUAD	cis	rs35987657	0.535	rs12493491	ENSG00000250643.1	RP11-93K22.6	-3.54	0.000441	0.0466	-0.18	-0.16	Restless legs syndrome;	chr3:130795746	chr3:129954105~129969294:-
LUAD	cis	rs12744310	0.887	rs12047439	ENSG00000235358.1	RP11-399E6.1	3.54	0.000441	0.0466	0.21	0.16	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41343968	chr1:41242373~41284861:+
LUAD	cis	rs8031584	0.918	rs34331396	ENSG00000259845.1	HERC2P10	3.54	0.000441	0.0466	0.18	0.16	Huntington's disease progression;	chr15:30956533	chr15:30815271~30844153:+
LUAD	cis	rs9381040	0.655	rs7775972	ENSG00000161912.16	ADCY10P1	3.54	0.000441	0.0466	0.14	0.16	Alzheimer's disease (late onset);	chr6:41070377	chr6:41101022~41140835:+
LUAD	cis	rs9341808	0.667	rs3805913	ENSG00000272129.1	RP11-250B2.6	3.54	0.000441	0.0466	0.2	0.16	Sitting height ratio;	chr6:80217605	chr6:80355424~80356859:+
LUAD	cis	rs166040	0.59	rs248505	ENSG00000277795.1	AC005752.10	-3.54	0.000441	0.0466	-0.25	-0.16	Major depressive disorder;	chr5:141829620	chr5:141259235~141261364:+
LUAD	cis	rs5770917	1	rs8137478	ENSG00000273272.1	CTA-384D8.34	3.54	0.000441	0.0466	0.34	0.16	Narcolepsy;	chr22:50578867	chr22:50542650~50543011:+
LUAD	cis	rs5770917	1	rs1056964	ENSG00000273272.1	CTA-384D8.34	3.54	0.000441	0.0466	0.34	0.16	Narcolepsy;	chr22:50579047	chr22:50542650~50543011:+
LUAD	cis	rs5770917	1	rs762676	ENSG00000273272.1	CTA-384D8.34	3.54	0.000441	0.0466	0.34	0.16	Narcolepsy;	chr22:50579365	chr22:50542650~50543011:+
LUAD	cis	rs12234571	1	rs111703270	ENSG00000214293.7	APTR	3.54	0.000441	0.0466	0.34	0.16	Obesity-related traits;	chr7:77740119	chr7:77657660~77696265:-
LUAD	cis	rs12234571	0.744	rs17157284	ENSG00000214293.7	APTR	3.54	0.000441	0.0466	0.34	0.16	Obesity-related traits;	chr7:77750413	chr7:77657660~77696265:-
LUAD	cis	rs11671005	0.611	rs56026876	ENSG00000268912.1	CTD-2619J13.17	-3.54	0.000441	0.0466	-0.22	-0.16	Mean platelet volume;	chr19:58494790	chr19:58428632~58431148:-
LUAD	cis	rs2243480	1	rs316313	ENSG00000222364.1	RNU6-96P	-3.54	0.000441	0.0466	-0.26	-0.16	Diabetic kidney disease;	chr7:66128561	chr7:66395191~66395286:+
LUAD	cis	rs2243480	1	rs316312	ENSG00000222364.1	RNU6-96P	-3.54	0.000441	0.0466	-0.26	-0.16	Diabetic kidney disease;	chr7:66131504	chr7:66395191~66395286:+
LUAD	cis	rs2243480	1	rs419603	ENSG00000222364.1	RNU6-96P	-3.54	0.000441	0.0466	-0.26	-0.16	Diabetic kidney disease;	chr7:66132354	chr7:66395191~66395286:+
LUAD	cis	rs2243480	1	rs387676	ENSG00000222364.1	RNU6-96P	-3.54	0.000441	0.0466	-0.26	-0.16	Diabetic kidney disease;	chr7:66133233	chr7:66395191~66395286:+
LUAD	cis	rs2243480	1	rs13310597	ENSG00000222364.1	RNU6-96P	-3.54	0.000441	0.0466	-0.26	-0.16	Diabetic kidney disease;	chr7:66133553	chr7:66395191~66395286:+
LUAD	cis	rs12908161	1	rs11638290	ENSG00000254414.1	RP11-182J1.1	3.54	0.000441	0.0466	0.21	0.16	Schizophrenia;	chr15:84684405	chr15:84631898~84633987:-
LUAD	cis	rs12908161	0.959	rs34028043	ENSG00000254414.1	RP11-182J1.1	3.54	0.000441	0.0466	0.21	0.16	Schizophrenia;	chr15:84688354	chr15:84631898~84633987:-
LUAD	cis	rs12908161	0.959	rs34784022	ENSG00000254414.1	RP11-182J1.1	3.54	0.000441	0.0466	0.21	0.16	Schizophrenia;	chr15:84688675	chr15:84631898~84633987:-
LUAD	cis	rs12908161	0.959	rs12908699	ENSG00000254414.1	RP11-182J1.1	3.54	0.000441	0.0466	0.21	0.16	Schizophrenia;	chr15:84697172	chr15:84631898~84633987:-
LUAD	cis	rs6496932	0.774	rs12901648	ENSG00000259630.2	CTD-2262B20.1	-3.54	0.000441	0.0466	-0.24	-0.16	Central corneal thickness;Corneal structure;	chr15:85408487	chr15:85415228~85415633:+
LUAD	cis	rs875971	0.577	rs34888281	ENSG00000273142.1	RP11-458F8.4	3.54	0.000441	0.0466	0.11	0.16	Aortic root size;	chr7:66120784	chr7:66902857~66906297:+
LUAD	cis	rs7107174	0.786	rs4945262	ENSG00000251323.2	RP11-452H21.4	3.54	0.000441	0.0466	0.21	0.16	Testicular germ cell tumor;	chr11:78279785	chr11:78423982~78429836:-
LUAD	cis	rs1009115	0.509	rs42955	ENSG00000272328.1	RP4-594A5.1	3.54	0.000441	0.0466	0.19	0.16	Post bronchodilator FEV1;	chr7:8383741	chr7:8303741~8341343:+
LUAD	cis	rs4853525	0.859	rs6434424	ENSG00000235852.1	AC005540.3	3.54	0.000442	0.0466	0.17	0.16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr2:190857400	chr2:190880797~190882059:-
LUAD	cis	rs1790761	0.505	rs6591245	ENSG00000184224.3	C11orf72	-3.54	0.000442	0.0466	-0.18	-0.16	Mean corpuscular volume;	chr11:67543465	chr11:67602880~67606706:-
LUAD	cis	rs9311474	0.607	rs4475032	ENSG00000243224.1	RP5-1157M23.2	-3.54	0.000442	0.0466	-0.16	-0.16	Electroencephalogram traits;	chr3:52526005	chr3:52239258~52241097:+
LUAD	cis	rs9311474	0.607	rs4687625	ENSG00000243224.1	RP5-1157M23.2	-3.54	0.000442	0.0466	-0.16	-0.16	Electroencephalogram traits;	chr3:52529702	chr3:52239258~52241097:+
LUAD	cis	rs9311474	0.607	rs28661185	ENSG00000243224.1	RP5-1157M23.2	-3.54	0.000442	0.0466	-0.16	-0.16	Electroencephalogram traits;	chr3:52533172	chr3:52239258~52241097:+
LUAD	cis	rs7772486	0.846	rs2748499	ENSG00000235652.6	RP11-545I5.3	3.54	0.000442	0.0466	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145993866	chr6:145799409~145886585:+
LUAD	cis	rs17189298	0.872	rs13025691	ENSG00000231013.1	AC013275.2	3.54	0.000442	0.0466	0.16	0.16	Cerebrospinal T-tau levels;	chr2:119110344	chr2:119476448~119487346:+
LUAD	cis	rs10520789	0.92	rs13329454	ENSG00000247809.6	NR2F2-AS1	3.54	0.000442	0.0466	0.24	0.16	Response to TNF-alpha inhibitors in rheumatoid arthritis;	chr15:95629087	chr15:96110040~96327361:-
LUAD	cis	rs10520789	0.92	rs13329139	ENSG00000247809.6	NR2F2-AS1	3.54	0.000442	0.0466	0.24	0.16	Response to TNF-alpha inhibitors in rheumatoid arthritis;	chr15:95629214	chr15:96110040~96327361:-
LUAD	cis	rs3126085	0.935	rs877776	ENSG00000237975.5	FLG-AS1	-3.54	0.000442	0.0466	-0.24	-0.16	Atopic dermatitis;	chr1:152205542	chr1:152168125~152445456:+
LUAD	cis	rs2173063	1	rs80024331	ENSG00000258741.3	RP11-386M24.4	3.54	0.000442	0.0466	0.42	0.16	Subcutaneous adipose tissue;	chr15:92592439	chr15:92715710~92734195:-
LUAD	cis	rs786425	0.77	rs35158437	ENSG00000278112.1	RP11-972P1.11	3.54	0.000442	0.0466	0.15	0.16	Pubertal anthropometrics;	chr12:123676217	chr12:123519390~123519856:-
LUAD	cis	rs1910358	0.614	rs7724548	ENSG00000248874.4	C5orf17	-3.54	0.000442	0.0466	-0.2	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23979557	chr5:23951348~24178263:+
LUAD	cis	rs6903823	0.508	rs1150718	ENSG00000176933.5	TOB2P1	-3.54	0.000442	0.0466	-0.18	-0.16	Pulmonary function;	chr6:28289170	chr6:28217643~28218634:-
LUAD	cis	rs6903823	0.508	rs1233660	ENSG00000176933.5	TOB2P1	-3.54	0.000442	0.0466	-0.18	-0.16	Pulmonary function;	chr6:28292472	chr6:28217643~28218634:-
LUAD	cis	rs891378	0.958	rs10746462	ENSG00000274245.1	RP11-357P18.2	-3.54	0.000442	0.0466	-0.2	-0.16	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207337203	chr1:207372559~207373252:+
LUAD	cis	rs957448	0.948	rs1470153	ENSG00000254057.1	RP3-388N13.3	3.54	0.000442	0.0466	0.17	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94514587	chr8:93834454~93846743:-
LUAD	cis	rs7204230	1	rs1133261	ENSG00000261291.1	RP11-295M3.2	3.54	0.000442	0.0466	0.19	0.16	Fibrinogen;	chr16:53298166	chr16:53168522~53169450:+
LUAD	cis	rs804280	0.662	rs810738	ENSG00000255046.1	RP11-297N6.4	-3.54	0.000442	0.0466	-0.23	-0.16	Myopia (pathological);	chr8:11753697	chr8:11797928~11802568:-
LUAD	cis	rs4965272	0.868	rs4965564	ENSG00000272808.2	RP11-66B24.7	3.54	0.000442	0.0466	0.21	0.16	Gastroesophageal reflux disease;	chr15:100048210	chr15:100849831~100865457:+
LUAD	cis	rs4374383	0.884	rs11683409	ENSG00000236307.2	EEF1E1P1	-3.54	0.000442	0.0467	-0.18	-0.16	Hepatitis C induced liver fibrosis;	chr2:112012557	chr2:111887914~111888741:+
LUAD	cis	rs2024714	0.967	rs2427193	ENSG00000273812.1	WI2-87327B8.2	-3.54	0.000442	0.0467	-0.17	-0.16	Longevity;	chr20:61628742	chr20:62596732~62603115:-
LUAD	cis	rs10206020	0.879	rs72778007	ENSG00000231482.2	AC141930.2	-3.54	0.000442	0.0467	-0.22	-0.16	IgG glycosylation;	chr2:1569406	chr2:1572554~1580311:-
LUAD	cis	rs10206020	0.797	rs72778008	ENSG00000231482.2	AC141930.2	-3.54	0.000442	0.0467	-0.22	-0.16	IgG glycosylation;	chr2:1569410	chr2:1572554~1580311:-
LUAD	cis	rs481331	0.676	rs210267	ENSG00000185904.10	LINC00839	-3.54	0.000442	0.0467	-0.27	-0.16	Systemic juvenile idiopathic arthritis;	chr10:42552510	chr10:42475543~42495336:+
LUAD	cis	rs481331	0.866	rs210221	ENSG00000185904.10	LINC00839	-3.54	0.000442	0.0467	-0.27	-0.16	Systemic juvenile idiopathic arthritis;	chr10:42561182	chr10:42475543~42495336:+
LUAD	cis	rs972578	0.501	rs5759126	ENSG00000230319.1	AL022476.2	3.54	0.000442	0.0467	0.18	0.16	Mean platelet volume;	chr22:43059659	chr22:43038585~43052366:+
LUAD	cis	rs2295359	1	rs11209006	ENSG00000275678.1	RP4-547N15.3	-3.54	0.000442	0.0467	-0.16	-0.16	Psoriasis;	chr1:67153576	chr1:67121605~67123956:-
LUAD	cis	rs2295359	1	rs11209007	ENSG00000275678.1	RP4-547N15.3	-3.54	0.000442	0.0467	-0.16	-0.16	Psoriasis;	chr1:67153662	chr1:67121605~67123956:-
LUAD	cis	rs10129255	0.5	rs10142931	ENSG00000211955.2	IGHV3-33	-3.54	0.000442	0.0467	-0.11	-0.16	Kawasaki disease;	chr14:106782288	chr14:106359793~106360324:-
LUAD	cis	rs5758659	0.652	rs133300	ENSG00000227370.1	RP4-669P10.19	-3.54	0.000442	0.0467	-0.15	-0.16	Cognitive function;	chr22:41993835	chr22:42132543~42132998:+
LUAD	cis	rs1038094	1	rs4887045	ENSG00000277749.1	RP11-60L3.6	3.54	0.000442	0.0467	0.23	0.16	Bipolar disorder;	chr15:73731718	chr15:74311516~74319688:-
LUAD	cis	rs3805389	0.504	rs10018932	ENSG00000249700.7	SRD5A3-AS1	-3.54	0.000442	0.0467	-0.23	-0.16	Waist-to-hip ratio adjusted for body mass index;	chr4:55601699	chr4:55363971~55395847:-
LUAD	cis	rs3805389	0.504	rs28756087	ENSG00000249700.7	SRD5A3-AS1	-3.54	0.000442	0.0467	-0.23	-0.16	Waist-to-hip ratio adjusted for body mass index;	chr4:55601940	chr4:55363971~55395847:-
LUAD	cis	rs3805389	0.504	rs28713371	ENSG00000249700.7	SRD5A3-AS1	-3.54	0.000442	0.0467	-0.23	-0.16	Waist-to-hip ratio adjusted for body mass index;	chr4:55602255	chr4:55363971~55395847:-
LUAD	cis	rs3805389	0.504	rs10011801	ENSG00000249700.7	SRD5A3-AS1	-3.54	0.000442	0.0467	-0.23	-0.16	Waist-to-hip ratio adjusted for body mass index;	chr4:55602567	chr4:55363971~55395847:-
LUAD	cis	rs3805389	0.504	rs10000512	ENSG00000249700.7	SRD5A3-AS1	-3.54	0.000442	0.0467	-0.23	-0.16	Waist-to-hip ratio adjusted for body mass index;	chr4:55602855	chr4:55363971~55395847:-
LUAD	cis	rs17826219	0.585	rs8064302	ENSG00000263603.1	CTD-2349P21.5	3.54	0.000442	0.0467	0.27	0.16	Body mass index;	chr17:30397920	chr17:30729469~30731202:+
LUAD	cis	rs2337406	1	rs17095456	ENSG00000280411.1	IGHV1-69-2	-3.54	0.000442	0.0467	-0.15	-0.16	Alzheimer's disease (late onset);	chr14:106676559	chr14:106762092~106762588:-
LUAD	cis	rs6453278	0.559	rs13183218	ENSG00000250802.5	ZBED3-AS1	-3.54	0.000442	0.0467	-0.2	-0.16	Autism;	chr5:77098982	chr5:77086740~77166909:+
LUAD	cis	rs13064773	0.546	rs340252	ENSG00000240207.5	RP11-379F4.4	-3.54	0.000442	0.0467	-0.17	-0.16	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr3:158881342	chr3:158732263~158784070:+
LUAD	cis	rs987044	0.7	rs1345421	ENSG00000257221.1	RP11-689B22.2	-3.54	0.000442	0.0467	-0.14	-0.16	Mean platelet volume;	chr12:108691259	chr12:108628687~108641318:+
LUAD	cis	rs987044	0.7	rs4964734	ENSG00000257221.1	RP11-689B22.2	-3.54	0.000442	0.0467	-0.14	-0.16	Mean platelet volume;	chr12:108693760	chr12:108628687~108641318:+
LUAD	cis	rs523522	0.962	rs651627	ENSG00000278344.1	RP11-18C24.8	3.54	0.000442	0.0467	0.22	0.16	High light scatter reticulocyte count;	chr12:120571395	chr12:120500735~120501090:-
LUAD	cis	rs5022636	0.533	rs4971029	ENSG00000232671.4	RP11-126K1.2	3.54	0.000442	0.0467	0.2	0.16	Gut microbiota (functional units);	chr1:151304783	chr1:151280024~151281929:-
LUAD	cis	rs5022636	0.507	rs2031797	ENSG00000232671.4	RP11-126K1.2	3.54	0.000442	0.0467	0.2	0.16	Gut microbiota (functional units);	chr1:151306029	chr1:151280024~151281929:-
LUAD	cis	rs17189298	0.935	rs6759463	ENSG00000231013.1	AC013275.2	-3.54	0.000442	0.0467	-0.16	-0.16	Cerebrospinal T-tau levels;	chr2:119086981	chr2:119476448~119487346:+
LUAD	cis	rs334353	0.798	rs1013186	ENSG00000255145.2	STX17-AS1	-3.54	0.000443	0.0467	-0.21	-0.16	Age-related macular degeneration;	chr9:99122055	chr9:99886322~99906601:-
LUAD	cis	rs683250	0.599	rs10501539	ENSG00000246067.6	RAB30-AS1	-3.54	0.000443	0.0467	-0.17	-0.16	Subcortical brain region volumes;	chr11:83355533	chr11:83072066~83106719:+
LUAD	cis	rs924712	0.506	rs62412647	ENSG00000261116.1	RP3-523K23.2	3.54	0.000443	0.0467	0.17	0.16	Breast cancer;	chr6:54846906	chr6:54943167~54945099:+
LUAD	cis	rs924712	0.526	rs12664732	ENSG00000261116.1	RP3-523K23.2	3.54	0.000443	0.0467	0.17	0.16	Breast cancer;	chr6:54846916	chr6:54943167~54945099:+
LUAD	cis	rs924712	0.545	rs9475040	ENSG00000261116.1	RP3-523K23.2	3.54	0.000443	0.0467	0.17	0.16	Breast cancer;	chr6:54847760	chr6:54943167~54945099:+
LUAD	cis	rs10502219	0.918	rs7947659	ENSG00000246100.3	LINC00900	-3.54	0.000443	0.0467	-0.2	-0.16	Mitochondrial DNA levels;	chr11:116549264	chr11:115754248~115760627:-
LUAD	cis	rs12579720	0.695	rs7358620	ENSG00000255910.1	RP11-405A12.2	3.54	0.000443	0.0467	0.2	0.16	Diastolic blood pressure;	chr12:20075397	chr12:19775451~20009937:+
LUAD	cis	rs12822507	0.732	rs7132530	ENSG00000275963.1	RP11-180M15.6	3.54	0.000443	0.0467	0.18	0.16	Systemic lupus erythematosus;	chr12:12601016	chr12:12648939~12649713:+
LUAD	cis	rs6797464	0.536	rs7638569	ENSG00000241479.1	RP11-641D5.2	-3.54	0.000443	0.0467	-0.25	-0.16	Overall survival in osteosarcoma;	chr3:169494579	chr3:169447867~169477052:+
LUAD	cis	rs4727027	0.704	rs12704083	ENSG00000244560.5	RP4-800G7.2	-3.54	0.000443	0.0467	-0.1	-0.16	Neutrophil percentage of granulocytes;Eosinophil counts;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr7:149212667	chr7:149285281~149297312:+
LUAD	cis	rs8085804	0.597	rs11874622	ENSG00000276174.1	RP11-687E1.2	-3.54	0.000443	0.0467	-0.22	-0.16	Cognitive performance;	chr18:42643923	chr18:42052705~42053030:+
LUAD	cis	rs4554975	0.514	rs11183672	ENSG00000274723.1	RP11-618L22.1	3.54	0.000443	0.0467	0.19	0.16	Metabolite levels (small molecules and protein measures);	chr12:46957283	chr12:46970504~46972155:+
LUAD	cis	rs2354432	0.607	rs68080346	ENSG00000237188.3	RP11-337C18.8	3.54	0.000443	0.0467	0.3	0.16	Mitochondrial DNA levels;	chr1:147236836	chr1:147172771~147211568:+
LUAD	cis	rs2354432	0.556	rs1932979	ENSG00000237188.3	RP11-337C18.8	3.54	0.000443	0.0467	0.3	0.16	Mitochondrial DNA levels;	chr1:147237263	chr1:147172771~147211568:+
LUAD	cis	rs10463554	0.963	rs11242483	ENSG00000250682.4	LINC00491	3.54	0.000443	0.0467	0.19	0.16	Parkinson's disease;	chr5:102988062	chr5:102609156~102671559:-
LUAD	cis	rs876983	0.634	rs2634434	ENSG00000244593.1	RP11-685B14.1	3.54	0.000443	0.0467	0.2	0.16	Schizophrenia;	chr8:18563965	chr8:18383274~18383917:-
LUAD	cis	rs2803122	0.967	rs10757040	ENSG00000273226.1	RP11-513M16.8	-3.54	0.000443	0.0467	-0.17	-0.16	Pulse pressure;	chr9:19241849	chr9:19375451~19375996:+
LUAD	cis	rs877356	1	rs13167664	ENSG00000250167.1	CTC-321K16.1	-3.54	0.000443	0.0467	-0.28	-0.16	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (dichotomous);	chr5:135826778	chr5:135559577~135634874:+
LUAD	cis	rs4700393	0.517	rs71592685	ENSG00000272308.1	RP11-231G3.1	3.54	0.000443	0.0467	0.2	0.16	Intelligence (multi-trait analysis);	chr5:60825411	chr5:60866457~60866935:-
LUAD	cis	rs62034325	0.697	rs710410	ENSG00000261766.1	RP11-22P6.2	-3.54	0.000443	0.0467	-0.14	-0.16	Body mass index;	chr16:28592021	chr16:28862166~28863340:-
LUAD	cis	rs7215564	0.908	rs2340773	ENSG00000232083.3	RPL31P7	-3.54	0.000443	0.0467	-0.25	-0.16	Myopia (pathological);	chr17:80770595	chr17:80602549~80602926:-
LUAD	cis	rs7200786	0.528	rs27839	ENSG00000274038.1	RP11-66H6.4	-3.54	0.000443	0.0467	-0.2	-0.16	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11159818	chr16:11056556~11057034:+
LUAD	cis	rs11951515	0.738	rs17244818	ENSG00000249779.1	RP11-447H19.3	3.54	0.000443	0.0467	0.19	0.16	Metabolite levels  (X-11787);	chr5:43339433	chr5:43206709~43207811:+
LUAD	cis	rs6921919	0.609	rs36018474	ENSG00000219392.1	RP1-265C24.5	-3.54	0.000443	0.0467	-0.21	-0.16	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28115628~28116551:+
LUAD	cis	rs9562987	0.578	rs7332114	ENSG00000123201.13	GUCY1B2	-3.54	0.000443	0.0467	-0.23	-0.16	Breast cancer;	chr13:50588833	chr13:50994511~51080862:-
LUAD	cis	rs5758659	0.652	rs133326	ENSG00000270083.1	RP1-257I20.14	3.54	0.000443	0.0467	0.15	0.16	Cognitive function;	chr22:42010881	chr22:42089630~42090028:-
LUAD	cis	rs10129255	0.5	rs8021941	ENSG00000211955.2	IGHV3-33	-3.54	0.000443	0.0467	-0.11	-0.16	Kawasaki disease;	chr14:106781490	chr14:106359793~106360324:-
LUAD	cis	rs2535633	0.631	rs9823697	ENSG00000243224.1	RP5-1157M23.2	-3.54	0.000443	0.0467	-0.17	-0.16	Body mass index;	chr3:52968134	chr3:52239258~52241097:+
LUAD	cis	rs8046148	0.724	rs7186889	ENSG00000279356.1	RP11-429P3.8	3.54	0.000443	0.0467	0.16	0.16	Testicular germ cell tumor;	chr16:50058380	chr16:50072862~50074986:+
LUAD	cis	rs11638352	1	rs2412854	ENSG00000205771.5	CATSPER2P1	3.54	0.000443	0.0468	0.35	0.16	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44002274	chr15:43726918~43747094:-
LUAD	cis	rs7714584	1	rs7709650	ENSG00000197083.10	ZNF300P1	3.54	0.000443	0.0468	0.3	0.16	Crohn's disease;	chr5:150867123	chr5:150930645~150946289:-
LUAD	cis	rs12438356	0.686	rs28787715	ENSG00000212766.8	EWSAT1	-3.54	0.000443	0.0468	-0.29	-0.16	CTACK levels;	chr15:69221382	chr15:69072926~69095820:+
LUAD	cis	rs6500602	0.727	rs11076836	ENSG00000280063.1	RP11-295D4.3	3.54	0.000443	0.0468	0.1	0.16	Schizophrenia;	chr16:4519330	chr16:4346694~4348648:-
LUAD	cis	rs2144940	0.506	rs844876	ENSG00000233746.1	LINC00656	3.54	0.000443	0.0468	0.34	0.16	Venous thromboembolism;	chr20:23121545	chr20:23125068~23132621:-
LUAD	cis	rs9813712	0.595	rs1901787	ENSG00000228252.7	COL6A4P2	3.54	0.000443	0.0468	0.15	0.16	Response to amphetamines;	chr3:130288678	chr3:130212823~130273806:+
LUAD	cis	rs6832769	0.961	rs7684810	ENSG00000272969.1	RP11-528I4.2	3.54	0.000444	0.0468	0.17	0.16	Personality dimensions;	chr4:55486627	chr4:55547112~55547889:+
LUAD	cis	rs11673344	0.642	rs55926714	ENSG00000267254.4	ZNF790-AS1	-3.54	0.000444	0.0468	-0.21	-0.16	Obesity-related traits;	chr19:37307974	chr19:36797518~36828115:+
LUAD	cis	rs28374715	0.733	rs9568	ENSG00000247556.5	OIP5-AS1	3.54	0.000444	0.0468	0.2	0.16	Ulcerative colitis;	chr15:41281414	chr15:41283990~41309737:+
LUAD	cis	rs6951245	0.882	rs10252404	ENSG00000224079.1	AC091729.7	-3.54	0.000444	0.0468	-0.24	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1169971	chr7:1074450~1078036:+
LUAD	cis	rs80130819	0.686	rs1793959	ENSG00000276691.1	RP5-1057I20.5	-3.54	0.000444	0.0468	-0.27	-0.16	Prostate cancer;	chr12:47996297	chr12:47788426~47788971:+
LUAD	cis	rs78487399	0.71	rs74382177	ENSG00000234936.1	AC010883.5	3.54	0.000444	0.0468	0.25	0.16	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43300918	chr2:43229573~43233394:+
LUAD	cis	rs10508774	0.81	rs77579695	ENSG00000231245.2	C1DP1	-3.54	0.000444	0.0468	-0.37	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:32597789	chr10:32511336~32511737:-
LUAD	cis	rs13113518	1	rs10462032	ENSG00000249700.7	SRD5A3-AS1	3.54	0.000444	0.0468	0.16	0.16	Height;	chr4:55479069	chr4:55363971~55395847:-
LUAD	cis	rs1722141	0.812	rs788707	ENSG00000229628.1	AC073115.7	3.54	0.000444	0.0468	0.25	0.16	Sitting height ratio;	chr7:45972854	chr7:45990905~46000898:+
LUAD	cis	rs10751667	0.58	rs7395515	ENSG00000255284.1	AP006621.5	3.54	0.000444	0.0468	0.14	0.16	Alzheimer's disease (late onset);	chr11:1005160	chr11:777578~784297:+
LUAD	cis	rs9467773	0.62	rs4368798	ENSG00000261353.1	CTA-14H9.5	-3.54	0.000444	0.0468	-0.18	-0.16	Intelligence (multi-trait analysis);	chr6:26593243	chr6:26527063~26527404:+
LUAD	cis	rs13068223	0.617	rs13061457	ENSG00000240875.4	LINC00886	-3.54	0.000444	0.0468	-0.17	-0.16	Age-related hearing impairment (SNP x SNP interaction);	chr3:156725596	chr3:156747346~156817062:-
LUAD	cis	rs2235642	0.685	rs2667681	ENSG00000280231.1	LA16c-380F5.3	-3.54	0.000444	0.0468	-0.22	-0.16	Coronary artery disease;	chr16:1603205	chr16:1553655~1554130:-
LUAD	cis	rs1431005	1	rs1431005	ENSG00000250658.1	RP11-138B4.1	-3.54	0.000444	0.0468	-0.2	-0.16	Response to statin therapy;	chr4:187424214	chr4:187304083~187309682:-
LUAD	cis	rs2072499	0.554	rs1052067	ENSG00000246203.2	RP11-29H23.5	3.54	0.000444	0.0468	0.22	0.16	Testicular germ cell tumor;	chr1:156236330	chr1:155614726~155660245:-
LUAD	cis	rs3740713	1	rs75740864	ENSG00000256464.1	YWHABP2	3.54	0.000444	0.0468	0.31	0.16	Amyotrophic lateral sclerosis (sporadic);	chr11:18449142	chr11:18490243~18490955:-
LUAD	cis	rs2024714	0.967	rs2427192	ENSG00000273812.1	WI2-87327B8.2	-3.54	0.000444	0.0468	-0.17	-0.16	Longevity;	chr20:61628566	chr20:62596732~62603115:-
LUAD	cis	rs2074518	0.875	rs2339122	ENSG00000267312.1	RP11-1094M14.7	3.54	0.000444	0.0468	0.18	0.16	QT interval;	chr17:35055782	chr17:35459481~35460550:-
LUAD	cis	rs786425	0.77	rs7308862	ENSG00000278112.1	RP11-972P1.11	3.54	0.000444	0.0468	0.15	0.16	Pubertal anthropometrics;	chr12:123686604	chr12:123519390~123519856:-
LUAD	cis	rs17189298	0.902	rs12476302	ENSG00000231013.1	AC013275.2	3.54	0.000444	0.0468	0.16	0.16	Cerebrospinal T-tau levels;	chr2:119113656	chr2:119476448~119487346:+
LUAD	cis	rs1065852	0.526	rs11090066	ENSG00000226450.2	CYP2D8P	3.54	0.000444	0.0468	0.13	0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42002191	chr22:42149886~42155001:-
LUAD	cis	rs858239	0.6	rs7787110	ENSG00000226816.2	AC005082.12	3.54	0.000444	0.0468	0.21	0.16	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23206013~23208045:+
LUAD	cis	rs75583333	0.655	rs77012002	ENSG00000253522.3	CTC-231O11.1	3.54	0.000444	0.0468	0.29	0.16	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr5:160033484	chr5:160468268~160487426:+
LUAD	cis	rs75583333	0.655	rs60201018	ENSG00000253522.3	CTC-231O11.1	3.54	0.000444	0.0468	0.29	0.16	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr5:160040434	chr5:160468268~160487426:+
LUAD	cis	rs4835473	0.932	rs12505628	ENSG00000249741.2	RP11-673E1.3	3.54	0.000444	0.0468	0.19	0.16	Immature fraction of reticulocytes;	chr4:143758468	chr4:143911514~143912053:-
LUAD	cis	rs4835473	0.9	rs12505663	ENSG00000249741.2	RP11-673E1.3	3.54	0.000444	0.0468	0.19	0.16	Immature fraction of reticulocytes;	chr4:143758491	chr4:143911514~143912053:-
LUAD	cis	rs4835473	0.868	rs12513078	ENSG00000249741.2	RP11-673E1.3	3.54	0.000444	0.0468	0.19	0.16	Immature fraction of reticulocytes;	chr4:143758494	chr4:143911514~143912053:-
LUAD	cis	rs4835473	0.9	rs12505665	ENSG00000249741.2	RP11-673E1.3	3.54	0.000444	0.0468	0.19	0.16	Immature fraction of reticulocytes;	chr4:143758515	chr4:143911514~143912053:-
LUAD	cis	rs4835473	0.9	rs12509716	ENSG00000249741.2	RP11-673E1.3	3.54	0.000444	0.0468	0.19	0.16	Immature fraction of reticulocytes;	chr4:143758520	chr4:143911514~143912053:-
LUAD	cis	rs2836950	0.545	rs1888489	ENSG00000238141.2	BRWD1-AS1	-3.54	0.000444	0.0468	-0.17	-0.16	Menarche (age at onset);	chr21:39161238	chr21:39315707~39323218:+
LUAD	cis	rs3740713	1	rs1848048	ENSG00000256464.1	YWHABP2	3.54	0.000444	0.0468	0.31	0.16	Amyotrophic lateral sclerosis (sporadic);	chr11:18447449	chr11:18490243~18490955:-
LUAD	cis	rs3740713	1	rs16935432	ENSG00000256464.1	YWHABP2	3.54	0.000444	0.0468	0.31	0.16	Amyotrophic lateral sclerosis (sporadic);	chr11:18448940	chr11:18490243~18490955:-
LUAD	cis	rs3740713	1	rs73440625	ENSG00000256464.1	YWHABP2	3.54	0.000444	0.0468	0.31	0.16	Amyotrophic lateral sclerosis (sporadic);	chr11:18449253	chr11:18490243~18490955:-
LUAD	cis	rs3740713	1	rs76599129	ENSG00000256464.1	YWHABP2	3.54	0.000444	0.0468	0.31	0.16	Amyotrophic lateral sclerosis (sporadic);	chr11:18450080	chr11:18490243~18490955:-
LUAD	cis	rs8028182	0.537	rs4371118	ENSG00000260274.1	RP11-817O13.8	3.54	0.000444	0.0468	0.18	0.16	Sudden cardiac arrest;	chr15:75606549	chr15:75368155~75369584:+
LUAD	cis	rs2744375	0.544	rs2744365	ENSG00000261211.1	RP1-80N2.3	-3.54	0.000444	0.0468	-0.19	-0.16	Resting heart rate;	chr6:7551787	chr6:6680309~6683633:-
LUAD	cis	rs4499344	0.556	rs259243	ENSG00000201388.1	SNORA68	3.54	0.000444	0.0469	0.19	0.16	Mean platelet volume;	chr19:32653820	chr19:32608337~32608469:-
LUAD	cis	rs4936099	0.54	rs2291344	ENSG00000175773.11	RP11-121M22.1	3.54	0.000445	0.0469	0.16	0.16	Optic cup area;Vertical cup-disc ratio;	chr11:130409029	chr11:130314993~130403657:+
LUAD	cis	rs72627123	1	rs72627117	ENSG00000259065.1	RP5-1021I20.1	-3.54	0.000445	0.0469	-0.25	-0.16	Morning vs. evening chronotype;	chr14:73888530	chr14:73787360~73803270:+
LUAD	cis	rs72627123	1	rs72627119	ENSG00000259065.1	RP5-1021I20.1	-3.54	0.000445	0.0469	-0.25	-0.16	Morning vs. evening chronotype;	chr14:73889571	chr14:73787360~73803270:+
LUAD	cis	rs2834288	0.535	rs7275560	ENSG00000273102.1	AP000569.9	-3.54	0.000445	0.0469	-0.2	-0.16	Gut microbiota (bacterial taxa);	chr21:33956140	chr21:33967101~33968573:-
LUAD	cis	rs3126085	0.515	rs11204995	ENSG00000237975.5	FLG-AS1	3.54	0.000445	0.0469	0.24	0.16	Atopic dermatitis;	chr1:152386692	chr1:152168125~152445456:+
LUAD	cis	rs3126085	0.515	rs1923506	ENSG00000237975.5	FLG-AS1	3.54	0.000445	0.0469	0.24	0.16	Atopic dermatitis;	chr1:152387224	chr1:152168125~152445456:+
LUAD	cis	rs3126085	0.515	rs1923503	ENSG00000237975.5	FLG-AS1	3.54	0.000445	0.0469	0.24	0.16	Atopic dermatitis;	chr1:152388344	chr1:152168125~152445456:+
LUAD	cis	rs6754311	0.593	rs10202489	ENSG00000226806.1	AC011893.3	-3.54	0.000445	0.0469	-0.2	-0.16	Mosquito bite size;	chr2:135736616	chr2:135820191~135823087:+
LUAD	cis	rs2239547	0.522	rs9311485	ENSG00000243224.1	RP5-1157M23.2	3.54	0.000445	0.0469	0.18	0.16	Schizophrenia;	chr3:52953629	chr3:52239258~52241097:+
LUAD	cis	rs6088590	1	rs6088590	ENSG00000275784.1	RP5-1125A11.6	-3.54	0.000445	0.0469	-0.17	-0.16	Coronary artery disease;	chr20:34725762	chr20:33989480~33991818:-
LUAD	cis	rs36093844	0.527	rs72961110	ENSG00000279742.1	RP11-700A24.1	-3.54	0.000445	0.0469	-0.19	-0.16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86007976	chr11:85852557~85854943:-
LUAD	cis	rs6432852	0.966	rs6710878	ENSG00000232411.1	AC009495.3	3.54	0.000445	0.0469	0.16	0.16	Diabetic kidney disease;	chr2:165882121	chr2:165833048~165839098:-
LUAD	cis	rs2742234	0.911	rs3004214	ENSG00000273008.1	RP11-351D16.3	-3.54	0.000445	0.0469	-0.17	-0.16	Hirschsprung disease;	chr10:43136250	chr10:43136824~43138334:-
LUAD	cis	rs6496667	1	rs58436485	ENSG00000259262.1	NDUFA3P4	3.54	0.000445	0.0469	0.24	0.16	Rheumatoid arthritis;	chr15:90357401	chr15:90385814~90386063:+
LUAD	cis	rs11233413	0.874	rs4944424	ENSG00000246067.6	RAB30-AS1	3.54	0.000445	0.0469	0.17	0.16	Economic and political preferences (feminism/equality);	chr11:83063823	chr11:83072066~83106719:+
LUAD	cis	rs62103177	0.525	rs4799116	ENSG00000261126.6	RP11-795F19.1	-3.54	0.000445	0.0469	-0.18	-0.16	Opioid sensitivity;	chr18:79976735	chr18:80046900~80095482:+
LUAD	cis	rs9595908	0.746	rs9591222	ENSG00000281026.1	N4BP2L2-IT2	-3.54	0.000445	0.0469	-0.1	-0.16	Body mass index;	chr13:32653261	chr13:32504506~32509395:-
LUAD	cis	rs131777	0.526	rs86337	ENSG00000272940.1	CTA-384D8.33	3.54	0.000445	0.0469	0.2	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50582239	chr22:50597152~50597599:+
LUAD	cis	rs916888	0.773	rs199457	ENSG00000260075.1	NSFP1	-3.54	0.000445	0.0469	-0.27	-0.16	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46372855~46487141:+
LUAD	cis	rs453301	0.597	rs7001187	ENSG00000233609.3	RP11-62H7.2	-3.54	0.000445	0.0469	-0.13	-0.16	Joint mobility (Beighton score);	chr8:8935272	chr8:8961200~8979025:+
LUAD	cis	rs11158026	0.603	rs3783646	ENSG00000258413.1	RP11-665C16.6	-3.54	0.000445	0.0469	-0.21	-0.16	Parkinson's disease;	chr14:55005169	chr14:55262767~55272075:-
LUAD	cis	rs12681366	0.919	rs13248829	ENSG00000254315.1	RP11-267M23.3	3.54	0.000445	0.0469	0.19	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94476750	chr8:94533628~94534391:+
LUAD	cis	rs683250	0.599	rs4121830	ENSG00000246067.6	RAB30-AS1	-3.54	0.000445	0.0469	-0.17	-0.16	Subcortical brain region volumes;	chr11:83377687	chr11:83072066~83106719:+
LUAD	cis	rs490234	0.552	rs2841327	ENSG00000232630.1	PRPS1P2	-3.54	0.000445	0.0469	-0.16	-0.16	Mean arterial pressure;	chr9:125394224	chr9:125150653~125151589:+
LUAD	cis	rs12586317	0.548	rs12590678	ENSG00000226677.3	IGBP1P1	3.54	0.000445	0.0469	0.24	0.16	Psoriasis;	chr14:35133750	chr14:34939324~34940332:+
LUAD	cis	rs12664251	0.666	rs1889561	ENSG00000253194.1	RP11-351A11.1	-3.54	0.000445	0.0469	-0.19	-0.16	Schizophrenia;	chr6:119014700	chr6:118934785~119031541:+
LUAD	cis	rs17772222	0.682	rs1864744	ENSG00000258983.2	RP11-507K2.2	-3.54	0.000445	0.0469	-0.17	-0.16	Coronary artery calcification;	chr14:88484662	chr14:88499334~88515502:+
LUAD	cis	rs7976269	0.583	rs4931131	ENSG00000275476.1	RP11-996F15.4	-3.54	0.000445	0.0469	-0.17	-0.16	Male-pattern baldness;	chr12:29015898	chr12:29277397~29277882:-
LUAD	cis	rs240993	0.516	rs465646	ENSG00000266032.1	AL357515.1	3.54	0.000445	0.0469	0.26	0.16	Inflammatory skin disease;Psoriasis;	chr6:111299555	chr6:110969773~110969872:-
LUAD	cis	rs2281558	0.876	rs6115135	ENSG00000125804.12	FAM182A	-3.54	0.000445	0.0469	-0.22	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25299242	chr20:26054655~26086917:+
LUAD	cis	rs7789940	1	rs76024966	ENSG00000230305.2	AC004980.9	3.54	0.000445	0.0469	0.21	0.16	Multiple sclerosis;	chr7:76365704	chr7:76524515~76532692:+
LUAD	cis	rs3935685	0.874	rs4477663	ENSG00000261143.1	ADAMTS7P3	-3.54	0.000445	0.0469	-0.15	-0.16	Intelligence (multi-trait analysis);	chr15:77714912	chr15:77976042~77993057:+
LUAD	cis	rs4713118	0.591	rs2056924	ENSG00000280107.1	AL022393.9	-3.54	0.000445	0.0469	-0.19	-0.16	Parkinson's disease;	chr6:27722395	chr6:28170845~28172521:+
LUAD	cis	rs6988985	0.818	rs6471583	ENSG00000247317.3	RP11-273G15.2	-3.54	0.000445	0.0469	-0.18	-0.16	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142909676	chr8:142981738~143018437:-
LUAD	cis	rs9457247	1	rs2149090	ENSG00000227598.1	RP1-167A14.2	3.54	0.000445	0.0469	0.17	0.16	Crohn's disease;	chr6:166959276	chr6:166969626~166999065:-
LUAD	cis	rs9457247	1	rs2149091	ENSG00000227598.1	RP1-167A14.2	3.54	0.000445	0.0469	0.17	0.16	Crohn's disease;	chr6:166959298	chr6:166969626~166999065:-
LUAD	cis	rs9309473	0.95	rs10206899	ENSG00000273245.1	RP11-434P11.2	3.54	0.000445	0.0469	0.2	0.16	Metabolite levels;	chr2:73673773	chr2:73750256~73750786:-
LUAD	cis	rs2288073	0.801	rs10176347	ENSG00000242628.4	AC009228.1	3.54	0.000445	0.0469	0.21	0.16	Venous thromboembolism (SNP x SNP interaction);	chr2:24145124	chr2:24214381~24221516:+
LUAD	cis	rs6928977	0.637	rs9647635	ENSG00000231028.7	LINC00271	3.54	0.000445	0.0469	0.19	0.16	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135519918	chr6:135497801~135716055:+
LUAD	cis	rs7560272	0.529	rs2421672	ENSG00000163016.8	ALMS1P	-3.54	0.000445	0.0469	-0.17	-0.16	Schizophrenia;	chr2:73728413	chr2:73644919~73685576:+
LUAD	cis	rs2243480	1	rs2465120	ENSG00000222364.1	RNU6-96P	-3.54	0.000446	0.0469	-0.27	-0.16	Diabetic kidney disease;	chr7:66155987	chr7:66395191~66395286:+
LUAD	cis	rs2243480	0.908	rs2460431	ENSG00000222364.1	RNU6-96P	3.54	0.000446	0.0469	0.27	0.16	Diabetic kidney disease;	chr7:66157859	chr7:66395191~66395286:+
LUAD	cis	rs2243480	1	rs4718309	ENSG00000222364.1	RNU6-96P	3.54	0.000446	0.0469	0.27	0.16	Diabetic kidney disease;	chr7:66162777	chr7:66395191~66395286:+
LUAD	cis	rs2243480	1	rs6460274	ENSG00000222364.1	RNU6-96P	3.54	0.000446	0.0469	0.27	0.16	Diabetic kidney disease;	chr7:66163497	chr7:66395191~66395286:+
LUAD	cis	rs2243480	1	rs7787230	ENSG00000222364.1	RNU6-96P	3.54	0.000446	0.0469	0.27	0.16	Diabetic kidney disease;	chr7:66164112	chr7:66395191~66395286:+
LUAD	cis	rs987724	0.593	rs4680317	ENSG00000240875.4	LINC00886	3.54	0.000446	0.0469	0.18	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156938964	chr3:156747346~156817062:-
LUAD	cis	rs4795519	0.583	rs4795494	ENSG00000266313.1	RP11-173M1.4	3.54	0.000446	0.0469	0.22	0.16	Chronic myeloid leukemia;	chr17:27150683	chr17:27333256~27348491:+
LUAD	cis	rs881375	0.9	rs1930786	ENSG00000238181.2	AHCYP2	-3.54	0.000446	0.047	-0.2	-0.16	Rheumatoid arthritis;	chr9:120929191	chr9:120720673~120721972:+
LUAD	cis	rs2708977	0.699	rs631746	ENSG00000237510.6	AC008268.2	-3.54	0.000446	0.047	-0.21	-0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96399761	chr2:95789654~95800166:+
LUAD	cis	rs467650	0.853	rs294031	ENSG00000248489.1	CTD-2007H13.3	3.54	0.000446	0.047	0.17	0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:98690903	chr5:98929171~98995013:+
LUAD	cis	rs1023500	0.505	rs134891	ENSG00000226450.2	CYP2D8P	3.54	0.000446	0.047	0.12	0.16	Schizophrenia;	chr22:42279876	chr22:42149886~42155001:-
LUAD	cis	rs34779708	0.931	rs4934697	ENSG00000271335.4	RP11-324I22.4	3.54	0.000446	0.047	0.17	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:34998264	chr10:35314552~35336401:-
LUAD	cis	rs61160187	0.549	rs61017995	ENSG00000215032.2	GNL3LP1	3.54	0.000446	0.047	0.19	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60968176	chr5:60891935~60893577:-
LUAD	cis	rs12220238	0.722	rs12360087	ENSG00000226051.5	ZNF503-AS1	3.54	0.000446	0.047	0.29	0.16	Soluble interleukin-2 receptor subunit alpha;	chr10:74614146	chr10:75269819~75373500:+
LUAD	cis	rs9813712	0.595	rs1453238	ENSG00000228252.7	COL6A4P2	3.54	0.000446	0.047	0.15	0.16	Response to amphetamines;	chr3:130290494	chr3:130212823~130273806:+
LUAD	cis	rs3135758	0.655	rs11598352	ENSG00000226864.1	ATE1-AS1	3.54	0.000446	0.047	0.42	0.16	Magnesium levels;	chr10:121624875	chr10:121928312~121951965:+
LUAD	cis	rs2039553	0.902	rs7139876	ENSG00000227676.3	LINC01068	3.54	0.000446	0.047	0.21	0.16	Pancreatic cancer;	chr13:79730044	chr13:79566727~79571436:+
LUAD	cis	rs7569084	0.687	rs1344891	ENSG00000237979.1	AC007389.1	3.54	0.000446	0.047	0.2	0.16	Sum eosinophil basophil counts;	chr2:65458890	chr2:65500993~65502138:-
LUAD	cis	rs513088	0.681	rs495489	ENSG00000225171.2	DUTP6	-3.54	0.000446	0.047	-0.21	-0.16	Schizophrenia;	chr1:166731394	chr1:166868748~166869209:+
LUAD	cis	rs4386084	0.588	rs12905409	ENSG00000242737.1	RP11-562A8.1	-3.54	0.000446	0.047	-0.18	-0.16	Basophil percentage of granulocytes;Basophil percentage of white cells;	chr15:49939567	chr15:50466738~50467096:+
LUAD	cis	rs13434995	0.513	rs62309729	ENSG00000249700.7	SRD5A3-AS1	-3.54	0.000446	0.047	-0.2	-0.16	Adiponectin levels;	chr4:55536679	chr4:55363971~55395847:-
LUAD	cis	rs6964587	0.967	rs10279210	ENSG00000188693.7	CYP51A1-AS1	-3.54	0.000446	0.047	-0.19	-0.16	Breast cancer;	chr7:91987577	chr7:92134604~92180725:+
LUAD	cis	rs4713118	0.513	rs6915987	ENSG00000216901.1	AL022393.7	-3.54	0.000446	0.047	-0.18	-0.16	Parkinson's disease;	chr6:27547997	chr6:28176188~28176674:+
LUAD	cis	rs7680126	0.536	rs3796841	ENSG00000163612.10	FAM86KP	-3.54	0.000446	0.047	-0.27	-0.16	Urate levels in obese individuals;Urate levels in lean individuals;Urate levels in overweight individuals;	chr4:10006280	chr4:9153296~9165451:+
LUAD	cis	rs6736093	0.966	rs11674883	ENSG00000207383.1	Y_RNA	3.54	0.000447	0.047	0.2	0.16	Coronary artery disease;	chr2:111955492	chr2:112579484~112579584:-
LUAD	cis	rs9860428	0.679	rs12494693	ENSG00000240057.4	RP11-572M11.4	-3.54	0.000447	0.047	-0.18	-0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112958682	chr3:113019532~113183301:+
LUAD	cis	rs1665050	0.598	rs8041221	ENSG00000277144.1	RP11-59H7.4	-3.54	0.000447	0.047	-0.19	-0.16	Atopic dermatitis;	chr15:59042609	chr15:59115547~59116089:-
LUAD	cis	rs3764021	0.87	rs10844622	ENSG00000278635.1	CTD-2318O12.1	-3.54	0.000447	0.047	-0.14	-0.16	Type 1 diabetes;	chr12:9732486	chr12:9415641~9416718:+
LUAD	cis	rs12539814	1	rs12666210	ENSG00000204959.4	ARHGEF34P	-3.54	0.000447	0.047	-0.26	-0.16	Diastolic blood pressure;	chr7:144435635	chr7:144272445~144286966:-
LUAD	cis	rs4888378	0.535	rs9319483	ENSG00000280152.1	RP11-331F4.5	3.54	0.000447	0.0471	0.14	0.16	Coronary artery disease;	chr16:75311893	chr16:75245994~75250077:-
LUAD	cis	rs11988997	0.867	rs78115784	ENSG00000281641.1	SAMD12-AS1	-3.54	0.000447	0.0471	-0.36	-0.16	Pancreatitis;	chr8:118715630	chr8:118621001~118858218:+
LUAD	cis	rs11988997	0.867	rs79682119	ENSG00000281641.1	SAMD12-AS1	-3.54	0.000447	0.0471	-0.36	-0.16	Pancreatitis;	chr8:118716454	chr8:118621001~118858218:+
LUAD	cis	rs1876905	0.68	rs7767302	ENSG00000230177.1	RP5-1112D6.4	3.54	0.000447	0.0471	0.19	0.16	Mean corpuscular hemoglobin;	chr6:111143942	chr6:111277932~111278742:+
LUAD	cis	rs11951515	0.508	rs1366410	ENSG00000248240.1	RP11-159F24.5	-3.54	0.000447	0.0471	-0.17	-0.16	Metabolite levels  (X-11787);	chr5:43601508	chr5:43515274~43525310:+
LUAD	cis	rs875971	0.545	rs73152714	ENSG00000224316.1	RP11-479O9.2	3.54	0.000447	0.0471	0.18	0.16	Aortic root size;	chr7:66534641	chr7:65773620~65802067:+
LUAD	cis	rs875971	0.545	rs4718364	ENSG00000224316.1	RP11-479O9.2	3.54	0.000447	0.0471	0.18	0.16	Aortic root size;	chr7:66536353	chr7:65773620~65802067:+
LUAD	cis	rs875971	0.545	rs6961853	ENSG00000224316.1	RP11-479O9.2	3.54	0.000447	0.0471	0.18	0.16	Aortic root size;	chr7:66537035	chr7:65773620~65802067:+
LUAD	cis	rs9900280	1	rs9916533	ENSG00000264808.1	RP11-802D6.1	3.54	0.000447	0.0471	0.19	0.16	Mean platelet volume;	chr17:29444110	chr17:29369717~29390777:-
LUAD	cis	rs11239930	0.517	rs584107	ENSG00000225603.3	RP11-325P15.1	-3.54	0.000447	0.0471	-0.2	-0.16	AIDS progression;	chr1:147075862	chr1:147050817~147052481:+
LUAD	cis	rs6743068	0.521	rs12472273	ENSG00000234842.1	AC007163.8	-3.54	0.000447	0.0471	-0.18	-0.16	Lymphocyte percentage of white cells;	chr2:201346972	chr2:201549631~201550307:+
LUAD	cis	rs7474896	0.537	rs2472149	ENSG00000226578.1	RP11-258F22.1	3.54	0.000447	0.0471	0.22	0.16	Obesity (extreme);	chr10:37973268	chr10:37775371~37784131:-
LUAD	cis	rs9921338	0.923	rs72771877	ENSG00000262703.1	RP11-485G7.6	-3.54	0.000447	0.0471	-0.17	-0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11274759	chr16:11348143~11349321:-
LUAD	cis	rs2688608	0.933	rs2633307	ENSG00000271816.1	BMS1P4	3.54	0.000447	0.0471	0.13	0.16	Inflammatory bowel disease;	chr10:73894123	chr10:73699151~73730487:-
LUAD	cis	rs9815354	0.627	rs80120812	ENSG00000273328.4	RP11-141M3.6	-3.54	0.000447	0.0471	-0.29	-0.16	Pulse pressure;Diastolic blood pressure;	chr3:41980268	chr3:42809414~42908105:+
LUAD	cis	rs9815354	0.537	rs73073272	ENSG00000273328.4	RP11-141M3.6	-3.54	0.000447	0.0471	-0.29	-0.16	Pulse pressure;Diastolic blood pressure;	chr3:41980954	chr3:42809414~42908105:+
LUAD	cis	rs9815354	0.68	rs73073274	ENSG00000273328.4	RP11-141M3.6	-3.54	0.000447	0.0471	-0.29	-0.16	Pulse pressure;Diastolic blood pressure;	chr3:41981318	chr3:42809414~42908105:+
LUAD	cis	rs9815354	0.597	rs79626430	ENSG00000273328.4	RP11-141M3.6	-3.54	0.000447	0.0471	-0.29	-0.16	Pulse pressure;Diastolic blood pressure;	chr3:41982294	chr3:42809414~42908105:+
LUAD	cis	rs9815354	0.68	rs112310714	ENSG00000273328.4	RP11-141M3.6	-3.54	0.000447	0.0471	-0.29	-0.16	Pulse pressure;Diastolic blood pressure;	chr3:41983305	chr3:42809414~42908105:+
LUAD	cis	rs9815354	0.556	rs73073276	ENSG00000273328.4	RP11-141M3.6	-3.54	0.000447	0.0471	-0.29	-0.16	Pulse pressure;Diastolic blood pressure;	chr3:41983862	chr3:42809414~42908105:+
LUAD	cis	rs9815354	0.68	rs73073280	ENSG00000273328.4	RP11-141M3.6	-3.54	0.000447	0.0471	-0.29	-0.16	Pulse pressure;Diastolic blood pressure;	chr3:41984280	chr3:42809414~42908105:+
LUAD	cis	rs9815354	0.638	rs56008529	ENSG00000273328.4	RP11-141M3.6	-3.54	0.000447	0.0471	-0.29	-0.16	Pulse pressure;Diastolic blood pressure;	chr3:41985263	chr3:42809414~42908105:+
LUAD	cis	rs9815354	0.556	rs116717051	ENSG00000273328.4	RP11-141M3.6	-3.54	0.000447	0.0471	-0.29	-0.16	Pulse pressure;Diastolic blood pressure;	chr3:41985919	chr3:42809414~42908105:+
LUAD	cis	rs9815354	0.68	rs73073285	ENSG00000273328.4	RP11-141M3.6	-3.54	0.000447	0.0471	-0.29	-0.16	Pulse pressure;Diastolic blood pressure;	chr3:41986074	chr3:42809414~42908105:+
LUAD	cis	rs9815354	0.68	rs73073288	ENSG00000273328.4	RP11-141M3.6	-3.54	0.000447	0.0471	-0.29	-0.16	Pulse pressure;Diastolic blood pressure;	chr3:41986145	chr3:42809414~42908105:+
LUAD	cis	rs9815354	0.68	rs73073290	ENSG00000273328.4	RP11-141M3.6	-3.54	0.000447	0.0471	-0.29	-0.16	Pulse pressure;Diastolic blood pressure;	chr3:41986192	chr3:42809414~42908105:+
LUAD	cis	rs9815354	0.68	rs73073291	ENSG00000273328.4	RP11-141M3.6	-3.54	0.000447	0.0471	-0.29	-0.16	Pulse pressure;Diastolic blood pressure;	chr3:41986512	chr3:42809414~42908105:+
LUAD	cis	rs6563842	0.563	rs9603786	ENSG00000168852.11	TPTE2P5	3.54	0.000447	0.0471	0.16	0.16	Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr13:40742228	chr13:40822296~40921749:-
LUAD	cis	rs782590	0.574	rs12991445	ENSG00000272606.1	RP11-554J4.1	-3.54	0.000447	0.0471	-0.16	-0.16	Metabolic syndrome;	chr2:55448803	chr2:55617909~55618373:+
LUAD	cis	rs9638182	0.778	rs35332062	ENSG00000274080.1	CTA-315H11.2	3.53	0.000447	0.0471	0.3	0.16	Triglycerides;	chr7:73597712	chr7:73609262~73611502:-
LUAD	cis	rs10197140	0.925	rs13429892	ENSG00000227992.1	AC108463.2	-3.53	0.000447	0.0471	-0.19	-0.16	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110867189	chr2:111203964~111206215:-
LUAD	cis	rs7223966	1	rs9747164	ENSG00000279369.1	RP11-51F16.1	-3.53	0.000447	0.0471	-0.18	-0.16	Hip circumference adjusted for BMI;Body mass index;	chr17:63787427	chr17:63700847~63702670:+
LUAD	cis	rs7893279	0.543	rs7086757	ENSG00000225527.1	RP11-383B4.4	3.53	0.000447	0.0471	0.23	0.16	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18597832	chr10:18531849~18533336:-
LUAD	cis	rs3002142	0.554	rs17531063	ENSG00000272750.1	RP11-378J18.8	3.53	0.000447	0.0471	0.26	0.16	LDL peak particle diameter (total fat intake interaction);	chr1:222648367	chr1:222658867~222661512:-
LUAD	cis	rs13014235	0.532	rs6729982	ENSG00000213090.2	AC007256.5	3.53	0.000447	0.0471	0.18	0.16	Basal cell carcinoma;	chr2:201416413	chr2:201410544~201413308:-
LUAD	cis	rs13014235	0.532	rs10497867	ENSG00000213090.2	AC007256.5	3.53	0.000447	0.0471	0.18	0.16	Basal cell carcinoma;	chr2:201420144	chr2:201410544~201413308:-
LUAD	cis	rs253959	0.696	rs1421846	ENSG00000248445.4	SEMA6A-AS1	3.53	0.000447	0.0471	0.12	0.16	Bipolar disorder and schizophrenia;	chr5:116365440	chr5:116447547~116508276:+
LUAD	cis	rs755249	0.545	rs12037073	ENSG00000182109.6	RP11-69E11.4	-3.53	0.000448	0.0471	-0.17	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39581225	chr1:39522280~39546187:-
LUAD	cis	rs6734238	1	rs6734238	ENSG00000236397.3	DDX11L2	3.53	0.000448	0.0471	0.21	0.16	Fibrinogen levels;C-reactive protein levels or total cholesterol levels (pleiotropy);Fibrinogen;C-reactive protein;White blood cell count;C-reactive protein levels;	chr2:113083453	chr2:113599036~113601261:-
LUAD	cis	rs6493858	0.809	rs4774847	ENSG00000277548.1	RP11-139H15.6	3.53	0.000448	0.0471	0.17	0.16	Relative hand skill in reading disability;	chr15:56144851	chr15:55346347~55346752:-
LUAD	cis	rs12216545	0.765	rs7785909	ENSG00000241134.3	BET1P1	-3.53	0.000448	0.0471	-0.16	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150525142	chr7:150749736~150750094:+
LUAD	cis	rs72799341	1	rs7200879	ENSG00000232748.3	RP11-196G11.6	-3.53	0.000448	0.0471	-0.22	-0.16	Diastolic blood pressure;	chr16:30936251	chr16:31056460~31062803:+
LUAD	cis	rs6472827	0.645	rs2956055	ENSG00000253983.2	RP1-16A9.1	3.53	0.000448	0.0471	0.23	0.16	Uterine fibroids;	chr8:74199718	chr8:74199396~74208441:+
LUAD	cis	rs7005380	0.785	rs55892034	ENSG00000279347.1	RP11-85I17.2	3.53	0.000448	0.0471	0.13	0.16	Interstitial lung disease;	chr8:119931267	chr8:119838736~119840385:-
LUAD	cis	rs6088590	0.735	rs6088618	ENSG00000276073.1	RP5-1125A11.7	-3.53	0.000448	0.0471	-0.16	-0.16	Coronary artery disease;	chr20:34821547	chr20:33985617~33988989:-
LUAD	cis	rs9467773	1	rs9467779	ENSG00000241549.7	GUSBP2	-3.53	0.000448	0.0471	-0.17	-0.16	Intelligence (multi-trait analysis);	chr6:26536459	chr6:26871484~26956554:-
LUAD	cis	rs4835473	0.932	rs35164917	ENSG00000249741.2	RP11-673E1.3	-3.53	0.000448	0.0471	-0.19	-0.16	Immature fraction of reticulocytes;	chr4:143748891	chr4:143911514~143912053:-
LUAD	cis	rs8050896	0.59	rs79004798	ENSG00000260695.1	RP11-513N24.1	-3.53	0.000448	0.0471	-0.34	-0.16	Response to antipsychotic treatment;	chr16:66141311	chr16:65861112~65863784:-
LUAD	cis	rs8050896	0.59	rs17678647	ENSG00000260695.1	RP11-513N24.1	-3.53	0.000448	0.0471	-0.34	-0.16	Response to antipsychotic treatment;	chr16:66142534	chr16:65861112~65863784:-
LUAD	cis	rs12220238	1	rs8255	ENSG00000272599.2	RP11-152N13.16	3.53	0.000448	0.0471	0.21	0.16	Soluble interleukin-2 receptor subunit alpha;	chr10:74119992	chr10:73124573~73125532:-
LUAD	cis	rs10129255	0.589	rs78599641	ENSG00000211947.2	IGHV3-21	-3.53	0.000448	0.0471	-0.11	-0.16	Kawasaki disease;	chr14:106637576	chr14:106235064~106235594:-
LUAD	cis	rs7674212	0.51	rs2720468	ENSG00000246560.2	RP11-10L12.4	3.53	0.000448	0.0471	0.2	0.16	Type 2 diabetes;	chr4:103163996	chr4:102828055~102844075:+
LUAD	cis	rs7809950	1	rs2712215	ENSG00000238832.1	snoU109	-3.53	0.000448	0.0471	-0.23	-0.16	Coronary artery disease;	chr7:107547762	chr7:107603363~107603507:+
LUAD	cis	rs75583333	0.655	rs17057453	ENSG00000253522.3	CTC-231O11.1	3.53	0.000448	0.0471	0.26	0.16	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr5:160102735	chr5:160468268~160487426:+
LUAD	cis	rs7474896	0.537	rs2505255	ENSG00000226578.1	RP11-258F22.1	-3.53	0.000448	0.0471	-0.22	-0.16	Obesity (extreme);	chr10:38070714	chr10:37775371~37784131:-
LUAD	cis	rs4934494	0.727	rs12764076	ENSG00000240996.1	RP11-80H5.7	-3.53	0.000448	0.0471	-0.22	-0.16	Red blood cell count;	chr10:89630443	chr10:89694295~89697928:-
LUAD	cis	rs4934494	0.634	rs12762448	ENSG00000240996.1	RP11-80H5.7	-3.53	0.000448	0.0471	-0.22	-0.16	Red blood cell count;	chr10:89630483	chr10:89694295~89697928:-
LUAD	cis	rs1447352	0.755	rs7951037	ENSG00000279684.1	RP11-755E23.2	-3.53	0.000448	0.0472	-0.2	-0.16	Metabolic traits;	chr11:92973009	chr11:93286629~93288903:-
LUAD	cis	rs4819052	0.807	rs4819047	ENSG00000215447.6	BX322557.10	-3.53	0.000448	0.0472	-0.19	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245224	chr21:45288052~45291738:+
LUAD	cis	rs987044	0.7	rs10861955	ENSG00000257221.1	RP11-689B22.2	-3.53	0.000448	0.0472	-0.13	-0.16	Mean platelet volume;	chr12:108644013	chr12:108628687~108641318:+
LUAD	cis	rs5770917	1	rs3180872	ENSG00000273272.1	CTA-384D8.34	3.53	0.000448	0.0472	0.34	0.16	Narcolepsy;	chr22:50578965	chr22:50542650~50543011:+
LUAD	cis	rs67311347	1	rs12108041	ENSG00000280739.1	EIF1B-AS1	3.53	0.000448	0.0472	0.17	0.16	Renal cell carcinoma;	chr3:40446044	chr3:40173145~40309698:-
LUAD	cis	rs67311347	1	rs1123019	ENSG00000280739.1	EIF1B-AS1	3.53	0.000448	0.0472	0.17	0.16	Renal cell carcinoma;	chr3:40446789	chr3:40173145~40309698:-
LUAD	cis	rs35542019	1	rs35542019	ENSG00000273102.1	AP000569.9	3.53	0.000448	0.0472	0.19	0.16	Hemoglobin concentration;Hematocrit;Red blood cell count;	chr21:33974555	chr21:33967101~33968573:-
LUAD	cis	rs4792901	0.959	rs7208294	ENSG00000198496.9	NBR2	3.53	0.000448	0.0472	0.17	0.16	Dupuytren's disease;	chr17:43580895	chr17:43125610~43153671:+
LUAD	cis	rs11220082	0.787	rs34632138	ENSG00000254671.2	STT3A-AS1	-3.53	0.000449	0.0472	-0.18	-0.16	Schizophrenia;	chr11:125428402	chr11:125570284~125592568:-
LUAD	cis	rs10129255	0.5	rs2027903	ENSG00000211955.2	IGHV3-33	-3.53	0.000449	0.0472	-0.11	-0.16	Kawasaki disease;	chr14:106807047	chr14:106359793~106360324:-
LUAD	cis	rs10129255	0.518	rs28378320	ENSG00000211955.2	IGHV3-33	-3.53	0.000449	0.0472	-0.11	-0.16	Kawasaki disease;	chr14:106808609	chr14:106359793~106360324:-
LUAD	cis	rs3764021	0.743	rs7973535	ENSG00000214776.8	RP11-726G1.1	3.53	0.000449	0.0472	0.18	0.16	Type 1 diabetes;	chr12:9727801	chr12:9467552~9576275:+
LUAD	cis	rs3764021	0.87	rs7973638	ENSG00000214776.8	RP11-726G1.1	3.53	0.000449	0.0472	0.18	0.16	Type 1 diabetes;	chr12:9727845	chr12:9467552~9576275:+
LUAD	cis	rs4268898	0.931	rs2551121	ENSG00000223754.1	AC008073.9	3.53	0.000449	0.0472	0.2	0.16	Asthma;	chr2:24317098	chr2:24199839~24201698:-
LUAD	cis	rs7870753	0.783	rs1885427	ENSG00000188801.9	ZNF322P1	3.53	0.000449	0.0472	0.22	0.16	Height;	chr9:96425966	chr9:97198303~97199511:-
LUAD	cis	rs131777	0.708	rs131749	ENSG00000272666.1	CTA-384D8.35	-3.53	0.000449	0.0472	-0.19	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586195	chr22:50542305~50542906:-
LUAD	cis	rs5742933	1	rs4666783	ENSG00000253559.1	OSGEPL1-AS1	-3.53	0.000449	0.0472	-0.2	-0.16	Ferritin levels;	chr2:189748254	chr2:189762704~189765556:+
LUAD	cis	rs4267450	0.793	rs73021318	ENSG00000267323.1	SLC25A1P5	3.53	0.000449	0.0472	0.29	0.16	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);	chr19:28357972	chr19:27805423~27806205:-
LUAD	cis	rs4268898	1	rs4268898	ENSG00000223754.1	AC008073.9	-3.53	0.000449	0.0472	-0.2	-0.16	Asthma;	chr2:24267544	chr2:24199839~24201698:-
LUAD	cis	rs3824488	0.765	rs10512247	ENSG00000237857.2	RP11-435O5.2	-3.53	0.000449	0.0472	-0.25	-0.16	Neuroticism;	chr9:95534121	chr9:95414834~95426796:-
LUAD	cis	rs7202877	0.656	rs4887812	ENSG00000280152.1	RP11-331F4.5	3.53	0.000449	0.0472	0.19	0.16	Type 1 diabetes;Type 2 diabetes;	chr16:75276154	chr16:75245994~75250077:-
LUAD	cis	rs11206226	1	rs1181186	ENSG00000235563.1	RP11-334A14.8	3.53	0.000449	0.0472	0.37	0.16	Nonalcoholic fatty liver disease;	chr1:53826353	chr1:53114576~53118609:+
LUAD	cis	rs73230612	0.676	rs1599119	ENSG00000242767.1	ZBTB20-AS4	-3.53	0.000449	0.0472	-0.22	-0.16	Type 2 diabetes;	chr3:115354824	chr3:115100423~115103061:+
LUAD	cis	rs73230612	0.676	rs6438243	ENSG00000242767.1	ZBTB20-AS4	-3.53	0.000449	0.0472	-0.22	-0.16	Type 2 diabetes;	chr3:115356576	chr3:115100423~115103061:+
LUAD	cis	rs73230612	0.629	rs7613779	ENSG00000242767.1	ZBTB20-AS4	-3.53	0.000449	0.0472	-0.22	-0.16	Type 2 diabetes;	chr3:115357784	chr3:115100423~115103061:+
LUAD	cis	rs73230612	0.629	rs9839774	ENSG00000242767.1	ZBTB20-AS4	-3.53	0.000449	0.0472	-0.22	-0.16	Type 2 diabetes;	chr3:115363223	chr3:115100423~115103061:+
LUAD	cis	rs9475752	0.552	rs13190784	ENSG00000231441.1	RP11-472M19.2	3.53	0.000449	0.0472	0.22	0.16	Menarche (age at onset);	chr6:56868254	chr6:56844002~56864078:+
LUAD	cis	rs8056893	0.775	rs6499172	ENSG00000274698.1	RP11-71L14.4	3.53	0.000449	0.0472	0.18	0.16	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68342667	chr16:68450283~68452318:+
LUAD	cis	rs910316	0.763	rs13712	ENSG00000279594.1	RP11-950C14.10	3.53	0.000449	0.0472	0.18	0.16	Height;	chr14:75017109	chr14:75011269~75012851:-
LUAD	cis	rs7017914	0.905	rs4738105	ENSG00000246366.5	RP11-382J12.1	-3.53	0.000449	0.0472	-0.15	-0.16	Bone mineral density;	chr8:71046683	chr8:70608577~70663279:+
LUAD	cis	rs9860428	0.526	rs9834353	ENSG00000242770.2	RP11-180K7.1	3.53	0.000449	0.0472	0.17	0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112942339	chr3:112802478~112812819:+
LUAD	cis	rs6964587	1	rs3753107	ENSG00000188693.7	CYP51A1-AS1	3.53	0.000449	0.0472	0.18	0.16	Breast cancer;	chr7:91999837	chr7:92134604~92180725:+
LUAD	cis	rs2548724	1	rs2600830	ENSG00000250682.4	LINC00491	-3.53	0.000449	0.0472	-0.22	-0.16	Type 2 diabetes;	chr5:102270466	chr5:102609156~102671559:-
LUAD	cis	rs4927850	1	rs7627868	ENSG00000278820.1	AC024937.1	3.53	0.000449	0.0472	0.14	0.16	Pancreatic cancer;	chr3:196026602	chr3:195960500~195960612:-
LUAD	cis	rs10254284	0.959	rs10275989	ENSG00000234336.5	JAZF1-AS1	-3.53	0.000449	0.0472	-0.19	-0.16	Systemic lupus erythematosus;Lymphocyte percentage of white cells;	chr7:28120077	chr7:28180322~28243917:+
LUAD	cis	rs61160187	0.582	rs4700402	ENSG00000215032.2	GNL3LP1	3.53	0.000449	0.0472	0.19	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60966220	chr5:60891935~60893577:-
LUAD	cis	rs970797	0.522	rs818356	ENSG00000237260.1	AC073069.2	-3.53	0.000449	0.0472	-0.19	-0.16	Monobrow;Lobe attachment (rater-scored or self-reported);	chr2:176341108	chr2:176338637~176339077:+
LUAD	cis	rs4865762	0.512	rs6860071	ENSG00000247796.2	CTD-2366F13.1	3.53	0.000449	0.0472	0.18	0.16	Intraocular pressure;	chr5:53214819	chr5:53109842~53115126:+
LUAD	cis	rs2885805	0.794	rs6685538	ENSG00000261654.1	RP11-96K19.4	3.53	0.000449	0.0473	0.23	0.16	Cytomegalovirus antibody response;	chr1:110851000	chr1:110936369~110942353:-
LUAD	cis	rs9475752	0.552	rs13209099	ENSG00000231441.1	RP11-472M19.2	3.53	0.000449	0.0473	0.25	0.16	Menarche (age at onset);	chr6:56869254	chr6:56844002~56864078:+
LUAD	cis	rs9475752	0.552	rs71564864	ENSG00000231441.1	RP11-472M19.2	3.53	0.000449	0.0473	0.25	0.16	Menarche (age at onset);	chr6:56869596	chr6:56844002~56864078:+
LUAD	cis	rs9475752	0.552	rs13216793	ENSG00000231441.1	RP11-472M19.2	3.53	0.000449	0.0473	0.25	0.16	Menarche (age at onset);	chr6:56874589	chr6:56844002~56864078:+
LUAD	cis	rs2702164	1	rs1147683	ENSG00000240661.1	RP11-174O3.3	-3.53	0.000449	0.0473	-0.19	-0.16	Gut microbiome composition (winter);	chr3:120365007	chr3:120349510~120367998:+
LUAD	cis	rs2702164	1	rs950650	ENSG00000240661.1	RP11-174O3.3	-3.53	0.000449	0.0473	-0.19	-0.16	Gut microbiome composition (winter);	chr3:120365320	chr3:120349510~120367998:+
LUAD	cis	rs2702164	0.962	rs1716846	ENSG00000240661.1	RP11-174O3.3	-3.53	0.000449	0.0473	-0.19	-0.16	Gut microbiome composition (winter);	chr3:120367520	chr3:120349510~120367998:+
LUAD	cis	rs2702164	1	rs1147691	ENSG00000240661.1	RP11-174O3.3	-3.53	0.000449	0.0473	-0.19	-0.16	Gut microbiome composition (winter);	chr3:120368490	chr3:120349510~120367998:+
LUAD	cis	rs2702164	1	rs1147692	ENSG00000240661.1	RP11-174O3.3	-3.53	0.000449	0.0473	-0.19	-0.16	Gut microbiome composition (winter);	chr3:120368855	chr3:120349510~120367998:+
LUAD	cis	rs13113518	1	rs13115828	ENSG00000223305.1	RN7SKP30	3.53	0.000449	0.0473	0.18	0.16	Height;	chr4:55551447	chr4:55540502~55540835:-
LUAD	cis	rs548181	0.736	rs1941558	ENSG00000254671.2	STT3A-AS1	-3.53	0.00045	0.0473	-0.27	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr11:125555710	chr11:125570284~125592568:-
LUAD	cis	rs14027	0.512	rs7012791	ENSG00000279347.1	RP11-85I17.2	3.53	0.00045	0.0473	0.13	0.16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119707451	chr8:119838736~119840385:-
LUAD	cis	rs7772486	0.875	rs2748498	ENSG00000235652.6	RP11-545I5.3	3.53	0.00045	0.0473	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145998030	chr6:145799409~145886585:+
LUAD	cis	rs4934494	0.677	rs11185810	ENSG00000232936.4	RP11-80H5.2	3.53	0.00045	0.0473	0.22	0.16	Red blood cell count;	chr10:89621724	chr10:89645282~89650667:+
LUAD	cis	rs7121538	0.756	rs61884006	ENSG00000254418.1	RP11-21L19.1	3.53	0.00045	0.0473	0.24	0.16	HDL cholesterol;	chr11:14385566	chr11:14262846~14273691:-
LUAD	cis	rs2147959	0.714	rs6659690	ENSG00000269934.1	RP5-1139B12.3	-3.53	0.00045	0.0473	-0.21	-0.16	Adult asthma;	chr1:228440469	chr1:228274584~228276066:-
LUAD	cis	rs3849150	0.95	rs2889698	ENSG00000235939.1	RP11-123B3.2	-3.53	0.00045	0.0473	-0.23	-0.16	Subclinical atherosclerosis traits (other);	chr10:48880239	chr10:49419277~49472903:+
LUAD	cis	rs3741404	0.825	rs11603384	ENSG00000256789.1	RP11-697H9.2	-3.53	0.00045	0.0473	-0.18	-0.16	Platelet count;	chr11:64181623	chr11:63637677~63658962:+
LUAD	cis	rs10483853	0.65	rs17126871	ENSG00000258695.2	RP3-414A15.2	-3.53	0.00045	0.0473	-0.2	-0.16	Coronary artery calcification;	chr14:73324614	chr14:73522878~73530610:+
LUAD	cis	rs4819052	0.851	rs4819040	ENSG00000215447.6	BX322557.10	-3.53	0.00045	0.0473	-0.19	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239847	chr21:45288052~45291738:+
LUAD	cis	rs13113518	1	rs4865013	ENSG00000249700.7	SRD5A3-AS1	3.53	0.00045	0.0473	0.16	0.16	Height;	chr4:55559957	chr4:55363971~55395847:-
LUAD	cis	rs2688608	0.933	rs2688614	ENSG00000271816.1	BMS1P4	3.53	0.00045	0.0473	0.13	0.16	Inflammatory bowel disease;	chr10:73893118	chr10:73699151~73730487:-
LUAD	cis	rs9549260	0.755	rs4325426	ENSG00000229456.1	RLIMP1	3.53	0.00045	0.0473	0.17	0.16	Red blood cell count;	chr13:40642300	chr13:40618738~40621348:+
LUAD	cis	rs13113518	1	rs13122619	ENSG00000223305.1	RN7SKP30	3.53	0.00045	0.0473	0.18	0.16	Height;	chr4:55479339	chr4:55540502~55540835:-
LUAD	cis	rs7178909	0.902	rs3784386	ENSG00000259677.1	RP11-493E3.1	3.53	0.00045	0.0473	0.17	0.16	Common traits (Other);	chr15:89894194	chr15:89876540~89877285:+
LUAD	cis	rs6671200	1	rs34396223	ENSG00000228852.5	RP11-57H12.5	3.53	0.00045	0.0473	0.26	0.16	Stearic acid (18:0) levels;	chr1:95232272	chr1:95243167~95278940:-
LUAD	cis	rs6671200	1	rs62625008	ENSG00000228852.5	RP11-57H12.5	3.53	0.00045	0.0473	0.26	0.16	Stearic acid (18:0) levels;	chr1:95237026	chr1:95243167~95278940:-
LUAD	cis	rs6671200	0.92	rs35403759	ENSG00000228852.5	RP11-57H12.5	3.53	0.00045	0.0473	0.26	0.16	Stearic acid (18:0) levels;	chr1:95237334	chr1:95243167~95278940:-
LUAD	cis	rs801193	0.569	rs7782587	ENSG00000106610.13	STAG3L4	-3.53	0.00045	0.0473	-0.2	-0.16	Aortic root size;	chr7:66701485	chr7:67302621~67321526:+
LUAD	cis	rs801193	0.569	rs4717315	ENSG00000106610.13	STAG3L4	-3.53	0.00045	0.0473	-0.2	-0.16	Aortic root size;	chr7:66713338	chr7:67302621~67321526:+
LUAD	cis	rs801193	0.527	rs2707837	ENSG00000106610.13	STAG3L4	-3.53	0.00045	0.0473	-0.2	-0.16	Aortic root size;	chr7:66716086	chr7:67302621~67321526:+
LUAD	cis	rs62458065	0.85	rs7785999	ENSG00000226468.2	AC018641.7	3.53	0.00045	0.0473	0.25	0.16	Metabolite levels (HVA/MHPG ratio);	chr7:32421650	chr7:32456963~32457758:-
LUAD	cis	rs11577318	0.579	rs11548246	ENSG00000238084.4	RP3-469D22.1	-3.53	0.00045	0.0473	-0.19	-0.16	Granulocyte percentage of myeloid white cells;	chr1:26370675	chr1:25398721~25399198:+
LUAD	cis	rs8062405	0.931	rs12928404	ENSG00000261766.1	RP11-22P6.2	-3.53	0.00045	0.0473	-0.14	-0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835925	chr16:28862166~28863340:-
LUAD	cis	rs6494488	0.5	rs72741325	ENSG00000259635.1	AC100830.3	-3.53	0.00045	0.0473	-0.37	-0.16	Coronary artery disease;	chr15:64438185	chr15:64701248~64719602:+
LUAD	cis	rs6494488	0.5	rs72741327	ENSG00000259635.1	AC100830.3	-3.53	0.00045	0.0473	-0.37	-0.16	Coronary artery disease;	chr15:64438623	chr15:64701248~64719602:+
LUAD	cis	rs4792901	0.959	rs55955027	ENSG00000198496.9	NBR2	3.53	0.00045	0.0473	0.18	0.16	Dupuytren's disease;	chr17:43543788	chr17:43125610~43153671:+
LUAD	cis	rs17122278	1	rs11216911	ENSG00000243431.1	RPL5P30	-3.53	0.00045	0.0473	-0.18	-0.16	Total cholesterol levels;	chr11:118581186	chr11:118560690~118561580:+
LUAD	cis	rs12122100	0.862	rs6689542	ENSG00000227242.3	NBPF13P	-3.53	0.00045	0.0473	-0.2	-0.16	HIV-1 control;	chr1:147035327	chr1:147021320~147124525:-
LUAD	cis	rs6819013	0.587	rs35499833	ENSG00000249234.1	RP11-452J21.2	3.53	0.000451	0.0473	0.18	0.16	QT interval;	chr4:16912517	chr4:16178939~16183120:+
LUAD	cis	rs12935418	0.616	rs13332902	ENSG00000278985.1	RP11-303E16.9	3.53	0.000451	0.0473	0.15	0.16	Mean corpuscular volume;	chr16:80971903	chr16:80982319~80984094:-
LUAD	cis	rs2439831	0.557	rs13329084	ENSG00000249839.1	AC011330.5	3.53	0.000451	0.0473	0.36	0.16	Lung cancer in ever smokers;	chr15:43858865	chr15:43663654~43684339:-
LUAD	cis	rs2440129	0.611	rs11571335	ENSG00000262089.1	RP11-589P10.5	3.53	0.000451	0.0474	0.16	0.16	Tonsillectomy;	chr17:7000944	chr17:6994642~6995189:-
LUAD	cis	rs6088590	1	rs6120708	ENSG00000275784.1	RP5-1125A11.6	-3.53	0.000451	0.0474	-0.17	-0.16	Coronary artery disease;	chr20:34747722	chr20:33989480~33991818:-
LUAD	cis	rs4819052	0.851	rs4819046	ENSG00000215447.6	BX322557.10	-3.53	0.000451	0.0474	-0.19	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245040	chr21:45288052~45291738:+
LUAD	cis	rs10017238	0.592	rs17074048	ENSG00000177822.6	AC108142.1	3.53	0.000451	0.0474	0.25	0.16	Response to amphetamines;	chr4:182768659	chr4:181874438~182145249:-
LUAD	cis	rs11976180	1	rs1919950	ENSG00000228960.5	OR2A9P	-3.53	0.000451	0.0474	-0.21	-0.16	Obesity-related traits;	chr7:144070805	chr7:144294480~144300934:+
LUAD	cis	rs916888	0.773	rs199445	ENSG00000260075.1	NSFP1	-3.53	0.000451	0.0474	-0.27	-0.16	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46372855~46487141:+
LUAD	cis	rs916888	0.773	rs199443	ENSG00000260075.1	NSFP1	-3.53	0.000451	0.0474	-0.27	-0.16	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46372855~46487141:+
LUAD	cis	rs17711722	0.523	rs365896	ENSG00000273024.4	INTS4P2	3.53	0.000451	0.0474	0.17	0.16	Calcium levels;	chr7:66045710	chr7:65647864~65715661:+
LUAD	cis	rs9457247	1	rs413232	ENSG00000227598.1	RP1-167A14.2	-3.53	0.000451	0.0474	-0.17	-0.16	Crohn's disease;	chr6:166987484	chr6:166969626~166999065:-
LUAD	cis	rs9457247	0.967	rs86755	ENSG00000227598.1	RP1-167A14.2	-3.53	0.000451	0.0474	-0.17	-0.16	Crohn's disease;	chr6:166989620	chr6:166969626~166999065:-
LUAD	cis	rs9457247	0.967	rs382009	ENSG00000227598.1	RP1-167A14.2	-3.53	0.000451	0.0474	-0.17	-0.16	Crohn's disease;	chr6:166989633	chr6:166969626~166999065:-
LUAD	cis	rs9457247	0.967	rs428805	ENSG00000227598.1	RP1-167A14.2	-3.53	0.000451	0.0474	-0.17	-0.16	Crohn's disease;	chr6:166989644	chr6:166969626~166999065:-
LUAD	cis	rs9457247	0.934	rs2345571	ENSG00000227598.1	RP1-167A14.2	-3.53	0.000451	0.0474	-0.17	-0.16	Crohn's disease;	chr6:166989912	chr6:166969626~166999065:-
LUAD	cis	rs2638953	0.924	rs7980441	ENSG00000278733.1	RP11-425D17.1	-3.53	0.000451	0.0474	-0.2	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28214748	chr12:28185625~28186190:-
LUAD	cis	rs2281603	0.762	rs10150987	ENSG00000259116.1	RP11-973N13.4	-3.53	0.000451	0.0474	-0.15	-0.16	Lymphocyte counts;	chr14:64571472	chr14:64514154~64540368:-
LUAD	cis	rs216345	0.67	rs307703	ENSG00000200834.1	Y_RNA	-3.53	0.000451	0.0474	-0.16	-0.16	Bipolar disorder;	chr9:33985467	chr9:33830978~33831078:+
LUAD	cis	rs9311474	0.607	rs34005367	ENSG00000243224.1	RP5-1157M23.2	-3.53	0.000451	0.0474	-0.16	-0.16	Electroencephalogram traits;	chr3:52524888	chr3:52239258~52241097:+
LUAD	cis	rs6840360	0.718	rs2136960	ENSG00000270265.1	RP11-731D1.4	3.53	0.000451	0.0474	0.16	0.16	Intelligence (multi-trait analysis);	chr4:151825037	chr4:151333775~151353224:-
LUAD	cis	rs8114671	0.74	rs3761141	ENSG00000277558.1	RP3-468O1.6	3.53	0.000451	0.0474	0.18	0.16	Height;	chr20:35150021	chr20:34476205~34476787:+
LUAD	cis	rs7246657	0.525	rs10410594	ENSG00000267309.1	CTD-2630F21.1	3.53	0.000451	0.0474	0.26	0.16	Coronary artery calcification;	chr19:36986856	chr19:36489649~36491040:+
LUAD	cis	rs9309473	1	rs10207220	ENSG00000230002.2	ALMS1-IT1	3.53	0.000451	0.0474	0.2	0.16	Metabolite levels;	chr2:73557919	chr2:73456764~73459484:+
LUAD	cis	rs2179367	0.568	rs6932778	ENSG00000216906.2	RP11-350J20.9	3.53	0.000451	0.0474	0.24	0.16	Dupuytren's disease;	chr6:149328293	chr6:149904243~149906418:+
LUAD	cis	rs755249	0.958	rs61781370	ENSG00000237624.1	OXCT2P1	3.53	0.000451	0.0474	0.24	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39579628	chr1:39514956~39516490:+
LUAD	cis	rs9900280	0.967	rs2559627	ENSG00000264808.1	RP11-802D6.1	-3.53	0.000451	0.0474	-0.19	-0.16	Mean platelet volume;	chr17:29514676	chr17:29369717~29390777:-
LUAD	cis	rs3892630	0.818	rs80137870	ENSG00000267475.1	CTD-2538C1.2	-3.53	0.000451	0.0474	-0.26	-0.16	Red blood cell traits;	chr19:32691844	chr19:32687089~32691750:-
LUAD	cis	rs3892630	0.757	rs8109823	ENSG00000267475.1	CTD-2538C1.2	-3.53	0.000451	0.0474	-0.26	-0.16	Red blood cell traits;	chr19:32692410	chr19:32687089~32691750:-
LUAD	cis	rs2235573	0.527	rs139865	ENSG00000235237.1	RP1-151B14.6	-3.53	0.000451	0.0474	-0.16	-0.16	Glioma;Glioblastoma;	chr22:37957925	chr22:37166757~37182850:+
LUAD	cis	rs13113518	1	rs3762837	ENSG00000273257.1	RP11-177J6.1	3.53	0.000451	0.0474	0.17	0.16	Height;	chr4:55511198	chr4:55387949~55388271:+
LUAD	cis	rs78572108	0.858	rs76755639	ENSG00000214691.7	AC104654.1	3.53	0.000452	0.0474	0.27	0.16	Total body bone mineral density;	chr2:42025130	chr2:41877074~41894046:+
LUAD	cis	rs78572108	0.858	rs4952566	ENSG00000214691.7	AC104654.1	3.53	0.000452	0.0474	0.27	0.16	Total body bone mineral density;	chr2:42026318	chr2:41877074~41894046:+
LUAD	cis	rs17689437	1	rs11864995	ENSG00000260084.1	RP11-615I2.1	-3.53	0.000452	0.0474	-0.26	-0.16	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);	chr16:68571320	chr16:68573782~68589512:-
LUAD	cis	rs7829975	0.514	rs2920983	ENSG00000233609.3	RP11-62H7.2	3.53	0.000452	0.0474	0.13	0.16	Mood instability;	chr8:8410553	chr8:8961200~8979025:+
LUAD	cis	rs7005380	0.531	rs4871011	ENSG00000279347.1	RP11-85I17.2	-3.53	0.000452	0.0475	-0.16	-0.16	Interstitial lung disease;	chr8:119895531	chr8:119838736~119840385:-
LUAD	cis	rs7200786	0.508	rs27908	ENSG00000274038.1	RP11-66H6.4	-3.53	0.000452	0.0475	-0.2	-0.16	Systemic lupus erythematosus;Multiple sclerosis;	chr16:11163244	chr16:11056556~11057034:+
LUAD	cis	rs7615952	0.599	rs7652883	ENSG00000250012.1	RP11-124N2.1	-3.53	0.000452	0.0475	-0.22	-0.16	Blood pressure (smoking interaction);	chr3:125989134	chr3:126084220~126095349:+
LUAD	cis	rs6502050	0.835	rs34673303	ENSG00000266654.1	RP11-1376P16.1	3.53	0.000452	0.0475	0.17	0.16	Life satisfaction;	chr17:82127268	chr17:82160056~82160452:+
LUAD	cis	rs6502050	0.805	rs62078303	ENSG00000266654.1	RP11-1376P16.1	3.53	0.000452	0.0475	0.17	0.16	Life satisfaction;	chr17:82127334	chr17:82160056~82160452:+
LUAD	cis	rs6502050	0.835	rs7213172	ENSG00000266654.1	RP11-1376P16.1	3.53	0.000452	0.0475	0.17	0.16	Life satisfaction;	chr17:82127827	chr17:82160056~82160452:+
LUAD	cis	rs6502050	0.805	rs11077970	ENSG00000266654.1	RP11-1376P16.1	3.53	0.000452	0.0475	0.17	0.16	Life satisfaction;	chr17:82128040	chr17:82160056~82160452:+
LUAD	cis	rs6502050	0.777	rs7406162	ENSG00000266654.1	RP11-1376P16.1	3.53	0.000452	0.0475	0.17	0.16	Life satisfaction;	chr17:82128510	chr17:82160056~82160452:+
LUAD	cis	rs6502050	0.777	rs4625783	ENSG00000266654.1	RP11-1376P16.1	3.53	0.000452	0.0475	0.17	0.16	Life satisfaction;	chr17:82128519	chr17:82160056~82160452:+
LUAD	cis	rs710913	0.646	rs2695325	ENSG00000237624.1	OXCT2P1	3.53	0.000452	0.0475	0.2	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39607957	chr1:39514956~39516490:+
LUAD	cis	rs12962334	0.508	rs9966036	ENSG00000266850.1	RP11-370A5.1	3.53	0.000452	0.0475	0.2	0.16	Breast cancer;	chr18:22936105	chr18:22723491~22907721:-
LUAD	cis	rs8056893	0.686	rs3826167	ENSG00000260441.4	RP11-96D1.7	-3.53	0.000452	0.0475	-0.19	-0.16	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68363627	chr16:68256162~68260443:-
LUAD	cis	rs647161	0.616	rs12054661	ENSG00000247627.2	MTND4P12	-3.53	0.000452	0.0475	-0.19	-0.16	Colorectal cancer;	chr5:135157157	chr5:134926660~134928036:-
LUAD	cis	rs13113518	1	rs55699500	ENSG00000223305.1	RN7SKP30	3.53	0.000452	0.0475	0.18	0.16	Height;	chr4:55540912	chr4:55540502~55540835:-
LUAD	cis	rs13113518	1	rs56362210	ENSG00000223305.1	RN7SKP30	3.53	0.000452	0.0475	0.18	0.16	Height;	chr4:55540972	chr4:55540502~55540835:-
LUAD	cis	rs4676049	1	rs17034806	ENSG00000235721.1	AC013268.3	-3.53	0.000452	0.0475	-0.26	-0.16	Alzheimer's disease (late onset);	chr2:109019449	chr2:110007675~110010783:+
LUAD	cis	rs7692995	1	rs7694806	ENSG00000235413.3	KRT18P63	3.53	0.000452	0.0475	0.25	0.16	Height;	chr4:18027477	chr4:17911674~17912976:+
LUAD	cis	rs7712401	0.755	rs1545696	ENSG00000249996.1	RP11-359P5.1	3.53	0.000452	0.0475	0.19	0.16	Mean platelet volume;	chr5:122766747	chr5:123036271~123054667:+
LUAD	cis	rs9309473	0.948	rs13392691	ENSG00000230002.2	ALMS1-IT1	3.53	0.000452	0.0475	0.2	0.16	Metabolite levels;	chr2:73521853	chr2:73456764~73459484:+
LUAD	cis	rs838147	0.563	rs281379	ENSG00000232871.7	SEC1P	3.53	0.000452	0.0475	0.18	0.16	Dietary macronutrient intake;	chr19:48711017	chr19:48638071~48682245:+
LUAD	cis	rs2288884	0.636	rs8101936	ENSG00000269959.1	SPACA6P-AS	-3.53	0.000452	0.0475	-0.17	-0.16	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52073226	chr19:51685363~51693456:-
LUAD	cis	rs2288884	0.636	rs8105801	ENSG00000269959.1	SPACA6P-AS	-3.53	0.000452	0.0475	-0.17	-0.16	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52074095	chr19:51685363~51693456:-
LUAD	cis	rs67478160	0.679	rs7156834	ENSG00000272533.1	SNORA28	3.53	0.000452	0.0475	0.16	0.16	Schizophrenia;	chr14:103744843	chr14:103337849~103337974:+
LUAD	cis	rs1799949	1	rs915945	ENSG00000267340.1	RP11-242D8.3	3.53	0.000452	0.0475	0.17	0.16	Menopause (age at onset);	chr17:43027847	chr17:43169880~43170077:-
LUAD	cis	rs1799949	1	rs12942277	ENSG00000267340.1	RP11-242D8.3	3.53	0.000452	0.0475	0.17	0.16	Menopause (age at onset);	chr17:43035957	chr17:43169880~43170077:-
LUAD	cis	rs1799949	0.965	rs34616041	ENSG00000267340.1	RP11-242D8.3	3.53	0.000452	0.0475	0.17	0.16	Menopause (age at onset);	chr17:43036769	chr17:43169880~43170077:-
LUAD	cis	rs2836974	0.644	rs7281853	ENSG00000232608.1	TIMM9P2	3.53	0.000452	0.0475	0.19	0.16	Cognitive function;	chr21:39321564	chr21:39216624~39217506:+
LUAD	cis	rs4218	0.543	rs4775110	ENSG00000277144.1	RP11-59H7.4	-3.53	0.000452	0.0475	-0.18	-0.16	Social communication problems;	chr15:59023685	chr15:59115547~59116089:-
LUAD	cis	rs2354432	0.607	rs66486822	ENSG00000237188.3	RP11-337C18.8	3.53	0.000452	0.0475	0.28	0.16	Mitochondrial DNA levels;	chr1:147330922	chr1:147172771~147211568:+
LUAD	cis	rs2354432	0.607	rs72692962	ENSG00000237188.3	RP11-337C18.8	3.53	0.000452	0.0475	0.28	0.16	Mitochondrial DNA levels;	chr1:147330943	chr1:147172771~147211568:+
LUAD	cis	rs2354432	0.607	rs6677679	ENSG00000237188.3	RP11-337C18.8	3.53	0.000452	0.0475	0.28	0.16	Mitochondrial DNA levels;	chr1:147331900	chr1:147172771~147211568:+
LUAD	cis	rs412050	0.594	rs113463481	ENSG00000224086.5	LL22NC03-86G7.1	-3.53	0.000452	0.0475	-0.2	-0.16	Attention deficit hyperactivity disorder;	chr22:21742941	chr22:21938293~21977632:+
LUAD	cis	rs7604827	0.722	rs6736717	ENSG00000230076.1	AC016708.2	3.53	0.000452	0.0475	0.23	0.16	PR interval;	chr2:214412629	chr2:214847128~214847445:+
LUAD	cis	rs6688537	0.508	rs12093821	ENSG00000228818.1	RP11-567G24.1	-3.53	0.000452	0.0475	-0.15	-0.16	Lung function (FEV1/FVC);	chr1:239660948	chr1:240142670~240145389:-
LUAD	cis	rs13113518	1	rs7662966	ENSG00000249700.7	SRD5A3-AS1	3.53	0.000452	0.0475	0.16	0.16	Height;	chr4:55548261	chr4:55363971~55395847:-
LUAD	cis	rs1790761	0.505	rs34802338	ENSG00000184224.3	C11orf72	-3.53	0.000452	0.0475	-0.18	-0.16	Mean corpuscular volume;	chr11:67544995	chr11:67602880~67606706:-
LUAD	cis	rs1348850	0.958	rs12471741	ENSG00000213963.5	AC074286.1	3.53	0.000453	0.0475	0.19	0.16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177583468	chr2:177283508~177392691:-
LUAD	cis	rs1348850	0.918	rs12463893	ENSG00000213963.5	AC074286.1	3.53	0.000453	0.0475	0.19	0.16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr2:177583831	chr2:177283508~177392691:-
LUAD	cis	rs13217239	0.511	rs4546474	ENSG00000219392.1	RP1-265C24.5	3.53	0.000453	0.0475	0.2	0.16	Schizophrenia;	chr6:27256854	chr6:28115628~28116551:+
LUAD	cis	rs763121	0.925	rs5757165	ENSG00000225450.1	RP3-508I15.14	-3.53	0.000453	0.0475	-0.15	-0.16	Menopause (age at onset);	chr22:38598572	chr22:38739003~38749041:+
LUAD	cis	rs7615952	0.546	rs4428131	ENSG00000243429.1	OR7E29P	3.53	0.000453	0.0475	0.22	0.16	Blood pressure (smoking interaction);	chr3:125627635	chr3:125712139~125713045:+
LUAD	cis	rs2738459	0.5	rs2738465	ENSG00000267174.4	CTC-510F12.4	3.53	0.000453	0.0475	0.22	0.16	LDL cholesterol;	chr19:11131820	chr19:11300777~11324441:-
LUAD	cis	rs1823913	0.614	rs4853576	ENSG00000230611.1	HMGB1P27	3.53	0.000453	0.0475	0.18	0.16	Obesity-related traits;	chr2:191296618	chr2:191174233~191174835:+
LUAD	cis	rs1065852	0.526	rs9611700	ENSG00000226450.2	CYP2D8P	3.53	0.000453	0.0475	0.13	0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42005510	chr22:42149886~42155001:-
LUAD	cis	rs1065852	0.526	rs2413663	ENSG00000226450.2	CYP2D8P	3.53	0.000453	0.0475	0.13	0.16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);	chr22:42006395	chr22:42149886~42155001:-
LUAD	cis	rs773506	0.565	rs4354431	ENSG00000237422.1	RP11-305L7.3	3.53	0.000453	0.0475	0.21	0.16	Type 2 diabetes nephropathy;	chr9:91347124	chr9:91119138~91163087:-
LUAD	cis	rs2274273	0.934	rs10139337	ENSG00000258413.1	RP11-665C16.6	-3.53	0.000453	0.0475	-0.21	-0.16	Protein biomarker;	chr14:55275395	chr14:55262767~55272075:-
LUAD	cis	rs9494145	0.526	rs7751525	ENSG00000232876.1	CTA-212D2.2	-3.53	0.000453	0.0475	-0.22	-0.16	Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count;	chr6:135142570	chr6:135055033~135060550:+
LUAD	cis	rs9543976	1	rs4885324	ENSG00000261105.4	LMO7-AS1	3.53	0.000453	0.0475	0.26	0.16	Diabetic retinopathy;	chr13:75599611	chr13:75604700~75635994:-
LUAD	cis	rs9815354	0.812	rs17284472	ENSG00000273328.4	RP11-141M3.6	3.53	0.000453	0.0475	0.26	0.16	Pulse pressure;Diastolic blood pressure;	chr3:41954812	chr3:42809414~42908105:+
LUAD	cis	rs9926296	0.533	rs9938865	ENSG00000260259.1	RP11-368I7.4	-3.53	0.000453	0.0475	-0.15	-0.16	Vitiligo;	chr16:89801389	chr16:89682620~89686569:-
LUAD	cis	rs12216545	0.711	rs9632622	ENSG00000241134.3	BET1P1	-3.53	0.000453	0.0475	-0.17	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150536131	chr7:150749736~150750094:+
LUAD	cis	rs1823913	0.637	rs4853465	ENSG00000230611.1	HMGB1P27	3.53	0.000453	0.0475	0.18	0.16	Obesity-related traits;	chr2:191294768	chr2:191174233~191174835:+
LUAD	cis	rs1823913	0.637	rs4853573	ENSG00000230611.1	HMGB1P27	3.53	0.000453	0.0475	0.18	0.16	Obesity-related traits;	chr2:191295866	chr2:191174233~191174835:+
LUAD	cis	rs1823913	0.614	rs4853466	ENSG00000230611.1	HMGB1P27	3.53	0.000453	0.0475	0.18	0.16	Obesity-related traits;	chr2:191295943	chr2:191174233~191174835:+
LUAD	cis	rs1823913	0.637	rs4853574	ENSG00000230611.1	HMGB1P27	3.53	0.000453	0.0475	0.18	0.16	Obesity-related traits;	chr2:191296113	chr2:191174233~191174835:+
LUAD	cis	rs9291683	0.609	rs13149985	ENSG00000250413.1	RP11-448G15.1	-3.53	0.000453	0.0475	-0.2	-0.16	Bone mineral density;	chr4:10026766	chr4:10006482~10009725:+
LUAD	cis	rs7017914	0.935	rs6472551	ENSG00000246366.5	RP11-382J12.1	3.53	0.000453	0.0475	0.15	0.16	Bone mineral density;	chr8:70869614	chr8:70608577~70663279:+
LUAD	cis	rs4980785	0.788	rs7102236	ENSG00000212093.1	AP000807.1	-3.53	0.000453	0.0475	-0.16	-0.16	Renal cell carcinoma;	chr11:69415653	chr11:68506083~68506166:-
LUAD	cis	rs9457247	0.967	rs443570	ENSG00000227598.1	RP1-167A14.2	-3.53	0.000453	0.0475	-0.17	-0.16	Crohn's disease;	chr6:166976437	chr6:166969626~166999065:-
LUAD	cis	rs2236178	0.579	rs6035868	ENSG00000227063.5	RPL41P1	-3.53	0.000453	0.0475	-0.2	-0.16	Lupus nephritis in systemic lupus erythematosus;	chr20:21395188	chr20:21755270~21755350:+
LUAD	cis	rs4835473	0.932	rs13135034	ENSG00000249741.2	RP11-673E1.3	-3.53	0.000453	0.0476	-0.19	-0.16	Immature fraction of reticulocytes;	chr4:143738247	chr4:143911514~143912053:-
LUAD	cis	rs2933343	0.729	rs6767104	ENSG00000231305.3	RP11-723O4.2	-3.53	0.000453	0.0476	-0.17	-0.16	IgG glycosylation;	chr3:128929274	chr3:128861313~128871540:-
LUAD	cis	rs11216126	0.556	rs1893460	ENSG00000280143.1	AP000892.6	-3.53	0.000453	0.0476	-0.24	-0.16	HDL cholesterol;	chr11:116732961	chr11:117204967~117210292:+
LUAD	cis	rs2281603	0.57	rs1966865	ENSG00000259116.1	RP11-973N13.4	-3.53	0.000453	0.0476	-0.14	-0.16	Lymphocyte counts;	chr14:64509143	chr14:64514154~64540368:-
LUAD	cis	rs12681963	0.748	rs12546330	ENSG00000272375.1	RP11-51J9.6	-3.53	0.000453	0.0476	-0.2	-0.16	Migraine;	chr8:30044958	chr8:30197404~30198048:+
LUAD	cis	rs7178909	0.872	rs28468074	ENSG00000259677.1	RP11-493E3.1	3.53	0.000453	0.0476	0.17	0.16	Common traits (Other);	chr15:89892368	chr15:89876540~89877285:+
LUAD	cis	rs7178909	0.872	rs61345389	ENSG00000259677.1	RP11-493E3.1	3.53	0.000453	0.0476	0.17	0.16	Common traits (Other);	chr15:89892653	chr15:89876540~89877285:+
LUAD	cis	rs17507216	0.628	rs4627310	ENSG00000276710.3	CSPG4P8	-3.53	0.000453	0.0476	-0.18	-0.16	Excessive daytime sleepiness;	chr15:82708330	chr15:82459472~82477258:+
LUAD	cis	rs6496932	0.503	rs7170370	ENSG00000259630.2	CTD-2262B20.1	-3.53	0.000453	0.0476	-0.2	-0.16	Central corneal thickness;Corneal structure;	chr15:85414505	chr15:85415228~85415633:+
LUAD	cis	rs2625529	0.652	rs28650442	ENSG00000260173.1	RP11-2I17.4	-3.53	0.000453	0.0476	-0.19	-0.16	Red blood cell count;	chr15:71863104	chr15:72140504~72155459:-
LUAD	cis	rs12935418	0.616	rs2549854	ENSG00000278985.1	RP11-303E16.9	3.53	0.000453	0.0476	0.15	0.16	Mean corpuscular volume;	chr16:80993034	chr16:80982319~80984094:-
LUAD	cis	rs9341808	0.618	rs6916507	ENSG00000233967.5	RP11-250B2.3	3.53	0.000453	0.0476	0.16	0.16	Sitting height ratio;	chr6:80152548	chr6:80443344~80465927:+
LUAD	cis	rs440932	0.798	rs330942	ENSG00000253893.2	FAM85B	-3.53	0.000453	0.0476	-0.2	-0.16	High light scatter reticulocyte percentage of red cells;	chr8:9162929	chr8:8167819~8226614:-
LUAD	cis	rs12744310	0.887	rs12046670	ENSG00000235358.1	RP11-399E6.1	3.53	0.000453	0.0476	0.21	0.16	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41343640	chr1:41242373~41284861:+
LUAD	cis	rs72681920	0.881	rs72679827	ENSG00000246090.5	RP11-696N14.1	-3.53	0.000453	0.0476	-0.28	-0.16	Alcohol dependence;	chr4:99155805	chr4:99088857~99301356:+
LUAD	cis	rs1355223	0.833	rs286885	ENSG00000271369.1	RP11-350D17.3	3.53	0.000453	0.0476	0.19	0.16	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34665799	chr11:34709600~34710161:+
LUAD	cis	rs76382185	0.756	rs4367796	ENSG00000233184.5	RP11-421L21.3	3.53	0.000453	0.0476	0.29	0.16	Lymphocyte counts;	chr1:101118798	chr1:101025878~101087268:+
LUAD	cis	rs7904368	0.806	rs1130684	ENSG00000229190.1	RP11-390B4.3	-3.53	0.000454	0.0476	-0.21	-0.16	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;	chr10:16817336	chr10:17695709~17700232:-
LUAD	cis	rs7829975	0.617	rs4841072	ENSG00000253981.4	ALG1L13P	-3.53	0.000454	0.0476	-0.18	-0.16	Mood instability;	chr8:8933743	chr8:8236003~8244667:-
LUAD	cis	rs950027	0.596	rs2467865	ENSG00000259479.5	SORD2P	3.53	0.000454	0.0476	0.19	0.16	Response to fenofibrate (adiponectin levels);	chr15:45346109	chr15:44826371~44884694:-
LUAD	cis	rs2657294	0.761	rs1259498	ENSG00000226051.5	ZNF503-AS1	-3.53	0.000454	0.0476	-0.21	-0.16	Pneumonia;	chr10:75226983	chr10:75269819~75373500:+
LUAD	cis	rs4499344	0.96	rs17833075	ENSG00000267475.1	CTD-2538C1.2	-3.53	0.000454	0.0476	-0.21	-0.16	Mean platelet volume;	chr19:32584228	chr19:32687089~32691750:-
LUAD	cis	rs2880765	0.835	rs4360874	ENSG00000259407.1	RP11-158M2.3	-3.53	0.000454	0.0476	-0.14	-0.16	Coronary artery disease;	chr15:85497589	chr15:85744109~85750281:-
LUAD	cis	rs9810888	0.706	rs2680654	ENSG00000271916.1	RP11-884K10.6	-3.53	0.000454	0.0476	-0.16	-0.16	Hypertension;Diastolic blood pressure;Systolic blood pressure;	chr3:53643849	chr3:53797764~53798019:-
LUAD	cis	rs830124	0.789	rs1169085	ENSG00000280138.1	RP11-463O12.5	3.53	0.000454	0.0476	0.17	0.16	Urinary metabolites;	chr12:122007327	chr12:122870059~122888720:-
LUAD	cis	rs5752773	0.61	rs695700	ENSG00000272858.1	CTA-292E10.8	-3.53	0.000454	0.0476	-0.17	-0.16	Vertical cup-disc ratio;	chr22:28486854	chr22:28814914~28815662:+
LUAD	cis	rs5752773	0.61	rs695318	ENSG00000272858.1	CTA-292E10.8	-3.53	0.000454	0.0476	-0.17	-0.16	Vertical cup-disc ratio;	chr22:28486985	chr22:28814914~28815662:+
LUAD	cis	rs11992162	0.573	rs13264994	ENSG00000255046.1	RP11-297N6.4	3.53	0.000454	0.0476	0.2	0.16	Monocyte count;	chr8:11925250	chr8:11797928~11802568:-
LUAD	cis	rs4363385	0.693	rs6656812	ENSG00000223599.1	RP11-216N14.7	3.53	0.000454	0.0476	0.19	0.16	Inflammatory skin disease;	chr1:152957778	chr1:153852106~153853414:-
LUAD	cis	rs6460942	0.915	rs6968695	ENSG00000226690.5	AC005281.1	3.53	0.000454	0.0476	0.29	0.16	Coronary artery disease;	chr7:12404252	chr7:12496429~12541910:+
LUAD	cis	rs6460942	0.915	rs6945067	ENSG00000226690.5	AC005281.1	3.53	0.000454	0.0476	0.29	0.16	Coronary artery disease;	chr7:12405105	chr7:12496429~12541910:+
LUAD	cis	rs6568686	0.786	rs6568682	ENSG00000255389.1	C6orf3	-3.53	0.000454	0.0476	-0.22	-0.16	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111492974	chr6:111599875~111602295:+
LUAD	cis	rs67601088	0.54	rs740141	ENSG00000227855.3	DPY19L2P3	3.53	0.000454	0.0476	0.19	0.16	Pediatric bone mineral density (spine);	chr7:29858392	chr7:29650227~29742594:+
LUAD	cis	rs4072705	1	rs4836985	ENSG00000236643.1	RP11-175D17.3	-3.53	0.000454	0.0476	-0.18	-0.16	Menarche (age at onset);	chr9:124645615	chr9:124770123~124772927:+
LUAD	cis	rs950169	0.887	rs220333	ENSG00000188388.10	GOLGA6L3	3.53	0.000454	0.0476	0.21	0.16	Schizophrenia;	chr15:84547902	chr15:85240472~85247170:+
LUAD	cis	rs2408955	0.521	rs1476607	ENSG00000273765.1	RP11-370I10.11	-3.53	0.000454	0.0476	-0.17	-0.16	Glycated hemoglobin levels;	chr12:48131021	chr12:48360920~48361377:+
LUAD	cis	rs35520189	0.523	rs66591921	ENSG00000227368.1	AC079753.5	3.53	0.000454	0.0476	0.2	0.16	Obstructive sleep apnea trait (apnea hypopnea index);	chr2:112950000	chr2:112932625~112933171:+
LUAD	cis	rs6538678	0.746	rs703693	ENSG00000257150.2	PGAM1P5	3.53	0.000454	0.0476	0.2	0.16	Lupus nephritis in systemic lupus erythematosus;	chr12:95866214	chr12:95551582~95673999:+
LUAD	cis	rs10510102	0.935	rs79360006	ENSG00000276742.1	RP11-500G22.4	3.53	0.000454	0.0477	0.27	0.16	Breast cancer;	chr10:121912856	chr10:121956782~121957098:+
LUAD	cis	rs7141336	0.864	rs7148903	ENSG00000258884.1	CTD-3035D6.2	3.53	0.000454	0.0477	0.17	0.16	Anxiety disorder;	chr14:90821483	chr14:90822365~90828128:-
LUAD	cis	rs1334894	0.584	rs3798344	ENSG00000228559.1	RP3-340B19.3	-3.53	0.000454	0.0477	-0.28	-0.16	Coronary artery disease;	chr6:35499123	chr6:35544632~35545669:+
LUAD	cis	rs6589563	0.609	rs60972755	ENSG00000280143.1	AP000892.6	3.53	0.000454	0.0477	0.31	0.16	Eosinophil counts;	chr11:116764897	chr11:117204967~117210292:+
LUAD	cis	rs12272004	0.59	rs12294259	ENSG00000280143.1	AP000892.6	3.53	0.000454	0.0477	0.31	0.16	Triglycerides;Cholesterol, total;LDL cholesterol;Carotenoid and tocopherol levels;	chr11:116766430	chr11:117204967~117210292:+
LUAD	cis	rs75920871	0.589	rs4938342	ENSG00000280143.1	AP000892.6	3.53	0.000454	0.0477	0.24	0.16	Subjective well-being;	chr11:117132704	chr11:117204967~117210292:+
LUAD	cis	rs6502050	0.805	rs11651863	ENSG00000266654.1	RP11-1376P16.1	3.53	0.000454	0.0477	0.17	0.16	Life satisfaction;	chr17:82126663	chr17:82160056~82160452:+
LUAD	cis	rs13113518	0.966	rs4864544	ENSG00000223305.1	RN7SKP30	3.53	0.000454	0.0477	0.18	0.16	Height;	chr4:55515292	chr4:55540502~55540835:-
LUAD	cis	rs13113518	1	rs6847529	ENSG00000223305.1	RN7SKP30	3.53	0.000454	0.0477	0.18	0.16	Height;	chr4:55518776	chr4:55540502~55540835:-
LUAD	cis	rs7178424	1	rs12442212	ENSG00000259251.2	RP11-643M14.1	-3.53	0.000454	0.0477	-0.16	-0.16	Height;	chr15:62088283	chr15:62060503~62062434:+
LUAD	cis	rs9311474	0.713	rs352167	ENSG00000243224.1	RP5-1157M23.2	3.53	0.000454	0.0477	0.15	0.16	Electroencephalogram traits;	chr3:52204640	chr3:52239258~52241097:+
LUAD	cis	rs4474465	1	rs7933612	ENSG00000251323.2	RP11-452H21.4	-3.53	0.000454	0.0477	-0.2	-0.16	Alzheimer's disease (survival time);	chr11:78498320	chr11:78423982~78429836:-
LUAD	cis	rs854765	0.619	rs4561528	ENSG00000223979.2	SMCR2	-3.53	0.000454	0.0477	-0.19	-0.16	Total body bone mineral density;	chr17:18075785	chr17:17674026~17677688:-
LUAD	cis	rs7474896	0.583	rs1735621	ENSG00000226578.1	RP11-258F22.1	3.53	0.000454	0.0477	0.22	0.16	Obesity (extreme);	chr10:37878795	chr10:37775371~37784131:-
LUAD	cis	rs17122278	1	rs11216909	ENSG00000243431.1	RPL5P30	3.53	0.000455	0.0477	0.19	0.16	Total cholesterol levels;	chr11:118579031	chr11:118560690~118561580:+
LUAD	cis	rs12682352	0.602	rs13260419	ENSG00000233609.3	RP11-62H7.2	3.53	0.000455	0.0477	0.13	0.16	Neuroticism;	chr8:8817666	chr8:8961200~8979025:+
LUAD	cis	rs804280	0.542	rs34117651	ENSG00000255046.1	RP11-297N6.4	-3.53	0.000455	0.0477	-0.2	-0.16	Myopia (pathological);	chr8:11934108	chr8:11797928~11802568:-
LUAD	cis	rs11030122	0.66	rs10767680	ENSG00000225101.4	OR52K3P	-3.53	0.000455	0.0477	-0.18	-0.16	Mean platelet volume;Platelet distribution width;	chr11:3890911	chr11:4474813~4475755:+
LUAD	cis	rs6502050	0.865	rs56193110	ENSG00000266654.1	RP11-1376P16.1	-3.53	0.000455	0.0477	-0.17	-0.16	Life satisfaction;	chr17:82193625	chr17:82160056~82160452:+
LUAD	cis	rs6951245	1	rs11763020	ENSG00000199023.2	MIR339	-3.53	0.000455	0.0477	-0.28	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1020652	chr7:1022935~1023045:-
LUAD	cis	rs2274273	1	rs7140872	ENSG00000259318.1	RP11-454L9.2	3.53	0.000455	0.0477	0.14	0.16	Protein biomarker;	chr14:55146026	chr14:55394940~55395233:-
LUAD	cis	rs2274273	1	rs15870	ENSG00000259318.1	RP11-454L9.2	3.53	0.000455	0.0477	0.14	0.16	Protein biomarker;	chr14:55152593	chr14:55394940~55395233:-
LUAD	cis	rs6586111	1	rs6586107	ENSG00000226659.1	RP11-137H2.4	3.53	0.000455	0.0477	0.2	0.16	Capecitabine sensitivity;	chr10:80613760	chr10:80529597~80535942:-
LUAD	cis	rs6502050	0.805	rs7225560	ENSG00000266654.1	RP11-1376P16.1	-3.53	0.000455	0.0477	-0.17	-0.16	Life satisfaction;	chr17:82203008	chr17:82160056~82160452:+
LUAD	cis	rs7107174	0.892	rs10899487	ENSG00000251323.2	RP11-452H21.4	3.53	0.000455	0.0477	0.21	0.16	Testicular germ cell tumor;	chr11:78374428	chr11:78423982~78429836:-
LUAD	cis	rs8014252	0.667	rs8005522	ENSG00000259158.2	ADAM20P1	-3.53	0.000455	0.0477	-0.21	-0.16	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70317506	chr14:70468881~70483756:-
LUAD	cis	rs8062405	0.789	rs28676837	ENSG00000261766.1	RP11-22P6.2	3.53	0.000455	0.0477	0.14	0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28615742	chr16:28862166~28863340:-
LUAD	cis	rs2555155	0.807	rs2253104	ENSG00000254595.1	CTD-2010I16.1	3.53	0.000455	0.0477	0.14	0.16	DNA methylation (variation);	chr11:6479079	chr11:6488186~6489377:-
LUAD	cis	rs910316	0.737	rs175049	ENSG00000279594.1	RP11-950C14.10	-3.53	0.000455	0.0477	-0.18	-0.16	Height;	chr14:75014665	chr14:75011269~75012851:-
LUAD	cis	rs3772130	1	rs13087578	ENSG00000243544.3	RN7SL172P	3.53	0.000455	0.0477	0.19	0.16	Cognitive performance;	chr3:121650360	chr3:121653994~121654296:-
LUAD	cis	rs9325144	0.577	rs10876008	ENSG00000257718.1	RP11-396F22.1	-3.53	0.000455	0.0477	-0.19	-0.16	Morning vs. evening chronotype;	chr12:38732948	chr12:38906451~38909592:+
LUAD	cis	rs7819412	0.522	rs4841497	ENSG00000255046.1	RP11-297N6.4	3.53	0.000455	0.0477	0.2	0.16	Triglycerides;	chr8:11127630	chr8:11797928~11802568:-
LUAD	cis	rs277939	1	rs157044	ENSG00000251634.2	RP11-1280N14.3	3.53	0.000455	0.0477	0.17	0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr5:71601624	chr5:71102898~71128753:-
LUAD	cis	rs763121	0.853	rs1013338	ENSG00000228274.3	RP3-508I15.9	-3.53	0.000455	0.0477	-0.15	-0.16	Menopause (age at onset);	chr22:38578149	chr22:38667585~38681820:-
LUAD	cis	rs2836974	0.836	rs8129355	ENSG00000232608.1	TIMM9P2	-3.53	0.000455	0.0477	-0.19	-0.16	Cognitive function;	chr21:39207943	chr21:39216624~39217506:+
LUAD	cis	rs2548724	0.812	rs2161601	ENSG00000250682.4	LINC00491	-3.53	0.000455	0.0477	-0.21	-0.16	Type 2 diabetes;	chr5:102269167	chr5:102609156~102671559:-
LUAD	cis	rs2932538	0.922	rs6671645	ENSG00000235299.2	MRPL53P1	3.53	0.000455	0.0477	0.19	0.16	Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension;	chr1:112586506	chr1:112625906~112626224:-
LUAD	cis	rs2932538	0.922	rs6691917	ENSG00000235299.2	MRPL53P1	3.53	0.000455	0.0477	0.19	0.16	Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension;	chr1:112594421	chr1:112625906~112626224:-
LUAD	cis	rs10934524	0.676	rs326301	ENSG00000243547.1	HNRNPKP4	3.53	0.000455	0.0477	0.12	0.16	Longevity;	chr3:96426485	chr3:96349554~96350939:+
LUAD	cis	rs8067545	0.641	rs203481	ENSG00000270091.1	RP11-78O7.2	-3.53	0.000455	0.0477	-0.13	-0.16	Schizophrenia;	chr17:19925415	chr17:19896590~19897287:-
LUAD	cis	rs8067545	0.616	rs203477	ENSG00000270091.1	RP11-78O7.2	-3.53	0.000455	0.0477	-0.13	-0.16	Schizophrenia;	chr17:19928506	chr17:19896590~19897287:-
LUAD	cis	rs8067545	0.641	rs850623	ENSG00000270091.1	RP11-78O7.2	-3.53	0.000455	0.0477	-0.13	-0.16	Schizophrenia;	chr17:19933817	chr17:19896590~19897287:-
LUAD	cis	rs9303542	1	rs7209855	ENSG00000264920.1	RP11-6N17.4	-3.53	0.000455	0.0478	-0.2	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48311441	chr17:47891255~47895812:-
LUAD	cis	rs7077256	0.542	rs1046521	ENSG00000272767.1	JMJD1C-AS1	3.53	0.000455	0.0478	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63154707	chr10:63465229~63466563:+
LUAD	cis	rs28386778	0.769	rs6504179	ENSG00000240280.5	TCAM1P	-3.53	0.000456	0.0478	-0.19	-0.16	Prudent dietary pattern;	chr17:63735635	chr17:63849292~63864379:+
LUAD	cis	rs2337406	0.587	rs10129888	ENSG00000211938.2	IGHV3-7	-3.53	0.000456	0.0478	-0.15	-0.16	Alzheimer's disease (late onset);	chr14:106647421	chr14:106062151~106062683:-
LUAD	cis	rs9325144	0.624	rs10506126	ENSG00000257718.1	RP11-396F22.1	-3.53	0.000456	0.0478	-0.19	-0.16	Morning vs. evening chronotype;	chr12:38729442	chr12:38906451~38909592:+
LUAD	cis	rs4802666	1	rs56354891	ENSG00000171101.12	SIGLEC17P	-3.53	0.000456	0.0478	-0.18	-0.16	Disc degeneration (lumbar);	chr19:50224253	chr19:51167328~51173524:+
LUAD	cis	rs4819052	0.851	rs28442024	ENSG00000223768.1	LINC00205	-3.53	0.000456	0.0478	-0.19	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254560	chr21:45293285~45297354:+
LUAD	cis	rs4417855	0.665	rs6444247	ENSG00000233565.1	RP11-42D20.1	-3.53	0.000456	0.0478	-0.15	-0.16	Granulocyte percentage of myeloid white cells;	chr3:187695433	chr3:186922286~186922753:-
LUAD	cis	rs4417855	0.665	rs7653032	ENSG00000233565.1	RP11-42D20.1	-3.53	0.000456	0.0478	-0.15	-0.16	Granulocyte percentage of myeloid white cells;	chr3:187695600	chr3:186922286~186922753:-
LUAD	cis	rs1910358	0.614	rs11955052	ENSG00000248874.4	C5orf17	-3.53	0.000456	0.0478	-0.2	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23979128	chr5:23951348~24178263:+
LUAD	cis	rs1910358	0.614	rs7714758	ENSG00000248874.4	C5orf17	-3.53	0.000456	0.0478	-0.2	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23980922	chr5:23951348~24178263:+
LUAD	cis	rs7617773	0.817	rs9819094	ENSG00000199476.1	Y_RNA	-3.53	0.000456	0.0478	-0.2	-0.16	Coronary artery disease;	chr3:48278068	chr3:48288587~48288694:+
LUAD	cis	rs10908557	0.758	rs113165037	ENSG00000223599.1	RP11-216N14.7	3.53	0.000456	0.0478	0.2	0.16	Age at first birth;	chr1:154017260	chr1:153852106~153853414:-
LUAD	cis	rs838147	0.508	rs507766	ENSG00000232871.7	SEC1P	3.53	0.000456	0.0478	0.17	0.16	Dietary macronutrient intake;	chr19:48705286	chr19:48638071~48682245:+
LUAD	cis	rs6832769	1	rs9998146	ENSG00000272969.1	RP11-528I4.2	-3.53	0.000456	0.0478	-0.17	-0.16	Personality dimensions;	chr4:55531810	chr4:55547112~55547889:+
LUAD	cis	rs2921073	0.509	rs2976931	ENSG00000173295.6	FAM86B3P	3.53	0.000456	0.0478	0.17	0.16	Parkinson's disease;	chr8:8399807	chr8:8228595~8244865:+
LUAD	cis	rs11105298	0.891	rs11105287	ENSG00000270344.2	RP11-734K2.4	3.53	0.000456	0.0478	0.2	0.16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89435693	chr12:89525654~89548005:+
LUAD	cis	rs763121	0.853	rs6001175	ENSG00000225450.1	RP3-508I15.14	-3.53	0.000456	0.0478	-0.15	-0.16	Menopause (age at onset);	chr22:38622329	chr22:38739003~38749041:+
LUAD	cis	rs1046491	1	rs12455304	ENSG00000264964.1	RP11-888D10.3	3.53	0.000456	0.0478	0.34	0.16	Scarlet fever;	chr18:9200840	chr18:9315194~9334441:-
LUAD	cis	rs1009077	0.578	rs2389863	ENSG00000245958.5	RP11-33B1.1	-3.53	0.000456	0.0478	-0.15	-0.16	Endometriosis;	chr4:119586509	chr4:119454791~119552025:+
LUAD	cis	rs34779708	0.931	rs17582416	ENSG00000271335.4	RP11-324I22.4	3.53	0.000456	0.0478	0.16	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:34998722	chr10:35314552~35336401:-
LUAD	cis	rs438034	0.524	rs34760325	ENSG00000230461.7	PROX1-AS1	3.53	0.000456	0.0478	0.2	0.16	Response to antineoplastic agents;	chr1:214728992	chr1:213817751~213988508:-
LUAD	cis	rs523522	0.962	rs509445	ENSG00000278344.1	RP11-18C24.8	3.53	0.000456	0.0478	0.22	0.16	High light scatter reticulocyte count;	chr12:120579440	chr12:120500735~120501090:-
LUAD	cis	rs2682471	0.585	rs4763533	ENSG00000245648.1	RP11-277P12.20	3.53	0.000456	0.0478	0.19	0.16	Macrophage inflammatory protein 1a levels;	chr12:10446828	chr12:10363769~10398506:+
LUAD	cis	rs9457247	1	rs393558	ENSG00000227598.1	RP1-167A14.2	-3.53	0.000456	0.0478	-0.17	-0.16	Crohn's disease;	chr6:166984262	chr6:166969626~166999065:-
LUAD	cis	rs9457247	1	rs394522	ENSG00000227598.1	RP1-167A14.2	-3.53	0.000456	0.0478	-0.17	-0.16	Crohn's disease;	chr6:166984583	chr6:166969626~166999065:-
LUAD	cis	rs9457247	1	rs408040	ENSG00000227598.1	RP1-167A14.2	-3.53	0.000456	0.0478	-0.17	-0.16	Crohn's disease;	chr6:166985415	chr6:166969626~166999065:-
LUAD	cis	rs13113518	1	rs11133388	ENSG00000249700.7	SRD5A3-AS1	-3.53	0.000456	0.0478	-0.16	-0.16	Height;	chr4:55477866	chr4:55363971~55395847:-
LUAD	cis	rs4819052	0.788	rs9978857	ENSG00000184274.3	LINC00315	-3.53	0.000456	0.0478	-0.23	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285240	chr21:45300245~45305257:-
LUAD	cis	rs9313772	0.775	rs4704936	ENSG00000276778.1	RP11-524N5.1	3.53	0.000456	0.0478	0.16	0.16	Blood pressure;	chr5:158389037	chr5:158320683~158409773:-
LUAD	cis	rs8012947	0.959	rs2233752	ENSG00000279636.2	LINC00216	-3.53	0.000456	0.0478	-0.18	-0.16	Alcohol consumption in current drinkers;	chr14:58288762	chr14:58288033~58289158:+
LUAD	cis	rs8012947	1	rs10133305	ENSG00000279636.2	LINC00216	-3.53	0.000456	0.0478	-0.18	-0.16	Alcohol consumption in current drinkers;	chr14:58294411	chr14:58288033~58289158:+
LUAD	cis	rs1046491	1	rs11660889	ENSG00000264964.1	RP11-888D10.3	3.53	0.000456	0.0478	0.33	0.16	Scarlet fever;	chr18:9177299	chr18:9315194~9334441:-
LUAD	cis	rs9366999	0.77	rs1744401	ENSG00000235033.6	RP11-61I13.3	-3.53	0.000456	0.0478	-0.17	-0.16	Obesity-related traits;	chr6:39250265	chr6:39881804~39900071:-
LUAD	cis	rs9366999	0.809	rs1744402	ENSG00000235033.6	RP11-61I13.3	-3.53	0.000456	0.0478	-0.17	-0.16	Obesity-related traits;	chr6:39250266	chr6:39881804~39900071:-
LUAD	cis	rs13192613	0.792	rs13198059	ENSG00000272472.1	RP11-95G17.2	3.53	0.000456	0.0478	0.2	0.16	Prostate cancer (SNP x SNP interaction);	chr6:122920535	chr6:122643388~122644771:+
LUAD	cis	rs13113518	1	rs4864547	ENSG00000223305.1	RN7SKP30	3.53	0.000456	0.0478	0.18	0.16	Height;	chr4:55538228	chr4:55540502~55540835:-
LUAD	cis	rs4332428	0.881	rs4531365	ENSG00000238840.1	U8	3.53	0.000456	0.0478	0.26	0.16	Height;	chr10:4942141	chr10:4962436~4962568:-
LUAD	cis	rs970797	0.522	rs818364	ENSG00000237260.1	AC073069.2	3.53	0.000456	0.0478	0.19	0.16	Monobrow;Lobe attachment (rater-scored or self-reported);	chr2:176337387	chr2:176338637~176339077:+
LUAD	cis	rs3749855	0.596	rs13195965	ENSG00000220920.1	RP3-525L6.2	3.53	0.000456	0.0478	0.33	0.16	Glucose homeostasis traits;	chr6:17263619	chr6:17953572~17953930:+
LUAD	cis	rs4372836	0.681	rs13025377	ENSG00000226833.4	AC097724.3	3.53	0.000456	0.0478	0.17	0.16	Body mass index;	chr2:28730690	chr2:28708953~28736205:-
LUAD	cis	rs4372836	0.681	rs13394863	ENSG00000226833.4	AC097724.3	3.53	0.000456	0.0478	0.17	0.16	Body mass index;	chr2:28733818	chr2:28708953~28736205:-
LUAD	cis	rs922182	0.547	rs12907026	ENSG00000259635.1	AC100830.3	-3.53	0.000456	0.0478	-0.17	-0.16	Blood protein levels;	chr15:63979405	chr15:64701248~64719602:+
LUAD	cis	rs3018066	0.748	rs6823347	ENSG00000251259.1	AC004069.2	-3.53	0.000457	0.0479	-0.19	-0.16	Cancer;	chr4:106041568	chr4:105137280~105140619:-
LUAD	cis	rs17680741	0.697	rs11185829	ENSG00000226659.1	RP11-137H2.4	3.53	0.000457	0.0479	0.28	0.16	Coronary artery disease;	chr10:80508094	chr10:80529597~80535942:-
LUAD	cis	rs1075265	0.722	rs2111623	ENSG00000272156.1	RP11-477N3.1	3.53	0.000457	0.0479	0.19	0.16	Chronotype;Morning vs. evening chronotype;	chr2:53757820	chr2:54082554~54085066:+
LUAD	cis	rs253959	0.921	rs254174	ENSG00000248445.4	SEMA6A-AS1	3.53	0.000457	0.0479	0.12	0.16	Bipolar disorder and schizophrenia;	chr5:116285906	chr5:116447547~116508276:+
LUAD	cis	rs3925075	0.515	rs4459557	ENSG00000260911.2	RP11-196G11.2	-3.53	0.000457	0.0479	-0.15	-0.16	IgA nephropathy;	chr16:31350322	chr16:31043150~31049868:+
LUAD	cis	rs17640804	0.918	rs846314	ENSG00000224017.1	LINC01449	3.53	0.000457	0.0479	0.2	0.16	middle facial morphology traits (quantitative measurement);facial morphology traits (multivariate analysis);	chr7:42088296	chr7:41101604~41133507:+
LUAD	cis	rs6964587	0.692	rs2027950	ENSG00000188693.7	CYP51A1-AS1	3.53	0.000457	0.0479	0.18	0.16	Breast cancer;	chr7:92234386	chr7:92134604~92180725:+
LUAD	cis	rs7789940	1	rs7789940	ENSG00000230305.2	AC004980.9	3.53	0.000457	0.0479	0.21	0.16	Multiple sclerosis;	chr7:76321913	chr7:76524515~76532692:+
LUAD	cis	rs6001482	0.507	rs62234784	ENSG00000215456.5	BCRP4	3.53	0.000457	0.0479	0.22	0.16	Diastolic blood pressure;	chr22:22234610	chr22:22630061~22636153:+
LUAD	cis	rs2390582	0.679	rs12733663	ENSG00000233593.5	RP4-665J23.1	3.53	0.000457	0.0479	0.24	0.16	Coronary artery calcification;	chr1:90602106	chr1:90782986~90851650:-
LUAD	cis	rs877356	0.831	rs34134222	ENSG00000250167.1	CTC-321K16.1	-3.53	0.000457	0.0479	-0.31	-0.16	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (dichotomous);	chr5:135830466	chr5:135559577~135634874:+
LUAD	cis	rs7477	1	rs7477	ENSG00000275413.1	CTC-529I10.1	-3.53	0.000457	0.0479	-0.13	-0.16	Amyotrophic lateral sclerosis;	chr17:16342702	chr17:16023323~16023653:-
LUAD	cis	rs4664293	0.528	rs1549386	ENSG00000230783.1	AC009961.2	3.53	0.000457	0.0479	0.2	0.16	Monocyte percentage of white cells;	chr2:159558015	chr2:159689217~159690291:-
LUAD	cis	rs8180040	0.966	rs11707895	ENSG00000271161.1	BOLA2P2	-3.53	0.000457	0.0479	-0.15	-0.16	Colorectal cancer;	chr3:47533447	chr3:47499841~47500407:+
LUAD	cis	rs12446632	0.723	rs4782289	ENSG00000261195.1	CTD-2380F24.1	-3.53	0.000457	0.0479	-0.24	-0.16	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Menarche (age at onset);Obesity;Childhood body mass index;Waist circumference;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr16:19848010	chr16:19761172~19766099:-
LUAD	cis	rs6502050	0.835	rs62080004	ENSG00000266654.1	RP11-1376P16.1	3.53	0.000457	0.0479	0.17	0.16	Life satisfaction;	chr17:82121203	chr17:82160056~82160452:+
LUAD	cis	rs6502050	0.835	rs7219138	ENSG00000266654.1	RP11-1376P16.1	3.53	0.000457	0.0479	0.17	0.16	Life satisfaction;	chr17:82122020	chr17:82160056~82160452:+
LUAD	cis	rs6502050	0.835	rs7219180	ENSG00000266654.1	RP11-1376P16.1	3.53	0.000457	0.0479	0.17	0.16	Life satisfaction;	chr17:82122092	chr17:82160056~82160452:+
LUAD	cis	rs6502050	0.835	rs7212441	ENSG00000266654.1	RP11-1376P16.1	3.53	0.000457	0.0479	0.17	0.16	Life satisfaction;	chr17:82122171	chr17:82160056~82160452:+
LUAD	cis	rs6502050	0.805	rs7406858	ENSG00000266654.1	RP11-1376P16.1	3.53	0.000457	0.0479	0.17	0.16	Life satisfaction;	chr17:82122747	chr17:82160056~82160452:+
LUAD	cis	rs6502050	0.777	rs6502058	ENSG00000266654.1	RP11-1376P16.1	3.53	0.000457	0.0479	0.17	0.16	Life satisfaction;	chr17:82124624	chr17:82160056~82160452:+
LUAD	cis	rs6502050	0.835	rs6502059	ENSG00000266654.1	RP11-1376P16.1	3.53	0.000457	0.0479	0.17	0.16	Life satisfaction;	chr17:82125010	chr17:82160056~82160452:+
LUAD	cis	rs6502050	0.835	rs7405738	ENSG00000266654.1	RP11-1376P16.1	3.53	0.000457	0.0479	0.17	0.16	Life satisfaction;	chr17:82126351	chr17:82160056~82160452:+
LUAD	cis	rs6502050	0.805	rs7406682	ENSG00000266654.1	RP11-1376P16.1	3.53	0.000457	0.0479	0.17	0.16	Life satisfaction;	chr17:82126492	chr17:82160056~82160452:+
LUAD	cis	rs6502050	0.769	rs11658272	ENSG00000266654.1	RP11-1376P16.1	3.53	0.000457	0.0479	0.17	0.16	Life satisfaction;	chr17:82126720	chr17:82160056~82160452:+
LUAD	cis	rs6502050	0.835	rs11658335	ENSG00000266654.1	RP11-1376P16.1	3.53	0.000457	0.0479	0.17	0.16	Life satisfaction;	chr17:82126945	chr17:82160056~82160452:+
LUAD	cis	rs12534093	0.67	rs11773147	ENSG00000234286.1	AC006026.13	-3.53	0.000457	0.0479	-0.23	-0.16	Infant length;Height;	chr7:23549567	chr7:23680195~23680786:-
LUAD	cis	rs3018066	0.748	rs6846579	ENSG00000251259.1	AC004069.2	-3.53	0.000457	0.0479	-0.19	-0.16	Cancer;	chr4:106090599	chr4:105137280~105140619:-
LUAD	cis	rs2732480	0.5	rs2732461	ENSG00000273765.1	RP11-370I10.11	3.53	0.000457	0.0479	0.17	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48299019	chr12:48360920~48361377:+
LUAD	cis	rs7615952	0.515	rs7637246	ENSG00000248787.1	RP11-666A20.4	-3.53	0.000457	0.0479	-0.25	-0.16	Blood pressure (smoking interaction);	chr3:125959863	chr3:125908005~125910272:-
LUAD	cis	rs10129255	0.957	rs10141052	ENSG00000211947.2	IGHV3-21	-3.53	0.000457	0.0479	-0.1	-0.16	Kawasaki disease;	chr14:106776528	chr14:106235064~106235594:-
LUAD	cis	rs7100689	0.646	rs11202751	ENSG00000226659.1	RP11-137H2.4	-3.53	0.000458	0.0479	-0.22	-0.16	Post bronchodilator FEV1;	chr10:80388046	chr10:80529597~80535942:-
LUAD	cis	rs6430585	0.583	rs58509842	ENSG00000226806.1	AC011893.3	3.53	0.000458	0.0479	0.24	0.16	Corneal structure;	chr2:135828457	chr2:135820191~135823087:+
LUAD	cis	rs6977955	1	rs10951192	ENSG00000234336.5	JAZF1-AS1	3.53	0.000458	0.0479	0.21	0.16	Allergic disease (asthma, hay fever or eczema);	chr7:28121414	chr7:28180322~28243917:+
LUAD	cis	rs4763879	0.634	rs61915473	ENSG00000256582.1	RP11-75L1.1	-3.53	0.000458	0.0479	-0.16	-0.16	Type 1 diabetes;	chr12:9705282	chr12:9704077~9709350:+
LUAD	cis	rs2274273	0.84	rs28493647	ENSG00000258413.1	RP11-665C16.6	-3.53	0.000458	0.0479	-0.2	-0.16	Protein biomarker;	chr14:55357745	chr14:55262767~55272075:-
LUAD	cis	rs2274273	0.84	rs17674463	ENSG00000258413.1	RP11-665C16.6	-3.53	0.000458	0.0479	-0.2	-0.16	Protein biomarker;	chr14:55358145	chr14:55262767~55272075:-
LUAD	cis	rs2274273	0.805	rs8012156	ENSG00000259318.1	RP11-454L9.2	3.53	0.000458	0.0479	0.14	0.16	Protein biomarker;	chr14:55085782	chr14:55394940~55395233:-
LUAD	cis	rs4073582	0.595	rs1115508	ENSG00000255517.5	CTD-3074O7.5	-3.53	0.000458	0.0479	-0.17	-0.16	Gout;	chr11:66155678	chr11:66473490~66480233:-
LUAD	cis	rs7142881	0.514	rs4981915	ENSG00000258525.1	RP11-829H16.3	-3.53	0.000458	0.0479	-0.18	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31813681	chr14:30876179~30889808:-
LUAD	cis	rs2274273	0.624	rs66464079	ENSG00000258413.1	RP11-665C16.6	-3.53	0.000458	0.0479	-0.21	-0.16	Protein biomarker;	chr14:55299446	chr14:55262767~55272075:-
LUAD	cis	rs7551222	0.681	rs4245739	ENSG00000240219.1	RP11-430C7.5	3.53	0.000458	0.0479	0.18	0.16	Schizophrenia;	chr1:204549714	chr1:204626775~204629712:+
LUAD	cis	rs1881797	1	rs1881797	ENSG00000221953.5	C1orf229	-3.53	0.000458	0.048	-0.2	-0.16	Acute lymphoblastic leukemia (childhood);	chr1:247526230	chr1:247110160~247112417:-
LUAD	cis	rs7692995	1	rs12506752	ENSG00000235413.3	KRT18P63	3.53	0.000458	0.048	0.25	0.16	Height;	chr4:17946729	chr4:17911674~17912976:+
LUAD	cis	rs7692995	1	rs11936915	ENSG00000235413.3	KRT18P63	3.53	0.000458	0.048	0.25	0.16	Height;	chr4:17946874	chr4:17911674~17912976:+
LUAD	cis	rs7692995	1	rs6850259	ENSG00000235413.3	KRT18P63	3.53	0.000458	0.048	0.25	0.16	Height;	chr4:17947984	chr4:17911674~17912976:+
LUAD	cis	rs7692995	1	rs34934312	ENSG00000235413.3	KRT18P63	3.53	0.000458	0.048	0.25	0.16	Height;	chr4:17948549	chr4:17911674~17912976:+
LUAD	cis	rs7692995	1	rs16896101	ENSG00000235413.3	KRT18P63	3.53	0.000458	0.048	0.25	0.16	Height;	chr4:17949003	chr4:17911674~17912976:+
LUAD	cis	rs7692995	0.92	rs16896113	ENSG00000235413.3	KRT18P63	3.53	0.000458	0.048	0.25	0.16	Height;	chr4:17949227	chr4:17911674~17912976:+
LUAD	cis	rs7692995	1	rs7657678	ENSG00000235413.3	KRT18P63	3.53	0.000458	0.048	0.25	0.16	Height;	chr4:17949412	chr4:17911674~17912976:+
LUAD	cis	rs7692995	1	rs6843330	ENSG00000235413.3	KRT18P63	3.53	0.000458	0.048	0.25	0.16	Height;	chr4:17950433	chr4:17911674~17912976:+
LUAD	cis	rs721917	0.565	rs7476563	ENSG00000244733.5	RP11-506M13.3	-3.53	0.000458	0.048	-0.17	-0.16	Chronic obstructive pulmonary disease;	chr10:79975318	chr10:79660891~79677996:+
LUAD	cis	rs13113518	0.934	rs11935823	ENSG00000273257.1	RP11-177J6.1	3.53	0.000458	0.048	0.18	0.16	Height;	chr4:55589624	chr4:55387949~55388271:+
LUAD	cis	rs7210990	0.687	rs11078327	ENSG00000275413.1	CTC-529I10.1	-3.53	0.000458	0.048	-0.14	-0.16	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr17:16049627	chr17:16023323~16023653:-
LUAD	cis	rs80226907	0.634	rs59169706	ENSG00000239686.1	RP11-665C16.1	3.53	0.000458	0.048	0.29	0.16	Mean platelet volume;	chr14:55446364	chr14:55282296~55282643:-
LUAD	cis	rs6928977	0.5	rs9494308	ENSG00000231028.7	LINC00271	3.53	0.000458	0.048	0.19	0.16	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135627666	chr6:135497801~135716055:+
LUAD	cis	rs6494488	0.5	rs72744710	ENSG00000239465.1	RP11-330L19.2	3.53	0.000458	0.048	0.34	0.16	Coronary artery disease;	chr15:64721879	chr15:64631109~64631914:-
LUAD	cis	rs4474465	0.79	rs6592784	ENSG00000251323.2	RP11-452H21.4	-3.53	0.000458	0.048	-0.21	-0.16	Alzheimer's disease (survival time);	chr11:78523744	chr11:78423982~78429836:-
LUAD	cis	rs10510102	0.872	rs12247367	ENSG00000276742.1	RP11-500G22.4	3.53	0.000458	0.048	0.27	0.16	Breast cancer;	chr10:121961556	chr10:121956782~121957098:+
LUAD	cis	rs526231	0.578	rs35100629	ENSG00000250682.4	LINC00491	3.53	0.000458	0.048	0.19	0.16	Primary biliary cholangitis;	chr5:102910381	chr5:102609156~102671559:-
LUAD	cis	rs2390582	0.891	rs1832256	ENSG00000233593.5	RP4-665J23.1	3.53	0.000458	0.048	0.23	0.16	Coronary artery calcification;	chr1:90494223	chr1:90782986~90851650:-
LUAD	cis	rs1400816	0.619	rs4668417	ENSG00000228389.1	AC068039.4	3.53	0.000458	0.048	0.26	0.16	Amyotrophic lateral sclerosis (sporadic);	chr2:171862805	chr2:171773482~171775844:+
LUAD	cis	rs12908161	1	rs12910012	ENSG00000259654.1	RP11-245C17.2	-3.53	0.000458	0.048	-0.22	-0.16	Schizophrenia;	chr15:84755431	chr15:84685884~84686946:+
LUAD	cis	rs12908161	1	rs12899981	ENSG00000259654.1	RP11-245C17.2	-3.53	0.000458	0.048	-0.22	-0.16	Schizophrenia;	chr15:84759142	chr15:84685884~84686946:+
LUAD	cis	rs3764021	0.87	rs2192437	ENSG00000214776.8	RP11-726G1.1	3.53	0.000458	0.048	0.18	0.16	Type 1 diabetes;	chr12:9726639	chr12:9467552~9576275:+
LUAD	cis	rs3764021	0.87	rs10844617	ENSG00000214776.8	RP11-726G1.1	3.53	0.000458	0.048	0.18	0.16	Type 1 diabetes;	chr12:9726772	chr12:9467552~9576275:+
LUAD	cis	rs3764021	0.87	rs2401395	ENSG00000214776.8	RP11-726G1.1	3.53	0.000458	0.048	0.18	0.16	Type 1 diabetes;	chr12:9726944	chr12:9467552~9576275:+
LUAD	cis	rs7208859	0.614	rs73265646	ENSG00000265443.1	CTD-2349P21.6	-3.53	0.000458	0.048	-0.27	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917005	chr17:30726305~30727564:-
LUAD	cis	rs7208859	0.623	rs58908911	ENSG00000265443.1	CTD-2349P21.6	-3.53	0.000458	0.048	-0.27	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917540	chr17:30726305~30727564:-
LUAD	cis	rs2638953	0.853	rs10843179	ENSG00000247934.4	RP11-967K21.1	3.53	0.000458	0.048	0.21	0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28462125	chr12:28163298~28190738:-
LUAD	cis	rs448720	0.811	rs694267	ENSG00000259673.4	IQCH-AS1	3.53	0.000458	0.048	0.17	0.16	Cognitive performance;	chr15:67891039	chr15:67403619~67521844:-
LUAD	cis	rs524281	0.861	rs918299	ENSG00000255320.1	RP11-755F10.1	3.53	0.000458	0.048	0.23	0.16	Electroencephalogram traits;	chr11:66160136	chr11:66244840~66246239:-
LUAD	cis	rs9309473	0.848	rs17009159	ENSG00000230002.2	ALMS1-IT1	3.53	0.000458	0.048	0.2	0.16	Metabolite levels;	chr2:73570635	chr2:73456764~73459484:+
LUAD	cis	rs9309473	1	rs7586463	ENSG00000230002.2	ALMS1-IT1	3.53	0.000458	0.048	0.2	0.16	Metabolite levels;	chr2:73571349	chr2:73456764~73459484:+
LUAD	cis	rs2057178	0.696	rs12278882	ENSG00000183242.10	WT1-AS	3.53	0.000458	0.048	0.21	0.16	Tuberculosis;	chr11:32330854	chr11:32435518~32458769:+
LUAD	cis	rs4363385	0.693	rs7556517	ENSG00000223599.1	RP11-216N14.7	3.53	0.000458	0.048	0.19	0.16	Inflammatory skin disease;	chr1:152953279	chr1:153852106~153853414:-
LUAD	cis	rs12478296	1	rs55717005	ENSG00000261186.2	RP11-341N2.1	-3.53	0.000458	0.048	-0.28	-0.16	Obesity-related traits;	chr2:242098920	chr2:242087351~242088457:-
LUAD	cis	rs683250	0.63	rs1943744	ENSG00000246067.6	RAB30-AS1	-3.53	0.000458	0.048	-0.17	-0.16	Subcortical brain region volumes;	chr11:83372255	chr11:83072066~83106719:+
LUAD	cis	rs9903692	0.657	rs1452665	ENSG00000266601.1	RP11-6N17.3	-3.53	0.000458	0.048	-0.22	-0.16	Pulse pressure;	chr17:48219789	chr17:47929682~47933106:-
LUAD	cis	rs9903692	0.954	rs9889470	ENSG00000266601.1	RP11-6N17.3	-3.53	0.000458	0.048	-0.22	-0.16	Pulse pressure;	chr17:48233713	chr17:47929682~47933106:-
LUAD	cis	rs9894429	0.634	rs11655346	ENSG00000263853.1	AC139530.1	3.53	0.000459	0.048	0.16	0.16	Eye color traits;	chr17:81605373	chr17:81676001~81676086:+
LUAD	cis	rs2115630	1	rs8037423	ENSG00000259728.4	LINC00933	-3.53	0.000459	0.048	-0.19	-0.16	P wave terminal force;	chr15:84812263	chr15:84570649~84580175:+
LUAD	cis	rs12935418	0.616	rs8045512	ENSG00000261061.1	RP11-303E16.2	-3.53	0.000459	0.048	-0.2	-0.16	Mean corpuscular volume;	chr16:80952410	chr16:81030770~81031485:+
LUAD	cis	rs12935418	0.616	rs718954	ENSG00000261061.1	RP11-303E16.2	-3.53	0.000459	0.048	-0.2	-0.16	Mean corpuscular volume;	chr16:80953219	chr16:81030770~81031485:+
LUAD	cis	rs9900280	0.967	rs2958212	ENSG00000264808.1	RP11-802D6.1	-3.53	0.000459	0.048	-0.18	-0.16	Mean platelet volume;	chr17:29518364	chr17:29369717~29390777:-
LUAD	cis	rs4072705	1	rs6478671	ENSG00000236643.1	RP11-175D17.3	-3.53	0.000459	0.048	-0.18	-0.16	Menarche (age at onset);	chr9:124611716	chr9:124770123~124772927:+
LUAD	cis	rs4474465	0.92	rs10793321	ENSG00000251323.2	RP11-452H21.4	-3.53	0.000459	0.048	-0.21	-0.16	Alzheimer's disease (survival time);	chr11:78526520	chr11:78423982~78429836:-
LUAD	cis	rs523522	1	rs523522	ENSG00000278344.1	RP11-18C24.8	3.53	0.000459	0.048	0.22	0.16	High light scatter reticulocyte count;	chr12:120582447	chr12:120500735~120501090:-
LUAD	cis	rs11650494	0.516	rs9900373	ENSG00000248714.5	RP11-1079K10.3	3.53	0.000459	0.048	0.32	0.16	Prostate cancer;	chr17:49435583	chr17:49361165~49369998:+
LUAD	cis	rs11650494	0.57	rs9901650	ENSG00000248714.5	RP11-1079K10.3	3.53	0.000459	0.048	0.32	0.16	Prostate cancer;	chr17:49435765	chr17:49361165~49369998:+
LUAD	cis	rs7692995	1	rs7668933	ENSG00000235413.3	KRT18P63	3.53	0.000459	0.048	0.25	0.16	Height;	chr4:17986518	chr4:17911674~17912976:+
LUAD	cis	rs6472235	0.681	rs66644630	ENSG00000200714.1	Y_RNA	-3.53	0.000459	0.048	-0.21	-0.16	Plateletcrit;Myopia (pathological);	chr8:65956483	chr8:65592731~65592820:+
LUAD	cis	rs10876993	0.89	rs12302350	ENSG00000270039.1	RP11-571M6.17	3.53	0.000459	0.048	0.19	0.16	Celiac disease or Rheumatoid arthritis;	chr12:57668806	chr12:57803838~57804415:+
LUAD	cis	rs10876993	0.89	rs12302351	ENSG00000270039.1	RP11-571M6.17	3.53	0.000459	0.048	0.19	0.16	Celiac disease or Rheumatoid arthritis;	chr12:57668807	chr12:57803838~57804415:+
LUAD	cis	rs7100689	0.598	rs35353819	ENSG00000226659.1	RP11-137H2.4	-3.53	0.000459	0.048	-0.22	-0.16	Post bronchodilator FEV1;	chr10:80375981	chr10:80529597~80535942:-
LUAD	cis	rs2662776	1	rs10753609	ENSG00000232995.6	RGS5	-3.53	0.000459	0.048	-0.14	-0.16	Lead levels in blood;	chr1:163190547	chr1:163244505~163321894:-
LUAD	cis	rs2749097	0.668	rs2269240	ENSG00000244256.3	RN7SL130P	-3.53	0.000459	0.048	-0.21	-0.16	Alcohol consumption (transferrin glycosylation);	chr1:63643593	chr1:63655743~63656047:+
LUAD	cis	rs7937890	0.681	rs4756784	ENSG00000251991.1	RNU7-49P	-3.53	0.000459	0.048	-0.17	-0.16	Mitochondrial DNA levels;	chr11:14249358	chr11:14478892~14478953:+
LUAD	cis	rs3811273	0.614	rs4982594	ENSG00000211816.2	TRAV38-1	-3.53	0.000459	0.048	-0.22	-0.16	Periodontal disease-related phenotypes;	chr14:22266671	chr14:22271968~22272563:+
LUAD	cis	rs3811273	0.614	rs4982595	ENSG00000211816.2	TRAV38-1	-3.53	0.000459	0.048	-0.22	-0.16	Periodontal disease-related phenotypes;	chr14:22266915	chr14:22271968~22272563:+
LUAD	cis	rs12579720	0.673	rs2728576	ENSG00000255910.1	RP11-405A12.2	3.53	0.000459	0.048	0.22	0.16	Diastolic blood pressure;	chr12:20055296	chr12:19775451~20009937:+
LUAD	cis	rs6496044	0.634	rs4843066	ENSG00000259416.2	RP11-158M2.5	3.53	0.000459	0.048	0.17	0.16	Interstitial lung disease;	chr15:85519680	chr15:85754941~85756237:-
LUAD	cis	rs9381040	0.655	rs9381029	ENSG00000161912.16	ADCY10P1	3.53	0.000459	0.048	0.14	0.16	Alzheimer's disease (late onset);	chr6:41058714	chr6:41101022~41140835:+
LUAD	cis	rs6502050	0.731	rs4789730	ENSG00000275966.1	RP11-1055B8.9	-3.53	0.000459	0.048	-0.16	-0.16	Life satisfaction;	chr17:82188107	chr17:81345476~81345966:-
LUAD	cis	rs7208859	0.614	rs216412	ENSG00000265443.1	CTD-2349P21.6	3.53	0.000459	0.048	0.21	0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576376	chr17:30726305~30727564:-
LUAD	cis	rs3126085	1	rs11590365	ENSG00000237975.5	FLG-AS1	3.53	0.000459	0.048	0.26	0.16	Atopic dermatitis;	chr1:152193013	chr1:152168125~152445456:+
LUAD	cis	rs6694672	1	rs1412639	ENSG00000235582.2	RP11-448G4.2	-3.53	0.000459	0.048	-0.23	-0.16	Asthma;	chr1:197034463	chr1:197735636~197736107:+
LUAD	cis	rs13113518	1	rs13152173	ENSG00000223305.1	RN7SKP30	3.53	0.000459	0.048	0.18	0.16	Height;	chr4:55534788	chr4:55540502~55540835:-
LUAD	cis	rs13113518	1	rs13141049	ENSG00000223305.1	RN7SKP30	3.53	0.000459	0.048	0.18	0.16	Height;	chr4:55535489	chr4:55540502~55540835:-
LUAD	cis	rs13113518	0.967	rs12507722	ENSG00000223305.1	RN7SKP30	3.53	0.000459	0.048	0.18	0.16	Height;	chr4:55536421	chr4:55540502~55540835:-
LUAD	cis	rs13113518	0.967	rs7696832	ENSG00000223305.1	RN7SKP30	3.53	0.000459	0.048	0.18	0.16	Height;	chr4:55537080	chr4:55540502~55540835:-
LUAD	cis	rs13113518	0.902	rs12505266	ENSG00000249700.7	SRD5A3-AS1	3.53	0.000459	0.048	0.16	0.16	Height;	chr4:55546002	chr4:55363971~55395847:-
LUAD	cis	rs13113518	1	rs56154935	ENSG00000249700.7	SRD5A3-AS1	3.53	0.000459	0.048	0.16	0.16	Height;	chr4:55546378	chr4:55363971~55395847:-
LUAD	cis	rs11252926	0.624	rs7085214	ENSG00000232656.6	IDI2-AS1	3.53	0.000459	0.048	0.18	0.16	Psychosis in Alzheimer's disease;	chr10:422193	chr10:1022666~1044201:+
LUAD	cis	rs4474465	0.646	rs7927503	ENSG00000251323.2	RP11-452H21.4	-3.53	0.000459	0.048	-0.19	-0.16	Alzheimer's disease (survival time);	chr11:78569561	chr11:78423982~78429836:-
LUAD	cis	rs28374715	0.629	rs2118740	ENSG00000247556.5	OIP5-AS1	3.53	0.000459	0.0481	0.22	0.16	Ulcerative colitis;	chr15:41285034	chr15:41283990~41309737:+
LUAD	cis	rs288326	0.561	rs17265824	ENSG00000213958.2	KRT18P29	-3.53	0.000459	0.0481	-0.34	-0.16	Blood protein levels;	chr2:182847242	chr2:181961212~181962478:-
LUAD	cis	rs288326	0.561	rs79908577	ENSG00000213958.2	KRT18P29	-3.53	0.000459	0.0481	-0.34	-0.16	Blood protein levels;	chr2:182847444	chr2:181961212~181962478:-
LUAD	cis	rs288326	0.561	rs80252162	ENSG00000213958.2	KRT18P29	-3.53	0.000459	0.0481	-0.34	-0.16	Blood protein levels;	chr2:182852377	chr2:181961212~181962478:-
LUAD	cis	rs288326	0.561	rs17265859	ENSG00000213958.2	KRT18P29	-3.53	0.000459	0.0481	-0.34	-0.16	Blood protein levels;	chr2:182859884	chr2:181961212~181962478:-
LUAD	cis	rs2625529	0.652	rs11634608	ENSG00000260173.1	RP11-2I17.4	3.53	0.000459	0.0481	0.19	0.16	Red blood cell count;	chr15:71963377	chr15:72140504~72155459:-
LUAD	cis	rs6942407	0.546	rs10228392	ENSG00000224046.1	AC005076.5	-3.53	0.000459	0.0481	-0.24	-0.16	Food allergy;	chr7:87170357	chr7:87151423~87152420:-
LUAD	cis	rs6942407	0.546	rs10257953	ENSG00000224046.1	AC005076.5	-3.53	0.000459	0.0481	-0.24	-0.16	Food allergy;	chr7:87170410	chr7:87151423~87152420:-
LUAD	cis	rs3126085	0.935	rs11589587	ENSG00000237975.5	FLG-AS1	3.53	0.000459	0.0481	0.26	0.16	Atopic dermatitis;	chr1:152211653	chr1:152168125~152445456:+
LUAD	cis	rs2625529	0.775	rs16956273	ENSG00000260173.1	RP11-2I17.4	-3.53	0.000459	0.0481	-0.2	-0.16	Red blood cell count;	chr15:71824761	chr15:72140504~72155459:-
LUAD	cis	rs73411413	0.661	rs11599981	ENSG00000233930.3	KRTAP5-AS1	-3.53	0.000459	0.0481	-0.24	-0.16	Myringotomy;	chr11:1498833	chr11:1571353~1599184:+
LUAD	cis	rs6832769	1	rs4865008	ENSG00000272969.1	RP11-528I4.2	-3.53	0.000459	0.0481	-0.17	-0.16	Personality dimensions;	chr4:55544688	chr4:55547112~55547889:+
LUAD	cis	rs6460942	0.544	rs4719292	ENSG00000226690.5	AC005281.1	3.53	0.000459	0.0481	0.31	0.16	Coronary artery disease;	chr7:12099990	chr7:12496429~12541910:+
LUAD	cis	rs17620991	1	rs17688571	ENSG00000259826.1	RP11-467D6.1	3.53	0.000459	0.0481	0.2	0.16	Alcohol dependence;	chr7:40823164	chr7:39947522~39949755:-
LUAD	cis	rs13434995	0.513	rs62303728	ENSG00000249700.7	SRD5A3-AS1	-3.53	0.000459	0.0481	-0.19	-0.16	Adiponectin levels;	chr4:55495762	chr4:55363971~55395847:-
LUAD	cis	rs7260598	0.792	rs11670331	ENSG00000268442.1	CTD-2027I19.2	3.53	0.000459	0.0481	0.25	0.16	Response to taxane treatment (placlitaxel);	chr19:24155040	chr19:24162370~24163425:-
LUAD	cis	rs34779708	0.897	rs35784065	ENSG00000271335.4	RP11-324I22.4	3.53	0.000459	0.0481	0.17	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:35064646	chr10:35314552~35336401:-
LUAD	cis	rs12908161	1	rs12908161	ENSG00000254414.1	RP11-182J1.1	3.53	0.00046	0.0481	0.21	0.16	Schizophrenia;	chr15:84664594	chr15:84631898~84633987:-
LUAD	cis	rs1501138	0.506	rs4317201	ENSG00000263327.5	TAPT1-AS1	-3.53	0.00046	0.0481	-0.24	-0.16	Systemic juvenile idiopathic arthritis;	chr4:16207396	chr4:16226685~16320140:+
LUAD	cis	rs2235573	0.551	rs139892	ENSG00000235237.1	RP1-151B14.6	-3.53	0.00046	0.0481	-0.16	-0.16	Glioma;Glioblastoma;	chr22:37992196	chr22:37166757~37182850:+
LUAD	cis	rs7474896	0.537	rs1208587	ENSG00000226578.1	RP11-258F22.1	3.53	0.00046	0.0481	0.22	0.16	Obesity (extreme);	chr10:37918831	chr10:37775371~37784131:-
LUAD	cis	rs10510102	0.935	rs11200263	ENSG00000276742.1	RP11-500G22.4	3.53	0.00046	0.0481	0.27	0.16	Breast cancer;	chr10:121922836	chr10:121956782~121957098:+
LUAD	cis	rs72843166	0.853	rs114352914	ENSG00000265282.1	RP11-269G24.4	3.53	0.00046	0.0481	0.25	0.16	Intelligence (multi-trait analysis);	chr17:63304092	chr17:63430468~63432211:-
LUAD	cis	rs6087771	0.662	rs6058298	ENSG00000230613.1	HM13-AS1	3.53	0.00046	0.0481	0.2	0.16	Putamen volume;Subcortical brain region volumes;	chr20:31660113	chr20:31567707~31573263:-
LUAD	cis	rs6964587	0.621	rs38798	ENSG00000188693.7	CYP51A1-AS1	3.53	0.00046	0.0481	0.19	0.16	Breast cancer;	chr7:92415225	chr7:92134604~92180725:+
LUAD	cis	rs2115630	0.967	rs11073731	ENSG00000259728.4	LINC00933	-3.53	0.00046	0.0481	-0.19	-0.16	P wave terminal force;	chr15:84811882	chr15:84570649~84580175:+
LUAD	cis	rs7119	0.604	rs2271396	ENSG00000259362.2	RP11-307C19.1	3.53	0.00046	0.0481	0.19	0.16	Type 2 diabetes;	chr15:77615193	chr15:77525540~77534110:+
LUAD	cis	rs16846053	0.71	rs11891120	ENSG00000227403.1	AC009299.3	-3.53	0.00046	0.0481	-0.27	-0.16	Blood osmolality (transformed sodium);	chr2:161795748	chr2:161244739~161249050:+
LUAD	cis	rs739496	0.527	rs11066079	ENSG00000234608.6	MAPKAPK5-AS1	3.53	0.00046	0.0481	0.17	0.16	Platelet count;	chr12:111912599	chr12:111839764~111842902:-
LUAD	cis	rs17596685	0.932	rs1021188	ENSG00000271216.1	LINC01050	3.53	0.00046	0.0481	0.24	0.16	C-reactive protein levels;	chr13:42541997	chr13:42810366~42812562:-
LUAD	cis	rs7845219	0.51	rs10113282	ENSG00000253528.2	RP11-347C18.4	3.53	0.00046	0.0481	0.16	0.16	Type 2 diabetes;	chr8:95026024	chr8:94974573~94974853:-
LUAD	cis	rs7061710	0.871	rs7063044	ENSG00000231424.2	RP1-45C12.1	-3.53	0.00046	0.0481	-0.21	-0.16	Blood metabolite levels;	chr1:171147621	chr1:171247580~171251794:-
LUAD	cis	rs74233809	0.591	rs284853	ENSG00000213277.3	MARCKSL1P1	-3.53	0.00046	0.0481	-0.22	-0.16	Birth weight;	chr10:102814885	chr10:103175554~103176094:+
LUAD	cis	rs3018066	0.748	rs12509366	ENSG00000251259.1	AC004069.2	-3.53	0.00046	0.0481	-0.19	-0.16	Cancer;	chr4:106082186	chr4:105137280~105140619:-
LUAD	cis	rs3018066	0.72	rs7662592	ENSG00000251259.1	AC004069.2	-3.53	0.00046	0.0481	-0.19	-0.16	Cancer;	chr4:106082922	chr4:105137280~105140619:-
LUAD	cis	rs4239252	0.929	rs4796116	ENSG00000270977.1	AC015849.16	-3.53	0.00046	0.0481	-0.21	-0.16	Blood protein levels;	chr17:35841496	chr17:35893707~35911023:-
LUAD	cis	rs915286	0.664	rs7332788	ENSG00000229473.2	RGS17P1	-3.53	0.00046	0.0481	-0.2	-0.16	Crohn's disease;Inflammatory bowel disease;	chr13:40129376	chr13:40992779~40993331:-
LUAD	cis	rs9549260	0.709	rs2721072	ENSG00000229456.1	RLIMP1	3.53	0.00046	0.0481	0.17	0.16	Red blood cell count;	chr13:40570782	chr13:40618738~40621348:+
LUAD	cis	rs2554380	0.8	rs2562768	ENSG00000259570.1	RP11-671M22.4	-3.53	0.00046	0.0481	-0.22	-0.16	Height;	chr15:83714201	chr15:84394512~84395514:+
LUAD	cis	rs1710990	1	rs1275417	ENSG00000259165.1	DDX18P1	3.53	0.00046	0.0481	0.19	0.16	Intelligence (multi-trait analysis);	chr14:69150998	chr14:69083398~69085389:+
LUAD	cis	rs2765539	0.701	rs12068932	ENSG00000231365.4	RP11-418J17.1	-3.53	0.00046	0.0481	-0.22	-0.16	Waist-hip ratio;	chr1:119113057	chr1:119140396~119275973:+
LUAD	cis	rs6743068	0.541	rs6714736	ENSG00000234842.1	AC007163.8	3.53	0.00046	0.0481	0.18	0.16	Lymphocyte percentage of white cells;	chr2:201349425	chr2:201549631~201550307:+
LUAD	cis	rs6724465	0.714	rs72951802	ENSG00000272644.1	RP11-33O4.1	3.53	0.00046	0.0481	0.24	0.16	Height;	chr2:219141408	chr2:219069354~219069809:-
LUAD	cis	rs9341808	0.905	rs3805903	ENSG00000272129.1	RP11-250B2.6	3.53	0.00046	0.0481	0.19	0.16	Sitting height ratio;	chr6:80266112	chr6:80355424~80356859:+
LUAD	cis	rs34779708	0.931	rs35317849	ENSG00000271335.4	RP11-324I22.4	3.53	0.00046	0.0481	0.17	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:34996793	chr10:35314552~35336401:-
LUAD	cis	rs11123406	0.501	rs10864954	ENSG00000227992.1	AC108463.2	-3.53	0.00046	0.0482	-0.22	-0.16	Type 2 diabetes;	chr2:111209370	chr2:111203964~111206215:-
LUAD	cis	rs10109025	0.67	rs7825690	ENSG00000255046.1	RP11-297N6.4	3.53	0.000461	0.0482	0.2	0.16	Joint mobility (Beighton score);	chr8:11000747	chr8:11797928~11802568:-
LUAD	cis	rs10851411	0.862	rs1060291	ENSG00000261002.4	RP11-546B15.1	3.53	0.000461	0.0482	0.14	0.16	Glucose homeostasis traits;	chr15:42528391	chr15:42208413~42226990:+
LUAD	cis	rs875971	0.545	rs7811204	ENSG00000224316.1	RP11-479O9.2	3.53	0.000461	0.0482	0.19	0.16	Aortic root size;	chr7:66387213	chr7:65773620~65802067:+
LUAD	cis	rs7560272	0.501	rs17350188	ENSG00000163016.8	ALMS1P	3.53	0.000461	0.0482	0.17	0.16	Schizophrenia;	chr2:73737715	chr2:73644919~73685576:+
LUAD	cis	rs853679	0.657	rs1778483	ENSG00000168126.3	OR2W6P	3.53	0.000461	0.0482	0.18	0.16	Depression;	chr6:28273214	chr6:27937465~27938403:+
LUAD	cis	rs853679	0.657	rs1778482	ENSG00000168126.3	OR2W6P	3.53	0.000461	0.0482	0.18	0.16	Depression;	chr6:28273215	chr6:27937465~27938403:+
LUAD	cis	rs4835473	0.932	rs6851999	ENSG00000249741.2	RP11-673E1.3	-3.53	0.000461	0.0482	-0.19	-0.16	Immature fraction of reticulocytes;	chr4:143742567	chr4:143911514~143912053:-
LUAD	cis	rs9400467	0.528	rs10872067	ENSG00000266032.1	AL357515.1	3.53	0.000461	0.0482	0.2	0.16	Amino acid levels;Blood metabolite levels;	chr6:111467188	chr6:110969773~110969872:-
LUAD	cis	rs1910358	0.69	rs951856	ENSG00000248874.4	C5orf17	-3.53	0.000461	0.0482	-0.21	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23976614	chr5:23951348~24178263:+
LUAD	cis	rs1910358	0.664	rs951855	ENSG00000248874.4	C5orf17	-3.53	0.000461	0.0482	-0.21	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23976864	chr5:23951348~24178263:+
LUAD	cis	rs1799949	1	rs4793189	ENSG00000267340.1	RP11-242D8.3	3.53	0.000461	0.0482	0.17	0.16	Menopause (age at onset);	chr17:43038698	chr17:43169880~43170077:-
LUAD	cis	rs1799949	1	rs11657053	ENSG00000267340.1	RP11-242D8.3	3.53	0.000461	0.0482	0.17	0.16	Menopause (age at onset);	chr17:43039112	chr17:43169880~43170077:-
LUAD	cis	rs6964587	0.655	rs6465351	ENSG00000188693.7	CYP51A1-AS1	-3.53	0.000461	0.0482	-0.18	-0.16	Breast cancer;	chr7:92143899	chr7:92134604~92180725:+
LUAD	cis	rs6964587	0.692	rs7807490	ENSG00000188693.7	CYP51A1-AS1	-3.53	0.000461	0.0482	-0.18	-0.16	Breast cancer;	chr7:92144045	chr7:92134604~92180725:+
LUAD	cis	rs4561483	0.801	rs33643	ENSG00000261216.1	RP11-166B2.5	-3.53	0.000461	0.0482	-0.16	-0.16	Testicular germ cell tumor;	chr16:11892292	chr16:11908208~11908916:+
LUAD	cis	rs67981189	0.593	rs8007425	ENSG00000269927.1	RP6-91H8.3	3.53	0.000461	0.0482	0.19	0.16	Schizophrenia;	chr14:71041483	chr14:71141125~71143253:-
LUAD	cis	rs9910055	0.529	rs615070	ENSG00000267080.4	ASB16-AS1	-3.53	0.000461	0.0482	-0.15	-0.16	Total body bone mineral density;	chr17:44099223	chr17:44175973~44186717:-
LUAD	cis	rs1823913	0.637	rs4853579	ENSG00000230611.1	HMGB1P27	3.53	0.000461	0.0482	0.18	0.16	Obesity-related traits;	chr2:191297413	chr2:191174233~191174835:+
LUAD	cis	rs1497546	0.867	rs61196885	ENSG00000206712.1	RNU6-26P	-3.53	0.000461	0.0482	-0.35	-0.16	Drug-induced liver injury (flucloxacillin);	chr3:98284735	chr3:98804978~98805084:-
LUAD	cis	rs10129255	0.518	rs2006284	ENSG00000232216.1	IGHV3-43	3.53	0.000461	0.0482	0.13	0.16	Kawasaki disease;	chr14:106676185	chr14:106470264~106470800:-
LUAD	cis	rs6095360	0.966	rs6019545	ENSG00000222365.1	SNORD12B	-3.53	0.000461	0.0482	-0.16	-0.16	Intelligence (multi-trait analysis);	chr20:48940477	chr20:49280319~49280409:+
LUAD	cis	rs412050	0.744	rs238781	ENSG00000224086.5	LL22NC03-86G7.1	-3.53	0.000461	0.0482	-0.2	-0.16	Attention deficit hyperactivity disorder;	chr22:21987474	chr22:21938293~21977632:+
LUAD	cis	rs11853189	0.938	rs16969705	ENSG00000259562.2	RP11-762H8.2	3.53	0.000461	0.0482	0.18	0.16	Red cell distribution width;	chr15:78301020	chr15:78290527~78291221:-
LUAD	cis	rs683250	0.661	rs2510471	ENSG00000246067.6	RAB30-AS1	-3.53	0.000461	0.0482	-0.17	-0.16	Subcortical brain region volumes;	chr11:83425074	chr11:83072066~83106719:+
LUAD	cis	rs838147	0.537	rs504963	ENSG00000232871.7	SEC1P	3.53	0.000461	0.0482	0.17	0.16	Dietary macronutrient intake;	chr19:48705608	chr19:48638071~48682245:+
LUAD	cis	rs17596685	1	rs9533161	ENSG00000271216.1	LINC01050	3.53	0.000461	0.0482	0.23	0.16	C-reactive protein levels;	chr13:42581696	chr13:42810366~42812562:-
LUAD	cis	rs17596685	1	rs1536237	ENSG00000271216.1	LINC01050	3.53	0.000461	0.0482	0.23	0.16	C-reactive protein levels;	chr13:42583131	chr13:42810366~42812562:-
LUAD	cis	rs4819052	0.851	rs34101026	ENSG00000215447.6	BX322557.10	-3.53	0.000461	0.0482	-0.19	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242285	chr21:45288052~45291738:+
LUAD	cis	rs4819052	0.851	rs13052312	ENSG00000215447.6	BX322557.10	-3.53	0.000461	0.0482	-0.19	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242444	chr21:45288052~45291738:+
LUAD	cis	rs4819052	0.851	rs2838828	ENSG00000215447.6	BX322557.10	-3.53	0.000461	0.0482	-0.19	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243508	chr21:45288052~45291738:+
LUAD	cis	rs4819052	0.851	rs13049337	ENSG00000215447.6	BX322557.10	-3.53	0.000461	0.0482	-0.19	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243545	chr21:45288052~45291738:+
LUAD	cis	rs1044826	1	rs13085888	ENSG00000214280.3	RP11-553K23.2	3.53	0.000461	0.0482	0.18	0.16	Obesity-related traits;	chr3:139446032	chr3:139582928~139583593:-
LUAD	cis	rs7772486	0.875	rs10457796	ENSG00000235652.6	RP11-545I5.3	3.53	0.000461	0.0482	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:146094951	chr6:145799409~145886585:+
LUAD	cis	rs12368653	0.591	rs1552842	ENSG00000245651.2	RP11-620J15.2	3.53	0.000461	0.0482	0.16	0.16	Multiple sclerosis;	chr12:57618380	chr12:57869835~57896482:-
LUAD	cis	rs6728302	0.655	rs882098	ENSG00000223198.1	RNU2-22P	3.53	0.000461	0.0482	0.32	0.16	Height;	chr2:232244147	chr2:231501990~231502201:-
LUAD	cis	rs2274273	0.934	rs10137307	ENSG00000258413.1	RP11-665C16.6	-3.53	0.000461	0.0482	-0.21	-0.16	Protein biomarker;	chr14:55378467	chr14:55262767~55272075:-
LUAD	cis	rs8085804	0.584	rs1954958	ENSG00000276174.1	RP11-687E1.2	-3.53	0.000461	0.0482	-0.21	-0.16	Cognitive performance;	chr18:42693994	chr18:42052705~42053030:+
LUAD	cis	rs7178424	1	rs8038932	ENSG00000259251.2	RP11-643M14.1	-3.53	0.000461	0.0482	-0.16	-0.16	Height;	chr15:62072058	chr15:62060503~62062434:+
LUAD	cis	rs6120849	0.707	rs6120826	ENSG00000202150.1	RNU6-407P	3.53	0.000461	0.0482	0.22	0.16	Protein C levels;	chr20:35084028	chr20:35030317~35030420:-
LUAD	cis	rs7503168	0.643	rs17676508	ENSG00000267592.1	CTC-507E2.2	3.53	0.000461	0.0482	0.34	0.16	Plateletcrit;	chr17:35693589	chr17:35596904~35597128:-
LUAD	cis	rs73990293	0.531	rs74324437	ENSG00000267592.1	CTC-507E2.2	3.53	0.000461	0.0482	0.34	0.16	Clopidogrel active metabolite levels;	chr17:35712668	chr17:35596904~35597128:-
LUAD	cis	rs2115630	0.645	rs4842978	ENSG00000275120.1	RP11-182J1.17	-3.53	0.000461	0.0482	-0.21	-0.16	P wave terminal force;	chr15:84654022	chr15:84599434~84606463:-
LUAD	cis	rs11742741	0.806	rs62349718	ENSG00000248874.4	C5orf17	-3.53	0.000461	0.0482	-0.2	-0.16	Educational attainment;	chr5:24046398	chr5:23951348~24178263:+
LUAD	cis	rs740698	0.529	rs9895414	ENSG00000265702.1	RP11-156L14.1	-3.53	0.000461	0.0482	-0.19	-0.16	Pulse pressure;	chr17:62716038	chr17:62699244~62737922:+
LUAD	cis	rs6901152	0.525	rs1345993	ENSG00000227192.1	RP1-45I4.3	-3.53	0.000461	0.0482	-0.2	-0.16	Acute lymphoblastic leukemia (childhood);	chr6:143370437	chr6:143039425~143042324:-
LUAD	cis	rs3109133	0.565	rs3115025	ENSG00000226953.6	AC010890.1	3.53	0.000461	0.0482	0.17	0.16	Calcium levels;	chr2:132547066	chr2:133264968~133284762:+
LUAD	cis	rs10129255	0.957	rs1024349	ENSG00000211967.3	IGHV3-53	-3.53	0.000461	0.0482	-0.12	-0.16	Kawasaki disease;	chr14:106689997	chr14:106592676~106593347:-
LUAD	cis	rs11951515	0.738	rs4866825	ENSG00000249779.1	RP11-447H19.3	-3.53	0.000461	0.0482	-0.19	-0.16	Metabolite levels  (X-11787);	chr5:43359517	chr5:43206709~43207811:+
LUAD	cis	rs11951515	0.738	rs59814709	ENSG00000249779.1	RP11-447H19.3	-3.53	0.000461	0.0482	-0.19	-0.16	Metabolite levels  (X-11787);	chr5:43359992	chr5:43206709~43207811:+
LUAD	cis	rs10197140	0.925	rs932078	ENSG00000227992.1	AC108463.2	3.53	0.000462	0.0482	0.19	0.16	Red blood cell count;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr2:110863376	chr2:111203964~111206215:-
LUAD	cis	rs7260598	0.642	rs73023276	ENSG00000269421.1	ZNF92P3	-3.53	0.000462	0.0482	-0.25	-0.16	Response to taxane treatment (placlitaxel);	chr19:23976045	chr19:23935220~23936173:+
LUAD	cis	rs6951245	0.935	rs112554101	ENSG00000229043.2	AC091729.9	-3.53	0.000462	0.0482	-0.23	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1025899	chr7:1160374~1165267:+
LUAD	cis	rs11846409	0.932	rs60659763	ENSG00000211972.2	IGHV3-66	3.53	0.000462	0.0482	0.16	0.16	Rheumatic heart disease;	chr14:106634172	chr14:106675017~106675544:-
LUAD	cis	rs11846409	0.932	rs57080270	ENSG00000211972.2	IGHV3-66	3.53	0.000462	0.0482	0.16	0.16	Rheumatic heart disease;	chr14:106634215	chr14:106675017~106675544:-
LUAD	cis	rs11846409	0.932	rs60917084	ENSG00000211972.2	IGHV3-66	3.53	0.000462	0.0482	0.16	0.16	Rheumatic heart disease;	chr14:106634621	chr14:106675017~106675544:-
LUAD	cis	rs1198430	0.562	rs7523811	ENSG00000232482.2	RP4-654C18.1	3.53	0.000462	0.0483	0.21	0.16	Total cholesterol levels;	chr1:23463074	chr1:23410832~23412146:+
LUAD	cis	rs4927850	0.881	rs7630489	ENSG00000278820.1	AC024937.1	3.53	0.000462	0.0483	0.14	0.16	Pancreatic cancer;	chr3:196026530	chr3:195960500~195960612:-
LUAD	cis	rs1598856	1	rs1598856	ENSG00000246560.2	RP11-10L12.4	3.53	0.000462	0.0483	0.2	0.16	Primary biliary cholangitis;	chr4:102524958	chr4:102828055~102844075:+
LUAD	cis	rs1075265	0.729	rs7571086	ENSG00000272156.1	RP11-477N3.1	-3.53	0.000462	0.0483	-0.19	-0.16	Chronotype;Morning vs. evening chronotype;	chr2:54007899	chr2:54082554~54085066:+
LUAD	cis	rs8056893	0.714	rs9931501	ENSG00000260441.4	RP11-96D1.7	-3.53	0.000462	0.0483	-0.18	-0.16	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68368783	chr16:68256162~68260443:-
LUAD	cis	rs7674212	0.556	rs34475639	ENSG00000230069.3	LRRC37A15P	-3.53	0.000462	0.0483	-0.17	-0.16	Type 2 diabetes;	chr4:103033694	chr4:102727274~102730721:-
LUAD	cis	rs6496932	0.802	rs6497006	ENSG00000259630.2	CTD-2262B20.1	3.53	0.000462	0.0483	0.2	0.16	Central corneal thickness;Corneal structure;	chr15:85330306	chr15:85415228~85415633:+
LUAD	cis	rs9457247	0.967	rs387733	ENSG00000227598.1	RP1-167A14.2	3.53	0.000462	0.0483	0.17	0.16	Crohn's disease;	chr6:166996283	chr6:166969626~166999065:-
LUAD	cis	rs11955398	0.502	rs290514	ENSG00000272308.1	RP11-231G3.1	-3.53	0.000462	0.0483	-0.19	-0.16	Intelligence (multi-trait analysis);	chr5:60934494	chr5:60866457~60866935:-
LUAD	cis	rs4660214	0.724	rs11205695	ENSG00000182109.6	RP11-69E11.4	-3.53	0.000462	0.0483	-0.17	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39155285	chr1:39522280~39546187:-
LUAD	cis	rs7615952	0.576	rs2276726	ENSG00000250012.1	RP11-124N2.1	-3.53	0.000462	0.0483	-0.21	-0.16	Blood pressure (smoking interaction);	chr3:126107444	chr3:126084220~126095349:+
LUAD	cis	rs975752	1	rs975752	ENSG00000227492.1	RP11-316M21.6	3.53	0.000462	0.0483	0.25	0.16	Schizophrenia;	chr10:100146576	chr10:100229667~100234000:+
LUAD	cis	rs11603020	0.95	rs28362947	ENSG00000255299.4	RP11-655C2.3	-3.53	0.000462	0.0483	-0.19	-0.16	Blood protein levels;	chr11:57601535	chr11:58497888~58505758:-
LUAD	cis	rs11603020	0.95	rs28362948	ENSG00000255299.4	RP11-655C2.3	-3.53	0.000462	0.0483	-0.19	-0.16	Blood protein levels;	chr11:57601540	chr11:58497888~58505758:-
LUAD	cis	rs13113518	0.812	rs4864996	ENSG00000249700.7	SRD5A3-AS1	3.53	0.000462	0.0483	0.17	0.16	Height;	chr4:55452921	chr4:55363971~55395847:-
LUAD	cis	rs13014235	0.532	rs3731709	ENSG00000213090.2	AC007256.5	3.53	0.000462	0.0483	0.18	0.16	Basal cell carcinoma;	chr2:201381311	chr2:201410544~201413308:-
LUAD	cis	rs6988985	0.703	rs6988323	ENSG00000247317.3	RP11-273G15.2	-3.53	0.000462	0.0483	-0.18	-0.16	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;	chr8:142865067	chr8:142981738~143018437:-
LUAD	cis	rs586688	0.625	rs601757	ENSG00000249007.1	RP11-510N19.5	-3.53	0.000462	0.0483	-0.18	-0.16	Obesity-related traits;	chr1:201688380	chr1:202011370~202015657:+
LUAD	cis	rs4700393	0.517	rs12516248	ENSG00000272308.1	RP11-231G3.1	3.53	0.000462	0.0483	0.2	0.16	Intelligence (multi-trait analysis);	chr5:60835824	chr5:60866457~60866935:-
LUAD	cis	rs6688613	0.685	rs10918600	ENSG00000225171.2	DUTP6	3.53	0.000462	0.0483	0.19	0.16	Refractive astigmatism;	chr1:166950105	chr1:166868748~166869209:+
LUAD	cis	rs6754311	0.773	rs4988183	ENSG00000226806.1	AC011893.3	3.53	0.000462	0.0483	0.2	0.16	Mosquito bite size;	chr2:135864476	chr2:135820191~135823087:+
LUAD	cis	rs2281603	0.57	rs28766386	ENSG00000259116.1	RP11-973N13.4	-3.53	0.000462	0.0483	-0.13	-0.16	Lymphocyte counts;	chr14:64479679	chr14:64514154~64540368:-
LUAD	cis	rs12499086	0.607	rs1076215	ENSG00000249635.1	RP11-710F7.3	-3.53	0.000462	0.0483	-0.17	-0.16	Economic and political preferences (time);	chr4:105491094	chr4:106003317~106022478:-
LUAD	cis	rs2489715	0.723	rs2801942	ENSG00000273008.1	RP11-351D16.3	-3.53	0.000462	0.0483	-0.2	-0.16	Helix rolling;	chr10:42443920	chr10:43136824~43138334:-
LUAD	cis	rs9426935	0.687	rs10494303	ENSG00000272030.1	RP1-178F15.4	-3.53	0.000463	0.0483	-0.15	-0.16	Lentiform nucleus volume;	chr1:153920547	chr1:153631438~153634397:-
LUAD	cis	rs1799949	0.501	rs9675035	ENSG00000267340.1	RP11-242D8.3	3.53	0.000463	0.0483	0.17	0.16	Menopause (age at onset);	chr17:43337648	chr17:43169880~43170077:-
LUAD	cis	rs12681366	0.537	rs2919659	ENSG00000253704.1	RP11-267M23.4	3.53	0.000463	0.0483	0.19	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94459544	chr8:94553722~94569745:+
LUAD	cis	rs12681366	0.537	rs2919656	ENSG00000253704.1	RP11-267M23.4	3.53	0.000463	0.0483	0.19	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94460806	chr8:94553722~94569745:+
LUAD	cis	rs12681366	0.537	rs3019284	ENSG00000253704.1	RP11-267M23.4	3.53	0.000463	0.0483	0.19	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94460848	chr8:94553722~94569745:+
LUAD	cis	rs13113518	1	rs6822740	ENSG00000223305.1	RN7SKP30	3.53	0.000463	0.0483	0.18	0.16	Height;	chr4:55518922	chr4:55540502~55540835:-
LUAD	cis	rs6687758	0.732	rs72740077	ENSG00000238042.4	RP11-815M8.1	3.53	0.000463	0.0483	0.22	0.16	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221940827	chr1:221880981~221978523:-
LUAD	cis	rs9549260	0.569	rs7328453	ENSG00000168852.11	TPTE2P5	3.53	0.000463	0.0483	0.21	0.16	Red blood cell count;	chr13:40760191	chr13:40822296~40921749:-
LUAD	cis	rs6951245	0.638	rs74976697	ENSG00000226291.1	AC091729.8	-3.53	0.000463	0.0483	-0.26	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1120869	chr7:1080863~1082178:+
LUAD	cis	rs786425	0.77	rs7313261	ENSG00000278112.1	RP11-972P1.11	3.53	0.000463	0.0483	0.15	0.16	Pubertal anthropometrics;	chr12:123682390	chr12:123519390~123519856:-
LUAD	cis	rs13021401	1	rs342091	ENSG00000228950.1	AC023137.2	3.53	0.000463	0.0484	0.18	0.16	Systemic sclerosis;	chr2:20498325	chr2:20451042~20452947:+
LUAD	cis	rs10129255	0.5	rs1974468	ENSG00000211955.2	IGHV3-33	-3.53	0.000463	0.0484	-0.11	-0.16	Kawasaki disease;	chr14:106686149	chr14:106359793~106360324:-
LUAD	cis	rs5762752	0.528	rs695796	ENSG00000272858.1	CTA-292E10.8	-3.53	0.000463	0.0484	-0.18	-0.16	Optic disc area;	chr22:28473444	chr22:28814914~28815662:+
LUAD	cis	rs34779708	0.931	rs11597483	ENSG00000271335.4	RP11-324I22.4	3.53	0.000463	0.0484	0.17	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:34996189	chr10:35314552~35336401:-
LUAD	cis	rs7142881	0.815	rs11625312	ENSG00000258525.1	RP11-829H16.3	-3.53	0.000463	0.0484	-0.18	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31614856	chr14:30876179~30889808:-
LUAD	cis	rs13113518	0.966	rs7677952	ENSG00000249700.7	SRD5A3-AS1	3.53	0.000463	0.0484	0.16	0.16	Height;	chr4:55425312	chr4:55363971~55395847:-
LUAD	cis	rs7017914	0.967	rs2732087	ENSG00000246366.5	RP11-382J12.1	3.53	0.000463	0.0484	0.15	0.16	Bone mineral density;	chr8:70948204	chr8:70608577~70663279:+
LUAD	cis	rs755249	1	rs2293476	ENSG00000237624.1	OXCT2P1	-3.53	0.000463	0.0484	-0.24	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39571175	chr1:39514956~39516490:+
LUAD	cis	rs123509	0.913	rs123506	ENSG00000173811.9	CCDC13-AS1	3.53	0.000463	0.0484	0.2	0.16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr3:42734484	chr3:42732575~42746768:+
LUAD	cis	rs9860428	0.844	rs10804505	ENSG00000242770.2	RP11-180K7.1	-3.53	0.000463	0.0484	-0.17	-0.16	Rheumatoid arthritis;Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive);	chr3:112855409	chr3:112802478~112812819:+
LUAD	cis	rs7618915	0.524	rs12488461	ENSG00000243224.1	RP5-1157M23.2	-3.53	0.000463	0.0484	-0.16	-0.16	Bipolar disorder;	chr3:52664401	chr3:52239258~52241097:+
LUAD	cis	rs7618915	0.547	rs6768697	ENSG00000243224.1	RP5-1157M23.2	-3.53	0.000463	0.0484	-0.16	-0.16	Bipolar disorder;	chr3:52669599	chr3:52239258~52241097:+
LUAD	cis	rs7618915	0.547	rs34610142	ENSG00000243224.1	RP5-1157M23.2	-3.53	0.000463	0.0484	-0.16	-0.16	Bipolar disorder;	chr3:52674413	chr3:52239258~52241097:+
LUAD	cis	rs7618915	0.547	rs12496476	ENSG00000243224.1	RP5-1157M23.2	-3.53	0.000463	0.0484	-0.16	-0.16	Bipolar disorder;	chr3:52674721	chr3:52239258~52241097:+
LUAD	cis	rs17653445	1	rs17653445	ENSG00000151963.4	RP11-775A3.1	-3.53	0.000463	0.0484	-0.26	-0.16	Hirschsprung disease;	chr10:37546726	chr10:37883594~37884109:+
LUAD	cis	rs4578769	0.55	rs930909	ENSG00000266850.1	RP11-370A5.1	3.53	0.000463	0.0484	0.2	0.16	Eosinophil percentage of white cells;	chr18:22976361	chr18:22723491~22907721:-
LUAD	cis	rs8014204	1	rs8014374	ENSG00000279594.1	RP11-950C14.10	-3.53	0.000463	0.0484	-0.18	-0.16	Caffeine consumption;	chr14:74856211	chr14:75011269~75012851:-
LUAD	cis	rs6743068	0.522	rs7597617	ENSG00000234842.1	AC007163.8	-3.53	0.000463	0.0484	-0.18	-0.16	Lymphocyte percentage of white cells;	chr2:201338512	chr2:201549631~201550307:+
LUAD	cis	rs950881	0.799	rs72823669	ENSG00000234389.1	AC007278.3	3.53	0.000463	0.0484	0.2	0.16	Allergy;	chr2:102365573	chr2:102438713~102440475:+
LUAD	cis	rs2731006	1	rs2731006	ENSG00000257114.2	RP11-25I15.3	-3.53	0.000463	0.0484	-0.24	-0.16	Panic disorder;	chr12:42767023	chr12:42692216~42717119:+
LUAD	cis	rs4908768	0.911	rs79769442	ENSG00000232912.4	RP5-1115A15.1	-3.53	0.000463	0.0484	-0.19	-0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8598418	chr1:8424645~8434838:+
LUAD	cis	rs6832769	0.925	rs4371676	ENSG00000272969.1	RP11-528I4.2	3.53	0.000463	0.0484	0.17	0.16	Personality dimensions;	chr4:55462841	chr4:55547112~55547889:+
LUAD	cis	rs6832769	1	rs4864998	ENSG00000272969.1	RP11-528I4.2	3.53	0.000463	0.0484	0.17	0.16	Personality dimensions;	chr4:55466439	chr4:55547112~55547889:+
LUAD	cis	rs6832769	0.961	rs2140077	ENSG00000272969.1	RP11-528I4.2	3.53	0.000463	0.0484	0.17	0.16	Personality dimensions;	chr4:55472786	chr4:55547112~55547889:+
LUAD	cis	rs10911232	0.507	rs4266836	ENSG00000224468.3	RP11-181K3.4	-3.53	0.000463	0.0484	-0.14	-0.16	Hypertriglyceridemia;	chr1:183059935	chr1:183138402~183141282:-
LUAD	cis	rs9900280	1	rs576426	ENSG00000264808.1	RP11-802D6.1	-3.53	0.000464	0.0484	-0.18	-0.16	Mean platelet volume;	chr17:29523184	chr17:29369717~29390777:-
LUAD	cis	rs10392	0.543	rs56660421	ENSG00000274825.1	RP4-616B8.5	-3.53	0.000464	0.0484	-0.2	-0.16	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;	chr20:38930686	chr20:38955910~38956547:+
LUAD	cis	rs6840360	1	rs17360475	ENSG00000270265.1	RP11-731D1.4	3.53	0.000464	0.0484	0.16	0.16	Intelligence (multi-trait analysis);	chr4:151750488	chr4:151333775~151353224:-
LUAD	cis	rs11105298	0.891	rs8181784	ENSG00000270344.2	RP11-734K2.4	3.53	0.000464	0.0484	0.19	0.16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89434814	chr12:89525654~89548005:+
LUAD	cis	rs9952991	0.566	rs482160	ENSG00000260302.1	RP11-973H7.1	-3.53	0.000464	0.0484	-0.27	-0.16	Inflammatory skin disease;	chr18:12855647	chr18:12774651~12775923:-
LUAD	cis	rs12887734	0.546	rs12886637	ENSG00000258914.1	CTD-2134A5.3	3.53	0.000464	0.0484	0.19	0.16	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr14:103756555	chr14:103875055~103877478:+
LUAD	cis	rs11018904	0.906	rs12793836	ENSG00000280367.1	RP11-121L10.2	3.53	0.000464	0.0484	0.2	0.16	Intelligence (multi-trait analysis);	chr11:90220325	chr11:90223153~90226538:+
LUAD	cis	rs7474896	0.526	rs1208633	ENSG00000226578.1	RP11-258F22.1	3.53	0.000464	0.0484	0.22	0.16	Obesity (extreme);	chr10:37867945	chr10:37775371~37784131:-
LUAD	cis	rs7474896	0.559	rs1779075	ENSG00000226578.1	RP11-258F22.1	3.53	0.000464	0.0484	0.22	0.16	Obesity (extreme);	chr10:37878602	chr10:37775371~37784131:-
LUAD	cis	rs7474896	0.559	rs2753880	ENSG00000226578.1	RP11-258F22.1	3.53	0.000464	0.0484	0.22	0.16	Obesity (extreme);	chr10:37884410	chr10:37775371~37784131:-
LUAD	cis	rs875971	0.928	rs2036263	ENSG00000273448.1	RP11-166O4.6	-3.53	0.000464	0.0484	-0.15	-0.16	Aortic root size;	chr7:66335210	chr7:67333047~67334383:+
LUAD	cis	rs875971	0.862	rs10240949	ENSG00000273448.1	RP11-166O4.6	-3.53	0.000464	0.0484	-0.15	-0.16	Aortic root size;	chr7:66339430	chr7:67333047~67334383:+
LUAD	cis	rs875971	0.862	rs7782704	ENSG00000273448.1	RP11-166O4.6	-3.53	0.000464	0.0484	-0.15	-0.16	Aortic root size;	chr7:66340379	chr7:67333047~67334383:+
LUAD	cis	rs875971	0.862	rs6959268	ENSG00000273448.1	RP11-166O4.6	-3.53	0.000464	0.0484	-0.15	-0.16	Aortic root size;	chr7:66347979	chr7:67333047~67334383:+
LUAD	cis	rs2071518	1	rs1461691	ENSG00000254343.2	RP11-760H22.2	-3.53	0.000464	0.0484	-0.19	-0.16	Blood pressure;Pulse pressure;	chr8:119428576	chr8:120052180~120056201:+
LUAD	cis	rs137603	0.603	rs137581	ENSG00000225450.1	RP3-508I15.14	-3.53	0.000464	0.0484	-0.14	-0.16	Primary biliary cholangitis;	chr22:39281833	chr22:38739003~38749041:+
LUAD	cis	rs875971	0.522	rs1880556	ENSG00000234585.5	CCT6P3	3.53	0.000464	0.0484	0.15	0.16	Aortic root size;	chr7:65967557	chr7:65038354~65074713:+
LUAD	cis	rs4386084	1	rs35132544	ENSG00000242737.1	RP11-562A8.1	-3.53	0.000464	0.0484	-0.21	-0.16	Basophil percentage of granulocytes;Basophil percentage of white cells;	chr15:49939176	chr15:50466738~50467096:+
LUAD	cis	rs6736093	0.966	rs3811633	ENSG00000207383.1	Y_RNA	-3.53	0.000464	0.0484	-0.2	-0.16	Coronary artery disease;	chr2:111997303	chr2:112579484~112579584:-
LUAD	cis	rs6736093	0.966	rs3811634	ENSG00000207383.1	Y_RNA	-3.53	0.000464	0.0484	-0.2	-0.16	Coronary artery disease;	chr2:111997366	chr2:112579484~112579584:-
LUAD	cis	rs6736093	0.966	rs34527376	ENSG00000207383.1	Y_RNA	-3.53	0.000464	0.0484	-0.2	-0.16	Coronary artery disease;	chr2:111998122	chr2:112579484~112579584:-
LUAD	cis	rs449789	0.524	rs1553480	ENSG00000235086.1	FNDC1-IT1	-3.53	0.000464	0.0484	-0.22	-0.16	Pulse pressure;	chr6:159321564	chr6:159240786~159243329:+
LUAD	cis	rs2115630	0.645	rs6496284	ENSG00000259728.4	LINC00933	-3.53	0.000464	0.0484	-0.2	-0.16	P wave terminal force;	chr15:84635039	chr15:84570649~84580175:+
LUAD	cis	rs651386	0.529	rs2206063	ENSG00000271811.1	RP1-79C4.4	-3.53	0.000464	0.0484	-0.2	-0.16	Atrial fibrillation;	chr1:170615956	chr1:170667381~170669425:+
LUAD	cis	rs910316	0.763	rs175450	ENSG00000279594.1	RP11-950C14.10	-3.53	0.000464	0.0484	-0.18	-0.16	Height;	chr14:75123637	chr14:75011269~75012851:-
LUAD	cis	rs62246343	0.719	rs73115804	ENSG00000206573.7	THUMPD3-AS1	-3.52	0.000464	0.0485	-0.17	-0.16	Fibrinogen levels;	chr3:9399858	chr3:9349689~9398579:-
LUAD	cis	rs62246343	0.719	rs62246276	ENSG00000206573.7	THUMPD3-AS1	-3.52	0.000464	0.0485	-0.17	-0.16	Fibrinogen levels;	chr3:9403489	chr3:9349689~9398579:-
LUAD	cis	rs7260598	0.792	rs73021416	ENSG00000268442.1	CTD-2027I19.2	3.52	0.000464	0.0485	0.24	0.16	Response to taxane treatment (placlitaxel);	chr19:24081849	chr19:24162370~24163425:-
LUAD	cis	rs7260598	0.685	rs73021422	ENSG00000268442.1	CTD-2027I19.2	3.52	0.000464	0.0485	0.24	0.16	Response to taxane treatment (placlitaxel);	chr19:24082919	chr19:24162370~24163425:-
LUAD	cis	rs6494488	0.5	rs72742999	ENSG00000239465.1	RP11-330L19.2	3.52	0.000464	0.0485	0.34	0.16	Coronary artery disease;	chr15:64718311	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs72743002	ENSG00000239465.1	RP11-330L19.2	3.52	0.000464	0.0485	0.34	0.16	Coronary artery disease;	chr15:64718996	chr15:64631109~64631914:-
LUAD	cis	rs6494488	0.5	rs72744704	ENSG00000239465.1	RP11-330L19.2	3.52	0.000464	0.0485	0.34	0.16	Coronary artery disease;	chr15:64719308	chr15:64631109~64631914:-
LUAD	cis	rs7916697	0.52	rs10762201	ENSG00000233590.1	RP11-153K11.3	3.52	0.000464	0.0485	0.19	0.16	Optic disc area;	chr10:68280354	chr10:68233251~68242379:-
LUAD	cis	rs6496932	0.663	rs8040940	ENSG00000259630.2	CTD-2262B20.1	-3.52	0.000464	0.0485	-0.2	-0.16	Central corneal thickness;Corneal structure;	chr15:85361817	chr15:85415228~85415633:+
LUAD	cis	rs1910358	0.548	rs2055522	ENSG00000248874.4	C5orf17	-3.52	0.000464	0.0485	-0.2	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23931067	chr5:23951348~24178263:+
LUAD	cis	rs17275866	0.862	rs11934791	ENSG00000251584.1	RP11-440I14.3	3.52	0.000464	0.0485	0.2	0.16	Chin dimples;	chr4:174139571	chr4:174536640~174540784:+
LUAD	cis	rs10921219	0.966	rs7544767	ENSG00000276735.1	Metazoa_SRP	-3.52	0.000464	0.0485	-0.17	-0.16	Survival in colon cancer;	chr1:192612201	chr1:193236794~193237107:-
LUAD	cis	rs445114	0.578	rs670725	ENSG00000254166.1	CASC19	-3.52	0.000464	0.0485	-0.16	-0.16	Prostate cancer;Prostate cancer (SNP x SNP interaction);	chr8:127334912	chr8:127185635~127203222:-
LUAD	cis	rs7077256	0.564	rs34603929	ENSG00000272767.1	JMJD1C-AS1	3.52	0.000464	0.0485	0.24	0.16	Intelligence (multi-trait analysis);	chr10:63143183	chr10:63465229~63466563:+
LUAD	cis	rs73252553	0.615	rs1973604	ENSG00000281501.1	SEPSECS-AS1	-3.52	0.000464	0.0485	-0.25	-0.16	Cannabis dependence symptom count;	chr4:25252741	chr4:25160641~25201440:+
LUAD	cis	rs3740713	1	rs61081934	ENSG00000256464.1	YWHABP2	3.52	0.000464	0.0485	0.3	0.16	Amyotrophic lateral sclerosis (sporadic);	chr11:18432770	chr11:18490243~18490955:-
LUAD	cis	rs3740713	0.92	rs112818034	ENSG00000256464.1	YWHABP2	3.52	0.000464	0.0485	0.3	0.16	Amyotrophic lateral sclerosis (sporadic);	chr11:18433633	chr11:18490243~18490955:-
LUAD	cis	rs3740713	1	rs76708296	ENSG00000256464.1	YWHABP2	3.52	0.000464	0.0485	0.3	0.16	Amyotrophic lateral sclerosis (sporadic);	chr11:18434586	chr11:18490243~18490955:-
LUAD	cis	rs3740713	1	rs73438668	ENSG00000256464.1	YWHABP2	3.52	0.000464	0.0485	0.3	0.16	Amyotrophic lateral sclerosis (sporadic);	chr11:18434989	chr11:18490243~18490955:-
LUAD	cis	rs3740713	1	rs75647856	ENSG00000256464.1	YWHABP2	3.52	0.000464	0.0485	0.3	0.16	Amyotrophic lateral sclerosis (sporadic);	chr11:18438259	chr11:18490243~18490955:-
LUAD	cis	rs3740713	1	rs73438687	ENSG00000256464.1	YWHABP2	3.52	0.000464	0.0485	0.3	0.16	Amyotrophic lateral sclerosis (sporadic);	chr11:18438312	chr11:18490243~18490955:-
LUAD	cis	rs3740713	1	rs74663287	ENSG00000256464.1	YWHABP2	3.52	0.000464	0.0485	0.3	0.16	Amyotrophic lateral sclerosis (sporadic);	chr11:18438753	chr11:18490243~18490955:-
LUAD	cis	rs7851726	1	rs1016013	ENSG00000231806.2	PCAT7	3.52	0.000464	0.0485	0.21	0.16	Urinary albumin-to-creatinine ratio;	chr9:94714202	chr9:94555069~94568127:+
LUAD	cis	rs9926296	0.605	rs12599180	ENSG00000260259.1	RP11-368I7.4	3.52	0.000464	0.0485	0.16	0.16	Vitiligo;	chr16:89772898	chr16:89682620~89686569:-
LUAD	cis	rs7215564	0.818	rs1872431	ENSG00000232083.3	RPL31P7	3.52	0.000464	0.0485	0.28	0.16	Myopia (pathological);	chr17:80661400	chr17:80602549~80602926:-
LUAD	cis	rs7215564	0.818	rs35929483	ENSG00000232083.3	RPL31P7	3.52	0.000464	0.0485	0.28	0.16	Myopia (pathological);	chr17:80662144	chr17:80602549~80602926:-
LUAD	cis	rs2625529	0.652	rs9302260	ENSG00000260173.1	RP11-2I17.4	3.52	0.000464	0.0485	0.19	0.16	Red blood cell count;	chr15:71882270	chr15:72140504~72155459:-
LUAD	cis	rs9549367	0.713	rs2146750	ENSG00000233613.4	DCUN1D2-AS	3.52	0.000464	0.0485	0.19	0.16	Platelet distribution width;	chr13:113168216	chr13:113468901~113476135:+
LUAD	cis	rs11158026	0.603	rs943914	ENSG00000258413.1	RP11-665C16.6	-3.52	0.000464	0.0485	-0.2	-0.16	Parkinson's disease;	chr14:54973350	chr14:55262767~55272075:-
LUAD	cis	rs6502050	0.835	rs62078304	ENSG00000266654.1	RP11-1376P16.1	3.52	0.000465	0.0485	0.17	0.16	Life satisfaction;	chr17:82127348	chr17:82160056~82160452:+
LUAD	cis	rs6502050	0.805	rs6502061	ENSG00000266654.1	RP11-1376P16.1	3.52	0.000465	0.0485	0.17	0.16	Life satisfaction;	chr17:82128282	chr17:82160056~82160452:+
LUAD	cis	rs6502050	0.749	rs7406163	ENSG00000266654.1	RP11-1376P16.1	3.52	0.000465	0.0485	0.17	0.16	Life satisfaction;	chr17:82128513	chr17:82160056~82160452:+
LUAD	cis	rs10875976	0.507	rs4898539	ENSG00000257464.1	RP11-161H23.8	-3.52	0.000465	0.0485	-0.16	-0.16	Obesity;	chr12:49858127	chr12:49442424~49442652:-
LUAD	cis	rs6460942	0.915	rs62448594	ENSG00000226690.5	AC005281.1	3.52	0.000465	0.0485	0.29	0.16	Coronary artery disease;	chr7:12402603	chr7:12496429~12541910:+
LUAD	cis	rs6460942	0.915	rs80345607	ENSG00000226690.5	AC005281.1	3.52	0.000465	0.0485	0.29	0.16	Coronary artery disease;	chr7:12402623	chr7:12496429~12541910:+
LUAD	cis	rs860295	0.729	rs4971072	ENSG00000225855.5	RUSC1-AS1	-3.52	0.000465	0.0485	-0.11	-0.16	Body mass index;	chr1:155304078	chr1:155316863~155324176:-
LUAD	cis	rs10911232	0.507	rs6672306	ENSG00000224468.3	RP11-181K3.4	-3.52	0.000465	0.0485	-0.14	-0.16	Hypertriglyceridemia;	chr1:183089763	chr1:183138402~183141282:-
LUAD	cis	rs4713118	0.614	rs9468209	ENSG00000280107.1	AL022393.9	-3.52	0.000465	0.0485	-0.18	-0.16	Parkinson's disease;	chr6:27726642	chr6:28170845~28172521:+
LUAD	cis	rs12493885	0.725	rs73158427	ENSG00000243069.6	ARHGEF26-AS1	-3.52	0.000465	0.0485	-0.25	-0.16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154003704	chr3:154024401~154121332:-
LUAD	cis	rs12493885	0.725	rs11718315	ENSG00000243069.6	ARHGEF26-AS1	-3.52	0.000465	0.0485	-0.25	-0.16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154006408	chr3:154024401~154121332:-
LUAD	cis	rs17772222	0.606	rs449338	ENSG00000258789.1	RP11-507K2.3	3.52	0.000465	0.0485	0.19	0.16	Coronary artery calcification;	chr14:88411690	chr14:88551597~88552493:+
LUAD	cis	rs7824557	0.606	rs2736273	ENSG00000255046.1	RP11-297N6.4	-3.52	0.000465	0.0485	-0.2	-0.16	Retinal vascular caliber;	chr8:11342429	chr8:11797928~11802568:-
LUAD	cis	rs13113518	0.934	rs11935823	ENSG00000223305.1	RN7SKP30	3.52	0.000465	0.0485	0.18	0.16	Height;	chr4:55589624	chr4:55540502~55540835:-
LUAD	cis	rs12446632	0.941	rs11640504	ENSG00000261195.1	CTD-2380F24.1	-3.52	0.000465	0.0485	-0.23	-0.16	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Menarche (age at onset);Obesity;Childhood body mass index;Waist circumference;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr16:19920723	chr16:19761172~19766099:-
LUAD	cis	rs728616	0.558	rs61859793	ENSG00000225484.5	NUTM2B-AS1	-3.52	0.000465	0.0485	-0.33	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79927007	chr10:79663088~79826594:-
LUAD	cis	rs7260598	0.642	rs8104784	ENSG00000269421.1	ZNF92P3	-3.52	0.000465	0.0485	-0.25	-0.16	Response to taxane treatment (placlitaxel);	chr19:23961732	chr19:23935220~23936173:+
LUAD	cis	rs651907	0.557	rs13099674	ENSG00000244119.1	PDCL3P4	3.52	0.000465	0.0485	0.16	0.16	Colorectal cancer;	chr3:101770785	chr3:101712472~101713191:+
LUAD	cis	rs214785	1	rs214776	ENSG00000234684.5	SDCBP2-AS1	-3.52	0.000465	0.0485	-0.19	-0.16	Basal cell carcinoma;	chr20:2299745	chr20:1325405~1378734:+
LUAD	cis	rs2613514	1	rs2311440	ENSG00000204282.4	TNRC6C-AS1	-3.52	0.000465	0.0485	-0.28	-0.16	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr17:78071204	chr17:78107398~78111799:-
LUAD	cis	rs2380205	0.967	rs2380208	ENSG00000232807.2	RP11-536K7.3	-3.52	0.000465	0.0485	-0.17	-0.16	Breast cancer;	chr10:5858069	chr10:5934270~5945900:-
LUAD	cis	rs7976269	0.609	rs4931137	ENSG00000275476.1	RP11-996F15.4	-3.52	0.000465	0.0485	-0.17	-0.16	Male-pattern baldness;	chr12:29049701	chr12:29277397~29277882:-
LUAD	cis	rs1044826	0.642	rs295481	ENSG00000214280.3	RP11-553K23.2	-3.52	0.000465	0.0485	-0.18	-0.16	Obesity-related traits;	chr3:139509969	chr3:139582928~139583593:-
LUAD	cis	rs6832769	1	rs10016506	ENSG00000272969.1	RP11-528I4.2	-3.52	0.000465	0.0485	-0.16	-0.16	Personality dimensions;	chr4:55530507	chr4:55547112~55547889:+
LUAD	cis	rs6832769	0.961	rs28790098	ENSG00000272969.1	RP11-528I4.2	-3.52	0.000465	0.0485	-0.16	-0.16	Personality dimensions;	chr4:55531942	chr4:55547112~55547889:+
LUAD	cis	rs2144940	0.506	rs844878	ENSG00000233746.1	LINC00656	3.52	0.000465	0.0485	0.34	0.16	Venous thromboembolism;	chr20:23121864	chr20:23125068~23132621:-
LUAD	cis	rs3743266	0.507	rs56261931	ENSG00000245534.5	RORA-AS1	-3.52	0.000465	0.0485	-0.21	-0.16	Menarche (age at onset);	chr15:60439419	chr15:60479178~60630637:+
LUAD	cis	rs1910358	0.664	rs2134240	ENSG00000248874.4	C5orf17	-3.52	0.000465	0.0485	-0.2	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23939030	chr5:23951348~24178263:+
LUAD	cis	rs1910358	0.69	rs1501937	ENSG00000248874.4	C5orf17	-3.52	0.000465	0.0485	-0.2	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23941957	chr5:23951348~24178263:+
LUAD	cis	rs10791097	0.728	rs10894265	ENSG00000255455.2	RP11-890B15.3	3.52	0.000465	0.0485	0.15	0.16	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr11:130844718	chr11:130866254~130870247:-
LUAD	cis	rs763121	0.853	rs4821798	ENSG00000228274.3	RP3-508I15.9	-3.52	0.000465	0.0486	-0.15	-0.16	Menopause (age at onset);	chr22:38625160	chr22:38667585~38681820:-
LUAD	cis	rs1823913	0.637	rs12624271	ENSG00000230611.1	HMGB1P27	3.52	0.000465	0.0486	0.18	0.16	Obesity-related traits;	chr2:191288586	chr2:191174233~191174835:+
LUAD	cis	rs2708977	0.692	rs17685766	ENSG00000237510.6	AC008268.2	3.52	0.000465	0.0486	0.22	0.16	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;	chr2:96653797	chr2:95789654~95800166:+
LUAD	cis	rs9951698	0.66	rs472702	ENSG00000266969.1	RP11-773H22.4	3.52	0.000465	0.0486	0.2	0.16	Intelligence (multi-trait analysis);	chr18:13058495	chr18:12984694~12991173:-
LUAD	cis	rs473651	0.935	rs515412	ENSG00000229915.1	AC016999.2	-3.52	0.000465	0.0486	-0.21	-0.16	Multiple system atrophy;	chr2:238436753	chr2:238427077~238427729:-
LUAD	cis	rs11577318	0.579	rs11247934	ENSG00000238084.4	RP3-469D22.1	-3.52	0.000465	0.0486	-0.19	-0.16	Granulocyte percentage of myeloid white cells;	chr1:26369267	chr1:25398721~25399198:+
LUAD	cis	rs12493885	0.725	rs11718646	ENSG00000243069.6	ARHGEF26-AS1	-3.52	0.000465	0.0486	-0.26	-0.16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154024207	chr3:154024401~154121332:-
LUAD	cis	rs12493885	0.725	rs11707232	ENSG00000243069.6	ARHGEF26-AS1	-3.52	0.000465	0.0486	-0.26	-0.16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154024288	chr3:154024401~154121332:-
LUAD	cis	rs12493885	0.725	rs61791493	ENSG00000243069.6	ARHGEF26-AS1	-3.52	0.000465	0.0486	-0.26	-0.16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;	chr3:154025784	chr3:154024401~154121332:-
LUAD	cis	rs1823913	0.637	rs4853577	ENSG00000230611.1	HMGB1P27	3.52	0.000465	0.0486	0.18	0.16	Obesity-related traits;	chr2:191297118	chr2:191174233~191174835:+
LUAD	cis	rs9900280	1	rs6505128	ENSG00000264808.1	RP11-802D6.1	3.52	0.000465	0.0486	0.18	0.16	Mean platelet volume;	chr17:29421159	chr17:29369717~29390777:-
LUAD	cis	rs8114671	0.901	rs6119581	ENSG00000269202.1	RP4-614O4.12	-3.52	0.000466	0.0486	-0.16	-0.16	Height;	chr20:35185886	chr20:35201747~35203288:-
LUAD	cis	rs8114671	0.933	rs6087683	ENSG00000269202.1	RP4-614O4.12	-3.52	0.000466	0.0486	-0.16	-0.16	Height;	chr20:35186641	chr20:35201747~35203288:-
LUAD	cis	rs8114671	0.967	rs4911472	ENSG00000269202.1	RP4-614O4.12	-3.52	0.000466	0.0486	-0.16	-0.16	Height;	chr20:35187574	chr20:35201747~35203288:-
LUAD	cis	rs8024893	1	rs8038787	ENSG00000270055.1	CTD-3092A11.2	3.52	0.000466	0.0486	0.2	0.16	Red cell distribution width;	chr15:31246171	chr15:30487963~30490313:+
LUAD	cis	rs3126085	1	rs72696963	ENSG00000237975.5	FLG-AS1	3.52	0.000466	0.0486	0.26	0.16	Atopic dermatitis;	chr1:152208713	chr1:152168125~152445456:+
LUAD	cis	rs13108904	0.87	rs3755927	ENSG00000196810.4	CTBP1-AS2	3.52	0.000466	0.0486	0.19	0.16	Obesity-related traits;	chr4:1244458	chr4:1249300~1288291:+
LUAD	cis	rs13108904	0.87	rs3755924	ENSG00000196810.4	CTBP1-AS2	3.52	0.000466	0.0486	0.19	0.16	Obesity-related traits;	chr4:1244575	chr4:1249300~1288291:+
LUAD	cis	rs12146727	0.881	rs10849546	ENSG00000247853.2	RP5-940J5.6	3.52	0.000466	0.0486	0.26	0.16	Blood protein levels;	chr12:7068900	chr12:6578622~6584739:+
LUAD	cis	rs6951245	0.832	rs10266519	ENSG00000229043.2	AC091729.9	-3.52	0.000466	0.0486	-0.24	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1103341	chr7:1160374~1165267:+
LUAD	cis	rs6502050	0.637	rs74765203	ENSG00000266654.1	RP11-1376P16.1	-3.52	0.000466	0.0486	-0.17	-0.16	Life satisfaction;	chr17:82160347	chr17:82160056~82160452:+
LUAD	cis	rs6479901	0.947	rs7909692	ENSG00000232075.1	MRPL35P2	-3.52	0.000466	0.0486	-0.22	-0.16	Intelligence (multi-trait analysis);	chr10:63368517	chr10:63634317~63634827:-
LUAD	cis	rs11779988	0.545	rs427168	ENSG00000253671.1	RP11-806O11.1	-3.52	0.000466	0.0486	-0.2	-0.16	Breast cancer;	chr8:17927320	chr8:17808941~17820868:+
LUAD	cis	rs913672	0.553	rs8184807	ENSG00000229222.1	KRT18P4	-3.52	0.000466	0.0486	-0.21	-0.16	Monocyte count;	chr20:50292379	chr20:49956745~49958032:+
LUAD	cis	rs13113518	1	rs4864999	ENSG00000249700.7	SRD5A3-AS1	3.52	0.000466	0.0486	0.16	0.16	Height;	chr4:55476736	chr4:55363971~55395847:-
LUAD	cis	rs13113518	0.966	rs12506788	ENSG00000249700.7	SRD5A3-AS1	3.52	0.000466	0.0486	0.16	0.16	Height;	chr4:55477426	chr4:55363971~55395847:-
LUAD	cis	rs13113518	0.966	rs10517344	ENSG00000249700.7	SRD5A3-AS1	3.52	0.000466	0.0486	0.16	0.16	Height;	chr4:55477545	chr4:55363971~55395847:-
LUAD	cis	rs2880765	0.525	rs35899940	ENSG00000259407.1	RP11-158M2.3	-3.52	0.000466	0.0486	-0.15	-0.16	Coronary artery disease;	chr15:85510466	chr15:85744109~85750281:-
LUAD	cis	rs75968099	0.678	rs73068054	ENSG00000234073.1	AC011816.1	3.52	0.000466	0.0486	0.18	0.16	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr3:36904303	chr3:36880184~36880729:-
LUAD	cis	rs7208859	0.623	rs7220289	ENSG00000265443.1	CTD-2349P21.6	-3.52	0.000466	0.0486	-0.25	-0.16	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30776744	chr17:30726305~30727564:-
LUAD	cis	rs159572	0.784	rs161210	ENSG00000250853.1	RNF138P1	-3.52	0.000466	0.0486	-0.19	-0.16	Post-traumatic stress disorder;	chr5:56235356	chr5:55530156~55530701:-
LUAD	cis	rs9652601	0.622	rs7194305	ENSG00000262222.1	RP11-876N24.4	-3.52	0.000466	0.0486	-0.14	-0.16	Systemic lupus erythematosus;	chr16:11005850	chr16:10940719~10943021:+
LUAD	cis	rs710913	0.738	rs1180347	ENSG00000237624.1	OXCT2P1	-3.52	0.000466	0.0486	-0.2	-0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39531044	chr1:39514956~39516490:+
LUAD	cis	rs7178909	0.831	rs1910587	ENSG00000259677.1	RP11-493E3.1	3.52	0.000466	0.0486	0.17	0.16	Common traits (Other);	chr15:89897255	chr15:89876540~89877285:+
LUAD	cis	rs7178909	0.797	rs1910586	ENSG00000259677.1	RP11-493E3.1	3.52	0.000466	0.0486	0.17	0.16	Common traits (Other);	chr15:89897257	chr15:89876540~89877285:+
LUAD	cis	rs9341808	0.65	rs6909546	ENSG00000233967.5	RP11-250B2.3	3.52	0.000466	0.0486	0.15	0.16	Sitting height ratio;	chr6:80160206	chr6:80443344~80465927:+
LUAD	cis	rs7017914	0.905	rs2732104	ENSG00000246366.5	RP11-382J12.1	3.52	0.000466	0.0486	0.15	0.16	Bone mineral density;	chr8:71011284	chr8:70608577~70663279:+
LUAD	cis	rs3126085	0.932	rs72696991	ENSG00000237975.5	FLG-AS1	3.52	0.000466	0.0486	0.27	0.16	Atopic dermatitis;	chr1:152277759	chr1:152168125~152445456:+
LUAD	cis	rs3126085	0.935	rs10888483	ENSG00000237975.5	FLG-AS1	3.52	0.000466	0.0486	0.27	0.16	Atopic dermatitis;	chr1:152280313	chr1:152168125~152445456:+
LUAD	cis	rs3126085	0.935	rs72696997	ENSG00000237975.5	FLG-AS1	3.52	0.000466	0.0486	0.27	0.16	Atopic dermatitis;	chr1:152284623	chr1:152168125~152445456:+
LUAD	cis	rs3126085	1	rs11204971	ENSG00000237975.5	FLG-AS1	3.52	0.000466	0.0486	0.27	0.16	Atopic dermatitis;	chr1:152286602	chr1:152168125~152445456:+
LUAD	cis	rs10129255	0.957	rs10141009	ENSG00000211947.2	IGHV3-21	-3.52	0.000466	0.0486	-0.1	-0.16	Kawasaki disease;	chr14:106776695	chr14:106235064~106235594:-
LUAD	cis	rs10129255	0.912	rs6576227	ENSG00000211947.2	IGHV3-21	-3.52	0.000466	0.0486	-0.1	-0.16	Kawasaki disease;	chr14:106778202	chr14:106235064~106235594:-
LUAD	cis	rs10129255	0.957	rs6576228	ENSG00000211947.2	IGHV3-21	-3.52	0.000466	0.0486	-0.1	-0.16	Kawasaki disease;	chr14:106778401	chr14:106235064~106235594:-
LUAD	cis	rs4388249	0.687	rs3797689	ENSG00000271849.1	CTC-332L22.1	-3.52	0.000466	0.0486	-0.22	-0.16	Schizophrenia;	chr5:109764814	chr5:109687802~109688329:-
LUAD	cis	rs957448	0.554	rs12682601	ENSG00000253175.1	RP11-267M23.6	3.52	0.000466	0.0486	0.18	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94582492	chr8:94565036~94565715:+
LUAD	cis	rs926340	0.705	rs136380	ENSG00000279699.1	RP1-102K2.9	-3.52	0.000466	0.0486	-0.2	-0.16	Colorectal cancer;	chr22:30720766	chr22:30275215~30276951:-
LUAD	cis	rs10050311	0.698	rs67867077	ENSG00000261496.1	RP13-514E23.1	-3.52	0.000466	0.0486	-0.18	-0.16	Insulin-related traits;	chr4:86722593	chr4:86012296~86013874:-
LUAD	cis	rs1046491	0.901	rs8085669	ENSG00000264964.1	RP11-888D10.3	3.52	0.000466	0.0486	0.33	0.16	Scarlet fever;	chr18:9190644	chr18:9315194~9334441:-
LUAD	cis	rs4308124	0.708	rs28766030	ENSG00000230499.1	AC108463.1	-3.52	0.000466	0.0486	-0.22	-0.16	Vitiligo;	chr2:111204852	chr2:111195963~111206494:+
LUAD	cis	rs4308124	0.708	rs28871990	ENSG00000230499.1	AC108463.1	-3.52	0.000466	0.0486	-0.22	-0.16	Vitiligo;	chr2:111204864	chr2:111195963~111206494:+
LUAD	cis	rs4308124	0.708	rs67816163	ENSG00000230499.1	AC108463.1	-3.52	0.000466	0.0486	-0.22	-0.16	Vitiligo;	chr2:111205733	chr2:111195963~111206494:+
LUAD	cis	rs2505998	0.871	rs2505990	ENSG00000273008.1	RP11-351D16.3	-3.52	0.000466	0.0486	-0.17	-0.16	Hirschsprung disease;	chr10:43069900	chr10:43136824~43138334:-
LUAD	cis	rs3771317	0.887	rs16832798	ENSG00000235852.1	AC005540.3	-3.52	0.000467	0.0487	-0.24	-0.16	Primary biliary cholangitis;	chr2:190669646	chr2:190880797~190882059:-
LUAD	cis	rs72843166	0.853	rs12601056	ENSG00000226797.1	AC015923.1	-3.52	0.000467	0.0487	-0.21	-0.16	Intelligence (multi-trait analysis);	chr17:63265971	chr17:63381231~63414312:-
LUAD	cis	rs3740713	1	rs73440614	ENSG00000256464.1	YWHABP2	3.52	0.000467	0.0487	0.3	0.16	Amyotrophic lateral sclerosis (sporadic);	chr11:18445153	chr11:18490243~18490955:-
LUAD	cis	rs7077256	0.564	rs12780983	ENSG00000272767.1	JMJD1C-AS1	3.52	0.000467	0.0487	0.23	0.16	Intelligence (multi-trait analysis);	chr10:63402026	chr10:63465229~63466563:+
LUAD	cis	rs782590	0.967	rs62165173	ENSG00000272606.1	RP11-554J4.1	-3.52	0.000467	0.0487	-0.16	-0.16	Metabolic syndrome;	chr2:55514530	chr2:55617909~55618373:+
LUAD	cis	rs4908768	0.906	rs6656249	ENSG00000232912.4	RP5-1115A15.1	-3.52	0.000467	0.0487	-0.18	-0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8520956	chr1:8424645~8434838:+
LUAD	cis	rs6493487	0.512	rs71471523	ENSG00000273674.3	CTD-2378E12.1	3.52	0.000467	0.0487	0.23	0.16	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr15:50905127	chr15:50839875~50908599:-
LUAD	cis	rs7429990	0.965	rs6772396	ENSG00000228638.1	FCF1P2	-3.52	0.000467	0.0487	-0.19	-0.16	Educational attainment (years of education);	chr3:47918280	chr3:48290793~48291375:-
LUAD	cis	rs875971	0.964	rs55748098	ENSG00000273142.1	RP11-458F8.4	3.52	0.000467	0.0487	0.11	0.16	Aortic root size;	chr7:66298631	chr7:66902857~66906297:+
LUAD	cis	rs797680	0.786	rs10874772	ENSG00000223745.6	RP4-717I23.3	3.52	0.000467	0.0487	0.12	0.16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93322213	chr1:93262186~93346025:-
LUAD	cis	rs7772486	0.875	rs2748501	ENSG00000235652.6	RP11-545I5.3	3.52	0.000467	0.0487	0.16	0.16	Lobe attachment (rater-scored or self-reported);	chr6:145991122	chr6:145799409~145886585:+
LUAD	cis	rs6908034	0.66	rs76322282	ENSG00000228412.5	RP4-625H18.2	3.52	0.000467	0.0487	0.32	0.16	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19801429	chr6:19802164~19804752:-
LUAD	cis	rs6908034	0.607	rs111533721	ENSG00000228412.5	RP4-625H18.2	3.52	0.000467	0.0487	0.32	0.16	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19803514	chr6:19802164~19804752:-
LUAD	cis	rs6908034	0.505	rs76709285	ENSG00000228412.5	RP4-625H18.2	3.52	0.000467	0.0487	0.32	0.16	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804099	chr6:19802164~19804752:-
LUAD	cis	rs2348418	0.864	rs7314984	ENSG00000247934.4	RP11-967K21.1	3.52	0.000467	0.0487	0.18	0.16	Lung function (FEV1);Lung function (FVC);	chr12:28557936	chr12:28163298~28190738:-
LUAD	cis	rs703842	0.616	rs4760332	ENSG00000270039.1	RP11-571M6.17	3.52	0.000467	0.0487	0.19	0.16	Multiple sclerosis;	chr12:57828889	chr12:57803838~57804415:+
LUAD	cis	rs7584330	0.704	rs11884395	ENSG00000222032.1	AC112721.2	3.52	0.000467	0.0487	0.2	0.16	Prostate cancer;	chr2:237450723	chr2:237428920~237434822:-
LUAD	cis	rs4304977	0.552	rs989990	ENSG00000271763.1	RP11-386M24.9	-3.52	0.000467	0.0487	-0.15	-0.16	DNA methylation (variation);	chr15:92224948	chr15:92602910~92620015:+
LUAD	cis	rs9840812	0.623	rs1394092	ENSG00000239213.4	NCK1-AS1	3.52	0.000467	0.0487	0.19	0.16	Fibrinogen levels;	chr3:136477229	chr3:136841726~136862054:-
LUAD	cis	rs12146727	0.881	rs12368783	ENSG00000247853.2	RP5-940J5.6	3.52	0.000467	0.0487	0.26	0.16	Blood protein levels;	chr12:7072096	chr12:6578622~6584739:+
LUAD	cis	rs3741404	0.825	rs7111753	ENSG00000256789.1	RP11-697H9.2	-3.52	0.000467	0.0487	-0.18	-0.16	Platelet count;	chr11:64174717	chr11:63637677~63658962:+
LUAD	cis	rs2278907	0.537	rs4073958	ENSG00000227620.4	ALG1L8P	-3.52	0.000467	0.0487	-0.2	-0.16	Total body bone mineral density;	chr11:68714165	chr11:67785273~67792335:+
LUAD	cis	rs2115630	0.967	rs8027779	ENSG00000259295.5	CSPG4P12	-3.52	0.000467	0.0487	-0.19	-0.16	P wave terminal force;	chr15:84712154	chr15:85191438~85213905:+
LUAD	cis	rs1023500	1	rs1023497	ENSG00000205702.9	CYP2D7	-3.52	0.000467	0.0487	-0.15	-0.16	Schizophrenia;	chr22:41944504	chr22:42140203~42144577:-
LUAD	cis	rs9303542	0.918	rs1553752	ENSG00000264920.1	RP11-6N17.4	-3.52	0.000467	0.0487	-0.21	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48343346	chr17:47891255~47895812:-
LUAD	cis	rs9303542	1	rs9897162	ENSG00000264920.1	RP11-6N17.4	-3.52	0.000467	0.0487	-0.21	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48347427	chr17:47891255~47895812:-
LUAD	cis	rs9303542	1	rs9909002	ENSG00000264920.1	RP11-6N17.4	-3.52	0.000467	0.0487	-0.21	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48349106	chr17:47891255~47895812:-
LUAD	cis	rs16940212	0.618	rs920917	ENSG00000242747.1	RP11-30K9.1	-3.52	0.000467	0.0487	-0.23	-0.16	HDL cholesterol;HDL cholesterol levels;	chr15:58396279	chr15:58869659~58870134:+
LUAD	cis	rs875971	0.545	rs73146609	ENSG00000224316.1	RP11-479O9.2	3.52	0.000467	0.0487	0.19	0.16	Aortic root size;	chr7:66302477	chr7:65773620~65802067:+
LUAD	cis	rs875971	0.545	rs2173571	ENSG00000224316.1	RP11-479O9.2	3.52	0.000467	0.0487	0.19	0.16	Aortic root size;	chr7:66305392	chr7:65773620~65802067:+
LUAD	cis	rs35000415	0.938	rs13239597	ENSG00000275106.1	RP11-309L24.10	-3.52	0.000467	0.0487	-0.31	-0.16	Systemic lupus erythematosus;	chr7:129055929	chr7:128952527~128953316:-
LUAD	cis	rs35000415	0.745	rs117944677	ENSG00000275106.1	RP11-309L24.10	-3.52	0.000467	0.0487	-0.31	-0.16	Systemic lupus erythematosus;	chr7:129058131	chr7:128952527~128953316:-
LUAD	cis	rs35000415	0.745	rs117473643	ENSG00000275106.1	RP11-309L24.10	-3.52	0.000467	0.0487	-0.31	-0.16	Systemic lupus erythematosus;	chr7:129058132	chr7:128952527~128953316:-
LUAD	cis	rs891378	1	rs6662070	ENSG00000274245.1	RP11-357P18.2	-3.52	0.000467	0.0487	-0.2	-0.16	Spherical equivalent (joint analysis main effects and education interaction);	chr1:207332364	chr1:207372559~207373252:+
LUAD	cis	rs6547741	1	rs6749052	ENSG00000223522.1	AC093690.1	3.52	0.000467	0.0487	0.15	0.16	Oral cavity cancer;	chr2:27550012	chr2:28307691~28310459:-
LUAD	cis	rs7615952	0.546	rs2979340	ENSG00000243429.1	OR7E29P	3.52	0.000467	0.0487	0.22	0.16	Blood pressure (smoking interaction);	chr3:125622540	chr3:125712139~125713045:+
LUAD	cis	rs7615952	0.546	rs2979338	ENSG00000243429.1	OR7E29P	3.52	0.000467	0.0487	0.22	0.16	Blood pressure (smoking interaction);	chr3:125624282	chr3:125712139~125713045:+
LUAD	cis	rs7615952	0.546	rs2922171	ENSG00000243429.1	OR7E29P	3.52	0.000467	0.0487	0.22	0.16	Blood pressure (smoking interaction);	chr3:125624349	chr3:125712139~125713045:+
LUAD	cis	rs7615952	0.546	rs112919177	ENSG00000243429.1	OR7E29P	3.52	0.000467	0.0487	0.22	0.16	Blood pressure (smoking interaction);	chr3:125627226	chr3:125712139~125713045:+
LUAD	cis	rs3617	0.625	rs2240915	ENSG00000242142.1	SERBP1P3	3.52	0.000467	0.0487	0.17	0.16	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52825510	chr3:53064283~53065091:-
LUAD	cis	rs3617	0.625	rs2245647	ENSG00000242142.1	SERBP1P3	3.52	0.000467	0.0487	0.17	0.16	Red blood cell count;Autism spectrum disorder or schizophrenia;	chr3:52828737	chr3:53064283~53065091:-
LUAD	cis	rs6951245	1	rs11764748	ENSG00000199023.2	MIR339	-3.52	0.000467	0.0487	-0.27	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054872	chr7:1022935~1023045:-
LUAD	cis	rs2638953	0.886	rs11049470	ENSG00000278733.1	RP11-425D17.1	-3.52	0.000468	0.0487	-0.2	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28221449	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs10843140	ENSG00000278733.1	RP11-425D17.1	-3.52	0.000468	0.0487	-0.2	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28227273	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.924	rs11049472	ENSG00000278733.1	RP11-425D17.1	-3.52	0.000468	0.0487	-0.2	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28229772	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.888	rs2061760	ENSG00000278733.1	RP11-425D17.1	-3.52	0.000468	0.0487	-0.2	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28234492	chr12:28185625~28186190:-
LUAD	cis	rs2638953	0.886	rs11049474	ENSG00000278733.1	RP11-425D17.1	-3.52	0.000468	0.0487	-0.2	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28235512	chr12:28185625~28186190:-
LUAD	cis	rs701145	0.585	rs447429	ENSG00000243069.6	ARHGEF26-AS1	3.52	0.000468	0.0487	0.27	0.16	Coronary artery disease;	chr3:154192157	chr3:154024401~154121332:-
LUAD	cis	rs701145	0.585	rs398512	ENSG00000243069.6	ARHGEF26-AS1	3.52	0.000468	0.0487	0.27	0.16	Coronary artery disease;	chr3:154192199	chr3:154024401~154121332:-
LUAD	cis	rs1443267	0.867	rs2586073	ENSG00000229590.3	MSX2P1	3.52	0.000468	0.0487	0.21	0.16	Obstetric antiphospholipid syndrome;	chr17:57822206	chr17:58157028~58157800:+
LUAD	cis	rs638893	0.636	rs6589687	ENSG00000255422.1	AP002954.4	-3.52	0.000468	0.0487	-0.28	-0.16	Vitiligo;	chr11:118744951	chr11:118704607~118750263:+
LUAD	cis	rs1858037	0.836	rs2576923	ENSG00000237979.1	AC007389.1	-3.52	0.000468	0.0487	-0.2	-0.16	Rheumatoid arthritis;	chr2:65406750	chr2:65500993~65502138:-
LUAD	cis	rs4835473	0.897	rs7678190	ENSG00000249741.2	RP11-673E1.3	-3.52	0.000468	0.0487	-0.19	-0.16	Immature fraction of reticulocytes;	chr4:143722421	chr4:143911514~143912053:-
LUAD	cis	rs7714584	1	rs7724036	ENSG00000197083.10	ZNF300P1	-3.52	0.000468	0.0487	-0.28	-0.16	Crohn's disease;	chr5:150905246	chr5:150930645~150946289:-
LUAD	cis	rs4144027	0.869	rs55924227	ENSG00000258534.1	CTD-2134A5.4	-3.52	0.000468	0.0487	-0.18	-0.16	Blood metabolite levels;	chr14:103895013	chr14:103854366~103880111:-
LUAD	cis	rs4784934	1	rs4784935	ENSG00000260186.4	RP11-481J2.2	3.52	0.000468	0.0487	0.2	0.16	QT interval;	chr16:58426438	chr16:58421326~58462470:+
LUAD	cis	rs304029	0.687	rs304091	ENSG00000231249.1	ITPR1-AS1	-3.52	0.000468	0.0487	-0.17	-0.16	Diabetic kidney disease;	chr3:4477611	chr3:4490891~4493163:-
LUAD	cis	rs2286379	0.565	rs7138924	ENSG00000256271.1	CACNA1C-AS2	3.52	0.000468	0.0487	0.15	0.16	Blood pressure (smoking interaction);	chr12:1680869	chr12:2668500~2672220:-
LUAD	cis	rs875971	0.577	rs35072105	ENSG00000273142.1	RP11-458F8.4	3.52	0.000468	0.0487	0.11	0.16	Aortic root size;	chr7:66144830	chr7:66902857~66906297:+
LUAD	cis	rs2732480	0.538	rs1387260	ENSG00000273765.1	RP11-370I10.11	3.52	0.000468	0.0487	0.18	0.16	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309308	chr12:48360920~48361377:+
LUAD	cis	rs8180040	0.764	rs4683324	ENSG00000271161.1	BOLA2P2	3.52	0.000468	0.0488	0.15	0.16	Colorectal cancer;	chr3:47209794	chr3:47499841~47500407:+
LUAD	cis	rs449789	0.948	rs1875817	ENSG00000235086.1	FNDC1-IT1	-3.52	0.000468	0.0488	-0.26	-0.16	Pulse pressure;	chr6:159299924	chr6:159240786~159243329:+
LUAD	cis	rs6496932	0.802	rs67928464	ENSG00000259630.2	CTD-2262B20.1	3.52	0.000468	0.0488	0.2	0.16	Central corneal thickness;Corneal structure;	chr15:85338535	chr15:85415228~85415633:+
LUAD	cis	rs1075265	0.836	rs1421622	ENSG00000272156.1	RP11-477N3.1	3.52	0.000468	0.0488	0.19	0.16	Chronotype;Morning vs. evening chronotype;	chr2:54062644	chr2:54082554~54085066:+
LUAD	cis	rs6430585	0.528	rs309161	ENSG00000226806.1	AC011893.3	-3.52	0.000468	0.0488	-0.23	-0.16	Corneal structure;	chr2:135931179	chr2:135820191~135823087:+
LUAD	cis	rs2011013	1	rs56373916	ENSG00000259570.1	RP11-671M22.4	-3.52	0.000468	0.0488	-0.2	-0.16	Sitting height ratio;	chr15:83957989	chr15:84394512~84395514:+
LUAD	cis	rs7017914	0.905	rs12542300	ENSG00000246366.5	RP11-382J12.1	-3.52	0.000468	0.0488	-0.15	-0.16	Bone mineral density;	chr8:71039160	chr8:70608577~70663279:+
LUAD	cis	rs4523957	0.89	rs216218	ENSG00000262333.1	HNRNPA1P16	-3.52	0.000468	0.0488	-0.13	-0.16	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2242035	chr17:2306761~2307715:+
LUAD	cis	rs4523957	0.928	rs216219	ENSG00000262333.1	HNRNPA1P16	-3.52	0.000468	0.0488	-0.13	-0.16	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2243997	chr17:2306761~2307715:+
LUAD	cis	rs523522	0.926	rs10849766	ENSG00000278344.1	RP11-18C24.8	3.52	0.000468	0.0488	0.22	0.16	High light scatter reticulocyte count;	chr12:120588091	chr12:120500735~120501090:-
LUAD	cis	rs4784934	0.819	rs28627526	ENSG00000260186.4	RP11-481J2.2	3.52	0.000468	0.0488	0.19	0.16	QT interval;	chr16:58433835	chr16:58421326~58462470:+
LUAD	cis	rs881375	0.967	rs2416806	ENSG00000238181.2	AHCYP2	-3.52	0.000468	0.0488	-0.2	-0.16	Rheumatoid arthritis;	chr9:120928014	chr9:120720673~120721972:+
LUAD	cis	rs7107174	0.892	rs4945273	ENSG00000251323.2	RP11-452H21.4	3.52	0.000468	0.0488	0.21	0.16	Testicular germ cell tumor;	chr11:78385931	chr11:78423982~78429836:-
LUAD	cis	rs7107174	0.892	rs10793310	ENSG00000251323.2	RP11-452H21.4	3.52	0.000468	0.0488	0.21	0.16	Testicular germ cell tumor;	chr11:78387968	chr11:78423982~78429836:-
LUAD	cis	rs4845570	1	rs3790514	ENSG00000203288.3	RP11-98D18.9	-3.52	0.000468	0.0488	-0.24	-0.16	Coronary artery disease;	chr1:151771692	chr1:151790804~151794402:+
LUAD	cis	rs4713118	0.662	rs156744	ENSG00000226314.6	ZNF192P1	-3.52	0.000468	0.0488	-0.2	-0.16	Parkinson's disease;	chr6:27999496	chr6:28161781~28169594:+
LUAD	cis	rs4713118	0.662	rs149947	ENSG00000226314.6	ZNF192P1	-3.52	0.000468	0.0488	-0.2	-0.16	Parkinson's disease;	chr6:28004655	chr6:28161781~28169594:+
LUAD	cis	rs12908161	0.959	rs62019472	ENSG00000259654.1	RP11-245C17.2	-3.52	0.000468	0.0488	-0.23	-0.16	Schizophrenia;	chr15:84788262	chr15:84685884~84686946:+
LUAD	cis	rs2836974	0.932	rs73221193	ENSG00000232608.1	TIMM9P2	-3.52	0.000468	0.0488	-0.19	-0.16	Cognitive function;	chr21:39182767	chr21:39216624~39217506:+
LUAD	cis	rs9659323	0.623	rs12091291	ENSG00000231365.4	RP11-418J17.1	3.52	0.000468	0.0488	0.19	0.16	Body mass index;	chr1:118936205	chr1:119140396~119275973:+
LUAD	cis	rs1858037	0.867	rs4671660	ENSG00000237979.1	AC007389.1	3.52	0.000468	0.0488	0.2	0.16	Rheumatoid arthritis;	chr2:65349302	chr2:65500993~65502138:-
LUAD	cis	rs2645424	0.671	rs2294138	ENSG00000255046.1	RP11-297N6.4	3.52	0.000468	0.0488	0.2	0.16	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);	chr8:11847630	chr8:11797928~11802568:-
LUAD	cis	rs2880765	0.743	rs12906308	ENSG00000259630.2	CTD-2262B20.1	3.52	0.000468	0.0488	0.18	0.16	Coronary artery disease;	chr15:85464828	chr15:85415228~85415633:+
LUAD	cis	rs2880765	0.743	rs8039049	ENSG00000259630.2	CTD-2262B20.1	-3.52	0.000468	0.0488	-0.18	-0.16	Coronary artery disease;	chr15:85464398	chr15:85415228~85415633:+
LUAD	cis	rs2880765	0.743	rs8039631	ENSG00000259630.2	CTD-2262B20.1	-3.52	0.000468	0.0488	-0.18	-0.16	Coronary artery disease;	chr15:85464700	chr15:85415228~85415633:+
LUAD	cis	rs9810888	0.738	rs9883910	ENSG00000271916.1	RP11-884K10.6	-3.52	0.000468	0.0488	-0.16	-0.16	Hypertension;Diastolic blood pressure;Systolic blood pressure;	chr3:53636259	chr3:53797764~53798019:-
LUAD	cis	rs12210905	1	rs72843611	ENSG00000261353.1	CTA-14H9.5	3.52	0.000468	0.0488	0.33	0.16	Hip circumference adjusted for BMI;	chr6:27163603	chr6:26527063~26527404:+
LUAD	cis	rs1876905	0.764	rs9398265	ENSG00000230177.1	RP5-1112D6.4	-3.52	0.000468	0.0488	-0.19	-0.16	Mean corpuscular hemoglobin;	chr6:111101399	chr6:111277932~111278742:+
LUAD	cis	rs3213758	1	rs12597693	ENSG00000279589.1	RP11-454F8.4	3.52	0.000469	0.0488	0.36	0.16	Vitiligo (non-segmental);	chr16:53537558	chr16:53310797~53311989:+
LUAD	cis	rs1401999	0.807	rs9869029	ENSG00000223882.1	ABCC5-AS1	-3.52	0.000469	0.0488	-0.17	-0.16	Anterior chamber depth;	chr3:184017498	chr3:184006338~184011419:+
LUAD	cis	rs4908768	0.906	rs55858268	ENSG00000232912.4	RP5-1115A15.1	-3.52	0.000469	0.0488	-0.19	-0.16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8494636	chr1:8424645~8434838:+
LUAD	cis	rs12050794	0.671	rs2052713	ENSG00000260173.1	RP11-2I17.4	3.52	0.000469	0.0488	0.19	0.16	Metabolite levels (HVA/MHPG ratio);	chr15:72228051	chr15:72140504~72155459:-
LUAD	cis	rs875971	0.545	rs3936065	ENSG00000224316.1	RP11-479O9.2	3.52	0.000469	0.0488	0.19	0.16	Aortic root size;	chr7:66325577	chr7:65773620~65802067:+
LUAD	cis	rs6493858	0.55	rs2414466	ENSG00000277548.1	RP11-139H15.6	3.52	0.000469	0.0488	0.16	0.16	Relative hand skill in reading disability;	chr15:56231397	chr15:55346347~55346752:-
LUAD	cis	rs7829975	0.711	rs12682352	ENSG00000233609.3	RP11-62H7.2	3.52	0.000469	0.0488	0.13	0.16	Mood instability;	chr8:8788736	chr8:8961200~8979025:+
LUAD	cis	rs4716602	0.596	rs28451598	ENSG00000235029.1	MNX1-AS2	-3.52	0.000469	0.0488	-0.19	-0.16	Anti-saccade response;	chr7:156366280	chr7:157006307~157007132:+
LUAD	cis	rs7809950	1	rs2894475	ENSG00000238832.1	snoU109	-3.52	0.000469	0.0488	-0.23	-0.16	Coronary artery disease;	chr7:107622113	chr7:107603363~107603507:+
LUAD	cis	rs748404	0.631	rs2412781	ENSG00000166763.7	STRCP1	-3.52	0.000469	0.0488	-0.19	-0.16	Lung cancer;	chr15:43375702	chr15:43699488~43718184:-
LUAD	cis	rs7178424	0.875	rs7172967	ENSG00000259251.2	RP11-643M14.1	3.52	0.000469	0.0489	0.17	0.16	Height;	chr15:61926369	chr15:62060503~62062434:+
LUAD	cis	rs7246967	0.611	rs56944174	ENSG00000236312.3	RPL34P34	3.52	0.000469	0.0489	0.27	0.16	Bronchopulmonary dysplasia;	chr19:22738872	chr19:22368599~22368952:-
LUAD	cis	rs67981189	0.788	rs34093157	ENSG00000269927.1	RP6-91H8.3	3.52	0.000469	0.0489	0.2	0.16	Schizophrenia;	chr14:71101966	chr14:71141125~71143253:-
LUAD	cis	rs2281603	0.57	rs10133696	ENSG00000259116.1	RP11-973N13.4	-3.52	0.000469	0.0489	-0.14	-0.16	Lymphocyte counts;	chr14:64504441	chr14:64514154~64540368:-
LUAD	cis	rs2494663	0.61	rs11265099	ENSG00000223599.1	RP11-216N14.7	-3.52	0.000469	0.0489	-0.19	-0.16	Mean platelet volume;	chr1:154108481	chr1:153852106~153853414:-
LUAD	cis	rs8014204	0.935	rs2300596	ENSG00000279594.1	RP11-950C14.10	3.52	0.000469	0.0489	0.18	0.16	Caffeine consumption;	chr14:74887152	chr14:75011269~75012851:-
LUAD	cis	rs17711722	0.522	rs6957759	ENSG00000213640.3	EEF1DP4	-3.52	0.000469	0.0489	-0.19	-0.16	Calcium levels;	chr7:65806798	chr7:64862999~64864370:+
LUAD	cis	rs7015630	0.738	rs11785163	ENSG00000251136.7	RP11-37B2.1	-3.52	0.000469	0.0489	-0.2	-0.16	Inflammatory bowel disease;Crohn's disease;	chr8:89857181	chr8:89609409~89757727:-
LUAD	cis	rs2880765	0.835	rs730372	ENSG00000259407.1	RP11-158M2.3	3.52	0.000469	0.0489	0.14	0.16	Coronary artery disease;	chr15:85494962	chr15:85744109~85750281:-
LUAD	cis	rs7615952	0.512	rs1077621	ENSG00000241288.6	RP11-379B18.5	-3.52	0.000469	0.0489	-0.21	-0.16	Blood pressure (smoking interaction);	chr3:126100956	chr3:125827238~125916384:-
LUAD	cis	rs7615952	0.512	rs4646765	ENSG00000241288.6	RP11-379B18.5	-3.52	0.000469	0.0489	-0.21	-0.16	Blood pressure (smoking interaction);	chr3:126101864	chr3:125827238~125916384:-
LUAD	cis	rs7615952	0.576	rs4646763	ENSG00000241288.6	RP11-379B18.5	-3.52	0.000469	0.0489	-0.21	-0.16	Blood pressure (smoking interaction);	chr3:126103286	chr3:125827238~125916384:-
LUAD	cis	rs7615952	0.576	rs4646759	ENSG00000241288.6	RP11-379B18.5	-3.52	0.000469	0.0489	-0.21	-0.16	Blood pressure (smoking interaction);	chr3:126104103	chr3:125827238~125916384:-
LUAD	cis	rs4811196	0.518	rs238304	ENSG00000226144.2	RPS27AP3	3.52	0.000469	0.0489	0.16	0.16	Bone mineral density;	chr20:37783476	chr20:37049254~37049707:+
LUAD	cis	rs8054556	0.647	rs11863174	ENSG00000261367.1	RP11-455F5.4	-3.52	0.000469	0.0489	-0.18	-0.16	Autism spectrum disorder or schizophrenia;	chr16:30008054	chr16:30107675~30110541:+
LUAD	cis	rs701145	0.585	rs62276842	ENSG00000243069.6	ARHGEF26-AS1	-3.52	0.000469	0.0489	-0.25	-0.16	Coronary artery disease;	chr3:154066259	chr3:154024401~154121332:-
LUAD	cis	rs701145	0.585	rs1612933	ENSG00000243069.6	ARHGEF26-AS1	-3.52	0.000469	0.0489	-0.25	-0.16	Coronary artery disease;	chr3:154068330	chr3:154024401~154121332:-
LUAD	cis	rs701145	0.585	rs1713843	ENSG00000243069.6	ARHGEF26-AS1	-3.52	0.000469	0.0489	-0.25	-0.16	Coronary artery disease;	chr3:154068605	chr3:154024401~154121332:-
LUAD	cis	rs477687	1	rs625343	ENSG00000243648.1	RP11-215P8.1	3.52	0.000469	0.0489	0.26	0.16	AIDS progression;	chr5:135133024	chr5:134422838~134423335:+
LUAD	cis	rs3738443	0.545	rs12566906	ENSG00000225300.1	RP11-1086F11.1	-3.52	0.000469	0.0489	-0.17	-0.16	Alcohol dependence;	chr1:247224904	chr1:246605873~246608102:+
LUAD	cis	rs38055	1	rs251528	ENSG00000247796.2	CTD-2366F13.1	3.52	0.00047	0.0489	0.18	0.16	Acne (severe);	chr5:53267694	chr5:53109842~53115126:+
LUAD	cis	rs4819052	0.765	rs2838854	ENSG00000223768.1	LINC00205	-3.52	0.00047	0.0489	-0.19	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260449	chr21:45293285~45297354:+
LUAD	cis	rs7246657	0.653	rs10401525	ENSG00000226686.6	LINC01535	-3.52	0.00047	0.0489	-0.27	-0.16	Coronary artery calcification;	chr19:37168077	chr19:37251912~37265535:+
LUAD	cis	rs2115536	0.704	rs2163005	ENSG00000278600.1	RP11-81A1.6	-3.52	0.00047	0.0489	-0.13	-0.16	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;	chr15:79902138	chr15:79920195~79922455:-
LUAD	cis	rs12935418	0.583	rs2167889	ENSG00000278985.1	RP11-303E16.9	-3.52	0.00047	0.0489	-0.15	-0.16	Mean corpuscular volume;	chr16:80987867	chr16:80982319~80984094:-
LUAD	cis	rs12935418	0.552	rs2911148	ENSG00000278985.1	RP11-303E16.9	-3.52	0.00047	0.0489	-0.15	-0.16	Mean corpuscular volume;	chr16:80988289	chr16:80982319~80984094:-
LUAD	cis	rs12935418	0.552	rs2549833	ENSG00000278985.1	RP11-303E16.9	-3.52	0.00047	0.0489	-0.15	-0.16	Mean corpuscular volume;	chr16:80988627	chr16:80982319~80984094:-
LUAD	cis	rs12935418	0.552	rs2602448	ENSG00000278985.1	RP11-303E16.9	-3.52	0.00047	0.0489	-0.15	-0.16	Mean corpuscular volume;	chr16:80989067	chr16:80982319~80984094:-
LUAD	cis	rs8192282	0.69	rs9427076	ENSG00000272030.1	RP1-178F15.4	3.52	0.00047	0.0489	0.22	0.16	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);	chr1:154530546	chr1:153631438~153634397:-
LUAD	cis	rs858239	0.539	rs6965833	ENSG00000226816.2	AC005082.12	3.52	0.00047	0.0489	0.21	0.16	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23206013~23208045:+
LUAD	cis	rs858239	0.539	rs6949363	ENSG00000226816.2	AC005082.12	3.52	0.00047	0.0489	0.21	0.16	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23206013~23208045:+
LUAD	cis	rs1894292	0.715	rs2010987	ENSG00000221639.1	SNORA3	-3.52	0.00047	0.0489	-0.17	-0.16	Prostate cancer;	chr4:73607159	chr4:73263960~73264084:+
LUAD	cis	rs16893526	0.615	rs6925561	ENSG00000224995.1	LINC01526	-3.52	0.00047	0.0489	-0.29	-0.16	Coronary heart disease;	chr6:81812022	chr6:81813286~81814157:-
LUAD	cis	rs159572	0.559	rs2547529	ENSG00000250853.1	RNF138P1	3.52	0.00047	0.0489	0.19	0.16	Post-traumatic stress disorder;	chr5:56257075	chr5:55530156~55530701:-
LUAD	cis	rs180730	0.752	rs2667195	ENSG00000251609.2	SETP12	3.52	0.00047	0.0489	0.27	0.16	Fasting plasma glucose;	chr4:120886535	chr4:120895494~120897083:-
LUAD	cis	rs703842	1	rs10877019	ENSG00000245651.2	RP11-620J15.2	-3.52	0.00047	0.0489	-0.16	-0.16	Multiple sclerosis;	chr12:57779146	chr12:57869835~57896482:-
LUAD	cis	rs801193	0.569	rs2659907	ENSG00000273448.1	RP11-166O4.6	3.52	0.00047	0.0489	0.15	0.16	Aortic root size;	chr7:66699045	chr7:67333047~67334383:+
LUAD	cis	rs10118776	0.677	rs13298301	ENSG00000231967.1	RP11-12D24.6	3.52	0.00047	0.0489	0.4	0.16	Small cell lung carcinoma;	chr9:6187242	chr9:5356312~5356525:-
LUAD	cis	rs10118776	0.677	rs13296741	ENSG00000231967.1	RP11-12D24.6	3.52	0.00047	0.0489	0.4	0.16	Small cell lung carcinoma;	chr9:6187395	chr9:5356312~5356525:-
LUAD	cis	rs2447820	0.588	rs72798802	ENSG00000263432.2	RN7SL689P	3.52	0.00047	0.0489	0.26	0.16	Migraine;	chr5:123063848	chr5:123022487~123022783:-
LUAD	cis	rs6502050	0.805	rs62080003	ENSG00000266654.1	RP11-1376P16.1	3.52	0.00047	0.0489	0.17	0.16	Life satisfaction;	chr17:82121081	chr17:82160056~82160452:+
LUAD	cis	rs6502050	0.835	rs7406529	ENSG00000266654.1	RP11-1376P16.1	3.52	0.00047	0.0489	0.17	0.16	Life satisfaction;	chr17:82123001	chr17:82160056~82160452:+
LUAD	cis	rs6736093	0.966	rs11683694	ENSG00000207383.1	Y_RNA	-3.52	0.00047	0.0489	-0.2	-0.16	Coronary artery disease;	chr2:111945070	chr2:112579484~112579584:-
LUAD	cis	rs10853057	0.541	rs8076716	ENSG00000265912.1	RP11-583F2.2	-3.52	0.00047	0.0489	-0.28	-0.16	White matter microstructure (global fractional anisotropy);	chr17:65051891	chr17:64943262~64951054:+
LUAD	cis	rs17711722	0.51	rs11767457	ENSG00000213640.3	EEF1DP4	-3.52	0.00047	0.0489	-0.19	-0.16	Calcium levels;	chr7:65825628	chr7:64862999~64864370:+
LUAD	cis	rs4578769	0.788	rs12962334	ENSG00000265943.1	RP11-739L10.1	3.52	0.00047	0.0489	0.2	0.16	Eosinophil percentage of white cells;	chr18:22897971	chr18:22699481~22933764:-
LUAD	cis	rs9309473	0.607	rs1522926	ENSG00000230002.2	ALMS1-IT1	3.52	0.00047	0.0489	0.18	0.16	Metabolite levels;	chr2:73364113	chr2:73456764~73459484:+
LUAD	cis	rs9923856	0.542	rs11859698	ENSG00000280153.1	RP11-876N24.3	-3.52	0.00047	0.049	-0.11	-0.16	Atopic dermatitis;Adult asthma;	chr16:11032878	chr16:10933903~10936280:+
LUAD	cis	rs2239547	0.603	rs6805298	ENSG00000239799.1	ITIH4-AS1	-3.52	0.00047	0.049	-0.18	-0.16	Schizophrenia;	chr3:53062536	chr3:52823935~52825314:+
LUAD	cis	rs681343	0.746	rs633372	ENSG00000232871.7	SEC1P	3.52	0.00047	0.049	0.18	0.16	Primary sclerosing cholangitis;Childhood ear infection;Lung adenocarcinoma;	chr19:48705969	chr19:48638071~48682245:+
LUAD	cis	rs12565755	0.556	rs12745176	ENSG00000226476.2	RP11-776H12.1	3.52	0.00047	0.049	0.26	0.16	Response to tocilizumab in rheumatoid arthritis;	chr1:60505810	chr1:60540249~60640491:-
LUAD	cis	rs4937076	1	rs4430526	ENSG00000254671.2	STT3A-AS1	3.52	0.00047	0.049	0.18	0.16	Primary tooth development (time to first tooth eruption);	chr11:125966533	chr11:125570284~125592568:-
LUAD	cis	rs17507216	0.628	rs28371837	ENSG00000276710.3	CSPG4P8	-3.52	0.00047	0.049	-0.18	-0.16	Excessive daytime sleepiness;	chr15:82714435	chr15:82459472~82477258:+
LUAD	cis	rs357618	1	rs357618	ENSG00000272112.1	CTB-113P19.5	-3.52	0.00047	0.049	-0.15	-0.16	Basophil percentage of white cells;	chr5:151467051	chr5:151724831~151725356:-
LUAD	cis	rs6940638	0.606	rs6456771	ENSG00000228223.2	HCG11	3.52	0.00047	0.049	0.19	0.16	Intelligence (multi-trait analysis);	chr6:27264616	chr6:26523450~26526579:+
LUAD	cis	rs7178424	0.967	rs72749770	ENSG00000259251.2	RP11-643M14.1	-3.52	0.00047	0.049	-0.16	-0.16	Height;	chr15:62073266	chr15:62060503~62062434:+
LUAD	cis	rs8073060	0.586	rs8074800	ENSG00000267592.1	CTC-507E2.2	-3.52	0.00047	0.049	-0.22	-0.16	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35652129	chr17:35596904~35597128:-
LUAD	cis	rs6585424	1	rs2304410	ENSG00000225484.5	NUTM2B-AS1	-3.52	0.00047	0.049	-0.26	-0.16	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80162054	chr10:79663088~79826594:-
LUAD	cis	rs12210905	1	rs12196084	ENSG00000261353.1	CTA-14H9.5	3.52	0.00047	0.049	0.32	0.16	Hip circumference adjusted for BMI;	chr6:27230425	chr6:26527063~26527404:+
LUAD	cis	rs6928977	0.66	rs9373131	ENSG00000231028.7	LINC00271	3.52	0.00047	0.049	0.18	0.16	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135478786	chr6:135497801~135716055:+
LUAD	cis	rs4792901	0.959	rs2293015	ENSG00000198496.9	NBR2	3.52	0.00047	0.049	0.18	0.16	Dupuytren's disease;	chr17:43544631	chr17:43125610~43153671:+
LUAD	cis	rs4792901	0.918	rs79868029	ENSG00000198496.9	NBR2	3.52	0.00047	0.049	0.18	0.16	Dupuytren's disease;	chr17:43545139	chr17:43125610~43153671:+
LUAD	cis	rs4792901	0.918	rs2271959	ENSG00000198496.9	NBR2	3.52	0.00047	0.049	0.18	0.16	Dupuytren's disease;	chr17:43545372	chr17:43125610~43153671:+
LUAD	cis	rs72627123	1	rs76553384	ENSG00000259065.1	RP5-1021I20.1	-3.52	0.000471	0.049	-0.25	-0.16	Morning vs. evening chronotype;	chr14:73916976	chr14:73787360~73803270:+
LUAD	cis	rs2553026	0.718	rs748044	ENSG00000229754.1	CXCR2P1	-3.52	0.000471	0.049	-0.16	-0.16	Height;	chr2:217289319	chr2:218059155~218065729:-
LUAD	cis	rs1823913	0.637	rs1349938	ENSG00000230611.1	HMGB1P27	3.52	0.000471	0.049	0.18	0.16	Obesity-related traits;	chr2:191299970	chr2:191174233~191174835:+
LUAD	cis	rs1823913	0.592	rs1349939	ENSG00000230611.1	HMGB1P27	3.52	0.000471	0.049	0.18	0.16	Obesity-related traits;	chr2:191300079	chr2:191174233~191174835:+
LUAD	cis	rs1823913	0.637	rs4853581	ENSG00000230611.1	HMGB1P27	3.52	0.000471	0.049	0.18	0.16	Obesity-related traits;	chr2:191301533	chr2:191174233~191174835:+
LUAD	cis	rs1823913	0.614	rs7565987	ENSG00000230611.1	HMGB1P27	3.52	0.000471	0.049	0.18	0.16	Obesity-related traits;	chr2:191301815	chr2:191174233~191174835:+
LUAD	cis	rs1823913	0.614	rs1973067	ENSG00000230611.1	HMGB1P27	3.52	0.000471	0.049	0.18	0.16	Obesity-related traits;	chr2:191302021	chr2:191174233~191174835:+
LUAD	cis	rs1823913	0.637	rs1973068	ENSG00000230611.1	HMGB1P27	3.52	0.000471	0.049	0.18	0.16	Obesity-related traits;	chr2:191302227	chr2:191174233~191174835:+
LUAD	cis	rs1823913	0.637	rs7569231	ENSG00000230611.1	HMGB1P27	3.52	0.000471	0.049	0.18	0.16	Obesity-related traits;	chr2:191302373	chr2:191174233~191174835:+
LUAD	cis	rs1823913	0.637	rs6434461	ENSG00000230611.1	HMGB1P27	3.52	0.000471	0.049	0.18	0.16	Obesity-related traits;	chr2:191302661	chr2:191174233~191174835:+
LUAD	cis	rs1823913	0.614	rs6434462	ENSG00000230611.1	HMGB1P27	3.52	0.000471	0.049	0.18	0.16	Obesity-related traits;	chr2:191302705	chr2:191174233~191174835:+
LUAD	cis	rs1823913	0.637	rs6750360	ENSG00000230611.1	HMGB1P27	3.52	0.000471	0.049	0.18	0.16	Obesity-related traits;	chr2:191303089	chr2:191174233~191174835:+
LUAD	cis	rs1823913	0.637	rs11677694	ENSG00000230611.1	HMGB1P27	3.52	0.000471	0.049	0.18	0.16	Obesity-related traits;	chr2:191303203	chr2:191174233~191174835:+
LUAD	cis	rs1823913	0.571	rs6737307	ENSG00000230611.1	HMGB1P27	3.52	0.000471	0.049	0.18	0.16	Obesity-related traits;	chr2:191303247	chr2:191174233~191174835:+
LUAD	cis	rs1823913	0.637	rs4853582	ENSG00000230611.1	HMGB1P27	3.52	0.000471	0.049	0.18	0.16	Obesity-related traits;	chr2:191303483	chr2:191174233~191174835:+
LUAD	cis	rs1823913	0.637	rs35200176	ENSG00000230611.1	HMGB1P27	3.52	0.000471	0.049	0.18	0.16	Obesity-related traits;	chr2:191303534	chr2:191174233~191174835:+
LUAD	cis	rs1823913	0.637	rs17348013	ENSG00000230611.1	HMGB1P27	3.52	0.000471	0.049	0.18	0.16	Obesity-related traits;	chr2:191303726	chr2:191174233~191174835:+
LUAD	cis	rs2664588	0.503	rs6012309	ENSG00000224565.1	RP1-148H17.1	-3.52	0.000471	0.049	-0.17	-0.16	Cerebrospinal fluid AB1-42 levels;	chr20:47968726	chr20:47391929~47412327:-
LUAD	cis	rs440932	0.747	rs330946	ENSG00000254367.4	RP11-211C9.1	-3.52	0.000471	0.049	-0.21	-0.16	High light scatter reticulocyte percentage of red cells;	chr8:9164667	chr8:8723693~8782479:-
LUAD	cis	rs1577917	0.629	rs7761762	ENSG00000220563.1	PKMP3	3.52	0.000471	0.049	0.15	0.16	Response to antipsychotic treatment;	chr6:85496250	chr6:85659892~85660606:-
LUAD	cis	rs273259	0.583	rs11162518	ENSG00000235400.1	RP4-641G12.4	3.52	0.000471	0.049	0.23	0.16	Febrile seizures (MMR vaccine-related);Febrile seizures;	chr1:78608126	chr1:78749073~78750659:+
LUAD	cis	rs789852	0.764	rs1773184	ENSG00000229334.1	AC046143.3	-3.52	0.000471	0.049	-0.29	-0.16	QT interval;	chr3:194593103	chr3:194632923~194645401:+
LUAD	cis	rs860295	0.702	rs11264387	ENSG00000273002.1	RP11-336K24.12	3.52	0.000471	0.049	0.14	0.16	Body mass index;	chr1:155593361	chr1:155978799~155982986:+
LUAD	cis	rs9638182	0.72	rs13235543	ENSG00000274080.1	CTA-315H11.2	3.52	0.000471	0.049	0.29	0.16	Triglycerides;	chr7:73599571	chr7:73609262~73611502:-
LUAD	cis	rs4927850	0.958	rs1975582	ENSG00000278820.1	AC024937.1	3.52	0.000471	0.049	0.14	0.16	Pancreatic cancer;	chr3:196024568	chr3:195960500~195960612:-
LUAD	cis	rs1910358	0.614	rs7721412	ENSG00000248874.4	C5orf17	-3.52	0.000471	0.049	-0.2	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23933135	chr5:23951348~24178263:+
LUAD	cis	rs1910358	0.614	rs7714895	ENSG00000248874.4	C5orf17	-3.52	0.000471	0.049	-0.2	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23937383	chr5:23951348~24178263:+
LUAD	cis	rs1910358	0.506	rs2331688	ENSG00000248874.4	C5orf17	-3.52	0.000471	0.049	-0.2	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23940321	chr5:23951348~24178263:+
LUAD	cis	rs1910358	0.592	rs4315895	ENSG00000248874.4	C5orf17	-3.52	0.000471	0.049	-0.2	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23940473	chr5:23951348~24178263:+
LUAD	cis	rs1910358	0.614	rs35378139	ENSG00000248874.4	C5orf17	-3.52	0.000471	0.049	-0.2	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23942261	chr5:23951348~24178263:+
LUAD	cis	rs1910358	0.614	rs1604453	ENSG00000248874.4	C5orf17	-3.52	0.000471	0.049	-0.2	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23945779	chr5:23951348~24178263:+
LUAD	cis	rs1910358	0.614	rs1119833	ENSG00000248874.4	C5orf17	-3.52	0.000471	0.049	-0.2	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23945905	chr5:23951348~24178263:+
LUAD	cis	rs1910358	0.53	rs2331686	ENSG00000248874.4	C5orf17	-3.52	0.000471	0.049	-0.2	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23947618	chr5:23951348~24178263:+
LUAD	cis	rs3770081	0.826	rs1019591	ENSG00000273080.1	RP11-301O19.1	-3.52	0.000471	0.049	-0.37	-0.16	Facial emotion recognition (sad faces);	chr2:86071476	chr2:86195590~86196049:+
LUAD	cis	rs9810888	0.738	rs754063	ENSG00000271916.1	RP11-884K10.6	-3.52	0.000471	0.049	-0.16	-0.16	Hypertension;Diastolic blood pressure;Systolic blood pressure;	chr3:53638163	chr3:53797764~53798019:-
LUAD	cis	rs1766786	1	rs1766792	ENSG00000226172.2	RP4-712E4.1	-3.52	0.000471	0.049	-0.24	-0.16	Chin dimples;	chr1:118923058	chr1:119000344~119001392:-
LUAD	cis	rs6743068	0.541	rs6435079	ENSG00000234842.1	AC007163.8	-3.52	0.000471	0.049	-0.18	-0.16	Lymphocyte percentage of white cells;	chr2:201335608	chr2:201549631~201550307:+
LUAD	cis	rs838147	0.534	rs2638280	ENSG00000232871.7	SEC1P	3.52	0.000471	0.049	0.18	0.16	Dietary macronutrient intake;	chr19:48706061	chr19:48638071~48682245:+
LUAD	cis	rs9532669	0.926	rs9532691	ENSG00000229473.2	RGS17P1	-3.52	0.000471	0.049	-0.19	-0.16	Cervical cancer;	chr13:40969358	chr13:40992779~40993331:-
LUAD	cis	rs987044	0.726	rs7969979	ENSG00000257221.1	RP11-689B22.2	-3.52	0.000471	0.049	-0.13	-0.16	Mean platelet volume;	chr12:108714119	chr12:108628687~108641318:+
LUAD	cis	rs4523957	0.748	rs12603592	ENSG00000262333.1	HNRNPA1P16	3.52	0.000471	0.049	0.13	0.16	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr17:2216524	chr17:2306761~2307715:+
LUAD	cis	rs10861342	1	rs7305712	ENSG00000257999.1	RP11-61E11.2	3.52	0.000471	0.049	0.28	0.16	IgG glycosylation;	chr12:105125410	chr12:105102472~105107179:-
LUAD	cis	rs9659323	1	rs10923715	ENSG00000231365.4	RP11-418J17.1	3.52	0.000471	0.049	0.18	0.16	Body mass index;	chr1:118992711	chr1:119140396~119275973:+
LUAD	cis	rs7428	0.545	rs4832163	ENSG00000246575.2	AC093162.5	3.52	0.000471	0.049	0.15	0.16	Ear protrusion;	chr2:85313960	chr2:85315041~85316529:+
LUAD	cis	rs4842666	0.85	rs11105328	ENSG00000258302.2	RP11-981P6.1	3.52	0.000471	0.049	0.23	0.16	Blood pressure;	chr12:89548613	chr12:89561129~89594878:+
LUAD	cis	rs4386084	1	rs12908522	ENSG00000242737.1	RP11-562A8.1	-3.52	0.000471	0.049	-0.21	-0.16	Basophil percentage of granulocytes;Basophil percentage of white cells;	chr15:49952350	chr15:50466738~50467096:+
LUAD	cis	rs786425	0.77	rs7974279	ENSG00000278112.1	RP11-972P1.11	3.52	0.000471	0.049	0.15	0.16	Pubertal anthropometrics;	chr12:123681864	chr12:123519390~123519856:-
LUAD	cis	rs786425	0.77	rs7964443	ENSG00000278112.1	RP11-972P1.11	3.52	0.000471	0.049	0.15	0.16	Pubertal anthropometrics;	chr12:123681953	chr12:123519390~123519856:-
LUAD	cis	rs3126085	0.935	rs74127901	ENSG00000237975.5	FLG-AS1	3.52	0.000471	0.049	0.25	0.16	Atopic dermatitis;	chr1:152223103	chr1:152168125~152445456:+
LUAD	cis	rs763121	0.853	rs10135	ENSG00000225450.1	RP3-508I15.14	3.52	0.000472	0.049	0.15	0.16	Menopause (age at onset);	chr22:38686169	chr22:38739003~38749041:+
LUAD	cis	rs741668	0.641	rs1022951	ENSG00000235903.6	CPB2-AS1	3.52	0.000472	0.0491	0.2	0.16	Cerebrospinal fluid clusterin levels;	chr13:46075319	chr13:46052806~46113332:+
LUAD	cis	rs7809950	0.954	rs3779494	ENSG00000238832.1	snoU109	3.52	0.000472	0.0491	0.24	0.16	Coronary artery disease;	chr7:107609910	chr7:107603363~107603507:+
LUAD	cis	rs4578769	0.531	rs12964304	ENSG00000266850.1	RP11-370A5.1	3.52	0.000472	0.0491	0.2	0.16	Eosinophil percentage of white cells;	chr18:22928641	chr18:22723491~22907721:-
LUAD	cis	rs4578769	0.531	rs12968784	ENSG00000266850.1	RP11-370A5.1	3.52	0.000472	0.0491	0.2	0.16	Eosinophil percentage of white cells;	chr18:22928645	chr18:22723491~22907721:-
LUAD	cis	rs12138950	0.948	rs16822442	ENSG00000270728.1	RP4-657E11.10	-3.52	0.000472	0.0491	-0.18	-0.16	Hypothyroidism;Thyroid volume;	chr1:19501476	chr1:19297080~19297903:+
LUAD	cis	rs17685	0.961	rs41301394	ENSG00000205485.12	AC004980.7	-3.52	0.000472	0.0491	-0.17	-0.16	Coffee consumption (cups per day);Coffee consumption;	chr7:75983485	chr7:76549360~76627982:+
LUAD	cis	rs2117029	0.727	rs10875910	ENSG00000258017.1	RP11-386G11.10	-3.52	0.000472	0.0491	-0.2	-0.16	Intelligence (multi-trait analysis);	chr12:49008610	chr12:49127782~49147869:+
LUAD	cis	rs36093844	0.576	rs17745153	ENSG00000279742.1	RP11-700A24.1	-3.52	0.000472	0.0491	-0.19	-0.16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86012484	chr11:85852557~85854943:-
LUAD	cis	rs36093844	0.626	rs4944552	ENSG00000279742.1	RP11-700A24.1	-3.52	0.000472	0.0491	-0.19	-0.16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:86012763	chr11:85852557~85854943:-
LUAD	cis	rs7142881	0.844	rs2378897	ENSG00000258525.1	RP11-829H16.3	-3.52	0.000472	0.0491	-0.18	-0.16	Response to iloperidone treatment (QT prolongation);	chr14:31593898	chr14:30876179~30889808:-
LUAD	cis	rs591584	0.874	rs10831246	ENSG00000255893.1	RP11-685N10.1	-3.52	0.000472	0.0491	-0.18	-0.16	Macrophage Migration Inhibitory Factor levels;	chr11:94589529	chr11:94472908~94473570:-
LUAD	cis	rs200367988	1	rs200367988	ENSG00000227165.6	WDR11-AS1	-3.52	0.000472	0.0491	-0.19	-0.16	Prostate-specific antigen levels (conditioned on lead SNPs);Prostate-specific antigen levels;	chr10:120915337	chr10:120761812~120851345:-
LUAD	cis	rs2836754	0.841	rs8126698	ENSG00000205622.8	AF064858.6	-3.52	0.000472	0.0491	-0.18	-0.16	Body mass index;Crohn's disease;	chr21:38922444	chr21:38863676~38956467:-
LUAD	cis	rs6502050	0.835	rs9646397	ENSG00000266654.1	RP11-1376P16.1	3.52	0.000472	0.0491	0.17	0.16	Life satisfaction;	chr17:82125658	chr17:82160056~82160452:+
LUAD	cis	rs9900280	0.967	rs7210047	ENSG00000264808.1	RP11-802D6.1	3.52	0.000472	0.0491	0.19	0.16	Mean platelet volume;	chr17:29401478	chr17:29369717~29390777:-
LUAD	cis	rs310008	0.609	rs2927337	ENSG00000260229.1	RP11-391L3.5	3.52	0.000472	0.0491	0.29	0.16	Menarche (age at onset);	chr16:81471263	chr16:81476023~81476519:-
LUAD	cis	rs11841001	0.731	rs17065046	ENSG00000261105.4	LMO7-AS1	3.52	0.000472	0.0491	0.39	0.16	Corneal astigmatism;	chr13:75792486	chr13:75604700~75635994:-
LUAD	cis	rs10853057	0.541	rs77675516	ENSG00000265912.1	RP11-583F2.2	-3.52	0.000472	0.0491	-0.28	-0.16	White matter microstructure (global fractional anisotropy);	chr17:65050690	chr17:64943262~64951054:+
LUAD	cis	rs6928977	0.675	rs12206850	ENSG00000231028.7	LINC00271	-3.52	0.000472	0.0491	-0.19	-0.16	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135476670	chr6:135497801~135716055:+
LUAD	cis	rs1044826	0.913	rs12488939	ENSG00000214280.3	RP11-553K23.2	-3.52	0.000472	0.0491	-0.2	-0.16	Obesity-related traits;	chr3:139331989	chr3:139582928~139583593:-
LUAD	cis	rs4308124	0.708	rs7585313	ENSG00000230499.1	AC108463.1	-3.52	0.000472	0.0491	-0.22	-0.16	Vitiligo;	chr2:111217626	chr2:111195963~111206494:+
LUAD	cis	rs11951515	0.738	rs4866822	ENSG00000249779.1	RP11-447H19.3	-3.52	0.000472	0.0491	-0.19	-0.16	Metabolite levels  (X-11787);	chr5:43357992	chr5:43206709~43207811:+
LUAD	cis	rs11951515	0.663	rs11742171	ENSG00000249779.1	RP11-447H19.3	-3.52	0.000472	0.0491	-0.19	-0.16	Metabolite levels  (X-11787);	chr5:43358607	chr5:43206709~43207811:+
LUAD	cis	rs11951515	0.738	rs7708779	ENSG00000249779.1	RP11-447H19.3	-3.52	0.000472	0.0491	-0.19	-0.16	Metabolite levels  (X-11787);	chr5:43359181	chr5:43206709~43207811:+
LUAD	cis	rs11951515	0.738	rs4866824	ENSG00000249779.1	RP11-447H19.3	-3.52	0.000472	0.0491	-0.19	-0.16	Metabolite levels  (X-11787);	chr5:43359343	chr5:43206709~43207811:+
LUAD	cis	rs1423688	0.857	rs1239334	ENSG00000249740.1	OSMR-AS1	3.52	0.000472	0.0491	0.2	0.16	Antipsychotic drug-induced QTc interval change in schizophrenia;	chr5:38904261	chr5:38736055~38845829:-
LUAD	cis	rs875971	0.528	rs801213	ENSG00000224316.1	RP11-479O9.2	-3.52	0.000472	0.0491	-0.18	-0.16	Aortic root size;	chr7:66549931	chr7:65773620~65802067:+
LUAD	cis	rs875971	0.545	rs801212	ENSG00000224316.1	RP11-479O9.2	-3.52	0.000472	0.0491	-0.18	-0.16	Aortic root size;	chr7:66550643	chr7:65773620~65802067:+
LUAD	cis	rs875971	0.545	rs801199	ENSG00000224316.1	RP11-479O9.2	-3.52	0.000472	0.0491	-0.18	-0.16	Aortic root size;	chr7:66560286	chr7:65773620~65802067:+
LUAD	cis	rs6472235	0.681	rs67768803	ENSG00000200714.1	Y_RNA	-3.52	0.000472	0.0491	-0.21	-0.16	Plateletcrit;Myopia (pathological);	chr8:65955957	chr8:65592731~65592820:+
LUAD	cis	rs7577696	0.889	rs212730	ENSG00000276334.1	AL133243.1	3.52	0.000473	0.0491	0.19	0.16	Inflammatory biomarkers;	chr2:32246604	chr2:32521927~32523547:+
LUAD	cis	rs526231	0.543	rs32851	ENSG00000250682.4	LINC00491	3.52	0.000473	0.0491	0.2	0.16	Primary biliary cholangitis;	chr5:103132967	chr5:102609156~102671559:-
LUAD	cis	rs2281603	0.57	rs10131416	ENSG00000259116.1	RP11-973N13.4	-3.52	0.000473	0.0491	-0.13	-0.16	Lymphocyte counts;	chr14:64477555	chr14:64514154~64540368:-
LUAD	cis	rs12682352	0.579	rs7006589	ENSG00000253893.2	FAM85B	-3.52	0.000473	0.0491	-0.2	-0.16	Neuroticism;	chr8:8810976	chr8:8167819~8226614:-
LUAD	cis	rs8085804	0.571	rs12458032	ENSG00000276174.1	RP11-687E1.2	-3.52	0.000473	0.0491	-0.22	-0.16	Cognitive performance;	chr18:42646199	chr18:42052705~42053030:+
LUAD	cis	rs4218	0.608	rs59282449	ENSG00000277144.1	RP11-59H7.4	-3.52	0.000473	0.0491	-0.21	-0.16	Social communication problems;	chr15:59078881	chr15:59115547~59116089:-
LUAD	cis	rs926340	0.634	rs136388	ENSG00000279699.1	RP1-102K2.9	3.52	0.000473	0.0491	0.2	0.16	Colorectal cancer;	chr22:30712237	chr22:30275215~30276951:-
LUAD	cis	rs8046148	0.951	rs2356837	ENSG00000279356.1	RP11-429P3.8	3.52	0.000473	0.0491	0.19	0.16	Testicular germ cell tumor;	chr16:50086982	chr16:50072862~50074986:+
LUAD	cis	rs6496932	0.755	rs6497021	ENSG00000259630.2	CTD-2262B20.1	-3.52	0.000473	0.0491	-0.2	-0.16	Central corneal thickness;Corneal structure;	chr15:85353036	chr15:85415228~85415633:+
LUAD	cis	rs9341808	0.69	rs6930534	ENSG00000233967.5	RP11-250B2.3	3.52	0.000473	0.0492	0.16	0.16	Sitting height ratio;	chr6:80186333	chr6:80443344~80465927:+
LUAD	cis	rs957448	1	rs72674843	ENSG00000254057.1	RP3-388N13.3	3.52	0.000473	0.0492	0.17	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94520772	chr8:93834454~93846743:-
LUAD	cis	rs42490	0.664	rs39515	ENSG00000251136.7	RP11-37B2.1	-3.52	0.000473	0.0492	-0.16	-0.16	Leprosy;	chr8:89816761	chr8:89609409~89757727:-
LUAD	cis	rs9291683	0.609	rs36084205	ENSG00000250413.1	RP11-448G15.1	-3.52	0.000473	0.0492	-0.2	-0.16	Bone mineral density;	chr4:10027054	chr4:10006482~10009725:+
LUAD	cis	rs9291683	0.609	rs13141233	ENSG00000250413.1	RP11-448G15.1	-3.52	0.000473	0.0492	-0.2	-0.16	Bone mineral density;	chr4:10027105	chr4:10006482~10009725:+
LUAD	cis	rs9291683	0.609	rs34709913	ENSG00000250413.1	RP11-448G15.1	-3.52	0.000473	0.0492	-0.2	-0.16	Bone mineral density;	chr4:10027331	chr4:10006482~10009725:+
LUAD	cis	rs2303149	0.577	rs4808452	ENSG00000270802.2	AC005776.1	-3.52	0.000473	0.0492	-0.17	-0.16	Mean platelet volume;	chr19:16094866	chr19:15338948~15339237:+
LUAD	cis	rs453301	0.686	rs7814328	ENSG00000233609.3	RP11-62H7.2	-3.52	0.000473	0.0492	-0.14	-0.16	Joint mobility (Beighton score);	chr8:9018719	chr8:8961200~8979025:+
LUAD	cis	rs875971	0.66	rs10229345	ENSG00000232546.1	RP11-458F8.1	-3.52	0.000473	0.0492	-0.14	-0.16	Aortic root size;	chr7:66517181	chr7:66848496~66858136:+
LUAD	cis	rs3738443	0.644	rs2799177	ENSG00000225300.1	RP11-1086F11.1	3.52	0.000473	0.0492	0.2	0.16	Alcohol dependence;	chr1:247235898	chr1:246605873~246608102:+
LUAD	cis	rs17507216	0.671	rs28582623	ENSG00000276710.3	CSPG4P8	-3.52	0.000473	0.0492	-0.18	-0.16	Excessive daytime sleepiness;	chr15:82577381	chr15:82459472~82477258:+
LUAD	cis	rs3781264	0.595	rs7085378	ENSG00000273450.1	RP11-76P2.4	3.52	0.000473	0.0492	0.2	0.16	Esophageal cancer and gastric cancer;	chr10:94349568	chr10:94314907~94315327:-
LUAD	cis	rs116095464	0.558	rs10079760	ENSG00000248925.1	CTD-2083E4.6	3.52	0.000473	0.0492	0.26	0.16	Breast cancer;	chr5:230663	chr5:269858~271516:-
LUAD	cis	rs2057178	1	rs2057178	ENSG00000183242.10	WT1-AS	3.52	0.000473	0.0492	0.25	0.16	Tuberculosis;	chr11:32342641	chr11:32435518~32458769:+
LUAD	cis	rs875971	0.545	rs75577046	ENSG00000222364.1	RNU6-96P	-3.52	0.000473	0.0492	-0.2	-0.16	Aortic root size;	chr7:66493729	chr7:66395191~66395286:+
LUAD	cis	rs2613514	0.568	rs2290905	ENSG00000204282.4	TNRC6C-AS1	-3.52	0.000473	0.0492	-0.2	-0.16	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr17:78098030	chr17:78107398~78111799:-
LUAD	cis	rs13113518	0.51	rs10049561	ENSG00000249700.7	SRD5A3-AS1	3.52	0.000473	0.0492	0.16	0.16	Height;	chr4:55426623	chr4:55363971~55395847:-
LUAD	cis	rs1075265	0.704	rs805410	ENSG00000272156.1	RP11-477N3.1	-3.52	0.000473	0.0492	-0.19	-0.16	Chronotype;Morning vs. evening chronotype;	chr2:53893360	chr2:54082554~54085066:+
LUAD	cis	rs7942368	0.941	rs10899283	ENSG00000254632.1	RP11-21L23.4	3.52	0.000473	0.0492	0.17	0.16	Endometriosis;	chr11:76794158	chr11:76759916~76768223:-
LUAD	cis	rs548181	1	rs548181	ENSG00000254671.2	STT3A-AS1	-3.52	0.000473	0.0492	-0.28	-0.16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr11:125591814	chr11:125570284~125592568:-
LUAD	cis	rs854765	0.583	rs8070128	ENSG00000264177.1	RP1-37N7.1	3.52	0.000473	0.0492	0.15	0.16	Total body bone mineral density;	chr17:17901411	chr17:18379855~18388984:-
LUAD	cis	rs7829975	0.84	rs555617	ENSG00000233609.3	RP11-62H7.2	-3.52	0.000473	0.0492	-0.13	-0.16	Mood instability;	chr8:8735335	chr8:8961200~8979025:+
LUAD	cis	rs11707813	0.593	rs11714760	ENSG00000226360.5	RPL10AP6	-3.52	0.000474	0.0492	-0.19	-0.16	Lip morphology;	chr3:61198805	chr3:61742455~61743106:-
LUAD	cis	rs8114671	0.562	rs6119536	ENSG00000276073.1	RP5-1125A11.7	3.52	0.000474	0.0492	0.15	0.16	Height;	chr20:34862238	chr20:33985617~33988989:-
LUAD	cis	rs4363385	0.776	rs2879490	ENSG00000223599.1	RP11-216N14.7	-3.52	0.000474	0.0492	-0.19	-0.16	Inflammatory skin disease;	chr1:152974687	chr1:153852106~153853414:-
LUAD	cis	rs56046484	0.789	rs896364	ENSG00000259295.5	CSPG4P12	3.52	0.000474	0.0492	0.22	0.16	Testicular germ cell tumor;	chr15:84976426	chr15:85191438~85213905:+
LUAD	cis	rs2880765	0.743	rs7168345	ENSG00000259630.2	CTD-2262B20.1	3.52	0.000474	0.0492	0.18	0.16	Coronary artery disease;	chr15:85470370	chr15:85415228~85415633:+
LUAD	cis	rs6496932	1	rs35156762	ENSG00000202081.1	RNU6-1280P	3.52	0.000474	0.0492	0.22	0.16	Central corneal thickness;Corneal structure;	chr15:85281243	chr15:85651522~85651628:-
LUAD	cis	rs7131987	0.565	rs1991113	ENSG00000257176.2	RP11-996F15.2	-3.52	0.000474	0.0492	-0.16	-0.16	QT interval;	chr12:29239070	chr12:29280418~29317848:-
LUAD	cis	rs56046484	0.778	rs1606119	ENSG00000259630.2	CTD-2262B20.1	-3.52	0.000474	0.0492	-0.19	-0.16	Testicular germ cell tumor;	chr15:85128148	chr15:85415228~85415633:+
LUAD	cis	rs2408955	0.522	rs11168408	ENSG00000273765.1	RP11-370I10.11	-3.52	0.000474	0.0492	-0.17	-0.16	Glycated hemoglobin levels;	chr12:48104544	chr12:48360920~48361377:+
LUAD	cis	rs6496932	0.635	rs2200214	ENSG00000218052.5	ADAMTS7P4	-3.52	0.000474	0.0492	-0.18	-0.16	Central corneal thickness;Corneal structure;	chr15:85383745	chr15:85255369~85330334:-
LUAD	cis	rs3805389	0.504	rs59571323	ENSG00000249700.7	SRD5A3-AS1	-3.52	0.000474	0.0492	-0.23	-0.16	Waist-to-hip ratio adjusted for body mass index;	chr4:55611187	chr4:55363971~55395847:-
LUAD	cis	rs13434995	0.838	rs57178140	ENSG00000249700.7	SRD5A3-AS1	-3.52	0.000474	0.0492	-0.23	-0.16	Adiponectin levels;	chr4:55611361	chr4:55363971~55395847:-
LUAD	cis	rs12928939	0.815	rs8049163	ENSG00000262140.1	RP11-417N10.3	-3.52	0.000474	0.0493	-0.18	-0.16	Post bronchodilator FEV1;	chr16:71685450	chr16:71833787~71835932:+
LUAD	cis	rs786425	0.77	rs12828633	ENSG00000278112.1	RP11-972P1.11	3.52	0.000474	0.0493	0.15	0.16	Pubertal anthropometrics;	chr12:123695073	chr12:123519390~123519856:-
LUAD	cis	rs3733585	0.783	rs13148371	ENSG00000250413.1	RP11-448G15.1	-3.52	0.000474	0.0493	-0.2	-0.16	Cleft plate (environmental tobacco smoke interaction);	chr4:10030937	chr4:10006482~10009725:+
LUAD	cis	rs13113518	0.812	rs6825774	ENSG00000249700.7	SRD5A3-AS1	3.52	0.000474	0.0493	0.16	0.16	Height;	chr4:55491150	chr4:55363971~55395847:-
LUAD	cis	rs13113518	0.812	rs3805153	ENSG00000249700.7	SRD5A3-AS1	3.52	0.000474	0.0493	0.16	0.16	Height;	chr4:55493557	chr4:55363971~55395847:-
LUAD	cis	rs13113518	1	rs13136282	ENSG00000223305.1	RN7SKP30	3.52	0.000474	0.0493	0.18	0.16	Height;	chr4:55551845	chr4:55540502~55540835:-
LUAD	cis	rs13113518	1	rs11934897	ENSG00000223305.1	RN7SKP30	3.52	0.000474	0.0493	0.18	0.16	Height;	chr4:55553396	chr4:55540502~55540835:-
LUAD	cis	rs13113518	0.934	rs11932293	ENSG00000223305.1	RN7SKP30	3.52	0.000474	0.0493	0.18	0.16	Height;	chr4:55554025	chr4:55540502~55540835:-
LUAD	cis	rs13113518	1	rs4865011	ENSG00000223305.1	RN7SKP30	3.52	0.000474	0.0493	0.18	0.16	Height;	chr4:55554456	chr4:55540502~55540835:-
LUAD	cis	rs2553026	0.559	rs2113825	ENSG00000229754.1	CXCR2P1	-3.52	0.000474	0.0493	-0.19	-0.16	Height;	chr2:217279008	chr2:218059155~218065729:-
LUAD	cis	rs8062405	0.789	rs28676837	ENSG00000261419.1	RP11-57A19.4	3.52	0.000474	0.0493	0.17	0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28615742	chr16:28659696~28740781:-
LUAD	cis	rs6460942	0.545	rs17448114	ENSG00000226690.5	AC005281.1	3.52	0.000474	0.0493	0.3	0.16	Coronary artery disease;	chr7:12484832	chr7:12496429~12541910:+
LUAD	cis	rs6460942	0.597	rs17545416	ENSG00000226690.5	AC005281.1	3.52	0.000474	0.0493	0.3	0.16	Coronary artery disease;	chr7:12486318	chr7:12496429~12541910:+
LUAD	cis	rs6460942	0.597	rs13245635	ENSG00000226690.5	AC005281.1	3.52	0.000474	0.0493	0.3	0.16	Coronary artery disease;	chr7:12486828	chr7:12496429~12541910:+
LUAD	cis	rs6460942	0.597	rs12699381	ENSG00000226690.5	AC005281.1	3.52	0.000474	0.0493	0.3	0.16	Coronary artery disease;	chr7:12487400	chr7:12496429~12541910:+
LUAD	cis	rs2297363	1	rs3777399	ENSG00000213073.4	RP11-288H12.3	-3.52	0.000474	0.0493	-0.19	-0.16	Total cholesterol levels;Blood protein levels;	chr6:160092761	chr6:160093082~160096212:+
LUAD	cis	rs6804368	0.553	rs9829308	ENSG00000227260.1	AC116035.1	3.52	0.000474	0.0493	0.17	0.16	Blood metabolite levels;	chr3:30721581	chr3:30524745~30527185:+
LUAD	cis	rs9291683	0.609	rs12500810	ENSG00000250413.1	RP11-448G15.1	-3.52	0.000474	0.0493	-0.2	-0.16	Bone mineral density;	chr4:10029444	chr4:10006482~10009725:+
LUAD	cis	rs910316	0.763	rs175014	ENSG00000259138.1	RP11-950C14.7	-3.52	0.000474	0.0493	-0.17	-0.16	Height;	chr14:74990224	chr14:75127153~75136930:+
LUAD	cis	rs4218	0.574	rs12907957	ENSG00000277144.1	RP11-59H7.4	-3.52	0.000474	0.0493	-0.19	-0.16	Social communication problems;	chr15:59109486	chr15:59115547~59116089:-
LUAD	cis	rs9926296	0.744	rs164749	ENSG00000260259.1	RP11-368I7.4	3.52	0.000474	0.0493	0.15	0.16	Vitiligo;	chr16:89641816	chr16:89682620~89686569:-
LUAD	cis	rs2279168	0.867	rs77799869	ENSG00000202081.1	RNU6-1280P	-3.52	0.000474	0.0493	-0.28	-0.16	Response to platinum-based chemotherapy (carboplatin);	chr15:85471796	chr15:85651522~85651628:-
LUAD	cis	rs1876905	0.68	rs373526	ENSG00000271789.1	RP5-1112D6.7	3.52	0.000474	0.0493	0.22	0.16	Mean corpuscular hemoglobin;	chr6:111190261	chr6:111297126~111298510:+
LUAD	cis	rs9813712	0.547	rs6807290	ENSG00000228252.7	COL6A4P2	3.52	0.000475	0.0493	0.15	0.16	Response to amphetamines;	chr3:130297952	chr3:130212823~130273806:+
LUAD	cis	rs2905347	0.757	rs1006509	ENSG00000179428.2	AC073072.5	-3.52	0.000475	0.0493	-0.19	-0.16	Major depression and alcohol dependence;	chr7:22658847	chr7:22725395~22727620:-
LUAD	cis	rs4927850	1	rs4927850	ENSG00000278820.1	AC024937.1	-3.52	0.000475	0.0493	-0.14	-0.16	Pancreatic cancer;	chr3:196024759	chr3:195960500~195960612:-
LUAD	cis	rs4474465	0.833	rs10899540	ENSG00000251323.2	RP11-452H21.4	-3.52	0.000475	0.0493	-0.19	-0.16	Alzheimer's disease (survival time);	chr11:78534503	chr11:78423982~78429836:-
LUAD	cis	rs1667255	1	rs1375446	ENSG00000266521.1	RP11-650P15.1	3.52	0.000475	0.0493	0.19	0.16	Retinol levels;	chr18:31577372	chr18:31496645~31497195:-
LUAD	cis	rs4811196	0.957	rs2179320	ENSG00000226144.2	RPS27AP3	-3.52	0.000475	0.0493	-0.19	-0.16	Bone mineral density;	chr20:37843383	chr20:37049254~37049707:+
LUAD	cis	rs867186	1	rs867186	ENSG00000222460.1	RN7SKP271	3.52	0.000475	0.0493	0.25	0.16	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35176751	chr20:35643143~35643462:+
LUAD	cis	rs3126085	0.935	rs4845426	ENSG00000237975.5	FLG-AS1	-3.52	0.000475	0.0493	-0.24	-0.16	Atopic dermatitis;	chr1:152222883	chr1:152168125~152445456:+
LUAD	cis	rs11988997	1	rs73327166	ENSG00000281641.1	SAMD12-AS1	-3.52	0.000475	0.0493	-0.38	-0.16	Pancreatitis;	chr8:118759116	chr8:118621001~118858218:+
LUAD	cis	rs7772486	0.875	rs2814863	ENSG00000235652.6	RP11-545I5.3	-3.52	0.000475	0.0493	-0.16	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:146026163	chr6:145799409~145886585:+
LUAD	cis	rs875971	0.54	rs1723268	ENSG00000273142.1	RP11-458F8.4	-3.52	0.000475	0.0493	-0.11	-0.16	Aortic root size;	chr7:66008093	chr7:66902857~66906297:+
LUAD	cis	rs10876993	0.89	rs7976852	ENSG00000270039.1	RP11-571M6.17	3.52	0.000475	0.0493	0.19	0.16	Celiac disease or Rheumatoid arthritis;	chr12:57706768	chr12:57803838~57804415:+
LUAD	cis	rs5751614	0.557	rs5759666	ENSG00000230701.2	FBXW4P1	3.52	0.000475	0.0493	0.19	0.16	Height;	chr22:23260155	chr22:23262767~23265005:+
LUAD	cis	rs1009115	0.62	rs10256790	ENSG00000229970.3	AC007128.1	-3.52	0.000475	0.0493	-0.21	-0.16	Post bronchodilator FEV1;	chr7:8377770	chr7:8262264~8344516:+
LUAD	cis	rs1044826	0.642	rs1080371	ENSG00000214280.3	RP11-553K23.2	-3.52	0.000475	0.0493	-0.18	-0.16	Obesity-related traits;	chr3:139492052	chr3:139582928~139583593:-
LUAD	cis	rs2011013	0.956	rs2277849	ENSG00000259570.1	RP11-671M22.4	-3.52	0.000475	0.0494	-0.21	-0.16	Sitting height ratio;	chr15:83970598	chr15:84394512~84395514:+
LUAD	cis	rs34792	0.637	rs2450356	ENSG00000275910.1	RP11-680G24.6	3.52	0.000475	0.0494	0.15	0.16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15477487	chr16:15015828~15016390:-
LUAD	cis	rs7772486	0.776	rs4316025	ENSG00000235652.6	RP11-545I5.3	-3.52	0.000475	0.0494	-0.16	-0.16	Lobe attachment (rater-scored or self-reported);	chr6:145916896	chr6:145799409~145886585:+
LUAD	cis	rs7017914	0.667	rs1481801	ENSG00000246366.5	RP11-382J12.1	3.52	0.000475	0.0494	0.15	0.16	Bone mineral density;	chr8:71077484	chr8:70608577~70663279:+
LUAD	cis	rs9638182	0.614	rs79624003	ENSG00000274080.1	CTA-315H11.2	3.52	0.000475	0.0494	0.3	0.16	Triglycerides;	chr7:73598455	chr7:73609262~73611502:-
LUAD	cis	rs2436845	0.603	rs2679753	ENSG00000253669.3	KB-1732A1.1	-3.52	0.000475	0.0494	-0.19	-0.16	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102855232	chr8:102805517~102809971:+
LUAD	cis	rs6502050	0.805	rs4789740	ENSG00000266654.1	RP11-1376P16.1	-3.52	0.000475	0.0494	-0.17	-0.16	Life satisfaction;	chr17:82161326	chr17:82160056~82160452:+
LUAD	cis	rs8012947	1	rs11628909	ENSG00000279636.2	LINC00216	3.52	0.000475	0.0494	0.18	0.16	Alcohol consumption in current drinkers;	chr14:58352508	chr14:58288033~58289158:+
LUAD	cis	rs12744310	0.887	rs35410722	ENSG00000235358.1	RP11-399E6.1	3.52	0.000475	0.0494	0.21	0.16	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41330592	chr1:41242373~41284861:+
LUAD	cis	rs12744310	0.887	rs34539673	ENSG00000235358.1	RP11-399E6.1	3.52	0.000475	0.0494	0.21	0.16	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41331145	chr1:41242373~41284861:+
LUAD	cis	rs6568686	0.679	rs6913489	ENSG00000255389.1	C6orf3	-3.52	0.000475	0.0494	-0.22	-0.16	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111524370	chr6:111599875~111602295:+
LUAD	cis	rs6568686	0.73	rs6936935	ENSG00000255389.1	C6orf3	-3.52	0.000475	0.0494	-0.22	-0.16	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;	chr6:111524571	chr6:111599875~111602295:+
LUAD	cis	rs9650657	0.737	rs4551304	ENSG00000255046.1	RP11-297N6.4	3.52	0.000475	0.0494	0.2	0.16	Neuroticism;	chr8:10807559	chr8:11797928~11802568:-
LUAD	cis	rs4811196	1	rs2235458	ENSG00000226144.2	RPS27AP3	3.52	0.000475	0.0494	0.2	0.16	Bone mineral density;	chr20:37853690	chr20:37049254~37049707:+
LUAD	cis	rs2733201	1	rs4923969	ENSG00000205771.5	CATSPER2P1	3.52	0.000475	0.0494	0.38	0.16	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44016338	chr15:43726918~43747094:-
LUAD	cis	rs11638352	1	rs8037441	ENSG00000205771.5	CATSPER2P1	3.52	0.000475	0.0494	0.38	0.16	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44019718	chr15:43726918~43747094:-
LUAD	cis	rs794185	0.681	rs901870	ENSG00000231249.1	ITPR1-AS1	3.52	0.000476	0.0494	0.18	0.16	Multiple sclerosis--Brain Glutamate Levels;	chr3:4469418	chr3:4490891~4493163:-
LUAD	cis	rs11742741	0.806	rs62349719	ENSG00000248874.4	C5orf17	-3.52	0.000476	0.0494	-0.2	-0.16	Educational attainment;	chr5:24046751	chr5:23951348~24178263:+
LUAD	cis	rs8085804	0.597	rs718571	ENSG00000276174.1	RP11-687E1.2	-3.52	0.000476	0.0494	-0.22	-0.16	Cognitive performance;	chr18:42642213	chr18:42052705~42053030:+
LUAD	cis	rs6558174	0.965	rs4072394	ENSG00000253200.1	RP11-582J16.5	3.52	0.000476	0.0494	0.13	0.16	Breast cancer;	chr8:22633287	chr8:22613908~22616657:-
LUAD	cis	rs1823913	0.637	rs12622194	ENSG00000230611.1	HMGB1P27	3.52	0.000476	0.0494	0.18	0.16	Obesity-related traits;	chr2:191298680	chr2:191174233~191174835:+
LUAD	cis	rs1823913	0.637	rs13019567	ENSG00000230611.1	HMGB1P27	3.52	0.000476	0.0494	0.18	0.16	Obesity-related traits;	chr2:191298736	chr2:191174233~191174835:+
LUAD	cis	rs12148488	0.816	rs4886655	ENSG00000260269.4	CTD-2323K18.1	-3.52	0.000476	0.0494	-0.2	-0.16	Caffeine consumption;	chr15:75093227	chr15:75527150~75601205:-
LUAD	cis	rs9813712	0.571	rs11715351	ENSG00000253540.4	FAM86HP	-3.52	0.000476	0.0494	-0.16	-0.16	Response to amphetamines;	chr3:130214704	chr3:130099092~130111472:-
LUAD	cis	rs847649	0.804	rs4729866	ENSG00000233297.4	RASA4DP	-3.52	0.000476	0.0494	-0.2	-0.16	Morning vs. evening chronotype;	chr7:103045114	chr7:102681836~102690469:-
LUAD	cis	rs6504108	0.624	rs2278868	ENSG00000278765.1	RP5-890E16.5	-3.52	0.000476	0.0494	-0.18	-0.16	Body mass index;	chr17:48184809	chr17:48066704~48067293:-
LUAD	cis	rs67981189	0.789	rs12101246	ENSG00000269927.1	RP6-91H8.3	3.52	0.000476	0.0494	0.2	0.16	Schizophrenia;	chr14:71084618	chr14:71141125~71143253:-
LUAD	cis	rs3758785	0.586	rs637114	ENSG00000255893.1	RP11-685N10.1	3.52	0.000476	0.0494	0.18	0.16	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94337519	chr11:94472908~94473570:-
LUAD	cis	rs763121	0.925	rs9611008	ENSG00000225450.1	RP3-508I15.14	-3.52	0.000476	0.0494	-0.15	-0.16	Menopause (age at onset);	chr22:38702782	chr22:38739003~38749041:+
LUAD	cis	rs3096299	0.591	rs748940	ENSG00000261574.1	RP1-168P16.2	3.52	0.000476	0.0494	0.18	0.16	Multiple myeloma (IgH translocation);	chr16:89374349	chr16:89392375~89412564:-
LUAD	cis	rs1910358	0.569	rs6861265	ENSG00000248874.4	C5orf17	-3.52	0.000476	0.0494	-0.2	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23984586	chr5:23951348~24178263:+
LUAD	cis	rs1910358	0.614	rs6861270	ENSG00000248874.4	C5orf17	-3.52	0.000476	0.0494	-0.2	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23984593	chr5:23951348~24178263:+
LUAD	cis	rs7515577	0.588	rs79160953	ENSG00000223787.2	RP4-593M8.1	3.52	0.000476	0.0494	0.32	0.16	Cholesterol, total;	chr1:92484958	chr1:92580476~92580821:-
LUAD	cis	rs12519773	0.501	rs4449514	ENSG00000251361.1	CTD-2091N23.1	-3.52	0.000476	0.0494	-0.17	-0.16	Migraine;	chr5:93185316	chr5:93019663~93068669:-
LUAD	cis	rs858239	0.601	rs10224327	ENSG00000226816.2	AC005082.12	3.52	0.000476	0.0494	0.21	0.16	Cerebrospinal fluid biomarker levels;	chr7:23122201	chr7:23206013~23208045:+
LUAD	cis	rs4388249	0.687	rs10059767	ENSG00000271849.1	CTC-332L22.1	-3.52	0.000476	0.0494	-0.22	-0.16	Schizophrenia;	chr5:109765049	chr5:109687802~109688329:-
LUAD	cis	rs1007190	0.881	rs9914884	ENSG00000267505.1	CTC-296K1.3	3.52	0.000476	0.0494	0.28	0.16	DNA methylation (variation);	chr17:44878221	chr17:44793199~44794474:+
LUAD	cis	rs1007190	0.881	rs11079378	ENSG00000267505.1	CTC-296K1.3	3.52	0.000476	0.0494	0.28	0.16	DNA methylation (variation);	chr17:44880094	chr17:44793199~44794474:+
LUAD	cis	rs1007190	0.881	rs9915066	ENSG00000267505.1	CTC-296K1.3	3.52	0.000476	0.0494	0.28	0.16	DNA methylation (variation);	chr17:44884798	chr17:44793199~44794474:+
LUAD	cis	rs1007190	0.881	rs34854300	ENSG00000267505.1	CTC-296K1.3	3.52	0.000476	0.0494	0.28	0.16	DNA methylation (variation);	chr17:44891645	chr17:44793199~44794474:+
LUAD	cis	rs1007190	0.881	rs9909048	ENSG00000267505.1	CTC-296K1.3	3.52	0.000476	0.0494	0.28	0.16	DNA methylation (variation);	chr17:44896149	chr17:44793199~44794474:+
LUAD	cis	rs1150668	0.83	rs213240	ENSG00000168126.3	OR2W6P	3.52	0.000476	0.0494	0.18	0.16	Pubertal anthropometrics;	chr6:28348098	chr6:27937465~27938403:+
LUAD	cis	rs875971	0.66	rs3764903	ENSG00000222364.1	RNU6-96P	3.52	0.000476	0.0494	0.18	0.16	Aortic root size;	chr7:66633495	chr7:66395191~66395286:+
LUAD	cis	rs9921338	0.961	rs7626	ENSG00000262703.1	RP11-485G7.6	-3.52	0.000476	0.0494	-0.16	-0.16	Vein graft stenosis in coronary artery bypass grafting;	chr16:11351739	chr16:11348143~11349321:-
LUAD	cis	rs3805389	0.504	rs10026315	ENSG00000249700.7	SRD5A3-AS1	-3.52	0.000476	0.0494	-0.23	-0.16	Waist-to-hip ratio adjusted for body mass index;	chr4:55612195	chr4:55363971~55395847:-
LUAD	cis	rs7731783	1	rs7731783	ENSG00000247679.2	RP11-1277A3.1	3.52	0.000476	0.0494	0.16	0.16	Methadone dose in opioid dependence;	chr5:177633311	chr5:177611253~177619754:+
LUAD	cis	rs7610301	1	rs6799581	ENSG00000276925.1	RP11-708J19.3	3.52	0.000476	0.0495	0.19	0.16	Blood protein levels;	chr3:46603419	chr3:47469777~47469987:+
LUAD	cis	rs2117029	0.767	rs11614738	ENSG00000269514.1	RP11-370I10.12	3.52	0.000476	0.0495	0.14	0.16	Intelligence (multi-trait analysis);	chr12:49030833	chr12:48198387~48202031:+
LUAD	cis	rs875971	0.545	rs10950036	ENSG00000224316.1	RP11-479O9.2	3.52	0.000476	0.0495	0.18	0.16	Aortic root size;	chr7:66353241	chr7:65773620~65802067:+
LUAD	cis	rs13113518	0.966	rs11133387	ENSG00000249700.7	SRD5A3-AS1	3.52	0.000476	0.0495	0.16	0.16	Height;	chr4:55475130	chr4:55363971~55395847:-
LUAD	cis	rs4819052	0.819	rs13046807	ENSG00000223768.1	LINC00205	-3.52	0.000476	0.0495	-0.19	-0.16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252371	chr21:45293285~45297354:+
LUAD	cis	rs2302045	1	rs55938551	ENSG00000216921.6	AC131097.4	3.52	0.000476	0.0495	0.31	0.16	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio);	chr2:241094178	chr2:241893985~241902551:-
LUAD	cis	rs9549260	0.632	rs7323267	ENSG00000176268.5	CYCSP34	3.52	0.000476	0.0495	0.19	0.16	Red blood cell count;	chr13:40629878	chr13:40863599~40863902:-
LUAD	cis	rs854765	0.929	rs2955360	ENSG00000223979.2	SMCR2	3.52	0.000476	0.0495	0.18	0.16	Total body bone mineral density;	chr17:18071573	chr17:17674026~17677688:-
LUAD	cis	rs7003550	1	rs7003550	ENSG00000254028.1	AC083843.2	3.52	0.000476	0.0495	0.21	0.16	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr8:134838655	chr8:134832747~134834482:+
LUAD	cis	rs67311347	1	rs73078158	ENSG00000280739.1	EIF1B-AS1	3.52	0.000476	0.0495	0.17	0.16	Renal cell carcinoma;	chr3:40431076	chr3:40173145~40309698:-
LUAD	cis	rs67311347	1	rs73078164	ENSG00000280739.1	EIF1B-AS1	3.52	0.000476	0.0495	0.17	0.16	Renal cell carcinoma;	chr3:40438798	chr3:40173145~40309698:-
LUAD	cis	rs1044826	0.667	rs295471	ENSG00000214280.3	RP11-553K23.2	-3.52	0.000476	0.0495	-0.18	-0.16	Obesity-related traits;	chr3:139495080	chr3:139582928~139583593:-
LUAD	cis	rs9926296	0.546	rs6500442	ENSG00000260259.1	RP11-368I7.4	-3.52	0.000477	0.0495	-0.15	-0.16	Vitiligo;	chr16:89762454	chr16:89682620~89686569:-
LUAD	cis	rs6088590	1	rs2295353	ENSG00000275784.1	RP5-1125A11.6	-3.52	0.000477	0.0495	-0.17	-0.16	Coronary artery disease;	chr20:34768708	chr20:33989480~33991818:-
LUAD	cis	rs7178909	0.866	rs3784388	ENSG00000259677.1	RP11-493E3.1	3.52	0.000477	0.0495	0.17	0.16	Common traits (Other);	chr15:89894069	chr15:89876540~89877285:+
LUAD	cis	rs7178909	0.872	rs3784387	ENSG00000259677.1	RP11-493E3.1	3.52	0.000477	0.0495	0.17	0.16	Common traits (Other);	chr15:89894138	chr15:89876540~89877285:+
LUAD	cis	rs7178909	0.8	rs3825866	ENSG00000259677.1	RP11-493E3.1	3.52	0.000477	0.0495	0.17	0.16	Common traits (Other);	chr15:89894406	chr15:89876540~89877285:+
LUAD	cis	rs7178909	0.902	rs28372736	ENSG00000259677.1	RP11-493E3.1	3.52	0.000477	0.0495	0.17	0.16	Common traits (Other);	chr15:89894626	chr15:89876540~89877285:+
LUAD	cis	rs7178909	0.902	rs10459674	ENSG00000259677.1	RP11-493E3.1	3.52	0.000477	0.0495	0.17	0.16	Common traits (Other);	chr15:89895063	chr15:89876540~89877285:+
LUAD	cis	rs727479	0.597	rs6493487	ENSG00000259306.2	RP11-108K3.2	-3.52	0.000477	0.0495	-0.18	-0.16	Estradiol levels;	chr15:51221532	chr15:51315841~51321996:+
LUAD	cis	rs4835473	0.868	rs4629390	ENSG00000249741.2	RP11-673E1.3	3.52	0.000477	0.0495	0.19	0.16	Immature fraction of reticulocytes;	chr4:143735302	chr4:143911514~143912053:-
LUAD	cis	rs4835473	0.838	rs4583708	ENSG00000249741.2	RP11-673E1.3	3.52	0.000477	0.0495	0.19	0.16	Immature fraction of reticulocytes;	chr4:143735610	chr4:143911514~143912053:-
LUAD	cis	rs4835473	0.932	rs34257944	ENSG00000249741.2	RP11-673E1.3	3.52	0.000477	0.0495	0.19	0.16	Immature fraction of reticulocytes;	chr4:143736443	chr4:143911514~143912053:-
LUAD	cis	rs4792901	0.802	rs72833123	ENSG00000108785.7	HSD17B1P1	3.52	0.000477	0.0495	0.2	0.16	Dupuytren's disease;	chr17:43475035	chr17:42546764~42548706:+
LUAD	cis	rs773506	0.602	rs10761110	ENSG00000237422.1	RP11-305L7.3	3.52	0.000477	0.0495	0.2	0.16	Type 2 diabetes nephropathy;	chr9:91167602	chr9:91119138~91163087:-
LUAD	cis	rs7674212	0.541	rs2720448	ENSG00000246560.2	RP11-10L12.4	3.52	0.000477	0.0495	0.2	0.16	Type 2 diabetes;	chr4:103109432	chr4:102828055~102844075:+
LUAD	cis	rs7674212	0.541	rs2623064	ENSG00000246560.2	RP11-10L12.4	3.52	0.000477	0.0495	0.2	0.16	Type 2 diabetes;	chr4:103109635	chr4:102828055~102844075:+
LUAD	cis	rs9341808	0.538	rs12176343	ENSG00000260645.1	RP11-250B2.5	-3.52	0.000477	0.0495	-0.16	-0.16	Sitting height ratio;	chr6:80317670	chr6:80466958~80469080:+
LUAD	cis	rs10908557	0.758	rs12408260	ENSG00000223599.1	RP11-216N14.7	3.52	0.000477	0.0495	0.19	0.16	Age at first birth;	chr1:154010449	chr1:153852106~153853414:-
LUAD	cis	rs10908557	0.758	rs6672856	ENSG00000223599.1	RP11-216N14.7	3.52	0.000477	0.0495	0.19	0.16	Age at first birth;	chr1:154013643	chr1:153852106~153853414:-
LUAD	cis	rs6964587	0.692	rs4729025	ENSG00000188693.7	CYP51A1-AS1	-3.52	0.000477	0.0495	-0.18	-0.16	Breast cancer;	chr7:92218190	chr7:92134604~92180725:+
LUAD	cis	rs1549118	0.669	rs11621178	ENSG00000239272.1	RPL21P10	3.52	0.000477	0.0495	0.17	0.16	Resting heart rate;	chr14:77908885	chr14:77683202~77683989:-
LUAD	cis	rs2069426	0.591	rs17694493	ENSG00000265194.1	RP11-70L8.4	3.52	0.000477	0.0495	0.22	0.16	Acute lymphoblastic leukemia (childhood);	chr9:22041999	chr9:21858910~21861926:-
LUAD	cis	rs28510890	0.828	rs78417563	ENSG00000260337.3	RP11-386M24.6	3.52	0.000477	0.0495	0.21	0.16	Lung cancer in ever smokers;	chr15:92580224	chr15:92592574~92596462:-
LUAD	cis	rs2302045	1	rs16843245	ENSG00000216921.6	AC131097.4	-3.52	0.000477	0.0495	-0.32	-0.16	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio);	chr2:241093294	chr2:241893985~241902551:-
LUAD	cis	rs2985684	1	rs2985697	ENSG00000278009.1	RP11-649E7.8	3.52	0.000477	0.0495	0.21	0.16	Carotid intima media thickness;	chr14:49626184	chr14:49601011~49601124:-
LUAD	cis	rs6088590	0.561	rs3891369	ENSG00000276073.1	RP5-1125A11.7	-3.52	0.000477	0.0495	-0.15	-0.16	Coronary artery disease;	chr20:34573323	chr20:33985617~33988989:-
LUAD	cis	rs10483853	0.806	rs10146612	ENSG00000258695.2	RP3-414A15.2	-3.52	0.000477	0.0495	-0.2	-0.16	Coronary artery calcification;	chr14:73291217	chr14:73522878~73530610:+
LUAD	cis	rs6502050	0.805	rs4789721	ENSG00000275966.1	RP11-1055B8.9	-3.52	0.000477	0.0495	-0.16	-0.16	Life satisfaction;	chr17:82199577	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.731	rs12150589	ENSG00000275966.1	RP11-1055B8.9	-3.52	0.000477	0.0495	-0.16	-0.16	Life satisfaction;	chr17:82200357	chr17:81345476~81345966:-
LUAD	cis	rs6502050	0.835	rs8065037	ENSG00000275966.1	RP11-1055B8.9	-3.52	0.000477	0.0495	-0.16	-0.16	Life satisfaction;	chr17:82201090	chr17:81345476~81345966:-
LUAD	cis	rs2274273	1	rs7493394	ENSG00000259318.1	RP11-454L9.2	3.52	0.000477	0.0495	0.14	0.16	Protein biomarker;	chr14:55151037	chr14:55394940~55395233:-
LUAD	cis	rs2274273	0.967	rs11622740	ENSG00000259318.1	RP11-454L9.2	3.52	0.000477	0.0495	0.14	0.16	Protein biomarker;	chr14:55151126	chr14:55394940~55395233:-
LUAD	cis	rs7824557	0.569	rs35418978	ENSG00000255046.1	RP11-297N6.4	-3.52	0.000477	0.0495	-0.2	-0.16	Retinal vascular caliber;	chr8:11328944	chr8:11797928~11802568:-
LUAD	cis	rs7824557	0.606	rs2736264	ENSG00000255046.1	RP11-297N6.4	-3.52	0.000477	0.0495	-0.2	-0.16	Retinal vascular caliber;	chr8:11329130	chr8:11797928~11802568:-
LUAD	cis	rs736408	0.609	rs1029871	ENSG00000243224.1	RP5-1157M23.2	-3.52	0.000477	0.0495	-0.16	-0.16	Bipolar disorder;	chr3:52763618	chr3:52239258~52241097:+
LUAD	cis	rs2030114	0.948	rs56377292	ENSG00000224578.4	HNRNPA1P48	-3.52	0.000477	0.0495	-0.15	-0.16	Blood pressure measurement (high sodium and potassium intervention);	chr16:51573984	chr16:51645756~51647132:+
LUAD	cis	rs2030114	0.848	rs8043891	ENSG00000224578.4	HNRNPA1P48	-3.52	0.000477	0.0495	-0.15	-0.16	Blood pressure measurement (high sodium and potassium intervention);	chr16:51574731	chr16:51645756~51647132:+
LUAD	cis	rs449789	0.619	rs3913674	ENSG00000235086.1	FNDC1-IT1	-3.52	0.000477	0.0495	-0.28	-0.16	Pulse pressure;	chr6:159356538	chr6:159240786~159243329:+
LUAD	cis	rs7572733	0.773	rs13427590	ENSG00000222017.1	AC011997.1	3.52	0.000477	0.0495	0.2	0.16	Dermatomyositis;	chr2:197652097	chr2:197693106~197774823:+
LUAD	cis	rs736408	0.609	rs2268025	ENSG00000243224.1	RP5-1157M23.2	-3.52	0.000477	0.0495	-0.16	-0.16	Bipolar disorder;	chr3:52761208	chr3:52239258~52241097:+
LUAD	cis	rs2932538	0.961	rs4838960	ENSG00000235299.2	MRPL53P1	-3.52	0.000477	0.0495	-0.2	-0.16	Diastolic blood pressure;Systolic blood pressure;Blood pressure;Hypertension;	chr1:112621010	chr1:112625906~112626224:-
LUAD	cis	rs3739070	0.504	rs6737046	ENSG00000234949.2	AC104667.3	3.52	0.000477	0.0495	0.25	0.16	Iris characteristics;	chr2:238579201	chr2:237591020~237595981:+
LUAD	cis	rs1046491	0.901	rs11663175	ENSG00000264964.1	RP11-888D10.3	3.52	0.000477	0.0495	0.33	0.16	Scarlet fever;	chr18:9175448	chr18:9315194~9334441:-
LUAD	cis	rs10208649	0.908	rs11889527	ENSG00000233266.1	HMGB1P31	3.52	0.000478	0.0495	0.41	0.16	Body mass index;	chr2:53999178	chr2:54051334~54051760:+
LUAD	cis	rs10208649	1	rs72904915	ENSG00000233266.1	HMGB1P31	3.52	0.000478	0.0495	0.41	0.16	Body mass index;	chr2:54000213	chr2:54051334~54051760:+
LUAD	cis	rs607541	1	rs674568	ENSG00000259520.4	CTD-2651B20.3	-3.52	0.000478	0.0495	-0.23	-0.16	Obesity-related traits;	chr15:45644389	chr15:45251580~45279251:-
LUAD	cis	rs7546668	1	rs2295626	ENSG00000272510.1	RP4-680D5.8	3.52	0.000478	0.0495	0.2	0.16	Glomerular filtration rate (creatinine);	chr1:15548466	chr1:15565611~15565956:-
LUAD	cis	rs7546668	0.947	rs10803391	ENSG00000272510.1	RP4-680D5.8	3.52	0.000478	0.0495	0.2	0.16	Glomerular filtration rate (creatinine);	chr1:15550083	chr1:15565611~15565956:-
LUAD	cis	rs12216545	0.765	rs6464082	ENSG00000241134.3	BET1P1	-3.52	0.000478	0.0495	-0.16	-0.16	Bone ultrasound measurement (broadband ultrasound attenuation);	chr7:150563519	chr7:150749736~150750094:+
LUAD	cis	rs2272990	0.867	rs2064310	ENSG00000228793.1	RP1-223B1.1	3.52	0.000478	0.0495	0.41	0.16	Preschool internalizing problems;	chr6:3080090	chr6:3594247~3624747:-
LUAD	cis	rs17098356	1	rs17098356	ENSG00000258926.1	RP11-47I22.1	3.52	0.000478	0.0495	0.15	0.16	Reading and spelling;	chr14:61432121	chr14:61537508~61545287:-
LUAD	cis	rs9549260	0.592	rs9532588	ENSG00000229456.1	RLIMP1	3.52	0.000478	0.0496	0.17	0.16	Red blood cell count;	chr13:40728777	chr13:40618738~40621348:+
LUAD	cis	rs1002107	0.84	rs7967057	ENSG00000257526.2	RP11-20E24.1	-3.52	0.000478	0.0496	-0.22	-0.16	Methadone dose in opioid dependence;	chr12:77302312	chr12:76562294~76615567:+
LUAD	cis	rs2018683	0.691	rs4722881	ENSG00000228421.2	AC005013.5	-3.52	0.000478	0.0496	-0.17	-0.16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28961944	chr7:28957667~28959345:+
LUAD	cis	rs9815354	0.597	rs73073281	ENSG00000273328.4	RP11-141M3.6	-3.52	0.000478	0.0496	-0.29	-0.16	Pulse pressure;Diastolic blood pressure;	chr3:41984874	chr3:42809414~42908105:+
LUAD	cis	rs277939	0.967	rs157049	ENSG00000251634.2	RP11-1280N14.3	3.52	0.000478	0.0496	0.16	0.16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr5:71632738	chr5:71102898~71128753:-
LUAD	cis	rs55702914	0.65	rs6715690	ENSG00000222017.1	AC011997.1	-3.52	0.000478	0.0496	-0.2	-0.16	Major depression and alcohol dependence;	chr2:197283647	chr2:197693106~197774823:+
LUAD	cis	rs2977125	0.815	rs2977160	ENSG00000251468.2	RP11-369K16.1	-3.52	0.000478	0.0496	-0.24	-0.16	Schizophrenia;	chr8:12884460	chr8:12958387~12962200:+
LUAD	cis	rs12200782	0.505	rs1535275	ENSG00000241549.7	GUSBP2	3.52	0.000478	0.0496	0.21	0.16	Small cell lung carcinoma;	chr6:26520539	chr6:26871484~26956554:-
LUAD	cis	rs7870753	0.578	rs10820386	ENSG00000188801.9	ZNF322P1	3.52	0.000478	0.0496	0.25	0.16	Height;	chr9:96335028	chr9:97198303~97199511:-
LUAD	cis	rs11638352	1	rs4924731	ENSG00000205771.5	CATSPER2P1	3.52	0.000478	0.0496	0.37	0.16	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44004526	chr15:43726918~43747094:-
LUAD	cis	rs11638352	1	rs6493093	ENSG00000205771.5	CATSPER2P1	3.52	0.000478	0.0496	0.37	0.16	Lipoprotein phospholipase A2 activity in cardiovascular disease;	chr15:44013297	chr15:43726918~43747094:-
LUAD	cis	rs9900280	0.967	rs6505120	ENSG00000264808.1	RP11-802D6.1	3.52	0.000478	0.0496	0.19	0.16	Mean platelet volume;	chr17:29381694	chr17:29369717~29390777:-
LUAD	cis	rs9900280	0.967	rs6505121	ENSG00000264808.1	RP11-802D6.1	3.52	0.000478	0.0496	0.19	0.16	Mean platelet volume;	chr17:29381699	chr17:29369717~29390777:-
LUAD	cis	rs12681366	0.881	rs2960121	ENSG00000254057.1	RP3-388N13.3	3.52	0.000478	0.0496	0.17	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94417678	chr8:93834454~93846743:-
LUAD	cis	rs2880765	0.677	rs7181410	ENSG00000259630.2	CTD-2262B20.1	3.52	0.000478	0.0496	0.17	0.16	Coronary artery disease;	chr15:85463104	chr15:85415228~85415633:+
LUAD	cis	rs6860806	0.661	rs28472559	ENSG00000263597.1	MIR3936	3.52	0.000478	0.0496	0.16	0.16	Breast cancer;	chr5:132245918	chr5:132365490~132365599:-
LUAD	cis	rs3738443	0.951	rs4582838	ENSG00000215795.2	RP11-488L18.3	-3.52	0.000478	0.0496	-0.25	-0.16	Alcohol dependence;	chr1:247210269	chr1:247183813~247185482:-
LUAD	cis	rs61160187	0.549	rs62367879	ENSG00000215032.2	GNL3LP1	3.52	0.000478	0.0496	0.19	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60996384	chr5:60891935~60893577:-
LUAD	cis	rs3018066	0.692	rs6824682	ENSG00000251259.1	AC004069.2	-3.52	0.000478	0.0496	-0.19	-0.16	Cancer;	chr4:106086762	chr4:105137280~105140619:-
LUAD	cis	rs36093844	0.527	rs1596739	ENSG00000279742.1	RP11-700A24.1	-3.52	0.000478	0.0496	-0.2	-0.16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85922325	chr11:85852557~85854943:-
LUAD	cis	rs10129255	0.957	rs11846893	ENSG00000211947.2	IGHV3-21	-3.52	0.000478	0.0496	-0.1	-0.16	Kawasaki disease;	chr14:106779068	chr14:106235064~106235594:-
LUAD	cis	rs8062405	1	rs2008514	ENSG00000261766.1	RP11-22P6.2	3.52	0.000478	0.0496	0.14	0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28862166~28863340:-
LUAD	cis	rs7212590	0.748	rs7220187	ENSG00000263422.1	AC005702.1	3.52	0.000478	0.0496	0.36	0.16	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59820248	chr17:60042361~60042442:-
LUAD	cis	rs7212590	0.748	rs7213697	ENSG00000263422.1	AC005702.1	3.52	0.000478	0.0496	0.36	0.16	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59825680	chr17:60042361~60042442:-
LUAD	cis	rs7893279	0.505	rs7089083	ENSG00000225527.1	RP11-383B4.4	3.52	0.000478	0.0496	0.23	0.16	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr10:18623473	chr10:18531849~18533336:-
LUAD	cis	rs6460942	0.908	rs59410610	ENSG00000226690.5	AC005281.1	3.52	0.000478	0.0496	0.28	0.16	Coronary artery disease;	chr7:12243221	chr7:12496429~12541910:+
LUAD	cis	rs8050896	0.793	rs79330551	ENSG00000260695.1	RP11-513N24.1	-3.52	0.000478	0.0496	-0.32	-0.16	Response to antipsychotic treatment;	chr16:66115834	chr16:65861112~65863784:-
LUAD	cis	rs9840812	0.769	rs4678428	ENSG00000239213.4	NCK1-AS1	3.52	0.000478	0.0496	0.2	0.16	Fibrinogen levels;	chr3:136269570	chr3:136841726~136862054:-
LUAD	cis	rs561341	0.739	rs7213369	ENSG00000265798.5	RP11-271K11.5	-3.52	0.000478	0.0496	-0.22	-0.16	Hip circumference adjusted for BMI;	chr17:31884859	chr17:31038575~31059121:-
LUAD	cis	rs10510102	0.935	rs12243529	ENSG00000276742.1	RP11-500G22.4	3.52	0.000478	0.0496	0.26	0.16	Breast cancer;	chr10:121880321	chr10:121956782~121957098:+
LUAD	cis	rs12984174	1	rs403439	ENSG00000241464.3	RPL39P38	3.52	0.000478	0.0496	0.21	0.16	Pulmonary function in asthmatics;	chr19:18031265	chr19:18285343~18285495:-
LUAD	cis	rs9889262	0.663	rs8081878	ENSG00000248714.5	RP11-1079K10.3	3.52	0.000478	0.0496	0.16	0.16	Eosinophil percentage of granulocytes;Allergic disease (asthma, hay fever or eczema);Eosinophil counts;	chr17:49359450	chr17:49361165~49369998:+
LUAD	cis	rs757081	0.637	rs34941502	ENSG00000260196.1	RP1-239B22.5	-3.52	0.000478	0.0496	-0.21	-0.16	Systolic blood pressure;	chr11:17133885	chr11:17380649~17383531:+
LUAD	cis	rs4699052	0.625	rs6828829	ENSG00000246560.2	RP11-10L12.4	3.52	0.000479	0.0496	0.2	0.16	Testicular germ cell tumor;	chr4:103414510	chr4:102828055~102844075:+
LUAD	cis	rs7429990	0.932	rs60446735	ENSG00000228638.1	FCF1P2	-3.52	0.000479	0.0496	-0.19	-0.16	Educational attainment (years of education);	chr3:47929958	chr3:48290793~48291375:-
LUAD	cis	rs875971	0.638	rs10249404	ENSG00000222364.1	RNU6-96P	3.52	0.000479	0.0496	0.18	0.16	Aortic root size;	chr7:66581737	chr7:66395191~66395286:+
LUAD	cis	rs9381040	0.61	rs2268191	ENSG00000161912.16	ADCY10P1	3.52	0.000479	0.0496	0.14	0.16	Alzheimer's disease (late onset);	chr6:41059914	chr6:41101022~41140835:+
LUAD	cis	rs2039553	0.935	rs4591027	ENSG00000227676.3	LINC01068	3.52	0.000479	0.0496	0.2	0.16	Pancreatic cancer;	chr13:79732615	chr13:79566727~79571436:+
LUAD	cis	rs12188164	0.62	rs1043356	ENSG00000188242.4	PP7080	-3.52	0.000479	0.0496	-0.21	-0.16	Cystic fibrosis severity;	chr5:480833	chr5:466124~473098:-
LUAD	cis	rs2051773	0.567	rs58047221	ENSG00000260196.1	RP1-239B22.5	-3.52	0.000479	0.0496	-0.23	-0.16	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr11:17035087	chr11:17380649~17383531:+
LUAD	cis	rs34783982	0.529	rs8039998	ENSG00000261441.1	RP11-217B1.2	-3.52	0.000479	0.0496	-0.2	-0.16	Squamous cell lung carcinoma;	chr15:88931428	chr15:89335053~89336161:+
LUAD	cis	rs6687821	0.515	rs507966	ENSG00000261737.1	RP4-612B15.3	-3.52	0.000479	0.0496	-0.22	-0.16	Yeast infection;	chr1:86904391	chr1:86703502~86704462:-
LUAD	cis	rs11673344	0.642	rs73025481	ENSG00000267254.4	ZNF790-AS1	-3.52	0.000479	0.0496	-0.21	-0.16	Obesity-related traits;	chr19:37346437	chr19:36797518~36828115:+
LUAD	cis	rs910316	0.687	rs175059	ENSG00000279594.1	RP11-950C14.10	-3.52	0.000479	0.0496	-0.18	-0.16	Height;	chr14:75023964	chr14:75011269~75012851:-
LUAD	cis	rs360798	0.512	rs7603495	ENSG00000231609.4	AC009501.4	3.52	0.000479	0.0496	0.17	0.16	Coronary artery disease;	chr2:62611323	chr2:63043922~63048640:-
LUAD	cis	rs360798	0.512	rs1527967	ENSG00000231609.4	AC009501.4	3.52	0.000479	0.0496	0.17	0.16	Coronary artery disease;	chr2:62612239	chr2:63043922~63048640:-
LUAD	cis	rs3733418	0.929	rs17623445	ENSG00000248632.1	RP11-366M4.11	3.52	0.000479	0.0497	0.25	0.16	Obesity-related traits;	chr4:164973506	chr4:164968587~164970002:-
LUAD	cis	rs4713118	0.621	rs9295756	ENSG00000280107.1	AL022393.9	-3.52	0.000479	0.0497	-0.21	-0.16	Parkinson's disease;	chr6:28065618	chr6:28170845~28172521:+
LUAD	cis	rs3740713	1	rs73440604	ENSG00000256464.1	YWHABP2	3.52	0.000479	0.0497	0.3	0.16	Amyotrophic lateral sclerosis (sporadic);	chr11:18442124	chr11:18490243~18490955:-
LUAD	cis	rs3740713	1	rs73440610	ENSG00000256464.1	YWHABP2	3.52	0.000479	0.0497	0.3	0.16	Amyotrophic lateral sclerosis (sporadic);	chr11:18442922	chr11:18490243~18490955:-
LUAD	cis	rs2147959	0.882	rs6666241	ENSG00000269934.1	RP5-1139B12.3	-3.52	0.000479	0.0497	-0.21	-0.16	Adult asthma;	chr1:228442058	chr1:228274584~228276066:-
LUAD	cis	rs2717559	0.561	rs7841267	ENSG00000253741.1	CTD-2292P10.4	3.52	0.000479	0.0497	0.19	0.16	Urinary tract infection frequency;	chr8:142800267	chr8:142702252~142726973:-
LUAD	cis	rs13434995	0.513	rs17776975	ENSG00000249700.7	SRD5A3-AS1	-3.52	0.000479	0.0497	-0.19	-0.16	Adiponectin levels;	chr4:55410728	chr4:55363971~55395847:-
LUAD	cis	rs61160187	0.582	rs12652878	ENSG00000215032.2	GNL3LP1	3.52	0.000479	0.0497	0.19	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:60868949	chr5:60891935~60893577:-
LUAD	cis	rs881375	0.933	rs7031096	ENSG00000238181.2	AHCYP2	-3.52	0.000479	0.0497	-0.2	-0.16	Rheumatoid arthritis;	chr9:120932664	chr9:120720673~120721972:+
LUAD	cis	rs881375	0.967	rs10739580	ENSG00000238181.2	AHCYP2	-3.52	0.000479	0.0497	-0.2	-0.16	Rheumatoid arthritis;	chr9:120933004	chr9:120720673~120721972:+
LUAD	cis	rs2274273	0.87	rs3783652	ENSG00000258413.1	RP11-665C16.6	-3.52	0.000479	0.0497	-0.21	-0.16	Protein biomarker;	chr14:55387490	chr14:55262767~55272075:-
LUAD	cis	rs9896933	0.775	rs79299098	ENSG00000262663.1	RP11-497H17.1	3.52	0.000479	0.0497	0.2	0.16	Bone mineral accretion in asthma (oral corticosteroid dose interaction);	chr17:82873068	chr17:82918282~82918785:+
LUAD	cis	rs9367486	0.53	rs17592303	ENSG00000202198.1	RN7SK	3.52	0.000479	0.0497	0.29	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr6:52454803	chr6:52995620~52995950:+
LUAD	cis	rs950169	0.84	rs4842854	ENSG00000188388.10	GOLGA6L3	3.52	0.000479	0.0497	0.21	0.16	Schizophrenia;	chr15:84387641	chr15:85240472~85247170:+
LUAD	cis	rs950169	0.58	rs11635597	ENSG00000254414.1	RP11-182J1.1	3.52	0.000479	0.0497	0.21	0.16	Schizophrenia;	chr15:84622468	chr15:84631898~84633987:-
LUAD	cis	rs7615952	0.512	rs2922175	ENSG00000171084.14	FAM86JP	3.52	0.000479	0.0497	0.2	0.16	Blood pressure (smoking interaction);	chr3:125642516	chr3:125916620~125930024:+
LUAD	cis	rs2390582	0.891	rs1336880	ENSG00000233593.5	RP4-665J23.1	3.52	0.000479	0.0497	0.23	0.16	Coronary artery calcification;	chr1:90495595	chr1:90782986~90851650:-
LUAD	cis	rs2911132	0.564	rs17401719	ENSG00000272109.1	CTD-2260A17.3	3.52	0.000479	0.0497	0.17	0.16	Urate levels (BMI interaction);	chr5:96753342	chr5:96804353~96806105:+
LUAD	cis	rs4835473	0.9	rs71612420	ENSG00000249741.2	RP11-673E1.3	3.52	0.000479	0.0497	0.19	0.16	Immature fraction of reticulocytes;	chr4:143779107	chr4:143911514~143912053:-
LUAD	cis	rs4835473	0.9	rs13134869	ENSG00000249741.2	RP11-673E1.3	3.52	0.000479	0.0497	0.19	0.16	Immature fraction of reticulocytes;	chr4:143782301	chr4:143911514~143912053:-
LUAD	cis	rs2460905	1	rs2466255	ENSG00000251468.2	RP11-369K16.1	-3.52	0.000479	0.0497	-0.37	-0.16	Post-traumatic stress disorder;	chr8:12977064	chr8:12958387~12962200:+
LUAD	cis	rs2460905	1	rs2460347	ENSG00000251468.2	RP11-369K16.1	-3.52	0.000479	0.0497	-0.37	-0.16	Post-traumatic stress disorder;	chr8:12977197	chr8:12958387~12962200:+
LUAD	cis	rs506597	0.92	rs221796	ENSG00000281827.1	AC005071.4	3.52	0.000479	0.0497	0.27	0.16	Pursuit maintenance gain in psychotic disorders;	chr7:100687290	chr7:100344375~100344475:-
LUAD	cis	rs867371	0.614	rs1814739	ENSG00000259315.1	RP11-752G15.9	-3.52	0.00048	0.0497	-0.16	-0.16	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82234283	chr15:82725873~82738904:-
LUAD	cis	rs6674176	0.561	rs7161	ENSG00000237950.1	RP11-7O11.3	-3.52	0.00048	0.0497	-0.19	-0.16	Cognitive ability;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr1:43973302	chr1:43944370~43946551:-
LUAD	cis	rs7572733	0.935	rs700659	ENSG00000222017.1	AC011997.1	3.52	0.00048	0.0497	0.2	0.16	Dermatomyositis;	chr2:197795199	chr2:197693106~197774823:+
LUAD	cis	rs926392	0.799	rs742274	ENSG00000274825.1	RP4-616B8.5	-3.52	0.00048	0.0497	-0.19	-0.16	Dialysis-related mortality;	chr20:39052301	chr20:38955910~38956547:+
LUAD	cis	rs7246967	0.673	rs16999519	ENSG00000236312.3	RPL34P34	-3.52	0.00048	0.0497	-0.2	-0.16	Bronchopulmonary dysplasia;	chr19:22631274	chr19:22368599~22368952:-
LUAD	cis	rs875971	0.66	rs801192	ENSG00000273142.1	RP11-458F8.4	3.52	0.00048	0.0497	0.11	0.16	Aortic root size;	chr7:66566965	chr7:66902857~66906297:+
LUAD	cis	rs875971	0.66	rs801190	ENSG00000273142.1	RP11-458F8.4	3.52	0.00048	0.0497	0.11	0.16	Aortic root size;	chr7:66568046	chr7:66902857~66906297:+
LUAD	cis	rs875971	0.66	rs3857686	ENSG00000273142.1	RP11-458F8.4	3.52	0.00048	0.0497	0.11	0.16	Aortic root size;	chr7:66571204	chr7:66902857~66906297:+
LUAD	cis	rs875971	0.638	rs3898855	ENSG00000273142.1	RP11-458F8.4	3.52	0.00048	0.0497	0.11	0.16	Aortic root size;	chr7:66571411	chr7:66902857~66906297:+
LUAD	cis	rs875971	0.638	rs10278816	ENSG00000273142.1	RP11-458F8.4	3.52	0.00048	0.0497	0.11	0.16	Aortic root size;	chr7:66572000	chr7:66902857~66906297:+
LUAD	cis	rs875971	0.66	rs10281080	ENSG00000273142.1	RP11-458F8.4	3.52	0.00048	0.0497	0.11	0.16	Aortic root size;	chr7:66577454	chr7:66902857~66906297:+
LUAD	cis	rs950169	0.58	rs11633762	ENSG00000254414.1	RP11-182J1.1	3.52	0.00048	0.0497	0.21	0.16	Schizophrenia;	chr15:84643921	chr15:84631898~84633987:-
LUAD	cis	rs9660992	0.573	rs4400674	ENSG00000240710.1	RP11-430C7.4	-3.52	0.00048	0.0497	-0.17	-0.16	Mean corpuscular volume;Mean platelet volume;	chr1:205249297	chr1:204603035~204616565:+
LUAD	cis	rs8035452	0.964	rs12592851	ENSG00000259240.1	RP11-108K3.1	-3.52	0.00048	0.0497	-0.18	-0.16	Alzheimer's disease (late onset);	chr15:50743278	chr15:51037488~51293912:+
LUAD	cis	rs8035452	0.964	rs12595118	ENSG00000259240.1	RP11-108K3.1	-3.52	0.00048	0.0497	-0.18	-0.16	Alzheimer's disease (late onset);	chr15:50743287	chr15:51037488~51293912:+
LUAD	cis	rs2274273	1	rs1047556	ENSG00000259318.1	RP11-454L9.2	3.52	0.00048	0.0497	0.14	0.16	Protein biomarker;	chr14:55133564	chr14:55394940~55395233:-
LUAD	cis	rs8062405	1	rs7187776	ENSG00000261419.1	RP11-57A19.4	-3.52	0.00048	0.0497	-0.18	-0.16	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28659696~28740781:-
LUAD	cis	rs9549260	0.564	rs9646110	ENSG00000168852.11	TPTE2P5	-3.52	0.00048	0.0497	-0.16	-0.16	Red blood cell count;	chr13:40734165	chr13:40822296~40921749:-
LUAD	cis	rs5015933	0.902	rs2841333	ENSG00000232630.1	PRPS1P2	-3.52	0.00048	0.0497	-0.15	-0.16	Body mass index;	chr9:125364368	chr9:125150653~125151589:+
LUAD	cis	rs567508	0.534	rs585134	ENSG00000254905.1	RP11-712L6.7	-3.52	0.00048	0.0497	-0.27	-0.16	Lung function (FEV1);	chr11:126157017	chr11:126292922~126294254:-
LUAD	cis	rs9593057	0.892	rs58422786	ENSG00000234835.1	PHBP13	-3.52	0.00048	0.0497	-0.31	-0.16	Lobe attachment (rater-scored or self-reported);	chr13:35034664	chr13:35251070~35251829:+
LUAD	cis	rs9593057	0.786	rs74678801	ENSG00000234835.1	PHBP13	-3.52	0.00048	0.0497	-0.31	-0.16	Lobe attachment (rater-scored or self-reported);	chr13:35037896	chr13:35251070~35251829:+
LUAD	cis	rs11076805	0.51	rs399218	ENSG00000275056.1	RP11-127I20.8	-3.52	0.00048	0.0497	-0.16	-0.16	Breast cancer (estrogen-receptor negative);Breast cancer;	chr16:4101586	chr16:4839244~4840334:-
LUAD	cis	rs2554380	0.843	rs7182216	ENSG00000259570.1	RP11-671M22.4	-3.52	0.00048	0.0497	-0.22	-0.16	Height;	chr15:83753754	chr15:84394512~84395514:+
LUAD	cis	rs10129255	0.957	rs2013423	ENSG00000274576.2	IGHV2-70	3.52	0.00048	0.0497	0.14	0.16	Kawasaki disease;	chr14:106690675	chr14:106770577~106771020:-
LUAD	cis	rs2279168	0.867	rs79691262	ENSG00000202081.1	RNU6-1280P	-3.52	0.00048	0.0497	-0.29	-0.16	Response to platinum-based chemotherapy (carboplatin);	chr15:85494633	chr15:85651522~85651628:-
LUAD	cis	rs3018066	0.748	rs28391259	ENSG00000251259.1	AC004069.2	-3.52	0.00048	0.0497	-0.19	-0.16	Cancer;	chr4:106092855	chr4:105137280~105140619:-
LUAD	cis	rs9549260	0.755	rs7988604	ENSG00000229456.1	RLIMP1	3.52	0.00048	0.0497	0.17	0.16	Red blood cell count;	chr13:40641665	chr13:40618738~40621348:+
LUAD	cis	rs67981189	0.858	rs17108877	ENSG00000269927.1	RP6-91H8.3	3.52	0.00048	0.0498	0.2	0.16	Schizophrenia;	chr14:71007092	chr14:71141125~71143253:-
LUAD	cis	rs7302981	0.845	rs56709084	ENSG00000200428.1	Y_RNA	-3.52	0.00048	0.0498	-0.19	-0.16	Systolic blood pressure;	chr12:50170107	chr12:50743568~50743684:+
LUAD	cis	rs9467773	0.935	rs11752946	ENSG00000124549.13	BTN2A3P	3.52	0.00048	0.0498	0.15	0.16	Intelligence (multi-trait analysis);	chr6:26560136	chr6:26421391~26432383:+
LUAD	cis	rs3738443	0.817	rs6698690	ENSG00000215795.2	RP11-488L18.3	-3.52	0.00048	0.0498	-0.23	-0.16	Alcohol dependence;	chr1:247199176	chr1:247183813~247185482:-
LUAD	cis	rs4474465	0.85	rs10899539	ENSG00000251323.2	RP11-452H21.4	-3.52	0.00048	0.0498	-0.19	-0.16	Alzheimer's disease (survival time);	chr11:78532697	chr11:78423982~78429836:-
LUAD	cis	rs4474465	0.85	rs4945289	ENSG00000251323.2	RP11-452H21.4	-3.52	0.00048	0.0498	-0.19	-0.16	Alzheimer's disease (survival time);	chr11:78534288	chr11:78423982~78429836:-
LUAD	cis	rs445114	0.601	rs13275275	ENSG00000254166.1	CASC19	-3.52	0.00048	0.0498	-0.16	-0.16	Prostate cancer;Prostate cancer (SNP x SNP interaction);	chr8:127337482	chr8:127185635~127203222:-
LUAD	cis	rs445114	0.578	rs13248140	ENSG00000254166.1	CASC19	-3.52	0.00048	0.0498	-0.16	-0.16	Prostate cancer;Prostate cancer (SNP x SNP interaction);	chr8:127337643	chr8:127185635~127203222:-
LUAD	cis	rs445114	0.578	rs10956360	ENSG00000254166.1	CASC19	-3.52	0.00048	0.0498	-0.16	-0.16	Prostate cancer;Prostate cancer (SNP x SNP interaction);	chr8:127337725	chr8:127185635~127203222:-
LUAD	cis	rs445114	0.578	rs10956362	ENSG00000254166.1	CASC19	-3.52	0.00048	0.0498	-0.16	-0.16	Prostate cancer;Prostate cancer (SNP x SNP interaction);	chr8:127338141	chr8:127185635~127203222:-
LUAD	cis	rs445114	0.578	rs59351655	ENSG00000254166.1	CASC19	-3.52	0.00048	0.0498	-0.16	-0.16	Prostate cancer;Prostate cancer (SNP x SNP interaction);	chr8:127338803	chr8:127185635~127203222:-
LUAD	cis	rs445114	0.578	rs56898669	ENSG00000254166.1	CASC19	-3.52	0.00048	0.0498	-0.16	-0.16	Prostate cancer;Prostate cancer (SNP x SNP interaction);	chr8:127339197	chr8:127185635~127203222:-
LUAD	cis	rs445114	0.578	rs10956363	ENSG00000254166.1	CASC19	-3.52	0.00048	0.0498	-0.16	-0.16	Prostate cancer;Prostate cancer (SNP x SNP interaction);	chr8:127339528	chr8:127185635~127203222:-
LUAD	cis	rs9788721	0.504	rs6495314	ENSG00000259562.2	RP11-762H8.2	-3.52	0.00048	0.0498	-0.11	-0.16	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78668187	chr15:78290527~78291221:-
LUAD	cis	rs12190007	0.573	rs3006218	ENSG00000224999.1	VTA1P1	3.52	0.00048	0.0498	0.15	0.16	Obesity-related traits;	chr6:169468674	chr6:169296471~169297959:-
LUAD	cis	rs8050896	0.793	rs11860990	ENSG00000260695.1	RP11-513N24.1	-3.52	0.000481	0.0498	-0.33	-0.16	Response to antipsychotic treatment;	chr16:66116952	chr16:65861112~65863784:-
LUAD	cis	rs4268898	0.965	rs13033241	ENSG00000242628.4	AC009228.1	-3.52	0.000481	0.0498	-0.21	-0.16	Asthma;	chr2:24253249	chr2:24214381~24221516:+
LUAD	cis	rs875971	0.545	rs73376401	ENSG00000224316.1	RP11-479O9.2	3.52	0.000481	0.0498	0.18	0.16	Aortic root size;	chr7:66174841	chr7:65773620~65802067:+
LUAD	cis	rs2179367	0.887	rs506268	ENSG00000216906.2	RP11-350J20.9	3.52	0.000481	0.0498	0.19	0.16	Dupuytren's disease;	chr6:149364481	chr6:149904243~149906418:+
LUAD	cis	rs6088590	1	rs12626122	ENSG00000275784.1	RP5-1125A11.6	-3.52	0.000481	0.0498	-0.18	-0.16	Coronary artery disease;	chr20:34837997	chr20:33989480~33991818:-
LUAD	cis	rs67981189	0.896	rs4048474	ENSG00000269927.1	RP6-91H8.3	3.52	0.000481	0.0498	0.2	0.16	Schizophrenia;	chr14:71060982	chr14:71141125~71143253:-
LUAD	cis	rs9595908	0.746	rs2301391	ENSG00000281026.1	N4BP2L2-IT2	-3.52	0.000481	0.0498	-0.1	-0.16	Body mass index;	chr13:32668398	chr13:32504506~32509395:-
LUAD	cis	rs5022636	0.507	rs4579761	ENSG00000232671.4	RP11-126K1.2	3.52	0.000481	0.0498	0.2	0.16	Gut microbiota (functional units);	chr1:151363433	chr1:151280024~151281929:-
LUAD	cis	rs4474465	0.85	rs4945294	ENSG00000251323.2	RP11-452H21.4	-3.52	0.000481	0.0498	-0.19	-0.16	Alzheimer's disease (survival time);	chr11:78545818	chr11:78423982~78429836:-
LUAD	cis	rs7727544	0.582	rs4361509	ENSG00000233006.5	AC034220.3	-3.52	0.000481	0.0498	-0.14	-0.16	Blood metabolite levels;	chr5:132201060	chr5:132311285~132369916:-
LUAD	cis	rs3916	0.911	rs12829722	ENSG00000277423.1	RP11-173P15.9	-3.52	0.000481	0.0498	-0.2	-0.16	Urinary metabolites (H-NMR features);	chr12:120717819	chr12:120703867~120704282:+
LUAD	cis	rs10829156	0.732	rs7075678	ENSG00000240291.1	RP11-499P20.2	3.52	0.000481	0.0498	0.15	0.16	Sudden cardiac arrest;	chr10:18585174	chr10:18513115~18545651:-
LUAD	cis	rs6573604	1	rs17102598	ENSG00000258878.1	CTD-2509G16.3	-3.52	0.000481	0.0498	-0.2	-0.16	N-glycan levels;	chr14:65318142	chr14:65234515~65235101:-
LUAD	cis	rs34779708	0.931	rs11597392	ENSG00000271335.4	RP11-324I22.4	3.52	0.000481	0.0498	0.17	0.16	Inflammatory bowel disease;Crohn's disease;	chr10:34999647	chr10:35314552~35336401:-
LUAD	cis	rs4374383	0.884	rs4303721	ENSG00000236307.2	EEF1E1P1	-3.52	0.000481	0.0498	-0.18	-0.16	Hepatitis C induced liver fibrosis;	chr2:112003457	chr2:111887914~111888741:+
LUAD	cis	rs4664293	0.867	rs6720304	ENSG00000227055.1	AC009961.5	3.52	0.000481	0.0498	0.18	0.16	Monocyte percentage of white cells;	chr2:159787321	chr2:159812234~159814009:-
LUAD	cis	rs4664293	0.867	rs3764968	ENSG00000227055.1	AC009961.5	3.52	0.000481	0.0498	0.18	0.16	Monocyte percentage of white cells;	chr2:159790579	chr2:159812234~159814009:-
LUAD	cis	rs4664293	0.867	rs6740910	ENSG00000227055.1	AC009961.5	3.52	0.000481	0.0498	0.18	0.16	Monocyte percentage of white cells;	chr2:159792709	chr2:159812234~159814009:-
LUAD	cis	rs6502050	0.799	rs8082355	ENSG00000266654.1	RP11-1376P16.1	-3.52	0.000481	0.0498	-0.17	-0.16	Life satisfaction;	chr17:82162440	chr17:82160056~82160452:+
LUAD	cis	rs1023500	0.505	rs134889	ENSG00000273366.1	CTA-989H11.1	-3.52	0.000481	0.0498	-0.18	-0.16	Schizophrenia;	chr22:42278344	chr22:42278188~42278846:+
LUAD	cis	rs216345	0.67	rs307664	ENSG00000200834.1	Y_RNA	-3.52	0.000481	0.0498	-0.16	-0.16	Bipolar disorder;	chr9:33961354	chr9:33830978~33831078:+
LUAD	cis	rs5758659	0.714	rs5751220	ENSG00000270083.1	RP1-257I20.14	-3.52	0.000481	0.0498	-0.15	-0.16	Cognitive function;	chr22:42120201	chr22:42089630~42090028:-
LUAD	cis	rs6951245	1	rs6951245	ENSG00000199023.2	MIR339	-3.52	0.000481	0.0498	-0.28	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1018557	chr7:1022935~1023045:-
LUAD	cis	rs73230612	1	rs9811889	ENSG00000242767.1	ZBTB20-AS4	3.52	0.000481	0.0498	0.25	0.16	Type 2 diabetes;	chr3:115252683	chr3:115100423~115103061:+
LUAD	cis	rs1799949	1	rs11653460	ENSG00000267340.1	RP11-242D8.3	3.52	0.000481	0.0498	0.17	0.16	Menopause (age at onset);	chr17:43179289	chr17:43169880~43170077:-
LUAD	cis	rs61542988	0.532	rs12673996	ENSG00000221740.1	SNORD93	3.52	0.000481	0.0498	0.2	0.16	Fibrinogen levels;	chr7:22793781	chr7:22856613~22856686:+
LUAD	cis	rs8012947	0.959	rs10132929	ENSG00000279636.2	LINC00216	-3.52	0.000481	0.0498	-0.18	-0.16	Alcohol consumption in current drinkers;	chr14:58292289	chr14:58288033~58289158:+
LUAD	cis	rs8012947	0.959	rs7146801	ENSG00000279636.2	LINC00216	-3.52	0.000481	0.0498	-0.18	-0.16	Alcohol consumption in current drinkers;	chr14:58292769	chr14:58288033~58289158:+
LUAD	cis	rs2788913	0.553	rs13040868	ENSG00000273998.1	RP4-777L9.2	3.52	0.000481	0.0498	0.22	0.16	Myringotomy;	chr20:16255140	chr20:16576068~16579615:+
LUAD	cis	rs7107174	0.892	rs2512540	ENSG00000251323.2	RP11-452H21.4	3.51	0.000481	0.0499	0.21	0.16	Testicular germ cell tumor;	chr11:78268253	chr11:78423982~78429836:-
LUAD	cis	rs7107174	1	rs2510049	ENSG00000251323.2	RP11-452H21.4	3.51	0.000481	0.0499	0.21	0.16	Testicular germ cell tumor;	chr11:78274413	chr11:78423982~78429836:-
LUAD	cis	rs7107174	1	rs2510048	ENSG00000251323.2	RP11-452H21.4	3.51	0.000481	0.0499	0.21	0.16	Testicular germ cell tumor;	chr11:78276418	chr11:78423982~78429836:-
LUAD	cis	rs7107174	1	rs2510046	ENSG00000251323.2	RP11-452H21.4	3.51	0.000481	0.0499	0.21	0.16	Testicular germ cell tumor;	chr11:78277771	chr11:78423982~78429836:-
LUAD	cis	rs7107174	1	rs4945261	ENSG00000251323.2	RP11-452H21.4	-3.51	0.000481	0.0499	-0.21	-0.16	Testicular germ cell tumor;	chr11:78279214	chr11:78423982~78429836:-
LUAD	cis	rs2274273	0.87	rs10147434	ENSG00000258413.1	RP11-665C16.6	-3.51	0.000482	0.0499	-0.2	-0.16	Protein biomarker;	chr14:55208129	chr14:55262767~55272075:-
LUAD	cis	rs995000	0.64	rs4915853	ENSG00000234318.1	RP4-771M4.3	3.51	0.000482	0.0499	0.19	0.16	Triglyceride levels;	chr1:62725906	chr1:62896009~62901639:+
LUAD	cis	rs12908161	1	rs12905057	ENSG00000254414.1	RP11-182J1.1	3.51	0.000482	0.0499	0.21	0.16	Schizophrenia;	chr15:84667534	chr15:84631898~84633987:-
LUAD	cis	rs875971	0.66	rs1860470	ENSG00000222364.1	RNU6-96P	3.51	0.000482	0.0499	0.18	0.16	Aortic root size;	chr7:66638707	chr7:66395191~66395286:+
LUAD	cis	rs7546668	1	rs7516435	ENSG00000272510.1	RP4-680D5.8	3.51	0.000482	0.0499	0.2	0.16	Glomerular filtration rate (creatinine);	chr1:15542197	chr1:15565611~15565956:-
LUAD	cis	rs73242632	1	rs10026915	ENSG00000269949.1	RP11-738E22.3	3.51	0.000482	0.0499	0.39	0.16	Congenital heart disease (maternal effect);	chr4:56991605	chr4:56960927~56961373:-
LUAD	cis	rs4664293	0.899	rs7588710	ENSG00000227055.1	AC009961.5	3.51	0.000482	0.0499	0.18	0.16	Monocyte percentage of white cells;	chr2:159673011	chr2:159812234~159814009:-
LUAD	cis	rs61160187	0.555	rs34608	ENSG00000215032.2	GNL3LP1	3.51	0.000482	0.0499	0.19	0.16	Educational attainment (years of education);Educational attainment (college completion);	chr5:61161807	chr5:60891935~60893577:-
LUAD	cis	rs2638953	0.893	rs10771432	ENSG00000278733.1	RP11-425D17.1	-3.51	0.000482	0.0499	-0.18	-0.16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28507798	chr12:28185625~28186190:-
LUAD	cis	rs1044826	0.913	rs9825064	ENSG00000214280.3	RP11-553K23.2	-3.51	0.000482	0.0499	-0.19	-0.16	Obesity-related traits;	chr3:139330962	chr3:139582928~139583593:-
LUAD	cis	rs170183	0.934	rs35734452	ENSG00000230479.1	AP000695.6	-3.51	0.000482	0.0499	-0.15	-0.16	Bone mineral density;	chr21:36483703	chr21:36430360~36481070:+
LUAD	cis	rs8180040	0.587	rs1466741	ENSG00000260236.1	RP11-708J19.1	-3.51	0.000482	0.0499	-0.14	-0.16	Colorectal cancer;	chr3:47205724	chr3:47379089~47380999:-
LUAD	cis	rs76382185	0.61	rs12741486	ENSG00000233184.5	RP11-421L21.3	3.51	0.000482	0.0499	0.31	0.16	Lymphocyte counts;	chr1:101106743	chr1:101025878~101087268:+
LUAD	cis	rs76382185	0.61	rs67317828	ENSG00000233184.5	RP11-421L21.3	3.51	0.000482	0.0499	0.31	0.16	Lymphocyte counts;	chr1:101107149	chr1:101025878~101087268:+
LUAD	cis	rs12681366	0.537	rs2919664	ENSG00000253704.1	RP11-267M23.4	3.51	0.000482	0.0499	0.19	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94456485	chr8:94553722~94569745:+
LUAD	cis	rs2279168	0.867	rs58720149	ENSG00000202081.1	RNU6-1280P	-3.51	0.000482	0.0499	-0.28	-0.16	Response to platinum-based chemotherapy (carboplatin);	chr15:85501600	chr15:85651522~85651628:-
LUAD	cis	rs1910358	0.664	rs6881440	ENSG00000248874.4	C5orf17	-3.51	0.000482	0.0499	-0.2	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23912358	chr5:23951348~24178263:+
LUAD	cis	rs1910358	0.664	rs10069401	ENSG00000248874.4	C5orf17	-3.51	0.000482	0.0499	-0.2	-0.16	Venous thromboembolism (SNP x SNP interaction);	chr5:23924942	chr5:23951348~24178263:+
LUAD	cis	rs17772222	0.636	rs10484010	ENSG00000258983.2	RP11-507K2.2	3.51	0.000482	0.0499	0.19	0.16	Coronary artery calcification;	chr14:88831944	chr14:88499334~88515502:+
LUAD	cis	rs10090774	0.769	rs56352956	ENSG00000280303.2	ERICD	3.51	0.000482	0.0499	0.18	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140730167	chr8:140636281~140638283:+
LUAD	cis	rs10090774	0.87	rs6994744	ENSG00000280303.2	ERICD	3.51	0.000482	0.0499	0.18	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140730769	chr8:140636281~140638283:+
LUAD	cis	rs1075265	0.749	rs805434	ENSG00000272156.1	RP11-477N3.1	-3.51	0.000482	0.0499	-0.19	-0.16	Chronotype;Morning vs. evening chronotype;	chr2:53836196	chr2:54082554~54085066:+
LUAD	cis	rs72843166	0.853	rs72845236	ENSG00000265282.1	RP11-269G24.4	3.51	0.000482	0.0499	0.24	0.16	Intelligence (multi-trait analysis);	chr17:63275800	chr17:63430468~63432211:-
LUAD	cis	rs62244186	0.535	rs59726036	ENSG00000233509.2	ZNF197-AS1	3.51	0.000482	0.0499	0.17	0.16	Depressive symptoms;	chr3:44808582	chr3:44617128~44624797:-
LUAD	cis	rs2299587	0.623	rs7009476	ENSG00000253671.1	RP11-806O11.1	-3.51	0.000482	0.0499	-0.17	-0.16	Economic and political preferences;	chr8:17912867	chr8:17808941~17820868:+
LUAD	cis	rs4959677	0.755	rs4959670	ENSG00000272277.1	RP1-40E16.12	-3.51	0.000482	0.0499	-0.18	-0.16	Orthostatic hypotension;	chr6:2469555	chr6:3068045~3068894:-
LUAD	cis	rs6951245	0.935	rs79143504	ENSG00000226291.1	AC091729.8	-3.51	0.000482	0.0499	-0.28	-0.16	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1070576	chr7:1080863~1082178:+
LUAD	cis	rs950169	0.84	rs2896002	ENSG00000188388.10	GOLGA6L3	3.51	0.000482	0.0499	0.21	0.16	Schizophrenia;	chr15:84390423	chr15:85240472~85247170:+
LUAD	cis	rs911555	0.504	rs745079	ENSG00000269940.1	RP11-73M18.7	3.51	0.000482	0.0499	0.16	0.16	Intelligence (multi-trait analysis);	chr14:103607214	chr14:103694560~103695170:+
LUAD	cis	rs7560272	0.513	rs7558546	ENSG00000163016.8	ALMS1P	-3.51	0.000482	0.0499	-0.17	-0.16	Schizophrenia;	chr2:73710605	chr2:73644919~73685576:+
LUAD	cis	rs7134599	0.508	rs1861488	ENSG00000255733.4	IFNG-AS1	3.51	0.000482	0.0499	0.13	0.16	Inflammatory bowel disease;Ulcerative colitis;	chr12:68075499	chr12:67989445~68234686:+
LUAD	cis	rs910316	0.737	rs398896	ENSG00000279594.1	RP11-950C14.10	-3.51	0.000482	0.0499	-0.18	-0.16	Height;	chr14:75016124	chr14:75011269~75012851:-
LUAD	cis	rs4727963	0.755	rs1525471	ENSG00000240499.6	RP5-1101C3.1	-3.51	0.000482	0.0499	-0.14	-0.16	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);	chr7:123093908	chr7:122328469~122440388:+
LUAD	cis	rs683250	0.661	rs999429	ENSG00000246067.6	RAB30-AS1	-3.51	0.000482	0.0499	-0.17	-0.16	Subcortical brain region volumes;	chr11:83425835	chr11:83072066~83106719:+
LUAD	cis	rs8073060	0.586	rs225296	ENSG00000267592.1	CTC-507E2.2	3.51	0.000482	0.0499	0.23	0.16	Platelet distribution width;Platelet count;Immature fraction of reticulocytes;	chr17:35597828	chr17:35596904~35597128:-
LUAD	cis	rs6754311	0.773	rs680428	ENSG00000231890.6	DARS-AS1	3.51	0.000482	0.0499	0.22	0.16	Mosquito bite size;	chr2:135873187	chr2:135985176~136022593:+
LUAD	cis	rs6754311	0.773	rs188680	ENSG00000231890.6	DARS-AS1	3.51	0.000482	0.0499	0.22	0.16	Mosquito bite size;	chr2:135873419	chr2:135985176~136022593:+
LUAD	cis	rs6754311	0.773	rs309130	ENSG00000231890.6	DARS-AS1	3.51	0.000482	0.0499	0.22	0.16	Mosquito bite size;	chr2:135873461	chr2:135985176~136022593:+
LUAD	cis	rs12744310	0.887	rs12040046	ENSG00000235358.1	RP11-399E6.1	-3.51	0.000482	0.0499	-0.21	-0.16	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41331911	chr1:41242373~41284861:+
LUAD	cis	rs4268898	0.932	rs7577964	ENSG00000223754.1	AC008073.9	-3.51	0.000482	0.0499	-0.19	-0.16	Asthma;	chr2:24375410	chr2:24199839~24201698:-
LUAD	cis	rs1501138	0.688	rs1121630	ENSG00000263327.5	TAPT1-AS1	-3.51	0.000482	0.0499	-0.23	-0.16	Systemic juvenile idiopathic arthritis;	chr4:16285117	chr4:16226685~16320140:+
LUAD	cis	rs8046148	1	rs4785381	ENSG00000279356.1	RP11-429P3.8	3.51	0.000482	0.0499	0.19	0.16	Testicular germ cell tumor;	chr16:50099878	chr16:50072862~50074986:+
LUAD	cis	rs6460942	1	rs6460942	ENSG00000226690.5	AC005281.1	3.51	0.000482	0.0499	0.28	0.16	Coronary artery disease;	chr7:12381363	chr7:12496429~12541910:+
LUAD	cis	rs72843166	0.812	rs10438776	ENSG00000226797.1	AC015923.1	-3.51	0.000482	0.0499	-0.19	-0.16	Intelligence (multi-trait analysis);	chr17:63085708	chr17:63381231~63414312:-
LUAD	cis	rs12681366	0.537	rs6999976	ENSG00000253704.1	RP11-267M23.4	3.51	0.000483	0.0499	0.19	0.16	Nonsyndromic cleft lip with cleft palate;	chr8:94470194	chr8:94553722~94569745:+
LUAD	cis	rs10090774	0.687	rs13267705	ENSG00000280303.2	ERICD	-3.51	0.000483	0.0499	-0.17	-0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140655273	chr8:140636281~140638283:+
LUAD	cis	rs7017914	0.69	rs3098872	ENSG00000246366.5	RP11-382J12.1	-3.51	0.000483	0.0499	-0.15	-0.16	Bone mineral density;	chr8:71019969	chr8:70608577~70663279:+
LUAD	cis	rs6964587	0.692	rs6970629	ENSG00000188693.7	CYP51A1-AS1	-3.51	0.000483	0.0499	-0.18	-0.16	Breast cancer;	chr7:92217285	chr7:92134604~92180725:+
LUAD	cis	rs13437751	0.764	rs11979168	ENSG00000213640.3	EEF1DP4	3.51	0.000483	0.0499	0.33	0.16	QT interval (drug interaction);	chr7:64004281	chr7:64862999~64864370:+
LUAD	cis	rs13437751	0.764	rs59958427	ENSG00000213640.3	EEF1DP4	3.51	0.000483	0.0499	0.33	0.16	QT interval (drug interaction);	chr7:64004519	chr7:64862999~64864370:+
LUAD	cis	rs13437751	0.764	rs1439146	ENSG00000213640.3	EEF1DP4	3.51	0.000483	0.0499	0.33	0.16	QT interval (drug interaction);	chr7:64029724	chr7:64862999~64864370:+
LUAD	cis	rs13437751	0.764	rs11972314	ENSG00000213640.3	EEF1DP4	3.51	0.000483	0.0499	0.33	0.16	QT interval (drug interaction);	chr7:64031875	chr7:64862999~64864370:+
LUAD	cis	rs13437751	0.649	rs4717970	ENSG00000213640.3	EEF1DP4	3.51	0.000483	0.0499	0.33	0.16	QT interval (drug interaction);	chr7:64052030	chr7:64862999~64864370:+
LUAD	cis	rs4077515	0.967	rs3812558	ENSG00000238058.1	RP11-432J22.2	-3.51	0.000483	0.05	-0.17	-0.16	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;IgA nephropathy;	chr9:136374683	chr9:135907812~135913513:+
LUAD	cis	rs1555322	0.53	rs2425042	ENSG00000261582.1	RP4-614O4.11	-3.51	0.000483	0.05	-0.2	-0.16	Attention deficit hyperactivity disorder;	chr20:35278092	chr20:35267885~35280043:-
LUAD	cis	rs1555322	0.53	rs7004	ENSG00000261582.1	RP4-614O4.11	-3.51	0.000483	0.05	-0.2	-0.16	Attention deficit hyperactivity disorder;	chr20:35278950	chr20:35267885~35280043:-
LUAD	cis	rs10090774	0.841	rs13438888	ENSG00000280303.2	ERICD	3.51	0.000483	0.05	0.18	0.16	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr8:140831843	chr8:140636281~140638283:+
LUAD	cis	rs9309473	0.95	rs13431529	ENSG00000230002.2	ALMS1-IT1	3.51	0.000483	0.05	0.2	0.16	Metabolite levels;	chr2:73648914	chr2:73456764~73459484:+
LUAD	cis	rs12681963	0.748	rs7833115	ENSG00000272375.1	RP11-51J9.6	-3.51	0.000483	0.05	-0.2	-0.16	Migraine;	chr8:30058676	chr8:30197404~30198048:+
LUAD	cis	rs9959145	0.778	rs2186906	ENSG00000267108.1	RP11-861E21.1	3.51	0.000483	0.05	0.25	0.16	Immune response to smallpox vaccine (IL-6);	chr18:12572196	chr18:12432897~12437635:+
LUAD	cis	rs9959145	0.929	rs113231666	ENSG00000267108.1	RP11-861E21.1	3.51	0.000483	0.05	0.25	0.16	Immune response to smallpox vaccine (IL-6);	chr18:12574011	chr18:12432897~12437635:+
LUAD	cis	rs6964587	0.626	rs2269810	ENSG00000188693.7	CYP51A1-AS1	3.51	0.000483	0.05	0.19	0.16	Breast cancer;	chr7:91879523	chr7:92134604~92180725:+
LUAD	cis	rs6754311	0.593	rs1438305	ENSG00000226806.1	AC011893.3	-3.51	0.000483	0.05	-0.2	-0.16	Mosquito bite size;	chr2:135745222	chr2:135820191~135823087:+
LUAD	cis	rs6754311	0.513	rs1438304	ENSG00000226806.1	AC011893.3	-3.51	0.000483	0.05	-0.2	-0.16	Mosquito bite size;	chr2:135745587	chr2:135820191~135823087:+
LUAD	cis	rs11992162	0.551	rs59191504	ENSG00000255046.1	RP11-297N6.4	3.51	0.000483	0.05	0.2	0.16	Monocyte count;	chr8:11927572	chr8:11797928~11802568:-
LUAD	cis	rs6964587	0.692	rs4727268	ENSG00000188693.7	CYP51A1-AS1	-3.51	0.000483	0.05	-0.18	-0.16	Breast cancer;	chr7:92211410	chr7:92134604~92180725:+
LUAD	cis	rs737008	0.959	rs11865598	ENSG00000262703.1	RP11-485G7.6	3.51	0.000483	0.05	0.15	0.16	Obesity-related traits;	chr16:11309575	chr16:11348143~11349321:-
LUAD	cis	rs1799955	0.554	rs11571662	ENSG00000215515.2	IFIT1P1	-3.51	0.000483	0.05	-0.2	-0.16	LDL cholesterol levels;	chr13:32341387	chr13:32384660~32386108:+
LUAD	cis	rs4218	0.619	rs10851643	ENSG00000277144.1	RP11-59H7.4	-3.51	0.000483	0.05	-0.19	-0.16	Social communication problems;	chr15:59102985	chr15:59115547~59116089:-
LUAD	cis	rs3764021	0.87	rs2401394	ENSG00000256582.1	RP11-75L1.1	3.51	0.000483	0.05	0.16	0.16	Type 1 diabetes;	chr12:9726830	chr12:9704077~9709350:+
LUAD	trans	rs928391	0.681	rs12161427	ENSG00000227183.3	HDGFP1	34.63	1.01e-132	3.94e-124	1.12	0.84	Platelet count;	chr1:156736030	chrX:131646639~131646890:+
LUAD	trans	rs928391	0.681	rs12145743	ENSG00000227183.3	HDGFP1	34.4	9.48e-132	3.56e-123	1.13	0.84	Platelet count;	chr1:156730859	chrX:131646639~131646890:+
LUAD	trans	rs928391	0.681	rs3806417	ENSG00000227183.3	HDGFP1	34.36	1.4e-131	5.22e-123	1.12	0.84	Platelet count;	chr1:156741831	chrX:131646639~131646890:+
LUAD	trans	rs928391	0.624	rs4399146	ENSG00000227183.3	HDGFP1	34.11	1.75e-130	6.4e-122	1.12	0.84	Platelet count;	chr1:156743766	chrX:131646639~131646890:+
LUAD	trans	rs928391	0.681	rs11264533	ENSG00000227183.3	HDGFP1	33.84	2.56e-129	9.21e-121	1.11	0.84	Platelet count;	chr1:156748656	chrX:131646639~131646890:+
LUAD	trans	rs13177918	0.677	rs3857421	ENSG00000213058.3	RP4-765C7.2	-33.69	1.15e-128	4.09e-120	-1.26	-0.84	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr1:178411616~178411972:+
LUAD	trans	rs928391	0.681	rs11264535	ENSG00000227183.3	HDGFP1	33.43	1.59e-127	5.61e-119	1.11	0.84	Platelet count;	chr1:156752632	chrX:131646639~131646890:+
LUAD	trans	rs6477998	0.58	rs9299214	ENSG00000238072.1	RP11-305M3.2	33.17	2.09e-126	7.04e-118	1.18	0.83	Hematology traits;	chr9:113273416	chr7:129410113~129410370:-
LUAD	trans	rs13177918	0.677	rs13171800	ENSG00000213058.3	RP4-765C7.2	33.06	6.57e-126	2.18e-117	1.24	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr1:178411616~178411972:+
LUAD	trans	rs13177918	0.677	rs2070841	ENSG00000213058.3	RP4-765C7.2	33.06	6.57e-126	2.18e-117	1.24	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr1:178411616~178411972:+
LUAD	trans	rs7949030	0.626	rs11231141	ENSG00000186676.3	EEF1GP1	33.05	7.33e-126	2.39e-117	1.13	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62558793	chr7:125033453~125035301:+
LUAD	trans	rs7949030	0.626	rs7943191	ENSG00000186676.3	EEF1GP1	33.05	7.33e-126	2.39e-117	1.13	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561079	chr7:125033453~125035301:+
LUAD	trans	rs13177918	0.677	rs13161099	ENSG00000213058.3	RP4-765C7.2	33	1.2e-125	3.67e-117	1.23	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr1:178411616~178411972:+
LUAD	trans	rs13177918	0.677	rs13161417	ENSG00000213058.3	RP4-765C7.2	33	1.2e-125	3.67e-117	1.23	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr1:178411616~178411972:+
LUAD	trans	rs13177918	0.677	rs13161156	ENSG00000213058.3	RP4-765C7.2	33	1.2e-125	3.67e-117	1.23	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr1:178411616~178411972:+
LUAD	trans	rs13177918	0.677	rs13181401	ENSG00000213058.3	RP4-765C7.2	33	1.2e-125	3.67e-117	1.23	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr1:178411616~178411972:+
LUAD	trans	rs13177918	0.677	rs4541646	ENSG00000213058.3	RP4-765C7.2	33	1.2e-125	3.67e-117	1.23	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr1:178411616~178411972:+
LUAD	trans	rs13177918	0.677	rs3900644	ENSG00000213058.3	RP4-765C7.2	33	1.2e-125	3.67e-117	1.23	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr1:178411616~178411972:+
LUAD	trans	rs13177918	0.677	rs2070844	ENSG00000213058.3	RP4-765C7.2	33	1.2e-125	3.67e-117	1.23	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr1:178411616~178411972:+
LUAD	trans	rs13177918	0.629	rs2070842	ENSG00000213058.3	RP4-765C7.2	33	1.2e-125	3.67e-117	1.23	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr1:178411616~178411972:+
LUAD	trans	rs7949030	0.626	rs11231144	ENSG00000186676.3	EEF1GP1	32.93	2.4e-125	7.3e-117	1.13	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62560566	chr7:125033453~125035301:+
LUAD	trans	rs13177918	0.629	rs13161261	ENSG00000213058.3	RP4-765C7.2	32.92	2.74e-125	8.29e-117	1.23	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr1:178411616~178411972:+
LUAD	trans	rs1816752	0.774	rs55888616	ENSG00000237917.1	PARP4P1	32.91	2.95e-125	8.9e-117	1.02	0.83	Obesity-related traits;	chr13:24441954	chrY:26594851~26634652:-
LUAD	trans	rs7949030	0.626	rs1061093	ENSG00000186676.3	EEF1GP1	32.87	4.34e-125	1.29e-116	1.12	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62567436	chr7:125033453~125035301:+
LUAD	trans	rs1816752	0.905	rs9511266	ENSG00000237917.1	PARP4P1	32.78	1.17e-124	3.39e-116	1.02	0.83	Obesity-related traits;	chr13:24438366	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.817	rs7985394	ENSG00000237917.1	PARP4P1	32.78	1.17e-124	3.39e-116	1.02	0.83	Obesity-related traits;	chr13:24438714	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.789	rs7986037	ENSG00000237917.1	PARP4P1	32.78	1.17e-124	3.39e-116	1.02	0.83	Obesity-related traits;	chr13:24438715	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.805	rs61614647	ENSG00000237917.1	PARP4P1	32.73	1.86e-124	5.38e-116	1.02	0.83	Obesity-related traits;	chr13:24441829	chrY:26594851~26634652:-
LUAD	trans	rs928391	0.681	rs11264534	ENSG00000227183.3	HDGFP1	32.7	2.42e-124	6.94e-116	1.11	0.83	Platelet count;	chr1:156750758	chrX:131646639~131646890:+
LUAD	trans	rs928391	0.652	rs12030654	ENSG00000227183.3	HDGFP1	32.7	2.42e-124	6.94e-116	1.11	0.83	Platelet count;	chr1:156751240	chrX:131646639~131646890:+
LUAD	trans	rs1816752	0.87	rs7320102	ENSG00000237917.1	PARP4P1	32.67	3.39e-124	9.62e-116	1.02	0.83	Obesity-related traits;	chr13:24437435	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.905	rs7339140	ENSG00000237917.1	PARP4P1	32.67	3.51e-124	9.79e-116	1.02	0.83	Obesity-related traits;	chr13:24437764	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.87	rs9511261	ENSG00000237917.1	PARP4P1	32.67	3.51e-124	9.79e-116	1.02	0.83	Obesity-related traits;	chr13:24437880	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.905	rs9511262	ENSG00000237917.1	PARP4P1	32.67	3.51e-124	9.79e-116	1.02	0.83	Obesity-related traits;	chr13:24437885	chrY:26594851~26634652:-
LUAD	trans	rs7949030	0.626	rs11231145	ENSG00000186676.3	EEF1GP1	32.66	3.78e-124	1.05e-115	1.13	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561382	chr7:125033453~125035301:+
LUAD	trans	rs13177918	0.677	rs2073472	ENSG00000213058.3	RP4-765C7.2	32.65	4.06e-124	1.12e-115	1.23	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr1:178411616~178411972:+
LUAD	trans	rs1816752	0.87	rs3825449	ENSG00000237917.1	PARP4P1	32.59	7.92e-124	2.18e-115	1.01	0.83	Obesity-related traits;	chr13:24440303	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.905	rs7995909	ENSG00000237917.1	PARP4P1	32.58	8.4e-124	2.21e-115	1.01	0.83	Obesity-related traits;	chr13:24439159	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.905	rs6490927	ENSG00000237917.1	PARP4P1	32.58	8.4e-124	2.21e-115	1.01	0.83	Obesity-related traits;	chr13:24439802	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.905	rs6490928	ENSG00000237917.1	PARP4P1	32.58	8.4e-124	2.21e-115	1.01	0.83	Obesity-related traits;	chr13:24439921	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.905	rs6490929	ENSG00000237917.1	PARP4P1	32.58	8.4e-124	2.21e-115	1.01	0.83	Obesity-related traits;	chr13:24440114	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.87	rs7998797	ENSG00000237917.1	PARP4P1	32.58	8.4e-124	2.21e-115	1.01	0.83	Obesity-related traits;	chr13:24440850	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.87	rs7981337	ENSG00000237917.1	PARP4P1	32.58	8.4e-124	2.21e-115	1.01	0.83	Obesity-related traits;	chr13:24440915	chrY:26594851~26634652:-
LUAD	trans	rs13177918	0.677	rs13177951	ENSG00000213058.3	RP4-765C7.2	32.58	8.99e-124	2.33e-115	1.24	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr1:178411616~178411972:+
LUAD	trans	rs13177918	0.677	rs13177970	ENSG00000213058.3	RP4-765C7.2	32.58	8.99e-124	2.33e-115	1.24	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr1:178411616~178411972:+
LUAD	trans	rs13177918	0.677	rs13164105	ENSG00000213058.3	RP4-765C7.2	32.58	8.99e-124	2.33e-115	1.24	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr1:178411616~178411972:+
LUAD	trans	rs1816752	0.87	rs7981480	ENSG00000237917.1	PARP4P1	32.54	1.32e-123	3.36e-115	1.01	0.83	Obesity-related traits;	chr13:24440966	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.837	rs4769355	ENSG00000237917.1	PARP4P1	32.54	1.32e-123	3.36e-115	1.01	0.83	Obesity-related traits;	chr13:24441059	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.905	rs4770680	ENSG00000237917.1	PARP4P1	32.54	1.32e-123	3.36e-115	1.01	0.83	Obesity-related traits;	chr13:24441110	chrY:26594851~26634652:-
LUAD	trans	rs13177918	0.677	rs57890152	ENSG00000213058.3	RP4-765C7.2	32.53	1.39e-123	3.47e-115	1.22	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr1:178411616~178411972:+
LUAD	trans	rs13177918	0.686	rs12654827	ENSG00000213058.3	RP4-765C7.2	32.53	1.39e-123	3.47e-115	1.22	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr1:178411616~178411972:+
LUAD	trans	rs13177918	0.677	rs13160685	ENSG00000213058.3	RP4-765C7.2	32.53	1.39e-123	3.47e-115	1.22	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr1:178411616~178411972:+
LUAD	trans	rs1816752	0.905	rs9511264	ENSG00000237917.1	PARP4P1	-32.52	1.5e-123	3.74e-115	-1	-0.83	Obesity-related traits;	chr13:24438079	chrY:26594851~26634652:-
LUAD	trans	rs13177918	0.677	rs3797622	ENSG00000213058.3	RP4-765C7.2	32.5	1.98e-123	4.91e-115	1.22	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr1:178411616~178411972:+
LUAD	trans	rs7949030	0.626	rs72927213	ENSG00000186676.3	EEF1GP1	32.49	2.1e-123	5.16e-115	1.13	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62583726	chr7:125033453~125035301:+
LUAD	trans	rs7949030	0.626	rs71490390	ENSG00000186676.3	EEF1GP1	32.49	2.19e-123	5.35e-115	1.13	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561713	chr7:125033453~125035301:+
LUAD	trans	rs1816752	0.905	rs7995492	ENSG00000237917.1	PARP4P1	32.48	2.3e-123	5.6e-115	1	0.83	Obesity-related traits;	chr13:24438885	chrY:26594851~26634652:-
LUAD	trans	rs7949030	0.591	rs12049914	ENSG00000186676.3	EEF1GP1	32.47	2.6e-123	6.26e-115	1.13	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62601964	chr7:125033453~125035301:+
LUAD	trans	rs7949030	0.591	rs35156678	ENSG00000186676.3	EEF1GP1	32.47	2.6e-123	6.26e-115	1.13	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602409	chr7:125033453~125035301:+
LUAD	trans	rs7949030	0.596	rs71490394	ENSG00000186676.3	EEF1GP1	32.47	2.6e-123	6.26e-115	1.13	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602683	chr7:125033453~125035301:+
LUAD	trans	rs7949030	0.626	rs7124057	ENSG00000186676.3	EEF1GP1	32.46	2.77e-123	6.64e-115	1.13	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62566624	chr7:125033453~125035301:+
LUAD	trans	rs1816752	0.905	rs9511260	ENSG00000237917.1	PARP4P1	32.43	3.85e-123	9.2e-115	1.02	0.83	Obesity-related traits;	chr13:24437038	chrY:26594851~26634652:-
LUAD	trans	rs7949030	0.626	rs11231154	ENSG00000186676.3	EEF1GP1	32.42	4.46e-123	1.06e-114	1.13	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62594821	chr7:125033453~125035301:+
LUAD	trans	rs7949030	0.591	rs11231156	ENSG00000186676.3	EEF1GP1	32.42	4.46e-123	1.06e-114	1.13	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598982	chr7:125033453~125035301:+
LUAD	trans	rs7949030	0.626	rs7930896	ENSG00000186676.3	EEF1GP1	32.28	1.75e-122	4.11e-114	1.12	0.83	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62557800	chr7:125033453~125035301:+
LUAD	trans	rs13177918	0.677	rs4841	ENSG00000213058.3	RP4-765C7.2	32.24	2.63e-122	6.09e-114	1.22	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr1:178411616~178411972:+
LUAD	trans	rs13177918	0.677	rs13183077	ENSG00000213058.3	RP4-765C7.2	32.24	2.63e-122	6.09e-114	1.22	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr1:178411616~178411972:+
LUAD	trans	rs1816752	0.806	rs3816218	ENSG00000237917.1	PARP4P1	32.24	2.83e-122	6.38e-114	1.02	0.83	Obesity-related traits;	chr13:24443033	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.666	rs7994022	ENSG00000237917.1	PARP4P1	32.24	2.83e-122	6.38e-114	1.02	0.83	Obesity-related traits;	chr13:24443092	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.712	rs6490932	ENSG00000237917.1	PARP4P1	32.24	2.83e-122	6.38e-114	1.02	0.83	Obesity-related traits;	chr13:24443313	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.713	rs7336357	ENSG00000237917.1	PARP4P1	32.24	2.83e-122	6.38e-114	1.02	0.83	Obesity-related traits;	chr13:24443452	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.683	rs7330532	ENSG00000237917.1	PARP4P1	32.24	2.83e-122	6.38e-114	1.02	0.83	Obesity-related traits;	chr13:24443453	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.59	rs61947036	ENSG00000237917.1	PARP4P1	32.24	2.83e-122	6.38e-114	1.02	0.83	Obesity-related traits;	chr13:24443544	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.87	rs2033955	ENSG00000237917.1	PARP4P1	32.15	7.13e-122	1.58e-113	1.02	0.83	Obesity-related traits;	chr13:24436406	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.87	rs2033954	ENSG00000237917.1	PARP4P1	32.15	7.13e-122	1.58e-113	1.02	0.83	Obesity-related traits;	chr13:24436429	chrY:26594851~26634652:-
LUAD	trans	rs928391	0.681	rs4501833	ENSG00000227183.3	HDGFP1	32.03	2.23e-121	4.93e-113	1.11	0.83	Platelet count;	chr1:156746806	chrX:131646639~131646890:+
LUAD	trans	rs1816752	0.87	rs8000215	ENSG00000237917.1	PARP4P1	31.98	3.71e-121	8.17e-113	1.02	0.82	Obesity-related traits;	chr13:24435648	chrY:26594851~26634652:-
LUAD	trans	rs13253073	0.657	rs35135010	ENSG00000260318.1	COX6CP1	31.88	1.05e-120	2.3e-112	1.32	0.82	Glucose homeostasis traits;	chr8:99864209	chr16:11903923~11904137:-
LUAD	trans	rs1816752	0.905	rs1050112	ENSG00000237917.1	PARP4P1	31.77	3.32e-120	7.17e-112	1.02	0.82	Obesity-related traits;	chr13:24435159	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.776	rs7998843	ENSG00000237917.1	PARP4P1	31.72	5.34e-120	1.15e-111	1.02	0.82	Obesity-related traits;	chr13:24443147	chrY:26594851~26634652:-
LUAD	trans	rs6477998	0.603	rs10117451	ENSG00000238072.1	RP11-305M3.2	31.71	6.4e-120	1.37e-111	1.16	0.82	Hematology traits;	chr9:113273610	chr7:129410113~129410370:-
LUAD	trans	rs13253073	0.723	rs7812991	ENSG00000260318.1	COX6CP1	31.69	7.76e-120	1.64e-111	1.32	0.82	Glucose homeostasis traits;	chr8:99884095	chr16:11903923~11904137:-
LUAD	trans	rs1816752	0.905	rs11839006	ENSG00000237917.1	PARP4P1	31.67	8.96e-120	1.88e-111	1.02	0.82	Obesity-related traits;	chr13:24435893	chrY:26594851~26634652:-
LUAD	trans	rs13253073	0.723	rs34830464	ENSG00000260318.1	COX6CP1	31.65	1.13e-119	2.36e-111	1.32	0.82	Glucose homeostasis traits;	chr8:99866638	chr16:11903923~11904137:-
LUAD	trans	rs1816752	0.905	rs13428	ENSG00000237917.1	PARP4P1	31.58	2.31e-119	4.79e-111	1.02	0.82	Obesity-related traits;	chr13:24435303	chrY:26594851~26634652:-
LUAD	trans	rs7949030	0.626	rs61296092	ENSG00000186676.3	EEF1GP1	31.48	6.42e-119	1.33e-110	1.12	0.82	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62553366	chr7:125033453~125035301:+
LUAD	trans	rs7949030	0.591	rs35880596	ENSG00000186676.3	EEF1GP1	31.41	1.35e-118	2.79e-110	1.12	0.82	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602412	chr7:125033453~125035301:+
LUAD	trans	rs1816752	0.746	rs9511270	ENSG00000237917.1	PARP4P1	31.23	8.99e-118	1.85e-109	1.02	0.82	Obesity-related traits;	chr13:24444542	chrY:26594851~26634652:-
LUAD	trans	rs7949030	0.59	rs12225213	ENSG00000186676.3	EEF1GP1	31.23	9e-118	1.85e-109	1.12	0.82	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62582776	chr7:125033453~125035301:+
LUAD	trans	rs13177918	0.677	rs3857421	ENSG00000224114.1	RP11-343H5.4	-31.13	2.44e-117	4.99e-109	-1.23	-0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr1:206695837~206696269:-
LUAD	trans	rs13253073	0.723	rs12548840	ENSG00000260318.1	COX6CP1	31.1	3.33e-117	6.79e-109	1.32	0.82	Glucose homeostasis traits;	chr8:99885580	chr16:11903923~11904137:-
LUAD	trans	rs1816752	0.875	rs1050110	ENSG00000237917.1	PARP4P1	31.08	4.19e-117	8.48e-109	1.02	0.82	Obesity-related traits;	chr13:24435347	chrY:26594851~26634652:-
LUAD	trans	rs13177918	0.75	rs58256223	ENSG00000213058.3	RP4-765C7.2	30.96	1.41e-116	2.83e-108	1.2	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr1:178411616~178411972:+
LUAD	trans	rs13177918	0.75	rs59354956	ENSG00000213058.3	RP4-765C7.2	30.96	1.41e-116	2.83e-108	1.2	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr1:178411616~178411972:+
LUAD	trans	rs1816752	0.776	rs9511268	ENSG00000237917.1	PARP4P1	30.95	1.6e-116	3.18e-108	1.03	0.82	Obesity-related traits;	chr13:24444182	chrY:26594851~26634652:-
LUAD	trans	rs1816752	1	rs9511265	ENSG00000237917.1	PARP4P1	30.78	8.89e-116	1.76e-107	1.03	0.81	Obesity-related traits;	chr13:24438221	chrY:26594851~26634652:-
LUAD	trans	rs13177918	0.677	rs13171800	ENSG00000224114.1	RP11-343H5.4	30.76	1.12e-115	2.2e-107	1.21	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr1:206695837~206696269:-
LUAD	trans	rs13177918	0.677	rs2070841	ENSG00000224114.1	RP11-343H5.4	30.76	1.12e-115	2.2e-107	1.21	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr1:206695837~206696269:-
LUAD	trans	rs13253073	0.723	rs1135382	ENSG00000260318.1	COX6CP1	30.69	2.44e-115	4.76e-107	1.33	0.81	Glucose homeostasis traits;	chr8:99879402	chr16:11903923~11904137:-
LUAD	trans	rs13253073	0.723	rs4510829	ENSG00000260318.1	COX6CP1	30.65	3.45e-115	6.71e-107	1.32	0.81	Glucose homeostasis traits;	chr8:99878982	chr16:11903923~11904137:-
LUAD	trans	rs13253073	0.723	rs1130474	ENSG00000260318.1	COX6CP1	30.63	4.59e-115	8.87e-107	1.31	0.81	Glucose homeostasis traits;	chr8:99892049	chr16:11903923~11904137:-
LUAD	trans	rs13177918	0.629	rs13161261	ENSG00000224114.1	RP11-343H5.4	30.62	4.89e-115	9.38e-107	1.2	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr1:206695837~206696269:-
LUAD	trans	rs13177918	0.677	rs13161099	ENSG00000224114.1	RP11-343H5.4	30.61	5.29e-115	9.78e-107	1.2	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr1:206695837~206696269:-
LUAD	trans	rs13177918	0.677	rs13161417	ENSG00000224114.1	RP11-343H5.4	30.61	5.29e-115	9.78e-107	1.2	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr1:206695837~206696269:-
LUAD	trans	rs13177918	0.677	rs13161156	ENSG00000224114.1	RP11-343H5.4	30.61	5.29e-115	9.78e-107	1.2	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr1:206695837~206696269:-
LUAD	trans	rs13177918	0.677	rs13181401	ENSG00000224114.1	RP11-343H5.4	30.61	5.29e-115	9.78e-107	1.2	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr1:206695837~206696269:-
LUAD	trans	rs13177918	0.677	rs4541646	ENSG00000224114.1	RP11-343H5.4	30.61	5.29e-115	9.78e-107	1.2	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr1:206695837~206696269:-
LUAD	trans	rs13177918	0.677	rs3900644	ENSG00000224114.1	RP11-343H5.4	30.61	5.29e-115	9.78e-107	1.2	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr1:206695837~206696269:-
LUAD	trans	rs13177918	0.677	rs2070844	ENSG00000224114.1	RP11-343H5.4	30.61	5.29e-115	9.78e-107	1.2	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr1:206695837~206696269:-
LUAD	trans	rs13177918	0.629	rs2070842	ENSG00000224114.1	RP11-343H5.4	30.61	5.29e-115	9.78e-107	1.2	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr1:206695837~206696269:-
LUAD	trans	rs13253073	0.723	rs35429753	ENSG00000260318.1	COX6CP1	30.57	8.02e-115	1.48e-106	1.31	0.81	Glucose homeostasis traits;	chr8:99891015	chr16:11903923~11904137:-
LUAD	trans	rs13177918	0.677	rs57890152	ENSG00000224114.1	RP11-343H5.4	30.5	1.75e-114	3.19e-106	1.19	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr1:206695837~206696269:-
LUAD	trans	rs13177918	0.686	rs12654827	ENSG00000224114.1	RP11-343H5.4	30.5	1.75e-114	3.19e-106	1.19	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr1:206695837~206696269:-
LUAD	trans	rs13177918	0.677	rs13160685	ENSG00000224114.1	RP11-343H5.4	30.5	1.75e-114	3.19e-106	1.19	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr1:206695837~206696269:-
LUAD	trans	rs13253073	0.723	rs7828241	ENSG00000260318.1	COX6CP1	30.44	3.13e-114	5.69e-106	1.33	0.81	Glucose homeostasis traits;	chr8:99880417	chr16:11903923~11904137:-
LUAD	trans	rs13177918	0.677	rs2073472	ENSG00000224114.1	RP11-343H5.4	30.38	6.15e-114	1.11e-105	1.2	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr1:206695837~206696269:-
LUAD	trans	rs13253073	0.723	rs4626565	ENSG00000260318.1	COX6CP1	30.32	1.13e-113	2.01e-105	1.32	0.81	Glucose homeostasis traits;	chr8:99878314	chr16:11903923~11904137:-
LUAD	trans	rs1816752	0.935	rs3816219	ENSG00000237917.1	PARP4P1	30.28	1.64e-113	2.92e-105	1.03	0.81	Obesity-related traits;	chr13:24442995	chrY:26594851~26634652:-
LUAD	trans	rs13177918	0.677	rs13177951	ENSG00000224114.1	RP11-343H5.4	30.23	2.68e-113	4.71e-105	1.2	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr1:206695837~206696269:-
LUAD	trans	rs13177918	0.677	rs13177970	ENSG00000224114.1	RP11-343H5.4	30.23	2.68e-113	4.71e-105	1.2	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr1:206695837~206696269:-
LUAD	trans	rs13177918	0.677	rs13164105	ENSG00000224114.1	RP11-343H5.4	30.23	2.68e-113	4.71e-105	1.2	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr1:206695837~206696269:-
LUAD	trans	rs1816752	1	rs7999554	ENSG00000237917.1	PARP4P1	30.22	3.09e-113	5.42e-105	1.03	0.81	Obesity-related traits;	chr13:24435631	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.719	rs11841989	ENSG00000237917.1	PARP4P1	30.2	3.76e-113	6.53e-105	0.99	0.81	Obesity-related traits;	chr13:24423560	chrY:26594851~26634652:-
LUAD	trans	rs13177918	0.557	rs12520101	ENSG00000213058.3	RP4-765C7.2	30.19	4.25e-113	7.38e-105	1.2	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr1:178411616~178411972:+
LUAD	trans	rs1816752	0.638	rs9578730	ENSG00000237917.1	PARP4P1	30.18	4.82e-113	8.33e-105	1.01	0.81	Obesity-related traits;	chr13:24425545	chrY:26594851~26634652:-
LUAD	trans	rs13177918	0.677	rs3857421	ENSG00000239528.1	RPS14P8	-30.14	6.99e-113	1.21e-104	-1.25	-0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr5:116562562~116562930:+
LUAD	trans	rs1816752	0.935	rs4770676	ENSG00000237917.1	PARP4P1	30.11	1.01e-112	1.73e-104	1.03	0.81	Obesity-related traits;	chr13:24429745	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.905	rs8002215	ENSG00000237917.1	PARP4P1	30.11	1.03e-112	1.76e-104	0.99	0.81	Obesity-related traits;	chr13:24416229	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.905	rs7400631	ENSG00000237917.1	PARP4P1	30.11	1.03e-112	1.76e-104	0.99	0.81	Obesity-related traits;	chr13:24415927	chrY:26594851~26634652:-
LUAD	trans	rs13253073	0.723	rs7844439	ENSG00000260318.1	COX6CP1	30.07	1.47e-112	2.5e-104	1.31	0.81	Glucose homeostasis traits;	chr8:99878567	chr16:11903923~11904137:-
LUAD	trans	rs1816752	1	rs7326932	ENSG00000237917.1	PARP4P1	29.96	4.76e-112	8.04e-104	1.03	0.81	Obesity-related traits;	chr13:24430355	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.905	rs4770666	ENSG00000237917.1	PARP4P1	29.96	4.86e-112	8.19e-104	0.98	0.81	Obesity-related traits;	chr13:24414891	chrY:26594851~26634652:-
LUAD	trans	rs13177918	0.677	rs4841	ENSG00000224114.1	RP11-343H5.4	29.95	5.06e-112	8.49e-104	1.19	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr1:206695837~206696269:-
LUAD	trans	rs13177918	0.677	rs13183077	ENSG00000224114.1	RP11-343H5.4	29.95	5.06e-112	8.49e-104	1.19	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr1:206695837~206696269:-
LUAD	trans	rs1816752	0.905	rs7991450	ENSG00000237917.1	PARP4P1	29.95	5.24e-112	8.74e-104	0.98	0.81	Obesity-related traits;	chr13:24425898	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.774	rs7986162	ENSG00000237917.1	PARP4P1	29.95	5.24e-112	8.74e-104	0.98	0.81	Obesity-related traits;	chr13:24425941	chrY:26594851~26634652:-
LUAD	trans	rs13177918	0.677	rs3797622	ENSG00000224114.1	RP11-343H5.4	29.94	5.79e-112	9.63e-104	1.18	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr1:206695837~206696269:-
LUAD	trans	rs13177918	0.677	rs13171800	ENSG00000239528.1	RPS14P8	29.94	5.95e-112	9.8e-104	1.23	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr5:116562562~116562930:+
LUAD	trans	rs13177918	0.677	rs2070841	ENSG00000239528.1	RPS14P8	29.94	5.95e-112	9.8e-104	1.23	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr5:116562562~116562930:+
LUAD	trans	rs1816752	0.905	rs4769352	ENSG00000237917.1	PARP4P1	29.86	1.35e-111	2.2e-103	0.98	0.81	Obesity-related traits;	chr13:24426237	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.805	rs4769353	ENSG00000237917.1	PARP4P1	29.86	1.35e-111	2.2e-103	0.98	0.81	Obesity-related traits;	chr13:24426318	chrY:26594851~26634652:-
LUAD	trans	rs13177918	0.677	rs13161099	ENSG00000239528.1	RPS14P8	29.79	2.69e-111	4.23e-103	1.22	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr5:116562562~116562930:+
LUAD	trans	rs13177918	0.677	rs13161417	ENSG00000239528.1	RPS14P8	29.79	2.69e-111	4.23e-103	1.22	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr5:116562562~116562930:+
LUAD	trans	rs13177918	0.677	rs13161156	ENSG00000239528.1	RPS14P8	29.79	2.69e-111	4.23e-103	1.22	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr5:116562562~116562930:+
LUAD	trans	rs13177918	0.677	rs13181401	ENSG00000239528.1	RPS14P8	29.79	2.69e-111	4.23e-103	1.22	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr5:116562562~116562930:+
LUAD	trans	rs13177918	0.677	rs4541646	ENSG00000239528.1	RPS14P8	29.79	2.69e-111	4.23e-103	1.22	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr5:116562562~116562930:+
LUAD	trans	rs13177918	0.677	rs3900644	ENSG00000239528.1	RPS14P8	29.79	2.69e-111	4.23e-103	1.22	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr5:116562562~116562930:+
LUAD	trans	rs13177918	0.677	rs2070844	ENSG00000239528.1	RPS14P8	29.79	2.69e-111	4.23e-103	1.22	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr5:116562562~116562930:+
LUAD	trans	rs13177918	0.629	rs2070842	ENSG00000239528.1	RPS14P8	29.79	2.69e-111	4.23e-103	1.22	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr5:116562562~116562930:+
LUAD	trans	rs1816752	0.905	rs9511242	ENSG00000237917.1	PARP4P1	29.77	3.51e-111	5.5e-103	0.99	0.81	Obesity-related traits;	chr13:24419261	chrY:26594851~26634652:-
LUAD	trans	rs1816752	1	rs7988810	ENSG00000237917.1	PARP4P1	29.76	4e-111	6.25e-103	1.03	0.8	Obesity-related traits;	chr13:24444958	chrY:26594851~26634652:-
LUAD	trans	rs13253073	0.723	rs1130569	ENSG00000260318.1	COX6CP1	29.7	7.18e-111	1.12e-102	1.29	0.8	Glucose homeostasis traits;	chr8:99887565	chr16:11903923~11904137:-
LUAD	trans	rs1816752	0.905	rs7571	ENSG00000237917.1	PARP4P1	29.7	7.55e-111	1.17e-102	0.98	0.8	Obesity-related traits;	chr13:24426479	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.87	rs9318529	ENSG00000237917.1	PARP4P1	29.65	1.18e-110	1.82e-102	0.96	0.8	Obesity-related traits;	chr13:24424190	chrY:26594851~26634652:-
LUAD	trans	rs13177918	0.677	rs57890152	ENSG00000239528.1	RPS14P8	29.63	1.52e-110	2.32e-102	1.22	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr5:116562562~116562930:+
LUAD	trans	rs13177918	0.686	rs12654827	ENSG00000239528.1	RPS14P8	29.63	1.52e-110	2.32e-102	1.22	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr5:116562562~116562930:+
LUAD	trans	rs13177918	0.677	rs13160685	ENSG00000239528.1	RPS14P8	29.63	1.52e-110	2.32e-102	1.22	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr5:116562562~116562930:+
LUAD	trans	rs13177918	0.677	rs13177951	ENSG00000239528.1	RPS14P8	29.63	1.58e-110	2.39e-102	1.23	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr5:116562562~116562930:+
LUAD	trans	rs13177918	0.677	rs13177970	ENSG00000239528.1	RPS14P8	29.63	1.58e-110	2.39e-102	1.23	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr5:116562562~116562930:+
LUAD	trans	rs13177918	0.677	rs13164105	ENSG00000239528.1	RPS14P8	29.63	1.58e-110	2.39e-102	1.23	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr5:116562562~116562930:+
LUAD	trans	rs7949030	0.596	rs11231138	ENSG00000186676.3	EEF1GP1	29.6	2.01e-110	3.03e-102	1.09	0.8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62548723	chr7:125033453~125035301:+
LUAD	trans	rs13177918	0.75	rs58256223	ENSG00000224114.1	RP11-343H5.4	29.6	2.03e-110	3.03e-102	1.18	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr1:206695837~206696269:-
LUAD	trans	rs13177918	0.75	rs59354956	ENSG00000224114.1	RP11-343H5.4	29.6	2.03e-110	3.03e-102	1.18	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr1:206695837~206696269:-
LUAD	trans	rs13177918	0.629	rs13161261	ENSG00000239528.1	RPS14P8	29.59	2.31e-110	3.44e-102	1.22	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr5:116562562~116562930:+
LUAD	trans	rs1816752	0.905	rs7317850	ENSG00000237917.1	PARP4P1	29.55	3.4e-110	5.05e-102	0.99	0.8	Obesity-related traits;	chr13:24419899	chrY:26594851~26634652:-
LUAD	trans	rs13177918	0.677	rs2073472	ENSG00000239528.1	RPS14P8	29.55	3.56e-110	5.27e-102	1.22	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr5:116562562~116562930:+
LUAD	trans	rs1816752	0.87	rs9581025	ENSG00000237917.1	PARP4P1	29.53	4.13e-110	6.07e-102	0.97	0.8	Obesity-related traits;	chr13:24423687	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.87	rs9581027	ENSG00000237917.1	PARP4P1	29.53	4.13e-110	6.07e-102	0.97	0.8	Obesity-related traits;	chr13:24423790	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.87	rs9581029	ENSG00000237917.1	PARP4P1	29.51	5.07e-110	7.42e-102	0.97	0.8	Obesity-related traits;	chr13:24425147	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.905	rs9511249	ENSG00000237917.1	PARP4P1	29.51	5.07e-110	7.42e-102	0.97	0.8	Obesity-related traits;	chr13:24425457	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.633	rs9578729	ENSG00000237917.1	PARP4P1	29.41	1.54e-109	2.23e-101	0.96	0.8	Obesity-related traits;	chr13:24425106	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.719	rs11843470	ENSG00000237917.1	PARP4P1	29.39	1.8e-109	2.59e-101	0.98	0.8	Obesity-related traits;	chr13:24423561	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.837	rs7324645	ENSG00000237917.1	PARP4P1	29.37	2.36e-109	3.4e-101	0.97	0.8	Obesity-related traits;	chr13:24426717	chrY:26594851~26634652:-
LUAD	trans	rs13177918	0.626	rs12186649	ENSG00000213058.3	RP4-765C7.2	29.34	3.23e-109	4.63e-101	1.22	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150438963	chr1:178411616~178411972:+
LUAD	trans	rs13177918	0.651	rs13184111	ENSG00000213058.3	RP4-765C7.2	29.31	4.49e-109	6.41e-101	1.22	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150434649	chr1:178411616~178411972:+
LUAD	trans	rs1816752	0.905	rs9581026	ENSG00000237917.1	PARP4P1	29.28	6.1e-109	8.69e-101	0.97	0.8	Obesity-related traits;	chr13:24423788	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.837	rs9318530	ENSG00000237917.1	PARP4P1	-29.15	2.24e-108	3.18e-100	-0.95	-0.8	Obesity-related traits;	chr13:24424419	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.87	rs73469543	ENSG00000237917.1	PARP4P1	29.13	2.84e-108	4.02e-100	0.96	0.8	Obesity-related traits;	chr13:24424832	chrY:26594851~26634652:-
LUAD	trans	rs13177918	0.677	rs3797622	ENSG00000239528.1	RPS14P8	29.08	4.8e-108	6.77e-100	1.2	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr5:116562562~116562930:+
LUAD	trans	rs13253073	0.723	rs7813557	ENSG00000260318.1	COX6CP1	28.96	1.82e-107	2.56e-99	1.35	0.8	Glucose homeostasis traits;	chr8:99878665	chr16:11903923~11904137:-
LUAD	trans	rs13177918	0.677	rs4841	ENSG00000239528.1	RPS14P8	28.92	2.56e-107	3.57e-99	1.21	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr5:116562562~116562930:+
LUAD	trans	rs13177918	0.677	rs13183077	ENSG00000239528.1	RPS14P8	28.92	2.56e-107	3.57e-99	1.21	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr5:116562562~116562930:+
LUAD	trans	rs1816752	0.837	rs7139748	ENSG00000237917.1	PARP4P1	28.9	3.21e-107	4.46e-99	0.97	0.8	Obesity-related traits;	chr13:24411531	chrY:26594851~26634652:-
LUAD	trans	rs12291225	0.679	rs34238445	ENSG00000236360.2	RP11-334A14.2	28.86	5.16e-107	7.14e-99	1.09	0.8	Sense of smell;	chr11:14294369	chr1:52993201~52993702:-
LUAD	trans	rs12291225	0.753	rs1431374	ENSG00000236360.2	RP11-334A14.2	28.8	9.27e-107	1.28e-98	1.09	0.8	Sense of smell;	chr11:14282429	chr1:52993201~52993702:-
LUAD	trans	rs12291225	0.637	rs8570	ENSG00000236360.2	RP11-334A14.2	28.76	1.49e-106	2.06e-98	1.09	0.8	Sense of smell;	chr11:14279213	chr1:52993201~52993702:-
LUAD	trans	rs13253073	0.662	rs4434590	ENSG00000260318.1	COX6CP1	28.74	1.75e-106	2.41e-98	1.31	0.79	Glucose homeostasis traits;	chr8:99848429	chr16:11903923~11904137:-
LUAD	trans	rs13253073	0.723	rs12546882	ENSG00000260318.1	COX6CP1	28.71	2.4e-106	3.29e-98	1.33	0.79	Glucose homeostasis traits;	chr8:99869919	chr16:11903923~11904137:-
LUAD	trans	rs1816752	1	rs9507341	ENSG00000237917.1	PARP4P1	-28.69	2.96e-106	4.05e-98	-1.02	-0.79	Obesity-related traits;	chr13:24432440	chrY:26594851~26634652:-
LUAD	trans	rs12291225	0.679	rs11023178	ENSG00000236360.2	RP11-334A14.2	28.61	6.98e-106	9.49e-98	1.09	0.79	Sense of smell;	chr11:14288736	chr1:52993201~52993702:-
LUAD	trans	rs1816752	0.819	rs7400583	ENSG00000237917.1	PARP4P1	28.58	1.02e-105	1.39e-97	0.97	0.79	Obesity-related traits;	chr13:24415916	chrY:26594851~26634652:-
LUAD	trans	rs12291225	0.679	rs10832240	ENSG00000236360.2	RP11-334A14.2	28.57	1.12e-105	1.52e-97	1.09	0.79	Sense of smell;	chr11:14283198	chr1:52993201~52993702:-
LUAD	trans	rs12291225	0.679	rs7934671	ENSG00000236360.2	RP11-334A14.2	28.57	1.12e-105	1.52e-97	1.09	0.79	Sense of smell;	chr11:14283555	chr1:52993201~52993702:-
LUAD	trans	rs7949030	0.688	rs11231155	ENSG00000186676.3	EEF1GP1	28.55	1.41e-105	1.89e-97	1.08	0.79	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598147	chr7:125033453~125035301:+
LUAD	trans	rs1816752	0.633	rs8002387	ENSG00000237917.1	PARP4P1	28.53	1.71e-105	2.3e-97	0.97	0.79	Obesity-related traits;	chr13:24416306	chrY:26594851~26634652:-
LUAD	trans	rs13177918	0.75	rs58256223	ENSG00000239528.1	RPS14P8	28.48	2.94e-105	3.92e-97	1.19	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr5:116562562~116562930:+
LUAD	trans	rs13177918	0.75	rs59354956	ENSG00000239528.1	RPS14P8	28.48	2.94e-105	3.92e-97	1.19	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr5:116562562~116562930:+
LUAD	trans	rs941207	0.724	rs4788	ENSG00000121089.4	NACA3P	28.43	4.8e-105	6.37e-97	1.08	0.79	Platelet count;	chr12:56712876	chr4:164943290~164943937:+
LUAD	trans	rs1816752	0.819	rs4770665	ENSG00000237917.1	PARP4P1	28.42	5.11e-105	6.73e-97	0.97	0.79	Obesity-related traits;	chr13:24414810	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.749	rs77832754	ENSG00000237917.1	PARP4P1	28.42	5.11e-105	6.73e-97	0.97	0.79	Obesity-related traits;	chr13:24416016	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.721	rs7399656	ENSG00000237917.1	PARP4P1	28.41	5.64e-105	7.4e-97	0.96	0.79	Obesity-related traits;	chr13:24415708	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.819	rs7985478	ENSG00000237917.1	PARP4P1	28.34	1.21e-104	1.58e-96	0.97	0.79	Obesity-related traits;	chr13:24417135	chrY:26594851~26634652:-
LUAD	trans	rs12291225	0.679	rs4757245	ENSG00000236360.2	RP11-334A14.2	28.32	1.53e-104	1.99e-96	1.08	0.79	Sense of smell;	chr11:14276326	chr1:52993201~52993702:-
LUAD	trans	rs13253073	0.76	rs62534633	ENSG00000260318.1	COX6CP1	28.29	2.04e-104	2.65e-96	1.33	0.79	Glucose homeostasis traits;	chr8:99884533	chr16:11903923~11904137:-
LUAD	trans	rs1816752	0.819	rs6490917	ENSG00000237917.1	PARP4P1	28.29	2.14e-104	2.78e-96	0.96	0.79	Obesity-related traits;	chr13:24423119	chrY:26594851~26634652:-
LUAD	trans	rs13253073	0.723	rs7009713	ENSG00000260318.1	COX6CP1	28.26	2.87e-104	3.7e-96	1.31	0.79	Glucose homeostasis traits;	chr8:99869626	chr16:11903923~11904137:-
LUAD	trans	rs12291225	0.645	rs3763950	ENSG00000236360.2	RP11-334A14.2	28.22	4.33e-104	5.55e-96	1.08	0.79	Sense of smell;	chr11:14256503	chr1:52993201~52993702:-
LUAD	trans	rs7949030	0.653	rs2516634	ENSG00000186676.3	EEF1GP1	-28.22	4.66e-104	5.96e-96	-1.06	-0.79	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62599714	chr7:125033453~125035301:+
LUAD	trans	rs12291225	0.679	rs11605531	ENSG00000236360.2	RP11-334A14.2	28.19	6.43e-104	8.14e-96	1.07	0.79	Sense of smell;	chr11:14270048	chr1:52993201~52993702:-
LUAD	trans	rs12291225	0.639	rs61883858	ENSG00000236360.2	RP11-334A14.2	28.19	6.43e-104	8.14e-96	1.07	0.79	Sense of smell;	chr11:14273162	chr1:52993201~52993702:-
LUAD	trans	rs12291225	0.679	rs11023170	ENSG00000236360.2	RP11-334A14.2	28.19	6.43e-104	8.14e-96	1.07	0.79	Sense of smell;	chr11:14273363	chr1:52993201~52993702:-
LUAD	trans	rs12291225	0.679	rs4756786	ENSG00000236360.2	RP11-334A14.2	28.16	8.2e-104	1.03e-95	1.08	0.79	Sense of smell;	chr11:14264354	chr1:52993201~52993702:-
LUAD	trans	rs12291225	0.679	rs11023172	ENSG00000236360.2	RP11-334A14.2	28.13	1.22e-103	1.53e-95	1.07	0.79	Sense of smell;	chr11:14273821	chr1:52993201~52993702:-
LUAD	trans	rs13253073	0.723	rs7157	ENSG00000260318.1	COX6CP1	27.97	6.23e-103	7.72e-95	1.34	0.79	Glucose homeostasis traits;	chr8:99877449	chr16:11903923~11904137:-
LUAD	trans	rs1816752	1	rs1816752	ENSG00000237917.1	PARP4P1	27.9	1.32e-102	1.62e-94	1.01	0.79	Obesity-related traits;	chr13:24406811	chrY:26594851~26634652:-
LUAD	trans	rs13253073	0.723	rs6468695	ENSG00000260318.1	COX6CP1	27.88	1.75e-102	2.14e-94	1.31	0.79	Glucose homeostasis traits;	chr8:99857123	chr16:11903923~11904137:-
LUAD	trans	rs13253073	0.723	rs6468696	ENSG00000260318.1	COX6CP1	27.88	1.75e-102	2.14e-94	1.31	0.79	Glucose homeostasis traits;	chr8:99857130	chr16:11903923~11904137:-
LUAD	trans	rs1816752	0.783	rs7317439	ENSG00000237917.1	PARP4P1	27.85	2.19e-102	2.63e-94	0.96	0.79	Obesity-related traits;	chr13:24410939	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.783	rs7139527	ENSG00000237917.1	PARP4P1	27.85	2.19e-102	2.63e-94	0.96	0.79	Obesity-related traits;	chr13:24411374	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.819	rs9511240	ENSG00000237917.1	PARP4P1	27.85	2.19e-102	2.63e-94	0.96	0.79	Obesity-related traits;	chr13:24411768	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.819	rs7988388	ENSG00000237917.1	PARP4P1	27.85	2.19e-102	2.63e-94	0.96	0.79	Obesity-related traits;	chr13:24412675	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.875	rs7993132	ENSG00000237917.1	PARP4P1	27.85	2.19e-102	2.63e-94	0.96	0.79	Obesity-related traits;	chr13:24412903	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.792	rs7330956	ENSG00000237917.1	PARP4P1	27.81	3.61e-102	4.28e-94	0.96	0.79	Obesity-related traits;	chr13:24413174	chrY:26594851~26634652:-
LUAD	trans	rs941207	0.756	rs2926743	ENSG00000121089.4	NACA3P	27.79	4.23e-102	5.01e-94	1.05	0.79	Platelet count;	chr12:56720316	chr4:164943290~164943937:+
LUAD	trans	rs13177918	0.557	rs12520101	ENSG00000224114.1	RP11-343H5.4	27.79	4.34e-102	5.13e-94	1.17	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr1:206695837~206696269:-
LUAD	trans	rs1816752	0.819	rs7316961	ENSG00000237917.1	PARP4P1	27.76	6.04e-102	7.12e-94	0.96	0.78	Obesity-related traits;	chr13:24411039	chrY:26594851~26634652:-
LUAD	trans	rs13177918	0.557	rs12520101	ENSG00000239528.1	RPS14P8	27.75	6.92e-102	8.15e-94	1.2	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr5:116562562~116562930:+
LUAD	trans	rs1816752	0.819	rs4770664	ENSG00000237917.1	PARP4P1	27.71	1e-101	1.18e-93	0.97	0.78	Obesity-related traits;	chr13:24414695	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.819	rs7317504	ENSG00000237917.1	PARP4P1	27.69	1.21e-101	1.42e-93	0.96	0.78	Obesity-related traits;	chr13:24411287	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.783	rs7317712	ENSG00000237917.1	PARP4P1	27.69	1.21e-101	1.42e-93	0.96	0.78	Obesity-related traits;	chr13:24411365	chrY:26594851~26634652:-
LUAD	trans	rs7949030	0.62	rs2428551	ENSG00000186676.3	EEF1GP1	27.68	1.44e-101	1.68e-93	1.05	0.78	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62562286	chr7:125033453~125035301:+
LUAD	trans	rs1816752	0.712	rs2862898	ENSG00000237917.1	PARP4P1	27.63	2.35e-101	2.72e-93	0.97	0.78	Obesity-related traits;	chr13:24414323	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.652	rs2902356	ENSG00000237917.1	PARP4P1	27.63	2.35e-101	2.72e-93	0.97	0.78	Obesity-related traits;	chr13:24414333	chrY:26594851~26634652:-
LUAD	trans	rs941207	0.724	rs1979325	ENSG00000121089.4	NACA3P	27.59	3.61e-101	4.18e-93	1.06	0.78	Platelet count;	chr12:56728152	chr4:164943290~164943937:+
LUAD	trans	rs941207	0.756	rs2958149	ENSG00000121089.4	NACA3P	27.59	3.86e-101	4.46e-93	1.07	0.78	Platelet count;	chr12:56716008	chr4:164943290~164943937:+
LUAD	trans	rs13253073	0.723	rs12548344	ENSG00000260318.1	COX6CP1	27.56	5.27e-101	6.06e-93	1.3	0.78	Glucose homeostasis traits;	chr8:99868676	chr16:11903923~11904137:-
LUAD	trans	rs12291225	0.679	rs11369	ENSG00000236360.2	RP11-334A14.2	27.54	6.11e-101	7.01e-93	1.06	0.78	Sense of smell;	chr11:14266550	chr1:52993201~52993702:-
LUAD	trans	rs1816752	0.905	rs1348110	ENSG00000237917.1	PARP4P1	27.53	6.82e-101	7.79e-93	0.96	0.78	Obesity-related traits;	chr13:24406537	chrY:26594851~26634652:-
LUAD	trans	rs13253073	0.723	rs12548542	ENSG00000260318.1	COX6CP1	27.51	8.68e-101	9.89e-93	1.32	0.78	Glucose homeostasis traits;	chr8:99890167	chr16:11903923~11904137:-
LUAD	trans	rs7949030	0.653	rs17773169	ENSG00000186676.3	EEF1GP1	27.46	1.43e-100	1.62e-92	1.05	0.78	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62551058	chr7:125033453~125035301:+
LUAD	trans	rs12291225	0.679	rs11238	ENSG00000236360.2	RP11-334A14.2	-27.45	1.65e-100	1.86e-92	-1.06	-0.78	Sense of smell;	chr11:14266582	chr1:52993201~52993702:-
LUAD	trans	rs1816752	0.777	rs6490915	ENSG00000237917.1	PARP4P1	27.4	2.87e-100	3.23e-92	0.96	0.78	Obesity-related traits;	chr13:24413724	chrY:26594851~26634652:-
LUAD	trans	rs7949030	0.688	rs2849031	ENSG00000186676.3	EEF1GP1	-27.33	5.72e-100	6.4e-92	-1.04	-0.78	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598193	chr7:125033453~125035301:+
LUAD	trans	rs7949030	0.653	rs2849030	ENSG00000186676.3	EEF1GP1	-27.33	5.72e-100	6.4e-92	-1.04	-0.78	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62599514	chr7:125033453~125035301:+
LUAD	trans	rs13177918	0.626	rs12186649	ENSG00000224114.1	RP11-343H5.4	27.29	9.64e-100	1.07e-91	1.18	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150438963	chr1:206695837~206696269:-
LUAD	trans	rs1816752	0.905	rs2000153	ENSG00000237917.1	PARP4P1	27.23	1.73e-99	1.92e-91	0.96	0.78	Obesity-related traits;	chr13:24405752	chrY:26594851~26634652:-
LUAD	trans	rs941207	0.756	rs7313074	ENSG00000121089.4	NACA3P	-27.2	2.55e-99	2.82e-91	-1.05	-0.78	Platelet count;	chr12:56760705	chr4:164943290~164943937:+
LUAD	trans	rs6477998	0.58	rs10759638	ENSG00000238072.1	RP11-305M3.2	-27.16	3.62e-99	3.99e-91	-1.09	-0.78	Hematology traits;	chr9:113280212	chr7:129410113~129410370:-
LUAD	trans	rs13177918	0.651	rs13184111	ENSG00000239528.1	RPS14P8	27.08	8.43e-99	9.27e-91	1.21	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150434649	chr5:116562562~116562930:+
LUAD	trans	rs13177918	0.651	rs13184111	ENSG00000224114.1	RP11-343H5.4	27.08	8.73e-99	9.58e-91	1.18	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150434649	chr1:206695837~206696269:-
LUAD	trans	rs13177918	0.626	rs12186649	ENSG00000239528.1	RPS14P8	27.07	1.01e-98	1.11e-90	1.21	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150438963	chr5:116562562~116562930:+
LUAD	trans	rs6477998	0.58	rs7027833	ENSG00000238072.1	RP11-305M3.2	27.06	1.09e-98	1.19e-90	1.08	0.78	Hematology traits;	chr9:113301377	chr7:129410113~129410370:-
LUAD	trans	rs1816752	0.774	rs2862895	ENSG00000237917.1	PARP4P1	26.98	2.61e-98	2.84e-90	0.95	0.78	Obesity-related traits;	chr13:24410328	chrY:26594851~26634652:-
LUAD	trans	rs6477998	0.58	rs11552582	ENSG00000238072.1	RP11-305M3.2	26.93	4.6e-98	4.99e-90	1.1	0.78	Hematology traits;	chr9:113282718	chr7:129410113~129410370:-
LUAD	trans	rs928391	0.681	rs9427242	ENSG00000227183.3	HDGFP1	-26.85	1.03e-97	1.1e-89	-0.97	-0.77	Platelet count;	chr1:156755209	chrX:131646639~131646890:+
LUAD	trans	rs1816752	0.755	rs1981277	ENSG00000237917.1	PARP4P1	26.8	1.8e-97	1.92e-89	0.94	0.77	Obesity-related traits;	chr13:24409375	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.712	rs9507335	ENSG00000237917.1	PARP4P1	26.8	1.8e-97	1.92e-89	0.94	0.77	Obesity-related traits;	chr13:24409766	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.811	rs9507337	ENSG00000237917.1	PARP4P1	26.8	1.8e-97	1.92e-89	0.94	0.77	Obesity-related traits;	chr13:24410807	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.819	rs1981276	ENSG00000237917.1	PARP4P1	26.78	2.18e-97	2.31e-89	0.94	0.77	Obesity-related traits;	chr13:24409361	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.837	rs57052031	ENSG00000237917.1	PARP4P1	26.78	2.18e-97	2.31e-89	0.94	0.77	Obesity-related traits;	chr13:24409730	chrY:26594851~26634652:-
LUAD	trans	rs941207	0.756	rs7978685	ENSG00000121089.4	NACA3P	26.74	3.4e-97	3.59e-89	1.06	0.77	Platelet count;	chr12:56709370	chr4:164943290~164943937:+
LUAD	trans	rs1816752	0.748	rs6490912	ENSG00000237917.1	PARP4P1	26.7	5.21e-97	5.5e-89	0.94	0.77	Obesity-related traits;	chr13:24408941	chrY:26594851~26634652:-
LUAD	trans	rs6477998	0.58	rs2296073	ENSG00000238072.1	RP11-305M3.2	26.48	5.37e-96	5.62e-88	1.06	0.77	Hematology traits;	chr9:113299348	chr7:129410113~129410370:-
LUAD	trans	rs13253073	0.723	rs7831963	ENSG00000260318.1	COX6CP1	26.3	3.76e-95	3.88e-87	1.31	0.77	Glucose homeostasis traits;	chr8:99853014	chr16:11903923~11904137:-
LUAD	trans	rs13253073	0.723	rs7832488	ENSG00000260318.1	COX6CP1	26.3	3.76e-95	3.88e-87	1.31	0.77	Glucose homeostasis traits;	chr8:99853185	chr16:11903923~11904137:-
LUAD	trans	rs13177918	1	rs35007082	ENSG00000213058.3	RP4-765C7.2	26.17	1.67e-94	1.71e-86	1.2	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr1:178411616~178411972:+
LUAD	trans	rs6477998	0.535	rs3750535	ENSG00000238072.1	RP11-305M3.2	26.16	1.84e-94	1.87e-86	1.08	0.77	Hematology traits;	chr9:113297453	chr7:129410113~129410370:-
LUAD	trans	rs941207	0.756	rs67046307	ENSG00000121089.4	NACA3P	-26.08	4.14e-94	4.2e-86	-1.03	-0.77	Platelet count;	chr12:56651152	chr4:164943290~164943937:+
LUAD	trans	rs941207	0.789	rs2958145	ENSG00000121089.4	NACA3P	-26.07	4.52e-94	4.57e-86	-1.02	-0.77	Platelet count;	chr12:56662290	chr4:164943290~164943937:+
LUAD	trans	rs941207	0.756	rs7315472	ENSG00000121089.4	NACA3P	-26.07	4.7e-94	4.75e-86	-1.03	-0.77	Platelet count;	chr12:56648276	chr4:164943290~164943937:+
LUAD	trans	rs941207	0.756	rs2958153	ENSG00000121089.4	NACA3P	26.05	5.99e-94	6.02e-86	1.02	0.76	Platelet count;	chr12:56687733	chr4:164943290~164943937:+
LUAD	trans	rs941207	0.756	rs10876915	ENSG00000121089.4	NACA3P	-26.04	6.83e-94	6.84e-86	-1.03	-0.76	Platelet count;	chr12:56655280	chr4:164943290~164943937:+
LUAD	trans	rs13177918	1	rs13177918	ENSG00000213058.3	RP4-765C7.2	25.99	1.13e-93	1.13e-85	1.2	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446307	chr1:178411616~178411972:+
LUAD	trans	rs13177918	0.906	rs12652032	ENSG00000213058.3	RP4-765C7.2	25.89	3.33e-93	3.28e-85	1.2	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442060	chr1:178411616~178411972:+
LUAD	trans	rs13177918	1	rs13161334	ENSG00000213058.3	RP4-765C7.2	25.86	4.68e-93	4.61e-85	1.19	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr1:178411616~178411972:+
LUAD	trans	rs6477998	0.557	rs3750534	ENSG00000238072.1	RP11-305M3.2	25.83	6.46e-93	6.32e-85	1.08	0.76	Hematology traits;	chr9:113297844	chr7:129410113~129410370:-
LUAD	trans	rs6477998	0.58	rs3750532	ENSG00000238072.1	RP11-305M3.2	25.76	1.31e-92	1.27e-84	1.08	0.76	Hematology traits;	chr9:113298207	chr7:129410113~129410370:-
LUAD	trans	rs6477998	0.58	rs10981715	ENSG00000238072.1	RP11-305M3.2	25.6	7.92e-92	7.62e-84	1.07	0.76	Hematology traits;	chr9:113287218	chr7:129410113~129410370:-
LUAD	trans	rs13253073	0.723	rs7840626	ENSG00000260318.1	COX6CP1	25.58	9.35e-92	8.99e-84	1.32	0.76	Glucose homeostasis traits;	chr8:99867598	chr16:11903923~11904137:-
LUAD	trans	rs941207	0.756	rs2950388	ENSG00000121089.4	NACA3P	-25.57	1.07e-91	1.03e-83	-1.03	-0.76	Platelet count;	chr12:56639569	chr4:164943290~164943937:+
LUAD	trans	rs12291225	0.679	rs1043237	ENSG00000236360.2	RP11-334A14.2	25.52	1.76e-91	1.68e-83	1.02	0.76	Sense of smell;	chr11:14267507	chr1:52993201~52993702:-
LUAD	trans	rs13253073	0.662	rs34513504	ENSG00000260318.1	COX6CP1	25.43	4.96e-91	4.65e-83	1.31	0.76	Glucose homeostasis traits;	chr8:99848918	chr16:11903923~11904137:-
LUAD	trans	rs6477998	0.58	rs4979231	ENSG00000238072.1	RP11-305M3.2	25.43	5.02e-91	4.7e-83	1.06	0.76	Hematology traits;	chr9:113286475	chr7:129410113~129410370:-
LUAD	trans	rs13253073	0.8	rs7015733	ENSG00000260318.1	COX6CP1	25.41	5.73e-91	5.35e-83	1.21	0.76	Glucose homeostasis traits;	chr8:99899353	chr16:11903923~11904137:-
LUAD	trans	rs1816752	0.875	rs8001187	ENSG00000237917.1	PARP4P1	25.41	6.15e-91	5.72e-83	0.94	0.76	Obesity-related traits;	chr13:24402276	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.783	rs9507333	ENSG00000237917.1	PARP4P1	25.41	6.15e-91	5.72e-83	0.94	0.76	Obesity-related traits;	chr13:24404172	chrY:26594851~26634652:-
LUAD	trans	rs941207	0.756	rs1465081	ENSG00000121089.4	NACA3P	-25.27	2.84e-90	2.62e-82	-1.01	-0.76	Platelet count;	chr12:56656390	chr4:164943290~164943937:+
LUAD	trans	rs13177918	0.626	rs3819332	ENSG00000213058.3	RP4-765C7.2	25.26	3.02e-90	2.78e-82	1.04	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449187	chr1:178411616~178411972:+
LUAD	trans	rs13177918	0.626	rs13170300	ENSG00000213058.3	RP4-765C7.2	25.12	1.34e-89	1.21e-81	1.04	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449748	chr1:178411616~178411972:+
LUAD	trans	rs941207	0.756	rs2950394	ENSG00000121089.4	NACA3P	-25.1	1.74e-89	1.57e-81	-1.01	-0.75	Platelet count;	chr12:56644548	chr4:164943290~164943937:+
LUAD	trans	rs13253073	0.723	rs62534626	ENSG00000260318.1	COX6CP1	24.96	8.37e-89	7.47e-81	1.33	0.75	Glucose homeostasis traits;	chr8:99866119	chr16:11903923~11904137:-
LUAD	trans	rs13177918	0.603	rs13175992	ENSG00000213058.3	RP4-765C7.2	24.94	9.52e-89	8.48e-81	1.04	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr1:178411616~178411972:+
LUAD	trans	rs13177918	1	rs35007082	ENSG00000224114.1	RP11-343H5.4	24.77	6.38e-88	5.61e-80	1.17	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr1:206695837~206696269:-
LUAD	trans	rs941207	0.756	rs9634246	ENSG00000121089.4	NACA3P	-24.77	6.61e-88	5.8e-80	-1.01	-0.75	Platelet count;	chr12:56640604	chr4:164943290~164943937:+
LUAD	trans	rs13177918	0.626	rs13175436	ENSG00000213058.3	RP4-765C7.2	24.75	8.32e-88	7.28e-80	1.03	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr1:178411616~178411972:+
LUAD	trans	rs13177918	0.626	rs3819332	ENSG00000224114.1	RP11-343H5.4	24.7	1.3e-87	1.13e-79	1.03	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449187	chr1:206695837~206696269:-
LUAD	trans	rs13177918	0.626	rs13170300	ENSG00000224114.1	RP11-343H5.4	24.66	2.23e-87	1.93e-79	1.03	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449748	chr1:206695837~206696269:-
LUAD	trans	rs13177918	0.626	rs67026795	ENSG00000213058.3	RP4-765C7.2	24.65	2.34e-87	2.02e-79	1.03	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr1:178411616~178411972:+
LUAD	trans	rs13177918	0.906	rs12652032	ENSG00000224114.1	RP11-343H5.4	24.61	3.81e-87	3.28e-79	1.17	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442060	chr1:206695837~206696269:-
LUAD	trans	rs13177918	0.578	rs35919198	ENSG00000213058.3	RP4-765C7.2	24.6	4.05e-87	3.48e-79	1.04	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452428	chr1:178411616~178411972:+
LUAD	trans	rs13177918	0.603	rs10447222	ENSG00000213058.3	RP4-765C7.2	24.57	5.66e-87	4.84e-79	1.04	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr1:178411616~178411972:+
LUAD	trans	rs13177918	1	rs13177918	ENSG00000224114.1	RP11-343H5.4	24.54	7.77e-87	6.64e-79	1.17	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446307	chr1:206695837~206696269:-
LUAD	trans	rs13177918	1	rs13161334	ENSG00000224114.1	RP11-343H5.4	24.47	1.62e-86	1.38e-78	1.16	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr1:206695837~206696269:-
LUAD	trans	rs13177918	0.603	rs13175992	ENSG00000224114.1	RP11-343H5.4	24.46	1.88e-86	1.59e-78	1.03	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr1:206695837~206696269:-
LUAD	trans	rs13177918	1	rs35007082	ENSG00000239528.1	RPS14P8	24.39	3.97e-86	3.36e-78	1.2	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr5:116562562~116562930:+
LUAD	trans	rs13177918	0.626	rs13175436	ENSG00000224114.1	RP11-343H5.4	24.37	5.11e-86	4.31e-78	1.03	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr1:206695837~206696269:-
LUAD	trans	rs13177918	1	rs13177918	ENSG00000239528.1	RPS14P8	24.31	9.47e-86	7.95e-78	1.2	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446307	chr5:116562562~116562930:+
LUAD	trans	rs13177918	0.626	rs67026795	ENSG00000224114.1	RP11-343H5.4	24.24	2.01e-85	1.68e-77	1.02	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr1:206695837~206696269:-
LUAD	trans	rs6477998	0.557	rs11789755	ENSG00000238072.1	RP11-305M3.2	24.23	2.27e-85	1.89e-77	1.06	0.74	Hematology traits;	chr9:113292796	chr7:129410113~129410370:-
LUAD	trans	rs13177918	0.906	rs12652032	ENSG00000239528.1	RPS14P8	24.18	3.93e-85	3.26e-77	1.19	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442060	chr5:116562562~116562930:+
LUAD	trans	rs6477998	0.58	rs3750533	ENSG00000238072.1	RP11-305M3.2	24.15	5.73e-85	4.74e-77	1.08	0.74	Hematology traits;	chr9:113297941	chr7:129410113~129410370:-
LUAD	trans	rs13177918	1	rs13161334	ENSG00000239528.1	RPS14P8	24.06	1.57e-84	1.29e-76	1.18	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr5:116562562~116562930:+
LUAD	trans	rs13177918	0.578	rs35919198	ENSG00000224114.1	RP11-343H5.4	24.01	2.58e-84	2.1e-76	1.02	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452428	chr1:206695837~206696269:-
LUAD	trans	rs6477998	0.58	rs4979233	ENSG00000238072.1	RP11-305M3.2	23.97	4.03e-84	3.26e-76	1.07	0.74	Hematology traits;	chr9:113295501	chr7:129410113~129410370:-
LUAD	trans	rs13177918	0.603	rs10447222	ENSG00000224114.1	RP11-343H5.4	23.96	4.42e-84	3.57e-76	1.02	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr1:206695837~206696269:-
LUAD	trans	rs6477998	0.58	rs12343629	ENSG00000238072.1	RP11-305M3.2	23.92	7.02e-84	5.64e-76	1.05	0.74	Hematology traits;	chr9:113279301	chr7:129410113~129410370:-
LUAD	trans	rs7554547	0.739	rs7518827	ENSG00000261819.1	RP11-680G24.4	23.9	8.17e-84	6.54e-76	0.94	0.74	Nonsyndromic cleft lip with cleft palate;	chr1:11916688	chr16:14988259~14990160:-
LUAD	trans	rs7554547	0.668	rs2038028	ENSG00000261819.1	RP11-680G24.4	23.9	8.17e-84	6.54e-76	0.94	0.74	Nonsyndromic cleft lip with cleft palate;	chr1:11919499	chr16:14988259~14990160:-
LUAD	trans	rs1816752	0.819	rs4769349	ENSG00000237917.1	PARP4P1	-23.66	1.15e-82	9.16e-75	-0.88	-0.73	Obesity-related traits;	chr13:24408694	chrY:26594851~26634652:-
LUAD	trans	rs9611565	0.694	rs5758347	ENSG00000268568.1	AC007228.9	23.59	2.56e-82	1.99e-74	1.11	0.73	Vitiligo;	chr22:41425015	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.694	rs202613	ENSG00000268568.1	AC007228.9	23.59	2.56e-82	1.99e-74	1.11	0.73	Vitiligo;	chr22:41425989	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.649	rs202614	ENSG00000268568.1	AC007228.9	23.59	2.56e-82	1.99e-74	1.11	0.73	Vitiligo;	chr22:41426146	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.694	rs202616	ENSG00000268568.1	AC007228.9	23.59	2.56e-82	1.99e-74	1.11	0.73	Vitiligo;	chr22:41426217	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.569	rs188057	ENSG00000268568.1	AC007228.9	23.59	2.56e-82	1.99e-74	1.11	0.73	Vitiligo;	chr22:41426301	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.694	rs202618	ENSG00000268568.1	AC007228.9	23.59	2.56e-82	1.99e-74	1.11	0.73	Vitiligo;	chr22:41426852	chr19:56672574~56673901:-
LUAD	trans	rs7554547	0.739	rs3209284	ENSG00000261819.1	RP11-680G24.4	23.52	5.44e-82	4.21e-74	0.94	0.73	Nonsyndromic cleft lip with cleft palate;	chr1:11919852	chr16:14988259~14990160:-
LUAD	trans	rs13253073	0.723	rs13274441	ENSG00000260318.1	COX6CP1	23.49	7.97e-82	6.15e-74	1.32	0.73	Glucose homeostasis traits;	chr8:99861038	chr16:11903923~11904137:-
LUAD	trans	rs12291225	0.546	rs12795545	ENSG00000236360.2	RP11-334A14.2	23.41	1.86e-81	1.43e-73	0.95	0.73	Sense of smell;	chr11:14334018	chr1:52993201~52993702:-
LUAD	trans	rs9611565	0.649	rs5751108	ENSG00000268568.1	AC007228.9	23.37	2.96e-81	2.26e-73	1.1	0.73	Vitiligo;	chr22:41462031	chr19:56672574~56673901:-
LUAD	trans	rs13177918	0.626	rs3819332	ENSG00000239528.1	RPS14P8	23.25	1.07e-80	8.09e-73	1.03	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449187	chr5:116562562~116562930:+
LUAD	trans	rs5758343	1	rs5758343	ENSG00000268568.1	AC007228.9	23.25	1.11e-80	8.31e-73	1.1	0.73	Allergic disease (asthma, hay fever or eczema);	chr22:41420648	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.649	rs5758344	ENSG00000268568.1	AC007228.9	23.25	1.11e-80	8.31e-73	1.1	0.73	Vitiligo;	chr22:41421681	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.694	rs2142505	ENSG00000268568.1	AC007228.9	23.25	1.11e-80	8.31e-73	1.1	0.73	Vitiligo;	chr22:41424537	chr19:56672574~56673901:-
LUAD	trans	rs7554547	0.63	rs4845889	ENSG00000261819.1	RP11-680G24.4	23.23	1.36e-80	1.02e-72	0.93	0.73	Nonsyndromic cleft lip with cleft palate;	chr1:11911288	chr16:14988259~14990160:-
LUAD	trans	rs7554547	0.667	rs7525521	ENSG00000261819.1	RP11-680G24.4	23.22	1.41e-80	1.06e-72	0.93	0.73	Nonsyndromic cleft lip with cleft palate;	chr1:11915109	chr16:14988259~14990160:-
LUAD	trans	rs12291225	0.585	rs10832242	ENSG00000236360.2	RP11-334A14.2	-23.2	1.75e-80	1.31e-72	-0.93	-0.73	Sense of smell;	chr11:14318958	chr1:52993201~52993702:-
LUAD	trans	rs13177918	0.626	rs13170300	ENSG00000239528.1	RPS14P8	23.2	1.76e-80	1.31e-72	1.03	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449748	chr5:116562562~116562930:+
LUAD	trans	rs13177918	0.626	rs13175436	ENSG00000239528.1	RPS14P8	23.2	1.78e-80	1.32e-72	1.03	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr5:116562562~116562930:+
LUAD	trans	rs13177918	0.603	rs13175992	ENSG00000239528.1	RPS14P8	23.2	1.88e-80	1.39e-72	1.03	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr5:116562562~116562930:+
LUAD	trans	rs9611565	0.694	rs202617	ENSG00000268568.1	AC007228.9	23.19	2.12e-80	1.54e-72	1.1	0.73	Vitiligo;	chr22:41426789	chr19:56672574~56673901:-
LUAD	trans	rs12291225	0.546	rs12291662	ENSG00000236360.2	RP11-334A14.2	23.17	2.48e-80	1.8e-72	0.94	0.73	Sense of smell;	chr11:14321403	chr1:52993201~52993702:-
LUAD	trans	rs12291225	0.545	rs11023187	ENSG00000236360.2	RP11-334A14.2	23.17	2.48e-80	1.8e-72	0.94	0.73	Sense of smell;	chr11:14324013	chr1:52993201~52993702:-
LUAD	trans	rs9611565	0.649	rs202657	ENSG00000268568.1	AC007228.9	23.15	3.22e-80	2.33e-72	1.13	0.73	Vitiligo;	chr22:41448782	chr19:56672574~56673901:-
LUAD	trans	rs8081395	0.741	rs180519	ENSG00000187870.7	RNFT1P3	23.11	4.77e-80	3.41e-72	0.87	0.73	White blood cell count;	chr17:59938910	chr17:20743333~20754501:-
LUAD	trans	rs12291225	0.585	rs4517475	ENSG00000236360.2	RP11-334A14.2	23.11	4.87e-80	3.48e-72	0.95	0.73	Sense of smell;	chr11:14364599	chr1:52993201~52993702:-
LUAD	trans	rs13177918	0.626	rs67026795	ENSG00000239528.1	RPS14P8	23.1	5.59e-80	3.98e-72	1.03	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr5:116562562~116562930:+
LUAD	trans	rs8081395	0.741	rs180532	ENSG00000187870.7	RNFT1P3	23.09	5.96e-80	4.21e-72	0.87	0.73	White blood cell count;	chr17:59925936	chr17:20743333~20754501:-
LUAD	trans	rs8081395	0.741	rs180530	ENSG00000187870.7	RNFT1P3	23.09	5.96e-80	4.21e-72	0.87	0.73	White blood cell count;	chr17:59926233	chr17:20743333~20754501:-
LUAD	trans	rs12291225	0.585	rs12270374	ENSG00000236360.2	RP11-334A14.2	23.08	6.82e-80	4.81e-72	0.95	0.72	Sense of smell;	chr11:14353533	chr1:52993201~52993702:-
LUAD	trans	rs8081395	0.805	rs2645485	ENSG00000187870.7	RNFT1P3	23.06	8.71e-80	6.12e-72	0.87	0.72	White blood cell count;	chr17:59866920	chr17:20743333~20754501:-
LUAD	trans	rs12291225	0.585	rs10832246	ENSG00000236360.2	RP11-334A14.2	23.05	9.18e-80	6.43e-72	0.95	0.72	Sense of smell;	chr11:14359282	chr1:52993201~52993702:-
LUAD	trans	rs8081395	0.775	rs2645482	ENSG00000187870.7	RNFT1P3	23.04	1.05e-79	7.35e-72	0.87	0.72	White blood cell count;	chr17:59865754	chr17:20743333~20754501:-
LUAD	trans	rs9611565	0.649	rs202645	ENSG00000268568.1	AC007228.9	23.04	1.07e-79	7.46e-72	1.09	0.72	Vitiligo;	chr22:41402516	chr19:56672574~56673901:-
LUAD	trans	rs8081395	0.711	rs11368	ENSG00000187870.7	RNFT1P3	23.01	1.45e-79	9.98e-72	0.87	0.72	White blood cell count;	chr17:59954051	chr17:20743333~20754501:-
LUAD	trans	rs13177918	0.578	rs35919198	ENSG00000239528.1	RPS14P8	22.96	2.6e-79	1.78e-71	1.03	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452428	chr5:116562562~116562930:+
LUAD	trans	rs12291225	0.585	rs34171876	ENSG00000236360.2	RP11-334A14.2	22.95	2.78e-79	1.9e-71	0.95	0.72	Sense of smell;	chr11:14332411	chr1:52993201~52993702:-
LUAD	trans	rs7121616	0.563	rs4936770	ENSG00000234176.1	HSPA8P1	22.95	2.8e-79	1.91e-71	0.87	0.72	Breast cancer;	chr11:123058167	chrX:121203182~121205014:-
LUAD	trans	rs7554547	0.765	rs6541010	ENSG00000261819.1	RP11-680G24.4	22.95	2.82e-79	1.92e-71	0.93	0.72	Nonsyndromic cleft lip with cleft palate;	chr1:11913785	chr16:14988259~14990160:-
LUAD	trans	rs8081395	0.741	rs2645462	ENSG00000187870.7	RNFT1P3	22.95	2.87e-79	1.94e-71	0.87	0.72	White blood cell count;	chr17:59906198	chr17:20743333~20754501:-
LUAD	trans	rs8081395	0.711	rs1292034	ENSG00000187870.7	RNFT1P3	22.95	2.87e-79	1.94e-71	0.87	0.72	White blood cell count;	chr17:59912499	chr17:20743333~20754501:-
LUAD	trans	rs8081395	0.737	rs4968401	ENSG00000187870.7	RNFT1P3	-22.91	4.58e-79	3.07e-71	-0.86	-0.72	White blood cell count;	chr17:59963369	chr17:20743333~20754501:-
LUAD	trans	rs13177918	0.603	rs10447222	ENSG00000239528.1	RPS14P8	22.84	9.92e-79	6.64e-71	1.03	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr5:116562562~116562930:+
LUAD	trans	rs9611565	0.694	rs202622	ENSG00000268568.1	AC007228.9	22.83	1.1e-78	7.35e-71	1.11	0.72	Vitiligo;	chr22:41429338	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.694	rs7285041	ENSG00000268568.1	AC007228.9	22.83	1.1e-78	7.35e-71	1.11	0.72	Vitiligo;	chr22:41433145	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.649	rs202625	ENSG00000268568.1	AC007228.9	22.82	1.23e-78	8.16e-71	1.11	0.72	Vitiligo;	chr22:41431078	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.694	rs202656	ENSG00000268568.1	AC007228.9	22.79	1.65e-78	1.09e-70	1.11	0.72	Vitiligo;	chr22:41446199	chr19:56672574~56673901:-
LUAD	trans	rs8081395	0.741	rs1292055	ENSG00000187870.7	RNFT1P3	22.78	1.91e-78	1.26e-70	0.86	0.72	White blood cell count;	chr17:59881707	chr17:20743333~20754501:-
LUAD	trans	rs7949030	0.523	rs12223627	ENSG00000186676.3	EEF1GP1	22.77	2e-78	1.32e-70	1.04	0.72	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62601085	chr7:125033453~125035301:+
LUAD	trans	rs12291225	0.585	rs11023197	ENSG00000236360.2	RP11-334A14.2	22.74	2.71e-78	1.78e-70	0.95	0.72	Sense of smell;	chr11:14359452	chr1:52993201~52993702:-
LUAD	trans	rs9611565	0.694	rs202639	ENSG00000268568.1	AC007228.9	22.7	4.24e-78	2.75e-70	1.08	0.72	Vitiligo;	chr22:41460133	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.694	rs5758365	ENSG00000268568.1	AC007228.9	22.7	4.24e-78	2.75e-70	1.08	0.72	Vitiligo;	chr22:41462653	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.649	rs79009	ENSG00000268568.1	AC007228.9	22.7	4.24e-78	2.75e-70	1.08	0.72	Vitiligo;	chr22:41464860	chr19:56672574~56673901:-
LUAD	trans	rs12291225	0.585	rs4757250	ENSG00000236360.2	RP11-334A14.2	22.68	5.59e-78	3.61e-70	0.95	0.72	Sense of smell;	chr11:14354137	chr1:52993201~52993702:-
LUAD	trans	rs12291225	0.585	rs11023194	ENSG00000236360.2	RP11-334A14.2	22.67	5.85e-78	3.76e-70	0.93	0.72	Sense of smell;	chr11:14348223	chr1:52993201~52993702:-
LUAD	trans	rs9611565	0.643	rs202634	ENSG00000268568.1	AC007228.9	22.65	7.51e-78	4.81e-70	1.09	0.72	Vitiligo;	chr22:41413619	chr19:56672574~56673901:-
LUAD	trans	rs7554547	0.667	rs4846072	ENSG00000261819.1	RP11-680G24.4	22.64	8.16e-78	5.22e-70	0.93	0.72	Nonsyndromic cleft lip with cleft palate;	chr1:11890334	chr16:14988259~14990160:-
LUAD	trans	rs13177918	0.559	rs10447224	ENSG00000213058.3	RP4-765C7.2	22.62	1.03e-77	6.58e-70	0.98	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr1:178411616~178411972:+
LUAD	trans	rs13177918	0.559	rs10447225	ENSG00000213058.3	RP4-765C7.2	22.62	1.03e-77	6.58e-70	0.98	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr1:178411616~178411972:+
LUAD	trans	rs9611565	0.694	rs106860	ENSG00000268568.1	AC007228.9	-22.62	1.11e-77	7.03e-70	-1.09	-0.72	Vitiligo;	chr22:41444403	chr19:56672574~56673901:-
LUAD	trans	rs7943191	0.805	rs12226821	ENSG00000186676.3	EEF1GP1	22.61	1.23e-77	7.79e-70	1.04	0.72	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62601546	chr7:125033453~125035301:+
LUAD	trans	rs13177918	0.559	rs12109637	ENSG00000213058.3	RP4-765C7.2	22.6	1.3e-77	8.16e-70	0.96	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr1:178411616~178411972:+
LUAD	trans	rs1816752	0.905	rs3818938	ENSG00000237917.1	PARP4P1	22.53	2.88e-77	1.8e-69	0.9	0.72	Obesity-related traits;	chr13:24454945	chrY:26594851~26634652:-
LUAD	trans	rs7121616	0.563	rs1461494	ENSG00000234176.1	HSPA8P1	22.52	3.07e-77	1.91e-69	0.86	0.72	Breast cancer;	chr11:123055777	chrX:121203182~121205014:-
LUAD	trans	rs7943191	0.81	rs7942154	ENSG00000186676.3	EEF1GP1	22.44	7.35e-77	4.53e-69	1.02	0.72	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62569691	chr7:125033453~125035301:+
LUAD	trans	rs7121616	0.576	rs4802	ENSG00000234176.1	HSPA8P1	22.44	8.03e-77	4.94e-69	0.87	0.72	Breast cancer;	chr11:123057914	chrX:121203182~121205014:-
LUAD	trans	rs9611565	0.765	rs132907	ENSG00000268568.1	AC007228.9	22.4	1.15e-76	7.05e-69	1.08	0.71	Vitiligo;	chr22:41405264	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.681	rs6002372	ENSG00000268568.1	AC007228.9	22.4	1.15e-76	7.05e-69	1.08	0.71	Vitiligo;	chr22:41405295	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.765	rs132908	ENSG00000268568.1	AC007228.9	22.4	1.15e-76	7.05e-69	1.08	0.71	Vitiligo;	chr22:41405791	chr19:56672574~56673901:-
LUAD	trans	rs7943191	0.768	rs34065644	ENSG00000186676.3	EEF1GP1	22.39	1.31e-76	7.96e-69	1.05	0.71	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62604466	chr7:125033453~125035301:+
LUAD	trans	rs7554547	0.667	rs2336377	ENSG00000261819.1	RP11-680G24.4	-22.35	1.98e-76	1.2e-68	-0.92	-0.71	Nonsyndromic cleft lip with cleft palate;	chr1:11889913	chr16:14988259~14990160:-
LUAD	trans	rs9611565	0.592	rs5751101	ENSG00000268568.1	AC007228.9	22.32	2.95e-76	1.77e-68	1.11	0.71	Vitiligo;	chr22:41432107	chr19:56672574~56673901:-
LUAD	trans	rs2950393	0.509	rs10459247	ENSG00000121089.4	NACA3P	-22.3	3.73e-76	2.23e-68	-1.02	-0.71	Platelet distribution width;	chr12:56777732	chr4:164943290~164943937:+
LUAD	trans	rs8081395	0.805	rs1295927	ENSG00000187870.7	RNFT1P3	22.29	4.15e-76	2.48e-68	0.84	0.71	White blood cell count;	chr17:59852174	chr17:20743333~20754501:-
LUAD	trans	rs9611565	0.694	rs5751107	ENSG00000268568.1	AC007228.9	22.25	6.57e-76	3.9e-68	1.09	0.71	Vitiligo;	chr22:41461808	chr19:56672574~56673901:-
LUAD	trans	rs7949030	0.626	rs35587183	ENSG00000186676.3	EEF1GP1	22.22	8.3e-76	4.92e-68	1.03	0.71	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62551184	chr7:125033453~125035301:+
LUAD	trans	rs13177918	0.559	rs12109637	ENSG00000224114.1	RP11-343H5.4	22.18	1.27e-75	7.45e-68	0.95	0.71	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr1:206695837~206696269:-
LUAD	trans	rs7943191	0.81	rs7942991	ENSG00000186676.3	EEF1GP1	-22.15	1.83e-75	1.06e-67	-1.02	-0.71	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62569731	chr7:125033453~125035301:+
LUAD	trans	rs9611565	0.685	rs169363	ENSG00000268568.1	AC007228.9	22.14	2.12e-75	1.22e-67	1.05	0.71	Vitiligo;	chr22:41457113	chr19:56672574~56673901:-
LUAD	trans	rs8081395	0.707	rs1024637	ENSG00000187870.7	RNFT1P3	-22.04	6.06e-75	3.45e-67	-0.86	-0.71	White blood cell count;	chr17:59961532	chr17:20743333~20754501:-
LUAD	trans	rs941207	0.805	rs2958139	ENSG00000121089.4	NACA3P	-22.02	7.75e-75	4.39e-67	-0.97	-0.71	Platelet count;	chr12:56610884	chr4:164943290~164943937:+
LUAD	trans	rs8081395	0.801	rs2645479	ENSG00000187870.7	RNFT1P3	21.94	1.89e-74	1.04e-66	0.84	0.71	White blood cell count;	chr17:59843171	chr17:20743333~20754501:-
LUAD	trans	rs9611565	0.694	rs79008	ENSG00000268568.1	AC007228.9	-21.85	5.18e-74	2.82e-66	-1.04	-0.71	Vitiligo;	chr22:41454496	chr19:56672574~56673901:-
LUAD	trans	rs941207	0.855	rs2256341	ENSG00000121089.4	NACA3P	-21.8	9.16e-74	4.94e-66	-0.97	-0.7	Platelet count;	chr12:56599930	chr4:164943290~164943937:+
LUAD	trans	rs11332131	1	rs11332131	ENSG00000187870.7	RNFT1P3	21.72	2.09e-73	1.11e-65	0.83	0.7	Platelet distribution width;	chr17:59849031	chr17:20743333~20754501:-
LUAD	trans	rs13177918	0.559	rs10447224	ENSG00000224114.1	RP11-343H5.4	21.72	2.14e-73	1.14e-65	0.96	0.7	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr1:206695837~206696269:-
LUAD	trans	rs13177918	0.559	rs10447225	ENSG00000224114.1	RP11-343H5.4	21.72	2.14e-73	1.14e-65	0.96	0.7	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr1:206695837~206696269:-
LUAD	trans	rs8081395	0.741	rs180520	ENSG00000187870.7	RNFT1P3	21.68	3.19e-73	1.69e-65	0.84	0.7	White blood cell count;	chr17:59937788	chr17:20743333~20754501:-
LUAD	trans	rs7121616	0.576	rs4936767	ENSG00000234176.1	HSPA8P1	21.68	3.42e-73	1.81e-65	0.85	0.7	Breast cancer;	chr11:123047451	chrX:121203182~121205014:-
LUAD	trans	rs8081395	0.741	rs1292051	ENSG00000187870.7	RNFT1P3	21.61	6.8e-73	3.57e-65	0.85	0.7	White blood cell count;	chr17:59886562	chr17:20743333~20754501:-
LUAD	trans	rs7121616	0.562	rs7131452	ENSG00000234176.1	HSPA8P1	21.56	1.16e-72	6.07e-65	0.86	0.7	Breast cancer;	chr11:123065314	chrX:121203182~121205014:-
LUAD	trans	rs13177918	0.626	rs2748240	ENSG00000224114.1	RP11-343H5.4	21.41	6.66e-72	3.45e-64	0.91	0.7	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449305	chr1:206695837~206696269:-
LUAD	trans	rs8081395	0.741	rs1292056	ENSG00000187870.7	RNFT1P3	21.37	9.41e-72	4.85e-64	0.83	0.7	White blood cell count;	chr17:59881686	chr17:20743333~20754501:-
LUAD	trans	rs13253073	0.55	rs6468697	ENSG00000260318.1	COX6CP1	21.37	1.03e-71	5.32e-64	1	0.7	Glucose homeostasis traits;	chr8:99858154	chr16:11903923~11904137:-
LUAD	trans	rs1816752	0.74	rs6490924	ENSG00000237917.1	PARP4P1	-21.32	1.78e-71	9.12e-64	-0.86	-0.7	Obesity-related traits;	chr13:24432914	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.583	rs6490918	ENSG00000237917.1	PARP4P1	-21.29	2.31e-71	1.18e-63	-0.86	-0.7	Obesity-related traits;	chr13:24427977	chrY:26594851~26634652:-
LUAD	trans	rs7121616	0.562	rs2061602	ENSG00000234176.1	HSPA8P1	21.26	3.2e-71	1.63e-63	0.86	0.7	Breast cancer;	chr11:123065079	chrX:121203182~121205014:-
LUAD	trans	rs8081395	0.836	rs1292061	ENSG00000187870.7	RNFT1P3	-21.24	4.05e-71	2.06e-63	-0.81	-0.7	White blood cell count;	chr17:59833869	chr17:20743333~20754501:-
LUAD	trans	rs8081395	0.836	rs1295926	ENSG00000187870.7	RNFT1P3	-21.24	4.23e-71	2.14e-63	-0.81	-0.7	White blood cell count;	chr17:59832012	chr17:20743333~20754501:-
LUAD	trans	rs8081395	0.801	rs12938273	ENSG00000187870.7	RNFT1P3	-21.23	4.35e-71	2.2e-63	-0.81	-0.7	White blood cell count;	chr17:59824291	chr17:20743333~20754501:-
LUAD	trans	rs13177918	0.626	rs2748240	ENSG00000213058.3	RP4-765C7.2	21.18	7.92e-71	3.97e-63	0.9	0.69	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449305	chr1:178411616~178411972:+
LUAD	trans	rs13177918	0.603	rs2748241	ENSG00000213058.3	RP4-765C7.2	21.16	9.7e-71	4.84e-63	0.88	0.69	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447931	chr1:178411616~178411972:+
LUAD	trans	rs9611565	0.729	rs4822027	ENSG00000268568.1	AC007228.9	-21.13	1.34e-70	6.65e-63	-1.04	-0.69	Vitiligo;	chr22:41390223	chr19:56672574~56673901:-
LUAD	trans	rs7949030	0.596	rs11231137	ENSG00000186676.3	EEF1GP1	21.11	1.62e-70	8.06e-63	1	0.69	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62548227	chr7:125033453~125035301:+
LUAD	trans	rs9611565	0.729	rs73176686	ENSG00000268568.1	AC007228.9	-21.08	2.49e-70	1.23e-62	-1.03	-0.69	Vitiligo;	chr22:41386115	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.694	rs79011	ENSG00000268568.1	AC007228.9	21.06	2.82e-70	1.39e-62	1.02	0.69	Vitiligo;	chr22:41470934	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.659	rs169361	ENSG00000268568.1	AC007228.9	21.04	3.75e-70	1.84e-62	1.07	0.69	Vitiligo;	chr22:41481985	chr19:56672574~56673901:-
LUAD	trans	rs8081395	0.836	rs2150879	ENSG00000187870.7	RNFT1P3	-20.99	6.43e-70	3.15e-62	-0.81	-0.69	White blood cell count;	chr17:59781849	chr17:20743333~20754501:-
LUAD	trans	rs13177918	0.603	rs2748241	ENSG00000224114.1	RP11-343H5.4	20.97	7.64e-70	3.72e-62	0.88	0.69	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447931	chr1:206695837~206696269:-
LUAD	trans	rs8081395	0.801	rs2777895	ENSG00000187870.7	RNFT1P3	-20.94	1.12e-69	5.46e-62	-0.8	-0.69	White blood cell count;	chr17:59802249	chr17:20743333~20754501:-
LUAD	trans	rs8081395	0.769	rs12449331	ENSG00000187870.7	RNFT1P3	-20.94	1.12e-69	5.46e-62	-0.8	-0.69	White blood cell count;	chr17:59806285	chr17:20743333~20754501:-
LUAD	trans	rs13253073	0.545	rs13265660	ENSG00000260318.1	COX6CP1	20.78	6.21e-69	2.98e-61	1.22	0.69	Glucose homeostasis traits;	chr8:99815931	chr16:11903923~11904137:-
LUAD	trans	rs9611565	0.729	rs2413646	ENSG00000268568.1	AC007228.9	-20.76	8.26e-69	3.96e-61	-1.08	-0.69	Vitiligo;	chr22:41510321	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.694	rs202665	ENSG00000268568.1	AC007228.9	20.74	9.5e-69	4.55e-61	1	0.69	Vitiligo;	chr22:41418397	chr19:56672574~56673901:-
LUAD	trans	rs13177918	0.559	rs12109637	ENSG00000239528.1	RPS14P8	20.73	1.06e-68	5.05e-61	0.95	0.69	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr5:116562562~116562930:+
LUAD	trans	rs5022636	0.594	rs7489	ENSG00000180764.13	PIPSL	20.73	1.12e-68	5.35e-61	0.83	0.69	Gut microbiota (functional units);	chr1:151266575	chr10:93958191~93961540:-
LUAD	trans	rs9611565	0.649	rs202666	ENSG00000268568.1	AC007228.9	20.71	1.42e-68	6.76e-61	1	0.69	Vitiligo;	chr22:41418715	chr19:56672574~56673901:-
LUAD	trans	rs5022636	0.559	rs41302131	ENSG00000180764.13	PIPSL	20.67	2.1e-68	9.94e-61	0.81	0.69	Gut microbiota (functional units);	chr1:151267532	chr10:93958191~93961540:-
LUAD	trans	rs9611565	0.729	rs2413647	ENSG00000268568.1	AC007228.9	-20.65	2.57e-68	1.22e-60	-1.07	-0.69	Vitiligo;	chr22:41511144	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.659	rs1569516	ENSG00000268568.1	AC007228.9	-20.65	2.57e-68	1.22e-60	-1.07	-0.69	Vitiligo;	chr22:41514240	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.802	rs73176694	ENSG00000268568.1	AC007228.9	-20.55	7.69e-68	3.6e-60	-1.02	-0.68	Vitiligo;	chr22:41390784	chr19:56672574~56673901:-
LUAD	trans	rs1816752	0.669	rs7984513	ENSG00000237917.1	PARP4P1	-20.55	8.19e-68	3.83e-60	-0.83	-0.68	Obesity-related traits;	chr13:24445117	chrY:26594851~26634652:-
LUAD	trans	rs6477998	0.535	rs10981712	ENSG00000238072.1	RP11-305M3.2	20.54	9.03e-68	4.21e-60	1.03	0.68	Hematology traits;	chr9:113283846	chr7:129410113~129410370:-
LUAD	trans	rs9611565	0.659	rs1810461	ENSG00000268568.1	AC007228.9	-20.52	1.09e-67	5.07e-60	-1.07	-0.68	Vitiligo;	chr22:41531816	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.659	rs73178626	ENSG00000268568.1	AC007228.9	-20.52	1.09e-67	5.07e-60	-1.07	-0.68	Vitiligo;	chr22:41532367	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.765	rs9607800	ENSG00000268568.1	AC007228.9	-20.51	1.3e-67	5.99e-60	-1.02	-0.68	Vitiligo;	chr22:41388558	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.694	rs202664	ENSG00000268568.1	AC007228.9	20.51	1.3e-67	5.99e-60	0.99	0.68	Vitiligo;	chr22:41417882	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.681	rs5751094	ENSG00000268568.1	AC007228.9	20.48	1.75e-67	8.01e-60	1	0.68	Vitiligo;	chr22:41407275	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.765	rs132914	ENSG00000268568.1	AC007228.9	20.48	1.75e-67	8.01e-60	1	0.68	Vitiligo;	chr22:41409745	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.765	rs132915	ENSG00000268568.1	AC007228.9	20.48	1.75e-67	8.01e-60	1	0.68	Vitiligo;	chr22:41409778	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.722	rs202635	ENSG00000268568.1	AC007228.9	20.48	1.75e-67	8.01e-60	1	0.68	Vitiligo;	chr22:41413633	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.765	rs132920	ENSG00000268568.1	AC007228.9	20.48	1.75e-67	8.01e-60	1	0.68	Vitiligo;	chr22:41414166	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.802	rs73176692	ENSG00000268568.1	AC007228.9	-20.46	2.09e-67	9.48e-60	-1.02	-0.68	Vitiligo;	chr22:41389731	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.765	rs28604950	ENSG00000268568.1	AC007228.9	-20.44	2.69e-67	1.22e-59	-1.02	-0.68	Vitiligo;	chr22:41389808	chr19:56672574~56673901:-
LUAD	trans	rs13177918	0.559	rs10447224	ENSG00000239528.1	RPS14P8	20.44	2.78e-67	1.26e-59	0.95	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr5:116562562~116562930:+
LUAD	trans	rs13177918	0.559	rs10447225	ENSG00000239528.1	RPS14P8	20.44	2.78e-67	1.26e-59	0.95	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr5:116562562~116562930:+
LUAD	trans	rs13177918	0.626	rs2748240	ENSG00000239528.1	RPS14P8	20.42	3.34e-67	1.51e-59	0.91	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449305	chr5:116562562~116562930:+
LUAD	trans	rs9611565	0.659	rs12483786	ENSG00000268568.1	AC007228.9	-20.41	3.53e-67	1.59e-59	-1.08	-0.68	Vitiligo;	chr22:41542532	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.694	rs19573	ENSG00000268568.1	AC007228.9	20.39	4.56e-67	2.05e-59	0.99	0.68	Vitiligo;	chr22:41469805	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.765	rs132909	ENSG00000268568.1	AC007228.9	20.36	6.5e-67	2.9e-59	1	0.68	Vitiligo;	chr22:41406027	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.765	rs132905	ENSG00000268568.1	AC007228.9	20.34	7.97e-67	3.55e-59	0.99	0.68	Vitiligo;	chr22:41403102	chr19:56672574~56673901:-
LUAD	trans	rs8081395	0.801	rs2665404	ENSG00000187870.7	RNFT1P3	20.28	1.53e-66	6.75e-59	0.78	0.68	White blood cell count;	chr17:59798035	chr17:20743333~20754501:-
LUAD	trans	rs7121616	0.595	rs7949414	ENSG00000234176.1	HSPA8P1	20.28	1.59e-66	6.98e-59	0.83	0.68	Breast cancer;	chr11:123072787	chrX:121203182~121205014:-
LUAD	trans	rs9611565	0.659	rs17367716	ENSG00000268568.1	AC007228.9	-20.27	1.67e-66	7.35e-59	-1.05	-0.68	Vitiligo;	chr22:41517840	chr19:56672574~56673901:-
LUAD	trans	rs12291225	0.877	rs2303974	ENSG00000236360.2	RP11-334A14.2	20.27	1.72e-66	7.55e-59	0.92	0.68	Sense of smell;	chr11:14243433	chr1:52993201~52993702:-
LUAD	trans	rs5022636	0.594	rs12048670	ENSG00000180764.13	PIPSL	20.26	1.85e-66	8.07e-59	0.82	0.68	Gut microbiota (functional units);	chr1:151272510	chr10:93958191~93961540:-
LUAD	trans	rs928391	0.895	rs11264547	ENSG00000227183.3	HDGFP1	20.25	2.07e-66	9.01e-59	0.99	0.68	Platelet count;	chr1:156776326	chrX:131646639~131646890:+
LUAD	trans	rs9611565	0.659	rs73178641	ENSG00000268568.1	AC007228.9	-20.24	2.41e-66	1.05e-58	-1.07	-0.68	Vitiligo;	chr22:41556071	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.659	rs4822035	ENSG00000268568.1	AC007228.9	20.23	2.67e-66	1.16e-58	1.06	0.68	Vitiligo;	chr22:41539908	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.659	rs1810460	ENSG00000268568.1	AC007228.9	-20.22	2.82e-66	1.23e-58	-1.04	-0.68	Vitiligo;	chr22:41531696	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.765	rs202663	ENSG00000268568.1	AC007228.9	20.19	3.94e-66	1.7e-58	0.98	0.68	Vitiligo;	chr22:41416815	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.659	rs56319767	ENSG00000268568.1	AC007228.9	-20.19	3.94e-66	1.7e-58	-1.07	-0.68	Vitiligo;	chr22:41537833	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.659	rs73178632	ENSG00000268568.1	AC007228.9	-20.19	3.94e-66	1.7e-58	-1.07	-0.68	Vitiligo;	chr22:41538569	chr19:56672574~56673901:-
LUAD	trans	rs13177918	0.603	rs2343806	ENSG00000213058.3	RP4-765C7.2	20.19	4.22e-66	1.82e-58	0.88	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452422	chr1:178411616~178411972:+
LUAD	trans	rs8010715	1	rs3742500	ENSG00000248988.1	RP11-815N9.2	20.19	4.35e-66	1.87e-58	0.9	0.68	IgG glycosylation;	chr14:24142769	chr4:159007119~159007835:+
LUAD	trans	rs9611565	0.765	rs202659	ENSG00000268568.1	AC007228.9	20.16	5.81e-66	2.49e-58	0.99	0.68	Vitiligo;	chr22:41415616	chr19:56672574~56673901:-
LUAD	trans	rs1816752	0.716	rs9553289	ENSG00000237917.1	PARP4P1	-20.14	7.08e-66	3.02e-58	-0.82	-0.68	Obesity-related traits;	chr13:24400640	chrY:26594851~26634652:-
LUAD	trans	rs928391	0.947	rs11264549	ENSG00000227183.3	HDGFP1	20.13	8.07e-66	3.43e-58	0.98	0.68	Platelet count;	chr1:156781017	chrX:131646639~131646890:+
LUAD	trans	rs928391	1	rs12134991	ENSG00000227183.3	HDGFP1	20.13	8.07e-66	3.43e-58	0.98	0.68	Platelet count;	chr1:156781285	chrX:131646639~131646890:+
LUAD	trans	rs9611565	0.659	rs12483998	ENSG00000268568.1	AC007228.9	-20.12	8.75e-66	3.72e-58	-1.07	-0.68	Vitiligo;	chr22:41539358	chr19:56672574~56673901:-
LUAD	trans	rs8081395	0.836	rs2063353	ENSG00000187870.7	RNFT1P3	-20.12	8.92e-66	3.79e-58	-0.8	-0.68	White blood cell count;	chr17:59811831	chr17:20743333~20754501:-
LUAD	trans	rs8081395	0.576	rs1292032	ENSG00000187870.7	RNFT1P3	20.12	8.93e-66	3.79e-58	0.81	0.68	White blood cell count;	chr17:59914982	chr17:20743333~20754501:-
LUAD	trans	rs9611565	0.527	rs2234053	ENSG00000268568.1	AC007228.9	-20.12	9.1e-66	3.86e-58	-0.99	-0.68	Vitiligo;	chr22:41381311	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.729	rs73176689	ENSG00000268568.1	AC007228.9	-20.1	1.06e-65	4.49e-58	-0.98	-0.68	Vitiligo;	chr22:41386629	chr19:56672574~56673901:-
LUAD	trans	rs5022636	0.525	rs6587559	ENSG00000180764.13	PIPSL	20.1	1.09e-65	4.61e-58	0.82	0.68	Gut microbiota (functional units);	chr1:151245262	chr10:93958191~93961540:-
LUAD	trans	rs9611565	0.659	rs9611602	ENSG00000268568.1	AC007228.9	-20.1	1.11e-65	4.69e-58	-1.05	-0.68	Vitiligo;	chr22:41512401	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.802	rs2234058	ENSG00000268568.1	AC007228.9	-20.09	1.24e-65	5.23e-58	-0.99	-0.68	Vitiligo;	chr22:41381879	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.84	rs2234059	ENSG00000268568.1	AC007228.9	-20.09	1.24e-65	5.23e-58	-0.99	-0.68	Vitiligo;	chr22:41381909	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.765	rs767593	ENSG00000268568.1	AC007228.9	-20.09	1.28e-65	5.41e-58	-0.99	-0.68	Vitiligo;	chr22:41383967	chr19:56672574~56673901:-
LUAD	trans	rs928391	1	rs12043405	ENSG00000227183.3	HDGFP1	20.07	1.55e-65	6.52e-58	0.98	0.68	Platelet count;	chr1:156784508	chrX:131646639~131646890:+
LUAD	trans	rs928391	0.895	rs12042999	ENSG00000227183.3	HDGFP1	20.06	1.67e-65	6.98e-58	0.99	0.67	Platelet count;	chr1:156768636	chrX:131646639~131646890:+
LUAD	trans	rs9611565	0.84	rs3788584	ENSG00000268568.1	AC007228.9	-20.05	1.98e-65	8.27e-58	-0.99	-0.67	Vitiligo;	chr22:41383069	chr19:56672574~56673901:-
LUAD	trans	rs13177918	0.603	rs2748241	ENSG00000239528.1	RPS14P8	20.04	2.09e-65	8.71e-58	0.88	0.67	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447931	chr5:116562562~116562930:+
LUAD	trans	rs9611565	0.694	rs202631	ENSG00000268568.1	AC007228.9	20.04	2.1e-65	8.76e-58	0.97	0.67	Vitiligo;	chr22:41467419	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.659	rs9611604	ENSG00000268568.1	AC007228.9	-20.04	2.11e-65	8.78e-58	-1.06	-0.67	Vitiligo;	chr22:41519997	chr19:56672574~56673901:-
LUAD	trans	rs928391	1	rs2274501	ENSG00000227183.3	HDGFP1	20.03	2.41e-65	1e-57	0.98	0.67	Platelet count;	chr1:156782460	chrX:131646639~131646890:+
LUAD	trans	rs9611565	0.694	rs202637	ENSG00000268568.1	AC007228.9	20.02	2.6e-65	1.08e-57	1.06	0.67	Vitiligo;	chr22:41457924	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.579	rs73178621	ENSG00000268568.1	AC007228.9	-20.01	2.88e-65	1.19e-57	-1.06	-0.67	Vitiligo;	chr22:41525661	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.84	rs4822025	ENSG00000268568.1	AC007228.9	-19.99	3.58e-65	1.48e-57	-0.99	-0.67	Vitiligo;	chr22:41380642	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.659	rs28530678	ENSG00000268568.1	AC007228.9	-19.98	4.13e-65	1.71e-57	-1.07	-0.67	Vitiligo;	chr22:41538957	chr19:56672574~56673901:-
LUAD	trans	rs13177918	0.603	rs2343806	ENSG00000224114.1	RP11-343H5.4	19.96	4.92e-65	2.03e-57	0.88	0.67	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452422	chr1:206695837~206696269:-
LUAD	trans	rs8081395	0.775	rs2526355	ENSG00000187870.7	RNFT1P3	19.96	5e-65	2.06e-57	0.81	0.67	White blood cell count;	chr17:59875872	chr17:20743333~20754501:-
LUAD	trans	rs9611565	0.659	rs9611603	ENSG00000268568.1	AC007228.9	-19.96	5.1e-65	2.09e-57	-1.04	-0.67	Vitiligo;	chr22:41516746	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.659	rs4822037	ENSG00000268568.1	AC007228.9	-19.95	5.77e-65	2.37e-57	-1.08	-0.67	Vitiligo;	chr22:41549109	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.659	rs4822036	ENSG00000268568.1	AC007228.9	-19.94	6.12e-65	2.51e-57	-1.06	-0.67	Vitiligo;	chr22:41540015	chr19:56672574~56673901:-
LUAD	trans	rs1292048	1	rs1292048	ENSG00000187870.7	RNFT1P3	19.94	6.13e-65	2.51e-57	0.81	0.67	Red cell distribution width;	chr17:59877710	chr17:20743333~20754501:-
LUAD	trans	rs9611565	0.527	rs73178638	ENSG00000268568.1	AC007228.9	-19.92	7.65e-65	3.13e-57	-1.08	-0.67	Vitiligo;	chr22:41546900	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.546	rs2092274	ENSG00000268568.1	AC007228.9	19.91	8.82e-65	3.59e-57	1.04	0.67	Vitiligo;	chr22:41727733	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.625	rs73178625	ENSG00000268568.1	AC007228.9	-19.88	1.25e-64	5.06e-57	-1.04	-0.67	Vitiligo;	chr22:41532316	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.659	rs9611610	ENSG00000268568.1	AC007228.9	-19.87	1.31e-64	5.31e-57	-1.04	-0.67	Vitiligo;	chr22:41553255	chr19:56672574~56673901:-
LUAD	trans	rs8081395	0.801	rs2665405	ENSG00000187870.7	RNFT1P3	-19.87	1.41e-64	5.67e-57	-0.79	-0.67	White blood cell count;	chr17:59797931	chr17:20743333~20754501:-
LUAD	trans	rs9611565	0.659	rs17367849	ENSG00000268568.1	AC007228.9	-19.84	1.84e-64	7.36e-57	-1.06	-0.67	Vitiligo;	chr22:41527640	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.659	rs4822034	ENSG00000268568.1	AC007228.9	-19.82	2.36e-64	9.38e-57	-1.06	-0.67	Vitiligo;	chr22:41535006	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.625	rs9611606	ENSG00000268568.1	AC007228.9	-19.82	2.36e-64	9.38e-57	-1.06	-0.67	Vitiligo;	chr22:41535070	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.659	rs116959331	ENSG00000268568.1	AC007228.9	-19.82	2.36e-64	9.38e-57	-1.06	-0.67	Vitiligo;	chr22:41536770	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.592	rs5758427	ENSG00000268568.1	AC007228.9	19.81	2.51e-64	9.95e-57	1.04	0.67	Vitiligo;	chr22:41703684	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.546	rs5758430	ENSG00000268568.1	AC007228.9	19.81	2.51e-64	9.95e-57	1.04	0.67	Vitiligo;	chr22:41713840	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.546	rs5758431	ENSG00000268568.1	AC007228.9	19.81	2.51e-64	9.95e-57	1.04	0.67	Vitiligo;	chr22:41713913	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.659	rs12484228	ENSG00000268568.1	AC007228.9	-19.79	3.4e-64	1.34e-56	-1.05	-0.67	Vitiligo;	chr22:41543735	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.659	rs12484175	ENSG00000268568.1	AC007228.9	-19.78	3.48e-64	1.37e-56	-1.06	-0.67	Vitiligo;	chr22:41557735	chr19:56672574~56673901:-
LUAD	trans	rs928391	1	rs61816272	ENSG00000227183.3	HDGFP1	19.77	3.91e-64	1.53e-56	0.99	0.67	Platelet count;	chr1:156778073	chrX:131646639~131646890:+
LUAD	trans	rs5022636	0.525	rs6681163	ENSG00000180764.13	PIPSL	19.77	4.16e-64	1.63e-56	0.78	0.67	Gut microbiota (functional units);	chr1:151259161	chr10:93958191~93961540:-
LUAD	trans	rs7121616	0.576	rs11218967	ENSG00000234176.1	HSPA8P1	19.75	5.24e-64	2.05e-56	0.83	0.67	Breast cancer;	chr11:123087551	chrX:121203182~121205014:-
LUAD	trans	rs9611565	0.659	rs9607815	ENSG00000268568.1	AC007228.9	-19.74	5.71e-64	2.23e-56	-1.05	-0.67	Vitiligo;	chr22:41554667	chr19:56672574~56673901:-
LUAD	trans	rs1816752	0.875	rs59531061	ENSG00000237917.1	PARP4P1	19.7	8.95e-64	3.47e-56	0.85	0.67	Obesity-related traits;	chr13:24507297	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.875	rs59686377	ENSG00000237917.1	PARP4P1	19.69	9.37e-64	3.63e-56	0.84	0.67	Obesity-related traits;	chr13:24475869	chrY:26594851~26634652:-
LUAD	trans	rs7554547	1	rs926271	ENSG00000261819.1	RP11-680G24.4	19.69	9.38e-64	3.63e-56	0.85	0.67	Nonsyndromic cleft lip with cleft palate;	chr1:11909860	chr16:14988259~14990160:-
LUAD	trans	rs7554547	0.967	rs4845888	ENSG00000261819.1	RP11-680G24.4	19.69	9.38e-64	3.63e-56	0.85	0.67	Nonsyndromic cleft lip with cleft palate;	chr1:11910946	chr16:14988259~14990160:-
LUAD	trans	rs928391	1	rs2768767	ENSG00000227183.3	HDGFP1	19.69	9.53e-64	3.68e-56	0.97	0.67	Platelet count;	chr1:156797933	chrX:131646639~131646890:+
LUAD	trans	rs9611565	0.694	rs9607816	ENSG00000268568.1	AC007228.9	-19.69	9.69e-64	3.74e-56	-1.05	-0.67	Vitiligo;	chr22:41554893	chr19:56672574~56673901:-
LUAD	trans	rs8010715	0.816	rs1134340	ENSG00000248988.1	RP11-815N9.2	19.69	9.99e-64	3.85e-56	0.85	0.67	IgG glycosylation;	chr14:24125004	chr4:159007119~159007835:+
LUAD	trans	rs5022636	0.525	rs4971013	ENSG00000180764.13	PIPSL	19.67	1.27e-63	4.88e-56	0.81	0.67	Gut microbiota (functional units);	chr1:151200637	chr10:93958191~93961540:-
LUAD	trans	rs928391	1	rs2644615	ENSG00000227183.3	HDGFP1	19.65	1.59e-63	6.08e-56	0.97	0.67	Platelet count;	chr1:156791826	chrX:131646639~131646890:+
LUAD	trans	rs12291225	0.877	rs11023160	ENSG00000236360.2	RP11-334A14.2	19.65	1.6e-63	6.1e-56	0.91	0.67	Sense of smell;	chr11:14242679	chr1:52993201~52993702:-
LUAD	trans	rs7554547	1	rs7554547	ENSG00000261819.1	RP11-680G24.4	19.64	1.7e-63	6.48e-56	0.85	0.67	Nonsyndromic cleft lip with cleft palate;	chr1:11913831	chr16:14988259~14990160:-
LUAD	trans	rs7554547	1	rs2336378	ENSG00000261819.1	RP11-680G24.4	19.64	1.7e-63	6.48e-56	0.85	0.67	Nonsyndromic cleft lip with cleft palate;	chr1:11915626	chr16:14988259~14990160:-
LUAD	trans	rs9611565	0.659	rs28623192	ENSG00000268568.1	AC007228.9	-19.63	1.84e-63	7.01e-56	-1.06	-0.67	Vitiligo;	chr22:41544520	chr19:56672574~56673901:-
LUAD	trans	rs8010715	0.816	rs6573573	ENSG00000248988.1	RP11-815N9.2	19.62	2.07e-63	7.86e-56	0.85	0.67	IgG glycosylation;	chr14:24130048	chr4:159007119~159007835:+
LUAD	trans	rs5022636	0.564	rs2275900	ENSG00000180764.13	PIPSL	19.61	2.49e-63	9.42e-56	0.78	0.67	Gut microbiota (functional units);	chr1:151265746	chr10:93958191~93961540:-
LUAD	trans	rs5022636	0.594	rs10888408	ENSG00000180764.13	PIPSL	19.61	2.49e-63	9.42e-56	0.78	0.67	Gut microbiota (functional units);	chr1:151267094	chr10:93958191~93961540:-
LUAD	trans	rs9611565	0.659	rs12484694	ENSG00000268568.1	AC007228.9	-19.59	2.98e-63	1.12e-55	-1.04	-0.67	Vitiligo;	chr22:41523326	chr19:56672574~56673901:-
LUAD	trans	rs202629	1	rs202629	ENSG00000268568.1	AC007228.9	19.58	3.44e-63	1.29e-55	0.95	0.67	Cannabis dependence symptom count;	chr22:41453971	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.659	rs11090049	ENSG00000268568.1	AC007228.9	-19.57	3.71e-63	1.39e-55	-1.06	-0.67	Vitiligo;	chr22:41519325	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.681	rs132918	ENSG00000268568.1	AC007228.9	19.57	3.78e-63	1.42e-55	0.96	0.67	Vitiligo;	chr22:41412346	chr19:56672574~56673901:-
LUAD	trans	rs1816752	0.875	rs17384871	ENSG00000237917.1	PARP4P1	19.56	4.15e-63	1.55e-55	0.84	0.67	Obesity-related traits;	chr13:24484959	chrY:26594851~26634652:-
LUAD	trans	rs928391	1	rs2777929	ENSG00000227183.3	HDGFP1	19.55	4.63e-63	1.73e-55	0.97	0.67	Platelet count;	chr1:156797879	chrX:131646639~131646890:+
LUAD	trans	rs8081395	0.741	rs1292053	ENSG00000187870.7	RNFT1P3	-19.55	4.69e-63	1.74e-55	-0.78	-0.67	White blood cell count;	chr17:59886176	chr17:20743333~20754501:-
LUAD	trans	rs9611565	0.659	rs56364401	ENSG00000268568.1	AC007228.9	-19.54	5.28e-63	1.96e-55	-1.04	-0.67	Vitiligo;	chr22:41555239	chr19:56672574~56673901:-
LUAD	trans	rs8010715	0.816	rs762093	ENSG00000248988.1	RP11-815N9.2	19.52	6.45e-63	2.38e-55	0.84	0.66	IgG glycosylation;	chr14:24122709	chr4:159007119~159007835:+
LUAD	trans	rs9611565	0.659	rs9607812	ENSG00000268568.1	AC007228.9	-19.52	6.62e-63	2.43e-55	-1.06	-0.66	Vitiligo;	chr22:41545239	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.659	rs9607813	ENSG00000268568.1	AC007228.9	-19.52	6.62e-63	2.43e-55	-1.06	-0.66	Vitiligo;	chr22:41545475	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.694	rs202628	ENSG00000268568.1	AC007228.9	-19.51	7.09e-63	2.61e-55	-0.94	-0.66	Vitiligo;	chr22:41453509	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.659	rs9611609	ENSG00000268568.1	AC007228.9	-19.49	9.17e-63	3.36e-55	-1.06	-0.66	Vitiligo;	chr22:41549353	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.512	rs4822052	ENSG00000268568.1	AC007228.9	-19.47	1.06e-62	3.86e-55	-1.03	-0.66	Vitiligo;	chr22:41797737	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.765	rs132921	ENSG00000268568.1	AC007228.9	19.47	1.08e-62	3.94e-55	0.96	0.66	Vitiligo;	chr22:41416040	chr19:56672574~56673901:-
LUAD	trans	rs1816752	0.875	rs3783076	ENSG00000237917.1	PARP4P1	19.45	1.35e-62	4.92e-55	0.85	0.66	Obesity-related traits;	chr13:24490319	chrY:26594851~26634652:-
LUAD	trans	rs9611565	0.694	rs5758368	ENSG00000268568.1	AC007228.9	-19.45	1.4e-62	5.1e-55	-0.96	-0.66	Vitiligo;	chr22:41466284	chr19:56672574~56673901:-
LUAD	trans	rs13177918	0.603	rs2343806	ENSG00000239528.1	RPS14P8	19.41	2.16e-62	7.83e-55	0.89	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452422	chr5:116562562~116562930:+
LUAD	trans	rs6477998	0.535	rs10817475	ENSG00000238072.1	RP11-305M3.2	19.36	3.5e-62	1.26e-54	1.03	0.66	Hematology traits;	chr9:113296774	chr7:129410113~129410370:-
LUAD	trans	rs9611565	0.918	rs7290404	ENSG00000268568.1	AC007228.9	-19.35	4.02e-62	1.44e-54	-0.99	-0.66	Vitiligo;	chr22:41353792	chr19:56672574~56673901:-
LUAD	trans	rs7121616	0.595	rs7941144	ENSG00000234176.1	HSPA8P1	19.33	4.91e-62	1.75e-54	0.81	0.66	Breast cancer;	chr11:123079805	chrX:121203182~121205014:-
LUAD	trans	rs9611565	0.694	rs202641	ENSG00000268568.1	AC007228.9	19.31	5.97e-62	2.12e-54	0.96	0.66	Vitiligo;	chr22:41437112	chr19:56672574~56673901:-
LUAD	trans	rs7949030	1	rs10897289	ENSG00000186676.3	EEF1GP1	19.29	8.08e-62	2.85e-54	0.9	0.66	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62632544	chr7:125033453~125035301:+
LUAD	trans	rs9611565	0.649	rs79005	ENSG00000268568.1	AC007228.9	19.26	1.1e-61	3.88e-54	0.96	0.66	Vitiligo;	chr22:41439540	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.802	rs9611571	ENSG00000268568.1	AC007228.9	-19.25	1.14e-61	4e-54	-0.95	-0.66	Vitiligo;	chr22:41388863	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.649	rs202655	ENSG00000268568.1	AC007228.9	19.25	1.17e-61	4.12e-54	0.96	0.66	Vitiligo;	chr22:41445560	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.592	rs4822038	ENSG00000268568.1	AC007228.9	-19.25	1.19e-61	4.19e-54	-1.1	-0.66	Vitiligo;	chr22:41562491	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.659	rs202653	ENSG00000268568.1	AC007228.9	19.24	1.4e-61	4.9e-54	0.95	0.66	Vitiligo;	chr22:41444154	chr19:56672574~56673901:-
LUAD	trans	rs8010715	0.816	rs2332224	ENSG00000248988.1	RP11-815N9.2	19.23	1.53e-61	5.36e-54	0.84	0.66	IgG glycosylation;	chr14:24129335	chr4:159007119~159007835:+
LUAD	trans	rs9611565	0.608	rs202652	ENSG00000268568.1	AC007228.9	19.17	2.75e-61	9.53e-54	0.96	0.66	Vitiligo;	chr22:41442788	chr19:56672574~56673901:-
LUAD	trans	rs8010715	0.816	rs7153156	ENSG00000248988.1	RP11-815N9.2	19.16	3.22e-61	1.12e-53	0.83	0.66	IgG glycosylation;	chr14:24129637	chr4:159007119~159007835:+
LUAD	trans	rs8010715	0.785	rs2877611	ENSG00000248988.1	RP11-815N9.2	19.15	3.44e-61	1.19e-53	0.83	0.66	IgG glycosylation;	chr14:24126221	chr4:159007119~159007835:+
LUAD	trans	rs8010715	0.816	rs6573572	ENSG00000248988.1	RP11-815N9.2	19.1	5.95e-61	2.05e-53	0.83	0.66	IgG glycosylation;	chr14:24130021	chr4:159007119~159007835:+
LUAD	trans	rs13253073	1	rs4409375	ENSG00000260318.1	COX6CP1	19.1	6.08e-61	2.1e-53	1.21	0.66	Glucose homeostasis traits;	chr8:99877759	chr16:11903923~11904137:-
LUAD	trans	rs928391	1	rs12129173	ENSG00000227183.3	HDGFP1	19.09	6.7e-61	2.31e-53	0.96	0.66	Platelet count;	chr1:156803833	chrX:131646639~131646890:+
LUAD	trans	rs5022636	0.525	rs4971021	ENSG00000180764.13	PIPSL	19.05	1.01e-60	3.44e-53	0.77	0.66	Gut microbiota (functional units);	chr1:151246152	chr10:93958191~93961540:-
LUAD	trans	rs8010715	0.816	rs8015168	ENSG00000248988.1	RP11-815N9.2	19.05	1.04e-60	3.54e-53	0.83	0.66	IgG glycosylation;	chr14:24130663	chr4:159007119~159007835:+
LUAD	trans	rs8010715	1	rs8010715	ENSG00000248988.1	RP11-815N9.2	18.98	2.17e-60	7.31e-53	0.87	0.65	IgG glycosylation;	chr14:24139938	chr4:159007119~159007835:+
LUAD	trans	rs727563	0.58	rs202626	ENSG00000268568.1	AC007228.9	18.97	2.45e-60	8.22e-53	0.95	0.65	Crohn's disease;Inflammatory bowel disease;	chr22:41451186	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.532	rs202627	ENSG00000268568.1	AC007228.9	18.97	2.45e-60	8.22e-53	0.95	0.65	Vitiligo;	chr22:41451363	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.918	rs9611566	ENSG00000268568.1	AC007228.9	18.97	2.48e-60	8.31e-53	0.96	0.65	Vitiligo;	chr22:41372621	chr19:56672574~56673901:-
LUAD	trans	rs8010715	0.816	rs6573565	ENSG00000248988.1	RP11-815N9.2	-18.97	2.5e-60	8.37e-53	-0.83	-0.65	IgG glycosylation;	chr14:24125524	chr4:159007119~159007835:+
LUAD	trans	rs61990749	0.597	rs72685264	ENSG00000235400.1	RP4-641G12.4	-18.94	3.37e-60	1.12e-52	-1.01	-0.65	Fibroblast growth factor basic levels;	chr14:77686655	chr1:78749073~78750659:+
LUAD	trans	rs9611565	0.802	rs9611577	ENSG00000268568.1	AC007228.9	-18.9	5.64e-60	1.86e-52	-0.94	-0.65	Vitiligo;	chr22:41397086	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.918	rs9611561	ENSG00000268568.1	AC007228.9	-18.89	5.83e-60	1.92e-52	-0.98	-0.65	Vitiligo;	chr22:41361230	chr19:56672574~56673901:-
LUAD	trans	rs61990749	0.597	rs4903643	ENSG00000235400.1	RP4-641G12.4	18.87	7.22e-60	2.37e-52	1.01	0.65	Fibroblast growth factor basic levels;	chr14:77788448	chr1:78749073~78750659:+
LUAD	trans	rs8010715	0.771	rs2277481	ENSG00000248988.1	RP11-815N9.2	18.87	7.69e-60	2.52e-52	0.82	0.65	IgG glycosylation;	chr14:24118336	chr4:159007119~159007835:+
LUAD	trans	rs5022636	0.525	rs7539584	ENSG00000180764.13	PIPSL	18.85	9.24e-60	3.02e-52	0.77	0.65	Gut microbiota (functional units);	chr1:151210477	chr10:93958191~93961540:-
LUAD	trans	rs2950393	0.857	rs1563896	ENSG00000121089.4	NACA3P	18.83	1.11e-59	3.63e-52	0.84	0.65	Platelet distribution width;	chr12:56699312	chr4:164943290~164943937:+
LUAD	trans	rs6477998	0.535	rs4979232	ENSG00000238072.1	RP11-305M3.2	-18.83	1.17e-59	3.81e-52	-1.01	-0.65	Hematology traits;	chr9:113286594	chr7:129410113~129410370:-
LUAD	trans	rs61990749	0.597	rs7142390	ENSG00000235400.1	RP4-641G12.4	18.82	1.23e-59	4.03e-52	1.02	0.65	Fibroblast growth factor basic levels;	chr14:77766537	chr1:78749073~78750659:+
LUAD	trans	rs5022636	0.594	rs11204791	ENSG00000180764.13	PIPSL	18.81	1.52e-59	4.95e-52	0.76	0.65	Gut microbiota (functional units);	chr1:151268066	chr10:93958191~93961540:-
LUAD	trans	rs61990749	0.597	rs2112136	ENSG00000235400.1	RP4-641G12.4	18.79	1.76e-59	5.72e-52	1.01	0.65	Fibroblast growth factor basic levels;	chr14:77782609	chr1:78749073~78750659:+
LUAD	trans	rs5022636	0.525	rs4520422	ENSG00000180764.13	PIPSL	18.78	2.05e-59	6.64e-52	0.77	0.65	Gut microbiota (functional units);	chr1:151207467	chr10:93958191~93961540:-
LUAD	trans	rs941207	0.526	rs7303216	ENSG00000121089.4	NACA3P	18.77	2.18e-59	7.04e-52	0.82	0.65	Platelet count;	chr12:56680909	chr4:164943290~164943937:+
LUAD	trans	rs13253073	1	rs13252579	ENSG00000260318.1	COX6CP1	18.77	2.35e-59	7.59e-52	1.23	0.65	Glucose homeostasis traits;	chr8:99885073	chr16:11903923~11904137:-
LUAD	trans	rs13253073	1	rs13253073	ENSG00000260318.1	COX6CP1	18.77	2.35e-59	7.59e-52	1.23	0.65	Glucose homeostasis traits;	chr8:99885155	chr16:11903923~11904137:-
LUAD	trans	rs2950393	0.895	rs2958154	ENSG00000121089.4	NACA3P	-18.74	3.03e-59	9.75e-52	-0.81	-0.65	Platelet distribution width;	chr12:56671929	chr4:164943290~164943937:+
LUAD	trans	rs9611565	0.838	rs4239894	ENSG00000268568.1	AC007228.9	-18.74	3.06e-59	9.85e-52	-0.97	-0.65	Vitiligo;	chr22:41349544	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.512	rs139571	ENSG00000268568.1	AC007228.9	-18.73	3.49e-59	1.11e-51	-1.06	-0.65	Vitiligo;	chr22:41818234	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.918	rs12484074	ENSG00000268568.1	AC007228.9	-18.68	5.63e-59	1.79e-51	-0.99	-0.65	Vitiligo;	chr22:41356743	chr19:56672574~56673901:-
LUAD	trans	rs61990749	0.597	rs10142722	ENSG00000235400.1	RP4-641G12.4	18.67	6.94e-59	2.2e-51	1	0.65	Fibroblast growth factor basic levels;	chr14:77809206	chr1:78749073~78750659:+
LUAD	trans	rs13253073	1	rs12544943	ENSG00000260318.1	COX6CP1	18.65	8e-59	2.53e-51	1.17	0.65	Glucose homeostasis traits;	chr8:99891662	chr16:11903923~11904137:-
LUAD	trans	rs9611565	0.546	rs739134	ENSG00000268568.1	AC007228.9	18.64	8.95e-59	2.82e-51	1.01	0.65	Vitiligo;	chr22:41693619	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.625	rs9607819	ENSG00000268568.1	AC007228.9	-18.63	1.05e-58	3.29e-51	-0.98	-0.65	Vitiligo;	chr22:41562858	chr19:56672574~56673901:-
LUAD	trans	rs61990749	0.544	rs7151211	ENSG00000235400.1	RP4-641G12.4	-18.63	1.07e-58	3.33e-51	-0.98	-0.65	Fibroblast growth factor basic levels;	chr14:77685558	chr1:78749073~78750659:+
LUAD	trans	rs61990749	0.597	rs7147516	ENSG00000235400.1	RP4-641G12.4	-18.63	1.07e-58	3.33e-51	-0.98	-0.65	Fibroblast growth factor basic levels;	chr14:77687637	chr1:78749073~78750659:+
LUAD	trans	rs61990749	0.597	rs8016447	ENSG00000235400.1	RP4-641G12.4	18.62	1.16e-58	3.62e-51	1	0.65	Fibroblast growth factor basic levels;	chr14:77755725	chr1:78749073~78750659:+
LUAD	trans	rs61990749	0.597	rs6574402	ENSG00000235400.1	RP4-641G12.4	18.61	1.21e-58	3.78e-51	1	0.65	Fibroblast growth factor basic levels;	chr14:77801607	chr1:78749073~78750659:+
LUAD	trans	rs61990749	0.597	rs2267761	ENSG00000235400.1	RP4-641G12.4	-18.59	1.51e-58	4.68e-51	-0.98	-0.65	Fibroblast growth factor basic levels;	chr14:77681506	chr1:78749073~78750659:+
LUAD	trans	rs9611565	0.592	rs5758405	ENSG00000268568.1	AC007228.9	18.56	2.1e-58	6.43e-51	1.01	0.65	Vitiligo;	chr22:41680377	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.592	rs5758406	ENSG00000268568.1	AC007228.9	18.56	2.1e-58	6.43e-51	1.01	0.65	Vitiligo;	chr22:41680637	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.5	rs10775759	ENSG00000268568.1	AC007228.9	18.56	2.1e-58	6.43e-51	1.01	0.65	Vitiligo;	chr22:41692154	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.605	rs202638	ENSG00000268568.1	AC007228.9	18.56	2.1e-58	6.44e-51	0.93	0.65	Vitiligo;	chr22:41459454	chr19:56672574~56673901:-
LUAD	trans	rs13253073	1	rs4480092	ENSG00000260318.1	COX6CP1	18.56	2.18e-58	6.67e-51	1.22	0.65	Glucose homeostasis traits;	chr8:99873372	chr16:11903923~11904137:-
LUAD	trans	rs9611565	0.512	rs1534932	ENSG00000268568.1	AC007228.9	18.55	2.46e-58	7.53e-51	1.04	0.65	Vitiligo;	chr22:41754142	chr19:56672574~56673901:-
LUAD	trans	rs12291225	0.883	rs1864658	ENSG00000236360.2	RP11-334A14.2	-18.53	2.95e-58	9e-51	-0.86	-0.65	Sense of smell;	chr11:14234898	chr1:52993201~52993702:-
LUAD	trans	rs8010715	0.816	rs11574503	ENSG00000248988.1	RP11-815N9.2	-18.49	4.86e-58	1.47e-50	-0.82	-0.64	IgG glycosylation;	chr14:24132109	chr4:159007119~159007835:+
LUAD	trans	rs941207	0.507	rs7297289	ENSG00000121089.4	NACA3P	18.49	4.87e-58	1.48e-50	0.81	0.64	Platelet count;	chr12:56682703	chr4:164943290~164943937:+
LUAD	trans	rs941207	0.526	rs4759028	ENSG00000121089.4	NACA3P	18.49	4.87e-58	1.48e-50	0.81	0.64	Platelet count;	chr12:56686399	chr4:164943290~164943937:+
LUAD	trans	rs9611565	0.559	rs1006407	ENSG00000268568.1	AC007228.9	-18.48	4.92e-58	1.49e-50	-1.08	-0.64	Vitiligo;	chr22:41576028	chr19:56672574~56673901:-
LUAD	trans	rs727563	0.569	rs73178647	ENSG00000268568.1	AC007228.9	-18.47	5.83e-58	1.76e-50	-1.08	-0.64	Crohn's disease;Inflammatory bowel disease;	chr22:41568164	chr19:56672574~56673901:-
LUAD	trans	rs727563	0.648	rs6002406	ENSG00000268568.1	AC007228.9	-18.47	5.83e-58	1.76e-50	-1.08	-0.64	Crohn's disease;Inflammatory bowel disease;	chr22:41569233	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.918	rs9611562	ENSG00000268568.1	AC007228.9	-18.46	6.2e-58	1.87e-50	-0.97	-0.64	Vitiligo;	chr22:41364168	chr19:56672574~56673901:-
LUAD	trans	rs7949030	1	rs2956993	ENSG00000186676.3	EEF1GP1	-18.45	7.05e-58	2.13e-50	-0.87	-0.64	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62638690	chr7:125033453~125035301:+
LUAD	trans	rs13253073	0.545	rs13260744	ENSG00000260318.1	COX6CP1	18.45	7.07e-58	2.13e-50	1.21	0.64	Glucose homeostasis traits;	chr8:99819032	chr16:11903923~11904137:-
LUAD	trans	rs13253073	1	rs10955222	ENSG00000260318.1	COX6CP1	-18.45	7.28e-58	2.19e-50	-1.19	-0.64	Glucose homeostasis traits;	chr8:99875122	chr16:11903923~11904137:-
LUAD	trans	rs9611565	0.512	rs139561	ENSG00000268568.1	AC007228.9	18.41	1.09e-57	3.25e-50	1.03	0.64	Vitiligo;	chr22:41799406	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.84	rs2234052	ENSG00000268568.1	AC007228.9	-18.4	1.28e-57	3.83e-50	-0.91	-0.64	Vitiligo;	chr22:41381237	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.84	rs9607799	ENSG00000268568.1	AC007228.9	-18.4	1.28e-57	3.83e-50	-0.91	-0.64	Vitiligo;	chr22:41381554	chr19:56672574~56673901:-
LUAD	trans	rs2950393	0.895	rs2926740	ENSG00000121089.4	NACA3P	18.39	1.44e-57	4.26e-50	0.81	0.64	Platelet distribution width;	chr12:56666751	chr4:164943290~164943937:+
LUAD	trans	rs928391	0.948	rs2735657	ENSG00000227183.3	HDGFP1	18.38	1.52e-57	4.52e-50	0.87	0.64	Platelet count;	chr1:156810514	chrX:131646639~131646890:+
LUAD	trans	rs7949030	0.754	rs36104523	ENSG00000186676.3	EEF1GP1	-18.38	1.61e-57	4.79e-50	-0.86	-0.64	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62628268	chr7:125033453~125035301:+
LUAD	trans	rs9611565	0.918	rs4822024	ENSG00000268568.1	AC007228.9	-18.33	2.62e-57	7.49e-50	-0.95	-0.64	Vitiligo;	chr22:41361643	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.512	rs139562	ENSG00000268568.1	AC007228.9	-18.33	2.65e-57	7.57e-50	-1.04	-0.64	Vitiligo;	chr22:41800680	chr19:56672574~56673901:-
LUAD	trans	rs61990749	0.597	rs176943	ENSG00000235400.1	RP4-641G12.4	-18.33	2.67e-57	7.61e-50	-0.99	-0.64	Fibroblast growth factor basic levels;	chr14:77709454	chr1:78749073~78750659:+
LUAD	trans	rs61990749	0.544	rs11628888	ENSG00000235400.1	RP4-641G12.4	-18.31	3.21e-57	9.14e-50	-0.96	-0.64	Fibroblast growth factor basic levels;	chr14:77695163	chr1:78749073~78750659:+
LUAD	trans	rs61990749	0.597	rs11624101	ENSG00000235400.1	RP4-641G12.4	-18.31	3.43e-57	9.75e-50	-1	-0.64	Fibroblast growth factor basic levels;	chr14:77671716	chr1:78749073~78750659:+
LUAD	trans	rs9611565	0.503	rs5751156	ENSG00000268568.1	AC007228.9	18.3	3.7e-57	1.05e-49	1.03	0.64	Vitiligo;	chr22:41774021	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.512	rs6519289	ENSG00000268568.1	AC007228.9	18.3	3.7e-57	1.05e-49	1.03	0.64	Vitiligo;	chr22:41774428	chr19:56672574~56673901:-
LUAD	trans	rs5022636	0.631	rs6587562	ENSG00000180764.13	PIPSL	-18.3	3.74e-57	1.06e-49	-0.76	-0.64	Gut microbiota (functional units);	chr1:151273765	chr10:93958191~93961540:-
LUAD	trans	rs61990749	0.544	rs8003979	ENSG00000235400.1	RP4-641G12.4	18.29	3.85e-57	1.09e-49	0.99	0.64	Fibroblast growth factor basic levels;	chr14:77744947	chr1:78749073~78750659:+
LUAD	trans	rs61990749	0.597	rs8016416	ENSG00000235400.1	RP4-641G12.4	18.29	3.85e-57	1.09e-49	0.99	0.64	Fibroblast growth factor basic levels;	chr14:77746757	chr1:78749073~78750659:+
LUAD	trans	rs9611565	0.512	rs5758439	ENSG00000268568.1	AC007228.9	18.28	4.56e-57	1.28e-49	1.03	0.64	Vitiligo;	chr22:41735758	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.512	rs5751145	ENSG00000268568.1	AC007228.9	18.28	4.56e-57	1.28e-49	1.03	0.64	Vitiligo;	chr22:41737548	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.512	rs768414	ENSG00000268568.1	AC007228.9	18.28	4.56e-57	1.28e-49	1.03	0.64	Vitiligo;	chr22:41739747	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.512	rs8141103	ENSG00000268568.1	AC007228.9	18.28	4.56e-57	1.28e-49	1.03	0.64	Vitiligo;	chr22:41740926	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.512	rs5751147	ENSG00000268568.1	AC007228.9	18.28	4.56e-57	1.28e-49	1.03	0.64	Vitiligo;	chr22:41743050	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.512	rs5751148	ENSG00000268568.1	AC007228.9	18.28	4.56e-57	1.28e-49	1.03	0.64	Vitiligo;	chr22:41743074	chr19:56672574~56673901:-
LUAD	trans	rs727563	0.635	rs5751149	ENSG00000268568.1	AC007228.9	18.28	4.56e-57	1.28e-49	1.03	0.64	Crohn's disease;Inflammatory bowel disease;	chr22:41743497	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.512	rs9607842	ENSG00000268568.1	AC007228.9	-18.27	4.95e-57	1.39e-49	-1.02	-0.64	Vitiligo;	chr22:41796718	chr19:56672574~56673901:-
LUAD	trans	rs941207	0.526	rs12229457	ENSG00000121089.4	NACA3P	-18.27	5.22e-57	1.46e-49	-0.81	-0.64	Platelet count;	chr12:56639896	chr4:164943290~164943937:+
LUAD	trans	rs916888	0.773	rs199448	ENSG00000264070.1	DND1P1	18.25	6.02e-57	1.68e-49	0.96	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45585871~45586929:+
LUAD	trans	rs9611565	0.512	rs715498	ENSG00000268568.1	AC007228.9	18.25	6.47e-57	1.8e-49	1.03	0.64	Vitiligo;	chr22:41752463	chr19:56672574~56673901:-
LUAD	trans	rs928391	1	rs2644606	ENSG00000227183.3	HDGFP1	18.24	6.76e-57	1.88e-49	0.92	0.64	Platelet count;	chr1:156808053	chrX:131646639~131646890:+
LUAD	trans	rs13253073	1	rs13259066	ENSG00000260318.1	COX6CP1	18.24	6.95e-57	1.93e-49	1.22	0.64	Glucose homeostasis traits;	chr8:99889455	chr16:11903923~11904137:-
LUAD	trans	rs9611565	0.512	rs139573	ENSG00000268568.1	AC007228.9	-18.24	7.03e-57	1.95e-49	-1.04	-0.64	Vitiligo;	chr22:41818781	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.559	rs739136	ENSG00000268568.1	AC007228.9	-18.23	7.64e-57	2.12e-49	-1.03	-0.64	Vitiligo;	chr22:41704271	chr19:56672574~56673901:-
LUAD	trans	rs6477998	0.513	rs10981720	ENSG00000238072.1	RP11-305M3.2	18.23	7.77e-57	2.15e-49	1.01	0.64	Hematology traits;	chr9:113293831	chr7:129410113~129410370:-
LUAD	trans	rs9611565	0.512	rs139566	ENSG00000268568.1	AC007228.9	-18.23	7.84e-57	2.17e-49	-1.04	-0.64	Vitiligo;	chr22:41803273	chr19:56672574~56673901:-
LUAD	trans	rs12709013	0.591	rs30842	ENSG00000230849.2	GOT2P2	-18.22	8.28e-57	2.29e-49	-0.84	-0.64	Blood metabolite ratios;	chr16:58709550	chr1:173141100~173142350:-
LUAD	trans	rs9611565	0.512	rs1983576	ENSG00000268568.1	AC007228.9	18.22	8.73e-57	2.41e-49	1.03	0.64	Vitiligo;	chr22:41770482	chr19:56672574~56673901:-
LUAD	trans	rs941207	0.526	rs2950390	ENSG00000121089.4	NACA3P	18.22	8.88e-57	2.45e-49	0.8	0.64	Platelet count;	chr12:56661507	chr4:164943290~164943937:+
LUAD	trans	rs9611565	0.512	rs4820446	ENSG00000268568.1	AC007228.9	-18.22	8.94e-57	2.46e-49	-1.04	-0.64	Vitiligo;	chr22:41819680	chr19:56672574~56673901:-
LUAD	trans	rs13253073	1	rs34029308	ENSG00000260318.1	COX6CP1	18.2	1.06e-56	2.92e-49	1.19	0.64	Glucose homeostasis traits;	chr8:99892425	chr16:11903923~11904137:-
LUAD	trans	rs13253073	1	rs35935983	ENSG00000260318.1	COX6CP1	18.2	1.07e-56	2.93e-49	1.18	0.64	Glucose homeostasis traits;	chr8:99888966	chr16:11903923~11904137:-
LUAD	trans	rs941207	0.542	rs12370142	ENSG00000121089.4	NACA3P	-18.19	1.15e-56	3.15e-49	-0.85	-0.64	Platelet count;	chr12:56790801	chr4:164943290~164943937:+
LUAD	trans	rs12367822	0.956	rs9706160	ENSG00000121089.4	NACA3P	-18.19	1.15e-56	3.15e-49	-0.85	-0.64	Platelet aggregation;	chr12:56791119	chr4:164943290~164943937:+
LUAD	trans	rs9611565	0.512	rs4820444	ENSG00000268568.1	AC007228.9	18.18	1.29e-56	3.5e-49	1.04	0.64	Vitiligo;	chr22:41806602	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.512	rs139560	ENSG00000268568.1	AC007228.9	-18.18	1.29e-56	3.51e-49	-1.03	-0.64	Vitiligo;	chr22:41798958	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.559	rs132765	ENSG00000268568.1	AC007228.9	18.17	1.47e-56	3.99e-49	1.03	0.64	Vitiligo;	chr22:41612064	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.512	rs964899	ENSG00000268568.1	AC007228.9	18.17	1.5e-56	4.06e-49	1.02	0.64	Vitiligo;	chr22:41746382	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.512	rs4512	ENSG00000268568.1	AC007228.9	-18.16	1.61e-56	4.3e-49	-1.05	-0.64	Vitiligo;	chr22:41810080	chr19:56672574~56673901:-
LUAD	trans	rs916888	0.687	rs199456	ENSG00000264070.1	DND1P1	18.16	1.65e-56	4.39e-49	0.99	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45585871~45586929:+
LUAD	trans	rs2950393	0.927	rs11171914	ENSG00000121089.4	NACA3P	-18.16	1.71e-56	4.56e-49	-0.8	-0.64	Platelet distribution width;	chr12:56649462	chr4:164943290~164943937:+
LUAD	trans	rs916888	0.773	rs199534	ENSG00000264070.1	DND1P1	18.13	2.22e-56	5.91e-49	0.99	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45585871~45586929:+
LUAD	trans	rs9611565	0.546	rs739132	ENSG00000268568.1	AC007228.9	18.13	2.33e-56	6.14e-49	1.03	0.64	Vitiligo;	chr22:41727095	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.512	rs5758436	ENSG00000268568.1	AC007228.9	18.13	2.33e-56	6.14e-49	1.03	0.64	Vitiligo;	chr22:41728261	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.512	rs7291736	ENSG00000268568.1	AC007228.9	18.13	2.33e-56	6.14e-49	1.03	0.64	Vitiligo;	chr22:41728870	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.512	rs2050033	ENSG00000268568.1	AC007228.9	18.13	2.39e-56	6.28e-49	1.03	0.64	Vitiligo;	chr22:41763225	chr19:56672574~56673901:-
LUAD	trans	rs727563	0.593	rs5758461	ENSG00000268568.1	AC007228.9	18.13	2.39e-56	6.28e-49	1.03	0.64	Crohn's disease;Inflammatory bowel disease;	chr22:41766185	chr19:56672574~56673901:-
LUAD	trans	rs727563	0.635	rs2899348	ENSG00000268568.1	AC007228.9	18.13	2.39e-56	6.28e-49	1.03	0.64	Crohn's disease;Inflammatory bowel disease;	chr22:41768512	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.512	rs2899349	ENSG00000268568.1	AC007228.9	18.13	2.39e-56	6.28e-49	1.03	0.64	Vitiligo;	chr22:41768656	chr19:56672574~56673901:-
LUAD	trans	rs7554547	0.871	rs6661289	ENSG00000261819.1	RP11-680G24.4	18.12	2.44e-56	6.41e-49	0.81	0.64	Nonsyndromic cleft lip with cleft palate;	chr1:11882724	chr16:14988259~14990160:-
LUAD	trans	rs928391	1	rs3765787	ENSG00000227183.3	HDGFP1	-18.12	2.45e-56	6.44e-49	-0.91	-0.64	Platelet count;	chr1:156784673	chrX:131646639~131646890:+
LUAD	trans	rs9611565	0.802	rs4822028	ENSG00000268568.1	AC007228.9	-18.12	2.48e-56	6.51e-49	-0.9	-0.64	Vitiligo;	chr22:41393404	chr19:56672574~56673901:-
LUAD	trans	rs941207	0.526	rs2950393	ENSG00000121089.4	NACA3P	-18.12	2.6e-56	6.83e-49	-0.8	-0.64	Platelet count;	chr12:56642239	chr4:164943290~164943937:+
LUAD	trans	rs9611565	0.592	rs12484467	ENSG00000268568.1	AC007228.9	-18.12	2.67e-56	7e-49	-1.05	-0.64	Vitiligo;	chr22:41561606	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.503	rs5996062	ENSG00000268568.1	AC007228.9	18.11	2.98e-56	7.81e-49	1.03	0.64	Vitiligo;	chr22:41771460	chr19:56672574~56673901:-
LUAD	trans	rs727563	0.638	rs4820443	ENSG00000268568.1	AC007228.9	-18.1	3.27e-56	8.54e-49	-1.01	-0.64	Crohn's disease;Inflammatory bowel disease;	chr22:41797909	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.512	rs9611672	ENSG00000268568.1	AC007228.9	-18.09	3.55e-56	9.25e-49	-1.05	-0.64	Vitiligo;	chr22:41813918	chr19:56672574~56673901:-
LUAD	trans	rs941207	0.526	rs11171916	ENSG00000121089.4	NACA3P	-18.09	3.63e-56	9.47e-49	-0.8	-0.64	Platelet count;	chr12:56653236	chr4:164943290~164943937:+
LUAD	trans	rs9611565	0.512	rs6002474	ENSG00000268568.1	AC007228.9	18.09	3.67e-56	9.56e-49	1.03	0.64	Vitiligo;	chr22:41772177	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.512	rs5996063	ENSG00000268568.1	AC007228.9	18.09	3.67e-56	9.56e-49	1.03	0.64	Vitiligo;	chr22:41772763	chr19:56672574~56673901:-
LUAD	trans	rs727563	0.638	rs5996058	ENSG00000268568.1	AC007228.9	18.07	4.31e-56	1.12e-48	1.02	0.64	Crohn's disease;Inflammatory bowel disease;	chr22:41745448	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.512	rs5758450	ENSG00000268568.1	AC007228.9	18.07	4.31e-56	1.12e-48	1.02	0.64	Vitiligo;	chr22:41745636	chr19:56672574~56673901:-
LUAD	trans	rs916888	0.773	rs199457	ENSG00000264070.1	DND1P1	18.06	4.78e-56	1.24e-48	0.98	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45585871~45586929:+
LUAD	trans	rs4822044	0.56	rs7284839	ENSG00000268568.1	AC007228.9	18.06	5.06e-56	1.31e-48	1.02	0.64	Cannabis dependence symptom count;	chr22:41614898	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.592	rs5751139	ENSG00000268568.1	AC007228.9	18.05	5.47e-56	1.41e-48	1.02	0.64	Vitiligo;	chr22:41703977	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.559	rs5758428	ENSG00000268568.1	AC007228.9	18.05	5.47e-56	1.41e-48	1.02	0.64	Vitiligo;	chr22:41710212	chr19:56672574~56673901:-
LUAD	trans	rs727563	0.636	rs2413653	ENSG00000268568.1	AC007228.9	18.05	5.47e-56	1.41e-48	1.02	0.64	Crohn's disease;Inflammatory bowel disease;	chr22:41710992	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.545	rs5758432	ENSG00000268568.1	AC007228.9	18.05	5.47e-56	1.41e-48	1.02	0.64	Vitiligo;	chr22:41715689	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.546	rs739129	ENSG00000268568.1	AC007228.9	18.05	5.47e-56	1.41e-48	1.02	0.64	Vitiligo;	chr22:41722245	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.559	rs132768	ENSG00000268568.1	AC007228.9	18.04	5.85e-56	1.5e-48	1.02	0.64	Vitiligo;	chr22:41617519	chr19:56672574~56673901:-
LUAD	trans	rs13177918	0.798	rs12514700	ENSG00000213058.3	RP4-765C7.2	18.04	5.89e-56	1.51e-48	0.95	0.64	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr1:178411616~178411972:+
LUAD	trans	rs61990749	0.597	rs176971	ENSG00000235400.1	RP4-641G12.4	18.03	6.7e-56	1.72e-48	0.96	0.64	Fibroblast growth factor basic levels;	chr14:77725256	chr1:78749073~78750659:+
LUAD	trans	rs61990749	0.597	rs1048147	ENSG00000235400.1	RP4-641G12.4	-18.03	7.05e-56	1.81e-48	-0.97	-0.63	Fibroblast growth factor basic levels;	chr14:77673645	chr1:78749073~78750659:+
LUAD	trans	rs61990749	0.597	rs2267758	ENSG00000235400.1	RP4-641G12.4	-18.03	7.05e-56	1.81e-48	-0.97	-0.63	Fibroblast growth factor basic levels;	chr14:77681086	chr1:78749073~78750659:+
LUAD	trans	rs9611565	0.559	rs132761	ENSG00000268568.1	AC007228.9	18.01	8.09e-56	2.06e-48	1.02	0.63	Vitiligo;	chr22:41608367	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.729	rs137831	ENSG00000268568.1	AC007228.9	-18.01	8.28e-56	2.11e-48	-0.89	-0.63	Vitiligo;	chr22:41507809	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.729	rs132902	ENSG00000268568.1	AC007228.9	-18	9.21e-56	2.35e-48	-0.9	-0.63	Vitiligo;	chr22:41401754	chr19:56672574~56673901:-
LUAD	trans	rs12709013	0.574	rs839418	ENSG00000230849.2	GOT2P2	17.99	1.09e-55	2.76e-48	0.84	0.63	Blood metabolite ratios;	chr16:58705426	chr1:173141100~173142350:-
LUAD	trans	rs916888	0.773	rs199533	ENSG00000264070.1	DND1P1	17.98	1.12e-55	2.85e-48	0.99	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45585871~45586929:+
LUAD	trans	rs4822044	0.68	rs8138780	ENSG00000268568.1	AC007228.9	17.98	1.14e-55	2.9e-48	1.03	0.63	Cannabis dependence symptom count;	chr22:41701458	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.512	rs964898	ENSG00000268568.1	AC007228.9	-17.97	1.3e-55	3.3e-48	-1	-0.63	Vitiligo;	chr22:41746302	chr19:56672574~56673901:-
LUAD	trans	rs1816752	0.679	rs8181826	ENSG00000237917.1	PARP4P1	-17.97	1.3e-55	3.3e-48	-0.77	-0.63	Obesity-related traits;	chr13:24396570	chrY:26594851~26634652:-
LUAD	trans	rs9611565	0.559	rs132771	ENSG00000268568.1	AC007228.9	17.96	1.38e-55	3.48e-48	1.02	0.63	Vitiligo;	chr22:41629346	chr19:56672574~56673901:-
LUAD	trans	rs928391	1	rs928391	ENSG00000227183.3	HDGFP1	17.95	1.53e-55	3.85e-48	0.91	0.63	Platelet count;	chr1:156806925	chrX:131646639~131646890:+
LUAD	trans	rs13253073	1	rs13273257	ENSG00000260318.1	COX6CP1	17.95	1.68e-55	4.22e-48	1.21	0.63	Glucose homeostasis traits;	chr8:99852468	chr16:11903923~11904137:-
LUAD	trans	rs916888	0.773	rs169201	ENSG00000264070.1	DND1P1	17.92	2.09e-55	5.23e-48	0.99	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45585871~45586929:+
LUAD	trans	rs12709013	0.591	rs30841	ENSG00000230849.2	GOT2P2	17.92	2.27e-55	5.68e-48	0.84	0.63	Blood metabolite ratios;	chr16:58709819	chr1:173141100~173142350:-
LUAD	trans	rs9611565	0.512	rs9611667	ENSG00000268568.1	AC007228.9	-17.92	2.3e-55	5.76e-48	-1.02	-0.63	Vitiligo;	chr22:41791011	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.559	rs5751160	ENSG00000268568.1	AC007228.9	17.9	2.6e-55	6.49e-48	1.02	0.63	Vitiligo;	chr22:41779691	chr19:56672574~56673901:-
LUAD	trans	rs61990749	0.597	rs2299930	ENSG00000235400.1	RP4-641G12.4	-17.9	2.62e-55	6.53e-48	-0.95	-0.63	Fibroblast growth factor basic levels;	chr14:77697379	chr1:78749073~78750659:+
LUAD	trans	rs9611565	0.559	rs5758397	ENSG00000268568.1	AC007228.9	17.89	3.09e-55	7.69e-48	1.02	0.63	Vitiligo;	chr22:41623247	chr19:56672574~56673901:-
LUAD	trans	rs12709013	0.591	rs30840	ENSG00000230849.2	GOT2P2	17.88	3.42e-55	8.48e-48	0.84	0.63	Blood metabolite ratios;	chr16:58710165	chr1:173141100~173142350:-
LUAD	trans	rs9611565	0.559	rs4822048	ENSG00000268568.1	AC007228.9	-17.88	3.57e-55	8.84e-48	-1.05	-0.63	Vitiligo;	chr22:41592221	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.559	rs4822049	ENSG00000268568.1	AC007228.9	-17.88	3.57e-55	8.84e-48	-1.05	-0.63	Vitiligo;	chr22:41597492	chr19:56672574~56673901:-
LUAD	trans	rs61990749	0.597	rs3783980	ENSG00000235400.1	RP4-641G12.4	17.87	3.63e-55	8.97e-48	0.96	0.63	Fibroblast growth factor basic levels;	chr14:77753464	chr1:78749073~78750659:+
LUAD	trans	rs61990749	0.597	rs1477262	ENSG00000235400.1	RP4-641G12.4	17.87	3.63e-55	8.97e-48	0.96	0.63	Fibroblast growth factor basic levels;	chr14:77760310	chr1:78749073~78750659:+
LUAD	trans	rs61990749	0.544	rs176962	ENSG00000235400.1	RP4-641G12.4	17.86	4.23e-55	1.04e-47	0.96	0.63	Fibroblast growth factor basic levels;	chr14:77719167	chr1:78749073~78750659:+
LUAD	trans	rs9611565	0.57	rs12159188	ENSG00000268568.1	AC007228.9	17.86	4.37e-55	1.07e-47	0.93	0.63	Vitiligo;	chr22:41725121	chr19:56672574~56673901:-
LUAD	trans	rs61990749	0.597	rs6574391	ENSG00000235400.1	RP4-641G12.4	17.84	5.19e-55	1.27e-47	0.96	0.63	Fibroblast growth factor basic levels;	chr14:77741778	chr1:78749073~78750659:+
LUAD	trans	rs941207	0.542	rs11171978	ENSG00000121089.4	NACA3P	17.84	5.39e-55	1.32e-47	0.83	0.63	Platelet count;	chr12:56800015	chr4:164943290~164943937:+
LUAD	trans	rs9611565	0.512	rs5758465	ENSG00000268568.1	AC007228.9	17.82	6.53e-55	1.6e-47	1.02	0.63	Vitiligo;	chr22:41779310	chr19:56672574~56673901:-
LUAD	trans	rs916888	0.773	rs199451	ENSG00000264070.1	DND1P1	17.81	6.85e-55	1.67e-47	0.98	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45585871~45586929:+
LUAD	trans	rs5751150	1	rs5751150	ENSG00000268568.1	AC007228.9	17.8	8.31e-55	2.02e-47	1.03	0.63	Cannabis dependence symptom count;	chr22:41757288	chr19:56672574~56673901:-
LUAD	trans	rs727563	0.562	rs5758458	ENSG00000268568.1	AC007228.9	17.8	8.31e-55	2.02e-47	1.03	0.63	Crohn's disease;Inflammatory bowel disease;	chr22:41758128	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.512	rs2899347	ENSG00000268568.1	AC007228.9	17.8	8.31e-55	2.02e-47	1.03	0.63	Vitiligo;	chr22:41762200	chr19:56672574~56673901:-
LUAD	trans	rs727563	0.635	rs713988	ENSG00000268568.1	AC007228.9	17.8	8.31e-55	2.02e-47	1.03	0.63	Crohn's disease;Inflammatory bowel disease;	chr22:41763068	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.512	rs2050031	ENSG00000268568.1	AC007228.9	17.79	9.07e-55	2.2e-47	1.03	0.63	Vitiligo;	chr22:41756262	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.921	rs761366	ENSG00000268568.1	AC007228.9	-17.79	9.12e-55	2.21e-47	-0.94	-0.63	Vitiligo;	chr22:41348018	chr19:56672574~56673901:-
LUAD	trans	rs7121616	0.545	rs116414356	ENSG00000234176.1	HSPA8P1	17.79	9.14e-55	2.21e-47	0.81	0.63	Breast cancer;	chr11:123082611	chrX:121203182~121205014:-
LUAD	trans	rs727563	0.636	rs2187795	ENSG00000268568.1	AC007228.9	17.78	9.51e-55	2.3e-47	1.03	0.63	Crohn's disease;Inflammatory bowel disease;	chr22:41696221	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.512	rs45500192	ENSG00000268568.1	AC007228.9	-17.78	9.73e-55	2.35e-47	-1.03	-0.63	Vitiligo;	chr22:41781895	chr19:56672574~56673901:-
LUAD	trans	rs61990749	0.597	rs1008988	ENSG00000235400.1	RP4-641G12.4	17.77	1.06e-54	2.57e-47	0.96	0.63	Fibroblast growth factor basic levels;	chr14:77794452	chr1:78749073~78750659:+
LUAD	trans	rs928391	1	rs10157555	ENSG00000227183.3	HDGFP1	-17.77	1.08e-54	2.6e-47	-0.9	-0.63	Platelet count;	chr1:156802060	chrX:131646639~131646890:+
LUAD	trans	rs61990749	0.597	rs1477260	ENSG00000235400.1	RP4-641G12.4	17.77	1.09e-54	2.63e-47	0.96	0.63	Fibroblast growth factor basic levels;	chr14:77790475	chr1:78749073~78750659:+
LUAD	trans	rs9611565	0.918	rs9538	ENSG00000268568.1	AC007228.9	-17.77	1.11e-54	2.67e-47	-0.95	-0.63	Vitiligo;	chr22:41359853	chr19:56672574~56673901:-
LUAD	trans	rs941207	0.762	rs10450	ENSG00000121089.4	NACA3P	17.76	1.3e-54	3.13e-47	0.77	0.63	Platelet count;	chr12:56590822	chr4:164943290~164943937:+
LUAD	trans	rs12709013	0.569	rs30837	ENSG00000230849.2	GOT2P2	17.75	1.41e-54	3.37e-47	0.84	0.63	Blood metabolite ratios;	chr16:58711942	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.591	rs30834	ENSG00000230849.2	GOT2P2	17.75	1.41e-54	3.37e-47	0.84	0.63	Blood metabolite ratios;	chr16:58715394	chr1:173141100~173142350:-
LUAD	trans	rs9611565	0.765	rs727563	ENSG00000268568.1	AC007228.9	17.74	1.5e-54	3.59e-47	0.89	0.63	Vitiligo;	chr22:41471373	chr19:56672574~56673901:-
LUAD	trans	rs61990749	0.597	rs59848135	ENSG00000235400.1	RP4-641G12.4	-17.73	1.64e-54	3.92e-47	-0.99	-0.63	Fibroblast growth factor basic levels;	chr14:77662657	chr1:78749073~78750659:+
LUAD	trans	rs916888	0.773	rs1378358	ENSG00000264070.1	DND1P1	17.73	1.67e-54	3.99e-47	0.98	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45585871~45586929:+
LUAD	trans	rs9611565	0.512	rs9607841	ENSG00000268568.1	AC007228.9	-17.73	1.79e-54	4.25e-47	-1.02	-0.63	Vitiligo;	chr22:41790834	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.592	rs8779	ENSG00000268568.1	AC007228.9	17.72	1.82e-54	4.31e-47	1.02	0.63	Vitiligo;	chr22:41674272	chr19:56672574~56673901:-
LUAD	trans	rs727563	0.594	rs132807	ENSG00000268568.1	AC007228.9	17.72	1.82e-54	4.31e-47	1.02	0.63	Crohn's disease;Inflammatory bowel disease;	chr22:41675580	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.592	rs1811113	ENSG00000268568.1	AC007228.9	17.72	1.82e-54	4.31e-47	1.02	0.63	Vitiligo;	chr22:41677130	chr19:56672574~56673901:-
LUAD	trans	rs727563	0.594	rs5758408	ENSG00000268568.1	AC007228.9	17.72	1.82e-54	4.31e-47	1.02	0.63	Crohn's disease;Inflammatory bowel disease;	chr22:41681733	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.559	rs5758412	ENSG00000268568.1	AC007228.9	17.72	1.82e-54	4.31e-47	1.02	0.63	Vitiligo;	chr22:41684799	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.559	rs13056262	ENSG00000268568.1	AC007228.9	17.72	1.82e-54	4.31e-47	1.02	0.63	Vitiligo;	chr22:41685917	chr19:56672574~56673901:-
LUAD	trans	rs61990749	0.597	rs117131659	ENSG00000235400.1	RP4-641G12.4	-17.72	1.89e-54	4.47e-47	-0.98	-0.63	Fibroblast growth factor basic levels;	chr14:77664783	chr1:78749073~78750659:+
LUAD	trans	rs727563	0.608	rs2076200	ENSG00000268568.1	AC007228.9	-17.72	1.96e-54	4.62e-47	-1.04	-0.63	Crohn's disease;Inflammatory bowel disease;	chr22:41589952	chr19:56672574~56673901:-
LUAD	trans	rs727563	0.552	rs4822045	ENSG00000268568.1	AC007228.9	-17.72	1.96e-54	4.62e-47	-1.04	-0.63	Crohn's disease;Inflammatory bowel disease;	chr22:41589954	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.559	rs9611619	ENSG00000268568.1	AC007228.9	-17.72	1.96e-54	4.62e-47	-1.04	-0.63	Vitiligo;	chr22:41590710	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.592	rs4822046	ENSG00000268568.1	AC007228.9	-17.72	1.96e-54	4.62e-47	-1.04	-0.63	Vitiligo;	chr22:41591539	chr19:56672574~56673901:-
LUAD	trans	rs61990749	0.597	rs2032781	ENSG00000235400.1	RP4-641G12.4	17.71	2.04e-54	4.81e-47	0.95	0.63	Fibroblast growth factor basic levels;	chr14:77748532	chr1:78749073~78750659:+
LUAD	trans	rs941207	0.542	rs1813109	ENSG00000121089.4	NACA3P	-17.71	2.2e-54	5.17e-47	-0.84	-0.63	Platelet count;	chr12:56798079	chr4:164943290~164943937:+
LUAD	trans	rs727563	0.52	rs132773	ENSG00000268568.1	AC007228.9	17.7	2.48e-54	5.83e-47	1.02	0.63	Crohn's disease;Inflammatory bowel disease;	chr22:41635764	chr19:56672574~56673901:-
LUAD	trans	rs941207	0.542	rs4277148	ENSG00000121089.4	NACA3P	-17.69	2.58e-54	6.03e-47	-0.84	-0.63	Platelet count;	chr12:56787071	chr4:164943290~164943937:+
LUAD	trans	rs941207	0.542	rs2888095	ENSG00000121089.4	NACA3P	-17.69	2.58e-54	6.03e-47	-0.84	-0.63	Platelet count;	chr12:56793689	chr4:164943290~164943937:+
LUAD	trans	rs941207	0.542	rs2888096	ENSG00000121089.4	NACA3P	-17.69	2.58e-54	6.03e-47	-0.84	-0.63	Platelet count;	chr12:56793851	chr4:164943290~164943937:+
LUAD	trans	rs7554547	0.871	rs11588551	ENSG00000261819.1	RP11-680G24.4	-17.69	2.69e-54	6.29e-47	-0.8	-0.63	Nonsyndromic cleft lip with cleft palate;	chr1:11881879	chr16:14988259~14990160:-
LUAD	trans	rs61990749	0.597	rs9323650	ENSG00000235400.1	RP4-641G12.4	17.68	3.05e-54	7.1e-47	0.92	0.63	Fibroblast growth factor basic levels;	chr14:77683993	chr1:78749073~78750659:+
LUAD	trans	rs941207	0.542	rs7315786	ENSG00000121089.4	NACA3P	-17.64	4.44e-54	1.03e-46	-0.84	-0.63	Platelet count;	chr12:56801595	chr4:164943290~164943937:+
LUAD	trans	rs8010715	1	rs2236352	ENSG00000248988.1	RP11-815N9.2	17.64	4.52e-54	1.05e-46	0.83	0.63	IgG glycosylation;	chr14:24141524	chr4:159007119~159007835:+
LUAD	trans	rs13177918	0.798	rs12514700	ENSG00000224114.1	RP11-343H5.4	17.63	5.26e-54	1.21e-46	0.93	0.63	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr1:206695837~206696269:-
LUAD	trans	rs941207	0.542	rs6581106	ENSG00000121089.4	NACA3P	-17.62	5.39e-54	1.24e-46	-0.83	-0.63	Platelet count;	chr12:56796759	chr4:164943290~164943937:+
LUAD	trans	rs13177918	0.798	rs13182116	ENSG00000213058.3	RP4-765C7.2	-17.62	5.57e-54	1.28e-46	-0.94	-0.63	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr1:178411616~178411972:+
LUAD	trans	rs941207	0.542	rs7311381	ENSG00000121089.4	NACA3P	-17.61	6.14e-54	1.41e-46	-0.83	-0.63	Platelet count;	chr12:56800286	chr4:164943290~164943937:+
LUAD	trans	rs9611565	0.921	rs3927	ENSG00000268568.1	AC007228.9	-17.61	6.34e-54	1.45e-46	-0.92	-0.63	Vitiligo;	chr22:41326860	chr19:56672574~56673901:-
LUAD	trans	rs12291225	0.535	rs11023203	ENSG00000236360.2	RP11-334A14.2	17.61	6.46e-54	1.48e-46	0.82	0.63	Sense of smell;	chr11:14388269	chr1:52993201~52993702:-
LUAD	trans	rs6708331	0.752	rs6721306	ENSG00000232654.1	FAM136BP	17.6	7.24e-54	1.65e-46	0.9	0.63	Obesity-related traits;	chr2:70190013	chr6:3045384~3045800:+
LUAD	trans	rs941207	0.542	rs1870674	ENSG00000121089.4	NACA3P	-17.59	7.88e-54	1.8e-46	-0.83	-0.63	Platelet count;	chr12:56805721	chr4:164943290~164943937:+
LUAD	trans	rs727563	0.635	rs5751141	ENSG00000268568.1	AC007228.9	17.58	8.16e-54	1.86e-46	0.99	0.63	Crohn's disease;Inflammatory bowel disease;	chr22:41711741	chr19:56672574~56673901:-
LUAD	trans	rs941207	0.542	rs6581107	ENSG00000121089.4	NACA3P	-17.58	8.24e-54	1.87e-46	-0.83	-0.63	Platelet count;	chr12:56801197	chr4:164943290~164943937:+
LUAD	trans	rs941207	0.542	rs11171980	ENSG00000121089.4	NACA3P	-17.56	1.07e-53	2.41e-46	-0.83	-0.63	Platelet count;	chr12:56806397	chr4:164943290~164943937:+
LUAD	trans	rs941207	0.542	rs12367339	ENSG00000121089.4	NACA3P	-17.56	1.07e-53	2.41e-46	-0.83	-0.63	Platelet count;	chr12:56809521	chr4:164943290~164943937:+
LUAD	trans	rs12709013	0.591	rs30838	ENSG00000230849.2	GOT2P2	17.55	1.15e-53	2.6e-46	0.84	0.62	Blood metabolite ratios;	chr16:58711513	chr1:173141100~173142350:-
LUAD	trans	rs9611565	0.592	rs4822044	ENSG00000268568.1	AC007228.9	-17.55	1.2e-53	2.71e-46	-1.04	-0.62	Vitiligo;	chr22:41583664	chr19:56672574~56673901:-
LUAD	trans	rs941207	0.542	rs11171979	ENSG00000121089.4	NACA3P	-17.55	1.24e-53	2.81e-46	-0.82	-0.62	Platelet count;	chr12:56802199	chr4:164943290~164943937:+
LUAD	trans	rs9611565	0.918	rs73176685	ENSG00000268568.1	AC007228.9	-17.53	1.51e-53	3.39e-46	-0.87	-0.62	Vitiligo;	chr22:41385090	chr19:56672574~56673901:-
LUAD	trans	rs941207	0.542	rs6581102	ENSG00000121089.4	NACA3P	-17.5	2.12e-53	4.73e-46	-0.83	-0.62	Platelet count;	chr12:56790632	chr4:164943290~164943937:+
LUAD	trans	rs941207	0.542	rs6581103	ENSG00000121089.4	NACA3P	-17.5	2.12e-53	4.73e-46	-0.83	-0.62	Platelet count;	chr12:56790641	chr4:164943290~164943937:+
LUAD	trans	rs2950393	0.804	rs1026565	ENSG00000121089.4	NACA3P	17.47	2.69e-53	5.99e-46	0.75	0.62	Platelet distribution width;	chr12:56744044	chr4:164943290~164943937:+
LUAD	trans	rs916888	0.779	rs199528	ENSG00000264070.1	DND1P1	17.47	2.72e-53	6.04e-46	0.98	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45585871~45586929:+
LUAD	trans	rs916888	0.821	rs199525	ENSG00000264070.1	DND1P1	17.47	2.72e-53	6.04e-46	0.98	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45585871~45586929:+
LUAD	trans	rs9611565	0.512	rs132767	ENSG00000268568.1	AC007228.9	-17.47	2.78e-53	6.19e-46	-1	-0.62	Vitiligo;	chr22:41613516	chr19:56672574~56673901:-
LUAD	trans	rs61990749	0.597	rs9788540	ENSG00000235400.1	RP4-641G12.4	-17.46	3.02e-53	6.71e-46	-0.95	-0.62	Fibroblast growth factor basic levels;	chr14:77665829	chr1:78749073~78750659:+
LUAD	trans	rs9611565	0.729	rs12165508	ENSG00000268568.1	AC007228.9	17.45	3.37e-53	7.46e-46	0.88	0.62	Vitiligo;	chr22:41423956	chr19:56672574~56673901:-
LUAD	trans	rs916888	0.773	rs199447	ENSG00000264070.1	DND1P1	17.42	4.62e-53	1.02e-45	0.99	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45585871~45586929:+
LUAD	trans	rs12291225	0.839	rs4757244	ENSG00000236360.2	RP11-334A14.2	-17.42	4.89e-53	1.08e-45	-0.82	-0.62	Sense of smell;	chr11:14237109	chr1:52993201~52993702:-
LUAD	trans	rs61990749	0.597	rs10148373	ENSG00000235400.1	RP4-641G12.4	17.42	4.96e-53	1.09e-45	0.98	0.62	Fibroblast growth factor basic levels;	chr14:77813856	chr1:78749073~78750659:+
LUAD	trans	rs9611565	0.921	rs6002333	ENSG00000268568.1	AC007228.9	-17.41	5.05e-53	1.11e-45	-0.92	-0.62	Vitiligo;	chr22:41323465	chr19:56672574~56673901:-
LUAD	trans	rs61990749	0.597	rs176946	ENSG00000235400.1	RP4-641G12.4	17.41	5.51e-53	1.21e-45	0.94	0.62	Fibroblast growth factor basic levels;	chr14:77712096	chr1:78749073~78750659:+
LUAD	trans	rs941207	0.542	rs12366897	ENSG00000121089.4	NACA3P	-17.4	5.63e-53	1.23e-45	-0.83	-0.62	Platelet count;	chr12:56808329	chr4:164943290~164943937:+
LUAD	trans	rs941207	0.542	rs12367312	ENSG00000121089.4	NACA3P	-17.4	5.63e-53	1.23e-45	-0.83	-0.62	Platelet count;	chr12:56809369	chr4:164943290~164943937:+
LUAD	trans	rs941207	0.542	rs12367822	ENSG00000121089.4	NACA3P	-17.4	5.63e-53	1.23e-45	-0.83	-0.62	Platelet count;	chr12:56810376	chr4:164943290~164943937:+
LUAD	trans	rs727563	0.593	rs132770	ENSG00000268568.1	AC007228.9	17.4	5.86e-53	1.28e-45	1	0.62	Crohn's disease;Inflammatory bowel disease;	chr22:41621260	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.513	rs739135	ENSG00000268568.1	AC007228.9	17.39	6.5e-53	1.42e-45	1.02	0.62	Vitiligo;	chr22:41694065	chr19:56672574~56673901:-
LUAD	trans	rs55665837	0.524	rs2882128	ENSG00000236360.2	RP11-334A14.2	17.37	8.55e-53	1.86e-45	0.82	0.62	Vitamin D levels;	chr11:14393088	chr1:52993201~52993702:-
LUAD	trans	rs9467773	0.62	rs2101582	ENSG00000242375.1	RP11-498P14.3	17.36	8.83e-53	1.92e-45	0.79	0.62	Intelligence (multi-trait analysis);	chr6:26622506	chr9:97195351~97197687:-
LUAD	trans	rs12709013	0.636	rs1646268	ENSG00000230849.2	GOT2P2	17.36	8.94e-53	1.94e-45	0.8	0.62	Blood metabolite ratios;	chr16:58743292	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.613	rs4238801	ENSG00000230849.2	GOT2P2	17.35	9.71e-53	2.1e-45	0.81	0.62	Blood metabolite ratios;	chr16:58738275	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.636	rs4575523	ENSG00000230849.2	GOT2P2	17.35	9.71e-53	2.1e-45	0.81	0.62	Blood metabolite ratios;	chr16:58738559	chr1:173141100~173142350:-
LUAD	trans	rs12291225	0.535	rs10832248	ENSG00000236360.2	RP11-334A14.2	17.35	1.04e-52	2.25e-45	0.82	0.62	Sense of smell;	chr11:14391541	chr1:52993201~52993702:-
LUAD	trans	rs9611565	0.625	rs12483991	ENSG00000268568.1	AC007228.9	-17.34	1.08e-52	2.34e-45	-0.9	-0.62	Vitiligo;	chr22:41539281	chr19:56672574~56673901:-
LUAD	trans	rs928391	1	rs2768766	ENSG00000227183.3	HDGFP1	17.34	1.11e-52	2.39e-45	0.89	0.62	Platelet count;	chr1:156805842	chrX:131646639~131646890:+
LUAD	trans	rs928391	1	rs928392	ENSG00000227183.3	HDGFP1	17.33	1.23e-52	2.65e-45	0.88	0.62	Platelet count;	chr1:156801024	chrX:131646639~131646890:+
LUAD	trans	rs12709013	0.646	rs8046154	ENSG00000230849.2	GOT2P2	-17.33	1.28e-52	2.75e-45	-0.81	-0.62	Blood metabolite ratios;	chr16:58773978	chr1:173141100~173142350:-
LUAD	trans	rs9467773	0.62	rs2504571	ENSG00000242375.1	RP11-498P14.3	17.32	1.36e-52	2.92e-45	0.8	0.62	Intelligence (multi-trait analysis);	chr6:26643207	chr9:97195351~97197687:-
LUAD	trans	rs13253073	0.941	rs13264726	ENSG00000260318.1	COX6CP1	17.32	1.4e-52	2.99e-45	1.21	0.62	Glucose homeostasis traits;	chr8:99851139	chr16:11903923~11904137:-
LUAD	trans	rs9611565	0.729	rs505533	ENSG00000268568.1	AC007228.9	17.31	1.63e-52	3.47e-45	0.87	0.62	Vitiligo;	chr22:41468212	chr19:56672574~56673901:-
LUAD	trans	rs61990749	0.686	rs11159288	ENSG00000235400.1	RP4-641G12.4	17.29	1.83e-52	3.9e-45	0.93	0.62	Fibroblast growth factor basic levels;	chr14:77750629	chr1:78749073~78750659:+
LUAD	trans	rs61990749	0.5	rs8011337	ENSG00000235400.1	RP4-641G12.4	17.29	1.95e-52	4.14e-45	0.94	0.62	Fibroblast growth factor basic levels;	chr14:77806283	chr1:78749073~78750659:+
LUAD	trans	rs55665837	0.583	rs78843135	ENSG00000236360.2	RP11-334A14.2	17.29	1.97e-52	4.19e-45	0.82	0.62	Vitamin D levels;	chr11:14389708	chr1:52993201~52993702:-
LUAD	trans	rs12709013	0.597	rs1616072	ENSG00000230849.2	GOT2P2	17.28	2.06e-52	4.36e-45	0.8	0.62	Blood metabolite ratios;	chr16:58747194	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.636	rs2575374	ENSG00000230849.2	GOT2P2	17.28	2.06e-52	4.36e-45	0.8	0.62	Blood metabolite ratios;	chr16:58747494	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.636	rs1646282	ENSG00000230849.2	GOT2P2	17.27	2.38e-52	5.02e-45	0.8	0.62	Blood metabolite ratios;	chr16:58741296	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.636	rs4784977	ENSG00000230849.2	GOT2P2	17.27	2.38e-52	5.02e-45	0.8	0.62	Blood metabolite ratios;	chr16:58742120	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.636	rs1657161	ENSG00000230849.2	GOT2P2	17.27	2.38e-52	5.02e-45	0.8	0.62	Blood metabolite ratios;	chr16:58743234	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.636	rs1646269	ENSG00000230849.2	GOT2P2	17.27	2.38e-52	5.02e-45	0.8	0.62	Blood metabolite ratios;	chr16:58743412	chr1:173141100~173142350:-
LUAD	trans	rs2950393	0.929	rs2290893	ENSG00000121089.4	NACA3P	17.27	2.39e-52	5.03e-45	0.75	0.62	Platelet distribution width;	chr12:56684836	chr4:164943290~164943937:+
LUAD	trans	rs9611565	0.625	rs2076199	ENSG00000268568.1	AC007228.9	-17.27	2.42e-52	5.1e-45	-0.86	-0.62	Vitiligo;	chr22:41507739	chr19:56672574~56673901:-
LUAD	trans	rs61990749	0.597	rs176955	ENSG00000235400.1	RP4-641G12.4	17.26	2.53e-52	5.32e-45	0.93	0.62	Fibroblast growth factor basic levels;	chr14:77714877	chr1:78749073~78750659:+
LUAD	trans	rs9467773	0.62	rs2494696	ENSG00000242375.1	RP11-498P14.3	17.26	2.78e-52	5.83e-45	0.8	0.62	Intelligence (multi-trait analysis);	chr6:26620666	chr9:97195351~97197687:-
LUAD	trans	rs9611565	0.765	rs132906	ENSG00000268568.1	AC007228.9	17.25	3.04e-52	6.37e-45	0.87	0.62	Vitiligo;	chr22:41403763	chr19:56672574~56673901:-
LUAD	trans	rs12709013	0.585	rs7188608	ENSG00000230849.2	GOT2P2	17.24	3.21e-52	6.72e-45	0.8	0.62	Blood metabolite ratios;	chr16:58736236	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.636	rs1657176	ENSG00000230849.2	GOT2P2	17.24	3.21e-52	6.72e-45	0.8	0.62	Blood metabolite ratios;	chr16:58736833	chr1:173141100~173142350:-
LUAD	trans	rs9611565	0.694	rs9611591	ENSG00000268568.1	AC007228.9	17.24	3.24e-52	6.77e-45	0.89	0.62	Vitiligo;	chr22:41434208	chr19:56672574~56673901:-
LUAD	trans	rs12709013	0.536	rs1646260	ENSG00000230849.2	GOT2P2	17.23	3.7e-52	7.69e-45	0.82	0.62	Blood metabolite ratios;	chr16:58734951	chr1:173141100~173142350:-
LUAD	trans	rs9467773	0.62	rs2451737	ENSG00000242375.1	RP11-498P14.3	17.22	4.2e-52	8.7e-45	0.8	0.62	Intelligence (multi-trait analysis);	chr6:26618813	chr9:97195351~97197687:-
LUAD	trans	rs9467773	0.596	rs2494693	ENSG00000242375.1	RP11-498P14.3	17.22	4.2e-52	8.7e-45	0.8	0.62	Intelligence (multi-trait analysis);	chr6:26618998	chr9:97195351~97197687:-
LUAD	trans	rs9467773	0.62	rs2494694	ENSG00000242375.1	RP11-498P14.3	17.22	4.2e-52	8.7e-45	0.8	0.62	Intelligence (multi-trait analysis);	chr6:26619100	chr9:97195351~97197687:-
LUAD	trans	rs2950393	0.794	rs1563897	ENSG00000121089.4	NACA3P	17.2	4.81e-52	9.93e-45	0.76	0.62	Platelet distribution width;	chr12:56699316	chr4:164943290~164943937:+
LUAD	trans	rs4822044	0.568	rs1883370	ENSG00000268568.1	AC007228.9	17.2	4.93e-52	1.02e-44	1	0.62	Cannabis dependence symptom count;	chr22:41747736	chr19:56672574~56673901:-
LUAD	trans	rs9467773	0.595	rs2451736	ENSG00000242375.1	RP11-498P14.3	17.2	5.02e-52	1.04e-44	0.8	0.62	Intelligence (multi-trait analysis);	chr6:26620316	chr9:97195351~97197687:-
LUAD	trans	rs13177918	0.798	rs13182116	ENSG00000224114.1	RP11-343H5.4	-17.2	5.21e-52	1.07e-44	-0.92	-0.62	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr1:206695837~206696269:-
LUAD	trans	rs2950393	0.929	rs7980835	ENSG00000121089.4	NACA3P	17.2	5.28e-52	1.09e-44	0.74	0.62	Platelet distribution width;	chr12:56676847	chr4:164943290~164943937:+
LUAD	trans	rs2950393	0.929	rs10747769	ENSG00000121089.4	NACA3P	17.2	5.28e-52	1.09e-44	0.74	0.62	Platelet distribution width;	chr12:56677056	chr4:164943290~164943937:+
LUAD	trans	rs13253073	1	rs12541837	ENSG00000260318.1	COX6CP1	-17.19	5.75e-52	1.18e-44	-1.2	-0.62	Glucose homeostasis traits;	chr8:99869645	chr16:11903923~11904137:-
LUAD	trans	rs916888	0.773	rs199439	ENSG00000264070.1	DND1P1	17.18	5.96e-52	1.23e-44	0.95	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45585871~45586929:+
LUAD	trans	rs9467773	0.62	rs2101581	ENSG00000242375.1	RP11-498P14.3	17.18	6.28e-52	1.29e-44	0.79	0.62	Intelligence (multi-trait analysis);	chr6:26622541	chr9:97195351~97197687:-
LUAD	trans	rs7949030	1	rs7949030	ENSG00000186676.3	EEF1GP1	17.17	6.86e-52	1.41e-44	0.81	0.62	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62627409	chr7:125033453~125035301:+
LUAD	trans	rs9611565	0.802	rs132916	ENSG00000268568.1	AC007228.9	17.16	7.44e-52	1.52e-44	0.86	0.62	Vitiligo;	chr22:41410764	chr19:56672574~56673901:-
LUAD	trans	rs2950393	0.857	rs9989034	ENSG00000121089.4	NACA3P	17.15	8.53e-52	1.74e-44	0.74	0.62	Platelet distribution width;	chr12:56674508	chr4:164943290~164943937:+
LUAD	trans	rs916888	0.773	rs199535	ENSG00000264070.1	DND1P1	17.14	9.65e-52	1.97e-44	0.95	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45585871~45586929:+
LUAD	trans	rs12709013	0.613	rs1657178	ENSG00000230849.2	GOT2P2	17.12	1.13e-51	2.29e-44	0.8	0.62	Blood metabolite ratios;	chr16:58735300	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.636	rs4538000	ENSG00000230849.2	GOT2P2	17.11	1.3e-51	2.64e-44	0.8	0.62	Blood metabolite ratios;	chr16:58744506	chr1:173141100~173142350:-
LUAD	trans	rs9611565	0.729	rs203320	ENSG00000268568.1	AC007228.9	-17.09	1.55e-51	3.13e-44	-0.86	-0.61	Vitiligo;	chr22:41517473	chr19:56672574~56673901:-
LUAD	trans	rs2950393	0.929	rs10876916	ENSG00000121089.4	NACA3P	17.09	1.58e-51	3.2e-44	0.76	0.61	Platelet distribution width;	chr12:56692728	chr4:164943290~164943937:+
LUAD	trans	rs13253073	0.941	rs4076509	ENSG00000260318.1	COX6CP1	17.09	1.69e-51	3.41e-44	1.2	0.61	Glucose homeostasis traits;	chr8:99842928	chr16:11903923~11904137:-
LUAD	trans	rs941207	0.542	rs2126068	ENSG00000121089.4	NACA3P	-17.08	1.77e-51	3.56e-44	-0.81	-0.61	Platelet count;	chr12:56804716	chr4:164943290~164943937:+
LUAD	trans	rs941207	0.542	rs67808059	ENSG00000121089.4	NACA3P	-17.08	1.77e-51	3.56e-44	-0.81	-0.61	Platelet count;	chr12:56805228	chr4:164943290~164943937:+
LUAD	trans	rs2950393	0.895	rs2958123	ENSG00000121089.4	NACA3P	17.07	1.96e-51	3.93e-44	0.74	0.61	Platelet distribution width;	chr12:56668441	chr4:164943290~164943937:+
LUAD	trans	rs916888	0.773	rs199439	ENSG00000214425.5	LRRC37A4P	-17.07	1.99e-51	4e-44	-0.91	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45506741~45550335:-
LUAD	trans	rs727563	0.635	rs5758444	ENSG00000268568.1	AC007228.9	17.04	2.81e-51	5.62e-44	0.96	0.61	Crohn's disease;Inflammatory bowel disease;	chr22:41737917	chr19:56672574~56673901:-
LUAD	trans	rs12291225	0.535	rs12806025	ENSG00000236360.2	RP11-334A14.2	17.04	2.88e-51	5.75e-44	0.81	0.61	Sense of smell;	chr11:14392271	chr1:52993201~52993702:-
LUAD	trans	rs10716881	1	rs10716881	ENSG00000121089.4	NACA3P	-17.03	2.93e-51	5.85e-44	-0.75	-0.61	High light scatter reticulocyte count;	chr12:56644387	chr4:164943290~164943937:+
LUAD	trans	rs12709013	0.636	rs72792430	ENSG00000230849.2	GOT2P2	-17.03	3.04e-51	6.05e-44	-0.8	-0.61	Blood metabolite ratios;	chr16:58746990	chr1:173141100~173142350:-
LUAD	trans	rs916888	0.773	rs538628	ENSG00000214425.5	LRRC37A4P	-17.03	3.06e-51	6.1e-44	-0.91	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45506741~45550335:-
LUAD	trans	rs12709013	0.537	rs1657167	ENSG00000230849.2	GOT2P2	17.02	3.29e-51	6.55e-44	0.8	0.61	Blood metabolite ratios;	chr16:58748955	chr1:173141100~173142350:-
LUAD	trans	rs9611565	0.729	rs202654	ENSG00000268568.1	AC007228.9	17.01	3.63e-51	7.21e-44	0.88	0.61	Vitiligo;	chr22:41445030	chr19:56672574~56673901:-
LUAD	trans	rs9467773	0.596	rs2451750	ENSG00000242375.1	RP11-498P14.3	17.01	3.85e-51	7.63e-44	0.79	0.61	Intelligence (multi-trait analysis);	chr6:26646351	chr9:97195351~97197687:-
LUAD	trans	rs9467773	0.596	rs2451751	ENSG00000242375.1	RP11-498P14.3	17.01	3.85e-51	7.63e-44	0.79	0.61	Intelligence (multi-trait analysis);	chr6:26646486	chr9:97195351~97197687:-
LUAD	trans	rs9467773	0.62	rs2504600	ENSG00000242375.1	RP11-498P14.3	17.01	3.85e-51	7.63e-44	0.79	0.61	Intelligence (multi-trait analysis);	chr6:26648106	chr9:97195351~97197687:-
LUAD	trans	rs9467773	0.62	rs2130657	ENSG00000242375.1	RP11-498P14.3	17.01	3.85e-51	7.63e-44	0.79	0.61	Intelligence (multi-trait analysis);	chr6:26650598	chr9:97195351~97197687:-
LUAD	trans	rs9467773	0.62	rs2498351	ENSG00000242375.1	RP11-498P14.3	17.01	3.85e-51	7.63e-44	0.79	0.61	Intelligence (multi-trait analysis);	chr6:26659414	chr9:97195351~97197687:-
LUAD	trans	rs9467773	0.62	rs2504566	ENSG00000242375.1	RP11-498P14.3	17.01	3.85e-51	7.63e-44	0.79	0.61	Intelligence (multi-trait analysis);	chr6:26660260	chr9:97195351~97197687:-
LUAD	trans	rs9467773	0.62	rs2494716	ENSG00000242375.1	RP11-498P14.3	17.01	3.85e-51	7.63e-44	0.79	0.61	Intelligence (multi-trait analysis);	chr6:26662508	chr9:97195351~97197687:-
LUAD	trans	rs916888	0.773	rs199457	ENSG00000214425.5	LRRC37A4P	-16.97	5.56e-51	1.09e-43	-0.92	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45506741~45550335:-
LUAD	trans	rs9611565	0.592	rs9611612	ENSG00000268568.1	AC007228.9	-16.96	6.4e-51	1.26e-43	-0.9	-0.61	Vitiligo;	chr22:41565185	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.918	rs4820438	ENSG00000268568.1	AC007228.9	-16.96	6.52e-51	1.28e-43	-0.87	-0.61	Vitiligo;	chr22:41371131	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.729	rs169362	ENSG00000268568.1	AC007228.9	16.96	6.54e-51	1.29e-43	0.87	0.61	Vitiligo;	chr22:41431585	chr19:56672574~56673901:-
LUAD	trans	rs2950393	0.929	rs2958155	ENSG00000121089.4	NACA3P	16.96	6.66e-51	1.31e-43	0.74	0.61	Platelet distribution width;	chr12:56670761	chr4:164943290~164943937:+
LUAD	trans	rs916888	0.773	rs199445	ENSG00000264070.1	DND1P1	16.95	6.95e-51	1.36e-43	0.95	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45585871~45586929:+
LUAD	trans	rs916888	0.773	rs199443	ENSG00000264070.1	DND1P1	16.95	6.95e-51	1.36e-43	0.95	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45585871~45586929:+
LUAD	trans	rs916888	0.773	rs1378358	ENSG00000214425.5	LRRC37A4P	-16.95	7.11e-51	1.39e-43	-0.92	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45506741~45550335:-
LUAD	trans	rs9611565	0.592	rs9611613	ENSG00000268568.1	AC007228.9	-16.95	7.14e-51	1.4e-43	-0.9	-0.61	Vitiligo;	chr22:41565827	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.559	rs12483860	ENSG00000268568.1	AC007228.9	-16.95	7.14e-51	1.4e-43	-0.9	-0.61	Vitiligo;	chr22:41565912	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.592	rs12484254	ENSG00000268568.1	AC007228.9	-16.95	7.14e-51	1.4e-43	-0.9	-0.61	Vitiligo;	chr22:41565999	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.559	rs7290990	ENSG00000268568.1	AC007228.9	-16.95	7.14e-51	1.4e-43	-0.9	-0.61	Vitiligo;	chr22:41568353	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.559	rs7290991	ENSG00000268568.1	AC007228.9	-16.95	7.14e-51	1.4e-43	-0.9	-0.61	Vitiligo;	chr22:41568357	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.592	rs5996037	ENSG00000268568.1	AC007228.9	-16.95	7.14e-51	1.4e-43	-0.9	-0.61	Vitiligo;	chr22:41569288	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.592	rs5996038	ENSG00000268568.1	AC007228.9	-16.95	7.14e-51	1.4e-43	-0.9	-0.61	Vitiligo;	chr22:41569296	chr19:56672574~56673901:-
LUAD	trans	rs13253073	1	rs6468694	ENSG00000260318.1	COX6CP1	16.95	7.29e-51	1.42e-43	1.23	0.61	Glucose homeostasis traits;	chr8:99853608	chr16:11903923~11904137:-
LUAD	trans	rs13253073	1	rs6986006	ENSG00000260318.1	COX6CP1	16.95	7.29e-51	1.42e-43	1.23	0.61	Glucose homeostasis traits;	chr8:99857251	chr16:11903923~11904137:-
LUAD	trans	rs9611565	0.921	rs8137373	ENSG00000268568.1	AC007228.9	16.94	7.84e-51	1.53e-43	0.88	0.61	Vitiligo;	chr22:41333212	chr19:56672574~56673901:-
LUAD	trans	rs12709013	0.636	rs1646272	ENSG00000230849.2	GOT2P2	16.94	8.07e-51	1.57e-43	0.79	0.61	Blood metabolite ratios;	chr16:58746508	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.66	rs1657163	ENSG00000230849.2	GOT2P2	16.94	8.07e-51	1.57e-43	0.79	0.61	Blood metabolite ratios;	chr16:58746688	chr1:173141100~173142350:-
LUAD	trans	rs916888	0.773	rs169201	ENSG00000214425.5	LRRC37A4P	-16.94	8.1e-51	1.58e-43	-0.92	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45506741~45550335:-
LUAD	trans	rs12709013	0.636	rs1595180	ENSG00000230849.2	GOT2P2	16.93	8.6e-51	1.67e-43	0.8	0.61	Blood metabolite ratios;	chr16:58770545	chr1:173141100~173142350:-
LUAD	trans	rs941207	0.542	rs11171983	ENSG00000121089.4	NACA3P	-16.93	8.71e-51	1.69e-43	-0.81	-0.61	Platelet count;	chr12:56814461	chr4:164943290~164943937:+
LUAD	trans	rs12709013	0.636	rs1657164	ENSG00000230849.2	GOT2P2	16.93	8.89e-51	1.73e-43	0.8	0.61	Blood metabolite ratios;	chr16:58747949	chr1:173141100~173142350:-
LUAD	trans	rs9467773	0.62	rs2494700	ENSG00000242375.1	RP11-498P14.3	16.92	9.56e-51	1.85e-43	0.8	0.61	Intelligence (multi-trait analysis);	chr6:26631078	chr9:97195351~97197687:-
LUAD	trans	rs9467773	0.584	rs1021372	ENSG00000242375.1	RP11-498P14.3	16.92	9.56e-51	1.85e-43	0.8	0.61	Intelligence (multi-trait analysis);	chr6:26632216	chr9:97195351~97197687:-
LUAD	trans	rs9467773	0.583	rs1021373	ENSG00000242375.1	RP11-498P14.3	16.92	9.56e-51	1.85e-43	0.8	0.61	Intelligence (multi-trait analysis);	chr6:26632229	chr9:97195351~97197687:-
LUAD	trans	rs9467773	0.62	rs2451744	ENSG00000242375.1	RP11-498P14.3	16.92	9.56e-51	1.85e-43	0.8	0.61	Intelligence (multi-trait analysis);	chr6:26633235	chr9:97195351~97197687:-
LUAD	trans	rs9467773	0.62	rs2494701	ENSG00000242375.1	RP11-498P14.3	16.92	9.56e-51	1.85e-43	0.8	0.61	Intelligence (multi-trait analysis);	chr6:26634204	chr9:97195351~97197687:-
LUAD	trans	rs9467773	0.62	rs1027204	ENSG00000242375.1	RP11-498P14.3	16.92	9.56e-51	1.85e-43	0.8	0.61	Intelligence (multi-trait analysis);	chr6:26639385	chr9:97195351~97197687:-
LUAD	trans	rs61990749	0.597	rs717683	ENSG00000235400.1	RP4-641G12.4	16.92	9.7e-51	1.87e-43	0.9	0.61	Fibroblast growth factor basic levels;	chr14:77789110	chr1:78749073~78750659:+
LUAD	trans	rs61990749	0.544	rs1477259	ENSG00000235400.1	RP4-641G12.4	16.92	9.7e-51	1.87e-43	0.9	0.61	Fibroblast growth factor basic levels;	chr14:77789795	chr1:78749073~78750659:+
LUAD	trans	rs61990749	0.597	rs10136053	ENSG00000235400.1	RP4-641G12.4	-16.92	1.02e-50	1.97e-43	-0.9	-0.61	Fibroblast growth factor basic levels;	chr14:77688862	chr1:78749073~78750659:+
LUAD	trans	rs12709013	0.591	rs9932967	ENSG00000230849.2	GOT2P2	16.92	1.03e-50	2e-43	0.81	0.61	Blood metabolite ratios;	chr16:58805583	chr1:173141100~173142350:-
LUAD	trans	rs9611565	0.592	rs4822040	ENSG00000268568.1	AC007228.9	-16.91	1.08e-50	2.08e-43	-0.9	-0.61	Vitiligo;	chr22:41567549	chr19:56672574~56673901:-
LUAD	trans	rs9467773	0.62	rs2451711	ENSG00000242375.1	RP11-498P14.3	16.91	1.09e-50	2.1e-43	0.79	0.61	Intelligence (multi-trait analysis);	chr6:26662882	chr9:97195351~97197687:-
LUAD	trans	rs2950393	0.804	rs2958127	ENSG00000121089.4	NACA3P	16.91	1.1e-50	2.13e-43	0.74	0.61	Platelet distribution width;	chr12:56720523	chr4:164943290~164943937:+
LUAD	trans	rs12709013	0.636	rs4499224	ENSG00000230849.2	GOT2P2	16.9	1.19e-50	2.29e-43	0.8	0.61	Blood metabolite ratios;	chr16:58770364	chr1:173141100~173142350:-
LUAD	trans	rs61990749	0.597	rs759808	ENSG00000235400.1	RP4-641G12.4	16.9	1.19e-50	2.29e-43	0.9	0.61	Fibroblast growth factor basic levels;	chr14:77784502	chr1:78749073~78750659:+
LUAD	trans	rs12709013	0.597	rs8051078	ENSG00000230849.2	GOT2P2	16.9	1.22e-50	2.34e-43	0.8	0.61	Blood metabolite ratios;	chr16:58774200	chr1:173141100~173142350:-
LUAD	trans	rs9467773	0.62	rs2451731	ENSG00000242375.1	RP11-498P14.3	16.89	1.33e-50	2.55e-43	0.8	0.61	Intelligence (multi-trait analysis);	chr6:26624594	chr9:97195351~97197687:-
LUAD	trans	rs9467773	0.62	rs9295701	ENSG00000242375.1	RP11-498P14.3	16.89	1.33e-50	2.55e-43	0.8	0.61	Intelligence (multi-trait analysis);	chr6:26627280	chr9:97195351~97197687:-
LUAD	trans	rs13177918	0.798	rs12514700	ENSG00000239528.1	RPS14P8	16.89	1.35e-50	2.59e-43	0.94	0.61	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr5:116562562~116562930:+
LUAD	trans	rs12709013	0.636	rs9937713	ENSG00000230849.2	GOT2P2	16.89	1.42e-50	2.72e-43	0.8	0.61	Blood metabolite ratios;	chr16:58771921	chr1:173141100~173142350:-
LUAD	trans	rs916888	0.773	rs538628	ENSG00000264070.1	DND1P1	16.88	1.49e-50	2.86e-43	0.93	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45585871~45586929:+
LUAD	trans	rs2950393	0.804	rs1466382	ENSG00000121089.4	NACA3P	-16.86	1.84e-50	3.51e-43	-0.73	-0.61	Platelet distribution width;	chr12:56723050	chr4:164943290~164943937:+
LUAD	trans	rs9467773	0.62	rs2504599	ENSG00000242375.1	RP11-498P14.3	16.86	1.91e-50	3.65e-43	0.79	0.61	Intelligence (multi-trait analysis);	chr6:26640832	chr9:97195351~97197687:-
LUAD	trans	rs9611565	0.729	rs203319	ENSG00000268568.1	AC007228.9	-16.84	2.27e-50	4.33e-43	-0.83	-0.61	Vitiligo;	chr22:41518589	chr19:56672574~56673901:-
LUAD	trans	rs941207	0.507	rs73337030	ENSG00000121089.4	NACA3P	-16.84	2.37e-50	4.51e-43	-0.74	-0.61	Platelet count;	chr12:56652410	chr4:164943290~164943937:+
LUAD	trans	rs941207	0.526	rs2255074	ENSG00000121089.4	NACA3P	-16.84	2.44e-50	4.64e-43	-0.75	-0.61	Platelet count;	chr12:56636242	chr4:164943290~164943937:+
LUAD	trans	rs12709013	0.591	rs2406234	ENSG00000230849.2	GOT2P2	16.84	2.44e-50	4.64e-43	0.81	0.61	Blood metabolite ratios;	chr16:58801840	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.591	rs2086206	ENSG00000230849.2	GOT2P2	16.84	2.44e-50	4.64e-43	0.81	0.61	Blood metabolite ratios;	chr16:58802094	chr1:173141100~173142350:-
LUAD	trans	rs2950393	0.804	rs1131514	ENSG00000121089.4	NACA3P	-16.83	2.46e-50	4.67e-43	-0.73	-0.61	Platelet distribution width;	chr12:56739356	chr4:164943290~164943937:+
LUAD	trans	rs9467773	0.62	rs2451732	ENSG00000242375.1	RP11-498P14.3	-16.83	2.48e-50	4.72e-43	-0.77	-0.61	Intelligence (multi-trait analysis);	chr6:26622676	chr9:97195351~97197687:-
LUAD	trans	rs12291225	0.535	rs16930126	ENSG00000236360.2	RP11-334A14.2	-16.83	2.51e-50	4.77e-43	-0.78	-0.61	Sense of smell;	chr11:14383437	chr1:52993201~52993702:-
LUAD	trans	rs9467773	0.62	rs2504540	ENSG00000242375.1	RP11-498P14.3	16.82	2.8e-50	5.3e-43	0.79	0.61	Intelligence (multi-trait analysis);	chr6:26641398	chr9:97195351~97197687:-
LUAD	trans	rs12709013	0.536	rs9930758	ENSG00000230849.2	GOT2P2	16.82	2.81e-50	5.32e-43	0.81	0.61	Blood metabolite ratios;	chr16:58803167	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.514	rs8062639	ENSG00000230849.2	GOT2P2	16.82	2.82e-50	5.34e-43	0.81	0.61	Blood metabolite ratios;	chr16:58800264	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.636	rs1865836	ENSG00000230849.2	GOT2P2	16.82	2.89e-50	5.47e-43	0.8	0.61	Blood metabolite ratios;	chr16:58768143	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.591	rs4410065	ENSG00000230849.2	GOT2P2	16.82	2.96e-50	5.6e-43	0.81	0.61	Blood metabolite ratios;	chr16:58800968	chr1:173141100~173142350:-
LUAD	trans	rs61990749	0.597	rs12896026	ENSG00000235400.1	RP4-641G12.4	16.8	3.38e-50	6.38e-43	0.89	0.61	Fibroblast growth factor basic levels;	chr14:77778093	chr1:78749073~78750659:+
LUAD	trans	rs61990749	0.544	rs12435761	ENSG00000235400.1	RP4-641G12.4	16.8	3.38e-50	6.38e-43	0.89	0.61	Fibroblast growth factor basic levels;	chr14:77779734	chr1:78749073~78750659:+
LUAD	trans	rs9611565	0.512	rs139572	ENSG00000268568.1	AC007228.9	-16.8	3.41e-50	6.43e-43	-0.99	-0.61	Vitiligo;	chr22:41818528	chr19:56672574~56673901:-
LUAD	trans	rs9467773	0.62	rs2451741	ENSG00000242375.1	RP11-498P14.3	16.8	3.47e-50	6.53e-43	0.79	0.61	Intelligence (multi-trait analysis);	chr6:26629176	chr9:97195351~97197687:-
LUAD	trans	rs61990749	0.597	rs176980	ENSG00000235400.1	RP4-641G12.4	-16.8	3.56e-50	6.7e-43	-0.89	-0.61	Fibroblast growth factor basic levels;	chr14:77732106	chr1:78749073~78750659:+
LUAD	trans	rs2950393	0.777	rs7966391	ENSG00000121089.4	NACA3P	16.8	3.69e-50	6.95e-43	0.74	0.61	Platelet distribution width;	chr12:56745272	chr4:164943290~164943937:+
LUAD	trans	rs12709013	0.636	rs1646281	ENSG00000230849.2	GOT2P2	16.79	3.84e-50	7.22e-43	0.81	0.61	Blood metabolite ratios;	chr16:58750512	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.613	rs8049462	ENSG00000230849.2	GOT2P2	16.79	3.84e-50	7.22e-43	0.81	0.61	Blood metabolite ratios;	chr16:58757654	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.66	rs257629	ENSG00000230849.2	GOT2P2	16.79	3.84e-50	7.22e-43	0.81	0.61	Blood metabolite ratios;	chr16:58758044	chr1:173141100~173142350:-
LUAD	trans	rs55665837	0.524	rs61884009	ENSG00000236360.2	RP11-334A14.2	16.79	4.06e-50	7.63e-43	0.82	0.61	Vitamin D levels;	chr11:14404916	chr1:52993201~52993702:-
LUAD	trans	rs9467773	0.62	rs2504565	ENSG00000242375.1	RP11-498P14.3	16.79	4.1e-50	7.69e-43	0.79	0.61	Intelligence (multi-trait analysis);	chr6:26656662	chr9:97195351~97197687:-
LUAD	trans	rs55665837	0.559	rs11023210	ENSG00000236360.2	RP11-334A14.2	-16.79	4.14e-50	7.77e-43	-0.81	-0.61	Vitamin D levels;	chr11:14401216	chr1:52993201~52993702:-
LUAD	trans	rs6477998	0.934	rs4979223	ENSG00000238072.1	RP11-305M3.2	16.78	4.23e-50	7.93e-43	0.81	0.61	Hematology traits;	chr9:113219836	chr7:129410113~129410370:-
LUAD	trans	rs916888	0.821	rs70600	ENSG00000264070.1	DND1P1	16.78	4.31e-50	8.09e-43	0.95	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45585871~45586929:+
LUAD	trans	rs5022636	0.896	rs4971032	ENSG00000180764.13	PIPSL	16.78	4.33e-50	8.11e-43	0.7	0.61	Gut microbiota (functional units);	chr1:151317948	chr10:93958191~93961540:-
LUAD	trans	rs12709013	0.613	rs1618602	ENSG00000230849.2	GOT2P2	16.78	4.4e-50	8.25e-43	0.81	0.61	Blood metabolite ratios;	chr16:58756080	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.636	rs8045466	ENSG00000230849.2	GOT2P2	16.78	4.4e-50	8.25e-43	0.81	0.61	Blood metabolite ratios;	chr16:58765113	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.561	rs1657174	ENSG00000230849.2	GOT2P2	16.78	4.45e-50	8.33e-43	0.8	0.61	Blood metabolite ratios;	chr16:58755139	chr1:173141100~173142350:-
LUAD	trans	rs2950393	0.804	rs10783796	ENSG00000121089.4	NACA3P	16.77	4.72e-50	8.83e-43	0.74	0.61	Platelet distribution width;	chr12:56733387	chr4:164943290~164943937:+
LUAD	trans	rs55665837	0.559	rs11023209	ENSG00000236360.2	RP11-334A14.2	16.77	4.98e-50	9.31e-43	0.81	0.61	Vitamin D levels;	chr11:14401054	chr1:52993201~52993702:-
LUAD	trans	rs12709013	0.636	rs1646279	ENSG00000230849.2	GOT2P2	16.76	5.36e-50	1e-42	0.8	0.61	Blood metabolite ratios;	chr16:58750235	chr1:173141100~173142350:-
LUAD	trans	rs941207	0.507	rs1107479	ENSG00000121089.4	NACA3P	-16.76	5.63e-50	1.05e-42	-0.75	-0.61	Platelet count;	chr12:56636902	chr4:164943290~164943937:+
LUAD	trans	rs2950393	0.929	rs7973157	ENSG00000121089.4	NACA3P	-16.75	5.74e-50	1.07e-42	-0.73	-0.61	Platelet distribution width;	chr12:56655409	chr4:164943290~164943937:+
LUAD	trans	rs9467773	0.62	rs2504592	ENSG00000242375.1	RP11-498P14.3	16.75	6.16e-50	1.15e-42	0.79	0.61	Intelligence (multi-trait analysis);	chr6:26640723	chr9:97195351~97197687:-
LUAD	trans	rs2950393	0.804	rs2958130	ENSG00000121089.4	NACA3P	16.75	6.19e-50	1.15e-42	0.74	0.61	Platelet distribution width;	chr12:56746722	chr4:164943290~164943937:+
LUAD	trans	rs9611565	0.918	rs28638318	ENSG00000268568.1	AC007228.9	-16.75	6.29e-50	1.17e-42	-0.92	-0.61	Vitiligo;	chr22:41357055	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.504	rs5758452	ENSG00000268568.1	AC007228.9	16.74	6.66e-50	1.23e-42	0.86	0.61	Vitiligo;	chr22:41748923	chr19:56672574~56673901:-
LUAD	trans	rs12709013	0.636	rs1646284	ENSG00000230849.2	GOT2P2	16.74	6.71e-50	1.25e-42	0.81	0.61	Blood metabolite ratios;	chr16:58752093	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.636	rs10852565	ENSG00000230849.2	GOT2P2	16.73	7.11e-50	1.32e-42	0.8	0.61	Blood metabolite ratios;	chr16:58771277	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.636	rs8054414	ENSG00000230849.2	GOT2P2	16.73	7.69e-50	1.41e-42	0.8	0.61	Blood metabolite ratios;	chr16:58749772	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.597	rs11076259	ENSG00000230849.2	GOT2P2	16.73	7.69e-50	1.41e-42	0.8	0.61	Blood metabolite ratios;	chr16:58749860	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.636	rs12325516	ENSG00000230849.2	GOT2P2	16.73	7.69e-50	1.41e-42	0.8	0.61	Blood metabolite ratios;	chr16:58749899	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.636	rs11076260	ENSG00000230849.2	GOT2P2	16.73	7.69e-50	1.41e-42	0.8	0.61	Blood metabolite ratios;	chr16:58749942	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.636	rs1646278	ENSG00000230849.2	GOT2P2	16.73	7.69e-50	1.41e-42	0.8	0.61	Blood metabolite ratios;	chr16:58750084	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.636	rs1646280	ENSG00000230849.2	GOT2P2	16.73	7.69e-50	1.41e-42	0.8	0.61	Blood metabolite ratios;	chr16:58750420	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.597	rs1646286	ENSG00000230849.2	GOT2P2	16.73	7.69e-50	1.41e-42	0.8	0.61	Blood metabolite ratios;	chr16:58752651	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.636	rs1624301	ENSG00000230849.2	GOT2P2	16.73	7.69e-50	1.41e-42	0.8	0.61	Blood metabolite ratios;	chr16:58753491	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.636	rs1626006	ENSG00000230849.2	GOT2P2	16.73	7.69e-50	1.41e-42	0.8	0.61	Blood metabolite ratios;	chr16:58753691	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.684	rs1646287	ENSG00000230849.2	GOT2P2	16.73	7.69e-50	1.41e-42	0.8	0.61	Blood metabolite ratios;	chr16:58753774	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.671	rs1369933	ENSG00000230849.2	GOT2P2	16.73	7.69e-50	1.41e-42	0.8	0.61	Blood metabolite ratios;	chr16:58753927	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.636	rs1369934	ENSG00000230849.2	GOT2P2	16.73	7.69e-50	1.41e-42	0.8	0.61	Blood metabolite ratios;	chr16:58754124	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.613	rs1646288	ENSG00000230849.2	GOT2P2	16.73	7.69e-50	1.41e-42	0.8	0.61	Blood metabolite ratios;	chr16:58755576	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.561	rs727484	ENSG00000230849.2	GOT2P2	16.73	7.69e-50	1.41e-42	0.8	0.61	Blood metabolite ratios;	chr16:58756568	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.636	rs257627	ENSG00000230849.2	GOT2P2	16.73	7.69e-50	1.41e-42	0.8	0.61	Blood metabolite ratios;	chr16:58758956	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.636	rs191783	ENSG00000230849.2	GOT2P2	16.73	7.69e-50	1.41e-42	0.8	0.61	Blood metabolite ratios;	chr16:58759994	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.636	rs257624	ENSG00000230849.2	GOT2P2	16.73	7.69e-50	1.41e-42	0.8	0.61	Blood metabolite ratios;	chr16:58760994	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.559	rs8060721	ENSG00000230849.2	GOT2P2	16.73	7.69e-50	1.41e-42	0.8	0.61	Blood metabolite ratios;	chr16:58765581	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.636	rs8044542	ENSG00000230849.2	GOT2P2	16.73	7.69e-50	1.41e-42	0.8	0.61	Blood metabolite ratios;	chr16:58765620	chr1:173141100~173142350:-
LUAD	trans	rs916888	0.687	rs199456	ENSG00000214425.5	LRRC37A4P	-16.72	8.18e-50	1.5e-42	-0.91	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45506741~45550335:-
LUAD	trans	rs12709013	0.591	rs6499980	ENSG00000230849.2	GOT2P2	16.7	1.01e-49	1.85e-42	0.8	0.61	Blood metabolite ratios;	chr16:58787972	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.591	rs899375	ENSG00000230849.2	GOT2P2	16.7	1.01e-49	1.85e-42	0.8	0.61	Blood metabolite ratios;	chr16:58792325	chr1:173141100~173142350:-
LUAD	trans	rs61990749	0.597	rs1006039	ENSG00000235400.1	RP4-641G12.4	-16.7	1.07e-49	1.95e-42	-0.92	-0.61	Fibroblast growth factor basic levels;	chr14:77796853	chr1:78749073~78750659:+
LUAD	trans	rs2950393	0.804	rs2035081	ENSG00000121089.4	NACA3P	16.7	1.08e-49	1.97e-42	0.73	0.61	Platelet distribution width;	chr12:56732095	chr4:164943290~164943937:+
LUAD	trans	rs916888	0.773	rs199451	ENSG00000214425.5	LRRC37A4P	-16.69	1.19e-49	2.16e-42	-0.91	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45506741~45550335:-
LUAD	trans	rs9611565	0.568	rs5758441	ENSG00000268568.1	AC007228.9	16.69	1.2e-49	2.17e-42	0.86	0.61	Vitiligo;	chr22:41736884	chr19:56672574~56673901:-
LUAD	trans	rs61990749	0.597	rs4632066	ENSG00000235400.1	RP4-641G12.4	-16.68	1.25e-49	2.26e-42	-0.89	-0.61	Fibroblast growth factor basic levels;	chr14:77780939	chr1:78749073~78750659:+
LUAD	trans	rs9611565	0.649	rs5758442	ENSG00000268568.1	AC007228.9	16.68	1.28e-49	2.31e-42	0.86	0.61	Vitiligo;	chr22:41737056	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.58	rs5758449	ENSG00000268568.1	AC007228.9	16.68	1.28e-49	2.31e-42	0.86	0.61	Vitiligo;	chr22:41744156	chr19:56672574~56673901:-
LUAD	trans	rs12709013	0.613	rs6499984	ENSG00000230849.2	GOT2P2	16.68	1.31e-49	2.37e-42	0.81	0.61	Blood metabolite ratios;	chr16:58810209	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.574	rs9302706	ENSG00000230849.2	GOT2P2	16.68	1.31e-49	2.37e-42	0.81	0.61	Blood metabolite ratios;	chr16:58812060	chr1:173141100~173142350:-
LUAD	trans	rs916888	0.773	rs199448	ENSG00000214425.5	LRRC37A4P	-16.68	1.32e-49	2.39e-42	-0.88	-0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45506741~45550335:-
LUAD	trans	rs61990749	0.597	rs2364584	ENSG00000235400.1	RP4-641G12.4	-16.67	1.38e-49	2.5e-42	-0.89	-0.61	Fibroblast growth factor basic levels;	chr14:77685943	chr1:78749073~78750659:+
LUAD	trans	rs2950393	0.804	rs898609	ENSG00000121089.4	NACA3P	16.67	1.46e-49	2.64e-42	0.73	0.61	Platelet distribution width;	chr12:56713026	chr4:164943290~164943937:+
LUAD	trans	rs2950393	0.804	rs4902	ENSG00000121089.4	NACA3P	16.67	1.46e-49	2.64e-42	0.73	0.61	Platelet distribution width;	chr12:56714419	chr4:164943290~164943937:+
LUAD	trans	rs2950393	0.804	rs2926748	ENSG00000121089.4	NACA3P	16.67	1.46e-49	2.64e-42	0.73	0.61	Platelet distribution width;	chr12:56715628	chr4:164943290~164943937:+
LUAD	trans	rs12709013	0.597	rs1657171	ENSG00000230849.2	GOT2P2	16.67	1.47e-49	2.65e-42	0.8	0.61	Blood metabolite ratios;	chr16:58752083	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.636	rs1646285	ENSG00000230849.2	GOT2P2	16.67	1.47e-49	2.65e-42	0.8	0.61	Blood metabolite ratios;	chr16:58752102	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.636	rs967852	ENSG00000230849.2	GOT2P2	16.65	1.68e-49	3.03e-42	0.81	0.6	Blood metabolite ratios;	chr16:58807313	chr1:173141100~173142350:-
LUAD	trans	rs9611565	0.546	rs132793	ENSG00000268568.1	AC007228.9	16.64	1.99e-49	3.58e-42	1	0.6	Vitiligo;	chr22:41667677	chr19:56672574~56673901:-
LUAD	trans	rs916888	0.773	rs199535	ENSG00000214425.5	LRRC37A4P	-16.64	2.01e-49	3.62e-42	-0.9	-0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45506741~45550335:-
LUAD	trans	rs9467773	0.62	rs2504567	ENSG00000242375.1	RP11-498P14.3	16.64	2.02e-49	3.64e-42	0.78	0.6	Intelligence (multi-trait analysis);	chr6:26662692	chr9:97195351~97197687:-
LUAD	trans	rs12709013	0.636	rs257628	ENSG00000230849.2	GOT2P2	16.63	2.16e-49	3.87e-42	0.79	0.6	Blood metabolite ratios;	chr16:58758924	chr1:173141100~173142350:-
LUAD	trans	rs9611565	0.694	rs4822032	ENSG00000268568.1	AC007228.9	-16.62	2.28e-49	4.09e-42	-0.85	-0.6	Vitiligo;	chr22:41529531	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.921	rs4822021	ENSG00000268568.1	AC007228.9	-16.62	2.5e-49	4.47e-42	-0.88	-0.6	Vitiligo;	chr22:41330049	chr19:56672574~56673901:-
LUAD	trans	rs9611565	1	rs9611565	ENSG00000268568.1	AC007228.9	-16.6	2.82e-49	5.04e-42	-0.86	-0.6	Vitiligo;	chr22:41371482	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.649	rs2413659	ENSG00000268568.1	AC007228.9	16.59	3.23e-49	5.76e-42	0.86	0.6	Vitiligo;	chr22:41768858	chr19:56672574~56673901:-
LUAD	trans	rs916888	0.773	rs199534	ENSG00000214425.5	LRRC37A4P	-16.59	3.36e-49	5.99e-42	-0.91	-0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45506741~45550335:-
LUAD	trans	rs941207	0.507	rs2958124	ENSG00000121089.4	NACA3P	-16.56	4.75e-49	8.42e-42	-0.74	-0.6	Platelet count;	chr12:56633837	chr4:164943290~164943937:+
LUAD	trans	rs12709013	0.574	rs35321124	ENSG00000230849.2	GOT2P2	16.55	4.94e-49	8.74e-42	0.8	0.6	Blood metabolite ratios;	chr16:58786561	chr1:173141100~173142350:-
LUAD	trans	rs941207	0.542	rs10876928	ENSG00000121089.4	NACA3P	-16.55	5.13e-49	9.07e-42	-0.78	-0.6	Platelet count;	chr12:56813646	chr4:164943290~164943937:+
LUAD	trans	rs61990749	0.544	rs176979	ENSG00000235400.1	RP4-641G12.4	16.55	5.27e-49	9.3e-42	0.89	0.6	Fibroblast growth factor basic levels;	chr14:77731729	chr1:78749073~78750659:+
LUAD	trans	rs2950393	0.777	rs12828563	ENSG00000121089.4	NACA3P	16.54	5.67e-49	1e-41	0.74	0.6	Platelet distribution width;	chr12:56709378	chr4:164943290~164943937:+
LUAD	trans	rs13177918	0.798	rs13182116	ENSG00000239528.1	RPS14P8	-16.54	5.77e-49	1.02e-41	-0.92	-0.6	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr5:116562562~116562930:+
LUAD	trans	rs9467773	0.62	rs1490488	ENSG00000242375.1	RP11-498P14.3	16.52	6.59e-49	1.16e-41	0.77	0.6	Intelligence (multi-trait analysis);	chr6:26614580	chr9:97195351~97197687:-
LUAD	trans	rs9467773	0.62	rs2494692	ENSG00000242375.1	RP11-498P14.3	16.52	6.59e-49	1.16e-41	0.77	0.6	Intelligence (multi-trait analysis);	chr6:26614995	chr9:97195351~97197687:-
LUAD	trans	rs2950393	0.804	rs11171951	ENSG00000121089.4	NACA3P	16.52	6.87e-49	1.21e-41	0.73	0.6	Platelet distribution width;	chr12:56718853	chr4:164943290~164943937:+
LUAD	trans	rs8010715	0.848	rs2277483	ENSG00000248988.1	RP11-815N9.2	16.52	7.23e-49	1.27e-41	0.78	0.6	IgG glycosylation;	chr14:24122683	chr4:159007119~159007835:+
LUAD	trans	rs916888	0.773	rs199445	ENSG00000214425.5	LRRC37A4P	-16.5	8.87e-49	1.56e-41	-0.9	-0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45506741~45550335:-
LUAD	trans	rs916888	0.773	rs199443	ENSG00000214425.5	LRRC37A4P	-16.5	8.87e-49	1.56e-41	-0.9	-0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45506741~45550335:-
LUAD	trans	rs1816752	0.669	rs9553309	ENSG00000237917.1	PARP4P1	-16.49	9.23e-49	1.62e-41	-0.72	-0.6	Obesity-related traits;	chr13:24471476	chrY:26594851~26634652:-
LUAD	trans	rs9611565	0.649	rs139559	ENSG00000268568.1	AC007228.9	-16.47	1.22e-48	2.13e-41	-0.84	-0.6	Vitiligo;	chr22:41795632	chr19:56672574~56673901:-
LUAD	trans	rs9467773	0.62	rs9467810	ENSG00000242375.1	RP11-498P14.3	16.45	1.5e-48	2.6e-41	0.77	0.6	Intelligence (multi-trait analysis);	chr6:26608033	chr9:97195351~97197687:-
LUAD	trans	rs9611565	0.559	rs6002408	ENSG00000268568.1	AC007228.9	-16.43	1.81e-48	3.14e-41	-0.9	-0.6	Vitiligo;	chr22:41571866	chr19:56672574~56673901:-
LUAD	trans	rs12709013	0.535	rs9924136	ENSG00000230849.2	GOT2P2	16.42	2.04e-48	3.53e-41	0.8	0.6	Blood metabolite ratios;	chr16:58779573	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.636	rs6499976	ENSG00000230849.2	GOT2P2	16.42	2.06e-48	3.56e-41	0.78	0.6	Blood metabolite ratios;	chr16:58770330	chr1:173141100~173142350:-
LUAD	trans	rs8010715	0.848	rs8009511	ENSG00000248988.1	RP11-815N9.2	16.41	2.1e-48	3.63e-41	0.77	0.6	IgG glycosylation;	chr14:24124771	chr4:159007119~159007835:+
LUAD	trans	rs8010715	0.804	rs1134334	ENSG00000248988.1	RP11-815N9.2	16.41	2.1e-48	3.63e-41	0.77	0.6	IgG glycosylation;	chr14:24124905	chr4:159007119~159007835:+
LUAD	trans	rs6477998	0.903	rs7041615	ENSG00000238072.1	RP11-305M3.2	16.41	2.16e-48	3.73e-41	0.8	0.6	Hematology traits;	chr9:113244747	chr7:129410113~129410370:-
LUAD	trans	rs2950393	0.804	rs3214051	ENSG00000121089.4	NACA3P	16.41	2.23e-48	3.85e-41	0.73	0.6	Platelet distribution width;	chr12:56725452	chr4:164943290~164943937:+
LUAD	trans	rs7554547	0.778	rs2008113	ENSG00000261819.1	RP11-680G24.4	-16.4	2.34e-48	4.03e-41	-0.73	-0.6	Nonsyndromic cleft lip with cleft palate;	chr1:11878809	chr16:14988259~14990160:-
LUAD	trans	rs916888	0.773	rs199533	ENSG00000214425.5	LRRC37A4P	-16.4	2.39e-48	4.1e-41	-0.9	-0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45506741~45550335:-
LUAD	trans	rs55665837	0.559	rs9667144	ENSG00000236360.2	RP11-334A14.2	-16.39	2.64e-48	4.53e-41	-0.8	-0.6	Vitamin D levels;	chr11:14399555	chr1:52993201~52993702:-
LUAD	trans	rs12709013	0.591	rs4784986	ENSG00000230849.2	GOT2P2	16.39	2.69e-48	4.62e-41	0.78	0.6	Blood metabolite ratios;	chr16:58803007	chr1:173141100~173142350:-
LUAD	trans	rs727563	0.565	rs132774	ENSG00000268568.1	AC007228.9	-16.38	2.94e-48	5.03e-41	-0.84	-0.6	Crohn's disease;Inflammatory bowel disease;	chr22:41635949	chr19:56672574~56673901:-
LUAD	trans	rs61990749	0.597	rs13379065	ENSG00000235400.1	RP4-641G12.4	-16.38	3.02e-48	5.15e-41	-0.89	-0.6	Fibroblast growth factor basic levels;	chr14:77674952	chr1:78749073~78750659:+
LUAD	trans	rs61990749	0.597	rs17106157	ENSG00000235400.1	RP4-641G12.4	-16.38	3.02e-48	5.15e-41	-0.89	-0.6	Fibroblast growth factor basic levels;	chr14:77680535	chr1:78749073~78750659:+
LUAD	trans	rs61990749	0.597	rs2267759	ENSG00000235400.1	RP4-641G12.4	-16.38	3.02e-48	5.15e-41	-0.89	-0.6	Fibroblast growth factor basic levels;	chr14:77681272	chr1:78749073~78750659:+
LUAD	trans	rs2950393	0.804	rs2926752	ENSG00000121089.4	NACA3P	16.38	3.14e-48	5.35e-41	0.73	0.6	Platelet distribution width;	chr12:56710144	chr4:164943290~164943937:+
LUAD	trans	rs2950393	0.777	rs2958148	ENSG00000121089.4	NACA3P	16.38	3.14e-48	5.35e-41	0.73	0.6	Platelet distribution width;	chr12:56710153	chr4:164943290~164943937:+
LUAD	trans	rs2950393	0.777	rs2926747	ENSG00000121089.4	NACA3P	16.38	3.18e-48	5.42e-41	0.72	0.6	Platelet distribution width;	chr12:56716147	chr4:164943290~164943937:+
LUAD	trans	rs12709013	0.576	rs2432622	ENSG00000230849.2	GOT2P2	16.37	3.28e-48	5.57e-41	0.79	0.6	Blood metabolite ratios;	chr16:58749681	chr1:173141100~173142350:-
LUAD	trans	rs61990749	0.597	rs11623088	ENSG00000235400.1	RP4-641G12.4	-16.37	3.33e-48	5.66e-41	-0.89	-0.6	Fibroblast growth factor basic levels;	chr14:77671392	chr1:78749073~78750659:+
LUAD	trans	rs12709013	0.591	rs7184377	ENSG00000230849.2	GOT2P2	16.37	3.39e-48	5.74e-41	0.81	0.6	Blood metabolite ratios;	chr16:58808765	chr1:173141100~173142350:-
LUAD	trans	rs4822044	0.617	rs13054514	ENSG00000268568.1	AC007228.9	16.37	3.4e-48	5.75e-41	0.85	0.6	Cannabis dependence symptom count;	chr22:41734379	chr19:56672574~56673901:-
LUAD	trans	rs2950393	0.804	rs2290894	ENSG00000121089.4	NACA3P	16.37	3.44e-48	5.82e-41	0.72	0.6	Platelet distribution width;	chr12:56714911	chr4:164943290~164943937:+
LUAD	trans	rs9467773	0.583	rs2498380	ENSG00000242375.1	RP11-498P14.3	-16.35	4.01e-48	6.76e-41	-0.77	-0.6	Intelligence (multi-trait analysis);	chr6:26643768	chr9:97195351~97197687:-
LUAD	trans	rs941207	0.542	rs1903370	ENSG00000121089.4	NACA3P	-16.35	4.02e-48	6.76e-41	-0.78	-0.6	Platelet count;	chr12:56812900	chr4:164943290~164943937:+
LUAD	trans	rs7554547	0.838	rs885770	ENSG00000261819.1	RP11-680G24.4	16.35	4.21e-48	7.07e-41	0.76	0.6	Nonsyndromic cleft lip with cleft palate;	chr1:11878699	chr16:14988259~14990160:-
LUAD	trans	rs8010715	0.52	rs12435994	ENSG00000248988.1	RP11-815N9.2	16.35	4.24e-48	7.12e-41	0.78	0.6	IgG glycosylation;	chr14:24120252	chr4:159007119~159007835:+
LUAD	trans	rs8010715	0.596	rs12435995	ENSG00000248988.1	RP11-815N9.2	16.35	4.24e-48	7.12e-41	0.78	0.6	IgG glycosylation;	chr14:24120255	chr4:159007119~159007835:+
LUAD	trans	rs61990749	0.597	rs2267768	ENSG00000235400.1	RP4-641G12.4	16.35	4.25e-48	7.13e-41	0.88	0.6	Fibroblast growth factor basic levels;	chr14:77749671	chr1:78749073~78750659:+
LUAD	trans	rs61990749	0.597	rs1549119	ENSG00000235400.1	RP4-641G12.4	16.35	4.25e-48	7.13e-41	0.88	0.6	Fibroblast growth factor basic levels;	chr14:77753469	chr1:78749073~78750659:+
LUAD	trans	rs61990749	0.597	rs1978416	ENSG00000235400.1	RP4-641G12.4	16.35	4.25e-48	7.13e-41	0.88	0.6	Fibroblast growth factor basic levels;	chr14:77761558	chr1:78749073~78750659:+
LUAD	trans	rs61990749	0.544	rs3759728	ENSG00000235400.1	RP4-641G12.4	16.35	4.25e-48	7.13e-41	0.88	0.6	Fibroblast growth factor basic levels;	chr14:77763816	chr1:78749073~78750659:+
LUAD	trans	rs1816752	0.716	rs9553330	ENSG00000237917.1	PARP4P1	-16.35	4.38e-48	7.35e-41	-0.72	-0.6	Obesity-related traits;	chr13:24516018	chrY:26594851~26634652:-
LUAD	trans	rs13253073	0.825	rs6984511	ENSG00000260318.1	COX6CP1	16.33	5.09e-48	8.51e-41	1.22	0.6	Glucose homeostasis traits;	chr8:99869513	chr16:11903923~11904137:-
LUAD	trans	rs12709013	0.601	rs2432621	ENSG00000230849.2	GOT2P2	16.32	5.47e-48	9.13e-41	0.78	0.6	Blood metabolite ratios;	chr16:58749676	chr1:173141100~173142350:-
LUAD	trans	rs9611565	0.592	rs80477	ENSG00000268568.1	AC007228.9	16.31	6.03e-48	1e-40	0.87	0.6	Vitiligo;	chr22:41605179	chr19:56672574~56673901:-
LUAD	trans	rs61990749	0.597	rs12887282	ENSG00000235400.1	RP4-641G12.4	16.31	6.7e-48	1.11e-40	0.88	0.6	Fibroblast growth factor basic levels;	chr14:77734242	chr1:78749073~78750659:+
LUAD	trans	rs61990749	0.597	rs12887606	ENSG00000235400.1	RP4-641G12.4	16.31	6.7e-48	1.11e-40	0.88	0.6	Fibroblast growth factor basic levels;	chr14:77734277	chr1:78749073~78750659:+
LUAD	trans	rs61990749	0.597	rs176952	ENSG00000235400.1	RP4-641G12.4	16.3	7.26e-48	1.2e-40	0.88	0.6	Fibroblast growth factor basic levels;	chr14:77714393	chr1:78749073~78750659:+
LUAD	trans	rs61990749	0.544	rs2544566	ENSG00000235400.1	RP4-641G12.4	16.3	7.26e-48	1.2e-40	0.88	0.6	Fibroblast growth factor basic levels;	chr14:77715395	chr1:78749073~78750659:+
LUAD	trans	rs61990749	0.544	rs2544567	ENSG00000235400.1	RP4-641G12.4	16.3	7.26e-48	1.2e-40	0.88	0.6	Fibroblast growth factor basic levels;	chr14:77715396	chr1:78749073~78750659:+
LUAD	trans	rs9611565	0.568	rs2413656	ENSG00000268568.1	AC007228.9	16.29	7.8e-48	1.29e-40	0.85	0.6	Vitiligo;	chr22:41733353	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.532	rs4401299	ENSG00000268568.1	AC007228.9	16.29	7.92e-48	1.31e-40	0.86	0.6	Vitiligo;	chr22:41760513	chr19:56672574~56673901:-
LUAD	trans	rs12709013	0.636	rs8060717	ENSG00000230849.2	GOT2P2	16.28	8.39e-48	1.39e-40	0.78	0.6	Blood metabolite ratios;	chr16:58765574	chr1:173141100~173142350:-
LUAD	trans	rs1816752	0.692	rs2282409	ENSG00000237917.1	PARP4P1	-16.26	1.06e-47	1.75e-40	-0.73	-0.6	Obesity-related traits;	chr13:24512388	chrY:26594851~26634652:-
LUAD	trans	rs9611565	0.592	rs5751129	ENSG00000268568.1	AC007228.9	16.26	1.13e-47	1.86e-40	0.85	0.6	Vitiligo;	chr22:41619761	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.649	rs2064189	ENSG00000268568.1	AC007228.9	16.25	1.16e-47	1.91e-40	0.84	0.6	Vitiligo;	chr22:41731995	chr19:56672574~56673901:-
LUAD	trans	rs61990749	0.597	rs28534379	ENSG00000235400.1	RP4-641G12.4	-16.25	1.24e-47	2.03e-40	-0.88	-0.6	Fibroblast growth factor basic levels;	chr14:77705797	chr1:78749073~78750659:+
LUAD	trans	rs61990749	0.597	rs176944	ENSG00000235400.1	RP4-641G12.4	-16.25	1.24e-47	2.03e-40	-0.88	-0.6	Fibroblast growth factor basic levels;	chr14:77709868	chr1:78749073~78750659:+
LUAD	trans	rs7121616	0.531	rs11218941	ENSG00000234176.1	HSPA8P1	16.24	1.39e-47	2.28e-40	0.76	0.59	Breast cancer;	chr11:123061701	chrX:121203182~121205014:-
LUAD	trans	rs3749237	0.595	rs12489092	ENSG00000197582.5	GPX1P1	16.23	1.44e-47	2.36e-40	0.74	0.59	Resting heart rate;	chr3:49513481	chrX:13378735~13379340:-
LUAD	trans	rs3749237	0.595	rs3870337	ENSG00000197582.5	GPX1P1	16.23	1.44e-47	2.36e-40	0.74	0.59	Resting heart rate;	chr3:49519662	chrX:13378735~13379340:-
LUAD	trans	rs5022636	1	rs4970948	ENSG00000180764.13	PIPSL	16.22	1.65e-47	2.7e-40	0.68	0.59	Gut microbiota (functional units);	chr1:151318767	chr10:93958191~93961540:-
LUAD	trans	rs3749237	0.595	rs4855839	ENSG00000197582.5	GPX1P1	16.21	1.74e-47	2.83e-40	0.75	0.59	Resting heart rate;	chr3:49470414	chrX:13378735~13379340:-
LUAD	trans	rs61990749	0.597	rs8003691	ENSG00000235400.1	RP4-641G12.4	16.21	1.76e-47	2.86e-40	0.88	0.59	Fibroblast growth factor basic levels;	chr14:77744882	chr1:78749073~78750659:+
LUAD	trans	rs5022636	0.927	rs943637	ENSG00000180764.13	PIPSL	16.21	1.78e-47	2.89e-40	0.68	0.59	Gut microbiota (functional units);	chr1:151310543	chr10:93958191~93961540:-
LUAD	trans	rs5022636	0.964	rs7518924	ENSG00000180764.13	PIPSL	16.21	1.78e-47	2.89e-40	0.68	0.59	Gut microbiota (functional units);	chr1:151319225	chr10:93958191~93961540:-
LUAD	trans	rs9611565	0.649	rs9623450	ENSG00000268568.1	AC007228.9	16.2	2.07e-47	3.35e-40	0.85	0.59	Vitiligo;	chr22:41779227	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.568	rs5751159	ENSG00000268568.1	AC007228.9	16.2	2.07e-47	3.35e-40	0.85	0.59	Vitiligo;	chr22:41779361	chr19:56672574~56673901:-
LUAD	trans	rs1816752	0.669	rs2862906	ENSG00000237917.1	PARP4P1	-16.2	2.11e-47	3.42e-40	-0.73	-0.59	Obesity-related traits;	chr13:24494482	chrY:26594851~26634652:-
LUAD	trans	rs9611565	0.592	rs4481089	ENSG00000268568.1	AC007228.9	-16.2	2.12e-47	3.44e-40	-0.87	-0.59	Vitiligo;	chr22:41584888	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.592	rs5996039	ENSG00000268568.1	AC007228.9	-16.2	2.12e-47	3.44e-40	-0.87	-0.59	Vitiligo;	chr22:41585953	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.592	rs57102627	ENSG00000268568.1	AC007228.9	-16.2	2.12e-47	3.44e-40	-0.87	-0.59	Vitiligo;	chr22:41591623	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.592	rs28750375	ENSG00000268568.1	AC007228.9	-16.2	2.12e-47	3.44e-40	-0.87	-0.59	Vitiligo;	chr22:41594640	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.559	rs8139993	ENSG00000268568.1	AC007228.9	-16.2	2.12e-47	3.44e-40	-0.87	-0.59	Vitiligo;	chr22:41599331	chr19:56672574~56673901:-
LUAD	trans	rs3749237	0.595	rs11720264	ENSG00000197582.5	GPX1P1	16.19	2.33e-47	3.78e-40	0.74	0.59	Resting heart rate;	chr3:49542914	chrX:13378735~13379340:-
LUAD	trans	rs6477998	0.903	rs4979226	ENSG00000238072.1	RP11-305M3.2	16.18	2.47e-47	3.99e-40	0.79	0.59	Hematology traits;	chr9:113239516	chr7:129410113~129410370:-
LUAD	trans	rs9611565	0.694	rs5758389	ENSG00000268568.1	AC007228.9	-16.17	2.64e-47	4.28e-40	-0.85	-0.59	Vitiligo;	chr22:41545745	chr19:56672574~56673901:-
LUAD	trans	rs6477998	0.868	rs10513189	ENSG00000238072.1	RP11-305M3.2	16.17	2.7e-47	4.37e-40	0.78	0.59	Hematology traits;	chr9:113227941	chr7:129410113~129410370:-
LUAD	trans	rs9467773	0.62	rs9461276	ENSG00000242375.1	RP11-498P14.3	16.17	2.8e-47	4.53e-40	0.76	0.59	Intelligence (multi-trait analysis);	chr6:26594940	chr9:97195351~97197687:-
LUAD	trans	rs2950393	0.804	rs2958132	ENSG00000121089.4	NACA3P	16.17	2.85e-47	4.61e-40	0.72	0.59	Platelet distribution width;	chr12:56750749	chr4:164943290~164943937:+
LUAD	trans	rs8010715	0.848	rs927494	ENSG00000248988.1	RP11-815N9.2	16.17	2.92e-47	4.71e-40	0.76	0.59	IgG glycosylation;	chr14:24131181	chr4:159007119~159007835:+
LUAD	trans	rs3749237	0.595	rs11130196	ENSG00000197582.5	GPX1P1	16.16	2.97e-47	4.8e-40	0.75	0.59	Resting heart rate;	chr3:49452716	chrX:13378735~13379340:-
LUAD	trans	rs916888	0.773	rs199447	ENSG00000214425.5	LRRC37A4P	-16.16	3e-47	4.84e-40	-0.91	-0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45506741~45550335:-
LUAD	trans	rs12709013	0.621	rs6499974	ENSG00000230849.2	GOT2P2	16.16	3.08e-47	4.96e-40	0.78	0.59	Blood metabolite ratios;	chr16:58769642	chr1:173141100~173142350:-
LUAD	trans	rs3749237	0.537	rs4459909	ENSG00000197582.5	GPX1P1	16.15	3.28e-47	5.27e-40	0.75	0.59	Resting heart rate;	chr3:49431784	chrX:13378735~13379340:-
LUAD	trans	rs9467773	0.595	rs7767847	ENSG00000242375.1	RP11-498P14.3	16.15	3.33e-47	5.36e-40	0.76	0.59	Intelligence (multi-trait analysis);	chr6:26597665	chr9:97195351~97197687:-
LUAD	trans	rs9467773	0.62	rs9461275	ENSG00000242375.1	RP11-498P14.3	16.14	3.85e-47	6.18e-40	0.76	0.59	Intelligence (multi-trait analysis);	chr6:26590573	chr9:97195351~97197687:-
LUAD	trans	rs6708331	0.504	rs2169837	ENSG00000232654.1	FAM136BP	16.14	3.91e-47	6.28e-40	0.73	0.59	Obesity-related traits;	chr2:70324775	chr6:3045384~3045800:+
LUAD	trans	rs9611565	0.649	rs139553	ENSG00000268568.1	AC007228.9	16.13	4.18e-47	6.69e-40	0.84	0.59	Vitiligo;	chr22:41791195	chr19:56672574~56673901:-
LUAD	trans	rs1816752	0.716	rs1441058	ENSG00000237917.1	PARP4P1	-16.13	4.26e-47	6.81e-40	-0.72	-0.59	Obesity-related traits;	chr13:24516275	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.692	rs6490944	ENSG00000237917.1	PARP4P1	-16.13	4.32e-47	6.91e-40	-0.72	-0.59	Obesity-related traits;	chr13:24513866	chrY:26594851~26634652:-
LUAD	trans	rs3749237	0.555	rs7637665	ENSG00000197582.5	GPX1P1	16.12	4.61e-47	7.36e-40	0.74	0.59	Resting heart rate;	chr3:49514862	chrX:13378735~13379340:-
LUAD	trans	rs7121616	0.531	rs10892958	ENSG00000234176.1	HSPA8P1	16.12	4.74e-47	7.57e-40	0.76	0.59	Breast cancer;	chr11:123061415	chrX:121203182~121205014:-
LUAD	trans	rs6477998	0.874	rs10739390	ENSG00000238072.1	RP11-305M3.2	16.12	4.85e-47	7.75e-40	0.79	0.59	Hematology traits;	chr9:113226209	chr7:129410113~129410370:-
LUAD	trans	rs6477998	0.966	rs10759637	ENSG00000238072.1	RP11-305M3.2	16.11	4.99e-47	7.96e-40	0.8	0.59	Hematology traits;	chr9:113262744	chr7:129410113~129410370:-
LUAD	trans	rs916888	0.773	rs9896243	ENSG00000264070.1	DND1P1	16.11	5.15e-47	8.2e-40	0.89	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45585871~45586929:+
LUAD	trans	rs9467773	0.62	rs4368798	ENSG00000242375.1	RP11-498P14.3	16.11	5.32e-47	8.48e-40	0.76	0.59	Intelligence (multi-trait analysis);	chr6:26593243	chr9:97195351~97197687:-
LUAD	trans	rs6477998	0.9	rs7850357	ENSG00000238072.1	RP11-305M3.2	16.1	5.75e-47	9.15e-40	0.79	0.59	Hematology traits;	chr9:113222319	chr7:129410113~129410370:-
LUAD	trans	rs3749237	0.595	rs4855877	ENSG00000197582.5	GPX1P1	16.1	5.87e-47	9.32e-40	0.74	0.59	Resting heart rate;	chr3:49411094	chrX:13378735~13379340:-
LUAD	trans	rs3749237	0.595	rs17595772	ENSG00000197582.5	GPX1P1	16.1	5.94e-47	9.42e-40	0.74	0.59	Resting heart rate;	chr3:49372271	chrX:13378735~13379340:-
LUAD	trans	rs3749237	0.595	rs7621003	ENSG00000197582.5	GPX1P1	16.1	5.94e-47	9.42e-40	0.74	0.59	Resting heart rate;	chr3:49373971	chrX:13378735~13379340:-
LUAD	trans	rs3749237	0.595	rs4955412	ENSG00000197582.5	GPX1P1	16.1	5.94e-47	9.42e-40	0.74	0.59	Resting heart rate;	chr3:49380735	chrX:13378735~13379340:-
LUAD	trans	rs3749237	0.557	rs7631908	ENSG00000197582.5	GPX1P1	16.1	5.94e-47	9.42e-40	0.74	0.59	Resting heart rate;	chr3:49388274	chrX:13378735~13379340:-
LUAD	trans	rs3749237	0.615	rs55957735	ENSG00000197582.5	GPX1P1	16.1	5.94e-47	9.42e-40	0.74	0.59	Resting heart rate;	chr3:49400725	chrX:13378735~13379340:-
LUAD	trans	rs3749237	0.595	rs2878298	ENSG00000197582.5	GPX1P1	16.09	6.58e-47	1.04e-39	0.74	0.59	Resting heart rate;	chr3:49368647	chrX:13378735~13379340:-
LUAD	trans	rs3749237	0.576	rs4241406	ENSG00000197582.5	GPX1P1	16.09	6.69e-47	1.06e-39	0.74	0.59	Resting heart rate;	chr3:49562993	chrX:13378735~13379340:-
LUAD	trans	rs3749237	0.595	rs4855864	ENSG00000197582.5	GPX1P1	16.08	6.88e-47	1.09e-39	0.74	0.59	Resting heart rate;	chr3:49484541	chrX:13378735~13379340:-
LUAD	trans	rs3749237	0.595	rs11130199	ENSG00000197582.5	GPX1P1	16.08	6.88e-47	1.09e-39	0.74	0.59	Resting heart rate;	chr3:49501366	chrX:13378735~13379340:-
LUAD	trans	rs9611565	0.649	rs5758466	ENSG00000268568.1	AC007228.9	16.08	7.23e-47	1.14e-39	0.85	0.59	Vitiligo;	chr22:41780055	chr19:56672574~56673901:-
LUAD	trans	rs7554547	0.818	rs4993566	ENSG00000261819.1	RP11-680G24.4	16.07	7.55e-47	1.19e-39	0.76	0.59	Nonsyndromic cleft lip with cleft palate;	chr1:11909937	chr16:14988259~14990160:-
LUAD	trans	rs1816752	0.646	rs2862905	ENSG00000237917.1	PARP4P1	-16.07	7.76e-47	1.22e-39	-0.73	-0.59	Obesity-related traits;	chr13:24485142	chrY:26594851~26634652:-
LUAD	trans	rs3749237	0.595	rs1464566	ENSG00000197582.5	GPX1P1	16.07	8.33e-47	1.31e-39	0.74	0.59	Resting heart rate;	chr3:49421943	chrX:13378735~13379340:-
LUAD	trans	rs9467773	0.596	rs3001369	ENSG00000242375.1	RP11-498P14.3	16.05	9.98e-47	1.56e-39	0.77	0.59	Intelligence (multi-trait analysis);	chr6:26670741	chr9:97195351~97197687:-
LUAD	trans	rs3749237	0.595	rs4855873	ENSG00000197582.5	GPX1P1	16.05	1.02e-46	1.59e-39	0.74	0.59	Resting heart rate;	chr3:49421681	chrX:13378735~13379340:-
LUAD	trans	rs3749237	0.595	rs10865955	ENSG00000197582.5	GPX1P1	16.04	1.03e-46	1.62e-39	0.75	0.59	Resting heart rate;	chr3:49462396	chrX:13378735~13379340:-
LUAD	trans	rs1816752	0.716	rs1539096	ENSG00000237917.1	PARP4P1	-16.03	1.15e-46	1.79e-39	-0.73	-0.59	Obesity-related traits;	chr13:24501721	chrY:26594851~26634652:-
LUAD	trans	rs6477998	0.932	rs4129395	ENSG00000238072.1	RP11-305M3.2	16.03	1.21e-46	1.88e-39	0.8	0.59	Hematology traits;	chr9:113213109	chr7:129410113~129410370:-
LUAD	trans	rs6477998	0.966	rs7859354	ENSG00000238072.1	RP11-305M3.2	16.03	1.21e-46	1.88e-39	0.8	0.59	Hematology traits;	chr9:113214165	chr7:129410113~129410370:-
LUAD	trans	rs5022636	0.927	rs10888409	ENSG00000180764.13	PIPSL	16.03	1.24e-46	1.94e-39	0.67	0.59	Gut microbiota (functional units);	chr1:151299306	chr10:93958191~93961540:-
LUAD	trans	rs9467773	0.549	rs9467805	ENSG00000242375.1	RP11-498P14.3	16.03	1.25e-46	1.94e-39	0.76	0.59	Intelligence (multi-trait analysis);	chr6:26583138	chr9:97195351~97197687:-
LUAD	trans	rs13096760	1	rs13096760	ENSG00000197582.5	GPX1P1	16.02	1.3e-46	2.02e-39	0.75	0.59	Intelligence (multi-trait analysis);	chr3:49439373	chrX:13378735~13379340:-
LUAD	trans	rs1816752	0.716	rs9553331	ENSG00000237917.1	PARP4P1	-16.02	1.35e-46	2.1e-39	-0.72	-0.59	Obesity-related traits;	chr13:24516030	chrY:26594851~26634652:-
LUAD	trans	rs3749237	0.615	rs11130202	ENSG00000197582.5	GPX1P1	16.02	1.36e-46	2.11e-39	0.74	0.59	Resting heart rate;	chr3:49529282	chrX:13378735~13379340:-
LUAD	trans	rs2950393	0.804	rs7980317	ENSG00000121089.4	NACA3P	16.02	1.38e-46	2.15e-39	0.71	0.59	Platelet distribution width;	chr12:56764399	chr4:164943290~164943937:+
LUAD	trans	rs5022636	1	rs5022636	ENSG00000180764.13	PIPSL	16.01	1.42e-46	2.2e-39	0.68	0.59	Gut microbiota (functional units);	chr1:151322585	chr10:93958191~93961540:-
LUAD	trans	rs1816752	0.716	rs7995304	ENSG00000237917.1	PARP4P1	-16.01	1.51e-46	2.34e-39	-0.72	-0.59	Obesity-related traits;	chr13:24514284	chrY:26594851~26634652:-
LUAD	trans	rs9467773	0.62	rs6925087	ENSG00000242375.1	RP11-498P14.3	16.01	1.56e-46	2.41e-39	0.76	0.59	Intelligence (multi-trait analysis);	chr6:26592625	chr9:97195351~97197687:-
LUAD	trans	rs9611565	0.649	rs5751144	ENSG00000268568.1	AC007228.9	-16	1.58e-46	2.45e-39	-0.83	-0.59	Vitiligo;	chr22:41732093	chr19:56672574~56673901:-
LUAD	trans	rs7811142	0.83	rs6955367	ENSG00000228546.2	CTA-313A17.3	15.99	1.86e-46	2.87e-39	0.87	0.59	Platelet count;	chr7:100363571	chr7:102337316~102339115:+
LUAD	trans	rs13253073	0.941	rs12548827	ENSG00000260318.1	COX6CP1	15.99	1.87e-46	2.88e-39	1.21	0.59	Glucose homeostasis traits;	chr8:99841495	chr16:11903923~11904137:-
LUAD	trans	rs3749237	0.595	rs11130192	ENSG00000197582.5	GPX1P1	15.98	1.97e-46	3.03e-39	0.74	0.59	Resting heart rate;	chr3:49429773	chrX:13378735~13379340:-
LUAD	trans	rs9467773	0.62	rs3800303	ENSG00000242375.1	RP11-498P14.3	15.98	2.02e-46	3.11e-39	0.76	0.59	Intelligence (multi-trait analysis);	chr6:26597960	chr9:97195351~97197687:-
LUAD	trans	rs3749237	0.576	rs3877784	ENSG00000197582.5	GPX1P1	15.98	2.1e-46	3.23e-39	0.74	0.59	Resting heart rate;	chr3:49501984	chrX:13378735~13379340:-
LUAD	trans	rs9899728	0.764	rs7219493	ENSG00000234925.2	ATP5HP4	15.97	2.27e-46	3.48e-39	0.83	0.59	Alzheimer's disease or small vessel stroke;	chr17:75048093	chr12:68642519~68642993:-
LUAD	trans	rs2950393	0.804	rs7967600	ENSG00000121089.4	NACA3P	15.96	2.41e-46	3.7e-39	0.71	0.59	Platelet distribution width;	chr12:56768208	chr4:164943290~164943937:+
LUAD	trans	rs3749237	0.615	rs6792911	ENSG00000197582.5	GPX1P1	15.95	2.67e-46	4.09e-39	0.74	0.59	Resting heart rate;	chr3:49392423	chrX:13378735~13379340:-
LUAD	trans	rs4822044	0.561	rs132781	ENSG00000268568.1	AC007228.9	15.95	2.72e-46	4.17e-39	0.99	0.59	Cannabis dependence symptom count;	chr22:41650118	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.512	rs132784	ENSG00000268568.1	AC007228.9	15.95	2.72e-46	4.17e-39	0.99	0.59	Vitiligo;	chr22:41656359	chr19:56672574~56673901:-
LUAD	trans	rs3749237	0.636	rs1568662	ENSG00000197582.5	GPX1P1	15.95	2.76e-46	4.22e-39	0.74	0.59	Resting heart rate;	chr3:49483830	chrX:13378735~13379340:-
LUAD	trans	rs3749237	0.595	rs3924462	ENSG00000197582.5	GPX1P1	15.95	2.76e-46	4.22e-39	0.74	0.59	Resting heart rate;	chr3:49486803	chrX:13378735~13379340:-
LUAD	trans	rs3749237	0.595	rs4855861	ENSG00000197582.5	GPX1P1	15.95	2.76e-46	4.22e-39	0.74	0.59	Resting heart rate;	chr3:49488529	chrX:13378735~13379340:-
LUAD	trans	rs3749237	0.595	rs4855859	ENSG00000197582.5	GPX1P1	15.95	2.76e-46	4.22e-39	0.74	0.59	Resting heart rate;	chr3:49488867	chrX:13378735~13379340:-
LUAD	trans	rs3749237	0.595	rs7637999	ENSG00000197582.5	GPX1P1	15.95	2.76e-46	4.22e-39	0.74	0.59	Resting heart rate;	chr3:49497682	chrX:13378735~13379340:-
LUAD	trans	rs9611565	0.649	rs6002480	ENSG00000268568.1	AC007228.9	-15.95	2.76e-46	4.22e-39	-0.84	-0.59	Vitiligo;	chr22:41780913	chr19:56672574~56673901:-
LUAD	trans	rs12709013	0.636	rs1646256	ENSG00000230849.2	GOT2P2	15.95	2.84e-46	4.34e-39	0.77	0.59	Blood metabolite ratios;	chr16:58712114	chr1:173141100~173142350:-
LUAD	trans	rs3749237	0.595	rs7643845	ENSG00000197582.5	GPX1P1	15.94	2.98e-46	4.55e-39	0.74	0.59	Resting heart rate;	chr3:49493278	chrX:13378735~13379340:-
LUAD	trans	rs9611565	0.573	rs9306355	ENSG00000268568.1	AC007228.9	15.94	3.02e-46	4.6e-39	0.83	0.59	Vitiligo;	chr22:41715892	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.649	rs5758434	ENSG00000268568.1	AC007228.9	15.94	3.02e-46	4.6e-39	0.83	0.59	Vitiligo;	chr22:41720159	chr19:56672574~56673901:-
LUAD	trans	rs3749237	0.595	rs6784820	ENSG00000197582.5	GPX1P1	-15.93	3.45e-46	5.26e-39	-0.73	-0.59	Resting heart rate;	chr3:49413431	chrX:13378735~13379340:-
LUAD	trans	rs7811142	0.83	rs11768967	ENSG00000228546.2	CTA-313A17.3	15.92	3.7e-46	5.63e-39	0.87	0.59	Platelet count;	chr7:100370021	chr7:102337316~102339115:+
LUAD	trans	rs7811142	0.83	rs6975660	ENSG00000228546.2	CTA-313A17.3	15.92	3.7e-46	5.63e-39	0.87	0.59	Platelet count;	chr7:100377643	chr7:102337316~102339115:+
LUAD	trans	rs7811142	0.83	rs73401443	ENSG00000228546.2	CTA-313A17.3	15.92	3.7e-46	5.63e-39	0.87	0.59	Platelet count;	chr7:100379959	chr7:102337316~102339115:+
LUAD	trans	rs7811142	0.83	rs10085549	ENSG00000228546.2	CTA-313A17.3	15.92	3.7e-46	5.63e-39	0.87	0.59	Platelet count;	chr7:100385512	chr7:102337316~102339115:+
LUAD	trans	rs3749237	0.595	rs885592	ENSG00000197582.5	GPX1P1	15.9	4.8e-46	7.27e-39	0.74	0.59	Resting heart rate;	chr3:49460450	chrX:13378735~13379340:-
LUAD	trans	rs9611565	0.546	rs5758426	ENSG00000268568.1	AC007228.9	15.9	4.95e-46	7.5e-39	0.86	0.59	Vitiligo;	chr22:41702759	chr19:56672574~56673901:-
LUAD	trans	rs941207	0.514	rs6581105	ENSG00000121089.4	NACA3P	-15.89	5.3e-46	8.01e-39	-0.8	-0.59	Platelet count;	chr12:56792184	chr4:164943290~164943937:+
LUAD	trans	rs9611565	0.5	rs2011053	ENSG00000268568.1	AC007228.9	15.89	5.43e-46	8.21e-39	0.83	0.59	Vitiligo;	chr22:41725274	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.649	rs738422	ENSG00000268568.1	AC007228.9	15.89	5.43e-46	8.21e-39	0.83	0.59	Vitiligo;	chr22:41727395	chr19:56672574~56673901:-
LUAD	trans	rs3749237	0.555	rs2117939	ENSG00000197582.5	GPX1P1	15.88	5.61e-46	8.47e-39	0.73	0.59	Resting heart rate;	chr3:49377746	chrX:13378735~13379340:-
LUAD	trans	rs3749237	0.595	rs6797765	ENSG00000197582.5	GPX1P1	15.88	5.61e-46	8.47e-39	0.73	0.59	Resting heart rate;	chr3:49386543	chrX:13378735~13379340:-
LUAD	trans	rs3749237	0.595	rs35701831	ENSG00000197582.5	GPX1P1	15.87	6.33e-46	9.52e-39	0.73	0.59	Resting heart rate;	chr3:49477567	chrX:13378735~13379340:-
LUAD	trans	rs6477998	1	rs10759636	ENSG00000238072.1	RP11-305M3.2	15.87	6.36e-46	9.57e-39	0.79	0.59	Hematology traits;	chr9:113256497	chr7:129410113~129410370:-
LUAD	trans	rs916888	0.779	rs199528	ENSG00000214425.5	LRRC37A4P	-15.85	8.15e-46	1.22e-38	-0.89	-0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45506741~45550335:-
LUAD	trans	rs916888	0.821	rs199525	ENSG00000214425.5	LRRC37A4P	-15.85	8.15e-46	1.22e-38	-0.89	-0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45506741~45550335:-
LUAD	trans	rs2950393	0.804	rs898611	ENSG00000121089.4	NACA3P	-15.83	9.76e-46	1.46e-38	-0.71	-0.59	Platelet distribution width;	chr12:56769532	chr4:164943290~164943937:+
LUAD	trans	rs6477998	1	rs10739388	ENSG00000238072.1	RP11-305M3.2	15.83	9.78e-46	1.46e-38	0.8	0.59	Hematology traits;	chr9:113214895	chr7:129410113~129410370:-
LUAD	trans	rs7811142	0.775	rs1059129	ENSG00000228546.2	CTA-313A17.3	15.83	9.79e-46	1.46e-38	0.87	0.59	Platelet count;	chr7:100328899	chr7:102337316~102339115:+
LUAD	trans	rs7811142	0.562	rs7786844	ENSG00000228546.2	CTA-313A17.3	15.83	9.79e-46	1.46e-38	0.87	0.59	Platelet count;	chr7:100336385	chr7:102337316~102339115:+
LUAD	trans	rs7811142	0.83	rs6979910	ENSG00000228546.2	CTA-313A17.3	15.83	9.79e-46	1.46e-38	0.87	0.59	Platelet count;	chr7:100343007	chr7:102337316~102339115:+
LUAD	trans	rs6477998	1	rs7038769	ENSG00000238072.1	RP11-305M3.2	15.83	9.8e-46	1.46e-38	0.78	0.59	Hematology traits;	chr9:113245303	chr7:129410113~129410370:-
LUAD	trans	rs6477998	1	rs7022397	ENSG00000238072.1	RP11-305M3.2	15.83	9.8e-46	1.46e-38	0.78	0.59	Hematology traits;	chr9:113245397	chr7:129410113~129410370:-
LUAD	trans	rs3749237	0.595	rs1464568	ENSG00000197582.5	GPX1P1	15.83	1.01e-45	1.5e-38	0.74	0.59	Resting heart rate;	chr3:49420833	chrX:13378735~13379340:-
LUAD	trans	rs9467773	0.62	rs2451738	ENSG00000242375.1	RP11-498P14.3	-15.8	1.31e-45	1.95e-38	-0.75	-0.58	Intelligence (multi-trait analysis);	chr6:26618231	chr9:97195351~97197687:-
LUAD	trans	rs7811142	0.667	rs3873746	ENSG00000228546.2	CTA-313A17.3	15.8	1.32e-45	1.96e-38	0.87	0.58	Platelet count;	chr7:100337474	chr7:102337316~102339115:+
LUAD	trans	rs9611565	0.607	rs132792	ENSG00000268568.1	AC007228.9	15.79	1.46e-45	2.16e-38	0.84	0.58	Vitiligo;	chr22:41666818	chr19:56672574~56673901:-
LUAD	trans	rs6477998	1	rs4560868	ENSG00000238072.1	RP11-305M3.2	-15.79	1.47e-45	2.17e-38	-0.8	-0.58	Hematology traits;	chr9:113223219	chr7:129410113~129410370:-
LUAD	trans	rs9899728	0.764	rs9660	ENSG00000234925.2	ATP5HP4	15.78	1.62e-45	2.4e-38	0.82	0.58	Alzheimer's disease or small vessel stroke;	chr17:75042651	chr12:68642519~68642993:-
LUAD	trans	rs9611565	0.649	rs4822050	ENSG00000268568.1	AC007228.9	-15.78	1.65e-45	2.43e-38	-0.83	-0.58	Vitiligo;	chr22:41781449	chr19:56672574~56673901:-
LUAD	trans	rs2731664	0.792	rs335435	ENSG00000215571.5	GRK6P1	15.75	2.31e-45	3.39e-38	0.69	0.58	Intelligence (multi-trait analysis);	chr5:177440942	chr13:21319156~21320866:+
LUAD	trans	rs7811142	0.83	rs7792959	ENSG00000228546.2	CTA-313A17.3	15.75	2.37e-45	3.47e-38	0.87	0.58	Platelet count;	chr7:100374780	chr7:102337316~102339115:+
LUAD	trans	rs3749237	0.595	rs3870338	ENSG00000197582.5	GPX1P1	15.74	2.41e-45	3.54e-38	0.72	0.58	Resting heart rate;	chr3:49519618	chrX:13378735~13379340:-
LUAD	trans	rs9611565	0.592	rs6519270	ENSG00000268568.1	AC007228.9	15.73	2.66e-45	3.9e-38	0.85	0.58	Vitiligo;	chr22:41682662	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.644	rs2413652	ENSG00000268568.1	AC007228.9	15.7	3.71e-45	5.39e-38	0.83	0.58	Vitiligo;	chr22:41701234	chr19:56672574~56673901:-
LUAD	trans	rs1045902	0.967	rs10207625	ENSG00000236165.1	PRADC1P1	15.67	5.2e-45	7.53e-38	0.77	0.58	Intelligence (multi-trait analysis);	chr2:73237680	chr3:36976316~36976840:+
LUAD	trans	rs1045902	0.967	rs1469530	ENSG00000236165.1	PRADC1P1	15.67	5.2e-45	7.53e-38	0.77	0.58	Intelligence (multi-trait analysis);	chr2:73237820	chr3:36976316~36976840:+
LUAD	trans	rs1816752	0.646	rs9507355	ENSG00000237917.1	PARP4P1	15.65	6.27e-45	9.03e-38	0.68	0.58	Obesity-related traits;	chr13:24476819	chrY:26594851~26634652:-
LUAD	trans	rs9611565	0.649	rs139540	ENSG00000268568.1	AC007228.9	-15.65	6.62e-45	9.54e-38	-0.81	-0.58	Vitiligo;	chr22:41782036	chr19:56672574~56673901:-
LUAD	trans	rs3749237	0.595	rs1568661	ENSG00000197582.5	GPX1P1	15.63	7.67e-45	1.1e-37	0.72	0.58	Resting heart rate;	chr3:49483525	chrX:13378735~13379340:-
LUAD	trans	rs3749237	0.595	rs1050088	ENSG00000197582.5	GPX1P1	-15.6	1.12e-44	1.61e-37	-0.73	-0.58	Resting heart rate;	chr3:49533449	chrX:13378735~13379340:-
LUAD	trans	rs941207	0.542	rs11171986	ENSG00000121089.4	NACA3P	-15.57	1.52e-44	2.15e-37	-0.78	-0.58	Platelet count;	chr12:56819043	chr4:164943290~164943937:+
LUAD	trans	rs916888	0.821	rs199506	ENSG00000264070.1	DND1P1	-15.56	1.6e-44	2.26e-37	-0.88	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45585871~45586929:+
LUAD	trans	rs8081395	0.603	rs1292047	ENSG00000187870.7	RNFT1P3	15.55	1.8e-44	2.53e-37	0.74	0.58	White blood cell count;	chr17:59877805	chr17:20743333~20754501:-
LUAD	trans	rs2731664	0.765	rs2630766	ENSG00000215571.5	GRK6P1	15.54	2.06e-44	2.88e-37	0.67	0.58	Intelligence (multi-trait analysis);	chr5:177447940	chr13:21319156~21320866:+
LUAD	trans	rs3749237	0.595	rs1464567	ENSG00000197582.5	GPX1P1	-15.53	2.13e-44	2.98e-37	-0.75	-0.58	Resting heart rate;	chr3:49421819	chrX:13378735~13379340:-
LUAD	trans	rs9899728	0.665	rs2307008	ENSG00000234925.2	ATP5HP4	15.53	2.27e-44	3.16e-37	0.82	0.58	Alzheimer's disease or small vessel stroke;	chr17:75046587	chr12:68642519~68642993:-
LUAD	trans	rs7811142	0.83	rs6945952	ENSG00000228546.2	CTA-313A17.3	15.52	2.35e-44	3.28e-37	0.88	0.58	Platelet count;	chr7:100384152	chr7:102337316~102339115:+
LUAD	trans	rs7811142	0.83	rs73401451	ENSG00000228546.2	CTA-313A17.3	15.52	2.35e-44	3.28e-37	0.88	0.58	Platelet count;	chr7:100384272	chr7:102337316~102339115:+
LUAD	trans	rs4240897	0.561	rs12043045	ENSG00000261819.1	RP11-680G24.4	15.51	2.75e-44	3.83e-37	0.75	0.58	Tuberculosis;	chr1:11900294	chr16:14988259~14990160:-
LUAD	trans	rs4240897	0.544	rs7542773	ENSG00000261819.1	RP11-680G24.4	15.51	2.75e-44	3.83e-37	0.75	0.58	Tuberculosis;	chr1:11901073	chr16:14988259~14990160:-
LUAD	trans	rs7554547	0.508	rs7520898	ENSG00000261819.1	RP11-680G24.4	15.51	2.75e-44	3.83e-37	0.75	0.58	Nonsyndromic cleft lip with cleft palate;	chr1:11901078	chr16:14988259~14990160:-
LUAD	trans	rs10940346	0.967	rs2353436	ENSG00000231752.4	EMBP1	15.51	2.8e-44	3.89e-37	0.75	0.58	Schizophrenia;	chr5:50445695	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.967	rs1849200	ENSG00000231752.4	EMBP1	15.51	2.8e-44	3.89e-37	0.75	0.58	Schizophrenia;	chr5:50448053	chr1:121519112~121571892:+
LUAD	trans	rs10940346	1	rs6899048	ENSG00000231752.4	EMBP1	15.51	2.8e-44	3.89e-37	0.75	0.58	Schizophrenia;	chr5:50451256	chr1:121519112~121571892:+
LUAD	trans	rs10940346	1	rs2102454	ENSG00000231752.4	EMBP1	15.51	2.8e-44	3.89e-37	0.75	0.58	Schizophrenia;	chr5:50452446	chr1:121519112~121571892:+
LUAD	trans	rs9611565	0.694	rs5758411	ENSG00000268568.1	AC007228.9	15.5	2.97e-44	4.11e-37	0.83	0.58	Vitiligo;	chr22:41683730	chr19:56672574~56673901:-
LUAD	trans	rs10242455	0.557	rs73401516	ENSG00000228834.1	RP11-249L21.4	15.5	3.08e-44	4.26e-37	1.54	0.58	Blood metabolite levels;	chr7:99470728	chr6:108907615~108907873:-
LUAD	trans	rs10242455	0.557	rs77997620	ENSG00000228834.1	RP11-249L21.4	15.5	3.08e-44	4.26e-37	1.54	0.58	Blood metabolite levels;	chr7:99472792	chr6:108907615~108907873:-
LUAD	trans	rs10242455	0.702	rs59240302	ENSG00000228834.1	RP11-249L21.4	15.5	3.08e-44	4.26e-37	1.54	0.58	Blood metabolite levels;	chr7:99475368	chr6:108907615~108907873:-
LUAD	trans	rs10242455	0.702	rs73403247	ENSG00000228834.1	RP11-249L21.4	15.5	3.08e-44	4.26e-37	1.54	0.58	Blood metabolite levels;	chr7:99491107	chr6:108907615~108907873:-
LUAD	trans	rs10940346	1	rs1328254	ENSG00000231752.4	EMBP1	-15.5	3.09e-44	4.27e-37	-0.74	-0.58	Schizophrenia;	chr5:50265025	chr1:121519112~121571892:+
LUAD	trans	rs2731664	0.792	rs466256	ENSG00000215571.5	GRK6P1	15.49	3.4e-44	4.71e-37	0.68	0.58	Intelligence (multi-trait analysis);	chr5:177448955	chr13:21319156~21320866:+
LUAD	trans	rs10940346	0.967	rs2353437	ENSG00000231752.4	EMBP1	15.49	3.46e-44	4.79e-37	0.75	0.58	Schizophrenia;	chr5:50452078	chr1:121519112~121571892:+
LUAD	trans	rs2731664	0.792	rs2630765	ENSG00000215571.5	GRK6P1	15.49	3.55e-44	4.91e-37	0.68	0.58	Intelligence (multi-trait analysis);	chr5:177449824	chr13:21319156~21320866:+
LUAD	trans	rs4240897	0.548	rs12085006	ENSG00000261819.1	RP11-680G24.4	15.48	3.83e-44	5.29e-37	0.74	0.58	Tuberculosis;	chr1:11898666	chr16:14988259~14990160:-
LUAD	trans	rs1816752	0.608	rs4770690	ENSG00000237917.1	PARP4P1	-15.47	4.16e-44	5.74e-37	-0.69	-0.58	Obesity-related traits;	chr13:24467049	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.624	rs9553312	ENSG00000237917.1	PARP4P1	-15.47	4.23e-44	5.83e-37	-0.7	-0.58	Obesity-related traits;	chr13:24474055	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.609	rs4770692	ENSG00000237917.1	PARP4P1	-15.47	4.25e-44	5.86e-37	-0.7	-0.58	Obesity-related traits;	chr13:24468689	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.609	rs4770694	ENSG00000237917.1	PARP4P1	-15.47	4.25e-44	5.86e-37	-0.7	-0.58	Obesity-related traits;	chr13:24468891	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.624	rs9507354	ENSG00000237917.1	PARP4P1	-15.47	4.27e-44	5.88e-37	-0.7	-0.58	Obesity-related traits;	chr13:24469227	chrY:26594851~26634652:-
LUAD	trans	rs9611565	0.512	rs5758464	ENSG00000268568.1	AC007228.9	15.45	5.02e-44	6.9e-37	0.99	0.58	Vitiligo;	chr22:41775296	chr19:56672574~56673901:-
LUAD	trans	rs5022636	0.964	rs1056847	ENSG00000180764.13	PIPSL	15.43	6.34e-44	8.65e-37	0.65	0.58	Gut microbiota (functional units);	chr1:151315696	chr10:93958191~93961540:-
LUAD	trans	rs1816752	0.603	rs7984094	ENSG00000237917.1	PARP4P1	-15.43	6.38e-44	8.7e-37	-0.7	-0.58	Obesity-related traits;	chr13:24496212	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.624	rs7330766	ENSG00000237917.1	PARP4P1	-15.43	6.43e-44	8.76e-37	-0.7	-0.58	Obesity-related traits;	chr13:24495579	chrY:26594851~26634652:-
LUAD	trans	rs10940346	0.967	rs13173678	ENSG00000231752.4	EMBP1	15.42	6.64e-44	9.05e-37	0.74	0.58	Schizophrenia;	chr5:50422314	chr1:121519112~121571892:+
LUAD	trans	rs10940346	1	rs6450108	ENSG00000231752.4	EMBP1	15.42	6.64e-44	9.05e-37	0.74	0.58	Schizophrenia;	chr5:50434427	chr1:121519112~121571892:+
LUAD	trans	rs10940346	1	rs28445612	ENSG00000231752.4	EMBP1	15.42	6.64e-44	9.05e-37	0.74	0.58	Schizophrenia;	chr5:50439676	chr1:121519112~121571892:+
LUAD	trans	rs10940346	1	rs6450164	ENSG00000231752.4	EMBP1	-15.42	7.35e-44	9.98e-37	-0.74	-0.58	Schizophrenia;	chr5:50502814	chr1:121519112~121571892:+
LUAD	trans	rs10940346	1	rs1962832	ENSG00000231752.4	EMBP1	-15.42	7.35e-44	9.98e-37	-0.74	-0.58	Schizophrenia;	chr5:50502962	chr1:121519112~121571892:+
LUAD	trans	rs10940346	1	rs2016360	ENSG00000231752.4	EMBP1	-15.41	7.77e-44	1.05e-36	-0.74	-0.57	Schizophrenia;	chr5:50491064	chr1:121519112~121571892:+
LUAD	trans	rs10940346	1	rs7378983	ENSG00000231752.4	EMBP1	-15.41	7.77e-44	1.05e-36	-0.74	-0.57	Schizophrenia;	chr5:50491889	chr1:121519112~121571892:+
LUAD	trans	rs616147	0.627	rs816487	ENSG00000183298.5	RP11-556K13.1	-15.41	8.08e-44	1.09e-36	-0.75	-0.57	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39445999	chr1:101786340~101787219:-
LUAD	trans	rs10940346	0.967	rs62365887	ENSG00000231752.4	EMBP1	15.4	8.98e-44	1.21e-36	0.74	0.57	Schizophrenia;	chr5:50408254	chr1:121519112~121571892:+
LUAD	trans	rs6477998	0.966	rs7851395	ENSG00000238072.1	RP11-305M3.2	15.39	9.06e-44	1.22e-36	0.77	0.57	Hematology traits;	chr9:113240184	chr7:129410113~129410370:-
LUAD	trans	rs10940346	0.967	rs13154223	ENSG00000231752.4	EMBP1	15.39	9.06e-44	1.22e-36	0.75	0.57	Schizophrenia;	chr5:50403152	chr1:121519112~121571892:+
LUAD	trans	rs4240897	0.548	rs10746496	ENSG00000261819.1	RP11-680G24.4	15.38	1.03e-43	1.39e-36	0.74	0.57	Tuberculosis;	chr1:11904090	chr16:14988259~14990160:-
LUAD	trans	rs10940346	0.967	rs4030572	ENSG00000231752.4	EMBP1	15.38	1.03e-43	1.39e-36	0.74	0.57	Schizophrenia;	chr5:50375897	chr1:121519112~121571892:+
LUAD	trans	rs10940346	1	rs2883164	ENSG00000231752.4	EMBP1	15.38	1.03e-43	1.39e-36	0.74	0.57	Schizophrenia;	chr5:50397624	chr1:121519112~121571892:+
LUAD	trans	rs10940346	1	rs7712749	ENSG00000231752.4	EMBP1	15.38	1.03e-43	1.39e-36	0.74	0.57	Schizophrenia;	chr5:50400441	chr1:121519112~121571892:+
LUAD	trans	rs7503168	0.558	rs71381463	ENSG00000234130.2	RP13-88F20.1	15.38	1.04e-43	1.4e-36	1.16	0.57	Plateletcrit;	chr17:35610247	chrX:93222220~93225015:-
LUAD	trans	rs7503168	0.558	rs12936539	ENSG00000234130.2	RP13-88F20.1	15.38	1.04e-43	1.4e-36	1.16	0.57	Plateletcrit;	chr17:35611677	chrX:93222220~93225015:-
LUAD	trans	rs7503168	0.558	rs34063751	ENSG00000234130.2	RP13-88F20.1	15.38	1.04e-43	1.4e-36	1.16	0.57	Plateletcrit;	chr17:35611893	chrX:93222220~93225015:-
LUAD	trans	rs7503168	0.558	rs11650225	ENSG00000234130.2	RP13-88F20.1	15.38	1.04e-43	1.4e-36	1.16	0.57	Plateletcrit;	chr17:35613947	chrX:93222220~93225015:-
LUAD	trans	rs7503168	0.558	rs17669281	ENSG00000234130.2	RP13-88F20.1	15.38	1.04e-43	1.4e-36	1.16	0.57	Plateletcrit;	chr17:35616776	chrX:93222220~93225015:-
LUAD	trans	rs7503168	0.558	rs17606150	ENSG00000234130.2	RP13-88F20.1	15.38	1.04e-43	1.4e-36	1.16	0.57	Plateletcrit;	chr17:35616789	chrX:93222220~93225015:-
LUAD	trans	rs7503168	0.558	rs12940422	ENSG00000234130.2	RP13-88F20.1	15.38	1.04e-43	1.4e-36	1.16	0.57	Plateletcrit;	chr17:35620400	chrX:93222220~93225015:-
LUAD	trans	rs7503168	0.558	rs12949877	ENSG00000234130.2	RP13-88F20.1	15.38	1.04e-43	1.4e-36	1.16	0.57	Plateletcrit;	chr17:35621517	chrX:93222220~93225015:-
LUAD	trans	rs1816752	0.646	rs9511309	ENSG00000237917.1	PARP4P1	-15.37	1.13e-43	1.51e-36	-0.69	-0.57	Obesity-related traits;	chr13:24515435	chrY:26594851~26634652:-
LUAD	trans	rs727563	0.555	rs5751136	ENSG00000268568.1	AC007228.9	15.37	1.14e-43	1.52e-36	0.88	0.57	Crohn's disease;Inflammatory bowel disease;	chr22:41679577	chr19:56672574~56673901:-
LUAD	trans	rs1816752	0.583	rs9511284	ENSG00000237917.1	PARP4P1	-15.37	1.14e-43	1.52e-36	-0.69	-0.57	Obesity-related traits;	chr13:24463660	chrY:26594851~26634652:-
LUAD	trans	rs7811142	0.666	rs28401739	ENSG00000228546.2	CTA-313A17.3	15.37	1.22e-43	1.63e-36	0.86	0.57	Platelet count;	chr7:100308061	chr7:102337316~102339115:+
LUAD	trans	rs7811142	0.83	rs73401450	ENSG00000228546.2	CTA-313A17.3	15.36	1.34e-43	1.78e-36	0.88	0.57	Platelet count;	chr7:100384236	chr7:102337316~102339115:+
LUAD	trans	rs916888	0.821	rs199505	ENSG00000264070.1	DND1P1	-15.36	1.34e-43	1.78e-36	-0.86	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45585871~45586929:+
LUAD	trans	rs916888	0.821	rs70602	ENSG00000264070.1	DND1P1	-15.36	1.34e-43	1.78e-36	-0.86	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45585871~45586929:+
LUAD	trans	rs1816752	0.646	rs9511295	ENSG00000237917.1	PARP4P1	-15.36	1.35e-43	1.79e-36	-0.69	-0.57	Obesity-related traits;	chr13:24467794	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.583	rs9553311	ENSG00000237917.1	PARP4P1	-15.35	1.43e-43	1.9e-36	-0.69	-0.57	Obesity-related traits;	chr13:24474016	chrY:26594851~26634652:-
LUAD	trans	rs6732160	0.593	rs2288630	ENSG00000236165.1	PRADC1P1	15.35	1.43e-43	1.9e-36	0.76	0.57	Intelligence (multi-trait analysis);	chr2:73230424	chr3:36976316~36976840:+
LUAD	trans	rs1816752	0.609	rs4769361	ENSG00000237917.1	PARP4P1	-15.35	1.46e-43	1.93e-36	-0.69	-0.57	Obesity-related traits;	chr13:24468834	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.609	rs4770693	ENSG00000237917.1	PARP4P1	-15.35	1.46e-43	1.93e-36	-0.69	-0.57	Obesity-related traits;	chr13:24468835	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.609	rs4770695	ENSG00000237917.1	PARP4P1	-15.35	1.46e-43	1.93e-36	-0.69	-0.57	Obesity-related traits;	chr13:24468895	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.646	rs7337981	ENSG00000237917.1	PARP4P1	-15.35	1.46e-43	1.93e-36	-0.69	-0.57	Obesity-related traits;	chr13:24469245	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.646	rs7328391	ENSG00000237917.1	PARP4P1	-15.35	1.46e-43	1.93e-36	-0.69	-0.57	Obesity-related traits;	chr13:24470325	chrY:26594851~26634652:-
LUAD	trans	rs2731664	0.792	rs2731662	ENSG00000215571.5	GRK6P1	-15.35	1.5e-43	1.98e-36	-0.67	-0.57	Intelligence (multi-trait analysis);	chr5:177445493	chr13:21319156~21320866:+
LUAD	trans	rs10940346	1	rs4865522	ENSG00000231752.4	EMBP1	-15.34	1.65e-43	2.17e-36	-0.73	-0.57	Schizophrenia;	chr5:50303674	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.967	rs10068272	ENSG00000231752.4	EMBP1	-15.34	1.65e-43	2.17e-36	-0.73	-0.57	Schizophrenia;	chr5:50313688	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.967	rs10940129	ENSG00000231752.4	EMBP1	-15.34	1.65e-43	2.17e-36	-0.73	-0.57	Schizophrenia;	chr5:50315257	chr1:121519112~121571892:+
LUAD	trans	rs5022636	0.927	rs10888410	ENSG00000180764.13	PIPSL	15.33	1.8e-43	2.37e-36	0.65	0.57	Gut microbiota (functional units);	chr1:151299975	chr10:93958191~93961540:-
LUAD	trans	rs10940346	0.875	rs13172257	ENSG00000231752.4	EMBP1	15.33	1.85e-43	2.43e-36	0.74	0.57	Schizophrenia;	chr5:50462916	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.967	rs6450134	ENSG00000231752.4	EMBP1	-15.33	1.86e-43	2.43e-36	-0.74	-0.57	Schizophrenia;	chr5:50471121	chr1:121519112~121571892:+
LUAD	trans	rs10940346	1	rs7380816	ENSG00000231752.4	EMBP1	-15.33	1.86e-43	2.43e-36	-0.74	-0.57	Schizophrenia;	chr5:50472059	chr1:121519112~121571892:+
LUAD	trans	rs10940346	1	rs10074196	ENSG00000231752.4	EMBP1	15.33	1.86e-43	2.43e-36	0.74	0.57	Schizophrenia;	chr5:50464713	chr1:121519112~121571892:+
LUAD	trans	rs10940346	1	rs13186891	ENSG00000231752.4	EMBP1	15.33	1.86e-43	2.43e-36	0.74	0.57	Schizophrenia;	chr5:50467244	chr1:121519112~121571892:+
LUAD	trans	rs12709013	0.591	rs30842	ENSG00000233719.3	GOT2P3	-15.32	2.03e-43	2.64e-36	-0.73	-0.57	Blood metabolite ratios;	chr16:58709550	chr12:9641802~9643007:+
LUAD	trans	rs7811142	1	rs7787620	ENSG00000228546.2	CTA-313A17.3	15.31	2.14e-43	2.78e-36	0.86	0.57	Platelet count;	chr7:100491611	chr7:102337316~102339115:+
LUAD	trans	rs7811142	1	rs11769700	ENSG00000228546.2	CTA-313A17.3	15.31	2.14e-43	2.78e-36	0.86	0.57	Platelet count;	chr7:100492426	chr7:102337316~102339115:+
LUAD	trans	rs1816752	0.646	rs9511301	ENSG00000237917.1	PARP4P1	-15.31	2.17e-43	2.81e-36	-0.69	-0.57	Obesity-related traits;	chr13:24477034	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.646	rs7332220	ENSG00000237917.1	PARP4P1	-15.31	2.17e-43	2.81e-36	-0.69	-0.57	Obesity-related traits;	chr13:24477081	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.624	rs11149109	ENSG00000237917.1	PARP4P1	-15.31	2.17e-43	2.81e-36	-0.69	-0.57	Obesity-related traits;	chr13:24477290	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.646	rs9511302	ENSG00000237917.1	PARP4P1	-15.31	2.17e-43	2.81e-36	-0.69	-0.57	Obesity-related traits;	chr13:24477580	chrY:26594851~26634652:-
LUAD	trans	rs7811142	1	rs60478351	ENSG00000228546.2	CTA-313A17.3	15.31	2.2e-43	2.85e-36	0.85	0.57	Platelet count;	chr7:100491394	chr7:102337316~102339115:+
LUAD	trans	rs10940346	1	rs2036901	ENSG00000231752.4	EMBP1	15.31	2.24e-43	2.9e-36	0.74	0.57	Schizophrenia;	chr5:50401306	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.967	rs2271236	ENSG00000231752.4	EMBP1	15.31	2.24e-43	2.9e-36	0.74	0.57	Schizophrenia;	chr5:50405921	chr1:121519112~121571892:+
LUAD	trans	rs10940346	1	rs34044167	ENSG00000231752.4	EMBP1	15.31	2.24e-43	2.9e-36	0.74	0.57	Schizophrenia;	chr5:50410136	chr1:121519112~121571892:+
LUAD	trans	rs916888	0.821	rs415430	ENSG00000264070.1	DND1P1	-15.31	2.25e-43	2.91e-36	-0.86	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45585871~45586929:+
LUAD	trans	rs916888	0.779	rs430685	ENSG00000264070.1	DND1P1	-15.31	2.25e-43	2.91e-36	-0.86	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45585871~45586929:+
LUAD	trans	rs1816752	0.646	rs4480642	ENSG00000237917.1	PARP4P1	-15.31	2.26e-43	2.93e-36	-0.69	-0.57	Obesity-related traits;	chr13:24471358	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.646	rs9551108	ENSG00000237917.1	PARP4P1	-15.31	2.26e-43	2.93e-36	-0.69	-0.57	Obesity-related traits;	chr13:24471434	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.603	rs4238178	ENSG00000237917.1	PARP4P1	-15.31	2.26e-43	2.93e-36	-0.69	-0.57	Obesity-related traits;	chr13:24472344	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.646	rs1361578	ENSG00000237917.1	PARP4P1	-15.31	2.28e-43	2.94e-36	-0.7	-0.57	Obesity-related traits;	chr13:24491117	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.646	rs2862903	ENSG00000237917.1	PARP4P1	-15.31	2.28e-43	2.94e-36	-0.69	-0.57	Obesity-related traits;	chr13:24473169	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.646	rs7995190	ENSG00000237917.1	PARP4P1	-15.3	2.31e-43	2.99e-36	-0.69	-0.57	Obesity-related traits;	chr13:24475709	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.608	rs7326664	ENSG00000237917.1	PARP4P1	-15.3	2.36e-43	3.05e-36	-0.69	-0.57	Obesity-related traits;	chr13:24475868	chrY:26594851~26634652:-
LUAD	trans	rs9467773	0.595	rs12525810	ENSG00000242375.1	RP11-498P14.3	15.3	2.38e-43	3.07e-36	0.77	0.57	Intelligence (multi-trait analysis);	chr6:26623283	chr9:97195351~97197687:-
LUAD	trans	rs10940346	0.936	rs10940171	ENSG00000231752.4	EMBP1	15.3	2.46e-43	3.17e-36	0.73	0.57	Schizophrenia;	chr5:50324613	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.936	rs7705285	ENSG00000231752.4	EMBP1	15.3	2.46e-43	3.17e-36	0.73	0.57	Schizophrenia;	chr5:50325579	chr1:121519112~121571892:+
LUAD	trans	rs10940346	1	rs35250488	ENSG00000231752.4	EMBP1	15.3	2.54e-43	3.27e-36	0.73	0.57	Schizophrenia;	chr5:50331004	chr1:121519112~121571892:+
LUAD	trans	rs10940346	1	rs10040323	ENSG00000231752.4	EMBP1	15.3	2.54e-43	3.27e-36	0.73	0.57	Schizophrenia;	chr5:50336779	chr1:121519112~121571892:+
LUAD	trans	rs10940346	1	rs2055909	ENSG00000231752.4	EMBP1	15.3	2.54e-43	3.27e-36	0.73	0.57	Schizophrenia;	chr5:50337474	chr1:121519112~121571892:+
LUAD	trans	rs10940346	1	rs1812994	ENSG00000231752.4	EMBP1	15.29	2.66e-43	3.42e-36	0.73	0.57	Schizophrenia;	chr5:50364397	chr1:121519112~121571892:+
LUAD	trans	rs10940346	1	rs3849670	ENSG00000231752.4	EMBP1	15.29	2.66e-43	3.42e-36	0.73	0.57	Schizophrenia;	chr5:50365641	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.905	rs4030569	ENSG00000231752.4	EMBP1	15.29	2.66e-43	3.42e-36	0.74	0.57	Schizophrenia;	chr5:50371779	chr1:121519112~121571892:+
LUAD	trans	rs10940346	1	rs4030570	ENSG00000231752.4	EMBP1	15.29	2.66e-43	3.42e-36	0.74	0.57	Schizophrenia;	chr5:50371829	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.875	rs10076490	ENSG00000231752.4	EMBP1	15.29	2.66e-43	3.42e-36	0.74	0.57	Schizophrenia;	chr5:50389037	chr1:121519112~121571892:+
LUAD	trans	rs916888	0.821	rs199512	ENSG00000264070.1	DND1P1	-15.28	2.9e-43	3.72e-36	-0.85	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45585871~45586929:+
LUAD	trans	rs916888	0.821	rs199509	ENSG00000264070.1	DND1P1	-15.28	2.9e-43	3.72e-36	-0.85	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45585871~45586929:+
LUAD	trans	rs916888	0.821	rs199507	ENSG00000264070.1	DND1P1	-15.28	2.9e-43	3.72e-36	-0.85	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45585871~45586929:+
LUAD	trans	rs7811142	1	rs2897358	ENSG00000228546.2	CTA-313A17.3	15.28	3.07e-43	3.93e-36	0.85	0.57	Platelet count;	chr7:100491017	chr7:102337316~102339115:+
LUAD	trans	rs916888	0.821	rs199514	ENSG00000264070.1	DND1P1	-15.27	3.27e-43	4.19e-36	-0.86	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45585871~45586929:+
LUAD	trans	rs916888	0.697	rs199516	ENSG00000264070.1	DND1P1	-15.27	3.39e-43	4.33e-36	-0.85	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45585871~45586929:+
LUAD	trans	rs10940346	1	rs2137132	ENSG00000231752.4	EMBP1	15.27	3.41e-43	4.35e-36	0.73	0.57	Schizophrenia;	chr5:50353988	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.967	rs1995795	ENSG00000231752.4	EMBP1	15.27	3.41e-43	4.35e-36	0.73	0.57	Schizophrenia;	chr5:50356233	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.967	rs6874829	ENSG00000231752.4	EMBP1	15.27	3.41e-43	4.35e-36	0.73	0.57	Schizophrenia;	chr5:50357573	chr1:121519112~121571892:+
LUAD	trans	rs10940346	1	rs7721808	ENSG00000231752.4	EMBP1	15.27	3.41e-43	4.35e-36	0.73	0.57	Schizophrenia;	chr5:50363136	chr1:121519112~121571892:+
LUAD	trans	rs10940346	1	rs13185587	ENSG00000231752.4	EMBP1	15.27	3.41e-43	4.35e-36	0.73	0.57	Schizophrenia;	chr5:50365409	chr1:121519112~121571892:+
LUAD	trans	rs10940346	1	rs11960661	ENSG00000231752.4	EMBP1	-15.26	3.53e-43	4.5e-36	-0.73	-0.57	Schizophrenia;	chr5:50266528	chr1:121519112~121571892:+
LUAD	trans	rs10940346	1	rs489407	ENSG00000231752.4	EMBP1	-15.26	3.53e-43	4.5e-36	-0.73	-0.57	Schizophrenia;	chr5:50266701	chr1:121519112~121571892:+
LUAD	trans	rs10940346	1	rs491470	ENSG00000231752.4	EMBP1	-15.26	3.53e-43	4.5e-36	-0.73	-0.57	Schizophrenia;	chr5:50266988	chr1:121519112~121571892:+
LUAD	trans	rs2731664	0.792	rs2544809	ENSG00000215571.5	GRK6P1	15.25	4.07e-43	5.19e-36	0.67	0.57	Intelligence (multi-trait analysis);	chr5:177458498	chr13:21319156~21320866:+
LUAD	trans	rs10242455	0.702	rs73401510	ENSG00000228834.1	RP11-249L21.4	15.25	4.12e-43	5.24e-36	1.53	0.57	Blood metabolite levels;	chr7:99468189	chr6:108907615~108907873:-
LUAD	trans	rs10940346	1	rs510897	ENSG00000231752.4	EMBP1	-15.24	4.3e-43	5.47e-36	-0.73	-0.57	Schizophrenia;	chr5:50263017	chr1:121519112~121571892:+
LUAD	trans	rs10940346	1	rs507396	ENSG00000231752.4	EMBP1	-15.24	4.3e-43	5.47e-36	-0.73	-0.57	Schizophrenia;	chr5:50263374	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.875	rs13159506	ENSG00000231752.4	EMBP1	15.24	4.35e-43	5.53e-36	0.74	0.57	Schizophrenia;	chr5:50415061	chr1:121519112~121571892:+
LUAD	trans	rs1816752	0.524	rs7996445	ENSG00000237917.1	PARP4P1	-15.24	4.68e-43	5.95e-36	-0.68	-0.57	Obesity-related traits;	chr13:24475329	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.646	rs4770700	ENSG00000237917.1	PARP4P1	-15.23	4.89e-43	6.21e-36	-0.7	-0.57	Obesity-related traits;	chr13:24494796	chrY:26594851~26634652:-
LUAD	trans	rs6732160	0.574	rs12465780	ENSG00000236165.1	PRADC1P1	-15.23	5.08e-43	6.45e-36	-0.76	-0.57	Intelligence (multi-trait analysis);	chr2:73244884	chr3:36976316~36976840:+
LUAD	trans	rs10940346	1	rs555458	ENSG00000231752.4	EMBP1	-15.23	5.1e-43	6.47e-36	-0.73	-0.57	Schizophrenia;	chr5:50262772	chr1:121519112~121571892:+
LUAD	trans	rs2731664	0.792	rs2630767	ENSG00000215571.5	GRK6P1	15.23	5.12e-43	6.49e-36	0.68	0.57	Intelligence (multi-trait analysis);	chr5:177443699	chr13:21319156~21320866:+
LUAD	trans	rs6732160	0.574	rs7557055	ENSG00000236165.1	PRADC1P1	15.23	5.17e-43	6.56e-36	0.76	0.57	Intelligence (multi-trait analysis);	chr2:73245542	chr3:36976316~36976840:+
LUAD	trans	rs9467773	0.62	rs1027203	ENSG00000242375.1	RP11-498P14.3	15.22	5.8e-43	7.33e-36	0.76	0.57	Intelligence (multi-trait analysis);	chr6:26639104	chr9:97195351~97197687:-
LUAD	trans	rs9467773	0.595	rs2172007	ENSG00000242375.1	RP11-498P14.3	15.22	5.8e-43	7.33e-36	0.76	0.57	Intelligence (multi-trait analysis);	chr6:26639549	chr9:97195351~97197687:-
LUAD	trans	rs8081395	0.627	rs12952730	ENSG00000187870.7	RNFT1P3	15.21	5.91e-43	7.47e-36	0.73	0.57	White blood cell count;	chr17:59901475	chr17:20743333~20754501:-
LUAD	trans	rs8081395	0.627	rs180536	ENSG00000187870.7	RNFT1P3	15.21	5.91e-43	7.47e-36	0.73	0.57	White blood cell count;	chr17:59919445	chr17:20743333~20754501:-
LUAD	trans	rs9611565	0.694	rs11090056	ENSG00000268568.1	AC007228.9	15.21	5.94e-43	7.51e-36	0.82	0.57	Vitiligo;	chr22:41699900	chr19:56672574~56673901:-
LUAD	trans	rs1816752	0.624	rs4770701	ENSG00000237917.1	PARP4P1	-15.21	6.13e-43	7.75e-36	-0.7	-0.57	Obesity-related traits;	chr13:24508806	chrY:26594851~26634652:-
LUAD	trans	rs112721625	1	rs112721625	ENSG00000187870.7	RNFT1P3	15.21	6.44e-43	8.14e-36	0.72	0.57	Monocyte count;	chr17:59850066	chr17:20743333~20754501:-
LUAD	trans	rs7811142	1	rs11559117	ENSG00000228546.2	CTA-313A17.3	15.19	7.44e-43	9.37e-36	0.84	0.57	Platelet count;	chr7:100478991	chr7:102337316~102339115:+
LUAD	trans	rs7811142	1	rs2406253	ENSG00000228546.2	CTA-313A17.3	15.19	7.44e-43	9.37e-36	0.84	0.57	Platelet count;	chr7:100479650	chr7:102337316~102339115:+
LUAD	trans	rs7811142	1	rs4463351	ENSG00000228546.2	CTA-313A17.3	15.19	7.44e-43	9.37e-36	0.84	0.57	Platelet count;	chr7:100480603	chr7:102337316~102339115:+
LUAD	trans	rs7811142	1	rs60844404	ENSG00000228546.2	CTA-313A17.3	15.19	7.44e-43	9.37e-36	0.84	0.57	Platelet count;	chr7:100482851	chr7:102337316~102339115:+
LUAD	trans	rs7811142	1	rs113738841	ENSG00000228546.2	CTA-313A17.3	15.19	7.44e-43	9.37e-36	0.84	0.57	Platelet count;	chr7:100483683	chr7:102337316~102339115:+
LUAD	trans	rs7811142	1	rs11763511	ENSG00000228546.2	CTA-313A17.3	15.19	7.44e-43	9.37e-36	0.84	0.57	Platelet count;	chr7:100484321	chr7:102337316~102339115:+
LUAD	trans	rs7811142	0.943	rs28660238	ENSG00000228546.2	CTA-313A17.3	15.19	7.44e-43	9.38e-36	0.83	0.57	Platelet count;	chr7:100425685	chr7:102337316~102339115:+
LUAD	trans	rs7811142	1	rs28490152	ENSG00000228546.2	CTA-313A17.3	15.19	7.48e-43	9.42e-36	0.83	0.57	Platelet count;	chr7:100423359	chr7:102337316~102339115:+
LUAD	trans	rs1816752	0.646	rs6490937	ENSG00000237917.1	PARP4P1	-15.19	7.88e-43	9.92e-36	-0.68	-0.57	Obesity-related traits;	chr13:24475834	chrY:26594851~26634652:-
LUAD	trans	rs2731664	0.792	rs335466	ENSG00000215571.5	GRK6P1	15.17	8.93e-43	1.12e-35	0.67	0.57	Intelligence (multi-trait analysis);	chr5:177462529	chr13:21319156~21320866:+
LUAD	trans	rs1816752	0.624	rs2096093	ENSG00000237917.1	PARP4P1	-15.17	9e-43	1.13e-35	-0.69	-0.57	Obesity-related traits;	chr13:24472753	chrY:26594851~26634652:-
LUAD	trans	rs6732160	0.525	rs2303907	ENSG00000236165.1	PRADC1P1	15.17	9.04e-43	1.13e-35	0.76	0.57	Intelligence (multi-trait analysis);	chr2:73243369	chr3:36976316~36976840:+
LUAD	trans	rs9611565	0.608	rs2003816	ENSG00000268568.1	AC007228.9	15.17	9.53e-43	1.19e-35	0.82	0.57	Vitiligo;	chr22:41699136	chr19:56672574~56673901:-
LUAD	trans	rs8081395	0.651	rs1292067	ENSG00000187870.7	RNFT1P3	-15.17	9.71e-43	1.21e-35	-0.68	-0.57	White blood cell count;	chr17:59853285	chr17:20743333~20754501:-
LUAD	trans	rs5022636	0.927	rs10788803	ENSG00000180764.13	PIPSL	15.16	1.03e-42	1.28e-35	0.65	0.57	Gut microbiota (functional units);	chr1:151291306	chr10:93958191~93961540:-
LUAD	trans	rs9611565	0.572	rs139569	ENSG00000268568.1	AC007228.9	-15.16	1.07e-42	1.34e-35	-0.82	-0.57	Vitiligo;	chr22:41815137	chr19:56672574~56673901:-
LUAD	trans	rs10940346	1	rs1328253	ENSG00000231752.4	EMBP1	-15.15	1.09e-42	1.36e-35	-0.73	-0.57	Schizophrenia;	chr5:50286916	chr1:121519112~121571892:+
LUAD	trans	rs1816752	0.669	rs3783072	ENSG00000237917.1	PARP4P1	-15.15	1.15e-42	1.44e-35	-0.69	-0.57	Obesity-related traits;	chr13:24493258	chrY:26594851~26634652:-
LUAD	trans	rs8081395	0.58	rs180515	ENSG00000187870.7	RNFT1P3	15.15	1.16e-42	1.44e-35	0.73	0.57	White blood cell count;	chr17:59946914	chr17:20743333~20754501:-
LUAD	trans	rs7730934	1	rs2228044	ENSG00000227018.1	IL6STP1	15.15	1.2e-42	1.49e-35	0.88	0.57	Blood protein levels;	chr5:55968325	chr17:15783288~15784307:+
LUAD	trans	rs7730934	1	rs7730934	ENSG00000227018.1	IL6STP1	15.15	1.2e-42	1.49e-35	0.88	0.57	Blood protein levels;	chr5:55970684	chr17:15783288~15784307:+
LUAD	trans	rs10940346	0.967	rs6449782	ENSG00000231752.4	EMBP1	-15.14	1.21e-42	1.51e-35	-0.73	-0.57	Schizophrenia;	chr5:50291694	chr1:121519112~121571892:+
LUAD	trans	rs1816752	0.646	rs9511291	ENSG00000237917.1	PARP4P1	-15.14	1.25e-42	1.55e-35	-0.68	-0.57	Obesity-related traits;	chr13:24467609	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.646	rs9511292	ENSG00000237917.1	PARP4P1	-15.14	1.25e-42	1.55e-35	-0.68	-0.57	Obesity-related traits;	chr13:24467623	chrY:26594851~26634652:-
LUAD	trans	rs7811142	0.943	rs67196635	ENSG00000228546.2	CTA-313A17.3	15.13	1.33e-42	1.65e-35	0.83	0.57	Platelet count;	chr7:100427941	chr7:102337316~102339115:+
LUAD	trans	rs7811142	1	rs6962151	ENSG00000228546.2	CTA-313A17.3	15.13	1.33e-42	1.65e-35	0.83	0.57	Platelet count;	chr7:100430861	chr7:102337316~102339115:+
LUAD	trans	rs7811142	0.943	rs67483801	ENSG00000228546.2	CTA-313A17.3	15.13	1.33e-42	1.65e-35	0.83	0.57	Platelet count;	chr7:100434135	chr7:102337316~102339115:+
LUAD	trans	rs7811142	1	rs11761784	ENSG00000228546.2	CTA-313A17.3	15.13	1.33e-42	1.65e-35	0.83	0.57	Platelet count;	chr7:100442347	chr7:102337316~102339115:+
LUAD	trans	rs7811142	1	rs112317829	ENSG00000228546.2	CTA-313A17.3	15.13	1.33e-42	1.65e-35	0.83	0.57	Platelet count;	chr7:100445550	chr7:102337316~102339115:+
LUAD	trans	rs7811142	1	rs67239991	ENSG00000228546.2	CTA-313A17.3	15.13	1.33e-42	1.65e-35	0.83	0.57	Platelet count;	chr7:100448881	chr7:102337316~102339115:+
LUAD	trans	rs7811142	0.943	rs111493473	ENSG00000228546.2	CTA-313A17.3	15.13	1.33e-42	1.65e-35	0.83	0.57	Platelet count;	chr7:100452119	chr7:102337316~102339115:+
LUAD	trans	rs916888	0.738	rs199515	ENSG00000264070.1	DND1P1	-15.13	1.4e-42	1.73e-35	-0.82	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45585871~45586929:+
LUAD	trans	rs7811142	0.943	rs111757992	ENSG00000228546.2	CTA-313A17.3	15.13	1.46e-42	1.81e-35	0.83	0.57	Platelet count;	chr7:100418731	chr7:102337316~102339115:+
LUAD	trans	rs1816752	0.646	rs750388	ENSG00000237917.1	PARP4P1	-15.12	1.53e-42	1.89e-35	-0.69	-0.57	Obesity-related traits;	chr13:24461690	chrY:26594851~26634652:-
LUAD	trans	rs9467773	0.596	rs62396201	ENSG00000242375.1	RP11-498P14.3	15.12	1.56e-42	1.93e-35	0.73	0.57	Intelligence (multi-trait analysis);	chr6:26667988	chr9:97195351~97197687:-
LUAD	trans	rs1816752	0.646	rs8002599	ENSG00000237917.1	PARP4P1	-15.12	1.59e-42	1.96e-35	-0.68	-0.57	Obesity-related traits;	chr13:24478486	chrY:26594851~26634652:-
LUAD	trans	rs12709013	0.591	rs30841	ENSG00000233719.3	GOT2P3	15.11	1.71e-42	2.1e-35	0.73	0.57	Blood metabolite ratios;	chr16:58709819	chr12:9641802~9643007:+
LUAD	trans	rs1816752	0.646	rs7319207	ENSG00000237917.1	PARP4P1	-15.09	2.11e-42	2.59e-35	-0.68	-0.57	Obesity-related traits;	chr13:24473220	chrY:26594851~26634652:-
LUAD	trans	rs12709013	0.591	rs30840	ENSG00000233719.3	GOT2P3	15.08	2.35e-42	2.88e-35	0.73	0.57	Blood metabolite ratios;	chr16:58710165	chr12:9641802~9643007:+
LUAD	trans	rs1816752	0.646	rs2862902	ENSG00000237917.1	PARP4P1	-15.08	2.45e-42	2.99e-35	-0.68	-0.57	Obesity-related traits;	chr13:24461965	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.646	rs734715	ENSG00000237917.1	PARP4P1	-15.08	2.45e-42	2.99e-35	-0.68	-0.57	Obesity-related traits;	chr13:24462041	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.646	rs730030	ENSG00000237917.1	PARP4P1	-15.08	2.45e-42	2.99e-35	-0.68	-0.57	Obesity-related traits;	chr13:24462509	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.609	rs7992667	ENSG00000237917.1	PARP4P1	-15.08	2.45e-42	2.99e-35	-0.68	-0.57	Obesity-related traits;	chr13:24462821	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.609	rs7995958	ENSG00000237917.1	PARP4P1	-15.08	2.45e-42	2.99e-35	-0.68	-0.57	Obesity-related traits;	chr13:24462895	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.609	rs8002741	ENSG00000237917.1	PARP4P1	-15.08	2.45e-42	2.99e-35	-0.68	-0.57	Obesity-related traits;	chr13:24462918	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.609	rs7998198	ENSG00000237917.1	PARP4P1	-15.08	2.45e-42	2.99e-35	-0.68	-0.57	Obesity-related traits;	chr13:24462979	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.609	rs7998203	ENSG00000237917.1	PARP4P1	-15.08	2.45e-42	2.99e-35	-0.68	-0.57	Obesity-related traits;	chr13:24462989	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.646	rs7998600	ENSG00000237917.1	PARP4P1	-15.08	2.45e-42	2.99e-35	-0.68	-0.57	Obesity-related traits;	chr13:24463222	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.624	rs9511282	ENSG00000237917.1	PARP4P1	-15.08	2.45e-42	2.99e-35	-0.68	-0.57	Obesity-related traits;	chr13:24463597	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.583	rs9511283	ENSG00000237917.1	PARP4P1	-15.08	2.45e-42	2.99e-35	-0.68	-0.57	Obesity-related traits;	chr13:24463656	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.646	rs9507351	ENSG00000237917.1	PARP4P1	-15.08	2.45e-42	2.99e-35	-0.68	-0.57	Obesity-related traits;	chr13:24465118	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.646	rs4770688	ENSG00000237917.1	PARP4P1	-15.08	2.45e-42	2.99e-35	-0.68	-0.57	Obesity-related traits;	chr13:24466007	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.646	rs4770689	ENSG00000237917.1	PARP4P1	-15.08	2.45e-42	2.99e-35	-0.68	-0.57	Obesity-related traits;	chr13:24466008	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.646	rs12431171	ENSG00000237917.1	PARP4P1	-15.08	2.45e-42	2.99e-35	-0.68	-0.57	Obesity-related traits;	chr13:24466380	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.646	rs12854523	ENSG00000237917.1	PARP4P1	-15.08	2.45e-42	2.99e-35	-0.68	-0.57	Obesity-related traits;	chr13:24466460	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.646	rs9578740	ENSG00000237917.1	PARP4P1	-15.08	2.45e-42	2.99e-35	-0.68	-0.57	Obesity-related traits;	chr13:24466692	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.631	rs4769358	ENSG00000237917.1	PARP4P1	-15.08	2.45e-42	2.99e-35	-0.68	-0.57	Obesity-related traits;	chr13:24466940	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.608	rs4769359	ENSG00000237917.1	PARP4P1	-15.08	2.45e-42	2.99e-35	-0.68	-0.57	Obesity-related traits;	chr13:24466966	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.608	rs4769360	ENSG00000237917.1	PARP4P1	-15.08	2.45e-42	2.99e-35	-0.68	-0.57	Obesity-related traits;	chr13:24467016	chrY:26594851~26634652:-
LUAD	trans	rs916888	0.738	rs199515	ENSG00000214425.5	LRRC37A4P	15.07	2.61e-42	3.18e-35	0.79	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45506741~45550335:-
LUAD	trans	rs7503168	0.558	rs12945102	ENSG00000234130.2	RP13-88F20.1	15.07	2.66e-42	3.25e-35	1.15	0.57	Plateletcrit;	chr17:35601894	chrX:93222220~93225015:-
LUAD	trans	rs1816752	0.646	rs9511279	ENSG00000237917.1	PARP4P1	-15.07	2.67e-42	3.25e-35	-0.68	-0.57	Obesity-related traits;	chr13:24463348	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.646	rs9511280	ENSG00000237917.1	PARP4P1	-15.07	2.67e-42	3.25e-35	-0.68	-0.57	Obesity-related traits;	chr13:24463364	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.646	rs9511281	ENSG00000237917.1	PARP4P1	-15.07	2.67e-42	3.25e-35	-0.68	-0.57	Obesity-related traits;	chr13:24463441	chrY:26594851~26634652:-
LUAD	trans	rs7503168	0.558	rs11650621	ENSG00000234130.2	RP13-88F20.1	15.06	2.83e-42	3.43e-35	1.15	0.57	Plateletcrit;	chr17:35631827	chrX:93222220~93225015:-
LUAD	trans	rs7503168	0.558	rs12947274	ENSG00000234130.2	RP13-88F20.1	15.06	2.83e-42	3.43e-35	1.15	0.57	Plateletcrit;	chr17:35635146	chrX:93222220~93225015:-
LUAD	trans	rs7503168	0.558	rs12936693	ENSG00000234130.2	RP13-88F20.1	15.06	2.83e-42	3.43e-35	1.15	0.57	Plateletcrit;	chr17:35639391	chrX:93222220~93225015:-
LUAD	trans	rs7503168	0.558	rs71381465	ENSG00000234130.2	RP13-88F20.1	15.06	2.83e-42	3.43e-35	1.15	0.57	Plateletcrit;	chr17:35647713	chrX:93222220~93225015:-
LUAD	trans	rs7503168	0.558	rs12943224	ENSG00000234130.2	RP13-88F20.1	15.06	2.83e-42	3.43e-35	1.15	0.57	Plateletcrit;	chr17:35650519	chrX:93222220~93225015:-
LUAD	trans	rs1816752	0.646	rs7322323	ENSG00000237917.1	PARP4P1	-15.06	2.87e-42	3.49e-35	-0.68	-0.57	Obesity-related traits;	chr13:24479189	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.646	rs9511293	ENSG00000237917.1	PARP4P1	-15.06	2.91e-42	3.53e-35	-0.68	-0.57	Obesity-related traits;	chr13:24467747	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.646	rs9511294	ENSG00000237917.1	PARP4P1	-15.06	2.91e-42	3.53e-35	-0.68	-0.57	Obesity-related traits;	chr13:24467773	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.646	rs9511296	ENSG00000237917.1	PARP4P1	-15.06	2.91e-42	3.53e-35	-0.68	-0.57	Obesity-related traits;	chr13:24467962	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.646	rs9634401	ENSG00000237917.1	PARP4P1	-15.06	2.91e-42	3.53e-35	-0.68	-0.57	Obesity-related traits;	chr13:24468072	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.624	rs9634402	ENSG00000237917.1	PARP4P1	-15.06	2.91e-42	3.53e-35	-0.68	-0.57	Obesity-related traits;	chr13:24468119	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.646	rs9634403	ENSG00000237917.1	PARP4P1	-15.06	2.91e-42	3.53e-35	-0.68	-0.57	Obesity-related traits;	chr13:24468211	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.646	rs9581064	ENSG00000237917.1	PARP4P1	-15.06	2.91e-42	3.53e-35	-0.68	-0.57	Obesity-related traits;	chr13:24468251	chrY:26594851~26634652:-
LUAD	trans	rs73990293	0.737	rs12951703	ENSG00000234130.2	RP13-88F20.1	15.06	2.93e-42	3.55e-35	1.15	0.57	Clopidogrel active metabolite levels;	chr17:35586035	chrX:93222220~93225015:-
LUAD	trans	rs7503168	0.558	rs79468963	ENSG00000234130.2	RP13-88F20.1	15.06	2.93e-42	3.55e-35	1.15	0.57	Plateletcrit;	chr17:35590408	chrX:93222220~93225015:-
LUAD	trans	rs7503168	0.558	rs71381461	ENSG00000234130.2	RP13-88F20.1	15.06	2.93e-42	3.55e-35	1.15	0.57	Plateletcrit;	chr17:35593601	chrX:93222220~93225015:-
LUAD	trans	rs7503168	0.558	rs34937989	ENSG00000234130.2	RP13-88F20.1	15.06	2.93e-42	3.55e-35	1.15	0.57	Plateletcrit;	chr17:35594744	chrX:93222220~93225015:-
LUAD	trans	rs10242455	0.557	rs2404487	ENSG00000228834.1	RP11-249L21.4	15.05	3.02e-42	3.66e-35	1.53	0.57	Blood metabolite levels;	chr7:99440434	chr6:108907615~108907873:-
LUAD	trans	rs10242455	0.702	rs73711280	ENSG00000228834.1	RP11-249L21.4	15.05	3.02e-42	3.66e-35	1.53	0.57	Blood metabolite levels;	chr7:99441981	chr6:108907615~108907873:-
LUAD	trans	rs10242455	0.702	rs73397499	ENSG00000228834.1	RP11-249L21.4	15.05	3.02e-42	3.66e-35	1.53	0.57	Blood metabolite levels;	chr7:99442004	chr6:108907615~108907873:-
LUAD	trans	rs10242455	0.702	rs45448997	ENSG00000228834.1	RP11-249L21.4	15.05	3.02e-42	3.66e-35	1.53	0.57	Blood metabolite levels;	chr7:99443975	chr6:108907615~108907873:-
LUAD	trans	rs10242455	0.557	rs45492501	ENSG00000228834.1	RP11-249L21.4	15.05	3.02e-42	3.66e-35	1.53	0.57	Blood metabolite levels;	chr7:99449407	chr6:108907615~108907873:-
LUAD	trans	rs10242455	0.702	rs17854665	ENSG00000228834.1	RP11-249L21.4	15.05	3.02e-42	3.66e-35	1.53	0.57	Blood metabolite levels;	chr7:99452416	chr6:108907615~108907873:-
LUAD	trans	rs10242455	0.702	rs45461000	ENSG00000228834.1	RP11-249L21.4	15.05	3.02e-42	3.66e-35	1.53	0.57	Blood metabolite levels;	chr7:99455087	chr6:108907615~108907873:-
LUAD	trans	rs12709013	0.569	rs30837	ENSG00000233719.3	GOT2P3	15.05	3.1e-42	3.74e-35	0.74	0.57	Blood metabolite ratios;	chr16:58711942	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.591	rs30834	ENSG00000233719.3	GOT2P3	15.05	3.1e-42	3.74e-35	0.74	0.57	Blood metabolite ratios;	chr16:58715394	chr12:9641802~9643007:+
LUAD	trans	rs1816752	0.608	rs9511290	ENSG00000237917.1	PARP4P1	-15.05	3.1e-42	3.75e-35	-0.68	-0.57	Obesity-related traits;	chr13:24467189	chrY:26594851~26634652:-
LUAD	trans	rs7811142	0.943	rs28578163	ENSG00000228546.2	CTA-313A17.3	15.05	3.15e-42	3.8e-35	0.82	0.57	Platelet count;	chr7:100447131	chr7:102337316~102339115:+
LUAD	trans	rs9611565	0.918	rs2281333	ENSG00000268568.1	AC007228.9	-15.05	3.15e-42	3.8e-35	-0.79	-0.57	Vitiligo;	chr22:41353626	chr19:56672574~56673901:-
LUAD	trans	rs10940346	1	rs492337	ENSG00000231752.4	EMBP1	-15.05	3.21e-42	3.87e-35	-0.73	-0.57	Schizophrenia;	chr5:50274706	chr1:121519112~121571892:+
LUAD	trans	rs7811142	0.83	rs705866	ENSG00000228546.2	CTA-313A17.3	15.05	3.3e-42	3.98e-35	0.9	0.57	Platelet count;	chr7:100367662	chr7:102337316~102339115:+
LUAD	trans	rs7811142	0.83	rs6965458	ENSG00000228546.2	CTA-313A17.3	15.05	3.3e-42	3.98e-35	0.9	0.57	Platelet count;	chr7:100375779	chr7:102337316~102339115:+
LUAD	trans	rs916888	0.821	rs70600	ENSG00000214425.5	LRRC37A4P	-15.05	3.31e-42	3.99e-35	-0.85	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45506741~45550335:-
LUAD	trans	rs10940346	1	rs4643959	ENSG00000231752.4	EMBP1	15.04	3.36e-42	4.05e-35	0.73	0.57	Schizophrenia;	chr5:50391631	chr1:121519112~121571892:+
LUAD	trans	rs12709013	0.574	rs839418	ENSG00000233719.3	GOT2P3	15.04	3.41e-42	4.11e-35	0.73	0.57	Blood metabolite ratios;	chr16:58705426	chr12:9641802~9643007:+
LUAD	trans	rs10940346	1	rs2668024	ENSG00000231752.4	EMBP1	-15.03	3.99e-42	4.79e-35	-0.75	-0.57	Schizophrenia;	chr5:50414421	chr1:121519112~121571892:+
LUAD	trans	rs6732160	0.574	rs1991612	ENSG00000236165.1	PRADC1P1	15.02	4.24e-42	5.09e-35	0.75	0.57	Intelligence (multi-trait analysis);	chr2:73253373	chr3:36976316~36976840:+
LUAD	trans	rs6732160	0.549	rs6744529	ENSG00000236165.1	PRADC1P1	15.02	4.24e-42	5.09e-35	0.75	0.57	Intelligence (multi-trait analysis);	chr2:73253741	chr3:36976316~36976840:+
LUAD	trans	rs10940346	1	rs6874697	ENSG00000231752.4	EMBP1	15.02	4.34e-42	5.2e-35	0.72	0.57	Schizophrenia;	chr5:50344307	chr1:121519112~121571892:+
LUAD	trans	rs9467773	0.549	rs9461273	ENSG00000242375.1	RP11-498P14.3	-15.01	4.72e-42	5.65e-35	-0.73	-0.56	Intelligence (multi-trait analysis);	chr6:26584298	chr9:97195351~97197687:-
LUAD	trans	rs10940346	0.934	rs303231	ENSG00000231752.4	EMBP1	15	5.09e-42	6.09e-35	0.74	0.56	Schizophrenia;	chr5:50447369	chr1:121519112~121571892:+
LUAD	trans	rs10242455	0.702	rs73403290	ENSG00000228834.1	RP11-249L21.4	15	5.21e-42	6.22e-35	1.51	0.56	Blood metabolite levels;	chr7:99560205	chr6:108907615~108907873:-
LUAD	trans	rs7503168	0.558	rs71381469	ENSG00000234130.2	RP13-88F20.1	15	5.32e-42	6.35e-35	1.16	0.56	Plateletcrit;	chr17:35712127	chrX:93222220~93225015:-
LUAD	trans	rs10940346	1	rs11948752	ENSG00000231752.4	EMBP1	-15	5.39e-42	6.43e-35	-0.74	-0.56	Schizophrenia;	chr5:50504082	chr1:121519112~121571892:+
LUAD	trans	rs916888	0.821	rs199504	ENSG00000264070.1	DND1P1	-15	5.55e-42	6.62e-35	-0.84	-0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45585871~45586929:+
LUAD	trans	rs7730934	1	rs2408157	ENSG00000227018.1	IL6STP1	14.99	5.75e-42	6.86e-35	0.88	0.56	Blood protein levels;	chr5:55974940	chr17:15783288~15784307:+
LUAD	trans	rs7811142	0.83	rs76798830	ENSG00000228546.2	CTA-313A17.3	14.99	6.14e-42	7.31e-35	0.89	0.56	Platelet count;	chr7:100355205	chr7:102337316~102339115:+
LUAD	trans	rs7811142	0.775	rs6946768	ENSG00000228546.2	CTA-313A17.3	14.99	6.14e-42	7.31e-35	0.89	0.56	Platelet count;	chr7:100356770	chr7:102337316~102339115:+
LUAD	trans	rs7811142	0.775	rs1636980	ENSG00000228546.2	CTA-313A17.3	-14.98	6.38e-42	7.59e-35	-0.87	-0.56	Platelet count;	chr7:100341241	chr7:102337316~102339115:+
LUAD	trans	rs7811142	0.83	rs75636500	ENSG00000228546.2	CTA-313A17.3	14.98	6.62e-42	7.87e-35	0.89	0.56	Platelet count;	chr7:100350034	chr7:102337316~102339115:+
LUAD	trans	rs7811142	1	rs68116612	ENSG00000228546.2	CTA-313A17.3	14.97	7.12e-42	8.44e-35	0.83	0.56	Platelet count;	chr7:100408870	chr7:102337316~102339115:+
LUAD	trans	rs7811142	0.83	rs7341507	ENSG00000228546.2	CTA-313A17.3	14.97	7.28e-42	8.62e-35	0.88	0.56	Platelet count;	chr7:100353692	chr7:102337316~102339115:+
LUAD	trans	rs73990293	0.737	rs4531775	ENSG00000234130.2	RP13-88F20.1	14.97	7.29e-42	8.63e-35	1.15	0.56	Clopidogrel active metabolite levels;	chr17:35559919	chrX:93222220~93225015:-
LUAD	trans	rs10940346	1	rs10940346	ENSG00000231752.4	EMBP1	-14.97	7.39e-42	8.75e-35	-0.73	-0.56	Schizophrenia;	chr5:50510208	chr1:121519112~121571892:+
LUAD	trans	rs13190036	1	rs34446750	ENSG00000217325.2	PRELID1P1	-14.96	8.04e-42	9.51e-35	-0.93	-0.56	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177168079	chr6:126643488~126644390:+
LUAD	trans	rs10940346	1	rs7708897	ENSG00000231752.4	EMBP1	-14.96	8.17e-42	9.66e-35	-0.74	-0.56	Schizophrenia;	chr5:50528209	chr1:121519112~121571892:+
LUAD	trans	rs7811142	0.83	rs7792525	ENSG00000228546.2	CTA-313A17.3	14.95	9.25e-42	1.09e-34	0.87	0.56	Platelet count;	chr7:100374499	chr7:102337316~102339115:+
LUAD	trans	rs1816752	0.646	rs7322329	ENSG00000237917.1	PARP4P1	-14.94	9.59e-42	1.13e-34	-0.68	-0.56	Obesity-related traits;	chr13:24479193	chrY:26594851~26634652:-
LUAD	trans	rs10940346	1	rs7380858	ENSG00000231752.4	EMBP1	-14.94	9.75e-42	1.15e-34	-0.74	-0.56	Schizophrenia;	chr5:50537022	chr1:121519112~121571892:+
LUAD	trans	rs7811142	0.72	rs112622797	ENSG00000228546.2	CTA-313A17.3	14.94	9.8e-42	1.16e-34	0.9	0.56	Platelet count;	chr7:100319793	chr7:102337316~102339115:+
LUAD	trans	rs7730934	0.892	rs11745285	ENSG00000227018.1	IL6STP1	14.94	9.88e-42	1.16e-34	0.87	0.56	Blood protein levels;	chr5:55967513	chr17:15783288~15784307:+
LUAD	trans	rs7730934	1	rs6450358	ENSG00000227018.1	IL6STP1	14.94	9.91e-42	1.17e-34	0.87	0.56	Blood protein levels;	chr5:55974176	chr17:15783288~15784307:+
LUAD	trans	rs7503168	0.558	rs34874930	ENSG00000234130.2	RP13-88F20.1	14.94	1.03e-41	1.21e-34	1.16	0.56	Plateletcrit;	chr17:35667961	chrX:93222220~93225015:-
LUAD	trans	rs7811142	1	rs7809801	ENSG00000228546.2	CTA-313A17.3	14.93	1.04e-41	1.22e-34	0.82	0.56	Platelet count;	chr7:100474408	chr7:102337316~102339115:+
LUAD	trans	rs7811142	1	rs11766752	ENSG00000228546.2	CTA-313A17.3	14.93	1.04e-41	1.22e-34	0.82	0.56	Platelet count;	chr7:100475669	chr7:102337316~102339115:+
LUAD	trans	rs13190036	0.901	rs4631	ENSG00000217325.2	PRELID1P1	14.93	1.04e-41	1.23e-34	0.94	0.56	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177306115	chr6:126643488~126644390:+
LUAD	trans	rs9611565	0.571	rs7364123	ENSG00000268568.1	AC007228.9	-14.93	1.05e-41	1.24e-34	-0.79	-0.56	Vitiligo;	chr22:41820322	chr19:56672574~56673901:-
LUAD	trans	rs13190036	1	rs4976682	ENSG00000217325.2	PRELID1P1	14.93	1.06e-41	1.25e-34	0.85	0.56	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177299001	chr6:126643488~126644390:+
LUAD	trans	rs13190036	1	rs13157667	ENSG00000217325.2	PRELID1P1	-14.93	1.12e-41	1.31e-34	-0.94	-0.56	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177186876	chr6:126643488~126644390:+
LUAD	trans	rs1816752	0.646	rs750389	ENSG00000237917.1	PARP4P1	-14.92	1.15e-41	1.35e-34	-0.68	-0.56	Obesity-related traits;	chr13:24461677	chrY:26594851~26634652:-
LUAD	trans	rs1816752	0.646	rs2902359	ENSG00000237917.1	PARP4P1	-14.92	1.15e-41	1.35e-34	-0.68	-0.56	Obesity-related traits;	chr13:24461783	chrY:26594851~26634652:-
LUAD	trans	rs7503168	0.558	rs11654542	ENSG00000234130.2	RP13-88F20.1	14.91	1.39e-41	1.63e-34	1.16	0.56	Plateletcrit;	chr17:35662289	chrX:93222220~93225015:-
LUAD	trans	rs10940346	0.934	rs2353960	ENSG00000231752.4	EMBP1	-14.9	1.47e-41	1.72e-34	-0.73	-0.56	Schizophrenia;	chr5:50481153	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.935	rs4971258	ENSG00000231752.4	EMBP1	-14.9	1.47e-41	1.72e-34	-0.73	-0.56	Schizophrenia;	chr5:50498560	chr1:121519112~121571892:+
LUAD	trans	rs7503168	0.558	rs71381460	ENSG00000234130.2	RP13-88F20.1	14.9	1.47e-41	1.72e-34	1.14	0.56	Plateletcrit;	chr17:35564602	chrX:93222220~93225015:-
LUAD	trans	rs7503168	0.558	rs11655098	ENSG00000234130.2	RP13-88F20.1	14.9	1.47e-41	1.72e-34	1.14	0.56	Plateletcrit;	chr17:35567831	chrX:93222220~93225015:-
LUAD	trans	rs7503168	0.558	rs17638076	ENSG00000234130.2	RP13-88F20.1	14.9	1.47e-41	1.72e-34	1.14	0.56	Plateletcrit;	chr17:35569254	chrX:93222220~93225015:-
LUAD	trans	rs7503168	0.558	rs12939138	ENSG00000234130.2	RP13-88F20.1	14.9	1.49e-41	1.74e-34	1.14	0.56	Plateletcrit;	chr17:35574559	chrX:93222220~93225015:-
LUAD	trans	rs7811142	0.72	rs7795656	ENSG00000228546.2	CTA-313A17.3	14.9	1.51e-41	1.77e-34	0.87	0.56	Platelet count;	chr7:100352674	chr7:102337316~102339115:+
LUAD	trans	rs7811142	1	rs4472444	ENSG00000228546.2	CTA-313A17.3	14.9	1.52e-41	1.77e-34	0.82	0.56	Platelet count;	chr7:100473135	chr7:102337316~102339115:+
LUAD	trans	rs10940346	1	rs56387400	ENSG00000231752.4	EMBP1	-14.89	1.7e-41	1.98e-34	-0.74	-0.56	Schizophrenia;	chr5:50517577	chr1:121519112~121571892:+
LUAD	trans	rs1816752	0.646	rs750390	ENSG00000237917.1	PARP4P1	-14.89	1.72e-41	2.01e-34	-0.68	-0.56	Obesity-related traits;	chr13:24461603	chrY:26594851~26634652:-
LUAD	trans	rs7503168	0.558	rs17670584	ENSG00000234130.2	RP13-88F20.1	14.88	1.81e-41	2.11e-34	1.16	0.56	Plateletcrit;	chr17:35671885	chrX:93222220~93225015:-
LUAD	trans	rs7503168	0.643	rs71381467	ENSG00000234130.2	RP13-88F20.1	14.87	1.95e-41	2.27e-34	1.16	0.56	Plateletcrit;	chr17:35693030	chrX:93222220~93225015:-
LUAD	trans	rs7503168	0.643	rs17608253	ENSG00000234130.2	RP13-88F20.1	14.87	1.95e-41	2.27e-34	1.16	0.56	Plateletcrit;	chr17:35699451	chrX:93222220~93225015:-
LUAD	trans	rs73990293	0.737	rs11657558	ENSG00000234130.2	RP13-88F20.1	14.87	1.95e-41	2.27e-34	1.16	0.56	Clopidogrel active metabolite levels;	chr17:35702305	chrX:93222220~93225015:-
LUAD	trans	rs13190036	1	rs13167431	ENSG00000217325.2	PRELID1P1	-14.87	2.03e-41	2.35e-34	-0.92	-0.56	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177194074	chr6:126643488~126644390:+
LUAD	trans	rs1816752	0.646	rs7997248	ENSG00000237917.1	PARP4P1	-14.86	2.21e-41	2.57e-34	-0.69	-0.56	Obesity-related traits;	chr13:24507050	chrY:26594851~26634652:-
LUAD	trans	rs7811142	0.83	rs11765869	ENSG00000228546.2	CTA-313A17.3	14.85	2.36e-41	2.72e-34	0.89	0.56	Platelet count;	chr7:100367166	chr7:102337316~102339115:+
LUAD	trans	rs10940346	0.934	rs2353222	ENSG00000231752.4	EMBP1	-14.83	2.89e-41	3.33e-34	-0.73	-0.56	Schizophrenia;	chr5:50174249	chr1:121519112~121571892:+
LUAD	trans	rs7811142	1	rs73161759	ENSG00000228546.2	CTA-313A17.3	14.83	3.03e-41	3.48e-34	0.84	0.56	Platelet count;	chr7:100412371	chr7:102337316~102339115:+
LUAD	trans	rs10940346	0.902	rs4865727	ENSG00000231752.4	EMBP1	-14.83	3.07e-41	3.52e-34	-0.73	-0.56	Schizophrenia;	chr5:50145945	chr1:121519112~121571892:+
LUAD	trans	rs9611565	0.879	rs4820437	ENSG00000268568.1	AC007228.9	-14.83	3.16e-41	3.63e-34	-0.78	-0.56	Vitiligo;	chr22:41365286	chr19:56672574~56673901:-
LUAD	trans	rs1816752	0.646	rs3783073	ENSG00000237917.1	PARP4P1	-14.82	3.21e-41	3.68e-34	-0.69	-0.56	Obesity-related traits;	chr13:24493222	chrY:26594851~26634652:-
LUAD	trans	rs10940346	1	rs12520874	ENSG00000231752.4	EMBP1	-14.82	3.43e-41	3.93e-34	-0.74	-0.56	Schizophrenia;	chr5:50523857	chr1:121519112~121571892:+
LUAD	trans	rs916888	0.821	rs199506	ENSG00000214425.5	LRRC37A4P	14.82	3.48e-41	3.99e-34	0.83	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45506741~45550335:-
LUAD	trans	rs10940346	0.653	rs4371800	ENSG00000231752.4	EMBP1	-14.81	3.64e-41	4.17e-34	-0.73	-0.56	Schizophrenia;	chr5:50225349	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.716	rs8188088	ENSG00000231752.4	EMBP1	-14.81	3.72e-41	4.25e-34	-0.73	-0.56	Schizophrenia;	chr5:50215591	chr1:121519112~121571892:+
LUAD	trans	rs2657294	0.62	rs7903537	ENSG00000172974.11	AC007318.5	14.81	3.73e-41	4.26e-34	0.61	0.56	Pneumonia;	chr10:75087732	chr2:65205108~65205988:+
LUAD	trans	rs2657294	0.62	rs2395136	ENSG00000172974.11	AC007318.5	14.81	3.73e-41	4.26e-34	0.61	0.56	Pneumonia;	chr10:75088213	chr2:65205108~65205988:+
LUAD	trans	rs7811142	0.83	rs6948685	ENSG00000228546.2	CTA-313A17.3	14.8	4.09e-41	4.66e-34	0.87	0.56	Platelet count;	chr7:100372565	chr7:102337316~102339115:+
LUAD	trans	rs9611565	0.879	rs5758311	ENSG00000268568.1	AC007228.9	-14.79	4.72e-41	5.36e-34	-0.78	-0.56	Vitiligo;	chr22:41363371	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.877	rs3817999	ENSG00000268568.1	AC007228.9	14.79	4.75e-41	5.4e-34	0.77	0.56	Vitiligo;	chr22:41351713	chr19:56672574~56673901:-
LUAD	trans	rs10940346	0.818	rs472278	ENSG00000231752.4	EMBP1	-14.78	5.02e-41	5.7e-34	-0.73	-0.56	Schizophrenia;	chr5:50215972	chr1:121519112~121571892:+
LUAD	trans	rs6732160	0.691	rs7599223	ENSG00000236165.1	PRADC1P1	14.78	5.27e-41	5.97e-34	0.73	0.56	Intelligence (multi-trait analysis);	chr2:73199975	chr3:36976316~36976840:+
LUAD	trans	rs7811142	0.83	rs11761253	ENSG00000228546.2	CTA-313A17.3	14.77	5.47e-41	6.18e-34	0.87	0.56	Platelet count;	chr7:100341698	chr7:102337316~102339115:+
LUAD	trans	rs9467773	0.595	rs13207371	ENSG00000242375.1	RP11-498P14.3	14.76	6.15e-41	6.93e-34	0.74	0.56	Intelligence (multi-trait analysis);	chr6:26590846	chr9:97195351~97197687:-
LUAD	trans	rs6732160	0.691	rs1960233	ENSG00000236165.1	PRADC1P1	14.76	6.17e-41	6.96e-34	0.74	0.56	Intelligence (multi-trait analysis);	chr2:73194250	chr3:36976316~36976840:+
LUAD	trans	rs6732160	0.691	rs2007191	ENSG00000236165.1	PRADC1P1	14.76	6.17e-41	6.96e-34	0.74	0.56	Intelligence (multi-trait analysis);	chr2:73194335	chr3:36976316~36976840:+
LUAD	trans	rs9611565	0.614	rs4822053	ENSG00000268568.1	AC007228.9	-14.75	6.66e-41	7.5e-34	-0.79	-0.56	Vitiligo;	chr22:41816932	chr19:56672574~56673901:-
LUAD	trans	rs10940346	0.714	rs12523073	ENSG00000231752.4	EMBP1	-14.75	6.84e-41	7.7e-34	-0.73	-0.56	Schizophrenia;	chr5:50153697	chr1:121519112~121571892:+
LUAD	trans	rs7811142	1	rs67471932	ENSG00000228546.2	CTA-313A17.3	14.75	6.92e-41	7.79e-34	0.84	0.56	Platelet count;	chr7:100412362	chr7:102337316~102339115:+
LUAD	trans	rs7811142	1	rs66632384	ENSG00000228546.2	CTA-313A17.3	14.75	7.07e-41	7.95e-34	0.83	0.56	Platelet count;	chr7:100421281	chr7:102337316~102339115:+
LUAD	trans	rs7811142	0.943	rs73403312	ENSG00000228546.2	CTA-313A17.3	14.75	7.07e-41	7.95e-34	0.83	0.56	Platelet count;	chr7:100426530	chr7:102337316~102339115:+
LUAD	trans	rs9611565	0.918	rs6002351	ENSG00000268568.1	AC007228.9	-14.74	7.4e-41	8.32e-34	-0.77	-0.56	Vitiligo;	chr22:41361219	chr19:56672574~56673901:-
LUAD	trans	rs7811142	0.83	rs78256546	ENSG00000228546.2	CTA-313A17.3	14.74	7.5e-41	8.41e-34	0.87	0.56	Platelet count;	chr7:100355347	chr7:102337316~102339115:+
LUAD	trans	rs7811142	0.83	rs41280971	ENSG00000228546.2	CTA-313A17.3	14.74	7.5e-41	8.41e-34	0.87	0.56	Platelet count;	chr7:100356834	chr7:102337316~102339115:+
LUAD	trans	rs7811142	0.83	rs3087502	ENSG00000228546.2	CTA-313A17.3	14.74	7.5e-41	8.41e-34	0.87	0.56	Platelet count;	chr7:100357741	chr7:102337316~102339115:+
LUAD	trans	rs7811142	0.83	rs61735533	ENSG00000228546.2	CTA-313A17.3	14.74	7.5e-41	8.41e-34	0.87	0.56	Platelet count;	chr7:100358243	chr7:102337316~102339115:+
LUAD	trans	rs7811142	0.83	rs11761426	ENSG00000228546.2	CTA-313A17.3	14.74	7.5e-41	8.41e-34	0.87	0.56	Platelet count;	chr7:100359270	chr7:102337316~102339115:+
LUAD	trans	rs7811142	0.83	rs77861211	ENSG00000228546.2	CTA-313A17.3	14.74	7.5e-41	8.41e-34	0.87	0.56	Platelet count;	chr7:100364473	chr7:102337316~102339115:+
LUAD	trans	rs7811142	0.83	rs11769057	ENSG00000228546.2	CTA-313A17.3	14.74	7.5e-41	8.41e-34	0.87	0.56	Platelet count;	chr7:100367038	chr7:102337316~102339115:+
LUAD	trans	rs7811142	0.943	rs3900792	ENSG00000228546.2	CTA-313A17.3	14.73	8.17e-41	9.16e-34	0.82	0.56	Platelet count;	chr7:100406954	chr7:102337316~102339115:+
LUAD	trans	rs7811142	0.779	rs77370288	ENSG00000228546.2	CTA-313A17.3	14.73	8.35e-41	9.35e-34	0.87	0.56	Platelet count;	chr7:100350274	chr7:102337316~102339115:+
LUAD	trans	rs2731664	0.792	rs652242	ENSG00000215571.5	GRK6P1	14.73	8.61e-41	9.64e-34	0.66	0.56	Intelligence (multi-trait analysis);	chr5:177446009	chr13:21319156~21320866:+
LUAD	trans	rs10940346	0.584	rs496108	ENSG00000231752.4	EMBP1	-14.72	9.51e-41	1.06e-33	-0.72	-0.56	Schizophrenia;	chr5:50236794	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.744	rs498951	ENSG00000231752.4	EMBP1	-14.72	9.51e-41	1.06e-33	-0.72	-0.56	Schizophrenia;	chr5:50238681	chr1:121519112~121571892:+
LUAD	trans	rs916888	0.821	rs415430	ENSG00000214425.5	LRRC37A4P	14.71	9.98e-41	1.12e-33	0.81	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45506741~45550335:-
LUAD	trans	rs916888	0.779	rs430685	ENSG00000214425.5	LRRC37A4P	14.71	9.98e-41	1.12e-33	0.81	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45506741~45550335:-
LUAD	trans	rs10940346	0.846	rs8188203	ENSG00000231752.4	EMBP1	-14.71	1.05e-40	1.18e-33	-0.72	-0.56	Schizophrenia;	chr5:50161448	chr1:121519112~121571892:+
LUAD	trans	rs7121616	0.576	rs1461495	ENSG00000234176.1	HSPA8P1	-14.71	1.07e-40	1.2e-33	-0.72	-0.56	Breast cancer;	chr11:123056136	chrX:121203182~121205014:-
LUAD	trans	rs7811142	0.83	rs11771936	ENSG00000228546.2	CTA-313A17.3	14.7	1.11e-40	1.24e-33	0.87	0.56	Platelet count;	chr7:100345660	chr7:102337316~102339115:+
LUAD	trans	rs916888	0.821	rs199505	ENSG00000214425.5	LRRC37A4P	14.7	1.13e-40	1.26e-33	0.81	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45506741~45550335:-
LUAD	trans	rs916888	0.821	rs70602	ENSG00000214425.5	LRRC37A4P	14.7	1.13e-40	1.26e-33	0.81	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45506741~45550335:-
LUAD	trans	rs6732160	0.691	rs11886257	ENSG00000236165.1	PRADC1P1	14.7	1.18e-40	1.31e-33	0.73	0.56	Intelligence (multi-trait analysis);	chr2:73189745	chr3:36976316~36976840:+
LUAD	trans	rs10940346	0.935	rs2353959	ENSG00000231752.4	EMBP1	-14.7	1.2e-40	1.33e-33	-0.73	-0.56	Schizophrenia;	chr5:50473217	chr1:121519112~121571892:+
LUAD	trans	rs7811142	1	rs74460138	ENSG00000228546.2	CTA-313A17.3	14.69	1.23e-40	1.37e-33	0.83	0.56	Platelet count;	chr7:100429716	chr7:102337316~102339115:+
LUAD	trans	rs7811142	1	rs4989959	ENSG00000228546.2	CTA-313A17.3	14.69	1.23e-40	1.37e-33	0.83	0.56	Platelet count;	chr7:100434665	chr7:102337316~102339115:+
LUAD	trans	rs6732160	0.691	rs6728147	ENSG00000236165.1	PRADC1P1	-14.69	1.28e-40	1.42e-33	-0.73	-0.56	Intelligence (multi-trait analysis);	chr2:73196362	chr3:36976316~36976840:+
LUAD	trans	rs916888	0.61	rs199529	ENSG00000214425.5	LRRC37A4P	-14.68	1.36e-40	1.51e-33	-0.78	-0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:45506741~45550335:-
LUAD	trans	rs12709013	0.755	rs1424245	ENSG00000230849.2	GOT2P2	14.68	1.36e-40	1.51e-33	0.69	0.56	Blood metabolite ratios;	chr16:58729926	chr1:173141100~173142350:-
LUAD	trans	rs7811142	0.83	rs1063945	ENSG00000228546.2	CTA-313A17.3	14.68	1.38e-40	1.53e-33	0.87	0.56	Platelet count;	chr7:100332824	chr7:102337316~102339115:+
LUAD	trans	rs9467773	0.523	rs2498399	ENSG00000242375.1	RP11-498P14.3	14.68	1.45e-40	1.61e-33	0.76	0.56	Intelligence (multi-trait analysis);	chr6:26795343	chr9:97195351~97197687:-
LUAD	trans	rs6708331	0.54	rs11890701	ENSG00000232654.1	FAM136BP	14.67	1.54e-40	1.71e-33	0.68	0.56	Obesity-related traits;	chr2:70133325	chr6:3045384~3045800:+
LUAD	trans	rs10940346	0.653	rs72768421	ENSG00000231752.4	EMBP1	-14.67	1.59e-40	1.76e-33	-0.72	-0.56	Schizophrenia;	chr5:50246898	chr1:121519112~121571892:+
LUAD	trans	rs5022636	0.927	rs4971030	ENSG00000180764.13	PIPSL	-14.67	1.62e-40	1.79e-33	-0.61	-0.56	Gut microbiota (functional units);	chr1:151308519	chr10:93958191~93961540:-
LUAD	trans	rs7811142	1	rs1000215	ENSG00000228546.2	CTA-313A17.3	14.66	1.64e-40	1.82e-33	0.8	0.56	Platelet count;	chr7:100406920	chr7:102337316~102339115:+
LUAD	trans	rs916888	0.697	rs199516	ENSG00000214425.5	LRRC37A4P	14.66	1.69e-40	1.87e-33	0.8	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45506741~45550335:-
LUAD	trans	rs7503168	0.558	rs80278654	ENSG00000234130.2	RP13-88F20.1	14.66	1.75e-40	1.94e-33	1.14	0.56	Plateletcrit;	chr17:35622193	chrX:93222220~93225015:-
LUAD	trans	rs7121616	0.531	rs1461497	ENSG00000234176.1	HSPA8P1	14.65	1.88e-40	2.07e-33	0.74	0.56	Breast cancer;	chr11:123060505	chrX:121203182~121205014:-
LUAD	trans	rs7121616	0.531	rs41361350	ENSG00000234176.1	HSPA8P1	14.65	1.88e-40	2.07e-33	0.74	0.56	Breast cancer;	chr11:123060917	chrX:121203182~121205014:-
LUAD	trans	rs2731664	0.792	rs2630764	ENSG00000215571.5	GRK6P1	14.65	1.95e-40	2.15e-33	0.65	0.56	Intelligence (multi-trait analysis);	chr5:177453084	chr13:21319156~21320866:+
LUAD	trans	rs10940346	0.936	rs303219	ENSG00000231752.4	EMBP1	14.64	2.03e-40	2.23e-33	0.73	0.56	Schizophrenia;	chr5:50407795	chr1:121519112~121571892:+
LUAD	trans	rs12709013	0.591	rs30838	ENSG00000233719.3	GOT2P3	14.64	2.2e-40	2.42e-33	0.72	0.56	Blood metabolite ratios;	chr16:58711513	chr12:9641802~9643007:+
LUAD	trans	rs10940346	0.905	rs10053631	ENSG00000231752.4	EMBP1	-14.63	2.33e-40	2.56e-33	-0.72	-0.55	Schizophrenia;	chr5:50164086	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.728	rs10053639	ENSG00000231752.4	EMBP1	-14.63	2.33e-40	2.56e-33	-0.72	-0.55	Schizophrenia;	chr5:50164113	chr1:121519112~121571892:+
LUAD	trans	rs13190036	0.901	rs28684504	ENSG00000217325.2	PRELID1P1	14.63	2.33e-40	2.56e-33	0.9	0.55	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177300437	chr6:126643488~126644390:+
LUAD	trans	rs2657294	0.62	rs7475340	ENSG00000172974.11	AC007318.5	14.63	2.43e-40	2.67e-33	0.59	0.55	Pneumonia;	chr10:75079597	chr2:65205108~65205988:+
LUAD	trans	rs10242455	0.702	rs73403286	ENSG00000228834.1	RP11-249L21.4	14.63	2.44e-40	2.68e-33	1.52	0.55	Blood metabolite levels;	chr7:99557242	chr6:108907615~108907873:-
LUAD	trans	rs10940346	0.846	rs2663076	ENSG00000231752.4	EMBP1	14.62	2.52e-40	2.76e-33	0.72	0.55	Schizophrenia;	chr5:50430593	chr1:121519112~121571892:+
LUAD	trans	rs6732160	0.691	rs13432787	ENSG00000236165.1	PRADC1P1	14.61	2.79e-40	3.05e-33	0.72	0.55	Intelligence (multi-trait analysis);	chr2:73203106	chr3:36976316~36976840:+
LUAD	trans	rs13190036	0.901	rs28715668	ENSG00000217325.2	PRELID1P1	14.6	3.28e-40	3.58e-33	0.91	0.55	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272267	chr6:126643488~126644390:+
LUAD	trans	rs9467773	0.534	rs34453863	ENSG00000242375.1	RP11-498P14.3	14.6	3.31e-40	3.61e-33	0.75	0.55	Intelligence (multi-trait analysis);	chr6:26627777	chr9:97195351~97197687:-
LUAD	trans	rs916888	0.821	rs199512	ENSG00000214425.5	LRRC37A4P	14.59	3.58e-40	3.91e-33	0.8	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45506741~45550335:-
LUAD	trans	rs916888	0.821	rs199509	ENSG00000214425.5	LRRC37A4P	14.59	3.58e-40	3.91e-33	0.8	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45506741~45550335:-
LUAD	trans	rs916888	0.821	rs199507	ENSG00000214425.5	LRRC37A4P	14.59	3.58e-40	3.91e-33	0.8	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45506741~45550335:-
LUAD	trans	rs2657294	0.62	rs9783273	ENSG00000172974.11	AC007318.5	14.58	3.75e-40	4.09e-33	0.59	0.55	Pneumonia;	chr10:75081982	chr2:65205108~65205988:+
LUAD	trans	rs2657294	0.62	rs4746259	ENSG00000172974.11	AC007318.5	14.58	3.75e-40	4.09e-33	0.59	0.55	Pneumonia;	chr10:75082310	chr2:65205108~65205988:+
LUAD	trans	rs2657294	0.62	rs2395132	ENSG00000172974.11	AC007318.5	14.57	4.25e-40	4.63e-33	0.58	0.55	Pneumonia;	chr10:75080840	chr2:65205108~65205988:+
LUAD	trans	rs6732160	0.657	rs10171459	ENSG00000236165.1	PRADC1P1	14.57	4.5e-40	4.89e-33	0.73	0.55	Intelligence (multi-trait analysis);	chr2:73207600	chr3:36976316~36976840:+
LUAD	trans	rs12709013	0.536	rs1646260	ENSG00000233719.3	GOT2P3	14.55	5.07e-40	5.51e-33	0.72	0.55	Blood metabolite ratios;	chr16:58734951	chr12:9641802~9643007:+
LUAD	trans	rs6708331	0.517	rs9989836	ENSG00000232654.1	FAM136BP	14.55	5.08e-40	5.52e-33	0.68	0.55	Obesity-related traits;	chr2:70115595	chr6:3045384~3045800:+
LUAD	trans	rs6732160	0.631	rs7557285	ENSG00000236165.1	PRADC1P1	14.55	5.15e-40	5.59e-33	0.73	0.55	Intelligence (multi-trait analysis);	chr2:73215684	chr3:36976316~36976840:+
LUAD	trans	rs9467773	0.572	rs62394558	ENSG00000242375.1	RP11-498P14.3	14.55	5.3e-40	5.76e-33	0.74	0.55	Intelligence (multi-trait analysis);	chr6:26604422	chr9:97195351~97197687:-
LUAD	trans	rs13190036	0.892	rs71601339	ENSG00000217325.2	PRELID1P1	-14.55	5.32e-40	5.77e-33	-0.9	-0.55	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177117495	chr6:126643488~126644390:+
LUAD	trans	rs13190036	1	rs35535623	ENSG00000217325.2	PRELID1P1	-14.54	5.73e-40	6.21e-33	-0.91	-0.55	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177202295	chr6:126643488~126644390:+
LUAD	trans	rs7503168	0.558	rs11651380	ENSG00000234130.2	RP13-88F20.1	14.53	6.31e-40	6.82e-33	1.14	0.55	Plateletcrit;	chr17:35654677	chrX:93222220~93225015:-
LUAD	trans	rs12709013	0.613	rs4238801	ENSG00000233719.3	GOT2P3	14.53	6.48e-40	7e-33	0.7	0.55	Blood metabolite ratios;	chr16:58738275	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.636	rs4575523	ENSG00000233719.3	GOT2P3	14.53	6.48e-40	7e-33	0.7	0.55	Blood metabolite ratios;	chr16:58738559	chr12:9641802~9643007:+
LUAD	trans	rs6732160	0.691	rs4536673	ENSG00000236165.1	PRADC1P1	14.53	6.58e-40	7.11e-33	0.73	0.55	Intelligence (multi-trait analysis);	chr2:73186334	chr3:36976316~36976840:+
LUAD	trans	rs6732160	0.691	rs13402225	ENSG00000236165.1	PRADC1P1	14.53	6.58e-40	7.11e-33	0.73	0.55	Intelligence (multi-trait analysis);	chr2:73189778	chr3:36976316~36976840:+
LUAD	trans	rs6732160	0.596	rs7605923	ENSG00000236165.1	PRADC1P1	14.53	6.61e-40	7.14e-33	0.73	0.55	Intelligence (multi-trait analysis);	chr2:73175205	chr3:36976316~36976840:+
LUAD	trans	rs2731664	0.792	rs2545795	ENSG00000215571.5	GRK6P1	14.52	7.09e-40	7.66e-33	0.66	0.55	Intelligence (multi-trait analysis);	chr5:177460105	chr13:21319156~21320866:+
LUAD	trans	rs7730934	1	rs10471960	ENSG00000227018.1	IL6STP1	14.51	7.95e-40	8.58e-33	0.84	0.55	Blood protein levels;	chr5:55940546	chr17:15783288~15784307:+
LUAD	trans	rs7503168	0.558	rs112693485	ENSG00000234130.2	RP13-88F20.1	14.51	8.04e-40	8.68e-33	1.13	0.55	Plateletcrit;	chr17:35643688	chrX:93222220~93225015:-
LUAD	trans	rs7121616	0.576	rs1841580	ENSG00000234176.1	HSPA8P1	14.51	8.1e-40	8.74e-33	0.72	0.55	Breast cancer;	chr11:123055956	chrX:121203182~121205014:-
LUAD	trans	rs13190036	0.901	rs28563911	ENSG00000217325.2	PRELID1P1	14.5	8.33e-40	8.98e-33	0.93	0.55	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177287942	chr6:126643488~126644390:+
LUAD	trans	rs10242455	0.702	rs74416635	ENSG00000228834.1	RP11-249L21.4	14.5	8.36e-40	9.01e-33	1.46	0.55	Blood metabolite levels;	chr7:99582946	chr6:108907615~108907873:-
LUAD	trans	rs7811142	0.83	rs118119933	ENSG00000228546.2	CTA-313A17.3	14.5	8.77e-40	9.44e-33	0.88	0.55	Platelet count;	chr7:100341427	chr7:102337316~102339115:+
LUAD	trans	rs13190036	1	rs34832871	ENSG00000217325.2	PRELID1P1	-14.5	8.95e-40	9.63e-33	-0.9	-0.55	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228928	chr6:126643488~126644390:+
LUAD	trans	rs13190036	1	rs28580074	ENSG00000217325.2	PRELID1P1	14.5	8.99e-40	9.66e-33	0.89	0.55	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177294197	chr6:126643488~126644390:+
LUAD	trans	rs7503168	0.558	rs75787089	ENSG00000234130.2	RP13-88F20.1	14.5	8.99e-40	9.67e-33	1.14	0.55	Plateletcrit;	chr17:35598042	chrX:93222220~93225015:-
LUAD	trans	rs2731664	0.756	rs2545796	ENSG00000215571.5	GRK6P1	14.5	9.03e-40	9.7e-33	0.66	0.55	Intelligence (multi-trait analysis);	chr5:177437268	chr13:21319156~21320866:+
LUAD	trans	rs616147	0.627	rs9871799	ENSG00000183298.5	RP11-556K13.1	14.5	9.14e-40	9.82e-33	0.68	0.55	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39442829	chr1:101786340~101787219:-
LUAD	trans	rs7503168	0.558	rs117414856	ENSG00000234130.2	RP13-88F20.1	14.49	9.53e-40	1.02e-32	1.13	0.55	Plateletcrit;	chr17:35604168	chrX:93222220~93225015:-
LUAD	trans	rs2731664	0.792	rs465670	ENSG00000215571.5	GRK6P1	14.48	1.04e-39	1.12e-32	0.66	0.55	Intelligence (multi-trait analysis);	chr5:177450623	chr13:21319156~21320866:+
LUAD	trans	rs76329678	1	rs76329678	ENSG00000231752.4	EMBP1	-14.48	1.11e-39	1.19e-32	-0.73	-0.55	Schizophrenia;	chr5:50534452	chr1:121519112~121571892:+
LUAD	trans	rs6708331	0.517	rs12617812	ENSG00000232654.1	FAM136BP	14.47	1.14e-39	1.23e-32	0.67	0.55	Obesity-related traits;	chr2:70132339	chr6:3045384~3045800:+
LUAD	trans	rs6708331	0.517	rs7599072	ENSG00000232654.1	FAM136BP	14.47	1.14e-39	1.23e-32	0.67	0.55	Obesity-related traits;	chr2:70132874	chr6:3045384~3045800:+
LUAD	trans	rs6708331	0.517	rs12992553	ENSG00000232654.1	FAM136BP	14.47	1.14e-39	1.23e-32	0.67	0.55	Obesity-related traits;	chr2:70133130	chr6:3045384~3045800:+
LUAD	trans	rs6708331	0.517	rs11890741	ENSG00000232654.1	FAM136BP	14.47	1.14e-39	1.23e-32	0.67	0.55	Obesity-related traits;	chr2:70133374	chr6:3045384~3045800:+
LUAD	trans	rs7811142	1	rs67163493	ENSG00000228546.2	CTA-313A17.3	14.46	1.27e-39	1.35e-32	0.82	0.55	Platelet count;	chr7:100426215	chr7:102337316~102339115:+
LUAD	trans	rs13177918	0.734	rs6579791	ENSG00000213058.3	RP4-765C7.2	14.46	1.31e-39	1.41e-32	0.76	0.55	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464440	chr1:178411616~178411972:+
LUAD	trans	rs9611565	1	rs5758314	ENSG00000268568.1	AC007228.9	-14.46	1.36e-39	1.46e-32	-0.77	-0.55	Vitiligo;	chr22:41366519	chr19:56672574~56673901:-
LUAD	trans	rs7121616	0.576	rs7111590	ENSG00000234176.1	HSPA8P1	14.46	1.38e-39	1.47e-32	0.72	0.55	Breast cancer;	chr11:123055419	chrX:121203182~121205014:-
LUAD	trans	rs6708331	0.54	rs28623550	ENSG00000232654.1	FAM136BP	14.44	1.56e-39	1.66e-32	0.67	0.55	Obesity-related traits;	chr2:70139260	chr6:3045384~3045800:+
LUAD	trans	rs7811142	0.943	rs10241492	ENSG00000228546.2	CTA-313A17.3	14.44	1.59e-39	1.69e-32	0.81	0.55	Platelet count;	chr7:100397190	chr7:102337316~102339115:+
LUAD	trans	rs7811142	1	rs11771419	ENSG00000228546.2	CTA-313A17.3	14.43	1.71e-39	1.82e-32	0.81	0.55	Platelet count;	chr7:100390780	chr7:102337316~102339115:+
LUAD	trans	rs7121616	0.576	rs1064585	ENSG00000234176.1	HSPA8P1	14.43	1.74e-39	1.85e-32	0.73	0.55	Breast cancer;	chr11:123058699	chrX:121203182~121205014:-
LUAD	trans	rs7811142	1	rs11763414	ENSG00000228546.2	CTA-313A17.3	14.43	1.75e-39	1.86e-32	0.82	0.55	Platelet count;	chr7:100419221	chr7:102337316~102339115:+
LUAD	trans	rs10940346	1	rs10940359	ENSG00000231752.4	EMBP1	-14.43	1.85e-39	1.97e-32	-0.73	-0.55	Schizophrenia;	chr5:50538645	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.537	rs8188099	ENSG00000231752.4	EMBP1	-14.42	2.01e-39	2.13e-32	-0.72	-0.55	Schizophrenia;	chr5:50183445	chr1:121519112~121571892:+
LUAD	trans	rs2731664	0.792	rs335452	ENSG00000215571.5	GRK6P1	14.41	2.13e-39	2.26e-32	0.65	0.55	Intelligence (multi-trait analysis);	chr5:177452670	chr13:21319156~21320866:+
LUAD	trans	rs7811142	1	rs6975729	ENSG00000228546.2	CTA-313A17.3	14.41	2.16e-39	2.28e-32	0.82	0.55	Platelet count;	chr7:100430564	chr7:102337316~102339115:+
LUAD	trans	rs7811142	1	rs1073	ENSG00000228546.2	CTA-313A17.3	14.41	2.16e-39	2.28e-32	0.82	0.55	Platelet count;	chr7:100433989	chr7:102337316~102339115:+
LUAD	trans	rs7811142	0.887	rs4074838	ENSG00000228546.2	CTA-313A17.3	14.41	2.16e-39	2.28e-32	0.82	0.55	Platelet count;	chr7:100435042	chr7:102337316~102339115:+
LUAD	trans	rs7811142	1	rs11764818	ENSG00000228546.2	CTA-313A17.3	14.41	2.16e-39	2.28e-32	0.82	0.55	Platelet count;	chr7:100445432	chr7:102337316~102339115:+
LUAD	trans	rs7811142	0.945	rs6955362	ENSG00000228546.2	CTA-313A17.3	14.41	2.16e-39	2.28e-32	0.82	0.55	Platelet count;	chr7:100458543	chr7:102337316~102339115:+
LUAD	trans	rs7811142	1	rs6975514	ENSG00000228546.2	CTA-313A17.3	14.41	2.16e-39	2.28e-32	0.82	0.55	Platelet count;	chr7:100458597	chr7:102337316~102339115:+
LUAD	trans	rs7811142	1	rs7811142	ENSG00000228546.2	CTA-313A17.3	14.41	2.16e-39	2.28e-32	0.82	0.55	Platelet count;	chr7:100467820	chr7:102337316~102339115:+
LUAD	trans	rs10940346	1	rs13360100	ENSG00000231752.4	EMBP1	-14.41	2.25e-39	2.37e-32	-0.71	-0.55	Schizophrenia;	chr5:50323389	chr1:121519112~121571892:+
LUAD	trans	rs7399018	0.739	rs10747608	ENSG00000223825.5	DAZAP2P1	14.41	2.28e-39	2.4e-32	0.69	0.55	Cisplatin-induced ototoxicity;	chr12:51222798	chr2:202201384~202201886:-
LUAD	trans	rs2731664	0.792	rs385981	ENSG00000215571.5	GRK6P1	14.4	2.28e-39	2.41e-32	0.65	0.55	Intelligence (multi-trait analysis);	chr5:177459538	chr13:21319156~21320866:+
LUAD	trans	rs10940346	1	rs12514818	ENSG00000231752.4	EMBP1	-14.4	2.36e-39	2.49e-32	-0.71	-0.55	Schizophrenia;	chr5:50349925	chr1:121519112~121571892:+
LUAD	trans	rs6708331	0.517	rs6546572	ENSG00000232654.1	FAM136BP	14.4	2.48e-39	2.61e-32	0.68	0.55	Obesity-related traits;	chr2:70146510	chr6:3045384~3045800:+
LUAD	trans	rs13177918	0.734	rs6579791	ENSG00000224114.1	RP11-343H5.4	14.39	2.54e-39	2.67e-32	0.76	0.55	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464440	chr1:206695837~206696269:-
LUAD	trans	rs7811142	1	rs67315960	ENSG00000228546.2	CTA-313A17.3	14.39	2.56e-39	2.7e-32	0.82	0.55	Platelet count;	chr7:100417501	chr7:102337316~102339115:+
LUAD	trans	rs916888	0.821	rs199504	ENSG00000214425.5	LRRC37A4P	14.39	2.56e-39	2.7e-32	0.79	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45506741~45550335:-
LUAD	trans	rs5022636	0.896	rs7531495	ENSG00000180764.13	PIPSL	14.39	2.57e-39	2.7e-32	0.63	0.55	Gut microbiota (functional units);	chr1:151352996	chr10:93958191~93961540:-
LUAD	trans	rs2731664	0.819	rs449351	ENSG00000215571.5	GRK6P1	14.39	2.72e-39	2.86e-32	0.65	0.55	Intelligence (multi-trait analysis);	chr5:177445590	chr13:21319156~21320866:+
LUAD	trans	rs7121616	0.576	rs7111598	ENSG00000234176.1	HSPA8P1	14.38	2.92e-39	3.06e-32	0.72	0.55	Breast cancer;	chr11:123055438	chrX:121203182~121205014:-
LUAD	trans	rs916888	0.821	rs199514	ENSG00000214425.5	LRRC37A4P	14.38	3.07e-39	3.22e-32	0.8	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45506741~45550335:-
LUAD	trans	rs916888	0.61	rs199529	ENSG00000264070.1	DND1P1	14.36	3.53e-39	3.69e-32	0.8	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:45585871~45586929:+
LUAD	trans	rs7811142	0.779	rs28680963	ENSG00000228546.2	CTA-313A17.3	14.35	4.02e-39	4.19e-32	0.86	0.55	Platelet count;	chr7:100307852	chr7:102337316~102339115:+
LUAD	trans	rs7811142	1	rs67040465	ENSG00000228546.2	CTA-313A17.3	14.35	4.04e-39	4.21e-32	0.83	0.55	Platelet count;	chr7:100485455	chr7:102337316~102339115:+
LUAD	trans	rs9611565	0.921	rs5758297	ENSG00000268568.1	AC007228.9	-14.34	4.21e-39	4.39e-32	-0.75	-0.55	Vitiligo;	chr22:41324693	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.921	rs5751077	ENSG00000268568.1	AC007228.9	-14.34	4.21e-39	4.39e-32	-0.75	-0.55	Vitiligo;	chr22:41324724	chr19:56672574~56673901:-
LUAD	trans	rs7811142	0.887	rs111972532	ENSG00000228546.2	CTA-313A17.3	14.33	4.88e-39	5.07e-32	0.83	0.55	Platelet count;	chr7:100471465	chr7:102337316~102339115:+
LUAD	trans	rs9611565	0.571	rs2050032	ENSG00000268568.1	AC007228.9	14.33	4.9e-39	5.1e-32	0.8	0.55	Vitiligo;	chr22:41756425	chr19:56672574~56673901:-
LUAD	trans	rs7503168	0.643	rs17676508	ENSG00000234130.2	RP13-88F20.1	14.32	5.28e-39	5.48e-32	1.14	0.55	Plateletcrit;	chr17:35693589	chrX:93222220~93225015:-
LUAD	trans	rs73990293	0.531	rs74324437	ENSG00000234130.2	RP13-88F20.1	14.32	5.28e-39	5.48e-32	1.14	0.55	Clopidogrel active metabolite levels;	chr17:35712668	chrX:93222220~93225015:-
LUAD	trans	rs2731664	0.792	rs335467	ENSG00000215571.5	GRK6P1	14.32	5.41e-39	5.61e-32	0.64	0.55	Intelligence (multi-trait analysis);	chr5:177463641	chr13:21319156~21320866:+
LUAD	trans	rs7121616	0.576	rs7942164	ENSG00000234176.1	HSPA8P1	14.31	5.72e-39	5.93e-32	0.72	0.55	Breast cancer;	chr11:123050459	chrX:121203182~121205014:-
LUAD	trans	rs7121616	0.576	rs56131320	ENSG00000234176.1	HSPA8P1	14.31	5.72e-39	5.93e-32	0.72	0.55	Breast cancer;	chr11:123053058	chrX:121203182~121205014:-
LUAD	trans	rs7121616	0.576	rs7929869	ENSG00000234176.1	HSPA8P1	14.31	5.72e-39	5.93e-32	0.72	0.55	Breast cancer;	chr11:123054435	chrX:121203182~121205014:-
LUAD	trans	rs7811142	1	rs6979335	ENSG00000228546.2	CTA-313A17.3	14.31	5.79e-39	6e-32	0.84	0.55	Platelet count;	chr7:100492237	chr7:102337316~102339115:+
LUAD	trans	rs7811142	1	rs73405353	ENSG00000228546.2	CTA-313A17.3	14.31	5.79e-39	6e-32	0.84	0.55	Platelet count;	chr7:100493592	chr7:102337316~102339115:+
LUAD	trans	rs7121616	0.545	rs11600517	ENSG00000234176.1	HSPA8P1	14.31	5.99e-39	6.2e-32	0.72	0.55	Breast cancer;	chr11:123047247	chrX:121203182~121205014:-
LUAD	trans	rs6732160	0.65	rs7560224	ENSG00000236165.1	PRADC1P1	14.3	6.53e-39	6.76e-32	0.72	0.55	Intelligence (multi-trait analysis);	chr2:73179054	chr3:36976316~36976840:+
LUAD	trans	rs12709013	0.585	rs7188608	ENSG00000233719.3	GOT2P3	14.29	7.06e-39	7.29e-32	0.69	0.55	Blood metabolite ratios;	chr16:58736236	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.636	rs1657176	ENSG00000233719.3	GOT2P3	14.29	7.06e-39	7.29e-32	0.69	0.55	Blood metabolite ratios;	chr16:58736833	chr12:9641802~9643007:+
LUAD	trans	rs13190036	1	rs71601343	ENSG00000217325.2	PRELID1P1	-14.27	8.52e-39	8.78e-32	-0.91	-0.55	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177205106	chr6:126643488~126644390:+
LUAD	trans	rs13190036	1	rs71601344	ENSG00000217325.2	PRELID1P1	-14.27	8.52e-39	8.78e-32	-0.91	-0.55	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206492	chr6:126643488~126644390:+
LUAD	trans	rs7121616	0.576	rs73610510	ENSG00000234176.1	HSPA8P1	14.27	8.54e-39	8.81e-32	0.71	0.55	Breast cancer;	chr11:123049365	chrX:121203182~121205014:-
LUAD	trans	rs13358908	0.599	rs34899679	ENSG00000231752.4	EMBP1	-14.27	9e-39	9.27e-32	-0.7	-0.55	Schizophrenia;	chr5:46372360	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.728	rs12655271	ENSG00000231752.4	EMBP1	-14.26	9.39e-39	9.67e-32	-0.72	-0.55	Schizophrenia;	chr5:50212921	chr1:121519112~121571892:+
LUAD	trans	rs55665837	0.778	rs11023212	ENSG00000236360.2	RP11-334A14.2	14.26	9.41e-39	9.68e-32	0.74	0.55	Vitamin D levels;	chr11:14410163	chr1:52993201~52993702:-
LUAD	trans	rs2731664	0.756	rs4976695	ENSG00000215571.5	GRK6P1	14.26	9.44e-39	9.71e-32	0.66	0.55	Intelligence (multi-trait analysis);	chr5:177435962	chr13:21319156~21320866:+
LUAD	trans	rs12709013	0.636	rs1646282	ENSG00000233719.3	GOT2P3	14.26	9.59e-39	9.86e-32	0.69	0.55	Blood metabolite ratios;	chr16:58741296	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.636	rs4784977	ENSG00000233719.3	GOT2P3	14.26	9.59e-39	9.86e-32	0.69	0.55	Blood metabolite ratios;	chr16:58742120	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.636	rs1657161	ENSG00000233719.3	GOT2P3	14.26	9.59e-39	9.86e-32	0.69	0.55	Blood metabolite ratios;	chr16:58743234	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.636	rs1646269	ENSG00000233719.3	GOT2P3	14.26	9.59e-39	9.86e-32	0.69	0.55	Blood metabolite ratios;	chr16:58743412	chr12:9641802~9643007:+
LUAD	trans	rs7811142	1	rs11773661	ENSG00000228546.2	CTA-313A17.3	14.26	9.88e-39	1.02e-31	0.82	0.55	Platelet count;	chr7:100475446	chr7:102337316~102339115:+
LUAD	trans	rs7811142	0.943	rs66958101	ENSG00000228546.2	CTA-313A17.3	14.26	9.88e-39	1.02e-31	0.82	0.55	Platelet count;	chr7:100476397	chr7:102337316~102339115:+
LUAD	trans	rs12709013	0.613	rs1657178	ENSG00000233719.3	GOT2P3	14.26	9.91e-39	1.02e-31	0.69	0.55	Blood metabolite ratios;	chr16:58735300	chr12:9641802~9643007:+
LUAD	trans	rs7121616	0.545	rs7109336	ENSG00000234176.1	HSPA8P1	14.25	1.04e-38	1.07e-31	0.72	0.54	Breast cancer;	chr11:123056530	chrX:121203182~121205014:-
LUAD	trans	rs7121616	0.576	rs7949127	ENSG00000234176.1	HSPA8P1	14.25	1.04e-38	1.07e-31	0.72	0.54	Breast cancer;	chr11:123057408	chrX:121203182~121205014:-
LUAD	trans	rs9467773	0.572	rs13213953	ENSG00000242375.1	RP11-498P14.3	14.25	1.08e-38	1.11e-31	0.72	0.54	Intelligence (multi-trait analysis);	chr6:26594306	chr9:97195351~97197687:-
LUAD	trans	rs10940346	1	rs4865674	ENSG00000231752.4	EMBP1	-14.24	1.16e-38	1.19e-31	-0.71	-0.54	Schizophrenia;	chr5:50277531	chr1:121519112~121571892:+
LUAD	trans	rs10242455	0.702	rs73405247	ENSG00000228834.1	RP11-249L21.4	14.24	1.18e-38	1.21e-31	1.43	0.54	Blood metabolite levels;	chr7:99561551	chr6:108907615~108907873:-
LUAD	trans	rs13190036	1	rs17078781	ENSG00000217325.2	PRELID1P1	-14.24	1.19e-38	1.22e-31	-0.88	-0.54	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177117227	chr6:126643488~126644390:+
LUAD	trans	rs7121616	0.576	rs7123232	ENSG00000234176.1	HSPA8P1	14.22	1.42e-38	1.45e-31	0.71	0.54	Breast cancer;	chr11:123056237	chrX:121203182~121205014:-
LUAD	trans	rs916888	0.773	rs9896243	ENSG00000214425.5	LRRC37A4P	-14.22	1.46e-38	1.49e-31	-0.79	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45506741~45550335:-
LUAD	trans	rs13190036	1	rs6889220	ENSG00000217325.2	PRELID1P1	14.22	1.54e-38	1.57e-31	0.91	0.54	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177266887	chr6:126643488~126644390:+
LUAD	trans	rs7121616	0.545	rs7109348	ENSG00000234176.1	HSPA8P1	14.22	1.54e-38	1.57e-31	0.72	0.54	Breast cancer;	chr11:123056555	chrX:121203182~121205014:-
LUAD	trans	rs7121616	0.576	rs7949220	ENSG00000234176.1	HSPA8P1	14.22	1.54e-38	1.57e-31	0.72	0.54	Breast cancer;	chr11:123057418	chrX:121203182~121205014:-
LUAD	trans	rs7121616	0.576	rs11600486	ENSG00000234176.1	HSPA8P1	14.21	1.59e-38	1.62e-31	0.71	0.54	Breast cancer;	chr11:123047060	chrX:121203182~121205014:-
LUAD	trans	rs7121616	0.576	rs73610509	ENSG00000234176.1	HSPA8P1	14.21	1.59e-38	1.62e-31	0.71	0.54	Breast cancer;	chr11:123048564	chrX:121203182~121205014:-
LUAD	trans	rs13358908	0.622	rs12652607	ENSG00000231752.4	EMBP1	-14.21	1.69e-38	1.72e-31	-0.7	-0.54	Schizophrenia;	chr5:46392338	chr1:121519112~121571892:+
LUAD	trans	rs12709013	0.755	rs1424245	ENSG00000233719.3	GOT2P3	14.21	1.7e-38	1.73e-31	0.66	0.54	Blood metabolite ratios;	chr16:58729926	chr12:9641802~9643007:+
LUAD	trans	rs6708331	0.517	rs9989876	ENSG00000232654.1	FAM136BP	14.2	1.74e-38	1.77e-31	0.67	0.54	Obesity-related traits;	chr2:70115578	chr6:3045384~3045800:+
LUAD	trans	rs6708331	0.517	rs10496178	ENSG00000232654.1	FAM136BP	14.2	1.74e-38	1.77e-31	0.67	0.54	Obesity-related traits;	chr2:70115683	chr6:3045384~3045800:+
LUAD	trans	rs7503168	0.558	rs17670614	ENSG00000234130.2	RP13-88F20.1	14.2	1.8e-38	1.83e-31	1.1	0.54	Plateletcrit;	chr17:35672348	chrX:93222220~93225015:-
LUAD	trans	rs7811142	0.779	rs111312383	ENSG00000228546.2	CTA-313A17.3	14.19	1.94e-38	1.97e-31	0.86	0.54	Platelet count;	chr7:100307702	chr7:102337316~102339115:+
LUAD	trans	rs916888	0.821	rs199513	ENSG00000264070.1	DND1P1	-14.19	2.05e-38	2.09e-31	-0.79	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45585871~45586929:+
LUAD	trans	rs5022636	0.865	rs12069445	ENSG00000180764.13	PIPSL	14.19	2.08e-38	2.11e-31	0.62	0.54	Gut microbiota (functional units);	chr1:151362964	chr10:93958191~93961540:-
LUAD	trans	rs6732160	0.691	rs10197935	ENSG00000236165.1	PRADC1P1	14.18	2.2e-38	2.23e-31	0.71	0.54	Intelligence (multi-trait analysis);	chr2:73185234	chr3:36976316~36976840:+
LUAD	trans	rs616147	0.627	rs816510	ENSG00000183298.5	RP11-556K13.1	-14.18	2.32e-38	2.35e-31	-0.7	-0.54	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39430804	chr1:101786340~101787219:-
LUAD	trans	rs2731664	0.792	rs163199	ENSG00000215571.5	GRK6P1	14.17	2.4e-38	2.43e-31	0.64	0.54	Intelligence (multi-trait analysis);	chr5:177463066	chr13:21319156~21320866:+
LUAD	trans	rs13190036	1	rs3733875	ENSG00000217325.2	PRELID1P1	-14.17	2.5e-38	2.53e-31	-0.9	-0.54	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210239	chr6:126643488~126644390:+
LUAD	trans	rs6708331	0.517	rs11692018	ENSG00000232654.1	FAM136BP	14.16	2.7e-38	2.72e-31	0.67	0.54	Obesity-related traits;	chr2:70142022	chr6:3045384~3045800:+
LUAD	trans	rs6708331	0.517	rs7579922	ENSG00000232654.1	FAM136BP	14.16	2.74e-38	2.76e-31	0.66	0.54	Obesity-related traits;	chr2:70134781	chr6:3045384~3045800:+
LUAD	trans	rs13190036	1	rs13185316	ENSG00000217325.2	PRELID1P1	-14.16	2.78e-38	2.81e-31	-0.9	-0.54	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177213339	chr6:126643488~126644390:+
LUAD	trans	rs9611565	0.649	rs126092	ENSG00000268568.1	AC007228.9	14.16	2.8e-38	2.83e-31	0.77	0.54	Vitiligo;	chr22:41782437	chr19:56672574~56673901:-
LUAD	trans	rs2731664	0.721	rs2450333	ENSG00000215571.5	GRK6P1	14.15	2.93e-38	2.95e-31	0.64	0.54	Intelligence (multi-trait analysis);	chr5:177472545	chr13:21319156~21320866:+
LUAD	trans	rs7503168	0.558	rs12945980	ENSG00000234130.2	RP13-88F20.1	14.15	3.06e-38	3.08e-31	1.09	0.54	Plateletcrit;	chr17:35603002	chrX:93222220~93225015:-
LUAD	trans	rs7811142	1	rs11761725	ENSG00000228546.2	CTA-313A17.3	14.14	3.18e-38	3.21e-31	0.83	0.54	Platelet count;	chr7:100442192	chr7:102337316~102339115:+
LUAD	trans	rs6708331	0.517	rs12999042	ENSG00000232654.1	FAM136BP	14.14	3.44e-38	3.46e-31	0.66	0.54	Obesity-related traits;	chr2:70139679	chr6:3045384~3045800:+
LUAD	trans	rs7399018	0.739	rs6580811	ENSG00000223825.5	DAZAP2P1	14.13	3.63e-38	3.64e-31	0.75	0.54	Cisplatin-induced ototoxicity;	chr12:51218717	chr2:202201384~202201886:-
LUAD	trans	rs13190036	1	rs13177748	ENSG00000217325.2	PRELID1P1	-14.13	3.77e-38	3.78e-31	-0.88	-0.54	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177216953	chr6:126643488~126644390:+
LUAD	trans	rs13358908	0.712	rs28873151	ENSG00000231752.4	EMBP1	-14.12	3.97e-38	3.98e-31	-0.7	-0.54	Schizophrenia;	chr5:46378558	chr1:121519112~121571892:+
LUAD	trans	rs13358908	0.715	rs12522625	ENSG00000231752.4	EMBP1	-14.12	3.97e-38	3.98e-31	-0.7	-0.54	Schizophrenia;	chr5:46389266	chr1:121519112~121571892:+
LUAD	trans	rs13358908	0.712	rs10941823	ENSG00000231752.4	EMBP1	-14.12	3.97e-38	3.98e-31	-0.7	-0.54	Schizophrenia;	chr5:46389481	chr1:121519112~121571892:+
LUAD	trans	rs2731664	0.756	rs335433	ENSG00000215571.5	GRK6P1	14.12	4.12e-38	4.12e-31	0.65	0.54	Intelligence (multi-trait analysis);	chr5:177440206	chr13:21319156~21320866:+
LUAD	trans	rs2731664	0.792	rs335432	ENSG00000215571.5	GRK6P1	14.12	4.17e-38	4.17e-31	0.65	0.54	Intelligence (multi-trait analysis);	chr5:177439257	chr13:21319156~21320866:+
LUAD	trans	rs2731664	0.792	rs335420	ENSG00000215571.5	GRK6P1	-14.11	4.44e-38	4.43e-31	-0.63	-0.54	Intelligence (multi-trait analysis);	chr5:177471618	chr13:21319156~21320866:+
LUAD	trans	rs9611565	0.921	rs5751080	ENSG00000268568.1	AC007228.9	-14.11	4.55e-38	4.54e-31	-0.75	-0.54	Vitiligo;	chr22:41340263	chr19:56672574~56673901:-
LUAD	trans	rs2731664	0.792	rs1130857	ENSG00000215571.5	GRK6P1	14.11	4.61e-38	4.59e-31	0.65	0.54	Intelligence (multi-trait analysis);	chr5:177436518	chr13:21319156~21320866:+
LUAD	trans	rs941207	0.526	rs2242497	ENSG00000121089.4	NACA3P	-14.11	4.67e-38	4.66e-31	-0.67	-0.54	Platelet count;	chr12:56598846	chr4:164943290~164943937:+
LUAD	trans	rs928391	0.592	rs6689750	ENSG00000227183.3	HDGFP1	-14.1	4.8e-38	4.78e-31	-0.84	-0.54	Platelet count;	chr1:156828933	chrX:131646639~131646890:+
LUAD	trans	rs12709013	0.597	rs1616072	ENSG00000233719.3	GOT2P3	14.1	4.82e-38	4.79e-31	0.68	0.54	Blood metabolite ratios;	chr16:58747194	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.636	rs2575374	ENSG00000233719.3	GOT2P3	14.1	4.82e-38	4.79e-31	0.68	0.54	Blood metabolite ratios;	chr16:58747494	chr12:9641802~9643007:+
LUAD	trans	rs7811142	1	rs7783159	ENSG00000228546.2	CTA-313A17.3	14.1	4.82e-38	4.8e-31	0.83	0.54	Platelet count;	chr7:100419831	chr7:102337316~102339115:+
LUAD	trans	rs616147	0.72	rs2965067	ENSG00000183298.5	RP11-556K13.1	-14.09	5.19e-38	5.16e-31	-0.71	-0.54	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461546	chr1:101786340~101787219:-
LUAD	trans	rs12709013	0.636	rs4538000	ENSG00000233719.3	GOT2P3	14.08	6.05e-38	6e-31	0.68	0.54	Blood metabolite ratios;	chr16:58744506	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.66	rs30839	ENSG00000230849.2	GOT2P2	14.07	6.34e-38	6.29e-31	0.67	0.54	Blood metabolite ratios;	chr16:58711437	chr1:173141100~173142350:-
LUAD	trans	rs7811142	1	rs2406255	ENSG00000228546.2	CTA-313A17.3	14.07	6.59e-38	6.51e-31	0.83	0.54	Platelet count;	chr7:100456067	chr7:102337316~102339115:+
LUAD	trans	rs616147	0.655	rs1707981	ENSG00000183298.5	RP11-556K13.1	-14.07	6.88e-38	6.79e-31	-0.71	-0.54	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461015	chr1:101786340~101787219:-
LUAD	trans	rs616147	0.72	rs1768209	ENSG00000183298.5	RP11-556K13.1	-14.07	6.88e-38	6.79e-31	-0.71	-0.54	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461184	chr1:101786340~101787219:-
LUAD	trans	rs7811142	1	rs60257855	ENSG00000228546.2	CTA-313A17.3	14.06	7.53e-38	7.42e-31	0.8	0.54	Platelet count;	chr7:100429157	chr7:102337316~102339115:+
LUAD	trans	rs7730934	1	rs11741953	ENSG00000227018.1	IL6STP1	14.05	7.79e-38	7.68e-31	0.88	0.54	Blood protein levels;	chr5:55971986	chr17:15783288~15784307:+
LUAD	trans	rs7811142	1	rs76913697	ENSG00000228546.2	CTA-313A17.3	14.05	8.31e-38	8.18e-31	0.81	0.54	Platelet count;	chr7:100405149	chr7:102337316~102339115:+
LUAD	trans	rs2731664	0.792	rs335434	ENSG00000215571.5	GRK6P1	14.04	9.05e-38	8.9e-31	0.65	0.54	Intelligence (multi-trait analysis);	chr5:177440275	chr13:21319156~21320866:+
LUAD	trans	rs2731664	0.792	rs337374	ENSG00000215571.5	GRK6P1	-14.03	1.02e-37	1e-30	-0.63	-0.54	Intelligence (multi-trait analysis);	chr5:177463415	chr13:21319156~21320866:+
LUAD	trans	rs8010715	0.636	rs2277482	ENSG00000248988.1	RP11-815N9.2	14.03	1.02e-37	1e-30	0.72	0.54	IgG glycosylation;	chr14:24118586	chr4:159007119~159007835:+
LUAD	trans	rs13177918	0.717	rs6874318	ENSG00000224114.1	RP11-343H5.4	-14.03	1.02e-37	1e-30	-0.71	-0.54	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150462836	chr1:206695837~206696269:-
LUAD	trans	rs13358908	0.621	rs28847123	ENSG00000231752.4	EMBP1	-14.03	1.02e-37	1e-30	-0.69	-0.54	Schizophrenia;	chr5:46378829	chr1:121519112~121571892:+
LUAD	trans	rs13358908	0.593	rs28855077	ENSG00000231752.4	EMBP1	-14.03	1.02e-37	1e-30	-0.69	-0.54	Schizophrenia;	chr5:46378855	chr1:121519112~121571892:+
LUAD	trans	rs13358908	0.632	rs35088345	ENSG00000231752.4	EMBP1	-14.02	1.05e-37	1.03e-30	-0.7	-0.54	Schizophrenia;	chr5:46372364	chr1:121519112~121571892:+
LUAD	trans	rs10242455	0.557	rs59672032	ENSG00000228834.1	RP11-249L21.4	14.02	1.07e-37	1.05e-30	1.39	0.54	Blood metabolite levels;	chr7:99461074	chr6:108907615~108907873:-
LUAD	trans	rs8010715	0.636	rs2277480	ENSG00000248988.1	RP11-815N9.2	14.01	1.25e-37	1.22e-30	0.72	0.54	IgG glycosylation;	chr14:24118306	chr4:159007119~159007835:+
LUAD	trans	rs6732160	0.684	rs2043095	ENSG00000236165.1	PRADC1P1	14	1.34e-37	1.31e-30	0.7	0.54	Intelligence (multi-trait analysis);	chr2:73180314	chr3:36976316~36976840:+
LUAD	trans	rs12709013	0.636	rs1646284	ENSG00000233719.3	GOT2P3	14	1.35e-37	1.32e-30	0.7	0.54	Blood metabolite ratios;	chr16:58752093	chr12:9641802~9643007:+
LUAD	trans	rs7811142	1	rs7783550	ENSG00000228546.2	CTA-313A17.3	-14	1.37e-37	1.33e-30	-0.79	-0.54	Platelet count;	chr7:100390182	chr7:102337316~102339115:+
LUAD	trans	rs10940346	0.557	rs2168922	ENSG00000231752.4	EMBP1	-14	1.37e-37	1.33e-30	-0.71	-0.54	Schizophrenia;	chr5:50151950	chr1:121519112~121571892:+
LUAD	trans	rs12709013	0.636	rs1646272	ENSG00000233719.3	GOT2P3	14	1.4e-37	1.36e-30	0.68	0.54	Blood metabolite ratios;	chr16:58746508	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.66	rs1657163	ENSG00000233719.3	GOT2P3	14	1.4e-37	1.36e-30	0.68	0.54	Blood metabolite ratios;	chr16:58746688	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.646	rs8046154	ENSG00000233719.3	GOT2P3	-13.97	1.72e-37	1.68e-30	-0.68	-0.54	Blood metabolite ratios;	chr16:58773978	chr12:9641802~9643007:+
LUAD	trans	rs7811142	1	rs7794485	ENSG00000228546.2	CTA-313A17.3	13.97	1.75e-37	1.71e-30	0.83	0.54	Platelet count;	chr7:100471313	chr7:102337316~102339115:+
LUAD	trans	rs6732160	0.656	rs2043093	ENSG00000236165.1	PRADC1P1	13.97	1.8e-37	1.75e-30	0.71	0.54	Intelligence (multi-trait analysis);	chr2:73180214	chr3:36976316~36976840:+
LUAD	trans	rs12709013	0.636	rs72792430	ENSG00000233719.3	GOT2P3	-13.97	1.81e-37	1.75e-30	-0.68	-0.54	Blood metabolite ratios;	chr16:58746990	chr12:9641802~9643007:+
LUAD	trans	rs13177918	0.717	rs6874318	ENSG00000213058.3	RP4-765C7.2	-13.97	1.89e-37	1.83e-30	-0.71	-0.54	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150462836	chr1:178411616~178411972:+
LUAD	trans	rs6708331	0.517	rs6743372	ENSG00000232654.1	FAM136BP	13.96	2.07e-37	2e-30	0.67	0.54	Obesity-related traits;	chr2:70125508	chr6:3045384~3045800:+
LUAD	trans	rs6708331	0.564	rs4632370	ENSG00000232654.1	FAM136BP	13.95	2.11e-37	2.04e-30	0.66	0.54	Obesity-related traits;	chr2:70149693	chr6:3045384~3045800:+
LUAD	trans	rs7121616	0.576	rs7948948	ENSG00000234176.1	HSPA8P1	13.95	2.12e-37	2.05e-30	0.72	0.54	Breast cancer;	chr11:123057467	chrX:121203182~121205014:-
LUAD	trans	rs13358908	0.631	rs6882540	ENSG00000231752.4	EMBP1	-13.94	2.35e-37	2.27e-30	-0.7	-0.54	Schizophrenia;	chr5:46345971	chr1:121519112~121571892:+
LUAD	trans	rs6708331	0.517	rs2028879	ENSG00000232654.1	FAM136BP	13.94	2.36e-37	2.28e-30	0.67	0.54	Obesity-related traits;	chr2:70127505	chr6:3045384~3045800:+
LUAD	trans	rs10940346	0.846	rs13356208	ENSG00000231752.4	EMBP1	-13.93	2.67e-37	2.58e-30	-0.71	-0.54	Schizophrenia;	chr5:50197970	chr1:121519112~121571892:+
LUAD	trans	rs10218795	1	rs10218795	ENSG00000259169.1	GNRHR2P1	13.92	3.02e-37	2.91e-30	1.26	0.54	Coronary heart disease (SNP X SNP interaction);	chr1:146018957	chr14:60398934~60400013:-
LUAD	trans	rs9611565	0.921	rs5751081	ENSG00000268568.1	AC007228.9	-13.91	3.15e-37	3.02e-30	-0.74	-0.54	Vitiligo;	chr22:41346784	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.921	rs2281332	ENSG00000268568.1	AC007228.9	-13.91	3.15e-37	3.02e-30	-0.74	-0.54	Vitiligo;	chr22:41350208	chr19:56672574~56673901:-
LUAD	trans	rs7503168	0.558	rs11656872	ENSG00000234130.2	RP13-88F20.1	-13.91	3.46e-37	3.32e-30	-1.03	-0.54	Plateletcrit;	chr17:35611585	chrX:93222220~93225015:-
LUAD	trans	rs7811142	1	rs7803454	ENSG00000228546.2	CTA-313A17.3	13.9	3.52e-37	3.38e-30	0.82	0.54	Platelet count;	chr7:100393925	chr7:102337316~102339115:+
LUAD	trans	rs7811142	0.943	rs11769886	ENSG00000228546.2	CTA-313A17.3	13.9	3.61e-37	3.46e-30	0.82	0.54	Platelet count;	chr7:100400984	chr7:102337316~102339115:+
LUAD	trans	rs5022636	0.896	rs744536	ENSG00000180764.13	PIPSL	13.89	3.86e-37	3.7e-30	0.61	0.54	Gut microbiota (functional units);	chr1:151356318	chr10:93958191~93961540:-
LUAD	trans	rs12709013	0.636	rs1646281	ENSG00000233719.3	GOT2P3	13.89	3.99e-37	3.82e-30	0.69	0.54	Blood metabolite ratios;	chr16:58750512	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.613	rs8049462	ENSG00000233719.3	GOT2P3	13.89	3.99e-37	3.82e-30	0.69	0.54	Blood metabolite ratios;	chr16:58757654	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.66	rs257629	ENSG00000233719.3	GOT2P3	13.89	3.99e-37	3.82e-30	0.69	0.54	Blood metabolite ratios;	chr16:58758044	chr12:9641802~9643007:+
LUAD	trans	rs7811142	1	rs73161762	ENSG00000228546.2	CTA-313A17.3	13.89	4.08e-37	3.9e-30	0.84	0.54	Platelet count;	chr7:100417223	chr7:102337316~102339115:+
LUAD	trans	rs12709013	0.636	rs1646268	ENSG00000233719.3	GOT2P3	13.88	4.63e-37	4.42e-30	0.67	0.53	Blood metabolite ratios;	chr16:58743292	chr12:9641802~9643007:+
LUAD	trans	rs8010715	0.636	rs3825584	ENSG00000248988.1	RP11-815N9.2	13.87	4.75e-37	4.53e-30	0.72	0.53	IgG glycosylation;	chr14:24118430	chr4:159007119~159007835:+
LUAD	trans	rs7811142	0.887	rs35111986	ENSG00000228546.2	CTA-313A17.3	13.87	5.12e-37	4.88e-30	0.82	0.53	Platelet count;	chr7:100402651	chr7:102337316~102339115:+
LUAD	trans	rs12709013	0.636	rs9937713	ENSG00000233719.3	GOT2P3	13.86	5.43e-37	5.18e-30	0.68	0.53	Blood metabolite ratios;	chr16:58771921	chr12:9641802~9643007:+
LUAD	trans	rs7811142	1	rs11771241	ENSG00000228546.2	CTA-313A17.3	13.86	5.5e-37	5.24e-30	0.8	0.53	Platelet count;	chr7:100397162	chr7:102337316~102339115:+
LUAD	trans	rs7730934	1	rs6450357	ENSG00000227018.1	IL6STP1	13.86	5.58e-37	5.31e-30	0.87	0.53	Blood protein levels;	chr5:55974168	chr17:15783288~15784307:+
LUAD	trans	rs13190036	1	rs628506	ENSG00000217325.2	PRELID1P1	-13.86	5.64e-37	5.37e-30	-0.77	-0.53	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107422	chr6:126643488~126644390:+
LUAD	trans	rs9611565	0.921	rs2235846	ENSG00000268568.1	AC007228.9	-13.85	6.05e-37	5.75e-30	-0.74	-0.53	Vitiligo;	chr22:41345038	chr19:56672574~56673901:-
LUAD	trans	rs12709013	0.537	rs1657167	ENSG00000233719.3	GOT2P3	13.85	6.12e-37	5.82e-30	0.68	0.53	Blood metabolite ratios;	chr16:58748955	chr12:9641802~9643007:+
LUAD	trans	rs10940346	0.721	rs60147402	ENSG00000231752.4	EMBP1	-13.84	6.34e-37	6.02e-30	-0.7	-0.53	Schizophrenia;	chr5:50230794	chr1:121519112~121571892:+
LUAD	trans	rs7730934	1	rs6875155	ENSG00000227018.1	IL6STP1	-13.84	6.4e-37	6.07e-30	-0.85	-0.53	Blood protein levels;	chr5:55975226	chr17:15783288~15784307:+
LUAD	trans	rs12709013	0.597	rs8051078	ENSG00000233719.3	GOT2P3	13.84	6.8e-37	6.45e-30	0.68	0.53	Blood metabolite ratios;	chr16:58774200	chr12:9641802~9643007:+
LUAD	trans	rs616147	0.616	rs1768234	ENSG00000183298.5	RP11-556K13.1	-13.83	7.27e-37	6.89e-30	-0.69	-0.53	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39459821	chr1:101786340~101787219:-
LUAD	trans	rs7730934	1	rs11739016	ENSG00000227018.1	IL6STP1	13.83	7.33e-37	6.94e-30	0.87	0.53	Blood protein levels;	chr5:55967545	chr17:15783288~15784307:+
LUAD	trans	rs55665837	1	rs2305306	ENSG00000236360.2	RP11-334A14.2	13.82	8.21e-37	7.76e-30	0.72	0.53	Vitamin D levels;	chr11:14513453	chr1:52993201~52993702:-
LUAD	trans	rs7121616	0.92	rs7109445	ENSG00000234176.1	HSPA8P1	13.82	8.45e-37	7.98e-30	0.61	0.53	Breast cancer;	chr11:123094779	chrX:121203182~121205014:-
LUAD	trans	rs13358908	0.595	rs4975942	ENSG00000231752.4	EMBP1	-13.81	8.92e-37	8.42e-30	-0.69	-0.53	Schizophrenia;	chr5:46371833	chr1:121519112~121571892:+
LUAD	trans	rs9467773	0.525	rs1535274	ENSG00000242375.1	RP11-498P14.3	13.8	9.48e-37	8.93e-30	0.71	0.53	Intelligence (multi-trait analysis);	chr6:26520519	chr9:97195351~97197687:-
LUAD	trans	rs9467773	0.565	rs6925047	ENSG00000242375.1	RP11-498P14.3	13.8	9.48e-37	8.93e-30	0.71	0.53	Intelligence (multi-trait analysis);	chr6:26521207	chr9:97195351~97197687:-
LUAD	trans	rs9467773	0.565	rs4343916	ENSG00000242375.1	RP11-498P14.3	13.8	9.48e-37	8.93e-30	0.71	0.53	Intelligence (multi-trait analysis);	chr6:26522447	chr9:97195351~97197687:-
LUAD	trans	rs7730934	1	rs2228043	ENSG00000227018.1	IL6STP1	13.8	1.01e-36	9.48e-30	0.82	0.53	Blood protein levels;	chr5:55956103	chr17:15783288~15784307:+
LUAD	trans	rs7973618	1	rs7973618	ENSG00000121089.4	NACA3P	-13.79	1.04e-36	9.8e-30	-0.66	-0.53	Mean platelet volume;	chr12:56625659	chr4:164943290~164943937:+
LUAD	trans	rs9611565	0.879	rs2235845	ENSG00000268568.1	AC007228.9	-13.79	1.08e-36	1.02e-29	-0.73	-0.53	Vitiligo;	chr22:41333290	chr19:56672574~56673901:-
LUAD	trans	rs7554547	0.905	rs4993564	ENSG00000261819.1	RP11-680G24.4	13.78	1.15e-36	1.08e-29	0.69	0.53	Nonsyndromic cleft lip with cleft palate;	chr1:11909934	chr16:14988259~14990160:-
LUAD	trans	rs941207	0.526	rs2950387	ENSG00000121089.4	NACA3P	-13.78	1.17e-36	1.1e-29	-0.66	-0.53	Platelet count;	chr12:56627222	chr4:164943290~164943937:+
LUAD	trans	rs12709013	0.636	rs1657164	ENSG00000233719.3	GOT2P3	13.77	1.29e-36	1.21e-29	0.68	0.53	Blood metabolite ratios;	chr16:58747949	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.613	rs1618602	ENSG00000233719.3	GOT2P3	13.77	1.31e-36	1.23e-29	0.69	0.53	Blood metabolite ratios;	chr16:58756080	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.636	rs8045466	ENSG00000233719.3	GOT2P3	13.77	1.31e-36	1.23e-29	0.69	0.53	Blood metabolite ratios;	chr16:58765113	chr12:9641802~9643007:+
LUAD	trans	rs7121616	0.576	rs60405069	ENSG00000234176.1	HSPA8P1	13.77	1.35e-36	1.26e-29	0.72	0.53	Breast cancer;	chr11:123043616	chrX:121203182~121205014:-
LUAD	trans	rs7121616	0.576	rs73608699	ENSG00000234176.1	HSPA8P1	13.76	1.41e-36	1.32e-29	0.72	0.53	Breast cancer;	chr11:123044718	chrX:121203182~121205014:-
LUAD	trans	rs12709013	0.636	rs1865836	ENSG00000233719.3	GOT2P3	13.76	1.5e-36	1.41e-29	0.68	0.53	Blood metabolite ratios;	chr16:58768143	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.576	rs2432622	ENSG00000233719.3	GOT2P3	13.76	1.51e-36	1.41e-29	0.69	0.53	Blood metabolite ratios;	chr16:58749681	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.574	rs35321124	ENSG00000233719.3	GOT2P3	13.75	1.54e-36	1.44e-29	0.69	0.53	Blood metabolite ratios;	chr16:58786561	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.591	rs6499980	ENSG00000233719.3	GOT2P3	13.75	1.63e-36	1.52e-29	0.69	0.53	Blood metabolite ratios;	chr16:58787972	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.591	rs899375	ENSG00000233719.3	GOT2P3	13.75	1.63e-36	1.52e-29	0.69	0.53	Blood metabolite ratios;	chr16:58792325	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.636	rs1595180	ENSG00000233719.3	GOT2P3	13.74	1.79e-36	1.67e-29	0.68	0.53	Blood metabolite ratios;	chr16:58770545	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.597	rs1657171	ENSG00000233719.3	GOT2P3	13.73	1.94e-36	1.81e-29	0.68	0.53	Blood metabolite ratios;	chr16:58752083	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.636	rs1646285	ENSG00000233719.3	GOT2P3	13.73	1.94e-36	1.81e-29	0.68	0.53	Blood metabolite ratios;	chr16:58752102	chr12:9641802~9643007:+
LUAD	trans	rs7121616	0.576	rs7102045	ENSG00000234176.1	HSPA8P1	13.73	1.96e-36	1.83e-29	0.71	0.53	Breast cancer;	chr11:123052713	chrX:121203182~121205014:-
LUAD	trans	rs55665837	1	rs2305305	ENSG00000236360.2	RP11-334A14.2	13.73	2.02e-36	1.88e-29	0.71	0.53	Vitamin D levels;	chr11:14519396	chr1:52993201~52993702:-
LUAD	trans	rs7730934	1	rs7726239	ENSG00000227018.1	IL6STP1	13.72	2.22e-36	2.07e-29	0.89	0.53	Blood protein levels;	chr5:55999478	chr17:15783288~15784307:+
LUAD	trans	rs12709013	0.636	rs4499224	ENSG00000233719.3	GOT2P3	13.72	2.23e-36	2.08e-29	0.68	0.53	Blood metabolite ratios;	chr16:58770364	chr12:9641802~9643007:+
LUAD	trans	rs7121616	0.961	rs11218976	ENSG00000234176.1	HSPA8P1	13.71	2.47e-36	2.3e-29	0.61	0.53	Breast cancer;	chr11:123090950	chrX:121203182~121205014:-
LUAD	trans	rs12709013	0.535	rs9924136	ENSG00000233719.3	GOT2P3	13.7	2.58e-36	2.4e-29	0.69	0.53	Blood metabolite ratios;	chr16:58779573	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.636	rs30835	ENSG00000230849.2	GOT2P2	13.7	2.59e-36	2.4e-29	0.67	0.53	Blood metabolite ratios;	chr16:58714117	chr1:173141100~173142350:-
LUAD	trans	rs928391	0.592	rs7522395	ENSG00000227183.3	HDGFP1	-13.7	2.68e-36	2.49e-29	-0.79	-0.53	Platelet count;	chr1:156826905	chrX:131646639~131646890:+
LUAD	trans	rs55665837	0.961	rs12576926	ENSG00000236360.2	RP11-334A14.2	13.68	3.16e-36	2.93e-29	0.7	0.53	Vitamin D levels;	chr11:14458746	chr1:52993201~52993702:-
LUAD	trans	rs9611565	0.921	rs2143695	ENSG00000268568.1	AC007228.9	-13.68	3.31e-36	3.06e-29	-0.72	-0.53	Vitiligo;	chr22:41332616	chr19:56672574~56673901:-
LUAD	trans	rs12709013	0.561	rs1657174	ENSG00000233719.3	GOT2P3	13.67	3.44e-36	3.18e-29	0.68	0.53	Blood metabolite ratios;	chr16:58755139	chr12:9641802~9643007:+
LUAD	trans	rs7399018	0.643	rs6580810	ENSG00000223825.5	DAZAP2P1	13.67	3.47e-36	3.21e-29	0.73	0.53	Cisplatin-induced ototoxicity;	chr12:51216694	chr2:202201384~202201886:-
LUAD	trans	rs12709013	0.636	rs1646256	ENSG00000233719.3	GOT2P3	13.65	4.25e-36	3.92e-29	0.67	0.53	Blood metabolite ratios;	chr16:58712114	chr12:9641802~9643007:+
LUAD	trans	rs6708331	0.517	rs6546570	ENSG00000232654.1	FAM136BP	13.64	4.59e-36	4.22e-29	0.65	0.53	Obesity-related traits;	chr2:70122901	chr6:3045384~3045800:+
LUAD	trans	rs928391	0.592	rs6427332	ENSG00000227183.3	HDGFP1	-13.64	4.62e-36	4.25e-29	-0.79	-0.53	Platelet count;	chr1:156827052	chrX:131646639~131646890:+
LUAD	trans	rs9467773	1	rs9467799	ENSG00000242375.1	RP11-498P14.3	13.64	4.7e-36	4.32e-29	0.7	0.53	Intelligence (multi-trait analysis);	chr6:26578136	chr9:97195351~97197687:-
LUAD	trans	rs9467773	0.967	rs10223792	ENSG00000242375.1	RP11-498P14.3	13.64	4.7e-36	4.32e-29	0.7	0.53	Intelligence (multi-trait analysis);	chr6:26579388	chr9:97195351~97197687:-
LUAD	trans	rs9467773	0.967	rs9461272	ENSG00000242375.1	RP11-498P14.3	13.64	4.7e-36	4.32e-29	0.7	0.53	Intelligence (multi-trait analysis);	chr6:26579420	chr9:97195351~97197687:-
LUAD	trans	rs12709013	0.636	rs8054414	ENSG00000233719.3	GOT2P3	13.63	5.18e-36	4.74e-29	0.67	0.53	Blood metabolite ratios;	chr16:58749772	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.597	rs11076259	ENSG00000233719.3	GOT2P3	13.63	5.18e-36	4.74e-29	0.67	0.53	Blood metabolite ratios;	chr16:58749860	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.636	rs12325516	ENSG00000233719.3	GOT2P3	13.63	5.18e-36	4.74e-29	0.67	0.53	Blood metabolite ratios;	chr16:58749899	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.636	rs11076260	ENSG00000233719.3	GOT2P3	13.63	5.18e-36	4.74e-29	0.67	0.53	Blood metabolite ratios;	chr16:58749942	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.636	rs1646278	ENSG00000233719.3	GOT2P3	13.63	5.18e-36	4.74e-29	0.67	0.53	Blood metabolite ratios;	chr16:58750084	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.636	rs1646280	ENSG00000233719.3	GOT2P3	13.63	5.18e-36	4.74e-29	0.67	0.53	Blood metabolite ratios;	chr16:58750420	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.597	rs1646286	ENSG00000233719.3	GOT2P3	13.63	5.18e-36	4.74e-29	0.67	0.53	Blood metabolite ratios;	chr16:58752651	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.636	rs1624301	ENSG00000233719.3	GOT2P3	13.63	5.18e-36	4.74e-29	0.67	0.53	Blood metabolite ratios;	chr16:58753491	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.636	rs1626006	ENSG00000233719.3	GOT2P3	13.63	5.18e-36	4.74e-29	0.67	0.53	Blood metabolite ratios;	chr16:58753691	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.684	rs1646287	ENSG00000233719.3	GOT2P3	13.63	5.18e-36	4.74e-29	0.67	0.53	Blood metabolite ratios;	chr16:58753774	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.671	rs1369933	ENSG00000233719.3	GOT2P3	13.63	5.18e-36	4.74e-29	0.67	0.53	Blood metabolite ratios;	chr16:58753927	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.636	rs1369934	ENSG00000233719.3	GOT2P3	13.63	5.18e-36	4.74e-29	0.67	0.53	Blood metabolite ratios;	chr16:58754124	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.613	rs1646288	ENSG00000233719.3	GOT2P3	13.63	5.18e-36	4.74e-29	0.67	0.53	Blood metabolite ratios;	chr16:58755576	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.561	rs727484	ENSG00000233719.3	GOT2P3	13.63	5.18e-36	4.74e-29	0.67	0.53	Blood metabolite ratios;	chr16:58756568	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.636	rs257627	ENSG00000233719.3	GOT2P3	13.63	5.18e-36	4.74e-29	0.67	0.53	Blood metabolite ratios;	chr16:58758956	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.636	rs191783	ENSG00000233719.3	GOT2P3	13.63	5.18e-36	4.74e-29	0.67	0.53	Blood metabolite ratios;	chr16:58759994	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.636	rs257624	ENSG00000233719.3	GOT2P3	13.63	5.18e-36	4.74e-29	0.67	0.53	Blood metabolite ratios;	chr16:58760994	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.559	rs8060721	ENSG00000233719.3	GOT2P3	13.63	5.18e-36	4.74e-29	0.67	0.53	Blood metabolite ratios;	chr16:58765581	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.636	rs8044542	ENSG00000233719.3	GOT2P3	13.63	5.18e-36	4.74e-29	0.67	0.53	Blood metabolite ratios;	chr16:58765620	chr12:9641802~9643007:+
LUAD	trans	rs13358908	0.596	rs9717195	ENSG00000231752.4	EMBP1	-13.63	5.23e-36	4.78e-29	-0.68	-0.53	Schizophrenia;	chr5:46302679	chr1:121519112~121571892:+
LUAD	trans	rs55665837	0.961	rs11023237	ENSG00000236360.2	RP11-334A14.2	13.62	5.66e-36	5.17e-29	0.7	0.53	Vitamin D levels;	chr11:14478788	chr1:52993201~52993702:-
LUAD	trans	rs55665837	1	rs10466412	ENSG00000236360.2	RP11-334A14.2	13.62	5.66e-36	5.17e-29	0.7	0.53	Vitamin D levels;	chr11:14483643	chr1:52993201~52993702:-
LUAD	trans	rs6708331	0.54	rs6546576	ENSG00000232654.1	FAM136BP	13.61	6.46e-36	5.86e-29	0.65	0.53	Obesity-related traits;	chr2:70174356	chr6:3045384~3045800:+
LUAD	trans	rs10940346	0.694	rs2219454	ENSG00000231752.4	EMBP1	-13.61	6.5e-36	5.89e-29	-0.7	-0.53	Schizophrenia;	chr5:50212798	chr1:121519112~121571892:+
LUAD	trans	rs55665837	1	rs12792120	ENSG00000236360.2	RP11-334A14.2	13.6	7.31e-36	6.62e-29	0.7	0.53	Vitamin D levels;	chr11:14447897	chr1:52993201~52993702:-
LUAD	trans	rs55665837	1	rs10832278	ENSG00000236360.2	RP11-334A14.2	13.58	8.48e-36	7.65e-29	0.7	0.53	Vitamin D levels;	chr11:14475073	chr1:52993201~52993702:-
LUAD	trans	rs7730934	1	rs6894414	ENSG00000227018.1	IL6STP1	13.58	8.53e-36	7.69e-29	0.86	0.53	Blood protein levels;	chr5:55956667	chr17:15783288~15784307:+
LUAD	trans	rs55665837	1	rs55665837	ENSG00000236360.2	RP11-334A14.2	13.55	1.13e-35	1.01e-28	0.7	0.53	Vitamin D levels;	chr11:14473503	chr1:52993201~52993702:-
LUAD	trans	rs4276421	0.574	rs80150384	ENSG00000231752.4	EMBP1	-13.55	1.19e-35	1.07e-28	-0.68	-0.53	P wave duration;	chr5:46296183	chr1:121519112~121571892:+
LUAD	trans	rs55665837	1	rs10832275	ENSG00000236360.2	RP11-334A14.2	13.55	1.22e-35	1.1e-28	0.7	0.53	Vitamin D levels;	chr11:14456678	chr1:52993201~52993702:-
LUAD	trans	rs616147	0.548	rs2370965	ENSG00000183298.5	RP11-556K13.1	-13.54	1.23e-35	1.1e-28	-0.68	-0.53	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39448996	chr1:101786340~101787219:-
LUAD	trans	rs12709013	0.636	rs257628	ENSG00000233719.3	GOT2P3	13.54	1.25e-35	1.12e-28	0.67	0.53	Blood metabolite ratios;	chr16:58758924	chr12:9641802~9643007:+
LUAD	trans	rs55665837	1	rs10832268	ENSG00000236360.2	RP11-334A14.2	13.54	1.26e-35	1.13e-28	0.7	0.53	Vitamin D levels;	chr11:14443522	chr1:52993201~52993702:-
LUAD	trans	rs55665837	1	rs10832269	ENSG00000236360.2	RP11-334A14.2	13.54	1.26e-35	1.13e-28	0.7	0.53	Vitamin D levels;	chr11:14443523	chr1:52993201~52993702:-
LUAD	trans	rs55665837	1	rs10832271	ENSG00000236360.2	RP11-334A14.2	13.54	1.26e-35	1.13e-28	0.7	0.53	Vitamin D levels;	chr11:14445373	chr1:52993201~52993702:-
LUAD	trans	rs13358908	0.715	rs8185301	ENSG00000231752.4	EMBP1	-13.53	1.37e-35	1.23e-28	-0.68	-0.53	Schizophrenia;	chr5:46312149	chr1:121519112~121571892:+
LUAD	trans	rs13358908	0.652	rs7293494	ENSG00000231752.4	EMBP1	-13.53	1.37e-35	1.23e-28	-0.68	-0.53	Schizophrenia;	chr5:46313550	chr1:121519112~121571892:+
LUAD	trans	rs5022636	0.896	rs10788804	ENSG00000180764.13	PIPSL	13.53	1.47e-35	1.31e-28	0.59	0.52	Gut microbiota (functional units);	chr1:151365312	chr10:93958191~93961540:-
LUAD	trans	rs12709013	0.514	rs8062639	ENSG00000233719.3	GOT2P3	13.53	1.48e-35	1.33e-28	0.68	0.52	Blood metabolite ratios;	chr16:58800264	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.591	rs9932967	ENSG00000233719.3	GOT2P3	13.52	1.54e-35	1.37e-28	0.68	0.52	Blood metabolite ratios;	chr16:58805583	chr12:9641802~9643007:+
LUAD	trans	rs7730934	1	rs11742271	ENSG00000227018.1	IL6STP1	13.52	1.56e-35	1.4e-28	0.79	0.52	Blood protein levels;	chr5:55967454	chr17:15783288~15784307:+
LUAD	trans	rs13177918	0.734	rs6579791	ENSG00000239528.1	RPS14P8	13.51	1.7e-35	1.51e-28	0.74	0.52	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464440	chr5:116562562~116562930:+
LUAD	trans	rs12709013	0.601	rs2432621	ENSG00000233719.3	GOT2P3	13.51	1.7e-35	1.52e-28	0.67	0.52	Blood metabolite ratios;	chr16:58749676	chr12:9641802~9643007:+
LUAD	trans	rs4276421	0.688	rs8188054	ENSG00000231752.4	EMBP1	13.51	1.71e-35	1.52e-28	0.68	0.52	P wave duration;	chr5:46215556	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.688	rs10061101	ENSG00000231752.4	EMBP1	13.51	1.71e-35	1.52e-28	0.68	0.52	P wave duration;	chr5:46217831	chr1:121519112~121571892:+
LUAD	trans	rs55665837	1	rs10766182	ENSG00000236360.2	RP11-334A14.2	13.51	1.78e-35	1.59e-28	0.7	0.52	Vitamin D levels;	chr11:14477990	chr1:52993201~52993702:-
LUAD	trans	rs55665837	1	rs12364959	ENSG00000236360.2	RP11-334A14.2	13.51	1.78e-35	1.59e-28	0.7	0.52	Vitamin D levels;	chr11:14485889	chr1:52993201~52993702:-
LUAD	trans	rs55665837	1	rs34980103	ENSG00000236360.2	RP11-334A14.2	13.51	1.78e-35	1.59e-28	0.7	0.52	Vitamin D levels;	chr11:14491339	chr1:52993201~52993702:-
LUAD	trans	rs55665837	1	rs11023246	ENSG00000236360.2	RP11-334A14.2	13.51	1.78e-35	1.59e-28	0.7	0.52	Vitamin D levels;	chr11:14515410	chr1:52993201~52993702:-
LUAD	trans	rs9467773	1	rs12663883	ENSG00000242375.1	RP11-498P14.3	13.5	1.89e-35	1.68e-28	0.69	0.52	Intelligence (multi-trait analysis);	chr6:26577098	chr9:97195351~97197687:-
LUAD	trans	rs9467773	0.967	rs6913877	ENSG00000242375.1	RP11-498P14.3	13.5	1.89e-35	1.68e-28	0.69	0.52	Intelligence (multi-trait analysis);	chr6:26577260	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs6918506	ENSG00000242375.1	RP11-498P14.3	13.5	1.89e-35	1.68e-28	0.69	0.52	Intelligence (multi-trait analysis);	chr6:26577629	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs6918360	ENSG00000242375.1	RP11-498P14.3	13.5	1.89e-35	1.68e-28	0.69	0.52	Intelligence (multi-trait analysis);	chr6:26577639	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs6918854	ENSG00000242375.1	RP11-498P14.3	13.5	1.89e-35	1.68e-28	0.69	0.52	Intelligence (multi-trait analysis);	chr6:26577696	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs9467800	ENSG00000242375.1	RP11-498P14.3	13.5	1.89e-35	1.68e-28	0.69	0.52	Intelligence (multi-trait analysis);	chr6:26578297	chr9:97195351~97197687:-
LUAD	trans	rs9467773	0.901	rs10223789	ENSG00000242375.1	RP11-498P14.3	13.5	1.89e-35	1.68e-28	0.69	0.52	Intelligence (multi-trait analysis);	chr6:26579381	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs9467802	ENSG00000242375.1	RP11-498P14.3	13.5	1.89e-35	1.68e-28	0.69	0.52	Intelligence (multi-trait analysis);	chr6:26580940	chr9:97195351~97197687:-
LUAD	trans	rs4276421	0.657	rs10941759	ENSG00000231752.4	EMBP1	-13.5	1.92e-35	1.7e-28	-0.68	-0.52	P wave duration;	chr5:46266862	chr1:121519112~121571892:+
LUAD	trans	rs916888	0.821	rs199513	ENSG00000214425.5	LRRC37A4P	13.49	2.16e-35	1.91e-28	0.73	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45506741~45550335:-
LUAD	trans	rs13358908	0.602	rs4975977	ENSG00000231752.4	EMBP1	-13.48	2.29e-35	2.02e-28	-0.68	-0.52	Schizophrenia;	chr5:46307988	chr1:121519112~121571892:+
LUAD	trans	rs7121616	0.96	rs7122306	ENSG00000234176.1	HSPA8P1	13.47	2.47e-35	2.16e-28	0.6	0.52	Breast cancer;	chr11:123096254	chrX:121203182~121205014:-
LUAD	trans	rs4276421	0.609	rs4975911	ENSG00000231752.4	EMBP1	-13.47	2.49e-35	2.18e-28	-0.68	-0.52	P wave duration;	chr5:46297143	chr1:121519112~121571892:+
LUAD	trans	rs2731664	0.792	rs2630763	ENSG00000215571.5	GRK6P1	13.47	2.55e-35	2.23e-28	0.62	0.52	Intelligence (multi-trait analysis);	chr5:177474004	chr13:21319156~21320866:+
LUAD	trans	rs928391	0.592	rs1888861	ENSG00000227183.3	HDGFP1	-13.46	2.73e-35	2.38e-28	-0.8	-0.52	Platelet count;	chr1:156828169	chrX:131646639~131646890:+
LUAD	trans	rs4276421	0.578	rs8185314	ENSG00000231752.4	EMBP1	-13.46	2.81e-35	2.45e-28	-0.68	-0.52	P wave duration;	chr5:46299648	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.846	rs8175378	ENSG00000231752.4	EMBP1	-13.46	2.81e-35	2.45e-28	-0.69	-0.52	Schizophrenia;	chr5:50182876	chr1:121519112~121571892:+
LUAD	trans	rs7258465	1	rs8109573	ENSG00000267533.1	RP11-815J4.7	13.45	3e-35	2.61e-28	0.64	0.52	Breast cancer;	chr19:18506341	chr18:12067173~12068417:-
LUAD	trans	rs928391	0.592	rs7516856	ENSG00000227183.3	HDGFP1	-13.45	3.07e-35	2.67e-28	-0.8	-0.52	Platelet count;	chr1:156828324	chrX:131646639~131646890:+
LUAD	trans	rs13177918	0.717	rs6874318	ENSG00000239528.1	RPS14P8	-13.44	3.29e-35	2.86e-28	-0.71	-0.52	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150462836	chr5:116562562~116562930:+
LUAD	trans	rs7121616	1	rs7121616	ENSG00000234176.1	HSPA8P1	13.44	3.33e-35	2.9e-28	0.6	0.52	Breast cancer;	chr11:123095918	chrX:121203182~121205014:-
LUAD	trans	rs55665837	1	rs11023224	ENSG00000236360.2	RP11-334A14.2	13.44	3.34e-35	2.9e-28	0.7	0.52	Vitamin D levels;	chr11:14436193	chr1:52993201~52993702:-
LUAD	trans	rs55665837	0.961	rs11023226	ENSG00000236360.2	RP11-334A14.2	13.44	3.34e-35	2.9e-28	0.7	0.52	Vitamin D levels;	chr11:14437271	chr1:52993201~52993702:-
LUAD	trans	rs55665837	1	rs10832264	ENSG00000236360.2	RP11-334A14.2	13.44	3.34e-35	2.9e-28	0.7	0.52	Vitamin D levels;	chr11:14438436	chr1:52993201~52993702:-
LUAD	trans	rs55665837	1	rs11023229	ENSG00000236360.2	RP11-334A14.2	13.44	3.34e-35	2.9e-28	0.7	0.52	Vitamin D levels;	chr11:14439455	chr1:52993201~52993702:-
LUAD	trans	rs7258465	0.931	rs8107347	ENSG00000267533.1	RP11-815J4.7	13.44	3.49e-35	3.02e-28	0.64	0.52	Breast cancer;	chr19:18501938	chr18:12067173~12068417:-
LUAD	trans	rs7258465	0.931	rs8107351	ENSG00000267533.1	RP11-815J4.7	13.44	3.49e-35	3.02e-28	0.64	0.52	Breast cancer;	chr19:18501948	chr18:12067173~12068417:-
LUAD	trans	rs12709013	0.636	rs1646279	ENSG00000233719.3	GOT2P3	13.44	3.54e-35	3.06e-28	0.67	0.52	Blood metabolite ratios;	chr16:58750235	chr12:9641802~9643007:+
LUAD	trans	rs4276421	0.587	rs4975957	ENSG00000231752.4	EMBP1	-13.43	3.66e-35	3.17e-28	-0.67	-0.52	P wave duration;	chr5:46265200	chr1:121519112~121571892:+
LUAD	trans	rs12709013	0.536	rs9930758	ENSG00000233719.3	GOT2P3	13.43	3.69e-35	3.2e-28	0.67	0.52	Blood metabolite ratios;	chr16:58803167	chr12:9641802~9643007:+
LUAD	trans	rs928391	0.592	rs1888862	ENSG00000227183.3	HDGFP1	-13.43	3.71e-35	3.21e-28	-0.8	-0.52	Platelet count;	chr1:156828113	chrX:131646639~131646890:+
LUAD	trans	rs7730934	1	rs11741161	ENSG00000227018.1	IL6STP1	13.42	4.07e-35	3.51e-28	0.87	0.52	Blood protein levels;	chr5:56018420	chr17:15783288~15784307:+
LUAD	trans	rs4276421	0.657	rs10941760	ENSG00000231752.4	EMBP1	-13.42	4.38e-35	3.78e-28	-0.67	-0.52	P wave duration;	chr5:46267360	chr1:121519112~121571892:+
LUAD	trans	rs9467773	1	rs1570059	ENSG00000242375.1	RP11-498P14.3	13.41	4.44e-35	3.83e-28	0.69	0.52	Intelligence (multi-trait analysis);	chr6:26573097	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs6456735	ENSG00000242375.1	RP11-498P14.3	13.41	4.44e-35	3.83e-28	0.69	0.52	Intelligence (multi-trait analysis);	chr6:26573921	chr9:97195351~97197687:-
LUAD	trans	rs4276421	0.688	rs10040808	ENSG00000231752.4	EMBP1	13.41	4.65e-35	4.01e-28	0.67	0.52	P wave duration;	chr5:46123599	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.684	rs8175395	ENSG00000231752.4	EMBP1	13.41	4.67e-35	4.02e-28	0.67	0.52	P wave duration;	chr5:46125498	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.716	rs13156708	ENSG00000231752.4	EMBP1	13.41	4.67e-35	4.02e-28	0.67	0.52	P wave duration;	chr5:46128924	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.744	rs13157345	ENSG00000231752.4	EMBP1	13.41	4.67e-35	4.02e-28	0.67	0.52	P wave duration;	chr5:46129304	chr1:121519112~121571892:+
LUAD	trans	rs7258465	1	rs10409483	ENSG00000267533.1	RP11-815J4.7	13.41	4.78e-35	4.11e-28	0.64	0.52	Breast cancer;	chr19:18479413	chr18:12067173~12068417:-
LUAD	trans	rs7258465	1	rs10409505	ENSG00000267533.1	RP11-815J4.7	13.41	4.78e-35	4.11e-28	0.64	0.52	Breast cancer;	chr19:18479441	chr18:12067173~12068417:-
LUAD	trans	rs4276421	0.805	rs7293302	ENSG00000231752.4	EMBP1	13.4	4.94e-35	4.25e-28	0.67	0.52	P wave duration;	chr5:46131077	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.657	rs13186103	ENSG00000231752.4	EMBP1	13.4	4.94e-35	4.25e-28	0.67	0.52	P wave duration;	chr5:46131553	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.656	rs8185376	ENSG00000231752.4	EMBP1	13.4	4.94e-35	4.25e-28	0.67	0.52	P wave duration;	chr5:46165191	chr1:121519112~121571892:+
LUAD	trans	rs7258465	0.965	rs7254249	ENSG00000267533.1	RP11-815J4.7	13.4	4.96e-35	4.26e-28	0.64	0.52	Breast cancer;	chr19:18480935	chr18:12067173~12068417:-
LUAD	trans	rs4276421	0.656	rs7293337	ENSG00000231752.4	EMBP1	13.4	4.98e-35	4.27e-28	0.67	0.52	P wave duration;	chr5:46203395	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.656	rs11960110	ENSG00000231752.4	EMBP1	13.4	4.98e-35	4.27e-28	0.67	0.52	P wave duration;	chr5:46210055	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.656	rs13172097	ENSG00000231752.4	EMBP1	13.4	4.98e-35	4.27e-28	0.67	0.52	P wave duration;	chr5:46211694	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.688	rs8188050	ENSG00000231752.4	EMBP1	13.4	5e-35	4.29e-28	0.67	0.52	P wave duration;	chr5:46201372	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.656	rs13188786	ENSG00000231752.4	EMBP1	13.4	5e-35	4.29e-28	0.67	0.52	P wave duration;	chr5:46201856	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.688	rs10064792	ENSG00000231752.4	EMBP1	13.4	5e-35	4.29e-28	0.67	0.52	P wave duration;	chr5:46202002	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.597	rs10072776	ENSG00000231752.4	EMBP1	13.4	5e-35	4.29e-28	0.67	0.52	P wave duration;	chr5:46202178	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.688	rs13168431	ENSG00000231752.4	EMBP1	13.4	5e-35	4.29e-28	0.67	0.52	P wave duration;	chr5:46205598	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.537	rs13166566	ENSG00000231752.4	EMBP1	13.4	5e-35	4.29e-28	0.67	0.52	P wave duration;	chr5:46210486	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.688	rs8185185	ENSG00000231752.4	EMBP1	13.4	5e-35	4.29e-28	0.67	0.52	P wave duration;	chr5:46214358	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.656	rs10064681	ENSG00000231752.4	EMBP1	13.4	5e-35	4.29e-28	0.67	0.52	P wave duration;	chr5:46222829	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.623	rs12109835	ENSG00000231752.4	EMBP1	13.4	5e-35	4.29e-28	0.67	0.52	P wave duration;	chr5:46222967	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.688	rs12697543	ENSG00000231752.4	EMBP1	13.4	5e-35	4.29e-28	0.67	0.52	P wave duration;	chr5:46235824	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.652	rs8185226	ENSG00000231752.4	EMBP1	13.39	5.45e-35	4.66e-28	0.67	0.52	P wave duration;	chr5:46160685	chr1:121519112~121571892:+
LUAD	trans	rs55665837	1	rs11023227	ENSG00000236360.2	RP11-334A14.2	13.39	5.48e-35	4.69e-28	0.69	0.52	Vitamin D levels;	chr11:14437541	chr1:52993201~52993702:-
LUAD	trans	rs12709013	0.591	rs4410065	ENSG00000233719.3	GOT2P3	13.39	5.48e-35	4.69e-28	0.67	0.52	Blood metabolite ratios;	chr16:58800968	chr12:9641802~9643007:+
LUAD	trans	rs7258465	0.965	rs8100767	ENSG00000267533.1	RP11-815J4.7	13.39	5.64e-35	4.83e-28	0.64	0.52	Breast cancer;	chr19:18478278	chr18:12067173~12068417:-
LUAD	trans	rs4276421	0.623	rs8188231	ENSG00000231752.4	EMBP1	13.39	5.83e-35	4.98e-28	0.67	0.52	P wave duration;	chr5:46186924	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.684	rs8188258	ENSG00000231752.4	EMBP1	13.39	5.83e-35	4.98e-28	0.67	0.52	P wave duration;	chr5:46187284	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.688	rs10065920	ENSG00000231752.4	EMBP1	13.39	5.83e-35	4.98e-28	0.67	0.52	P wave duration;	chr5:46190593	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.688	rs8188292	ENSG00000231752.4	EMBP1	13.39	5.83e-35	4.98e-28	0.67	0.52	P wave duration;	chr5:46191402	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.657	rs8175415	ENSG00000231752.4	EMBP1	13.39	5.83e-35	4.98e-28	0.67	0.52	P wave duration;	chr5:46193360	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.657	rs8188010	ENSG00000231752.4	EMBP1	13.39	5.83e-35	4.98e-28	0.67	0.52	P wave duration;	chr5:46194057	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.633	rs62370770	ENSG00000231752.4	EMBP1	13.39	5.83e-35	4.98e-28	0.67	0.52	P wave duration;	chr5:46195784	chr1:121519112~121571892:+
LUAD	trans	rs12091564	1	rs12091564	ENSG00000259169.1	GNRHR2P1	-13.38	6.39e-35	5.44e-28	-1.19	-0.52	Coronary heart disease (SNP X SNP interaction);	chr1:146039391	chr14:60398934~60400013:-
LUAD	trans	rs4276421	0.625	rs61187820	ENSG00000231752.4	EMBP1	13.38	6.49e-35	5.52e-28	0.67	0.52	P wave duration;	chr5:46199336	chr1:121519112~121571892:+
LUAD	trans	rs616147	0.671	rs674192	ENSG00000183298.5	RP11-556K13.1	-13.37	6.65e-35	5.66e-28	-0.67	-0.52	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39458653	chr1:101786340~101787219:-
LUAD	trans	rs55665837	1	rs12295888	ENSG00000236360.2	RP11-334A14.2	13.35	8.12e-35	6.87e-28	0.69	0.52	Vitamin D levels;	chr11:14428985	chr1:52993201~52993702:-
LUAD	trans	rs928391	0.541	rs1888863	ENSG00000227183.3	HDGFP1	-13.34	8.82e-35	7.46e-28	-0.8	-0.52	Platelet count;	chr1:156828046	chrX:131646639~131646890:+
LUAD	trans	rs12709013	0.591	rs2406234	ENSG00000233719.3	GOT2P3	13.34	9.16e-35	7.73e-28	0.67	0.52	Blood metabolite ratios;	chr16:58801840	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.591	rs2086206	ENSG00000233719.3	GOT2P3	13.34	9.16e-35	7.73e-28	0.67	0.52	Blood metabolite ratios;	chr16:58802094	chr12:9641802~9643007:+
LUAD	trans	rs4276421	0.684	rs8185055	ENSG00000231752.4	EMBP1	-13.34	9.36e-35	7.9e-28	-0.67	-0.52	P wave duration;	chr5:46262149	chr1:121519112~121571892:+
LUAD	trans	rs7730934	1	rs13170520	ENSG00000227018.1	IL6STP1	13.34	9.53e-35	8.04e-28	0.88	0.52	Blood protein levels;	chr5:55978014	chr17:15783288~15784307:+
LUAD	trans	rs7730934	1	rs11744301	ENSG00000227018.1	IL6STP1	13.34	9.53e-35	8.04e-28	0.88	0.52	Blood protein levels;	chr5:55978776	chr17:15783288~15784307:+
LUAD	trans	rs7730934	1	rs11748421	ENSG00000227018.1	IL6STP1	13.34	9.53e-35	8.04e-28	0.88	0.52	Blood protein levels;	chr5:55978844	chr17:15783288~15784307:+
LUAD	trans	rs7730934	1	rs11744523	ENSG00000227018.1	IL6STP1	13.34	9.53e-35	8.04e-28	0.88	0.52	Blood protein levels;	chr5:55980088	chr17:15783288~15784307:+
LUAD	trans	rs7730934	1	rs11574765	ENSG00000227018.1	IL6STP1	13.34	9.53e-35	8.04e-28	0.88	0.52	Blood protein levels;	chr5:55983139	chr17:15783288~15784307:+
LUAD	trans	rs7730934	1	rs35354044	ENSG00000227018.1	IL6STP1	13.34	9.53e-35	8.04e-28	0.88	0.52	Blood protein levels;	chr5:55986809	chr17:15783288~15784307:+
LUAD	trans	rs7258465	0.931	rs1560119	ENSG00000267533.1	RP11-815J4.7	13.33	1e-34	8.42e-28	0.64	0.52	Breast cancer;	chr19:18462865	chr18:12067173~12068417:-
LUAD	trans	rs55665837	1	rs12288873	ENSG00000236360.2	RP11-334A14.2	13.33	1.03e-34	8.69e-28	0.69	0.52	Vitamin D levels;	chr11:14428919	chr1:52993201~52993702:-
LUAD	trans	rs55665837	1	rs12283797	ENSG00000236360.2	RP11-334A14.2	13.32	1.08e-34	9.11e-28	0.69	0.52	Vitamin D levels;	chr11:14420716	chr1:52993201~52993702:-
LUAD	trans	rs55665837	1	rs10832256	ENSG00000236360.2	RP11-334A14.2	13.32	1.08e-34	9.11e-28	0.69	0.52	Vitamin D levels;	chr11:14421329	chr1:52993201~52993702:-
LUAD	trans	rs55665837	1	rs10832257	ENSG00000236360.2	RP11-334A14.2	13.32	1.08e-34	9.11e-28	0.69	0.52	Vitamin D levels;	chr11:14421770	chr1:52993201~52993702:-
LUAD	trans	rs55665837	0.961	rs12795972	ENSG00000236360.2	RP11-334A14.2	13.32	1.08e-34	9.11e-28	0.69	0.52	Vitamin D levels;	chr11:14422229	chr1:52993201~52993702:-
LUAD	trans	rs4276421	0.657	rs8188296	ENSG00000231752.4	EMBP1	13.32	1.09e-34	9.15e-28	0.67	0.52	P wave duration;	chr5:46221948	chr1:121519112~121571892:+
LUAD	trans	rs9467773	1	rs12665431	ENSG00000242375.1	RP11-498P14.3	13.32	1.09e-34	9.19e-28	0.69	0.52	Intelligence (multi-trait analysis);	chr6:26577080	chr9:97195351~97197687:-
LUAD	trans	rs55665837	1	rs10832276	ENSG00000236360.2	RP11-334A14.2	13.32	1.12e-34	9.43e-28	0.69	0.52	Vitamin D levels;	chr11:14461728	chr1:52993201~52993702:-
LUAD	trans	rs55665837	1	rs3923294	ENSG00000236360.2	RP11-334A14.2	13.32	1.13e-34	9.48e-28	0.69	0.52	Vitamin D levels;	chr11:14419856	chr1:52993201~52993702:-
LUAD	trans	rs55665837	1	rs12287715	ENSG00000236360.2	RP11-334A14.2	13.32	1.13e-34	9.48e-28	0.69	0.52	Vitamin D levels;	chr11:14423029	chr1:52993201~52993702:-
LUAD	trans	rs4276421	0.656	rs8185101	ENSG00000231752.4	EMBP1	13.32	1.17e-34	9.81e-28	0.67	0.52	P wave duration;	chr5:46183248	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.654	rs8185114	ENSG00000231752.4	EMBP1	13.31	1.18e-34	9.87e-28	0.67	0.52	P wave duration;	chr5:46181843	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.652	rs8188276	ENSG00000231752.4	EMBP1	13.31	1.18e-34	9.87e-28	0.67	0.52	P wave duration;	chr5:46182731	chr1:121519112~121571892:+
LUAD	trans	rs7554547	0.791	rs2064614	ENSG00000261819.1	RP11-680G24.4	13.31	1.18e-34	9.92e-28	0.67	0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11893883	chr16:14988259~14990160:-
LUAD	trans	rs13190036	1	rs655623	ENSG00000217325.2	PRELID1P1	13.31	1.2e-34	1e-27	0.79	0.52	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107515	chr6:126643488~126644390:+
LUAD	trans	rs10940346	1	rs7704686	ENSG00000231752.4	EMBP1	-13.31	1.22e-34	1.02e-27	-0.69	-0.52	Schizophrenia;	chr5:50548995	chr1:121519112~121571892:+
LUAD	trans	rs55665837	1	rs12295723	ENSG00000236360.2	RP11-334A14.2	13.31	1.28e-34	1.07e-27	0.69	0.52	Vitamin D levels;	chr11:14428655	chr1:52993201~52993702:-
LUAD	trans	rs7258465	0.931	rs271629	ENSG00000267533.1	RP11-815J4.7	13.3	1.31e-34	1.09e-27	0.64	0.52	Breast cancer;	chr19:18512388	chr18:12067173~12068417:-
LUAD	trans	rs12709013	0.636	rs967852	ENSG00000233719.3	GOT2P3	13.3	1.33e-34	1.11e-27	0.67	0.52	Blood metabolite ratios;	chr16:58807313	chr12:9641802~9643007:+
LUAD	trans	rs4276421	0.684	rs8185217	ENSG00000231752.4	EMBP1	13.3	1.34e-34	1.12e-27	0.67	0.52	P wave duration;	chr5:46169215	chr1:121519112~121571892:+
LUAD	trans	rs55665837	1	rs12276938	ENSG00000236360.2	RP11-334A14.2	13.3	1.37e-34	1.14e-27	0.69	0.52	Vitamin D levels;	chr11:14441942	chr1:52993201~52993702:-
LUAD	trans	rs4276421	0.684	rs10064829	ENSG00000231752.4	EMBP1	13.29	1.46e-34	1.22e-27	0.67	0.52	P wave duration;	chr5:46192959	chr1:121519112~121571892:+
LUAD	trans	rs7258465	0.931	rs875396	ENSG00000267533.1	RP11-815J4.7	13.29	1.51e-34	1.26e-27	0.64	0.52	Breast cancer;	chr19:18500337	chr18:12067173~12068417:-
LUAD	trans	rs7258465	0.965	rs271628	ENSG00000267533.1	RP11-815J4.7	13.29	1.53e-34	1.28e-27	0.63	0.52	Breast cancer;	chr19:18513523	chr18:12067173~12068417:-
LUAD	trans	rs12709013	0.694	rs1616798	ENSG00000230849.2	GOT2P2	13.29	1.54e-34	1.29e-27	0.63	0.52	Blood metabolite ratios;	chr16:58739433	chr1:173141100~173142350:-
LUAD	trans	rs7730934	1	rs1445872	ENSG00000227018.1	IL6STP1	13.28	1.59e-34	1.32e-27	0.89	0.52	Blood protein levels;	chr5:55962032	chr17:15783288~15784307:+
LUAD	trans	rs4276421	0.684	rs11958686	ENSG00000231752.4	EMBP1	13.28	1.62e-34	1.35e-27	0.67	0.52	P wave duration;	chr5:46173456	chr1:121519112~121571892:+
LUAD	trans	rs55665837	1	rs10047457	ENSG00000236360.2	RP11-334A14.2	13.28	1.64e-34	1.37e-27	0.68	0.52	Vitamin D levels;	chr11:14417913	chr1:52993201~52993702:-
LUAD	trans	rs12709013	0.591	rs4784986	ENSG00000233719.3	GOT2P3	13.28	1.71e-34	1.42e-27	0.66	0.52	Blood metabolite ratios;	chr16:58803007	chr12:9641802~9643007:+
LUAD	trans	rs7312770	0.637	rs705700	ENSG00000212994.5	RPS26P6	13.28	1.72e-34	1.42e-27	0.6	0.52	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr8:100895771~100896118:+
LUAD	trans	rs9467773	1	rs1001687	ENSG00000242375.1	RP11-498P14.3	13.27	1.74e-34	1.45e-27	0.68	0.52	Intelligence (multi-trait analysis);	chr6:26572990	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs1570060	ENSG00000242375.1	RP11-498P14.3	13.27	1.74e-34	1.45e-27	0.68	0.52	Intelligence (multi-trait analysis);	chr6:26573334	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs1977201	ENSG00000242375.1	RP11-498P14.3	13.27	1.74e-34	1.45e-27	0.68	0.52	Intelligence (multi-trait analysis);	chr6:26573446	chr9:97195351~97197687:-
LUAD	trans	rs9467773	0.967	rs1321482	ENSG00000242375.1	RP11-498P14.3	13.27	1.74e-34	1.45e-27	0.68	0.52	Intelligence (multi-trait analysis);	chr6:26574926	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs9467798	ENSG00000242375.1	RP11-498P14.3	13.27	1.74e-34	1.45e-27	0.68	0.52	Intelligence (multi-trait analysis);	chr6:26575469	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs1570061	ENSG00000242375.1	RP11-498P14.3	13.27	1.74e-34	1.45e-27	0.68	0.52	Intelligence (multi-trait analysis);	chr6:26575758	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs6913462	ENSG00000242375.1	RP11-498P14.3	13.27	1.74e-34	1.45e-27	0.68	0.52	Intelligence (multi-trait analysis);	chr6:26577302	chr9:97195351~97197687:-
LUAD	trans	rs4276421	0.716	rs12656601	ENSG00000231752.4	EMBP1	13.27	1.79e-34	1.48e-27	0.67	0.52	P wave duration;	chr5:46124483	chr1:121519112~121571892:+
LUAD	trans	rs55665837	1	rs10047429	ENSG00000236360.2	RP11-334A14.2	13.27	1.79e-34	1.48e-27	0.68	0.52	Vitamin D levels;	chr11:14417486	chr1:52993201~52993702:-
LUAD	trans	rs7730934	1	rs11739853	ENSG00000227018.1	IL6STP1	13.27	1.83e-34	1.52e-27	0.87	0.52	Blood protein levels;	chr5:55961688	chr17:15783288~15784307:+
LUAD	trans	rs7730934	1	rs11574769	ENSG00000227018.1	IL6STP1	13.27	1.83e-34	1.52e-27	0.87	0.52	Blood protein levels;	chr5:55962393	chr17:15783288~15784307:+
LUAD	trans	rs7554547	0.791	rs1321073	ENSG00000261819.1	RP11-680G24.4	13.25	2.13e-34	1.77e-27	0.66	0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11891569	chr16:14988259~14990160:-
LUAD	trans	rs6732160	0.619	rs12105975	ENSG00000236165.1	PRADC1P1	13.24	2.36e-34	1.95e-27	0.68	0.52	Intelligence (multi-trait analysis);	chr2:73178921	chr3:36976316~36976840:+
LUAD	trans	rs12709013	0.636	rs8060717	ENSG00000233719.3	GOT2P3	13.24	2.47e-34	2.04e-27	0.66	0.52	Blood metabolite ratios;	chr16:58765574	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.613	rs6499984	ENSG00000233719.3	GOT2P3	13.24	2.51e-34	2.07e-27	0.67	0.52	Blood metabolite ratios;	chr16:58810209	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.574	rs9302706	ENSG00000233719.3	GOT2P3	13.24	2.51e-34	2.07e-27	0.67	0.52	Blood metabolite ratios;	chr16:58812060	chr12:9641802~9643007:+
LUAD	trans	rs4276421	0.684	rs10072945	ENSG00000231752.4	EMBP1	13.24	2.55e-34	2.1e-27	0.67	0.52	P wave duration;	chr5:46151307	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.716	rs13155082	ENSG00000231752.4	EMBP1	13.24	2.55e-34	2.1e-27	0.67	0.52	P wave duration;	chr5:46155135	chr1:121519112~121571892:+
LUAD	trans	rs12709013	0.636	rs10852565	ENSG00000233719.3	GOT2P3	13.23	2.61e-34	2.15e-27	0.67	0.52	Blood metabolite ratios;	chr16:58771277	chr12:9641802~9643007:+
LUAD	trans	rs7258465	1	rs271623	ENSG00000267533.1	RP11-815J4.7	13.23	2.72e-34	2.24e-27	0.64	0.52	Breast cancer;	chr19:18518137	chr18:12067173~12068417:-
LUAD	trans	rs7258465	0.965	rs271622	ENSG00000267533.1	RP11-815J4.7	13.23	2.72e-34	2.24e-27	0.64	0.52	Breast cancer;	chr19:18518467	chr18:12067173~12068417:-
LUAD	trans	rs4276421	0.656	rs13188002	ENSG00000231752.4	EMBP1	13.23	2.82e-34	2.32e-27	0.67	0.52	P wave duration;	chr5:46184203	chr1:121519112~121571892:+
LUAD	trans	rs55665837	1	rs7121171	ENSG00000236360.2	RP11-334A14.2	13.23	2.82e-34	2.32e-27	0.68	0.52	Vitamin D levels;	chr11:14424874	chr1:52993201~52993702:-
LUAD	trans	rs7258465	1	rs7252848	ENSG00000267533.1	RP11-815J4.7	13.22	2.93e-34	2.41e-27	0.63	0.52	Breast cancer;	chr19:18501541	chr18:12067173~12068417:-
LUAD	trans	rs7554547	0.739	rs61527718	ENSG00000261819.1	RP11-680G24.4	13.22	3.07e-34	2.52e-27	0.67	0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11889583	chr16:14988259~14990160:-
LUAD	trans	rs7554547	0.791	rs17037520	ENSG00000261819.1	RP11-680G24.4	13.22	3.07e-34	2.52e-27	0.67	0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11892349	chr16:14988259~14990160:-
LUAD	trans	rs12709013	0.621	rs6499974	ENSG00000233719.3	GOT2P3	13.21	3.23e-34	2.65e-27	0.66	0.52	Blood metabolite ratios;	chr16:58769642	chr12:9641802~9643007:+
LUAD	trans	rs7554547	0.69	rs7516708	ENSG00000261819.1	RP11-680G24.4	13.2	3.68e-34	3.01e-27	0.67	0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11890148	chr16:14988259~14990160:-
LUAD	trans	rs7554547	0.765	rs4845886	ENSG00000261819.1	RP11-680G24.4	13.19	3.87e-34	3.16e-27	0.67	0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11888603	chr16:14988259~14990160:-
LUAD	trans	rs7554547	0.791	rs4846069	ENSG00000261819.1	RP11-680G24.4	13.19	3.87e-34	3.16e-27	0.67	0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11888974	chr16:14988259~14990160:-
LUAD	trans	rs7554547	0.791	rs11121837	ENSG00000261819.1	RP11-680G24.4	13.19	3.87e-34	3.16e-27	0.67	0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11889414	chr16:14988259~14990160:-
LUAD	trans	rs7554547	0.765	rs4846070	ENSG00000261819.1	RP11-680G24.4	13.19	3.87e-34	3.16e-27	0.67	0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11889464	chr16:14988259~14990160:-
LUAD	trans	rs7554547	0.714	rs4846071	ENSG00000261819.1	RP11-680G24.4	13.19	3.87e-34	3.16e-27	0.67	0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11889612	chr16:14988259~14990160:-
LUAD	trans	rs7554547	0.739	rs4846073	ENSG00000261819.1	RP11-680G24.4	13.19	3.87e-34	3.16e-27	0.67	0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11890521	chr16:14988259~14990160:-
LUAD	trans	rs7554547	0.791	rs57678332	ENSG00000261819.1	RP11-680G24.4	13.19	3.87e-34	3.16e-27	0.67	0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11890834	chr16:14988259~14990160:-
LUAD	trans	rs7554547	0.765	rs57176983	ENSG00000261819.1	RP11-680G24.4	13.19	3.87e-34	3.16e-27	0.67	0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11891041	chr16:14988259~14990160:-
LUAD	trans	rs7554547	0.791	rs1321072	ENSG00000261819.1	RP11-680G24.4	13.19	3.87e-34	3.16e-27	0.67	0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11891261	chr16:14988259~14990160:-
LUAD	trans	rs7554547	0.791	rs6665662	ENSG00000261819.1	RP11-680G24.4	13.19	3.87e-34	3.16e-27	0.67	0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11891804	chr16:14988259~14990160:-
LUAD	trans	rs7554547	0.791	rs34117126	ENSG00000261819.1	RP11-680G24.4	13.19	3.87e-34	3.16e-27	0.67	0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11892138	chr16:14988259~14990160:-
LUAD	trans	rs7554547	0.791	rs12749498	ENSG00000261819.1	RP11-680G24.4	13.19	3.87e-34	3.16e-27	0.67	0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11892570	chr16:14988259~14990160:-
LUAD	trans	rs7554547	0.791	rs12036266	ENSG00000261819.1	RP11-680G24.4	13.19	3.87e-34	3.16e-27	0.67	0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11893257	chr16:14988259~14990160:-
LUAD	trans	rs55665837	0.922	rs12287212	ENSG00000236360.2	RP11-334A14.2	13.19	3.88e-34	3.17e-27	0.68	0.52	Vitamin D levels;	chr11:14428315	chr1:52993201~52993702:-
LUAD	trans	rs6708331	0.517	rs13017427	ENSG00000232654.1	FAM136BP	13.19	3.93e-34	3.21e-27	0.64	0.52	Obesity-related traits;	chr2:70154399	chr6:3045384~3045800:+
LUAD	trans	rs6708331	0.54	rs9677885	ENSG00000232654.1	FAM136BP	13.19	3.93e-34	3.21e-27	0.64	0.52	Obesity-related traits;	chr2:70154687	chr6:3045384~3045800:+
LUAD	trans	rs6708331	0.54	rs9679269	ENSG00000232654.1	FAM136BP	13.19	3.93e-34	3.21e-27	0.64	0.52	Obesity-related traits;	chr2:70154696	chr6:3045384~3045800:+
LUAD	trans	rs7258465	1	rs7252707	ENSG00000267533.1	RP11-815J4.7	13.19	4.01e-34	3.27e-27	0.64	0.52	Breast cancer;	chr19:18501447	chr18:12067173~12068417:-
LUAD	trans	rs13358908	0.715	rs10053628	ENSG00000231752.4	EMBP1	-13.19	4.15e-34	3.39e-27	-0.66	-0.52	Schizophrenia;	chr5:46383233	chr1:121519112~121571892:+
LUAD	trans	rs55665837	1	rs34382046	ENSG00000236360.2	RP11-334A14.2	13.18	4.19e-34	3.41e-27	0.68	0.52	Vitamin D levels;	chr11:14429772	chr1:52993201~52993702:-
LUAD	trans	rs55665837	1	rs7945167	ENSG00000236360.2	RP11-334A14.2	13.18	4.19e-34	3.41e-27	0.68	0.52	Vitamin D levels;	chr11:14430274	chr1:52993201~52993702:-
LUAD	trans	rs55665837	0.961	rs60622588	ENSG00000236360.2	RP11-334A14.2	13.18	4.19e-34	3.41e-27	0.68	0.52	Vitamin D levels;	chr11:14435452	chr1:52993201~52993702:-
LUAD	trans	rs55665837	1	rs11023223	ENSG00000236360.2	RP11-334A14.2	13.18	4.19e-34	3.41e-27	0.68	0.52	Vitamin D levels;	chr11:14435566	chr1:52993201~52993702:-
LUAD	trans	rs9611565	1	rs5751086	ENSG00000268568.1	AC007228.9	-13.18	4.37e-34	3.56e-27	-0.68	-0.52	Vitiligo;	chr22:41372858	chr19:56672574~56673901:-
LUAD	trans	rs7554547	0.685	rs12724129	ENSG00000261819.1	RP11-680G24.4	13.18	4.53e-34	3.69e-27	0.67	0.52	Nonsyndromic cleft lip with cleft palate;	chr1:11897582	chr16:14988259~14990160:-
LUAD	trans	rs4276421	0.688	rs11950077	ENSG00000231752.4	EMBP1	13.17	4.67e-34	3.79e-27	0.67	0.51	P wave duration;	chr5:46179798	chr1:121519112~121571892:+
LUAD	trans	rs916888	0.779	rs199526	ENSG00000264070.1	DND1P1	-13.17	4.95e-34	4.02e-27	-0.7	-0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:45585871~45586929:+
LUAD	trans	rs12709013	0.792	rs1473206	ENSG00000230849.2	GOT2P2	13.16	5.42e-34	4.4e-27	0.63	0.51	Blood metabolite ratios;	chr16:58737529	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.792	rs1473205	ENSG00000230849.2	GOT2P2	13.16	5.42e-34	4.4e-27	0.63	0.51	Blood metabolite ratios;	chr16:58737547	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.591	rs7184377	ENSG00000233719.3	GOT2P3	13.16	5.46e-34	4.43e-27	0.68	0.51	Blood metabolite ratios;	chr16:58808765	chr12:9641802~9643007:+
LUAD	trans	rs7258465	1	rs4808133	ENSG00000267533.1	RP11-815J4.7	13.15	5.61e-34	4.55e-27	0.64	0.51	Breast cancer;	chr19:18497708	chr18:12067173~12068417:-
LUAD	trans	rs7258465	1	rs4808134	ENSG00000267533.1	RP11-815J4.7	13.15	5.61e-34	4.55e-27	0.64	0.51	Breast cancer;	chr19:18497769	chr18:12067173~12068417:-
LUAD	trans	rs7730934	1	rs35682251	ENSG00000227018.1	IL6STP1	13.15	5.85e-34	4.74e-27	0.92	0.51	Blood protein levels;	chr5:56011217	chr17:15783288~15784307:+
LUAD	trans	rs4276421	0.688	rs7713759	ENSG00000231752.4	EMBP1	13.15	6.09e-34	4.93e-27	0.67	0.51	P wave duration;	chr5:46143447	chr1:121519112~121571892:+
LUAD	trans	rs7258465	0.965	rs2561043	ENSG00000267533.1	RP11-815J4.7	13.14	6.33e-34	5.12e-27	0.63	0.51	Breast cancer;	chr19:18511873	chr18:12067173~12068417:-
LUAD	trans	rs7258465	1	rs76194	ENSG00000267533.1	RP11-815J4.7	13.14	6.4e-34	5.18e-27	0.63	0.51	Breast cancer;	chr19:18519770	chr18:12067173~12068417:-
LUAD	trans	rs7258465	1	rs8103622	ENSG00000267533.1	RP11-815J4.7	13.14	6.45e-34	5.22e-27	0.64	0.51	Breast cancer;	chr19:18462024	chr18:12067173~12068417:-
LUAD	trans	rs7258465	1	rs10425982	ENSG00000267533.1	RP11-815J4.7	13.14	6.65e-34	5.38e-27	0.63	0.51	Breast cancer;	chr19:18475709	chr18:12067173~12068417:-
LUAD	trans	rs7258465	0.965	rs7256534	ENSG00000267533.1	RP11-815J4.7	13.13	6.88e-34	5.56e-27	0.63	0.51	Breast cancer;	chr19:18475981	chr18:12067173~12068417:-
LUAD	trans	rs7554547	0.765	rs2050268	ENSG00000261819.1	RP11-680G24.4	13.13	6.9e-34	5.57e-27	0.68	0.51	Nonsyndromic cleft lip with cleft palate;	chr1:11886487	chr16:14988259~14990160:-
LUAD	trans	rs7554547	0.765	rs2050267	ENSG00000261819.1	RP11-680G24.4	13.13	6.9e-34	5.57e-27	0.68	0.51	Nonsyndromic cleft lip with cleft palate;	chr1:11886516	chr16:14988259~14990160:-
LUAD	trans	rs7554547	0.739	rs2050269	ENSG00000261819.1	RP11-680G24.4	13.12	7.6e-34	6.13e-27	0.68	0.51	Nonsyndromic cleft lip with cleft palate;	chr1:11886432	chr16:14988259~14990160:-
LUAD	trans	rs7258465	1	rs271621	ENSG00000267533.1	RP11-815J4.7	13.12	8.08e-34	6.51e-27	0.63	0.51	Breast cancer;	chr19:18520522	chr18:12067173~12068417:-
LUAD	trans	rs7554547	0.791	rs2065611	ENSG00000261819.1	RP11-680G24.4	13.12	8.09e-34	6.52e-27	0.67	0.51	Nonsyndromic cleft lip with cleft palate;	chr1:11893469	chr16:14988259~14990160:-
LUAD	trans	rs7554547	0.791	rs4492637	ENSG00000261819.1	RP11-680G24.4	13.12	8.09e-34	6.52e-27	0.67	0.51	Nonsyndromic cleft lip with cleft palate;	chr1:11895787	chr16:14988259~14990160:-
LUAD	trans	rs7554547	0.791	rs4846074	ENSG00000261819.1	RP11-680G24.4	13.12	8.09e-34	6.52e-27	0.67	0.51	Nonsyndromic cleft lip with cleft palate;	chr1:11896172	chr16:14988259~14990160:-
LUAD	trans	rs7730934	1	rs11574777	ENSG00000227018.1	IL6STP1	-13.11	8.3e-34	6.69e-27	-0.8	-0.51	Blood protein levels;	chr5:55953115	chr17:15783288~15784307:+
LUAD	trans	rs7730934	1	rs35450255	ENSG00000227018.1	IL6STP1	13.11	8.44e-34	6.8e-27	0.9	0.51	Blood protein levels;	chr5:56006116	chr17:15783288~15784307:+
LUAD	trans	rs7730934	1	rs13177475	ENSG00000227018.1	IL6STP1	13.11	8.44e-34	6.8e-27	0.9	0.51	Blood protein levels;	chr5:56006580	chr17:15783288~15784307:+
LUAD	trans	rs7730934	1	rs13166487	ENSG00000227018.1	IL6STP1	13.11	8.44e-34	6.8e-27	0.9	0.51	Blood protein levels;	chr5:56008123	chr17:15783288~15784307:+
LUAD	trans	rs55665837	1	rs10832254	ENSG00000236360.2	RP11-334A14.2	13.1	9.15e-34	7.36e-27	0.67	0.51	Vitamin D levels;	chr11:14413152	chr1:52993201~52993702:-
LUAD	trans	rs55665837	1	rs11023214	ENSG00000236360.2	RP11-334A14.2	13.1	9.15e-34	7.36e-27	0.67	0.51	Vitamin D levels;	chr11:14414713	chr1:52993201~52993702:-
LUAD	trans	rs12709013	0.635	rs6993	ENSG00000230849.2	GOT2P2	13.08	1.18e-33	9.43e-27	0.65	0.51	Blood metabolite ratios;	chr16:58707463	chr1:173141100~173142350:-
LUAD	trans	rs4276421	0.63	rs10054134	ENSG00000231752.4	EMBP1	-13.07	1.3e-33	1.04e-26	-0.67	-0.51	P wave duration;	chr5:46292175	chr1:121519112~121571892:+
LUAD	trans	rs7258465	1	rs2278238	ENSG00000267533.1	RP11-815J4.7	13.07	1.33e-33	1.06e-26	0.63	0.51	Breast cancer;	chr19:18465674	chr18:12067173~12068417:-
LUAD	trans	rs9467773	1	rs6456733	ENSG00000242375.1	RP11-498P14.3	13.07	1.34e-33	1.07e-26	0.66	0.51	Intelligence (multi-trait analysis);	chr6:26566576	chr9:97195351~97197687:-
LUAD	trans	rs12709013	0.729	rs1657179	ENSG00000230849.2	GOT2P2	13.06	1.44e-33	1.15e-26	0.63	0.51	Blood metabolite ratios;	chr16:58735115	chr1:173141100~173142350:-
LUAD	trans	rs2731664	0.792	rs335468	ENSG00000215571.5	GRK6P1	-13.05	1.54e-33	1.23e-26	-0.6	-0.51	Intelligence (multi-trait analysis);	chr5:177465348	chr13:21319156~21320866:+
LUAD	trans	rs13358908	0.652	rs8185385	ENSG00000231752.4	EMBP1	-13.05	1.56e-33	1.24e-26	-0.67	-0.51	Schizophrenia;	chr5:46318532	chr1:121519112~121571892:+
LUAD	trans	rs55665837	1	rs11023216	ENSG00000236360.2	RP11-334A14.2	13.04	1.67e-33	1.33e-26	0.67	0.51	Vitamin D levels;	chr11:14415607	chr1:52993201~52993702:-
LUAD	trans	rs4276421	0.695	rs8185255	ENSG00000231752.4	EMBP1	-13.03	1.8e-33	1.44e-26	-0.66	-0.51	P wave duration;	chr5:46263336	chr1:121519112~121571892:+
LUAD	trans	rs7258465	1	rs2007981	ENSG00000267533.1	RP11-815J4.7	13.03	1.84e-33	1.46e-26	0.63	0.51	Breast cancer;	chr19:18456745	chr18:12067173~12068417:-
LUAD	trans	rs7258465	1	rs10403249	ENSG00000267533.1	RP11-815J4.7	13.03	1.86e-33	1.48e-26	0.63	0.51	Breast cancer;	chr19:18494132	chr18:12067173~12068417:-
LUAD	trans	rs7258465	0.965	rs7253990	ENSG00000267533.1	RP11-815J4.7	13.03	1.93e-33	1.53e-26	0.63	0.51	Breast cancer;	chr19:18493275	chr18:12067173~12068417:-
LUAD	trans	rs4276421	0.688	rs10941746	ENSG00000231752.4	EMBP1	13.03	1.95e-33	1.55e-26	0.66	0.51	P wave duration;	chr5:46202737	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.777	rs8185098	ENSG00000231752.4	EMBP1	13.02	2.13e-33	1.7e-26	0.66	0.51	P wave duration;	chr5:46125388	chr1:121519112~121571892:+
LUAD	trans	rs7258465	0.931	rs7249020	ENSG00000267533.1	RP11-815J4.7	13.01	2.24e-33	1.78e-26	0.63	0.51	Breast cancer;	chr19:18497337	chr18:12067173~12068417:-
LUAD	trans	rs6732160	0.845	rs72807999	ENSG00000236165.1	PRADC1P1	13.01	2.38e-33	1.89e-26	0.67	0.51	Intelligence (multi-trait analysis);	chr2:73164567	chr3:36976316~36976840:+
LUAD	trans	rs1816752	0.646	rs9511293	ENSG00000224976.2	PARP4P2	13	2.43e-33	1.93e-26	0.57	0.51	Obesity-related traits;	chr13:24467747	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.646	rs9511294	ENSG00000224976.2	PARP4P2	13	2.43e-33	1.93e-26	0.57	0.51	Obesity-related traits;	chr13:24467773	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.646	rs9511296	ENSG00000224976.2	PARP4P2	13	2.43e-33	1.93e-26	0.57	0.51	Obesity-related traits;	chr13:24467962	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.646	rs9634401	ENSG00000224976.2	PARP4P2	13	2.43e-33	1.93e-26	0.57	0.51	Obesity-related traits;	chr13:24468072	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.624	rs9634402	ENSG00000224976.2	PARP4P2	13	2.43e-33	1.93e-26	0.57	0.51	Obesity-related traits;	chr13:24468119	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.646	rs9634403	ENSG00000224976.2	PARP4P2	13	2.44e-33	1.94e-26	0.57	0.51	Obesity-related traits;	chr13:24468211	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.646	rs9581064	ENSG00000224976.2	PARP4P2	13	2.44e-33	1.94e-26	0.57	0.51	Obesity-related traits;	chr13:24468251	chr13:19349137~19407962:+
LUAD	trans	rs4276421	0.688	rs13155792	ENSG00000231752.4	EMBP1	13	2.48e-33	1.97e-26	0.66	0.51	P wave duration;	chr5:46176452	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.688	rs10038249	ENSG00000231752.4	EMBP1	13	2.55e-33	2.02e-26	0.66	0.51	P wave duration;	chr5:46160595	chr1:121519112~121571892:+
LUAD	trans	rs1816752	0.646	rs2862902	ENSG00000224976.2	PARP4P2	13	2.59e-33	2.05e-26	0.57	0.51	Obesity-related traits;	chr13:24461965	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.646	rs734715	ENSG00000224976.2	PARP4P2	13	2.59e-33	2.05e-26	0.57	0.51	Obesity-related traits;	chr13:24462041	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.646	rs730030	ENSG00000224976.2	PARP4P2	13	2.59e-33	2.05e-26	0.57	0.51	Obesity-related traits;	chr13:24462509	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.609	rs7992667	ENSG00000224976.2	PARP4P2	13	2.59e-33	2.05e-26	0.57	0.51	Obesity-related traits;	chr13:24462821	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.609	rs7995958	ENSG00000224976.2	PARP4P2	13	2.59e-33	2.05e-26	0.57	0.51	Obesity-related traits;	chr13:24462895	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.609	rs8002741	ENSG00000224976.2	PARP4P2	13	2.59e-33	2.05e-26	0.57	0.51	Obesity-related traits;	chr13:24462918	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.609	rs7998198	ENSG00000224976.2	PARP4P2	13	2.59e-33	2.05e-26	0.57	0.51	Obesity-related traits;	chr13:24462979	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.609	rs7998203	ENSG00000224976.2	PARP4P2	13	2.59e-33	2.05e-26	0.57	0.51	Obesity-related traits;	chr13:24462989	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.646	rs7998600	ENSG00000224976.2	PARP4P2	13	2.59e-33	2.05e-26	0.57	0.51	Obesity-related traits;	chr13:24463222	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.624	rs9511282	ENSG00000224976.2	PARP4P2	13	2.59e-33	2.05e-26	0.57	0.51	Obesity-related traits;	chr13:24463597	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.583	rs9511283	ENSG00000224976.2	PARP4P2	13	2.59e-33	2.05e-26	0.57	0.51	Obesity-related traits;	chr13:24463656	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.646	rs9507351	ENSG00000224976.2	PARP4P2	13	2.59e-33	2.05e-26	0.57	0.51	Obesity-related traits;	chr13:24465118	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.646	rs4770688	ENSG00000224976.2	PARP4P2	13	2.59e-33	2.05e-26	0.57	0.51	Obesity-related traits;	chr13:24466007	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.646	rs4770689	ENSG00000224976.2	PARP4P2	13	2.59e-33	2.05e-26	0.57	0.51	Obesity-related traits;	chr13:24466008	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.646	rs12431171	ENSG00000224976.2	PARP4P2	13	2.59e-33	2.05e-26	0.57	0.51	Obesity-related traits;	chr13:24466380	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.646	rs12854523	ENSG00000224976.2	PARP4P2	13	2.59e-33	2.05e-26	0.57	0.51	Obesity-related traits;	chr13:24466460	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.646	rs9578740	ENSG00000224976.2	PARP4P2	13	2.59e-33	2.05e-26	0.57	0.51	Obesity-related traits;	chr13:24466692	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.631	rs4769358	ENSG00000224976.2	PARP4P2	13	2.59e-33	2.05e-26	0.57	0.51	Obesity-related traits;	chr13:24466940	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.608	rs4769359	ENSG00000224976.2	PARP4P2	13	2.59e-33	2.05e-26	0.57	0.51	Obesity-related traits;	chr13:24466966	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.608	rs4769360	ENSG00000224976.2	PARP4P2	13	2.59e-33	2.05e-26	0.57	0.51	Obesity-related traits;	chr13:24467016	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.646	rs9507355	ENSG00000224976.2	PARP4P2	-13	2.63e-33	2.08e-26	-0.56	-0.51	Obesity-related traits;	chr13:24476819	chr13:19349137~19407962:+
LUAD	trans	rs7258465	0.931	rs76195	ENSG00000267533.1	RP11-815J4.7	12.99	2.79e-33	2.2e-26	0.61	0.51	Breast cancer;	chr19:18519020	chr18:12067173~12068417:-
LUAD	trans	rs7258465	1	rs34256197	ENSG00000267533.1	RP11-815J4.7	12.99	2.81e-33	2.22e-26	0.63	0.51	Breast cancer;	chr19:18495662	chr18:12067173~12068417:-
LUAD	trans	rs7258465	1	rs10164323	ENSG00000267533.1	RP11-815J4.7	12.99	2.85e-33	2.25e-26	0.63	0.51	Breast cancer;	chr19:18458682	chr18:12067173~12068417:-
LUAD	trans	rs4276421	0.716	rs34186279	ENSG00000231752.4	EMBP1	12.98	2.98e-33	2.35e-26	0.66	0.51	P wave duration;	chr5:46221966	chr1:121519112~121571892:+
LUAD	trans	rs7554547	0.703	rs7543258	ENSG00000261819.1	RP11-680G24.4	12.98	3.03e-33	2.39e-26	0.68	0.51	Nonsyndromic cleft lip with cleft palate;	chr1:11901599	chr16:14988259~14990160:-
LUAD	trans	rs7554547	0.765	rs34175640	ENSG00000261819.1	RP11-680G24.4	-12.98	3.04e-33	2.39e-26	-0.66	-0.51	Nonsyndromic cleft lip with cleft palate;	chr1:11892155	chr16:14988259~14990160:-
LUAD	trans	rs7312770	0.612	rs773114	ENSG00000212994.5	RPS26P6	12.97	3.38e-33	2.66e-26	0.58	0.51	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr8:100895771~100896118:+
LUAD	trans	rs616147	0.671	rs675595	ENSG00000183298.5	RP11-556K13.1	-12.96	3.6e-33	2.83e-26	-0.66	-0.51	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39458987	chr1:101786340~101787219:-
LUAD	trans	rs1816752	0.646	rs9511291	ENSG00000224976.2	PARP4P2	12.96	3.81e-33	2.99e-26	0.57	0.51	Obesity-related traits;	chr13:24467609	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.646	rs9511292	ENSG00000224976.2	PARP4P2	12.96	3.81e-33	2.99e-26	0.57	0.51	Obesity-related traits;	chr13:24467623	chr13:19349137~19407962:+
LUAD	trans	rs7312770	0.637	rs705699	ENSG00000212994.5	RPS26P6	12.95	4.16e-33	3.26e-26	0.58	0.51	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr8:100895771~100896118:+
LUAD	trans	rs6477998	0.676	rs10981693	ENSG00000238072.1	RP11-305M3.2	-12.94	4.36e-33	3.41e-26	-0.74	-0.51	Hematology traits;	chr9:113223137	chr7:129410113~129410370:-
LUAD	trans	rs9467773	1	rs1884949	ENSG00000242375.1	RP11-498P14.3	12.94	4.45e-33	3.48e-26	0.66	0.51	Intelligence (multi-trait analysis);	chr6:26567839	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs9467796	ENSG00000242375.1	RP11-498P14.3	12.94	4.45e-33	3.48e-26	0.66	0.51	Intelligence (multi-trait analysis);	chr6:26568183	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs9467797	ENSG00000242375.1	RP11-498P14.3	12.94	4.45e-33	3.48e-26	0.66	0.51	Intelligence (multi-trait analysis);	chr6:26568245	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs1078679	ENSG00000242375.1	RP11-498P14.3	12.94	4.45e-33	3.48e-26	0.66	0.51	Intelligence (multi-trait analysis);	chr6:26568513	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs6932156	ENSG00000242375.1	RP11-498P14.3	12.94	4.45e-33	3.48e-26	0.66	0.51	Intelligence (multi-trait analysis);	chr6:26571278	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs6924838	ENSG00000242375.1	RP11-498P14.3	12.94	4.45e-33	3.48e-26	0.66	0.51	Intelligence (multi-trait analysis);	chr6:26571528	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs6925895	ENSG00000242375.1	RP11-498P14.3	12.94	4.45e-33	3.48e-26	0.66	0.51	Intelligence (multi-trait analysis);	chr6:26571937	chr9:97195351~97197687:-
LUAD	trans	rs9467773	0.873	rs9295698	ENSG00000242375.1	RP11-498P14.3	12.94	4.51e-33	3.52e-26	0.66	0.51	Intelligence (multi-trait analysis);	chr6:26565871	chr9:97195351~97197687:-
LUAD	trans	rs6477998	0.676	rs4978536	ENSG00000238072.1	RP11-305M3.2	12.94	4.54e-33	3.54e-26	0.75	0.51	Hematology traits;	chr9:113220123	chr7:129410113~129410370:-
LUAD	trans	rs1816752	0.608	rs9511290	ENSG00000224976.2	PARP4P2	12.94	4.61e-33	3.6e-26	0.57	0.51	Obesity-related traits;	chr13:24467189	chr13:19349137~19407962:+
LUAD	trans	rs7258465	1	rs7251653	ENSG00000267533.1	RP11-815J4.7	12.94	4.62e-33	3.61e-26	0.63	0.51	Breast cancer;	chr19:18497473	chr18:12067173~12068417:-
LUAD	trans	rs9467773	1	rs6456734	ENSG00000242375.1	RP11-498P14.3	12.94	4.68e-33	3.65e-26	0.66	0.51	Intelligence (multi-trait analysis);	chr6:26566737	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs1535277	ENSG00000242375.1	RP11-498P14.3	12.94	4.68e-33	3.65e-26	0.66	0.51	Intelligence (multi-trait analysis);	chr6:26567574	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs1884948	ENSG00000242375.1	RP11-498P14.3	12.94	4.68e-33	3.65e-26	0.66	0.51	Intelligence (multi-trait analysis);	chr6:26567760	chr9:97195351~97197687:-
LUAD	trans	rs55665837	1	rs12804549	ENSG00000236360.2	RP11-334A14.2	12.93	4.89e-33	3.81e-26	0.66	0.51	Vitamin D levels;	chr11:14416212	chr1:52993201~52993702:-
LUAD	trans	rs616147	1	rs1768208	ENSG00000183298.5	RP11-556K13.1	-12.93	4.91e-33	3.83e-26	-0.67	-0.51	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39481512	chr1:101786340~101787219:-
LUAD	trans	rs7730934	0.818	rs1373998	ENSG00000227018.1	IL6STP1	12.92	5.57e-33	4.34e-26	0.73	0.51	Blood protein levels;	chr5:55959737	chr17:15783288~15784307:+
LUAD	trans	rs6477998	0.627	rs10114381	ENSG00000238072.1	RP11-305M3.2	12.91	5.86e-33	4.56e-26	0.75	0.51	Hematology traits;	chr9:113213692	chr7:129410113~129410370:-
LUAD	trans	rs6477998	0.651	rs10114423	ENSG00000238072.1	RP11-305M3.2	12.91	5.86e-33	4.56e-26	0.75	0.51	Hematology traits;	chr9:113213751	chr7:129410113~129410370:-
LUAD	trans	rs6477998	0.603	rs7859189	ENSG00000238072.1	RP11-305M3.2	12.91	5.86e-33	4.56e-26	0.75	0.51	Hematology traits;	chr9:113217389	chr7:129410113~129410370:-
LUAD	trans	rs6477998	0.676	rs6477997	ENSG00000238072.1	RP11-305M3.2	12.91	5.86e-33	4.56e-26	0.75	0.51	Hematology traits;	chr9:113218833	chr7:129410113~129410370:-
LUAD	trans	rs6477998	0.627	rs3810914	ENSG00000238072.1	RP11-305M3.2	12.91	5.86e-33	4.56e-26	0.75	0.51	Hematology traits;	chr9:113219441	chr7:129410113~129410370:-
LUAD	trans	rs6732160	0.774	rs11890053	ENSG00000236165.1	PRADC1P1	12.91	5.87e-33	4.57e-26	0.68	0.51	Intelligence (multi-trait analysis);	chr2:73146320	chr3:36976316~36976840:+
LUAD	trans	rs6732160	0.774	rs1367291	ENSG00000236165.1	PRADC1P1	12.91	5.87e-33	4.57e-26	0.68	0.51	Intelligence (multi-trait analysis);	chr2:73147737	chr3:36976316~36976840:+
LUAD	trans	rs9467773	1	rs10214634	ENSG00000242375.1	RP11-498P14.3	12.91	6.17e-33	4.79e-26	0.65	0.51	Intelligence (multi-trait analysis);	chr6:26564354	chr9:97195351~97197687:-
LUAD	trans	rs7258465	1	rs28572537	ENSG00000267533.1	RP11-815J4.7	12.9	6.35e-33	4.93e-26	0.62	0.51	Breast cancer;	chr19:18441398	chr18:12067173~12068417:-
LUAD	trans	rs6477998	0.676	rs10817460	ENSG00000238072.1	RP11-305M3.2	12.9	6.88e-33	5.34e-26	0.75	0.51	Hematology traits;	chr9:113214118	chr7:129410113~129410370:-
LUAD	trans	rs7554547	0.791	rs4846076	ENSG00000261819.1	RP11-680G24.4	12.89	7.23e-33	5.61e-26	0.66	0.51	Nonsyndromic cleft lip with cleft palate;	chr1:11896708	chr16:14988259~14990160:-
LUAD	trans	rs7730934	0.818	rs16884703	ENSG00000227018.1	IL6STP1	12.89	7.54e-33	5.84e-26	0.74	0.51	Blood protein levels;	chr5:55993468	chr17:15783288~15784307:+
LUAD	trans	rs4276421	0.656	rs13180509	ENSG00000231752.4	EMBP1	12.88	7.72e-33	5.98e-26	0.66	0.51	P wave duration;	chr5:46239147	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.656	rs8188149	ENSG00000231752.4	EMBP1	12.88	7.72e-33	5.98e-26	0.66	0.51	P wave duration;	chr5:46242641	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.688	rs13436334	ENSG00000231752.4	EMBP1	12.88	7.72e-33	5.98e-26	0.66	0.51	P wave duration;	chr5:46243759	chr1:121519112~121571892:+
LUAD	trans	rs13190036	0.786	rs10068127	ENSG00000217325.2	PRELID1P1	-12.88	7.81e-33	6.05e-26	-0.83	-0.51	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177204786	chr6:126643488~126644390:+
LUAD	trans	rs7258465	1	rs10164319	ENSG00000267533.1	RP11-815J4.7	12.88	7.93e-33	6.14e-26	0.62	0.51	Breast cancer;	chr19:18459023	chr18:12067173~12068417:-
LUAD	trans	rs7258465	0.965	rs1560118	ENSG00000267533.1	RP11-815J4.7	12.88	7.93e-33	6.14e-26	0.62	0.51	Breast cancer;	chr19:18459225	chr18:12067173~12068417:-
LUAD	trans	rs877636	0.692	rs11171739	ENSG00000243403.1	RP11-330L19.1	12.87	8.56e-33	6.63e-26	0.53	0.51	Cognitive function;	chr12:56076841	chr15:64592979~64593326:+
LUAD	trans	rs7730934	0.818	rs11739048	ENSG00000227018.1	IL6STP1	12.87	9e-33	6.96e-26	0.73	0.51	Blood protein levels;	chr5:55967667	chr17:15783288~15784307:+
LUAD	trans	rs7730934	0.818	rs10066245	ENSG00000227018.1	IL6STP1	12.87	9.12e-33	7.05e-26	0.73	0.51	Blood protein levels;	chr5:55975457	chr17:15783288~15784307:+
LUAD	trans	rs7730934	0.818	rs6861772	ENSG00000227018.1	IL6STP1	12.87	9.12e-33	7.05e-26	0.73	0.51	Blood protein levels;	chr5:55975793	chr17:15783288~15784307:+
LUAD	trans	rs7730934	0.818	rs6873542	ENSG00000227018.1	IL6STP1	12.85	1.04e-32	8.05e-26	0.74	0.51	Blood protein levels;	chr5:55986790	chr17:15783288~15784307:+
LUAD	trans	rs7730934	0.818	rs62363895	ENSG00000227018.1	IL6STP1	12.85	1.12e-32	8.62e-26	0.73	0.51	Blood protein levels;	chr5:55958708	chr17:15783288~15784307:+
LUAD	trans	rs1816752	0.646	rs9511279	ENSG00000224976.2	PARP4P2	12.84	1.16e-32	8.98e-26	0.57	0.51	Obesity-related traits;	chr13:24463348	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.646	rs9511280	ENSG00000224976.2	PARP4P2	12.84	1.16e-32	8.98e-26	0.57	0.51	Obesity-related traits;	chr13:24463364	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.646	rs9511281	ENSG00000224976.2	PARP4P2	12.84	1.16e-32	8.98e-26	0.57	0.51	Obesity-related traits;	chr13:24463441	chr13:19349137~19407962:+
LUAD	trans	rs4276421	0.688	rs7293424	ENSG00000231752.4	EMBP1	12.84	1.17e-32	8.99e-26	0.66	0.51	P wave duration;	chr5:46184874	chr1:121519112~121571892:+
LUAD	trans	rs916888	0.779	rs199498	ENSG00000264070.1	DND1P1	12.84	1.21e-32	9.36e-26	0.73	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:45585871~45586929:+
LUAD	trans	rs7554547	0.765	rs2050270	ENSG00000261819.1	RP11-680G24.4	12.82	1.37e-32	1.05e-25	0.67	0.5	Nonsyndromic cleft lip with cleft palate;	chr1:11886399	chr16:14988259~14990160:-
LUAD	trans	rs6477998	0.676	rs4979225	ENSG00000238072.1	RP11-305M3.2	12.82	1.39e-32	1.07e-25	0.74	0.5	Hematology traits;	chr9:113225130	chr7:129410113~129410370:-
LUAD	trans	rs4276421	0.594	rs7293434	ENSG00000231752.4	EMBP1	12.82	1.42e-32	1.1e-25	0.66	0.5	P wave duration;	chr5:46257587	chr1:121519112~121571892:+
LUAD	trans	rs13190036	0.591	rs78523677	ENSG00000217325.2	PRELID1P1	-12.81	1.52e-32	1.17e-25	-0.76	-0.5	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177124102	chr6:126643488~126644390:+
LUAD	trans	rs9467773	0.967	rs1056347	ENSG00000242375.1	RP11-498P14.3	12.81	1.54e-32	1.18e-25	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26527296	chr9:97195351~97197687:-
LUAD	trans	rs7258465	1	rs8107367	ENSG00000267533.1	RP11-815J4.7	12.81	1.54e-32	1.18e-25	0.62	0.5	Breast cancer;	chr19:18453895	chr18:12067173~12068417:-
LUAD	trans	rs616147	1	rs616147	ENSG00000183298.5	RP11-556K13.1	-12.81	1.59e-32	1.22e-25	-0.68	-0.5	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39492990	chr1:101786340~101787219:-
LUAD	trans	rs2731664	0.74	rs2731670	ENSG00000215571.5	GRK6P1	-12.81	1.62e-32	1.24e-25	-0.6	-0.5	Intelligence (multi-trait analysis);	chr5:177421018	chr13:21319156~21320866:+
LUAD	trans	rs9467773	1	rs6922824	ENSG00000242375.1	RP11-498P14.3	-12.81	1.63e-32	1.25e-25	-0.65	-0.5	Intelligence (multi-trait analysis);	chr6:26553587	chr9:97195351~97197687:-
LUAD	trans	rs6708331	0.941	rs6749886	ENSG00000232654.1	FAM136BP	12.8	1.72e-32	1.32e-25	0.75	0.5	Obesity-related traits;	chr2:70062968	chr6:3045384~3045800:+
LUAD	trans	rs6732160	0.809	rs13387480	ENSG00000236165.1	PRADC1P1	12.8	1.79e-32	1.38e-25	0.67	0.5	Intelligence (multi-trait analysis);	chr2:73143879	chr3:36976316~36976840:+
LUAD	trans	rs7258465	1	rs10411009	ENSG00000267533.1	RP11-815J4.7	12.79	1.85e-32	1.42e-25	0.62	0.5	Breast cancer;	chr19:18495456	chr18:12067173~12068417:-
LUAD	trans	rs9467773	0.967	rs6941022	ENSG00000242375.1	RP11-498P14.3	12.78	2.01e-32	1.54e-25	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26553303	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs2224380	ENSG00000242375.1	RP11-498P14.3	12.78	2.01e-32	1.54e-25	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26553715	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs6930120	ENSG00000242375.1	RP11-498P14.3	12.78	2.01e-32	1.54e-25	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26555256	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs10484442	ENSG00000242375.1	RP11-498P14.3	12.78	2.01e-32	1.54e-25	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26555651	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs767471	ENSG00000242375.1	RP11-498P14.3	12.78	2.01e-32	1.54e-25	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26557626	chr9:97195351~97197687:-
LUAD	trans	rs6732160	0.845	rs13413175	ENSG00000236165.1	PRADC1P1	12.78	2.06e-32	1.58e-25	0.66	0.5	Intelligence (multi-trait analysis);	chr2:73162788	chr3:36976316~36976840:+
LUAD	trans	rs7258465	1	rs2303695	ENSG00000267533.1	RP11-815J4.7	12.78	2.09e-32	1.6e-25	0.62	0.5	Breast cancer;	chr19:18451814	chr18:12067173~12068417:-
LUAD	trans	rs9467773	1	rs6940053	ENSG00000242375.1	RP11-498P14.3	12.78	2.16e-32	1.66e-25	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26561894	chr9:97195351~97197687:-
LUAD	trans	rs7258465	0.896	rs8103660	ENSG00000267533.1	RP11-815J4.7	12.78	2.17e-32	1.66e-25	0.62	0.5	Breast cancer;	chr19:18455585	chr18:12067173~12068417:-
LUAD	trans	rs7258465	0.965	rs10408290	ENSG00000267533.1	RP11-815J4.7	12.77	2.39e-32	1.83e-25	0.62	0.5	Breast cancer;	chr19:18431891	chr18:12067173~12068417:-
LUAD	trans	rs7258465	0.965	rs10409003	ENSG00000267533.1	RP11-815J4.7	12.77	2.39e-32	1.83e-25	0.62	0.5	Breast cancer;	chr19:18432244	chr18:12067173~12068417:-
LUAD	trans	rs7258465	1	rs3810429	ENSG00000267533.1	RP11-815J4.7	12.76	2.48e-32	1.89e-25	0.62	0.5	Breast cancer;	chr19:18432460	chr18:12067173~12068417:-
LUAD	trans	rs1816752	0.583	rs9553311	ENSG00000224976.2	PARP4P2	12.76	2.51e-32	1.92e-25	0.57	0.5	Obesity-related traits;	chr13:24474016	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.646	rs7337981	ENSG00000224976.2	PARP4P2	12.76	2.53e-32	1.93e-25	0.57	0.5	Obesity-related traits;	chr13:24469245	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.646	rs7328391	ENSG00000224976.2	PARP4P2	12.76	2.53e-32	1.93e-25	0.57	0.5	Obesity-related traits;	chr13:24470325	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.609	rs4769361	ENSG00000224976.2	PARP4P2	12.76	2.53e-32	1.93e-25	0.57	0.5	Obesity-related traits;	chr13:24468834	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.609	rs4770693	ENSG00000224976.2	PARP4P2	12.76	2.53e-32	1.93e-25	0.57	0.5	Obesity-related traits;	chr13:24468835	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.609	rs4770695	ENSG00000224976.2	PARP4P2	12.76	2.53e-32	1.93e-25	0.57	0.5	Obesity-related traits;	chr13:24468895	chr13:19349137~19407962:+
LUAD	trans	rs7258465	1	rs4808801	ENSG00000267533.1	RP11-815J4.7	12.76	2.56e-32	1.95e-25	0.62	0.5	Breast cancer;	chr19:18460331	chr18:12067173~12068417:-
LUAD	trans	rs7258465	0.931	rs271626	ENSG00000267533.1	RP11-815J4.7	-12.76	2.57e-32	1.96e-25	-0.62	-0.5	Breast cancer;	chr19:18516257	chr18:12067173~12068417:-
LUAD	trans	rs6732160	0.809	rs13406142	ENSG00000236165.1	PRADC1P1	12.76	2.58e-32	1.97e-25	0.68	0.5	Intelligence (multi-trait analysis);	chr2:73156970	chr3:36976316~36976840:+
LUAD	trans	rs9467773	0.967	rs9295694	ENSG00000242375.1	RP11-498P14.3	12.75	2.7e-32	2.06e-25	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26512766	chr9:97195351~97197687:-
LUAD	trans	rs9467773	0.967	rs9467775	ENSG00000242375.1	RP11-498P14.3	12.75	2.7e-32	2.06e-25	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26513207	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs9393729	ENSG00000242375.1	RP11-498P14.3	12.75	2.7e-32	2.06e-25	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26513938	chr9:97195351~97197687:-
LUAD	trans	rs6732160	0.838	rs13411380	ENSG00000236165.1	PRADC1P1	12.75	2.72e-32	2.08e-25	0.68	0.5	Intelligence (multi-trait analysis);	chr2:73155718	chr3:36976316~36976840:+
LUAD	trans	rs9467773	1	rs4713006	ENSG00000242375.1	RP11-498P14.3	12.75	2.78e-32	2.12e-25	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26519644	chr9:97195351~97197687:-
LUAD	trans	rs9467773	0.967	rs6924865	ENSG00000242375.1	RP11-498P14.3	12.75	2.78e-32	2.12e-25	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26521125	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs6925703	ENSG00000242375.1	RP11-498P14.3	12.75	2.78e-32	2.12e-25	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26521361	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs6910899	ENSG00000242375.1	RP11-498P14.3	12.75	2.78e-32	2.12e-25	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26524111	chr9:97195351~97197687:-
LUAD	trans	rs9467773	0.967	rs9461267	ENSG00000242375.1	RP11-498P14.3	12.75	2.78e-32	2.12e-25	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26525227	chr9:97195351~97197687:-
LUAD	trans	rs9467773	0.967	rs6456732	ENSG00000242375.1	RP11-498P14.3	12.75	2.79e-32	2.12e-25	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26514217	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs9295695	ENSG00000242375.1	RP11-498P14.3	-12.75	2.91e-32	2.22e-25	-0.65	-0.5	Intelligence (multi-trait analysis);	chr6:26528022	chr9:97195351~97197687:-
LUAD	trans	rs6732160	0.741	rs6546806	ENSG00000236165.1	PRADC1P1	12.75	2.92e-32	2.22e-25	0.67	0.5	Intelligence (multi-trait analysis);	chr2:73159032	chr3:36976316~36976840:+
LUAD	trans	rs6732160	0.845	rs6546809	ENSG00000236165.1	PRADC1P1	12.74	2.97e-32	2.26e-25	0.66	0.5	Intelligence (multi-trait analysis);	chr2:73162553	chr3:36976316~36976840:+
LUAD	trans	rs7258465	1	rs4808136	ENSG00000267533.1	RP11-815J4.7	-12.74	3.18e-32	2.42e-25	-0.62	-0.5	Breast cancer;	chr19:18508057	chr18:12067173~12068417:-
LUAD	trans	rs7258465	1	rs10427083	ENSG00000267533.1	RP11-815J4.7	12.74	3.19e-32	2.42e-25	0.62	0.5	Breast cancer;	chr19:18439466	chr18:12067173~12068417:-
LUAD	trans	rs1816752	0.603	rs9511278	ENSG00000237917.1	PARP4P1	-12.73	3.24e-32	2.46e-25	-0.62	-0.5	Obesity-related traits;	chr13:24455766	chrY:26594851~26634652:-
LUAD	trans	rs6477998	0.676	rs4979224	ENSG00000238072.1	RP11-305M3.2	12.73	3.28e-32	2.49e-25	0.72	0.5	Hematology traits;	chr9:113219998	chr7:129410113~129410370:-
LUAD	trans	rs7312770	0.612	rs773114	ENSG00000225071.1	GS1-184P14.2	12.73	3.39e-32	2.57e-25	0.55	0.5	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chrX:24429573~24429920:-
LUAD	trans	rs7258465	1	rs2303697	ENSG00000267533.1	RP11-815J4.7	12.73	3.51e-32	2.66e-25	0.62	0.5	Breast cancer;	chr19:18435868	chr18:12067173~12068417:-
LUAD	trans	rs7121616	0.774	rs74693612	ENSG00000234176.1	HSPA8P1	12.73	3.52e-32	2.67e-25	0.59	0.5	Breast cancer;	chr11:123092310	chrX:121203182~121205014:-
LUAD	trans	rs1816752	0.646	rs7319207	ENSG00000224976.2	PARP4P2	12.72	3.71e-32	2.82e-25	0.56	0.5	Obesity-related traits;	chr13:24473220	chr13:19349137~19407962:+
LUAD	trans	rs9467773	1	rs9467783	ENSG00000242375.1	RP11-498P14.3	12.72	3.87e-32	2.93e-25	0.64	0.5	Intelligence (multi-trait analysis);	chr6:26542666	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs9393731	ENSG00000242375.1	RP11-498P14.3	12.71	3.98e-32	3.01e-25	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26529146	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs11756120	ENSG00000242375.1	RP11-498P14.3	12.71	3.98e-32	3.01e-25	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26529580	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs9393732	ENSG00000242375.1	RP11-498P14.3	12.71	3.98e-32	3.01e-25	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26530670	chr9:97195351~97197687:-
LUAD	trans	rs9467773	0.967	rs9358954	ENSG00000242375.1	RP11-498P14.3	12.71	3.98e-32	3.01e-25	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26530950	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs1321480	ENSG00000242375.1	RP11-498P14.3	12.71	3.98e-32	3.01e-25	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26532514	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs10946835	ENSG00000242375.1	RP11-498P14.3	12.71	3.98e-32	3.01e-25	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26533529	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs9467778	ENSG00000242375.1	RP11-498P14.3	12.71	3.98e-32	3.01e-25	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26534515	chr9:97195351~97197687:-
LUAD	trans	rs8067354	0.789	rs1292068	ENSG00000187870.7	RNFT1P3	12.71	4.07e-32	3.08e-25	0.63	0.5	Hemoglobin concentration;	chr17:59851958	chr17:20743333~20754501:-
LUAD	trans	rs9467773	1	rs28558133	ENSG00000242375.1	RP11-498P14.3	12.71	4.09e-32	3.09e-25	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26531205	chr9:97195351~97197687:-
LUAD	trans	rs7258465	1	rs34171762	ENSG00000267533.1	RP11-815J4.7	12.71	4.13e-32	3.12e-25	0.61	0.5	Breast cancer;	chr19:18448600	chr18:12067173~12068417:-
LUAD	trans	rs9467773	1	rs9467782	ENSG00000242375.1	RP11-498P14.3	12.71	4.27e-32	3.22e-25	0.64	0.5	Intelligence (multi-trait analysis);	chr6:26542545	chr9:97195351~97197687:-
LUAD	trans	rs9467773	0.935	rs9461270	ENSG00000242375.1	RP11-498P14.3	12.71	4.27e-32	3.22e-25	0.64	0.5	Intelligence (multi-trait analysis);	chr6:26543882	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs1884946	ENSG00000242375.1	RP11-498P14.3	12.71	4.27e-32	3.22e-25	0.64	0.5	Intelligence (multi-trait analysis);	chr6:26545080	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs4871	ENSG00000242375.1	RP11-498P14.3	12.71	4.27e-32	3.22e-25	0.64	0.5	Intelligence (multi-trait analysis);	chr6:26545404	chr9:97195351~97197687:-
LUAD	trans	rs7312770	0.637	rs705699	ENSG00000225071.1	GS1-184P14.2	12.7	4.37e-32	3.3e-25	0.55	0.5	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chrX:24429573~24429920:-
LUAD	trans	rs7258465	1	rs10442	ENSG00000267533.1	RP11-815J4.7	12.7	4.48e-32	3.38e-25	0.62	0.5	Breast cancer;	chr19:18434531	chr18:12067173~12068417:-
LUAD	trans	rs11098499	0.779	rs7699346	ENSG00000275858.1	RP11-291L22.8	12.7	4.6e-32	3.47e-25	0.62	0.5	Corneal astigmatism;	chr4:119389387	chr10:38450738~38451069:-
LUAD	trans	rs2950393	0.572	rs10783794	ENSG00000121089.4	NACA3P	-12.69	4.78e-32	3.6e-25	-0.6	-0.5	Platelet distribution width;	chr12:56593395	chr4:164943290~164943937:+
LUAD	trans	rs11098499	0.863	rs1383532	ENSG00000275858.1	RP11-291L22.8	-12.69	4.92e-32	3.71e-25	-0.62	-0.5	Corneal astigmatism;	chr4:119513249	chr10:38450738~38451069:-
LUAD	trans	rs9467773	0.967	rs7753565	ENSG00000242375.1	RP11-498P14.3	12.69	5.12e-32	3.86e-25	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26559784	chr9:97195351~97197687:-
LUAD	trans	rs959695	0.864	rs7844422	ENSG00000260318.1	COX6CP1	12.69	5.13e-32	3.86e-25	0.65	0.5	Hippocampal atrophy;	chr8:99837782	chr16:11903923~11904137:-
LUAD	trans	rs7258465	1	rs34746918	ENSG00000267533.1	RP11-815J4.7	12.68	5.25e-32	3.95e-25	0.62	0.5	Breast cancer;	chr19:18428934	chr18:12067173~12068417:-
LUAD	trans	rs9467773	1	rs1321481	ENSG00000242375.1	RP11-498P14.3	12.67	5.75e-32	4.32e-25	0.64	0.5	Intelligence (multi-trait analysis);	chr6:26537982	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs4713008	ENSG00000242375.1	RP11-498P14.3	12.67	5.75e-32	4.32e-25	0.64	0.5	Intelligence (multi-trait analysis);	chr6:26538040	chr9:97195351~97197687:-
LUAD	trans	rs9467773	0.967	rs6932865	ENSG00000242375.1	RP11-498P14.3	12.67	5.75e-32	4.32e-25	0.64	0.5	Intelligence (multi-trait analysis);	chr6:26539938	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs6933176	ENSG00000242375.1	RP11-498P14.3	12.67	5.75e-32	4.32e-25	0.64	0.5	Intelligence (multi-trait analysis);	chr6:26539950	chr9:97195351~97197687:-
LUAD	trans	rs7258465	1	rs7258465	ENSG00000267533.1	RP11-815J4.7	12.67	5.93e-32	4.46e-25	0.61	0.5	Breast cancer;	chr19:18422832	chr18:12067173~12068417:-
LUAD	trans	rs6732160	0.845	rs6546805	ENSG00000236165.1	PRADC1P1	12.67	6.03e-32	4.53e-25	0.67	0.5	Intelligence (multi-trait analysis);	chr2:73158987	chr3:36976316~36976840:+
LUAD	trans	rs1816752	0.646	rs9511295	ENSG00000224976.2	PARP4P2	12.67	6.08e-32	4.57e-25	0.56	0.5	Obesity-related traits;	chr13:24467794	chr13:19349137~19407962:+
LUAD	trans	rs9467773	1	rs2255070	ENSG00000242375.1	RP11-498P14.3	12.67	6.22e-32	4.67e-25	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26501549	chr9:97195351~97197687:-
LUAD	trans	rs9467773	0.844	rs2393669	ENSG00000242375.1	RP11-498P14.3	12.67	6.25e-32	4.69e-25	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26503645	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs9461259	ENSG00000242375.1	RP11-498P14.3	12.67	6.25e-32	4.69e-25	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26504607	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs9467774	ENSG00000242375.1	RP11-498P14.3	12.67	6.25e-32	4.69e-25	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26504808	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs3736781	ENSG00000242375.1	RP11-498P14.3	12.67	6.25e-32	4.69e-25	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26505134	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs3736782	ENSG00000242375.1	RP11-498P14.3	12.67	6.25e-32	4.69e-25	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26505175	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs2208331	ENSG00000242375.1	RP11-498P14.3	12.67	6.25e-32	4.69e-25	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26507091	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs9393728	ENSG00000242375.1	RP11-498P14.3	12.67	6.25e-32	4.69e-25	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26509102	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs1056667	ENSG00000242375.1	RP11-498P14.3	12.67	6.25e-32	4.69e-25	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26510336	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs9467773	ENSG00000242375.1	RP11-498P14.3	12.67	6.26e-32	4.7e-25	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26498198	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs6926629	ENSG00000242375.1	RP11-498P14.3	12.67	6.26e-32	4.7e-25	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26499675	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs6903973	ENSG00000242375.1	RP11-498P14.3	12.67	6.26e-32	4.7e-25	0.65	0.5	Intelligence (multi-trait analysis);	chr6:26499714	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs9467791	ENSG00000242375.1	RP11-498P14.3	-12.66	6.37e-32	4.78e-25	-0.65	-0.5	Intelligence (multi-trait analysis);	chr6:26562258	chr9:97195351~97197687:-
LUAD	trans	rs1816752	0.583	rs9511284	ENSG00000224976.2	PARP4P2	12.66	6.42e-32	4.81e-25	0.56	0.5	Obesity-related traits;	chr13:24463660	chr13:19349137~19407962:+
LUAD	trans	rs11098499	0.821	rs3775852	ENSG00000275858.1	RP11-291L22.8	12.66	6.46e-32	4.84e-25	0.62	0.5	Corneal astigmatism;	chr4:119533401	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.82	rs6534140	ENSG00000275858.1	RP11-291L22.8	12.66	6.46e-32	4.84e-25	0.62	0.5	Corneal astigmatism;	chr4:119534156	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs7657849	ENSG00000275858.1	RP11-291L22.8	12.66	6.46e-32	4.84e-25	0.62	0.5	Corneal astigmatism;	chr4:119534339	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs10034450	ENSG00000275858.1	RP11-291L22.8	12.66	6.46e-32	4.84e-25	0.62	0.5	Corneal astigmatism;	chr4:119534494	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs1480939	ENSG00000275858.1	RP11-291L22.8	12.66	6.46e-32	4.84e-25	0.62	0.5	Corneal astigmatism;	chr4:119535772	chr10:38450738~38451069:-
LUAD	trans	rs9467773	1	rs9461271	ENSG00000242375.1	RP11-498P14.3	12.66	6.64e-32	4.98e-25	0.64	0.5	Intelligence (multi-trait analysis);	chr6:26554740	chr9:97195351~97197687:-
LUAD	trans	rs9467773	1	rs9467787	ENSG00000242375.1	RP11-498P14.3	12.66	6.64e-32	4.98e-25	0.64	0.5	Intelligence (multi-trait analysis);	chr6:26556541	chr9:97195351~97197687:-
LUAD	trans	rs7258465	0.897	rs1043327	ENSG00000267533.1	RP11-815J4.7	12.65	7.12e-32	5.33e-25	0.61	0.5	Breast cancer;	chr19:18444162	chr18:12067173~12068417:-
LUAD	trans	rs877636	0.692	rs11171739	ENSG00000212994.5	RPS26P6	12.65	7.52e-32	5.63e-25	0.57	0.5	Cognitive function;	chr12:56076841	chr8:100895771~100896118:+
LUAD	trans	rs7258465	1	rs10405636	ENSG00000267533.1	RP11-815J4.7	12.64	7.75e-32	5.79e-25	0.62	0.5	Breast cancer;	chr19:18427932	chr18:12067173~12068417:-
LUAD	trans	rs11098499	0.863	rs1383533	ENSG00000275858.1	RP11-291L22.8	12.64	7.87e-32	5.87e-25	0.62	0.5	Corneal astigmatism;	chr4:119513421	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs2291185	ENSG00000275858.1	RP11-291L22.8	12.64	7.87e-32	5.87e-25	0.62	0.5	Corneal astigmatism;	chr4:119513678	chr10:38450738~38451069:-
LUAD	trans	rs9611519	0.78	rs9611546	ENSG00000268568.1	AC007228.9	-12.64	7.89e-32	5.89e-25	-0.72	-0.5	Neuroticism;	chr22:41302538	chr19:56672574~56673901:-
LUAD	trans	rs12709013	0.636	rs6499976	ENSG00000233719.3	GOT2P3	12.64	8.22e-32	6.13e-25	0.63	0.5	Blood metabolite ratios;	chr16:58770330	chr12:9641802~9643007:+
LUAD	trans	rs11098499	0.863	rs12502389	ENSG00000275858.1	RP11-291L22.8	12.64	8.26e-32	6.16e-25	0.62	0.5	Corneal astigmatism;	chr4:119533036	chr10:38450738~38451069:-
LUAD	trans	rs2657294	0.62	rs4746261	ENSG00000172974.11	AC007318.5	-12.64	8.36e-32	6.23e-25	-0.52	-0.5	Pneumonia;	chr10:75085874	chr2:65205108~65205988:+
LUAD	trans	rs1816752	0.646	rs750390	ENSG00000224976.2	PARP4P2	12.63	8.67e-32	6.45e-25	0.56	0.5	Obesity-related traits;	chr13:24461603	chr13:19349137~19407962:+
LUAD	trans	rs9467773	0.967	rs1535276	ENSG00000242375.1	RP11-498P14.3	12.63	9.08e-32	6.74e-25	0.64	0.5	Intelligence (multi-trait analysis);	chr6:26520713	chr9:97195351~97197687:-
LUAD	trans	rs7258465	1	rs4595905	ENSG00000267533.1	RP11-815J4.7	12.63	9.09e-32	6.75e-25	0.61	0.5	Breast cancer;	chr19:18436495	chr18:12067173~12068417:-
LUAD	trans	rs11098499	0.909	rs11723839	ENSG00000275858.1	RP11-291L22.8	12.63	9.1e-32	6.75e-25	0.62	0.5	Corneal astigmatism;	chr4:119378518	chr10:38450738~38451069:-
LUAD	trans	rs6732160	0.845	rs6752507	ENSG00000236165.1	PRADC1P1	12.62	9.61e-32	7.13e-25	0.67	0.5	Intelligence (multi-trait analysis);	chr2:73158030	chr3:36976316~36976840:+
LUAD	trans	rs1816752	0.646	rs2862903	ENSG00000224976.2	PARP4P2	12.62	9.89e-32	7.33e-25	0.56	0.5	Obesity-related traits;	chr13:24473169	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.646	rs4480642	ENSG00000224976.2	PARP4P2	12.62	9.97e-32	7.38e-25	0.56	0.5	Obesity-related traits;	chr13:24471358	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.646	rs9551108	ENSG00000224976.2	PARP4P2	12.62	9.97e-32	7.38e-25	0.56	0.5	Obesity-related traits;	chr13:24471434	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.603	rs4238178	ENSG00000224976.2	PARP4P2	12.62	9.97e-32	7.38e-25	0.56	0.5	Obesity-related traits;	chr13:24472344	chr13:19349137~19407962:+
LUAD	trans	rs9611565	0.525	rs9611548	ENSG00000268568.1	AC007228.9	-12.61	1.04e-31	7.67e-25	-0.71	-0.5	Vitiligo;	chr22:41308139	chr19:56672574~56673901:-
LUAD	trans	rs9467773	1	rs10946834	ENSG00000242375.1	RP11-498P14.3	12.61	1.04e-31	7.72e-25	0.64	0.5	Intelligence (multi-trait analysis);	chr6:26533436	chr9:97195351~97197687:-
LUAD	trans	rs928391	0.572	rs11264548	ENSG00000227183.3	HDGFP1	-12.6	1.12e-31	8.31e-25	-0.67	-0.5	Platelet count;	chr1:156779339	chrX:131646639~131646890:+
LUAD	trans	rs11098499	0.909	rs79026312	ENSG00000275858.1	RP11-291L22.8	12.6	1.13e-31	8.35e-25	0.62	0.5	Corneal astigmatism;	chr4:119519522	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.909	rs35111518	ENSG00000275858.1	RP11-291L22.8	12.6	1.13e-31	8.35e-25	0.62	0.5	Corneal astigmatism;	chr4:119519527	chr10:38450738~38451069:-
LUAD	trans	rs928391	0.744	rs2274503	ENSG00000227183.3	HDGFP1	-12.6	1.19e-31	8.76e-25	-0.67	-0.5	Platelet count;	chr1:156782256	chrX:131646639~131646890:+
LUAD	trans	rs9467773	1	rs2393670	ENSG00000242375.1	RP11-498P14.3	12.59	1.33e-31	9.78e-25	0.64	0.5	Intelligence (multi-trait analysis);	chr6:26535313	chr9:97195351~97197687:-
LUAD	trans	rs6732160	0.809	rs6728959	ENSG00000236165.1	PRADC1P1	12.59	1.33e-31	9.79e-25	0.66	0.5	Intelligence (multi-trait analysis);	chr2:73156199	chr3:36976316~36976840:+
LUAD	trans	rs9611565	0.506	rs2024566	ENSG00000268568.1	AC007228.9	-12.59	1.35e-31	9.95e-25	-0.7	-0.5	Vitiligo;	chr22:41301334	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.506	rs2024567	ENSG00000268568.1	AC007228.9	-12.59	1.35e-31	9.95e-25	-0.7	-0.5	Vitiligo;	chr22:41303202	chr19:56672574~56673901:-
LUAD	trans	rs9611565	0.506	rs4822020	ENSG00000268568.1	AC007228.9	-12.59	1.35e-31	9.95e-25	-0.7	-0.5	Vitiligo;	chr22:41304199	chr19:56672574~56673901:-
LUAD	trans	rs9611519	0.732	rs1883826	ENSG00000268568.1	AC007228.9	-12.59	1.35e-31	9.95e-25	-0.7	-0.5	Neuroticism;	chr22:41307424	chr19:56672574~56673901:-
LUAD	trans	rs1816752	0.646	rs750388	ENSG00000224976.2	PARP4P2	12.58	1.41e-31	1.04e-24	0.56	0.5	Obesity-related traits;	chr13:24461690	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.646	rs750389	ENSG00000224976.2	PARP4P2	12.58	1.44e-31	1.06e-24	0.56	0.5	Obesity-related traits;	chr13:24461677	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.646	rs2902359	ENSG00000224976.2	PARP4P2	12.58	1.44e-31	1.06e-24	0.56	0.5	Obesity-related traits;	chr13:24461783	chr13:19349137~19407962:+
LUAD	trans	rs7312770	0.637	rs705700	ENSG00000225071.1	GS1-184P14.2	12.57	1.51e-31	1.11e-24	0.55	0.5	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chrX:24429573~24429920:-
LUAD	trans	rs7121616	1	rs7123187	ENSG00000234176.1	HSPA8P1	12.57	1.56e-31	1.15e-24	0.58	0.5	Breast cancer;	chr11:123090915	chrX:121203182~121205014:-
LUAD	trans	rs11098499	0.954	rs6848389	ENSG00000275858.1	RP11-291L22.8	12.57	1.57e-31	1.15e-24	0.62	0.5	Corneal astigmatism;	chr4:119481467	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.818	rs7688802	ENSG00000275858.1	RP11-291L22.8	12.57	1.6e-31	1.17e-24	0.62	0.5	Corneal astigmatism;	chr4:119530513	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs7695620	ENSG00000275858.1	RP11-291L22.8	12.57	1.6e-31	1.17e-24	0.62	0.5	Corneal astigmatism;	chr4:119531621	chr10:38450738~38451069:-
LUAD	trans	rs6708331	0.646	rs12713688	ENSG00000232654.1	FAM136BP	12.56	1.71e-31	1.25e-24	0.68	0.5	Obesity-related traits;	chr2:70142371	chr6:3045384~3045800:+
LUAD	trans	rs9467773	1	rs12526680	ENSG00000242375.1	RP11-498P14.3	12.56	1.77e-31	1.3e-24	0.64	0.5	Intelligence (multi-trait analysis);	chr6:26550726	chr9:97195351~97197687:-
LUAD	trans	rs7258465	0.965	rs2385088	ENSG00000267533.1	RP11-815J4.7	12.56	1.78e-31	1.3e-24	0.61	0.5	Breast cancer;	chr19:18434730	chr18:12067173~12068417:-
LUAD	trans	rs11098499	0.863	rs6835635	ENSG00000275858.1	RP11-291L22.8	12.55	1.95e-31	1.43e-24	0.63	0.5	Corneal astigmatism;	chr4:119537712	chr10:38450738~38451069:-
LUAD	trans	rs6477998	0.651	rs10121845	ENSG00000238072.1	RP11-305M3.2	12.54	1.99e-31	1.46e-24	0.72	0.5	Hematology traits;	chr9:113227443	chr7:129410113~129410370:-
LUAD	trans	rs11098499	0.863	rs10013305	ENSG00000275858.1	RP11-291L22.8	12.54	2.04e-31	1.49e-24	0.62	0.5	Corneal astigmatism;	chr4:119529269	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs3775849	ENSG00000275858.1	RP11-291L22.8	12.54	2.04e-31	1.49e-24	0.62	0.5	Corneal astigmatism;	chr4:119529753	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs34868248	ENSG00000275858.1	RP11-291L22.8	12.54	2.06e-31	1.51e-24	0.62	0.5	Corneal astigmatism;	chr4:119521275	chr10:38450738~38451069:-
LUAD	trans	rs1816752	0.624	rs9553312	ENSG00000224976.2	PARP4P2	12.54	2.16e-31	1.58e-24	0.56	0.5	Obesity-related traits;	chr13:24474055	chr13:19349137~19407962:+
LUAD	trans	rs9467773	1	rs9986382	ENSG00000242375.1	RP11-498P14.3	12.53	2.21e-31	1.62e-24	0.64	0.5	Intelligence (multi-trait analysis);	chr6:26550391	chr9:97195351~97197687:-
LUAD	trans	rs1816752	0.624	rs9507354	ENSG00000224976.2	PARP4P2	12.53	2.23e-31	1.63e-24	0.56	0.5	Obesity-related traits;	chr13:24469227	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.609	rs4770692	ENSG00000224976.2	PARP4P2	12.53	2.23e-31	1.63e-24	0.56	0.5	Obesity-related traits;	chr13:24468689	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.609	rs4770694	ENSG00000224976.2	PARP4P2	12.53	2.23e-31	1.63e-24	0.56	0.5	Obesity-related traits;	chr13:24468891	chr13:19349137~19407962:+
LUAD	trans	rs928391	0.744	rs6700964	ENSG00000227183.3	HDGFP1	-12.53	2.25e-31	1.64e-24	-0.66	-0.5	Platelet count;	chr1:156790244	chrX:131646639~131646890:+
LUAD	trans	rs9467773	1	rs9467779	ENSG00000242375.1	RP11-498P14.3	-12.53	2.28e-31	1.66e-24	-0.63	-0.5	Intelligence (multi-trait analysis);	chr6:26536459	chr9:97195351~97197687:-
LUAD	trans	rs11098499	0.779	rs10011097	ENSG00000275858.1	RP11-291L22.8	12.53	2.31e-31	1.69e-24	0.62	0.5	Corneal astigmatism;	chr4:119389204	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs3733525	ENSG00000275858.1	RP11-291L22.8	12.53	2.37e-31	1.73e-24	0.62	0.5	Corneal astigmatism;	chr4:119525893	chr10:38450738~38451069:-
LUAD	trans	rs7258465	1	rs10413237	ENSG00000267533.1	RP11-815J4.7	12.52	2.4e-31	1.75e-24	0.61	0.5	Breast cancer;	chr19:18437439	chr18:12067173~12068417:-
LUAD	trans	rs11098499	0.954	rs12505469	ENSG00000275858.1	RP11-291L22.8	12.52	2.44e-31	1.77e-24	0.61	0.5	Corneal astigmatism;	chr4:119328430	chr10:38450738~38451069:-
LUAD	trans	rs1816752	0.646	rs9511301	ENSG00000224976.2	PARP4P2	12.52	2.45e-31	1.78e-24	0.55	0.5	Obesity-related traits;	chr13:24477034	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.646	rs7332220	ENSG00000224976.2	PARP4P2	12.52	2.45e-31	1.78e-24	0.55	0.5	Obesity-related traits;	chr13:24477081	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.624	rs11149109	ENSG00000224976.2	PARP4P2	12.52	2.45e-31	1.78e-24	0.55	0.5	Obesity-related traits;	chr13:24477290	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.646	rs9511302	ENSG00000224976.2	PARP4P2	12.52	2.45e-31	1.78e-24	0.55	0.5	Obesity-related traits;	chr13:24477580	chr13:19349137~19407962:+
LUAD	trans	rs11098499	0.863	rs1480940	ENSG00000275858.1	RP11-291L22.8	12.52	2.54e-31	1.85e-24	0.62	0.5	Corneal astigmatism;	chr4:119536527	chr10:38450738~38451069:-
LUAD	trans	rs1816752	0.624	rs2096093	ENSG00000224976.2	PARP4P2	12.52	2.61e-31	1.9e-24	0.56	0.5	Obesity-related traits;	chr13:24472753	chr13:19349137~19407962:+
LUAD	trans	rs9611565	0.506	rs1984839	ENSG00000268568.1	AC007228.9	-12.52	2.62e-31	1.9e-24	-0.69	-0.5	Vitiligo;	chr22:41289933	chr19:56672574~56673901:-
LUAD	trans	rs7730934	0.818	rs6888334	ENSG00000227018.1	IL6STP1	12.52	2.62e-31	1.91e-24	0.71	0.5	Blood protein levels;	chr5:55955329	chr17:15783288~15784307:+
LUAD	trans	rs7730934	0.818	rs10471419	ENSG00000227018.1	IL6STP1	12.52	2.62e-31	1.91e-24	0.71	0.5	Blood protein levels;	chr5:55955395	chr17:15783288~15784307:+
LUAD	trans	rs12709013	0.59	rs982848	ENSG00000233719.3	GOT2P3	12.51	2.72e-31	1.97e-24	0.58	0.5	Blood metabolite ratios;	chr16:58704294	chr12:9641802~9643007:+
LUAD	trans	rs11098499	0.863	rs10030660	ENSG00000275858.1	RP11-291L22.8	12.51	2.79e-31	2.02e-24	0.62	0.5	Corneal astigmatism;	chr4:119515549	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs13149407	ENSG00000275858.1	RP11-291L22.8	12.51	2.79e-31	2.02e-24	0.62	0.5	Corneal astigmatism;	chr4:119516670	chr10:38450738~38451069:-
LUAD	trans	rs9467773	1	rs6940188	ENSG00000242375.1	RP11-498P14.3	12.51	2.81e-31	2.04e-24	0.64	0.5	Intelligence (multi-trait analysis);	chr6:26561801	chr9:97195351~97197687:-
LUAD	trans	rs7730934	0.818	rs7719246	ENSG00000227018.1	IL6STP1	12.51	2.83e-31	2.05e-24	0.71	0.5	Blood protein levels;	chr5:55948949	chr17:15783288~15784307:+
LUAD	trans	rs13190036	0.551	rs28932178	ENSG00000217325.2	PRELID1P1	-12.51	2.84e-31	2.06e-24	-0.76	-0.5	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210575	chr6:126643488~126644390:+
LUAD	trans	rs1816752	0.646	rs6490937	ENSG00000224976.2	PARP4P2	12.51	2.88e-31	2.09e-24	0.56	0.5	Obesity-related traits;	chr13:24475834	chr13:19349137~19407962:+
LUAD	trans	rs11098499	0.863	rs3775847	ENSG00000275858.1	RP11-291L22.8	12.5	3.02e-31	2.19e-24	0.62	0.5	Corneal astigmatism;	chr4:119526487	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs3775848	ENSG00000275858.1	RP11-291L22.8	12.5	3.02e-31	2.19e-24	0.62	0.5	Corneal astigmatism;	chr4:119526569	chr10:38450738~38451069:-
LUAD	trans	rs1816752	0.524	rs7996445	ENSG00000224976.2	PARP4P2	12.5	3.05e-31	2.21e-24	0.55	0.5	Obesity-related traits;	chr13:24475329	chr13:19349137~19407962:+
LUAD	trans	rs11098499	0.954	rs10031483	ENSG00000275858.1	RP11-291L22.8	12.5	3.07e-31	2.22e-24	0.61	0.5	Corneal astigmatism;	chr4:119501481	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs10031665	ENSG00000275858.1	RP11-291L22.8	12.5	3.07e-31	2.22e-24	0.61	0.5	Corneal astigmatism;	chr4:119501697	chr10:38450738~38451069:-
LUAD	trans	rs1045902	0.583	rs2303904	ENSG00000236165.1	PRADC1P1	-12.5	3.11e-31	2.25e-24	-0.68	-0.5	Intelligence (multi-trait analysis);	chr2:73220647	chr3:36976316~36976840:+
LUAD	trans	rs928391	0.744	rs3765783	ENSG00000227183.3	HDGFP1	-12.49	3.19e-31	2.31e-24	-0.66	-0.5	Platelet count;	chr1:156796181	chrX:131646639~131646890:+
LUAD	trans	rs11098499	0.954	rs12506546	ENSG00000275858.1	RP11-291L22.8	12.49	3.43e-31	2.47e-24	0.62	0.49	Corneal astigmatism;	chr4:119380463	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs3733523	ENSG00000275858.1	RP11-291L22.8	12.49	3.44e-31	2.48e-24	0.61	0.49	Corneal astigmatism;	chr4:119502564	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs28685688	ENSG00000275858.1	RP11-291L22.8	12.48	3.58e-31	2.57e-24	0.61	0.49	Corneal astigmatism;	chr4:119499179	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs7687843	ENSG00000275858.1	RP11-291L22.8	12.48	3.58e-31	2.57e-24	0.61	0.49	Corneal astigmatism;	chr4:119500056	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs2306455	ENSG00000275858.1	RP11-291L22.8	12.48	3.58e-31	2.57e-24	0.61	0.49	Corneal astigmatism;	chr4:119500814	chr10:38450738~38451069:-
LUAD	trans	rs12709013	0.716	rs4784987	ENSG00000230849.2	GOT2P2	12.48	3.71e-31	2.66e-24	0.61	0.49	Blood metabolite ratios;	chr16:58824135	chr1:173141100~173142350:-
LUAD	trans	rs9467773	0.873	rs55930917	ENSG00000242375.1	RP11-498P14.3	12.47	3.93e-31	2.82e-24	0.67	0.49	Intelligence (multi-trait analysis);	chr6:26576958	chr9:97195351~97197687:-
LUAD	trans	rs12709013	0.686	rs151817	ENSG00000233719.3	GOT2P3	-12.47	3.98e-31	2.86e-24	-0.58	-0.49	Blood metabolite ratios;	chr16:58704014	chr12:9641802~9643007:+
LUAD	trans	rs9467773	1	rs9357010	ENSG00000242375.1	RP11-498P14.3	12.47	4.03e-31	2.89e-24	0.63	0.49	Intelligence (multi-trait analysis);	chr6:26527717	chr9:97195351~97197687:-
LUAD	trans	rs11098499	0.908	rs11098527	ENSG00000275858.1	RP11-291L22.8	12.46	4.43e-31	3.17e-24	0.61	0.49	Corneal astigmatism;	chr4:119478751	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.909	rs1546504	ENSG00000275858.1	RP11-291L22.8	12.46	4.57e-31	3.27e-24	0.61	0.49	Corneal astigmatism;	chr4:119320024	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs10006877	ENSG00000275858.1	RP11-291L22.8	12.46	4.57e-31	3.27e-24	0.61	0.49	Corneal astigmatism;	chr4:119321638	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.618	rs28491261	ENSG00000275858.1	RP11-291L22.8	12.46	4.6e-31	3.29e-24	0.62	0.49	Corneal astigmatism;	chr4:119373745	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.908	rs1002152	ENSG00000275858.1	RP11-291L22.8	12.45	4.77e-31	3.42e-24	0.61	0.49	Corneal astigmatism;	chr4:119352232	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs11729521	ENSG00000275858.1	RP11-291L22.8	12.45	4.9e-31	3.5e-24	0.61	0.49	Corneal astigmatism;	chr4:119495633	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs3822192	ENSG00000275858.1	RP11-291L22.8	12.44	5.2e-31	3.71e-24	0.62	0.49	Corneal astigmatism;	chr4:119524565	chr10:38450738~38451069:-
LUAD	trans	rs6732160	0.845	rs6718690	ENSG00000236165.1	PRADC1P1	-12.44	5.33e-31	3.81e-24	-0.65	-0.49	Intelligence (multi-trait analysis);	chr2:73160034	chr3:36976316~36976840:+
LUAD	trans	rs7121616	1	rs7113273	ENSG00000234176.1	HSPA8P1	-12.44	5.37e-31	3.83e-24	-0.58	-0.49	Breast cancer;	chr11:123092192	chrX:121203182~121205014:-
LUAD	trans	rs12709013	0.716	rs6416775	ENSG00000230849.2	GOT2P2	12.44	5.38e-31	3.84e-24	0.6	0.49	Blood metabolite ratios;	chr16:58830410	chr1:173141100~173142350:-
LUAD	trans	rs55665837	1	rs11023215	ENSG00000236360.2	RP11-334A14.2	12.44	5.4e-31	3.85e-24	0.65	0.49	Vitamin D levels;	chr11:14415424	chr1:52993201~52993702:-
LUAD	trans	rs11098499	0.954	rs59394118	ENSG00000275858.1	RP11-291L22.8	12.44	5.45e-31	3.88e-24	0.62	0.49	Corneal astigmatism;	chr4:119374396	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.865	rs9996417	ENSG00000275858.1	RP11-291L22.8	12.44	5.45e-31	3.88e-24	0.62	0.49	Corneal astigmatism;	chr4:119374707	chr10:38450738~38451069:-
LUAD	trans	rs1816752	0.646	rs8002599	ENSG00000224976.2	PARP4P2	12.44	5.52e-31	3.93e-24	0.55	0.49	Obesity-related traits;	chr13:24478486	chr13:19349137~19407962:+
LUAD	trans	rs877636	0.692	rs11171739	ENSG00000235459.5	RPS26P31	12.44	5.59e-31	3.99e-24	0.53	0.49	Cognitive function;	chr12:56076841	chr7:122681315~122681662:+
LUAD	trans	rs867371	0.722	rs8033050	ENSG00000235370.6	DNM1P51	-12.43	5.71e-31	4.07e-24	-0.6	-0.49	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82269648	chr15:84398316~84411701:-
LUAD	trans	rs61990749	0.571	rs2364841	ENSG00000235400.1	RP4-641G12.4	12.43	5.73e-31	4.08e-24	0.89	0.49	Fibroblast growth factor basic levels;	chr14:77817693	chr1:78749073~78750659:+
LUAD	trans	rs867371	0.717	rs3858954	ENSG00000235370.6	DNM1P51	-12.43	5.79e-31	4.13e-24	-0.6	-0.49	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82265693	chr15:84398316~84411701:-
LUAD	trans	rs11098499	0.954	rs3733519	ENSG00000275858.1	RP11-291L22.8	12.43	5.8e-31	4.13e-24	0.61	0.49	Corneal astigmatism;	chr4:119502293	chr10:38450738~38451069:-
LUAD	trans	rs928391	0.744	rs11264555	ENSG00000227183.3	HDGFP1	-12.43	5.81e-31	4.14e-24	-0.66	-0.49	Platelet count;	chr1:156794246	chrX:131646639~131646890:+
LUAD	trans	rs11098499	0.909	rs11723757	ENSG00000275858.1	RP11-291L22.8	12.43	6.01e-31	4.26e-24	0.61	0.49	Corneal astigmatism;	chr4:119378514	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs10014845	ENSG00000275858.1	RP11-291L22.8	12.43	6.01e-31	4.26e-24	0.61	0.49	Corneal astigmatism;	chr4:119379922	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.779	rs7674500	ENSG00000275858.1	RP11-291L22.8	12.43	6.01e-31	4.26e-24	0.61	0.49	Corneal astigmatism;	chr4:119382438	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.909	rs28884220	ENSG00000275858.1	RP11-291L22.8	12.43	6.01e-31	4.26e-24	0.61	0.49	Corneal astigmatism;	chr4:119386056	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.909	rs28793658	ENSG00000275858.1	RP11-291L22.8	12.43	6.01e-31	4.26e-24	0.61	0.49	Corneal astigmatism;	chr4:119386059	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.865	rs4507344	ENSG00000275858.1	RP11-291L22.8	12.43	6.01e-31	4.26e-24	0.61	0.49	Corneal astigmatism;	chr4:119386330	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.697	rs4373140	ENSG00000275858.1	RP11-291L22.8	12.43	6.01e-31	4.26e-24	0.61	0.49	Corneal astigmatism;	chr4:119386543	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs13113483	ENSG00000275858.1	RP11-291L22.8	12.43	6.01e-31	4.26e-24	0.61	0.49	Corneal astigmatism;	chr4:119387884	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.542	rs10440343	ENSG00000275858.1	RP11-291L22.8	12.43	6.01e-31	4.26e-24	0.61	0.49	Corneal astigmatism;	chr4:119388632	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.909	rs28668716	ENSG00000275858.1	RP11-291L22.8	12.43	6.01e-31	4.26e-24	0.61	0.49	Corneal astigmatism;	chr4:119388720	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.542	rs7677836	ENSG00000275858.1	RP11-291L22.8	12.43	6.01e-31	4.26e-24	0.61	0.49	Corneal astigmatism;	chr4:119389483	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.909	rs10002083	ENSG00000275858.1	RP11-291L22.8	12.43	6.01e-31	4.26e-24	0.61	0.49	Corneal astigmatism;	chr4:119389997	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs10024844	ENSG00000275858.1	RP11-291L22.8	12.43	6.01e-31	4.26e-24	0.61	0.49	Corneal astigmatism;	chr4:119390373	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.657	rs4463052	ENSG00000275858.1	RP11-291L22.8	12.43	6.01e-31	4.26e-24	0.61	0.49	Corneal astigmatism;	chr4:119392103	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs13151285	ENSG00000275858.1	RP11-291L22.8	12.43	6.01e-31	4.26e-24	0.61	0.49	Corneal astigmatism;	chr4:119393586	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs59866101	ENSG00000275858.1	RP11-291L22.8	12.43	6.16e-31	4.35e-24	0.62	0.49	Corneal astigmatism;	chr4:119375436	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.618	rs6858383	ENSG00000275858.1	RP11-291L22.8	12.43	6.16e-31	4.35e-24	0.62	0.49	Corneal astigmatism;	chr4:119375617	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.697	rs6832410	ENSG00000275858.1	RP11-291L22.8	12.43	6.16e-31	4.35e-24	0.62	0.49	Corneal astigmatism;	chr4:119375645	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.865	rs1112817	ENSG00000275858.1	RP11-291L22.8	12.43	6.16e-31	4.35e-24	0.62	0.49	Corneal astigmatism;	chr4:119376645	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.779	rs10016060	ENSG00000275858.1	RP11-291L22.8	12.43	6.16e-31	4.35e-24	0.62	0.49	Corneal astigmatism;	chr4:119377257	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs10005644	ENSG00000275858.1	RP11-291L22.8	12.43	6.16e-31	4.35e-24	0.62	0.49	Corneal astigmatism;	chr4:119377322	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.697	rs10016448	ENSG00000275858.1	RP11-291L22.8	12.43	6.16e-31	4.35e-24	0.62	0.49	Corneal astigmatism;	chr4:119377690	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.657	rs9996569	ENSG00000275858.1	RP11-291L22.8	12.43	6.16e-31	4.35e-24	0.62	0.49	Corneal astigmatism;	chr4:119377849	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.908	rs11729050	ENSG00000275858.1	RP11-291L22.8	12.43	6.16e-31	4.35e-24	0.62	0.49	Corneal astigmatism;	chr4:119378911	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs28429722	ENSG00000275858.1	RP11-291L22.8	12.43	6.16e-31	4.35e-24	0.62	0.49	Corneal astigmatism;	chr4:119378938	chr10:38450738~38451069:-
LUAD	trans	rs3779195	0.697	rs13232861	ENSG00000225169.1	BRI3P1	12.42	6.4e-31	4.52e-24	0.76	0.49	Sex hormone-binding globulin levels;	chr7:98299769	chr1:100213293~100213670:+
LUAD	trans	rs11098499	0.954	rs1480931	ENSG00000275858.1	RP11-291L22.8	12.42	6.5e-31	4.59e-24	0.6	0.49	Corneal astigmatism;	chr4:119474654	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs17006190	ENSG00000275858.1	RP11-291L22.8	12.42	6.7e-31	4.73e-24	0.61	0.49	Corneal astigmatism;	chr4:119497683	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs58452170	ENSG00000275858.1	RP11-291L22.8	12.41	7.36e-31	5.19e-24	0.62	0.49	Corneal astigmatism;	chr4:119538519	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs10008392	ENSG00000275858.1	RP11-291L22.8	12.41	7.38e-31	5.2e-24	0.61	0.49	Corneal astigmatism;	chr4:119397684	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs10017371	ENSG00000275858.1	RP11-291L22.8	12.4	7.64e-31	5.38e-24	0.61	0.49	Corneal astigmatism;	chr4:119372621	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs7664986	ENSG00000275858.1	RP11-291L22.8	12.4	7.71e-31	5.42e-24	0.61	0.49	Corneal astigmatism;	chr4:119508797	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.818	rs10008791	ENSG00000275858.1	RP11-291L22.8	12.4	7.71e-31	5.42e-24	0.61	0.49	Corneal astigmatism;	chr4:119510314	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs11736416	ENSG00000275858.1	RP11-291L22.8	12.4	7.71e-31	5.42e-24	0.61	0.49	Corneal astigmatism;	chr4:119510506	chr10:38450738~38451069:-
LUAD	trans	rs12709013	0.686	rs244919	ENSG00000233719.3	GOT2P3	-12.4	7.82e-31	5.5e-24	-0.58	-0.49	Blood metabolite ratios;	chr16:58704146	chr12:9641802~9643007:+
LUAD	trans	rs11098499	0.954	rs7437420	ENSG00000275858.1	RP11-291L22.8	12.4	7.98e-31	5.61e-24	0.61	0.49	Corneal astigmatism;	chr4:119391748	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs12502423	ENSG00000275858.1	RP11-291L22.8	12.4	7.99e-31	5.62e-24	0.61	0.49	Corneal astigmatism;	chr4:119503017	chr10:38450738~38451069:-
LUAD	trans	rs959695	1	rs2442756	ENSG00000260318.1	COX6CP1	12.4	8.11e-31	5.7e-24	0.63	0.49	Hippocampal atrophy;	chr8:99816910	chr16:11903923~11904137:-
LUAD	trans	rs6708331	1	rs13429940	ENSG00000232654.1	FAM136BP	12.39	8.48e-31	5.96e-24	0.68	0.49	Obesity-related traits;	chr2:70152736	chr6:3045384~3045800:+
LUAD	trans	rs6477998	0.647	rs10981704	ENSG00000238072.1	RP11-305M3.2	-12.39	8.95e-31	6.28e-24	-0.66	-0.49	Hematology traits;	chr9:113253989	chr7:129410113~129410370:-
LUAD	trans	rs11098499	0.697	rs4560394	ENSG00000275858.1	RP11-291L22.8	12.38	9.43e-31	6.61e-24	0.62	0.49	Corneal astigmatism;	chr4:119392280	chr10:38450738~38451069:-
LUAD	trans	rs867371	0.762	rs12905578	ENSG00000235370.6	DNM1P51	12.38	9.69e-31	6.8e-24	0.6	0.49	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82288923	chr15:84398316~84411701:-
LUAD	trans	rs11098499	0.954	rs7681544	ENSG00000275858.1	RP11-291L22.8	12.38	9.77e-31	6.84e-24	0.61	0.49	Corneal astigmatism;	chr4:119490100	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs11940028	ENSG00000275858.1	RP11-291L22.8	12.38	9.77e-31	6.84e-24	0.61	0.49	Corneal astigmatism;	chr4:119490752	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs11935596	ENSG00000275858.1	RP11-291L22.8	12.38	9.77e-31	6.84e-24	0.61	0.49	Corneal astigmatism;	chr4:119491302	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs12507964	ENSG00000275858.1	RP11-291L22.8	12.38	9.77e-31	6.84e-24	0.61	0.49	Corneal astigmatism;	chr4:119491906	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.909	rs11098530	ENSG00000275858.1	RP11-291L22.8	12.38	9.77e-31	6.84e-24	0.61	0.49	Corneal astigmatism;	chr4:119491999	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs6834796	ENSG00000275858.1	RP11-291L22.8	12.38	9.77e-31	6.84e-24	0.61	0.49	Corneal astigmatism;	chr4:119493538	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs11734241	ENSG00000275858.1	RP11-291L22.8	12.38	9.77e-31	6.84e-24	0.61	0.49	Corneal astigmatism;	chr4:119495717	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs4345162	ENSG00000275858.1	RP11-291L22.8	12.37	1.01e-30	7.08e-24	0.61	0.49	Corneal astigmatism;	chr4:119391804	chr10:38450738~38451069:-
LUAD	trans	rs916888	0.61	rs199453	ENSG00000214425.5	LRRC37A4P	-12.37	1.05e-30	7.32e-24	-0.62	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:45506741~45550335:-
LUAD	trans	rs6708331	0.941	rs11903933	ENSG00000232654.1	FAM136BP	12.37	1.05e-30	7.35e-24	0.68	0.49	Obesity-related traits;	chr2:70149812	chr6:3045384~3045800:+
LUAD	trans	rs11098499	0.58	rs12509234	ENSG00000275858.1	RP11-291L22.8	12.37	1.08e-30	7.52e-24	0.61	0.49	Corneal astigmatism;	chr4:119398279	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.909	rs10014719	ENSG00000275858.1	RP11-291L22.8	12.37	1.08e-30	7.52e-24	0.61	0.49	Corneal astigmatism;	chr4:119399560	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.908	rs7696649	ENSG00000275858.1	RP11-291L22.8	12.37	1.08e-30	7.52e-24	0.61	0.49	Corneal astigmatism;	chr4:119401022	chr10:38450738~38451069:-
LUAD	trans	rs12709013	0.694	rs1616798	ENSG00000233719.3	GOT2P3	12.36	1.12e-30	7.84e-24	0.59	0.49	Blood metabolite ratios;	chr16:58739433	chr12:9641802~9643007:+
LUAD	trans	rs13190036	1	rs13175695	ENSG00000217325.2	PRELID1P1	12.36	1.13e-30	7.91e-24	0.76	0.49	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272810	chr6:126643488~126644390:+
LUAD	trans	rs11098499	0.954	rs878373	ENSG00000275858.1	RP11-291L22.8	12.36	1.17e-30	8.13e-24	0.61	0.49	Corneal astigmatism;	chr4:119316329	chr10:38450738~38451069:-
LUAD	trans	rs877636	0.692	rs10876870	ENSG00000243403.1	RP11-330L19.1	-12.36	1.19e-30	8.32e-24	-0.51	-0.49	Cognitive function;	chr12:56084218	chr15:64592979~64593326:+
LUAD	trans	rs877636	0.692	rs7971751	ENSG00000243403.1	RP11-330L19.1	-12.36	1.19e-30	8.32e-24	-0.51	-0.49	Cognitive function;	chr12:56084874	chr15:64592979~64593326:+
LUAD	trans	rs8067354	0.872	rs1292060	ENSG00000187870.7	RNFT1P3	12.35	1.21e-30	8.4e-24	0.61	0.49	Hemoglobin concentration;	chr17:59836488	chr17:20743333~20754501:-
LUAD	trans	rs7258465	0.931	rs34053595	ENSG00000267533.1	RP11-815J4.7	12.35	1.21e-30	8.43e-24	0.61	0.49	Breast cancer;	chr19:18445939	chr18:12067173~12068417:-
LUAD	trans	rs11098499	0.908	rs7695996	ENSG00000275858.1	RP11-291L22.8	12.35	1.23e-30	8.6e-24	0.61	0.49	Corneal astigmatism;	chr4:119400878	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs1546505	ENSG00000275858.1	RP11-291L22.8	12.35	1.26e-30	8.8e-24	0.6	0.49	Corneal astigmatism;	chr4:119320069	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs11098531	ENSG00000275858.1	RP11-291L22.8	12.35	1.28e-30	8.87e-24	0.62	0.49	Corneal astigmatism;	chr4:119543846	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs11098532	ENSG00000275858.1	RP11-291L22.8	12.35	1.31e-30	9.1e-24	0.61	0.49	Corneal astigmatism;	chr4:119569571	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs13140391	ENSG00000275858.1	RP11-291L22.8	12.35	1.31e-30	9.1e-24	0.61	0.49	Corneal astigmatism;	chr4:119582282	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs13140409	ENSG00000275858.1	RP11-291L22.8	12.35	1.31e-30	9.1e-24	0.61	0.49	Corneal astigmatism;	chr4:119582305	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.909	rs1546502	ENSG00000275858.1	RP11-291L22.8	12.34	1.32e-30	9.18e-24	0.61	0.49	Corneal astigmatism;	chr4:119314743	chr10:38450738~38451069:-
LUAD	trans	rs4276421	1	rs11748089	ENSG00000231752.4	EMBP1	-12.34	1.36e-30	9.43e-24	-0.65	-0.49	P wave duration;	chr5:45810733	chr1:121519112~121571892:+
LUAD	trans	rs4276421	1	rs10037766	ENSG00000231752.4	EMBP1	-12.34	1.36e-30	9.43e-24	-0.65	-0.49	P wave duration;	chr5:45813215	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.967	rs10755272	ENSG00000231752.4	EMBP1	-12.34	1.36e-30	9.43e-24	-0.65	-0.49	P wave duration;	chr5:45815434	chr1:121519112~121571892:+
LUAD	trans	rs4276421	1	rs4866982	ENSG00000231752.4	EMBP1	-12.34	1.36e-30	9.43e-24	-0.65	-0.49	P wave duration;	chr5:45816754	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.954	rs6822679	ENSG00000275858.1	RP11-291L22.8	12.34	1.4e-30	9.68e-24	0.61	0.49	Corneal astigmatism;	chr4:119481547	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs4577559	ENSG00000275858.1	RP11-291L22.8	12.34	1.4e-30	9.68e-24	0.61	0.49	Corneal astigmatism;	chr4:119482888	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs7656252	ENSG00000275858.1	RP11-291L22.8	12.34	1.4e-30	9.68e-24	0.61	0.49	Corneal astigmatism;	chr4:119483113	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.865	rs28845498	ENSG00000275858.1	RP11-291L22.8	12.34	1.4e-30	9.68e-24	0.61	0.49	Corneal astigmatism;	chr4:119484031	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs56270433	ENSG00000275858.1	RP11-291L22.8	12.34	1.4e-30	9.68e-24	0.61	0.49	Corneal astigmatism;	chr4:119484875	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs7678400	ENSG00000275858.1	RP11-291L22.8	12.34	1.41e-30	9.74e-24	0.62	0.49	Corneal astigmatism;	chr4:119540802	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs1480936	ENSG00000275858.1	RP11-291L22.8	12.34	1.41e-30	9.74e-24	0.62	0.49	Corneal astigmatism;	chr4:119541706	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs10017543	ENSG00000275858.1	RP11-291L22.8	12.34	1.42e-30	9.85e-24	0.61	0.49	Corneal astigmatism;	chr4:119400265	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs10518328	ENSG00000275858.1	RP11-291L22.8	12.33	1.49e-30	1.03e-23	0.61	0.49	Corneal astigmatism;	chr4:119480624	chr10:38450738~38451069:-
LUAD	trans	rs6732160	0.845	rs11894833	ENSG00000236165.1	PRADC1P1	-12.33	1.5e-30	1.04e-23	-0.64	-0.49	Intelligence (multi-trait analysis);	chr2:73161290	chr3:36976316~36976840:+
LUAD	trans	rs11098499	0.863	rs3775843	ENSG00000275858.1	RP11-291L22.8	12.33	1.51e-30	1.04e-23	0.61	0.49	Corneal astigmatism;	chr4:119506689	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs3775844	ENSG00000275858.1	RP11-291L22.8	12.33	1.51e-30	1.04e-23	0.61	0.49	Corneal astigmatism;	chr4:119506878	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs3890049	ENSG00000275858.1	RP11-291L22.8	12.32	1.7e-30	1.17e-23	0.61	0.49	Corneal astigmatism;	chr4:119405128	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs71629403	ENSG00000275858.1	RP11-291L22.8	12.32	1.7e-30	1.17e-23	0.61	0.49	Corneal astigmatism;	chr4:119451412	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.909	rs28571712	ENSG00000275858.1	RP11-291L22.8	12.32	1.7e-30	1.17e-23	0.61	0.49	Corneal astigmatism;	chr4:119454825	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs11098526	ENSG00000275858.1	RP11-291L22.8	12.32	1.71e-30	1.18e-23	0.61	0.49	Corneal astigmatism;	chr4:119469204	chr10:38450738~38451069:-
LUAD	trans	rs867371	0.762	rs1846910	ENSG00000235370.6	DNM1P51	-12.31	1.76e-30	1.21e-23	-0.59	-0.49	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82279439	chr15:84398316~84411701:-
LUAD	trans	rs1045902	0.583	rs36106493	ENSG00000236165.1	PRADC1P1	12.31	1.78e-30	1.22e-23	0.67	0.49	Intelligence (multi-trait analysis);	chr2:73215211	chr3:36976316~36976840:+
LUAD	trans	rs11098499	0.863	rs2306456	ENSG00000275858.1	RP11-291L22.8	12.31	1.86e-30	1.28e-23	0.62	0.49	Corneal astigmatism;	chr4:119551267	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs11947234	ENSG00000275858.1	RP11-291L22.8	12.31	1.86e-30	1.28e-23	0.62	0.49	Corneal astigmatism;	chr4:119553704	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs11933966	ENSG00000275858.1	RP11-291L22.8	12.31	1.86e-30	1.28e-23	0.62	0.49	Corneal astigmatism;	chr4:119555560	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs36040693	ENSG00000275858.1	RP11-291L22.8	12.31	1.86e-30	1.28e-23	0.62	0.49	Corneal astigmatism;	chr4:119556461	chr10:38450738~38451069:-
LUAD	trans	rs4276421	0.695	rs4421114	ENSG00000231752.4	EMBP1	-12.31	1.89e-30	1.3e-23	-0.63	-0.49	P wave duration;	chr5:46069241	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.954	rs28572238	ENSG00000275858.1	RP11-291L22.8	12.31	1.9e-30	1.3e-23	0.61	0.49	Corneal astigmatism;	chr4:119395531	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.909	rs28714195	ENSG00000275858.1	RP11-291L22.8	12.31	1.9e-30	1.3e-23	0.61	0.49	Corneal astigmatism;	chr4:119395795	chr10:38450738~38451069:-
LUAD	trans	rs13190036	0.551	rs4976639	ENSG00000217325.2	PRELID1P1	12.3	2.08e-30	1.42e-23	0.71	0.49	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177123300	chr6:126643488~126644390:+
LUAD	trans	rs877636	0.692	rs11171739	ENSG00000234513.1	AC073072.7	12.3	2.08e-30	1.42e-23	0.55	0.49	Cognitive function;	chr12:56076841	chr7:22773646~22773993:-
LUAD	trans	rs11098499	0.909	rs6842762	ENSG00000275858.1	RP11-291L22.8	12.3	2.08e-30	1.43e-23	0.6	0.49	Corneal astigmatism;	chr4:119477081	chr10:38450738~38451069:-
LUAD	trans	rs4276421	0.967	rs10069793	ENSG00000231752.4	EMBP1	12.3	2.09e-30	1.44e-23	0.65	0.49	P wave duration;	chr5:45803049	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.863	rs28718422	ENSG00000275858.1	RP11-291L22.8	12.29	2.11e-30	1.45e-23	0.62	0.49	Corneal astigmatism;	chr4:119545149	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.818	rs12498599	ENSG00000275858.1	RP11-291L22.8	12.29	2.11e-30	1.45e-23	0.62	0.49	Corneal astigmatism;	chr4:119547348	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs3733524	ENSG00000275858.1	RP11-291L22.8	12.29	2.12e-30	1.45e-23	0.61	0.49	Corneal astigmatism;	chr4:119502574	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs9998585	ENSG00000275858.1	RP11-291L22.8	12.29	2.16e-30	1.48e-23	0.6	0.49	Corneal astigmatism;	chr4:119475647	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs59732491	ENSG00000275858.1	RP11-291L22.8	12.29	2.22e-30	1.52e-23	0.61	0.49	Corneal astigmatism;	chr4:119568433	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs11723090	ENSG00000275858.1	RP11-291L22.8	12.29	2.22e-30	1.52e-23	0.61	0.49	Corneal astigmatism;	chr4:119569437	chr10:38450738~38451069:-
LUAD	trans	rs1816752	0.646	rs7995190	ENSG00000224976.2	PARP4P2	12.29	2.27e-30	1.55e-23	0.55	0.49	Obesity-related traits;	chr13:24475709	chr13:19349137~19407962:+
LUAD	trans	rs8067354	0.872	rs2645488	ENSG00000187870.7	RNFT1P3	12.29	2.28e-30	1.56e-23	0.61	0.49	Hemoglobin concentration;	chr17:59812044	chr17:20743333~20754501:-
LUAD	trans	rs4276421	1	rs13175559	ENSG00000231752.4	EMBP1	12.29	2.28e-30	1.56e-23	0.65	0.49	P wave duration;	chr5:45854525	chr1:121519112~121571892:+
LUAD	trans	rs1816752	0.608	rs7326664	ENSG00000224976.2	PARP4P2	12.29	2.31e-30	1.58e-23	0.55	0.49	Obesity-related traits;	chr13:24475868	chr13:19349137~19407962:+
LUAD	trans	rs11098499	0.863	rs3775845	ENSG00000275858.1	RP11-291L22.8	12.28	2.32e-30	1.59e-23	0.61	0.49	Corneal astigmatism;	chr4:119511292	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs12499324	ENSG00000275858.1	RP11-291L22.8	12.28	2.35e-30	1.6e-23	0.6	0.49	Corneal astigmatism;	chr4:119472631	chr10:38450738~38451069:-
LUAD	trans	rs7730934	0.818	rs13179290	ENSG00000227018.1	IL6STP1	12.28	2.39e-30	1.63e-23	0.72	0.49	Blood protein levels;	chr5:56007013	chr17:15783288~15784307:+
LUAD	trans	rs1816752	0.646	rs7322329	ENSG00000224976.2	PARP4P2	12.28	2.42e-30	1.66e-23	0.55	0.49	Obesity-related traits;	chr13:24479193	chr13:19349137~19407962:+
LUAD	trans	rs877636	0.692	rs11171739	ENSG00000225071.1	GS1-184P14.2	12.28	2.49e-30	1.7e-23	0.53	0.49	Cognitive function;	chr12:56076841	chrX:24429573~24429920:-
LUAD	trans	rs11098499	0.865	rs28753180	ENSG00000275858.1	RP11-291L22.8	12.28	2.51e-30	1.71e-23	0.61	0.49	Corneal astigmatism;	chr4:119484212	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs1010740	ENSG00000275858.1	RP11-291L22.8	-12.27	2.73e-30	1.86e-23	-0.61	-0.49	Corneal astigmatism;	chr4:119542254	chr10:38450738~38451069:-
LUAD	trans	rs4276421	0.967	rs4541666	ENSG00000231752.4	EMBP1	12.27	2.76e-30	1.88e-23	0.65	0.49	P wave duration;	chr5:45857027	chr1:121519112~121571892:+
LUAD	trans	rs13190036	0.901	rs10056655	ENSG00000217325.2	PRELID1P1	12.27	2.78e-30	1.89e-23	0.76	0.49	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177249350	chr6:126643488~126644390:+
LUAD	trans	rs7258465	1	rs8105994	ENSG00000267533.1	RP11-815J4.7	12.26	2.81e-30	1.91e-23	0.61	0.49	Breast cancer;	chr19:18482743	chr18:12067173~12068417:-
LUAD	trans	rs11098499	0.954	rs67265404	ENSG00000275858.1	RP11-291L22.8	12.26	2.91e-30	1.98e-23	0.61	0.49	Corneal astigmatism;	chr4:119438115	chr10:38450738~38451069:-
LUAD	trans	rs877636	0.692	rs10876870	ENSG00000235459.5	RPS26P31	-12.26	3.05e-30	2.07e-23	-0.53	-0.49	Cognitive function;	chr12:56084218	chr7:122681315~122681662:+
LUAD	trans	rs877636	0.692	rs7971751	ENSG00000235459.5	RPS26P31	-12.26	3.05e-30	2.07e-23	-0.53	-0.49	Cognitive function;	chr12:56084874	chr7:122681315~122681662:+
LUAD	trans	rs7730934	1	rs11742754	ENSG00000227018.1	IL6STP1	12.26	3.05e-30	2.07e-23	0.9	0.49	Blood protein levels;	chr5:56002665	chr17:15783288~15784307:+
LUAD	trans	rs11098499	0.909	rs10020034	ENSG00000275858.1	RP11-291L22.8	12.25	3.08e-30	2.09e-23	0.61	0.49	Corneal astigmatism;	chr4:119373176	chr10:38450738~38451069:-
LUAD	trans	rs1816752	0.608	rs4770690	ENSG00000224976.2	PARP4P2	12.25	3.13e-30	2.12e-23	0.55	0.49	Obesity-related traits;	chr13:24467049	chr13:19349137~19407962:+
LUAD	trans	rs12709013	0.792	rs1473206	ENSG00000233719.3	GOT2P3	12.25	3.21e-30	2.18e-23	0.58	0.49	Blood metabolite ratios;	chr16:58737529	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.792	rs1473205	ENSG00000233719.3	GOT2P3	12.25	3.21e-30	2.18e-23	0.58	0.49	Blood metabolite ratios;	chr16:58737547	chr12:9641802~9643007:+
LUAD	trans	rs11098499	0.865	rs9994730	ENSG00000275858.1	RP11-291L22.8	12.25	3.27e-30	2.22e-23	0.61	0.49	Corneal astigmatism;	chr4:119460409	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs10006706	ENSG00000275858.1	RP11-291L22.8	12.25	3.29e-30	2.24e-23	0.61	0.49	Corneal astigmatism;	chr4:119487997	chr10:38450738~38451069:-
LUAD	trans	rs7258465	1	rs34010330	ENSG00000267533.1	RP11-815J4.7	12.24	3.47e-30	2.35e-23	0.61	0.49	Breast cancer;	chr19:18448847	chr18:12067173~12068417:-
LUAD	trans	rs12709013	0.686	rs151817	ENSG00000230849.2	GOT2P2	-12.24	3.48e-30	2.36e-23	-0.59	-0.49	Blood metabolite ratios;	chr16:58704014	chr1:173141100~173142350:-
LUAD	trans	rs11098499	0.863	rs10009626	ENSG00000275858.1	RP11-291L22.8	12.24	3.51e-30	2.38e-23	0.62	0.49	Corneal astigmatism;	chr4:119548850	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs1552092	ENSG00000275858.1	RP11-291L22.8	12.24	3.57e-30	2.42e-23	0.62	0.49	Corneal astigmatism;	chr4:119567341	chr10:38450738~38451069:-
LUAD	trans	rs9611519	0.78	rs1535048	ENSG00000268568.1	AC007228.9	-12.24	3.6e-30	2.44e-23	-0.67	-0.49	Neuroticism;	chr22:41288089	chr19:56672574~56673901:-
LUAD	trans	rs12709013	0.729	rs1657179	ENSG00000233719.3	GOT2P3	12.24	3.63e-30	2.46e-23	0.58	0.49	Blood metabolite ratios;	chr16:58735115	chr12:9641802~9643007:+
LUAD	trans	rs916888	0.61	rs199452	ENSG00000214425.5	LRRC37A4P	-12.23	3.96e-30	2.68e-23	-0.61	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:45506741~45550335:-
LUAD	trans	rs11098499	0.909	rs9759478	ENSG00000275858.1	RP11-291L22.8	12.23	4.02e-30	2.72e-23	0.61	0.49	Corneal astigmatism;	chr4:119446843	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs12510138	ENSG00000275858.1	RP11-291L22.8	12.23	4.07e-30	2.75e-23	0.6	0.49	Corneal astigmatism;	chr4:119502780	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.865	rs11098513	ENSG00000275858.1	RP11-291L22.8	12.23	4.07e-30	2.75e-23	0.61	0.49	Corneal astigmatism;	chr4:119394920	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs12508173	ENSG00000275858.1	RP11-291L22.8	12.22	4.11e-30	2.78e-23	0.61	0.49	Corneal astigmatism;	chr4:119397371	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.908	rs12504149	ENSG00000275858.1	RP11-291L22.8	12.22	4.11e-30	2.78e-23	0.61	0.49	Corneal astigmatism;	chr4:119397422	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs1022145	ENSG00000275858.1	RP11-291L22.8	12.22	4.34e-30	2.93e-23	0.61	0.49	Corneal astigmatism;	chr4:119309824	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs6833334	ENSG00000275858.1	RP11-291L22.8	12.21	4.55e-30	3.07e-23	0.61	0.49	Corneal astigmatism;	chr4:119583072	chr10:38450738~38451069:-
LUAD	trans	rs6708331	1	rs13000817	ENSG00000232654.1	FAM136BP	12.2	5.3e-30	3.57e-23	0.69	0.49	Obesity-related traits;	chr2:70046575	chr6:3045384~3045800:+
LUAD	trans	rs55665837	1	rs4412729	ENSG00000236360.2	RP11-334A14.2	12.2	5.31e-30	3.57e-23	0.65	0.49	Vitamin D levels;	chr11:14417454	chr1:52993201~52993702:-
LUAD	trans	rs11098499	0.954	rs11722872	ENSG00000275858.1	RP11-291L22.8	12.2	5.35e-30	3.6e-23	0.61	0.49	Corneal astigmatism;	chr4:119311875	chr10:38450738~38451069:-
LUAD	trans	rs7258465	1	rs8111708	ENSG00000267533.1	RP11-815J4.7	12.19	5.63e-30	3.77e-23	0.61	0.49	Breast cancer;	chr19:18448066	chr18:12067173~12068417:-
LUAD	trans	rs11098499	0.82	rs13128602	ENSG00000275858.1	RP11-291L22.8	-12.19	5.65e-30	3.78e-23	-0.61	-0.49	Corneal astigmatism;	chr4:119538211	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs3775841	ENSG00000275858.1	RP11-291L22.8	12.19	5.73e-30	3.83e-23	0.6	0.49	Corneal astigmatism;	chr4:119504622	chr10:38450738~38451069:-
LUAD	trans	rs877636	0.692	rs10876870	ENSG00000225071.1	GS1-184P14.2	-12.18	5.95e-30	3.98e-23	-0.53	-0.49	Cognitive function;	chr12:56084218	chrX:24429573~24429920:-
LUAD	trans	rs877636	0.692	rs7971751	ENSG00000225071.1	GS1-184P14.2	-12.18	5.95e-30	3.98e-23	-0.53	-0.49	Cognitive function;	chr12:56084874	chrX:24429573~24429920:-
LUAD	trans	rs8067354	0.789	rs4622571	ENSG00000187870.7	RNFT1P3	12.18	6.05e-30	4.05e-23	0.6	0.49	Hemoglobin concentration;	chr17:59807036	chr17:20743333~20754501:-
LUAD	trans	rs877636	0.692	rs2271194	ENSG00000235459.5	RPS26P31	-12.18	6.23e-30	4.16e-23	-0.53	-0.49	Cognitive function;	chr12:56083910	chr7:122681315~122681662:+
LUAD	trans	rs11098499	0.954	rs10008459	ENSG00000275858.1	RP11-291L22.8	12.17	6.56e-30	4.38e-23	0.6	0.49	Corneal astigmatism;	chr4:119473076	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs10019674	ENSG00000275858.1	RP11-291L22.8	-12.17	6.76e-30	4.51e-23	-0.61	-0.49	Corneal astigmatism;	chr4:119522334	chr10:38450738~38451069:-
LUAD	trans	rs4276421	0.745	rs10941722	ENSG00000231752.4	EMBP1	-12.17	6.77e-30	4.52e-23	-0.62	-0.49	P wave duration;	chr5:46067527	chr1:121519112~121571892:+
LUAD	trans	rs13190036	0.901	rs6898107	ENSG00000217325.2	PRELID1P1	12.17	6.77e-30	4.52e-23	0.76	0.49	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177252694	chr6:126643488~126644390:+
LUAD	trans	rs877636	0.692	rs2271194	ENSG00000243403.1	RP11-330L19.1	-12.17	6.89e-30	4.6e-23	-0.51	-0.49	Cognitive function;	chr12:56083910	chr15:64592979~64593326:+
LUAD	trans	rs6732160	0.809	rs4299358	ENSG00000236165.1	PRADC1P1	12.17	6.9e-30	4.6e-23	0.66	0.49	Intelligence (multi-trait analysis);	chr2:73132213	chr3:36976316~36976840:+
LUAD	trans	rs11098499	0.863	rs13134665	ENSG00000275858.1	RP11-291L22.8	12.17	6.99e-30	4.66e-23	0.6	0.49	Corneal astigmatism;	chr4:119505275	chr10:38450738~38451069:-
LUAD	trans	rs12709013	0.686	rs244919	ENSG00000230849.2	GOT2P2	-12.17	7e-30	4.67e-23	-0.59	-0.49	Blood metabolite ratios;	chr16:58704146	chr1:173141100~173142350:-
LUAD	trans	rs10242455	0.702	rs2293256	ENSG00000228834.1	RP11-249L21.4	-12.17	7.02e-30	4.68e-23	-1.15	-0.49	Blood metabolite levels;	chr7:99460078	chr6:108907615~108907873:-
LUAD	trans	rs877636	0.692	rs2271194	ENSG00000225071.1	GS1-184P14.2	-12.17	7.03e-30	4.69e-23	-0.53	-0.49	Cognitive function;	chr12:56083910	chrX:24429573~24429920:-
LUAD	trans	rs8067354	0.83	rs2453913	ENSG00000187870.7	RNFT1P3	12.17	7.07e-30	4.71e-23	0.61	0.49	Hemoglobin concentration;	chr17:59782789	chr17:20743333~20754501:-
LUAD	trans	rs6708331	1	rs35734267	ENSG00000232654.1	FAM136BP	12.17	7.14e-30	4.75e-23	0.69	0.49	Obesity-related traits;	chr2:70054058	chr6:3045384~3045800:+
LUAD	trans	rs6477998	0.676	rs10817470	ENSG00000238072.1	RP11-305M3.2	12.16	7.16e-30	4.77e-23	0.72	0.49	Hematology traits;	chr9:113252129	chr7:129410113~129410370:-
LUAD	trans	rs2657294	0.796	rs4746272	ENSG00000172974.11	AC007318.5	12.16	7.18e-30	4.78e-23	0.51	0.49	Pneumonia;	chr10:75203869	chr2:65205108~65205988:+
LUAD	trans	rs3779195	0.627	rs6950023	ENSG00000225169.1	BRI3P1	12.16	7.22e-30	4.81e-23	0.76	0.49	Sex hormone-binding globulin levels;	chr7:98286323	chr1:100213293~100213670:+
LUAD	trans	rs3779195	0.627	rs6967728	ENSG00000225169.1	BRI3P1	12.16	7.22e-30	4.81e-23	0.76	0.49	Sex hormone-binding globulin levels;	chr7:98286325	chr1:100213293~100213670:+
LUAD	trans	rs4276421	0.745	rs4441886	ENSG00000231752.4	EMBP1	-12.16	7.24e-30	4.82e-23	-0.62	-0.49	P wave duration;	chr5:46063034	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.865	rs11722183	ENSG00000275858.1	RP11-291L22.8	12.16	7.37e-30	4.9e-23	0.6	0.48	Corneal astigmatism;	chr4:119359442	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.818	rs55825515	ENSG00000275858.1	RP11-291L22.8	12.16	7.41e-30	4.93e-23	0.62	0.48	Corneal astigmatism;	chr4:119565247	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs66506550	ENSG00000275858.1	RP11-291L22.8	12.16	7.56e-30	5.03e-23	0.6	0.48	Corneal astigmatism;	chr4:119450290	chr10:38450738~38451069:-
LUAD	trans	rs4276421	0.774	rs7720482	ENSG00000231752.4	EMBP1	-12.16	7.82e-30	5.2e-23	-0.63	-0.48	P wave duration;	chr5:46106061	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.954	rs10006525	ENSG00000275858.1	RP11-291L22.8	12.15	7.91e-30	5.26e-23	0.6	0.48	Corneal astigmatism;	chr4:119487776	chr10:38450738~38451069:-
LUAD	trans	rs877636	0.692	rs10876870	ENSG00000212994.5	RPS26P6	-12.15	7.93e-30	5.27e-23	-0.55	-0.48	Cognitive function;	chr12:56084218	chr8:100895771~100896118:+
LUAD	trans	rs877636	0.692	rs7971751	ENSG00000212994.5	RPS26P6	-12.15	7.93e-30	5.27e-23	-0.55	-0.48	Cognitive function;	chr12:56084874	chr8:100895771~100896118:+
LUAD	trans	rs4276421	0.967	rs6878425	ENSG00000231752.4	EMBP1	12.15	8.05e-30	5.34e-23	0.64	0.48	P wave duration;	chr5:45843153	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.935	rs6898824	ENSG00000231752.4	EMBP1	-12.15	8.05e-30	5.34e-23	-0.64	-0.48	P wave duration;	chr5:45842058	chr1:121519112~121571892:+
LUAD	trans	rs2657294	0.796	rs2804535	ENSG00000172974.11	AC007318.5	-12.15	8.39e-30	5.56e-23	-0.51	-0.48	Pneumonia;	chr10:75212086	chr2:65205108~65205988:+
LUAD	trans	rs13190036	0.901	rs28684504	ENSG00000226986.4	RP11-543B16.2	12.15	8.47e-30	5.62e-23	0.74	0.48	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177300437	chr1:211207239~211207897:+
LUAD	trans	rs11098499	0.954	rs17005535	ENSG00000275858.1	RP11-291L22.8	12.14	9.37e-30	6.21e-23	0.6	0.48	Corneal astigmatism;	chr4:119490407	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs6838814	ENSG00000275858.1	RP11-291L22.8	12.13	9.76e-30	6.46e-23	0.6	0.48	Corneal astigmatism;	chr4:119471288	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs13133522	ENSG00000275858.1	RP11-291L22.8	12.13	9.85e-30	6.49e-23	0.6	0.48	Corneal astigmatism;	chr4:119403269	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs35091806	ENSG00000275858.1	RP11-291L22.8	12.13	9.85e-30	6.49e-23	0.6	0.48	Corneal astigmatism;	chr4:119404374	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.909	rs35165976	ENSG00000275858.1	RP11-291L22.8	12.13	9.85e-30	6.49e-23	0.6	0.48	Corneal astigmatism;	chr4:119404475	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs2389802	ENSG00000275858.1	RP11-291L22.8	12.13	9.85e-30	6.49e-23	0.6	0.48	Corneal astigmatism;	chr4:119404577	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs6846442	ENSG00000275858.1	RP11-291L22.8	12.13	9.85e-30	6.49e-23	0.6	0.48	Corneal astigmatism;	chr4:119405168	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.738	rs34566984	ENSG00000275858.1	RP11-291L22.8	12.13	9.85e-30	6.49e-23	0.6	0.48	Corneal astigmatism;	chr4:119440115	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs17009122	ENSG00000275858.1	RP11-291L22.8	12.13	9.85e-30	6.49e-23	0.6	0.48	Corneal astigmatism;	chr4:119441248	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs9685777	ENSG00000275858.1	RP11-291L22.8	12.13	9.85e-30	6.49e-23	0.6	0.48	Corneal astigmatism;	chr4:119444810	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs71614438	ENSG00000275858.1	RP11-291L22.8	12.13	9.85e-30	6.49e-23	0.6	0.48	Corneal astigmatism;	chr4:119450097	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.909	rs7659501	ENSG00000275858.1	RP11-291L22.8	12.13	9.85e-30	6.49e-23	0.6	0.48	Corneal astigmatism;	chr4:119450397	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.779	rs28495013	ENSG00000275858.1	RP11-291L22.8	12.13	9.85e-30	6.49e-23	0.6	0.48	Corneal astigmatism;	chr4:119454676	chr10:38450738~38451069:-
LUAD	trans	rs7312770	0.637	rs705699	ENSG00000243403.1	RP11-330L19.1	12.13	1e-29	6.6e-23	0.51	0.48	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr15:64592979~64593326:+
LUAD	trans	rs2657294	0.765	rs2804533	ENSG00000172974.11	AC007318.5	12.12	1.05e-29	6.9e-23	0.51	0.48	Pneumonia;	chr10:75207723	chr2:65205108~65205988:+
LUAD	trans	rs11098499	0.821	rs10032151	ENSG00000275858.1	RP11-291L22.8	12.12	1.06e-29	6.94e-23	0.6	0.48	Corneal astigmatism;	chr4:119470473	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.865	rs10032158	ENSG00000275858.1	RP11-291L22.8	12.12	1.06e-29	6.94e-23	0.6	0.48	Corneal astigmatism;	chr4:119470477	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs11098525	ENSG00000275858.1	RP11-291L22.8	12.12	1.13e-29	7.43e-23	0.6	0.48	Corneal astigmatism;	chr4:119468997	chr10:38450738~38451069:-
LUAD	trans	rs12709013	0.59	rs982848	ENSG00000230849.2	GOT2P2	12.12	1.13e-29	7.45e-23	0.58	0.48	Blood metabolite ratios;	chr16:58704294	chr1:173141100~173142350:-
LUAD	trans	rs4276421	0.967	rs4866979	ENSG00000231752.4	EMBP1	-12.11	1.21e-29	7.92e-23	-0.63	-0.48	P wave duration;	chr5:45804745	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.954	rs7436506	ENSG00000275858.1	RP11-291L22.8	12.1	1.33e-29	8.7e-23	0.6	0.48	Corneal astigmatism;	chr4:119472614	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.909	rs2127821	ENSG00000275858.1	RP11-291L22.8	12.1	1.33e-29	8.7e-23	0.6	0.48	Corneal astigmatism;	chr4:119473380	chr10:38450738~38451069:-
LUAD	trans	rs4276421	0.774	rs10042199	ENSG00000231752.4	EMBP1	-12.1	1.37e-29	8.98e-23	-0.63	-0.48	P wave duration;	chr5:46103946	chr1:121519112~121571892:+
LUAD	trans	rs13190036	1	rs13157667	ENSG00000226986.4	RP11-543B16.2	-12.1	1.37e-29	8.99e-23	-0.76	-0.48	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177186876	chr1:211207239~211207897:+
LUAD	trans	rs616147	0.85	rs631312	ENSG00000183298.5	RP11-556K13.1	-12.09	1.4e-29	9.16e-23	-0.66	-0.48	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39467477	chr1:101786340~101787219:-
LUAD	trans	rs11098499	0.954	rs12508504	ENSG00000275858.1	RP11-291L22.8	12.09	1.46e-29	9.54e-23	0.6	0.48	Corneal astigmatism;	chr4:119489452	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.908	rs2017057	ENSG00000275858.1	RP11-291L22.8	12.09	1.49e-29	9.77e-23	0.6	0.48	Corneal astigmatism;	chr4:119336556	chr10:38450738~38451069:-
LUAD	trans	rs877636	0.669	rs7297175	ENSG00000235459.5	RPS26P31	-12.09	1.51e-29	9.86e-23	-0.52	-0.48	Cognitive function;	chr12:56080024	chr7:122681315~122681662:+
LUAD	trans	rs6708331	0.938	rs13000514	ENSG00000232654.1	FAM136BP	12.08	1.64e-29	1.07e-22	0.67	0.48	Obesity-related traits;	chr2:70167884	chr6:3045384~3045800:+
LUAD	trans	rs9467773	1	rs1321479	ENSG00000242375.1	RP11-498P14.3	-12.07	1.67e-29	1.09e-22	-0.61	-0.48	Intelligence (multi-trait analysis);	chr6:26501669	chr9:97195351~97197687:-
LUAD	trans	rs11098499	0.909	rs71614422	ENSG00000275858.1	RP11-291L22.8	12.07	1.67e-29	1.09e-22	0.6	0.48	Corneal astigmatism;	chr4:119438185	chr10:38450738~38451069:-
LUAD	trans	rs4276421	0.774	rs72755668	ENSG00000231752.4	EMBP1	-12.07	1.76e-29	1.14e-22	-0.62	-0.48	P wave duration;	chr5:46102658	chr1:121519112~121571892:+
LUAD	trans	rs1816752	0.646	rs7322323	ENSG00000224976.2	PARP4P2	12.07	1.81e-29	1.17e-22	0.54	0.48	Obesity-related traits;	chr13:24479189	chr13:19349137~19407962:+
LUAD	trans	rs11098499	0.657	rs71614442	ENSG00000275858.1	RP11-291L22.8	12.06	1.83e-29	1.18e-22	0.6	0.48	Corneal astigmatism;	chr4:119458191	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs2892848	ENSG00000275858.1	RP11-291L22.8	12.06	1.83e-29	1.18e-22	0.6	0.48	Corneal astigmatism;	chr4:119460186	chr10:38450738~38451069:-
LUAD	trans	rs4276421	0.7	rs10070274	ENSG00000231752.4	EMBP1	12.06	1.87e-29	1.21e-22	0.63	0.48	P wave duration;	chr5:46030675	chr1:121519112~121571892:+
LUAD	trans	rs13190036	0.792	rs6874206	ENSG00000217325.2	PRELID1P1	-12.06	1.9e-29	1.23e-22	-0.74	-0.48	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177223970	chr6:126643488~126644390:+
LUAD	trans	rs13190036	0.901	rs10072499	ENSG00000217325.2	PRELID1P1	-12.06	1.9e-29	1.23e-22	-0.74	-0.48	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228236	chr6:126643488~126644390:+
LUAD	trans	rs11098499	0.505	rs75122014	ENSG00000275858.1	RP11-291L22.8	12.06	1.91e-29	1.24e-22	0.6	0.48	Corneal astigmatism;	chr4:119441271	chr10:38450738~38451069:-
LUAD	trans	rs3779195	1	rs3779195	ENSG00000225169.1	BRI3P1	-12.06	1.97e-29	1.28e-22	-0.76	-0.48	Sex hormone-binding globulin levels;	chr7:98364050	chr1:100213293~100213670:+
LUAD	trans	rs3779195	0.697	rs1688606	ENSG00000225169.1	BRI3P1	12.06	1.98e-29	1.29e-22	0.73	0.48	Sex hormone-binding globulin levels;	chr7:98345539	chr1:100213293~100213670:+
LUAD	trans	rs4276421	0.714	rs8185016	ENSG00000231752.4	EMBP1	12.06	2e-29	1.29e-22	0.62	0.48	P wave duration;	chr5:46121704	chr1:121519112~121571892:+
LUAD	trans	rs916888	0.61	rs199453	ENSG00000264070.1	DND1P1	12.06	2e-29	1.29e-22	0.63	0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:45585871~45586929:+
LUAD	trans	rs1816752	0.624	rs4770701	ENSG00000224976.2	PARP4P2	12.05	2.13e-29	1.38e-22	0.55	0.48	Obesity-related traits;	chr13:24508806	chr13:19349137~19407962:+
LUAD	trans	rs7312770	0.612	rs1873914	ENSG00000225071.1	GS1-184P14.2	12.05	2.19e-29	1.41e-22	0.53	0.48	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chrX:24429573~24429920:-
LUAD	trans	rs916888	0.531	rs183211	ENSG00000214425.5	LRRC37A4P	-12.04	2.21e-29	1.43e-22	-0.61	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:45506741~45550335:-
LUAD	trans	rs11098499	0.863	rs1552095	ENSG00000275858.1	RP11-291L22.8	12.04	2.28e-29	1.47e-22	0.61	0.48	Corneal astigmatism;	chr4:119539151	chr10:38450738~38451069:-
LUAD	trans	rs6708331	0.941	rs12989076	ENSG00000232654.1	FAM136BP	12.03	2.44e-29	1.57e-22	0.67	0.48	Obesity-related traits;	chr2:70176275	chr6:3045384~3045800:+
LUAD	trans	rs6708331	1	rs7578027	ENSG00000232654.1	FAM136BP	12.03	2.47e-29	1.59e-22	0.67	0.48	Obesity-related traits;	chr2:70173976	chr6:3045384~3045800:+
LUAD	trans	rs4276421	0.662	rs4367307	ENSG00000231752.4	EMBP1	-12.03	2.57e-29	1.65e-22	-0.62	-0.48	P wave duration;	chr5:46065857	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.779	rs80242894	ENSG00000275858.1	RP11-291L22.8	12.03	2.57e-29	1.66e-22	0.6	0.48	Corneal astigmatism;	chr4:119454597	chr10:38450738~38451069:-
LUAD	trans	rs916888	0.61	rs142167	ENSG00000214425.5	LRRC37A4P	12.03	2.58e-29	1.66e-22	0.6	0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:45506741~45550335:-
LUAD	trans	rs2657294	0.796	rs1259499	ENSG00000172974.11	AC007318.5	12.02	2.66e-29	1.71e-22	0.51	0.48	Pneumonia;	chr10:75228308	chr2:65205108~65205988:+
LUAD	trans	rs11098499	0.954	rs9993199	ENSG00000275858.1	RP11-291L22.8	-12.02	2.88e-29	1.85e-22	-0.59	-0.48	Corneal astigmatism;	chr4:119471718	chr10:38450738~38451069:-
LUAD	trans	rs2657294	0.726	rs4746275	ENSG00000172974.11	AC007318.5	12.01	2.97e-29	1.91e-22	0.51	0.48	Pneumonia;	chr10:75214940	chr2:65205108~65205988:+
LUAD	trans	rs7554547	0.69	rs10864544	ENSG00000261819.1	RP11-680G24.4	12.01	2.97e-29	1.91e-22	0.62	0.48	Nonsyndromic cleft lip with cleft palate;	chr1:11875666	chr16:14988259~14990160:-
LUAD	trans	rs916888	0.61	rs199438	ENSG00000214425.5	LRRC37A4P	-12.01	3.01e-29	1.93e-22	-0.61	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:45506741~45550335:-
LUAD	trans	rs4276421	0.695	rs4498260	ENSG00000231752.4	EMBP1	-12.01	3.03e-29	1.95e-22	-0.62	-0.48	P wave duration;	chr5:46079235	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.863	rs3822190	ENSG00000275858.1	RP11-291L22.8	12.01	3.09e-29	1.99e-22	0.6	0.48	Corneal astigmatism;	chr4:119506943	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs3822191	ENSG00000275858.1	RP11-291L22.8	12.01	3.09e-29	1.99e-22	0.6	0.48	Corneal astigmatism;	chr4:119506946	chr10:38450738~38451069:-
LUAD	trans	rs4276421	0.661	rs10059426	ENSG00000231752.4	EMBP1	-12.01	3.13e-29	2.01e-22	-0.62	-0.48	P wave duration;	chr5:46090412	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.697	rs11941899	ENSG00000275858.1	RP11-291L22.8	12	3.31e-29	2.12e-22	0.6	0.48	Corneal astigmatism;	chr4:119461603	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.909	rs7681978	ENSG00000275858.1	RP11-291L22.8	12	3.31e-29	2.12e-22	0.6	0.48	Corneal astigmatism;	chr4:119462620	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.821	rs28665282	ENSG00000275858.1	RP11-291L22.8	12	3.31e-29	2.12e-22	0.6	0.48	Corneal astigmatism;	chr4:119463031	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.738	rs10026493	ENSG00000275858.1	RP11-291L22.8	12	3.31e-29	2.12e-22	0.6	0.48	Corneal astigmatism;	chr4:119463039	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.909	rs7681214	ENSG00000275858.1	RP11-291L22.8	12	3.31e-29	2.12e-22	0.6	0.48	Corneal astigmatism;	chr4:119464165	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.908	rs71614449	ENSG00000275858.1	RP11-291L22.8	12	3.31e-29	2.12e-22	0.6	0.48	Corneal astigmatism;	chr4:119465900	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs35063680	ENSG00000275858.1	RP11-291L22.8	12	3.31e-29	2.12e-22	0.6	0.48	Corneal astigmatism;	chr4:119465947	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs34858317	ENSG00000275858.1	RP11-291L22.8	12	3.31e-29	2.12e-22	0.6	0.48	Corneal astigmatism;	chr4:119465955	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs17046116	ENSG00000275858.1	RP11-291L22.8	12	3.31e-29	2.12e-22	0.6	0.48	Corneal astigmatism;	chr4:119466104	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.909	rs17046118	ENSG00000275858.1	RP11-291L22.8	12	3.31e-29	2.12e-22	0.6	0.48	Corneal astigmatism;	chr4:119466341	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs7654587	ENSG00000275858.1	RP11-291L22.8	12	3.31e-29	2.12e-22	0.6	0.48	Corneal astigmatism;	chr4:119467251	chr10:38450738~38451069:-
LUAD	trans	rs9611519	0.78	rs9611542	ENSG00000268568.1	AC007228.9	-12	3.4e-29	2.18e-22	-0.66	-0.48	Neuroticism;	chr22:41281313	chr19:56672574~56673901:-
LUAD	trans	rs11098499	0.908	rs9995234	ENSG00000275858.1	RP11-291L22.8	11.99	3.54e-29	2.26e-22	0.6	0.48	Corneal astigmatism;	chr4:119400672	chr10:38450738~38451069:-
LUAD	trans	rs4276421	0.635	rs12186454	ENSG00000231752.4	EMBP1	-11.99	3.68e-29	2.35e-22	-0.62	-0.48	P wave duration;	chr5:46067621	chr1:121519112~121571892:+
LUAD	trans	rs916888	0.61	rs142167	ENSG00000264070.1	DND1P1	-11.99	3.75e-29	2.39e-22	-0.62	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:45585871~45586929:+
LUAD	trans	rs877636	0.692	rs2271194	ENSG00000212994.5	RPS26P6	-11.99	3.83e-29	2.44e-22	-0.55	-0.48	Cognitive function;	chr12:56083910	chr8:100895771~100896118:+
LUAD	trans	rs11098499	0.863	rs7699064	ENSG00000275858.1	RP11-291L22.8	-11.98	4e-29	2.55e-22	-0.6	-0.48	Corneal astigmatism;	chr4:119507154	chr10:38450738~38451069:-
LUAD	trans	rs916888	0.61	rs199444	ENSG00000264070.1	DND1P1	11.98	4.1e-29	2.61e-22	0.63	0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:45585871~45586929:+
LUAD	trans	rs916888	0.61	rs199442	ENSG00000264070.1	DND1P1	11.98	4.1e-29	2.61e-22	0.63	0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:45585871~45586929:+
LUAD	trans	rs2657294	0.796	rs2657290	ENSG00000172974.11	AC007318.5	11.98	4.21e-29	2.68e-22	0.51	0.48	Pneumonia;	chr10:75207404	chr2:65205108~65205988:+
LUAD	trans	rs4276421	0.683	rs4484447	ENSG00000231752.4	EMBP1	11.96	4.65e-29	2.95e-22	0.62	0.48	P wave duration;	chr5:46048757	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.908	rs28559989	ENSG00000275858.1	RP11-291L22.8	11.96	4.68e-29	2.98e-22	0.6	0.48	Corneal astigmatism;	chr4:119465472	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.909	rs28632018	ENSG00000275858.1	RP11-291L22.8	11.96	4.68e-29	2.98e-22	0.6	0.48	Corneal astigmatism;	chr4:119465575	chr10:38450738~38451069:-
LUAD	trans	rs13190036	1	rs4976682	ENSG00000226986.4	RP11-543B16.2	11.96	4.72e-29	3e-22	0.68	0.48	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177299001	chr1:211207239~211207897:+
LUAD	trans	rs3779195	0.86	rs12704986	ENSG00000225169.1	BRI3P1	11.96	4.79e-29	3.04e-22	0.73	0.48	Sex hormone-binding globulin levels;	chr7:98357118	chr1:100213293~100213670:+
LUAD	trans	rs3779195	0.858	rs3779196	ENSG00000225169.1	BRI3P1	11.96	4.79e-29	3.04e-22	0.73	0.48	Sex hormone-binding globulin levels;	chr7:98360794	chr1:100213293~100213670:+
LUAD	trans	rs3779195	0.789	rs6965424	ENSG00000225169.1	BRI3P1	11.96	4.79e-29	3.04e-22	0.73	0.48	Sex hormone-binding globulin levels;	chr7:98361813	chr1:100213293~100213670:+
LUAD	trans	rs11098499	0.82	rs28394116	ENSG00000275858.1	RP11-291L22.8	11.96	4.81e-29	3.05e-22	0.6	0.48	Corneal astigmatism;	chr4:119603128	chr10:38450738~38451069:-
LUAD	trans	rs4276421	0.774	rs6884716	ENSG00000231752.4	EMBP1	11.96	4.86e-29	3.09e-22	0.62	0.48	P wave duration;	chr5:46115267	chr1:121519112~121571892:+
LUAD	trans	rs4276421	1	rs4331911	ENSG00000231752.4	EMBP1	11.96	4.9e-29	3.11e-22	0.63	0.48	P wave duration;	chr5:45859273	chr1:121519112~121571892:+
LUAD	trans	rs4276421	1	rs4276421	ENSG00000231752.4	EMBP1	-11.96	4.99e-29	3.17e-22	-0.62	-0.48	P wave duration;	chr5:45801977	chr1:121519112~121571892:+
LUAD	trans	rs916888	0.61	rs199436	ENSG00000264070.1	DND1P1	-11.96	5.03e-29	3.19e-22	-0.63	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:45585871~45586929:+
LUAD	trans	rs9876781	1	rs13069724	ENSG00000235912.1	RP1-159A19.3	-11.95	5.13e-29	3.25e-22	-0.49	-0.48	Longevity;	chr3:48436629	chr1:27649419~27649610:+
LUAD	trans	rs11098499	0.954	rs10518331	ENSG00000275858.1	RP11-291L22.8	11.95	5.2e-29	3.3e-22	0.6	0.48	Corneal astigmatism;	chr4:119402440	chr10:38450738~38451069:-
LUAD	trans	rs2657294	0.761	rs1259498	ENSG00000172974.11	AC007318.5	11.95	5.22e-29	3.31e-22	0.51	0.48	Pneumonia;	chr10:75226983	chr2:65205108~65205988:+
LUAD	trans	rs4276421	0.744	rs4431354	ENSG00000231752.4	EMBP1	11.95	5.29e-29	3.35e-22	0.61	0.48	P wave duration;	chr5:46051284	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.954	rs13145352	ENSG00000275858.1	RP11-291L22.8	-11.95	5.52e-29	3.5e-22	-0.61	-0.48	Corneal astigmatism;	chr4:119488808	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.697	rs28655325	ENSG00000275858.1	RP11-291L22.8	11.94	5.63e-29	3.56e-22	0.6	0.48	Corneal astigmatism;	chr4:119451844	chr10:38450738~38451069:-
LUAD	trans	rs916888	0.647	rs199449	ENSG00000264070.1	DND1P1	11.94	5.66e-29	3.59e-22	0.63	0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:45585871~45586929:+
LUAD	trans	rs13190036	1	rs34446750	ENSG00000226986.4	RP11-543B16.2	-11.94	5.86e-29	3.71e-22	-0.74	-0.48	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177168079	chr1:211207239~211207897:+
LUAD	trans	rs3779195	0.929	rs10953259	ENSG00000225169.1	BRI3P1	-11.94	5.92e-29	3.75e-22	-0.74	-0.48	Sex hormone-binding globulin levels;	chr7:98383795	chr1:100213293~100213670:+
LUAD	trans	rs9467773	0.933	rs35355150	ENSG00000242375.1	RP11-498P14.3	11.94	6.09e-29	3.85e-22	0.62	0.48	Intelligence (multi-trait analysis);	chr6:26525811	chr9:97195351~97197687:-
LUAD	trans	rs2657294	0.796	rs1259501	ENSG00000172974.11	AC007318.5	11.94	6.09e-29	3.85e-22	0.5	0.48	Pneumonia;	chr10:75230427	chr2:65205108~65205988:+
LUAD	trans	rs4276421	0.774	rs10050829	ENSG00000231752.4	EMBP1	-11.93	6.13e-29	3.87e-22	-0.61	-0.48	P wave duration;	chr5:46072628	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.688	rs10067655	ENSG00000231752.4	EMBP1	-11.93	6.13e-29	3.87e-22	-0.61	-0.48	P wave duration;	chr5:46072803	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.745	rs13354272	ENSG00000231752.4	EMBP1	-11.93	6.13e-29	3.87e-22	-0.61	-0.48	P wave duration;	chr5:46078020	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.774	rs13361118	ENSG00000231752.4	EMBP1	-11.93	6.13e-29	3.87e-22	-0.61	-0.48	P wave duration;	chr5:46078308	chr1:121519112~121571892:+
LUAD	trans	rs6708331	0.816	rs10196979	ENSG00000232654.1	FAM136BP	11.93	6.15e-29	3.89e-22	0.65	0.48	Obesity-related traits;	chr2:70140265	chr6:3045384~3045800:+
LUAD	trans	rs4276421	0.774	rs10066479	ENSG00000231752.4	EMBP1	-11.93	6.16e-29	3.89e-22	-0.61	-0.48	P wave duration;	chr5:46097385	chr1:121519112~121571892:+
LUAD	trans	rs12709013	0.66	rs30839	ENSG00000233719.3	GOT2P3	11.93	6.27e-29	3.96e-22	0.58	0.48	Blood metabolite ratios;	chr16:58711437	chr12:9641802~9643007:+
LUAD	trans	rs916888	0.61	rs199436	ENSG00000214425.5	LRRC37A4P	11.93	6.3e-29	3.98e-22	0.6	0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:45506741~45550335:-
LUAD	trans	rs1816752	0.646	rs9511309	ENSG00000224976.2	PARP4P2	11.92	6.75e-29	4.25e-22	0.53	0.48	Obesity-related traits;	chr13:24515435	chr13:19349137~19407962:+
LUAD	trans	rs4276421	0.713	rs8188193	ENSG00000231752.4	EMBP1	11.92	6.95e-29	4.38e-22	0.62	0.48	P wave duration;	chr5:46122428	chr1:121519112~121571892:+
LUAD	trans	rs6477998	0.676	rs10981698	ENSG00000238072.1	RP11-305M3.2	11.92	7.02e-29	4.42e-22	0.7	0.48	Hematology traits;	chr9:113233500	chr7:129410113~129410370:-
LUAD	trans	rs6477998	0.676	rs10759631	ENSG00000238072.1	RP11-305M3.2	11.92	7.02e-29	4.42e-22	0.7	0.48	Hematology traits;	chr9:113233764	chr7:129410113~129410370:-
LUAD	trans	rs11098499	1	rs3749591	ENSG00000275858.1	RP11-291L22.8	11.92	7.11e-29	4.48e-22	0.58	0.48	Corneal astigmatism;	chr4:119292875	chr10:38450738~38451069:-
LUAD	trans	rs9876781	1	rs9838618	ENSG00000235912.1	RP1-159A19.3	-11.92	7.27e-29	4.58e-22	-0.5	-0.48	Longevity;	chr3:48445949	chr1:27649419~27649610:+
LUAD	trans	rs7312770	0.637	rs705700	ENSG00000196933.5	RPS26P11	11.91	7.9e-29	4.97e-22	0.55	0.48	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chrX:72044545~72044892:+
LUAD	trans	rs916888	0.61	rs199452	ENSG00000264070.1	DND1P1	11.9	8.14e-29	5.12e-22	0.62	0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:45585871~45586929:+
LUAD	trans	rs11098499	0.909	rs73842633	ENSG00000275858.1	RP11-291L22.8	11.9	8.19e-29	5.15e-22	0.6	0.48	Corneal astigmatism;	chr4:119454309	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.738	rs34965784	ENSG00000275858.1	RP11-291L22.8	11.9	8.65e-29	5.43e-22	0.59	0.48	Corneal astigmatism;	chr4:119440431	chr10:38450738~38451069:-
LUAD	trans	rs6708331	0.878	rs12994100	ENSG00000232654.1	FAM136BP	11.89	9.11e-29	5.72e-22	0.65	0.48	Obesity-related traits;	chr2:70133785	chr6:3045384~3045800:+
LUAD	trans	rs4276421	0.774	rs4499842	ENSG00000231752.4	EMBP1	11.89	9.28e-29	5.82e-22	0.61	0.48	P wave duration;	chr5:46034390	chr1:121519112~121571892:+
LUAD	trans	rs13190036	0.551	rs7732930	ENSG00000217325.2	PRELID1P1	-11.89	9.33e-29	5.85e-22	-0.68	-0.48	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177121593	chr6:126643488~126644390:+
LUAD	trans	rs11098499	0.82	rs13122709	ENSG00000275858.1	RP11-291L22.8	11.89	9.43e-29	5.91e-22	0.6	0.48	Corneal astigmatism;	chr4:119634201	chr10:38450738~38451069:-
LUAD	trans	rs61990749	0.571	rs11628049	ENSG00000235400.1	RP4-641G12.4	-11.88	1e-28	6.27e-22	-0.81	-0.48	Fibroblast growth factor basic levels;	chr14:77842108	chr1:78749073~78750659:+
LUAD	trans	rs11098499	0.78	rs12504773	ENSG00000275858.1	RP11-291L22.8	11.87	1.14e-28	7.15e-22	0.6	0.48	Corneal astigmatism;	chr4:119640994	chr10:38450738~38451069:-
LUAD	trans	rs13190036	0.901	rs6556309	ENSG00000217325.2	PRELID1P1	11.86	1.19e-28	7.43e-22	0.74	0.48	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177266834	chr6:126643488~126644390:+
LUAD	trans	rs12709013	0.636	rs30835	ENSG00000233719.3	GOT2P3	11.86	1.22e-28	7.62e-22	0.58	0.48	Blood metabolite ratios;	chr16:58714117	chr12:9641802~9643007:+
LUAD	trans	rs13190036	1	rs13167431	ENSG00000226986.4	RP11-543B16.2	-11.86	1.22e-28	7.64e-22	-0.74	-0.48	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177194074	chr1:211207239~211207897:+
LUAD	trans	rs4276421	0.774	rs4370277	ENSG00000231752.4	EMBP1	11.85	1.29e-28	8.01e-22	0.61	0.48	P wave duration;	chr5:46048566	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.954	rs6849561	ENSG00000275858.1	RP11-291L22.8	-11.85	1.32e-28	8.25e-22	-0.61	-0.48	Corneal astigmatism;	chr4:119488539	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.78	rs7680914	ENSG00000275858.1	RP11-291L22.8	11.85	1.35e-28	8.39e-22	0.6	0.48	Corneal astigmatism;	chr4:119641898	chr10:38450738~38451069:-
LUAD	trans	rs877636	0.669	rs7297175	ENSG00000243403.1	RP11-330L19.1	-11.85	1.38e-28	8.57e-22	-0.49	-0.48	Cognitive function;	chr12:56080024	chr15:64592979~64593326:+
LUAD	trans	rs6708331	0.938	rs13389246	ENSG00000232654.1	FAM136BP	11.84	1.41e-28	8.76e-22	0.67	0.48	Obesity-related traits;	chr2:70127099	chr6:3045384~3045800:+
LUAD	trans	rs7312770	0.637	rs705700	ENSG00000243403.1	RP11-330L19.1	11.84	1.48e-28	9.18e-22	0.5	0.48	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr15:64592979~64593326:+
LUAD	trans	rs12497850	0.627	rs4974078	ENSG00000197582.5	GPX1P1	11.84	1.52e-28	9.47e-22	0.61	0.47	Parkinson's disease;	chr3:48971953	chrX:13378735~13379340:-
LUAD	trans	rs6477998	0.676	rs10081797	ENSG00000238072.1	RP11-305M3.2	11.84	1.53e-28	9.53e-22	0.7	0.47	Hematology traits;	chr9:113237973	chr7:129410113~129410370:-
LUAD	trans	rs6477998	0.676	rs10759632	ENSG00000238072.1	RP11-305M3.2	11.84	1.53e-28	9.53e-22	0.7	0.47	Hematology traits;	chr9:113238703	chr7:129410113~129410370:-
LUAD	trans	rs916888	0.61	rs199438	ENSG00000264070.1	DND1P1	11.83	1.55e-28	9.62e-22	0.63	0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:45585871~45586929:+
LUAD	trans	rs11098499	0.866	rs3756156	ENSG00000275858.1	RP11-291L22.8	11.83	1.56e-28	9.67e-22	0.59	0.47	Corneal astigmatism;	chr4:119603686	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.82	rs28535956	ENSG00000275858.1	RP11-291L22.8	-11.83	1.56e-28	9.7e-22	-0.59	-0.47	Corneal astigmatism;	chr4:119615703	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.955	rs35434465	ENSG00000275858.1	RP11-291L22.8	11.83	1.59e-28	9.86e-22	0.58	0.47	Corneal astigmatism;	chr4:119248223	chr10:38450738~38451069:-
LUAD	trans	rs4276421	0.774	rs8188064	ENSG00000231752.4	EMBP1	11.83	1.61e-28	9.98e-22	0.61	0.47	P wave duration;	chr5:46045249	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.954	rs3733520	ENSG00000275858.1	RP11-291L22.8	11.83	1.63e-28	1.01e-21	0.59	0.47	Corneal astigmatism;	chr4:119502325	chr10:38450738~38451069:-
LUAD	trans	rs4276421	0.712	rs4389698	ENSG00000231752.4	EMBP1	11.82	1.78e-28	1.11e-21	0.61	0.47	P wave duration;	chr5:46051566	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.6	rs4426925	ENSG00000231752.4	EMBP1	11.82	1.78e-28	1.11e-21	0.61	0.47	P wave duration;	chr5:46055499	chr1:121519112~121571892:+
LUAD	trans	rs6708331	1	rs62151174	ENSG00000232654.1	FAM136BP	11.82	1.81e-28	1.12e-21	0.65	0.47	Obesity-related traits;	chr2:70136836	chr6:3045384~3045800:+
LUAD	trans	rs4276421	0.744	rs4541667	ENSG00000231752.4	EMBP1	11.82	1.82e-28	1.13e-21	0.62	0.47	P wave duration;	chr5:46060767	chr1:121519112~121571892:+
LUAD	trans	rs9898641	1	rs9898641	ENSG00000187870.7	RNFT1P3	11.81	1.89e-28	1.17e-21	0.6	0.47	Interleukin-1-beta levels;	chr17:59493672	chr17:20743333~20754501:-
LUAD	trans	rs6708331	1	rs12999430	ENSG00000232654.1	FAM136BP	11.81	1.89e-28	1.17e-21	0.67	0.47	Obesity-related traits;	chr2:70079653	chr6:3045384~3045800:+
LUAD	trans	rs11098499	1	rs11726229	ENSG00000275858.1	RP11-291L22.8	11.81	1.97e-28	1.22e-21	0.58	0.47	Corneal astigmatism;	chr4:119290425	chr10:38450738~38451069:-
LUAD	trans	rs916888	0.647	rs199449	ENSG00000214425.5	LRRC37A4P	-11.8	2.07e-28	1.28e-21	-0.6	-0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:45506741~45550335:-
LUAD	trans	rs4276421	0.774	rs12515804	ENSG00000231752.4	EMBP1	-11.8	2.07e-28	1.28e-21	-0.61	-0.47	P wave duration;	chr5:46098504	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.955	rs1511019	ENSG00000275858.1	RP11-291L22.8	11.8	2.19e-28	1.35e-21	0.58	0.47	Corneal astigmatism;	chr4:119244852	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.909	rs28555550	ENSG00000275858.1	RP11-291L22.8	11.8	2.21e-28	1.36e-21	0.58	0.47	Corneal astigmatism;	chr4:119289885	chr10:38450738~38451069:-
LUAD	trans	rs11098499	1	rs28419773	ENSG00000275858.1	RP11-291L22.8	11.8	2.21e-28	1.36e-21	0.58	0.47	Corneal astigmatism;	chr4:119289906	chr10:38450738~38451069:-
LUAD	trans	rs916888	0.61	rs199444	ENSG00000214425.5	LRRC37A4P	-11.79	2.24e-28	1.39e-21	-0.6	-0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:45506741~45550335:-
LUAD	trans	rs916888	0.61	rs199442	ENSG00000214425.5	LRRC37A4P	-11.79	2.24e-28	1.39e-21	-0.6	-0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:45506741~45550335:-
LUAD	trans	rs11098499	0.863	rs13136462	ENSG00000275858.1	RP11-291L22.8	11.79	2.25e-28	1.39e-21	0.59	0.47	Corneal astigmatism;	chr4:119622018	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.909	rs10026736	ENSG00000275858.1	RP11-291L22.8	11.79	2.43e-28	1.5e-21	0.6	0.47	Corneal astigmatism;	chr4:119463167	chr10:38450738~38451069:-
LUAD	trans	rs9876781	1	rs2279077	ENSG00000235912.1	RP1-159A19.3	-11.78	2.52e-28	1.55e-21	-0.49	-0.47	Longevity;	chr3:48432839	chr1:27649419~27649610:+
LUAD	trans	rs9876781	1	rs1109227	ENSG00000235912.1	RP1-159A19.3	-11.78	2.52e-28	1.55e-21	-0.49	-0.47	Longevity;	chr3:48437797	chr1:27649419~27649610:+
LUAD	trans	rs9876781	1	rs3774808	ENSG00000235912.1	RP1-159A19.3	-11.78	2.52e-28	1.55e-21	-0.49	-0.47	Longevity;	chr3:48440237	chr1:27649419~27649610:+
LUAD	trans	rs11098499	1	rs6837898	ENSG00000275858.1	RP11-291L22.8	11.78	2.56e-28	1.58e-21	0.57	0.47	Corneal astigmatism;	chr4:119257999	chr10:38450738~38451069:-
LUAD	trans	rs9876781	1	rs9883759	ENSG00000235912.1	RP1-159A19.3	-11.78	2.6e-28	1.6e-21	-0.49	-0.47	Longevity;	chr3:48422209	chr1:27649419~27649610:+
LUAD	trans	rs9876781	1	rs6442120	ENSG00000235912.1	RP1-159A19.3	-11.78	2.6e-28	1.6e-21	-0.49	-0.47	Longevity;	chr3:48423094	chr1:27649419~27649610:+
LUAD	trans	rs9876781	0.9	rs1037773	ENSG00000235912.1	RP1-159A19.3	-11.78	2.6e-28	1.6e-21	-0.49	-0.47	Longevity;	chr3:48426493	chr1:27649419~27649610:+
LUAD	trans	rs11098499	1	rs11098500	ENSG00000275858.1	RP11-291L22.8	11.77	2.72e-28	1.67e-21	0.58	0.47	Corneal astigmatism;	chr4:119298084	chr10:38450738~38451069:-
LUAD	trans	rs13253073	0.544	rs10955223	ENSG00000260318.1	COX6CP1	11.77	2.74e-28	1.68e-21	0.98	0.47	Glucose homeostasis traits;	chr8:99903454	chr16:11903923~11904137:-
LUAD	trans	rs13190036	0.901	rs4631	ENSG00000226986.4	RP11-543B16.2	11.77	2.77e-28	1.7e-21	0.74	0.47	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177306115	chr1:211207239~211207897:+
LUAD	trans	rs13190036	1	rs71601343	ENSG00000226986.4	RP11-543B16.2	-11.77	2.8e-28	1.72e-21	-0.74	-0.47	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177205106	chr1:211207239~211207897:+
LUAD	trans	rs13190036	1	rs71601344	ENSG00000226986.4	RP11-543B16.2	-11.77	2.8e-28	1.72e-21	-0.74	-0.47	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206492	chr1:211207239~211207897:+
LUAD	trans	rs11098499	0.73	rs12505735	ENSG00000275858.1	RP11-291L22.8	11.77	2.82e-28	1.73e-21	0.59	0.47	Corneal astigmatism;	chr4:119611801	chr10:38450738~38451069:-
LUAD	trans	rs10940346	1	rs6874016	ENSG00000231752.4	EMBP1	-11.77	2.91e-28	1.79e-21	-0.62	-0.47	Schizophrenia;	chr5:50549640	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.955	rs1511018	ENSG00000275858.1	RP11-291L22.8	11.75	3.25e-28	1.99e-21	0.57	0.47	Corneal astigmatism;	chr4:119240425	chr10:38450738~38451069:-
LUAD	trans	rs11098499	1	rs7659194	ENSG00000275858.1	RP11-291L22.8	11.75	3.32e-28	2.04e-21	0.57	0.47	Corneal astigmatism;	chr4:119285992	chr10:38450738~38451069:-
LUAD	trans	rs9876781	1	rs13091785	ENSG00000235912.1	RP1-159A19.3	-11.75	3.36e-28	2.06e-21	-0.49	-0.47	Longevity;	chr3:48452692	chr1:27649419~27649610:+
LUAD	trans	rs4276421	0.743	rs10060199	ENSG00000231752.4	EMBP1	11.75	3.38e-28	2.07e-21	0.62	0.47	P wave duration;	chr5:46064524	chr1:121519112~121571892:+
LUAD	trans	rs7730934	0.818	rs6450361	ENSG00000227018.1	IL6STP1	11.75	3.42e-28	2.09e-21	0.7	0.47	Blood protein levels;	chr5:56004698	chr17:15783288~15784307:+
LUAD	trans	rs916888	0.779	rs199526	ENSG00000214425.5	LRRC37A4P	11.75	3.52e-28	2.15e-21	0.62	0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:45506741~45550335:-
LUAD	trans	rs877636	0.692	rs2271194	ENSG00000234513.1	AC073072.7	-11.74	3.57e-28	2.18e-21	-0.54	-0.47	Cognitive function;	chr12:56083910	chr7:22773646~22773993:-
LUAD	trans	rs1816752	0.624	rs7330766	ENSG00000224976.2	PARP4P2	11.73	3.95e-28	2.41e-21	0.54	0.47	Obesity-related traits;	chr13:24495579	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.603	rs7984094	ENSG00000224976.2	PARP4P2	11.73	3.97e-28	2.43e-21	0.54	0.47	Obesity-related traits;	chr13:24496212	chr13:19349137~19407962:+
LUAD	trans	rs4276421	0.904	rs6862657	ENSG00000231752.4	EMBP1	-11.73	4.13e-28	2.52e-21	-0.62	-0.47	P wave duration;	chr5:45905895	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.955	rs13113112	ENSG00000275858.1	RP11-291L22.8	11.72	4.38e-28	2.67e-21	0.58	0.47	Corneal astigmatism;	chr4:119234885	chr10:38450738~38451069:-
LUAD	trans	rs4276421	0.623	rs12654375	ENSG00000231752.4	EMBP1	11.72	4.53e-28	2.76e-21	0.61	0.47	P wave duration;	chr5:46036452	chr1:121519112~121571892:+
LUAD	trans	rs13190036	0.901	rs28563911	ENSG00000226986.4	RP11-543B16.2	11.72	4.53e-28	2.76e-21	0.75	0.47	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177287942	chr1:211207239~211207897:+
LUAD	trans	rs7312770	0.612	rs773114	ENSG00000243403.1	RP11-330L19.1	11.72	4.61e-28	2.81e-21	0.49	0.47	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr15:64592979~64593326:+
LUAD	trans	rs13190036	1	rs3733875	ENSG00000226986.4	RP11-543B16.2	-11.71	5.06e-28	3.08e-21	-0.74	-0.47	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210239	chr1:211207239~211207897:+
LUAD	trans	rs3779195	0.929	rs2906184	ENSG00000225169.1	BRI3P1	-11.7	5.16e-28	3.13e-21	-0.73	-0.47	Sex hormone-binding globulin levels;	chr7:98310675	chr1:100213293~100213670:+
LUAD	trans	rs4276421	0.682	rs10054419	ENSG00000231752.4	EMBP1	11.7	5.36e-28	3.25e-21	0.61	0.47	P wave duration;	chr5:46036863	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.805	rs13168838	ENSG00000231752.4	EMBP1	11.7	5.41e-28	3.28e-21	0.6	0.47	P wave duration;	chr5:46016815	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.774	rs4302598	ENSG00000231752.4	EMBP1	11.7	5.41e-28	3.28e-21	0.6	0.47	P wave duration;	chr5:46019065	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.618	rs35265692	ENSG00000275858.1	RP11-291L22.8	11.69	5.99e-28	3.63e-21	0.59	0.47	Corneal astigmatism;	chr4:119403980	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs4309825	ENSG00000275858.1	RP11-291L22.8	-11.68	6.13e-28	3.71e-21	-0.58	-0.47	Corneal astigmatism;	chr4:119393726	chr10:38450738~38451069:-
LUAD	trans	rs13190036	1	rs13185316	ENSG00000226986.4	RP11-543B16.2	-11.68	6.4e-28	3.87e-21	-0.74	-0.47	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177213339	chr1:211207239~211207897:+
LUAD	trans	rs11098499	0.657	rs10434028	ENSG00000275858.1	RP11-291L22.8	11.68	6.43e-28	3.89e-21	0.55	0.47	Corneal astigmatism;	chr4:119373309	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.82	rs28578366	ENSG00000275858.1	RP11-291L22.8	-11.68	6.5e-28	3.93e-21	-0.58	-0.47	Corneal astigmatism;	chr4:119615750	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.954	rs6849171	ENSG00000275858.1	RP11-291L22.8	11.68	6.63e-28	4.01e-21	0.58	0.47	Corneal astigmatism;	chr4:119488394	chr10:38450738~38451069:-
LUAD	trans	rs1816752	0.669	rs9553309	ENSG00000224976.2	PARP4P2	11.67	6.96e-28	4.21e-21	0.53	0.47	Obesity-related traits;	chr13:24471476	chr13:19349137~19407962:+
LUAD	trans	rs877636	0.692	rs10876870	ENSG00000234513.1	AC073072.7	-11.67	7.11e-28	4.29e-21	-0.53	-0.47	Cognitive function;	chr12:56084218	chr7:22773646~22773993:-
LUAD	trans	rs877636	0.692	rs7971751	ENSG00000234513.1	AC073072.7	-11.67	7.11e-28	4.29e-21	-0.53	-0.47	Cognitive function;	chr12:56084874	chr7:22773646~22773993:-
LUAD	trans	rs6708331	0.941	rs7609359	ENSG00000232654.1	FAM136BP	11.67	7.13e-28	4.3e-21	0.64	0.47	Obesity-related traits;	chr2:70131844	chr6:3045384~3045800:+
LUAD	trans	rs11098499	0.866	rs72676074	ENSG00000275858.1	RP11-291L22.8	11.67	7.2e-28	4.35e-21	0.59	0.47	Corneal astigmatism;	chr4:119438686	chr10:38450738~38451069:-
LUAD	trans	rs8067354	0.872	rs1295925	ENSG00000187870.7	RNFT1P3	-11.67	7.29e-28	4.4e-21	-0.59	-0.47	Hemoglobin concentration;	chr17:59832902	chr17:20743333~20754501:-
LUAD	trans	rs616147	0.962	rs545397	ENSG00000183298.5	RP11-556K13.1	11.66	7.5e-28	4.52e-21	0.63	0.47	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39488592	chr1:101786340~101787219:-
LUAD	trans	rs13190036	1	rs28580074	ENSG00000226986.4	RP11-543B16.2	11.66	7.67e-28	4.62e-21	0.72	0.47	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177294197	chr1:211207239~211207897:+
LUAD	trans	rs11098499	0.865	rs28634456	ENSG00000275858.1	RP11-291L22.8	11.66	7.67e-28	4.62e-21	0.59	0.47	Corneal astigmatism;	chr4:119454623	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.909	rs78332141	ENSG00000275858.1	RP11-291L22.8	11.66	7.67e-28	4.62e-21	0.59	0.47	Corneal astigmatism;	chr4:119454627	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.731	rs6846966	ENSG00000275858.1	RP11-291L22.8	11.66	7.73e-28	4.66e-21	0.56	0.47	Corneal astigmatism;	chr4:119372053	chr10:38450738~38451069:-
LUAD	trans	rs12709013	0.716	rs6416775	ENSG00000233719.3	GOT2P3	11.66	8.04e-28	4.84e-21	0.56	0.47	Blood metabolite ratios;	chr16:58830410	chr12:9641802~9643007:+
LUAD	trans	rs11098499	0.738	rs28408407	ENSG00000275858.1	RP11-291L22.8	11.65	8.35e-28	5.02e-21	0.58	0.47	Corneal astigmatism;	chr4:119454875	chr10:38450738~38451069:-
LUAD	trans	rs13253073	0.544	rs13280341	ENSG00000260318.1	COX6CP1	11.65	8.43e-28	5.07e-21	0.98	0.47	Glucose homeostasis traits;	chr8:99908840	chr16:11903923~11904137:-
LUAD	trans	rs1816752	0.646	rs4770700	ENSG00000224976.2	PARP4P2	11.65	8.66e-28	5.2e-21	0.54	0.47	Obesity-related traits;	chr13:24494796	chr13:19349137~19407962:+
LUAD	trans	rs4276421	0.623	rs4409106	ENSG00000231752.4	EMBP1	11.65	8.79e-28	5.28e-21	0.6	0.47	P wave duration;	chr5:46038004	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.865	rs2389809	ENSG00000275858.1	RP11-291L22.8	11.64	8.93e-28	5.36e-21	0.59	0.47	Corneal astigmatism;	chr4:119456244	chr10:38450738~38451069:-
LUAD	trans	rs1816752	0.646	rs7997248	ENSG00000224976.2	PARP4P2	11.64	9.05e-28	5.43e-21	0.54	0.47	Obesity-related traits;	chr13:24507050	chr13:19349137~19407962:+
LUAD	trans	rs8067354	0.831	rs2333617	ENSG00000187870.7	RNFT1P3	-11.64	9.45e-28	5.66e-21	-0.58	-0.47	Hemoglobin concentration;	chr17:59818859	chr17:20743333~20754501:-
LUAD	trans	rs8067354	0.872	rs7224006	ENSG00000187870.7	RNFT1P3	-11.64	9.45e-28	5.66e-21	-0.58	-0.47	Hemoglobin concentration;	chr17:59818977	chr17:20743333~20754501:-
LUAD	trans	rs916888	0.779	rs199498	ENSG00000214425.5	LRRC37A4P	-11.64	9.58e-28	5.74e-21	-0.65	-0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:45506741~45550335:-
LUAD	trans	rs616147	0.962	rs1708104	ENSG00000183298.5	RP11-556K13.1	-11.64	9.63e-28	5.77e-21	-0.63	-0.47	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39493251	chr1:101786340~101787219:-
LUAD	trans	rs9467773	0.935	rs11752946	ENSG00000242375.1	RP11-498P14.3	11.64	9.66e-28	5.79e-21	0.61	0.47	Intelligence (multi-trait analysis);	chr6:26560136	chr9:97195351~97197687:-
LUAD	trans	rs4276421	0.682	rs10067983	ENSG00000231752.4	EMBP1	11.63	9.76e-28	5.85e-21	0.61	0.47	P wave duration;	chr5:46064294	chr1:121519112~121571892:+
LUAD	trans	rs1816752	0.669	rs3783072	ENSG00000224976.2	PARP4P2	11.62	1.1e-27	6.55e-21	0.53	0.47	Obesity-related traits;	chr13:24493258	chr13:19349137~19407962:+
LUAD	trans	rs4276421	0.745	rs10079238	ENSG00000231752.4	EMBP1	-11.62	1.1e-27	6.57e-21	-0.61	-0.47	P wave duration;	chr5:46066531	chr1:121519112~121571892:+
LUAD	trans	rs13190036	1	rs34832871	ENSG00000226986.4	RP11-543B16.2	-11.62	1.1e-27	6.58e-21	-0.72	-0.47	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228928	chr1:211207239~211207897:+
LUAD	trans	rs11098499	0.866	rs6847778	ENSG00000275858.1	RP11-291L22.8	11.62	1.13e-27	6.73e-21	0.55	0.47	Corneal astigmatism;	chr4:119372427	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.955	rs35197422	ENSG00000275858.1	RP11-291L22.8	11.62	1.13e-27	6.74e-21	0.56	0.47	Corneal astigmatism;	chr4:119248159	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.955	rs1511015	ENSG00000275858.1	RP11-291L22.8	11.62	1.13e-27	6.74e-21	0.56	0.47	Corneal astigmatism;	chr4:119249318	chr10:38450738~38451069:-
LUAD	trans	rs11098499	1	rs10029750	ENSG00000275858.1	RP11-291L22.8	11.62	1.13e-27	6.74e-21	0.56	0.47	Corneal astigmatism;	chr4:119251388	chr10:38450738~38451069:-
LUAD	trans	rs61990749	0.571	rs4903655	ENSG00000235400.1	RP4-641G12.4	11.62	1.14e-27	6.79e-21	0.79	0.47	Fibroblast growth factor basic levels;	chr14:77839983	chr1:78749073~78750659:+
LUAD	trans	rs9611519	0.754	rs4820435	ENSG00000268568.1	AC007228.9	-11.62	1.14e-27	6.81e-21	-0.64	-0.47	Neuroticism;	chr22:41256842	chr19:56672574~56673901:-
LUAD	trans	rs916888	0.773	rs199534	ENSG00000280022.1	RP11-707O23.1	11.61	1.17e-27	6.97e-21	0.71	0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45592621~45593369:+
LUAD	trans	rs4276421	0.837	rs6451829	ENSG00000231752.4	EMBP1	11.61	1.18e-27	7.07e-21	0.62	0.47	P wave duration;	chr5:45893260	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.904	rs7716296	ENSG00000231752.4	EMBP1	11.61	1.18e-27	7.07e-21	0.62	0.47	P wave duration;	chr5:45895783	chr1:121519112~121571892:+
LUAD	trans	rs867371	0.892	rs4344697	ENSG00000235370.6	DNM1P51	-11.61	1.19e-27	7.08e-21	-0.55	-0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82252873	chr15:84398316~84411701:-
LUAD	trans	rs11098499	0.863	rs9884402	ENSG00000275858.1	RP11-291L22.8	11.61	1.22e-27	7.26e-21	0.58	0.47	Corneal astigmatism;	chr4:119568827	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.731	rs9995026	ENSG00000275858.1	RP11-291L22.8	11.61	1.22e-27	7.26e-21	0.58	0.47	Corneal astigmatism;	chr4:119569344	chr10:38450738~38451069:-
LUAD	trans	rs4276421	0.874	rs6451830	ENSG00000231752.4	EMBP1	11.6	1.32e-27	7.87e-21	0.62	0.47	P wave duration;	chr5:45893354	chr1:121519112~121571892:+
LUAD	trans	rs13190036	1	rs13177748	ENSG00000226986.4	RP11-543B16.2	-11.6	1.33e-27	7.92e-21	-0.72	-0.47	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177216953	chr1:211207239~211207897:+
LUAD	trans	rs4276421	0.935	rs6882139	ENSG00000231752.4	EMBP1	11.6	1.35e-27	8.02e-21	0.62	0.47	P wave duration;	chr5:45897149	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.82	rs6829903	ENSG00000275858.1	RP11-291L22.8	11.6	1.36e-27	8.1e-21	0.58	0.47	Corneal astigmatism;	chr4:119585729	chr10:38450738~38451069:-
LUAD	trans	rs7312770	0.637	rs705700	ENSG00000234513.1	AC073072.7	11.6	1.38e-27	8.19e-21	0.54	0.47	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr7:22773646~22773993:-
LUAD	trans	rs4276421	0.904	rs34462057	ENSG00000231752.4	EMBP1	11.59	1.4e-27	8.33e-21	0.62	0.47	P wave duration;	chr5:45900215	chr1:121519112~121571892:+
LUAD	trans	rs9876781	1	rs6776700	ENSG00000235912.1	RP1-159A19.3	-11.59	1.43e-27	8.52e-21	-0.48	-0.47	Longevity;	chr3:48455358	chr1:27649419~27649610:+
LUAD	trans	rs13190036	0.901	rs28715668	ENSG00000226986.4	RP11-543B16.2	11.59	1.45e-27	8.62e-21	0.73	0.47	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272267	chr1:211207239~211207897:+
LUAD	trans	rs9611519	0.78	rs3171692	ENSG00000268568.1	AC007228.9	-11.59	1.48e-27	8.78e-21	-0.62	-0.47	Neuroticism;	chr22:41246208	chr19:56672574~56673901:-
LUAD	trans	rs9876781	1	rs9881491	ENSG00000235912.1	RP1-159A19.3	-11.59	1.48e-27	8.8e-21	-0.48	-0.47	Longevity;	chr3:48446507	chr1:27649419~27649610:+
LUAD	trans	rs11098499	0.909	rs1809406	ENSG00000275858.1	RP11-291L22.8	11.59	1.51e-27	8.97e-21	0.58	0.47	Corneal astigmatism;	chr4:119455967	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.909	rs9994810	ENSG00000275858.1	RP11-291L22.8	11.59	1.51e-27	8.97e-21	0.58	0.47	Corneal astigmatism;	chr4:119460435	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.697	rs10020027	ENSG00000275858.1	RP11-291L22.8	11.59	1.51e-27	8.97e-21	0.58	0.47	Corneal astigmatism;	chr4:119460724	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.779	rs7356491	ENSG00000275858.1	RP11-291L22.8	11.59	1.51e-27	8.97e-21	0.58	0.47	Corneal astigmatism;	chr4:119460819	chr10:38450738~38451069:-
LUAD	trans	rs11098499	1	rs35643470	ENSG00000275858.1	RP11-291L22.8	11.58	1.58e-27	9.38e-21	0.56	0.47	Corneal astigmatism;	chr4:119263793	chr10:38450738~38451069:-
LUAD	trans	rs916888	0.773	rs199533	ENSG00000280022.1	RP11-707O23.1	11.58	1.59e-27	9.44e-21	0.71	0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45592621~45593369:+
LUAD	trans	rs3749237	1	rs1317140	ENSG00000197582.5	GPX1P1	11.58	1.61e-27	9.55e-21	0.69	0.47	Resting heart rate;	chr3:49841219	chrX:13378735~13379340:-
LUAD	trans	rs11098499	0.863	rs10004484	ENSG00000275858.1	RP11-291L22.8	11.58	1.61e-27	9.57e-21	0.58	0.47	Corneal astigmatism;	chr4:119521273	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.69	rs7674713	ENSG00000275858.1	RP11-291L22.8	11.58	1.63e-27	9.67e-21	0.58	0.47	Corneal astigmatism;	chr4:119401102	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs1155576	ENSG00000275858.1	RP11-291L22.8	11.58	1.64e-27	9.69e-21	0.58	0.47	Corneal astigmatism;	chr4:119529004	chr10:38450738~38451069:-
LUAD	trans	rs6708331	0.941	rs10173330	ENSG00000232654.1	FAM136BP	11.58	1.65e-27	9.79e-21	0.64	0.47	Obesity-related traits;	chr2:70139981	chr6:3045384~3045800:+
LUAD	trans	rs11098499	0.913	rs11098496	ENSG00000275858.1	RP11-291L22.8	11.57	1.69e-27	9.98e-21	0.56	0.47	Corneal astigmatism;	chr4:119246311	chr10:38450738~38451069:-
LUAD	trans	rs916888	0.61	rs199446	ENSG00000264070.1	DND1P1	-11.57	1.7e-27	1e-20	-0.61	-0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:45585871~45586929:+
LUAD	trans	rs916888	0.61	rs199536	ENSG00000264070.1	DND1P1	-11.57	1.7e-27	1e-20	-0.61	-0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:45585871~45586929:+
LUAD	trans	rs11098499	1	rs58601355	ENSG00000275858.1	RP11-291L22.8	11.57	1.71e-27	1.01e-20	0.58	0.47	Corneal astigmatism;	chr4:119265212	chr10:38450738~38451069:-
LUAD	trans	rs11098499	1	rs28374891	ENSG00000275858.1	RP11-291L22.8	11.57	1.75e-27	1.03e-20	0.56	0.47	Corneal astigmatism;	chr4:119262395	chr10:38450738~38451069:-
LUAD	trans	rs1816752	0.646	rs1361578	ENSG00000224976.2	PARP4P2	11.57	1.75e-27	1.03e-20	0.54	0.47	Obesity-related traits;	chr13:24491117	chr13:19349137~19407962:+
LUAD	trans	rs11098499	0.954	rs13107475	ENSG00000275858.1	RP11-291L22.8	11.57	1.76e-27	1.04e-20	0.58	0.47	Corneal astigmatism;	chr4:119471856	chr10:38450738~38451069:-
LUAD	trans	rs11098499	1	rs11098499	ENSG00000275858.1	RP11-291L22.8	11.57	1.78e-27	1.05e-20	0.57	0.47	Corneal astigmatism;	chr4:119266456	chr10:38450738~38451069:-
LUAD	trans	rs13190036	1	rs35535623	ENSG00000226986.4	RP11-543B16.2	-11.57	1.8e-27	1.06e-20	-0.72	-0.47	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177202295	chr1:211207239~211207897:+
LUAD	trans	rs6708331	0.941	rs13028968	ENSG00000232654.1	FAM136BP	11.57	1.83e-27	1.08e-20	0.65	0.47	Obesity-related traits;	chr2:70179991	chr6:3045384~3045800:+
LUAD	trans	rs9611519	0.78	rs9611527	ENSG00000268568.1	AC007228.9	-11.56	1.89e-27	1.12e-20	-0.62	-0.47	Neuroticism;	chr22:41248424	chr19:56672574~56673901:-
LUAD	trans	rs11098499	1	rs13116504	ENSG00000275858.1	RP11-291L22.8	11.56	1.89e-27	1.12e-20	0.56	0.47	Corneal astigmatism;	chr4:119288257	chr10:38450738~38451069:-
LUAD	trans	rs9876781	0.967	rs9876891	ENSG00000235912.1	RP1-159A19.3	-11.56	1.98e-27	1.17e-20	-0.48	-0.47	Longevity;	chr3:48440024	chr1:27649419~27649610:+
LUAD	trans	rs11098499	0.863	rs3822195	ENSG00000275858.1	RP11-291L22.8	11.56	1.99e-27	1.18e-20	0.59	0.47	Corneal astigmatism;	chr4:119550505	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs3775854	ENSG00000275858.1	RP11-291L22.8	11.56	1.99e-27	1.18e-20	0.59	0.47	Corneal astigmatism;	chr4:119550816	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs2306457	ENSG00000275858.1	RP11-291L22.8	11.56	1.99e-27	1.18e-20	0.59	0.47	Corneal astigmatism;	chr4:119551684	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs6853998	ENSG00000275858.1	RP11-291L22.8	11.56	1.99e-27	1.18e-20	0.59	0.47	Corneal astigmatism;	chr4:119554705	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs6858777	ENSG00000275858.1	RP11-291L22.8	11.56	1.99e-27	1.18e-20	0.59	0.47	Corneal astigmatism;	chr4:119554811	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs11731756	ENSG00000275858.1	RP11-291L22.8	11.56	1.99e-27	1.18e-20	0.59	0.47	Corneal astigmatism;	chr4:119557541	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs34308924	ENSG00000275858.1	RP11-291L22.8	11.56	1.99e-27	1.18e-20	0.59	0.47	Corneal astigmatism;	chr4:119560276	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs2170276	ENSG00000275858.1	RP11-291L22.8	11.56	1.99e-27	1.18e-20	0.59	0.47	Corneal astigmatism;	chr4:119564669	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.913	rs10010696	ENSG00000275858.1	RP11-291L22.8	11.56	2e-27	1.18e-20	0.56	0.47	Corneal astigmatism;	chr4:119243148	chr10:38450738~38451069:-
LUAD	trans	rs13190036	1	rs6889220	ENSG00000226986.4	RP11-543B16.2	11.55	2.03e-27	1.2e-20	0.74	0.47	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177266887	chr1:211207239~211207897:+
LUAD	trans	rs4276421	0.935	rs12109652	ENSG00000231752.4	EMBP1	11.55	2.17e-27	1.28e-20	0.61	0.47	P wave duration;	chr5:45878206	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.863	rs6858592	ENSG00000275858.1	RP11-291L22.8	11.55	2.17e-27	1.28e-20	0.58	0.47	Corneal astigmatism;	chr4:119537537	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs12498539	ENSG00000275858.1	RP11-291L22.8	11.55	2.18e-27	1.28e-20	0.59	0.47	Corneal astigmatism;	chr4:119547215	chr10:38450738~38451069:-
LUAD	trans	rs916888	0.531	rs183211	ENSG00000264070.1	DND1P1	11.54	2.22e-27	1.31e-20	0.61	0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:45585871~45586929:+
LUAD	trans	rs11098499	0.955	rs1397608	ENSG00000275858.1	RP11-291L22.8	11.54	2.29e-27	1.35e-20	0.56	0.47	Corneal astigmatism;	chr4:119240589	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.955	rs7685268	ENSG00000275858.1	RP11-291L22.8	11.54	2.29e-27	1.35e-20	0.56	0.47	Corneal astigmatism;	chr4:119241033	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.955	rs7684942	ENSG00000275858.1	RP11-291L22.8	11.54	2.29e-27	1.35e-20	0.56	0.47	Corneal astigmatism;	chr4:119241046	chr10:38450738~38451069:-
LUAD	trans	rs4276421	0.736	rs7445572	ENSG00000231752.4	EMBP1	11.54	2.31e-27	1.36e-20	0.61	0.47	P wave duration;	chr5:45920315	chr1:121519112~121571892:+
LUAD	trans	rs4276421	1	rs28657933	ENSG00000231752.4	EMBP1	11.54	2.33e-27	1.37e-20	0.61	0.47	P wave duration;	chr5:45863597	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.954	rs10034623	ENSG00000275858.1	RP11-291L22.8	11.54	2.34e-27	1.38e-20	0.58	0.47	Corneal astigmatism;	chr4:119476674	chr10:38450738~38451069:-
LUAD	trans	rs4276421	0.704	rs57407363	ENSG00000231752.4	EMBP1	-11.53	2.44e-27	1.43e-20	-0.6	-0.47	P wave duration;	chr5:46073845	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.807	rs12520938	ENSG00000231752.4	EMBP1	-11.53	2.44e-27	1.43e-20	-0.6	-0.47	P wave duration;	chr5:46098683	chr1:121519112~121571892:+
LUAD	trans	rs4276421	1	rs6895191	ENSG00000231752.4	EMBP1	11.53	2.46e-27	1.44e-20	0.61	0.47	P wave duration;	chr5:45877572	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.863	rs3822194	ENSG00000275858.1	RP11-291L22.8	11.53	2.48e-27	1.46e-20	0.59	0.47	Corneal astigmatism;	chr4:119550493	chr10:38450738~38451069:-
LUAD	trans	rs6708331	0.941	rs7595262	ENSG00000232654.1	FAM136BP	11.53	2.52e-27	1.48e-20	0.64	0.47	Obesity-related traits;	chr2:70131865	chr6:3045384~3045800:+
LUAD	trans	rs6708331	0.938	rs36025045	ENSG00000232654.1	FAM136BP	11.53	2.53e-27	1.49e-20	0.65	0.47	Obesity-related traits;	chr2:70121829	chr6:3045384~3045800:+
LUAD	trans	rs4276421	0.807	rs10941740	ENSG00000231752.4	EMBP1	-11.53	2.55e-27	1.5e-20	-0.6	-0.47	P wave duration;	chr5:46100208	chr1:121519112~121571892:+
LUAD	trans	rs6708331	0.941	rs10173259	ENSG00000232654.1	FAM136BP	11.53	2.56e-27	1.51e-20	0.63	0.47	Obesity-related traits;	chr2:70140078	chr6:3045384~3045800:+
LUAD	trans	rs7554547	0.714	rs4845890	ENSG00000261819.1	RP11-680G24.4	11.53	2.58e-27	1.52e-20	0.61	0.47	Nonsyndromic cleft lip with cleft palate;	chr1:11912612	chr16:14988259~14990160:-
LUAD	trans	rs3749237	1	rs11710675	ENSG00000197582.5	GPX1P1	11.52	2.67e-27	1.57e-20	0.65	0.47	Resting heart rate;	chr3:49714467	chrX:13378735~13379340:-
LUAD	trans	rs9876781	1	rs11130170	ENSG00000235912.1	RP1-159A19.3	-11.52	2.71e-27	1.59e-20	-0.49	-0.47	Longevity;	chr3:48408490	chr1:27649419~27649610:+
LUAD	trans	rs916888	0.61	rs199454	ENSG00000264070.1	DND1P1	-11.52	2.73e-27	1.6e-20	-0.61	-0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:45585871~45586929:+
LUAD	trans	rs916888	0.61	rs199454	ENSG00000214425.5	LRRC37A4P	11.52	2.77e-27	1.63e-20	0.59	0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:45506741~45550335:-
LUAD	trans	rs4276421	1	rs10039283	ENSG00000231752.4	EMBP1	11.52	2.86e-27	1.67e-20	0.61	0.46	P wave duration;	chr5:45864741	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.967	rs4282324	ENSG00000231752.4	EMBP1	11.52	2.86e-27	1.67e-20	0.61	0.46	P wave duration;	chr5:45865330	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.955	rs56386062	ENSG00000275858.1	RP11-291L22.8	11.5	3.32e-27	1.93e-20	0.57	0.46	Corneal astigmatism;	chr4:119233980	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.955	rs4145951	ENSG00000275858.1	RP11-291L22.8	11.5	3.32e-27	1.93e-20	0.57	0.46	Corneal astigmatism;	chr4:119234662	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.955	rs35916640	ENSG00000275858.1	RP11-291L22.8	11.5	3.32e-27	1.93e-20	0.57	0.46	Corneal astigmatism;	chr4:119234697	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.955	rs13114751	ENSG00000275858.1	RP11-291L22.8	11.5	3.32e-27	1.93e-20	0.57	0.46	Corneal astigmatism;	chr4:119235462	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.913	rs35271032	ENSG00000275858.1	RP11-291L22.8	11.5	3.32e-27	1.93e-20	0.57	0.46	Corneal astigmatism;	chr4:119235504	chr10:38450738~38451069:-
LUAD	trans	rs616147	0.627	rs9871799	ENSG00000214263.2	RPSAP53	11.5	3.33e-27	1.94e-20	0.58	0.46	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39442829	chr13:67266845~67267706:-
LUAD	trans	rs61990749	0.571	rs4448861	ENSG00000235400.1	RP4-641G12.4	11.5	3.37e-27	1.97e-20	0.78	0.46	Fibroblast growth factor basic levels;	chr14:77841392	chr1:78749073~78750659:+
LUAD	trans	rs61990749	0.511	rs2052444	ENSG00000235400.1	RP4-641G12.4	11.5	3.41e-27	1.98e-20	0.79	0.46	Fibroblast growth factor basic levels;	chr14:77846575	chr1:78749073~78750659:+
LUAD	trans	rs11098499	0.865	rs4001305	ENSG00000275858.1	RP11-291L22.8	11.49	3.47e-27	2.02e-20	0.58	0.46	Corneal astigmatism;	chr4:119438081	chr10:38450738~38451069:-
LUAD	trans	rs13190036	1	rs6880798	ENSG00000217325.2	PRELID1P1	11.49	3.52e-27	2.05e-20	0.71	0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177277456	chr6:126643488~126644390:+
LUAD	trans	rs11098499	0.955	rs6815725	ENSG00000275858.1	RP11-291L22.8	11.49	3.53e-27	2.05e-20	0.56	0.46	Corneal astigmatism;	chr4:119237255	chr10:38450738~38451069:-
LUAD	trans	rs11098499	1	rs12506395	ENSG00000275858.1	RP11-291L22.8	11.49	3.53e-27	2.06e-20	0.56	0.46	Corneal astigmatism;	chr4:119263939	chr10:38450738~38451069:-
LUAD	trans	rs12709013	0.635	rs6993	ENSG00000233719.3	GOT2P3	11.49	3.54e-27	2.06e-20	0.57	0.46	Blood metabolite ratios;	chr16:58707463	chr12:9641802~9643007:+
LUAD	trans	rs13190036	0.892	rs71601339	ENSG00000226986.4	RP11-543B16.2	-11.49	3.54e-27	2.06e-20	-0.71	-0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177117495	chr1:211207239~211207897:+
LUAD	trans	rs4276421	0.845	rs4492122	ENSG00000231752.4	EMBP1	11.49	3.57e-27	2.07e-20	0.61	0.46	P wave duration;	chr5:45982952	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.955	rs1551	ENSG00000275858.1	RP11-291L22.8	11.49	3.57e-27	2.07e-20	0.56	0.46	Corneal astigmatism;	chr4:119237345	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs7669520	ENSG00000275858.1	RP11-291L22.8	11.49	3.68e-27	2.14e-20	0.58	0.46	Corneal astigmatism;	chr4:119594123	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.908	rs28499576	ENSG00000275858.1	RP11-291L22.8	11.49	3.71e-27	2.16e-20	0.58	0.46	Corneal astigmatism;	chr4:119465522	chr10:38450738~38451069:-
LUAD	trans	rs7399018	0.739	rs7399073	ENSG00000223825.5	DAZAP2P1	11.48	3.91e-27	2.27e-20	0.58	0.46	Cisplatin-induced ototoxicity;	chr12:51220266	chr2:202201384~202201886:-
LUAD	trans	rs7312770	0.612	rs1873914	ENSG00000212994.5	RPS26P6	11.48	3.92e-27	2.27e-20	0.53	0.46	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr8:100895771~100896118:+
LUAD	trans	rs877636	0.669	rs7297175	ENSG00000225071.1	GS1-184P14.2	-11.48	3.98e-27	2.31e-20	-0.5	-0.46	Cognitive function;	chr12:56080024	chrX:24429573~24429920:-
LUAD	trans	rs4276421	0.745	rs10041478	ENSG00000231752.4	EMBP1	-11.48	4.08e-27	2.36e-20	-0.61	-0.46	P wave duration;	chr5:46103187	chr1:121519112~121571892:+
LUAD	trans	rs8067354	0.872	rs2645466	ENSG00000187870.7	RNFT1P3	11.48	4.09e-27	2.37e-20	0.58	0.46	Hemoglobin concentration;	chr17:59775853	chr17:20743333~20754501:-
LUAD	trans	rs11098499	0.866	rs12501602	ENSG00000275858.1	RP11-291L22.8	11.47	4.19e-27	2.43e-20	0.55	0.46	Corneal astigmatism;	chr4:119366780	chr10:38450738~38451069:-
LUAD	trans	rs17711722	0.583	rs10085415	ENSG00000226824.5	RP4-756H11.3	11.47	4.19e-27	2.43e-20	0.59	0.46	Calcium levels;	chr7:65628655	chr7:66654538~66669855:+
LUAD	trans	rs11098499	0.738	rs28687057	ENSG00000275858.1	RP11-291L22.8	11.47	4.35e-27	2.51e-20	0.54	0.46	Corneal astigmatism;	chr4:119359657	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.775	rs67281037	ENSG00000275858.1	RP11-291L22.8	11.47	4.35e-27	2.51e-20	0.54	0.46	Corneal astigmatism;	chr4:119360002	chr10:38450738~38451069:-
LUAD	trans	rs10028773	0.506	rs12374346	ENSG00000275858.1	RP11-291L22.8	11.47	4.35e-27	2.51e-20	0.54	0.46	Educational attainment;	chr4:119360550	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.866	rs12374244	ENSG00000275858.1	RP11-291L22.8	11.47	4.35e-27	2.51e-20	0.54	0.46	Corneal astigmatism;	chr4:119360817	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.866	rs12374352	ENSG00000275858.1	RP11-291L22.8	11.47	4.35e-27	2.51e-20	0.54	0.46	Corneal astigmatism;	chr4:119360822	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.775	rs10021601	ENSG00000275858.1	RP11-291L22.8	11.47	4.35e-27	2.51e-20	0.54	0.46	Corneal astigmatism;	chr4:119361408	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.866	rs6857892	ENSG00000275858.1	RP11-291L22.8	11.47	4.35e-27	2.51e-20	0.54	0.46	Corneal astigmatism;	chr4:119361541	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.909	rs28581362	ENSG00000275858.1	RP11-291L22.8	11.47	4.35e-27	2.51e-20	0.54	0.46	Corneal astigmatism;	chr4:119362393	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.82	rs12503082	ENSG00000275858.1	RP11-291L22.8	11.47	4.35e-27	2.51e-20	0.54	0.46	Corneal astigmatism;	chr4:119363162	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.866	rs12499602	ENSG00000275858.1	RP11-291L22.8	11.47	4.35e-27	2.51e-20	0.54	0.46	Corneal astigmatism;	chr4:119363232	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.774	rs11098505	ENSG00000275858.1	RP11-291L22.8	11.47	4.35e-27	2.51e-20	0.54	0.46	Corneal astigmatism;	chr4:119363472	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.866	rs13105020	ENSG00000275858.1	RP11-291L22.8	11.47	4.35e-27	2.51e-20	0.54	0.46	Corneal astigmatism;	chr4:119364533	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.866	rs6824111	ENSG00000275858.1	RP11-291L22.8	11.47	4.35e-27	2.51e-20	0.54	0.46	Corneal astigmatism;	chr4:119364813	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.775	rs10029303	ENSG00000275858.1	RP11-291L22.8	11.47	4.35e-27	2.51e-20	0.54	0.46	Corneal astigmatism;	chr4:119365600	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.866	rs9995136	ENSG00000275858.1	RP11-291L22.8	11.47	4.35e-27	2.51e-20	0.54	0.46	Corneal astigmatism;	chr4:119365690	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.866	rs13125526	ENSG00000275858.1	RP11-291L22.8	11.47	4.35e-27	2.51e-20	0.54	0.46	Corneal astigmatism;	chr4:119366864	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.866	rs12513310	ENSG00000275858.1	RP11-291L22.8	11.47	4.35e-27	2.51e-20	0.54	0.46	Corneal astigmatism;	chr4:119366884	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.564	rs11098507	ENSG00000275858.1	RP11-291L22.8	11.47	4.35e-27	2.51e-20	0.54	0.46	Corneal astigmatism;	chr4:119367131	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.866	rs12510451	ENSG00000275858.1	RP11-291L22.8	11.47	4.35e-27	2.51e-20	0.54	0.46	Corneal astigmatism;	chr4:119367988	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.774	rs73842616	ENSG00000275858.1	RP11-291L22.8	11.47	4.35e-27	2.51e-20	0.54	0.46	Corneal astigmatism;	chr4:119369528	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.645	rs72676059	ENSG00000275858.1	RP11-291L22.8	11.47	4.35e-27	2.51e-20	0.54	0.46	Corneal astigmatism;	chr4:119369673	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.569	rs55845118	ENSG00000275858.1	RP11-291L22.8	11.47	4.35e-27	2.51e-20	0.54	0.46	Corneal astigmatism;	chr4:119369758	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.866	rs7677068	ENSG00000275858.1	RP11-291L22.8	11.47	4.35e-27	2.51e-20	0.54	0.46	Corneal astigmatism;	chr4:119370549	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.866	rs9991221	ENSG00000275858.1	RP11-291L22.8	11.47	4.35e-27	2.51e-20	0.54	0.46	Corneal astigmatism;	chr4:119370952	chr10:38450738~38451069:-
LUAD	trans	rs4276421	0.967	rs6865429	ENSG00000231752.4	EMBP1	-11.47	4.54e-27	2.62e-20	-0.61	-0.46	P wave duration;	chr5:45830406	chr1:121519112~121571892:+
LUAD	trans	rs12709013	0.716	rs4784987	ENSG00000233719.3	GOT2P3	11.47	4.54e-27	2.62e-20	0.56	0.46	Blood metabolite ratios;	chr16:58824135	chr12:9641802~9643007:+
LUAD	trans	rs916888	0.773	rs199451	ENSG00000280022.1	RP11-707O23.1	11.46	4.71e-27	2.72e-20	0.7	0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45592621~45593369:+
LUAD	trans	rs7730934	0.818	rs7736703	ENSG00000227018.1	IL6STP1	11.46	4.73e-27	2.73e-20	0.69	0.46	Blood protein levels;	chr5:56016434	chr17:15783288~15784307:+
LUAD	trans	rs877636	0.692	rs11171739	ENSG00000196933.5	RPS26P11	11.46	4.85e-27	2.8e-20	0.52	0.46	Cognitive function;	chr12:56076841	chrX:72044545~72044892:+
LUAD	trans	rs7312770	0.637	rs705699	ENSG00000234513.1	AC073072.7	11.46	4.91e-27	2.82e-20	0.53	0.46	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr7:22773646~22773993:-
LUAD	trans	rs9467773	0.935	rs1884947	ENSG00000242375.1	RP11-498P14.3	11.45	5.43e-27	3.11e-20	0.61	0.46	Intelligence (multi-trait analysis);	chr6:26553045	chr9:97195351~97197687:-
LUAD	trans	rs11098499	1	rs13435802	ENSG00000275858.1	RP11-291L22.8	-11.44	5.47e-27	3.13e-20	-0.55	-0.46	Corneal astigmatism;	chr4:119256805	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.866	rs11098506	ENSG00000275858.1	RP11-291L22.8	11.44	5.72e-27	3.28e-20	0.55	0.46	Corneal astigmatism;	chr4:119363816	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.604	rs12642411	ENSG00000275858.1	RP11-291L22.8	11.44	5.73e-27	3.28e-20	0.58	0.46	Corneal astigmatism;	chr4:119659370	chr10:38450738~38451069:-
LUAD	trans	rs9611519	0.78	rs1983631	ENSG00000268568.1	AC007228.9	-11.43	5.99e-27	3.43e-20	-0.61	-0.46	Neuroticism;	chr22:41248070	chr19:56672574~56673901:-
LUAD	trans	rs616147	0.962	rs1513219	ENSG00000183298.5	RP11-556K13.1	11.43	6.05e-27	3.46e-20	0.62	0.46	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39492268	chr1:101786340~101787219:-
LUAD	trans	rs7121616	0.515	rs76088419	ENSG00000234176.1	HSPA8P1	11.43	6.08e-27	3.48e-20	0.71	0.46	Breast cancer;	chr11:123066813	chrX:121203182~121205014:-
LUAD	trans	rs9876781	1	rs9864371	ENSG00000235912.1	RP1-159A19.3	-11.43	6.22e-27	3.56e-20	-0.48	-0.46	Longevity;	chr3:48385276	chr1:27649419~27649610:+
LUAD	trans	rs11098499	0.954	rs6847248	ENSG00000275858.1	RP11-291L22.8	11.43	6.52e-27	3.72e-20	0.59	0.46	Corneal astigmatism;	chr4:119304800	chr10:38450738~38451069:-
LUAD	trans	rs6708331	0.941	rs12989257	ENSG00000232654.1	FAM136BP	11.42	6.66e-27	3.8e-20	0.63	0.46	Obesity-related traits;	chr2:70141466	chr6:3045384~3045800:+
LUAD	trans	rs4276421	0.935	rs6451827	ENSG00000231752.4	EMBP1	11.42	6.68e-27	3.81e-20	0.61	0.46	P wave duration;	chr5:45879496	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.955	rs11931312	ENSG00000275858.1	RP11-291L22.8	11.42	6.9e-27	3.94e-20	0.56	0.46	Corneal astigmatism;	chr4:119237868	chr10:38450738~38451069:-
LUAD	trans	rs877636	0.692	rs11171739	ENSG00000242970.2	AC068522.4	11.42	7.04e-27	4.01e-20	0.53	0.46	Cognitive function;	chr12:56076841	chr8:58588420~58588764:-
LUAD	trans	rs867371	0.896	rs6495647	ENSG00000235370.6	DNM1P51	-11.41	7.25e-27	4.13e-20	-0.53	-0.46	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82244708	chr15:84398316~84411701:-
LUAD	trans	rs4276421	0.935	rs6451834	ENSG00000231752.4	EMBP1	11.41	7.54e-27	4.3e-20	0.62	0.46	P wave duration;	chr5:45927208	chr1:121519112~121571892:+
LUAD	trans	rs916888	0.773	rs169201	ENSG00000280022.1	RP11-707O23.1	11.4	8.46e-27	4.81e-20	0.7	0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45592621~45593369:+
LUAD	trans	rs916888	0.773	rs1378358	ENSG00000280022.1	RP11-707O23.1	11.39	8.75e-27	4.97e-20	0.69	0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45592621~45593369:+
LUAD	trans	rs11098499	0.604	rs17051352	ENSG00000275858.1	RP11-291L22.8	11.38	9.62e-27	5.46e-20	0.57	0.46	Corneal astigmatism;	chr4:119660272	chr10:38450738~38451069:-
LUAD	trans	rs7312770	0.637	rs705700	ENSG00000235459.5	RPS26P31	11.38	9.65e-27	5.47e-20	0.5	0.46	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr7:122681315~122681662:+
LUAD	trans	rs3749237	1	rs11130216	ENSG00000197582.5	GPX1P1	11.38	9.74e-27	5.53e-20	0.65	0.46	Resting heart rate;	chr3:49698739	chrX:13378735~13379340:-
LUAD	trans	rs3749237	1	rs6804655	ENSG00000197582.5	GPX1P1	11.38	9.74e-27	5.53e-20	0.65	0.46	Resting heart rate;	chr3:49701512	chrX:13378735~13379340:-
LUAD	trans	rs4276421	0.774	rs4601053	ENSG00000231752.4	EMBP1	11.38	9.77e-27	5.54e-20	0.61	0.46	P wave duration;	chr5:46101734	chr1:121519112~121571892:+
LUAD	trans	rs916888	0.687	rs199456	ENSG00000280022.1	RP11-707O23.1	11.38	1e-26	5.68e-20	0.69	0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45592621~45593369:+
LUAD	trans	rs12709013	0.792	rs1615326	ENSG00000230849.2	GOT2P2	11.37	1.03e-26	5.84e-20	0.56	0.46	Blood metabolite ratios;	chr16:58747148	chr1:173141100~173142350:-
LUAD	trans	rs11098499	0.955	rs13129661	ENSG00000275858.1	RP11-291L22.8	11.37	1.06e-26	5.99e-20	0.56	0.46	Corneal astigmatism;	chr4:119231754	chr10:38450738~38451069:-
LUAD	trans	rs916888	0.61	rs199446	ENSG00000214425.5	LRRC37A4P	11.36	1.13e-26	6.38e-20	0.58	0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:45506741~45550335:-
LUAD	trans	rs916888	0.61	rs199536	ENSG00000214425.5	LRRC37A4P	11.36	1.13e-26	6.38e-20	0.58	0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:45506741~45550335:-
LUAD	trans	rs3779195	0.929	rs1635612	ENSG00000225169.1	BRI3P1	11.36	1.16e-26	6.56e-20	0.7	0.46	Sex hormone-binding globulin levels;	chr7:98385737	chr1:100213293~100213670:+
LUAD	trans	rs4276421	0.774	rs8188072	ENSG00000231752.4	EMBP1	11.36	1.17e-26	6.63e-20	0.59	0.46	P wave duration;	chr5:46061883	chr1:121519112~121571892:+
LUAD	trans	rs2657294	0.796	rs2804534	ENSG00000172974.11	AC007318.5	-11.36	1.19e-26	6.73e-20	-0.48	-0.46	Pneumonia;	chr10:75208023	chr2:65205108~65205988:+
LUAD	trans	rs916888	0.773	rs199457	ENSG00000280022.1	RP11-707O23.1	11.35	1.27e-26	7.15e-20	0.69	0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45592621~45593369:+
LUAD	trans	rs11098499	0.604	rs34278750	ENSG00000275858.1	RP11-291L22.8	11.35	1.31e-26	7.4e-20	0.57	0.46	Corneal astigmatism;	chr4:119649981	chr10:38450738~38451069:-
LUAD	trans	rs9876781	1	rs7651407	ENSG00000235912.1	RP1-159A19.3	-11.35	1.32e-26	7.46e-20	-0.48	-0.46	Longevity;	chr3:48402409	chr1:27649419~27649610:+
LUAD	trans	rs9467773	0.935	rs1056668	ENSG00000242375.1	RP11-498P14.3	11.35	1.32e-26	7.46e-20	0.6	0.46	Intelligence (multi-trait analysis);	chr6:26510377	chr9:97195351~97197687:-
LUAD	trans	rs11098499	0.863	rs10018280	ENSG00000275858.1	RP11-291L22.8	11.34	1.35e-26	7.61e-20	0.58	0.46	Corneal astigmatism;	chr4:119556984	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs6534141	ENSG00000275858.1	RP11-291L22.8	11.34	1.35e-26	7.61e-20	0.58	0.46	Corneal astigmatism;	chr4:119564068	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs3775858	ENSG00000275858.1	RP11-291L22.8	11.34	1.35e-26	7.61e-20	0.58	0.46	Corneal astigmatism;	chr4:119564873	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.738	rs72918577	ENSG00000275858.1	RP11-291L22.8	11.34	1.35e-26	7.61e-20	0.58	0.46	Corneal astigmatism;	chr4:119405546	chr10:38450738~38451069:-
LUAD	trans	rs1816752	0.716	rs1441058	ENSG00000224976.2	PARP4P2	11.34	1.4e-26	7.88e-20	0.52	0.46	Obesity-related traits;	chr13:24516275	chr13:19349137~19407962:+
LUAD	trans	rs9611565	0.506	rs7364221	ENSG00000268568.1	AC007228.9	-11.34	1.45e-26	8.16e-20	-0.62	-0.46	Vitiligo;	chr22:41254186	chr19:56672574~56673901:-
LUAD	trans	rs7554547	0.667	rs12065911	ENSG00000261819.1	RP11-680G24.4	11.34	1.45e-26	8.17e-20	0.6	0.46	Nonsyndromic cleft lip with cleft palate;	chr1:11908323	chr16:14988259~14990160:-
LUAD	trans	rs4276421	0.935	rs35163964	ENSG00000231752.4	EMBP1	11.33	1.49e-26	8.4e-20	0.6	0.46	P wave duration;	chr5:45904860	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.566	rs7664440	ENSG00000275858.1	RP11-291L22.8	11.33	1.51e-26	8.49e-20	0.57	0.46	Corneal astigmatism;	chr4:119657385	chr10:38450738~38451069:-
LUAD	trans	rs7312770	0.612	rs1873914	ENSG00000235459.5	RPS26P31	11.33	1.52e-26	8.53e-20	0.5	0.46	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr7:122681315~122681662:+
LUAD	trans	rs11098499	0.954	rs6857105	ENSG00000275858.1	RP11-291L22.8	11.33	1.54e-26	8.65e-20	0.57	0.46	Corneal astigmatism;	chr4:119301143	chr10:38450738~38451069:-
LUAD	trans	rs9876781	1	rs6794875	ENSG00000235912.1	RP1-159A19.3	-11.33	1.56e-26	8.79e-20	-0.48	-0.46	Longevity;	chr3:48414217	chr1:27649419~27649610:+
LUAD	trans	rs6708331	1	rs7597199	ENSG00000232654.1	FAM136BP	11.33	1.59e-26	8.96e-20	0.64	0.46	Obesity-related traits;	chr2:70114443	chr6:3045384~3045800:+
LUAD	trans	rs11098499	0.779	rs10857066	ENSG00000275858.1	RP11-291L22.8	11.33	1.61e-26	9.03e-20	0.54	0.46	Corneal astigmatism;	chr4:119365441	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.604	rs10022185	ENSG00000275858.1	RP11-291L22.8	11.32	1.63e-26	9.16e-20	0.57	0.46	Corneal astigmatism;	chr4:119650610	chr10:38450738~38451069:-
LUAD	trans	rs3749237	1	rs4768	ENSG00000197582.5	GPX1P1	11.32	1.66e-26	9.32e-20	0.64	0.46	Resting heart rate;	chr3:49721331	chrX:13378735~13379340:-
LUAD	trans	rs11098499	0.78	rs10013652	ENSG00000275858.1	RP11-291L22.8	11.32	1.66e-26	9.33e-20	0.54	0.46	Corneal astigmatism;	chr4:119371101	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs1010739	ENSG00000275858.1	RP11-291L22.8	11.32	1.72e-26	9.68e-20	0.57	0.46	Corneal astigmatism;	chr4:119542316	chr10:38450738~38451069:-
LUAD	trans	rs916888	0.773	rs199448	ENSG00000280022.1	RP11-707O23.1	11.32	1.74e-26	9.76e-20	0.67	0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45592621~45593369:+
LUAD	trans	rs4276421	0.661	rs4455569	ENSG00000231752.4	EMBP1	-11.32	1.75e-26	9.81e-20	-0.6	-0.46	P wave duration;	chr5:46081782	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.657	rs4975885	ENSG00000231752.4	EMBP1	-11.32	1.75e-26	9.81e-20	-0.6	-0.46	P wave duration;	chr5:46083476	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.774	rs11949490	ENSG00000231752.4	EMBP1	-11.32	1.75e-26	9.81e-20	-0.6	-0.46	P wave duration;	chr5:46085951	chr1:121519112~121571892:+
LUAD	trans	rs9876781	1	rs11712561	ENSG00000235912.1	RP1-159A19.3	-11.31	1.78e-26	9.96e-20	-0.48	-0.46	Longevity;	chr3:48393807	chr1:27649419~27649610:+
LUAD	trans	rs13190036	0.551	rs7710269	ENSG00000217325.2	PRELID1P1	-11.31	1.83e-26	1.02e-19	-0.66	-0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177187528	chr6:126643488~126644390:+
LUAD	trans	rs6708331	1	rs6708331	ENSG00000232654.1	FAM136BP	11.31	1.89e-26	1.06e-19	0.62	0.46	Obesity-related traits;	chr2:70141791	chr6:3045384~3045800:+
LUAD	trans	rs3749237	1	rs2291542	ENSG00000197582.5	GPX1P1	11.31	1.9e-26	1.07e-19	0.64	0.46	Resting heart rate;	chr3:49714152	chrX:13378735~13379340:-
LUAD	trans	rs1816752	0.716	rs9553330	ENSG00000224976.2	PARP4P2	11.3	1.94e-26	1.08e-19	0.51	0.46	Obesity-related traits;	chr13:24516018	chr13:19349137~19407962:+
LUAD	trans	rs4276421	0.682	rs12657581	ENSG00000231752.4	EMBP1	11.3	1.95e-26	1.09e-19	0.6	0.46	P wave duration;	chr5:46080471	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.714	rs4259174	ENSG00000231752.4	EMBP1	-11.3	1.95e-26	1.09e-19	-0.59	-0.46	P wave duration;	chr5:46074351	chr1:121519112~121571892:+
LUAD	trans	rs13190036	1	rs17078781	ENSG00000226986.4	RP11-543B16.2	-11.3	1.97e-26	1.1e-19	-0.7	-0.46	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177117227	chr1:211207239~211207897:+
LUAD	trans	rs11098499	0.687	rs71610270	ENSG00000275858.1	RP11-291L22.8	11.3	2.03e-26	1.13e-19	0.54	0.46	Corneal astigmatism;	chr4:119366281	chr10:38450738~38451069:-
LUAD	trans	rs12709013	0.792	rs1646270	ENSG00000233719.3	GOT2P3	11.3	2.05e-26	1.14e-19	0.55	0.46	Blood metabolite ratios;	chr16:58745823	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.792	rs1646270	ENSG00000230849.2	GOT2P2	11.3	2.06e-26	1.15e-19	0.56	0.46	Blood metabolite ratios;	chr16:58745823	chr1:173141100~173142350:-
LUAD	trans	rs11098499	0.863	rs2127823	ENSG00000275858.1	RP11-291L22.8	11.3	2.11e-26	1.18e-19	0.57	0.46	Corneal astigmatism;	chr4:119564515	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.73	rs78971550	ENSG00000275858.1	RP11-291L22.8	11.29	2.14e-26	1.19e-19	0.54	0.46	Corneal astigmatism;	chr4:119359886	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.645	rs78422072	ENSG00000275858.1	RP11-291L22.8	11.29	2.14e-26	1.19e-19	0.54	0.46	Corneal astigmatism;	chr4:119359887	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.863	rs9997631	ENSG00000275858.1	RP11-291L22.8	11.29	2.28e-26	1.27e-19	0.57	0.46	Corneal astigmatism;	chr4:119548840	chr10:38450738~38451069:-
LUAD	trans	rs11098499	1	rs6849889	ENSG00000275858.1	RP11-291L22.8	11.29	2.31e-26	1.28e-19	0.56	0.46	Corneal astigmatism;	chr4:119265193	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.604	rs2389887	ENSG00000275858.1	RP11-291L22.8	11.28	2.35e-26	1.31e-19	0.57	0.46	Corneal astigmatism;	chr4:119649489	chr10:38450738~38451069:-
LUAD	trans	rs877636	0.692	rs10876870	ENSG00000196933.5	RPS26P11	-11.28	2.36e-26	1.31e-19	-0.52	-0.46	Cognitive function;	chr12:56084218	chrX:72044545~72044892:+
LUAD	trans	rs877636	0.692	rs7971751	ENSG00000196933.5	RPS26P11	-11.28	2.36e-26	1.31e-19	-0.52	-0.46	Cognitive function;	chr12:56084874	chrX:72044545~72044892:+
LUAD	trans	rs7312770	0.637	rs705699	ENSG00000235459.5	RPS26P31	11.28	2.38e-26	1.32e-19	0.5	0.46	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr7:122681315~122681662:+
LUAD	trans	rs7554547	0.667	rs11121839	ENSG00000261819.1	RP11-680G24.4	11.28	2.44e-26	1.35e-19	0.6	0.46	Nonsyndromic cleft lip with cleft palate;	chr1:11908280	chr16:14988259~14990160:-
LUAD	trans	rs77688320	0.517	rs10497868	ENSG00000235105.1	RP11-329A14.1	-11.28	2.46e-26	1.37e-19	-0.53	-0.46	Breast cancer;	chr2:201439317	chr1:48435967~48437223:+
LUAD	trans	rs12709013	0.792	rs1615326	ENSG00000233719.3	GOT2P3	11.28	2.49e-26	1.38e-19	0.54	0.46	Blood metabolite ratios;	chr16:58747148	chr12:9641802~9643007:+
LUAD	trans	rs4276421	0.816	rs6451835	ENSG00000231752.4	EMBP1	11.27	2.54e-26	1.41e-19	0.61	0.46	P wave duration;	chr5:45928735	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.743	rs4455568	ENSG00000231752.4	EMBP1	11.27	2.68e-26	1.48e-19	0.59	0.46	P wave duration;	chr5:46079755	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.745	rs11957047	ENSG00000231752.4	EMBP1	-11.27	2.68e-26	1.48e-19	-0.59	-0.46	P wave duration;	chr5:46080090	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.955	rs11944880	ENSG00000275858.1	RP11-291L22.8	-11.26	2.81e-26	1.56e-19	-0.55	-0.46	Corneal astigmatism;	chr4:119238179	chr10:38450738~38451069:-
LUAD	trans	rs4276421	0.694	rs10941732	ENSG00000231752.4	EMBP1	-11.26	2.81e-26	1.56e-19	-0.59	-0.46	P wave duration;	chr5:46080260	chr1:121519112~121571892:+
LUAD	trans	rs1816752	0.646	rs2862905	ENSG00000224976.2	PARP4P2	11.26	2.89e-26	1.6e-19	0.52	0.46	Obesity-related traits;	chr13:24485142	chr13:19349137~19407962:+
LUAD	trans	rs9876781	1	rs13076076	ENSG00000235912.1	RP1-159A19.3	-11.26	2.92e-26	1.62e-19	-0.47	-0.46	Longevity;	chr3:48437629	chr1:27649419~27649610:+
LUAD	trans	rs9876781	1	rs9883927	ENSG00000235912.1	RP1-159A19.3	-11.26	2.96e-26	1.63e-19	-0.47	-0.46	Longevity;	chr3:48422302	chr1:27649419~27649610:+
LUAD	trans	rs9876781	1	rs9817615	ENSG00000235912.1	RP1-159A19.3	-11.26	2.96e-26	1.63e-19	-0.47	-0.46	Longevity;	chr3:48429347	chr1:27649419~27649610:+
LUAD	trans	rs9876781	1	rs2290822	ENSG00000235912.1	RP1-159A19.3	-11.26	2.96e-26	1.63e-19	-0.47	-0.46	Longevity;	chr3:48431794	chr1:27649419~27649610:+
LUAD	trans	rs9876781	1	rs11130171	ENSG00000235912.1	RP1-159A19.3	-11.25	3.04e-26	1.68e-19	-0.47	-0.46	Longevity;	chr3:48421052	chr1:27649419~27649610:+
LUAD	trans	rs3749237	0.964	rs62260719	ENSG00000197582.5	GPX1P1	11.25	3.13e-26	1.73e-19	0.67	0.46	Resting heart rate;	chr3:49814986	chrX:13378735~13379340:-
LUAD	trans	rs877636	0.692	rs10876870	ENSG00000242970.2	AC068522.4	-11.25	3.15e-26	1.74e-19	-0.52	-0.46	Cognitive function;	chr12:56084218	chr8:58588420~58588764:-
LUAD	trans	rs877636	0.692	rs7971751	ENSG00000242970.2	AC068522.4	-11.25	3.15e-26	1.74e-19	-0.52	-0.46	Cognitive function;	chr12:56084874	chr8:58588420~58588764:-
LUAD	trans	rs9876781	0.967	rs1459249	ENSG00000235912.1	RP1-159A19.3	-11.25	3.16e-26	1.74e-19	-0.48	-0.46	Longevity;	chr3:48438208	chr1:27649419~27649610:+
LUAD	trans	rs4276421	0.904	rs7293482	ENSG00000231752.4	EMBP1	11.24	3.5e-26	1.92e-19	0.6	0.46	P wave duration;	chr5:46003984	chr1:121519112~121571892:+
LUAD	trans	rs6708331	0.941	rs6720799	ENSG00000232654.1	FAM136BP	-11.24	3.61e-26	1.98e-19	-0.64	-0.46	Obesity-related traits;	chr2:70144897	chr6:3045384~3045800:+
LUAD	trans	rs11098499	0.863	rs6534139	ENSG00000275858.1	RP11-291L22.8	-11.24	3.62e-26	1.99e-19	-0.57	-0.46	Corneal astigmatism;	chr4:119528301	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.69	rs34818745	ENSG00000275858.1	RP11-291L22.8	11.23	3.63e-26	1.99e-19	0.57	0.46	Corneal astigmatism;	chr4:119335900	chr10:38450738~38451069:-
LUAD	trans	rs877636	0.692	rs11171739	ENSG00000234354.3	RPS26P47	11.23	3.63e-26	1.99e-19	0.49	0.46	Cognitive function;	chr12:56076841	chr13:100539901~100540248:-
LUAD	trans	rs867371	1	rs13380319	ENSG00000235370.6	DNM1P51	-11.23	3.77e-26	2.07e-19	-0.52	-0.46	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214526	chr15:84398316~84411701:-
LUAD	trans	rs11098499	0.82	rs11737395	ENSG00000275858.1	RP11-291L22.8	11.22	4.15e-26	2.28e-19	0.57	0.46	Corneal astigmatism;	chr4:119599549	chr10:38450738~38451069:-
LUAD	trans	rs77688320	0.535	rs6435084	ENSG00000235105.1	RP11-329A14.1	11.22	4.25e-26	2.33e-19	0.54	0.46	Breast cancer;	chr2:201461274	chr1:48435967~48437223:+
LUAD	trans	rs4276421	0.805	rs13165481	ENSG00000231752.4	EMBP1	11.22	4.28e-26	2.35e-19	0.6	0.46	P wave duration;	chr5:46034214	chr1:121519112~121571892:+
LUAD	trans	rs9876781	1	rs13314659	ENSG00000235912.1	RP1-159A19.3	11.22	4.3e-26	2.35e-19	0.47	0.46	Longevity;	chr3:48407742	chr1:27649419~27649610:+
LUAD	trans	rs4276421	0.874	rs7727331	ENSG00000231752.4	EMBP1	11.21	4.33e-26	2.37e-19	0.59	0.46	P wave duration;	chr5:45945199	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.82	rs2389885	ENSG00000275858.1	RP11-291L22.8	11.21	4.35e-26	2.38e-19	0.58	0.46	Corneal astigmatism;	chr4:119612776	chr10:38450738~38451069:-
LUAD	trans	rs4276421	0.904	rs57299032	ENSG00000231752.4	EMBP1	11.21	4.41e-26	2.41e-19	0.6	0.46	P wave duration;	chr5:45998162	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.909	rs10017335	ENSG00000275858.1	RP11-291L22.8	-11.21	4.55e-26	2.48e-19	-0.56	-0.46	Corneal astigmatism;	chr4:119460368	chr10:38450738~38451069:-
LUAD	trans	rs4276421	0.904	rs4274988	ENSG00000231752.4	EMBP1	11.2	4.75e-26	2.59e-19	0.61	0.45	P wave duration;	chr5:45926339	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.935	rs7725537	ENSG00000231752.4	EMBP1	11.2	4.75e-26	2.59e-19	0.61	0.45	P wave duration;	chr5:45927191	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.935	rs35730142	ENSG00000231752.4	EMBP1	11.2	4.75e-26	2.59e-19	0.61	0.45	P wave duration;	chr5:45927453	chr1:121519112~121571892:+
LUAD	trans	rs916888	0.773	rs199447	ENSG00000280022.1	RP11-707O23.1	11.2	4.77e-26	2.6e-19	0.7	0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45592621~45593369:+
LUAD	trans	rs4276421	0.967	rs7725171	ENSG00000231752.4	EMBP1	11.2	4.87e-26	2.66e-19	0.61	0.45	P wave duration;	chr5:45923684	chr1:121519112~121571892:+
LUAD	trans	rs9467773	0.649	rs2145318	ENSG00000242375.1	RP11-498P14.3	11.2	4.98e-26	2.71e-19	0.59	0.45	Intelligence (multi-trait analysis);	chr6:26496375	chr9:97195351~97197687:-
LUAD	trans	rs4276421	0.967	rs35648163	ENSG00000231752.4	EMBP1	11.2	5.17e-26	2.82e-19	0.59	0.45	P wave duration;	chr5:45945778	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.904	rs6451843	ENSG00000231752.4	EMBP1	11.2	5.17e-26	2.82e-19	0.59	0.45	P wave duration;	chr5:45946683	chr1:121519112~121571892:+
LUAD	trans	rs7312770	0.612	rs773114	ENSG00000196933.5	RPS26P11	11.19	5.21e-26	2.84e-19	0.52	0.45	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chrX:72044545~72044892:+
LUAD	trans	rs7554547	0.69	rs4846064	ENSG00000261819.1	RP11-680G24.4	11.19	5.26e-26	2.86e-19	0.57	0.45	Nonsyndromic cleft lip with cleft palate;	chr1:11874785	chr16:14988259~14990160:-
LUAD	trans	rs877636	0.669	rs7297175	ENSG00000234513.1	AC073072.7	-11.19	5.42e-26	2.95e-19	-0.51	-0.45	Cognitive function;	chr12:56080024	chr7:22773646~22773993:-
LUAD	trans	rs4276421	0.904	rs4489075	ENSG00000231752.4	EMBP1	11.19	5.46e-26	2.97e-19	0.6	0.45	P wave duration;	chr5:46018903	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.774	rs4428422	ENSG00000231752.4	EMBP1	11.19	5.5e-26	2.99e-19	0.6	0.45	P wave duration;	chr5:46017216	chr1:121519112~121571892:+
LUAD	trans	rs77688320	0.517	rs2270315	ENSG00000235105.1	RP11-329A14.1	11.19	5.57e-26	3.03e-19	0.54	0.45	Breast cancer;	chr2:201452542	chr1:48435967~48437223:+
LUAD	trans	rs77688320	0.517	rs2287054	ENSG00000235105.1	RP11-329A14.1	11.19	5.57e-26	3.03e-19	0.54	0.45	Breast cancer;	chr2:201454315	chr1:48435967~48437223:+
LUAD	trans	rs77688320	0.5	rs10931948	ENSG00000235105.1	RP11-329A14.1	11.19	5.57e-26	3.03e-19	0.54	0.45	Breast cancer;	chr2:201459199	chr1:48435967~48437223:+
LUAD	trans	rs916888	0.773	rs199445	ENSG00000280022.1	RP11-707O23.1	11.19	5.62e-26	3.05e-19	0.68	0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45592621~45593369:+
LUAD	trans	rs916888	0.773	rs199443	ENSG00000280022.1	RP11-707O23.1	11.19	5.62e-26	3.05e-19	0.68	0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45592621~45593369:+
LUAD	trans	rs4276421	0.934	rs6451838	ENSG00000231752.4	EMBP1	11.18	5.76e-26	3.13e-19	0.59	0.45	P wave duration;	chr5:45935060	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.904	rs7444405	ENSG00000231752.4	EMBP1	11.18	5.81e-26	3.15e-19	0.61	0.45	P wave duration;	chr5:45915373	chr1:121519112~121571892:+
LUAD	trans	rs7937890	0.9	rs7118682	ENSG00000236360.2	RP11-334A14.2	-11.18	5.98e-26	3.24e-19	-0.56	-0.45	Mitochondrial DNA levels;	chr11:14253004	chr1:52993201~52993702:-
LUAD	trans	rs4276421	0.874	rs34501453	ENSG00000231752.4	EMBP1	11.18	6e-26	3.25e-19	0.59	0.45	P wave duration;	chr5:45947338	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.845	rs4371763	ENSG00000231752.4	EMBP1	11.17	6.23e-26	3.37e-19	0.6	0.45	P wave duration;	chr5:45983120	chr1:121519112~121571892:+
LUAD	trans	rs4276421	1	rs13340341	ENSG00000231752.4	EMBP1	11.17	6.28e-26	3.4e-19	0.59	0.45	P wave duration;	chr5:45860834	chr1:121519112~121571892:+
LUAD	trans	rs7312770	0.612	rs1873914	ENSG00000243403.1	RP11-330L19.1	11.17	6.33e-26	3.43e-19	0.48	0.45	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr15:64592979~64593326:+
LUAD	trans	rs1816752	0.692	rs6490944	ENSG00000224976.2	PARP4P2	11.17	6.52e-26	3.52e-19	0.52	0.45	Obesity-related traits;	chr13:24513866	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.646	rs3783073	ENSG00000224976.2	PARP4P2	11.17	6.66e-26	3.6e-19	0.52	0.45	Obesity-related traits;	chr13:24493222	chr13:19349137~19407962:+
LUAD	trans	rs4276421	0.839	rs7719401	ENSG00000231752.4	EMBP1	11.17	6.7e-26	3.62e-19	0.59	0.45	P wave duration;	chr5:45938713	chr1:121519112~121571892:+
LUAD	trans	rs9467773	0.935	rs4573	ENSG00000242375.1	RP11-498P14.3	11.16	6.9e-26	3.73e-19	0.59	0.45	Intelligence (multi-trait analysis);	chr6:26546580	chr9:97195351~97197687:-
LUAD	trans	rs9876781	1	rs9815103	ENSG00000235912.1	RP1-159A19.3	-11.16	6.98e-26	3.77e-19	-0.48	-0.45	Longevity;	chr3:48372725	chr1:27649419~27649610:+
LUAD	trans	rs4276421	0.659	rs8188026	ENSG00000231752.4	EMBP1	11.16	7.08e-26	3.82e-19	0.6	0.45	P wave duration;	chr5:46053462	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.863	rs3736115	ENSG00000275858.1	RP11-291L22.8	-11.16	7.35e-26	3.96e-19	-0.56	-0.45	Corneal astigmatism;	chr4:119567548	chr10:38450738~38451069:-
LUAD	trans	rs3749237	0.964	rs11714957	ENSG00000197582.5	GPX1P1	11.15	7.5e-26	4.05e-19	0.63	0.45	Resting heart rate;	chr3:49738745	chrX:13378735~13379340:-
LUAD	trans	rs9876781	1	rs7630741	ENSG00000235912.1	RP1-159A19.3	-11.15	7.7e-26	4.15e-19	-0.48	-0.45	Longevity;	chr3:48378233	chr1:27649419~27649610:+
LUAD	trans	rs10037055	0.853	rs9313749	ENSG00000217325.2	PRELID1P1	-11.15	8.09e-26	4.36e-19	-0.58	-0.45	Migraine without aura;	chr5:177170693	chr6:126643488~126644390:+
LUAD	trans	rs4276421	0.967	rs4541665	ENSG00000231752.4	EMBP1	-11.14	8.47e-26	4.56e-19	-0.6	-0.45	P wave duration;	chr5:45796444	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.604	rs2389886	ENSG00000275858.1	RP11-291L22.8	11.14	8.5e-26	4.57e-19	0.57	0.45	Corneal astigmatism;	chr4:119649267	chr10:38450738~38451069:-
LUAD	trans	rs867371	0.929	rs7176075	ENSG00000235370.6	DNM1P51	-11.14	8.65e-26	4.65e-19	-0.52	-0.45	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82178998	chr15:84398316~84411701:-
LUAD	trans	rs3749237	0.964	rs7431078	ENSG00000197582.5	GPX1P1	11.13	9.08e-26	4.88e-19	0.63	0.45	Resting heart rate;	chr3:49770757	chrX:13378735~13379340:-
LUAD	trans	rs3749237	0.964	rs34522271	ENSG00000197582.5	GPX1P1	11.13	9.08e-26	4.88e-19	0.63	0.45	Resting heart rate;	chr3:49771084	chrX:13378735~13379340:-
LUAD	trans	rs3749237	0.964	rs35210174	ENSG00000197582.5	GPX1P1	11.13	9.08e-26	4.88e-19	0.63	0.45	Resting heart rate;	chr3:49775173	chrX:13378735~13379340:-
LUAD	trans	rs1816752	0.716	rs9553331	ENSG00000224976.2	PARP4P2	11.13	9.19e-26	4.94e-19	0.52	0.45	Obesity-related traits;	chr13:24516030	chr13:19349137~19407962:+
LUAD	trans	rs10940346	0.807	rs4865843	ENSG00000231752.4	EMBP1	-11.13	9.62e-26	5.16e-19	-0.61	-0.45	Schizophrenia;	chr5:50569681	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.644	rs62365309	ENSG00000231752.4	EMBP1	-11.13	9.64e-26	5.17e-19	-0.61	-0.45	Schizophrenia;	chr5:50568902	chr1:121519112~121571892:+
LUAD	trans	rs867371	1	rs8041868	ENSG00000235370.6	DNM1P51	-11.12	9.9e-26	5.31e-19	-0.52	-0.45	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82179985	chr15:84398316~84411701:-
LUAD	trans	rs7554547	0.714	rs926269	ENSG00000261819.1	RP11-680G24.4	11.12	9.91e-26	5.31e-19	0.6	0.45	Nonsyndromic cleft lip with cleft palate;	chr1:11909691	chr16:14988259~14990160:-
LUAD	trans	rs916888	0.773	rs9896243	ENSG00000280022.1	RP11-707O23.1	11.12	1e-25	5.37e-19	0.66	0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45592621~45593369:+
LUAD	trans	rs3749237	1	rs11130214	ENSG00000197582.5	GPX1P1	-11.12	1.01e-25	5.39e-19	-0.63	-0.45	Resting heart rate;	chr3:49698313	chrX:13378735~13379340:-
LUAD	trans	rs7312770	0.637	rs705699	ENSG00000196933.5	RPS26P11	11.12	1.01e-25	5.4e-19	0.52	0.45	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chrX:72044545~72044892:+
LUAD	trans	rs4276421	0.874	rs4501347	ENSG00000231752.4	EMBP1	11.12	1.03e-25	5.51e-19	0.59	0.45	P wave duration;	chr5:45974779	chr1:121519112~121571892:+
LUAD	trans	rs9876781	1	rs9849509	ENSG00000235912.1	RP1-159A19.3	-11.12	1.06e-25	5.66e-19	-0.47	-0.45	Longevity;	chr3:48442021	chr1:27649419~27649610:+
LUAD	trans	rs9876781	1	rs60512868	ENSG00000235912.1	RP1-159A19.3	-11.12	1.06e-25	5.66e-19	-0.47	-0.45	Longevity;	chr3:48442035	chr1:27649419~27649610:+
LUAD	trans	rs877636	0.692	rs2271194	ENSG00000196933.5	RPS26P11	-11.11	1.08e-25	5.76e-19	-0.52	-0.45	Cognitive function;	chr12:56083910	chrX:72044545~72044892:+
LUAD	trans	rs4276421	0.874	rs4569881	ENSG00000231752.4	EMBP1	11.11	1.1e-25	5.91e-19	0.59	0.45	P wave duration;	chr5:46011667	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.816	rs13362078	ENSG00000231752.4	EMBP1	11.11	1.1e-25	5.91e-19	0.59	0.45	P wave duration;	chr5:46013351	chr1:121519112~121571892:+
LUAD	trans	rs7554547	0.714	rs2878679	ENSG00000261819.1	RP11-680G24.4	11.11	1.11e-25	5.92e-19	0.6	0.45	Nonsyndromic cleft lip with cleft palate;	chr1:11915586	chr16:14988259~14990160:-
LUAD	trans	rs4276421	0.845	rs62372987	ENSG00000231752.4	EMBP1	11.11	1.13e-25	6.03e-19	0.6	0.45	P wave duration;	chr5:45979889	chr1:121519112~121571892:+
LUAD	trans	rs7364180	0.582	rs139568	ENSG00000268568.1	AC007228.9	11.11	1.13e-25	6.05e-19	0.59	0.45	Alzheimer's disease biomarkers;	chr22:41814981	chr19:56672574~56673901:-
LUAD	trans	rs77688320	0.535	rs2540441	ENSG00000235105.1	RP11-329A14.1	-11.11	1.15e-25	6.12e-19	-0.54	-0.45	Breast cancer;	chr2:201481946	chr1:48435967~48437223:+
LUAD	trans	rs9876781	1	rs7636044	ENSG00000235912.1	RP1-159A19.3	-11.11	1.16e-25	6.17e-19	-0.46	-0.45	Longevity;	chr3:48443151	chr1:27649419~27649610:+
LUAD	trans	rs9876781	1	rs4490383	ENSG00000235912.1	RP1-159A19.3	-11.11	1.16e-25	6.17e-19	-0.46	-0.45	Longevity;	chr3:48443275	chr1:27649419~27649610:+
LUAD	trans	rs9876781	1	rs9812647	ENSG00000235912.1	RP1-159A19.3	11.1	1.25e-25	6.65e-19	0.47	0.45	Longevity;	chr3:48407507	chr1:27649419~27649610:+
LUAD	trans	rs916888	0.773	rs199535	ENSG00000280022.1	RP11-707O23.1	11.09	1.3e-25	6.9e-19	0.67	0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45592621~45593369:+
LUAD	trans	rs916888	0.779	rs199528	ENSG00000280022.1	RP11-707O23.1	11.09	1.3e-25	6.91e-19	0.69	0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45592621~45593369:+
LUAD	trans	rs916888	0.821	rs199525	ENSG00000280022.1	RP11-707O23.1	11.09	1.3e-25	6.91e-19	0.69	0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45592621~45593369:+
LUAD	trans	rs867371	0.964	rs7169961	ENSG00000235370.6	DNM1P51	-11.09	1.31e-25	6.98e-19	-0.52	-0.45	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186588	chr15:84398316~84411701:-
LUAD	trans	rs867371	1	rs6495643	ENSG00000235370.6	DNM1P51	-11.09	1.31e-25	6.98e-19	-0.52	-0.45	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186913	chr15:84398316~84411701:-
LUAD	trans	rs3749237	0.964	rs2234385	ENSG00000197582.5	GPX1P1	11.09	1.32e-25	7.04e-19	0.63	0.45	Resting heart rate;	chr3:49808608	chrX:13378735~13379340:-
LUAD	trans	rs3749237	0.964	rs1799843	ENSG00000197582.5	GPX1P1	11.09	1.32e-25	7.04e-19	0.63	0.45	Resting heart rate;	chr3:49812290	chrX:13378735~13379340:-
LUAD	trans	rs9876781	0.967	rs7618883	ENSG00000235912.1	RP1-159A19.3	-11.09	1.34e-25	7.12e-19	-0.47	-0.45	Longevity;	chr3:48457056	chr1:27649419~27649610:+
LUAD	trans	rs11098499	0.954	rs2389803	ENSG00000275858.1	RP11-291L22.8	-11.08	1.41e-25	7.51e-19	-0.57	-0.45	Corneal astigmatism;	chr4:119472356	chr10:38450738~38451069:-
LUAD	trans	rs1816752	0.716	rs7995304	ENSG00000224976.2	PARP4P2	11.08	1.41e-25	7.52e-19	0.51	0.45	Obesity-related traits;	chr13:24514284	chr13:19349137~19407962:+
LUAD	trans	rs2657294	0.965	rs10824286	ENSG00000172974.11	AC007318.5	11.08	1.42e-25	7.53e-19	0.48	0.45	Pneumonia;	chr10:75172251	chr2:65205108~65205988:+
LUAD	trans	rs12709013	0.792	rs1657165	ENSG00000233719.3	GOT2P3	11.08	1.43e-25	7.61e-19	0.54	0.45	Blood metabolite ratios;	chr16:58747980	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.818	rs1646273	ENSG00000233719.3	GOT2P3	11.08	1.43e-25	7.61e-19	0.54	0.45	Blood metabolite ratios;	chr16:58748318	chr12:9641802~9643007:+
LUAD	trans	rs11098499	0.566	rs17051356	ENSG00000275858.1	RP11-291L22.8	11.08	1.47e-25	7.79e-19	0.56	0.45	Corneal astigmatism;	chr4:119664153	chr10:38450738~38451069:-
LUAD	trans	rs4276421	0.874	rs71618219	ENSG00000231752.4	EMBP1	11.08	1.51e-25	8.01e-19	0.61	0.45	P wave duration;	chr5:45950598	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.901	rs10056175	ENSG00000231752.4	EMBP1	11.07	1.54e-25	8.18e-19	0.6	0.45	P wave duration;	chr5:45934503	chr1:121519112~121571892:+
LUAD	trans	rs10908521	0.685	rs7534418	ENSG00000227183.3	HDGFP1	-11.07	1.55e-25	8.22e-19	-0.57	-0.45	Uric acid clearance;	chr1:156836011	chrX:131646639~131646890:+
LUAD	trans	rs4276421	0.904	rs4569880	ENSG00000231752.4	EMBP1	11.07	1.63e-25	8.62e-19	0.59	0.45	P wave duration;	chr5:46011373	chr1:121519112~121571892:+
LUAD	trans	rs13190036	0.515	rs2878686	ENSG00000217325.2	PRELID1P1	-11.06	1.68e-25	8.89e-19	-0.65	-0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206748	chr6:126643488~126644390:+
LUAD	trans	rs61990749	0.511	rs724263	ENSG00000235400.1	RP4-641G12.4	11.06	1.7e-25	9e-19	0.76	0.45	Fibroblast growth factor basic levels;	chr14:77855531	chr1:78749073~78750659:+
LUAD	trans	rs7364180	0.515	rs6002503	ENSG00000268568.1	AC007228.9	-11.06	1.77e-25	9.35e-19	-0.58	-0.45	Alzheimer's disease biomarkers;	chr22:41812668	chr19:56672574~56673901:-
LUAD	trans	rs7312770	1	rs7312770	ENSG00000243403.1	RP11-330L19.1	-11.06	1.78e-25	9.42e-19	-0.46	-0.45	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr15:64592979~64593326:+
LUAD	trans	rs4276421	0.869	rs10036065	ENSG00000231752.4	EMBP1	-11.05	1.82e-25	9.61e-19	-0.6	-0.45	P wave duration;	chr5:45701926	chr1:121519112~121571892:+
LUAD	trans	rs9876781	1	rs10470686	ENSG00000235912.1	RP1-159A19.3	-11.05	1.83e-25	9.67e-19	-0.47	-0.45	Longevity;	chr3:48408549	chr1:27649419~27649610:+
LUAD	trans	rs4276421	0.967	rs10062508	ENSG00000231752.4	EMBP1	11.05	1.9e-25	1e-18	0.61	0.45	P wave duration;	chr5:45961764	chr1:121519112~121571892:+
LUAD	trans	rs9876781	1	rs2362450	ENSG00000235912.1	RP1-159A19.3	-11.05	1.93e-25	1.02e-18	-0.47	-0.45	Longevity;	chr3:48419904	chr1:27649419~27649610:+
LUAD	trans	rs877636	0.669	rs7297175	ENSG00000242970.2	AC068522.4	-11.05	1.95e-25	1.03e-18	-0.51	-0.45	Cognitive function;	chr12:56080024	chr8:58588420~58588764:-
LUAD	trans	rs1816752	0.692	rs2282409	ENSG00000224976.2	PARP4P2	11.03	2.19e-25	1.15e-18	0.51	0.45	Obesity-related traits;	chr13:24512388	chr13:19349137~19407962:+
LUAD	trans	rs12709013	0.716	rs11647582	ENSG00000230849.2	GOT2P2	11.03	2.19e-25	1.15e-18	0.55	0.45	Blood metabolite ratios;	chr16:58801474	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.792	rs35684307	ENSG00000230849.2	GOT2P2	11.03	2.19e-25	1.15e-18	0.55	0.45	Blood metabolite ratios;	chr16:58801651	chr1:173141100~173142350:-
LUAD	trans	rs7312770	0.612	rs773114	ENSG00000234513.1	AC073072.7	11.03	2.22e-25	1.16e-18	0.51	0.45	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr7:22773646~22773993:-
LUAD	trans	rs867371	1	rs2088858	ENSG00000235370.6	DNM1P51	-11.03	2.27e-25	1.19e-18	-0.52	-0.45	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182408	chr15:84398316~84411701:-
LUAD	trans	rs867371	1	rs4778982	ENSG00000235370.6	DNM1P51	-11.03	2.27e-25	1.19e-18	-0.52	-0.45	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182931	chr15:84398316~84411701:-
LUAD	trans	rs867371	1	rs2867579	ENSG00000235370.6	DNM1P51	-11.03	2.27e-25	1.19e-18	-0.52	-0.45	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183043	chr15:84398316~84411701:-
LUAD	trans	rs867371	1	rs881308	ENSG00000235370.6	DNM1P51	-11.03	2.27e-25	1.19e-18	-0.52	-0.45	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183456	chr15:84398316~84411701:-
LUAD	trans	rs916888	0.773	rs199439	ENSG00000280022.1	RP11-707O23.1	11.03	2.35e-25	1.23e-18	0.67	0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45592621~45593369:+
LUAD	trans	rs61990749	0.511	rs7146020	ENSG00000235400.1	RP4-641G12.4	11.02	2.43e-25	1.27e-18	0.74	0.45	Fibroblast growth factor basic levels;	chr14:77891976	chr1:78749073~78750659:+
LUAD	trans	rs12709013	0.792	rs1657165	ENSG00000230849.2	GOT2P2	11.02	2.43e-25	1.27e-18	0.55	0.45	Blood metabolite ratios;	chr16:58747980	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.818	rs1646273	ENSG00000230849.2	GOT2P2	11.02	2.43e-25	1.27e-18	0.55	0.45	Blood metabolite ratios;	chr16:58748318	chr1:173141100~173142350:-
LUAD	trans	rs867371	1	rs1392976	ENSG00000235370.6	DNM1P51	11.02	2.44e-25	1.27e-18	0.52	0.45	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82153834	chr15:84398316~84411701:-
LUAD	trans	rs867371	1	rs9944197	ENSG00000235370.6	DNM1P51	-11.02	2.44e-25	1.27e-18	-0.52	-0.45	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82158261	chr15:84398316~84411701:-
LUAD	trans	rs916888	0.61	rs199530	ENSG00000264070.1	DND1P1	-11.02	2.53e-25	1.32e-18	-0.58	-0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:45585871~45586929:+
LUAD	trans	rs867371	1	rs8041924	ENSG00000235370.6	DNM1P51	-11.02	2.57e-25	1.34e-18	-0.52	-0.45	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82181320	chr15:84398316~84411701:-
LUAD	trans	rs9467773	0.869	rs9295689	ENSG00000242375.1	RP11-498P14.3	11.01	2.6e-25	1.36e-18	0.59	0.45	Intelligence (multi-trait analysis);	chr6:26455583	chr9:97195351~97197687:-
LUAD	trans	rs4276421	0.904	rs10067132	ENSG00000231752.4	EMBP1	11.01	2.61e-25	1.36e-18	0.59	0.45	P wave duration;	chr5:46027600	chr1:121519112~121571892:+
LUAD	trans	rs4925166	1	rs4925166	ENSG00000263946.1	RP11-434D2.11	11.01	2.61e-25	1.36e-18	0.55	0.45	Multiple sclerosis;	chr17:18307496	chr17:20554971~20559410:-
LUAD	trans	rs12709013	0.792	rs11649133	ENSG00000230849.2	GOT2P2	11.01	2.66e-25	1.39e-18	0.55	0.45	Blood metabolite ratios;	chr16:58803275	chr1:173141100~173142350:-
LUAD	trans	rs3749237	1	rs11717256	ENSG00000197582.5	GPX1P1	11.01	2.72e-25	1.42e-18	0.63	0.45	Resting heart rate;	chr3:49831087	chrX:13378735~13379340:-
LUAD	trans	rs2657294	1	rs2657294	ENSG00000172974.11	AC007318.5	11.01	2.76e-25	1.44e-18	0.48	0.45	Pneumonia;	chr10:75193267	chr2:65205108~65205988:+
LUAD	trans	rs9467773	0.869	rs1796521	ENSG00000242375.1	RP11-498P14.3	-11.01	2.81e-25	1.47e-18	-0.58	-0.45	Intelligence (multi-trait analysis);	chr6:26421164	chr9:97195351~97197687:-
LUAD	trans	rs12709013	0.792	rs1646289	ENSG00000233719.3	GOT2P3	11	2.82e-25	1.47e-18	0.54	0.45	Blood metabolite ratios;	chr16:58755689	chr12:9641802~9643007:+
LUAD	trans	rs877636	0.692	rs2271194	ENSG00000242970.2	AC068522.4	-11	2.83e-25	1.47e-18	-0.52	-0.45	Cognitive function;	chr12:56083910	chr8:58588420~58588764:-
LUAD	trans	rs9876781	1	rs6442123	ENSG00000235912.1	RP1-159A19.3	-11	2.94e-25	1.53e-18	-0.46	-0.45	Longevity;	chr3:48458887	chr1:27649419~27649610:+
LUAD	trans	rs13190036	0.551	rs9313751	ENSG00000217325.2	PRELID1P1	-11	3.01e-25	1.57e-18	-0.65	-0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177217174	chr6:126643488~126644390:+
LUAD	trans	rs7937890	0.904	rs7484197	ENSG00000236360.2	RP11-334A14.2	11	3.03e-25	1.58e-18	0.56	0.45	Mitochondrial DNA levels;	chr11:14262108	chr1:52993201~52993702:-
LUAD	trans	rs916888	0.773	rs538628	ENSG00000280022.1	RP11-707O23.1	10.99	3.1e-25	1.61e-18	0.67	0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45592621~45593369:+
LUAD	trans	rs4276421	0.935	rs4502836	ENSG00000231752.4	EMBP1	10.99	3.11e-25	1.62e-18	0.6	0.45	P wave duration;	chr5:45956617	chr1:121519112~121571892:+
LUAD	trans	rs12709013	0.792	rs1657170	ENSG00000233719.3	GOT2P3	10.99	3.18e-25	1.66e-18	0.54	0.45	Blood metabolite ratios;	chr16:58752082	chr12:9641802~9643007:+
LUAD	trans	rs4276421	0.934	rs7443410	ENSG00000231752.4	EMBP1	10.99	3.2e-25	1.66e-18	0.6	0.45	P wave duration;	chr5:45960831	chr1:121519112~121571892:+
LUAD	trans	rs867371	1	rs8037224	ENSG00000235370.6	DNM1P51	-10.99	3.24e-25	1.69e-18	-0.52	-0.45	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82172189	chr15:84398316~84411701:-
LUAD	trans	rs867371	1	rs1501372	ENSG00000235370.6	DNM1P51	-10.98	3.41e-25	1.77e-18	-0.52	-0.45	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176114	chr15:84398316~84411701:-
LUAD	trans	rs867371	1	rs1846911	ENSG00000235370.6	DNM1P51	-10.98	3.41e-25	1.77e-18	-0.52	-0.45	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176309	chr15:84398316~84411701:-
LUAD	trans	rs916888	0.647	rs199523	ENSG00000264070.1	DND1P1	-10.98	3.42e-25	1.78e-18	-0.58	-0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:45585871~45586929:+
LUAD	trans	rs4276421	0.901	rs7447717	ENSG00000231752.4	EMBP1	-10.98	3.56e-25	1.85e-18	-0.59	-0.45	P wave duration;	chr5:45770150	chr1:121519112~121571892:+
LUAD	trans	rs877636	0.692	rs2271194	ENSG00000234354.3	RPS26P47	-10.97	3.69e-25	1.91e-18	-0.49	-0.45	Cognitive function;	chr12:56083910	chr13:100539901~100540248:-
LUAD	trans	rs877636	0.692	rs10876870	ENSG00000234354.3	RPS26P47	-10.97	3.77e-25	1.96e-18	-0.48	-0.45	Cognitive function;	chr12:56084218	chr13:100539901~100540248:-
LUAD	trans	rs877636	0.692	rs7971751	ENSG00000234354.3	RPS26P47	-10.97	3.77e-25	1.96e-18	-0.48	-0.45	Cognitive function;	chr12:56084874	chr13:100539901~100540248:-
LUAD	trans	rs11098499	0.913	rs67073020	ENSG00000275858.1	RP11-291L22.8	10.97	3.84e-25	1.99e-18	0.55	0.45	Corneal astigmatism;	chr4:119231402	chr10:38450738~38451069:-
LUAD	trans	rs7937890	0.904	rs67623158	ENSG00000236360.2	RP11-334A14.2	-10.97	3.93e-25	2.04e-18	-0.55	-0.45	Mitochondrial DNA levels;	chr11:14273650	chr1:52993201~52993702:-
LUAD	trans	rs9876781	1	rs1563736	ENSG00000235912.1	RP1-159A19.3	-10.97	3.95e-25	2.05e-18	-0.47	-0.45	Longevity;	chr3:48395329	chr1:27649419~27649610:+
LUAD	trans	rs9876781	1	rs28824259	ENSG00000235912.1	RP1-159A19.3	-10.96	4.01e-25	2.08e-18	-0.47	-0.45	Longevity;	chr3:48384185	chr1:27649419~27649610:+
LUAD	trans	rs9876781	1	rs12487542	ENSG00000235912.1	RP1-159A19.3	-10.96	4.01e-25	2.08e-18	-0.47	-0.45	Longevity;	chr3:48384586	chr1:27649419~27649610:+
LUAD	trans	rs9876781	1	rs73074358	ENSG00000235912.1	RP1-159A19.3	-10.96	4.01e-25	2.08e-18	-0.47	-0.45	Longevity;	chr3:48385757	chr1:27649419~27649610:+
LUAD	trans	rs9876781	0.967	rs34761139	ENSG00000235912.1	RP1-159A19.3	-10.96	4.01e-25	2.08e-18	-0.47	-0.45	Longevity;	chr3:48386489	chr1:27649419~27649610:+
LUAD	trans	rs9876781	0.868	rs9875280	ENSG00000235912.1	RP1-159A19.3	-10.96	4.01e-25	2.08e-18	-0.47	-0.45	Longevity;	chr3:48387420	chr1:27649419~27649610:+
LUAD	trans	rs9876781	1	rs6796491	ENSG00000235912.1	RP1-159A19.3	-10.96	4.01e-25	2.08e-18	-0.47	-0.45	Longevity;	chr3:48388977	chr1:27649419~27649610:+
LUAD	trans	rs9876781	1	rs9826195	ENSG00000235912.1	RP1-159A19.3	-10.96	4.01e-25	2.08e-18	-0.47	-0.45	Longevity;	chr3:48392157	chr1:27649419~27649610:+
LUAD	trans	rs9876781	0.967	rs9864815	ENSG00000235912.1	RP1-159A19.3	-10.96	4.01e-25	2.08e-18	-0.47	-0.45	Longevity;	chr3:48392588	chr1:27649419~27649610:+
LUAD	trans	rs9876781	1	rs9809843	ENSG00000235912.1	RP1-159A19.3	-10.96	4.01e-25	2.08e-18	-0.47	-0.45	Longevity;	chr3:48392923	chr1:27649419~27649610:+
LUAD	trans	rs3749237	1	rs2307021	ENSG00000197582.5	GPX1P1	10.96	4.07e-25	2.11e-18	0.63	0.45	Resting heart rate;	chr3:49728050	chrX:13378735~13379340:-
LUAD	trans	rs3749237	0.964	rs2352967	ENSG00000197582.5	GPX1P1	10.96	4.31e-25	2.23e-18	0.63	0.45	Resting heart rate;	chr3:49834208	chrX:13378735~13379340:-
LUAD	trans	rs7121616	0.515	rs11218966	ENSG00000234176.1	HSPA8P1	10.95	4.38e-25	2.27e-18	0.7	0.45	Breast cancer;	chr11:123086510	chrX:121203182~121205014:-
LUAD	trans	rs12709013	0.766	rs12599331	ENSG00000230849.2	GOT2P2	10.95	4.53e-25	2.34e-18	0.55	0.45	Blood metabolite ratios;	chr16:58805307	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.792	rs1646289	ENSG00000230849.2	GOT2P2	10.95	4.57e-25	2.36e-18	0.55	0.45	Blood metabolite ratios;	chr16:58755689	chr1:173141100~173142350:-
LUAD	trans	rs867371	1	rs11855089	ENSG00000235370.6	DNM1P51	-10.95	4.72e-25	2.43e-18	-0.52	-0.45	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82154924	chr15:84398316~84411701:-
LUAD	trans	rs12709013	0.792	rs11644344	ENSG00000230849.2	GOT2P2	10.95	4.77e-25	2.46e-18	0.55	0.45	Blood metabolite ratios;	chr16:58803080	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.792	rs11649387	ENSG00000230849.2	GOT2P2	10.95	4.77e-25	2.46e-18	0.55	0.45	Blood metabolite ratios;	chr16:58803176	chr1:173141100~173142350:-
LUAD	trans	rs9876781	1	rs2242150	ENSG00000235912.1	RP1-159A19.3	10.94	4.98e-25	2.56e-18	0.46	0.45	Longevity;	chr3:48464565	chr1:27649419~27649610:+
LUAD	trans	rs12709013	0.792	rs12935488	ENSG00000233719.3	GOT2P3	10.94	5e-25	2.58e-18	0.54	0.45	Blood metabolite ratios;	chr16:58766320	chr12:9641802~9643007:+
LUAD	trans	rs9611519	0.857	rs4820434	ENSG00000268568.1	AC007228.9	-10.94	5.05e-25	2.6e-18	-0.62	-0.45	Neuroticism;	chr22:41241115	chr19:56672574~56673901:-
LUAD	trans	rs867371	0.896	rs8033831	ENSG00000235370.6	DNM1P51	-10.94	5.21e-25	2.68e-18	-0.52	-0.45	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82220953	chr15:84398316~84411701:-
LUAD	trans	rs7554547	0.69	rs6669571	ENSG00000261819.1	RP11-680G24.4	10.93	5.27e-25	2.71e-18	0.59	0.45	Nonsyndromic cleft lip with cleft palate;	chr1:11887253	chr16:14988259~14990160:-
LUAD	trans	rs7554547	0.69	rs1474576	ENSG00000261819.1	RP11-680G24.4	10.93	5.27e-25	2.71e-18	0.59	0.45	Nonsyndromic cleft lip with cleft palate;	chr1:11887572	chr16:14988259~14990160:-
LUAD	trans	rs7554547	0.69	rs1474577	ENSG00000261819.1	RP11-680G24.4	10.93	5.27e-25	2.71e-18	0.59	0.45	Nonsyndromic cleft lip with cleft palate;	chr1:11887712	chr16:14988259~14990160:-
LUAD	trans	rs12709013	0.792	rs12325054	ENSG00000233719.3	GOT2P3	10.93	5.29e-25	2.72e-18	0.53	0.45	Blood metabolite ratios;	chr16:58749804	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.792	rs1646276	ENSG00000233719.3	GOT2P3	10.93	5.34e-25	2.74e-18	0.53	0.45	Blood metabolite ratios;	chr16:58749654	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.792	rs1646277	ENSG00000233719.3	GOT2P3	10.93	5.34e-25	2.74e-18	0.53	0.45	Blood metabolite ratios;	chr16:58750037	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.792	rs62066815	ENSG00000233719.3	GOT2P3	10.93	5.34e-25	2.74e-18	0.53	0.45	Blood metabolite ratios;	chr16:58751577	chr12:9641802~9643007:+
LUAD	trans	rs13190036	0.786	rs10068127	ENSG00000226986.4	RP11-543B16.2	-10.93	5.43e-25	2.79e-18	-0.69	-0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177204786	chr1:211207239~211207897:+
LUAD	trans	rs12709013	0.755	rs1628029	ENSG00000230849.2	GOT2P2	10.93	5.45e-25	2.8e-18	0.55	0.45	Blood metabolite ratios;	chr16:58763846	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.766	rs1657175	ENSG00000233719.3	GOT2P3	10.93	5.48e-25	2.82e-18	0.53	0.45	Blood metabolite ratios;	chr16:58755527	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.792	rs1646290	ENSG00000233719.3	GOT2P3	10.93	5.48e-25	2.82e-18	0.53	0.45	Blood metabolite ratios;	chr16:58755807	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.792	rs1364346	ENSG00000233719.3	GOT2P3	10.93	5.48e-25	2.82e-18	0.53	0.45	Blood metabolite ratios;	chr16:58756420	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.792	rs257626	ENSG00000233719.3	GOT2P3	10.93	5.48e-25	2.82e-18	0.53	0.45	Blood metabolite ratios;	chr16:58759574	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.792	rs257625	ENSG00000233719.3	GOT2P3	10.93	5.48e-25	2.82e-18	0.53	0.45	Blood metabolite ratios;	chr16:58759978	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.792	rs1646262	ENSG00000233719.3	GOT2P3	10.93	5.48e-25	2.82e-18	0.53	0.45	Blood metabolite ratios;	chr16:58760593	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.792	rs257623	ENSG00000233719.3	GOT2P3	10.93	5.48e-25	2.82e-18	0.53	0.45	Blood metabolite ratios;	chr16:58761247	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.693	rs1627257	ENSG00000233719.3	GOT2P3	10.93	5.48e-25	2.82e-18	0.53	0.45	Blood metabolite ratios;	chr16:58763764	chr12:9641802~9643007:+
LUAD	trans	rs867371	1	rs1174543	ENSG00000235370.6	DNM1P51	10.93	5.54e-25	2.85e-18	0.52	0.45	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82155732	chr15:84398316~84411701:-
LUAD	trans	rs13190036	0.551	rs11957608	ENSG00000217325.2	PRELID1P1	-10.93	5.6e-25	2.87e-18	-0.65	-0.45	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228344	chr6:126643488~126644390:+
LUAD	trans	rs12709013	0.792	rs12595974	ENSG00000233719.3	GOT2P3	10.93	5.61e-25	2.88e-18	0.53	0.45	Blood metabolite ratios;	chr16:58769132	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.792	rs1836877	ENSG00000233719.3	GOT2P3	10.93	5.61e-25	2.88e-18	0.53	0.45	Blood metabolite ratios;	chr16:58769821	chr12:9641802~9643007:+
LUAD	trans	rs11098499	1	rs1011054	ENSG00000275858.1	RP11-291L22.8	-10.93	5.62e-25	2.88e-18	-0.54	-0.45	Corneal astigmatism;	chr4:119281232	chr10:38450738~38451069:-
LUAD	trans	rs12709013	0.792	rs12926512	ENSG00000233719.3	GOT2P3	10.93	5.65e-25	2.89e-18	0.53	0.45	Blood metabolite ratios;	chr16:58768317	chr12:9641802~9643007:+
LUAD	trans	rs1816752	0.669	rs2862906	ENSG00000224976.2	PARP4P2	10.92	5.78e-25	2.96e-18	0.51	0.45	Obesity-related traits;	chr13:24494482	chr13:19349137~19407962:+
LUAD	trans	rs9876781	0.933	rs6442124	ENSG00000235912.1	RP1-159A19.3	-10.92	5.81e-25	2.98e-18	-0.46	-0.45	Longevity;	chr3:48463903	chr1:27649419~27649610:+
LUAD	trans	rs916888	0.647	rs199524	ENSG00000264070.1	DND1P1	-10.92	5.9e-25	3.02e-18	-0.57	-0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:45585871~45586929:+
LUAD	trans	rs1816752	0.524	rs1965154	ENSG00000237917.1	PARP4P1	-10.92	5.94e-25	3.04e-18	-0.56	-0.45	Obesity-related traits;	chr13:24498062	chrY:26594851~26634652:-
LUAD	trans	rs55665837	0.52	rs10766189	ENSG00000236360.2	RP11-334A14.2	10.92	6.15e-25	3.15e-18	0.59	0.45	Vitamin D levels;	chr11:14712377	chr1:52993201~52993702:-
LUAD	trans	rs4276421	0.87	rs4257782	ENSG00000231752.4	EMBP1	10.92	6.18e-25	3.16e-18	0.58	0.45	P wave duration;	chr5:45750292	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.967	rs10941703	ENSG00000231752.4	EMBP1	-10.91	6.33e-25	3.24e-18	-0.58	-0.45	P wave duration;	chr5:45781770	chr1:121519112~121571892:+
LUAD	trans	rs9876781	0.967	rs2885509	ENSG00000235912.1	RP1-159A19.3	10.91	6.64e-25	3.39e-18	0.47	0.45	Longevity;	chr3:48376729	chr1:27649419~27649610:+
LUAD	trans	rs916888	0.821	rs70600	ENSG00000280022.1	RP11-707O23.1	10.91	6.7e-25	3.42e-18	0.67	0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45592621~45593369:+
LUAD	trans	rs9467773	0.901	rs1407045	ENSG00000242375.1	RP11-498P14.3	10.91	6.74e-25	3.44e-18	0.57	0.45	Intelligence (multi-trait analysis);	chr6:26475927	chr9:97195351~97197687:-
LUAD	trans	rs9876781	1	rs13071337	ENSG00000235912.1	RP1-159A19.3	-10.91	6.79e-25	3.47e-18	-0.46	-0.45	Longevity;	chr3:48396724	chr1:27649419~27649610:+
LUAD	trans	rs877636	0.692	rs11171739	ENSG00000227887.1	RPS26P13	10.9	6.85e-25	3.5e-18	0.49	0.45	Cognitive function;	chr12:56076841	chr1:208697369~208697698:-
LUAD	trans	rs12709013	0.766	rs11648511	ENSG00000230849.2	GOT2P2	10.9	7.11e-25	3.63e-18	0.54	0.45	Blood metabolite ratios;	chr16:58798171	chr1:173141100~173142350:-
LUAD	trans	rs9876781	1	rs6442119	ENSG00000235912.1	RP1-159A19.3	-10.89	7.45e-25	3.8e-18	-0.46	-0.44	Longevity;	chr3:48398713	chr1:27649419~27649610:+
LUAD	trans	rs9611519	0.78	rs2284079	ENSG00000268568.1	AC007228.9	-10.89	7.58e-25	3.86e-18	-0.59	-0.44	Neuroticism;	chr22:41262628	chr19:56672574~56673901:-
LUAD	trans	rs4276421	0.901	rs4455566	ENSG00000231752.4	EMBP1	10.89	7.64e-25	3.89e-18	0.58	0.44	P wave duration;	chr5:45752760	chr1:121519112~121571892:+
LUAD	trans	rs9876781	1	rs922075	ENSG00000235912.1	RP1-159A19.3	10.89	7.84e-25	3.99e-18	0.47	0.44	Longevity;	chr3:48447994	chr1:27649419~27649610:+
LUAD	trans	rs9876781	1	rs2045554	ENSG00000235912.1	RP1-159A19.3	10.89	7.84e-25	3.99e-18	0.47	0.44	Longevity;	chr3:48453142	chr1:27649419~27649610:+
LUAD	trans	rs616147	0.816	rs1768190	ENSG00000183298.5	RP11-556K13.1	10.89	7.91e-25	4.03e-18	0.6	0.44	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39467949	chr1:101786340~101787219:-
LUAD	trans	rs867371	1	rs7166570	ENSG00000235370.6	DNM1P51	-10.89	7.99e-25	4.07e-18	-0.51	-0.44	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173880	chr15:84398316~84411701:-
LUAD	trans	rs10037055	0.636	rs13166688	ENSG00000217325.2	PRELID1P1	-10.88	8.2e-25	4.17e-18	-0.65	-0.44	Migraine without aura;	chr5:177156965	chr6:126643488~126644390:+
LUAD	trans	rs7937890	0.904	rs11023169	ENSG00000236360.2	RP11-334A14.2	-10.88	8.25e-25	4.2e-18	-0.55	-0.44	Mitochondrial DNA levels;	chr11:14269439	chr1:52993201~52993702:-
LUAD	trans	rs4276421	0.638	rs4551075	ENSG00000231752.4	EMBP1	10.88	8.3e-25	4.22e-18	0.58	0.44	P wave duration;	chr5:46011710	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.901	rs9687260	ENSG00000231752.4	EMBP1	10.88	8.41e-25	4.28e-18	0.58	0.44	P wave duration;	chr5:45759774	chr1:121519112~121571892:+
LUAD	trans	rs7554547	0.69	rs6667637	ENSG00000261819.1	RP11-680G24.4	10.88	8.49e-25	4.32e-18	0.58	0.44	Nonsyndromic cleft lip with cleft palate;	chr1:11887900	chr16:14988259~14990160:-
LUAD	trans	rs9467773	0.869	rs1796520	ENSG00000242375.1	RP11-498P14.3	-10.88	8.53e-25	4.34e-18	-0.57	-0.44	Intelligence (multi-trait analysis);	chr6:26410572	chr9:97195351~97197687:-
LUAD	trans	rs2657294	0.965	rs7079694	ENSG00000172974.11	AC007318.5	10.88	8.67e-25	4.41e-18	0.47	0.44	Pneumonia;	chr10:75136804	chr2:65205108~65205988:+
LUAD	trans	rs2657294	0.965	rs2657285	ENSG00000172974.11	AC007318.5	10.88	8.7e-25	4.42e-18	0.47	0.44	Pneumonia;	chr10:75164166	chr2:65205108~65205988:+
LUAD	trans	rs867371	0.929	rs1045508	ENSG00000235370.6	DNM1P51	10.88	8.79e-25	4.47e-18	0.51	0.44	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82157565	chr15:84398316~84411701:-
LUAD	trans	rs9876781	0.967	rs1870444	ENSG00000235912.1	RP1-159A19.3	-10.87	9.38e-25	4.76e-18	-0.46	-0.44	Longevity;	chr3:48445369	chr1:27649419~27649610:+
LUAD	trans	rs7312770	0.637	rs705699	ENSG00000242970.2	AC068522.4	10.87	9.48e-25	4.81e-18	0.51	0.44	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr8:58588420~58588764:-
LUAD	trans	rs9611519	0.761	rs35445172	ENSG00000268568.1	AC007228.9	-10.87	9.59e-25	4.86e-18	-0.59	-0.44	Neuroticism;	chr22:41264297	chr19:56672574~56673901:-
LUAD	trans	rs11098499	0.874	rs13139045	ENSG00000275858.1	RP11-291L22.8	10.86	9.82e-25	4.98e-18	0.51	0.44	Corneal astigmatism;	chr4:119247433	chr10:38450738~38451069:-
LUAD	trans	rs2657294	0.965	rs7899946	ENSG00000172974.11	AC007318.5	10.86	9.96e-25	5.05e-18	0.47	0.44	Pneumonia;	chr10:75166013	chr2:65205108~65205988:+
LUAD	trans	rs13190036	0.551	rs11955537	ENSG00000217325.2	PRELID1P1	-10.85	1.07e-24	5.41e-18	-0.64	-0.44	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177147087	chr6:126643488~126644390:+
LUAD	trans	rs12709013	0.792	rs62064940	ENSG00000230849.2	GOT2P2	10.85	1.07e-24	5.42e-18	0.54	0.44	Blood metabolite ratios;	chr16:58796560	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.755	rs1628029	ENSG00000233719.3	GOT2P3	10.85	1.07e-24	5.44e-18	0.53	0.44	Blood metabolite ratios;	chr16:58763846	chr12:9641802~9643007:+
LUAD	trans	rs7312770	0.612	rs773114	ENSG00000235459.5	RPS26P31	10.85	1.07e-24	5.44e-18	0.48	0.44	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr7:122681315~122681662:+
LUAD	trans	rs4276421	0.967	rs7443384	ENSG00000231752.4	EMBP1	10.85	1.08e-24	5.45e-18	0.6	0.44	P wave duration;	chr5:45960791	chr1:121519112~121571892:+
LUAD	trans	rs12709013	0.792	rs12325054	ENSG00000230849.2	GOT2P2	10.85	1.14e-24	5.77e-18	0.55	0.44	Blood metabolite ratios;	chr16:58749804	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.74	rs12927495	ENSG00000230849.2	GOT2P2	10.85	1.14e-24	5.78e-18	0.55	0.44	Blood metabolite ratios;	chr16:58821934	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.792	rs1646276	ENSG00000230849.2	GOT2P2	10.85	1.14e-24	5.78e-18	0.55	0.44	Blood metabolite ratios;	chr16:58749654	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.792	rs1646277	ENSG00000230849.2	GOT2P2	10.85	1.14e-24	5.78e-18	0.55	0.44	Blood metabolite ratios;	chr16:58750037	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.792	rs62066815	ENSG00000230849.2	GOT2P2	10.85	1.14e-24	5.78e-18	0.55	0.44	Blood metabolite ratios;	chr16:58751577	chr1:173141100~173142350:-
LUAD	trans	rs9876781	1	rs6810060	ENSG00000235912.1	RP1-159A19.3	-10.85	1.15e-24	5.8e-18	-0.46	-0.44	Longevity;	chr3:48393284	chr1:27649419~27649610:+
LUAD	trans	rs9876781	1	rs6770470	ENSG00000235912.1	RP1-159A19.3	-10.85	1.15e-24	5.8e-18	-0.46	-0.44	Longevity;	chr3:48393659	chr1:27649419~27649610:+
LUAD	trans	rs2657294	0.965	rs2657291	ENSG00000172974.11	AC007318.5	10.84	1.17e-24	5.89e-18	0.47	0.44	Pneumonia;	chr10:75166945	chr2:65205108~65205988:+
LUAD	trans	rs12709013	0.766	rs1657175	ENSG00000230849.2	GOT2P2	10.84	1.18e-24	5.95e-18	0.55	0.44	Blood metabolite ratios;	chr16:58755527	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.792	rs1646290	ENSG00000230849.2	GOT2P2	10.84	1.18e-24	5.95e-18	0.55	0.44	Blood metabolite ratios;	chr16:58755807	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.792	rs1364346	ENSG00000230849.2	GOT2P2	10.84	1.18e-24	5.95e-18	0.55	0.44	Blood metabolite ratios;	chr16:58756420	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.792	rs257626	ENSG00000230849.2	GOT2P2	10.84	1.18e-24	5.95e-18	0.55	0.44	Blood metabolite ratios;	chr16:58759574	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.792	rs257625	ENSG00000230849.2	GOT2P2	10.84	1.18e-24	5.95e-18	0.55	0.44	Blood metabolite ratios;	chr16:58759978	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.792	rs1646262	ENSG00000230849.2	GOT2P2	10.84	1.18e-24	5.95e-18	0.55	0.44	Blood metabolite ratios;	chr16:58760593	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.792	rs257623	ENSG00000230849.2	GOT2P2	10.84	1.18e-24	5.95e-18	0.55	0.44	Blood metabolite ratios;	chr16:58761247	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.693	rs1627257	ENSG00000230849.2	GOT2P2	10.84	1.18e-24	5.95e-18	0.55	0.44	Blood metabolite ratios;	chr16:58763764	chr1:173141100~173142350:-
LUAD	trans	rs867371	1	rs8042464	ENSG00000235370.6	DNM1P51	-10.84	1.18e-24	5.97e-18	-0.51	-0.44	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173195	chr15:84398316~84411701:-
LUAD	trans	rs13190036	1	rs628506	ENSG00000226986.4	RP11-543B16.2	-10.84	1.19e-24	6.01e-18	-0.6	-0.44	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107422	chr1:211207239~211207897:+
LUAD	trans	rs12709013	0.792	rs12926512	ENSG00000230849.2	GOT2P2	10.84	1.22e-24	6.14e-18	0.55	0.44	Blood metabolite ratios;	chr16:58768317	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.792	rs12595974	ENSG00000230849.2	GOT2P2	10.84	1.23e-24	6.18e-18	0.55	0.44	Blood metabolite ratios;	chr16:58769132	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.792	rs1836877	ENSG00000230849.2	GOT2P2	10.84	1.23e-24	6.18e-18	0.55	0.44	Blood metabolite ratios;	chr16:58769821	chr1:173141100~173142350:-
LUAD	trans	rs4276421	0.904	rs10070596	ENSG00000231752.4	EMBP1	10.84	1.24e-24	6.26e-18	0.6	0.44	P wave duration;	chr5:46004129	chr1:121519112~121571892:+
LUAD	trans	rs9467773	0.836	rs1624440	ENSG00000242375.1	RP11-498P14.3	-10.83	1.28e-24	6.43e-18	-0.58	-0.44	Intelligence (multi-trait analysis);	chr6:26433101	chr9:97195351~97197687:-
LUAD	trans	rs12709013	0.804	rs8051459	ENSG00000230849.2	GOT2P2	10.83	1.29e-24	6.48e-18	0.54	0.44	Blood metabolite ratios;	chr16:58783436	chr1:173141100~173142350:-
LUAD	trans	rs55665837	0.54	rs10832294	ENSG00000236360.2	RP11-334A14.2	10.83	1.33e-24	6.7e-18	0.59	0.44	Vitamin D levels;	chr11:14725881	chr1:52993201~52993702:-
LUAD	trans	rs55665837	0.54	rs10219313	ENSG00000236360.2	RP11-334A14.2	10.83	1.33e-24	6.7e-18	0.59	0.44	Vitamin D levels;	chr11:14728303	chr1:52993201~52993702:-
LUAD	trans	rs55665837	0.54	rs4144487	ENSG00000236360.2	RP11-334A14.2	10.83	1.33e-24	6.7e-18	0.59	0.44	Vitamin D levels;	chr11:14728905	chr1:52993201~52993702:-
LUAD	trans	rs55665837	0.519	rs10832297	ENSG00000236360.2	RP11-334A14.2	10.83	1.33e-24	6.7e-18	0.59	0.44	Vitamin D levels;	chr11:14736191	chr1:52993201~52993702:-
LUAD	trans	rs867371	1	rs7181655	ENSG00000235370.6	DNM1P51	-10.83	1.36e-24	6.83e-18	-0.52	-0.44	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163275	chr15:84398316~84411701:-
LUAD	trans	rs867371	1	rs7180584	ENSG00000235370.6	DNM1P51	-10.83	1.36e-24	6.83e-18	-0.52	-0.44	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163493	chr15:84398316~84411701:-
LUAD	trans	rs867371	1	rs6495642	ENSG00000235370.6	DNM1P51	-10.83	1.36e-24	6.83e-18	-0.52	-0.44	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82165156	chr15:84398316~84411701:-
LUAD	trans	rs4276421	0.934	rs6451840	ENSG00000231752.4	EMBP1	10.82	1.42e-24	7.12e-18	0.58	0.44	P wave duration;	chr5:45935584	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.87	rs6451842	ENSG00000231752.4	EMBP1	10.82	1.42e-24	7.12e-18	0.58	0.44	P wave duration;	chr5:45936431	chr1:121519112~121571892:+
LUAD	trans	rs9467773	0.838	rs3734540	ENSG00000242375.1	RP11-498P14.3	10.82	1.46e-24	7.32e-18	0.58	0.44	Intelligence (multi-trait analysis);	chr6:26463093	chr9:97195351~97197687:-
LUAD	trans	rs11098499	0.913	rs12186259	ENSG00000275858.1	RP11-291L22.8	10.82	1.49e-24	7.49e-18	0.55	0.44	Corneal astigmatism;	chr4:119230884	chr10:38450738~38451069:-
LUAD	trans	rs10037055	1	rs10037055	ENSG00000217325.2	PRELID1P1	-10.81	1.51e-24	7.59e-18	-0.58	-0.44	Migraine without aura;	chr5:177264278	chr6:126643488~126644390:+
LUAD	trans	rs4276421	0.845	rs4426926	ENSG00000231752.4	EMBP1	10.81	1.54e-24	7.74e-18	0.6	0.44	P wave duration;	chr5:45994241	chr1:121519112~121571892:+
LUAD	trans	rs10908521	0.685	rs11264568	ENSG00000227183.3	HDGFP1	-10.81	1.56e-24	7.8e-18	-0.57	-0.44	Uric acid clearance;	chr1:156836077	chrX:131646639~131646890:+
LUAD	trans	rs10908521	0.685	rs11264569	ENSG00000227183.3	HDGFP1	-10.81	1.56e-24	7.8e-18	-0.57	-0.44	Uric acid clearance;	chr1:156836098	chrX:131646639~131646890:+
LUAD	trans	rs10908521	0.626	rs11264570	ENSG00000227183.3	HDGFP1	-10.81	1.56e-24	7.8e-18	-0.57	-0.44	Uric acid clearance;	chr1:156836167	chrX:131646639~131646890:+
LUAD	trans	rs9876781	1	rs3214041	ENSG00000235912.1	RP1-159A19.3	-10.81	1.56e-24	7.82e-18	-0.46	-0.44	Longevity;	chr3:48413059	chr1:27649419~27649610:+
LUAD	trans	rs4276421	0.839	rs28885449	ENSG00000231752.4	EMBP1	10.81	1.61e-24	8.05e-18	0.6	0.44	P wave duration;	chr5:45994103	chr1:121519112~121571892:+
LUAD	trans	rs12709013	0.729	rs34324769	ENSG00000230849.2	GOT2P2	10.81	1.62e-24	8.14e-18	0.54	0.44	Blood metabolite ratios;	chr16:58778131	chr1:173141100~173142350:-
LUAD	trans	rs55665837	0.54	rs10128681	ENSG00000236360.2	RP11-334A14.2	10.8	1.67e-24	8.35e-18	0.59	0.44	Vitamin D levels;	chr11:14680030	chr1:52993201~52993702:-
LUAD	trans	rs55665837	0.54	rs7938266	ENSG00000236360.2	RP11-334A14.2	10.8	1.67e-24	8.35e-18	0.59	0.44	Vitamin D levels;	chr11:14687778	chr1:52993201~52993702:-
LUAD	trans	rs9876781	1	rs6804774	ENSG00000235912.1	RP1-159A19.3	-10.8	1.73e-24	8.66e-18	-0.46	-0.44	Longevity;	chr3:48389129	chr1:27649419~27649610:+
LUAD	trans	rs12709013	0.792	rs12325510	ENSG00000233719.3	GOT2P3	10.8	1.74e-24	8.68e-18	0.53	0.44	Blood metabolite ratios;	chr16:58749707	chr12:9641802~9643007:+
LUAD	trans	rs11098499	0.913	rs68128210	ENSG00000275858.1	RP11-291L22.8	10.8	1.75e-24	8.73e-18	0.55	0.44	Corneal astigmatism;	chr4:119216664	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.913	rs13126596	ENSG00000275858.1	RP11-291L22.8	10.8	1.75e-24	8.73e-18	0.55	0.44	Corneal astigmatism;	chr4:119219574	chr10:38450738~38451069:-
LUAD	trans	rs12709013	0.792	rs62064901	ENSG00000230849.2	GOT2P2	10.8	1.79e-24	8.93e-18	0.54	0.44	Blood metabolite ratios;	chr16:58776758	chr1:173141100~173142350:-
LUAD	trans	rs9611519	0.808	rs5751074	ENSG00000268568.1	AC007228.9	-10.79	1.81e-24	9.04e-18	-0.59	-0.44	Neuroticism;	chr22:41269718	chr19:56672574~56673901:-
LUAD	trans	rs9876781	1	rs2885510	ENSG00000235912.1	RP1-159A19.3	10.79	1.82e-24	9.07e-18	0.46	0.44	Longevity;	chr3:48376736	chr1:27649419~27649610:+
LUAD	trans	rs9876781	1	rs725309	ENSG00000235912.1	RP1-159A19.3	10.79	1.82e-24	9.07e-18	0.46	0.44	Longevity;	chr3:48377218	chr1:27649419~27649610:+
LUAD	trans	rs1816752	0.716	rs1539096	ENSG00000224976.2	PARP4P2	10.79	1.84e-24	9.16e-18	0.51	0.44	Obesity-related traits;	chr13:24501721	chr13:19349137~19407962:+
LUAD	trans	rs12709013	0.792	rs62066381	ENSG00000230849.2	GOT2P2	10.79	1.84e-24	9.2e-18	0.55	0.44	Blood metabolite ratios;	chr16:58807981	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.792	rs8049572	ENSG00000230849.2	GOT2P2	10.79	1.84e-24	9.2e-18	0.55	0.44	Blood metabolite ratios;	chr16:58809672	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.766	rs34438483	ENSG00000230849.2	GOT2P2	10.79	1.84e-24	9.2e-18	0.55	0.44	Blood metabolite ratios;	chr16:58810530	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.792	rs36098613	ENSG00000230849.2	GOT2P2	10.79	1.84e-24	9.2e-18	0.55	0.44	Blood metabolite ratios;	chr16:58810562	chr1:173141100~173142350:-
LUAD	trans	rs11098499	0.863	rs17050695	ENSG00000275858.1	RP11-291L22.8	10.79	1.93e-24	9.65e-18	0.54	0.44	Corneal astigmatism;	chr4:119568372	chr10:38450738~38451069:-
LUAD	trans	rs12709013	0.792	rs12928733	ENSG00000230849.2	GOT2P2	10.78	2.07e-24	1.03e-17	0.55	0.44	Blood metabolite ratios;	chr16:58807216	chr1:173141100~173142350:-
LUAD	trans	rs6708331	1	rs10195155	ENSG00000232654.1	FAM136BP	10.78	2.07e-24	1.03e-17	0.61	0.44	Obesity-related traits;	chr2:70127343	chr6:3045384~3045800:+
LUAD	trans	rs61990749	0.511	rs10130790	ENSG00000235400.1	RP4-641G12.4	10.78	2.08e-24	1.04e-17	0.76	0.44	Fibroblast growth factor basic levels;	chr14:77857849	chr1:78749073~78750659:+
LUAD	trans	rs61990749	0.511	rs10146144	ENSG00000235400.1	RP4-641G12.4	10.78	2.08e-24	1.04e-17	0.76	0.44	Fibroblast growth factor basic levels;	chr14:77858957	chr1:78749073~78750659:+
LUAD	trans	rs3749237	0.964	rs1799845	ENSG00000197582.5	GPX1P1	10.78	2.09e-24	1.04e-17	0.62	0.44	Resting heart rate;	chr3:49810190	chrX:13378735~13379340:-
LUAD	trans	rs4276421	0.81	rs10213756	ENSG00000231752.4	EMBP1	10.78	2.13e-24	1.06e-17	0.6	0.44	P wave duration;	chr5:45952498	chr1:121519112~121571892:+
LUAD	trans	rs9876781	1	rs898225	ENSG00000235912.1	RP1-159A19.3	10.77	2.15e-24	1.07e-17	0.46	0.44	Longevity;	chr3:48371689	chr1:27649419~27649610:+
LUAD	trans	rs11098499	0.604	rs2389882	ENSG00000275858.1	RP11-291L22.8	10.77	2.16e-24	1.08e-17	0.54	0.44	Corneal astigmatism;	chr4:119645578	chr10:38450738~38451069:-
LUAD	trans	rs7312770	0.637	rs705700	ENSG00000242970.2	AC068522.4	10.77	2.22e-24	1.1e-17	0.51	0.44	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr8:58588420~58588764:-
LUAD	trans	rs11098499	0.954	rs11098524	ENSG00000275858.1	RP11-291L22.8	10.77	2.24e-24	1.12e-17	0.55	0.44	Corneal astigmatism;	chr4:119468877	chr10:38450738~38451069:-
LUAD	trans	rs55665837	0.54	rs11023302	ENSG00000236360.2	RP11-334A14.2	10.77	2.27e-24	1.13e-17	0.59	0.44	Vitamin D levels;	chr11:14672389	chr1:52993201~52993702:-
LUAD	trans	rs9876781	1	rs7653691	ENSG00000235912.1	RP1-159A19.3	10.77	2.28e-24	1.14e-17	0.46	0.44	Longevity;	chr3:48378199	chr1:27649419~27649610:+
LUAD	trans	rs9467773	0.869	rs742090	ENSG00000242375.1	RP11-498P14.3	-10.76	2.34e-24	1.16e-17	-0.57	-0.44	Intelligence (multi-trait analysis);	chr6:26415409	chr9:97195351~97197687:-
LUAD	trans	rs12709013	0.792	rs1657170	ENSG00000230849.2	GOT2P2	10.76	2.43e-24	1.21e-17	0.54	0.44	Blood metabolite ratios;	chr16:58752082	chr1:173141100~173142350:-
LUAD	trans	rs7312770	1	rs7312770	ENSG00000235459.5	RPS26P31	-10.76	2.49e-24	1.24e-17	-0.46	-0.44	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr7:122681315~122681662:+
LUAD	trans	rs12709013	0.792	rs12935488	ENSG00000230849.2	GOT2P2	10.76	2.54e-24	1.26e-17	0.55	0.44	Blood metabolite ratios;	chr16:58766320	chr1:173141100~173142350:-
LUAD	trans	rs4276421	0.869	rs6451812	ENSG00000231752.4	EMBP1	10.75	2.66e-24	1.32e-17	0.58	0.44	P wave duration;	chr5:45692206	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.874	rs28452522	ENSG00000275858.1	RP11-291L22.8	10.75	2.72e-24	1.35e-17	0.55	0.44	Corneal astigmatism;	chr4:119189629	chr10:38450738~38451069:-
LUAD	trans	rs9876781	1	rs725310	ENSG00000235912.1	RP1-159A19.3	10.75	2.72e-24	1.35e-17	0.46	0.44	Longevity;	chr3:48377081	chr1:27649419~27649610:+
LUAD	trans	rs55665837	0.54	rs4757261	ENSG00000236360.2	RP11-334A14.2	10.75	2.74e-24	1.36e-17	0.59	0.44	Vitamin D levels;	chr11:14648256	chr1:52993201~52993702:-
LUAD	trans	rs4276421	0.87	rs7706116	ENSG00000231752.4	EMBP1	10.74	2.81e-24	1.39e-17	0.58	0.44	P wave duration;	chr5:45742522	chr1:121519112~121571892:+
LUAD	trans	rs4606360	1	rs4606360	ENSG00000213331.4	RP11-713C19.2	10.74	2.83e-24	1.4e-17	0.52	0.44	Subjective well-being;	chr1:173729868	chr4:187970273~187971284:+
LUAD	trans	rs9425766	0.511	rs10912676	ENSG00000213331.4	RP11-713C19.2	10.74	2.87e-24	1.42e-17	0.52	0.44	Life satisfaction;	chr1:173740477	chr4:187970273~187971284:+
LUAD	trans	rs7937890	0.874	rs2303972	ENSG00000236360.2	RP11-334A14.2	-10.74	2.94e-24	1.46e-17	-0.54	-0.44	Mitochondrial DNA levels;	chr11:14281736	chr1:52993201~52993702:-
LUAD	trans	rs877636	1	rs877636	ENSG00000243403.1	RP11-330L19.1	-10.74	3.02e-24	1.49e-17	-0.47	-0.44	Cognitive function;	chr12:56086799	chr15:64592979~64593326:+
LUAD	trans	rs4276421	0.869	rs7705696	ENSG00000231752.4	EMBP1	10.73	3.07e-24	1.52e-17	0.58	0.44	P wave duration;	chr5:45712387	chr1:121519112~121571892:+
LUAD	trans	rs7554547	0.714	rs6671723	ENSG00000261819.1	RP11-680G24.4	10.73	3.1e-24	1.53e-17	0.6	0.44	Nonsyndromic cleft lip with cleft palate;	chr1:11908021	chr16:14988259~14990160:-
LUAD	trans	rs9876781	1	rs9876781	ENSG00000235912.1	RP1-159A19.3	-10.73	3.16e-24	1.56e-17	-0.45	-0.44	Longevity;	chr3:48445934	chr1:27649419~27649610:+
LUAD	trans	rs12709013	0.792	rs7185513	ENSG00000230849.2	GOT2P2	10.73	3.18e-24	1.57e-17	0.53	0.44	Blood metabolite ratios;	chr16:58794889	chr1:173141100~173142350:-
LUAD	trans	rs877636	0.669	rs7297175	ENSG00000212994.5	RPS26P6	-10.73	3.2e-24	1.58e-17	-0.5	-0.44	Cognitive function;	chr12:56080024	chr8:100895771~100896118:+
LUAD	trans	rs4276421	0.556	rs10213679	ENSG00000231752.4	EMBP1	10.73	3.26e-24	1.61e-17	0.59	0.44	P wave duration;	chr5:45954206	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.904	rs4289566	ENSG00000231752.4	EMBP1	10.73	3.26e-24	1.61e-17	0.59	0.44	P wave duration;	chr5:45955499	chr1:121519112~121571892:+
LUAD	trans	rs9876781	1	rs6442118	ENSG00000235912.1	RP1-159A19.3	-10.72	3.42e-24	1.68e-17	-0.46	-0.44	Longevity;	chr3:48398582	chr1:27649419~27649610:+
LUAD	trans	rs4276421	0.869	rs13187565	ENSG00000231752.4	EMBP1	10.72	3.44e-24	1.69e-17	0.58	0.44	P wave duration;	chr5:45707436	chr1:121519112~121571892:+
LUAD	trans	rs9611519	0.78	rs2235850	ENSG00000268568.1	AC007228.9	-10.72	3.45e-24	1.7e-17	-0.58	-0.44	Neuroticism;	chr22:41261622	chr19:56672574~56673901:-
LUAD	trans	rs3779195	0.929	rs4268041	ENSG00000225169.1	BRI3P1	-10.72	3.45e-24	1.7e-17	-0.64	-0.44	Sex hormone-binding globulin levels;	chr7:98376226	chr1:100213293~100213670:+
LUAD	trans	rs10940346	0.807	rs6898102	ENSG00000231752.4	EMBP1	-10.72	3.51e-24	1.73e-17	-0.58	-0.44	Schizophrenia;	chr5:50578496	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.845	rs34040576	ENSG00000231752.4	EMBP1	10.72	3.53e-24	1.74e-17	0.59	0.44	P wave duration;	chr5:46005596	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.904	rs13360955	ENSG00000231752.4	EMBP1	10.72	3.53e-24	1.74e-17	0.59	0.44	P wave duration;	chr5:46005842	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.913	rs56122576	ENSG00000275858.1	RP11-291L22.8	10.72	3.54e-24	1.74e-17	0.55	0.44	Corneal astigmatism;	chr4:119208181	chr10:38450738~38451069:-
LUAD	trans	rs4276421	0.837	rs10078625	ENSG00000231752.4	EMBP1	10.72	3.58e-24	1.76e-17	0.58	0.44	P wave duration;	chr5:45707015	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.901	rs35381866	ENSG00000231752.4	EMBP1	10.71	3.61e-24	1.77e-17	0.58	0.44	P wave duration;	chr5:45690085	chr1:121519112~121571892:+
LUAD	trans	rs2657294	0.965	rs2395140	ENSG00000172974.11	AC007318.5	10.71	3.63e-24	1.78e-17	0.47	0.44	Pneumonia;	chr10:75139253	chr2:65205108~65205988:+
LUAD	trans	rs2657294	0.965	rs2997754	ENSG00000172974.11	AC007318.5	10.71	3.63e-24	1.78e-17	0.47	0.44	Pneumonia;	chr10:75144379	chr2:65205108~65205988:+
LUAD	trans	rs2657294	0.965	rs2047951	ENSG00000172974.11	AC007318.5	10.71	3.63e-24	1.78e-17	0.47	0.44	Pneumonia;	chr10:75161310	chr2:65205108~65205988:+
LUAD	trans	rs2657294	0.965	rs2804523	ENSG00000172974.11	AC007318.5	10.71	3.63e-24	1.78e-17	0.47	0.44	Pneumonia;	chr10:75161584	chr2:65205108~65205988:+
LUAD	trans	rs867371	1	rs13380317	ENSG00000235370.6	DNM1P51	10.71	3.63e-24	1.79e-17	0.5	0.44	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214449	chr15:84398316~84411701:-
LUAD	trans	rs4276421	0.776	rs10473392	ENSG00000231752.4	EMBP1	10.71	3.65e-24	1.79e-17	0.58	0.44	P wave duration;	chr5:45709959	chr1:121519112~121571892:+
LUAD	trans	rs55665837	0.519	rs1451677	ENSG00000236360.2	RP11-334A14.2	10.71	3.72e-24	1.83e-17	0.59	0.44	Vitamin D levels;	chr11:14724466	chr1:52993201~52993702:-
LUAD	trans	rs12709013	0.792	rs12325510	ENSG00000230849.2	GOT2P2	10.71	3.73e-24	1.83e-17	0.54	0.44	Blood metabolite ratios;	chr16:58749707	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.792	rs12598527	ENSG00000230849.2	GOT2P2	10.71	3.76e-24	1.84e-17	0.54	0.44	Blood metabolite ratios;	chr16:58772987	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.792	rs12600201	ENSG00000230849.2	GOT2P2	10.71	3.76e-24	1.84e-17	0.54	0.44	Blood metabolite ratios;	chr16:58773132	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.792	rs12600206	ENSG00000230849.2	GOT2P2	10.71	3.76e-24	1.84e-17	0.54	0.44	Blood metabolite ratios;	chr16:58773169	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.792	rs11076263	ENSG00000230849.2	GOT2P2	10.71	3.76e-24	1.84e-17	0.54	0.44	Blood metabolite ratios;	chr16:58773295	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.792	rs11646756	ENSG00000230849.2	GOT2P2	10.71	3.76e-24	1.84e-17	0.54	0.44	Blood metabolite ratios;	chr16:58773598	chr1:173141100~173142350:-
LUAD	trans	rs4276421	0.935	rs4473777	ENSG00000231752.4	EMBP1	10.71	3.78e-24	1.86e-17	0.59	0.44	P wave duration;	chr5:45968760	chr1:121519112~121571892:+
LUAD	trans	rs3749237	0.964	rs13084243	ENSG00000197582.5	GPX1P1	10.7	4.1e-24	2.01e-17	0.61	0.44	Resting heart rate;	chr3:49784445	chrX:13378735~13379340:-
LUAD	trans	rs3749237	1	rs11920900	ENSG00000197582.5	GPX1P1	10.7	4.1e-24	2.01e-17	0.61	0.44	Resting heart rate;	chr3:49785591	chrX:13378735~13379340:-
LUAD	trans	rs2657294	0.965	rs4746270	ENSG00000172974.11	AC007318.5	10.7	4.13e-24	2.03e-17	0.47	0.44	Pneumonia;	chr10:75185189	chr2:65205108~65205988:+
LUAD	trans	rs2657294	0.931	rs2804522	ENSG00000172974.11	AC007318.5	10.7	4.14e-24	2.03e-17	0.46	0.44	Pneumonia;	chr10:75159132	chr2:65205108~65205988:+
LUAD	trans	rs2657294	0.965	rs10824285	ENSG00000172974.11	AC007318.5	10.7	4.16e-24	2.04e-17	0.47	0.44	Pneumonia;	chr10:75153271	chr2:65205108~65205988:+
LUAD	trans	rs7312770	0.612	rs1873914	ENSG00000242970.2	AC068522.4	10.7	4.25e-24	2.08e-17	0.51	0.44	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr8:58588420~58588764:-
LUAD	trans	rs74781061	0.932	rs11072496	ENSG00000227288.3	RP5-837I24.1	10.69	4.35e-24	2.13e-17	0.63	0.44	Endometriosis;	chr15:74628191	chr1:81501794~81503468:+
LUAD	trans	rs11098499	0.739	rs10031033	ENSG00000275858.1	RP11-291L22.8	10.68	4.92e-24	2.4e-17	0.53	0.44	Corneal astigmatism;	chr4:119230297	chr10:38450738~38451069:-
LUAD	trans	rs4276421	0.762	rs10043270	ENSG00000231752.4	EMBP1	10.68	5.01e-24	2.45e-17	0.59	0.44	P wave duration;	chr5:45967846	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.913	rs10006304	ENSG00000275858.1	RP11-291L22.8	10.67	5.37e-24	2.62e-17	0.55	0.44	Corneal astigmatism;	chr4:119203150	chr10:38450738~38451069:-
LUAD	trans	rs2657294	0.965	rs10762658	ENSG00000172974.11	AC007318.5	10.67	5.38e-24	2.62e-17	0.46	0.44	Pneumonia;	chr10:75119804	chr2:65205108~65205988:+
LUAD	trans	rs916888	0.61	rs199530	ENSG00000214425.5	LRRC37A4P	10.67	5.47e-24	2.67e-17	0.54	0.44	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:45506741~45550335:-
LUAD	trans	rs2589161	1	rs2589161	ENSG00000231752.4	EMBP1	10.67	5.51e-24	2.69e-17	0.58	0.44	Breast cancer;	chr5:45653810	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.869	rs1405918	ENSG00000231752.4	EMBP1	10.67	5.51e-24	2.69e-17	0.58	0.44	P wave duration;	chr5:45654968	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.874	rs6851169	ENSG00000275858.1	RP11-291L22.8	10.66	5.72e-24	2.79e-17	0.54	0.44	Corneal astigmatism;	chr4:119196355	chr10:38450738~38451069:-
LUAD	trans	rs4276421	0.845	rs10434580	ENSG00000231752.4	EMBP1	10.66	5.73e-24	2.79e-17	0.58	0.44	P wave duration;	chr5:46010910	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.901	rs10044479	ENSG00000231752.4	EMBP1	10.66	5.76e-24	2.81e-17	0.58	0.44	P wave duration;	chr5:45751434	chr1:121519112~121571892:+
LUAD	trans	rs12709013	0.792	rs12596434	ENSG00000230849.2	GOT2P2	10.66	5.77e-24	2.81e-17	0.53	0.44	Blood metabolite ratios;	chr16:58792309	chr1:173141100~173142350:-
LUAD	trans	rs74781061	1	rs74781061	ENSG00000227288.3	RP5-837I24.1	10.66	5.88e-24	2.86e-17	0.62	0.44	Endometriosis;	chr15:74595855	chr1:81501794~81503468:+
LUAD	trans	rs2657294	0.965	rs4746264	ENSG00000172974.11	AC007318.5	10.66	5.9e-24	2.88e-17	0.46	0.44	Pneumonia;	chr10:75114194	chr2:65205108~65205988:+
LUAD	trans	rs867371	0.929	rs7173852	ENSG00000235370.6	DNM1P51	-10.65	6.17e-24	3e-17	-0.5	-0.44	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82169512	chr15:84398316~84411701:-
LUAD	trans	rs11098499	0.874	rs9995277	ENSG00000275858.1	RP11-291L22.8	10.65	6.22e-24	3.03e-17	0.54	0.44	Corneal astigmatism;	chr4:119187448	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.874	rs6826823	ENSG00000275858.1	RP11-291L22.8	10.65	6.22e-24	3.03e-17	0.54	0.44	Corneal astigmatism;	chr4:119190943	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.874	rs12509054	ENSG00000275858.1	RP11-291L22.8	10.65	6.22e-24	3.03e-17	0.54	0.44	Corneal astigmatism;	chr4:119193920	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.874	rs12502503	ENSG00000275858.1	RP11-291L22.8	10.65	6.22e-24	3.03e-17	0.54	0.44	Corneal astigmatism;	chr4:119195100	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.874	rs6832670	ENSG00000275858.1	RP11-291L22.8	10.65	6.22e-24	3.03e-17	0.54	0.44	Corneal astigmatism;	chr4:119197637	chr10:38450738~38451069:-
LUAD	trans	rs4276421	0.869	rs2589162	ENSG00000231752.4	EMBP1	-10.65	6.25e-24	3.04e-17	-0.58	-0.44	P wave duration;	chr5:45655791	chr1:121519112~121571892:+
LUAD	trans	rs9876781	1	rs1459242	ENSG00000235912.1	RP1-159A19.3	10.65	6.38e-24	3.1e-17	0.46	0.44	Longevity;	chr3:48372047	chr1:27649419~27649610:+
LUAD	trans	rs10037055	1	rs6886255	ENSG00000217325.2	PRELID1P1	10.65	6.54e-24	3.18e-17	0.56	0.44	Migraine without aura;	chr5:177291360	chr6:126643488~126644390:+
LUAD	trans	rs877636	1	rs877636	ENSG00000196933.5	RPS26P11	-10.65	6.56e-24	3.19e-17	-0.51	-0.44	Cognitive function;	chr12:56086799	chrX:72044545~72044892:+
LUAD	trans	rs9425766	0.639	rs10798295	ENSG00000213331.4	RP11-713C19.2	10.65	6.61e-24	3.21e-17	0.52	0.44	Life satisfaction;	chr1:173714815	chr4:187970273~187971284:+
LUAD	trans	rs7312770	0.612	rs773114	ENSG00000242970.2	AC068522.4	10.64	6.84e-24	3.32e-17	0.5	0.44	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr8:58588420~58588764:-
LUAD	trans	rs2657294	0.965	rs9299525	ENSG00000172974.11	AC007318.5	10.64	6.89e-24	3.34e-17	0.46	0.44	Pneumonia;	chr10:75118267	chr2:65205108~65205988:+
LUAD	trans	rs867371	1	rs7173339	ENSG00000235370.6	DNM1P51	-10.64	7.06e-24	3.42e-17	-0.51	-0.44	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82175253	chr15:84398316~84411701:-
LUAD	trans	rs10908521	0.717	rs11264572	ENSG00000227183.3	HDGFP1	-10.64	7.2e-24	3.49e-17	-0.57	-0.44	Uric acid clearance;	chr1:156836245	chrX:131646639~131646890:+
LUAD	trans	rs11098499	0.874	rs17839089	ENSG00000275858.1	RP11-291L22.8	10.63	7.25e-24	3.52e-17	0.54	0.44	Corneal astigmatism;	chr4:119189914	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.874	rs6822498	ENSG00000275858.1	RP11-291L22.8	10.63	7.33e-24	3.55e-17	0.54	0.44	Corneal astigmatism;	chr4:119199028	chr10:38450738~38451069:-
LUAD	trans	rs4276421	0.736	rs8188290	ENSG00000231752.4	EMBP1	10.63	7.41e-24	3.59e-17	0.59	0.44	P wave duration;	chr5:46047215	chr1:121519112~121571892:+
LUAD	trans	rs77688320	0.553	rs6722889	ENSG00000235105.1	RP11-329A14.1	-10.63	7.48e-24	3.63e-17	-0.52	-0.44	Breast cancer;	chr2:201439359	chr1:48435967~48437223:+
LUAD	trans	rs12138950	0.681	rs10917472	ENSG00000224237.1	MINOS1P3	10.63	7.57e-24	3.67e-17	0.56	0.44	Hypothyroidism;Thyroid volume;	chr1:19524218	chr3:27214816~27215018:-
LUAD	trans	rs11098499	0.874	rs7661020	ENSG00000275858.1	RP11-291L22.8	10.62	7.91e-24	3.83e-17	0.54	0.44	Corneal astigmatism;	chr4:119185827	chr10:38450738~38451069:-
LUAD	trans	rs9876781	1	rs6442117	ENSG00000235912.1	RP1-159A19.3	10.62	7.97e-24	3.86e-17	0.45	0.44	Longevity;	chr3:48378407	chr1:27649419~27649610:+
LUAD	trans	rs7554547	0.667	rs6687063	ENSG00000261819.1	RP11-680G24.4	10.62	8.27e-24	4e-17	0.59	0.44	Nonsyndromic cleft lip with cleft palate;	chr1:11908173	chr16:14988259~14990160:-
LUAD	trans	rs9425766	0.679	rs7552939	ENSG00000213331.4	RP11-713C19.2	10.62	8.43e-24	4.07e-17	0.51	0.44	Life satisfaction;	chr1:173798305	chr4:187970273~187971284:+
LUAD	trans	rs7312770	0.612	rs1873914	ENSG00000234513.1	AC073072.7	10.62	8.56e-24	4.14e-17	0.5	0.44	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr7:22773646~22773993:-
LUAD	trans	rs55665837	0.54	rs10832299	ENSG00000236360.2	RP11-334A14.2	10.62	8.57e-24	4.14e-17	0.59	0.44	Vitamin D levels;	chr11:14747846	chr1:52993201~52993702:-
LUAD	trans	rs77688320	0.553	rs2080320	ENSG00000235105.1	RP11-329A14.1	10.61	8.69e-24	4.2e-17	0.52	0.44	Breast cancer;	chr2:201514450	chr1:48435967~48437223:+
LUAD	trans	rs55665837	0.54	rs12788030	ENSG00000236360.2	RP11-334A14.2	10.61	9.01e-24	4.34e-17	0.59	0.44	Vitamin D levels;	chr11:14743138	chr1:52993201~52993702:-
LUAD	trans	rs55665837	0.54	rs12290926	ENSG00000236360.2	RP11-334A14.2	10.61	9.08e-24	4.38e-17	0.58	0.44	Vitamin D levels;	chr11:14673500	chr1:52993201~52993702:-
LUAD	trans	rs12709013	0.792	rs11649133	ENSG00000233719.3	GOT2P3	10.61	9.12e-24	4.4e-17	0.52	0.44	Blood metabolite ratios;	chr16:58803275	chr12:9641802~9643007:+
LUAD	trans	rs11098499	0.874	rs13123591	ENSG00000275858.1	RP11-291L22.8	10.6	9.5e-24	4.58e-17	0.54	0.44	Corneal astigmatism;	chr4:119184835	chr10:38450738~38451069:-
LUAD	trans	rs9876781	1	rs6784322	ENSG00000235912.1	RP1-159A19.3	-10.6	9.8e-24	4.72e-17	-0.46	-0.44	Longevity;	chr3:48380745	chr1:27649419~27649610:+
LUAD	trans	rs77688320	0.553	rs12473387	ENSG00000235105.1	RP11-329A14.1	10.59	1.03e-23	4.95e-17	0.52	0.43	Breast cancer;	chr2:201415778	chr1:48435967~48437223:+
LUAD	trans	rs77688320	0.553	rs4507084	ENSG00000235105.1	RP11-329A14.1	10.59	1.03e-23	4.95e-17	0.52	0.43	Breast cancer;	chr2:201420377	chr1:48435967~48437223:+
LUAD	trans	rs12709013	0.729	rs34324769	ENSG00000233719.3	GOT2P3	10.59	1.06e-23	5.07e-17	0.52	0.43	Blood metabolite ratios;	chr16:58778131	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.716	rs11647582	ENSG00000233719.3	GOT2P3	10.58	1.12e-23	5.36e-17	0.52	0.43	Blood metabolite ratios;	chr16:58801474	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.792	rs35684307	ENSG00000233719.3	GOT2P3	10.58	1.12e-23	5.36e-17	0.52	0.43	Blood metabolite ratios;	chr16:58801651	chr12:9641802~9643007:+
LUAD	trans	rs4276421	0.869	rs1527831	ENSG00000231752.4	EMBP1	10.58	1.19e-23	5.69e-17	0.57	0.43	P wave duration;	chr5:45656821	chr1:121519112~121571892:+
LUAD	trans	rs12709013	0.792	rs12598527	ENSG00000233719.3	GOT2P3	10.58	1.2e-23	5.74e-17	0.52	0.43	Blood metabolite ratios;	chr16:58772987	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.792	rs12600201	ENSG00000233719.3	GOT2P3	10.58	1.2e-23	5.74e-17	0.52	0.43	Blood metabolite ratios;	chr16:58773132	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.792	rs12600206	ENSG00000233719.3	GOT2P3	10.58	1.2e-23	5.74e-17	0.52	0.43	Blood metabolite ratios;	chr16:58773169	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.792	rs11076263	ENSG00000233719.3	GOT2P3	10.58	1.2e-23	5.74e-17	0.52	0.43	Blood metabolite ratios;	chr16:58773295	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.792	rs11646756	ENSG00000233719.3	GOT2P3	10.58	1.2e-23	5.74e-17	0.52	0.43	Blood metabolite ratios;	chr16:58773598	chr12:9641802~9643007:+
LUAD	trans	rs9876781	1	rs7635522	ENSG00000235912.1	RP1-159A19.3	-10.58	1.21e-23	5.78e-17	-0.46	-0.43	Longevity;	chr3:48382166	chr1:27649419~27649610:+
LUAD	trans	rs4276421	0.869	rs2879074	ENSG00000231752.4	EMBP1	10.57	1.24e-23	5.95e-17	0.58	0.43	P wave duration;	chr5:45716107	chr1:121519112~121571892:+
LUAD	trans	rs877636	0.692	rs2271194	ENSG00000227887.1	RPS26P13	-10.57	1.26e-23	6.05e-17	-0.49	-0.43	Cognitive function;	chr12:56083910	chr1:208697369~208697698:-
LUAD	trans	rs13014235	0.667	rs2540328	ENSG00000235105.1	RP11-329A14.1	-10.57	1.33e-23	6.34e-17	-0.52	-0.43	Basal cell carcinoma;	chr2:201384337	chr1:48435967~48437223:+
LUAD	trans	rs77688320	0.509	rs2714487	ENSG00000235105.1	RP11-329A14.1	-10.57	1.33e-23	6.34e-17	-0.52	-0.43	Breast cancer;	chr2:201384837	chr1:48435967~48437223:+
LUAD	trans	rs9611519	0.78	rs5751071	ENSG00000268568.1	AC007228.9	-10.56	1.38e-23	6.59e-17	-0.58	-0.43	Neuroticism;	chr22:41260328	chr19:56672574~56673901:-
LUAD	trans	rs2657294	0.965	rs2657286	ENSG00000172974.11	AC007318.5	-10.56	1.4e-23	6.68e-17	-0.46	-0.43	Pneumonia;	chr10:75145940	chr2:65205108~65205988:+
LUAD	trans	rs13190036	0.901	rs4631	ENSG00000228305.2	AC016734.2	10.56	1.42e-23	6.79e-17	0.64	0.43	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177306115	chr2:63622178~63622831:-
LUAD	trans	rs4276421	0.81	rs13190242	ENSG00000231752.4	EMBP1	10.55	1.47e-23	7.03e-17	0.58	0.43	P wave duration;	chr5:46054443	chr1:121519112~121571892:+
LUAD	trans	rs9876781	1	rs9311423	ENSG00000235912.1	RP1-159A19.3	-10.55	1.49e-23	7.1e-17	-0.45	-0.43	Longevity;	chr3:48378818	chr1:27649419~27649610:+
LUAD	trans	rs9876781	1	rs7634377	ENSG00000235912.1	RP1-159A19.3	-10.55	1.49e-23	7.1e-17	-0.45	-0.43	Longevity;	chr3:48379768	chr1:27649419~27649610:+
LUAD	trans	rs12709013	0.792	rs11644344	ENSG00000233719.3	GOT2P3	10.54	1.59e-23	7.59e-17	0.52	0.43	Blood metabolite ratios;	chr16:58803080	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.792	rs11649387	ENSG00000233719.3	GOT2P3	10.54	1.59e-23	7.59e-17	0.52	0.43	Blood metabolite ratios;	chr16:58803176	chr12:9641802~9643007:+
LUAD	trans	rs77688320	0.5	rs7603584	ENSG00000235105.1	RP11-329A14.1	10.54	1.61e-23	7.67e-17	0.51	0.43	Breast cancer;	chr2:201440422	chr1:48435967~48437223:+
LUAD	trans	rs77688320	0.553	rs2244438	ENSG00000235105.1	RP11-329A14.1	-10.54	1.63e-23	7.74e-17	-0.52	-0.43	Breast cancer;	chr2:201387816	chr1:48435967~48437223:+
LUAD	trans	rs11098499	0.78	rs7692994	ENSG00000275858.1	RP11-291L22.8	10.53	1.77e-23	8.4e-17	0.5	0.43	Corneal astigmatism;	chr4:119506334	chr10:38450738~38451069:-
LUAD	trans	rs7312770	1	rs7312770	ENSG00000225071.1	GS1-184P14.2	-10.53	1.78e-23	8.48e-17	-0.46	-0.43	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chrX:24429573~24429920:-
LUAD	trans	rs12709013	0.792	rs12596434	ENSG00000233719.3	GOT2P3	10.52	1.92e-23	9.11e-17	0.51	0.43	Blood metabolite ratios;	chr16:58792309	chr12:9641802~9643007:+
LUAD	trans	rs77688320	0.535	rs10186894	ENSG00000235105.1	RP11-329A14.1	10.52	1.93e-23	9.18e-17	0.52	0.43	Breast cancer;	chr2:201440909	chr1:48435967~48437223:+
LUAD	trans	rs877636	1	rs2292239	ENSG00000243403.1	RP11-330L19.1	10.52	1.98e-23	9.39e-17	0.45	0.43	Cognitive function;	chr12:56088396	chr15:64592979~64593326:+
LUAD	trans	rs11098499	0.874	rs10022508	ENSG00000275858.1	RP11-291L22.8	10.52	1.99e-23	9.46e-17	0.54	0.43	Corneal astigmatism;	chr4:119194073	chr10:38450738~38451069:-
LUAD	trans	rs13190036	1	rs4976682	ENSG00000228305.2	AC016734.2	10.52	2e-23	9.48e-17	0.57	0.43	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177299001	chr2:63622178~63622831:-
LUAD	trans	rs2657294	0.929	rs6480771	ENSG00000172974.11	AC007318.5	10.52	2.01e-23	9.54e-17	0.46	0.43	Pneumonia;	chr10:75101922	chr2:65205108~65205988:+
LUAD	trans	rs12709013	0.766	rs12599331	ENSG00000233719.3	GOT2P3	10.52	2.02e-23	9.58e-17	0.52	0.43	Blood metabolite ratios;	chr16:58805307	chr12:9641802~9643007:+
LUAD	trans	rs10940346	0.777	rs11744698	ENSG00000231752.4	EMBP1	-10.51	2.08e-23	9.85e-17	-0.58	-0.43	Schizophrenia;	chr5:50586024	chr1:121519112~121571892:+
LUAD	trans	rs9876781	1	rs2362452	ENSG00000235912.1	RP1-159A19.3	10.51	2.08e-23	9.86e-17	0.46	0.43	Longevity;	chr3:48376724	chr1:27649419~27649610:+
LUAD	trans	rs9876781	0.874	rs56298324	ENSG00000235912.1	RP1-159A19.3	10.51	2.08e-23	9.86e-17	0.46	0.43	Longevity;	chr3:48393626	chr1:27649419~27649610:+
LUAD	trans	rs74781061	0.872	rs4886598	ENSG00000227288.3	RP5-837I24.1	10.51	2.16e-23	1.02e-16	0.62	0.43	Endometriosis;	chr15:74484441	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.872	rs6495106	ENSG00000227288.3	RP5-837I24.1	10.51	2.16e-23	1.02e-16	0.62	0.43	Endometriosis;	chr15:74487006	chr1:81501794~81503468:+
LUAD	trans	rs12709013	0.792	rs62066381	ENSG00000233719.3	GOT2P3	10.51	2.17e-23	1.03e-16	0.52	0.43	Blood metabolite ratios;	chr16:58807981	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.792	rs8049572	ENSG00000233719.3	GOT2P3	10.51	2.17e-23	1.03e-16	0.52	0.43	Blood metabolite ratios;	chr16:58809672	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.766	rs34438483	ENSG00000233719.3	GOT2P3	10.51	2.17e-23	1.03e-16	0.52	0.43	Blood metabolite ratios;	chr16:58810530	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.792	rs36098613	ENSG00000233719.3	GOT2P3	10.51	2.17e-23	1.03e-16	0.52	0.43	Blood metabolite ratios;	chr16:58810562	chr12:9641802~9643007:+
LUAD	trans	rs4276421	0.55	rs34812524	ENSG00000231752.4	EMBP1	10.5	2.24e-23	1.06e-16	0.57	0.43	P wave duration;	chr5:46054030	chr1:121519112~121571892:+
LUAD	trans	rs616147	0.627	rs816510	ENSG00000214263.2	RPSAP53	-10.5	2.41e-23	1.14e-16	-0.56	-0.43	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39430804	chr13:67266845~67267706:-
LUAD	trans	rs7554547	0.69	rs57044570	ENSG00000261819.1	RP11-680G24.4	10.49	2.45e-23	1.16e-16	0.59	0.43	Nonsyndromic cleft lip with cleft palate;	chr1:11899181	chr16:14988259~14990160:-
LUAD	trans	rs77688320	0.553	rs2080322	ENSG00000235105.1	RP11-329A14.1	-10.49	2.48e-23	1.17e-16	-0.52	-0.43	Breast cancer;	chr2:201514317	chr1:48435967~48437223:+
LUAD	trans	rs7554547	0.69	rs7524721	ENSG00000261819.1	RP11-680G24.4	10.49	2.49e-23	1.17e-16	0.58	0.43	Nonsyndromic cleft lip with cleft palate;	chr1:11890119	chr16:14988259~14990160:-
LUAD	trans	rs7554547	0.667	rs12567187	ENSG00000261819.1	RP11-680G24.4	10.49	2.49e-23	1.17e-16	0.58	0.43	Nonsyndromic cleft lip with cleft palate;	chr1:11896095	chr16:14988259~14990160:-
LUAD	trans	rs7554547	0.69	rs12087996	ENSG00000261819.1	RP11-680G24.4	10.49	2.55e-23	1.2e-16	0.58	0.43	Nonsyndromic cleft lip with cleft palate;	chr1:11897152	chr16:14988259~14990160:-
LUAD	trans	rs77688320	0.553	rs2540330	ENSG00000235105.1	RP11-329A14.1	-10.49	2.58e-23	1.22e-16	-0.52	-0.43	Breast cancer;	chr2:201388133	chr1:48435967~48437223:+
LUAD	trans	rs77688320	0.553	rs2540331	ENSG00000235105.1	RP11-329A14.1	-10.49	2.58e-23	1.22e-16	-0.52	-0.43	Breast cancer;	chr2:201388150	chr1:48435967~48437223:+
LUAD	trans	rs74781061	0.932	rs7497342	ENSG00000227288.3	RP5-837I24.1	10.49	2.63e-23	1.24e-16	0.61	0.43	Endometriosis;	chr15:74655722	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.932	rs11072497	ENSG00000227288.3	RP5-837I24.1	10.49	2.63e-23	1.24e-16	0.61	0.43	Endometriosis;	chr15:74659016	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.932	rs11072498	ENSG00000227288.3	RP5-837I24.1	10.49	2.63e-23	1.24e-16	0.61	0.43	Endometriosis;	chr15:74661846	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.932	rs2415245	ENSG00000227288.3	RP5-837I24.1	10.49	2.63e-23	1.24e-16	0.61	0.43	Endometriosis;	chr15:74678091	chr1:81501794~81503468:+
LUAD	trans	rs2657294	0.895	rs4746262	ENSG00000172974.11	AC007318.5	10.48	2.76e-23	1.3e-16	0.46	0.43	Pneumonia;	chr10:75093631	chr2:65205108~65205988:+
LUAD	trans	rs74781061	0.86	rs6495102	ENSG00000227288.3	RP5-837I24.1	10.48	2.82e-23	1.33e-16	0.62	0.43	Endometriosis;	chr15:74470337	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.932	rs7176491	ENSG00000227288.3	RP5-837I24.1	10.48	2.83e-23	1.33e-16	0.62	0.43	Endometriosis;	chr15:74514875	chr1:81501794~81503468:+
LUAD	trans	rs9467773	0.933	rs2024970	ENSG00000242375.1	RP11-498P14.3	10.48	2.86e-23	1.35e-16	0.56	0.43	Intelligence (multi-trait analysis);	chr6:26497292	chr9:97195351~97197687:-
LUAD	trans	rs10037055	0.947	rs10063803	ENSG00000217325.2	PRELID1P1	10.46	3.24e-23	1.52e-16	0.58	0.43	Migraine without aura;	chr5:177240326	chr6:126643488~126644390:+
LUAD	trans	rs77688320	0.553	rs7582946	ENSG00000235105.1	RP11-329A14.1	10.46	3.32e-23	1.56e-16	0.52	0.43	Breast cancer;	chr2:201423969	chr1:48435967~48437223:+
LUAD	trans	rs77688320	0.553	rs2540339	ENSG00000235105.1	RP11-329A14.1	-10.46	3.32e-23	1.56e-16	-0.52	-0.43	Breast cancer;	chr2:201415725	chr1:48435967~48437223:+
LUAD	trans	rs77688320	0.553	rs2540340	ENSG00000235105.1	RP11-329A14.1	-10.46	3.32e-23	1.56e-16	-0.52	-0.43	Breast cancer;	chr2:201416477	chr1:48435967~48437223:+
LUAD	trans	rs12709013	0.766	rs11648511	ENSG00000233719.3	GOT2P3	10.44	3.92e-23	1.83e-16	0.51	0.43	Blood metabolite ratios;	chr16:58798171	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.792	rs7185513	ENSG00000233719.3	GOT2P3	10.43	4.24e-23	1.98e-16	0.51	0.43	Blood metabolite ratios;	chr16:58794889	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.804	rs8051459	ENSG00000233719.3	GOT2P3	10.43	4.29e-23	2e-16	0.51	0.43	Blood metabolite ratios;	chr16:58783436	chr12:9641802~9643007:+
LUAD	trans	rs13190036	0.901	rs10056655	ENSG00000226986.4	RP11-543B16.2	10.43	4.35e-23	2.03e-16	0.63	0.43	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177249350	chr1:211207239~211207897:+
LUAD	trans	rs4276421	0.805	rs6451810	ENSG00000231752.4	EMBP1	10.42	4.43e-23	2.07e-16	0.57	0.43	P wave duration;	chr5:45633898	chr1:121519112~121571892:+
LUAD	trans	rs1816752	0.716	rs9553289	ENSG00000224976.2	PARP4P2	10.42	4.45e-23	2.08e-16	0.49	0.43	Obesity-related traits;	chr13:24400640	chr13:19349137~19407962:+
LUAD	trans	rs74781061	0.932	rs74025818	ENSG00000227288.3	RP5-837I24.1	10.42	4.57e-23	2.13e-16	0.61	0.43	Endometriosis;	chr15:74618287	chr1:81501794~81503468:+
LUAD	trans	rs77688320	0.553	rs1558637	ENSG00000235105.1	RP11-329A14.1	-10.42	4.69e-23	2.19e-16	-0.52	-0.43	Breast cancer;	chr2:201398651	chr1:48435967~48437223:+
LUAD	trans	rs4276421	0.869	rs7718785	ENSG00000231752.4	EMBP1	10.41	4.88e-23	2.28e-16	0.56	0.43	P wave duration;	chr5:45725495	chr1:121519112~121571892:+
LUAD	trans	rs74781061	0.932	rs61168092	ENSG00000227288.3	RP5-837I24.1	10.41	4.89e-23	2.28e-16	0.62	0.43	Endometriosis;	chr15:74517619	chr1:81501794~81503468:+
LUAD	trans	rs877636	1	rs2292239	ENSG00000196933.5	RPS26P11	10.41	4.96e-23	2.31e-16	0.48	0.43	Cognitive function;	chr12:56088396	chrX:72044545~72044892:+
LUAD	trans	rs74781061	0.799	rs4372642	ENSG00000227288.3	RP5-837I24.1	10.41	5.01e-23	2.34e-16	0.62	0.43	Endometriosis;	chr15:74460095	chr1:81501794~81503468:+
LUAD	trans	rs13190036	0.792	rs6874206	ENSG00000226986.4	RP11-543B16.2	-10.41	5.15e-23	2.4e-16	-0.62	-0.43	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177223970	chr1:211207239~211207897:+
LUAD	trans	rs13190036	0.901	rs10072499	ENSG00000226986.4	RP11-543B16.2	-10.41	5.15e-23	2.4e-16	-0.62	-0.43	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228236	chr1:211207239~211207897:+
LUAD	trans	rs2657294	0.965	rs7088974	ENSG00000172974.11	AC007318.5	10.41	5.15e-23	2.4e-16	0.46	0.43	Pneumonia;	chr10:75131338	chr2:65205108~65205988:+
LUAD	trans	rs12709013	0.74	rs12927495	ENSG00000233719.3	GOT2P3	10.4	5.31e-23	2.47e-16	0.52	0.43	Blood metabolite ratios;	chr16:58821934	chr12:9641802~9643007:+
LUAD	trans	rs916888	0.647	rs199524	ENSG00000214425.5	LRRC37A4P	10.4	5.38e-23	2.5e-16	0.53	0.43	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:45506741~45550335:-
LUAD	trans	rs74781061	0.86	rs1456432	ENSG00000227288.3	RP5-837I24.1	10.39	5.76e-23	2.68e-16	0.63	0.43	Endometriosis;	chr15:74710710	chr1:81501794~81503468:+
LUAD	trans	rs4276421	0.901	rs12110137	ENSG00000231752.4	EMBP1	10.39	5.96e-23	2.77e-16	0.56	0.43	P wave duration;	chr5:45727764	chr1:121519112~121571892:+
LUAD	trans	rs7312770	0.637	rs705700	ENSG00000234354.3	RPS26P47	10.39	6.03e-23	2.81e-16	0.47	0.43	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr13:100539901~100540248:-
LUAD	trans	rs13190036	0.901	rs6898107	ENSG00000226986.4	RP11-543B16.2	10.39	6.17e-23	2.87e-16	0.63	0.43	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177252694	chr1:211207239~211207897:+
LUAD	trans	rs12709013	0.792	rs62064940	ENSG00000233719.3	GOT2P3	10.39	6.2e-23	2.88e-16	0.51	0.43	Blood metabolite ratios;	chr16:58796560	chr12:9641802~9643007:+
LUAD	trans	rs10037055	0.853	rs10077929	ENSG00000217325.2	PRELID1P1	10.39	6.2e-23	2.88e-16	0.54	0.43	Migraine without aura;	chr5:177270843	chr6:126643488~126644390:+
LUAD	trans	rs916888	0.647	rs199523	ENSG00000214425.5	LRRC37A4P	10.38	6.46e-23	3e-16	0.53	0.43	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:45506741~45550335:-
LUAD	trans	rs3749237	1	rs3749237	ENSG00000197582.5	GPX1P1	10.38	6.75e-23	3.13e-16	0.59	0.43	Resting heart rate;	chr3:49732599	chrX:13378735~13379340:-
LUAD	trans	rs7312770	1	rs7312770	ENSG00000212994.5	RPS26P6	-10.38	6.79e-23	3.15e-16	-0.47	-0.43	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr8:100895771~100896118:+
LUAD	trans	rs12709013	0.792	rs12928733	ENSG00000233719.3	GOT2P3	10.37	6.89e-23	3.2e-16	0.51	0.43	Blood metabolite ratios;	chr16:58807216	chr12:9641802~9643007:+
LUAD	trans	rs877636	0.859	rs3741499	ENSG00000243403.1	RP11-330L19.1	-10.37	7.3e-23	3.39e-16	-0.45	-0.43	Cognitive function;	chr12:56080595	chr15:64592979~64593326:+
LUAD	trans	rs12145833	0.538	rs61833885	ENSG00000154608.12	CEP170P1	-10.36	7.44e-23	3.45e-16	-0.73	-0.43	Obesity (early onset extreme);	chr1:243233886	chr4:118467590~118554204:+
LUAD	trans	rs7554547	0.667	rs2050266	ENSG00000261819.1	RP11-680G24.4	10.36	7.46e-23	3.46e-16	0.58	0.43	Nonsyndromic cleft lip with cleft palate;	chr1:11886531	chr16:14988259~14990160:-
LUAD	trans	rs77688320	0.553	rs2243791	ENSG00000235105.1	RP11-329A14.1	-10.36	7.54e-23	3.5e-16	-0.52	-0.43	Breast cancer;	chr2:201478079	chr1:48435967~48437223:+
LUAD	trans	rs13190036	1	rs13175695	ENSG00000226986.4	RP11-543B16.2	10.36	7.59e-23	3.52e-16	0.62	0.43	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272810	chr1:211207239~211207897:+
LUAD	trans	rs77688320	0.573	rs59674665	ENSG00000235105.1	RP11-329A14.1	-10.36	7.72e-23	3.58e-16	-0.52	-0.43	Breast cancer;	chr2:201514881	chr1:48435967~48437223:+
LUAD	trans	rs77688320	0.553	rs2714488	ENSG00000235105.1	RP11-329A14.1	-10.36	7.9e-23	3.66e-16	-0.51	-0.43	Breast cancer;	chr2:201405050	chr1:48435967~48437223:+
LUAD	trans	rs77688320	0.553	rs2249868	ENSG00000235105.1	RP11-329A14.1	-10.36	7.9e-23	3.66e-16	-0.51	-0.43	Breast cancer;	chr2:201412503	chr1:48435967~48437223:+
LUAD	trans	rs9611519	0.78	rs5751072	ENSG00000268568.1	AC007228.9	-10.36	7.98e-23	3.7e-16	-0.56	-0.43	Neuroticism;	chr22:41260505	chr19:56672574~56673901:-
LUAD	trans	rs10037055	0.812	rs11949435	ENSG00000217325.2	PRELID1P1	10.35	8.1e-23	3.75e-16	0.54	0.43	Migraine without aura;	chr5:177287931	chr6:126643488~126644390:+
LUAD	trans	rs7192380	0.756	rs12596945	ENSG00000257513.6	NPIPB1P	-10.35	8.27e-23	3.83e-16	-0.43	-0.43	Sjögren's syndrome;	chr16:69746916	chr18:11619509~11639699:-
LUAD	trans	rs9611519	0.78	rs2235852	ENSG00000268568.1	AC007228.9	-10.35	8.49e-23	3.93e-16	-0.58	-0.43	Neuroticism;	chr22:41265150	chr19:56672574~56673901:-
LUAD	trans	rs4276421	0.837	rs2696013	ENSG00000231752.4	EMBP1	10.34	8.84e-23	4.09e-16	0.57	0.43	P wave duration;	chr5:45603104	chr1:121519112~121571892:+
LUAD	trans	rs77688320	0.553	rs2540449	ENSG00000235105.1	RP11-329A14.1	-10.34	9.03e-23	4.17e-16	-0.51	-0.43	Breast cancer;	chr2:201451036	chr1:48435967~48437223:+
LUAD	trans	rs12709013	0.792	rs62064901	ENSG00000233719.3	GOT2P3	10.34	9.25e-23	4.27e-16	0.5	0.43	Blood metabolite ratios;	chr16:58776758	chr12:9641802~9643007:+
LUAD	trans	rs77688320	0.517	rs12991600	ENSG00000235105.1	RP11-329A14.1	10.34	9.26e-23	4.28e-16	0.5	0.43	Breast cancer;	chr2:201472513	chr1:48435967~48437223:+
LUAD	trans	rs877636	1	rs4759229	ENSG00000243403.1	RP11-330L19.1	-10.34	9.31e-23	4.3e-16	-0.46	-0.43	Cognitive function;	chr12:56080696	chr15:64592979~64593326:+
LUAD	trans	rs2657294	0.861	rs6480769	ENSG00000172974.11	AC007318.5	10.34	9.41e-23	4.35e-16	0.46	0.43	Pneumonia;	chr10:75091745	chr2:65205108~65205988:+
LUAD	trans	rs4276421	0.837	rs1483303	ENSG00000231752.4	EMBP1	10.33	9.69e-23	4.47e-16	0.56	0.43	P wave duration;	chr5:45571997	chr1:121519112~121571892:+
LUAD	trans	rs9876781	1	rs4858817	ENSG00000235912.1	RP1-159A19.3	10.33	9.84e-23	4.54e-16	0.45	0.43	Longevity;	chr3:48375266	chr1:27649419~27649610:+
LUAD	trans	rs77688320	0.529	rs2540438	ENSG00000235105.1	RP11-329A14.1	-10.33	1.02e-22	4.69e-16	-0.51	-0.43	Breast cancer;	chr2:201485833	chr1:48435967~48437223:+
LUAD	trans	rs3740713	0.669	rs2896526	ENSG00000235847.2	LDHAP7	10.33	1.04e-22	4.78e-16	0.69	0.43	Amyotrophic lateral sclerosis (sporadic);	chr11:18398259	chr2:84777259~84778223:-
LUAD	trans	rs7312770	1	rs7312770	ENSG00000234513.1	AC073072.7	-10.32	1.07e-22	4.91e-16	-0.47	-0.43	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr7:22773646~22773993:-
LUAD	trans	rs77688320	0.553	rs2540432	ENSG00000235105.1	RP11-329A14.1	-10.32	1.07e-22	4.93e-16	-0.51	-0.43	Breast cancer;	chr2:201500171	chr1:48435967~48437223:+
LUAD	trans	rs77688320	0.553	rs2908763	ENSG00000235105.1	RP11-329A14.1	-10.32	1.07e-22	4.93e-16	-0.51	-0.43	Breast cancer;	chr2:201503860	chr1:48435967~48437223:+
LUAD	trans	rs77688320	0.535	rs60148247	ENSG00000235105.1	RP11-329A14.1	-10.32	1.07e-22	4.93e-16	-0.51	-0.43	Breast cancer;	chr2:201513770	chr1:48435967~48437223:+
LUAD	trans	rs77688320	0.553	rs2080324	ENSG00000235105.1	RP11-329A14.1	-10.32	1.07e-22	4.93e-16	-0.51	-0.43	Breast cancer;	chr2:201514089	chr1:48435967~48437223:+
LUAD	trans	rs77688320	0.553	rs2080323	ENSG00000235105.1	RP11-329A14.1	-10.32	1.07e-22	4.93e-16	-0.51	-0.43	Breast cancer;	chr2:201514126	chr1:48435967~48437223:+
LUAD	trans	rs10940346	0.524	rs35601537	ENSG00000231752.4	EMBP1	-10.32	1.11e-22	5.1e-16	-0.57	-0.43	Schizophrenia;	chr5:50509460	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.754	rs17595608	ENSG00000275858.1	RP11-291L22.8	10.32	1.13e-22	5.18e-16	0.51	0.43	Corneal astigmatism;	chr4:119329351	chr10:38450738~38451069:-
LUAD	trans	rs7192380	0.63	rs2965749	ENSG00000257513.6	NPIPB1P	-10.32	1.13e-22	5.2e-16	-0.42	-0.43	Sjögren's syndrome;	chr16:69738011	chr18:11619509~11639699:-
LUAD	trans	rs3749237	0.929	rs62260715	ENSG00000197582.5	GPX1P1	10.32	1.13e-22	5.22e-16	0.61	0.43	Resting heart rate;	chr3:49791893	chrX:13378735~13379340:-
LUAD	trans	rs3740713	0.748	rs35292478	ENSG00000235847.2	LDHAP7	10.31	1.15e-22	5.28e-16	0.69	0.43	Amyotrophic lateral sclerosis (sporadic);	chr11:18408444	chr2:84777259~84778223:-
LUAD	trans	rs74781061	0.929	rs16969612	ENSG00000227288.3	RP5-837I24.1	-10.31	1.17e-22	5.4e-16	-0.63	-0.43	Endometriosis;	chr15:74514096	chr1:81501794~81503468:+
LUAD	trans	rs11098499	0.954	rs6820115	ENSG00000275858.1	RP11-291L22.8	10.31	1.18e-22	5.42e-16	0.49	0.43	Corneal astigmatism;	chr4:119477027	chr10:38450738~38451069:-
LUAD	trans	rs12709013	1	rs12709013	ENSG00000230849.2	GOT2P2	-10.31	1.21e-22	5.56e-16	-0.51	-0.43	Blood metabolite ratios;	chr16:58795886	chr1:173141100~173142350:-
LUAD	trans	rs4276421	0.753	rs7443976	ENSG00000231752.4	EMBP1	10.31	1.21e-22	5.58e-16	0.57	0.43	P wave duration;	chr5:45936323	chr1:121519112~121571892:+
LUAD	trans	rs77688320	0.573	rs2080327	ENSG00000235105.1	RP11-329A14.1	-10.31	1.23e-22	5.64e-16	-0.51	-0.43	Breast cancer;	chr2:201461495	chr1:48435967~48437223:+
LUAD	trans	rs4276421	0.837	rs2337483	ENSG00000231752.4	EMBP1	10.31	1.24e-22	5.68e-16	0.56	0.43	P wave duration;	chr5:45608220	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.739	rs4833612	ENSG00000275858.1	RP11-291L22.8	-10.3	1.32e-22	6.05e-16	-0.52	-0.43	Corneal astigmatism;	chr4:119226441	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.739	rs10013032	ENSG00000275858.1	RP11-291L22.8	-10.3	1.32e-22	6.05e-16	-0.52	-0.43	Corneal astigmatism;	chr4:119228264	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.754	rs1980027	ENSG00000275858.1	RP11-291L22.8	10.3	1.34e-22	6.14e-16	0.51	0.42	Corneal astigmatism;	chr4:119330422	chr10:38450738~38451069:-
LUAD	trans	rs9611519	0.78	rs2235849	ENSG00000268568.1	AC007228.9	-10.29	1.35e-22	6.22e-16	-0.55	-0.42	Neuroticism;	chr22:41257536	chr19:56672574~56673901:-
LUAD	trans	rs11098499	0.754	rs714899	ENSG00000275858.1	RP11-291L22.8	10.29	1.37e-22	6.27e-16	0.51	0.42	Corneal astigmatism;	chr4:119321880	chr10:38450738~38451069:-
LUAD	trans	rs3749237	0.964	rs11717463	ENSG00000197582.5	GPX1P1	10.29	1.41e-22	6.46e-16	0.6	0.42	Resting heart rate;	chr3:49771548	chrX:13378735~13379340:-
LUAD	trans	rs74781061	0.929	rs8025915	ENSG00000227288.3	RP5-837I24.1	10.29	1.41e-22	6.48e-16	0.65	0.42	Endometriosis;	chr15:74578188	chr1:81501794~81503468:+
LUAD	trans	rs4276421	0.869	rs2337951	ENSG00000231752.4	EMBP1	10.29	1.41e-22	6.48e-16	0.56	0.42	P wave duration;	chr5:45717834	chr1:121519112~121571892:+
LUAD	trans	rs13190036	1	rs655623	ENSG00000226986.4	RP11-543B16.2	10.29	1.43e-22	6.55e-16	0.61	0.42	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107515	chr1:211207239~211207897:+
LUAD	trans	rs74781061	0.929	rs11072493	ENSG00000227288.3	RP5-837I24.1	10.29	1.45e-22	6.65e-16	0.61	0.42	Endometriosis;	chr15:74536881	chr1:81501794~81503468:+
LUAD	trans	rs74781061	1	rs8040745	ENSG00000227288.3	RP5-837I24.1	10.29	1.45e-22	6.65e-16	0.61	0.42	Endometriosis;	chr15:74525791	chr1:81501794~81503468:+
LUAD	trans	rs4276421	0.869	rs2337952	ENSG00000231752.4	EMBP1	10.29	1.45e-22	6.65e-16	0.56	0.42	P wave duration;	chr5:45722022	chr1:121519112~121571892:+
LUAD	trans	rs9611519	0.78	rs9611528	ENSG00000268568.1	AC007228.9	-10.29	1.45e-22	6.66e-16	-0.56	-0.42	Neuroticism;	chr22:41252498	chr19:56672574~56673901:-
LUAD	trans	rs55665837	0.54	rs12416696	ENSG00000236360.2	RP11-334A14.2	10.29	1.46e-22	6.7e-16	0.57	0.42	Vitamin D levels;	chr11:14769343	chr1:52993201~52993702:-
LUAD	trans	rs2657294	0.895	rs3088142	ENSG00000172974.11	AC007318.5	10.28	1.48e-22	6.79e-16	0.45	0.42	Pneumonia;	chr10:75094806	chr2:65205108~65205988:+
LUAD	trans	rs74781061	0.932	rs6495121	ENSG00000227288.3	RP5-837I24.1	10.28	1.55e-22	7.11e-16	0.62	0.42	Endometriosis;	chr15:74711167	chr1:81501794~81503468:+
LUAD	trans	rs77688320	0.5	rs6755428	ENSG00000235105.1	RP11-329A14.1	10.28	1.55e-22	7.11e-16	0.5	0.42	Breast cancer;	chr2:201431043	chr1:48435967~48437223:+
LUAD	trans	rs4276421	0.837	rs6893773	ENSG00000231752.4	EMBP1	10.28	1.59e-22	7.29e-16	0.56	0.42	P wave duration;	chr5:45622394	chr1:121519112~121571892:+
LUAD	trans	rs55665837	0.523	rs10832301	ENSG00000236360.2	RP11-334A14.2	10.27	1.68e-22	7.68e-16	0.57	0.42	Vitamin D levels;	chr11:14767418	chr1:52993201~52993702:-
LUAD	trans	rs9876781	1	rs7636782	ENSG00000235912.1	RP1-159A19.3	-10.27	1.7e-22	7.78e-16	-0.45	-0.42	Longevity;	chr3:48379897	chr1:27649419~27649610:+
LUAD	trans	rs10037055	0.853	rs4976681	ENSG00000217325.2	PRELID1P1	10.27	1.71e-22	7.81e-16	0.53	0.42	Migraine without aura;	chr5:177277662	chr6:126643488~126644390:+
LUAD	trans	rs2665103	0.715	rs16973457	ENSG00000235370.6	DNM1P51	-10.27	1.71e-22	7.82e-16	-0.49	-0.42	Intelligence (multi-trait analysis);	chr15:82271650	chr15:84398316~84411701:-
LUAD	trans	rs74781061	0.932	rs2198843	ENSG00000227288.3	RP5-837I24.1	10.26	1.74e-22	7.95e-16	0.61	0.42	Endometriosis;	chr15:74708889	chr1:81501794~81503468:+
LUAD	trans	rs13190036	0.551	rs28932178	ENSG00000226986.4	RP11-543B16.2	-10.26	1.76e-22	8.05e-16	-0.61	-0.42	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210575	chr1:211207239~211207897:+
LUAD	trans	rs74781061	0.932	rs7161903	ENSG00000227288.3	RP5-837I24.1	10.26	1.77e-22	8.1e-16	0.61	0.42	Endometriosis;	chr15:74647929	chr1:81501794~81503468:+
LUAD	trans	rs10037055	0.853	rs4976680	ENSG00000217325.2	PRELID1P1	10.26	1.78e-22	8.15e-16	0.53	0.42	Migraine without aura;	chr5:177275745	chr6:126643488~126644390:+
LUAD	trans	rs55665837	0.54	rs1007392	ENSG00000236360.2	RP11-334A14.2	10.25	1.92e-22	8.77e-16	0.57	0.42	Vitamin D levels;	chr11:14753045	chr1:52993201~52993702:-
LUAD	trans	rs77688320	0.573	rs2714480	ENSG00000235105.1	RP11-329A14.1	-10.25	2.01e-22	9.17e-16	-0.51	-0.42	Breast cancer;	chr2:201486286	chr1:48435967~48437223:+
LUAD	trans	rs4276421	0.837	rs2580260	ENSG00000231752.4	EMBP1	10.25	2.03e-22	9.25e-16	0.56	0.42	P wave duration;	chr5:45638527	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.806	rs6451804	ENSG00000231752.4	EMBP1	10.24	2.1e-22	9.55e-16	0.57	0.42	P wave duration;	chr5:45492103	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.837	rs1384732	ENSG00000231752.4	EMBP1	10.24	2.18e-22	9.93e-16	0.56	0.42	P wave duration;	chr5:45553285	chr1:121519112~121571892:+
LUAD	trans	rs1816752	0.669	rs7984513	ENSG00000224976.2	PARP4P2	10.24	2.21e-22	1.01e-15	0.48	0.42	Obesity-related traits;	chr13:24445117	chr13:19349137~19407962:+
LUAD	trans	rs4276421	0.869	rs6892627	ENSG00000231752.4	EMBP1	10.24	2.23e-22	1.02e-15	0.56	0.42	P wave duration;	chr5:45722892	chr1:121519112~121571892:+
LUAD	trans	rs12138950	0.625	rs12041608	ENSG00000224237.1	MINOS1P3	-10.23	2.26e-22	1.03e-15	-0.54	-0.42	Hypothyroidism;Thyroid volume;	chr1:19515431	chr3:27214816~27215018:-
LUAD	trans	rs13190036	0.901	rs28684504	ENSG00000228305.2	AC016734.2	10.23	2.27e-22	1.03e-15	0.6	0.42	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177300437	chr2:63622178~63622831:-
LUAD	trans	rs10908521	0.685	rs12746582	ENSG00000227183.3	HDGFP1	-10.23	2.28e-22	1.04e-15	-0.54	-0.42	Uric acid clearance;	chr1:156836231	chrX:131646639~131646890:+
LUAD	trans	rs13190036	0.892	rs71601339	ENSG00000228305.2	AC016734.2	-10.23	2.29e-22	1.04e-15	-0.61	-0.42	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177117495	chr2:63622178~63622831:-
LUAD	trans	rs12709013	1	rs11641836	ENSG00000230849.2	GOT2P2	10.23	2.3e-22	1.05e-15	0.52	0.42	Blood metabolite ratios;	chr16:58798143	chr1:173141100~173142350:-
LUAD	trans	rs7554547	0.622	rs72864769	ENSG00000261819.1	RP11-680G24.4	10.23	2.32e-22	1.06e-15	0.57	0.42	Nonsyndromic cleft lip with cleft palate;	chr1:11881264	chr16:14988259~14990160:-
LUAD	trans	rs77688320	0.517	rs7605375	ENSG00000235105.1	RP11-329A14.1	10.23	2.35e-22	1.07e-15	0.49	0.42	Breast cancer;	chr2:201465907	chr1:48435967~48437223:+
LUAD	trans	rs4276421	0.806	rs10079739	ENSG00000231752.4	EMBP1	-10.23	2.4e-22	1.09e-15	-0.57	-0.42	P wave duration;	chr5:45607597	chr1:121519112~121571892:+
LUAD	trans	rs77688320	0.553	rs10804114	ENSG00000235105.1	RP11-329A14.1	10.23	2.44e-22	1.11e-15	0.5	0.42	Breast cancer;	chr2:201402139	chr1:48435967~48437223:+
LUAD	trans	rs11098499	0.754	rs9999724	ENSG00000275858.1	RP11-291L22.8	10.22	2.44e-22	1.11e-15	0.51	0.42	Corneal astigmatism;	chr4:119318789	chr10:38450738~38451069:-
LUAD	trans	rs4276421	0.837	rs6451807	ENSG00000231752.4	EMBP1	10.22	2.47e-22	1.12e-15	0.56	0.42	P wave duration;	chr5:45534321	chr1:121519112~121571892:+
LUAD	trans	rs2665103	0.715	rs7403041	ENSG00000235370.6	DNM1P51	10.22	2.58e-22	1.17e-15	0.49	0.42	Intelligence (multi-trait analysis);	chr15:82287841	chr15:84398316~84411701:-
LUAD	trans	rs74781061	0.932	rs11629946	ENSG00000227288.3	RP5-837I24.1	-10.21	2.79e-22	1.27e-15	-0.6	-0.42	Endometriosis;	chr15:74579550	chr1:81501794~81503468:+
LUAD	trans	rs55665837	0.502	rs12795794	ENSG00000236360.2	RP11-334A14.2	10.21	2.81e-22	1.27e-15	0.57	0.42	Vitamin D levels;	chr11:14825327	chr1:52993201~52993702:-
LUAD	trans	rs13358908	0.507	rs12521357	ENSG00000231752.4	EMBP1	-10.21	2.87e-22	1.3e-15	-0.57	-0.42	Schizophrenia;	chr5:46403146	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.739	rs6534130	ENSG00000275858.1	RP11-291L22.8	-10.21	2.87e-22	1.3e-15	-0.52	-0.42	Corneal astigmatism;	chr4:119210184	chr10:38450738~38451069:-
LUAD	trans	rs2665103	0.715	rs11639440	ENSG00000235370.6	DNM1P51	-10.2	2.93e-22	1.33e-15	-0.49	-0.42	Intelligence (multi-trait analysis);	chr15:82278705	chr15:84398316~84411701:-
LUAD	trans	rs74781061	0.929	rs11072495	ENSG00000227288.3	RP5-837I24.1	10.2	3e-22	1.36e-15	0.65	0.42	Endometriosis;	chr15:74598790	chr1:81501794~81503468:+
LUAD	trans	rs877636	0.692	rs10876870	ENSG00000227887.1	RPS26P13	-10.2	3.01e-22	1.36e-15	-0.47	-0.42	Cognitive function;	chr12:56084218	chr1:208697369~208697698:-
LUAD	trans	rs877636	0.692	rs7971751	ENSG00000227887.1	RPS26P13	-10.2	3.01e-22	1.36e-15	-0.47	-0.42	Cognitive function;	chr12:56084874	chr1:208697369~208697698:-
LUAD	trans	rs4276421	0.837	rs7727890	ENSG00000231752.4	EMBP1	10.2	3.14e-22	1.42e-15	0.56	0.42	P wave duration;	chr5:45478669	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.754	rs938056	ENSG00000275858.1	RP11-291L22.8	10.19	3.16e-22	1.43e-15	0.51	0.42	Corneal astigmatism;	chr4:119316298	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.754	rs878376	ENSG00000275858.1	RP11-291L22.8	10.19	3.16e-22	1.43e-15	0.51	0.42	Corneal astigmatism;	chr4:119316547	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.739	rs951570	ENSG00000275858.1	RP11-291L22.8	-10.19	3.17e-22	1.43e-15	-0.52	-0.42	Corneal astigmatism;	chr4:119229312	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.739	rs9884728	ENSG00000275858.1	RP11-291L22.8	-10.19	3.24e-22	1.47e-15	-0.52	-0.42	Corneal astigmatism;	chr4:119205924	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.739	rs2203039	ENSG00000275858.1	RP11-291L22.8	-10.19	3.24e-22	1.47e-15	-0.52	-0.42	Corneal astigmatism;	chr4:119211192	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.739	rs7441137	ENSG00000275858.1	RP11-291L22.8	-10.19	3.24e-22	1.47e-15	-0.52	-0.42	Corneal astigmatism;	chr4:119212066	chr10:38450738~38451069:-
LUAD	trans	rs74781061	0.929	rs9635320	ENSG00000227288.3	RP5-837I24.1	10.19	3.31e-22	1.5e-15	0.64	0.42	Endometriosis;	chr15:74592750	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.929	rs7176095	ENSG00000227288.3	RP5-837I24.1	10.19	3.31e-22	1.5e-15	0.64	0.42	Endometriosis;	chr15:74594070	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.929	rs11072494	ENSG00000227288.3	RP5-837I24.1	10.19	3.31e-22	1.5e-15	0.64	0.42	Endometriosis;	chr15:74596822	chr1:81501794~81503468:+
LUAD	trans	rs2657294	0.796	rs7082123	ENSG00000172974.11	AC007318.5	10.19	3.35e-22	1.51e-15	0.45	0.42	Pneumonia;	chr10:75091101	chr2:65205108~65205988:+
LUAD	trans	rs8175379	0.506	rs10035927	ENSG00000231752.4	EMBP1	-10.19	3.37e-22	1.52e-15	-0.56	-0.42	Interleukin-7 levels;	chr5:46404107	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.826	rs4472123	ENSG00000275858.1	RP11-291L22.8	10.18	3.45e-22	1.56e-15	0.51	0.42	Corneal astigmatism;	chr4:119315475	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.71	rs6851130	ENSG00000275858.1	RP11-291L22.8	-10.18	3.49e-22	1.58e-15	-0.52	-0.42	Corneal astigmatism;	chr4:119212557	chr10:38450738~38451069:-
LUAD	trans	rs2657294	0.895	rs2395137	ENSG00000172974.11	AC007318.5	10.18	3.52e-22	1.59e-15	0.45	0.42	Pneumonia;	chr10:75088235	chr2:65205108~65205988:+
LUAD	trans	rs11098499	0.754	rs66900435	ENSG00000275858.1	RP11-291L22.8	10.18	3.55e-22	1.6e-15	0.5	0.42	Corneal astigmatism;	chr4:119328270	chr10:38450738~38451069:-
LUAD	trans	rs10940346	0.601	rs7712849	ENSG00000231752.4	EMBP1	10.18	3.61e-22	1.63e-15	0.57	0.42	Schizophrenia;	chr5:50407774	chr1:121519112~121571892:+
LUAD	trans	rs55665837	0.54	rs10766192	ENSG00000236360.2	RP11-334A14.2	10.17	3.75e-22	1.69e-15	0.57	0.42	Vitamin D levels;	chr11:14790140	chr1:52993201~52993702:-
LUAD	trans	rs12709013	0.935	rs8046667	ENSG00000230849.2	GOT2P2	10.17	3.79e-22	1.71e-15	0.51	0.42	Blood metabolite ratios;	chr16:58790935	chr1:173141100~173142350:-
LUAD	trans	rs12709013	1	rs8046998	ENSG00000230849.2	GOT2P2	10.17	3.79e-22	1.71e-15	0.51	0.42	Blood metabolite ratios;	chr16:58791109	chr1:173141100~173142350:-
LUAD	trans	rs2665103	0.687	rs11633000	ENSG00000235370.6	DNM1P51	-10.17	4.02e-22	1.81e-15	-0.49	-0.42	Intelligence (multi-trait analysis);	chr15:82269320	chr15:84398316~84411701:-
LUAD	trans	rs4276421	0.806	rs2337412	ENSG00000231752.4	EMBP1	10.16	4.14e-22	1.86e-15	0.56	0.42	P wave duration;	chr5:45483410	chr1:121519112~121571892:+
LUAD	trans	rs12145833	0.538	rs10926977	ENSG00000154608.12	CEP170P1	-10.16	4.24e-22	1.91e-15	-0.73	-0.42	Obesity (early onset extreme);	chr1:243248065	chr4:118467590~118554204:+
LUAD	trans	rs4276421	0.869	rs2580258	ENSG00000231752.4	EMBP1	10.15	4.47e-22	2.01e-15	0.56	0.42	P wave duration;	chr5:45586815	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.662	rs13108589	ENSG00000275858.1	RP11-291L22.8	10.15	4.48e-22	2.01e-15	0.5	0.42	Corneal astigmatism;	chr4:119346947	chr10:38450738~38451069:-
LUAD	trans	rs4276421	0.776	rs7717787	ENSG00000231752.4	EMBP1	10.15	4.54e-22	2.04e-15	0.56	0.42	P wave duration;	chr5:45466514	chr1:121519112~121571892:+
LUAD	trans	rs7937890	1	rs2970335	ENSG00000236360.2	RP11-334A14.2	10.14	4.83e-22	2.17e-15	0.52	0.42	Mitochondrial DNA levels;	chr11:14303855	chr1:52993201~52993702:-
LUAD	trans	rs74781061	0.929	rs8027066	ENSG00000227288.3	RP5-837I24.1	10.13	5.22e-22	2.34e-15	0.63	0.42	Endometriosis;	chr15:74535682	chr1:81501794~81503468:+
LUAD	trans	rs10940346	0.562	rs7380318	ENSG00000231752.4	EMBP1	-10.13	5.45e-22	2.44e-15	-0.57	-0.42	Schizophrenia;	chr5:50510557	chr1:121519112~121571892:+
LUAD	trans	rs55665837	0.54	rs3206554	ENSG00000236360.2	RP11-334A14.2	10.13	5.62e-22	2.52e-15	0.56	0.42	Vitamin D levels;	chr11:14776399	chr1:52993201~52993702:-
LUAD	trans	rs72615157	0.612	rs7786505	ENSG00000228546.2	CTA-313A17.3	10.13	5.65e-22	2.53e-15	0.62	0.42	Lung function (FEV1/FVC);	chr7:100219962	chr7:102337316~102339115:+
LUAD	trans	rs72615157	0.664	rs6953580	ENSG00000228546.2	CTA-313A17.3	10.12	5.69e-22	2.54e-15	0.63	0.42	Lung function (FEV1/FVC);	chr7:100227652	chr7:102337316~102339115:+
LUAD	trans	rs13190036	0.901	rs6556309	ENSG00000226986.4	RP11-543B16.2	10.12	5.77e-22	2.58e-15	0.61	0.42	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177266834	chr1:211207239~211207897:+
LUAD	trans	rs4276421	0.869	rs6451814	ENSG00000231752.4	EMBP1	10.12	5.93e-22	2.65e-15	0.55	0.42	P wave duration;	chr5:45734981	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.562	rs10940336	ENSG00000231752.4	EMBP1	-10.12	6.04e-22	2.7e-15	-0.57	-0.42	Schizophrenia;	chr5:50505020	chr1:121519112~121571892:+
LUAD	trans	rs74781061	0.929	rs4887159	ENSG00000227288.3	RP5-837I24.1	10.12	6.09e-22	2.72e-15	0.63	0.42	Endometriosis;	chr15:74573541	chr1:81501794~81503468:+
LUAD	trans	rs877636	0.74	rs705698	ENSG00000243403.1	RP11-330L19.1	10.11	6.24e-22	2.79e-15	0.46	0.42	Cognitive function;	chr12:55990903	chr15:64592979~64593326:+
LUAD	trans	rs916888	0.821	rs199514	ENSG00000280022.1	RP11-707O23.1	-10.11	6.33e-22	2.82e-15	-0.61	-0.42	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45592621~45593369:+
LUAD	trans	rs10908521	1	rs10908521	ENSG00000227183.3	HDGFP1	10.11	6.52e-22	2.91e-15	0.57	0.42	Uric acid clearance;	chr1:156843858	chrX:131646639~131646890:+
LUAD	trans	rs4276421	0.806	rs7732970	ENSG00000231752.4	EMBP1	10.11	6.65e-22	2.97e-15	0.56	0.42	P wave duration;	chr5:45452044	chr1:121519112~121571892:+
LUAD	trans	rs74781061	0.929	rs8038730	ENSG00000227288.3	RP5-837I24.1	10.1	6.73e-22	3e-15	0.63	0.42	Endometriosis;	chr15:74501003	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.929	rs7178219	ENSG00000227288.3	RP5-837I24.1	10.1	6.73e-22	3e-15	0.63	0.42	Endometriosis;	chr15:74502552	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.929	rs1821847	ENSG00000227288.3	RP5-837I24.1	10.1	6.79e-22	3.02e-15	0.64	0.42	Endometriosis;	chr15:74516873	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.929	rs7173006	ENSG00000227288.3	RP5-837I24.1	10.1	6.79e-22	3.02e-15	0.64	0.42	Endometriosis;	chr15:74517792	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.929	rs78796673	ENSG00000227288.3	RP5-837I24.1	10.1	6.79e-22	3.02e-15	0.64	0.42	Endometriosis;	chr15:74520186	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.929	rs4261483	ENSG00000227288.3	RP5-837I24.1	10.1	6.79e-22	3.02e-15	0.64	0.42	Endometriosis;	chr15:74520993	chr1:81501794~81503468:+
LUAD	trans	rs4276421	0.904	rs4388219	ENSG00000231752.4	EMBP1	10.1	7.08e-22	3.15e-15	0.56	0.42	P wave duration;	chr5:45780648	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.754	rs10213554	ENSG00000275858.1	RP11-291L22.8	-10.1	7.26e-22	3.23e-15	-0.5	-0.42	Corneal astigmatism;	chr4:119339630	chr10:38450738~38451069:-
LUAD	trans	rs74781061	0.929	rs11072490	ENSG00000227288.3	RP5-837I24.1	10.09	7.4e-22	3.29e-15	0.63	0.42	Endometriosis;	chr15:74515169	chr1:81501794~81503468:+
LUAD	trans	rs4276421	0.805	rs13354798	ENSG00000231752.4	EMBP1	10.09	7.5e-22	3.33e-15	0.56	0.42	P wave duration;	chr5:45456975	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.866	rs10518329	ENSG00000275858.1	RP11-291L22.8	10.09	7.61e-22	3.38e-15	0.48	0.42	Corneal astigmatism;	chr4:119480680	chr10:38450738~38451069:-
LUAD	trans	rs74781061	0.929	rs12439505	ENSG00000227288.3	RP5-837I24.1	10.08	8.05e-22	3.57e-15	0.63	0.42	Endometriosis;	chr15:74494021	chr1:81501794~81503468:+
LUAD	trans	rs12709013	1	rs12599931	ENSG00000230849.2	GOT2P2	10.08	8.26e-22	3.67e-15	0.51	0.42	Blood metabolite ratios;	chr16:58792627	chr1:173141100~173142350:-
LUAD	trans	rs77688320	0.517	rs7573536	ENSG00000235105.1	RP11-329A14.1	10.08	8.6e-22	3.82e-15	0.49	0.42	Breast cancer;	chr2:201469676	chr1:48435967~48437223:+
LUAD	trans	rs7937890	1	rs2970334	ENSG00000236360.2	RP11-334A14.2	-10.07	8.73e-22	3.87e-15	-0.52	-0.42	Mitochondrial DNA levels;	chr11:14307809	chr1:52993201~52993702:-
LUAD	trans	rs916888	0.821	rs199505	ENSG00000280022.1	RP11-707O23.1	-10.07	9.09e-22	4.03e-15	-0.61	-0.42	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45592621~45593369:+
LUAD	trans	rs916888	0.821	rs70602	ENSG00000280022.1	RP11-707O23.1	-10.07	9.09e-22	4.03e-15	-0.61	-0.42	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45592621~45593369:+
LUAD	trans	rs11098499	0.866	rs7665125	ENSG00000275858.1	RP11-291L22.8	10.07	9.36e-22	4.14e-15	0.48	0.42	Corneal astigmatism;	chr4:119480924	chr10:38450738~38451069:-
LUAD	trans	rs2657294	0.895	rs2002023	ENSG00000172974.11	AC007318.5	10.07	9.39e-22	4.16e-15	0.45	0.42	Pneumonia;	chr10:75088766	chr2:65205108~65205988:+
LUAD	trans	rs4276421	0.806	rs6451801	ENSG00000231752.4	EMBP1	10.06	9.55e-22	4.23e-15	0.55	0.42	P wave duration;	chr5:45439331	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.806	rs13169726	ENSG00000231752.4	EMBP1	10.06	9.55e-22	4.23e-15	0.55	0.42	P wave duration;	chr5:45444967	chr1:121519112~121571892:+
LUAD	trans	rs7937890	0.967	rs963212	ENSG00000236360.2	RP11-334A14.2	-10.06	9.65e-22	4.27e-15	-0.52	-0.42	Mitochondrial DNA levels;	chr11:14303186	chr1:52993201~52993702:-
LUAD	trans	rs4276421	0.806	rs6860200	ENSG00000231752.4	EMBP1	10.06	9.69e-22	4.29e-15	0.55	0.42	P wave duration;	chr5:45440241	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.58	rs13357429	ENSG00000231752.4	EMBP1	10.06	9.93e-22	4.39e-15	0.56	0.42	Schizophrenia;	chr5:50413616	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs7720960	ENSG00000231752.4	EMBP1	10.06	9.94e-22	4.39e-15	0.56	0.42	Schizophrenia;	chr5:50450489	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs6863108	ENSG00000231752.4	EMBP1	10.06	9.94e-22	4.39e-15	0.56	0.42	Schizophrenia;	chr5:50451450	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.56	rs13180267	ENSG00000231752.4	EMBP1	10.06	9.94e-22	4.39e-15	0.56	0.42	Schizophrenia;	chr5:50452300	chr1:121519112~121571892:+
LUAD	trans	rs916888	0.821	rs199512	ENSG00000280022.1	RP11-707O23.1	-10.06	1.01e-21	4.46e-15	-0.6	-0.42	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45592621~45593369:+
LUAD	trans	rs916888	0.821	rs199509	ENSG00000280022.1	RP11-707O23.1	-10.06	1.01e-21	4.46e-15	-0.6	-0.42	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45592621~45593369:+
LUAD	trans	rs916888	0.821	rs199507	ENSG00000280022.1	RP11-707O23.1	-10.06	1.01e-21	4.46e-15	-0.6	-0.42	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45592621~45593369:+
LUAD	trans	rs10940346	0.601	rs4145844	ENSG00000231752.4	EMBP1	-10.06	1.01e-21	4.48e-15	-0.56	-0.42	Schizophrenia;	chr5:50478019	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.562	rs34950042	ENSG00000231752.4	EMBP1	-10.06	1.01e-21	4.48e-15	-0.56	-0.42	Schizophrenia;	chr5:50479299	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs3845167	ENSG00000231752.4	EMBP1	-10.06	1.01e-21	4.48e-15	-0.56	-0.42	Schizophrenia;	chr5:50480297	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.837	rs7706140	ENSG00000231752.4	EMBP1	10.06	1.02e-21	4.51e-15	0.55	0.42	P wave duration;	chr5:45474712	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.776	rs56908114	ENSG00000231752.4	EMBP1	10.05	1.06e-21	4.67e-15	0.55	0.42	P wave duration;	chr5:45416692	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.584	rs10061339	ENSG00000231752.4	EMBP1	-10.05	1.06e-21	4.68e-15	-0.56	-0.42	Schizophrenia;	chr5:50475952	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.754	rs1814813	ENSG00000275858.1	RP11-291L22.8	-10.05	1.08e-21	4.75e-15	-0.46	-0.42	Corneal astigmatism;	chr4:119337052	chr10:38450738~38451069:-
LUAD	trans	rs74781061	0.79	rs6495105	ENSG00000227288.3	RP5-837I24.1	10.05	1.08e-21	4.76e-15	0.63	0.42	Endometriosis;	chr15:74480512	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.858	rs12592906	ENSG00000227288.3	RP5-837I24.1	10.05	1.08e-21	4.76e-15	0.63	0.42	Endometriosis;	chr15:74481811	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.929	rs11855521	ENSG00000227288.3	RP5-837I24.1	10.05	1.08e-21	4.76e-15	0.63	0.42	Endometriosis;	chr15:74488038	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.929	rs55662551	ENSG00000227288.3	RP5-837I24.1	10.05	1.08e-21	4.76e-15	0.63	0.42	Endometriosis;	chr15:74488745	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.858	rs79923136	ENSG00000227288.3	RP5-837I24.1	10.05	1.08e-21	4.76e-15	0.63	0.42	Endometriosis;	chr15:74492219	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.858	rs35752918	ENSG00000227288.3	RP5-837I24.1	10.05	1.08e-21	4.76e-15	0.63	0.42	Endometriosis;	chr15:74494240	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.929	rs79534854	ENSG00000227288.3	RP5-837I24.1	10.05	1.08e-21	4.76e-15	0.63	0.42	Endometriosis;	chr15:74494257	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.858	rs4278699	ENSG00000227288.3	RP5-837I24.1	10.05	1.08e-21	4.76e-15	0.63	0.42	Endometriosis;	chr15:74500057	chr1:81501794~81503468:+
LUAD	trans	rs9876781	1	rs4858793	ENSG00000235912.1	RP1-159A19.3	10.05	1.08e-21	4.77e-15	0.44	0.42	Longevity;	chr3:48373517	chr1:27649419~27649610:+
LUAD	trans	rs10940346	0.58	rs13157992	ENSG00000231752.4	EMBP1	10.04	1.13e-21	4.97e-15	0.56	0.42	Schizophrenia;	chr5:50444074	chr1:121519112~121571892:+
LUAD	trans	rs74781061	0.929	rs8041807	ENSG00000227288.3	RP5-837I24.1	10.04	1.15e-21	5.07e-15	0.63	0.42	Endometriosis;	chr15:74534590	chr1:81501794~81503468:+
LUAD	trans	rs10037055	0.853	rs12660023	ENSG00000217325.2	PRELID1P1	10.04	1.15e-21	5.07e-15	0.52	0.42	Migraine without aura;	chr5:177273884	chr6:126643488~126644390:+
LUAD	trans	rs74781061	0.929	rs4886599	ENSG00000227288.3	RP5-837I24.1	10.04	1.16e-21	5.08e-15	0.63	0.42	Endometriosis;	chr15:74484442	chr1:81501794~81503468:+
LUAD	trans	rs77688320	0.5	rs4129010	ENSG00000235105.1	RP11-329A14.1	10.04	1.17e-21	5.14e-15	0.49	0.42	Breast cancer;	chr2:201443602	chr1:48435967~48437223:+
LUAD	trans	rs77688320	0.5	rs4129011	ENSG00000235105.1	RP11-329A14.1	10.04	1.17e-21	5.14e-15	0.49	0.42	Breast cancer;	chr2:201443863	chr1:48435967~48437223:+
LUAD	trans	rs916888	0.821	rs199506	ENSG00000280022.1	RP11-707O23.1	-10.04	1.17e-21	5.16e-15	-0.62	-0.42	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45592621~45593369:+
LUAD	trans	rs877636	0.702	rs773110	ENSG00000243403.1	RP11-330L19.1	10.04	1.19e-21	5.22e-15	0.47	0.42	Cognitive function;	chr12:55981353	chr15:64592979~64593326:+
LUAD	trans	rs877636	0.702	rs773111	ENSG00000243403.1	RP11-330L19.1	10.04	1.19e-21	5.22e-15	0.47	0.42	Cognitive function;	chr12:55981956	chr15:64592979~64593326:+
LUAD	trans	rs877636	0.702	rs773112	ENSG00000243403.1	RP11-330L19.1	10.04	1.19e-21	5.22e-15	0.47	0.42	Cognitive function;	chr12:55982097	chr15:64592979~64593326:+
LUAD	trans	rs74781061	0.929	rs8028163	ENSG00000227288.3	RP5-837I24.1	10.04	1.19e-21	5.23e-15	0.63	0.42	Endometriosis;	chr15:74530360	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.929	rs11072492	ENSG00000227288.3	RP5-837I24.1	10.04	1.19e-21	5.23e-15	0.63	0.42	Endometriosis;	chr15:74531782	chr1:81501794~81503468:+
LUAD	trans	rs12145833	0.538	rs10754798	ENSG00000154608.12	CEP170P1	10.04	1.19e-21	5.23e-15	0.66	0.42	Obesity (early onset extreme);	chr1:243146656	chr4:118467590~118554204:+
LUAD	trans	rs916888	0.821	rs415430	ENSG00000280022.1	RP11-707O23.1	-10.04	1.2e-21	5.25e-15	-0.6	-0.42	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45592621~45593369:+
LUAD	trans	rs916888	0.779	rs430685	ENSG00000280022.1	RP11-707O23.1	-10.04	1.2e-21	5.25e-15	-0.6	-0.42	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45592621~45593369:+
LUAD	trans	rs74781061	0.929	rs12594447	ENSG00000227288.3	RP5-837I24.1	10.04	1.21e-21	5.31e-15	0.63	0.42	Endometriosis;	chr15:74536392	chr1:81501794~81503468:+
LUAD	trans	rs12145833	0.596	rs12123491	ENSG00000154608.12	CEP170P1	-10.03	1.23e-21	5.41e-15	-0.73	-0.42	Obesity (early onset extreme);	chr1:243134622	chr4:118467590~118554204:+
LUAD	trans	rs12709013	1	rs12709013	ENSG00000233719.3	GOT2P3	-10.03	1.24e-21	5.44e-15	-0.49	-0.42	Blood metabolite ratios;	chr16:58795886	chr12:9641802~9643007:+
LUAD	trans	rs10940346	0.601	rs6450098	ENSG00000231752.4	EMBP1	10.03	1.27e-21	5.58e-15	0.56	0.42	Schizophrenia;	chr5:50420076	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs62365896	ENSG00000231752.4	EMBP1	10.03	1.27e-21	5.58e-15	0.56	0.42	Schizophrenia;	chr5:50422243	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.58	rs9292005	ENSG00000231752.4	EMBP1	10.03	1.27e-21	5.58e-15	0.56	0.42	Schizophrenia;	chr5:50430521	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.58	rs58756661	ENSG00000231752.4	EMBP1	10.03	1.27e-21	5.58e-15	0.56	0.42	Schizophrenia;	chr5:50436837	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.56	rs16879094	ENSG00000231752.4	EMBP1	10.03	1.27e-21	5.58e-15	0.56	0.42	Schizophrenia;	chr5:50442603	chr1:121519112~121571892:+
LUAD	trans	rs6477998	0.603	rs12338803	ENSG00000238072.1	RP11-305M3.2	10.03	1.28e-21	5.61e-15	0.7	0.42	Hematology traits;	chr9:113263148	chr7:129410113~129410370:-
LUAD	trans	rs10940346	0.601	rs4495185	ENSG00000231752.4	EMBP1	10.02	1.33e-21	5.81e-15	0.56	0.42	Schizophrenia;	chr5:50415453	chr1:121519112~121571892:+
LUAD	trans	rs74781061	0.929	rs4887153	ENSG00000227288.3	RP5-837I24.1	10.02	1.33e-21	5.82e-15	0.63	0.42	Endometriosis;	chr15:74484701	chr1:81501794~81503468:+
LUAD	trans	rs10940346	0.525	rs7728419	ENSG00000231752.4	EMBP1	-10.02	1.33e-21	5.83e-15	-0.56	-0.42	Schizophrenia;	chr5:50474238	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.524	rs1458763	ENSG00000231752.4	EMBP1	-10.02	1.34e-21	5.85e-15	-0.56	-0.42	Schizophrenia;	chr5:50265531	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs1458765	ENSG00000231752.4	EMBP1	-10.02	1.34e-21	5.85e-15	-0.56	-0.42	Schizophrenia;	chr5:50266141	chr1:121519112~121571892:+
LUAD	trans	rs77688320	0.517	rs6717641	ENSG00000235105.1	RP11-329A14.1	10.02	1.34e-21	5.85e-15	0.49	0.42	Breast cancer;	chr2:201450484	chr1:48435967~48437223:+
LUAD	trans	rs10940346	0.58	rs28528780	ENSG00000231752.4	EMBP1	10.02	1.35e-21	5.92e-15	0.56	0.42	Schizophrenia;	chr5:50441293	chr1:121519112~121571892:+
LUAD	trans	rs12709013	0.967	rs56107162	ENSG00000230849.2	GOT2P2	10.02	1.38e-21	6.04e-15	0.52	0.42	Blood metabolite ratios;	chr16:58804358	chr1:173141100~173142350:-
LUAD	trans	rs916888	0.697	rs199516	ENSG00000280022.1	RP11-707O23.1	-10.02	1.4e-21	6.12e-15	-0.6	-0.42	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45592621~45593369:+
LUAD	trans	rs12709013	1	rs11644891	ENSG00000230849.2	GOT2P2	10.02	1.41e-21	6.17e-15	0.51	0.42	Blood metabolite ratios;	chr16:58799921	chr1:173141100~173142350:-
LUAD	trans	rs12709013	1	rs11641566	ENSG00000230849.2	GOT2P2	10.02	1.41e-21	6.17e-15	0.51	0.42	Blood metabolite ratios;	chr16:58801276	chr1:173141100~173142350:-
LUAD	trans	rs4276421	0.806	rs6892594	ENSG00000231752.4	EMBP1	10.02	1.43e-21	6.23e-15	0.55	0.42	P wave duration;	chr5:45427071	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.806	rs12520124	ENSG00000231752.4	EMBP1	10.02	1.43e-21	6.23e-15	0.55	0.42	P wave duration;	chr5:45434917	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.806	rs34666220	ENSG00000231752.4	EMBP1	10.02	1.43e-21	6.23e-15	0.55	0.42	P wave duration;	chr5:45435884	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs62365901	ENSG00000231752.4	EMBP1	10.01	1.43e-21	6.25e-15	0.56	0.42	Schizophrenia;	chr5:50434497	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs62365902	ENSG00000231752.4	EMBP1	10.01	1.43e-21	6.25e-15	0.56	0.42	Schizophrenia;	chr5:50434594	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs28500170	ENSG00000231752.4	EMBP1	10.01	1.43e-21	6.25e-15	0.56	0.42	Schizophrenia;	chr5:50441594	chr1:121519112~121571892:+
LUAD	trans	rs74781061	0.929	rs4324083	ENSG00000227288.3	RP5-837I24.1	10.01	1.46e-21	6.35e-15	0.62	0.42	Endometriosis;	chr15:74479139	chr1:81501794~81503468:+
LUAD	trans	rs10940346	0.601	rs4029989	ENSG00000231752.4	EMBP1	-10.01	1.47e-21	6.4e-15	-0.57	-0.42	Schizophrenia;	chr5:50474501	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.806	rs6892290	ENSG00000231752.4	EMBP1	10.01	1.47e-21	6.4e-15	0.55	0.42	P wave duration;	chr5:45427035	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.776	rs7723380	ENSG00000231752.4	EMBP1	10.01	1.5e-21	6.52e-15	0.55	0.42	P wave duration;	chr5:45428433	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs7446951	ENSG00000231752.4	EMBP1	-10.01	1.56e-21	6.78e-15	-0.55	-0.42	Schizophrenia;	chr5:50314949	chr1:121519112~121571892:+
LUAD	trans	rs877636	0.702	rs773109	ENSG00000243403.1	RP11-330L19.1	10	1.56e-21	6.79e-15	0.47	0.42	Cognitive function;	chr12:55980911	chr15:64592979~64593326:+
LUAD	trans	rs3740713	0.592	rs73434674	ENSG00000235847.2	LDHAP7	10	1.57e-21	6.85e-15	0.68	0.41	Amyotrophic lateral sclerosis (sporadic);	chr11:18389950	chr2:84777259~84778223:-
LUAD	trans	rs12200782	0.505	rs9295696	ENSG00000242375.1	RP11-498P14.3	10	1.58e-21	6.89e-15	0.66	0.41	Small cell lung carcinoma;	chr6:26550060	chr9:97195351~97197687:-
LUAD	trans	rs74781061	0.929	rs8025976	ENSG00000227288.3	RP5-837I24.1	10	1.62e-21	7.07e-15	0.63	0.41	Endometriosis;	chr15:74577697	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.929	rs6495115	ENSG00000227288.3	RP5-837I24.1	10	1.62e-21	7.07e-15	0.63	0.41	Endometriosis;	chr15:74578122	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.858	rs4887162	ENSG00000227288.3	RP5-837I24.1	10	1.62e-21	7.07e-15	0.63	0.41	Endometriosis;	chr15:74580159	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.929	rs4887163	ENSG00000227288.3	RP5-837I24.1	10	1.62e-21	7.07e-15	0.63	0.41	Endometriosis;	chr15:74580405	chr1:81501794~81503468:+
LUAD	trans	rs916888	0.738	rs199515	ENSG00000280022.1	RP11-707O23.1	-10	1.65e-21	7.19e-15	-0.58	-0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45592621~45593369:+
LUAD	trans	rs11098499	0.754	rs9991959	ENSG00000275858.1	RP11-291L22.8	-10	1.66e-21	7.22e-15	-0.49	-0.41	Corneal astigmatism;	chr4:119332618	chr10:38450738~38451069:-
LUAD	trans	rs74781061	0.932	rs7178568	ENSG00000227288.3	RP5-837I24.1	9.99	1.69e-21	7.37e-15	0.6	0.41	Endometriosis;	chr15:74559075	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.932	rs8023479	ENSG00000227288.3	RP5-837I24.1	9.99	1.69e-21	7.37e-15	0.6	0.41	Endometriosis;	chr15:74561337	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.932	rs12437519	ENSG00000227288.3	RP5-837I24.1	9.99	1.69e-21	7.37e-15	0.6	0.41	Endometriosis;	chr15:74562109	chr1:81501794~81503468:+
LUAD	trans	rs77688320	0.535	rs10460403	ENSG00000235105.1	RP11-329A14.1	9.99	1.69e-21	7.37e-15	0.49	0.41	Breast cancer;	chr2:201478014	chr1:48435967~48437223:+
LUAD	trans	rs55665837	0.502	rs4757269	ENSG00000236360.2	RP11-334A14.2	9.99	1.72e-21	7.48e-15	0.57	0.41	Vitamin D levels;	chr11:14814646	chr1:52993201~52993702:-
LUAD	trans	rs10940346	0.601	rs7706105	ENSG00000231752.4	EMBP1	-9.99	1.72e-21	7.49e-15	-0.56	-0.41	Schizophrenia;	chr5:50501745	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs11948302	ENSG00000231752.4	EMBP1	-9.99	1.72e-21	7.49e-15	-0.56	-0.41	Schizophrenia;	chr5:50502317	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs10940335	ENSG00000231752.4	EMBP1	-9.99	1.72e-21	7.49e-15	-0.56	-0.41	Schizophrenia;	chr5:50502595	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.739	rs9996382	ENSG00000275858.1	RP11-291L22.8	9.99	1.72e-21	7.5e-15	0.5	0.41	Corneal astigmatism;	chr4:119229857	chr10:38450738~38451069:-
LUAD	trans	rs10940346	0.601	rs2036902	ENSG00000231752.4	EMBP1	9.99	1.74e-21	7.54e-15	0.55	0.41	Schizophrenia;	chr5:50401098	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs7717982	ENSG00000231752.4	EMBP1	9.99	1.74e-21	7.54e-15	0.55	0.41	Schizophrenia;	chr5:50401488	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs1833900	ENSG00000231752.4	EMBP1	-9.99	1.76e-21	7.65e-15	-0.56	-0.41	Schizophrenia;	chr5:50504668	chr1:121519112~121571892:+
LUAD	trans	rs74781061	0.929	rs8037436	ENSG00000227288.3	RP5-837I24.1	9.99	1.77e-21	7.7e-15	0.63	0.41	Endometriosis;	chr15:74506167	chr1:81501794~81503468:+
LUAD	trans	rs10940346	0.601	rs1458766	ENSG00000231752.4	EMBP1	-9.99	1.78e-21	7.72e-15	-0.55	-0.41	Schizophrenia;	chr5:50266457	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs514195	ENSG00000231752.4	EMBP1	-9.99	1.78e-21	7.72e-15	-0.55	-0.41	Schizophrenia;	chr5:50267123	chr1:121519112~121571892:+
LUAD	trans	rs877636	0.702	rs61937249	ENSG00000243403.1	RP11-330L19.1	9.99	1.81e-21	7.83e-15	0.47	0.41	Cognitive function;	chr12:55988132	chr15:64592979~64593326:+
LUAD	trans	rs11098499	0.644	rs28787668	ENSG00000275858.1	RP11-291L22.8	9.98	1.84e-21	7.98e-15	0.5	0.41	Corneal astigmatism;	chr4:119633532	chr10:38450738~38451069:-
LUAD	trans	rs7312770	0.637	rs705699	ENSG00000234354.3	RPS26P47	9.98	1.84e-21	7.99e-15	0.45	0.41	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr13:100539901~100540248:-
LUAD	trans	rs10940346	0.56	rs6450107	ENSG00000231752.4	EMBP1	9.98	1.92e-21	8.32e-15	0.56	0.41	Schizophrenia;	chr5:50430069	chr1:121519112~121571892:+
LUAD	trans	rs877636	0.669	rs7297175	ENSG00000227887.1	RPS26P13	-9.98	1.94e-21	8.41e-15	-0.46	-0.41	Cognitive function;	chr12:56080024	chr1:208697369~208697698:-
LUAD	trans	rs74781061	0.929	rs4887155	ENSG00000227288.3	RP5-837I24.1	9.98	1.96e-21	8.48e-15	0.63	0.41	Endometriosis;	chr15:74512119	chr1:81501794~81503468:+
LUAD	trans	rs877636	0.74	rs705702	ENSG00000243403.1	RP11-330L19.1	-9.98	1.97e-21	8.51e-15	-0.47	-0.41	Cognitive function;	chr12:55996852	chr15:64592979~64593326:+
LUAD	trans	rs8010715	1	rs8010715	ENSG00000238000.1	RP11-274E7.2	9.98	1.99e-21	8.6e-15	0.47	0.41	IgG glycosylation;	chr14:24139938	chr5:98213402~98214121:+
LUAD	trans	rs10940346	0.601	rs1016620	ENSG00000231752.4	EMBP1	-9.97	2.03e-21	8.74e-15	-0.56	-0.41	Schizophrenia;	chr5:50490763	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs2353961	ENSG00000231752.4	EMBP1	-9.97	2.03e-21	8.74e-15	-0.56	-0.41	Schizophrenia;	chr5:50491604	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs7379514	ENSG00000231752.4	EMBP1	-9.97	2.03e-21	8.74e-15	-0.56	-0.41	Schizophrenia;	chr5:50492052	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs10755228	ENSG00000231752.4	EMBP1	-9.97	2.03e-21	8.74e-15	-0.56	-0.41	Schizophrenia;	chr5:50493498	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs34371354	ENSG00000231752.4	EMBP1	-9.97	2.03e-21	8.74e-15	-0.56	-0.41	Schizophrenia;	chr5:50494203	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs55843201	ENSG00000231752.4	EMBP1	-9.97	2.03e-21	8.74e-15	-0.56	-0.41	Schizophrenia;	chr5:50494254	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.562	rs56251178	ENSG00000231752.4	EMBP1	-9.97	2.03e-21	8.74e-15	-0.56	-0.41	Schizophrenia;	chr5:50494837	chr1:121519112~121571892:+
LUAD	trans	rs12200782	0.505	rs1535275	ENSG00000242375.1	RP11-498P14.3	9.97	2.05e-21	8.86e-15	0.65	0.41	Small cell lung carcinoma;	chr6:26520539	chr9:97195351~97197687:-
LUAD	trans	rs72615157	0.613	rs56089143	ENSG00000228546.2	CTA-313A17.3	9.97	2.09e-21	9e-15	0.61	0.41	Lung function (FEV1/FVC);	chr7:100222221	chr7:102337316~102339115:+
LUAD	trans	rs74781061	1	rs11072488	ENSG00000227288.3	RP5-837I24.1	9.97	2.12e-21	9.13e-15	0.62	0.41	Endometriosis;	chr15:74494017	chr1:81501794~81503468:+
LUAD	trans	rs877636	0.74	rs772920	ENSG00000243403.1	RP11-330L19.1	9.96	2.23e-21	9.6e-15	0.47	0.41	Cognitive function;	chr12:55996580	chr15:64592979~64593326:+
LUAD	trans	rs10940346	0.645	rs6450162	ENSG00000231752.4	EMBP1	-9.96	2.28e-21	9.84e-15	-0.56	-0.41	Schizophrenia;	chr5:50498547	chr1:121519112~121571892:+
LUAD	trans	rs2657294	0.796	rs6480770	ENSG00000172974.11	AC007318.5	9.96	2.28e-21	9.84e-15	0.45	0.41	Pneumonia;	chr10:75098799	chr2:65205108~65205988:+
LUAD	trans	rs7312770	0.612	rs773114	ENSG00000234354.3	RPS26P47	9.96	2.34e-21	1.01e-14	0.45	0.41	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr13:100539901~100540248:-
LUAD	trans	rs74781061	0.929	rs8041030	ENSG00000227288.3	RP5-837I24.1	9.96	2.34e-21	1.01e-14	0.63	0.41	Endometriosis;	chr15:74525726	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.929	rs6495109	ENSG00000227288.3	RP5-837I24.1	9.95	2.38e-21	1.02e-14	0.63	0.41	Endometriosis;	chr15:74504720	chr1:81501794~81503468:+
LUAD	trans	rs10940346	0.562	rs7736775	ENSG00000231752.4	EMBP1	-9.95	2.38e-21	1.02e-14	-0.56	-0.41	Schizophrenia;	chr5:50472463	chr1:121519112~121571892:+
LUAD	trans	rs877636	1	rs2292239	ENSG00000235459.5	RPS26P31	9.95	2.4e-21	1.03e-14	0.44	0.41	Cognitive function;	chr12:56088396	chr7:122681315~122681662:+
LUAD	trans	rs74781061	0.929	rs59946128	ENSG00000227288.3	RP5-837I24.1	9.95	2.49e-21	1.07e-14	0.62	0.41	Endometriosis;	chr15:74493006	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.929	rs60777494	ENSG00000227288.3	RP5-837I24.1	9.95	2.49e-21	1.07e-14	0.62	0.41	Endometriosis;	chr15:74493007	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.929	rs57271230	ENSG00000227288.3	RP5-837I24.1	9.95	2.49e-21	1.07e-14	0.62	0.41	Endometriosis;	chr15:74493018	chr1:81501794~81503468:+
LUAD	trans	rs877636	0.702	rs773108	ENSG00000243403.1	RP11-330L19.1	9.95	2.52e-21	1.08e-14	0.47	0.41	Cognitive function;	chr12:55976127	chr15:64592979~64593326:+
LUAD	trans	rs916888	0.821	rs199504	ENSG00000280022.1	RP11-707O23.1	-9.95	2.53e-21	1.09e-14	-0.59	-0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45592621~45593369:+
LUAD	trans	rs10940346	0.601	rs7378969	ENSG00000231752.4	EMBP1	-9.94	2.57e-21	1.1e-14	-0.56	-0.41	Schizophrenia;	chr5:50471925	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.58	rs10044979	ENSG00000231752.4	EMBP1	9.94	2.57e-21	1.1e-14	0.56	0.41	Schizophrenia;	chr5:50464074	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs10045034	ENSG00000231752.4	EMBP1	9.94	2.57e-21	1.1e-14	0.56	0.41	Schizophrenia;	chr5:50464323	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.54	rs59940663	ENSG00000231752.4	EMBP1	9.94	2.57e-21	1.1e-14	0.56	0.41	Schizophrenia;	chr5:50467345	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.58	rs34586987	ENSG00000231752.4	EMBP1	9.94	2.57e-21	1.1e-14	0.56	0.41	Schizophrenia;	chr5:50467574	chr1:121519112~121571892:+
LUAD	trans	rs74781061	1	rs4887166	ENSG00000227288.3	RP5-837I24.1	9.94	2.57e-21	1.1e-14	0.62	0.41	Endometriosis;	chr15:74605257	chr1:81501794~81503468:+
LUAD	trans	rs74781061	1	rs6495117	ENSG00000227288.3	RP5-837I24.1	9.94	2.57e-21	1.1e-14	0.62	0.41	Endometriosis;	chr15:74607159	chr1:81501794~81503468:+
LUAD	trans	rs55665837	0.539	rs731042	ENSG00000236360.2	RP11-334A14.2	9.94	2.66e-21	1.14e-14	0.56	0.41	Vitamin D levels;	chr11:14853429	chr1:52993201~52993702:-
LUAD	trans	rs7554547	0.622	rs2179110	ENSG00000261819.1	RP11-680G24.4	9.94	2.71e-21	1.16e-14	0.58	0.41	Nonsyndromic cleft lip with cleft palate;	chr1:11912754	chr16:14988259~14990160:-
LUAD	trans	rs74781061	0.929	rs117379081	ENSG00000227288.3	RP5-837I24.1	9.94	2.74e-21	1.17e-14	0.61	0.41	Endometriosis;	chr15:74480106	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.929	rs79600239	ENSG00000227288.3	RP5-837I24.1	9.94	2.74e-21	1.17e-14	0.61	0.41	Endometriosis;	chr15:74481987	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.929	rs16969247	ENSG00000227288.3	RP5-837I24.1	9.94	2.74e-21	1.17e-14	0.61	0.41	Endometriosis;	chr15:74486541	chr1:81501794~81503468:+
LUAD	trans	rs10940346	0.601	rs1344339	ENSG00000231752.4	EMBP1	-9.94	2.77e-21	1.19e-14	-0.54	-0.41	Schizophrenia;	chr5:50327987	chr1:121519112~121571892:+
LUAD	trans	rs10917477	0.653	rs1770480	ENSG00000224237.1	MINOS1P3	9.93	2.84e-21	1.21e-14	0.5	0.41	Thyroid function;	chr1:19590290	chr3:27214816~27215018:-
LUAD	trans	rs6708331	0.517	rs12614547	ENSG00000232654.1	FAM136BP	9.93	2.89e-21	1.24e-14	0.49	0.41	Obesity-related traits;	chr2:70056839	chr6:3045384~3045800:+
LUAD	trans	rs13253073	0.556	rs13279371	ENSG00000260318.1	COX6CP1	9.93	2.89e-21	1.24e-14	1.01	0.41	Glucose homeostasis traits;	chr8:99407006	chr16:11903923~11904137:-
LUAD	trans	rs10940346	0.601	rs57300567	ENSG00000231752.4	EMBP1	9.93	2.91e-21	1.24e-14	0.55	0.41	Schizophrenia;	chr5:50467359	chr1:121519112~121571892:+
LUAD	trans	rs13190036	1	rs17078781	ENSG00000228305.2	AC016734.2	-9.93	2.91e-21	1.25e-14	-0.59	-0.41	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177117227	chr2:63622178~63622831:-
LUAD	trans	rs11098499	0.644	rs10050092	ENSG00000275858.1	RP11-291L22.8	9.93	2.97e-21	1.27e-14	0.5	0.41	Corneal astigmatism;	chr4:119610930	chr10:38450738~38451069:-
LUAD	trans	rs74781061	0.858	rs58473469	ENSG00000227288.3	RP5-837I24.1	9.93	2.98e-21	1.28e-14	0.64	0.41	Endometriosis;	chr15:74592722	chr1:81501794~81503468:+
LUAD	trans	rs11098499	0.57	rs6832740	ENSG00000275858.1	RP11-291L22.8	9.93	2.99e-21	1.28e-14	0.5	0.41	Corneal astigmatism;	chr4:119624981	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.644	rs6855918	ENSG00000275858.1	RP11-291L22.8	9.93	2.99e-21	1.28e-14	0.5	0.41	Corneal astigmatism;	chr4:119625144	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.644	rs7676296	ENSG00000275858.1	RP11-291L22.8	9.92	3.04e-21	1.3e-14	0.5	0.41	Corneal astigmatism;	chr4:119634532	chr10:38450738~38451069:-
LUAD	trans	rs10940346	0.601	rs1841103	ENSG00000231752.4	EMBP1	-9.92	3.07e-21	1.31e-14	-0.55	-0.41	Schizophrenia;	chr5:50263913	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.562	rs504773	ENSG00000231752.4	EMBP1	-9.92	3.07e-21	1.31e-14	-0.55	-0.41	Schizophrenia;	chr5:50264656	chr1:121519112~121571892:+
LUAD	trans	rs3740713	0.669	rs113003553	ENSG00000235847.2	LDHAP7	9.92	3.11e-21	1.33e-14	0.68	0.41	Amyotrophic lateral sclerosis (sporadic);	chr11:18389314	chr2:84777259~84778223:-
LUAD	trans	rs10940346	0.601	rs4865698	ENSG00000231752.4	EMBP1	-9.92	3.14e-21	1.34e-14	-0.55	-0.41	Schizophrenia;	chr5:50303332	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs4865699	ENSG00000231752.4	EMBP1	-9.92	3.14e-21	1.34e-14	-0.55	-0.41	Schizophrenia;	chr5:50303347	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs4865700	ENSG00000231752.4	EMBP1	-9.92	3.14e-21	1.34e-14	-0.55	-0.41	Schizophrenia;	chr5:50303862	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs13178993	ENSG00000231752.4	EMBP1	-9.92	3.14e-21	1.34e-14	-0.55	-0.41	Schizophrenia;	chr5:50305256	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.58	rs7447926	ENSG00000231752.4	EMBP1	-9.92	3.14e-21	1.34e-14	-0.55	-0.41	Schizophrenia;	chr5:50310902	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs1511738	ENSG00000231752.4	EMBP1	-9.92	3.14e-21	1.34e-14	-0.55	-0.41	Schizophrenia;	chr5:50313444	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs10062032	ENSG00000231752.4	EMBP1	-9.92	3.14e-21	1.34e-14	-0.55	-0.41	Schizophrenia;	chr5:50316138	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs10074359	ENSG00000231752.4	EMBP1	-9.92	3.14e-21	1.34e-14	-0.55	-0.41	Schizophrenia;	chr5:50316423	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs1606224	ENSG00000231752.4	EMBP1	-9.92	3.14e-21	1.34e-14	-0.55	-0.41	Schizophrenia;	chr5:50317405	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs7341010	ENSG00000231752.4	EMBP1	-9.92	3.14e-21	1.34e-14	-0.55	-0.41	Schizophrenia;	chr5:50317811	chr1:121519112~121571892:+
LUAD	trans	rs55665837	0.539	rs10832310	ENSG00000236360.2	RP11-334A14.2	9.92	3.14e-21	1.34e-14	0.56	0.41	Vitamin D levels;	chr11:14856896	chr1:52993201~52993702:-
LUAD	trans	rs55665837	0.539	rs10832311	ENSG00000236360.2	RP11-334A14.2	9.92	3.14e-21	1.34e-14	0.56	0.41	Vitamin D levels;	chr11:14860380	chr1:52993201~52993702:-
LUAD	trans	rs10940346	0.51	rs10038023	ENSG00000231752.4	EMBP1	-9.92	3.17e-21	1.35e-14	-0.55	-0.41	Schizophrenia;	chr5:50280387	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.644	rs7693919	ENSG00000275858.1	RP11-291L22.8	9.92	3.24e-21	1.38e-14	0.5	0.41	Corneal astigmatism;	chr4:119619416	chr10:38450738~38451069:-
LUAD	trans	rs8175379	0.506	rs8188256	ENSG00000231752.4	EMBP1	-9.92	3.26e-21	1.39e-14	-0.55	-0.41	Interleukin-7 levels;	chr5:46372404	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.623	rs7736990	ENSG00000231752.4	EMBP1	-9.92	3.26e-21	1.39e-14	-0.55	-0.41	Schizophrenia;	chr5:50300008	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs10079897	ENSG00000231752.4	EMBP1	-9.92	3.26e-21	1.39e-14	-0.55	-0.41	Schizophrenia;	chr5:50300032	chr1:121519112~121571892:+
LUAD	trans	rs10037055	0.741	rs2336405	ENSG00000217325.2	PRELID1P1	-9.91	3.31e-21	1.41e-14	-0.52	-0.41	Migraine without aura;	chr5:177230288	chr6:126643488~126644390:+
LUAD	trans	rs74781061	0.929	rs7171838	ENSG00000227288.3	RP5-837I24.1	9.91	3.32e-21	1.41e-14	0.62	0.41	Endometriosis;	chr15:74571778	chr1:81501794~81503468:+
LUAD	trans	rs10940346	0.601	rs2137129	ENSG00000231752.4	EMBP1	-9.91	3.46e-21	1.47e-14	-0.55	-0.41	Schizophrenia;	chr5:50300962	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs12513730	ENSG00000231752.4	EMBP1	-9.91	3.46e-21	1.47e-14	-0.55	-0.41	Schizophrenia;	chr5:50302800	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs1511737	ENSG00000231752.4	EMBP1	-9.91	3.46e-21	1.47e-14	-0.55	-0.41	Schizophrenia;	chr5:50312308	chr1:121519112~121571892:+
LUAD	trans	rs10917477	0.594	rs2792043	ENSG00000224237.1	MINOS1P3	9.91	3.52e-21	1.5e-14	0.5	0.41	Thyroid function;	chr1:19598168	chr3:27214816~27215018:-
LUAD	trans	rs10940346	0.601	rs7724645	ENSG00000231752.4	EMBP1	-9.91	3.57e-21	1.52e-14	-0.55	-0.41	Schizophrenia;	chr5:50299846	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.56	rs6892613	ENSG00000231752.4	EMBP1	9.9	3.65e-21	1.55e-14	0.55	0.41	Schizophrenia;	chr5:50353678	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs6450056	ENSG00000231752.4	EMBP1	9.9	3.65e-21	1.55e-14	0.55	0.41	Schizophrenia;	chr5:50356692	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs4637546	ENSG00000231752.4	EMBP1	9.9	3.65e-21	1.55e-14	0.55	0.41	Schizophrenia;	chr5:50358359	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs10073591	ENSG00000231752.4	EMBP1	9.9	3.65e-21	1.55e-14	0.55	0.41	Schizophrenia;	chr5:50359010	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.521	rs7730857	ENSG00000231752.4	EMBP1	9.9	3.65e-21	1.55e-14	0.55	0.41	Schizophrenia;	chr5:50361516	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.58	rs10071725	ENSG00000231752.4	EMBP1	9.9	3.65e-21	1.55e-14	0.55	0.41	Schizophrenia;	chr5:50361986	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs7732000	ENSG00000231752.4	EMBP1	9.9	3.65e-21	1.55e-14	0.55	0.41	Schizophrenia;	chr5:50364779	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs11959569	ENSG00000231752.4	EMBP1	9.9	3.65e-21	1.55e-14	0.55	0.41	Schizophrenia;	chr5:50369429	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs6450063	ENSG00000231752.4	EMBP1	9.9	3.65e-21	1.55e-14	0.55	0.41	Schizophrenia;	chr5:50374147	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs10042504	ENSG00000231752.4	EMBP1	9.9	3.65e-21	1.55e-14	0.55	0.41	Schizophrenia;	chr5:50386329	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs2353221	ENSG00000231752.4	EMBP1	-9.9	3.73e-21	1.58e-14	-0.55	-0.41	Schizophrenia;	chr5:50299085	chr1:121519112~121571892:+
LUAD	trans	rs12709013	0.875	rs9924389	ENSG00000230849.2	GOT2P2	9.9	3.86e-21	1.64e-14	0.5	0.41	Blood metabolite ratios;	chr16:58779849	chr1:173141100~173142350:-
LUAD	trans	rs12709013	1	rs11648514	ENSG00000230849.2	GOT2P2	9.9	3.88e-21	1.64e-14	0.51	0.41	Blood metabolite ratios;	chr16:58798176	chr1:173141100~173142350:-
LUAD	trans	rs12709013	1	rs8057892	ENSG00000230849.2	GOT2P2	9.9	3.88e-21	1.64e-14	0.51	0.41	Blood metabolite ratios;	chr16:58798855	chr1:173141100~173142350:-
LUAD	trans	rs13253073	0.556	rs35194538	ENSG00000260318.1	COX6CP1	9.89	3.91e-21	1.65e-14	1.01	0.41	Glucose homeostasis traits;	chr8:99397627	chr16:11903923~11904137:-
LUAD	trans	rs10940346	0.601	rs6449802	ENSG00000231752.4	EMBP1	-9.89	3.94e-21	1.67e-14	-0.54	-0.41	Schizophrenia;	chr5:50299390	chr1:121519112~121571892:+
LUAD	trans	rs1816752	0.679	rs8181826	ENSG00000224976.2	PARP4P2	9.89	3.97e-21	1.68e-14	0.47	0.41	Obesity-related traits;	chr13:24396570	chr13:19349137~19407962:+
LUAD	trans	rs74781061	0.929	rs8028430	ENSG00000227288.3	RP5-837I24.1	9.89	4e-21	1.69e-14	0.61	0.41	Endometriosis;	chr15:74553404	chr1:81501794~81503468:+
LUAD	trans	rs12200782	0.53	rs9379892	ENSG00000242375.1	RP11-498P14.3	9.89	4.1e-21	1.73e-14	0.67	0.41	Small cell lung carcinoma;	chr6:26582186	chr9:97195351~97197687:-
LUAD	trans	rs10940346	0.541	rs10041893	ENSG00000231752.4	EMBP1	9.89	4.18e-21	1.77e-14	0.56	0.41	Schizophrenia;	chr5:50460740	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs10940075	ENSG00000231752.4	EMBP1	-9.88	4.26e-21	1.8e-14	-0.55	-0.41	Schizophrenia;	chr5:50304547	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.644	rs3806808	ENSG00000275858.1	RP11-291L22.8	9.88	4.28e-21	1.81e-14	0.5	0.41	Corneal astigmatism;	chr4:119629930	chr10:38450738~38451069:-
LUAD	trans	rs12145833	0.596	rs12043646	ENSG00000154608.12	CEP170P1	-9.88	4.34e-21	1.83e-14	-0.72	-0.41	Obesity (early onset extreme);	chr1:243118690	chr4:118467590~118554204:+
LUAD	trans	rs72615157	0.628	rs7801070	ENSG00000228546.2	CTA-313A17.3	9.88	4.36e-21	1.84e-14	0.6	0.41	Lung function (FEV1/FVC);	chr7:100249524	chr7:102337316~102339115:+
LUAD	trans	rs10940346	0.601	rs3849669	ENSG00000231752.4	EMBP1	9.88	4.42e-21	1.86e-14	0.55	0.41	Schizophrenia;	chr5:50365710	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.56	rs2137134	ENSG00000231752.4	EMBP1	9.88	4.55e-21	1.92e-14	0.55	0.41	Schizophrenia;	chr5:50354188	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.54	rs57137858	ENSG00000231752.4	EMBP1	9.88	4.55e-21	1.92e-14	0.55	0.41	Schizophrenia;	chr5:50369737	chr1:121519112~121571892:+
LUAD	trans	rs7554547	0.667	rs6666533	ENSG00000261819.1	RP11-680G24.4	9.88	4.56e-21	1.92e-14	0.57	0.41	Nonsyndromic cleft lip with cleft palate;	chr1:11889068	chr16:14988259~14990160:-
LUAD	trans	rs11098499	0.644	rs34835603	ENSG00000275858.1	RP11-291L22.8	9.88	4.57e-21	1.92e-14	0.5	0.41	Corneal astigmatism;	chr4:119632273	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.615	rs28850368	ENSG00000275858.1	RP11-291L22.8	9.88	4.57e-21	1.92e-14	0.5	0.41	Corneal astigmatism;	chr4:119633158	chr10:38450738~38451069:-
LUAD	trans	rs4276421	0.776	rs4133429	ENSG00000231752.4	EMBP1	9.87	4.61e-21	1.94e-14	0.54	0.41	P wave duration;	chr5:45403633	chr1:121519112~121571892:+
LUAD	trans	rs13190036	1	rs34446750	ENSG00000228305.2	AC016734.2	-9.87	4.63e-21	1.95e-14	-0.59	-0.41	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177168079	chr2:63622178~63622831:-
LUAD	trans	rs77688320	0.517	rs10931949	ENSG00000235105.1	RP11-329A14.1	9.87	4.63e-21	1.95e-14	0.48	0.41	Breast cancer;	chr2:201459730	chr1:48435967~48437223:+
LUAD	trans	rs10940346	0.601	rs9291925	ENSG00000231752.4	EMBP1	9.87	4.65e-21	1.96e-14	0.55	0.41	Schizophrenia;	chr5:50320129	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs7722742	ENSG00000231752.4	EMBP1	9.87	4.65e-21	1.96e-14	0.55	0.41	Schizophrenia;	chr5:50320312	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.562	rs6449961	ENSG00000231752.4	EMBP1	9.87	4.65e-21	1.96e-14	0.55	0.41	Schizophrenia;	chr5:50320867	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.58	rs7705284	ENSG00000231752.4	EMBP1	9.87	4.65e-21	1.96e-14	0.55	0.41	Schizophrenia;	chr5:50325574	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs10054503	ENSG00000231752.4	EMBP1	9.87	4.65e-21	1.96e-14	0.55	0.41	Schizophrenia;	chr5:50326746	chr1:121519112~121571892:+
LUAD	trans	rs13190036	1	rs34832871	ENSG00000228305.2	AC016734.2	-9.87	4.84e-21	2.03e-14	-0.59	-0.41	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228928	chr2:63622178~63622831:-
LUAD	trans	rs7662987	0.793	rs7684735	ENSG00000233859.2	ADH5P4	9.87	4.87e-21	2.05e-14	0.59	0.41	Smoking initiation;	chr4:99070355	chr6:65836930~65838039:-
LUAD	trans	rs616147	0.548	rs2370965	ENSG00000214263.2	RPSAP53	-9.87	4.88e-21	2.05e-14	-0.54	-0.41	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39448996	chr13:67266845~67267706:-
LUAD	trans	rs1079467	1	rs1079467	ENSG00000233426.3	EIF3FP3	-9.87	4.94e-21	2.08e-14	-0.65	-0.41	Response to anti-TNF therapy in rheumatoid arthritis;	chr11:7948164	chr2:58251440~58252525:+
LUAD	trans	rs11098499	0.644	rs2389880	ENSG00000275858.1	RP11-291L22.8	9.86	5.05e-21	2.12e-14	0.5	0.41	Corneal astigmatism;	chr4:119638715	chr10:38450738~38451069:-
LUAD	trans	rs10940346	0.623	rs6863840	ENSG00000231752.4	EMBP1	9.86	5.08e-21	2.13e-14	0.55	0.41	Schizophrenia;	chr5:50328070	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.58	rs6871761	ENSG00000231752.4	EMBP1	9.86	5.08e-21	2.13e-14	0.55	0.41	Schizophrenia;	chr5:50328134	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs6877713	ENSG00000231752.4	EMBP1	9.86	5.08e-21	2.13e-14	0.55	0.41	Schizophrenia;	chr5:50329254	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs4337857	ENSG00000231752.4	EMBP1	9.86	5.08e-21	2.13e-14	0.55	0.41	Schizophrenia;	chr5:50329735	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.562	rs34601168	ENSG00000231752.4	EMBP1	9.86	5.08e-21	2.13e-14	0.55	0.41	Schizophrenia;	chr5:50330561	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs35740733	ENSG00000231752.4	EMBP1	9.86	5.08e-21	2.13e-14	0.55	0.41	Schizophrenia;	chr5:50330771	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.502	rs77189370	ENSG00000231752.4	EMBP1	9.86	5.08e-21	2.13e-14	0.55	0.41	Schizophrenia;	chr5:50334920	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.54	rs10039622	ENSG00000231752.4	EMBP1	9.86	5.08e-21	2.13e-14	0.55	0.41	Schizophrenia;	chr5:50336720	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs10064702	ENSG00000231752.4	EMBP1	9.86	5.08e-21	2.13e-14	0.55	0.41	Schizophrenia;	chr5:50336928	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs13160697	ENSG00000231752.4	EMBP1	9.86	5.08e-21	2.13e-14	0.55	0.41	Schizophrenia;	chr5:50339822	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.644	rs10012252	ENSG00000275858.1	RP11-291L22.8	9.86	5.09e-21	2.14e-14	0.5	0.41	Corneal astigmatism;	chr4:119637984	chr10:38450738~38451069:-
LUAD	trans	rs74781061	0.932	rs11857328	ENSG00000227288.3	RP5-837I24.1	9.86	5.11e-21	2.14e-14	0.61	0.41	Endometriosis;	chr15:74510550	chr1:81501794~81503468:+
LUAD	trans	rs10940346	0.58	rs6876902	ENSG00000231752.4	EMBP1	9.86	5.14e-21	2.16e-14	0.54	0.41	Schizophrenia;	chr5:50320934	chr1:121519112~121571892:+
LUAD	trans	rs11023332	0.832	rs10832289	ENSG00000236360.2	RP11-334A14.2	-9.86	5.14e-21	2.16e-14	-0.54	-0.41	Vitamin D levels;Adiponectin levels;	chr11:14647950	chr1:52993201~52993702:-
LUAD	trans	rs4276421	0.776	rs13175193	ENSG00000231752.4	EMBP1	9.86	5.19e-21	2.18e-14	0.54	0.41	P wave duration;	chr5:45408894	chr1:121519112~121571892:+
LUAD	trans	rs10917477	0.624	rs1320978	ENSG00000224237.1	MINOS1P3	9.86	5.33e-21	2.23e-14	0.5	0.41	Thyroid function;	chr1:19621479	chr3:27214816~27215018:-
LUAD	trans	rs7554547	0.622	rs28455075	ENSG00000261819.1	RP11-680G24.4	9.86	5.35e-21	2.24e-14	0.56	0.41	Nonsyndromic cleft lip with cleft palate;	chr1:11879663	chr16:14988259~14990160:-
LUAD	trans	rs10940346	0.601	rs11960276	ENSG00000231752.4	EMBP1	-9.85	5.44e-21	2.28e-14	-0.55	-0.41	Schizophrenia;	chr5:50265194	chr1:121519112~121571892:+
LUAD	trans	rs7662987	0.793	rs7669660	ENSG00000233859.2	ADH5P4	9.85	5.7e-21	2.39e-14	0.59	0.41	Smoking initiation;	chr4:99071451	chr6:65836930~65838039:-
LUAD	trans	rs7662987	0.793	rs12106	ENSG00000233859.2	ADH5P4	9.85	5.7e-21	2.39e-14	0.59	0.41	Smoking initiation;	chr4:99072199	chr6:65836930~65838039:-
LUAD	trans	rs10940346	0.601	rs7710841	ENSG00000231752.4	EMBP1	9.85	5.83e-21	2.44e-14	0.55	0.41	Schizophrenia;	chr5:50349986	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs7722623	ENSG00000231752.4	EMBP1	9.85	5.83e-21	2.44e-14	0.55	0.41	Schizophrenia;	chr5:50350496	chr1:121519112~121571892:+
LUAD	trans	rs74781061	0.929	rs2415242	ENSG00000227288.3	RP5-837I24.1	9.84	5.93e-21	2.48e-14	0.62	0.41	Endometriosis;	chr15:74546765	chr1:81501794~81503468:+
LUAD	trans	rs13190036	1	rs35535623	ENSG00000228305.2	AC016734.2	-9.84	6e-21	2.51e-14	-0.59	-0.41	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177202295	chr2:63622178~63622831:-
LUAD	trans	rs13190036	0.591	rs78523677	ENSG00000226986.4	RP11-543B16.2	-9.84	6.06e-21	2.53e-14	-0.58	-0.41	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177124102	chr1:211207239~211207897:+
LUAD	trans	rs4276421	0.869	rs1351720	ENSG00000231752.4	EMBP1	9.84	6.06e-21	2.54e-14	0.55	0.41	P wave duration;	chr5:45561801	chr1:121519112~121571892:+
LUAD	trans	rs74781061	0.929	rs4886601	ENSG00000227288.3	RP5-837I24.1	9.84	6.09e-21	2.55e-14	0.63	0.41	Endometriosis;	chr15:74591510	chr1:81501794~81503468:+
LUAD	trans	rs867371	1	rs867370	ENSG00000235370.6	DNM1P51	9.84	6.16e-21	2.57e-14	0.48	0.41	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82145921	chr15:84398316~84411701:-
LUAD	trans	rs867371	1	rs867371	ENSG00000235370.6	DNM1P51	9.84	6.16e-21	2.57e-14	0.48	0.41	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82146005	chr15:84398316~84411701:-
LUAD	trans	rs7312770	0.637	rs705699	ENSG00000227887.1	RPS26P13	9.84	6.18e-21	2.58e-14	0.46	0.41	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr1:208697369~208697698:-
LUAD	trans	rs10940346	0.601	rs4398636	ENSG00000231752.4	EMBP1	9.84	6.23e-21	2.6e-14	0.55	0.41	Schizophrenia;	chr5:50391957	chr1:121519112~121571892:+
LUAD	trans	rs77688320	0.553	rs2540430	ENSG00000235105.1	RP11-329A14.1	-9.84	6.28e-21	2.62e-14	-0.49	-0.41	Breast cancer;	chr2:201503791	chr1:48435967~48437223:+
LUAD	trans	rs10940346	0.601	rs4865675	ENSG00000231752.4	EMBP1	-9.84	6.36e-21	2.66e-14	-0.55	-0.41	Schizophrenia;	chr5:50279300	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs506919	ENSG00000231752.4	EMBP1	-9.84	6.36e-21	2.66e-14	-0.55	-0.41	Schizophrenia;	chr5:50279635	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs1858343	ENSG00000231752.4	EMBP1	-9.84	6.36e-21	2.66e-14	-0.55	-0.41	Schizophrenia;	chr5:50290180	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.58	rs1858344	ENSG00000231752.4	EMBP1	-9.84	6.36e-21	2.66e-14	-0.55	-0.41	Schizophrenia;	chr5:50290345	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.58	rs12332500	ENSG00000231752.4	EMBP1	9.83	6.46e-21	2.7e-14	0.54	0.41	Schizophrenia;	chr5:50349021	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs7723480	ENSG00000231752.4	EMBP1	9.83	6.46e-21	2.7e-14	0.54	0.41	Schizophrenia;	chr5:50350324	chr1:121519112~121571892:+
LUAD	trans	rs8010715	1	rs3742500	ENSG00000238000.1	RP11-274E7.2	9.83	6.54e-21	2.73e-14	0.47	0.41	IgG glycosylation;	chr14:24142769	chr5:98213402~98214121:+
LUAD	trans	rs4276421	0.806	rs13162651	ENSG00000231752.4	EMBP1	9.83	6.56e-21	2.74e-14	0.54	0.41	P wave duration;	chr5:45409798	chr1:121519112~121571892:+
LUAD	trans	rs12138950	0.681	rs9783019	ENSG00000224237.1	MINOS1P3	9.83	6.7e-21	2.79e-14	0.52	0.41	Hypothyroidism;Thyroid volume;	chr1:19523162	chr3:27214816~27215018:-
LUAD	trans	rs11023332	1	rs11023332	ENSG00000236360.2	RP11-334A14.2	9.83	6.73e-21	2.81e-14	0.55	0.41	Vitamin D levels;Adiponectin levels;	chr11:14762564	chr1:52993201~52993702:-
LUAD	trans	rs11098499	0.754	rs1546503	ENSG00000275858.1	RP11-291L22.8	9.83	6.8e-21	2.83e-14	0.49	0.41	Corneal astigmatism;	chr4:119320012	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.708	rs1546506	ENSG00000275858.1	RP11-291L22.8	9.83	6.8e-21	2.83e-14	0.49	0.41	Corneal astigmatism;	chr4:119320085	chr10:38450738~38451069:-
LUAD	trans	rs74781061	0.929	rs12442097	ENSG00000227288.3	RP5-837I24.1	9.83	6.81e-21	2.84e-14	0.62	0.41	Endometriosis;	chr15:74554792	chr1:81501794~81503468:+
LUAD	trans	rs74781061	1	rs6495116	ENSG00000227288.3	RP5-837I24.1	9.83	6.93e-21	2.89e-14	0.62	0.41	Endometriosis;	chr15:74593607	chr1:81501794~81503468:+
LUAD	trans	rs10037055	0.853	rs10035180	ENSG00000217325.2	PRELID1P1	-9.82	7.08e-21	2.95e-14	-0.52	-0.41	Migraine without aura;	chr5:177171501	chr6:126643488~126644390:+
LUAD	trans	rs10940346	0.668	rs6884426	ENSG00000231752.4	EMBP1	-9.82	7.21e-21	3e-14	-0.56	-0.41	Schizophrenia;	chr5:50492782	chr1:121519112~121571892:+
LUAD	trans	rs13190036	0.901	rs28715668	ENSG00000228305.2	AC016734.2	9.82	7.26e-21	3.02e-14	0.59	0.41	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272267	chr2:63622178~63622831:-
LUAD	trans	rs877636	0.669	rs7297175	ENSG00000234354.3	RPS26P47	-9.82	7.42e-21	3.09e-14	-0.44	-0.41	Cognitive function;	chr12:56080024	chr13:100539901~100540248:-
LUAD	trans	rs10940346	0.562	rs13182357	ENSG00000231752.4	EMBP1	9.82	7.49e-21	3.12e-14	0.57	0.41	Schizophrenia;	chr5:50404060	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.675	rs11098534	ENSG00000275858.1	RP11-291L22.8	9.81	7.87e-21	3.27e-14	0.5	0.41	Corneal astigmatism;	chr4:119635617	chr10:38450738~38451069:-
LUAD	trans	rs13190036	1	rs13167431	ENSG00000228305.2	AC016734.2	-9.81	8.09e-21	3.36e-14	-0.59	-0.41	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177194074	chr2:63622178~63622831:-
LUAD	trans	rs11098499	0.789	rs1980024	ENSG00000275858.1	RP11-291L22.8	9.81	8.19e-21	3.4e-14	0.49	0.41	Corneal astigmatism;	chr4:119331892	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.754	rs34425882	ENSG00000275858.1	RP11-291L22.8	9.81	8.19e-21	3.4e-14	0.49	0.41	Corneal astigmatism;	chr4:119332022	chr10:38450738~38451069:-
LUAD	trans	rs10940346	0.541	rs4865914	ENSG00000231752.4	EMBP1	-9.8	8.34e-21	3.47e-14	-0.55	-0.41	Schizophrenia;	chr5:50173322	chr1:121519112~121571892:+
LUAD	trans	rs616147	0.671	rs674192	ENSG00000214263.2	RPSAP53	-9.8	8.4e-21	3.49e-14	-0.53	-0.41	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39458653	chr13:67266845~67267706:-
LUAD	trans	rs11098499	0.754	rs12510269	ENSG00000275858.1	RP11-291L22.8	9.8	8.46e-21	3.51e-14	0.49	0.41	Corneal astigmatism;	chr4:119320491	chr10:38450738~38451069:-
LUAD	trans	rs10940346	0.562	rs563750	ENSG00000231752.4	EMBP1	-9.8	8.5e-21	3.53e-14	-0.54	-0.41	Schizophrenia;	chr5:50278004	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs507761	ENSG00000231752.4	EMBP1	-9.8	8.5e-21	3.53e-14	-0.54	-0.41	Schizophrenia;	chr5:50279558	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs494540	ENSG00000231752.4	EMBP1	-9.8	8.5e-21	3.53e-14	-0.54	-0.41	Schizophrenia;	chr5:50280228	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs471455	ENSG00000231752.4	EMBP1	-9.8	8.5e-21	3.53e-14	-0.54	-0.41	Schizophrenia;	chr5:50280427	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs13360551	ENSG00000231752.4	EMBP1	-9.8	8.5e-21	3.53e-14	-0.54	-0.41	Schizophrenia;	chr5:50287350	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs4865685	ENSG00000231752.4	EMBP1	-9.8	8.5e-21	3.53e-14	-0.54	-0.41	Schizophrenia;	chr5:50290682	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs6449779	ENSG00000231752.4	EMBP1	-9.8	8.5e-21	3.53e-14	-0.54	-0.41	Schizophrenia;	chr5:50290876	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.806	rs6414906	ENSG00000231752.4	EMBP1	9.8	8.7e-21	3.61e-14	0.55	0.41	P wave duration;	chr5:45406219	chr1:121519112~121571892:+
LUAD	trans	rs74781061	0.929	rs8029215	ENSG00000227288.3	RP5-837I24.1	9.8	8.81e-21	3.65e-14	0.62	0.41	Endometriosis;	chr15:74561147	chr1:81501794~81503468:+
LUAD	trans	rs877636	1	rs877636	ENSG00000212994.5	RPS26P6	-9.8	8.86e-21	3.67e-14	-0.48	-0.41	Cognitive function;	chr12:56086799	chr8:100895771~100896118:+
LUAD	trans	rs12709013	1	rs34319345	ENSG00000230849.2	GOT2P2	9.79	8.94e-21	3.7e-14	0.5	0.41	Blood metabolite ratios;	chr16:58786688	chr1:173141100~173142350:-
LUAD	trans	rs11098499	0.754	rs12506610	ENSG00000275858.1	RP11-291L22.8	9.79	9.02e-21	3.73e-14	0.49	0.41	Corneal astigmatism;	chr4:119320504	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.743	rs10003567	ENSG00000275858.1	RP11-291L22.8	9.79	9.02e-21	3.73e-14	0.49	0.41	Corneal astigmatism;	chr4:119320519	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.754	rs10006259	ENSG00000275858.1	RP11-291L22.8	9.79	9.02e-21	3.73e-14	0.49	0.41	Corneal astigmatism;	chr4:119320990	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.754	rs28652763	ENSG00000275858.1	RP11-291L22.8	9.79	9.02e-21	3.73e-14	0.49	0.41	Corneal astigmatism;	chr4:119321157	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.691	rs12510133	ENSG00000275858.1	RP11-291L22.8	9.79	9.13e-21	3.77e-14	0.46	0.41	Corneal astigmatism;	chr4:119350189	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.754	rs12506487	ENSG00000275858.1	RP11-291L22.8	9.79	9.13e-21	3.77e-14	0.46	0.41	Corneal astigmatism;	chr4:119350206	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.691	rs12502524	ENSG00000275858.1	RP11-291L22.8	9.79	9.13e-21	3.77e-14	0.46	0.41	Corneal astigmatism;	chr4:119350259	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.691	rs28396837	ENSG00000275858.1	RP11-291L22.8	9.79	9.13e-21	3.77e-14	0.46	0.41	Corneal astigmatism;	chr4:119350386	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.629	rs28369518	ENSG00000275858.1	RP11-291L22.8	9.79	9.13e-21	3.77e-14	0.46	0.41	Corneal astigmatism;	chr4:119350475	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.722	rs10025925	ENSG00000275858.1	RP11-291L22.8	9.79	9.13e-21	3.77e-14	0.46	0.41	Corneal astigmatism;	chr4:119350589	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.731	rs10015579	ENSG00000275858.1	RP11-291L22.8	9.79	9.13e-21	3.77e-14	0.46	0.41	Corneal astigmatism;	chr4:119350647	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.754	rs12513083	ENSG00000275858.1	RP11-291L22.8	9.79	9.14e-21	3.77e-14	0.49	0.41	Corneal astigmatism;	chr4:119328457	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.754	rs12509621	ENSG00000275858.1	RP11-291L22.8	9.79	9.14e-21	3.77e-14	0.49	0.41	Corneal astigmatism;	chr4:119328505	chr10:38450738~38451069:-
LUAD	trans	rs10940346	0.601	rs524184	ENSG00000231752.4	EMBP1	-9.79	9.36e-21	3.87e-14	-0.54	-0.41	Schizophrenia;	chr5:50276256	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.644	rs10009566	ENSG00000275858.1	RP11-291L22.8	9.79	9.48e-21	3.92e-14	0.49	0.41	Corneal astigmatism;	chr4:119637453	chr10:38450738~38451069:-
LUAD	trans	rs12709013	0.935	rs11648634	ENSG00000230849.2	GOT2P2	9.78	9.75e-21	4.02e-14	0.5	0.41	Blood metabolite ratios;	chr16:58785256	chr1:173141100~173142350:-
LUAD	trans	rs4276421	0.869	rs7736561	ENSG00000231752.4	EMBP1	9.78	9.76e-21	4.03e-14	0.54	0.41	P wave duration;	chr5:45716294	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.562	rs555704	ENSG00000231752.4	EMBP1	-9.78	9.88e-21	4.07e-14	-0.54	-0.41	Schizophrenia;	chr5:50277066	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.754	rs1511017	ENSG00000275858.1	RP11-291L22.8	9.78	9.95e-21	4.1e-14	0.49	0.41	Corneal astigmatism;	chr4:119329650	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.789	rs12498994	ENSG00000275858.1	RP11-291L22.8	9.78	9.95e-21	4.1e-14	0.49	0.41	Corneal astigmatism;	chr4:119329663	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.754	rs12507565	ENSG00000275858.1	RP11-291L22.8	9.78	9.95e-21	4.1e-14	0.49	0.41	Corneal astigmatism;	chr4:119329966	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.826	rs12511640	ENSG00000275858.1	RP11-291L22.8	9.78	9.95e-21	4.1e-14	0.49	0.41	Corneal astigmatism;	chr4:119330093	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.754	rs1980026	ENSG00000275858.1	RP11-291L22.8	9.78	9.95e-21	4.1e-14	0.49	0.41	Corneal astigmatism;	chr4:119330488	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.743	rs11098501	ENSG00000275858.1	RP11-291L22.8	9.78	9.95e-21	4.1e-14	0.49	0.41	Corneal astigmatism;	chr4:119330862	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.754	rs11098502	ENSG00000275858.1	RP11-291L22.8	9.78	9.95e-21	4.1e-14	0.49	0.41	Corneal astigmatism;	chr4:119330908	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.708	rs11732686	ENSG00000275858.1	RP11-291L22.8	9.78	9.95e-21	4.1e-14	0.49	0.41	Corneal astigmatism;	chr4:119331175	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.754	rs11724409	ENSG00000275858.1	RP11-291L22.8	9.78	9.95e-21	4.1e-14	0.49	0.41	Corneal astigmatism;	chr4:119331206	chr10:38450738~38451069:-
LUAD	trans	rs10940346	0.601	rs6860503	ENSG00000231752.4	EMBP1	9.78	1e-20	4.14e-14	0.57	0.41	Schizophrenia;	chr5:50446340	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs6861461	ENSG00000231752.4	EMBP1	9.78	1.02e-20	4.19e-14	0.54	0.41	Schizophrenia;	chr5:50348493	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.623	rs4865519	ENSG00000231752.4	EMBP1	-9.78	1.03e-20	4.24e-14	-0.54	-0.41	Schizophrenia;	chr5:50293002	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.663	rs9996501	ENSG00000275858.1	RP11-291L22.8	9.78	1.03e-20	4.26e-14	0.49	0.41	Corneal astigmatism;	chr4:119317763	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.697	rs28458294	ENSG00000275858.1	RP11-291L22.8	9.78	1.03e-20	4.26e-14	0.49	0.41	Corneal astigmatism;	chr4:119317769	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.663	rs28369503	ENSG00000275858.1	RP11-291L22.8	9.78	1.03e-20	4.26e-14	0.49	0.41	Corneal astigmatism;	chr4:119317770	chr10:38450738~38451069:-
LUAD	trans	rs12709013	1	rs12926993	ENSG00000230849.2	GOT2P2	9.78	1.04e-20	4.27e-14	0.5	0.41	Blood metabolite ratios;	chr16:58789218	chr1:173141100~173142350:-
LUAD	trans	rs10940346	0.601	rs34616519	ENSG00000231752.4	EMBP1	9.77	1.08e-20	4.46e-14	0.56	0.41	Schizophrenia;	chr5:50353638	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.562	rs1674514	ENSG00000231752.4	EMBP1	-9.77	1.09e-20	4.47e-14	-0.54	-0.41	Schizophrenia;	chr5:50269291	chr1:121519112~121571892:+
LUAD	trans	rs13190036	1	rs28580074	ENSG00000228305.2	AC016734.2	9.77	1.09e-20	4.5e-14	0.58	0.41	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177294197	chr2:63622178~63622831:-
LUAD	trans	rs74781061	0.929	rs12439113	ENSG00000227288.3	RP5-837I24.1	9.77	1.12e-20	4.61e-14	0.62	0.41	Endometriosis;	chr15:74563806	chr1:81501794~81503468:+
LUAD	trans	rs11098499	0.754	rs4107728	ENSG00000275858.1	RP11-291L22.8	9.77	1.12e-20	4.62e-14	0.49	0.41	Corneal astigmatism;	chr4:119332755	chr10:38450738~38451069:-
LUAD	trans	rs3740713	0.669	rs78098319	ENSG00000235847.2	LDHAP7	9.77	1.12e-20	4.62e-14	0.68	0.41	Amyotrophic lateral sclerosis (sporadic);	chr11:18382752	chr2:84777259~84778223:-
LUAD	trans	rs72615157	0.645	rs11771660	ENSG00000228546.2	CTA-313A17.3	9.76	1.21e-20	4.96e-14	0.6	0.41	Lung function (FEV1/FVC);	chr7:100253646	chr7:102337316~102339115:+
LUAD	trans	rs13190036	0.551	rs7732930	ENSG00000226986.4	RP11-543B16.2	-9.76	1.22e-20	5e-14	-0.55	-0.41	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177121593	chr1:211207239~211207897:+
LUAD	trans	rs10940346	0.601	rs496230	ENSG00000231752.4	EMBP1	-9.75	1.25e-20	5.13e-14	-0.54	-0.41	Schizophrenia;	chr5:50275179	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs526329	ENSG00000231752.4	EMBP1	-9.75	1.25e-20	5.13e-14	-0.54	-0.41	Schizophrenia;	chr5:50276141	chr1:121519112~121571892:+
LUAD	trans	rs6477998	0.702	rs7861707	ENSG00000238072.1	RP11-305M3.2	9.75	1.25e-20	5.14e-14	0.57	0.41	Hematology traits;	chr9:113251428	chr7:129410113~129410370:-
LUAD	trans	rs11098499	0.722	rs28713555	ENSG00000275858.1	RP11-291L22.8	9.75	1.26e-20	5.19e-14	0.49	0.41	Corneal astigmatism;	chr4:119330840	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.691	rs9996644	ENSG00000275858.1	RP11-291L22.8	9.75	1.28e-20	5.25e-14	0.49	0.41	Corneal astigmatism;	chr4:119317722	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.691	rs9996494	ENSG00000275858.1	RP11-291L22.8	9.75	1.28e-20	5.25e-14	0.49	0.41	Corneal astigmatism;	chr4:119317725	chr10:38450738~38451069:-
LUAD	trans	rs10037055	0.853	rs10056008	ENSG00000217325.2	PRELID1P1	-9.75	1.3e-20	5.32e-14	-0.51	-0.41	Migraine without aura;	chr5:177194147	chr6:126643488~126644390:+
LUAD	trans	rs10037055	0.853	rs10476219	ENSG00000217325.2	PRELID1P1	-9.75	1.3e-20	5.32e-14	-0.51	-0.41	Migraine without aura;	chr5:177201547	chr6:126643488~126644390:+
LUAD	trans	rs10908521	0.685	rs1998977	ENSG00000227183.3	HDGFP1	-9.75	1.31e-20	5.35e-14	-0.52	-0.41	Uric acid clearance;	chr1:156834329	chrX:131646639~131646890:+
LUAD	trans	rs11098499	0.754	rs12711071	ENSG00000275858.1	RP11-291L22.8	9.75	1.32e-20	5.4e-14	0.48	0.41	Corneal astigmatism;	chr4:119319779	chr10:38450738~38451069:-
LUAD	trans	rs74781061	0.929	rs1821848	ENSG00000227288.3	RP5-837I24.1	9.75	1.32e-20	5.4e-14	0.62	0.41	Endometriosis;	chr15:74541443	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.929	rs8043032	ENSG00000227288.3	RP5-837I24.1	9.75	1.32e-20	5.4e-14	0.62	0.41	Endometriosis;	chr15:74543975	chr1:81501794~81503468:+
LUAD	trans	rs10940346	0.58	rs6868713	ENSG00000231752.4	EMBP1	-9.75	1.32e-20	5.42e-14	-0.54	-0.41	Schizophrenia;	chr5:50276741	chr1:121519112~121571892:+
LUAD	trans	rs616147	0.627	rs816487	ENSG00000214263.2	RPSAP53	-9.74	1.36e-20	5.59e-14	-0.54	-0.41	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39445999	chr13:67266845~67267706:-
LUAD	trans	rs10037055	0.853	rs1363405	ENSG00000217325.2	PRELID1P1	9.74	1.37e-20	5.61e-14	0.5	0.41	Migraine without aura;	chr5:177209881	chr6:126643488~126644390:+
LUAD	trans	rs12138950	0.681	rs10799822	ENSG00000224237.1	MINOS1P3	9.74	1.38e-20	5.63e-14	0.52	0.41	Hypothyroidism;Thyroid volume;	chr1:19513327	chr3:27214816~27215018:-
LUAD	trans	rs10940346	0.601	rs10940242	ENSG00000231752.4	EMBP1	9.74	1.38e-20	5.65e-14	0.54	0.41	Schizophrenia;	chr5:50351018	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.56	rs10039233	ENSG00000231752.4	EMBP1	9.74	1.38e-20	5.65e-14	0.54	0.41	Schizophrenia;	chr5:50351630	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs1039798	ENSG00000231752.4	EMBP1	9.74	1.38e-20	5.66e-14	0.56	0.41	Schizophrenia;	chr5:50355909	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs10072182	ENSG00000231752.4	EMBP1	9.74	1.38e-20	5.66e-14	0.56	0.41	Schizophrenia;	chr5:50356818	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs7442762	ENSG00000231752.4	EMBP1	9.74	1.38e-20	5.66e-14	0.56	0.41	Schizophrenia;	chr5:50358137	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.56	rs10073530	ENSG00000231752.4	EMBP1	9.74	1.38e-20	5.66e-14	0.56	0.41	Schizophrenia;	chr5:50358823	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.54	rs12109228	ENSG00000231752.4	EMBP1	9.74	1.38e-20	5.66e-14	0.56	0.41	Schizophrenia;	chr5:50383135	chr1:121519112~121571892:+
LUAD	trans	rs8175379	0.509	rs4128583	ENSG00000231752.4	EMBP1	9.74	1.4e-20	5.71e-14	0.54	0.41	Interleukin-7 levels;	chr5:46251985	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs13174293	ENSG00000231752.4	EMBP1	9.74	1.4e-20	5.71e-14	0.54	0.41	Schizophrenia;	chr5:50352191	chr1:121519112~121571892:+
LUAD	trans	rs3740713	0.669	rs34740438	ENSG00000235847.2	LDHAP7	9.74	1.41e-20	5.76e-14	0.66	0.41	Amyotrophic lateral sclerosis (sporadic);	chr11:18393783	chr2:84777259~84778223:-
LUAD	trans	rs10940346	0.601	rs552892	ENSG00000231752.4	EMBP1	-9.74	1.44e-20	5.87e-14	-0.54	-0.41	Schizophrenia;	chr5:50269093	chr1:121519112~121571892:+
LUAD	trans	rs74781061	0.929	rs8029099	ENSG00000227288.3	RP5-837I24.1	9.73	1.48e-20	6.03e-14	0.6	0.41	Endometriosis;	chr15:74474429	chr1:81501794~81503468:+
LUAD	trans	rs877636	0.692	rs11171739	ENSG00000196656.7	AC004057.1	9.73	1.5e-20	6.14e-14	0.42	0.41	Cognitive function;	chr12:56076841	chr4:113214046~113217170:-
LUAD	trans	rs11098499	0.722	rs1814814	ENSG00000275858.1	RP11-291L22.8	9.73	1.51e-20	6.18e-14	0.45	0.41	Corneal astigmatism;	chr4:119336969	chr10:38450738~38451069:-
LUAD	trans	rs74781061	0.929	rs7177407	ENSG00000227288.3	RP5-837I24.1	9.73	1.51e-20	6.18e-14	0.62	0.41	Endometriosis;	chr15:74551444	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.929	rs8043082	ENSG00000227288.3	RP5-837I24.1	9.73	1.51e-20	6.18e-14	0.62	0.41	Endometriosis;	chr15:74564896	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.929	rs8026923	ENSG00000227288.3	RP5-837I24.1	9.73	1.51e-20	6.18e-14	0.62	0.41	Endometriosis;	chr15:74565721	chr1:81501794~81503468:+
LUAD	trans	rs10940346	0.601	rs35815956	ENSG00000231752.4	EMBP1	9.73	1.52e-20	6.19e-14	0.54	0.41	Schizophrenia;	chr5:50350905	chr1:121519112~121571892:+
LUAD	trans	rs5022636	0.507	rs4971035	ENSG00000180764.13	PIPSL	9.73	1.53e-20	6.24e-14	0.56	0.41	Gut microbiota (functional units);	chr1:151351582	chr10:93958191~93961540:-
LUAD	trans	rs11098499	0.789	rs9991166	ENSG00000275858.1	RP11-291L22.8	9.73	1.53e-20	6.24e-14	0.49	0.41	Corneal astigmatism;	chr4:119316696	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.708	rs10005237	ENSG00000275858.1	RP11-291L22.8	9.73	1.53e-20	6.24e-14	0.49	0.41	Corneal astigmatism;	chr4:119316742	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.754	rs878372	ENSG00000275858.1	RP11-291L22.8	9.73	1.53e-20	6.24e-14	0.49	0.41	Corneal astigmatism;	chr4:119317625	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.754	rs10213267	ENSG00000275858.1	RP11-291L22.8	9.73	1.53e-20	6.24e-14	0.49	0.41	Corneal astigmatism;	chr4:119317919	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.754	rs10212775	ENSG00000275858.1	RP11-291L22.8	9.73	1.53e-20	6.24e-14	0.49	0.41	Corneal astigmatism;	chr4:119318089	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.754	rs11732087	ENSG00000275858.1	RP11-291L22.8	9.73	1.53e-20	6.24e-14	0.49	0.41	Corneal astigmatism;	chr4:119318676	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.754	rs2964	ENSG00000275858.1	RP11-291L22.8	9.73	1.53e-20	6.24e-14	0.49	0.41	Corneal astigmatism;	chr4:119318976	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.754	rs1511025	ENSG00000275858.1	RP11-291L22.8	9.73	1.53e-20	6.24e-14	0.49	0.41	Corneal astigmatism;	chr4:119319083	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.532	rs4833624	ENSG00000275858.1	RP11-291L22.8	9.73	1.57e-20	6.39e-14	0.5	0.41	Corneal astigmatism;	chr4:119664342	chr10:38450738~38451069:-
LUAD	trans	rs10940346	0.519	rs10940514	ENSG00000231752.4	EMBP1	-9.73	1.57e-20	6.41e-14	-0.55	-0.41	Schizophrenia;	chr5:50146166	chr1:121519112~121571892:+
LUAD	trans	rs10917477	0.624	rs2745217	ENSG00000224237.1	MINOS1P3	-9.73	1.58e-20	6.43e-14	-0.49	-0.41	Thyroid function;	chr1:19595253	chr3:27214816~27215018:-
LUAD	trans	rs877636	1	rs877636	ENSG00000235459.5	RPS26P31	-9.73	1.58e-20	6.44e-14	-0.45	-0.41	Cognitive function;	chr12:56086799	chr7:122681315~122681662:+
LUAD	trans	rs12200782	0.53	rs6929908	ENSG00000242375.1	RP11-498P14.3	9.72	1.6e-20	6.53e-14	0.67	0.41	Small cell lung carcinoma;	chr6:26555061	chr9:97195351~97197687:-
LUAD	trans	rs12145833	0.538	rs12026408	ENSG00000154608.12	CEP170P1	-9.72	1.64e-20	6.68e-14	-0.72	-0.41	Obesity (early onset extreme);	chr1:243203503	chr4:118467590~118554204:+
LUAD	trans	rs74781061	0.929	rs6495118	ENSG00000227288.3	RP5-837I24.1	9.72	1.68e-20	6.84e-14	0.61	0.41	Endometriosis;	chr15:74619671	chr1:81501794~81503468:+
LUAD	trans	rs877636	1	rs705696	ENSG00000243403.1	RP11-330L19.1	9.72	1.7e-20	6.92e-14	0.44	0.41	Cognitive function;	chr12:56086864	chr15:64592979~64593326:+
LUAD	trans	rs9611519	1	rs9611510	ENSG00000268568.1	AC007228.9	-9.72	1.72e-20	6.97e-14	-0.57	-0.41	Neuroticism;	chr22:41173120	chr19:56672574~56673901:-
LUAD	trans	rs10940346	0.562	rs10051529	ENSG00000231752.4	EMBP1	-9.71	1.75e-20	7.12e-14	-0.56	-0.4	Schizophrenia;	chr5:50303103	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.58	rs10940533	ENSG00000231752.4	EMBP1	-9.71	1.77e-20	7.17e-14	-0.55	-0.4	Schizophrenia;	chr5:50146552	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.691	rs17009144	ENSG00000275858.1	RP11-291L22.8	-9.71	1.77e-20	7.18e-14	-0.46	-0.4	Corneal astigmatism;	chr4:119349640	chr10:38450738~38451069:-
LUAD	trans	rs7662987	0.793	rs78790289	ENSG00000233859.2	ADH5P4	9.71	1.82e-20	7.38e-14	0.58	0.4	Smoking initiation;	chr4:99066736	chr6:65836930~65838039:-
LUAD	trans	rs12709013	1	rs6499983	ENSG00000230849.2	GOT2P2	9.71	1.84e-20	7.45e-14	0.51	0.4	Blood metabolite ratios;	chr16:58810005	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.967	rs8054482	ENSG00000230849.2	GOT2P2	9.71	1.84e-20	7.45e-14	0.51	0.4	Blood metabolite ratios;	chr16:58810532	chr1:173141100~173142350:-
LUAD	trans	rs10242455	0.702	rs17161726	ENSG00000228834.1	RP11-249L21.4	9.7	1.88e-20	7.62e-14	1.01	0.4	Blood metabolite levels;	chr7:99410772	chr6:108907615~108907873:-
LUAD	trans	rs10037055	0.853	rs6890580	ENSG00000217325.2	PRELID1P1	-9.7	1.96e-20	7.93e-14	-0.51	-0.4	Migraine without aura;	chr5:177226519	chr6:126643488~126644390:+
LUAD	trans	rs13358908	0.511	rs34101830	ENSG00000231752.4	EMBP1	-9.7	1.97e-20	7.95e-14	-0.54	-0.4	Schizophrenia;	chr5:46349001	chr1:121519112~121571892:+
LUAD	trans	rs13358908	0.556	rs55638678	ENSG00000231752.4	EMBP1	-9.7	1.98e-20	8.01e-14	-0.54	-0.4	Schizophrenia;	chr5:46332618	chr1:121519112~121571892:+
LUAD	trans	rs877636	0.692	rs2271194	ENSG00000196656.7	AC004057.1	-9.69	2.08e-20	8.41e-14	-0.43	-0.4	Cognitive function;	chr12:56083910	chr4:113214046~113217170:-
LUAD	trans	rs12709013	0.935	rs8046667	ENSG00000233719.3	GOT2P3	9.69	2.1e-20	8.47e-14	0.48	0.4	Blood metabolite ratios;	chr16:58790935	chr12:9641802~9643007:+
LUAD	trans	rs12709013	1	rs8046998	ENSG00000233719.3	GOT2P3	9.69	2.1e-20	8.47e-14	0.48	0.4	Blood metabolite ratios;	chr16:58791109	chr12:9641802~9643007:+
LUAD	trans	rs13358908	0.503	rs10073687	ENSG00000231752.4	EMBP1	-9.69	2.17e-20	8.74e-14	-0.54	-0.4	Schizophrenia;	chr5:46352187	chr1:121519112~121571892:+
LUAD	trans	rs10037055	0.853	rs2336237	ENSG00000217325.2	PRELID1P1	9.68	2.2e-20	8.89e-14	0.52	0.4	Migraine without aura;	chr5:177238878	chr6:126643488~126644390:+
LUAD	trans	rs11098499	0.754	rs2036860	ENSG00000275858.1	RP11-291L22.8	9.68	2.32e-20	9.36e-14	0.48	0.4	Corneal astigmatism;	chr4:119327779	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.754	rs2036857	ENSG00000275858.1	RP11-291L22.8	9.68	2.32e-20	9.36e-14	0.48	0.4	Corneal astigmatism;	chr4:119328085	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.754	rs2036856	ENSG00000275858.1	RP11-291L22.8	9.68	2.32e-20	9.36e-14	0.48	0.4	Corneal astigmatism;	chr4:119328133	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.754	rs4443261	ENSG00000275858.1	RP11-291L22.8	9.68	2.32e-20	9.36e-14	0.48	0.4	Corneal astigmatism;	chr4:119328146	chr10:38450738~38451069:-
LUAD	trans	rs55665837	0.539	rs10766196	ENSG00000236360.2	RP11-334A14.2	9.68	2.36e-20	9.49e-14	0.54	0.4	Vitamin D levels;	chr11:14891585	chr1:52993201~52993702:-
LUAD	trans	rs12709013	0.935	rs34657766	ENSG00000230849.2	GOT2P2	9.67	2.43e-20	9.76e-14	0.5	0.4	Blood metabolite ratios;	chr16:58779468	chr1:173141100~173142350:-
LUAD	trans	rs12709013	0.729	rs71400031	ENSG00000230849.2	GOT2P2	9.67	2.43e-20	9.76e-14	0.5	0.4	Blood metabolite ratios;	chr16:58779554	chr1:173141100~173142350:-
LUAD	trans	rs10940346	0.601	rs1841104	ENSG00000231752.4	EMBP1	-9.67	2.44e-20	9.84e-14	-0.56	-0.4	Schizophrenia;	chr5:50263930	chr1:121519112~121571892:+
LUAD	trans	rs7662987	0.793	rs28730602	ENSG00000233859.2	ADH5P4	9.67	2.46e-20	9.89e-14	0.58	0.4	Smoking initiation;	chr4:99080531	chr6:65836930~65838039:-
LUAD	trans	rs12709013	0.967	rs11643969	ENSG00000230849.2	GOT2P2	9.67	2.5e-20	1.01e-13	0.5	0.4	Blood metabolite ratios;	chr16:58785354	chr1:173141100~173142350:-
LUAD	trans	rs10037055	0.687	rs6556308	ENSG00000217325.2	PRELID1P1	-9.67	2.52e-20	1.01e-13	-0.51	-0.4	Migraine without aura;	chr5:177219700	chr6:126643488~126644390:+
LUAD	trans	rs1816752	0.524	rs1965154	ENSG00000224976.2	PARP4P2	9.67	2.54e-20	1.02e-13	0.47	0.4	Obesity-related traits;	chr13:24498062	chr13:19349137~19407962:+
LUAD	trans	rs10940346	0.601	rs10042601	ENSG00000231752.4	EMBP1	-9.67	2.56e-20	1.03e-13	-0.55	-0.4	Schizophrenia;	chr5:50315248	chr1:121519112~121571892:+
LUAD	trans	rs8175379	0.575	rs8185283	ENSG00000231752.4	EMBP1	-9.67	2.57e-20	1.03e-13	-0.54	-0.4	Interleukin-7 levels;	chr5:46337706	chr1:121519112~121571892:+
LUAD	trans	rs8175379	0.515	rs8185067	ENSG00000231752.4	EMBP1	-9.67	2.57e-20	1.03e-13	-0.54	-0.4	Interleukin-7 levels;	chr5:46337722	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.562	rs549751	ENSG00000231752.4	EMBP1	-9.67	2.58e-20	1.03e-13	-0.54	-0.4	Schizophrenia;	chr5:50262114	chr1:121519112~121571892:+
LUAD	trans	rs11638815	0.52	rs4779032	ENSG00000235370.6	DNM1P51	-9.67	2.58e-20	1.04e-13	-0.46	-0.4	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82576576	chr15:84398316~84411701:-
LUAD	trans	rs8175379	0.509	rs7293427	ENSG00000231752.4	EMBP1	9.66	2.6e-20	1.04e-13	0.54	0.4	Interleukin-7 levels;	chr5:46253335	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.575	rs907204	ENSG00000275858.1	RP11-291L22.8	9.66	2.62e-20	1.05e-13	0.48	0.4	Corneal astigmatism;	chr4:119317499	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.575	rs907205	ENSG00000275858.1	RP11-291L22.8	9.66	2.62e-20	1.05e-13	0.48	0.4	Corneal astigmatism;	chr4:119317509	chr10:38450738~38451069:-
LUAD	trans	rs877636	1	rs705696	ENSG00000242970.2	AC068522.4	9.66	2.62e-20	1.05e-13	0.48	0.4	Cognitive function;	chr12:56086864	chr8:58588420~58588764:-
LUAD	trans	rs55665837	0.539	rs12794714	ENSG00000236360.2	RP11-334A14.2	9.66	2.64e-20	1.06e-13	0.54	0.4	Vitamin D levels;	chr11:14892029	chr1:52993201~52993702:-
LUAD	trans	rs12138950	0.681	rs60066365	ENSG00000224237.1	MINOS1P3	9.66	2.64e-20	1.06e-13	0.51	0.4	Hypothyroidism;Thyroid volume;	chr1:19512191	chr3:27214816~27215018:-
LUAD	trans	rs12709013	1	rs12599931	ENSG00000233719.3	GOT2P3	9.66	2.74e-20	1.1e-13	0.48	0.4	Blood metabolite ratios;	chr16:58792627	chr12:9641802~9643007:+
LUAD	trans	rs26067	0.689	rs285529	ENSG00000231752.4	EMBP1	-9.66	2.75e-20	1.1e-13	-0.53	-0.4	Breast cancer;	chr5:50843452	chr1:121519112~121571892:+
LUAD	trans	rs77688320	0.553	rs3795966	ENSG00000235105.1	RP11-329A14.1	9.66	2.78e-20	1.11e-13	0.48	0.4	Breast cancer;	chr2:201380521	chr1:48435967~48437223:+
LUAD	trans	rs77688320	0.517	rs12623282	ENSG00000235105.1	RP11-329A14.1	9.66	2.78e-20	1.11e-13	0.48	0.4	Breast cancer;	chr2:201382734	chr1:48435967~48437223:+
LUAD	trans	rs77688320	0.535	rs7579853	ENSG00000235105.1	RP11-329A14.1	9.66	2.78e-20	1.11e-13	0.48	0.4	Breast cancer;	chr2:201384256	chr1:48435967~48437223:+
LUAD	trans	rs10940346	0.601	rs6868380	ENSG00000231752.4	EMBP1	9.66	2.81e-20	1.12e-13	0.55	0.4	Schizophrenia;	chr5:50328473	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.58	rs34185098	ENSG00000231752.4	EMBP1	9.66	2.81e-20	1.12e-13	0.55	0.4	Schizophrenia;	chr5:50330100	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.58	rs9688065	ENSG00000231752.4	EMBP1	-9.65	2.95e-20	1.18e-13	-0.55	-0.4	Schizophrenia;	chr5:50147444	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs1674512	ENSG00000231752.4	EMBP1	9.65	2.95e-20	1.18e-13	0.54	0.4	Schizophrenia;	chr5:50268794	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs13175165	ENSG00000231752.4	EMBP1	-9.65	2.98e-20	1.19e-13	-0.55	-0.4	Schizophrenia;	chr5:50151463	chr1:121519112~121571892:+
LUAD	trans	rs13190036	1	rs13157667	ENSG00000228305.2	AC016734.2	-9.65	3.03e-20	1.21e-13	-0.59	-0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177186876	chr2:63622178~63622831:-
LUAD	trans	rs10940346	0.562	rs559096	ENSG00000231752.4	EMBP1	-9.65	3.04e-20	1.21e-13	-0.55	-0.4	Schizophrenia;	chr5:50226512	chr1:121519112~121571892:+
LUAD	trans	rs7121616	0.96	rs12361252	ENSG00000234176.1	HSPA8P1	9.64	3.13e-20	1.25e-13	0.48	0.4	Breast cancer;	chr11:123091564	chrX:121203182~121205014:-
LUAD	trans	rs10940346	0.562	rs4379243	ENSG00000231752.4	EMBP1	-9.63	3.34e-20	1.33e-13	-0.54	-0.4	Schizophrenia;	chr5:50149933	chr1:121519112~121571892:+
LUAD	trans	rs12200782	0.505	rs7765920	ENSG00000242375.1	RP11-498P14.3	9.63	3.39e-20	1.35e-13	0.62	0.4	Small cell lung carcinoma;	chr6:26514543	chr9:97195351~97197687:-
LUAD	trans	rs10940346	0.601	rs12697055	ENSG00000231752.4	EMBP1	9.63	3.39e-20	1.35e-13	0.53	0.4	Schizophrenia;	chr5:50317827	chr1:121519112~121571892:+
LUAD	trans	rs13190036	1	rs13177748	ENSG00000228305.2	AC016734.2	-9.63	3.41e-20	1.35e-13	-0.58	-0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177216953	chr2:63622178~63622831:-
LUAD	trans	rs8175379	0.521	rs10037109	ENSG00000231752.4	EMBP1	9.63	3.47e-20	1.38e-13	0.53	0.4	Interleukin-7 levels;	chr5:46328343	chr1:121519112~121571892:+
LUAD	trans	rs77688320	0.535	rs7561048	ENSG00000235105.1	RP11-329A14.1	9.63	3.47e-20	1.38e-13	0.48	0.4	Breast cancer;	chr2:201388316	chr1:48435967~48437223:+
LUAD	trans	rs10908521	0.611	rs7516736	ENSG00000227183.3	HDGFP1	-9.63	3.49e-20	1.38e-13	-0.52	-0.4	Uric acid clearance;	chr1:156825994	chrX:131646639~131646890:+
LUAD	trans	rs10865397	0.506	rs6546810	ENSG00000236165.1	PRADC1P1	9.63	3.5e-20	1.39e-13	0.53	0.4	Intelligence (multi-trait analysis);	chr2:73162588	chr3:36976316~36976840:+
LUAD	trans	rs3740713	0.719	rs78515595	ENSG00000235847.2	LDHAP7	9.63	3.57e-20	1.41e-13	0.68	0.4	Amyotrophic lateral sclerosis (sporadic);	chr11:18409830	chr2:84777259~84778223:-
LUAD	trans	rs877636	1	rs877636	ENSG00000242970.2	AC068522.4	-9.62	3.68e-20	1.45e-13	-0.47	-0.4	Cognitive function;	chr12:56086799	chr8:58588420~58588764:-
LUAD	trans	rs77688320	0.535	rs11680694	ENSG00000235105.1	RP11-329A14.1	9.62	3.76e-20	1.49e-13	0.47	0.4	Breast cancer;	chr2:201393498	chr1:48435967~48437223:+
LUAD	trans	rs10940346	0.601	rs7448495	ENSG00000231752.4	EMBP1	-9.62	3.82e-20	1.51e-13	-0.54	-0.4	Schizophrenia;	chr5:50300238	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.584	rs7293449	ENSG00000231752.4	EMBP1	-9.62	3.82e-20	1.51e-13	-0.54	-0.4	Schizophrenia;	chr5:50259959	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.54	rs34645496	ENSG00000231752.4	EMBP1	9.62	3.83e-20	1.51e-13	0.55	0.4	Schizophrenia;	chr5:50322419	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs35330444	ENSG00000231752.4	EMBP1	9.62	3.83e-20	1.51e-13	0.55	0.4	Schizophrenia;	chr5:50322606	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs6875734	ENSG00000231752.4	EMBP1	9.62	3.83e-20	1.51e-13	0.55	0.4	Schizophrenia;	chr5:50323203	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs1033108	ENSG00000231752.4	EMBP1	9.62	3.89e-20	1.54e-13	0.54	0.4	Schizophrenia;	chr5:50327764	chr1:121519112~121571892:+
LUAD	trans	rs7312770	0.637	rs705700	ENSG00000227887.1	RPS26P13	9.61	3.96e-20	1.56e-13	0.45	0.4	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr1:208697369~208697698:-
LUAD	trans	rs877636	0.669	rs7297175	ENSG00000196933.5	RPS26P11	-9.61	3.98e-20	1.57e-13	-0.45	-0.4	Cognitive function;	chr12:56080024	chrX:72044545~72044892:+
LUAD	trans	rs10028773	0.7	rs7671797	ENSG00000275858.1	RP11-291L22.8	9.61	4e-20	1.58e-13	0.48	0.4	Educational attainment;	chr4:119327002	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.754	rs7672594	ENSG00000275858.1	RP11-291L22.8	9.61	4e-20	1.58e-13	0.48	0.4	Corneal astigmatism;	chr4:119327388	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.754	rs7672778	ENSG00000275858.1	RP11-291L22.8	9.61	4e-20	1.58e-13	0.48	0.4	Corneal astigmatism;	chr4:119327430	chr10:38450738~38451069:-
LUAD	trans	rs74781061	0.86	rs6495103	ENSG00000227288.3	RP5-837I24.1	9.61	4.02e-20	1.59e-13	0.61	0.4	Endometriosis;	chr15:74470507	chr1:81501794~81503468:+
LUAD	trans	rs10940346	0.54	rs2199089	ENSG00000231752.4	EMBP1	-9.61	4.03e-20	1.59e-13	-0.55	-0.4	Schizophrenia;	chr5:50199332	chr1:121519112~121571892:+
LUAD	trans	rs12138950	0.681	rs28630511	ENSG00000224237.1	MINOS1P3	9.61	4.06e-20	1.6e-13	0.51	0.4	Hypothyroidism;Thyroid volume;	chr1:19516538	chr3:27214816~27215018:-
LUAD	trans	rs13190036	1	rs6880798	ENSG00000226986.4	RP11-543B16.2	9.61	4.07e-20	1.6e-13	0.58	0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177277456	chr1:211207239~211207897:+
LUAD	trans	rs877636	0.859	rs3741499	ENSG00000242970.2	AC068522.4	-9.61	4.15e-20	1.63e-13	-0.47	-0.4	Cognitive function;	chr12:56080595	chr8:58588420~58588764:-
LUAD	trans	rs13358908	0.51	rs4975991	ENSG00000231752.4	EMBP1	-9.61	4.15e-20	1.63e-13	-0.54	-0.4	Schizophrenia;	chr5:46328545	chr1:121519112~121571892:+
LUAD	trans	rs12138950	0.681	rs4362008	ENSG00000224237.1	MINOS1P3	9.61	4.16e-20	1.64e-13	0.51	0.4	Hypothyroidism;Thyroid volume;	chr1:19511064	chr3:27214816~27215018:-
LUAD	trans	rs12138950	0.711	rs10799821	ENSG00000224237.1	MINOS1P3	9.61	4.16e-20	1.64e-13	0.51	0.4	Hypothyroidism;Thyroid volume;	chr1:19511475	chr3:27214816~27215018:-
LUAD	trans	rs11098499	0.865	rs10213221	ENSG00000275858.1	RP11-291L22.8	9.6	4.24e-20	1.67e-13	0.48	0.4	Corneal astigmatism;	chr4:119334771	chr10:38450738~38451069:-
LUAD	trans	rs10940346	0.52	rs7293339	ENSG00000231752.4	EMBP1	-9.6	4.32e-20	1.7e-13	-0.55	-0.4	Schizophrenia;	chr5:50207465	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.607	rs8188210	ENSG00000231752.4	EMBP1	-9.6	4.32e-20	1.7e-13	-0.55	-0.4	Schizophrenia;	chr5:50211664	chr1:121519112~121571892:+
LUAD	trans	rs74781061	0.86	rs4077703	ENSG00000227288.3	RP5-837I24.1	9.6	4.37e-20	1.72e-13	0.61	0.4	Endometriosis;	chr15:74469821	chr1:81501794~81503468:+
LUAD	trans	rs10940346	0.601	rs5011669	ENSG00000231752.4	EMBP1	-9.6	4.4e-20	1.73e-13	-0.55	-0.4	Schizophrenia;	chr5:50311788	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.754	rs17049949	ENSG00000275858.1	RP11-291L22.8	9.6	4.43e-20	1.74e-13	0.48	0.4	Corneal astigmatism;	chr4:119334135	chr10:38450738~38451069:-
LUAD	trans	rs72615157	0.561	rs113401658	ENSG00000228546.2	CTA-313A17.3	9.6	4.47e-20	1.75e-13	0.63	0.4	Lung function (FEV1/FVC);	chr7:100260882	chr7:102337316~102339115:+
LUAD	trans	rs7312770	0.637	rs705700	ENSG00000196656.7	AC004057.1	9.6	4.52e-20	1.77e-13	0.42	0.4	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr4:113214046~113217170:-
LUAD	trans	rs10940346	0.601	rs2005573	ENSG00000231752.4	EMBP1	-9.6	4.53e-20	1.78e-13	-0.54	-0.4	Schizophrenia;	chr5:50301614	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs2011540	ENSG00000231752.4	EMBP1	-9.6	4.53e-20	1.78e-13	-0.54	-0.4	Schizophrenia;	chr5:50301634	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.58	rs4865801	ENSG00000231752.4	EMBP1	-9.59	4.64e-20	1.82e-13	-0.54	-0.4	Schizophrenia;	chr5:50163364	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs4865676	ENSG00000231752.4	EMBP1	9.59	4.67e-20	1.83e-13	0.53	0.4	Schizophrenia;	chr5:50279343	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.601	rs12651834	ENSG00000231752.4	EMBP1	9.59	4.69e-20	1.84e-13	0.55	0.4	Schizophrenia;	chr5:50351199	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.837	rs10073636	ENSG00000231752.4	EMBP1	-9.59	4.73e-20	1.85e-13	-0.54	-0.4	P wave duration;	chr5:45537197	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.754	rs7672372	ENSG00000275858.1	RP11-291L22.8	9.59	4.76e-20	1.86e-13	0.48	0.4	Corneal astigmatism;	chr4:119327251	chr10:38450738~38451069:-
LUAD	trans	rs10940346	0.601	rs13172932	ENSG00000231752.4	EMBP1	9.59	4.96e-20	1.94e-13	0.55	0.4	Schizophrenia;	chr5:50345364	chr1:121519112~121571892:+
LUAD	trans	rs7192380	0.639	rs7186296	ENSG00000257513.6	NPIPB1P	-9.58	5.05e-20	1.97e-13	-0.41	-0.4	Sjögren's syndrome;	chr16:69775095	chr18:11619509~11639699:-
LUAD	trans	rs13014235	0.592	rs55860809	ENSG00000235105.1	RP11-329A14.1	9.58	5.31e-20	2.07e-13	0.47	0.4	Basal cell carcinoma;	chr2:201394347	chr1:48435967~48437223:+
LUAD	trans	rs9611519	1	rs2057070	ENSG00000268568.1	AC007228.9	-9.57	5.4e-20	2.11e-13	-0.56	-0.4	Neuroticism;	chr22:41168283	chr19:56672574~56673901:-
LUAD	trans	rs9611519	0.929	rs9611509	ENSG00000268568.1	AC007228.9	-9.57	5.4e-20	2.11e-13	-0.56	-0.4	Neuroticism;	chr22:41169823	chr19:56672574~56673901:-
LUAD	trans	rs7312770	0.612	rs773114	ENSG00000227887.1	RPS26P13	9.57	5.47e-20	2.13e-13	0.45	0.4	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr1:208697369~208697698:-
LUAD	trans	rs877636	0.692	rs10876870	ENSG00000196656.7	AC004057.1	-9.57	5.48e-20	2.14e-13	-0.42	-0.4	Cognitive function;	chr12:56084218	chr4:113214046~113217170:-
LUAD	trans	rs877636	0.692	rs7971751	ENSG00000196656.7	AC004057.1	-9.57	5.48e-20	2.14e-13	-0.42	-0.4	Cognitive function;	chr12:56084874	chr4:113214046~113217170:-
LUAD	trans	rs1039766	0.778	rs13399786	ENSG00000224334.1	AP000357.4	-9.57	5.56e-20	2.17e-13	-0.67	-0.4	Lung adenocarcinoma;Lung cancer;	chr2:65283571	chr22:24686923~24688087:+
LUAD	trans	rs7192380	0.639	rs12448486	ENSG00000257513.6	NPIPB1P	-9.57	5.6e-20	2.18e-13	-0.41	-0.4	Sjögren's syndrome;	chr16:69768975	chr18:11619509~11639699:-
LUAD	trans	rs74781061	0.858	rs12592493	ENSG00000227288.3	RP5-837I24.1	9.57	5.62e-20	2.19e-13	0.61	0.4	Endometriosis;	chr15:74466999	chr1:81501794~81503468:+
LUAD	trans	rs7662987	0.793	rs28730632	ENSG00000233859.2	ADH5P4	9.57	5.64e-20	2.2e-13	0.58	0.4	Smoking initiation;	chr4:99074552	chr6:65836930~65838039:-
LUAD	trans	rs11098499	0.754	rs28643450	ENSG00000275858.1	RP11-291L22.8	9.57	5.76e-20	2.24e-13	0.48	0.4	Corneal astigmatism;	chr4:119324087	chr10:38450738~38451069:-
LUAD	trans	rs4276421	0.837	rs2049656	ENSG00000231752.4	EMBP1	-9.57	5.76e-20	2.24e-13	-0.54	-0.4	P wave duration;	chr5:45579590	chr1:121519112~121571892:+
LUAD	trans	rs77688320	0.535	rs11691118	ENSG00000235105.1	RP11-329A14.1	9.56	5.93e-20	2.31e-13	0.47	0.4	Breast cancer;	chr2:201405121	chr1:48435967~48437223:+
LUAD	trans	rs7662987	0.793	rs12697	ENSG00000233859.2	ADH5P4	-9.55	6.48e-20	2.51e-13	-0.56	-0.4	Smoking initiation;	chr4:99072225	chr6:65836930~65838039:-
LUAD	trans	rs7662987	0.793	rs4699700	ENSG00000233859.2	ADH5P4	9.55	6.65e-20	2.58e-13	0.58	0.4	Smoking initiation;	chr4:99077184	chr6:65836930~65838039:-
LUAD	trans	rs12709013	1	rs11641836	ENSG00000233719.3	GOT2P3	9.55	6.71e-20	2.6e-13	0.47	0.4	Blood metabolite ratios;	chr16:58798143	chr12:9641802~9643007:+
LUAD	trans	rs10940346	0.519	rs7293422	ENSG00000231752.4	EMBP1	-9.55	6.82e-20	2.64e-13	-0.55	-0.4	Schizophrenia;	chr5:50146010	chr1:121519112~121571892:+
LUAD	trans	rs13190036	0.901	rs28563911	ENSG00000228305.2	AC016734.2	9.54	6.89e-20	2.67e-13	0.59	0.4	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177287942	chr2:63622178~63622831:-
LUAD	trans	rs10037055	0.853	rs1546363	ENSG00000217325.2	PRELID1P1	-9.54	7.22e-20	2.79e-13	-0.51	-0.4	Migraine without aura;	chr5:177174030	chr6:126643488~126644390:+
LUAD	trans	rs74781061	0.86	rs3985310	ENSG00000227288.3	RP5-837I24.1	9.54	7.28e-20	2.81e-13	0.59	0.4	Endometriosis;	chr15:74442826	chr1:81501794~81503468:+
LUAD	trans	rs11098499	0.754	rs7689729	ENSG00000275858.1	RP11-291L22.8	9.54	7.31e-20	2.82e-13	0.48	0.4	Corneal astigmatism;	chr4:119335037	chr10:38450738~38451069:-
LUAD	trans	rs10028773	0.7	rs7690338	ENSG00000275858.1	RP11-291L22.8	9.54	7.31e-20	2.82e-13	0.48	0.4	Educational attainment;	chr4:119335313	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.865	rs3956464	ENSG00000275858.1	RP11-291L22.8	9.54	7.31e-20	2.82e-13	0.48	0.4	Corneal astigmatism;	chr4:119335609	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.619	rs28502463	ENSG00000275858.1	RP11-291L22.8	9.54	7.31e-20	2.82e-13	0.48	0.4	Corneal astigmatism;	chr4:119335868	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.648	rs2002047	ENSG00000275858.1	RP11-291L22.8	9.54	7.31e-20	2.82e-13	0.48	0.4	Corneal astigmatism;	chr4:119336073	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.775	rs2002049	ENSG00000275858.1	RP11-291L22.8	9.54	7.31e-20	2.82e-13	0.48	0.4	Corneal astigmatism;	chr4:119336262	chr10:38450738~38451069:-
LUAD	trans	rs7647973	0.506	rs11920251	ENSG00000197582.5	GPX1P1	9.54	7.31e-20	2.82e-13	0.49	0.4	Menarche (age at onset);	chr3:49319238	chrX:13378735~13379340:-
LUAD	trans	rs12709013	0.967	rs62064905	ENSG00000230849.2	GOT2P2	9.54	7.34e-20	2.83e-13	0.49	0.4	Blood metabolite ratios;	chr16:58778839	chr1:173141100~173142350:-
LUAD	trans	rs10940346	0.601	rs567248	ENSG00000231752.4	EMBP1	-9.53	7.53e-20	2.91e-13	-0.55	-0.4	Schizophrenia;	chr5:50277650	chr1:121519112~121571892:+
LUAD	trans	rs10940346	0.542	rs2219452	ENSG00000231752.4	EMBP1	-9.53	7.66e-20	2.95e-13	-0.55	-0.4	Schizophrenia;	chr5:50209813	chr1:121519112~121571892:+
LUAD	trans	rs616147	0.671	rs675595	ENSG00000214263.2	RPSAP53	-9.53	7.67e-20	2.95e-13	-0.53	-0.4	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39458987	chr13:67266845~67267706:-
LUAD	trans	rs10940346	0.601	rs1033109	ENSG00000231752.4	EMBP1	9.53	7.82e-20	3.01e-13	0.55	0.4	Schizophrenia;	chr5:50327705	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.837	rs755048	ENSG00000231752.4	EMBP1	-9.53	7.89e-20	3.03e-13	-0.54	-0.4	P wave duration;	chr5:45596256	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.837	rs10069510	ENSG00000231752.4	EMBP1	-9.53	7.89e-20	3.03e-13	-0.54	-0.4	P wave duration;	chr5:45596937	chr1:121519112~121571892:+
LUAD	trans	rs3779195	0.591	rs77968419	ENSG00000225169.1	BRI3P1	-9.53	8.01e-20	3.08e-13	-0.65	-0.4	Sex hormone-binding globulin levels;	chr7:98237168	chr1:100213293~100213670:+
LUAD	trans	rs11023332	0.706	rs11023380	ENSG00000236360.2	RP11-334A14.2	9.53	8.08e-20	3.1e-13	0.53	0.4	Vitamin D levels;Adiponectin levels;	chr11:14908512	chr1:52993201~52993702:-
LUAD	trans	rs11023332	0.8	rs12271890	ENSG00000236360.2	RP11-334A14.2	9.53	8.08e-20	3.1e-13	0.53	0.4	Vitamin D levels;Adiponectin levels;	chr11:14913140	chr1:52993201~52993702:-
LUAD	trans	rs11098499	0.532	rs4504231	ENSG00000275858.1	RP11-291L22.8	9.53	8.08e-20	3.1e-13	0.49	0.4	Corneal astigmatism;	chr4:119665736	chr10:38450738~38451069:-
LUAD	trans	rs13358908	0.526	rs4975974	ENSG00000231752.4	EMBP1	-9.52	8.14e-20	3.12e-13	-0.53	-0.4	Schizophrenia;	chr5:46307464	chr1:121519112~121571892:+
LUAD	trans	rs6477998	0.58	rs10817467	ENSG00000238072.1	RP11-305M3.2	9.52	8.63e-20	3.3e-13	0.66	0.4	Hematology traits;	chr9:113246803	chr7:129410113~129410370:-
LUAD	trans	rs10940346	0.56	rs7293410	ENSG00000231752.4	EMBP1	-9.52	8.63e-20	3.3e-13	-0.54	-0.4	Schizophrenia;	chr5:50163036	chr1:121519112~121571892:+
LUAD	trans	rs7312770	1	rs7312770	ENSG00000242970.2	AC068522.4	-9.51	9e-20	3.44e-13	-0.45	-0.4	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr8:58588420~58588764:-
LUAD	trans	rs10940346	0.58	rs12188257	ENSG00000231752.4	EMBP1	-9.51	9.08e-20	3.47e-13	-0.55	-0.4	Schizophrenia;	chr5:50147242	chr1:121519112~121571892:+
LUAD	trans	rs74781061	0.929	rs76160708	ENSG00000227288.3	RP5-837I24.1	9.51	9.45e-20	3.6e-13	0.61	0.4	Endometriosis;	chr15:74636901	chr1:81501794~81503468:+
LUAD	trans	rs80033912	0.713	rs7629936	ENSG00000197582.5	GPX1P1	9.5	1.02e-19	3.87e-13	0.6	0.4	Intelligence (multi-trait analysis);	chr3:49799274	chrX:13378735~13379340:-
LUAD	trans	rs74781061	0.86	rs7163775	ENSG00000227288.3	RP5-837I24.1	9.5	1.02e-19	3.88e-13	0.6	0.4	Endometriosis;	chr15:74452760	chr1:81501794~81503468:+
LUAD	trans	rs72615157	0.561	rs113844570	ENSG00000228546.2	CTA-313A17.3	9.5	1.02e-19	3.88e-13	0.62	0.4	Lung function (FEV1/FVC);	chr7:100276155	chr7:102337316~102339115:+
LUAD	trans	rs74781061	0.86	rs2289187	ENSG00000227288.3	RP5-837I24.1	9.5	1.03e-19	3.92e-13	0.6	0.4	Endometriosis;	chr15:74452058	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.86	rs7166701	ENSG00000227288.3	RP5-837I24.1	9.5	1.03e-19	3.92e-13	0.6	0.4	Endometriosis;	chr15:74456674	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.86	rs77655065	ENSG00000227288.3	RP5-837I24.1	9.5	1.03e-19	3.92e-13	0.6	0.4	Endometriosis;	chr15:74462699	chr1:81501794~81503468:+
LUAD	trans	rs3779195	0.585	rs73709460	ENSG00000225169.1	BRI3P1	-9.49	1.05e-19	4.01e-13	-0.65	-0.4	Sex hormone-binding globulin levels;	chr7:98265942	chr1:100213293~100213670:+
LUAD	trans	rs3779195	0.524	rs76976120	ENSG00000225169.1	BRI3P1	-9.49	1.09e-19	4.16e-13	-0.65	-0.4	Sex hormone-binding globulin levels;	chr7:98264860	chr1:100213293~100213670:+
LUAD	trans	rs3779195	0.585	rs56694862	ENSG00000225169.1	BRI3P1	-9.49	1.1e-19	4.17e-13	-0.65	-0.4	Sex hormone-binding globulin levels;	chr7:98267808	chr1:100213293~100213670:+
LUAD	trans	rs10940346	0.601	rs6892142	ENSG00000231752.4	EMBP1	-9.49	1.1e-19	4.17e-13	-0.55	-0.4	Schizophrenia;	chr5:50276518	chr1:121519112~121571892:+
LUAD	trans	rs9611519	0.828	rs4822008	ENSG00000268568.1	AC007228.9	-9.48	1.14e-19	4.33e-13	-0.56	-0.4	Neuroticism;	chr22:41143202	chr19:56672574~56673901:-
LUAD	trans	rs74781061	0.86	rs4544202	ENSG00000227288.3	RP5-837I24.1	9.48	1.15e-19	4.38e-13	0.59	0.4	Endometriosis;	chr15:74468654	chr1:81501794~81503468:+
LUAD	trans	rs10940346	0.601	rs16879414	ENSG00000231752.4	EMBP1	9.48	1.17e-19	4.43e-13	0.55	0.4	Schizophrenia;	chr5:50337969	chr1:121519112~121571892:+
LUAD	trans	rs74781061	0.86	rs8033841	ENSG00000227288.3	RP5-837I24.1	9.48	1.19e-19	4.52e-13	0.58	0.4	Endometriosis;	chr15:74471540	chr1:81501794~81503468:+
LUAD	trans	rs877636	1	rs4759229	ENSG00000242970.2	AC068522.4	-9.48	1.2e-19	4.56e-13	-0.47	-0.4	Cognitive function;	chr12:56080696	chr8:58588420~58588764:-
LUAD	trans	rs877636	1	rs2292239	ENSG00000242970.2	AC068522.4	9.47	1.22e-19	4.62e-13	0.45	0.4	Cognitive function;	chr12:56088396	chr8:58588420~58588764:-
LUAD	trans	rs10940346	0.537	rs7293378	ENSG00000231752.4	EMBP1	-9.47	1.24e-19	4.7e-13	-0.54	-0.4	Schizophrenia;	chr5:50192402	chr1:121519112~121571892:+
LUAD	trans	rs72615157	0.645	rs76281814	ENSG00000228546.2	CTA-313A17.3	9.47	1.25e-19	4.73e-13	0.62	0.4	Lung function (FEV1/FVC);	chr7:100248791	chr7:102337316~102339115:+
LUAD	trans	rs8175379	0.542	rs12657764	ENSG00000231752.4	EMBP1	-9.46	1.38e-19	5.22e-13	-0.53	-0.4	Interleukin-7 levels;	chr5:46281165	chr1:121519112~121571892:+
LUAD	trans	rs8175379	0.522	rs8185256	ENSG00000231752.4	EMBP1	-9.46	1.41e-19	5.31e-13	-0.53	-0.4	Interleukin-7 levels;	chr5:46298301	chr1:121519112~121571892:+
LUAD	trans	rs8175379	0.501	rs12514178	ENSG00000231752.4	EMBP1	-9.46	1.41e-19	5.31e-13	-0.53	-0.4	Interleukin-7 levels;	chr5:46309072	chr1:121519112~121571892:+
LUAD	trans	rs8175379	0.501	rs8185192	ENSG00000231752.4	EMBP1	-9.46	1.41e-19	5.31e-13	-0.53	-0.4	Interleukin-7 levels;	chr5:46309722	chr1:121519112~121571892:+
LUAD	trans	rs8010715	1	rs2236352	ENSG00000238000.1	RP11-274E7.2	9.46	1.42e-19	5.34e-13	0.45	0.4	IgG glycosylation;	chr14:24141524	chr5:98213402~98214121:+
LUAD	trans	rs74781061	0.789	rs1078011	ENSG00000227288.3	RP5-837I24.1	9.46	1.42e-19	5.34e-13	0.59	0.4	Endometriosis;	chr15:74442521	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.86	rs4887147	ENSG00000227288.3	RP5-837I24.1	9.46	1.42e-19	5.34e-13	0.59	0.4	Endometriosis;	chr15:74443863	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.86	rs4887151	ENSG00000227288.3	RP5-837I24.1	9.46	1.42e-19	5.34e-13	0.59	0.4	Endometriosis;	chr15:74445126	chr1:81501794~81503468:+
LUAD	trans	rs7937890	0.681	rs4756784	ENSG00000236360.2	RP11-334A14.2	-9.45	1.43e-19	5.39e-13	-0.51	-0.4	Mitochondrial DNA levels;	chr11:14249358	chr1:52993201~52993702:-
LUAD	trans	rs3779195	0.585	rs7777991	ENSG00000225169.1	BRI3P1	-9.45	1.5e-19	5.63e-13	-0.63	-0.4	Sex hormone-binding globulin levels;	chr7:98236445	chr1:100213293~100213670:+
LUAD	trans	rs72615157	0.595	rs112241539	ENSG00000228546.2	CTA-313A17.3	9.45	1.54e-19	5.77e-13	0.62	0.4	Lung function (FEV1/FVC);	chr7:100249614	chr7:102337316~102339115:+
LUAD	trans	rs916888	0.821	rs199513	ENSG00000280022.1	RP11-707O23.1	-9.44	1.55e-19	5.83e-13	-0.56	-0.4	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45592621~45593369:+
LUAD	trans	rs11023332	0.706	rs11023379	ENSG00000236360.2	RP11-334A14.2	9.44	1.65e-19	6.17e-13	0.53	0.4	Vitamin D levels;Adiponectin levels;	chr11:14908414	chr1:52993201~52993702:-
LUAD	trans	rs7662987	1	rs7683704	ENSG00000233859.2	ADH5P4	9.43	1.68e-19	6.3e-13	0.64	0.4	Smoking initiation;	chr4:99083075	chr6:65836930~65838039:-
LUAD	trans	rs10940346	0.601	rs579279	ENSG00000231752.4	EMBP1	-9.43	1.69e-19	6.33e-13	-0.52	-0.4	Schizophrenia;	chr5:50277308	chr1:121519112~121571892:+
LUAD	trans	rs11098499	0.532	rs12512646	ENSG00000275858.1	RP11-291L22.8	9.43	1.71e-19	6.39e-13	0.48	0.4	Corneal astigmatism;	chr4:119664578	chr10:38450738~38451069:-
LUAD	trans	rs9899728	0.539	rs56267297	ENSG00000234925.2	ATP5HP4	9.43	1.75e-19	6.55e-13	0.67	0.39	Alzheimer's disease or small vessel stroke;	chr17:75050901	chr12:68642519~68642993:-
LUAD	trans	rs9611519	0.964	rs20551	ENSG00000268568.1	AC007228.9	-9.43	1.79e-19	6.69e-13	-0.56	-0.39	Neuroticism;	chr22:41152004	chr19:56672574~56673901:-
LUAD	trans	rs8175379	0.551	rs4975969	ENSG00000231752.4	EMBP1	-9.42	1.82e-19	6.82e-13	-0.53	-0.39	Interleukin-7 levels;	chr5:46295887	chr1:121519112~121571892:+
LUAD	trans	rs8175379	0.584	rs8185180	ENSG00000231752.4	EMBP1	-9.42	1.84e-19	6.89e-13	-0.53	-0.39	Interleukin-7 levels;	chr5:46300291	chr1:121519112~121571892:+
LUAD	trans	rs13190036	0.551	rs7710269	ENSG00000226986.4	RP11-543B16.2	-9.42	1.87e-19	7e-13	-0.54	-0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177187528	chr1:211207239~211207897:+
LUAD	trans	rs10940346	0.54	rs12521033	ENSG00000231752.4	EMBP1	-9.42	1.9e-19	7.09e-13	-0.55	-0.39	Schizophrenia;	chr5:50145974	chr1:121519112~121571892:+
LUAD	trans	rs74781061	0.932	rs11854461	ENSG00000227288.3	RP5-837I24.1	9.42	1.96e-19	7.32e-13	0.59	0.39	Endometriosis;	chr15:74447400	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.86	rs6495101	ENSG00000227288.3	RP5-837I24.1	9.42	1.96e-19	7.32e-13	0.59	0.39	Endometriosis;	chr15:74450411	chr1:81501794~81503468:+
LUAD	trans	rs9899728	0.539	rs11077772	ENSG00000234925.2	ATP5HP4	9.41	2.01e-19	7.51e-13	0.68	0.39	Alzheimer's disease or small vessel stroke;	chr17:75039603	chr12:68642519~68642993:-
LUAD	trans	rs3779195	0.524	rs80195155	ENSG00000225169.1	BRI3P1	-9.41	2.03e-19	7.55e-13	-0.63	-0.39	Sex hormone-binding globulin levels;	chr7:98248841	chr1:100213293~100213670:+
LUAD	trans	rs7554511	1	rs41299637	ENSG00000244144.1	RP11-757F18.3	-9.41	2.06e-19	7.66e-13	-0.54	-0.39	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200908722	chr3:112185480~112185998:-
LUAD	trans	rs74781061	0.789	rs2289188	ENSG00000227288.3	RP5-837I24.1	9.41	2.06e-19	7.67e-13	0.59	0.39	Endometriosis;	chr15:74450127	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.789	rs12440654	ENSG00000227288.3	RP5-837I24.1	9.41	2.06e-19	7.67e-13	0.59	0.39	Endometriosis;	chr15:74453008	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.86	rs7169985	ENSG00000227288.3	RP5-837I24.1	9.41	2.06e-19	7.67e-13	0.59	0.39	Endometriosis;	chr15:74453437	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.86	rs8037211	ENSG00000227288.3	RP5-837I24.1	9.41	2.06e-19	7.67e-13	0.59	0.39	Endometriosis;	chr15:74455061	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.789	rs11852291	ENSG00000227288.3	RP5-837I24.1	9.41	2.06e-19	7.67e-13	0.59	0.39	Endometriosis;	chr15:74457624	chr1:81501794~81503468:+
LUAD	trans	rs74781061	0.86	rs4887152	ENSG00000227288.3	RP5-837I24.1	9.41	2.06e-19	7.67e-13	0.59	0.39	Endometriosis;	chr15:74464013	chr1:81501794~81503468:+
LUAD	trans	rs77688320	0.535	rs7579617	ENSG00000235105.1	RP11-329A14.1	9.41	2.07e-19	7.72e-13	0.47	0.39	Breast cancer;	chr2:201384065	chr1:48435967~48437223:+
LUAD	trans	rs9899728	0.539	rs113775187	ENSG00000234925.2	ATP5HP4	9.41	2.11e-19	7.85e-13	0.66	0.39	Alzheimer's disease or small vessel stroke;	chr17:75051195	chr12:68642519~68642993:-
LUAD	trans	rs10940346	0.505	rs2219453	ENSG00000231752.4	EMBP1	-9.41	2.12e-19	7.87e-13	-0.55	-0.39	Schizophrenia;	chr5:50212774	chr1:121519112~121571892:+
LUAD	trans	rs12138950	0.596	rs10917471	ENSG00000224237.1	MINOS1P3	9.4	2.15e-19	8.01e-13	0.5	0.39	Hypothyroidism;Thyroid volume;	chr1:19521118	chr3:27214816~27215018:-
LUAD	trans	rs55665837	0.701	rs2007361	ENSG00000236360.2	RP11-334A14.2	9.4	2.16e-19	8.02e-13	0.56	0.39	Vitamin D levels;	chr11:14641176	chr1:52993201~52993702:-
LUAD	trans	rs77688320	0.535	rs13027669	ENSG00000235105.1	RP11-329A14.1	9.4	2.24e-19	8.33e-13	0.46	0.39	Breast cancer;	chr2:201382596	chr1:48435967~48437223:+
LUAD	trans	rs12709013	0.967	rs2118019	ENSG00000230849.2	GOT2P2	-9.4	2.28e-19	8.45e-13	-0.49	-0.39	Blood metabolite ratios;	chr16:58797825	chr1:173141100~173142350:-
LUAD	trans	rs11098499	0.789	rs10212719	ENSG00000275858.1	RP11-291L22.8	9.4	2.29e-19	8.49e-13	0.48	0.39	Corneal astigmatism;	chr4:119333282	chr10:38450738~38451069:-
LUAD	trans	rs74781061	0.86	rs4887150	ENSG00000227288.3	RP5-837I24.1	9.4	2.3e-19	8.53e-13	0.59	0.39	Endometriosis;	chr15:74444683	chr1:81501794~81503468:+
LUAD	trans	rs7312770	0.637	rs705699	ENSG00000196656.7	AC004057.1	9.4	2.3e-19	8.54e-13	0.42	0.39	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr4:113214046~113217170:-
LUAD	trans	rs13190036	1	rs71601343	ENSG00000228305.2	AC016734.2	-9.39	2.37e-19	8.79e-13	-0.58	-0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177205106	chr2:63622178~63622831:-
LUAD	trans	rs13190036	1	rs71601344	ENSG00000228305.2	AC016734.2	-9.39	2.37e-19	8.79e-13	-0.58	-0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206492	chr2:63622178~63622831:-
LUAD	trans	rs7662987	1	rs11547772	ENSG00000233859.2	ADH5P4	9.39	2.45e-19	9.06e-13	0.65	0.39	Smoking initiation;	chr4:99071642	chr6:65836930~65838039:-
LUAD	trans	rs7662987	1	rs28730640	ENSG00000233859.2	ADH5P4	9.39	2.45e-19	9.06e-13	0.65	0.39	Smoking initiation;	chr4:99072902	chr6:65836930~65838039:-
LUAD	trans	rs7662987	1	rs7658118	ENSG00000233859.2	ADH5P4	9.39	2.45e-19	9.06e-13	0.65	0.39	Smoking initiation;	chr4:99073457	chr6:65836930~65838039:-
LUAD	trans	rs9611519	0.929	rs2064560	ENSG00000268568.1	AC007228.9	-9.39	2.46e-19	9.11e-13	-0.56	-0.39	Neuroticism;	chr22:41134036	chr19:56672574~56673901:-
LUAD	trans	rs13190036	1	rs3733875	ENSG00000228305.2	AC016734.2	-9.38	2.55e-19	9.44e-13	-0.57	-0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210239	chr2:63622178~63622831:-
LUAD	trans	rs77688320	0.535	rs2241118	ENSG00000235105.1	RP11-329A14.1	9.38	2.57e-19	9.51e-13	0.47	0.39	Breast cancer;	chr2:201388993	chr1:48435967~48437223:+
LUAD	trans	rs877636	1	rs877636	ENSG00000234513.1	AC073072.7	-9.38	2.58e-19	9.53e-13	-0.46	-0.39	Cognitive function;	chr12:56086799	chr7:22773646~22773993:-
LUAD	trans	rs74781061	0.858	rs8023865	ENSG00000227288.3	RP5-837I24.1	9.38	2.67e-19	9.86e-13	0.59	0.39	Endometriosis;	chr15:74561263	chr1:81501794~81503468:+
LUAD	trans	rs55665837	0.701	rs10766188	ENSG00000236360.2	RP11-334A14.2	9.38	2.67e-19	9.87e-13	0.55	0.39	Vitamin D levels;	chr11:14639280	chr1:52993201~52993702:-
LUAD	trans	rs3779195	0.52	rs17169479	ENSG00000225169.1	BRI3P1	9.38	2.68e-19	9.89e-13	0.62	0.39	Sex hormone-binding globulin levels;	chr7:98238721	chr1:100213293~100213670:+
LUAD	trans	rs11098499	0.697	rs35280960	ENSG00000275858.1	RP11-291L22.8	9.38	2.71e-19	1e-12	0.48	0.39	Corneal astigmatism;	chr4:119335904	chr10:38450738~38451069:-
LUAD	trans	rs7662987	1	rs7683802	ENSG00000233859.2	ADH5P4	9.37	2.74e-19	1.01e-12	0.64	0.39	Smoking initiation;	chr4:99073987	chr6:65836930~65838039:-
LUAD	trans	rs77688320	0.535	rs7575721	ENSG00000235105.1	RP11-329A14.1	9.37	2.77e-19	1.02e-12	0.46	0.39	Breast cancer;	chr2:201392055	chr1:48435967~48437223:+
LUAD	trans	rs77688320	0.535	rs3815515	ENSG00000235105.1	RP11-329A14.1	9.37	2.77e-19	1.02e-12	0.46	0.39	Breast cancer;	chr2:201393207	chr1:48435967~48437223:+
LUAD	trans	rs77688320	0.535	rs13001194	ENSG00000235105.1	RP11-329A14.1	9.37	2.77e-19	1.02e-12	0.46	0.39	Breast cancer;	chr2:201396452	chr1:48435967~48437223:+
LUAD	trans	rs77688320	0.535	rs7571761	ENSG00000235105.1	RP11-329A14.1	9.37	2.77e-19	1.02e-12	0.46	0.39	Breast cancer;	chr2:201396837	chr1:48435967~48437223:+
LUAD	trans	rs77688320	0.535	rs10931944	ENSG00000235105.1	RP11-329A14.1	9.37	2.77e-19	1.02e-12	0.46	0.39	Breast cancer;	chr2:201398875	chr1:48435967~48437223:+
LUAD	trans	rs77688320	0.553	rs11681526	ENSG00000235105.1	RP11-329A14.1	9.37	2.77e-19	1.02e-12	0.46	0.39	Breast cancer;	chr2:201399037	chr1:48435967~48437223:+
LUAD	trans	rs77688320	0.535	rs13022344	ENSG00000235105.1	RP11-329A14.1	9.37	2.77e-19	1.02e-12	0.46	0.39	Breast cancer;	chr2:201399433	chr1:48435967~48437223:+
LUAD	trans	rs77688320	0.535	rs6732993	ENSG00000235105.1	RP11-329A14.1	9.37	2.77e-19	1.02e-12	0.46	0.39	Breast cancer;	chr2:201399593	chr1:48435967~48437223:+
LUAD	trans	rs4925166	1	rs4925166	ENSG00000188933.13	USP32P1	9.37	2.78e-19	1.02e-12	0.51	0.39	Multiple sclerosis;	chr17:18307496	chr17:16786489~16804455:+
LUAD	trans	rs877636	0.859	rs3741499	ENSG00000235459.5	RPS26P31	-9.37	2.83e-19	1.04e-12	-0.43	-0.39	Cognitive function;	chr12:56080595	chr7:122681315~122681662:+
LUAD	trans	rs9611519	0.964	rs4820428	ENSG00000268568.1	AC007228.9	9.37	2.83e-19	1.04e-12	0.54	0.39	Neuroticism;	chr22:41141585	chr19:56672574~56673901:-
LUAD	trans	rs7554511	1	rs12132298	ENSG00000244144.1	RP11-757F18.3	-9.36	2.94e-19	1.08e-12	-0.54	-0.39	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200905967	chr3:112185480~112185998:-
LUAD	trans	rs7554511	1	rs12132349	ENSG00000244144.1	RP11-757F18.3	-9.36	2.94e-19	1.08e-12	-0.54	-0.39	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200906114	chr3:112185480~112185998:-
LUAD	trans	rs9611519	0.964	rs2092563	ENSG00000268568.1	AC007228.9	-9.36	2.99e-19	1.1e-12	-0.56	-0.39	Neuroticism;	chr22:41196673	chr19:56672574~56673901:-
LUAD	trans	rs9611519	1	rs9611519	ENSG00000268568.1	AC007228.9	-9.36	3e-19	1.1e-12	-0.55	-0.39	Neuroticism;	chr22:41217184	chr19:56672574~56673901:-
LUAD	trans	rs10865397	0.506	rs13414160	ENSG00000236165.1	PRADC1P1	9.36	3.03e-19	1.11e-12	0.53	0.39	Intelligence (multi-trait analysis);	chr2:73156133	chr3:36976316~36976840:+
LUAD	trans	rs6732160	0.51	rs57825971	ENSG00000236165.1	PRADC1P1	9.36	3.03e-19	1.11e-12	0.53	0.39	Intelligence (multi-trait analysis);	chr2:73157668	chr3:36976316~36976840:+
LUAD	trans	rs7662987	0.818	rs4699701	ENSG00000233859.2	ADH5P4	9.36	3.05e-19	1.12e-12	0.65	0.39	Smoking initiation;	chr4:99077296	chr6:65836930~65838039:-
LUAD	trans	rs7662987	1	rs13146416	ENSG00000233859.2	ADH5P4	9.36	3.05e-19	1.12e-12	0.65	0.39	Smoking initiation;	chr4:99078009	chr6:65836930~65838039:-
LUAD	trans	rs77688320	0.553	rs6761777	ENSG00000235105.1	RP11-329A14.1	9.36	3.06e-19	1.13e-12	0.46	0.39	Breast cancer;	chr2:201399879	chr1:48435967~48437223:+
LUAD	trans	rs7554511	1	rs35730213	ENSG00000244144.1	RP11-757F18.3	-9.36	3.14e-19	1.16e-12	-0.54	-0.39	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200905101	chr3:112185480~112185998:-
LUAD	trans	rs1045902	0.532	rs2288631	ENSG00000236165.1	PRADC1P1	9.36	3.15e-19	1.16e-12	0.58	0.39	Intelligence (multi-trait analysis);	chr2:73228619	chr3:36976316~36976840:+
LUAD	trans	rs1045902	0.532	rs10185579	ENSG00000236165.1	PRADC1P1	9.36	3.15e-19	1.16e-12	0.58	0.39	Intelligence (multi-trait analysis);	chr2:73229214	chr3:36976316~36976840:+
LUAD	trans	rs7662987	0.938	rs28730605	ENSG00000233859.2	ADH5P4	9.36	3.17e-19	1.16e-12	0.65	0.39	Smoking initiation;	chr4:99080389	chr6:65836930~65838039:-
LUAD	trans	rs13190036	1	rs13185316	ENSG00000228305.2	AC016734.2	-9.36	3.17e-19	1.17e-12	-0.57	-0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177213339	chr2:63622178~63622831:-
LUAD	trans	rs10865397	0.506	rs60764301	ENSG00000236165.1	PRADC1P1	9.35	3.28e-19	1.21e-12	0.53	0.39	Intelligence (multi-trait analysis);	chr2:73157722	chr3:36976316~36976840:+
LUAD	trans	rs13358908	0.506	rs7293471	ENSG00000231752.4	EMBP1	-9.35	3.42e-19	1.26e-12	-0.56	-0.39	Schizophrenia;	chr5:46404446	chr1:121519112~121571892:+
LUAD	trans	rs1045902	0.537	rs1018342	ENSG00000236165.1	PRADC1P1	9.34	3.48e-19	1.28e-12	0.57	0.39	Intelligence (multi-trait analysis);	chr2:73244525	chr3:36976316~36976840:+
LUAD	trans	rs7312770	0.612	rs1873914	ENSG00000234354.3	RPS26P47	9.34	3.5e-19	1.28e-12	0.43	0.39	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr13:100539901~100540248:-
LUAD	trans	rs77688320	0.535	rs12468504	ENSG00000235105.1	RP11-329A14.1	-9.34	3.52e-19	1.29e-12	-0.47	-0.39	Breast cancer;	chr2:201393746	chr1:48435967~48437223:+
LUAD	trans	rs9611519	1	rs9611505	ENSG00000268568.1	AC007228.9	-9.34	3.53e-19	1.29e-12	-0.55	-0.39	Neuroticism;	chr22:41144275	chr19:56672574~56673901:-
LUAD	trans	rs77688320	0.535	rs7597850	ENSG00000235105.1	RP11-329A14.1	9.34	3.54e-19	1.3e-12	0.46	0.39	Breast cancer;	chr2:201396679	chr1:48435967~48437223:+
LUAD	trans	rs7554511	0.964	rs59655222	ENSG00000244144.1	RP11-757F18.3	-9.34	3.58e-19	1.31e-12	-0.53	-0.39	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200906769	chr3:112185480~112185998:-
LUAD	trans	rs10865397	0.506	rs6546807	ENSG00000236165.1	PRADC1P1	9.34	3.62e-19	1.33e-12	0.52	0.39	Intelligence (multi-trait analysis);	chr2:73159084	chr3:36976316~36976840:+
LUAD	trans	rs11098499	0.615	rs59867181	ENSG00000275858.1	RP11-291L22.8	-9.34	3.67e-19	1.34e-12	-0.44	-0.39	Corneal astigmatism;	chr4:119635312	chr10:38450738~38451069:-
LUAD	trans	rs74781061	0.929	rs9672559	ENSG00000227288.3	RP5-837I24.1	9.33	3.8e-19	1.39e-12	0.61	0.39	Endometriosis;	chr15:74698995	chr1:81501794~81503468:+
LUAD	trans	rs12145833	0.538	rs4658547	ENSG00000154608.12	CEP170P1	9.33	3.8e-19	1.39e-12	0.65	0.39	Obesity (early onset extreme);	chr1:243227829	chr4:118467590~118554204:+
LUAD	trans	rs877636	1	rs4759229	ENSG00000235459.5	RPS26P31	-9.33	3.82e-19	1.4e-12	-0.43	-0.39	Cognitive function;	chr12:56080696	chr7:122681315~122681662:+
LUAD	trans	rs11098499	0.588	rs2389874	ENSG00000275858.1	RP11-291L22.8	-9.33	3.91e-19	1.43e-12	-0.45	-0.39	Corneal astigmatism;	chr4:119633836	chr10:38450738~38451069:-
LUAD	trans	rs1079467	0.786	rs2136907	ENSG00000233426.3	EIF3FP3	-9.33	3.91e-19	1.43e-12	-0.68	-0.39	Response to anti-TNF therapy in rheumatoid arthritis;	chr11:7951686	chr2:58251440~58252525:+
LUAD	trans	rs7662987	1	rs28730595	ENSG00000233859.2	ADH5P4	9.33	3.97e-19	1.45e-12	0.66	0.39	Smoking initiation;	chr4:99082182	chr6:65836930~65838039:-
LUAD	trans	rs7662987	0.938	rs28730592	ENSG00000233859.2	ADH5P4	9.33	3.97e-19	1.45e-12	0.66	0.39	Smoking initiation;	chr4:99082592	chr6:65836930~65838039:-
LUAD	trans	rs7662987	1	rs28730591	ENSG00000233859.2	ADH5P4	9.33	3.97e-19	1.45e-12	0.66	0.39	Smoking initiation;	chr4:99082596	chr6:65836930~65838039:-
LUAD	trans	rs12145833	0.538	rs9803701	ENSG00000154608.12	CEP170P1	9.33	3.99e-19	1.46e-12	0.65	0.39	Obesity (early onset extreme);	chr1:243228332	chr4:118467590~118554204:+
LUAD	trans	rs55665837	0.701	rs1522633	ENSG00000236360.2	RP11-334A14.2	9.32	4.06e-19	1.48e-12	0.55	0.39	Vitamin D levels;	chr11:14623692	chr1:52993201~52993702:-
LUAD	trans	rs77688320	0.535	rs10804115	ENSG00000235105.1	RP11-329A14.1	9.32	4.25e-19	1.55e-12	0.46	0.39	Breast cancer;	chr2:201415510	chr1:48435967~48437223:+
LUAD	trans	rs77688320	0.535	rs6751543	ENSG00000235105.1	RP11-329A14.1	9.32	4.31e-19	1.57e-12	0.46	0.39	Breast cancer;	chr2:201400210	chr1:48435967~48437223:+
LUAD	trans	rs77688320	0.535	rs34625194	ENSG00000235105.1	RP11-329A14.1	9.32	4.31e-19	1.57e-12	0.46	0.39	Breast cancer;	chr2:201406815	chr1:48435967~48437223:+
LUAD	trans	rs77688320	0.535	rs11691859	ENSG00000235105.1	RP11-329A14.1	9.32	4.31e-19	1.57e-12	0.46	0.39	Breast cancer;	chr2:201407268	chr1:48435967~48437223:+
LUAD	trans	rs77688320	0.517	rs11691865	ENSG00000235105.1	RP11-329A14.1	9.32	4.31e-19	1.57e-12	0.46	0.39	Breast cancer;	chr2:201407309	chr1:48435967~48437223:+
LUAD	trans	rs11098499	0.562	rs13101722	ENSG00000275858.1	RP11-291L22.8	-9.32	4.33e-19	1.58e-12	-0.44	-0.39	Corneal astigmatism;	chr4:119634820	chr10:38450738~38451069:-
LUAD	trans	rs877636	0.692	rs11171739	ENSG00000223416.3	RPS26P15	9.31	4.41e-19	1.61e-12	0.39	0.39	Cognitive function;	chr12:56076841	chr1:58056133~58056480:-
LUAD	trans	rs9611519	1	rs9611520	ENSG00000268568.1	AC007228.9	-9.31	4.42e-19	1.61e-12	-0.55	-0.39	Neuroticism;	chr22:41217299	chr19:56672574~56673901:-
LUAD	trans	rs867371	0.826	rs2047678	ENSG00000235370.6	DNM1P51	-9.31	4.53e-19	1.65e-12	-0.47	-0.39	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82205857	chr15:84398316~84411701:-
LUAD	trans	rs1079467	0.679	rs12286813	ENSG00000233426.3	EIF3FP3	-9.31	4.53e-19	1.65e-12	-0.67	-0.39	Response to anti-TNF therapy in rheumatoid arthritis;	chr11:7949826	chr2:58251440~58252525:+
LUAD	trans	rs6732160	0.934	rs2421390	ENSG00000236165.1	PRADC1P1	9.31	4.59e-19	1.67e-12	0.53	0.39	Intelligence (multi-trait analysis);	chr2:73151975	chr3:36976316~36976840:+
LUAD	trans	rs6732160	0.932	rs6546802	ENSG00000236165.1	PRADC1P1	9.31	4.59e-19	1.67e-12	0.53	0.39	Intelligence (multi-trait analysis);	chr2:73152436	chr3:36976316~36976840:+
LUAD	trans	rs11098499	0.661	rs10015965	ENSG00000275858.1	RP11-291L22.8	9.3	4.74e-19	1.72e-12	0.44	0.39	Corneal astigmatism;	chr4:119347082	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.535	rs10005542	ENSG00000275858.1	RP11-291L22.8	9.3	4.74e-19	1.72e-12	0.44	0.39	Corneal astigmatism;	chr4:119347147	chr10:38450738~38451069:-
LUAD	trans	rs10028773	0.6	rs4001390	ENSG00000275858.1	RP11-291L22.8	9.3	4.76e-19	1.73e-12	0.44	0.39	Educational attainment;	chr4:119344628	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.691	rs2136911	ENSG00000275858.1	RP11-291L22.8	9.3	4.76e-19	1.73e-12	0.44	0.39	Corneal astigmatism;	chr4:119344704	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.554	rs2175381	ENSG00000275858.1	RP11-291L22.8	9.3	4.76e-19	1.73e-12	0.44	0.39	Corneal astigmatism;	chr4:119344812	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.599	rs3864142	ENSG00000275858.1	RP11-291L22.8	9.3	4.76e-19	1.73e-12	0.44	0.39	Corneal astigmatism;	chr4:119345036	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.605	rs6833140	ENSG00000275858.1	RP11-291L22.8	9.3	4.76e-19	1.73e-12	0.44	0.39	Corneal astigmatism;	chr4:119345667	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.779	rs6815934	ENSG00000275858.1	RP11-291L22.8	9.3	4.76e-19	1.73e-12	0.44	0.39	Corneal astigmatism;	chr4:119346155	chr10:38450738~38451069:-
LUAD	trans	rs74781061	0.929	rs8029116	ENSG00000227288.3	RP5-837I24.1	9.3	4.89e-19	1.77e-12	0.59	0.39	Endometriosis;	chr15:74530753	chr1:81501794~81503468:+
LUAD	trans	rs12709013	0.875	rs9924389	ENSG00000233719.3	GOT2P3	9.3	4.96e-19	1.8e-12	0.46	0.39	Blood metabolite ratios;	chr16:58779849	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.967	rs11643969	ENSG00000233719.3	GOT2P3	9.29	5.17e-19	1.87e-12	0.47	0.39	Blood metabolite ratios;	chr16:58785354	chr12:9641802~9643007:+
LUAD	trans	rs11098499	0.754	rs1980025	ENSG00000275858.1	RP11-291L22.8	-9.28	5.61e-19	2.03e-12	-0.47	-0.39	Corneal astigmatism;	chr4:119331651	chr10:38450738~38451069:-
LUAD	trans	rs74781061	0.929	rs79600165	ENSG00000227288.3	RP5-837I24.1	9.28	5.72e-19	2.07e-12	0.6	0.39	Endometriosis;	chr15:74648650	chr1:81501794~81503468:+
LUAD	trans	rs8175379	0.502	rs8185361	ENSG00000231752.4	EMBP1	-9.28	5.8e-19	2.1e-12	-0.52	-0.39	Interleukin-7 levels;	chr5:46300238	chr1:121519112~121571892:+
LUAD	trans	rs3779195	0.585	rs58699591	ENSG00000225169.1	BRI3P1	-9.28	5.84e-19	2.11e-12	-0.62	-0.39	Sex hormone-binding globulin levels;	chr7:98247392	chr1:100213293~100213670:+
LUAD	trans	rs13190036	1	rs628506	ENSG00000228305.2	AC016734.2	-9.27	6.19e-19	2.24e-12	-0.5	-0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107422	chr2:63622178~63622831:-
LUAD	trans	rs12709013	1	rs11644891	ENSG00000233719.3	GOT2P3	9.27	6.24e-19	2.25e-12	0.47	0.39	Blood metabolite ratios;	chr16:58799921	chr12:9641802~9643007:+
LUAD	trans	rs12709013	1	rs11641566	ENSG00000233719.3	GOT2P3	9.27	6.24e-19	2.25e-12	0.47	0.39	Blood metabolite ratios;	chr16:58801276	chr12:9641802~9643007:+
LUAD	trans	rs867371	0.82	rs7164362	ENSG00000235370.6	DNM1P51	-9.27	6.32e-19	2.28e-12	-0.47	-0.39	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82194401	chr15:84398316~84411701:-
LUAD	trans	rs11098499	0.562	rs2389879	ENSG00000275858.1	RP11-291L22.8	-9.27	6.35e-19	2.29e-12	-0.44	-0.39	Corneal astigmatism;	chr4:119636529	chr10:38450738~38451069:-
LUAD	trans	rs1045902	0.574	rs1053329	ENSG00000236165.1	PRADC1P1	9.27	6.43e-19	2.32e-12	0.59	0.39	Intelligence (multi-trait analysis);	chr2:73234355	chr3:36976316~36976840:+
LUAD	trans	rs11098499	0.644	rs17517414	ENSG00000275858.1	RP11-291L22.8	9.27	6.44e-19	2.32e-12	0.44	0.39	Corneal astigmatism;	chr4:119340946	chr10:38450738~38451069:-
LUAD	trans	rs10028773	0.666	rs12498657	ENSG00000275858.1	RP11-291L22.8	9.27	6.44e-19	2.32e-12	0.44	0.39	Educational attainment;	chr4:119341711	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.722	rs10006192	ENSG00000275858.1	RP11-291L22.8	9.27	6.44e-19	2.32e-12	0.44	0.39	Corneal astigmatism;	chr4:119341867	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.615	rs28551750	ENSG00000275858.1	RP11-291L22.8	9.27	6.44e-19	2.32e-12	0.44	0.39	Corneal astigmatism;	chr4:119343746	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.691	rs9995716	ENSG00000275858.1	RP11-291L22.8	9.27	6.44e-19	2.32e-12	0.44	0.39	Corneal astigmatism;	chr4:119343841	chr10:38450738~38451069:-
LUAD	trans	rs12145833	0.596	rs61833906	ENSG00000154608.12	CEP170P1	-9.27	6.45e-19	2.32e-12	-0.71	-0.39	Obesity (early onset extreme);	chr1:243256404	chr4:118467590~118554204:+
LUAD	trans	rs12145833	0.665	rs78871868	ENSG00000154608.12	CEP170P1	-9.27	6.45e-19	2.32e-12	-0.71	-0.39	Obesity (early onset extreme);	chr1:243259020	chr4:118467590~118554204:+
LUAD	trans	rs7937890	0.732	rs7946902	ENSG00000236360.2	RP11-334A14.2	-9.26	6.63e-19	2.39e-12	-0.49	-0.39	Mitochondrial DNA levels;	chr11:14251762	chr1:52993201~52993702:-
LUAD	trans	rs12709013	0.967	rs56107162	ENSG00000233719.3	GOT2P3	9.26	6.69e-19	2.41e-12	0.47	0.39	Blood metabolite ratios;	chr16:58804358	chr12:9641802~9643007:+
LUAD	trans	rs7647973	0.516	rs4536858	ENSG00000197582.5	GPX1P1	9.26	6.82e-19	2.45e-12	0.51	0.39	Menarche (age at onset);	chr3:49155648	chrX:13378735~13379340:-
LUAD	trans	rs7662987	0.793	rs78790289	ENSG00000228407.2	RP4-800M22.1	9.26	6.91e-19	2.49e-12	0.7	0.39	Smoking initiation;	chr4:99066736	chr1:52160261~52160600:-
LUAD	trans	rs1045902	0.574	rs1474298	ENSG00000236165.1	PRADC1P1	9.26	6.92e-19	2.49e-12	0.56	0.39	Intelligence (multi-trait analysis);	chr2:73239464	chr3:36976316~36976840:+
LUAD	trans	rs7312770	0.612	rs773114	ENSG00000196656.7	AC004057.1	9.25	7.08e-19	2.55e-12	0.41	0.39	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr4:113214046~113217170:-
LUAD	trans	rs6732160	0.932	rs13417029	ENSG00000236165.1	PRADC1P1	9.25	7.34e-19	2.64e-12	0.53	0.39	Intelligence (multi-trait analysis);	chr2:73153295	chr3:36976316~36976840:+
LUAD	trans	rs6732160	0.932	rs6546803	ENSG00000236165.1	PRADC1P1	9.25	7.34e-19	2.64e-12	0.53	0.39	Intelligence (multi-trait analysis);	chr2:73154187	chr3:36976316~36976840:+
LUAD	trans	rs1039766	1	rs268882	ENSG00000224334.1	AP000357.4	-9.24	8.2e-19	2.94e-12	-0.6	-0.39	Lung adenocarcinoma;Lung cancer;	chr2:65275668	chr22:24686923~24688087:+
LUAD	trans	rs6732160	0.967	rs6760964	ENSG00000236165.1	PRADC1P1	9.23	8.31e-19	2.98e-12	0.52	0.39	Intelligence (multi-trait analysis);	chr2:73160258	chr3:36976316~36976840:+
LUAD	trans	rs13190036	0.551	rs11957608	ENSG00000226986.4	RP11-543B16.2	-9.23	8.35e-19	2.99e-12	-0.53	-0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228344	chr1:211207239~211207897:+
LUAD	trans	rs11098499	0.722	rs17595727	ENSG00000275858.1	RP11-291L22.8	-9.23	8.47e-19	3.04e-12	-0.44	-0.39	Corneal astigmatism;	chr4:119340919	chr10:38450738~38451069:-
LUAD	trans	rs10865397	0.539	rs13414338	ENSG00000236165.1	PRADC1P1	9.23	8.49e-19	3.04e-12	0.53	0.39	Intelligence (multi-trait analysis);	chr2:73156247	chr3:36976316~36976840:+
LUAD	trans	rs9611519	1	rs6002271	ENSG00000268568.1	AC007228.9	-9.23	8.6e-19	3.08e-12	-0.55	-0.39	Neuroticism;	chr22:41170591	chr19:56672574~56673901:-
LUAD	trans	rs7662987	1	rs7684986	ENSG00000233859.2	ADH5P4	9.23	8.65e-19	3.1e-12	0.64	0.39	Smoking initiation;	chr4:99070525	chr6:65836930~65838039:-
LUAD	trans	rs9425766	0.962	rs9425430	ENSG00000213331.4	RP11-713C19.2	9.23	8.77e-19	3.14e-12	0.46	0.39	Life satisfaction;	chr1:173888145	chr4:187970273~187971284:+
LUAD	trans	rs11098499	0.691	rs10028773	ENSG00000275858.1	RP11-291L22.8	-9.22	8.99e-19	3.22e-12	-0.43	-0.39	Corneal astigmatism;	chr4:119344104	chr10:38450738~38451069:-
LUAD	trans	rs6732160	0.932	rs768851	ENSG00000236165.1	PRADC1P1	9.22	9.06e-19	3.24e-12	0.53	0.39	Intelligence (multi-trait analysis);	chr2:73151113	chr3:36976316~36976840:+
LUAD	trans	rs10941710	0.579	rs8188241	ENSG00000231752.4	EMBP1	9.22	9.54e-19	3.41e-12	0.52	0.39	Neuroticism;	chr5:46204646	chr1:121519112~121571892:+
LUAD	trans	rs10242455	0.571	rs45593341	ENSG00000228834.1	RP11-249L21.4	9.21	9.95e-19	3.55e-12	0.94	0.39	Blood metabolite levels;	chr7:99707288	chr6:108907615~108907873:-
LUAD	trans	rs1079467	0.73	rs4259814	ENSG00000233426.3	EIF3FP3	-9.21	1.02e-18	3.64e-12	-0.67	-0.39	Response to anti-TNF therapy in rheumatoid arthritis;	chr11:7950941	chr2:58251440~58252525:+
LUAD	trans	rs1816752	0.583	rs6490918	ENSG00000224976.2	PARP4P2	9.21	1.03e-18	3.67e-12	0.45	0.39	Obesity-related traits;	chr13:24427977	chr13:19349137~19407962:+
LUAD	trans	rs1079467	0.735	rs75941265	ENSG00000233426.3	EIF3FP3	-9.21	1.03e-18	3.68e-12	-0.69	-0.39	Response to anti-TNF therapy in rheumatoid arthritis;	chr11:7949542	chr2:58251440~58252525:+
LUAD	trans	rs74781061	0.932	rs11629749	ENSG00000227288.3	RP5-837I24.1	9.21	1.03e-18	3.68e-12	0.53	0.39	Endometriosis;	chr15:74627252	chr1:81501794~81503468:+
LUAD	trans	rs13190036	0.551	rs9313751	ENSG00000226986.4	RP11-543B16.2	-9.21	1.03e-18	3.68e-12	-0.53	-0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177217174	chr1:211207239~211207897:+
LUAD	trans	rs10028773	0.568	rs6838457	ENSG00000275858.1	RP11-291L22.8	9.21	1.04e-18	3.7e-12	0.44	0.39	Educational attainment;	chr4:119346212	chr10:38450738~38451069:-
LUAD	trans	rs1045902	0.516	rs7851	ENSG00000236165.1	PRADC1P1	9.2	1.05e-18	3.75e-12	0.57	0.39	Intelligence (multi-trait analysis);	chr2:73251333	chr3:36976316~36976840:+
LUAD	trans	rs7554511	1	rs55838263	ENSG00000244144.1	RP11-757F18.3	-9.2	1.05e-18	3.76e-12	-0.53	-0.39	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200905600	chr3:112185480~112185998:-
LUAD	trans	rs10242455	0.85	rs3779354	ENSG00000228834.1	RP11-249L21.4	9.2	1.07e-18	3.82e-12	0.82	0.39	Blood metabolite levels;	chr7:99454805	chr6:108907615~108907873:-
LUAD	trans	rs11098499	0.588	rs6534149	ENSG00000275858.1	RP11-291L22.8	-9.2	1.07e-18	3.82e-12	-0.44	-0.39	Corneal astigmatism;	chr4:119638137	chr10:38450738~38451069:-
LUAD	trans	rs12709013	1	rs34319345	ENSG00000233719.3	GOT2P3	9.2	1.07e-18	3.82e-12	0.47	0.39	Blood metabolite ratios;	chr16:58786688	chr12:9641802~9643007:+
LUAD	trans	rs10940346	0.601	rs7709906	ENSG00000231752.4	EMBP1	9.2	1.07e-18	3.83e-12	0.51	0.39	Schizophrenia;	chr5:50299936	chr1:121519112~121571892:+
LUAD	trans	rs13190036	0.515	rs2878686	ENSG00000226986.4	RP11-543B16.2	-9.2	1.08e-18	3.86e-12	-0.53	-0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206748	chr1:211207239~211207897:+
LUAD	trans	rs4276421	0.869	rs11741075	ENSG00000231752.4	EMBP1	-9.2	1.09e-18	3.88e-12	-0.52	-0.39	P wave duration;	chr5:45556276	chr1:121519112~121571892:+
LUAD	trans	rs12709013	0.935	rs11648634	ENSG00000233719.3	GOT2P3	9.2	1.09e-18	3.89e-12	0.46	0.39	Blood metabolite ratios;	chr16:58785256	chr12:9641802~9643007:+
LUAD	trans	rs6732160	1	rs6732160	ENSG00000236165.1	PRADC1P1	9.2	1.12e-18	3.98e-12	0.52	0.39	Intelligence (multi-trait analysis);	chr2:73160100	chr3:36976316~36976840:+
LUAD	trans	rs13190036	1	rs6889220	ENSG00000228305.2	AC016734.2	9.2	1.12e-18	3.99e-12	0.57	0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177266887	chr2:63622178~63622831:-
LUAD	trans	rs7662987	1	rs1061187	ENSG00000233859.2	ADH5P4	9.2	1.12e-18	4e-12	0.64	0.39	Smoking initiation;	chr4:99071702	chr6:65836930~65838039:-
LUAD	trans	rs12709013	1	rs12926993	ENSG00000233719.3	GOT2P3	9.2	1.13e-18	4.01e-12	0.46	0.39	Blood metabolite ratios;	chr16:58789218	chr12:9641802~9643007:+
LUAD	trans	rs7554511	1	rs7554511	ENSG00000244144.1	RP11-757F18.3	9.2	1.13e-18	4.03e-12	0.52	0.39	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200908434	chr3:112185480~112185998:-
LUAD	trans	rs13190036	1	rs655623	ENSG00000228305.2	AC016734.2	9.19	1.14e-18	4.06e-12	0.52	0.39	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177107515	chr2:63622178~63622831:-
LUAD	trans	rs7662987	0.793	rs7669660	ENSG00000228407.2	RP4-800M22.1	9.19	1.18e-18	4.19e-12	0.69	0.39	Smoking initiation;	chr4:99071451	chr1:52160261~52160600:-
LUAD	trans	rs7662987	0.793	rs12106	ENSG00000228407.2	RP4-800M22.1	9.19	1.18e-18	4.19e-12	0.69	0.39	Smoking initiation;	chr4:99072199	chr1:52160261~52160600:-
LUAD	trans	rs8010715	0.816	rs2332224	ENSG00000238000.1	RP11-274E7.2	9.19	1.19e-18	4.22e-12	0.42	0.39	IgG glycosylation;	chr14:24129335	chr5:98213402~98214121:+
LUAD	trans	rs7647973	0.621	rs3774800	ENSG00000197582.5	GPX1P1	-9.19	1.19e-18	4.24e-12	-0.5	-0.39	Menarche (age at onset);	chr3:49297335	chrX:13378735~13379340:-
LUAD	trans	rs7312770	0.612	rs1873914	ENSG00000227887.1	RPS26P13	9.19	1.2e-18	4.26e-12	0.43	0.39	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr1:208697369~208697698:-
LUAD	trans	rs7662987	0.793	rs7684735	ENSG00000228407.2	RP4-800M22.1	9.19	1.21e-18	4.31e-12	0.7	0.39	Smoking initiation;	chr4:99070355	chr1:52160261~52160600:-
LUAD	trans	rs6477998	0.58	rs7851623	ENSG00000238072.1	RP11-305M3.2	9.18	1.24e-18	4.42e-12	0.65	0.39	Hematology traits;	chr9:113240285	chr7:129410113~129410370:-
LUAD	trans	rs74781061	0.932	rs4886605	ENSG00000227288.3	RP5-837I24.1	9.18	1.25e-18	4.43e-12	0.52	0.39	Endometriosis;	chr15:74733647	chr1:81501794~81503468:+
LUAD	trans	rs7662987	1	rs13145727	ENSG00000233859.2	ADH5P4	9.18	1.25e-18	4.45e-12	0.64	0.39	Smoking initiation;	chr4:99077715	chr6:65836930~65838039:-
LUAD	trans	rs7662987	1	rs13125919	ENSG00000233859.2	ADH5P4	9.18	1.25e-18	4.45e-12	0.64	0.39	Smoking initiation;	chr4:99078697	chr6:65836930~65838039:-
LUAD	trans	rs1039766	1	rs268878	ENSG00000224334.1	AP000357.4	9.18	1.27e-18	4.51e-12	0.61	0.39	Lung adenocarcinoma;Lung cancer;	chr2:65270437	chr22:24686923~24688087:+
LUAD	trans	rs877636	0.692	rs2271194	ENSG00000223416.3	RPS26P15	-9.18	1.28e-18	4.56e-12	-0.39	-0.39	Cognitive function;	chr12:56083910	chr1:58056133~58056480:-
LUAD	trans	rs11098499	0.691	rs9307471	ENSG00000275858.1	RP11-291L22.8	9.18	1.3e-18	4.63e-12	0.44	0.39	Corneal astigmatism;	chr4:119340107	chr10:38450738~38451069:-
LUAD	trans	rs76228276	0.737	rs7841162	ENSG00000260318.1	COX6CP1	9.18	1.32e-18	4.68e-12	1.04	0.39	Childhood ear infection;	chr8:99895567	chr16:11903923~11904137:-
LUAD	trans	rs2896526	0.736	rs78950598	ENSG00000235847.2	LDHAP7	9.18	1.33e-18	4.71e-12	0.66	0.39	Amyloid A serum levels;	chr11:18375599	chr2:84777259~84778223:-
LUAD	trans	rs74781061	0.929	rs2068982	ENSG00000227288.3	RP5-837I24.1	-9.17	1.34e-18	4.74e-12	-0.59	-0.39	Endometriosis;	chr15:74623547	chr1:81501794~81503468:+
LUAD	trans	rs7554511	1	rs12131796	ENSG00000244144.1	RP11-757F18.3	-9.17	1.39e-18	4.91e-12	-0.53	-0.39	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200909599	chr3:112185480~112185998:-
LUAD	trans	rs12145833	0.596	rs61833913	ENSG00000154608.12	CEP170P1	-9.17	1.44e-18	5.08e-12	-0.69	-0.39	Obesity (early onset extreme);	chr1:243276726	chr4:118467590~118554204:+
LUAD	trans	rs12145833	0.596	rs12026068	ENSG00000154608.12	CEP170P1	-9.17	1.44e-18	5.08e-12	-0.69	-0.39	Obesity (early onset extreme);	chr1:243277050	chr4:118467590~118554204:+
LUAD	trans	rs12145833	0.596	rs12134228	ENSG00000154608.12	CEP170P1	-9.17	1.44e-18	5.08e-12	-0.69	-0.39	Obesity (early onset extreme);	chr1:243284316	chr4:118467590~118554204:+
LUAD	trans	rs8010715	0.816	rs762093	ENSG00000238000.1	RP11-274E7.2	9.16	1.49e-18	5.27e-12	0.42	0.39	IgG glycosylation;	chr14:24122709	chr5:98213402~98214121:+
LUAD	trans	rs11098499	0.691	rs10010355	ENSG00000275858.1	RP11-291L22.8	9.16	1.49e-18	5.28e-12	0.44	0.39	Corneal astigmatism;	chr4:119339888	chr10:38450738~38451069:-
LUAD	trans	rs877636	0.74	rs705698	ENSG00000212994.5	RPS26P6	9.16	1.54e-18	5.44e-12	0.46	0.39	Cognitive function;	chr12:55990903	chr8:100895771~100896118:+
LUAD	trans	rs7662987	1	rs7662987	ENSG00000233859.2	ADH5P4	9.16	1.55e-18	5.46e-12	0.64	0.39	Smoking initiation;	chr4:99070491	chr6:65836930~65838039:-
LUAD	trans	rs1039766	1	rs268864	ENSG00000224334.1	AP000357.4	-9.15	1.58e-18	5.58e-12	-0.6	-0.39	Lung adenocarcinoma;Lung cancer;	chr2:65262608	chr22:24686923~24688087:+
LUAD	trans	rs1079467	0.73	rs74933956	ENSG00000233426.3	EIF3FP3	-9.15	1.6e-18	5.65e-12	-0.69	-0.39	Response to anti-TNF therapy in rheumatoid arthritis;	chr11:7950507	chr2:58251440~58252525:+
LUAD	trans	rs1079467	0.73	rs77880011	ENSG00000233426.3	EIF3FP3	-9.15	1.6e-18	5.65e-12	-0.69	-0.39	Response to anti-TNF therapy in rheumatoid arthritis;	chr11:7950656	chr2:58251440~58252525:+
LUAD	trans	rs877636	1	rs705696	ENSG00000196933.5	RPS26P11	9.15	1.68e-18	5.93e-12	0.46	0.38	Cognitive function;	chr12:56086864	chrX:72044545~72044892:+
LUAD	trans	rs12709013	1	rs11648514	ENSG00000233719.3	GOT2P3	9.14	1.71e-18	6.04e-12	0.46	0.38	Blood metabolite ratios;	chr16:58798176	chr12:9641802~9643007:+
LUAD	trans	rs12709013	1	rs8057892	ENSG00000233719.3	GOT2P3	9.14	1.71e-18	6.04e-12	0.46	0.38	Blood metabolite ratios;	chr16:58798855	chr12:9641802~9643007:+
LUAD	trans	rs9581094	0.505	rs6490945	ENSG00000237917.1	PARP4P1	9.14	1.73e-18	6.08e-12	0.53	0.38	Sudden cardiac arrest;	chr13:24514056	chrY:26594851~26634652:-
LUAD	trans	rs11098499	0.644	rs3986377	ENSG00000275858.1	RP11-291L22.8	9.14	1.73e-18	6.1e-12	0.44	0.38	Corneal astigmatism;	chr4:119339115	chr10:38450738~38451069:-
LUAD	trans	rs10028773	0.556	rs4473640	ENSG00000275858.1	RP11-291L22.8	9.14	1.73e-18	6.1e-12	0.44	0.38	Educational attainment;	chr4:119339282	chr10:38450738~38451069:-
LUAD	trans	rs10037055	0.636	rs13166688	ENSG00000226986.4	RP11-543B16.2	-9.14	1.75e-18	6.15e-12	-0.53	-0.38	Migraine without aura;	chr5:177156965	chr1:211207239~211207897:+
LUAD	trans	rs916888	0.61	rs199529	ENSG00000280022.1	RP11-707O23.1	9.14	1.78e-18	6.26e-12	0.54	0.38	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:45592621~45593369:+
LUAD	trans	rs2657294	0.674	rs10824268	ENSG00000172974.11	AC007318.5	9.13	1.84e-18	6.47e-12	0.41	0.38	Pneumonia;	chr10:75085937	chr2:65205108~65205988:+
LUAD	trans	rs12145833	0.596	rs1060643	ENSG00000154608.12	CEP170P1	-9.13	1.85e-18	6.51e-12	-0.69	-0.38	Obesity (early onset extreme);	chr1:243266674	chr4:118467590~118554204:+
LUAD	trans	rs10242455	0.571	rs45532337	ENSG00000228834.1	RP11-249L21.4	9.13	1.9e-18	6.69e-12	0.85	0.38	Blood metabolite levels;	chr7:99712696	chr6:108907615~108907873:-
LUAD	trans	rs7192380	0.639	rs2917666	ENSG00000257513.6	NPIPB1P	-9.13	1.93e-18	6.78e-12	-0.4	-0.38	Sjögren's syndrome;	chr16:69730057	chr18:11619509~11639699:-
LUAD	trans	rs7662987	1	rs7658127	ENSG00000233859.2	ADH5P4	9.13	1.97e-18	6.92e-12	0.63	0.38	Smoking initiation;	chr4:99073471	chr6:65836930~65838039:-
LUAD	trans	rs7662987	0.793	rs28730602	ENSG00000228407.2	RP4-800M22.1	9.12	1.98e-18	6.96e-12	0.69	0.38	Smoking initiation;	chr4:99080531	chr1:52160261~52160600:-
LUAD	trans	rs12709013	1	rs6499983	ENSG00000233719.3	GOT2P3	9.12	2.02e-18	7.1e-12	0.47	0.38	Blood metabolite ratios;	chr16:58810005	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.967	rs8054482	ENSG00000233719.3	GOT2P3	9.12	2.02e-18	7.1e-12	0.47	0.38	Blood metabolite ratios;	chr16:58810532	chr12:9641802~9643007:+
LUAD	trans	rs13190036	0.551	rs11955537	ENSG00000226986.4	RP11-543B16.2	-9.12	2.07e-18	7.25e-12	-0.53	-0.38	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177147087	chr1:211207239~211207897:+
LUAD	trans	rs877636	0.692	rs10876870	ENSG00000223416.3	RPS26P15	-9.11	2.16e-18	7.57e-12	-0.38	-0.38	Cognitive function;	chr12:56084218	chr1:58056133~58056480:-
LUAD	trans	rs877636	0.692	rs7971751	ENSG00000223416.3	RPS26P15	-9.11	2.16e-18	7.57e-12	-0.38	-0.38	Cognitive function;	chr12:56084874	chr1:58056133~58056480:-
LUAD	trans	rs9611519	0.964	rs5995992	ENSG00000268568.1	AC007228.9	-9.11	2.19e-18	7.66e-12	-0.55	-0.38	Neuroticism;	chr22:41091214	chr19:56672574~56673901:-
LUAD	trans	rs55665837	0.701	rs11023265	ENSG00000236360.2	RP11-334A14.2	9.11	2.21e-18	7.74e-12	0.53	0.38	Vitamin D levels;	chr11:14594492	chr1:52993201~52993702:-
LUAD	trans	rs7662987	1	rs4699699	ENSG00000233859.2	ADH5P4	9.11	2.24e-18	7.83e-12	0.64	0.38	Smoking initiation;	chr4:99076028	chr6:65836930~65838039:-
LUAD	trans	rs7662987	0.938	rs13118409	ENSG00000233859.2	ADH5P4	9.11	2.24e-18	7.83e-12	0.64	0.38	Smoking initiation;	chr4:99077585	chr6:65836930~65838039:-
LUAD	trans	rs7662987	1	rs13119035	ENSG00000233859.2	ADH5P4	9.11	2.24e-18	7.83e-12	0.64	0.38	Smoking initiation;	chr4:99077979	chr6:65836930~65838039:-
LUAD	trans	rs172166	0.61	rs156737	ENSG00000204709.4	LINC01556	9.11	2.26e-18	7.91e-12	0.46	0.38	Cardiac Troponin-T levels;	chr6:27927435	chr6:28943877~28944537:+
LUAD	trans	rs11098499	0.698	rs4422403	ENSG00000275858.1	RP11-291L22.8	9.1	2.31e-18	8.09e-12	0.44	0.38	Corneal astigmatism;	chr4:119337039	chr10:38450738~38451069:-
LUAD	trans	rs7647973	0.516	rs4499638	ENSG00000197582.5	GPX1P1	9.1	2.34e-18	8.18e-12	0.51	0.38	Menarche (age at onset);	chr3:49165349	chrX:13378735~13379340:-
LUAD	trans	rs72615157	0.634	rs79986079	ENSG00000228546.2	CTA-313A17.3	9.1	2.4e-18	8.38e-12	0.59	0.38	Lung function (FEV1/FVC);	chr7:100204421	chr7:102337316~102339115:+
LUAD	trans	rs1816752	0.74	rs6490924	ENSG00000224976.2	PARP4P2	9.1	2.42e-18	8.45e-12	0.44	0.38	Obesity-related traits;	chr13:24432914	chr13:19349137~19407962:+
LUAD	trans	rs72615157	0.634	rs7789890	ENSG00000228546.2	CTA-313A17.3	9.09	2.56e-18	8.93e-12	0.59	0.38	Lung function (FEV1/FVC);	chr7:100202936	chr7:102337316~102339115:+
LUAD	trans	rs1039766	0.929	rs268881	ENSG00000224334.1	AP000357.4	9.09	2.56e-18	8.94e-12	0.6	0.38	Lung adenocarcinoma;Lung cancer;	chr2:65274249	chr22:24686923~24688087:+
LUAD	trans	rs7647973	0.516	rs4308307	ENSG00000197582.5	GPX1P1	9.09	2.59e-18	9.05e-12	0.5	0.38	Menarche (age at onset);	chr3:49155783	chrX:13378735~13379340:-
LUAD	trans	rs1079467	0.73	rs72846600	ENSG00000233426.3	EIF3FP3	-9.09	2.66e-18	9.28e-12	-0.68	-0.38	Response to anti-TNF therapy in rheumatoid arthritis;	chr11:7952994	chr2:58251440~58252525:+
LUAD	trans	rs1039766	1	rs10116	ENSG00000224334.1	AP000357.4	9.09	2.68e-18	9.35e-12	0.6	0.38	Lung adenocarcinoma;Lung cancer;	chr2:65269595	chr22:24686923~24688087:+
LUAD	trans	rs9899728	0.539	rs12938889	ENSG00000234925.2	ATP5HP4	-9.08	2.72e-18	9.47e-12	-0.64	-0.38	Alzheimer's disease or small vessel stroke;	chr17:75043834	chr12:68642519~68642993:-
LUAD	trans	rs55665837	0.701	rs11023272	ENSG00000236360.2	RP11-334A14.2	9.08	2.78e-18	9.67e-12	0.53	0.38	Vitamin D levels;	chr11:14608824	chr1:52993201~52993702:-
LUAD	trans	rs7647973	0.516	rs12490393	ENSG00000197582.5	GPX1P1	9.08	2.85e-18	9.91e-12	0.5	0.38	Menarche (age at onset);	chr3:49158699	chrX:13378735~13379340:-
LUAD	trans	rs8010715	0.785	rs2877611	ENSG00000238000.1	RP11-274E7.2	9.08	2.92e-18	1.01e-11	0.42	0.38	IgG glycosylation;	chr14:24126221	chr5:98213402~98214121:+
LUAD	trans	rs55665837	0.701	rs12286408	ENSG00000236360.2	RP11-334A14.2	9.07	2.96e-18	1.03e-11	0.53	0.38	Vitamin D levels;	chr11:14557830	chr1:52993201~52993702:-
LUAD	trans	rs10037055	1	rs6886255	ENSG00000226986.4	RP11-543B16.2	9.07	2.98e-18	1.04e-11	0.46	0.38	Migraine without aura;	chr5:177291360	chr1:211207239~211207897:+
LUAD	trans	rs877636	0.74	rs772920	ENSG00000212994.5	RPS26P6	9.07	3e-18	1.04e-11	0.47	0.38	Cognitive function;	chr12:55996580	chr8:100895771~100896118:+
LUAD	trans	rs11098499	0.754	rs10518300	ENSG00000275858.1	RP11-291L22.8	-9.07	3.05e-18	1.06e-11	-0.47	-0.38	Corneal astigmatism;	chr4:119328344	chr10:38450738~38451069:-
LUAD	trans	rs11098499	0.569	rs10023641	ENSG00000275858.1	RP11-291L22.8	9.07	3.14e-18	1.09e-11	0.43	0.38	Corneal astigmatism;	chr4:119337255	chr10:38450738~38451069:-
LUAD	trans	rs5022636	0.507	rs4579761	ENSG00000180764.13	PIPSL	9.06	3.28e-18	1.14e-11	0.53	0.38	Gut microbiota (functional units);	chr1:151363433	chr10:93958191~93961540:-
LUAD	trans	rs55665837	0.665	rs11023273	ENSG00000236360.2	RP11-334A14.2	9.06	3.32e-18	1.15e-11	0.53	0.38	Vitamin D levels;	chr11:14609273	chr1:52993201~52993702:-
LUAD	trans	rs13190036	0.551	rs4976639	ENSG00000226986.4	RP11-543B16.2	9.06	3.37e-18	1.17e-11	0.52	0.38	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177123300	chr1:211207239~211207897:+
LUAD	trans	rs7647973	0.516	rs4955419	ENSG00000197582.5	GPX1P1	9.06	3.41e-18	1.18e-11	0.5	0.38	Menarche (age at onset);	chr3:49163259	chrX:13378735~13379340:-
LUAD	trans	rs9425766	0.886	rs1322775	ENSG00000213331.4	RP11-713C19.2	9.05	3.44e-18	1.19e-11	0.46	0.38	Life satisfaction;	chr1:173886160	chr4:187970273~187971284:+
LUAD	trans	rs7647973	0.516	rs4955418	ENSG00000197582.5	GPX1P1	9.05	3.55e-18	1.23e-11	0.5	0.38	Menarche (age at onset);	chr3:49163194	chrX:13378735~13379340:-
LUAD	trans	rs11098499	0.535	rs7671759	ENSG00000275858.1	RP11-291L22.8	9.05	3.64e-18	1.26e-11	0.47	0.38	Corneal astigmatism;	chr4:119326939	chr10:38450738~38451069:-
LUAD	trans	rs9425766	0.85	rs7349095	ENSG00000213331.4	RP11-713C19.2	9.04	3.71e-18	1.28e-11	0.45	0.38	Life satisfaction;	chr1:173887899	chr4:187970273~187971284:+
LUAD	trans	rs7554511	1	rs7522462	ENSG00000244144.1	RP11-757F18.3	9.04	3.77e-18	1.3e-11	0.51	0.38	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200912467	chr3:112185480~112185998:-
LUAD	trans	rs2657294	0.704	rs10824266	ENSG00000172974.11	AC007318.5	9.04	3.83e-18	1.33e-11	0.41	0.38	Pneumonia;	chr10:75083476	chr2:65205108~65205988:+
LUAD	trans	rs8010715	0.816	rs7153156	ENSG00000238000.1	RP11-274E7.2	9.04	3.92e-18	1.35e-11	0.42	0.38	IgG glycosylation;	chr14:24129637	chr5:98213402~98214121:+
LUAD	trans	rs55665837	0.701	rs10160597	ENSG00000236360.2	RP11-334A14.2	9.03	4.18e-18	1.44e-11	0.53	0.38	Vitamin D levels;	chr11:14582446	chr1:52993201~52993702:-
LUAD	trans	rs11098499	0.562	rs58583086	ENSG00000275858.1	RP11-291L22.8	-9.03	4.18e-18	1.44e-11	-0.43	-0.38	Corneal astigmatism;	chr4:119635207	chr10:38450738~38451069:-
LUAD	trans	rs8175379	0.53	rs12516847	ENSG00000231752.4	EMBP1	-9.03	4.22e-18	1.45e-11	-0.52	-0.38	Interleukin-7 levels;	chr5:46300736	chr1:121519112~121571892:+
LUAD	trans	rs7662987	1	rs28730587	ENSG00000233859.2	ADH5P4	9.02	4.38e-18	1.51e-11	0.65	0.38	Smoking initiation;	chr4:99083190	chr6:65836930~65838039:-
LUAD	trans	rs8010715	0.816	rs6573565	ENSG00000238000.1	RP11-274E7.2	-9.02	4.42e-18	1.52e-11	-0.42	-0.38	IgG glycosylation;	chr14:24125524	chr5:98213402~98214121:+
LUAD	trans	rs1039766	1	rs268862	ENSG00000224334.1	AP000357.4	9.02	4.6e-18	1.58e-11	0.59	0.38	Lung adenocarcinoma;Lung cancer;	chr2:65261404	chr22:24686923~24688087:+
LUAD	trans	rs7937890	1	rs7937890	ENSG00000236360.2	RP11-334A14.2	9.02	4.67e-18	1.61e-11	0.47	0.38	Mitochondrial DNA levels;	chr11:14374939	chr1:52993201~52993702:-
LUAD	trans	rs877636	0.692	rs11171739	ENSG00000244604.1	RP11-713H12.1	9.01	4.79e-18	1.65e-11	0.42	0.38	Cognitive function;	chr12:56076841	chr17:8561230~8561576:+
LUAD	trans	rs9899728	0.614	rs12949451	ENSG00000234925.2	ATP5HP4	-9.01	5e-18	1.72e-11	-0.72	-0.38	Alzheimer's disease or small vessel stroke;	chr17:75036224	chr12:68642519~68642993:-
LUAD	trans	rs877636	0.692	rs2271194	ENSG00000244604.1	RP11-713H12.1	-9.01	5.01e-18	1.72e-11	-0.42	-0.38	Cognitive function;	chr12:56083910	chr17:8561230~8561576:+
LUAD	trans	rs10037055	0.947	rs10063803	ENSG00000226986.4	RP11-543B16.2	9.01	5.02e-18	1.72e-11	0.48	0.38	Migraine without aura;	chr5:177240326	chr1:211207239~211207897:+
LUAD	trans	rs877636	1	rs705696	ENSG00000235459.5	RPS26P31	9.01	5.05e-18	1.73e-11	0.43	0.38	Cognitive function;	chr12:56086864	chr7:122681315~122681662:+
LUAD	trans	rs9858542	0.953	rs9814873	ENSG00000197582.5	GPX1P1	-9	5.05e-18	1.74e-11	-0.5	-0.38	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49416679	chrX:13378735~13379340:-
LUAD	trans	rs6132905	0.52	rs2422823	ENSG00000235559.1	NOP56P1	-9	5.09e-18	1.75e-11	-0.46	-0.38	Mumps;	chr20:2665687	chr6:28783633~28784004:-
LUAD	trans	rs7937890	1	rs6486190	ENSG00000236360.2	RP11-334A14.2	9	5.14e-18	1.76e-11	0.48	0.38	Mitochondrial DNA levels;	chr11:14379670	chr1:52993201~52993702:-
LUAD	trans	rs2657294	0.734	rs10740449	ENSG00000172974.11	AC007318.5	9	5.15e-18	1.77e-11	0.41	0.38	Pneumonia;	chr10:75086620	chr2:65205108~65205988:+
LUAD	trans	rs13190036	1	rs13175695	ENSG00000228305.2	AC016734.2	9	5.21e-18	1.79e-11	0.52	0.38	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177272810	chr2:63622178~63622831:-
LUAD	trans	rs7662987	1	rs17595424	ENSG00000233859.2	ADH5P4	9	5.45e-18	1.87e-11	0.6	0.38	Smoking initiation;	chr4:99072718	chr6:65836930~65838039:-
LUAD	trans	rs9858542	0.953	rs6997	ENSG00000197582.5	GPX1P1	-8.99	5.56e-18	1.9e-11	-0.51	-0.38	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49416401	chrX:13378735~13379340:-
LUAD	trans	rs26067	0.74	rs26079	ENSG00000231752.4	EMBP1	-8.99	5.71e-18	1.95e-11	-0.53	-0.38	Breast cancer;	chr5:50863180	chr1:121519112~121571892:+
LUAD	trans	rs877636	0.702	rs773109	ENSG00000212994.5	RPS26P6	8.99	5.74e-18	1.96e-11	0.46	0.38	Cognitive function;	chr12:55980911	chr8:100895771~100896118:+
LUAD	trans	rs10242455	0.557	rs57830676	ENSG00000228834.1	RP11-249L21.4	8.99	5.78e-18	1.98e-11	0.94	0.38	Blood metabolite levels;	chr7:99683740	chr6:108907615~108907873:-
LUAD	trans	rs877636	1	rs877636	ENSG00000234354.3	RPS26P47	-8.99	5.82e-18	1.99e-11	-0.42	-0.38	Cognitive function;	chr12:56086799	chr13:100539901~100540248:-
LUAD	trans	rs7312770	0.612	rs1873914	ENSG00000196933.5	RPS26P11	8.98	6.29e-18	2.15e-11	0.43	0.38	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chrX:72044545~72044892:+
LUAD	trans	rs8175379	0.521	rs8175430	ENSG00000231752.4	EMBP1	-8.98	6.31e-18	2.16e-11	-0.53	-0.38	Interleukin-7 levels;	chr5:46305095	chr1:121519112~121571892:+
LUAD	trans	rs877636	1	rs2292239	ENSG00000234513.1	AC073072.7	8.98	6.37e-18	2.18e-11	0.42	0.38	Cognitive function;	chr12:56088396	chr7:22773646~22773993:-
LUAD	trans	rs877636	0.74	rs772920	ENSG00000196933.5	RPS26P11	8.97	6.46e-18	2.21e-11	0.47	0.38	Cognitive function;	chr12:55996580	chrX:72044545~72044892:+
LUAD	trans	rs8010715	0.816	rs8015168	ENSG00000238000.1	RP11-274E7.2	8.97	6.48e-18	2.21e-11	0.41	0.38	IgG glycosylation;	chr14:24130663	chr5:98213402~98214121:+
LUAD	trans	rs11098499	0.754	rs10212714	ENSG00000275858.1	RP11-291L22.8	8.97	6.53e-18	2.23e-11	0.47	0.38	Corneal astigmatism;	chr4:119333147	chr10:38450738~38451069:-
LUAD	trans	rs7662987	0.793	rs4699700	ENSG00000228407.2	RP4-800M22.1	8.97	6.55e-18	2.23e-11	0.69	0.38	Smoking initiation;	chr4:99077184	chr1:52160261~52160600:-
LUAD	trans	rs877636	0.702	rs61937249	ENSG00000212994.5	RPS26P6	8.97	6.6e-18	2.25e-11	0.46	0.38	Cognitive function;	chr12:55988132	chr8:100895771~100896118:+
LUAD	trans	rs26067	0.689	rs152839	ENSG00000231752.4	EMBP1	-8.97	6.67e-18	2.28e-11	-0.51	-0.38	Breast cancer;	chr5:50849432	chr1:121519112~121571892:+
LUAD	trans	rs9425766	0.962	rs1322777	ENSG00000213331.4	RP11-713C19.2	8.97	6.81e-18	2.32e-11	0.45	0.38	Life satisfaction;	chr1:173889962	chr4:187970273~187971284:+
LUAD	trans	rs877636	0.692	rs2271194	ENSG00000224553.1	AC008065.1	-8.96	6.95e-18	2.37e-11	-0.39	-0.38	Cognitive function;	chr12:56083910	chr2:171374931~171375278:-
LUAD	trans	rs8175379	0.509	rs10078317	ENSG00000231752.4	EMBP1	8.96	6.96e-18	2.37e-11	0.52	0.38	Interleukin-7 levels;	chr5:46254038	chr1:121519112~121571892:+
LUAD	trans	rs10037055	1	rs10037055	ENSG00000226986.4	RP11-543B16.2	-8.96	7.02e-18	2.39e-11	-0.47	-0.38	Migraine without aura;	chr5:177264278	chr1:211207239~211207897:+
LUAD	trans	rs877636	0.702	rs773110	ENSG00000212994.5	RPS26P6	8.96	7.03e-18	2.39e-11	0.46	0.38	Cognitive function;	chr12:55981353	chr8:100895771~100896118:+
LUAD	trans	rs877636	0.702	rs773111	ENSG00000212994.5	RPS26P6	8.96	7.03e-18	2.39e-11	0.46	0.38	Cognitive function;	chr12:55981956	chr8:100895771~100896118:+
LUAD	trans	rs877636	0.702	rs773112	ENSG00000212994.5	RPS26P6	8.96	7.03e-18	2.39e-11	0.46	0.38	Cognitive function;	chr12:55982097	chr8:100895771~100896118:+
LUAD	trans	rs1039766	1	rs268861	ENSG00000224334.1	AP000357.4	8.96	7.2e-18	2.45e-11	0.59	0.38	Lung adenocarcinoma;Lung cancer;	chr2:65261026	chr22:24686923~24688087:+
LUAD	trans	rs9876781	0.624	rs12491849	ENSG00000235912.1	RP1-159A19.3	-8.96	7.43e-18	2.53e-11	-0.42	-0.38	Longevity;	chr3:48489975	chr1:27649419~27649610:+
LUAD	trans	rs9611519	0.929	rs11090039	ENSG00000268568.1	AC007228.9	-8.95	7.75e-18	2.63e-11	-0.54	-0.38	Neuroticism;	chr22:41100796	chr19:56672574~56673901:-
LUAD	trans	rs4276421	0.837	rs7446182	ENSG00000231752.4	EMBP1	-8.94	8.16e-18	2.77e-11	-0.49	-0.38	P wave duration;	chr5:45401715	chr1:121519112~121571892:+
LUAD	trans	rs877636	0.74	rs705702	ENSG00000212994.5	RPS26P6	-8.94	8.17e-18	2.78e-11	-0.46	-0.38	Cognitive function;	chr12:55996852	chr8:100895771~100896118:+
LUAD	trans	rs7554511	0.858	rs12140420	ENSG00000244144.1	RP11-757F18.3	-8.94	8.5e-18	2.88e-11	-0.52	-0.38	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200993159	chr3:112185480~112185998:-
LUAD	trans	rs877636	1	rs877636	ENSG00000225071.1	GS1-184P14.2	-8.94	8.51e-18	2.89e-11	-0.42	-0.38	Cognitive function;	chr12:56086799	chrX:24429573~24429920:-
LUAD	trans	rs8175379	0.509	rs7293453	ENSG00000231752.4	EMBP1	8.94	8.56e-18	2.9e-11	0.52	0.38	Interleukin-7 levels;	chr5:46253007	chr1:121519112~121571892:+
LUAD	trans	rs8010715	0.816	rs6573572	ENSG00000238000.1	RP11-274E7.2	8.94	8.69e-18	2.95e-11	0.41	0.38	IgG glycosylation;	chr14:24130021	chr5:98213402~98214121:+
LUAD	trans	rs867371	0.82	rs12443224	ENSG00000235370.6	DNM1P51	-8.93	8.93e-18	3.03e-11	-0.45	-0.38	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82203269	chr15:84398316~84411701:-
LUAD	trans	rs9425766	0.85	rs1322770	ENSG00000213331.4	RP11-713C19.2	8.93	9.03e-18	3.06e-11	0.45	0.38	Life satisfaction;	chr1:173863198	chr4:187970273~187971284:+
LUAD	trans	rs8175379	0.509	rs8185010	ENSG00000231752.4	EMBP1	-8.93	9.1e-18	3.08e-11	-0.51	-0.38	Interleukin-7 levels;	chr5:46306373	chr1:121519112~121571892:+
LUAD	trans	rs877636	0.74	rs705702	ENSG00000242970.2	AC068522.4	-8.93	9.15e-18	3.1e-11	-0.47	-0.38	Cognitive function;	chr12:55996852	chr8:58588420~58588764:-
LUAD	trans	rs9425766	0.927	rs9425757	ENSG00000213331.4	RP11-713C19.2	8.93	9.24e-18	3.13e-11	0.45	0.38	Life satisfaction;	chr1:173855675	chr4:187970273~187971284:+
LUAD	trans	rs55665837	0.701	rs11023278	ENSG00000236360.2	RP11-334A14.2	8.93	9.26e-18	3.13e-11	0.52	0.38	Vitamin D levels;	chr11:14619638	chr1:52993201~52993702:-
LUAD	trans	rs7647973	0.56	rs7638154	ENSG00000197582.5	GPX1P1	8.93	9.39e-18	3.18e-11	0.49	0.38	Menarche (age at onset);	chr3:49261942	chrX:13378735~13379340:-
LUAD	trans	rs877636	0.74	rs705702	ENSG00000196933.5	RPS26P11	-8.92	9.71e-18	3.28e-11	-0.46	-0.38	Cognitive function;	chr12:55996852	chrX:72044545~72044892:+
LUAD	trans	rs877636	0.669	rs7297175	ENSG00000196656.7	AC004057.1	-8.92	9.72e-18	3.29e-11	-0.39	-0.38	Cognitive function;	chr12:56080024	chr4:113214046~113217170:-
LUAD	trans	rs7662987	0.793	rs12697	ENSG00000228407.2	RP4-800M22.1	-8.92	9.86e-18	3.33e-11	-0.66	-0.38	Smoking initiation;	chr4:99072225	chr1:52160261~52160600:-
LUAD	trans	rs10242455	1	rs2301889	ENSG00000228834.1	RP11-249L21.4	8.92	1e-17	3.39e-11	0.85	0.38	Blood metabolite levels;	chr7:99333482	chr6:108907615~108907873:-
LUAD	trans	rs7312770	1	rs7312770	ENSG00000234354.3	RPS26P47	-8.92	1.01e-17	3.4e-11	-0.4	-0.38	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr13:100539901~100540248:-
LUAD	trans	rs10242455	0.571	rs41258334	ENSG00000228834.1	RP11-249L21.4	8.91	1.04e-17	3.52e-11	0.99	0.38	Blood metabolite levels;	chr7:99674185	chr6:108907615~108907873:-
LUAD	trans	rs10242455	0.571	rs28365067	ENSG00000228834.1	RP11-249L21.4	8.91	1.04e-17	3.52e-11	0.99	0.38	Blood metabolite levels;	chr7:99674687	chr6:108907615~108907873:-
LUAD	trans	rs12709013	0.935	rs34657766	ENSG00000233719.3	GOT2P3	8.91	1.05e-17	3.53e-11	0.45	0.38	Blood metabolite ratios;	chr16:58779468	chr12:9641802~9643007:+
LUAD	trans	rs12709013	0.729	rs71400031	ENSG00000233719.3	GOT2P3	8.91	1.05e-17	3.53e-11	0.45	0.38	Blood metabolite ratios;	chr16:58779554	chr12:9641802~9643007:+
LUAD	trans	rs877636	0.692	rs11171739	ENSG00000224553.1	AC008065.1	8.91	1.07e-17	3.62e-11	0.38	0.38	Cognitive function;	chr12:56076841	chr2:171374931~171375278:-
LUAD	trans	rs9425766	0.924	rs5877	ENSG00000213331.4	RP11-713C19.2	8.91	1.09e-17	3.66e-11	0.45	0.38	Life satisfaction;	chr1:173909724	chr4:187970273~187971284:+
LUAD	trans	rs7312770	0.612	rs773114	ENSG00000223416.3	RPS26P15	8.91	1.09e-17	3.68e-11	0.37	0.38	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr1:58056133~58056480:-
LUAD	trans	rs12138950	0.681	rs10917468	ENSG00000224237.1	MINOS1P3	-8.9	1.11e-17	3.73e-11	-0.47	-0.38	Hypothyroidism;Thyroid volume;	chr1:19516860	chr3:27214816~27215018:-
LUAD	trans	rs7662987	0.793	rs28730632	ENSG00000228407.2	RP4-800M22.1	8.9	1.12e-17	3.76e-11	0.68	0.38	Smoking initiation;	chr4:99074552	chr1:52160261~52160600:-
LUAD	trans	rs877636	0.74	rs705698	ENSG00000225071.1	GS1-184P14.2	8.9	1.14e-17	3.83e-11	0.43	0.38	Cognitive function;	chr12:55990903	chrX:24429573~24429920:-
LUAD	trans	rs4240897	0.935	rs3766744	ENSG00000261819.1	RP11-680G24.4	8.9	1.14e-17	3.84e-11	0.47	0.38	Tuberculosis;	chr1:11983660	chr16:14988259~14990160:-
LUAD	trans	rs74781061	0.929	rs6495108	ENSG00000227288.3	RP5-837I24.1	8.9	1.17e-17	3.93e-11	0.55	0.38	Endometriosis;	chr15:74502186	chr1:81501794~81503468:+
LUAD	trans	rs9611519	0.894	rs9623320	ENSG00000268568.1	AC007228.9	-8.89	1.19e-17	4.02e-11	-0.53	-0.38	Neuroticism;	chr22:41082478	chr19:56672574~56673901:-
LUAD	trans	rs11098499	0.722	rs7673476	ENSG00000275858.1	RP11-291L22.8	8.89	1.22e-17	4.1e-11	0.44	0.38	Corneal astigmatism;	chr4:119327528	chr10:38450738~38451069:-
LUAD	trans	rs877636	0.74	rs772920	ENSG00000242970.2	AC068522.4	8.89	1.24e-17	4.16e-11	0.47	0.38	Cognitive function;	chr12:55996580	chr8:58588420~58588764:-
LUAD	trans	rs10028773	0.515	rs9994488	ENSG00000275858.1	RP11-291L22.8	8.88	1.29e-17	4.31e-11	0.44	0.38	Educational attainment;	chr4:119666626	chr10:38450738~38451069:-
LUAD	trans	rs8010715	0.816	rs11574503	ENSG00000238000.1	RP11-274E7.2	-8.88	1.35e-17	4.53e-11	-0.41	-0.38	IgG glycosylation;	chr14:24132109	chr5:98213402~98214121:+
LUAD	trans	rs7554511	0.858	rs12118735	ENSG00000244144.1	RP11-757F18.3	-8.88	1.35e-17	4.54e-11	-0.52	-0.38	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200981832	chr3:112185480~112185998:-
LUAD	trans	rs877636	1	rs2292239	ENSG00000227887.1	RPS26P13	8.87	1.39e-17	4.65e-11	0.41	0.38	Cognitive function;	chr12:56088396	chr1:208697369~208697698:-
LUAD	trans	rs9425766	0.962	rs2065171	ENSG00000213331.4	RP11-713C19.2	8.87	1.42e-17	4.74e-11	0.45	0.38	Life satisfaction;	chr1:173876972	chr4:187970273~187971284:+
LUAD	trans	rs9425766	0.962	rs4652229	ENSG00000213331.4	RP11-713C19.2	8.87	1.42e-17	4.74e-11	0.45	0.38	Life satisfaction;	chr1:173877452	chr4:187970273~187971284:+
LUAD	trans	rs9425766	0.927	rs9425765	ENSG00000213331.4	RP11-713C19.2	8.87	1.42e-17	4.74e-11	0.45	0.38	Life satisfaction;	chr1:173878871	chr4:187970273~187971284:+
LUAD	trans	rs877636	0.702	rs773109	ENSG00000225071.1	GS1-184P14.2	8.87	1.44e-17	4.83e-11	0.44	0.37	Cognitive function;	chr12:55980911	chrX:24429573~24429920:-
LUAD	trans	rs877636	0.702	rs61937249	ENSG00000225071.1	GS1-184P14.2	8.87	1.46e-17	4.87e-11	0.44	0.37	Cognitive function;	chr12:55988132	chrX:24429573~24429920:-
LUAD	trans	rs7647973	0.6	rs35174559	ENSG00000197582.5	GPX1P1	8.87	1.47e-17	4.9e-11	0.49	0.37	Menarche (age at onset);	chr3:49250326	chrX:13378735~13379340:-
LUAD	trans	rs877636	0.692	rs11171739	ENSG00000204652.6	RPS26P8	8.86	1.55e-17	5.16e-11	0.43	0.37	Cognitive function;	chr12:56076841	chr17:45608571~45608918:+
LUAD	trans	rs5022636	0.533	rs4971029	ENSG00000180764.13	PIPSL	8.86	1.56e-17	5.21e-11	0.52	0.37	Gut microbiota (functional units);	chr1:151304783	chr10:93958191~93961540:-
LUAD	trans	rs5022636	0.507	rs2031797	ENSG00000180764.13	PIPSL	8.86	1.56e-17	5.21e-11	0.52	0.37	Gut microbiota (functional units);	chr1:151306029	chr10:93958191~93961540:-
LUAD	trans	rs7647973	0.6	rs11920267	ENSG00000197582.5	GPX1P1	8.86	1.56e-17	5.21e-11	0.49	0.37	Menarche (age at onset);	chr3:49238531	chrX:13378735~13379340:-
LUAD	trans	rs72615157	0.634	rs11762932	ENSG00000228546.2	CTA-313A17.3	-8.86	1.58e-17	5.27e-11	-0.58	-0.37	Lung function (FEV1/FVC);	chr7:100195043	chr7:102337316~102339115:+
LUAD	trans	rs673253	1	rs673253	ENSG00000231007.5	CDC20P1	8.86	1.59e-17	5.29e-11	0.47	0.37	Intelligence (multi-trait analysis);	chr1:43596483	chr9:87011652~87013151:+
LUAD	trans	rs2657294	0.734	rs2894244	ENSG00000172974.11	AC007318.5	8.86	1.6e-17	5.34e-11	0.41	0.37	Pneumonia;	chr10:75087112	chr2:65205108~65205988:+
LUAD	trans	rs7647973	0.58	rs35218722	ENSG00000197582.5	GPX1P1	8.85	1.64e-17	5.45e-11	0.49	0.37	Menarche (age at onset);	chr3:49238372	chrX:13378735~13379340:-
LUAD	trans	rs7662987	1	rs6852848	ENSG00000233859.2	ADH5P4	-8.85	1.74e-17	5.78e-11	-0.6	-0.37	Smoking initiation;	chr4:99080781	chr6:65836930~65838039:-
LUAD	trans	rs877636	0.702	rs773110	ENSG00000225071.1	GS1-184P14.2	8.84	1.75e-17	5.82e-11	0.44	0.37	Cognitive function;	chr12:55981353	chrX:24429573~24429920:-
LUAD	trans	rs877636	0.702	rs773111	ENSG00000225071.1	GS1-184P14.2	8.84	1.75e-17	5.82e-11	0.44	0.37	Cognitive function;	chr12:55981956	chrX:24429573~24429920:-
LUAD	trans	rs877636	0.702	rs773112	ENSG00000225071.1	GS1-184P14.2	8.84	1.75e-17	5.82e-11	0.44	0.37	Cognitive function;	chr12:55982097	chrX:24429573~24429920:-
LUAD	trans	rs9425766	0.886	rs9661233	ENSG00000213331.4	RP11-713C19.2	8.84	1.77e-17	5.87e-11	0.45	0.37	Life satisfaction;	chr1:173874913	chr4:187970273~187971284:+
LUAD	trans	rs7554511	0.861	rs11583546	ENSG00000244144.1	RP11-757F18.3	-8.84	1.77e-17	5.89e-11	-0.52	-0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200933479	chr3:112185480~112185998:-
LUAD	trans	rs9425766	0.962	rs1322780	ENSG00000213331.4	RP11-713C19.2	8.84	1.83e-17	6.07e-11	0.45	0.37	Life satisfaction;	chr1:173896448	chr4:187970273~187971284:+
LUAD	trans	rs9425766	0.962	rs9425435	ENSG00000213331.4	RP11-713C19.2	8.84	1.83e-17	6.07e-11	0.45	0.37	Life satisfaction;	chr1:173896936	chr4:187970273~187971284:+
LUAD	trans	rs9858542	0.903	rs11921590	ENSG00000197582.5	GPX1P1	-8.84	1.87e-17	6.21e-11	-0.51	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49606760	chrX:13378735~13379340:-
LUAD	trans	rs10028773	0.515	rs9994651	ENSG00000275858.1	RP11-291L22.8	8.84	1.88e-17	6.24e-11	0.44	0.37	Educational attainment;	chr4:119666648	chr10:38450738~38451069:-
LUAD	trans	rs2657294	0.646	rs10762656	ENSG00000172974.11	AC007318.5	8.83	1.9e-17	6.31e-11	0.4	0.37	Pneumonia;	chr10:75085706	chr2:65205108~65205988:+
LUAD	trans	rs877636	0.74	rs772920	ENSG00000225071.1	GS1-184P14.2	8.83	1.91e-17	6.33e-11	0.44	0.37	Cognitive function;	chr12:55996580	chrX:24429573~24429920:-
LUAD	trans	rs8175379	0.509	rs4128582	ENSG00000231752.4	EMBP1	8.83	1.91e-17	6.35e-11	0.53	0.37	Interleukin-7 levels;	chr5:46252001	chr1:121519112~121571892:+
LUAD	trans	rs8175379	0.509	rs8185235	ENSG00000231752.4	EMBP1	8.83	1.91e-17	6.35e-11	0.53	0.37	Interleukin-7 levels;	chr5:46252306	chr1:121519112~121571892:+
LUAD	trans	rs9425766	0.962	rs941989	ENSG00000213331.4	RP11-713C19.2	-8.83	1.92e-17	6.37e-11	-0.45	-0.37	Life satisfaction;	chr1:173912733	chr4:187970273~187971284:+
LUAD	trans	rs72615157	0.634	rs74774557	ENSG00000228546.2	CTA-313A17.3	8.83	1.92e-17	6.38e-11	0.57	0.37	Lung function (FEV1/FVC);	chr7:100212802	chr7:102337316~102339115:+
LUAD	trans	rs8175379	0.505	rs10073477	ENSG00000231752.4	EMBP1	-8.83	1.98e-17	6.57e-11	-0.52	-0.37	Interleukin-7 levels;	chr5:46338025	chr1:121519112~121571892:+
LUAD	trans	rs877636	0.692	rs2271194	ENSG00000204652.6	RPS26P8	-8.83	1.99e-17	6.59e-11	-0.44	-0.37	Cognitive function;	chr12:56083910	chr17:45608571~45608918:+
LUAD	trans	rs72615157	0.634	rs74742883	ENSG00000228546.2	CTA-313A17.3	8.82	2.06e-17	6.84e-11	0.56	0.37	Lung function (FEV1/FVC);	chr7:100188142	chr7:102337316~102339115:+
LUAD	trans	rs8175379	0.505	rs12189292	ENSG00000231752.4	EMBP1	-8.82	2.09e-17	6.93e-11	-0.52	-0.37	Interleukin-7 levels;	chr5:46340498	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.597	rs8188245	ENSG00000231752.4	EMBP1	-8.82	2.13e-17	7.07e-11	-0.49	-0.37	P wave duration;	chr5:46174762	chr1:121519112~121571892:+
LUAD	trans	rs877636	1	rs705696	ENSG00000212994.5	RPS26P6	8.82	2.14e-17	7.1e-11	0.44	0.37	Cognitive function;	chr12:56086864	chr8:100895771~100896118:+
LUAD	trans	rs9425766	0.924	rs9286895	ENSG00000213331.4	RP11-713C19.2	8.82	2.15e-17	7.12e-11	0.45	0.37	Life satisfaction;	chr1:173873329	chr4:187970273~187971284:+
LUAD	trans	rs877636	0.859	rs3741499	ENSG00000196933.5	RPS26P11	-8.82	2.16e-17	7.14e-11	-0.43	-0.37	Cognitive function;	chr12:56080595	chrX:72044545~72044892:+
LUAD	trans	rs72615157	0.634	rs2272343	ENSG00000228546.2	CTA-313A17.3	8.82	2.2e-17	7.28e-11	0.56	0.37	Lung function (FEV1/FVC);	chr7:100180662	chr7:102337316~102339115:+
LUAD	trans	rs9858542	0.953	rs3811697	ENSG00000197582.5	GPX1P1	-8.81	2.22e-17	7.33e-11	-0.5	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49553337	chrX:13378735~13379340:-
LUAD	trans	rs9858542	0.953	rs9837027	ENSG00000197582.5	GPX1P1	-8.81	2.22e-17	7.33e-11	-0.5	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49559580	chrX:13378735~13379340:-
LUAD	trans	rs9858542	0.953	rs9858280	ENSG00000197582.5	GPX1P1	-8.81	2.22e-17	7.33e-11	-0.5	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49560304	chrX:13378735~13379340:-
LUAD	trans	rs13190036	0.792	rs6874206	ENSG00000228305.2	AC016734.2	-8.81	2.3e-17	7.61e-11	-0.5	-0.37	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177223970	chr2:63622178~63622831:-
LUAD	trans	rs13190036	0.901	rs10072499	ENSG00000228305.2	AC016734.2	-8.81	2.3e-17	7.61e-11	-0.5	-0.37	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228236	chr2:63622178~63622831:-
LUAD	trans	rs7647973	0.58	rs4955432	ENSG00000197582.5	GPX1P1	8.81	2.31e-17	7.65e-11	0.48	0.37	Menarche (age at onset);	chr3:49229339	chrX:13378735~13379340:-
LUAD	trans	rs4276421	0.507	rs7293474	ENSG00000231752.4	EMBP1	-8.8	2.39e-17	7.88e-11	-0.52	-0.37	P wave duration;	chr5:46286705	chr1:121519112~121571892:+
LUAD	trans	rs877636	1	rs877636	ENSG00000196656.7	AC004057.1	-8.8	2.55e-17	8.41e-11	-0.4	-0.37	Cognitive function;	chr12:56086799	chr4:113214046~113217170:-
LUAD	trans	rs12709013	0.967	rs62064905	ENSG00000233719.3	GOT2P3	8.79	2.68e-17	8.84e-11	0.45	0.37	Blood metabolite ratios;	chr16:58778839	chr12:9641802~9643007:+
LUAD	trans	rs1039766	1	rs12104748	ENSG00000224334.1	AP000357.4	-8.79	2.71e-17	8.94e-11	-0.6	-0.37	Lung adenocarcinoma;Lung cancer;	chr2:65290112	chr22:24686923~24688087:+
LUAD	trans	rs7312770	1	rs7312770	ENSG00000227887.1	RPS26P13	-8.78	2.78e-17	9.16e-11	-0.4	-0.37	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr1:208697369~208697698:-
LUAD	trans	rs9858542	0.953	rs11713474	ENSG00000197582.5	GPX1P1	-8.78	2.8e-17	9.2e-11	-0.5	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49574024	chrX:13378735~13379340:-
LUAD	trans	rs9858542	0.953	rs9811982	ENSG00000197582.5	GPX1P1	-8.78	2.8e-17	9.2e-11	-0.5	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49586944	chrX:13378735~13379340:-
LUAD	trans	rs7554511	0.858	rs11584383	ENSG00000244144.1	RP11-757F18.3	8.78	2.83e-17	9.32e-11	0.5	0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200966738	chr3:112185480~112185998:-
LUAD	trans	rs8010715	0.771	rs2277481	ENSG00000238000.1	RP11-274E7.2	8.78	2.91e-17	9.56e-11	0.4	0.37	IgG glycosylation;	chr14:24118336	chr5:98213402~98214121:+
LUAD	trans	rs877636	0.692	rs10876870	ENSG00000224553.1	AC008065.1	-8.78	2.93e-17	9.65e-11	-0.38	-0.37	Cognitive function;	chr12:56084218	chr2:171374931~171375278:-
LUAD	trans	rs877636	0.692	rs7971751	ENSG00000224553.1	AC008065.1	-8.78	2.93e-17	9.65e-11	-0.38	-0.37	Cognitive function;	chr12:56084874	chr2:171374931~171375278:-
LUAD	trans	rs7647973	0.58	rs12637576	ENSG00000197582.5	GPX1P1	8.78	2.96e-17	9.74e-11	0.48	0.37	Menarche (age at onset);	chr3:49199901	chrX:13378735~13379340:-
LUAD	trans	rs9425766	0.85	rs9425755	ENSG00000213331.4	RP11-713C19.2	8.78	2.98e-17	9.8e-11	0.44	0.37	Life satisfaction;	chr1:173843501	chr4:187970273~187971284:+
LUAD	trans	rs877636	0.702	rs773110	ENSG00000242970.2	AC068522.4	8.77	3e-17	9.87e-11	0.46	0.37	Cognitive function;	chr12:55981353	chr8:58588420~58588764:-
LUAD	trans	rs877636	0.702	rs773111	ENSG00000242970.2	AC068522.4	8.77	3e-17	9.87e-11	0.46	0.37	Cognitive function;	chr12:55981956	chr8:58588420~58588764:-
LUAD	trans	rs877636	0.702	rs773112	ENSG00000242970.2	AC068522.4	8.77	3e-17	9.87e-11	0.46	0.37	Cognitive function;	chr12:55982097	chr8:58588420~58588764:-
LUAD	trans	rs9858542	0.953	rs4625	ENSG00000197582.5	GPX1P1	-8.77	3.11e-17	1.02e-10	-0.5	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49534707	chrX:13378735~13379340:-
LUAD	trans	rs72615157	0.697	rs2056726	ENSG00000228546.2	CTA-313A17.3	8.77	3.11e-17	1.02e-10	0.56	0.37	Lung function (FEV1/FVC);	chr7:100182660	chr7:102337316~102339115:+
LUAD	trans	rs7554511	0.858	rs3208703	ENSG00000244144.1	RP11-757F18.3	-8.77	3.13e-17	1.03e-10	-0.51	-0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200970514	chr3:112185480~112185998:-
LUAD	trans	rs877636	0.702	rs773109	ENSG00000196933.5	RPS26P11	8.77	3.18e-17	1.04e-10	0.45	0.37	Cognitive function;	chr12:55980911	chrX:72044545~72044892:+
LUAD	trans	rs4240897	0.935	rs2236055	ENSG00000261819.1	RP11-680G24.4	8.77	3.2e-17	1.05e-10	0.46	0.37	Tuberculosis;	chr1:11982204	chr16:14988259~14990160:-
LUAD	trans	rs13190036	0.901	rs10056655	ENSG00000228305.2	AC016734.2	8.77	3.22e-17	1.05e-10	0.51	0.37	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177249350	chr2:63622178~63622831:-
LUAD	trans	rs12709013	0.967	rs2118019	ENSG00000233719.3	GOT2P3	-8.76	3.26e-17	1.07e-10	-0.45	-0.37	Blood metabolite ratios;	chr16:58797825	chr12:9641802~9643007:+
LUAD	trans	rs9858542	0.953	rs10640	ENSG00000197582.5	GPX1P1	-8.76	3.27e-17	1.07e-10	-0.5	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49416844	chrX:13378735~13379340:-
LUAD	trans	rs10940346	0.517	rs12659073	ENSG00000231752.4	EMBP1	-8.76	3.36e-17	1.1e-10	-0.51	-0.37	Schizophrenia;	chr5:50558564	chr1:121519112~121571892:+
LUAD	trans	rs8010715	0.816	rs1134340	ENSG00000238000.1	RP11-274E7.2	8.76	3.36e-17	1.1e-10	0.41	0.37	IgG glycosylation;	chr14:24125004	chr5:98213402~98214121:+
LUAD	trans	rs7312770	0.637	rs705700	ENSG00000223416.3	RPS26P15	8.76	3.36e-17	1.1e-10	0.37	0.37	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr1:58056133~58056480:-
LUAD	trans	rs9858542	0.953	rs9827708	ENSG00000197582.5	GPX1P1	-8.75	3.48e-17	1.14e-10	-0.51	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49612556	chrX:13378735~13379340:-
LUAD	trans	rs877636	0.702	rs773108	ENSG00000212994.5	RPS26P6	8.75	3.5e-17	1.15e-10	0.46	0.37	Cognitive function;	chr12:55976127	chr8:100895771~100896118:+
LUAD	trans	rs877636	0.702	rs61937249	ENSG00000242970.2	AC068522.4	8.75	3.54e-17	1.16e-10	0.46	0.37	Cognitive function;	chr12:55988132	chr8:58588420~58588764:-
LUAD	trans	rs877636	0.702	rs773109	ENSG00000242970.2	AC068522.4	8.75	3.61e-17	1.18e-10	0.46	0.37	Cognitive function;	chr12:55980911	chr8:58588420~58588764:-
LUAD	trans	rs7647973	0.6	rs12631989	ENSG00000197582.5	GPX1P1	8.74	3.77e-17	1.23e-10	0.48	0.37	Menarche (age at onset);	chr3:49236563	chrX:13378735~13379340:-
LUAD	trans	rs7647973	0.6	rs13064780	ENSG00000197582.5	GPX1P1	8.74	3.77e-17	1.23e-10	0.48	0.37	Menarche (age at onset);	chr3:49237393	chrX:13378735~13379340:-
LUAD	trans	rs877636	0.702	rs61937249	ENSG00000196933.5	RPS26P11	8.74	3.78e-17	1.24e-10	0.45	0.37	Cognitive function;	chr12:55988132	chrX:72044545~72044892:+
LUAD	trans	rs7617480	0.519	rs6790914	ENSG00000197582.5	GPX1P1	8.74	3.81e-17	1.24e-10	0.5	0.37	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49168885	chrX:13378735~13379340:-
LUAD	trans	rs877636	0.692	rs10876870	ENSG00000244604.1	RP11-713H12.1	-8.74	3.89e-17	1.27e-10	-0.41	-0.37	Cognitive function;	chr12:56084218	chr17:8561230~8561576:+
LUAD	trans	rs877636	0.692	rs7971751	ENSG00000244604.1	RP11-713H12.1	-8.74	3.89e-17	1.27e-10	-0.41	-0.37	Cognitive function;	chr12:56084874	chr17:8561230~8561576:+
LUAD	trans	rs12497850	0.764	rs6784111	ENSG00000197582.5	GPX1P1	8.74	3.9e-17	1.27e-10	0.49	0.37	Parkinson's disease;	chr3:49141413	chrX:13378735~13379340:-
LUAD	trans	rs12497850	0.864	rs12493001	ENSG00000197582.5	GPX1P1	8.74	3.9e-17	1.27e-10	0.49	0.37	Parkinson's disease;	chr3:49144452	chrX:13378735~13379340:-
LUAD	trans	rs12497850	0.829	rs12636030	ENSG00000197582.5	GPX1P1	8.74	3.9e-17	1.27e-10	0.49	0.37	Parkinson's disease;	chr3:49144804	chrX:13378735~13379340:-
LUAD	trans	rs4240897	0.835	rs4845891	ENSG00000261819.1	RP11-680G24.4	8.74	3.92e-17	1.28e-10	0.46	0.37	Tuberculosis;	chr1:11982449	chr16:14988259~14990160:-
LUAD	trans	rs877636	0.692	rs10876870	ENSG00000204652.6	RPS26P8	-8.74	4.05e-17	1.32e-10	-0.43	-0.37	Cognitive function;	chr12:56084218	chr17:45608571~45608918:+
LUAD	trans	rs877636	0.692	rs7971751	ENSG00000204652.6	RPS26P8	-8.74	4.05e-17	1.32e-10	-0.43	-0.37	Cognitive function;	chr12:56084874	chr17:45608571~45608918:+
LUAD	trans	rs1039766	0.925	rs268863	ENSG00000224334.1	AP000357.4	8.73	4.09e-17	1.33e-10	0.57	0.37	Lung adenocarcinoma;Lung cancer;	chr2:65261669	chr22:24686923~24688087:+
LUAD	trans	rs7312770	0.637	rs705699	ENSG00000224553.1	AC008065.1	8.73	4.1e-17	1.34e-10	0.38	0.37	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr2:171374931~171375278:-
LUAD	trans	rs959695	0.834	rs6468693	ENSG00000260318.1	COX6CP1	-8.73	4.11e-17	1.34e-10	-0.46	-0.37	Hippocampal atrophy;	chr8:99839040	chr16:11903923~11904137:-
LUAD	trans	rs9858542	0.953	rs3811699	ENSG00000197582.5	GPX1P1	-8.73	4.12e-17	1.34e-10	-0.5	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49358927	chrX:13378735~13379340:-
LUAD	trans	rs148734725	1	rs148734725	ENSG00000197582.5	GPX1P1	-8.73	4.12e-17	1.34e-10	-0.5	-0.37	Educational attainment (college completion);	chr3:49369275	chrX:13378735~13379340:-
LUAD	trans	rs9858542	0.953	rs34588335	ENSG00000197582.5	GPX1P1	-8.73	4.12e-17	1.34e-10	-0.5	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49370227	chrX:13378735~13379340:-
LUAD	trans	rs9858542	0.953	rs6809216	ENSG00000197582.5	GPX1P1	-8.73	4.12e-17	1.34e-10	-0.5	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49375126	chrX:13378735~13379340:-
LUAD	trans	rs9858542	0.953	rs7623659	ENSG00000197582.5	GPX1P1	-8.73	4.12e-17	1.34e-10	-0.5	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49377358	chrX:13378735~13379340:-
LUAD	trans	rs9858542	0.953	rs35169793	ENSG00000197582.5	GPX1P1	-8.73	4.12e-17	1.34e-10	-0.5	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49385841	chrX:13378735~13379340:-
LUAD	trans	rs9858542	0.953	rs9878943	ENSG00000197582.5	GPX1P1	-8.73	4.12e-17	1.34e-10	-0.5	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49397221	chrX:13378735~13379340:-
LUAD	trans	rs9858542	0.953	rs6779524	ENSG00000197582.5	GPX1P1	-8.73	4.12e-17	1.34e-10	-0.5	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49413016	chrX:13378735~13379340:-
LUAD	trans	rs7554511	0.928	rs905634	ENSG00000244144.1	RP11-757F18.3	-8.73	4.16e-17	1.35e-10	-0.49	-0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200915857	chr3:112185480~112185998:-
LUAD	trans	rs6424115	0.867	rs34902309	ENSG00000228217.1	AL390877.1	8.73	4.18e-17	1.36e-10	0.48	0.37	Immature fraction of reticulocytes;	chr1:23865710	chr1:117778087~117778506:-
LUAD	trans	rs1039766	1	rs268870	ENSG00000224334.1	AP000357.4	8.73	4.27e-17	1.39e-10	0.56	0.37	Lung adenocarcinoma;Lung cancer;	chr2:65256415	chr22:24686923~24688087:+
LUAD	trans	rs877636	1	rs705696	ENSG00000234513.1	AC073072.7	8.73	4.33e-17	1.41e-10	0.44	0.37	Cognitive function;	chr12:56086864	chr7:22773646~22773993:-
LUAD	trans	rs877636	1	rs4759229	ENSG00000196933.5	RPS26P11	-8.73	4.33e-17	1.41e-10	-0.43	-0.37	Cognitive function;	chr12:56080696	chrX:72044545~72044892:+
LUAD	trans	rs7554511	0.858	rs7539693	ENSG00000244144.1	RP11-757F18.3	-8.72	4.44e-17	1.45e-10	-0.51	-0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200986438	chr3:112185480~112185998:-
LUAD	trans	rs9858542	0.953	rs71324979	ENSG00000197582.5	GPX1P1	-8.71	4.77e-17	1.55e-10	-0.5	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49582218	chrX:13378735~13379340:-
LUAD	trans	rs9858542	0.903	rs9875617	ENSG00000197582.5	GPX1P1	-8.71	4.77e-17	1.55e-10	-0.5	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49597263	chrX:13378735~13379340:-
LUAD	trans	rs1039766	1	rs1039766	ENSG00000224334.1	AP000357.4	-8.71	4.83e-17	1.57e-10	-0.58	-0.37	Lung adenocarcinoma;Lung cancer;	chr2:65293011	chr22:24686923~24688087:+
LUAD	trans	rs9876781	0.563	rs4858821	ENSG00000235912.1	RP1-159A19.3	8.71	4.91e-17	1.6e-10	0.42	0.37	Longevity;	chr3:48512515	chr1:27649419~27649610:+
LUAD	trans	rs7312770	0.637	rs705700	ENSG00000224553.1	AC008065.1	8.71	4.94e-17	1.6e-10	0.38	0.37	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr2:171374931~171375278:-
LUAD	trans	rs877636	0.702	rs773110	ENSG00000196933.5	RPS26P11	8.71	4.99e-17	1.62e-10	0.45	0.37	Cognitive function;	chr12:55981353	chrX:72044545~72044892:+
LUAD	trans	rs877636	0.702	rs773111	ENSG00000196933.5	RPS26P11	8.71	4.99e-17	1.62e-10	0.45	0.37	Cognitive function;	chr12:55981956	chrX:72044545~72044892:+
LUAD	trans	rs877636	0.702	rs773112	ENSG00000196933.5	RPS26P11	8.71	4.99e-17	1.62e-10	0.45	0.37	Cognitive function;	chr12:55982097	chrX:72044545~72044892:+
LUAD	trans	rs877636	0.74	rs705702	ENSG00000225071.1	GS1-184P14.2	-8.7	5.11e-17	1.66e-10	-0.43	-0.37	Cognitive function;	chr12:55996852	chrX:24429573~24429920:-
LUAD	trans	rs4240897	0.935	rs1474868	ENSG00000261819.1	RP11-680G24.4	-8.7	5.15e-17	1.67e-10	-0.46	-0.37	Tuberculosis;	chr1:11984107	chr16:14988259~14990160:-
LUAD	trans	rs8175379	0.509	rs8188019	ENSG00000231752.4	EMBP1	8.69	5.51e-17	1.78e-10	0.52	0.37	Interleukin-7 levels;	chr5:46130910	chr1:121519112~121571892:+
LUAD	trans	rs9858542	0.953	rs7633271	ENSG00000197582.5	GPX1P1	-8.69	5.69e-17	1.84e-10	-0.49	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49518530	chrX:13378735~13379340:-
LUAD	trans	rs55665837	0.701	rs12787709	ENSG00000236360.2	RP11-334A14.2	8.69	5.77e-17	1.87e-10	0.52	0.37	Vitamin D levels;	chr11:14617711	chr1:52993201~52993702:-
LUAD	trans	rs10940346	0.506	rs12657678	ENSG00000231752.4	EMBP1	8.69	5.8e-17	1.87e-10	0.49	0.37	Schizophrenia;	chr5:50564284	chr1:121519112~121571892:+
LUAD	trans	rs9858542	0.903	rs35999162	ENSG00000197582.5	GPX1P1	-8.69	5.89e-17	1.9e-10	-0.49	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49559797	chrX:13378735~13379340:-
LUAD	trans	rs877636	1	rs877636	ENSG00000227887.1	RPS26P13	-8.68	5.96e-17	1.93e-10	-0.42	-0.37	Cognitive function;	chr12:56086799	chr1:208697369~208697698:-
LUAD	trans	rs10242455	0.571	rs55830753	ENSG00000228834.1	RP11-249L21.4	8.68	6.08e-17	1.97e-10	0.91	0.37	Blood metabolite levels;	chr7:99694599	chr6:108907615~108907873:-
LUAD	trans	rs8175379	0.509	rs10074483	ENSG00000231752.4	EMBP1	8.68	6.15e-17	1.99e-10	0.52	0.37	Interleukin-7 levels;	chr5:46238631	chr1:121519112~121571892:+
LUAD	trans	rs7647973	0.58	rs2117938	ENSG00000197582.5	GPX1P1	-8.68	6.18e-17	2e-10	-0.47	-0.37	Menarche (age at onset);	chr3:49226417	chrX:13378735~13379340:-
LUAD	trans	rs7312770	1	rs7312770	ENSG00000196933.5	RPS26P11	-8.68	6.21e-17	2.01e-10	-0.41	-0.37	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chrX:72044545~72044892:+
LUAD	trans	rs7312770	0.612	rs1873914	ENSG00000196656.7	AC004057.1	8.68	6.22e-17	2.01e-10	0.39	0.37	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr4:113214046~113217170:-
LUAD	trans	rs616147	0.72	rs2965067	ENSG00000214263.2	RPSAP53	-8.68	6.31e-17	2.04e-10	-0.49	-0.37	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461546	chr13:67266845~67267706:-
LUAD	trans	rs12497850	0.864	rs4955410	ENSG00000197582.5	GPX1P1	8.67	6.43e-17	2.08e-10	0.48	0.37	Parkinson's disease;	chr3:49143785	chrX:13378735~13379340:-
LUAD	trans	rs7113874	0.578	rs1026021	ENSG00000266891.1	RP11-692N5.2	-8.67	6.52e-17	2.1e-10	-0.55	-0.37	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8543231	chr18:9734882~9735602:-
LUAD	trans	rs13190036	0.786	rs10068127	ENSG00000228305.2	AC016734.2	-8.67	6.56e-17	2.12e-10	-0.53	-0.37	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177204786	chr2:63622178~63622831:-
LUAD	trans	rs1039766	1	rs72822431	ENSG00000224334.1	AP000357.4	-8.67	6.68e-17	2.15e-10	-0.59	-0.37	Lung adenocarcinoma;Lung cancer;	chr2:65294682	chr22:24686923~24688087:+
LUAD	trans	rs9858542	0.953	rs11926781	ENSG00000197582.5	GPX1P1	-8.67	6.7e-17	2.16e-10	-0.49	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49565856	chrX:13378735~13379340:-
LUAD	trans	rs9425766	1	rs9425766	ENSG00000213331.4	RP11-713C19.2	8.67	6.76e-17	2.18e-10	0.43	0.37	Life satisfaction;	chr1:173883989	chr4:187970273~187971284:+
LUAD	trans	rs9858542	0.903	rs11917431	ENSG00000197582.5	GPX1P1	-8.67	6.85e-17	2.21e-10	-0.5	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49606579	chrX:13378735~13379340:-
LUAD	trans	rs7121616	1	rs75228513	ENSG00000234176.1	HSPA8P1	8.67	6.89e-17	2.22e-10	0.45	0.37	Breast cancer;	chr11:123096160	chrX:121203182~121205014:-
LUAD	trans	rs7121616	1	rs79401687	ENSG00000234176.1	HSPA8P1	8.67	6.89e-17	2.22e-10	0.45	0.37	Breast cancer;	chr11:123096264	chrX:121203182~121205014:-
LUAD	trans	rs9858542	0.953	rs7648841	ENSG00000197582.5	GPX1P1	-8.66	7.42e-17	2.39e-10	-0.49	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49379392	chrX:13378735~13379340:-
LUAD	trans	rs9858542	0.953	rs6446264	ENSG00000197582.5	GPX1P1	-8.66	7.42e-17	2.39e-10	-0.49	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49379810	chrX:13378735~13379340:-
LUAD	trans	rs8010715	0.816	rs6573573	ENSG00000238000.1	RP11-274E7.2	8.65	7.53e-17	2.42e-10	0.4	0.37	IgG glycosylation;	chr14:24130048	chr5:98213402~98214121:+
LUAD	trans	rs9858542	0.953	rs6446272	ENSG00000197582.5	GPX1P1	-8.65	7.79e-17	2.5e-10	-0.5	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49425854	chrX:13378735~13379340:-
LUAD	trans	rs9858542	0.953	rs9859556	ENSG00000197582.5	GPX1P1	-8.64	8.1e-17	2.6e-10	-0.5	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49418553	chrX:13378735~13379340:-
LUAD	trans	rs8175379	0.501	rs10064455	ENSG00000231752.4	EMBP1	-8.64	8.11e-17	2.6e-10	-0.52	-0.37	Interleukin-7 levels;	chr5:46293430	chr1:121519112~121571892:+
LUAD	trans	rs5022636	0.533	rs1752387	ENSG00000180764.13	PIPSL	-8.64	8.12e-17	2.61e-10	-0.5	-0.37	Gut microbiota (functional units);	chr1:151341903	chr10:93958191~93961540:-
LUAD	trans	rs616147	0.655	rs1707981	ENSG00000214263.2	RPSAP53	-8.64	8.16e-17	2.62e-10	-0.49	-0.37	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461015	chr13:67266845~67267706:-
LUAD	trans	rs616147	0.72	rs1768209	ENSG00000214263.2	RPSAP53	-8.64	8.16e-17	2.62e-10	-0.49	-0.37	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461184	chr13:67266845~67267706:-
LUAD	trans	rs7312770	0.612	rs1873914	ENSG00000223416.3	RPS26P15	8.64	8.22e-17	2.64e-10	0.37	0.37	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr1:58056133~58056480:-
LUAD	trans	rs9858542	0.953	rs11922013	ENSG00000197582.5	GPX1P1	-8.64	8.53e-17	2.73e-10	-0.49	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49420922	chrX:13378735~13379340:-
LUAD	trans	rs9858542	0.953	rs9827021	ENSG00000197582.5	GPX1P1	-8.64	8.54e-17	2.73e-10	-0.49	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49477331	chrX:13378735~13379340:-
LUAD	trans	rs9858542	0.953	rs9818590	ENSG00000197582.5	GPX1P1	-8.64	8.54e-17	2.73e-10	-0.49	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49487663	chrX:13378735~13379340:-
LUAD	trans	rs9858542	0.953	rs35261698	ENSG00000197582.5	GPX1P1	-8.64	8.54e-17	2.73e-10	-0.49	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49500406	chrX:13378735~13379340:-
LUAD	trans	rs9858542	0.953	rs6766131	ENSG00000197582.5	GPX1P1	-8.64	8.54e-17	2.73e-10	-0.49	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49501499	chrX:13378735~13379340:-
LUAD	trans	rs9858542	0.953	rs9821311	ENSG00000197582.5	GPX1P1	-8.64	8.54e-17	2.73e-10	-0.49	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49506223	chrX:13378735~13379340:-
LUAD	trans	rs5022636	0.507	rs2800953	ENSG00000180764.13	PIPSL	-8.64	8.61e-17	2.76e-10	-0.5	-0.37	Gut microbiota (functional units);	chr1:151366094	chr10:93958191~93961540:-
LUAD	trans	rs12497850	0.765	rs12487580	ENSG00000197582.5	GPX1P1	8.63	8.75e-17	2.8e-10	0.48	0.37	Parkinson's disease;	chr3:49145499	chrX:13378735~13379340:-
LUAD	trans	rs12497850	0.797	rs61583136	ENSG00000197582.5	GPX1P1	8.63	8.75e-17	2.8e-10	0.48	0.37	Parkinson's disease;	chr3:49151762	chrX:13378735~13379340:-
LUAD	trans	rs8175379	1	rs8175379	ENSG00000231752.4	EMBP1	-8.63	8.81e-17	2.82e-10	-0.52	-0.37	Interleukin-7 levels;	chr5:46263441	chr1:121519112~121571892:+
LUAD	trans	rs9858542	0.953	rs11711485	ENSG00000197582.5	GPX1P1	-8.63	8.84e-17	2.83e-10	-0.49	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49454550	chrX:13378735~13379340:-
LUAD	trans	rs1039766	0.925	rs268850	ENSG00000224334.1	AP000357.4	8.63	9.01e-17	2.88e-10	0.6	0.37	Lung adenocarcinoma;Lung cancer;	chr2:65281152	chr22:24686923~24688087:+
LUAD	trans	rs7554511	0.893	rs10494828	ENSG00000244144.1	RP11-757F18.3	-8.63	9.03e-17	2.89e-10	-0.51	-0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200987904	chr3:112185480~112185998:-
LUAD	trans	rs7554511	0.893	rs6427868	ENSG00000244144.1	RP11-757F18.3	-8.63	9.13e-17	2.92e-10	-0.5	-0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200960354	chr3:112185480~112185998:-
LUAD	trans	rs11098499	0.754	rs1849457	ENSG00000275858.1	RP11-291L22.8	8.62	9.39e-17	3e-10	0.45	0.37	Corneal astigmatism;	chr4:119333200	chr10:38450738~38451069:-
LUAD	trans	rs12497850	0.864	rs4513485	ENSG00000197582.5	GPX1P1	8.62	9.57e-17	3.06e-10	0.48	0.37	Parkinson's disease;	chr3:49102533	chrX:13378735~13379340:-
LUAD	trans	rs9858542	0.953	rs1801143	ENSG00000197582.5	GPX1P1	-8.62	9.98e-17	3.18e-10	-0.5	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49532767	chrX:13378735~13379340:-
LUAD	trans	rs9858542	0.951	rs1800668	ENSG00000197582.5	GPX1P1	-8.61	1.05e-16	3.35e-10	-0.49	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49358324	chrX:13378735~13379340:-
LUAD	trans	rs9858542	0.953	rs1987628	ENSG00000197582.5	GPX1P1	-8.61	1.05e-16	3.35e-10	-0.49	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49361826	chrX:13378735~13379340:-
LUAD	trans	rs9858542	0.953	rs11706370	ENSG00000197582.5	GPX1P1	-8.61	1.05e-16	3.35e-10	-0.49	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49403658	chrX:13378735~13379340:-
LUAD	trans	rs8175379	0.509	rs8185053	ENSG00000231752.4	EMBP1	-8.61	1.08e-16	3.44e-10	-0.52	-0.37	Interleukin-7 levels;	chr5:46261842	chr1:121519112~121571892:+
LUAD	trans	rs7113874	0.578	rs12787407	ENSG00000266891.1	RP11-692N5.2	8.61	1.08e-16	3.45e-10	0.56	0.37	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8532605	chr18:9734882~9735602:-
LUAD	trans	rs877636	0.74	rs705698	ENSG00000196933.5	RPS26P11	8.61	1.09e-16	3.46e-10	0.44	0.37	Cognitive function;	chr12:55990903	chrX:72044545~72044892:+
LUAD	trans	rs6708331	0.646	rs12989348	ENSG00000232654.1	FAM136BP	-8.6	1.09e-16	3.47e-10	-0.66	-0.37	Obesity-related traits;	chr2:70150521	chr6:3045384~3045800:+
LUAD	trans	rs9858542	0.953	rs9824092	ENSG00000197582.5	GPX1P1	-8.6	1.09e-16	3.49e-10	-0.5	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49636714	chrX:13378735~13379340:-
LUAD	trans	rs9858542	0.953	rs9862080	ENSG00000197582.5	GPX1P1	-8.6	1.09e-16	3.49e-10	-0.5	-0.37	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49637025	chrX:13378735~13379340:-
LUAD	trans	rs1039766	0.929	rs55843720	ENSG00000224334.1	AP000357.4	8.6	1.14e-16	3.62e-10	0.58	0.37	Lung adenocarcinoma;Lung cancer;	chr2:65268436	chr22:24686923~24688087:+
LUAD	trans	rs10242455	1	rs6948775	ENSG00000228834.1	RP11-249L21.4	8.6	1.14e-16	3.63e-10	0.81	0.37	Blood metabolite levels;	chr7:99347857	chr6:108907615~108907873:-
LUAD	trans	rs6424115	0.594	rs10799802	ENSG00000228217.1	AL390877.1	-8.6	1.15e-16	3.65e-10	-0.47	-0.36	Immature fraction of reticulocytes;	chr1:23683054	chr1:117778087~117778506:-
LUAD	trans	rs7647973	0.58	rs7652746	ENSG00000197582.5	GPX1P1	-8.59	1.18e-16	3.74e-10	-0.47	-0.36	Menarche (age at onset);	chr3:49224874	chrX:13378735~13379340:-
LUAD	trans	rs9467773	0.804	rs2073526	ENSG00000242375.1	RP11-498P14.3	-8.59	1.18e-16	3.76e-10	-0.47	-0.36	Intelligence (multi-trait analysis);	chr6:26374430	chr9:97195351~97197687:-
LUAD	trans	rs877636	0.702	rs773108	ENSG00000196933.5	RPS26P11	8.59	1.19e-16	3.77e-10	0.45	0.36	Cognitive function;	chr12:55976127	chrX:72044545~72044892:+
LUAD	trans	rs4240897	0.935	rs4846082	ENSG00000261819.1	RP11-680G24.4	8.59	1.2e-16	3.83e-10	0.45	0.36	Tuberculosis;	chr1:11982386	chr16:14988259~14990160:-
LUAD	trans	rs74781061	0.929	rs12441932	ENSG00000227288.3	RP5-837I24.1	8.59	1.23e-16	3.9e-10	0.58	0.36	Endometriosis;	chr15:74617658	chr1:81501794~81503468:+
LUAD	trans	rs10242455	1	rs73395557	ENSG00000228834.1	RP11-249L21.4	8.59	1.26e-16	4.02e-10	0.83	0.36	Blood metabolite levels;	chr7:99336801	chr6:108907615~108907873:-
LUAD	trans	rs1039766	1	rs268871	ENSG00000224334.1	AP000357.4	8.59	1.27e-16	4.02e-10	0.55	0.36	Lung adenocarcinoma;Lung cancer;	chr2:65253874	chr22:24686923~24688087:+
LUAD	trans	rs7647973	0.58	rs2334958	ENSG00000197582.5	GPX1P1	8.58	1.28e-16	4.07e-10	0.47	0.36	Menarche (age at onset);	chr3:49214931	chrX:13378735~13379340:-
LUAD	trans	rs7554511	0.858	rs12142704	ENSG00000244144.1	RP11-757F18.3	-8.58	1.29e-16	4.11e-10	-0.51	-0.36	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200988569	chr3:112185480~112185998:-
LUAD	trans	rs877636	0.669	rs7297175	ENSG00000224553.1	AC008065.1	-8.58	1.3e-16	4.14e-10	-0.37	-0.36	Cognitive function;	chr12:56080024	chr2:171374931~171375278:-
LUAD	trans	rs877636	1	rs2292239	ENSG00000212994.5	RPS26P6	8.58	1.32e-16	4.18e-10	0.41	0.36	Cognitive function;	chr12:56088396	chr8:100895771~100896118:+
LUAD	trans	rs7647973	0.58	rs11716334	ENSG00000197582.5	GPX1P1	8.58	1.36e-16	4.3e-10	0.47	0.36	Menarche (age at onset);	chr3:49192663	chrX:13378735~13379340:-
LUAD	trans	rs877636	1	rs4759229	ENSG00000234513.1	AC073072.7	-8.58	1.36e-16	4.31e-10	-0.42	-0.36	Cognitive function;	chr12:56080696	chr7:22773646~22773993:-
LUAD	trans	rs877636	1	rs4759229	ENSG00000227887.1	RPS26P13	-8.57	1.39e-16	4.4e-10	-0.42	-0.36	Cognitive function;	chr12:56080696	chr1:208697369~208697698:-
LUAD	trans	rs877636	1	rs705696	ENSG00000225071.1	GS1-184P14.2	8.57	1.39e-16	4.41e-10	0.42	0.36	Cognitive function;	chr12:56086864	chrX:24429573~24429920:-
LUAD	trans	rs877636	1	rs2292239	ENSG00000225071.1	GS1-184P14.2	8.57	1.4e-16	4.44e-10	0.39	0.36	Cognitive function;	chr12:56088396	chrX:24429573~24429920:-
LUAD	trans	rs9858542	0.953	rs7646366	ENSG00000197582.5	GPX1P1	-8.57	1.43e-16	4.54e-10	-0.49	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49433235	chrX:13378735~13379340:-
LUAD	trans	rs9858542	0.953	rs67216675	ENSG00000197582.5	GPX1P1	-8.57	1.43e-16	4.54e-10	-0.49	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49455718	chrX:13378735~13379340:-
LUAD	trans	rs7647973	0.58	rs11130184	ENSG00000197582.5	GPX1P1	8.56	1.51e-16	4.77e-10	0.47	0.36	Menarche (age at onset);	chr3:49192497	chrX:13378735~13379340:-
LUAD	trans	rs1039766	0.866	rs2160263	ENSG00000224334.1	AP000357.4	8.56	1.52e-16	4.8e-10	0.59	0.36	Lung adenocarcinoma;Lung cancer;	chr2:65282104	chr22:24686923~24688087:+
LUAD	trans	rs10940346	0.506	rs12659667	ENSG00000231752.4	EMBP1	-8.56	1.54e-16	4.86e-10	-0.49	-0.36	Schizophrenia;	chr5:50566091	chr1:121519112~121571892:+
LUAD	trans	rs9611519	0.894	rs4821990	ENSG00000268568.1	AC007228.9	-8.56	1.56e-16	4.92e-10	-0.51	-0.36	Neuroticism;	chr22:41042706	chr19:56672574~56673901:-
LUAD	trans	rs9858542	0.953	rs9853683	ENSG00000197582.5	GPX1P1	-8.56	1.57e-16	4.96e-10	-0.49	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49475155	chrX:13378735~13379340:-
LUAD	trans	rs9858542	0.953	rs12330269	ENSG00000197582.5	GPX1P1	-8.56	1.57e-16	4.96e-10	-0.49	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49476477	chrX:13378735~13379340:-
LUAD	trans	rs9858542	0.953	rs11719996	ENSG00000197582.5	GPX1P1	-8.56	1.57e-16	4.96e-10	-0.49	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49488525	chrX:13378735~13379340:-
LUAD	trans	rs9858542	0.953	rs34363169	ENSG00000197582.5	GPX1P1	-8.56	1.57e-16	4.96e-10	-0.49	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49500279	chrX:13378735~13379340:-
LUAD	trans	rs9858542	0.953	rs6766581	ENSG00000197582.5	GPX1P1	-8.56	1.57e-16	4.96e-10	-0.49	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49501968	chrX:13378735~13379340:-
LUAD	trans	rs26067	0.643	rs693082	ENSG00000231752.4	EMBP1	8.55	1.67e-16	5.25e-10	0.49	0.36	Breast cancer;	chr5:50808537	chr1:121519112~121571892:+
LUAD	trans	rs877636	0.859	rs3741499	ENSG00000227887.1	RPS26P13	-8.55	1.69e-16	5.32e-10	-0.41	-0.36	Cognitive function;	chr12:56080595	chr1:208697369~208697698:-
LUAD	trans	rs1355223	0.545	rs7106831	ENSG00000225531.1	RP11-196I18.3	8.55	1.69e-16	5.32e-10	0.45	0.36	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34857995	chr9:107116829~107117557:+
LUAD	trans	rs7647973	0.58	rs12629759	ENSG00000197582.5	GPX1P1	8.54	1.72e-16	5.39e-10	0.47	0.36	Menarche (age at onset);	chr3:49199961	chrX:13378735~13379340:-
LUAD	trans	rs8175379	0.509	rs8185339	ENSG00000231752.4	EMBP1	8.54	1.83e-16	5.73e-10	0.51	0.36	Interleukin-7 levels;	chr5:46247513	chr1:121519112~121571892:+
LUAD	trans	rs9858542	0.953	rs6803222	ENSG00000197582.5	GPX1P1	-8.54	1.83e-16	5.75e-10	-0.5	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49628543	chrX:13378735~13379340:-
LUAD	trans	rs11638815	0.603	rs2678448	ENSG00000235370.6	DNM1P51	-8.53	1.86e-16	5.83e-10	-0.45	-0.36	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82594655	chr15:84398316~84411701:-
LUAD	trans	rs7617480	0.61	rs10865954	ENSG00000197582.5	GPX1P1	8.53	1.9e-16	5.96e-10	0.48	0.36	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49174556	chrX:13378735~13379340:-
LUAD	trans	rs10940346	0.506	rs7721806	ENSG00000231752.4	EMBP1	-8.52	2e-16	6.27e-10	-0.49	-0.36	Schizophrenia;	chr5:50576182	chr1:121519112~121571892:+
LUAD	trans	rs9858542	0.953	rs35115732	ENSG00000197582.5	GPX1P1	-8.52	2.02e-16	6.32e-10	-0.49	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49437722	chrX:13378735~13379340:-
LUAD	trans	rs28647808	0.881	rs28617580	ENSG00000234981.1	RP11-534L20.4	8.52	2.06e-16	6.44e-10	0.63	0.36	Blood protein levels;	chr9:133387168	chr1:206528915~206529706:+
LUAD	trans	rs11023332	0.617	rs1879888	ENSG00000236360.2	RP11-334A14.2	8.52	2.07e-16	6.47e-10	0.46	0.36	Vitamin D levels;Adiponectin levels;	chr11:14657701	chr1:52993201~52993702:-
LUAD	trans	rs9858542	0.953	rs1873625	ENSG00000197582.5	GPX1P1	-8.52	2.07e-16	6.48e-10	-0.5	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49629531	chrX:13378735~13379340:-
LUAD	trans	rs877636	0.859	rs3741499	ENSG00000225071.1	GS1-184P14.2	-8.52	2.12e-16	6.62e-10	-0.4	-0.36	Cognitive function;	chr12:56080595	chrX:24429573~24429920:-
LUAD	trans	rs11098499	0.71	rs4145952	ENSG00000275858.1	RP11-291L22.8	8.51	2.2e-16	6.88e-10	0.41	0.36	Corneal astigmatism;	chr4:119234651	chr10:38450738~38451069:-
LUAD	trans	rs9858542	0.953	rs9841110	ENSG00000197582.5	GPX1P1	-8.51	2.21e-16	6.89e-10	-0.49	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49455048	chrX:13378735~13379340:-
LUAD	trans	rs1355223	0.506	rs12294339	ENSG00000225531.1	RP11-196I18.3	8.51	2.22e-16	6.95e-10	0.45	0.36	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34838652	chr9:107116829~107117557:+
LUAD	trans	rs7312770	0.637	rs705699	ENSG00000223416.3	RPS26P15	8.5	2.34e-16	7.3e-10	0.36	0.36	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr1:58056133~58056480:-
LUAD	trans	rs6499255	0.638	rs57824734	ENSG00000257513.6	NPIPB1P	8.5	2.4e-16	7.48e-10	0.4	0.36	IgE levels;	chr16:69778092	chr18:11619509~11639699:-
LUAD	trans	rs10242455	1	rs73395547	ENSG00000228834.1	RP11-249L21.4	8.5	2.41e-16	7.52e-10	0.82	0.36	Blood metabolite levels;	chr7:99325123	chr6:108907615~108907873:-
LUAD	trans	rs1039766	1	rs7558347	ENSG00000224334.1	AP000357.4	8.49	2.58e-16	8.04e-10	0.58	0.36	Lung adenocarcinoma;Lung cancer;	chr2:65245666	chr22:24686923~24688087:+
LUAD	trans	rs4276421	0.638	rs6895453	ENSG00000231752.4	EMBP1	8.49	2.63e-16	8.19e-10	0.52	0.36	P wave duration;	chr5:45850134	chr1:121519112~121571892:+
LUAD	trans	rs9425766	0.962	rs6663875	ENSG00000213331.4	RP11-713C19.2	8.48	2.69e-16	8.37e-10	0.43	0.36	Life satisfaction;	chr1:173894071	chr4:187970273~187971284:+
LUAD	trans	rs5877	0.512	rs56753505	ENSG00000213331.4	RP11-713C19.2	8.48	2.73e-16	8.48e-10	0.47	0.36	Subjective well-being (multi-trait analysis);	chr1:173898114	chr4:187970273~187971284:+
LUAD	trans	rs877636	0.74	rs772920	ENSG00000234513.1	AC073072.7	8.48	2.79e-16	8.68e-10	0.44	0.36	Cognitive function;	chr12:55996580	chr7:22773646~22773993:-
LUAD	trans	rs9858542	0.953	rs11710037	ENSG00000197582.5	GPX1P1	-8.48	2.87e-16	8.9e-10	-0.5	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49637901	chrX:13378735~13379340:-
LUAD	trans	rs7113874	0.545	rs72855149	ENSG00000266891.1	RP11-692N5.2	8.48	2.89e-16	8.97e-10	0.56	0.36	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8586160	chr18:9734882~9735602:-
LUAD	trans	rs3740713	1	rs73438686	ENSG00000235847.2	LDHAP7	8.47	2.93e-16	9.09e-10	0.66	0.36	Amyotrophic lateral sclerosis (sporadic);	chr11:18438238	chr2:84777259~84778223:-
LUAD	trans	rs877636	0.702	rs773108	ENSG00000242970.2	AC068522.4	8.47	2.96e-16	9.19e-10	0.45	0.36	Cognitive function;	chr12:55976127	chr8:58588420~58588764:-
LUAD	trans	rs9858542	0.953	rs7622302	ENSG00000197582.5	GPX1P1	-8.47	2.98e-16	9.24e-10	-0.49	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49510128	chrX:13378735~13379340:-
LUAD	trans	rs13090388	1	rs13090388	ENSG00000197582.5	GPX1P1	-8.47	3.07e-16	9.51e-10	-0.49	-0.36	Educational attainment (years of education);Intelligence (multi-trait analysis);	chr3:49353649	chrX:13378735~13379340:-
LUAD	trans	rs877636	0.859	rs3741499	ENSG00000234513.1	AC073072.7	-8.47	3.1e-16	9.61e-10	-0.42	-0.36	Cognitive function;	chr12:56080595	chr7:22773646~22773993:-
LUAD	trans	rs10940346	0.506	rs4605740	ENSG00000231752.4	EMBP1	-8.46	3.22e-16	9.97e-10	-0.49	-0.36	Schizophrenia;	chr5:50574869	chr1:121519112~121571892:+
LUAD	trans	rs877636	1	rs4759229	ENSG00000225071.1	GS1-184P14.2	-8.46	3.25e-16	1.01e-09	-0.4	-0.36	Cognitive function;	chr12:56080696	chrX:24429573~24429920:-
LUAD	trans	rs7113874	0.511	rs35091649	ENSG00000266891.1	RP11-692N5.2	8.46	3.28e-16	1.01e-09	0.56	0.36	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8526636	chr18:9734882~9735602:-
LUAD	trans	rs4929947	0.515	rs67191473	ENSG00000266891.1	RP11-692N5.2	8.45	3.47e-16	1.07e-09	0.56	0.36	Menarche (age at onset);	chr11:8530643	chr18:9734882~9735602:-
LUAD	trans	rs72615157	0.716	rs75779608	ENSG00000228546.2	CTA-313A17.3	8.45	3.55e-16	1.1e-09	0.57	0.36	Lung function (FEV1/FVC);	chr7:100171334	chr7:102337316~102339115:+
LUAD	trans	rs12497850	0.864	rs6779394	ENSG00000197582.5	GPX1P1	8.45	3.58e-16	1.11e-09	0.48	0.36	Parkinson's disease;	chr3:49120338	chrX:13378735~13379340:-
LUAD	trans	rs7113874	0.613	rs35225809	ENSG00000266891.1	RP11-692N5.2	8.45	3.61e-16	1.12e-09	0.56	0.36	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8512038	chr18:9734882~9735602:-
LUAD	trans	rs877636	0.74	rs705698	ENSG00000242970.2	AC068522.4	8.44	3.67e-16	1.14e-09	0.43	0.36	Cognitive function;	chr12:55990903	chr8:58588420~58588764:-
LUAD	trans	rs3740713	1	rs76062966	ENSG00000235847.2	LDHAP7	8.44	3.7e-16	1.15e-09	0.64	0.36	Amyotrophic lateral sclerosis (sporadic);	chr11:18440857	chr2:84777259~84778223:-
LUAD	trans	rs877636	0.74	rs772920	ENSG00000235459.5	RPS26P31	8.44	3.73e-16	1.15e-09	0.42	0.36	Cognitive function;	chr12:55996580	chr7:122681315~122681662:+
LUAD	trans	rs877636	0.702	rs773108	ENSG00000225071.1	GS1-184P14.2	8.44	3.75e-16	1.16e-09	0.43	0.36	Cognitive function;	chr12:55976127	chrX:24429573~24429920:-
LUAD	trans	rs7662987	1	rs7683704	ENSG00000228407.2	RP4-800M22.1	8.44	3.88e-16	1.2e-09	0.73	0.36	Smoking initiation;	chr4:99083075	chr1:52160261~52160600:-
LUAD	trans	rs10037055	0.853	rs9313749	ENSG00000226986.4	RP11-543B16.2	-8.43	3.95e-16	1.22e-09	-0.43	-0.36	Migraine without aura;	chr5:177170693	chr1:211207239~211207897:+
LUAD	trans	rs877636	1	rs2292239	ENSG00000234354.3	RPS26P47	8.43	4.04e-16	1.25e-09	0.38	0.36	Cognitive function;	chr12:56088396	chr13:100539901~100540248:-
LUAD	trans	rs9611519	0.929	rs4820425	ENSG00000268568.1	AC007228.9	-8.43	4.05e-16	1.25e-09	-0.52	-0.36	Neuroticism;	chr22:41035338	chr19:56672574~56673901:-
LUAD	trans	rs7554511	0.792	rs12126806	ENSG00000244144.1	RP11-757F18.3	-8.42	4.31e-16	1.33e-09	-0.48	-0.36	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200994697	chr3:112185480~112185998:-
LUAD	trans	rs7113874	0.512	rs7952429	ENSG00000266891.1	RP11-692N5.2	8.42	4.42e-16	1.36e-09	0.56	0.36	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8516370	chr18:9734882~9735602:-
LUAD	trans	rs6424115	0.83	rs2501423	ENSG00000228217.1	AL390877.1	-8.42	4.45e-16	1.37e-09	-0.46	-0.36	Immature fraction of reticulocytes;	chr1:23872536	chr1:117778087~117778506:-
LUAD	trans	rs7113874	0.545	rs12791925	ENSG00000266891.1	RP11-692N5.2	8.42	4.45e-16	1.37e-09	0.56	0.36	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8530038	chr18:9734882~9735602:-
LUAD	trans	rs616147	0.616	rs1768234	ENSG00000214263.2	RPSAP53	-8.41	4.66e-16	1.43e-09	-0.47	-0.36	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39459821	chr13:67266845~67267706:-
LUAD	trans	rs12497850	0.931	rs4974082	ENSG00000197582.5	GPX1P1	8.41	4.67e-16	1.44e-09	0.47	0.36	Parkinson's disease;	chr3:48961890	chrX:13378735~13379340:-
LUAD	trans	rs3740713	1	rs76586692	ENSG00000235847.2	LDHAP7	8.41	4.76e-16	1.46e-09	0.64	0.36	Amyotrophic lateral sclerosis (sporadic);	chr11:18432179	chr2:84777259~84778223:-
LUAD	trans	rs6424115	0.8	rs2229583	ENSG00000228217.1	AL390877.1	-8.4	4.94e-16	1.52e-09	-0.46	-0.36	Immature fraction of reticulocytes;	chr1:23874493	chr1:117778087~117778506:-
LUAD	trans	rs7113874	0.592	rs34009921	ENSG00000266891.1	RP11-692N5.2	8.4	4.97e-16	1.53e-09	0.57	0.36	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8597314	chr18:9734882~9735602:-
LUAD	trans	rs7554511	0.929	rs55757739	ENSG00000244144.1	RP11-757F18.3	-8.4	5.08e-16	1.56e-09	-0.49	-0.36	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200997848	chr3:112185480~112185998:-
LUAD	trans	rs7503168	1	rs7503168	ENSG00000234130.2	RP13-88F20.1	8.4	5.13e-16	1.58e-09	0.47	0.36	Plateletcrit;	chr17:35558885	chrX:93222220~93225015:-
LUAD	trans	rs6132905	0.52	rs2422824	ENSG00000235559.1	NOP56P1	8.4	5.22e-16	1.6e-09	0.43	0.36	Mumps;	chr20:2666724	chr6:28783633~28784004:-
LUAD	trans	rs3740713	1	rs57311859	ENSG00000235847.2	LDHAP7	8.39	5.27e-16	1.62e-09	0.64	0.36	Amyotrophic lateral sclerosis (sporadic);	chr11:18432863	chr2:84777259~84778223:-
LUAD	trans	rs3740713	0.92	rs112973292	ENSG00000235847.2	LDHAP7	8.39	5.27e-16	1.62e-09	0.64	0.36	Amyotrophic lateral sclerosis (sporadic);	chr11:18434341	chr2:84777259~84778223:-
LUAD	trans	rs3740713	0.92	rs73438656	ENSG00000235847.2	LDHAP7	8.39	5.27e-16	1.62e-09	0.64	0.36	Amyotrophic lateral sclerosis (sporadic);	chr11:18434388	chr2:84777259~84778223:-
LUAD	trans	rs3740713	0.92	rs73438659	ENSG00000235847.2	LDHAP7	8.39	5.27e-16	1.62e-09	0.64	0.36	Amyotrophic lateral sclerosis (sporadic);	chr11:18434406	chr2:84777259~84778223:-
LUAD	trans	rs3740713	1	rs73438666	ENSG00000235847.2	LDHAP7	8.39	5.27e-16	1.62e-09	0.64	0.36	Amyotrophic lateral sclerosis (sporadic);	chr11:18434964	chr2:84777259~84778223:-
LUAD	trans	rs3740713	1	rs16935424	ENSG00000235847.2	LDHAP7	8.39	5.27e-16	1.62e-09	0.64	0.36	Amyotrophic lateral sclerosis (sporadic);	chr11:18435190	chr2:84777259~84778223:-
LUAD	trans	rs3740713	1	rs73438674	ENSG00000235847.2	LDHAP7	8.39	5.27e-16	1.62e-09	0.64	0.36	Amyotrophic lateral sclerosis (sporadic);	chr11:18435342	chr2:84777259~84778223:-
LUAD	trans	rs3740713	1	rs78549183	ENSG00000235847.2	LDHAP7	8.39	5.27e-16	1.62e-09	0.64	0.36	Amyotrophic lateral sclerosis (sporadic);	chr11:18438168	chr2:84777259~84778223:-
LUAD	trans	rs3740713	1	rs73438690	ENSG00000235847.2	LDHAP7	8.39	5.27e-16	1.62e-09	0.64	0.36	Amyotrophic lateral sclerosis (sporadic);	chr11:18439667	chr2:84777259~84778223:-
LUAD	trans	rs9425766	0.927	rs5878	ENSG00000213331.4	RP11-713C19.2	8.39	5.27e-16	1.62e-09	0.42	0.36	Life satisfaction;	chr1:173909694	chr4:187970273~187971284:+
LUAD	trans	rs10940346	0.506	rs7704183	ENSG00000231752.4	EMBP1	-8.39	5.41e-16	1.66e-09	-0.49	-0.36	Schizophrenia;	chr5:50576738	chr1:121519112~121571892:+
LUAD	trans	rs7113874	0.592	rs12808779	ENSG00000266891.1	RP11-692N5.2	8.39	5.47e-16	1.68e-09	0.56	0.36	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8416280	chr18:9734882~9735602:-
LUAD	trans	rs3740713	1	rs73440615	ENSG00000235847.2	LDHAP7	8.39	5.47e-16	1.68e-09	0.64	0.36	Amyotrophic lateral sclerosis (sporadic);	chr11:18445736	chr2:84777259~84778223:-
LUAD	trans	rs3740713	1	rs73438695	ENSG00000235847.2	LDHAP7	8.39	5.51e-16	1.69e-09	0.64	0.36	Amyotrophic lateral sclerosis (sporadic);	chr11:18440554	chr2:84777259~84778223:-
LUAD	trans	rs3740713	1	rs73440606	ENSG00000235847.2	LDHAP7	8.39	5.53e-16	1.69e-09	0.64	0.36	Amyotrophic lateral sclerosis (sporadic);	chr11:18442573	chr2:84777259~84778223:-
LUAD	trans	rs12497850	0.864	rs4279134	ENSG00000197582.5	GPX1P1	8.39	5.56e-16	1.7e-09	0.48	0.36	Parkinson's disease;	chr3:49119243	chrX:13378735~13379340:-
LUAD	trans	rs877636	0.74	rs705702	ENSG00000235459.5	RPS26P31	-8.38	5.85e-16	1.79e-09	-0.42	-0.36	Cognitive function;	chr12:55996852	chr7:122681315~122681662:+
LUAD	trans	rs877636	1	rs2292239	ENSG00000196656.7	AC004057.1	8.37	6.09e-16	1.86e-09	0.37	0.36	Cognitive function;	chr12:56088396	chr4:113214046~113217170:-
LUAD	trans	rs7113874	0.578	rs35807094	ENSG00000266891.1	RP11-692N5.2	8.37	6.11e-16	1.86e-09	0.55	0.36	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8528798	chr18:9734882~9735602:-
LUAD	trans	rs6424115	0.8	rs4649123	ENSG00000228217.1	AL390877.1	-8.37	6.17e-16	1.88e-09	-0.45	-0.36	Immature fraction of reticulocytes;	chr1:23871206	chr1:117778087~117778506:-
LUAD	trans	rs9611519	0.929	rs12484971	ENSG00000268568.1	AC007228.9	-8.37	6.18e-16	1.88e-09	-0.51	-0.36	Neuroticism;	chr22:41043300	chr19:56672574~56673901:-
LUAD	trans	rs9611519	0.929	rs13055800	ENSG00000268568.1	AC007228.9	-8.37	6.18e-16	1.88e-09	-0.51	-0.36	Neuroticism;	chr22:41044420	chr19:56672574~56673901:-
LUAD	trans	rs9611519	0.929	rs4821991	ENSG00000268568.1	AC007228.9	-8.37	6.18e-16	1.88e-09	-0.51	-0.36	Neuroticism;	chr22:41044679	chr19:56672574~56673901:-
LUAD	trans	rs9611519	0.894	rs9611488	ENSG00000268568.1	AC007228.9	-8.37	6.22e-16	1.9e-09	-0.5	-0.36	Neuroticism;	chr22:41066588	chr19:56672574~56673901:-
LUAD	trans	rs9611519	0.894	rs4821998	ENSG00000268568.1	AC007228.9	-8.37	6.22e-16	1.9e-09	-0.5	-0.36	Neuroticism;	chr22:41072269	chr19:56672574~56673901:-
LUAD	trans	rs9611519	0.894	rs8136923	ENSG00000268568.1	AC007228.9	-8.37	6.22e-16	1.9e-09	-0.5	-0.36	Neuroticism;	chr22:41074518	chr19:56672574~56673901:-
LUAD	trans	rs9611519	0.929	rs73174657	ENSG00000268568.1	AC007228.9	-8.37	6.46e-16	1.97e-09	-0.51	-0.36	Neuroticism;	chr22:41038154	chr19:56672574~56673901:-
LUAD	trans	rs9611519	0.929	rs9611474	ENSG00000268568.1	AC007228.9	-8.37	6.46e-16	1.97e-09	-0.51	-0.36	Neuroticism;	chr22:41038854	chr19:56672574~56673901:-
LUAD	trans	rs9858542	0.953	rs9837341	ENSG00000197582.5	GPX1P1	-8.36	6.58e-16	2e-09	-0.49	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49627334	chrX:13378735~13379340:-
LUAD	trans	rs6732160	0.834	rs57456443	ENSG00000236165.1	PRADC1P1	8.36	6.58e-16	2e-09	0.5	0.36	Intelligence (multi-trait analysis);	chr2:73139313	chr3:36976316~36976840:+
LUAD	trans	rs7312770	0.612	rs773114	ENSG00000224553.1	AC008065.1	8.36	6.6e-16	2.01e-09	0.37	0.36	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr2:171374931~171375278:-
LUAD	trans	rs1355223	0.525	rs10836316	ENSG00000225531.1	RP11-196I18.3	8.36	6.66e-16	2.03e-09	0.44	0.36	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34852748	chr9:107116829~107117557:+
LUAD	trans	rs1355223	0.545	rs7123029	ENSG00000225531.1	RP11-196I18.3	8.36	6.66e-16	2.03e-09	0.44	0.36	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34853268	chr9:107116829~107117557:+
LUAD	trans	rs1355223	0.545	rs7111695	ENSG00000225531.1	RP11-196I18.3	8.36	6.66e-16	2.03e-09	0.44	0.36	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34853359	chr9:107116829~107117557:+
LUAD	trans	rs1355223	0.507	rs11032903	ENSG00000225531.1	RP11-196I18.3	8.36	6.66e-16	2.03e-09	0.44	0.36	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34854629	chr9:107116829~107117557:+
LUAD	trans	rs1355223	0.545	rs12278318	ENSG00000225531.1	RP11-196I18.3	8.36	6.66e-16	2.03e-09	0.44	0.36	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34854960	chr9:107116829~107117557:+
LUAD	trans	rs12497850	0.931	rs6446205	ENSG00000197582.5	GPX1P1	8.36	6.77e-16	2.06e-09	0.47	0.36	Parkinson's disease;	chr3:48997778	chrX:13378735~13379340:-
LUAD	trans	rs3740713	1	rs75740864	ENSG00000235847.2	LDHAP7	8.36	6.85e-16	2.08e-09	0.65	0.36	Amyotrophic lateral sclerosis (sporadic);	chr11:18449142	chr2:84777259~84778223:-
LUAD	trans	rs9858542	0.903	rs17080528	ENSG00000197582.5	GPX1P1	-8.36	6.87e-16	2.09e-09	-0.49	-0.36	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49352409	chrX:13378735~13379340:-
LUAD	trans	rs72615157	0.606	rs941288	ENSG00000228546.2	CTA-313A17.3	8.36	6.96e-16	2.11e-09	0.53	0.36	Lung function (FEV1/FVC);	chr7:100179185	chr7:102337316~102339115:+
LUAD	trans	rs9611519	0.929	rs73174660	ENSG00000268568.1	AC007228.9	-8.35	7.16e-16	2.17e-09	-0.51	-0.36	Neuroticism;	chr22:41041300	chr19:56672574~56673901:-
LUAD	trans	rs12497850	1	rs4858798	ENSG00000197582.5	GPX1P1	8.35	7.2e-16	2.19e-09	0.45	0.36	Parkinson's disease;	chr3:48689679	chrX:13378735~13379340:-
LUAD	trans	rs6424115	0.83	rs2501425	ENSG00000228217.1	AL390877.1	-8.35	7.21e-16	2.19e-09	-0.46	-0.36	Immature fraction of reticulocytes;	chr1:23872849	chr1:117778087~117778506:-
LUAD	trans	rs6424115	0.83	rs2502994	ENSG00000228217.1	AL390877.1	-8.35	7.21e-16	2.19e-09	-0.46	-0.36	Immature fraction of reticulocytes;	chr1:23872873	chr1:117778087~117778506:-
LUAD	trans	rs6424115	0.83	rs2501426	ENSG00000228217.1	AL390877.1	-8.35	7.21e-16	2.19e-09	-0.46	-0.36	Immature fraction of reticulocytes;	chr1:23872874	chr1:117778087~117778506:-
LUAD	trans	rs13190036	0.591	rs78523677	ENSG00000228305.2	AC016734.2	-8.35	7.35e-16	2.23e-09	-0.47	-0.36	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177124102	chr2:63622178~63622831:-
LUAD	trans	rs7113874	0.578	rs34059271	ENSG00000266891.1	RP11-692N5.2	8.35	7.53e-16	2.28e-09	0.56	0.36	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8546311	chr18:9734882~9735602:-
LUAD	trans	rs7662987	0.938	rs28730605	ENSG00000228407.2	RP4-800M22.1	8.35	7.53e-16	2.28e-09	0.74	0.36	Smoking initiation;	chr4:99080389	chr1:52160261~52160600:-
LUAD	trans	rs7662987	1	rs28730595	ENSG00000228407.2	RP4-800M22.1	8.34	8.13e-16	2.46e-09	0.75	0.36	Smoking initiation;	chr4:99082182	chr1:52160261~52160600:-
LUAD	trans	rs7662987	0.938	rs28730592	ENSG00000228407.2	RP4-800M22.1	8.34	8.13e-16	2.46e-09	0.75	0.36	Smoking initiation;	chr4:99082592	chr1:52160261~52160600:-
LUAD	trans	rs7662987	1	rs28730591	ENSG00000228407.2	RP4-800M22.1	8.34	8.13e-16	2.46e-09	0.75	0.36	Smoking initiation;	chr4:99082596	chr1:52160261~52160600:-
LUAD	trans	rs13190036	0.901	rs6898107	ENSG00000228305.2	AC016734.2	8.33	8.29e-16	2.51e-09	0.49	0.36	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177252694	chr2:63622178~63622831:-
LUAD	trans	rs12497850	0.864	rs3212	ENSG00000197582.5	GPX1P1	8.33	8.33e-16	2.52e-09	0.47	0.36	Parkinson's disease;	chr3:49108308	chrX:13378735~13379340:-
LUAD	trans	rs877636	0.74	rs705698	ENSG00000234513.1	AC073072.7	8.33	8.49e-16	2.57e-09	0.42	0.36	Cognitive function;	chr12:55990903	chr7:22773646~22773993:-
LUAD	trans	rs3740713	1	rs73436638	ENSG00000235847.2	LDHAP7	8.33	8.49e-16	2.57e-09	0.63	0.36	Amyotrophic lateral sclerosis (sporadic);	chr11:18418758	chr2:84777259~84778223:-
LUAD	trans	rs3740713	1	rs73436666	ENSG00000235847.2	LDHAP7	8.33	8.49e-16	2.57e-09	0.63	0.36	Amyotrophic lateral sclerosis (sporadic);	chr11:18421383	chr2:84777259~84778223:-
LUAD	trans	rs3740713	1	rs73438611	ENSG00000235847.2	LDHAP7	8.33	8.49e-16	2.57e-09	0.63	0.36	Amyotrophic lateral sclerosis (sporadic);	chr11:18426129	chr2:84777259~84778223:-
LUAD	trans	rs3740713	1	rs2643872	ENSG00000235847.2	LDHAP7	8.33	8.49e-16	2.57e-09	0.63	0.36	Amyotrophic lateral sclerosis (sporadic);	chr11:18428897	chr2:84777259~84778223:-
LUAD	trans	rs3740713	1	rs75381502	ENSG00000235847.2	LDHAP7	8.33	8.49e-16	2.57e-09	0.63	0.36	Amyotrophic lateral sclerosis (sporadic);	chr11:18430339	chr2:84777259~84778223:-
LUAD	trans	rs7662987	0.818	rs4699701	ENSG00000228407.2	RP4-800M22.1	8.33	8.54e-16	2.58e-09	0.73	0.36	Smoking initiation;	chr4:99077296	chr1:52160261~52160600:-
LUAD	trans	rs7662987	1	rs13146416	ENSG00000228407.2	RP4-800M22.1	8.33	8.54e-16	2.58e-09	0.73	0.36	Smoking initiation;	chr4:99078009	chr1:52160261~52160600:-
LUAD	trans	rs6683419	0.729	rs10917477	ENSG00000224237.1	MINOS1P3	-8.33	8.74e-16	2.64e-09	-0.43	-0.35	Serum thyroid-stimulating hormone levels;	chr1:19534612	chr3:27214816~27215018:-
LUAD	trans	rs6424115	0.83	rs3003333	ENSG00000228217.1	AL390877.1	8.32	9.14e-16	2.76e-09	0.44	0.35	Immature fraction of reticulocytes;	chr1:23867524	chr1:117778087~117778506:-
LUAD	trans	rs13190036	0.901	rs6556309	ENSG00000228305.2	AC016734.2	8.32	9.15e-16	2.76e-09	0.48	0.35	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177266834	chr2:63622178~63622831:-
LUAD	trans	rs6424115	0.733	rs2502996	ENSG00000228217.1	AL390877.1	-8.32	9.16e-16	2.77e-09	-0.45	-0.35	Immature fraction of reticulocytes;	chr1:23872551	chr1:117778087~117778506:-
LUAD	trans	rs6424115	0.83	rs2502995	ENSG00000228217.1	AL390877.1	-8.32	9.16e-16	2.77e-09	-0.45	-0.35	Immature fraction of reticulocytes;	chr1:23872800	chr1:117778087~117778506:-
LUAD	trans	rs877636	0.702	rs773110	ENSG00000235459.5	RPS26P31	8.32	9.26e-16	2.79e-09	0.41	0.35	Cognitive function;	chr12:55981353	chr7:122681315~122681662:+
LUAD	trans	rs877636	0.702	rs773111	ENSG00000235459.5	RPS26P31	8.32	9.26e-16	2.79e-09	0.41	0.35	Cognitive function;	chr12:55981956	chr7:122681315~122681662:+
LUAD	trans	rs877636	0.702	rs773112	ENSG00000235459.5	RPS26P31	8.32	9.26e-16	2.79e-09	0.41	0.35	Cognitive function;	chr12:55982097	chr7:122681315~122681662:+
LUAD	trans	rs1816752	0.603	rs9511278	ENSG00000224976.2	PARP4P2	8.31	9.56e-16	2.88e-09	0.41	0.35	Obesity-related traits;	chr13:24455766	chr13:19349137~19407962:+
LUAD	trans	rs6424115	0.83	rs4649124	ENSG00000228217.1	AL390877.1	-8.31	9.93e-16	2.99e-09	-0.46	-0.35	Immature fraction of reticulocytes;	chr1:23874867	chr1:117778087~117778506:-
LUAD	trans	rs6424115	0.83	rs3003336	ENSG00000228217.1	AL390877.1	-8.31	9.93e-16	2.99e-09	-0.46	-0.35	Immature fraction of reticulocytes;	chr1:23874958	chr1:117778087~117778506:-
LUAD	trans	rs6424115	0.83	rs2501431	ENSG00000228217.1	AL390877.1	-8.31	9.93e-16	2.99e-09	-0.46	-0.35	Immature fraction of reticulocytes;	chr1:23875153	chr1:117778087~117778506:-
LUAD	trans	rs3003334	1	rs3003334	ENSG00000228217.1	AL390877.1	-8.31	9.96e-16	3e-09	-0.46	-0.35	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;	chr1:23873379	chr1:117778087~117778506:-
LUAD	trans	rs6424115	0.83	rs1130321	ENSG00000228217.1	AL390877.1	-8.31	9.96e-16	3e-09	-0.46	-0.35	Immature fraction of reticulocytes;	chr1:23874034	chr1:117778087~117778506:-
LUAD	trans	rs6424115	0.83	rs1130320	ENSG00000228217.1	AL390877.1	-8.31	9.96e-16	3e-09	-0.46	-0.35	Immature fraction of reticulocytes;	chr1:23874116	chr1:117778087~117778506:-
LUAD	trans	rs6424115	0.83	rs1106	ENSG00000228217.1	AL390877.1	-8.31	9.96e-16	3e-09	-0.46	-0.35	Immature fraction of reticulocytes;	chr1:23874282	chr1:117778087~117778506:-
LUAD	trans	rs6424115	0.83	rs1105	ENSG00000228217.1	AL390877.1	-8.31	9.96e-16	3e-09	-0.46	-0.35	Immature fraction of reticulocytes;	chr1:23874310	chr1:117778087~117778506:-
LUAD	trans	rs6424115	0.83	rs2229585	ENSG00000228217.1	AL390877.1	-8.31	9.96e-16	3e-09	-0.46	-0.35	Immature fraction of reticulocytes;	chr1:23874431	chr1:117778087~117778506:-
LUAD	trans	rs6424115	0.83	rs2229584	ENSG00000228217.1	AL390877.1	-8.31	9.96e-16	3e-09	-0.46	-0.35	Immature fraction of reticulocytes;	chr1:23874479	chr1:117778087~117778506:-
LUAD	trans	rs6424115	0.8	rs2229581	ENSG00000228217.1	AL390877.1	-8.31	9.96e-16	3e-09	-0.46	-0.35	Immature fraction of reticulocytes;	chr1:23874604	chr1:117778087~117778506:-
LUAD	trans	rs6424115	0.743	rs2229580	ENSG00000228217.1	AL390877.1	-8.31	9.96e-16	3e-09	-0.46	-0.35	Immature fraction of reticulocytes;	chr1:23874619	chr1:117778087~117778506:-
LUAD	trans	rs6424115	0.83	rs2502993	ENSG00000228217.1	AL390877.1	-8.31	9.96e-16	3e-09	-0.46	-0.35	Immature fraction of reticulocytes;	chr1:23874772	chr1:117778087~117778506:-
LUAD	trans	rs6424115	0.83	rs6680132	ENSG00000228217.1	AL390877.1	-8.31	1.01e-15	3.03e-09	-0.45	-0.35	Immature fraction of reticulocytes;	chr1:23872314	chr1:117778087~117778506:-
LUAD	trans	rs6424115	0.83	rs6672157	ENSG00000228217.1	AL390877.1	-8.31	1.01e-15	3.03e-09	-0.45	-0.35	Immature fraction of reticulocytes;	chr1:23872350	chr1:117778087~117778506:-
LUAD	trans	rs9611519	0.894	rs13053242	ENSG00000268568.1	AC007228.9	-8.3	1.02e-15	3.08e-09	-0.5	-0.35	Neuroticism;	chr22:41063482	chr19:56672574~56673901:-
LUAD	trans	rs6424115	0.83	rs6663474	ENSG00000228217.1	AL390877.1	-8.3	1.03e-15	3.1e-09	-0.45	-0.35	Immature fraction of reticulocytes;	chr1:23873152	chr1:117778087~117778506:-
LUAD	trans	rs6424115	0.83	rs3003335	ENSG00000228217.1	AL390877.1	-8.3	1.04e-15	3.13e-09	-0.45	-0.35	Immature fraction of reticulocytes;	chr1:23873562	chr1:117778087~117778506:-
LUAD	trans	rs6424115	0.8	rs6665733	ENSG00000228217.1	AL390877.1	-8.3	1.04e-15	3.13e-09	-0.45	-0.35	Immature fraction of reticulocytes;	chr1:23873668	chr1:117778087~117778506:-
LUAD	trans	rs9611519	0.894	rs9611486	ENSG00000268568.1	AC007228.9	-8.3	1.06e-15	3.2e-09	-0.5	-0.35	Neuroticism;	chr22:41062780	chr19:56672574~56673901:-
LUAD	trans	rs877636	0.74	rs705702	ENSG00000234513.1	AC073072.7	-8.3	1.07e-15	3.23e-09	-0.43	-0.35	Cognitive function;	chr12:55996852	chr7:22773646~22773993:-
LUAD	trans	rs877636	1	rs705696	ENSG00000227887.1	RPS26P13	8.3	1.09e-15	3.26e-09	0.41	0.35	Cognitive function;	chr12:56086864	chr1:208697369~208697698:-
LUAD	trans	rs10242455	1	rs28468623	ENSG00000228834.1	RP11-249L21.4	8.3	1.1e-15	3.3e-09	0.8	0.35	Blood metabolite levels;	chr7:99325189	chr6:108907615~108907873:-
LUAD	trans	rs877636	0.859	rs3741499	ENSG00000212994.5	RPS26P6	-8.29	1.1e-15	3.31e-09	-0.41	-0.35	Cognitive function;	chr12:56080595	chr8:100895771~100896118:+
LUAD	trans	rs7192380	0.767	rs8061725	ENSG00000257513.6	NPIPB1P	8.29	1.12e-15	3.36e-09	0.36	0.35	Sjögren's syndrome;	chr16:69547174	chr18:11619509~11639699:-
LUAD	trans	rs7312770	0.637	rs705699	ENSG00000243538.1	CTB-55B8.1	8.29	1.13e-15	3.4e-09	0.38	0.35	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr5:16902294~16902641:-
LUAD	trans	rs9858542	1	rs9836291	ENSG00000197582.5	GPX1P1	-8.29	1.17e-15	3.5e-09	-0.48	-0.35	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49660026	chrX:13378735~13379340:-
LUAD	trans	rs7192380	0.651	rs34769743	ENSG00000257513.6	NPIPB1P	8.29	1.17e-15	3.52e-09	0.36	0.35	Sjögren's syndrome;	chr16:69546587	chr18:11619509~11639699:-
LUAD	trans	rs9611519	0.828	rs28814423	ENSG00000268568.1	AC007228.9	-8.29	1.17e-15	3.52e-09	-0.5	-0.35	Neuroticism;	chr22:41056297	chr19:56672574~56673901:-
LUAD	trans	rs10037055	0.853	rs10077929	ENSG00000226986.4	RP11-543B16.2	8.29	1.18e-15	3.53e-09	0.42	0.35	Migraine without aura;	chr5:177270843	chr1:211207239~211207897:+
LUAD	trans	rs58106596	0.66	rs62197212	ENSG00000259020.3	RP11-529H20.3	8.28	1.18e-15	3.55e-09	0.54	0.35	Lymphocyte counts;White blood cell count;	chr2:231698017	chr14:92026566~92026887:+
LUAD	trans	rs6424115	0.83	rs2503002	ENSG00000228217.1	AL390877.1	-8.28	1.21e-15	3.61e-09	-0.45	-0.35	Immature fraction of reticulocytes;	chr1:23870467	chr1:117778087~117778506:-
LUAD	trans	rs7554511	0.861	rs296563	ENSG00000244144.1	RP11-757F18.3	8.28	1.22e-15	3.66e-09	0.47	0.35	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200975712	chr3:112185480~112185998:-
LUAD	trans	rs6424115	0.83	rs2503000	ENSG00000228217.1	AL390877.1	-8.28	1.25e-15	3.74e-09	-0.45	-0.35	Immature fraction of reticulocytes;	chr1:23871408	chr1:117778087~117778506:-
LUAD	trans	rs6424115	0.83	rs2502992	ENSG00000228217.1	AL390877.1	-8.28	1.27e-15	3.8e-09	-0.45	-0.35	Immature fraction of reticulocytes;	chr1:23875429	chr1:117778087~117778506:-
LUAD	trans	rs6424115	0.867	rs2501432	ENSG00000228217.1	AL390877.1	-8.28	1.27e-15	3.8e-09	-0.45	-0.35	Immature fraction of reticulocytes;	chr1:23875430	chr1:117778087~117778506:-
LUAD	trans	rs6424115	0.83	rs2502999	ENSG00000228217.1	AL390877.1	-8.27	1.34e-15	4.01e-09	-0.45	-0.35	Immature fraction of reticulocytes;	chr1:23871831	chr1:117778087~117778506:-
LUAD	trans	rs6424115	0.793	rs2502998	ENSG00000228217.1	AL390877.1	-8.27	1.34e-15	4.01e-09	-0.45	-0.35	Immature fraction of reticulocytes;	chr1:23871837	chr1:117778087~117778506:-
LUAD	trans	rs8067354	0.645	rs2102507	ENSG00000187870.7	RNFT1P3	8.27	1.34e-15	4.02e-09	0.5	0.35	Hemoglobin concentration;	chr17:59798546	chr17:20743333~20754501:-
LUAD	trans	rs8067354	0.645	rs2645491	ENSG00000187870.7	RNFT1P3	8.27	1.34e-15	4.02e-09	0.5	0.35	Hemoglobin concentration;	chr17:59799688	chr17:20743333~20754501:-
LUAD	trans	rs8067354	0.645	rs2665400	ENSG00000187870.7	RNFT1P3	8.27	1.34e-15	4.02e-09	0.5	0.35	Hemoglobin concentration;	chr17:59802840	chr17:20743333~20754501:-
LUAD	trans	rs867371	0.656	rs2665103	ENSG00000235370.6	DNM1P51	8.27	1.35e-15	4.04e-09	0.39	0.35	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82140374	chr15:84398316~84411701:-
LUAD	trans	rs7554511	0.825	rs11576681	ENSG00000244144.1	RP11-757F18.3	-8.26	1.39e-15	4.14e-09	-0.48	-0.35	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201034923	chr3:112185480~112185998:-
LUAD	trans	rs7554511	0.893	rs17419032	ENSG00000244144.1	RP11-757F18.3	8.26	1.39e-15	4.14e-09	0.48	0.35	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201029403	chr3:112185480~112185998:-
LUAD	trans	rs877636	1	rs4759229	ENSG00000212994.5	RPS26P6	-8.26	1.39e-15	4.14e-09	-0.41	-0.35	Cognitive function;	chr12:56080696	chr8:100895771~100896118:+
LUAD	trans	rs3740713	1	rs35593189	ENSG00000235847.2	LDHAP7	8.26	1.4e-15	4.17e-09	0.64	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18446831	chr2:84777259~84778223:-
LUAD	trans	rs9611519	0.929	rs9611465	ENSG00000268568.1	AC007228.9	-8.26	1.4e-15	4.18e-09	-0.51	-0.35	Neuroticism;	chr22:41030135	chr19:56672574~56673901:-
LUAD	trans	rs9611519	0.929	rs9611466	ENSG00000268568.1	AC007228.9	-8.26	1.4e-15	4.18e-09	-0.51	-0.35	Neuroticism;	chr22:41030295	chr19:56672574~56673901:-
LUAD	trans	rs9611519	0.929	rs4820423	ENSG00000268568.1	AC007228.9	-8.26	1.4e-15	4.18e-09	-0.51	-0.35	Neuroticism;	chr22:41034334	chr19:56672574~56673901:-
LUAD	trans	rs12497850	0.931	rs4974085	ENSG00000197582.5	GPX1P1	8.26	1.4e-15	4.19e-09	0.46	0.35	Parkinson's disease;	chr3:48887467	chrX:13378735~13379340:-
LUAD	trans	rs1355223	0.506	rs1509660	ENSG00000225531.1	RP11-196I18.3	8.26	1.42e-15	4.23e-09	0.44	0.35	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34843470	chr9:107116829~107117557:+
LUAD	trans	rs1355223	0.506	rs1509659	ENSG00000225531.1	RP11-196I18.3	8.26	1.42e-15	4.23e-09	0.44	0.35	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34843586	chr9:107116829~107117557:+
LUAD	trans	rs1355223	0.506	rs11032894	ENSG00000225531.1	RP11-196I18.3	8.26	1.42e-15	4.23e-09	0.44	0.35	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34843997	chr9:107116829~107117557:+
LUAD	trans	rs1355223	0.506	rs7947848	ENSG00000225531.1	RP11-196I18.3	8.26	1.42e-15	4.23e-09	0.44	0.35	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34844673	chr9:107116829~107117557:+
LUAD	trans	rs9858542	1	rs6770670	ENSG00000197582.5	GPX1P1	-8.26	1.44e-15	4.29e-09	-0.49	-0.35	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49649249	chrX:13378735~13379340:-
LUAD	trans	rs7662987	1	rs4699699	ENSG00000228407.2	RP4-800M22.1	8.26	1.44e-15	4.3e-09	0.73	0.35	Smoking initiation;	chr4:99076028	chr1:52160261~52160600:-
LUAD	trans	rs7662987	0.938	rs13118409	ENSG00000228407.2	RP4-800M22.1	8.26	1.44e-15	4.3e-09	0.73	0.35	Smoking initiation;	chr4:99077585	chr1:52160261~52160600:-
LUAD	trans	rs7662987	1	rs13119035	ENSG00000228407.2	RP4-800M22.1	8.26	1.44e-15	4.3e-09	0.73	0.35	Smoking initiation;	chr4:99077979	chr1:52160261~52160600:-
LUAD	trans	rs7554511	0.894	rs296543	ENSG00000244144.1	RP11-757F18.3	8.26	1.45e-15	4.33e-09	0.47	0.35	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200920705	chr3:112185480~112185998:-
LUAD	trans	rs9858542	1	rs11709525	ENSG00000197582.5	GPX1P1	-8.25	1.48e-15	4.41e-09	-0.49	-0.35	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49653063	chrX:13378735~13379340:-
LUAD	trans	rs7554511	0.894	rs404339	ENSG00000244144.1	RP11-757F18.3	-8.25	1.49e-15	4.43e-09	-0.47	-0.35	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200917763	chr3:112185480~112185998:-
LUAD	trans	rs7312770	0.612	rs1873914	ENSG00000224553.1	AC008065.1	8.25	1.5e-15	4.47e-09	0.36	0.35	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr2:171374931~171375278:-
LUAD	trans	rs9858542	1	rs34762726	ENSG00000197582.5	GPX1P1	-8.25	1.53e-15	4.55e-09	-0.49	-0.35	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49651777	chrX:13378735~13379340:-
LUAD	trans	rs9611519	0.531	rs1967708	ENSG00000268568.1	AC007228.9	-8.25	1.57e-15	4.66e-09	-0.45	-0.35	Neuroticism;	chr22:41048440	chr19:56672574~56673901:-
LUAD	trans	rs877636	0.702	rs61937249	ENSG00000235459.5	RPS26P31	8.24	1.62e-15	4.81e-09	0.41	0.35	Cognitive function;	chr12:55988132	chr7:122681315~122681662:+
LUAD	trans	rs7312770	0.612	rs773114	ENSG00000204652.6	RPS26P8	8.24	1.64e-15	4.88e-09	0.41	0.35	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr17:45608571~45608918:+
LUAD	trans	rs7662987	1	rs28730587	ENSG00000228407.2	RP4-800M22.1	8.24	1.68e-15	4.99e-09	0.75	0.35	Smoking initiation;	chr4:99083190	chr1:52160261~52160600:-
LUAD	trans	rs7662987	1	rs7683802	ENSG00000228407.2	RP4-800M22.1	8.24	1.68e-15	5e-09	0.72	0.35	Smoking initiation;	chr4:99073987	chr1:52160261~52160600:-
LUAD	trans	rs12497850	0.931	rs7430198	ENSG00000197582.5	GPX1P1	8.24	1.69e-15	5.02e-09	0.47	0.35	Parkinson's disease;	chr3:48951327	chrX:13378735~13379340:-
LUAD	trans	rs1051424	0.642	rs115869798	ENSG00000187870.7	RNFT1P3	8.23	1.71e-15	5.07e-09	0.49	0.35	Obesity-related traits;	chr17:59815468	chr17:20743333~20754501:-
LUAD	trans	rs1051424	0.651	rs1292063	ENSG00000187870.7	RNFT1P3	-8.23	1.71e-15	5.07e-09	-0.49	-0.35	Obesity-related traits;	chr17:59830407	chr17:20743333~20754501:-
LUAD	trans	rs3740713	1	rs60376560	ENSG00000235847.2	LDHAP7	8.23	1.78e-15	5.27e-09	0.64	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18432195	chr2:84777259~84778223:-
LUAD	trans	rs9858542	1	rs13316695	ENSG00000197582.5	GPX1P1	-8.23	1.8e-15	5.33e-09	-0.48	-0.35	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49647484	chrX:13378735~13379340:-
LUAD	trans	rs7662987	1	rs13145727	ENSG00000228407.2	RP4-800M22.1	8.23	1.81e-15	5.37e-09	0.73	0.35	Smoking initiation;	chr4:99077715	chr1:52160261~52160600:-
LUAD	trans	rs7662987	1	rs13125919	ENSG00000228407.2	RP4-800M22.1	8.23	1.81e-15	5.37e-09	0.73	0.35	Smoking initiation;	chr4:99078697	chr1:52160261~52160600:-
LUAD	trans	rs3740713	1	rs73436642	ENSG00000235847.2	LDHAP7	8.23	1.81e-15	5.37e-09	0.62	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18419088	chr2:84777259~84778223:-
LUAD	trans	rs4713118	0.505	rs276371	ENSG00000204709.4	LINC01556	8.23	1.83e-15	5.42e-09	0.41	0.35	Parkinson's disease;	chr6:27942930	chr6:28943877~28944537:+
LUAD	trans	rs8067354	0.645	rs2645489	ENSG00000187870.7	RNFT1P3	8.22	1.87e-15	5.52e-09	0.49	0.35	Hemoglobin concentration;	chr17:59806010	chr17:20743333~20754501:-
LUAD	trans	rs8067354	0.645	rs2645486	ENSG00000187870.7	RNFT1P3	8.22	1.87e-15	5.52e-09	0.49	0.35	Hemoglobin concentration;	chr17:59808540	chr17:20743333~20754501:-
LUAD	trans	rs8067354	0.645	rs2645487	ENSG00000187870.7	RNFT1P3	8.22	1.87e-15	5.52e-09	0.49	0.35	Hemoglobin concentration;	chr17:59808764	chr17:20743333~20754501:-
LUAD	trans	rs9611519	0.929	rs12484477	ENSG00000268568.1	AC007228.9	-8.22	1.89e-15	5.6e-09	-0.5	-0.35	Neuroticism;	chr22:41033080	chr19:56672574~56673901:-
LUAD	trans	rs6424115	1	rs4237	ENSG00000228217.1	AL390877.1	-8.22	1.9e-15	5.62e-09	-0.44	-0.35	Immature fraction of reticulocytes;	chr1:23787639	chr1:117778087~117778506:-
LUAD	trans	rs7554511	0.858	rs11583328	ENSG00000244144.1	RP11-757F18.3	8.22	1.91e-15	5.64e-09	0.48	0.35	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201033045	chr3:112185480~112185998:-
LUAD	trans	rs7617480	0.61	rs4955420	ENSG00000197582.5	GPX1P1	8.22	1.92e-15	5.67e-09	0.47	0.35	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49171432	chrX:13378735~13379340:-
LUAD	trans	rs9611519	0.929	rs9611469	ENSG00000268568.1	AC007228.9	-8.22	1.92e-15	5.69e-09	-0.5	-0.35	Neuroticism;	chr22:41037315	chr19:56672574~56673901:-
LUAD	trans	rs6424115	0.83	rs2502991	ENSG00000228217.1	AL390877.1	-8.22	1.95e-15	5.76e-09	-0.45	-0.35	Immature fraction of reticulocytes;	chr1:23875828	chr1:117778087~117778506:-
LUAD	trans	rs877636	0.702	rs773109	ENSG00000235459.5	RPS26P31	8.22	1.98e-15	5.84e-09	0.41	0.35	Cognitive function;	chr12:55980911	chr7:122681315~122681662:+
LUAD	trans	rs3740713	1	rs1848048	ENSG00000235847.2	LDHAP7	8.21	1.99e-15	5.87e-09	0.64	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18447449	chr2:84777259~84778223:-
LUAD	trans	rs3740713	1	rs16935432	ENSG00000235847.2	LDHAP7	8.21	1.99e-15	5.87e-09	0.64	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18448940	chr2:84777259~84778223:-
LUAD	trans	rs3740713	1	rs73440625	ENSG00000235847.2	LDHAP7	8.21	1.99e-15	5.87e-09	0.64	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18449253	chr2:84777259~84778223:-
LUAD	trans	rs3740713	1	rs76599129	ENSG00000235847.2	LDHAP7	8.21	1.99e-15	5.87e-09	0.64	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18450080	chr2:84777259~84778223:-
LUAD	trans	rs3740713	1	rs75487138	ENSG00000235847.2	LDHAP7	8.21	1.99e-15	5.88e-09	0.64	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18440331	chr2:84777259~84778223:-
LUAD	trans	rs7554511	0.893	rs72749166	ENSG00000244144.1	RP11-757F18.3	-8.21	1.99e-15	5.89e-09	-0.49	-0.35	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201031177	chr3:112185480~112185998:-
LUAD	trans	rs10940346	0.506	rs11741135	ENSG00000231752.4	EMBP1	-8.21	2e-15	5.9e-09	-0.48	-0.35	Schizophrenia;	chr5:50579604	chr1:121519112~121571892:+
LUAD	trans	rs3740713	1	rs73440614	ENSG00000235847.2	LDHAP7	8.21	2e-15	5.91e-09	0.64	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18445153	chr2:84777259~84778223:-
LUAD	trans	rs877636	1	rs2292239	ENSG00000224553.1	AC008065.1	8.21	2.02e-15	5.97e-09	0.35	0.35	Cognitive function;	chr12:56088396	chr2:171374931~171375278:-
LUAD	trans	rs11638815	0.626	rs11633829	ENSG00000235370.6	DNM1P51	8.21	2.02e-15	5.97e-09	0.43	0.35	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82658186	chr15:84398316~84411701:-
LUAD	trans	rs3740713	0.925	rs55727925	ENSG00000235847.2	LDHAP7	8.21	2.03e-15	6e-09	0.62	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18432146	chr2:84777259~84778223:-
LUAD	trans	rs7113874	0.527	rs12790154	ENSG00000266891.1	RP11-692N5.2	8.21	2.07e-15	6.11e-09	0.55	0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8383601	chr18:9734882~9735602:-
LUAD	trans	rs12497850	0.805	rs6446198	ENSG00000197582.5	GPX1P1	8.21	2.11e-15	6.24e-09	0.47	0.35	Parkinson's disease;	chr3:48970205	chrX:13378735~13379340:-
LUAD	trans	rs1355223	0.506	rs11032898	ENSG00000225531.1	RP11-196I18.3	8.2	2.13e-15	6.29e-09	0.43	0.35	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34848564	chr9:107116829~107117557:+
LUAD	trans	rs1355223	0.506	rs1828299	ENSG00000225531.1	RP11-196I18.3	8.2	2.13e-15	6.29e-09	0.43	0.35	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34848871	chr9:107116829~107117557:+
LUAD	trans	rs9858542	1	rs9822268	ENSG00000197582.5	GPX1P1	-8.2	2.13e-15	6.29e-09	-0.48	-0.35	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49682296	chrX:13378735~13379340:-
LUAD	trans	rs9858542	1	rs13085791	ENSG00000197582.5	GPX1P1	-8.2	2.13e-15	6.29e-09	-0.48	-0.35	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49684365	chrX:13378735~13379340:-
LUAD	trans	rs7312770	0.637	rs705699	ENSG00000204652.6	RPS26P8	8.2	2.22e-15	6.54e-09	0.41	0.35	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr17:45608571~45608918:+
LUAD	trans	rs1355223	0.525	rs55796371	ENSG00000225531.1	RP11-196I18.3	8.2	2.25e-15	6.62e-09	0.43	0.35	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34851222	chr9:107116829~107117557:+
LUAD	trans	rs1355223	0.525	rs12280958	ENSG00000225531.1	RP11-196I18.3	8.2	2.25e-15	6.62e-09	0.43	0.35	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34851252	chr9:107116829~107117557:+
LUAD	trans	rs12497850	0.931	rs11920534	ENSG00000197582.5	GPX1P1	8.2	2.28e-15	6.7e-09	0.46	0.35	Parkinson's disease;	chr3:48900328	chrX:13378735~13379340:-
LUAD	trans	rs9611519	0.507	rs12484525	ENSG00000268568.1	AC007228.9	-8.19	2.29e-15	6.76e-09	-0.45	-0.35	Neuroticism;	chr22:41047873	chr19:56672574~56673901:-
LUAD	trans	rs7662987	1	rs11547772	ENSG00000228407.2	RP4-800M22.1	8.19	2.3e-15	6.78e-09	0.72	0.35	Smoking initiation;	chr4:99071642	chr1:52160261~52160600:-
LUAD	trans	rs7662987	1	rs28730640	ENSG00000228407.2	RP4-800M22.1	8.19	2.3e-15	6.78e-09	0.72	0.35	Smoking initiation;	chr4:99072902	chr1:52160261~52160600:-
LUAD	trans	rs7662987	1	rs7658118	ENSG00000228407.2	RP4-800M22.1	8.19	2.3e-15	6.78e-09	0.72	0.35	Smoking initiation;	chr4:99073457	chr1:52160261~52160600:-
LUAD	trans	rs8067354	0.574	rs2250526	ENSG00000187870.7	RNFT1P3	8.19	2.31e-15	6.81e-09	0.56	0.35	Hemoglobin concentration;	chr17:59874612	chr17:20743333~20754501:-
LUAD	trans	rs12497850	0.931	rs6446196	ENSG00000197582.5	GPX1P1	8.19	2.34e-15	6.88e-09	0.46	0.35	Parkinson's disease;	chr3:48967290	chrX:13378735~13379340:-
LUAD	trans	rs7113874	0.534	rs2311392	ENSG00000266891.1	RP11-692N5.2	8.19	2.35e-15	6.93e-09	0.54	0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8468889	chr18:9734882~9735602:-
LUAD	trans	rs7312770	0.637	rs705700	ENSG00000204652.6	RPS26P8	8.19	2.4e-15	7.06e-09	0.41	0.35	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr17:45608571~45608918:+
LUAD	trans	rs616147	0.816	rs1768190	ENSG00000214263.2	RPSAP53	8.19	2.42e-15	7.11e-09	0.48	0.35	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39467949	chr13:67266845~67267706:-
LUAD	trans	rs12497850	0.864	rs4521268	ENSG00000197582.5	GPX1P1	8.19	2.46e-15	7.22e-09	0.47	0.35	Parkinson's disease;	chr3:49100471	chrX:13378735~13379340:-
LUAD	trans	rs1355223	0.506	rs11032899	ENSG00000225531.1	RP11-196I18.3	8.18	2.48e-15	7.28e-09	0.43	0.35	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34848687	chr9:107116829~107117557:+
LUAD	trans	rs12497850	0.897	rs6781790	ENSG00000197582.5	GPX1P1	8.18	2.55e-15	7.48e-09	0.46	0.35	Parkinson's disease;	chr3:49007334	chrX:13378735~13379340:-
LUAD	trans	rs13416322	0.699	rs2309849	ENSG00000214286.2	PDCL3P3	8.18	2.56e-15	7.51e-09	0.47	0.35	Intelligence (multi-trait analysis);	chr2:100557847	chr3:17877455~17878169:-
LUAD	trans	rs4240897	1	rs4240897	ENSG00000261819.1	RP11-680G24.4	-8.18	2.56e-15	7.51e-09	-0.44	-0.35	Tuberculosis;	chr1:11982698	chr16:14988259~14990160:-
LUAD	trans	rs8067354	0.609	rs1292066	ENSG00000187870.7	RNFT1P3	8.18	2.56e-15	7.52e-09	0.5	0.35	Hemoglobin concentration;	chr17:59854953	chr17:20743333~20754501:-
LUAD	trans	rs3740713	1	rs73438697	ENSG00000235847.2	LDHAP7	8.18	2.57e-15	7.55e-09	0.62	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18440830	chr2:84777259~84778223:-
LUAD	trans	rs3740713	1	rs114330751	ENSG00000235847.2	LDHAP7	8.18	2.57e-15	7.55e-09	0.62	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18440928	chr2:84777259~84778223:-
LUAD	trans	rs7113874	0.578	rs67067089	ENSG00000266891.1	RP11-692N5.2	8.18	2.58e-15	7.58e-09	0.54	0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8508480	chr18:9734882~9735602:-
LUAD	trans	rs877636	0.669	rs7297175	ENSG00000223416.3	RPS26P15	-8.18	2.62e-15	7.7e-09	-0.34	-0.35	Cognitive function;	chr12:56080024	chr1:58056133~58056480:-
LUAD	trans	rs1355223	0.506	rs7131229	ENSG00000225531.1	RP11-196I18.3	-8.18	2.63e-15	7.7e-09	-0.43	-0.35	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34847781	chr9:107116829~107117557:+
LUAD	trans	rs12497850	0.863	rs4974084	ENSG00000197582.5	GPX1P1	8.17	2.65e-15	7.77e-09	0.47	0.35	Parkinson's disease;	chr3:48901647	chrX:13378735~13379340:-
LUAD	trans	rs10940346	0.506	rs12187591	ENSG00000231752.4	EMBP1	-8.17	2.67e-15	7.84e-09	-0.49	-0.35	Schizophrenia;	chr5:50586789	chr1:121519112~121571892:+
LUAD	trans	rs877636	0.692	rs11171739	ENSG00000227586.5	RP11-162A23.5	8.17	2.76e-15	8.1e-09	0.39	0.35	Cognitive function;	chr12:56076841	chr10:123171535~123171875:-
LUAD	trans	rs26067	0.689	rs282546	ENSG00000231752.4	EMBP1	-8.17	2.78e-15	8.14e-09	-0.47	-0.35	Breast cancer;	chr5:50762209	chr1:121519112~121571892:+
LUAD	trans	rs9611519	0.558	rs8137906	ENSG00000268568.1	AC007228.9	-8.17	2.8e-15	8.18e-09	-0.44	-0.35	Neuroticism;	chr22:41046562	chr19:56672574~56673901:-
LUAD	trans	rs7662987	1	rs7658127	ENSG00000228407.2	RP4-800M22.1	8.17	2.81e-15	8.21e-09	0.72	0.35	Smoking initiation;	chr4:99073471	chr1:52160261~52160600:-
LUAD	trans	rs7662987	1	rs7662987	ENSG00000228407.2	RP4-800M22.1	8.17	2.81e-15	8.22e-09	0.72	0.35	Smoking initiation;	chr4:99070491	chr1:52160261~52160600:-
LUAD	trans	rs9611519	0.565	rs8135524	ENSG00000268568.1	AC007228.9	-8.17	2.81e-15	8.22e-09	-0.45	-0.35	Neuroticism;	chr22:41040438	chr19:56672574~56673901:-
LUAD	trans	rs12497850	0.931	rs7623023	ENSG00000197582.5	GPX1P1	8.17	2.81e-15	8.23e-09	0.45	0.35	Parkinson's disease;	chr3:48876805	chrX:13378735~13379340:-
LUAD	trans	rs9611519	0.58	rs7286603	ENSG00000268568.1	AC007228.9	-8.16	2.87e-15	8.38e-09	-0.44	-0.35	Neuroticism;	chr22:41044057	chr19:56672574~56673901:-
LUAD	trans	rs1355223	0.525	rs7129533	ENSG00000225531.1	RP11-196I18.3	8.16	2.9e-15	8.48e-09	0.43	0.35	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34850745	chr9:107116829~107117557:+
LUAD	trans	rs8067354	0.645	rs2645467	ENSG00000187870.7	RNFT1P3	8.16	2.96e-15	8.65e-09	0.5	0.35	Hemoglobin concentration;	chr17:59777422	chr17:20743333~20754501:-
LUAD	trans	rs12497850	0.931	rs6414613	ENSG00000197582.5	GPX1P1	8.16	3e-15	8.75e-09	0.46	0.35	Parkinson's disease;	chr3:48998452	chrX:13378735~13379340:-
LUAD	trans	rs9858542	1	rs4283605	ENSG00000197582.5	GPX1P1	-8.16	3.02e-15	8.81e-09	-0.48	-0.35	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49641218	chrX:13378735~13379340:-
LUAD	trans	rs6424115	1	rs58035855	ENSG00000228217.1	AL390877.1	8.16	3.03e-15	8.85e-09	0.44	0.35	Immature fraction of reticulocytes;	chr1:23838758	chr1:117778087~117778506:-
LUAD	trans	rs8010715	0.52	rs12435994	ENSG00000238000.1	RP11-274E7.2	8.16	3.03e-15	8.86e-09	0.39	0.35	IgG glycosylation;	chr14:24120252	chr5:98213402~98214121:+
LUAD	trans	rs8010715	0.596	rs12435995	ENSG00000238000.1	RP11-274E7.2	8.16	3.03e-15	8.86e-09	0.39	0.35	IgG glycosylation;	chr14:24120255	chr5:98213402~98214121:+
LUAD	trans	rs10940346	0.506	rs10454829	ENSG00000231752.4	EMBP1	-8.16	3.05e-15	8.9e-09	-0.48	-0.35	Schizophrenia;	chr5:50585120	chr1:121519112~121571892:+
LUAD	trans	rs10242455	0.571	rs11734	ENSG00000228834.1	RP11-249L21.4	-8.16	3.06e-15	8.93e-09	-0.83	-0.35	Blood metabolite levels;	chr7:99632145	chr6:108907615~108907873:-
LUAD	trans	rs3740713	1	rs73436668	ENSG00000235847.2	LDHAP7	8.15	3.06e-15	8.94e-09	0.63	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18421546	chr2:84777259~84778223:-
LUAD	trans	rs12497850	0.931	rs3774628	ENSG00000197582.5	GPX1P1	8.15	3.12e-15	9.09e-09	0.45	0.35	Parkinson's disease;	chr3:48764407	chrX:13378735~13379340:-
LUAD	trans	rs11638815	0.626	rs11635624	ENSG00000235370.6	DNM1P51	-8.15	3.18e-15	9.29e-09	-0.42	-0.35	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82646980	chr15:84398316~84411701:-
LUAD	trans	rs12497850	0.931	rs7628719	ENSG00000197582.5	GPX1P1	8.15	3.21e-15	9.36e-09	0.45	0.35	Parkinson's disease;	chr3:48958054	chrX:13378735~13379340:-
LUAD	trans	rs4276421	0.571	rs59968174	ENSG00000231752.4	EMBP1	8.15	3.25e-15	9.48e-09	0.49	0.35	P wave duration;	chr5:46027939	chr1:121519112~121571892:+
LUAD	trans	rs3740713	1	rs113497813	ENSG00000235847.2	LDHAP7	8.15	3.28e-15	9.57e-09	0.62	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18432127	chr2:84777259~84778223:-
LUAD	trans	rs13190036	0.551	rs7732930	ENSG00000228305.2	AC016734.2	-8.14	3.31e-15	9.64e-09	-0.44	-0.35	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177121593	chr2:63622178~63622831:-
LUAD	trans	rs877636	1	rs705696	ENSG00000196656.7	AC004057.1	8.14	3.37e-15	9.83e-09	0.38	0.35	Cognitive function;	chr12:56086864	chr4:113214046~113217170:-
LUAD	trans	rs877636	1	rs705696	ENSG00000224553.1	AC008065.1	8.14	3.41e-15	9.93e-09	0.37	0.35	Cognitive function;	chr12:56086864	chr2:171374931~171375278:-
LUAD	trans	rs8067354	0.574	rs1295923	ENSG00000187870.7	RNFT1P3	8.14	3.44e-15	1e-08	0.56	0.35	Hemoglobin concentration;	chr17:59883075	chr17:20743333~20754501:-
LUAD	trans	rs13014235	0.562	rs2080325	ENSG00000235105.1	RP11-329A14.1	-8.14	3.46e-15	1.01e-08	-0.41	-0.35	Basal cell carcinoma;	chr2:201513640	chr1:48435967~48437223:+
LUAD	trans	rs7662987	1	rs7684986	ENSG00000228407.2	RP4-800M22.1	8.13	3.55e-15	1.03e-08	0.72	0.35	Smoking initiation;	chr4:99070525	chr1:52160261~52160600:-
LUAD	trans	rs12497850	0.931	rs62262517	ENSG00000197582.5	GPX1P1	8.13	3.56e-15	1.04e-08	0.46	0.35	Parkinson's disease;	chr3:49097481	chrX:13378735~13379340:-
LUAD	trans	rs9611519	0.929	rs926914	ENSG00000268568.1	AC007228.9	-8.13	3.57e-15	1.04e-08	-0.51	-0.35	Neuroticism;	chr22:41022150	chr19:56672574~56673901:-
LUAD	trans	rs7662987	1	rs1061187	ENSG00000228407.2	RP4-800M22.1	8.13	3.58e-15	1.04e-08	0.72	0.35	Smoking initiation;	chr4:99071702	chr1:52160261~52160600:-
LUAD	trans	rs13190036	1	rs6880798	ENSG00000228305.2	AC016734.2	8.13	3.58e-15	1.04e-08	0.47	0.35	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177277456	chr2:63622178~63622831:-
LUAD	trans	rs7192380	0.737	rs7204433	ENSG00000257513.6	NPIPB1P	8.13	3.59e-15	1.04e-08	0.34	0.35	Sjögren's syndrome;	chr16:69556021	chr18:11619509~11639699:-
LUAD	trans	rs3740713	1	rs113036885	ENSG00000235847.2	LDHAP7	8.13	3.6e-15	1.04e-08	0.62	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18431185	chr2:84777259~84778223:-
LUAD	trans	rs3740713	1	rs112410494	ENSG00000235847.2	LDHAP7	8.13	3.6e-15	1.04e-08	0.62	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18431208	chr2:84777259~84778223:-
LUAD	trans	rs3740713	1	rs74741949	ENSG00000235847.2	LDHAP7	8.13	3.6e-15	1.04e-08	0.62	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18431501	chr2:84777259~84778223:-
LUAD	trans	rs3740713	1	rs61081934	ENSG00000235847.2	LDHAP7	8.13	3.6e-15	1.04e-08	0.62	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18432770	chr2:84777259~84778223:-
LUAD	trans	rs3740713	0.92	rs112818034	ENSG00000235847.2	LDHAP7	8.13	3.6e-15	1.04e-08	0.62	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18433633	chr2:84777259~84778223:-
LUAD	trans	rs3740713	1	rs76708296	ENSG00000235847.2	LDHAP7	8.13	3.6e-15	1.04e-08	0.62	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18434586	chr2:84777259~84778223:-
LUAD	trans	rs3740713	1	rs73438668	ENSG00000235847.2	LDHAP7	8.13	3.6e-15	1.04e-08	0.62	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18434989	chr2:84777259~84778223:-
LUAD	trans	rs3740713	1	rs75647856	ENSG00000235847.2	LDHAP7	8.13	3.6e-15	1.04e-08	0.62	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18438259	chr2:84777259~84778223:-
LUAD	trans	rs3740713	1	rs73438687	ENSG00000235847.2	LDHAP7	8.13	3.6e-15	1.04e-08	0.62	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18438312	chr2:84777259~84778223:-
LUAD	trans	rs3740713	1	rs74663287	ENSG00000235847.2	LDHAP7	8.13	3.6e-15	1.04e-08	0.62	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18438753	chr2:84777259~84778223:-
LUAD	trans	rs13416322	0.591	rs3748929	ENSG00000214286.2	PDCL3P3	8.13	3.65e-15	1.06e-08	0.46	0.35	Intelligence (multi-trait analysis);	chr2:100556794	chr3:17877455~17878169:-
LUAD	trans	rs12497850	0.897	rs6795025	ENSG00000197582.5	GPX1P1	8.13	3.66e-15	1.06e-08	0.46	0.35	Parkinson's disease;	chr3:49043814	chrX:13378735~13379340:-
LUAD	trans	rs7113874	0.659	rs67320655	ENSG00000266891.1	RP11-692N5.2	8.13	3.68e-15	1.07e-08	0.54	0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8497662	chr18:9734882~9735602:-
LUAD	trans	rs7113874	0.625	rs35760680	ENSG00000266891.1	RP11-692N5.2	8.13	3.68e-15	1.07e-08	0.54	0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8500525	chr18:9734882~9735602:-
LUAD	trans	rs7113874	0.659	rs2121313	ENSG00000266891.1	RP11-692N5.2	8.13	3.68e-15	1.07e-08	0.54	0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8501495	chr18:9734882~9735602:-
LUAD	trans	rs11638815	0.581	rs783535	ENSG00000235370.6	DNM1P51	-8.13	3.68e-15	1.07e-08	-0.43	-0.35	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82581676	chr15:84398316~84411701:-
LUAD	trans	rs3740713	1	rs73438699	ENSG00000235847.2	LDHAP7	8.13	3.75e-15	1.09e-08	0.62	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18441137	chr2:84777259~84778223:-
LUAD	trans	rs12497850	0.931	rs9311434	ENSG00000197582.5	GPX1P1	8.13	3.77e-15	1.09e-08	0.45	0.35	Parkinson's disease;	chr3:48846714	chrX:13378735~13379340:-
LUAD	trans	rs3740713	1	rs73440604	ENSG00000235847.2	LDHAP7	8.13	3.77e-15	1.09e-08	0.62	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18442124	chr2:84777259~84778223:-
LUAD	trans	rs3740713	1	rs73440610	ENSG00000235847.2	LDHAP7	8.13	3.77e-15	1.09e-08	0.62	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18442922	chr2:84777259~84778223:-
LUAD	trans	rs7032940	0.677	rs1331310	ENSG00000228236.2	TXNP5	8.13	3.79e-15	1.1e-08	0.39	0.35	Height;	chr9:110179601	chr2:149068596~149068910:-
LUAD	trans	rs6424115	0.83	rs3123554	ENSG00000228217.1	AL390877.1	8.12	3.9e-15	1.13e-08	0.43	0.35	Immature fraction of reticulocytes;	chr1:23869911	chr1:117778087~117778506:-
LUAD	trans	rs12497850	0.931	rs13064911	ENSG00000197582.5	GPX1P1	8.12	3.99e-15	1.15e-08	0.46	0.35	Parkinson's disease;	chr3:48914952	chrX:13378735~13379340:-
LUAD	trans	rs13416322	0.699	rs6730933	ENSG00000214286.2	PDCL3P3	8.12	4.02e-15	1.16e-08	0.46	0.35	Intelligence (multi-trait analysis);	chr2:100545642	chr3:17877455~17878169:-
LUAD	trans	rs9858542	1	rs9812791	ENSG00000197582.5	GPX1P1	-8.12	4.05e-15	1.17e-08	-0.48	-0.35	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49644878	chrX:13378735~13379340:-
LUAD	trans	rs2069408	1	rs2069408	ENSG00000243403.1	RP11-330L19.1	-8.12	4.06e-15	1.18e-08	-0.4	-0.35	Asthma;	chr12:55970537	chr15:64592979~64593326:+
LUAD	trans	rs877636	1	rs877636	ENSG00000224553.1	AC008065.1	-8.12	4.08e-15	1.18e-08	-0.36	-0.35	Cognitive function;	chr12:56086799	chr2:171374931~171375278:-
LUAD	trans	rs10037055	0.812	rs11949435	ENSG00000226986.4	RP11-543B16.2	8.11	4.12e-15	1.19e-08	0.41	0.35	Migraine without aura;	chr5:177287931	chr1:211207239~211207897:+
LUAD	trans	rs11638815	0.626	rs1313492	ENSG00000235370.6	DNM1P51	-8.11	4.38e-15	1.26e-08	-0.43	-0.35	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82604206	chr15:84398316~84411701:-
LUAD	trans	rs7554547	0.6	rs2180180	ENSG00000261819.1	RP11-680G24.4	-8.1	4.43e-15	1.28e-08	-0.47	-0.35	Nonsyndromic cleft lip with cleft palate;	chr1:11959312	chr16:14988259~14990160:-
LUAD	trans	rs7554511	0.893	rs11589573	ENSG00000244144.1	RP11-757F18.3	-8.1	4.48e-15	1.29e-08	-0.48	-0.35	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201005987	chr3:112185480~112185998:-
LUAD	trans	rs1614887	1	rs1614887	ENSG00000242375.1	RP11-498P14.3	8.1	4.48e-15	1.29e-08	0.45	0.35	Lobe attachment (rater-scored or self-reported);Intelligence (multi-trait analysis);	chr6:26392793	chr9:97195351~97197687:-
LUAD	trans	rs7032940	0.651	rs7873398	ENSG00000228236.2	TXNP5	8.1	4.51e-15	1.3e-08	0.38	0.35	Height;	chr9:110194413	chr2:149068596~149068910:-
LUAD	trans	rs7554511	0.861	rs10753888	ENSG00000244144.1	RP11-757F18.3	-8.1	4.59e-15	1.32e-08	-0.45	-0.35	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201037057	chr3:112185480~112185998:-
LUAD	trans	rs9611519	1	rs4820433	ENSG00000268568.1	AC007228.9	-8.1	4.6e-15	1.33e-08	-0.47	-0.35	Neuroticism;	chr22:41211061	chr19:56672574~56673901:-
LUAD	trans	rs9611519	1	rs3818003	ENSG00000268568.1	AC007228.9	-8.1	4.6e-15	1.33e-08	-0.47	-0.35	Neuroticism;	chr22:41213686	chr19:56672574~56673901:-
LUAD	trans	rs8010715	0.848	rs2277483	ENSG00000238000.1	RP11-274E7.2	8.1	4.66e-15	1.34e-08	0.39	0.35	IgG glycosylation;	chr14:24122683	chr5:98213402~98214121:+
LUAD	trans	rs8010715	0.848	rs8009511	ENSG00000238000.1	RP11-274E7.2	8.1	4.69e-15	1.35e-08	0.39	0.35	IgG glycosylation;	chr14:24124771	chr5:98213402~98214121:+
LUAD	trans	rs8010715	0.804	rs1134334	ENSG00000238000.1	RP11-274E7.2	8.1	4.69e-15	1.35e-08	0.39	0.35	IgG glycosylation;	chr14:24124905	chr5:98213402~98214121:+
LUAD	trans	rs12497850	0.931	rs9682444	ENSG00000197582.5	GPX1P1	8.09	4.75e-15	1.37e-08	0.46	0.35	Parkinson's disease;	chr3:48815206	chrX:13378735~13379340:-
LUAD	trans	rs12497850	0.931	rs9835307	ENSG00000197582.5	GPX1P1	8.09	4.75e-15	1.37e-08	0.46	0.35	Parkinson's disease;	chr3:48820372	chrX:13378735~13379340:-
LUAD	trans	rs12497850	0.866	rs6791234	ENSG00000197582.5	GPX1P1	8.09	4.76e-15	1.37e-08	0.46	0.35	Parkinson's disease;	chr3:48958704	chrX:13378735~13379340:-
LUAD	trans	rs13190036	0.551	rs4976639	ENSG00000228305.2	AC016734.2	8.09	4.78e-15	1.38e-08	0.44	0.35	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177123300	chr2:63622178~63622831:-
LUAD	trans	rs7662987	0.818	rs35123946	ENSG00000233859.2	ADH5P4	8.09	4.81e-15	1.38e-08	0.67	0.35	Smoking initiation;	chr4:99079760	chr6:65836930~65838039:-
LUAD	trans	rs12497850	0.931	rs7431710	ENSG00000197582.5	GPX1P1	8.09	4.82e-15	1.39e-08	0.45	0.35	Parkinson's disease;	chr3:48898150	chrX:13378735~13379340:-
LUAD	trans	rs12497850	0.543	rs6446218	ENSG00000197582.5	GPX1P1	8.09	4.89e-15	1.41e-08	0.46	0.35	Parkinson's disease;	chr3:49038080	chrX:13378735~13379340:-
LUAD	trans	rs9858542	1	rs9823546	ENSG00000197582.5	GPX1P1	-8.09	4.91e-15	1.41e-08	-0.47	-0.35	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49668079	chrX:13378735~13379340:-
LUAD	trans	rs9858542	1	rs11130213	ENSG00000197582.5	GPX1P1	-8.09	4.92e-15	1.42e-08	-0.47	-0.35	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49674864	chrX:13378735~13379340:-
LUAD	trans	rs9858542	1	rs1131095	ENSG00000197582.5	GPX1P1	-8.09	4.92e-15	1.42e-08	-0.47	-0.35	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49676792	chrX:13378735~13379340:-
LUAD	trans	rs11638815	0.581	rs28808991	ENSG00000235370.6	DNM1P51	-8.09	4.97e-15	1.43e-08	-0.42	-0.35	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82592229	chr15:84398316~84411701:-
LUAD	trans	rs7113874	0.592	rs10840057	ENSG00000266891.1	RP11-692N5.2	8.09	4.99e-15	1.43e-08	0.53	0.35	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8476681	chr18:9734882~9735602:-
LUAD	trans	rs4276421	0.509	rs10042628	ENSG00000231752.4	EMBP1	8.08	5.08e-15	1.46e-08	0.49	0.35	P wave duration;	chr5:46004627	chr1:121519112~121571892:+
LUAD	trans	rs6708331	0.887	rs6546565	ENSG00000232654.1	FAM136BP	8.08	5.34e-15	1.53e-08	0.44	0.35	Obesity-related traits;	chr2:70070173	chr6:3045384~3045800:+
LUAD	trans	rs3740713	1	rs79199586	ENSG00000235847.2	LDHAP7	8.08	5.38e-15	1.55e-08	0.64	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18430599	chr2:84777259~84778223:-
LUAD	trans	rs12497850	0.931	rs9755490	ENSG00000197582.5	GPX1P1	8.08	5.39e-15	1.55e-08	0.46	0.35	Parkinson's disease;	chr3:48834231	chrX:13378735~13379340:-
LUAD	trans	rs12497850	0.897	rs9681717	ENSG00000197582.5	GPX1P1	8.08	5.39e-15	1.55e-08	0.46	0.35	Parkinson's disease;	chr3:48835565	chrX:13378735~13379340:-
LUAD	trans	rs12497850	0.931	rs9840684	ENSG00000197582.5	GPX1P1	8.08	5.39e-15	1.55e-08	0.46	0.35	Parkinson's disease;	chr3:48856347	chrX:13378735~13379340:-
LUAD	trans	rs12497850	0.931	rs4974079	ENSG00000197582.5	GPX1P1	8.08	5.39e-15	1.55e-08	0.46	0.35	Parkinson's disease;	chr3:48869036	chrX:13378735~13379340:-
LUAD	trans	rs13416322	0.699	rs6716167	ENSG00000214286.2	PDCL3P3	8.08	5.41e-15	1.55e-08	0.47	0.35	Intelligence (multi-trait analysis);	chr2:100550092	chr3:17877455~17878169:-
LUAD	trans	rs7554511	0.894	rs11589638	ENSG00000244144.1	RP11-757F18.3	-8.07	5.49e-15	1.58e-08	-0.47	-0.35	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200925807	chr3:112185480~112185998:-
LUAD	trans	rs12497850	1	rs12497850	ENSG00000197582.5	GPX1P1	8.07	5.54e-15	1.59e-08	0.45	0.35	Parkinson's disease;	chr3:48711556	chrX:13378735~13379340:-
LUAD	trans	rs12497850	1	rs6788650	ENSG00000197582.5	GPX1P1	8.07	5.56e-15	1.6e-08	0.45	0.35	Parkinson's disease;	chr3:48712110	chrX:13378735~13379340:-
LUAD	trans	rs7192380	0.767	rs11641686	ENSG00000257513.6	NPIPB1P	8.07	5.64e-15	1.62e-08	0.35	0.35	Sjögren's syndrome;	chr16:69546496	chr18:11619509~11639699:-
LUAD	trans	rs7192380	0.737	rs11641722	ENSG00000257513.6	NPIPB1P	8.07	5.64e-15	1.62e-08	0.35	0.35	Sjögren's syndrome;	chr16:69546499	chr18:11619509~11639699:-
LUAD	trans	rs7554511	0.894	rs296545	ENSG00000244144.1	RP11-757F18.3	8.07	5.64e-15	1.62e-08	0.46	0.35	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200921564	chr3:112185480~112185998:-
LUAD	trans	rs3740713	1	rs73436645	ENSG00000235847.2	LDHAP7	8.07	5.66e-15	1.62e-08	0.61	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18419236	chr2:84777259~84778223:-
LUAD	trans	rs3740713	0.925	rs73436650	ENSG00000235847.2	LDHAP7	8.07	5.66e-15	1.62e-08	0.61	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18419751	chr2:84777259~84778223:-
LUAD	trans	rs3740713	1	rs73436655	ENSG00000235847.2	LDHAP7	8.07	5.66e-15	1.62e-08	0.61	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18420420	chr2:84777259~84778223:-
LUAD	trans	rs3740713	0.92	rs80254575	ENSG00000235847.2	LDHAP7	8.07	5.66e-15	1.62e-08	0.61	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18420919	chr2:84777259~84778223:-
LUAD	trans	rs3740713	1	rs73436662	ENSG00000235847.2	LDHAP7	8.07	5.66e-15	1.62e-08	0.61	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18421076	chr2:84777259~84778223:-
LUAD	trans	rs3740713	1	rs113725670	ENSG00000235847.2	LDHAP7	8.07	5.66e-15	1.62e-08	0.61	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18421753	chr2:84777259~84778223:-
LUAD	trans	rs3740713	1	rs73436682	ENSG00000235847.2	LDHAP7	8.07	5.66e-15	1.62e-08	0.61	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18422142	chr2:84777259~84778223:-
LUAD	trans	rs3740713	1	rs73436685	ENSG00000235847.2	LDHAP7	8.07	5.66e-15	1.62e-08	0.61	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18422229	chr2:84777259~84778223:-
LUAD	trans	rs3740713	1	rs2056781	ENSG00000235847.2	LDHAP7	8.07	5.66e-15	1.62e-08	0.61	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18423442	chr2:84777259~84778223:-
LUAD	trans	rs3740713	1	rs73436701	ENSG00000235847.2	LDHAP7	8.07	5.66e-15	1.62e-08	0.61	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18425116	chr2:84777259~84778223:-
LUAD	trans	rs3740713	1	rs73438607	ENSG00000235847.2	LDHAP7	8.07	5.66e-15	1.62e-08	0.61	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18425974	chr2:84777259~84778223:-
LUAD	trans	rs3740713	1	rs75010364	ENSG00000235847.2	LDHAP7	8.07	5.66e-15	1.62e-08	0.61	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18427419	chr2:84777259~84778223:-
LUAD	trans	rs3740713	1	rs73438627	ENSG00000235847.2	LDHAP7	8.07	5.66e-15	1.62e-08	0.61	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18430369	chr2:84777259~84778223:-
LUAD	trans	rs3740713	1	rs73438631	ENSG00000235847.2	LDHAP7	8.07	5.66e-15	1.62e-08	0.61	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18430571	chr2:84777259~84778223:-
LUAD	trans	rs3740713	1	rs73438634	ENSG00000235847.2	LDHAP7	8.07	5.66e-15	1.62e-08	0.61	0.35	Amyotrophic lateral sclerosis (sporadic);	chr11:18430809	chr2:84777259~84778223:-
LUAD	trans	rs12497850	0.931	rs7626445	ENSG00000197582.5	GPX1P1	8.06	5.88e-15	1.68e-08	0.45	0.35	Parkinson's disease;	chr3:49077111	chrX:13378735~13379340:-
LUAD	trans	rs7662987	1	rs17595424	ENSG00000228407.2	RP4-800M22.1	8.06	5.88e-15	1.68e-08	0.69	0.35	Smoking initiation;	chr4:99072718	chr1:52160261~52160600:-
LUAD	trans	rs9858542	1	rs9882740	ENSG00000197582.5	GPX1P1	-8.06	5.89e-15	1.68e-08	-0.47	-0.35	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49665051	chrX:13378735~13379340:-
LUAD	trans	rs1355223	0.506	rs7131272	ENSG00000225531.1	RP11-196I18.3	-8.06	5.98e-15	1.71e-08	-0.43	-0.35	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34848001	chr9:107116829~107117557:+
LUAD	trans	rs4276421	0.509	rs4504391	ENSG00000231752.4	EMBP1	8.06	6.15e-15	1.76e-08	0.49	0.34	P wave duration;	chr5:46035678	chr1:121519112~121571892:+
LUAD	trans	rs7554511	0.858	rs6701496	ENSG00000244144.1	RP11-757F18.3	-8.06	6.19e-15	1.77e-08	-0.48	-0.34	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201038700	chr3:112185480~112185998:-
LUAD	trans	rs3740713	1	rs73438604	ENSG00000235847.2	LDHAP7	8.06	6.2e-15	1.77e-08	0.61	0.34	Amyotrophic lateral sclerosis (sporadic);	chr11:18425556	chr2:84777259~84778223:-
LUAD	trans	rs12497850	0.931	rs13315711	ENSG00000197582.5	GPX1P1	8.06	6.25e-15	1.79e-08	0.45	0.34	Parkinson's disease;	chr3:48948966	chrX:13378735~13379340:-
LUAD	trans	rs7554511	0.893	rs55862304	ENSG00000244144.1	RP11-757F18.3	-8.06	6.28e-15	1.79e-08	-0.48	-0.34	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201020647	chr3:112185480~112185998:-
LUAD	trans	rs13014235	0.532	rs3731709	ENSG00000235105.1	RP11-329A14.1	8.05	6.36e-15	1.82e-08	0.41	0.34	Basal cell carcinoma;	chr2:201381311	chr1:48435967~48437223:+
LUAD	trans	rs12497850	0.931	rs28642807	ENSG00000197582.5	GPX1P1	8.05	6.38e-15	1.82e-08	0.45	0.34	Parkinson's disease;	chr3:48889383	chrX:13378735~13379340:-
LUAD	trans	rs7554511	0.894	rs296546	ENSG00000244144.1	RP11-757F18.3	8.05	6.43e-15	1.84e-08	0.46	0.34	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200921963	chr3:112185480~112185998:-
LUAD	trans	rs12497850	0.931	rs9840050	ENSG00000197582.5	GPX1P1	8.05	6.46e-15	1.84e-08	0.45	0.34	Parkinson's disease;	chr3:49095877	chrX:13378735~13379340:-
LUAD	trans	rs2134046	0.555	rs11854483	ENSG00000235370.6	DNM1P51	-8.05	6.5e-15	1.86e-08	-0.4	-0.34	Cognitive ability;	chr15:82267217	chr15:84398316~84411701:-
LUAD	trans	rs13014235	0.532	rs11681592	ENSG00000235105.1	RP11-329A14.1	8.05	6.56e-15	1.87e-08	0.41	0.34	Basal cell carcinoma;	chr2:201399178	chr1:48435967~48437223:+
LUAD	trans	rs877636	0.669	rs7297175	ENSG00000244604.1	RP11-713H12.1	-8.05	6.73e-15	1.92e-08	-0.38	-0.34	Cognitive function;	chr12:56080024	chr17:8561230~8561576:+
LUAD	trans	rs7312770	1	rs7312770	ENSG00000196656.7	AC004057.1	-8.05	6.76e-15	1.93e-08	-0.35	-0.34	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr4:113214046~113217170:-
LUAD	trans	rs12497850	0.829	rs8926	ENSG00000197582.5	GPX1P1	8.04	6.88e-15	1.96e-08	0.46	0.34	Parkinson's disease;	chr3:49015352	chrX:13378735~13379340:-
LUAD	trans	rs7192380	0.729	rs11648335	ENSG00000257513.6	NPIPB1P	8.04	7.2e-15	2.05e-08	0.34	0.34	Sjögren's syndrome;	chr16:69563414	chr18:11619509~11639699:-
LUAD	trans	rs1355223	0.525	rs7129517	ENSG00000225531.1	RP11-196I18.3	8.04	7.23e-15	2.06e-08	0.42	0.34	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34850689	chr9:107116829~107117557:+
LUAD	trans	rs877636	0.702	rs773109	ENSG00000234513.1	AC073072.7	8.03	7.39e-15	2.1e-08	0.42	0.34	Cognitive function;	chr12:55980911	chr7:22773646~22773993:-
LUAD	trans	rs6424115	0.83	rs12744386	ENSG00000228217.1	AL390877.1	8.03	7.45e-15	2.12e-08	0.45	0.34	Immature fraction of reticulocytes;	chr1:23841529	chr1:117778087~117778506:-
LUAD	trans	rs877636	0.702	rs773110	ENSG00000234513.1	AC073072.7	8.03	7.49e-15	2.13e-08	0.42	0.34	Cognitive function;	chr12:55981353	chr7:22773646~22773993:-
LUAD	trans	rs877636	0.702	rs773111	ENSG00000234513.1	AC073072.7	8.03	7.49e-15	2.13e-08	0.42	0.34	Cognitive function;	chr12:55981956	chr7:22773646~22773993:-
LUAD	trans	rs877636	0.702	rs773112	ENSG00000234513.1	AC073072.7	8.03	7.49e-15	2.13e-08	0.42	0.34	Cognitive function;	chr12:55982097	chr7:22773646~22773993:-
LUAD	trans	rs7554511	0.893	rs11580823	ENSG00000244144.1	RP11-757F18.3	-8.03	7.62e-15	2.16e-08	-0.48	-0.34	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201014361	chr3:112185480~112185998:-
LUAD	trans	rs36064799	1	rs36064799	ENSG00000234130.2	RP13-88F20.1	8.03	7.81e-15	2.22e-08	0.87	0.34	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:35553480	chrX:93222220~93225015:-
LUAD	trans	rs1355223	0.506	rs6484738	ENSG00000225531.1	RP11-196I18.3	8.02	7.92e-15	2.25e-08	0.43	0.34	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34839311	chr9:107116829~107117557:+
LUAD	trans	rs12497850	0.931	rs4974087	ENSG00000197582.5	GPX1P1	8.02	8.12e-15	2.3e-08	0.45	0.34	Parkinson's disease;	chr3:48881799	chrX:13378735~13379340:-
LUAD	trans	rs6708331	0.752	rs7558246	ENSG00000232654.1	FAM136BP	8.02	8.21e-15	2.33e-08	0.43	0.34	Obesity-related traits;	chr2:69975481	chr6:3045384~3045800:+
LUAD	trans	rs877636	0.702	rs61937249	ENSG00000234513.1	AC073072.7	8.02	8.22e-15	2.33e-08	0.42	0.34	Cognitive function;	chr12:55988132	chr7:22773646~22773993:-
LUAD	trans	rs7032940	0.677	rs4279674	ENSG00000228236.2	TXNP5	8.02	8.22e-15	2.33e-08	0.39	0.34	Height;	chr9:110179726	chr2:149068596~149068910:-
LUAD	trans	rs9858542	1	rs2172252	ENSG00000197582.5	GPX1P1	-8.02	8.28e-15	2.35e-08	-0.48	-0.34	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49640874	chrX:13378735~13379340:-
LUAD	trans	rs7113874	0.625	rs16938253	ENSG00000266891.1	RP11-692N5.2	8.02	8.38e-15	2.38e-08	0.52	0.34	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8478833	chr18:9734882~9735602:-
LUAD	trans	rs877636	0.702	rs773108	ENSG00000235459.5	RPS26P31	8.01	8.48e-15	2.4e-08	0.4	0.34	Cognitive function;	chr12:55976127	chr7:122681315~122681662:+
LUAD	trans	rs12497850	1	rs10865952	ENSG00000197582.5	GPX1P1	8.01	8.52e-15	2.41e-08	0.45	0.34	Parkinson's disease;	chr3:48707051	chrX:13378735~13379340:-
LUAD	trans	rs6424115	0.867	rs4649119	ENSG00000228217.1	AL390877.1	8.01	8.6e-15	2.44e-08	0.45	0.34	Immature fraction of reticulocytes;	chr1:23845053	chr1:117778087~117778506:-
LUAD	trans	rs6424115	0.867	rs10917431	ENSG00000228217.1	AL390877.1	8.01	8.6e-15	2.44e-08	0.45	0.34	Immature fraction of reticulocytes;	chr1:23847603	chr1:117778087~117778506:-
LUAD	trans	rs12497850	0.931	rs7627404	ENSG00000197582.5	GPX1P1	8.01	8.61e-15	2.44e-08	0.45	0.34	Parkinson's disease;	chr3:48782235	chrX:13378735~13379340:-
LUAD	trans	rs11638815	0.581	rs783537	ENSG00000235370.6	DNM1P51	-8.01	8.67e-15	2.45e-08	-0.43	-0.34	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82584058	chr15:84398316~84411701:-
LUAD	trans	rs7662987	1	rs6852848	ENSG00000228407.2	RP4-800M22.1	-8.01	8.68e-15	2.46e-08	-0.69	-0.34	Smoking initiation;	chr4:99080781	chr1:52160261~52160600:-
LUAD	trans	rs12497850	0.931	rs9876848	ENSG00000197582.5	GPX1P1	8.01	8.69e-15	2.46e-08	0.45	0.34	Parkinson's disease;	chr3:48806626	chrX:13378735~13379340:-
LUAD	trans	rs13014235	0.532	rs6729982	ENSG00000235105.1	RP11-329A14.1	8.01	8.7e-15	2.46e-08	0.41	0.34	Basal cell carcinoma;	chr2:201416413	chr1:48435967~48437223:+
LUAD	trans	rs13014235	0.532	rs10497867	ENSG00000235105.1	RP11-329A14.1	8.01	8.7e-15	2.46e-08	0.41	0.34	Basal cell carcinoma;	chr2:201420144	chr1:48435967~48437223:+
LUAD	trans	rs916888	0.687	rs199456	ENSG00000204650.12	CRHR1-IT1	8.01	8.72e-15	2.47e-08	0.48	0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45620328~45648216:+
LUAD	trans	rs13014235	0.532	rs13029007	ENSG00000235105.1	RP11-329A14.1	8.01	8.75e-15	2.48e-08	0.41	0.34	Basal cell carcinoma;	chr2:201400154	chr1:48435967~48437223:+
LUAD	trans	rs6732160	0.624	rs10865397	ENSG00000236165.1	PRADC1P1	8.01	8.88e-15	2.51e-08	0.46	0.34	Intelligence (multi-trait analysis);	chr2:73131164	chr3:36976316~36976840:+
LUAD	trans	rs12497850	0.897	rs7373778	ENSG00000197582.5	GPX1P1	8	9.17e-15	2.59e-08	0.45	0.34	Parkinson's disease;	chr3:48798959	chrX:13378735~13379340:-
LUAD	trans	rs12497850	0.931	rs7616815	ENSG00000197582.5	GPX1P1	8	9.19e-15	2.6e-08	0.45	0.34	Parkinson's disease;	chr3:48742282	chrX:13378735~13379340:-
LUAD	trans	rs4713118	0.662	rs4713120	ENSG00000204709.4	LINC01556	8	9.49e-15	2.68e-08	0.42	0.34	Parkinson's disease;	chr6:27754056	chr6:28943877~28944537:+
LUAD	trans	rs12497850	0.897	rs7432989	ENSG00000197582.5	GPX1P1	8	9.54e-15	2.7e-08	0.45	0.34	Parkinson's disease;	chr3:49067703	chrX:13378735~13379340:-
LUAD	trans	rs6708331	0.793	rs6546566	ENSG00000232654.1	FAM136BP	8	9.63e-15	2.72e-08	0.43	0.34	Obesity-related traits;	chr2:70070865	chr6:3045384~3045800:+
LUAD	trans	rs8067354	0.574	rs2526358	ENSG00000187870.7	RNFT1P3	8	9.69e-15	2.74e-08	0.56	0.34	Hemoglobin concentration;	chr17:59865224	chr17:20743333~20754501:-
LUAD	trans	rs12497850	0.931	rs13064784	ENSG00000197582.5	GPX1P1	8	9.71e-15	2.74e-08	0.45	0.34	Parkinson's disease;	chr3:49098528	chrX:13378735~13379340:-
LUAD	trans	rs877636	1	rs4759229	ENSG00000196656.7	AC004057.1	-7.99	9.71e-15	2.74e-08	-0.37	-0.34	Cognitive function;	chr12:56080696	chr4:113214046~113217170:-
LUAD	trans	rs7312770	0.612	rs773114	ENSG00000243538.1	CTB-55B8.1	7.99	9.75e-15	2.75e-08	0.36	0.34	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr5:16902294~16902641:-
LUAD	trans	rs11638815	0.603	rs783520	ENSG00000235370.6	DNM1P51	-7.99	9.81e-15	2.77e-08	-0.42	-0.34	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82610755	chr15:84398316~84411701:-
LUAD	trans	rs4276421	0.638	rs10061699	ENSG00000231752.4	EMBP1	7.99	9.84e-15	2.78e-08	0.48	0.34	P wave duration;	chr5:45864788	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.638	rs4282323	ENSG00000231752.4	EMBP1	7.99	9.84e-15	2.78e-08	0.48	0.34	P wave duration;	chr5:45865241	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.638	rs4283798	ENSG00000231752.4	EMBP1	7.99	9.84e-15	2.78e-08	0.48	0.34	P wave duration;	chr5:45866041	chr1:121519112~121571892:+
LUAD	trans	rs7554511	0.894	rs2297909	ENSG00000244144.1	RP11-757F18.3	-7.99	9.88e-15	2.79e-08	-0.45	-0.34	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200991179	chr3:112185480~112185998:-
LUAD	trans	rs916888	0.773	rs199448	ENSG00000204650.12	CRHR1-IT1	7.99	1e-14	2.83e-08	0.47	0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45620328~45648216:+
LUAD	trans	rs616147	0.962	rs1708104	ENSG00000214263.2	RPSAP53	-7.99	1.01e-14	2.84e-08	-0.47	-0.34	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39493251	chr13:67266845~67267706:-
LUAD	trans	rs7312770	0.612	rs1873914	ENSG00000243538.1	CTB-55B8.1	7.98	1.05e-14	2.95e-08	0.36	0.34	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr5:16902294~16902641:-
LUAD	trans	rs12497850	0.931	rs13316620	ENSG00000197582.5	GPX1P1	7.98	1.06e-14	2.97e-08	0.46	0.34	Parkinson's disease;	chr3:49007922	chrX:13378735~13379340:-
LUAD	trans	rs7554511	0.861	rs10920074	ENSG00000244144.1	RP11-757F18.3	-7.98	1.07e-14	3e-08	-0.47	-0.34	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200943599	chr3:112185480~112185998:-
LUAD	trans	rs2069408	1	rs2069408	ENSG00000225071.1	GS1-184P14.2	-7.98	1.07e-14	3.01e-08	-0.41	-0.34	Asthma;	chr12:55970537	chrX:24429573~24429920:-
LUAD	trans	rs6424115	1	rs6424115	ENSG00000228217.1	AL390877.1	7.98	1.07e-14	3.02e-08	0.43	0.34	Immature fraction of reticulocytes;	chr1:23826741	chr1:117778087~117778506:-
LUAD	trans	rs7503168	1	rs12604067	ENSG00000234130.2	RP13-88F20.1	7.98	1.07e-14	3.02e-08	0.45	0.34	Plateletcrit;	chr17:35625084	chrX:93222220~93225015:-
LUAD	trans	rs7503168	0.73	rs11655803	ENSG00000234130.2	RP13-88F20.1	7.98	1.07e-14	3.02e-08	0.45	0.34	Plateletcrit;	chr17:35625677	chrX:93222220~93225015:-
LUAD	trans	rs877636	0.74	rs772920	ENSG00000227887.1	RPS26P13	7.98	1.07e-14	3.02e-08	0.41	0.34	Cognitive function;	chr12:55996580	chr1:208697369~208697698:-
LUAD	trans	rs4276421	0.615	rs4626346	ENSG00000231752.4	EMBP1	7.98	1.1e-14	3.08e-08	0.5	0.34	P wave duration;	chr5:45857435	chr1:121519112~121571892:+
LUAD	trans	rs877636	0.74	rs705698	ENSG00000235459.5	RPS26P31	7.97	1.14e-14	3.21e-08	0.39	0.34	Cognitive function;	chr12:55990903	chr7:122681315~122681662:+
LUAD	trans	rs877636	1	rs705696	ENSG00000234354.3	RPS26P47	7.97	1.15e-14	3.22e-08	0.39	0.34	Cognitive function;	chr12:56086864	chr13:100539901~100540248:-
LUAD	trans	rs7260598	0.535	rs13343732	ENSG00000261770.1	CTC-459F4.1	7.97	1.16e-14	3.27e-08	0.45	0.34	Response to taxane treatment (placlitaxel);	chr19:23928479	chr19:27757184~27760849:-
LUAD	trans	rs12497850	1	rs4858828	ENSG00000197582.5	GPX1P1	7.97	1.17e-14	3.29e-08	0.44	0.34	Parkinson's disease;	chr3:48687378	chrX:13378735~13379340:-
LUAD	trans	rs12497850	0.863	rs4858799	ENSG00000197582.5	GPX1P1	7.97	1.17e-14	3.29e-08	0.45	0.34	Parkinson's disease;	chr3:48690771	chrX:13378735~13379340:-
LUAD	trans	rs12497850	0.897	rs9884022	ENSG00000197582.5	GPX1P1	7.97	1.2e-14	3.36e-08	0.45	0.34	Parkinson's disease;	chr3:48919429	chrX:13378735~13379340:-
LUAD	trans	rs12497850	0.897	rs6446252	ENSG00000197582.5	GPX1P1	7.97	1.2e-14	3.37e-08	0.45	0.34	Parkinson's disease;	chr3:48873692	chrX:13378735~13379340:-
LUAD	trans	rs10037055	0.853	rs4976680	ENSG00000226986.4	RP11-543B16.2	7.97	1.2e-14	3.37e-08	0.4	0.34	Migraine without aura;	chr5:177275745	chr1:211207239~211207897:+
LUAD	trans	rs4276421	0.571	rs6414908	ENSG00000231752.4	EMBP1	7.96	1.25e-14	3.51e-08	0.48	0.34	P wave duration;	chr5:45879332	chr1:121519112~121571892:+
LUAD	trans	rs12497850	0.931	rs11924597	ENSG00000197582.5	GPX1P1	7.96	1.26e-14	3.54e-08	0.45	0.34	Parkinson's disease;	chr3:48900357	chrX:13378735~13379340:-
LUAD	trans	rs10037055	0.853	rs4976681	ENSG00000226986.4	RP11-543B16.2	7.95	1.31e-14	3.67e-08	0.4	0.34	Migraine without aura;	chr5:177277662	chr1:211207239~211207897:+
LUAD	trans	rs6708331	0.887	rs13016716	ENSG00000232654.1	FAM136BP	7.95	1.34e-14	3.75e-08	0.43	0.34	Obesity-related traits;	chr2:70036128	chr6:3045384~3045800:+
LUAD	trans	rs12497850	0.931	rs4974080	ENSG00000197582.5	GPX1P1	7.95	1.34e-14	3.76e-08	0.45	0.34	Parkinson's disease;	chr3:48993395	chrX:13378735~13379340:-
LUAD	trans	rs3740713	1	rs73440637	ENSG00000235847.2	LDHAP7	7.95	1.35e-14	3.79e-08	0.65	0.34	Amyotrophic lateral sclerosis (sporadic);	chr11:18452581	chr2:84777259~84778223:-
LUAD	trans	rs877636	0.859	rs3741499	ENSG00000234354.3	RPS26P47	-7.95	1.36e-14	3.79e-08	-0.37	-0.34	Cognitive function;	chr12:56080595	chr13:100539901~100540248:-
LUAD	trans	rs1039766	1	rs268853	ENSG00000224334.1	AP000357.4	7.95	1.37e-14	3.82e-08	0.56	0.34	Lung adenocarcinoma;Lung cancer;	chr2:65250869	chr22:24686923~24688087:+
LUAD	trans	rs7662987	1	rs1803037	ENSG00000233859.2	ADH5P4	7.95	1.37e-14	3.84e-08	0.52	0.34	Smoking initiation;	chr4:99072000	chr6:65836930~65838039:-
LUAD	trans	rs13086611	1	rs13086611	ENSG00000197582.5	GPX1P1	-7.94	1.42e-14	3.97e-08	-0.47	-0.34	Educational attainment;	chr3:49347984	chrX:13378735~13379340:-
LUAD	trans	rs2288327	0.557	rs60488846	ENSG00000269800.1	PLEKHA3P1	7.94	1.43e-14	4e-08	0.47	0.34	Atrial fibrillation;	chr2:178493115	chr19:41521043~41521989:-
LUAD	trans	rs12497850	0.897	rs9850134	ENSG00000197582.5	GPX1P1	7.94	1.45e-14	4.05e-08	0.45	0.34	Parkinson's disease;	chr3:48919714	chrX:13378735~13379340:-
LUAD	trans	rs12497850	0.931	rs9867373	ENSG00000197582.5	GPX1P1	7.94	1.45e-14	4.05e-08	0.45	0.34	Parkinson's disease;	chr3:48923505	chrX:13378735~13379340:-
LUAD	trans	rs6424115	0.79	rs72874118	ENSG00000228217.1	AL390877.1	7.93	1.5e-14	4.17e-08	0.44	0.34	Immature fraction of reticulocytes;	chr1:23851310	chr1:117778087~117778506:-
LUAD	trans	rs6915893	0.669	rs10456213	ENSG00000267156.1	TPMTP1	7.93	1.51e-14	4.21e-08	0.42	0.34	Intrinsic epigenetic age acceleration;	chr6:18118881	chr18:47630112~47630848:+
LUAD	trans	rs12497850	0.931	rs4072859	ENSG00000197582.5	GPX1P1	7.93	1.56e-14	4.35e-08	0.45	0.34	Parkinson's disease;	chr3:48994772	chrX:13378735~13379340:-
LUAD	trans	rs877636	1	rs4759229	ENSG00000224553.1	AC008065.1	-7.92	1.61e-14	4.48e-08	-0.36	-0.34	Cognitive function;	chr12:56080696	chr2:171374931~171375278:-
LUAD	trans	rs7503168	1	rs16971217	ENSG00000234130.2	RP13-88F20.1	7.92	1.63e-14	4.54e-08	0.45	0.34	Plateletcrit;	chr17:35617036	chrX:93222220~93225015:-
LUAD	trans	rs2288327	0.557	rs7588593	ENSG00000269800.1	PLEKHA3P1	7.92	1.64e-14	4.56e-08	0.47	0.34	Atrial fibrillation;	chr2:178487723	chr19:41521043~41521989:-
LUAD	trans	rs2288327	0.557	rs7577862	ENSG00000269800.1	PLEKHA3P1	7.92	1.64e-14	4.56e-08	0.47	0.34	Atrial fibrillation;	chr2:178488130	chr19:41521043~41521989:-
LUAD	trans	rs58106596	0.8	rs11693819	ENSG00000259020.3	RP11-529H20.3	7.92	1.64e-14	4.57e-08	0.49	0.34	Lymphocyte counts;White blood cell count;	chr2:231701496	chr14:92026566~92026887:+
LUAD	trans	rs12497850	0.805	rs11130176	ENSG00000197582.5	GPX1P1	7.92	1.64e-14	4.57e-08	0.45	0.34	Parkinson's disease;	chr3:48806644	chrX:13378735~13379340:-
LUAD	trans	rs12497850	0.931	rs9311430	ENSG00000197582.5	GPX1P1	7.92	1.64e-14	4.57e-08	0.45	0.34	Parkinson's disease;	chr3:48807818	chrX:13378735~13379340:-
LUAD	trans	rs7554511	0.894	rs11579874	ENSG00000244144.1	RP11-757F18.3	7.92	1.72e-14	4.77e-08	0.46	0.34	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200951234	chr3:112185480~112185998:-
LUAD	trans	rs8067354	0.574	rs1292043	ENSG00000187870.7	RNFT1P3	7.91	1.73e-14	4.79e-08	0.54	0.34	Hemoglobin concentration;	chr17:59856808	chr17:20743333~20754501:-
LUAD	trans	rs12497850	0.931	rs7636057	ENSG00000197582.5	GPX1P1	7.91	1.74e-14	4.84e-08	0.45	0.34	Parkinson's disease;	chr3:48955149	chrX:13378735~13379340:-
LUAD	trans	rs12497850	0.931	rs7643368	ENSG00000197582.5	GPX1P1	7.91	1.74e-14	4.84e-08	0.45	0.34	Parkinson's disease;	chr3:48955422	chrX:13378735~13379340:-
LUAD	trans	rs12145833	0.596	rs3926866	ENSG00000154608.12	CEP170P1	-7.91	1.76e-14	4.89e-08	-0.66	-0.34	Obesity (early onset extreme);	chr1:243274330	chr4:118467590~118554204:+
LUAD	trans	rs9858542	1	rs11718165	ENSG00000197582.5	GPX1P1	-7.91	1.79e-14	4.95e-08	-0.46	-0.34	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49659364	chrX:13378735~13379340:-
LUAD	trans	rs9858542	1	rs9858542	ENSG00000197582.5	GPX1P1	7.91	1.81e-14	5.03e-08	0.46	0.34	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49664550	chrX:13378735~13379340:-
LUAD	trans	rs12497850	0.931	rs9311432	ENSG00000197582.5	GPX1P1	7.91	1.83e-14	5.07e-08	0.44	0.34	Parkinson's disease;	chr3:48813010	chrX:13378735~13379340:-
LUAD	trans	rs10242455	1	rs17161692	ENSG00000228834.1	RP11-249L21.4	-7.91	1.84e-14	5.1e-08	-0.7	-0.34	Blood metabolite levels;	chr7:99356240	chr6:108907615~108907873:-
LUAD	trans	rs8067354	0.574	rs1292033	ENSG00000187870.7	RNFT1P3	7.91	1.84e-14	5.11e-08	0.54	0.34	Hemoglobin concentration;	chr17:59913236	chr17:20743333~20754501:-
LUAD	trans	rs6424115	1	rs12116511	ENSG00000228217.1	AL390877.1	7.9	1.85e-14	5.13e-08	0.43	0.34	Immature fraction of reticulocytes;	chr1:23836172	chr1:117778087~117778506:-
LUAD	trans	rs877636	0.702	rs773108	ENSG00000234513.1	AC073072.7	7.9	1.85e-14	5.14e-08	0.42	0.34	Cognitive function;	chr12:55976127	chr7:22773646~22773993:-
LUAD	trans	rs7554511	0.823	rs67602696	ENSG00000244144.1	RP11-757F18.3	-7.9	1.86e-14	5.16e-08	-0.47	-0.34	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201043809	chr3:112185480~112185998:-
LUAD	trans	rs7503168	1	rs9894057	ENSG00000234130.2	RP13-88F20.1	7.9	1.87e-14	5.18e-08	0.45	0.34	Plateletcrit;	chr17:35562904	chrX:93222220~93225015:-
LUAD	trans	rs6424115	1	rs4649115	ENSG00000228217.1	AL390877.1	7.9	1.9e-14	5.26e-08	0.43	0.34	Immature fraction of reticulocytes;	chr1:23829241	chr1:117778087~117778506:-
LUAD	trans	rs916888	0.773	rs199457	ENSG00000204650.12	CRHR1-IT1	7.9	1.92e-14	5.32e-08	0.48	0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45620328~45648216:+
LUAD	trans	rs916888	0.773	rs1378358	ENSG00000204650.12	CRHR1-IT1	7.9	1.94e-14	5.36e-08	0.48	0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45620328~45648216:+
LUAD	trans	rs7312770	0.637	rs705700	ENSG00000243538.1	CTB-55B8.1	7.89	1.99e-14	5.5e-08	0.36	0.34	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr5:16902294~16902641:-
LUAD	trans	rs877636	0.859	rs3741499	ENSG00000224553.1	AC008065.1	-7.89	2e-14	5.53e-08	-0.35	-0.34	Cognitive function;	chr12:56080595	chr2:171374931~171375278:-
LUAD	trans	rs6424115	1	rs2179395	ENSG00000228217.1	AL390877.1	-7.89	2.01e-14	5.56e-08	-0.43	-0.34	Immature fraction of reticulocytes;	chr1:23821875	chr1:117778087~117778506:-
LUAD	trans	rs7113874	0.559	rs34378489	ENSG00000266891.1	RP11-692N5.2	7.89	2.01e-14	5.57e-08	0.52	0.34	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8407803	chr18:9734882~9735602:-
LUAD	trans	rs8067354	0.574	rs1291947	ENSG00000187870.7	RNFT1P3	7.89	2.04e-14	5.63e-08	0.54	0.34	Hemoglobin concentration;	chr17:59918975	chr17:20743333~20754501:-
LUAD	trans	rs616147	0.962	rs545397	ENSG00000214263.2	RPSAP53	7.89	2.05e-14	5.67e-08	0.46	0.34	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39488592	chr13:67266845~67267706:-
LUAD	trans	rs12497850	0.931	rs7647813	ENSG00000197582.5	GPX1P1	7.89	2.05e-14	5.67e-08	0.44	0.34	Parkinson's disease;	chr3:48795915	chrX:13378735~13379340:-
LUAD	trans	rs12497850	0.931	rs9311433	ENSG00000197582.5	GPX1P1	7.89	2.06e-14	5.69e-08	0.44	0.34	Parkinson's disease;	chr3:48826402	chrX:13378735~13379340:-
LUAD	trans	rs12497850	0.931	rs7430501	ENSG00000197582.5	GPX1P1	7.89	2.06e-14	5.69e-08	0.44	0.34	Parkinson's disease;	chr3:48852686	chrX:13378735~13379340:-
LUAD	trans	rs12497850	0.931	rs10780033	ENSG00000197582.5	GPX1P1	7.89	2.06e-14	5.69e-08	0.44	0.34	Parkinson's disease;	chr3:48853842	chrX:13378735~13379340:-
LUAD	trans	rs12497850	0.864	rs7431857	ENSG00000197582.5	GPX1P1	7.89	2.06e-14	5.69e-08	0.44	0.34	Parkinson's disease;	chr3:48862914	chrX:13378735~13379340:-
LUAD	trans	rs8067354	0.574	rs2526353	ENSG00000187870.7	RNFT1P3	7.89	2.08e-14	5.73e-08	0.55	0.34	Hemoglobin concentration;	chr17:59911246	chr17:20743333~20754501:-
LUAD	trans	rs8067354	0.574	rs1292035	ENSG00000187870.7	RNFT1P3	7.89	2.08e-14	5.73e-08	0.55	0.34	Hemoglobin concentration;	chr17:59912196	chr17:20743333~20754501:-
LUAD	trans	rs9425766	0.888	rs1799876	ENSG00000213331.4	RP11-713C19.2	7.89	2.08e-14	5.75e-08	0.41	0.34	Life satisfaction;	chr1:173909333	chr4:187970273~187971284:+
LUAD	trans	rs10037055	0.853	rs6890580	ENSG00000226986.4	RP11-543B16.2	-7.89	2.1e-14	5.81e-08	-0.4	-0.34	Migraine without aura;	chr5:177226519	chr1:211207239~211207897:+
LUAD	trans	rs8067354	0.507	rs2645478	ENSG00000187870.7	RNFT1P3	7.89	2.1e-14	5.81e-08	0.54	0.34	Hemoglobin concentration;	chr17:59937351	chr17:20743333~20754501:-
LUAD	trans	rs9858213	1	rs9858213	ENSG00000197582.5	GPX1P1	-7.89	2.11e-14	5.81e-08	-0.47	-0.34	Educational attainment;	chr3:49694428	chrX:13378735~13379340:-
LUAD	trans	rs7113874	0.592	rs10500703	ENSG00000266891.1	RP11-692N5.2	7.89	2.11e-14	5.84e-08	0.52	0.34	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8412317	chr18:9734882~9735602:-
LUAD	trans	rs9858542	1	rs3197999	ENSG00000197582.5	GPX1P1	-7.88	2.15e-14	5.94e-08	-0.48	-0.34	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49684099	chrX:13378735~13379340:-
LUAD	trans	rs616147	1	rs1768208	ENSG00000214263.2	RPSAP53	-7.88	2.17e-14	5.98e-08	-0.46	-0.34	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39481512	chr13:67266845~67267706:-
LUAD	trans	rs8067354	0.574	rs7219089	ENSG00000187870.7	RNFT1P3	7.88	2.19e-14	6.04e-08	0.55	0.34	Hemoglobin concentration;	chr17:59955504	chr17:20743333~20754501:-
LUAD	trans	rs616147	0.962	rs1513219	ENSG00000214263.2	RPSAP53	7.88	2.21e-14	6.09e-08	0.46	0.34	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39492268	chr13:67266845~67267706:-
LUAD	trans	rs12497850	0.931	rs7621015	ENSG00000197582.5	GPX1P1	7.88	2.22e-14	6.11e-08	0.44	0.34	Parkinson's disease;	chr3:48978623	chrX:13378735~13379340:-
LUAD	trans	rs9611519	1	rs2273085	ENSG00000268568.1	AC007228.9	-7.88	2.26e-14	6.23e-08	-0.46	-0.34	Neuroticism;	chr22:41219372	chr19:56672574~56673901:-
LUAD	trans	rs7554511	0.825	rs12122809	ENSG00000244144.1	RP11-757F18.3	-7.88	2.28e-14	6.27e-08	-0.47	-0.34	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201045838	chr3:112185480~112185998:-
LUAD	trans	rs877636	0.74	rs705702	ENSG00000227887.1	RPS26P13	-7.87	2.33e-14	6.42e-08	-0.41	-0.34	Cognitive function;	chr12:55996852	chr1:208697369~208697698:-
LUAD	trans	rs7503168	0.908	rs9907772	ENSG00000234130.2	RP13-88F20.1	7.87	2.33e-14	6.42e-08	0.45	0.34	Plateletcrit;	chr17:35673609	chrX:93222220~93225015:-
LUAD	trans	rs11638815	0.603	rs10162807	ENSG00000235370.6	DNM1P51	-7.87	2.36e-14	6.49e-08	-0.42	-0.34	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82620430	chr15:84398316~84411701:-
LUAD	trans	rs877636	0.702	rs773110	ENSG00000227887.1	RPS26P13	7.87	2.37e-14	6.52e-08	0.4	0.34	Cognitive function;	chr12:55981353	chr1:208697369~208697698:-
LUAD	trans	rs877636	0.702	rs773111	ENSG00000227887.1	RPS26P13	7.87	2.37e-14	6.52e-08	0.4	0.34	Cognitive function;	chr12:55981956	chr1:208697369~208697698:-
LUAD	trans	rs877636	0.702	rs773112	ENSG00000227887.1	RPS26P13	7.87	2.37e-14	6.52e-08	0.4	0.34	Cognitive function;	chr12:55982097	chr1:208697369~208697698:-
LUAD	trans	rs916888	0.773	rs169201	ENSG00000204650.12	CRHR1-IT1	7.87	2.39e-14	6.56e-08	0.48	0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45620328~45648216:+
LUAD	trans	rs9611519	1	rs5758267	ENSG00000268568.1	AC007228.9	7.87	2.42e-14	6.65e-08	0.45	0.34	Neuroticism;	chr22:41223346	chr19:56672574~56673901:-
LUAD	trans	rs8067354	0.54	rs72840315	ENSG00000187870.7	RNFT1P3	7.87	2.42e-14	6.66e-08	0.54	0.34	Hemoglobin concentration;	chr17:59940781	chr17:20743333~20754501:-
LUAD	trans	rs7503168	1	rs10512472	ENSG00000234130.2	RP13-88F20.1	7.86	2.47e-14	6.78e-08	0.45	0.34	Plateletcrit;	chr17:35557785	chrX:93222220~93225015:-
LUAD	trans	rs877636	1	rs4759229	ENSG00000234354.3	RPS26P47	-7.86	2.53e-14	6.96e-08	-0.37	-0.34	Cognitive function;	chr12:56080696	chr13:100539901~100540248:-
LUAD	trans	rs8067354	0.574	rs1292050	ENSG00000187870.7	RNFT1P3	7.86	2.55e-14	7.02e-08	0.54	0.34	Hemoglobin concentration;	chr17:59887808	chr17:20743333~20754501:-
LUAD	trans	rs6424115	0.546	rs35993651	ENSG00000228217.1	AL390877.1	7.86	2.56e-14	7.03e-08	0.43	0.34	Immature fraction of reticulocytes;	chr1:23854123	chr1:117778087~117778506:-
LUAD	trans	rs6424115	0.557	rs35904775	ENSG00000228217.1	AL390877.1	7.86	2.56e-14	7.03e-08	0.43	0.34	Immature fraction of reticulocytes;	chr1:23854133	chr1:117778087~117778506:-
LUAD	trans	rs8067354	0.574	rs2531898	ENSG00000187870.7	RNFT1P3	7.86	2.58e-14	7.09e-08	0.54	0.34	Hemoglobin concentration;	chr17:59934990	chr17:20743333~20754501:-
LUAD	trans	rs8067354	0.574	rs9789060	ENSG00000187870.7	RNFT1P3	7.86	2.58e-14	7.09e-08	0.54	0.34	Hemoglobin concentration;	chr17:59941209	chr17:20743333~20754501:-
LUAD	trans	rs7554547	0.6	rs2273290	ENSG00000261819.1	RP11-680G24.4	7.86	2.59e-14	7.1e-08	0.47	0.34	Nonsyndromic cleft lip with cleft palate;	chr1:11958321	chr16:14988259~14990160:-
LUAD	trans	rs12497850	0.966	rs6792510	ENSG00000197582.5	GPX1P1	7.86	2.62e-14	7.18e-08	0.45	0.34	Parkinson's disease;	chr3:48685869	chrX:13378735~13379340:-
LUAD	trans	rs1355223	0.506	rs7130678	ENSG00000225531.1	RP11-196I18.3	7.85	2.67e-14	7.31e-08	0.42	0.34	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34847634	chr9:107116829~107117557:+
LUAD	trans	rs4276421	0.593	rs13176359	ENSG00000231752.4	EMBP1	-7.85	2.67e-14	7.31e-08	-0.5	-0.34	P wave duration;	chr5:45814173	chr1:121519112~121571892:+
LUAD	trans	rs877636	0.702	rs773109	ENSG00000227887.1	RPS26P13	7.85	2.7e-14	7.41e-08	0.4	0.34	Cognitive function;	chr12:55980911	chr1:208697369~208697698:-
LUAD	trans	rs10037055	0.853	rs12660023	ENSG00000226986.4	RP11-543B16.2	7.85	2.75e-14	7.54e-08	0.4	0.34	Migraine without aura;	chr5:177273884	chr1:211207239~211207897:+
LUAD	trans	rs10037055	0.853	rs10056008	ENSG00000226986.4	RP11-543B16.2	-7.85	2.77e-14	7.59e-08	-0.4	-0.34	Migraine without aura;	chr5:177194147	chr1:211207239~211207897:+
LUAD	trans	rs10037055	0.853	rs10476219	ENSG00000226986.4	RP11-543B16.2	-7.85	2.77e-14	7.59e-08	-0.4	-0.34	Migraine without aura;	chr5:177201547	chr1:211207239~211207897:+
LUAD	trans	rs12497850	0.931	rs12493289	ENSG00000197582.5	GPX1P1	7.84	2.86e-14	7.85e-08	0.44	0.34	Parkinson's disease;	chr3:48867728	chrX:13378735~13379340:-
LUAD	trans	rs6708331	0.715	rs11899723	ENSG00000232654.1	FAM136BP	7.84	2.87e-14	7.86e-08	0.43	0.34	Obesity-related traits;	chr2:69968887	chr6:3045384~3045800:+
LUAD	trans	rs8010715	0.848	rs927494	ENSG00000238000.1	RP11-274E7.2	7.84	2.88e-14	7.87e-08	0.37	0.34	IgG glycosylation;	chr14:24131181	chr5:98213402~98214121:+
LUAD	trans	rs1355223	0.506	rs7130774	ENSG00000225531.1	RP11-196I18.3	7.84	2.91e-14	7.97e-08	0.41	0.34	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34847720	chr9:107116829~107117557:+
LUAD	trans	rs12497850	0.931	rs6791542	ENSG00000197582.5	GPX1P1	7.84	2.99e-14	8.17e-08	0.44	0.34	Parkinson's disease;	chr3:48749786	chrX:13378735~13379340:-
LUAD	trans	rs916888	0.773	rs199535	ENSG00000204650.12	CRHR1-IT1	7.84	3.03e-14	8.28e-08	0.47	0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45620328~45648216:+
LUAD	trans	rs6424115	0.931	rs2473377	ENSG00000228217.1	AL390877.1	-7.83	3.04e-14	8.31e-08	-0.42	-0.34	Immature fraction of reticulocytes;	chr1:23821770	chr1:117778087~117778506:-
LUAD	trans	rs11023332	0.641	rs4281505	ENSG00000236360.2	RP11-334A14.2	7.83	3.17e-14	8.66e-08	0.43	0.34	Vitamin D levels;Adiponectin levels;	chr11:14779114	chr1:52993201~52993702:-
LUAD	trans	rs9858542	0.953	rs11715915	ENSG00000197582.5	GPX1P1	7.83	3.19e-14	8.7e-08	0.48	0.34	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49417897	chrX:13378735~13379340:-
LUAD	trans	rs8067354	0.574	rs1296279	ENSG00000187870.7	RNFT1P3	7.83	3.19e-14	8.71e-08	0.54	0.34	Hemoglobin concentration;	chr17:59888370	chr17:20743333~20754501:-
LUAD	trans	rs10037055	0.853	rs1546363	ENSG00000226986.4	RP11-543B16.2	-7.82	3.29e-14	8.98e-08	-0.4	-0.34	Migraine without aura;	chr5:177174030	chr1:211207239~211207897:+
LUAD	trans	rs10037055	0.741	rs2336405	ENSG00000226986.4	RP11-543B16.2	-7.82	3.38e-14	9.22e-08	-0.4	-0.34	Migraine without aura;	chr5:177230288	chr1:211207239~211207897:+
LUAD	trans	rs7312770	1	rs7312770	ENSG00000244604.1	RP11-713H12.1	-7.82	3.39e-14	9.25e-08	-0.36	-0.34	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr17:8561230~8561576:+
LUAD	trans	rs9611519	1	rs5758264	ENSG00000268568.1	AC007228.9	-7.82	3.42e-14	9.34e-08	-0.46	-0.34	Neuroticism;	chr22:41220280	chr19:56672574~56673901:-
LUAD	trans	rs12497850	0.865	rs13072911	ENSG00000197582.5	GPX1P1	7.81	3.5e-14	9.54e-08	0.44	0.34	Parkinson's disease;	chr3:48924695	chrX:13378735~13379340:-
LUAD	trans	rs6708331	0.887	rs6546567	ENSG00000232654.1	FAM136BP	7.81	3.51e-14	9.56e-08	0.43	0.34	Obesity-related traits;	chr2:70081390	chr6:3045384~3045800:+
LUAD	trans	rs8067354	0.574	rs2526354	ENSG00000187870.7	RNFT1P3	7.81	3.58e-14	9.77e-08	0.54	0.34	Hemoglobin concentration;	chr17:59899297	chr17:20743333~20754501:-
LUAD	trans	rs916888	0.779	rs199498	ENSG00000280022.1	RP11-707O23.1	7.81	3.6e-14	9.81e-08	0.47	0.34	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:45592621~45593369:+
LUAD	trans	rs10037055	0.853	rs1363405	ENSG00000226986.4	RP11-543B16.2	7.81	3.61e-14	9.84e-08	0.39	0.34	Migraine without aura;	chr5:177209881	chr1:211207239~211207897:+
LUAD	trans	rs12497850	0.865	rs7649458	ENSG00000197582.5	GPX1P1	7.8	3.8e-14	1.04e-07	0.44	0.34	Parkinson's disease;	chr3:48882694	chrX:13378735~13379340:-
LUAD	trans	rs7399018	1	rs7399018	ENSG00000223825.5	DAZAP2P1	-7.8	3.86e-14	1.05e-07	-0.44	-0.34	Cisplatin-induced ototoxicity;	chr12:51216581	chr2:202201384~202201886:-
LUAD	trans	rs11023332	0.617	rs1451678	ENSG00000236360.2	RP11-334A14.2	7.8	3.86e-14	1.05e-07	0.43	0.34	Vitamin D levels;Adiponectin levels;	chr11:14760075	chr1:52993201~52993702:-
LUAD	trans	rs8067354	0.527	rs1292039	ENSG00000187870.7	RNFT1P3	7.8	3.97e-14	1.08e-07	0.54	0.33	Hemoglobin concentration;	chr17:59897552	chr17:20743333~20754501:-
LUAD	trans	rs7312770	1	rs7312770	ENSG00000224553.1	AC008065.1	-7.8	4e-14	1.09e-07	-0.33	-0.33	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr2:171374931~171375278:-
LUAD	trans	rs7554511	0.861	rs965321	ENSG00000244144.1	RP11-757F18.3	7.8	4.01e-14	1.09e-07	0.44	0.33	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201036374	chr3:112185480~112185998:-
LUAD	trans	rs7503168	1	rs1037590	ENSG00000234130.2	RP13-88F20.1	7.79	4.03e-14	1.1e-07	0.45	0.33	Plateletcrit;	chr17:35575616	chrX:93222220~93225015:-
LUAD	trans	rs8067354	0.54	rs7221472	ENSG00000187870.7	RNFT1P3	7.79	4.11e-14	1.12e-07	0.54	0.33	Hemoglobin concentration;	chr17:59959376	chr17:20743333~20754501:-
LUAD	trans	rs916888	0.773	rs199534	ENSG00000204650.12	CRHR1-IT1	7.79	4.14e-14	1.12e-07	0.47	0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45620328~45648216:+
LUAD	trans	rs6424115	1	rs7521961	ENSG00000228217.1	AL390877.1	7.79	4.14e-14	1.13e-07	0.42	0.33	Immature fraction of reticulocytes;	chr1:23831144	chr1:117778087~117778506:-
LUAD	trans	rs6424115	1	rs7515969	ENSG00000228217.1	AL390877.1	7.79	4.14e-14	1.13e-07	0.42	0.33	Immature fraction of reticulocytes;	chr1:23831908	chr1:117778087~117778506:-
LUAD	trans	rs916888	0.779	rs199526	ENSG00000280022.1	RP11-707O23.1	-7.79	4.21e-14	1.14e-07	-0.44	-0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:45592621~45593369:+
LUAD	trans	rs12497850	1	rs4858831	ENSG00000197582.5	GPX1P1	7.79	4.22e-14	1.15e-07	0.44	0.33	Parkinson's disease;	chr3:48698125	chrX:13378735~13379340:-
LUAD	trans	rs877636	0.692	rs10876870	ENSG00000233778.3	RP11-777J24.1	-7.79	4.24e-14	1.15e-07	-0.36	-0.33	Cognitive function;	chr12:56084218	chr8:92144088~92144435:-
LUAD	trans	rs877636	0.692	rs7971751	ENSG00000233778.3	RP11-777J24.1	-7.79	4.24e-14	1.15e-07	-0.36	-0.33	Cognitive function;	chr12:56084874	chr8:92144088~92144435:-
LUAD	trans	rs8067354	0.54	rs1051424	ENSG00000187870.7	RNFT1P3	7.79	4.26e-14	1.16e-07	0.54	0.33	Hemoglobin concentration;	chr17:59946963	chr17:20743333~20754501:-
LUAD	trans	rs11638815	0.581	rs2870965	ENSG00000235370.6	DNM1P51	-7.79	4.27e-14	1.16e-07	-0.42	-0.33	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82632278	chr15:84398316~84411701:-
LUAD	trans	rs13416322	0.699	rs57152574	ENSG00000214286.2	PDCL3P3	7.78	4.34e-14	1.18e-07	0.46	0.33	Intelligence (multi-trait analysis);	chr2:100563529	chr3:17877455~17878169:-
LUAD	trans	rs5758265	1	rs5758265	ENSG00000268568.1	AC007228.9	-7.78	4.53e-14	1.23e-07	-0.46	-0.33	Depressive symptoms (multi-trait analysis);	chr22:41221893	chr19:56672574~56673901:-
LUAD	trans	rs10037055	0.687	rs6556308	ENSG00000226986.4	RP11-543B16.2	-7.78	4.55e-14	1.23e-07	-0.4	-0.33	Migraine without aura;	chr5:177219700	chr1:211207239~211207897:+
LUAD	trans	rs7503168	0.818	rs9902765	ENSG00000234130.2	RP13-88F20.1	7.77	4.63e-14	1.26e-07	0.44	0.33	Plateletcrit;	chr17:35586124	chrX:93222220~93225015:-
LUAD	trans	rs11653357	1	rs11653357	ENSG00000234130.2	RP13-88F20.1	7.77	4.63e-14	1.26e-07	0.44	0.33	Platelet count;Platelet distribution width;	chr17:35596588	chrX:93222220~93225015:-
LUAD	trans	rs12497850	0.931	rs9846123	ENSG00000197582.5	GPX1P1	-7.77	4.69e-14	1.27e-07	-0.44	-0.33	Parkinson's disease;	chr3:49050679	chrX:13378735~13379340:-
LUAD	trans	rs7554511	0.893	rs11586763	ENSG00000244144.1	RP11-757F18.3	-7.77	4.71e-14	1.28e-07	-0.47	-0.33	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201020316	chr3:112185480~112185998:-
LUAD	trans	rs8067354	0.574	rs1292042	ENSG00000187870.7	RNFT1P3	7.77	4.8e-14	1.3e-07	0.54	0.33	Hemoglobin concentration;	chr17:59857634	chr17:20743333~20754501:-
LUAD	trans	rs9611519	0.964	rs2179744	ENSG00000268568.1	AC007228.9	-7.77	4.85e-14	1.31e-07	-0.46	-0.33	Neuroticism;	chr22:41225710	chr19:56672574~56673901:-
LUAD	trans	rs9611519	1	rs5758268	ENSG00000268568.1	AC007228.9	-7.77	4.85e-14	1.31e-07	-0.46	-0.33	Neuroticism;	chr22:41226415	chr19:56672574~56673901:-
LUAD	trans	rs4276421	0.593	rs7448901	ENSG00000231752.4	EMBP1	7.77	4.85e-14	1.31e-07	0.47	0.33	P wave duration;	chr5:45941482	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.615	rs7445658	ENSG00000231752.4	EMBP1	7.77	4.85e-14	1.31e-07	0.47	0.33	P wave duration;	chr5:45941513	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.593	rs10076636	ENSG00000231752.4	EMBP1	7.77	4.85e-14	1.31e-07	0.47	0.33	P wave duration;	chr5:45942052	chr1:121519112~121571892:+
LUAD	trans	rs916888	0.773	rs199533	ENSG00000204650.12	CRHR1-IT1	7.76	5.02e-14	1.36e-07	0.47	0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45620328~45648216:+
LUAD	trans	rs6424115	1	rs34477640	ENSG00000228217.1	AL390877.1	7.76	5.06e-14	1.37e-07	0.42	0.33	Immature fraction of reticulocytes;	chr1:23827577	chr1:117778087~117778506:-
LUAD	trans	rs6424115	1	rs7519554	ENSG00000228217.1	AL390877.1	7.76	5.06e-14	1.37e-07	0.42	0.33	Immature fraction of reticulocytes;	chr1:23828076	chr1:117778087~117778506:-
LUAD	trans	rs12497850	0.931	rs11705888	ENSG00000197582.5	GPX1P1	7.76	5.08e-14	1.37e-07	0.44	0.33	Parkinson's disease;	chr3:48779856	chrX:13378735~13379340:-
LUAD	trans	rs6424115	0.964	rs2473375	ENSG00000228217.1	AL390877.1	-7.76	5.1e-14	1.38e-07	-0.42	-0.33	Immature fraction of reticulocytes;	chr1:23810055	chr1:117778087~117778506:-
LUAD	trans	rs4713118	0.614	rs9380007	ENSG00000204709.4	LINC01556	7.76	5.19e-14	1.4e-07	0.41	0.33	Parkinson's disease;	chr6:27692729	chr6:28943877~28944537:+
LUAD	trans	rs4276421	0.593	rs10066821	ENSG00000231752.4	EMBP1	7.76	5.22e-14	1.41e-07	0.5	0.33	P wave duration;	chr5:45844236	chr1:121519112~121571892:+
LUAD	trans	rs916888	0.773	rs199447	ENSG00000204650.12	CRHR1-IT1	7.75	5.36e-14	1.45e-07	0.48	0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45620328~45648216:+
LUAD	trans	rs7554511	0.858	rs10920084	ENSG00000244144.1	RP11-757F18.3	-7.75	5.41e-14	1.46e-07	-0.42	-0.33	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200993667	chr3:112185480~112185998:-
LUAD	trans	rs877636	0.74	rs772920	ENSG00000234354.3	RPS26P47	7.75	5.59e-14	1.51e-07	0.39	0.33	Cognitive function;	chr12:55996580	chr13:100539901~100540248:-
LUAD	trans	rs67340775	0.541	rs200965	ENSG00000204709.4	LINC01556	7.74	5.72e-14	1.54e-07	0.56	0.33	Lung cancer in ever smokers;	chr6:27898606	chr6:28943877~28944537:+
LUAD	trans	rs7554511	0.893	rs12122721	ENSG00000244144.1	RP11-757F18.3	7.74	5.85e-14	1.58e-07	0.45	0.33	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201015352	chr3:112185480~112185998:-
LUAD	trans	rs916888	0.773	rs538628	ENSG00000204650.12	CRHR1-IT1	7.74	6.06e-14	1.63e-07	0.46	0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45620328~45648216:+
LUAD	trans	rs877636	0.702	rs61937249	ENSG00000227887.1	RPS26P13	7.74	6.11e-14	1.64e-07	0.4	0.33	Cognitive function;	chr12:55988132	chr1:208697369~208697698:-
LUAD	trans	rs877636	0.74	rs705702	ENSG00000234354.3	RPS26P47	-7.73	6.32e-14	1.7e-07	-0.39	-0.33	Cognitive function;	chr12:55996852	chr13:100539901~100540248:-
LUAD	trans	rs9611519	0.603	rs9607764	ENSG00000268568.1	AC007228.9	-7.73	6.37e-14	1.71e-07	-0.42	-0.33	Neuroticism;	chr22:41015800	chr19:56672574~56673901:-
LUAD	trans	rs10037055	0.853	rs10035180	ENSG00000226986.4	RP11-543B16.2	-7.72	6.73e-14	1.81e-07	-0.4	-0.33	Migraine without aura;	chr5:177171501	chr1:211207239~211207897:+
LUAD	trans	rs6915893	0.692	rs4074443	ENSG00000267156.1	TPMTP1	7.72	6.76e-14	1.82e-07	0.41	0.33	Intrinsic epigenetic age acceleration;	chr6:18106371	chr18:47630112~47630848:+
LUAD	trans	rs10242455	0.717	rs58649180	ENSG00000228834.1	RP11-249L21.4	7.72	6.84e-14	1.84e-07	0.74	0.33	Blood metabolite levels;	chr7:99738422	chr6:108907615~108907873:-
LUAD	trans	rs11023332	0.65	rs2122942	ENSG00000236360.2	RP11-334A14.2	7.72	6.99e-14	1.88e-07	0.43	0.33	Vitamin D levels;Adiponectin levels;	chr11:14785829	chr1:52993201~52993702:-
LUAD	trans	rs7503168	1	rs35237539	ENSG00000234130.2	RP13-88F20.1	7.71	7.07e-14	1.9e-07	0.44	0.33	Plateletcrit;	chr17:35602563	chrX:93222220~93225015:-
LUAD	trans	rs66887589	0.592	rs2175383	ENSG00000275858.1	RP11-291L22.8	7.71	7.09e-14	1.9e-07	0.36	0.33	Diastolic blood pressure;	chr4:119294681	chr10:38450738~38451069:-
LUAD	trans	rs1391708	0.504	rs74995587	ENSG00000121089.4	NACA3P	-7.71	7.23e-14	1.94e-07	-0.61	-0.33	Airway wall thickness;	chr12:56870642	chr4:164943290~164943937:+
LUAD	trans	rs10037055	1	rs6886255	ENSG00000228305.2	AC016734.2	7.71	7.25e-14	1.95e-07	0.38	0.33	Migraine without aura;	chr5:177291360	chr2:63622178~63622831:-
LUAD	trans	rs67340775	0.541	rs200973	ENSG00000204709.4	LINC01556	7.71	7.27e-14	1.95e-07	0.53	0.33	Lung cancer in ever smokers;	chr6:27890643	chr6:28943877~28944537:+
LUAD	trans	rs12497850	1	rs1352420	ENSG00000197582.5	GPX1P1	7.71	7.31e-14	1.96e-07	0.45	0.33	Parkinson's disease;	chr3:48719858	chrX:13378735~13379340:-
LUAD	trans	rs877636	0.859	rs3741499	ENSG00000196656.7	AC004057.1	-7.7	7.62e-14	2.04e-07	-0.35	-0.33	Cognitive function;	chr12:56080595	chr4:113214046~113217170:-
LUAD	trans	rs9611519	0.589	rs8138917	ENSG00000268568.1	AC007228.9	-7.7	7.64e-14	2.05e-07	-0.42	-0.33	Neuroticism;	chr22:41016421	chr19:56672574~56673901:-
LUAD	trans	rs9611519	0.58	rs8138349	ENSG00000268568.1	AC007228.9	-7.7	7.64e-14	2.05e-07	-0.42	-0.33	Neuroticism;	chr22:41016719	chr19:56672574~56673901:-
LUAD	trans	rs9611519	0.602	rs8138520	ENSG00000268568.1	AC007228.9	-7.7	7.64e-14	2.05e-07	-0.42	-0.33	Neuroticism;	chr22:41016924	chr19:56672574~56673901:-
LUAD	trans	rs877636	0.74	rs705698	ENSG00000234354.3	RPS26P47	7.7	7.69e-14	2.06e-07	0.38	0.33	Cognitive function;	chr12:55990903	chr13:100539901~100540248:-
LUAD	trans	rs4276421	0.571	rs28895306	ENSG00000231752.4	EMBP1	7.7	8.05e-14	2.15e-07	0.52	0.33	P wave duration;	chr5:45851383	chr1:121519112~121571892:+
LUAD	trans	rs13217239	0.646	rs7768407	ENSG00000242375.1	RP11-498P14.3	7.69	8.28e-14	2.21e-07	0.43	0.33	Schizophrenia;	chr6:27049016	chr9:97195351~97197687:-
LUAD	trans	rs6424115	1	rs12121387	ENSG00000228217.1	AL390877.1	7.69	8.28e-14	2.21e-07	0.42	0.33	Immature fraction of reticulocytes;	chr1:23840046	chr1:117778087~117778506:-
LUAD	trans	rs9611519	0.579	rs8136274	ENSG00000268568.1	AC007228.9	-7.69	8.52e-14	2.28e-07	-0.42	-0.33	Neuroticism;	chr22:41019307	chr19:56672574~56673901:-
LUAD	trans	rs916888	0.773	rs199445	ENSG00000204650.12	CRHR1-IT1	7.69	8.54e-14	2.28e-07	0.46	0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45620328~45648216:+
LUAD	trans	rs916888	0.773	rs199443	ENSG00000204650.12	CRHR1-IT1	7.69	8.54e-14	2.28e-07	0.46	0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45620328~45648216:+
LUAD	trans	rs10242455	0.571	rs45527841	ENSG00000228834.1	RP11-249L21.4	7.69	8.64e-14	2.31e-07	0.77	0.33	Blood metabolite levels;	chr7:99713342	chr6:108907615~108907873:-
LUAD	trans	rs11638815	0.626	rs4779041	ENSG00000235370.6	DNM1P51	7.68	8.79e-14	2.35e-07	0.41	0.33	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82668307	chr15:84398316~84411701:-
LUAD	trans	rs916888	0.773	rs199439	ENSG00000204650.12	CRHR1-IT1	7.68	8.93e-14	2.38e-07	0.46	0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45620328~45648216:+
LUAD	trans	rs10242455	0.571	rs73713595	ENSG00000228834.1	RP11-249L21.4	7.67	9.29e-14	2.48e-07	0.76	0.33	Blood metabolite levels;	chr7:99729036	chr6:108907615~108907873:-
LUAD	trans	rs28647808	0.881	rs4962139	ENSG00000234981.1	RP11-534L20.4	-7.67	9.54e-14	2.54e-07	-0.5	-0.33	Blood protein levels;	chr9:133402740	chr1:206528915~206529706:+
LUAD	trans	rs9611519	0.59	rs4821980	ENSG00000268568.1	AC007228.9	-7.67	9.56e-14	2.55e-07	-0.42	-0.33	Neuroticism;	chr22:41019475	chr19:56672574~56673901:-
LUAD	trans	rs6915893	0.548	rs6899431	ENSG00000267156.1	TPMTP1	7.67	9.77e-14	2.6e-07	0.41	0.33	Intrinsic epigenetic age acceleration;	chr6:18110212	chr18:47630112~47630848:+
LUAD	trans	rs877636	0.702	rs773108	ENSG00000227887.1	RPS26P13	7.67	9.94e-14	2.65e-07	0.4	0.33	Cognitive function;	chr12:55976127	chr1:208697369~208697698:-
LUAD	trans	rs9611519	0.566	rs4821981	ENSG00000268568.1	AC007228.9	7.66	1e-13	2.67e-07	0.42	0.33	Neuroticism;	chr22:41019640	chr19:56672574~56673901:-
LUAD	trans	rs67340775	0.541	rs200964	ENSG00000204709.4	LINC01556	7.66	1.01e-13	2.7e-07	0.56	0.33	Lung cancer in ever smokers;	chr6:27899165	chr6:28943877~28944537:+
LUAD	trans	rs7121616	0.842	rs11825379	ENSG00000234176.1	HSPA8P1	7.65	1.1e-13	2.91e-07	0.44	0.33	Breast cancer;	chr11:123126599	chrX:121203182~121205014:-
LUAD	trans	rs8067354	0.54	rs12600680	ENSG00000187870.7	RNFT1P3	7.65	1.1e-13	2.92e-07	0.53	0.33	Hemoglobin concentration;	chr17:59960013	chr17:20743333~20754501:-
LUAD	trans	rs877636	0.74	rs772920	ENSG00000196656.7	AC004057.1	7.65	1.11e-13	2.94e-07	0.37	0.33	Cognitive function;	chr12:55996580	chr4:113214046~113217170:-
LUAD	trans	rs66887589	0.616	rs6822808	ENSG00000275858.1	RP11-291L22.8	7.65	1.12e-13	2.97e-07	0.36	0.33	Diastolic blood pressure;	chr4:119296210	chr10:38450738~38451069:-
LUAD	trans	rs8067354	0.645	rs2665403	ENSG00000187870.7	RNFT1P3	7.65	1.12e-13	2.98e-07	0.49	0.33	Hemoglobin concentration;	chr17:59812624	chr17:20743333~20754501:-
LUAD	trans	rs8067354	0.645	rs2173120	ENSG00000187870.7	RNFT1P3	7.65	1.12e-13	2.98e-07	0.49	0.33	Hemoglobin concentration;	chr17:59815279	chr17:20743333~20754501:-
LUAD	trans	rs2657294	0.659	rs1259500	ENSG00000172974.11	AC007318.5	7.65	1.14e-13	3.02e-07	0.39	0.33	Pneumonia;	chr10:75230355	chr2:65205108~65205988:+
LUAD	trans	rs2657294	0.632	rs1259503	ENSG00000172974.11	AC007318.5	7.65	1.14e-13	3.02e-07	0.39	0.33	Pneumonia;	chr10:75232686	chr2:65205108~65205988:+
LUAD	trans	rs4713118	0.715	rs200480	ENSG00000204709.4	LINC01556	7.64	1.15e-13	3.05e-07	0.4	0.33	Parkinson's disease;	chr6:27805886	chr6:28943877~28944537:+
LUAD	trans	rs10242455	0.867	rs73410654	ENSG00000228834.1	RP11-249L21.4	7.64	1.21e-13	3.2e-07	0.61	0.33	Blood metabolite levels;	chr7:99729040	chr6:108907615~108907873:-
LUAD	trans	rs6424115	1	rs6697805	ENSG00000228217.1	AL390877.1	7.64	1.21e-13	3.21e-07	0.41	0.33	Immature fraction of reticulocytes;	chr1:23825506	chr1:117778087~117778506:-
LUAD	trans	rs1039766	0.706	rs72822420	ENSG00000224334.1	AP000357.4	-7.63	1.24e-13	3.27e-07	-0.63	-0.33	Lung adenocarcinoma;Lung cancer;	chr2:65286633	chr22:24686923~24688087:+
LUAD	trans	rs9611519	0.542	rs8139770	ENSG00000268568.1	AC007228.9	-7.63	1.24e-13	3.29e-07	-0.42	-0.33	Neuroticism;	chr22:41020177	chr19:56672574~56673901:-
LUAD	trans	rs12439619	0.508	rs11856561	ENSG00000235370.6	DNM1P51	-7.63	1.24e-13	3.29e-07	-0.37	-0.33	Intelligence (multi-trait analysis);	chr15:82161415	chr15:84398316~84411701:-
LUAD	trans	rs616147	0.85	rs631312	ENSG00000214263.2	RPSAP53	-7.63	1.26e-13	3.34e-07	-0.46	-0.33	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39467477	chr13:67266845~67267706:-
LUAD	trans	rs67340775	0.541	rs200968	ENSG00000204709.4	LINC01556	7.63	1.26e-13	3.35e-07	0.54	0.33	Lung cancer in ever smokers;	chr6:27891790	chr6:28943877~28944537:+
LUAD	trans	rs8067354	0.645	rs11079389	ENSG00000187870.7	RNFT1P3	7.63	1.27e-13	3.36e-07	0.49	0.33	Hemoglobin concentration;	chr17:59810591	chr17:20743333~20754501:-
LUAD	trans	rs10037055	0.853	rs2336237	ENSG00000226986.4	RP11-543B16.2	7.63	1.27e-13	3.36e-07	0.4	0.33	Migraine without aura;	chr5:177238878	chr1:211207239~211207897:+
LUAD	trans	rs11638815	0.626	rs1367841	ENSG00000235370.6	DNM1P51	7.63	1.27e-13	3.37e-07	0.4	0.33	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82641874	chr15:84398316~84411701:-
LUAD	trans	rs7503168	1	rs16971227	ENSG00000234130.2	RP13-88F20.1	7.63	1.29e-13	3.41e-07	0.44	0.33	Plateletcrit;	chr17:35622203	chrX:93222220~93225015:-
LUAD	trans	rs66887589	0.616	rs1052633	ENSG00000275858.1	RP11-291L22.8	7.63	1.31e-13	3.48e-07	0.36	0.33	Diastolic blood pressure;	chr4:119294159	chr10:38450738~38451069:-
LUAD	trans	rs2069408	1	rs2069408	ENSG00000196933.5	RPS26P11	-7.62	1.32e-13	3.49e-07	-0.41	-0.33	Asthma;	chr12:55970537	chrX:72044545~72044892:+
LUAD	trans	rs11638815	0.626	rs4779039	ENSG00000235370.6	DNM1P51	7.62	1.33e-13	3.52e-07	0.4	0.33	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82649016	chr15:84398316~84411701:-
LUAD	trans	rs28647808	0.881	rs71483207	ENSG00000234981.1	RP11-534L20.4	7.62	1.34e-13	3.55e-07	0.53	0.33	Blood protein levels;	chr9:133393575	chr1:206528915~206529706:+
LUAD	trans	rs6424115	1	rs35385477	ENSG00000228217.1	AL390877.1	-7.62	1.35e-13	3.58e-07	-0.41	-0.33	Immature fraction of reticulocytes;	chr1:23829434	chr1:117778087~117778506:-
LUAD	trans	rs9611519	1	rs5751069	ENSG00000268568.1	AC007228.9	-7.62	1.39e-13	3.67e-07	-0.45	-0.33	Neuroticism;	chr22:41231771	chr19:56672574~56673901:-
LUAD	trans	rs8067354	0.574	rs2531899	ENSG00000187870.7	RNFT1P3	-7.62	1.39e-13	3.68e-07	-0.52	-0.33	Hemoglobin concentration;	chr17:59929832	chr17:20743333~20754501:-
LUAD	trans	rs8067354	0.645	rs2132715	ENSG00000187870.7	RNFT1P3	7.62	1.4e-13	3.69e-07	0.5	0.33	Hemoglobin concentration;	chr17:59781013	chr17:20743333~20754501:-
LUAD	trans	rs8067354	0.645	rs2173119	ENSG00000187870.7	RNFT1P3	7.62	1.4e-13	3.69e-07	0.5	0.33	Hemoglobin concentration;	chr17:59782344	chr17:20743333~20754501:-
LUAD	trans	rs66887589	0.616	rs6843509	ENSG00000275858.1	RP11-291L22.8	7.61	1.46e-13	3.87e-07	0.36	0.33	Diastolic blood pressure;	chr4:119299041	chr10:38450738~38451069:-
LUAD	trans	rs66887589	0.616	rs11732621	ENSG00000275858.1	RP11-291L22.8	7.61	1.47e-13	3.88e-07	0.35	0.33	Diastolic blood pressure;	chr4:119291728	chr10:38450738~38451069:-
LUAD	trans	rs6743068	0.541	rs7578456	ENSG00000235105.1	RP11-329A14.1	7.61	1.5e-13	3.96e-07	0.38	0.33	Lymphocyte percentage of white cells;	chr2:201370625	chr1:48435967~48437223:+
LUAD	trans	rs916888	0.773	rs199451	ENSG00000204650.12	CRHR1-IT1	7.6	1.58e-13	4.16e-07	0.46	0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45620328~45648216:+
LUAD	trans	rs67340775	0.541	rs200975	ENSG00000204709.4	LINC01556	7.6	1.6e-13	4.2e-07	0.54	0.33	Lung cancer in ever smokers;	chr6:27887847	chr6:28943877~28944537:+
LUAD	trans	rs67340775	0.541	rs200974	ENSG00000204709.4	LINC01556	7.6	1.6e-13	4.2e-07	0.54	0.33	Lung cancer in ever smokers;	chr6:27888067	chr6:28943877~28944537:+
LUAD	trans	rs4276421	0.554	rs7724971	ENSG00000231752.4	EMBP1	-7.59	1.62e-13	4.26e-07	-0.48	-0.33	P wave duration;	chr5:45814638	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.593	rs4866973	ENSG00000231752.4	EMBP1	-7.59	1.62e-13	4.26e-07	-0.48	-0.33	P wave duration;	chr5:45816584	chr1:121519112~121571892:+
LUAD	trans	rs66887589	0.616	rs7659403	ENSG00000275858.1	RP11-291L22.8	7.59	1.66e-13	4.36e-07	0.35	0.33	Diastolic blood pressure;	chr4:119286099	chr10:38450738~38451069:-
LUAD	trans	rs877636	0.692	rs2271194	ENSG00000233778.3	RP11-777J24.1	-7.59	1.66e-13	4.38e-07	-0.35	-0.33	Cognitive function;	chr12:56083910	chr8:92144088~92144435:-
LUAD	trans	rs6424115	1	rs974698	ENSG00000228217.1	AL390877.1	-7.59	1.69e-13	4.45e-07	-0.4	-0.33	Immature fraction of reticulocytes;	chr1:23806295	chr1:117778087~117778506:-
LUAD	trans	rs7312770	0.637	rs705700	ENSG00000244604.1	RP11-713H12.1	7.59	1.73e-13	4.55e-07	0.36	0.33	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr17:8561230~8561576:+
LUAD	trans	rs4276421	0.55	rs4478331	ENSG00000231752.4	EMBP1	7.58	1.77e-13	4.65e-07	0.48	0.33	P wave duration;	chr5:46005323	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.615	rs60927048	ENSG00000231752.4	EMBP1	7.58	1.82e-13	4.78e-07	0.49	0.33	P wave duration;	chr5:45854618	chr1:121519112~121571892:+
LUAD	trans	rs67340775	0.541	rs200966	ENSG00000204709.4	LINC01556	7.58	1.83e-13	4.81e-07	0.54	0.33	Lung cancer in ever smokers;	chr6:27894374	chr6:28943877~28944537:+
LUAD	trans	rs13190036	0.551	rs28932178	ENSG00000228305.2	AC016734.2	-7.57	1.86e-13	4.9e-07	-0.44	-0.33	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177210575	chr2:63622178~63622831:-
LUAD	trans	rs877636	0.74	rs705702	ENSG00000196656.7	AC004057.1	-7.57	1.87e-13	4.92e-07	-0.37	-0.33	Cognitive function;	chr12:55996852	chr4:113214046~113217170:-
LUAD	trans	rs4276421	0.54	rs4242125	ENSG00000231752.4	EMBP1	-7.57	1.96e-13	5.15e-07	-0.48	-0.33	P wave duration;	chr5:45820055	chr1:121519112~121571892:+
LUAD	trans	rs4713118	0.55	rs9368527	ENSG00000204709.4	LINC01556	7.56	1.99e-13	5.23e-07	0.4	0.33	Parkinson's disease;	chr6:27711666	chr6:28943877~28944537:+
LUAD	trans	rs1816752	0.875	rs17384871	ENSG00000224976.2	PARP4P2	-7.56	2.01e-13	5.26e-07	-0.38	-0.33	Obesity-related traits;	chr13:24484959	chr13:19349137~19407962:+
LUAD	trans	rs7121616	0.563	rs4936770	ENSG00000229091.2	HSPA8P8	7.56	2.01e-13	5.27e-07	0.42	0.33	Breast cancer;	chr11:123058167	chr7:10451311~10452526:+
LUAD	trans	rs2134046	0.587	rs11854289	ENSG00000235370.6	DNM1P51	7.56	2.07e-13	5.42e-07	0.38	0.33	Cognitive ability;	chr15:82266461	chr15:84398316~84411701:-
LUAD	trans	rs7121616	0.576	rs4936767	ENSG00000229091.2	HSPA8P8	7.56	2.1e-13	5.51e-07	0.42	0.33	Breast cancer;	chr11:123047451	chr7:10451311~10452526:+
LUAD	trans	rs6424115	0.965	rs2502979	ENSG00000228217.1	AL390877.1	-7.56	2.12e-13	5.55e-07	-0.41	-0.33	Immature fraction of reticulocytes;	chr1:23822825	chr1:117778087~117778506:-
LUAD	trans	rs916888	0.61	rs199444	ENSG00000280022.1	RP11-707O23.1	7.55	2.16e-13	5.65e-07	0.42	0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:45592621~45593369:+
LUAD	trans	rs916888	0.61	rs199442	ENSG00000280022.1	RP11-707O23.1	7.55	2.16e-13	5.65e-07	0.42	0.33	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:45592621~45593369:+
LUAD	trans	rs6424115	0.931	rs11800561	ENSG00000228217.1	AL390877.1	-7.55	2.16e-13	5.67e-07	-0.41	-0.33	Immature fraction of reticulocytes;	chr1:23837908	chr1:117778087~117778506:-
LUAD	trans	rs4276421	0.593	rs4380674	ENSG00000231752.4	EMBP1	7.55	2.18e-13	5.7e-07	0.47	0.33	P wave duration;	chr5:45769295	chr1:121519112~121571892:+
LUAD	trans	rs66887589	0.616	rs11098497	ENSG00000275858.1	RP11-291L22.8	7.55	2.2e-13	5.76e-07	0.35	0.33	Diastolic blood pressure;	chr4:119265913	chr10:38450738~38451069:-
LUAD	trans	rs4276421	0.53	rs13356313	ENSG00000231752.4	EMBP1	7.55	2.23e-13	5.84e-07	0.48	0.33	P wave duration;	chr5:45963787	chr1:121519112~121571892:+
LUAD	trans	rs67340775	0.541	rs169287	ENSG00000204709.4	LINC01556	7.55	2.25e-13	5.89e-07	0.54	0.33	Lung cancer in ever smokers;	chr6:27886982	chr6:28943877~28944537:+
LUAD	trans	rs877636	0.74	rs705698	ENSG00000227887.1	RPS26P13	7.55	2.26e-13	5.91e-07	0.38	0.33	Cognitive function;	chr12:55990903	chr1:208697369~208697698:-
LUAD	trans	rs877636	1	rs877636	ENSG00000244604.1	RP11-713H12.1	-7.54	2.32e-13	6.06e-07	-0.37	-0.33	Cognitive function;	chr12:56086799	chr17:8561230~8561576:+
LUAD	trans	rs1190596	0.525	rs4601978	ENSG00000181359.5	HSP90AA6P	-7.54	2.36e-13	6.17e-07	-0.36	-0.33	Behavioural disinhibition (generation interaction);	chr14:102284740	chr4:170581470~170605450:-
LUAD	trans	rs7192380	0.825	rs3811348	ENSG00000257513.6	NPIPB1P	-7.54	2.4e-13	6.27e-07	-0.32	-0.33	Sjögren's syndrome;	chr16:69748952	chr18:11619509~11639699:-
LUAD	trans	rs6424115	0.931	rs2982390	ENSG00000228217.1	AL390877.1	-7.54	2.4e-13	6.27e-07	-0.41	-0.33	Immature fraction of reticulocytes;	chr1:23821340	chr1:117778087~117778506:-
LUAD	trans	rs1816752	0.875	rs59686377	ENSG00000224976.2	PARP4P2	-7.54	2.41e-13	6.29e-07	-0.38	-0.33	Obesity-related traits;	chr13:24475869	chr13:19349137~19407962:+
LUAD	trans	rs66887589	0.616	rs11098498	ENSG00000275858.1	RP11-291L22.8	7.54	2.42e-13	6.31e-07	0.35	0.32	Diastolic blood pressure;	chr4:119265964	chr10:38450738~38451069:-
LUAD	trans	rs13217239	0.646	rs10946897	ENSG00000242375.1	RP11-498P14.3	7.54	2.42e-13	6.33e-07	0.41	0.32	Schizophrenia;	chr6:27027472	chr9:97195351~97197687:-
LUAD	trans	rs877636	1	rs877636	ENSG00000233778.3	RP11-777J24.1	-7.53	2.46e-13	6.43e-07	-0.36	-0.32	Cognitive function;	chr12:56086799	chr8:92144088~92144435:-
LUAD	trans	rs55665837	0.539	rs10500804	ENSG00000236360.2	RP11-334A14.2	7.53	2.47e-13	6.46e-07	0.43	0.32	Vitamin D levels;	chr11:14888727	chr1:52993201~52993702:-
LUAD	trans	rs4276421	0.593	rs6898480	ENSG00000231752.4	EMBP1	-7.53	2.48e-13	6.48e-07	-0.48	-0.32	P wave duration;	chr5:45825479	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.615	rs7733616	ENSG00000231752.4	EMBP1	-7.53	2.51e-13	6.55e-07	-0.46	-0.32	P wave duration;	chr5:45798621	chr1:121519112~121571892:+
LUAD	trans	rs916888	0.61	rs199453	ENSG00000280022.1	RP11-707O23.1	7.53	2.52e-13	6.57e-07	0.41	0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:45592621~45593369:+
LUAD	trans	rs4276421	0.571	rs7293493	ENSG00000231752.4	EMBP1	7.53	2.53e-13	6.61e-07	0.48	0.32	P wave duration;	chr5:46028749	chr1:121519112~121571892:+
LUAD	trans	rs66887589	0.616	rs10032299	ENSG00000275858.1	RP11-291L22.8	7.53	2.56e-13	6.69e-07	0.35	0.32	Diastolic blood pressure;	chr4:119285264	chr10:38450738~38451069:-
LUAD	trans	rs26067	0.74	rs27683	ENSG00000231752.4	EMBP1	7.53	2.59e-13	6.75e-07	0.46	0.32	Breast cancer;	chr5:50865708	chr1:121519112~121571892:+
LUAD	trans	rs10242455	0.717	rs72494455	ENSG00000228834.1	RP11-249L21.4	7.53	2.6e-13	6.77e-07	0.72	0.32	Blood metabolite levels;	chr7:99739154	chr6:108907615~108907873:-
LUAD	trans	rs67340775	0.541	rs200979	ENSG00000204709.4	LINC01556	7.53	2.61e-13	6.81e-07	0.54	0.32	Lung cancer in ever smokers;	chr6:27884579	chr6:28943877~28944537:+
LUAD	trans	rs4276421	0.571	rs4368738	ENSG00000231752.4	EMBP1	7.52	2.72e-13	7.09e-07	0.47	0.32	P wave duration;	chr5:45892686	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.593	rs10223123	ENSG00000231752.4	EMBP1	7.52	2.72e-13	7.09e-07	0.47	0.32	P wave duration;	chr5:45893554	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.593	rs9292929	ENSG00000231752.4	EMBP1	7.52	2.72e-13	7.09e-07	0.47	0.32	P wave duration;	chr5:45894168	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.593	rs6871250	ENSG00000231752.4	EMBP1	-7.52	2.74e-13	7.13e-07	-0.48	-0.32	P wave duration;	chr5:45801662	chr1:121519112~121571892:+
LUAD	trans	rs7113874	0.802	rs10769938	ENSG00000266891.1	RP11-692N5.2	7.52	2.74e-13	7.13e-07	0.44	0.32	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8650000	chr18:9734882~9735602:-
LUAD	trans	rs673253	0.557	rs34898652	ENSG00000231007.5	CDC20P1	7.51	2.87e-13	7.46e-07	0.41	0.32	Intelligence (multi-trait analysis);	chr1:43508420	chr9:87011652~87013151:+
LUAD	trans	rs916888	0.61	rs142167	ENSG00000280022.1	RP11-707O23.1	-7.51	2.87e-13	7.47e-07	-0.41	-0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:45592621~45593369:+
LUAD	trans	rs916888	0.647	rs199449	ENSG00000280022.1	RP11-707O23.1	7.51	2.9e-13	7.54e-07	0.41	0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:45592621~45593369:+
LUAD	trans	rs546131	0.928	rs516228	ENSG00000225531.1	RP11-196I18.3	7.51	2.94e-13	7.64e-07	0.41	0.32	Lung disease severity in cystic fibrosis;	chr11:34817276	chr9:107116829~107117557:+
LUAD	trans	rs7113874	0.659	rs7935453	ENSG00000266891.1	RP11-692N5.2	7.51	2.98e-13	7.74e-07	0.45	0.32	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8625216	chr18:9734882~9735602:-
LUAD	trans	rs7937890	0.874	rs6486191	ENSG00000236360.2	RP11-334A14.2	7.5	3.02e-13	7.85e-07	0.4	0.32	Mitochondrial DNA levels;	chr11:14382193	chr1:52993201~52993702:-
LUAD	trans	rs9899728	0.656	rs9904728	ENSG00000234925.2	ATP5HP4	7.5	3.04e-13	7.89e-07	0.53	0.32	Alzheimer's disease or small vessel stroke;	chr17:75034540	chr12:68642519~68642993:-
LUAD	trans	rs10242455	0.571	rs80045298	ENSG00000228834.1	RP11-249L21.4	7.5	3.08e-13	8e-07	0.8	0.32	Blood metabolite levels;	chr7:99709830	chr6:108907615~108907873:-
LUAD	trans	rs10242455	0.571	rs41279866	ENSG00000228834.1	RP11-249L21.4	7.5	3.08e-13	8e-07	0.8	0.32	Blood metabolite levels;	chr7:99717653	chr6:108907615~108907873:-
LUAD	trans	rs6424115	1	rs12031592	ENSG00000228217.1	AL390877.1	-7.5	3.09e-13	8.03e-07	-0.4	-0.32	Immature fraction of reticulocytes;	chr1:23801374	chr1:117778087~117778506:-
LUAD	trans	rs877636	0.692	rs2271194	ENSG00000243538.1	CTB-55B8.1	-7.5	3.15e-13	8.17e-07	-0.34	-0.32	Cognitive function;	chr12:56083910	chr5:16902294~16902641:-
LUAD	trans	rs4276421	0.615	rs12108961	ENSG00000231752.4	EMBP1	7.5	3.16e-13	8.2e-07	0.49	0.32	P wave duration;	chr5:45845859	chr1:121519112~121571892:+
LUAD	trans	rs916888	0.779	rs199528	ENSG00000204650.12	CRHR1-IT1	7.5	3.17e-13	8.22e-07	0.46	0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45620328~45648216:+
LUAD	trans	rs916888	0.821	rs199525	ENSG00000204650.12	CRHR1-IT1	7.5	3.17e-13	8.22e-07	0.46	0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45620328~45648216:+
LUAD	trans	rs4713118	0.614	rs9468209	ENSG00000204709.4	LINC01556	7.49	3.24e-13	8.39e-07	0.39	0.32	Parkinson's disease;	chr6:27726642	chr6:28943877~28944537:+
LUAD	trans	rs74781061	0.929	rs10459648	ENSG00000227288.3	RP5-837I24.1	-7.49	3.27e-13	8.48e-07	-0.48	-0.32	Endometriosis;	chr15:74573099	chr1:81501794~81503468:+
LUAD	trans	rs889398	0.641	rs7200258	ENSG00000257513.6	NPIPB1P	7.49	3.3e-13	8.55e-07	0.31	0.32	Body mass index;	chr16:69863566	chr18:11619509~11639699:-
LUAD	trans	rs1816752	0.905	rs3818938	ENSG00000224976.2	PARP4P2	-7.49	3.32e-13	8.61e-07	-0.38	-0.32	Obesity-related traits;	chr13:24454945	chr13:19349137~19407962:+
LUAD	trans	rs4276421	0.593	rs7718780	ENSG00000231752.4	EMBP1	-7.49	3.37e-13	8.73e-07	-0.48	-0.32	P wave duration;	chr5:45804191	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.638	rs62371967	ENSG00000231752.4	EMBP1	7.49	3.42e-13	8.85e-07	0.47	0.32	P wave duration;	chr5:45897706	chr1:121519112~121571892:+
LUAD	trans	rs7937890	0.598	rs10734225	ENSG00000236360.2	RP11-334A14.2	7.48	3.56e-13	9.2e-07	0.43	0.32	Mitochondrial DNA levels;	chr11:14421448	chr1:52993201~52993702:-
LUAD	trans	rs10037055	0.947	rs10063803	ENSG00000228305.2	AC016734.2	7.48	3.6e-13	9.3e-07	0.38	0.32	Migraine without aura;	chr5:177240326	chr2:63622178~63622831:-
LUAD	trans	rs1816752	0.875	rs3783076	ENSG00000224976.2	PARP4P2	-7.47	3.7e-13	9.56e-07	-0.39	-0.32	Obesity-related traits;	chr13:24490319	chr13:19349137~19407962:+
LUAD	trans	rs7937890	0.572	rs2597218	ENSG00000236360.2	RP11-334A14.2	7.47	3.75e-13	9.69e-07	0.43	0.32	Mitochondrial DNA levels;	chr11:14510792	chr1:52993201~52993702:-
LUAD	trans	rs2069408	1	rs2069408	ENSG00000212994.5	RPS26P6	-7.47	3.81e-13	9.83e-07	-0.4	-0.32	Asthma;	chr12:55970537	chr8:100895771~100896118:+
LUAD	trans	rs13217239	0.646	rs10946888	ENSG00000242375.1	RP11-498P14.3	7.47	3.82e-13	9.88e-07	0.41	0.32	Schizophrenia;	chr6:26983899	chr9:97195351~97197687:-
LUAD	trans	rs4276421	0.577	rs10054424	ENSG00000231752.4	EMBP1	7.47	3.85e-13	9.94e-07	0.45	0.32	P wave duration;	chr5:45748769	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.593	rs13359915	ENSG00000231752.4	EMBP1	-7.47	3.87e-13	9.98e-07	-0.48	-0.32	P wave duration;	chr5:45769816	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.615	rs7730617	ENSG00000231752.4	EMBP1	7.46	3.97e-13	1.02e-06	0.47	0.32	P wave duration;	chr5:45840201	chr1:121519112~121571892:+
LUAD	trans	rs1190596	1	rs1190596	ENSG00000181359.5	HSP90AA6P	7.46	3.98e-13	1.03e-06	0.4	0.32	Behavioural disinhibition (generation interaction);	chr14:102129288	chr4:170581470~170605450:-
LUAD	trans	rs10242455	0.571	rs73713594	ENSG00000228834.1	RP11-249L21.4	7.46	4.02e-13	1.04e-06	0.74	0.32	Blood metabolite levels;	chr7:99728875	chr6:108907615~108907873:-
LUAD	trans	rs11868206	1	rs11868206	ENSG00000234130.2	RP13-88F20.1	7.46	4.05e-13	1.04e-06	0.43	0.32	Mean platelet volume;	chr17:35632228	chrX:93222220~93225015:-
LUAD	trans	rs4276421	0.593	rs6451820	ENSG00000231752.4	EMBP1	-7.46	4.05e-13	1.04e-06	-0.48	-0.32	P wave duration;	chr5:45775207	chr1:121519112~121571892:+
LUAD	trans	rs3740713	1	rs3740713	ENSG00000235847.2	LDHAP7	7.46	4.16e-13	1.07e-06	0.59	0.32	Amyotrophic lateral sclerosis (sporadic);	chr11:18429549	chr2:84777259~84778223:-
LUAD	trans	rs12497850	0.931	rs1134591	ENSG00000197582.5	GPX1P1	7.46	4.2e-13	1.08e-06	0.42	0.32	Parkinson's disease;	chr3:48935459	chrX:13378735~13379340:-
LUAD	trans	rs12497850	0.931	rs6442130	ENSG00000197582.5	GPX1P1	7.46	4.21e-13	1.08e-06	0.43	0.32	Parkinson's disease;	chr3:48740594	chrX:13378735~13379340:-
LUAD	trans	rs13217239	0.646	rs10946898	ENSG00000242375.1	RP11-498P14.3	7.45	4.24e-13	1.09e-06	0.4	0.32	Schizophrenia;	chr6:27036105	chr9:97195351~97197687:-
LUAD	trans	rs7554511	0.763	rs3913893	ENSG00000244144.1	RP11-757F18.3	-7.45	4.34e-13	1.12e-06	-0.43	-0.32	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201046655	chr3:112185480~112185998:-
LUAD	trans	rs7192380	0.893	rs12921782	ENSG00000257513.6	NPIPB1P	-7.45	4.41e-13	1.13e-06	-0.32	-0.32	Sjögren's syndrome;	chr16:69746119	chr18:11619509~11639699:-
LUAD	trans	rs877636	0.669	rs7297175	ENSG00000227586.5	RP11-162A23.5	-7.44	4.66e-13	1.2e-06	-0.36	-0.32	Cognitive function;	chr12:56080024	chr10:123171535~123171875:-
LUAD	trans	rs6424115	1	rs1018396	ENSG00000228217.1	AL390877.1	-7.43	4.84e-13	1.24e-06	-0.4	-0.32	Immature fraction of reticulocytes;	chr1:23807122	chr1:117778087~117778506:-
LUAD	trans	rs12439619	0.508	rs8023960	ENSG00000235370.6	DNM1P51	-7.43	4.9e-13	1.26e-06	-0.36	-0.32	Intelligence (multi-trait analysis);	chr15:82206704	chr15:84398316~84411701:-
LUAD	trans	rs616147	1	rs616147	ENSG00000214263.2	RPSAP53	-7.43	5.17e-13	1.32e-06	-0.44	-0.32	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39492990	chr13:67266845~67267706:-
LUAD	trans	rs877636	0.692	rs10876870	ENSG00000227586.5	RP11-162A23.5	-7.42	5.19e-13	1.33e-06	-0.36	-0.32	Cognitive function;	chr12:56084218	chr10:123171535~123171875:-
LUAD	trans	rs877636	0.692	rs7971751	ENSG00000227586.5	RP11-162A23.5	-7.42	5.19e-13	1.33e-06	-0.36	-0.32	Cognitive function;	chr12:56084874	chr10:123171535~123171875:-
LUAD	trans	rs73110464	0.505	rs2638503	ENSG00000254285.3	KRT8P3	-7.42	5.22e-13	1.33e-06	-0.42	-0.32	Cancer (pleiotropy);	chr12:52913585	chr8:61578220~61579668:+
LUAD	trans	rs1292059	1	rs1292059	ENSG00000187870.7	RNFT1P3	7.42	5.27e-13	1.35e-06	0.51	0.32	Eosinophil percentage of granulocytes;	chr17:59880527	chr17:20743333~20754501:-
LUAD	trans	rs877636	0.702	rs773110	ENSG00000196656.7	AC004057.1	7.42	5.31e-13	1.36e-06	0.36	0.32	Cognitive function;	chr12:55981353	chr4:113214046~113217170:-
LUAD	trans	rs877636	0.702	rs773111	ENSG00000196656.7	AC004057.1	7.42	5.31e-13	1.36e-06	0.36	0.32	Cognitive function;	chr12:55981956	chr4:113214046~113217170:-
LUAD	trans	rs877636	0.702	rs773112	ENSG00000196656.7	AC004057.1	7.42	5.31e-13	1.36e-06	0.36	0.32	Cognitive function;	chr12:55982097	chr4:113214046~113217170:-
LUAD	trans	rs4276421	0.593	rs6451822	ENSG00000231752.4	EMBP1	-7.42	5.43e-13	1.39e-06	-0.47	-0.32	P wave duration;	chr5:45804888	chr1:121519112~121571892:+
LUAD	trans	rs877636	0.702	rs773110	ENSG00000234354.3	RPS26P47	7.42	5.47e-13	1.4e-06	0.37	0.32	Cognitive function;	chr12:55981353	chr13:100539901~100540248:-
LUAD	trans	rs877636	0.702	rs773111	ENSG00000234354.3	RPS26P47	7.42	5.47e-13	1.4e-06	0.37	0.32	Cognitive function;	chr12:55981956	chr13:100539901~100540248:-
LUAD	trans	rs877636	0.702	rs773112	ENSG00000234354.3	RPS26P47	7.42	5.47e-13	1.4e-06	0.37	0.32	Cognitive function;	chr12:55982097	chr13:100539901~100540248:-
LUAD	trans	rs4276421	0.593	rs10462095	ENSG00000231752.4	EMBP1	-7.42	5.51e-13	1.41e-06	-0.47	-0.32	P wave duration;	chr5:45797500	chr1:121519112~121571892:+
LUAD	trans	rs66887589	0.616	rs11731675	ENSG00000275858.1	RP11-291L22.8	7.42	5.51e-13	1.41e-06	0.35	0.32	Diastolic blood pressure;	chr4:119291359	chr10:38450738~38451069:-
LUAD	trans	rs877636	0.702	rs773109	ENSG00000196656.7	AC004057.1	7.42	5.53e-13	1.41e-06	0.36	0.32	Cognitive function;	chr12:55980911	chr4:113214046~113217170:-
LUAD	trans	rs4276421	0.593	rs4551074	ENSG00000231752.4	EMBP1	-7.42	5.53e-13	1.41e-06	-0.47	-0.32	P wave duration;	chr5:45792651	chr1:121519112~121571892:+
LUAD	trans	rs916888	0.773	rs9896243	ENSG00000204650.12	CRHR1-IT1	7.41	5.55e-13	1.42e-06	0.44	0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45620328~45648216:+
LUAD	trans	rs877636	0.692	rs11171739	ENSG00000243538.1	CTB-55B8.1	7.41	5.71e-13	1.46e-06	0.34	0.32	Cognitive function;	chr12:56076841	chr5:16902294~16902641:-
LUAD	trans	rs7930295	0.505	rs34303332	ENSG00000236257.1	EI24P2	7.41	5.76e-13	1.47e-06	0.45	0.32	Schizophrenia;	chr11:125544288	chr1:158454198~158455273:+
LUAD	trans	rs4276421	0.615	rs12109205	ENSG00000231752.4	EMBP1	7.41	5.9e-13	1.5e-06	0.47	0.32	P wave duration;	chr5:45876576	chr1:121519112~121571892:+
LUAD	trans	rs7121616	0.576	rs4802	ENSG00000229091.2	HSPA8P8	7.4	5.93e-13	1.51e-06	0.42	0.32	Breast cancer;	chr11:123057914	chr7:10451311~10452526:+
LUAD	trans	rs4276421	0.593	rs7706676	ENSG00000231752.4	EMBP1	-7.4	5.98e-13	1.53e-06	-0.47	-0.32	P wave duration;	chr5:45784368	chr1:121519112~121571892:+
LUAD	trans	rs877636	0.669	rs7297175	ENSG00000204652.6	RPS26P8	-7.4	6.06e-13	1.54e-06	-0.37	-0.32	Cognitive function;	chr12:56080024	chr17:45608571~45608918:+
LUAD	trans	rs877636	0.669	rs7297175	ENSG00000233778.3	RP11-777J24.1	-7.4	6.08e-13	1.55e-06	-0.34	-0.32	Cognitive function;	chr12:56080024	chr8:92144088~92144435:-
LUAD	trans	rs7662987	0.762	rs2903160	ENSG00000233859.2	ADH5P4	7.4	6.11e-13	1.56e-06	0.58	0.32	Smoking initiation;	chr4:99107818	chr6:65836930~65838039:-
LUAD	trans	rs4276421	0.615	rs10064278	ENSG00000231752.4	EMBP1	-7.4	6.23e-13	1.59e-06	-0.45	-0.32	P wave duration;	chr5:45786496	chr1:121519112~121571892:+
LUAD	trans	rs12439619	0.508	rs8042665	ENSG00000235370.6	DNM1P51	-7.4	6.3e-13	1.6e-06	-0.36	-0.32	Intelligence (multi-trait analysis);	chr15:82189008	chr15:84398316~84411701:-
LUAD	trans	rs4276421	0.593	rs6898646	ENSG00000231752.4	EMBP1	7.4	6.32e-13	1.61e-06	0.46	0.32	P wave duration;	chr5:45841837	chr1:121519112~121571892:+
LUAD	trans	rs7312770	1	rs7312770	ENSG00000227586.5	RP11-162A23.5	-7.39	6.34e-13	1.61e-06	-0.35	-0.32	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr10:123171535~123171875:-
LUAD	trans	rs673253	0.686	rs1887402	ENSG00000231007.5	CDC20P1	7.39	6.38e-13	1.62e-06	0.4	0.32	Intelligence (multi-trait analysis);	chr1:43570414	chr9:87011652~87013151:+
LUAD	trans	rs1816752	0.875	rs59531061	ENSG00000224976.2	PARP4P2	-7.39	6.47e-13	1.64e-06	-0.38	-0.32	Obesity-related traits;	chr13:24507297	chr13:19349137~19407962:+
LUAD	trans	rs4276421	0.593	rs10056041	ENSG00000231752.4	EMBP1	-7.39	6.49e-13	1.65e-06	-0.47	-0.32	P wave duration;	chr5:45786075	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.593	rs7706959	ENSG00000231752.4	EMBP1	-7.39	6.53e-13	1.66e-06	-0.48	-0.32	P wave duration;	chr5:45793689	chr1:121519112~121571892:+
LUAD	trans	rs7937890	0.56	rs2597194	ENSG00000236360.2	RP11-334A14.2	7.39	6.54e-13	1.66e-06	0.42	0.32	Mitochondrial DNA levels;	chr11:14475723	chr1:52993201~52993702:-
LUAD	trans	rs7937890	0.593	rs2597189	ENSG00000236360.2	RP11-334A14.2	7.39	6.54e-13	1.66e-06	0.42	0.32	Mitochondrial DNA levels;	chr11:14490514	chr1:52993201~52993702:-
LUAD	trans	rs1190596	0.526	rs1190572	ENSG00000181359.5	HSP90AA6P	7.39	6.59e-13	1.67e-06	0.36	0.32	Behavioural disinhibition (generation interaction);	chr14:102168252	chr4:170581470~170605450:-
LUAD	trans	rs7312770	0.637	rs705700	ENSG00000227586.5	RP11-162A23.5	7.39	6.62e-13	1.68e-06	0.36	0.32	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr10:123171535~123171875:-
LUAD	trans	rs3740713	1	rs73440636	ENSG00000235847.2	LDHAP7	7.39	6.71e-13	1.7e-06	0.57	0.32	Amyotrophic lateral sclerosis (sporadic);	chr11:18452009	chr2:84777259~84778223:-
LUAD	trans	rs916888	0.61	rs199530	ENSG00000280022.1	RP11-707O23.1	-7.39	6.75e-13	1.71e-06	-0.4	-0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:45592621~45593369:+
LUAD	trans	rs8067354	0.645	rs72838857	ENSG00000187870.7	RNFT1P3	7.38	6.87e-13	1.74e-06	0.49	0.32	Hemoglobin concentration;	chr17:59759406	chr17:20743333~20754501:-
LUAD	trans	rs8067354	0.645	rs16943838	ENSG00000187870.7	RNFT1P3	7.38	6.87e-13	1.74e-06	0.49	0.32	Hemoglobin concentration;	chr17:59762243	chr17:20743333~20754501:-
LUAD	trans	rs8067354	0.645	rs1874548	ENSG00000187870.7	RNFT1P3	7.38	6.87e-13	1.74e-06	0.49	0.32	Hemoglobin concentration;	chr17:59763996	chr17:20743333~20754501:-
LUAD	trans	rs13190036	0.515	rs2878686	ENSG00000228305.2	AC016734.2	-7.38	6.9e-13	1.75e-06	-0.41	-0.32	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177206748	chr2:63622178~63622831:-
LUAD	trans	rs4276421	0.55	rs62373044	ENSG00000231752.4	EMBP1	7.38	6.91e-13	1.75e-06	0.48	0.32	P wave duration;	chr5:46005052	chr1:121519112~121571892:+
LUAD	trans	rs673253	0.686	rs943513	ENSG00000231007.5	CDC20P1	7.38	6.96e-13	1.76e-06	0.4	0.32	Intelligence (multi-trait analysis);	chr1:43569801	chr9:87011652~87013151:+
LUAD	trans	rs10037055	1	rs10037055	ENSG00000228305.2	AC016734.2	-7.38	6.97e-13	1.77e-06	-0.37	-0.32	Migraine without aura;	chr5:177264278	chr2:63622178~63622831:-
LUAD	trans	rs673253	0.638	rs552638	ENSG00000231007.5	CDC20P1	7.38	7.12e-13	1.8e-06	0.4	0.32	Intelligence (multi-trait analysis);	chr1:43577721	chr9:87011652~87013151:+
LUAD	trans	rs13217239	0.621	rs12527231	ENSG00000242375.1	RP11-498P14.3	7.38	7.17e-13	1.82e-06	0.4	0.32	Schizophrenia;	chr6:27033509	chr9:97195351~97197687:-
LUAD	trans	rs13217239	0.646	rs12523820	ENSG00000242375.1	RP11-498P14.3	7.38	7.17e-13	1.82e-06	0.4	0.32	Schizophrenia;	chr6:27033723	chr9:97195351~97197687:-
LUAD	trans	rs1816752	0.905	rs11839006	ENSG00000224976.2	PARP4P2	-7.38	7.18e-13	1.82e-06	-0.37	-0.32	Obesity-related traits;	chr13:24435893	chr13:19349137~19407962:+
LUAD	trans	rs13217239	0.646	rs6937880	ENSG00000242375.1	RP11-498P14.3	7.38	7.21e-13	1.82e-06	0.4	0.32	Schizophrenia;	chr6:27032457	chr9:97195351~97197687:-
LUAD	trans	rs3740713	1	rs12289603	ENSG00000235847.2	LDHAP7	7.38	7.24e-13	1.83e-06	0.56	0.32	Amyotrophic lateral sclerosis (sporadic);	chr11:18449823	chr2:84777259~84778223:-
LUAD	trans	rs7121616	0.576	rs11218967	ENSG00000229091.2	HSPA8P8	7.38	7.25e-13	1.83e-06	0.42	0.32	Breast cancer;	chr11:123087551	chr7:10451311~10452526:+
LUAD	trans	rs13190036	0.551	rs9313751	ENSG00000228305.2	AC016734.2	-7.37	7.28e-13	1.84e-06	-0.41	-0.32	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177217174	chr2:63622178~63622831:-
LUAD	trans	rs916888	0.61	rs199452	ENSG00000280022.1	RP11-707O23.1	7.37	7.3e-13	1.85e-06	0.4	0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:45592621~45593369:+
LUAD	trans	rs9467773	0.511	rs11755443	ENSG00000242375.1	RP11-498P14.3	7.37	7.32e-13	1.85e-06	0.41	0.32	Intelligence (multi-trait analysis);	chr6:26923824	chr9:97195351~97197687:-
LUAD	trans	rs673253	0.71	rs56175694	ENSG00000231007.5	CDC20P1	7.37	7.33e-13	1.85e-06	0.41	0.32	Intelligence (multi-trait analysis);	chr1:43599477	chr9:87011652~87013151:+
LUAD	trans	rs1816752	0.87	rs2033955	ENSG00000224976.2	PARP4P2	-7.37	7.5e-13	1.89e-06	-0.37	-0.32	Obesity-related traits;	chr13:24436406	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.87	rs2033954	ENSG00000224976.2	PARP4P2	-7.37	7.5e-13	1.89e-06	-0.37	-0.32	Obesity-related traits;	chr13:24436429	chr13:19349137~19407962:+
LUAD	trans	rs8067354	0.645	rs2645492	ENSG00000187870.7	RNFT1P3	-7.37	7.59e-13	1.92e-06	-0.47	-0.32	Hemoglobin concentration;	chr17:59798193	chr17:20743333~20754501:-
LUAD	trans	rs13217239	0.646	rs12527111	ENSG00000242375.1	RP11-498P14.3	7.37	7.62e-13	1.92e-06	0.4	0.32	Schizophrenia;	chr6:27038696	chr9:97195351~97197687:-
LUAD	trans	rs12439619	0.53	rs7162177	ENSG00000235370.6	DNM1P51	-7.37	7.66e-13	1.93e-06	-0.36	-0.32	Intelligence (multi-trait analysis);	chr15:82181728	chr15:84398316~84411701:-
LUAD	trans	rs673253	0.686	rs596522	ENSG00000231007.5	CDC20P1	7.37	7.67e-13	1.93e-06	0.41	0.32	Intelligence (multi-trait analysis);	chr1:43600753	chr9:87011652~87013151:+
LUAD	trans	rs3096299	0.503	rs4785677	ENSG00000215030.5	RPL13P12	-7.36	8e-13	2.02e-06	-0.35	-0.32	Multiple myeloma (IgH translocation);	chr16:89488693	chr17:17383377~17384012:-
LUAD	trans	rs380904	0.519	rs10102146	ENSG00000213130.3	EEF1DP5	7.36	8.06e-13	2.03e-06	0.48	0.32	Venous thromboembolism (SNP x SNP interaction);	chr8:143566986	chr6:128580113~128580884:-
LUAD	trans	rs13190036	0.551	rs7710269	ENSG00000228305.2	AC016734.2	-7.36	8.15e-13	2.05e-06	-0.41	-0.32	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177187528	chr2:63622178~63622831:-
LUAD	trans	rs877636	0.692	rs2271194	ENSG00000227586.5	RP11-162A23.5	-7.36	8.22e-13	2.07e-06	-0.36	-0.32	Cognitive function;	chr12:56083910	chr10:123171535~123171875:-
LUAD	trans	rs7121616	0.563	rs1461494	ENSG00000229091.2	HSPA8P8	7.36	8.24e-13	2.07e-06	0.41	0.32	Breast cancer;	chr11:123055777	chr7:10451311~10452526:+
LUAD	trans	rs4276421	0.533	rs34930360	ENSG00000231752.4	EMBP1	7.36	8.27e-13	2.08e-06	0.5	0.32	P wave duration;	chr5:46120740	chr1:121519112~121571892:+
LUAD	trans	rs546131	0.928	rs572690	ENSG00000225531.1	RP11-196I18.3	7.35	8.36e-13	2.1e-06	0.4	0.32	Lung disease severity in cystic fibrosis;	chr11:34812067	chr9:107116829~107117557:+
LUAD	trans	rs673253	0.593	rs3791134	ENSG00000231007.5	CDC20P1	7.35	8.37e-13	2.11e-06	0.4	0.32	Intelligence (multi-trait analysis);	chr1:43583485	chr9:87011652~87013151:+
LUAD	trans	rs673253	0.662	rs61769642	ENSG00000231007.5	CDC20P1	7.35	8.37e-13	2.11e-06	0.4	0.32	Intelligence (multi-trait analysis);	chr1:43585959	chr9:87011652~87013151:+
LUAD	trans	rs673253	0.686	rs3791139	ENSG00000231007.5	CDC20P1	7.35	8.37e-13	2.11e-06	0.4	0.32	Intelligence (multi-trait analysis);	chr1:43586100	chr9:87011652~87013151:+
LUAD	trans	rs7113874	0.659	rs2166470	ENSG00000266891.1	RP11-692N5.2	-7.35	8.38e-13	2.11e-06	-0.45	-0.32	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8501625	chr18:9734882~9735602:-
LUAD	trans	rs877636	0.702	rs773109	ENSG00000234354.3	RPS26P47	7.35	8.4e-13	2.11e-06	0.37	0.32	Cognitive function;	chr12:55980911	chr13:100539901~100540248:-
LUAD	trans	rs877636	0.702	rs61937249	ENSG00000196656.7	AC004057.1	7.35	8.63e-13	2.17e-06	0.36	0.32	Cognitive function;	chr12:55988132	chr4:113214046~113217170:-
LUAD	trans	rs546131	0.963	rs539044	ENSG00000225531.1	RP11-196I18.3	7.35	8.63e-13	2.17e-06	0.4	0.32	Lung disease severity in cystic fibrosis;	chr11:34819995	chr9:107116829~107117557:+
LUAD	trans	rs7121616	0.531	rs10892958	ENSG00000229091.2	HSPA8P8	7.35	8.68e-13	2.18e-06	0.44	0.32	Breast cancer;	chr11:123061415	chr7:10451311~10452526:+
LUAD	trans	rs4276421	0.593	rs9687374	ENSG00000231752.4	EMBP1	-7.35	8.76e-13	2.2e-06	-0.47	-0.32	P wave duration;	chr5:45796838	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.593	rs4866978	ENSG00000231752.4	EMBP1	-7.35	8.76e-13	2.2e-06	-0.47	-0.32	P wave duration;	chr5:45800636	chr1:121519112~121571892:+
LUAD	trans	rs916888	0.61	rs199436	ENSG00000280022.1	RP11-707O23.1	-7.35	8.76e-13	2.2e-06	-0.4	-0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:45592621~45593369:+
LUAD	trans	rs4276421	0.593	rs6872194	ENSG00000231752.4	EMBP1	-7.35	8.78e-13	2.2e-06	-0.47	-0.32	P wave duration;	chr5:45792959	chr1:121519112~121571892:+
LUAD	trans	rs6424115	0.867	rs11588187	ENSG00000228217.1	AL390877.1	-7.35	8.87e-13	2.22e-06	-0.39	-0.32	Immature fraction of reticulocytes;	chr1:23818557	chr1:117778087~117778506:-
LUAD	trans	rs7937890	0.572	rs2597202	ENSG00000236360.2	RP11-334A14.2	7.34	9.02e-13	2.26e-06	0.42	0.32	Mitochondrial DNA levels;	chr11:14463099	chr1:52993201~52993702:-
LUAD	trans	rs3096299	0.503	rs9925045	ENSG00000215030.5	RPL13P12	-7.34	9.02e-13	2.26e-06	-0.35	-0.32	Multiple myeloma (IgH translocation);	chr16:89490068	chr17:17383377~17384012:-
LUAD	trans	rs4276421	0.509	rs10067206	ENSG00000231752.4	EMBP1	7.34	9.08e-13	2.27e-06	0.48	0.32	P wave duration;	chr5:46027737	chr1:121519112~121571892:+
LUAD	trans	rs13416322	0.68	rs12623848	ENSG00000214286.2	PDCL3P3	7.34	9.13e-13	2.29e-06	0.42	0.32	Intelligence (multi-trait analysis);	chr2:100536576	chr3:17877455~17878169:-
LUAD	trans	rs916888	0.61	rs199446	ENSG00000280022.1	RP11-707O23.1	-7.34	9.22e-13	2.31e-06	-0.4	-0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:45592621~45593369:+
LUAD	trans	rs916888	0.61	rs199536	ENSG00000280022.1	RP11-707O23.1	-7.34	9.22e-13	2.31e-06	-0.4	-0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:45592621~45593369:+
LUAD	trans	rs1816752	0.905	rs9511260	ENSG00000224976.2	PARP4P2	-7.34	9.3e-13	2.33e-06	-0.37	-0.32	Obesity-related traits;	chr13:24437038	chr13:19349137~19407962:+
LUAD	trans	rs7937890	0.706	rs7115393	ENSG00000236360.2	RP11-334A14.2	-7.34	9.36e-13	2.34e-06	-0.39	-0.32	Mitochondrial DNA levels;	chr11:14246832	chr1:52993201~52993702:-
LUAD	trans	rs877636	1	rs2292239	ENSG00000233778.3	RP11-777J24.1	7.34	9.37e-13	2.34e-06	0.33	0.32	Cognitive function;	chr12:56088396	chr8:92144088~92144435:-
LUAD	trans	rs4276421	0.593	rs4569882	ENSG00000231752.4	EMBP1	7.33	9.56e-13	2.39e-06	0.48	0.32	P wave duration;	chr5:46011875	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.593	rs13361609	ENSG00000231752.4	EMBP1	7.33	9.65e-13	2.41e-06	0.47	0.32	P wave duration;	chr5:45697360	chr1:121519112~121571892:+
LUAD	trans	rs10946940	0.632	rs9366698	ENSG00000204709.4	LINC01556	7.33	9.66e-13	2.42e-06	0.41	0.32	Systemic lupus erythematosus;	chr6:27704256	chr6:28943877~28944537:+
LUAD	trans	rs7121616	0.531	rs11218941	ENSG00000229091.2	HSPA8P8	7.33	9.77e-13	2.44e-06	0.44	0.32	Breast cancer;	chr11:123061701	chr7:10451311~10452526:+
LUAD	trans	rs6424115	0.965	rs2502986	ENSG00000228217.1	AL390877.1	-7.33	9.85e-13	2.46e-06	-0.39	-0.32	Immature fraction of reticulocytes;	chr1:23808802	chr1:117778087~117778506:-
LUAD	trans	rs877636	0.692	rs11171739	ENSG00000233778.3	RP11-777J24.1	7.33	9.87e-13	2.47e-06	0.34	0.32	Cognitive function;	chr12:56076841	chr8:92144088~92144435:-
LUAD	trans	rs13217239	0.646	rs10456352	ENSG00000242375.1	RP11-498P14.3	7.33	9.99e-13	2.49e-06	0.4	0.32	Schizophrenia;	chr6:27022579	chr9:97195351~97197687:-
LUAD	trans	rs13217239	0.646	rs4583981	ENSG00000242375.1	RP11-498P14.3	7.33	9.99e-13	2.49e-06	0.4	0.32	Schizophrenia;	chr6:27024244	chr9:97195351~97197687:-
LUAD	trans	rs12497850	0.644	rs11928552	ENSG00000197582.5	GPX1P1	7.32	1.02e-12	2.54e-06	0.43	0.32	Parkinson's disease;	chr3:48702450	chrX:13378735~13379340:-
LUAD	trans	rs1816752	0.819	rs7317504	ENSG00000224976.2	PARP4P2	-7.32	1.04e-12	2.6e-06	-0.36	-0.32	Obesity-related traits;	chr13:24411287	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.783	rs7317712	ENSG00000224976.2	PARP4P2	-7.32	1.04e-12	2.6e-06	-0.36	-0.32	Obesity-related traits;	chr13:24411365	chr13:19349137~19407962:+
LUAD	trans	rs673253	0.686	rs3791136	ENSG00000231007.5	CDC20P1	7.32	1.06e-12	2.64e-06	0.4	0.32	Intelligence (multi-trait analysis);	chr1:43584276	chr9:87011652~87013151:+
LUAD	trans	rs673253	0.686	rs6698389	ENSG00000231007.5	CDC20P1	7.32	1.06e-12	2.64e-06	0.4	0.32	Intelligence (multi-trait analysis);	chr1:43585903	chr9:87011652~87013151:+
LUAD	trans	rs673253	0.638	rs3791140	ENSG00000231007.5	CDC20P1	7.32	1.06e-12	2.64e-06	0.4	0.32	Intelligence (multi-trait analysis);	chr1:43586107	chr9:87011652~87013151:+
LUAD	trans	rs673253	0.686	rs501299	ENSG00000231007.5	CDC20P1	7.32	1.06e-12	2.64e-06	0.4	0.32	Intelligence (multi-trait analysis);	chr1:43586163	chr9:87011652~87013151:+
LUAD	trans	rs73110464	0.505	rs2682296	ENSG00000254285.3	KRT8P3	-7.31	1.11e-12	2.76e-06	-0.41	-0.32	Cancer (pleiotropy);	chr12:52914481	chr8:61578220~61579668:+
LUAD	trans	rs877636	0.74	rs705698	ENSG00000196656.7	AC004057.1	7.31	1.11e-12	2.77e-06	0.35	0.32	Cognitive function;	chr12:55990903	chr4:113214046~113217170:-
LUAD	trans	rs66887589	0.592	rs62320740	ENSG00000275858.1	RP11-291L22.8	7.31	1.11e-12	2.77e-06	0.35	0.32	Diastolic blood pressure;	chr4:119358331	chr10:38450738~38451069:-
LUAD	trans	rs877636	0.692	rs10876870	ENSG00000243538.1	CTB-55B8.1	-7.31	1.12e-12	2.79e-06	-0.33	-0.32	Cognitive function;	chr12:56084218	chr5:16902294~16902641:-
LUAD	trans	rs877636	0.692	rs7971751	ENSG00000243538.1	CTB-55B8.1	-7.31	1.12e-12	2.79e-06	-0.33	-0.32	Cognitive function;	chr12:56084874	chr5:16902294~16902641:-
LUAD	trans	rs7662987	0.818	rs35123946	ENSG00000228407.2	RP4-800M22.1	7.31	1.12e-12	2.79e-06	0.77	0.32	Smoking initiation;	chr4:99079760	chr1:52160261~52160600:-
LUAD	trans	rs11638815	0.603	rs7171180	ENSG00000235370.6	DNM1P51	7.31	1.14e-12	2.82e-06	0.38	0.32	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82640357	chr15:84398316~84411701:-
LUAD	trans	rs7113874	0.613	rs4326784	ENSG00000266891.1	RP11-692N5.2	7.31	1.14e-12	2.82e-06	0.46	0.32	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8511602	chr18:9734882~9735602:-
LUAD	trans	rs7113874	0.545	rs2084187	ENSG00000266891.1	RP11-692N5.2	7.31	1.14e-12	2.82e-06	0.46	0.32	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8515394	chr18:9734882~9735602:-
LUAD	trans	rs7113874	0.613	rs2100067	ENSG00000266891.1	RP11-692N5.2	7.31	1.14e-12	2.82e-06	0.46	0.32	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8515503	chr18:9734882~9735602:-
LUAD	trans	rs4276421	0.593	rs4437383	ENSG00000231752.4	EMBP1	7.31	1.15e-12	2.85e-06	0.47	0.32	P wave duration;	chr5:45679534	chr1:121519112~121571892:+
LUAD	trans	rs877636	1	rs705696	ENSG00000244604.1	RP11-713H12.1	7.31	1.15e-12	2.86e-06	0.37	0.32	Cognitive function;	chr12:56086864	chr17:8561230~8561576:+
LUAD	trans	rs1391708	0.504	rs11832720	ENSG00000121089.4	NACA3P	-7.31	1.16e-12	2.87e-06	-0.57	-0.32	Airway wall thickness;	chr12:56863460	chr4:164943290~164943937:+
LUAD	trans	rs66887589	0.592	rs28580295	ENSG00000275858.1	RP11-291L22.8	7.3	1.18e-12	2.92e-06	0.35	0.32	Diastolic blood pressure;	chr4:119357718	chr10:38450738~38451069:-
LUAD	trans	rs1190596	0.525	rs72698572	ENSG00000181359.5	HSP90AA6P	-7.3	1.18e-12	2.93e-06	-0.35	-0.32	Behavioural disinhibition (generation interaction);	chr14:102289870	chr4:170581470~170605450:-
LUAD	trans	rs1190596	0.525	rs8010950	ENSG00000181359.5	HSP90AA6P	-7.3	1.18e-12	2.93e-06	-0.35	-0.32	Behavioural disinhibition (generation interaction);	chr14:102291520	chr4:170581470~170605450:-
LUAD	trans	rs1816752	0.905	rs7339140	ENSG00000224976.2	PARP4P2	-7.3	1.2e-12	2.97e-06	-0.36	-0.32	Obesity-related traits;	chr13:24437764	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.87	rs9511261	ENSG00000224976.2	PARP4P2	-7.3	1.2e-12	2.97e-06	-0.36	-0.32	Obesity-related traits;	chr13:24437880	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.905	rs9511262	ENSG00000224976.2	PARP4P2	-7.3	1.2e-12	2.97e-06	-0.36	-0.32	Obesity-related traits;	chr13:24437885	chr13:19349137~19407962:+
LUAD	trans	rs673253	0.556	rs11577403	ENSG00000231007.5	CDC20P1	7.3	1.2e-12	2.98e-06	0.4	0.32	Intelligence (multi-trait analysis);	chr1:43524102	chr9:87011652~87013151:+
LUAD	trans	rs1816752	0.87	rs7320102	ENSG00000224976.2	PARP4P2	-7.3	1.23e-12	3.04e-06	-0.36	-0.32	Obesity-related traits;	chr13:24437435	chr13:19349137~19407962:+
LUAD	trans	rs916888	0.61	rs199438	ENSG00000280022.1	RP11-707O23.1	7.3	1.23e-12	3.05e-06	0.4	0.32	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:45592621~45593369:+
LUAD	trans	rs7200543	1	rs6498540	ENSG00000250569.1	NTAN1P2	7.29	1.25e-12	3.1e-06	0.36	0.32	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036737	chr8:86481754~86483002:-
LUAD	trans	rs877636	0.859	rs3741499	ENSG00000233778.3	RP11-777J24.1	-7.29	1.27e-12	3.14e-06	-0.34	-0.32	Cognitive function;	chr12:56080595	chr8:92144088~92144435:-
LUAD	trans	rs7113874	0.613	rs10840066	ENSG00000266891.1	RP11-692N5.2	7.29	1.27e-12	3.15e-06	0.46	0.32	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8510456	chr18:9734882~9735602:-
LUAD	trans	rs4276421	0.593	rs6894784	ENSG00000231752.4	EMBP1	7.29	1.28e-12	3.16e-06	0.47	0.32	P wave duration;	chr5:45710935	chr1:121519112~121571892:+
LUAD	trans	rs9467773	0.511	rs17278688	ENSG00000242375.1	RP11-498P14.3	7.29	1.28e-12	3.17e-06	0.41	0.32	Intelligence (multi-trait analysis);	chr6:26922357	chr9:97195351~97197687:-
LUAD	trans	rs877636	0.702	rs61937249	ENSG00000234354.3	RPS26P47	7.29	1.29e-12	3.18e-06	0.37	0.32	Cognitive function;	chr12:55988132	chr13:100539901~100540248:-
LUAD	trans	rs4276421	0.593	rs10214362	ENSG00000231752.4	EMBP1	7.29	1.29e-12	3.19e-06	0.47	0.32	P wave duration;	chr5:45952814	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.55	rs16902186	ENSG00000231752.4	EMBP1	7.29	1.29e-12	3.19e-06	0.48	0.32	P wave duration;	chr5:45611886	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.593	rs6873359	ENSG00000231752.4	EMBP1	7.29	1.3e-12	3.2e-06	0.47	0.32	P wave duration;	chr5:45694473	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.593	rs7719703	ENSG00000231752.4	EMBP1	-7.29	1.3e-12	3.21e-06	-0.47	-0.32	P wave duration;	chr5:45781860	chr1:121519112~121571892:+
LUAD	trans	rs10037055	0.853	rs10077929	ENSG00000228305.2	AC016734.2	7.28	1.34e-12	3.3e-06	0.35	0.32	Migraine without aura;	chr5:177270843	chr2:63622178~63622831:-
LUAD	trans	rs7113874	0.578	rs7924477	ENSG00000266891.1	RP11-692N5.2	7.28	1.34e-12	3.31e-06	0.46	0.32	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8516700	chr18:9734882~9735602:-
LUAD	trans	rs4276421	0.593	rs13178796	ENSG00000231752.4	EMBP1	7.28	1.36e-12	3.35e-06	0.47	0.32	P wave duration;	chr5:45684414	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.571	rs7703405	ENSG00000231752.4	EMBP1	-7.28	1.36e-12	3.36e-06	-0.45	-0.32	P wave duration;	chr5:45872218	chr1:121519112~121571892:+
LUAD	trans	rs7312770	0.637	rs705699	ENSG00000244604.1	RP11-713H12.1	7.28	1.37e-12	3.38e-06	0.35	0.32	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr17:8561230~8561576:+
LUAD	trans	rs4276421	0.509	rs10062391	ENSG00000231752.4	EMBP1	7.28	1.38e-12	3.4e-06	0.48	0.31	P wave duration;	chr5:45994818	chr1:121519112~121571892:+
LUAD	trans	rs1816752	0.783	rs7317439	ENSG00000224976.2	PARP4P2	-7.28	1.4e-12	3.44e-06	-0.36	-0.31	Obesity-related traits;	chr13:24410939	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.783	rs7139527	ENSG00000224976.2	PARP4P2	-7.28	1.4e-12	3.44e-06	-0.36	-0.31	Obesity-related traits;	chr13:24411374	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.819	rs9511240	ENSG00000224976.2	PARP4P2	-7.28	1.4e-12	3.44e-06	-0.36	-0.31	Obesity-related traits;	chr13:24411768	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.819	rs7988388	ENSG00000224976.2	PARP4P2	-7.28	1.4e-12	3.44e-06	-0.36	-0.31	Obesity-related traits;	chr13:24412675	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.875	rs7993132	ENSG00000224976.2	PARP4P2	-7.28	1.4e-12	3.44e-06	-0.36	-0.31	Obesity-related traits;	chr13:24412903	chr13:19349137~19407962:+
LUAD	trans	rs916888	0.821	rs70600	ENSG00000204650.12	CRHR1-IT1	7.28	1.4e-12	3.44e-06	0.44	0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45620328~45648216:+
LUAD	trans	rs877636	1	rs4759229	ENSG00000233778.3	RP11-777J24.1	-7.28	1.4e-12	3.46e-06	-0.34	-0.31	Cognitive function;	chr12:56080696	chr8:92144088~92144435:-
LUAD	trans	rs4276421	0.554	rs35304078	ENSG00000231752.4	EMBP1	7.28	1.41e-12	3.47e-06	0.47	0.31	P wave duration;	chr5:45685489	chr1:121519112~121571892:+
LUAD	trans	rs2060793	0.506	rs10741658	ENSG00000236360.2	RP11-334A14.2	7.27	1.42e-12	3.49e-06	0.4	0.31	Vitamin D levels;	chr11:14903190	chr1:52993201~52993702:-
LUAD	trans	rs2243480	0.706	rs6460257	ENSG00000273142.1	RP11-458F8.4	-7.27	1.42e-12	3.49e-06	-0.29	-0.31	Diabetic kidney disease;	chr7:65731813	chr7:66902857~66906297:+
LUAD	trans	rs7113874	0.802	rs7118611	ENSG00000266891.1	RP11-692N5.2	7.27	1.47e-12	3.61e-06	0.43	0.31	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8664138	chr18:9734882~9735602:-
LUAD	trans	rs7113874	0.802	rs11042030	ENSG00000266891.1	RP11-692N5.2	7.27	1.47e-12	3.61e-06	0.43	0.31	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8669171	chr18:9734882~9735602:-
LUAD	trans	rs916888	0.647	rs199524	ENSG00000280022.1	RP11-707O23.1	-7.27	1.47e-12	3.62e-06	-0.39	-0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:45592621~45593369:+
LUAD	trans	rs1816752	0.792	rs7330956	ENSG00000224976.2	PARP4P2	-7.27	1.48e-12	3.64e-06	-0.36	-0.31	Obesity-related traits;	chr13:24413174	chr13:19349137~19407962:+
LUAD	trans	rs4276421	0.53	rs10078485	ENSG00000231752.4	EMBP1	7.27	1.49e-12	3.65e-06	0.47	0.31	P wave duration;	chr5:45879307	chr1:121519112~121571892:+
LUAD	trans	rs877636	0.702	rs773108	ENSG00000196656.7	AC004057.1	7.26	1.52e-12	3.72e-06	0.36	0.31	Cognitive function;	chr12:55976127	chr4:113214046~113217170:-
LUAD	trans	rs7937890	0.599	rs2597204	ENSG00000236360.2	RP11-334A14.2	7.26	1.54e-12	3.78e-06	0.42	0.31	Mitochondrial DNA levels;	chr11:14459471	chr1:52993201~52993702:-
LUAD	trans	rs4276421	0.615	rs6877477	ENSG00000231752.4	EMBP1	7.26	1.57e-12	3.84e-06	0.47	0.31	P wave duration;	chr5:45825707	chr1:121519112~121571892:+
LUAD	trans	rs1816752	0.819	rs7316961	ENSG00000224976.2	PARP4P2	-7.26	1.57e-12	3.84e-06	-0.36	-0.31	Obesity-related traits;	chr13:24411039	chr13:19349137~19407962:+
LUAD	trans	rs7192380	0.893	rs12924052	ENSG00000257513.6	NPIPB1P	-7.26	1.57e-12	3.86e-06	-0.31	-0.31	Sjögren's syndrome;	chr16:69743343	chr18:11619509~11639699:-
LUAD	trans	rs916888	0.531	rs183211	ENSG00000280022.1	RP11-707O23.1	7.26	1.58e-12	3.88e-06	0.4	0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:45592621~45593369:+
LUAD	trans	rs13217239	0.646	rs35691005	ENSG00000242375.1	RP11-498P14.3	7.26	1.59e-12	3.88e-06	0.4	0.31	Schizophrenia;	chr6:27004291	chr9:97195351~97197687:-
LUAD	trans	rs13217239	0.646	rs10946891	ENSG00000242375.1	RP11-498P14.3	7.26	1.59e-12	3.88e-06	0.4	0.31	Schizophrenia;	chr6:27005436	chr9:97195351~97197687:-
LUAD	trans	rs13217239	0.646	rs12201393	ENSG00000242375.1	RP11-498P14.3	7.26	1.59e-12	3.88e-06	0.4	0.31	Schizophrenia;	chr6:27007911	chr9:97195351~97197687:-
LUAD	trans	rs916888	0.647	rs199523	ENSG00000280022.1	RP11-707O23.1	-7.26	1.61e-12	3.93e-06	-0.39	-0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:45592621~45593369:+
LUAD	trans	rs7937890	0.869	rs2915404	ENSG00000236360.2	RP11-334A14.2	7.26	1.61e-12	3.93e-06	0.39	0.31	Mitochondrial DNA levels;	chr11:14383279	chr1:52993201~52993702:-
LUAD	trans	rs4276421	0.53	rs72751925	ENSG00000231752.4	EMBP1	7.26	1.61e-12	3.94e-06	0.47	0.31	P wave duration;	chr5:45962607	chr1:121519112~121571892:+
LUAD	trans	rs4713118	0.523	rs2179096	ENSG00000204709.4	LINC01556	7.26	1.61e-12	3.94e-06	0.38	0.31	Parkinson's disease;	chr6:27698141	chr6:28943877~28944537:+
LUAD	trans	rs9581094	0.505	rs6490945	ENSG00000224976.2	PARP4P2	-7.25	1.63e-12	3.98e-06	-0.4	-0.31	Sudden cardiac arrest;	chr13:24514056	chr13:19349137~19407962:+
LUAD	trans	rs7113874	0.802	rs35319120	ENSG00000266891.1	RP11-692N5.2	7.25	1.64e-12	4.01e-06	0.42	0.31	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8648147	chr18:9734882~9735602:-
LUAD	trans	rs7312770	0.612	rs1873914	ENSG00000204652.6	RPS26P8	7.25	1.66e-12	4.05e-06	0.37	0.31	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr17:45608571~45608918:+
LUAD	trans	rs13217239	0.646	rs12209886	ENSG00000242375.1	RP11-498P14.3	7.25	1.67e-12	4.09e-06	0.4	0.31	Schizophrenia;	chr6:27016978	chr9:97195351~97197687:-
LUAD	trans	rs6940638	0.531	rs12211984	ENSG00000242375.1	RP11-498P14.3	7.25	1.67e-12	4.09e-06	0.4	0.31	Intelligence (multi-trait analysis);	chr6:27018275	chr9:97195351~97197687:-
LUAD	trans	rs13217239	0.646	rs10456351	ENSG00000242375.1	RP11-498P14.3	7.25	1.67e-12	4.09e-06	0.4	0.31	Schizophrenia;	chr6:27019013	chr9:97195351~97197687:-
LUAD	trans	rs4276421	0.55	rs62372041	ENSG00000231752.4	EMBP1	7.25	1.68e-12	4.11e-06	0.47	0.31	P wave duration;	chr5:45954946	chr1:121519112~121571892:+
LUAD	trans	rs7503168	0.908	rs9897552	ENSG00000234130.2	RP13-88F20.1	7.25	1.68e-12	4.11e-06	0.42	0.31	Plateletcrit;	chr17:35647462	chrX:93222220~93225015:-
LUAD	trans	rs8067354	0.645	rs2271304	ENSG00000187870.7	RNFT1P3	7.25	1.69e-12	4.14e-06	0.48	0.31	Hemoglobin concentration;	chr17:59737280	chr17:20743333~20754501:-
LUAD	trans	rs889398	0.617	rs4985447	ENSG00000257513.6	NPIPB1P	7.25	1.71e-12	4.17e-06	0.3	0.31	Body mass index;	chr16:69851263	chr18:11619509~11639699:-
LUAD	trans	rs4276421	0.571	rs10214057	ENSG00000231752.4	EMBP1	7.24	1.75e-12	4.28e-06	0.47	0.31	P wave duration;	chr5:45954403	chr1:121519112~121571892:+
LUAD	trans	rs7113874	0.802	rs10840102	ENSG00000266891.1	RP11-692N5.2	7.24	1.77e-12	4.33e-06	0.43	0.31	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8654691	chr18:9734882~9735602:-
LUAD	trans	rs7113874	0.802	rs7941510	ENSG00000266891.1	RP11-692N5.2	7.24	1.77e-12	4.33e-06	0.43	0.31	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8655516	chr18:9734882~9735602:-
LUAD	trans	rs889398	0.641	rs9936723	ENSG00000257513.6	NPIPB1P	7.24	1.79e-12	4.36e-06	0.3	0.31	Body mass index;	chr16:69850951	chr18:11619509~11639699:-
LUAD	trans	rs2657294	0.606	rs10824290	ENSG00000172974.11	AC007318.5	7.24	1.83e-12	4.45e-06	0.37	0.31	Pneumonia;	chr10:75204210	chr2:65205108~65205988:+
LUAD	trans	rs1816752	0.905	rs7995492	ENSG00000224976.2	PARP4P2	-7.24	1.84e-12	4.48e-06	-0.35	-0.31	Obesity-related traits;	chr13:24438885	chr13:19349137~19407962:+
LUAD	trans	rs6424115	1	rs2256179	ENSG00000228217.1	AL390877.1	7.24	1.85e-12	4.5e-06	0.39	0.31	Immature fraction of reticulocytes;	chr1:23805815	chr1:117778087~117778506:-
LUAD	trans	rs4276421	0.593	rs10058269	ENSG00000231752.4	EMBP1	7.23	1.91e-12	4.65e-06	0.47	0.31	P wave duration;	chr5:45750039	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.571	rs12386473	ENSG00000231752.4	EMBP1	7.23	1.92e-12	4.66e-06	0.47	0.31	P wave duration;	chr5:45961509	chr1:121519112~121571892:+
LUAD	trans	rs13190036	0.551	rs11957608	ENSG00000228305.2	AC016734.2	-7.23	1.93e-12	4.7e-06	-0.4	-0.31	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177228344	chr2:63622178~63622831:-
LUAD	trans	rs2288327	0.643	rs16866334	ENSG00000269800.1	PLEKHA3P1	7.23	1.96e-12	4.76e-06	0.41	0.31	Atrial fibrillation;	chr2:178471945	chr19:41521043~41521989:-
LUAD	trans	rs546131	0.928	rs535719	ENSG00000225531.1	RP11-196I18.3	7.23	1.97e-12	4.78e-06	0.4	0.31	Lung disease severity in cystic fibrosis;	chr11:34831835	chr9:107116829~107117557:+
LUAD	trans	rs4276421	0.55	rs62372974	ENSG00000231752.4	EMBP1	7.23	1.97e-12	4.78e-06	0.47	0.31	P wave duration;	chr5:45960277	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.593	rs10074312	ENSG00000231752.4	EMBP1	7.22	2.02e-12	4.91e-06	0.47	0.31	P wave duration;	chr5:45671565	chr1:121519112~121571892:+
LUAD	trans	rs7312770	0.637	rs705699	ENSG00000233778.3	RP11-777J24.1	7.22	2.03e-12	4.94e-06	0.34	0.31	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr8:92144088~92144435:-
LUAD	trans	rs7937890	0.559	rs2597196	ENSG00000236360.2	RP11-334A14.2	-7.22	2.05e-12	4.97e-06	-0.39	-0.31	Mitochondrial DNA levels;	chr11:14470055	chr1:52993201~52993702:-
LUAD	trans	rs11951515	0.509	rs12521249	ENSG00000174977.8	AC026271.5	7.22	2.05e-12	4.98e-06	0.32	0.31	Metabolite levels  (X-11787);	chr5:43558527	chr17:18650195~18651542:+
LUAD	trans	rs4276421	0.55	rs10038082	ENSG00000231752.4	EMBP1	7.22	2.05e-12	4.98e-06	0.47	0.31	P wave duration;	chr5:45963148	chr1:121519112~121571892:+
LUAD	trans	rs3740713	1	rs73440634	ENSG00000235847.2	LDHAP7	7.22	2.09e-12	5.06e-06	0.55	0.31	Amyotrophic lateral sclerosis (sporadic);	chr11:18451999	chr2:84777259~84778223:-
LUAD	trans	rs1816752	0.819	rs6490917	ENSG00000224976.2	PARP4P2	-7.22	2.1e-12	5.08e-06	-0.36	-0.31	Obesity-related traits;	chr13:24423119	chr13:19349137~19407962:+
LUAD	trans	rs12439619	0.693	rs7165536	ENSG00000235370.6	DNM1P51	-7.21	2.12e-12	5.14e-06	-0.43	-0.31	Intelligence (multi-trait analysis);	chr15:82273743	chr15:84398316~84411701:-
LUAD	trans	rs6499255	1	rs6499255	ENSG00000257513.6	NPIPB1P	7.21	2.12e-12	5.14e-06	0.36	0.31	IgE levels;	chr16:69796425	chr18:11619509~11639699:-
LUAD	trans	rs7554511	0.624	rs5010839	ENSG00000244144.1	RP11-757F18.3	-7.21	2.13e-12	5.16e-06	-0.43	-0.31	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201042916	chr3:112185480~112185998:-
LUAD	trans	rs1816752	0.721	rs7399656	ENSG00000224976.2	PARP4P2	-7.21	2.13e-12	5.17e-06	-0.35	-0.31	Obesity-related traits;	chr13:24415708	chr13:19349137~19407962:+
LUAD	trans	rs4276421	0.55	rs62372979	ENSG00000231752.4	EMBP1	7.21	2.17e-12	5.26e-06	0.47	0.31	P wave duration;	chr5:45964899	chr1:121519112~121571892:+
LUAD	trans	rs860295	0.529	rs1475766	ENSG00000241627.3	UBQLN4P1	7.21	2.18e-12	5.28e-06	0.29	0.31	Body mass index;	chr1:156011698	chr3:148985868~148987668:-
LUAD	trans	rs2657294	0.632	rs2657289	ENSG00000172974.11	AC007318.5	7.21	2.22e-12	5.36e-06	0.37	0.31	Pneumonia;	chr10:75206705	chr2:65205108~65205988:+
LUAD	trans	rs2288327	0.643	rs1559908	ENSG00000269800.1	PLEKHA3P1	-7.21	2.23e-12	5.39e-06	-0.41	-0.31	Atrial fibrillation;	chr2:178471620	chr19:41521043~41521989:-
LUAD	trans	rs12477438	0.52	rs6717729	ENSG00000276576.1	MRPL30P1	7.21	2.23e-12	5.41e-06	0.36	0.31	Chronic sinus infection;	chr2:99140478	chr6:57029521~57029988:+
LUAD	trans	rs28647808	0.881	rs4549850	ENSG00000234981.1	RP11-534L20.4	7.2	2.31e-12	5.59e-06	0.5	0.31	Blood protein levels;	chr9:133400111	chr1:206528915~206529706:+
LUAD	trans	rs1816752	0.774	rs2862895	ENSG00000224976.2	PARP4P2	-7.2	2.31e-12	5.59e-06	-0.36	-0.31	Obesity-related traits;	chr13:24410328	chr13:19349137~19407962:+
LUAD	trans	rs6743068	0.541	rs6761514	ENSG00000235105.1	RP11-329A14.1	7.2	2.32e-12	5.61e-06	0.36	0.31	Lymphocyte percentage of white cells;	chr2:201362826	chr1:48435967~48437223:+
LUAD	trans	rs4276421	0.593	rs10062641	ENSG00000231752.4	EMBP1	7.2	2.33e-12	5.64e-06	0.46	0.31	P wave duration;	chr5:45930240	chr1:121519112~121571892:+
LUAD	trans	rs7312770	0.612	rs773114	ENSG00000244604.1	RP11-713H12.1	7.2	2.33e-12	5.64e-06	0.35	0.31	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr17:8561230~8561576:+
LUAD	trans	rs7200543	1	rs1121	ENSG00000250569.1	NTAN1P2	7.2	2.34e-12	5.66e-06	0.35	0.31	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15037219	chr8:86481754~86483002:-
LUAD	trans	rs7200543	1	rs4985154	ENSG00000250569.1	NTAN1P2	7.2	2.34e-12	5.66e-06	0.35	0.31	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15037785	chr8:86481754~86483002:-
LUAD	trans	rs7200543	1	rs1135999	ENSG00000250569.1	NTAN1P2	7.2	2.34e-12	5.66e-06	0.35	0.31	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038105	chr8:86481754~86483002:-
LUAD	trans	rs7200543	1	rs1136001	ENSG00000250569.1	NTAN1P2	7.2	2.34e-12	5.66e-06	0.35	0.31	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038117	chr8:86481754~86483002:-
LUAD	trans	rs13217239	0.646	rs11756275	ENSG00000242375.1	RP11-498P14.3	-7.2	2.35e-12	5.69e-06	-0.39	-0.31	Schizophrenia;	chr6:27039334	chr9:97195351~97197687:-
LUAD	trans	rs7200543	1	rs2740	ENSG00000250569.1	NTAN1P2	7.2	2.38e-12	5.75e-06	0.35	0.31	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038251	chr8:86481754~86483002:-
LUAD	trans	rs28647808	0.881	rs7040821	ENSG00000234981.1	RP11-534L20.4	7.2	2.4e-12	5.79e-06	0.5	0.31	Blood protein levels;	chr9:133398457	chr1:206528915~206529706:+
LUAD	trans	rs28647808	0.881	rs7029256	ENSG00000234981.1	RP11-534L20.4	7.2	2.4e-12	5.79e-06	0.5	0.31	Blood protein levels;	chr9:133398528	chr1:206528915~206529706:+
LUAD	trans	rs28647808	0.881	rs7029386	ENSG00000234981.1	RP11-534L20.4	7.2	2.4e-12	5.79e-06	0.5	0.31	Blood protein levels;	chr9:133398609	chr1:206528915~206529706:+
LUAD	trans	rs28647808	0.881	rs28625799	ENSG00000234981.1	RP11-534L20.4	7.2	2.4e-12	5.79e-06	0.5	0.31	Blood protein levels;	chr9:133399428	chr1:206528915~206529706:+
LUAD	trans	rs28647808	0.881	rs4246171	ENSG00000234981.1	RP11-534L20.4	7.2	2.4e-12	5.79e-06	0.5	0.31	Blood protein levels;	chr9:133399602	chr1:206528915~206529706:+
LUAD	trans	rs28647808	0.881	rs28494844	ENSG00000234981.1	RP11-534L20.4	7.2	2.4e-12	5.79e-06	0.5	0.31	Blood protein levels;	chr9:133401060	chr1:206528915~206529706:+
LUAD	trans	rs28647808	0.881	rs7042326	ENSG00000234981.1	RP11-534L20.4	7.2	2.4e-12	5.79e-06	0.5	0.31	Blood protein levels;	chr9:133401507	chr1:206528915~206529706:+
LUAD	trans	rs28647808	0.618	rs7025970	ENSG00000234981.1	RP11-534L20.4	7.2	2.4e-12	5.79e-06	0.5	0.31	Blood protein levels;	chr9:133402044	chr1:206528915~206529706:+
LUAD	trans	rs28647808	0.748	rs28721280	ENSG00000234981.1	RP11-534L20.4	7.2	2.4e-12	5.79e-06	0.5	0.31	Blood protein levels;	chr9:133402189	chr1:206528915~206529706:+
LUAD	trans	rs28647808	0.881	rs28622217	ENSG00000234981.1	RP11-534L20.4	7.2	2.4e-12	5.79e-06	0.5	0.31	Blood protein levels;	chr9:133402194	chr1:206528915~206529706:+
LUAD	trans	rs28647808	0.881	rs28602295	ENSG00000234981.1	RP11-534L20.4	7.2	2.4e-12	5.79e-06	0.5	0.31	Blood protein levels;	chr9:133402342	chr1:206528915~206529706:+
LUAD	trans	rs12477438	0.52	rs4402818	ENSG00000276576.1	MRPL30P1	7.19	2.44e-12	5.88e-06	0.36	0.31	Chronic sinus infection;	chr2:99101145	chr6:57029521~57029988:+
LUAD	trans	rs4713118	1	rs4713118	ENSG00000204709.4	LINC01556	7.19	2.47e-12	5.96e-06	0.42	0.31	Parkinson's disease;	chr6:27709015	chr6:28943877~28944537:+
LUAD	trans	rs4713118	1	rs13215072	ENSG00000204709.4	LINC01556	7.19	2.47e-12	5.96e-06	0.42	0.31	Parkinson's disease;	chr6:27709949	chr6:28943877~28944537:+
LUAD	trans	rs7200543	1	rs16966953	ENSG00000250569.1	NTAN1P2	7.19	2.52e-12	6.08e-06	0.35	0.31	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15041997	chr8:86481754~86483002:-
LUAD	trans	rs7662987	0.762	rs13109048	ENSG00000233859.2	ADH5P4	7.19	2.54e-12	6.13e-06	0.55	0.31	Smoking initiation;	chr4:99086315	chr6:65836930~65838039:-
LUAD	trans	rs877636	0.74	rs772920	ENSG00000224553.1	AC008065.1	7.19	2.57e-12	6.19e-06	0.34	0.31	Cognitive function;	chr12:55996580	chr2:171374931~171375278:-
LUAD	trans	rs4276421	0.55	rs4242126	ENSG00000231752.4	EMBP1	-7.18	2.62e-12	6.3e-06	-0.47	-0.31	P wave duration;	chr5:45826271	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.593	rs28473745	ENSG00000231752.4	EMBP1	7.18	2.63e-12	6.33e-06	0.46	0.31	P wave duration;	chr5:45740468	chr1:121519112~121571892:+
LUAD	trans	rs7200543	1	rs34614532	ENSG00000250569.1	NTAN1P2	7.18	2.67e-12	6.42e-06	0.35	0.31	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15039051	chr8:86481754~86483002:-
LUAD	trans	rs916888	0.821	rs199514	ENSG00000204650.12	CRHR1-IT1	-7.18	2.67e-12	6.42e-06	-0.42	-0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45620328~45648216:+
LUAD	trans	rs3096299	0.504	rs4785574	ENSG00000215030.5	RPL13P12	-7.18	2.73e-12	6.56e-06	-0.35	-0.31	Multiple myeloma (IgH translocation);	chr16:89502467	chr17:17383377~17384012:-
LUAD	trans	rs916888	0.61	rs199454	ENSG00000280022.1	RP11-707O23.1	-7.17	2.77e-12	6.65e-06	-0.39	-0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:45592621~45593369:+
LUAD	trans	rs4276421	0.53	rs4552614	ENSG00000231752.4	EMBP1	7.17	2.79e-12	6.69e-06	0.47	0.31	P wave duration;	chr5:46017620	chr1:121519112~121571892:+
LUAD	trans	rs1816752	0.633	rs8002387	ENSG00000224976.2	PARP4P2	-7.17	2.79e-12	6.7e-06	-0.36	-0.31	Obesity-related traits;	chr13:24416306	chr13:19349137~19407962:+
LUAD	trans	rs7200543	0.961	rs1741	ENSG00000250569.1	NTAN1P2	7.17	2.79e-12	6.7e-06	0.35	0.31	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036494	chr8:86481754~86483002:-
LUAD	trans	rs4276421	0.593	rs72750046	ENSG00000231752.4	EMBP1	7.17	2.8e-12	6.72e-06	0.46	0.31	P wave duration;	chr5:45930775	chr1:121519112~121571892:+
LUAD	trans	rs673253	0.608	rs605709	ENSG00000231007.5	CDC20P1	7.17	2.82e-12	6.76e-06	0.4	0.31	Intelligence (multi-trait analysis);	chr1:43592796	chr9:87011652~87013151:+
LUAD	trans	rs673253	0.71	rs583040	ENSG00000231007.5	CDC20P1	7.17	2.82e-12	6.76e-06	0.4	0.31	Intelligence (multi-trait analysis);	chr1:43594812	chr9:87011652~87013151:+
LUAD	trans	rs673253	0.71	rs673242	ENSG00000231007.5	CDC20P1	7.17	2.82e-12	6.76e-06	0.4	0.31	Intelligence (multi-trait analysis);	chr1:43596488	chr9:87011652~87013151:+
LUAD	trans	rs1816752	0.87	rs8000215	ENSG00000224976.2	PARP4P2	-7.17	2.85e-12	6.83e-06	-0.36	-0.31	Obesity-related traits;	chr13:24435648	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.777	rs6490915	ENSG00000224976.2	PARP4P2	-7.17	2.89e-12	6.93e-06	-0.35	-0.31	Obesity-related traits;	chr13:24413724	chr13:19349137~19407962:+
LUAD	trans	rs916888	0.821	rs199506	ENSG00000204650.12	CRHR1-IT1	-7.17	2.92e-12	6.99e-06	-0.43	-0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45620328~45648216:+
LUAD	trans	rs889398	0.641	rs9936589	ENSG00000257513.6	NPIPB1P	7.17	2.92e-12	7e-06	0.3	0.31	Body mass index;	chr16:69850914	chr18:11619509~11639699:-
LUAD	trans	rs6756513	1	rs6756513	ENSG00000232654.1	FAM136BP	7.17	2.92e-12	7e-06	0.4	0.31	Breast cancer;Platelet count;	chr2:69945455	chr6:3045384~3045800:+
LUAD	trans	rs12145833	0.92	rs12354170	ENSG00000154608.12	CEP170P1	-7.16	2.94e-12	7.05e-06	-0.54	-0.31	Obesity (early onset extreme);	chr1:243294474	chr4:118467590~118554204:+
LUAD	trans	rs7200543	1	rs35574015	ENSG00000250569.1	NTAN1P2	7.16	2.96e-12	7.1e-06	0.35	0.31	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15052204	chr8:86481754~86483002:-
LUAD	trans	rs673253	0.686	rs17371903	ENSG00000231007.5	CDC20P1	7.16	3.03e-12	7.24e-06	0.4	0.31	Intelligence (multi-trait analysis);	chr1:43605020	chr9:87011652~87013151:+
LUAD	trans	rs12145833	1	rs12145833	ENSG00000154608.12	CEP170P1	7.16	3.03e-12	7.26e-06	0.52	0.31	Obesity (early onset extreme);	chr1:243320452	chr4:118467590~118554204:+
LUAD	trans	rs1816752	0.819	rs7985478	ENSG00000224976.2	PARP4P2	-7.16	3.06e-12	7.32e-06	-0.36	-0.31	Obesity-related traits;	chr13:24417135	chr13:19349137~19407962:+
LUAD	trans	rs12210905	0.748	rs6901225	ENSG00000242375.1	RP11-498P14.3	-7.16	3.12e-12	7.46e-06	-0.65	-0.31	Hip circumference adjusted for BMI;	chr6:26670263	chr9:97195351~97197687:-
LUAD	trans	rs1816752	0.819	rs4770665	ENSG00000224976.2	PARP4P2	-7.15	3.17e-12	7.57e-06	-0.35	-0.31	Obesity-related traits;	chr13:24414810	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.749	rs77832754	ENSG00000224976.2	PARP4P2	-7.15	3.17e-12	7.57e-06	-0.35	-0.31	Obesity-related traits;	chr13:24416016	chr13:19349137~19407962:+
LUAD	trans	rs7121616	0.562	rs7131452	ENSG00000229091.2	HSPA8P8	7.15	3.22e-12	7.69e-06	0.41	0.31	Breast cancer;	chr11:123065314	chr7:10451311~10452526:+
LUAD	trans	rs889398	0.617	rs11648348	ENSG00000257513.6	NPIPB1P	7.15	3.26e-12	7.79e-06	0.3	0.31	Body mass index;	chr16:69856819	chr18:11619509~11639699:-
LUAD	trans	rs889398	0.617	rs55887947	ENSG00000257513.6	NPIPB1P	7.15	3.28e-12	7.83e-06	0.3	0.31	Body mass index;	chr16:69859440	chr18:11619509~11639699:-
LUAD	trans	rs7662987	0.527	rs13106879	ENSG00000233859.2	ADH5P4	7.15	3.28e-12	7.83e-06	0.56	0.31	Smoking initiation;	chr4:99128867	chr6:65836930~65838039:-
LUAD	trans	rs4276421	0.571	rs6894273	ENSG00000231752.4	EMBP1	7.15	3.28e-12	7.84e-06	0.47	0.31	P wave duration;	chr5:45701407	chr1:121519112~121571892:+
LUAD	trans	rs6132905	0.52	rs2422823	ENSG00000257956.1	NOP56P3	-7.15	3.31e-12	7.9e-06	-0.39	-0.31	Mumps;	chr20:2665687	chr12:79558782~79559166:+
LUAD	trans	rs7200543	1	rs55727637	ENSG00000250569.1	NTAN1P2	7.14	3.37e-12	8.04e-06	0.36	0.31	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15051395	chr8:86481754~86483002:-
LUAD	trans	rs7769051	1	rs5006218	ENSG00000227615.1	RP11-864N7.2	7.14	3.39e-12	8.07e-06	0.5	0.31	Type 2 diabetes nephropathy;	chr6:132805081	chr11:74745716~74746114:-
LUAD	trans	rs7200543	1	rs14347	ENSG00000250569.1	NTAN1P2	7.14	3.42e-12	8.14e-06	0.35	0.31	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15040032	chr8:86481754~86483002:-
LUAD	trans	rs916888	0.821	rs415430	ENSG00000204650.12	CRHR1-IT1	-7.14	3.43e-12	8.17e-06	-0.42	-0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45620328~45648216:+
LUAD	trans	rs916888	0.779	rs430685	ENSG00000204650.12	CRHR1-IT1	-7.14	3.43e-12	8.17e-06	-0.42	-0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45620328~45648216:+
LUAD	trans	rs877636	1	rs705696	ENSG00000233778.3	RP11-777J24.1	7.14	3.53e-12	8.41e-06	0.35	0.31	Cognitive function;	chr12:56086864	chr8:92144088~92144435:-
LUAD	trans	rs673253	0.686	rs72673082	ENSG00000231007.5	CDC20P1	7.14	3.54e-12	8.43e-06	0.39	0.31	Intelligence (multi-trait analysis);	chr1:43593571	chr9:87011652~87013151:+
LUAD	trans	rs1391708	1	rs1391708	ENSG00000121089.4	NACA3P	-7.14	3.55e-12	8.46e-06	-0.51	-0.31	Airway wall thickness;	chr12:56911796	chr4:164943290~164943937:+
LUAD	trans	rs7937890	0.668	rs12361851	ENSG00000236360.2	RP11-334A14.2	-7.14	3.57e-12	8.49e-06	-0.38	-0.31	Mitochondrial DNA levels;	chr11:14246122	chr1:52993201~52993702:-
LUAD	trans	rs12497850	1	rs12493578	ENSG00000197582.5	GPX1P1	-7.13	3.59e-12	8.55e-06	-0.42	-0.31	Parkinson's disease;	chr3:48692683	chrX:13378735~13379340:-
LUAD	trans	rs7192380	0.893	rs1469908	ENSG00000257513.6	NPIPB1P	-7.13	3.63e-12	8.63e-06	-0.3	-0.31	Sjögren's syndrome;	chr16:69730509	chr18:11619509~11639699:-
LUAD	trans	rs10037055	0.636	rs13166688	ENSG00000228305.2	AC016734.2	-7.13	3.63e-12	8.64e-06	-0.4	-0.31	Migraine without aura;	chr5:177156965	chr2:63622178~63622831:-
LUAD	trans	rs7312770	0.637	rs705699	ENSG00000227586.5	RP11-162A23.5	7.13	3.63e-12	8.64e-06	0.35	0.31	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr10:123171535~123171875:-
LUAD	trans	rs1391708	0.504	rs75465620	ENSG00000121089.4	NACA3P	-7.13	3.68e-12	8.75e-06	-0.56	-0.31	Airway wall thickness;	chr12:56865907	chr4:164943290~164943937:+
LUAD	trans	rs1816752	0.905	rs9511266	ENSG00000224976.2	PARP4P2	-7.13	3.77e-12	8.94e-06	-0.35	-0.31	Obesity-related traits;	chr13:24438366	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.817	rs7985394	ENSG00000224976.2	PARP4P2	-7.13	3.77e-12	8.94e-06	-0.35	-0.31	Obesity-related traits;	chr13:24438714	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.789	rs7986037	ENSG00000224976.2	PARP4P2	-7.13	3.77e-12	8.94e-06	-0.35	-0.31	Obesity-related traits;	chr13:24438715	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.905	rs7995909	ENSG00000224976.2	PARP4P2	-7.12	3.97e-12	9.4e-06	-0.35	-0.31	Obesity-related traits;	chr13:24439159	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.905	rs6490927	ENSG00000224976.2	PARP4P2	-7.12	3.97e-12	9.4e-06	-0.35	-0.31	Obesity-related traits;	chr13:24439802	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.905	rs6490928	ENSG00000224976.2	PARP4P2	-7.12	3.97e-12	9.4e-06	-0.35	-0.31	Obesity-related traits;	chr13:24439921	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.905	rs6490929	ENSG00000224976.2	PARP4P2	-7.12	3.97e-12	9.4e-06	-0.35	-0.31	Obesity-related traits;	chr13:24440114	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.87	rs7998797	ENSG00000224976.2	PARP4P2	-7.12	3.97e-12	9.4e-06	-0.35	-0.31	Obesity-related traits;	chr13:24440850	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.87	rs7981337	ENSG00000224976.2	PARP4P2	-7.12	3.97e-12	9.4e-06	-0.35	-0.31	Obesity-related traits;	chr13:24440915	chr13:19349137~19407962:+
LUAD	trans	rs4276421	0.571	rs4560554	ENSG00000231752.4	EMBP1	7.12	3.99e-12	9.45e-06	0.47	0.31	P wave duration;	chr5:45867574	chr1:121519112~121571892:+
LUAD	trans	rs916888	0.697	rs199516	ENSG00000204650.12	CRHR1-IT1	-7.12	4.03e-12	9.54e-06	-0.42	-0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45620328~45648216:+
LUAD	trans	rs1816752	0.905	rs13428	ENSG00000224976.2	PARP4P2	-7.12	4.05e-12	9.6e-06	-0.36	-0.31	Obesity-related traits;	chr13:24435303	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.87	rs7981480	ENSG00000224976.2	PARP4P2	-7.12	4.08e-12	9.66e-06	-0.35	-0.31	Obesity-related traits;	chr13:24440966	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.837	rs4769355	ENSG00000224976.2	PARP4P2	-7.12	4.08e-12	9.66e-06	-0.35	-0.31	Obesity-related traits;	chr13:24441059	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.905	rs4770680	ENSG00000224976.2	PARP4P2	-7.12	4.08e-12	9.66e-06	-0.35	-0.31	Obesity-related traits;	chr13:24441110	chr13:19349137~19407962:+
LUAD	trans	rs6743068	0.521	rs2349078	ENSG00000235105.1	RP11-329A14.1	7.11	4.09e-12	9.69e-06	0.36	0.31	Lymphocyte percentage of white cells;	chr2:201369342	chr1:48435967~48437223:+
LUAD	trans	rs7200543	1	rs7200543	ENSG00000250569.1	NTAN1P2	-7.11	4.15e-12	9.83e-06	-0.34	-0.31	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036113	chr8:86481754~86483002:-
LUAD	trans	rs66887589	0.66	rs4833613	ENSG00000275858.1	RP11-291L22.8	-7.11	4.2e-12	9.94e-06	-0.35	-0.31	Diastolic blood pressure;	chr4:119229001	chr10:38450738~38451069:-
LUAD	trans	rs1816752	0.875	rs8001187	ENSG00000224976.2	PARP4P2	-7.11	4.21e-12	9.96e-06	-0.36	-0.31	Obesity-related traits;	chr13:24402276	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.783	rs9507333	ENSG00000224976.2	PARP4P2	-7.11	4.21e-12	9.96e-06	-0.36	-0.31	Obesity-related traits;	chr13:24404172	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.875	rs1050110	ENSG00000224976.2	PARP4P2	-7.11	4.22e-12	9.98e-06	-0.36	-0.31	Obesity-related traits;	chr13:24435347	chr13:19349137~19407962:+
LUAD	trans	rs7833986	0.534	rs17814089	ENSG00000244245.1	RP11-120B7.1	-7.11	4.24e-12	1e-05	-0.35	-0.31	Height;	chr8:56053004	chr5:108593609~108593967:+
LUAD	trans	rs2060793	0.55	rs1037378	ENSG00000236360.2	RP11-334A14.2	7.11	4.27e-12	1.01e-05	0.39	0.31	Vitamin D levels;	chr11:14830944	chr1:52993201~52993702:-
LUAD	trans	rs916888	0.821	rs199505	ENSG00000204650.12	CRHR1-IT1	-7.11	4.27e-12	1.01e-05	-0.42	-0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45620328~45648216:+
LUAD	trans	rs916888	0.821	rs70602	ENSG00000204650.12	CRHR1-IT1	-7.11	4.27e-12	1.01e-05	-0.42	-0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45620328~45648216:+
LUAD	trans	rs3096299	0.503	rs9940093	ENSG00000215030.5	RPL13P12	-7.11	4.28e-12	1.01e-05	-0.34	-0.31	Multiple myeloma (IgH translocation);	chr16:89492297	chr17:17383377~17384012:-
LUAD	trans	rs7937890	0.631	rs7118886	ENSG00000236360.2	RP11-334A14.2	7.11	4.28e-12	1.01e-05	0.38	0.31	Mitochondrial DNA levels;	chr11:14405971	chr1:52993201~52993702:-
LUAD	trans	rs1816752	0.755	rs1981277	ENSG00000224976.2	PARP4P2	-7.11	4.31e-12	1.02e-05	-0.35	-0.31	Obesity-related traits;	chr13:24409375	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.712	rs9507335	ENSG00000224976.2	PARP4P2	-7.11	4.31e-12	1.02e-05	-0.35	-0.31	Obesity-related traits;	chr13:24409766	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.811	rs9507337	ENSG00000224976.2	PARP4P2	-7.11	4.31e-12	1.02e-05	-0.35	-0.31	Obesity-related traits;	chr13:24410807	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.87	rs3825449	ENSG00000224976.2	PARP4P2	-7.11	4.32e-12	1.02e-05	-0.35	-0.31	Obesity-related traits;	chr13:24440303	chr13:19349137~19407962:+
LUAD	trans	rs877636	0.74	rs705702	ENSG00000224553.1	AC008065.1	-7.11	4.34e-12	1.02e-05	-0.34	-0.31	Cognitive function;	chr12:55996852	chr2:171374931~171375278:-
LUAD	trans	rs7192380	0.964	rs55780735	ENSG00000257513.6	NPIPB1P	-7.11	4.34e-12	1.03e-05	-0.3	-0.31	Sjögren's syndrome;	chr16:69706471	chr18:11619509~11639699:-
LUAD	trans	rs916888	0.821	rs199512	ENSG00000204650.12	CRHR1-IT1	-7.1	4.39e-12	1.04e-05	-0.42	-0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45620328~45648216:+
LUAD	trans	rs916888	0.821	rs199509	ENSG00000204650.12	CRHR1-IT1	-7.1	4.39e-12	1.04e-05	-0.42	-0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45620328~45648216:+
LUAD	trans	rs916888	0.821	rs199507	ENSG00000204650.12	CRHR1-IT1	-7.1	4.39e-12	1.04e-05	-0.42	-0.31	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45620328~45648216:+
LUAD	trans	rs4276421	0.593	rs61012768	ENSG00000231752.4	EMBP1	7.1	4.43e-12	1.04e-05	0.46	0.31	P wave duration;	chr5:45941000	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.593	rs7448897	ENSG00000231752.4	EMBP1	7.1	4.43e-12	1.04e-05	0.46	0.31	P wave duration;	chr5:45941347	chr1:121519112~121571892:+
LUAD	trans	rs13190036	0.551	rs11955537	ENSG00000228305.2	AC016734.2	-7.1	4.46e-12	1.05e-05	-0.39	-0.31	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;	chr5:177147087	chr2:63622178~63622831:-
LUAD	trans	rs2237234	0.542	rs7755997	ENSG00000242375.1	RP11-498P14.3	7.1	4.46e-12	1.05e-05	0.4	0.31	Autism spectrum disorder or schizophrenia;	chr6:26482820	chr9:97195351~97197687:-
LUAD	trans	rs1190596	0.525	rs7153005	ENSG00000181359.5	HSP90AA6P	7.1	4.47e-12	1.06e-05	0.33	0.31	Behavioural disinhibition (generation interaction);	chr14:102232262	chr4:170581470~170605450:-
LUAD	trans	rs4276421	0.593	rs6886950	ENSG00000231752.4	EMBP1	7.1	4.48e-12	1.06e-05	0.46	0.31	P wave duration;	chr5:45742867	chr1:121519112~121571892:+
LUAD	trans	rs7312770	0.612	rs1873914	ENSG00000233778.3	RP11-777J24.1	7.1	4.57e-12	1.08e-05	0.33	0.31	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr8:92144088~92144435:-
LUAD	trans	rs7200543	1	rs4500751	ENSG00000250569.1	NTAN1P2	7.1	4.58e-12	1.08e-05	0.35	0.31	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15046354	chr8:86481754~86483002:-
LUAD	trans	rs4276421	0.593	rs4132311	ENSG00000231752.4	EMBP1	7.1	4.65e-12	1.09e-05	0.47	0.31	P wave duration;	chr5:45867992	chr1:121519112~121571892:+
LUAD	trans	rs7200543	1	rs72774845	ENSG00000250569.1	NTAN1P2	7.1	4.65e-12	1.1e-05	0.35	0.31	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15054097	chr8:86481754~86483002:-
LUAD	trans	rs877636	1	rs877636	ENSG00000223416.3	RPS26P15	-7.09	4.67e-12	1.1e-05	-0.31	-0.31	Cognitive function;	chr12:56086799	chr1:58056133~58056480:-
LUAD	trans	rs7113874	0.802	rs10128597	ENSG00000266891.1	RP11-692N5.2	7.09	4.7e-12	1.11e-05	0.42	0.31	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8673283	chr18:9734882~9735602:-
LUAD	trans	rs673253	0.581	rs11210860	ENSG00000231007.5	CDC20P1	-7.09	4.71e-12	1.11e-05	-0.38	-0.31	Intelligence (multi-trait analysis);	chr1:43516856	chr9:87011652~87013151:+
LUAD	trans	rs4276421	0.571	rs62371969	ENSG00000231752.4	EMBP1	7.09	4.72e-12	1.11e-05	0.46	0.31	P wave duration;	chr5:45904700	chr1:121519112~121571892:+
LUAD	trans	rs2060793	0.526	rs10766194	ENSG00000236360.2	RP11-334A14.2	7.09	4.72e-12	1.11e-05	0.39	0.31	Vitamin D levels;	chr11:14842668	chr1:52993201~52993702:-
LUAD	trans	rs4276421	0.509	rs8185343	ENSG00000231752.4	EMBP1	7.09	4.78e-12	1.12e-05	0.46	0.31	P wave duration;	chr5:46012100	chr1:121519112~121571892:+
LUAD	trans	rs7769051	1	rs9493443	ENSG00000227615.1	RP11-864N7.2	7.09	4.83e-12	1.13e-05	0.49	0.31	Type 2 diabetes nephropathy;	chr6:132800210	chr11:74745716~74746114:-
LUAD	trans	rs7769051	1	rs12203977	ENSG00000227615.1	RP11-864N7.2	7.09	4.83e-12	1.13e-05	0.49	0.31	Type 2 diabetes nephropathy;	chr6:132801621	chr11:74745716~74746114:-
LUAD	trans	rs7769051	1	rs9493445	ENSG00000227615.1	RP11-864N7.2	7.09	4.83e-12	1.13e-05	0.49	0.31	Type 2 diabetes nephropathy;	chr6:132804270	chr11:74745716~74746114:-
LUAD	trans	rs7769051	1	rs9493446	ENSG00000227615.1	RP11-864N7.2	7.09	4.83e-12	1.13e-05	0.49	0.31	Type 2 diabetes nephropathy;	chr6:132804504	chr11:74745716~74746114:-
LUAD	trans	rs877636	0.702	rs773110	ENSG00000233778.3	RP11-777J24.1	7.09	4.89e-12	1.15e-05	0.35	0.31	Cognitive function;	chr12:55981353	chr8:92144088~92144435:-
LUAD	trans	rs877636	0.702	rs773111	ENSG00000233778.3	RP11-777J24.1	7.09	4.89e-12	1.15e-05	0.35	0.31	Cognitive function;	chr12:55981956	chr8:92144088~92144435:-
LUAD	trans	rs877636	0.702	rs773112	ENSG00000233778.3	RP11-777J24.1	7.09	4.89e-12	1.15e-05	0.35	0.31	Cognitive function;	chr12:55982097	chr8:92144088~92144435:-
LUAD	trans	rs6499244	0.508	rs11642008	ENSG00000257513.6	NPIPB1P	7.08	4.98e-12	1.17e-05	0.3	0.31	Menarche (age at onset);	chr16:69894736	chr18:11619509~11639699:-
LUAD	trans	rs1816752	0.905	rs1050112	ENSG00000224976.2	PARP4P2	-7.08	5.03e-12	1.18e-05	-0.36	-0.31	Obesity-related traits;	chr13:24435159	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.905	rs9511264	ENSG00000224976.2	PARP4P2	7.08	5.08e-12	1.19e-05	0.35	0.31	Obesity-related traits;	chr13:24438079	chr13:19349137~19407962:+
LUAD	trans	rs12477438	0.52	rs34766932	ENSG00000276576.1	MRPL30P1	7.08	5.13e-12	1.2e-05	0.36	0.31	Chronic sinus infection;	chr2:99120810	chr6:57029521~57029988:+
LUAD	trans	rs1816752	0.776	rs7998843	ENSG00000224976.2	PARP4P2	-7.08	5.16e-12	1.21e-05	-0.36	-0.31	Obesity-related traits;	chr13:24443147	chr13:19349137~19407962:+
LUAD	trans	rs58106596	0.8	rs11675826	ENSG00000259020.3	RP11-529H20.3	7.08	5.18e-12	1.21e-05	0.41	0.31	Lymphocyte counts;White blood cell count;	chr2:231700797	chr14:92026566~92026887:+
LUAD	trans	rs12477438	0.52	rs11123764	ENSG00000276576.1	MRPL30P1	7.08	5.19e-12	1.22e-05	0.35	0.31	Chronic sinus infection;	chr2:99134214	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.501	rs9941561	ENSG00000276576.1	MRPL30P1	7.08	5.19e-12	1.22e-05	0.35	0.31	Chronic sinus infection;	chr2:99137366	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.501	rs12995473	ENSG00000276576.1	MRPL30P1	7.08	5.19e-12	1.22e-05	0.35	0.31	Chronic sinus infection;	chr2:99148421	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.501	rs11685756	ENSG00000276576.1	MRPL30P1	7.08	5.19e-12	1.22e-05	0.35	0.31	Chronic sinus infection;	chr2:99149752	chr6:57029521~57029988:+
LUAD	trans	rs877636	1	rs2292239	ENSG00000244604.1	RP11-713H12.1	7.08	5.26e-12	1.23e-05	0.33	0.31	Cognitive function;	chr12:56088396	chr17:8561230~8561576:+
LUAD	trans	rs4276421	0.571	rs13361098	ENSG00000231752.4	EMBP1	7.08	5.28e-12	1.24e-05	0.46	0.31	P wave duration;	chr5:45967499	chr1:121519112~121571892:+
LUAD	trans	rs1816752	0.746	rs9511270	ENSG00000224976.2	PARP4P2	-7.08	5.3e-12	1.24e-05	-0.36	-0.31	Obesity-related traits;	chr13:24444542	chr13:19349137~19407962:+
LUAD	trans	rs673253	0.662	rs61769611	ENSG00000231007.5	CDC20P1	7.07	5.45e-12	1.28e-05	0.4	0.31	Intelligence (multi-trait analysis);	chr1:43563242	chr9:87011652~87013151:+
LUAD	trans	rs12439619	0.846	rs28470877	ENSG00000235370.6	DNM1P51	-7.07	5.46e-12	1.28e-05	-0.43	-0.31	Intelligence (multi-trait analysis);	chr15:82245797	chr15:84398316~84411701:-
LUAD	trans	rs1816752	0.819	rs4770664	ENSG00000224976.2	PARP4P2	-7.07	5.47e-12	1.28e-05	-0.35	-0.31	Obesity-related traits;	chr13:24414695	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.819	rs1981276	ENSG00000224976.2	PARP4P2	-7.07	5.48e-12	1.28e-05	-0.35	-0.31	Obesity-related traits;	chr13:24409361	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.837	rs57052031	ENSG00000224976.2	PARP4P2	-7.07	5.48e-12	1.28e-05	-0.35	-0.31	Obesity-related traits;	chr13:24409730	chr13:19349137~19407962:+
LUAD	trans	rs673253	0.662	rs11586016	ENSG00000231007.5	CDC20P1	7.07	5.52e-12	1.29e-05	0.38	0.31	Intelligence (multi-trait analysis);	chr1:43566122	chr9:87011652~87013151:+
LUAD	trans	rs4276421	0.593	rs7719500	ENSG00000231752.4	EMBP1	7.07	5.52e-12	1.29e-05	0.46	0.31	P wave duration;	chr5:45577870	chr1:121519112~121571892:+
LUAD	trans	rs16937956	0.626	rs34922792	ENSG00000266891.1	RP11-692N5.2	7.07	5.53e-12	1.29e-05	0.44	0.31	Body mass index;	chr11:8394952	chr18:9734882~9735602:-
LUAD	trans	rs16937956	0.597	rs35022013	ENSG00000266891.1	RP11-692N5.2	7.07	5.53e-12	1.29e-05	0.44	0.31	Body mass index;	chr11:8395956	chr18:9734882~9735602:-
LUAD	trans	rs4276421	0.55	rs1534392	ENSG00000231752.4	EMBP1	7.07	5.64e-12	1.32e-05	0.46	0.31	P wave duration;	chr5:45633255	chr1:121519112~121571892:+
LUAD	trans	rs6743068	0.541	rs10206231	ENSG00000235105.1	RP11-329A14.1	7.07	5.66e-12	1.32e-05	0.36	0.31	Lymphocyte percentage of white cells;	chr2:201364502	chr1:48435967~48437223:+
LUAD	trans	rs7200543	0.583	rs4985149	ENSG00000250569.1	NTAN1P2	7.06	5.79e-12	1.35e-05	0.35	0.31	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15053481	chr8:86481754~86483002:-
LUAD	trans	rs4713118	1	rs9468195	ENSG00000204709.4	LINC01556	7.06	5.82e-12	1.36e-05	0.41	0.31	Parkinson's disease;	chr6:27708530	chr6:28943877~28944537:+
LUAD	trans	rs4276421	0.509	rs10041094	ENSG00000231752.4	EMBP1	7.06	5.94e-12	1.38e-05	0.46	0.31	P wave duration;	chr5:45996800	chr1:121519112~121571892:+
LUAD	trans	rs12477438	0.52	rs6542869	ENSG00000276576.1	MRPL30P1	7.06	5.95e-12	1.39e-05	0.35	0.31	Chronic sinus infection;	chr2:99166940	chr6:57029521~57029988:+
LUAD	trans	rs4276421	0.593	rs16902199	ENSG00000231752.4	EMBP1	7.06	5.97e-12	1.39e-05	0.46	0.31	P wave duration;	chr5:45648655	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.593	rs2337954	ENSG00000231752.4	EMBP1	7.06	5.97e-12	1.39e-05	0.46	0.31	P wave duration;	chr5:45651767	chr1:121519112~121571892:+
LUAD	trans	rs837841	0.864	rs1660903	ENSG00000220842.6	RP11-572P18.1	-7.06	6.03e-12	1.4e-05	-0.31	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);	chr2:129289106	chr10:120354701~120355183:-
LUAD	trans	rs10242455	0.717	rs4646461	ENSG00000228834.1	RP11-249L21.4	7.06	6.04e-12	1.41e-05	0.66	0.31	Blood metabolite levels;	chr7:99733850	chr6:108907615~108907873:-
LUAD	trans	rs7113874	0.659	rs57757082	ENSG00000266891.1	RP11-692N5.2	7.05	6.06e-12	1.41e-05	0.45	0.31	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8507106	chr18:9734882~9735602:-
LUAD	trans	rs12477438	0.52	rs4851187	ENSG00000276576.1	MRPL30P1	-7.05	6.07e-12	1.41e-05	-0.35	-0.31	Chronic sinus infection;	chr2:99129397	chr6:57029521~57029988:+
LUAD	trans	rs889398	0.594	rs8047194	ENSG00000257513.6	NPIPB1P	7.05	6.09e-12	1.42e-05	0.29	0.31	Body mass index;	chr16:69857607	chr18:11619509~11639699:-
LUAD	trans	rs12477438	0.52	rs13035311	ENSG00000276576.1	MRPL30P1	7.05	6.22e-12	1.45e-05	0.35	0.31	Chronic sinus infection;	chr2:99100859	chr6:57029521~57029988:+
LUAD	trans	rs28647808	0.748	rs114667516	ENSG00000234981.1	RP11-534L20.4	7.05	6.25e-12	1.45e-05	0.49	0.31	Blood protein levels;	chr9:133393414	chr1:206528915~206529706:+
LUAD	trans	rs4276421	0.593	rs16902221	ENSG00000231752.4	EMBP1	7.05	6.25e-12	1.45e-05	0.46	0.31	P wave duration;	chr5:45739938	chr1:121519112~121571892:+
LUAD	trans	rs889398	0.617	rs4985450	ENSG00000257513.6	NPIPB1P	-7.05	6.28e-12	1.46e-05	-0.29	-0.31	Body mass index;	chr16:69867203	chr18:11619509~11639699:-
LUAD	trans	rs12439619	0.693	rs4778989	ENSG00000235370.6	DNM1P51	-7.05	6.28e-12	1.46e-05	-0.42	-0.31	Intelligence (multi-trait analysis);	chr15:82276963	chr15:84398316~84411701:-
LUAD	trans	rs6424115	1	rs7514394	ENSG00000228217.1	AL390877.1	7.05	6.28e-12	1.46e-05	0.38	0.31	Immature fraction of reticulocytes;	chr1:23773733	chr1:117778087~117778506:-
LUAD	trans	rs12439619	0.693	rs17269819	ENSG00000235370.6	DNM1P51	-7.05	6.39e-12	1.49e-05	-0.42	-0.31	Intelligence (multi-trait analysis);	chr15:82174660	chr15:84398316~84411701:-
LUAD	trans	rs12477438	0.52	rs6741772	ENSG00000276576.1	MRPL30P1	7.05	6.45e-12	1.5e-05	0.35	0.31	Chronic sinus infection;	chr2:99122498	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.52	rs6741773	ENSG00000276576.1	MRPL30P1	7.05	6.45e-12	1.5e-05	0.35	0.31	Chronic sinus infection;	chr2:99122499	chr6:57029521~57029988:+
LUAD	trans	rs4713118	1	rs1139226	ENSG00000204709.4	LINC01556	7.05	6.45e-12	1.5e-05	0.41	0.31	Parkinson's disease;	chr6:27707511	chr6:28943877~28944537:+
LUAD	trans	rs673253	0.581	rs2152113	ENSG00000231007.5	CDC20P1	-7.04	6.58e-12	1.53e-05	-0.39	-0.31	Intelligence (multi-trait analysis);	chr1:43517898	chr9:87011652~87013151:+
LUAD	trans	rs7312770	0.612	rs773114	ENSG00000227586.5	RP11-162A23.5	7.04	6.77e-12	1.57e-05	0.35	0.31	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr10:123171535~123171875:-
LUAD	trans	rs877636	0.74	rs772920	ENSG00000233778.3	RP11-777J24.1	7.04	6.78e-12	1.57e-05	0.35	0.31	Cognitive function;	chr12:55996580	chr8:92144088~92144435:-
LUAD	trans	rs1391708	1	rs7957145	ENSG00000121089.4	NACA3P	-7.04	6.79e-12	1.57e-05	-0.51	-0.31	Airway wall thickness;	chr12:56908336	chr4:164943290~164943937:+
LUAD	trans	rs1391708	0.834	rs4403833	ENSG00000121089.4	NACA3P	-7.04	6.85e-12	1.59e-05	-0.51	-0.31	Airway wall thickness;	chr12:56872137	chr4:164943290~164943937:+
LUAD	trans	rs28647808	0.748	rs28502181	ENSG00000234981.1	RP11-534L20.4	7.04	6.85e-12	1.59e-05	0.49	0.31	Blood protein levels;	chr9:133392016	chr1:206528915~206529706:+
LUAD	trans	rs7200543	0.961	rs3803573	ENSG00000250569.1	NTAN1P2	7.03	6.99e-12	1.62e-05	0.35	0.31	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15044556	chr8:86481754~86483002:-
LUAD	trans	rs7554511	0.763	rs55734382	ENSG00000244144.1	RP11-757F18.3	-7.03	7.02e-12	1.63e-05	-0.41	-0.31	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201049931	chr3:112185480~112185998:-
LUAD	trans	rs673253	0.593	rs3791151	ENSG00000231007.5	CDC20P1	7.03	7.06e-12	1.64e-05	0.4	0.31	Intelligence (multi-trait analysis);	chr1:43612931	chr9:87011652~87013151:+
LUAD	trans	rs7113874	0.612	rs11517715	ENSG00000266891.1	RP11-692N5.2	7.03	7.09e-12	1.64e-05	0.45	0.31	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8490341	chr18:9734882~9735602:-
LUAD	trans	rs7113874	0.659	rs12577287	ENSG00000266891.1	RP11-692N5.2	7.03	7.09e-12	1.64e-05	0.45	0.31	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8498370	chr18:9734882~9735602:-
LUAD	trans	rs7113874	0.659	rs12274454	ENSG00000266891.1	RP11-692N5.2	7.03	7.09e-12	1.64e-05	0.45	0.31	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8500419	chr18:9734882~9735602:-
LUAD	trans	rs7113874	0.659	rs7931834	ENSG00000266891.1	RP11-692N5.2	7.03	7.09e-12	1.64e-05	0.45	0.31	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8503746	chr18:9734882~9735602:-
LUAD	trans	rs7618501	0.966	rs2352974	ENSG00000197582.5	GPX1P1	7.03	7.19e-12	1.66e-05	0.38	0.31	Intelligence (multi-trait analysis);	chr3:49853180	chrX:13378735~13379340:-
LUAD	trans	rs6499255	0.951	rs16959025	ENSG00000257513.6	NPIPB1P	-7.03	7.23e-12	1.67e-05	-0.4	-0.31	IgE levels;	chr16:69661686	chr18:11619509~11639699:-
LUAD	trans	rs12145833	1	rs76473275	ENSG00000154608.12	CEP170P1	-7.03	7.23e-12	1.67e-05	-0.53	-0.31	Obesity (early onset extreme);	chr1:243297253	chr4:118467590~118554204:+
LUAD	trans	rs889398	0.617	rs6499265	ENSG00000257513.6	NPIPB1P	7.02	7.42e-12	1.71e-05	0.29	0.3	Body mass index;	chr16:69864095	chr18:11619509~11639699:-
LUAD	trans	rs889398	0.617	rs11075742	ENSG00000257513.6	NPIPB1P	7.02	7.46e-12	1.72e-05	0.29	0.3	Body mass index;	chr16:69865031	chr18:11619509~11639699:-
LUAD	trans	rs13217239	0.646	rs62401067	ENSG00000242375.1	RP11-498P14.3	7.02	7.59e-12	1.75e-05	0.39	0.3	Schizophrenia;	chr6:27050322	chr9:97195351~97197687:-
LUAD	trans	rs1816752	0.748	rs6490912	ENSG00000224976.2	PARP4P2	-7.02	7.64e-12	1.77e-05	-0.35	-0.3	Obesity-related traits;	chr13:24408941	chr13:19349137~19407962:+
LUAD	trans	rs4276421	0.593	rs12659948	ENSG00000231752.4	EMBP1	-7.02	7.69e-12	1.78e-05	-0.45	-0.3	P wave duration;	chr5:45739534	chr1:121519112~121571892:+
LUAD	trans	rs1816752	0.819	rs7400583	ENSG00000224976.2	PARP4P2	-7.02	7.72e-12	1.78e-05	-0.35	-0.3	Obesity-related traits;	chr13:24415916	chr13:19349137~19407962:+
LUAD	trans	rs7937890	0.684	rs12799007	ENSG00000236360.2	RP11-334A14.2	7.02	7.75e-12	1.79e-05	0.38	0.3	Mitochondrial DNA levels;	chr11:14404938	chr1:52993201~52993702:-
LUAD	trans	rs4276421	0.533	rs35197327	ENSG00000231752.4	EMBP1	7.02	7.81e-12	1.8e-05	0.46	0.3	P wave duration;	chr5:45616911	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.55	rs62367712	ENSG00000231752.4	EMBP1	7.01	7.86e-12	1.81e-05	0.47	0.3	P wave duration;	chr5:45766262	chr1:121519112~121571892:+
LUAD	trans	rs10037055	0.853	rs9313749	ENSG00000228305.2	AC016734.2	-7.01	7.89e-12	1.82e-05	-0.34	-0.3	Migraine without aura;	chr5:177170693	chr2:63622178~63622831:-
LUAD	trans	rs28647808	0.786	rs28458971	ENSG00000234981.1	RP11-534L20.4	7.01	7.94e-12	1.83e-05	0.49	0.3	Blood protein levels;	chr9:133389952	chr1:206528915~206529706:+
LUAD	trans	rs28647808	0.786	rs28590601	ENSG00000234981.1	RP11-534L20.4	7.01	7.94e-12	1.83e-05	0.49	0.3	Blood protein levels;	chr9:133390448	chr1:206528915~206529706:+
LUAD	trans	rs28647808	0.786	rs4962134	ENSG00000234981.1	RP11-534L20.4	7.01	7.94e-12	1.83e-05	0.49	0.3	Blood protein levels;	chr9:133390850	chr1:206528915~206529706:+
LUAD	trans	rs28647808	0.786	rs4962135	ENSG00000234981.1	RP11-534L20.4	7.01	7.94e-12	1.83e-05	0.49	0.3	Blood protein levels;	chr9:133390854	chr1:206528915~206529706:+
LUAD	trans	rs28647808	0.786	rs4962136	ENSG00000234981.1	RP11-534L20.4	7.01	7.94e-12	1.83e-05	0.49	0.3	Blood protein levels;	chr9:133391018	chr1:206528915~206529706:+
LUAD	trans	rs28647808	0.786	rs4962137	ENSG00000234981.1	RP11-534L20.4	7.01	7.94e-12	1.83e-05	0.49	0.3	Blood protein levels;	chr9:133391050	chr1:206528915~206529706:+
LUAD	trans	rs28647808	0.881	rs71483208	ENSG00000234981.1	RP11-534L20.4	7.01	7.94e-12	1.83e-05	0.49	0.3	Blood protein levels;	chr9:133393697	chr1:206528915~206529706:+
LUAD	trans	rs28647808	0.881	rs41316982	ENSG00000234981.1	RP11-534L20.4	7.01	7.94e-12	1.83e-05	0.49	0.3	Blood protein levels;	chr9:133393990	chr1:206528915~206529706:+
LUAD	trans	rs28647808	0.881	rs41316984	ENSG00000234981.1	RP11-534L20.4	7.01	7.94e-12	1.83e-05	0.49	0.3	Blood protein levels;	chr9:133394104	chr1:206528915~206529706:+
LUAD	trans	rs28647808	1	rs28591209	ENSG00000234981.1	RP11-534L20.4	7.01	7.94e-12	1.83e-05	0.49	0.3	Blood protein levels;	chr9:133394541	chr1:206528915~206529706:+
LUAD	trans	rs28647808	0.881	rs41297211	ENSG00000234981.1	RP11-534L20.4	7.01	7.94e-12	1.83e-05	0.49	0.3	Blood protein levels;	chr9:133395594	chr1:206528915~206529706:+
LUAD	trans	rs28647808	0.881	rs57394597	ENSG00000234981.1	RP11-534L20.4	7.01	7.94e-12	1.83e-05	0.49	0.3	Blood protein levels;	chr9:133395903	chr1:206528915~206529706:+
LUAD	trans	rs28647808	0.881	rs28461467	ENSG00000234981.1	RP11-534L20.4	7.01	7.94e-12	1.83e-05	0.49	0.3	Blood protein levels;	chr9:133396161	chr1:206528915~206529706:+
LUAD	trans	rs28647808	0.881	rs4962047	ENSG00000234981.1	RP11-534L20.4	7.01	7.94e-12	1.83e-05	0.49	0.3	Blood protein levels;	chr9:133397789	chr1:206528915~206529706:+
LUAD	trans	rs7937890	0.81	rs10734224	ENSG00000236360.2	RP11-334A14.2	7.01	7.98e-12	1.84e-05	0.38	0.3	Mitochondrial DNA levels;	chr11:14402578	chr1:52993201~52993702:-
LUAD	trans	rs4263408	0.934	rs2381428	ENSG00000237550.5	UBE2Q2P6	7.01	8e-12	1.84e-05	0.36	0.3	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39761846	chr15:82372196~82372912:-
LUAD	trans	rs4276421	0.593	rs10941704	ENSG00000231752.4	EMBP1	-7.01	8.21e-12	1.89e-05	-0.47	-0.3	P wave duration;	chr5:45783404	chr1:121519112~121571892:+
LUAD	trans	rs673253	0.556	rs35393217	ENSG00000231007.5	CDC20P1	7.01	8.22e-12	1.89e-05	0.4	0.3	Intelligence (multi-trait analysis);	chr1:43635977	chr9:87011652~87013151:+
LUAD	trans	rs12477438	0.52	rs7604557	ENSG00000276576.1	MRPL30P1	7.01	8.31e-12	1.91e-05	0.35	0.3	Chronic sinus infection;	chr2:99131366	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.52	rs6717723	ENSG00000276576.1	MRPL30P1	7.01	8.31e-12	1.91e-05	0.35	0.3	Chronic sinus infection;	chr2:99140467	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.52	rs11685759	ENSG00000276576.1	MRPL30P1	7.01	8.31e-12	1.91e-05	0.35	0.3	Chronic sinus infection;	chr2:99149754	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.52	rs11123765	ENSG00000276576.1	MRPL30P1	7.01	8.31e-12	1.91e-05	0.35	0.3	Chronic sinus infection;	chr2:99151601	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.501	rs2632260	ENSG00000276576.1	MRPL30P1	7.01	8.31e-12	1.91e-05	0.35	0.3	Chronic sinus infection;	chr2:99155127	chr6:57029521~57029988:+
LUAD	trans	rs877636	0.702	rs61937249	ENSG00000233778.3	RP11-777J24.1	7	8.39e-12	1.93e-05	0.35	0.3	Cognitive function;	chr12:55988132	chr8:92144088~92144435:-
LUAD	trans	rs1816752	0.638	rs9578730	ENSG00000224976.2	PARP4P2	-7	8.45e-12	1.94e-05	-0.35	-0.3	Obesity-related traits;	chr13:24425545	chr13:19349137~19407962:+
LUAD	trans	rs28647808	0.786	rs28649804	ENSG00000234981.1	RP11-534L20.4	7	8.47e-12	1.95e-05	0.49	0.3	Blood protein levels;	chr9:133391933	chr1:206528915~206529706:+
LUAD	trans	rs4713118	0.615	rs9348772	ENSG00000204709.4	LINC01556	7	8.52e-12	1.96e-05	0.37	0.3	Parkinson's disease;	chr6:27688311	chr6:28943877~28944537:+
LUAD	trans	rs12477438	0.52	rs2516829	ENSG00000276576.1	MRPL30P1	7	8.64e-12	1.99e-05	0.35	0.3	Chronic sinus infection;	chr2:99156738	chr6:57029521~57029988:+
LUAD	trans	rs13014235	0.846	rs10454127	ENSG00000235105.1	RP11-329A14.1	7	8.64e-12	1.99e-05	0.35	0.3	Basal cell carcinoma;	chr2:201347651	chr1:48435967~48437223:+
LUAD	trans	rs7312770	0.612	rs1873914	ENSG00000227586.5	RP11-162A23.5	7	8.66e-12	1.99e-05	0.35	0.3	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr10:123171535~123171875:-
LUAD	trans	rs4276421	0.55	rs1852598	ENSG00000231752.4	EMBP1	7	8.71e-12	2e-05	0.47	0.3	P wave duration;	chr5:45602874	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.55	rs6898825	ENSG00000231752.4	EMBP1	-7	8.73e-12	2e-05	-0.47	-0.3	P wave duration;	chr5:45842061	chr1:121519112~121571892:+
LUAD	trans	rs13416322	0.754	rs56890545	ENSG00000214286.2	PDCL3P3	7	8.75e-12	2.01e-05	0.42	0.3	Intelligence (multi-trait analysis);	chr2:100541138	chr3:17877455~17878169:-
LUAD	trans	rs7121616	0.562	rs2061602	ENSG00000229091.2	HSPA8P8	7	8.81e-12	2.02e-05	0.4	0.3	Breast cancer;	chr11:123065079	chr7:10451311~10452526:+
LUAD	trans	rs16937956	0.597	rs34617462	ENSG00000266891.1	RP11-692N5.2	7	8.86e-12	2.03e-05	0.44	0.3	Body mass index;	chr11:8403484	chr18:9734882~9735602:-
LUAD	trans	rs877636	0.702	rs773109	ENSG00000233778.3	RP11-777J24.1	7	8.9e-12	2.04e-05	0.35	0.3	Cognitive function;	chr12:55980911	chr8:92144088~92144435:-
LUAD	trans	rs1816752	0.712	rs2862898	ENSG00000224976.2	PARP4P2	-6.99	8.97e-12	2.06e-05	-0.35	-0.3	Obesity-related traits;	chr13:24414323	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.652	rs2902356	ENSG00000224976.2	PARP4P2	-6.99	8.97e-12	2.06e-05	-0.35	-0.3	Obesity-related traits;	chr13:24414333	chr13:19349137~19407962:+
LUAD	trans	rs4276421	0.53	rs16902217	ENSG00000231752.4	EMBP1	6.99	9.21e-12	2.11e-05	0.45	0.3	P wave duration;	chr5:45719223	chr1:121519112~121571892:+
LUAD	trans	rs1816752	0.805	rs61614647	ENSG00000224976.2	PARP4P2	-6.99	9.46e-12	2.17e-05	-0.35	-0.3	Obesity-related traits;	chr13:24441829	chr13:19349137~19407962:+
LUAD	trans	rs9468186	1	rs9468186	ENSG00000204709.4	LINC01556	6.99	9.5e-12	2.17e-05	0.4	0.3	Neuroticism;	chr6:27658852	chr6:28943877~28944537:+
LUAD	trans	rs7200543	1	rs16966952	ENSG00000250569.1	NTAN1P2	6.98	9.53e-12	2.18e-05	0.34	0.3	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15042086	chr8:86481754~86483002:-
LUAD	trans	rs12439619	0.693	rs28689861	ENSG00000235370.6	DNM1P51	-6.98	9.57e-12	2.19e-05	-0.41	-0.3	Intelligence (multi-trait analysis);	chr15:82206369	chr15:84398316~84411701:-
LUAD	trans	rs877636	0.702	rs773108	ENSG00000234354.3	RPS26P47	6.98	9.58e-12	2.19e-05	0.36	0.3	Cognitive function;	chr12:55976127	chr13:100539901~100540248:-
LUAD	trans	rs7192380	0.928	rs12933210	ENSG00000257513.6	NPIPB1P	-6.98	9.63e-12	2.2e-05	-0.3	-0.3	Sjögren's syndrome;	chr16:69708145	chr18:11619509~11639699:-
LUAD	trans	rs1816752	0.806	rs3816218	ENSG00000224976.2	PARP4P2	-6.98	9.67e-12	2.21e-05	-0.35	-0.3	Obesity-related traits;	chr13:24443033	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.666	rs7994022	ENSG00000224976.2	PARP4P2	-6.98	9.67e-12	2.21e-05	-0.35	-0.3	Obesity-related traits;	chr13:24443092	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.712	rs6490932	ENSG00000224976.2	PARP4P2	-6.98	9.67e-12	2.21e-05	-0.35	-0.3	Obesity-related traits;	chr13:24443313	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.713	rs7336357	ENSG00000224976.2	PARP4P2	-6.98	9.67e-12	2.21e-05	-0.35	-0.3	Obesity-related traits;	chr13:24443452	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.683	rs7330532	ENSG00000224976.2	PARP4P2	-6.98	9.67e-12	2.21e-05	-0.35	-0.3	Obesity-related traits;	chr13:24443453	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.59	rs61947036	ENSG00000224976.2	PARP4P2	-6.98	9.67e-12	2.21e-05	-0.35	-0.3	Obesity-related traits;	chr13:24443544	chr13:19349137~19407962:+
LUAD	trans	rs12477438	0.52	rs6708576	ENSG00000276576.1	MRPL30P1	6.98	9.68e-12	2.21e-05	0.35	0.3	Chronic sinus infection;	chr2:99184845	chr6:57029521~57029988:+
LUAD	trans	rs1383484	0.798	rs28645965	ENSG00000278603.1	RP13-608F4.5	6.98	9.69e-12	2.22e-05	0.41	0.3	Height;	chr15:83869893	chr15:82472203~82472426:+
LUAD	trans	rs1383484	0.798	rs28545666	ENSG00000278603.1	RP13-608F4.5	6.98	9.69e-12	2.22e-05	0.41	0.3	Height;	chr15:83869959	chr15:82472203~82472426:+
LUAD	trans	rs58106596	0.8	rs67402940	ENSG00000259020.3	RP11-529H20.3	6.98	9.82e-12	2.24e-05	0.4	0.3	Lymphocyte counts;White blood cell count;	chr2:231701789	chr14:92026566~92026887:+
LUAD	trans	rs7312770	1	rs7312770	ENSG00000223416.3	RPS26P15	-6.98	9.85e-12	2.25e-05	-0.29	-0.3	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr1:58056133~58056480:-
LUAD	trans	rs7200543	0.666	rs34955778	ENSG00000250569.1	NTAN1P2	6.98	9.88e-12	2.26e-05	0.32	0.3	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15045737	chr8:86481754~86483002:-
LUAD	trans	rs546131	0.928	rs553789	ENSG00000225531.1	RP11-196I18.3	6.98	9.96e-12	2.27e-05	0.38	0.3	Lung disease severity in cystic fibrosis;	chr11:34806032	chr9:107116829~107117557:+
LUAD	trans	rs1816752	1	rs9511265	ENSG00000224976.2	PARP4P2	-6.98	1.01e-11	2.32e-05	-0.36	-0.3	Obesity-related traits;	chr13:24438221	chr13:19349137~19407962:+
LUAD	trans	rs12439619	0.693	rs8034801	ENSG00000235370.6	DNM1P51	-6.97	1.02e-11	2.32e-05	-0.41	-0.3	Intelligence (multi-trait analysis);	chr15:82183996	chr15:84398316~84411701:-
LUAD	trans	rs1816752	1	rs7999554	ENSG00000224976.2	PARP4P2	-6.97	1.02e-11	2.33e-05	-0.36	-0.3	Obesity-related traits;	chr13:24435631	chr13:19349137~19407962:+
LUAD	trans	rs1383484	0.798	rs28728297	ENSG00000278603.1	RP13-608F4.5	6.97	1.02e-11	2.34e-05	0.41	0.3	Height;	chr15:83877660	chr15:82472203~82472426:+
LUAD	trans	rs1383484	0.798	rs28578450	ENSG00000278603.1	RP13-608F4.5	6.97	1.02e-11	2.34e-05	0.41	0.3	Height;	chr15:83877661	chr15:82472203~82472426:+
LUAD	trans	rs13217239	0.646	rs4403259	ENSG00000242375.1	RP11-498P14.3	6.97	1.04e-11	2.37e-05	0.39	0.3	Schizophrenia;	chr6:27029838	chr9:97195351~97197687:-
LUAD	trans	rs877636	0.74	rs705702	ENSG00000233778.3	RP11-777J24.1	-6.97	1.04e-11	2.37e-05	-0.35	-0.3	Cognitive function;	chr12:55996852	chr8:92144088~92144435:-
LUAD	trans	rs16937956	0.657	rs3751095	ENSG00000266891.1	RP11-692N5.2	6.97	1.04e-11	2.37e-05	0.44	0.3	Body mass index;	chr11:8413530	chr18:9734882~9735602:-
LUAD	trans	rs16937956	0.657	rs3751096	ENSG00000266891.1	RP11-692N5.2	6.97	1.04e-11	2.37e-05	0.44	0.3	Body mass index;	chr11:8413531	chr18:9734882~9735602:-
LUAD	trans	rs12145833	1	rs10926984	ENSG00000154608.12	CEP170P1	-6.97	1.07e-11	2.44e-05	-0.52	-0.3	Obesity (early onset extreme);	chr1:243298851	chr4:118467590~118554204:+
LUAD	trans	rs7200543	1	rs6498541	ENSG00000250569.1	NTAN1P2	6.97	1.08e-11	2.46e-05	0.34	0.3	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15046800	chr8:86481754~86483002:-
LUAD	trans	rs2243480	1	rs4718269	ENSG00000273142.1	RP11-458F8.4	6.96	1.09e-11	2.48e-05	0.32	0.3	Diabetic kidney disease;	chr7:65735810	chr7:66902857~66906297:+
LUAD	trans	rs6732160	0.588	rs13407363	ENSG00000236165.1	PRADC1P1	6.96	1.1e-11	2.51e-05	0.43	0.3	Intelligence (multi-trait analysis);	chr2:73145430	chr3:36976316~36976840:+
LUAD	trans	rs673253	0.571	rs55684236	ENSG00000231007.5	CDC20P1	6.96	1.11e-11	2.53e-05	0.4	0.3	Intelligence (multi-trait analysis);	chr1:43614338	chr9:87011652~87013151:+
LUAD	trans	rs80033912	0.64	rs6785832	ENSG00000197582.5	GPX1P1	6.96	1.14e-11	2.59e-05	0.42	0.3	Intelligence (multi-trait analysis);	chr3:49186883	chrX:13378735~13379340:-
LUAD	trans	rs1383484	0.754	rs8038109	ENSG00000278603.1	RP13-608F4.5	6.96	1.14e-11	2.6e-05	0.4	0.3	Height;	chr15:83913552	chr15:82472203~82472426:+
LUAD	trans	rs12477438	0.52	rs11123763	ENSG00000276576.1	MRPL30P1	6.96	1.15e-11	2.6e-05	0.35	0.3	Chronic sinus infection;	chr2:99134210	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.501	rs12992218	ENSG00000276576.1	MRPL30P1	6.96	1.15e-11	2.6e-05	0.35	0.3	Chronic sinus infection;	chr2:99137371	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.52	rs11677247	ENSG00000276576.1	MRPL30P1	6.96	1.15e-11	2.6e-05	0.35	0.3	Chronic sinus infection;	chr2:99139895	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.52	rs11890338	ENSG00000276576.1	MRPL30P1	6.96	1.15e-11	2.6e-05	0.35	0.3	Chronic sinus infection;	chr2:99151405	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.508	rs2516832	ENSG00000276576.1	MRPL30P1	6.96	1.15e-11	2.6e-05	0.35	0.3	Chronic sinus infection;	chr2:99154805	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.52	rs2516827	ENSG00000276576.1	MRPL30P1	6.96	1.15e-11	2.6e-05	0.35	0.3	Chronic sinus infection;	chr2:99156102	chr6:57029521~57029988:+
LUAD	trans	rs4276421	0.571	rs62371974	ENSG00000231752.4	EMBP1	6.96	1.15e-11	2.61e-05	0.46	0.3	P wave duration;	chr5:45910184	chr1:121519112~121571892:+
LUAD	trans	rs12439619	0.846	rs7496227	ENSG00000235370.6	DNM1P51	-6.96	1.15e-11	2.62e-05	-0.42	-0.3	Intelligence (multi-trait analysis);	chr15:82275241	chr15:84398316~84411701:-
LUAD	trans	rs12439619	0.693	rs9944185	ENSG00000235370.6	DNM1P51	-6.95	1.16e-11	2.64e-05	-0.4	-0.3	Intelligence (multi-trait analysis);	chr15:82157927	chr15:84398316~84411701:-
LUAD	trans	rs546131	0.928	rs499183	ENSG00000225531.1	RP11-196I18.3	6.95	1.17e-11	2.66e-05	0.38	0.3	Lung disease severity in cystic fibrosis;	chr11:34815131	chr9:107116829~107117557:+
LUAD	trans	rs12477438	0.52	rs11123762	ENSG00000276576.1	MRPL30P1	6.95	1.18e-11	2.67e-05	0.35	0.3	Chronic sinus infection;	chr2:99111326	chr6:57029521~57029988:+
LUAD	trans	rs1816752	0.837	rs7324645	ENSG00000224976.2	PARP4P2	-6.95	1.19e-11	2.7e-05	-0.34	-0.3	Obesity-related traits;	chr13:24426717	chr13:19349137~19407962:+
LUAD	trans	rs7746199	0.736	rs13202295	ENSG00000204709.4	LINC01556	6.95	1.2e-11	2.72e-05	0.65	0.3	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731058	chr6:28943877~28944537:+
LUAD	trans	rs673253	0.686	rs11580258	ENSG00000231007.5	CDC20P1	6.95	1.22e-11	2.77e-05	0.39	0.3	Intelligence (multi-trait analysis);	chr1:43550344	chr9:87011652~87013151:+
LUAD	trans	rs673253	0.662	rs11210869	ENSG00000231007.5	CDC20P1	6.94	1.24e-11	2.8e-05	0.39	0.3	Intelligence (multi-trait analysis);	chr1:43560369	chr9:87011652~87013151:+
LUAD	trans	rs546131	0.928	rs483976	ENSG00000225531.1	RP11-196I18.3	6.94	1.24e-11	2.82e-05	0.38	0.3	Lung disease severity in cystic fibrosis;	chr11:34818620	chr9:107116829~107117557:+
LUAD	trans	rs877636	0.702	rs773110	ENSG00000224553.1	AC008065.1	6.94	1.25e-11	2.82e-05	0.33	0.3	Cognitive function;	chr12:55981353	chr2:171374931~171375278:-
LUAD	trans	rs877636	0.702	rs773111	ENSG00000224553.1	AC008065.1	6.94	1.25e-11	2.82e-05	0.33	0.3	Cognitive function;	chr12:55981956	chr2:171374931~171375278:-
LUAD	trans	rs877636	0.702	rs773112	ENSG00000224553.1	AC008065.1	6.94	1.25e-11	2.82e-05	0.33	0.3	Cognitive function;	chr12:55982097	chr2:171374931~171375278:-
LUAD	trans	rs10100465	0.596	rs218009	ENSG00000233762.3	AC007969.5	6.94	1.28e-11	2.89e-05	0.31	0.3	Leprosy;	chr8:117704036	chr2:171517270~171517716:-
LUAD	trans	rs7833986	0.501	rs2976012	ENSG00000244245.1	RP11-120B7.1	6.94	1.28e-11	2.91e-05	0.35	0.3	Height;	chr8:56061784	chr5:108593609~108593967:+
LUAD	trans	rs7200543	1	rs3803575	ENSG00000250569.1	NTAN1P2	6.94	1.3e-11	2.95e-05	0.34	0.3	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15044590	chr8:86481754~86483002:-
LUAD	trans	rs889398	0.617	rs3790082	ENSG00000257513.6	NPIPB1P	6.94	1.31e-11	2.96e-05	0.29	0.3	Body mass index;	chr16:69862851	chr18:11619509~11639699:-
LUAD	trans	rs74781061	0.722	rs4073149	ENSG00000227288.3	RP5-837I24.1	-6.94	1.31e-11	2.96e-05	-0.53	-0.3	Endometriosis;	chr15:74606078	chr1:81501794~81503468:+
LUAD	trans	rs877636	0.702	rs61937249	ENSG00000224553.1	AC008065.1	6.93	1.33e-11	3.01e-05	0.33	0.3	Cognitive function;	chr12:55988132	chr2:171374931~171375278:-
LUAD	trans	rs916888	0.738	rs199515	ENSG00000204650.12	CRHR1-IT1	-6.93	1.34e-11	3.02e-05	-0.39	-0.3	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45620328~45648216:+
LUAD	trans	rs4276421	0.555	rs2589181	ENSG00000231752.4	EMBP1	6.93	1.35e-11	3.04e-05	0.42	0.3	P wave duration;	chr5:45611931	chr1:121519112~121571892:+
LUAD	trans	rs4263408	0.967	rs11947966	ENSG00000237550.5	UBE2Q2P6	6.93	1.35e-11	3.05e-05	0.35	0.3	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39765721	chr15:82372196~82372912:-
LUAD	trans	rs2243480	1	rs4718270	ENSG00000273142.1	RP11-458F8.4	-6.93	1.36e-11	3.06e-05	-0.32	-0.3	Diabetic kidney disease;	chr7:65737415	chr7:66902857~66906297:+
LUAD	trans	rs2243480	0.901	rs2900904	ENSG00000273142.1	RP11-458F8.4	-6.93	1.36e-11	3.06e-05	-0.32	-0.3	Diabetic kidney disease;	chr7:65739282	chr7:66902857~66906297:+
LUAD	trans	rs7200543	0.884	rs72789542	ENSG00000250569.1	NTAN1P2	6.93	1.37e-11	3.08e-05	0.34	0.3	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15033678	chr8:86481754~86483002:-
LUAD	trans	rs7833986	0.501	rs2953922	ENSG00000244245.1	RP11-120B7.1	6.93	1.38e-11	3.11e-05	0.35	0.3	Height;	chr8:56064926	chr5:108593609~108593967:+
LUAD	trans	rs7833986	0.501	rs2953897	ENSG00000244245.1	RP11-120B7.1	6.93	1.38e-11	3.11e-05	0.35	0.3	Height;	chr8:56068010	chr5:108593609~108593967:+
LUAD	trans	rs7833986	0.501	rs2953898	ENSG00000244245.1	RP11-120B7.1	6.93	1.38e-11	3.11e-05	0.35	0.3	Height;	chr8:56068244	chr5:108593609~108593967:+
LUAD	trans	rs7833986	0.501	rs2953901	ENSG00000244245.1	RP11-120B7.1	6.93	1.38e-11	3.11e-05	0.35	0.3	Height;	chr8:56069265	chr5:108593609~108593967:+
LUAD	trans	rs889398	0.617	rs1566456	ENSG00000257513.6	NPIPB1P	6.93	1.38e-11	3.12e-05	0.29	0.3	Body mass index;	chr16:69866323	chr18:11619509~11639699:-
LUAD	trans	rs12477438	0.52	rs11678456	ENSG00000276576.1	MRPL30P1	6.93	1.4e-11	3.14e-05	0.35	0.3	Chronic sinus infection;	chr2:99091774	chr6:57029521~57029988:+
LUAD	trans	rs1816752	0.935	rs4770676	ENSG00000224976.2	PARP4P2	-6.93	1.4e-11	3.15e-05	-0.36	-0.3	Obesity-related traits;	chr13:24429745	chr13:19349137~19407962:+
LUAD	trans	rs10037055	0.812	rs11949435	ENSG00000228305.2	AC016734.2	6.92	1.41e-11	3.18e-05	0.33	0.3	Migraine without aura;	chr5:177287931	chr2:63622178~63622831:-
LUAD	trans	rs9876781	0.559	rs7610524	ENSG00000235912.1	RP1-159A19.3	-6.92	1.43e-11	3.22e-05	-0.31	-0.3	Longevity;	chr3:48353882	chr1:27649419~27649610:+
LUAD	trans	rs877636	0.702	rs773108	ENSG00000233778.3	RP11-777J24.1	6.92	1.44e-11	3.24e-05	0.35	0.3	Cognitive function;	chr12:55976127	chr8:92144088~92144435:-
LUAD	trans	rs2243480	1	rs6460260	ENSG00000273142.1	RP11-458F8.4	6.92	1.44e-11	3.25e-05	0.32	0.3	Diabetic kidney disease;	chr7:65750468	chr7:66902857~66906297:+
LUAD	trans	rs2243480	1	rs6460261	ENSG00000273142.1	RP11-458F8.4	6.92	1.44e-11	3.25e-05	0.32	0.3	Diabetic kidney disease;	chr7:65750593	chr7:66902857~66906297:+
LUAD	trans	rs12477438	0.52	rs11695379	ENSG00000276576.1	MRPL30P1	6.92	1.44e-11	3.25e-05	0.34	0.3	Chronic sinus infection;	chr2:99125698	chr6:57029521~57029988:+
LUAD	trans	rs1816752	0.774	rs55888616	ENSG00000224976.2	PARP4P2	-6.92	1.45e-11	3.25e-05	-0.34	-0.3	Obesity-related traits;	chr13:24441954	chr13:19349137~19407962:+
LUAD	trans	rs6915893	0.74	rs12189652	ENSG00000267156.1	TPMTP1	6.92	1.45e-11	3.26e-05	0.36	0.3	Intrinsic epigenetic age acceleration;	chr6:18103080	chr18:47630112~47630848:+
LUAD	trans	rs1391708	0.834	rs58911887	ENSG00000121089.4	NACA3P	-6.92	1.46e-11	3.27e-05	-0.5	-0.3	Airway wall thickness;	chr12:56884858	chr4:164943290~164943937:+
LUAD	trans	rs1391708	0.834	rs34465459	ENSG00000121089.4	NACA3P	-6.92	1.46e-11	3.27e-05	-0.5	-0.3	Airway wall thickness;	chr12:56885552	chr4:164943290~164943937:+
LUAD	trans	rs4713118	0.513	rs2294480	ENSG00000204709.4	LINC01556	6.92	1.47e-11	3.3e-05	0.37	0.3	Parkinson's disease;	chr6:27616182	chr6:28943877~28944537:+
LUAD	trans	rs12477438	0.501	rs6751927	ENSG00000276576.1	MRPL30P1	6.92	1.47e-11	3.31e-05	0.34	0.3	Chronic sinus infection;	chr2:99123712	chr6:57029521~57029988:+
LUAD	trans	rs76228276	0.737	rs1979117	ENSG00000260318.1	COX6CP1	-6.92	1.49e-11	3.34e-05	-0.73	-0.3	Childhood ear infection;	chr8:99807661	chr16:11903923~11904137:-
LUAD	trans	rs12477438	0.52	rs4588238	ENSG00000276576.1	MRPL30P1	6.92	1.49e-11	3.34e-05	0.34	0.3	Chronic sinus infection;	chr2:99132887	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.52	rs13018891	ENSG00000276576.1	MRPL30P1	6.92	1.49e-11	3.34e-05	0.34	0.3	Chronic sinus infection;	chr2:99138636	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.52	rs6542865	ENSG00000276576.1	MRPL30P1	6.92	1.49e-11	3.34e-05	0.34	0.3	Chronic sinus infection;	chr2:99148058	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.52	rs13010904	ENSG00000276576.1	MRPL30P1	6.92	1.49e-11	3.35e-05	0.34	0.3	Chronic sinus infection;	chr2:99137826	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.52	rs13012481	ENSG00000276576.1	MRPL30P1	6.92	1.49e-11	3.35e-05	0.34	0.3	Chronic sinus infection;	chr2:99137827	chr6:57029521~57029988:+
LUAD	trans	rs73108077	0.607	rs6057566	ENSG00000279352.1	RP11-411B10.7	6.91	1.5e-11	3.37e-05	0.52	0.3	Red blood cell density in sickle cell anemia;	chr20:31227621	chr18:14010054~14010917:+
LUAD	trans	rs1383484	0.754	rs12439867	ENSG00000278603.1	RP13-608F4.5	6.91	1.52e-11	3.4e-05	0.4	0.3	Height;	chr15:83913137	chr15:82472203~82472426:+
LUAD	trans	rs916888	0.821	rs199504	ENSG00000204650.12	CRHR1-IT1	-6.91	1.52e-11	3.42e-05	-0.4	-0.3	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45620328~45648216:+
LUAD	trans	rs1816752	1	rs7326932	ENSG00000224976.2	PARP4P2	-6.91	1.52e-11	3.42e-05	-0.36	-0.3	Obesity-related traits;	chr13:24430355	chr13:19349137~19407962:+
LUAD	trans	rs877636	0.692	rs11171739	ENSG00000234192.1	RP11-57C13.5	6.91	1.53e-11	3.43e-05	0.31	0.3	Cognitive function;	chr12:56076841	chr10:87642607~87642954:+
LUAD	trans	rs7833986	0.501	rs2953909	ENSG00000244245.1	RP11-120B7.1	6.91	1.53e-11	3.43e-05	0.35	0.3	Height;	chr8:56055641	chr5:108593609~108593967:+
LUAD	trans	rs7833986	0.501	rs2953910	ENSG00000244245.1	RP11-120B7.1	6.91	1.53e-11	3.43e-05	0.35	0.3	Height;	chr8:56056202	chr5:108593609~108593967:+
LUAD	trans	rs877636	1	rs2292239	ENSG00000223416.3	RPS26P15	6.91	1.54e-11	3.45e-05	0.29	0.3	Cognitive function;	chr12:56088396	chr1:58056133~58056480:-
LUAD	trans	rs7113874	0.659	rs12574009	ENSG00000266891.1	RP11-692N5.2	6.91	1.54e-11	3.45e-05	0.44	0.3	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8498406	chr18:9734882~9735602:-
LUAD	trans	rs7113874	0.659	rs12295855	ENSG00000266891.1	RP11-692N5.2	6.91	1.54e-11	3.45e-05	0.44	0.3	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8505871	chr18:9734882~9735602:-
LUAD	trans	rs6915893	0.74	rs12194394	ENSG00000267156.1	TPMTP1	-6.91	1.55e-11	3.47e-05	-0.38	-0.3	Intrinsic epigenetic age acceleration;	chr6:18103050	chr18:47630112~47630848:+
LUAD	trans	rs9467773	0.587	rs10946813	ENSG00000242375.1	RP11-498P14.3	6.91	1.57e-11	3.51e-05	0.39	0.3	Intelligence (multi-trait analysis);	chr6:26344913	chr9:97195351~97197687:-
LUAD	trans	rs929843	1	rs929843	ENSG00000257513.6	NPIPB1P	6.9	1.6e-11	3.58e-05	0.37	0.3	Menarche (age at onset);	chr16:70011845	chr18:11619509~11639699:-
LUAD	trans	rs13217239	0.646	rs4269366	ENSG00000242375.1	RP11-498P14.3	6.9	1.65e-11	3.69e-05	0.39	0.3	Schizophrenia;	chr6:27048634	chr9:97195351~97197687:-
LUAD	trans	rs864643	0.513	rs1768149	ENSG00000183298.5	RP11-556K13.1	6.9	1.66e-11	3.71e-05	0.43	0.3	Attention deficit hyperactivity disorder;	chr3:39466089	chr1:101786340~101787219:-
LUAD	trans	rs7833986	0.501	rs72653953	ENSG00000244245.1	RP11-120B7.1	6.9	1.67e-11	3.74e-05	0.35	0.3	Height;	chr8:56058236	chr5:108593609~108593967:+
LUAD	trans	rs673253	0.556	rs660899	ENSG00000231007.5	CDC20P1	6.9	1.68e-11	3.76e-05	0.39	0.3	Intelligence (multi-trait analysis);	chr1:43651335	chr9:87011652~87013151:+
LUAD	trans	rs4276421	0.571	rs12109155	ENSG00000231752.4	EMBP1	6.9	1.69e-11	3.77e-05	0.45	0.3	P wave duration;	chr5:45727897	chr1:121519112~121571892:+
LUAD	trans	rs4713118	0.539	rs200988	ENSG00000204709.4	LINC01556	6.9	1.69e-11	3.79e-05	0.39	0.3	Parkinson's disease;	chr6:27851575	chr6:28943877~28944537:+
LUAD	trans	rs6743068	0.521	rs7578970	ENSG00000235105.1	RP11-329A14.1	6.89	1.72e-11	3.85e-05	0.35	0.3	Lymphocyte percentage of white cells;	chr2:201365061	chr1:48435967~48437223:+
LUAD	trans	rs12477438	0.52	rs11123766	ENSG00000276576.1	MRPL30P1	6.89	1.74e-11	3.88e-05	0.34	0.3	Chronic sinus infection;	chr2:99164452	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.52	rs2964969	ENSG00000276576.1	MRPL30P1	6.89	1.74e-11	3.88e-05	0.34	0.3	Chronic sinus infection;	chr2:99166348	chr6:57029521~57029988:+
LUAD	trans	rs7032940	0.626	rs10816929	ENSG00000228236.2	TXNP5	6.89	1.75e-11	3.91e-05	0.33	0.3	Height;	chr9:110173466	chr2:149068596~149068910:-
LUAD	trans	rs877636	0.702	rs773109	ENSG00000224553.1	AC008065.1	6.89	1.77e-11	3.94e-05	0.33	0.3	Cognitive function;	chr12:55980911	chr2:171374931~171375278:-
LUAD	trans	rs58106596	0.8	rs28883318	ENSG00000259020.3	RP11-529H20.3	6.89	1.77e-11	3.95e-05	0.4	0.3	Lymphocyte counts;White blood cell count;	chr2:231698225	chr14:92026566~92026887:+
LUAD	trans	rs6498068	0.522	rs10775284	ENSG00000278702.1	Metazoa_SRP	6.89	1.78e-11	3.98e-05	0.41	0.3	Metabolite levels (MHPG);	chr16:10535402	chr1:35399997~35400319:+
LUAD	trans	rs12477438	0.52	rs36071868	ENSG00000276576.1	MRPL30P1	6.89	1.79e-11	3.98e-05	0.34	0.3	Chronic sinus infection;	chr2:99120657	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.52	rs34252185	ENSG00000276576.1	MRPL30P1	6.89	1.79e-11	3.98e-05	0.34	0.3	Chronic sinus infection;	chr2:99121183	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.52	rs13023744	ENSG00000276576.1	MRPL30P1	6.89	1.79e-11	3.98e-05	0.34	0.3	Chronic sinus infection;	chr2:99121761	chr6:57029521~57029988:+
LUAD	trans	rs12439619	0.846	rs28697264	ENSG00000235370.6	DNM1P51	-6.89	1.79e-11	3.99e-05	-0.41	-0.3	Intelligence (multi-trait analysis);	chr15:82265559	chr15:84398316~84411701:-
LUAD	trans	rs7200543	1	rs4985124	ENSG00000250569.1	NTAN1P2	6.89	1.79e-11	4e-05	0.33	0.3	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15031584	chr8:86481754~86483002:-
LUAD	trans	rs12477438	0.52	rs4340581	ENSG00000276576.1	MRPL30P1	6.89	1.79e-11	4e-05	0.34	0.3	Chronic sinus infection;	chr2:99108562	chr6:57029521~57029988:+
LUAD	trans	rs673253	0.556	rs35290231	ENSG00000231007.5	CDC20P1	6.89	1.8e-11	4.02e-05	0.39	0.3	Intelligence (multi-trait analysis);	chr1:43637362	chr9:87011652~87013151:+
LUAD	trans	rs7769051	1	rs73554431	ENSG00000227615.1	RP11-864N7.2	6.89	1.81e-11	4.03e-05	0.49	0.3	Type 2 diabetes nephropathy;	chr6:132808783	chr11:74745716~74746114:-
LUAD	trans	rs7312770	0.612	rs1873914	ENSG00000244604.1	RP11-713H12.1	6.88	1.84e-11	4.1e-05	0.33	0.3	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr17:8561230~8561576:+
LUAD	trans	rs877636	1	rs2292239	ENSG00000227586.5	RP11-162A23.5	6.88	1.86e-11	4.14e-05	0.33	0.3	Cognitive function;	chr12:56088396	chr10:123171535~123171875:-
LUAD	trans	rs6732160	0.588	rs62151795	ENSG00000236165.1	PRADC1P1	6.88	1.87e-11	4.16e-05	0.43	0.3	Intelligence (multi-trait analysis);	chr2:73149712	chr3:36976316~36976840:+
LUAD	trans	rs12439619	0.774	rs2867649	ENSG00000235370.6	DNM1P51	-6.88	1.89e-11	4.2e-05	-0.41	-0.3	Intelligence (multi-trait analysis);	chr15:82262331	chr15:84398316~84411701:-
LUAD	trans	rs13217239	0.646	rs6456767	ENSG00000242375.1	RP11-498P14.3	-6.88	1.91e-11	4.24e-05	-0.39	-0.3	Schizophrenia;	chr6:27102764	chr9:97195351~97197687:-
LUAD	trans	rs7769051	1	rs6934161	ENSG00000227615.1	RP11-864N7.2	-6.88	1.92e-11	4.26e-05	-0.49	-0.3	Type 2 diabetes nephropathy;	chr6:132802938	chr11:74745716~74746114:-
LUAD	trans	rs12477438	0.52	rs6739579	ENSG00000276576.1	MRPL30P1	6.88	1.92e-11	4.27e-05	0.35	0.3	Chronic sinus infection;	chr2:99115089	chr6:57029521~57029988:+
LUAD	trans	rs6743068	0.521	rs6710974	ENSG00000235105.1	RP11-329A14.1	6.88	1.93e-11	4.28e-05	0.34	0.3	Lymphocyte percentage of white cells;	chr2:201348659	chr1:48435967~48437223:+
LUAD	trans	rs1075232	1	rs12440544	ENSG00000270055.1	CTD-3092A11.2	-6.87	1.96e-11	4.35e-05	-0.62	-0.3	Survival in colorectal cancer (non-distant metastatic);	chr15:31804301	chr15:30487963~30490313:+
LUAD	trans	rs877636	0.702	rs773108	ENSG00000224553.1	AC008065.1	6.87	1.97e-11	4.37e-05	0.33	0.3	Cognitive function;	chr12:55976127	chr2:171374931~171375278:-
LUAD	trans	rs4263408	1	rs7661070	ENSG00000237550.5	UBE2Q2P6	6.87	1.98e-11	4.39e-05	0.36	0.3	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39722745	chr15:82372196~82372912:-
LUAD	trans	rs889398	0.594	rs7202233	ENSG00000257513.6	NPIPB1P	6.87	1.98e-11	4.4e-05	0.29	0.3	Body mass index;	chr16:69860529	chr18:11619509~11639699:-
LUAD	trans	rs12477438	0.52	rs1044575	ENSG00000276576.1	MRPL30P1	6.87	2e-11	4.43e-05	0.34	0.3	Chronic sinus infection;	chr2:99195607	chr6:57029521~57029988:+
LUAD	trans	rs4276421	0.55	rs10473403	ENSG00000231752.4	EMBP1	6.87	2e-11	4.43e-05	0.45	0.3	P wave duration;	chr5:45921272	chr1:121519112~121571892:+
LUAD	trans	rs7554511	0.691	rs10920091	ENSG00000244144.1	RP11-757F18.3	-6.87	2e-11	4.44e-05	-0.38	-0.3	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201005936	chr3:112185480~112185998:-
LUAD	trans	rs2243480	0.908	rs4718273	ENSG00000273142.1	RP11-458F8.4	6.87	2e-11	4.44e-05	0.31	0.3	Diabetic kidney disease;	chr7:65751112	chr7:66902857~66906297:+
LUAD	trans	rs1391708	1	rs34285886	ENSG00000121089.4	NACA3P	-6.87	2.01e-11	4.46e-05	-0.48	-0.3	Airway wall thickness;	chr12:56908736	chr4:164943290~164943937:+
LUAD	trans	rs12439619	0.846	rs62012056	ENSG00000235370.6	DNM1P51	-6.87	2.05e-11	4.54e-05	-0.41	-0.3	Intelligence (multi-trait analysis);	chr15:82247278	chr15:84398316~84411701:-
LUAD	trans	rs7113874	0.659	rs1867810	ENSG00000266891.1	RP11-692N5.2	6.86	2.09e-11	4.63e-05	0.43	0.3	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8483981	chr18:9734882~9735602:-
LUAD	trans	rs12145833	1	rs61833916	ENSG00000154608.12	CEP170P1	-6.86	2.09e-11	4.63e-05	-0.51	-0.3	Obesity (early onset extreme);	chr1:243306644	chr4:118467590~118554204:+
LUAD	trans	rs7769051	1	rs3813347	ENSG00000227615.1	RP11-864N7.2	6.86	2.1e-11	4.65e-05	0.49	0.3	Type 2 diabetes nephropathy;	chr6:132798639	chr11:74745716~74746114:-
LUAD	trans	rs7312770	0.637	rs705700	ENSG00000233778.3	RP11-777J24.1	6.86	2.11e-11	4.66e-05	0.32	0.3	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr8:92144088~92144435:-
LUAD	trans	rs7746199	0.736	rs13210634	ENSG00000204709.4	LINC01556	6.86	2.12e-11	4.7e-05	0.64	0.3	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27678713	chr6:28943877~28944537:+
LUAD	trans	rs7746199	0.736	rs13215275	ENSG00000204709.4	LINC01556	6.86	2.12e-11	4.7e-05	0.64	0.3	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27679730	chr6:28943877~28944537:+
LUAD	trans	rs7746199	0.736	rs17749927	ENSG00000204709.4	LINC01556	6.86	2.12e-11	4.7e-05	0.64	0.3	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27702197	chr6:28943877~28944537:+
LUAD	trans	rs7746199	0.736	rs13192965	ENSG00000204709.4	LINC01556	6.86	2.12e-11	4.7e-05	0.64	0.3	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27704046	chr6:28943877~28944537:+
LUAD	trans	rs4276421	0.571	rs10074470	ENSG00000231752.4	EMBP1	6.86	2.16e-11	4.77e-05	0.44	0.3	P wave duration;	chr5:45940922	chr1:121519112~121571892:+
LUAD	trans	rs6921919	0.673	rs13201681	ENSG00000253570.1	RNF5P1	6.86	2.17e-11	4.81e-05	0.69	0.3	Autism spectrum disorder or schizophrenia;	chr6:28426903	chr8:38600661~38601200:-
LUAD	trans	rs16937956	0.657	rs35976355	ENSG00000266891.1	RP11-692N5.2	6.86	2.18e-11	4.82e-05	0.43	0.3	Body mass index;	chr11:8407110	chr18:9734882~9735602:-
LUAD	trans	rs12439619	0.81	rs28876157	ENSG00000235370.6	DNM1P51	-6.86	2.19e-11	4.83e-05	-0.41	-0.3	Intelligence (multi-trait analysis);	chr15:82216708	chr15:84398316~84411701:-
LUAD	trans	rs380904	0.519	rs1377663	ENSG00000213130.3	EEF1DP5	-6.85	2.22e-11	4.9e-05	-0.43	-0.3	Venous thromboembolism (SNP x SNP interaction);	chr8:143562617	chr6:128580113~128580884:-
LUAD	trans	rs7312770	1	rs7312770	ENSG00000204652.6	RPS26P8	-6.85	2.24e-11	4.94e-05	-0.34	-0.3	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr17:45608571~45608918:+
LUAD	trans	rs775326	0.849	rs16891858	ENSG00000250461.1	RP11-631M6.2	-6.85	2.24e-11	4.94e-05	-0.33	-0.3	Educational attainment (years of education);	chr5:63453919	chr5:61375112~61375855:+
LUAD	trans	rs7769051	1	rs12204027	ENSG00000227615.1	RP11-864N7.2	6.85	2.24e-11	4.95e-05	0.49	0.3	Type 2 diabetes nephropathy;	chr6:132801692	chr11:74745716~74746114:-
LUAD	trans	rs7769051	1	rs9493444	ENSG00000227615.1	RP11-864N7.2	6.85	2.24e-11	4.95e-05	0.49	0.3	Type 2 diabetes nephropathy;	chr6:132804181	chr11:74745716~74746114:-
LUAD	trans	rs6424115	0.708	rs34570472	ENSG00000228217.1	AL390877.1	6.85	2.25e-11	4.97e-05	0.41	0.3	Immature fraction of reticulocytes;	chr1:23865230	chr1:117778087~117778506:-
LUAD	trans	rs6743068	0.521	rs2349074	ENSG00000235105.1	RP11-329A14.1	6.85	2.26e-11	4.99e-05	0.34	0.3	Lymphocyte percentage of white cells;	chr2:201357784	chr1:48435967~48437223:+
LUAD	trans	rs1391708	0.834	rs4612852	ENSG00000121089.4	NACA3P	-6.85	2.27e-11	5.01e-05	-0.5	-0.3	Airway wall thickness;	chr12:56902257	chr4:164943290~164943937:+
LUAD	trans	rs13217239	0.574	rs9366680	ENSG00000242375.1	RP11-498P14.3	6.85	2.27e-11	5.01e-05	0.38	0.3	Schizophrenia;	chr6:27038344	chr9:97195351~97197687:-
LUAD	trans	rs4276421	0.571	rs7712920	ENSG00000231752.4	EMBP1	6.85	2.28e-11	5.03e-05	0.46	0.3	P wave duration;	chr5:45589104	chr1:121519112~121571892:+
LUAD	trans	rs35491132	1	rs35491132	ENSG00000204709.4	LINC01556	6.85	2.28e-11	5.04e-05	0.62	0.3	Urinary tract infection frequency;	chr6:27559449	chr6:28943877~28944537:+
LUAD	trans	rs889398	0.617	rs3790083	ENSG00000257513.6	NPIPB1P	-6.85	2.3e-11	5.07e-05	-0.29	-0.3	Body mass index;	chr16:69861383	chr18:11619509~11639699:-
LUAD	trans	rs877636	1	rs877636	ENSG00000204652.6	RPS26P8	-6.85	2.32e-11	5.11e-05	-0.36	-0.3	Cognitive function;	chr12:56086799	chr17:45608571~45608918:+
LUAD	trans	rs45509595	0.556	rs34409918	ENSG00000204709.4	LINC01556	6.85	2.33e-11	5.13e-05	0.64	0.3	Breast cancer;	chr6:27717569	chr6:28943877~28944537:+
LUAD	trans	rs7746199	0.736	rs34064842	ENSG00000204709.4	LINC01556	6.85	2.33e-11	5.13e-05	0.64	0.3	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27720846	chr6:28943877~28944537:+
LUAD	trans	rs7746199	0.736	rs13212318	ENSG00000204709.4	LINC01556	6.85	2.33e-11	5.13e-05	0.64	0.3	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27721062	chr6:28943877~28944537:+
LUAD	trans	rs7746199	0.736	rs72845070	ENSG00000204709.4	LINC01556	6.85	2.33e-11	5.13e-05	0.66	0.3	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27700521	chr6:28943877~28944537:+
LUAD	trans	rs13416322	0.796	rs78865022	ENSG00000214286.2	PDCL3P3	6.85	2.34e-11	5.14e-05	0.42	0.3	Intelligence (multi-trait analysis);	chr2:100526262	chr3:17877455~17878169:-
LUAD	trans	rs853679	0.546	rs13213152	ENSG00000253570.1	RNF5P1	6.84	2.36e-11	5.2e-05	0.68	0.3	Depression;	chr6:28381921	chr8:38600661~38601200:-
LUAD	trans	rs7200543	1	rs16966947	ENSG00000250569.1	NTAN1P2	6.84	2.38e-11	5.24e-05	0.34	0.3	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15047188	chr8:86481754~86483002:-
LUAD	trans	rs12439619	0.846	rs62012059	ENSG00000235370.6	DNM1P51	-6.84	2.38e-11	5.24e-05	-0.41	-0.3	Intelligence (multi-trait analysis);	chr15:82251669	chr15:84398316~84411701:-
LUAD	trans	rs7312770	1	rs7312770	ENSG00000233778.3	RP11-777J24.1	-6.84	2.41e-11	5.29e-05	-0.31	-0.3	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr8:92144088~92144435:-
LUAD	trans	rs889398	0.594	rs2133799	ENSG00000257513.6	NPIPB1P	6.84	2.41e-11	5.3e-05	0.29	0.3	Body mass index;	chr16:69879123	chr18:11619509~11639699:-
LUAD	trans	rs74781061	0.722	rs77102700	ENSG00000227288.3	RP5-837I24.1	6.84	2.42e-11	5.32e-05	0.53	0.3	Endometriosis;	chr15:74604600	chr1:81501794~81503468:+
LUAD	trans	rs12477438	0.52	rs6743355	ENSG00000276576.1	MRPL30P1	6.84	2.42e-11	5.32e-05	0.34	0.3	Chronic sinus infection;	chr2:99115897	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.52	rs13004491	ENSG00000276576.1	MRPL30P1	6.84	2.42e-11	5.32e-05	0.34	0.3	Chronic sinus infection;	chr2:99121545	chr6:57029521~57029988:+
LUAD	trans	rs10242455	0.717	rs2741872	ENSG00000228834.1	RP11-249L21.4	-6.84	2.43e-11	5.33e-05	-0.59	-0.3	Blood metabolite levels;	chr7:99742153	chr6:108907615~108907873:-
LUAD	trans	rs12477438	0.52	rs6712704	ENSG00000276576.1	MRPL30P1	6.84	2.43e-11	5.33e-05	0.34	0.3	Chronic sinus infection;	chr2:99103224	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.52	rs6542863	ENSG00000276576.1	MRPL30P1	6.84	2.43e-11	5.33e-05	0.34	0.3	Chronic sinus infection;	chr2:99108675	chr6:57029521~57029988:+
LUAD	trans	rs10037055	0.853	rs4976681	ENSG00000228305.2	AC016734.2	6.84	2.43e-11	5.35e-05	0.33	0.3	Migraine without aura;	chr5:177277662	chr2:63622178~63622831:-
LUAD	trans	rs380904	0.517	rs11775744	ENSG00000213130.3	EEF1DP5	-6.84	2.44e-11	5.35e-05	-0.43	-0.3	Venous thromboembolism (SNP x SNP interaction);	chr8:143567022	chr6:128580113~128580884:-
LUAD	trans	rs1383484	0.761	rs10906981	ENSG00000278603.1	RP13-608F4.5	6.84	2.46e-11	5.4e-05	0.41	0.3	Height;	chr15:83853807	chr15:82472203~82472426:+
LUAD	trans	rs1383484	0.798	rs1871731	ENSG00000278603.1	RP13-608F4.5	6.83	2.5e-11	5.49e-05	0.4	0.3	Height;	chr15:83869280	chr15:82472203~82472426:+
LUAD	trans	rs673253	0.686	rs2842185	ENSG00000231007.5	CDC20P1	-6.83	2.53e-11	5.56e-05	-0.39	-0.3	Intelligence (multi-trait analysis);	chr1:43554060	chr9:87011652~87013151:+
LUAD	trans	rs4713118	0.615	rs57252182	ENSG00000204709.4	LINC01556	6.83	2.59e-11	5.68e-05	0.36	0.3	Parkinson's disease;	chr6:27752470	chr6:28943877~28944537:+
LUAD	trans	rs10037055	0.853	rs4976680	ENSG00000228305.2	AC016734.2	6.83	2.6e-11	5.7e-05	0.33	0.3	Migraine without aura;	chr5:177275745	chr2:63622178~63622831:-
LUAD	trans	rs4276421	0.55	rs7722380	ENSG00000231752.4	EMBP1	-6.83	2.6e-11	5.71e-05	-0.45	-0.3	P wave duration;	chr5:45678276	chr1:121519112~121571892:+
LUAD	trans	rs10037055	0.853	rs12660023	ENSG00000228305.2	AC016734.2	6.83	2.61e-11	5.71e-05	0.33	0.3	Migraine without aura;	chr5:177273884	chr2:63622178~63622831:-
LUAD	trans	rs12477438	0.52	rs11123761	ENSG00000276576.1	MRPL30P1	6.83	2.63e-11	5.75e-05	0.34	0.3	Chronic sinus infection;	chr2:99089440	chr6:57029521~57029988:+
LUAD	trans	rs2069408	1	rs2069408	ENSG00000242970.2	AC068522.4	-6.83	2.63e-11	5.76e-05	-0.37	-0.3	Asthma;	chr12:55970537	chr8:58588420~58588764:-
LUAD	trans	rs12439619	0.846	rs62013464	ENSG00000235370.6	DNM1P51	-6.83	2.63e-11	5.76e-05	-0.41	-0.3	Intelligence (multi-trait analysis);	chr15:82288250	chr15:84398316~84411701:-
LUAD	trans	rs7769051	1	rs58832890	ENSG00000227615.1	RP11-864N7.2	6.83	2.64e-11	5.78e-05	0.49	0.3	Type 2 diabetes nephropathy;	chr6:132806000	chr11:74745716~74746114:-
LUAD	trans	rs853679	0.607	rs13194781	ENSG00000204709.4	LINC01556	6.83	2.64e-11	5.78e-05	0.63	0.3	Depression;	chr6:27847861	chr6:28943877~28944537:+
LUAD	trans	rs853679	0.546	rs36116761	ENSG00000204709.4	LINC01556	6.83	2.64e-11	5.78e-05	0.63	0.3	Depression;	chr6:27850704	chr6:28943877~28944537:+
LUAD	trans	rs853679	0.546	rs34194357	ENSG00000204709.4	LINC01556	6.83	2.64e-11	5.78e-05	0.63	0.3	Depression;	chr6:27850757	chr6:28943877~28944537:+
LUAD	trans	rs12145833	1	rs10926986	ENSG00000154608.12	CEP170P1	6.82	2.68e-11	5.86e-05	0.5	0.3	Obesity (early onset extreme);	chr1:243304309	chr4:118467590~118554204:+
LUAD	trans	rs6732160	0.588	rs3891890	ENSG00000236165.1	PRADC1P1	6.82	2.75e-11	6e-05	0.43	0.3	Intelligence (multi-trait analysis);	chr2:73150921	chr3:36976316~36976840:+
LUAD	trans	rs12477438	0.52	rs2171359	ENSG00000276576.1	MRPL30P1	6.82	2.76e-11	6.02e-05	0.34	0.3	Chronic sinus infection;	chr2:99178897	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.52	rs6542870	ENSG00000276576.1	MRPL30P1	6.82	2.76e-11	6.02e-05	0.34	0.3	Chronic sinus infection;	chr2:99180175	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.52	rs11883676	ENSG00000276576.1	MRPL30P1	6.82	2.76e-11	6.02e-05	0.34	0.3	Chronic sinus infection;	chr2:99184351	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.501	rs6753063	ENSG00000276576.1	MRPL30P1	6.82	2.76e-11	6.02e-05	0.34	0.3	Chronic sinus infection;	chr2:99185006	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.52	rs6756650	ENSG00000276576.1	MRPL30P1	6.82	2.76e-11	6.02e-05	0.34	0.3	Chronic sinus infection;	chr2:99185337	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.52	rs11692699	ENSG00000276576.1	MRPL30P1	6.82	2.76e-11	6.02e-05	0.34	0.3	Chronic sinus infection;	chr2:99114194	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.52	rs13022329	ENSG00000276576.1	MRPL30P1	6.82	2.76e-11	6.02e-05	0.34	0.3	Chronic sinus infection;	chr2:99114726	chr6:57029521~57029988:+
LUAD	trans	rs7746199	0.673	rs72845046	ENSG00000204709.4	LINC01556	6.82	2.77e-11	6.04e-05	0.64	0.3	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27607489	chr6:28943877~28944537:+
LUAD	trans	rs11951515	0.508	rs11958046	ENSG00000174977.8	AC026271.5	-6.82	2.78e-11	6.06e-05	-0.31	-0.3	Metabolite levels  (X-11787);	chr5:43583287	chr17:18650195~18651542:+
LUAD	trans	rs546131	1	rs546131	ENSG00000225531.1	RP11-196I18.3	6.82	2.79e-11	6.08e-05	0.37	0.3	Lung disease severity in cystic fibrosis;	chr11:34830213	chr9:107116829~107117557:+
LUAD	trans	rs73110464	0.505	rs2638503	ENSG00000220378.3	KRT8P42	-6.82	2.79e-11	6.09e-05	-0.42	-0.3	Cancer (pleiotropy);	chr12:52913585	chr6:134296997~134298695:-
LUAD	trans	rs7746199	0.673	rs72847313	ENSG00000204709.4	LINC01556	6.82	2.8e-11	6.1e-05	0.62	0.3	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762303	chr6:28943877~28944537:+
LUAD	trans	rs7746199	0.611	rs17750747	ENSG00000204709.4	LINC01556	6.82	2.8e-11	6.1e-05	0.62	0.3	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762555	chr6:28943877~28944537:+
LUAD	trans	rs853679	0.505	rs200992	ENSG00000204709.4	LINC01556	6.82	2.81e-11	6.13e-05	0.58	0.3	Depression;	chr6:27846899	chr6:28943877~28944537:+
LUAD	trans	rs1816752	1	rs7988810	ENSG00000224976.2	PARP4P2	-6.82	2.81e-11	6.13e-05	-0.35	-0.3	Obesity-related traits;	chr13:24444958	chr13:19349137~19407962:+
LUAD	trans	rs73108077	0.736	rs6060596	ENSG00000279352.1	RP11-411B10.7	6.82	2.82e-11	6.14e-05	0.51	0.3	Red blood cell density in sickle cell anemia;	chr20:31261457	chr18:14010054~14010917:+
LUAD	trans	rs73108077	0.736	rs6060617	ENSG00000279352.1	RP11-411B10.7	6.82	2.82e-11	6.14e-05	0.51	0.3	Red blood cell density in sickle cell anemia;	chr20:31261849	chr18:14010054~14010917:+
LUAD	trans	rs889398	0.594	rs1466863	ENSG00000257513.6	NPIPB1P	-6.81	2.84e-11	6.18e-05	-0.28	-0.3	Body mass index;	chr16:69870235	chr18:11619509~11639699:-
LUAD	trans	rs10242455	0.867	rs2687077	ENSG00000228834.1	RP11-249L21.4	-6.81	2.85e-11	6.21e-05	-0.54	-0.3	Blood metabolite levels;	chr7:99708943	chr6:108907615~108907873:-
LUAD	trans	rs10242455	0.867	rs2257401	ENSG00000228834.1	RP11-249L21.4	-6.81	2.85e-11	6.21e-05	-0.54	-0.3	Blood metabolite levels;	chr7:99709062	chr6:108907615~108907873:-
LUAD	trans	rs1816752	0.935	rs3816219	ENSG00000224976.2	PARP4P2	-6.81	2.88e-11	6.28e-05	-0.35	-0.3	Obesity-related traits;	chr13:24442995	chr13:19349137~19407962:+
LUAD	trans	rs2243480	1	rs34703416	ENSG00000273142.1	RP11-458F8.4	-6.81	2.88e-11	6.28e-05	-0.31	-0.3	Diabetic kidney disease;	chr7:65835655	chr7:66902857~66906297:+
LUAD	trans	rs7746199	0.736	rs35848276	ENSG00000204709.4	LINC01556	6.81	2.9e-11	6.32e-05	0.64	0.3	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27553317	chr6:28943877~28944537:+
LUAD	trans	rs7554511	0.928	rs169850	ENSG00000244144.1	RP11-757F18.3	6.81	2.91e-11	6.32e-05	0.39	0.3	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200960016	chr3:112185480~112185998:-
LUAD	trans	rs73108077	0.736	rs6060993	ENSG00000279352.1	RP11-411B10.7	6.81	2.91e-11	6.32e-05	0.51	0.3	Red blood cell density in sickle cell anemia;	chr20:31278917	chr18:14010054~14010917:+
LUAD	trans	rs6732160	0.613	rs58317144	ENSG00000236165.1	PRADC1P1	6.81	2.92e-11	6.35e-05	0.42	0.3	Intelligence (multi-trait analysis);	chr2:73161025	chr3:36976316~36976840:+
LUAD	trans	rs7200543	0.883	rs4985148	ENSG00000250569.1	NTAN1P2	6.81	2.94e-11	6.38e-05	0.34	0.3	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15053931	chr8:86481754~86483002:-
LUAD	trans	rs66887589	0.592	rs11731571	ENSG00000275858.1	RP11-291L22.8	6.81	2.95e-11	6.41e-05	0.32	0.3	Diastolic blood pressure;	chr4:119300030	chr10:38450738~38451069:-
LUAD	trans	rs34034915	1	rs34034915	ENSG00000204709.4	LINC01556	6.81	2.95e-11	6.42e-05	0.36	0.3	Hepatitis A;	chr6:27752924	chr6:28943877~28944537:+
LUAD	trans	rs4713118	0.527	rs36042294	ENSG00000204709.4	LINC01556	6.81	2.95e-11	6.42e-05	0.36	0.3	Parkinson's disease;	chr6:27752933	chr6:28943877~28944537:+
LUAD	trans	rs11098499	0.526	rs10026625	ENSG00000275858.1	RP11-291L22.8	6.81	2.97e-11	6.44e-05	0.33	0.3	Corneal astigmatism;	chr4:119358981	chr10:38450738~38451069:-
LUAD	trans	rs11122895	0.509	rs55937046	ENSG00000204745.3	AC083899.3	6.81	2.99e-11	6.49e-05	0.32	0.3	Allergic sensitization;	chr2:111689719	chr2:87125390~87196647:+
LUAD	trans	rs13217239	0.572	rs9379958	ENSG00000242375.1	RP11-498P14.3	-6.8	3.04e-11	6.6e-05	-0.39	-0.3	Schizophrenia;	chr6:27098384	chr9:97195351~97197687:-
LUAD	trans	rs13217239	0.646	rs9393789	ENSG00000242375.1	RP11-498P14.3	-6.8	3.04e-11	6.6e-05	-0.39	-0.3	Schizophrenia;	chr6:27099249	chr9:97195351~97197687:-
LUAD	trans	rs877636	1	rs4759229	ENSG00000244604.1	RP11-713H12.1	-6.8	3.08e-11	6.68e-05	-0.34	-0.3	Cognitive function;	chr12:56080696	chr17:8561230~8561576:+
LUAD	trans	rs853679	0.607	rs67101035	ENSG00000204709.4	LINC01556	6.8	3.1e-11	6.72e-05	0.63	0.3	Depression;	chr6:27831109	chr6:28943877~28944537:+
LUAD	trans	rs67340775	0.748	rs13212651	ENSG00000204709.4	LINC01556	6.8	3.1e-11	6.72e-05	0.63	0.3	Lung cancer in ever smokers;	chr6:27839207	chr6:28943877~28944537:+
LUAD	trans	rs4276421	0.55	rs1405916	ENSG00000231752.4	EMBP1	6.8	3.12e-11	6.76e-05	0.46	0.3	P wave duration;	chr5:45673782	chr1:121519112~121571892:+
LUAD	trans	rs7746199	0.736	rs35037868	ENSG00000204709.4	LINC01556	6.8	3.16e-11	6.86e-05	0.65	0.3	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27791336	chr6:28943877~28944537:+
LUAD	trans	rs13217239	0.608	rs6930508	ENSG00000242375.1	RP11-498P14.3	-6.8	3.2e-11	6.93e-05	-0.38	-0.3	Schizophrenia;	chr6:27085363	chr9:97195351~97197687:-
LUAD	trans	rs13217239	0.646	rs2142685	ENSG00000242375.1	RP11-498P14.3	-6.8	3.2e-11	6.93e-05	-0.38	-0.3	Schizophrenia;	chr6:27086718	chr9:97195351~97197687:-
LUAD	trans	rs12439619	0.846	rs62010071	ENSG00000235370.6	DNM1P51	-6.8	3.21e-11	6.94e-05	-0.41	-0.3	Intelligence (multi-trait analysis);	chr15:82289442	chr15:84398316~84411701:-
LUAD	trans	rs12477438	0.52	rs8179690	ENSG00000276576.1	MRPL30P1	-6.79	3.22e-11	6.96e-05	-0.34	-0.3	Chronic sinus infection;	chr2:99178837	chr6:57029521~57029988:+
LUAD	trans	rs877636	0.692	rs2271194	ENSG00000234192.1	RP11-57C13.5	-6.79	3.26e-11	7.06e-05	-0.31	-0.3	Cognitive function;	chr12:56083910	chr10:87642607~87642954:+
LUAD	trans	rs853679	0.546	rs200949	ENSG00000204709.4	LINC01556	6.79	3.28e-11	7.1e-05	0.54	0.3	Depression;	chr6:27867657	chr6:28943877~28944537:+
LUAD	trans	rs12477438	0.52	rs7572660	ENSG00000276576.1	MRPL30P1	6.79	3.3e-11	7.14e-05	0.34	0.3	Chronic sinus infection;	chr2:99172119	chr6:57029521~57029988:+
LUAD	trans	rs12145833	0.538	rs12042959	ENSG00000154608.12	CEP170P1	-6.79	3.31e-11	7.16e-05	-0.53	-0.3	Obesity (early onset extreme);	chr1:243369971	chr4:118467590~118554204:+
LUAD	trans	rs877636	0.692	rs2271194	ENSG00000212829.8	RPS26P3	-6.79	3.32e-11	7.17e-05	-0.31	-0.3	Cognitive function;	chr12:56083910	chr9:9090898~9091245:+
LUAD	trans	rs728478	0.845	rs758379	ENSG00000187870.7	RNFT1P3	6.79	3.32e-11	7.18e-05	0.36	0.3	QT interval;	chr17:59400255	chr17:20743333~20754501:-
LUAD	trans	rs6743068	0.521	rs12472273	ENSG00000235105.1	RP11-329A14.1	6.79	3.33e-11	7.19e-05	0.34	0.3	Lymphocyte percentage of white cells;	chr2:201346972	chr1:48435967~48437223:+
LUAD	trans	rs2243480	1	rs34702770	ENSG00000273142.1	RP11-458F8.4	-6.79	3.34e-11	7.21e-05	-0.31	-0.3	Diabetic kidney disease;	chr7:65879836	chr7:66902857~66906297:+
LUAD	trans	rs6743068	0.541	rs12052257	ENSG00000235105.1	RP11-329A14.1	-6.79	3.35e-11	7.23e-05	-0.34	-0.3	Lymphocyte percentage of white cells;	chr2:201376871	chr1:48435967~48437223:+
LUAD	trans	rs7113874	0.625	rs10743073	ENSG00000266891.1	RP11-692N5.2	-6.79	3.35e-11	7.24e-05	-0.42	-0.3	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8483072	chr18:9734882~9735602:-
LUAD	trans	rs1816752	0.776	rs9511268	ENSG00000224976.2	PARP4P2	-6.79	3.38e-11	7.3e-05	-0.35	-0.3	Obesity-related traits;	chr13:24444182	chr13:19349137~19407962:+
LUAD	trans	rs673253	0.686	rs2842188	ENSG00000231007.5	CDC20P1	-6.79	3.4e-11	7.34e-05	-0.38	-0.3	Intelligence (multi-trait analysis);	chr1:43548609	chr9:87011652~87013151:+
LUAD	trans	rs2243480	1	rs34815098	ENSG00000273142.1	RP11-458F8.4	-6.79	3.42e-11	7.38e-05	-0.31	-0.3	Diabetic kidney disease;	chr7:65827267	chr7:66902857~66906297:+
LUAD	trans	rs2243480	1	rs4548056	ENSG00000273142.1	RP11-458F8.4	-6.79	3.42e-11	7.38e-05	-0.31	-0.3	Diabetic kidney disease;	chr7:65833886	chr7:66902857~66906297:+
LUAD	trans	rs2243480	1	rs7456042	ENSG00000273142.1	RP11-458F8.4	-6.79	3.42e-11	7.38e-05	-0.31	-0.3	Diabetic kidney disease;	chr7:65834791	chr7:66902857~66906297:+
LUAD	trans	rs2243480	1	rs35735127	ENSG00000273142.1	RP11-458F8.4	-6.79	3.42e-11	7.38e-05	-0.31	-0.3	Diabetic kidney disease;	chr7:65835436	chr7:66902857~66906297:+
LUAD	trans	rs2243480	0.901	rs35256305	ENSG00000273142.1	RP11-458F8.4	-6.79	3.42e-11	7.38e-05	-0.31	-0.3	Diabetic kidney disease;	chr7:65841418	chr7:66902857~66906297:+
LUAD	trans	rs2243480	1	rs73142121	ENSG00000273142.1	RP11-458F8.4	-6.79	3.42e-11	7.38e-05	-0.31	-0.3	Diabetic kidney disease;	chr7:65846219	chr7:66902857~66906297:+
LUAD	trans	rs2243480	0.803	rs34004500	ENSG00000273142.1	RP11-458F8.4	-6.79	3.42e-11	7.38e-05	-0.31	-0.3	Diabetic kidney disease;	chr7:65847191	chr7:66902857~66906297:+
LUAD	trans	rs2243480	1	rs35825738	ENSG00000273142.1	RP11-458F8.4	-6.79	3.42e-11	7.38e-05	-0.31	-0.3	Diabetic kidney disease;	chr7:65853040	chr7:66902857~66906297:+
LUAD	trans	rs673253	0.556	rs55666439	ENSG00000231007.5	CDC20P1	6.78	3.43e-11	7.4e-05	0.39	0.3	Intelligence (multi-trait analysis);	chr1:43645541	chr9:87011652~87013151:+
LUAD	trans	rs673253	0.571	rs61768370	ENSG00000231007.5	CDC20P1	6.78	3.43e-11	7.4e-05	0.39	0.3	Intelligence (multi-trait analysis);	chr1:43646292	chr9:87011652~87013151:+
LUAD	trans	rs546131	0.928	rs558967	ENSG00000225531.1	RP11-196I18.3	6.78	3.45e-11	7.45e-05	0.37	0.3	Lung disease severity in cystic fibrosis;	chr11:34805621	chr9:107116829~107117557:+
LUAD	trans	rs3956705	0.762	rs13311608	ENSG00000176826.14	FKBP9P1	6.78	3.46e-11	7.45e-05	0.36	0.3	Red cell distribution width;	chr7:32959989	chr7:55681074~55713252:-
LUAD	trans	rs7200543	0.848	rs62039480	ENSG00000250569.1	NTAN1P2	6.78	3.51e-11	7.57e-05	0.33	0.3	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15043593	chr8:86481754~86483002:-
LUAD	trans	rs73108077	0.736	rs77855283	ENSG00000279352.1	RP11-411B10.7	6.78	3.54e-11	7.62e-05	0.5	0.3	Red blood cell density in sickle cell anemia;	chr20:31262576	chr18:14010054~14010917:+
LUAD	trans	rs853679	0.556	rs34706883	ENSG00000204709.4	LINC01556	6.78	3.55e-11	7.66e-05	0.63	0.3	Depression;	chr6:27837477	chr6:28943877~28944537:+
LUAD	trans	rs853679	0.546	rs35819751	ENSG00000204709.4	LINC01556	6.78	3.55e-11	7.66e-05	0.63	0.3	Depression;	chr6:27842791	chr6:28943877~28944537:+
LUAD	trans	rs7746199	0.736	rs13195636	ENSG00000204709.4	LINC01556	6.78	3.58e-11	7.72e-05	0.62	0.3	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27541714	chr6:28943877~28944537:+
LUAD	trans	rs7769051	1	rs6910639	ENSG00000227615.1	RP11-864N7.2	6.77	3.67e-11	7.9e-05	0.48	0.3	Type 2 diabetes nephropathy;	chr6:132799414	chr11:74745716~74746114:-
LUAD	trans	rs45509595	0.841	rs200501	ENSG00000204709.4	LINC01556	6.77	3.67e-11	7.9e-05	0.55	0.3	Breast cancer;	chr6:27821164	chr6:28943877~28944537:+
LUAD	trans	rs12477438	0.52	rs13009147	ENSG00000276576.1	MRPL30P1	6.77	3.68e-11	7.91e-05	0.34	0.3	Chronic sinus infection;	chr2:99187535	chr6:57029521~57029988:+
LUAD	trans	rs11122895	0.509	rs6708131	ENSG00000204745.3	AC083899.3	6.77	3.68e-11	7.91e-05	0.32	0.3	Allergic sensitization;	chr2:111688082	chr2:87125390~87196647:+
LUAD	trans	rs4713118	0.506	rs9366697	ENSG00000204709.4	LINC01556	6.77	3.7e-11	7.95e-05	0.36	0.3	Parkinson's disease;	chr6:27665239	chr6:28943877~28944537:+
LUAD	trans	rs877636	0.74	rs705698	ENSG00000224553.1	AC008065.1	6.77	3.71e-11	7.98e-05	0.32	0.3	Cognitive function;	chr12:55990903	chr2:171374931~171375278:-
LUAD	trans	rs877636	0.859	rs3741499	ENSG00000227586.5	RP11-162A23.5	-6.77	3.72e-11	8.01e-05	-0.34	-0.3	Cognitive function;	chr12:56080595	chr10:123171535~123171875:-
LUAD	trans	rs853679	0.546	rs35017208	ENSG00000253570.1	RNF5P1	6.77	3.74e-11	8.03e-05	0.67	0.29	Depression;	chr6:28377505	chr8:38600661~38601200:-
LUAD	trans	rs6743068	0.541	rs1966423	ENSG00000235105.1	RP11-329A14.1	6.77	3.76e-11	8.08e-05	0.34	0.29	Lymphocyte percentage of white cells;	chr2:201351938	chr1:48435967~48437223:+
LUAD	trans	rs6743068	0.521	rs6705845	ENSG00000235105.1	RP11-329A14.1	6.77	3.76e-11	8.08e-05	0.34	0.29	Lymphocyte percentage of white cells;	chr2:201354316	chr1:48435967~48437223:+
LUAD	trans	rs4263408	0.934	rs4975036	ENSG00000237550.5	UBE2Q2P6	6.77	3.78e-11	8.12e-05	0.35	0.29	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39713470	chr15:82372196~82372912:-
LUAD	trans	rs1383484	0.754	rs906425	ENSG00000278603.1	RP13-608F4.5	6.77	3.78e-11	8.12e-05	0.39	0.29	Height;	chr15:83920070	chr15:82472203~82472426:+
LUAD	trans	rs546131	0.928	rs552868	ENSG00000225531.1	RP11-196I18.3	6.77	3.81e-11	8.17e-05	0.37	0.29	Lung disease severity in cystic fibrosis;	chr11:34809147	chr9:107116829~107117557:+
LUAD	trans	rs853679	0.546	rs34546986	ENSG00000253570.1	RNF5P1	6.77	3.82e-11	8.19e-05	0.68	0.29	Depression;	chr6:28394532	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.546	rs34871267	ENSG00000253570.1	RNF5P1	6.77	3.82e-11	8.19e-05	0.68	0.29	Depression;	chr6:28396455	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.546	rs35883476	ENSG00000253570.1	RNF5P1	6.77	3.82e-11	8.19e-05	0.68	0.29	Depression;	chr6:28400731	chr8:38600661~38601200:-
LUAD	trans	rs9467773	0.626	rs6935803	ENSG00000242375.1	RP11-498P14.3	-6.77	3.83e-11	8.22e-05	-0.38	-0.29	Intelligence (multi-trait analysis);	chr6:26350267	chr9:97195351~97197687:-
LUAD	trans	rs9467773	0.626	rs6936006	ENSG00000242375.1	RP11-498P14.3	-6.77	3.83e-11	8.22e-05	-0.38	-0.29	Intelligence (multi-trait analysis);	chr6:26350337	chr9:97195351~97197687:-
LUAD	trans	rs12477438	0.52	rs11695751	ENSG00000276576.1	MRPL30P1	6.77	3.84e-11	8.24e-05	0.34	0.29	Chronic sinus infection;	chr2:99091784	chr6:57029521~57029988:+
LUAD	trans	rs1816752	0.905	rs4769352	ENSG00000224976.2	PARP4P2	-6.77	3.84e-11	8.25e-05	-0.33	-0.29	Obesity-related traits;	chr13:24426237	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.805	rs4769353	ENSG00000224976.2	PARP4P2	-6.77	3.84e-11	8.25e-05	-0.33	-0.29	Obesity-related traits;	chr13:24426318	chr13:19349137~19407962:+
LUAD	trans	rs9425766	0.679	rs7537517	ENSG00000213331.4	RP11-713C19.2	6.77	3.85e-11	8.25e-05	0.35	0.29	Life satisfaction;	chr1:174207225	chr4:187970273~187971284:+
LUAD	trans	rs6732160	0.588	rs10192654	ENSG00000236165.1	PRADC1P1	-6.77	3.86e-11	8.28e-05	-0.41	-0.29	Intelligence (multi-trait analysis);	chr2:73143754	chr3:36976316~36976840:+
LUAD	trans	rs1816752	0.905	rs7991450	ENSG00000224976.2	PARP4P2	-6.77	3.88e-11	8.32e-05	-0.33	-0.29	Obesity-related traits;	chr13:24425898	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.774	rs7986162	ENSG00000224976.2	PARP4P2	-6.77	3.88e-11	8.32e-05	-0.33	-0.29	Obesity-related traits;	chr13:24425941	chr13:19349137~19407962:+
LUAD	trans	rs9393777	0.92	rs34150729	ENSG00000204709.4	LINC01556	6.76	3.91e-11	8.37e-05	0.62	0.29	Intelligence (multi-trait analysis);	chr6:27420975	chr6:28943877~28944537:+
LUAD	trans	rs9393777	0.92	rs13191227	ENSG00000204709.4	LINC01556	6.76	3.91e-11	8.37e-05	0.62	0.29	Intelligence (multi-trait analysis);	chr6:27422336	chr6:28943877~28944537:+
LUAD	trans	rs11122895	0.509	rs3860380	ENSG00000204745.3	AC083899.3	-6.76	3.95e-11	8.46e-05	-0.31	-0.29	Allergic sensitization;	chr2:111693810	chr2:87125390~87196647:+
LUAD	trans	rs12477438	0.52	rs2632276	ENSG00000276576.1	MRPL30P1	6.76	3.96e-11	8.49e-05	0.34	0.29	Chronic sinus infection;	chr2:99163192	chr6:57029521~57029988:+
LUAD	trans	rs9584850	0.834	rs3783005	ENSG00000230079.1	STK24P1	-6.76	3.97e-11	8.5e-05	-0.34	-0.29	Neuroticism;	chr13:98459083	chrX:136295690~136300298:-
LUAD	trans	rs2243480	0.803	rs35480979	ENSG00000273142.1	RP11-458F8.4	-6.76	3.97e-11	8.5e-05	-0.31	-0.29	Diabetic kidney disease;	chr7:65892097	chr7:66902857~66906297:+
LUAD	trans	rs7746199	0.736	rs13212093	ENSG00000204709.4	LINC01556	6.76	4.02e-11	8.59e-05	0.63	0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27638937	chr6:28943877~28944537:+
LUAD	trans	rs7746199	0.736	rs34038546	ENSG00000204709.4	LINC01556	6.76	4.02e-11	8.59e-05	0.63	0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27639881	chr6:28943877~28944537:+
LUAD	trans	rs141342723	1	rs141342723	ENSG00000204709.4	LINC01556	6.76	4.02e-11	8.59e-05	0.63	0.29	Autism spectrum disorder or schizophrenia;	chr6:27654305	chr6:28943877~28944537:+
LUAD	trans	rs7746199	0.736	rs34543938	ENSG00000204709.4	LINC01556	6.76	4.02e-11	8.59e-05	0.63	0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27656861	chr6:28943877~28944537:+
LUAD	trans	rs7746199	0.736	rs56405707	ENSG00000204709.4	LINC01556	6.76	4.02e-11	8.59e-05	0.63	0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27672467	chr6:28943877~28944537:+
LUAD	trans	rs6732160	0.588	rs7578991	ENSG00000236165.1	PRADC1P1	6.76	4.04e-11	8.65e-05	0.42	0.29	Intelligence (multi-trait analysis);	chr2:73149043	chr3:36976316~36976840:+
LUAD	trans	rs6732160	0.564	rs7605716	ENSG00000236165.1	PRADC1P1	6.76	4.04e-11	8.65e-05	0.42	0.29	Intelligence (multi-trait analysis);	chr2:73149122	chr3:36976316~36976840:+
LUAD	trans	rs12477438	0.539	rs720228	ENSG00000276576.1	MRPL30P1	6.76	4.04e-11	8.65e-05	0.34	0.29	Chronic sinus infection;	chr2:99088084	chr6:57029521~57029988:+
LUAD	trans	rs4276421	0.577	rs4367308	ENSG00000231752.4	EMBP1	-6.76	4.06e-11	8.68e-05	-0.41	-0.29	P wave duration;	chr5:45715651	chr1:121519112~121571892:+
LUAD	trans	rs7260598	0.792	rs10500223	ENSG00000261770.1	CTC-459F4.1	6.76	4.06e-11	8.69e-05	0.49	0.29	Response to taxane treatment (placlitaxel);	chr19:24163222	chr19:27757184~27760849:-
LUAD	trans	rs6915893	0.74	rs9477622	ENSG00000267156.1	TPMTP1	-6.75	4.2e-11	8.98e-05	-0.35	-0.29	Intrinsic epigenetic age acceleration;	chr6:18103430	chr18:47630112~47630848:+
LUAD	trans	rs8010715	0.636	rs2277482	ENSG00000238000.1	RP11-274E7.2	6.75	4.22e-11	9.01e-05	0.34	0.29	IgG glycosylation;	chr14:24118586	chr5:98213402~98214121:+
LUAD	trans	rs61041336	0.534	rs59234479	ENSG00000230849.2	GOT2P2	-6.75	4.22e-11	9.01e-05	-0.61	-0.29	Neuritic plaque;	chr16:58673724	chr1:173141100~173142350:-
LUAD	trans	rs13416322	0.647	rs12620328	ENSG00000214286.2	PDCL3P3	6.75	4.22e-11	9.02e-05	0.39	0.29	Intelligence (multi-trait analysis);	chr2:100533457	chr3:17877455~17878169:-
LUAD	trans	rs7260598	0.792	rs17620072	ENSG00000261770.1	CTC-459F4.1	6.75	4.24e-11	9.07e-05	0.48	0.29	Response to taxane treatment (placlitaxel);	chr19:24177850	chr19:27757184~27760849:-
LUAD	trans	rs7260598	0.792	rs73031010	ENSG00000261770.1	CTC-459F4.1	6.75	4.24e-11	9.07e-05	0.48	0.29	Response to taxane treatment (placlitaxel);	chr19:24178160	chr19:27757184~27760849:-
LUAD	trans	rs7260598	0.792	rs7260592	ENSG00000261770.1	CTC-459F4.1	6.75	4.24e-11	9.07e-05	0.48	0.29	Response to taxane treatment (placlitaxel);	chr19:24178786	chr19:27757184~27760849:-
LUAD	trans	rs4263408	1	rs7687557	ENSG00000237550.5	UBE2Q2P6	6.75	4.25e-11	9.09e-05	0.34	0.29	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39767640	chr15:82372196~82372912:-
LUAD	trans	rs7746199	0.736	rs13209332	ENSG00000204709.4	LINC01556	6.75	4.4e-11	9.38e-05	0.62	0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27552973	chr6:28943877~28944537:+
LUAD	trans	rs7746199	0.736	rs34965299	ENSG00000204709.4	LINC01556	6.75	4.4e-11	9.38e-05	0.62	0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27554077	chr6:28943877~28944537:+
LUAD	trans	rs7746199	0.736	rs67652222	ENSG00000204709.4	LINC01556	6.75	4.4e-11	9.39e-05	0.63	0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27618441	chr6:28943877~28944537:+
LUAD	trans	rs6424115	0.708	rs12755062	ENSG00000228217.1	AL390877.1	6.74	4.43e-11	9.45e-05	0.4	0.29	Immature fraction of reticulocytes;	chr1:23858535	chr1:117778087~117778506:-
LUAD	trans	rs8010715	0.636	rs3825584	ENSG00000238000.1	RP11-274E7.2	6.74	4.44e-11	9.48e-05	0.34	0.29	IgG glycosylation;	chr14:24118430	chr5:98213402~98214121:+
LUAD	trans	rs9467773	0.587	rs12214031	ENSG00000242375.1	RP11-498P14.3	-6.74	4.46e-11	9.51e-05	-0.39	-0.29	Intelligence (multi-trait analysis);	chr6:26376400	chr9:97195351~97197687:-
LUAD	trans	rs11122895	0.509	rs10174353	ENSG00000204745.3	AC083899.3	6.74	4.48e-11	9.56e-05	0.32	0.29	Allergic sensitization;	chr2:111690311	chr2:87125390~87196647:+
LUAD	trans	rs6732160	0.613	rs62151837	ENSG00000236165.1	PRADC1P1	6.74	4.67e-11	9.95e-05	0.41	0.29	Intelligence (multi-trait analysis);	chr2:73163268	chr3:36976316~36976840:+
LUAD	trans	rs9584850	0.834	rs3803253	ENSG00000230079.1	STK24P1	6.74	4.68e-11	9.96e-05	0.35	0.29	Neuroticism;	chr13:98464895	chrX:136295690~136300298:-
LUAD	trans	rs853679	0.546	rs200990	ENSG00000204709.4	LINC01556	6.73	4.71e-11	1e-04	0.56	0.29	Depression;	chr6:27848045	chr6:28943877~28944537:+
LUAD	trans	rs7312770	0.612	rs773114	ENSG00000233778.3	RP11-777J24.1	6.73	4.73e-11	0.000101	0.31	0.29	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr8:92144088~92144435:-
LUAD	trans	rs8010715	0.636	rs2277480	ENSG00000238000.1	RP11-274E7.2	6.73	4.75e-11	0.000101	0.34	0.29	IgG glycosylation;	chr14:24118306	chr5:98213402~98214121:+
LUAD	trans	rs4276421	0.571	rs4431353	ENSG00000231752.4	EMBP1	6.73	4.75e-11	0.000101	0.44	0.29	P wave duration;	chr5:45926171	chr1:121519112~121571892:+
LUAD	trans	rs728478	0.809	rs1451507	ENSG00000187870.7	RNFT1P3	6.73	4.75e-11	0.000101	0.36	0.29	QT interval;	chr17:59399912	chr17:20743333~20754501:-
LUAD	trans	rs13416322	0.796	rs4147028	ENSG00000214286.2	PDCL3P3	-6.73	4.79e-11	0.000102	-0.41	-0.29	Intelligence (multi-trait analysis);	chr2:100526616	chr3:17877455~17878169:-
LUAD	trans	rs7746199	0.736	rs13202291	ENSG00000204709.4	LINC01556	6.73	4.8e-11	0.000102	0.6	0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731078	chr6:28943877~28944537:+
LUAD	trans	rs7746199	0.736	rs17750424	ENSG00000204709.4	LINC01556	6.73	4.8e-11	0.000102	0.6	0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27733343	chr6:28943877~28944537:+
LUAD	trans	rs7746199	0.736	rs13193542	ENSG00000204709.4	LINC01556	6.73	4.8e-11	0.000102	0.6	0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734646	chr6:28943877~28944537:+
LUAD	trans	rs7746199	0.736	rs13193480	ENSG00000204709.4	LINC01556	6.73	4.8e-11	0.000102	0.6	0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734782	chr6:28943877~28944537:+
LUAD	trans	rs877636	0.692	rs10876870	ENSG00000212829.8	RPS26P3	-6.73	4.8e-11	0.000102	-0.31	-0.29	Cognitive function;	chr12:56084218	chr9:9090898~9091245:+
LUAD	trans	rs877636	0.692	rs7971751	ENSG00000212829.8	RPS26P3	-6.73	4.8e-11	0.000102	-0.31	-0.29	Cognitive function;	chr12:56084874	chr9:9090898~9091245:+
LUAD	trans	rs6732160	0.588	rs28626211	ENSG00000236165.1	PRADC1P1	6.73	4.82e-11	0.000102	0.42	0.29	Intelligence (multi-trait analysis);	chr2:73151394	chr3:36976316~36976840:+
LUAD	trans	rs7833986	0.501	rs2719257	ENSG00000244245.1	RP11-120B7.1	6.73	4.82e-11	0.000103	0.35	0.29	Height;	chr8:56027614	chr5:108593609~108593967:+
LUAD	trans	rs6732160	0.588	rs2043100	ENSG00000236165.1	PRADC1P1	6.73	4.83e-11	0.000103	0.42	0.29	Intelligence (multi-trait analysis);	chr2:73146968	chr3:36976316~36976840:+
LUAD	trans	rs6732160	0.588	rs2043099	ENSG00000236165.1	PRADC1P1	6.73	4.83e-11	0.000103	0.42	0.29	Intelligence (multi-trait analysis);	chr2:73147028	chr3:36976316~36976840:+
LUAD	trans	rs6732160	0.588	rs11126392	ENSG00000236165.1	PRADC1P1	6.73	4.83e-11	0.000103	0.42	0.29	Intelligence (multi-trait analysis);	chr2:73147326	chr3:36976316~36976840:+
LUAD	trans	rs9876781	1	rs9838618	ENSG00000225528.1	RP3-370M22.8	-6.73	4.95e-11	0.000105	-0.3	-0.29	Longevity;	chr3:48445949	chr22:39960397~39964683:+
LUAD	trans	rs7769051	1	rs7761365	ENSG00000227615.1	RP11-864N7.2	6.73	4.97e-11	0.000105	0.48	0.29	Type 2 diabetes nephropathy;	chr6:132780422	chr11:74745716~74746114:-
LUAD	trans	rs7769051	1	rs7765224	ENSG00000227615.1	RP11-864N7.2	6.73	4.97e-11	0.000105	0.48	0.29	Type 2 diabetes nephropathy;	chr6:132780485	chr11:74745716~74746114:-
LUAD	trans	rs7769051	0.614	rs6912936	ENSG00000227615.1	RP11-864N7.2	6.73	4.97e-11	0.000105	0.48	0.29	Type 2 diabetes nephropathy;	chr6:132781525	chr11:74745716~74746114:-
LUAD	trans	rs6732160	0.564	rs2043096	ENSG00000236165.1	PRADC1P1	6.72	5.01e-11	0.000106	0.42	0.29	Intelligence (multi-trait analysis);	chr2:73148595	chr3:36976316~36976840:+
LUAD	trans	rs12439619	0.739	rs62012046	ENSG00000235370.6	DNM1P51	-6.72	5.11e-11	0.000108	-0.41	-0.29	Intelligence (multi-trait analysis);	chr15:82236824	chr15:84398316~84411701:-
LUAD	trans	rs12439619	0.774	rs62012047	ENSG00000235370.6	DNM1P51	-6.72	5.11e-11	0.000108	-0.41	-0.29	Intelligence (multi-trait analysis);	chr15:82236852	chr15:84398316~84411701:-
LUAD	trans	rs12439619	0.81	rs62012049	ENSG00000235370.6	DNM1P51	-6.72	5.11e-11	0.000108	-0.41	-0.29	Intelligence (multi-trait analysis);	chr15:82237722	chr15:84398316~84411701:-
LUAD	trans	rs6732160	0.613	rs57208378	ENSG00000236165.1	PRADC1P1	6.72	5.15e-11	0.000109	0.42	0.29	Intelligence (multi-trait analysis);	chr2:73162871	chr3:36976316~36976840:+
LUAD	trans	rs853679	0.546	rs13213986	ENSG00000253570.1	RNF5P1	6.72	5.23e-11	0.000111	0.67	0.29	Depression;	chr6:28390232	chr8:38600661~38601200:-
LUAD	trans	rs12145833	0.679	rs12048498	ENSG00000154608.12	CEP170P1	-6.72	5.25e-11	0.000111	-0.53	-0.29	Obesity (early onset extreme);	chr1:243387345	chr4:118467590~118554204:+
LUAD	trans	rs7746199	0.736	rs34105070	ENSG00000204709.4	LINC01556	6.71	5.34e-11	0.000113	0.62	0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27593026	chr6:28943877~28944537:+
LUAD	trans	rs7121616	0.595	rs7949414	ENSG00000229091.2	HSPA8P8	6.71	5.34e-11	0.000113	0.39	0.29	Breast cancer;	chr11:123072787	chr7:10451311~10452526:+
LUAD	trans	rs7260598	0.792	rs73031013	ENSG00000261770.1	CTC-459F4.1	6.71	5.4e-11	0.000114	0.48	0.29	Response to taxane treatment (placlitaxel);	chr19:24182049	chr19:27757184~27760849:-
LUAD	trans	rs13416322	0.796	rs17024489	ENSG00000214286.2	PDCL3P3	6.71	5.41e-11	0.000114	0.41	0.29	Intelligence (multi-trait analysis);	chr2:100527254	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.796	rs75863441	ENSG00000214286.2	PDCL3P3	6.71	5.41e-11	0.000114	0.41	0.29	Intelligence (multi-trait analysis);	chr2:100527462	chr3:17877455~17878169:-
LUAD	trans	rs1816752	0.87	rs9581029	ENSG00000224976.2	PARP4P2	-6.71	5.46e-11	0.000115	-0.33	-0.29	Obesity-related traits;	chr13:24425147	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.905	rs9511249	ENSG00000224976.2	PARP4P2	-6.71	5.46e-11	0.000115	-0.33	-0.29	Obesity-related traits;	chr13:24425457	chr13:19349137~19407962:+
LUAD	trans	rs12477438	0.52	rs6542864	ENSG00000276576.1	MRPL30P1	6.71	5.54e-11	0.000117	0.33	0.29	Chronic sinus infection;	chr2:99108760	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.52	rs11689265	ENSG00000276576.1	MRPL30P1	6.71	5.61e-11	0.000119	0.33	0.29	Chronic sinus infection;	chr2:99182804	chr6:57029521~57029988:+
LUAD	trans	rs380904	0.519	rs12541790	ENSG00000213130.3	EEF1DP5	-6.71	5.66e-11	0.00012	-0.43	-0.29	Venous thromboembolism (SNP x SNP interaction);	chr8:143561151	chr6:128580113~128580884:-
LUAD	trans	rs6732160	0.588	rs1430344	ENSG00000236165.1	PRADC1P1	6.7	5.67e-11	0.00012	0.42	0.29	Intelligence (multi-trait analysis);	chr2:73146216	chr3:36976316~36976840:+
LUAD	trans	rs7113874	0.802	rs4272783	ENSG00000266891.1	RP11-692N5.2	6.7	5.68e-11	0.00012	0.4	0.29	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8663846	chr18:9734882~9735602:-
LUAD	trans	rs673253	0.556	rs517191	ENSG00000231007.5	CDC20P1	6.7	5.76e-11	0.000122	0.38	0.29	Intelligence (multi-trait analysis);	chr1:43650795	chr9:87011652~87013151:+
LUAD	trans	rs7833986	0.501	rs2667999	ENSG00000244245.1	RP11-120B7.1	6.7	5.8e-11	0.000123	0.34	0.29	Height;	chr8:56037915	chr5:108593609~108593967:+
LUAD	trans	rs61041336	0.534	rs2280398	ENSG00000230849.2	GOT2P2	-6.7	5.81e-11	0.000123	-0.59	-0.29	Neuritic plaque;	chr16:58678226	chr1:173141100~173142350:-
LUAD	trans	rs853679	0.546	rs2232426	ENSG00000253570.1	RNF5P1	6.7	5.9e-11	0.000125	0.66	0.29	Depression;	chr6:28392882	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.546	rs2232423	ENSG00000253570.1	RNF5P1	6.7	5.9e-11	0.000125	0.66	0.29	Depression;	chr6:28398374	chr8:38600661~38601200:-
LUAD	trans	rs13416322	0.796	rs12233152	ENSG00000214286.2	PDCL3P3	6.7	5.9e-11	0.000125	0.41	0.29	Intelligence (multi-trait analysis);	chr2:100531509	chr3:17877455~17878169:-
LUAD	trans	rs12439619	0.768	rs28694364	ENSG00000235370.6	DNM1P51	-6.7	5.98e-11	0.000126	-0.41	-0.29	Intelligence (multi-trait analysis);	chr15:82208119	chr15:84398316~84411701:-
LUAD	trans	rs1816752	0.633	rs9578729	ENSG00000224976.2	PARP4P2	-6.7	5.99e-11	0.000126	-0.33	-0.29	Obesity-related traits;	chr13:24425106	chr13:19349137~19407962:+
LUAD	trans	rs4276421	0.55	rs34423213	ENSG00000231752.4	EMBP1	6.7	6e-11	0.000127	0.46	0.29	P wave duration;	chr5:45680866	chr1:121519112~121571892:+
LUAD	trans	rs9467773	0.587	rs10946812	ENSG00000242375.1	RP11-498P14.3	-6.7	6.01e-11	0.000127	-0.38	-0.29	Intelligence (multi-trait analysis);	chr6:26344747	chr9:97195351~97197687:-
LUAD	trans	rs12477438	0.501	rs2632284	ENSG00000276576.1	MRPL30P1	6.7	6.03e-11	0.000127	0.33	0.29	Chronic sinus infection;	chr2:99159402	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.52	rs2969379	ENSG00000276576.1	MRPL30P1	6.7	6.03e-11	0.000127	0.33	0.29	Chronic sinus infection;	chr2:99160223	chr6:57029521~57029988:+
LUAD	trans	rs9467773	0.626	rs9379860	ENSG00000242375.1	RP11-498P14.3	-6.69	6.04e-11	0.000127	-0.38	-0.29	Intelligence (multi-trait analysis);	chr6:26370377	chr9:97195351~97197687:-
LUAD	trans	rs7647973	1	rs9860055	ENSG00000197582.5	GPX1P1	-6.69	6.06e-11	0.000128	-0.4	-0.29	Menarche (age at onset);	chr3:49469467	chrX:13378735~13379340:-
LUAD	trans	rs7647973	1	rs74471041	ENSG00000197582.5	GPX1P1	-6.69	6.06e-11	0.000128	-0.4	-0.29	Menarche (age at onset);	chr3:49505110	chrX:13378735~13379340:-
LUAD	trans	rs7647973	1	rs7644148	ENSG00000197582.5	GPX1P1	-6.69	6.06e-11	0.000128	-0.4	-0.29	Menarche (age at onset);	chr3:49507808	chrX:13378735~13379340:-
LUAD	trans	rs17301013	0.93	rs6425279	ENSG00000213331.4	RP11-713C19.2	-6.69	6.1e-11	0.000129	-0.34	-0.29	Systemic lupus erythematosus;	chr1:174418717	chr4:187970273~187971284:+
LUAD	trans	rs546131	0.928	rs552627	ENSG00000225531.1	RP11-196I18.3	6.69	6.11e-11	0.000129	0.37	0.29	Lung disease severity in cystic fibrosis;	chr11:34805133	chr9:107116829~107117557:+
LUAD	trans	rs1190596	0.525	rs2236493	ENSG00000181359.5	HSP90AA6P	-6.69	6.2e-11	0.000131	-0.33	-0.29	Behavioural disinhibition (generation interaction);	chr14:102229356	chr4:170581470~170605450:-
LUAD	trans	rs12477438	0.52	rs10865029	ENSG00000276576.1	MRPL30P1	6.69	6.21e-11	0.000131	0.33	0.29	Chronic sinus infection;	chr2:99101835	chr6:57029521~57029988:+
LUAD	trans	rs4276421	0.555	rs10041767	ENSG00000231752.4	EMBP1	6.69	6.32e-11	0.000133	0.41	0.29	P wave duration;	chr5:45767317	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.555	rs10041772	ENSG00000231752.4	EMBP1	6.69	6.32e-11	0.000133	0.41	0.29	P wave duration;	chr5:45767386	chr1:121519112~121571892:+
LUAD	trans	rs12439619	0.846	rs62012003	ENSG00000235370.6	DNM1P51	-6.69	6.39e-11	0.000134	-0.4	-0.29	Intelligence (multi-trait analysis);	chr15:82183236	chr15:84398316~84411701:-
LUAD	trans	rs1190596	0.525	rs10134693	ENSG00000181359.5	HSP90AA6P	-6.69	6.39e-11	0.000135	-0.33	-0.29	Behavioural disinhibition (generation interaction);	chr14:102266987	chr4:170581470~170605450:-
LUAD	trans	rs7746199	0.736	rs58616630	ENSG00000204709.4	LINC01556	6.69	6.4e-11	0.000135	0.61	0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27506936	chr6:28943877~28944537:+
LUAD	trans	rs546131	0.82	rs744841	ENSG00000225531.1	RP11-196I18.3	6.68	6.42e-11	0.000135	0.37	0.29	Lung disease severity in cystic fibrosis;	chr11:34836120	chr9:107116829~107117557:+
LUAD	trans	rs877636	0.859	rs3741499	ENSG00000244604.1	RP11-713H12.1	-6.68	6.42e-11	0.000135	-0.33	-0.29	Cognitive function;	chr12:56080595	chr17:8561230~8561576:+
LUAD	trans	rs4263408	1	rs4263408	ENSG00000237550.5	UBE2Q2P6	6.68	6.47e-11	0.000136	0.34	0.29	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39783656	chr15:82372196~82372912:-
LUAD	trans	rs6132905	0.52	rs2422824	ENSG00000257956.1	NOP56P3	6.68	6.5e-11	0.000137	0.36	0.29	Mumps;	chr20:2666724	chr12:79558782~79559166:+
LUAD	trans	rs6743068	0.541	rs10178982	ENSG00000235105.1	RP11-329A14.1	6.68	6.52e-11	0.000137	0.34	0.29	Lymphocyte percentage of white cells;	chr2:201362917	chr1:48435967~48437223:+
LUAD	trans	rs7113874	0.802	rs11042029	ENSG00000266891.1	RP11-692N5.2	6.68	6.54e-11	0.000138	0.4	0.29	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8666578	chr18:9734882~9735602:-
LUAD	trans	rs7647973	0.961	rs7638750	ENSG00000197582.5	GPX1P1	-6.68	6.57e-11	0.000138	-0.41	-0.29	Menarche (age at onset);	chr3:49415524	chrX:13378735~13379340:-
LUAD	trans	rs12477438	0.52	rs12621007	ENSG00000276576.1	MRPL30P1	6.68	6.68e-11	0.00014	0.33	0.29	Chronic sinus infection;	chr2:99175483	chr6:57029521~57029988:+
LUAD	trans	rs7647973	1	rs62259933	ENSG00000197582.5	GPX1P1	-6.68	6.68e-11	0.00014	-0.4	-0.29	Menarche (age at onset);	chr3:49432270	chrX:13378735~13379340:-
LUAD	trans	rs864643	0.513	rs1707944	ENSG00000183298.5	RP11-556K13.1	6.68	6.75e-11	0.000142	0.41	0.29	Attention deficit hyperactivity disorder;	chr3:39487141	chr1:101786340~101787219:-
LUAD	trans	rs728478	0.845	rs7207830	ENSG00000187870.7	RNFT1P3	6.68	6.79e-11	0.000142	0.36	0.29	QT interval;	chr17:59402382	chr17:20743333~20754501:-
LUAD	trans	rs4276421	0.571	rs28405556	ENSG00000231752.4	EMBP1	6.67	6.85e-11	0.000144	0.43	0.29	P wave duration;	chr5:45636684	chr1:121519112~121571892:+
LUAD	trans	rs546131	0.928	rs546521	ENSG00000225531.1	RP11-196I18.3	6.67	6.91e-11	0.000145	0.37	0.29	Lung disease severity in cystic fibrosis;	chr11:34803226	chr9:107116829~107117557:+
LUAD	trans	rs1383484	0.798	rs7179241	ENSG00000278603.1	RP13-608F4.5	6.67	6.93e-11	0.000145	0.4	0.29	Height;	chr15:83882959	chr15:82472203~82472426:+
LUAD	trans	rs728478	0.845	rs9905500	ENSG00000187870.7	RNFT1P3	6.67	6.94e-11	0.000145	0.36	0.29	QT interval;	chr17:59398535	chr17:20743333~20754501:-
LUAD	trans	rs1816752	0.905	rs7571	ENSG00000224976.2	PARP4P2	-6.67	6.99e-11	0.000146	-0.33	-0.29	Obesity-related traits;	chr13:24426479	chr13:19349137~19407962:+
LUAD	trans	rs1190596	0.525	rs28607975	ENSG00000181359.5	HSP90AA6P	-6.67	7e-11	0.000147	-0.33	-0.29	Behavioural disinhibition (generation interaction);	chr14:102252082	chr4:170581470~170605450:-
LUAD	trans	rs1190596	0.525	rs3783372	ENSG00000181359.5	HSP90AA6P	-6.67	7e-11	0.000147	-0.33	-0.29	Behavioural disinhibition (generation interaction);	chr14:102253283	chr4:170581470~170605450:-
LUAD	trans	rs1190596	0.525	rs10145478	ENSG00000181359.5	HSP90AA6P	-6.67	7e-11	0.000147	-0.33	-0.29	Behavioural disinhibition (generation interaction);	chr14:102254559	chr4:170581470~170605450:-
LUAD	trans	rs1816752	0.719	rs11843470	ENSG00000224976.2	PARP4P2	-6.67	7.01e-11	0.000147	-0.33	-0.29	Obesity-related traits;	chr13:24423561	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.905	rs9581026	ENSG00000224976.2	PARP4P2	-6.67	7.04e-11	0.000148	-0.33	-0.29	Obesity-related traits;	chr13:24423788	chr13:19349137~19407962:+
LUAD	trans	rs877636	0.74	rs705698	ENSG00000233778.3	RP11-777J24.1	6.67	7.21e-11	0.000151	0.33	0.29	Cognitive function;	chr12:55990903	chr8:92144088~92144435:-
LUAD	trans	rs45509595	0.841	rs9368531	ENSG00000204709.4	LINC01556	6.67	7.21e-11	0.000151	0.55	0.29	Breast cancer;	chr6:27814094	chr6:28943877~28944537:+
LUAD	trans	rs45509595	0.841	rs2747054	ENSG00000204709.4	LINC01556	6.67	7.21e-11	0.000151	0.55	0.29	Breast cancer;	chr6:27815581	chr6:28943877~28944537:+
LUAD	trans	rs6732160	0.613	rs6546804	ENSG00000236165.1	PRADC1P1	6.67	7.26e-11	0.000152	0.41	0.29	Intelligence (multi-trait analysis);	chr2:73158791	chr3:36976316~36976840:+
LUAD	trans	rs7746199	0.673	rs35501037	ENSG00000204709.4	LINC01556	6.66	7.31e-11	0.000153	0.61	0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27771787	chr6:28943877~28944537:+
LUAD	trans	rs12477438	0.52	rs13030961	ENSG00000276576.1	MRPL30P1	6.66	7.33e-11	0.000153	0.33	0.29	Chronic sinus infection;	chr2:99183057	chr6:57029521~57029988:+
LUAD	trans	rs6915893	0.74	rs6910353	ENSG00000267156.1	TPMTP1	-6.66	7.35e-11	0.000154	-0.35	-0.29	Intrinsic epigenetic age acceleration;	chr6:18102327	chr18:47630112~47630848:+
LUAD	trans	rs6732160	0.588	rs13394018	ENSG00000236165.1	PRADC1P1	6.66	7.35e-11	0.000154	0.41	0.29	Intelligence (multi-trait analysis);	chr2:73145477	chr3:36976316~36976840:+
LUAD	trans	rs7192380	1	rs7192380	ENSG00000257513.6	NPIPB1P	6.66	7.39e-11	0.000154	0.28	0.29	Sjögren's syndrome;	chr16:69670439	chr18:11619509~11639699:-
LUAD	trans	rs546131	0.89	rs496558	ENSG00000225531.1	RP11-196I18.3	6.66	7.39e-11	0.000154	0.36	0.29	Lung disease severity in cystic fibrosis;	chr11:34804878	chr9:107116829~107117557:+
LUAD	trans	rs9467773	0.566	rs66972160	ENSG00000242375.1	RP11-498P14.3	-6.66	7.43e-11	0.000155	-0.38	-0.29	Intelligence (multi-trait analysis);	chr6:26359078	chr9:97195351~97197687:-
LUAD	trans	rs9467773	0.526	rs9348710	ENSG00000242375.1	RP11-498P14.3	-6.66	7.43e-11	0.000155	-0.38	-0.29	Intelligence (multi-trait analysis);	chr6:26360258	chr9:97195351~97197687:-
LUAD	trans	rs7618501	1	rs7634902	ENSG00000197582.5	GPX1P1	-6.66	7.51e-11	0.000157	-0.37	-0.29	Intelligence (multi-trait analysis);	chr3:49725229	chrX:13378735~13379340:-
LUAD	trans	rs7618501	1	rs1049256	ENSG00000197582.5	GPX1P1	-6.66	7.51e-11	0.000157	-0.37	-0.29	Intelligence (multi-trait analysis);	chr3:49725905	chrX:13378735~13379340:-
LUAD	trans	rs7618501	1	rs3749241	ENSG00000197582.5	GPX1P1	-6.66	7.52e-11	0.000157	-0.37	-0.29	Intelligence (multi-trait analysis);	chr3:49706959	chrX:13378735~13379340:-
LUAD	trans	rs7618501	1	rs3749240	ENSG00000197582.5	GPX1P1	-6.66	7.52e-11	0.000157	-0.37	-0.29	Intelligence (multi-trait analysis);	chr3:49712755	chrX:13378735~13379340:-
LUAD	trans	rs1383484	0.798	rs12438269	ENSG00000278603.1	RP13-608F4.5	6.66	7.55e-11	0.000157	0.39	0.29	Height;	chr15:83833797	chr15:82472203~82472426:+
LUAD	trans	rs877636	1	rs877636	ENSG00000234192.1	RP11-57C13.5	-6.66	7.55e-11	0.000158	-0.31	-0.29	Cognitive function;	chr12:56086799	chr10:87642607~87642954:+
LUAD	trans	rs4742971	0.5	rs10816353	ENSG00000262902.1	RP11-750B16.1	6.66	7.56e-11	0.000158	0.51	0.29	Protein quantitative trait loci;	chr9:105921319	chr17:53105734~53106358:+
LUAD	trans	rs4276421	0.511	rs62371976	ENSG00000231752.4	EMBP1	6.66	7.56e-11	0.000158	0.44	0.29	P wave duration;	chr5:45914178	chr1:121519112~121571892:+
LUAD	trans	rs9581094	0.591	rs9553318	ENSG00000237917.1	PARP4P1	-6.66	7.6e-11	0.000158	-0.42	-0.29	Sudden cardiac arrest;	chr13:24477107	chrY:26594851~26634652:-
LUAD	trans	rs2243480	1	rs34637256	ENSG00000273142.1	RP11-458F8.4	-6.66	7.7e-11	0.000161	-0.31	-0.29	Diabetic kidney disease;	chr7:65895144	chr7:66902857~66906297:+
LUAD	trans	rs2243480	1	rs35391607	ENSG00000273142.1	RP11-458F8.4	-6.66	7.7e-11	0.000161	-0.31	-0.29	Diabetic kidney disease;	chr7:65895842	chr7:66902857~66906297:+
LUAD	trans	rs2243480	1	rs13220979	ENSG00000273142.1	RP11-458F8.4	-6.66	7.7e-11	0.000161	-0.31	-0.29	Diabetic kidney disease;	chr7:65898217	chr7:66902857~66906297:+
LUAD	trans	rs2243480	1	rs34974928	ENSG00000273142.1	RP11-458F8.4	-6.66	7.7e-11	0.000161	-0.31	-0.29	Diabetic kidney disease;	chr7:65899019	chr7:66902857~66906297:+
LUAD	trans	rs77686669	1	rs77686669	ENSG00000228546.2	CTA-313A17.3	6.65	7.77e-11	0.000162	0.41	0.29	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr7:100146949	chr7:102337316~102339115:+
LUAD	trans	rs11951515	0.508	rs6898866	ENSG00000174977.8	AC026271.5	-6.65	7.83e-11	0.000163	-0.3	-0.29	Metabolite levels  (X-11787);	chr5:43586273	chr17:18650195~18651542:+
LUAD	trans	rs4713118	0.911	rs9295746	ENSG00000204709.4	LINC01556	6.65	7.86e-11	0.000164	0.4	0.29	Parkinson's disease;	chr6:27762285	chr6:28943877~28944537:+
LUAD	trans	rs4834770	0.746	rs2389747	ENSG00000275858.1	RP11-291L22.8	6.65	7.88e-11	0.000164	0.35	0.29	Blood protein levels;	chr4:119314947	chr10:38450738~38451069:-
LUAD	trans	rs4834770	0.717	rs1022146	ENSG00000275858.1	RP11-291L22.8	6.65	7.88e-11	0.000164	0.35	0.29	Blood protein levels;	chr4:119314948	chr10:38450738~38451069:-
LUAD	trans	rs7258465	0.563	rs10854166	ENSG00000267533.1	RP11-815J4.7	-6.65	7.89e-11	0.000164	-0.36	-0.29	Breast cancer;	chr19:18542034	chr18:12067173~12068417:-
LUAD	trans	rs7113874	0.797	rs4503528	ENSG00000266891.1	RP11-692N5.2	-6.65	7.94e-11	0.000165	-0.39	-0.29	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8642907	chr18:9734882~9735602:-
LUAD	trans	rs7121616	0.545	rs116414356	ENSG00000229091.2	HSPA8P8	6.65	8.03e-11	0.000167	0.4	0.29	Breast cancer;	chr11:123082611	chr7:10451311~10452526:+
LUAD	trans	rs853679	0.546	rs36092177	ENSG00000253570.1	RNF5P1	6.65	8.03e-11	0.000167	0.66	0.29	Depression;	chr6:28390030	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.546	rs2232429	ENSG00000253570.1	RNF5P1	6.65	8.03e-11	0.000167	0.66	0.29	Depression;	chr6:28391855	chr8:38600661~38601200:-
LUAD	trans	rs860295	0.529	rs10908486	ENSG00000241627.3	UBQLN4P1	6.65	8.12e-11	0.000169	0.27	0.29	Body mass index;	chr1:156008753	chr3:148985868~148987668:-
LUAD	trans	rs7113874	0.802	rs885114	ENSG00000266891.1	RP11-692N5.2	6.65	8.15e-11	0.00017	0.39	0.29	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8657209	chr18:9734882~9735602:-
LUAD	trans	rs45509595	0.822	rs200484	ENSG00000204709.4	LINC01556	6.65	8.18e-11	0.00017	0.55	0.29	Breast cancer;	chr6:27807896	chr6:28943877~28944537:+
LUAD	trans	rs4263408	0.967	rs4974948	ENSG00000237550.5	UBE2Q2P6	6.64	8.25e-11	0.000172	0.34	0.29	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39751016	chr15:82372196~82372912:-
LUAD	trans	rs6743068	0.521	rs1406122	ENSG00000235105.1	RP11-329A14.1	-6.64	8.29e-11	0.000172	-0.33	-0.29	Lymphocyte percentage of white cells;	chr2:201346720	chr1:48435967~48437223:+
LUAD	trans	rs7113874	0.802	rs1502317	ENSG00000266891.1	RP11-692N5.2	6.64	8.29e-11	0.000172	0.39	0.29	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8660471	chr18:9734882~9735602:-
LUAD	trans	rs2243480	1	rs3885839	ENSG00000273142.1	RP11-458F8.4	-6.64	8.33e-11	0.000173	-0.31	-0.29	Diabetic kidney disease;	chr7:65825416	chr7:66902857~66906297:+
LUAD	trans	rs2243480	0.901	rs3813708	ENSG00000273142.1	RP11-458F8.4	-6.64	8.33e-11	0.000173	-0.31	-0.29	Diabetic kidney disease;	chr7:65840645	chr7:66902857~66906297:+
LUAD	trans	rs2243480	1	rs73142122	ENSG00000273142.1	RP11-458F8.4	-6.64	8.33e-11	0.000173	-0.31	-0.29	Diabetic kidney disease;	chr7:65846311	chr7:66902857~66906297:+
LUAD	trans	rs2243480	0.901	rs73142137	ENSG00000273142.1	RP11-458F8.4	-6.64	8.33e-11	0.000173	-0.31	-0.29	Diabetic kidney disease;	chr7:65878455	chr7:66902857~66906297:+
LUAD	trans	rs1816752	0.87	rs9318529	ENSG00000224976.2	PARP4P2	-6.64	8.33e-11	0.000173	-0.32	-0.29	Obesity-related traits;	chr13:24424190	chr13:19349137~19407962:+
LUAD	trans	rs7647973	1	rs6446275	ENSG00000197582.5	GPX1P1	-6.64	8.35e-11	0.000174	-0.4	-0.29	Menarche (age at onset);	chr3:49429438	chrX:13378735~13379340:-
LUAD	trans	rs1816752	0.837	rs9318530	ENSG00000224976.2	PARP4P2	6.64	8.47e-11	0.000176	0.32	0.29	Obesity-related traits;	chr13:24424419	chr13:19349137~19407962:+
LUAD	trans	rs9393777	0.92	rs13207689	ENSG00000204709.4	LINC01556	6.64	8.47e-11	0.000176	0.61	0.29	Intelligence (multi-trait analysis);	chr6:27401925	chr6:28943877~28944537:+
LUAD	trans	rs6424115	0.708	rs13551	ENSG00000228217.1	AL390877.1	6.64	8.55e-11	0.000177	0.39	0.29	Immature fraction of reticulocytes;	chr1:23854472	chr1:117778087~117778506:-
LUAD	trans	rs6424115	0.708	rs12748109	ENSG00000228217.1	AL390877.1	6.64	8.55e-11	0.000177	0.39	0.29	Immature fraction of reticulocytes;	chr1:23854687	chr1:117778087~117778506:-
LUAD	trans	rs9425766	0.679	rs6667267	ENSG00000213331.4	RP11-713C19.2	6.64	8.58e-11	0.000178	0.34	0.29	Life satisfaction;	chr1:174243623	chr4:187970273~187971284:+
LUAD	trans	rs7554511	0.666	rs2221581	ENSG00000244144.1	RP11-757F18.3	-6.64	8.61e-11	0.000178	-0.37	-0.29	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201012797	chr3:112185480~112185998:-
LUAD	trans	rs12145833	1	rs2802727	ENSG00000154608.12	CEP170P1	6.64	8.64e-11	0.000179	0.47	0.29	Obesity (early onset extreme);	chr1:243320024	chr4:118467590~118554204:+
LUAD	trans	rs6499255	1	rs4464069	ENSG00000257513.6	NPIPB1P	6.64	8.68e-11	0.00018	0.34	0.29	IgE levels;	chr16:69782381	chr18:11619509~11639699:-
LUAD	trans	rs1383484	0.798	rs28544951	ENSG00000278603.1	RP13-608F4.5	6.64	8.68e-11	0.00018	0.39	0.29	Height;	chr15:83850088	chr15:82472203~82472426:+
LUAD	trans	rs9425766	0.732	rs6658543	ENSG00000213331.4	RP11-713C19.2	6.63	8.78e-11	0.000182	0.34	0.29	Life satisfaction;	chr1:174183338	chr4:187970273~187971284:+
LUAD	trans	rs877636	0.669	rs7297175	ENSG00000243538.1	CTB-55B8.1	-6.63	8.84e-11	0.000183	-0.3	-0.29	Cognitive function;	chr12:56080024	chr5:16902294~16902641:-
LUAD	trans	rs1190596	0.578	rs12887161	ENSG00000181359.5	HSP90AA6P	-6.63	9.09e-11	0.000188	-0.33	-0.29	Behavioural disinhibition (generation interaction);	chr14:102240581	chr4:170581470~170605450:-
LUAD	trans	rs7618501	0.722	rs9853458	ENSG00000197582.5	GPX1P1	-6.63	9.1e-11	0.000188	-0.37	-0.29	Intelligence (multi-trait analysis);	chr3:49745778	chrX:13378735~13379340:-
LUAD	trans	rs864643	0.513	rs6599028	ENSG00000183298.5	RP11-556K13.1	6.63	9.1e-11	0.000188	0.41	0.29	Attention deficit hyperactivity disorder;	chr3:39492344	chr1:101786340~101787219:-
LUAD	trans	rs7618501	0.735	rs9876508	ENSG00000197582.5	GPX1P1	-6.63	9.11e-11	0.000189	-0.37	-0.29	Intelligence (multi-trait analysis);	chr3:49743411	chrX:13378735~13379340:-
LUAD	trans	rs7618501	1	rs7649348	ENSG00000197582.5	GPX1P1	-6.63	9.15e-11	0.000189	-0.37	-0.29	Intelligence (multi-trait analysis);	chr3:49734942	chrX:13378735~13379340:-
LUAD	trans	rs7618501	1	rs7618501	ENSG00000197582.5	GPX1P1	-6.63	9.15e-11	0.000189	-0.37	-0.29	Intelligence (multi-trait analysis);	chr3:49735214	chrX:13378735~13379340:-
LUAD	trans	rs7618501	1	rs7618519	ENSG00000197582.5	GPX1P1	-6.63	9.15e-11	0.000189	-0.37	-0.29	Intelligence (multi-trait analysis);	chr3:49735275	chrX:13378735~13379340:-
LUAD	trans	rs13416322	0.647	rs7596463	ENSG00000214286.2	PDCL3P3	6.62	9.37e-11	0.000194	0.39	0.29	Intelligence (multi-trait analysis);	chr2:100533692	chr3:17877455~17878169:-
LUAD	trans	rs864643	0.513	rs1707956	ENSG00000183298.5	RP11-556K13.1	-6.62	9.38e-11	0.000194	-0.41	-0.29	Attention deficit hyperactivity disorder;	chr3:39482025	chr1:101786340~101787219:-
LUAD	trans	rs853679	0.556	rs45509595	ENSG00000204709.4	LINC01556	6.62	9.38e-11	0.000194	0.64	0.29	Depression;	chr6:27873148	chr6:28943877~28944537:+
LUAD	trans	rs7260598	0.581	rs17311328	ENSG00000261770.1	CTC-459F4.1	6.62	9.42e-11	0.000195	0.48	0.29	Response to taxane treatment (placlitaxel);	chr19:24186640	chr19:27757184~27760849:-
LUAD	trans	rs7647973	1	rs10865956	ENSG00000197582.5	GPX1P1	6.62	9.62e-11	0.000198	0.4	0.29	Menarche (age at onset);	chr3:49544126	chrX:13378735~13379340:-
LUAD	trans	rs56114371	0.777	rs200482	ENSG00000204709.4	LINC01556	6.62	9.63e-11	0.000199	0.52	0.29	Breast cancer;	chr6:27806126	chr6:28943877~28944537:+
LUAD	trans	rs9584850	0.834	rs2031239	ENSG00000230079.1	STK24P1	6.62	9.67e-11	0.000199	0.34	0.29	Neuroticism;	chr13:98459306	chrX:136295690~136300298:-
LUAD	trans	rs7833986	0.534	rs17813240	ENSG00000244245.1	RP11-120B7.1	6.62	9.72e-11	2e-04	0.34	0.29	Height;	chr8:56013232	chr5:108593609~108593967:+
LUAD	trans	rs2243480	1	rs13247184	ENSG00000273142.1	RP11-458F8.4	-6.62	9.8e-11	0.000202	-0.31	-0.29	Diabetic kidney disease;	chr7:65893941	chr7:66902857~66906297:+
LUAD	trans	rs2243480	1	rs35283677	ENSG00000273142.1	RP11-458F8.4	-6.62	9.8e-11	0.000202	-0.31	-0.29	Diabetic kidney disease;	chr7:65894246	chr7:66902857~66906297:+
LUAD	trans	rs2243480	1	rs35421653	ENSG00000273142.1	RP11-458F8.4	-6.62	9.8e-11	0.000202	-0.31	-0.29	Diabetic kidney disease;	chr7:65898442	chr7:66902857~66906297:+
LUAD	trans	rs1383484	0.798	rs59355989	ENSG00000278603.1	RP13-608F4.5	6.62	9.84e-11	0.000203	0.39	0.29	Height;	chr15:83841979	chr15:82472203~82472426:+
LUAD	trans	rs4276421	0.571	rs10473389	ENSG00000231752.4	EMBP1	6.62	9.92e-11	0.000204	0.44	0.29	P wave duration;	chr5:45561699	chr1:121519112~121571892:+
LUAD	trans	rs7746199	0.736	rs6904596	ENSG00000204709.4	LINC01556	6.61	9.97e-11	0.000205	0.54	0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27523520	chr6:28943877~28944537:+
LUAD	trans	rs7746199	0.736	rs10484399	ENSG00000204709.4	LINC01556	6.61	9.98e-11	0.000205	0.59	0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27566749	chr6:28943877~28944537:+
LUAD	trans	rs7192380	0.895	rs2917671	ENSG00000257513.6	NPIPB1P	-6.61	9.99e-11	0.000206	-0.29	-0.29	Sjögren's syndrome;	chr16:69724838	chr18:11619509~11639699:-
LUAD	trans	rs9425766	0.679	rs4650989	ENSG00000213331.4	RP11-713C19.2	6.61	1e-10	0.000207	0.34	0.29	Life satisfaction;	chr1:174289739	chr4:187970273~187971284:+
LUAD	trans	rs1383484	0.798	rs2086441	ENSG00000278603.1	RP13-608F4.5	6.61	1.01e-10	0.000207	0.39	0.29	Height;	chr15:83881728	chr15:82472203~82472426:+
LUAD	trans	rs7647973	1	rs9842132	ENSG00000197582.5	GPX1P1	-6.61	1.01e-10	0.000208	-0.4	-0.29	Menarche (age at onset);	chr3:49390500	chrX:13378735~13379340:-
LUAD	trans	rs7647973	1	rs6785045	ENSG00000197582.5	GPX1P1	-6.61	1.01e-10	0.000208	-0.4	-0.29	Menarche (age at onset);	chr3:49397810	chrX:13378735~13379340:-
LUAD	trans	rs7647973	1	rs7648995	ENSG00000197582.5	GPX1P1	-6.61	1.01e-10	0.000208	-0.4	-0.29	Menarche (age at onset);	chr3:49401370	chrX:13378735~13379340:-
LUAD	trans	rs7647973	1	rs2140270	ENSG00000197582.5	GPX1P1	-6.61	1.01e-10	0.000208	-0.4	-0.29	Menarche (age at onset);	chr3:49402007	chrX:13378735~13379340:-
LUAD	trans	rs7647973	1	rs2177268	ENSG00000197582.5	GPX1P1	-6.61	1.01e-10	0.000208	-0.4	-0.29	Menarche (age at onset);	chr3:49402292	chrX:13378735~13379340:-
LUAD	trans	rs9611519	0.929	rs71327107	ENSG00000268568.1	AC007228.9	-6.61	1.02e-10	0.00021	-0.44	-0.29	Neuroticism;	chr22:41022225	chr19:56672574~56673901:-
LUAD	trans	rs9611519	0.828	rs9611460	ENSG00000268568.1	AC007228.9	-6.61	1.02e-10	0.00021	-0.44	-0.29	Neuroticism;	chr22:41022293	chr19:56672574~56673901:-
LUAD	trans	rs7647973	1	rs56127630	ENSG00000197582.5	GPX1P1	-6.61	1.03e-10	0.000211	-0.4	-0.29	Menarche (age at onset);	chr3:49400603	chrX:13378735~13379340:-
LUAD	trans	rs864643	0.588	rs604869	ENSG00000183298.5	RP11-556K13.1	6.61	1.03e-10	0.000211	0.41	0.29	Attention deficit hyperactivity disorder;	chr3:39486307	chr1:101786340~101787219:-
LUAD	trans	rs853679	0.546	rs200996	ENSG00000204709.4	LINC01556	6.61	1.03e-10	0.000212	0.55	0.29	Depression;	chr6:27844050	chr6:28943877~28944537:+
LUAD	trans	rs7647973	1	rs3448	ENSG00000197582.5	GPX1P1	6.61	1.04e-10	0.000213	0.4	0.29	Menarche (age at onset);	chr3:49359318	chrX:13378735~13379340:-
LUAD	trans	rs7647973	1	rs11130190	ENSG00000197582.5	GPX1P1	6.61	1.04e-10	0.000213	0.4	0.29	Menarche (age at onset);	chr3:49364704	chrX:13378735~13379340:-
LUAD	trans	rs9425766	0.679	rs4652234	ENSG00000213331.4	RP11-713C19.2	6.61	1.04e-10	0.000214	0.34	0.29	Life satisfaction;	chr1:174181712	chr4:187970273~187971284:+
LUAD	trans	rs864643	0.513	rs614823	ENSG00000183298.5	RP11-556K13.1	6.61	1.04e-10	0.000214	0.41	0.29	Attention deficit hyperactivity disorder;	chr3:39493267	chr1:101786340~101787219:-
LUAD	trans	rs12477438	0.52	rs7605843	ENSG00000276576.1	MRPL30P1	6.61	1.04e-10	0.000214	0.33	0.29	Chronic sinus infection;	chr2:99195431	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.52	rs13798	ENSG00000276576.1	MRPL30P1	6.61	1.04e-10	0.000214	0.33	0.29	Chronic sinus infection;	chr2:99197151	chr6:57029521~57029988:+
LUAD	trans	rs7113874	0.802	rs11042025	ENSG00000266891.1	RP11-692N5.2	-6.61	1.04e-10	0.000214	-0.39	-0.29	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8653928	chr18:9734882~9735602:-
LUAD	trans	rs6732160	0.613	rs59979991	ENSG00000236165.1	PRADC1P1	6.61	1.05e-10	0.000215	0.41	0.29	Intelligence (multi-trait analysis);	chr2:73157294	chr3:36976316~36976840:+
LUAD	trans	rs6732160	0.613	rs10179063	ENSG00000236165.1	PRADC1P1	6.61	1.05e-10	0.000215	0.41	0.29	Intelligence (multi-trait analysis);	chr2:73157983	chr3:36976316~36976840:+
LUAD	trans	rs9467773	0.587	rs9467722	ENSG00000242375.1	RP11-498P14.3	-6.61	1.05e-10	0.000216	-0.37	-0.29	Intelligence (multi-trait analysis);	chr6:26352338	chr9:97195351~97197687:-
LUAD	trans	rs1816752	0.905	rs9511242	ENSG00000224976.2	PARP4P2	-6.6	1.06e-10	0.000217	-0.33	-0.29	Obesity-related traits;	chr13:24419261	chr13:19349137~19407962:+
LUAD	trans	rs853679	0.607	rs13199772	ENSG00000204709.4	LINC01556	6.6	1.07e-10	0.00022	0.62	0.29	Depression;	chr6:27866307	chr6:28943877~28944537:+
LUAD	trans	rs853679	0.607	rs13199906	ENSG00000204709.4	LINC01556	6.6	1.07e-10	0.00022	0.62	0.29	Depression;	chr6:27866361	chr6:28943877~28944537:+
LUAD	trans	rs853679	0.607	rs17763089	ENSG00000204709.4	LINC01556	6.6	1.07e-10	0.00022	0.62	0.29	Depression;	chr6:27867440	chr6:28943877~28944537:+
LUAD	trans	rs853679	0.546	rs17695758	ENSG00000204709.4	LINC01556	6.6	1.07e-10	0.00022	0.62	0.29	Depression;	chr6:27869405	chr6:28943877~28944537:+
LUAD	trans	rs853679	0.546	rs200989	ENSG00000204709.4	LINC01556	6.6	1.08e-10	0.000222	0.55	0.29	Depression;	chr6:27848664	chr6:28943877~28944537:+
LUAD	trans	rs7647973	1	rs9871024	ENSG00000197582.5	GPX1P1	-6.6	1.09e-10	0.000223	-0.4	-0.29	Menarche (age at onset);	chr3:49516808	chrX:13378735~13379340:-
LUAD	trans	rs7647973	1	rs13322887	ENSG00000197582.5	GPX1P1	-6.6	1.09e-10	0.000223	-0.4	-0.29	Menarche (age at onset);	chr3:49518150	chrX:13378735~13379340:-
LUAD	trans	rs7647973	0.922	rs7620024	ENSG00000197582.5	GPX1P1	-6.6	1.09e-10	0.000224	-0.4	-0.29	Menarche (age at onset);	chr3:49414258	chrX:13378735~13379340:-
LUAD	trans	rs1383484	0.761	rs28401196	ENSG00000278603.1	RP13-608F4.5	6.6	1.09e-10	0.000224	0.39	0.29	Height;	chr15:83878609	chr15:82472203~82472426:+
LUAD	trans	rs4263408	0.935	rs62310129	ENSG00000237550.5	UBE2Q2P6	6.6	1.1e-10	0.000225	0.34	0.29	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39772802	chr15:82372196~82372912:-
LUAD	trans	rs9425766	0.679	rs6670617	ENSG00000213331.4	RP11-713C19.2	6.6	1.1e-10	0.000225	0.34	0.29	Life satisfaction;	chr1:174277574	chr4:187970273~187971284:+
LUAD	trans	rs73108077	0.736	rs56047717	ENSG00000279352.1	RP11-411B10.7	6.6	1.11e-10	0.000228	0.48	0.29	Red blood cell density in sickle cell anemia;	chr20:31279756	chr18:14010054~14010917:+
LUAD	trans	rs9425766	0.679	rs4650990	ENSG00000213331.4	RP11-713C19.2	6.6	1.11e-10	0.000228	0.34	0.29	Life satisfaction;	chr1:174289943	chr4:187970273~187971284:+
LUAD	trans	rs9425766	0.679	rs9787001	ENSG00000213331.4	RP11-713C19.2	6.59	1.13e-10	0.000231	0.34	0.29	Life satisfaction;	chr1:174222556	chr4:187970273~187971284:+
LUAD	trans	rs1816752	0.719	rs11841989	ENSG00000224976.2	PARP4P2	-6.59	1.13e-10	0.000231	-0.33	-0.29	Obesity-related traits;	chr13:24423560	chr13:19349137~19407962:+
LUAD	trans	rs12477438	0.501	rs7349217	ENSG00000276576.1	MRPL30P1	6.59	1.14e-10	0.000233	0.33	0.29	Chronic sinus infection;	chr2:99198683	chr6:57029521~57029988:+
LUAD	trans	rs4263408	0.654	rs305827	ENSG00000237550.5	UBE2Q2P6	6.59	1.14e-10	0.000233	0.36	0.29	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39758369	chr15:82372196~82372912:-
LUAD	trans	rs6921919	0.562	rs13198809	ENSG00000253570.1	RNF5P1	6.59	1.14e-10	0.000234	0.65	0.29	Autism spectrum disorder or schizophrenia;	chr6:28355925	chr8:38600661~38601200:-
LUAD	trans	rs1383484	0.754	rs9921007	ENSG00000278603.1	RP13-608F4.5	6.59	1.14e-10	0.000234	0.38	0.29	Height;	chr15:83901099	chr15:82472203~82472426:+
LUAD	trans	rs853679	0.546	rs200981	ENSG00000204709.4	LINC01556	6.59	1.16e-10	0.000237	0.55	0.29	Depression;	chr6:27865396	chr6:28943877~28944537:+
LUAD	trans	rs673253	0.686	rs2782641	ENSG00000231007.5	CDC20P1	6.59	1.16e-10	0.000237	0.37	0.29	Intelligence (multi-trait analysis);	chr1:43547684	chr9:87011652~87013151:+
LUAD	trans	rs7833986	0.501	rs2953911	ENSG00000244245.1	RP11-120B7.1	6.59	1.17e-10	0.000238	0.34	0.29	Height;	chr8:56035450	chr5:108593609~108593967:+
LUAD	trans	rs546131	0.928	rs547504	ENSG00000225531.1	RP11-196I18.3	6.59	1.17e-10	0.00024	0.36	0.29	Lung disease severity in cystic fibrosis;	chr11:34825678	chr9:107116829~107117557:+
LUAD	trans	rs853679	0.546	rs34295134	ENSG00000204709.4	LINC01556	6.59	1.17e-10	0.00024	0.55	0.29	Depression;	chr6:27860373	chr6:28943877~28944537:+
LUAD	trans	rs7769051	1	rs10484629	ENSG00000227615.1	RP11-864N7.2	6.59	1.18e-10	0.00024	0.48	0.29	Type 2 diabetes nephropathy;	chr6:132796731	chr11:74745716~74746114:-
LUAD	trans	rs1563304	1	rs1563304	ENSG00000264070.1	DND1P1	6.59	1.18e-10	0.000241	0.48	0.29	Neuroticism;	chr17:46797087	chr17:45585871~45586929:+
LUAD	trans	rs1816752	0.87	rs9581025	ENSG00000224976.2	PARP4P2	-6.59	1.18e-10	0.000241	-0.32	-0.29	Obesity-related traits;	chr13:24423687	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.87	rs9581027	ENSG00000224976.2	PARP4P2	-6.59	1.18e-10	0.000241	-0.32	-0.29	Obesity-related traits;	chr13:24423790	chr13:19349137~19407962:+
LUAD	trans	rs77688320	1	rs2714486	ENSG00000235105.1	RP11-329A14.1	-6.59	1.19e-10	0.000242	-0.44	-0.29	Breast cancer;	chr2:201384985	chr1:48435967~48437223:+
LUAD	trans	rs9425766	0.679	rs2064149	ENSG00000213331.4	RP11-713C19.2	6.59	1.19e-10	0.000244	0.34	0.29	Life satisfaction;	chr1:174255856	chr4:187970273~187971284:+
LUAD	trans	rs7113874	0.802	rs4291677	ENSG00000266891.1	RP11-692N5.2	6.58	1.2e-10	0.000245	0.39	0.29	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8659344	chr18:9734882~9735602:-
LUAD	trans	rs13016963	0.546	rs11691602	ENSG00000235105.1	RP11-329A14.1	6.58	1.2e-10	0.000245	0.33	0.29	Esophageal squamous cell carcinoma;Melanoma;	chr2:201362976	chr1:48435967~48437223:+
LUAD	trans	rs7833986	0.501	rs72653959	ENSG00000244245.1	RP11-120B7.1	6.58	1.2e-10	0.000246	0.34	0.29	Height;	chr8:56083957	chr5:108593609~108593967:+
LUAD	trans	rs7833986	0.501	rs72653962	ENSG00000244245.1	RP11-120B7.1	6.58	1.2e-10	0.000246	0.34	0.29	Height;	chr8:56084946	chr5:108593609~108593967:+
LUAD	trans	rs7833986	0.501	rs72653967	ENSG00000244245.1	RP11-120B7.1	6.58	1.2e-10	0.000246	0.34	0.29	Height;	chr8:56086873	chr5:108593609~108593967:+
LUAD	trans	rs1816752	0.905	rs7317850	ENSG00000224976.2	PARP4P2	-6.58	1.21e-10	0.000246	-0.33	-0.29	Obesity-related traits;	chr13:24419899	chr13:19349137~19407962:+
LUAD	trans	rs673253	0.686	rs2842187	ENSG00000231007.5	CDC20P1	-6.58	1.21e-10	0.000247	-0.37	-0.29	Intelligence (multi-trait analysis);	chr1:43549278	chr9:87011652~87013151:+
LUAD	trans	rs16937956	0.657	rs16938063	ENSG00000266891.1	RP11-692N5.2	-6.58	1.21e-10	0.000247	-0.41	-0.29	Body mass index;	chr11:8410110	chr18:9734882~9735602:-
LUAD	trans	rs7647973	1	rs4241407	ENSG00000197582.5	GPX1P1	6.58	1.21e-10	0.000247	0.4	0.29	Menarche (age at onset);	chr3:49562886	chrX:13378735~13379340:-
LUAD	trans	rs1478897	0.575	rs12679960	ENSG00000253893.2	FAM85B	-6.58	1.22e-10	0.000248	-0.39	-0.29	Systemic lupus erythematosus;	chr8:11573481	chr8:8167819~8226614:-
LUAD	trans	rs6499255	0.904	rs9929720	ENSG00000257513.6	NPIPB1P	-6.58	1.22e-10	0.00025	-0.33	-0.29	IgE levels;	chr16:69523193	chr18:11619509~11639699:-
LUAD	trans	rs2524276	1	rs2524276	ENSG00000230521.1	HCG4P7	6.58	1.23e-10	0.00025	0.63	0.29	Capecitabine sensitivity;	chr6:31440488	chr6:29887294~29888268:-
LUAD	trans	rs4713118	0.866	rs9468217	ENSG00000204709.4	LINC01556	6.58	1.23e-10	0.00025	0.4	0.29	Parkinson's disease;	chr6:27758688	chr6:28943877~28944537:+
LUAD	trans	rs12439619	0.846	rs62011975	ENSG00000235370.6	DNM1P51	-6.58	1.25e-10	0.000256	-0.4	-0.29	Intelligence (multi-trait analysis);	chr15:82159213	chr15:84398316~84411701:-
LUAD	trans	rs673253	0.556	rs489319	ENSG00000231007.5	CDC20P1	6.58	1.26e-10	0.000256	0.36	0.29	Intelligence (multi-trait analysis);	chr1:43666123	chr9:87011652~87013151:+
LUAD	trans	rs3779195	0.584	rs1688605	ENSG00000225169.1	BRI3P1	-6.58	1.26e-10	0.000257	-0.47	-0.29	Sex hormone-binding globulin levels;	chr7:98410534	chr1:100213293~100213670:+
LUAD	trans	rs673253	0.686	rs2819333	ENSG00000231007.5	CDC20P1	6.58	1.26e-10	0.000257	0.35	0.29	Intelligence (multi-trait analysis);	chr1:43548902	chr9:87011652~87013151:+
LUAD	trans	rs6732160	0.564	rs60796597	ENSG00000236165.1	PRADC1P1	6.57	1.27e-10	0.00026	0.41	0.29	Intelligence (multi-trait analysis);	chr2:73155786	chr3:36976316~36976840:+
LUAD	trans	rs7618501	1	rs7374277	ENSG00000197582.5	GPX1P1	-6.57	1.28e-10	0.000261	-0.36	-0.29	Intelligence (multi-trait analysis);	chr3:49747344	chrX:13378735~13379340:-
LUAD	trans	rs7618501	1	rs7372730	ENSG00000197582.5	GPX1P1	-6.57	1.28e-10	0.000261	-0.36	-0.29	Intelligence (multi-trait analysis);	chr3:49753249	chrX:13378735~13379340:-
LUAD	trans	rs7618501	1	rs9855505	ENSG00000197582.5	GPX1P1	-6.57	1.28e-10	0.000261	-0.36	-0.29	Intelligence (multi-trait analysis);	chr3:49754725	chrX:13378735~13379340:-
LUAD	trans	rs673253	0.556	rs2274465	ENSG00000231007.5	CDC20P1	-6.57	1.29e-10	0.000264	-0.38	-0.29	Intelligence (multi-trait analysis);	chr1:43655886	chr9:87011652~87013151:+
LUAD	trans	rs66887589	0.616	rs13113885	ENSG00000275858.1	RP11-291L22.8	6.57	1.3e-10	0.000265	0.32	0.29	Diastolic blood pressure;	chr4:119300021	chr10:38450738~38451069:-
LUAD	trans	rs4713118	0.869	rs4713121	ENSG00000204709.4	LINC01556	6.57	1.31e-10	0.000266	0.39	0.29	Parkinson's disease;	chr6:27754285	chr6:28943877~28944537:+
LUAD	trans	rs9393777	0.777	rs35984974	ENSG00000204709.4	LINC01556	6.57	1.31e-10	0.000268	0.52	0.29	Intelligence (multi-trait analysis);	chr6:27442643	chr6:28943877~28944537:+
LUAD	trans	rs7746199	0.736	rs34573979	ENSG00000204709.4	LINC01556	6.57	1.32e-10	0.000268	0.6	0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27512747	chr6:28943877~28944537:+
LUAD	trans	rs673253	0.686	rs2819336	ENSG00000231007.5	CDC20P1	-6.57	1.32e-10	0.000269	-0.37	-0.29	Intelligence (multi-trait analysis);	chr1:43550138	chr9:87011652~87013151:+
LUAD	trans	rs7113874	0.802	rs10769936	ENSG00000266891.1	RP11-692N5.2	6.57	1.32e-10	0.000269	0.4	0.29	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8632981	chr18:9734882~9735602:-
LUAD	trans	rs9425766	0.679	rs972361	ENSG00000213331.4	RP11-713C19.2	6.57	1.33e-10	0.000271	0.34	0.29	Life satisfaction;	chr1:174228270	chr4:187970273~187971284:+
LUAD	trans	rs728478	0.845	rs9747559	ENSG00000187870.7	RNFT1P3	-6.57	1.33e-10	0.000271	-0.35	-0.29	QT interval;	chr17:59403334	chr17:20743333~20754501:-
LUAD	trans	rs4879656	0.564	rs1537253	ENSG00000215007.3	DNAJA1P3	-6.57	1.33e-10	0.000271	-0.33	-0.29	Menopause (age at onset);	chr9:32983373	chrX:107351650~107352843:-
LUAD	trans	rs864643	0.677	rs1708087	ENSG00000183298.5	RP11-556K13.1	6.57	1.33e-10	0.000271	0.42	0.29	Attention deficit hyperactivity disorder;	chr3:39468197	chr1:101786340~101787219:-
LUAD	trans	rs7647973	1	rs1982861	ENSG00000197582.5	GPX1P1	6.57	1.34e-10	0.000272	0.4	0.29	Menarche (age at onset);	chr3:49540232	chrX:13378735~13379340:-
LUAD	trans	rs7647973	1	rs8897	ENSG00000197582.5	GPX1P1	6.57	1.34e-10	0.000273	0.38	0.29	Menarche (age at onset);	chr3:49422974	chrX:13378735~13379340:-
LUAD	trans	rs7937890	0.505	rs1403248	ENSG00000236360.2	RP11-334A14.2	6.57	1.34e-10	0.000273	0.37	0.29	Mitochondrial DNA levels;	chr11:14657471	chr1:52993201~52993702:-
LUAD	trans	rs11951515	0.508	rs7706431	ENSG00000174977.8	AC026271.5	-6.56	1.38e-10	0.00028	-0.3	-0.29	Metabolite levels  (X-11787);	chr5:43582321	chr17:18650195~18651542:+
LUAD	trans	rs673253	0.65	rs2819335	ENSG00000231007.5	CDC20P1	-6.56	1.38e-10	0.000281	-0.36	-0.29	Intelligence (multi-trait analysis);	chr1:43549154	chr9:87011652~87013151:+
LUAD	trans	rs1383484	0.761	rs11259923	ENSG00000278603.1	RP13-608F4.5	6.56	1.39e-10	0.000283	0.39	0.29	Height;	chr15:83866952	chr15:82472203~82472426:+
LUAD	trans	rs13016963	0.526	rs7577057	ENSG00000235105.1	RP11-329A14.1	6.56	1.4e-10	0.000285	0.33	0.29	Esophageal squamous cell carcinoma;Melanoma;	chr2:201343270	chr1:48435967~48437223:+
LUAD	trans	rs853679	0.546	rs200995	ENSG00000204709.4	LINC01556	-6.56	1.44e-10	0.000291	-0.52	-0.29	Depression;	chr6:27845916	chr6:28943877~28944537:+
LUAD	trans	rs7260598	0.792	rs17620029	ENSG00000261770.1	CTC-459F4.1	6.55	1.45e-10	0.000294	0.46	0.29	Response to taxane treatment (placlitaxel);	chr19:24171510	chr19:27757184~27760849:-
LUAD	trans	rs9611519	0.639	rs7290458	ENSG00000268568.1	AC007228.9	6.55	1.45e-10	0.000295	0.37	0.29	Neuroticism;	chr22:41080333	chr19:56672574~56673901:-
LUAD	trans	rs73110464	0.505	rs2682296	ENSG00000220378.3	KRT8P42	-6.55	1.47e-10	0.000298	-0.4	-0.29	Cancer (pleiotropy);	chr12:52914481	chr6:134296997~134298695:-
LUAD	trans	rs7833986	0.534	rs10504198	ENSG00000244245.1	RP11-120B7.1	6.55	1.47e-10	0.000298	0.34	0.29	Height;	chr8:56093695	chr5:108593609~108593967:+
LUAD	trans	rs7833986	0.534	rs2976022	ENSG00000244245.1	RP11-120B7.1	6.55	1.47e-10	0.000298	0.34	0.29	Height;	chr8:56095284	chr5:108593609~108593967:+
LUAD	trans	rs7833986	0.501	rs2976018	ENSG00000244245.1	RP11-120B7.1	6.55	1.47e-10	0.000298	0.34	0.29	Height;	chr8:56102193	chr5:108593609~108593967:+
LUAD	trans	rs7833986	0.501	rs72653978	ENSG00000244245.1	RP11-120B7.1	6.55	1.47e-10	0.000298	0.34	0.29	Height;	chr8:56105834	chr5:108593609~108593967:+
LUAD	trans	rs45509595	0.749	rs401763	ENSG00000204709.4	LINC01556	6.55	1.48e-10	0.000299	0.54	0.29	Breast cancer;	chr6:27814750	chr6:28943877~28944537:+
LUAD	trans	rs45509595	0.659	rs390764	ENSG00000204709.4	LINC01556	6.55	1.48e-10	0.000299	0.54	0.29	Breast cancer;	chr6:27814757	chr6:28943877~28944537:+
LUAD	trans	rs45509595	0.841	rs401754	ENSG00000204709.4	LINC01556	6.55	1.48e-10	0.000299	0.54	0.29	Breast cancer;	chr6:27814760	chr6:28943877~28944537:+
LUAD	trans	rs6732160	0.588	rs1430345	ENSG00000236165.1	PRADC1P1	6.55	1.49e-10	0.000302	0.4	0.29	Intelligence (multi-trait analysis);	chr2:73143554	chr3:36976316~36976840:+
LUAD	trans	rs9393777	0.844	rs72839477	ENSG00000204709.4	LINC01556	6.55	1.5e-10	0.000305	0.61	0.29	Intelligence (multi-trait analysis);	chr6:27359221	chr6:28943877~28944537:+
LUAD	trans	rs2243480	1	rs1404147	ENSG00000273142.1	RP11-458F8.4	-6.55	1.5e-10	0.000305	-0.27	-0.29	Diabetic kidney disease;	chr7:65799537	chr7:66902857~66906297:+
LUAD	trans	rs6499255	0.951	rs3169315	ENSG00000257513.6	NPIPB1P	6.55	1.5e-10	0.000305	0.34	0.29	IgE levels;	chr16:69687061	chr18:11619509~11639699:-
LUAD	trans	rs1816752	0.837	rs7139748	ENSG00000224976.2	PARP4P2	-6.55	1.51e-10	0.000306	-0.33	-0.29	Obesity-related traits;	chr13:24411531	chr13:19349137~19407962:+
LUAD	trans	rs7192380	0.895	rs2917670	ENSG00000257513.6	NPIPB1P	-6.55	1.52e-10	0.000307	-0.28	-0.29	Sjögren's syndrome;	chr16:69725060	chr18:11619509~11639699:-
LUAD	trans	rs7618501	1	rs11130219	ENSG00000197582.5	GPX1P1	-6.55	1.52e-10	0.000307	-0.36	-0.29	Intelligence (multi-trait analysis);	chr3:49714994	chrX:13378735~13379340:-
LUAD	trans	rs7618501	1	rs34614773	ENSG00000197582.5	GPX1P1	-6.55	1.52e-10	0.000307	-0.36	-0.29	Intelligence (multi-trait analysis);	chr3:49715570	chrX:13378735~13379340:-
LUAD	trans	rs7618501	0.932	rs4855850	ENSG00000197582.5	GPX1P1	-6.55	1.52e-10	0.000308	-0.36	-0.29	Intelligence (multi-trait analysis);	chr3:49724138	chrX:13378735~13379340:-
LUAD	trans	rs7618501	1	rs3811696	ENSG00000197582.5	GPX1P1	-6.55	1.52e-10	0.000308	-0.36	-0.29	Intelligence (multi-trait analysis);	chr3:49724172	chrX:13378735~13379340:-
LUAD	trans	rs61041336	0.534	rs11641633	ENSG00000230849.2	GOT2P2	6.55	1.52e-10	0.000308	0.58	0.29	Neuritic plaque;	chr16:58679717	chr1:173141100~173142350:-
LUAD	trans	rs9393777	0.92	rs13195040	ENSG00000204709.4	LINC01556	-6.55	1.52e-10	0.000308	-0.54	-0.29	Intelligence (multi-trait analysis);	chr6:27446145	chr6:28943877~28944537:+
LUAD	trans	rs6499255	0.904	rs10852458	ENSG00000257513.6	NPIPB1P	6.55	1.52e-10	0.000308	0.34	0.29	IgE levels;	chr16:69638507	chr18:11619509~11639699:-
LUAD	trans	rs7618501	1	rs11716575	ENSG00000197582.5	GPX1P1	-6.55	1.52e-10	0.000308	-0.36	-0.29	Intelligence (multi-trait analysis);	chr3:49707457	chrX:13378735~13379340:-
LUAD	trans	rs7618501	1	rs4855867	ENSG00000197582.5	GPX1P1	-6.55	1.52e-10	0.000308	-0.36	-0.29	Intelligence (multi-trait analysis);	chr3:49708389	chrX:13378735~13379340:-
LUAD	trans	rs7618501	1	rs4855862	ENSG00000197582.5	GPX1P1	-6.55	1.52e-10	0.000308	-0.36	-0.29	Intelligence (multi-trait analysis);	chr3:49711400	chrX:13378735~13379340:-
LUAD	trans	rs6743068	0.541	rs6435081	ENSG00000235105.1	RP11-329A14.1	6.54	1.54e-10	0.000311	0.33	0.29	Lymphocyte percentage of white cells;	chr2:201355900	chr1:48435967~48437223:+
LUAD	trans	rs6743068	0.541	rs6737085	ENSG00000235105.1	RP11-329A14.1	6.54	1.54e-10	0.000311	0.33	0.29	Lymphocyte percentage of white cells;	chr2:201356718	chr1:48435967~48437223:+
LUAD	trans	rs864643	0.678	rs617068	ENSG00000183298.5	RP11-556K13.1	-6.54	1.54e-10	0.000311	-0.4	-0.29	Attention deficit hyperactivity disorder;	chr3:39492781	chr1:101786340~101787219:-
LUAD	trans	rs7618501	1	rs6785549	ENSG00000197582.5	GPX1P1	-6.54	1.54e-10	0.000312	-0.36	-0.29	Intelligence (multi-trait analysis);	chr3:49699132	chrX:13378735~13379340:-
LUAD	trans	rs7618501	1	rs1491986	ENSG00000197582.5	GPX1P1	-6.54	1.54e-10	0.000312	-0.36	-0.29	Intelligence (multi-trait analysis);	chr3:49701653	chrX:13378735~13379340:-
LUAD	trans	rs12145833	0.79	rs74666281	ENSG00000154608.12	CEP170P1	-6.54	1.55e-10	0.000313	-0.48	-0.29	Obesity (early onset extreme);	chr1:243352678	chr4:118467590~118554204:+
LUAD	trans	rs9393777	0.92	rs41269265	ENSG00000204709.4	LINC01556	6.54	1.55e-10	0.000313	0.56	0.29	Intelligence (multi-trait analysis);	chr6:27457570	chr6:28943877~28944537:+
LUAD	trans	rs9425766	0.679	rs4652237	ENSG00000213331.4	RP11-713C19.2	6.54	1.55e-10	0.000314	0.33	0.29	Life satisfaction;	chr1:174189718	chr4:187970273~187971284:+
LUAD	trans	rs7930295	0.556	rs35904963	ENSG00000236257.1	EI24P2	6.54	1.56e-10	0.000316	0.4	0.29	Schizophrenia;	chr11:125476956	chr1:158454198~158455273:+
LUAD	trans	rs10242455	0.867	rs2222411	ENSG00000228834.1	RP11-249L21.4	-6.54	1.56e-10	0.000316	-0.52	-0.29	Blood metabolite levels;	chr7:99712708	chr6:108907615~108907873:-
LUAD	trans	rs4713118	0.539	rs200951	ENSG00000204709.4	LINC01556	6.54	1.58e-10	0.00032	0.37	0.29	Parkinson's disease;	chr6:27868152	chr6:28943877~28944537:+
LUAD	trans	rs1816752	1	rs9507341	ENSG00000224976.2	PARP4P2	6.54	1.58e-10	0.00032	0.34	0.29	Obesity-related traits;	chr13:24432440	chr13:19349137~19407962:+
LUAD	trans	rs9425766	0.679	rs12087441	ENSG00000213331.4	RP11-713C19.2	6.54	1.58e-10	0.00032	0.33	0.29	Life satisfaction;	chr1:174188696	chr4:187970273~187971284:+
LUAD	trans	rs4276421	0.571	rs7724350	ENSG00000231752.4	EMBP1	-6.54	1.6e-10	0.000323	-0.4	-0.29	P wave duration;	chr5:45939572	chr1:121519112~121571892:+
LUAD	trans	rs4263408	1	rs7656037	ENSG00000237550.5	UBE2Q2P6	6.54	1.6e-10	0.000324	0.34	0.29	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39716345	chr15:82372196~82372912:-
LUAD	trans	rs616147	0.627	rs816487	ENSG00000188856.6	RPSAP47	-6.54	1.6e-10	0.000324	-0.31	-0.29	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39445999	chr8:80558870~80559757:+
LUAD	trans	rs9393777	0.92	rs35716472	ENSG00000204709.4	LINC01556	6.54	1.61e-10	0.000325	0.55	0.29	Intelligence (multi-trait analysis);	chr6:27438828	chr6:28943877~28944537:+
LUAD	trans	rs9393777	0.92	rs13196692	ENSG00000204709.4	LINC01556	6.54	1.61e-10	0.000326	0.58	0.29	Intelligence (multi-trait analysis);	chr6:27411340	chr6:28943877~28944537:+
LUAD	trans	rs1816752	1	rs1816752	ENSG00000224976.2	PARP4P2	-6.54	1.62e-10	0.000326	-0.34	-0.29	Obesity-related traits;	chr13:24406811	chr13:19349137~19407962:+
LUAD	trans	rs16937956	0.597	rs4584570	ENSG00000266891.1	RP11-692N5.2	6.54	1.62e-10	0.000327	0.42	0.29	Body mass index;	chr11:8384489	chr18:9734882~9735602:-
LUAD	trans	rs16937956	0.597	rs2311434	ENSG00000266891.1	RP11-692N5.2	6.54	1.62e-10	0.000327	0.42	0.29	Body mass index;	chr11:8384502	chr18:9734882~9735602:-
LUAD	trans	rs12439619	0.846	rs62012004	ENSG00000235370.6	DNM1P51	-6.53	1.63e-10	0.000328	-0.4	-0.29	Intelligence (multi-trait analysis);	chr15:82183924	chr15:84398316~84411701:-
LUAD	trans	rs7554511	0.707	rs3767501	ENSG00000244144.1	RP11-757F18.3	6.53	1.63e-10	0.00033	0.38	0.29	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201053951	chr3:112185480~112185998:-
LUAD	trans	rs7937890	0.559	rs2597208	ENSG00000236360.2	RP11-334A14.2	6.53	1.64e-10	0.00033	0.36	0.29	Mitochondrial DNA levels;	chr11:14450783	chr1:52993201~52993702:-
LUAD	trans	rs6743068	0.541	rs2349075	ENSG00000235105.1	RP11-329A14.1	6.53	1.65e-10	0.000332	0.33	0.29	Lymphocyte percentage of white cells;	chr2:201358843	chr1:48435967~48437223:+
LUAD	trans	rs7260598	0.792	rs17620048	ENSG00000261770.1	CTC-459F4.1	6.53	1.66e-10	0.000334	0.46	0.29	Response to taxane treatment (placlitaxel);	chr19:24174677	chr19:27757184~27760849:-
LUAD	trans	rs9876781	0.507	rs1824362	ENSG00000235912.1	RP1-159A19.3	6.53	1.66e-10	0.000335	0.3	0.29	Longevity;	chr3:48360459	chr1:27649419~27649610:+
LUAD	trans	rs6732160	0.588	rs13403748	ENSG00000236165.1	PRADC1P1	6.53	1.68e-10	0.000339	0.41	0.29	Intelligence (multi-trait analysis);	chr2:73144347	chr3:36976316~36976840:+
LUAD	trans	rs6732160	0.588	rs13390460	ENSG00000236165.1	PRADC1P1	6.53	1.68e-10	0.000339	0.41	0.29	Intelligence (multi-trait analysis);	chr2:73144348	chr3:36976316~36976840:+
LUAD	trans	rs6732160	0.588	rs72841902	ENSG00000236165.1	PRADC1P1	6.53	1.68e-10	0.000339	0.41	0.29	Intelligence (multi-trait analysis);	chr2:73145084	chr3:36976316~36976840:+
LUAD	trans	rs7769051	1	rs9493454	ENSG00000227615.1	RP11-864N7.2	-6.53	1.68e-10	0.000339	-0.47	-0.29	Type 2 diabetes nephropathy;	chr6:132823490	chr11:74745716~74746114:-
LUAD	trans	rs17301013	0.965	rs7548540	ENSG00000213331.4	RP11-713C19.2	6.53	1.69e-10	0.00034	0.33	0.29	Systemic lupus erythematosus;	chr1:174411672	chr4:187970273~187971284:+
LUAD	trans	rs17301013	0.965	rs2179214	ENSG00000213331.4	RP11-713C19.2	6.53	1.69e-10	0.00034	0.33	0.29	Systemic lupus erythematosus;	chr1:174413954	chr4:187970273~187971284:+
LUAD	trans	rs17301013	0.93	rs7523263	ENSG00000213331.4	RP11-713C19.2	6.53	1.69e-10	0.00034	0.33	0.29	Systemic lupus erythematosus;	chr1:174414542	chr4:187970273~187971284:+
LUAD	trans	rs1075232	1	rs16956838	ENSG00000270055.1	CTD-3092A11.2	-6.53	1.72e-10	0.000346	-0.51	-0.29	Survival in colorectal cancer (non-distant metastatic);	chr15:31527492	chr15:30487963~30490313:+
LUAD	trans	rs9876781	0.53	rs35516531	ENSG00000235912.1	RP1-159A19.3	-6.53	1.72e-10	0.000346	-0.31	-0.29	Longevity;	chr3:48364275	chr1:27649419~27649610:+
LUAD	trans	rs9584850	0.718	rs6491427	ENSG00000230079.1	STK24P1	6.52	1.76e-10	0.000353	0.34	0.29	Neuroticism;	chr13:98460912	chrX:136295690~136300298:-
LUAD	trans	rs7647973	0.961	rs62259943	ENSG00000197582.5	GPX1P1	-6.52	1.77e-10	0.000356	-0.4	-0.28	Menarche (age at onset);	chr3:49387734	chrX:13378735~13379340:-
LUAD	trans	rs35365539	1	rs35365539	ENSG00000197582.5	GPX1P1	-6.52	1.81e-10	0.000363	-0.36	-0.28	Blood protein levels;	chr3:49756914	chrX:13378735~13379340:-
LUAD	trans	rs916888	0.61	rs199529	ENSG00000204650.12	CRHR1-IT1	6.52	1.82e-10	0.000365	0.37	0.28	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:45620328~45648216:+
LUAD	trans	rs7647973	1	rs892974	ENSG00000197582.5	GPX1P1	6.52	1.82e-10	0.000365	0.4	0.28	Menarche (age at onset);	chr3:49361081	chrX:13378735~13379340:-
LUAD	trans	rs7647973	1	rs12583	ENSG00000197582.5	GPX1P1	-6.52	1.82e-10	0.000365	-0.4	-0.28	Menarche (age at onset);	chr3:49534029	chrX:13378735~13379340:-
LUAD	trans	rs2243480	0.706	rs6460257	ENSG00000232546.1	RP11-458F8.1	-6.52	1.82e-10	0.000366	-0.33	-0.28	Diabetic kidney disease;	chr7:65731813	chr7:66848496~66858136:+
LUAD	trans	rs7618501	1	rs35261599	ENSG00000197582.5	GPX1P1	-6.52	1.83e-10	0.000367	-0.36	-0.28	Intelligence (multi-trait analysis);	chr3:49735803	chrX:13378735~13379340:-
LUAD	trans	rs12477438	0.52	rs2632277	ENSG00000276576.1	MRPL30P1	6.52	1.83e-10	0.000368	0.32	0.28	Chronic sinus infection;	chr2:99162522	chr6:57029521~57029988:+
LUAD	trans	rs6424115	0.729	rs586173	ENSG00000228217.1	AL390877.1	6.51	1.84e-10	0.00037	0.37	0.28	Immature fraction of reticulocytes;	chr1:23729228	chr1:117778087~117778506:-
LUAD	trans	rs6831352	0.819	rs1230155	ENSG00000233859.2	ADH5P4	-6.51	1.88e-10	0.000377	-0.31	-0.28	Alcohol dependence;	chr4:99068108	chr6:65836930~65838039:-
LUAD	trans	rs7260598	0.685	rs73021420	ENSG00000261770.1	CTC-459F4.1	6.51	1.89e-10	0.000379	0.48	0.28	Response to taxane treatment (placlitaxel);	chr19:24082833	chr19:27757184~27760849:-
LUAD	trans	rs673253	0.65	rs951740	ENSG00000231007.5	CDC20P1	-6.51	1.91e-10	0.000382	-0.37	-0.28	Intelligence (multi-trait analysis);	chr1:43546066	chr9:87011652~87013151:+
LUAD	trans	rs7647973	1	rs7613491	ENSG00000197582.5	GPX1P1	-6.51	1.91e-10	0.000383	-0.4	-0.28	Menarche (age at onset);	chr3:49471543	chrX:13378735~13379340:-
LUAD	trans	rs7647973	1	rs7647973	ENSG00000197582.5	GPX1P1	-6.51	1.91e-10	0.000383	-0.4	-0.28	Menarche (age at onset);	chr3:49473498	chrX:13378735~13379340:-
LUAD	trans	rs7647973	1	rs6783003	ENSG00000197582.5	GPX1P1	-6.51	1.91e-10	0.000383	-0.4	-0.28	Menarche (age at onset);	chr3:49487345	chrX:13378735~13379340:-
LUAD	trans	rs45509595	0.841	rs17751184	ENSG00000204709.4	LINC01556	6.51	1.95e-10	0.000391	0.6	0.28	Breast cancer;	chr6:27807250	chr6:28943877~28944537:+
LUAD	trans	rs7554511	0.707	rs6702590	ENSG00000244144.1	RP11-757F18.3	6.5	1.96e-10	0.000392	0.37	0.28	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201050977	chr3:112185480~112185998:-
LUAD	trans	rs864643	0.524	rs9822783	ENSG00000183298.5	RP11-556K13.1	6.5	1.96e-10	0.000393	0.48	0.28	Attention deficit hyperactivity disorder;	chr3:39463311	chr1:101786340~101787219:-
LUAD	trans	rs10420951	0.542	rs2303693	ENSG00000267533.1	RP11-815J4.7	-6.5	1.97e-10	0.000394	-0.49	-0.28	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18446863	chr18:12067173~12068417:-
LUAD	trans	rs7618501	1	rs6446295	ENSG00000197582.5	GPX1P1	6.5	1.97e-10	0.000394	0.36	0.28	Intelligence (multi-trait analysis);	chr3:49771630	chrX:13378735~13379340:-
LUAD	trans	rs7618501	1	rs34451146	ENSG00000197582.5	GPX1P1	6.5	1.97e-10	0.000394	0.36	0.28	Intelligence (multi-trait analysis);	chr3:49775580	chrX:13378735~13379340:-
LUAD	trans	rs7618501	1	rs11130221	ENSG00000197582.5	GPX1P1	6.5	1.97e-10	0.000394	0.36	0.28	Intelligence (multi-trait analysis);	chr3:49781669	chrX:13378735~13379340:-
LUAD	trans	rs7618501	0.966	rs13063621	ENSG00000197582.5	GPX1P1	6.5	1.97e-10	0.000394	0.36	0.28	Intelligence (multi-trait analysis);	chr3:49784192	chrX:13378735~13379340:-
LUAD	trans	rs2237234	0.58	rs7763910	ENSG00000242375.1	RP11-498P14.3	-6.5	1.97e-10	0.000395	-0.36	-0.28	Autism spectrum disorder or schizophrenia;	chr6:26472427	chr9:97195351~97197687:-
LUAD	trans	rs877636	1	rs4759229	ENSG00000227586.5	RP11-162A23.5	-6.5	2e-10	0.000399	-0.33	-0.28	Cognitive function;	chr12:56080696	chr10:123171535~123171875:-
LUAD	trans	rs200986	1	rs200986	ENSG00000204709.4	LINC01556	6.5	2.01e-10	0.000401	0.37	0.28	Autism spectrum disorder or schizophrenia;	chr6:27856988	chr6:28943877~28944537:+
LUAD	trans	rs7192380	1	rs7191292	ENSG00000257513.6	NPIPB1P	6.5	2.01e-10	0.000402	0.28	0.28	Sjögren's syndrome;	chr16:69635524	chr18:11619509~11639699:-
LUAD	trans	rs13217239	0.646	rs9379956	ENSG00000242375.1	RP11-498P14.3	-6.5	2.01e-10	0.000402	-0.36	-0.28	Schizophrenia;	chr6:27065956	chr9:97195351~97197687:-
LUAD	trans	rs13217239	0.646	rs7747454	ENSG00000242375.1	RP11-498P14.3	-6.5	2.01e-10	0.000402	-0.36	-0.28	Schizophrenia;	chr6:27066474	chr9:97195351~97197687:-
LUAD	trans	rs4775413	0.619	rs11857462	ENSG00000229512.1	AC068580.5	6.5	2.01e-10	0.000403	0.28	0.28	Schizophrenia;	chr15:61563812	chr11:1763009~1763749:-
LUAD	trans	rs4713118	0.869	rs7773070	ENSG00000204709.4	LINC01556	6.5	2.02e-10	0.000403	0.38	0.28	Parkinson's disease;	chr6:27761048	chr6:28943877~28944537:+
LUAD	trans	rs864643	0.513	rs481523	ENSG00000183298.5	RP11-556K13.1	6.5	2.02e-10	0.000405	0.4	0.28	Attention deficit hyperactivity disorder;	chr3:39477849	chr1:101786340~101787219:-
LUAD	trans	rs149866169	1	rs149866169	ENSG00000204709.4	LINC01556	6.5	2.03e-10	0.000405	0.54	0.28	Subjective well-being (multi-trait analysis);Lung cancer;Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Squamous cell lung carcinoma;	chr6:27473944	chr6:28943877~28944537:+
LUAD	trans	rs7647973	1	rs6446268	ENSG00000197582.5	GPX1P1	-6.5	2.04e-10	0.000407	-0.4	-0.28	Menarche (age at onset);	chr3:49408262	chrX:13378735~13379340:-
LUAD	trans	rs6743068	0.541	rs6435079	ENSG00000235105.1	RP11-329A14.1	6.5	2.05e-10	0.000409	0.32	0.28	Lymphocyte percentage of white cells;	chr2:201335608	chr1:48435967~48437223:+
LUAD	trans	rs4713118	0.568	rs9468213	ENSG00000204709.4	LINC01556	6.49	2.08e-10	0.000414	0.35	0.28	Parkinson's disease;	chr6:27738401	chr6:28943877~28944537:+
LUAD	trans	rs6499255	0.951	rs12232410	ENSG00000257513.6	NPIPB1P	6.49	2.1e-10	0.000419	0.33	0.28	IgE levels;	chr16:69702948	chr18:11619509~11639699:-
LUAD	trans	rs7554511	0.655	rs3767502	ENSG00000244144.1	RP11-757F18.3	6.49	2.11e-10	0.000421	0.38	0.28	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201053970	chr3:112185480~112185998:-
LUAD	trans	rs1816752	0.819	rs4769349	ENSG00000224976.2	PARP4P2	6.49	2.13e-10	0.000424	0.32	0.28	Obesity-related traits;	chr13:24408694	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.87	rs73469543	ENSG00000224976.2	PARP4P2	-6.49	2.14e-10	0.000427	-0.32	-0.28	Obesity-related traits;	chr13:24424832	chr13:19349137~19407962:+
LUAD	trans	rs9393777	0.841	rs13191474	ENSG00000204709.4	LINC01556	6.49	2.15e-10	0.00043	0.55	0.28	Intelligence (multi-trait analysis);	chr6:27445566	chr6:28943877~28944537:+
LUAD	trans	rs673253	0.686	rs2819334	ENSG00000231007.5	CDC20P1	-6.49	2.16e-10	0.00043	-0.36	-0.28	Intelligence (multi-trait analysis);	chr1:43549064	chr9:87011652~87013151:+
LUAD	trans	rs9611519	0.639	rs7289989	ENSG00000268568.1	AC007228.9	-6.49	2.19e-10	0.000436	-0.36	-0.28	Neuroticism;	chr22:41080795	chr19:56672574~56673901:-
LUAD	trans	rs4713118	0.591	rs2056924	ENSG00000204709.4	LINC01556	6.49	2.2e-10	0.000438	0.35	0.28	Parkinson's disease;	chr6:27722395	chr6:28943877~28944537:+
LUAD	trans	rs7260598	0.792	rs73021461	ENSG00000261770.1	CTC-459F4.1	6.49	2.2e-10	0.000439	0.48	0.28	Response to taxane treatment (placlitaxel);	chr19:24140154	chr19:27757184~27760849:-
LUAD	trans	rs6499255	0.904	rs74029403	ENSG00000257513.6	NPIPB1P	6.48	2.21e-10	0.00044	0.36	0.28	IgE levels;	chr16:69676569	chr18:11619509~11639699:-
LUAD	trans	rs7618501	1	rs11709680	ENSG00000197582.5	GPX1P1	-6.48	2.22e-10	0.000441	-0.36	-0.28	Intelligence (multi-trait analysis);	chr3:49707755	chrX:13378735~13379340:-
LUAD	trans	rs4263408	0.935	rs62310123	ENSG00000237550.5	UBE2Q2P6	6.48	2.22e-10	0.000443	0.33	0.28	Plasma amyloid beta peptide concentrations (ABx-40);	chr4:39744462	chr15:82372196~82372912:-
LUAD	trans	rs9584850	0.789	rs7988345	ENSG00000230079.1	STK24P1	6.48	2.25e-10	0.000447	0.34	0.28	Neuroticism;	chr13:98465431	chrX:136295690~136300298:-
LUAD	trans	rs853679	0.546	rs200948	ENSG00000204709.4	LINC01556	6.48	2.26e-10	0.000449	0.54	0.28	Depression;	chr6:27867494	chr6:28943877~28944537:+
LUAD	trans	rs853679	0.546	rs200950	ENSG00000204709.4	LINC01556	6.48	2.26e-10	0.000449	0.54	0.28	Depression;	chr6:27867994	chr6:28943877~28944537:+
LUAD	trans	rs853679	0.546	rs200952	ENSG00000204709.4	LINC01556	6.48	2.26e-10	0.000449	0.54	0.28	Depression;	chr6:27869198	chr6:28943877~28944537:+
LUAD	trans	rs877636	0.692	rs10876870	ENSG00000234192.1	RP11-57C13.5	-6.48	2.26e-10	0.000449	-0.3	-0.28	Cognitive function;	chr12:56084218	chr10:87642607~87642954:+
LUAD	trans	rs877636	0.692	rs7971751	ENSG00000234192.1	RP11-57C13.5	-6.48	2.26e-10	0.000449	-0.3	-0.28	Cognitive function;	chr12:56084874	chr10:87642607~87642954:+
LUAD	trans	rs7746199	0.668	rs7749305	ENSG00000204709.4	LINC01556	6.48	2.28e-10	0.000455	0.53	0.28	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27478787	chr6:28943877~28944537:+
LUAD	trans	rs7746199	0.668	rs34864796	ENSG00000204709.4	LINC01556	6.48	2.28e-10	0.000455	0.53	0.28	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27492144	chr6:28943877~28944537:+
LUAD	trans	rs7260598	0.792	rs11670331	ENSG00000261770.1	CTC-459F4.1	6.48	2.29e-10	0.000456	0.47	0.28	Response to taxane treatment (placlitaxel);	chr19:24155040	chr19:27757184~27760849:-
LUAD	trans	rs9425766	0.679	rs7555067	ENSG00000213331.4	RP11-713C19.2	6.48	2.3e-10	0.000457	0.33	0.28	Life satisfaction;	chr1:174297504	chr4:187970273~187971284:+
LUAD	trans	rs9425766	0.679	rs6695636	ENSG00000213331.4	RP11-713C19.2	6.48	2.3e-10	0.000457	0.33	0.28	Life satisfaction;	chr1:174303087	chr4:187970273~187971284:+
LUAD	trans	rs1391708	0.834	rs34263825	ENSG00000121089.4	NACA3P	-6.48	2.31e-10	0.000459	-0.46	-0.28	Airway wall thickness;	chr12:56902465	chr4:164943290~164943937:+
LUAD	trans	rs616147	0.655	rs1707981	ENSG00000188856.6	RPSAP47	-6.48	2.33e-10	0.000463	-0.31	-0.28	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461015	chr8:80558870~80559757:+
LUAD	trans	rs616147	0.72	rs1768209	ENSG00000188856.6	RPSAP47	-6.48	2.33e-10	0.000463	-0.31	-0.28	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461184	chr8:80558870~80559757:+
LUAD	trans	rs864643	0.513	rs1398666	ENSG00000183298.5	RP11-556K13.1	6.48	2.34e-10	0.000465	0.39	0.28	Attention deficit hyperactivity disorder;	chr3:39475540	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.513	rs1768202	ENSG00000183298.5	RP11-556K13.1	6.48	2.34e-10	0.000465	0.39	0.28	Attention deficit hyperactivity disorder;	chr3:39476053	chr1:101786340~101787219:-
LUAD	trans	rs9876781	1	rs6776700	ENSG00000225528.1	RP3-370M22.8	-6.47	2.36e-10	0.000469	-0.29	-0.28	Longevity;	chr3:48455358	chr22:39960397~39964683:+
LUAD	trans	rs9876781	1	rs13091785	ENSG00000225528.1	RP3-370M22.8	-6.47	2.36e-10	0.000469	-0.28	-0.28	Longevity;	chr3:48452692	chr22:39960397~39964683:+
LUAD	trans	rs853679	0.546	rs175597	ENSG00000204709.4	LINC01556	6.47	2.36e-10	0.00047	0.54	0.28	Depression;	chr6:27842848	chr6:28943877~28944537:+
LUAD	trans	rs7647973	1	rs11710434	ENSG00000197582.5	GPX1P1	6.47	2.38e-10	0.000473	0.39	0.28	Menarche (age at onset);	chr3:49308697	chrX:13378735~13379340:-
LUAD	trans	rs616147	0.72	rs2965067	ENSG00000188856.6	RPSAP47	-6.47	2.38e-10	0.000474	-0.31	-0.28	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461546	chr8:80558870~80559757:+
LUAD	trans	rs4713118	0.869	rs7776351	ENSG00000204709.4	LINC01556	-6.47	2.38e-10	0.000474	-0.38	-0.28	Parkinson's disease;	chr6:27758952	chr6:28943877~28944537:+
LUAD	trans	rs6499255	1	rs12446201	ENSG00000257513.6	NPIPB1P	6.47	2.39e-10	0.000476	0.33	0.28	IgE levels;	chr16:69781683	chr18:11619509~11639699:-
LUAD	trans	rs7937890	0.559	rs2575853	ENSG00000236360.2	RP11-334A14.2	6.47	2.4e-10	0.000477	0.36	0.28	Mitochondrial DNA levels;	chr11:14512417	chr1:52993201~52993702:-
LUAD	trans	rs58106596	0.747	rs6731997	ENSG00000259020.3	RP11-529H20.3	6.47	2.46e-10	0.000488	0.36	0.28	Lymphocyte counts;White blood cell count;	chr2:231695701	chr14:92026566~92026887:+
LUAD	trans	rs7260598	0.792	rs11671489	ENSG00000261770.1	CTC-459F4.1	6.46	2.49e-10	0.000495	0.47	0.28	Response to taxane treatment (placlitaxel);	chr19:24156070	chr19:27757184~27760849:-
LUAD	trans	rs7260598	0.792	rs60773823	ENSG00000261770.1	CTC-459F4.1	6.46	2.49e-10	0.000495	0.47	0.28	Response to taxane treatment (placlitaxel);	chr19:24156730	chr19:27757184~27760849:-
LUAD	trans	rs73108077	0.764	rs75475053	ENSG00000279352.1	RP11-411B10.7	6.46	2.5e-10	0.000496	0.59	0.28	Red blood cell density in sickle cell anemia;	chr20:31217143	chr18:14010054~14010917:+
LUAD	trans	rs73108077	0.621	rs7261582	ENSG00000279352.1	RP11-411B10.7	6.46	2.5e-10	0.000496	0.59	0.28	Red blood cell density in sickle cell anemia;	chr20:31226977	chr18:14010054~14010917:+
LUAD	trans	rs73108077	0.57	rs73119526	ENSG00000279352.1	RP11-411B10.7	6.46	2.5e-10	0.000496	0.59	0.28	Red blood cell density in sickle cell anemia;	chr20:31252117	chr18:14010054~14010917:+
LUAD	trans	rs3812762	0.871	rs11042068	ENSG00000266891.1	RP11-692N5.2	6.46	2.51e-10	0.000497	0.38	0.28	Hypospadias;	chr11:8794052	chr18:9734882~9735602:-
LUAD	trans	rs9425766	0.679	rs10912761	ENSG00000213331.4	RP11-713C19.2	6.46	2.51e-10	0.000498	0.33	0.28	Life satisfaction;	chr1:174312466	chr4:187970273~187971284:+
LUAD	trans	rs7833986	0.501	rs72653951	ENSG00000244245.1	RP11-120B7.1	6.46	2.52e-10	0.000499	0.32	0.28	Height;	chr8:56049278	chr5:108593609~108593967:+
LUAD	trans	rs7618501	1	rs7374183	ENSG00000197582.5	GPX1P1	-6.46	2.52e-10	0.000499	-0.35	-0.28	Intelligence (multi-trait analysis);	chr3:49747700	chrX:13378735~13379340:-
LUAD	trans	rs7833986	0.534	rs17759244	ENSG00000244245.1	RP11-120B7.1	6.46	2.54e-10	0.000503	0.33	0.28	Height;	chr8:56121209	chr5:108593609~108593967:+
LUAD	trans	rs6424115	0.708	rs2076343	ENSG00000228217.1	AL390877.1	6.46	2.55e-10	0.000504	0.38	0.28	Immature fraction of reticulocytes;	chr1:23802636	chr1:117778087~117778506:-
LUAD	trans	rs2243480	0.666	rs1880311	ENSG00000273142.1	RP11-458F8.4	6.46	2.56e-10	0.000507	0.31	0.28	Diabetic kidney disease;	chr7:65811765	chr7:66902857~66906297:+
LUAD	trans	rs10037055	0.741	rs2336405	ENSG00000228305.2	AC016734.2	-6.46	2.56e-10	0.000507	-0.32	-0.28	Migraine without aura;	chr5:177230288	chr2:63622178~63622831:-
LUAD	trans	rs7618501	0.933	rs1128535	ENSG00000197582.5	GPX1P1	6.46	2.56e-10	0.000507	0.35	0.28	Intelligence (multi-trait analysis);	chr3:49828959	chrX:13378735~13379340:-
LUAD	trans	rs7618501	0.902	rs7645061	ENSG00000197582.5	GPX1P1	6.46	2.56e-10	0.000507	0.35	0.28	Intelligence (multi-trait analysis);	chr3:49831409	chrX:13378735~13379340:-
LUAD	trans	rs7618501	1	rs695238	ENSG00000197582.5	GPX1P1	6.46	2.56e-10	0.000507	0.35	0.28	Intelligence (multi-trait analysis);	chr3:49831725	chrX:13378735~13379340:-
LUAD	trans	rs9425766	0.692	rs4652294	ENSG00000213331.4	RP11-713C19.2	6.46	2.58e-10	0.00051	0.33	0.28	Life satisfaction;	chr1:174272027	chr4:187970273~187971284:+
LUAD	trans	rs6424115	0.708	rs11803575	ENSG00000228217.1	AL390877.1	6.46	2.58e-10	0.000511	0.38	0.28	Immature fraction of reticulocytes;	chr1:23855858	chr1:117778087~117778506:-
LUAD	trans	rs56114371	0.777	rs200481	ENSG00000204709.4	LINC01556	6.46	2.59e-10	0.000512	0.49	0.28	Breast cancer;	chr6:27806054	chr6:28943877~28944537:+
LUAD	trans	rs7554511	0.707	rs10800756	ENSG00000244144.1	RP11-757F18.3	6.46	2.59e-10	0.000513	0.38	0.28	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201054931	chr3:112185480~112185998:-
LUAD	trans	rs877636	1	rs877636	ENSG00000227586.5	RP11-162A23.5	-6.46	2.59e-10	0.000513	-0.33	-0.28	Cognitive function;	chr12:56086799	chr10:123171535~123171875:-
LUAD	trans	rs16937956	0.597	rs72852616	ENSG00000266891.1	RP11-692N5.2	6.46	2.6e-10	0.000513	0.41	0.28	Body mass index;	chr11:8385339	chr18:9734882~9735602:-
LUAD	trans	rs16937956	0.597	rs12788149	ENSG00000266891.1	RP11-692N5.2	6.46	2.6e-10	0.000513	0.41	0.28	Body mass index;	chr11:8385383	chr18:9734882~9735602:-
LUAD	trans	rs7647973	1	rs73088137	ENSG00000197582.5	GPX1P1	-6.46	2.6e-10	0.000514	-0.4	-0.28	Menarche (age at onset);	chr3:49410990	chrX:13378735~13379340:-
LUAD	trans	rs6464772	0.54	rs10952668	ENSG00000238222.3	MKRN4P	6.46	2.64e-10	0.000521	0.33	0.28	Creatinine levels in ischemic stroke;	chr7:140443720	chrX:40834485~40836005:+
LUAD	trans	rs853679	0.546	rs200490	ENSG00000204709.4	LINC01556	6.46	2.64e-10	0.000521	0.54	0.28	Depression;	chr6:27829157	chr6:28943877~28944537:+
LUAD	trans	rs12439619	0.508	rs8023960	ENSG00000259295.5	CSPG4P12	-6.46	2.65e-10	0.000523	-0.32	-0.28	Intelligence (multi-trait analysis);	chr15:82206704	chr15:85191438~85213905:+
LUAD	trans	rs66887589	0.807	rs7694483	ENSG00000275858.1	RP11-291L22.8	6.45	2.69e-10	0.000531	0.3	0.28	Diastolic blood pressure;	chr4:119484774	chr10:38450738~38451069:-
LUAD	trans	rs45509595	0.841	rs370155	ENSG00000204709.4	LINC01556	6.45	2.69e-10	0.000531	0.53	0.28	Breast cancer;	chr6:27814253	chr6:28943877~28944537:+
LUAD	trans	rs6743068	0.522	rs6757783	ENSG00000235105.1	RP11-329A14.1	6.45	2.73e-10	0.000538	0.32	0.28	Lymphocyte percentage of white cells;	chr2:201335101	chr1:48435967~48437223:+
LUAD	trans	rs9584850	0.834	rs9584854	ENSG00000230079.1	STK24P1	6.45	2.73e-10	0.000539	0.33	0.28	Neuroticism;	chr13:98466336	chrX:136295690~136300298:-
LUAD	trans	rs864643	0.524	rs72869124	ENSG00000183298.5	RP11-556K13.1	6.45	2.74e-10	0.00054	0.48	0.28	Attention deficit hyperactivity disorder;	chr3:39469788	chr1:101786340~101787219:-
LUAD	trans	rs9425766	0.679	rs7523938	ENSG00000213331.4	RP11-713C19.2	6.45	2.75e-10	0.000542	0.33	0.28	Life satisfaction;	chr1:174327373	chr4:187970273~187971284:+
LUAD	trans	rs9425766	0.64	rs6681780	ENSG00000213331.4	RP11-713C19.2	6.45	2.75e-10	0.000542	0.33	0.28	Life satisfaction;	chr1:174328980	chr4:187970273~187971284:+
LUAD	trans	rs9425766	0.55	rs57366619	ENSG00000213331.4	RP11-713C19.2	6.45	2.75e-10	0.000542	0.33	0.28	Life satisfaction;	chr1:174334929	chr4:187970273~187971284:+
LUAD	trans	rs9425766	0.64	rs7512930	ENSG00000213331.4	RP11-713C19.2	6.45	2.75e-10	0.000542	0.33	0.28	Life satisfaction;	chr1:174319464	chr4:187970273~187971284:+
LUAD	trans	rs9425766	0.679	rs7523460	ENSG00000213331.4	RP11-713C19.2	6.45	2.75e-10	0.000542	0.33	0.28	Life satisfaction;	chr1:174319664	chr4:187970273~187971284:+
LUAD	trans	rs9425766	0.679	rs7552830	ENSG00000213331.4	RP11-713C19.2	6.45	2.75e-10	0.000542	0.33	0.28	Life satisfaction;	chr1:174321643	chr4:187970273~187971284:+
LUAD	trans	rs877636	0.692	rs11171739	ENSG00000212829.8	RPS26P3	6.45	2.76e-10	0.000544	0.29	0.28	Cognitive function;	chr12:56076841	chr9:9090898~9091245:+
LUAD	trans	rs56114371	0.777	rs200483	ENSG00000204709.4	LINC01556	6.45	2.78e-10	0.000547	0.5	0.28	Breast cancer;	chr6:27807046	chr6:28943877~28944537:+
LUAD	trans	rs7554511	0.707	rs10800755	ENSG00000244144.1	RP11-757F18.3	6.45	2.79e-10	0.00055	0.38	0.28	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201054852	chr3:112185480~112185998:-
LUAD	trans	rs853679	0.546	rs200953	ENSG00000204709.4	LINC01556	6.45	2.79e-10	0.000551	0.54	0.28	Depression;	chr6:27869489	chr6:28943877~28944537:+
LUAD	trans	rs13014235	0.579	rs6745435	ENSG00000235105.1	RP11-329A14.1	6.44	2.82e-10	0.000555	0.33	0.28	Basal cell carcinoma;	chr2:201337840	chr1:48435967~48437223:+
LUAD	trans	rs13014235	0.644	rs10201587	ENSG00000235105.1	RP11-329A14.1	6.44	2.82e-10	0.000555	0.33	0.28	Basal cell carcinoma;	chr2:201338068	chr1:48435967~48437223:+
LUAD	trans	rs4276421	0.509	rs4532370	ENSG00000231752.4	EMBP1	-6.44	2.82e-10	0.000557	-0.43	-0.28	P wave duration;	chr5:45506716	chr1:121519112~121571892:+
LUAD	trans	rs9584850	0.834	rs12869627	ENSG00000230079.1	STK24P1	6.44	2.85e-10	0.000561	0.33	0.28	Neuroticism;	chr13:98468198	chrX:136295690~136300298:-
LUAD	trans	rs1816752	0.905	rs7400631	ENSG00000224976.2	PARP4P2	-6.44	2.86e-10	0.000564	-0.32	-0.28	Obesity-related traits;	chr13:24415927	chr13:19349137~19407962:+
LUAD	trans	rs1816752	0.905	rs8002215	ENSG00000224976.2	PARP4P2	-6.44	2.87e-10	0.000564	-0.32	-0.28	Obesity-related traits;	chr13:24416229	chr13:19349137~19407962:+
LUAD	trans	rs79149102	0.522	rs8023786	ENSG00000227288.3	RP5-837I24.1	6.44	2.88e-10	0.000566	0.51	0.28	Lung cancer;	chr15:74530155	chr1:81501794~81503468:+
LUAD	trans	rs1190596	0.578	rs35601191	ENSG00000181359.5	HSP90AA6P	-6.44	2.89e-10	0.000569	-0.32	-0.28	Behavioural disinhibition (generation interaction);	chr14:102276489	chr4:170581470~170605450:-
LUAD	trans	rs4276421	0.555	rs2247112	ENSG00000231752.4	EMBP1	6.44	2.9e-10	0.000571	0.4	0.28	P wave duration;	chr5:45628908	chr1:121519112~121571892:+
LUAD	trans	rs9876781	0.53	rs11708617	ENSG00000235912.1	RP1-159A19.3	-6.44	2.9e-10	0.000571	-0.3	-0.28	Longevity;	chr3:48354819	chr1:27649419~27649610:+
LUAD	trans	rs9584850	0.834	rs4294654	ENSG00000230079.1	STK24P1	6.44	2.92e-10	0.000575	0.33	0.28	Neuroticism;	chr13:98467353	chrX:136295690~136300298:-
LUAD	trans	rs7260598	0.792	rs73029291	ENSG00000261770.1	CTC-459F4.1	6.44	2.93e-10	0.000576	0.45	0.28	Response to taxane treatment (placlitaxel);	chr19:24171866	chr19:27757184~27760849:-
LUAD	trans	rs7937890	0.504	rs2575847	ENSG00000236360.2	RP11-334A14.2	6.44	2.94e-10	0.000578	0.36	0.28	Mitochondrial DNA levels;	chr11:14449626	chr1:52993201~52993702:-
LUAD	trans	rs7937890	0.559	rs2575825	ENSG00000236360.2	RP11-334A14.2	6.44	2.94e-10	0.000578	0.36	0.28	Mitochondrial DNA levels;	chr11:14450550	chr1:52993201~52993702:-
LUAD	trans	rs9425766	0.679	rs6681618	ENSG00000213331.4	RP11-713C19.2	-6.44	2.94e-10	0.000578	-0.33	-0.28	Life satisfaction;	chr1:174201203	chr4:187970273~187971284:+
LUAD	trans	rs6683419	0.967	rs6426808	ENSG00000224237.1	MINOS1P3	-6.44	2.98e-10	0.000586	-0.34	-0.28	Serum thyroid-stimulating hormone levels;	chr1:19508921	chr3:27214816~27215018:-
LUAD	trans	rs7930295	0.556	rs6590146	ENSG00000236257.1	EI24P2	6.44	2.98e-10	0.000586	0.39	0.28	Schizophrenia;	chr11:125479933	chr1:158454198~158455273:+
LUAD	trans	rs877636	0.702	rs773110	ENSG00000227586.5	RP11-162A23.5	6.44	2.98e-10	0.000587	0.34	0.28	Cognitive function;	chr12:55981353	chr10:123171535~123171875:-
LUAD	trans	rs877636	0.702	rs773111	ENSG00000227586.5	RP11-162A23.5	6.44	2.98e-10	0.000587	0.34	0.28	Cognitive function;	chr12:55981956	chr10:123171535~123171875:-
LUAD	trans	rs877636	0.702	rs773112	ENSG00000227586.5	RP11-162A23.5	6.44	2.98e-10	0.000587	0.34	0.28	Cognitive function;	chr12:55982097	chr10:123171535~123171875:-
LUAD	trans	rs6424115	0.737	rs10917430	ENSG00000228217.1	AL390877.1	6.44	2.99e-10	0.000587	0.38	0.28	Immature fraction of reticulocytes;	chr1:23843968	chr1:117778087~117778506:-
LUAD	trans	rs7121616	0.576	rs4936767	ENSG00000256356.1	HSPA8P5	6.43	3.03e-10	0.000595	0.31	0.28	Breast cancer;	chr11:123047451	chr12:4097451~4099519:+
LUAD	trans	rs7618501	0.933	rs3811695	ENSG00000197582.5	GPX1P1	-6.43	3.03e-10	0.000596	-0.35	-0.28	Intelligence (multi-trait analysis);	chr3:49724180	chrX:13378735~13379340:-
LUAD	trans	rs7647973	1	rs13096474	ENSG00000197582.5	GPX1P1	-6.43	3.06e-10	0.000602	-0.38	-0.28	Menarche (age at onset);	chr3:49405648	chrX:13378735~13379340:-
LUAD	trans	rs45509595	0.841	rs200485	ENSG00000204709.4	LINC01556	6.43	3.07e-10	0.000602	0.53	0.28	Breast cancer;	chr6:27807919	chr6:28943877~28944537:+
LUAD	trans	rs877636	0.74	rs705702	ENSG00000227586.5	RP11-162A23.5	-6.43	3.09e-10	0.000607	-0.34	-0.28	Cognitive function;	chr12:55996852	chr10:123171535~123171875:-
LUAD	trans	rs7192380	0.965	rs7205551	ENSG00000257513.6	NPIPB1P	6.43	3.1e-10	0.000609	0.27	0.28	Sjögren's syndrome;	chr16:69572065	chr18:11619509~11639699:-
LUAD	trans	rs4713118	0.955	rs9468204	ENSG00000204709.4	LINC01556	6.43	3.12e-10	0.000613	0.38	0.28	Parkinson's disease;	chr6:27721030	chr6:28943877~28944537:+
LUAD	trans	rs877636	1	rs877636	ENSG00000243538.1	CTB-55B8.1	-6.43	3.14e-10	0.000616	-0.3	-0.28	Cognitive function;	chr12:56086799	chr5:16902294~16902641:-
LUAD	trans	rs4713118	0.869	rs9461405	ENSG00000204709.4	LINC01556	6.42	3.18e-10	0.000623	0.37	0.28	Parkinson's disease;	chr6:27751596	chr6:28943877~28944537:+
LUAD	trans	rs7937890	0.559	rs2597201	ENSG00000236360.2	RP11-334A14.2	6.42	3.18e-10	0.000623	0.35	0.28	Mitochondrial DNA levels;	chr11:14463858	chr1:52993201~52993702:-
LUAD	trans	rs7937890	0.532	rs2575832	ENSG00000236360.2	RP11-334A14.2	6.42	3.18e-10	0.000623	0.35	0.28	Mitochondrial DNA levels;	chr11:14467264	chr1:52993201~52993702:-
LUAD	trans	rs9393777	0.92	rs67859638	ENSG00000204709.4	LINC01556	6.42	3.18e-10	0.000624	0.62	0.28	Intelligence (multi-trait analysis);	chr6:27390199	chr6:28943877~28944537:+
LUAD	trans	rs7937890	0.507	rs4463820	ENSG00000236360.2	RP11-334A14.2	6.42	3.19e-10	0.000626	0.35	0.28	Mitochondrial DNA levels;	chr11:14534796	chr1:52993201~52993702:-
LUAD	trans	rs11951515	0.508	rs10065689	ENSG00000174977.8	AC026271.5	-6.42	3.2e-10	0.000627	-0.29	-0.28	Metabolite levels  (X-11787);	chr5:43604156	chr17:18650195~18651542:+
LUAD	trans	rs7937890	0.559	rs2597206	ENSG00000236360.2	RP11-334A14.2	6.42	3.2e-10	0.000628	0.35	0.28	Mitochondrial DNA levels;	chr11:14455992	chr1:52993201~52993702:-
LUAD	trans	rs916888	0.779	rs199526	ENSG00000204650.12	CRHR1-IT1	-6.42	3.2e-10	0.000628	-0.35	-0.28	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:45620328~45648216:+
LUAD	trans	rs1816752	0.905	rs4770666	ENSG00000224976.2	PARP4P2	-6.42	3.21e-10	0.00063	-0.32	-0.28	Obesity-related traits;	chr13:24414891	chr13:19349137~19407962:+
LUAD	trans	rs7833986	0.501	rs2719258	ENSG00000244245.1	RP11-120B7.1	6.42	3.22e-10	0.000631	0.33	0.28	Height;	chr8:56028830	chr5:108593609~108593967:+
LUAD	trans	rs7833986	0.501	rs2719259	ENSG00000244245.1	RP11-120B7.1	6.42	3.22e-10	0.000631	0.33	0.28	Height;	chr8:56029071	chr5:108593609~108593967:+
LUAD	trans	rs7647973	1	rs6446262	ENSG00000197582.5	GPX1P1	6.42	3.22e-10	0.000631	0.39	0.28	Menarche (age at onset);	chr3:49363720	chrX:13378735~13379340:-
LUAD	trans	rs7647973	1	rs62259947	ENSG00000197582.5	GPX1P1	-6.42	3.22e-10	0.000631	-0.39	-0.28	Menarche (age at onset);	chr3:49402491	chrX:13378735~13379340:-
LUAD	trans	rs7554511	0.707	rs3861928	ENSG00000244144.1	RP11-757F18.3	-6.42	3.23e-10	0.000633	-0.35	-0.28	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201051446	chr3:112185480~112185998:-
LUAD	trans	rs6499255	1	rs4985523	ENSG00000257513.6	NPIPB1P	6.42	3.24e-10	0.000634	0.33	0.28	IgE levels;	chr16:69763289	chr18:11619509~11639699:-
LUAD	trans	rs7746199	0.736	rs17693963	ENSG00000204709.4	LINC01556	6.42	3.24e-10	0.000634	0.57	0.28	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27742386	chr6:28943877~28944537:+
LUAD	trans	rs13217239	0.646	rs7451149	ENSG00000242375.1	RP11-498P14.3	-6.42	3.25e-10	0.000636	-0.37	-0.28	Schizophrenia;	chr6:27089739	chr9:97195351~97197687:-
LUAD	trans	rs7833986	0.534	rs2667980	ENSG00000244245.1	RP11-120B7.1	6.42	3.3e-10	0.000646	0.34	0.28	Height;	chr8:55983982	chr5:108593609~108593967:+
LUAD	trans	rs7833986	0.501	rs72653921	ENSG00000244245.1	RP11-120B7.1	6.42	3.3e-10	0.000646	0.34	0.28	Height;	chr8:55984598	chr5:108593609~108593967:+
LUAD	trans	rs7618501	1	rs6802890	ENSG00000197582.5	GPX1P1	6.42	3.3e-10	0.000646	0.35	0.28	Intelligence (multi-trait analysis);	chr3:49794828	chrX:13378735~13379340:-
LUAD	trans	rs12477438	0.501	rs13008171	ENSG00000276576.1	MRPL30P1	6.42	3.32e-10	0.00065	0.32	0.28	Chronic sinus infection;	chr2:99126956	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.52	rs4850897	ENSG00000276576.1	MRPL30P1	6.42	3.32e-10	0.00065	0.32	0.28	Chronic sinus infection;	chr2:99151956	chr6:57029521~57029988:+
LUAD	trans	rs853679	0.607	rs13208096	ENSG00000253570.1	RNF5P1	6.42	3.33e-10	0.000651	0.63	0.28	Depression;	chr6:28257533	chr8:38600661~38601200:-
LUAD	trans	rs7412746	0.658	rs6677420	ENSG00000180764.13	PIPSL	-6.42	3.33e-10	0.000652	-0.32	-0.28	Melanoma;	chr1:150974014	chr10:93958191~93961540:-
LUAD	trans	rs7833986	0.501	rs17814658	ENSG00000244245.1	RP11-120B7.1	6.42	3.34e-10	0.000653	0.33	0.28	Height;	chr8:56076571	chr5:108593609~108593967:+
LUAD	trans	rs7833986	0.501	rs72653957	ENSG00000244245.1	RP11-120B7.1	6.42	3.34e-10	0.000653	0.33	0.28	Height;	chr8:56077489	chr5:108593609~108593967:+
LUAD	trans	rs2899832	0.568	rs17597267	ENSG00000229083.1	PSMA6P2	6.42	3.35e-10	0.000656	0.44	0.28	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35312698	chrX:12825840~12826833:+
LUAD	trans	rs9876781	0.559	rs7630053	ENSG00000235912.1	RP1-159A19.3	-6.42	3.37e-10	0.000658	-0.3	-0.28	Longevity;	chr3:48357096	chr1:27649419~27649610:+
LUAD	trans	rs9876781	0.559	rs11130167	ENSG00000235912.1	RP1-159A19.3	-6.42	3.37e-10	0.000658	-0.3	-0.28	Longevity;	chr3:48358570	chr1:27649419~27649610:+
LUAD	trans	rs9876781	0.559	rs13073692	ENSG00000235912.1	RP1-159A19.3	-6.42	3.37e-10	0.000658	-0.3	-0.28	Longevity;	chr3:48361812	chr1:27649419~27649610:+
LUAD	trans	rs9876781	0.559	rs7611415	ENSG00000235912.1	RP1-159A19.3	-6.42	3.37e-10	0.000658	-0.3	-0.28	Longevity;	chr3:48363659	chr1:27649419~27649610:+
LUAD	trans	rs9584850	0.834	rs745638	ENSG00000230079.1	STK24P1	-6.41	3.37e-10	0.000659	-0.32	-0.28	Neuroticism;	chr13:98467053	chrX:136295690~136300298:-
LUAD	trans	rs7312770	1	rs7312770	ENSG00000243538.1	CTB-55B8.1	-6.41	3.39e-10	0.000662	-0.29	-0.28	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr5:16902294~16902641:-
LUAD	trans	rs6499255	1	rs73579458	ENSG00000257513.6	NPIPB1P	6.41	3.41e-10	0.000665	0.33	0.28	IgE levels;	chr16:69770861	chr18:11619509~11639699:-
LUAD	trans	rs79149102	0.522	rs79811537	ENSG00000227288.3	RP5-837I24.1	6.41	3.43e-10	0.000669	0.51	0.28	Lung cancer;	chr15:74579474	chr1:81501794~81503468:+
LUAD	trans	rs7937890	0.505	rs4403769	ENSG00000236360.2	RP11-334A14.2	6.41	3.43e-10	0.000669	0.35	0.28	Mitochondrial DNA levels;	chr11:14428630	chr1:52993201~52993702:-
LUAD	trans	rs79149102	0.649	rs9788672	ENSG00000227288.3	RP5-837I24.1	6.41	3.43e-10	0.00067	0.51	0.28	Lung cancer;	chr15:74584012	chr1:81501794~81503468:+
LUAD	trans	rs7937890	0.559	rs2575836	ENSG00000236360.2	RP11-334A14.2	6.41	3.45e-10	0.000673	0.35	0.28	Mitochondrial DNA levels;	chr11:14476318	chr1:52993201~52993702:-
LUAD	trans	rs7937890	0.531	rs2575859	ENSG00000236360.2	RP11-334A14.2	6.41	3.45e-10	0.000673	0.35	0.28	Mitochondrial DNA levels;	chr11:14489190	chr1:52993201~52993702:-
LUAD	trans	rs7937890	0.559	rs2597188	ENSG00000236360.2	RP11-334A14.2	6.41	3.45e-10	0.000673	0.35	0.28	Mitochondrial DNA levels;	chr11:14495360	chr1:52993201~52993702:-
LUAD	trans	rs7937890	0.504	rs2575822	ENSG00000236360.2	RP11-334A14.2	6.41	3.45e-10	0.000673	0.35	0.28	Mitochondrial DNA levels;	chr11:14498305	chr1:52993201~52993702:-
LUAD	trans	rs7937890	0.559	rs2575823	ENSG00000236360.2	RP11-334A14.2	6.41	3.45e-10	0.000673	0.35	0.28	Mitochondrial DNA levels;	chr11:14499808	chr1:52993201~52993702:-
LUAD	trans	rs7937890	0.559	rs2597221	ENSG00000236360.2	RP11-334A14.2	6.41	3.45e-10	0.000673	0.35	0.28	Mitochondrial DNA levels;	chr11:14505529	chr1:52993201~52993702:-
LUAD	trans	rs7937890	0.559	rs6486197	ENSG00000236360.2	RP11-334A14.2	6.41	3.45e-10	0.000673	0.35	0.28	Mitochondrial DNA levels;	chr11:14508328	chr1:52993201~52993702:-
LUAD	trans	rs7937890	0.559	rs2597219	ENSG00000236360.2	RP11-334A14.2	6.41	3.45e-10	0.000673	0.35	0.28	Mitochondrial DNA levels;	chr11:14509320	chr1:52993201~52993702:-
LUAD	trans	rs7937890	0.559	rs2575852	ENSG00000236360.2	RP11-334A14.2	6.41	3.45e-10	0.000673	0.35	0.28	Mitochondrial DNA levels;	chr11:14511822	chr1:52993201~52993702:-
LUAD	trans	rs7937890	0.531	rs2597216	ENSG00000236360.2	RP11-334A14.2	6.41	3.45e-10	0.000673	0.35	0.28	Mitochondrial DNA levels;	chr11:14512370	chr1:52993201~52993702:-
LUAD	trans	rs7937890	0.559	rs1548074	ENSG00000236360.2	RP11-334A14.2	6.41	3.45e-10	0.000673	0.35	0.28	Mitochondrial DNA levels;	chr11:14513279	chr1:52993201~52993702:-
LUAD	trans	rs7937890	0.561	rs2575849	ENSG00000236360.2	RP11-334A14.2	6.41	3.45e-10	0.000673	0.35	0.28	Mitochondrial DNA levels;	chr11:14518093	chr1:52993201~52993702:-
LUAD	trans	rs7647973	1	rs62261249	ENSG00000197582.5	GPX1P1	-6.41	3.46e-10	0.000676	-0.4	-0.28	Menarche (age at onset);	chr3:49556627	chrX:13378735~13379340:-
LUAD	trans	rs1816752	0.905	rs2000153	ENSG00000224976.2	PARP4P2	-6.41	3.47e-10	0.000676	-0.32	-0.28	Obesity-related traits;	chr13:24405752	chr13:19349137~19407962:+
LUAD	trans	rs7260598	0.892	rs67180860	ENSG00000261770.1	CTC-459F4.1	6.41	3.47e-10	0.000676	0.46	0.28	Response to taxane treatment (placlitaxel);	chr19:24023433	chr19:27757184~27760849:-
LUAD	trans	rs3096299	0.754	rs2965816	ENSG00000215030.5	RPL13P12	6.41	3.51e-10	0.000684	0.31	0.28	Multiple myeloma (IgH translocation);	chr16:89447775	chr17:17383377~17384012:-
LUAD	trans	rs7618501	1	rs2234391	ENSG00000197582.5	GPX1P1	6.41	3.54e-10	0.00069	0.35	0.28	Intelligence (multi-trait analysis);	chr3:49805192	chrX:13378735~13379340:-
LUAD	trans	rs7618501	1	rs7648987	ENSG00000197582.5	GPX1P1	6.41	3.54e-10	0.00069	0.35	0.28	Intelligence (multi-trait analysis);	chr3:49831022	chrX:13378735~13379340:-
LUAD	trans	rs58106596	0.95	rs11695646	ENSG00000259020.3	RP11-529H20.3	-6.41	3.55e-10	0.000691	-0.34	-0.28	Lymphocyte counts;White blood cell count;	chr2:231720097	chr14:92026566~92026887:+
LUAD	trans	rs853679	0.546	rs35744819	ENSG00000253570.1	RNF5P1	6.41	3.56e-10	0.000694	0.63	0.28	Depression;	chr6:28350554	chr8:38600661~38601200:-
LUAD	trans	rs7937890	0.532	rs2575827	ENSG00000236360.2	RP11-334A14.2	6.41	3.57e-10	0.000695	0.36	0.28	Mitochondrial DNA levels;	chr11:14453969	chr1:52993201~52993702:-
LUAD	trans	rs7937890	0.532	rs2256884	ENSG00000236360.2	RP11-334A14.2	6.41	3.57e-10	0.000695	0.36	0.28	Mitochondrial DNA levels;	chr11:14454856	chr1:52993201~52993702:-
LUAD	trans	rs2899832	0.568	rs17597281	ENSG00000229083.1	PSMA6P2	-6.4	3.59e-10	7e-04	-0.44	-0.28	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35313094	chrX:12825840~12826833:+
LUAD	trans	rs4713118	0.955	rs9380010	ENSG00000204709.4	LINC01556	6.4	3.61e-10	0.000702	0.38	0.28	Parkinson's disease;	chr6:27715793	chr6:28943877~28944537:+
LUAD	trans	rs4713118	0.955	rs9368528	ENSG00000204709.4	LINC01556	6.4	3.61e-10	0.000702	0.38	0.28	Parkinson's disease;	chr6:27716019	chr6:28943877~28944537:+
LUAD	trans	rs4713118	0.955	rs9380011	ENSG00000204709.4	LINC01556	6.4	3.61e-10	0.000702	0.38	0.28	Parkinson's disease;	chr6:27716145	chr6:28943877~28944537:+
LUAD	trans	rs4713118	0.955	rs9380012	ENSG00000204709.4	LINC01556	6.4	3.61e-10	0.000702	0.38	0.28	Parkinson's disease;	chr6:27716875	chr6:28943877~28944537:+
LUAD	trans	rs4879656	0.564	rs7864363	ENSG00000215007.3	DNAJA1P3	-6.4	3.61e-10	0.000702	-0.31	-0.28	Menopause (age at onset);	chr9:33022002	chrX:107351650~107352843:-
LUAD	trans	rs4713118	0.868	rs2893928	ENSG00000204709.4	LINC01556	6.4	3.61e-10	0.000703	0.4	0.28	Parkinson's disease;	chr6:27770651	chr6:28943877~28944537:+
LUAD	trans	rs9425766	0.64	rs17301013	ENSG00000213331.4	RP11-713C19.2	6.4	3.62e-10	0.000704	0.33	0.28	Life satisfaction;	chr1:174343675	chr4:187970273~187971284:+
LUAD	trans	rs2060793	0.712	rs11023310	ENSG00000236360.2	RP11-334A14.2	6.4	3.63e-10	0.000706	0.36	0.28	Vitamin D levels;	chr11:14703717	chr1:52993201~52993702:-
LUAD	trans	rs853679	0.546	rs35353359	ENSG00000253570.1	RNF5P1	6.4	3.64e-10	0.000708	0.62	0.28	Depression;	chr6:28356601	chr8:38600661~38601200:-
LUAD	trans	rs9425766	0.64	rs10912734	ENSG00000213331.4	RP11-713C19.2	6.4	3.65e-10	0.000711	0.33	0.28	Life satisfaction;	chr1:174141977	chr4:187970273~187971284:+
LUAD	trans	rs9425766	0.64	rs6693423	ENSG00000213331.4	RP11-713C19.2	6.4	3.66e-10	0.000712	0.32	0.28	Life satisfaction;	chr1:174364680	chr4:187970273~187971284:+
LUAD	trans	rs9425766	0.679	rs60363188	ENSG00000213331.4	RP11-713C19.2	6.4	3.66e-10	0.000712	0.32	0.28	Life satisfaction;	chr1:174375959	chr4:187970273~187971284:+
LUAD	trans	rs9425766	0.679	rs12084119	ENSG00000213331.4	RP11-713C19.2	6.4	3.66e-10	0.000712	0.32	0.28	Life satisfaction;	chr1:174377138	chr4:187970273~187971284:+
LUAD	trans	rs12477438	0.501	rs12619780	ENSG00000276576.1	MRPL30P1	6.4	3.68e-10	0.000715	0.32	0.28	Chronic sinus infection;	chr2:99090844	chr6:57029521~57029988:+
LUAD	trans	rs7937890	0.535	rs2575857	ENSG00000236360.2	RP11-334A14.2	6.4	3.69e-10	0.000717	0.35	0.28	Mitochondrial DNA levels;	chr11:14479750	chr1:52993201~52993702:-
LUAD	trans	rs11951515	0.508	rs1366410	ENSG00000174977.8	AC026271.5	-6.4	3.69e-10	0.000717	-0.29	-0.28	Metabolite levels  (X-11787);	chr5:43601508	chr17:18650195~18651542:+
LUAD	trans	rs3096299	0.719	rs2911262	ENSG00000215030.5	RPL13P12	-6.4	3.69e-10	0.000717	-0.3	-0.28	Multiple myeloma (IgH translocation);	chr16:89448633	chr17:17383377~17384012:-
LUAD	trans	rs877636	1	rs705696	ENSG00000223416.3	RPS26P15	6.4	3.7e-10	0.00072	0.29	0.28	Cognitive function;	chr12:56086864	chr1:58056133~58056480:-
LUAD	trans	rs6743068	0.522	rs7597617	ENSG00000235105.1	RP11-329A14.1	6.4	3.74e-10	0.000726	0.32	0.28	Lymphocyte percentage of white cells;	chr2:201338512	chr1:48435967~48437223:+
LUAD	trans	rs9584850	0.834	rs7339274	ENSG00000230079.1	STK24P1	-6.4	3.74e-10	0.000727	-0.33	-0.28	Neuroticism;	chr13:98468018	chrX:136295690~136300298:-
LUAD	trans	rs2899832	0.568	rs10467708	ENSG00000229083.1	PSMA6P2	6.4	3.77e-10	0.000732	0.44	0.28	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35317808	chrX:12825840~12826833:+
LUAD	trans	rs6499255	0.762	rs12325186	ENSG00000257513.6	NPIPB1P	6.4	3.78e-10	0.000734	0.33	0.28	IgE levels;	chr16:69624904	chr18:11619509~11639699:-
LUAD	trans	rs12145833	0.679	rs6429425	ENSG00000154608.12	CEP170P1	-6.4	3.78e-10	0.000735	-0.48	-0.28	Obesity (early onset extreme);	chr1:243427688	chr4:118467590~118554204:+
LUAD	trans	rs4883201	0.518	rs887782	ENSG00000179899.8	PHC1P1	-6.4	3.8e-10	0.000737	-0.34	-0.28	Total cholesterol levels;Cholesterol, total;	chr12:8932082	chr12:55411727~55414787:-
LUAD	trans	rs7833986	0.501	rs72653948	ENSG00000244245.1	RP11-120B7.1	6.4	3.8e-10	0.000738	0.32	0.28	Height;	chr8:56043130	chr5:108593609~108593967:+
LUAD	trans	rs853679	0.607	rs201002	ENSG00000204709.4	LINC01556	6.39	3.81e-10	0.00074	0.5	0.28	Depression;	chr6:27840414	chr6:28943877~28944537:+
LUAD	trans	rs7618501	1	rs7431106	ENSG00000197582.5	GPX1P1	6.39	3.83e-10	0.000744	0.35	0.28	Intelligence (multi-trait analysis);	chr3:49770941	chrX:13378735~13379340:-
LUAD	trans	rs7618501	1	rs57648519	ENSG00000197582.5	GPX1P1	6.39	3.83e-10	0.000744	0.35	0.28	Intelligence (multi-trait analysis);	chr3:49775736	chrX:13378735~13379340:-
LUAD	trans	rs7937890	0.559	rs2575829	ENSG00000236360.2	RP11-334A14.2	6.39	3.85e-10	0.000747	0.35	0.28	Mitochondrial DNA levels;	chr11:14463475	chr1:52993201~52993702:-
LUAD	trans	rs7937890	0.559	rs2597200	ENSG00000236360.2	RP11-334A14.2	6.39	3.85e-10	0.000747	0.35	0.28	Mitochondrial DNA levels;	chr11:14464054	chr1:52993201~52993702:-
LUAD	trans	rs7937890	0.559	rs2575830	ENSG00000236360.2	RP11-334A14.2	6.39	3.85e-10	0.000747	0.35	0.28	Mitochondrial DNA levels;	chr11:14464056	chr1:52993201~52993702:-
LUAD	trans	rs7937890	0.559	rs2575831	ENSG00000236360.2	RP11-334A14.2	6.39	3.85e-10	0.000747	0.35	0.28	Mitochondrial DNA levels;	chr11:14464648	chr1:52993201~52993702:-
LUAD	trans	rs7937890	0.559	rs2597197	ENSG00000236360.2	RP11-334A14.2	6.39	3.85e-10	0.000747	0.35	0.28	Mitochondrial DNA levels;	chr11:14468286	chr1:52993201~52993702:-
LUAD	trans	rs12439619	0.508	rs11856561	ENSG00000259295.5	CSPG4P12	-6.39	3.85e-10	0.000748	-0.32	-0.28	Intelligence (multi-trait analysis);	chr15:82161415	chr15:85191438~85213905:+
LUAD	trans	rs864643	0.678	rs1768191	ENSG00000183298.5	RP11-556K13.1	6.39	3.87e-10	0.00075	0.41	0.28	Attention deficit hyperactivity disorder;	chr3:39469772	chr1:101786340~101787219:-
LUAD	trans	rs7192380	1	rs8061052	ENSG00000257513.6	NPIPB1P	6.39	3.88e-10	0.000752	0.27	0.28	Sjögren's syndrome;	chr16:69622629	chr18:11619509~11639699:-
LUAD	trans	rs4713118	0.955	rs9468201	ENSG00000204709.4	LINC01556	6.39	3.88e-10	0.000753	0.38	0.28	Parkinson's disease;	chr6:27719256	chr6:28943877~28944537:+
LUAD	trans	rs7937890	0.532	rs2575833	ENSG00000236360.2	RP11-334A14.2	6.39	3.94e-10	0.000764	0.35	0.28	Mitochondrial DNA levels;	chr11:14470959	chr1:52993201~52993702:-
LUAD	trans	rs9584850	0.874	rs9168	ENSG00000230079.1	STK24P1	6.39	3.94e-10	0.000764	0.32	0.28	Neuroticism;	chr13:98449329	chrX:136295690~136300298:-
LUAD	trans	rs2243480	1	rs34703416	ENSG00000232546.1	RP11-458F8.1	-6.39	3.95e-10	0.000766	-0.38	-0.28	Diabetic kidney disease;	chr7:65835655	chr7:66848496~66858136:+
LUAD	trans	rs7937890	0.559	rs4369365	ENSG00000236360.2	RP11-334A14.2	6.39	3.95e-10	0.000766	0.35	0.28	Mitochondrial DNA levels;	chr11:14422969	chr1:52993201~52993702:-
LUAD	trans	rs877636	0.74	rs772920	ENSG00000227586.5	RP11-162A23.5	6.39	3.96e-10	0.000768	0.34	0.28	Cognitive function;	chr12:55996580	chr10:123171535~123171875:-
LUAD	trans	rs1816752	0.905	rs1348110	ENSG00000224976.2	PARP4P2	-6.39	3.98e-10	0.000772	-0.32	-0.28	Obesity-related traits;	chr13:24406537	chr13:19349137~19407962:+
LUAD	trans	rs7618501	1	rs11130218	ENSG00000197582.5	GPX1P1	-6.39	4.01e-10	0.000777	-0.35	-0.28	Intelligence (multi-trait analysis);	chr3:49714939	chrX:13378735~13379340:-
LUAD	trans	rs853679	0.607	rs71559070	ENSG00000253570.1	RNF5P1	6.39	4.03e-10	0.00078	0.62	0.28	Depression;	chr6:28071151	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.607	rs35902873	ENSG00000253570.1	RNF5P1	6.39	4.03e-10	0.00078	0.62	0.28	Depression;	chr6:28091171	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.607	rs13197574	ENSG00000253570.1	RNF5P1	6.39	4.03e-10	0.00078	0.62	0.28	Depression;	chr6:28092461	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.607	rs34166054	ENSG00000253570.1	RNF5P1	6.39	4.03e-10	0.00078	0.62	0.28	Depression;	chr6:28098023	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.607	rs34662244	ENSG00000253570.1	RNF5P1	6.39	4.03e-10	0.00078	0.62	0.28	Depression;	chr6:28106103	chr8:38600661~38601200:-
LUAD	trans	rs35952432	1	rs35952432	ENSG00000253570.1	RNF5P1	6.39	4.03e-10	0.00078	0.62	0.28	Lung cancer;	chr6:28107123	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.607	rs13203816	ENSG00000253570.1	RNF5P1	6.39	4.03e-10	0.00078	0.62	0.28	Depression;	chr6:28111820	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.556	rs34588114	ENSG00000253570.1	RNF5P1	6.39	4.03e-10	0.00078	0.62	0.28	Depression;	chr6:28112850	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.546	rs34371502	ENSG00000253570.1	RNF5P1	6.39	4.03e-10	0.00078	0.62	0.28	Depression;	chr6:28113980	chr8:38600661~38601200:-
LUAD	trans	rs4742971	0.5	rs7030289	ENSG00000262902.1	RP11-750B16.1	6.38	4.06e-10	0.000785	0.55	0.28	Protein quantitative trait loci;	chr9:105910028	chr17:53105734~53106358:+
LUAD	trans	rs7937890	0.559	rs2597187	ENSG00000236360.2	RP11-334A14.2	6.38	4.08e-10	0.000789	0.35	0.28	Mitochondrial DNA levels;	chr11:14495473	chr1:52993201~52993702:-
LUAD	trans	rs7937890	0.559	rs2034480	ENSG00000236360.2	RP11-334A14.2	6.38	4.08e-10	0.000789	0.35	0.28	Mitochondrial DNA levels;	chr11:14445377	chr1:52993201~52993702:-
LUAD	trans	rs847577	0.677	rs951988	ENSG00000225169.1	BRI3P1	-6.38	4.08e-10	0.000789	-0.33	-0.28	Breast cancer;	chr7:98133162	chr1:100213293~100213670:+
LUAD	trans	rs7662987	1	rs1803037	ENSG00000228407.2	RP4-800M22.1	6.38	4.11e-10	0.000795	0.54	0.28	Smoking initiation;	chr4:99072000	chr1:52160261~52160600:-
LUAD	trans	rs7937890	0.559	rs2575837	ENSG00000236360.2	RP11-334A14.2	6.38	4.17e-10	0.000806	0.35	0.28	Mitochondrial DNA levels;	chr11:14476455	chr1:52993201~52993702:-
LUAD	trans	rs7937890	0.559	rs2575838	ENSG00000236360.2	RP11-334A14.2	6.38	4.17e-10	0.000806	0.35	0.28	Mitochondrial DNA levels;	chr11:14476675	chr1:52993201~52993702:-
LUAD	trans	rs7937890	0.559	rs2167160	ENSG00000236360.2	RP11-334A14.2	6.38	4.17e-10	0.000806	0.35	0.28	Mitochondrial DNA levels;	chr11:14485903	chr1:52993201~52993702:-
LUAD	trans	rs7937890	0.559	rs2597217	ENSG00000236360.2	RP11-334A14.2	6.38	4.17e-10	0.000806	0.35	0.28	Mitochondrial DNA levels;	chr11:14511337	chr1:52993201~52993702:-
LUAD	trans	rs7937890	0.531	rs2575828	ENSG00000236360.2	RP11-334A14.2	6.38	4.18e-10	0.000809	0.35	0.28	Mitochondrial DNA levels;	chr11:14462646	chr1:52993201~52993702:-
LUAD	trans	rs877636	0.702	rs773109	ENSG00000227586.5	RP11-162A23.5	6.38	4.21e-10	0.000813	0.34	0.28	Cognitive function;	chr12:55980911	chr10:123171535~123171875:-
LUAD	trans	rs877636	0.669	rs7297175	ENSG00000212829.8	RPS26P3	-6.38	4.21e-10	0.000814	-0.29	-0.28	Cognitive function;	chr12:56080024	chr9:9090898~9091245:+
LUAD	trans	rs4713118	0.669	rs200997	ENSG00000204709.4	LINC01556	6.38	4.21e-10	0.000814	0.35	0.28	Parkinson's disease;	chr6:27844037	chr6:28943877~28944537:+
LUAD	trans	rs6499255	1	rs4497676	ENSG00000257513.6	NPIPB1P	6.38	4.22e-10	0.000816	0.32	0.28	IgE levels;	chr16:69781047	chr18:11619509~11639699:-
LUAD	trans	rs11122895	0.61	rs13397902	ENSG00000204745.3	AC083899.3	6.38	4.26e-10	0.000824	0.31	0.28	Allergic sensitization;	chr2:111849928	chr2:87125390~87196647:+
LUAD	trans	rs864643	0.625	rs1708083	ENSG00000183298.5	RP11-556K13.1	6.38	4.27e-10	0.000825	0.4	0.28	Attention deficit hyperactivity disorder;	chr3:39464295	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.625	rs1768182	ENSG00000183298.5	RP11-556K13.1	6.38	4.27e-10	0.000825	0.4	0.28	Attention deficit hyperactivity disorder;	chr3:39464531	chr1:101786340~101787219:-
LUAD	trans	rs7618501	0.966	rs9882639	ENSG00000197582.5	GPX1P1	6.38	4.29e-10	0.000828	0.35	0.28	Intelligence (multi-trait analysis);	chr3:49762042	chrX:13378735~13379340:-
LUAD	trans	rs7618501	1	rs60205400	ENSG00000197582.5	GPX1P1	6.38	4.29e-10	0.000828	0.35	0.28	Intelligence (multi-trait analysis);	chr3:49762839	chrX:13378735~13379340:-
LUAD	trans	rs7618501	0.933	rs6809431	ENSG00000197582.5	GPX1P1	6.38	4.29e-10	0.000828	0.35	0.28	Intelligence (multi-trait analysis);	chr3:49766686	chrX:13378735~13379340:-
LUAD	trans	rs61041336	0.534	rs2280399	ENSG00000230849.2	GOT2P2	-6.37	4.31e-10	0.000833	-0.57	-0.28	Neuritic plaque;	chr16:58677628	chr1:173141100~173142350:-
LUAD	trans	rs9914988	0.943	rs4795467	ENSG00000225067.4	RPL23AP2	-6.37	4.33e-10	0.000836	-0.32	-0.28	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28853766	chr19:15611657~15612122:+
LUAD	trans	rs6499255	0.951	rs7196943	ENSG00000257513.6	NPIPB1P	6.37	4.35e-10	0.000839	0.33	0.28	IgE levels;	chr16:69558546	chr18:11619509~11639699:-
LUAD	trans	rs6499255	0.951	rs11642030	ENSG00000257513.6	NPIPB1P	6.37	4.35e-10	0.000839	0.33	0.28	IgE levels;	chr16:69571308	chr18:11619509~11639699:-
LUAD	trans	rs13016963	0.526	rs6726823	ENSG00000235105.1	RP11-329A14.1	6.37	4.37e-10	0.000842	0.32	0.28	Esophageal squamous cell carcinoma;Melanoma;	chr2:201352193	chr1:48435967~48437223:+
LUAD	trans	rs7769051	0.711	rs7770081	ENSG00000227615.1	RP11-864N7.2	6.37	4.38e-10	0.000845	0.47	0.28	Type 2 diabetes nephropathy;	chr6:132768430	chr11:74745716~74746114:-
LUAD	trans	rs4713118	0.955	rs9368529	ENSG00000204709.4	LINC01556	6.37	4.45e-10	0.000857	0.38	0.28	Parkinson's disease;	chr6:27716852	chr6:28943877~28944537:+
LUAD	trans	rs7192380	0.965	rs7187634	ENSG00000257513.6	NPIPB1P	6.37	4.48e-10	0.000863	0.27	0.28	Sjögren's syndrome;	chr16:69629468	chr18:11619509~11639699:-
LUAD	trans	rs4713118	0.955	rs9393848	ENSG00000204709.4	LINC01556	6.37	4.49e-10	0.000865	0.37	0.28	Parkinson's disease;	chr6:27720590	chr6:28943877~28944537:+
LUAD	trans	rs12477438	0.501	rs12613624	ENSG00000276576.1	MRPL30P1	-6.37	4.5e-10	0.000868	-0.31	-0.28	Chronic sinus infection;	chr2:99116278	chr6:57029521~57029988:+
LUAD	trans	rs9876781	0.56	rs2362451	ENSG00000235912.1	RP1-159A19.3	6.37	4.51e-10	0.000868	0.3	0.28	Longevity;	chr3:48358338	chr1:27649419~27649610:+
LUAD	trans	rs9393777	0.92	rs34953377	ENSG00000204709.4	LINC01556	6.37	4.52e-10	0.000871	0.54	0.28	Intelligence (multi-trait analysis);	chr6:27413881	chr6:28943877~28944537:+
LUAD	trans	rs12477438	0.52	rs4851188	ENSG00000276576.1	MRPL30P1	6.37	4.52e-10	0.000872	0.31	0.28	Chronic sinus infection;	chr2:99129435	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.501	rs11683107	ENSG00000276576.1	MRPL30P1	6.37	4.52e-10	0.000872	0.31	0.28	Chronic sinus infection;	chr2:99142772	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.52	rs6542866	ENSG00000276576.1	MRPL30P1	6.37	4.52e-10	0.000872	0.31	0.28	Chronic sinus infection;	chr2:99148129	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.501	rs7608938	ENSG00000276576.1	MRPL30P1	6.37	4.54e-10	0.000875	0.31	0.28	Chronic sinus infection;	chr2:99165763	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.501	rs6542868	ENSG00000276576.1	MRPL30P1	6.37	4.54e-10	0.000875	0.31	0.28	Chronic sinus infection;	chr2:99166385	chr6:57029521~57029988:+
LUAD	trans	rs12439619	0.693	rs9944185	ENSG00000259295.5	CSPG4P12	-6.37	4.56e-10	0.000878	-0.37	-0.28	Intelligence (multi-trait analysis);	chr15:82157927	chr15:85191438~85213905:+
LUAD	trans	rs9876781	1	rs9881491	ENSG00000225528.1	RP3-370M22.8	-6.36	4.57e-10	0.00088	-0.28	-0.28	Longevity;	chr3:48446507	chr22:39960397~39964683:+
LUAD	trans	rs7647973	1	rs11130189	ENSG00000197582.5	GPX1P1	6.36	4.61e-10	0.000887	0.38	0.28	Menarche (age at onset);	chr3:49309924	chrX:13378735~13379340:-
LUAD	trans	rs12477438	0.52	rs2516830	ENSG00000276576.1	MRPL30P1	6.36	4.7e-10	0.000905	0.31	0.28	Chronic sinus infection;	chr2:99157239	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.52	rs2632283	ENSG00000276576.1	MRPL30P1	6.36	4.7e-10	0.000905	0.31	0.28	Chronic sinus infection;	chr2:99159537	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.501	rs2516833	ENSG00000276576.1	MRPL30P1	6.36	4.7e-10	0.000905	0.31	0.28	Chronic sinus infection;	chr2:99160942	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.52	rs2516835	ENSG00000276576.1	MRPL30P1	6.36	4.7e-10	0.000905	0.31	0.28	Chronic sinus infection;	chr2:99162668	chr6:57029521~57029988:+
LUAD	trans	rs853679	0.607	rs56075693	ENSG00000253570.1	RNF5P1	6.36	4.72e-10	0.000908	0.62	0.28	Depression;	chr6:28322551	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.607	rs34218844	ENSG00000253570.1	RNF5P1	6.36	4.72e-10	0.000908	0.62	0.28	Depression;	chr6:28322870	chr8:38600661~38601200:-
LUAD	trans	rs10037055	0.853	rs6890580	ENSG00000228305.2	AC016734.2	-6.36	4.72e-10	0.000908	-0.31	-0.28	Migraine without aura;	chr5:177226519	chr2:63622178~63622831:-
LUAD	trans	rs877636	0.702	rs773110	ENSG00000223416.3	RPS26P15	6.36	4.76e-10	0.000916	0.3	0.28	Cognitive function;	chr12:55981353	chr1:58056133~58056480:-
LUAD	trans	rs877636	0.702	rs773111	ENSG00000223416.3	RPS26P15	6.36	4.76e-10	0.000916	0.3	0.28	Cognitive function;	chr12:55981956	chr1:58056133~58056480:-
LUAD	trans	rs877636	0.702	rs773112	ENSG00000223416.3	RPS26P15	6.36	4.76e-10	0.000916	0.3	0.28	Cognitive function;	chr12:55982097	chr1:58056133~58056480:-
LUAD	trans	rs11172055	0.846	rs7306442	ENSG00000121089.4	NACA3P	-6.36	4.77e-10	0.000918	-0.35	-0.28	Migraine;	chr12:56859089	chr4:164943290~164943937:+
LUAD	trans	rs864643	0.678	rs1768158	ENSG00000183298.5	RP11-556K13.1	-6.36	4.79e-10	0.000921	-0.39	-0.28	Attention deficit hyperactivity disorder;	chr3:39465870	chr1:101786340~101787219:-
LUAD	trans	rs73198271	1	rs11784958	ENSG00000273129.1	PACERR	6.36	4.8e-10	0.000923	0.37	0.28	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8750271	chr1:186680622~186681446:+
LUAD	trans	rs7769051	0.711	rs9493436	ENSG00000227615.1	RP11-864N7.2	6.36	4.82e-10	0.000926	0.46	0.28	Type 2 diabetes nephropathy;	chr6:132767136	chr11:74745716~74746114:-
LUAD	trans	rs7769051	0.711	rs9493437	ENSG00000227615.1	RP11-864N7.2	6.36	4.82e-10	0.000926	0.46	0.28	Type 2 diabetes nephropathy;	chr6:132767266	chr11:74745716~74746114:-
LUAD	trans	rs853679	0.607	rs200489	ENSG00000204709.4	LINC01556	6.36	4.82e-10	0.000927	0.53	0.28	Depression;	chr6:27830479	chr6:28943877~28944537:+
LUAD	trans	rs4713118	0.869	rs9283880	ENSG00000204709.4	LINC01556	6.36	4.83e-10	0.000927	0.37	0.28	Parkinson's disease;	chr6:27747464	chr6:28943877~28944537:+
LUAD	trans	rs4713118	0.869	rs9283881	ENSG00000204709.4	LINC01556	6.36	4.83e-10	0.000927	0.37	0.28	Parkinson's disease;	chr6:27747476	chr6:28943877~28944537:+
LUAD	trans	rs4713118	0.869	rs9283882	ENSG00000204709.4	LINC01556	6.36	4.83e-10	0.000927	0.37	0.28	Parkinson's disease;	chr6:27747479	chr6:28943877~28944537:+
LUAD	trans	rs12477438	0.501	rs13033012	ENSG00000276576.1	MRPL30P1	6.36	4.84e-10	0.00093	0.31	0.28	Chronic sinus infection;	chr2:99178686	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.501	rs13000731	ENSG00000276576.1	MRPL30P1	6.36	4.84e-10	0.00093	0.31	0.28	Chronic sinus infection;	chr2:99178768	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.501	rs6708878	ENSG00000276576.1	MRPL30P1	6.36	4.84e-10	0.00093	0.31	0.28	Chronic sinus infection;	chr2:99185101	chr6:57029521~57029988:+
LUAD	trans	rs6683419	0.967	rs10917470	ENSG00000224237.1	MINOS1P3	-6.35	4.87e-10	0.000935	-0.34	-0.28	Serum thyroid-stimulating hormone levels;	chr1:19518712	chr3:27214816~27215018:-
LUAD	trans	rs2243480	1	rs34815098	ENSG00000232546.1	RP11-458F8.1	-6.35	4.94e-10	0.000948	-0.37	-0.28	Diabetic kidney disease;	chr7:65827267	chr7:66848496~66858136:+
LUAD	trans	rs2243480	1	rs4548056	ENSG00000232546.1	RP11-458F8.1	-6.35	4.94e-10	0.000948	-0.37	-0.28	Diabetic kidney disease;	chr7:65833886	chr7:66848496~66858136:+
LUAD	trans	rs2243480	1	rs7456042	ENSG00000232546.1	RP11-458F8.1	-6.35	4.94e-10	0.000948	-0.37	-0.28	Diabetic kidney disease;	chr7:65834791	chr7:66848496~66858136:+
LUAD	trans	rs2243480	1	rs35735127	ENSG00000232546.1	RP11-458F8.1	-6.35	4.94e-10	0.000948	-0.37	-0.28	Diabetic kidney disease;	chr7:65835436	chr7:66848496~66858136:+
LUAD	trans	rs2243480	0.901	rs35256305	ENSG00000232546.1	RP11-458F8.1	-6.35	4.94e-10	0.000948	-0.37	-0.28	Diabetic kidney disease;	chr7:65841418	chr7:66848496~66858136:+
LUAD	trans	rs2243480	1	rs73142121	ENSG00000232546.1	RP11-458F8.1	-6.35	4.94e-10	0.000948	-0.37	-0.28	Diabetic kidney disease;	chr7:65846219	chr7:66848496~66858136:+
LUAD	trans	rs2243480	0.803	rs34004500	ENSG00000232546.1	RP11-458F8.1	-6.35	4.94e-10	0.000948	-0.37	-0.28	Diabetic kidney disease;	chr7:65847191	chr7:66848496~66858136:+
LUAD	trans	rs6743068	0.521	rs9288318	ENSG00000235105.1	RP11-329A14.1	6.35	4.95e-10	0.000951	0.32	0.28	Lymphocyte percentage of white cells;	chr2:201331340	chr1:48435967~48437223:+
LUAD	trans	rs7618501	0.966	rs7372966	ENSG00000197582.5	GPX1P1	-6.35	4.97e-10	0.000953	-0.35	-0.28	Intelligence (multi-trait analysis);	chr3:49751536	chrX:13378735~13379340:-
LUAD	trans	rs7618501	1	rs7372725	ENSG00000197582.5	GPX1P1	-6.35	4.97e-10	0.000953	-0.35	-0.28	Intelligence (multi-trait analysis);	chr3:49753111	chrX:13378735~13379340:-
LUAD	trans	rs7769051	0.711	rs9493435	ENSG00000227615.1	RP11-864N7.2	6.35	5e-10	0.000959	0.47	0.28	Type 2 diabetes nephropathy;	chr6:132767066	chr11:74745716~74746114:-
LUAD	trans	rs9393777	0.778	rs66841633	ENSG00000204709.4	LINC01556	6.35	5.02e-10	0.000962	0.54	0.28	Intelligence (multi-trait analysis);	chr6:27414607	chr6:28943877~28944537:+
LUAD	trans	rs853679	0.607	rs35001169	ENSG00000253570.1	RNF5P1	6.35	5.02e-10	0.000963	0.63	0.28	Depression;	chr6:28219854	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.546	rs35656932	ENSG00000253570.1	RNF5P1	6.35	5.02e-10	0.000963	0.63	0.28	Depression;	chr6:28223510	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.607	rs34243448	ENSG00000253570.1	RNF5P1	6.35	5.02e-10	0.000963	0.63	0.28	Depression;	chr6:28225324	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.607	rs13204012	ENSG00000253570.1	RNF5P1	6.35	5.02e-10	0.000963	0.63	0.28	Depression;	chr6:28233753	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.607	rs13205211	ENSG00000253570.1	RNF5P1	6.35	5.02e-10	0.000963	0.63	0.28	Depression;	chr6:28235278	chr8:38600661~38601200:-
LUAD	trans	rs670523	0.804	rs2364400	ENSG00000241627.3	UBQLN4P1	6.35	5.02e-10	0.000963	0.26	0.28	Crohn's disease;Inflammatory bowel disease;	chr1:156027382	chr3:148985868~148987668:-
LUAD	trans	rs853679	0.607	rs56189111	ENSG00000253570.1	RNF5P1	6.35	5.03e-10	0.000965	0.62	0.28	Depression;	chr6:28304196	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.607	rs35072899	ENSG00000253570.1	RNF5P1	6.35	5.03e-10	0.000965	0.62	0.28	Depression;	chr6:28313764	chr8:38600661~38601200:-
LUAD	trans	rs4948102	0.595	rs7793921	ENSG00000186940.6	CHCHD2P9	-6.35	5.04e-10	0.000967	-0.33	-0.28	Plasma homocysteine levels (post-methionine load test);	chr7:56053188	chr9:79391304~79391759:+
LUAD	trans	rs4948102	0.595	rs10255049	ENSG00000186940.6	CHCHD2P9	-6.35	5.04e-10	0.000967	-0.33	-0.28	Plasma homocysteine levels (post-methionine load test);	chr7:56053611	chr9:79391304~79391759:+
LUAD	trans	rs6499255	1	rs1139178	ENSG00000257513.6	NPIPB1P	6.35	5.1e-10	0.000977	0.33	0.28	IgE levels;	chr16:69747565	chr18:11619509~11639699:-
LUAD	trans	rs77688320	1	rs2540334	ENSG00000235105.1	RP11-329A14.1	-6.34	5.15e-10	0.000987	-0.42	-0.28	Breast cancer;	chr2:201406624	chr1:48435967~48437223:+
LUAD	trans	rs7647973	1	rs11720542	ENSG00000197582.5	GPX1P1	6.34	5.24e-10	0.001	0.38	0.28	Menarche (age at onset);	chr3:49319994	chrX:13378735~13379340:-
LUAD	trans	rs12439619	0.693	rs7165536	ENSG00000259295.5	CSPG4P12	-6.34	5.3e-10	0.00101	-0.38	-0.28	Intelligence (multi-trait analysis);	chr15:82273743	chr15:85191438~85213905:+
LUAD	trans	rs877636	0.702	rs61937249	ENSG00000227586.5	RP11-162A23.5	6.34	5.31e-10	0.00102	0.34	0.28	Cognitive function;	chr12:55988132	chr10:123171535~123171875:-
LUAD	trans	rs61041336	0.583	rs11647748	ENSG00000230849.2	GOT2P2	-6.34	5.33e-10	0.00102	-0.56	-0.28	Neuritic plaque;	chr16:58697980	chr1:173141100~173142350:-
LUAD	trans	rs7833986	0.534	rs72653928	ENSG00000244245.1	RP11-120B7.1	6.34	5.34e-10	0.00102	0.33	0.28	Height;	chr8:55995176	chr5:108593609~108593967:+
LUAD	trans	rs7618501	1	rs6775384	ENSG00000197582.5	GPX1P1	6.34	5.38e-10	0.00103	0.35	0.28	Intelligence (multi-trait analysis);	chr3:49815640	chrX:13378735~13379340:-
LUAD	trans	rs6732160	0.588	rs2043101	ENSG00000236165.1	PRADC1P1	6.34	5.38e-10	0.00103	0.39	0.28	Intelligence (multi-trait analysis);	chr2:73146922	chr3:36976316~36976840:+
LUAD	trans	rs2069408	1	rs2069408	ENSG00000224553.1	AC008065.1	-6.34	5.38e-10	0.00103	-0.31	-0.28	Asthma;	chr12:55970537	chr2:171374931~171375278:-
LUAD	trans	rs4713118	0.869	rs9295743	ENSG00000204709.4	LINC01556	6.34	5.38e-10	0.00103	0.37	0.28	Parkinson's disease;	chr6:27747323	chr6:28943877~28944537:+
LUAD	trans	rs2243480	0.706	rs6460257	ENSG00000230295.1	RP11-458F8.2	-6.34	5.4e-10	0.00103	-0.3	-0.28	Diabetic kidney disease;	chr7:65731813	chr7:66880708~66882981:+
LUAD	trans	rs7833986	0.501	rs72653986	ENSG00000244245.1	RP11-120B7.1	6.34	5.4e-10	0.00103	0.33	0.28	Height;	chr8:56122489	chr5:108593609~108593967:+
LUAD	trans	rs12477438	0.501	rs6727749	ENSG00000276576.1	MRPL30P1	6.34	5.41e-10	0.00104	0.31	0.28	Chronic sinus infection;	chr2:99177127	chr6:57029521~57029988:+
LUAD	trans	rs9584850	0.874	rs3742136	ENSG00000230079.1	STK24P1	6.34	5.41e-10	0.00104	0.32	0.28	Neuroticism;	chr13:98450353	chrX:136295690~136300298:-
LUAD	trans	rs7554511	0.707	rs3767498	ENSG00000244144.1	RP11-757F18.3	-6.34	5.42e-10	0.00104	-0.36	-0.28	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201051599	chr3:112185480~112185998:-
LUAD	trans	rs12477438	0.52	rs1133978	ENSG00000276576.1	MRPL30P1	6.34	5.43e-10	0.00104	0.31	0.28	Chronic sinus infection;	chr2:99125501	chr6:57029521~57029988:+
LUAD	trans	rs9584850	0.834	rs9584855	ENSG00000230079.1	STK24P1	-6.33	5.52e-10	0.00106	-0.32	-0.28	Neuroticism;	chr13:98466746	chrX:136295690~136300298:-
LUAD	trans	rs673253	0.556	rs9787076	ENSG00000231007.5	CDC20P1	6.33	5.55e-10	0.00106	0.37	0.28	Intelligence (multi-trait analysis);	chr1:43675478	chr9:87011652~87013151:+
LUAD	trans	rs9393777	0.92	rs35120058	ENSG00000204709.4	LINC01556	6.33	5.56e-10	0.00106	0.54	0.28	Intelligence (multi-trait analysis);	chr6:27390387	chr6:28943877~28944537:+
LUAD	trans	rs9467773	0.595	rs4320356	ENSG00000242375.1	RP11-498P14.3	-6.33	5.6e-10	0.00107	-0.37	-0.28	Intelligence (multi-trait analysis);	chr6:26423332	chr9:97195351~97197687:-
LUAD	trans	rs673253	0.52	rs3791034	ENSG00000231007.5	CDC20P1	6.33	5.62e-10	0.00107	0.37	0.28	Intelligence (multi-trait analysis);	chr1:43679459	chr9:87011652~87013151:+
LUAD	trans	rs9611519	0.603	rs4821999	ENSG00000268568.1	AC007228.9	-6.33	5.66e-10	0.00108	-0.36	-0.28	Neuroticism;	chr22:41073997	chr19:56672574~56673901:-
LUAD	trans	rs9611519	0.603	rs8142276	ENSG00000268568.1	AC007228.9	-6.33	5.66e-10	0.00108	-0.36	-0.28	Neuroticism;	chr22:41075443	chr19:56672574~56673901:-
LUAD	trans	rs9611519	0.567	rs8141730	ENSG00000268568.1	AC007228.9	-6.33	5.66e-10	0.00108	-0.36	-0.28	Neuroticism;	chr22:41077057	chr19:56672574~56673901:-
LUAD	trans	rs4276421	0.55	rs10214369	ENSG00000231752.4	EMBP1	-6.33	5.69e-10	0.00109	-0.41	-0.28	P wave duration;	chr5:45638409	chr1:121519112~121571892:+
LUAD	trans	rs853679	0.607	rs71559070	ENSG00000281831.1	HCP5B	6.33	5.71e-10	0.00109	0.62	0.28	Depression;	chr6:28071151	chr6:29871895~29873783:-
LUAD	trans	rs853679	0.607	rs35902873	ENSG00000281831.1	HCP5B	6.33	5.71e-10	0.00109	0.62	0.28	Depression;	chr6:28091171	chr6:29871895~29873783:-
LUAD	trans	rs853679	0.607	rs13197574	ENSG00000281831.1	HCP5B	6.33	5.71e-10	0.00109	0.62	0.28	Depression;	chr6:28092461	chr6:29871895~29873783:-
LUAD	trans	rs853679	0.607	rs34166054	ENSG00000281831.1	HCP5B	6.33	5.71e-10	0.00109	0.62	0.28	Depression;	chr6:28098023	chr6:29871895~29873783:-
LUAD	trans	rs853679	0.607	rs34662244	ENSG00000281831.1	HCP5B	6.33	5.71e-10	0.00109	0.62	0.28	Depression;	chr6:28106103	chr6:29871895~29873783:-
LUAD	trans	rs35952432	1	rs35952432	ENSG00000281831.1	HCP5B	6.33	5.71e-10	0.00109	0.62	0.28	Lung cancer;	chr6:28107123	chr6:29871895~29873783:-
LUAD	trans	rs853679	0.607	rs13203816	ENSG00000281831.1	HCP5B	6.33	5.71e-10	0.00109	0.62	0.28	Depression;	chr6:28111820	chr6:29871895~29873783:-
LUAD	trans	rs853679	0.556	rs34588114	ENSG00000281831.1	HCP5B	6.33	5.71e-10	0.00109	0.62	0.28	Depression;	chr6:28112850	chr6:29871895~29873783:-
LUAD	trans	rs853679	0.546	rs34371502	ENSG00000281831.1	HCP5B	6.33	5.71e-10	0.00109	0.62	0.28	Depression;	chr6:28113980	chr6:29871895~29873783:-
LUAD	trans	rs11638815	0.639	rs6603030	ENSG00000235370.6	DNM1P51	-6.33	5.72e-10	0.00109	-0.42	-0.28	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82561353	chr15:84398316~84411701:-
LUAD	trans	rs12477438	0.52	rs4347885	ENSG00000276576.1	MRPL30P1	6.33	5.72e-10	0.00109	0.31	0.28	Chronic sinus infection;	chr2:99187544	chr6:57029521~57029988:+
LUAD	trans	rs864643	0.574	rs1768192	ENSG00000183298.5	RP11-556K13.1	6.33	5.76e-10	0.0011	0.4	0.28	Attention deficit hyperactivity disorder;	chr3:39470669	chr1:101786340~101787219:-
LUAD	trans	rs847577	0.575	rs41278842	ENSG00000225169.1	BRI3P1	-6.33	5.76e-10	0.0011	-0.33	-0.28	Breast cancer;	chr7:98186687	chr1:100213293~100213670:+
LUAD	trans	rs7192380	1	rs8049728	ENSG00000257513.6	NPIPB1P	6.33	5.78e-10	0.0011	0.27	0.28	Sjögren's syndrome;	chr16:69620887	chr18:11619509~11639699:-
LUAD	trans	rs860295	0.529	rs11577179	ENSG00000241627.3	UBQLN4P1	6.32	5.8e-10	0.00111	0.26	0.28	Body mass index;	chr1:156013919	chr3:148985868~148987668:-
LUAD	trans	rs6499255	0.904	rs7190652	ENSG00000257513.6	NPIPB1P	6.32	5.83e-10	0.00111	0.32	0.28	IgE levels;	chr16:69582389	chr18:11619509~11639699:-
LUAD	trans	rs864643	0.678	rs1609646	ENSG00000183298.5	RP11-556K13.1	6.32	5.85e-10	0.00112	0.39	0.28	Attention deficit hyperactivity disorder;	chr3:39491415	chr1:101786340~101787219:-
LUAD	trans	rs10037055	0.853	rs2336237	ENSG00000228305.2	AC016734.2	6.32	5.85e-10	0.00112	0.31	0.28	Migraine without aura;	chr5:177238878	chr2:63622178~63622831:-
LUAD	trans	rs877636	0.702	rs61937249	ENSG00000223416.3	RPS26P15	6.32	5.86e-10	0.00112	0.3	0.28	Cognitive function;	chr12:55988132	chr1:58056133~58056480:-
LUAD	trans	rs79149102	0.522	rs4887156	ENSG00000227288.3	RP5-837I24.1	6.32	5.88e-10	0.00112	0.51	0.28	Lung cancer;	chr15:74538844	chr1:81501794~81503468:+
LUAD	trans	rs11122895	0.527	rs10186692	ENSG00000204745.3	AC083899.3	6.32	5.89e-10	0.00112	0.3	0.28	Allergic sensitization;	chr2:111686719	chr2:87125390~87196647:+
LUAD	trans	rs4948102	0.642	rs6593297	ENSG00000186940.6	CHCHD2P9	6.32	5.91e-10	0.00113	0.33	0.28	Plasma homocysteine levels (post-methionine load test);	chr7:56054365	chr9:79391304~79391759:+
LUAD	trans	rs2060793	0.712	rs10832290	ENSG00000236360.2	RP11-334A14.2	6.32	5.97e-10	0.00114	0.36	0.28	Vitamin D levels;	chr11:14650684	chr1:52993201~52993702:-
LUAD	trans	rs2060793	0.774	rs1403249	ENSG00000236360.2	RP11-334A14.2	6.32	5.97e-10	0.00114	0.36	0.28	Vitamin D levels;	chr11:14651438	chr1:52993201~52993702:-
LUAD	trans	rs74781061	0.79	rs74788606	ENSG00000227288.3	RP5-837I24.1	6.32	5.97e-10	0.00114	0.51	0.28	Endometriosis;	chr15:74532649	chr1:81501794~81503468:+
LUAD	trans	rs12477438	0.52	rs2309581	ENSG00000276576.1	MRPL30P1	-6.32	6.01e-10	0.00115	-0.33	-0.28	Chronic sinus infection;	chr2:99167829	chr6:57029521~57029988:+
LUAD	trans	rs10420951	0.617	rs7246328	ENSG00000267533.1	RP11-815J4.7	6.32	6.11e-10	0.00116	0.49	0.28	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18508247	chr18:12067173~12068417:-
LUAD	trans	rs6499255	1	rs7189424	ENSG00000257513.6	NPIPB1P	6.31	6.15e-10	0.00117	0.33	0.28	IgE levels;	chr16:69748843	chr18:11619509~11639699:-
LUAD	trans	rs864643	0.574	rs1768213	ENSG00000183298.5	RP11-556K13.1	6.31	6.21e-10	0.00118	0.4	0.28	Attention deficit hyperactivity disorder;	chr3:39486790	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.678	rs493794	ENSG00000183298.5	RP11-556K13.1	6.31	6.21e-10	0.00118	0.4	0.28	Attention deficit hyperactivity disorder;	chr3:39486804	chr1:101786340~101787219:-
LUAD	trans	rs6499255	0.951	rs7198242	ENSG00000257513.6	NPIPB1P	-6.31	6.21e-10	0.00118	-0.32	-0.28	IgE levels;	chr16:69614592	chr18:11619509~11639699:-
LUAD	trans	rs6499255	0.951	rs78772829	ENSG00000257513.6	NPIPB1P	6.31	6.22e-10	0.00118	0.32	0.28	IgE levels;	chr16:69573195	chr18:11619509~11639699:-
LUAD	trans	rs4879656	0.564	rs20583	ENSG00000215007.3	DNAJA1P3	6.31	6.22e-10	0.00118	0.32	0.28	Menopause (age at onset);	chr9:33026574	chrX:107351650~107352843:-
LUAD	trans	rs12145833	0.748	rs11807162	ENSG00000154608.12	CEP170P1	-6.31	6.29e-10	0.0012	-0.42	-0.28	Obesity (early onset extreme);	chr1:243291378	chr4:118467590~118554204:+
LUAD	trans	rs7312770	0.612	rs773114	ENSG00000234192.1	RP11-57C13.5	6.31	6.29e-10	0.0012	0.29	0.28	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr10:87642607~87642954:+
LUAD	trans	rs66887589	0.774	rs9307477	ENSG00000275858.1	RP11-291L22.8	6.31	6.31e-10	0.0012	0.3	0.28	Diastolic blood pressure;	chr4:119500654	chr10:38450738~38451069:-
LUAD	trans	rs6499255	1	rs60231938	ENSG00000257513.6	NPIPB1P	6.31	6.35e-10	0.00121	0.33	0.28	IgE levels;	chr16:69796512	chr18:11619509~11639699:-
LUAD	trans	rs10037055	0.853	rs10056008	ENSG00000228305.2	AC016734.2	-6.31	6.37e-10	0.00121	-0.31	-0.28	Migraine without aura;	chr5:177194147	chr2:63622178~63622831:-
LUAD	trans	rs10037055	0.853	rs10476219	ENSG00000228305.2	AC016734.2	-6.31	6.37e-10	0.00121	-0.31	-0.28	Migraine without aura;	chr5:177201547	chr2:63622178~63622831:-
LUAD	trans	rs79149102	0.522	rs11857192	ENSG00000227288.3	RP5-837I24.1	6.31	6.41e-10	0.00122	0.51	0.28	Lung cancer;	chr15:74530103	chr1:81501794~81503468:+
LUAD	trans	rs6424115	0.729	rs1737362	ENSG00000228217.1	AL390877.1	-6.31	6.44e-10	0.00122	-0.36	-0.28	Immature fraction of reticulocytes;	chr1:23728310	chr1:117778087~117778506:-
LUAD	trans	rs7192380	0.964	rs11075729	ENSG00000257513.6	NPIPB1P	6.31	6.47e-10	0.00123	0.27	0.28	Sjögren's syndrome;	chr16:69586375	chr18:11619509~11639699:-
LUAD	trans	rs4713118	0.615	rs9295747	ENSG00000204709.4	LINC01556	-6.31	6.49e-10	0.00123	-0.34	-0.28	Parkinson's disease;	chr6:27769214	chr6:28943877~28944537:+
LUAD	trans	rs7618501	1	rs9872864	ENSG00000197582.5	GPX1P1	-6.31	6.51e-10	0.00124	-0.35	-0.28	Intelligence (multi-trait analysis);	chr3:49754590	chrX:13378735~13379340:-
LUAD	trans	rs867371	0.614	rs7183805	ENSG00000235370.6	DNM1P51	-6.31	6.53e-10	0.00124	-0.38	-0.28	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82247090	chr15:84398316~84411701:-
LUAD	trans	rs2060793	0.741	rs4344519	ENSG00000236360.2	RP11-334A14.2	6.3	6.55e-10	0.00124	0.36	0.28	Vitamin D levels;	chr11:14701347	chr1:52993201~52993702:-
LUAD	trans	rs847577	0.646	rs10270222	ENSG00000225169.1	BRI3P1	-6.3	6.59e-10	0.00125	-0.33	-0.28	Breast cancer;	chr7:98152487	chr1:100213293~100213670:+
LUAD	trans	rs9467773	0.587	rs3208733	ENSG00000242375.1	RP11-498P14.3	-6.3	6.66e-10	0.00126	-0.36	-0.28	Intelligence (multi-trait analysis);	chr6:26414197	chr9:97195351~97197687:-
LUAD	trans	rs4276421	0.571	rs1527833	ENSG00000231752.4	EMBP1	-6.3	6.68e-10	0.00127	-0.41	-0.28	P wave duration;	chr5:45570915	chr1:121519112~121571892:+
LUAD	trans	rs6499255	0.951	rs11639947	ENSG00000257513.6	NPIPB1P	6.3	6.76e-10	0.00128	0.32	0.28	IgE levels;	chr16:69612219	chr18:11619509~11639699:-
LUAD	trans	rs864643	0.678	rs625898	ENSG00000183298.5	RP11-556K13.1	-6.3	6.79e-10	0.00129	-0.39	-0.28	Attention deficit hyperactivity disorder;	chr3:39471624	chr1:101786340~101787219:-
LUAD	trans	rs66887589	0.807	rs13134517	ENSG00000275858.1	RP11-291L22.8	6.3	6.8e-10	0.00129	0.3	0.28	Diastolic blood pressure;	chr4:119484107	chr10:38450738~38451069:-
LUAD	trans	rs66887589	0.837	rs6534135	ENSG00000275858.1	RP11-291L22.8	6.3	6.8e-10	0.00129	0.3	0.28	Diastolic blood pressure;	chr4:119485147	chr10:38450738~38451069:-
LUAD	trans	rs66887589	0.837	rs7661498	ENSG00000275858.1	RP11-291L22.8	6.3	6.8e-10	0.00129	0.3	0.28	Diastolic blood pressure;	chr4:119486953	chr10:38450738~38451069:-
LUAD	trans	rs6940638	0.513	rs4424065	ENSG00000242375.1	RP11-498P14.3	-6.3	6.85e-10	0.0013	-0.35	-0.28	Intelligence (multi-trait analysis);	chr6:27068677	chr9:97195351~97197687:-
LUAD	trans	rs9322817	0.583	rs7770002	ENSG00000220842.6	RP11-572P18.1	6.3	6.85e-10	0.0013	0.33	0.28	Thyroid stimulating hormone;	chr6:104725570	chr10:120354701~120355183:-
LUAD	trans	rs2060793	0.712	rs6486202	ENSG00000236360.2	RP11-334A14.2	6.3	6.87e-10	0.0013	0.36	0.28	Vitamin D levels;	chr11:14777260	chr1:52993201~52993702:-
LUAD	trans	rs9467773	0.595	rs6907924	ENSG00000242375.1	RP11-498P14.3	-6.3	6.9e-10	0.00131	-0.36	-0.28	Intelligence (multi-trait analysis);	chr6:26438589	chr9:97195351~97197687:-
LUAD	trans	rs9467773	0.55	rs9379874	ENSG00000242375.1	RP11-498P14.3	-6.3	6.9e-10	0.00131	-0.36	-0.28	Intelligence (multi-trait analysis);	chr6:26440201	chr9:97195351~97197687:-
LUAD	trans	rs58106596	0.605	rs58212470	ENSG00000259020.3	RP11-529H20.3	6.3	6.92e-10	0.00131	0.36	0.28	Lymphocyte counts;White blood cell count;	chr2:231696869	chr14:92026566~92026887:+
LUAD	trans	rs7746199	0.736	rs58616630	ENSG00000253570.1	RNF5P1	6.3	6.92e-10	0.00131	0.59	0.28	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27506936	chr8:38600661~38601200:-
LUAD	trans	rs6499255	0.951	rs10852457	ENSG00000257513.6	NPIPB1P	6.29	6.95e-10	0.00131	0.32	0.28	IgE levels;	chr16:69573950	chr18:11619509~11639699:-
LUAD	trans	rs73108077	0.736	rs732860	ENSG00000279352.1	RP11-411B10.7	6.29	6.96e-10	0.00132	0.46	0.28	Red blood cell density in sickle cell anemia;	chr20:31269641	chr18:14010054~14010917:+
LUAD	trans	rs73108077	0.736	rs6121224	ENSG00000279352.1	RP11-411B10.7	6.29	6.96e-10	0.00132	0.46	0.28	Red blood cell density in sickle cell anemia;	chr20:31272881	chr18:14010054~14010917:+
LUAD	trans	rs73108077	0.736	rs6061028	ENSG00000279352.1	RP11-411B10.7	6.29	6.96e-10	0.00132	0.46	0.28	Red blood cell density in sickle cell anemia;	chr20:31285774	chr18:14010054~14010917:+
LUAD	trans	rs7833986	0.534	rs2458083	ENSG00000244245.1	RP11-120B7.1	6.29	6.98e-10	0.00132	0.34	0.28	Height;	chr8:55986226	chr5:108593609~108593967:+
LUAD	trans	rs3812762	0.843	rs34599227	ENSG00000266891.1	RP11-692N5.2	6.29	6.99e-10	0.00132	0.37	0.28	Hypospadias;	chr11:8760973	chr18:9734882~9735602:-
LUAD	trans	rs673253	0.556	rs618678	ENSG00000231007.5	CDC20P1	6.29	7.05e-10	0.00133	0.35	0.28	Intelligence (multi-trait analysis);	chr1:43667628	chr9:87011652~87013151:+
LUAD	trans	rs9393777	0.777	rs56114371	ENSG00000204709.4	LINC01556	6.29	7.14e-10	0.00135	0.58	0.28	Intelligence (multi-trait analysis);	chr6:27307055	chr6:28943877~28944537:+
LUAD	trans	rs6499255	0.951	rs16958970	ENSG00000257513.6	NPIPB1P	6.29	7.16e-10	0.00135	0.32	0.28	IgE levels;	chr16:69593890	chr18:11619509~11639699:-
LUAD	trans	rs847577	0.677	rs1495525	ENSG00000225169.1	BRI3P1	-6.29	7.16e-10	0.00135	-0.33	-0.28	Breast cancer;	chr7:98196920	chr1:100213293~100213670:+
LUAD	trans	rs7121616	0.733	rs10892967	ENSG00000234176.1	HSPA8P1	6.29	7.17e-10	0.00135	0.31	0.28	Breast cancer;	chr11:123130350	chrX:121203182~121205014:-
LUAD	trans	rs17301013	0.932	rs6425281	ENSG00000213331.4	RP11-713C19.2	6.29	7.19e-10	0.00136	0.32	0.28	Systemic lupus erythematosus;	chr1:174449784	chr4:187970273~187971284:+
LUAD	trans	rs9876781	0.967	rs1870444	ENSG00000225528.1	RP3-370M22.8	-6.29	7.22e-10	0.00136	-0.28	-0.28	Longevity;	chr3:48445369	chr22:39960397~39964683:+
LUAD	trans	rs12477438	0.52	rs1453563	ENSG00000276576.1	MRPL30P1	6.29	7.24e-10	0.00137	0.31	0.28	Chronic sinus infection;	chr2:99103804	chr6:57029521~57029988:+
LUAD	trans	rs12477438	0.501	rs11683188	ENSG00000276576.1	MRPL30P1	6.29	7.24e-10	0.00137	0.31	0.28	Chronic sinus infection;	chr2:99108049	chr6:57029521~57029988:+
LUAD	trans	rs7833986	0.501	rs72653981	ENSG00000244245.1	RP11-120B7.1	6.29	7.25e-10	0.00137	0.32	0.28	Height;	chr8:56115255	chr5:108593609~108593967:+
LUAD	trans	rs7833986	0.501	rs2976036	ENSG00000244245.1	RP11-120B7.1	6.29	7.25e-10	0.00137	0.32	0.28	Height;	chr8:56119162	chr5:108593609~108593967:+
LUAD	trans	rs1190596	0.525	rs35350456	ENSG00000181359.5	HSP90AA6P	-6.29	7.25e-10	0.00137	-0.31	-0.28	Behavioural disinhibition (generation interaction);	chr14:102238414	chr4:170581470~170605450:-
LUAD	trans	rs17301013	0.932	rs6425280	ENSG00000213331.4	RP11-713C19.2	6.29	7.29e-10	0.00138	0.32	0.28	Systemic lupus erythematosus;	chr1:174422186	chr4:187970273~187971284:+
LUAD	trans	rs12145833	0.619	rs12035042	ENSG00000154608.12	CEP170P1	-6.29	7.3e-10	0.00138	-0.46	-0.28	Obesity (early onset extreme);	chr1:243420597	chr4:118467590~118554204:+
LUAD	trans	rs7647973	0.961	rs4955430	ENSG00000197582.5	GPX1P1	6.29	7.32e-10	0.00138	0.38	0.28	Menarche (age at onset);	chr3:49340655	chrX:13378735~13379340:-
LUAD	trans	rs864643	0.678	rs1708089	ENSG00000183298.5	RP11-556K13.1	6.29	7.35e-10	0.00139	0.4	0.28	Attention deficit hyperactivity disorder;	chr3:39470371	chr1:101786340~101787219:-
LUAD	trans	rs10420951	0.617	rs8101992	ENSG00000267533.1	RP11-815J4.7	6.28	7.37e-10	0.00139	0.5	0.28	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18503613	chr18:12067173~12068417:-
LUAD	trans	rs6499255	0.951	rs10500551	ENSG00000257513.6	NPIPB1P	6.28	7.37e-10	0.00139	0.32	0.28	IgE levels;	chr16:69633067	chr18:11619509~11639699:-
LUAD	trans	rs12477438	0.501	rs34272114	ENSG00000276576.1	MRPL30P1	6.28	7.43e-10	0.0014	0.31	0.28	Chronic sinus infection;	chr2:99120980	chr6:57029521~57029988:+
LUAD	trans	rs853679	0.607	rs13207345	ENSG00000253570.1	RNF5P1	6.28	7.47e-10	0.00141	0.6	0.28	Depression;	chr6:28297795	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.607	rs72854513	ENSG00000253570.1	RNF5P1	6.28	7.47e-10	0.00141	0.6	0.28	Depression;	chr6:28298177	chr8:38600661~38601200:-
LUAD	trans	rs17301013	0.932	rs6664764	ENSG00000213331.4	RP11-713C19.2	6.28	7.49e-10	0.00141	0.32	0.28	Systemic lupus erythematosus;	chr1:174443402	chr4:187970273~187971284:+
LUAD	trans	rs12477438	0.501	rs11692336	ENSG00000276576.1	MRPL30P1	6.28	7.55e-10	0.00142	0.31	0.28	Chronic sinus infection;	chr2:99124143	chr6:57029521~57029988:+
LUAD	trans	rs35491132	1	rs35491132	ENSG00000253570.1	RNF5P1	6.28	7.61e-10	0.00143	0.58	0.28	Urinary tract infection frequency;	chr6:27559449	chr8:38600661~38601200:-
LUAD	trans	rs7647973	1	rs1009051	ENSG00000197582.5	GPX1P1	6.28	7.61e-10	0.00143	0.37	0.28	Menarche (age at onset);	chr3:49484116	chrX:13378735~13379340:-
LUAD	trans	rs7647973	1	rs3870339	ENSG00000197582.5	GPX1P1	6.28	7.61e-10	0.00143	0.37	0.28	Menarche (age at onset);	chr3:49499430	chrX:13378735~13379340:-
LUAD	trans	rs853679	0.607	rs68188794	ENSG00000253570.1	RNF5P1	6.28	7.65e-10	0.00144	0.64	0.28	Depression;	chr6:28112999	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.546	rs13195291	ENSG00000253570.1	RNF5P1	6.28	7.68e-10	0.00145	0.62	0.28	Depression;	chr6:28201463	chr8:38600661~38601200:-
LUAD	trans	rs2060793	0.684	rs1597689	ENSG00000236360.2	RP11-334A14.2	6.28	7.68e-10	0.00145	0.36	0.28	Vitamin D levels;	chr11:14824638	chr1:52993201~52993702:-
LUAD	trans	rs4713118	0.824	rs2179095	ENSG00000204709.4	LINC01556	-6.28	7.68e-10	0.00145	-0.36	-0.28	Parkinson's disease;	chr6:27783079	chr6:28943877~28944537:+
LUAD	trans	rs4713118	0.955	rs34752872	ENSG00000204709.4	LINC01556	6.28	7.72e-10	0.00145	0.37	0.28	Parkinson's disease;	chr6:27715465	chr6:28943877~28944537:+
LUAD	trans	rs853679	0.546	rs200954	ENSG00000204709.4	LINC01556	6.28	7.73e-10	0.00146	0.52	0.28	Depression;	chr6:27870986	chr6:28943877~28944537:+
LUAD	trans	rs9393777	0.92	rs67859638	ENSG00000253570.1	RNF5P1	6.28	7.74e-10	0.00146	0.61	0.28	Intelligence (multi-trait analysis);	chr6:27390199	chr8:38600661~38601200:-
LUAD	trans	rs837841	0.864	rs1660903	ENSG00000233762.3	AC007969.5	-6.27	7.83e-10	0.00147	-0.23	-0.28	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);	chr2:129289106	chr2:171517270~171517716:-
LUAD	trans	rs864643	0.678	rs568085	ENSG00000183298.5	RP11-556K13.1	6.27	7.83e-10	0.00147	0.39	0.28	Attention deficit hyperactivity disorder;	chr3:39472661	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.625	rs628725	ENSG00000183298.5	RP11-556K13.1	6.27	7.83e-10	0.00147	0.39	0.28	Attention deficit hyperactivity disorder;	chr3:39472887	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.625	rs570136	ENSG00000183298.5	RP11-556K13.1	6.27	7.83e-10	0.00147	0.39	0.28	Attention deficit hyperactivity disorder;	chr3:39472922	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.678	rs7615732	ENSG00000183298.5	RP11-556K13.1	6.27	7.83e-10	0.00147	0.39	0.28	Attention deficit hyperactivity disorder;	chr3:39473732	chr1:101786340~101787219:-
LUAD	trans	rs9393777	0.841	rs34332556	ENSG00000204709.4	LINC01556	6.27	7.88e-10	0.00148	0.54	0.28	Intelligence (multi-trait analysis);	chr6:27389635	chr6:28943877~28944537:+
LUAD	trans	rs853679	0.607	rs13207345	ENSG00000281831.1	HCP5B	6.27	8.02e-10	0.00151	0.6	0.27	Depression;	chr6:28297795	chr6:29871895~29873783:-
LUAD	trans	rs853679	0.607	rs72854513	ENSG00000281831.1	HCP5B	6.27	8.02e-10	0.00151	0.6	0.27	Depression;	chr6:28298177	chr6:29871895~29873783:-
LUAD	trans	rs12439619	0.693	rs4778989	ENSG00000259295.5	CSPG4P12	-6.27	8.03e-10	0.00151	-0.38	-0.27	Intelligence (multi-trait analysis);	chr15:82276963	chr15:85191438~85213905:+
LUAD	trans	rs9467773	0.595	rs2237236	ENSG00000242375.1	RP11-498P14.3	-6.27	8.04e-10	0.00151	-0.36	-0.27	Intelligence (multi-trait analysis);	chr6:26451325	chr9:97195351~97197687:-
LUAD	trans	rs1040555	0.516	rs242547	ENSG00000253915.1	MAPRE1P1	6.27	8.05e-10	0.00151	0.32	0.27	Lymphocyte percentage of white cells;	chr20:32830775	chr8:135625185~135625981:-
LUAD	trans	rs10420951	0.617	rs2303694	ENSG00000267533.1	RP11-815J4.7	6.27	8.05e-10	0.00151	0.49	0.27	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18451628	chr18:12067173~12068417:-
LUAD	trans	rs10420951	0.617	rs79257623	ENSG00000267533.1	RP11-815J4.7	6.27	8.05e-10	0.00151	0.49	0.27	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18452904	chr18:12067173~12068417:-
LUAD	trans	rs10420951	0.617	rs8103520	ENSG00000267533.1	RP11-815J4.7	6.27	8.05e-10	0.00151	0.49	0.27	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18453160	chr18:12067173~12068417:-
LUAD	trans	rs10420951	0.617	rs3746176	ENSG00000267533.1	RP11-815J4.7	6.27	8.08e-10	0.00152	0.49	0.27	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18458141	chr18:12067173~12068417:-
LUAD	trans	rs10420951	0.617	rs79888481	ENSG00000267533.1	RP11-815J4.7	6.27	8.08e-10	0.00152	0.49	0.27	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18459147	chr18:12067173~12068417:-
LUAD	trans	rs1190596	0.525	rs6575901	ENSG00000181359.5	HSP90AA6P	-6.27	8.1e-10	0.00152	-0.3	-0.27	Behavioural disinhibition (generation interaction);	chr14:102225517	chr4:170581470~170605450:-
LUAD	trans	rs6499255	1	rs73579497	ENSG00000257513.6	NPIPB1P	6.27	8.1e-10	0.00152	0.33	0.27	IgE levels;	chr16:69790247	chr18:11619509~11639699:-
LUAD	trans	rs2243480	1	rs6460260	ENSG00000232546.1	RP11-458F8.1	6.27	8.14e-10	0.00153	0.37	0.27	Diabetic kidney disease;	chr7:65750468	chr7:66848496~66858136:+
LUAD	trans	rs2243480	1	rs6460261	ENSG00000232546.1	RP11-458F8.1	6.27	8.14e-10	0.00153	0.37	0.27	Diabetic kidney disease;	chr7:65750593	chr7:66848496~66858136:+
LUAD	trans	rs12145833	0.619	rs10927006	ENSG00000154608.12	CEP170P1	-6.27	8.17e-10	0.00153	-0.48	-0.27	Obesity (early onset extreme);	chr1:243394357	chr4:118467590~118554204:+
LUAD	trans	rs7647973	0.925	rs9881860	ENSG00000197582.5	GPX1P1	6.27	8.17e-10	0.00153	0.38	0.27	Menarche (age at onset);	chr3:49315089	chrX:13378735~13379340:-
LUAD	trans	rs853679	0.546	rs35016036	ENSG00000253570.1	RNF5P1	6.27	8.2e-10	0.00154	0.62	0.27	Depression;	chr6:28347103	chr8:38600661~38601200:-
LUAD	trans	rs7833986	0.501	rs2667981	ENSG00000244245.1	RP11-120B7.1	6.27	8.24e-10	0.00155	0.33	0.27	Height;	chr8:55981744	chr5:108593609~108593967:+
LUAD	trans	rs7833986	0.501	rs2719245	ENSG00000244245.1	RP11-120B7.1	6.27	8.24e-10	0.00155	0.33	0.27	Height;	chr8:55981800	chr5:108593609~108593967:+
LUAD	trans	rs1383484	0.754	rs11259927	ENSG00000278603.1	RP13-608F4.5	6.27	8.24e-10	0.00155	0.37	0.27	Height;	chr15:83897792	chr15:82472203~82472426:+
LUAD	trans	rs7647973	1	rs13088309	ENSG00000197582.5	GPX1P1	6.27	8.25e-10	0.00155	0.38	0.27	Menarche (age at onset);	chr3:49330884	chrX:13378735~13379340:-
LUAD	trans	rs7833986	0.501	rs9650314	ENSG00000244245.1	RP11-120B7.1	6.26	8.29e-10	0.00155	0.33	0.27	Height;	chr8:55991051	chr5:108593609~108593967:+
LUAD	trans	rs7833986	0.534	rs72653924	ENSG00000244245.1	RP11-120B7.1	6.26	8.29e-10	0.00155	0.33	0.27	Height;	chr8:55993529	chr5:108593609~108593967:+
LUAD	trans	rs7833986	0.534	rs2667972	ENSG00000244245.1	RP11-120B7.1	6.26	8.29e-10	0.00155	0.33	0.27	Height;	chr8:55994102	chr5:108593609~108593967:+
LUAD	trans	rs79149102	0.522	rs117774781	ENSG00000227288.3	RP5-837I24.1	6.26	8.31e-10	0.00156	0.5	0.27	Lung cancer;	chr15:74480109	chr1:81501794~81503468:+
LUAD	trans	rs7554511	0.535	rs10920090	ENSG00000244144.1	RP11-757F18.3	-6.26	8.34e-10	0.00156	-0.33	-0.27	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201003326	chr3:112185480~112185998:-
LUAD	trans	rs1190596	0.526	rs8003556	ENSG00000181359.5	HSP90AA6P	-6.26	8.37e-10	0.00157	-0.3	-0.27	Behavioural disinhibition (generation interaction);	chr14:102193330	chr4:170581470~170605450:-
LUAD	trans	rs7937890	0.559	rs1116739	ENSG00000236360.2	RP11-334A14.2	6.26	8.42e-10	0.00158	0.35	0.27	Mitochondrial DNA levels;	chr11:14467636	chr1:52993201~52993702:-
LUAD	trans	rs4713118	0.868	rs760587	ENSG00000204709.4	LINC01556	6.26	8.43e-10	0.00158	0.39	0.27	Parkinson's disease;	chr6:27772521	chr6:28943877~28944537:+
LUAD	trans	rs6424115	0.729	rs561733	ENSG00000228217.1	AL390877.1	-6.26	8.51e-10	0.00159	-0.35	-0.27	Immature fraction of reticulocytes;	chr1:23723105	chr1:117778087~117778506:-
LUAD	trans	rs17301013	0.932	rs10912804	ENSG00000213331.4	RP11-713C19.2	6.26	8.51e-10	0.00159	0.32	0.27	Systemic lupus erythematosus;	chr1:174527412	chr4:187970273~187971284:+
LUAD	trans	rs17301013	0.9	rs12088073	ENSG00000213331.4	RP11-713C19.2	6.26	8.51e-10	0.00159	0.32	0.27	Systemic lupus erythematosus;	chr1:174528504	chr4:187970273~187971284:+
LUAD	trans	rs4713118	0.955	rs9468200	ENSG00000204709.4	LINC01556	6.26	8.53e-10	0.0016	0.37	0.27	Parkinson's disease;	chr6:27715284	chr6:28943877~28944537:+
LUAD	trans	rs7260598	0.786	rs59387271	ENSG00000261770.1	CTC-459F4.1	6.26	8.56e-10	0.0016	0.46	0.27	Response to taxane treatment (placlitaxel);	chr19:24009130	chr19:27757184~27760849:-
LUAD	trans	rs6831352	0.819	rs896992	ENSG00000233859.2	ADH5P4	-6.26	8.56e-10	0.0016	-0.3	-0.27	Alcohol dependence;	chr4:99081221	chr6:65836930~65838039:-
LUAD	trans	rs6499255	0.951	rs60099379	ENSG00000257513.6	NPIPB1P	6.26	8.57e-10	0.0016	0.33	0.27	IgE levels;	chr16:69548201	chr18:11619509~11639699:-
LUAD	trans	rs7833986	0.501	rs72653953	ENSG00000236862.1	RPS20P24	6.26	8.58e-10	0.00161	0.34	0.27	Height;	chr8:56058236	chr9:72655832~72656192:-
LUAD	trans	rs7647973	1	rs7619789	ENSG00000197582.5	GPX1P1	6.26	8.59e-10	0.00161	0.37	0.27	Menarche (age at onset);	chr3:49438830	chrX:13378735~13379340:-
LUAD	trans	rs7833986	0.501	rs2976038	ENSG00000244245.1	RP11-120B7.1	6.26	8.67e-10	0.00162	0.32	0.27	Height;	chr8:56116305	chr5:108593609~108593967:+
LUAD	trans	rs12145833	0.619	rs12132986	ENSG00000154608.12	CEP170P1	-6.26	8.68e-10	0.00162	-0.47	-0.27	Obesity (early onset extreme);	chr1:243429295	chr4:118467590~118554204:+
LUAD	trans	rs7647973	1	rs9862534	ENSG00000197582.5	GPX1P1	6.26	8.7e-10	0.00163	0.37	0.27	Menarche (age at onset);	chr3:49560631	chrX:13378735~13379340:-
LUAD	trans	rs7833986	0.501	rs2667983	ENSG00000244245.1	RP11-120B7.1	6.26	8.73e-10	0.00163	0.33	0.27	Height;	chr8:55981528	chr5:108593609~108593967:+
LUAD	trans	rs12439619	0.508	rs8042665	ENSG00000259295.5	CSPG4P12	-6.26	8.74e-10	0.00163	-0.31	-0.27	Intelligence (multi-trait analysis);	chr15:82189008	chr15:85191438~85213905:+
LUAD	trans	rs877636	0.702	rs773109	ENSG00000223416.3	RPS26P15	6.26	8.76e-10	0.00164	0.29	0.27	Cognitive function;	chr12:55980911	chr1:58056133~58056480:-
LUAD	trans	rs12477438	0.501	rs1133977	ENSG00000276576.1	MRPL30P1	-6.26	8.78e-10	0.00164	-0.31	-0.27	Chronic sinus infection;	chr2:99125521	chr6:57029521~57029988:+
LUAD	trans	rs7746199	0.736	rs72845070	ENSG00000253570.1	RNF5P1	6.25	8.86e-10	0.00166	0.61	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27700521	chr8:38600661~38601200:-
LUAD	trans	rs10037055	0.687	rs6556308	ENSG00000228305.2	AC016734.2	-6.25	8.93e-10	0.00167	-0.31	-0.27	Migraine without aura;	chr5:177219700	chr2:63622178~63622831:-
LUAD	trans	rs58106596	0.747	rs10166046	ENSG00000259020.3	RP11-529H20.3	-6.25	8.94e-10	0.00167	-0.35	-0.27	Lymphocyte counts;White blood cell count;	chr2:231696274	chr14:92026566~92026887:+
LUAD	trans	rs66887589	0.627	rs3872807	ENSG00000275858.1	RP11-291L22.8	6.25	8.94e-10	0.00167	0.29	0.27	Diastolic blood pressure;	chr4:119439096	chr10:38450738~38451069:-
LUAD	trans	rs916888	0.821	rs199513	ENSG00000204650.12	CRHR1-IT1	-6.25	8.94e-10	0.00167	-0.36	-0.27	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45620328~45648216:+
LUAD	trans	rs7833986	0.501	rs72653917	ENSG00000244245.1	RP11-120B7.1	6.25	8.96e-10	0.00167	0.33	0.27	Height;	chr8:55980285	chr5:108593609~108593967:+
LUAD	trans	rs4713118	0.911	rs2394000	ENSG00000204709.4	LINC01556	6.25	9.02e-10	0.00169	0.37	0.27	Parkinson's disease;	chr6:27719212	chr6:28943877~28944537:+
LUAD	trans	rs4713118	0.955	rs9393847	ENSG00000204709.4	LINC01556	6.25	9.02e-10	0.00169	0.37	0.27	Parkinson's disease;	chr6:27720194	chr6:28943877~28944537:+
LUAD	trans	rs7618501	1	rs2271961	ENSG00000197582.5	GPX1P1	-6.25	9.11e-10	0.0017	-0.34	-0.27	Intelligence (multi-trait analysis);	chr3:49840680	chrX:13378735~13379340:-
LUAD	trans	rs3096299	0.632	rs4399533	ENSG00000215030.5	RPL13P12	-6.25	9.16e-10	0.00171	-0.3	-0.27	Multiple myeloma (IgH translocation);	chr16:89472974	chr17:17383377~17384012:-
LUAD	trans	rs7746199	0.736	rs13195636	ENSG00000253570.1	RNF5P1	6.25	9.22e-10	0.00172	0.58	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27541714	chr8:38600661~38601200:-
LUAD	trans	rs73108077	0.736	rs6119831	ENSG00000279352.1	RP11-411B10.7	6.25	9.25e-10	0.00173	0.45	0.27	Red blood cell density in sickle cell anemia;	chr20:31328473	chr18:14010054~14010917:+
LUAD	trans	rs11512640	1	rs11220138	ENSG00000236257.1	EI24P2	6.25	9.27e-10	0.00173	0.59	0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125585927	chr1:158454198~158455273:+
LUAD	trans	rs4276421	0.53	rs62371973	ENSG00000231752.4	EMBP1	6.25	9.29e-10	0.00173	0.44	0.27	P wave duration;	chr5:45907824	chr1:121519112~121571892:+
LUAD	trans	rs453301	0.571	rs2929453	ENSG00000253893.2	FAM85B	6.25	9.3e-10	0.00173	0.35	0.27	Joint mobility (Beighton score);	chr8:9226831	chr8:8167819~8226614:-
LUAD	trans	rs73108077	0.736	rs6058492	ENSG00000279352.1	RP11-411B10.7	6.24	9.34e-10	0.00174	0.46	0.27	Red blood cell density in sickle cell anemia;	chr20:31286965	chr18:14010054~14010917:+
LUAD	trans	rs6499255	0.951	rs11075728	ENSG00000257513.6	NPIPB1P	6.24	9.35e-10	0.00174	0.32	0.27	IgE levels;	chr16:69577679	chr18:11619509~11639699:-
LUAD	trans	rs9393777	0.92	rs34071253	ENSG00000204709.4	LINC01556	6.24	9.38e-10	0.00175	0.53	0.27	Intelligence (multi-trait analysis);	chr6:27424023	chr6:28943877~28944537:+
LUAD	trans	rs853679	0.546	rs483143	ENSG00000204709.4	LINC01556	6.24	9.43e-10	0.00176	0.54	0.27	Depression;	chr6:27878966	chr6:28943877~28944537:+
LUAD	trans	rs66887589	0.56	rs9684327	ENSG00000275858.1	RP11-291L22.8	6.24	9.48e-10	0.00177	0.29	0.27	Diastolic blood pressure;	chr4:119444286	chr10:38450738~38451069:-
LUAD	trans	rs17301013	0.896	rs13375788	ENSG00000213331.4	RP11-713C19.2	6.24	9.51e-10	0.00177	0.32	0.27	Systemic lupus erythematosus;	chr1:174524207	chr4:187970273~187971284:+
LUAD	trans	rs4713118	0.826	rs2893929	ENSG00000204709.4	LINC01556	6.24	9.55e-10	0.00178	0.38	0.27	Parkinson's disease;	chr6:27770953	chr6:28943877~28944537:+
LUAD	trans	rs4713118	0.666	rs4140646	ENSG00000204709.4	LINC01556	6.24	9.55e-10	0.00178	0.38	0.27	Parkinson's disease;	chr6:27771022	chr6:28943877~28944537:+
LUAD	trans	rs4713118	0.666	rs2893930	ENSG00000204709.4	LINC01556	6.24	9.55e-10	0.00178	0.38	0.27	Parkinson's disease;	chr6:27771027	chr6:28943877~28944537:+
LUAD	trans	rs6499255	0.951	rs56282083	ENSG00000257513.6	NPIPB1P	6.24	9.55e-10	0.00178	0.32	0.27	IgE levels;	chr16:69791825	chr18:11619509~11639699:-
LUAD	trans	rs7833986	0.534	rs17814089	ENSG00000236862.1	RPS20P24	-6.24	9.62e-10	0.00179	-0.33	-0.27	Height;	chr8:56053004	chr9:72655832~72656192:-
LUAD	trans	rs9584850	0.874	rs3742137	ENSG00000230079.1	STK24P1	6.24	9.62e-10	0.00179	0.32	0.27	Neuroticism;	chr13:98450195	chrX:136295690~136300298:-
LUAD	trans	rs71537559	1	rs71537559	ENSG00000204709.4	LINC01556	6.24	9.63e-10	0.00179	0.55	0.27	Squamous cell lung carcinoma;	chr6:27342000	chr6:28943877~28944537:+
LUAD	trans	rs853679	0.607	rs67040724	ENSG00000204709.4	LINC01556	6.24	9.69e-10	0.00181	0.61	0.27	Depression;	chr6:27937731	chr6:28943877~28944537:+
LUAD	trans	rs79149102	0.522	rs28854237	ENSG00000227288.3	RP5-837I24.1	6.24	9.73e-10	0.00181	0.5	0.27	Lung cancer;	chr15:74511279	chr1:81501794~81503468:+
LUAD	trans	rs13016963	0.506	rs11684505	ENSG00000235105.1	RP11-329A14.1	6.24	9.8e-10	0.00182	0.32	0.27	Esophageal squamous cell carcinoma;Melanoma;	chr2:201376440	chr1:48435967~48437223:+
LUAD	trans	rs7618501	1	rs9859153	ENSG00000197582.5	GPX1P1	6.24	9.81e-10	0.00183	0.34	0.27	Intelligence (multi-trait analysis);	chr3:49769652	chrX:13378735~13379340:-
LUAD	trans	rs7769051	1	rs7769051	ENSG00000227615.1	RP11-864N7.2	6.24	9.81e-10	0.00183	0.44	0.27	Type 2 diabetes nephropathy;	chr6:132825657	chr11:74745716~74746114:-
LUAD	trans	rs2060793	0.741	rs10741653	ENSG00000236360.2	RP11-334A14.2	6.24	9.86e-10	0.00184	0.35	0.27	Vitamin D levels;	chr11:14683294	chr1:52993201~52993702:-
LUAD	trans	rs6831352	0.819	rs13832	ENSG00000233859.2	ADH5P4	-6.24	9.87e-10	0.00184	-0.3	-0.27	Alcohol dependence;	chr4:99071924	chr6:65836930~65838039:-
LUAD	trans	rs2243480	0.908	rs4718273	ENSG00000232546.1	RP11-458F8.1	6.24	9.88e-10	0.00184	0.37	0.27	Diabetic kidney disease;	chr7:65751112	chr7:66848496~66858136:+
LUAD	trans	rs12477438	0.501	rs17759607	ENSG00000276576.1	MRPL30P1	6.24	9.89e-10	0.00184	0.31	0.27	Chronic sinus infection;	chr2:99120542	chr6:57029521~57029988:+
LUAD	trans	rs9584850	0.834	rs12463	ENSG00000230079.1	STK24P1	6.23	9.94e-10	0.00185	0.32	0.27	Neuroticism;	chr13:98453048	chrX:136295690~136300298:-
LUAD	trans	rs9584850	0.834	rs8481	ENSG00000230079.1	STK24P1	6.23	9.94e-10	0.00185	0.32	0.27	Neuroticism;	chr13:98453141	chrX:136295690~136300298:-
LUAD	trans	rs7746199	0.736	rs13209332	ENSG00000253570.1	RNF5P1	6.23	9.95e-10	0.00185	0.58	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27552973	chr8:38600661~38601200:-
LUAD	trans	rs7746199	0.736	rs34965299	ENSG00000253570.1	RNF5P1	6.23	9.95e-10	0.00185	0.58	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27554077	chr8:38600661~38601200:-
LUAD	trans	rs2250402	0.51	rs2291619	ENSG00000234106.3	RP11-288E14.2	-6.23	1e-09	0.00186	-0.42	-0.27	Corneal curvature;	chr15:40036832	chr11:93535468~93535816:+
LUAD	trans	rs73108077	0.736	rs13433373	ENSG00000279352.1	RP11-411B10.7	6.23	1.01e-09	0.00187	0.45	0.27	Red blood cell density in sickle cell anemia;	chr20:31296736	chr18:14010054~14010917:+
LUAD	trans	rs73108077	0.688	rs6061150	ENSG00000279352.1	RP11-411B10.7	6.23	1.01e-09	0.00187	0.45	0.27	Red blood cell density in sickle cell anemia;	chr20:31301527	chr18:14010054~14010917:+
LUAD	trans	rs3096299	0.728	rs1011749	ENSG00000215030.5	RPL13P12	-6.23	1.01e-09	0.00187	-0.31	-0.27	Multiple myeloma (IgH translocation);	chr16:89444461	chr17:17383377~17384012:-
LUAD	trans	rs3956705	0.762	rs13437980	ENSG00000176826.14	FKBP9P1	-6.23	1.01e-09	0.00188	-0.34	-0.27	Red cell distribution width;	chr7:32958137	chr7:55681074~55713252:-
LUAD	trans	rs9467773	0.595	rs3846845	ENSG00000242375.1	RP11-498P14.3	-6.23	1.01e-09	0.00188	-0.36	-0.27	Intelligence (multi-trait analysis);	chr6:26444687	chr9:97195351~97197687:-
LUAD	trans	rs9467773	0.572	rs3846846	ENSG00000242375.1	RP11-498P14.3	-6.23	1.01e-09	0.00188	-0.36	-0.27	Intelligence (multi-trait analysis);	chr6:26444811	chr9:97195351~97197687:-
LUAD	trans	rs73108077	0.736	rs6119276	ENSG00000279352.1	RP11-411B10.7	6.23	1.01e-09	0.00188	0.45	0.27	Red blood cell density in sickle cell anemia;	chr20:31363733	chr18:14010054~14010917:+
LUAD	trans	rs6499255	0.951	rs10454066	ENSG00000257513.6	NPIPB1P	6.23	1.01e-09	0.00189	0.32	0.27	IgE levels;	chr16:69665102	chr18:11619509~11639699:-
LUAD	trans	rs7647973	1	rs940045	ENSG00000197582.5	GPX1P1	6.23	1.02e-09	0.00189	0.37	0.27	Menarche (age at onset);	chr3:49412205	chrX:13378735~13379340:-
LUAD	trans	rs673253	0.597	rs58097944	ENSG00000231007.5	CDC20P1	6.23	1.02e-09	0.00189	0.33	0.27	Intelligence (multi-trait analysis);	chr1:43589323	chr9:87011652~87013151:+
LUAD	trans	rs6499255	0.951	rs11641233	ENSG00000257513.6	NPIPB1P	6.23	1.02e-09	0.00189	0.32	0.27	IgE levels;	chr16:69700660	chr18:11619509~11639699:-
LUAD	trans	rs864643	0.524	rs6810264	ENSG00000183298.5	RP11-556K13.1	6.23	1.02e-09	0.00189	0.46	0.27	Attention deficit hyperactivity disorder;	chr3:39471605	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.524	rs11706953	ENSG00000183298.5	RP11-556K13.1	6.23	1.02e-09	0.00189	0.46	0.27	Attention deficit hyperactivity disorder;	chr3:39472119	chr1:101786340~101787219:-
LUAD	trans	rs740160	0.558	rs12538893	ENSG00000228834.1	RP11-249L21.4	6.23	1.02e-09	0.0019	0.52	0.27	Dehydroepiandrosterone sulphate levels;	chr7:99310874	chr6:108907615~108907873:-
LUAD	trans	rs6424115	0.76	rs2999566	ENSG00000228217.1	AL390877.1	-6.23	1.02e-09	0.0019	-0.35	-0.27	Immature fraction of reticulocytes;	chr1:23724634	chr1:117778087~117778506:-
LUAD	trans	rs7746199	0.736	rs34573979	ENSG00000253570.1	RNF5P1	6.23	1.02e-09	0.0019	0.57	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27512747	chr8:38600661~38601200:-
LUAD	trans	rs3096299	0.692	rs4785565	ENSG00000215030.5	RPL13P12	-6.23	1.03e-09	0.0019	-0.3	-0.27	Multiple myeloma (IgH translocation);	chr16:89449351	chr17:17383377~17384012:-
LUAD	trans	rs853679	0.546	rs71537572	ENSG00000281831.1	HCP5B	6.23	1.03e-09	0.00191	0.61	0.27	Depression;	chr6:28002937	chr6:29871895~29873783:-
LUAD	trans	rs7212590	0.881	rs7216675	ENSG00000187870.7	RNFT1P3	6.23	1.03e-09	0.00191	0.58	0.27	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59805313	chr17:20743333~20754501:-
LUAD	trans	rs7212590	1	rs73315284	ENSG00000187870.7	RNFT1P3	6.23	1.03e-09	0.00191	0.58	0.27	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59807507	chr17:20743333~20754501:-
LUAD	trans	rs7212590	1	rs7212590	ENSG00000187870.7	RNFT1P3	6.23	1.03e-09	0.00191	0.58	0.27	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59808348	chr17:20743333~20754501:-
LUAD	trans	rs67340775	0.834	rs13218875	ENSG00000204709.4	LINC01556	6.23	1.03e-09	0.00191	0.6	0.27	Lung cancer in ever smokers;	chr6:27916234	chr6:28943877~28944537:+
LUAD	trans	rs13014235	0.652	rs6435080	ENSG00000235105.1	RP11-329A14.1	6.23	1.03e-09	0.00191	0.32	0.27	Basal cell carcinoma;	chr2:201341597	chr1:48435967~48437223:+
LUAD	trans	rs2899832	0.568	rs77796720	ENSG00000229083.1	PSMA6P2	6.23	1.03e-09	0.00192	0.42	0.27	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35314500	chrX:12825840~12826833:+
LUAD	trans	rs17507216	1	rs17356118	ENSG00000235370.6	DNM1P51	-6.23	1.03e-09	0.00192	-0.36	-0.27	Excessive daytime sleepiness;	chr15:82569149	chr15:84398316~84411701:-
LUAD	trans	rs7769051	0.808	rs1467404	ENSG00000227615.1	RP11-864N7.2	-6.23	1.03e-09	0.00192	-0.42	-0.27	Type 2 diabetes nephropathy;	chr6:132769002	chr11:74745716~74746114:-
LUAD	trans	rs3096299	0.719	rs2965817	ENSG00000215030.5	RPL13P12	-6.23	1.04e-09	0.00193	-0.3	-0.27	Multiple myeloma (IgH translocation);	chr16:89446826	chr17:17383377~17384012:-
LUAD	trans	rs877636	0.702	rs773108	ENSG00000227586.5	RP11-162A23.5	6.23	1.04e-09	0.00193	0.33	0.27	Cognitive function;	chr12:55976127	chr10:123171535~123171875:-
LUAD	trans	rs7618501	0.966	rs2246832	ENSG00000197582.5	GPX1P1	6.23	1.04e-09	0.00194	0.35	0.27	Intelligence (multi-trait analysis);	chr3:49843701	chrX:13378735~13379340:-
LUAD	trans	rs11172055	0.902	rs10783807	ENSG00000121089.4	NACA3P	-6.22	1.05e-09	0.00195	-0.32	-0.27	Migraine;	chr12:56872529	chr4:164943290~164943937:+
LUAD	trans	rs714543	0.811	rs13238404	ENSG00000226038.5	PPIAP21	6.22	1.06e-09	0.00196	0.31	0.27	Plateletcrit;	chr7:44811812	chr20:43230760~43231260:+
LUAD	trans	rs7618501	0.966	rs13085679	ENSG00000197582.5	GPX1P1	6.22	1.07e-09	0.00198	0.35	0.27	Intelligence (multi-trait analysis);	chr3:49832198	chrX:13378735~13379340:-
LUAD	trans	rs2243480	1	rs4718270	ENSG00000232546.1	RP11-458F8.1	-6.22	1.08e-09	0.00199	-0.36	-0.27	Diabetic kidney disease;	chr7:65737415	chr7:66848496~66858136:+
LUAD	trans	rs2243480	0.901	rs2900904	ENSG00000232546.1	RP11-458F8.1	-6.22	1.08e-09	0.00199	-0.36	-0.27	Diabetic kidney disease;	chr7:65739282	chr7:66848496~66858136:+
LUAD	trans	rs877636	1	rs4759229	ENSG00000223416.3	RPS26P15	-6.22	1.08e-09	0.002	-0.28	-0.27	Cognitive function;	chr12:56080696	chr1:58056133~58056480:-
LUAD	trans	rs10420951	0.579	rs75445489	ENSG00000267533.1	RP11-815J4.7	6.22	1.08e-09	0.002	0.49	0.27	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18460340	chr18:12067173~12068417:-
LUAD	trans	rs73108077	0.736	rs6058637	ENSG00000279352.1	RP11-411B10.7	6.22	1.08e-09	0.00201	0.45	0.27	Red blood cell density in sickle cell anemia;	chr20:31325430	chr18:14010054~14010917:+
LUAD	trans	rs73108077	0.736	rs6057561	ENSG00000279352.1	RP11-411B10.7	6.22	1.08e-09	0.00201	0.45	0.27	Red blood cell density in sickle cell anemia;	chr20:31327238	chr18:14010054~14010917:+
LUAD	trans	rs9393777	0.844	rs28360634	ENSG00000204709.4	LINC01556	6.22	1.09e-09	0.00201	0.53	0.27	Intelligence (multi-trait analysis);	chr6:27365112	chr6:28943877~28944537:+
LUAD	trans	rs6499255	0.951	rs689455	ENSG00000257513.6	NPIPB1P	6.22	1.09e-09	0.00202	0.33	0.27	IgE levels;	chr16:69727758	chr18:11619509~11639699:-
LUAD	trans	rs73108077	0.736	rs6119830	ENSG00000279352.1	RP11-411B10.7	6.22	1.1e-09	0.00203	0.45	0.27	Red blood cell density in sickle cell anemia;	chr20:31327636	chr18:14010054~14010917:+
LUAD	trans	rs7260598	0.892	rs58931976	ENSG00000261770.1	CTC-459F4.1	6.22	1.1e-09	0.00203	0.45	0.27	Response to taxane treatment (placlitaxel);	chr19:24008247	chr19:27757184~27760849:-
LUAD	trans	rs7260598	0.892	rs59831281	ENSG00000261770.1	CTC-459F4.1	6.22	1.1e-09	0.00203	0.45	0.27	Response to taxane treatment (placlitaxel);	chr19:24008258	chr19:27757184~27760849:-
LUAD	trans	rs9584850	0.874	rs7988959	ENSG00000230079.1	STK24P1	6.22	1.11e-09	0.00204	0.32	0.27	Neuroticism;	chr13:98451750	chrX:136295690~136300298:-
LUAD	trans	rs7930295	0.556	rs9704355	ENSG00000236257.1	EI24P2	6.22	1.11e-09	0.00205	0.37	0.27	Schizophrenia;	chr11:125478435	chr1:158454198~158455273:+
LUAD	trans	rs889398	0.715	rs13330951	ENSG00000257513.6	NPIPB1P	6.22	1.11e-09	0.00205	0.26	0.27	Body mass index;	chr16:69529939	chr18:11619509~11639699:-
LUAD	trans	rs7746199	0.736	rs13202291	ENSG00000253570.1	RNF5P1	6.22	1.11e-09	0.00205	0.57	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731078	chr8:38600661~38601200:-
LUAD	trans	rs7746199	0.736	rs17750424	ENSG00000253570.1	RNF5P1	6.22	1.11e-09	0.00205	0.57	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27733343	chr8:38600661~38601200:-
LUAD	trans	rs7746199	0.736	rs13193542	ENSG00000253570.1	RNF5P1	6.22	1.11e-09	0.00205	0.57	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734646	chr8:38600661~38601200:-
LUAD	trans	rs7746199	0.736	rs13193480	ENSG00000253570.1	RNF5P1	6.22	1.11e-09	0.00205	0.57	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734782	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.556	rs34706883	ENSG00000253570.1	RNF5P1	6.22	1.11e-09	0.00206	0.59	0.27	Depression;	chr6:27837477	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.546	rs35819751	ENSG00000253570.1	RNF5P1	6.22	1.11e-09	0.00206	0.59	0.27	Depression;	chr6:27842791	chr8:38600661~38601200:-
LUAD	trans	rs13201294	1	rs13201294	ENSG00000204709.4	LINC01556	6.21	1.12e-09	0.00207	0.51	0.27	Squamous cell lung carcinoma;	chr6:27588362	chr6:28943877~28944537:+
LUAD	trans	rs2060793	0.741	rs7119073	ENSG00000236360.2	RP11-334A14.2	6.21	1.12e-09	0.00207	0.35	0.27	Vitamin D levels;	chr11:14669416	chr1:52993201~52993702:-
LUAD	trans	rs4713118	0.869	rs9283883	ENSG00000204709.4	LINC01556	6.21	1.12e-09	0.00207	0.37	0.27	Parkinson's disease;	chr6:27747691	chr6:28943877~28944537:+
LUAD	trans	rs12477438	0.559	rs6733285	ENSG00000276576.1	MRPL30P1	6.21	1.13e-09	0.00209	0.31	0.27	Chronic sinus infection;	chr2:99109112	chr6:57029521~57029988:+
LUAD	trans	rs864643	0.678	rs1768206	ENSG00000183298.5	RP11-556K13.1	6.21	1.15e-09	0.00212	0.4	0.27	Attention deficit hyperactivity disorder;	chr3:39480342	chr1:101786340~101787219:-
LUAD	trans	rs9584850	0.794	rs9630321	ENSG00000230079.1	STK24P1	6.21	1.15e-09	0.00212	0.31	0.27	Neuroticism;	chr13:98454725	chrX:136295690~136300298:-
LUAD	trans	rs2243480	1	rs3885839	ENSG00000232546.1	RP11-458F8.1	-6.21	1.15e-09	0.00213	-0.37	-0.27	Diabetic kidney disease;	chr7:65825416	chr7:66848496~66858136:+
LUAD	trans	rs2243480	0.901	rs3813708	ENSG00000232546.1	RP11-458F8.1	-6.21	1.15e-09	0.00213	-0.37	-0.27	Diabetic kidney disease;	chr7:65840645	chr7:66848496~66858136:+
LUAD	trans	rs2243480	1	rs73142122	ENSG00000232546.1	RP11-458F8.1	-6.21	1.15e-09	0.00213	-0.37	-0.27	Diabetic kidney disease;	chr7:65846311	chr7:66848496~66858136:+
LUAD	trans	rs864643	0.678	rs1768201	ENSG00000183298.5	RP11-556K13.1	6.21	1.15e-09	0.00213	0.39	0.27	Attention deficit hyperactivity disorder;	chr3:39476050	chr1:101786340~101787219:-
LUAD	trans	rs7647973	1	rs1464569	ENSG00000197582.5	GPX1P1	6.21	1.17e-09	0.00215	0.37	0.27	Menarche (age at onset);	chr3:49422917	chrX:13378735~13379340:-
LUAD	trans	rs860295	0.5	rs34995046	ENSG00000241627.3	UBQLN4P1	6.21	1.17e-09	0.00215	0.26	0.27	Body mass index;	chr1:156018694	chr3:148985868~148987668:-
LUAD	trans	rs7647973	1	rs6805609	ENSG00000197582.5	GPX1P1	-6.21	1.17e-09	0.00216	-0.41	-0.27	Menarche (age at onset);	chr3:49434089	chrX:13378735~13379340:-
LUAD	trans	rs864643	0.678	rs1768203	ENSG00000183298.5	RP11-556K13.1	6.21	1.17e-09	0.00216	0.39	0.27	Attention deficit hyperactivity disorder;	chr3:39476377	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.678	rs1708100	ENSG00000183298.5	RP11-556K13.1	6.21	1.17e-09	0.00216	0.39	0.27	Attention deficit hyperactivity disorder;	chr3:39476400	chr1:101786340~101787219:-
LUAD	trans	rs4713118	0.868	rs742047	ENSG00000204709.4	LINC01556	6.21	1.17e-09	0.00216	0.38	0.27	Parkinson's disease;	chr6:27771601	chr6:28943877~28944537:+
LUAD	trans	rs17301013	0.932	rs1653632	ENSG00000213331.4	RP11-713C19.2	-6.2	1.18e-09	0.00218	-0.32	-0.27	Systemic lupus erythematosus;	chr1:174786459	chr4:187970273~187971284:+
LUAD	trans	rs864643	0.625	rs602408	ENSG00000183298.5	RP11-556K13.1	6.2	1.19e-09	0.00219	0.39	0.27	Attention deficit hyperactivity disorder;	chr3:39493754	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.625	rs601925	ENSG00000183298.5	RP11-556K13.1	6.2	1.19e-09	0.00219	0.39	0.27	Attention deficit hyperactivity disorder;	chr3:39493871	chr1:101786340~101787219:-
LUAD	trans	rs12145833	1	rs12145004	ENSG00000154608.12	CEP170P1	-6.2	1.2e-09	0.00222	-0.49	-0.27	Obesity (early onset extreme);	chr1:243320063	chr4:118467590~118554204:+
LUAD	trans	rs73198271	1	rs11776513	ENSG00000273129.1	PACERR	6.2	1.22e-09	0.00224	0.36	0.27	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751547	chr1:186680622~186681446:+
LUAD	trans	rs7647973	1	rs974495	ENSG00000197582.5	GPX1P1	6.2	1.22e-09	0.00225	0.37	0.27	Menarche (age at onset);	chr3:49363049	chrX:13378735~13379340:-
LUAD	trans	rs7647973	1	rs11719762	ENSG00000197582.5	GPX1P1	6.2	1.22e-09	0.00225	0.37	0.27	Menarche (age at onset);	chr3:49371569	chrX:13378735~13379340:-
LUAD	trans	rs7647973	1	rs10155014	ENSG00000197582.5	GPX1P1	6.2	1.22e-09	0.00225	0.37	0.27	Menarche (age at onset);	chr3:49394888	chrX:13378735~13379340:-
LUAD	trans	rs7833986	0.534	rs17759244	ENSG00000236862.1	RPS20P24	6.2	1.22e-09	0.00225	0.33	0.27	Height;	chr8:56121209	chr9:72655832~72656192:-
LUAD	trans	rs3096299	0.719	rs12934708	ENSG00000215030.5	RPL13P12	-6.2	1.23e-09	0.00225	-0.3	-0.27	Multiple myeloma (IgH translocation);	chr16:89457382	chr17:17383377~17384012:-
LUAD	trans	rs13016963	0.546	rs10186527	ENSG00000235105.1	RP11-329A14.1	6.2	1.23e-09	0.00226	0.31	0.27	Esophageal squamous cell carcinoma;Melanoma;	chr2:201335852	chr1:48435967~48437223:+
LUAD	trans	rs4879656	0.564	rs1197774	ENSG00000215007.3	DNAJA1P3	6.2	1.23e-09	0.00226	0.31	0.27	Menopause (age at onset);	chr9:33001451	chrX:107351650~107352843:-
LUAD	trans	rs860295	0.5	rs12032631	ENSG00000241627.3	UBQLN4P1	6.2	1.23e-09	0.00226	0.26	0.27	Body mass index;	chr1:156025289	chr3:148985868~148987668:-
LUAD	trans	rs73198271	1	rs11775476	ENSG00000273129.1	PACERR	6.2	1.24e-09	0.00228	0.36	0.27	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8750359	chr1:186680622~186681446:+
LUAD	trans	rs73198271	1	rs73198279	ENSG00000273129.1	PACERR	6.2	1.24e-09	0.00228	0.36	0.27	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8750994	chr1:186680622~186681446:+
LUAD	trans	rs7833986	0.501	rs2719233	ENSG00000244245.1	RP11-120B7.1	6.2	1.25e-09	0.0023	0.34	0.27	Height;	chr8:55973597	chr5:108593609~108593967:+
LUAD	trans	rs9584850	0.915	rs7983438	ENSG00000230079.1	STK24P1	6.2	1.25e-09	0.0023	0.32	0.27	Neuroticism;	chr13:98451063	chrX:136295690~136300298:-
LUAD	trans	rs2243480	1	rs34702770	ENSG00000230295.1	RP11-458F8.2	-6.19	1.25e-09	0.0023	-0.34	-0.27	Diabetic kidney disease;	chr7:65879836	chr7:66880708~66882981:+
LUAD	trans	rs7746199	0.736	rs13210634	ENSG00000253570.1	RNF5P1	6.19	1.26e-09	0.00231	0.59	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27678713	chr8:38600661~38601200:-
LUAD	trans	rs7746199	0.736	rs13215275	ENSG00000253570.1	RNF5P1	6.19	1.26e-09	0.00231	0.59	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27679730	chr8:38600661~38601200:-
LUAD	trans	rs7746199	0.736	rs17749927	ENSG00000253570.1	RNF5P1	6.19	1.26e-09	0.00231	0.59	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27702197	chr8:38600661~38601200:-
LUAD	trans	rs7746199	0.736	rs13192965	ENSG00000253570.1	RNF5P1	6.19	1.26e-09	0.00231	0.59	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27704046	chr8:38600661~38601200:-
LUAD	trans	rs6499255	0.904	rs2161631	ENSG00000257513.6	NPIPB1P	6.19	1.26e-09	0.00231	0.32	0.27	IgE levels;	chr16:69523045	chr18:11619509~11639699:-
LUAD	trans	rs10037055	0.853	rs10035180	ENSG00000228305.2	AC016734.2	-6.19	1.26e-09	0.00232	-0.3	-0.27	Migraine without aura;	chr5:177171501	chr2:63622178~63622831:-
LUAD	trans	rs45509595	0.556	rs34409918	ENSG00000253570.1	RNF5P1	6.19	1.27e-09	0.00233	0.59	0.27	Breast cancer;	chr6:27717569	chr8:38600661~38601200:-
LUAD	trans	rs7746199	0.736	rs34064842	ENSG00000253570.1	RNF5P1	6.19	1.27e-09	0.00233	0.59	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27720846	chr8:38600661~38601200:-
LUAD	trans	rs7746199	0.736	rs13212318	ENSG00000253570.1	RNF5P1	6.19	1.27e-09	0.00233	0.59	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27721062	chr8:38600661~38601200:-
LUAD	trans	rs7260598	0.685	rs73524177	ENSG00000261770.1	CTC-459F4.1	6.19	1.28e-09	0.00235	0.43	0.27	Response to taxane treatment (placlitaxel);	chr19:24156376	chr19:27757184~27760849:-
LUAD	trans	rs9584850	0.874	rs4584	ENSG00000230079.1	STK24P1	6.19	1.28e-09	0.00235	0.31	0.27	Neuroticism;	chr13:98449615	chrX:136295690~136300298:-
LUAD	trans	rs889398	0.74	rs56096139	ENSG00000257513.6	NPIPB1P	-6.19	1.28e-09	0.00236	-0.26	-0.27	Body mass index;	chr16:69529509	chr18:11619509~11639699:-
LUAD	trans	rs867371	0.614	rs1814739	ENSG00000235370.6	DNM1P51	-6.19	1.29e-09	0.00237	-0.38	-0.27	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82234283	chr15:84398316~84411701:-
LUAD	trans	rs864643	0.678	rs1398668	ENSG00000183298.5	RP11-556K13.1	6.19	1.3e-09	0.00239	0.39	0.27	Attention deficit hyperactivity disorder;	chr3:39475753	chr1:101786340~101787219:-
LUAD	trans	rs11951515	0.508	rs7705166	ENSG00000174977.8	AC026271.5	-6.19	1.3e-09	0.00239	-0.28	-0.27	Metabolite levels  (X-11787);	chr5:43587346	chr17:18650195~18651542:+
LUAD	trans	rs17301013	0.861	rs34819375	ENSG00000213331.4	RP11-713C19.2	6.19	1.32e-09	0.00242	0.32	0.27	Systemic lupus erythematosus;	chr1:174654958	chr4:187970273~187971284:+
LUAD	trans	rs7192380	0.964	rs6499231	ENSG00000257513.6	NPIPB1P	6.19	1.32e-09	0.00242	0.27	0.27	Sjögren's syndrome;	chr16:69554113	chr18:11619509~11639699:-
LUAD	trans	rs9584850	1	rs9584850	ENSG00000230079.1	STK24P1	6.19	1.32e-09	0.00242	0.32	0.27	Neuroticism;	chr13:98449172	chrX:136295690~136300298:-
LUAD	trans	rs853679	0.607	rs67101035	ENSG00000253570.1	RNF5P1	6.19	1.32e-09	0.00243	0.58	0.27	Depression;	chr6:27831109	chr8:38600661~38601200:-
LUAD	trans	rs67340775	0.748	rs13212651	ENSG00000253570.1	RNF5P1	6.19	1.32e-09	0.00243	0.58	0.27	Lung cancer in ever smokers;	chr6:27839207	chr8:38600661~38601200:-
LUAD	trans	rs7746199	0.736	rs10484399	ENSG00000253570.1	RNF5P1	6.18	1.33e-09	0.00244	0.56	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27566749	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.607	rs35030260	ENSG00000253570.1	RNF5P1	6.18	1.35e-09	0.00247	0.61	0.27	Depression;	chr6:28337731	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.607	rs13217619	ENSG00000253570.1	RNF5P1	6.18	1.35e-09	0.00247	0.61	0.27	Depression;	chr6:28338894	chr8:38600661~38601200:-
LUAD	trans	rs864643	0.678	rs1707953	ENSG00000183298.5	RP11-556K13.1	6.18	1.36e-09	0.00248	0.39	0.27	Attention deficit hyperactivity disorder;	chr3:39483918	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.678	rs683089	ENSG00000183298.5	RP11-556K13.1	6.18	1.36e-09	0.00248	0.39	0.27	Attention deficit hyperactivity disorder;	chr3:39484334	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.678	rs590805	ENSG00000183298.5	RP11-556K13.1	6.18	1.36e-09	0.00248	0.39	0.27	Attention deficit hyperactivity disorder;	chr3:39485463	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.678	rs606973	ENSG00000183298.5	RP11-556K13.1	6.18	1.36e-09	0.00248	0.39	0.27	Attention deficit hyperactivity disorder;	chr3:39485876	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.678	rs656071	ENSG00000183298.5	RP11-556K13.1	6.18	1.36e-09	0.00248	0.39	0.27	Attention deficit hyperactivity disorder;	chr3:39488646	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.625	rs1708112	ENSG00000183298.5	RP11-556K13.1	6.18	1.36e-09	0.00248	0.39	0.27	Attention deficit hyperactivity disorder;	chr3:39489034	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.678	rs1708111	ENSG00000183298.5	RP11-556K13.1	6.18	1.36e-09	0.00248	0.39	0.27	Attention deficit hyperactivity disorder;	chr3:39489098	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.678	rs1768219	ENSG00000183298.5	RP11-556K13.1	6.18	1.36e-09	0.00248	0.39	0.27	Attention deficit hyperactivity disorder;	chr3:39489162	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.678	rs1398675	ENSG00000183298.5	RP11-556K13.1	6.18	1.36e-09	0.00248	0.39	0.27	Attention deficit hyperactivity disorder;	chr3:39489772	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.678	rs1708109	ENSG00000183298.5	RP11-556K13.1	6.18	1.36e-09	0.00248	0.39	0.27	Attention deficit hyperactivity disorder;	chr3:39490085	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.625	rs1768220	ENSG00000183298.5	RP11-556K13.1	6.18	1.36e-09	0.00248	0.39	0.27	Attention deficit hyperactivity disorder;	chr3:39490545	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.678	rs1768221	ENSG00000183298.5	RP11-556K13.1	6.18	1.36e-09	0.00248	0.39	0.27	Attention deficit hyperactivity disorder;	chr3:39490789	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.678	rs1768222	ENSG00000183298.5	RP11-556K13.1	6.18	1.36e-09	0.00248	0.39	0.27	Attention deficit hyperactivity disorder;	chr3:39490852	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.678	rs3856566	ENSG00000183298.5	RP11-556K13.1	6.18	1.36e-09	0.00248	0.39	0.27	Attention deficit hyperactivity disorder;	chr3:39491097	chr1:101786340~101787219:-
LUAD	trans	rs6499255	1	rs12925371	ENSG00000257513.6	NPIPB1P	6.18	1.36e-09	0.00249	0.32	0.27	IgE levels;	chr16:69739982	chr18:11619509~11639699:-
LUAD	trans	rs4713118	0.869	rs6930992	ENSG00000204709.4	LINC01556	6.18	1.36e-09	0.00249	0.36	0.27	Parkinson's disease;	chr6:27744341	chr6:28943877~28944537:+
LUAD	trans	rs730566	1	rs4858819	ENSG00000235912.1	RP1-159A19.3	6.18	1.36e-09	0.00249	0.32	0.27	Prion diseases;	chr3:48436678	chr1:27649419~27649610:+
LUAD	trans	rs12200782	1	rs4292511	ENSG00000242375.1	RP11-498P14.3	-6.18	1.37e-09	0.00251	-0.63	-0.27	Small cell lung carcinoma;	chr6:26622062	chr9:97195351~97197687:-
LUAD	trans	rs7647973	1	rs3905330	ENSG00000197582.5	GPX1P1	6.18	1.38e-09	0.00252	0.37	0.27	Menarche (age at onset);	chr3:49513341	chrX:13378735~13379340:-
LUAD	trans	rs4911253	0.527	rs853859	ENSG00000253915.1	MAPRE1P1	6.18	1.38e-09	0.00253	0.31	0.27	Lymphocyte counts;	chr20:32814463	chr8:135625185~135625981:-
LUAD	trans	rs4713118	0.911	rs9461406	ENSG00000204709.4	LINC01556	-6.18	1.38e-09	0.00253	-0.36	-0.27	Parkinson's disease;	chr6:27751985	chr6:28943877~28944537:+
LUAD	trans	rs7212590	0.655	rs62081824	ENSG00000187870.7	RNFT1P3	6.18	1.38e-09	0.00253	0.58	0.27	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59830589	chr17:20743333~20754501:-
LUAD	trans	rs7212590	0.748	rs9904374	ENSG00000187870.7	RNFT1P3	6.18	1.38e-09	0.00253	0.58	0.27	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59830735	chr17:20743333~20754501:-
LUAD	trans	rs116002988	0.752	rs10484065	ENSG00000249592.4	RP11-440L14.1	-6.18	1.39e-09	0.00254	-0.33	-0.27	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr14:98982431	chr4:762387~781849:-
LUAD	trans	rs7937890	0.505	rs9971395	ENSG00000236360.2	RP11-334A14.2	6.18	1.39e-09	0.00254	0.35	0.27	Mitochondrial DNA levels;	chr11:14745580	chr1:52993201~52993702:-
LUAD	trans	rs7937890	0.506	rs10741655	ENSG00000236360.2	RP11-334A14.2	6.18	1.39e-09	0.00254	0.35	0.27	Mitochondrial DNA levels;	chr11:14746838	chr1:52993201~52993702:-
LUAD	trans	rs7647973	1	rs3866330	ENSG00000197582.5	GPX1P1	6.18	1.4e-09	0.00256	0.37	0.27	Menarche (age at onset);	chr3:49545561	chrX:13378735~13379340:-
LUAD	trans	rs12210905	1	rs7759955	ENSG00000242375.1	RP11-498P14.3	-6.18	1.41e-09	0.00257	-0.64	-0.27	Hip circumference adjusted for BMI;	chr6:26792463	chr9:97195351~97197687:-
LUAD	trans	rs4713118	0.868	rs9468220	ENSG00000204709.4	LINC01556	-6.17	1.41e-09	0.00258	-0.37	-0.27	Parkinson's disease;	chr6:27765197	chr6:28943877~28944537:+
LUAD	trans	rs2060793	0.712	rs10741654	ENSG00000236360.2	RP11-334A14.2	6.17	1.42e-09	0.00259	0.35	0.27	Vitamin D levels;	chr11:14726506	chr1:52993201~52993702:-
LUAD	trans	rs6499255	0.951	rs61310815	ENSG00000257513.6	NPIPB1P	6.17	1.42e-09	0.0026	0.32	0.27	IgE levels;	chr16:69667336	chr18:11619509~11639699:-
LUAD	trans	rs864643	0.678	rs521226	ENSG00000183298.5	RP11-556K13.1	6.17	1.42e-09	0.0026	0.39	0.27	Attention deficit hyperactivity disorder;	chr3:39486099	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.678	rs519385	ENSG00000183298.5	RP11-556K13.1	6.17	1.42e-09	0.0026	0.39	0.27	Attention deficit hyperactivity disorder;	chr3:39486304	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.678	rs604831	ENSG00000183298.5	RP11-556K13.1	6.17	1.42e-09	0.0026	0.39	0.27	Attention deficit hyperactivity disorder;	chr3:39486327	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.625	rs517376	ENSG00000183298.5	RP11-556K13.1	6.17	1.42e-09	0.0026	0.39	0.27	Attention deficit hyperactivity disorder;	chr3:39486571	chr1:101786340~101787219:-
LUAD	trans	rs9425766	0.655	rs6666767	ENSG00000213331.4	RP11-713C19.2	6.17	1.42e-09	0.0026	0.31	0.27	Life satisfaction;	chr1:174357564	chr4:187970273~187971284:+
LUAD	trans	rs9467773	0.595	rs9366657	ENSG00000242375.1	RP11-498P14.3	6.17	1.43e-09	0.00261	0.36	0.27	Intelligence (multi-trait analysis);	chr6:26434686	chr9:97195351~97197687:-
LUAD	trans	rs12145833	0.679	rs12037698	ENSG00000154608.12	CEP170P1	-6.17	1.43e-09	0.00261	-0.47	-0.27	Obesity (early onset extreme);	chr1:243421043	chr4:118467590~118554204:+
LUAD	trans	rs853679	0.556	rs13197633	ENSG00000253570.1	RNF5P1	6.17	1.44e-09	0.00263	0.61	0.27	Depression;	chr6:28206979	chr8:38600661~38601200:-
LUAD	trans	rs4276421	0.509	rs1351719	ENSG00000231752.4	EMBP1	6.17	1.44e-09	0.00263	0.42	0.27	P wave duration;	chr5:45520383	chr1:121519112~121571892:+
LUAD	trans	rs1190596	0.525	rs34440178	ENSG00000181359.5	HSP90AA6P	-6.17	1.44e-09	0.00264	-0.31	-0.27	Behavioural disinhibition (generation interaction);	chr14:102244864	chr4:170581470~170605450:-
LUAD	trans	rs7746199	0.673	rs72847313	ENSG00000253570.1	RNF5P1	6.17	1.45e-09	0.00264	0.57	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762303	chr8:38600661~38601200:-
LUAD	trans	rs7746199	0.611	rs17750747	ENSG00000253570.1	RNF5P1	6.17	1.45e-09	0.00264	0.57	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762555	chr8:38600661~38601200:-
LUAD	trans	rs7192380	1	rs11640319	ENSG00000257513.6	NPIPB1P	6.17	1.45e-09	0.00265	0.26	0.27	Sjögren's syndrome;	chr16:69599612	chr18:11619509~11639699:-
LUAD	trans	rs3096299	0.685	rs8050512	ENSG00000215030.5	RPL13P12	-6.17	1.45e-09	0.00265	-0.3	-0.27	Multiple myeloma (IgH translocation);	chr16:89485912	chr17:17383377~17384012:-
LUAD	trans	rs11220082	0.627	rs34912904	ENSG00000236257.1	EI24P2	-6.17	1.45e-09	0.00266	-0.29	-0.27	Schizophrenia;	chr11:125475460	chr1:158454198~158455273:+
LUAD	trans	rs2243480	1	rs4718269	ENSG00000232546.1	RP11-458F8.1	6.17	1.46e-09	0.00266	0.36	0.27	Diabetic kidney disease;	chr7:65735810	chr7:66848496~66858136:+
LUAD	trans	rs6743068	0.541	rs6714736	ENSG00000235105.1	RP11-329A14.1	-6.17	1.46e-09	0.00266	-0.31	-0.27	Lymphocyte percentage of white cells;	chr2:201349425	chr1:48435967~48437223:+
LUAD	trans	rs17301013	0.861	rs332770	ENSG00000213331.4	RP11-713C19.2	6.17	1.46e-09	0.00267	0.32	0.27	Systemic lupus erythematosus;	chr1:174681511	chr4:187970273~187971284:+
LUAD	trans	rs4713118	0.539	rs510987	ENSG00000204709.4	LINC01556	6.17	1.47e-09	0.00268	0.35	0.27	Parkinson's disease;	chr6:27879739	chr6:28943877~28944537:+
LUAD	trans	rs10420951	0.617	rs74497531	ENSG00000267533.1	RP11-815J4.7	6.17	1.47e-09	0.00268	0.5	0.27	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18467368	chr18:12067173~12068417:-
LUAD	trans	rs546131	0.89	rs485845	ENSG00000225531.1	RP11-196I18.3	-6.17	1.47e-09	0.00269	-0.33	-0.27	Lung disease severity in cystic fibrosis;	chr11:34808842	chr9:107116829~107117557:+
LUAD	trans	rs864643	0.524	rs72869131	ENSG00000183298.5	RP11-556K13.1	6.17	1.47e-09	0.00269	0.45	0.27	Attention deficit hyperactivity disorder;	chr3:39472959	chr1:101786340~101787219:-
LUAD	trans	rs6499255	1	rs11644838	ENSG00000257513.6	NPIPB1P	6.17	1.48e-09	0.00271	0.32	0.27	IgE levels;	chr16:69778802	chr18:11619509~11639699:-
LUAD	trans	rs9425766	0.679	rs4650945	ENSG00000213331.4	RP11-713C19.2	-6.17	1.49e-09	0.00271	-0.32	-0.27	Life satisfaction;	chr1:174114966	chr4:187970273~187971284:+
LUAD	trans	rs12145833	0.538	rs10927014	ENSG00000154608.12	CEP170P1	-6.17	1.49e-09	0.00272	-0.47	-0.27	Obesity (early onset extreme);	chr1:243429374	chr4:118467590~118554204:+
LUAD	trans	rs12477438	0.52	rs720229	ENSG00000276576.1	MRPL30P1	6.17	1.49e-09	0.00272	0.31	0.27	Chronic sinus infection;	chr2:99087810	chr6:57029521~57029988:+
LUAD	trans	rs6921919	0.562	rs13198809	ENSG00000281831.1	HCP5B	6.17	1.49e-09	0.00272	0.61	0.27	Autism spectrum disorder or schizophrenia;	chr6:28355925	chr6:29871895~29873783:-
LUAD	trans	rs2060793	0.741	rs4757268	ENSG00000236360.2	RP11-334A14.2	6.16	1.5e-09	0.00274	0.35	0.27	Vitamin D levels;	chr11:14789216	chr1:52993201~52993702:-
LUAD	trans	rs73108077	0.736	rs2376545	ENSG00000279352.1	RP11-411B10.7	6.16	1.52e-09	0.00278	0.45	0.27	Red blood cell density in sickle cell anemia;	chr20:31293314	chr18:14010054~14010917:+
LUAD	trans	rs877636	0.859	rs3741499	ENSG00000223416.3	RPS26P15	-6.16	1.53e-09	0.00279	-0.27	-0.27	Cognitive function;	chr12:56080595	chr1:58056133~58056480:-
LUAD	trans	rs853679	0.607	rs33932084	ENSG00000281831.1	HCP5B	6.16	1.54e-09	0.00281	0.58	0.27	Depression;	chr6:28301047	chr6:29871895~29873783:-
LUAD	trans	rs7833986	0.501	rs2953909	ENSG00000236862.1	RPS20P24	6.16	1.55e-09	0.00281	0.33	0.27	Height;	chr8:56055641	chr9:72655832~72656192:-
LUAD	trans	rs7833986	0.501	rs2953910	ENSG00000236862.1	RPS20P24	6.16	1.55e-09	0.00281	0.33	0.27	Height;	chr8:56056202	chr9:72655832~72656192:-
LUAD	trans	rs4713118	0.513	rs6915987	ENSG00000204709.4	LINC01556	-6.16	1.56e-09	0.00283	-0.33	-0.27	Parkinson's disease;	chr6:27547997	chr6:28943877~28944537:+
LUAD	trans	rs864643	0.678	rs10510702	ENSG00000183298.5	RP11-556K13.1	6.16	1.56e-09	0.00284	0.39	0.27	Attention deficit hyperactivity disorder;	chr3:39492461	chr1:101786340~101787219:-
LUAD	trans	rs853679	0.607	rs13205911	ENSG00000281831.1	HCP5B	6.16	1.56e-09	0.00284	0.61	0.27	Depression;	chr6:28156336	chr6:29871895~29873783:-
LUAD	trans	rs853679	0.607	rs13197176	ENSG00000281831.1	HCP5B	6.16	1.56e-09	0.00284	0.61	0.27	Depression;	chr6:28161454	chr6:29871895~29873783:-
LUAD	trans	rs853679	0.607	rs13201308	ENSG00000281831.1	HCP5B	6.16	1.56e-09	0.00284	0.61	0.27	Depression;	chr6:28162311	chr6:29871895~29873783:-
LUAD	trans	rs853679	0.607	rs34765154	ENSG00000281831.1	HCP5B	6.16	1.56e-09	0.00284	0.61	0.27	Depression;	chr6:28162672	chr6:29871895~29873783:-
LUAD	trans	rs853679	0.607	rs34505829	ENSG00000281831.1	HCP5B	6.16	1.56e-09	0.00284	0.61	0.27	Depression;	chr6:28165461	chr6:29871895~29873783:-
LUAD	trans	rs853679	0.607	rs35098436	ENSG00000281831.1	HCP5B	6.16	1.56e-09	0.00284	0.61	0.27	Depression;	chr6:28166443	chr6:29871895~29873783:-
LUAD	trans	rs853679	0.607	rs72846794	ENSG00000281831.1	HCP5B	6.16	1.56e-09	0.00284	0.61	0.27	Depression;	chr6:28169721	chr6:29871895~29873783:-
LUAD	trans	rs853679	0.607	rs13217984	ENSG00000281831.1	HCP5B	6.16	1.56e-09	0.00284	0.61	0.27	Depression;	chr6:28171932	chr6:29871895~29873783:-
LUAD	trans	rs853679	0.556	rs67297533	ENSG00000281831.1	HCP5B	6.16	1.56e-09	0.00284	0.61	0.27	Depression;	chr6:28173475	chr6:29871895~29873783:-
LUAD	trans	rs853679	0.505	rs35781323	ENSG00000281831.1	HCP5B	6.16	1.56e-09	0.00284	0.61	0.27	Depression;	chr6:28177054	chr6:29871895~29873783:-
LUAD	trans	rs11098499	0.575	rs9996586	ENSG00000275858.1	RP11-291L22.8	6.16	1.57e-09	0.00285	0.29	0.27	Corneal astigmatism;	chr4:119405787	chr10:38450738~38451069:-
LUAD	trans	rs17301013	0.932	rs2987874	ENSG00000213331.4	RP11-713C19.2	-6.16	1.57e-09	0.00285	-0.32	-0.27	Systemic lupus erythematosus;	chr1:174801053	chr4:187970273~187971284:+
LUAD	trans	rs3096299	0.642	rs12934829	ENSG00000215030.5	RPL13P12	-6.16	1.58e-09	0.00287	-0.3	-0.27	Multiple myeloma (IgH translocation);	chr16:89456941	chr17:17383377~17384012:-
LUAD	trans	rs13016963	0.526	rs2110684	ENSG00000235105.1	RP11-329A14.1	6.16	1.58e-09	0.00287	0.31	0.27	Esophageal squamous cell carcinoma;Melanoma;	chr2:201357198	chr1:48435967~48437223:+
LUAD	trans	rs10783779	0.647	rs705708	ENSG00000242970.2	AC068522.4	6.16	1.58e-09	0.00288	0.3	0.27	Educational attainment;	chr12:56095129	chr8:58588420~58588764:-
LUAD	trans	rs9584850	0.834	rs745639	ENSG00000230079.1	STK24P1	6.16	1.58e-09	0.00288	0.32	0.27	Neuroticism;	chr13:98467025	chrX:136295690~136300298:-
LUAD	trans	rs877636	1	rs705696	ENSG00000227586.5	RP11-162A23.5	6.15	1.6e-09	0.0029	0.32	0.27	Cognitive function;	chr12:56086864	chr10:123171535~123171875:-
LUAD	trans	rs7192380	1	rs11075726	ENSG00000257513.6	NPIPB1P	6.15	1.6e-09	0.00291	0.27	0.27	Sjögren's syndrome;	chr16:69550620	chr18:11619509~11639699:-
LUAD	trans	rs6499255	1	rs11075733	ENSG00000257513.6	NPIPB1P	6.15	1.6e-09	0.00291	0.32	0.27	IgE levels;	chr16:69739532	chr18:11619509~11639699:-
LUAD	trans	rs6499255	0.857	rs11643926	ENSG00000257513.6	NPIPB1P	6.15	1.61e-09	0.00292	0.32	0.27	IgE levels;	chr16:69773379	chr18:11619509~11639699:-
LUAD	trans	rs77688320	1	rs80273648	ENSG00000235105.1	RP11-329A14.1	-6.15	1.61e-09	0.00293	-0.43	-0.27	Breast cancer;	chr2:201446432	chr1:48435967~48437223:+
LUAD	trans	rs7212590	0.748	rs8074176	ENSG00000187870.7	RNFT1P3	6.15	1.61e-09	0.00293	0.57	0.27	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59784634	chr17:20743333~20754501:-
LUAD	trans	rs4742971	0.5	rs72732742	ENSG00000262902.1	RP11-750B16.1	6.15	1.61e-09	0.00293	0.51	0.27	Protein quantitative trait loci;	chr9:105916555	chr17:53105734~53106358:+
LUAD	trans	rs4742971	0.5	rs2417659	ENSG00000262902.1	RP11-750B16.1	6.15	1.61e-09	0.00293	0.51	0.27	Protein quantitative trait loci;	chr9:105917907	chr17:53105734~53106358:+
LUAD	trans	rs853679	0.556	rs13200214	ENSG00000281831.1	HCP5B	6.15	1.62e-09	0.00294	0.6	0.27	Depression;	chr6:28049472	chr6:29871895~29873783:-
LUAD	trans	rs66887589	0.807	rs9799664	ENSG00000275858.1	RP11-291L22.8	6.15	1.62e-09	0.00295	0.29	0.27	Diastolic blood pressure;	chr4:119405523	chr10:38450738~38451069:-
LUAD	trans	rs1190596	0.525	rs12896377	ENSG00000181359.5	HSP90AA6P	-6.15	1.62e-09	0.00295	-0.31	-0.27	Behavioural disinhibition (generation interaction);	chr14:102247244	chr4:170581470~170605450:-
LUAD	trans	rs1190596	0.562	rs1307671	ENSG00000181359.5	HSP90AA6P	6.15	1.63e-09	0.00296	0.36	0.27	Behavioural disinhibition (generation interaction);	chr14:102176116	chr4:170581470~170605450:-
LUAD	trans	rs864643	0.678	rs6779639	ENSG00000183298.5	RP11-556K13.1	6.15	1.63e-09	0.00296	0.39	0.27	Attention deficit hyperactivity disorder;	chr3:39477191	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.678	rs6782255	ENSG00000183298.5	RP11-556K13.1	6.15	1.63e-09	0.00296	0.39	0.27	Attention deficit hyperactivity disorder;	chr3:39477236	chr1:101786340~101787219:-
LUAD	trans	rs9876781	1	rs13069724	ENSG00000225528.1	RP3-370M22.8	-6.15	1.63e-09	0.00296	-0.27	-0.27	Longevity;	chr3:48436629	chr22:39960397~39964683:+
LUAD	trans	rs17301013	0.932	rs1653626	ENSG00000213331.4	RP11-713C19.2	-6.15	1.64e-09	0.00297	-0.32	-0.27	Systemic lupus erythematosus;	chr1:174770348	chr4:187970273~187971284:+
LUAD	trans	rs12200782	1	rs6456741	ENSG00000242375.1	RP11-498P14.3	-6.15	1.64e-09	0.00297	-0.63	-0.27	Small cell lung carcinoma;	chr6:26616830	chr9:97195351~97197687:-
LUAD	trans	rs12200782	1	rs6456742	ENSG00000242375.1	RP11-498P14.3	-6.15	1.64e-09	0.00297	-0.63	-0.27	Small cell lung carcinoma;	chr6:26616847	chr9:97195351~97197687:-
LUAD	trans	rs877636	1	rs2292239	ENSG00000212829.8	RPS26P3	6.15	1.64e-09	0.00298	0.28	0.27	Cognitive function;	chr12:56088396	chr9:9090898~9091245:+
LUAD	trans	rs616147	0.616	rs1768234	ENSG00000188856.6	RPSAP47	-6.15	1.65e-09	0.00299	-0.29	-0.27	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39459821	chr8:80558870~80559757:+
LUAD	trans	rs853679	0.607	rs35749575	ENSG00000281831.1	HCP5B	6.15	1.65e-09	0.00299	0.61	0.27	Depression;	chr6:28147040	chr6:29871895~29873783:-
LUAD	trans	rs853679	0.607	rs72846780	ENSG00000281831.1	HCP5B	6.15	1.65e-09	0.00299	0.61	0.27	Depression;	chr6:28151277	chr6:29871895~29873783:-
LUAD	trans	rs6499255	1	rs6499253	ENSG00000257513.6	NPIPB1P	6.15	1.65e-09	0.003	0.32	0.27	IgE levels;	chr16:69768769	chr18:11619509~11639699:-
LUAD	trans	rs3096299	0.685	rs4785675	ENSG00000215030.5	RPL13P12	-6.15	1.66e-09	0.00301	-0.3	-0.27	Multiple myeloma (IgH translocation);	chr16:89473566	chr17:17383377~17384012:-
LUAD	trans	rs3096299	0.685	rs4238830	ENSG00000215030.5	RPL13P12	-6.15	1.67e-09	0.00302	-0.3	-0.27	Multiple myeloma (IgH translocation);	chr16:89473833	chr17:17383377~17384012:-
LUAD	trans	rs73108077	0.736	rs6058479	ENSG00000279352.1	RP11-411B10.7	6.14	1.68e-09	0.00305	0.44	0.27	Red blood cell density in sickle cell anemia;	chr20:31282419	chr18:14010054~14010917:+
LUAD	trans	rs864643	0.678	rs7639473	ENSG00000183298.5	RP11-556K13.1	6.14	1.68e-09	0.00305	0.39	0.27	Attention deficit hyperactivity disorder;	chr3:39492324	chr1:101786340~101787219:-
LUAD	trans	rs36022378	0.504	rs4688688	ENSG00000197582.5	GPX1P1	-6.14	1.69e-09	0.00306	-0.45	-0.27	Diastolic blood pressure;	chr3:50005257	chrX:13378735~13379340:-
LUAD	trans	rs2069408	1	rs2069408	ENSG00000227887.1	RPS26P13	-6.14	1.7e-09	0.00308	-0.33	-0.27	Asthma;	chr12:55970537	chr1:208697369~208697698:-
LUAD	trans	rs1391708	0.834	rs4759040	ENSG00000121089.4	NACA3P	6.14	1.7e-09	0.00309	0.43	0.27	Airway wall thickness;	chr12:56887746	chr4:164943290~164943937:+
LUAD	trans	rs1391708	0.764	rs4759265	ENSG00000121089.4	NACA3P	6.14	1.7e-09	0.00309	0.43	0.27	Airway wall thickness;	chr12:56887788	chr4:164943290~164943937:+
LUAD	trans	rs9876781	1	rs922075	ENSG00000225528.1	RP3-370M22.8	6.14	1.71e-09	0.00309	0.28	0.27	Longevity;	chr3:48447994	chr22:39960397~39964683:+
LUAD	trans	rs9876781	1	rs2045554	ENSG00000225528.1	RP3-370M22.8	6.14	1.71e-09	0.00309	0.28	0.27	Longevity;	chr3:48453142	chr22:39960397~39964683:+
LUAD	trans	rs7260598	0.792	rs11669251	ENSG00000261770.1	CTC-459F4.1	6.14	1.72e-09	0.00311	0.43	0.27	Response to taxane treatment (placlitaxel);	chr19:24154192	chr19:27757184~27760849:-
LUAD	trans	rs73198271	0.96	rs11776546	ENSG00000273129.1	PACERR	6.14	1.72e-09	0.00311	0.36	0.27	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751671	chr1:186680622~186681446:+
LUAD	trans	rs73198271	1	rs11775821	ENSG00000273129.1	PACERR	6.14	1.72e-09	0.00311	0.36	0.27	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751643	chr1:186680622~186681446:+
LUAD	trans	rs17301013	0.612	rs56199565	ENSG00000213331.4	RP11-713C19.2	6.14	1.73e-09	0.00313	0.32	0.27	Systemic lupus erythematosus;	chr1:174640992	chr4:187970273~187971284:+
LUAD	trans	rs4713118	0.869	rs9366700	ENSG00000204709.4	LINC01556	6.14	1.73e-09	0.00314	0.36	0.27	Parkinson's disease;	chr6:27729172	chr6:28943877~28944537:+
LUAD	trans	rs864643	0.625	rs7613883	ENSG00000183298.5	RP11-556K13.1	6.14	1.73e-09	0.00314	0.38	0.27	Attention deficit hyperactivity disorder;	chr3:39476825	chr1:101786340~101787219:-
LUAD	trans	rs7260598	0.792	rs73021416	ENSG00000261770.1	CTC-459F4.1	6.14	1.74e-09	0.00315	0.43	0.27	Response to taxane treatment (placlitaxel);	chr19:24081849	chr19:27757184~27760849:-
LUAD	trans	rs7260598	0.685	rs73021422	ENSG00000261770.1	CTC-459F4.1	6.14	1.74e-09	0.00315	0.43	0.27	Response to taxane treatment (placlitaxel);	chr19:24082919	chr19:27757184~27760849:-
LUAD	trans	rs9584850	0.834	rs7985565	ENSG00000230079.1	STK24P1	6.14	1.75e-09	0.00316	0.31	0.27	Neuroticism;	chr13:98461217	chrX:136295690~136300298:-
LUAD	trans	rs9584850	0.834	rs17574378	ENSG00000230079.1	STK24P1	6.14	1.76e-09	0.00318	0.31	0.27	Neuroticism;	chr13:98464130	chrX:136295690~136300298:-
LUAD	trans	rs17301013	0.869	rs3133270	ENSG00000213331.4	RP11-713C19.2	-6.14	1.76e-09	0.00318	-0.32	-0.27	Systemic lupus erythematosus;	chr1:174819547	chr4:187970273~187971284:+
LUAD	trans	rs4713118	0.869	rs6456802	ENSG00000204709.4	LINC01556	6.14	1.77e-09	0.0032	0.36	0.27	Parkinson's disease;	chr6:27730576	chr6:28943877~28944537:+
LUAD	trans	rs4713118	0.869	rs9393851	ENSG00000204709.4	LINC01556	6.14	1.77e-09	0.0032	0.36	0.27	Parkinson's disease;	chr6:27731802	chr6:28943877~28944537:+
LUAD	trans	rs4713118	0.869	rs9461400	ENSG00000204709.4	LINC01556	6.14	1.77e-09	0.0032	0.36	0.27	Parkinson's disease;	chr6:27732780	chr6:28943877~28944537:+
LUAD	trans	rs4713118	0.869	rs9295742	ENSG00000204709.4	LINC01556	6.14	1.77e-09	0.0032	0.36	0.27	Parkinson's disease;	chr6:27735053	chr6:28943877~28944537:+
LUAD	trans	rs4713118	0.869	rs9461401	ENSG00000204709.4	LINC01556	6.14	1.77e-09	0.0032	0.36	0.27	Parkinson's disease;	chr6:27735512	chr6:28943877~28944537:+
LUAD	trans	rs4713118	0.869	rs6914924	ENSG00000204709.4	LINC01556	6.14	1.77e-09	0.0032	0.36	0.27	Parkinson's disease;	chr6:27743751	chr6:28943877~28944537:+
LUAD	trans	rs3740713	0.669	rs2896526	ENSG00000236090.2	LDHAP3	6.14	1.77e-09	0.0032	0.45	0.27	Amyotrophic lateral sclerosis (sporadic);	chr11:18398259	chr2:41819747~41820754:+
LUAD	trans	rs4276421	0.571	rs10805694	ENSG00000231752.4	EMBP1	-6.14	1.77e-09	0.0032	-0.4	-0.27	P wave duration;	chr5:45539757	chr1:121519112~121571892:+
LUAD	trans	rs864643	0.898	rs1473864	ENSG00000183298.5	RP11-556K13.1	6.14	1.77e-09	0.0032	0.37	0.27	Attention deficit hyperactivity disorder;	chr3:39499703	chr1:101786340~101787219:-
LUAD	trans	rs7260598	0.685	rs73021424	ENSG00000261770.1	CTC-459F4.1	6.13	1.78e-09	0.00322	0.43	0.27	Response to taxane treatment (placlitaxel);	chr19:24090897	chr19:27757184~27760849:-
LUAD	trans	rs7260598	0.685	rs11667970	ENSG00000261770.1	CTC-459F4.1	6.13	1.78e-09	0.00322	0.43	0.27	Response to taxane treatment (placlitaxel);	chr19:24094893	chr19:27757184~27760849:-
LUAD	trans	rs7260598	0.581	rs73021432	ENSG00000261770.1	CTC-459F4.1	6.13	1.78e-09	0.00322	0.43	0.27	Response to taxane treatment (placlitaxel);	chr19:24101827	chr19:27757184~27760849:-
LUAD	trans	rs7260598	0.685	rs11671000	ENSG00000261770.1	CTC-459F4.1	6.13	1.78e-09	0.00322	0.43	0.27	Response to taxane treatment (placlitaxel);	chr19:24110025	chr19:27757184~27760849:-
LUAD	trans	rs17301013	0.9	rs1793300	ENSG00000213331.4	RP11-713C19.2	-6.13	1.78e-09	0.00322	-0.32	-0.27	Systemic lupus erythematosus;	chr1:174768559	chr4:187970273~187971284:+
LUAD	trans	rs853679	0.607	rs34788973	ENSG00000204709.4	LINC01556	6.13	1.78e-09	0.00322	0.6	0.27	Depression;	chr6:27911422	chr6:28943877~28944537:+
LUAD	trans	rs853679	0.607	rs61742093	ENSG00000204709.4	LINC01556	6.13	1.78e-09	0.00322	0.6	0.27	Depression;	chr6:27912204	chr6:28943877~28944537:+
LUAD	trans	rs9584850	0.794	rs72655609	ENSG00000230079.1	STK24P1	6.13	1.79e-09	0.00322	0.32	0.27	Neuroticism;	chr13:98476368	chrX:136295690~136300298:-
LUAD	trans	rs2243480	1	rs34703416	ENSG00000230295.1	RP11-458F8.2	-6.13	1.79e-09	0.00322	-0.34	-0.27	Diabetic kidney disease;	chr7:65835655	chr7:66880708~66882981:+
LUAD	trans	rs7617480	0.648	rs9864243	ENSG00000197582.5	GPX1P1	6.13	1.79e-09	0.00322	0.39	0.27	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48945299	chrX:13378735~13379340:-
LUAD	trans	rs4948102	0.551	rs4275190	ENSG00000186940.6	CHCHD2P9	-6.13	1.8e-09	0.00324	-0.33	-0.27	Plasma homocysteine levels (post-methionine load test);	chr7:56036695	chr9:79391304~79391759:+
LUAD	trans	rs853679	0.607	rs13194781	ENSG00000253570.1	RNF5P1	6.13	1.8e-09	0.00325	0.58	0.27	Depression;	chr6:27847861	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.546	rs36116761	ENSG00000253570.1	RNF5P1	6.13	1.8e-09	0.00325	0.58	0.27	Depression;	chr6:27850704	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.546	rs34194357	ENSG00000253570.1	RNF5P1	6.13	1.8e-09	0.00325	0.58	0.27	Depression;	chr6:27850757	chr8:38600661~38601200:-
LUAD	trans	rs7192380	0.965	rs4633710	ENSG00000257513.6	NPIPB1P	6.13	1.8e-09	0.00325	0.26	0.27	Sjögren's syndrome;	chr16:69599058	chr18:11619509~11639699:-
LUAD	trans	rs7192380	0.965	rs9938213	ENSG00000257513.6	NPIPB1P	6.13	1.8e-09	0.00325	0.26	0.27	Sjögren's syndrome;	chr16:69606687	chr18:11619509~11639699:-
LUAD	trans	rs7192380	0.965	rs3848278	ENSG00000257513.6	NPIPB1P	6.13	1.8e-09	0.00325	0.26	0.27	Sjögren's syndrome;	chr16:69606964	chr18:11619509~11639699:-
LUAD	trans	rs1190596	0.525	rs6575897	ENSG00000181359.5	HSP90AA6P	-6.13	1.8e-09	0.00325	-0.3	-0.27	Behavioural disinhibition (generation interaction);	chr14:102180788	chr4:170581470~170605450:-
LUAD	trans	rs7833986	0.501	rs2976012	ENSG00000236862.1	RPS20P24	6.13	1.8e-09	0.00326	0.33	0.27	Height;	chr8:56061784	chr9:72655832~72656192:-
LUAD	trans	rs853679	0.607	rs67998226	ENSG00000281831.1	HCP5B	6.13	1.81e-09	0.00326	0.58	0.27	Depression;	chr6:28270281	chr6:29871895~29873783:-
LUAD	trans	rs10420951	0.617	rs77571703	ENSG00000267533.1	RP11-815J4.7	6.13	1.81e-09	0.00327	0.49	0.27	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18468174	chr18:12067173~12068417:-
LUAD	trans	rs10420951	0.617	rs75245298	ENSG00000267533.1	RP11-815J4.7	6.13	1.81e-09	0.00327	0.49	0.27	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18470417	chr18:12067173~12068417:-
LUAD	trans	rs10420951	0.617	rs78855479	ENSG00000267533.1	RP11-815J4.7	6.13	1.81e-09	0.00327	0.49	0.27	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18471106	chr18:12067173~12068417:-
LUAD	trans	rs546131	0.928	rs552171	ENSG00000225531.1	RP11-196I18.3	6.13	1.82e-09	0.00329	0.33	0.27	Lung disease severity in cystic fibrosis;	chr11:34809162	chr9:107116829~107117557:+
LUAD	trans	rs546131	0.928	rs550313	ENSG00000225531.1	RP11-196I18.3	6.13	1.82e-09	0.00329	0.33	0.27	Lung disease severity in cystic fibrosis;	chr11:34809372	chr9:107116829~107117557:+
LUAD	trans	rs6790105	1	rs6790105	ENSG00000197582.5	GPX1P1	6.13	1.83e-09	0.00329	0.37	0.27	Childhood ear infection;	chr3:49355976	chrX:13378735~13379340:-
LUAD	trans	rs2243480	1	rs34815098	ENSG00000230295.1	RP11-458F8.2	-6.13	1.83e-09	0.0033	-0.33	-0.27	Diabetic kidney disease;	chr7:65827267	chr7:66880708~66882981:+
LUAD	trans	rs2243480	1	rs4548056	ENSG00000230295.1	RP11-458F8.2	-6.13	1.83e-09	0.0033	-0.33	-0.27	Diabetic kidney disease;	chr7:65833886	chr7:66880708~66882981:+
LUAD	trans	rs2243480	1	rs7456042	ENSG00000230295.1	RP11-458F8.2	-6.13	1.83e-09	0.0033	-0.33	-0.27	Diabetic kidney disease;	chr7:65834791	chr7:66880708~66882981:+
LUAD	trans	rs2243480	1	rs35735127	ENSG00000230295.1	RP11-458F8.2	-6.13	1.83e-09	0.0033	-0.33	-0.27	Diabetic kidney disease;	chr7:65835436	chr7:66880708~66882981:+
LUAD	trans	rs2243480	0.901	rs35256305	ENSG00000230295.1	RP11-458F8.2	-6.13	1.83e-09	0.0033	-0.33	-0.27	Diabetic kidney disease;	chr7:65841418	chr7:66880708~66882981:+
LUAD	trans	rs2243480	1	rs73142121	ENSG00000230295.1	RP11-458F8.2	-6.13	1.83e-09	0.0033	-0.33	-0.27	Diabetic kidney disease;	chr7:65846219	chr7:66880708~66882981:+
LUAD	trans	rs2243480	0.803	rs34004500	ENSG00000230295.1	RP11-458F8.2	-6.13	1.83e-09	0.0033	-0.33	-0.27	Diabetic kidney disease;	chr7:65847191	chr7:66880708~66882981:+
LUAD	trans	rs2243480	1	rs35825738	ENSG00000230295.1	RP11-458F8.2	-6.13	1.83e-09	0.0033	-0.33	-0.27	Diabetic kidney disease;	chr7:65853040	chr7:66880708~66882981:+
LUAD	trans	rs853679	0.607	rs66868086	ENSG00000204709.4	LINC01556	6.13	1.85e-09	0.00333	0.6	0.27	Depression;	chr6:27898124	chr6:28943877~28944537:+
LUAD	trans	rs847577	0.832	rs1799068	ENSG00000225169.1	BRI3P1	-6.13	1.85e-09	0.00333	-0.32	-0.27	Breast cancer;	chr7:98077757	chr1:100213293~100213670:+
LUAD	trans	rs11512640	0.655	rs77468344	ENSG00000236257.1	EI24P2	6.13	1.85e-09	0.00334	0.58	0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125586910	chr1:158454198~158455273:+
LUAD	trans	rs7833986	0.501	rs2719226	ENSG00000236862.1	RPS20P24	6.13	1.86e-09	0.00334	0.33	0.27	Height;	chr8:56131507	chr9:72655832~72656192:-
LUAD	trans	rs17301013	0.932	rs332771	ENSG00000213331.4	RP11-713C19.2	6.13	1.86e-09	0.00335	0.32	0.27	Systemic lupus erythematosus;	chr1:174704141	chr4:187970273~187971284:+
LUAD	trans	rs2899832	0.81	rs8015051	ENSG00000229083.1	PSMA6P2	6.13	1.86e-09	0.00335	0.36	0.27	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35315396	chrX:12825840~12826833:+
LUAD	trans	rs2294426	0.766	rs2294428	ENSG00000245904.3	RP11-796E2.4	6.13	1.86e-09	0.00335	0.29	0.27	Orofacial clefts (maternal alcohol consumption interaction);	chr6:11729609	chr12:92145573~92189660:+
LUAD	trans	rs2294426	0.766	rs2294427	ENSG00000245904.3	RP11-796E2.4	6.13	1.86e-09	0.00335	0.29	0.27	Orofacial clefts (maternal alcohol consumption interaction);	chr6:11729619	chr12:92145573~92189660:+
LUAD	trans	rs6831352	0.819	rs1230158	ENSG00000233859.2	ADH5P4	-6.13	1.87e-09	0.00336	-0.3	-0.27	Alcohol dependence;	chr4:99069035	chr6:65836930~65838039:-
LUAD	trans	rs6499255	0.951	rs9788837	ENSG00000257513.6	NPIPB1P	6.13	1.87e-09	0.00337	0.32	0.27	IgE levels;	chr16:69654510	chr18:11619509~11639699:-
LUAD	trans	rs6499255	1	rs8045682	ENSG00000257513.6	NPIPB1P	6.13	1.87e-09	0.00337	0.32	0.27	IgE levels;	chr16:69752189	chr18:11619509~11639699:-
LUAD	trans	rs6499255	1	rs4985518	ENSG00000257513.6	NPIPB1P	6.13	1.87e-09	0.00337	0.32	0.27	IgE levels;	chr16:69753255	chr18:11619509~11639699:-
LUAD	trans	rs7647973	1	rs62259944	ENSG00000197582.5	GPX1P1	-6.12	1.89e-09	0.0034	-0.38	-0.27	Menarche (age at onset);	chr3:49393450	chrX:13378735~13379340:-
LUAD	trans	rs7260598	0.642	rs67908565	ENSG00000261770.1	CTC-459F4.1	6.12	1.9e-09	0.00342	0.43	0.27	Response to taxane treatment (placlitaxel);	chr19:23998579	chr19:27757184~27760849:-
LUAD	trans	rs864643	0.625	rs656454	ENSG00000183298.5	RP11-556K13.1	6.12	1.91e-09	0.00343	0.38	0.27	Attention deficit hyperactivity disorder;	chr3:39488711	chr1:101786340~101787219:-
LUAD	trans	rs1933488	0.931	rs9479510	ENSG00000278974.1	RP11-756P10.6	6.12	1.91e-09	0.00343	0.33	0.27	Prostate cancer;	chr6:153106382	chr4:188740507~188741281:-
LUAD	trans	rs73108077	0.736	rs1997741	ENSG00000279352.1	RP11-411B10.7	6.12	1.91e-09	0.00343	0.44	0.27	Red blood cell density in sickle cell anemia;	chr20:31323198	chr18:14010054~14010917:+
LUAD	trans	rs7192380	1	rs11647110	ENSG00000257513.6	NPIPB1P	6.12	1.91e-09	0.00343	0.26	0.27	Sjögren's syndrome;	chr16:69555460	chr18:11619509~11639699:-
LUAD	trans	rs12200782	1	rs72844496	ENSG00000242375.1	RP11-498P14.3	-6.12	1.92e-09	0.00346	-0.63	-0.27	Small cell lung carcinoma;	chr6:26611380	chr9:97195351~97197687:-
LUAD	trans	rs17301013	0.896	rs3118980	ENSG00000213331.4	RP11-713C19.2	-6.12	1.93e-09	0.00346	-0.32	-0.27	Systemic lupus erythematosus;	chr1:174793701	chr4:187970273~187971284:+
LUAD	trans	rs66887589	0.775	rs6843229	ENSG00000275858.1	RP11-291L22.8	6.12	1.93e-09	0.00347	0.29	0.27	Diastolic blood pressure;	chr4:119502932	chr10:38450738~38451069:-
LUAD	trans	rs6831352	0.734	rs2602856	ENSG00000233859.2	ADH5P4	-6.12	1.93e-09	0.00347	-0.29	-0.27	Alcohol dependence;	chr4:99107994	chr6:65836930~65838039:-
LUAD	trans	rs864643	0.678	rs512923	ENSG00000183298.5	RP11-556K13.1	6.12	1.93e-09	0.00348	0.39	0.27	Attention deficit hyperactivity disorder;	chr3:39480472	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.678	rs621842	ENSG00000183298.5	RP11-556K13.1	6.12	1.93e-09	0.00348	0.39	0.27	Attention deficit hyperactivity disorder;	chr3:39480785	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.678	rs1768224	ENSG00000183298.5	RP11-556K13.1	6.12	1.94e-09	0.00349	0.38	0.27	Attention deficit hyperactivity disorder;	chr3:39491843	chr1:101786340~101787219:-
LUAD	trans	rs7647973	1	rs3870341	ENSG00000197582.5	GPX1P1	6.12	1.94e-09	0.00349	0.36	0.27	Menarche (age at onset);	chr3:49547312	chrX:13378735~13379340:-
LUAD	trans	rs7312770	0.637	rs705700	ENSG00000234192.1	RP11-57C13.5	6.12	1.94e-09	0.00349	0.29	0.27	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr10:87642607~87642954:+
LUAD	trans	rs12200782	1	rs4515370	ENSG00000242375.1	RP11-498P14.3	-6.12	1.94e-09	0.00349	-0.64	-0.27	Small cell lung carcinoma;	chr6:26625091	chr9:97195351~97197687:-
LUAD	trans	rs9876781	0.967	rs7618883	ENSG00000225528.1	RP3-370M22.8	-6.12	1.95e-09	0.0035	-0.27	-0.27	Longevity;	chr3:48457056	chr22:39960397~39964683:+
LUAD	trans	rs7647973	0.826	rs9834535	ENSG00000197582.5	GPX1P1	6.12	1.95e-09	0.00351	0.37	0.27	Menarche (age at onset);	chr3:49341364	chrX:13378735~13379340:-
LUAD	trans	rs7412746	0.658	rs12405726	ENSG00000180764.13	PIPSL	-6.12	1.96e-09	0.00352	-0.31	-0.27	Melanoma;	chr1:150983652	chr10:93958191~93961540:-
LUAD	trans	rs853679	0.599	rs13193295	ENSG00000281831.1	HCP5B	6.12	1.96e-09	0.00352	0.6	0.27	Depression;	chr6:28035450	chr6:29871895~29873783:-
LUAD	trans	rs4713118	0.699	rs200978	ENSG00000204709.4	LINC01556	6.12	1.97e-09	0.00354	0.37	0.27	Parkinson's disease;	chr6:27885390	chr6:28943877~28944537:+
LUAD	trans	rs11220082	0.666	rs2241514	ENSG00000236257.1	EI24P2	-6.12	1.97e-09	0.00354	-0.29	-0.27	Schizophrenia;	chr11:125456130	chr1:158454198~158455273:+
LUAD	trans	rs7833986	0.501	rs2719255	ENSG00000236862.1	RPS20P24	6.12	1.97e-09	0.00354	0.33	0.27	Height;	chr8:56124099	chr9:72655832~72656192:-
LUAD	trans	rs7833986	0.501	rs72653990	ENSG00000236862.1	RPS20P24	6.12	1.97e-09	0.00354	0.33	0.27	Height;	chr8:56124556	chr9:72655832~72656192:-
LUAD	trans	rs7833986	0.501	rs17815934	ENSG00000236862.1	RPS20P24	6.12	1.97e-09	0.00354	0.33	0.27	Height;	chr8:56125836	chr9:72655832~72656192:-
LUAD	trans	rs66887589	0.967	rs59516282	ENSG00000275858.1	RP11-291L22.8	-6.12	1.98e-09	0.00356	-0.28	-0.27	Diastolic blood pressure;	chr4:119580861	chr10:38450738~38451069:-
LUAD	trans	rs864643	0.524	rs78956370	ENSG00000183298.5	RP11-556K13.1	6.12	1.99e-09	0.00357	0.47	0.27	Attention deficit hyperactivity disorder;	chr3:39463883	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.678	rs1768244	ENSG00000183298.5	RP11-556K13.1	6.12	1.99e-09	0.00357	0.38	0.27	Attention deficit hyperactivity disorder;	chr3:39500688	chr1:101786340~101787219:-
LUAD	trans	rs7809615	0.551	rs952319	ENSG00000228834.1	RP11-249L21.4	6.12	1.99e-09	0.00357	0.41	0.27	Blood metabolite ratios;	chr7:99573826	chr6:108907615~108907873:-
LUAD	trans	rs6499255	0.951	rs8052086	ENSG00000257513.6	NPIPB1P	6.12	1.99e-09	0.00358	0.32	0.27	IgE levels;	chr16:69658565	chr18:11619509~11639699:-
LUAD	trans	rs6499244	0.529	rs7200005	ENSG00000257513.6	NPIPB1P	6.12	2e-09	0.00359	0.27	0.27	Menarche (age at onset);	chr16:69895234	chr18:11619509~11639699:-
LUAD	trans	rs4713118	0.868	rs7756968	ENSG00000204709.4	LINC01556	6.11	2.01e-09	0.0036	0.38	0.27	Parkinson's disease;	chr6:27767175	chr6:28943877~28944537:+
LUAD	trans	rs853679	0.556	rs13200214	ENSG00000253570.1	RNF5P1	6.11	2.02e-09	0.00362	0.6	0.27	Depression;	chr6:28049472	chr8:38600661~38601200:-
LUAD	trans	rs6424115	0.692	rs573361	ENSG00000228217.1	AL390877.1	-6.11	2.03e-09	0.00364	-0.34	-0.27	Immature fraction of reticulocytes;	chr1:23727184	chr1:117778087~117778506:-
LUAD	trans	rs9876781	1	rs6442123	ENSG00000225528.1	RP3-370M22.8	-6.11	2.04e-09	0.00365	-0.27	-0.27	Longevity;	chr3:48458887	chr22:39960397~39964683:+
LUAD	trans	rs7260598	0.792	rs11672468	ENSG00000261770.1	CTC-459F4.1	6.11	2.04e-09	0.00365	0.43	0.27	Response to taxane treatment (placlitaxel);	chr19:24119770	chr19:27757184~27760849:-
LUAD	trans	rs7260598	0.792	rs73021445	ENSG00000261770.1	CTC-459F4.1	6.11	2.04e-09	0.00365	0.43	0.27	Response to taxane treatment (placlitaxel);	chr19:24121306	chr19:27757184~27760849:-
LUAD	trans	rs7260598	0.792	rs7252836	ENSG00000261770.1	CTC-459F4.1	6.11	2.04e-09	0.00365	0.43	0.27	Response to taxane treatment (placlitaxel);	chr19:24122787	chr19:27757184~27760849:-
LUAD	trans	rs7260598	0.792	rs61737180	ENSG00000261770.1	CTC-459F4.1	6.11	2.04e-09	0.00365	0.43	0.27	Response to taxane treatment (placlitaxel);	chr19:24127230	chr19:27757184~27760849:-
LUAD	trans	rs7260598	0.792	rs73021454	ENSG00000261770.1	CTC-459F4.1	6.11	2.04e-09	0.00365	0.43	0.27	Response to taxane treatment (placlitaxel);	chr19:24133074	chr19:27757184~27760849:-
LUAD	trans	rs7260598	0.792	rs11671960	ENSG00000261770.1	CTC-459F4.1	6.11	2.04e-09	0.00365	0.43	0.27	Response to taxane treatment (placlitaxel);	chr19:24135019	chr19:27757184~27760849:-
LUAD	trans	rs7260598	0.792	rs59756985	ENSG00000261770.1	CTC-459F4.1	6.11	2.04e-09	0.00365	0.43	0.27	Response to taxane treatment (placlitaxel);	chr19:24141664	chr19:27757184~27760849:-
LUAD	trans	rs7260598	0.792	rs73021467	ENSG00000261770.1	CTC-459F4.1	6.11	2.04e-09	0.00365	0.43	0.27	Response to taxane treatment (placlitaxel);	chr19:24142863	chr19:27757184~27760849:-
LUAD	trans	rs7260598	0.792	rs4019979	ENSG00000261770.1	CTC-459F4.1	6.11	2.04e-09	0.00365	0.43	0.27	Response to taxane treatment (placlitaxel);	chr19:24143881	chr19:27757184~27760849:-
LUAD	trans	rs7260598	0.792	rs11672981	ENSG00000261770.1	CTC-459F4.1	6.11	2.04e-09	0.00365	0.43	0.27	Response to taxane treatment (placlitaxel);	chr19:24144735	chr19:27757184~27760849:-
LUAD	trans	rs7554511	0.861	rs378672	ENSG00000244144.1	RP11-757F18.3	6.11	2.05e-09	0.00367	0.33	0.27	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200917205	chr3:112185480~112185998:-
LUAD	trans	rs853679	0.607	rs13211507	ENSG00000281831.1	HCP5B	6.11	2.05e-09	0.00367	0.58	0.27	Depression;	chr6:28289600	chr6:29871895~29873783:-
LUAD	trans	rs853679	0.607	rs34691223	ENSG00000281831.1	HCP5B	6.11	2.05e-09	0.00367	0.58	0.27	Depression;	chr6:28290431	chr6:29871895~29873783:-
LUAD	trans	rs17301013	0.932	rs11804941	ENSG00000213331.4	RP11-713C19.2	-6.11	2.05e-09	0.00367	-0.31	-0.27	Systemic lupus erythematosus;	chr1:174624074	chr4:187970273~187971284:+
LUAD	trans	rs7260598	0.792	rs11669295	ENSG00000261770.1	CTC-459F4.1	6.11	2.05e-09	0.00367	0.43	0.27	Response to taxane treatment (placlitaxel);	chr19:24154184	chr19:27757184~27760849:-
LUAD	trans	rs7260598	0.792	rs11670299	ENSG00000261770.1	CTC-459F4.1	6.11	2.05e-09	0.00368	0.43	0.27	Response to taxane treatment (placlitaxel);	chr19:24154959	chr19:27757184~27760849:-
LUAD	trans	rs17301013	0.896	rs332773	ENSG00000213331.4	RP11-713C19.2	6.11	2.05e-09	0.00368	0.31	0.27	Systemic lupus erythematosus;	chr1:174695711	chr4:187970273~187971284:+
LUAD	trans	rs17301013	0.932	rs444678	ENSG00000213331.4	RP11-713C19.2	6.11	2.05e-09	0.00368	0.31	0.27	Systemic lupus erythematosus;	chr1:174706080	chr4:187970273~187971284:+
LUAD	trans	rs17301013	0.896	rs332791	ENSG00000213331.4	RP11-713C19.2	6.11	2.05e-09	0.00368	0.31	0.27	Systemic lupus erythematosus;	chr1:174709784	chr4:187970273~187971284:+
LUAD	trans	rs17301013	0.861	rs332789	ENSG00000213331.4	RP11-713C19.2	6.11	2.06e-09	0.00368	0.32	0.27	Systemic lupus erythematosus;	chr1:174735754	chr4:187970273~187971284:+
LUAD	trans	rs17301013	0.932	rs461910	ENSG00000213331.4	RP11-713C19.2	6.11	2.06e-09	0.00368	0.32	0.27	Systemic lupus erythematosus;	chr1:174736351	chr4:187970273~187971284:+
LUAD	trans	rs4276421	0.509	rs17293295	ENSG00000231752.4	EMBP1	6.11	2.06e-09	0.00369	0.42	0.27	P wave duration;	chr5:45509473	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.509	rs12656485	ENSG00000231752.4	EMBP1	6.11	2.06e-09	0.00369	0.42	0.27	P wave duration;	chr5:45513518	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.509	rs1483311	ENSG00000231752.4	EMBP1	6.11	2.06e-09	0.00369	0.42	0.27	P wave duration;	chr5:45514872	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.509	rs1483312	ENSG00000231752.4	EMBP1	6.11	2.06e-09	0.00369	0.42	0.27	P wave duration;	chr5:45514982	chr1:121519112~121571892:+
LUAD	trans	rs4276421	0.509	rs1483313	ENSG00000231752.4	EMBP1	6.11	2.06e-09	0.00369	0.42	0.27	P wave duration;	chr5:45515322	chr1:121519112~121571892:+
LUAD	trans	rs7260598	0.892	rs2116956	ENSG00000261770.1	CTC-459F4.1	6.11	2.06e-09	0.00369	0.44	0.27	Response to taxane treatment (placlitaxel);	chr19:24005987	chr19:27757184~27760849:-
LUAD	trans	rs17301013	0.932	rs10912807	ENSG00000213331.4	RP11-713C19.2	6.11	2.07e-09	0.0037	0.31	0.27	Systemic lupus erythematosus;	chr1:174547228	chr4:187970273~187971284:+
LUAD	trans	rs7647973	0.922	rs57273516	ENSG00000197582.5	GPX1P1	6.11	2.07e-09	0.0037	0.36	0.27	Menarche (age at onset);	chr3:49445641	chrX:13378735~13379340:-
LUAD	trans	rs4713118	0.955	rs9468206	ENSG00000204709.4	LINC01556	6.11	2.08e-09	0.00372	0.36	0.27	Parkinson's disease;	chr6:27722674	chr6:28943877~28944537:+
LUAD	trans	rs79149102	0.522	rs6495119	ENSG00000227288.3	RP5-837I24.1	6.11	2.08e-09	0.00372	0.51	0.27	Lung cancer;	chr15:74642099	chr1:81501794~81503468:+
LUAD	trans	rs12210905	0.925	rs12214640	ENSG00000242375.1	RP11-498P14.3	-6.11	2.09e-09	0.00374	-0.63	-0.27	Hip circumference adjusted for BMI;	chr6:26739806	chr9:97195351~97197687:-
LUAD	trans	rs12145833	0.679	rs12029086	ENSG00000154608.12	CEP170P1	-6.11	2.1e-09	0.00375	-0.47	-0.27	Obesity (early onset extreme);	chr1:243401420	chr4:118467590~118554204:+
LUAD	trans	rs7833986	0.501	rs17812659	ENSG00000244245.1	RP11-120B7.1	6.11	2.1e-09	0.00375	0.33	0.27	Height;	chr8:55977303	chr5:108593609~108593967:+
LUAD	trans	rs66887589	0.87	rs10518336	ENSG00000275858.1	RP11-291L22.8	6.11	2.1e-09	0.00376	0.3	0.27	Diastolic blood pressure;	chr4:119601779	chr10:38450738~38451069:-
LUAD	trans	rs6499255	0.857	rs16959035	ENSG00000257513.6	NPIPB1P	6.11	2.11e-09	0.00377	0.31	0.27	IgE levels;	chr16:69673742	chr18:11619509~11639699:-
LUAD	trans	rs12200782	1	rs12204145	ENSG00000242375.1	RP11-498P14.3	-6.11	2.11e-09	0.00378	-0.6	-0.27	Small cell lung carcinoma;	chr6:26599928	chr9:97195351~97197687:-
LUAD	trans	rs17301013	0.932	rs6425282	ENSG00000213331.4	RP11-713C19.2	6.11	2.12e-09	0.00378	0.31	0.27	Systemic lupus erythematosus;	chr1:174493387	chr4:187970273~187971284:+
LUAD	trans	rs17301013	0.932	rs7555533	ENSG00000213331.4	RP11-713C19.2	6.1	2.13e-09	0.0038	0.32	0.27	Systemic lupus erythematosus;	chr1:174589983	chr4:187970273~187971284:+
LUAD	trans	rs7647973	0.731	rs13084037	ENSG00000197582.5	GPX1P1	6.1	2.13e-09	0.00381	0.4	0.27	Menarche (age at onset);	chr3:49176633	chrX:13378735~13379340:-
LUAD	trans	rs66887589	0.72	rs2036858	ENSG00000275858.1	RP11-291L22.8	6.1	2.13e-09	0.00381	0.29	0.27	Diastolic blood pressure;	chr4:119328082	chr10:38450738~38451069:-
LUAD	trans	rs864643	0.524	rs80322842	ENSG00000183298.5	RP11-556K13.1	6.1	2.15e-09	0.00384	0.45	0.27	Attention deficit hyperactivity disorder;	chr3:39483682	chr1:101786340~101787219:-
LUAD	trans	rs79149102	0.522	rs6495112	ENSG00000227288.3	RP5-837I24.1	6.1	2.15e-09	0.00384	0.49	0.27	Lung cancer;	chr15:74540457	chr1:81501794~81503468:+
LUAD	trans	rs79149102	0.522	rs7175512	ENSG00000227288.3	RP5-837I24.1	6.1	2.15e-09	0.00384	0.49	0.27	Lung cancer;	chr15:74540640	chr1:81501794~81503468:+
LUAD	trans	rs16937956	0.597	rs16937958	ENSG00000266891.1	RP11-692N5.2	6.1	2.16e-09	0.00386	0.39	0.27	Body mass index;	chr11:8382988	chr18:9734882~9735602:-
LUAD	trans	rs17301013	0.932	rs727279	ENSG00000213331.4	RP11-713C19.2	6.1	2.16e-09	0.00386	0.31	0.27	Systemic lupus erythematosus;	chr1:174496026	chr4:187970273~187971284:+
LUAD	trans	rs17301013	0.794	rs6425283	ENSG00000213331.4	RP11-713C19.2	6.1	2.16e-09	0.00386	0.31	0.27	Systemic lupus erythematosus;	chr1:174499853	chr4:187970273~187971284:+
LUAD	trans	rs17301013	0.932	rs2072760	ENSG00000213331.4	RP11-713C19.2	6.1	2.16e-09	0.00386	0.31	0.27	Systemic lupus erythematosus;	chr1:174510186	chr4:187970273~187971284:+
LUAD	trans	rs17301013	0.932	rs10912797	ENSG00000213331.4	RP11-713C19.2	6.1	2.16e-09	0.00386	0.31	0.27	Systemic lupus erythematosus;	chr1:174511225	chr4:187970273~187971284:+
LUAD	trans	rs17301013	0.932	rs6668053	ENSG00000213331.4	RP11-713C19.2	6.1	2.16e-09	0.00386	0.31	0.27	Systemic lupus erythematosus;	chr1:174515139	chr4:187970273~187971284:+
LUAD	trans	rs1600249	0.562	rs17153419	ENSG00000253893.2	FAM85B	6.1	2.17e-09	0.00387	0.37	0.27	Rheumatoid arthritis;	chr8:11536724	chr8:8167819~8226614:-
LUAD	trans	rs1190596	0.525	rs10133613	ENSG00000181359.5	HSP90AA6P	-6.1	2.17e-09	0.00388	-0.3	-0.27	Behavioural disinhibition (generation interaction);	chr14:102269846	chr4:170581470~170605450:-
LUAD	trans	rs7260598	0.792	rs11669171	ENSG00000261770.1	CTC-459F4.1	6.1	2.18e-09	0.00389	0.43	0.27	Response to taxane treatment (placlitaxel);	chr19:24153957	chr19:27757184~27760849:-
LUAD	trans	rs877636	1	rs705696	ENSG00000243538.1	CTB-55B8.1	6.1	2.19e-09	0.0039	0.3	0.27	Cognitive function;	chr12:56086864	chr5:16902294~16902641:-
LUAD	trans	rs17040773	1	rs17040773	ENSG00000204745.3	AC083899.3	6.1	2.2e-09	0.00392	0.36	0.27	Bone mineral density;	chr2:111742458	chr2:87125390~87196647:+
LUAD	trans	rs864643	0.524	rs12106854	ENSG00000183298.5	RP11-556K13.1	6.1	2.2e-09	0.00393	0.45	0.27	Attention deficit hyperactivity disorder;	chr3:39487321	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.524	rs17038967	ENSG00000183298.5	RP11-556K13.1	6.1	2.2e-09	0.00393	0.45	0.27	Attention deficit hyperactivity disorder;	chr3:39489530	chr1:101786340~101787219:-
LUAD	trans	rs9425766	0.679	rs12085290	ENSG00000213331.4	RP11-713C19.2	-6.1	2.21e-09	0.00395	-0.31	-0.27	Life satisfaction;	chr1:174124699	chr4:187970273~187971284:+
LUAD	trans	rs7647973	0.925	rs6446257	ENSG00000197582.5	GPX1P1	-6.1	2.22e-09	0.00395	-0.37	-0.27	Menarche (age at onset);	chr3:49216059	chrX:13378735~13379340:-
LUAD	trans	rs670523	0.722	rs4661079	ENSG00000241627.3	UBQLN4P1	6.1	2.22e-09	0.00395	0.25	0.27	Crohn's disease;Inflammatory bowel disease;	chr1:156013507	chr3:148985868~148987668:-
LUAD	trans	rs12200782	1	rs12205909	ENSG00000242375.1	RP11-498P14.3	-6.1	2.22e-09	0.00395	-0.63	-0.27	Small cell lung carcinoma;	chr6:26630771	chr9:97195351~97197687:-
LUAD	trans	rs12200782	1	rs72845509	ENSG00000242375.1	RP11-498P14.3	-6.1	2.22e-09	0.00395	-0.63	-0.27	Small cell lung carcinoma;	chr6:26639637	chr9:97195351~97197687:-
LUAD	trans	rs1933488	0.898	rs1971152	ENSG00000278974.1	RP11-756P10.6	-6.1	2.22e-09	0.00396	-0.33	-0.27	Prostate cancer;	chr6:153104109	chr4:188740507~188741281:-
LUAD	trans	rs6499255	0.951	rs8054096	ENSG00000257513.6	NPIPB1P	6.1	2.23e-09	0.00398	0.31	0.27	IgE levels;	chr16:69661983	chr18:11619509~11639699:-
LUAD	trans	rs6499255	0.951	rs8046314	ENSG00000257513.6	NPIPB1P	6.1	2.23e-09	0.00398	0.31	0.27	IgE levels;	chr16:69664019	chr18:11619509~11639699:-
LUAD	trans	rs853679	0.546	rs35353359	ENSG00000281831.1	HCP5B	6.1	2.24e-09	0.00399	0.59	0.27	Depression;	chr6:28356601	chr6:29871895~29873783:-
LUAD	trans	rs6831352	0.819	rs1154401	ENSG00000233859.2	ADH5P4	-6.09	2.25e-09	0.004	-0.28	-0.27	Alcohol dependence;	chr4:99088587	chr6:65836930~65838039:-
LUAD	trans	rs864643	0.678	rs610006	ENSG00000183298.5	RP11-556K13.1	6.09	2.25e-09	0.004	0.38	0.27	Attention deficit hyperactivity disorder;	chr3:39481104	chr1:101786340~101787219:-
LUAD	trans	rs12200782	1	rs3800304	ENSG00000242375.1	RP11-498P14.3	-6.09	2.26e-09	0.00402	-0.63	-0.27	Small cell lung carcinoma;	chr6:26598570	chr9:97195351~97197687:-
LUAD	trans	rs12200782	1	rs72844495	ENSG00000242375.1	RP11-498P14.3	-6.09	2.26e-09	0.00402	-0.63	-0.27	Small cell lung carcinoma;	chr6:26610412	chr9:97195351~97197687:-
LUAD	trans	rs853679	0.607	rs66886492	ENSG00000253570.1	RNF5P1	6.09	2.26e-09	0.00402	0.6	0.27	Depression;	chr6:28121953	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.607	rs35345226	ENSG00000253570.1	RNF5P1	6.09	2.26e-09	0.00402	0.6	0.27	Depression;	chr6:28123802	chr8:38600661~38601200:-
LUAD	trans	rs4713118	0.824	rs7759217	ENSG00000204709.4	LINC01556	6.09	2.26e-09	0.00402	0.36	0.27	Parkinson's disease;	chr6:27762684	chr6:28943877~28944537:+
LUAD	trans	rs4713118	0.784	rs9468219	ENSG00000204709.4	LINC01556	6.09	2.26e-09	0.00402	0.36	0.27	Parkinson's disease;	chr6:27763976	chr6:28943877~28944537:+
LUAD	trans	rs7412746	0.658	rs4970988	ENSG00000180764.13	PIPSL	6.09	2.27e-09	0.00403	0.3	0.27	Melanoma;	chr1:150977586	chr10:93958191~93961540:-
LUAD	trans	rs4742971	0.5	rs3884524	ENSG00000262902.1	RP11-750B16.1	6.09	2.27e-09	0.00403	0.5	0.27	Protein quantitative trait loci;	chr9:105919688	chr17:53105734~53106358:+
LUAD	trans	rs877636	0.74	rs705698	ENSG00000227586.5	RP11-162A23.5	6.09	2.27e-09	0.00405	0.32	0.27	Cognitive function;	chr12:55990903	chr10:123171535~123171875:-
LUAD	trans	rs853679	0.546	rs13195291	ENSG00000281831.1	HCP5B	6.09	2.28e-09	0.00406	0.6	0.27	Depression;	chr6:28201463	chr6:29871895~29873783:-
LUAD	trans	rs17301013	0.932	rs6683602	ENSG00000213331.4	RP11-713C19.2	6.09	2.28e-09	0.00406	0.31	0.27	Systemic lupus erythematosus;	chr1:174617615	chr4:187970273~187971284:+
LUAD	trans	rs17301013	0.932	rs6696197	ENSG00000213331.4	RP11-713C19.2	6.09	2.28e-09	0.00406	0.31	0.27	Systemic lupus erythematosus;	chr1:174617860	chr4:187970273~187971284:+
LUAD	trans	rs17301013	0.73	rs12060177	ENSG00000213331.4	RP11-713C19.2	6.09	2.28e-09	0.00406	0.31	0.27	Systemic lupus erythematosus;	chr1:174618545	chr4:187970273~187971284:+
LUAD	trans	rs17301013	0.932	rs6671824	ENSG00000213331.4	RP11-713C19.2	6.09	2.29e-09	0.00407	0.31	0.27	Systemic lupus erythematosus;	chr1:174603721	chr4:187970273~187971284:+
LUAD	trans	rs17301013	0.861	rs6672148	ENSG00000213331.4	RP11-713C19.2	6.09	2.29e-09	0.00407	0.31	0.27	Systemic lupus erythematosus;	chr1:174604016	chr4:187970273~187971284:+
LUAD	trans	rs17301013	0.932	rs10912813	ENSG00000213331.4	RP11-713C19.2	6.09	2.29e-09	0.00407	0.31	0.27	Systemic lupus erythematosus;	chr1:174607342	chr4:187970273~187971284:+
LUAD	trans	rs2294426	0.716	rs4713834	ENSG00000245904.3	RP11-796E2.4	6.09	2.29e-09	0.00407	0.29	0.27	Orofacial clefts (maternal alcohol consumption interaction);	chr6:11729227	chr12:92145573~92189660:+
LUAD	trans	rs7260598	0.792	rs73021412	ENSG00000261770.1	CTC-459F4.1	6.09	2.29e-09	0.00408	0.43	0.27	Response to taxane treatment (placlitaxel);	chr19:24070755	chr19:27757184~27760849:-
LUAD	trans	rs9425766	0.628	rs6425274	ENSG00000213331.4	RP11-713C19.2	6.09	2.32e-09	0.00412	0.31	0.27	Life satisfaction;	chr1:174144270	chr4:187970273~187971284:+
LUAD	trans	rs9425766	0.566	rs6696076	ENSG00000213331.4	RP11-713C19.2	6.09	2.32e-09	0.00412	0.31	0.27	Life satisfaction;	chr1:174149900	chr4:187970273~187971284:+
LUAD	trans	rs9876781	1	rs9876781	ENSG00000225528.1	RP3-370M22.8	-6.09	2.33e-09	0.00414	-0.27	-0.27	Longevity;	chr3:48445934	chr22:39960397~39964683:+
LUAD	trans	rs853679	0.607	rs34878803	ENSG00000281831.1	HCP5B	6.09	2.33e-09	0.00414	0.57	0.27	Depression;	chr6:28282402	chr6:29871895~29873783:-
LUAD	trans	rs853679	0.607	rs34396849	ENSG00000281831.1	HCP5B	6.09	2.33e-09	0.00414	0.57	0.27	Depression;	chr6:28283178	chr6:29871895~29873783:-
LUAD	trans	rs864643	0.836	rs1708009	ENSG00000183298.5	RP11-556K13.1	6.09	2.33e-09	0.00414	0.37	0.27	Attention deficit hyperactivity disorder;	chr3:39496851	chr1:101786340~101787219:-
LUAD	trans	rs7746199	0.736	rs17693963	ENSG00000253570.1	RNF5P1	6.09	2.33e-09	0.00414	0.55	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27742386	chr8:38600661~38601200:-
LUAD	trans	rs6499255	0.904	rs60010276	ENSG00000257513.6	NPIPB1P	6.09	2.34e-09	0.00416	0.31	0.27	IgE levels;	chr16:69640902	chr18:11619509~11639699:-
LUAD	trans	rs6499255	0.951	rs2361838	ENSG00000257513.6	NPIPB1P	6.09	2.34e-09	0.00416	0.31	0.27	IgE levels;	chr16:69642183	chr18:11619509~11639699:-
LUAD	trans	rs6499255	0.951	rs76407217	ENSG00000257513.6	NPIPB1P	6.09	2.34e-09	0.00416	0.31	0.27	IgE levels;	chr16:69656452	chr18:11619509~11639699:-
LUAD	trans	rs4713118	0.869	rs6901520	ENSG00000204709.4	LINC01556	6.09	2.35e-09	0.00417	0.36	0.27	Parkinson's disease;	chr6:27746796	chr6:28943877~28944537:+
LUAD	trans	rs4713118	0.699	rs200969	ENSG00000204709.4	LINC01556	6.09	2.35e-09	0.00418	0.37	0.27	Parkinson's disease;	chr6:27891675	chr6:28943877~28944537:+
LUAD	trans	rs2277458	0.623	rs1998194	ENSG00000214249.3	CTAGE11P	-6.09	2.38e-09	0.00422	-0.36	-0.27	Vitamin D levels;	chr14:39221650	chr13:75237944~75240296:-
LUAD	trans	rs2899832	0.568	rs2277460	ENSG00000229083.1	PSMA6P2	6.09	2.38e-09	0.00422	0.42	0.27	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35292367	chrX:12825840~12826833:+
LUAD	trans	rs1190596	0.581	rs1190571	ENSG00000181359.5	HSP90AA6P	6.09	2.38e-09	0.00422	0.3	0.27	Behavioural disinhibition (generation interaction);	chr14:102168564	chr4:170581470~170605450:-
LUAD	trans	rs6499255	0.903	rs1800566	ENSG00000257513.6	NPIPB1P	6.09	2.38e-09	0.00422	0.32	0.27	IgE levels;	chr16:69711242	chr18:11619509~11639699:-
LUAD	trans	rs6499255	0.951	rs3743673	ENSG00000257513.6	NPIPB1P	6.09	2.38e-09	0.00422	0.32	0.27	IgE levels;	chr16:69677408	chr18:11619509~11639699:-
LUAD	trans	rs864643	0.524	rs17038918	ENSG00000183298.5	RP11-556K13.1	6.08	2.38e-09	0.00423	0.45	0.27	Attention deficit hyperactivity disorder;	chr3:39480975	chr1:101786340~101787219:-
LUAD	trans	rs17301013	0.9	rs56347239	ENSG00000213331.4	RP11-713C19.2	6.08	2.4e-09	0.00425	0.31	0.27	Systemic lupus erythematosus;	chr1:174564476	chr4:187970273~187971284:+
LUAD	trans	rs17301013	0.932	rs7542389	ENSG00000213331.4	RP11-713C19.2	6.08	2.4e-09	0.00425	0.31	0.27	Systemic lupus erythematosus;	chr1:174565104	chr4:187970273~187971284:+
LUAD	trans	rs17301013	0.932	rs12074753	ENSG00000213331.4	RP11-713C19.2	6.08	2.4e-09	0.00425	0.31	0.27	Systemic lupus erythematosus;	chr1:174565768	chr4:187970273~187971284:+
LUAD	trans	rs17301013	0.932	rs1016466	ENSG00000213331.4	RP11-713C19.2	6.08	2.4e-09	0.00426	0.31	0.27	Systemic lupus erythematosus;	chr1:174570652	chr4:187970273~187971284:+
LUAD	trans	rs17301013	0.932	rs10753086	ENSG00000213331.4	RP11-713C19.2	6.08	2.4e-09	0.00426	0.31	0.27	Systemic lupus erythematosus;	chr1:174580802	chr4:187970273~187971284:+
LUAD	trans	rs853679	0.607	rs13199649	ENSG00000204709.4	LINC01556	6.08	2.41e-09	0.00428	0.59	0.27	Depression;	chr6:27901014	chr6:28943877~28944537:+
LUAD	trans	rs6499255	1	rs11075734	ENSG00000257513.6	NPIPB1P	6.08	2.42e-09	0.00429	0.31	0.27	IgE levels;	chr16:69767494	chr18:11619509~11639699:-
LUAD	trans	rs12439619	0.846	rs7496227	ENSG00000259295.5	CSPG4P12	-6.08	2.44e-09	0.00432	-0.37	-0.27	Intelligence (multi-trait analysis);	chr15:82275241	chr15:85191438~85213905:+
LUAD	trans	rs7746199	0.736	rs13202295	ENSG00000253570.1	RNF5P1	6.08	2.44e-09	0.00433	0.58	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731058	chr8:38600661~38601200:-
LUAD	trans	rs7833986	0.501	rs2953922	ENSG00000236862.1	RPS20P24	6.08	2.44e-09	0.00433	0.33	0.27	Height;	chr8:56064926	chr9:72655832~72656192:-
LUAD	trans	rs7833986	0.501	rs2953897	ENSG00000236862.1	RPS20P24	6.08	2.44e-09	0.00433	0.33	0.27	Height;	chr8:56068010	chr9:72655832~72656192:-
LUAD	trans	rs7833986	0.501	rs2953898	ENSG00000236862.1	RPS20P24	6.08	2.44e-09	0.00433	0.33	0.27	Height;	chr8:56068244	chr9:72655832~72656192:-
LUAD	trans	rs7833986	0.501	rs2953901	ENSG00000236862.1	RPS20P24	6.08	2.44e-09	0.00433	0.33	0.27	Height;	chr8:56069265	chr9:72655832~72656192:-
LUAD	trans	rs6499255	0.951	rs12596823	ENSG00000257513.6	NPIPB1P	6.08	2.48e-09	0.00439	0.31	0.27	IgE levels;	chr16:69600854	chr18:11619509~11639699:-
LUAD	trans	rs1383484	0.575	rs28694702	ENSG00000278603.1	RP13-608F4.5	6.08	2.48e-09	0.00439	0.34	0.27	Height;	chr15:83945534	chr15:82472203~82472426:+
LUAD	trans	rs853679	0.607	rs68188794	ENSG00000281831.1	HCP5B	6.08	2.49e-09	0.00441	0.62	0.27	Depression;	chr6:28112999	chr6:29871895~29873783:-
LUAD	trans	rs11951515	0.508	rs10059993	ENSG00000174977.8	AC026271.5	-6.08	2.51e-09	0.00445	-0.27	-0.27	Metabolite levels  (X-11787);	chr5:43598250	chr17:18650195~18651542:+
LUAD	trans	rs853679	0.546	rs71537572	ENSG00000253570.1	RNF5P1	6.08	2.51e-09	0.00445	0.59	0.27	Depression;	chr6:28002937	chr8:38600661~38601200:-
LUAD	trans	rs9584850	0.708	rs4411372	ENSG00000230079.1	STK24P1	6.08	2.52e-09	0.00446	0.31	0.27	Neuroticism;	chr13:98478169	chrX:136295690~136300298:-
LUAD	trans	rs17301013	0.932	rs332795	ENSG00000213331.4	RP11-713C19.2	6.07	2.53e-09	0.00448	0.31	0.27	Systemic lupus erythematosus;	chr1:174726785	chr4:187970273~187971284:+
LUAD	trans	rs7746199	0.736	rs34105070	ENSG00000253570.1	RNF5P1	6.07	2.56e-09	0.00452	0.58	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27593026	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.607	rs35749575	ENSG00000253570.1	RNF5P1	6.07	2.56e-09	0.00452	0.6	0.27	Depression;	chr6:28147040	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.607	rs72846780	ENSG00000253570.1	RNF5P1	6.07	2.56e-09	0.00452	0.6	0.27	Depression;	chr6:28151277	chr8:38600661~38601200:-
LUAD	trans	rs11992162	1	rs7460395	ENSG00000253981.4	ALG1L13P	6.07	2.57e-09	0.00453	0.31	0.27	Monocyte count;	chr8:11977866	chr8:8236003~8244667:-
LUAD	trans	rs17301013	0.932	rs4233195	ENSG00000213331.4	RP11-713C19.2	-6.07	2.58e-09	0.00455	-0.31	-0.27	Systemic lupus erythematosus;	chr1:174806736	chr4:187970273~187971284:+
LUAD	trans	rs453301	0.571	rs330048	ENSG00000253893.2	FAM85B	6.07	2.58e-09	0.00455	0.34	0.27	Joint mobility (Beighton score);	chr8:9229768	chr8:8167819~8226614:-
LUAD	trans	rs853679	0.607	rs13205911	ENSG00000253570.1	RNF5P1	6.07	2.6e-09	0.00459	0.6	0.27	Depression;	chr6:28156336	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.607	rs13197176	ENSG00000253570.1	RNF5P1	6.07	2.6e-09	0.00459	0.6	0.27	Depression;	chr6:28161454	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.607	rs13201308	ENSG00000253570.1	RNF5P1	6.07	2.6e-09	0.00459	0.6	0.27	Depression;	chr6:28162311	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.607	rs34765154	ENSG00000253570.1	RNF5P1	6.07	2.6e-09	0.00459	0.6	0.27	Depression;	chr6:28162672	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.607	rs34505829	ENSG00000253570.1	RNF5P1	6.07	2.6e-09	0.00459	0.6	0.27	Depression;	chr6:28165461	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.607	rs35098436	ENSG00000253570.1	RNF5P1	6.07	2.6e-09	0.00459	0.6	0.27	Depression;	chr6:28166443	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.607	rs72846794	ENSG00000253570.1	RNF5P1	6.07	2.6e-09	0.00459	0.6	0.27	Depression;	chr6:28169721	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.607	rs13217984	ENSG00000253570.1	RNF5P1	6.07	2.6e-09	0.00459	0.6	0.27	Depression;	chr6:28171932	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.556	rs67297533	ENSG00000253570.1	RNF5P1	6.07	2.6e-09	0.00459	0.6	0.27	Depression;	chr6:28173475	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.505	rs35781323	ENSG00000253570.1	RNF5P1	6.07	2.6e-09	0.00459	0.6	0.27	Depression;	chr6:28177054	chr8:38600661~38601200:-
LUAD	trans	rs4713118	0.588	rs200994	ENSG00000204709.4	LINC01556	-6.07	2.63e-09	0.00464	-0.37	-0.27	Parkinson's disease;	chr6:27846035	chr6:28943877~28944537:+
LUAD	trans	rs864643	0.678	rs1707957	ENSG00000183298.5	RP11-556K13.1	6.07	2.64e-09	0.00466	0.38	0.27	Attention deficit hyperactivity disorder;	chr3:39482000	chr1:101786340~101787219:-
LUAD	trans	rs7412746	0.658	rs4970987	ENSG00000180764.13	PIPSL	-6.07	2.65e-09	0.00467	-0.3	-0.27	Melanoma;	chr1:150977206	chr10:93958191~93961540:-
LUAD	trans	rs7412746	0.634	rs12562939	ENSG00000180764.13	PIPSL	-6.07	2.65e-09	0.00467	-0.3	-0.27	Melanoma;	chr1:150978976	chr10:93958191~93961540:-
LUAD	trans	rs847577	0.715	rs4729402	ENSG00000225169.1	BRI3P1	6.07	2.65e-09	0.00467	0.32	0.27	Breast cancer;	chr7:98078419	chr1:100213293~100213670:+
LUAD	trans	rs1075232	0.649	rs7177058	ENSG00000270055.1	CTD-3092A11.2	6.07	2.66e-09	0.00468	0.39	0.27	Survival in colorectal cancer (non-distant metastatic);	chr15:31938737	chr15:30487963~30490313:+
LUAD	trans	rs17301013	0.9	rs1754351	ENSG00000213331.4	RP11-713C19.2	-6.07	2.66e-09	0.00468	-0.31	-0.27	Systemic lupus erythematosus;	chr1:174762458	chr4:187970273~187971284:+
LUAD	trans	rs853679	0.607	rs66886492	ENSG00000281831.1	HCP5B	6.07	2.66e-09	0.00469	0.6	0.27	Depression;	chr6:28121953	chr6:29871895~29873783:-
LUAD	trans	rs853679	0.607	rs35345226	ENSG00000281831.1	HCP5B	6.07	2.66e-09	0.00469	0.6	0.27	Depression;	chr6:28123802	chr6:29871895~29873783:-
LUAD	trans	rs73108077	0.736	rs6060436	ENSG00000279352.1	RP11-411B10.7	6.07	2.67e-09	0.0047	0.43	0.27	Red blood cell density in sickle cell anemia;	chr20:31258500	chr18:14010054~14010917:+
LUAD	trans	rs7746199	0.736	rs13212093	ENSG00000253570.1	RNF5P1	6.06	2.68e-09	0.00471	0.58	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27638937	chr8:38600661~38601200:-
LUAD	trans	rs7746199	0.736	rs34038546	ENSG00000253570.1	RNF5P1	6.06	2.68e-09	0.00471	0.58	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27639881	chr8:38600661~38601200:-
LUAD	trans	rs141342723	1	rs141342723	ENSG00000253570.1	RNF5P1	6.06	2.68e-09	0.00471	0.58	0.27	Autism spectrum disorder or schizophrenia;	chr6:27654305	chr8:38600661~38601200:-
LUAD	trans	rs7746199	0.736	rs34543938	ENSG00000253570.1	RNF5P1	6.06	2.68e-09	0.00471	0.58	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27656861	chr8:38600661~38601200:-
LUAD	trans	rs7746199	0.736	rs56405707	ENSG00000253570.1	RNF5P1	6.06	2.68e-09	0.00471	0.58	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27672467	chr8:38600661~38601200:-
LUAD	trans	rs11951515	0.508	rs6860493	ENSG00000174977.8	AC026271.5	-6.06	2.68e-09	0.00471	-0.28	-0.27	Metabolite levels  (X-11787);	chr5:43602611	chr17:18650195~18651542:+
LUAD	trans	rs76228276	0.737	rs77547719	ENSG00000260318.1	COX6CP1	6.06	2.68e-09	0.00472	0.81	0.27	Childhood ear infection;	chr8:99583331	chr16:11903923~11904137:-
LUAD	trans	rs116002988	0.627	rs117686950	ENSG00000249592.4	RP11-440L14.1	-6.06	2.69e-09	0.00473	-0.32	-0.27	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr14:98981594	chr4:762387~781849:-
LUAD	trans	rs7769051	0.808	rs1467403	ENSG00000227615.1	RP11-864N7.2	6.06	2.7e-09	0.00475	0.45	0.27	Type 2 diabetes nephropathy;	chr6:132768813	chr11:74745716~74746114:-
LUAD	trans	rs7192380	0.931	rs9302604	ENSG00000257513.6	NPIPB1P	6.06	2.7e-09	0.00475	0.27	0.27	Sjögren's syndrome;	chr16:69542991	chr18:11619509~11639699:-
LUAD	trans	rs4713118	0.739	rs2893931	ENSG00000204709.4	LINC01556	6.06	2.71e-09	0.00476	0.36	0.27	Parkinson's disease;	chr6:27780231	chr6:28943877~28944537:+
LUAD	trans	rs4713118	0.824	rs2092075	ENSG00000204709.4	LINC01556	6.06	2.71e-09	0.00476	0.36	0.27	Parkinson's disease;	chr6:27781551	chr6:28943877~28944537:+
LUAD	trans	rs7746199	0.736	rs67652222	ENSG00000253570.1	RNF5P1	6.06	2.71e-09	0.00476	0.58	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27618441	chr8:38600661~38601200:-
LUAD	trans	rs1455244	0.7	rs7229302	ENSG00000233762.3	AC007969.5	6.06	2.71e-09	0.00476	0.22	0.27	Schizophrenia;	chr18:11508905	chr2:171517270~171517716:-
LUAD	trans	rs73108077	0.736	rs6058546	ENSG00000279352.1	RP11-411B10.7	6.06	2.72e-09	0.00478	0.44	0.27	Red blood cell density in sickle cell anemia;	chr20:31314582	chr18:14010054~14010917:+
LUAD	trans	rs10037055	0.853	rs1546363	ENSG00000228305.2	AC016734.2	-6.06	2.73e-09	0.0048	-0.3	-0.27	Migraine without aura;	chr5:177174030	chr2:63622178~63622831:-
LUAD	trans	rs13016963	0.526	rs11681616	ENSG00000235105.1	RP11-329A14.1	6.06	2.74e-09	0.00482	0.31	0.27	Esophageal squamous cell carcinoma;Melanoma;	chr2:201360013	chr1:48435967~48437223:+
LUAD	trans	rs3812762	0.843	rs2292046	ENSG00000266891.1	RP11-692N5.2	-6.06	2.74e-09	0.00482	-0.34	-0.27	Hypospadias;	chr11:8785632	chr18:9734882~9735602:-
LUAD	trans	rs6499255	1	rs4078387	ENSG00000257513.6	NPIPB1P	6.06	2.74e-09	0.00482	0.31	0.27	IgE levels;	chr16:69780144	chr18:11619509~11639699:-
LUAD	trans	rs17301013	0.932	rs12077622	ENSG00000213331.4	RP11-713C19.2	6.06	2.76e-09	0.00484	0.31	0.27	Systemic lupus erythematosus;	chr1:174442507	chr4:187970273~187971284:+
LUAD	trans	rs9876781	1	rs2279077	ENSG00000225528.1	RP3-370M22.8	-6.06	2.76e-09	0.00484	-0.27	-0.27	Longevity;	chr3:48432839	chr22:39960397~39964683:+
LUAD	trans	rs9876781	1	rs1109227	ENSG00000225528.1	RP3-370M22.8	-6.06	2.76e-09	0.00484	-0.27	-0.27	Longevity;	chr3:48437797	chr22:39960397~39964683:+
LUAD	trans	rs9876781	1	rs3774808	ENSG00000225528.1	RP3-370M22.8	-6.06	2.76e-09	0.00484	-0.27	-0.27	Longevity;	chr3:48440237	chr22:39960397~39964683:+
LUAD	trans	rs7833986	0.501	rs2719261	ENSG00000244245.1	RP11-120B7.1	6.06	2.76e-09	0.00485	0.3	0.27	Height;	chr8:56029423	chr5:108593609~108593967:+
LUAD	trans	rs7833986	0.501	rs72653941	ENSG00000244245.1	RP11-120B7.1	6.06	2.76e-09	0.00485	0.3	0.27	Height;	chr8:56029688	chr5:108593609~108593967:+
LUAD	trans	rs17301013	0.932	rs67967476	ENSG00000213331.4	RP11-713C19.2	6.06	2.78e-09	0.00488	0.31	0.27	Systemic lupus erythematosus;	chr1:174616119	chr4:187970273~187971284:+
LUAD	trans	rs7192380	1	rs2161630	ENSG00000257513.6	NPIPB1P	6.06	2.79e-09	0.00489	0.26	0.27	Sjögren's syndrome;	chr16:69572558	chr18:11619509~11639699:-
LUAD	trans	rs7746199	0.736	rs13202295	ENSG00000281831.1	HCP5B	6.06	2.81e-09	0.00493	0.58	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731058	chr6:29871895~29873783:-
LUAD	trans	rs4948102	0.599	rs2230197	ENSG00000186940.6	CHCHD2P9	-6.06	2.81e-09	0.00493	-0.32	-0.27	Plasma homocysteine levels (post-methionine load test);	chr7:56058667	chr9:79391304~79391759:+
LUAD	trans	rs3096299	0.719	rs2353581	ENSG00000215030.5	RPL13P12	-6.06	2.81e-09	0.00493	-0.3	-0.27	Multiple myeloma (IgH translocation);	chr16:89452500	chr17:17383377~17384012:-
LUAD	trans	rs17507216	1	rs17507216	ENSG00000235370.6	DNM1P51	6.06	2.83e-09	0.00496	0.37	0.27	Excessive daytime sleepiness;	chr15:82558175	chr15:84398316~84411701:-
LUAD	trans	rs7833986	0.501	rs2719257	ENSG00000236862.1	RPS20P24	6.06	2.83e-09	0.00496	0.33	0.27	Height;	chr8:56027614	chr9:72655832~72656192:-
LUAD	trans	rs1190596	0.525	rs8004474	ENSG00000181359.5	HSP90AA6P	-6.05	2.84e-09	0.00497	-0.3	-0.27	Behavioural disinhibition (generation interaction);	chr14:102290161	chr4:170581470~170605450:-
LUAD	trans	rs66887589	0.777	rs4643791	ENSG00000275858.1	RP11-291L22.8	-6.05	2.84e-09	0.00497	-0.28	-0.27	Diastolic blood pressure;	chr4:119344464	chr10:38450738~38451069:-
LUAD	trans	rs2060793	0.741	rs10734227	ENSG00000236360.2	RP11-334A14.2	6.05	2.84e-09	0.00498	0.34	0.27	Vitamin D levels;	chr11:14767471	chr1:52993201~52993702:-
LUAD	trans	rs12477438	0.501	rs11688004	ENSG00000276576.1	MRPL30P1	6.05	2.84e-09	0.00498	0.3	0.27	Chronic sinus infection;	chr2:99118589	chr6:57029521~57029988:+
LUAD	trans	rs4713118	0.699	rs573179	ENSG00000204709.4	LINC01556	6.05	2.84e-09	0.00498	0.37	0.27	Parkinson's disease;	chr6:27881898	chr6:28943877~28944537:+
LUAD	trans	rs7833986	0.501	rs17814658	ENSG00000236862.1	RPS20P24	6.05	2.84e-09	0.00498	0.33	0.27	Height;	chr8:56076571	chr9:72655832~72656192:-
LUAD	trans	rs7833986	0.501	rs72653957	ENSG00000236862.1	RPS20P24	6.05	2.84e-09	0.00498	0.33	0.27	Height;	chr8:56077489	chr9:72655832~72656192:-
LUAD	trans	rs4713118	0.955	rs9468203	ENSG00000204709.4	LINC01556	6.05	2.86e-09	0.00501	0.35	0.27	Parkinson's disease;	chr6:27720888	chr6:28943877~28944537:+
LUAD	trans	rs66887589	0.72	rs11724758	ENSG00000275858.1	RP11-291L22.8	6.05	2.86e-09	0.00501	0.29	0.27	Diastolic blood pressure;	chr4:119318723	chr10:38450738~38451069:-
LUAD	trans	rs12200782	0.932	rs12212145	ENSG00000242375.1	RP11-498P14.3	-6.05	2.87e-09	0.00502	-0.63	-0.27	Small cell lung carcinoma;	chr6:26646190	chr9:97195351~97197687:-
LUAD	trans	rs12200782	0.799	rs72845515	ENSG00000242375.1	RP11-498P14.3	-6.05	2.87e-09	0.00502	-0.63	-0.27	Small cell lung carcinoma;	chr6:26646643	chr9:97195351~97197687:-
LUAD	trans	rs12210905	0.8	rs12209651	ENSG00000242375.1	RP11-498P14.3	-6.05	2.87e-09	0.00502	-0.63	-0.27	Hip circumference adjusted for BMI;	chr6:26660697	chr9:97195351~97197687:-
LUAD	trans	rs12210905	0.8	rs12201890	ENSG00000242375.1	RP11-498P14.3	-6.05	2.87e-09	0.00502	-0.63	-0.27	Hip circumference adjusted for BMI;	chr6:26662398	chr9:97195351~97197687:-
LUAD	trans	rs7258465	0.511	rs11668719	ENSG00000267533.1	RP11-815J4.7	6.05	2.87e-09	0.00502	0.32	0.27	Breast cancer;	chr19:18404931	chr18:12067173~12068417:-
LUAD	trans	rs6499255	0.951	rs56316408	ENSG00000257513.6	NPIPB1P	6.05	2.87e-09	0.00503	0.31	0.27	IgE levels;	chr16:69624873	chr18:11619509~11639699:-
LUAD	trans	rs864643	0.678	rs7627794	ENSG00000183298.5	RP11-556K13.1	6.05	2.88e-09	0.00504	0.38	0.27	Attention deficit hyperactivity disorder;	chr3:39492039	chr1:101786340~101787219:-
LUAD	trans	rs2070677	0.866	rs2492664	ENSG00000250148.1	KRT8P31	-6.05	2.89e-09	0.00507	-0.41	-0.27	Gout;	chr10:133573736	chr5:60743563~60744970:-
LUAD	trans	rs1933488	0.898	rs11155895	ENSG00000278974.1	RP11-756P10.6	-6.05	2.89e-09	0.00507	-0.33	-0.27	Prostate cancer;	chr6:153100410	chr4:188740507~188741281:-
LUAD	trans	rs11512640	1	rs11220136	ENSG00000236257.1	EI24P2	6.05	2.9e-09	0.00508	0.55	0.27	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125582185	chr1:158454198~158455273:+
LUAD	trans	rs853679	0.607	rs34788973	ENSG00000253570.1	RNF5P1	6.05	2.92e-09	0.00511	0.6	0.27	Depression;	chr6:27911422	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.607	rs61742093	ENSG00000253570.1	RNF5P1	6.05	2.92e-09	0.00511	0.6	0.27	Depression;	chr6:27912204	chr8:38600661~38601200:-
LUAD	trans	rs545610	0.78	rs11031118	ENSG00000261105.4	LMO7-AS1	6.05	2.92e-09	0.00512	0.34	0.27	Dental caries;	chr11:30498616	chr13:75604700~75635994:-
LUAD	trans	rs6499255	1	rs55992518	ENSG00000257513.6	NPIPB1P	6.05	2.93e-09	0.00512	0.31	0.27	IgE levels;	chr16:69787504	chr18:11619509~11639699:-
LUAD	trans	rs6499255	0.951	rs60472033	ENSG00000257513.6	NPIPB1P	6.05	2.93e-09	0.00513	0.31	0.27	IgE levels;	chr16:69643806	chr18:11619509~11639699:-
LUAD	trans	rs3812762	0.826	rs2292045	ENSG00000266891.1	RP11-692N5.2	6.05	2.94e-09	0.00514	0.35	0.27	Hypospadias;	chr11:8785162	chr18:9734882~9735602:-
LUAD	trans	rs9876781	1	rs9883759	ENSG00000225528.1	RP3-370M22.8	-6.05	2.94e-09	0.00514	-0.27	-0.27	Longevity;	chr3:48422209	chr22:39960397~39964683:+
LUAD	trans	rs9876781	1	rs6442120	ENSG00000225528.1	RP3-370M22.8	-6.05	2.94e-09	0.00514	-0.27	-0.27	Longevity;	chr3:48423094	chr22:39960397~39964683:+
LUAD	trans	rs9876781	0.9	rs1037773	ENSG00000225528.1	RP3-370M22.8	-6.05	2.94e-09	0.00514	-0.27	-0.27	Longevity;	chr3:48426493	chr22:39960397~39964683:+
LUAD	trans	rs7192380	0.964	rs8055756	ENSG00000257513.6	NPIPB1P	-6.05	2.95e-09	0.00516	-0.26	-0.27	Sjögren's syndrome;	chr16:69614750	chr18:11619509~11639699:-
LUAD	trans	rs11220082	0.666	rs35203305	ENSG00000236257.1	EI24P2	-6.05	2.97e-09	0.00519	-0.29	-0.27	Schizophrenia;	chr11:125468987	chr1:158454198~158455273:+
LUAD	trans	rs9425766	0.64	rs9425756	ENSG00000213331.4	RP11-713C19.2	6.05	2.98e-09	0.00522	0.34	0.27	Life satisfaction;	chr1:173847448	chr4:187970273~187971284:+
LUAD	trans	rs9425766	0.546	rs6691001	ENSG00000213331.4	RP11-713C19.2	6.05	2.98e-09	0.00522	0.34	0.27	Life satisfaction;	chr1:173849938	chr4:187970273~187971284:+
LUAD	trans	rs2899832	0.568	rs17458583	ENSG00000229083.1	PSMA6P2	6.05	3e-09	0.00524	0.42	0.27	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35293295	chrX:12825840~12826833:+
LUAD	trans	rs9876781	1	rs2362450	ENSG00000225528.1	RP3-370M22.8	-6.04	3.01e-09	0.00526	-0.27	-0.27	Longevity;	chr3:48419904	chr22:39960397~39964683:+
LUAD	trans	rs11220082	0.666	rs7103665	ENSG00000236257.1	EI24P2	-6.04	3.01e-09	0.00526	-0.29	-0.27	Schizophrenia;	chr11:125472998	chr1:158454198~158455273:+
LUAD	trans	rs11220082	0.644	rs61917855	ENSG00000236257.1	EI24P2	-6.04	3.01e-09	0.00526	-0.29	-0.27	Schizophrenia;	chr11:125473652	chr1:158454198~158455273:+
LUAD	trans	rs7746199	0.736	rs35848276	ENSG00000253570.1	RNF5P1	6.04	3.02e-09	0.00528	0.58	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27553317	chr8:38600661~38601200:-
LUAD	trans	rs9467773	0.526	rs3734536	ENSG00000242375.1	RP11-498P14.3	-6.04	3.07e-09	0.00535	-0.34	-0.27	Intelligence (multi-trait analysis);	chr6:26365118	chr9:97195351~97197687:-
LUAD	trans	rs673253	0.556	rs10789442	ENSG00000231007.5	CDC20P1	-6.04	3.08e-09	0.00537	-0.35	-0.27	Intelligence (multi-trait analysis);	chr1:43674404	chr9:87011652~87013151:+
LUAD	trans	rs853679	0.599	rs13193295	ENSG00000253570.1	RNF5P1	6.04	3.08e-09	0.00538	0.59	0.27	Depression;	chr6:28035450	chr8:38600661~38601200:-
LUAD	trans	rs4713118	0.869	rs9468214	ENSG00000204709.4	LINC01556	6.04	3.09e-09	0.0054	0.35	0.27	Parkinson's disease;	chr6:27745520	chr6:28943877~28944537:+
LUAD	trans	rs6499255	0.951	rs12595878	ENSG00000257513.6	NPIPB1P	6.04	3.14e-09	0.00548	0.31	0.27	IgE levels;	chr16:69594314	chr18:11619509~11639699:-
LUAD	trans	rs6499255	0.951	rs74026882	ENSG00000257513.6	NPIPB1P	6.04	3.14e-09	0.00548	0.31	0.27	IgE levels;	chr16:69601156	chr18:11619509~11639699:-
LUAD	trans	rs6499255	0.857	rs8060588	ENSG00000257513.6	NPIPB1P	6.04	3.15e-09	0.0055	0.31	0.27	IgE levels;	chr16:69622597	chr18:11619509~11639699:-
LUAD	trans	rs17301013	0.932	rs1754355	ENSG00000213331.4	RP11-713C19.2	-6.04	3.16e-09	0.00551	-0.31	-0.27	Systemic lupus erythematosus;	chr1:174807407	chr4:187970273~187971284:+
LUAD	trans	rs864643	0.947	rs704962	ENSG00000183298.5	RP11-556K13.1	-6.04	3.17e-09	0.00553	-0.38	-0.27	Attention deficit hyperactivity disorder;	chr3:39515629	chr1:101786340~101787219:-
LUAD	trans	rs6499255	0.951	rs12595869	ENSG00000257513.6	NPIPB1P	6.04	3.18e-09	0.00553	0.32	0.27	IgE levels;	chr16:69695891	chr18:11619509~11639699:-
LUAD	trans	rs6831352	0.819	rs2851274	ENSG00000233859.2	ADH5P4	-6.03	3.2e-09	0.00557	-0.28	-0.27	Alcohol dependence;	chr4:99104715	chr6:65836930~65838039:-
LUAD	trans	rs864643	0.524	rs11715885	ENSG00000183298.5	RP11-556K13.1	6.03	3.22e-09	0.0056	0.46	0.27	Attention deficit hyperactivity disorder;	chr3:39475107	chr1:101786340~101787219:-
LUAD	trans	rs7647973	0.961	rs56324858	ENSG00000197582.5	GPX1P1	-6.03	3.22e-09	0.00561	-0.4	-0.27	Menarche (age at onset);	chr3:49506796	chrX:13378735~13379340:-
LUAD	trans	rs9876781	1	rs7636044	ENSG00000225528.1	RP3-370M22.8	-6.03	3.23e-09	0.00562	-0.27	-0.27	Longevity;	chr3:48443151	chr22:39960397~39964683:+
LUAD	trans	rs9876781	1	rs4490383	ENSG00000225528.1	RP3-370M22.8	-6.03	3.23e-09	0.00562	-0.27	-0.27	Longevity;	chr3:48443275	chr22:39960397~39964683:+
LUAD	trans	rs9467773	0.526	rs10946817	ENSG00000242375.1	RP11-498P14.3	-6.03	3.23e-09	0.00562	-0.34	-0.27	Intelligence (multi-trait analysis);	chr6:26363828	chr9:97195351~97197687:-
LUAD	trans	rs9467773	0.506	rs9393709	ENSG00000242375.1	RP11-498P14.3	-6.03	3.23e-09	0.00562	-0.34	-0.27	Intelligence (multi-trait analysis);	chr6:26364919	chr9:97195351~97197687:-
LUAD	trans	rs9467773	0.526	rs12199613	ENSG00000242375.1	RP11-498P14.3	-6.03	3.23e-09	0.00562	-0.34	-0.27	Intelligence (multi-trait analysis);	chr6:26366990	chr9:97195351~97197687:-
LUAD	trans	rs9467773	0.526	rs9688946	ENSG00000242375.1	RP11-498P14.3	-6.03	3.23e-09	0.00562	-0.34	-0.27	Intelligence (multi-trait analysis);	chr6:26367217	chr9:97195351~97197687:-
LUAD	trans	rs73198271	1	rs55971558	ENSG00000273129.1	PACERR	6.03	3.24e-09	0.00563	0.36	0.27	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8756893	chr1:186680622~186681446:+
LUAD	trans	rs2243480	1	rs1404147	ENSG00000232546.1	RP11-458F8.1	-6.03	3.24e-09	0.00564	-0.32	-0.27	Diabetic kidney disease;	chr7:65799537	chr7:66848496~66858136:+
LUAD	trans	rs453301	0.571	rs2929452	ENSG00000253893.2	FAM85B	6.03	3.24e-09	0.00564	0.33	0.27	Joint mobility (Beighton score);	chr8:9226955	chr8:8167819~8226614:-
LUAD	trans	rs8177253	0.665	rs6774822	ENSG00000256243.2	RPL7AP3	6.03	3.25e-09	0.00566	0.3	0.27	Iron status biomarkers;	chr3:133723168	chr14:35235180~35235651:-
LUAD	trans	rs877636	1	rs2292239	ENSG00000204652.6	RPS26P8	6.03	3.26e-09	0.00567	0.3	0.27	Cognitive function;	chr12:56088396	chr17:45608571~45608918:+
LUAD	trans	rs864643	0.678	rs1707959	ENSG00000183298.5	RP11-556K13.1	6.03	3.26e-09	0.00568	0.38	0.27	Attention deficit hyperactivity disorder;	chr3:39481807	chr1:101786340~101787219:-
LUAD	trans	rs6499255	0.951	rs57488237	ENSG00000257513.6	NPIPB1P	6.03	3.28e-09	0.0057	0.31	0.27	IgE levels;	chr16:69707668	chr18:11619509~11639699:-
LUAD	trans	rs13016963	0.546	rs11898821	ENSG00000235105.1	RP11-329A14.1	6.03	3.3e-09	0.00574	0.3	0.27	Esophageal squamous cell carcinoma;Melanoma;	chr2:201334965	chr1:48435967~48437223:+
LUAD	trans	rs1133146	1	rs1133146	ENSG00000227081.5	RP11-543P15.1	6.03	3.31e-09	0.00576	0.24	0.27	Yu-Zhi constitution type in type 2 diabetes;	chr19:53163407	chr12:3211663~3211917:-
LUAD	trans	rs12439619	0.693	rs17269819	ENSG00000259295.5	CSPG4P12	-6.03	3.32e-09	0.00576	-0.36	-0.27	Intelligence (multi-trait analysis);	chr15:82174660	chr15:85191438~85213905:+
LUAD	trans	rs877636	0.74	rs705698	ENSG00000223416.3	RPS26P15	6.03	3.34e-09	0.00581	0.28	0.26	Cognitive function;	chr12:55990903	chr1:58056133~58056480:-
LUAD	trans	rs17301013	0.932	rs1793297	ENSG00000213331.4	RP11-713C19.2	-6.03	3.36e-09	0.00583	-0.31	-0.26	Systemic lupus erythematosus;	chr1:174784411	chr4:187970273~187971284:+
LUAD	trans	rs73198271	0.96	rs73198286	ENSG00000273129.1	PACERR	6.03	3.36e-09	0.00583	0.36	0.26	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8754512	chr1:186680622~186681446:+
LUAD	trans	rs73198271	0.96	rs73198287	ENSG00000273129.1	PACERR	6.03	3.36e-09	0.00583	0.36	0.26	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8755276	chr1:186680622~186681446:+
LUAD	trans	rs7647973	0.925	rs7429661	ENSG00000197582.5	GPX1P1	6.03	3.36e-09	0.00583	0.37	0.26	Menarche (age at onset);	chr3:49191367	chrX:13378735~13379340:-
LUAD	trans	rs4713118	0.824	rs13211701	ENSG00000204709.4	LINC01556	6.02	3.39e-09	0.00589	0.35	0.26	Parkinson's disease;	chr6:27782300	chr6:28943877~28944537:+
LUAD	trans	rs4713118	0.824	rs9468229	ENSG00000204709.4	LINC01556	6.02	3.39e-09	0.00589	0.35	0.26	Parkinson's disease;	chr6:27782307	chr6:28943877~28944537:+
LUAD	trans	rs12439619	0.846	rs62013464	ENSG00000259295.5	CSPG4P12	-6.02	3.4e-09	0.0059	-0.36	-0.26	Intelligence (multi-trait analysis);	chr15:82288250	chr15:85191438~85213905:+
LUAD	trans	rs4713118	0.513	rs149878	ENSG00000204709.4	LINC01556	6.02	3.4e-09	0.0059	0.34	0.26	Parkinson's disease;	chr6:27910960	chr6:28943877~28944537:+
LUAD	trans	rs7746199	0.673	rs35501037	ENSG00000253570.1	RNF5P1	6.02	3.44e-09	0.00596	0.56	0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27771787	chr8:38600661~38601200:-
LUAD	trans	rs61041336	1	rs61041336	ENSG00000230849.2	GOT2P2	-6.02	3.46e-09	0.006	-0.48	-0.26	Neuritic plaque;	chr16:58699258	chr1:173141100~173142350:-
LUAD	trans	rs9329221	0.905	rs10283145	ENSG00000253893.2	FAM85B	6.02	3.5e-09	0.00607	0.33	0.26	Neuroticism;	chr8:10383901	chr8:8167819~8226614:-
LUAD	trans	rs6499255	1	rs11641521	ENSG00000257513.6	NPIPB1P	6.02	3.53e-09	0.00613	0.31	0.26	IgE levels;	chr16:69789178	chr18:11619509~11639699:-
LUAD	trans	rs16937956	0.597	rs12788830	ENSG00000266891.1	RP11-692N5.2	6.02	3.54e-09	0.00614	0.39	0.26	Body mass index;	chr11:8380429	chr18:9734882~9735602:-
LUAD	trans	rs16937956	0.597	rs12793685	ENSG00000266891.1	RP11-692N5.2	6.02	3.54e-09	0.00614	0.39	0.26	Body mass index;	chr11:8380583	chr18:9734882~9735602:-
LUAD	trans	rs7746199	0.736	rs35037868	ENSG00000253570.1	RNF5P1	6.02	3.55e-09	0.00616	0.58	0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27791336	chr8:38600661~38601200:-
LUAD	trans	rs9329221	0.905	rs6601451	ENSG00000253893.2	FAM85B	6.02	3.56e-09	0.00617	0.33	0.26	Neuroticism;	chr8:10386171	chr8:8167819~8226614:-
LUAD	trans	rs853679	0.607	rs33932084	ENSG00000253570.1	RNF5P1	6.02	3.56e-09	0.00617	0.57	0.26	Depression;	chr6:28301047	chr8:38600661~38601200:-
LUAD	trans	rs17664267	1	rs1401006	ENSG00000239005.1	ACA64	6.01	3.58e-09	0.0062	0.41	0.26	Conduct disorder (maternal expressed emotions interaction);	chr18:43254745	chr4:139436368~139436494:-
LUAD	trans	rs17664267	1	rs12454087	ENSG00000239005.1	ACA64	6.01	3.58e-09	0.0062	0.41	0.26	Conduct disorder (maternal expressed emotions interaction);	chr18:43254990	chr4:139436368~139436494:-
LUAD	trans	rs3812762	1	rs3812762	ENSG00000266891.1	RP11-692N5.2	6.01	3.61e-09	0.00624	0.35	0.26	Hypospadias;	chr11:8730093	chr18:9734882~9735602:-
LUAD	trans	rs1933488	0.931	rs6557272	ENSG00000278974.1	RP11-756P10.6	-6.01	3.62e-09	0.00627	-0.33	-0.26	Prostate cancer;	chr6:153116979	chr4:188740507~188741281:-
LUAD	trans	rs16937956	0.597	rs12793878	ENSG00000266891.1	RP11-692N5.2	6.01	3.64e-09	0.0063	0.39	0.26	Body mass index;	chr11:8380662	chr18:9734882~9735602:-
LUAD	trans	rs17301013	0.827	rs1793309	ENSG00000213331.4	RP11-713C19.2	-6.01	3.65e-09	0.00632	-0.31	-0.26	Systemic lupus erythematosus;	chr1:174826199	chr4:187970273~187971284:+
LUAD	trans	rs17301013	0.932	rs6689170	ENSG00000213331.4	RP11-713C19.2	6.01	3.67e-09	0.00635	0.31	0.26	Systemic lupus erythematosus;	chr1:174639596	chr4:187970273~187971284:+
LUAD	trans	rs7833986	0.501	rs2719255	ENSG00000244245.1	RP11-120B7.1	6.01	3.68e-09	0.00636	0.31	0.26	Height;	chr8:56124099	chr5:108593609~108593967:+
LUAD	trans	rs7833986	0.501	rs72653990	ENSG00000244245.1	RP11-120B7.1	6.01	3.68e-09	0.00636	0.31	0.26	Height;	chr8:56124556	chr5:108593609~108593967:+
LUAD	trans	rs7833986	0.501	rs17815934	ENSG00000244245.1	RP11-120B7.1	6.01	3.68e-09	0.00636	0.31	0.26	Height;	chr8:56125836	chr5:108593609~108593967:+
LUAD	trans	rs616147	0.627	rs816510	ENSG00000188856.6	RPSAP47	-6.01	3.68e-09	0.00636	-0.28	-0.26	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39430804	chr8:80558870~80559757:+
LUAD	trans	rs9876781	0.967	rs9876891	ENSG00000225528.1	RP3-370M22.8	-6.01	3.68e-09	0.00637	-0.27	-0.26	Longevity;	chr3:48440024	chr22:39960397~39964683:+
LUAD	trans	rs2060793	0.741	rs10741656	ENSG00000236360.2	RP11-334A14.2	6.01	3.74e-09	0.00647	0.34	0.26	Vitamin D levels;	chr11:14803699	chr1:52993201~52993702:-
LUAD	trans	rs17507216	0.958	rs28648832	ENSG00000235370.6	DNM1P51	-6.01	3.75e-09	0.00648	-0.35	-0.26	Excessive daytime sleepiness;	chr15:82567642	chr15:84398316~84411701:-
LUAD	trans	rs66887589	0.777	rs10015883	ENSG00000275858.1	RP11-291L22.8	6	3.78e-09	0.00654	0.28	0.26	Diastolic blood pressure;	chr4:119346991	chr10:38450738~38451069:-
LUAD	trans	rs7121616	0.563	rs1461494	ENSG00000256356.1	HSPA8P5	6	3.8e-09	0.00656	0.29	0.26	Breast cancer;	chr11:123055777	chr12:4097451~4099519:+
LUAD	trans	rs3740713	0.592	rs73434674	ENSG00000236090.2	LDHAP3	6	3.83e-09	0.00661	0.45	0.26	Amyotrophic lateral sclerosis (sporadic);	chr11:18389950	chr2:41819747~41820754:+
LUAD	trans	rs7833986	0.501	rs2976038	ENSG00000236862.1	RPS20P24	6	3.83e-09	0.00661	0.33	0.26	Height;	chr8:56116305	chr9:72655832~72656192:-
LUAD	trans	rs864643	0.577	rs76395532	ENSG00000183298.5	RP11-556K13.1	6	3.85e-09	0.00665	0.46	0.26	Attention deficit hyperactivity disorder;	chr3:39490370	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.524	rs77060785	ENSG00000183298.5	RP11-556K13.1	6	3.85e-09	0.00665	0.46	0.26	Attention deficit hyperactivity disorder;	chr3:39491177	chr1:101786340~101787219:-
LUAD	trans	rs7032940	0.784	rs1010072	ENSG00000228236.2	TXNP5	6	3.86e-09	0.00666	0.34	0.26	Height;	chr9:110204444	chr2:149068596~149068910:-
LUAD	trans	rs9425766	0.54	rs2294492	ENSG00000213331.4	RP11-713C19.2	6	3.86e-09	0.00666	0.31	0.26	Life satisfaction;	chr1:174157884	chr4:187970273~187971284:+
LUAD	trans	rs6499255	0.904	rs7194753	ENSG00000257513.6	NPIPB1P	-6	3.87e-09	0.00668	-0.31	-0.26	IgE levels;	chr16:69530461	chr18:11619509~11639699:-
LUAD	trans	rs17301013	0.932	rs1653627	ENSG00000213331.4	RP11-713C19.2	-6	3.88e-09	0.00669	-0.31	-0.26	Systemic lupus erythematosus;	chr1:174771879	chr4:187970273~187971284:+
LUAD	trans	rs7312770	1	rs7312770	ENSG00000212829.8	RPS26P3	-6	3.88e-09	0.00669	-0.27	-0.26	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr9:9090898~9091245:+
LUAD	trans	rs4713118	0.869	rs2056925	ENSG00000204709.4	LINC01556	6	3.89e-09	0.00671	0.36	0.26	Parkinson's disease;	chr6:27723126	chr6:28943877~28944537:+
LUAD	trans	rs45509595	0.841	rs17751184	ENSG00000253570.1	RNF5P1	6	3.9e-09	0.00672	0.56	0.26	Breast cancer;	chr6:27807250	chr8:38600661~38601200:-
LUAD	trans	rs6499255	0.951	rs7200935	ENSG00000257513.6	NPIPB1P	6	3.91e-09	0.00674	0.31	0.26	IgE levels;	chr16:69530594	chr18:11619509~11639699:-
LUAD	trans	rs6499255	0.951	rs75815213	ENSG00000257513.6	NPIPB1P	6	3.91e-09	0.00674	0.31	0.26	IgE levels;	chr16:69668951	chr18:11619509~11639699:-
LUAD	trans	rs9876781	1	rs11130170	ENSG00000225528.1	RP3-370M22.8	-6	3.91e-09	0.00674	-0.27	-0.26	Longevity;	chr3:48408490	chr22:39960397~39964683:+
LUAD	trans	rs11638815	0.689	rs1267656	ENSG00000235370.6	DNM1P51	-6	3.91e-09	0.00674	-0.42	-0.26	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82551349	chr15:84398316~84411701:-
LUAD	trans	rs17301013	0.932	rs1754349	ENSG00000213331.4	RP11-713C19.2	-6	3.92e-09	0.00675	-0.31	-0.26	Systemic lupus erythematosus;	chr1:174837663	chr4:187970273~187971284:+
LUAD	trans	rs10213084	0.915	rs13115523	ENSG00000221413.1	AC023593.1	-6	3.92e-09	0.00676	-0.42	-0.26	Heart rate;	chr4:146589458	chr3:127664704~127664810:+
LUAD	trans	rs10213084	1	rs13115724	ENSG00000221413.1	AC023593.1	-6	3.92e-09	0.00676	-0.42	-0.26	Heart rate;	chr4:146589528	chr3:127664704~127664810:+
LUAD	trans	rs9876781	0.967	rs1459249	ENSG00000225528.1	RP3-370M22.8	-6	3.93e-09	0.00677	-0.27	-0.26	Longevity;	chr3:48438208	chr22:39960397~39964683:+
LUAD	trans	rs6424115	0.767	rs11591202	ENSG00000228217.1	AL390877.1	6	3.93e-09	0.00677	0.35	0.26	Immature fraction of reticulocytes;	chr1:23775590	chr1:117778087~117778506:-
LUAD	trans	rs3096299	0.685	rs4785676	ENSG00000215030.5	RPL13P12	-6	3.93e-09	0.00678	-0.29	-0.26	Multiple myeloma (IgH translocation);	chr16:89487216	chr17:17383377~17384012:-
LUAD	trans	rs864643	0.678	rs1609647	ENSG00000183298.5	RP11-556K13.1	6	3.94e-09	0.00679	0.38	0.26	Attention deficit hyperactivity disorder;	chr3:39491580	chr1:101786340~101787219:-
LUAD	trans	rs453301	0.624	rs330058	ENSG00000253893.2	FAM85B	6	3.95e-09	0.00681	0.33	0.26	Joint mobility (Beighton score);	chr8:9232299	chr8:8167819~8226614:-
LUAD	trans	rs73252553	1	rs424573	ENSG00000257924.1	RP11-493L12.5	-6	3.96e-09	0.00681	-0.42	-0.26	Cannabis dependence symptom count;	chr4:25211186	chr12:47353754~47369935:+
LUAD	trans	rs4713118	0.869	rs6902689	ENSG00000204709.4	LINC01556	5.99	4e-09	0.0069	0.35	0.26	Parkinson's disease;	chr6:27741662	chr6:28943877~28944537:+
LUAD	trans	rs6499255	1	rs55863174	ENSG00000257513.6	NPIPB1P	5.99	4.01e-09	0.0069	0.31	0.26	IgE levels;	chr16:69786093	chr18:11619509~11639699:-
LUAD	trans	rs7212590	0.748	rs7220187	ENSG00000187870.7	RNFT1P3	5.99	4.03e-09	0.00693	0.57	0.26	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59820248	chr17:20743333~20754501:-
LUAD	trans	rs7212590	0.748	rs7213697	ENSG00000187870.7	RNFT1P3	5.99	4.03e-09	0.00693	0.57	0.26	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59825680	chr17:20743333~20754501:-
LUAD	trans	rs453301	0.624	rs330056	ENSG00000253893.2	FAM85B	5.99	4.05e-09	0.00696	0.33	0.26	Joint mobility (Beighton score);	chr8:9232185	chr8:8167819~8226614:-
LUAD	trans	rs4906172	1	rs2253998	ENSG00000181359.5	HSP90AA6P	5.99	4.05e-09	0.00696	0.31	0.26	Menopause (age at onset);	chr14:102030015	chr4:170581470~170605450:-
LUAD	trans	rs877636	0.74	rs705702	ENSG00000223416.3	RPS26P15	-5.99	4.05e-09	0.00697	-0.28	-0.26	Cognitive function;	chr12:55996852	chr1:58056133~58056480:-
LUAD	trans	rs58106596	0.66	rs13398149	ENSG00000259020.3	RP11-529H20.3	5.99	4.06e-09	0.00699	0.38	0.26	Lymphocyte counts;White blood cell count;	chr2:231700171	chr14:92026566~92026887:+
LUAD	trans	rs9876781	1	rs9849509	ENSG00000225528.1	RP3-370M22.8	-5.99	4.07e-09	0.007	-0.27	-0.26	Longevity;	chr3:48442021	chr22:39960397~39964683:+
LUAD	trans	rs9876781	1	rs60512868	ENSG00000225528.1	RP3-370M22.8	-5.99	4.07e-09	0.007	-0.27	-0.26	Longevity;	chr3:48442035	chr22:39960397~39964683:+
LUAD	trans	rs2294426	0.766	rs932345	ENSG00000245904.3	RP11-796E2.4	5.99	4.09e-09	0.00703	0.27	0.26	Orofacial clefts (maternal alcohol consumption interaction);	chr6:11734629	chr12:92145573~92189660:+
LUAD	trans	rs9876781	0.933	rs6442124	ENSG00000225528.1	RP3-370M22.8	-5.99	4.11e-09	0.00707	-0.27	-0.26	Longevity;	chr3:48463903	chr22:39960397~39964683:+
LUAD	trans	rs9467773	0.55	rs4712987	ENSG00000242375.1	RP11-498P14.3	-5.99	4.13e-09	0.00709	-0.35	-0.26	Intelligence (multi-trait analysis);	chr6:26399387	chr9:97195351~97197687:-
LUAD	trans	rs7833986	0.501	rs72653981	ENSG00000236862.1	RPS20P24	5.99	4.14e-09	0.00711	0.32	0.26	Height;	chr8:56115255	chr9:72655832~72656192:-
LUAD	trans	rs7833986	0.501	rs2976036	ENSG00000236862.1	RPS20P24	5.99	4.14e-09	0.00711	0.32	0.26	Height;	chr8:56119162	chr9:72655832~72656192:-
LUAD	trans	rs9425766	0.64	rs2295366	ENSG00000213331.4	RP11-713C19.2	5.99	4.16e-09	0.00714	0.33	0.26	Life satisfaction;	chr1:173856554	chr4:187970273~187971284:+
LUAD	trans	rs864643	0.678	rs1707960	ENSG00000183298.5	RP11-556K13.1	-5.99	4.17e-09	0.00716	-0.37	-0.26	Attention deficit hyperactivity disorder;	chr3:39481761	chr1:101786340~101787219:-
LUAD	trans	rs7647973	0.922	rs56049603	ENSG00000197582.5	GPX1P1	-5.99	4.21e-09	0.00724	-0.4	-0.26	Menarche (age at onset);	chr3:49547810	chrX:13378735~13379340:-
LUAD	trans	rs7618501	1	rs2271960	ENSG00000197582.5	GPX1P1	5.98	4.24e-09	0.00728	0.34	0.26	Intelligence (multi-trait analysis);	chr3:49840645	chrX:13378735~13379340:-
LUAD	trans	rs12439619	0.53	rs7162177	ENSG00000259295.5	CSPG4P12	-5.98	4.27e-09	0.00733	-0.3	-0.26	Intelligence (multi-trait analysis);	chr15:82181728	chr15:85191438~85213905:+
LUAD	trans	rs853679	0.546	rs35744819	ENSG00000281831.1	HCP5B	5.98	4.27e-09	0.00734	0.59	0.26	Depression;	chr6:28350554	chr6:29871895~29873783:-
LUAD	trans	rs7312770	0.637	rs705699	ENSG00000234192.1	RP11-57C13.5	5.98	4.3e-09	0.00738	0.28	0.26	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr10:87642607~87642954:+
LUAD	trans	rs10213084	1	rs28617320	ENSG00000221413.1	AC023593.1	-5.98	4.31e-09	0.00739	-0.42	-0.26	Heart rate;	chr4:146558946	chr3:127664704~127664810:+
LUAD	trans	rs17301013	0.932	rs6664864	ENSG00000213331.4	RP11-713C19.2	5.98	4.32e-09	0.00741	0.31	0.26	Systemic lupus erythematosus;	chr1:174622912	chr4:187970273~187971284:+
LUAD	trans	rs864643	0.947	rs1708040	ENSG00000183298.5	RP11-556K13.1	5.98	4.32e-09	0.00742	0.37	0.26	Attention deficit hyperactivity disorder;	chr3:39523258	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.947	rs505176	ENSG00000183298.5	RP11-556K13.1	5.98	4.32e-09	0.00742	0.37	0.26	Attention deficit hyperactivity disorder;	chr3:39524857	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.947	rs1708000	ENSG00000183298.5	RP11-556K13.1	5.98	4.32e-09	0.00742	0.37	0.26	Attention deficit hyperactivity disorder;	chr3:39525645	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.947	rs1708001	ENSG00000183298.5	RP11-556K13.1	5.98	4.32e-09	0.00742	0.37	0.26	Attention deficit hyperactivity disorder;	chr3:39525714	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.947	rs816519	ENSG00000183298.5	RP11-556K13.1	5.98	4.32e-09	0.00742	0.37	0.26	Attention deficit hyperactivity disorder;	chr3:39527786	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.731	rs1417148	ENSG00000183298.5	RP11-556K13.1	5.98	4.32e-09	0.00742	0.37	0.26	Attention deficit hyperactivity disorder;	chr3:39534217	chr1:101786340~101787219:-
LUAD	trans	rs16937956	0.597	rs11822608	ENSG00000266891.1	RP11-692N5.2	5.98	4.33e-09	0.00743	0.39	0.26	Body mass index;	chr11:8380117	chr18:9734882~9735602:-
LUAD	trans	rs7212590	0.618	rs56142307	ENSG00000187870.7	RNFT1P3	5.98	4.34e-09	0.00745	0.56	0.26	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59800788	chr17:20743333~20754501:-
LUAD	trans	rs7647973	1	rs11928090	ENSG00000197582.5	GPX1P1	5.98	4.4e-09	0.00754	0.36	0.26	Menarche (age at onset);	chr3:49567471	chrX:13378735~13379340:-
LUAD	trans	rs3934047	0.967	rs7180569	ENSG00000188002.9	RP11-43F13.1	-5.98	4.41e-09	0.00756	-0.33	-0.26	Response to paliperidone in schizophrenia (positive Marder score);	chr15:81692111	chr5:1598920~1634005:-
LUAD	trans	rs453301	0.624	rs330060	ENSG00000253893.2	FAM85B	5.98	4.44e-09	0.00761	0.33	0.26	Joint mobility (Beighton score);	chr8:9233392	chr8:8167819~8226614:-
LUAD	trans	rs10917477	0.576	rs10917476	ENSG00000224237.1	MINOS1P3	-5.98	4.46e-09	0.00765	-0.34	-0.26	Thyroid function;	chr1:19534346	chr3:27214816~27215018:-
LUAD	trans	rs877636	0.702	rs773108	ENSG00000223416.3	RPS26P15	5.98	4.47e-09	0.00765	0.28	0.26	Cognitive function;	chr12:55976127	chr1:58056133~58056480:-
LUAD	trans	rs853679	0.607	rs67998226	ENSG00000253570.1	RNF5P1	5.97	4.49e-09	0.00769	0.57	0.26	Depression;	chr6:28270281	chr8:38600661~38601200:-
LUAD	trans	rs4713118	0.824	rs9468223	ENSG00000204709.4	LINC01556	5.97	4.49e-09	0.0077	0.35	0.26	Parkinson's disease;	chr6:27772887	chr6:28943877~28944537:+
LUAD	trans	rs7833986	0.501	rs72653986	ENSG00000236862.1	RPS20P24	5.97	4.5e-09	0.00771	0.32	0.26	Height;	chr8:56122489	chr9:72655832~72656192:-
LUAD	trans	rs6499255	1	rs4580150	ENSG00000257513.6	NPIPB1P	5.97	4.52e-09	0.00774	0.31	0.26	IgE levels;	chr16:69781050	chr18:11619509~11639699:-
LUAD	trans	rs7647973	0.961	rs6778080	ENSG00000197582.5	GPX1P1	-5.97	4.54e-09	0.00777	-0.36	-0.26	Menarche (age at onset);	chr3:49279905	chrX:13378735~13379340:-
LUAD	trans	rs9425766	0.679	rs12079063	ENSG00000213331.4	RP11-713C19.2	5.97	4.58e-09	0.00783	0.3	0.26	Life satisfaction;	chr1:174110447	chr4:187970273~187971284:+
LUAD	trans	rs10420951	0.579	rs79341622	ENSG00000267533.1	RP11-815J4.7	5.97	4.58e-09	0.00784	0.48	0.26	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18487403	chr18:12067173~12068417:-
LUAD	trans	rs453301	0.571	rs330057	ENSG00000253893.2	FAM85B	5.97	4.59e-09	0.00784	0.33	0.26	Joint mobility (Beighton score);	chr8:9232283	chr8:8167819~8226614:-
LUAD	trans	rs7121616	0.733	rs10790554	ENSG00000234176.1	HSPA8P1	5.97	4.59e-09	0.00785	0.29	0.26	Breast cancer;	chr11:123130376	chrX:121203182~121205014:-
LUAD	trans	rs9425766	0.679	rs2860846	ENSG00000213331.4	RP11-713C19.2	5.97	4.59e-09	0.00785	0.3	0.26	Life satisfaction;	chr1:174106786	chr4:187970273~187971284:+
LUAD	trans	rs9425766	0.679	rs2860847	ENSG00000213331.4	RP11-713C19.2	5.97	4.59e-09	0.00785	0.3	0.26	Life satisfaction;	chr1:174106787	chr4:187970273~187971284:+
LUAD	trans	rs9425766	0.679	rs6672986	ENSG00000213331.4	RP11-713C19.2	5.97	4.59e-09	0.00785	0.3	0.26	Life satisfaction;	chr1:174107726	chr4:187970273~187971284:+
LUAD	trans	rs9425766	0.679	rs7526024	ENSG00000213331.4	RP11-713C19.2	5.97	4.59e-09	0.00785	0.3	0.26	Life satisfaction;	chr1:174109722	chr4:187970273~187971284:+
LUAD	trans	rs9425766	0.679	rs12094341	ENSG00000213331.4	RP11-713C19.2	5.97	4.59e-09	0.00785	0.3	0.26	Life satisfaction;	chr1:174110562	chr4:187970273~187971284:+
LUAD	trans	rs9425766	0.679	rs12079062	ENSG00000213331.4	RP11-713C19.2	5.97	4.64e-09	0.00793	0.3	0.26	Life satisfaction;	chr1:174110446	chr4:187970273~187971284:+
LUAD	trans	rs7212590	0.881	rs7214032	ENSG00000187870.7	RNFT1P3	5.97	4.66e-09	0.00796	0.56	0.26	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59808467	chr17:20743333~20754501:-
LUAD	trans	rs7833986	0.501	rs72653959	ENSG00000236862.1	RPS20P24	5.97	4.66e-09	0.00796	0.33	0.26	Height;	chr8:56083957	chr9:72655832~72656192:-
LUAD	trans	rs7833986	0.501	rs72653962	ENSG00000236862.1	RPS20P24	5.97	4.66e-09	0.00796	0.33	0.26	Height;	chr8:56084946	chr9:72655832~72656192:-
LUAD	trans	rs7833986	0.501	rs72653967	ENSG00000236862.1	RPS20P24	5.97	4.66e-09	0.00796	0.33	0.26	Height;	chr8:56086873	chr9:72655832~72656192:-
LUAD	trans	rs3934047	0.935	rs7173665	ENSG00000188002.9	RP11-43F13.1	-5.97	4.67e-09	0.00797	-0.33	-0.26	Response to paliperidone in schizophrenia (positive Marder score);	chr15:81688785	chr5:1598920~1634005:-
LUAD	trans	rs860295	0.529	rs17381047	ENSG00000241627.3	UBQLN4P1	5.97	4.69e-09	0.00801	0.25	0.26	Body mass index;	chr1:156013857	chr3:148985868~148987668:-
LUAD	trans	rs4948102	0.642	rs766333	ENSG00000186940.6	CHCHD2P9	-5.97	4.7e-09	0.00802	-0.31	-0.26	Plasma homocysteine levels (post-methionine load test);	chr7:56059011	chr9:79391304~79391759:+
LUAD	trans	rs7819412	0.522	rs3021495	ENSG00000253893.2	FAM85B	5.97	4.71e-09	0.00803	0.34	0.26	Triglycerides;	chr8:11137233	chr8:8167819~8226614:-
LUAD	trans	rs4713118	0.824	rs9468225	ENSG00000204709.4	LINC01556	5.97	4.73e-09	0.00808	0.35	0.26	Parkinson's disease;	chr6:27777940	chr6:28943877~28944537:+
LUAD	trans	rs79149102	0.522	rs8028893	ENSG00000227288.3	RP5-837I24.1	5.97	4.74e-09	0.00808	0.49	0.26	Lung cancer;	chr15:74553582	chr1:81501794~81503468:+
LUAD	trans	rs853679	0.556	rs45509595	ENSG00000281831.1	HCP5B	5.97	4.74e-09	0.00808	0.59	0.26	Depression;	chr6:27873148	chr6:29871895~29873783:-
LUAD	trans	rs7412746	0.658	rs12067685	ENSG00000180764.13	PIPSL	-5.97	4.74e-09	0.00809	-0.3	-0.26	Melanoma;	chr1:150980441	chr10:93958191~93961540:-
LUAD	trans	rs12439619	0.693	rs28689861	ENSG00000259295.5	CSPG4P12	-5.97	4.74e-09	0.00809	-0.36	-0.26	Intelligence (multi-trait analysis);	chr15:82206369	chr15:85191438~85213905:+
LUAD	trans	rs9467711	0.72	rs1417998	ENSG00000204709.4	LINC01556	5.96	4.76e-09	0.00811	0.48	0.26	Autism spectrum disorder or schizophrenia;	chr6:26161791	chr6:28943877~28944537:+
LUAD	trans	rs79149102	0.522	rs4887158	ENSG00000227288.3	RP5-837I24.1	5.96	4.81e-09	0.00819	0.49	0.26	Lung cancer;	chr15:74555473	chr1:81501794~81503468:+
LUAD	trans	rs17301013	0.896	rs6425292	ENSG00000213331.4	RP11-713C19.2	5.96	4.83e-09	0.00822	0.31	0.26	Systemic lupus erythematosus;	chr1:174618364	chr4:187970273~187971284:+
LUAD	trans	rs11220082	0.602	rs10893383	ENSG00000236257.1	EI24P2	-5.96	4.84e-09	0.00824	-0.28	-0.26	Schizophrenia;	chr11:125466237	chr1:158454198~158455273:+
LUAD	trans	rs4713118	0.869	rs9348775	ENSG00000204709.4	LINC01556	5.96	4.84e-09	0.00825	0.35	0.26	Parkinson's disease;	chr6:27727550	chr6:28943877~28944537:+
LUAD	trans	rs2899832	0.568	rs28461608	ENSG00000229083.1	PSMA6P2	5.96	4.86e-09	0.00828	0.41	0.26	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35258767	chrX:12825840~12826833:+
LUAD	trans	rs2899832	0.568	rs7140912	ENSG00000229083.1	PSMA6P2	5.96	4.86e-09	0.00828	0.41	0.26	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35258823	chrX:12825840~12826833:+
LUAD	trans	rs2553218	0.69	rs8032415	ENSG00000281383.1	CH507-513H4.5	5.96	4.89e-09	0.00833	0.31	0.26	Immune response to smallpox vaccine (IL-6);	chr15:54559747	chr21:8254592~8255514:-
LUAD	trans	rs9329221	0.657	rs17694485	ENSG00000253981.4	ALG1L13P	5.96	4.9e-09	0.00834	0.29	0.26	Neuroticism;	chr8:10256948	chr8:8236003~8244667:-
LUAD	trans	rs11172055	0.967	rs10876953	ENSG00000121089.4	NACA3P	5.96	4.9e-09	0.00835	0.3	0.26	Migraine;	chr12:56916418	chr4:164943290~164943937:+
LUAD	trans	rs7121616	0.92	rs7109445	ENSG00000229091.2	HSPA8P8	5.96	4.91e-09	0.00836	0.32	0.26	Breast cancer;	chr11:123094779	chr7:10451311~10452526:+
LUAD	trans	rs73198271	0.96	rs11778970	ENSG00000273129.1	PACERR	5.96	4.91e-09	0.00837	0.35	0.26	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8751824	chr1:186680622~186681446:+
LUAD	trans	rs73198271	0.96	rs10503392	ENSG00000273129.1	PACERR	5.96	4.91e-09	0.00837	0.35	0.26	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8752045	chr1:186680622~186681446:+
LUAD	trans	rs3812762	0.912	rs4929936	ENSG00000266891.1	RP11-692N5.2	5.96	4.92e-09	0.00837	0.35	0.26	Hypospadias;	chr11:8771075	chr18:9734882~9735602:-
LUAD	trans	rs877636	0.74	rs772920	ENSG00000223416.3	RPS26P15	5.96	4.93e-09	0.00839	0.28	0.26	Cognitive function;	chr12:55996580	chr1:58056133~58056480:-
LUAD	trans	rs6499255	0.951	rs7186002	ENSG00000257513.6	NPIPB1P	5.96	4.95e-09	0.00843	0.32	0.26	IgE levels;	chr16:69717162	chr18:11619509~11639699:-
LUAD	trans	rs1318772	1	rs26965	ENSG00000231990.1	RP11-53B5.1	-5.96	4.95e-09	0.00843	-0.4	-0.26	F-cell distribution;	chr5:113403320	chr9:93857083~93858333:+
LUAD	trans	rs10213084	1	rs79837090	ENSG00000221413.1	AC023593.1	-5.96	4.96e-09	0.00844	-0.42	-0.26	Heart rate;	chr4:146585250	chr3:127664704~127664810:+
LUAD	trans	rs9467711	0.656	rs34961555	ENSG00000253570.1	RNF5P1	5.96	4.97e-09	0.00846	0.67	0.26	Autism spectrum disorder or schizophrenia;	chr6:26199675	chr8:38600661~38601200:-
LUAD	trans	rs7617480	0.648	rs7653408	ENSG00000197582.5	GPX1P1	5.96	4.99e-09	0.0085	0.37	0.26	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48934918	chrX:13378735~13379340:-
LUAD	trans	rs7644634	1	rs7644634	ENSG00000230732.4	AC127904.2	5.96	5e-09	0.0085	0.27	0.26	Itch intensity from mosquito bite;	chr3:105761447	chr3:196912646~196914579:+
LUAD	trans	rs7833986	0.501	rs2667978	ENSG00000244245.1	RP11-120B7.1	5.96	5e-09	0.00851	0.31	0.26	Height;	chr8:55985392	chr5:108593609~108593967:+
LUAD	trans	rs4879656	0.525	rs7852206	ENSG00000215007.3	DNAJA1P3	5.96	5.01e-09	0.00852	0.29	0.26	Menopause (age at onset);	chr9:33017383	chrX:107351650~107352843:-
LUAD	trans	rs6683419	0.967	rs2088825	ENSG00000224237.1	MINOS1P3	-5.96	5.01e-09	0.00853	-0.32	-0.26	Serum thyroid-stimulating hormone levels;	chr1:19495346	chr3:27214816~27215018:-
LUAD	trans	rs7833986	0.501	rs2953911	ENSG00000236862.1	RPS20P24	5.95	5.02e-09	0.00854	0.32	0.26	Height;	chr8:56035450	chr9:72655832~72656192:-
LUAD	trans	rs3812762	0.917	rs905289	ENSG00000266891.1	RP11-692N5.2	-5.95	5.03e-09	0.00855	-0.34	-0.26	Hypospadias;	chr11:8732005	chr18:9734882~9735602:-
LUAD	trans	rs7833986	0.501	rs2667999	ENSG00000236862.1	RPS20P24	5.95	5.05e-09	0.00859	0.32	0.26	Height;	chr8:56037915	chr9:72655832~72656192:-
LUAD	trans	rs1933488	0.804	rs9397586	ENSG00000278974.1	RP11-756P10.6	-5.95	5.05e-09	0.00859	-0.33	-0.26	Prostate cancer;	chr6:153093152	chr4:188740507~188741281:-
LUAD	trans	rs7647973	0.925	rs4955439	ENSG00000197582.5	GPX1P1	-5.95	5.06e-09	0.0086	-0.36	-0.26	Menarche (age at onset);	chr3:49208212	chrX:13378735~13379340:-
LUAD	trans	rs17507216	0.958	rs72751643	ENSG00000235370.6	DNM1P51	-5.95	5.09e-09	0.00865	-0.36	-0.26	Excessive daytime sleepiness;	chr15:82559444	chr15:84398316~84411701:-
LUAD	trans	rs17301013	0.896	rs6425287	ENSG00000213331.4	RP11-713C19.2	5.95	5.1e-09	0.00867	0.31	0.26	Systemic lupus erythematosus;	chr1:174566264	chr4:187970273~187971284:+
LUAD	trans	rs7833986	0.534	rs10504198	ENSG00000236862.1	RPS20P24	5.95	5.11e-09	0.00868	0.33	0.26	Height;	chr8:56093695	chr9:72655832~72656192:-
LUAD	trans	rs7833986	0.534	rs2976022	ENSG00000236862.1	RPS20P24	5.95	5.11e-09	0.00868	0.33	0.26	Height;	chr8:56095284	chr9:72655832~72656192:-
LUAD	trans	rs7833986	0.501	rs2976018	ENSG00000236862.1	RPS20P24	5.95	5.11e-09	0.00868	0.33	0.26	Height;	chr8:56102193	chr9:72655832~72656192:-
LUAD	trans	rs7833986	0.501	rs72653978	ENSG00000236862.1	RPS20P24	5.95	5.11e-09	0.00868	0.33	0.26	Height;	chr8:56105834	chr9:72655832~72656192:-
LUAD	trans	rs9876781	0.559	rs1841178	ENSG00000235912.1	RP1-159A19.3	-5.95	5.12e-09	0.0087	-0.28	-0.26	Longevity;	chr3:48355556	chr1:27649419~27649610:+
LUAD	trans	rs864643	0.524	rs77309543	ENSG00000183298.5	RP11-556K13.1	5.95	5.13e-09	0.00871	0.46	0.26	Attention deficit hyperactivity disorder;	chr3:39489578	chr1:101786340~101787219:-
LUAD	trans	rs6030712	0.948	rs6124577	ENSG00000211897.6	IGHG3	5.95	5.14e-09	0.00872	0.25	0.26	Height;	chr20:37044679	chr14:105769102~106038345:-
LUAD	trans	rs8077577	0.747	rs16961153	ENSG00000188933.13	USP32P1	-5.95	5.14e-09	0.00873	-0.36	-0.26	Obesity-related traits;	chr17:18323787	chr17:16786489~16804455:+
LUAD	trans	rs79149102	0.522	rs59665282	ENSG00000227288.3	RP5-837I24.1	5.95	5.15e-09	0.00874	0.48	0.26	Lung cancer;	chr15:74572227	chr1:81501794~81503468:+
LUAD	trans	rs11172055	0.775	rs10876940	ENSG00000121089.4	NACA3P	5.95	5.16e-09	0.00875	0.31	0.26	Migraine;	chr12:56871233	chr4:164943290~164943937:+
LUAD	trans	rs1391708	0.834	rs4259865	ENSG00000121089.4	NACA3P	5.95	5.17e-09	0.00876	0.41	0.26	Airway wall thickness;	chr12:56881229	chr4:164943290~164943937:+
LUAD	trans	rs1391708	0.834	rs7358569	ENSG00000121089.4	NACA3P	5.95	5.17e-09	0.00876	0.41	0.26	Airway wall thickness;	chr12:56883608	chr4:164943290~164943937:+
LUAD	trans	rs7617480	0.558	rs12715430	ENSG00000197582.5	GPX1P1	5.95	5.2e-09	0.00883	0.38	0.26	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48905422	chrX:13378735~13379340:-
LUAD	trans	rs6915893	0.967	rs10949483	ENSG00000267156.1	TPMTP1	5.95	5.26e-09	0.00891	0.31	0.26	Intrinsic epigenetic age acceleration;	chr6:18122275	chr18:47630112~47630848:+
LUAD	trans	rs7746199	0.673	rs72845046	ENSG00000253570.1	RNF5P1	5.95	5.26e-09	0.00891	0.57	0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27607489	chr8:38600661~38601200:-
LUAD	trans	rs12210905	1	rs12153912	ENSG00000242375.1	RP11-498P14.3	5.95	5.27e-09	0.00893	0.56	0.26	Hip circumference adjusted for BMI;	chr6:27212050	chr9:97195351~97197687:-
LUAD	trans	rs4713118	0.866	rs2179094	ENSG00000204709.4	LINC01556	5.95	5.27e-09	0.00893	0.35	0.26	Parkinson's disease;	chr6:27774046	chr6:28943877~28944537:+
LUAD	trans	rs7312770	0.637	rs705700	ENSG00000212829.8	RPS26P3	5.95	5.28e-09	0.00894	0.28	0.26	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr9:9090898~9091245:+
LUAD	trans	rs847577	0.715	rs12665986	ENSG00000225169.1	BRI3P1	-5.95	5.29e-09	0.00896	-0.32	-0.26	Breast cancer;	chr7:98090364	chr1:100213293~100213670:+
LUAD	trans	rs66887589	0.777	rs2017058	ENSG00000275858.1	RP11-291L22.8	5.95	5.3e-09	0.00897	0.28	0.26	Diastolic blood pressure;	chr4:119336584	chr10:38450738~38451069:-
LUAD	trans	rs66887589	0.777	rs1814815	ENSG00000275858.1	RP11-291L22.8	5.95	5.3e-09	0.00897	0.28	0.26	Diastolic blood pressure;	chr4:119336936	chr10:38450738~38451069:-
LUAD	trans	rs7121616	0.595	rs7941144	ENSG00000229091.2	HSPA8P8	5.95	5.3e-09	0.00897	0.35	0.26	Breast cancer;	chr11:123079805	chr7:10451311~10452526:+
LUAD	trans	rs67340775	0.834	rs13218875	ENSG00000253570.1	RNF5P1	5.94	5.33e-09	0.00902	0.59	0.26	Lung cancer in ever smokers;	chr6:27916234	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.882	rs9468287	ENSG00000281831.1	HCP5B	5.94	5.33e-09	0.00902	0.45	0.26	Depression;	chr6:28111963	chr6:29871895~29873783:-
LUAD	trans	rs9876781	1	rs6442119	ENSG00000225528.1	RP3-370M22.8	-5.94	5.33e-09	0.00902	-0.26	-0.26	Longevity;	chr3:48398713	chr22:39960397~39964683:+
LUAD	trans	rs66887589	0.748	rs28439855	ENSG00000275858.1	RP11-291L22.8	5.94	5.35e-09	0.00906	0.28	0.26	Diastolic blood pressure;	chr4:119341101	chr10:38450738~38451069:-
LUAD	trans	rs17507216	0.718	rs4779034	ENSG00000235370.6	DNM1P51	-5.94	5.36e-09	0.00907	-0.36	-0.26	Excessive daytime sleepiness;	chr15:82576799	chr15:84398316~84411701:-
LUAD	trans	rs17301013	0.932	rs2987869	ENSG00000213331.4	RP11-713C19.2	-5.94	5.38e-09	0.0091	-0.31	-0.26	Systemic lupus erythematosus;	chr1:174820269	chr4:187970273~187971284:+
LUAD	trans	rs6499255	0.904	rs12447883	ENSG00000257513.6	NPIPB1P	5.94	5.38e-09	0.00911	0.32	0.26	IgE levels;	chr16:69688894	chr18:11619509~11639699:-
LUAD	trans	rs9379850	0.528	rs67575965	ENSG00000253570.1	RNF5P1	5.94	5.39e-09	0.00911	0.38	0.26	Intelligence (multi-trait analysis);	chr6:26196365	chr8:38600661~38601200:-
LUAD	trans	rs4883201	0.656	rs1805248	ENSG00000179899.8	PHC1P1	5.94	5.42e-09	0.00916	0.32	0.26	Total cholesterol levels;Cholesterol, total;	chr12:8948541	chr12:55411727~55414787:-
LUAD	trans	rs6030712	1	rs6030712	ENSG00000211897.6	IGHG3	5.94	5.46e-09	0.00923	0.25	0.26	Height;	chr20:37008995	chr14:105769102~106038345:-
LUAD	trans	rs6030712	0.738	rs6017001	ENSG00000211897.6	IGHG3	5.94	5.46e-09	0.00923	0.25	0.26	Height;	chr20:37015543	chr14:105769102~106038345:-
LUAD	trans	rs853679	0.607	rs13190888	ENSG00000253570.1	RNF5P1	5.94	5.47e-09	0.00924	0.57	0.26	Depression;	chr6:28318208	chr8:38600661~38601200:-
LUAD	trans	rs7554511	0.8	rs296539	ENSG00000244144.1	RP11-757F18.3	5.94	5.48e-09	0.00926	0.32	0.26	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200918529	chr3:112185480~112185998:-
LUAD	trans	rs7819412	0.522	rs4841497	ENSG00000253893.2	FAM85B	5.94	5.48e-09	0.00926	0.33	0.26	Triglycerides;	chr8:11127630	chr8:8167819~8226614:-
LUAD	trans	rs1383484	0.575	rs8024422	ENSG00000278603.1	RP13-608F4.5	5.94	5.49e-09	0.00928	0.33	0.26	Height;	chr15:83951228	chr15:82472203~82472426:+
LUAD	trans	rs7554511	0.535	rs1995681	ENSG00000244144.1	RP11-757F18.3	5.94	5.51e-09	0.0093	0.31	0.26	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201036678	chr3:112185480~112185998:-
LUAD	trans	rs116002988	0.752	rs72700715	ENSG00000249592.4	RP11-440L14.1	-5.94	5.52e-09	0.00932	-0.31	-0.26	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr14:98983658	chr4:762387~781849:-
LUAD	trans	rs4713118	0.869	rs10214440	ENSG00000204709.4	LINC01556	5.94	5.54e-09	0.00936	0.35	0.26	Parkinson's disease;	chr6:27734661	chr6:28943877~28944537:+
LUAD	trans	rs255788	1	rs1191745	ENSG00000238005.2	RP11-443B7.1	5.94	5.56e-09	0.00939	0.42	0.26	Response to platinum-based chemotherapy (carboplatin);	chr5:120077344	chr1:234957342~234970062:-
LUAD	trans	rs853679	0.882	rs9393908	ENSG00000281831.1	HCP5B	5.94	5.6e-09	0.00944	0.45	0.26	Depression;	chr6:28223052	chr6:29871895~29873783:-
LUAD	trans	rs853679	0.882	rs9366717	ENSG00000281831.1	HCP5B	5.94	5.6e-09	0.00944	0.45	0.26	Depression;	chr6:28223279	chr6:29871895~29873783:-
LUAD	trans	rs864643	0.625	rs1707958	ENSG00000183298.5	RP11-556K13.1	5.94	5.6e-09	0.00945	0.37	0.26	Attention deficit hyperactivity disorder;	chr3:39481931	chr1:101786340~101787219:-
LUAD	trans	rs9425766	0.64	rs6658769	ENSG00000213331.4	RP11-713C19.2	5.94	5.62e-09	0.00949	0.3	0.26	Life satisfaction;	chr1:174100843	chr4:187970273~187971284:+
LUAD	trans	rs12145833	0.596	rs10927016	ENSG00000154608.12	CEP170P1	-5.93	5.63e-09	0.0095	-0.45	-0.26	Obesity (early onset extreme);	chr1:243431834	chr4:118467590~118554204:+
LUAD	trans	rs9425766	0.655	rs2145376	ENSG00000213331.4	RP11-713C19.2	5.93	5.65e-09	0.00953	0.3	0.26	Life satisfaction;	chr1:174098911	chr4:187970273~187971284:+
LUAD	trans	rs9425766	0.679	rs6663794	ENSG00000213331.4	RP11-713C19.2	5.93	5.65e-09	0.00953	0.3	0.26	Life satisfaction;	chr1:174099791	chr4:187970273~187971284:+
LUAD	trans	rs6915893	0.903	rs6921836	ENSG00000267156.1	TPMTP1	5.93	5.66e-09	0.00955	0.32	0.26	Intrinsic epigenetic age acceleration;	chr6:18104045	chr18:47630112~47630848:+
LUAD	trans	rs12145833	0.679	rs10927010	ENSG00000154608.12	CEP170P1	5.93	5.69e-09	0.0096	0.45	0.26	Obesity (early onset extreme);	chr1:243415510	chr4:118467590~118554204:+
LUAD	trans	rs3740713	0.669	rs113003553	ENSG00000236090.2	LDHAP3	5.93	5.7e-09	0.00961	0.45	0.26	Amyotrophic lateral sclerosis (sporadic);	chr11:18389314	chr2:41819747~41820754:+
LUAD	trans	rs2899832	0.5	rs28522717	ENSG00000229083.1	PSMA6P2	5.93	5.71e-09	0.00963	0.41	0.26	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35266346	chrX:12825840~12826833:+
LUAD	trans	rs864643	0.678	rs1768198	ENSG00000183298.5	RP11-556K13.1	5.93	5.75e-09	0.00968	0.37	0.26	Attention deficit hyperactivity disorder;	chr3:39474994	chr1:101786340~101787219:-
LUAD	trans	rs877636	1	rs877636	ENSG00000212829.8	RPS26P3	-5.93	5.76e-09	0.00971	-0.28	-0.26	Cognitive function;	chr12:56086799	chr9:9090898~9091245:+
LUAD	trans	rs853679	0.607	rs34950484	ENSG00000253570.1	RNF5P1	5.93	5.78e-09	0.00973	0.57	0.26	Depression;	chr6:28310911	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.607	rs34661125	ENSG00000253570.1	RNF5P1	5.93	5.78e-09	0.00973	0.57	0.26	Depression;	chr6:28314117	chr8:38600661~38601200:-
LUAD	trans	rs7617480	0.648	rs6766238	ENSG00000197582.5	GPX1P1	5.93	5.81e-09	0.00978	0.38	0.26	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48764496	chrX:13378735~13379340:-
LUAD	trans	rs545610	0.809	rs11031105	ENSG00000261105.4	LMO7-AS1	5.93	5.84e-09	0.00983	0.33	0.26	Dental caries;	chr11:30470523	chr13:75604700~75635994:-
LUAD	trans	rs7554511	0.555	rs11807626	ENSG00000244144.1	RP11-757F18.3	5.93	5.88e-09	0.00989	0.32	0.26	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201031226	chr3:112185480~112185998:-
LUAD	trans	rs11951515	0.508	rs67261887	ENSG00000174977.8	AC026271.5	-5.93	5.9e-09	0.00992	-0.27	-0.26	Metabolite levels  (X-11787);	chr5:43612339	chr17:18650195~18651542:+
LUAD	trans	rs12439619	0.693	rs8034801	ENSG00000259295.5	CSPG4P12	-5.93	5.9e-09	0.00992	-0.36	-0.26	Intelligence (multi-trait analysis);	chr15:82183996	chr15:85191438~85213905:+
LUAD	trans	rs6030712	0.894	rs6017076	ENSG00000211897.6	IGHG3	5.93	5.9e-09	0.00992	0.25	0.26	Height;	chr20:37032643	chr14:105769102~106038345:-
LUAD	trans	rs6030712	0.894	rs6031009	ENSG00000211897.6	IGHG3	5.93	5.9e-09	0.00992	0.25	0.26	Height;	chr20:37050654	chr14:105769102~106038345:-
LUAD	trans	rs6030712	0.895	rs6031084	ENSG00000211897.6	IGHG3	5.93	5.9e-09	0.00992	0.25	0.26	Height;	chr20:37063142	chr14:105769102~106038345:-
LUAD	trans	rs6030712	0.841	rs6124605	ENSG00000211897.6	IGHG3	5.93	5.9e-09	0.00992	0.25	0.26	Height;	chr20:37078888	chr14:105769102~106038345:-
LUAD	trans	rs7617480	0.549	rs9879978	ENSG00000197582.5	GPX1P1	5.93	5.91e-09	0.00994	0.38	0.26	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48809167	chrX:13378735~13379340:-
LUAD	trans	rs3740713	0.748	rs35292478	ENSG00000236090.2	LDHAP3	5.92	6.01e-09	0.0101	0.44	0.26	Amyotrophic lateral sclerosis (sporadic);	chr11:18408444	chr2:41819747~41820754:+
LUAD	trans	rs16937956	0.536	rs12362113	ENSG00000266891.1	RP11-692N5.2	-5.92	6.03e-09	0.0101	-0.34	-0.26	Body mass index;	chr11:8379019	chr18:9734882~9735602:-
LUAD	trans	rs7325116	0.519	rs9523466	ENSG00000241244.1	IGKV1D-16	5.92	6.03e-09	0.0101	0.2	0.26	Blood protein levels;	chr13:91985106	chr2:90100236~90100738:+
LUAD	trans	rs7042864	1	rs10120623	ENSG00000225178.4	RPSAP56	5.92	6.05e-09	0.0101	0.3	0.26	Tonometry;	chr9:108106252	chr16:73940639~73941524:-
LUAD	trans	rs17301013	0.803	rs2187562	ENSG00000213331.4	RP11-713C19.2	5.92	6.05e-09	0.0101	0.3	0.26	Systemic lupus erythematosus;	chr1:174842513	chr4:187970273~187971284:+
LUAD	trans	rs9914988	0.943	rs4795467	ENSG00000267449.1	RP11-264B14.2	5.92	6.07e-09	0.0102	0.37	0.26	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28853766	chr17:61069856~61070356:-
LUAD	trans	rs864643	0.678	rs500507	ENSG00000183298.5	RP11-556K13.1	5.92	6.07e-09	0.0102	0.37	0.26	Attention deficit hyperactivity disorder;	chr3:39492886	chr1:101786340~101787219:-
LUAD	trans	rs4818225	0.895	rs2837996	ENSG00000249840.2	GAPDHP76	-5.92	6.08e-09	0.0102	-0.33	-0.26	Educational attainment;	chr21:41254779	chr19:11585246~11587135:+
LUAD	trans	rs6743068	0.541	rs13014235	ENSG00000235105.1	RP11-329A14.1	5.92	6.09e-09	0.0102	0.3	0.26	Lymphocyte percentage of white cells;	chr2:201350769	chr1:48435967~48437223:+
LUAD	trans	rs7312770	0.637	rs705699	ENSG00000212829.8	RPS26P3	5.92	6.1e-09	0.0102	0.28	0.26	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr9:9090898~9091245:+
LUAD	trans	rs4574684	0.918	rs9387696	ENSG00000248124.6	RRN3P1	5.92	6.2e-09	0.0104	0.24	0.26	Systemic lupus erythematosus;	chr6:119969687	chr16:21796106~21820410:-
LUAD	trans	rs13016963	0.526	rs11687854	ENSG00000235105.1	RP11-329A14.1	5.92	6.23e-09	0.0104	0.31	0.26	Esophageal squamous cell carcinoma;Melanoma;	chr2:201363879	chr1:48435967~48437223:+
LUAD	trans	rs4713118	0.868	rs35069907	ENSG00000204709.4	LINC01556	5.92	6.23e-09	0.0104	0.36	0.26	Parkinson's disease;	chr6:27778913	chr6:28943877~28944537:+
LUAD	trans	rs73108077	0.736	rs7273790	ENSG00000279352.1	RP11-411B10.7	-5.92	6.24e-09	0.0104	-0.51	-0.26	Red blood cell density in sickle cell anemia;	chr20:31312478	chr18:14010054~14010917:+
LUAD	trans	rs853679	0.607	rs67040724	ENSG00000253570.1	RNF5P1	5.92	6.27e-09	0.0105	0.58	0.26	Depression;	chr6:27937731	chr8:38600661~38601200:-
LUAD	trans	rs2060793	0.659	rs1839834	ENSG00000236360.2	RP11-334A14.2	5.92	6.28e-09	0.0105	0.34	0.26	Vitamin D levels;	chr11:14807914	chr1:52993201~52993702:-
LUAD	trans	rs4713118	0.738	rs200465	ENSG00000204709.4	LINC01556	5.92	6.28e-09	0.0105	0.34	0.26	Parkinson's disease;	chr6:27789875	chr6:28943877~28944537:+
LUAD	trans	rs34375054	0.573	rs12581813	ENSG00000256340.7	ABCC6P1	5.91	6.31e-09	0.0106	0.37	0.26	Post bronchodilator FEV1/FVC ratio;	chr12:125171856	chr16:18571162~18598328:+
LUAD	trans	rs847577	0.677	rs10242903	ENSG00000225169.1	BRI3P1	-5.91	6.31e-09	0.0106	-0.31	-0.26	Breast cancer;	chr7:98112483	chr1:100213293~100213670:+
LUAD	trans	rs7647973	1	rs2312462	ENSG00000197582.5	GPX1P1	5.91	6.34e-09	0.0106	0.35	0.26	Menarche (age at onset);	chr3:49563822	chrX:13378735~13379340:-
LUAD	trans	rs10213084	1	rs28739535	ENSG00000221413.1	AC023593.1	-5.91	6.4e-09	0.0107	-0.42	-0.26	Heart rate;	chr4:146565678	chr3:127664704~127664810:+
LUAD	trans	rs10213084	1	rs28548763	ENSG00000221413.1	AC023593.1	-5.91	6.4e-09	0.0107	-0.42	-0.26	Heart rate;	chr4:146565714	chr3:127664704~127664810:+
LUAD	trans	rs8077577	0.747	rs11869582	ENSG00000188933.13	USP32P1	5.91	6.4e-09	0.0107	0.39	0.26	Obesity-related traits;	chr17:18233267	chr17:16786489~16804455:+
LUAD	trans	rs11512640	0.677	rs11220077	ENSG00000236257.1	EI24P2	5.91	6.43e-09	0.0107	0.53	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125447153	chr1:158454198~158455273:+
LUAD	trans	rs11220082	0.644	rs34435097	ENSG00000236257.1	EI24P2	-5.91	6.48e-09	0.0108	-0.28	-0.26	Schizophrenia;	chr11:125469075	chr1:158454198~158455273:+
LUAD	trans	rs9393777	0.92	rs66462181	ENSG00000253570.1	RNF5P1	5.91	6.49e-09	0.0108	0.6	0.26	Intelligence (multi-trait analysis);	chr6:27123882	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.546	rs493161	ENSG00000204709.4	LINC01556	5.91	6.51e-09	0.0109	0.52	0.26	Depression;	chr6:27882936	chr6:28943877~28944537:+
LUAD	trans	rs17301013	0.761	rs332805	ENSG00000213331.4	RP11-713C19.2	5.91	6.52e-09	0.0109	0.31	0.26	Systemic lupus erythematosus;	chr1:174652487	chr4:187970273~187971284:+
LUAD	trans	rs877636	1	rs705696	ENSG00000204652.6	RPS26P8	5.91	6.56e-09	0.0109	0.32	0.26	Cognitive function;	chr12:56086864	chr17:45608571~45608918:+
LUAD	trans	rs7647973	0.925	rs6769821	ENSG00000197582.5	GPX1P1	5.91	6.56e-09	0.0109	0.37	0.26	Menarche (age at onset);	chr3:49207224	chrX:13378735~13379340:-
LUAD	trans	rs9876781	1	rs2242150	ENSG00000225528.1	RP3-370M22.8	5.91	6.57e-09	0.011	0.26	0.26	Longevity;	chr3:48464565	chr22:39960397~39964683:+
LUAD	trans	rs9425766	0.679	rs2901785	ENSG00000213331.4	RP11-713C19.2	5.91	6.61e-09	0.011	0.3	0.26	Life satisfaction;	chr1:174135605	chr4:187970273~187971284:+
LUAD	trans	rs7746199	0.736	rs35037868	ENSG00000281831.1	HCP5B	5.91	6.62e-09	0.011	0.57	0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27791336	chr6:29871895~29873783:-
LUAD	trans	rs79149102	0.522	rs6495104	ENSG00000227288.3	RP5-837I24.1	5.91	6.62e-09	0.011	0.43	0.26	Lung cancer;	chr15:74475760	chr1:81501794~81503468:+
LUAD	trans	rs11668609	0.505	rs60888272	ENSG00000261770.1	CTC-459F4.1	5.91	6.64e-09	0.0111	0.4	0.26	Response to taxane treatment (docetaxel);	chr19:23968491	chr19:27757184~27760849:-
LUAD	trans	rs916888	0.61	rs199530	ENSG00000204650.12	CRHR1-IT1	-5.91	6.66e-09	0.0111	-0.3	-0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:45620328~45648216:+
LUAD	trans	rs10032931	0.962	rs1385671	ENSG00000188662.6	HILS1	-5.91	6.67e-09	0.0111	-0.32	-0.26	Optic nerve measurement (cup-to-disc ratio);	chr4:95534816	chr17:50171428~50181178:-
LUAD	trans	rs11668609	0.505	rs60605343	ENSG00000261770.1	CTC-459F4.1	5.9	6.73e-09	0.0112	0.4	0.26	Response to taxane treatment (docetaxel);	chr19:23968486	chr19:27757184~27760849:-
LUAD	trans	rs9329221	0.525	rs4394398	ENSG00000253981.4	ALG1L13P	-5.9	6.82e-09	0.0113	-0.3	-0.26	Neuroticism;	chr8:10226884	chr8:8236003~8244667:-
LUAD	trans	rs7647973	0.961	rs7626076	ENSG00000197582.5	GPX1P1	5.9	6.83e-09	0.0114	0.36	0.26	Menarche (age at onset);	chr3:49260706	chrX:13378735~13379340:-
LUAD	trans	rs853679	0.546	rs200977	ENSG00000204709.4	LINC01556	5.9	6.85e-09	0.0114	0.52	0.26	Depression;	chr6:27886523	chr6:28943877~28944537:+
LUAD	trans	rs545610	0.752	rs11031114	ENSG00000261105.4	LMO7-AS1	-5.9	6.88e-09	0.0114	-0.33	-0.26	Dental caries;	chr11:30496265	chr13:75604700~75635994:-
LUAD	trans	rs545610	0.78	rs11031115	ENSG00000261105.4	LMO7-AS1	-5.9	6.88e-09	0.0114	-0.33	-0.26	Dental caries;	chr11:30496368	chr13:75604700~75635994:-
LUAD	trans	rs10213084	1	rs71614592	ENSG00000221413.1	AC023593.1	-5.9	6.9e-09	0.0115	-0.41	-0.26	Heart rate;	chr4:146585111	chr3:127664704~127664810:+
LUAD	trans	rs10213084	1	rs2174304	ENSG00000221413.1	AC023593.1	-5.9	6.9e-09	0.0115	-0.41	-0.26	Heart rate;	chr4:146586311	chr3:127664704~127664810:+
LUAD	trans	rs2060793	0.741	rs2060794	ENSG00000236360.2	RP11-334A14.2	5.9	6.91e-09	0.0115	0.34	0.26	Vitamin D levels;	chr11:14791437	chr1:52993201~52993702:-
LUAD	trans	rs2060793	0.741	rs3740823	ENSG00000236360.2	RP11-334A14.2	5.9	6.91e-09	0.0115	0.34	0.26	Vitamin D levels;	chr11:14804158	chr1:52993201~52993702:-
LUAD	trans	rs1933488	1	rs1933488	ENSG00000278974.1	RP11-756P10.6	-5.9	6.93e-09	0.0115	-0.32	-0.26	Prostate cancer;	chr6:153119944	chr4:188740507~188741281:-
LUAD	trans	rs17507216	0.718	rs72751675	ENSG00000235370.6	DNM1P51	-5.9	6.97e-09	0.0116	-0.37	-0.26	Excessive daytime sleepiness;	chr15:82630452	chr15:84398316~84411701:-
LUAD	trans	rs17507216	0.671	rs28582623	ENSG00000235370.6	DNM1P51	-5.9	6.98e-09	0.0116	-0.36	-0.26	Excessive daytime sleepiness;	chr15:82577381	chr15:84398316~84411701:-
LUAD	trans	rs73193808	0.851	rs11911017	ENSG00000225972.1	MTND1P23	5.9	7e-09	0.0116	0.32	0.26	Coronary artery disease;	chr21:29195620	chr1:629062~629433:+
LUAD	trans	rs1933488	0.931	rs3870364	ENSG00000278974.1	RP11-756P10.6	-5.9	7.01e-09	0.0116	-0.32	-0.26	Prostate cancer;	chr6:153105544	chr4:188740507~188741281:-
LUAD	trans	rs545610	0.78	rs11031108	ENSG00000261105.4	LMO7-AS1	-5.9	7.02e-09	0.0117	-0.33	-0.26	Dental caries;	chr11:30474863	chr13:75604700~75635994:-
LUAD	trans	rs5758511	0.573	rs2284082	ENSG00000268568.1	AC007228.9	-5.9	7.02e-09	0.0117	-0.35	-0.26	Birth weight;	chr22:41844793	chr19:56672574~56673901:-
LUAD	trans	rs10037055	0.853	rs1363405	ENSG00000228305.2	AC016734.2	5.9	7.03e-09	0.0117	0.28	0.26	Migraine without aura;	chr5:177209881	chr2:63622178~63622831:-
LUAD	trans	rs9467773	0.595	rs3799379	ENSG00000242375.1	RP11-498P14.3	-5.9	7.03e-09	0.0117	-0.34	-0.26	Intelligence (multi-trait analysis);	chr6:26404466	chr9:97195351~97197687:-
LUAD	trans	rs4911253	0.509	rs66499347	ENSG00000253915.1	MAPRE1P1	-5.9	7.04e-09	0.0117	-0.31	-0.26	Lymphocyte counts;	chr20:32860890	chr8:135625185~135625981:-
LUAD	trans	rs6499255	0.904	rs7187653	ENSG00000257513.6	NPIPB1P	5.89	7.07e-09	0.0117	0.31	0.26	IgE levels;	chr16:69528935	chr18:11619509~11639699:-
LUAD	trans	rs864643	0.577	rs76395532	ENSG00000214263.2	RPSAP53	-5.89	7.07e-09	0.0117	-0.46	-0.26	Attention deficit hyperactivity disorder;	chr3:39490370	chr13:67266845~67267706:-
LUAD	trans	rs864643	0.524	rs77060785	ENSG00000214263.2	RPSAP53	-5.89	7.07e-09	0.0117	-0.46	-0.26	Attention deficit hyperactivity disorder;	chr3:39491177	chr13:67266845~67267706:-
LUAD	trans	rs7032940	0.784	rs10980253	ENSG00000228236.2	TXNP5	5.89	7.08e-09	0.0117	0.33	0.26	Height;	chr9:110205555	chr2:149068596~149068910:-
LUAD	trans	rs1933488	1	rs3870366	ENSG00000278974.1	RP11-756P10.6	-5.89	7.08e-09	0.0117	-0.32	-0.26	Prostate cancer;	chr6:153118632	chr4:188740507~188741281:-
LUAD	trans	rs1933488	0.898	rs6939447	ENSG00000278974.1	RP11-756P10.6	-5.89	7.08e-09	0.0117	-0.32	-0.26	Prostate cancer;	chr6:153118864	chr4:188740507~188741281:-
LUAD	trans	rs1933488	1	rs6917538	ENSG00000278974.1	RP11-756P10.6	-5.89	7.08e-09	0.0117	-0.32	-0.26	Prostate cancer;	chr6:153119062	chr4:188740507~188741281:-
LUAD	trans	rs1933488	1	rs9384082	ENSG00000278974.1	RP11-756P10.6	-5.89	7.08e-09	0.0117	-0.32	-0.26	Prostate cancer;	chr6:153119380	chr4:188740507~188741281:-
LUAD	trans	rs1933488	1	rs7740380	ENSG00000278974.1	RP11-756P10.6	-5.89	7.08e-09	0.0117	-0.32	-0.26	Prostate cancer;	chr6:153119576	chr4:188740507~188741281:-
LUAD	trans	rs6499255	0.951	rs1437135	ENSG00000257513.6	NPIPB1P	5.89	7.09e-09	0.0117	0.31	0.26	IgE levels;	chr16:69723925	chr18:11619509~11639699:-
LUAD	trans	rs7833986	0.501	rs72653951	ENSG00000236862.1	RPS20P24	5.89	7.09e-09	0.0118	0.31	0.26	Height;	chr8:56049278	chr9:72655832~72656192:-
LUAD	trans	rs116002988	0.752	rs72700717	ENSG00000249592.4	RP11-440L14.1	-5.89	7.1e-09	0.0118	-0.31	-0.26	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr14:98983777	chr4:762387~781849:-
LUAD	trans	rs7647973	0.922	rs6809851	ENSG00000197582.5	GPX1P1	5.89	7.11e-09	0.0118	0.36	0.26	Menarche (age at onset);	chr3:49272354	chrX:13378735~13379340:-
LUAD	trans	rs1933488	0.866	rs7756810	ENSG00000278974.1	RP11-756P10.6	-5.89	7.12e-09	0.0118	-0.32	-0.26	Prostate cancer;	chr6:153094998	chr4:188740507~188741281:-
LUAD	trans	rs2899832	0.568	rs8014594	ENSG00000229083.1	PSMA6P2	5.89	7.17e-09	0.0119	0.42	0.26	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35296623	chrX:12825840~12826833:+
LUAD	trans	rs2899832	0.568	rs7158019	ENSG00000229083.1	PSMA6P2	5.89	7.17e-09	0.0119	0.42	0.26	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35305912	chrX:12825840~12826833:+
LUAD	trans	rs6030712	0.948	rs6130318	ENSG00000211897.6	IGHG3	5.89	7.27e-09	0.012	0.25	0.26	Height;	chr20:37010328	chr14:105769102~106038345:-
LUAD	trans	rs2060793	0.741	rs1542291	ENSG00000236360.2	RP11-334A14.2	5.89	7.3e-09	0.0121	0.34	0.26	Vitamin D levels;	chr11:14784720	chr1:52993201~52993702:-
LUAD	trans	rs7937890	0.559	rs10766184	ENSG00000236360.2	RP11-334A14.2	5.89	7.32e-09	0.0121	0.33	0.26	Mitochondrial DNA levels;	chr11:14521031	chr1:52993201~52993702:-
LUAD	trans	rs4276421	0.571	rs1483308	ENSG00000231752.4	EMBP1	-5.89	7.33e-09	0.0121	-0.38	-0.26	P wave duration;	chr5:45538282	chr1:121519112~121571892:+
LUAD	trans	rs7212590	0.748	rs62081818	ENSG00000187870.7	RNFT1P3	5.89	7.35e-09	0.0122	0.56	0.26	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59813268	chr17:20743333~20754501:-
LUAD	trans	rs7212590	0.748	rs59685433	ENSG00000187870.7	RNFT1P3	5.89	7.35e-09	0.0122	0.56	0.26	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59813846	chr17:20743333~20754501:-
LUAD	trans	rs1933488	0.931	rs9397587	ENSG00000278974.1	RP11-756P10.6	-5.89	7.38e-09	0.0122	-0.32	-0.26	Prostate cancer;	chr6:153095777	chr4:188740507~188741281:-
LUAD	trans	rs10420951	0.617	rs7251067	ENSG00000267533.1	RP11-815J4.7	5.89	7.38e-09	0.0122	0.48	0.26	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr19:18489246	chr18:12067173~12068417:-
LUAD	trans	rs9581094	0.591	rs9553318	ENSG00000224976.2	PARP4P2	5.89	7.4e-09	0.0122	0.35	0.26	Sudden cardiac arrest;	chr13:24477107	chr13:19349137~19407962:+
LUAD	trans	rs7212590	0.748	rs73315252	ENSG00000187870.7	RNFT1P3	5.89	7.42e-09	0.0123	0.56	0.26	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59777494	chr17:20743333~20754501:-
LUAD	trans	rs7212590	0.748	rs8073489	ENSG00000187870.7	RNFT1P3	5.89	7.42e-09	0.0123	0.56	0.26	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59784433	chr17:20743333~20754501:-
LUAD	trans	rs889398	0.51	rs11646575	ENSG00000257513.6	NPIPB1P	5.89	7.43e-09	0.0123	0.26	0.26	Body mass index;	chr16:69533878	chr18:11619509~11639699:-
LUAD	trans	rs7617480	0.648	rs14018	ENSG00000197582.5	GPX1P1	5.89	7.43e-09	0.0123	0.39	0.26	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48746837	chrX:13378735~13379340:-
LUAD	trans	rs847577	0.508	rs12538837	ENSG00000225169.1	BRI3P1	5.89	7.45e-09	0.0123	0.33	0.26	Breast cancer;	chr7:98055156	chr1:100213293~100213670:+
LUAD	trans	rs10032931	1	rs10032931	ENSG00000188662.6	HILS1	-5.89	7.45e-09	0.0123	-0.33	-0.26	Optic nerve measurement (cup-to-disc ratio);	chr4:95537282	chr17:50171428~50181178:-
LUAD	trans	rs853679	0.607	rs67040724	ENSG00000281831.1	HCP5B	5.88	7.49e-09	0.0124	0.58	0.26	Depression;	chr6:27937731	chr6:29871895~29873783:-
LUAD	trans	rs10213084	0.92	rs1472728	ENSG00000221413.1	AC023593.1	-5.88	7.49e-09	0.0124	-0.41	-0.26	Heart rate;	chr4:146585702	chr3:127664704~127664810:+
LUAD	trans	rs7746199	0.736	rs72845070	ENSG00000281831.1	HCP5B	5.88	7.51e-09	0.0124	0.58	0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27700521	chr6:29871895~29873783:-
LUAD	trans	rs79149102	0.522	rs12441794	ENSG00000227288.3	RP5-837I24.1	5.88	7.52e-09	0.0124	0.46	0.26	Lung cancer;	chr15:74471808	chr1:81501794~81503468:+
LUAD	trans	rs7746199	0.736	rs35848276	ENSG00000281831.1	HCP5B	5.88	7.53e-09	0.0124	0.56	0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27553317	chr6:29871895~29873783:-
LUAD	trans	rs2899832	0.866	rs8004236	ENSG00000229083.1	PSMA6P2	5.88	7.56e-09	0.0125	0.35	0.26	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35267829	chrX:12825840~12826833:+
LUAD	trans	rs877636	1	rs2292239	ENSG00000243538.1	CTB-55B8.1	5.88	7.56e-09	0.0125	0.27	0.26	Cognitive function;	chr12:56088396	chr5:16902294~16902641:-
LUAD	trans	rs853679	0.607	rs13199772	ENSG00000253570.1	RNF5P1	5.88	7.57e-09	0.0125	0.56	0.26	Depression;	chr6:27866307	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.607	rs13199906	ENSG00000253570.1	RNF5P1	5.88	7.57e-09	0.0125	0.56	0.26	Depression;	chr6:27866361	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.607	rs17763089	ENSG00000253570.1	RNF5P1	5.88	7.57e-09	0.0125	0.56	0.26	Depression;	chr6:27867440	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.546	rs17695758	ENSG00000253570.1	RNF5P1	5.88	7.57e-09	0.0125	0.56	0.26	Depression;	chr6:27869405	chr8:38600661~38601200:-
LUAD	trans	rs67340775	0.834	rs13218875	ENSG00000281831.1	HCP5B	5.88	7.62e-09	0.0126	0.58	0.26	Lung cancer in ever smokers;	chr6:27916234	chr6:29871895~29873783:-
LUAD	trans	rs7260598	0.792	rs4635459	ENSG00000261770.1	CTC-459F4.1	5.88	7.63e-09	0.0126	0.41	0.26	Response to taxane treatment (placlitaxel);	chr19:23999020	chr19:27757184~27760849:-
LUAD	trans	rs853679	0.556	rs45509595	ENSG00000253570.1	RNF5P1	5.88	7.66e-09	0.0126	0.58	0.26	Depression;	chr6:27873148	chr8:38600661~38601200:-
LUAD	trans	rs3096299	0.658	rs12443705	ENSG00000215030.5	RPL13P12	-5.88	7.67e-09	0.0126	-0.29	-0.26	Multiple myeloma (IgH translocation);	chr16:89480646	chr17:17383377~17384012:-
LUAD	trans	rs6499255	0.951	rs1437136	ENSG00000257513.6	NPIPB1P	5.88	7.68e-09	0.0126	0.31	0.26	IgE levels;	chr16:69638772	chr18:11619509~11639699:-
LUAD	trans	rs7032940	0.677	rs4279674	ENSG00000262519.1	TXNP4	5.88	7.7e-09	0.0127	0.32	0.26	Height;	chr9:110179726	chr17:4572206~4572515:+
LUAD	trans	rs6030712	0.948	rs6130371	ENSG00000211897.6	IGHG3	5.88	7.71e-09	0.0127	0.25	0.26	Height;	chr20:37027317	chr14:105769102~106038345:-
LUAD	trans	rs6030712	0.894	rs6124608	ENSG00000211897.6	IGHG3	5.88	7.71e-09	0.0127	0.25	0.26	Height;	chr20:37080616	chr14:105769102~106038345:-
LUAD	trans	rs7312770	0.612	rs1873914	ENSG00000212829.8	RPS26P3	5.88	7.72e-09	0.0127	0.27	0.26	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr9:9090898~9091245:+
LUAD	trans	rs11638815	0.639	rs783542	ENSG00000235370.6	DNM1P51	-5.88	7.72e-09	0.0127	-0.41	-0.26	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82567264	chr15:84398316~84411701:-
LUAD	trans	rs4906172	0.773	rs941792	ENSG00000181359.5	HSP90AA6P	5.88	7.77e-09	0.0128	0.3	0.26	Menopause (age at onset);	chr14:102048376	chr4:170581470~170605450:-
LUAD	trans	rs8077577	0.689	rs62072515	ENSG00000188933.13	USP32P1	5.88	7.79e-09	0.0128	0.36	0.26	Obesity-related traits;	chr17:18310121	chr17:16786489~16804455:+
LUAD	trans	rs10783779	0.647	rs705708	ENSG00000243403.1	RP11-330L19.1	5.88	7.79e-09	0.0128	0.26	0.26	Educational attainment;	chr12:56095129	chr15:64592979~64593326:+
LUAD	trans	rs6499255	0.951	rs9921045	ENSG00000257513.6	NPIPB1P	5.88	7.88e-09	0.013	0.3	0.26	IgE levels;	chr16:69674795	chr18:11619509~11639699:-
LUAD	trans	rs853679	0.607	rs13211507	ENSG00000253570.1	RNF5P1	5.88	7.89e-09	0.013	0.56	0.26	Depression;	chr6:28289600	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.607	rs34691223	ENSG00000253570.1	RNF5P1	5.88	7.89e-09	0.013	0.56	0.26	Depression;	chr6:28290431	chr8:38600661~38601200:-
LUAD	trans	rs4879656	0.564	rs1888869	ENSG00000215007.3	DNAJA1P3	-5.87	7.91e-09	0.013	-0.29	-0.26	Menopause (age at onset);	chr9:32998239	chrX:107351650~107352843:-
LUAD	trans	rs6030712	0.792	rs62206477	ENSG00000211897.6	IGHG3	5.87	7.91e-09	0.013	0.25	0.26	Height;	chr20:37005026	chr14:105769102~106038345:-
LUAD	trans	rs6030712	0.894	rs6130402	ENSG00000211897.6	IGHG3	5.87	7.91e-09	0.013	0.25	0.26	Height;	chr20:37038901	chr14:105769102~106038345:-
LUAD	trans	rs6030712	0.948	rs6124573	ENSG00000211897.6	IGHG3	5.87	7.91e-09	0.013	0.25	0.26	Height;	chr20:37041759	chr14:105769102~106038345:-
LUAD	trans	rs6030712	0.894	rs8183757	ENSG00000211897.6	IGHG3	5.87	7.91e-09	0.013	0.25	0.26	Height;	chr20:37049742	chr14:105769102~106038345:-
LUAD	trans	rs6030712	0.948	rs6130488	ENSG00000211897.6	IGHG3	5.87	7.91e-09	0.013	0.25	0.26	Height;	chr20:37084591	chr14:105769102~106038345:-
LUAD	trans	rs8077577	0.747	rs62072509	ENSG00000188933.13	USP32P1	5.87	7.95e-09	0.0131	0.36	0.26	Obesity-related traits;	chr17:18279079	chr17:16786489~16804455:+
LUAD	trans	rs11220082	0.666	rs12224788	ENSG00000236257.1	EI24P2	-5.87	7.96e-09	0.0131	-0.28	-0.26	Schizophrenia;	chr11:125459165	chr1:158454198~158455273:+
LUAD	trans	rs17664267	0.906	rs1424397	ENSG00000239005.1	ACA64	5.87	7.97e-09	0.0131	0.39	0.26	Conduct disorder (maternal expressed emotions interaction);	chr18:43222793	chr4:139436368~139436494:-
LUAD	trans	rs4713118	0.869	rs6922574	ENSG00000204709.4	LINC01556	5.87	8.01e-09	0.0132	0.35	0.26	Parkinson's disease;	chr6:27725224	chr6:28943877~28944537:+
LUAD	trans	rs10213084	1	rs10014502	ENSG00000221413.1	AC023593.1	-5.87	8.03e-09	0.0132	-0.41	-0.26	Heart rate;	chr4:146592899	chr3:127664704~127664810:+
LUAD	trans	rs10213084	0.92	rs35656432	ENSG00000221413.1	AC023593.1	-5.87	8.03e-09	0.0132	-0.41	-0.26	Heart rate;	chr4:146593387	chr3:127664704~127664810:+
LUAD	trans	rs9393777	0.92	rs72839445	ENSG00000204709.4	LINC01556	5.87	8.06e-09	0.0132	0.55	0.26	Intelligence (multi-trait analysis);	chr6:27281907	chr6:28943877~28944537:+
LUAD	trans	rs8077577	0.747	rs8081155	ENSG00000188933.13	USP32P1	5.87	8.08e-09	0.0133	0.36	0.26	Obesity-related traits;	chr17:18288634	chr17:16786489~16804455:+
LUAD	trans	rs864643	0.891	rs1708032	ENSG00000183298.5	RP11-556K13.1	5.87	8.1e-09	0.0133	0.37	0.26	Attention deficit hyperactivity disorder;	chr3:39497642	chr1:101786340~101787219:-
LUAD	trans	rs6831352	0.589	rs2924584	ENSG00000233859.2	ADH5P4	-5.87	8.15e-09	0.0134	-0.26	-0.26	Alcohol dependence;	chr4:99067057	chr6:65836930~65838039:-
LUAD	trans	rs11172055	1	rs11172055	ENSG00000121089.4	NACA3P	5.87	8.17e-09	0.0134	0.3	0.26	Migraine;	chr12:56914476	chr4:164943290~164943937:+
LUAD	trans	rs9393777	0.92	rs35768595	ENSG00000253570.1	RNF5P1	5.87	8.18e-09	0.0134	0.6	0.26	Intelligence (multi-trait analysis);	chr6:27174125	chr8:38600661~38601200:-
LUAD	trans	rs1933488	0.898	rs6557261	ENSG00000278974.1	RP11-756P10.6	-5.87	8.19e-09	0.0134	-0.32	-0.26	Prostate cancer;	chr6:153094233	chr4:188740507~188741281:-
LUAD	trans	rs1933488	0.898	rs9479505	ENSG00000278974.1	RP11-756P10.6	-5.87	8.19e-09	0.0134	-0.32	-0.26	Prostate cancer;	chr6:153094516	chr4:188740507~188741281:-
LUAD	trans	rs1933488	0.835	rs9371280	ENSG00000278974.1	RP11-756P10.6	-5.87	8.2e-09	0.0135	-0.32	-0.26	Prostate cancer;	chr6:153093138	chr4:188740507~188741281:-
LUAD	trans	rs545610	0.78	rs11031116	ENSG00000261105.4	LMO7-AS1	-5.87	8.22e-09	0.0135	-0.33	-0.26	Dental caries;	chr11:30497747	chr13:75604700~75635994:-
LUAD	trans	rs4920799	0.793	rs305728	ENSG00000237484.5	AP000476.1	-5.87	8.24e-09	0.0135	-0.29	-0.26	Echocardiographic traits;	chr5:85338274	chr21:24428740~24547942:+
LUAD	trans	rs4639966	0.589	rs480958	ENSG00000219773.1	RP11-506B6.3	5.87	8.29e-09	0.0136	0.26	0.26	Systemic lupus erythematosus;	chr11:118707281	chr6:112355841~112356714:-
LUAD	trans	rs6499255	0.953	rs3811349	ENSG00000257513.6	NPIPB1P	5.87	8.29e-09	0.0136	0.3	0.26	IgE levels;	chr16:69757363	chr18:11619509~11639699:-
LUAD	trans	rs864643	0.524	rs77309543	ENSG00000214263.2	RPSAP53	-5.87	8.32e-09	0.0136	-0.46	-0.26	Attention deficit hyperactivity disorder;	chr3:39489578	chr13:67266845~67267706:-
LUAD	trans	rs853679	0.607	rs13199649	ENSG00000253570.1	RNF5P1	5.87	8.33e-09	0.0136	0.58	0.26	Depression;	chr6:27901014	chr8:38600661~38601200:-
LUAD	trans	rs453301	0.507	rs2929306	ENSG00000253893.2	FAM85B	5.87	8.35e-09	0.0137	0.33	0.26	Joint mobility (Beighton score);	chr8:9227399	chr8:8167819~8226614:-
LUAD	trans	rs4920799	0.752	rs305717	ENSG00000237484.5	AP000476.1	-5.86	8.43e-09	0.0138	-0.29	-0.26	Echocardiographic traits;	chr5:85336680	chr21:24428740~24547942:+
LUAD	trans	rs4920799	0.793	rs305718	ENSG00000237484.5	AP000476.1	-5.86	8.43e-09	0.0138	-0.29	-0.26	Echocardiographic traits;	chr5:85336922	chr21:24428740~24547942:+
LUAD	trans	rs4920799	0.793	rs305719	ENSG00000237484.5	AP000476.1	-5.86	8.43e-09	0.0138	-0.29	-0.26	Echocardiographic traits;	chr5:85336980	chr21:24428740~24547942:+
LUAD	trans	rs4920799	0.793	rs305721	ENSG00000237484.5	AP000476.1	-5.86	8.43e-09	0.0138	-0.29	-0.26	Echocardiographic traits;	chr5:85337243	chr21:24428740~24547942:+
LUAD	trans	rs4920799	0.793	rs305722	ENSG00000237484.5	AP000476.1	-5.86	8.43e-09	0.0138	-0.29	-0.26	Echocardiographic traits;	chr5:85337298	chr21:24428740~24547942:+
LUAD	trans	rs4920799	0.752	rs305723	ENSG00000237484.5	AP000476.1	-5.86	8.43e-09	0.0138	-0.29	-0.26	Echocardiographic traits;	chr5:85337461	chr21:24428740~24547942:+
LUAD	trans	rs4920799	0.793	rs305724	ENSG00000237484.5	AP000476.1	-5.86	8.43e-09	0.0138	-0.29	-0.26	Echocardiographic traits;	chr5:85337644	chr21:24428740~24547942:+
LUAD	trans	rs4920799	0.793	rs305725	ENSG00000237484.5	AP000476.1	-5.86	8.43e-09	0.0138	-0.29	-0.26	Echocardiographic traits;	chr5:85337736	chr21:24428740~24547942:+
LUAD	trans	rs4920799	0.793	rs305726	ENSG00000237484.5	AP000476.1	-5.86	8.43e-09	0.0138	-0.29	-0.26	Echocardiographic traits;	chr5:85337911	chr21:24428740~24547942:+
LUAD	trans	rs4920799	0.793	rs305727	ENSG00000237484.5	AP000476.1	-5.86	8.43e-09	0.0138	-0.29	-0.26	Echocardiographic traits;	chr5:85338219	chr21:24428740~24547942:+
LUAD	trans	rs7312933	0.51	rs61942483	ENSG00000223551.1	TMSB4XP4	5.86	8.43e-09	0.0138	0.27	0.26	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42105736	chr9:128342153~128342770:+
LUAD	trans	rs9425766	0.679	rs6682017	ENSG00000213331.4	RP11-713C19.2	5.86	8.45e-09	0.0138	0.3	0.26	Life satisfaction;	chr1:174097809	chr4:187970273~187971284:+
LUAD	trans	rs8064024	0.599	rs3185547	ENSG00000279933.1	RP4-671O14.5	5.86	8.46e-09	0.0138	0.25	0.26	Cancer;	chr16:4881099	chr22:44183031~44187739:-
LUAD	trans	rs7833986	0.501	rs72651502	ENSG00000244245.1	RP11-120B7.1	5.86	8.48e-09	0.0139	0.32	0.26	Height;	chr8:55962974	chr5:108593609~108593967:+
LUAD	trans	rs10213084	1	rs10213045	ENSG00000221413.1	AC023593.1	-5.86	8.49e-09	0.0139	-0.41	-0.26	Heart rate;	chr4:146579823	chr3:127664704~127664810:+
LUAD	trans	rs864643	0.945	rs1707972	ENSG00000183298.5	RP11-556K13.1	5.86	8.5e-09	0.0139	0.36	0.26	Attention deficit hyperactivity disorder;	chr3:39507243	chr1:101786340~101787219:-
LUAD	trans	rs3812762	0.871	rs11603335	ENSG00000266891.1	RP11-692N5.2	-5.86	8.5e-09	0.0139	-0.34	-0.26	Hypospadias;	chr11:8788297	chr18:9734882~9735602:-
LUAD	trans	rs9425766	0.523	rs6668959	ENSG00000213331.4	RP11-713C19.2	5.86	8.52e-09	0.0139	0.3	0.26	Life satisfaction;	chr1:174088488	chr4:187970273~187971284:+
LUAD	trans	rs9425766	0.665	rs7553788	ENSG00000213331.4	RP11-713C19.2	5.86	8.52e-09	0.0139	0.3	0.26	Life satisfaction;	chr1:174093773	chr4:187970273~187971284:+
LUAD	trans	rs4920799	0.793	rs305730	ENSG00000237484.5	AP000476.1	-5.86	8.55e-09	0.014	-0.29	-0.26	Echocardiographic traits;	chr5:85338876	chr21:24428740~24547942:+
LUAD	trans	rs4920799	0.752	rs305731	ENSG00000237484.5	AP000476.1	-5.86	8.55e-09	0.014	-0.29	-0.26	Echocardiographic traits;	chr5:85339516	chr21:24428740~24547942:+
LUAD	trans	rs4920799	0.715	rs305732	ENSG00000237484.5	AP000476.1	-5.86	8.55e-09	0.014	-0.29	-0.26	Echocardiographic traits;	chr5:85339646	chr21:24428740~24547942:+
LUAD	trans	rs4920799	0.73	rs305733	ENSG00000237484.5	AP000476.1	-5.86	8.55e-09	0.014	-0.29	-0.26	Echocardiographic traits;	chr5:85339846	chr21:24428740~24547942:+
LUAD	trans	rs4920799	0.793	rs305734	ENSG00000237484.5	AP000476.1	-5.86	8.55e-09	0.014	-0.29	-0.26	Echocardiographic traits;	chr5:85339879	chr21:24428740~24547942:+
LUAD	trans	rs4920799	0.793	rs305735	ENSG00000237484.5	AP000476.1	-5.86	8.55e-09	0.014	-0.29	-0.26	Echocardiographic traits;	chr5:85340134	chr21:24428740~24547942:+
LUAD	trans	rs4920799	0.793	rs305736	ENSG00000237484.5	AP000476.1	-5.86	8.55e-09	0.014	-0.29	-0.26	Echocardiographic traits;	chr5:85340284	chr21:24428740~24547942:+
LUAD	trans	rs4920799	0.793	rs305737	ENSG00000237484.5	AP000476.1	-5.86	8.55e-09	0.014	-0.29	-0.26	Echocardiographic traits;	chr5:85340323	chr21:24428740~24547942:+
LUAD	trans	rs853679	0.824	rs34712084	ENSG00000281831.1	HCP5B	5.86	8.55e-09	0.014	0.45	0.26	Depression;	chr6:28076050	chr6:29871895~29873783:-
LUAD	trans	rs853679	0.824	rs1321505	ENSG00000281831.1	HCP5B	5.86	8.55e-09	0.014	0.45	0.26	Depression;	chr6:28085045	chr6:29871895~29873783:-
LUAD	trans	rs10213084	0.915	rs10212988	ENSG00000221413.1	AC023593.1	-5.86	8.59e-09	0.014	-0.41	-0.26	Heart rate;	chr4:146579848	chr3:127664704~127664810:+
LUAD	trans	rs10213084	1	rs10212994	ENSG00000221413.1	AC023593.1	-5.86	8.59e-09	0.014	-0.41	-0.26	Heart rate;	chr4:146580073	chr3:127664704~127664810:+
LUAD	trans	rs10213084	1	rs10212996	ENSG00000221413.1	AC023593.1	-5.86	8.59e-09	0.014	-0.41	-0.26	Heart rate;	chr4:146580149	chr3:127664704~127664810:+
LUAD	trans	rs453301	0.571	rs2929305	ENSG00000253893.2	FAM85B	5.86	8.59e-09	0.014	0.32	0.26	Joint mobility (Beighton score);	chr8:9227707	chr8:8167819~8226614:-
LUAD	trans	rs11512640	0.655	rs80057612	ENSG00000236257.1	EI24P2	5.86	8.63e-09	0.0141	0.54	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125542949	chr1:158454198~158455273:+
LUAD	trans	rs7121616	0.576	rs4802	ENSG00000256356.1	HSPA8P5	5.86	8.7e-09	0.0142	0.28	0.26	Breast cancer;	chr11:123057914	chr12:4097451~4099519:+
LUAD	trans	rs3096299	0.685	rs12446145	ENSG00000215030.5	RPL13P12	-5.86	8.71e-09	0.0142	-0.29	-0.26	Multiple myeloma (IgH translocation);	chr16:89476287	chr17:17383377~17384012:-
LUAD	trans	rs3740713	0.748	rs35292478	ENSG00000214110.3	LDHAP4	5.86	8.74e-09	0.0143	0.42	0.26	Amyotrophic lateral sclerosis (sporadic);	chr11:18408444	chr9:14921337~14922334:-
LUAD	trans	rs6940638	0.688	rs9379960	ENSG00000204709.4	LINC01556	5.86	8.76e-09	0.0143	0.32	0.26	Intelligence (multi-trait analysis);	chr6:27153546	chr6:28943877~28944537:+
LUAD	trans	rs7260598	0.642	rs4313914	ENSG00000261770.1	CTC-459F4.1	5.86	8.82e-09	0.0144	0.38	0.26	Response to taxane treatment (placlitaxel);	chr19:23994194	chr19:27757184~27760849:-
LUAD	trans	rs116002988	0.752	rs72700718	ENSG00000249592.4	RP11-440L14.1	-5.86	8.83e-09	0.0144	-0.31	-0.26	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr14:98983930	chr4:762387~781849:-
LUAD	trans	rs116002988	0.752	rs72700719	ENSG00000249592.4	RP11-440L14.1	-5.86	8.83e-09	0.0144	-0.31	-0.26	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr14:98984019	chr4:762387~781849:-
LUAD	trans	rs116002988	0.752	rs72700721	ENSG00000249592.4	RP11-440L14.1	-5.86	8.83e-09	0.0144	-0.31	-0.26	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr14:98984430	chr4:762387~781849:-
LUAD	trans	rs11668609	0.81	rs17000162	ENSG00000261770.1	CTC-459F4.1	5.85	8.85e-09	0.0144	0.4	0.26	Response to taxane treatment (docetaxel);	chr19:24185347	chr19:27757184~27760849:-
LUAD	trans	rs10032931	0.926	rs17024152	ENSG00000188662.6	HILS1	-5.85	8.86e-09	0.0145	-0.32	-0.26	Optic nerve measurement (cup-to-disc ratio);	chr4:95535251	chr17:50171428~50181178:-
LUAD	trans	rs3812762	0.868	rs7934519	ENSG00000266891.1	RP11-692N5.2	-5.85	8.87e-09	0.0145	-0.34	-0.26	Hypospadias;	chr11:8770434	chr18:9734882~9735602:-
LUAD	trans	rs2899832	0.568	rs8017330	ENSG00000229083.1	PSMA6P2	5.85	8.94e-09	0.0146	0.4	0.26	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35263163	chrX:12825840~12826833:+
LUAD	trans	rs7647973	0.961	rs7619016	ENSG00000197582.5	GPX1P1	5.85	8.98e-09	0.0146	0.36	0.26	Menarche (age at onset);	chr3:49235156	chrX:13378735~13379340:-
LUAD	trans	rs10028773	0.546	rs13117947	ENSG00000275858.1	RP11-291L22.8	5.85	9.05e-09	0.0147	0.27	0.26	Educational attainment;	chr4:119335905	chr10:38450738~38451069:-
LUAD	trans	rs853679	0.607	rs67340775	ENSG00000253570.1	RNF5P1	5.85	9.06e-09	0.0148	0.57	0.26	Depression;	chr6:28336607	chr8:38600661~38601200:-
LUAD	trans	rs6915893	1	rs9477630	ENSG00000267156.1	TPMTP1	5.85	9.08e-09	0.0148	0.31	0.26	Intrinsic epigenetic age acceleration;	chr6:18117867	chr18:47630112~47630848:+
LUAD	trans	rs2243480	1	rs6460260	ENSG00000230295.1	RP11-458F8.2	5.85	9.14e-09	0.0149	0.32	0.26	Diabetic kidney disease;	chr7:65750468	chr7:66880708~66882981:+
LUAD	trans	rs2243480	1	rs6460261	ENSG00000230295.1	RP11-458F8.2	5.85	9.14e-09	0.0149	0.32	0.26	Diabetic kidney disease;	chr7:65750593	chr7:66880708~66882981:+
LUAD	trans	rs8177253	0.665	rs11921527	ENSG00000256243.2	RPL7AP3	5.85	9.15e-09	0.0149	0.3	0.26	Iron status biomarkers;	chr3:133722323	chr14:35235180~35235651:-
LUAD	trans	rs916888	0.779	rs199498	ENSG00000204650.12	CRHR1-IT1	5.85	9.16e-09	0.0149	0.34	0.26	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:45620328~45648216:+
LUAD	trans	rs10447419	0.6	rs9492544	ENSG00000240718.3	RN7SL851P	-5.85	9.19e-09	0.0149	-0.27	-0.26	PR interval;	chr6:130317605	chr7:6047721~6048023:-
LUAD	trans	rs3812762	0.879	rs3844099	ENSG00000266891.1	RP11-692N5.2	-5.85	9.19e-09	0.015	-0.33	-0.26	Hypospadias;	chr11:8786705	chr18:9734882~9735602:-
LUAD	trans	rs9467711	1	rs9467704	ENSG00000204709.4	LINC01556	-5.85	9.28e-09	0.0151	-0.46	-0.26	Autism spectrum disorder or schizophrenia;	chr6:26319258	chr6:28943877~28944537:+
LUAD	trans	rs5758511	0.573	rs1883205	ENSG00000268568.1	AC007228.9	-5.85	9.3e-09	0.0151	-0.35	-0.26	Birth weight;	chr22:41847016	chr19:56672574~56673901:-
LUAD	trans	rs8077577	0.747	rs3817992	ENSG00000188933.13	USP32P1	5.85	9.31e-09	0.0151	0.36	0.26	Obesity-related traits;	chr17:18290697	chr17:16786489~16804455:+
LUAD	trans	rs8077577	0.747	rs2294913	ENSG00000188933.13	USP32P1	5.85	9.31e-09	0.0151	0.36	0.26	Obesity-related traits;	chr17:18299682	chr17:16786489~16804455:+
LUAD	trans	rs10213084	1	rs11734800	ENSG00000221413.1	AC023593.1	-5.85	9.34e-09	0.0152	-0.41	-0.26	Heart rate;	chr4:146581499	chr3:127664704~127664810:+
LUAD	trans	rs10213084	1	rs28557374	ENSG00000221413.1	AC023593.1	-5.85	9.34e-09	0.0152	-0.41	-0.26	Heart rate;	chr4:146581989	chr3:127664704~127664810:+
LUAD	trans	rs10213084	1	rs13122002	ENSG00000221413.1	AC023593.1	-5.85	9.34e-09	0.0152	-0.41	-0.26	Heart rate;	chr4:146582602	chr3:127664704~127664810:+
LUAD	trans	rs728478	0.566	rs7221185	ENSG00000187870.7	RNFT1P3	5.84	9.38e-09	0.0152	0.31	0.26	QT interval;	chr17:59399292	chr17:20743333~20754501:-
LUAD	trans	rs853679	0.607	rs34878803	ENSG00000253570.1	RNF5P1	5.84	9.38e-09	0.0152	0.55	0.26	Depression;	chr6:28282402	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.607	rs34396849	ENSG00000253570.1	RNF5P1	5.84	9.38e-09	0.0152	0.55	0.26	Depression;	chr6:28283178	chr8:38600661~38601200:-
LUAD	trans	rs10213084	1	rs13113553	ENSG00000221413.1	AC023593.1	-5.84	9.48e-09	0.0154	-0.41	-0.26	Heart rate;	chr4:146573196	chr3:127664704~127664810:+
LUAD	trans	rs10213084	1	rs28477577	ENSG00000221413.1	AC023593.1	-5.84	9.48e-09	0.0154	-0.41	-0.26	Heart rate;	chr4:146574819	chr3:127664704~127664810:+
LUAD	trans	rs10213084	1	rs7670221	ENSG00000221413.1	AC023593.1	-5.84	9.48e-09	0.0154	-0.41	-0.26	Heart rate;	chr4:146576445	chr3:127664704~127664810:+
LUAD	trans	rs10213084	1	rs7671823	ENSG00000221413.1	AC023593.1	-5.84	9.48e-09	0.0154	-0.41	-0.26	Heart rate;	chr4:146576555	chr3:127664704~127664810:+
LUAD	trans	rs10213084	1	rs56221117	ENSG00000221413.1	AC023593.1	-5.84	9.48e-09	0.0154	-0.41	-0.26	Heart rate;	chr4:146577164	chr3:127664704~127664810:+
LUAD	trans	rs10213084	1	rs10212913	ENSG00000221413.1	AC023593.1	-5.84	9.48e-09	0.0154	-0.41	-0.26	Heart rate;	chr4:146577906	chr3:127664704~127664810:+
LUAD	trans	rs10213084	1	rs10212914	ENSG00000221413.1	AC023593.1	-5.84	9.48e-09	0.0154	-0.41	-0.26	Heart rate;	chr4:146577933	chr3:127664704~127664810:+
LUAD	trans	rs10213084	1	rs10212917	ENSG00000221413.1	AC023593.1	-5.84	9.48e-09	0.0154	-0.41	-0.26	Heart rate;	chr4:146578163	chr3:127664704~127664810:+
LUAD	trans	rs10213084	1	rs10213084	ENSG00000221413.1	AC023593.1	-5.84	9.48e-09	0.0154	-0.41	-0.26	Heart rate;	chr4:146578186	chr3:127664704~127664810:+
LUAD	trans	rs10213084	1	rs10213649	ENSG00000221413.1	AC023593.1	-5.84	9.48e-09	0.0154	-0.41	-0.26	Heart rate;	chr4:146578402	chr3:127664704~127664810:+
LUAD	trans	rs616147	0.548	rs2370965	ENSG00000188856.6	RPSAP47	-5.84	9.5e-09	0.0154	-0.28	-0.26	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39448996	chr8:80558870~80559757:+
LUAD	trans	rs73108077	0.704	rs73119542	ENSG00000279352.1	RP11-411B10.7	5.84	9.66e-09	0.0156	0.51	0.26	Red blood cell density in sickle cell anemia;	chr20:31268950	chr18:14010054~14010917:+
LUAD	trans	rs73108077	0.79	rs73102048	ENSG00000279352.1	RP11-411B10.7	5.84	9.66e-09	0.0156	0.51	0.26	Red blood cell density in sickle cell anemia;	chr20:31277508	chr18:14010054~14010917:+
LUAD	trans	rs73108077	0.704	rs7273922	ENSG00000279352.1	RP11-411B10.7	5.84	9.66e-09	0.0156	0.51	0.26	Red blood cell density in sickle cell anemia;	chr20:31282601	chr18:14010054~14010917:+
LUAD	trans	rs4818225	0.895	rs2183588	ENSG00000249840.2	GAPDHP76	5.84	9.66e-09	0.0156	0.33	0.26	Educational attainment;	chr21:41254955	chr19:11585246~11587135:+
LUAD	trans	rs7647973	0.769	rs7434187	ENSG00000197582.5	GPX1P1	5.84	9.7e-09	0.0157	0.39	0.26	Menarche (age at onset);	chr3:48995534	chrX:13378735~13379340:-
LUAD	trans	rs76228276	0.737	rs1979115	ENSG00000260318.1	COX6CP1	-5.84	9.74e-09	0.0158	-0.71	-0.26	Childhood ear infection;	chr8:99807548	chr16:11903923~11904137:-
LUAD	trans	rs12439619	0.846	rs62010071	ENSG00000259295.5	CSPG4P12	-5.84	9.75e-09	0.0158	-0.36	-0.26	Intelligence (multi-trait analysis);	chr15:82289442	chr15:85191438~85213905:+
LUAD	trans	rs7833986	0.501	rs2719226	ENSG00000244245.1	RP11-120B7.1	5.84	9.76e-09	0.0158	0.3	0.26	Height;	chr8:56131507	chr5:108593609~108593967:+
LUAD	trans	rs5758511	0.573	rs2267438	ENSG00000268568.1	AC007228.9	-5.84	9.78e-09	0.0158	-0.35	-0.26	Birth weight;	chr22:41841561	chr19:56672574~56673901:-
LUAD	trans	rs5758511	0.573	rs2267439	ENSG00000268568.1	AC007228.9	-5.84	9.78e-09	0.0158	-0.35	-0.26	Birth weight;	chr22:41841765	chr19:56672574~56673901:-
LUAD	trans	rs3812762	0.879	rs4929910	ENSG00000266891.1	RP11-692N5.2	-5.84	9.79e-09	0.0158	-0.33	-0.26	Hypospadias;	chr11:8763322	chr18:9734882~9735602:-
LUAD	trans	rs8077577	0.689	rs16961114	ENSG00000188933.13	USP32P1	5.84	9.81e-09	0.0159	0.36	0.26	Obesity-related traits;	chr17:18312025	chr17:16786489~16804455:+
LUAD	trans	rs80256351	0.52	rs13032851	ENSG00000279469.1	RP11-215P8.2	-5.84	9.82e-09	0.0159	-0.51	-0.26	Schizophrenia;	chr2:58168535	chr5:134394360~134395008:-
LUAD	trans	rs9425766	0.679	rs7533430	ENSG00000213331.4	RP11-713C19.2	5.84	9.83e-09	0.0159	0.3	0.26	Life satisfaction;	chr1:174109279	chr4:187970273~187971284:+
LUAD	trans	rs6940638	0.688	rs2022272	ENSG00000204709.4	LINC01556	5.84	9.84e-09	0.0159	0.32	0.26	Intelligence (multi-trait analysis);	chr6:27135801	chr6:28943877~28944537:+
LUAD	trans	rs11220082	0.666	rs12789687	ENSG00000236257.1	EI24P2	-5.84	9.85e-09	0.0159	-0.28	-0.26	Schizophrenia;	chr11:125461254	chr1:158454198~158455273:+
LUAD	trans	rs12439619	0.846	rs28697264	ENSG00000259295.5	CSPG4P12	-5.84	9.87e-09	0.016	-0.35	-0.26	Intelligence (multi-trait analysis);	chr15:82265559	chr15:85191438~85213905:+
LUAD	trans	rs853679	0.556	rs13197633	ENSG00000281831.1	HCP5B	5.83	9.97e-09	0.0161	0.58	0.26	Depression;	chr6:28206979	chr6:29871895~29873783:-
LUAD	trans	rs4713118	0.868	rs10484401	ENSG00000204709.4	LINC01556	-5.83	1e-08	0.0162	-0.35	-0.26	Parkinson's disease;	chr6:27778811	chr6:28943877~28944537:+
LUAD	trans	rs8077577	0.747	rs12449313	ENSG00000188933.13	USP32P1	5.83	1e-08	0.0162	0.36	0.26	Obesity-related traits;	chr17:18317696	chr17:16786489~16804455:+
LUAD	trans	rs17507216	1	rs17158413	ENSG00000235370.6	DNM1P51	-5.83	1e-08	0.0162	-0.34	-0.26	Excessive daytime sleepiness;	chr15:82566658	chr15:84398316~84411701:-
LUAD	trans	rs9467711	0.72	rs3857546	ENSG00000204709.4	LINC01556	5.83	1.01e-08	0.0163	0.48	0.26	Autism spectrum disorder or schizophrenia;	chr6:26157534	chr6:28943877~28944537:+
LUAD	trans	rs864643	0.678	rs7631217	ENSG00000183298.5	RP11-556K13.1	-5.83	1.02e-08	0.0164	-0.37	-0.26	Attention deficit hyperactivity disorder;	chr3:39478568	chr1:101786340~101787219:-
LUAD	trans	rs9393777	0.668	rs16897515	ENSG00000204709.4	LINC01556	-5.83	1.03e-08	0.0166	-0.39	-0.26	Intelligence (multi-trait analysis);	chr6:27310241	chr6:28943877~28944537:+
LUAD	trans	rs4879656	0.564	rs4879657	ENSG00000215007.3	DNAJA1P3	5.83	1.03e-08	0.0166	0.29	0.26	Menopause (age at onset);	chr9:33012467	chrX:107351650~107352843:-
LUAD	trans	rs10117734	0.632	rs10974525	ENSG00000279786.1	CTD-2014D20.1	5.83	1.03e-08	0.0166	0.28	0.26	Parental extreme longevity (95 years and older);	chr9:4417406	chr8:140820599~140822414:-
LUAD	trans	rs6499255	0.951	rs10163235	ENSG00000257513.6	NPIPB1P	5.83	1.03e-08	0.0166	0.31	0.26	IgE levels;	chr16:69705964	chr18:11619509~11639699:-
LUAD	trans	rs853679	0.882	rs4713140	ENSG00000281831.1	HCP5B	5.83	1.04e-08	0.0168	0.43	0.26	Depression;	chr6:28129415	chr6:29871895~29873783:-
LUAD	trans	rs73108077	0.736	rs73119535	ENSG00000279352.1	RP11-411B10.7	5.82	1.05e-08	0.0169	0.51	0.26	Red blood cell density in sickle cell anemia;	chr20:31260483	chr18:14010054~14010917:+
LUAD	trans	rs3743102	0.591	rs17841171	ENSG00000235370.6	DNM1P51	-5.82	1.06e-08	0.017	-0.46	-0.26	Colorectal adenoma (advanced);	chr15:82689636	chr15:84398316~84411701:-
LUAD	trans	rs77688320	1	rs78053840	ENSG00000235105.1	RP11-329A14.1	-5.82	1.06e-08	0.017	-0.41	-0.26	Breast cancer;	chr2:201502845	chr1:48435967~48437223:+
LUAD	trans	rs77688320	1	rs77688320	ENSG00000235105.1	RP11-329A14.1	-5.82	1.06e-08	0.017	-0.41	-0.26	Breast cancer;	chr2:201502866	chr1:48435967~48437223:+
LUAD	trans	rs13416322	0.891	rs10164820	ENSG00000214286.2	PDCL3P3	5.82	1.06e-08	0.017	0.37	0.26	Intelligence (multi-trait analysis);	chr2:100433891	chr3:17877455~17878169:-
LUAD	trans	rs2243480	0.666	rs1880311	ENSG00000230295.1	RP11-458F8.2	5.82	1.06e-08	0.0171	0.33	0.26	Diabetic kidney disease;	chr7:65811765	chr7:66880708~66882981:+
LUAD	trans	rs3812762	0.833	rs35670750	ENSG00000266891.1	RP11-692N5.2	5.82	1.07e-08	0.0172	0.34	0.26	Hypospadias;	chr11:8760897	chr18:9734882~9735602:-
LUAD	trans	rs7647973	0.769	rs4974081	ENSG00000197582.5	GPX1P1	-5.82	1.07e-08	0.0172	-0.37	-0.26	Menarche (age at onset);	chr3:49033066	chrX:13378735~13379340:-
LUAD	trans	rs864643	1	rs816492	ENSG00000183298.5	RP11-556K13.1	5.82	1.08e-08	0.0173	0.36	0.26	Attention deficit hyperactivity disorder;	chr3:39514664	chr1:101786340~101787219:-
LUAD	trans	rs17507216	0.671	rs4779035	ENSG00000235370.6	DNM1P51	-5.82	1.08e-08	0.0174	-0.37	-0.26	Excessive daytime sleepiness;	chr15:82591686	chr15:84398316~84411701:-
LUAD	trans	rs2243480	0.666	rs1880311	ENSG00000232546.1	RP11-458F8.1	5.82	1.09e-08	0.0174	0.35	0.26	Diabetic kidney disease;	chr7:65811765	chr7:66848496~66858136:+
LUAD	trans	rs9329221	0.527	rs10903328	ENSG00000253981.4	ALG1L13P	5.82	1.09e-08	0.0174	0.29	0.26	Neuroticism;	chr8:10474657	chr8:8236003~8244667:-
LUAD	trans	rs9876781	1	rs7651407	ENSG00000225528.1	RP3-370M22.8	-5.82	1.09e-08	0.0175	-0.26	-0.26	Longevity;	chr3:48402409	chr22:39960397~39964683:+
LUAD	trans	rs3749237	1	rs2291542	ENSG00000271314.1	RP11-435O5.6	5.82	1.09e-08	0.0175	0.3	0.26	Resting heart rate;	chr3:49714152	chr9:95494924~95495379:+
LUAD	trans	rs9393777	0.92	rs34150729	ENSG00000281831.1	HCP5B	5.82	1.1e-08	0.0177	0.54	0.26	Intelligence (multi-trait analysis);	chr6:27420975	chr6:29871895~29873783:-
LUAD	trans	rs9393777	0.92	rs13191227	ENSG00000281831.1	HCP5B	5.82	1.1e-08	0.0177	0.54	0.26	Intelligence (multi-trait analysis);	chr6:27422336	chr6:29871895~29873783:-
LUAD	trans	rs6915893	0.967	rs12199316	ENSG00000267156.1	TPMTP1	5.82	1.1e-08	0.0177	0.3	0.26	Intrinsic epigenetic age acceleration;	chr6:18123271	chr18:47630112~47630848:+
LUAD	trans	rs9329221	0.521	rs17693945	ENSG00000253981.4	ALG1L13P	-5.82	1.1e-08	0.0177	-0.29	-0.26	Neuroticism;	chr8:10248500	chr8:8236003~8244667:-
LUAD	trans	rs950394	1	rs62152281	ENSG00000231682.1	AC097713.4	-5.82	1.11e-08	0.0178	-0.32	-0.26	Schizophrenia;	chr2:104364220	chr2:234444590~234454595:-
LUAD	trans	rs9575182	0.962	rs9565815	ENSG00000228763.1	AC010095.5	5.81	1.11e-08	0.0178	0.3	0.26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr13:82823401	chr2:108676795~108678601:-
LUAD	trans	rs7937890	0.559	rs6486193	ENSG00000236360.2	RP11-334A14.2	5.81	1.11e-08	0.0178	0.32	0.26	Mitochondrial DNA levels;	chr11:14416061	chr1:52993201~52993702:-
LUAD	trans	rs7554511	0.8	rs296547	ENSG00000244144.1	RP11-757F18.3	5.81	1.11e-08	0.0179	0.31	0.26	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200923009	chr3:112185480~112185998:-
LUAD	trans	rs7554511	0.8	rs370411	ENSG00000244144.1	RP11-757F18.3	5.81	1.11e-08	0.0179	0.31	0.26	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200923135	chr3:112185480~112185998:-
LUAD	trans	rs7212590	0.655	rs8067568	ENSG00000187870.7	RNFT1P3	5.81	1.11e-08	0.0179	0.51	0.26	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59921854	chr17:20743333~20754501:-
LUAD	trans	rs10736455	1	rs11213779	ENSG00000268027.4	AC006129.2	5.81	1.12e-08	0.0179	0.34	0.26	Major depressive disorder;	chr11:111206990	chr19:41545192~41555462:+
LUAD	trans	rs34375054	0.573	rs12811438	ENSG00000256340.7	ABCC6P1	5.81	1.12e-08	0.0179	0.36	0.26	Post bronchodilator FEV1/FVC ratio;	chr12:125168944	chr16:18571162~18598328:+
LUAD	trans	rs2243480	1	rs3885839	ENSG00000230295.1	RP11-458F8.2	-5.81	1.12e-08	0.0179	-0.32	-0.26	Diabetic kidney disease;	chr7:65825416	chr7:66880708~66882981:+
LUAD	trans	rs2243480	0.901	rs3813708	ENSG00000230295.1	RP11-458F8.2	-5.81	1.12e-08	0.0179	-0.32	-0.26	Diabetic kidney disease;	chr7:65840645	chr7:66880708~66882981:+
LUAD	trans	rs2243480	1	rs73142122	ENSG00000230295.1	RP11-458F8.2	-5.81	1.12e-08	0.0179	-0.32	-0.26	Diabetic kidney disease;	chr7:65846311	chr7:66880708~66882981:+
LUAD	trans	rs2243480	0.901	rs73142137	ENSG00000230295.1	RP11-458F8.2	-5.81	1.12e-08	0.0179	-0.32	-0.26	Diabetic kidney disease;	chr7:65878455	chr7:66880708~66882981:+
LUAD	trans	rs4879656	0.564	rs2183870	ENSG00000215007.3	DNAJA1P3	-5.81	1.12e-08	0.018	-0.29	-0.26	Menopause (age at onset);	chr9:32994502	chrX:107351650~107352843:-
LUAD	trans	rs6732160	0.564	rs1430346	ENSG00000236165.1	PRADC1P1	5.81	1.12e-08	0.018	0.37	0.26	Intelligence (multi-trait analysis);	chr2:73140117	chr3:36976316~36976840:+
LUAD	trans	rs3812762	0.917	rs11042066	ENSG00000266891.1	RP11-692N5.2	-5.81	1.12e-08	0.018	-0.33	-0.26	Hypospadias;	chr11:8788013	chr18:9734882~9735602:-
LUAD	trans	rs10213084	1	rs10002085	ENSG00000221413.1	AC023593.1	-5.81	1.13e-08	0.018	-0.41	-0.26	Heart rate;	chr4:146570008	chr3:127664704~127664810:+
LUAD	trans	rs616147	0.671	rs675595	ENSG00000188856.6	RPSAP47	-5.81	1.13e-08	0.0181	-0.28	-0.26	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39458987	chr8:80558870~80559757:+
LUAD	trans	rs2243480	0.908	rs4718273	ENSG00000230295.1	RP11-458F8.2	5.81	1.13e-08	0.0182	0.32	0.26	Diabetic kidney disease;	chr7:65751112	chr7:66880708~66882981:+
LUAD	trans	rs3812762	0.868	rs7952335	ENSG00000266891.1	RP11-692N5.2	-5.81	1.14e-08	0.0182	-0.33	-0.26	Hypospadias;	chr11:8732484	chr18:9734882~9735602:-
LUAD	trans	rs9393777	1	rs9393777	ENSG00000204709.4	LINC01556	5.81	1.14e-08	0.0182	0.47	0.26	Intelligence (multi-trait analysis);	chr6:26974248	chr6:28943877~28944537:+
LUAD	trans	rs4713118	0.824	rs9366702	ENSG00000204709.4	LINC01556	5.81	1.14e-08	0.0183	0.34	0.26	Parkinson's disease;	chr6:27766691	chr6:28943877~28944537:+
LUAD	trans	rs7121616	0.563	rs4936770	ENSG00000256356.1	HSPA8P5	5.81	1.16e-08	0.0185	0.28	0.26	Breast cancer;	chr11:123058167	chr12:4097451~4099519:+
LUAD	trans	rs2602836	0.83	rs2602874	ENSG00000233859.2	ADH5P4	-5.81	1.16e-08	0.0185	-0.26	-0.26	HDL cholesterol;HDL cholesterol levels;	chr4:99118245	chr6:65836930~65838039:-
LUAD	trans	rs380904	0.552	rs10099003	ENSG00000213130.3	EEF1DP5	-5.81	1.16e-08	0.0186	-0.35	-0.26	Venous thromboembolism (SNP x SNP interaction);	chr8:143563290	chr6:128580113~128580884:-
LUAD	trans	rs9393777	0.92	rs13212562	ENSG00000204709.4	LINC01556	5.81	1.17e-08	0.0187	0.46	0.26	Intelligence (multi-trait analysis);	chr6:27332531	chr6:28943877~28944537:+
LUAD	trans	rs616147	0.627	rs9871799	ENSG00000188856.6	RPSAP47	5.8	1.17e-08	0.0187	0.26	0.26	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39442829	chr8:80558870~80559757:+
LUAD	trans	rs616147	0.671	rs674192	ENSG00000188856.6	RPSAP47	-5.8	1.17e-08	0.0188	-0.27	-0.26	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39458653	chr8:80558870~80559757:+
LUAD	trans	rs17507216	1	rs3850610	ENSG00000235370.6	DNM1P51	5.8	1.18e-08	0.0188	0.33	0.26	Excessive daytime sleepiness;	chr15:82552642	chr15:84398316~84411701:-
LUAD	trans	rs7325116	0.519	rs7982480	ENSG00000241244.1	IGKV1D-16	5.8	1.18e-08	0.0189	0.2	0.26	Blood protein levels;	chr13:91988115	chr2:90100236~90100738:+
LUAD	trans	rs853679	0.607	rs67662114	ENSG00000253570.1	RNF5P1	5.8	1.19e-08	0.0189	0.58	0.26	Depression;	chr6:27964523	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.607	rs13216117	ENSG00000253570.1	RNF5P1	5.8	1.19e-08	0.0189	0.58	0.26	Depression;	chr6:27970706	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.607	rs36101351	ENSG00000253570.1	RNF5P1	5.8	1.19e-08	0.0189	0.58	0.26	Depression;	chr6:27975591	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.607	rs28360499	ENSG00000253570.1	RNF5P1	5.8	1.19e-08	0.0189	0.58	0.26	Depression;	chr6:27977618	chr8:38600661~38601200:-
LUAD	trans	rs3096299	0.658	rs4291902	ENSG00000215030.5	RPL13P12	-5.8	1.19e-08	0.019	-0.28	-0.26	Multiple myeloma (IgH translocation);	chr16:89493907	chr17:17383377~17384012:-
LUAD	trans	rs864643	0.524	rs11715885	ENSG00000214263.2	RPSAP53	-5.8	1.2e-08	0.0191	-0.45	-0.26	Attention deficit hyperactivity disorder;	chr3:39475107	chr13:67266845~67267706:-
LUAD	trans	rs73108077	0.736	rs73119530	ENSG00000279352.1	RP11-411B10.7	5.8	1.2e-08	0.0192	0.51	0.26	Red blood cell density in sickle cell anemia;	chr20:31258810	chr18:14010054~14010917:+
LUAD	trans	rs73108077	0.736	rs17325435	ENSG00000279352.1	RP11-411B10.7	5.8	1.2e-08	0.0192	0.51	0.26	Red blood cell density in sickle cell anemia;	chr20:31259887	chr18:14010054~14010917:+
LUAD	trans	rs853679	0.546	rs13213152	ENSG00000281831.1	HCP5B	5.8	1.2e-08	0.0192	0.58	0.26	Depression;	chr6:28381921	chr6:29871895~29873783:-
LUAD	trans	rs1933488	0.931	rs3870365	ENSG00000278974.1	RP11-756P10.6	-5.8	1.2e-08	0.0192	-0.32	-0.26	Prostate cancer;	chr6:153105797	chr4:188740507~188741281:-
LUAD	trans	rs864643	0.947	rs1708053	ENSG00000183298.5	RP11-556K13.1	5.8	1.21e-08	0.0192	0.37	0.26	Attention deficit hyperactivity disorder;	chr3:39499706	chr1:101786340~101787219:-
LUAD	trans	rs7819412	0.502	rs4840548	ENSG00000253893.2	FAM85B	5.8	1.21e-08	0.0193	0.33	0.26	Triglycerides;	chr8:11135373	chr8:8167819~8226614:-
LUAD	trans	rs9581094	1	rs73154395	ENSG00000237917.1	PARP4P1	-5.8	1.21e-08	0.0193	-0.45	-0.26	Sudden cardiac arrest;	chr13:24507665	chrY:26594851~26634652:-
LUAD	trans	rs7578180	1	rs7578180	ENSG00000239830.1	RPS4XP22	5.8	1.22e-08	0.0194	0.29	0.26	Severe gingival inflammation;	chr2:157915546	chr19:9683294~9684073:-
LUAD	trans	rs11638815	0.668	rs11635460	ENSG00000235370.6	DNM1P51	-5.8	1.22e-08	0.0194	-0.31	-0.26	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;	chr15:82725801	chr15:84398316~84411701:-
LUAD	trans	rs6030712	0.744	rs1744762	ENSG00000211897.6	IGHG3	-5.8	1.22e-08	0.0194	-0.24	-0.26	Height;	chr20:37093456	chr14:105769102~106038345:-
LUAD	trans	rs9581094	1	rs73154401	ENSG00000237917.1	PARP4P1	-5.8	1.22e-08	0.0194	-0.46	-0.26	Sudden cardiac arrest;	chr13:24511529	chrY:26594851~26634652:-
LUAD	trans	rs17507216	0.718	rs4779033	ENSG00000235370.6	DNM1P51	5.8	1.22e-08	0.0195	0.36	0.26	Excessive daytime sleepiness;	chr15:82576634	chr15:84398316~84411701:-
LUAD	trans	rs6915893	1	rs4074444	ENSG00000267156.1	TPMTP1	5.8	1.23e-08	0.0195	0.31	0.26	Intrinsic epigenetic age acceleration;	chr6:18106258	chr18:47630112~47630848:+
LUAD	trans	rs7647973	0.566	rs57630346	ENSG00000197582.5	GPX1P1	5.8	1.23e-08	0.0196	0.37	0.26	Menarche (age at onset);	chr3:49048782	chrX:13378735~13379340:-
LUAD	trans	rs8077577	0.689	rs16961133	ENSG00000188933.13	USP32P1	5.8	1.23e-08	0.0196	0.36	0.26	Obesity-related traits;	chr17:18320234	chr17:16786489~16804455:+
LUAD	trans	rs8077577	0.747	rs57697650	ENSG00000188933.13	USP32P1	5.8	1.23e-08	0.0196	0.36	0.26	Obesity-related traits;	chr17:18321381	chr17:16786489~16804455:+
LUAD	trans	rs2069408	1	rs2069408	ENSG00000235459.5	RPS26P31	-5.79	1.24e-08	0.0198	-0.3	-0.26	Asthma;	chr12:55970537	chr7:122681315~122681662:+
LUAD	trans	rs3096299	0.685	rs4329923	ENSG00000215030.5	RPL13P12	-5.79	1.24e-08	0.0198	-0.29	-0.26	Multiple myeloma (IgH translocation);	chr16:89493770	chr17:17383377~17384012:-
LUAD	trans	rs2395128	0.748	rs10824255	ENSG00000233590.1	RP11-153K11.3	-5.79	1.25e-08	0.0198	-0.5	-0.26	Ulcerative colitis;Inflammatory bowel disease;	chr10:74980983	chr10:68233251~68242379:-
LUAD	trans	rs6915893	1	rs12189658	ENSG00000267156.1	TPMTP1	5.79	1.25e-08	0.0198	0.3	0.26	Intrinsic epigenetic age acceleration;	chr6:18103106	chr18:47630112~47630848:+
LUAD	trans	rs1933488	1	rs6901126	ENSG00000278974.1	RP11-756P10.6	5.79	1.26e-08	0.02	0.31	0.26	Prostate cancer;	chr6:153118927	chr4:188740507~188741281:-
LUAD	trans	rs8077577	0.747	rs62072540	ENSG00000188933.13	USP32P1	5.79	1.27e-08	0.0201	0.36	0.26	Obesity-related traits;	chr17:18321914	chr17:16786489~16804455:+
LUAD	trans	rs8077577	0.747	rs62072511	ENSG00000188933.13	USP32P1	5.79	1.27e-08	0.0201	0.36	0.26	Obesity-related traits;	chr17:18289843	chr17:16786489~16804455:+
LUAD	trans	rs11220082	0.666	rs12223186	ENSG00000236257.1	EI24P2	-5.79	1.27e-08	0.0201	-0.27	-0.26	Schizophrenia;	chr11:125461743	chr1:158454198~158455273:+
LUAD	trans	rs950394	1	rs12465971	ENSG00000231682.1	AC097713.4	-5.79	1.27e-08	0.0201	-0.34	-0.26	Schizophrenia;	chr2:104373921	chr2:234444590~234454595:-
LUAD	trans	rs853679	0.607	rs35030260	ENSG00000281831.1	HCP5B	5.79	1.27e-08	0.0201	0.57	0.26	Depression;	chr6:28337731	chr6:29871895~29873783:-
LUAD	trans	rs853679	0.607	rs13217619	ENSG00000281831.1	HCP5B	5.79	1.27e-08	0.0201	0.57	0.26	Depression;	chr6:28338894	chr6:29871895~29873783:-
LUAD	trans	rs12439619	0.846	rs28470877	ENSG00000259295.5	CSPG4P12	-5.79	1.27e-08	0.0202	-0.35	-0.26	Intelligence (multi-trait analysis);	chr15:82245797	chr15:85191438~85213905:+
LUAD	trans	rs3812762	0.879	rs10769959	ENSG00000266891.1	RP11-692N5.2	-5.79	1.28e-08	0.0203	-0.33	-0.26	Hypospadias;	chr11:8797286	chr18:9734882~9735602:-
LUAD	trans	rs66887589	0.967	rs1155577	ENSG00000275858.1	RP11-291L22.8	-5.79	1.29e-08	0.0204	-0.27	-0.26	Diastolic blood pressure;	chr4:119528655	chr10:38450738~38451069:-
LUAD	trans	rs673078	0.66	rs7136216	ENSG00000273372.1	RP11-479O17.10	-5.79	1.29e-08	0.0205	-0.28	-0.26	Glucose homeostasis traits;	chr12:118170475	chr10:79968213~79973213:+
LUAD	trans	rs853679	0.607	rs56075693	ENSG00000281831.1	HCP5B	5.79	1.29e-08	0.0205	0.57	0.26	Depression;	chr6:28322551	chr6:29871895~29873783:-
LUAD	trans	rs853679	0.607	rs34218844	ENSG00000281831.1	HCP5B	5.79	1.29e-08	0.0205	0.57	0.26	Depression;	chr6:28322870	chr6:29871895~29873783:-
LUAD	trans	rs853679	0.607	rs56189111	ENSG00000281831.1	HCP5B	5.79	1.3e-08	0.0206	0.57	0.26	Depression;	chr6:28304196	chr6:29871895~29873783:-
LUAD	trans	rs853679	0.607	rs35072899	ENSG00000281831.1	HCP5B	5.79	1.3e-08	0.0206	0.57	0.26	Depression;	chr6:28313764	chr6:29871895~29873783:-
LUAD	trans	rs7554511	0.5	rs296548	ENSG00000244144.1	RP11-757F18.3	5.79	1.3e-08	0.0206	0.31	0.26	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200923715	chr3:112185480~112185998:-
LUAD	trans	rs714543	1	rs1990053	ENSG00000226038.5	PPIAP21	-5.79	1.3e-08	0.0206	-0.29	-0.26	Plateletcrit;	chr7:44886297	chr20:43230760~43231260:+
LUAD	trans	rs714543	0.935	rs2331174	ENSG00000226038.5	PPIAP21	-5.79	1.3e-08	0.0206	-0.29	-0.26	Plateletcrit;	chr7:44887228	chr20:43230760~43231260:+
LUAD	trans	rs6030712	0.894	rs6124521	ENSG00000211897.6	IGHG3	5.79	1.3e-08	0.0206	0.24	0.26	Height;	chr20:36996187	chr14:105769102~106038345:-
LUAD	trans	rs10404486	1	rs10404486	ENSG00000230613.1	HM13-AS1	5.79	1.3e-08	0.0206	0.38	0.26	Phospholipid levels (plasma);	chr19:52780882	chr20:31567707~31573263:-
LUAD	trans	rs8177253	0.665	rs9869257	ENSG00000256243.2	RPL7AP3	5.79	1.3e-08	0.0206	0.29	0.26	Iron status biomarkers;	chr3:133732568	chr14:35235180~35235651:-
LUAD	trans	rs8177253	0.665	rs9831392	ENSG00000256243.2	RPL7AP3	5.79	1.3e-08	0.0206	0.29	0.26	Iron status biomarkers;	chr3:133732629	chr14:35235180~35235651:-
LUAD	trans	rs8177253	0.665	rs9869535	ENSG00000256243.2	RPL7AP3	5.79	1.3e-08	0.0206	0.29	0.26	Iron status biomarkers;	chr3:133732737	chr14:35235180~35235651:-
LUAD	trans	rs4948102	0.642	rs4948104	ENSG00000186940.6	CHCHD2P9	-5.79	1.3e-08	0.0207	-0.31	-0.26	Plasma homocysteine levels (post-methionine load test);	chr7:56074826	chr9:79391304~79391759:+
LUAD	trans	rs847577	0.677	rs4729403	ENSG00000225169.1	BRI3P1	-5.79	1.31e-08	0.0207	-0.31	-0.26	Breast cancer;	chr7:98078529	chr1:100213293~100213670:+
LUAD	trans	rs2524005	1	rs2524005	ENSG00000253570.1	RNF5P1	5.78	1.31e-08	0.0208	0.36	0.26	Bipolar disorder and schizophrenia;	chr6:29931900	chr8:38600661~38601200:-
LUAD	trans	rs9393777	0.92	rs72839445	ENSG00000253570.1	RNF5P1	5.78	1.32e-08	0.0209	0.55	0.25	Intelligence (multi-trait analysis);	chr6:27281907	chr8:38600661~38601200:-
LUAD	trans	rs4948102	0.597	rs12669623	ENSG00000186940.6	CHCHD2P9	-5.78	1.32e-08	0.0209	-0.31	-0.25	Plasma homocysteine levels (post-methionine load test);	chr7:56071486	chr9:79391304~79391759:+
LUAD	trans	rs8177253	0.665	rs12493887	ENSG00000256243.2	RPL7AP3	5.78	1.32e-08	0.0209	0.29	0.25	Iron status biomarkers;	chr3:133721893	chr14:35235180~35235651:-
LUAD	trans	rs9584850	0.794	rs17470961	ENSG00000230079.1	STK24P1	5.78	1.32e-08	0.0209	0.3	0.25	Neuroticism;	chr13:98483060	chrX:136295690~136300298:-
LUAD	trans	rs2911280	0.764	rs76006132	ENSG00000231483.1	RP11-336A10.5	-5.78	1.32e-08	0.021	-0.66	-0.25	Dehydroepiandrosterone sulphate levels;	chr16:81554966	chr10:5608475~5610793:-
LUAD	trans	rs6030712	0.894	rs6124523	ENSG00000211897.6	IGHG3	5.78	1.33e-08	0.021	0.24	0.25	Height;	chr20:36998167	chr14:105769102~106038345:-
LUAD	trans	rs282544	1	rs55932149	ENSG00000231752.4	EMBP1	-5.78	1.33e-08	0.021	-0.36	-0.25	Myopia (pathological);	chr5:50687303	chr1:121519112~121571892:+
LUAD	trans	rs877636	0.702	rs773110	ENSG00000243538.1	CTB-55B8.1	5.78	1.33e-08	0.021	0.29	0.25	Cognitive function;	chr12:55981353	chr5:16902294~16902641:-
LUAD	trans	rs877636	0.702	rs773111	ENSG00000243538.1	CTB-55B8.1	5.78	1.33e-08	0.021	0.29	0.25	Cognitive function;	chr12:55981956	chr5:16902294~16902641:-
LUAD	trans	rs877636	0.702	rs773112	ENSG00000243538.1	CTB-55B8.1	5.78	1.33e-08	0.021	0.29	0.25	Cognitive function;	chr12:55982097	chr5:16902294~16902641:-
LUAD	trans	rs255788	0.92	rs1596459	ENSG00000238005.2	RP11-443B7.1	5.78	1.33e-08	0.0211	0.41	0.25	Response to platinum-based chemotherapy (carboplatin);	chr5:120115833	chr1:234957342~234970062:-
LUAD	trans	rs9425766	0.679	rs12563301	ENSG00000213331.4	RP11-713C19.2	5.78	1.34e-08	0.0211	0.3	0.25	Life satisfaction;	chr1:174090924	chr4:187970273~187971284:+
LUAD	trans	rs2243480	1	rs4718270	ENSG00000230295.1	RP11-458F8.2	-5.78	1.34e-08	0.0212	-0.31	-0.25	Diabetic kidney disease;	chr7:65737415	chr7:66880708~66882981:+
LUAD	trans	rs2243480	0.901	rs2900904	ENSG00000230295.1	RP11-458F8.2	-5.78	1.34e-08	0.0212	-0.31	-0.25	Diabetic kidney disease;	chr7:65739282	chr7:66880708~66882981:+
LUAD	trans	rs66887589	0.967	rs6844263	ENSG00000275858.1	RP11-291L22.8	5.78	1.35e-08	0.0213	0.27	0.25	Diastolic blood pressure;	chr4:119512652	chr10:38450738~38451069:-
LUAD	trans	rs9393777	0.92	rs13196692	ENSG00000281831.1	HCP5B	5.78	1.35e-08	0.0213	0.53	0.25	Intelligence (multi-trait analysis);	chr6:27411340	chr6:29871895~29873783:-
LUAD	trans	rs13177918	0.677	rs3857421	ENSG00000226396.1	RP5-1056L3.3	-5.78	1.36e-08	0.0214	-0.28	-0.25	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr1:19608114~19608568:+
LUAD	trans	rs254562	0.897	rs254570	ENSG00000236439.4	RP11-175B9.3	-5.78	1.36e-08	0.0214	-0.31	-0.25	Ulcerative colitis;	chr5:135100662	chr1:202471864~202472117:-
LUAD	trans	rs9914988	0.537	rs28448745	ENSG00000225067.4	RPL23AP2	5.78	1.36e-08	0.0214	0.29	0.25	Glycated hemoglobin levels;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;	chr17:28861278	chr19:15611657~15612122:+
LUAD	trans	rs7312770	0.612	rs773114	ENSG00000212829.8	RPS26P3	5.78	1.36e-08	0.0215	0.27	0.25	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr9:9090898~9091245:+
LUAD	trans	rs7412746	0.658	rs6669855	ENSG00000180764.13	PIPSL	-5.78	1.36e-08	0.0215	-0.3	-0.25	Melanoma;	chr1:150888753	chr10:93958191~93961540:-
LUAD	trans	rs12505188	0.963	rs6839480	ENSG00000263470.1	RP11-160O5.1	-5.78	1.36e-08	0.0215	-0.27	-0.25	Red cell distribution width;	chr4:152761745	chr17:65100812~65111058:+
LUAD	trans	rs616147	0.85	rs631312	ENSG00000188856.6	RPSAP47	-5.78	1.37e-08	0.0217	-0.29	-0.25	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39467477	chr8:80558870~80559757:+
LUAD	trans	rs1383484	0.575	rs986118	ENSG00000278603.1	RP13-608F4.5	5.78	1.37e-08	0.0217	0.32	0.25	Height;	chr15:83946437	chr15:82472203~82472426:+
LUAD	trans	rs80264589	1	rs80264589	ENSG00000204709.4	LINC01556	5.78	1.38e-08	0.0218	0.55	0.25	Intelligence (multi-trait analysis);Lung cancer;	chr6:26959823	chr6:28943877~28944537:+
LUAD	trans	rs11172055	0.807	rs7314567	ENSG00000121089.4	NACA3P	5.77	1.39e-08	0.0219	0.3	0.25	Migraine;	chr12:56864231	chr4:164943290~164943937:+
LUAD	trans	rs9379945	1	rs9379945	ENSG00000204709.4	LINC01556	5.77	1.39e-08	0.0219	0.47	0.25	Intelligence (multi-trait analysis);	chr6:26940052	chr6:28943877~28944537:+
LUAD	trans	rs11108495	0.789	rs10745761	ENSG00000212961.4	HNRNPA1P40	-5.77	1.39e-08	0.022	-0.28	-0.25	Weight;	chr12:96417587	chr11:74354443~74355720:+
LUAD	trans	rs116002988	0.592	rs72700713	ENSG00000249592.4	RP11-440L14.1	-5.77	1.39e-08	0.022	-0.3	-0.25	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr14:98980064	chr4:762387~781849:-
LUAD	trans	rs9356009	0.892	rs9347732	ENSG00000257512.1	RP11-486A14.1	-5.77	1.4e-08	0.022	-0.5	-0.25	Lipoprotein (a) - cholesterol levels;	chr6:157886728	chr12:93314809~93315941:+
LUAD	trans	rs3812762	0.957	rs6484008	ENSG00000266891.1	RP11-692N5.2	-5.77	1.4e-08	0.0221	-0.33	-0.25	Hypospadias;	chr11:8732601	chr18:9734882~9735602:-
LUAD	trans	rs3096299	0.658	rs3934737	ENSG00000215030.5	RPL13P12	-5.77	1.41e-08	0.0221	-0.28	-0.25	Multiple myeloma (IgH translocation);	chr16:89493801	chr17:17383377~17384012:-
LUAD	trans	rs7647973	0.771	rs9865051	ENSG00000197582.5	GPX1P1	5.77	1.41e-08	0.0222	0.38	0.25	Menarche (age at onset);	chr3:49128636	chrX:13378735~13379340:-
LUAD	trans	rs2070677	0.799	rs11101854	ENSG00000250148.1	KRT8P31	-5.77	1.41e-08	0.0222	-0.4	-0.25	Gout;	chr10:133580926	chr5:60743563~60744970:-
LUAD	trans	rs864643	0.947	rs1417147	ENSG00000183298.5	RP11-556K13.1	5.77	1.42e-08	0.0224	0.35	0.25	Attention deficit hyperactivity disorder;	chr3:39499236	chr1:101786340~101787219:-
LUAD	trans	rs3096299	0.719	rs2965945	ENSG00000215030.5	RPL13P12	-5.77	1.43e-08	0.0224	-0.28	-0.25	Multiple myeloma (IgH translocation);	chr16:89447609	chr17:17383377~17384012:-
LUAD	trans	rs962856	0.537	rs643741	ENSG00000179082.3	C9orf106	-5.77	1.43e-08	0.0225	-0.29	-0.25	Pancreatic cancer;	chr2:67449409	chr9:129321016~129324905:+
LUAD	trans	rs11512640	1	rs11220129	ENSG00000236257.1	EI24P2	5.77	1.43e-08	0.0225	0.53	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125564929	chr1:158454198~158455273:+
LUAD	trans	rs7647973	0.925	rs4955421	ENSG00000197582.5	GPX1P1	5.77	1.43e-08	0.0225	0.35	0.25	Menarche (age at onset);	chr3:49181455	chrX:13378735~13379340:-
LUAD	trans	rs8177253	0.634	rs6798547	ENSG00000256243.2	RPL7AP3	5.77	1.44e-08	0.0226	0.29	0.25	Iron status biomarkers;	chr3:133729655	chr14:35235180~35235651:-
LUAD	trans	rs8177253	0.665	rs7646118	ENSG00000256243.2	RPL7AP3	5.77	1.44e-08	0.0226	0.29	0.25	Iron status biomarkers;	chr3:133731195	chr14:35235180~35235651:-
LUAD	trans	rs853679	0.607	rs34788973	ENSG00000281831.1	HCP5B	5.77	1.44e-08	0.0227	0.57	0.25	Depression;	chr6:27911422	chr6:29871895~29873783:-
LUAD	trans	rs853679	0.607	rs61742093	ENSG00000281831.1	HCP5B	5.77	1.44e-08	0.0227	0.57	0.25	Depression;	chr6:27912204	chr6:29871895~29873783:-
LUAD	trans	rs7412746	0.658	rs11204750	ENSG00000180764.13	PIPSL	-5.77	1.44e-08	0.0227	-0.29	-0.25	Melanoma;	chr1:150967268	chr10:93958191~93961540:-
LUAD	trans	rs7412746	0.658	rs6656535	ENSG00000180764.13	PIPSL	-5.77	1.44e-08	0.0227	-0.29	-0.25	Melanoma;	chr1:150967881	chr10:93958191~93961540:-
LUAD	trans	rs7594192	0.744	rs4356658	ENSG00000225972.1	MTND1P23	-5.77	1.45e-08	0.0227	-0.31	-0.25	Educational attainment;	chr2:198504680	chr1:629062~629433:+
LUAD	trans	rs9348739	1	rs9348739	ENSG00000204709.4	LINC01556	5.77	1.45e-08	0.0228	0.47	0.25	Autism spectrum disorder or schizophrenia;	chr6:26955320	chr6:28943877~28944537:+
LUAD	trans	rs853679	0.607	rs67662114	ENSG00000281831.1	HCP5B	5.77	1.45e-08	0.0228	0.57	0.25	Depression;	chr6:27964523	chr6:29871895~29873783:-
LUAD	trans	rs853679	0.607	rs13216117	ENSG00000281831.1	HCP5B	5.77	1.45e-08	0.0228	0.57	0.25	Depression;	chr6:27970706	chr6:29871895~29873783:-
LUAD	trans	rs853679	0.607	rs36101351	ENSG00000281831.1	HCP5B	5.77	1.45e-08	0.0228	0.57	0.25	Depression;	chr6:27975591	chr6:29871895~29873783:-
LUAD	trans	rs853679	0.607	rs28360499	ENSG00000281831.1	HCP5B	5.77	1.45e-08	0.0228	0.57	0.25	Depression;	chr6:27977618	chr6:29871895~29873783:-
LUAD	trans	rs7819412	0.765	rs7000132	ENSG00000253893.2	FAM85B	5.77	1.45e-08	0.0228	0.31	0.25	Triglycerides;	chr8:11173426	chr8:8167819~8226614:-
LUAD	trans	rs853679	0.766	rs9368561	ENSG00000281831.1	HCP5B	5.77	1.45e-08	0.0228	0.44	0.25	Depression;	chr6:28200565	chr6:29871895~29873783:-
LUAD	trans	rs282544	1	rs66912405	ENSG00000231752.4	EMBP1	-5.77	1.46e-08	0.0229	-0.36	-0.25	Myopia (pathological);	chr5:50666332	chr1:121519112~121571892:+
LUAD	trans	rs616147	1	rs616147	ENSG00000188856.6	RPSAP47	-5.77	1.46e-08	0.0229	-0.28	-0.25	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39492990	chr8:80558870~80559757:+
LUAD	trans	rs6499255	0.951	rs8045705	ENSG00000257513.6	NPIPB1P	5.76	1.46e-08	0.023	0.3	0.25	IgE levels;	chr16:69547769	chr18:11619509~11639699:-
LUAD	trans	rs7412746	0.611	rs2228099	ENSG00000180764.13	PIPSL	-5.76	1.46e-08	0.023	-0.28	-0.25	Melanoma;	chr1:150836413	chr10:93958191~93961540:-
LUAD	trans	rs7260598	0.642	rs11667315	ENSG00000261770.1	CTC-459F4.1	5.76	1.47e-08	0.023	0.39	0.25	Response to taxane treatment (placlitaxel);	chr19:23932336	chr19:27757184~27760849:-
LUAD	trans	rs9467711	0.651	rs13212534	ENSG00000253570.1	RNF5P1	5.76	1.47e-08	0.0231	0.68	0.25	Autism spectrum disorder or schizophrenia;	chr6:25982782	chr8:38600661~38601200:-
LUAD	trans	rs2070677	0.935	rs11101885	ENSG00000250148.1	KRT8P31	-5.76	1.47e-08	0.0231	-0.39	-0.25	Gout;	chr10:133603584	chr5:60743563~60744970:-
LUAD	trans	rs4920799	0.793	rs186257	ENSG00000237484.5	AP000476.1	-5.76	1.47e-08	0.0231	-0.29	-0.25	Echocardiographic traits;	chr5:85335780	chr21:24428740~24547942:+
LUAD	trans	rs4920799	0.752	rs177606	ENSG00000237484.5	AP000476.1	-5.76	1.47e-08	0.0231	-0.29	-0.25	Echocardiographic traits;	chr5:85335866	chr21:24428740~24547942:+
LUAD	trans	rs4920799	0.793	rs499154	ENSG00000237484.5	AP000476.1	-5.76	1.47e-08	0.0231	-0.29	-0.25	Echocardiographic traits;	chr5:85336112	chr21:24428740~24547942:+
LUAD	trans	rs4920799	0.793	rs305716	ENSG00000237484.5	AP000476.1	-5.76	1.47e-08	0.0231	-0.29	-0.25	Echocardiographic traits;	chr5:85336383	chr21:24428740~24547942:+
LUAD	trans	rs34546498	1	rs34546498	ENSG00000253570.1	RNF5P1	5.76	1.48e-08	0.0232	0.59	0.25	Breast cancer;	chr6:26993501	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.607	rs35001169	ENSG00000281831.1	HCP5B	5.76	1.48e-08	0.0232	0.57	0.25	Depression;	chr6:28219854	chr6:29871895~29873783:-
LUAD	trans	rs853679	0.546	rs35656932	ENSG00000281831.1	HCP5B	5.76	1.48e-08	0.0232	0.57	0.25	Depression;	chr6:28223510	chr6:29871895~29873783:-
LUAD	trans	rs853679	0.607	rs34243448	ENSG00000281831.1	HCP5B	5.76	1.48e-08	0.0232	0.57	0.25	Depression;	chr6:28225324	chr6:29871895~29873783:-
LUAD	trans	rs853679	0.607	rs13204012	ENSG00000281831.1	HCP5B	5.76	1.48e-08	0.0232	0.57	0.25	Depression;	chr6:28233753	chr6:29871895~29873783:-
LUAD	trans	rs853679	0.607	rs13205211	ENSG00000281831.1	HCP5B	5.76	1.48e-08	0.0232	0.57	0.25	Depression;	chr6:28235278	chr6:29871895~29873783:-
LUAD	trans	rs12439619	0.705	rs17354185	ENSG00000235370.6	DNM1P51	5.76	1.48e-08	0.0233	0.36	0.25	Intelligence (multi-trait analysis);	chr15:82133829	chr15:84398316~84411701:-
LUAD	trans	rs4646450	0.838	rs10229569	ENSG00000228834.1	RP11-249L21.4	5.76	1.49e-08	0.0233	0.4	0.25	Blood metabolite levels;	chr7:99586081	chr6:108907615~108907873:-
LUAD	trans	rs2899832	0.568	rs10144186	ENSG00000229083.1	PSMA6P2	5.76	1.5e-08	0.0235	0.4	0.25	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35295199	chrX:12825840~12826833:+
LUAD	trans	rs962993	0.553	rs2146602	ENSG00000237372.2	UNQ6494	-5.76	1.5e-08	0.0235	-0.26	-0.25	Self-reported allergy;	chr10:9059222	chr9:89639814~89719759:+
LUAD	trans	rs12350534	1	rs12342165	ENSG00000252200.1	snoZ6	5.76	1.5e-08	0.0235	0.54	0.25	White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy;	chr9:86947004	chr19:44725984~44726058:-
LUAD	trans	rs453301	0.682	rs2929451	ENSG00000253893.2	FAM85B	-5.76	1.5e-08	0.0236	-0.31	-0.25	Joint mobility (Beighton score);	chr8:9227785	chr8:8167819~8226614:-
LUAD	trans	rs4906172	0.773	rs4534770	ENSG00000181359.5	HSP90AA6P	-5.76	1.51e-08	0.0236	-0.29	-0.25	Menopause (age at onset);	chr14:102045820	chr4:170581470~170605450:-
LUAD	trans	rs3096299	0.563	rs4600467	ENSG00000215030.5	RPL13P12	-5.76	1.51e-08	0.0236	-0.28	-0.25	Multiple myeloma (IgH translocation);	chr16:89496108	chr17:17383377~17384012:-
LUAD	trans	rs853679	0.607	rs13199649	ENSG00000281831.1	HCP5B	5.76	1.52e-08	0.0238	0.57	0.25	Depression;	chr6:27901014	chr6:29871895~29873783:-
LUAD	trans	rs7260598	0.642	rs66750293	ENSG00000261770.1	CTC-459F4.1	5.76	1.52e-08	0.0239	0.4	0.25	Response to taxane treatment (placlitaxel);	chr19:23997819	chr19:27757184~27760849:-
LUAD	trans	rs916888	0.61	rs199454	ENSG00000204650.12	CRHR1-IT1	-5.76	1.53e-08	0.024	-0.3	-0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:45620328~45648216:+
LUAD	trans	rs2027099	0.606	rs9564321	ENSG00000237032.1	RP11-398C13.2	5.76	1.54e-08	0.0241	0.31	0.25	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr13:66545709	chr10:14723171~14724055:-
LUAD	trans	rs66887589	0.967	rs13104219	ENSG00000275858.1	RP11-291L22.8	5.76	1.54e-08	0.0241	0.27	0.25	Diastolic blood pressure;	chr4:119517019	chr10:38450738~38451069:-
LUAD	trans	rs7833986	0.501	rs2719227	ENSG00000236862.1	RPS20P24	-5.76	1.54e-08	0.0241	-0.31	-0.25	Height;	chr8:56131235	chr9:72655832~72656192:-
LUAD	trans	rs10032931	0.962	rs1385670	ENSG00000188662.6	HILS1	-5.75	1.55e-08	0.0242	-0.31	-0.25	Optic nerve measurement (cup-to-disc ratio);	chr4:95535016	chr17:50171428~50181178:-
LUAD	trans	rs916888	0.61	rs199438	ENSG00000204650.12	CRHR1-IT1	5.75	1.55e-08	0.0242	0.3	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:45620328~45648216:+
LUAD	trans	rs2898290	0.54	rs12677146	ENSG00000253893.2	FAM85B	5.75	1.55e-08	0.0243	0.32	0.25	Systolic blood pressure;	chr8:11593228	chr8:8167819~8226614:-
LUAD	trans	rs545610	0.809	rs4367923	ENSG00000261105.4	LMO7-AS1	-5.75	1.56e-08	0.0244	-0.32	-0.25	Dental caries;	chr11:30479263	chr13:75604700~75635994:-
LUAD	trans	rs916888	0.531	rs183211	ENSG00000204650.12	CRHR1-IT1	5.75	1.56e-08	0.0244	0.3	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:45620328~45648216:+
LUAD	trans	rs9393777	0.764	rs35565446	ENSG00000253570.1	RNF5P1	5.75	1.56e-08	0.0244	0.59	0.25	Intelligence (multi-trait analysis);	chr6:27177562	chr8:38600661~38601200:-
LUAD	trans	rs663970	0.573	rs1452007	ENSG00000251596.1	HADHAP1	-5.75	1.57e-08	0.0245	-0.35	-0.25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr5:21697316	chr4:165404067~165406350:-
LUAD	trans	rs7412746	0.611	rs4319334	ENSG00000180764.13	PIPSL	-5.75	1.58e-08	0.0247	-0.29	-0.25	Melanoma;	chr1:150794346	chr10:93958191~93961540:-
LUAD	trans	rs12439619	0.774	rs2867649	ENSG00000259295.5	CSPG4P12	-5.75	1.59e-08	0.0248	-0.35	-0.25	Intelligence (multi-trait analysis);	chr15:82262331	chr15:85191438~85213905:+
LUAD	trans	rs7819412	0.522	rs13276708	ENSG00000253893.2	FAM85B	5.75	1.59e-08	0.0248	0.32	0.25	Triglycerides;	chr8:11131696	chr8:8167819~8226614:-
LUAD	trans	rs7819412	0.522	rs13266785	ENSG00000253893.2	FAM85B	5.75	1.59e-08	0.0248	0.32	0.25	Triglycerides;	chr8:11132011	chr8:8167819~8226614:-
LUAD	trans	rs13416322	0.945	rs13383207	ENSG00000214286.2	PDCL3P3	5.75	1.6e-08	0.0249	0.35	0.25	Intelligence (multi-trait analysis);	chr2:100447793	chr3:17877455~17878169:-
LUAD	trans	rs7412746	0.658	rs3768015	ENSG00000180764.13	PIPSL	-5.75	1.6e-08	0.0249	-0.29	-0.25	Melanoma;	chr1:150840478	chr10:93958191~93961540:-
LUAD	trans	rs7833986	0.501	rs2719258	ENSG00000236862.1	RPS20P24	5.75	1.6e-08	0.0249	0.31	0.25	Height;	chr8:56028830	chr9:72655832~72656192:-
LUAD	trans	rs7833986	0.501	rs2719259	ENSG00000236862.1	RPS20P24	5.75	1.6e-08	0.0249	0.31	0.25	Height;	chr8:56029071	chr9:72655832~72656192:-
LUAD	trans	rs11512640	1	rs12363935	ENSG00000236257.1	EI24P2	5.75	1.6e-08	0.0249	0.53	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125558406	chr1:158454198~158455273:+
LUAD	trans	rs4906172	0.659	rs1190607	ENSG00000181359.5	HSP90AA6P	-5.75	1.6e-08	0.025	-0.29	-0.25	Menopause (age at onset);	chr14:102045260	chr4:170581470~170605450:-
LUAD	trans	rs73108077	0.736	rs2206384	ENSG00000279352.1	RP11-411B10.7	5.75	1.6e-08	0.025	0.4	0.25	Red blood cell density in sickle cell anemia;	chr20:31339363	chr18:14010054~14010917:+
LUAD	trans	rs12477438	0.539	rs12999417	ENSG00000276576.1	MRPL30P1	-5.75	1.61e-08	0.025	-0.28	-0.25	Chronic sinus infection;	chr2:99249085	chr6:57029521~57029988:+
LUAD	trans	rs5758511	0.573	rs4501042	ENSG00000268568.1	AC007228.9	-5.75	1.61e-08	0.025	-0.34	-0.25	Birth weight;	chr22:41849759	chr19:56672574~56673901:-
LUAD	trans	rs10213084	1	rs28415874	ENSG00000221413.1	AC023593.1	-5.75	1.61e-08	0.0251	-0.4	-0.25	Heart rate;	chr4:146564836	chr3:127664704~127664810:+
LUAD	trans	rs2243480	1	rs4718269	ENSG00000230295.1	RP11-458F8.2	5.75	1.61e-08	0.0251	0.31	0.25	Diabetic kidney disease;	chr7:65735810	chr7:66880708~66882981:+
LUAD	trans	rs2131877	0.83	rs62290331	ENSG00000254503.1	CTD-2521M24.4	5.75	1.62e-08	0.0252	0.38	0.25	Non-small cell lung cancer;	chr3:195123070	chr19:17417031~17418288:-
LUAD	trans	rs282544	1	rs11954386	ENSG00000231752.4	EMBP1	-5.75	1.62e-08	0.0252	-0.36	-0.25	Myopia (pathological);	chr5:50689818	chr1:121519112~121571892:+
LUAD	trans	rs282544	0.965	rs2354533	ENSG00000231752.4	EMBP1	-5.75	1.62e-08	0.0252	-0.36	-0.25	Myopia (pathological);	chr5:50676103	chr1:121519112~121571892:+
LUAD	trans	rs1426153	0.544	rs2005404	ENSG00000240137.4	ERICH6-AS1	-5.75	1.62e-08	0.0253	-0.34	-0.25	Alcohol and nicotine co-dependence;	chr11:125304084	chr3:150703564~150720146:+
LUAD	trans	rs8077577	0.731	rs11869952	ENSG00000188933.13	USP32P1	5.75	1.63e-08	0.0253	0.35	0.25	Obesity-related traits;	chr17:18318399	chr17:16786489~16804455:+
LUAD	trans	rs2899832	0.866	rs1884715	ENSG00000229083.1	PSMA6P2	5.75	1.63e-08	0.0253	0.34	0.25	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35274367	chrX:12825840~12826833:+
LUAD	trans	rs6915893	0.933	rs4588678	ENSG00000267156.1	TPMTP1	5.75	1.63e-08	0.0254	0.3	0.25	Intrinsic epigenetic age acceleration;	chr6:18119246	chr18:47630112~47630848:+
LUAD	trans	rs6424115	0.545	rs11576333	ENSG00000228217.1	AL390877.1	5.74	1.63e-08	0.0254	0.34	0.25	Immature fraction of reticulocytes;	chr1:23739280	chr1:117778087~117778506:-
LUAD	trans	rs73108077	0.79	rs73105930	ENSG00000279352.1	RP11-411B10.7	5.74	1.65e-08	0.0256	0.49	0.25	Red blood cell density in sickle cell anemia;	chr20:31327265	chr18:14010054~14010917:+
LUAD	trans	rs2419374	0.793	rs12728994	ENSG00000256210.3	AC005255.3	-5.74	1.65e-08	0.0257	-0.33	-0.25	Suicide ideation score in major depressive disorder;	chr1:190103805	chr19:14792318~14792533:+
LUAD	trans	rs7833986	0.534	rs17813240	ENSG00000236862.1	RPS20P24	5.74	1.67e-08	0.0259	0.32	0.25	Height;	chr8:56013232	chr9:72655832~72656192:-
LUAD	trans	rs12439619	0.768	rs28694364	ENSG00000259295.5	CSPG4P12	-5.74	1.67e-08	0.0259	-0.35	-0.25	Intelligence (multi-trait analysis);	chr15:82208119	chr15:85191438~85213905:+
LUAD	trans	rs6940638	0.688	rs9461335	ENSG00000204709.4	LINC01556	5.74	1.67e-08	0.026	0.32	0.25	Intelligence (multi-trait analysis);	chr6:27170750	chr6:28943877~28944537:+
LUAD	trans	rs6030712	0.948	rs1744776	ENSG00000211897.6	IGHG3	-5.74	1.67e-08	0.026	-0.23	-0.25	Height;	chr20:37097648	chr14:105769102~106038345:-
LUAD	trans	rs864643	0.891	rs1708057	ENSG00000183298.5	RP11-556K13.1	5.74	1.67e-08	0.026	0.37	0.25	Attention deficit hyperactivity disorder;	chr3:39499895	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.947	rs1768241	ENSG00000183298.5	RP11-556K13.1	5.74	1.67e-08	0.026	0.37	0.25	Attention deficit hyperactivity disorder;	chr3:39499987	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.891	rs1708059	ENSG00000183298.5	RP11-556K13.1	5.74	1.67e-08	0.026	0.37	0.25	Attention deficit hyperactivity disorder;	chr3:39500059	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.947	rs1768242	ENSG00000183298.5	RP11-556K13.1	5.74	1.67e-08	0.026	0.37	0.25	Attention deficit hyperactivity disorder;	chr3:39500222	chr1:101786340~101787219:-
LUAD	trans	rs9467773	0.572	rs2076029	ENSG00000242375.1	RP11-498P14.3	-5.74	1.68e-08	0.026	-0.34	-0.25	Intelligence (multi-trait analysis);	chr6:26390602	chr9:97195351~97197687:-
LUAD	trans	rs3096299	0.509	rs4785691	ENSG00000215030.5	RPL13P12	-5.74	1.68e-08	0.026	-0.28	-0.25	Multiple myeloma (IgH translocation);	chr16:89530813	chr17:17383377~17384012:-
LUAD	trans	rs7647973	0.696	rs7100	ENSG00000197582.5	GPX1P1	5.74	1.68e-08	0.0261	0.37	0.25	Menarche (age at onset);	chr3:49015786	chrX:13378735~13379340:-
LUAD	trans	rs1933488	0.866	rs63739861	ENSG00000278974.1	RP11-756P10.6	-5.74	1.68e-08	0.0261	-0.31	-0.25	Prostate cancer;	chr6:153109733	chr4:188740507~188741281:-
LUAD	trans	rs2069408	1	rs2069408	ENSG00000234513.1	AC073072.7	-5.74	1.69e-08	0.0262	-0.31	-0.25	Asthma;	chr12:55970537	chr7:22773646~22773993:-
LUAD	trans	rs7819412	0.56	rs13265553	ENSG00000253893.2	FAM85B	5.74	1.69e-08	0.0262	0.32	0.25	Triglycerides;	chr8:11131547	chr8:8167819~8226614:-
LUAD	trans	rs9393777	0.778	rs4452638	ENSG00000204709.4	LINC01556	-5.74	1.69e-08	0.0262	-0.47	-0.25	Intelligence (multi-trait analysis);	chr6:27261486	chr6:28943877~28944537:+
LUAD	trans	rs10085978	0.51	rs7461193	ENSG00000250948.1	RP11-1079K10.2	-5.74	1.69e-08	0.0262	-0.32	-0.25	Mosquito bite size;	chr8:142145437	chr17:49375380~49380094:+
LUAD	trans	rs112861654	1	rs112861654	ENSG00000196295.10	AC005154.6	5.74	1.69e-08	0.0262	0.33	0.25	Monokine induced by gamma interferon levels;	chr21:42179062	chr7:30516309~30594809:-
LUAD	trans	rs889398	0.616	rs35808754	ENSG00000257513.6	NPIPB1P	-5.74	1.7e-08	0.0263	-0.25	-0.25	Body mass index;	chr16:69737807	chr18:11619509~11639699:-
LUAD	trans	rs282544	1	rs12055210	ENSG00000231752.4	EMBP1	-5.74	1.7e-08	0.0263	-0.36	-0.25	Myopia (pathological);	chr5:50693867	chr1:121519112~121571892:+
LUAD	trans	rs1386478	0.849	rs324555	ENSG00000218502.3	H2AFZP3	-5.74	1.7e-08	0.0264	-0.29	-0.25	Crohn's disease and psoriasis;	chr3:114011261	chr13:99215372~99215758:-
LUAD	trans	rs2478333	0.528	rs2677594	ENSG00000268931.1	RP11-886P16.6	5.74	1.71e-08	0.0264	0.3	0.25	QT interval;	chr13:47628061	chr19:8423355~8427827:-
LUAD	trans	rs864643	0.524	rs9822783	ENSG00000188856.6	RPSAP47	5.74	1.71e-08	0.0264	0.36	0.25	Attention deficit hyperactivity disorder;	chr3:39463311	chr8:80558870~80559757:+
LUAD	trans	rs10009124	0.52	rs17048453	ENSG00000182841.11	RRP7B	5.74	1.71e-08	0.0265	0.26	0.25	Number of pregnancies;Number of children;	chr4:136084597	chr22:42555223~42582038:-
LUAD	trans	rs45509595	0.556	rs34409918	ENSG00000281831.1	HCP5B	5.74	1.72e-08	0.0266	0.55	0.25	Breast cancer;	chr6:27717569	chr6:29871895~29873783:-
LUAD	trans	rs7746199	0.736	rs34064842	ENSG00000281831.1	HCP5B	5.74	1.72e-08	0.0266	0.55	0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27720846	chr6:29871895~29873783:-
LUAD	trans	rs7746199	0.736	rs13212318	ENSG00000281831.1	HCP5B	5.74	1.72e-08	0.0266	0.55	0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27721062	chr6:29871895~29873783:-
LUAD	trans	rs6940638	0.688	rs7744759	ENSG00000204709.4	LINC01556	5.74	1.72e-08	0.0266	0.32	0.25	Intelligence (multi-trait analysis);	chr6:27152047	chr6:28943877~28944537:+
LUAD	trans	rs7412746	0.611	rs7532045	ENSG00000180764.13	PIPSL	-5.74	1.72e-08	0.0266	-0.29	-0.25	Melanoma;	chr1:150849371	chr10:93958191~93961540:-
LUAD	trans	rs7833986	0.501	rs2976044	ENSG00000244245.1	RP11-120B7.1	5.74	1.72e-08	0.0266	0.28	0.25	Height;	chr8:56074178	chr5:108593609~108593967:+
LUAD	trans	rs28673968	0.623	rs74288556	ENSG00000214846.4	RP11-115L11.1	5.73	1.73e-08	0.0267	0.54	0.25	Idiopathic pulmonary fibrosis;	chr4:89580381	chr4:15730962~15731627:-
LUAD	trans	rs916888	0.61	rs199436	ENSG00000204650.12	CRHR1-IT1	-5.73	1.73e-08	0.0267	-0.3	-0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:45620328~45648216:+
LUAD	trans	rs864643	0.947	rs538972	ENSG00000183298.5	RP11-556K13.1	5.73	1.73e-08	0.0267	0.37	0.25	Attention deficit hyperactivity disorder;	chr3:39497652	chr1:101786340~101787219:-
LUAD	trans	rs6831352	0.589	rs1133483	ENSG00000233859.2	ADH5P4	-5.73	1.73e-08	0.0267	-0.26	-0.25	Alcohol dependence;	chr4:99102772	chr6:65836930~65838039:-
LUAD	trans	rs7647973	0.577	rs6446247	ENSG00000197582.5	GPX1P1	5.73	1.73e-08	0.0267	0.37	0.25	Menarche (age at onset);	chr3:49064568	chrX:13378735~13379340:-
LUAD	trans	rs853679	0.607	rs13208096	ENSG00000281831.1	HCP5B	5.73	1.73e-08	0.0267	0.57	0.25	Depression;	chr6:28257533	chr6:29871895~29873783:-
LUAD	trans	rs864643	0.947	rs1768243	ENSG00000183298.5	RP11-556K13.1	5.73	1.74e-08	0.0269	0.37	0.25	Attention deficit hyperactivity disorder;	chr3:39500306	chr1:101786340~101787219:-
LUAD	trans	rs17507216	0.718	rs28587782	ENSG00000235370.6	DNM1P51	-5.73	1.74e-08	0.0269	-0.35	-0.25	Excessive daytime sleepiness;	chr15:82576881	chr15:84398316~84411701:-
LUAD	trans	rs1933488	0.965	rs28642896	ENSG00000278974.1	RP11-756P10.6	-5.73	1.74e-08	0.0269	-0.31	-0.25	Prostate cancer;	chr6:153106933	chr4:188740507~188741281:-
LUAD	trans	rs1933488	1	rs9383649	ENSG00000278974.1	RP11-756P10.6	-5.73	1.74e-08	0.0269	-0.31	-0.25	Prostate cancer;	chr6:153106967	chr4:188740507~188741281:-
LUAD	trans	rs864643	0.947	rs1708015	ENSG00000183298.5	RP11-556K13.1	5.73	1.75e-08	0.027	0.37	0.25	Attention deficit hyperactivity disorder;	chr3:39496891	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.891	rs1708018	ENSG00000183298.5	RP11-556K13.1	5.73	1.75e-08	0.027	0.37	0.25	Attention deficit hyperactivity disorder;	chr3:39496978	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.947	rs535220	ENSG00000183298.5	RP11-556K13.1	5.73	1.75e-08	0.027	0.37	0.25	Attention deficit hyperactivity disorder;	chr3:39497234	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.947	rs538214	ENSG00000183298.5	RP11-556K13.1	5.73	1.75e-08	0.027	0.37	0.25	Attention deficit hyperactivity disorder;	chr3:39497603	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.947	rs614359	ENSG00000183298.5	RP11-556K13.1	5.73	1.75e-08	0.027	0.37	0.25	Attention deficit hyperactivity disorder;	chr3:39498035	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.947	rs1768237	ENSG00000183298.5	RP11-556K13.1	5.73	1.75e-08	0.027	0.37	0.25	Attention deficit hyperactivity disorder;	chr3:39498712	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.947	rs482495	ENSG00000183298.5	RP11-556K13.1	5.73	1.75e-08	0.027	0.37	0.25	Attention deficit hyperactivity disorder;	chr3:39498924	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.947	rs645403	ENSG00000183298.5	RP11-556K13.1	5.73	1.75e-08	0.027	0.37	0.25	Attention deficit hyperactivity disorder;	chr3:39498968	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.947	rs645457	ENSG00000183298.5	RP11-556K13.1	5.73	1.75e-08	0.027	0.37	0.25	Attention deficit hyperactivity disorder;	chr3:39499006	chr1:101786340~101787219:-
LUAD	trans	rs7192380	0.571	rs10852456	ENSG00000257513.6	NPIPB1P	5.73	1.75e-08	0.027	0.25	0.25	Sjögren's syndrome;	chr16:69571710	chr18:11619509~11639699:-
LUAD	trans	rs7172677	0.737	rs7178625	ENSG00000225407.3	CTD-2384B11.2	-5.73	1.76e-08	0.0271	-0.29	-0.25	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75148676	chr5:76691439~76716215:-
LUAD	trans	rs7647973	0.731	rs9831648	ENSG00000197582.5	GPX1P1	5.73	1.76e-08	0.0272	0.37	0.25	Menarche (age at onset);	chr3:49176870	chrX:13378735~13379340:-
LUAD	trans	rs13061878	0.925	rs4447759	ENSG00000236545.1	AP001619.3	5.73	1.77e-08	0.0273	0.45	0.25	Bipolar disorder or attention deficit hyperactivity disorder;	chr3:61595238	chr21:41870633~41872054:+
LUAD	trans	rs4948102	0.642	rs6593297	ENSG00000215006.4	CHCHD2P2	5.73	1.78e-08	0.0274	0.33	0.25	Plasma homocysteine levels (post-methionine load test);	chr7:56054365	chr5:69333929~69334249:+
LUAD	trans	rs7929679	0.602	rs1588354	ENSG00000225531.1	RP11-196I18.3	5.73	1.78e-08	0.0274	0.32	0.25	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34786939	chr9:107116829~107117557:+
LUAD	trans	rs7929679	0.602	rs10836310	ENSG00000225531.1	RP11-196I18.3	5.73	1.78e-08	0.0274	0.32	0.25	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34787373	chr9:107116829~107117557:+
LUAD	trans	rs7781370	1	rs7781370	ENSG00000233762.3	AC007969.5	-5.73	1.78e-08	0.0274	-0.22	-0.25	Bone mineral density (hip);	chr7:96504219	chr2:171517270~171517716:-
LUAD	trans	rs7819412	0.522	rs10088853	ENSG00000253893.2	FAM85B	5.73	1.79e-08	0.0275	0.32	0.25	Triglycerides;	chr8:11130457	chr8:8167819~8226614:-
LUAD	trans	rs864643	0.947	rs1708064	ENSG00000183298.5	RP11-556K13.1	5.73	1.79e-08	0.0276	0.37	0.25	Attention deficit hyperactivity disorder;	chr3:39500679	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.812	rs1513218	ENSG00000183298.5	RP11-556K13.1	5.73	1.79e-08	0.0276	0.34	0.25	Attention deficit hyperactivity disorder;	chr3:39504097	chr1:101786340~101787219:-
LUAD	trans	rs9329221	0.527	rs7833781	ENSG00000253981.4	ALG1L13P	5.73	1.79e-08	0.0276	0.29	0.25	Neuroticism;	chr8:10475967	chr8:8236003~8244667:-
LUAD	trans	rs73108077	0.79	rs73102082	ENSG00000279352.1	RP11-411B10.7	5.73	1.79e-08	0.0276	0.5	0.25	Red blood cell density in sickle cell anemia;	chr20:31288687	chr18:14010054~14010917:+
LUAD	trans	rs7647973	0.925	rs6808036	ENSG00000197582.5	GPX1P1	5.73	1.79e-08	0.0276	0.35	0.25	Menarche (age at onset);	chr3:49199006	chrX:13378735~13379340:-
LUAD	trans	rs9467773	0.572	rs9467737	ENSG00000242375.1	RP11-498P14.3	-5.73	1.8e-08	0.0277	-0.34	-0.25	Intelligence (multi-trait analysis);	chr6:26381402	chr9:97195351~97197687:-
LUAD	trans	rs8077577	0.747	rs1925	ENSG00000188933.13	USP32P1	5.73	1.8e-08	0.0277	0.35	0.25	Obesity-related traits;	chr17:18274401	chr17:16786489~16804455:+
LUAD	trans	rs6558530	0.73	rs4875958	ENSG00000220842.6	RP11-572P18.1	5.73	1.8e-08	0.0277	0.29	0.25	Systolic blood pressure;	chr8:1772924	chr10:120354701~120355183:-
LUAD	trans	rs13416322	0.945	rs10176221	ENSG00000214286.2	PDCL3P3	5.73	1.81e-08	0.0279	0.35	0.25	Intelligence (multi-trait analysis);	chr2:100460306	chr3:17877455~17878169:-
LUAD	trans	rs740160	0.558	rs17161669	ENSG00000228834.1	RP11-249L21.4	5.72	1.82e-08	0.028	0.49	0.25	Dehydroepiandrosterone sulphate levels;	chr7:99311040	chr6:108907615~108907873:-
LUAD	trans	rs7647973	0.696	rs3087866	ENSG00000197582.5	GPX1P1	5.72	1.82e-08	0.028	0.36	0.25	Menarche (age at onset);	chr3:49017259	chrX:13378735~13379340:-
LUAD	trans	rs950394	1	rs17029774	ENSG00000231682.1	AC097713.4	-5.72	1.83e-08	0.0282	-0.34	-0.25	Schizophrenia;	chr2:104373578	chr2:234444590~234454595:-
LUAD	trans	rs950394	1	rs56230702	ENSG00000231682.1	AC097713.4	-5.72	1.83e-08	0.0282	-0.34	-0.25	Schizophrenia;	chr2:104373769	chr2:234444590~234454595:-
LUAD	trans	rs864643	0.898	rs636476	ENSG00000183298.5	RP11-556K13.1	5.72	1.83e-08	0.0282	0.35	0.25	Attention deficit hyperactivity disorder;	chr3:39549841	chr1:101786340~101787219:-
LUAD	trans	rs2351491	0.553	rs953066	ENSG00000227634.1	RP11-431K24.3	-5.72	1.83e-08	0.0282	-0.31	-0.25	Height;	chr15:88859665	chr1:8208672~8215210:+
LUAD	trans	rs11512640	1	rs11220120	ENSG00000236257.1	EI24P2	5.72	1.84e-08	0.0282	0.53	0.25	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:125529894	chr1:158454198~158455273:+
LUAD	trans	rs8077577	0.747	rs62072507	ENSG00000188933.13	USP32P1	5.72	1.84e-08	0.0282	0.35	0.25	Obesity-related traits;	chr17:18269021	chr17:16786489~16804455:+
LUAD	trans	rs3812762	0.833	rs10500707	ENSG00000266891.1	RP11-692N5.2	-5.72	1.84e-08	0.0282	-0.34	-0.25	Hypospadias;	chr11:8796033	chr18:9734882~9735602:-
LUAD	trans	rs4851551	0.867	rs3171845	ENSG00000207973.1	MIR589	5.72	1.84e-08	0.0283	0.59	0.25	Blood protein levels;	chr2:102174921	chr7:5495819~5495917:-
LUAD	trans	rs4851551	0.867	rs3917330	ENSG00000207973.1	MIR589	5.72	1.84e-08	0.0283	0.59	0.25	Blood protein levels;	chr2:102179965	chr7:5495819~5495917:-
LUAD	trans	rs4851551	0.867	rs3917331	ENSG00000207973.1	MIR589	5.72	1.84e-08	0.0283	0.59	0.25	Blood protein levels;	chr2:102179966	chr7:5495819~5495917:-
LUAD	trans	rs7819412	0.745	rs4841498	ENSG00000253893.2	FAM85B	5.72	1.86e-08	0.0285	0.31	0.25	Triglycerides;	chr8:11127922	chr8:8167819~8226614:-
LUAD	trans	rs282544	1	rs7717033	ENSG00000231752.4	EMBP1	-5.72	1.86e-08	0.0285	-0.35	-0.25	Myopia (pathological);	chr5:50686892	chr1:121519112~121571892:+
LUAD	trans	rs7746199	0.736	rs13210634	ENSG00000281831.1	HCP5B	5.72	1.86e-08	0.0286	0.55	0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27678713	chr6:29871895~29873783:-
LUAD	trans	rs7746199	0.736	rs13215275	ENSG00000281831.1	HCP5B	5.72	1.86e-08	0.0286	0.55	0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27679730	chr6:29871895~29873783:-
LUAD	trans	rs7746199	0.736	rs17749927	ENSG00000281831.1	HCP5B	5.72	1.86e-08	0.0286	0.55	0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27702197	chr6:29871895~29873783:-
LUAD	trans	rs7746199	0.736	rs13192965	ENSG00000281831.1	HCP5B	5.72	1.86e-08	0.0286	0.55	0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27704046	chr6:29871895~29873783:-
LUAD	trans	rs3812762	0.783	rs34524863	ENSG00000266891.1	RP11-692N5.2	5.72	1.86e-08	0.0286	0.34	0.25	Hypospadias;	chr11:8755861	chr18:9734882~9735602:-
LUAD	trans	rs7833986	0.501	rs72653948	ENSG00000236862.1	RPS20P24	5.72	1.87e-08	0.0286	0.3	0.25	Height;	chr8:56043130	chr9:72655832~72656192:-
LUAD	trans	rs728478	0.566	rs1451508	ENSG00000187870.7	RNFT1P3	5.72	1.87e-08	0.0287	0.3	0.25	QT interval;	chr17:59399874	chr17:20743333~20754501:-
LUAD	trans	rs7412746	0.634	rs4451553	ENSG00000180764.13	PIPSL	-5.72	1.87e-08	0.0287	-0.29	-0.25	Melanoma;	chr1:150964853	chr10:93958191~93961540:-
LUAD	trans	rs66887589	0.967	rs3775842	ENSG00000275858.1	RP11-291L22.8	5.72	1.87e-08	0.0287	0.27	0.25	Diastolic blood pressure;	chr4:119506577	chr10:38450738~38451069:-
LUAD	trans	rs7647973	0.731	rs7617480	ENSG00000197582.5	GPX1P1	-5.72	1.87e-08	0.0287	-0.36	-0.25	Menarche (age at onset);	chr3:49173299	chrX:13378735~13379340:-
LUAD	trans	rs13416322	0.838	rs17024446	ENSG00000214286.2	PDCL3P3	5.72	1.88e-08	0.0288	0.35	0.25	Intelligence (multi-trait analysis);	chr2:100498224	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.945	rs12613298	ENSG00000214286.2	PDCL3P3	5.72	1.88e-08	0.0288	0.35	0.25	Intelligence (multi-trait analysis);	chr2:100448763	chr3:17877455~17878169:-
LUAD	trans	rs8077577	0.747	rs16961153	ENSG00000263946.1	RP11-434D2.11	-5.72	1.88e-08	0.0288	-0.33	-0.25	Obesity-related traits;	chr17:18323787	chr17:20554971~20559410:-
LUAD	trans	rs864643	0.625	rs694380	ENSG00000183298.5	RP11-556K13.1	5.72	1.88e-08	0.0289	0.38	0.25	Attention deficit hyperactivity disorder;	chr3:39494399	chr1:101786340~101787219:-
LUAD	trans	rs7412746	0.634	rs12409208	ENSG00000180764.13	PIPSL	-5.72	1.89e-08	0.0289	-0.29	-0.25	Melanoma;	chr1:150887579	chr10:93958191~93961540:-
LUAD	trans	rs7412746	0.658	rs12410394	ENSG00000180764.13	PIPSL	-5.72	1.89e-08	0.0289	-0.29	-0.25	Melanoma;	chr1:150887710	chr10:93958191~93961540:-
LUAD	trans	rs282544	1	rs10471414	ENSG00000231752.4	EMBP1	-5.72	1.89e-08	0.029	-0.36	-0.25	Myopia (pathological);	chr5:50664839	chr1:121519112~121571892:+
LUAD	trans	rs11668609	1	rs66972560	ENSG00000261770.1	CTC-459F4.1	5.72	1.89e-08	0.029	0.34	0.25	Response to taxane treatment (docetaxel);	chr19:24178138	chr19:27757184~27760849:-
LUAD	trans	rs714543	1	rs10278679	ENSG00000226038.5	PPIAP21	-5.72	1.9e-08	0.029	-0.29	-0.25	Plateletcrit;	chr7:44825465	chr20:43230760~43231260:+
LUAD	trans	rs9575182	1	rs9575168	ENSG00000228763.1	AC010095.5	5.72	1.9e-08	0.0291	0.3	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr13:82774637	chr2:108676795~108678601:-
LUAD	trans	rs7042864	1	rs10816630	ENSG00000225178.4	RPSAP56	5.72	1.9e-08	0.0291	0.29	0.25	Tonometry;	chr9:108106101	chr16:73940639~73941524:-
LUAD	trans	rs864643	0.812	rs1398669	ENSG00000183298.5	RP11-556K13.1	-5.72	1.9e-08	0.0291	-0.34	-0.25	Attention deficit hyperactivity disorder;	chr3:39504500	chr1:101786340~101787219:-
LUAD	trans	rs1023500	1	rs1023497	ENSG00000268568.1	AC007228.9	-5.72	1.91e-08	0.0292	-0.37	-0.25	Schizophrenia;	chr22:41944504	chr19:56672574~56673901:-
LUAD	trans	rs714543	0.61	rs4724320	ENSG00000226038.5	PPIAP21	-5.72	1.91e-08	0.0292	-0.28	-0.25	Plateletcrit;	chr7:44775735	chr20:43230760~43231260:+
LUAD	trans	rs4920799	0.793	rs305748	ENSG00000237484.5	AP000476.1	-5.72	1.91e-08	0.0292	-0.29	-0.25	Echocardiographic traits;	chr5:85345886	chr21:24428740~24547942:+
LUAD	trans	rs4920799	0.793	rs305749	ENSG00000237484.5	AP000476.1	-5.72	1.91e-08	0.0292	-0.29	-0.25	Echocardiographic traits;	chr5:85346157	chr21:24428740~24547942:+
LUAD	trans	rs546131	0.642	rs566798	ENSG00000225531.1	RP11-196I18.3	-5.72	1.91e-08	0.0292	-0.33	-0.25	Lung disease severity in cystic fibrosis;	chr11:34830730	chr9:107116829~107117557:+
LUAD	trans	rs7617480	0.648	rs9859473	ENSG00000197582.5	GPX1P1	5.72	1.91e-08	0.0292	0.36	0.25	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48799749	chrX:13378735~13379340:-
LUAD	trans	rs2785173	1	rs2785173	ENSG00000243802.2	RP11-390K5.1	-5.72	1.92e-08	0.0293	-0.55	-0.25	Response to Vitamin E supplementation;	chr11:35134185	chr11:47191181~47191542:-
LUAD	trans	rs9329221	0.527	rs34259385	ENSG00000253981.4	ALG1L13P	-5.72	1.92e-08	0.0294	-0.29	-0.25	Neuroticism;	chr8:10467946	chr8:8236003~8244667:-
LUAD	trans	rs864643	0.524	rs78956370	ENSG00000214263.2	RPSAP53	-5.72	1.92e-08	0.0294	-0.44	-0.25	Attention deficit hyperactivity disorder;	chr3:39463883	chr13:67266845~67267706:-
LUAD	trans	rs4920799	0.648	rs305739	ENSG00000237484.5	AP000476.1	-5.72	1.93e-08	0.0294	-0.29	-0.25	Echocardiographic traits;	chr5:85340985	chr21:24428740~24547942:+
LUAD	trans	rs9393777	0.92	rs13195040	ENSG00000281831.1	HCP5B	-5.72	1.93e-08	0.0294	-0.49	-0.25	Intelligence (multi-trait analysis);	chr6:27446145	chr6:29871895~29873783:-
LUAD	trans	rs6940638	0.744	rs858964	ENSG00000204709.4	LINC01556	-5.71	1.93e-08	0.0295	-0.31	-0.25	Intelligence (multi-trait analysis);	chr6:27174835	chr6:28943877~28944537:+
LUAD	trans	rs71403859	0.502	rs35981926	ENSG00000265407.1	MIR4324	5.71	1.93e-08	0.0295	0.48	0.25	Post bronchodilator FEV1;	chr16:71466852	chr19:49308797~49308868:-
LUAD	trans	rs7647973	0.961	rs11130186	ENSG00000197582.5	GPX1P1	5.71	1.93e-08	0.0295	0.34	0.25	Menarche (age at onset);	chr3:49238395	chrX:13378735~13379340:-
LUAD	trans	rs7647973	0.961	rs10154992	ENSG00000197582.5	GPX1P1	5.71	1.93e-08	0.0295	0.34	0.25	Menarche (age at onset);	chr3:49238644	chrX:13378735~13379340:-
LUAD	trans	rs7647973	0.961	rs4955443	ENSG00000197582.5	GPX1P1	5.71	1.93e-08	0.0295	0.34	0.25	Menarche (age at onset);	chr3:49249185	chrX:13378735~13379340:-
LUAD	trans	rs3740713	0.669	rs2896526	ENSG00000214110.3	LDHAP4	5.71	1.94e-08	0.0297	0.4	0.25	Amyotrophic lateral sclerosis (sporadic);	chr11:18398259	chr9:14921337~14922334:-
LUAD	trans	rs8077577	0.562	rs8081042	ENSG00000188933.13	USP32P1	5.71	1.96e-08	0.0299	0.35	0.25	Obesity-related traits;	chr17:18295753	chr17:16786489~16804455:+
LUAD	trans	rs2899832	0.5	rs10151128	ENSG00000229083.1	PSMA6P2	5.71	1.96e-08	0.0299	0.4	0.25	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35306578	chrX:12825840~12826833:+
LUAD	trans	rs71403859	0.502	rs12927456	ENSG00000265407.1	MIR4324	5.71	1.96e-08	0.0299	0.43	0.25	Post bronchodilator FEV1;	chr16:71471803	chr19:49308797~49308868:-
LUAD	trans	rs4920799	0.752	rs305740	ENSG00000237484.5	AP000476.1	-5.71	1.96e-08	0.03	-0.29	-0.25	Echocardiographic traits;	chr5:85340993	chr21:24428740~24547942:+
LUAD	trans	rs7809615	0.515	rs11772470	ENSG00000228834.1	RP11-249L21.4	5.71	1.96e-08	0.03	0.39	0.25	Blood metabolite ratios;	chr7:99583473	chr6:108907615~108907873:-
LUAD	trans	rs853679	0.546	rs13213986	ENSG00000281831.1	HCP5B	5.71	1.99e-08	0.0303	0.57	0.25	Depression;	chr6:28390232	chr6:29871895~29873783:-
LUAD	trans	rs9467773	0.609	rs12663780	ENSG00000242375.1	RP11-498P14.3	-5.71	1.99e-08	0.0304	-0.34	-0.25	Intelligence (multi-trait analysis);	chr6:26397345	chr9:97195351~97197687:-
LUAD	trans	rs116002988	0.752	rs17546515	ENSG00000249592.4	RP11-440L14.1	5.71	2e-08	0.0304	0.29	0.25	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr14:98982127	chr4:762387~781849:-
LUAD	trans	rs7044355	0.504	rs10815778	ENSG00000228401.4	RP11-251M1.1	-5.71	2e-08	0.0304	-0.26	-0.25	Platelet aggregation;	chr9:8187329	chr9:136648610~136660421:-
LUAD	trans	rs853679	0.882	rs9380069	ENSG00000281831.1	HCP5B	5.71	2e-08	0.0305	0.42	0.25	Depression;	chr6:28235522	chr6:29871895~29873783:-
LUAD	trans	rs6673267	0.904	rs6701469	ENSG00000244144.1	RP11-757F18.3	-5.71	2e-08	0.0305	-0.3	-0.25	Lobe attachment (rater-scored or self-reported);	chr1:201029691	chr3:112185480~112185998:-
LUAD	trans	rs7617480	0.616	rs7429596	ENSG00000197582.5	GPX1P1	5.71	2e-08	0.0305	0.38	0.25	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48771098	chrX:13378735~13379340:-
LUAD	trans	rs7984972	1	rs7984972	ENSG00000251600.4	RP11-673E1.1	-5.71	2e-08	0.0305	-0.28	-0.25	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr13:31433871	chr4:143912331~143982454:+
LUAD	trans	rs9368481	0.761	rs12661756	ENSG00000242375.1	RP11-498P14.3	5.71	2.01e-08	0.0306	0.34	0.25	Autism spectrum disorder or schizophrenia;	chr6:27035704	chr9:97195351~97197687:-
LUAD	trans	rs9733	0.744	rs3754211	ENSG00000180764.13	PIPSL	-5.71	2.01e-08	0.0307	-0.27	-0.25	Tonsillectomy;	chr1:150979381	chr10:93958191~93961540:-
LUAD	trans	rs13416322	0.945	rs13386458	ENSG00000214286.2	PDCL3P3	5.71	2.02e-08	0.0307	0.35	0.25	Intelligence (multi-trait analysis);	chr2:100448229	chr3:17877455~17878169:-
LUAD	trans	rs4948102	0.667	rs7811270	ENSG00000186940.6	CHCHD2P9	-5.7	2.04e-08	0.031	-0.31	-0.25	Plasma homocysteine levels (post-methionine load test);	chr7:56072297	chr9:79391304~79391759:+
LUAD	trans	rs3096299	0.719	rs2965818	ENSG00000215030.5	RPL13P12	-5.7	2.04e-08	0.031	-0.28	-0.25	Multiple myeloma (IgH translocation);	chr16:89444086	chr17:17383377~17384012:-
LUAD	trans	rs13416322	0.945	rs13418897	ENSG00000214286.2	PDCL3P3	5.7	2.04e-08	0.031	0.35	0.25	Intelligence (multi-trait analysis);	chr2:100442182	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.945	rs13384702	ENSG00000214286.2	PDCL3P3	5.7	2.04e-08	0.031	0.35	0.25	Intelligence (multi-trait analysis);	chr2:100443195	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.945	rs13390447	ENSG00000214286.2	PDCL3P3	5.7	2.04e-08	0.031	0.35	0.25	Intelligence (multi-trait analysis);	chr2:100443622	chr3:17877455~17878169:-
LUAD	trans	rs7364180	1	rs7364180	ENSG00000268568.1	AC007228.9	-5.7	2.04e-08	0.0311	-0.36	-0.25	Alzheimer's disease biomarkers;	chr22:41822852	chr19:56672574~56673901:-
LUAD	trans	rs7647973	0.925	rs4955423	ENSG00000197582.5	GPX1P1	5.7	2.05e-08	0.0311	0.35	0.25	Menarche (age at onset);	chr3:49183015	chrX:13378735~13379340:-
LUAD	trans	rs2304725	0.526	rs1601364	ENSG00000259826.1	RP11-467D6.1	-5.7	2.05e-08	0.0312	-0.22	-0.25	Pulmonary function in asthmatics;	chr3:10788565	chr7:39947522~39949755:-
LUAD	trans	rs7819412	0.74	rs7844536	ENSG00000253893.2	FAM85B	5.7	2.05e-08	0.0312	0.3	0.25	Triglycerides;	chr8:11176519	chr8:8167819~8226614:-
LUAD	trans	rs877636	0.702	rs61937249	ENSG00000243538.1	CTB-55B8.1	5.7	2.05e-08	0.0313	0.29	0.25	Cognitive function;	chr12:55988132	chr5:16902294~16902641:-
LUAD	trans	rs9575182	1	rs61962328	ENSG00000228763.1	AC010095.5	5.7	2.06e-08	0.0313	0.29	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr13:82773735	chr2:108676795~108678601:-
LUAD	trans	rs7617480	0.587	rs9311431	ENSG00000197582.5	GPX1P1	5.7	2.06e-08	0.0313	0.38	0.25	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48811354	chrX:13378735~13379340:-
LUAD	trans	rs7617480	0.648	rs4974088	ENSG00000197582.5	GPX1P1	5.7	2.06e-08	0.0313	0.38	0.25	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48861316	chrX:13378735~13379340:-
LUAD	trans	rs7746199	0.736	rs67652222	ENSG00000281831.1	HCP5B	5.7	2.06e-08	0.0313	0.55	0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27618441	chr6:29871895~29873783:-
LUAD	trans	rs7412746	0.588	rs10305664	ENSG00000180764.13	PIPSL	-5.7	2.06e-08	0.0314	-0.29	-0.25	Melanoma;	chr1:150867210	chr10:93958191~93961540:-
LUAD	trans	rs7260598	0.642	rs8104784	ENSG00000261770.1	CTC-459F4.1	5.7	2.06e-08	0.0314	0.38	0.25	Response to taxane treatment (placlitaxel);	chr19:23961732	chr19:27757184~27760849:-
LUAD	trans	rs74976893	1	rs2429935	ENSG00000262902.1	RP11-750B16.1	5.7	2.06e-08	0.0314	0.56	0.25	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);Response to abacavir-containing treatment in HIV-1 infection (virologic failure);	chr17:71723279	chr17:53105734~53106358:+
LUAD	trans	rs877636	0.702	rs773109	ENSG00000243538.1	CTB-55B8.1	5.7	2.07e-08	0.0315	0.29	0.25	Cognitive function;	chr12:55980911	chr5:16902294~16902641:-
LUAD	trans	rs7412746	0.611	rs12410869	ENSG00000180764.13	PIPSL	-5.7	2.08e-08	0.0316	-0.29	-0.25	Melanoma;	chr1:150883677	chr10:93958191~93961540:-
LUAD	trans	rs7412746	0.611	rs36008098	ENSG00000180764.13	PIPSL	-5.7	2.08e-08	0.0316	-0.29	-0.25	Melanoma;	chr1:150884330	chr10:93958191~93961540:-
LUAD	trans	rs3812762	0.879	rs10769952	ENSG00000266891.1	RP11-692N5.2	-5.7	2.08e-08	0.0317	-0.33	-0.25	Hypospadias;	chr11:8755153	chr18:9734882~9735602:-
LUAD	trans	rs255788	0.92	rs7732528	ENSG00000238005.2	RP11-443B7.1	5.7	2.09e-08	0.0317	0.41	0.25	Response to platinum-based chemotherapy (carboplatin);	chr5:120115174	chr1:234957342~234970062:-
LUAD	trans	rs6424115	0.679	rs2267961	ENSG00000228217.1	AL390877.1	5.7	2.09e-08	0.0317	0.34	0.25	Immature fraction of reticulocytes;	chr1:23744558	chr1:117778087~117778506:-
LUAD	trans	rs3096299	0.658	rs4785679	ENSG00000215030.5	RPL13P12	-5.7	2.1e-08	0.0318	-0.28	-0.25	Multiple myeloma (IgH translocation);	chr16:89499705	chr17:17383377~17384012:-
LUAD	trans	rs7833986	0.501	rs2719227	ENSG00000244245.1	RP11-120B7.1	-5.7	2.1e-08	0.0319	-0.29	-0.25	Height;	chr8:56131235	chr5:108593609~108593967:+
LUAD	trans	rs12439619	0.846	rs62012003	ENSG00000259295.5	CSPG4P12	-5.7	2.1e-08	0.0319	-0.35	-0.25	Intelligence (multi-trait analysis);	chr15:82183236	chr15:85191438~85213905:+
LUAD	trans	rs7647973	0.961	rs11130187	ENSG00000197582.5	GPX1P1	5.7	2.11e-08	0.0321	0.34	0.25	Menarche (age at onset);	chr3:49270439	chrX:13378735~13379340:-
LUAD	trans	rs17507216	0.718	rs17158403	ENSG00000235370.6	DNM1P51	-5.7	2.11e-08	0.0321	-0.35	-0.25	Excessive daytime sleepiness;	chr15:82572478	chr15:84398316~84411701:-
LUAD	trans	rs877636	1	rs4759229	ENSG00000243538.1	CTB-55B8.1	-5.7	2.12e-08	0.0321	-0.27	-0.25	Cognitive function;	chr12:56080696	chr5:16902294~16902641:-
LUAD	trans	rs17507216	0.718	rs7165690	ENSG00000235370.6	DNM1P51	-5.7	2.13e-08	0.0323	-0.36	-0.25	Excessive daytime sleepiness;	chr15:82654804	chr15:84398316~84411701:-
LUAD	trans	rs7181649	0.735	rs72741257	ENSG00000280294.1	RP11-177H2.1	-5.7	2.15e-08	0.0326	-0.36	-0.25	Mean corpuscular hemoglobin;	chr15:65736252	chr8:10856085~10859436:-
LUAD	trans	rs3934047	0.967	rs8027665	ENSG00000188002.9	RP11-43F13.1	-5.69	2.16e-08	0.0327	-0.33	-0.25	Response to paliperidone in schizophrenia (positive Marder score);	chr15:81696703	chr5:1598920~1634005:-
LUAD	trans	rs864643	0.891	rs55780606	ENSG00000183298.5	RP11-556K13.1	5.69	2.16e-08	0.0328	0.36	0.25	Attention deficit hyperactivity disorder;	chr3:39496599	chr1:101786340~101787219:-
LUAD	trans	rs1933488	0.931	rs7750498	ENSG00000278974.1	RP11-756P10.6	-5.69	2.16e-08	0.0328	-0.31	-0.25	Prostate cancer;	chr6:153102920	chr4:188740507~188741281:-
LUAD	trans	rs7618501	0.815	rs3819325	ENSG00000197582.5	GPX1P1	5.69	2.18e-08	0.0329	0.32	0.25	Intelligence (multi-trait analysis);	chr3:49806290	chrX:13378735~13379340:-
LUAD	trans	rs7569376	1	rs6735824	ENSG00000206337.9	HCP5	-5.69	2.18e-08	0.033	-0.28	-0.25	Body mass index;	chr2:204521519	chr6:31400702~31477506:+
LUAD	trans	rs4906172	0.773	rs34509705	ENSG00000181359.5	HSP90AA6P	-5.69	2.18e-08	0.033	-0.29	-0.25	Menopause (age at onset);	chr14:102046707	chr4:170581470~170605450:-
LUAD	trans	rs6424115	0.862	rs34845821	ENSG00000228217.1	AL390877.1	5.69	2.18e-08	0.0331	0.34	0.25	Immature fraction of reticulocytes;	chr1:23739996	chr1:117778087~117778506:-
LUAD	trans	rs7647973	0.925	rs11130183	ENSG00000197582.5	GPX1P1	5.69	2.19e-08	0.0331	0.35	0.25	Menarche (age at onset);	chr3:49191513	chrX:13378735~13379340:-
LUAD	trans	rs714543	1	rs13245012	ENSG00000226038.5	PPIAP21	-5.69	2.19e-08	0.0331	-0.28	-0.25	Plateletcrit;	chr7:44826120	chr20:43230760~43231260:+
LUAD	trans	rs13416322	0.945	rs4396743	ENSG00000214286.2	PDCL3P3	5.69	2.19e-08	0.0332	0.35	0.25	Intelligence (multi-trait analysis);	chr2:100447253	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.891	rs56388165	ENSG00000214286.2	PDCL3P3	5.69	2.19e-08	0.0332	0.35	0.25	Intelligence (multi-trait analysis);	chr2:100447515	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.891	rs56168814	ENSG00000214286.2	PDCL3P3	5.69	2.19e-08	0.0332	0.35	0.25	Intelligence (multi-trait analysis);	chr2:100447516	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.945	rs13385933	ENSG00000214286.2	PDCL3P3	5.69	2.19e-08	0.0332	0.35	0.25	Intelligence (multi-trait analysis);	chr2:100447775	chr3:17877455~17878169:-
LUAD	trans	rs9329221	0.512	rs12546887	ENSG00000253981.4	ALG1L13P	5.69	2.19e-08	0.0332	0.29	0.25	Neuroticism;	chr8:10435366	chr8:8236003~8244667:-
LUAD	trans	rs546131	0.642	rs836950	ENSG00000225531.1	RP11-196I18.3	-5.69	2.21e-08	0.0334	-0.34	-0.25	Lung disease severity in cystic fibrosis;	chr11:34830473	chr9:107116829~107117557:+
LUAD	trans	rs13416322	1	rs78064224	ENSG00000214286.2	PDCL3P3	5.69	2.21e-08	0.0334	0.35	0.25	Intelligence (multi-trait analysis);	chr2:100437133	chr3:17877455~17878169:-
LUAD	trans	rs13416322	1	rs78790759	ENSG00000214286.2	PDCL3P3	5.69	2.21e-08	0.0334	0.35	0.25	Intelligence (multi-trait analysis);	chr2:100438769	chr3:17877455~17878169:-
LUAD	trans	rs13416322	1	rs77323318	ENSG00000214286.2	PDCL3P3	5.69	2.21e-08	0.0334	0.35	0.25	Intelligence (multi-trait analysis);	chr2:100438808	chr3:17877455~17878169:-
LUAD	trans	rs10009124	0.689	rs13435860	ENSG00000182841.11	RRP7B	5.69	2.21e-08	0.0334	0.25	0.25	Number of pregnancies;Number of children;	chr4:136054390	chr22:42555223~42582038:-
LUAD	trans	rs7412746	0.658	rs12068264	ENSG00000180764.13	PIPSL	-5.69	2.21e-08	0.0335	-0.29	-0.25	Melanoma;	chr1:150754853	chr10:93958191~93961540:-
LUAD	trans	rs837841	0.864	rs1660903	ENSG00000212802.4	RPL15P3	-5.69	2.22e-08	0.0335	-0.19	-0.25	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);	chr2:129289106	chr6:12514110~12514724:+
LUAD	trans	rs1386478	0.888	rs324553	ENSG00000218502.3	H2AFZP3	-5.69	2.22e-08	0.0335	-0.29	-0.25	Crohn's disease and psoriasis;	chr3:114007904	chr13:99215372~99215758:-
LUAD	trans	rs4742971	0.5	rs10816353	ENSG00000230916.2	RP11-10B2.1	5.69	2.22e-08	0.0336	0.49	0.25	Protein quantitative trait loci;	chr9:105921319	chrX:126471705~126472403:+
LUAD	trans	rs6030712	0.802	rs112984321	ENSG00000211897.6	IGHG3	5.69	2.23e-08	0.0336	0.24	0.25	Height;	chr20:36979076	chr14:105769102~106038345:-
LUAD	trans	rs6424115	0.679	rs2076345	ENSG00000228217.1	AL390877.1	5.69	2.23e-08	0.0336	0.34	0.25	Immature fraction of reticulocytes;	chr1:23757004	chr1:117778087~117778506:-
LUAD	trans	rs12935229	0.756	rs2077813	ENSG00000249834.3	PGBD4P3	-5.69	2.23e-08	0.0336	-0.36	-0.25	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr16:77269885	chr5:148307298~148308258:+
LUAD	trans	rs7746199	0.736	rs13212093	ENSG00000281831.1	HCP5B	5.69	2.23e-08	0.0337	0.54	0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27638937	chr6:29871895~29873783:-
LUAD	trans	rs7746199	0.736	rs34038546	ENSG00000281831.1	HCP5B	5.69	2.23e-08	0.0337	0.54	0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27639881	chr6:29871895~29873783:-
LUAD	trans	rs141342723	1	rs141342723	ENSG00000281831.1	HCP5B	5.69	2.23e-08	0.0337	0.54	0.25	Autism spectrum disorder or schizophrenia;	chr6:27654305	chr6:29871895~29873783:-
LUAD	trans	rs7746199	0.736	rs34543938	ENSG00000281831.1	HCP5B	5.69	2.23e-08	0.0337	0.54	0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27656861	chr6:29871895~29873783:-
LUAD	trans	rs7746199	0.736	rs56405707	ENSG00000281831.1	HCP5B	5.69	2.23e-08	0.0337	0.54	0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27672467	chr6:29871895~29873783:-
LUAD	trans	rs853679	0.546	rs34546986	ENSG00000281831.1	HCP5B	5.69	2.24e-08	0.0338	0.58	0.25	Depression;	chr6:28394532	chr6:29871895~29873783:-
LUAD	trans	rs853679	0.546	rs34871267	ENSG00000281831.1	HCP5B	5.69	2.24e-08	0.0338	0.58	0.25	Depression;	chr6:28396455	chr6:29871895~29873783:-
LUAD	trans	rs853679	0.546	rs35883476	ENSG00000281831.1	HCP5B	5.69	2.24e-08	0.0338	0.58	0.25	Depression;	chr6:28400731	chr6:29871895~29873783:-
LUAD	trans	rs7412746	0.611	rs10888398	ENSG00000180764.13	PIPSL	5.69	2.24e-08	0.0338	0.28	0.25	Melanoma;	chr1:150914306	chr10:93958191~93961540:-
LUAD	trans	rs8077577	0.747	rs62072537	ENSG00000188933.13	USP32P1	5.69	2.24e-08	0.0338	0.35	0.25	Obesity-related traits;	chr17:18312786	chr17:16786489~16804455:+
LUAD	trans	rs7929679	0.545	rs2421740	ENSG00000225531.1	RP11-196I18.3	5.69	2.24e-08	0.0338	0.31	0.25	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34775207	chr9:107116829~107117557:+
LUAD	trans	rs7929679	0.571	rs2136508	ENSG00000225531.1	RP11-196I18.3	5.69	2.24e-08	0.0338	0.31	0.25	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34775299	chr9:107116829~107117557:+
LUAD	trans	rs7929679	0.571	rs10768099	ENSG00000225531.1	RP11-196I18.3	5.69	2.24e-08	0.0338	0.31	0.25	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34775787	chr9:107116829~107117557:+
LUAD	trans	rs7929679	0.571	rs10768100	ENSG00000225531.1	RP11-196I18.3	5.69	2.24e-08	0.0338	0.31	0.25	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34777388	chr9:107116829~107117557:+
LUAD	trans	rs7929679	0.571	rs11032860	ENSG00000225531.1	RP11-196I18.3	5.69	2.24e-08	0.0338	0.31	0.25	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34777798	chr9:107116829~107117557:+
LUAD	trans	rs7929679	0.521	rs10836307	ENSG00000225531.1	RP11-196I18.3	5.69	2.24e-08	0.0338	0.31	0.25	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34778681	chr9:107116829~107117557:+
LUAD	trans	rs546131	0.642	rs579926	ENSG00000225531.1	RP11-196I18.3	5.69	2.24e-08	0.0338	0.34	0.25	Lung disease severity in cystic fibrosis;	chr11:34831608	chr9:107116829~107117557:+
LUAD	trans	rs6087990	0.584	rs6058897	ENSG00000253915.1	MAPRE1P1	-5.69	2.25e-08	0.0339	-0.29	-0.25	Ulcerative colitis;	chr20:32810299	chr8:135625185~135625981:-
LUAD	trans	rs17433710	0.929	rs17486566	ENSG00000225057.2	AC096574.4	5.69	2.25e-08	0.0339	0.36	0.25	Dupuytren's disease;	chr1:162700674	chr2:238231684~238255633:+
LUAD	trans	rs28673968	0.72	rs1390281	ENSG00000214846.4	RP11-115L11.1	5.69	2.25e-08	0.0339	0.51	0.25	Idiopathic pulmonary fibrosis;	chr4:89590948	chr4:15730962~15731627:-
LUAD	trans	rs4920799	0.68	rs305738	ENSG00000237484.5	AP000476.1	-5.69	2.25e-08	0.034	-0.28	-0.25	Echocardiographic traits;	chr5:85340939	chr21:24428740~24547942:+
LUAD	trans	rs4920799	0.793	rs305741	ENSG00000237484.5	AP000476.1	-5.69	2.25e-08	0.034	-0.28	-0.25	Echocardiographic traits;	chr5:85341180	chr21:24428740~24547942:+
LUAD	trans	rs4920799	0.793	rs247685	ENSG00000237484.5	AP000476.1	-5.69	2.25e-08	0.034	-0.28	-0.25	Echocardiographic traits;	chr5:85342248	chr21:24428740~24547942:+
LUAD	trans	rs4920799	0.793	rs160093	ENSG00000237484.5	AP000476.1	-5.69	2.25e-08	0.034	-0.28	-0.25	Echocardiographic traits;	chr5:85342413	chr21:24428740~24547942:+
LUAD	trans	rs4920799	0.793	rs185060	ENSG00000237484.5	AP000476.1	-5.69	2.25e-08	0.034	-0.28	-0.25	Echocardiographic traits;	chr5:85344211	chr21:24428740~24547942:+
LUAD	trans	rs4920799	0.793	rs247686	ENSG00000237484.5	AP000476.1	-5.69	2.25e-08	0.034	-0.28	-0.25	Echocardiographic traits;	chr5:85344679	chr21:24428740~24547942:+
LUAD	trans	rs393155	0.517	rs330050	ENSG00000253893.2	FAM85B	5.69	2.25e-08	0.034	0.32	0.25	Neuroticism;	chr8:9230169	chr8:8167819~8226614:-
LUAD	trans	rs7260598	0.642	rs10405341	ENSG00000261770.1	CTC-459F4.1	5.69	2.26e-08	0.034	0.38	0.25	Response to taxane treatment (placlitaxel);	chr19:23924450	chr19:27757184~27760849:-
LUAD	trans	rs7819412	0.522	rs11776603	ENSG00000253893.2	FAM85B	5.69	2.26e-08	0.034	0.31	0.25	Triglycerides;	chr8:11162803	chr8:8167819~8226614:-
LUAD	trans	rs10242455	0.867	rs2740565	ENSG00000228834.1	RP11-249L21.4	5.69	2.26e-08	0.034	0.47	0.25	Blood metabolite levels;	chr7:99695852	chr6:108907615~108907873:-
LUAD	trans	rs6673267	0.869	rs10920094	ENSG00000244144.1	RP11-757F18.3	-5.69	2.27e-08	0.0342	-0.29	-0.25	Lobe attachment (rater-scored or self-reported);	chr1:201011868	chr3:112185480~112185998:-
LUAD	trans	rs700059	0.689	rs1089996	ENSG00000232177.1	MTND4P24	-5.69	2.27e-08	0.0342	-0.3	-0.25	Birth weight;	chr9:123201905	chrX:126472885~126473281:+
LUAD	trans	rs10736455	1	rs4936355	ENSG00000268027.4	AC006129.2	5.69	2.27e-08	0.0342	0.34	0.25	Major depressive disorder;	chr11:111187279	chr19:41545192~41555462:+
LUAD	trans	rs351855	0.642	rs2546095	ENSG00000217325.2	PRELID1P1	5.68	2.27e-08	0.0342	0.29	0.25	Waist-to-hip ratio adjusted for body mass index;	chr5:177082583	chr6:126643488~126644390:+
LUAD	trans	rs864643	0.678	rs1629282	ENSG00000183298.5	RP11-556K13.1	-5.68	2.27e-08	0.0343	-0.35	-0.25	Attention deficit hyperactivity disorder;	chr3:39491770	chr1:101786340~101787219:-
LUAD	trans	rs2419374	0.793	rs9651058	ENSG00000256210.3	AC005255.3	-5.68	2.28e-08	0.0343	-0.33	-0.25	Suicide ideation score in major depressive disorder;	chr1:190094437	chr19:14792318~14792533:+
LUAD	trans	rs13416322	1	rs13427398	ENSG00000214286.2	PDCL3P3	5.68	2.28e-08	0.0343	0.35	0.25	Intelligence (multi-trait analysis);	chr2:100440109	chr3:17877455~17878169:-
LUAD	trans	rs4948102	0.924	rs13241866	ENSG00000186940.6	CHCHD2P9	-5.68	2.28e-08	0.0343	-0.3	-0.25	Plasma homocysteine levels (post-methionine load test);	chr7:56023185	chr9:79391304~79391759:+
LUAD	trans	rs13177918	0.677	rs57890152	ENSG00000226396.1	RP5-1056L3.3	5.68	2.28e-08	0.0343	0.27	0.25	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr1:19608114~19608568:+
LUAD	trans	rs13177918	0.686	rs12654827	ENSG00000226396.1	RP5-1056L3.3	5.68	2.28e-08	0.0343	0.27	0.25	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr1:19608114~19608568:+
LUAD	trans	rs13177918	0.677	rs13160685	ENSG00000226396.1	RP5-1056L3.3	5.68	2.28e-08	0.0343	0.27	0.25	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr1:19608114~19608568:+
LUAD	trans	rs7984972	1	rs9531974	ENSG00000251600.4	RP11-673E1.1	-5.68	2.29e-08	0.0345	-0.28	-0.25	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);	chr13:31432752	chr4:143912331~143982454:+
LUAD	trans	rs3812762	0.912	rs10769954	ENSG00000266891.1	RP11-692N5.2	-5.68	2.29e-08	0.0345	-0.33	-0.25	Hypospadias;	chr11:8762166	chr18:9734882~9735602:-
LUAD	trans	rs2070677	0.542	rs7086127	ENSG00000250148.1	KRT8P31	-5.68	2.3e-08	0.0345	-0.4	-0.25	Gout;	chr10:133580227	chr5:60743563~60744970:-
LUAD	trans	rs12439619	0.81	rs28876157	ENSG00000259295.5	CSPG4P12	-5.68	2.3e-08	0.0346	-0.35	-0.25	Intelligence (multi-trait analysis);	chr15:82216708	chr15:85191438~85213905:+
LUAD	trans	rs13416322	0.945	rs13398213	ENSG00000214286.2	PDCL3P3	5.68	2.3e-08	0.0346	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100448637	chr3:17877455~17878169:-
LUAD	trans	rs17433710	0.929	rs16843630	ENSG00000225057.2	AC096574.4	5.68	2.3e-08	0.0346	0.35	0.25	Dupuytren's disease;	chr1:162700253	chr2:238231684~238255633:+
LUAD	trans	rs795943	0.877	rs795944	ENSG00000131797.11	CLUHP3	-5.68	2.31e-08	0.0347	-0.27	-0.25	Neurocognitive impairment in HIV-1 infection (dichotomous);	chr12:78268527	chr16:31700590~31711986:+
LUAD	trans	rs889398	0.677	rs68161338	ENSG00000257513.6	NPIPB1P	-5.68	2.31e-08	0.0348	-0.25	-0.25	Body mass index;	chr16:69789875	chr18:11619509~11639699:-
LUAD	trans	rs7647973	0.848	rs4955426	ENSG00000197582.5	GPX1P1	5.68	2.32e-08	0.0348	0.39	0.25	Menarche (age at onset);	chr3:49106005	chrX:13378735~13379340:-
LUAD	trans	rs2302464	1	rs12651052	ENSG00000280111.1	CTA-292E10.9	5.68	2.32e-08	0.0348	0.42	0.25	Cerebrospinal fluid biomarker levels;	chr4:15726813	chr22:28784360~28809287:+
LUAD	trans	rs2302464	1	rs56381553	ENSG00000280111.1	CTA-292E10.9	5.68	2.32e-08	0.0348	0.42	0.25	Cerebrospinal fluid biomarker levels;	chr4:15726824	chr22:28784360~28809287:+
LUAD	trans	rs2302464	1	rs12645513	ENSG00000280111.1	CTA-292E10.9	5.68	2.32e-08	0.0348	0.42	0.25	Cerebrospinal fluid biomarker levels;	chr4:15727155	chr22:28784360~28809287:+
LUAD	trans	rs2302464	1	rs58335439	ENSG00000280111.1	CTA-292E10.9	5.68	2.32e-08	0.0348	0.42	0.25	Cerebrospinal fluid biomarker levels;	chr4:15727183	chr22:28784360~28809287:+
LUAD	trans	rs2302464	1	rs73123625	ENSG00000280111.1	CTA-292E10.9	5.68	2.32e-08	0.0348	0.42	0.25	Cerebrospinal fluid biomarker levels;	chr4:15727550	chr22:28784360~28809287:+
LUAD	trans	rs6915893	1	rs4294009	ENSG00000267156.1	TPMTP1	5.68	2.32e-08	0.0349	0.3	0.25	Intrinsic epigenetic age acceleration;	chr6:18105845	chr18:47630112~47630848:+
LUAD	trans	rs4906172	0.773	rs1004904	ENSG00000181359.5	HSP90AA6P	-5.68	2.33e-08	0.0349	-0.29	-0.25	Menopause (age at onset);	chr14:102048834	chr4:170581470~170605450:-
LUAD	trans	rs4906172	0.812	rs1190610	ENSG00000181359.5	HSP90AA6P	-5.68	2.33e-08	0.035	-0.28	-0.25	Menopause (age at onset);	chr14:102052637	chr4:170581470~170605450:-
LUAD	trans	rs73198271	0.96	rs73198288	ENSG00000273129.1	PACERR	5.68	2.35e-08	0.0352	0.34	0.25	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8756430	chr1:186680622~186681446:+
LUAD	trans	rs255788	0.92	rs17146113	ENSG00000238005.2	RP11-443B7.1	5.68	2.35e-08	0.0352	0.41	0.25	Response to platinum-based chemotherapy (carboplatin);	chr5:120112454	chr1:234957342~234970062:-
LUAD	trans	rs2294426	0.766	rs9366877	ENSG00000245904.3	RP11-796E2.4	5.68	2.35e-08	0.0353	0.26	0.25	Orofacial clefts (maternal alcohol consumption interaction);	chr6:11730645	chr12:92145573~92189660:+
LUAD	trans	rs1190596	0.558	rs3087686	ENSG00000181359.5	HSP90AA6P	-5.68	2.36e-08	0.0354	-0.27	-0.25	Behavioural disinhibition (generation interaction);	chr14:102229226	chr4:170581470~170605450:-
LUAD	trans	rs9876781	1	rs9812647	ENSG00000225528.1	RP3-370M22.8	5.68	2.37e-08	0.0355	0.26	0.25	Longevity;	chr3:48407507	chr22:39960397~39964683:+
LUAD	trans	rs9876781	1	rs13076076	ENSG00000225528.1	RP3-370M22.8	-5.68	2.37e-08	0.0355	-0.25	-0.25	Longevity;	chr3:48437629	chr22:39960397~39964683:+
LUAD	trans	rs10487112	0.536	rs7779628	ENSG00000219133.2	RP11-203F10.6	-5.68	2.37e-08	0.0355	-0.31	-0.25	Perceived unattractiveness to mosquitoes;	chr7:90377944	chr1:204346776~204347258:-
LUAD	trans	rs7342953	0.579	rs9901108	ENSG00000236824.1	BCYRN1	-5.68	2.37e-08	0.0355	-0.4	-0.25	Large artery stroke;	chr17:65195800	chr2:47331060~47344517:+
LUAD	trans	rs7412746	0.563	rs3768013	ENSG00000180764.13	PIPSL	-5.68	2.37e-08	0.0355	-0.28	-0.25	Melanoma;	chr1:150842935	chr10:93958191~93961540:-
LUAD	trans	rs7833986	0.501	rs2719261	ENSG00000236862.1	RPS20P24	5.68	2.38e-08	0.0356	0.3	0.25	Height;	chr8:56029423	chr9:72655832~72656192:-
LUAD	trans	rs7833986	0.501	rs72653941	ENSG00000236862.1	RPS20P24	5.68	2.38e-08	0.0356	0.3	0.25	Height;	chr8:56029688	chr9:72655832~72656192:-
LUAD	trans	rs313426	0.51	rs2671399	ENSG00000263219.1	RYKP1	5.68	2.38e-08	0.0357	0.3	0.25	Toenail selenium levels;	chr11:103386034	chr17:4222091~4223828:+
LUAD	trans	rs313426	0.569	rs2566939	ENSG00000263219.1	RYKP1	5.68	2.39e-08	0.0357	0.3	0.25	Toenail selenium levels;	chr11:103384008	chr17:4222091~4223828:+
LUAD	trans	rs1023500	1	rs3752591	ENSG00000268568.1	AC007228.9	-5.68	2.39e-08	0.0358	-0.37	-0.25	Schizophrenia;	chr22:41943512	chr19:56672574~56673901:-
LUAD	trans	rs925255	0.711	rs12478126	ENSG00000196114.3	RP3-391O22.3	5.68	2.39e-08	0.0358	0.32	0.25	Inflammatory bowel disease;Crohn's disease;	chr2:28423081	chr6:34576258~34576656:-
LUAD	trans	rs2898290	0.54	rs35005793	ENSG00000253893.2	FAM85B	-5.68	2.4e-08	0.0359	-0.32	-0.25	Systolic blood pressure;	chr8:11592963	chr8:8167819~8226614:-
LUAD	trans	rs9322369	1	rs9322369	ENSG00000228519.3	RP11-298C3.2	5.67	2.4e-08	0.036	0.24	0.25	Post bronchodilator FEV1;	chr6:152346796	chrX:25645722~25646327:-
LUAD	trans	rs1553477	0.747	rs10045465	ENSG00000280055.1	TMEM75	-5.67	2.41e-08	0.0361	-0.26	-0.25	Monobrow;	chr5:53848207	chr8:127946559~127948723:-
LUAD	trans	rs1553477	0.727	rs10037842	ENSG00000280055.1	TMEM75	-5.67	2.41e-08	0.0361	-0.26	-0.25	Monobrow;	chr5:53848239	chr8:127946559~127948723:-
LUAD	trans	rs2060793	0.601	rs35321904	ENSG00000236360.2	RP11-334A14.2	5.67	2.42e-08	0.0362	0.33	0.25	Vitamin D levels;	chr11:14854914	chr1:52993201~52993702:-
LUAD	trans	rs453301	0.571	rs330054	ENSG00000253893.2	FAM85B	5.67	2.42e-08	0.0362	0.32	0.25	Joint mobility (Beighton score);	chr8:9230781	chr8:8167819~8226614:-
LUAD	trans	rs9876781	1	rs11130171	ENSG00000225528.1	RP3-370M22.8	-5.67	2.42e-08	0.0362	-0.25	-0.25	Longevity;	chr3:48421052	chr22:39960397~39964683:+
LUAD	trans	rs7032940	0.677	rs1331310	ENSG00000262519.1	TXNP4	5.67	2.42e-08	0.0362	0.3	0.25	Height;	chr9:110179601	chr17:4572206~4572515:+
LUAD	trans	rs3812762	0.833	rs10500705	ENSG00000266891.1	RP11-692N5.2	5.67	2.42e-08	0.0362	0.33	0.25	Hypospadias;	chr11:8783714	chr18:9734882~9735602:-
LUAD	trans	rs9876781	1	rs9883927	ENSG00000225528.1	RP3-370M22.8	-5.67	2.43e-08	0.0363	-0.25	-0.25	Longevity;	chr3:48422302	chr22:39960397~39964683:+
LUAD	trans	rs9876781	1	rs9817615	ENSG00000225528.1	RP3-370M22.8	-5.67	2.43e-08	0.0363	-0.25	-0.25	Longevity;	chr3:48429347	chr22:39960397~39964683:+
LUAD	trans	rs9876781	1	rs2290822	ENSG00000225528.1	RP3-370M22.8	-5.67	2.43e-08	0.0363	-0.25	-0.25	Longevity;	chr3:48431794	chr22:39960397~39964683:+
LUAD	trans	rs929843	1	rs929843	ENSG00000196796.5	CTB-134H23.2	5.67	2.44e-08	0.0364	0.28	0.25	Menarche (age at onset);	chr16:70011845	chr16:29038655~29052726:+
LUAD	trans	rs2899832	1	rs2899832	ENSG00000229083.1	PSMA6P2	5.67	2.44e-08	0.0365	0.33	0.25	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35271735	chrX:12825840~12826833:+
LUAD	trans	rs9467773	0.529	rs7356988	ENSG00000242375.1	RP11-498P14.3	-5.67	2.44e-08	0.0365	-0.33	-0.25	Intelligence (multi-trait analysis);	chr6:26396499	chr9:97195351~97197687:-
LUAD	trans	rs7312933	0.51	rs10880223	ENSG00000223551.1	TMSB4XP4	5.67	2.44e-08	0.0365	0.26	0.25	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr12:42019641	chr9:128342153~128342770:+
LUAD	trans	rs740160	0.558	rs73395508	ENSG00000228834.1	RP11-249L21.4	5.67	2.44e-08	0.0365	0.49	0.25	Dehydroepiandrosterone sulphate levels;	chr7:99304271	chr6:108907615~108907873:-
LUAD	trans	rs740160	0.558	rs68164591	ENSG00000228834.1	RP11-249L21.4	5.67	2.44e-08	0.0365	0.49	0.25	Dehydroepiandrosterone sulphate levels;	chr7:99306817	chr6:108907615~108907873:-
LUAD	trans	rs73108077	0.79	rs73104050	ENSG00000279352.1	RP11-411B10.7	5.67	2.45e-08	0.0366	0.49	0.25	Red blood cell density in sickle cell anemia;	chr20:31289961	chr18:14010054~14010917:+
LUAD	trans	rs73108077	0.79	rs73104055	ENSG00000279352.1	RP11-411B10.7	5.67	2.45e-08	0.0366	0.49	0.25	Red blood cell density in sickle cell anemia;	chr20:31293082	chr18:14010054~14010917:+
LUAD	trans	rs8014252	0.518	rs58919501	ENSG00000269072.1	CTD-3187F8.14	5.67	2.45e-08	0.0366	0.45	0.25	Plasma estrone levels in resected estrogen-receptor positive breast cancer;	chr14:70602305	chr19:51152923~51181966:-
LUAD	trans	rs864643	0.947	rs6762335	ENSG00000183298.5	RP11-556K13.1	5.67	2.46e-08	0.0367	0.36	0.25	Attention deficit hyperactivity disorder;	chr3:39496043	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.947	rs6762416	ENSG00000183298.5	RP11-556K13.1	5.67	2.46e-08	0.0367	0.36	0.25	Attention deficit hyperactivity disorder;	chr3:39496111	chr1:101786340~101787219:-
LUAD	trans	rs9329221	0.527	rs6989657	ENSG00000253981.4	ALG1L13P	5.67	2.46e-08	0.0368	0.28	0.25	Neuroticism;	chr8:10473363	chr8:8236003~8244667:-
LUAD	trans	rs7412746	0.658	rs7526489	ENSG00000180764.13	PIPSL	-5.67	2.47e-08	0.0369	-0.29	-0.25	Melanoma;	chr1:150753762	chr10:93958191~93961540:-
LUAD	trans	rs962856	0.515	rs588454	ENSG00000179082.3	C9orf106	-5.67	2.47e-08	0.0369	-0.28	-0.25	Pancreatic cancer;	chr2:67451550	chr9:129321016~129324905:+
LUAD	trans	rs5758511	0.573	rs738248	ENSG00000268568.1	AC007228.9	-5.67	2.47e-08	0.0369	-0.34	-0.25	Birth weight;	chr22:41800463	chr19:56672574~56673901:-
LUAD	trans	rs5758511	0.541	rs6002494	ENSG00000268568.1	AC007228.9	-5.67	2.47e-08	0.0369	-0.34	-0.25	Birth weight;	chr22:41803856	chr19:56672574~56673901:-
LUAD	trans	rs5758511	0.573	rs5996069	ENSG00000268568.1	AC007228.9	-5.67	2.47e-08	0.0369	-0.34	-0.25	Birth weight;	chr22:41805181	chr19:56672574~56673901:-
LUAD	trans	rs6673267	0.869	rs6687260	ENSG00000244144.1	RP11-757F18.3	-5.67	2.48e-08	0.037	-0.29	-0.25	Lobe attachment (rater-scored or self-reported);	chr1:201011570	chr3:112185480~112185998:-
LUAD	trans	rs7260598	0.642	rs10425299	ENSG00000261770.1	CTC-459F4.1	5.67	2.48e-08	0.037	0.37	0.25	Response to taxane treatment (placlitaxel);	chr19:23995757	chr19:27757184~27760849:-
LUAD	trans	rs3812762	0.871	rs3844100	ENSG00000266891.1	RP11-692N5.2	-5.67	2.48e-08	0.037	-0.32	-0.25	Hypospadias;	chr11:8796261	chr18:9734882~9735602:-
LUAD	trans	rs73198271	0.813	rs56007835	ENSG00000273129.1	PACERR	5.67	2.48e-08	0.037	0.32	0.25	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8752516	chr1:186680622~186681446:+
LUAD	trans	rs255788	0.85	rs7707595	ENSG00000238005.2	RP11-443B7.1	5.67	2.48e-08	0.037	0.41	0.25	Response to platinum-based chemotherapy (carboplatin);	chr5:120126257	chr1:234957342~234970062:-
LUAD	trans	rs714543	0.934	rs10275962	ENSG00000226038.5	PPIAP21	-5.67	2.48e-08	0.037	-0.28	-0.25	Plateletcrit;	chr7:44809141	chr20:43230760~43231260:+
LUAD	trans	rs66887589	0.934	rs12648182	ENSG00000275858.1	RP11-291L22.8	-5.67	2.49e-08	0.0371	-0.26	-0.25	Diastolic blood pressure;	chr4:119582736	chr10:38450738~38451069:-
LUAD	trans	rs2899832	0.866	rs73239074	ENSG00000229083.1	PSMA6P2	5.67	2.49e-08	0.0371	0.33	0.25	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35280886	chrX:12825840~12826833:+
LUAD	trans	rs714543	0.967	rs11762008	ENSG00000226038.5	PPIAP21	-5.67	2.5e-08	0.0372	-0.28	-0.25	Plateletcrit;	chr7:44864065	chr20:43230760~43231260:+
LUAD	trans	rs10767971	0.692	rs197705	ENSG00000265724.1	MIR4284	5.67	2.5e-08	0.0373	0.23	0.25	Parkinson's disease (age of onset);	chr11:32822756	chr7:73711317~73711397:+
LUAD	trans	rs9329221	0.662	rs11249996	ENSG00000253893.2	FAM85B	5.67	2.51e-08	0.0373	0.32	0.25	Neuroticism;	chr8:10387953	chr8:8167819~8226614:-
LUAD	trans	rs354225	0.608	rs168505	ENSG00000255649.1	RP11-502N13.2	5.67	2.52e-08	0.0376	0.28	0.25	Schizophrenia;	chr2:54693831	chr12:14530151~14533229:+
LUAD	trans	rs8087799	0.522	rs11660602	ENSG00000281538.1	RP4-669P10.20	5.66	2.56e-08	0.038	0.26	0.25	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr18:22579593	chr22:42138060~42139726:+
LUAD	trans	rs8087799	0.522	rs11660800	ENSG00000281538.1	RP4-669P10.20	5.66	2.56e-08	0.038	0.26	0.25	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr18:22579680	chr22:42138060~42139726:+
LUAD	trans	rs282544	1	rs12186752	ENSG00000231752.4	EMBP1	-5.66	2.56e-08	0.038	-0.35	-0.25	Myopia (pathological);	chr5:50697648	chr1:121519112~121571892:+
LUAD	trans	rs7773456	0.74	rs6917179	ENSG00000257497.2	RP11-585P4.5	-5.66	2.56e-08	0.038	-0.34	-0.25	Lupus nephritis in systemic lupus erythematosus;	chr6:19817570	chr12:75483454~75489820:-
LUAD	trans	rs4713118	0.696	rs2394002	ENSG00000204709.4	LINC01556	5.66	2.56e-08	0.0381	0.33	0.25	Parkinson's disease;	chr6:27780236	chr6:28943877~28944537:+
LUAD	trans	rs13416322	0.945	rs12617044	ENSG00000214286.2	PDCL3P3	5.66	2.56e-08	0.0381	0.35	0.25	Intelligence (multi-trait analysis);	chr2:100453306	chr3:17877455~17878169:-
LUAD	trans	rs9329221	0.527	rs34308302	ENSG00000253981.4	ALG1L13P	-5.66	2.56e-08	0.0381	-0.28	-0.25	Neuroticism;	chr8:10474512	chr8:8236003~8244667:-
LUAD	trans	rs962856	0.537	rs619884	ENSG00000179082.3	C9orf106	-5.66	2.56e-08	0.0381	-0.28	-0.25	Pancreatic cancer;	chr2:67451180	chr9:129321016~129324905:+
LUAD	trans	rs3812762	0.871	rs10734637	ENSG00000266891.1	RP11-692N5.2	-5.66	2.56e-08	0.0381	-0.32	-0.25	Hypospadias;	chr11:8766678	chr18:9734882~9735602:-
LUAD	trans	rs8177253	0.574	rs6775042	ENSG00000256243.2	RPL7AP3	5.66	2.57e-08	0.0381	0.29	0.25	Iron status biomarkers;	chr3:133723401	chr14:35235180~35235651:-
LUAD	trans	rs61041336	1	rs61041336	ENSG00000233719.3	GOT2P3	-5.66	2.57e-08	0.0381	-0.44	-0.25	Neuritic plaque;	chr16:58699258	chr12:9641802~9643007:+
LUAD	trans	rs950394	1	rs17029753	ENSG00000231682.1	AC097713.4	5.66	2.57e-08	0.0382	0.31	0.25	Schizophrenia;	chr2:104365522	chr2:234444590~234454595:-
LUAD	trans	rs6673267	0.904	rs6427870	ENSG00000244144.1	RP11-757F18.3	-5.66	2.57e-08	0.0382	-0.29	-0.25	Lobe attachment (rater-scored or self-reported);	chr1:201027061	chr3:112185480~112185998:-
LUAD	trans	rs1563304	1	rs1563304	ENSG00000214425.5	LRRC37A4P	-5.66	2.59e-08	0.0384	-0.41	-0.25	Neuroticism;	chr17:46797087	chr17:45506741~45550335:-
LUAD	trans	rs71403859	0.502	rs71403849	ENSG00000265407.1	MIR4324	5.66	2.6e-08	0.0385	0.4	0.25	Post bronchodilator FEV1;	chr16:71450462	chr19:49308797~49308868:-
LUAD	trans	rs9843304	0.528	rs12488846	ENSG00000220842.6	RP11-572P18.1	-5.66	2.62e-08	0.0388	-0.26	-0.25	Gallstone disease;	chr3:149468274	chr10:120354701~120355183:-
LUAD	trans	rs9575182	1	rs9565807	ENSG00000228763.1	AC010095.5	5.66	2.63e-08	0.039	0.29	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr13:82776251	chr2:108676795~108678601:-
LUAD	trans	rs10129255	0.872	rs8015406	ENSG00000213538.5	KRT8P41	5.66	2.65e-08	0.0392	0.34	0.25	Kawasaki disease;	chr14:106670611	chr11:9094377~9095890:+
LUAD	trans	rs13416322	0.945	rs57179311	ENSG00000214286.2	PDCL3P3	5.66	2.65e-08	0.0392	0.35	0.25	Intelligence (multi-trait analysis);	chr2:100449243	chr3:17877455~17878169:-
LUAD	trans	rs300890	0.507	rs1397526	ENSG00000250938.4	RP11-679C8.2	5.66	2.66e-08	0.0393	0.3	0.25	Nasopharyngeal carcinoma;	chr4:143405256	chr4:120066958~120416766:+
LUAD	trans	rs79149102	0.522	rs7170734	ENSG00000227288.3	RP5-837I24.1	5.66	2.66e-08	0.0393	0.49	0.25	Lung cancer;	chr15:74697065	chr1:81501794~81503468:+
LUAD	trans	rs950394	1	rs77071600	ENSG00000231682.1	AC097713.4	-5.66	2.66e-08	0.0394	-0.32	-0.25	Schizophrenia;	chr2:104364236	chr2:234444590~234454595:-
LUAD	trans	rs3779195	0.929	rs10953259	ENSG00000230273.1	AC087163.3	-5.66	2.67e-08	0.0395	-0.35	-0.25	Sex hormone-binding globulin levels;	chr7:98383795	chr17:17981192~17981572:-
LUAD	trans	rs12145833	0.85	rs2490392	ENSG00000154608.12	CEP170P1	5.66	2.67e-08	0.0395	0.35	0.25	Obesity (early onset extreme);	chr1:243299221	chr4:118467590~118554204:+
LUAD	trans	rs10484434	0.818	rs11755492	ENSG00000279622.1	RP11-254F19.4	5.66	2.67e-08	0.0395	0.43	0.25	HIV-1 viral setpoint;	chr6:26045930	chr16:84917377~84919923:-
LUAD	trans	rs12982903	1	rs543519	ENSG00000189166.6	TNRC18P3	5.66	2.67e-08	0.0395	0.5	0.25	Heart rate variability traits (SDNN);	chr19:5906384	chr7:56991888~57009149:+
LUAD	trans	rs2885805	1	rs2885805	ENSG00000219693.3	RP11-262H14.11	-5.65	2.68e-08	0.0396	-0.35	-0.25	Cytomegalovirus antibody response;	chr1:110875293	chr9:62888535~62889921:+
LUAD	trans	rs7573615	0.777	rs1533076	ENSG00000269102.1	CTD-2525I3.5	5.65	2.69e-08	0.0397	0.32	0.25	Post bronchodilator FEV1/FVC ratio;	chr2:52982941	chr19:52284780~52297920:-
LUAD	trans	rs61680841	1	rs62026609	ENSG00000271743.1	CTD-2541M15.3	-5.65	2.69e-08	0.0398	-0.63	-0.25	Age-related hearing impairment;	chr15:91272538	chr8:6615604~6617198:-
LUAD	trans	rs877636	0.74	rs772920	ENSG00000243538.1	CTB-55B8.1	5.65	2.69e-08	0.0398	0.29	0.25	Cognitive function;	chr12:55996580	chr5:16902294~16902641:-
LUAD	trans	rs6831352	0.693	rs2602875	ENSG00000233859.2	ADH5P4	-5.65	2.69e-08	0.0398	-0.27	-0.25	Alcohol dependence;	chr4:99118344	chr6:65836930~65838039:-
LUAD	trans	rs6831352	0.703	rs4235435	ENSG00000233859.2	ADH5P4	-5.65	2.69e-08	0.0398	-0.27	-0.25	Alcohol dependence;	chr4:99118427	chr6:65836930~65838039:-
LUAD	trans	rs73108077	0.79	rs8122544	ENSG00000279352.1	RP11-411B10.7	5.65	2.7e-08	0.0399	0.48	0.25	Red blood cell density in sickle cell anemia;	chr20:31346428	chr18:14010054~14010917:+
LUAD	trans	rs2419374	0.793	rs1418811	ENSG00000256210.3	AC005255.3	-5.65	2.7e-08	0.0399	-0.33	-0.25	Suicide ideation score in major depressive disorder;	chr1:190095035	chr19:14792318~14792533:+
LUAD	trans	rs12200782	0.932	rs12189841	ENSG00000242375.1	RP11-498P14.3	-5.65	2.71e-08	0.04	-0.57	-0.25	Small cell lung carcinoma;	chr6:26544570	chr9:97195351~97197687:-
LUAD	trans	rs6755404	0.54	rs17403136	ENSG00000232869.2	TRBV29-1	5.65	2.71e-08	0.04	0.25	0.25	Malaria;	chr2:185178166	chr7:142740206~142740894:+
LUAD	trans	rs9393777	0.778	rs35741362	ENSG00000204709.4	LINC01556	5.65	2.71e-08	0.0401	0.45	0.25	Intelligence (multi-trait analysis);	chr6:27039908	chr6:28943877~28944537:+
LUAD	trans	rs12200782	1	rs72843802	ENSG00000242375.1	RP11-498P14.3	-5.65	2.72e-08	0.0401	-0.58	-0.25	Small cell lung carcinoma;	chr6:26517287	chr9:97195351~97197687:-
LUAD	trans	rs12200782	0.674	rs12207224	ENSG00000242375.1	RP11-498P14.3	-5.65	2.72e-08	0.0401	-0.58	-0.25	Small cell lung carcinoma;	chr6:26519052	chr9:97195351~97197687:-
LUAD	trans	rs9329221	0.662	rs35472251	ENSG00000253893.2	FAM85B	-5.65	2.74e-08	0.0404	-0.33	-0.25	Neuroticism;	chr8:10389159	chr8:8167819~8226614:-
LUAD	trans	rs3812762	0.879	rs3763920	ENSG00000266891.1	RP11-692N5.2	5.65	2.74e-08	0.0405	0.32	0.25	Hypospadias;	chr11:8787040	chr18:9734882~9735602:-
LUAD	trans	rs6498068	0.633	rs7194566	ENSG00000278702.1	Metazoa_SRP	5.65	2.75e-08	0.0405	0.35	0.25	Metabolite levels (MHPG);	chr16:10532140	chr1:35399997~35400319:+
LUAD	trans	rs889398	0.802	rs12925700	ENSG00000257513.6	NPIPB1P	-5.65	2.75e-08	0.0406	-0.25	-0.25	Body mass index;	chr16:69759560	chr18:11619509~11639699:-
LUAD	trans	rs73108077	0.79	rs73104064	ENSG00000279352.1	RP11-411B10.7	5.65	2.76e-08	0.0407	0.49	0.25	Red blood cell density in sickle cell anemia;	chr20:31297920	chr18:14010054~14010917:+
LUAD	trans	rs73108077	0.79	rs73104067	ENSG00000279352.1	RP11-411B10.7	5.65	2.76e-08	0.0407	0.49	0.25	Red blood cell density in sickle cell anemia;	chr20:31298693	chr18:14010054~14010917:+
LUAD	trans	rs9393777	0.841	rs67092078	ENSG00000204709.4	LINC01556	5.65	2.77e-08	0.0407	0.57	0.25	Intelligence (multi-trait analysis);	chr6:27086993	chr6:28943877~28944537:+
LUAD	trans	rs864643	0.947	rs1708073	ENSG00000183298.5	RP11-556K13.1	5.65	2.77e-08	0.0408	0.37	0.25	Attention deficit hyperactivity disorder;	chr3:39501530	chr1:101786340~101787219:-
LUAD	trans	rs9876781	1	rs3214041	ENSG00000225528.1	RP3-370M22.8	-5.65	2.77e-08	0.0408	-0.25	-0.25	Longevity;	chr3:48413059	chr22:39960397~39964683:+
LUAD	trans	rs9575182	1	rs9318909	ENSG00000228763.1	AC010095.5	5.65	2.78e-08	0.0409	0.29	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr13:82785956	chr2:108676795~108678601:-
LUAD	trans	rs9575182	1	rs9575171	ENSG00000228763.1	AC010095.5	5.65	2.78e-08	0.0409	0.29	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr13:82786342	chr2:108676795~108678601:-
LUAD	trans	rs282544	1	rs4548483	ENSG00000231752.4	EMBP1	-5.65	2.78e-08	0.0409	-0.35	-0.25	Myopia (pathological);	chr5:50703291	chr1:121519112~121571892:+
LUAD	trans	rs10115586	0.854	rs7045671	ENSG00000266750.1	MIR4645	-5.65	2.78e-08	0.041	-0.31	-0.25	IgG glycosylation;	chr9:117783530	chr6:2854031~2854107:-
LUAD	trans	rs7647973	0.925	rs4384984	ENSG00000197582.5	GPX1P1	5.65	2.79e-08	0.041	0.34	0.25	Menarche (age at onset);	chr3:49252445	chrX:13378735~13379340:-
LUAD	trans	rs3812762	0.871	rs3862352	ENSG00000266891.1	RP11-692N5.2	5.65	2.79e-08	0.0411	0.33	0.25	Hypospadias;	chr11:8796473	chr18:9734882~9735602:-
LUAD	trans	rs545610	0.505	rs11606309	ENSG00000261105.4	LMO7-AS1	-5.65	2.8e-08	0.0412	-0.36	-0.25	Dental caries;	chr11:30513628	chr13:75604700~75635994:-
LUAD	trans	rs3812762	0.917	rs2873297	ENSG00000266891.1	RP11-692N5.2	-5.65	2.8e-08	0.0412	-0.32	-0.25	Hypospadias;	chr11:8769680	chr18:9734882~9735602:-
LUAD	trans	rs7618501	0.516	rs2856236	ENSG00000197582.5	GPX1P1	-5.65	2.8e-08	0.0412	-0.34	-0.25	Intelligence (multi-trait analysis);	chr3:50124284	chrX:13378735~13379340:-
LUAD	trans	rs6940638	0.688	rs1028308	ENSG00000204709.4	LINC01556	5.65	2.8e-08	0.0412	0.31	0.25	Intelligence (multi-trait analysis);	chr6:27161978	chr6:28943877~28944537:+
LUAD	trans	rs8177253	0.665	rs12639304	ENSG00000256243.2	RPL7AP3	5.65	2.8e-08	0.0412	0.29	0.25	Iron status biomarkers;	chr3:133722750	chr14:35235180~35235651:-
LUAD	trans	rs8177253	0.665	rs10935074	ENSG00000256243.2	RPL7AP3	5.65	2.8e-08	0.0412	0.29	0.25	Iron status biomarkers;	chr3:133722848	chr14:35235180~35235651:-
LUAD	trans	rs2419374	0.753	rs10920500	ENSG00000256210.3	AC005255.3	-5.65	2.8e-08	0.0412	-0.33	-0.25	Suicide ideation score in major depressive disorder;	chr1:190092676	chr19:14792318~14792533:+
LUAD	trans	rs2419374	0.793	rs10920502	ENSG00000256210.3	AC005255.3	-5.65	2.8e-08	0.0412	-0.33	-0.25	Suicide ideation score in major depressive disorder;	chr1:190092918	chr19:14792318~14792533:+
LUAD	trans	rs2419374	0.793	rs1418810	ENSG00000256210.3	AC005255.3	-5.65	2.8e-08	0.0412	-0.33	-0.25	Suicide ideation score in major depressive disorder;	chr1:190095087	chr19:14792318~14792533:+
LUAD	trans	rs78487399	0.71	rs57696714	ENSG00000259134.4	LINC00924	5.65	2.8e-08	0.0412	0.52	0.25	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43399382	chr15:95433095~95507847:+
LUAD	trans	rs78487399	0.71	rs57381820	ENSG00000259134.4	LINC00924	5.65	2.8e-08	0.0412	0.52	0.25	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43399529	chr15:95433095~95507847:+
LUAD	trans	rs78487399	0.71	rs72879276	ENSG00000259134.4	LINC00924	5.65	2.8e-08	0.0412	0.52	0.25	Sum neutrophil eosinophil counts;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Inflammatory bowel disease;	chr2:43399962	chr15:95433095~95507847:+
LUAD	trans	rs7260598	0.642	rs56977104	ENSG00000261770.1	CTC-459F4.1	5.65	2.81e-08	0.0412	0.37	0.25	Response to taxane treatment (placlitaxel);	chr19:23956560	chr19:27757184~27760849:-
LUAD	trans	rs7260598	0.642	rs8112289	ENSG00000261770.1	CTC-459F4.1	5.65	2.81e-08	0.0412	0.37	0.25	Response to taxane treatment (placlitaxel);	chr19:23956571	chr19:27757184~27760849:-
LUAD	trans	rs313426	0.569	rs10791614	ENSG00000263219.1	RYKP1	-5.65	2.81e-08	0.0413	-0.29	-0.25	Toenail selenium levels;	chr11:103406480	chr17:4222091~4223828:+
LUAD	trans	rs853679	0.769	rs7752608	ENSG00000253570.1	RNF5P1	5.65	2.81e-08	0.0413	0.51	0.25	Depression;	chr6:28333418	chr8:38600661~38601200:-
LUAD	trans	rs2965260	0.621	rs12609049	ENSG00000225062.1	CATIP-AS1	5.65	2.82e-08	0.0415	0.38	0.25	IgG glycosylation;	chr19:53259284	chr2:218366665~218367835:-
LUAD	trans	rs714543	0.811	rs13238404	ENSG00000214975.4	PPIAP29	5.65	2.82e-08	0.0415	0.28	0.25	Plateletcrit;	chr7:44811812	chr6:24976419~24976982:+
LUAD	trans	rs877636	0.74	rs705698	ENSG00000243538.1	CTB-55B8.1	5.64	2.83e-08	0.0416	0.28	0.25	Cognitive function;	chr12:55990903	chr5:16902294~16902641:-
LUAD	trans	rs12200782	1	rs12200782	ENSG00000242375.1	RP11-498P14.3	-5.64	2.84e-08	0.0416	-0.54	-0.25	Small cell lung carcinoma;	chr6:26402808	chr9:97195351~97197687:-
LUAD	trans	rs10824518	0.612	rs10824539	ENSG00000279192.1	PWAR5	5.64	2.84e-08	0.0417	0.29	0.25	Myopia;	chr10:77397375	chr15:24985053~24988232:+
LUAD	trans	rs12210905	1	rs12189835	ENSG00000242375.1	RP11-498P14.3	-5.64	2.84e-08	0.0417	-0.6	-0.25	Hip circumference adjusted for BMI;	chr6:27230492	chr9:97195351~97197687:-
LUAD	trans	rs12210905	1	rs72843640	ENSG00000242375.1	RP11-498P14.3	-5.64	2.84e-08	0.0417	-0.6	-0.25	Hip circumference adjusted for BMI;	chr6:27234314	chr9:97195351~97197687:-
LUAD	trans	rs12210905	1	rs72843641	ENSG00000242375.1	RP11-498P14.3	-5.64	2.84e-08	0.0417	-0.6	-0.25	Hip circumference adjusted for BMI;	chr6:27235556	chr9:97195351~97197687:-
LUAD	trans	rs255788	0.92	rs7721564	ENSG00000238005.2	RP11-443B7.1	5.64	2.84e-08	0.0417	0.4	0.25	Response to platinum-based chemotherapy (carboplatin);	chr5:120113155	chr1:234957342~234970062:-
LUAD	trans	rs255788	0.915	rs60669924	ENSG00000238005.2	RP11-443B7.1	5.64	2.84e-08	0.0417	0.4	0.25	Response to platinum-based chemotherapy (carboplatin);	chr5:120113824	chr1:234957342~234970062:-
LUAD	trans	rs9876781	1	rs10470686	ENSG00000225528.1	RP3-370M22.8	-5.64	2.85e-08	0.0418	-0.25	-0.25	Longevity;	chr3:48408549	chr22:39960397~39964683:+
LUAD	trans	rs2404602	0.684	rs1011084	ENSG00000233760.1	AC004947.2	-5.64	2.85e-08	0.0419	-0.3	-0.25	Blood metabolite levels;	chr15:76715139	chr7:26551822~26557200:+
LUAD	trans	rs2404602	0.647	rs11629727	ENSG00000233760.1	AC004947.2	-5.64	2.85e-08	0.0419	-0.3	-0.25	Blood metabolite levels;	chr15:76716697	chr7:26551822~26557200:+
LUAD	trans	rs66887589	0.934	rs2389873	ENSG00000275858.1	RP11-291L22.8	-5.64	2.85e-08	0.0419	-0.26	-0.25	Diastolic blood pressure;	chr4:119633559	chr10:38450738~38451069:-
LUAD	trans	rs73220188	0.681	rs78869517	ENSG00000254991.1	RP13-631K18.3	5.64	2.86e-08	0.0419	0.55	0.25	Intraocular pressure;	chr5:108714373	chr11:12066929~12073014:+
LUAD	trans	rs12210905	1	rs115268625	ENSG00000242375.1	RP11-498P14.3	-5.64	2.86e-08	0.0419	-0.61	-0.25	Hip circumference adjusted for BMI;	chr6:26980450	chr9:97195351~97197687:-
LUAD	trans	rs334353	0.798	rs10760673	ENSG00000273487.1	RP4-621B10.8	5.64	2.86e-08	0.042	0.3	0.25	Age-related macular degeneration;	chr9:99116340	chr1:92189237~92190707:+
LUAD	trans	rs313426	0.506	rs2243980	ENSG00000263219.1	RYKP1	5.64	2.86e-08	0.042	0.29	0.25	Toenail selenium levels;	chr11:103378144	chr17:4222091~4223828:+
LUAD	trans	rs6921919	0.848	rs6903652	ENSG00000227766.1	HCG4P5	-5.64	2.87e-08	0.0421	-0.37	-0.25	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:29942075~29943067:-
LUAD	trans	rs1933488	1	rs7747003	ENSG00000278974.1	RP11-756P10.6	-5.64	2.87e-08	0.0421	-0.31	-0.25	Prostate cancer;	chr6:153107847	chr4:188740507~188741281:-
LUAD	trans	rs877636	0.74	rs705702	ENSG00000243538.1	CTB-55B8.1	-5.64	2.87e-08	0.0422	-0.28	-0.25	Cognitive function;	chr12:55996852	chr5:16902294~16902641:-
LUAD	trans	rs3096299	0.632	rs8051537	ENSG00000215030.5	RPL13P12	-5.64	2.89e-08	0.0423	-0.27	-0.25	Multiple myeloma (IgH translocation);	chr16:89477976	chr17:17383377~17384012:-
LUAD	trans	rs17507216	0.718	rs72751662	ENSG00000235370.6	DNM1P51	-5.64	2.9e-08	0.0425	-0.36	-0.25	Excessive daytime sleepiness;	chr15:82594705	chr15:84398316~84411701:-
LUAD	trans	rs9575182	1	rs9565808	ENSG00000228763.1	AC010095.5	5.64	2.91e-08	0.0426	0.29	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr13:82777465	chr2:108676795~108678601:-
LUAD	trans	rs7172809	0.573	rs74025074	ENSG00000230091.5	TMEM254-AS1	5.64	2.91e-08	0.0426	0.34	0.25	Glucose homeostasis traits;	chr15:77147021	chr10:80046860~80078912:-
LUAD	trans	rs7172809	0.573	rs13380152	ENSG00000230091.5	TMEM254-AS1	5.64	2.91e-08	0.0427	0.34	0.25	Glucose homeostasis traits;	chr15:77144044	chr10:80046860~80078912:-
LUAD	trans	rs7412746	0.611	rs752376	ENSG00000180764.13	PIPSL	-5.64	2.92e-08	0.0427	-0.28	-0.25	Melanoma;	chr1:150968905	chr10:93958191~93961540:-
LUAD	trans	rs2899832	0.789	rs28470932	ENSG00000229083.1	PSMA6P2	5.64	2.92e-08	0.0427	0.33	0.25	Response to zileuton treatment in asthma (FEV1 change interaction);	chr14:35282637	chrX:12825840~12826833:+
LUAD	trans	rs13091206	1	rs13091206	ENSG00000197582.5	GPX1P1	5.64	2.92e-08	0.0427	0.38	0.25	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr3:49201285	chrX:13378735~13379340:-
LUAD	trans	rs2070677	0.935	rs11812637	ENSG00000250148.1	KRT8P31	-5.64	2.92e-08	0.0428	-0.39	-0.25	Gout;	chr10:133599914	chr5:60743563~60744970:-
LUAD	trans	rs2070677	0.935	rs4350328	ENSG00000250148.1	KRT8P31	-5.64	2.92e-08	0.0428	-0.39	-0.25	Gout;	chr10:133601444	chr5:60743563~60744970:-
LUAD	trans	rs2070677	0.935	rs4300354	ENSG00000250148.1	KRT8P31	-5.64	2.92e-08	0.0428	-0.39	-0.25	Gout;	chr10:133602386	chr5:60743563~60744970:-
LUAD	trans	rs2070677	0.935	rs7907312	ENSG00000250148.1	KRT8P31	-5.64	2.92e-08	0.0428	-0.39	-0.25	Gout;	chr10:133603860	chr5:60743563~60744970:-
LUAD	trans	rs853679	0.607	rs34950484	ENSG00000281831.1	HCP5B	5.64	2.93e-08	0.0428	0.55	0.25	Depression;	chr6:28310911	chr6:29871895~29873783:-
LUAD	trans	rs853679	0.607	rs34661125	ENSG00000281831.1	HCP5B	5.64	2.93e-08	0.0428	0.55	0.25	Depression;	chr6:28314117	chr6:29871895~29873783:-
LUAD	trans	rs4713118	0.786	rs200502	ENSG00000204709.4	LINC01556	5.64	2.93e-08	0.0429	0.33	0.25	Parkinson's disease;	chr6:27820284	chr6:28943877~28944537:+
LUAD	trans	rs66887589	0.967	rs1480933	ENSG00000275858.1	RP11-291L22.8	5.64	2.93e-08	0.0429	0.27	0.25	Diastolic blood pressure;	chr4:119512093	chr10:38450738~38451069:-
LUAD	trans	rs6673267	1	rs6673267	ENSG00000244144.1	RP11-757F18.3	-5.64	2.93e-08	0.0429	-0.29	-0.25	Lobe attachment (rater-scored or self-reported);	chr1:201037533	chr3:112185480~112185998:-
LUAD	trans	rs853679	0.607	rs13190888	ENSG00000281831.1	HCP5B	5.64	2.93e-08	0.0429	0.55	0.25	Depression;	chr6:28318208	chr6:29871895~29873783:-
LUAD	trans	rs546131	0.614	rs473885	ENSG00000225531.1	RP11-196I18.3	5.64	2.94e-08	0.0429	0.33	0.25	Lung disease severity in cystic fibrosis;	chr11:34830414	chr9:107116829~107117557:+
LUAD	trans	rs546131	0.642	rs473848	ENSG00000225531.1	RP11-196I18.3	5.64	2.94e-08	0.0429	0.33	0.25	Lung disease severity in cystic fibrosis;	chr11:34830430	chr9:107116829~107117557:+
LUAD	trans	rs13416322	0.945	rs13391216	ENSG00000214286.2	PDCL3P3	5.64	2.94e-08	0.043	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100444521	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.945	rs13429260	ENSG00000214286.2	PDCL3P3	5.64	2.94e-08	0.043	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100444788	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.945	rs13403117	ENSG00000214286.2	PDCL3P3	5.64	2.94e-08	0.043	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100444829	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.945	rs13391679	ENSG00000214286.2	PDCL3P3	5.64	2.94e-08	0.043	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100444968	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.945	rs55885310	ENSG00000214286.2	PDCL3P3	5.64	2.94e-08	0.043	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100446003	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.891	rs55939586	ENSG00000214286.2	PDCL3P3	5.64	2.94e-08	0.043	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100446092	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.945	rs13398154	ENSG00000214286.2	PDCL3P3	5.64	2.94e-08	0.043	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100446141	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.945	rs56402605	ENSG00000214286.2	PDCL3P3	5.64	2.94e-08	0.043	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100446162	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.945	rs13395802	ENSG00000214286.2	PDCL3P3	5.64	2.94e-08	0.043	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100446447	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.945	rs13398539	ENSG00000214286.2	PDCL3P3	5.64	2.94e-08	0.043	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100446513	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.945	rs2309845	ENSG00000214286.2	PDCL3P3	5.64	2.94e-08	0.043	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100446783	chr3:17877455~17878169:-
LUAD	trans	rs8077577	0.747	rs62072541	ENSG00000188933.13	USP32P1	5.64	2.94e-08	0.043	0.34	0.25	Obesity-related traits;	chr17:18323385	chr17:16786489~16804455:+
LUAD	trans	rs714543	1	rs10267576	ENSG00000226038.5	PPIAP21	-5.64	2.96e-08	0.0433	-0.28	-0.25	Plateletcrit;	chr7:44831334	chr20:43230760~43231260:+
LUAD	trans	rs6493271	0.948	rs1486898	ENSG00000273297.1	RP11-38M8.1	5.64	2.97e-08	0.0434	0.34	0.25	Educational attainment (years of education);	chr15:47350306	chr7:134416290~134432453:-
LUAD	trans	rs66887589	0.967	rs2892869	ENSG00000275858.1	RP11-291L22.8	-5.64	2.97e-08	0.0434	-0.27	-0.25	Diastolic blood pressure;	chr4:119600142	chr10:38450738~38451069:-
LUAD	trans	rs1490157	0.753	rs986043	ENSG00000273455.1	RP11-305O4.3	-5.64	2.97e-08	0.0434	-0.34	-0.25	Partial epilepsies;	chr3:21642791	chr3:136087475~136087913:-
LUAD	trans	rs1957895	0.522	rs10483734	ENSG00000213434.2	VTI1BP2	-5.64	2.97e-08	0.0434	-0.49	-0.25	Rheumatoid arthritis;	chr14:61471083	chr4:183483490~183484185:+
LUAD	trans	rs351855	0.642	rs2546095	ENSG00000228305.2	AC016734.2	5.64	2.98e-08	0.0435	0.25	0.25	Waist-to-hip ratio adjusted for body mass index;	chr5:177082583	chr2:63622178~63622831:-
LUAD	trans	rs950394	0.887	rs62152282	ENSG00000231682.1	AC097713.4	-5.64	2.98e-08	0.0435	-0.32	-0.25	Schizophrenia;	chr2:104365291	chr2:234444590~234454595:-
LUAD	trans	rs8077577	0.747	rs3829956	ENSG00000188933.13	USP32P1	5.63	2.99e-08	0.0436	0.34	0.25	Obesity-related traits;	chr17:18316521	chr17:16786489~16804455:+
LUAD	trans	rs13416322	0.891	rs12623208	ENSG00000214286.2	PDCL3P3	5.63	2.99e-08	0.0436	0.35	0.25	Intelligence (multi-trait analysis);	chr2:100441373	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.945	rs12611675	ENSG00000214286.2	PDCL3P3	5.63	2.99e-08	0.0436	0.35	0.25	Intelligence (multi-trait analysis);	chr2:100441583	chr3:17877455~17878169:-
LUAD	trans	rs66887589	0.934	rs4834792	ENSG00000275858.1	RP11-291L22.8	-5.63	2.99e-08	0.0437	-0.26	-0.25	Diastolic blood pressure;	chr4:119634541	chr10:38450738~38451069:-
LUAD	trans	rs4639966	0.569	rs603486	ENSG00000219773.1	RP11-506B6.3	5.63	3e-08	0.0437	0.24	0.25	Systemic lupus erythematosus;	chr11:118716638	chr6:112355841~112356714:-
LUAD	trans	rs10772939	0.967	rs11611893	ENSG00000272914.1	RP11-330O11.3	-5.63	3e-08	0.0438	-0.28	-0.25	Economic and political preferences;	chr12:16427361	chr10:30831828~30833387:-
LUAD	trans	rs9660992	0.7	rs7547565	ENSG00000256616.3	RP11-815J4.6	-5.63	3e-08	0.0438	-0.32	-0.25	Mean corpuscular volume;Mean platelet volume;	chr1:205290274	chr18:12073232~12076654:-
LUAD	trans	rs7325116	0.603	rs3906157	ENSG00000241244.1	IGKV1D-16	5.63	3e-08	0.0438	0.19	0.25	Blood protein levels;	chr13:91959125	chr2:90100236~90100738:+
LUAD	trans	rs9575182	0.925	rs9575163	ENSG00000228763.1	AC010095.5	5.63	3.02e-08	0.044	0.29	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr13:82755522	chr2:108676795~108678601:-
LUAD	trans	rs2070677	0.935	rs11101869	ENSG00000250148.1	KRT8P31	-5.63	3.03e-08	0.0441	-0.39	-0.25	Gout;	chr10:133587127	chr5:60743563~60744970:-
LUAD	trans	rs2070677	1	rs12263487	ENSG00000250148.1	KRT8P31	-5.63	3.03e-08	0.0441	-0.38	-0.25	Gout;	chr10:133590081	chr5:60743563~60744970:-
LUAD	trans	rs7212590	0.655	rs16943969	ENSG00000187870.7	RNFT1P3	5.63	3.04e-08	0.0443	0.51	0.25	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59953792	chr17:20743333~20754501:-
LUAD	trans	rs916888	0.61	rs199444	ENSG00000204650.12	CRHR1-IT1	5.63	3.04e-08	0.0443	0.3	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:45620328~45648216:+
LUAD	trans	rs916888	0.61	rs199442	ENSG00000204650.12	CRHR1-IT1	5.63	3.04e-08	0.0443	0.3	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:45620328~45648216:+
LUAD	trans	rs3807766	1	rs3807766	ENSG00000267009.5	RP11-120M18.2	5.63	3.04e-08	0.0443	0.3	0.25	3-hydroxypropylmercapturic acid levels in smokers;	chr7:78053573	chr17:68413623~68524949:+
LUAD	trans	rs7172809	0.573	rs13379686	ENSG00000230091.5	TMEM254-AS1	5.63	3.04e-08	0.0443	0.34	0.25	Glucose homeostasis traits;	chr15:77143849	chr10:80046860~80078912:-
LUAD	trans	rs2018683	0.834	rs2012754	ENSG00000279319.1	RP11-693M3.1	5.63	3.05e-08	0.0444	0.26	0.25	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28986641	chr18:44986109~44989203:+
LUAD	trans	rs6087990	0.735	rs1003522	ENSG00000253915.1	MAPRE1P1	5.63	3.05e-08	0.0444	0.29	0.25	Ulcerative colitis;	chr20:32780754	chr8:135625185~135625981:-
LUAD	trans	rs3096299	0.719	rs2911265	ENSG00000215030.5	RPL13P12	-5.63	3.05e-08	0.0444	-0.28	-0.25	Multiple myeloma (IgH translocation);	chr16:89444920	chr17:17383377~17384012:-
LUAD	trans	rs79149102	0.522	rs10459601	ENSG00000227288.3	RP5-837I24.1	5.63	3.06e-08	0.0445	0.44	0.25	Lung cancer;	chr15:74573068	chr1:81501794~81503468:+
LUAD	trans	rs7618501	0.669	rs7634084	ENSG00000197582.5	GPX1P1	5.63	3.06e-08	0.0445	0.33	0.25	Intelligence (multi-trait analysis);	chr3:49912401	chrX:13378735~13379340:-
LUAD	trans	rs8087799	0.522	rs11081999	ENSG00000281538.1	RP4-669P10.20	5.63	3.06e-08	0.0445	0.26	0.25	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr18:22571543	chr22:42138060~42139726:+
LUAD	trans	rs2419374	0.793	rs10920501	ENSG00000256210.3	AC005255.3	-5.63	3.07e-08	0.0446	-0.33	-0.25	Suicide ideation score in major depressive disorder;	chr1:190092815	chr19:14792318~14792533:+
LUAD	trans	rs4908768	0.501	rs12030885	ENSG00000273306.1	RP11-527J8.1	5.63	3.07e-08	0.0446	0.24	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8721337	chr2:99405218~99405843:+
LUAD	trans	rs6940638	0.688	rs6921388	ENSG00000204709.4	LINC01556	5.63	3.08e-08	0.0447	0.31	0.25	Intelligence (multi-trait analysis);	chr6:27112426	chr6:28943877~28944537:+
LUAD	trans	rs7412746	0.587	rs3849279	ENSG00000180764.13	PIPSL	-5.63	3.08e-08	0.0447	-0.28	-0.25	Melanoma;	chr1:150972231	chr10:93958191~93961540:-
LUAD	trans	rs5758511	0.513	rs7292782	ENSG00000268568.1	AC007228.9	-5.63	3.08e-08	0.0448	-0.34	-0.25	Birth weight;	chr22:41804320	chr19:56672574~56673901:-
LUAD	trans	rs9467711	0.651	rs17528178	ENSG00000253570.1	RNF5P1	5.63	3.08e-08	0.0448	0.66	0.25	Autism spectrum disorder or schizophrenia;	chr6:25983549	chr8:38600661~38601200:-
LUAD	trans	rs9467711	0.591	rs13202688	ENSG00000253570.1	RNF5P1	5.63	3.08e-08	0.0448	0.66	0.25	Autism spectrum disorder or schizophrenia;	chr6:25993241	chr8:38600661~38601200:-
LUAD	trans	rs962856	0.537	rs685211	ENSG00000179082.3	C9orf106	5.63	3.08e-08	0.0448	0.28	0.25	Pancreatic cancer;	chr2:67451726	chr9:129321016~129324905:+
LUAD	trans	rs6673267	0.904	rs10800751	ENSG00000244144.1	RP11-757F18.3	-5.63	3.09e-08	0.0449	-0.29	-0.25	Lobe attachment (rater-scored or self-reported);	chr1:201030798	chr3:112185480~112185998:-
LUAD	trans	rs6831352	0.734	rs2602857	ENSG00000233859.2	ADH5P4	-5.63	3.09e-08	0.0449	-0.27	-0.25	Alcohol dependence;	chr4:99109167	chr6:65836930~65838039:-
LUAD	trans	rs6831352	0.734	rs3018046	ENSG00000233859.2	ADH5P4	-5.63	3.09e-08	0.0449	-0.27	-0.25	Alcohol dependence;	chr4:99109237	chr6:65836930~65838039:-
LUAD	trans	rs6831352	0.734	rs3100630	ENSG00000233859.2	ADH5P4	-5.63	3.09e-08	0.0449	-0.27	-0.25	Alcohol dependence;	chr4:99110564	chr6:65836930~65838039:-
LUAD	trans	rs6831352	0.703	rs3133152	ENSG00000233859.2	ADH5P4	-5.63	3.09e-08	0.0449	-0.27	-0.25	Alcohol dependence;	chr4:99110570	chr6:65836930~65838039:-
LUAD	trans	rs6831352	0.703	rs2602862	ENSG00000233859.2	ADH5P4	-5.63	3.09e-08	0.0449	-0.27	-0.25	Alcohol dependence;	chr4:99112070	chr6:65836930~65838039:-
LUAD	trans	rs6831352	0.734	rs2851259	ENSG00000233859.2	ADH5P4	-5.63	3.09e-08	0.0449	-0.27	-0.25	Alcohol dependence;	chr4:99112835	chr6:65836930~65838039:-
LUAD	trans	rs5768709	0.571	rs2071781	ENSG00000258479.4	LINC00640	-5.63	3.09e-08	0.0449	-0.3	-0.25	Pancreatic cancer;	chr22:48523914	chr14:51333393~51365557:+
LUAD	trans	rs8064024	0.599	rs1876359	ENSG00000279933.1	RP4-671O14.5	5.63	3.1e-08	0.045	0.24	0.25	Cancer;	chr16:4880099	chr22:44183031~44187739:-
LUAD	trans	rs950394	1	rs6713653	ENSG00000231682.1	AC097713.4	-5.63	3.1e-08	0.045	-0.32	-0.25	Schizophrenia;	chr2:104358226	chr2:234444590~234454595:-
LUAD	trans	rs11888559	0.655	rs13397552	ENSG00000100058.11	CRYBB2P1	-5.63	3.1e-08	0.045	-0.48	-0.25	Height;	chr2:203104713	chr22:25448105~25520854:+
LUAD	trans	rs9329221	0.741	rs534523	ENSG00000253893.2	FAM85B	5.63	3.1e-08	0.045	0.3	0.25	Neuroticism;	chr8:10027489	chr8:8167819~8226614:-
LUAD	trans	rs950394	0.767	rs11903674	ENSG00000231682.1	AC097713.4	-5.63	3.1e-08	0.0451	-0.28	-0.25	Schizophrenia;	chr2:104364542	chr2:234444590~234454595:-
LUAD	trans	rs2665103	0.632	rs3902959	ENSG00000235370.6	DNM1P51	-5.63	3.1e-08	0.0451	-0.28	-0.25	Intelligence (multi-trait analysis);	chr15:82252586	chr15:84398316~84411701:-
LUAD	trans	rs9733	0.744	rs4970976	ENSG00000180764.13	PIPSL	5.63	3.11e-08	0.0451	0.28	0.25	Tonsillectomy;	chr1:150807048	chr10:93958191~93961540:-
LUAD	trans	rs4908768	0.52	rs11121224	ENSG00000273306.1	RP11-527J8.1	5.63	3.11e-08	0.0451	0.24	0.25	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8713456	chr2:99405218~99405843:+
LUAD	trans	rs7412746	0.524	rs58304714	ENSG00000180764.13	PIPSL	-5.63	3.11e-08	0.0451	-0.29	-0.25	Melanoma;	chr1:150859085	chr10:93958191~93961540:-
LUAD	trans	rs1933488	1	rs17083581	ENSG00000278974.1	RP11-756P10.6	-5.63	3.11e-08	0.0451	-0.31	-0.25	Prostate cancer;	chr6:153108312	chr4:188740507~188741281:-
LUAD	trans	rs1933488	1	rs6931160	ENSG00000278974.1	RP11-756P10.6	-5.63	3.11e-08	0.0451	-0.31	-0.25	Prostate cancer;	chr6:153109316	chr4:188740507~188741281:-
LUAD	trans	rs864643	0.812	rs3821372	ENSG00000183298.5	RP11-556K13.1	-5.63	3.11e-08	0.0451	-0.34	-0.25	Attention deficit hyperactivity disorder;	chr3:39506880	chr1:101786340~101787219:-
LUAD	trans	rs995758	0.647	rs1489761	ENSG00000281383.1	CH507-513H4.5	5.63	3.11e-08	0.0451	0.28	0.25	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;	chr4:144534339	chr21:8254592~8255514:-
LUAD	trans	rs2404602	0.735	rs11638767	ENSG00000233760.1	AC004947.2	-5.63	3.11e-08	0.0451	-0.28	-0.25	Blood metabolite levels;	chr15:76363597	chr7:26551822~26557200:+
LUAD	trans	rs453301	0.624	rs330049	ENSG00000173295.6	FAM86B3P	5.63	3.11e-08	0.0452	0.27	0.25	Joint mobility (Beighton score);	chr8:9229789	chr8:8228595~8244865:+
LUAD	trans	rs28673968	0.614	rs17015858	ENSG00000214846.4	RP11-115L11.1	5.63	3.12e-08	0.0452	0.53	0.25	Idiopathic pulmonary fibrosis;	chr4:89584417	chr4:15730962~15731627:-
LUAD	trans	rs714543	1	rs714543	ENSG00000226038.5	PPIAP21	-5.63	3.13e-08	0.0454	-0.28	-0.25	Plateletcrit;	chr7:44847477	chr20:43230760~43231260:+
LUAD	trans	rs714543	1	rs757693	ENSG00000226038.5	PPIAP21	-5.63	3.13e-08	0.0454	-0.28	-0.25	Plateletcrit;	chr7:44848430	chr20:43230760~43231260:+
LUAD	trans	rs1421334	0.74	rs2344121	ENSG00000261457.3	AC002519.6	-5.63	3.14e-08	0.0455	-0.3	-0.25	Intelligence (multi-trait analysis);	chr8:30984006	chr16:31802947~31807973:+
LUAD	trans	rs17507216	0.718	rs72751657	ENSG00000235370.6	DNM1P51	-5.63	3.14e-08	0.0455	-0.36	-0.25	Excessive daytime sleepiness;	chr15:82581259	chr15:84398316~84411701:-
LUAD	trans	rs1933488	1	rs12055786	ENSG00000278974.1	RP11-756P10.6	-5.63	3.14e-08	0.0455	-0.31	-0.25	Prostate cancer;	chr6:153109990	chr4:188740507~188741281:-
LUAD	trans	rs1933488	1	rs7743683	ENSG00000278974.1	RP11-756P10.6	-5.63	3.14e-08	0.0455	-0.31	-0.25	Prostate cancer;	chr6:153111850	chr4:188740507~188741281:-
LUAD	trans	rs1933488	1	rs6557265	ENSG00000278974.1	RP11-756P10.6	-5.63	3.14e-08	0.0455	-0.31	-0.25	Prostate cancer;	chr6:153112267	chr4:188740507~188741281:-
LUAD	trans	rs1933488	1	rs6557266	ENSG00000278974.1	RP11-756P10.6	-5.63	3.14e-08	0.0455	-0.31	-0.25	Prostate cancer;	chr6:153112399	chr4:188740507~188741281:-
LUAD	trans	rs1933488	1	rs6907823	ENSG00000278974.1	RP11-756P10.6	-5.63	3.14e-08	0.0455	-0.31	-0.25	Prostate cancer;	chr6:153112407	chr4:188740507~188741281:-
LUAD	trans	rs11665867	0.648	rs2604910	ENSG00000260176.1	CTD-3126B10.4	5.63	3.15e-08	0.0456	0.38	0.25	Hematocrit;	chr19:40791349	chr16:2644084~2645214:-
LUAD	trans	rs11665867	0.616	rs2604909	ENSG00000260176.1	CTD-3126B10.4	5.63	3.15e-08	0.0456	0.38	0.25	Hematocrit;	chr19:40791710	chr16:2644084~2645214:-
LUAD	trans	rs7647973	0.925	rs6446256	ENSG00000197582.5	GPX1P1	5.63	3.15e-08	0.0456	0.34	0.25	Menarche (age at onset);	chr3:49186777	chrX:13378735~13379340:-
LUAD	trans	rs6424115	0.679	rs2294495	ENSG00000228217.1	AL390877.1	5.63	3.15e-08	0.0456	0.34	0.25	Immature fraction of reticulocytes;	chr1:23749386	chr1:117778087~117778506:-
LUAD	trans	rs7260598	0.642	rs7259787	ENSG00000261770.1	CTC-459F4.1	5.63	3.15e-08	0.0456	0.37	0.25	Response to taxane treatment (placlitaxel);	chr19:23935633	chr19:27757184~27760849:-
LUAD	trans	rs7260598	0.71	rs10402319	ENSG00000261770.1	CTC-459F4.1	5.63	3.15e-08	0.0456	0.37	0.25	Response to taxane treatment (placlitaxel);	chr19:23945263	chr19:27757184~27760849:-
LUAD	trans	rs6921919	0.848	rs56131013	ENSG00000227766.1	HCG4P5	-5.62	3.16e-08	0.0457	-0.37	-0.25	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:29942075~29943067:-
LUAD	trans	rs9393777	0.92	rs34953377	ENSG00000281831.1	HCP5B	5.62	3.17e-08	0.0458	0.49	0.25	Intelligence (multi-trait analysis);	chr6:27413881	chr6:29871895~29873783:-
LUAD	trans	rs11748684	1	rs59463904	ENSG00000240869.3	RN7SL128P	5.62	3.17e-08	0.0458	0.58	0.25	Response to taxane treatment (docetaxel);	chr5:42559371	chr6:20421583~20421887:-
LUAD	trans	rs17664267	1	rs17664267	ENSG00000239005.1	ACA64	5.62	3.17e-08	0.0458	0.37	0.25	Conduct disorder (maternal expressed emotions interaction);	chr18:43228833	chr4:139436368~139436494:-
LUAD	trans	rs3934047	0.967	rs7177303	ENSG00000188002.9	RP11-43F13.1	-5.62	3.17e-08	0.0458	-0.31	-0.25	Response to paliperidone in schizophrenia (positive Marder score);	chr15:81703523	chr5:1598920~1634005:-
LUAD	trans	rs7325116	0.519	rs9301769	ENSG00000241244.1	IGKV1D-16	5.62	3.17e-08	0.0459	0.19	0.25	Blood protein levels;	chr13:91989292	chr2:90100236~90100738:+
LUAD	trans	rs864643	0.947	rs4113192	ENSG00000183298.5	RP11-556K13.1	5.62	3.17e-08	0.0459	0.36	0.25	Attention deficit hyperactivity disorder;	chr3:39495699	chr1:101786340~101787219:-
LUAD	trans	rs864643	0.947	rs4113193	ENSG00000183298.5	RP11-556K13.1	5.62	3.17e-08	0.0459	0.36	0.25	Attention deficit hyperactivity disorder;	chr3:39495779	chr1:101786340~101787219:-
LUAD	trans	rs1979967	1	rs1979967	ENSG00000189238.5	LINC00943	5.62	3.18e-08	0.046	0.28	0.25	Interleukin-18 levels;	chr15:79367271	chr12:126726270~126746252:+
LUAD	trans	rs3812762	0.879	rs10743089	ENSG00000266891.1	RP11-692N5.2	5.62	3.19e-08	0.0462	0.32	0.25	Hypospadias;	chr11:8766621	chr18:9734882~9735602:-
LUAD	trans	rs313426	0.569	rs7122988	ENSG00000263219.1	RYKP1	-5.62	3.19e-08	0.0462	-0.29	-0.25	Toenail selenium levels;	chr11:103397016	chr17:4222091~4223828:+
LUAD	trans	rs950394	1	rs7570787	ENSG00000231682.1	AC097713.4	-5.62	3.19e-08	0.0462	-0.32	-0.25	Schizophrenia;	chr2:104366869	chr2:234444590~234454595:-
LUAD	trans	rs950394	1	rs7558724	ENSG00000231682.1	AC097713.4	-5.62	3.19e-08	0.0462	-0.32	-0.25	Schizophrenia;	chr2:104366872	chr2:234444590~234454595:-
LUAD	trans	rs7412746	0.658	rs2230061	ENSG00000180764.13	PIPSL	-5.62	3.2e-08	0.0462	-0.29	-0.25	Melanoma;	chr1:150755063	chr10:93958191~93961540:-
LUAD	trans	rs9393777	0.778	rs66841633	ENSG00000281831.1	HCP5B	5.62	3.21e-08	0.0464	0.49	0.25	Intelligence (multi-trait analysis);	chr6:27414607	chr6:29871895~29873783:-
LUAD	trans	rs916888	0.61	rs199446	ENSG00000204650.12	CRHR1-IT1	-5.62	3.21e-08	0.0464	-0.29	-0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:45620328~45648216:+
LUAD	trans	rs916888	0.61	rs199536	ENSG00000204650.12	CRHR1-IT1	-5.62	3.21e-08	0.0464	-0.29	-0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:45620328~45648216:+
LUAD	trans	rs4948102	0.924	rs13240915	ENSG00000186940.6	CHCHD2P9	-5.62	3.21e-08	0.0464	-0.31	-0.25	Plasma homocysteine levels (post-methionine load test);	chr7:56023059	chr9:79391304~79391759:+
LUAD	trans	rs2404602	0.735	rs2280306	ENSG00000233760.1	AC004947.2	-5.62	3.22e-08	0.0465	-0.28	-0.25	Blood metabolite levels;	chr15:76359917	chr7:26551822~26557200:+
LUAD	trans	rs10783779	0.647	rs705708	ENSG00000196933.5	RPS26P11	5.62	3.22e-08	0.0466	0.27	0.25	Educational attainment;	chr12:56095129	chrX:72044545~72044892:+
LUAD	trans	rs9329221	0.592	rs7832708	ENSG00000253893.2	FAM85B	-5.62	3.23e-08	0.0466	-0.3	-0.25	Neuroticism;	chr8:10332530	chr8:8167819~8226614:-
LUAD	trans	rs3743266	0.613	rs2414669	ENSG00000235082.2	SUMO1P3	-5.62	3.23e-08	0.0466	-0.24	-0.25	Menarche (age at onset);	chr15:60416625	chr1:160317403~160317706:+
LUAD	trans	rs8077577	0.747	rs11869582	ENSG00000263946.1	RP11-434D2.11	5.62	3.24e-08	0.0467	0.35	0.25	Obesity-related traits;	chr17:18233267	chr17:20554971~20559410:-
LUAD	trans	rs4740829	0.531	rs7039532	ENSG00000250230.2	RP11-855O10.2	5.62	3.26e-08	0.047	0.31	0.25	Gut microbiome composition (winter);	chr9:5876558	chr11:61588494~61607550:+
LUAD	trans	rs9575182	1	rs7318661	ENSG00000228763.1	AC010095.5	5.62	3.27e-08	0.0471	0.29	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr13:82811563	chr2:108676795~108678601:-
LUAD	trans	rs6499244	0.552	rs7196917	ENSG00000257513.6	NPIPB1P	5.62	3.27e-08	0.0472	0.25	0.25	Menarche (age at onset);	chr16:69862624	chr18:11619509~11639699:-
LUAD	trans	rs663970	0.573	rs504319	ENSG00000251596.1	HADHAP1	5.62	3.27e-08	0.0472	0.34	0.25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr5:21690715	chr4:165404067~165406350:-
LUAD	trans	rs7929679	0.602	rs11032866	ENSG00000225531.1	RP11-196I18.3	5.62	3.3e-08	0.0475	0.31	0.25	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34781885	chr9:107116829~107117557:+
LUAD	trans	rs7929679	0.602	rs1396885	ENSG00000225531.1	RP11-196I18.3	5.62	3.3e-08	0.0475	0.31	0.25	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34783663	chr9:107116829~107117557:+
LUAD	trans	rs7929679	0.602	rs11032872	ENSG00000225531.1	RP11-196I18.3	5.62	3.3e-08	0.0475	0.31	0.25	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34784645	chr9:107116829~107117557:+
LUAD	trans	rs6831352	0.703	rs2602854	ENSG00000233859.2	ADH5P4	-5.62	3.3e-08	0.0475	-0.27	-0.25	Alcohol dependence;	chr4:99107500	chr6:65836930~65838039:-
LUAD	trans	rs3779195	0.929	rs1635612	ENSG00000230273.1	AC087163.3	5.62	3.31e-08	0.0476	0.34	0.25	Sex hormone-binding globulin levels;	chr7:98385737	chr17:17981192~17981572:-
LUAD	trans	rs889398	0.835	rs62050037	ENSG00000257513.6	NPIPB1P	-5.62	3.31e-08	0.0476	-0.24	-0.25	Body mass index;	chr16:69750767	chr18:11619509~11639699:-
LUAD	trans	rs3812762	0.871	rs2173999	ENSG00000266891.1	RP11-692N5.2	-5.62	3.32e-08	0.0478	-0.32	-0.25	Hypospadias;	chr11:8756530	chr18:9734882~9735602:-
LUAD	trans	rs12210905	1	rs72843629	ENSG00000242375.1	RP11-498P14.3	-5.62	3.32e-08	0.0478	-0.58	-0.25	Hip circumference adjusted for BMI;	chr6:27207436	chr9:97195351~97197687:-
LUAD	trans	rs13416322	0.945	rs750562	ENSG00000214286.2	PDCL3P3	5.62	3.33e-08	0.0479	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100447087	chr3:17877455~17878169:-
LUAD	trans	rs7824557	0.547	rs2409745	ENSG00000253981.4	ALG1L13P	5.62	3.33e-08	0.0479	0.28	0.25	Retinal vascular caliber;	chr8:11219126	chr8:8236003~8244667:-
LUAD	trans	rs7618501	0.633	rs13060128	ENSG00000197582.5	GPX1P1	5.61	3.34e-08	0.0481	0.33	0.25	Intelligence (multi-trait analysis);	chr3:49987595	chrX:13378735~13379340:-
LUAD	trans	rs7618501	0.633	rs2353579	ENSG00000197582.5	GPX1P1	5.61	3.34e-08	0.0481	0.33	0.25	Intelligence (multi-trait analysis);	chr3:49990341	chrX:13378735~13379340:-
LUAD	trans	rs4150642	1	rs7103375	ENSG00000235847.2	LDHAP7	-5.61	3.34e-08	0.0481	-0.41	-0.25	Amyloid A serum levels;	chr11:18353986	chr2:84777259~84778223:-
LUAD	trans	rs9663362	1	rs2689691	ENSG00000250564.1	RP11-215P8.4	5.61	3.35e-08	0.0482	0.27	0.25	Blood pressure;	chr10:94140176	chr5:134429051~134460615:-
LUAD	trans	rs10211296	0.861	rs12621848	ENSG00000221413.1	AC023593.1	-5.61	3.35e-08	0.0482	-0.27	-0.25	Risky sexual behaviors in alcohol dependence;	chr2:165618788	chr3:127664704~127664810:+
LUAD	trans	rs7112043	1	rs7112043	ENSG00000225531.1	RP11-196I18.3	5.61	3.36e-08	0.0483	0.31	0.25	Lung disease severity in cystic fibrosis;	chr11:34767839	chr9:107116829~107117557:+
LUAD	trans	rs916888	0.61	rs199453	ENSG00000204650.12	CRHR1-IT1	5.61	3.36e-08	0.0483	0.29	0.25	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:45620328~45648216:+
LUAD	trans	rs1904173	0.736	rs7732066	ENSG00000231789.2	PIK3CD-AS2	-5.61	3.37e-08	0.0484	-0.41	-0.25	IgG glycosylation;	chr5:25435140	chr1:9672426~9687555:-
LUAD	trans	rs73198271	0.96	rs73198290	ENSG00000273129.1	PACERR	5.61	3.37e-08	0.0485	0.33	0.25	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8758499	chr1:186680622~186681446:+
LUAD	trans	rs17664267	0.953	rs2037273	ENSG00000239005.1	ACA64	5.61	3.38e-08	0.0485	0.39	0.25	Conduct disorder (maternal expressed emotions interaction);	chr18:43223423	chr4:139436368~139436494:-
LUAD	trans	rs3812762	0.917	rs10743087	ENSG00000266891.1	RP11-692N5.2	-5.61	3.38e-08	0.0486	-0.32	-0.25	Hypospadias;	chr11:8764511	chr18:9734882~9735602:-
LUAD	trans	rs7809615	0.515	rs6961634	ENSG00000228834.1	RP11-249L21.4	5.61	3.39e-08	0.0486	0.38	0.25	Blood metabolite ratios;	chr7:99584216	chr6:108907615~108907873:-
LUAD	trans	rs17664267	1	rs62092109	ENSG00000239005.1	ACA64	5.61	3.39e-08	0.0487	0.38	0.25	Conduct disorder (maternal expressed emotions interaction);	chr18:43231035	chr4:139436368~139436494:-
LUAD	trans	rs4407350	0.761	rs11702972	ENSG00000275383.1	RP11-615I2.6	5.61	3.39e-08	0.0487	0.28	0.25	Intelligence (multi-trait analysis);	chr22:44528514	chr16:68591382~68594424:+
LUAD	trans	rs9467711	0.79	rs17598658	ENSG00000253570.1	RNF5P1	5.61	3.42e-08	0.049	0.59	0.25	Autism spectrum disorder or schizophrenia;	chr6:26175638	chr8:38600661~38601200:-
LUAD	trans	rs7644634	0.966	rs6437612	ENSG00000230732.4	AC127904.2	-5.61	3.42e-08	0.049	-0.25	-0.25	Itch intensity from mosquito bite;	chr3:105759951	chr3:196912646~196914579:+
LUAD	trans	rs3740713	0.592	rs73434674	ENSG00000214110.3	LDHAP4	5.61	3.42e-08	0.0491	0.4	0.25	Amyotrophic lateral sclerosis (sporadic);	chr11:18389950	chr9:14921337~14922334:-
LUAD	trans	rs9467711	0.538	rs13191445	ENSG00000253570.1	RNF5P1	5.61	3.42e-08	0.0491	0.65	0.25	Autism spectrum disorder or schizophrenia;	chr6:26015261	chr8:38600661~38601200:-
LUAD	trans	rs13416322	0.836	rs13430275	ENSG00000214286.2	PDCL3P3	5.61	3.43e-08	0.0492	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100463278	chr3:17877455~17878169:-
LUAD	trans	rs7412746	0.587	rs11204722	ENSG00000180764.13	PIPSL	5.61	3.44e-08	0.0492	0.28	0.25	Melanoma;	chr1:150757708	chr10:93958191~93961540:-
LUAD	trans	rs17664267	1	rs17664605	ENSG00000239005.1	ACA64	5.61	3.44e-08	0.0493	0.39	0.25	Conduct disorder (maternal expressed emotions interaction);	chr18:43246434	chr4:139436368~139436494:-
LUAD	trans	rs545610	0.505	rs61884730	ENSG00000261105.4	LMO7-AS1	-5.61	3.44e-08	0.0493	-0.35	-0.25	Dental caries;	chr11:30508340	chr13:75604700~75635994:-
LUAD	trans	rs11935423	0.735	rs7693979	ENSG00000220842.6	RP11-572P18.1	-5.61	3.45e-08	0.0494	-0.29	-0.25	Gut microbiome composition (summer);	chr4:99543408	chr10:120354701~120355183:-
LUAD	trans	rs2243480	1	rs1404147	ENSG00000230295.1	RP11-458F8.2	-5.61	3.46e-08	0.0495	-0.28	-0.25	Diabetic kidney disease;	chr7:65799537	chr7:66880708~66882981:+
LUAD	trans	rs13416322	0.891	rs61530065	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100450329	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.945	rs1437974	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100452190	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.891	rs13412926	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100452907	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.735	rs112415219	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100453593	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.891	rs1437977	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100454031	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.891	rs4549109	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100454614	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.945	rs4366926	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100454628	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.945	rs13395614	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100455095	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.945	rs13411582	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100455201	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.838	rs13411791	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100455407	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.945	rs10194971	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100456047	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.945	rs10192505	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100456113	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.945	rs1837140	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100456925	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.945	rs13427911	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100457426	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.945	rs12623030	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100457471	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.945	rs13419111	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100457496	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.945	rs12618805	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100457585	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.945	rs13399940	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100457595	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.945	rs2083150	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100458381	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.945	rs10199108	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100460269	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.945	rs10188492	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100460341	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.945	rs77408958	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100461680	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.891	rs77913335	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100461745	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.945	rs1437979	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100461798	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.891	rs1519653	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100462027	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.945	rs1356723	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100462264	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.891	rs13404791	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100462608	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.945	rs13420763	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100462639	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.786	rs13404898	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100462679	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.838	rs28515048	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100462900	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.838	rs35634085	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100463076	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.836	rs13430155	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100463147	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.685	rs13424410	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100463752	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.945	rs13421699	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100463755	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.891	rs10201438	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100464075	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.945	rs10201739	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100464316	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.945	rs10201765	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100464413	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.945	rs10204375	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100464622	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.836	rs55963083	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100465121	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.836	rs9653443	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100465139	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.891	rs9653444	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100465159	chr3:17877455~17878169:-
LUAD	trans	rs13416322	0.891	rs13425866	ENSG00000214286.2	PDCL3P3	5.61	3.46e-08	0.0495	0.34	0.25	Intelligence (multi-trait analysis);	chr2:100465279	chr3:17877455~17878169:-
LUAD	trans	rs9467711	0.79	rs45527431	ENSG00000253570.1	RNF5P1	5.61	3.48e-08	0.0497	0.57	0.25	Autism spectrum disorder or schizophrenia;	chr6:26599281	chr8:38600661~38601200:-
LUAD	trans	rs9467711	0.79	rs66488313	ENSG00000253570.1	RNF5P1	5.61	3.48e-08	0.0497	0.57	0.25	Autism spectrum disorder or schizophrenia;	chr6:26631340	chr8:38600661~38601200:-
LUAD	trans	rs853679	0.546	rs35016036	ENSG00000281831.1	HCP5B	5.61	3.48e-08	0.0498	0.56	0.25	Depression;	chr6:28347103	chr6:29871895~29873783:-
LUAD	trans	rs3812762	0.879	rs10743088	ENSG00000266891.1	RP11-692N5.2	-5.61	3.48e-08	0.0498	-0.32	-0.25	Hypospadias;	chr11:8766073	chr18:9734882~9735602:-
LUAD	trans	rs6011368	0.84	rs2427638	ENSG00000226210.3	WASH7P	5.61	3.49e-08	0.0498	0.28	0.25	Clozapine-induced cytotoxicity;	chr20:64269364	chr12:14522~32015:-
LUAD	trans	rs4920799	0.793	rs566303	ENSG00000237484.5	AP000476.1	-5.61	3.5e-08	0.05	-0.28	-0.25	Echocardiographic traits;	chr5:85335455	chr21:24428740~24547942:+